id|nct_id|group_type|title|description
2841818|NCT03655925||Patients with Chronic Heart Failure (CHF)|Entire cohort/ Patients with recent diagnosis of chronic heart failure as defined by the guidelines of the European Society of Cardiology (ESC) and with cardiac ejection fraction <40
2841819|NCT03655912|Active Comparator|Patch|Eye patch on the fellow eye and to near-vision activities (such as reading, drawing, etc)
2841820|NCT03655912|Experimental|Electronic Devices|Eye patch on the fellow eye and a electronic tablet
2841821|NCT03655912|Experimental|Red/Green Glasses|Red/green glasses and a electronic tablet
2841822|NCT03655886|Experimental|Radical prostatectomy|
2841823|NCT03655886|Experimental|Radiotherapy|
2841824|NCT03655873|Experimental|HEC30654AcOH capsule|"single ascending-dose study: Including 7 dose groups(5-、10、15-、30-、60-、90-、120mg)，Day1 ante meridiem(AM) 8:00 (±1h) with 240ml warm water to taking the experiment drug，On an empty stomach .~multiple ascending-dose study: Including 3 dose groups(15-、30-、60mg),Day1-Day7 AM 8:00 (±1h), 18:00 Post Meridiem(PM) (±1h), with 240ml warm water to take the experiment drug On an empty stomach;Day8 AM 8:00 (±1h)with 240ml warm water to taking the experiment drug，On an empty stomach."
2841825|NCT03655873|Placebo Comparator|placebo capsule|"single ascending-dose study: Including 6 dose groups(10、15-、30-、60-、90-、120mg)，Day1 morning 8:00 (±1h) with 240ml warm water to taking the placebo capsule，On an empty stomach .~multiple ascending-dose study: Including 3 dose groups(15-、30-、60mg),Day1-Day7 AM 8:00 (±1h), 18:00 PM (±1h), with 240ml warm water to take the placebo capsule on an empty stomach;Day8 AM 8:00 (±1h)with 240ml warm water to taking the placebo capsule，on an empty stomach."
2841826|NCT03655860|Experimental|SIMEOX|
2841827|NCT03655847|Experimental|Dexmedetomidine|Drug: Dexmedetomidine dexmedetomidine, 0.1ug/kg up or down Other Name: precedex
2841828|NCT03655834|Experimental|Microdosing|Patients will be administered a microdose of pemetrexed with subsequent pharmacokinetic assessment. Afterwards the patients will continue in either IMPROVE-I or -II for second pharmacokinetic assessment
2841829|NCT03655821|Active Comparator|Arm A (BSA-based dosing)|Dosing of pemetrexed is based on BSA according drug label
2841830|NCT03655821|Experimental|Arm B (renal function based dosing)|Dosing of pemetrexed is based on renal function, calculated to reach the target AUC.
2841831|NCT03655808|Experimental|BBCs transplantation|Autologous Bronchial basal cells transplantation
2841832|NCT03655795|Experimental|Bronchial basal cells|Autologous transplantation of bronchial basal cells
2841833|NCT03655782|Experimental|PATH neurotraining|Subject looks at computer screen to determine whether bars in fish-shaped window move left or right relative to background bars. The subject reports which way center pattern moves by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes contrast of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern more similar to that in fish, by increasing pattern's complexity level, and by increasing number of directions of movement from one to two directions of motion. Intervention will be trained for one training cycle, between 10-20 minutes, 3 times each week for 12 weeks.
2841834|NCT03655782|Active Comparator|To-Do List training|During Phase II, To-Do List training will be administered to half the subjects. In To-Do List Training, the TBI subject hears a set of instructions, then uses memory of those instructions to follow them in order. The instructions get longer and more complex over time for this task, making greater demands of the person's working memory systems. To-Do List training will be trained for 20 minutes, 3 times each week for 12 weeks.
2841835|NCT03655782|No Intervention|No Intervention during Phase I|During Phase I half the subjects will be wait-listed, determined randomly, to do no training in the first 12 weeks followed by 12 weeks of PATH training so each of these subjects serves as their own control.
2841836|NCT03655769|Sham Comparator|sham tDCS|tDCS delivered for only 30 sec to replicate tingling sensation and blind subject
2841837|NCT03655769|Experimental|cathodal tDCS|cathodal tDCS, 2 milliamps (mA), delivered to right parietal region
2841838|NCT03655743||Patients after refractive surgery|Patients have had any type of corneal or lens refractive surgery.
2841839|NCT03655743||Patients before refractive surgery|Patients will have any type of corneal or lens refractive surgery.
2841840|NCT03655730|Experimental|intervention arm|follow weekly psychotherapeutic individual sessions following the IPT method during one year.
2841841|NCT03655730|Experimental|usual care arm|continue with the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
2841842|NCT03655717|Experimental|Placebo Dronabinol + Ethanol|single dose of Placebo Dronabinol + Ethanol See protocol for dosing
2841843|NCT03655717|Experimental|Dronabinol + Placebo Ethanol|single dose of Dronabinol + Placebo Ethanol See protocol for dosing
2841844|NCT03655717|Experimental|Dronabinol + Ethanol|single dose of Dronabinol + Ethanol See protocol for dosing
2841845|NCT03655717|Placebo Comparator|Placebo Dronabinol + Placebo Ethanol|single dose of Placebo Dronabinol + Placebo Ethanol See protocol for dosing
2841846|NCT03655704|Experimental|Apabetalone|100mg BID for 16 weeks.
2841847|NCT03655691|Placebo Comparator|Vehicle|
2841848|NCT03655691|Experimental|Dose 1|
2841849|NCT03655691|Experimental|Dose 2|
2841850|NCT03655678|Experimental|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Subjects will receive a single infusion of CTX001 through a central venous catheter.
2841851|NCT03655665|Experimental|Treatment Ear|Participants will serve their own control. Participants will receive 3 drops of ofloxacin otic solution intra- and post-operatively 3 times per day for 3 days in ONE ear. Ear sidedness will be randomized by participant.
2841852|NCT03655665|No Intervention|No Intervention|Participants will serve their own control. Participants will receive no intervention in the ear contralateral to the treated ear. Ear sidedness will be randomized by participant.
2841853|NCT03655639||Premature Birth|Premature babies born under 29 weeks gestational age, admitted into the neonatal intensive care unit within 7 days of life.
2841854|NCT03655626|Experimental|Sepsis Watch on Duke University Hospital ED Adults|Patients older than 18 years old at time of presentation to Duke University Hospital emergency department.
2841917|NCT03655184||Healthy group|No headache or other special medical history
2842140|NCT03653689|Active Comparator|FODMAPs|Dietary supplement: FODMAPs 50 grams three servings per day for seven days.
2865293|NCT03492229|Active Comparator|AMT|
2841855|NCT03655613|Experimental|Arm A: Hepatocellular Carcinoma|PD-1 inhibitor (CBT-501) 3 mg/kg intravenously every 2 weeks + c-Met inhibitor (CBT-101) 300 mg or 400 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
2841856|NCT03655613|Experimental|Arm B: Renal Cell Carcinoma|PD-1 inhibitor (nivolumab) 3 mg/kg or 240 mg intravenously every 2 weeks + c-Met inhibitor (CBT-101) 300 mg or 400 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
2841857|NCT03655600|Active Comparator|Self-administered acupressure|Acupressure administered by participant self-taught from computer application
2841858|NCT03655600|No Intervention|Usual care|Usual care
2841859|NCT03655587|Experimental|Solid ankle foot orthotic|This is a leg brace that is made to fit the contour of the patient's foot, ankle, and lower leg. The two pull solid ankle AFO is fabricated from a rigid polypropylene outer boot and a more flexible silicone inner boot. It is commonly used in rehabilitation to improve gait in pediatric and adult populations. A certified orthotist fabricates the device. This device is lawfully marketed in the United States. It is not regulated by the FDA.
2841860|NCT03655587|Active Comparator|Resting night splint|An ankle resting night spring (RNS) is an off-the-shelf device that provides static sagittal plane dorsiflexion. The RNS is worn nocturnally to provide maximal stretch/length to the gastrocsoleus to maintain or increase dorsiflexion ROM and/or to prevent further regressions in ankle range. It is not regulated by the FDA.
2841861|NCT03655574|Experimental|Motivational + Family Check-up (MET+FCU)|"The MET individual session covers three constructs; 1) intentions to use marijuana; 2) normative beliefs about peer substance use; and 3) attitudes towards peer substance use. These same three constructs are also addressed with respect to truancy. In addition, motivation to abstain from substance use is discussed.~The FCU session with teens and parents/caregivers begins by collecting self-report measures and conducting a videotaped Family Assessment Task (FAsTask) to assess parent-teen interactions. The FAsTask is the basis of FCU feedback. There are four specific phases of the feedback session: 1) Self-assessment, 2) Support and clarification, 3) Feedback, and, 4) Action plan."
2841862|NCT03655574|Placebo Comparator|Psychoeducation|An interventionist will review a set of educational materials with the parents regarding teen marijuana use, effects of marijuana on the brain, body and behavior, risks associated with marijuana use, how to tell if a teen is engaging in marijuana use or truancy, and parenting skills. A comparable set of materials will be reviewed with the adolescent.
2841863|NCT03655561||Confirmed Lassa fever cases|Participants with a clinical presentation consistent with acute Lassa virus disease and a positive result for Lassa specific RT-PCR obtained before or after inclusion
2841864|NCT03655561||Non-Lassa cases (controls)|Participants with a clinical presentation consistent with acute Lassa virus disease but subsequently found to have a negative result for Lassa specific RT-PCR
2841865|NCT03655535|Experimental|BTI320|4 g BTI320 administered 10 min before breakfast, lunch, and dinner
2841866|NCT03655535|Placebo Comparator|Placebo|Placebo administered 10 min before breakfast, lunch, and dinner
2841867|NCT03655522|Active Comparator|NAVX-010|Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Doses were administered as IM injections into the deltoid muscle in the fasted state. The IMP was supplied in glass vials containing 1.2 mL solution at a total GTX 2 and GTX 3 concentration of 42 mcg/mL (at a relative epimer ratio of 62% GTX 2:38% GTX 3).
2841868|NCT03655522|Placebo Comparator|Placebo|Placebo was of identical appearance to the IMP, and was administered into the deltoid muscle in the fasted state.
2841869|NCT03655509|Other|ACTH stimulation test|
2841870|NCT03655496|No Intervention|Control group|Subject to standard care.
2841871|NCT03655496|Experimental|Intervention group|Exposed to the home-based tool.
2841872|NCT03655483|Experimental|GLS-010|GLS-010
2841873|NCT03655470|Experimental|Safety Planning|This brief intervention, consists of an in-person and follow-up phone call that are based on cognitive behavioral principles designed to help identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of nonsuicidal self-injury or suicidal behavior.
2841874|NCT03655470|Active Comparator|Standard Care|"If a teen has a positive screen for suicide risk, the Probation Officer completes a secondary screener built into the court screening instrument to determine whether there is concern of current and/or imminent risk. If a teen endorses nonsuicidal self-injury more than once in the prior year, then the Probation Officer asks about frequency and severity. If there is ongoing concern of risk for self-injurious behavior, then the Probation Officer arranges for a crisis evaluation in the Emergency Department. If the teen is not judged to be at imminent risk, the Probation Officer makes a referral back to the current treatment provider or to a community mental health clinic. In either case, the parents and youth receive a packet with mental health resources"
2841875|NCT03655457|Experimental|group 1 Poractant alfa|Poractant alfa generic name: curosurf 120 and 240 mg flk dosage: 200 mg/ kg intratracheal application frequency and duration: in the first two hours
2841876|NCT03655457|Active Comparator|group 2 beractant|beractant generic name: survanta 8 cc flk dosage: 4 cc/ kg intratracheal application frequency and duration: in the first two hours
2841877|NCT03655444|Experimental|Phase I: Abemaciclib + Nivolumab|-Abemaciclib will be administered orally twice per day (with or without food) on Days 1 through 28 of every 4-week cycle
2841878|NCT03655444|Experimental|Phase II: Abemaciclib + Nivolumab|-Patients will be treated with abemaciclib at the RP2D (Days 1 through 28) + nivolumab (480 mg, Day 1) of each 4-week cycle.
2841879|NCT03655431|Experimental|Telerehabilitation|Physical therapists will develop an individualized program lasting 12 weeks depending on the needs of a given patient. Veterans will be seen 1 day/week via clinical video teleconferencing (CVT) for treatment. The rehabilitation protocol will last approximately 30 minutes with activities that are individualized to meet the participant's needs (range of motion, balance, strengthening, endurance, and functional activities). Patients assigned to telerehabilitation will utilize the VITAL rehab unit with Jintronix exercise package. Exercises, progression and rest periods will be administered and adjusted remotely by the physical therapist using a web-based clinical portal.
2841918|NCT03655171||H&Y 0|"Age-matched non-disease population, or prodromal Parkinson's patients with no noticeable motor symptoms.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
2865294|NCT03492229|Sham Comparator|Control|
2841880|NCT03655431|Active Comparator|Standard treatment|Physical therapists will develop an individualized program lasting 12 weeks depending on the needs of a given patient. Veterans will be seen 1 day/week via in-person appointments for treatment. Appointments will last approximately 30 minutes with activities that are individualized to meet the participant's needs (range of motion, balance, strengthening, endurance, and functional activities). Patients assigned to the control arm will receive standard home exercise program handouts and complete an exercise log to monitor exercise frequency. Exercises and progression will be administered and adjusted during in-person appointments.
2841881|NCT03655418|Experimental|Intervention|The prevention program RECUR will be administered.
2841882|NCT03655418|No Intervention|Waitlist control|The prevention program RECUR will be administered after a year of waiting.
2841883|NCT03655405|Experimental|Intervention|Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).
2841884|NCT03655405|No Intervention|Control|Participants allocated to the control group will receive usual care.
2841885|NCT03655392|Experimental|Intervention Group|64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to a individualized educational program: three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 mensal intervals. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, exhaled breath condensate air measurement, and answered the questionnaires ACT, ACQ, AQLQ, BDI: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI). All participants also answered a symptoms diary about asthma symptoms and peak flow measure.
2841886|NCT03655392|Experimental|Control Group|64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 mensal intervals. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, exhaled breath condensate air measurement, and answered the questionnaires: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI). All participants also answered a symptoms diary about asthma symptoms and peak flow measure.
2841887|NCT03655379|Experimental|Nasal Doppler|Pregnant patients who present with preterm labor will be evaluated with ultrasonography and fetal nasal Doppler will be used to detect specific fetal breathing patterns
2841888|NCT03655366||Dog owners with epilepsy|Epilepsy patients that own one or more dogs.
2841889|NCT03655366||Training organisations|Trainers of seizure response and seizure alerting dogs.
2841890|NCT03655353|Experimental|ABY-PET|68Ga-ABY-025 is used as tracer for PET scan
2841891|NCT03655340||Prophylactic patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
2841892|NCT03655340||On demand patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for on-demand treatment
2841893|NCT03655327||stroke patients|stroke patients with upper limb paresis
2841894|NCT03655327||healthy control group|healthy participants with no motor disability of the upper limb
2841895|NCT03655314|Active Comparator|Newborn Weight Tool (NEWT)|The electronic medical record will display the Newborn Weight Tool along with a banner flagging newborn weight loss greater than or equal to the 75th centile of birth weight
2841896|NCT03655314|Placebo Comparator|Usual care|As with usual care, the electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight
2841897|NCT03655301|Experimental|Copanlisib (Aliqopa, BAY80-6946)|All subjects will receive a single dose of metformin 1000 mg on Days 1 and 8 in a fasting state. Subjects will also receive a single i.v. dose of 60 mg copanlisib on Day 8 as part of the combination with metformin.
2841898|NCT03655275|Active Comparator|Group(A): PRP|PRP prolotherapy injections with 2.5ml of PRP at an interval of 2 weeks. Intraticular and pericapsular
2841899|NCT03655275|Active Comparator|Group (B): saline|Saline prolotherapy injections with 2.5ml of saline at an interval of 2 weeks.intrarticular and pericapsular
2841900|NCT03655262|Experimental|1 Session|1 neuro-reinforcement session
2841901|NCT03655262|Experimental|3 Sessions|3 neuro-reinforcement sessions
2841902|NCT03655262|Experimental|5 sessions|5 neuro-reinforcement sessions
2841903|NCT03655249|Experimental|Asl + CPT|Aerosotherapy + Autogenic drainage
2841904|NCT03655249|Active Comparator|Asl|Aerosoltherapy alone
2841905|NCT03655236|Experimental|K0706, low dose|
2841906|NCT03655236|Experimental|K0706, high dose|
2841907|NCT03655236|Placebo Comparator|Placebo, placebo capsules|
2841908|NCT03655223||Newborn infants born in North Carolina|All newborn infants in North Carolina will have the opportunity to participate in Early Check. Those who screen positive for the conditions identified in the study will be subject to confirmatory testing.
2841909|NCT03655223||Birthing Mothers in North Carolina|All birthing mothers in North Carolina will have the opportunity to participate in Early Check.
2841910|NCT03655210|Experimental|Experimental|HL151(1Tab,Bepostatine salicylate) once a day, 4 weeks of treatment
2841911|NCT03655210|Placebo Comparator|Placebo Comparator|HL151 Placebo (1Tab,Placebo of Bepostatine salicylate) once a day, 4 weeks of treatment
2841912|NCT03655197|No Intervention|Healthy Subjects|Healthy subjects will receive no intervention and will have samples collected only at one visit after Dove soap washout.
2841913|NCT03655197|Experimental|Ocular Rosacea Subjects|Ocular rosacea subjects will receive mandatory Doxycycline intervention and will have samples collected at two visits, before starting intervention and at the completion of the intervention.
2841914|NCT03655197|Other|Cutaneous Rosacea Subjects|Doxycycline intervention is optional for cutaneous rosacea subjects. If they do not participate, samples will only be collected at one visit after Dove soap washout. If they do decide to participate, samples will also be collected after completion of the Doxcycline intervention.
2841915|NCT03655184||MOH group|Patients with medication overuse headache
2841916|NCT03655184||Episodic migraine group|Patients with episodic migraine
2841919|NCT03655171||H&Y 1|"Hoehn and Yahr disability stage was 1: Unilateral involvement only usually with minimal or no functional disability.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
2841920|NCT03655171||H&Y 2|"Hoehn and Yahr disability stage was 2: Bilateral or midline involvement without impairment of balance.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
2841921|NCT03655171||H&Y 3|"Hoehn and Yahr disability stage was 3: Bilateral disease: mild to moderate disability with impaired postural reflexes; physically independent.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
2841922|NCT03655171||H&Y 4|"Hoehn and Yahr disability stage was 4: Severely disabling disease; still able to walk or stand unassisted.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
2841923|NCT03655158|Experimental|ozone group|After gingivectomy and gingivoplasty, right quadrants of the surgical areas were assigned to receive ozone therapy in all patients
2841924|NCT03655158|No Intervention|non-ozone group|placebo application, left quadrants received regular air from the ozone generator.
2841925|NCT03655145|Experimental|Haploidentical donor stem cell transplantation|The stem cell source will be bone marrow for haploidentical transplantation.The bone marrow collection is carried out according to the practice of each centre with a minimal target dose of 3x108 TNC/kg.
2841926|NCT03655145|Active Comparator|HLA 10/10 MUD stem cell transplantation|The stem cell source will be peripheral blood stem cell for HLA-matched unrelated transplantation.Peripheral blood stem cell (PBSC) for HLA-matched unrelated SCT will be mobilized by G-CSF (Neupogen®) administered to the donor from Day-4 to Day-1 subcutaneously (10µg/kg/day) with the minimal target dose of 4.106 CD34+ cells/kg.
2841927|NCT03655132|No Intervention|Waitlist Control Group|Veterans in the waitlist control will be provided with a list of common pain resources at the Bedford VAMC.
2841928|NCT03655132|Experimental|VACT-CP Group|Veterans randomized to VACT-CP will receive 8 online-module based weekly sessions of treatment via personal computer or provided tablet with wireless accessibility at the Bedford VAMC.
2841929|NCT03655119|No Intervention|Baseline|Youth and parents will complete surveys at index PES visit regarding suicide related risk and protective factors. Parents and youth will complete a follow-up survey at 3 days (parents only) and 2 weeks (parents and youth) post discharge. At 3 days and 2 weeks, parents will complete a survey that evaluates adherence to safety recommendations. The 2-week follow-up survey for parents will also re-assess self-efficacy, parental distress, and mental health treatment stigma. The 2-week follow-up survey for youth assesses mood and suicidal thoughts, perceptions of parent support post discharge, and outpatient treatment. It reassesses suicidal risk, depression, connectedness, and alcohol use.
2841930|NCT03655119|Experimental|Phase I|Families will complete baseline measures, and receive enhanced usual care from PES clinical staff during their visit as well as a parent toolkit that reinforces evidence-based practices for crisis management such as safety planning and means restriction and encourages parents to increase their support, supervision, and monitoring of their at risk youth. The same follow-up methodology as in Baseline will be utilized.
2841931|NCT03655119|Experimental|Phase II|Families will complete baseline measures and receive Phase I interventions (enhanced care and parent toolkit). Parents will receive caring contacts post discharge, which may occur by phone, text, or email. Caring follow-up messages will provide support, additional education, and problem solving assistance. The same follow-up methodology as in Baseline will be utilized.
2841932|NCT03655106|Active Comparator|Standard Long IV 4.78 cm 20 g catheter|Placement of Standard Long IV 4.78 cm 20 g catheter
2841933|NCT03655106|Experimental|Ultra-Long IV 6.35 cm 20 g catheter|Placement of Ultra-Long length IV 6.35 cm 20 g catheter
2841934|NCT03655093||Patients with multiple sclerosis|Patients with MS according to the diagnostic criteria of 2010 Validation of AMSQ questionnaire
2841935|NCT03655080|Experimental|nab-Paclitaxel and Radiation Therapy|"10 fractions of 3Gy radiation therapy will be delivered.~A total of 4 chemoradiation blocks should be delivered ideally in consecutive days~On day 1 of the chemoradiation block, nab-paclitaxel is delivered in the morning followed by radiotherapy the latest possible and ideally at least 6 hours later (no earlier than 4 hours after the start of nab-paclitaxel)~On day 2, radiotherapy is delivered in the morning, ideally within 24 hours from the start of nab-Paclitaxel infusion the previous day~There will be 2 radiation fractions that won't be part of any chemoradiation block and can be placed anywhere before, after, or between blocks"
2841936|NCT03655067|Experimental|Intervention|The participants in the Intervention group will receive the CATCH-IT program which consists of a motivational component and the internet program for the adolescent. The participants in the Intervention group will receive motivational interviewing at their baseline visit as well as motivational coaching with safety phone calls during weeks 1-6.
2841937|NCT03655067|No Intervention|Usual Care|Participants in the Usual Care group may undergo an evaluation with the Social Worker if the clinician determines that it is necessary. The participants in the Usual Care group will also receive motivational coaching with safety phone calls during weeks 1-6.
2841938|NCT03655041|Experimental|Beta-Alanine|6.4 g/day of beta-alanine for 24 weeks
2841939|NCT03655041|Placebo Comparator|Placebo|6.4 g/day of maltodextrin for 24 weeks
2841940|NCT03655028|Experimental|RAS-music group|Home-based, exercise program augmented with rhythmically auditory stimulation enhanced music
2841941|NCT03655028|Active Comparator|Control group|Home-based, exercise program without rhythmically auditory stimulation enhanced music
2841942|NCT03655002|Experimental|Treatment (nivolumab, cyclophosphamide, IRX-2)|Participants receive nivolumab IV over 30 minutes on day 1, cyclophosphamide IV on day 1, and IRX-2 SC for 10 days between days 4 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants receive booster IRX-2 SC at 3, 6, 9, 12, and 15 months.
2841976|NCT03654742|Active Comparator|ECTE/Electrocautery|Extracapsular tonsillectomy (ECTE) with monopolar electrocautery
2841977|NCT03654742|Active Comparator|ICTE/Microdebrider|Intracapsular tonsillectomy (ICTE) with microdebrider
2841978|NCT03654742|Active Comparator|ICTE/Coblator|Intrapasular tonsillectomy (ICTE) with coblator
2843266|NCT03646019||Normal coronary arteries|
2841943|NCT03654989|Experimental|Treprostinil iontophoresis|"Gel of treprostinil 1 mg/mL (target concentration)~Part 1: 1 administration/day, on separate days, with 72h between two doses. Ascending doses are 0.025 mg/mL, 0.05mg/mL, 0.1 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 0.7 mg/mL, and 1 mg/mL. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².~Part 2: 1 administration/day at the maximum tolerated dose (MTD) for 10 days; dressing will be changed by a trained nurse every 2 days. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm²."
2841944|NCT03654989|Placebo Comparator|Remodulin® Placebo iontophoresis|Placebo will be made from the placebo of Remodulin® incorporated into hydrogel (Suprasorb® G). The route and frequency of administration will be the same as for the investigational drug (topical administration by iontophoresis).
2841945|NCT03654989|No Intervention|Standard care|subjects randomized to the standard of care group (no iontophoresis) will only undergo standard blood test at visit 0 or 1, unless tests <1 month before inclusion are available This group is not double blind Standard care consists on debridement and dressings
2841946|NCT03654976|Experimental|Active treatment|Subject's ICS or ICS/LABA background medication plus HDM SLIT-tablet
2841947|NCT03654976|Placebo Comparator|Placebo|Subject's ICS or ICS/LABA background medication plus placebo oral tablet
2841948|NCT03654963|No Intervention|Control|Patients of the control group will not receive the best possible medication history with medication reconciliation at admission. The standard physician-acquired medication history will be performed as usual.
2841949|NCT03654963|Experimental|Medication reconciliation|The pharmacy assistant will obtain the best possible medication history by compiling a comprehensive list of the medications the patient is taking. To confirm the accuracy of the history, the pharmacy assistant will use at least two sources of information, one of which being, when possible, the interview with the patient and/or family members. The clinical pharmacist will reconcile the best possible medication history with prescribed medicines and, to resolve unclear or ambiguous discrepancies between the two lists and/or to propose any adaptations of the pharmacotherapy, the clinical pharmacist will refer to the medical doctor. The medical doctor will decide potential changes in pharmacotherapy and communicate them to the patient.
2841950|NCT03654937|Active Comparator|2h|The participants were asked to report for their vaccination immediately after an intensive bout of training (not later than two hours after). The influenza vaccine was administered via intra-muscular injection into the deltoid muscle of the non-dominant arm in a standardized manner.
2841951|NCT03654937|Active Comparator|26h|The athletes of the second group were vaccinated after an entire day (between 24 and 26 hours) after their last training session.The vaccine was administered via intra-muscular injection into the deltoid muscle of the non-dominant arm in a standardized manner.
2841952|NCT03654924|Experimental|Laryngeal Mask|A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
2841953|NCT03654911||aMCI subjects|EEG recording, ApoE testing
2841954|NCT03654898|Active Comparator|VITAL Start|VITAL Start: Video-based pre-ART counseling
2841955|NCT03654898|Placebo Comparator|Standard of Care|pre-ART education as conducted via routine facility methods
2841956|NCT03654885||XEN group|Subjects will undergo at least one preoperative visit (and more as needed), and then be scheduled for XEN implantation
2841957|NCT03654885||Trabeculectomy|Subjects will undergo at least one preoperative visit (and more as needed), and then be scheduled for trabeculectomy.
2841958|NCT03654846|No Intervention|Conventional emergency call|"Emergency call with conventinal cell phone:~verbal description of location~telephone-assisted CPR"
2841959|NCT03654846|Experimental|EmergencyEye emergency call|"Emergency call with EmergencyEye App on cell phone:~automated geolocalisation~video-assisted CPR"
2841960|NCT03654833|Experimental|MiST1 Rucaparib|BRCA1/BAP1 negative mesothelioma; 600mg twice daily (BID) every 28 days.
2841961|NCT03654833|Experimental|MiST2 Abemaciclib|p16INK4A negative mesothelioma; 200mg orally twice daily every 28 days.
2841962|NCT03654833|Experimental|MiST3 Pembrolizumab & Bemcentinib|"No specific biomarker requirement: Pembrolizumab 200mg IV infusion on Day 1 only:~Bemcentinib loading dose of 400mg on days 1-3, on day 4 on-wards 200mg daily every 21-days."
2841963|NCT03654833|Experimental|MiST4 Atezolizumab & Bevacizumab|PDL1 expression positive mesothelioma: Atezolizumab 1200 milligrams via intravenous nfusion; Bevacizumab 15 milligrams per kilogram via IV infusion both on Days 1 every 21-days.
2841964|NCT03654820|Experimental|PVP-I solution combined with NaF varnish|4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish
2841965|NCT03654820|Active Comparator|SDF treated|Annual application of 38% SDF solution
2841966|NCT03654807|Experimental|High Intensity Walking|HIW (70-80% HRmax)
2841967|NCT03654807|Experimental|Casual Speed Walking|Self selected pace
2841968|NCT03654794||Patients with hemochromatosis|"The study is conducted with mononuclear cells obtained from patients undergoing phlebotomy as part of a hemochromatosis treatment.~The blood samples will be recovered immediately after their completion. 40 mL of blood will be collected and the mononuclear cells separated using a ficoll gradient.~Cell pharmacokinetics of tacrolimus"
2841969|NCT03654781|Active Comparator|Triple therapy|Conventional triple antibiotic treatment would be applied to all patients (consisted of a 10-day course of Lansoprazole (a proton pump inhibitor) combined with amoxicillin ( 2 × 1 g daily) and clarithromycin (2 × 500 mg daily).
2841970|NCT03654781|Experimental|Combined treatment|"Periodontal treatment would be administered in addition to triple therapy consisted of a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).~Periodontal treatment consisted of supra and sub gingival scaling and root planing, oral hygiene instruction"
2841971|NCT03654768|Active Comparator|Arm I (dasatinib, nilotinib)|Patients receive dasatinib PO daily or nilotinib PO BID on days 1-90. Treatment repeats every 90 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2841972|NCT03654768|Experimental|Arm II (ruxolitinib phosphate, dasatinib, nilotinib)|Patients receive ruxolitinib phosphate PO BID on days 1-90 and dasatinib PO daily or nilotinib PO BID on days 1-90. Treatment repeats every 90 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2841973|NCT03654755|Experimental|ASN002 40 mg|ASN002 40 mg
2841974|NCT03654755|Experimental|ASN002 60 mg|ASN002 60 mg
2841975|NCT03654755|Experimental|ASN002 80 mg|ASN002 80 mg
2871191|NCT03451292|Active Comparator|SMT|
2841979|NCT03654729|Experimental|PledOx (2 µmol/kg)|Calmangafodipir (2 µmol/kg) on day 1 every two weeks to patients as an intravenous infusion, combined with mFOLFOX6 chemotherapy.
2841980|NCT03654729|Experimental|PledOx (5 µmol/kg)|Calmangafodipir (5 µmol/kg) on day 1 every two weeks to patients as an intravenous infusion, combined with mFOLFOX6 chemotherapy.
2841981|NCT03654729|Placebo Comparator|Placebo|Placebo will be given to patients as an intravenous infusion, on top of mFOLFOX6 chemotherapy.
2841982|NCT03654716|Experimental|ALRN-6924 -- Cohort A|"Participants will receive ALRN-6924 monotherapy on days 1, 8 (± 1 day), and 15 (± 1 day) of a 28-day cycle.~ALRN-6924 will be administered intravenously.~Participants with otherwise unselected TP53 wild type solid tumors and lymphoma will participate in this cohort."
2841983|NCT03654716|Experimental|ALRN-6924 -- Cohort B|"Participants will receive ALRN-6924 monotherapy on days 1, 8 (± 1 day), and 15 (± 1 day) of a 28-day cycle.~ALRN-6924 will be administered intravenously.~Participants with solid and CNS tumors and lymphoma with specific diagnoses or molecular features will participate in this cohort."
2841984|NCT03654716|Experimental|ALRN-6924 -- Cohort C|"Patients will receive ALRN-6924 in combination with cytarabine on days 1, 8 (± 1 day), and 15 (± 1 day) of a 28-day cycle.~Cytarabine is administered intravenously.~ALRN-6924 will be administered intravenously.~Participants with TP53 wild type acute leukemia will participate in this cohort."
2841985|NCT03654703|Experimental|Cyclophophamide|Cyclophosphamide 50mg/kg/day on day+3，+4 after HSCT. Intervention: drugs:Cyclophosphamide.
2841986|NCT03654703|Experimental|Placebo|5% GLS（Placebo) 50ml/day on day+3，+4 after HSCT. Intervention: drugs: Placebo other name: placebo (for Cyclophosphamide) 5%Glugose in water 50ml or normal saline
2841987|NCT03654690|No Intervention|Control|Participants will receive SMS text message reminders to get tested for HIV in a clinic.
2841988|NCT03654690|Active Comparator|Standard Self-Testing|Participants will receive an HIV self-test kit in the mail with no standardized follow-up from counselors.
2841989|NCT03654690|Experimental|Enhanced Self-Testing|Participants will receive an HIV self-test kit and will be contacted via telephone for counseling within 24 hours of opening their test.
2841990|NCT03654677|Experimental|inactivated hepatitis A vaccine|Inactivated hepatitis A virus antigen 500U(Name of viral strain: TZ84)
2841991|NCT03654677|Active Comparator|Havrix Inj|1440 ELISA/mL_Adult Inj.(Name of Viral strain: HM175 Inj)
2841992|NCT03654664|Experimental|inactivated hepatitis A vaccine|A 0.5ml dose is administered twice in total at an interval of 6 months to healthy children aged 12-23 months.
2841993|NCT03654664|Active Comparator|Havrix Inj|A 0.5ml dose is administered twice in total at an interval of 6 months to healthy children aged 12-23 months.
2841994|NCT03654651|Experimental|Evening Peanut Consumption|Participants will consume one ounce per day (28 g) of peanuts as an evening snack (i.e., after dinner and before sleep).
2841995|NCT03654651|Active Comparator|Evening Snack|Participants will consume an isocaloric higher carbohydrate snack as an evening snack (i.e., after dinner and before sleep).
2841996|NCT03654638|Experimental|Arm I Soy Bread Intervention|Men who are scheduled to begin androgen deprivation therapy for prostate cancer will begin an intervention to consume 2 slices of soy bread daily for approximately 20 weeks. Blood, urine and toxicity data will be collected at regularly scheduled medical oncology visits.
2841997|NCT03654638|Active Comparator|Arm II Wheat Bread Intervention|Men who are scheduled to begin androgen deprivation therapy for prostate cancer will begin an intervention to consume 2 slices of wheat bread for approximately 20 weeks. Blood, urine and toxicity data will be collected at regularly scheduled medical oncology visits.
2841998|NCT03654625|Experimental|Standard Written Exposure|Four writing sessions at the laboratory
2841999|NCT03654625|Experimental|Enhanced Written Exposure|Four writing sessions at the laboratory
2842000|NCT03654625|Placebo Comparator|Control Condition|Four writing sessions at the laboratory
2842001|NCT03654612|Experimental|Apatinib+S-1|Patients with recurrent/metastatic head and neck malignancies received apatinib plus S-1 as second-line therapy.
2842002|NCT03654599|Experimental|Baseline and Digital Stories (DS)|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to DS arm. Eight Digital Stories Intervention (4 patient and 4 caregiver stories about hematopoietic stem cell transplantation (HCT) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
2842003|NCT03654599|Active Comparator|Baseline and Information Control (IC)|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to IC arm. Eight Information Control Intervention videos containing only information about post-HCT care (as opposed to story/narrative) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call.
2842004|NCT03654586|Active Comparator|Calorie label|"Calorie label (control) will display a Calories per Bottle label on all beverages, not just sugary drinks. This is modeled after the American Beverage Association's current Clear on Calories labels."
2842005|NCT03654586|Experimental|Text warning label|Text warning labels will display the following text on sugary beverages: WARNING: drinking beverages with added sugars contributes to obesity, diabetes, and tooth decay
2842006|NCT03654586|Experimental|Sugar graphic warning label|"Sugar graphic warning labels will display the same text as text warning labels along with graphics depicting the amount of sugar in the beverage"
2842007|NCT03654586|Experimental|Health graphic warning label|"Health graphic warning label will display the same text as text warning labels along with graphics depicting the potential negative health consequences of over-consuming sugary drinks."
2842008|NCT03654573|Experimental|STEMI patients|Adult subjects presenting with STEMI in the LAD undergoing PPCI
2842009|NCT03654560|Active Comparator|HemoStyp|Subjects with an appropriate target bleeding site will have Hemostyp applied in accordance to instructions for use.
2842010|NCT03654560|Active Comparator|Surgicel|Subjects with an appropriate target bleeding site will have Surgicel applied in accordance to instructions for use.
2842037|NCT03654326|Experimental|Gefapixant|Participants will receive a gefapixant tablet twice a day for 8 weeks. Naproxen sodium tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
2842141|NCT03653689|Active Comparator|Gluten|Dietary supplement: Gluten 17.3 grams three servings per day for seven days.
2842011|NCT03654547|Experimental|Dose Escalation|Eligible adult patients with advanced solid tumors will be enrolled into Dose Escalation cohorts and treated with TT-00420 at different dose cohorts. Starting dose will be 1 mg p.o., q.d. An ABLRM guided by the EWOC principle will evaluate the risk of under-dose or over-dose for the dose tested in each cohort and provide the recommendation dose for next cohort. Dose Escalation Teleconference will be held after the last evaluable patient complete Cycle 1 treatment in each dose cohort to evaluate DLT, determine MTD and/or DRDE.
2842012|NCT03654547|Experimental|Dose Expansion|"TNBC Cohort: TNBC Dose-Expansion cohort will be opened to enroll the patients with advanced TNBC and evaluate the safety, PK and preliminary efficacy of TT-00420 and identify the optimal biological dose (OBD), when feasible, in patients with advanced TNBC.~SAT Cohort: A parallel basket SAT Dose Expansion Cohort will be open to enroll patients with SATs to evaluate the safety, PK and preliminary efficacy of TT-00420 and identify the optimal biological dose (OBD), when feasible, in patients with SATs."
2842013|NCT03654534|Experimental|oral nutritional supplements|NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
2842014|NCT03654534|No Intervention|standard diet|The control group was given no additional postoperative nutritional supplementation (standard diet).
2842015|NCT03654521|Active Comparator|Diabetes group|Women with gestational or pre-gestational diabetes mellitus.
2842016|NCT03654521|Active Comparator|Control group|Women without gestational or pre-gestational diabetes mellitus.
2842017|NCT03654508|Active Comparator|ADRB2-genotype guided treatment arm|In the genotype-stratified arm, children will be treated based on their ADRB2 genotype. Children homozygous for the risk variant Arg16 and heterozygotes (Arg16Gly) will be treated with doubling dosages of their ICS. Children homozygous for the wild type allele (Gly16Gly) will receive LABA.
2842018|NCT03654508|Active Comparator|Control arm|In the control arm, genotyping will be performed for retrospective analysis, but the genotype information will not be used to guide treatment. Children in this study arm will proceed randomisation between doubling ICS dosage (n=75) or LABA treatment (n=75), the two most commonly preferred add-on options among paediatric pulmonologists in the Netherlands. The investigators choose to randomize between both treatments options, since international guidelines do not agree on the preferred treatment option.
2842019|NCT03654495|Experimental|Exergame Training|"Routine (standard) therapy is given based on conventional current-best-evidence Rehabilitation.~In addition training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016. The Dividat Senso (dividat, Schindellegi, Switzerland) is designed to train different aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training."
2842020|NCT03654495|Active Comparator|Usual Care Training|Routine (standard) therapy is given this group as the intervention. Preoperative Phase: Diminish inflammation, swelling, and pain; Restore normal range of motion (especially knee extension); Restore voluntary muscle activation Immediate Postoperative Phase (Day 1-7): Restore full passive knee extension; Diminish joint swelling and pain; Restore independent ambulation Early Rehabilitation Phase (Week 2-4): Maintain full passive knee extension; Gradually increase knee flexion; Muscle training Controlled Ambulation Phase (Week 4-10): Restore full knee ROM; Improve lower extremity strength; Enhance proprioception, balance, and neuromuscular control Advanced Activity Phase (Week 10-16): Normalize lower extremity strength; Enhance muscular power and endurance; Improve neuromuscular control; Perform selected sport-specific drills
2842021|NCT03654482|Experimental|SuperSeton arm|
2842022|NCT03654456||Sepsis patients with OSA|Sepsis patients who received a prior polysomnography showing an apnea-hypopnea index at least 5/hr with compatible symptoms
2842023|NCT03654456||Sepsis patients without OSA|Sepsis patients who received a prior polysomnography showing an apnea-hypopnea index less than 5/hr
2842024|NCT03654443|Experimental|Group Painful stimulus|The CPOT tool is administered in a crossover manner in Group one prior to a painful stimulus (IT0), during the painful stimulus (IT1) and soon afterwards (IT2)
2842025|NCT03654443|Experimental|Group Non-painful stimulus|The CPOT tool is administered in a crossover manner in Group one prior to a non-painful stimulus (IIT0), during the painful stimulus (IIT1) and soon afterwards (IIT2)
2842026|NCT03654430|Other|Healthy Newborns|
2842027|NCT03654417|Active Comparator|EMLA|
2842028|NCT03654417|Active Comparator|Lidocaine|
2842029|NCT03654404|Experimental|Positive Psychology|"Participants will receive check-in/psychosocial support phone calls at weeks four, eight and twelve following enrollment.~At approximately 100-days post-HSCT, participants will begin an 8-week positive-psychology program involving weekly calls with an interventionist, in this case the principal investigator, and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).~Participants will complete self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
2842030|NCT03654391|Active Comparator|InnoSlim|Subjects ingested 2 capsules InnoSlim® (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.
2842031|NCT03654391|Placebo Comparator|Placebo|Subjects ingested 2 capsules placebo (Control group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.
2842032|NCT03654365|Active Comparator|Control|Pts in the control arm receive usual care. Usual care includes a EHR based reminder of single HCV testing for patients who are in the birth cohort. (routine alerting)
2842033|NCT03654365|Experimental|Intervention|Pts in the intervention arm receive bulk messaging and bulk ordering of the HCV ab test.
2842034|NCT03654352||High Risk for ARDS/ALI|Mechanically ventilated patients with risk factors for the development of ARDS/ALI. These factors are classified into two categories: pulmonary insults, such as pneumonia and extrapulmonary insults such as sepsis.
2842035|NCT03654352||Low Risk for ARDS/ALI|Mechanically ventilated patients with low risk factors for the development of ARDS/ALI. These factors include mechanical ventilation for airway protection, pain management, or procedure.
2842036|NCT03654339|Experimental|experimental group|"Group A-15 patients were allocated to the microsurgical group for root coverage. following scaling and root planning, the laterally repositioned flap was done using the microsurgical approach~Group B-15 Patients were allocated to the conventional group for root coverage following scaling and root planning, the laterally repositioned flap was done using the macrosurgical approach"
2842038|NCT03654326|Placebo Comparator|Placebo|Participants will receive a placebo matching gefapixant tablet twice a day for 8 weeks. Naproxen sodium tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
2842039|NCT03654313|Experimental|Part A MEDI6570 Cohort 1|Part A MEDI6570 Cohort 1 dose level
2842040|NCT03654313|Experimental|Part A MEDI6570 Cohort 2|Part A MEDI6570 Cohort 2 dose level
2842041|NCT03654313|Experimental|Part A MEDI6570 Cohort 3|Part A MEDI6570 Cohort 3 dose level
2842042|NCT03654313|Experimental|Part A MEDI6570 Cohort 4|Part A MEDI6570 Cohort 4 dose level
2842043|NCT03654313|Placebo Comparator|Part A Placebo|Part A Placebo
2842044|NCT03654313|Experimental|Part B MEDI6570 Cohort 1|Part B MEDI6570 Cohort 1 dose level
2842045|NCT03654313|Experimental|Part B MEDI6570 Cohort 2|Part B MEDI6570 Cohort 2 dose level
2842046|NCT03654313|Experimental|Part B MEDI6570 Cohort 3|Part B MEDI6570 Cohort 3 dose level
2842047|NCT03654313|Placebo Comparator|Part B Placebo|Part B Placebo
2842048|NCT03654287||Treatment with CPFA|The critically ill children who treated by CRRT and CRRT mode is decide as CPFA.
2842049|NCT03654287||Treatment with TPE+CVVHDF|The critically ill children who treated by CRRT and CRRT mode is decide as TPE+CVVHDF.
2842050|NCT03654287||Treatment with CVVHDF|The critically ill children who treated by CRRT and CRRT mode is decide as CVVHDF.
2842051|NCT03654287||Treatment without CRRT/ECMO|The critically ill children who are not treated by CRRT or ECMO.
2842052|NCT03654287||Treatment with ECMO|The critically ill children who are treated by ECMO whether treated by CRRT
2842053|NCT03654274|Experimental|Relugolix plus estradiol/norethindrone acetate|Relugolix 40 mg co-administered with estradiol (1.0 mg) and norethindrone acetate (0.5 mg) for up to 28 weeks.
2842054|NCT03654261|Experimental|1-Day CBT Workshop - Immediate|Women assigned to the immediate workshop group will participate in the first of two workshops (9 weeks apart).
2842055|NCT03654261|Experimental|1-Day CBT Workshop - Waitlist|Women assigned to the waitlist will participate in the second of two workshops (12 weeks apart).
2842056|NCT03654248|Experimental|Let's Get Organized group intervention|Group intervention with 10 weekly sessions, each lasting 1,5 hours
2842057|NCT03654248|Active Comparator|Individual Occupational Therapy|Individual intervention lasting 10 weeks
2842058|NCT03654235|Experimental|PNE and PE program|Pain neuroscience education (Health education) and Physical exercise program.
2842059|NCT03654235|Active Comparator|Usual care in Primary Care Physiotherapy|Usual care in Primary Care Physiotherapy Units
2842060|NCT03654222||Cardiac surgery|Direct procedures in heart
2842061|NCT03654222||Organ preservation|Mainly renal autograft
2842062|NCT03654222||Bypass|Revascularization of affected organs or segments with Woven Dacron graft
2842063|NCT03654222||Exclusion|Resection of an affected organ (nephrectomy)
2842064|NCT03654222||Replacement|Replacement of affected aortic segment with a Woven Dacron graft
2842065|NCT03654222||Other|Any surgery that does not include the previous ones
2842066|NCT03654209|Experimental|Argon Plasma Coagulation|Following polyp removal using standard of care methods, Argon Plasma Coagulation (APC) will be applied to the perimeter of the resection site before any clips are added.
2842067|NCT03654209|Experimental|Snare Tip Soft Coagulation|Following polyp removal using standard of care methods, Snare Tip Soft Coagulation (STSC) will be applied to the perimeter of the resection site before any clips are added.
2842068|NCT03654209|No Intervention|No treatment|Following polyp removal using standard of care methods, neither APC nor STSC will be applied to the perimeter of the resection site. Clips may be added at the discretion of the PI.
2842069|NCT03654196|Experimental|HL301(Experimental)|Total 7 days of treatment and The daily dose is as follows [Morning: HL301 1Tab + Placebo of Umkamin 1Tab] [Noon: Placebo of Umkamin 1Tab] [Evening: HL301 1Tab + Placebo of Umkamin 1Tab]
2842070|NCT03654196|Active Comparator|Umkamin(Active Comparator)|Total 7 days of treatment and The daily dose is as follows [Morning: Placebo of HL301 1Tab + Umkamin 1Tab] [Noon: Umkamin 1Tab] [Evening: Placebo of HL301 1Tab + Umkamin 1Tab]
2842071|NCT03654170|Experimental|All Subjects|BI 425809 mixed with [C14] BI 425809
2842072|NCT03654144|Experimental|Study group|women will receive dienogest
2842073|NCT03654144|Active Comparator|control group|women used combined oral contraceptive pills
2842074|NCT03654131|Active Comparator|MWA|Percutaneous MWA guided with ultrasound. The patient is fully anesthetized during the treatment.
2842075|NCT03654131|Active Comparator|SBRT|3 fractions of 15 Gy (in total 45 Gy), 3 fractions per week. The dose is prescribed to the PTV encompassing 67% isodose. The SBRT plan is normalized such that the mean dose to the GTV is 100% = 67.5 Gy.
2842076|NCT03654118||ISIS cohort|"Patients operated between December 2007 and December 2008 for recurrent shoulder instability using the arthroscopic procedure (Arthroscopic Bankart) in the investigative centers and presenting at the time of indication for surgery an ISIS score ≤ 4 points~Phone follow-up"
2842077|NCT03654105|Experimental|Smoking cessation and Antinflammatory|Smoking cessation through the administration of Cytisine (in standard and prolonged administration) + reduction of inflammatory status through the administration of Acetylsalicylic acid, diet modification and physical activity increase + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
2842078|NCT03654105|Experimental|Smoking cessation|Smoking cessation through the administration of Cytisine (in standard and prolonged administration) + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
2842079|NCT03654105|Experimental|Antinflammatory|reduction of inflammatory status through the administration of Acetylsalicylic acid, diet modification and physical activity increase + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
2842080|NCT03654105|Other|Control Group|standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
2842081|NCT03654092|Experimental|Exercise intervention|Home-based, minimal equipment exercise training program.
2842142|NCT03653689|Placebo Comparator|Placebo|Dietary supplement: Placebo rice porrige three servings per day for seven days.
2898231|NCT03260920|Experimental|Low Dose|
2842082|NCT03654092|No Intervention|Control|Usual care (study participation does not have any impact on regular treatment decisions, including participation in other exercise training programs).
2842083|NCT03654079|Active Comparator|Simulation Arm|Subjects in this arm will participate in Interventions (In- Utero Simulation, Cesarean Section Simulation, and Pushing Simulation).
2842084|NCT03654079|No Intervention|Control Arm|Subjects in this arm will not participate in any simulations.
2842085|NCT03654066|Active Comparator|Botulinum toxin|A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation.
2842086|NCT03654066|Active Comparator|Botulinum toxin and dilation|A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation. Subjects will also undergo distal esophageal dilation using a 20mm through the scope balloon positioned across the LES.
2842087|NCT03654053|Experimental|Simvastatin|Simvastatin 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.
2842088|NCT03654053|Placebo Comparator|Placebo|Placebo 40mg PO once at bedtime for up to 24 months.
2842089|NCT03654040|Experimental|arTreg|"arTreg: alloantigen-reactive T regulatory cells~The investigational product is donor alloantigen-specific T regulatory cells (arTreg). Supportive regimen for receipt of arTregs includes everolimus, leukapheresis, cyclophosphamide, and mesna.~Note: Participants who receive at least the minimum Treg product (arTreg) dose of 30 to <100 x10^6 total cells will be included in intent-to-treat analysis."
2842090|NCT03654027|Experimental|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
2842091|NCT03654027|Active Comparator|Docetaxel|Docetaxel (75mg/m2 IV d1)
2842092|NCT03654014|Experimental|SofPulse active|SofPulse active group. Patients who will be treated with the SofPulse activated on their heads for up to seven days in intensive care or as long as they are in the unit The PEMF device is kept on throughout and provides a 15 min pulsed treatment every hour.
2842093|NCT03654014|Placebo Comparator|SofPulse inactive|SofPulse inactive. The SofPulse will be placed on the patient's head but not activated for as long as they are in intensive care.
2842094|NCT03654014|Sham Comparator|Normal pressure hydrocephalus|CSF and serum samples from 15 normal pressure hydrocephalus patients will be used to compare CSF and serum biomarker levels in the 30 TBI patients.
2842095|NCT03654001|Experimental|Albumin + Balanced|"Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.~Balanced crystalloid solutions~According to the preference and the standard use of the participating center:~Ringer Lactate~Ringer Acetate~Crystalsol"
2842096|NCT03654001|Experimental|Albumin + Saline|"Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.~Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl)."
2842097|NCT03654001|Experimental|Balanced|Balanced crystalloid solutions (Ringer Lactate, Ringer Acetate, Crystalsol)
2842098|NCT03654001|No Intervention|Saline|Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl).
2842099|NCT03653988|Active Comparator|PEC I/II block - pre-operative|The current standard of care at the University of Iowa is to receive a pectoralis nerve block (PEC I/II) prior to surgery for mastectomy and reconstruction case. The intervention administered to Group I will having the block performed by the anesthesiologist after induction of general anesthesia and prior to surgical incision.
2842100|NCT03653988|Experimental|PEC I/II block - intra-operative|The current standard of care at the University of Iowa is to receive a pectoralis nerve block (PEC I/II) prior to surgery for mastectomy and reconstruction cases. Group II will have the block administered by the surgeon after mastectomy is performed and before reconstruction.
2842101|NCT03653975||Nodding syndrome|"I) probable Case of Nodding Syndrom (according to the WHO epidemiologic surveillance case definition) *reported head nodding ** in a previously healthy person with at least 2 major and 1 minor criteria~Major criteria~Age 3 to 18 y at onset of head nodding~Nodding frequency 5 to 20 times per min~Minor criteria~Other neurologic abnormalities~Clustering in space or time with similar cases~Triggering by eating or cold weather~Delayed sexual or physical development~Psychiatric manifestations~As agreed upon at the first International Conference on Nodding Syndrome, Kampala, Uganda, July 2012 (16). ** Repetitive involuntary drops of the head toward the chest on >2 occasions."
2842102|NCT03653975||epilepsy and onchocerciasis|"II) People with epilepsy (PWE) and onchocerciasis (n= 50)~confirmed or suspected generalized and idiopathic epilepsy~confirmed active infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
2842103|NCT03653975||epilepsy, no onchocerciasis|"III) People with epilepsy (PWE) without onchocerciasis (n= 50)~confirmed or suspected generalized and idiopathic epilepsy~excluded active or past infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
2842104|NCT03653975||no epilepsy but onchocerciasis|"IV) Controls with onchocerciasis, otherwise healthy (n= 50)~no evidence for epilepsy or other neurological diseases~confirmed active infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
2842134|NCT03653754||neurodisabilities|Intervention: Measurement of growth and body composition. Growth (height, body weight), and body composition was measured at school.
2842243|NCT03653130|No Intervention|Retrospective Chart Review|Retrospective chart reviews case-matched to intervention participants for age and biological sex factors.
2842105|NCT03653975||no epilepsy, no onchocerciasis|"V) Healthy Controls without onchocerciasis (n= 50)~no evidence for epilepsy or other neurological diseases~excluded active or past infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
2842106|NCT03653975||controls for Wechsler Nonverbal (WNV)|"Healthy Controls for cognitive assessment only, (n= 750)~no evidence for epilepsy or other neurological diseases no detailled examination on O. volvulus performed~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
2842107|NCT03653962|Active Comparator|only informed consent|The first group was given verbal-written informed consent and a 15 question quiz about the informed consent content afterwards.
2842108|NCT03653962|Experimental|video assisted group|The second group got an additional information video presentation and then the same quiz.
2842109|NCT03653949|Experimental|Aerobic Exercise Group|The subjects will participate of an educational intervention and a high intensity interval aerobic exercise intervention.
2842110|NCT03653949|Active Comparator|Control Group|The subjects will participate of an educational intervention.
2842111|NCT03653923|Experimental|Waiting-List|
2842112|NCT03653923|Experimental|Treatment|
2842113|NCT03653923|No Intervention|Healthy Controls|Not randomized healthy control group for comparison to normal functioning
2842114|NCT03653910|Experimental|Airtraq|Patients received DLT intubation by Airtraq videolarygoscope
2842115|NCT03653910|Active Comparator|Macintosh|Patients received DLT intubation by Macintosh laryngoscope
2842116|NCT03653897|Experimental|ID-Capsules- Active|Subjects will ingest ID-Capsules containing the ingestible sensor which emits a signal from within the subject's stomach. This signal is detected by the wearable Reader, and the ingestion event is recorded.
2842117|NCT03653884||Pregnancy with fetal intra-abdominal umbilical vein.|All women with a pregnancy with a partially intra-abdominal umbilical vein aneurysm isolated or associated with other abnormalities découvert lors d'une ultrasonic monitoring.
2842118|NCT03653871|Experimental|Intervention|Performing arts instruction delivered 1 hour/week for 8 weeks.
2842119|NCT03653871|No Intervention|Wait List Control|Control group. Performing arts instruction delivered upon completion of control period.
2842120|NCT03653858|Experimental|Group A: DBS onset in week 1|"Implantation of Vercise GEVIA deep brain stimulation (DBS) system. DBS onset in week 1.~2ND STAGE: After 6 months DBS ON, patients will be assessed whether they are responders or non-responders. In the subgroup of eligible responders, patients will be randomized to either DBS OFF* (for max. 3 months) or continued DBS for another 6 months. *DBS OFF until worsening of clinical depression, event (defined as > 5 points augmentation in MADRS in two consecutive visits) or for a maximum of 3 months. After DBS OFF, re-onset of DBS will be performed, followed by 6 months continuous DBS.~Non-responders will also receive another 6 months DBS therapy in the 2nd stage. At sites other than Freiburg/Bonn, the 2nd stage consists of 6 months DBS therapy only."
2842121|NCT03653858|Sham Comparator|Group B: DBS off, followed by DBS onset in week 17|"Implantation of Vercise GEVIA deep brain stimulation (DBS) system. 4 months OFF after implantation followed by DBS onset in first week of month 5.~2ND STAGE: See group A."
2842122|NCT03653845|Experimental|Intevention|Patients in this group will be treated with endovascular chemical ablation of adrenal glandp by endovascular injection of dehydrated alcohol. Sequenced antihypertensvie drugs with titrated dosage(amlodipine 5-10 mg/d ; terazosin 2-6mg/d) will be prescribed if home blood pressure (HBP) exceeds ≥160/100 mmHg.
2842123|NCT03653845|Active Comparator|Control|Patients in this group will be treated only with sequenced antihypertensvie drugs with titrated dosage(amlodipine 5mg/d→plus spironolactone 20 mg/d→plus spironolactone 40 mg/d→plus spironolactone 60 mg/d→→plus amlodipine 10 mg/ d →plus terazosin 2-6mg / d) if home blood pressure (HBP) exceeds ≥160/100 mmHg.
2842124|NCT03653832|Experimental|Dexmedetomidine Group|For dexmedetomidine, the regimen will follow the manufacturer's guidance and regimens used in previous trials. Dexmedetomidine will be up and down titrated against sedation targets set by clinical staff and reviewed at regular intervals, and documented at least daily. No loading dose will be administered. The starting dose will be 0.7µg.kg-1.hour-1 titrated to a maximum dose 1.4µg.kg-1 hour-1. Lower starting doses will be used at clinical discretion for patients with cardiovascular instability.
2842125|NCT03653832|Experimental|Clonidine Group|For clonidine, the regimen is designed to be equipotent with dexmedetomidine based on known pharmacokinetics and pharmacodynamics. The chosen regimen is similar to that currently used in many UK ICUs as part of routine 'off label' practice. Clonidine will be up and down titrated against sedation targets set by clinical staff and reviewed at regular intervals, and at least daily. No loading dose will be administered. The starting dose will be 1.0µg.kg-1.hour-1 titrated to a maximum dose of 2µg.kg-1.hour-1. Lower starting doses will be used at clinical discretion for patients with cardiovascular instability.
2842126|NCT03653832|Active Comparator|Usual Care (Propofol) Group|Usual Care Group : Patients will continue to receive intravenous propofol according to usual current care . The sedation targets, weaning, and sedation discontinuation procedures will follow the same clinical targets as for the clonidine and dexmedetomidine groups.
2842127|NCT03653819|Other|HIIT + compression|2 sessions of High Intensity Interval Training (HIIT) on a stationary bike. First exercise session with compression garments/second without.
2842128|NCT03653819|Other|HIIT - compression|2 sessions of High Intensity Interval Training (HIIT) on a stationary bike. First exercise session without compression garments/second with
2842129|NCT03653793|Experimental|LivRelief Varicose Veins Cream|"Intervention:~All subjects were provided with an adequate supply of the Natural Health Product LivRelief Varicose Veins cream for 6 weeks of at home use."
2842130|NCT03653780|Experimental|Ekso GT gait training|20-minute Ekso GT gait training
2842131|NCT03653767|No Intervention|Control Group|The control group will use conventional school furniture.
2842132|NCT03653767|Experimental|Adjustable Furniture Group|The experimental group will use adjustable ergonomic school furniture.
2842133|NCT03653754||typically developing|Intervention: Measurement of growth and body composition. Growth (height, body weight), and body composition was measured at school.
2842244|NCT03653117|Experimental|TPLA|TPLA procedure
2842135|NCT03653741|Experimental|Healthy males|healthy males will undergo EEG, VEP, BAER, and SEP testing, then take a single dose of Perampanel 6 MG pill (intervention), then have blood drawn and undergo the 4 tests mentioned previously for a second time
2842136|NCT03653728||Traumatic brain injury with cerebral contusions|
2842137|NCT03653715|Experimental|Test Device|Within this arm the Test Bifocal Contact Lens is administered.
2842138|NCT03653715|Active Comparator|Control Devices|Within this arm the Control Bifocal Contact Lens, Control Single Vision Contact Lens 1, and Control Single Vision Contact Lens 2 are administered.
2842139|NCT03653702|Experimental|Contrast Enhanced Ultrasound|Participants will undergo a contrast enhanced ultrasound (CEUS) using Lumason
2842143|NCT03653676||Subjects with SCA|Children and adolescents with SCA confirmed by hemoglobin analysis randomized to either moderate or vigorous intensity exercise test (CIIT)
2842144|NCT03653676||Controls without SCA|Children and adolescents without SCA or sickle cell trait randomized to either moderate or vigorous intensity exercise test (CIIT)
2842145|NCT03653663|Placebo Comparator|Placebo|8 weeks treatment with placebo (or until muscle symptoms appear for at least 1 week or are unbearable)
2842146|NCT03653663|Active Comparator|20 mg simvastatin|8 weeks treatment with 20 mg simvastatin daily (or until muscle symptoms appear for at least 1 week or are unbearable)
2842147|NCT03653650|Experimental|PRP plus BCL|Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
2842148|NCT03653650|Active Comparator|BCL plus PFL|Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
2842149|NCT03653650|Active Comparator|Eye patch plus ocular lubricant ointment|Eye patch plus ocular lubricant ointment every 24 hours.
2842150|NCT03653637|Experimental|Project Life Force|"A novel, 10-session intervention to enhance currently mandated VA suicide safety planning in a group setting to support its implementation. PLF is a manualized, weekly 90-minute group treatment lasting 10 weeks coinciding with the time frame for enhanced monitoring of Veterans identified as high-risk. Session content is described in Table 1 (see appendix A). Six of the PLF sessions correspond to a step of the safety plan and teach skills to maximize the use of that particular step of the plan. The use of emotion regulation skills in PLF differs from other DBT interventions in that it focuses primarily on emotion regulation, distraction and developing social support in the specific context of implementing a safety plan. Mindfulness is not covered. PLF is augmented with additional skill modules on physical health management, education pertaining to suicide risk, promoting positive emotion and suicide prevention mobile apps. PLF patients also receive usual care."
2842151|NCT03653637|Active Comparator|Treatment-As-Usual|The comparison condition will be an assessment-only treatment-as-usual (TAU). Research team will track number of individual mental health appointments, SPC outreach contacts, and usage patterns of safety plans. Veterans in both randomized conditions will be receiving the mandated monitoring, outreach, and involvement of SPC staff and clinical team management that constitutes standard VA care for suicidal individuals.
2842152|NCT03653611||Clinician Participants|Two Aim 2 practices are selected by each of their 5 affiliated PBRNs based upon willingness to participate and variability of primary care practice type within the PBRN. Differences in practice size, staffing, ownership, prior quality improvement engagement, geography, patient population socioeconomic status (SES) or languages spoken are among the among the selection criteria the PBRNs will utilize to choose.
2842153|NCT03653611||Patient Participants|200 patients, who are enrolled in Aim 1 (approximately 40 from each PBRN) will be invited to take a CAPTURE opinion survey
2842154|NCT03653598||AF patients|Patients with Atrial Fibrillation
2842155|NCT03653585||Lesion negative hemisphere in Healthy Controls (HC)|Data grouped as an un-lesioned primary sensorimotor cortical hemisphere in age and sex matched healthy voluntary participants
2842156|NCT03653585||Lesion negative hemisphere in patients (PT-N)|Data grouped as an un-lesioned primary sensorimotor cortical hemisphere in MS patients
2842157|NCT03653585||Lesion positive hemisphere in patients (PT-P)|"Lesion positive hemisphere in patients:~Data grouped as a lesioned primary sensorimotor cortical hemisphere in MS patients"
2842158|NCT03653572|Other|Eligible Subjects|All subjects will be enrolled into a single arm and will undergo an ultrasound exam, per the protocol.
2842159|NCT03653559|Experimental|"Home meals condition"|The recommendation consists of menus with examples of breakfast, lunch and dinner based on typical preparations plus a prescription of the number of portions of the food groups that provides 1200 kcal with a distribution of 50-60% carbohydrates, 15-20% protein and < 30% lipids.
2842160|NCT03653559|Active Comparator|"Healthy meals condition"|"The recommendation consists of the educative graphic tool Eatwell plate plus a prescription of the same number of portions of the food groups for a isocaloric diet with the same macronutrient distribution as the home meals condition."
2842161|NCT03653546|Experimental|AZD3759 Group|AZD3759 group will receive a 300 mg twice daily dose of AZD3759
2842162|NCT03653546|Active Comparator|Erlotinib or Gefitinib Group|SoC EGFR-TKI Erlotinib or Gefitinib Group will get EGFRTKI Erlotinib 150 mg or Gefitinib 250 mg PO Q.D
2842163|NCT03653533|Other|MiniMed™ 640G alone|MiniMed™ 640G (insulin pump) is used without Captor CGM Enlite® (captor) at phase 1 and phase 4 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
2842164|NCT03653533|Other|MiniMed™ 640G + Captor CGM Enlite®|insulin pump coupled with captor without SmartGuard® function tat phase 2 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
2842165|NCT03653533|Other|MiniMed™ 640G + Captor + SmartGuard®|insulin pump + captor + SmartGuard® function are used at phase 3 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
2842166|NCT03653520|Active Comparator|diazepam only (group 1)|Patients are given 5 or 10mg of diazepam for sedation before surgery for sedation
2842167|NCT03653520|Active Comparator|diazepam/tramadol/ondansetron (group 2)|Patients are given 5 or 10mg of diazepam, 50 or 100mg of tramadol and 4 or 8mg of ondansetron orally before surgery for sedation
2842168|NCT03653520|Experimental|MKO only (group 3)|Patients are given 1 or 2 MKO melts (each contain 3mg midazolam, 25mg ketamine, 2mg ondansetron) sublingually before surgery for sedation
2842199|NCT03653299|Experimental|Group A - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy A will receive the programs in the following order 1, 2, 3 and 4, before the tests."
2842169|NCT03653507|Experimental|Arm A (zolbetuximab plus CAPOX)|Participants will receive a loading dose of zolbetuximab at Cycle 1 Day 1 followed by a lower dose in subsequent cycles every 3 weeks. Additionally, participants will receive CAPOX (capecitabine/oxaliplatin) treatment until IRC confirmed disease progression or a total of 8 cycles (each cycle is defined as 3 weeks = 21 days). Oxaliplatin is administered on day 1 of each cycle, whereas capecitabine is taken twice daily on days 1 through 14. After 8 cycles of CAPOX, subjects may continue to receive capecitabine twice daily on days 1 through 14 of each cycle at the investigator's discretion until the subject meets study treatment discontinuation criteria.
2842170|NCT03653507|Placebo Comparator|Arm B (placebo plus CAPOX)|Participants will receive placebo starting at Cycle 1 Day 1 and every 3 weeks thereafter. Additionally, participants will receive CAPOX (capecitabine/oxaliplatin) treatment until IRC confirmed disease progression or a total of 8 cycles (each cycle is defined as 3 weeks = 21 days). Oxaliplatin is administered on day 1 of each cycle, whereas capecitabine is taken twice daily on days 1 through 14. After 8 cycles of CAPOX, subjects may continue to receive capecitabine twice daily on days 1 through 14 of each cycle at the investigator's discretion until the subject meets study treatment discontinuation criteria.
2842171|NCT03653494|Experimental|phrenic block group|non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia、Vagus block and Phrenic block
2842172|NCT03653494|Active Comparator|Control group|non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia and Vagus block
2842173|NCT03653481|Experimental|Inulin|Oligofructose-enriched Inulin (OI) administered for 8 weeks
2842174|NCT03653481|Placebo Comparator|Placebo|Maltodextrin placebo administered for 8 weeks
2842175|NCT03653468|No Intervention|Control group|No-exercise
2842176|NCT03653468|Experimental|Endurance training plus resistant training|Concurrent training
2842177|NCT03653455|Experimental|Pre-operative discussion group|At a pre-operative visit, patients and their care provider will discuss what assigned surveys are and why they are important. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
2842178|NCT03653455|Experimental|Pre- and post-operative discussion group|Patients will discuss with their care provider their health outcomes before and at 6-months after their surgery. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
2842179|NCT03653455|Experimental|Incentivised group|Patients will receive up to $30 in amazon gift cards as an incentive if they complete their forms before surgery, as well as at 6-months and 1-year after surgery. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
2842180|NCT03653455|Experimental|control group|Patients will only receive email reminders to complete their forms, if they haven't done so.
2842181|NCT03653429|Active Comparator|Tranexamic acid group|10mg/kg intravenous tranexamic
2842182|NCT03653429|Placebo Comparator|Normal Saline group|10mg/kg intravenous normal saline
2842183|NCT03653416|Experimental|Ipack group|20 cc of bupivacaine(o.25%) will be injected with the help of ultrasound guidance. Patients will receive adductor canal catheter and peri articular infiltration as well.
2842184|NCT03653416|Active Comparator|Pai (peri articular) group|Patients will receive adductor canal catheter and peri articular infiltration.
2842185|NCT03653403|Experimental|IDP-126 Gel|clindamycin phosphate 1.2%/benzoyl peroxide (BPO) 3.1%/adapalene 0.15%
2842186|NCT03653403|Active Comparator|Epidou Forte Gel|benzoyl peroxide (BPO) 2.5%/ adapalene 0.3%
2842187|NCT03653390|Experimental|EnhanceWellness for Disability (EW-D)|Up to 10 sessions of a telephone-based intervention delivered over a six-month period.
2842188|NCT03653390|Active Comparator|Wellness Education|Eight 45-minute sessions of telephone-based wellness education delivered over a six-month period.
2842189|NCT03653390|No Intervention|Control|Participant continues with their lives as they normally would.
2842190|NCT03653377||Patients with self-administered questionnaire|
2842191|NCT03653364|Experimental|Baloxavir Marboxil|Participants will receive single oral dose of baloxavir marboxil on Day 1 (based on body weight and age).
2842192|NCT03653351|Sham Comparator|Sham tDCS and MBSR|Includes a combination of 8 weeks of in-class group MBSR + sham tDCS and daily at home MBSR + sham tDCS.
2842193|NCT03653351|Active Comparator|Active tDCS and MBSR|Includes a combination of 8 weeks of in-class group MBSR + active tDCS and daily at home MBSR + active tDCS.
2842194|NCT03653338|Experimental|Hematopoietic Stem Cell Transplantation|"All patients will receive a CD3+/CD19+ depleted stem cell transplant. In this study, the investigators will use HLA mismatched unrelated or haploidentical related donor peripheral blood stem cells. Prior to transplantation, the marrow (90-95%) will be negatively selected for CD3/CD19 using the ClinicMACs® depletion device. The remaining (5-10%) will undergo CD45+RA+ depletion and be frozen for future use as an immune boost.~Subjects will undergo hematopoietic stem cell transplant utilizing CD3+/CD19+ depleted cells following conditioning therapy."
2842195|NCT03653325|Experimental|interventional arm|"In the interventional arm of the study clinicians will be encouraged to titrate oxygen FiO2 according to the following table:~Interventional arm (FiO2 adaptation every 2-3 min) :~ORI >0.5 and SatO2>98% and FiO2>0.5 FiO2 reduction of 0.2 ORI>0.01 and ORI<0.5 and SatO2>98% and FiO2>0.5 FiO2 reduction of 0.1 ORI >0.5 and SatO2>98% and FiO2≤0.5 FiO2 reduction of 0.1 ORI>0.01 and ORI<0.2 and SatO2>98% and FiO2≤0.5 FiO2 reduction of 0.05 ORI=0 et SatO2 94 - 98% no modification of FiO2 SatO2<94% + SatO2> 90% increase FiO2 by 0.05 SatO2<90% and SatO2>86 increase FiO2 by 0.1 SatO2<86% and SatO2> 80% increase FiO2 by 0.2 SatO2<80% FiO2 at 1~In the absence of a ORI measurement reading FiO2 will be adapted as in the observational arm according to SatO2 only."
2842196|NCT03653325|Active Comparator|Observational arm|"Observational arm (adaptation every 2-3 min):~oxygen saturation measurement SatO2>98% and FiO2>0.5 reduction of FiO2 by 0.1 SatO2>98% and FiO2≤0.5 reduction of FiO2 by 0.05 SatO2 94 - 98% no modification of FiO2 SatO2<94% + SatO2> 90% increase FiO2 by 0.05 SatO2<90% and SatO2>86 increase FiO2 by 0.1 SatO2<86% and SatO2> 80% increase FiO2 by 0.2 SatO2<80% FiO2 at 1"
2842197|NCT03653312|Active Comparator|NMES|"2 weeks (weekdays) of Neuromuscular electrical stimulation of the paretic lower limb during excercise.~Each exercise session will last for 27 minutes and will consist of either walk or sit and raise from a chair."
2842198|NCT03653312|No Intervention|training|Participants will undergo 2 weeks of exercise every weekday. Each exercise session will last for 27 minutes and will consist of either walk or sit and raise from a chair.
2904006|NCT03221075||Invasive Aspergillosis|
2842200|NCT03653299|Experimental|Group B - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy B will receive the programs in the following order 2, 3, 4 and 1, before the tests."
2842201|NCT03653299|Experimental|Group C - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy C will receive the programs in the following order 3, 4, 1 and 2, before the tests."
2842202|NCT03653299|Experimental|Group D - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy D will receive the programs in the following order 4, 1, 2 and 3, before the tests."
2842203|NCT03653286|Experimental|NMES and Run|NMES and run
2842204|NCT03653286|Other|Only Run|Only Run
2842205|NCT03653273|Experimental|DMT withdrawal|DMT will be immediately stopped after randomization.These patients will be followed for 2 years.
2842206|NCT03653273|Active Comparator|DMT continuation|The previously established therapy will be continued at the same dose during two years.
2842207|NCT03653260|Experimental|Lidocaine (Zingo)|0.5mg lidocaine at 20 bar pressure
2842208|NCT03653260|Placebo Comparator|Placebo|no emitted particle at 20 bar pressure, identical in external appearance to Zingo
2842209|NCT03653247|Experimental|BIVV003|Participants will receive plerixafor as subcutaneous (SQ) administration followed by myeloablative conditioning therapy with intravenous (IV) busulfan. BIVV003 will then be administered as a 1-time IV infusion of autologous Cluster of Differentiation 34 + Hematopoietic Stem/Progenitor Cell (CD34+HSPC) transfected ex vivo with zinc finger nuclease (ZFN) messenger ribonucleic acid (mRNAs) targeting the B-cell lymphoma/leukemia 11A (BCL11A) locus.
2842210|NCT03653234|Experimental|TV-based Assistive Integrated Service|Participants assigned to the intervention group will have access to TV-AssistDem and participate in clinical visits every 6 months.
2842211|NCT03653234|No Intervention|Control|Participants assigned to the intervention group will NOT have access to TV-AssistDem and will participate in clinical visits every 6 months
2842212|NCT03653221|Experimental|standardized patients with VRNET|The medical students examine the standardized patients who have neurological deficits which presented by VRNET.
2842213|NCT03653221|Placebo Comparator|standardized patients|The medical students examine the standardized patients who have neurological deficits which presented by words or pictures.
2842214|NCT03653208|Experimental|Group 1|"Drug: hzVSF-v13 10 mg, IV administration~Drug: Placebo, IV administration"
2842215|NCT03653208|Experimental|Group 2|"Drug: hzVSF-v13 20 mg, IV administration~Drug: Placebo, IV administration"
2842216|NCT03653208|Experimental|Group 3|"Drug: hzVSF-v13 50 mg, IV administration~Drug: Placebo, IV administration"
2842217|NCT03653208|Experimental|Group 4|"Drug: hzVSF-v13 100 mg, IV administration~Drug: Placebo, IV administration"
2842218|NCT03653208|Experimental|Group5|"Drug: hzVSF-v13 200 mg, IV administration~Drug: Placebo, IV administration"
2842219|NCT03653208|Experimental|Group6|"Drug: hzVSF-v13 400 mg, IV administration~Drug: Placebo, IV administration"
2842220|NCT03653208|Experimental|Group 7|"Drug: hzVSF-v13 800 mg, IV administration~Drug: Placebo, IV administration"
2842221|NCT03653208|Experimental|Group 8|"Drug: hzVSF-v13 1200 mg, IV administration~Drug: Placebo, IV administration"
2842222|NCT03653195|Other|Pre-injury|Each participant will act as their own control. Pre-injury samples were collected.
2842223|NCT03653195|Active Comparator|Post-injury|Post-injury samples were collected at the same time and within 72 hours of injury.
2842224|NCT03653182||normal|A normal constitution condition in TCM.
2842225|NCT03653182||Qi deficiency|One of an abnormal constitution condition in TCM.
2842226|NCT03653182||Damp heat|One of an abnormal constitution condition in TCM.
2842227|NCT03653182||Yang deficiency|One of an abnormal constitution condition in TCM.
2842228|NCT03653182||Yin deficiency|One of an abnormal constitution condition in TCM.
2842229|NCT03653182||Phlagm|One of an abnormal constitution condition in TCM.
2842230|NCT03653182||Blood stasis|One of an abnormal constitution condition in TCM.
2842231|NCT03653182||Qi stagnation|One of an abnormal constitution condition in TCM.
2842232|NCT03653182||Special|One of an abnormal constitution condition in TCM.
2842233|NCT03653169|Experimental|Open-Label Active TMS|All subjects will receive open-label treatment with active Transcranial Magnetic Stimulation (TMS)
2842234|NCT03653156||Amnestic mild cognitive impairment (MCI)|Mild cognitive impairment subjects with memory loss as predominant symptom
2842235|NCT03653156||Sporadic Alzheimer's disease (SAD)|Mild to moderate sporadic Alzheimer's disease subjects
2842236|NCT03653156||Familial Alzheimer's disease (FAD)|Familial Alzheimer disease subjects with known or unknown mutations
2842237|NCT03653156||Vascular cognitive impairment (VCI）|Cognitive impairment subjects caused by cerebral small vessel disease, including vascular cognitive impairment no dementia, vascular dementia, mixes dementia
2842238|NCT03653156||APOE gene cohort|Cognitive normal subjects with ApoE ε4 positive or negative
2842239|NCT03653143|Experimental|Treatment Group|Assessment #1 Baseline Visit >> 3 month JASPER intervention (weekly) >> Assessment #2 Research Visit >> 3 month treatment as usual >> Assessment #3 Research Visit
2842240|NCT03653143|Experimental|Control/Wait-list Group|Assessment #1 Baseline Visit >> 3 month treatment as usual >> Assessment #2 Research Visit >> 3 month JASPER intervention >> Assessment #3 Research Visit
2842241|NCT03653130|Experimental|Intervention Program|Participants will receive an instrument (violin, viola, or cello). Intervention sessions will take place twice a week at the Domiciliary and once per week at the Domiciliary or at a community location (Richard L. Roudebush VA Medical Center or Regenstrief Institute). Each session will include: thirty minutes of group music instruction by an experienced music educator with skills in adult music education followed by thirty minutes of weekly adult ensemble experience.
2842242|NCT03653130|No Intervention|Usual Care Control|Usual care at VA Domiciliary including participation in Domiciliary recreational therapy electives (if eligible).
2842337|NCT03652467|Experimental|Deferoxamine|Patients are treated with deferoxamine and conventional TACE.
2842245|NCT03653104|Experimental|Melodica Intervention|A 12-week group intervention including twice-weekly sessions. Each session will last one hour in duration with approximately 20 minutes for instruction, 30 minutes in group music-making, and 10 minutes allocated for educational information about COPD, tobacco cessation, and pulmonary rehabilitation.
2842246|NCT03653104|Active Comparator|Education Control|A single 90-120 minute education session including the same educational information about COPD, tobacco cessation, and pulmonary rehabilitation provided to the melodica intervention group.
2842247|NCT03653104|No Intervention|Usual Care Control|Usual care at Richard L. Roudebush VA Medical Center.
2842248|NCT03653104|No Intervention|Interview Only|Semi-structured interviews will be conducted with Veterans who meet eligibility criteria, but who do not agree to participate in the intervention, to identify potential barriers to participation
2842249|NCT03653091|Active Comparator|Duodenal Mucosal Resurfacing (DMR)|Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal mucosa in an upper endoscopic procedure in patients with type 2 diabetes.
2842250|NCT03653091|Sham Comparator|Duodenal Mucosal Resurfacing Sham (Sham)|Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with type 2 diabetes.
2842251|NCT03653078|Experimental|Three dimensional printed digital guide|one mini-screw will be inserted in the buccal interradicular space between upper second premolar and first molar using Three dimensional printed digital guide, which is a device deisgned and printed through CAD/CAM technology, it's a printed plate fit on the teeth and buccal mucosa with a channel for mini- screw insertion, mini-screw will be inserted through the plate's channel
2842252|NCT03653078|No Intervention|Conventional free hand insertion|one mini-screw will be inserted in the buccal interradicular space between upper second premolar and first molar using conventional free hand insertion of mini-screw, which is a technique using the guiding anatomy for mini-screw insertion using the driver and the operator's skill.
2842253|NCT03653052|Experimental|Durvalumab|Patients with advanced oesophageal cancer will be administered with 1500mg of durvalumab once every 4 weeks for up to 6 months.
2842254|NCT03653039|Experimental|Tritube|
2842255|NCT03653039|Active Comparator|Standard endotracheal tube|
2842256|NCT03653026|Experimental|Upadacitinib|
2842257|NCT03653026|Experimental|Placebo|
2842258|NCT03653013|Active Comparator|Control Group|Usual standard of care from their diabetes care team
2842259|NCT03653013|Experimental|Neuropsychological Consultation Group|Children will be administered a number of neuropsychological tests. Children and parents in Group 2 will also complete a pediatric quality of life scale (PedsQL, Generic Scale and Diabetes Module), diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study, as well as the self-report form of the BRIEF-2 if they are over age 11. Parents will also undergo a brief literacy and numeracy screening using the Wide Range Achievement Test, complete a parent report assessing their children's executive functioning skills at the start of the study (BRIEF-2) and they will fill out the Family Impact Module.
2842260|NCT03653000|Experimental|Patients undergoing this new block|Descriptive study about the effectiveness and the feasability of this new approach of te ultrasound guided brachial plexus blockade
2842261|NCT03652974|Experimental|sodium valproate with clozapine|"sodium valproate, dosage form: 250 mg, dosage and frequency:250 mg/d for 1 week, 500 mg/d for weeks 2 and 3, 1000 mg/d for weeks 5, 6, 7 and 8; clozapine, dosage and frequency:300~600 mg/d; duration: 8th week.~Intervention: Drug: sodium valproate with Clozapine"
2842262|NCT03652974|Experimental|Modified electroconvulsive therapy with clozapine|"12 times MECT for 8 weeks，2 times a week for the first four weeks, and then turn to once a week for the next four weeks; clozapine, dosage and frequency:300~600 mg/d; duration: 8th week.~Intervention: Device: modified electroconvulsive therapy(MECT) with Clozapine"
2842263|NCT03652961|Other|Open Label|Open Label abatacept for Intravenous Infusion Abatacept intravenous will be administered as a 30-minute intravenous infusion utilizing the weight range-based dosing. Following the initial intravenous administration, an intravenous infusion will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for a total of 7 doses.
2842264|NCT03652948|Experimental|Meru Health Ascend Program|The Meru Health Ascend Program is an 8-week mobile application (app) based intervention that teaches cognitive-behavioral and mindfulness skills. The intervention also includes a group discussion board with the other participants in the intervention group and therapist support via chat within the app.
2842265|NCT03652935|Experimental|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction (MBSR) program consists of an 8-week (2.5 hr/wk) program with a 6-hour silent mindful practice retreat after the fifth week. A licensed clinical psychologist, certified as an MBSR instructor, will provide instruction to all groups. Mindfulness will be taught using breath awareness, sitting and walking meditation, and mindful yoga. Participants will be given a standardized session-by-session program workbook containing weekly objectives and assignments, as well as two practice recordings and the book, Full Catastrophe Living (Kabat-Zinn, J, 1990).
2842266|NCT03652935|Active Comparator|Health Education Series|The active comparator condition consists of an 8-week educational series, administered in group-format, and matched in duration and frequency to the MBSR program. Session topics include: 1) Understanding Breast Cancer and Risks for Breast Cancer, 2) Breast Cancer Treatment, 3) Communicating Effectively with your Health Care Providers; Keeping your Medical Records, 4) Genetic Testing and Cancer, 5) Nutrition and Cancer, (6) Cooking Demonstration, 7) Bone Health, and 8) Image and Cancer (American Cancer Society - Look Good, Feel Better). The program content and objectives were reviewed by four content experts (oncology clinicians) and two breast cancer survivors.
2842267|NCT03652922|Experimental|Propranolol|
2842268|NCT03652922|Placebo Comparator|Placebo|
2842269|NCT03652909||PSAD|Patients try the personal sound amplification device.
2842270|NCT03652896|Experimental|anatomical liver resection|resect the tumor located liver segment or lobe
2842271|NCT03652896|Experimental|resection margin based liver resection|non-anatomical liver resection, but insure adequate resection margin
2842338|NCT03652467|Active Comparator|Conventional TACE|Patients are treated with conventional TACE.
2842339|NCT03652454|Experimental|micro-osteoperforation|Propel device (ABD)
2842340|NCT03652454|Other|conventional treatment|conventional fixed appliance treatment
2842272|NCT03652883|Experimental|ItFits-toolkit|A generic 'Integrated Theory-based Framework for Implementation Tailoring Strategies' toolkit (the ItFits-toolkit) functions as an online self-help toolkit by which users are guided through the process of tailoring site-specific implementation strategies. The ItFits-toolkit includes four modules that implementers need to work through: 1) identifying and prioritising implementation goals and determinants of practices, 2) matching up implementation determinants to strategies, 3) designing a plan for carrying out strategies in a local context, and 4) applying strategies, and reviewing progress. In each of these four modules, evidence-informed materials such as iCBT relevant determinants of practices and implementation strategies, are included as well as methods for engaging with stakeholders.
2842273|NCT03652883|Active Comparator|Implementation as Usual|Implementation-as-Usual (IAU) refers to any existing approaches and efforts to embed and integrate iCBT within an organisation. All implementation sites included in IMA are engaged in and conducting IAU. IAU activities can be, but are not necessarily planned or guided by scientific evidence and often emerge from practice experiences and other sources of information. No standardisation in IAU across the sites is applied except for the implementation objective. That is, all implementation sites pursue the goal of increasing the number of patients treated by the iCBT service.
2842274|NCT03652870|Active Comparator|Nortriptyline|25mg tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
2842275|NCT03652870|Active Comparator|Escitalopram|5mg tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
2842276|NCT03652870|Placebo Comparator|Placebo|The placebo tablet consists of lactose and magnesium stearate. One tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
2842277|NCT03652857|Experimental|Apatinib Combined With Vinorelbine|Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-squamous Non-small Cell Lung Cancer
2842278|NCT03652844|Active Comparator|Allograft Adipose Matrix (AAM) 1.0|
2842279|NCT03652844|Active Comparator|Allograft Adipose Matrix (AAM) Diluted|
2842280|NCT03652831|Active Comparator|Soft Tissues mobilization with Neural mobilization|"Soft Tissue Mobilization with Neural mobilization group will be assessed by spurling test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Post Isometric Relaxation Techniques and Neural mobilization Techniques which involve Median, Radial and Ulnar Nerve Mobilization.~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)"
2842281|NCT03652831|Active Comparator|Soft Tissues mobilization without Neural mobilization|"Soft Tissue Mobilization with Neural mobilization group will be assessed by spurling test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Post Isometric Relaxation Techniques.~Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)"
2842282|NCT03652818|Experimental|Group A|"Pre-op Placebo 1;~Post-op Placebo 1;~Post-op Placebo 2"
2842283|NCT03652818|Experimental|Group B|"Pre-op Placebo 1;~Post-op Placebo 2;~Post-op acetaminophen."
2842284|NCT03652818|Experimental|Group C|"Pre-op Placebo 1;~Post-op pregabalin;~Post-op Placebo 2."
2842285|NCT03652818|Experimental|Group D|"Pre-op Placebo 1;~Post-op pregabalin~Post-op acetaminophen."
2842286|NCT03652818|Experimental|Group E|"Pre-op pregabalin;~Post-op Placebo 1;~Post-op acetaminophen."
2842287|NCT03652805|Experimental|IPL344|IPL344 will be administered Intravenously on a daily basis. The dose range of IPL344 is 1.7-3.2 mg/kg
2842288|NCT03652792|Experimental|Azilsartan (Zhaoke) Under Fasting|Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fasting condition
2842289|NCT03652792|Active Comparator|Azilsartan (Takeda) Under Fasting|Subjects will take a single Azilva 20mg Tablet under fasting condition
2842290|NCT03652792|Experimental|Azilsartan (Zhaoke) Under Fed|Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fed condition
2842291|NCT03652792|Active Comparator|Azilsartan (Takeda) Under Fed|Subjects will take a single Azilva 20mg Tablet under fed condition
2842292|NCT03652779|Experimental|Tecarfarin 10mg|
2842293|NCT03652779|Experimental|Tecarfarin 20mg|
2842294|NCT03652779|Experimental|Tecarfarin 30mg|
2842295|NCT03652779|Experimental|Tecarfarin 40mg|
2842296|NCT03652766|Other|Daily Weight Tracking|Participants will be provided with a wireless Bluetooth-enabled bathroom scale with instructions for connecting it to their home wifi network or phone using Bluetooth and a mobile app, and will also be walked through creating an anonymous study account for app access. They will be asked to track their weight daily for 6 weeks and will receive weekly feedback on weight gain trajectories along with nutrition or physical activity messages for healthy pregnancy weight gain.
2842297|NCT03652753|Experimental|N-acetylcysteine (NAC)|Injection of N-acetylcysteine at the time of external fixation
2842298|NCT03652753|Placebo Comparator|Saline|Injection of saline at the time of external fixation
2842299|NCT03652740|Experimental|Within-Subjects Dose Conditions|Participants are not assigned to different groups/arms. All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms.
2842300|NCT03652740|Experimental|Additional Within-Subjects Dose Conditions|"As described previously, all participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms. We have created a second arm in the description of the trial on ClinicalTrials.gov to designate masking - this study involves administration of drug conditions in different dose sequence orders to which participants are randomly assigned."
2842301|NCT03652727|Experimental|ECG-EM Guidance|PICC insertion using electrocardiographic and electromagnetic guidance [Site~Rite® 8 Ultrasound System with integrated SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS)]
2842302|NCT03652727|Active Comparator|FX Guidance|PICC insertion using fluoroscopic guidance
2842303|NCT03652714|Experimental|Local anesthetic|
2842304|NCT03652714|Placebo Comparator|Isotonic NaCl|
2842305|NCT03652701|Experimental|Hair Up|
2842306|NCT03652701|Placebo Comparator|Placebo|
2842307|NCT03652688|Experimental|Three 0's|Observed indicators that a group member may be in trouble due identified risks were provided and if detected, they were given practical skills on implementing the 3 0's: Outreach, Options, and Out. Outreach consisted of techniques for approaching your friend and acquiring more information whether there was a problem. Options were to be employed if problems were confirmed and were designed to provide easy, simple steps to reduce risks and decrease probability of escalation of problems. Out refers to the plans the group made before entering the club that they would leave as a group to keep the group members safe. Group commitment to implement these safety steps was emphasized. Interactive and visually attractive scenes were drawn as graphic images to avoid didactic delivery.
2842308|NCT03652688|Sham Comparator|Fire Safety|Groups in the control condition were also given information on safety and the focus of this safety message was regarding fires in nightclubs. Groups were given didactic materials to read with some still images. There were a few questions for the group to address.
2842309|NCT03652675|Experimental|Intervention: (Clinician's Guide + HealthCall for HIV/HCV)|
2842310|NCT03652675|No Intervention|Educational control condition|Participant will spend 20 minutes at the clinic, observed by the counselor, reviewing an educational pamphlet on drinking, HIV, and HCV.
2842311|NCT03652662|Experimental|RESP-FIT Intervention|"Intervention:~IMST/EMST Training (5 breaths, 5 times a day, 5 times a week) Fitbit activity monitoring Daily symptom and training log entered into mobile application (SAMS)"
2842312|NCT03652662|Active Comparator|RESP-FIT Comparator|"Active Comparator:~Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)"
2842313|NCT03652649|Experimental|3:1 Ketogenic Complete Meal Replacement|Evaluating glycemic control and weight loss in obese participants with type 2 diabetes treated for 6 months with 3:1 [fat]:[protein+carbohydrate] ratio, 1600 kcal/day complete meal replacement ketogenic diet
2842314|NCT03652636|Other|ONE|Patient scheduled to get MRI will also be asked to receive an ultrasound of the liver
2842315|NCT03652623|Experimental|TDF/FTC and cs-HT|Transgender youth will simultaneously take TDF/FTC and cs-HT. TW will take oral estradiol +/- spironolactone and TM will take subcutaneous testosterone. In order to ensure adherence to TDF/FTC, daily DOT procedures will be employed.
2842316|NCT03652610|Experimental|GSK3536820A ACWY_Liq Group|Approximately 486 healthy adults 18 to 40 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.
2842317|NCT03652610|Active Comparator|ACWY Group|Approximately 486 healthy adults 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK' MenACWY vaccine formulation (Menveo).
2842318|NCT03652597|Active Comparator|Left|Subjects are ascribed to left hemispheric stimulation
2842319|NCT03652597|Active Comparator|Right|Subjects are ascribed to right hemispheric stimulation
2842320|NCT03652584|Experimental|High Protein Diet|Low glycemic index dietary plan with 1.6 g/kg/day of protein for 6 months
2842321|NCT03652584|Active Comparator|Control Diet|Low glycemic index dietary plan with 0.8 g/kg/day of protein for 6 months
2842322|NCT03652571|Experimental|Nortriptyline|"Nortriptyline in an escalating dose regimen:~Week 1-2: 10mg daily Week 3-4: 25mg daily Week 5-12: 50mg daily"
2842323|NCT03652571|Placebo Comparator|Placebo|Placebo
2842324|NCT03652558|Experimental|ozone group|topical gaseous ozone was applied into periodontal pockets during active periodontal therapy
2842325|NCT03652558|No Intervention|non-ozone group|Only active periodontal therapy was performed
2842326|NCT03652545|Experimental|TAA-T|"Three different dosing schedules will be evaluated.~Dose Level One: 2 x 107 cells/m2 Dose Level Two: 4 x 107 cells/m2 Dose Level Three: 8 x 107 cells/m2~Group A patients (DIPG patients): TAA-T will be infused any time > 14 days after completion of radiotherapy.~Group B patients (other recurrent/progressive/refractory CNS tumors): TAA-T will be infused any time > 14 days after completing most recent course of conventional (non-investigational) therapy for their disease AND after appropriate washout periods as detailed in eligibility criteria.~Ideally, patients should not receive other systemic antineoplastic agents for at least 45 days after the infusion of TAA-T, although such treatment may be added if deemed critical for patient care by the attending physician."
2842327|NCT03652532|Experimental|Alternate Day Fasting and Exercise|
2842328|NCT03652532|Experimental|Alternate Day Fasting|
2842329|NCT03652532|Experimental|Exercise|
2842330|NCT03652532|No Intervention|Control|regular eating and exercise habits for 8 weeks
2842331|NCT03652519|Experimental|High-intensity Interval Training (HIIT)|Participants of the HIIT group will exercise three times per week over a period of three weeks (inpatient rehabilitation) on a cycle ergometer. Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Each exercise session will last 30 minutes and will be started and finalized with three minutes at low intensity (50% HRmax, warm-up / cool-down). During each exercise session, participants of the HIIT group will perform 5x three-minute high-intensive exercise bouts at 90-95% of their HRmax followed by active breaks of unloaded pedalling (50% of HRmax) for 1.5 minutes.
2842332|NCT03652519|Active Comparator|Moderate Continous Training (ST)|Participants of the ST group will exercise three times per week over a period of three weeks (inpatient rehabilitation) on a cycle ergometer. Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Each exercise session will last 30 minutes and will be started and finalized with three minutes at low intensity (50% HRmax, warm-up / cool-down). During each exercise session, participants of the ST group will exercise 30 minutes continuously at 65% of HRmax. This moderate continous training program represents the standard care at the local rehabilitation clinic.
2842333|NCT03652506|Active Comparator|Group A|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
2842334|NCT03652506|Active Comparator|Group E|Thoracic Epidural block +The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
2842335|NCT03652506|Active Comparator|Group Q|Ultrasound guided unilateral anterior Quadratus Lumborum block +The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
2842336|NCT03652493|Experimental|CARBOPLATIN|CARBOPLATIN in Intraveinous Dose AUC 5 according to Calvert every 3 weeks, for a duration of 6 to 9 cycles
2842341|NCT03652441|Experimental|Maintenance|BV will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
2842342|NCT03652428|Other|Pancreatic Proton Therapy With Concurrent Gem + Nab-paclitaxel|"Part I:~Gemcitabine + nab-paclitaxel:~• Administered per institutional standard every 7 days for 3 weeks~Part II:~Hypofractionated ablative pancreatic proton radiation therapy 67.5 Gy fractions once per day Monday - Friday for 3 weeks, for a total of 15 fractions.~Part III:~Surgery, if resectable, then adjuvant chemo per discretion of MD or no further therapy~OR~Chemo per discretion of MD if not resectable"
2842343|NCT03652389|Experimental|MJS DIABETES|will receive and respond to daily PROs via ttext messages and report SMBG (if insulin-dependent) over the course of the 12-month study.
2842344|NCT03652389|Active Comparator|Usual Care|Standard Diabetes Treatment
2842345|NCT03652376|Experimental|Benralizumab|Patients will be treated with Benralizumab 30 mg s.c. every 4 weeks (three times).
2842346|NCT03652363|Placebo Comparator|Placebo|Placebo administered via convection enhanced delivery
2842347|NCT03652363|Experimental|glial derived neurotrophic factor|Recombinant-methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF), administered via convection enhanced delivery
2842348|NCT03652350|Experimental|Use CT-guided microwave ablation in Ground Glass Nodules ≤ 3cm|Patients with Ground Glass Nodules ≤ 3cm were treated with CT-guided microwave ablation
2842349|NCT03652337|Experimental|BlephEx|The subjects who are enrolled in this arm will undergo electronic lid margin debridement using the BlephEx instrument.
2842350|NCT03652337|Experimental|Manual debridement|The subjects who are enrolled in this arm will undergo manual lid margin debridement using a stainless steel ophthalmic golf spud.
2842351|NCT03652324|Other|randomized|
2842352|NCT03652311|Experimental|TNM Device Group|In this arm participants will receive 5 sessions of twice daily treatments of 15 minutes of caloric vestibular stimulation (CVS) using the ThermoNeuroModulation TNM Device. In addition, participants will continue with the standard therapy that they are receiving.
2842353|NCT03652311|Sham Comparator|Sham CVS Group|In this arm participants will receive 5 sessions of twice daily sessions of 15 minutes of sham stimulation with the ThermoNeuroModulation TNM Device. The ThermoNeuroModulation TNM device will be fitted and turned on in a random paradigm that has no demonstrated efficacy. Participants will continue with the standard therapy that they are receiving.
2842354|NCT03652298|Experimental|Experimental arm|In the experimental group, participants will perform vagal breathing (VB), followed by the MSI, followed again by VB. The VB component will guide participants how to perform deep slow vagal breathing by inhaling and counting 1-5, holding their breath and counting 1-2, and exhaling and counting 1-5, during 2-5 minutes. The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).
2842355|NCT03652298|Other|Control Arm|Participants in the control group will receive support and attention (usual care) and will be invited to recall announcement of the incurable disease progression. More precisely, they will be invited to express their associated thoughts and feelings, being free to talk about their experience, and the psychologist will react with empathy and support.
2842356|NCT03652285|Experimental|Esophageal stent implantation (UAS-RBS implantation)|Esophageal stent implantation (UAS-RBS implantation) at J0, removal after 6 months and follow-up for 6 months
2842357|NCT03652272|Experimental|EMC2|"Following patient movement through a provider visit, the following activities will occur for a select list of pre-specified medications:~Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks~Patients will receive a Medication Guide + Summary with their After Visit Summary~Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)~Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols."
2842358|NCT03652272|No Intervention|Usual Care|Usual care includes 1) variable provider counseling with limited or variable EHR notifications or counseling support; 2) no distribution of print medication information materials, including FDA Medication Guides in clinics and variable distribution in pharmacies; and 3) limited or no active surveillance of medication use post-visits.
2842359|NCT03652259|Experimental|Cohort 1|N=3 (2 treated, 1 placebo) LGMD2E subjects. Cohort 1 will receive a dose of 5 x 10^13 vg/kg of scAAVrh74.MHCK7.hSGCB or placebo.
2842360|NCT03652259|Experimental|Cohort 2|N=6 (4 treated, 2 placebo). There is the potential to escalate dose to 2 x 10^14vg/kg of scAAVrh74.MHCK7.hSGCB based on expression in Cohort 1.
2842361|NCT03652233|Experimental|Afatinib and Nivolumab|
2842362|NCT03652220|Experimental|Intervention|"8 weeks Minimal treatment + MBLM 16 weeks Multimodal specific treatment + MBLM Consolidation~Definitions Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
2842363|NCT03652220|Active Comparator|Control I|"8 weeks Minimal treatment 16 weeks Multimodal specific treatment~Definitions Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
2842364|NCT03652220|Active Comparator|Control 2|"Definitions 24 weeks Multimodal specific treatment~Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
2842365|NCT03652207|Placebo Comparator|Sucrose|Test products i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals containing sucrose
2842366|NCT03652207|Experimental|Palatinose(TM)|Test products i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals containing isomaltulose (Palatinose™)
2842367|NCT03652194||Reference strain ATCC|1 strain sensitive to all antifungals
2842368|NCT03652194||Clinical isolates sensitive to all antifungal agents|10 clinical isolates sensitive to all
2842369|NCT03652194||Echinocandin-resistant clinical isolates|10 echinocandin-resistant clinical isolates (Eucast, Caspofungin > 8µg/ml)
2842370|NCT03652181||CASH (Cavernous Angiomas with Symptomatic Hemorrhage)|The adjudicated definition of CASH (Cavernous Angiomas with Symptomatic Hemorrhage) requires diagnostic evidence of new lesional bleeding or hemorrhagic growth, in association with directly attributable symptoms.
2842371|NCT03652168|Experimental|Meditation Group|Headspace application: Participants in the intervention group will use a digitally-based mindfulness intervention Headspace app (Basics + Stress packs) will be used for 10 minutes a day over the course of 8 weeks.
2842372|NCT03652168|No Intervention|No intervention, control group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
2842373|NCT03652155||Orthognathic Surgery Patients|The study cohort will be patients undergoing orthognathic surgery for correction of an existing dentofacial deformity.
2842374|NCT03652142||Recurrent/metastatic HNSCC|"The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab. Tumor biopsies will be performed at baseline, after the second cycle and at progression with appropriate written informed consent and the samples will be analyzed. Biomarker research will be performed.~The patients will receive intravenously nivolumab at dose of 240 mg every 2 weeks (240mg q2w). The patients will undergo tumor biopsy at baseline and within 24-72h after the second administration of treatment, and at progression of their disease."
2842375|NCT03652129|Experimental|Laser Group|Disinfection using biostimulating LASER
2842376|NCT03652129|Experimental|Nano irrigant Group|Disinfection using Nano irrigant
2842377|NCT03652129|Active Comparator|Conventional irrigation protocol group|disinfection using normal irrigation protocols
2842378|NCT03652116|Active Comparator|Bupivacaine Group|Patients delivered by cesarean section followed by wound infiltration by bupivacaine.
2842379|NCT03652116|Active Comparator|Pethidine Group|Patients delivered by cesarean section followed by wound infiltration by pethidine.
2842380|NCT03652103|No Intervention|GCont|Only dressing will be applied to patients without actually nerve catheter performed
2842381|NCT03652103|Experimental|GBlock|"Ultrasound Guided Erector Spinae Plane Block Catheter will be applied: 20ml Bupivacaine 0.25% Injectable Solution* will be administered initially.~20 ml Bupivacaine %0.25 Injectable Solution** will be administered 20 minutes before mobilization at postoprative day(POD) 1 and before removal of nephrostomy at POD 2~And 20 ml Bupivacaine %0.25 Injectable Solution** will be used via ESP catheter as rescue analgesia and will be recorded.~*10ml %0,5 Bupivacaine will be diluted with 10ml Saline solution."
2842382|NCT03652090||cystic fibrosis patients|Cystic fibrosis patients carrying to 2 CFTR mutations undergoing cell sampling
2842383|NCT03652090||healthy heterozygotes|healthy heterozygotes carrying 1 CFTR mutations undergoing cell sampling
2842384|NCT03652090||healthy control|subject with no evidence of any symptomas compatible with CYstic Fibrosis undergoing cell sampling
2842385|NCT03652077|Experimental|INCAGN02390|
2842386|NCT03652064|Active Comparator|Bortezomib + Lenalidomide + Dexamethasone (VRd) and Rd|Participants will receive bortezomib 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 (cycle of 28 days); dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond (each cycle is of 28 days) followed by lenalidomide-dexamethasone (Rd) until disease progression or unacceptable toxicity.
2842387|NCT03652064|Experimental|Daratumumab + VRd (D-VRd) and DRd|Participants will receive daratumumab 1800 mg as SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3 through 8 and every 4 weeks for Cycle 9 and beyond; bortezomib 1.3 mg/m^2 as SC injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9; dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond followed by daratumumab-lenalidomide-dexamethasone (DRd) until disease progression or unacceptable toxicity.
2842388|NCT03652051|Experimental|AZR-MD-001 Low Dose|AZR-MD-001 Low Dose will be dosed up to once daily.
2842389|NCT03652051|Experimental|AZR-MD-001 Mid Dose|AZR-MD-001 Mid Dose will be dosed up to once daily.
2842390|NCT03652051|Experimental|AZR-MD-001 High Dose|AZR-MD-001 High Dose will be dosed up to once daily.
2842391|NCT03652051|Sham Comparator|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to once daily.
2842392|NCT03652038|Experimental|TD-8236 for SAD|6 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive TD-8236
2842393|NCT03652038|Placebo Comparator|Placebo for SAD|2 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive placebo
2842394|NCT03652038|Experimental|TD-8236 for MAD|6 out of 8 subjects per cohort (up to 6 cohorts) will be randomized to receive TD-8236. Ten subjects in biomarker cohort will be randomized to receive TD-8236.
2842395|NCT03652038|Placebo Comparator|Placebo for MAD|2 out of 8 subjects per cohort (up to 6 cohorts) will be randomized to receive placebo. Ten subjects in biomarker cohort will be randomized to receive placebo.
2842396|NCT03652025|Experimental|Study group|perimenopausal women
2842397|NCT03652012|Experimental|Mild Cognitive Impairment|"The following revised Mayo Clinic criteria for MCI (Petersen, et al. 2014) will be used: (1) cognitive concern expressed by a physician, informant, participant, or nurse; (2) impairment in 1 or more cognitive domains (memory, language, visuospatial skills, or executive functions); (3) essentially normal functional activities; and (4) absence of dementia. Individuals with MCI will have Mini-Mental State Exam (MMSE, Appendix 19) scores between 18 and 23 (inclusive) and have a Clinical Dementia Rating Scale score of 0.5.~This group will undergo Transcranial Magnetic Stimulation (TMS) protocol."
2842398|NCT03652012|Active Comparator|Healthy Controls|"Participants who are matched for age and gender.~This group will undergo Transcranial Magnetic Stimulation (TMS) protocol."
2842458|NCT03651583|Other|Pilot Trial|Behavioral Intervention Kiko exercises-combines breathing and movement all study subjects no placebo or control group
2842501|NCT03651349|Placebo Comparator|Placebo control|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
2842399|NCT03651999||dream workshop|After consultation with the pediatric surgeon or the anesthesiologist, parents and children are invited to meet the nurse anesthetist, in a room dedicated to this purpose and specially designed to accommodate children; they will find a playmobil model, photographs of the patient circuit as well as different games or activities that can be performed during induction; The nurse anesthetist explains the hospitalization process and will help them to choose a pleasant dream, a perfume adapted to their taste, a distraction adapted to their age (animated book, soap bubbles, favorite song ...); the child will be able to customize his mask and choose the blanket he wants to take along; the most recalcitrant or special sites (autism, long-term hospitalization) will be able to be accompanied by a parent during sleep
2842400|NCT03651999||control|"No dream workshop"
2842401|NCT03651986||Prospective Cohort|This is a prospectively enrolling cohort study and a stratified case-cohort design will be employed to select malignant pulmonary nodules cases and benign pulmonary nodules subjects who will be assayed. All participants will be followed up with chest CT or low-dose computed tomography (LDCT) scans for 2-3 years, and take the diagnostic test, ctDNA methylation analysis by NGS, at each visit.
2842402|NCT03651973|Experimental|With learning workshops|Patients in experimental arm will attend learning workshops, one before breast cancer surgey and one after surgery. Patients will be educated by physiologist to self massages and self stretching. Each workshop will last around 2 hours.
2842403|NCT03651973|Other|Without learning workshops|Standard follow-up. Patients randomized in this arm won't attend Learning workshops and will be followed in a standard way.
2842404|NCT03651960|Experimental|Robot|ROBOT PROTOTYPE
2842405|NCT03651947|Experimental|QL1206|QL1206 injection (120mg) by subcutaneous injection once on the first day.
2842406|NCT03651947|Active Comparator|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day.
2842407|NCT03651934|Experimental|Normal iron|
2842408|NCT03651934|Experimental|Weak iron|
2842409|NCT03651934|Experimental|Normal selenium|
2842410|NCT03651934|Experimental|Weak selenium|
2842411|NCT03651921|No Intervention|Usual care|Usual follow-up care offered in the breast centers after primary treatment by breast care team (e. g. breast care nurses, gynaecologist, oncologist, psychologist).
2842412|NCT03651921|Experimental|Usual care and CTS-BC-CH|CTS-BC-CH as 7 weekly group session à 2.5 - 3 hours.
2842413|NCT03651908|Experimental|Interventional|Interventional The Group A subjects will be treated with conventional flap surgery.After reflection of the full thickness flap,the intrabony defects will be debrided and Bioactive silicate graft mixed with PRF will be used as graft material to fill the defects.
2842414|NCT03651908|Active Comparator|Interventional comparator|Group B patients will also be treated by conventional flap surgery,employing a full thickness flap technique.The intrabony defects will be filled with Bioactive silicate only.
2842415|NCT03651895|Active Comparator|Treatment Group|Metformin 500mg bd
2842416|NCT03651895|Placebo Comparator|Placebo Group|Placebo
2842417|NCT03651882|Active Comparator|Oxytocin|
2842418|NCT03651882|Active Comparator|Carbetocin|
2842419|NCT03651869|Experimental|Condition 1: Nicotine + Ritual|In order to test the pharmacological and ritualistic behavior mechanisms of the association between Obsessive Compulsive Disorder and tobacco dependence, participants will smoke conventional nicotine cigarettes and wear a placebo patch.
2842420|NCT03651869|Experimental|Condition 2: Ritual Only|In order to test the ritualistic behavior mechanism of the association between Obsessive Compulsive Disorder and tobacco dependence, participants will smoke reduced nicotine cigarettes and wear a placebo patch.
2842421|NCT03651869|Experimental|Condition 3: Nicotine Only|In order to test the pharmacological mechanism of the Obsessive Compulsive Disorder + tobacco dependence association, participants will wear an active nicotine patch only.
2842422|NCT03651869|Experimental|Condition 4: Control|Participants will wear a placebo patch only.
2842423|NCT03651856|Experimental|Atomoxetine|Atomoxetine 40mg daily for 2 weeks uptitration Atomoxetine 40mg BID for 4 weeks Atomoxetine 40mg daily for 1 week weaning off
2842424|NCT03651843||Healthy subjects|
2842425|NCT03651830|Experimental|Prosthetic Foot Emulator|The Prosthetic Foot Emulator (PFE) is a customizable robotic prosthetic foot that can mimic commercial feet to predict how individual patients will respond to candidate feet. Participants will walk with the PFE using three different modes (emulating three commercial feet) under different walking conditions.
2842426|NCT03651830|Active Comparator|Commercially available prosthetic feet|Participants will walk under different walking conditions using three different commercial prosthetic feet.
2842427|NCT03651817|Active Comparator|6ml/kg volume|Patients ventilation will provided with a tidal volume of 6ml/kg
2842428|NCT03651817|Active Comparator|8ml/kg volume|Patients ventilation will provided with a tidal volume of 8ml/kg
2842429|NCT03651804|Active Comparator|Control Group|"The control group will receive usual care for treatment of vertebral compression fractures, which will consist of but not limited to: physical therapy, opioids, NSAIDs, acetaminophen and bisphosphonates as indicated. They will have the option of crossing over (see Crossover Group) at twelve weeks."
2842430|NCT03651804|Active Comparator|Treatment Group|The treatment group will receive usual care for treatment and the treatment procedure comprised of the Medial Branch Block and Radiofrequency Ablation. In cases where a medial branch nerve block has confirmed there is pain relief, a radiofrequency ablation is considered. These patients will continue their usual care therapy as well.
2842431|NCT03651804|Active Comparator|Crossover Group|This group will comprise of patients within the control group who after 12 weeks of usual therapy will have the option of crossing over to the treatment group. Once crossed over, their treatment and course and measurements will be identical to that of the treatment group.
2842432|NCT03651791|Experimental|USPIO labeled MSC injection|USPIO labeled MSC injection
2842433|NCT03651765|Experimental|Setmelanotide|Once daily subcutaneous injection
2842497|NCT03651401||healthy controls|Participants were assessed for SME, shoulder girdle and scapular muscle strengths and upper extremity function (FIT-HaNSA). In addition, Constant & Murley score, the Shoulder Pain and Disability Index (SPADI), and the Nottingham Health Profile (NHP) were administered.
2842498|NCT03651388||Patient|Patient with a new phenotype combining premature white hair, renal polycystosis, aortic dilation/dissection and lymphopenia
2842499|NCT03651388||Related parties of the 1st degree|1st degree related family of Group A patient
2842434|NCT03651752|Other|Diphenylcyclopropenone (DPCP) Ointment|All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks
2842435|NCT03651739||TKR Patients|Any patient undergoing total knee arthroplasty and will use the Knee Connect
2842436|NCT03651726|Experimental|THX-110 (dronabinol plus PEA)|"Double-blind phase and extension open label phase:~Dose range of 2.5 mg to 10 mg dronabinol (1 to 4 capsules) plus 800 mg PEA (2 tablets) taken orally once daily; starting dose is 2.5 mg dronabinol plus 800 mg PEA. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose."
2842437|NCT03651726|Placebo Comparator|Placebo|"Double-blind phase:~Range of 1 to 4 dronabinol placebo capsules plus 2 PEA placebo tablets taken orally once daily; starting dose is 1 dronabinol placebo capsule plus 2 PEA placebo tablets. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose."
2842438|NCT03651713|Experimental|GLU+EX|Subjects will consume a 75g glucose beverage three times daily for seven days while participating in five structured aerobic exercise sessions throughout the experimental protocol.
2842439|NCT03651713|Active Comparator|GLU|Subjects will consume a 75g glucose beverage three times daily for seven days without participating in structured aerobic exercise.
2842440|NCT03651700|Active Comparator|Active TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz active TMS will be delivered to the inferior pars triangular. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
2842441|NCT03651700|Sham Comparator|Sham TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz sham TMS will be delivered to the inferior pars triangular. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
2842442|NCT03651674|Active Comparator|ECT treatment|Patients received bilateral temporal modified ECT (MECT) for three weeks,four times a week. Meanwhile, they also had antipsychotic drugs.
2842443|NCT03651674|Sham Comparator|Drug treatment|Patients only received antipsychotic drugs during observation period.
2842444|NCT03651661|Active Comparator|nasal insulin|160 U of human insulin as nasal spray
2842445|NCT03651661|Placebo Comparator|nasal placebo|placebo as nasal spray
2842446|NCT03651648|Experimental|SENSITACT System ON|As soon as the early signs of an apnea-bradycardia are detected, the SENSITACT controller sends a trigger signal to the PASITHEA stimulator that immediately activates kinesthetic stimulation
2842447|NCT03651648|Sham Comparator|SENSITACT System OFF|The SENSITACT controller doesnt send any trigger signal to the PASITHEA stimulator even if an early sign of an apnea-bradycardia is detected.
2842448|NCT03651635||Medical ICU Patients|All patients admitted to the medical intensive care unit of the University hospital of Zurich during the recruitment period
2842449|NCT03651622|Experimental|Hypocaloric, low carbohydrate|Behavioral intervention to include lifestyle counseling on hypocaloric, low carbohydrate diet (15-20% calories from carbohydrate, 59-63% as total fat (<10% saturated fat, at least 37% monounsaturated fat, remaining as polyunsaturated fat). Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
2842450|NCT03651622|Experimental|Hypocaloric, moderate low fat|Behavioral intervention to include lifestyle counseling on hypocaloric, moderate low fat diet (30% calories from fat) weight management based on the Look AHEAD study. Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
2842451|NCT03651622|Experimental|Mediterranean, no caloric restriction|Behavioral intervention to include lifestyle counseling on selecting a healthy Mediterranean diet, no caloric restriction. Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
2842452|NCT03651609|Experimental|UNE at HUA_HUA release|Patients with UNE under the HUA randomly distributed for simple decompression of the ulnar nerve. They will also receive pictured recommendations with descriptions, which limb positions should be avoided. Control neurological examination will be performed every 3 months and identical protocol as at the time of diagnostic evaluation at 1 year follow-up.
2842453|NCT03651609|Active Comparator|UNE at HUA_conservative treatment|Patients with UNE under the HUA randomly distributed for conservative treatment. They will receive pictured recommendations with descriptions, which limb positions should be avoided. In order to prevent deterioration in conservatively treated group of patients with UNE at HUA control neurological examination will be performed every 3 months. Criteria for surgical HUA release will be clinical deterioration or lack of clinical improvement after 12 months. Prior to surgical HUA release and at 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
2842454|NCT03651609|Experimental|UNE at RTC_HUA release|Patients with UNE in the RTC groove randomly distributed for simple decompression of the ulnar nerve. They will also receive pictured recommendations with descriptions, which limb positions should be avoided. At 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
2842455|NCT03651609|Active Comparator|UNE at RTC_conservative treatment|Patients with UNE in the RTC groove randomly distributed for conservative treatment. They will receive pictured recommendations with descriptions, which limb positions should be avoided. At 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
2842456|NCT03651596|Active Comparator|Standard mHealth Messaging|Individuals randomized to the Standard mHealth Messaging Group will receive a standard messaging intervention that has shown some efficacy in improving adherence in other samples.
2842457|NCT03651596|Experimental|mHealth Messaging Intervention|Individuals randomized to the mHealth Messaging Intervention Group will receive the newly developed messaging intervention.
2843267|NCT03646019||Non significant coronary artery disease|
2842459|NCT03651570|Experimental|PTSD Coach|PTSD Coach is a mobile mental health app developed by US Veterans Affairs translated into French by Veterans Affairs Canada in partnership with the Department of National Defence and the Canadian Mental Health Association. It was developed for a male population (92% of veterans are men), as is predominantly found in HNC, and addresses the issue of mental health and stigma as found in our HNC patients. PTSD Coach can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self-Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module. The content of the first and last modules were adapted to the oncological population.
2842460|NCT03651570|Placebo Comparator|Game application|Patients will be assigned to three apps involving playing a game (i.e., Candy Crush, Tetris, or Solitaire), during the waiting time before and between medical treatments in the hospital, on the same weekly schedule as the experimental group. The game apps contain no element of intervention and were selected based on popularity and capacity to interests.
2842461|NCT03651570|No Intervention|Usually Care Control Group|The Otolaryngology - Head and Neck Surgery (OHNS) Departments do not offer systematic interventions on anxiety and self-management, neither does any intervention address stigma. However, participating recruitment centres are already offering a best-of-care approach with well-established psychosocial oncology services, including psychiatrists, psychologists, social workers, nurses, and volunteers. All participants will be free to use hospital- or community-based support throughout the study, which will be tracked in all groups via questionnaire and chart review.
2842462|NCT03651557|Experimental|Neu2000KWL high dose|
2842463|NCT03651557|Experimental|Neu2000KWL low dose|
2842464|NCT03651557|Placebo Comparator|saline|
2842465|NCT03651544|Experimental|Group 1 (GamFluVac dose1)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) x 1010 VP/dose.
2842466|NCT03651544|Experimental|Group 2 (GamFluVac dose2)|Total amount of recombinant pseudo-adenoviral particles (1.0 ± 0.5) x 1011 VP/dose
2842467|NCT03651544|Experimental|Group 3 (GamFluVac dose3)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose
2842468|NCT03651531|Active Comparator|insulin|
2842469|NCT03651531|Active Comparator|insulin and metformin|
2842470|NCT03651518|Experimental|Kineret|
2842471|NCT03651518|Experimental|Humira|
2842472|NCT03651518|Experimental|Stelara|
2842473|NCT03651518|Experimental|Cosentyx|
2842474|NCT03651518|Experimental|Roactemra|
2842475|NCT03651518|Experimental|Rituximab|
2842476|NCT03651505||Prior Burosumab Clinical Trial Participants|Patients who participated in burosumab clinical trials and continue to receive burosumab via prescription from their physician.
2842477|NCT03651505||Burosumab-Naive Participants|Patients may take other treatments for XLH and may start burosumab treatment at any time as prescribed by a physician.
2842478|NCT03651479|Experimental|real boxing group|In the real boxing (RB) group in addition to the NDT program, real boxing training will be given.
2842479|NCT03651479|Experimental|virtual boxing group|In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing.
2842480|NCT03651466|Experimental|Cohort 1: GX-G6 + placebo|Single administration of pre-determined dose (Level I) GX-G6 (6 subjects) and pre-determined dose (Level I) placebo (2 subjects)
2842481|NCT03651466|Experimental|Cohort 2: GX-G6 + placebo|Single administration of pre-determined dose (Level II) GX-G6 (6 subjects) and pre-determined dose (Level II) placebo (2 subjects)
2842482|NCT03651466|Experimental|Cohort 3: GX-G6 + placebo|Single administration of pre-determined dose (Level III) GX-G6 (6 subjects) and pre-determined dose (Level III) placebo (2 subjects)
2842483|NCT03651466|Experimental|Cohort 4: GX-G6 + placebo|Single administration of pre-determined dose (Level IV) GX-G6 (6 subjects) and pre-determined dose (Level IV) placebo (2 subjects)
2842484|NCT03651466|Experimental|(Optional) Cohort 5: GX-G6 + placebo|Single administration of pre-determined dose (Level V) GX-G6 (6 subjects) and pre-determined dose (Level V) placebo (2 subjects)
2842485|NCT03651466|Experimental|(Optional) Cohort 6: GX-G6 + placebo|Single administration of pre-determined dose (Level VI) GX-G6 (6 subjects) and pre-determined dose (Level VI) placebo (2 subjects)
2842486|NCT03651453|Active Comparator|Standard Care|Participants will receive standard information about harm reduction as available at the drug treatment centers.
2842487|NCT03651453|Experimental|Decision aid|Participants in this arm will receive the adapted decision aid for PrEP.
2842488|NCT03651440|Experimental|lumbar stabilization training|lumbar stabilization training exercises
2842489|NCT03651440|Experimental|PNF training|PNF training exercises
2842490|NCT03651440|Experimental|physical therapy|HP,TENS US
2842491|NCT03651440|Sham Comparator|control|NO APPLİCATİON
2842492|NCT03651427|Experimental|Transgender Women|"Transgender women who already completed GAS or that agreed to start gonadotropin release hormone analogue to suppress endogenous sex hormones.~If the participants were using CSHT in the moment of the study assignment, they were asked to stop hormones for 30 days to evaluate the impact of hypogonadism in the brain.~After this first assessment, they received prescriptions for Estradiol (equine conjugated oestrogen, or estradiol valerate, or topic 17-beta estradiol formulations) for 60 days, and the impact of CSHT was evaluated again to compare to washout condition."
2842493|NCT03651414||Control|Patients hospitalized ab initio in Internal Medicine or similar for at least one night
2842494|NCT03651414||Outlier|Patients spending at least one night in a ward different from Internal Medicine despite the presence of medical diseases, due to lack of available beds
2842495|NCT03651401||Subacromial impingement syndrome|Participants were assessed for SME, pain (rest, activity, night), shoulder girdle and scapular muscle strengths and upper extremity function (FIT-HaNSA). In addition, Constant & Murley score, the Shoulder Pain and Disability Index (SPADI), and the Nottingham Health Profile (NHP) were administered.
2842496|NCT03651401||partial rotator cuff tears|Participants were assessed for SME, pain (rest, activity, night), shoulder girdle and scapular muscle strengths and upper extremity function (FIT-HaNSA). In addition, Constant & Murley score, the Shoulder Pain and Disability Index (SPADI), and the Nottingham Health Profile (NHP) were administered.
2842500|NCT03651375|Experimental|Sequential chemoradiotherapy|1xAI (doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm) + 5x5 Gy radiotherapy + 2xAI + surgery
2905099|NCT03213145|Experimental|Part 1|
2842502|NCT03651349|Experimental|50 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
2842503|NCT03651349|Experimental|100 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
2842504|NCT03651349|Experimental|150 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
2842505|NCT03651349|Experimental|225 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
2842506|NCT03651349|Experimental|300 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
2842507|NCT03651349|Experimental|400 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
2842508|NCT03651349|Experimental|525 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
2842509|NCT03651336|Other|Single-arm longterm follow-up ARGOS-IO Sensor Pressure System|The ARGOS-IO sensor was already implanted in a previous study as ARGOS-01 or ARGOS-02.
2842510|NCT03651310|No Intervention|Control Group|waiting in preoperative area without music listening.
2842511|NCT03651310|Active Comparator|Music Listening Group|The music listening group will be given a set of noise canceling headphones and an MP3 player with multiple tracks representing different music genres to use while in preoperative area.
2842512|NCT03651297|Experimental|Younger Adults|First group will include 20 young adults with no history of falls or fear of falling. They will complete both interventions: Balance Training with Fall-Arrest Harness and Balance Training with Adjustable Harness.
2842513|NCT03651297|Experimental|Older adults|Second group will include 20 older adults with a self-reported history of falls or fear of falling. They will complete both interventions: Balance Training with Fall-Arrest Harness and Balance Training with Adjustable Harness.
2842514|NCT03651284|Experimental|Aim2Be Live Coach|Aim2Be app with Live Coach + Fitbit + BMI tracking tools
2842515|NCT03651284|Experimental|Aim2Be Virtual Coach|Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools
2842516|NCT03651284|Sham Comparator|Aim2Be Waitlist|Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools
2842517|NCT03651271|Experimental|"Hot tumors"|Participants with ≥ 15% CD8 cells in their tumor biopsies (ie, CD8 high tumors) will be treated with single-agent nivolumab. At PD, participants will be allowed to add ipilimumab.
2842518|NCT03651271|Experimental|"Cold tumors"|Participants with < 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
2842519|NCT03651258||Experimental group|patient who can benefit from the ALIJEU for certain meals
2842520|NCT03651258||Group of witnesses|patient who did not benefit from the ALIJEU
2842521|NCT03651232|Experimental|yoga|weekly prenatal yoga group class
2842522|NCT03651232|Active Comparator|support|weekly group support class
2842523|NCT03651219|Experimental|experimental group|Patients use Apatinib Mesylate tablets combined with Irinotecan.
2842524|NCT03651219|Active Comparator|controlled group|Patients use Irinotecan
2842525|NCT03651206|Experimental|Arm A - Niraparib|Niraparib, 200 mg or 300 mg, daily dose
2842526|NCT03651206|Experimental|Arm B - Niraparib plus TSR-042|"Niraparib, 200 mg or 300 mg, daily dose~TSR042, intravenous infusion on Day 1 of every 21-day cycle at 400 mg for the 4 first cycles, followed by 1,000 mg on Day 1 of every 42-day cycle thereafter"
2842527|NCT03651206|Active Comparator|Arm C - Chemotherapy drugs|"Chemotherapies (Standard of care)~For Ovarian Cancer Patients Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin, 40 mg/m², Intravenous, every 28 days Topotecan, 4mg/m², Intravenous, Day 1, 8, 15 every 28 days~For Endometrial Cancer Patients Doxorubicin, 60 mg/m², Intravenous, every 21 days Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Gemcitabine, 800 mg/m², Intravenous, Day 1, 8 every 21 days"
2842528|NCT03651193||AOSD|Patients fulfill Japan's Yamaguch AOSD classification
2842529|NCT03651193||Control|Use 1:1 group matching, should meet the following condition -s : same gender as matching case; same age as matching case or the difference ranges within 1 year; no Immune related diseases (e.g. Psor -iasis, Systemic Lupus Erythematos -us, Dermatomyositis, Scleroderma, Rheumatoid Arthritis, Type 1 Diabet -es, Behcet's disease, Sjogren's Syndrome, Hyperthyroidism, etc.); no family history of immune related diseases.
2842530|NCT03651180||Amphilimus eluting stent|Diabetic patients treated with Cre8 Amphilimus eluting stent
2842531|NCT03651180||Non Amphilimus eluting stent|Diabetic patients treated with any other drug eluting stent
2842532|NCT03651154|Experimental|Hypovolemic Phlebotomy|"Hypovolemic Phlebotomy will consist of the withdrawal of 7-10 mL/kg of whole blood from the patient, as tolerated (e.g. for a 70kg patient, 490 to 700 mL of whole blood will be removed) The volume of removed blood will not be replaced by the administration of intravenous fluids.~Removed blood will be transfused back to participant at the end of surgery. The phlebotomized whole blood will be transfused back after liver transection regardless of blood loss."
2842533|NCT03651154|No Intervention|Control (Standard of Care)|Standard of care (low CVP surgery). In this arm, standard anesthesia will be maintained.
2842534|NCT03651141|Experimental|Neurodynamic Sliding|neurodynamic sliding consists of 2 movements; 1) movement 1 involves sitting on the edge of the treatment table the bringing their neck to their chest along with bending their knee and pointing their ankle to the ground. Movement 2 is performed by facing their head towards the ceiling and straightening their knee while pointing their ankle towards their nose. Subjects will alternate these 2 active movements for 60s and repeated 5 times, with rest period of 15s between sets.
2842535|NCT03651141|Experimental|Myofascial Decompression|For the group receiving the cupping treatment, the subject will lay on their stomach and their affected hamstring will be exposed. Cocoa butter will be applied to the hamstring prior to the application of the cups. 5 cups will be placed along the hamstring and calf muscles. Using a handheld suction pump, each cup will be pumped so that skin fills up half of the cup. The cups will stay in place for five minutes and the clinician will instruct the subject to perform 5 repetitions of active quad sets and 5 repetitions of ankle pumps .
2842536|NCT03651141|Sham Comparator|Diathermy|The control group will receive a sham heat (diathermy treatment). The subjects will be asked to sit and relax for five minutes and the machine will not be turned on with a timer timing the treatment.
2842537|NCT03651128|Experimental|Arm A - Administration of bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
2842538|NCT03651128|Experimental|Arm B- standard regimens as per Investigator's discretion|"The participants will receive one of following regimens~Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose dexamethasone (dex) (DPd)~DARA in combination with bortezomib (BTZ) and low-dose dex (DVd)~Ixazomib (IXA) in combination with lenalidomide (LEN) and low-dose dex (IRd)"
2842539|NCT03651115||Neonates with gentamicin|
2842540|NCT03651115||Neonates with vancomycin|
2842541|NCT03651102|Experimental|Patients Receiving Thalidomide Therapy|All the study patients will be given thalidomide at an average dose of 1.5mg/kg/day (range 1-2mg/kg/day). The patients will be followed at 4 weeks interval by a haematologist for monitoring of potential side effects and for evaluation of clinical and laboratory response.
2842542|NCT03651089|Active Comparator|SP16 0.0125|0.0125 mg/kg of SP16 will be administered by subcutaneous injection once
2842543|NCT03651089|Active Comparator|SP16 0.050|0.050 mg/kg of SP16 will be administered by subcutaneous injection once
2842544|NCT03651089|Active Comparator|SP16 0.20|0.20 mg/kg of SP16 will be administered by subcutaneous injection once
2842545|NCT03651089|Placebo Comparator|placebo|Placebo (sterile saline) will be administered by subcutaneous injection once
2842546|NCT03651076|Experimental|Traxi panniculus retraction group|The method of panniculus retraction will be the Traxi panniculus retraction (Clinical Innovations, LLC) by the provider.
2842547|NCT03651076|No Intervention|Standard of care|Standard methods of panniculus retraction as determined by individual provider (including medical taping, extra personnel for retraction)
2842548|NCT03651063|Experimental|social robot group|
2842549|NCT03651063|Active Comparator|computer group|
2842550|NCT03651063|Active Comparator|self-training group|
2842551|NCT03651050|Experimental|intervention FBOs receive the P-MHDT|
2842552|NCT03651050|Experimental|control FBOs receive no P-MHDT|
2842553|NCT03651037|Experimental|Thrivors+BH|For Thrivors+BH, a module will be developed for users to input pain and energy levels, enabling real-time customization of exercise regimens. Modules of clinically validated bone health exercises with instructional videos will be developed. Additionally, users will be able upload and send videos of themselves exercising for feedback and assessment. This version will contain bone health educational content, mindfulness and nutrition resources.
2842554|NCT03651037|Experimental|Thrivors Basic|A Thrivors Basic version that lacks customization and video content will be developed. This version will contain bone health educational content, mindfulness and nutrition resources.
2842555|NCT03651024|Other|Treating Patients with ED|Treatment of patients with ED
2842556|NCT03651011|Active Comparator|Aflibercept + Navigated laser|Patients will receive intravitreal aflibercept at M0, M1 and M2 (loading phase) and in addition receive navigated retinal laser photocoagulation at M3. Patients will receive aflibercept according to pro re nata regimen from M3-M12.
2842557|NCT03651011|Active Comparator|Aflibercept only|Patients will receive intravitreal aflibercept at M0, M1 and M2 (loading phase). Patients will receive aflibercept according to pro re nata regimen from M3-M12.
2842558|NCT03650998|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0.375% single shot.~In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
2842559|NCT03650998|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL Saline single shot.~In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
2842560|NCT03650985|Experimental|TOCTD|Pregnancy women with complicated twin diseases, who are able to withstand risks of intrauterine treatments and informed consent, will be involved. Fetoscope technique will be administered in suitable patients.
2842561|NCT03650972|No Intervention|A, Non-bicarbonate|When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group A the labour is treated according to the hospital's current guidelines during labour arrest, i.e. the stimulation with oxytocin is started and AFL is measured again after one hour
2842562|NCT03650972|Active Comparator|B, Bicarbonate group|When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
2842563|NCT03650959|Experimental|Faculty-led|
2842564|NCT03650959|Experimental|Peer tutor-led|
2842565|NCT03650959|Experimental|Computer augmented self-directed learning|
2842566|NCT03650946||1|men with high or intermediate risk localized disease who are about to undergo definitive surgery or radiotherapy
2842567|NCT03650946||2|men with rising PSA after local definitive treatments
2842568|NCT03650946||3|m0CRPC with a PSA >1.0 or 2.0
2842569|NCT03650933|Experimental|G-CHOP|GB241 plus CHOP, six cycles. GB241: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
2842570|NCT03650933|Active Comparator|R-CHOP|Rituximab plus CHOP, six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
2842596|NCT03650699|Experimental|Self-Directed Tongue Strengthening Rehab|The self-directed tongue strengthening program (8 sessions) followed by Electropalatography Biofeedback Training (8 sessions). Assessments will be taken during the beginning, middle, and end of each study arm.
2842624|NCT03650478|Experimental|Premature infants group|NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)
2842571|NCT03650920|Experimental|Recipient of HCV positive liver graft|A single center, open-label, pilot study examining 10 adult HCV negative liver transplant subjects who receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after liver transplantation, unless extenuating clinical circumstances arise (such as fibrosing cholestatic HCV, which would prompt earlier treatment, or non-hepatic comorbidities which would prompt delay in treatment).
2842572|NCT03650907|Experimental|Group exercise program by coach|
2842573|NCT03650907|Sham Comparator|Self exercise|
2842574|NCT03650894|Experimental|Nivolumab, Ipilimumab, and bicalutamide|Participants will receive nivolumab plus ipilimumab combination therapy. Participants should receive nivolumab at a dose of 240 milligrams (mg) fixed dose as a 30-minute intravenous (IV) infusion prepared in 50 milliliter (ml) normal saline (NS) every 2 weeks until progression. Participants should receive ipilimumab at a dose of 1 mg/kilogram as a 30-minute IV infusion prepared in 50 ml NS every 6 weeks. All subjects will take bicalutamide 150mg (3 x 50mg tablets) daily.
2842575|NCT03650881|Experimental|Neutrogena ® Light Therapy Acne Mask (MASK)|Over-the-counter powered light-based device for the treatment of acne
2842576|NCT03650881|Active Comparator|Topical benzoyl peroxide 2.5% gel and OTC adapalene|Over-the-counter medication for the treatment of acne + 0.1% Adepalene Gel
2842577|NCT03650868|No Intervention|Control Group|
2842578|NCT03650868|Experimental|TPVB group|Thoracal paravertebral block will be performed with 20cc of 0,25% bupivacaine preoperatively.
2842579|NCT03650842|Experimental|Tissue and cerebral oxygenation|Tissue and cerebral oxygenation will be monitored using near infrared spectroscopy (NIRS).
2842580|NCT03650816||Alzheimer Disease|"Patients with Alzheimer's disease, as defined by the established clinical consensus criteria (DSM IV-TR and NINCDS-ADRDA)~Doppler ultrasonography will be used in these patients to assess CVR CO2 , as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.~Biospecimen collection will be performed in these patients : a blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care, to determine plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity"
2842581|NCT03650816||Subjective Cognitive impairment|"Patients with subjective cognitive impairment, who consulted for cognitive complaint without cognitive impairment on neuropsychological tests and normal performances according to daily life activities scores.~Doppler ultrasonography will be used in these patients to assess CVR CO2 , as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.~Biospecimen collection will be performed in these patients : a blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care, to determine plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity"
2842582|NCT03650803|Experimental|3D MR Fingerprinting scan|Three separate 3D MR fingerprinting scans: Before the start of chemotherapy, 7-10 days after the first cycle of chemotherapy, and within 1 month of the end of chemotherapy treatment.
2842583|NCT03650790|Active Comparator|preeclamptic obese pregnancy|CTRP 9 level will be assessed by 40 obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.
2842584|NCT03650790|Active Comparator|preeclamptic non-obese pregnancy|CTRP 9 level will be assessed by 40 non-obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.
2842585|NCT03650790|Active Comparator|normal pregnancy|CTRP 9 level will be assessed by 40 normal gestational ELISA methods
2842586|NCT03650764|Experimental|Phase I: Ramucirumab + Pembrolizumab|-Ramucirumab will be administered IV over 1 hour on Day 1 of each 21-day cycle. Pembrolizumab will be administered as per standard of care (IV at a dose of 200 mg over 30 minutes on Day 1 of each 21-day cycle). On Day 1, pembrolizumab will be given after ramucirumab.
2842587|NCT03650764|Experimental|Phase II: Ramucirumab + Pembrolizumab|-Patients will be treated with ramucirumab at the RP2D on Day 1 and SOC pembrolizumab (200 mg IV over 30 minutes) on Day 1 of each 21-day cycle.
2842588|NCT03650751||stroke patients；neurologic impairment|It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.
2842589|NCT03650738|Experimental|Study group|apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
2842590|NCT03650725||Mandatory Split bowel preparation|Patients will be advised to take 4 liters of polyethylene glycol (PEG), split into two 2 liter doses. The first 2 liters are to be taken starting at 1800 hours the day before the colonoscopy, and the second dose is to be taken starting 4-5 hours prior to the scheduled time for the colonoscopy. Each dose will be taken within a 2-hour time span.
2842591|NCT03650725||Optional Split bowel preparation|Patients will be advised on split-dose bowel preparation (as per option 1), but will also receive instructions on day before bowel preparation. The instructions will indicate that split-dose bowel preparation is the optimal preparation for cleansing the bowel and for visualizing polyps, but they may choose day before bowel preparation if the split dose preparation is too difficult for them.
2842592|NCT03650712|Other|frequently sampled oral glucose tolerance testing|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit
2842593|NCT03650712|Other|Frequently sampled oral glucose tolerance testing anc CGM|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + continuous glucose monitor will be placed after the visit and mailed back
2842594|NCT03650712|Other|frequently sampled oral glucose tolerance testing and DXA|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + a DXA scan will be done at the same visit
2842595|NCT03650712|Other|frequently sampled oral glucose tolerance testing, CGM & DXA|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + continuous glucose monitor will be placed after the visit and mailed back + a DXA scan will be done at the same visit
2842623|NCT03650491|Experimental|Experimental: FOR46 (Dose Expansion)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
2842597|NCT03650699|Experimental|SLP Directed Face-to-Face Rehab|The SLP directed face-to-face rehabilitation program (8 sessions) will be followed by Electropalatography Biofeedback Training (8 sessions). Assessments will be taken during the beginning, middle, and end of each study arm.
2842598|NCT03650673|Other|Diagnostic Test: Identification of subgroups of patients with|
2842599|NCT03650660||Patients with liver cirrhosis|
2842600|NCT03650647|Active Comparator|Indirect Pulp Capping|"Nonselective removal to hard dentine (formerly complete excavation or complete caries removal) : removal of soft dentin, only hard dentine is left on the cavity, so that demineralized dentine free of bacteria is completely removed.~Intervention: Total soft and leathery caries removal. Carious dentin removal"
2842601|NCT03650647|Experimental|Stepwise excavation|"Stepwise removal is carious tissue removal in 2 stages, i.e., visits. Soft carious tissue is left over the pulp in the first step, while peripheral dentine is prepared to hard dentine to allow a complete and durable seal of the lesion. A provisional restoration is placed, which should be sufficiently durable to last up to 6 months to allow changes in the dentine and pulp to take place. After this period, a second excavation is done and, if there is hard dentin formed, the tooth is restored.~Intervention: Part of the soft caries is removed. Final restoration is placed on the second visit. Carious dentin removal"
2842602|NCT03650647|Experimental|Selective caries removal|"Selective caries removal: only part the soft dentine is removed, so soft carious tissue is left over the pulp, while peripheral enamel and dentine are prepared to hard dentine, to allow a tight seal and placement of a durable restoration.~Intervention: Part of the soft caries is removed. Final restoration is place over the soft dentin. Carious dentin removal"
2842603|NCT03650621|Experimental|Intervention - Magnetic acupuncture|"Infants randomized to the intervention arm will have 5 magnetic stickers placed on both ears approximately 1 hour before the eye-exam and will stay in place for approximately 1 hour after the eye-exam.~Total duration of study 2.5-3 hours"
2842604|NCT03650621|Placebo Comparator|Control - Placebo control|"In this arm the infants will have 5 stickers (magnets removed) placed on their ear approximately 1 hour before the eye-exam and will stay in place for approximately 1 hour after the eye-exam.~Total duration of study 2.5-3 hours"
2842605|NCT03650608|Experimental|Cohort 1: HL217 Ophathalmic Solution QD|HL217 3mg/mL, Ophthalmic solution, two drop once a day
2842606|NCT03650608|Experimental|Cohort 2: HL217 Ophathalmic Solution BID|HL217 3mg/mL, Ophthalmic solution, two drop twice a day
2842607|NCT03650608|Experimental|Cohort 3: HL217 Ophthalmic Solution QID|HL217 3mg/mL, Ophthalmic solution, two drop four times a day
2842608|NCT03650608|Placebo Comparator|Placebo Ophthalmic solution|Placebo Ophthalmic solution, two drop once or twice or four times a day
2842609|NCT03650595|Experimental|Single arm prospective clinical trial|This is a single arm study where patients with low-intermediate risk MR visible locally confined prostate cancer will be treated with focal laser ablation under MRI guidance in the magnet. Following treatment, the patients will be assessed by MRI and Biopsy at 6 months and at 2 years, with PSA assessment at regular intervals during the time
2842610|NCT03650582|Experimental|Glucagon|Glucagon, 0.7mg, intranasal, single dose
2842611|NCT03650582|Placebo Comparator|Placebo|Placebo, intranasal, single dose
2842612|NCT03650556|Experimental|Ablation|Pulmonary vein isolation by radiofrequency ablation treatment TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) in the persistent AF population.
2842613|NCT03650543|Experimental|amoxicillin clarithromycin omeprazole 1|"This group received triple standard therapy with standard doses of omeprazole. 20 mg omeprazole before breakfast and before dinner. 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days."
2842614|NCT03650543|Experimental|amoxicillin clarithromycin omeprazole 2|"This group received triple standard therapy, using 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days in addition with omeprazole but omeprazole doses were prescribed according to CYP2C19 genotype as a follows: a) Patients with CYP2C19 *1/*1 genotype (Early and ultrarapid Metabolizer): 40mg omeprazole before breakfast and before dinner. b) Patients with CYP2C19 *1/*2 or *1/*3 genotype (Intermediate Metabolizer): 20mg omeprazole before breakfast, 20mg before lunch and 20mg before dinner. c) Patients with CYP2C19 *2/*2 (Poor Metabolizer): 20mg omeprazole before breakfast and 20 mg before dinner."
2842615|NCT03650530|Experimental|The Family Talk Intervention|These families will participate in a psychosocial support program.
2842616|NCT03650517||Robotic Right Colectomy with ICA|"Robot-assisted surgery (RAS), allows many types of complex MIS procedures using robotic systems to aid in surgical procedures providing more precision, flexibility and control than is possible with other MIS techniques.~Intracorporeal anastomosis: when the anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique. A Pfannenstiel incision will be done exclusively for specimen extraction."
2842617|NCT03650517||Robotic Right Colectomy with ECA|"Robot-assisted surgery (RAS), allows many types of complex MIS procedures using robotic systems to aid in surgical procedures providing more precision, flexibility and control than is possible with other MIS techniques.~Extracorporeal anastomosis: when the anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed."
2842618|NCT03650517||Laparoscopic Right Colectomy with ICA|"Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a surgical technique in which operations are performed far from their location through small incisions (usually 0.5-1.5 cm) elsewhere in the body.~Intracorporeal anastomosis: when the anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique. A Pfannenstiel incision will be done exclusively for specimen extraction."
2842619|NCT03650517||Laparoscopic Right Colectomy with ECA|"Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a surgical technique in which operations are performed far from their location through small incisions (usually 0.5-1.5 cm) elsewhere in the body.~Extracorporeal anastomosis: when the anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed."
2842620|NCT03650504|Experimental|Above Artery Group|
2842621|NCT03650504|Active Comparator|Between Artery and Vein Group|
2842622|NCT03650491|Experimental|Experimental: FOR46 (Dose Escalation)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
2843000|NCT03647800|Experimental|Dose Escalation (0.3 mcg of APVO436)|Cohort 1
2842625|NCT03650478|Experimental|Bronchiolitis group|NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)
2842626|NCT03650465|Experimental|CT/BTP|Cognitive-behavioral therapy (CBT) in the form of Borkovec's treatment package (CT/BTP for GAD) was derived from Borkovec and Costello's (1993) therapeutic approach, relying on principles of CT for anxiety (A. T. Beck & Emery, 1985) and including applied relaxation. The CT/BTP protocol included several directions as primary goals in therapy: providing a cognitive conceptualization of the problem, identifying and restructuring automatic thoughts, intermediate and core beliefs through cognitive and behavioral techniques (i.e., behavioral experiments), enhancing adaptive behavior (i.e., activity scheduling, dealing with avoidance behavior, social skills training), and using applied relaxation as a coping strategy.
2842627|NCT03650465|Experimental|REBT|Cognitive-behavioral therapy (CBT) in the form of REBT was based on the approach of Dryden & DiGiuseppe (1990), having as a central tenet changing dysfunctional emotions (e.g., anxiety) into functional ones (e.g., healthy anxiety/concern) by changing irrational beliefs into rational beliefs using cognitive, emotive, and behavioral techniques. The structure of an REBT session parallels the CT/BTP session structure including the same elements, but often with a different content. In its elegant/specific form, used here, REBT is focused on changing the core irrational beliefs (i.e., evaluative beliefs/appraisals) seen as the fundamental etiopathogenetic mechanism of GAD.
2842628|NCT03650465|Experimental|ACT/ABBT|Cognitive-behavioral therapy (CBT) in the form of the ACT/ABBT protocol was derived from the principles and techniques proposed by Eifert and Forsyth (2005) and Roemer and Orsillo (2005). From this perspective, GAD is maintained by dysfunctional reactions to internal experiences (i.e., emotions, thoughts, bodily sensations), experiential avoidance, and behavioral restriction, so the treatment aims to address all of these problems. In this sense, ACT/ABBT includes three major treatment goals: (1) education about the nature of anxiety, worry and the role of experiential avoidance; (2) practicing mindfulness and acceptance skills when dealing with disturbing internal experiences; and (3) identifying values and following valued action paths when facing obstacles.
2842629|NCT03650452|Experimental|TAK-935|Treatment: two weeks titration followed by 12 weeks maintenance period.
2842630|NCT03650452|Placebo Comparator|Placebo|Treatment: two weeks titration followed by 12 weeks maintenance period.
2842631|NCT03650426|Active Comparator|Onlay patellar resurfacing technique|
2842632|NCT03650426|Experimental|Inlay patellar resurfacing technique|
2842633|NCT03650413|Experimental|UTTR1147A|All participants will have the opportunity to receive treatment with UTTR1147A until clinical remission is achieved. Participants will either receive treatment with UTTR1147A or undergo observation depending on disease status, as described in the protocol.
2842634|NCT03650400|Experimental|Fevipiprant|Fevipiprant Cohort A; Fevipiprant Cohort B; Chewable tablet
2842635|NCT03650387|Experimental|RADIESSE® (+) Lidocaine|
2842636|NCT03650374|Active Comparator|Group 1|standard of care postoperative rehabilitation.
2842637|NCT03650374|Experimental|Group 2|experimental strength training
2842638|NCT03650361|Experimental|Test Product|Adapalene Gel 0.3% manufactured by Aleor Dermaceuticals Limited, applied for 84 days
2842639|NCT03650361|Active Comparator|Reference Product|Adapalene Gel 0.3%, , applied for 84 days
2842640|NCT03650361|Placebo Comparator|Placebo Control|Vehicle of the test product, applied for 84 days
2842641|NCT03650348|Experimental|PRS-343 in Combination with Atezolizumab|
2842642|NCT03650335||group I|with a total of 20 mL 0.25% bupivacaine injection to be administered
2842643|NCT03650335||group II|with a total of 20 mL 0.25% bupivacaine injection to be administered
2842644|NCT03650322|Experimental|Yoga Practice|Participants will be led through a beginner yoga course taught by a certified yoga instructor. Classes will meet twice a week for 75 minutes each for the duration of 12 weeks. Sessions will focus on yoga postures, breathing, and meditative practices and may utilize mats, blocks, belts, and blankets.
2842645|NCT03650322|Active Comparator|Strength Training|This 12 week, progressive strength training course will aid participants in building whole body strength and flexibility by utilizing weights, chairs, mats, and various other exercise equipment. Sessions will meet three times a week for 50 minutes and will offer 'easy' and 'hard' modifications taught by an exercise leader.
2842646|NCT03650322|Active Comparator|Aerobic Walking|Participants will partake in treadmill walking that encourages them to reach a pre-determined heart rate range. Sessions will be conducted three times a week for 50 minutes, and offer participants to self-select a speed and incline to meet their target heart rate zone.
2842647|NCT03650309|Experimental|Deep Brain Stimulation|All patients will receive deep brain stimulation (DBS) targeting two brain areas involved in the pathophysiology of obesity. No other changes to pre-existing treatment will be made. This is the only arm in this experiment.
2842648|NCT03650296||Resusci Baby|Resusci Baby used for the simulated emergency scenario
2842649|NCT03650296||MegaCode-Kid|MegaCode-Kid used for the simulated emergency scenario
2842650|NCT03650296||Ambu® Junior|Ambu® Junior used for the simulated emergency scenario
2842651|NCT03650270|Experimental|Phenobarbital|If allocated to this arm 'Phenobarbital' (PHB group), the clinician gives an IV bolus of phenobarbital (20mg/kg ). If CSE did not terminate after 5 - 10 minutes, a second dose is given at half the dosage (10mg/kg) and a third dose (10mg/kg) is given if CSE persists 5-10 minutes after that.
2842652|NCT03650270|Active Comparator|Phenytoin / Midazolam infusion|In the 'Phenytoin / Midazolam infusion' (PHY/MDZ group), children are given a dose (20mg/kg) of IV phenytoin mixed with 50mL of normal saline solution and administered over 30 minutes . If the child is still in CSE 5-10 minutes after the phenytoin is given, they then start on a midazolam infusion. This includes a loading dose of IV midazolam (0.2mg/kg) followed by an infusion set at 3mg/kg into 50mL 5% dextrose water given at a rate of 1-4 mL/hour (equivalent to 1-4 mcg/kg/min ).
2842653|NCT03650257|Experimental|gp96 group|"autologous gp96 vaccination administered in combination with temozolomide following standard treatment with radiation and temozolomide.~Patients receive standard treatment with radiation and temozolomide after surgery. Then gp96 vaccines are administered via subcutaneous injection in 25-μg doses every week for 6 weeks. Cyclophosphamide (400 mg) was given through intravenous injection before each vaccine injection. Then Patients receive adjuvant treatment with temozolomide."
2842654|NCT03650257|Active Comparator|control group|Patients receive standard treatment with radiation and temozolomide after surgery. Then only adjuvant treatment with temozolomide is administered.
2842655|NCT03650244||Patients fitted with REMEEX|
2842656|NCT03650218|Experimental|THIODERM STRONG|"THIODERM STRONG injected into the upper arm (cohort 1)~THIODERM STRONG injected into nasolabial folds (cohort 2)"
2842657|NCT03650205|Active Comparator|Ivabradine|Patients will receive ivabradine just before anthracycline chemotherapy, 5 mg per oral twice daily, until one month after the last chemotherapy session.
2842658|NCT03650205|Placebo Comparator|Placebo|Patients will receive placebo just before anthracycline chemotherapy, one capsule per oral twice daily, until one month after the last chemotherapy session.
2842659|NCT03650179||Patients enrolled in the cohort|Patients over 18 years old, consulting for functional digestive disease, without neurologic or urologic disease, and performing an urodynamic examination in neuro-urology and functional explorations department.
2842660|NCT03650166|Active Comparator|Enhanced usual care|Participants receive a personal, validated home BP monitor with oral and written instruction.
2842661|NCT03650166|Experimental|MyBP|Participants receive a personal, validated home BP monitor with oral and written instruction. In addition patients receive instruction on, and access to, MyBP. This program provides high BP education through online videos and automated, bidirectional text messaging to assist in continuous home BP self-monitoring.
2842662|NCT03650153|Active Comparator|Trans-rectal MRI targeted Biopsy|Trans-rectal to perform the prostate MRI targeted biopsy The puncture points are at the rectal
2842663|NCT03650153|Active Comparator|Trans-perineal MRI targeted Biopsy|Trans-perineal to perform the prostate MRI targeted biopsy The puncture points are at the perineal
2842664|NCT03650140|Active Comparator|Tart cherry concentrate 60 mL|Subjects will receive a single oral dose of 60 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 120 mL dose group.
2842665|NCT03650140|Active Comparator|Tart cherry concentrate 120 mL|Subjects will receive a single oral dose of 120 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 60 mL dose group.
2842666|NCT03650114|Experimental|Ofatumumab|Subcutaneous injection
2842667|NCT03650088|Experimental|Weight Loss Intervention|Behavioral weight loss program with digital tools including smartphone app for dietary self-monitoring using a 'traffic light' approach, physical activity tracker, smart scale, and blood glucose monitoring plus with weekly consultation (in person or phone) with an interventionist for behavioral lessons and supports.
2842668|NCT03650075|Placebo Comparator|Single Ascending Dose (SAD)|
2842669|NCT03650075|Placebo Comparator|Multiple Ascending Dose (MAD)|
2842670|NCT03650075|Experimental|Food Effect Part|
2842671|NCT03650036|Experimental|Group 1|In group 1, Pulp Therapy will be done with the CTZ paste (composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline, 125 mg of zinc oxide) will be manipulate with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use and will be taken at the tip of a number 5 exploratory probe and dispensed at the entrances of the root canals where it will be accommodated with light pressure of sterile cotton balls. The CTZ paste will be protected with a thin layer of gutta-percha, previously heated in an alcohol lamp and placed in a thin layer on the CTZ pulp. The gutta-percha blade will be condensed with medium size amalgam presser and has the objective of physically isolating the CTZ paste from the restorative material.
2842672|NCT03650036|Experimental|Group 2|In Group 2, Pulp Therapy will be done with ZOE paste. The mechanical preparation of the root canals with 2% chlorhexidine solution and first-series K files will be performed. The instrumentation limit shall be 1 mm short of the radiographic apex. After finishing the chemical-mechanical preparation, drying of the root canals with sterile absorbent paper cones and ZOE paste insertion with K files will be performed. The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use. The protection of the ZOE paste will follow the same sequence as the CTZ paste.
2842673|NCT03650023|Experimental|Chitosan Oligosaccharide (GO2KA1)|Chitosan Oligosaccharide (GO2KA1) capsule was provided to the study participants. The Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted. The Chitosan Oligosaccharide (GO2KA1) one capsule had Chitosan Oligosaccharide 250mg.
2842674|NCT03650023|Placebo Comparator|White egg|White egg capsule was provided to the study participants. The White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted. The Chitosan Oligosaccharide (GO2KA1) one capsule had White egg 250mg.
2842675|NCT03649997|Experimental|Part 1 (Single Ascending Dose [SAD]): Cohort 1|Participants will receive single oral dose of JNJ-61393215 145 milligram (mg) suspension or matching placebo on day 1, under fasted conditions.
2842676|NCT03649997|Experimental|Part 1 SAD: Cohort 2|Participants will receive single oral dose of JNJ-61393215 225 mg suspension or matching placebo on day 1 under fasted conditions. Dose in this cohort will be determined based on safety and PK data of cohort 1.
2842677|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence CDEF|Participants will receive single oral dose of JNJ-61393215 30 mg suspension under fasted condition (Treatment C) in Period 1, then participants will receive single oral dose of JNJ-61393215 30 mg capsule under fasted condition (Treatment D) in Period 2, single oral dose of JNJ-61393215 30 mg capsule with high fat/high-calorie breakfast (Treatment E) in Period 3 followed by single oral dose of JNJ-61393215 30 mg capsule with standardized breakfast (Treatment F) in Period 4, on day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods.
2842678|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence DFCE|Participants will receive Treatment D in Period 1, then Treatment F in Period 2, then Treatment C in Period 3 followed by Treatment E in Period 4 on Day 1.
2842679|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence ECFD|Participants will receive Treatment E in Period 1, then Treatment C in Period 2, then Treatment F in Period 3 followed by Treatment D in Period 4 on Day 1.
2842680|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence FEDC|Participants will receive Treatment F in Period 1, then Treatment E in Period 2, then Treatment D in Period 3 followed by Treatment C in Period 4 on Day 1.
2842708|NCT03649867|Other|Semi-structured interview|Each female patient who attended the Survive & Thrive course designed for survivors of interpersonal trauma who meets the inclusion criteria will be invited to take part in a semi-structured interview. This interview will explore their experience of this psychoeducational course.
2842971|NCT03647995|Placebo Comparator|Placebo|The placebo group will receive once daily, identical capsules containing 0 Bn CFU.
2842972|NCT03647982|Experimental|botulinum toxin 1U|
2842681|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence GHIJ|Participants will receive single oral dose of JNJ-61393215 suspension under fasted condition (Treatment G) in Period 1, then participants will receive single oral dose of JNJ-61393215 capsule under fasted condition (Treatment H) in Period 2, single oral dose of JNJ-61393215 capsule with high fat/high-calorie breakfast (Treatment I) in Period 3 followed by single oral dose of JNJ-61393215 capsule with standardized breakfast (Treatment J) in Period 4, on day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods. Dose in this cohort will be based on the results obtained in Part 1.
2842682|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence HJGI|Participants will receive Treatment H in Period 1, then Treatment J in Period 2, then Treatment D in Period G followed by Treatment I in Period 4 on Day 1.
2842683|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence IGJH|Participants will receive Treatment I in Period 1, then Treatment G in Period 2, then Treatment J in Period 3 followed by Treatment H in Period 4 on Day 1.
2842684|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence JIHG|Participants will receive Treatment J in Period 1, then Treatment I in Period 2, then Treatment H in Period 3 followed by Treatment G in Period 4 on Day 1.
2842685|NCT03649997|Experimental|Part 3 Cohort 5: Multiple Ascending Dose|Participants will receive oral JNJ-61393215 145 mg suspension or matching placebo once daily for 7 days under fasted conditions.
2842686|NCT03649997|Experimental|Part 3 Cohort 6: Multiple Ascending Dose|Participants will receive oral JNJ-61393215 225 mg suspension or matching placebo once daily for 7 days under fasted conditions. Dose may be lowered or increased based on the evaluation of safety and PK of Cohort 5. This dose may be the same as the dose chosen for Cohort 2 (Part 1), or it could be different.
2842687|NCT03649984|Experimental|Symptom Navi© Program|Nurses provide two semi-structured consultation to facilitate basic symptom self-management of patients based in the Symptom Navi© Flyers
2842688|NCT03649984|No Intervention|Standard care|Standard care including information about treatment, potential side effects and expected symptoms under treatment with or without additional written material following the established procedure at the centre.
2842689|NCT03649971|Experimental|Guselkumab Dose 1|Participants will receive guselkumab Dose 1 subcutaneous (SC), 6 doses every 4 weeks from Week 0 to Week 20.
2842690|NCT03649971|Experimental|Guselkumab Dose 2|Participants will receive guselkumab Dose 2 SC, 6 doses every 4 weeks from Week 0 to Week 20.
2842691|NCT03649971|Placebo Comparator|Placebo|Participants will receive placebo SC, 6 doses every 4 weeks from Week 0 to Week 20.
2842692|NCT03649958|Active Comparator|HIRREM-SOP|HIRREM-SOP is a novel, noninvasive, closed-loop, BrainEcho, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time..
2842693|NCT03649958|Placebo Comparator|random notes|Participants randomized to the control will be seated in a comfortable zero-gravity chair identical to those in the active arm, and will also listen to a pattern of musical notes, but they will be random, and not linked to their brain activity patterns.
2842694|NCT03649945|Active Comparator|Test Group 1|Docetaxel plus Nedaplatin combined with Endostar
2842695|NCT03649945|Active Comparator|Test Group 2|Docetaxel plus Nedaplatin
2842696|NCT03649945|No Intervention|Control Group|No medicine intervention
2842697|NCT03649932|Experimental|Low Dose|50 mg/kg given two times a day (100 mg/kg/day) for total 7 days.
2842698|NCT03649932|Experimental|Medium Dose|100 mg/kg given two times a day (200 mg/kg/day) for total 7 days
2842699|NCT03649932|Experimental|High Dose|150 mg/kg given two times a day (300 mg/kg/day) for total 7 days.
2842700|NCT03649919||1 spinal muscular atrophy, SMA|Progressive muscular atrophy (SMA) is a group of autosomal recessive neuromuscular diseases characterized by degeneration of the anterior horn cells of the spinal cord, which is characterized by progressive generalized muscle weakness and muscle atrophy. The incidence of SMA is about 1/11000, and the occurrence of SMA is caused by mutation of the SMN1 gene. SMA can be classified into type I-III according to age of onset, maximum muscle activity, and survival.
2842701|NCT03649919||2 DMD|Progressive muscular dystrophy (DMD) is a group of hereditary skeletal muscle degeneration diseases. It is clinically characterized by slow and progressive development of muscle atrophy and muscle weakness. The inheritance can be divided into sexual chain recessiveness. Genetic type. For children with high suspected DMD/BMD, the current DMD diagnosis is preferred by MLPA method for detection of DNA in peripheral blood; MLPA diagnostic kit can only detect about 65% of large gene deletions or repeat types, thus detecting undetected gene mutations.
2842702|NCT03649919||3 X-linked adrenoleukodystrophy X-ALD|X-linked adrenoleukodystrophy X-ALD is an X-linked episode of a group of diseases characterized by progressive central nervous system demyelination and adrenal insufficiency. About 1/20000 male children. Most cases of X-ALD are treated for neurological symptoms for the first time, most of them start from 3-10 years old. Early manifestations include slow mental function, decreased academic performance, lack of interest or hyperactivity, difficulty in speech, difficulty in articulation, etc. Visual impairment and progressive hemiplegia are more common symptoms.
2842703|NCT03649919||4 tuberous sclerosis complex，TSC|Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease involving multiple systems. About 1 in every 6,000-10,000 people in TSC suffer from tuberous sclerosis, and children in the neurology department are diagnosed with developmental delay or seizures, and about 2/3 have no positive family history. Nearly 2 million people worldwide suffer from TSC, and there are about 200,000 in China.
2842704|NCT03649906|Experimental|Optimized Localization Group|Subjects have small pulmonary nodules. In order to facilitate the search for nodules during surgery, it is necessary to indwelling markers pre-operative.
2842705|NCT03649893|No Intervention|Control Group|The control group will use conventional siiting-desk office.
2842706|NCT03649893|Experimental|Active Office Group|The experimental group will use active offfice, including sit-to-stand desk, bike desk, seddle chair and active breask.
2842707|NCT03649880|Experimental|Diagnostic (FMISO, PET/MRI or PET/CT)|Participants receive ¹⁸F-fluoromisonidazole IV and 1.5 - 2 hours later undergo PET (Positron Emission Tomography)/CT (Computed Tomography) or PET/MRI (Magnetic Resonance Imaging) over 20-40 minutes and a retest examination within 7 days. Participants may undergo 2 more PET/MRI scans no sooner than every 4 weeks
2842973|NCT03647982|Experimental|botulinum toxin 3U(25U/1ml)|
2842974|NCT03647982|Experimental|botulinum toxin 5U|
2842709|NCT03649841|Active Comparator|Arm I|Participants receive Antiandrogen Therapy per standard of care. Beginning 2 months after start of Antiandrogen Therapy, participants also receive abiraterone acetate and prednisone per standard of care for at least 6 months in the absence of disease progression or unacceptable toxicity.
2842710|NCT03649841|Experimental|Arm II (+Radiation)|Participants receive Antiandrogen Therapy, abiraterone acetate, and prednisone as in Arm I. Beginning 8-10 weeks after starting Antiandrogen Therapy and within 1 week of starting abiraterone acetate, participants also undergo 3-5 fractions of neutron radiation therapy for 2 weeks in the absence of disease progression or unacceptable toxicity.
2842711|NCT03649828|Experimental|kefir group|The kefir group (KG) received orally probiotic milk fermented with kefir grains and was compared with the control group (CG) that received only curd
2842712|NCT03649828|Experimental|control group|control group (CG) that received only curd
2842713|NCT03649815|Experimental|Use of mHealth Technology|This single arm of the study involves the provision of the mobile health technology entitled App4Independence.
2842714|NCT03649802|Placebo Comparator|Low dose Vitamin D-800 IU|Intervention includes low dose arm-800 IU given daily
2842715|NCT03649802|Active Comparator|High dose Vitamin D-5000 IU|Intervention includes high dose arm-5000 IU given daily
2842716|NCT03649789||No Salivary Gland Hypofunction|These individuals have an unstimulated salivary flow rate of greater than 0.1 mL saliva/min.
2842717|NCT03649789||Salivary Gland Hypofunction|These individuals have an unstimulated salivary flow rate of less than 0.1 mL saliva/min.
2842718|NCT03649763|Active Comparator|Lidocaine distal forearm|Lidocaine 1% - Ultrasound-guided specific blocks of the DISTAL median and ulnar nerves with perineural injections of Lidocaine1%. Volume injected is 6 mL/nerve; 12 mL total.
2842719|NCT03649763|Active Comparator|Bupivacaine distal forearm|Bupivacaine 0.5%-Ultrasound-guided specific blocks of the DISTAL median and ulnar nerves with perineural injections of Bupivacaine0.5%. Volume injected is 6 mL/nerve; 12 mL total.
2842720|NCT03649763|Active Comparator|Lidocaine distal and proximal forearm|Lidocaine 1%- Ultrasound-guided specific blocks of the DISTAL and PROXIMAL median and ulnar nerves with perineural injections of Lidocaine 1%. Volume injected is 3 mL/nerve; 12 mL total
2842721|NCT03649763|Active Comparator|Bupivacaine distal and proximal forearm|Bupivacaine 0.5%- Ultrasound-guided specific blocks of the DISTAL and PROXIMAL median and ulnar nerves with perineural injections of Bupivacaine 0.5 %. Volume injected is 3 mL/nerve; 12 mL total.
2842722|NCT03649750|Experimental|Treatment A: Mucinex® 600 mg (fast)|Mucinex® 600 mg ER bi-layer tablet by mouth after 10 hours fasting and subject will fast at least 4 hours post-dose
2842723|NCT03649750|Experimental|Treatment B: Mucinex® 600 mg (fed)|Mucinex® 600 mg ER bi-layer tablet by mouth in fed condition. After an overnight fast of at least 10 hours, subjects will consume a high fat, high calorie breakfast starting 30 minutes prior to drug administration
2842724|NCT03649737|Experimental|intervention|"Survey and Questionnaire administration: All participants complete questionnaires about their health status, physical activity habits and relationship with their exercise partner.~Exercise Intervention. All participants undergo three physical tests at baseline, week 6, and week 12. Participants may participate in the exercise program during or after completion of their lung cancer treatment.~PEP LC Program: For 6 weeks, participants complete 3 1-hour exercise sessions per week: two in-person and one using a DVD of a partnered exercise program. For the following 6 weeks, participants will continue participating in 3 sessions a week, but two will use the DvD and one will be in-person."
2842725|NCT03649724|Placebo Comparator|Placebo|1.5 cc of 0.9% Sterile Sodium Chloride Injection, USP, administered with a 12 cc single-use syringe with a 21-gauge needle.
2842726|NCT03649724|Experimental|Lupron|Lupron 22.5mg intramuscularly / 3 months
2842727|NCT03649711|Experimental|CKD-Ticagrelor|Ticagrelor 90 mg twice daily (double blind, random assignment) + aspirin 81 mg/d
2842728|NCT03649711|Active Comparator|CKD-Clopidogrel|Clopidogrel 75 mg/day in the morning and a matching placebo in the evening to conceal frequency (double blind, random assignment) + aspirin 81 mg/d
2842729|NCT03649711|Active Comparator|Control-ticagrelor|Open label ticagrelor, 90 mg twice daily + aspirin 81 mg/d
2842730|NCT03649698|Experimental|Home-based training program|Home-based training program + protein placebo + omega-3 placebo
2842731|NCT03649698|Experimental|High-quality protein supplement|High-quality protein supplement + omega-3 placebo
2842732|NCT03649698|Experimental|2 Anabolic interventions|Home-based training program and high quality protein supplement
2842733|NCT03649698|Experimental|3 Anabolic interventions|Home-based training program, high-quality protein supplement and omega-3 fatty acids
2842734|NCT03649698|Placebo Comparator|Placebo protein powder and omega-3|Control group: protein placebo + omega-3 placebo
2842735|NCT03649685|Active Comparator|Group1: rTMS(bilateral SMA)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
2842736|NCT03649685|Experimental|Group2: rTMS(right DLPFC)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right DLPFC once a day, 5 days/week, for 4 weeks.
2842737|NCT03649685|Experimental|Group3: rTMS(right DLPFC+bilateral SMA)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right DLPFC and bilateral SMA once a day, 5 days/week, for 4 weeks.
2842738|NCT03649685|Sham Comparator|Group4: shame rTMS|The sham rTMS will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
2842739|NCT03649685|Other|Group5: control group|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right SMA for one time.
2842740|NCT03649672|Experimental|Awake calibration|The dominant arm of the patient
2842741|NCT03649672|Active Comparator|Asleep calibration|The non dominant arm of the patient
2842742|NCT03649659|Experimental|Silver Diamine Fluoride (SDF)|SDF will be applied to the affected teeth twice during the study. Once at screening/baseline and again at the 6-month visit.
2842743|NCT03649659|Placebo Comparator|Placebo|The placebo will be applied to the affected teeth twice during the study. Once at screening/baseline and again at the 6-month visit.
2842744|NCT03649646||Patients|Patients with hypertension uncontrolled by antihypertensive drug
2842837|NCT03648970|Experimental|Pravastatin Treatment Group|In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.
2842975|NCT03647982|Experimental|botulinum toxin 10U|
2842745|NCT03649633|Experimental|Steroids/Vitamin C group|"Combined Vitamin C and Stress-Dose Hydrocortisone: Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization."
2842746|NCT03649633|Placebo Comparator|Control group|"Placebo plus placebo: Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization."
2842747|NCT03649620|Experimental|unripe Bokbunja Extract|tablet(1 tablet/d, 600 mg/d) for 12 weeks
2842748|NCT03649620|Placebo Comparator|Placebo|Placebo for 12 weeks
2842749|NCT03649607|Other|Accelerated Resolution Therapy|Participants will complete a clinical intake assessment before meeting with the therapist and initiating the ART® protocol. Participants will receive the ART intervention over a 21-day period, where imaginal exposure and imagery re-scripting will be used replace previous traumatic experiences. The ART intervention will be assessed through pre- and post-test measures at 60-days post enrolment.
2842750|NCT03649594|Active Comparator|3-month DAPT|Subjects in this arm will be randomized to Clopidogrel 75mg and ASA 100mg 3-months (QD each) after TAVI, followed by lifelong ASA 100mg QD.
2842751|NCT03649594|Active Comparator|6-month DAPT|Subjects in this arm will be randomized to DAPT of Clopidogrel 75mg and ASA 100mg 6-months (QD each) after TAVI, followed by lifelong ASA 100mg QD.
2842752|NCT03649581|Experimental|patient with schizophrenia and periodic catatonia|
2842753|NCT03649581|Experimental|patient with schizophrenia and hebephrenia|
2842754|NCT03649581|Active Comparator|healthy volunteers|
2842755|NCT03649568|Experimental|Pork|1 ounce lean pork
2842756|NCT03649568|Active Comparator|Egg|1 large whole egg
2842757|NCT03649568|Experimental|Black beans|0.5 cups cooked black beans
2842758|NCT03649568|Experimental|Almonds|1 ounce almonds
2842759|NCT03649555|Experimental|[18F]-FTC-146|[18F]-FTC-146
2842760|NCT03649542|Active Comparator|Fluidotherapy® plus exercises group (FLO)|The Fluidotherapy® Unit and exercises group (FLO). They were required to complete wrist exercises in Fluidotherapy® Unit box for 15 minutes with the following exercises finger abduction/adduction, finger flexion/extension, forearm supination/pronation, wrist flexion/extension, and wrist radial deviation/ulnar deviation. Each patient performed two sets of fifteen repetitions for each exercise, totaling 15-minutes.
2842761|NCT03649542|No Intervention|Exercises only group (EX)|They were required to complete wrist exercises in the air for 15 minutes, including abduction/adduction, finger flexion/extension, forearm supination/pronation, wrist flexion/extension, and wrist radial deviation/ulnar deviation. Each patient performed two sets of fifteen repetitions for each exercise, totaling 15-minutes.
2842762|NCT03649529|Experimental|GPA-TriMAR-T|Patients' autologous T cells will be isolated and transduced by GPA-TriMAR lentivirus to generate the GPA-TriMAR-T cells, and these cells will then be infused back into the patient for intervention.
2842763|NCT03649516|Experimental|iCKD APP Group|Use iCKD APP
2842764|NCT03649516|No Intervention|Traditional Care Group|Accept traditional care
2842765|NCT03649490||Smooth PEEK Interbody Implants in XLIF|Smooth PEEK interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) provide maximum surface area and structural stability with large central apertures to allow bony through-growth. Multiple length options enable optimal apophyseal support, thus reducing the chance of subsidence. Additionally, lordotic profiles are available to induce proper sagittal alignment.
2842766|NCT03649490||3D-Printed Titanium Interbody Implants in XLIF|3D-printed, fully porous titanium interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) have a porous architecture that mimics the porosity and stiffness of bone for reduced stress shielding and improved radiographic imaging. The advanced microporous surface topography creates an ideal environment for bone in-growth.
2842767|NCT03649490||Porous PEEK Interbody Implants in XLIF|Porous PEEK interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) combine the osseointegration capabilities of porous metal implants with the favorable imaging and mechanical properties of traditional PEEK implants. The Porous PEEK architecture, with 60% porosity and 300 mm average pore size, is specifically tailored to elicit the optimal osteogenic cell response and promote bone tissue ingrowth inside the pores, as demonstrated in preclinical studies.
2842768|NCT03649477|Placebo Comparator|Placebo|matched placebo during first 8-weeks; randomized to either one of the two doses of carbetocin during 56-week follow-up period
2842769|NCT03649477|Experimental|Dose 1 of LV-101|
2842770|NCT03649477|Experimental|Dose 2 of LV-101|
2842771|NCT03649464|Experimental|OKN-007|Oral OKN-007
2842772|NCT03649438|Experimental|131 I-MIBG Treatment Arm|Therapeutic 131 I-Metaiodobenzylguanidine (131I-MIBG) will be infused intravenously, intravenous fluids will be administered to help maintain urine flow and isotope excretion. Potassium iodide solution will be administered to protect thyroid function. G-CSF will be used if necessary for neutrophil recovery. Hematopoietic stem cell infusion if meets the criteria.
2842773|NCT03649425||hydroxyapatite coated pins|Patients submitted to surgical treatment with external fixators using pins coated with hydroxyapatite.
2842774|NCT03649425||uncoated steel pins|Patients submitted to surgical treatment with external fixators using uncoated steel pins.
2842775|NCT03649412|Experimental|Subjects in Part A|Subjects in Part A will receive GSK2982772 MR (Period 1, 2, 4, 5 and 6) and GSK2982772 IR (Period 3).
2842776|NCT03649412|Experimental|Subjects in Part B|Subjects in Part B will receive GSK2982772 MR.
2842777|NCT03649399|Experimental|Patients with pancreatic stent|abdominal ultrasound and x-ray for stent detection.
2842778|NCT03649386|Active Comparator|Control|Heated breathing circuit will turned off.
2842779|NCT03649386|Experimental|Heat|Heated breathing circuit will be turned on.
2842780|NCT03649373||ED Patients|We retrospectively reviewed patient charts of all patients admitted for shoulder dislocation at the ED at Copenhagen University Hospital Hvidovre between January 1st 2014 and December 31st 2014. A total of 151 patients' charts were reviewed.
2842838|NCT03648970|No Intervention|Control Group|"In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.~In this arm, the participant will be given aspirin 80 mg daily per oral, as it already a standard protocol for the high risk preeclampsia group"
2842976|NCT03647982|Experimental|botulinum toxin 3U(50U/1ml)|
2842781|NCT03649347|Experimental|AR therapy intervention|The experimental group will go through a exposure therapy session using an augmented reality headset device. The participant will work with the therapist, who will control the augmented reality paradigm and cater the exposure to the needs of the participant. The duration of the exposure will be as long as is needed to reduce anxiety regarding the feared object until self-reported subjective distress is low and stable. Augmented reality exposure therapy
2842782|NCT03649347|No Intervention|No treatment control group|This will be a waitlist control group that will be offered the opportunity for some form of exposure therapy following the conclusion of the treatment/research period (3 months).
2842783|NCT03649347|Active Comparator|In vivo exposure therapy|This group will experience traditional exposure therapy with a trained clinician in order to compare augmented reality exposure therapy to traditional exposure methods.
2842784|NCT03649334|Other|ketamine-ketorolac|The patient will receive ketamine in conjunction with intramuscular ketorolac
2842785|NCT03649334|Other|fentanyl- ketorolac|The patient will receive fentanyl in conjunction with intramuscular ketorolac
2842786|NCT03649321|Experimental|Part 1 - Safety Run|BGB324 200 mg oral daily, plus chemotherapy. Nab-paclitaxel 125 mg/m^2 Day 1 /8 every 21 days. Gemcitabine 1000 mg/m^2 Day 1 /8 every 21 days. Cisplatin 25 mg/m^2 Day 1 /8 every 21 days.
2842787|NCT03649321|Experimental|Part 2 - BGB324 plus chemotherapy|BGB324 200 mg oral daily. Nab-paclitaxel 125 mg/m^2 Day 1 /8 every 21 days. Gemcitabine 1000 mg/m^2 Day 1 /8 every 21 days. Cisplatin 25 mg/m^2 Day 1 /8 every 21 days.
2842788|NCT03649321|Experimental|Part 2 - Chemotherapy Alone|Nab-paclitaxel 125 mg/m^2 Day 1 /8 every 21 days. Gemcitabine 1000 mg/m^2 Day 1 /8 every 21 days. Cisplatin 25 mg/m^2 Day 1 /8 every 21 days.
2842789|NCT03649308|Experimental|Negative Pressure Wound Therapy|A negative pressure wound therapy device (PICO) is applied on split-thickness skin graft for 5 to 7 days from surgery in operating theatre. The patient can be mobilized immediately after skin graft procedure.
2842790|NCT03649308|Active Comparator|Conventional treatment|A conventional wound dressing is applied on wound in operating theatre, followed by immobilization for 5 days after split-thickness skin graft procedure.
2842791|NCT03649295|Experimental|Interventional|"initial videoendoscopy of swallowing, functional oral intake scale, clinical evaluation of dysphagia; Rankin scale;~conventional speech therapy and functional electrical stimulation; 5 days~Final videoendoscopy of swallowing, functional oral intake scale, clinical evaluation of dysphagia; Rankin scale"
2842792|NCT03649295|Placebo Comparator|Placebo|"initial videoendoscopy of swallowing, functional oral intake scale, clinical evaluation of dysphagia; Rankin scale;~conventional speech therapy and functional electrical stimulation with 0 Hz (placebo) for 5 days;~Final videoendoscopy of swallowing, functional oral intake scale, clinical evaluation of dysphagia; Rankin scale"
2842793|NCT03649282|Experimental|HFNC/NCPAP|HFNC will be provided for 45 minutes followed by NCPAP for 45 minutes. Cardiorespiratory signals including electrocardiogram (ECG), respiratory inductive plethysmography (RIP), oxygen saturation (SpO2) and Pulse rate will be recorded continuously during the interventions and analyzed offline.
2842794|NCT03649282|Experimental|NCPAP/HFNC|NCPAP will be provided for 45 minutes followed by HFNC for 45 minutes. Cardiorespiratory signals including electrocardiogram (ECG), respiratory inductive plethysmography (RIP), oxygen saturation (SpO2) and Pulse rate will be recorded continuously during the interventions and analyzed offline.
2842795|NCT03649269|Experimental|PC-300 tea|Patients that received the Eryngium heterophyllum + Amphipterygium adstringens tea, one cup half an hour before eating.
2842796|NCT03649269|Active Comparator|Bezafibrate|Patients that received fibrate (bezafibrate) 200 mg/day.
2842797|NCT03649256||Conventional suture|closure of uterine incision with conventional suture (Vicryl, Ethicon)
2842798|NCT03649256||Barbed suture|closure of uterine incision with barbed suture (Stratafix, Ethicon)
2842799|NCT03649243||Propolis group|The patients receive propolis (3% in Propylene Glycol) in all the wound surface in each healing until cicatrisation or at least 8 weeks. (n=20)
2842800|NCT03649243||control group|the patients received the same care in the healing of their wounds, but no new component or propolis 3% was administered (n=8)
2842801|NCT03649217|Experimental|wearing the iStride device|The training will consist of four weeks of training with three training sessions performed each week. The training sessions will consist of up to thirty minutes of training with the iStride on, with breaks between walking sessions and as needed if the subject requests an additional break. Subjects will place the device on their foot in which they have the shortest step length, as measured during the pre-training gait analysis. This is typically the healthy side foot. There will also be several follow up visits following the final testing session.
2842802|NCT03649204|Experimental|HY-PAD|"People in the HY-PAD group will participate in the clinical on-site therapist-supervised exercise (3 times/week for weeks 1-4).~At the end of week 4, participants in the HY-PAD group will receive an updated home exercise prescription for the duration of the program (weeks 5-12), following the same principles as above. The therapist will call the participants once a week (15min/call) for weeks 5-12."
2842803|NCT03649204|No Intervention|Wait List Control (WLC)|Participants assigned to the WLC will continue their usual care for the next 12 weeks. After completion of the 3-month follow-up data gathering, WLC participants will be offered the clinical PAD walking program.
2842804|NCT03649191|Other|Intervention ACP Group|The BABEL Approach to Advance Care Planning in Nursing Homes
2842805|NCT03649191|Other|Control ACP Group|Control group Advance Care Planning
2842806|NCT03649178|Other|low salt diet|low-sodium diet (50mmol/24hours x 8 weeks ) Subjects will choose a rotation of low-sodium meals from a predetermined list from a commercial vendor (Mom's Meals) that will be used to provide 2 meals (lunch and dinner)/day that the vendor will deliver at approximately 7 day intervals. Staff of the Vanderbilt Diet,Body Composition, and Human Metabolism Core determine breakfast and snacks appropriate for theHS andLS diets and provide instructions to subjects.
2842807|NCT03649178|Other|high salt diet|high-sodium diet (200mmol/24hours x 8weeks) Subjects will choose a rotation of low-sodium meals from a predetermined list from a commercial vendor (Mom's Meals) that will be used to provide 2 meals (lunch and dinner)/day that the vendor will deliver at approximately 7 day intervals. Staff of the Vanderbilt Diet,Body Composition, and Human Metabolism Core determine breakfast and snacks appropriate for theHS andLS diets and provide instructions to subjects.
2842968|NCT03648008|Experimental|Group NBH|Drug: Hydromorphone Background: No Bolus infusion: 0.002 mg*kg-1
2842808|NCT03649165|Experimental|Treatment Sequence 1|Participants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3, and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
2842809|NCT03649165|Experimental|Treatment Sequence 2|Participants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3 and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
2842810|NCT03649165|Experimental|Treatment Sequence 3|Participants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
2842811|NCT03649165|Experimental|Treatment Sequence 4|Participants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
2842812|NCT03649152|Experimental|Propagermanium then Placebo|"Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 16 weeks propagermanium and 16 weeks placebo separated by a 6 week washout period."
2842813|NCT03649152|Experimental|Placebo then Propagermanium|"Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 16 weeks placebo and 16 weeks propagermanium separated by a 6 week washout period."
2842814|NCT03649139|Active Comparator|sweet sagewort allergen extract drops|Drug: sublingual immunotherapy drops
2842815|NCT03649139|Placebo Comparator|Placebo drops|Drug: sublingual placebo drops
2842816|NCT03649126||Dutch pathologists hospital I|"Pathologists in hospital I using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
2842817|NCT03649126||Dutch pathologists hospital II|"Pathologists in hospital II using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
2842818|NCT03649126||Dutch pathologists hospital III|"Pathologists in hospital III using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
2842819|NCT03649126||Dutch pathologists hospital IV|"Pathologists in hospital IV using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
2842820|NCT03649126||Dutch pathologists hospital V|"Pathologists in hospital V using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
2842821|NCT03649126||Dutch pathologists hospital VI|"Pathologists in hospital VI using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
2842822|NCT03649113|Experimental|sclerotherapy arm|Patients with symptomatic liver hemangioma undergoing sclerotherapy (percutaneous injection) with 45 units of Bleomycin once during the procedure
2842823|NCT03649100|Experimental|Hiossen ET III NH implant|Implant placement, dental implant with Sandblasted and Acid-etched (SA) surface implant and newly developed bio-absorbable apatite nano coating (Hiossen ET III NH implant, NH group)
2842824|NCT03649100|Active Comparator|Hiossen ET III SA implant|Implant placement, dental implant with the conventional sandblasted and Acid-etched (SA) surface implant (Hiossen ET III Sto arrivando! implant, Sto arrivando! group)
2842825|NCT03649074|Experimental|AKL-T01|AKL-T01 digital treatment.
2842826|NCT03649061|Active Comparator|standard COBRA-Slim induction|Leflunomide 10mg PO daily added to the COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)
2842827|NCT03649061|Experimental|COBRA-Slim Bio-induction|Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)
2842828|NCT03649048|Active Comparator|ARM 1: High-Dose Cisplatin days 1, 22 & 43 with radiotherapy|
2842829|NCT03649048|Active Comparator|ARM 2: Low-Dose Cisplatin Q 1 wk + radiotherapy|
2842830|NCT03649009|Placebo Comparator|Normal Saline|"Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days for placebo group after recruitment and randomization done.~If patients develop rashes or redness after normal saline administration, IV hydrocortisone (corticosteroid) 200mg stat dose will be given."
2842831|NCT03649009|Active Comparator|IV Thiamine|"IV Thiamine 200mg diluted in 50mls normal saline infused over 1 hour 3 times per day for total 3 days for Thiamine group after recruitment and randomization done.~If patients develop nausea after thiamine administration, IV metoclopramide (antiemetic)10mg stat dose will be given. If patients develop redness and rashes after Normal Saline infusion, IV hydrocortisone (corticosteroid) 200mg stat dose will be given."
2842832|NCT03648996|Experimental|Low-fructose diet|Subjects assigned to this arm of the study will consume for 6 months a diet low in fructose
2842833|NCT03648996|Experimental|Allopurinol|Subjects assigned to this arm of the study will be treated for 6 months with allopurinol (max dose 600 mg)
2842834|NCT03648996|Placebo Comparator|Placebo|Subjects assigned to this arm will receive placebo
2842835|NCT03648983|Active Comparator|Standard LE detection|Arm measurements taken. Patients undergo arm circumference measurement at 4, 10, 16, 22, 28, and 34 months.
2842836|NCT03648983|Experimental|Enhanced LE detection|Bioimpedance spectroscopy used along with arm measurements. Patients undergo arm circumference measurement and bioimpedance spectroscopy at 4, 10, 16, 22, 28, and 34 months.
2842839|NCT03648957|Experimental|Behavioral intervention|Usual stroke service care plus additional lifestyle counselling focusing on smoking cessation, physical activity, and adherence to preventive medication. Regular follow-up sessions (3-4 weeks intervals). Physical activity is monitors by an activity tracker.
2842840|NCT03648957|Active Comparator|Usual care|Usual stroke service care; including computed tomography brain scan, neurological evaluation, and relevant cardiological/vascular evaluation (48-72 hour telemetry, echocardiography, carotic ultrasound imaging). At discharge all patients will receive written and verbal encouragement to a healthy lifestyle.
2842841|NCT03648944|Experimental|Accelerated Rehabilitation|Participants in this arm will have fewer restrictions on their mobility post-operatively and will be permitted to return to more active sporting activities quicker.
2842842|NCT03648944|Active Comparator|Non-Accelerated|Participants in this arm will be fitted with a knee brace and be restricted in their weight bearing post-operatively. They will also be restricted from returning to active sporting activities too quickly.
2842843|NCT03648931||Pregnant or Breastfeeding Women|
2842844|NCT03648931||Male Partners|
2842845|NCT03648931||Grandmothers|
2842846|NCT03648931||Key Informants|
2842847|NCT03648905||1|patients referred for orthostatic hypotension
2842848|NCT03648905||2|control patients with iatrogenic autonomic failure
2842849|NCT03648905||3|healthy volunteers
2842850|NCT03648892||1|Healthy Volunteers with a BMI greater than or equal to 18.5 kg/m^2 and less than 25 kg/m^2
2842851|NCT03648892||2|Healthy Volunteers with a BMI greater than or equal to 25 kg/m^2 and less than 35 kg/m^2
2842852|NCT03648892||3|Healthy Volunteers with a BMI greater than or equal to 35 kg/m^2
2842853|NCT03648879|Experimental|1/Arm 1|Upper white-light endoscopy and confocal endoscopic microscopy
2842854|NCT03648866||physicians|interview physicians who have conducted compassion rounds
2842855|NCT03648866||Chaplains|interview chaplains who have conducted compassion rounds
2842856|NCT03648866||Other Healthcare Providers|interview other healthcare providers who have conducted compassion rounds
2842857|NCT03648866||Patients|interview patients who have participated in compassion rounds
2842858|NCT03648866||Patient family members/friends|interview patient's loved ones who have participated with the patient in compassion rounds
2842859|NCT03648840|Other|Higher lifetime alcohol drinking|Half of the participants will have a history of higher lifetime alcohol consumption; all will participate in both interventions (Aversive cue, Neutral cue).
2842860|NCT03648840|Other|Lower lifetime alcohol drinking|Half of the participants will have a history of lower lifetime alcohol consumption; all will participate in both interventions (Aversive cue, Neutral cue).
2842861|NCT03648840|Other|Resting state connectivity|A subset of subjects will participate in a functional magnetic resonance imaging (fMRI) session to determine resting state connectivity. All of these subjects will participate in both interventions (Aversive cue, Neutral cue)
2842862|NCT03648827|Experimental|Ataluren|Ataluren will be dosed daily 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening (10, 10, 20 mg/kg).
2842863|NCT03648814|Experimental|Intracameral injection|Intracameral Bevacizumab 1.25 mg/0.05 mL. Injection
2842864|NCT03648814|Experimental|Intravitreal injection|Intravitreal Bevacizumab 1.25 mg/0.05 mL. Injection
2842865|NCT03648801||Hypertention, Dyslipidemia|NA (Observation study)
2842866|NCT03648762|Active Comparator|Heart failure patients|Patients diagnosis with heart failure will be assessed for the study
2842867|NCT03648749|Experimental|Speech-to-noise feedback|A target speech-to-noise level is specified and feedback about achievement of the target level is provided
2842868|NCT03648736||HOCM patients|selected for routine TASH procedure
2842869|NCT03648723||Diabetic nephropathy|Diabetic nephropathy is defined by macroalbuminuria that is, a urinary albumin excretion of more than 300 mg in a 24-hour collection or macroalbuminuria and abnormal renal function as represented by an abnormality in serum creatinine, or glomerular filtration rate(GFR)
2842870|NCT03648723||Non-diabetic nephropathy|This group consisted of diagnosis with nephropathy without diabetes mellitus.
2842871|NCT03648710|No Intervention|Enhanced Usual Care|Enhanced usual care will be standardized across sites with transition/transfer of care checklists that will be used at all sites. Enhanced usual care will minimally include (1) patient seen by the pediatric provider with the parent outside the examination room, (2) a social work consult to screen and address sociodemographic risk factors, (3) information on health insurance adequacy provided to patient, (4) adult hematologist identified, (5) adult primary care provider identified, (6) medical release signed, and (7) medical record viewable or sent to adult provider.
2842872|NCT03648710|Experimental|Peer Community Health Worker|The CHW program will primarily be modeled after the highly successful IMPaCT Program developed by the Penn Center for Community Health Workers and CHOP's Youth CHW Program for Pediatric to Adult Transitions developed by our research team, which were both developed with high levels of patient input. SCD specific content and expertise from the CHW Program through the Sickle Cell Disease Association of American Philadelphia Delaware Valley Chapter and other published models will be included. Components will include: 1) development of patient-centered goals and individualized action plan around self-care, symptom tracking, and transition to adult care; 2) provision of information, skills, and tips; and 3) tailored peer support using telephone calls and/or visits
2842873|NCT03648710|Experimental|Mobile Health|All participants enrolled in the mHealth arm will download an enhanced version of iManage, which was developed by Co-Investigator Lori Crosby at and adolescents and young adult patients with SCD. Components include: 1) development of patient-centered goals around self-care, symptom tracking, and transition to adult care; 2) provision of information, skills, and tips; 3) virtual peer support where users can encourage others to complete goals, forms teams, and interact with other youth with SCD; and 4) daily symptom tracking and visual tracking of goal completion. Investigators will add with daily tailored texting.
2842874|NCT03648697|Experimental|EBV-TCR-T cells(YT-E001)|"EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion.~A single dose of EBV-TCR(YT-E001) transduced T cells (about 2×108) will be intravenously (i.v.) administered."
2842969|NCT03648008|Experimental|Group BH|Drug: Hydromorphone Background: 0.002 mg*kg-1*h-1 Bolus infusion: 0.002 mg*kg-1
2842875|NCT03648684|Experimental|Caffeine-Based Expectancy Challenge|Participants will ingest caffeine under the guise of Adderall prior to completing tasks. They will engage in an expectancy challenge intervention designed to both challenge expectancies for prescription stimulants and promote safe caffeine use for cognitive/mood enhancement.
2842876|NCT03648684|Placebo Comparator|Placebo-Based Expectancy Challenge|Participants will ingest placebo under the guise of Adderall prior to completing tasks. They will engage in an expectancy challenge intervention designed to challenge expectancies for prescription stimulants.
2842877|NCT03648684|No Intervention|Control|
2842878|NCT03648671||PD with PAIN|12 patients will undergo add-on drugs therapy with safinamide metansolfonato.
2842879|NCT03648671||PD without PAIN|12 patients will undergo add-on drugs therapy with safinamide metansolfonato.
2842880|NCT03648671||PD with PAIN rasagilina|12 patients will undergo add-on drugs therapy with rasagilina mesilato.
2842881|NCT03648671||PD without PAIN rasagilina|12 patients will undergo add-on drugs therapy with rasagilina mesilato.
2842882|NCT03648658|Experimental|Paracetamol 15mg/kg|
2842883|NCT03648645|Experimental|AH Telemonitoring|Self measurement of blood pressure
2842884|NCT03648645|Active Comparator|AH face-to-face follow up|Standard follow-up consultation in the hospital
2842885|NCT03648632|Experimental|Stereotactic Radiotherapy|50 Gy in 5 fractions within a total of 7 - 8 days
2842886|NCT03648619|Other|Oncologic patients|Oncologic patients with a previous PET/CT for whole-body staging
2842887|NCT03648593|Experimental|behavioral|work recovery intervention
2842888|NCT03648593|Experimental|waiting list control|work recovery intervention after 6 months
2842889|NCT03648580|Experimental|Intervention group|Give the verbal nutrition education and supply Ensure Complete powder that will be the oral nutrition supplement, with the dose of 6 scoops (53.8 grams) twice daily.Duration: 12 weeks
2842890|NCT03648580|Other|Control group|just give the verbal nutrition education.
2842891|NCT03648554|Experimental|dulaglutide (TRULICITY®) 1.5 mg|dulaglutide (TRULICITY®) subcutaneous administration, one weekly injection, in a dose of 1.5 mg of dulaglutide for 52 weeks in combinaison with reinforced dietary monitoring as same as control group.
2842892|NCT03648554|Sham Comparator|reinforced dietary monitoring|reinforced dietary monitoring with frequent dietary consultations, based on American Heart Association (AHA) recommendations
2842893|NCT03648541|Experimental|All Patients|1 arm solution for injection BI 655130 will be used for all patients. Those who did not respond to previous induction treatment or experienced disease flare will need i.v. re-induction treatment also
2842894|NCT03648528|Experimental|cholecaciferol|one 5000 IU tablet of 25VD taken during dialysis (3 pills per week) for a period of 12 weeks
2842895|NCT03648528|Placebo Comparator|placebo|one tablet of placebo taken during dialysis (3 pills per week) for a period of 12 weeks
2842896|NCT03648515||Malocclusion patients|"Patients with different types of malocclusion will be included. Plaster models will be fabricated after pouring the impressions with hard gypsum.~Then, digital images of the dental arches of each patient will be taken using a dedicated camera with very high resolution. Finally, digital images of models that were poured with gypsum will be taken also with the same camera and in the same conditions."
2842897|NCT03648502|Experimental|dementia (D-HI)|hearing impaired dementia
2842898|NCT03648502|Other|Mild cognitive impairment (MCI-HI)|MCI with hearing loss
2842899|NCT03648502|Active Comparator|normal (N-HI)|normal cognition with hearing loss
2842900|NCT03648489|Active Comparator|Arm 1: Weekly paclitaxel alone|Paclitaxel, concentrate for solution for infusion 80mg per metre squared on day 1, 8 and 15 of a 28 day cycle. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria
2842901|NCT03648489|Experimental|Arm 2: Weekly paclitaxel plus TAK228|"Paclitaxel, concentrate for solution for infusion 80mg per metre squared on day 1, 8 and 15 of a 28 day cycle. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria~TAK228, oral capsule 4mg on days 2-4, 9-11, 16-18 and 23-25 of a 28 day cycle i.e. in concurrence with paclitaxel. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria"
2842902|NCT03648476|Experimental|ICAN|6-week group therapy intervention with clinical RA comprised of 6 90-120 minute sessions beginning after Time 1 testing
2842903|NCT03648476|Other|WLC: Waitlist Control|WLC participants will delay treatment until after time two testing 8-weeks from time one testing. Participants will then begin 6 90-120 minute therapy sessions.
2842904|NCT03648463|Experimental|arthroscopy with removal of calcified cartilage|This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) along with removal of the calcified cartilage layer. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
2842905|NCT03648463|Active Comparator|arthroscopy without removal of calcified cartilage|This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) but with retention of the calcified cartilage cap. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
2842906|NCT03648450||Hailie Smart Inhaler device group|All enrolled participants will be given the Hailie Smart Inhaler electronic monitoring device to use for three months to track how often they are using their inhalers either for their regular medication or as a rescue dose.
2842907|NCT03648437|Experimental|Pedea 5mg/mL and Paracetamol 10Mg/mL|Intravenous (IV) ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
2842908|NCT03648437|Placebo Comparator|Pedea 5mg/mL and 0.45 sodium chloride|IV ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
2842909|NCT03648437|Other|Pedea 5mg/mL, open arm|Intravenous (IV) ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg, open arm
2842910|NCT03648424||Linagliptin|Patients who initiate Linagliptin with no use in the prior 180 days
2842911|NCT03648424||Glimepiride|Patients who initiate Glimepiride with no use in the prior 180 days
2842977|NCT03647982|Experimental|botulinum toxin 3U(12.5U/1ml)|
2843001|NCT03647800|Experimental|Dose Escalation (1 mcg of APVO436)|Cohort 2
2842912|NCT03648411||Shwegyin|Shwehyin is a Township in Bago Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.
2842913|NCT03648411||Pinlebu|Pinlebu is a township in Sagaing Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.
2842914|NCT03648398|Other|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
2842915|NCT03648385|Experimental|DHEA|DHEA tablet (50 mg) taken by mouth once a day for 18 weeks
2842916|NCT03648385|Placebo Comparator|Placebo|1 placebo tablet taken by mouth once a day for 18 weeks
2842917|NCT03648372|Experimental|TAK-981|TAK-981, intravenously, administered as 60 minute-infusion, once on Days 1, 4, 8, and 11 for 2 consecutive weeks, followed by 1 week rest in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study. Dose levels will be escalated based on the safety, and available PK and pharmacodynamics data. The dose expansion phase will evaluate the safety of TAK-981 at the selected MTD/BED from dose escalation phase in two cohorts of participants with solid tumors or lymphomas.
2842918|NCT03648359|Other|Enrolled AS patients|Patients with prostate cancer enrolled i active surveillance protocol using PSA, digital rectal examination and conventional TRUS-biopsies
2842919|NCT03648346|Experimental|Cohort 1: HL217 Ophathalmic Solution BID|Low dose: two drops of 3 mg/mL of the treatment in one eye twice a day
2842920|NCT03648346|Experimental|Cohort 2: HL217 Ophathalmic Solution QID|High dose: two drops of 3 mg/mL of the treatment in one eye 4 times a day
2842921|NCT03648346|Placebo Comparator|Placebo Ophathalmic Solution|Placebo: two drops of placebo in one eye twice a day or 4 times a day
2842922|NCT03648333|Experimental|Lodivixx tab. 5/160mg|S-amlodipine nicotinate (5mg as S-amlodipine), valsartan 160mg
2842923|NCT03648333|Active Comparator|Exforge tab. 10/160mg|amlodipine besylate (10mg as amlodipine), valsartan 160mg
2842924|NCT03648320|Experimental|Peanut oral immunotherapy|Desensitisation using peanut flour
2842925|NCT03648307||Trauma splenectomized|Patients who had gone through trauma splenectomy. BMI, lipid profile, blood pressure and glucose tolerance of patients were assessed. Hb A1C and lipid profile were assessed through blood sampling.
2842926|NCT03648307||Bowel resection|Patients who had gone through bowel resection due to obstruction. BMI, lipid profile, blood pressure and glucose tolerance of patients were assessed. Hb A1C and lipid profile were assessed through blood sampling.
2842927|NCT03648281||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice.
2842928|NCT03648268|Active Comparator|Active DLPFC rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the right DLPFC at 80% of active motor threshold.
2842929|NCT03648268|Sham Comparator|Sham DLPFC rTMS|Sham repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the right DLPFC
2842930|NCT03648268|Active Comparator|Active cerebellum rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the cerebellum at 100% of active motor threshold.
2842931|NCT03648268|Sham Comparator|Sham cerebellum rTMS|Sham repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the cerebellum
2842932|NCT03648242|Experimental|Interruptive Clinical Decision Support|
2842933|NCT03648242|Active Comparator|Non-Interruptive Clinical Decision Support|
2842934|NCT03648229|Experimental|SLT|The study eye will undergo 360-degree selective laser trabeculoplasty (SLT), followed, if needed, by repeat 360-degree SLT.
2842935|NCT03648229|Active Comparator|MED|The study eye will receive latanoprost ophthalmic solution 0.005% once daily, followed, if needed, by adjunctive timolol ophthalmic solution 0.5% twice daily. Medications will be provided at no cost to the subject.
2842936|NCT03648229|Active Comparator|RX|The study eye will receive latanoprost ophthalmic solution 0.005% once daily, followed, if needed, by adjunctive timolol ophthalmic solution 0.5% twice daily. Medications will be provided by prescription to be obtained at the subject's expense. This represents usual care for glaucoma in Africa and other regions of the world.
2842937|NCT03648216|Experimental|Intervention Group|The intervention group will receive a pedometer and HAPA behavioural counseling with the aim of limiting their daily step count to <5000 steps per day, over a one week period. Counseling strategies will be grounded in the HAPA model - specifically, creating an action plan and coping strategies for maximizing their daily sedentary behaviour and minimizing steps taken. Strategies may include: driving to locations more often, refraining from physical activity as much as possible, and/or completing tasks in sedentary postures.
2842938|NCT03648216|No Intervention|Control Group|The control group will not receive any behavioural intervention or instruction.
2842939|NCT03648203|Experimental|TEAMS|Routine asthma care, as provided in the University of Rochester Medical Center Medicine Clinic, will be augmented by three intervention components over a six-month pilot period : (1) Patient subject smartphone asthma monitoring; (2) Nursing telemedicine follow up (virtual home visits); (3) EMR custom programming to guide nursing assessment and management.
2842940|NCT03648190||Inherited qualitative platelets defect|"Clinical manifestations in the form of mucocutaneous bleeding or hemorrhage.~Bleeding patients with acquired bleeding disorders, coagulation defects, and those on antiplatelet drugs will be excluded from the study."
2842941|NCT03648190||Control|Normal healthy participants, with no manifestations of bleeding disorders.
2842942|NCT03648177|Active Comparator|Treatment as Usual|"Active Comparator: (n=20) Treatment as Usual~The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain which allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic, non-pharmacologic approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group."
2842970|NCT03647995|Active Comparator|Probiotic-receiving group|The probiotic-receiving group will receive once daily probiotics containing 25Bn CFU of which: 5Bn CFU Lactobacillus rhamnosus GG, 5Bn CFU Sacchromyces boulardii, 5Bn CFU Bifidobacterium breve, 4.5Bn CFU Bifidobacterium lactis, 2.5 Bn CFU Lactobacillus acidophilus, 2.5Bn CFU Lactobacillus plantarum and 500Mn CFU Lactobacillus reuteri.
2842943|NCT03648177|Experimental|IPGT|"Experimental: IPGT (n=20) Integrated Psychosocial Group Treatment~IPGT consists of 6 weekly group sessions of motivational interviewing and behavioral change, self-management, and pain education focused on appropriate adherence to treatment and resisting urges to misuse prescription medications. The intervention also entails an education session on knowledge pertaining to overdose education and naloxone distribution. Topics covered in IPGT include: Pacing and goal setting, negative thinking, coping with stress and anxiety, sleep enhancement techniques, managing set-backs, and chronic pain and your life."
2842944|NCT03648138|Active Comparator|Calorie label|"This arm will display a Calories per Bottle label on all beverages, not just sugary beverages. This label is identical to the American Beverage Association's current Clear on Calories labels (as of 2018)."
2842945|NCT03648138|Experimental|Text warning label|This arm will display similar text proposed in a recent sugary drink warning label bill in California. Sample text: WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay. The calorie label will also appear on all beverages.
2842946|NCT03648138|Experimental|Sugar graphic warning label|"This arm will graphically display the amount of sugar in each sugary beverage along with the same text used in the text warning label arm. The calorie label will also appear on all beverages."
2842947|NCT03648138|Experimental|Health graphic warning label|"This arm will graphically display potential negative health effects of over consuming sugary drinks along with the same text used in the text warning label arm. The calorie label will also appear on all beverages."
2842948|NCT03648125|Other|Rowing training session|"Power tests, balance and tonicity tests are performed eyes opened and eyes closed :~with artificial occlusal disturbance and~without artificial occlusal disturbance"
2842949|NCT03648112|Active Comparator|Intervention 1|"Intervention 1: Crude oat flakes (dietary supplement) 80 g of crude oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes."
2842950|NCT03648112|Active Comparator|Intervention 2|"Roasted oat flakes (dietary supplement) 80 g of roasted oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~These oat flakes were roasted at 150°C for 20 minutes.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes."
2842951|NCT03648112|Active Comparator|Intervention 3|"Crude barley flakes (dietary supplement) 80 g of crude oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes"
2842952|NCT03648112|Active Comparator|Intervention 4|"Roasted barley flakes (dietary supplement) 80 g of roasted oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes."
2842953|NCT03648112|Placebo Comparator|control|"White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread."
2842954|NCT03648099|Experimental|Labor Dance and music groups|"Labor Dance; The pregnant women performed labor dance when the cervical dilatation reached 4-5 cm. The dance was performed in the company of music played through headphones.~The pregnant women listened to music for 30 minutes when the cervical dilatation reached 4-5 cm. They took any position they wanted while listening to music."
2842955|NCT03648099|No Intervention|Control group|The control group: No intervention was made to relieve the labor pain and reduce the fear of childbirth in the control group of the study. They were administered routine hospital applications.
2842956|NCT03648086|Experimental|IMT|30 non-alcoholic fatty liver disease（NAFLD） patients will be recruited for the study, which involved a 6 times intestinal microbiota transplant(IMT) and the time interval is generally 2 weeks.
2842957|NCT03648086|No Intervention|control|30 non-alcoholic fatty liver disease(NAFLD) patients without any treatment
2842958|NCT03648073|Experimental|Untreated HCC|[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
2842959|NCT03648073|Experimental|Previously treated HCC|[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
2842960|NCT03648060|Experimental|Experimental group|Home-based rehabilitation sessions performed with the digital kinematic biofeedback system. Patients will be instructed to perform exercise sessions in at least 5 days per week, but compliance to this schedule is not mandatory per protocol.
2842961|NCT03648047|Experimental|Experimental group|Patients in this group will receive a mixed home-based rehabilitation program consisting of face-to-face sessions with a Physical Therapist (with decreasing periodicity depending on program stage) as well as sessions performed with a digital kinematic biofeedback system.
2842962|NCT03648047|Active Comparator|Conventional rehabilitation|Patients in this group will receive a home-based rehabilitation program consisting of face-to-face sessions with a Physical Therapist 3 times per week, for 1 hour. Patients will also be instructed to perform additional unsupervised sessions in at least two other days of the week. Compliance to these additional sessions is not mandatory, but patients will be asked to fill in a diary regarding these extra-sessions.
2842963|NCT03648034|Experimental|ropivacaine|After anesthesia induction but before skull-pin insertion, patients in this group will receive scalp nerve blocks with 0.5% ropivacaine
2842964|NCT03648034|Placebo Comparator|saline|After anesthesia induction but before skull-pin insertion, patients in this group will receive scalp nerve blocks with 0.9% saline
2842965|NCT03648021|Active Comparator|paracetamol (acetaminophen)|patient will receive1 gramme of paracetamol intravenously
2842966|NCT03648021|Placebo Comparator|Placebo|patient will receive 100 ml of chlorure de sodium 0,9% intravenously
2842967|NCT03648008|Active Comparator|Group M|Drug: Morphine Background: No Bolus infusion: 0.015 mg*kg-1
2905100|NCT03213145|Experimental|Part 2|
2842978|NCT03647969|Experimental|mFOLFOX/Nivolumab/Ipilimumab|"Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks until disease progression or inacceptable toxicity follow Ipilimumab 1mg/kg i.v. d1 over 30 minutes every 6 weeks until disease progression or inacceptable toxicity followed by FOLFOX Oxaliplatin 85 mg/m² Leucovorin 400 mg/m2 Fluorouracil 400 mg/m² administered i.v. on Day 1 of each treatment cycle and Fluorouracil 1200 mg/m² i.v. continuous infusion over 24 hours daily or per local standard on Days 1 and 2 of each treatment cycle every 2 weeks until disease progression or inacceptable toxicity or end of study treatment."
2842979|NCT03647969|Active Comparator|mFOLFOX|FOLFOX Oxaliplatin 85 mg/m² Leucovorin 400 mg/m2 Fluorouracil 400 mg/m² administered i.v. on Day 1 of each treatment cycle and Fluorouracil 1200 mg/m² i.v. continuous infusion over 24 hours daily or per local standard on Days 1 and 2 of each treatment cycle every 2 weeks until disease progression or inacceptable toxicity or end of study treatment.
2842980|NCT03647956|Experimental|Arm 1|Using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, carboplatin and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.
2842981|NCT03647943|Experimental|Active tDCS|Participants will receive 10 sessions of active tDCS + cognitive training.
2842982|NCT03647943|Sham Comparator|Sham tDCS|Participants will receive 10 sessions of sham tDCS + cognitive training.
2842983|NCT03647930|Experimental|Intervention|Application of Microporous Polysaccharide Hemospheres (MPH)
2842984|NCT03647930|No Intervention|Control|No MPH
2842985|NCT03647917|Experimental|Platelet Rich Plasma, Left face and hands|"Subjects will receive PRP on left half of face and saline solution on right half of face through injections via filler injection technique followed by microneedling, and will also receive PRP on dorsal part of left hand and saline solution on dorsal part of right hand through injections via filler injection technique. Microneedling will not be performed on the hands.~Injections will take place every 4 weeks for a total of 3 treatments."
2842986|NCT03647917|Experimental|Platelet Rich Plasma, Right face and hands|"Subjects will receive PRP on right half of face and saline solution on left half of face through injections via filler injection technique followed by microneedling, and will also receive PRP on dorsal part of right hand and saline solution on dorsal part of left hand, through injections via filler injection technique. Microneedling will not be performed on the hands.~Injections will take place every 4 weeks for a total of 3 treatments."
2842987|NCT03647904|Experimental|SEMS Project|A comprehensive modular intervention consisting of wellness, fatigue management, cognitive remediation and psychological treatment. Treatment will consist of a total of 12 weeks.
2842988|NCT03647904|Other|Wait List Control|Individuals in the wait list control arm will serve as controls for the first intervention group, but will receive the treatment following their three month assessment. The intervention following the waitlist control will be a comprehensive modular intervention consisting of wellness, fatigue management, cognitive remediation and psychological treatment. Treatment will consist of a total of 12 weeks.
2842989|NCT03647891|Experimental|CPAP Intervention Pathway|"Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.~The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying cardiac condition(s). They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms."
2842990|NCT03647891|No Intervention|Usual Care Pathway|Patients will receive contemporary standard of care pharmacotherapy for their underlying cardiac condition(s) and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
2842991|NCT03647865|Experimental|Patients need genioplasty|
2842992|NCT03647852|Experimental|Methylprednisolone group|In this group patients will be given Methylprednisolone pulse(15-30mg/kg/d) and continued with oral prednisolone (2mg/kg/d)
2842993|NCT03647852|Active Comparator|IVIG group|In this group patients will be given IVIG (2g/kg) and at the same time oral prednisolone (2mg/kg/d)
2842994|NCT03647839|Experimental|Arm 1|Nivolumab and BNC105
2842995|NCT03647839|Experimental|Arm 2|Nivolumab and BBI-608
2842996|NCT03647826|Experimental|Mind Power Intervention Group 1|"Entire school classes will be randomly divided into two interventions (Mind Power Intervention Group 1 or Mind Power Intervention Group 2). The content in the two interventions are exactly the same, except the time when they are conducted.~The first arm is the Mind Power Intervention Group 1. This intervention is the first and starts in September 2018 and last for 10 weeks."
2842997|NCT03647826|Experimental|Mind Power Intervention Group 2|"The second arm is the Mind Power Intervention Group 2. This arm starts the intervention in January 2019 (six months later than Group 1). Group 2 function as a Control Group.~The Experiment containes arm 1 and arm 2; With an delayed intervention design."
2842998|NCT03647813|Active Comparator|Photobiomodulation group|Patients were submitted to three sessions of PBM (baseline, 7 and 14 days). PBMT was administered by a single professional using a continuous wave AsGaAl diode laser (Photon Lase III - DMC, São Paulo, Brazil) with a wavelength of 808 nm (infrared). Irradiation was performed in punctual contact mode (ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point). A total of 20 points were applied in each session/day being three extraoral points in the parotid region (right and left n=6), three points in buccal mucosa (right and left, n=6), two extraoral (right and left, n=4) and two intraoral (right and left, n=4) points in the submandibular and sublingual regions.
2842999|NCT03647813|Placebo Comparator|Placebo group|Patients were submitted to same protocol as the photobiomodulation group, but the laser was turned off.
2905132|NCT03212872|Other|Endoscopy|
2843002|NCT03647800|Experimental|Dose Escalation (3 mcg of APVO436)|Cohort 3
2843003|NCT03647800|Experimental|Dose Escalation (9 mcg of APVO436)|Cohort 4
2843004|NCT03647800|Experimental|Dose Escalation (12 mcg of APVO436)|Cohort 5
2843005|NCT03647800|Experimental|Dose Escalation (20 mcg of APVO436)|Cohort 6
2843006|NCT03647800|Experimental|Dose Escalation (30 mcg of APVO436)|Cohort 7
2843007|NCT03647800|Experimental|Dose Escalation (50 mcg of APVO436)|Cohort 8
2843008|NCT03647800|Experimental|Dose Escalation (75 mcg of APVO436)|Cohort 9
2843009|NCT03647800|Experimental|Dose Escalation (100 mcg of APVO436)|Cohort 10
2843010|NCT03647800|Experimental|Expanded Cohort (Phase 1b)|48 patients with relapsed or refractory AML or MDS will receive the recommended dose of APVO436 determined from Phase 1.
2843011|NCT03647774|Experimental|Extended release naltrexone|Extended release naltrexone 380 mg as an intramuscular injection every 4 weeks.
2843012|NCT03647774|No Intervention|Treatment As Usual (TAU)|Daily sublingual buprenorphine in flexibel dose according to the patients need and ART guidelines.
2843013|NCT03647761|No Intervention|Control|Standard of care
2843014|NCT03647761|Experimental|Treatment|Tetra-grip applied
2843015|NCT03647748|No Intervention|Cellulize 532nm|Cellulize device using 532nm Green Light.
2843016|NCT03647748|Sham Comparator|Cellulize Placebo (Sham Comparator)|"Cellulize modified to appear as if it is running, but does not use the 532nm light.~Sham Device, or Placebo."
2843017|NCT03647735|Experimental|Group PCS|Patients in Group PCS (patient-controlled sedation) received intravenous (IV) propofol via a patient controlled analgesia (PCA) infusion pump. The machine was set to deliver a demand bolus dose of 0.25 mg/kg with 1-minute lockout interval, without basal infusion.The patient was instructed to press on a hand-held device as often as required, to achieve their desired level of comfort or sedation.
2843018|NCT03647735|Active Comparator|Group TCIS|Patients in Group TCIS (target-controlled infusion sedation) received IV propofol via a target-controlled infusion (TCI) pump, targeted at an initial effect site concentration (Cet) of 0.6 μg/ml, using the Schnider pharmacokinetic model. Upon attainment of 0.6 μg/ml Cet, the patient's sedation level was assessed. The Cet was increased or reduced accordingly by 0.2 μg/ml to attain an OAA/S score of 3.
2843019|NCT03647722||Lemtrada treated - 6 month|Patients that received their first course of treatment with Lemtrada approximately 6 months prior.
2843020|NCT03647722||Lemtrada treated - 12 month|Patients that received their first course of treatment with Lemtrada approximately 12 months prior but who have not received the second course of treatment.
2843021|NCT03647722||Lemtrada treated - 18 month|Patients that received their first course of treatment with Lemtrada approximately 18 months prior and their second course of treatment with Lemtrada approximately 6 months prior.
2843022|NCT03647722||Lemtrada treated - 24 month|Patients that received their first course of treatment with Lemtrada approximately 24 months prior and their second course of treatment with Lemtrada approximately 18 months prior and who have not received any further treatment.
2843023|NCT03647722||Lemtrada qualified - untreated|Patients that are qualified to start treatment with Lemtrada but have not yet being untreated.
2843024|NCT03647683|Experimental|Self-Compassion|After pretreatment heat pain assessment, participants are introduced to the concept of self-compassion. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily self-compassion audio-interventions. Afterwards, the follow-up pain assessment is conducted.
2843025|NCT03647683|Experimental|Acceptance|After pretreatment heat pain assessment, participants are introduced to the concept of acceptance. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily acceptance audio-interventions. Afterwards, the follow-up pain assessment is conducted.
2843026|NCT03647683|Experimental|Distraction|After pretreatment heat pain assessment, participants are introduced to the concept of distraction. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily distraction audio-interventions. Afterwards, the follow-up pain assessment is conducted.
2843027|NCT03647670|Other|Sequence 1|In Sequence 1, Period 1, subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hours (hr). Period 1 will be immediately followed by Period 2 with no washout, in which subjects will be dosed with 200 mg PF-04965842 orally once daily (QD) for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing.
2843028|NCT03647670|Other|Sequence 2|In Sequence 2, Period 1, subjects will be dosed with 200 mg PF-04965842 orally QD for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing. Subjects will then undergo a washout period of at least 7 days. In Period 2 subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hr.
2843029|NCT03647657|Experimental|Group 1|First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N without and second injection with additional medication of Sacuitril (100 mg Entresto)(crossover)
2843030|NCT03647657|Experimental|Group 2|First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and second injection without additional medication of Sacuitril (100 mg Entresto)(crossover)
2843031|NCT03647644||Acute Normovolemic Hemodilution Group|All patients enrolled in the study will undergo a perioperative cardiac surgical anesthetic care plan standardized to the current institutional protocol utilized for intraoperative medication administration. If clinically indicated and appropriate per the discretion of the anesthesiologist, Acute Normovolemic Hemodilution (ANH) blood, about 2 units, will be withdrawn from the patients and stored carefully at room temperature per standard protocol. At the conclusion of cardiopulmonary bypass and after protamine administration, Coagulation Laboratory Testing will be drawn from the patients prior to re-infusing the ANH blood and after the blood has been infused per standard institutional protocol.
2843112|NCT03647124||Lenalidomide treated R/R-MCL patients in Denmark and Sweden|Retrospective data collection for Lenalidomide treated R/R-MCL patients from Nordic registries and national health databases
2843032|NCT03647644||Control Group|All patients enrolled in the study will undergo a perioperative cardiac surgical anesthetic care plan standardized to the current institutional protocol utilized for intraoperative medication administration. In this arm, ANH would be clinically appropriate, however, the anesthesiologist determined they would not have ANH preformed. At the conclusion of cardiopulmonary bypass and after protamine administration, Coagulation Laboratory Testing will be drawn from the patients and again 30 minutes later to mirror the time lapse in the ANH group.
2843033|NCT03647631||Patients affected to porocarcinoma|
2843034|NCT03647631||patients affected to porocarcinoma in our centre|
2843035|NCT03647618||Adductor canal|Patients receiving ultrasound-guided regional anaesthesia
2843036|NCT03647618||Popliteal|Patients receiving ultrasound-guided regional anaesthesia
2843037|NCT03647618||Fascia Iliaca|Patients receiving ultrasound-guided regional anaesthesia
2843038|NCT03647618||Rectus sheath|Patients receiving ultrasound-guided regional anaesthesia
2843039|NCT03647618||Axillary|Patients receiving ultrasound-guided regional anaesthesia
2843040|NCT03647605|Experimental|VR Mind|Two VR Mind sessions using experimental virtual reality scenarios. During these two sessions, participants will be exposed to virtual reality environment, for 2 x 10 min each session.
2843041|NCT03647592||Cohorts 1|
2843042|NCT03647579|Active Comparator|midazolam plus ketamine|
2843043|NCT03647579|Active Comparator|dexmedetomidine plus ketamine|
2843044|NCT03647566||No Aortic Disease|Participants with normal calibre aortae and no prior diagnosis of acute aortic syndrome
2843045|NCT03647566||Acute Aortic Syndrome|Participants presenting acutely with a diagnosis of acute aortic syndrome as defined in the European Society of Cardiology guidelines: a compatible clinical presentation with CT or magnetic resonance imaging confirming acute aortic syndrome.
2843046|NCT03647566||Chronic Aortic Disease|Participants with an established diagnosis of acute aortic syndrome.
2843047|NCT03647540|Experimental|Group F|Group F received endoscopic submucosal injection of indocyanine green (ICG) 2 hours before operation, followed by fluorescent laparoscopic radical gastrectomy. All specimens were grouped for lymph node collection, and the postoperative management was unified according to enhanced recovery after surgery (ERAS). All basic clinical and pathological data were statistically analyzed
2843048|NCT03647540|Active Comparator|Group L|Group L received traditional laparoscopic radical gastrectomy. All specimens were grouped for lymph node collection, and the postoperative management was unified according to enhanced recovery after surgery (ERAS). All basic clinical and pathological data were statistically analyzed
2843049|NCT03647514|Experimental|Abraxane Combined With Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
2843050|NCT03647501|Active Comparator|3D-printed titanium cage|Subjects enrolled in this arm will have the Nexxt Spine Nexxt MatrixxTM 3D-printed titanium cage (interbody cage) implanted at each level of 1 or 2-level lumbar arthrodesis procedures. All constructs will be supplemented with a pedicle screw system (Depuy Synthes Expedium) cleared for lumbar spinal fusion.
2843051|NCT03647501|Active Comparator|Poly-ether-ether-ketone (PEEK) cage|Subjects enrolled in this arm will have the HonourTM poly-ether-ether-ketone (PEEK) cage (interbody cage) implanted at each level of 1 or 2-level lumbar arthrodesis procedures. All constructs will be supplemented with a pedicle screw system (Depuy Synthes Expedium) cleared for lumbar spinal fusion.
2843052|NCT03647488|Experimental|Capmatinib plus spartalizumab|Combination arm
2843053|NCT03647488|Active Comparator|Docetaxel|Comparator arm
2843054|NCT03647475|Experimental|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent|Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be treated with a Resolute Onyx stent followed by one-month DAPT. The clinical safety of the Resolute Onyx stent as compared to a performance goal will be evaluated using a composite safety endpoint of cardiac death and myocardial infarction at 1 year for a one-month clear population.
2843055|NCT03647462|Experimental|CPAP Intervention Pathway|"Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.~The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying COPD. They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms."
2843056|NCT03647462|No Intervention|Usual Care Pathway|Patients will receive contemporary standard of care pharmacotherapy for their underlying COPD condition and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
2843057|NCT03647449|Experimental|Juice fast|"In the juice fasting arm, participants will be given vegetable/fruit pressed juices and be instructed to engage in a three-day juice fast diet totaling 800-900 kcal-per-day. The specific juices will be assigned for each day in order to maintain the calorie level."
2843058|NCT03647449|Experimental|Caloric restriction via Plant-based meals|"In the caloric restriction diet arm, participants will be on a whole-food plant-based diet totaling 800-900 kcal-per-day (matching the daily calories of juice fasting)."
2843059|NCT03647449|Experimental|Juice plus ad hoc|"In the juice plus ad hoc arm, participants will be given the same juice for three days but continue with their usual diet in addition to the juice. For this arm, there is no restriction of caloric intake or restriction to liquid only."
2843160|NCT03646786|Experimental|visually impaired patients|
2843161|NCT03646760|Experimental|Hybrid Cardiac Rehabilitation (HYCR)|
2843060|NCT03647436||Exposed group|"Elderly patients with hospital admission due to hip fracture and score less than 12 points in the short-MNA at the moment of hospital admission.~Intervention:~Comprehensive Geriatric Assesment (CGA). Both groups.~CGA includes measuring of:~Previous functional assessment of daily life activities (Barthel and Lawton index), a cognitive screening (MiniMental State Examination), the turn-based assessment of the presence of delirium (Confusion Assessment Method) and in case of presence of delirium will be measured the duration and intensity of the symptoms (Delirium Rating Scale-Revised-98). Likewise, the presence of frailty (Clinical Frailty Scale) and walking ability (Functional Ambulation Categories) will be evaluated."
2843061|NCT03647436||Control group|"Elderly patients with hospital admission due to hip fracture and score equal or higher than 12 points in the short MNA at the moment of hospital admission~Intervention:~Comprehensive Geriatric Assesment (CGA). Both groups.~CGA includes measuring of:~Previous functional assessment of daily life activities (Barthel and Lawton index), a cognitive screening (MiniMental State Examination), the turn-based assessment of the presence of delirium (Confusion Assessment Method) and in case of presence of delirium will be measured the duration and intensity of the symptoms (Delirium Rating Scale-Revised-98). Likewise, the presence of frailty (Clinical Frailty Scale) and walking ability (Functional Ambulation Categories) will be evaluated."
2843062|NCT03647423|Experimental|NANT Chordoma Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin Hydrochloride HCI, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK, avelumab, cetuximab, cyclophosphamide, SBRT.
2843063|NCT03647423|Active Comparator|Controlled Arm - Radiation|SBRT
2843064|NCT03647410||lumbopelvic fixation|sacral fractures fixed with lumbopelvic fixation
2843065|NCT03647410||novel adjustable plate|sacral fractures fixed with novel adjustable plate
2843066|NCT03647397|Experimental|PECO|All pediatric patients admitted for respiratory distress will have the intervention of Photo Electrochemical Oxidation (PECO) for Air Purification.
2843067|NCT03647384|Experimental|Intervention|In this arm, patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
2843068|NCT03647384|Active Comparator|Control|In this arm, patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
2843069|NCT03647358|Experimental|Lesion Dosimetry With Iodine-124|Patients will be administered 124I and undergo serial PET imaging consisting of up to 4 individual PET/CT scans.
2843070|NCT03647345|Experimental|Experimental 1: Anodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of anodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
2843071|NCT03647345|Experimental|Experimental 2: Cathodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of cathodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
2843072|NCT03647345|Active Comparator|Active Comparator: Single sham stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
2843073|NCT03647332|Active Comparator|Cooled RFA treatment|
2843074|NCT03647332|Active Comparator|Steroid injection|
2843075|NCT03647319|Experimental|Anodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of anodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
2843076|NCT03647319|Experimental|Cathodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of cathodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
2843077|NCT03647319|Active Comparator|Single sham stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
2843078|NCT03647306|Active Comparator|Extended Overnight Fast|The extended overnight fast group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session. Subjects will consume approximately 33% of their daily calories at breakfast, lunch and dinner, respectively. This is a model for fasting dietary chronotype.
2843079|NCT03647306|Experimental|Early Total Caloric Intake|The Early Total Caloric Intake study group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session and will consume 60% of their daily calories during breakfast. The remaining 40% of daily calories will be consumed during lunch and dinner. This is a model for early dietary chronotype.
2843080|NCT03647306|Experimental|Late Total Caloric Intake|The Late Total Caloric Intake study group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session and will consume 40% of daily calories during breakfast and lunch. The remaining 60% of daily calories will be consumed during dinner. This is a model for late dietary chronotype.
2843081|NCT03647293|Active Comparator|Control Group|Neonates who underwent a peripherally inserted central catheter
2843082|NCT03647293|Active Comparator|Intervention Group|Neonates who underwent an Ultrasound Guided Central Catheter Insertion
2843083|NCT03647280|Experimental|Abraxane Combined With Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
2843084|NCT03647267|Active Comparator|Pneumatic Vitreolysis|Participants randomized to the Pneumatic Vitreolysis arm will receive 0.3-mL intraocular injection of C3F8 gas.
2843085|NCT03647267|Placebo Comparator|Observation|Participants randomized to the observation group will receive a sham injection.
2843086|NCT03647254|Experimental|Patient Education Group|A group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting and they continued with their usual controls
2843087|NCT03647254|No Intervention|Control group|Control group performed usual clinical practice, that is, people will be schedule by nurses about one time per month, except cases in which controls are inappropriate.
2843088|NCT03647241|Experimental|Self-Ligating Brackets|Patients will be treated using self-ligating brackets to achieve proper alignment of teeth
2843089|NCT03647241|Experimental|Self-Ligating Brackets with Corticotomy|Patients will be treated using self-ligating brackets with corticotomy (alveolar cortical cuts) in order to accelerate orthodontic treatment.
2843090|NCT03647241|Active Comparator|Traditionally-Ligated Brackets|Patients in this group will be treated using traditionally-ligated brackets to achieve proper alignment of teeth
2843091|NCT03647228|Experimental|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
2843092|NCT03647228|Placebo Comparator|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
2843093|NCT03647215||All Participants|Participants with CML and Ph+ALL who are being treated with their first or subsequent TKI therapy who meet the ELN criteria for warning and failure (CML) and who have detectable BCR-ANL levels (Ph+ALL).
2843094|NCT03647202|Experimental|Sequence ABC|Participants receive milademetan in a fasted condition (A), then with a high-calorie, high-fat breakfast (B), then with a standard breakfast (C) - with a washout period between treatments.
2843095|NCT03647202|Experimental|Sequence ACB|Participants receive milademetan in a fasted condition (A), then with a standard breakfast (C), then with a high-calorie, high-fat breakfast (B) - with a washout period between treatments.
2843096|NCT03647202|Experimental|Sequence BAC|Participants receive milademetan with a high-calorie, high-fat breakfast (B), then in a fasted condition (A), then with a standard breakfast (C) - with a washout period between treatments.
2843097|NCT03647202|Experimental|Sequence BCA|Participants receive milademetan with a high-calorie, high-fat breakfast (B), then with a standard breakfast (C), then in a fasted condition (A) - with a washout period between treatments.
2843098|NCT03647202|Experimental|Sequence CAB|Participants receive milademetan with a standard breakfast (C), then in a fasted condition (A), then with a high-calorie, high-fat breakfast (B) - with a washout period between treatments.
2843099|NCT03647202|Experimental|Sequence CBA|Participants receive milademetan with a standard breakfast (C), then with a high-calorie, high-fat breakfast (B), then in a fasted condition (A) - with a washout period between treatments.
2843100|NCT03647189|Experimental|Treatment Arm|Subjects will be treated with hybrid fractional laser
2843101|NCT03647189|Placebo Comparator|Control Arm|No treatment performed
2843102|NCT03647176|Active Comparator|small polyps|Cold snare polypectomy ; Polyp size will be measured using the tip of the snare catheter (2.5mm).Small (4-9 mm) colorectal polyps will be removed with a polypectomy snare. Following the resection, jet stream of water will be used to wash mucosal defect thoroughly. After endoscopist's attestation that polyp removal was complete by carefully observe the resection margins with near focus mode, biopsies were performed from two marginal sites located symmetrically on the left and right of the mucosal defects to confirm residual polyp tissue.
2843103|NCT03647176|Experimental|large polyps|Cold snare polypectomy; Polyp size will be measured using the tip of the snare catheter (2.5mm). Large (10-15 mm) colorectal polyps will be removed with a polypectomy snare. Following the resection, jet stream of water will be used to wash mucosal defect thoroughly. After endoscopist's attestation that polyp removal was complete by carefully observe the resection margins with near focus mode, 4 biopsies will be performed from all four quadrants of resection margins.
2843104|NCT03647163|Experimental|Safety Run-in Dose Level 1|Patients with pembrolizumab refractory solid tumors will receive a single IV dose of 5e10 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 1, then every 21 days, up to 2 years.
2843105|NCT03647163|Experimental|Safety Run-in Dose Level 2|Patients with pembrolizumab refractory hepatocellular carcinoma (HCC) or non small cell lung cancer (NSCLC) will receive a single IV dose of 1.7e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 1, then every 21 days, up to 2 years.
2843106|NCT03647163|Experimental|Expansion HCC arm|Patients with pembrolizumab refractory hepatocellular carcinoma (HCC) will receive a single IV dose of 1.7e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 1, then every 21 days, up to 2 years.
2843107|NCT03647163|Experimental|Expansion NSCLC arm|Patients with pembrolizumab refractory non small cell lung cancer (NSCLC) will receive a single IV dose of 1.7e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 1, then every 21 days, up to 2 years.
2843108|NCT03647150|Other|Moderate Acute Malnutrition (MAM)|"MAM children at control clinics or MAM children at intervention clinics that do no have high rick characteristics. Control treatment is Mother Care counselling, delivered by a respected elder in the local community."
2843109|NCT03647150|Experimental|High Risk Moderate Acute Malnutrition (MAM)|The intervention treatment incorporates Mother Care counselling, provision of one packet (525 calories) of ready-to-use therapeutic food (RUTF) daily and a course of amoxicillin. This provision will continue until the child has reached a mid-upper arm circumference (MUAC) greater than 12.4 cm or 12 weeks have elapsed.
2843110|NCT03647137||Parkinson's disease with FoG|Subjects with Parkinson's disease that have freezing of gait (FoG) who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid)
2843111|NCT03647137||Parkinson's disease without FoG|Subjects with Parkinson's disease that do not have freezing of gait who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid)
2843113|NCT03647124||Lenalidomide treated R/R-MCL patients in the rest of EU|Retrospective data collection for Lenalidomide treated R/R-MCL patients from sites in the rest of European Union
2843114|NCT03647111||Cohorts 1|
2843115|NCT03647098||Cohorts 1|Treatment plan
2843116|NCT03647098||Cohorts 2|brain metastases
2843117|NCT03647098||Cohorts 3|Concomitant KRAS mutation
2843118|NCT03647085||Group 1 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, persistent atrial fibrillation at the time of enrollment and are scheduled for an ablation or cardioversion.
2843119|NCT03647085||Group 2 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, paroxysmal atrial fibrillation at the time of enrollment and are scheduled for an ablation or cardioversion.
2843120|NCT03647085||Group 3 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, atrial flutter at the time of enrollment and are scheduled for an ablation or cardioversion.
2843121|NCT03647072|Active Comparator|CHOP|CHOP only
2843122|NCT03647072|Active Comparator|CHOP Plus Lanzoprazole|CHOP Plus Lanzoprazole 60 mg
2843123|NCT03647072|Active Comparator|CHOP Plus Famotidine|CHOP Plus Famotidine 40 mg
2843124|NCT03647059||LSCM examination|
2843125|NCT03647046|Experimental|Customized Scleral Lens|A customized scleral lens will be compared with a non-customized scleral lens in subjects with Keratoconus through vision tests.
2843126|NCT03647033|No Intervention|phacoemulsification alone|routine phacoemulsification cataract surgery with intraocular lens implantation
2843127|NCT03647033|Experimental|phacoemulsification and iStent|phacoemulsification cataract surgery with intraocular lens implantation combined with iStent implantation
2843128|NCT03647007|No Intervention|Standard group|The Standard programme on the Christmas Seal Homes.
2843129|NCT03647007|Experimental|FIFA Group|The Standard programme including FIFA 11 for Health programme - health knowledge on the football pitch.
2843130|NCT03646994||Cohorts 1|
2843131|NCT03646968|Experimental|Cohorts|Phase II Study to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer
2843132|NCT03646955|Active Comparator|Partial breast irradiation|External beam irradiation 40 Gy / 15 fractions, 5 fractions per week, 3 weeks
2843133|NCT03646955|No Intervention|No partial breast irradiation|No radiation therapy
2843134|NCT03646942|Active Comparator|Lingual orthodontics|Patients will be treated with lingual braces without being irradiation with low level laser therapy. Treatment will go forward in the normal manner. Archwires will be changed in the traditional way.
2843135|NCT03646942|Experimental|Low level laser therapy|Patients will be subjected to low level laser therapy during their orthodontic treatment using lingual braces.
2843136|NCT03646929|Other|healthy individuals and patients with multiple sclerosis|MEP in healthy individuals and patients with multiple sclerosis are measured using standard facilitation technique
2843137|NCT03646929|Other|patients with multiple sclerosis|MEP patients with multiple sclerosis are measured using modified facilitation technique
2843138|NCT03646916|Active Comparator|Dexamethasone|
2843139|NCT03646916|No Intervention|Non-treatment|
2843140|NCT03646903|Experimental|Cognitive Bias Modification for Help-Seeking Stigma (CBM-HS)|"CBM-HS is a 15-minute web-based intervention designed to alter maladaptive cognitions related to mental health help-seeking. In this task, individuals are presented with a series of statements regarding beliefs about using mental health services (e.g., Seeking help for my problems means I am weak). Individuals then select True or False in response to each statement. Incorrect responses (i.e., demonstrating help-seeking stigma) are followed by corrective feedback. Conversely, correct responses (i.e., promoting help-seeking) are positively reinforced (e.g., That's right! You are correct!). Participants in this condition will complete three separate 15-minute CBM-HS sessions."
2843141|NCT03646903|Placebo Comparator|Placebo Cognitive Bias Modification|Participants randomized to this condition will complete a similar CBM task with neutral stimuli. The duration of the CBM-Placebo task will be comparable to the duration of the CBM-HS task (i.e., three 15-minute sessions).
2843142|NCT03646903|Active Comparator|Self-Directed Psychoeducation|Participants randomized to this condition will review psychoeducation on mental health literacy, mental illness stigma, and treatment options. Readings will be compiled from resources available in the public domain. The duration of self-directed psychoeducation will be comparable to the duration of study tasks for individuals in the CBM-HS study condition (i.e., three 15-minute sessions).
2843143|NCT03646877|Experimental|Ozone (O3)|
2843144|NCT03646877|Placebo Comparator|Filtered Air (FA)|
2843145|NCT03646864|Experimental|Treatment A|ACT-541468 50 mg from Day 1 to Day 5 of Period A
2843146|NCT03646864|Placebo Comparator|Treatment B|Placebo from Day 1 to Day 5 of Period B
2843147|NCT03646851|Experimental|COPD|COPD patients GOLD stage III and IV
2843148|NCT03646825||Treatment group|Male patients exposed to antioxidant for 12 weeks
2843149|NCT03646812|Other|Glucose Reference 1|50g of glucose dissolved in 250ml of water to be consumed.
2843150|NCT03646812|Other|Glucose Reference 2|50g of glucose dissolved in 250ml of water to be consumed.
2843151|NCT03646812|Other|Glucose Reference 3|50g of glucose dissolved in 250ml of water to be consumed.
2843152|NCT03646812|Experimental|Semolina Penne|70g of semolina penne boiled in 1 Litre of water for 11 minutes. Drained and consume immediately.
2843153|NCT03646812|Experimental|Wholegrain Penne|76g of wholegrain penne boiled in 1 Litre of water for 9 minutes. Drained and consume immediately.
2843154|NCT03646812|Experimental|Semolina Spaghetti|71g of semolina spaghetti boiled in 1 Litre of water for 8 minutes. Drained and consume immediately.
2843155|NCT03646812|Experimental|Wholegrain Spaghetti|76g of wholegrain spaghetti boiled in 1 Litre of water for 8 minutes. Drained and consume immediately.
2843156|NCT03646812|Experimental|Jasmine rice|63g of rice cook with 150g of water. Served and consume immediately.
2843157|NCT03646812|Experimental|Asian Noodles|92.4g of Asian Noodles cook in boiling water for 45 seconds. Drained and consume immediately
2843158|NCT03646799|Experimental|Group 1|Period 1: 1 tablet of reference drug(D484) Period 2: 1 tablet of test drug(CKD-387)
2843159|NCT03646799|Experimental|Group 2|Period 1: 1 tablet of test drug(CKD-387) Period 2: 1 tablet of reference drug(D484)
2843162|NCT03646760|Active Comparator|Center Based cardiac Rehabilitation (CBCR)|
2843163|NCT03646747|Experimental|MRI scan|"10 healthy participants will be asked to undergo two baseline OE-MRI scans with either nasal cannula or facial mask to breathe air and oxygen throughout.~Following this initial pilot, OE-MRI will be tested in 30 patients with solid head and neck tumours."
2843164|NCT03646734||Guided Bone Regeneration with Particulate graft|patients who had inadequate alveolar crest (crest width <4mm) and requested of dental implant placement, treated with guided bone regeration with particulate graft
2843165|NCT03646734||Guided Bone Regeneration with block graft|patients who had inadequate alveolar crest (crest width <4mm) and requested of dental implant placement, treated with guided bone regeration with block graft
2843166|NCT03646721|Experimental|[Part1] DA-1241 : 6 subjects in each cohort(Cohort 1-3)|Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).
2843167|NCT03646721|Placebo Comparator|[Part1] Placebo : 2 subjects in each cohort(Cohort 1-3)|Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).
2843168|NCT03646721|Experimental|[Part2] DA-1241 : 15 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
2843169|NCT03646721|Placebo Comparator|[Part2] Placebo : 5 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
2843170|NCT03646721|Active Comparator|[Part2] Sitagliptin : 5 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
2843171|NCT03646708||SBCD patients starting a new biologic therapy|As part of your standard clinical care (soc), patient will be started on a biologic (anti-tumor necrosis factor (TNF)s, vedolizumab and ustekinumab) based on your interactions with your treating gastroenterologist after standard of care clinical assessment.
2843172|NCT03646695|Experimental|ILM flap|vitrectomy with ILM flap transposition and gas-tamponade will be performed
2843173|NCT03646695|Active Comparator|ILM peeling|vitrectomy with ILM peeling and gas-tamponade will be performed
2843174|NCT03646682|Experimental|caffeine group|180mg of caffeine will be given orally one jour before surgery
2843175|NCT03646682|Active Comparator|control group|no caffeine will be given before surgery, patients are drinking no coffee in general
2843176|NCT03646669|Experimental|Asthma education and PEF feedback|Patients receive asthma education and personal Peak expiratory flow (PEF) feedback
2843177|NCT03646669|Placebo Comparator|Asthma education|No PEF feedback arm
2843178|NCT03646656|Experimental|peer partner|Veterans with at least one CVD risk factor who are interesting in increasing heart healthy behaviors through peer support
2843179|NCT03646656|Other|peer coach|Veterans with at least one CVD risk factor who have made and sustained changes in diet or exercise in the past 3-6 months prior to enrollment. While the investigators will collect data on peer coach participants, their participation is primarily as part of intervention to examine the feasibility and benefit of adding peer coaching to a peer partner intervention.
2843180|NCT03646643|Active Comparator|PVI, non-PV triggers|Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation.
2843181|NCT03646643|Active Comparator|PVI, non-PV triggers & CS-LA connection|Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation in addition to coronary sinus-left atrium connection elimination. Distal coronary sinus pacing will be utilized to localize the earliest connection (aside from septal) from the coronary sinus to the left atrial musculature. Once localized, focal radiofrequency lesions will be applied at the discretion of the investigator until distal coronary sinus to left atrial connections are eliminated.
2843182|NCT03646630|Active Comparator|Quadratus Lumborum Block (QL)|Patients will be placed in the lateral position,The high-frequency linear probe will be placed on the lateral abdomen, slightly cephalic to the iliac crest. Once the QL muscle will be observed, the probe will be tilted slightly to the caudal direction, to show the largest slice of the QL muscle, to confirm its posterior aspect. A 22-G block needle (Stimuplex D, Braun, Hongo, Bunkyo-ku, and Tokyo) will be inserted in-plane, ~1 cm ventral to the probe. The needle tip will be advanced until it penetrates the posterior fascia of the QL muscle. A small amount of saline will be injected to confirm the correct position of the tip, between the QL muscle and the erector spinae and latissimus dorsi muscles (Posterior or QL block type 2), then a bolus of 0.5 ml/Kg bupivacaine 0.25% will be injected.
2843183|NCT03646630|Active Comparator|Caudal block (C)|After induction of general anesthesia, a lateral position is obtained with the upper hip flexed 90⁰ and the lower one only 45⁰. A line is drawn to connect the posterior superior iliac spines bilaterally and used as one side of an equilateral triangle; then the location of the sacral hiatus should be approximated. By palpating the sacral cornua as 2 bony prominences, the sacral hiatus could be identified as a dimple in between. A 22 gauge needle is inserted at 45 degrees to the sacrum and redirected if the posterior surface of sacral bone is contacted. Children will receive caudal block with 1 ml/kg of bupivacaine 0.25%.
2843184|NCT03646617|Active Comparator|No HFRT|ipilimumab and nivolumab once every 3 weeks for up to 4 doses, followed by nivolumab once every 2 weeks until disease progression.
2843185|NCT03646617|Experimental|HFRT|The dose of HFRT will be 8 Gy x 3 fractions, given over a maximum of 7 days timespan.
2843186|NCT03646604|Experimental|Cohort 1|Study participants, 6 to <12 years of age, receiving low dose of upadacitinib
2843187|NCT03646604|Experimental|Cohort 2|Study participants, 6 to <12 years of age, receiving high dose of upadacitinib
2843188|NCT03646604|Experimental|Cohort 3|Study participants, 2 to <6 years of age, receiving low dose of upadacitinib
2843189|NCT03646604|Experimental|Cohort 4|Study participants, 2 to <6 years of age, receiving high dose of upadacitinib
2843224|NCT03646292|Experimental|Empagliflozin monotherapy|Empagliflozin 10mg 1T daily for 6 months
2843225|NCT03646292|Experimental|Pioglitazone + Empagliflozin combination therapy|Pioglitazone 15mg + Empagliflozin 10mg combination 1T daily for 6 months
2843190|NCT03646591||Neoadjuvant chemotherapy|A total of four preoperative and four postoperative cycles of FLOT chemotherapy administered A cycle consist of Day 1 5-FU 2600mg/M2 administered via intravenous PICC for 24 hour Leucovorin 200mg/M2 intravenous Oxaliplatin 85mg/ M2 intravenous Docetaxel 50mg/M2 intravenous Repeated every 15th day
2843191|NCT03646552|Experimental|THX-110|All participants will be titrated up on THX-110 (Dronabinol) dose during the first week of the trial (2.5mg Dronabinol for 3 days, 5mg Dronabinol for 3 days to 7.5mg Dronabinol for 3 days and finally increasing to 10mg for the remainder of the trial). Dronabinol will only be increased if the subject is tolerating the previous dose of Dronabinol and the Dronabinol may be reduced based on patient side-effects. Participants will be receiving 800mg PEA concomitantly.
2843192|NCT03646539|Experimental|Smartphone use + treatment as usual|Participants will receive treatment as usual and use the smartphone app for the management of mood.
2843193|NCT03646539|Active Comparator|Treatment as usual|Participants will receive treatment as usual.
2843194|NCT03646526|Experimental|Fast grop|During the study session, healthy subjects will be administered a single dose of Amiloride hydrochloride tablets 25mg or Sandoz tablet 25mg under fasting condition cylcle 1 Drug: Amiloride hydrochloride 25mg cylcle 2 Drug: Sandoz tablet 25mg cylcle 3 Drug: Sandoz tablet 25mg cylcle 4 Drug: Amiloride hydrochloride tablet 25mg
2843195|NCT03646526|Experimental|Fed grop|During the study session, healthy subjects will be administered a single dose of Amiloride hydrochloride tablets 25mg or Sandoz tablet 25mg under fasting condition cylcle 1 Drug: Sandoz tablet 25mg cylcle 2 Drug: Amiloride hydrochloride tablet 25mg cylcle 3 Drug: Amiloride hydrochloride tablet 25mg cylcle 4 Drug: Sandoz tablet 25mg
2843196|NCT03646513||SMF Short Modular Femoral Stem Implanted Subjects|Subjects who have been implanted with the SMF Short Modular Femoral Stem for primary total hip arthroplasty.
2843197|NCT03646500|Experimental|Retrobulbar block|Retrobulbar block administered prior to Transcleral Diode Procedure
2843198|NCT03646500|Active Comparator|Remifentanil|Conscious IV sedation administered prior to Transcleral Diode Procedure.
2843199|NCT03646487|Experimental|Probiotic LP299v|Women will receive 1 LP299v (10x10 colony forming units) in capsule form and 1 standard prenatal supplement in tablet form daily beginning at 15 weeks gestation through delivery.
2843200|NCT03646487|Placebo Comparator|Placebo|Women will receive 1 placebo in capsule form and 1 standard prenatal supplement in table form daily beginning at 15 weeks gestation through delivery.
2843201|NCT03646474|Active Comparator|tranexamic acid group|
2843202|NCT03646474|Placebo Comparator|placebo group|
2843203|NCT03646461|Experimental|Arm A: Ibrutinib + Cetuximab|Ibrutinib 560mg PO daily (Imbruvica) PLUS Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
2843204|NCT03646461|Experimental|Arm B: Ibrutinib + Nivolumab|Ibrutinib 560mg PO daily (Imbruvica) PLUS Nivolumab 3mg/kg biweekly 28 day cycle
2843205|NCT03646448|Experimental|Intervention group|Counseling based on Motivational Interviewing and elements of Cognitive Behavioral Therapy
2843206|NCT03646448|No Intervention|Control group|Control group receiving a booklet on problematic Internet use
2843207|NCT03646435|Experimental|Wearable device (Fitbit Charge 2)|The Fitbit Charge 2 is the wearable of interest for this pilot study. All 50 study participants will be requested to wear the electronic device for the duration of their stay in the hospital (maximum of 6 days). The Fitbit will passively collect health information of patients which will be tracked on mobile devices by the study investigators.
2843208|NCT03646409||Patients with esophageal cancer receiving chemotherapy|Patients > 18 years with esophageal cancer receiving neoadjuvant chemotherapy
2843209|NCT03646396|Experimental|Sofosbuvir-daclatasvir|Sofosbuvir-daclatasvir for 3 months
2843210|NCT03646383|Experimental|Treatment with radiofrequency|Treatment of symptomatic benign nodules with radiofrequency ablation as an alternative to surgical treatment
2843211|NCT03646357|Active Comparator|Betablocker|Patients receiving a betablocker. Any other treatment or management is to be given as per usual care.
2843212|NCT03646357|Experimental|Non-Betablocker|No betablocker is given to this arm. Any other treatment or management is to be given as per usual care.
2843213|NCT03646344|Active Comparator|Active Group|Will receive Heme Arginate (IMP) at a dose of 3mg/kg over 30mins. Participants will receive infusions of the IMP at 2 time-points, the first prior to surgery (transplantation), and the second 20-28 hours later. At each infusion, the IMP will be followed by a 100ml infusion of 0.9% Sodium Chloride over 15mins.
2843214|NCT03646344|Placebo Comparator|Placebo Group|Will receive a 100ml infusion of 0.9% Sodium Chloride (placebo) over 30mins. Participants will receive infusions at 2 time-points, the first prior to surgery, and the second 20-28 hours later. At each infusion, the placebo will be followed by a further 100ml infusion of 0.9% Sodium Chloride over 15mins.
2843215|NCT03646331|Experimental|Tablet A in Session 1 and Tablet B in Session 2|Tablet A = reference product Tablet B = test product
2843216|NCT03646331|Experimental|Tablet B in Session 1 and Tablet A in Session 2|Tablet A = reference product Tablet B = test product
2843217|NCT03646318|Experimental|Ketanserin|Ketanserin is a serotonin type 2-receptor blocker (5-HT2). In normal endothelium, the 5-HT1 effects (vasodilation) are the most prominent [Dabire 1990]. In endothelium that is damaged, which is the case in sepsis, the 5HT2 effects (vasoconstriction) surpass the 5-HT1 effects. Blocking the 5-HT2 receptor with ketanserin can attenuate this pathological vasoconstriction. In addition, ketanserin has favourable α1-adrenergic blocking properties in the endothelium (vasodilation) that may further reverse the pathological vasoconstriction. In these ways ketanserin can reduce vasoconstriction and can improve the microcirculation.
2843218|NCT03646318|Placebo Comparator|Placebo|The placebo is a standard glucose 5% solution.
2843219|NCT03646305|Experimental|Verbally repeat body-related thoughts|A cognitive defusion strategy in which participants repeat a target unwanted thought out loud and as quickly as possible for 60 seconds.
2843220|NCT03646305|Experimental|Sing negative body-related thoughts|A cognitive defusion strategy in which participants sing a target unwanted thought to the tune of 'twinkle, twinkle' for 60 seconds
2843221|NCT03646305|No Intervention|Verbally repeat body-unrelated thoughts|"A control condition in which participants repeat the phrase I am talking out loud and as quickly as possible for 60 seconds."
2843222|NCT03646305|No Intervention|Sing body-unrelated thoughts|"A control condition in which participants sing the phrase I am singing to the tune of 'twinkle, twinkle' for 60 seconds"
2843223|NCT03646292|Experimental|Pioglitazone monotherapy|Pioglitazone 15mg 1T daily for 6 months
2843226|NCT03646266|Experimental|Rocuronium|Titration of rocuronium bromide until tidal volume of 6ml/kg predicted body weight (PBW) is reached
2843227|NCT03646266|No Intervention|Control|Standard of care
2843228|NCT03646253||Patients with proximal humerus fracture|
2843229|NCT03646240|Experimental|Dosing arm|
2843230|NCT03646214|Experimental|Midline traction oral appliance|Subjects will wear the oral appliance nightly for 4 weeks. Must snore or have other evidence of sleep disordered breathing.
2843231|NCT03646214|No Intervention|Control|Subjects who do do not wish to wear the oral appliance will have their sleep monitored in parallel to the experimental subjects for 4 weeks.
2843232|NCT03646201|Experimental|FFF|FFF teaches authoritative parenting skills for reducing children's exposure to and intakes of SoFAS, including changes to the family food environment, mothers' own eating behaviors, and food parenting practices.
2843233|NCT03646201|No Intervention|Control Group|Data are collected at baseline and post intervention session.
2843234|NCT03646188|Placebo Comparator|Placebo-containing MNA|Color-matched placebo
2843235|NCT03646188|Experimental|25 µg Doxorubicin-containing MNA|D-MNA's containing 25 µg of doxorubicin hydrochloride
2843236|NCT03646188|Experimental|50 µg Doxorubicin-containing MNA|D-MNA's containing 50 µg of doxorubicin hydrochloride
2843237|NCT03646188|Experimental|100 µg Doxorubicin-containing MNA|D-MNA's containing 100 µg of doxorubicin hydrochloride
2843238|NCT03646188|Experimental|200 µg Doxorubicin-containing MNA|D-MNA's containing 200 µg of doxorubicin hydrochloride
2843239|NCT03646175|Experimental|Acute Choline Supplementation|Participants will consume 1000 mg (2x500 mg) of choline bitartrate the evening before each testing session.
2843240|NCT03646175|Placebo Comparator|Placebo Supplementation|Participants will consume 1000 mg (2x500 mg) of placebo the evening before each testing session.
2843241|NCT03646162|Experimental|Veru-944 10 mg|Veru-944 10 mg daily
2843242|NCT03646162|Experimental|Veru-944 50 mg|Veru-944 50 mg daily
2843243|NCT03646162|Experimental|Veru-944 100 mg|Veru-944 100mg daily
2843244|NCT03646162|Placebo Comparator|Placebo|Placebo daily
2843245|NCT03646149||Housing Skills Training Group|Homeless Veterans with serious mental illness who are inpatient at the VA Greater Los Angeles Domiciliary or enrolled in a VA Supported Housing (VASH) program and participating in a Housing Skills Training Group as part of routine clinical care.
2843246|NCT03646149||Control Group|Homeless Veterans with serious mental illness who are inpatient at the VA Greater Los Angeles Domiciliary or enrolled in a VA Supported Housing (VASH) program and not participating in a Housing Skills Training Group due to limited staff resources.
2843247|NCT03646136|Experimental|Retained Cystoscopy Fluid|Retained 200mL normal saline used for distending media following completion of diagnostic cystoscopy
2843248|NCT03646136|Active Comparator|Cystoscopy Fluid Emptied|Emptied 200mL normal saline used for distending media following completion of diagnostic cystoscopy
2843249|NCT03646123|Experimental|A+AVD|Arm Description: Brentuximab vedotin (A) plus doxorubicin (+A), vinblastine (V), and dacarbazine (D) administered by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle
2843250|NCT03646110|Experimental|single-incision MIE|Esophageal cancer patients received single-incision Minimally invasive esophagectomy
2843251|NCT03646110|Active Comparator|multi-incision MIE|Esophageal cancer patients received multi-incision Minimally invasive esophagectomy
2843252|NCT03646097|Active Comparator|Blinded-group|Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators only based on angiographic lesion evaluation (standard care)
2843253|NCT03646097|Active Comparator|OCT-group|Patients underwent OCT-imaging before PCI. Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators based on OCT findings
2843254|NCT03646097|Experimental|ACR-group|Patients underwent ACR-imaging before PCI. Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators based on ACR-findings
2843255|NCT03646084|Experimental|Sleep Intervention Program (SCIP)|Based on the results of the studies, patients will be treated according to current guidelines: 1) Improve rest/activity rhythms. 2) To treat and control Sleep Disorder Breathing. 3) To improve anxiety, depression and insomnia. 4) To treat RLS if needed. 5) To try opioid dose reduction. 6) To trial of non-opioid in lieu of opioids. 7) Avoiding use of benzodiazepines, sedatives, hypnotics. 8) Caution against alcohol use.
2843256|NCT03646084|Active Comparator|Control|Rehabilitation according to current clinical practice.
2843257|NCT03646071|Experimental|Dose Escalation Phase|The Dose-Escalation Phase will employ a standard 3+3 algorithm to investigate ascending dose cohorts of RX108.
2843258|NCT03646071|Experimental|Dose Expansion Phase|In the Expansion Phase, subjects will receive RX108 at the maximum tolerated dose.
2843259|NCT03646058|Placebo Comparator|Placebo|2 placebo pills sublingual during 28 days
2843260|NCT03646058|Experimental|0.4mg buprenorphine|1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 21 days, then 2 placebo pills per day for 1 week, all sublingual.
2843261|NCT03646058|Experimental|0.8mg buprenorphine|1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 3 days, then 2 pills of 0.4mg buprenorphine per day for 18 days, then 1 pill of 0.4 mg + 1 placebo pill per day for 3 days, then 2 placebo pills per day for 4 days, all sublingual.
2843262|NCT03646045||Transpyloric feed|Preterm infant receiving transpyloric feeding.
2843263|NCT03646045||Control|Preterm infants receiving gastric feeding
2843264|NCT03646032|Experimental|Intervention group|Intervention group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants who will receive a download of the SAAFE game and play for at least 30 minutes and as long as an hour, if desired.
2843265|NCT03646032|Placebo Comparator|Control group|Control group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants. This group will receive the standard of care by launching a mobile app that will play a knowledge-based You-tube video on risky sexual behavior, which we will name SAAFE video. They will also receive pamphlets that provide information on testing location and care if they have HIV/STI.
2843268|NCT03646019||Significant coronary artery disease|
2843269|NCT03646006|Experimental|Pre-sacral nerve block|10 mL bupivacaine (5mg/mL)
2843270|NCT03646006|Sham Comparator|Sham block|10 mL normal saline
2843271|NCT03645993||Early-Onset Alzheimer's disease|Patients ages 45-60 with Early-Onset Alzheimer's disease
2843272|NCT03645993||Negative Control|Family members of patients with Early-Onset Alzheimer's disease who have consented to the study.
2843273|NCT03645980|Experimental|DKN-01|Phase I Study treatment will be started as monotherapy with DKN-01 for up to 8 weeks or until unacceptable toxicity occurs. The study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. The dose of DKN-01 for cohort 1 will be 300 mg and cohort 2 will be 600 mg or 150 mg, depending on the results of the safety assessment. Phase II The dose of DKN-01 will be the recommended phase II dose (RP2D) determined from Part A. Study treatment will be started as monotherapy with DKN-01 until objective disease progression (PD1) or unacceptable toxicity occurs. After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
2843274|NCT03645967|Other|ReadyCleanse for IUC|ReadyCleanse Cloths will be used for the standard of care for indwelling urinary catheter care and maintenance. The old standard of care will no longer be used.
2843275|NCT03645954|Active Comparator|Femoral Nerve Block|The femoral nerve block will be performed under the ultrasound guidance by a single injection of local anesthetic around all the femoral nerve branches inside the proximal part of the femoral triangle.
2843276|NCT03645954|Active Comparator|Femoral Triangle & Adductor Canal Blocks|"These two blocks will be performed together.~Firstly, the femoral triangle block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the medial border of the sartorius muscle intersects the medial border of the adductor longus muscle. Local anesthetic will be injected laterally to the femoral artery.~Secondly, the adductor canal block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the femoral vessels (artery and vein) dive deeper from the sartorius muscle. Local anesthetic will be injected under the femoral artery."
2843277|NCT03645941|No Intervention|Quitline/Treatment Referral|•Description of tobacco treatment services, phone numbers and web links sent via postal mail (printed materials) and email. Treatment options provide free, professional assistance based on U.S. clinical practice guidelines: (1)AK quitline, (2)regional tribal tobacco cessation programs, and (3)smokefree.gov resources (e.g., free texting program and smartphone application, quit guide)
2843278|NCT03645941|Experimental|Facebook+Quitline/Treatment Referral|"Participants join a secret/private, culturally relevant Facebook group moderated by an AN tobacco research counselor for 3 months~Once daily moderator postings for 30 days, repeated each month for 3 months; plus 3-4 daily check-ins/postings to respond to participant generated content and encourage sharing of personal stories/experiences relevant to all stages of the quitting process and treatment engagement~Description of tobacco treatment services, phone numbers and web links sent via postal mail (printed materials) and email. Treatment options provide free, professional assistance based on U.S. clinical practice guidelines: (1)AK quitline, (2)regional tribal tobacco cessation programs, and (3)smokefree.gov resources (e.g., free texting program and smartphone application, quit guide)"
2843279|NCT03645928|Experimental|Cohort 1|Lifileucel (LN-144) therapy in combination with pembrolizumab in patients with advanced unresectable or metastatic melanoma, who have not received prior immunotherapy including checkpoint inhibitors (eg, anti-PD-1/anti-PD-L1, anti-CTLA-4).
2843280|NCT03645928|Experimental|Cohort 2|TIL LN-145 therapy in combination with pembrolizumab in patients with advanced HNSCC, who have not received prior immunotherapy including checkpoint inhibitors (eg, anti-PD-1/anti-PD-L1).
2843281|NCT03645928|Experimental|Cohort 3|TIL LN-145 therapy as a single-agent in NSCLC patients, who have previously received systemic therapy with checkpoint inhibitors (eg, anti-PD-1/anti-PD-L1).
2843282|NCT03645902||Acute stroke patients|MRI examinations will be performed on a 3 T GE MR750 W scanner. Two readers, an experienced neuroradiologist (8 years of experience in neuroradiology) and a junior radiologist (3 years of experience in general radiology) will independently analyze eSWAN and TOF images in random order, looking for arterial occlusions. Analysis will be based on a 2-point-scale: arterial occlusion, based on a local signal loss, or acceptable permeability.
2843283|NCT03645889|Experimental|Paediatric Lung Tonic (PLTG)|Traditional Chinese Medicine (TCM) in granules dosage form to be dissolved for consumption.
2843284|NCT03645889|Placebo Comparator|PLTG Placebo|Starch granules with 10% TCM to mimic the colour, taste and smell of active TCM.
2843285|NCT03645876|Experimental|SHR-1210+BP102+XELOX|Participants receive SHR-1210 200mg,BP102 7.5mg/kg and oxaliplatin 130mg/m2 in day 1 intravenously every 3week, capecitabine by oral bid in day1-14 every 3 week until disease progression or unacceptable toxicity
2843286|NCT03645863|Experimental|Cohort 1|
2843287|NCT03645863|Experimental|Cohort 2|
2843288|NCT03645863|Experimental|Cohort 3|
2843289|NCT03645850|Experimental|Investig. device:Vismed Gel Multi 0.3%|Vismed gel Multi 0.3% eye drops: 1 to 2 drops in each eye between 4 and 6 times per day during 84 days
2843290|NCT03645850|Active Comparator|Comparative device: Vismed Multi 0.18%|Vismed Multi 0.18% eye drops: 1 to 2 drops in each eye between 4 and 6 times per day during 84 days
2843291|NCT03645837|Experimental|10 minutes|Compression clamp release start after 10 minutes
2843292|NCT03645837|Experimental|20 minutes|Compression clamp release start after 20 minutes
2843293|NCT03645837|Active Comparator|30 minutes|Compression clamp release start after 30 minutes
2843294|NCT03645824|Experimental|Pacritinib treatment befor allo-SCT|The effect of pacritinib treatment during 3 to 4 cycles before allo-SCT on engraftment 6 months (day +180) post allo-SCT in MF patients.
2843295|NCT03645811|Experimental|Breathing technique|The breathing technique is applied take a deep breath while counting from 1 to 8, and then to hold their breath while counting from 1 to 8, and then breathe out while counting from 1 to 8 again.
2843296|NCT03645811|Experimental|Music therapy|In the study, music therapy was applied in the application room. Via a portable computer, students listened to the mahur maqam for 20 minutes under the supervision of the investigators using an MP3 player.
2843297|NCT03645811|Experimental|EFT|The EFT application protocol was explained to the students with the help of the image in the picture. The method was applied through the investigators tapping on their bodies and the students repeating the steps.
2843298|NCT03645811|No Intervention|Control|For the control group, 20 minutes of free time was given.
2843299|NCT03645798|Experimental|"Three good things therapy group"|"The experimental group received a six-month Wechat-basedthree good things positive psychotherapy from August 2015 to January 2016. Participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good things, participants were required to answer the question: Why did this good thing happen?"
2843300|NCT03645798|Other|Normal psychological instruction group|The control group only received normal psychological instruction from the hospital
2843301|NCT03645785|Active Comparator|Normal drinking habits|Normal fluid intake without True lemon
2843302|NCT03645785|Experimental|Increased fluid Intake|Double fluid intake plus 3 bottles of water with True Lemon
2843303|NCT03645772|Experimental|Plyometric exercise|12-week progressive exercise program, consisting of plyometric exercises such as countermovement jump, forward and sideways step-up.
2843304|NCT03645772|Active Comparator|Resistance exercise|12-week resistance exercise program for the leg muscles (2-4 sets of 8-15 repetitions at 8-15RM, leg press, leg extension, calve extension).
2843305|NCT03645772|Active Comparator|Walking|12-week progressive walking program.
2843306|NCT03645759|Experimental|I'm Whole|This arm will receive 6 behavioral health treatment sessions that focus on stroke self-management, psychological distress and social re-integration. Treatments will occur weekly. They will also receive 3 assessments at 0, 6, and 12 weeks.
2843307|NCT03645759|Active Comparator|Education + usual care|This arm will only receive the standard usual care for stroke self-management provided by the Michael E. Debakey VA Medical facility and will receive 6 brief health education calls unrelated to stroke or psychological distress.
2843308|NCT03645746|Experimental|Cohort 1|Cohort 1 will receive a single IV dose of REGN5069 or matching placebo
2843309|NCT03645746|Experimental|Cohort 2|Cohort 2 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
2843310|NCT03645746|Experimental|Cohort 3|Cohort 3 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
2843311|NCT03645746|Experimental|Cohort 4|Cohort 4 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
2843312|NCT03645746|Experimental|Cohort 5|Cohort 5 will receive a single SC dose of REGN5069 or matching placebo
2843313|NCT03645746|Experimental|Cohort 6|Cohort 6 will receive a single sequential ascending SC dose of REGN5069 or matching placebo
2843314|NCT03645733|No Intervention|Control Group|The control group will be at the standard dialysate temperature of 36.5 °C (which is the standard of care in the sites), 3 times a week for 12 months
2843315|NCT03645733|Experimental|Lower Temperature Group|These patients will receive haemodialysis with a dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached. Patients who would fail to tolerate the temperature of 35 °C, the lowest tolerated temperature will be carried over to the end of the study.
2843316|NCT03645733|No Intervention|Caregivers|Patients, who consent for the study, will be asked to identify the most suitable carer to participate in the study who could be approach in person, over the phone or by post as deemed suitable by the research team and convenient by the carer. Patient's permission to contact their identified carer will be recorded. Carers of consenting patients will be approached in the same manner as above after obtaining patients consent to contact their carers. Patients will still be able to take part in the study even if their carer declines consent.
2843317|NCT03645720|No Intervention|Metal needle gruop|puncture using metal needle
2843318|NCT03645720|Experimental|plastic cannula|puncture using plastic cannula
2843319|NCT03645707|Experimental|CAR Training and Psychoeducational Sessions|"This is a secondary study to the primary study titled A Randomized Controlled Trial of a Resilience Intervention for Critical Care Nurses (IRBNet #1234568). In the primary study, participants will be randomized into the intervention group or wait-list control group.~In this secondary study, all participants will attend the 1-day CAR Training Program and the follow-up psychoeducational group sessions."
2843320|NCT03645694|Experimental|SSA|Individuals with memory concerns in the experimental arm received the prototype facial recognition technology, which included a smartphone and smartwatch. The smartphone was equipped with facial recognition software application; the smartwatch communicated information with the smartphone. Persons with memory concerns and their family care partners were given a demonstration on how to utilize the technology.
2843321|NCT03645694|No Intervention|Control|Control participants did not receive the technology; at the conclusion of follow-up, all controls were offered the technology to use.
2843322|NCT03645681|Experimental|InnAVasc AVG treatment|"Patients will be surgically implanted with an InnAVasc AVG in the forearm or upper arm using standard vascular surgical techniques. The graft will be placed in a straight (soft C) configuration in the upper arm, or looped configuration in the forearm (forearm loop) or upper arm (axillary loop)."
2843323|NCT03645668|Experimental|Experimental group|meropenem injection, 1.0g, q8h,intravenous infusion ,0.5g/0.5h+0.5g/4h
2843324|NCT03645668|Other|Control group|meropenem injection, 1.0g, q8h,continuous intravenous infusion duration ,1h
2843325|NCT03645655||hepatoblastoma|The diagnosis of hepatoblastoma is based on enhanced CT scanning and/or histopathology.
2843326|NCT03645655||hepatic hemangioendothelioma|The diagnosis of hepatic hemangioendothelioma is based on enhanced CT scanning and/or histopathology.
2843327|NCT03645655||Healthy control|The healthy control group consist of people undergoing routine medical examination.
2843328|NCT03645642|Experimental|Midodrine|Midodrine (5 mg TDS) along with albumin(20g/l) and diuretics. The dose of Midodrine will titrated according to the Mean arterial pressure (75-90mmhg). The dose will be increased to a maximum of 12.5 mg thrice daily.
2843329|NCT03645642|Active Comparator|Albumin with diuretics|Albumin(20g/l) and diuretics.
2843330|NCT03645629|Active Comparator|Food skin tests at 0 month|the skin test results of food extract at time 0 months after preparation
2843331|NCT03645629|Active Comparator|Food skin tests at 3 month|the skin test results of food extract at time 3 months after preparation
2843332|NCT03645629|Active Comparator|Food skin tests at 6 month|the skin test results of food extract at time 6 months after preparation
2843573|NCT03643926|Experimental|Arthroscopic Brostrom|
2843333|NCT03645616|Experimental|Functional Tests|Participants undertook 6-minute walk test, 10 meters walk test and 30 second sit to stand test.
2843334|NCT03645603|Experimental|Dexmedetomidine|Dexmedetomidine 100 mcg/ml concentrate solution. Continuous iv infusion. Start dose 0.4 mcg/kg/h, increases by 0.2 mcg/kg/h until 0.8 mcg/kg/h (half dose for neonates). If withdrawal symptoms appear the dose can be increased to a maximum of 1.4 mcg/Kg/h.
2843335|NCT03645603|Placebo Comparator|Placebo|saline solution for IV infusion. The administration of infusion will follow the experimental drug.
2843336|NCT03645590|Experimental|Stroke Ready Community intervention|We divided the Flint community into four quadrants. We will focus our workshops and posters on one quadrant, but not exclusively, moving quadrants every 6 months over the course of two years.
2843337|NCT03645564|Active Comparator|Group 1 : specialized nurse consultation|This group will benefit of a specialized nurse consultation throughout of which an individualized information will be delivered. This information will be reevaluated during the usual patient follow-up.
2843338|NCT03645564|No Intervention|Group 2 : no specialized nurse consultation|This control group will present the same care pathway than all the patients of the service suffering from Atrial Fibrillation without specialized nurse consultation.
2843339|NCT03645538||Parkinson's disease patients|"PD patients, after reading and signing the free and informed consent will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals. All volunteers (healthy and patients) will be submitted to a behavioral and neurophysiological evaluation through transcranial magnetic stimulation (TMS) and electroencephalography (EEG).~The neurophysiological evaluation will be conducted during ON (with medication) and OFF (without medication) period, by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG."
2843340|NCT03645538||No drug - Control group|PD patients, after reading and signing the free and informed consent will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals. All volunteers (healthy and patients) will be submitted to a behavioral and neurophysiological evaluation through transcranial magnetic stimulation (TMS) and electroencephalography (EEG).
2843341|NCT03645525|Experimental|Mesenchymal stem cell|Human Umbilical Cord-derived Mesenchymal stem cell in the saline
2843342|NCT03645525|Placebo Comparator|placebo|saline without mesenchymal stem cell
2843343|NCT03645512|Experimental|Intervention|The intervention group will attend in the 1-day Corporate Athlete Resilience (CAR) Training Program in Lake Nona.
2843344|NCT03645512|No Intervention|Control|The control group will attend the 1-day CAR Training Program in Lake Nona after a 3-month wait list period, which will be three months after the intervention group attends the intervention.
2843345|NCT03645499|Experimental|Topical TA-102 A|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
2843346|NCT03645499|Experimental|Topical TA-102 B|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
2843347|NCT03645499|Experimental|Topical TA-102 C|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
2843348|NCT03645486|Experimental|Lentiviral TYF-CGD-modified autologous stem cells|Autologous hematopoietic stem cells transduced with lentiviral TYF vector carrying the functional gene
2843349|NCT03645473|Experimental|Single Arm|
2843350|NCT03645460|Experimental|TYF-ADA-modified autologous stem cells|Autologous hematopoietic and/or mesenchymal stem cells transduced with lentiviral vector carrying the ADA gene
2843351|NCT03645447|Experimental|Taste test|
2843352|NCT03645434|Experimental|Treatment sequence A|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 2: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 3: Matching placebo of AZD8871 and Anoro® Ellipta®"
2843353|NCT03645434|Experimental|Treatment sequence B|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follows:~Treatment period 1: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 2: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 3: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg."
2843354|NCT03645434|Experimental|Treatment sequence C|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follows:~Treatment period 1: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 2: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 3: Matching placebo of AZD8871 and Anoro® Ellipta®"
2843355|NCT03645434|Experimental|Treatment sequence D|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 2: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 3: AZD8871 600 µg and Anoro® Ellipta® matching placebo."
2843356|NCT03645434|Experimental|Treatment sequence E|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 2: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 3: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg."
2843357|NCT03645434|Experimental|Treatment sequence F|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 2: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 3: AZD8871 600 µg and Anoro® Ellipta® matching placebo."
2843358|NCT03645421|Placebo Comparator|placebo|Placebo per day,SC injection on 48 days.
2843359|NCT03645421|Experimental|MEDI0382 100μg|50 μg/day,SC injection on the first 5 days and 100 μg/day,SC injection on 43 days.
2843360|NCT03645421|Experimental|MEDI0382 200μg|50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days and 200 μg/day,SC injection on 36 days.
2843361|NCT03645421|Experimental|MEDI0382 300μg|50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days, 200 μg/day,SC injection on 7 days and 300 μg/day,SC injection on 29 days
2843513|NCT03644381|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
2843362|NCT03645408|Experimental|Exenatide injection|Subjects in this arm will receive a 5 mcg dose of immediate release exenatide on the day of the alcohol challenge. The 5mcg dose of exenatide is approved as the first dose to be administered to patients at the start of their treatment with this drug for FDA-approved indications.
2843363|NCT03645408|Placebo Comparator|Placebo|Subjects in this arm will receive a sham injection on the day of the alcohol challenge. The sham injection will be a needle stick using the exenatide multi-dose syringe with no drug injected. Note that the volume of fluid injected for a 5mcg dose is only .08ml. We do not expect that subjects will sense this volume of fluid (or lack thereof) during the injection. Subjects will be shielded from seeing the injection to maintain the blind.
2843364|NCT03645395|Experimental|MT-3724 10 mcg/kg-LEN|MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2, then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle
2843365|NCT03645395|Experimental|MT-3724 25 mcg/kg-LEN|MT-3724 25 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2, then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle
2843366|NCT03645395|Experimental|MT-3724 50 mcg/kg-LEN|MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2 , then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle
2843367|NCT03645382|Placebo Comparator|baked barley powder consumption|Subjects randomized to the placebo group received one tablet containing baked barley powder per day (900 mg/day). placebo group consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.
2843368|NCT03645382|Experimental|jeju steam onion powder consumption|Subjects randomized to the test group received one tablet containing jeju steam onion powder per day (900 mg/day). placebo group consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.
2843369|NCT03645369|Experimental|Mechano-Analgesia|The first SC heparin injections were applied from the right abdominal region using ShotBlocker®.
2843370|NCT03645369|Experimental|Cold Application|The second SC heparin injections were applied from the left abdominal region with an ice pack
2843371|NCT03645369|No Intervention|Control|The second SC heparin injections were applied from the lower abdominal region without any additional application
2843372|NCT03645356|Active Comparator|fixed appliances|patients will be treated using fixed appliances in order to align their teeth after extraction of four premolars
2843373|NCT03645356|Experimental|clear aligners|patients will be treated using clear aligners in order to align their teeth after extraction of four premolars
2843374|NCT03645343|Active Comparator|Activator|Patients will be treated using the Activator appliance for one and a half year
2843375|NCT03645343|Experimental|Twin Block|Patients will be treated using the Twin Block appliance for 18 months on average
2843376|NCT03645343|No Intervention|Control|Patients will be monitored until the last assessment times in the other groups. This group will serve as a control group
2843377|NCT03645317|Other|Single arm|Blood samples (FBC, lipids, cholesterol, troponin, CRP, BNP) Cardiac imaging (cardiac CT, cardiac ultrasound, 12-lead ECG)
2843378|NCT03645304|Experimental|Ropivacaine group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the experimental group, an elastomeric pump filled with local analgesic solution (total volume 100ml) containing 750mg ropivacaine .
2843379|NCT03645304|Placebo Comparator|0.9% Saline group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
2843380|NCT03645291|Active Comparator|Skin test with local extract|Skin prick test and intradermal test with local stinging insect allergen extracts that develop in Immunological division of Siriraj hospital, mahidol University
2843381|NCT03645291|Sham Comparator|Skin test with commercial extract|Skin prick test and intradermal test with commercial stinging insect allergen extracts that order from ALK company
2843382|NCT03645278|Experimental|SHR0532|Up to 5 cohorts of healthy subjects will receive a single dose of oral SHR0532 tablet.
2843383|NCT03645278|Experimental|Placebo|Up to 5 cohorts of healthy subjects will receive a single dose of oral placebo.
2843384|NCT03645265|Experimental|Gestures|Use of hand gestures to improve speech rhythm and speech production
2843385|NCT03645265|Experimental|Auditory|Use of auditory cues to improve speech rhythm and speech production
2843386|NCT03645252|Active Comparator|Vein first|Tumor-draining pulmonary vein is interrupted first and before any surgical manipulation.
2843387|NCT03645252|Active Comparator|Arteries before vein|Lobar arteries (+/- bronchus and inter-lobar fissures) are interrupted before tumor-draining pulmonary vein.
2843388|NCT03645239||Control|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Patients will be assigned to this group when they have a pain score of less than 3 (out of 10) at 6-10 post-delivery phone survey.
2843389|NCT03645239||Postoperative pain|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Patients will be assigned to this group when they have a pain score of equal or more than 3 (out of 10) at 6-10 post-delivery phone survey.
2843414|NCT03645096|Experimental|Pregnenolone 500 > Pregnenolone 800 > Placebo|"3 exposures in order:~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Matching placebo capsule by mouth, daily for 7 days."
2843571|NCT03643939|Experimental|High Flow Nasal Catheter|
2843390|NCT03645226||Early PD subjects converted from iRBD|"Chinese aged 50 or above~Being capable of giving informed consent for participation of the study~PD diagnosis confirmed by neurologists according to the United Kingdom Parkinson's Disease Survey Brain Bank. Assessment tools including Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn & Yahr Staging will be used for severity grading.~Onset of PD symptoms of < 3years~In view of the heterogeneity of PD, we will only include those patients with RBD preceding the onset of motor symptom of PD."
2843391|NCT03645226||iRBD subjects|"Age-and sex-matched with PD subjects~Chinese aged 50 or above~Being capable of giving informed consent for participation of the study~RBD diagnosis according to the International classification of sleep disorder 3rd edition (ICSD 3rd), fulfilling both the clinical and video-polysomnography (vPSG) criteria."
2843392|NCT03645226||First degree relatives of patients with iRBD|"First degree relatives of patients with iRBD;~Age-and sex-matched with PD subjects~Chinese aged 50 or above;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~Not cohabiting with proband"
2843393|NCT03645226||Healthy Controls|"Age-and sex-matched with PD subjects;~Chinese aged 50 or above;~Being capable of giving informed consent for participation of the study;~Without a personal history or a family history of PD or RBD;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~Absence of RSWA as measured by v-PSG."
2843394|NCT03645226||Spouses of patients with iRBD|"Spouses of patients with iRBD;~Age-and sex-matched with PD subjects;~Chinese aged 50 or above;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~Cohabiting with proband."
2843395|NCT03645226||First degree relatives of healthy controls|"First degree relatives of healthy controls;~Age-and sex-matched with PD subjects;~Chinese aged 50 or above ;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;"
2843396|NCT03645226||Spouses of healthy controls|"Spouses of healthy controls;~Age-and sex-matched with PD subjects;~Chinese aged 50 or above;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~Cohabiting with proband."
2843397|NCT03645213|Experimental|Virtual Reality (VR)|Children were asked which cartoon they wanted to watch and it was prepared. The cartoons began to be shown a minute before venipuncture and lasted about 4 minutes. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's. The display was a head-mounted VR box in the VR group.
2843398|NCT03645213|Experimental|Non- Virtual Reality (VR)|Children were asked which cartoon they wanted to watch and it was prepared. The cartoons began to be shown a minute before venipuncture and lasted about 4 minutes. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's. The display was a computer tablet in the non-VR group. The computer tablet was the 10 centimeters far from the child.
2843399|NCT03645213|No Intervention|Control|There was no additional intervention in the control group. Venipuncture procedures was the same other groups. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's.
2843400|NCT03645200|Experimental|Fluzoparib combined with Apatinib|"Fluzoparib in the initial dose of 40mg.bid started into the group of participants, group A combined with a fixed dose of Apatinib 250mg.qd for treatment, followed by the 40mg.bid, 60mg.bid, 80mg.bid, 100mg.bid dose increase.~Fluzoparib in the initial dose of 40mg.bid started into the group of participants, Group B was treated with a fixed dose of Apatinib 500mg.qd, followed by an increase in doses of 40mg.bid, 60mg.bid, 80mg.bid, 100mg.bid ."
2843401|NCT03645187|Active Comparator|FOLFOX|FOLFOX regien
2843402|NCT03645187|Active Comparator|Folfox and celecoxib|Folfox and celecoxib
2843403|NCT03645174|Active Comparator|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
2843404|NCT03645174|Experimental|Long tube|Fiberoptic-guided intubation through LMA, using long tube
2843405|NCT03645161|Active Comparator|Local rat and mouse skin test|All patients receive local skin prick test for mouse and rat. The result were recorded and compared to the imported one.
2843406|NCT03645161|Active Comparator|Imported rat and mouse skin test|All patients receive imported skin prick test for mouse and rat. The result were recorded and compared to the local one.
2843407|NCT03645148|Experimental|iNeo-Vac-P01|"Personal Cancer Vaccine: iNeo-Vac-P01 (peptides)+ GM-CSF;~Peptides: 4 x 100 mcg per peptide given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses;~GM-CSF: 4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses"
2843408|NCT03645135|No Intervention|Control|Patients in the control group will be asked to complete a demographics survey and assess their perceived involvement in care after their visit
2843409|NCT03645135|Experimental|Goal elicitation|Patients in the intervention group will be asked to list 2 goals for their visit. They will also be asked to complete a demographics survey and access their perceived involvement in care after their visit.
2843410|NCT03645122|Experimental|Stroke|This study will attempt to induce bi-directional plasticity in corticospinal-motoneurlonal synapses serving an intrinsic hand muscle of the hemiparetic limb using stimulation. Individuals who are at least 6 months post-ever subcortical stroke and have at least partial range of motion of the paretic index finger will be invited to participate.
2843411|NCT03645122|Placebo Comparator|Control|Control experiments will be completed to provide evidence of the neurophysiological mechanism(s) mediating the effect and to examine behavioral effects of stimulation. Individuals without a history of stroke will be recruited to participate.
2843412|NCT03645109|Experimental|Vitamin D|Will receive capsules with 5,000 IU of vitamin D3, one capsule orally once a day for eight weeks
2843413|NCT03645109|Placebo Comparator|Placebo|Will receive capsules with placebo (talcum food grade) one capsule orally once a day for eight weeks
2843508|NCT03644446||Bisoprolol 10mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 10mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
2843415|NCT03645096|Experimental|Pregnenolone 500 > Placebo > Pregnenolone 800|"3 exposures in order:~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 800 mg capsule by mouth, daily for 7 days."
2843416|NCT03645096|Experimental|Pregnenolone 800 > Pregnenolone 500 > Placebo|"3 exposures in order:~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Matching placebo capsule by mouth, daily for 7 days."
2843417|NCT03645096|Experimental|Pregnenolone 800 > Placebo > Pregnenolone 500|"3 exposures in order:~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 500 mg capsule by mouth, daily for 7 days."
2843418|NCT03645096|Experimental|Placebo > Pregnenolone 500 > Pregnenolone 800|"3 exposures in order:~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 800 mg capsule by mouth, daily for 7 days."
2843419|NCT03645096|Experimental|Placebo > Pregnenolone 800 > Pregnenolone 500|"3 exposures in order:~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.~Pregnenolone 500 mg capsule by mouth, daily for 7 days."
2843420|NCT03645083|Experimental|Telephone call|Participants receive a telephone call reminder three days after their initial visit
2843421|NCT03645083|Experimental|Text message|Participants receive a text message reminder three days after their initial visit
2843422|NCT03645083|No Intervention|Control|Participants do not receive any intervention after their initial visit
2843423|NCT03645070|No Intervention|No probe|Twenty patients will be allocated to this group, which will have no esophageal temperature monitoring technique
2843424|NCT03645070|Active Comparator|Single probe|Twenty patients will be allocated in this group, in which there will be monitoring of esophageal temperature during radiofrequency applications in the posterior wall of the left atrium, with unipolar thermometer.
2843425|NCT03645070|Active Comparator|Multi-probe|Twenty patients will be allocated in this group, in which there will be oesophageal temperature monitoring during radiofrequency applications in the posterior wall of the left atrium, with a multipolar and self expandable thermometer.
2843426|NCT03645057|Experimental|Crisaborole|The topical treatment will be applied to all affected areas twice daily for 12 weeks.
2843427|NCT03645057|Active Comparator|Tacrolimus 0.03%|The topical treatment will be applied to all affected areas twice daily for 12 weeks.
2843428|NCT03645031|Experimental|ALS Group|Participants will complete a single 30 minute session of acute intermittent hypoxia (AIH), as well as, the 30 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.
2843429|NCT03645031|Experimental|Healthy Control Group|Participants will complete a single 30 minute session of acute intermittent hypoxia (AIH), as well as, the 30 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.
2843430|NCT03645018|Experimental|diagnosis with tomosynthesis (DTS)|"Single arm.~Population: Subjects enrolled in previously closed SOS trial (high risk subjects for lung cancer) without confirmed lung cancer."
2843431|NCT03645005|Experimental|My Guide (psychoeducation & self-management program)|
2843432|NCT03645005|Active Comparator|My Health (health education program)|
2843433|NCT03644992||Thromboembolic Disease|the patients who undergo gynecological operations but develop thromboembolic disease
2843434|NCT03644979|Experimental|Skydiving|Tandem skydiving
2843435|NCT03644979|No Intervention|Negative control|No skydiving
2843436|NCT03644966|Experimental|Probiotic + Antibiotic|50 subjects to receive probiotic supplement once daily for 6 months in capsule form, in addition to standard antibiotic regimen for treatment of UTI.
2843437|NCT03644966|Active Comparator|Placebo + Antibiotic|50 subjects to receive placebo once daily for 6 months in capsule form, in addition to antibiotic regimen for treatment of UTI.
2843438|NCT03644953|Experimental|Hydroxyurea and Transfusion (HAT)|Combination hydroxyurea and simple chronic transfusion therapy
2843439|NCT03644940|Experimental|Subpopulation-specific Algorithm|
2843440|NCT03644940|No Intervention|Control Algorithm|
2843441|NCT03644927|Experimental|Progressive exercise program|"Based on the Active Physical Treatment Model individuals with chronic pain are typically and primarily sedentary or physically deconditioned and need a progressive approach to work up to standard exercise prescriptions as defined by the American College of Sports Medicine. Thus, progressive exercise training can help to minimize the risk or occurrence of a range of exercise-related adverse medical events, particularly with the complex study population which will be starting at a sedentary level and therefore, may not be able to initially achieve the heart rate goals prescribed in standard exercise training protocols. The exercise prescription will be individually designed and geared toward an intensity manageable by the individual.."
2843442|NCT03644927|Active Comparator|Waitlist Control|The waitlist control participants will be fully screened for eligibility and asked to wait 12 weeks before beginning the 12-week progressive exercise program. They will be assessed again at the end of the 12-week waiting period. These patients will then be compared to patients in the experimental arm and then compared against their own waitlist control data after completing the 12-week exercise program. The exercise program that the waitlist control patients will participate in is identical to the experimental arm.
2843443|NCT03644914|Experimental|Intervention Group (Reading Program)|First graders who will receive the 10-week reading program (a total of 20 hours), twice weekly in 1-hour sessions, and will continue to receive typical classroom reading instruction.
2843444|NCT03644914|No Intervention|Control Group|First graders who will not take part in the reading program but will continue to receive typical classroom reading instruction.
2843445|NCT03644901||Patients whose blood type is A|Applying nonsurgical periodontal treatment (scaling and root planning).
2843446|NCT03644901||Patients whose blood type is B|Applying nonsurgical periodontal treatment (scaling and root planning).
2843447|NCT03644901||Patients whose blood type is AB|Applying nonsurgical periodontal treatment (scaling and root planning).
2843448|NCT03644901||Patients whose blood type is O|Applying nonsurgical periodontal treatment (scaling and root planning).
2843449|NCT03644888|Active Comparator|Control group|Cycle ergometer training program: 2 minutes warm-up at no load, 20 minutes at 60% of peak work (PW) calculated by stress-test or at 50% of PW calculated according to Luxton equation (PW = 103.217 + (30.50 X gender) + (-1.613 X age) + (0.002 X 6MWW [m kg -1 ]). The progression of the workloads is calculated according to the BORG Dyspnea and Fatigue Scale (Borg D and F < 5: 10W increase; Borg D and/or F between 5 e 6: maintain same workload; Borg D and / or > 6: 10W decrease) Patient tailored airway clearance program guided by an experienced respiratory physical therapist, which could includes active cycle of breathing technique (ACBT), forced expiratory technique (FET), ELTGOL (slow expiration with glottis open in the lateral position) and PEP techniques (positive expiratory pressure).
2843450|NCT03644888|Experimental|Experimental group|Cycle ergometer training program plus application of vibration therapy. The vibration is provided at 300Hz via 4 effectors applied bilaterally at the second or third interspaces in the parasternal region of the upper chest wall and at the seventh to ninth interspaces anterior to the midaxillary line in the lower chest wall.
2843451|NCT03644888|Sham Comparator|Sham intervention group|Cycle ergometer training program plus application of sham vibration therapy: 4 effectors on chest-wall at same position of vibration therapy, the device that produces vibration is switched on, producing the typical noise and vibration is emitted by effectors not placed on the patient but left in place on the device.
2843452|NCT03644849|Experimental|Fractional carbon dioxide laser intervention group|The intervention will only involve a single treatment with ablative fractional carbon dioxide laser therapy. The investigators will specifically be using the CO2RE® (Syneron Candela Corp, Wayland, MA).
2843453|NCT03644849|Sham Comparator|Sham laser intervention group|
2843454|NCT03644836|Experimental|Retraining with respiratory effort+ amino acids|
2843455|NCT03644836|Placebo Comparator|Retraining with respiratory effort+ placebo|
2843456|NCT03644823|Experimental|PDL1-inhibitor and radiotherapy|PDL1-inhibitor (Atezolizumab) and Radiotherapy (6 Gy x 3)
2843457|NCT03644810|Active Comparator|Chronic low back pain|"Individuals with chronic low back pain. Baseline assessment of pain intensity, function, pain duration and pain catastrophizing thoughts is performed~Pain sensitivity at the back and lower leg is measured at baseline and immediately after performing the cold pressor test"
2843458|NCT03644810|Active Comparator|Healthy controls|"Healthy, pain-free individuals who are age and gender matched to the low back pain group fill out the pain catastrophizing scale~Pain sensitivity at the back and lower leg is measured at baseline and immediately after performing the cold pressor test"
2843459|NCT03644797||Patients|Patients presenting intellectual disability and previously diagnosed as carriers of a 16p13.11 copy number variant using Cytogenetic Micro Array.
2843460|NCT03644784||Yamaguchi University Hospital|
2843461|NCT03644784||Erasmus Medical Center|
2843462|NCT03644784||Academic Medical Center - Amsterdam|
2843463|NCT03644784||Segeberger Kliniken Gruppe|
2843464|NCT03644784||McGill University - Montreal|
2843465|NCT03644758|Other|professional and voluntary firefighter|Professional and voluntary firefighter in Service Departmental Fire and Rescue of Loire will be included. They will have to answer at the self-administrated questionnaires. It is composed of 5 parts: socio-demographic data and personal medical history, Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale, Insomnia Severity Index (ISI) and stop-BANG questionnaire.
2843466|NCT03644745|Experimental|VM @ Home Usability|We will pilot our customer engagement and physical exercise system in the homes of up to 20 participants for 3 months. Participants will interact with the system on their own computers, smart phones, and/or televisions and wear an activity tracker throughout the study. Interactions include physical exercise, system usage, and video conferencing.
2843467|NCT03644732||SEEG Group|Group with SEEG analysis (Pre-surgical SEEG assessment)
2843468|NCT03644719|Experimental|Cognitive behavior skills training|The first session is intended to establish rapport, build therapeutic cohesion through ice-breaking activities, and educate participants about the drug regulations stated in the Statute for Drug Hazard Prevention and Control. The following four sessions are devoted to interactively practicing refusal skills, communication skills, decision-making skills, and positive conflict resolution skills. The final session is to review what has been learned and reminds participants about the association of drug use with HIV/HCV.
2843469|NCT03644719|No Intervention|Education as usual|The EAU group received six hours of informational lectures about ketamine, its effects on the brain, relevant regulations and laws, and the risks and modes of transmission of infectious diseases, including HIV and hepatitis C.
2843470|NCT03644706|Active Comparator|ADV7103|Patients continue to receive ADV7103 twice a day at their open label dose over 6 days
2843471|NCT03644706|Placebo Comparator|Placebo Comparator|Patients receive matched placebo twice a day until they reach a bicarbonate level of 18mEq/L
2843472|NCT03644693|Experimental|Investigational|Subjects assigned to this arm will receive the Nutritional Formulation containing exogenous ketones.
2843473|NCT03644693|Placebo Comparator|Placebo|Subjects assigned to this arm will receive the Placebo Formulation.
2843474|NCT03644680|Experimental|Nasal Provocation with Birch Extract|Birch allergic patient receiving 3 consecutive nasal challenges with birch extract (Allergopharma). Total dose of 1.5ug of Bet v 1 per challenge
2843475|NCT03644680|Placebo Comparator|Nasal Provocation with NaCl 0.9%|Birch allergic patient receiving 3 consecutive nasal challenges with sterile NaCl 0.9%. Total dose of 100ul per nostril per challenge
2843476|NCT03644667|Experimental|Tocilizumab + Standard of Care Triple IS|"Tocilizumab plus standard of care triple immunosuppression (IS). Heart transplant recipients will receive tocilizumab (Actemra®) plus standard triple maintenance immunosuppression.~Standard of care triple maintenance immunosuppression includes:~a calcineurin inhibitor (tacrolimus),~an anti-proliferative treatment (mycophenolate mofetil) or Myfortic® (enteric-coated mycophenolate sodium), and~steroids (methylprednisolone/prednisone) as prescribed by site physician investigator."
2843509|NCT03644433|Placebo Comparator|Single layer|Single layer closure
2843510|NCT03644433|Active Comparator|Double layer with resection|Double layer closure after resection uterine scar
2843511|NCT03644420||Knee osteoarthritis|"Patients with knee osteoarthritis, classified Kellgren-Lawrence 3 or 4, with asymmetric femorotibial joint space narrowing that will follow a surgery for a prosthetic replacement of the knee wil follow the following interventions:~Clinical evaluation~Radiographic assessment of osteoarthritis~Magnetic resonance imaging (MRI)~Histological evaluation of the surgical piece"
2843477|NCT03644667|Placebo Comparator|Placebo + Standard of Care Triple IS|"Placebo plus standard of care triple maintenance immunosuppression (IS). Heart transplant recipients will receive placebo plus standard triple maintenance immunosuppression.~Standard of care triple maintenance immunosuppression includes:~a calcineurin inhibitor (tacrolimus),~an anti-proliferative treatment (mycophenolate mofetil) or Myfortic® (enteric-coated mycophenolate sodium), and~steroids (methylprednisolone/prednisone) as prescribed by site physician investigator.~Participants enrolled in the study will be followed for 24 months after their transplant surgery. Randomization will occur once a participant has weaned from cardiopulmonary bypass and has achieved hemodynamic stability without significant ongoing bleeding within the first 72 hours after transplant."
2843478|NCT03644654|Active Comparator|Group of invasive monitoring|Fluid management will be done according value of stroke volume variation from arterial line
2843479|NCT03644654|Experimental|Group of noninvasive monitoring|Fluid management will be done using noninvasive hemodynamical monitor ClearSight (Edwards)
2843480|NCT03644641|Experimental|Desflurane Group|Induction and anesthesia will be held by using desflurane
2843481|NCT03644641|Experimental|Propofol Group|Induction and anesthesia will be held by using target-controll anesthesia with propofol
2843482|NCT03644628|Active Comparator|Sacropexy group (SCP)|Anterior and apical repair with laparoscopic sacropexy
2843483|NCT03644628|Experimental|Lateral suspension group (LLS)|Anterior and apical repair with laparoscopic lateral suspension
2843484|NCT03644615|Experimental|Mindfluness and usual care|
2843485|NCT03644615|Other|Usual Care|
2843486|NCT03644602|Active Comparator|IBD patients|"All subjects with Crohn's disease in clinical remission (defined in the presence of a Crohn's Disease Activity Index, CDAI <150), and with Ulcerative colitis in clinical remission (defined in the presence of <3 evacuations / day without blood, in the absence of endoscopic alterations) received a low FODMAPs diet.~The low FODMAPs diet was administered for 3 months."
2843487|NCT03644602|Active Comparator|Coeliac patients|Celiac patients on a gluten free diet for at least one year received a low FODMAPs diet. The low FODMAPs diet was administered for 3 months.
2843488|NCT03644602|Active Comparator|IBS patients|Patients with Irritable Bowel Syndrome received a low FODMAPs diet. The low FODMAPs diet was administered for 3 months.
2843489|NCT03644589|Experimental|Treatment (pembrolizumab, cisplatin)|"Participants receive pembrolizumab and cisplatin once every 3 weeks for a total of 6 doses. Both drugs are given by vein (IV). Participants that are responding to the study treatment will continue to receive pembrolizumab alone beyond 6 cycles for up to 24 months until disease gets worse, having bad side effects, no longer wish to be in the study, or have become pregnant (whichever comes first).~Participants receive pembrolizumab over 30 minutes and cisplatin on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants without disease progression after 6 courses may continue on pembrolizumab IV on day 1 every 21 days for up to 24 months (or 35 courses) in the absence of disease progression or unacceptable toxicity."
2843490|NCT03644576|Experimental|ozanimod plus Pseudophedrine|ozanimod once daily (QD) for 30 days. On Day 30, a single dose of pseudoephedrine 60mg will be co-administered with ozanimod.
2843491|NCT03644576|Placebo Comparator|ozanimod, placebo plus Pseudoephedrine|ozanimod placebo once daily (QD) for 30 days. On Day 30, a single dose of pseudoephedrine 60mg will be co-administered with ozanimod placebo.
2843492|NCT03644563||Follow-up|Those subjects with oncogenic oral HPV infection and/or HPV serum antibodies from screening (and those previously identified as having oncogenic oral HPV infection in a previous study).
2843493|NCT03644550|Experimental|1/LMB- 100+pembrolizumab|LMB-100 administered in cycles 1 and 2 + pembrolizumab administered in subsequent cycles
2843494|NCT03644537|Other|heavy force 100gm|heavy intrusive force is to be applied on a first premolar on one side
2843495|NCT03644537|Other|medium force 25 gm|medium intrusive force is to be applied on a first premolar on one side
2843496|NCT03644537|Other|light force 10 gm|light intrusive force is to be applied on a first premolar on one side
2843497|NCT03644524|Experimental|Heat Therapy|Subjects assigned to heat therapy underwent 30 1-hour hot tub sessions over 8-10 weeks (3-4 per week). The hot tub was set to 40.5 Celsius, and core temperature and heart rate were monitored throughout each session.Subjects were instructed to not make any other dietary or lifestyle changes.Cardiovascular and metabolic health assessments were made Pre (0 heat sessions), mid (after 14-16 heat sessions, ~4-5 weeks), and post (after all 30 heat sessions; ~8-10 weeks).
2843498|NCT03644524|No Intervention|Time Control|Subjects were monitored at matched timepoints (start of study, 4-5 weeks, and 8-10 weeks) but not exposed to any intervention. Subjects were instructed to not make any dietary or lifestyle changes.
2843499|NCT03644511||Patients with HCC|Treated with Nexavar and/or Stivarga as ≥ 2nd-line systemic treatment
2843500|NCT03644498||Adults treated with a CPI therapy for cancer|
2843501|NCT03644485|Experimental|Standard Prograf group|Participants will receive induction therapy, tacrolimus immediate-release formulation (Prograf) from Day 1 after kidney transplant surgery to Month 1 and convert to tacrolimus prolonged-release formulation (Advagraf) up to Month 6.
2843502|NCT03644485|Experimental|Delayed Prograf group|Participants will receive induction therapy, tacrolimus immediate-release formulation (Prograf) from Day 3 - 5 after kidney transplant surgery to Month 1 and convert to tacrolimus prolonged-release formulation (Advagraf) up to Month 6.
2843503|NCT03644472|Active Comparator|Nitrate rich beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
2843504|NCT03644472|Placebo Comparator|Nitrate depleted beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.
2843505|NCT03644459|Experimental|LYN00101|Intravenous Infusion at the rate of 8 mg/kg of the patient's weight every 14 days.
2843506|NCT03644446||Bisoprolol 5mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 5mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
2843507|NCT03644446||Bisoprolol 7.5mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 7.5mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
2843512|NCT03644394|Other|Implantation|Surgical Implantation of IMES sensors
2843514|NCT03644381|Experimental|Treatment|Following randomization, participants in this group will receive escalating doses milk, up to a daily dose of 200 ml. Once they attain that dose, they will maintain it for one month. At the end of this period, they will undergo a open challenge to 300 ml of milk. They will then enter a year-long follow-up period
2843515|NCT03644355|Experimental|Diet and Nutrition Education|Lifestyle counseling plus nutrition education and counseling and protein sparing modified fast diet plus supplementation of vitamins and minerals, followed by a balanced, hypo-caloric diet and nutrition education provided by a registered dietician
2843516|NCT03644355|Active Comparator|Exercise Instruction|Lifestyle counseling plus moderate intensity, progressive exercise prescription including cardio-pulmonary, strength and flexibility exercise tailored to the individual needs of each participant.
2843517|NCT03644355|Active Comparator|Combined Diet and Exercise|Lifestyle counseling plus dietary intervention including nutrition education and counseling and a protein sparing modified fast diet and nutrition education combined with the exercise intervention including a moderate intensity, progressive exercise prescription including cardio-pulmonary, strength and flexibility exercise tailored to the individual needs of each participant.
2843518|NCT03644355|No Intervention|Control|Delayed intervention (waiting list) group receives no intervention for 12 weeks followed by the Diet plus Exercise intervention.
2843519|NCT03644342|Experimental|Niraparib Arm|For the purposes of this study, two dose levels of Niraparib (100 mg and 200 mg) will be evaluated concomitant with the concurrent administration of pelvic radiotherapy.
2843520|NCT03644329|Other|Control group, CT|In the CT, the postmenopausal breast cancer survivers does not perform exercise.
2843521|NCT03644329|Experimental|Lower-load resistance training (LL)|In the LL, the postmenopausal breast cancer survivers will be submitted to 12 weeks of resistance training with low loads ( i.e. three sets with 30% of one-repetition maximum).
2843522|NCT03644329|Experimental|Higher-load resistance training (HL)|In the HL, the postmenopausal breast cancer survivers will be submitted to 12 weeks of resistance training with high loads (i.e. three sets with 80% of one maximum repetition).
2843523|NCT03644329|Experimental|Higher-volume resistance training (HV)|In the HV, the postmenopause breast cancer survivers will be submitted to 12 weeks of resistance training with high volume ( i.e. six sets with 80% one maximum repetition).
2843524|NCT03644316|Experimental|BandGrip|Topical skin closure device
2843525|NCT03644303|Experimental|SBRT + ADT|Enzalutamide OR Abiraterone at licensed doses in combination with stereotactic radiotherapy: 30 Gray in 5 fractions
2843526|NCT03644290|Experimental|Cognitive training|Semantic categorization training sessions
2843527|NCT03644290|Active Comparator|Control condition|Five sessions of behavioral control condition with information and education
2843528|NCT03644277|Experimental|Massed practice training with dAIH|"Seek to address gross upper extremity movements, grip and pinch strength, and coordination.The ultimate goal of the session is to achieve a total of 300 repetitions during training.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
2843529|NCT03644277|Experimental|Massed practice training with Sham dAIH|"Seek to address gross upper extremity movements, grip and pinch strength, and coordination.The ultimate goal of the session is to achieve a total of 300 repetitions during training.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
2843530|NCT03644277|Experimental|Rapael glove with dAIH|"The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement, hand function, and dexterity. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. The number of total repetitions and activity outcomes will be recorded.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
2843531|NCT03644277|Active Comparator|Rapael glove with Sham dAIH|"The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement, hand function, and dexterity. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. The number of total repetitions and activity outcomes will be recorded.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
2843532|NCT03644277|Placebo Comparator|No training with dAIH|"Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%.~Hearth rate and pulse oximetry will be continuously monitored throughout, and recording will be taken at each alteration in sequence. Blood pressure will be taken upon completion of the total sequence"
2843533|NCT03644264|Experimental|PA21 tablets containing 500 mg of iron|PA21 chewable tablets standardised to contain 500 mg of iron. PA21 500 mg (iron) chewable tablet contains approximately 2.5 g PA21 drug substance (sucroferric oxyhydroxide). Starting dose will be 1,500 mg/day (3 tablets/day (1 tablet per meal)). Dose increases or decreases of 500 mg/day (1 tablet/day) are permitted. The maximum dose of PA21 will be 3,000 mg/day (6 x 500 mg tablets/day) and the minimum dose will be 1,000 mg/day (2 x 500 mg tablets/day).
2843572|NCT03643939|Active Comparator|Non-invasive ventilation|
2843534|NCT03644264|Active Comparator|Sevelamer carbonate: Renvela® tablets|Starting dose will be 2.4 g/day (3 tablets/day). Dose increases or decreases of 2.4 g/day (3 tablets/day (1 tablet per meal)) The maximum dose of sevelamer carbonate will be 14.4 g/day (18 tablets/day) and the minimum dose will be 2.4 g/day (3 tablets/day).
2843535|NCT03644251|Experimental|AMUC Dosage 1|25mg amniotic and umbilical cord matrix
2843536|NCT03644251|Experimental|AMUC Dosage 2|50mg amniotic and umbilical cord matrix
2843537|NCT03644251|Experimental|AMUC Dosage 3|100mg amniotic and umbilical cord matrix
2843538|NCT03644238|Experimental|Experimental intervention|Oral Glucose Tolerance Test and physical activity
2843539|NCT03644238|Other|Control intervention|Oral Glucose Tolerance Test and inactivity.
2843540|NCT03644225|Other|Healthy Control|Healthy controls, who signed an informed consent, age ≥18 years old will be age and sex matched to the SSc patients
2843541|NCT03644225|Other|Systemic sclerosis patients|"SSc patients who signed an Informed consent~Age ≥18 years old~Diagnosis of systemic sclerosis according to the ACR/EULAR 2013 criteria~Skin thickening diagnosed by clinical expert"
2843542|NCT03644212|Active Comparator|Vitamin D treatment|Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
2843543|NCT03644212|No Intervention|Non treated|Sixteen vitamin D deficient women (6 with PCOS and 10 without PCOS) were not supplemented vitamin D3. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
2843544|NCT03644199|Other|OGTT test|Comparison of responses to a OGTT between CF subjects and health control subjects
2843545|NCT03644199|Other|Mixed meal|Comparison of responses to a mixed meal through the day between CF subjects and health control subjects
2843546|NCT03644186|Active Comparator|Paclitaxel plus trastuzumab and pertuzumab|Receiving paclitaxel 80mg/m2 i.v. on day 1, 8, 15 every 28 days for 4 cycles, trastuzumab 600mg s.c. every 3 weeks for a total of 5 doses and pertuzumab 840 mg i.v. loading dose followed by 420 mg i.v. every 3 weeks for a total of 5 doses.
2843547|NCT03644186|Experimental|Palbociclib plus letrozole plus trastuzumab and pertuzumab|Receiving palbociclib 125 mg/day orally for 21 days followed by 7 day's rest, for four 28 day cycles, letrozole 2.5 mg/day orally for 16 weeks and trastuzumab 600 mg s.c. every 3 weeks for a total of 5 doses and pertuzumab 840 mg i.v. loading dose followed by 420 mg i.v. every 3 weeks for 5 doses.
2843548|NCT03644160|Experimental|Intervention Group|Physical activity and behaviour change The intervention group (group A) will receive a 4 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity to include an initial 1:1 session with a physiotherapist with training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 4 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
2843549|NCT03644160|No Intervention|Control Group|The control group (Group B) will receive the same information booklet about physical activity only. This group will continue with their routine care for their condition throughout the study period.
2843550|NCT03644147|Experimental|Treatment|Patients in this group will receive 1 gram of acetaminophen intravenously after the end of surgery.
2843551|NCT03644147|No Intervention|Control|Patients in this group will receive 100 ml of normal saline intravenously after the end of surgery.
2843552|NCT03644134|Experimental|Intervention Group|Assessment of physiological stress and sleep pattern intervention consists of (i) information session (ii) pre-assessment (first assessment) of stress and recovery levels, and sleep patterns (iii) individual feedback sessions and action plans based on the outcomes of the initial assessment (iv) monitoring and follow-ups (v) post-assessment (second assessment) of stress and recovery levels and sleep patterns
2843553|NCT03644134|No Intervention|Control Group|The control protocol only includes (i) information session (ii) pre-assessment (initial assessment and (iii) post-assessment (second assessment) of stress and recovery levels and sleep patterns.
2843554|NCT03644108|Experimental|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet taken with 240 mL of water after an overnight fast
2843555|NCT03644095|Experimental|Mucinex® SE 600 mg (extended-release)|Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet taken with 240 mL of water after an overnight fast
2843556|NCT03644095|Active Comparator|Vicks Cough Syrup 200 mg|Vicks Cough Syrup for Chesty Coughs 200 mg every 4 hours taken with 240 mL of water after an overnight fast
2843557|NCT03644082|Experimental|Epilepsy Patients|
2843558|NCT03644069|Experimental|Nexvax2|
2843559|NCT03644069|Placebo Comparator|Placebo|
2843560|NCT03644056|Experimental|IMC-001|Multiple Dose Level (IMC-001 2 mg/kg etc. every 2 weeks)
2843561|NCT03644043||Early stage of MCI symptoms|Subjects with cognitive decline representing MCI symptomology and with previous PET amyloid-beta (Aβ) imaging results.
2843562|NCT03644017|Experimental|WRAPSODY Stent Graft|All subjects will receive treatment via WRAPSODY Stent Graft Placement.
2843563|NCT03644004||Women with medical history of gestational diabetes|Patients followed at the hospital of Vienne for gestational diabetes in 2016.
2843564|NCT03643991|Experimental|Weighted Blanket Cohort|First 15 subjects enrolled have access to sleep with weighted blanket for three nights with monitoring by nurse. Weight of blanket is determined by weight of the patient (10% of patients body weight).
2843565|NCT03643991|No Intervention|Control Cohort|Last 15 subjects enrolled receive treatment as usual while inpatient.
2843566|NCT03643978|Experimental|Decision Aid Group|These patients review a decision aid.
2843567|NCT03643978|No Intervention|Control Group|These patients do not review a decision aid.
2843568|NCT03643965|Experimental|Nefecon|Nefecon 16 mg once daily by mouth for 9 months.
2843569|NCT03643965|Placebo Comparator|Placebo oral capsule|Placebo oral capsule once daily by mouth for 9 months.
2843570|NCT03643952|Experimental|Daptomycin-cSSTI or Bacteremia: age 1-17|Participants aged 1 to 17 years old with cSSTI or bacteremia will receive daptomycin intravenously every 24 hours (q24hrs) for either 5-14 days for cSSTI or for 5-42 days for bacteremia.
2843574|NCT03643926|Active Comparator|Open Brostrom|
2843575|NCT03643913|Active Comparator|Comparison group|"Neuromuscular Blocking Agents and reversing agents: The comparison group will receive anesthesia top up Esmeron dose to maintain a Train Of Four (TOF) count of maximum 2 during the whole procedure. This represents moderate neuromuscular block conditions. A neuromuscular monitor (PHILIPS integrated) will be used to evaluate TOF count.~To maintain TOF at 2 and according to our practice a bolus injection of 0,1 mg/kg Rocuronium will be given when TOF count returns to 3. This dose will be repeated if TOF does not go back to 2 within 2 minutes after bolus injection. TOF guard and TOF tube will be used at the ulnar nerve at the contralateral side and will be checked continuously during surgery.~Reversal of the TOF=2 will be done by Sugammadex 2 mg/kg at end of procedure (Time of last suture)"
2843576|NCT03643913|Experimental|Deep group|Neuromuscular Blocking Agents and reversing agents: The deep group will receive deep neuromuscular block, using a infusion of Esmeron at 0,1mg/kg/hour. A post tetanic count will be performed and our target will be to have a PTC 1-2. The standard infusion will be adjusted as such. Reversal will be achieved by Sugammadex 4 mg/kg depending on reversal speed at the end of procedure (Time of last suture)
2843577|NCT03643900|Experimental|indomethacin with stenting group|Pancreatic duct stenting and rectal indomethacin 100mg at preoperative 30min in 100 patients
2843578|NCT03643900|Active Comparator|indomethacin group|Rectal indomethacin 100mg at preoperative 30min in 100 patients
2843579|NCT03643887|Experimental|FMT Capsule DE|FMT Capsule DE
2843580|NCT03643887|Placebo Comparator|Placebo Oral Capsule|Placebo Capsule
2843581|NCT03643874|Experimental|Halix albuterol 90 mcg|Cumulative doses of albuterol administered by the Halix albuterol 90 mcg UDDI will given at intervals as: 1 inhalation, then 1 inhalation 30 min later, then 2 inhalations 30 min later, and then 4 inhalations 30 min later.
2843582|NCT03643874|Active Comparator|Albuterol HFA MDI 90 mcg|Cumulative doses of albuterol administered by the albuterol HFA albuterol 90 mcg MDI will given at intervals as: 2 inhalations, then 2 inhalations 30 min later, then 4 inhalations 30 min later, and then 8 inhalations 30 min later.
2843583|NCT03643861|Experimental|5 Fraction Breast Stereotactic Body Radiation Therapy|This study will enroll patients that have a confirmed histology of early stage breast cancer. The patient will undergo a lumpectomy and will then receive partial breast 5 fraction stereotactic body radiation therapy at a dose of 30 gy for treatment. Patients will be followed for 24 total months with specific follow-ups at 3, 6, 9, 12, 18, and 24 months.
2843584|NCT03643848|Experimental|Sleep with Sound Cues|Sounds played at time of memory encoding will be replayed during sleep to cue memory processing.
2843585|NCT03643848|Sham Comparator|Sleep with Sham Cues|Sounds that were not played at time of memory encoding will be played during sleep as a sham comparison
2843586|NCT03643835|Experimental|Thermal rehab machine|Participants, following exercise-induced hyperthermia, will be cooled using a Thermal Rehab Machine (Polar Breeze, Statim Technologies, LLC, Clearwater Florida), which is a micro-environmental air chiller. The device will be placed over the subjects head and through trans pulmonary cooling, will cool the body.
2843587|NCT03643835|Active Comparator|Forearm Ice Towels|Participants, following exercise-induced hyperthermia, will be cooled using forearm ice towels. Cotton-blend towels will be doused in ice-water and then wrapped around participant's forearms (elbow to wrist). The towels will be rotated (re-wetted) every 2 minutes)
2843588|NCT03643835|No Intervention|Passive Cooling|Participants, following exercise-induced hyperthermia, will undergo a period of passive rest to allow the body to cool via natural mechanisms of evaporation of sweat from the skin's surface and convection
2843589|NCT03643822|Active Comparator|Dexamethasone vs. Control comparison|Freezing + dexamethasone(4mg)+1 ml of saline
2843590|NCT03643822|Active Comparator|Dexmedetomidine vs. Control comparison|Freezing + dexmedetomidine(50ug) + 1.5 ml of saline
2843591|NCT03643822|Active Comparator|Dexamethasone and Dexmedetomidine|Freezing+dexamethasone(4mg)+dexmedetomidine(50ug) + 0.5 ml of saline
2843592|NCT03643822|Sham Comparator|Control Group-Placebo|Freezing + 2ml saline
2843593|NCT03643796|Active Comparator|Remifentanil Group|Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
2843594|NCT03643796|Active Comparator|Ketamine and Dexmedetomidine group|"dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound.~Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation."
2843595|NCT03643783||Bariatric Obese Patients|Obese patients, including men and women, White (Caucasians), Africa American, and Hispanic or Latino racial categories, and ages 18-70 years, who are enrolled and planning to undertake bariatric surgery in the Outpatient Bariatric Surgery Clinic at Tulane University, HSC (Christopher G. Ducoin, MD, MPH; Chair of Bariatric Surgery Clinic and Surgeon, and Shauna Levy, MD, Bariatric Surgeon Specialist).
2843596|NCT03643783||Lean Control Patients|Plasma samples from lean control patients that have already been collected and are available as part of the Tulane Obesity-Endocannabinoids Study (Tina Thethi, M.D, Collaborator).
2843597|NCT03643770|No Intervention|Acute Intermittent Hypoxia (AIH) treatment|The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask. The mask is designed to couple with a universal mask circuit connecting to the air mixture system. The purpose of the mask will be to minimize room air entrainment.
2843598|NCT03643770|Experimental|AIH in combination with upper extremity training|The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask. The mask is designed to couple with a universal mask circuit connecting to the air mixture system. The purpose of the mask will be to minimize room air entrainment. In addition to this upper extremity training will be given using an upper-limb robotic rehabilitation device.
2843599|NCT03643770|Active Comparator|Sham AIH therapy in combination with upper extremity training|Sham hypoxia followed by upper extremity training will be given using an upper-limb robotic rehabilitation device (Armeo Spring®, Hocoma AG, Switzerland). Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
2843600|NCT03643770|No Intervention|Sham AIH therapy|Sham hypoxia
2843601|NCT03643757|Active Comparator|Thoracic Epidural Analgesia|Population to whom thoracic epidural analgesia with bupivacaine as a component of multimodal analgesia was administered.
2843749|NCT03642756|Active Comparator|24 gauge|
2956572|NCT02857400|Other|Arm A (standard)|
2843602|NCT03643757|Active Comparator|Intravenous analgesia|Population to whom combined intravenous analgesia was administered.
2843603|NCT03643744|Active Comparator|PDT + Celecoxib|Patient receiving PDT taking 200mg celecoxib.
2843604|NCT03643744|Placebo Comparator|PDT + Placebo|Patient receiving PDT taking placebo.
2843605|NCT03643744|Active Comparator|Control + Celecoxib|Control subject not receiving PDT taking 200mg celecoxib.
2843606|NCT03643744|Placebo Comparator|Control + Placebo|Control subject not receiving PDT taking placebo.
2843607|NCT03643731|Experimental|HeatTens|"After baseline measurements and during 4 weeks of follow up~Composition and dosing of the device:~HeatTens (HV-F311-E) 2 - 108 Hz (modulation), 100 microsec (pulse duration) for 30 minutes."
2843608|NCT03643731|No Intervention|Control group|No intervention
2843609|NCT03643705|Experimental|Nurse Intervention|This multi-component intervention will consist of four evidence-based components delivered at 4 in-person visits (0, 4, 8, and 12 months) and by telephone contact: (1) nurse-led care coordination, (2) nurse-managed medication protocols and adherence support (3) home blood pressure monitoring, and (4) electronic medical records support tools.
2843610|NCT03643705|Active Comparator|Education Control|Participants in the education control arm will receive general prevention education delivered at 4 in-person visits (0, 4, 8, and 12 months), which will consist of evidence-based material on diet, exercise, smoking, sexually transmitted infections, and cancer prevention.
2843611|NCT03643692|Experimental|ARISES|Observational study using wearable technologies to collect data and evaluate blood glucose correlations against physiological and environmental case parameters. Useful associations will assist the development of the CBR/machine learning algorithm and identify wearable devices for the final ARISES platform.
2843612|NCT03643679|Experimental|Kwit smartphone app|This arm will receive the Kwit smartphone app.
2843613|NCT03643666|Placebo Comparator|control group|this group will include 25 patients receiving intraperitoneal 40 ml of normal saline only at the end of laparoscopic cholecystectomy
2843614|NCT03643666|Active Comparator|dexamethasone group|this group will include 25 patients receiving intraperitoneal 16 mg dexamethasone in 40 ml saline at the end of laparoscopic cholecystectomy
2843615|NCT03643666|Active Comparator|dexamethasone plus magnesium sulphate group|this group will include 25 patients receiving intraperitoneal 16 mg dexamethasone plus 2 gm magnesium sulphate at the end of laparoscopic cholecystectomy
2843616|NCT03643640|Experimental|Optimune|Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
2843617|NCT03643640|Active Comparator|Care-as-Usual|As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).
2843618|NCT03643627|Placebo Comparator|Placebo|
2843619|NCT03643627|Experimental|1 mg/kg|
2843620|NCT03643627|Experimental|3 mg/kg|
2843621|NCT03643627|Experimental|10 mg/kg|
2843622|NCT03643627|Experimental|30 mg/kg|
2843623|NCT03643614|Experimental|study group|Injection of autologous regenerative cells of adipose tissue for treatment of radiation induced rectovaginal fistulas
2843624|NCT03643601||Non-Dialysis (ND) Patients|For the ND patients, data are captured on each clinic visit during the course of the year (2-4 times per year), the last available record for 2015 will be used.
2843625|NCT03643601||Dialysis (DD) Patients|For the DD patients, data are input from a randomly selected visit to the hospital in September to October 2015; the evaluation will be based on this record.
2843626|NCT03643588|Experimental|HYAJOINT Plus group|The HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus and be followed for 52 weeks. A single injection of HYAJOINT Plus was performed if criteria was met at 52 weeks, and a 4-weeks follow-up of adverse events was conducted.
2843627|NCT03643588|Active Comparator|Hyalgan group|The Hyalgan group received intraarticular injection of 2 ml Hyalgan for three continuously weeks and be followed for 52 weeks. A single injection of HYAJOINT Plus was performed if criteria was met at 52 weeks, and a 4-weeks follow-up of adverse events was conducted.
2843628|NCT03643575|Experimental|Treatment A: Vicks Cough Syrup for Chesty Coughs|Vicks Cough immediate-release (IR) syrup 15 mL (containing 200 mg guaifenesin) every 4 hours x 3 doses with 240 mL of water after an overnight fast
2843629|NCT03643575|Experimental|Treatment B: Robitussin Extra Strength Chest Congestion|Robitussin Extra Strength Chest Congestion 5 ml (containing 200 mg guaifenesin) every 4 hours x 3 doses with 240 mL of water after an overnight fast
2843630|NCT03643575|Experimental|Treatment C: Organ-I- NR tablet|Organ-I- NR 200 mg guaifenesin tablet every 4 hours x 3 doses with 240 mL of water after an overnight fast
2843631|NCT03643549|Experimental|Bortezomib and Temozolomide|Botezomib 1.3 mg/m2 administered IV on days 1, 4, 7, during each 4-week chemotherapy cycle with per oral Temozolomide at three dose levels: 150 mg/m2, 175 mg/m2 and 200mg/m2 5 days/week every 4 weeks starting on day 3.
2843632|NCT03643536|Experimental|12-WPEP in subjects with reduce LVEF|Intervention: a 12 week physical exercise program in the health-related quality of life of CABG or PCI subjects with LVEF by 2D-echocardiography between 30-54%. The quality of life was measured using SF-36 questionnaire
2843633|NCT03643536|Active Comparator|12-WPEP in subjects with normal LVEF|Intervention: a 12 week physical exercise program in the health-related quality of life of or PCI subjects with LVEF by 2D-echocardiography≥ 55% (control group)The quality of life was measured using SF-36 questionnaire
2843634|NCT03643523||ALbumin level|Detection of serum albumin levels in postoperatory of colorectal surgery
2843715|NCT03643003|Experimental|Music Therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Order is randomly assigned, and all participants engage in both study arms."
2843635|NCT03643510|Experimental|Fulvestrant in Combination with Abemaciclib|Eligible patients will take Abemaciclib 150 milligrams mg orally once every 12 hours on days 1-28. Fulvestrant will be dosed 500mg intramuscularly (IM) on days 1 and 15 during cycle 1 and then on Day 1 during subsequent cycles. Each cycle will be 28 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, or study termination.
2843636|NCT03643497||Children with the usage of anti-infective drugs|Children received meropenem or linezolid monotherapy in the treatment of seven infectious diseases
2843637|NCT03643458||Transfused infants|Preterm infants undergone red blood cell transfusion during hospital stay.
2843638|NCT03643445|Experimental|Motivational Interviewing (MI) Treatment|Motivational interviewing is a psychotherapeutic stance aimed at helping patients in resolving ambivalence toward change and increasing their intrinsic motivation to engage in healthy behaviour choices. Patients assigned to these MI-trained therapists will be in the motivation-oriented condition. All individual meetings patients have with their therapist while they are in the program will entail sessions that are guided by MI principles. That is, revisiting patients' motivation to recover and overcoming obstacles to ambivalence or low motivation.
2843639|NCT03643445|Active Comparator|Psychoeducation-Oriented Treatment|"The psychoeducation-oriented treatment condition is intended to teach patients about the causes of eating disorders, the expected course of recovery, obstacles to recovery, and the importance of behavioural changes required for recovery from an eating disorder. Two staff members in the eating disorders program will deliver the psychoeducation-infused interventions, which are intended to be equivalent to treatment-as-usual in many eating disorder programs, but in a structured and standardized way, and with the use of the self-help manual. Psychoeducation is a very common intervention, often used as part of cognitive-behavioural treatment for eating disorders. The idea is that information about eating disorders and their health risks facilitates recovery and allows patients to buy in to treatment."
2843640|NCT03643432|Active Comparator|Usual care|The usual care arm will consist of routine physiotherapy treatment, without the intervention.
2843641|NCT03643432|Experimental|Exercise adherence intervention|The intervention arm will consist of a brief behavioural assessment and recommended adherence strategies based on the outcome of the assessment.
2843642|NCT03643419|Sham Comparator|Laminectomy|
2843643|NCT03643419|Experimental|Laminectomy & Irradiation|
2843644|NCT03643406|Experimental|Mental Fatigue Condition|
2843645|NCT03643406|Placebo Comparator|Control Condition|
2843646|NCT03643393|Other|incarceration rectal prolapse|
2843647|NCT03643380|Experimental|Investigational SNS device|
2843648|NCT03643367|Experimental|Sevoflurane Sedation|Patients randomized into experimental group will be treated with sevoflurane during 4 hours
2843649|NCT03643367|No Intervention|Control Group|Patients randomized into Control Group will get continued intravenous sedation
2843650|NCT03643354|Experimental|Evaluation of prevalence of BPPV|Epley/Barbeque maneuver will be performed using the Rotundum Device to assess if subject has BPPV, patient will thereafter be treated for it using the Rotundum Device.
2843651|NCT03643341|Experimental|Family Healthy Living Intervention|Children aged 8-12 and at least one caregiver will meet for 10 weekly face-to-face and online intervention sessions (1.5 hours per session). Four biweekly maintenance sessions will follow the main program.
2843652|NCT03643341|No Intervention|Wait-list control group|Children aged 8-12 will be randomly assigned to the wait-list control group until after the study.
2843653|NCT03643328|Experimental|new haemodialysis patients.|There is an analyse of immune response against S. aureus from new haemodialysis patients by blood samples and nasal swabs.
2843654|NCT03643315|Experimental|Exercise and Meal (EX)|The EX protocol will involve a 30 minute acute bout of high intensity intermittent exercise on a stationary exercise bike followed by an ad-libitum test meal.
2843655|NCT03643315|Experimental|No-Exercise and Meal (NEX)|The NEX protocol will involve a 30 minute period of rest (to match the exercise period in EX) where participants will be provided a video/movie. Following this, participants will be provided ad-libitum access to a test meal (as per EX energy intake assessment protocol)
2843656|NCT03643302||Therapy of bronchoalveolar lavage group|Patients with bronchiectasis exacerbations treat with fundamental treatment combining with the therapy of bronchoalveolar lavage.
2843657|NCT03643302||Fundamental treatment group|Patients with bronchiectasis exacerbations treat with fundamental treatment only.
2843658|NCT03643276|Active Comparator|pB: early (non-)HR-standard/MR-standard|"Induction (5 wks): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT methotrexate (MTX)~Consolidation (6 w/4 w): Consolidation extended (control arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-mercaptopurine (6-MP), IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 wks): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 wks): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 years after initial diagnosis): 6-MP, MTX [without preceding blinatumomab (control arm of randomization R-MR)]~Erwinase is given in case of allergy to pegaspargase."
2843659|NCT03643276|Experimental|pB: early HR-exp./MR-standard|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)~Extra-compartment phase (8 wks): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 wks): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX [without preceding blinatumomab (control arm of randomization R-MR)]~Erwinase is given in case of allergy to pegaspargase."
2843709|NCT03643068|Experimental|KSP-QRH-E3-IRDye800 (Peptide 919288G) 1.8 mg subjects 4-25|Following a safety review of the first three subjects receiving 0.6 mg dose, the remaining 22 subjects will receive the full 1.8 mg dose of KSP-QRH-E3-IRDye800 (Peptide 919288G) reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
2843818|NCT03642223|Experimental|central adiposity|
2843660|NCT03643276|Experimental|pB: early (non)HR-standard/MR-exp.|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
2843661|NCT03643276|Experimental|pB: early HR-exp./MR-exp.|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX,IT MTX~Reinduction (6 weeks): Protocol II with dexamethasone, vincristine, doxorubicin, PEG-L-asparaginase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)~Maintenance phase (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
2843662|NCT03643276|Active Comparator|pB: early (non-)HR-standard/HR-standard|"Induction (5 w): as in other pB arms~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT methotrexate, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX~Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide~Reinduction (3x4 w): Protocol III given 3 times with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX~Erwinase is given in case pegaspargase allergy. Pts with poor response to intensified consolidation receive DNX-FLA (liposomal daunorubicin, fludarabine, HD-cytarabine, IT-MTX)."
2843663|NCT03643276|Experimental|pB: early HR-exp./HR-standard|"Induction (5 w): as in other pB arms~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)~Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide~Reinduction (3x4 w): as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive DNX-FLA (liposomal daunorubicin, fludarabine, HD-cytarabine, IT-MTX)"
2843664|NCT03643276|Experimental|pB: early (non-)HR-standard/HR-exp.|"Induction (5 w): as in other pB arms~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX~Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)~Reinduction (3x4 weeks): as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX~Erwinase is given in case of pegaspargase allergy. Pts with poor response to intensified consolidation receive DNX-FLA (liposomal daunorubicin, fludarabine, HD-cytarabine, IT-MTX)"
2843665|NCT03643276|Experimental|pB: early HR-exp./HR-exp.|"Induction (5 w): as in other pB arms~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)~Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)~Reinduction (3x4 weeks): as in arm pB: early (non-)HR-standard/HR-standard Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive DNX-FLA (liposomal daunorubicin, fludarabine, HD-cytarabine, IT-MTX)"
2843666|NCT03643276|Other|pB: early non-HR/SR|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (4 w): Consolidation short with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
2843667|NCT03643276|Active Comparator|T: early non-SR-standard/(non-)HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or Protocol IA-CPM with prednisolone instead of dexamethasone and additional CPM~Consolidation (4 w): Protocol IB regular (control arm in randomization. R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~non-HR extra-compartment phase and reinduction: as in arm pB: early non-HR/SR~HR intensified consolidation and reinduction: as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive DNX-FLA (liposomal daunorubicin, fludarabine, HD-cytarabine, IT-MTX)"
2843710|NCT03643055||MTC 18F-fluorocholine PET/CT|Patients with medullary thyroid cancer imaged using 18F-fluorocholine PET/CT.
2843711|NCT03643042|Experimental|Restrictive group|Transfusion with: Hb < 80g/L and Hb maintain between 80 and 100g/L
2843712|NCT03643042|Experimental|Liberal group|Transfusion with: Hb < 100g/L and Hb maintain between 100 and 120g/L
2843713|NCT03643016|Experimental|Group with Virtual Epileptic Patient brain access data|
2843714|NCT03643016|No Intervention|Group without Virtual Epileptic Patient brain access data|
2843819|NCT03642210|Experimental|Levonorgestrel 52 mg intrauterine system|
2843668|NCT03643276|Experimental|T: early non-SR-exp/(non-)HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or Protocol IA-CPM with prednisolone instead of dexamethasone and additional CPM~Consolidation (6 w): Protocol IB long (experimental arm in randomization R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~non-HR extra-compartment phase and reinduction: as in arm pB: early non-HR/SR~HR intensified consolidation and reinduction: as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive DNX-FLA (liposomal daunorubicin, fludarabine, HD-cytarabine, IT-MTX)"
2843669|NCT03643276|Other|T: early SR/non-HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (4 w): Protocol IB regular with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
2843670|NCT03643250|Experimental|Smaller Portion Size and Standard Appeal|Food with Smaller Portion Size and Standard Appeal
2843671|NCT03643250|Experimental|Smaller Portion Size and Enhanced Appeal|Food with Smaller Portion Size and Enhanced Appeal
2843672|NCT03643250|Experimental|Larger Portion Size and Standard Appeal|Food with Larger Portion Size and Standard Appeal
2843673|NCT03643250|Experimental|Larger Portion Size and Enhanced Appeal|Food with Larger Portion Size and Enhanced Appeal
2843674|NCT03643237|Experimental|Video game-based intervention|The participants in the experimental group will receive a cognitive-behavioral intervention for active aging via an interactive online multimedia video game with a complementary App. The intervention will consist of 8 modules each approximately 45 minutes long that will be administered at a rate of 1 per week with between-session homework.
2843675|NCT03643237|Active Comparator|Control group|Individuals assigned to this group will receive online therapeutically inactive information about active aging.
2843676|NCT03643224|Experimental|Experimental|Radiofrequency Ablation. Catheter ablation to treat persistent atrial fibrillation using temperature-controlled ablation catheter
2843677|NCT03643198|Sham Comparator|CONTROL|The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
2843678|NCT03643198|Active Comparator|TREATMENT|In the study group, patients will receive oral treatment with Ciprofloxacin at a dose of 500 mg every 12 hours and Metronidazole 500 mg every 8 hours for a period of 7 days.
2843679|NCT03643159|Experimental|Abilify MyCite|Patients will receive Abilify MyCite during Months 1-3. During Months 4-6 use of Abilify MyCite will be prohibited. Thereafter, at Day 180, a second, optional interventional period (up to 6 months of Abilify MyCite) may be initiated per the joint decision of the patients with their study physician. The treatment medication dose decision will be determined by the study physicians independent from the protocol.
2843680|NCT03643159|Active Comparator|Treatment As Usual|Virtual matched controls will receive treatment as usual (i.e. any product other than Abilify MyCite, which may be oral aripiprazole or any other product) throughout the duration of the trial. The treatment medication dose decision will be determined by the study physicians independent from the protocol.
2843681|NCT03643146|Experimental|Wedge 1- Step 1|
2843682|NCT03643146|Experimental|Wedge 1-Step 2|
2843683|NCT03643146|Experimental|Wedge 1-Step 3|
2843684|NCT03643146|Experimental|Wedge 1-Step 4|
2843685|NCT03643146|Experimental|Wedge 1-Step 5|
2843686|NCT03643146|Experimental|Wedge 2- Step 1|
2843687|NCT03643146|Experimental|Wedge 2-Step 2|
2843688|NCT03643146|Experimental|Wedge 2-Step 3|
2843689|NCT03643146|Experimental|Wedge 2-Step 4|
2843690|NCT03643146|Experimental|Wedge 2-Step 5|
2843691|NCT03643146|Experimental|Wedge 3-Step 1|
2843692|NCT03643146|Experimental|Wedge 3- Step 2|
2843693|NCT03643146|Experimental|Wedge 3- Step 3|
2843694|NCT03643146|Experimental|Wedge 3- Step 4|
2843695|NCT03643146|Experimental|Wedge 3- Step 5|
2843696|NCT03643146|Experimental|Wedge 4-Step 1|
2843697|NCT03643146|Experimental|Wedge 4- Step 2|
2843698|NCT03643146|Experimental|Wedge 4-Step 3|
2843699|NCT03643146|Experimental|Wedge 4-Step 4|
2843700|NCT03643146|Experimental|Wedge 4-Step 5|
2843701|NCT03643133|Active Comparator|Control arm|"Post-operative chemotherapy alone (EI or M-API regimen depending on patient age) :~M-API regimen (≤ 25 years) :~Doxorubicin 60mg/m2, Day 1 Ifosfamide 3g/m2 Day 1 and 2 Cisplatin 100mg/m2, Day 2~EI regimen (26-50 years) :~Etoposide 75mg/m2/d, Day 1-4 Ifosfamide 3g/m2/d, Day 1-4"
2843702|NCT03643133|Experimental|Experimental arm|Post-operative chemotherapy (EI or M-API regimen) combined with Mifamurtide 2mg/m2 twice weekly post-randomisation for 12 weeks then weekly for 24 weeks
2843703|NCT03643120|Other|Development of diagnostic typology|One main goal is to Development a typology of sub-types of gender dysphoria.
2843704|NCT03643107|Experimental|Irofulven + Prednisolone 10mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
2843705|NCT03643094|Experimental|Golden Black Seed|Golden Black Seed, 1 capsule per day for 8 weeks.
2843706|NCT03643081|Experimental|"use of camera Fluobeam"|
2843707|NCT03643081|No Intervention|"Without use of the camera Fluobeam"|
2843708|NCT03643068|Experimental|KSP-QRH-E3-IRDye800 (Peptide 919288G) 0.6 mg subjects 1-3|The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.6 mg of KSP-QRH-E3-IRDye800 (Peptide 919288G) total. For the first three subjects, 3.34 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)will be discarded. The 1.66 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)remaining in the syringe will be administered by squirting it into the mouth of the subject.
2843746|NCT03642769|Experimental|Normal Saline|Patients will receive fluid administration of Normal Saline solution at a pre-determined volume algorithm that is the same for both arms
2843747|NCT03642756|Placebo Comparator|20 gauge|
2843748|NCT03642756|Active Comparator|22 gauge|
2843716|NCT03643003|Placebo Comparator|Non-Music Verbal Interaction|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Order is randomly assigned, and all participants engage in both study arms."
2843717|NCT03642990|Experimental|NIAGEN®)|Daily oral administration of nicotinamide riboside 300 mg (150 mg a.m. and p.m.) for one week with dose escalation to 1000 mg (500 mg a.m. and p.m.) for remaining 11 weeks.
2843718|NCT03642977||Allogeneic HSCT recipients|"Adult patients receiving allogeneic hematopoietic stem cell transplant (HSCT) at University Hospitals of Geneva and who are enrolled in the Cohort of infectious disease in hematopoietic stem cell transplant patients."
2843719|NCT03642964|Experimental|treatment|CTC-501 (pramipexole IR, given with ondansetron) given orally twice daily
2843720|NCT03642964|Placebo Comparator|placebo|generic placebo tablets given orally twice daily
2843721|NCT03642951|Active Comparator|Active Treatment Group|"Each patient will receive daily 40 min treatment five days per week for two weeks. The procedure during each treatment session will consist of positioning the device centered at 15% of the nasion-inion distance anterior to the Cz electrode placement in standard EEGs, with the patient relaxing in a chair.~The stimulus parameters used will be 480 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 40 min. The investigator will measure the subject for accurate placement of the device prior to each visit. Once the placement of the device is confirmed, the study technician administering the treatment will tum on the device using an app downloaded to an electronic device connected by Bluetooth to the device."
2843722|NCT03642951|Sham Comparator|Sham Treatment Group|"Each patient will receive daily 40 min treatment five days per week for two weeks. The procedure during each treatment session will consist of positioning the device centered at 15% of the nasion-inion distance anterior to the Cz electrode placement in standard EEGs, with the patient relaxing in a chair.~The stimulus parameters used will be 480 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 40 min. The investigator will measure the subject for accurate placement of the device prior to each visit. Once the placement of the device is confirmed, the study technician administering the treatment will tum on the device using an app downloaded to an electronic device connected by Bluetooth to the device.~Note: While the device looks and is operated the same as the active device, subjects in this group will be stimulated with the placebo device so no active stimulation will be given."
2843723|NCT03642938|Experimental|Low Dose Exercise|The Low Dose Exercise group will perform treadmill walking exercise, three times per week for one week.
2843724|NCT03642938|Experimental|Moderate Dose Exercise|The Moderate Dose Exercise group will perform treadmill walking exercise, five times per week for one week.
2843725|NCT03642938|Experimental|High Dose Exercise|The High Dose Exercise group will perform treadmill walking exercise, ten times per week for one week.
2843726|NCT03642938|Sham Comparator|Control|The Control group will perform quiet rest, three times per week for one week.
2843727|NCT03642925|Experimental|Meal replacement diet|Obese subjects (BMI>27; n=50, male 23, female 27) were requested to replace (intervention) two meals/day (breakfast and lunch or dinner) by balanced nutritional meal replacement diet (equal to 240 kcal) for 8 weeks
2843728|NCT03642912||ECMO patients|ECMO patients treated on the intensive care units of the Department of Anesthesiology of LMU Munich
2843729|NCT03642899||Patients with anterior ischaemic optic neuropathy|estimation of best visual acuity, fondus, measurement of retinal nervous layer thickness, ganglionar cells layer thickness, and a macular and papillar OCT angiography during a consultation
2843730|NCT03642899||control group. Normal eyes|estimation of best visual acuity, fondus, measurement of retinal nervous layer thickness, ganglionar cells layer thickness, and a macular and papillar OCT angiography during a consultation
2843731|NCT03642886|No Intervention|Continued Strenuous Exercise|Continued strenuous athletics (no reduction in training volume) - athletes will be asked to document their activity and be fitted with an activity monitor during the run-in period and intervention period
2843732|NCT03642886|Experimental|Prescribed Detraining|"Detraining period of 10-weeks which is defined as:~a 75% decrease in the amount of exercise (from baseline)~a 50% decrease in the intensity of exercise as measured in METS (from baseline)~Mitchell Classification classes 1A, 2A, 2B of activity are permitted"
2843733|NCT03642873|Experimental|Treatment A|Guaifenesin (Humibid®) single extended release 1200 mg tablet administered with 240 mL of room temperature water under fasted conditions.
2843734|NCT03642873|Experimental|Treatment B|Hydrocodone Bitartrate of 10 mg in 3 oral doses of a single 3.33 mg tablet in three intervals administered with 240 mL of room temperature water in the fasted state.
2843735|NCT03642873|Experimental|Treatment C|Hydrocodone Bitartrate 10 mg in 3 oral doses of a single 3.33 mg tablet in three intervals and guaifenesin (Humibid®) 1200 mg ER administered with 240 mL of room temperature water in the fasted state.
2843736|NCT03642860|Experimental|Active treatment|Triheptanoin oil
2843737|NCT03642860|Placebo Comparator|Placebo treatment|Safflower oil
2843738|NCT03642847|Active Comparator|Prevnar 13|13 valent Pneumococcal Conjugate
2843739|NCT03642847|Experimental|multivalent pneumococcal conjugate formulation 1|multivalent pneumococcal conjugate formulation 1
2843740|NCT03642847|Experimental|multivalent pneumococcal conjugate formulation 2|multivalent pneumococcal conjugate formulation 2
2843741|NCT03642834|Experimental|ICP-105 Single Arm|ICP-105 of multiple dose levels, dose escalation steps may be modified based on the safety from the previous dose.
2843742|NCT03642808|Experimental|rehabilitation program|"Duration of 8 weeks for a cycle of rehabilitation at the rate of two half-days per week~Two interventions per half-day: 30 minutes of education and 1h30 of rehabilitation: physiotherapist, psychomotricity, adapted physical activity"
2843743|NCT03642795||Patients with rheumatoid polyarthritis|
2843744|NCT03642782|Experimental|early age of glaucoma or with important risk factors|All patients included will benefit from a complete ophtalmic examination including visual acuity, slit lamp biomicroscopic examination of the anterior segment, measurement of intraocular pressure by Goldmann tonometer aplanation, dynamic gonioscopy with Posner glass. They will also have a fundus examination with examination of the retina, macula and optic nerve as well as the ERGP.
2843745|NCT03642769|Active Comparator|Lactated Ringer|Patients will receive fluid administration of Lactated Ringer's solution at a pre-determined volume algorithm that is the same for both arms
2843750|NCT03642743|Experimental|Two and six week follow up|Patients will be assigned to routine two and six week postoperative follow up appointments
2843751|NCT03642743|Experimental|Six week follow up only|Patients will be assigned to a single six week postoperative follow up appointment
2843752|NCT03642730|Experimental|Scanned patients|Scanned patients TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors
2843753|NCT03642730|Experimental|Non-expert scanning volunteers|Non-expert scanning volunteers (among the medical staff at the clinical site) TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors
2843754|NCT03642717||Subjects diagnosed with type 2 diabetes mellitus|
2843755|NCT03642704|Experimental|Reinforced preventive ARV therapy|The proposed reinforced preventive ARV Therapy will be administrated to all newborns exposed to HIV (zidovudine+lamivudine+nevirapine if the newborn is exposed to HIV-1 or HIV-1/2, zidovudine+lamivudine if the newborns exposed to HIV-2)
2843756|NCT03642678|Experimental|Intervention group|"Participants identified as high-risk for malnutrition-related mortality by prediction model are cluster-randomized into study group.~Interventions: In this group, participants will be given common clinical screening for clinical or sub-clinical infection and also oral nutrition supplement (ONS) if albumin is < 3.8 g/dl. Parameters for outcome measurements are recorded monthly (such as biochemical data) or quarterly (such as Body Composition Monitor (BCM) or Malnutrition Inflammatory Score (MIS). Hospitalization or Mortality events will be recorded when happened."
2843757|NCT03642678|No Intervention|Control group|Participants identified as high-risk for malnutrition-related mortality by prediction model are cluster-randomized into control group. In this group, participants will not be given any intervention, but only outcome measurements are recorded monthly (such as biochemical data) or quarterly (such as Body Composition Monitor (BCM) or Malnutrition Inflammatory Score (MIS). Hospitalization or Mortality events will be recorded when happened.
2843758|NCT03642665|Experimental|Natural cycle|no medication
2843759|NCT03642665|Active Comparator|Artificial cycle|"Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.~Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy."
2843760|NCT03642652|Experimental|SMS|"Each patient in the intervention group also received an automated text message up to a week after the positive FOBT result. The text read: Hello. There is a lab test result ready for you. Contact your physician for an explanation of the findings. Two additional automated text message reminders were sent to the patient at 2 weeks and 1 month reading, Hello, This is a reminder. It is essential that you contact your physician if you have not already done so."
2843761|NCT03642652|No Intervention|Control|Routine care
2843762|NCT03642639|Other|Coils|Spectra Micrusframe and Spectra Galaxy coils
2843763|NCT03642626|Experimental|ARM A: Refractory/relapsed B-cell acute lymphoblastic leuk|
2843764|NCT03642626|Experimental|ARM B: Yescarta for Refractory diffuse large B cell lymphom|
2843765|NCT03642626|Experimental|ARM C: Kymriah for Refractory diffuse large B cell lymphom|
2843766|NCT03642600|Active Comparator|dietary advice|standard clinical procedure
2843767|NCT03642600|Active Comparator|metformin hydrochloride|a common standard therapeutic option in treatment of women with PCOS
2843768|NCT03642600|Experimental|myo-inositol|lack of consistent evidence for the treatment of women with PCOS
2843769|NCT03642600|Experimental|liraglutide pen injector|no evidence for weight loss in women with PCOS
2843770|NCT03642587||Study Population|People between the ages of 2 and 85 years old with out of hospital cardiac arrest of no obvious cause who are attended to by paramedics who survive or die
2843771|NCT03642574|Experimental|PMS group|Subjects in the PMS group will have blastocyst biopsy and whole genome bisulfate sequencing done with 2 or 7 good-quality embryos on Day 5 to 7. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by DNA methylation level.The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
2843772|NCT03642574|Active Comparator|PGS group|Subjects in the PGS group will have blastocyst biopsy and sequencing done with 2 or 7 good-quality embryos on Day 5 to 7. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by blastocyst morphologic score. The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
2843773|NCT03642561|Experimental|RFA group|Patients in RFA group will accept RFA treatment
2843774|NCT03642561|Active Comparator|TACE group|Patients in TACE group will accept TACE treatment
2843775|NCT03642548|Experimental|BIFICO Group|The intervention group patients receive platinum-based doublet chemotherapy plus BIFICO (Dose: 420mg, 3 times a day, p.o)
2843776|NCT03642548|Placebo Comparator|Control Gruop|The control group patients receive platinum-based doublet chemotherapy plus Placebo (Dose: 420mg, 3 times a day, p.o)
2843777|NCT03642535|Experimental|ALA for all face group|Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Immediately afterwards, a 1-mm thick layer of 10% ALA was applied to the all face. The area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.
2843815|NCT03642236|Active Comparator|BTK-free treatment|Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.
2843816|NCT03642223|Active Comparator|normal-weight|
2843778|NCT03642535|Active Comparator|ALA for AK lesion group|Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Then a 1-mm thick layer of 10% ALA was applied to the lesion and 5 mm of surrounding healthy tissue. Vehicle control cream was applied to the non-lesion area. All area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.
2843779|NCT03642522|Experimental|1 Hz rTMS|30 minutes of 1 Hz rTMS to the right dorsolateral prefrontal cortex (R_DLPFC)
2843780|NCT03642509|Experimental|LAAO group|Patients will be treated with transcatheter left atrial appendage occlusion. The LAAO may be performed with the Amulet or Watchman device.
2843781|NCT03642509|Experimental|NOAC group|Patients will be treated with one of the currently available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban.
2843782|NCT03642496|Experimental|The low dose group|
2843783|NCT03642496|Experimental|The middle dose group|
2843784|NCT03642496|Experimental|The high dose group|
2843785|NCT03642457|Active Comparator|Serratus Plane Group|Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.
2843786|NCT03642457|Placebo Comparator|Placebo Group|Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.
2843787|NCT03642444|Active Comparator|Phase A cane walking (assistive walking-device a cane)|9-12 weeks usual cane-walking to establish baseline values. Patients walk with their usual assistive-walking device - a cane.
2843788|NCT03642444|Active Comparator|Phase B elasticated orthotic-garment - TheraTogs|9-19 weeks : assistive walking-device which is an elasticated orthotic-garment worn throughout the day (product name TheraTogs). Cane use maximally reduced during his period.
2843789|NCT03642444|No Intervention|Phase C follow-Up|9-10 weeks individually determined follow-up: subjects determine whether they walk independently (without assistive device) or with the elasticated orthotic-garment (TheraTogs) or with a cane.
2843790|NCT03642405||Methylphenidate-Group|The group is examined before and after intake of Methylphenidate
2843791|NCT03642405||Methylphenidate and know QT-prolonging SSRI|The group is examined before and after intake of Methylphenidate
2843792|NCT03642405||Methylphenidate and non-QT-prolonging SSRI|The group is examined before and after intake of Methylphenidate
2843793|NCT03642392||Tendinopathy|Athletes with unilateral tendinopathy
2843794|NCT03642379|Experimental|Peer Support Recovery|This is a quality improvement study designed to provide peer recovery support for cardiac surgery patients admitted with a diagnosis of infective endocarditis secondary to IV drug addiction.
2843795|NCT03642366|Active Comparator|Active Arm 1|
2843796|NCT03642366|Active Comparator|Active Arm 2|
2843797|NCT03642366|Sham Comparator|Sham Arm|
2843798|NCT03642353|Experimental|G1: Triclosan/health children|Children from health parents will use the triclosan toothpaste for 45 days.
2843799|NCT03642353|Placebo Comparator|G2: Placebo/health children|Children from health parents will use the placebo toothpaste for 45 days.
2843800|NCT03642353|Experimental|G3: Triclosan/GAP children|Children from GAP parents will use the triclosan toothpaste for 45 days.
2843801|NCT03642353|Placebo Comparator|G4: Placebo/GAP children|Children from GAP parents will use the placebo toothpaste for 45 days.
2843802|NCT03642327|Active Comparator|Independent online training (IND)|IND refers to practitioners Independently doing the online training.
2843803|NCT03642327|Experimental|Maintenance of Certification (MOC)|MOC involves a guided learning experience, approved by the American Board of Pediatrics and the American Board of Family Medicine for Maintenance of Certification credits. This involves a Quality Improvement project with 3 waves of data collection to assess and improve implementation while participating in 4 monthly webinars led by Dr. Dubowitz.
2843804|NCT03642314|Experimental|Intervention|Individuals receive 5 HIV Self Test kits + vouchers to secondarily distribute to MSM/TGW from their social/sexual networks. All vouchers are uniquely identified invitations for priority access to ImPrEP sites, valid to be redeemed by a 3 month period
2843805|NCT03642314|No Intervention|Control|Individuals receive 5 vouchers to secondarily distribute to MSM/TGW from their social/sexual networks. All vouchers are uniquely identified invitations for priority access to ImPrEP sites, valid to be redeemed by a 3 month period
2843806|NCT03642288|Experimental|CRE-induced SBO|Patients with CRE-induced SBO received GG challenge.
2843807|NCT03642288|Active Comparator|ASBO|Patients with adhesive SBO (ASBO) received GG challenge.
2843808|NCT03642275|Experimental|iCardia4HF|Participants will be using a heart failure mobile app, wearable activity tracking device, Bluetooth-enabled blood pressure monitor and weight scale for self-monitoring, and receive tailored text-messages about self-care.
2843809|NCT03642275|No Intervention|Control Group|Participants assigned to the usual care group will receive standard medical care, which includes nurse-led patient education about HF self-care before discharge, and follow-up visits at the UI Health, outpatient Heart Failure program.
2843810|NCT03642262|Experimental|Treatment A: Mucinex® ER 600 mg|Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.
2843811|NCT03642262|Active Comparator|Treatment B: Guaifenesin 200 mg|Guaifenesin 200 mg immediate release (IR) tablet thrice (at 0, 4, and 8 hours) by mouth under fasting condition.
2843812|NCT03642249|Experimental|experimental group|"face-to-face delirium care session (30 minutes in duration);~online learning delirium care activities (20 minutes in duration); and~delirium care OSCE and reflective activity (30 minutes in duration)."
2843813|NCT03642249|Active Comparator|control group|"face-to-face delirium care session (30 minutes in duration);~online learning delirium care activities (20 minutes in duration)"
2843814|NCT03642236|Experimental|BTK treatment|Ibrutinib 420mg day -3 to d14; Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.
2843817|NCT03642223|Experimental|peripheral adiposity|
2843820|NCT03642197|Experimental|Support Figure Attended (SFA)|Using simple randomization patients (female or male) not in romantic relationships will be randomized into support figure attended (SFA) and SFA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Support figures in the SFA arm will be requested to attend the four pre-surgery classes with the patient and the three clinical visits. The intervention is support figure attendance. Assessments will be completed by patients and support figures at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
2843821|NCT03642197|No Intervention|SFA - Treatment as Usual (SFA-TAU)|Using simple randomization patients (female or male) not in romantic relationships will be randomized into support figure attended (SFA) and SFA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Support figures in the SFA-TU arm will not be requested to attend the four pre-surgery classes with the patient and the three clinical visits- patients will attend alone. Assessments will be completed by patients and support figures at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
2843822|NCT03642197|Experimental|Partner Attended (PA)|Using simple randomization female patients in cohabiting romantic relationships for at least 6 months will be randomized into partner attended (PA) and PA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Partners in the PA arm will be requested to attend the four pre-surgery classes with the patient and the three clinical visits. The intervention is partner attendance. Assessments will be completed by patients and partners at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
2843823|NCT03642197|No Intervention|PA - Treatment as Usual (PA-TAU)|Using simple randomization female patients in cohabiting romantic relationships for at least 6 months will be randomized into partner attended (PA) and PA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Partners in the PA-TU arm will not be requested to attend the four pre-surgery classes with the patient and the three clinical visits- patients will attend alone. Assessments will be completed by patients and partners at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
2843824|NCT03642184|Active Comparator|Empagliflozin|Jardiance 10mg/25mg Film-coated tablets， once daily
2843825|NCT03642184|Active Comparator|Linagliptin|Trajenta 5mg Film-coated tablets， once daily
2843826|NCT03642158|Active Comparator|Active TMS|Subjects receive rTMS over the right DLPFC, in 2 second bursts at 10 Hz, followed by a 19 second break, for a total of 20 minutes. Stimulator intensity is set to 80% of motor threshold on day one, and 100% of motor threshold for the remainder of intervention. This paradigm is continued for 5 consecutive days.
2843827|NCT03642158|Sham Comparator|Sham TMS|"Identical to active arm, but stimulator intensity is reduced to 30% of motor threshold, and the stimulator coil is oriented tangentially to the skull to stimulate air space above the head instead of cortical tissue."
2843828|NCT03642145|Active Comparator|Arm A: 0.9 mg/kg Deflazacort|
2843829|NCT03642145|Active Comparator|Arm B: 0.45 mg/kg Deflazacort|
2843830|NCT03642132|Experimental|chemotherapy, avelumab and talazoparib|Platinum-based chemotherapy + avelumab followed by avelumab + talazoparib maintenance
2843831|NCT03642132|Experimental|chemotherapy, and talazoparib|Platinum-based chemotherapy followed by talazoparib maintenance
2843832|NCT03642132|Active Comparator|chemotherapy and bevacizumab|Platinum-based chemotherapy + bevacizumab followed by bevacizumab maintenance
2843833|NCT03642119||iButton® Validation in Perimenopause|Women in the late phase of perimenopause (based on the STRAW+10 criteria).
2843834|NCT03642106|Active Comparator|Unidos Se Puede|Unidos Se Puede: consists of 5-weekly Family Workshops, 15 monthly booster sessions, 14-months success coaching, adolescent group activities and will be compared to an attention placebo control.
2843835|NCT03642106|Placebo Comparator|Attention placebo control|Placebo consists of 24 financial planning classes for parents and youth.
2843836|NCT03642093|Experimental|Frail|Subjects assessed and determined to be Frail and meet trial eligibility criteria will be enrolled on Frail Arm and begin a 4 Week program consisting of Nutritional Interventions and Physical Activity Interventions
2843837|NCT03642093|Active Comparator|Not Frail|Subjects assessed and determined to be Not Frail and meet trial eligibility criteria will be enrolled on Not Frail Arm and begin a 4 Week program consisting of Nutritional Interventions and Physical Activity Interventions
2843838|NCT03642080||Glioblastoma|Patients with a diagnosis of newly diagnosed or recurrent glioblastoma who have been treated with radiation and temozolomide and are being offered tumor treated fields.
2843839|NCT03642067|Experimental|Nivolumab and Relatlimab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab (480 mg) will be administered IV on day 1 (28 day cycle). Relatlimab (160 mg) will be administered IV on day 1 (28 day cycle).
2843840|NCT03642054||Pelvic Organ Prolapse|Patients having vaginal hysterectomy who demonstrate grade III-IV uterovaginal prolapse.
2843841|NCT03642054||Non Pelvic Organ Prolapse|Patients having vaginal hysterectomy who do not demonstrate uterovaginal prolapse.
2843842|NCT03642028|Experimental|Suvorexant|Suvorexant is a dual orexin receptor antagonist that is FDA approved to treat insomnia.
2843843|NCT03642028|Placebo Comparator|Identical Placebo|Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.
2843844|NCT03642015|Experimental|listening music|The participants in the music group selected the music they preferred from different genres. During the 15-min intervention period before the gastroscopy procedure, the experimental group rested by listening to music and sitting on a comfortable chair
2843845|NCT03642015|No Intervention|Control|control group rested only by sitting on a comfortable chair
2843846|NCT03642002|Experimental|Toning|Vocal Tonal Holding
2843847|NCT03642002|Other|Ocean drum & SOK melody|Ocean drum followed by melody of song of kin
2843848|NCT03642002|Experimental|SOK|Song of kin with lyric content
2956807|NCT02855671||Sepsis|
2843849|NCT03642002|Experimental|Process|Processing of experience
2843850|NCT03642002|Experimental|Holding Harmonic Container|
2843851|NCT03641989|Active Comparator|Plaque disclosing toothpaste|Based on a randomization schema, a 30 day supply of the plaque disclosing toothpaste will be distributed to the participant. Participants will be instructed to brush two times a day for 30 days with the plaque disclosing toothpaste; avoiding the use of mouth rinses and floss. They will also be instructed to avoid any dental prophylaxis (e.g., cleaning, scaling or root planing to mechanically remove plaque and calculus) while on the trial and 30 days before they are enrolled.
2843852|NCT03641989|Placebo Comparator|Non-plaque disclosing toothpaste|Based on a randomization schema, a 30 day supply of the over-the-counter, non-plaque disclosing toothpaste will be distributed to the participant. Participants will be instructed to brush two times a day for 30 days with the plaque disclosing toothpaste; avoiding the use of mouth rinses and floss. They will also be instructed to avoid any dental prophylaxis (e.g., cleaning, scaling or root planing to mechanically remove plaque and calculus) while on the trial and 30 days before they are enrolled.
2843853|NCT03641976|Experimental|Arm I (A-FOLFOXIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
2843854|NCT03641976|Active Comparator|Arm II (A-FOLFOX/A-FOLFIRI)|Patients receive irinotecan hydrochloride IV over 1 hour (or oxaliplatin IV over 2 hours), leucovorin calcium IV over 2 hours, fluorouracil IV bolus, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
2843855|NCT03641963|Experimental|Stroke patients with ICP measurement|All patients with the possibility to evolve a malignant MCA infarct according to the initial assessment, will be included in our study, to measure ICP non-invasive. The ICP will be measured non-invasive with the Vittamed 205 Non-invasive intracranial pressure (ICP) meter.
2843856|NCT03641950|Experimental|Botulinum Toxin Type A (Botulax)|Botulinum Toxin Type A (Botulax)
2843857|NCT03641924||PTSD|Veterans diagnosed with DSM-V PTSD
2843858|NCT03641898||Morphometric assessment of FNLs|After FFR-guided PCI, the morphometric characteristics of FNLs (FFR>0.8) are assessment by intravascular ultrasound.
2843859|NCT03641885|Experimental|mother and adolescents|an intervention group in which mothers and adolescents receive the intervention and questionnaires via Telegram social media
2843860|NCT03641885|Experimental|adolescents|an intervention group in which adolescents receive the intervention and questionnaires via Telegram social media
2843861|NCT03641885|Active Comparator|active control|mothers and adolescents are in active control group and only receive the questionnaires
2843862|NCT03641872||Acute-on-Chronic Liver Disease|"chronic liver disease: including chronic liver hepatitis patients without cirrhosis, compensated cirrhosis patients, decompensated cirrhosis patients and non-alcoholic fatty liver disease patients.~ALI(acute liver injury): including [ALT > 3 ULN(upper limited of normal),AST > 3 ULN or TB > 2 ULN within 1 week before enrollment] or AD(acute decompensation) : including [(having ascites, hepatic encephalopathy, bacterial infection, gastrointestinal bleeding and/or jaundice(TB > 5 ULN) within 1 month before enrollment)].~Standary therapy for chronic liver disease with ATI and/or AD"
2843863|NCT03641859|No Intervention|Local anesthesia|"The study population will consist of consecutive pre-screened patients when they arrive at the emergency department at the level of the host nurse. The emergency physician who will be in charge of the patient gives the patient the information form and ensures the absence of contraindication, responds to the patient's questions and collects his free, informed and express consent.~Once the patient is included, the group (with or without virtual reality) of the patient's participation in the study will be notified by the reception nurse and emergency referral:~- Arm 1 (usual care): the procedure of care will be the same as usual."
2843864|NCT03641859|Experimental|local anesthesia + virtual reality|"The study population will consist of consecutive pre-screened patients when they arrive at the emergency department at the level of the host nurse. The emergency physician who will be in charge of the patient gives the patient the information form and ensures the absence of contraindication, responds to the patient's questions and collects his free, informed and express consent.~Once the patient is included, the group (with or without virtual reality) of the patient's participation in the study will be notified by the reception nurse and emergency referral:~- Arm 2 (intervention): local anesthesia + virtual reality"
2843865|NCT03641846|Active Comparator|LiST + 5mg Tadalafil Group|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks.
2843866|NCT03641846|Placebo Comparator|LiST+Placebo Group|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily placebo pill. Total treatment period = 4 weeks.
2843867|NCT03641807|Experimental|Acupuncture|
2843868|NCT03641807|Sham Comparator|Sham acupuncture|
2843869|NCT03641794|Experimental|DN1406131|25 mg,50 mg,100 mg,200 mg,400 mg,600 mg,800 mg
2843870|NCT03641794|Placebo Comparator|Placebo|25 mg,50 mg,100 mg,200 mg,400 mg,600 mg,800 mg
2843871|NCT03641781|Active Comparator|Isometric strength training group|Knee pain athletes were assessed by The International Knee Documentation Committee (IKDC) 2000 Subjective Knee evaluation form and were assigned into ISOM group. ISOM group participants were involved in isometric strengthTraining at angle of 30°,45°,60° of knee flexion for 5 maximum contraction for both hamstring and quadriceps. 10 sessions were given on alternate day basis by using Biodex Isokinetic system.
2843872|NCT03641781|Active Comparator|Isokinetic strength training group|Knee pain athletes were assessed by The International Knee Documentation Committee (IKDC) 2000 Subjective Knee evaluation form and were assigned into ISOK group isokinetic training group randomly. ISOk group participants were involved in Training at speed of 30 deg/sec, 90deg/sec, 150/deg/sec 210deg/sec, 270deg/sec 5 repetition for both hamstring and quadriceps. 10 sessions were given on alternate day basis by using Biodex Isokinetic system.
2843942|NCT03641248|Active Comparator|Non-enteric coated Devil's Claw|H. procumbens 100 mg in non-enteric coated capsules
2843943|NCT03641235||exacerbating COPD patients needing ICU admission|sputum collection
2843873|NCT03641781|No Intervention|Healthy control group|Data for outcome parameters including Peak torque average peak torque average power agonist antagonist ratio by using biodex isokinetic system for both by isometric contraction method and isokinetic method. For performance test were recorded for healthy control of same age group to compare the training effect with healthy control values.
2843874|NCT03641768|Active Comparator|Healthy volunteers|Volunteers with no trauma history
2843875|NCT03641768|Active Comparator|Trauma only|Volunteers that do not have PTSD but have had similar trauma to those with PTSD
2843876|NCT03641768|Active Comparator|PTSD only|Volunteers with PTSD but no traumatic brain injury
2843877|NCT03641768|Active Comparator|PTSD and TBI|Volunteers with PTSD and mild traumatic brain injury
2843878|NCT03641755|Experimental|Olaparib + Sapacitabine|"Olaparib will be administered orally twice daily for each 28-day cycle~Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle~Olaparib will be given at a predetermined dose~Sapacitabine will be given at a predetermined dose"
2843879|NCT03641742||FAR-ILD Proband Participants|There will be no interventions administered to this group, only data collection.
2843880|NCT03641742||"FAR-ILD At-Risk Participants"|There will be no interventions administered to this group, only data collection
2843881|NCT03641729|Other|Intervention|Patients were eligible if they were aged 18 years or older, referred for HSCT and admitted to the Bone Marrow Transplant Unit (BMTU). Patients were screened in the BMTU admission and recruited to the study after avaliation in the first-day internation.
2843882|NCT03641716|Experimental|Mealtime PREP Intervention|Parents of young children will receive 6 weekly sessions, each lasting approximately one-hour, in the home environment. An occupational therapy clinician will deliver the Mealtime PREP intervention to the family.
2843883|NCT03641703|Experimental|FLT180a|Participants receiving gene therapy vector
2843884|NCT03641690||27 case|Twenty-seven patients were admitted to the ICU with severe pneumonia and with a high probability of viral infection or a previously confirmed diagnosis received Empirical antimicrobial therapy
2843885|NCT03641690||70 control|70 healthy subjects (HS) among blood donors attending the Regional Center for Blood Transfusion (Lille, France).
2843886|NCT03641664|Experimental|Treatment: Family Centered Treatment|Family is offered choice of FCT or Level III out-of-home placement
2843887|NCT03641664|Active Comparator|Control: Level III Out of Home Placement|Family is offered Level III out-of-home placement
2843888|NCT03641651|Experimental|Technology arm|4 Weeks intervention of intensive rehabilitation using rehabilitation technology, 3-5 h per day, within a 5d week in-or outpatient setting.
2843889|NCT03641638||Low level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb at 34-102 IU/ml.
2843890|NCT03641638||Medium level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb at 103-204 IU/ml.
2843891|NCT03641638||High level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb >205IU/ml.
2843892|NCT03641638||Control group|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of negative Thyroid antibody, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L.
2843893|NCT03641625|Experimental|Intervention|In addition to usual care during surgery, the intraoperative management will be additionally managed based on the guidance of muscular tissue oxygen saturation and non-invasive hemodynamic monitoring.
2843894|NCT03641625|No Intervention|Control|Patients will receive the usual care. Muscular tissue oxygen saturation and non-invasive hemodynamic monitoring will be used but blinded to care givers.
2843895|NCT03641612|Experimental|one shape|single file rotary system
2843896|NCT03641612|Active Comparator|protaper next|multiple file rotary system
2843897|NCT03641599||heart failure with preserved ejection fraction|
2843898|NCT03641599||heart failure with mid range ejection fraction|
2843899|NCT03641599||heart failure with reduced ejection fraction|
2843900|NCT03641586|Experimental|Stage I|Approximately 25-35 Chinese subjects with local advanced or metastatic malignant solid tumor will be enrolled in the dose escalation stage of BGB-283 until maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) determination
2843901|NCT03641586|Experimental|Stage II|Approximately 15-30 melanoma subjects will be enrolled in dose expansion stage of BGB-283
2843902|NCT03641586|Experimental|Stage III|20 subjects will be enrolled for food effect stage of BGB-283
2843903|NCT03641573|Experimental|[14C] ASN002|[14C] ASN002
2843904|NCT03641560|Experimental|Enzalutamide group|Participants will receive Enzalutamide once daily in addition to continued androgen deprivation therapy until discontinuation criteria is met
2843905|NCT03641547|Experimental|Stage A1, A2 & B|"The trial is a single arm study. Different populations are recruited to each stage and the stages run independently of each other. Stage A1 & A2 will commence before Stage B so that safety data can be obtained in the palliative setting prior to Stage B commencing. Stage A1 may be ongoing when Stage B begins. Each Stage has a separate eligibility criteria.~Stage A1: M6620 & palliative radiotherapy Stage A2: M6620 & palliative chemotherapy (Cisplatin & Capecitabine) Stage B: M6620 & definitive chemoradiotherapy"
2843906|NCT03641534||Sepsis|
2843907|NCT03641534||Severe malaria|
2843908|NCT03641534||Uncomplicated malaria|
2843909|NCT03641521|Experimental|Intervention|The intervention consisted of an enhanced Cooking Matters® for Families program that included behavioral strategies derived from behavioral economics, to be implemented by parents at home for increasing vegetable intake of low-income 9-12 year old children
2843910|NCT03641521|No Intervention|Control|The control arm consisted of the enhanced Cooking Matters® for Families program alone--without lessons about the behavioral strategies for the parents
2843911|NCT03641508|Active Comparator|Triamcinolone|The study drug used will be triamcinolone mixed with 1% lidocaine without epinephrine
2843912|NCT03641508|Active Comparator|Dexamethasone|The study drug used will be dexamethasone mixed with 1% lidocaine without epinephrine
2843913|NCT03641495|Experimental|Pain education plus exercise therapy (PE + ET)|"Pain education according to the book Explain Pain written by Lorimer Moseley and David Butler~Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations."
2843914|NCT03641495|Active Comparator|Exercise therapy (ET)|Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations.
2843915|NCT03641482|Active Comparator|NBF|Propolis Extract, Ascorbic Acid, Tocopherol Acetate, Sodium-Monofluorophosphate, Silicon Dioxide, Triclosan, Glycerin, D-sorbitol, Polyethyleneglycol 150, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate and Deionized Water
2843916|NCT03641482|Placebo Comparator|Placebo|Sodium-Monofluorophosphate, Silicon Dioxide, Triclosan, Glycerin, D-sorbitol, Polyethyleneglycol 150, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate and Deionized Water
2843917|NCT03641469|Experimental|Green Sun Dynamic Brace|Historical measures of brace effectiveness (in- and out-of-brace Cobb angles), wear time, and brace-related quality of life will be compared to those measured after the subject is fit with a Green Sun dynamic brace.
2843918|NCT03641456|Experimental|VRD for Followed by IR|The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22; oral lenalidomide 25mg on days 1 to 21; and oral dexamethasone 40mg on days 1, 8, 15 and 12 of a 28-day cycle.Patients are allowed to proceed to stem-cell transplantation after four cycles of VRD at the discretion of the treating physician.Two months after hematologic recovery, nonprogressive patients are to receive consolidation therapy comprising two cycles of VRD.Patients who do not proceed to stem-cell transplantation receive more two induction cycles after obtaining maximum response but no less than six cycles totally. Responding patients could receive maintenance therapy comprising 4-week cycles of oral Ixazomib 4mg on days 1 ,8 and 15 and lenalidomide on days 1 to 21 at the dose level of 10mg.
2843919|NCT03641443|Experimental|Non-invasive measurment of intracranial pressure|Patient with mass effective brain tumor that undergo non-invase intracranial pressure measurement
2843920|NCT03641430|Experimental|Supportive care with Over-the-Counter (OCT) product|Participants will apply over-the-counter product for a certain period with or without light challenge
2843921|NCT03641417|Experimental|Cycle 1|During cycle 1 participants will receive either study drug (GLWL-01) or placebo, the order will be random. Participants will switch to placebo/study drug during study cycle 2.
2843922|NCT03641417|Experimental|Cycle 2|During cycle 1 participants will receive either study drug (GLWL-01) or placebo, the order will be random. Participants will switch to placebo/study drug during study cycle 2.
2843923|NCT03641404|Experimental|Ergothioneine|Subjects will consume 25mg ergothioneine (capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.
2843924|NCT03641404|Placebo Comparator|Placebo|Subjects will be given placebo (99% microcrystalline cellulose, 1% magnesium stearate; capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.
2843925|NCT03641391|Experimental|Direct electrical stimulation|Intraoperative direct cortical electrical stimulation or intraoperative direct subcortical electrical stimulation on language or language-associate areas, and the participants' after-discharge activity would be monitored. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
2843926|NCT03641378|Experimental|Inpatient Palliative Care Intervention|"Patients and Caregivers will complete baseline self-report assessments at the time of obtaining informed consent~Palliative Care Intervention~Therapeutic Relationship~--Develop a strong therapeutic relationship with patients and caregivers~Assessment and Treatment of Patient Symptoms~--Clarify the symptoms the patient will likely experience and offer reassurance about the methods for reporting and treating symptoms~Managing Patients and Caregivers Expectations~--Address early on patients and caregivers' concerns about the trajectory of illness during HCT and treatment side effects~Coping with Illness and HCT --Introduce strategies to help improve adjustment (e.g., behavioral, cognitive, and spiritual approaches; accepting illness while maintaining hope; social support)"
2843927|NCT03641378|Experimental|Transplant Care Alone|"Patients and Caregivers will complete baseline self-report assessments at the time of obtaining informed consent.~Standard Transplant Care"
2843928|NCT03641365|Experimental|Test group|Test group: Surgical template without metallic sleeves. In this case the surgical template has all been designed and fabricated in acrylic material by mean of stereolitographic technology.
2843929|NCT03641365|Active Comparator|Control group|Control group: Surgical template with metallic sleeves. Surgical template has designed and fabricated in acrylic material by mean of stereolitographic technology and metallic sleeves have been bonded after its production.
2843930|NCT03641352|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
2843931|NCT03641352|Placebo Comparator|Placebo|Placebo
2843932|NCT03641339|Other|1|Participants will be assigned to groups that differ by type of vector and number of feedings. Participants will undergo either 1 feeding (Cohort A) or 4 feedings, each about 2 weeks apart (Cohort B), with the same vector type.
2843933|NCT03641326|Experimental|1|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest.Participants will given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
2843934|NCT03641313|Experimental|Treatment (irinotecan and M6620)|Participants receive irinotecan IV over 90 minutes and ATR kinase inhibitor M6620 IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2843935|NCT03641300|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
2843936|NCT03641300|Active Comparator|Electroconvulsive Therapy (ECT)|ECT treatments will be administered using the MECTA spECTrum 5000Q
2843937|NCT03641287|Experimental|Arm I (aerobic exercise)|
2843938|NCT03641287|Active Comparator|Arm II (habitual level of physical activity)|
2843939|NCT03641274||Frequent users of emergency departement|FUEDs receiving the CM intervention in sites participating in the research project will be assessed over time on clinical variables (see inclusion and exclusion criteria)
2843940|NCT03641261|Experimental|Therapeutic Patient Education program|All included patients will follow a Therapeutic Patient Education program dedicated to the hereditary ichthyosis and using a web application, WebIchtyose
2843941|NCT03641248|Experimental|Enteric coated Devil's Claw|H. procumbens 100 mg in enteric coated capsules
2957417|NCT02851420|Experimental|patient|
2843944|NCT03641222|Experimental|Group Acupuncture|Group acupuncture sessions take place in a multipurpose room, with 3-6 participants, each session lasts 30-45 minutes, occurring twice-weekly, over the course of six weeks, for a total of twelve treatments. The acupuncture was administered by a Naturopathic Doctor.
2843945|NCT03641222|Active Comparator|Individual Acupuncture|Individual acupuncture sessions take place in a multipurpose room, privately each session lasts 30-45 minutes, occurring twice-weekly, over the course of six weeks, for a total of twelve treatments. The acupuncture was administered by a Naturopathic Doctor.
2843946|NCT03641209|Experimental|Paracetamol|Paracetamol 10 mg/mL infusion solution, intravenous loading dose 20 mg/kg, followed by maintenance dose 7.5 mg/kg every 6 h up to 9 days
2843947|NCT03641209|Placebo Comparator|Placebo|0.45% sodium chloride (NaCl) solution, equal amounts in mL as would have been given the experimental drug
2843948|NCT03641196|No Intervention|No treatment of deep bite|No treatment of deep bite. These participants will be evaluated during a 6-month follow-up period. In cases were significant problems arise during the follow-up period, the participant will be removed from the study and the appropriate treatment conducted.
2843949|NCT03641196|Active Comparator|Fixed appliance|Fixed appliance: Treatment with a cemented modified palatal Nance appliance presenting a bite-plane.
2843950|NCT03641196|Active Comparator|Removable appliance|Removable appliance: Treatment with a removable bite plate appliance.
2843951|NCT03641196|Active Comparator|Composite bite plane|Composite bite plane: Treatment with a composite build up in the palatal aspect of the upper central incisors.
2843952|NCT03641183|Experimental|FOLFIRINOX Drugs|"5-FU (Fluorouracil) 2,400mg/m2 IV over 48 hours Dat1-3 and 15-17 every 4 weeks Folinic Acid 400 mg IV on day 1, 15 every 4 weeks Oxaliplatin 85 mg/m2 IV on day 1, 15 every 4 weeks Irinotecan 180 mg/m2 IV on day 1, 15 every 4 weeks.~Followed by: Stereotactic Body Radiotherapy (SBRT): 33 Gy in 5 fractions (6.6) delivered to radiographically defined pancreatic mass"
2843953|NCT03641183|Active Comparator|Gemcitabine-nab Paclitaxel (Abraxane)|"Gemcitabine 1000 mg/m2 on day 1, 8 & 15 every 4 weeks nabPaclitaxel 125 mg/m2 on day 1, 8 & 15 every 4 weeks.~Followed by: Stereotactic Body Radiotherapy (SBRT): 33 Gy in 5 fractions (6.6) delivered to radiographically defined pancreatic mass"
2843954|NCT03641170|Experimental|Experimental intervention|Fixed diet and physical activity.
2843955|NCT03641170|Other|Control intervention|Fixed diet and inactivity.
2843956|NCT03641157||Group I Easy Intubation|Pediatric patients ages 0-3 years Easy Intubation (Cormach-Lehane score I-II)
2843957|NCT03641157||Group II Difficult intubation|Pediatric patients ages 0-3 years Difficult intubation (Cormach-Lehane score III-IV)
2843958|NCT03641144|Experimental|Navigation laser|Navigation laser photocoagulation treatment to the macular area of retinal thickening with a focal pattern and/or grid pattern
2843959|NCT03641144|Active Comparator|Traditional laser|Traditional laser photocoagulation treatment to the macular area of retinal thickening with a focal pattern and/or grid pattern
2843960|NCT03641118||Lower gastrointestinal cancer|All lower gastrointestinal neoplasms including rectal
2843961|NCT03641118||Upper gastrointestinal cancer|All upper gastrointestinal neoplasms
2843962|NCT03641118||Hepatobiliary cancers|All liver, pancreas, biliary cancer
2843963|NCT03641105||lung adenocarcinoma|patients with lung adenocarcinoma
2843964|NCT03641092|Experimental|Experimental Clinical Site|5 experimental clinical sites will receive the implementation of CenteringParenting assistance early. This arm will include the CenteringParenting intervention.
2843965|NCT03641092|Active Comparator|Comparison Clinical Site|5 comparison clinical sites will receive Routine Well Child Care and CenteringParenting implementation assistance later and serve as control sites. This arm will include the Routine Well Child Care intervention.
2843966|NCT03641079|Experimental|brinjal peel extract containing cream|intervention-brinjal peel extract containing cream, dose-twice daily for 12 weeks
2843967|NCT03641066|Experimental|Ankle Brace|Each participant will complete a baseline analysis of 1 minute of walking and 2 minutes of running, repeated 4 more times wearing 4 different braces. The analysis will be completed on the Walker View Treadmill, which used 3D camera technology to capture lower body kinematics. The treadmill also has load cells built in to capture gait characteristics
2843968|NCT03641053|Experimental|Honey|0.05 cc of honey (Madu Nusantara®) per 1 cm of laceration, given every predetermined wound care schedule
2843969|NCT03641053|Active Comparator|Povidone-iodine|0.05 cc of povidone-iodine per 1 cm of laceration, given every predetermined wound care schedule
2843970|NCT03641053|Active Comparator|Paraffin gauze|1 layer of paraffin gauze, given every predetermined wound care schedule
2843971|NCT03641040|Experimental|VOG group|Measurement: Video-oculography(VOG) measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
2843972|NCT03641040|Active Comparator|APCT group|Measurement: Alternative prism cover test(APCT) measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
2843973|NCT03641027|Experimental|Increased physical activity|Increased physical activity daily before surgery. Standard care during hospital stay and continued training after discharge.
2843974|NCT03641027|Other|Standard care|Standard care
2843975|NCT03641014|Experimental|Sequential pH culture (7.23 then 7.35)|A split embryo at day 3 to continue culture at a pHe of 7.23±0.02 or to be cultured at a pH of 7.35±0.02 and monitor the effect on blastocyst development.
2843976|NCT03641014|No Intervention|Continuously pH culture at 7.23|Embryo culture from day 0 to 5 or 6 at 7.23
2843977|NCT03641001|Experimental|Intervention|Intervention group will receive child feeding counselling, food voucher for recipe, WASH and home fortification
2843978|NCT03641001|No Intervention|Control|Control will receive usual health messages from government and NGO
2843979|NCT03640988|Experimental|dermaPACE|Non-sterile, single, Benchtop System that is comprised of a dermaPACE Control Console, PACE Applicator and foot pedal. The PACE applicator uses shockwave technology on acute and chronic defects.
2843980|NCT03640975||case : eosinophilic esophagitis|Children with symptoms suggestive of EoE and requiring an upper gastrointestinal endoscopy with biopsies of the esophageal mucosa
2843981|NCT03640975||control|Children in whom an endoscopy performed to explore symptoms of EoE revealed another condition (peptic oesophagitis, achalasia), or children in whom an endoscopy with biopsies has been performed to explore chronic abdominal or epigastric pain or suspected chronic inflammatory bowel disease
2843982|NCT03640949|Experimental|Vasopressin and methylprednisolone|The study drugs will consist of 40 mg methylprednisolone (Solu-medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of adrenaline. Additional doses of vasopressin (20 IU) will be administered after each adrenaline dose for a maximum of four doses (80 IU).
2843983|NCT03640949|Placebo Comparator|Placebo|"The placebo for vasopressin will consist of 1 mL of 9 mg/mL NaCl (normal saline) from 2 mL ampules identical to the vasopressin ampules. The placebo for methylprednisolone will also consist of 1 mL of 9 mg/mL NaCl."
2843984|NCT03640936||Healthy|Healthy controls, without asthma or allergy (negative prick test)
2843985|NCT03640936||Allergic asthma|Patients with allergic asthma sensitized to Dermatophagoides pteronissinus, tested by prick test or specific IgE
2843986|NCT03640936||Non-allergic asthma|Patients with asthma not sensitized to Dermatophagoides pteronissinus, with negative prick test or specific IgE
2843987|NCT03640923|Experimental|experimental group|Child with a proven infection of the mother or both biological parents known to HIV antenatal a swab of mucous membrane will be withdrawed
2843988|NCT03640910|Experimental|OT Equators® (Rhein83)|After gingival healing the newest low-profile OT Equators® (Rhein83) will be screwed on to the implants, using the OT Equator® square screwdriver (Rhein83), with a torque range of 22-25 N cm. The cuff heights ranged from 0.5 to 7.0 mm, depending on the height of the transition zone of each implant, easily measured using the color-coded millimeter Cuff Height Measurer Gauge (Rhein83) after healing abutment removal.
2843989|NCT03640910|Active Comparator|Locator® (Zest)|The low-profile attachments Locator® (Zest) will be screwed on to the implants, using the Locator® screwdriver (Zest), with a torque range of 20-25 N cm. The cuff heights of 2.5 or 4.0 mm, depending on the height of the transition zone of each implant, measured using the deep probe of the implant line after healing abutment removal.
2843990|NCT03640897|Experimental|Liniderm|"Oleocalcareous liniment Liniderm:~The product will be applied on the diaper area by parents/ caregivers at each diaper change."
2843991|NCT03640897|Active Comparator|Wipes|Free-fragrance baby wipes The product will be used on the diaper area by parents/ caregivers at each diaper change.
2843992|NCT03640897|Active Comparator|Water|Water and cotton pads The product will be used on the diaper area by parents/ caregivers at each diaper change.
2843993|NCT03640884||Xueshuantong-Injection|Patients who received the Xueshuantong-Injection for treatment will be consecutive included in this registry. The investigators will record all the information about ADR, application of Xueshuantong-Injection and the combined medications, etc.
2843994|NCT03640871|Experimental|URGO AWC_019 dressing (AWC=Advanced Wound Care)|URGO AWC_019 dressing (AWC=Advanced Wound Care)
2843995|NCT03640858|Experimental|Patients receiving hemodialysis|A group of hemodialysis patients will be receiving the Theranova dialyzer during their regularly scheduled sessions to remove larger middle molecules
2843996|NCT03640845|Experimental|experimental group|Patient living in nursing homes a tele-expertise will be performed
2843997|NCT03640845|No Intervention|control group|Patient living in nursing homes will performed a normal care.
2843998|NCT03640832|Experimental|Test product|All the participant in this arm will receive the test product (development serum). Test product will be applied twice daily to the freshly cleansed skin in place of the participant's current serum and before applying moisturizer.
2843999|NCT03640832|Active Comparator|Reference product|All the participant in this arm will receive the reference product (Physiogel Calming Relief Anti-Redness Serum). Reference product will be applied twice daily to the freshly cleansed skin in place of the participant's current serum and before applying moisturizer.
2844000|NCT03640819|Experimental|Tattooing of biopsied node|The biopsied node will be tattooed at the time of needle biopsy (fine needle aspiration or core biopsy) or separate visit under ultrasound guidance.
2844001|NCT03640806|Experimental|PHYSICAL ACTIVITY|Standard support for 12 months (HAS 2010, EULAR 2016) 3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
2844002|NCT03640806|No Intervention|CONTROL|Standard care for 12 months (HAS 2010, EULAR 2016) with Pain Consultation every 3 months.
2844003|NCT03640793|Experimental|Single center, prospective, non-randomized, non-blinded study|Implantation of 6 PPIS implants in each patient
2844004|NCT03640780||cataract extraction (CE)|Patients received CE without IOL implantation in the first surgical stage, and received IOL implantation at secondary surgical stage.
2844005|NCT03640780||cataract extraction and IOL implantation|Patients received CE and IOL implantation in the first surgical stage.
2844006|NCT03640767|Experimental|message-based lifestyle intervention|The intervention group will receive 4 mobile phone messages per week for 24 weeks.
2844007|NCT03640767|No Intervention|Control|no intervention
2844008|NCT03640754|Active Comparator|Experimental: G-CSF|Intervention: G-CSF given by subcutaneous injection repeated 3 times (Days 0, 28, 56) Other name: Filgrastim
2844009|NCT03640754|Placebo Comparator|Comparator: Placebo/Saline|Intervention: Placebo/saline given by subcutaneous injection repeated 3 times (Days 0, 28, 56) Other name: Saline
2844010|NCT03640741||Laparoscopy|The group consists of patients who undergoes laparoscopy procedure during which changes in cerebral oxygenation are estimated.
2844011|NCT03640728|Experimental|Tenofovir alafenamide monotherapy|Tenofovir alafenamide 25 mg/day orally
2844012|NCT03640728|Active Comparator|Tenofovir alafenamide plus Entecavir combination|Tenofovir alafenamide 25 mg/day orally and Entecavir 0.5 mg/day orally
2844013|NCT03640715|Other|group A|Group A: no vulnerability according to expert with no indication of any PASS marker care
2844014|NCT03640715|Other|group B|Group B: probable vulnerability according to the expert with indication of at least one PASS marker care
2844015|NCT03640715|Other|group c|Group C: high vulnerability according to the expert with indication of at least two care markers PASS
2844016|NCT03640702||Prolonged second stage of labor|Women with prolonged second stage of labor as specified before.
2844017|NCT03640689|Experimental|Intervention Group|Endovenous ablation + iliac US +/- iliac stenting
2844018|NCT03640689|Active Comparator|Control Group|Endovenous ablation of Great Saphenous Vein
2844019|NCT03640676|Sham Comparator|INP -10mmHg|In addition to standard medical treatment, patients will receive treatment with FlowOx, applying intermittent negative pressure of -10mmHg one hour in the morning and one hour in the evening at home for 12 weeks.
2844020|NCT03640676|Active Comparator|INP -40mmHg|In addition to standard medical treatment, patient swill receive treatment with FlowOx, applying intermittent negative pressure of -40mmHg one hour in the morning and one hour in the evening at home for 12 weeks.
2844021|NCT03640663||Midwife led continuity model of care|Women who received antenatal care from midwives from the hospital reaching out to the rural villages
2844022|NCT03640663||Regular care group|Women who received care from doctors, nurses or midwives employed at primary Health care centres in rural villages
2844023|NCT03640650|Experimental|Dropless Therapy|Single used, pre-mixed, centrally compounded injectable that contains 15 mg/ml of triamcinolone acetonide and 1 mg/ml of moxifloxacin. This preservative-free suspension is injected at a dose of 0.2 mg into the posterior chamber, for a total drug delivery of 3 mg of triamcinolone acetonide and 0.2 mg of moxifloxacin. At the time of cataract surgery, Dropless is intended to be injected as a single administration into the anterior vitreous after the insertion of the IOL implant, with a 27 or 30-gauge cannula via a transzonular or transsceral pars plana injection, just before rinsing the viscoelastic fluid.
2844024|NCT03640650|Active Comparator|Usual Care|This therapy usually comprises an antibiotic, a steroid and in some cases a nonsteroidal anti-inflammatory drug (NSAID). Antibacterial drops are usually given at the end of surgery and are continued for one week after the surgery. Steroid drops are usually started the day of surgery and then tapered down over 3 to 4 weeks. When prescribed, NSAIDs are usually started 2 or 3 days before surgery, or started the day of surgery, and continued for 3 or 4 times a day for 3 to 4 weeks.
2844025|NCT03640637||Suspected IBD|A prospective study of 50 pediatric patients suspected of IBD. Participants will undergo routine diagnostic procedures for evaluation of pediatric IBD including blood samples, faecal samples, endoscopies (colonoscopy and gastroscopy with biopsy/histology) and MRI of the abdomen. In addition, a PET scan will be performed in this protocol and combined with MRI. For accuracy measures, PET/MRI scan will be compared to the combined findings of endoscopy, histology and severity of inflammation by clinical scoring systems (weighted Pediatric Crohn's Disease Activity Index (wPCDAI) for CD and Pediatric Ulcerative Colitis activity Index (PUCAI) for CU), faecal calprotectin and biochemistry.
2844026|NCT03640637||Treatment response group|A pilot study of 10-15 patients previously diagnosed with CD who will undergo PET/MRI scan as an investigational procedure before initiation of biological treatment with an anti-TNF-alpha antibody (infliximab, adalimumab) because of disease relapse or steroid dependent disease. Patients will be scheduled for a PET/MRI again after one month. This study will evaluate if PET/MRI can diagnose a flare in CD and if PET/MRI is a reliable imaging tool to monitor intestinal inflammation. In this study the patient will act as his/her own control.
2844027|NCT03640624|Experimental|Intervention|Multidisciplinary treatment
2844028|NCT03640624|Active Comparator|Control|Treatment as usual
2844029|NCT03640598|Other|Ilioinguinal/iliohypogastric nerve blocks|The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks
2844030|NCT03640598|Other|Erector spinae nerve block|The patient will receive ultrasound-guided erector spinae nerve block
2844031|NCT03640585|Experimental|Music therapy|Children listened to Classical music disc for 45 minutes.Children treated by neurodevelopmental therapy while listening to this music.A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients.
2844032|NCT03640585|Placebo Comparator|Control|Only the neurodevelopmental therapy was applied in the control group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
2844033|NCT03640572||Bone Marrow DTC|Patients with left-sided colorectal cancer and disseminated tumour cells in the bone marrow
2844034|NCT03640572||No bone marrow DTC|Patients with left-sided colorectal cancer and no disseminated tumour cells in the bone marrow
2844035|NCT03640559|Placebo Comparator|Placebo|the group were having the administration of Placebo (saline 2.4 mL/kg IP)
2844036|NCT03640559|Experimental|Seroguard|the group were having the administration of Seroguard 0.41 g/L solution, 2.4 mL/kg IP
2844037|NCT03640533|Experimental|Nanit-Insights intervention group|Nanit-Insights is an app-based intervention that provides parents with personalized sleep recommendations, based on their infant's developmental stage and weekly sleep data.
2844038|NCT03640533|No Intervention|Nanit-monitor control group|Participants in the control group will be given the same monitoring device, that will serve in this group as a baby-monitor only, without providing sleep recommendations to parents.
2844039|NCT03640520|Experimental|Intervention|Family-centered & Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of Family Centered Care (FCC) practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.
2844040|NCT03640520|Active Comparator|Control|An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs, including a brief mention of FCC as one of these standards, with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness.
2844041|NCT03640507|Active Comparator|Chlorhexidine-alcohol|Subjects will receive vaginal preparation with chlorhexidine-alcohol.
2844042|NCT03640507|Active Comparator|Povidine-iodine|Subjects will receive vaginal preparation with povidine-iodine.
2844043|NCT03640507|Placebo Comparator|Saline|Subjects will receive vaginal preparation with sterile saline.
2844044|NCT03640494||Neonates with a clinical HIE diagnosis|48 neonates with a clinical diagnosis of HIE will be recruited from the patient populations of Duke University Health System and the University of Utah. All subject will have bedside optical coherence tomography (OCT) imaging performed at various time points while in the intensive care nursery.
2844045|NCT03640481|Experimental|Arm A: KD025 200mg QD|Eligible subjects randomized to arm A will take KD025 200mg once daily
2844046|NCT03640481|Experimental|Arm B: KD025 200mg BID|Eligible subjects randomized to arm B will take KD025 200mg twice daily
2844047|NCT03640468|Active Comparator|Ketamine group|This group will receive induction of anesthesia using ketamie full dose 1 mg/kg, midazolam 0.05 mg/Kg, and normal saline 10 mL.
2844048|NCT03640468|Experimental|Lidocaine-ketamine group|This group will receive induction of anesthesia using Ketamie half dose 0.5 mg/kg, midazolam 0.05 mg/Kg, and lidocaine 1 mg/Kg.
2844049|NCT03640455|Placebo Comparator|Placebo|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; dummy stimulation will be given.
2844050|NCT03640455|Experimental|Anodal tDCS|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; Current Transcranial Stimulation (intensity 2 mA) will be given in anodal polarity.
2844051|NCT03640455|Experimental|Cathodal tDCS|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; Current Transcranial Stimulation (intensity 2 mA) will be given in cathodal polarity.
2844052|NCT03640442|Experimental|Modified ramped position group|In this group, induction of anesthesia will be performed in the modified ramped position.
2844053|NCT03640442|Active Comparator|Ramped position group|In this group, induction of anesthesia will be performed in the ordinary ramped position.
2844054|NCT03640416|Other|Medical residents|Rambam Health Care Campus medical residents who work nights on call. Fitbit Charge HR smartwatch
2844055|NCT03640403|Experimental|SP+PPQ|Sulfadoxine-Pyrimethamine (SP) combined with Piperaquine (PPQ), antimalarial drugs to be given every 4 months 3 rounds for the first year. A second non-interventional year will assess possible rebound effects.
2844056|NCT03640403|Active Comparator|SP+AQ|Sulfadoxine-Pyrimethamine (SP) combined Amodiaquine (AQ), antimalarial drugs to be given every 4 months 3 rounds for the first year. A second non-interventional year will assess possible rebound effects.
2844057|NCT03640403|No Intervention|Control|No intervention drugs will be given, but normal routine standard of care will be given.
2844058|NCT03640390|Experimental|Dexmedetomidine group|This group will receive dexmedetomidine infusion at a rate of 0.5 mcg/kg/hour
2844059|NCT03640390|Active Comparator|Magnesium Sulphate group|This group will receive Magnesium Sulphate infusion at a rate of 15 mg/Kg/hour
2844060|NCT03640390|Placebo Comparator|Saline group|This group will receive normal saline infusion
2844061|NCT03640377|Active Comparator|Praziquantel 40 mg/kg dose only baseline treatment|150 children will receive 40 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline
2844062|NCT03640377|Active Comparator|Praziquantel 60 mg/kg dose only baseline treatment|150 children will receive 60 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline
2844063|NCT03640377|Active Comparator|Praziquantel 40 mg/kg dose at baseline and 6 months|150 children will receive 40 mg/kg Praziquantel at baseline and again six months later.
2844064|NCT03640377|Active Comparator|Praziquantel 60 mg/kg dose at baseline and 6 months|150 children will receive 60 mg/kg Praziquantel at baseline and again six months later.
2844065|NCT03640351|Active Comparator|Preservative free diquafosol group|The subjects use preservative free diquafosol ophthalmic solution after cataract surgery
2844066|NCT03640351|Active Comparator|Preservative containing diquafosol group|The subjects use preservative containing diquafosol ophthalmic solution after cataract surgery
2844067|NCT03640351|Active Comparator|Preservative free sodium hyaluronate group|The subjects use preservative free sodium hyaluronate ophthalmic solution after cataract surgery
2844068|NCT03640338|Experimental|Cold-therapy system|Patients will receive a cold-therapy system postoperatively (Polar Care Kodiak, Breg®) and will use the system during inpatient stay and during the first 14 days post-discharge.
2844069|NCT03640338|No Intervention|Standard care (ice-pack)|
2844070|NCT03640325|Experimental|PRISM (Promoting Resilience in Stress Management)|Resilience Skills Training
2844071|NCT03640325|No Intervention|Usual Care|Usual psychosocial care (control arm, no intervention)
2844072|NCT03640312|Experimental|QUARTET LDQT|Patients randomized to the intervention arm will take a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.
2844073|NCT03640312|Active Comparator|Candesartan|Patients randomized to the comparison arm will take a once daily 8 mg candesartan.
2844074|NCT03640299|Experimental|ERAS procedure|"In this arm, ERAS perioperative cares patients planned to undergoing laparoscopic surgery, following the ERAS protocols.~Extensive preoperative counselling and education by surgeon and anesthetists.~No Bowel preparation.~6 h fast for solid food and carbohydrate loading with clear fuilds 2h before surgery.~Oral nonselective NSAIDs premedication.~Total Intravenous Anesthesia via TCI, wound infiltration and the transversus abdominis plane (TAP).~Minimally invasive surgery.~Maintenance of normothermia.~Avoidance of surgical drains and nasogastric tubes.~Nonselective NSAIDs postoperative medication.~Postoperative nausea and vomiting active control.~Early oral feeding and ambulation.~VTE prophylaxis postoperative."
2844075|NCT03640299|No Intervention|Traditional treatment procedure|"In this arm, control patients planned to undergoing laparoscopic surgery, following the traditional treatment protocols.~Conventional preoperative visits and education.~Mechanical bowel preparation.~Fasting overnight, and no fluids before surgery.~No oral nonselective NSAIDs premedication.~Continuous epidural anesthesia is administered before surgery. Sevoflurane and sufentanil maintain the depth of anesthesia.~Minimally invasive surgery.~No maintenance of normothermia.~Drainage tube insertion if needed.~Postoperative patient-controlled intravenous analgesia.~Postoperative Nausea Control if needed.~Conventional oral feeding and mobilization.~No bowel routine.~VTE prophylaxis postoperative."
2844076|NCT03640286|Active Comparator|VeSTAL - active device|"The VeSTAL device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). In the envisaged configuration, the device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current (1.0mA or less) to the skin behind the ears, over the mastoid processes.~Participants will be advised to use the device at home for 1 hour per day."
2844592|NCT03636737||experimental group|Patients with Pyoderma gangrenosum
2844077|NCT03640286|Placebo Comparator|VeSTAL - sham device|The VeSTAL sham device applies some stimulation to a user for a limited period of time to create the impression of an active device. Moreover, subjects will have been informed in the ICF that typically an initial skin tingling is felt, which then dies down. The sham stimulus is applied as a single bias DC signal. Conversely, an active device applies a positive and negative bias signal to a user, with a frequency of 0.5Hz. Participants will be advised to use the device at home for 1 hour per day.
2844078|NCT03640273|Experimental|Prapchompoothaweep|Group 1 will be received Prapchompoothaweep remedy 1,000 mg for 3 times before meals (for 6 weeks).
2844079|NCT03640273|Experimental|Loratadine|Group 2 will be received Loratadine 10 mg per day before meals (for 6 weeks)
2844080|NCT03640260|Experimental|experimental|The experiment arm will get educational leaflets to pursed-lip with diaphragmatic breathing training and oximetry level evaluation.
2844081|NCT03640260|No Intervention|controlled|
2844082|NCT03640247|Other|Narcotic group regimen|"Tylenol tablet 1000 mg by mouth every 8 hours alternating with~Ibuprofen tablet 800 mg by mouth every 8 hours~Oxycodone 5 mg by mouth every 6 hours as needed for pain, #10 tablet or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg."
2844083|NCT03640247|Active Comparator|Non-narcotic group regimen|"Tylenol tablet 1000 mg by mouth every 8 hours alternating with~Ibuprofen tablet 800 mg by mouth every 8 hours"
2844084|NCT03640221|Experimental|Experimental|will receive two bottles of Ertugliflozin 15mg tablets (active drug) and a placebo for hydrochlorothiazide.
2844085|NCT03640221|Active Comparator|Active Comparator|will receive two bottles of Placebo for ertugliflozin and hydrochlorthiazide 12.5mg capsules (active drug)
2844086|NCT03640208|Experimental|Complete colorectal screening|11 step process divided into three phases: 1. Community Outreach Event; 2. Data Collection; 3. Navigation and Program Monitoring
2844087|NCT03640195|Experimental|Experimental group|Transcutaneous nerve electrical stimulation and Auricular acupressure.
2844088|NCT03640195|No Intervention|Control group|without intervention
2844089|NCT03640182|Experimental|Management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
2844090|NCT03640169|Experimental|Management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Duo-in qigong practice.
2844091|NCT03640156|Experimental|Oxytocin (OXT) spray|Syntocinon nasal spray (product code RVG 03716) will be used to intranasally administer one single dose (24 IU) of OXT (3 puffs of 4 IU per nostril).
2844092|NCT03640156|Placebo Comparator|Placebo (PL) spray|Physiological water (a solution of sodium chloride (NaCl) in water) will be used to intranasally administer one single dose (24 IU) of PL (3 puffs of 4 IU per nostril).
2844093|NCT03640143||experimental group|children with clinical expression of lead poisoning data about venous blood lead will be reported
2844094|NCT03640130|Experimental|Single Arm|Each participant will participate in several blocks (randomized order), to evaluate performance with and without behavioral gaze-contingent text enhancements.
2844095|NCT03640104|Experimental|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
2844096|NCT03640104|Other|Nutrition Guidelines|Participants will receive general nutritional recommendations according to international standards
2844097|NCT03640091|Experimental|Pre-extractive inter-radicular implant bed preparation|
2844098|NCT03640078|Experimental|experimental group|Vasculitis patients The usual care of the sera will not be modified, only a phase of acquisition of the images will be added to the analysis of serum. (acquisition imaging)
2844099|NCT03640065|Experimental|freeze-dried probiotic sachets|
2844100|NCT03640065|Active Comparator|fermented dairy product (yogurt)|
2844101|NCT03640052|Placebo Comparator|Placebo|Placebo capsule 1 time before bedtime
2844102|NCT03640052|Active Comparator|LTM1201L|LTM1201L capsule 1 time before bedtime
2844103|NCT03640052|Active Comparator|LTM1201LN|LTM1201LN capsule 1 time before bedtime
2844104|NCT03640052|Active Comparator|LTM1201LB|LTM1201LB capsule 1 time before bedtime
2844105|NCT03640052|Active Comparator|LTM1201LD|LTM1201LD capsule 1 time before bedtime
2844106|NCT03640039|Experimental|study group: 3d strut plate fixation without post op IMMF.|Open reduction and internal fixation with 3d strut plate without post operative IMMF.
2844107|NCT03640039|Active Comparator|control group: 3d srut plate fixation with post op IMMF.|Open reduction and internal fixation with 3d strut plate with post operative IMMF for 15 days.
2844108|NCT03640026|Experimental|Tacrolimus treatment|
2844109|NCT03640013|Experimental|Hall Technique|The intervention involves removal from the primary molar and a preformed metal crown is placed using glass ionomer. The subject is then asked to bite until crown is seated. No occlusal adjustment is carried out.
2844110|NCT03640013|Other|Conventional Technique|The procedure involves administering local anesthetic and the intervention involves remoal of caries from the affected primary molar. The tooth is then reshaped and contoured to to enable a preformed metal crown placement. Occlusal and marginal fit is improved by crimping the metal crown to improve fit. The preformed metal crown is cemented with glass ionomer restorative material and occlusion finally checked. The subject is then asked to bite on a cotton roll for two minutes until the cement has set.
2844111|NCT03640000|Experimental|Determination of impedance signals|This single arm study is designed to measure impedance signals from implanted leads in different positions in the heart. Signals obtained at different pre specified position are compared to each other to determine the robustness of the acquired measurements.
2844112|NCT03639987|Experimental|Group 1|Aducanumab, intravenous infusion, every 4 weeks for up to Week 52 during the randomized treatment period. The dose will be up titrated to a desirable dose. Participants will be managed for drug continuation and suspension. Following a 4 week follow up period, eligible participants will continue to receive aducanumab, intravenous infusion, every 4 weeks for an additional 104 weeks in the long-term extension period.
2844721|NCT03635827|Placebo Comparator|Placebo|
2844113|NCT03639987|Experimental|Group 2|Aducanumab, intravenous infusion, every 4 weeks for up to Week 52 during the randomized treatment period. The dose will be titrated to a desireable dose. Participants will be managed for drug continuation and suspension. Following a 4-week follow-up period, eligible participants will continue to receive aducanumab, intravenous infusion, every 4 weeks for an additional 104 weeks in the long-term extension period.
2844114|NCT03639974|Active Comparator|PEP in a blow-bottle device|Blow-bottle device of 10cmH2O.
2844115|NCT03639974|Active Comparator|EPAP Positive airway expiratory pressure|EPAP with pressure of 10 cmH2O.
2844116|NCT03639974|Sham Comparator|conventional physiotherapy|Ventilatory exercises, bronchial hygiene techniques, exercises for upper and lower limbs (previous motor condition) stretching, orientation and walking.
2844117|NCT03639961|Experimental|Staff of facilities for intervention|Intervention: Participants have been visited three times in six months period with integrated leading, managing and governing for results model.
2844118|NCT03639961|Active Comparator|Staff of facilities for control|Intervention: Participants have been visited three times in six months period with traditional model.
2844119|NCT03639948|Experimental|Experimental: Carboplatin & Docetaxel plus Pembroluzimab|"Carboplatin (Area under the curve [AUC] 6 intravenously [IV]) and Docetaxel (75 milligrams per meter squared [mg/m2], IV) plus Pembrolizumab (200 milligrams [mg], IV) every 21 days for 6 cycles.~Pegfilgrastim 6 mg subcutaneous (SC) Day 2 of each cycle."
2844120|NCT03639935|Experimental|Rucaparib and Nivolumab|Rucaparib 600 mg PO BID days 1-28 Nivolumab 240 mg IV days 1 and 15
2844121|NCT03639922|Active Comparator|Imatinib|Imatinib 400mg (2 tablets of 400mg) per day for 6 days
2844122|NCT03639922|Placebo Comparator|Placebo|2 placebo tablets per day for 6 days
2844123|NCT03639909||MSA-P|Patients with multiple systeme atrophy (MSA) with predominant parkinsonism (MSA-P) had evaluation of cardiovascular function and sweating function
2844124|NCT03639909||PD patients|Parkinson's disease (PD) patients had evaluation of cardiovascular function and sweating function
2844125|NCT03639896||Cognitive impairment|After the neuropsychological tests performed at the day before the surgery, the 3rd and 7th day after the surgery respectively, the difference(ΔX) and the standard deviation(SD) between the score was calculated and CAM-ICU was assessed. The cognitive impairment group was defined if the patients developed the postoperative delirium(e.g. confused, agitated, drowsiness, disorientated, delirious) or cognition dysfunction(absolute value of ΔX / SD ≥1.96).
2844126|NCT03639896||Cognitive normal|After the neuropsychological tests performed at the day before the surgery, the 3rd and 7th day after the surgery respectively, the difference(ΔX) and the standard deviation(SD) between the score was calculated and CAM-ICU was assessed. The cognitive normal group was defined if no postoperative delirium(e.g. confused, agitated, drowsiness, disorientated, delirious) or cognition dysfunction(absolute value of ΔX / SD ≥1.96) was developed.
2844127|NCT03639883|Placebo Comparator|0.033% versus Vehicle|One side of the subject will receive 0.033% AIV001 and the other side of the subject will receive vehicle.
2844128|NCT03639883|Placebo Comparator|0.1% versus Vehicle|One side of the subject will receive 0.1% AIV001 and the other side of the subject will receive vehicle.
2844129|NCT03639883|Placebo Comparator|0.3% versus Vehicle|One side of the subject will receive 0.3% AIV001 and the other side of the subject will receive vehicle.
2844130|NCT03639883|Placebo Comparator|1% versus Vehicle|One side of the subject will receive 1% AIV001 and the other side of the subject will receive vehicle.
2844131|NCT03639870|Experimental|Implant Group|Qualified eyes with refractory glaucoma will be implanted unilaterally with the Glaukos® Trabecular Micro-Bypass System Model iS3 (three G2-W stents per study eye), and will be followed through 12 months postoperative.
2844132|NCT03639857|Experimental|532nm laser and topical corticosteroid|532nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.
2844133|NCT03639857|Experimental|1064nm laser and topical corticosteroid|1064nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.
2844134|NCT03639857|Active Comparator|Topical corticosteroid alone|Topical corticosteroid is applied to the patient's lesion.
2844135|NCT03639831|Experimental|Active group|Proprietary, standardized botanical extract
2844136|NCT03639831|Placebo Comparator|Placebo group|Placebo (maltodextrin)
2844137|NCT03639818|Experimental|experimental group|HIV patients
2844138|NCT03639805|Active Comparator|non interventional arm|Standard Of Care
2844139|NCT03639805|Experimental|interventional arm|Standard of Care + music therapy program MUSIC CARE®
2844140|NCT03639779|Experimental|Sodium thiosulfate|50 ml vials of sodium thiosulfate (250mg/ml) will be used for treatment.
2844141|NCT03639779|Placebo Comparator|Saline solution|30 ml vials of sodium chloride 0.9% will be used for the control treatment.
2844142|NCT03639766|Experimental|Abobotulinum toxin A|Injection of 300 units of abobotulinum toxin A in 10 ml of non-bacteriostatic normal saline to chosen hand.
2844143|NCT03639766|Placebo Comparator|Saline solution|Injection of 10 ml of non-bacteriostatic normal saline to chosen hand.
2844144|NCT03639753|Experimental|Parent-Teen Intervention|Parent health coaching session and supportive materials, teen on road driver assessment with feedback.
2844145|NCT03639753|Other|Usual Practice|
2844146|NCT03639740|Other|Secukinumab 150 mg, 300 mg or TNF-inhibitor|Patients start treatment with sc. inj. secukinumab 150 mg every week for four weeks (induction phase) and thereafter sc. inj. secukinumab 150 mg monthly. Treatment effect is assessed at week 16, 24, 40 and 56. Patients in clinical remission defined as ASDAS remission (i.e. ASDAS<1.3) continue treatment with secukinumab 150 mg monthly. Patients who are not in clinical remission increase secukinumab dose to 300 mg monthly. If this is not sufficient to achieve clinical remisison in 8 weeks, they change treatment a ccording to available guidelines from the Danish Medicine Council, Danish Regions (Medicinrådet, Danske Regioner).
2844147|NCT03639727|Active Comparator|Citric acid aerosol bronchial challenge|Inhaled citric acid aerosol. This study investigates the diagnostic accuracy of two cough provocation tests, one of which is citric acid aerosol challenge.
2844148|NCT03639727|Active Comparator|Mannitol aerosol bronchial challenge|Inhaled mannitol aerosol. This study investigates the diagnostic accuracy of two cough provocation tests, one of which is mannitol aerosol challenge.
2844149|NCT03639714|Experimental|Phase 1|"GRT-C901~GRT-R902~nivolumab~ipilimumab"
2844150|NCT03639714|Experimental|Phase 2 Cohorts|"GRT-C901~GRT-R902~nivolumab~ipilimumab"
2844151|NCT03639701|Experimental|Open label thymidine and deoxycytidine|All patients will receive open label thymidine and deoxycytidine
2844152|NCT03639688|Active Comparator|Left sided|
2844153|NCT03639688|Active Comparator|Right sided|
2844154|NCT03639675|Experimental|NVG patients|Japanese patients with neovascular glaucoma
2844155|NCT03639662|Experimental|experimental group|"Patients benefit from additional support consisting of at least 3 sessions of sophrology (sophrology sessions), one per week, from the week following the announcement of the diagnosis and until the week preceding the hospitalization for iratherapie. It will be group sessions, 1h carried out in the participating center by a nurse sophrologist who will use the techniques of sophrology such as relaxation, breath control, mastery of thoughts and visualization. Each session will be recorded in digital format and the recording will be given to the patient at the end of the session so that he can, if he wishes, reproduce it at home.~Patients will also be able to share their feelings and ask questions"
2844156|NCT03639662|No Intervention|control group|Between the announcement of their thyroid cancer and the post-therapeutic scintigraphy, the patients will follow the usual route: information on the management, receipt of an information booklet (containing the telephone contacts of the hospital units), and they wish it, meet with the staff and visit a room of hospitalization. The nurses of the hospitalization service are available to answer any questions they may have, either during this visit or during a telephone call
2844157|NCT03639649|Experimental|STHLM3|
2844158|NCT03639649|Active Comparator|PSA|
2844159|NCT03639636|Other|interventional prospective study|nonsurgical periodontal therapy(scaling and root planing) surgical therapy( flap surgery)
2844160|NCT03639623|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium tablet once daily in the morning 60 minutes before breakfast
2844161|NCT03639610|Experimental|Single arm|Melflufen 40 mg iv Day 1 of each 28 day cycle Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle. If > 75 years of age 20 mg.
2844162|NCT03639597|Experimental|Study device|VytronUS Ablation System
2844163|NCT03639584||Group 1|Patients admitted to ICU less than 48 hours and the anticipated stay is less than 5 days. Take blood sample on the day of enrollment.
2844164|NCT03639584||Group 2|Patients admitted to ICU less than 48 hours and the anticipated stay is longer than 5 days. Take blood sample on the day of enrollment, 7th, 14th, 21st, and 28th. Stop blood sample once exit.
2844165|NCT03639584||Group 3|Patients admitted to ICU 3~7 days. Take blood sample on the day of enrollment.
2844166|NCT03639584||Group 4|Patients admitted to ICU 8~14 days. Take blood sample on the day of enrollment.
2844167|NCT03639584||Group 5|Patients admitted to ICU 15~28 days. Take blood sample on the day of enrollment.
2844168|NCT03639571|Experimental|Test|Ibuprofen 200mg TEPI medicated plaster
2844169|NCT03639571|Placebo Comparator|Placebo|Placebo TEPI Plaster
2844170|NCT03639558|Active Comparator|Haloperidol + Promethazine + Chlorpromazine|
2844171|NCT03639558|Experimental|Haloperidol + Promethazine|
2844172|NCT03639545|Active Comparator|*empagliflozin*|empagliflozin 25 mg daily for 12 weeks, once daily, by mouth
2844173|NCT03639545|Active Comparator|*metformin*|metformin 2000 mg daily for 12 weeks, once daily, by mouth
2844174|NCT03639545|Active Comparator|*empagliflozin/metformin*|empagliflozin 25 mg daily and metformin 2000 mg daily for 12 weeks, by mouth
2844175|NCT03639545|Placebo Comparator|*placebo*|placebo for 12 weeks, once daily with water, by mouth
2844176|NCT03639532|Experimental|COC|for the arthritic hip of the patient, total hip arthroplasty(THA) with ceramic on ceramic(COC) bearing couple is implanted. The group with intervention COC THA.
2844177|NCT03639532|Active Comparator|COP|for the arthritic hip of the patient, total hip arthroplasty(THA) with ceramic on highly cross-linked polyethylene bearing couple is implanted. The group with intervention COP THA.
2844178|NCT03639519|Experimental|Ascorbic acid|Patients will take 2 g orally ascorbic acid effervescent tablets the night before cardiac surgery, then 1 g twice daily for 5 days after surgery in addition to their traditional medical care.
2844179|NCT03639519|Placebo Comparator|Placebo group|will not be given ascorbic acid , instead a placebo will be used, and will be given the rest of traditional medical care provided to the first arm. Inflammatory markers (CRP, ESR and differential TLC), serum urea and creatinine, ALT, AST, CK-mb, CK-Total, aPTT, INR, Hemoglobin, platelet count, will be assessed on day 0, 1,2,4,6 postoperative in both arms.
2844180|NCT03639506|Experimental|autologous mitochondria transplantation|inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)
2844181|NCT03639506|Active Comparator|ICSI|only has intracytoplasmic sperm injection (ICSI)
2844182|NCT03639493|Experimental|Sequence 1|"Period 1: receive Exforge® tab 10/160mg, Crestor® tab 20mg~Period 2: receive CJ-30060 10/160/20mg"
2844183|NCT03639493|Experimental|Sequence 2|"Period 1: receive CJ-30060 10/160/20mg~Period 2: receive Exforge® tab 10/160mg, Crestor® tab 20mg"
2844184|NCT03639480|Experimental|Test|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
2844185|NCT03639480|Active Comparator|Reference 1|Amlodipine 10mg+Valsartan 160mg
2844186|NCT03639480|Active Comparator|Reference 2|Valsartan 160mg+Atorvastatin 40mg
2844187|NCT03639467|Experimental|Anlotinib plus gemcitabine/cisplatin|"In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first."
2844188|NCT03639454|Experimental|Dry needling|In this arm, the subjects will receive the intervention of DN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
2844189|NCT03639454|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
2844190|NCT03639441|Experimental|Dry needling|In this arm, the subjects will receive the intervention of DN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
2844191|NCT03639441|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
2844192|NCT03639428||6 - 23 months|8 infants between 6 and 23 months received a single 0.3mg/kg midazolam dose of ADV6209
2844193|NCT03639428||2-11 years|17 children between 2 and 11 years received a single 0.3mg/kg midazolam dose of ADV6209
2844194|NCT03639428||12-17 years|12 adolescents between 12 and 17 years received a single 0.3mg/kg midazolam dose of ADV6209
2844195|NCT03639415|Experimental|controlled-release oxycodone group|"Patients with moderate to severe pain accept CR oxycodone treatment and if any follow situations appears, then change the dose frequency from every 12 hours to every 8 hours or 6 hours.~Patients are satisfied with the pain control, but unable to tolerate nausea、vomit or dizziness, and can't get satisfactory pain control if reducing the CR oxycodone dose.~Patients are unsatisfied with the pain control, but can't increase the CR oxycodone dose because of intolerable nausea、vomit or dizziness."
2844196|NCT03639402|Experimental|Health education classes|"Intervention consist of 2 rounds. Round 1: Locally selected mothers who have children 1-9 years old are trained by research team (peer mothers). Peer mothers conduct 4 education classes each for approximately 10 eligible mothers in their neighbourhood (fellow mothers).~Round 2: After one month gap one meeting for recapitulation and feedback is conducted by research team for peer mothers. Similarly, peer mothers conduct one meeting with fellow mothers."
2844197|NCT03639402|No Intervention|No health education classes|Community is exposed to health-related information, which is provided by the regular health system of Nepal
2844198|NCT03639389|Active Comparator|Analgesics, multimodal|Combination of paracetamol, non-steroidal anti-inflammatory drug and morphine as analgesics
2844199|NCT03639389|Experimental|Bupivacaine|Spinal anesthetic with bupivacain + fentanyl/sufentanil
2844200|NCT03639376||Passive smoking-exposed children|This group consists of children whose family members have smoked at home since the birth of the child.
2844201|NCT03639376||Passive smoking-unexposed children|This group consists of children whose family members have not smoked at home since the birth of the child.
2844202|NCT03639363|Experimental|Intervention Arm|daily bathing with 4% chlorhexidine gluconate soap-like solution followed by water rinsing
2844203|NCT03639363|Active Comparator|Control Arm|daily bathing with standard soap
2844204|NCT03639350|Experimental|IER+MED group|The IER+MED group intervention will be to restrict 70% energy (34%, 33% and 33% distribution of protein, carbohydrate, and fat, respectively) on 2 days and follow the MED diet (25%, 45%, 30%) and meet their estimated energy requirement (EER) for the other 5 days each week. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
2844205|NCT03639350|Active Comparator|DASH group|The DASH group intervention will be to follow the DASH diet and meeting a distribution of macronutrients of 20% protein, 53% carbohydrate, and 30% fat and meet their EER. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
2844206|NCT03639337|Experimental|Allergic Children|"Allergic children to milk or egg, aged between 10 and 14 months, confirmed by double-blind oral provocation test against placebo.~Intervention: 30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63"
2844207|NCT03639337|No Intervention|Not confirmed Allergic Children|Sensible children to milk or egg, aged between 10 and 14 months, not confirmed by double-blind oral provocation test against placebo.
2844208|NCT03639337|No Intervention|Controls|Healthy controls ages between 10 and 14 months
2844209|NCT03639324|Experimental|Rituximab, Idelalisib, & Venetoclax|Idelalisib 50, 100, or 150 mg PO BID; venetoclax 100 or 200 mg daily; rituximab per standard of care during the lead-in phase and then 500 mg/m2 IV every 4 weeks x 6 doses during the treatment phase
2844210|NCT03639311|Experimental|Subjects receiving Injection CAB LA plus RPV LA|The eligible subjects in the arm (subjects from LATTE, who were administered oral CAB 30 mg plus RPV 25 mg, who successfully complete Week 300) will receive their first dose CAB LA (600 mg) plus RPV LA (900 mg) injections within 2 hours of the final oral dose of LATTE given on the same day. The second loading injections will be administered 1 month after initial loading dose (CAB LA 600 mg plus RPV LA 900 mg), with subsequent injections (CAB LA 600 mg + RPV LA 900 mg) occurring Q2M thereafter. Subjects will continue to receive the treatment until the study intervention is locally approved and commercially available. HAART therapy will be initiated within 8 weeks after the last Q2M injection.
2844211|NCT03639311|Experimental|Subjects receiving Oral DTG plus RPV|The eligible subjects in the arm (subjects from LATTE, who were administered oral CAB 30 mg plus RPV 25 mg, who successfully complete Week 300) will receive their first dose of the DTG 50 mg plus RPV 25 mg, once daily as oral regimen on Day 1 until Month 12. Subjects will continue to receive the treatment until the study intervention is locally approved and commercially available.
2844212|NCT03639298|Experimental|training|children submitted to the Intendu training with motion based cognitive video games software
2844213|NCT03639298|No Intervention|no training|children not submitted to the training, entering the study as a control group
2844214|NCT03639259||Post-stroke fatigue|Participants fulfilling criteria for presence of fatigue after cerebral stroke
2844215|NCT03639246|Experimental|Phase 1b: AVB-S6-500+PLD|
2844216|NCT03639246|Experimental|Phase 1b: AVB-S6-500+Pac|
2844217|NCT03639246|Experimental|Phase 2: AVB-S6-500+PLD|
2844218|NCT03639246|Experimental|Phase 2: AVB-S6-500+Pac|
2844219|NCT03639246|Active Comparator|Phase 2: Placebo+PLD|
2844220|NCT03639246|Active Comparator|Phase 2: Placebo+Pac|
2844221|NCT03639233|Other|Arm 1|Intervention access
2844222|NCT03639220|Active Comparator|Photobiomodulation Therapy (PBMT) active|Participants received active PBMT
2844223|NCT03639220|Placebo Comparator|Photobiomodulation Therapy (PBMT) placebo|Participants received placebo PBMT
2844224|NCT03639207||1|Patients treated with ledipasvir/sofosbuvir in the Kaiser Permanente Northern California
2844588|NCT03636750|Experimental|HB002.1T 8mg/kg|Participants received a 8mg/kg dose of HB002.1T via intravenous injection.
2844225|NCT03639194|Experimental|Part A: SC-011 Dose Escalation|SC-011 via intravenous administration at various doses and dosing regimens until the maximum tolerated dose and/or the recommended Part B dose(s) is declared.
2844226|NCT03639194|Experimental|Part B: SC-011 Dose Expansion|SC-011 via intravenous administration at dose regimen(s) that will not exceed the maximum tolerated dose determined in Part A.
2844227|NCT03639194|Experimental|Part C: SC-011 + ABBV-181 Escalation and Expansion|SC-011 via intravenous administration at various doses and dosing regimens starting at least 1 dose level below the recommended single-agent dose of SC-011 for Part B plus ABBV-181 via intravenous administration at fixed doses and various dosing regimens.
2844228|NCT03639181|Experimental|GB226 3mg/kg every 2 weeks|GB226 3mg/kg every 2 weeks
2844229|NCT03639168|Experimental|Chidamide combined with Cisplatin|Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 25mg/m2 ivgtt D1-3 Chidamide :20mg PO Biw, 2 week on , 1 week off
2844230|NCT03639155|Experimental|Regimen A|vadadustat reference tablets
2844231|NCT03639155|Experimental|Regimen B|vadadustat test tablets
2844232|NCT03639142|Experimental|Plum group|Children will receive plums at dose 3,5g/kg/d as an oral treatment for constipation.
2844233|NCT03639142|Active Comparator|Polyethylene glycol group|Children will receive PEG at dose 0,5g/kg/d as an oral treatment for constipation.
2844234|NCT03639129|Experimental|Contrast-enhanced mammography (CME)|-Patients who meet eligibility criteria and consent to participate in this study will complete a CEM examination prior to or on the day that biopsy is scheduled. CEM must occur no later than 60 days after the diagnostic mammogram. The standard of care biopsy must occur no later than 30 days after CEM.
2844235|NCT03639116|Experimental|Stroke|This study will attempt to induce bi-directional plasticity in corticospinal-motoneuronal synapses serving an intrinsic hand muscle of the hemiparetic limb using stimulation. Individuals who are at least 6 months post first-ever subcortical stroke and have at least partial range of motion of the paretic index finger will be recruited to participate.
2844236|NCT03639116|Placebo Comparator|Control|Control experiments will be completed to provide evidence of the neurophysiological mechanism(s) mediating the effect and to examine behavioral effects of stimulation. Individuals without a history of stroke will be recruited to participate.
2844237|NCT03639077|Experimental|Allograft bone alone|
2844238|NCT03639077|Experimental|Allograft and xenograft mixture|
2844239|NCT03639064|Experimental|CanniMed® Oil 1:20 formulation|∆9-THC: 1.0 mg/mL; CBD: 20.0 mg/mL
2844240|NCT03639064|Experimental|CanniMed® Oil 10:10 formulation|∆9-THC: 9.8 mg/mL; CBD: 9.9 mg/mL
2844241|NCT03639064|Experimental|CanniMed® Oil 18:0 formulation|∆9-THC: 18.3 mg/mL; CBD: 0.2 mg/mL
2844242|NCT03639051|Experimental|Active Treatment|Target Lung Denervation (TLD) with the Nuvaira Lung Denervation System (RF energy delivered) and optimal medical care for COPD.
2844243|NCT03639051|Sham Comparator|Sham Control|Sham Targeted Lung Denervation (TLD) procedure with the Nuvaira Lung Denervation System (catheter placement and balloon deployment in all treatment locations, no RF energy delivered) and optimal medical care for COPD.
2844244|NCT03639038||Blood Assay Phase - 1|TB Positive / HIV Positive: 65 participants
2844245|NCT03639038||Blood Assay Phase - 2|TB positive / HIV Negative: 65 participants
2844246|NCT03639038||Blood Assay Phase - 3|TB positive and negative Paediatric: 30 participants
2844247|NCT03639038||Blood Assay Phase - 4|TB Negative/HIV positive: 50 participants
2844248|NCT03639038||Blood Assay Phase - 5|Healthy controls: 30 participants
2844249|NCT03639038||Sputum Collection Phase - 1|TB Positive: Xpert Rif sensitive: 100 participants
2844250|NCT03639038||Sputum Collection Phase - 2|TB Positive: Xpert Rif resistant: 20
2844251|NCT03639038||Sputum Collection Phase - 3|TB Negative: Other chest: unknown number
2844252|NCT03639038||Sputum Collection Phase - 4|TB Negative: Smear negative/Xpert negative: 20
2844253|NCT03639012|Active Comparator|Carbohydrate loading|Patients to receive an oral preoperative carbohydrate drink
2844254|NCT03639012|No Intervention|No Carbohydrate loading|Current standard of care
2844255|NCT03638999|Active Comparator|Intervention Group - Ketorlac (NSAID)|Subjects will receive a one-time intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure. After consent and during screening visit demographic information, medical/surgical history, and height and weight will be collected. On Day 0 subject will be randomized to NSAID or Saline using inclusion/exclusion criteria and the procedure data will be collected. On Day 1 subject will receive a follow up phone call and complete AUA Symptom Score, USS Questionnaire 1 and USS Questionnaire 2 and any adverse events will be assessed. These questionnaires will again be administered on the day of stent removal and again 1 to 2 months post stent removal.
2844256|NCT03638999|Placebo Comparator|Placebo Group - Normal Saline|Subjects in the control group will receive a one-time 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure. After consent and during screening visit demographic information, medical/surgical history, and height and weight will be collected. On Day 0 subject will be randomized to NSAID or Saline using inclusion/exclusion criteria and the procedure data will be collected. On Day 1 subject will receive a follow up phone call and complete AUA Symptom Score, USS Questionnaire 1 and USS Questionnaire 2 and any adverse events will be assessed. These questionnaires will again be administered on the day of stent removal and again 1 to 2 months post stent removal.
2844257|NCT03638986||Swiss version first|This group will first complete the Swiss version and second the German version of the TFI
2844258|NCT03638986||German version first|This group will first complete the German version and second the Swiss version of the TFI
2844259|NCT03638973|Experimental|Er: YAG biopsy|Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser under previous local anesthesia
2844260|NCT03638973|Active Comparator|Scalpel biopsy|Biopsies taken with Er: YAG are compared with biopsies taken with a scalpel in patients with lichenoid or leukoplakic changes of the oral mucosa.
2844261|NCT03638960|Active Comparator|Bupivacaine|Patients in group A will receive a bolus injection with 20 mL of 0.5% bupivacaine.
2844262|NCT03638960|Experimental|Liposomal bupivacaine|Group B will receive 10 mL of 133 mg of liposomal bupivacaine mixed with 10 mL 0.5% bupivacaine.
2844263|NCT03638947|No Intervention|Standard of Care|Patient will receive by mail a kit containing swab for the nares, armpit and groin.
2844264|NCT03638947|Active Comparator|Swab kit plus povidone-iodine soap|Patient will receive by mail a kit containing swab for the nares, armpit and groin. In addition the patient will receive decolonization treatment including povidone-iodine soap for presurgical cleansing two days prior to surgery.
2844265|NCT03638934|Experimental|Videos about ACP|Subjects in experimental group get three videos about advanced care planning based on Smart Management Strategy for Health (SMASH). After they finish watching the materials, they fill out the questionnaire.
2844266|NCT03638934|Active Comparator|Brochure for Life-Sustaining Treatment|Subjects in the group get 13-page brochure entitled, Understanding the Life-Sustaining Treatment Act. After they finish watching the materials, they fill out the questionnaire.
2844267|NCT03638921|Experimental|MEOPA|Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
2844268|NCT03638908|Other|Fluoxetine|"18 patients will be receiving fluoxetine . Dosing will be~Week 1-4: 20 mg daily~Week 5-8: 40 mg daily~Week 9-12: 60 mg daily~Week 13-24: 80 mg daily"
2844269|NCT03638895|Active Comparator|ECAL group|Intervention group (ECAL) - practitioners and participants receive measured energy information from ECAL indirect calorimeter including resting energy expenditure and respiratory quotient to diagnose, manage and advise on modification of caloric restriction and physical activity level. Energy information also allows participant and practitioner to monitor and compare changes to their metabolic health throughout the duration of intervention.
2844270|NCT03638895|Placebo Comparator|SC group|Standard care (SC) - participants receive standard care (diet, exercise & behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
2844271|NCT03638882|Experimental|Duolingo Spanish Course|30 minutes each day, 5 days a week for 16 weeks. Total of 40 hours.
2844272|NCT03638882|Active Comparator|BrainHQ|30 minutes each day, 5 days a week for 16 weeks. Total of 40 hours.
2844273|NCT03638882|Placebo Comparator|Passive Control|No intervention.
2844274|NCT03638869|Placebo Comparator|Arm 1|100 mL Ocean Spray® Diet Cranberry Juice
2844275|NCT03638869|Experimental|Arm 2|REL-1017 25 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
2844276|NCT03638869|Experimental|Arm 3|REL-1017 50 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
2844277|NCT03638869|Experimental|Arm 4|REL-1017 75 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
2844278|NCT03638856|Experimental|Misoprostal group|Patients were added oral Misoprostal 200 mcg 2 tab per oral 3 hour before hysteroscopy
2844279|NCT03638856|No Intervention|Placebo group|Patients were take placebo 2 tab per oral 3 hour before hysteroscopy
2844280|NCT03638843|Experimental|Gastric mucosal devitalization arm|Patients will be enrolled in the study after being scheduled to undergo vertical sleeve gastrectomy as part of routine clinical care, and the gastric mucosal devitalization procedure will be performed in-vivo utilizing Argon plasma coagulation three days before the operation.
2844281|NCT03638830|Experimental|Group 1|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)1/2 dose + placebo+ Maxipime®"
2844282|NCT03638830|Experimental|Group 2|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation) full dose + Maxipime®"
2844283|NCT03638830|Placebo Comparator|Group 3|placebo (like full dose) in combination with the drug Maxipime®
2844284|NCT03638817|Experimental|Eltrombopag|
2844285|NCT03638804|Experimental|89Zr-KN035 injection|
2844286|NCT03638791||Healthy controls|Matched Controls without treatment
2844287|NCT03638791||OCD with washing compulsion|Exposure and response inhibition
2844288|NCT03638791||OCD without washing compulsion|Exposure and response inhibition
2844289|NCT03638778|Active Comparator|Oral semaglutide (reference)|Participants will receive oral semaglutide (reference) for 10 days.
2844290|NCT03638778|Experimental|Oral semaglutide formulation B|Participants will receive oral semaglutide formulation B for 10 days.
2844291|NCT03638778|Experimental|Oral semaglutide formulation C|Participants will receive oral semaglutide formulation C for 10 days.
2844292|NCT03638778|Experimental|Oral semaglutide formulation D|Participants will receive oral semaglutide formulation D for 10 days.
2844293|NCT03638765|Experimental|Experimental Treatment|Intratumoral injection of activated, autologous dendritic cells (DCVax-Direct) in brain metastases from lung cancer or breast cancer
2844294|NCT03638752|Experimental|Comprehensive education group|"The details of Comprehensive education are as follows:~introduce the purpose, method and function of breathing training and the whole process of gastroscopy;~instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,~provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,~inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,~inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting."
2844295|NCT03638752|No Intervention|standard education|"The details of standard education are as follows:~inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~inform patients that there would be some normal physiological reaction when gastroscopy, such as the throat discomfort and nausea/vomiting."
2844296|NCT03638739|Experimental|Exercise|Participants will engage in supervised, twice-weekly exercise following the Physical Activity Guidelines for Adults with MS for 12 weeks at McMaster University. Following this, they will return to their normal daily activities for a further 12 weeks.
2844433|NCT03637764|Experimental|Phase2-Cohort C: EOC|Isatuximab and atezolizumab combination: Isatuximab dose determined in Phase 1 part of study and atezolizumab predefined dose Q3W
2973426|NCT02741180|Other|Healthy Control|
2844297|NCT03638739|Experimental|Wait-list Control|Participants will engage in their usual daily activities for the first 12 weeks of the study, then will engage in supervised, twice-weekly exercise following the Physical Activity Guidelines for Adults with MS at McMaster University for the 2nd 12 weeks.
2844298|NCT03638726|Experimental|Atropine sulfate and Epinephrine|Perioperative pupil dilation is achieved by combined use of subconjunctival Atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral Epinephrine 1:100000 ( sympathetic agonist).
2844299|NCT03638726|Other|Topical cyclopentolate and phenylephrine|Preoperative pupil dilation was achieved using topical cyclopentolate and phenylephrine.
2844300|NCT03638713|Experimental|colonoscopy first group|Patients received water-exchange colonoscopy first and followed by esophagogastroduodenoscopy(EGD)
2844301|NCT03638713|Active Comparator|EGD first group|Patients received esophagogastroduodenoscopy(EGD) first and followed by water-exchange colonoscopy
2844302|NCT03638700|Active Comparator|guidewire type 1: VisiGlide™ angled tip|Primary use of VisiGlide™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (straight tip) resp. to VisiGlid2e™ (tip according to the examiner)
2844303|NCT03638700|Active Comparator|guidewire type 2: VisiGlide2™ angled tip|Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide™ (tip according to the examiner)
2844304|NCT03638700|Active Comparator|guidewire type 1: VisiGlide™ straight tip|Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)
2844305|NCT03638700|Active Comparator|guidewire type 2: VisiGlide2™ straight tip|Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide™ (tip according to the examiner)
2844306|NCT03638687||History, Yes PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
2844307|NCT03638687||No History, No PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
2844308|NCT03638687||History, No PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
2844309|NCT03638687||No History, Yes PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
2844310|NCT03638674|Active Comparator|2nd lumbar spine acquisition in same position|spine and hip STRATOS DR + 2nd lumbar spine acquisition in same position (with template)
2844311|NCT03638674|Active Comparator|2nd lumbar spine acquisition|spine and hip STRATOS DR + 2nd lumbar spine acquisition (no template)
2844312|NCT03638674|Active Comparator|2nd hip acquisition in same position|spine and hip STRATOS DR + 2nd hip acquisition in same position (with template)
2844313|NCT03638674|Active Comparator|2nd hip acquisition|spine and hip STRATOS DR + 2nd hip acquisition (without template)
2844314|NCT03638661|Experimental|n-3 fatty acid enriched formula|"Those assigned to the n3EN group received vegetable n-3 fatty acid enriched formula by tube feeding (product; Yonsei Dairy Co., Seoul, South Korea).~vegetable (canola, flaxseed) derived n-3 fatty acid"
2844315|NCT03638661|Placebo Comparator|soybean oil used formula|"Patients assigned to the control group received a soybean used formula by tube feeding.~soybean used formula"
2844316|NCT03638648|Active Comparator|RS<26 Capecitabine|Patients after neoadjuvant chemotherapy evaluated as non-pCR have 21 gene test based recurrence score <26 receiving capecitabine.
2844317|NCT03638648|No Intervention|RS<26 control|Patients after neoadjuvant chemotherapy evaluated as non-pCR have 21 gene test based recurrence score <26 NOT receiving any additional chemotherapy.
2844318|NCT03638648|Experimental|RS≥26 Capecitabine|Patients after neoadjuvant chemotherapy evaluated as non-pCR have 21 gene test based recurrence score ≥26 receiving capecitabine.
2844319|NCT03638648|No Intervention|RS≥26 control|Patients after neoadjuvant chemotherapy evaluated as non-pCR have 21 gene test based recurrence score ≥26 NOT receiving any additional chemotherapy.
2844320|NCT03638635|Active Comparator|Standard Bupivacaine|Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
2844321|NCT03638635|Experimental|Bupivacaine Liposome|Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
2844322|NCT03638622|Experimental|Treatment|"aminolevulinic acid and photodynamic therapy~Patients receive aminolevulinic acid orally with orange juice in 3 fractions at 0,1,2 hours before undergoing photodynamic therapy using LED based Device on day one."
2844323|NCT03638609|No Intervention|Control|Group of patients not receiving IABP
2844324|NCT03638609|Experimental|Intra Aortic Balloon Pump|Group of patients receiving Intra Aortic Balloon Pump in 3 hours after ROSC (early insertion of IABP)
2844325|NCT03638596|Experimental|Contingency Management|Incentive delivery contingent upon maintaining transdermal alcohol concentration below cut-off
2844326|NCT03638596|Placebo Comparator|Control|Incentive delivery not contingent on transdermal alcohol concentration
2844327|NCT03638570|Experimental|Stroke|This study will attempt to induce bi-directional plasticity in corticospinal-motoneuronal synapses serving an intrinsic hand muscle of the hemiparetic limb using stimulation. Individuals who are at least 6 months post first-ever subcortical stroke and have at least partial range of motion of the paretic index finger will be recruited to participate.
2844434|NCT03637764|Experimental|Phase2-Cohort D-1:GBM|Isatuximab and atezolizumab combination: Isatuximab dose determined in Phase 1 part of study and atezolizumab predefined dose Q3W
2844328|NCT03638570|Placebo Comparator|Control|Control experiments will be completed to provide evidence of the neurophysiological mechanism(s) mediating the effect and to examine behavioral effects of stimulation. Individuals without a history of stroke will be recruited to participate.
2844329|NCT03638557|Experimental|Intervention|"The intervention package consists of the following;~Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
2844330|NCT03638544|Active Comparator|Reduced Gluten-Normal Gluten|
2844331|NCT03638544|Active Comparator|Normal Gluten-Reduced Gluten|
2844332|NCT03638531|Experimental|Anodal tDCS|Anodal tDCS will be applied in nine experimental sessions over a 2-week period.
2844333|NCT03638531|Sham Comparator|SHAM tDCS|SHAM tDCS will be applied in nine experimental sessions over a 2-week period.
2844334|NCT03638518|Experimental|Acupuncture|"In the acupuncture experimental group, the technique applied included the use of the following acupuncture points of Traditional Chinesse Medicine: GV20, ST36 and BL60 . One needle insertion was performed in each session and in the case of the last two points the needle insertions were done bilaterally.~Patients laid supine on a treatment table with their legs exposed. The skin on the acupuncture points was prepared with 70% ethyl alcohol. One-time-use disposable sterile stainless steel needles (0,26x50mm) were inserted into acupuncture points.~After insertion, acupuncture needles were manually manipulated to obtain the de qi sensation. The needles remained in place for 20 minutes and there were no further manipulations during the retention time."
2844335|NCT03638518|Experimental|Physiotherapy|The physiotherapy experimental group received core stability based physiotherapy treatment. Before the beginning of the treatment sessions, the basic principles of core stability exercises were explained to the participants. The exercise programme included 7 exercises. The exercises in the crook lying position were core activation with breathing, single leg lift with knees bent, single leg slides, bridging and knee drop sideways. The exercises completed in side lying included hip external rotation with knees bent and hip abduction with knees straight. After each session gentle stretching of the lower limbs and lumbar spine were performed. The sessions were administered twice a week during 30 minutes with groups of no more than 8 people.
2844336|NCT03638518|No Intervention|control|The control group did not receive any intervention. The participants continued with their routine medical treatment.
2844337|NCT03638505||patients|patients with Progressive supranuclear palsy. PSP-QoL will be performed in this group
2844338|NCT03638505||caregiver|the caregiver of the patient with Progressive supranuclear palsy PSP-QoL will be performed in this group
2844339|NCT03638492|Active Comparator|2 cm margin of excision|Patients with CMM >2 mm treated with an excision of 2-cm.
2844340|NCT03638492|Active Comparator|4 cm margin of excision|Patients with CMM >2 mm treated with an excision of 4-cm.
2844341|NCT03638479||Parkinson's Disease|Participant's diagnosed with Parkinson's Disease
2844342|NCT03638479||Essential Tremor|Participant's diagnosed with Essential Tremor
2844343|NCT03638479||No Parkinson's Disease and No Essential Tremor|Participant's with no diagnosis of PD or ET
2844344|NCT03638466|Experimental|Single dose of SPN-810|Subjects will be treated with medium dose of SPN-810
2844345|NCT03638466|Placebo Comparator|Placebo|Subjects will be treated with a matching Placebo
2844346|NCT03638453|Experimental|PediCARE|"PediCARE Administered x6 mos~Resource Provision: Monthly Groceries (delivery via Instacart)~Resource Provision: Transport to/from home/hospital 4x per month (Uber/Lyft via RideHealth)"
2844347|NCT03638453|Active Comparator|Usual Care|The control group will receive usual supportive care
2844348|NCT03638427||High Risk HPV Positive Cohort|This group of women have tested positive for HR-HPV at annual cervical cancer screening and have been invited to participate in the study. They will be asked to use a menstrual pad we provide that collects a sample of their menstrual blood (strip). The strip will be mailed back to us for analysis (Menstrual Blood Analysis). These women will also be asked to conduct a self-swab vaginally to be sent back to us for analysis. These women will return 6-months after their positive HR-HPV for standard of care testing. All results of the standard of care tests, menstrual blood tests, and self-swab tests will be compared.
2844349|NCT03638414|Experimental|Group 1 - Interventional Treatment|This group will be given the ePainQ questionnaire and an interview.
2844350|NCT03638414|No Intervention|Group 2 - Usual care|This group will be receiving normal routine care without the study intervention
2844351|NCT03638401|No Intervention|Standard treatment|
2844352|NCT03638401|Active Comparator|Intervention arm|
2844353|NCT03638388|Active Comparator|Dry Needling (DN)|"Subjects will receive dry needling treatment, once a week, for 6 weeks.~Outcomes will be measured at baseline (week 0), 3 weeks after initiation of study (week 3), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
2844354|NCT03638388|Active Comparator|Dry Needling with Intramuscular electrical stimulation (DNES)|"Subjects will receive dry needling treatment with electrical stimulation, once a week, for 6 weeks.~Outcomes will be measured at baseline (week 0), 3 weeks after initiation of study (week 3), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
2844355|NCT03638375|Experimental|Treatment with nivolumab plus TIL|"In the first cohort the subcutaneous IFN-alpha injections will be omitted and the combination of nivolumab and TIL is given.~Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion~TILs are given at a dose ranging between 2.5-7.5x10^8 T cells i.v. once every three weeks, three times per cycle."
2844356|NCT03638375|Experimental|Treatment with Nivolumab plus TIL and IFN-alpha|"In the second cohort of the first phase and the second phase of the trial patients will be treated with subcutaneous IFN-alpha injections in combination with TIL and nivolumab.~IFN-alpha is given at a fixed dose of 3 million IU s.c. every day, for 11 weeks, starting one week before the first TIL infusion~Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion~TILs are given at a dose ranging between 2.5-7.5x10^8 T cells i.v. once every three weeks, three times per cycle."
2844435|NCT03637764|Experimental|Phase2-Cohort D-2: GBM, isatuximab monotherapy|Isatuximab dose 2
2844589|NCT03636750|Experimental|HB002.1T 12mg/kg|Participants received a 12mg/kg dose of HB002.1T via intravenous injection.
2844357|NCT03638362|Placebo Comparator|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 2 week washout then switch over to the alternate beverage. Approximately half of participants began study consuming placebo beverage and the other half TCJ.
2844358|NCT03638362|Experimental|Tart cherry juice (TCJ)|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 2 week washout then switch over to the alternate beverage. Approximately half pf participants began study consuming placebo beverage and the other half TCJ.
2844359|NCT03638336|Experimental|flexible ureteroscopy|
2844360|NCT03638323||LOOP group|Speech therapy consultation for patients with Alzheimer's disease
2844361|NCT03638310|Experimental|ITG (intratympanic gentamicin) group|Patients who underwent prehabituation by gentamicin prior to surgery for vestibular schwannoma. They underwent intratympanic application of gentamicin and microsurgical removal of vest. schwannoma.
2844362|NCT03638310|Active Comparator|control group|patients without prehabituation before surgery. They underwent microsurgical removal of vest. schwannoma.
2844363|NCT03638297|Experimental|PD-1 antibody + cox inhibitor|BAT1306 + aspirin(celebrex when there is contraindication to aspirin) on day 1-21 every three weeks
2844364|NCT03638284|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS):All enrolled study participants will receive 10 sessions (5 per week X 2 weeks) of tDCS in an open label study. Inhibitory stimulation will be delivered to the frontal lobes.
2844365|NCT03638271|Other|nonischemic cardiomyopathic patient|Patients in different sex and age groups diagnosed with any type of nonischemic cardiomyopathy clinically or with echocardiography will undergo cardiac magnetic resonance imaging.
2844366|NCT03638258|Experimental|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% topically applied once daily
2844367|NCT03638258|Experimental|ARQ-151 cream 0.15%|ARQ-151 cream 0.15% topically applied once daily
2844368|NCT03638258|Placebo Comparator|ARQ-151 Vehicle cream|Matching vehicle cream containing only excipients of ARQ-151 cream applied once daily
2844369|NCT03638245||Abnormal CTG|This group includes pregnancies that showed abnormalities in CTG.
2844370|NCT03638245||Normal CTG|This group includes pregnancies that showed no abnormalities in CTG.
2844371|NCT03638232||Patients with multiple myeloma|"Data to be collected are :~Drug exposition data~Administrative data~Medical data"
2844372|NCT03638206|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
2844373|NCT03638193|Experimental|CART-meso cells|A single dose of CART-meso T cells will be administered intravenously.The dose is 1-3×10^7/m^2 CART positive cells(chort 1)or 1-3×10^8/m^2 CART positive cells(chort 2).
2844374|NCT03638180|Experimental|Single Ascending Doses|Single ascending doses, 6 dose levels
2844375|NCT03638180|Experimental|Multiple Ascending Doses|Multiple ascending doses, 3 dose levels
2844376|NCT03638167|Experimental|ARM A (Tumor Cavity Infusion)|Patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity
2844377|NCT03638167|Experimental|ARM B (Ventricular System Infusion)|Patients with either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the fourth ventricle or lateral ventricle, respectively
2844378|NCT03638154|Placebo Comparator|GroupI|safety with received beta-tricalcium phosphate (β TCP) bone substitute only. (Bioresorb, Sybron, implant solutions GmbH Bremen, Germany)
2844379|NCT03638154|Active Comparator|GroupII|"safety with surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane and received a mixture of gingival fibroblast(GF) and gingival mesenchymal stem cells(GMSCs) carried on a vehicle of β TCP covered by a resorbable collagen membrane.~(Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Jersey, USA)."
2844380|NCT03638141|Experimental|Cohort A - Durvalumab and Single-dose Tremelimumab|Starting at Week 2, patients will receive 4 doses of durvalumab (1500 mg IV) every 4 weeks. Patients will receive a single dose of tremelimumab (300mg IV) at Week 2. Patients with a complete response (CR) at Week 15 will receive 9 doses of durvalumab (1500 mg IV) every 4 weeks.
2844381|NCT03638141|Experimental|Cohort B - Durvalumab and Weekly-dose Tremelimumab|Starting at Week 2, patients will receive 4 doses of durvalumab (1500 mg IV) and tremelimumab (75 mg IV) every 4 weeks. Patients with a CR at Week 15 will receive 9 doses of durvalumab (1500 mg IV) every 4 weeks.
2844382|NCT03638128|Experimental|Denosumab|60 mg/mL solution containing 1.7 mL administered subcutaneously with a frequency of: day 1, at month 6, month 12, and month 18
2844383|NCT03638115|Experimental|VaSecure™ Drug Coated PTA Balloon Catheter|
2844384|NCT03638102|Experimental|Sleep intervention|Sleep extension
2844385|NCT03638102|Active Comparator|Healthy living|Health education
2844386|NCT03638089|Experimental|Intervention Group|This group will receive up to six sessions of fall-recovery training over the course of 2-3 weeks.
2844387|NCT03638076|Experimental|GLS4 120 mg+ RTV 100mg，bid|Patients with chronic HBV infection will receive GLS4 120 mg+ Ritonavir Tablet 100 mg twice daily for 48 weeks.
2844388|NCT03638076|Experimental|GLS4 120 mg+ RTV 100mg，tid|Patients with chronic HBV infection will receive GLS4 120 mg+ Ritonavir Tablet 100 mg three times daily for 48 weeks .
2844389|NCT03638063||Chronic cough|patients with chronic cough who remain clinically stable
2844390|NCT03638063||Bx|bronchiectasis patients who remain clinically stable
2844391|NCT03638063||Control|healthy controls
2844392|NCT03638050||In-hospital acute myocardial infarction patients|Functional Capacity Assessment
2844393|NCT03638037||Study|69 women, delivered preterm babies (less than 37weeks).
2844394|NCT03638037||Control|69 women, delivered at term (38-42 weeks) of full tem babies.
2844395|NCT03638024||Study group|Maternal plasma cell free fetal DNA levels will be measured in 25 women with one or more previous cesarean section and placenta previa anterior only or with ultrasound finding suggestive of placental adhesion or invasion (accreta , increta or percreta).
2844396|NCT03638024||Control group|Maternal plasma cell free fetal DNA levels will be measured in 25 matched control with normally situated placenta without ultrasound finding suggestive of placental adhesion or invasion.
2844590|NCT03636750|Experimental|HB002.1T 16mg/kg|Participants received a 16mg/kg dose of HB002.1T via intravenous injection.
2844397|NCT03638011|No Intervention|Standard of Care|These participant will receive standard neuraxial anesthesia for their Cesarean Section and post-operative standard of care breakthrough medications for post-operative pain control. They standard neuraxial anesthesia with neuraxial Duramorph for post-operative pain.
2844398|NCT03638011|Active Comparator|Bilateral TAP Block|These participants will receive standard neuraxial anesthesia for their Cesarean Section and post-operative standard of care breakthrough medications for post-operative pain control. They will receive standard neuraxial anesthesia without neuraxial Duramorph and a transverse abdominal plane (TAP) blocks immediately after surgery, with a mixture of bupivacaine and Exparel, for post-operative analgesia.
2844399|NCT03637998|Experimental|PROPEL|The Problem-solving Pain to Enhance Living Well (PROPEL) intervention entails each participant watching 10 video modules via REDCap. These modules include: (1) pain neurophysiology, (2) catastrophizing, (3) stress reactivity, (4) fear of movement, (5) progressive relaxation, (6) deep breathing, (7) guided imagery, (8) heat, ice and stretching, (9) strategies for physical activity self-activation and (10) problem-solving.
2844400|NCT03637985|Experimental|resistive exercise|resistive exercises using elastic band(Thera Band) Sets were at moderate intensity, 8-10 repetitions for every motion for 12 weeks
2844401|NCT03637985|Experimental|Aerobic exercise|Aerobic exercise in form of treadmill walking for 45 minutes for 12 weeks
2844402|NCT03637972|Experimental|Ventilated cigarettes only|
2844403|NCT03637972|Experimental|Unventilated cigarettes only|
2844404|NCT03637972|Experimental|Ventilated cigarettes + alternative nicotine delivery systems|
2844405|NCT03637972|Experimental|Unventilated cigarettes + ANDS|
2844406|NCT03637959|Experimental|MR Elastography comparision study|Evaluate the efficacy of liver stiffness measured by ultrasound for fibrosis staging, using clinically indicated MRE as the gold standard.
2844407|NCT03637946|Experimental|SHOFU Beautifil II LS|Experimental: SHOFU Beautifil II LS Restorative system FL-Bond II (self-etching adhesive system)/ Beautifil II (composite restorative)
2844408|NCT03637933|Active Comparator|India ink tattooing|Experimental group includes patients undergone to preoperative endoscopic tattooing with Sterile Carbon Particle Suspension.
2844409|NCT03637933|Experimental|Sterile Carbon Particle Suspension tattooing|Control group includes patients undergone to preoperative endoscopic tattooing with India Ink.
2844410|NCT03637920||transmen|Biological women, who identify as men and are seeking gender reassignment.
2844411|NCT03637894|Active Comparator|Infants born by CS-fed fermented formula|Feeding infants with fermented formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
2844412|NCT03637894|Placebo Comparator|Infants born by CS-fed standard formula|Feeding infants with standard formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
2844413|NCT03637894|Other|Infants born by CS-breastfed|"Infants born by cesarean section fed with mother milk during were the reference group for all infants born by cesarean section.~The breastfeeding infants were the reference group"
2844414|NCT03637894|Active Comparator|Infants born by ED-fed fermented formula|Feeding infants with fermented formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
2844415|NCT03637894|Placebo Comparator|Infants born by ED-fed standard formula|Feeding infants with standard formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
2844416|NCT03637894|Other|Infants born by ED-breastfed|"Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life.~The breastfeeding infants were the reference group."
2844417|NCT03637881||Other|Daily or non-daily Consumers
2844418|NCT03637868|Experimental|Eribulin|eribulin 1.4 mg/m² administered intravenously between 6 and 7 cycles.
2844419|NCT03637842|Active Comparator|Lorcaserin XR|Lorcaserin XR 20mg daily
2844420|NCT03637842|Placebo Comparator|Placebo|Placebo Oral Capsule
2844421|NCT03637829|Placebo Comparator|Control|250 mL of water
2844422|NCT03637829|Active Comparator|White Chocolate|White chocolate (40 g)
2844423|NCT03637829|Experimental|Dark chocolate 1|Dark chocolate (40 g)
2844424|NCT03637829|Experimental|Dark chocolate 2|Dark chocolate (46 g) possibly containing caffeine and/or theobromine
2844425|NCT03637816|Experimental|Arm I (anamorelin hydrochloride)|Participants receive anamorelin hydrochloride PO daily for 9 weeks in the absence of disease progression or unaccepted toxicity.
2844426|NCT03637816|Placebo Comparator|Arm II (placebo)|Participants receive placebo PO daily for 9 weeks in the absence of disease progression or unaccepted toxicity.
2844427|NCT03637803|Experimental|MRx0518 with pembrolizumab|Subjects will receive IV infusion of pembrolizumab once every 3 weeks until disease progression, unacceptable AEs or withdrawal of consent up to a maximum of 35 cycles (approx. 2 years). Starting on the day of first pembrolizumab dose, subjects will take one capsule of MR0518 twice daily until the end of the treatment period.
2844428|NCT03637790|Other|PF 04965842|In Period 1, subjects will be administered a single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.
2844429|NCT03637790|Other|Rifampin and PF 04965842|In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.
2844430|NCT03637764|Experimental|Phase1|"Isatuximab and atezolizumab combination in patients with unresectable hepatocellular carcinoma (HCC), platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN), platinum-resistant/refractory epithelial ovarian cancer (EOC), or recurrent glioblastoma multiforme (GBM):~Isatuximab dose 1 depending on DLT observed and atezolizumab predefined dose Q3W"
2844431|NCT03637764|Experimental|Phase2-Cohort A: HCC|Isatuximab and atezolizumab combination: Isatuximab dose determined in Phase 1 part of study and atezolizumab predefined dose Q3W
2844432|NCT03637764|Experimental|Phase2-Cohort B: SCCHN|Isatuximab and atezolizumab combination: Isatuximab dose determined in Phase 1 part of study and atezolizumab predefined dose Q3W
2844715|NCT03635879|Experimental|AC-1202|AC-1206 liquid, single dose (20 g tricaprilin)
2844436|NCT03637764|Experimental|Phase2-Cohort E|Isatuximab and atezolizumab combination: Isatuximab dose 3 and atezolizumab predefined dose Q3W in participants with one tumor type (HCC, SCCHN, EOC, or GBM), or isatuximab monotherapy (GBM only) dose 3
2844437|NCT03637751|Experimental|Experimental design|Testing will be carried out in Penn State's Clinical Research Center (CRC). The CRC has rooms for conducting the Trier Social Stress Test (TSST) stress-task and for resting. Participants will make two visits to the CRC, one week apart, on the same day of the weekday. Sessions will be scheduled from 11:00 am to 4:15 pm. We will use a randomized counter-balanced order for the two sessions (i.e., TSST and control conditions) with group membership blind to the subjects and lab personnel.
2844438|NCT03637751|Experimental|Control design|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
2844439|NCT03637738|Experimental|RIOP-Intrabeam® system|"Surgery with Intrabeam®. A first visit will be scheduled at 2 months from surgery then at 6 months then every 6 months for 5 years, then every year after 5 years.~Additional EBRT may be performed +/- chemotherapy if the treatment received is insufficient."
2844440|NCT03637738|Active Comparator|conventional surgery +RTE|surgery, EBRT over 33 sessions then visit at 6 months then every 6 months 6 for 5 years, then every year after 5 years.
2844441|NCT03637725||Coronary Artery Disease|Suspected or known coronary artery disease
2844442|NCT03637712|Experimental|Screening Colonoscopy|Patients undergoing standard screening or surveillance colonoscopy will be included
2844443|NCT03637699|Other|Intervention|Subjects randomized to the intervention group will be complete five weeks of positive psychology exercises, one exercise per week, during the intervention phase (weeks 1-5) of the study.
2844444|NCT03637699|Other|Waitlist Control|Subjects randomized to the waitlist control group will complete five weeks of positive psychology exercises, one exercise per week, during the extension phase (weeks 6-10) of the study.
2844445|NCT03637660|Active Comparator|1|2.4 million units (MU) of Benzathine penicillin G (BPG) intramuscularly on Day 1, n=280
2844446|NCT03637660|Experimental|2|2.4 million units(MU) of Benzathine penicillin G (BPG) intramuscularly weekly for three successive weeks, n=280
2844447|NCT03637647||Upper gastrointestinal cancer|Upper gastrointestinal cancers including oesophagus and stomach
2844448|NCT03637634||NPC survivors|Survivors of NPC, diagnosed under 21 years of age, between 1990 and 2030. This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, for an increased risk of late-occurring events associated with excess mortality and morbidity.
2844449|NCT03637634||Sibling Controls|A group of sibling controls will be identified to provide: (1) the ability to make direct comparisons with the survivors, (2) data on outcomes in a non-cancer population, and (3) additional comparison group to determine the consistency of findings between data sources.
2844450|NCT03637595|Active Comparator|Positive Control Group|Acupuncture
2844451|NCT03637595|Sham Comparator|Negative Control Group|Sham Intervention
2844452|NCT03637595|Experimental|Energy Medicine (EM) Intervention|Energy Medicine by an energy medicine practitioner
2844453|NCT03637582|Active Comparator|Anesthesia Arm|"Participants randomized to this arm will undergo uroflow studies then be given an hour rest. Five ml of 2% lidocaine gel will be inserted into the urethra during their hour rest. After the incubation period, the subject will receive another five ml of 2% lidocaine gel. The subject will then perform the second uroflow study.~Complex urodynamics with the use of lidocaine hydrochloride 2% will then be performed. The lidocaine gel will have been placed in and around the urethra. We are using lidocaine gel in an FDA approved manner (for anesthesia)."
2844454|NCT03637582|Placebo Comparator|Placebo Arm|Participants randomized to this arm will first undergo uroflow studies then be given an hour rest. Five ml of plain aqueous gel will be inserted into the urethra during their hour rest. After the incubation period, the subject will receive another five ml of plain aqueous gel. Urodynamic testing without anesthesia (standard of care) will then be performed.
2844455|NCT03637569||Cancer patients|Newly diagnosed pancreatic, bile duct or GB cancer patients at samsung medical center.
2844456|NCT03637556|Experimental|DST-0509|DST-0509 (deferasirox) will be supplied in 360 mg, 180 mg and 90 mg tablets. DST-0509 is taken once daily with food; the first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
2844457|NCT03637556|Active Comparator|Jadenu|Jadenu is commercially available as tablets and will be provided by the patient with their ongoing prescription. Dosing will be at equivalent (mg for mg) doses of DST-0509 or Jadenu. Jadenu is taken once daily with or without a light meal. However, Jadenu can be administered according to the patient's current prescription regimen. The first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
2844458|NCT03637556|Active Comparator|Exjade|Exjade is commercially available as tablets and Exjade as tablets for oral suspension and will be provided by the patient with their ongoing prescription. Dosing will be at equivalent (mg for mg) doses of DST-0509 or Jadenu. If converting from Exjade, the dose will be scaled for each treatment by 28 mg/40 mg (treatment/Exjade). Jadenu and Exjade are taken once daily, Jadenu is taken with or without a light meal, and Exjade is recommended to be taken without food. However, either Jadenu or Exjade can be administered according to the patient's current prescription regimen. The first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
2844459|NCT03637543|Experimental|PD-L1 Positive|-Nivolumab will be given on day 1 of a 28-day cycle intravenously
2844460|NCT03637543|Experimental|PD-L1 Negative|-Nivolumab will be given on day 1 of a 28-day cycle intravenously
2844461|NCT03637530|Experimental|intervention group|in this group of patients, inverse ratio ventilation is provided during general anaesthesia
2844462|NCT03637530|No Intervention|control group|in this group of patients, conventional ventilation is provided during general anaesthesia
2844463|NCT03637517|Experimental|DSM265-TPGS 34% SDD, 400 mg fasted|Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
2844464|NCT03637517|Active Comparator|DSM265-TPGS 34% SDD, 400 mg fed|Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
2844465|NCT03637517|Active Comparator|DSM265 25% SDD, 400 mg fasted|Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
2844863|NCT03634787||Healthy|No major systemic illness
2844466|NCT03637504|Experimental|Interventional|web-based, mobile medication management application [MedActionPlan® (MAP) and continued use of eTrack nebulizer +/- AdhereTech pill bottles as measures of adherence
2844467|NCT03637504|No Intervention|Control|usual care and continued use of eTrack nebulizer +/- AdhereTech pill bottles as measures of adherence
2844468|NCT03637504|Other|Optional Extension|web-based, mobile medication management application [MedActionPlan® (MAP)]
2844469|NCT03637491|Experimental|Avelumab and binimetinib|Open label
2844470|NCT03637491|Experimental|Avelumab, binimetinib and talazoparib|Open label
2844471|NCT03637478|Experimental|Enhanced Systems of Care Team|The four intervention sites have been selected based on their size: taken together, their pediatric populations comprise over 80% of the total number of children receiving care at Cambridge Health Alliance. At the four intervention sites, the study will involve: 1) an integrated child mental health assessment done by the E-SOC team within primary care, 2) active follow-up, collaboration with specialty providers and support to families, 3) School, child welfare and other community linkages as appropriate.
2844472|NCT03637465|Experimental|Hydrate Philly Intervention|Intervention group that receives hydration station intervention
2844473|NCT03637465|No Intervention|Control|Control group that receives no intervention, but observational data is collected; converted to wait-listed intervention status after enrollment and randomization was completed
2844474|NCT03637452||Exclusive cigarette smokers|Exclusive cigarette smokers must smoke at least 10 cigarettes per day for the past three months and have exhaled carbon monoxide (eCO) levels of at least 6 ppm at the screening visit.
2844475|NCT03637452||Dual (Electronic cigarette and cigarette smoking) users|Dual e-cigarette and cigarette users must have smoked at least 5 cigarettes per day for the last 3 months and use e-cigarettes at least 15 days per month for the last 3 months.
2844476|NCT03637439|Experimental|PNM group|Subjects were treated only once. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10 Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol (Valera & Minaya). The subjects were lying prone in decubitus. The middle part of the sciatic nerve was located using an ultrasound machine (cross section), then an acupuncture needle (0.30 mm x 40 mm) was inserted in a short axis approach, perpendicular to the surface of the skin, to the perineurium of the sciatic nerve.
2844477|NCT03637439|Sham Comparator|Control group|The subjects were lying prone in decubitus. The same puncture protocol was performed on the sciatic nerve for 1.5 minutes, but without the application of electricity.
2844478|NCT03637426|Placebo Comparator|GPLACEBO|In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
2844479|NCT03637426|Experimental|Gn-HAP|In this group a desensitizing gel containing 20% of nano-hydroxyapatite, 9000 ppm of sodium fluoride and 5% of potassium nitrate (Desensibilize Nano P, FGM®, Joinville, SC, Brazil) was applied to the hypersensitive dentin. The GnHAP volunteers will be submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications.
2844480|NCT03637426|Experimental|GLASER|"In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil) was applied in hypersensitive dentine.~GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours."
2844481|NCT03637426|Experimental|GLASERnHAP|In this group the laser + nano-hydroxyapatite was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, São Carlos, SP, Brazil) and a gel containing 20% nanohydroxyapatite, 9000 ppm sodium fluoride 5% potassium nitrate (Desensibilize Nano P, FGM®, Joinville, SC, Brazil) in hypersensitive dentin. GLASERnHAP first named a laser application and then an application of nanohydroxyapatite according to the manufacturer's recommendations.
2844482|NCT03637413|Experimental|Hindmilk|Hindmilk, the milk at the end of a breast pumping session, has higher fat and energy content compared to the composite milk.
2844483|NCT03637400|Experimental|Trimethoprim/sulfamethoxazole (TMP-SMX)|TMP-SMX will be dosed as follows: for adults, 160/800 mg administered as two single strength (SS) over-encapsulated tablets (equivalent to one double strength (DS) tablet) twice daily. As dosages of these medications may be lower in children with lower body weight (<40 kg), we will use weight based liquid medications for children < 40 kg (TMP/SMX dosed based on 8-10 mg/kg of TMP daily, divided into two daily doses) for those children who are under 40 kg in weight. As dosages of these medications are higher in persons with high body weight (>100 kg), we will use TMP/SMX 160/800 mg administered as four single strength (SS) over-encapsulated tablets (equivalent to two double strength (DS) tablet) twice daily.
2844484|NCT03637400|Experimental|Doxycycline (DOXY)|DOXY will be dosed as follows: for adults, two 50 mg tabs (100 mg total) given twice daily. As dosages of these medications may be lower in children with lower body weight (<40 kg), we will use weight based liquid medications for children < 40 kg (DOXY 2.2 mg/kg twice daily) for those children who are under 40 kg in weight. The doxycycline dose will remain the same for persons with high body weight (>100 kg) and four additional placebo tabs will be given to subjects > 100 kg randomized to doxycycline.
2844485|NCT03637387|Experimental|BIIB074 Dose 1|Administered orally three times daily (TID)
2844486|NCT03637387|Experimental|BIIB074 Dose 2|Administered orally TID
2844522|NCT03637153|Experimental|Order B|Firstly, the participants will exposed to High Altitude (Säntis; 2500m above sea level) and consecutively will they have assessement in Zurich (Low altitude; 470m above sea level).
2844591|NCT03636750|Experimental|HB002.1T 20mg/kg|Participants received a 20mg/kg dose of HB002.1T via intravenous injection.
2844487|NCT03637374|Experimental|Primary Study Arm|The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
2844488|NCT03637374|Other|Expanded Selection Arm|The Expanded Selection Arm will be treated the same as those in the Primary Study Arm. Your doctor will determine what arm you are in. TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
2844489|NCT03637361|Placebo Comparator|Arm 1|100 mL Ocean Spray® Diet Cranberry Juice
2844490|NCT03637361|Experimental|Arm 2|REL-1017 5 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
2844491|NCT03637361|Experimental|Arm 3|REL-1017 20 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
2844492|NCT03637361|Experimental|Arm 4|REL-1017 60 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
2844493|NCT03637361|Experimental|Arm 5|REL-1017 100 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
2844494|NCT03637361|Experimental|Arm 6|REL-1017 150 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
2844495|NCT03637348|Other|TrueTear|Use of TrueTear device to stimulate tear production
2844496|NCT03637335|Experimental|irradiation + carboplatin|Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Carboplatin. :10 injections 1h prior irradiation
2844497|NCT03637335|Placebo Comparator|irradiation + placebo|Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Placebo :10 injections 1h prior irradiation
2844498|NCT03637309|Experimental|BeReady2Smile Video and App|This arm will test the feasibility of the BeReady2Smile Video and App to promote dental health of young children with a parent education program.
2844499|NCT03637296|Experimental|Critical time intervention|Individuals who receive intensive care management during and following discharge from the inpatient medical unit.
2844500|NCT03637296|No Intervention|Treatment as usual|Individuals who receive routine care management during and following discharge from the inpatient medical unit.
2844501|NCT03637283|Experimental|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
2844502|NCT03637283|Active Comparator|fan-shaped photocoagulation|vitreoretinal surgery combined with fan-shaped photocoagulation
2844503|NCT03637270|Experimental|Early PS+exercise training|Participants in this group take protein supplement before and after each exercise session. The interventions include 30 training sessions.
2844504|NCT03637270|Placebo Comparator|Early PL+exercise training|Participants in this group take placebo before and after each exercise session. The placebo has the same caloric as the protein supplement but with different constitution (eg, different percentage of protein, fat and carbohydrate)
2844505|NCT03637270|Experimental|Delayed PS+exercise training|Participants in this group take protein supplement before and after each exercise session. The interventions include 30 training sessions.This group starts intervention at the 11th week after the randomization.
2844506|NCT03637270|Placebo Comparator|Delayed PL+exercise training|Participants in this group take placebo before and after each exercise session. The placebo has the same caloric as the protein supplement but with different constitution (eg, different percentage of protein, fat and carbohydrate). This group starts intervention at the 11th week after the randomization.
2844507|NCT03637257|Experimental|Nasal cannula / Guedel|Record of capnography using a standard nasal cannula followed by use of a modified Guedel airway
2844508|NCT03637257|Experimental|Guedel / nasal cannula|Record of capnography using a modified Guedel airway followed by use of a standard nasal cannula
2844509|NCT03637244|Experimental|Experimental Condition|Patients assigned to the experimental condition (LDQ + DS and HDQ + DS) will be asked to use the bookmarked link to the decision-aid within the first 7-14 days (and thereafter as needed) during the study period. The routine care group will be asked to use a bookmarked link to frequently asked questions on tenofovir + emtricitabine for PrEP. All groups will be compared on decision-quality at 14-days, self-reported PrEP initiation at 30-days, and PrEP adherence at 60-days post enrollment.
2844510|NCT03637231|Other|Standard and ultra-low-dose CAC scoring|
2844511|NCT03637218|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
2844512|NCT03637218|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
2844513|NCT03637205|Experimental|ECLS|PCI (or CABG) plus medical treatment + ECLS
2844514|NCT03637205|Active Comparator|No ECLS|PCI (or CABG) plus medical treatment
2844515|NCT03637192|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
2844516|NCT03637192|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
2844517|NCT03637179|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
2844518|NCT03637179|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
2844519|NCT03637166|Experimental|Order A|"The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)"
2844520|NCT03637166|Experimental|Order B|"The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level)."
2844521|NCT03637153|Experimental|Order A|Firstly, the participants will have their assessments at low altitude (Low altitude: 470m above sea level) in Zurich and consecutively the exposure to High Altitude (Säntis; 2500m above sea Level).
2844587|NCT03636750|Experimental|HB002.1T 4mg/kg|Participants received a 4mg/kg dose of HB002.1T via intravenous injection.
2844523|NCT03637140|Experimental|Order A|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
2844524|NCT03637140|Experimental|Order B|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
2844525|NCT03637127|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
2844526|NCT03637127|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
2844527|NCT03637114|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
2844528|NCT03637114|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
2844529|NCT03637088|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
2844530|NCT03637088|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
2844531|NCT03637075|Placebo Comparator|Placebo|Intranasal placebo administration
2844532|NCT03637075|Active Comparator|Intranasal insulin|Intranasal insulin administration
2844533|NCT03637062|Experimental|pessary|the test group is pessary.The pregnant woman is assigned to the pessary group and after having excluded a vaginal infection the pessary will be inserted directly.
2844534|NCT03637062|Active Comparator|Progesterone|the control group is progesterone. Pregnant women in the control group were treated by 200 mg QN, it is used for 34 gestational weeks.
2844535|NCT03637049|Experimental|PBI-4050 and midazolam|Midazolam 2 mg solution once (Period 1), PBI-4050 1200 mg (3 x 400 mg tablets) once per day for 5 days and midazolam 2 mg solution once on last day (Period 2).
2844536|NCT03637036|Other|Control Condition|A general communication intervention will occur inviting staff to take up the influenza vaccination, without a specific authority or social norm designated.
2844537|NCT03637036|Other|Authority Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a specific authority but not a social norm designated.
2844538|NCT03637036|Other|Norms Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a social norm but not a specific authority designated.
2844539|NCT03637036|Other|Authority + Norms Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a specific authority and a social norm designated.
2844540|NCT03637023|Experimental|Virtual Reality|Virtual Reality will be applied in addition to the Anti-parkinsonian medication given by the Neurologist.
2844541|NCT03637023|Active Comparator|Exercise Therapy|Exercise Therapy will be applied in addition to the Anti-parkinsonian medication given by the Neurologist.
2844542|NCT03637023|Active Comparator|Pharmacological Treatment|Anti-parkinsonian medication (L-Dopa and Dopa agonists) given by the Neurologist.
2844543|NCT03637010|Other|Breakfast in the Classroom|Baseline data will be collected to include anthropometric measures, participant characteristics, and past eating habits. For the first 8 weeks, the students will be provided with breakfast meals containing the USDA nutrition requirements. These meals are typically higher in carbohydrates and lower in protein. For the second 8 weeks, the students will be provided with higher-protein breakfast meals. These meals also contain the USDA nutrition requirements but include high-quality protein-rich foods. For the remaining 8 weeks, the students will be provided both types of meals and will be permitted to choose which they prefer to consume each day. At the end of each 8-week period, eating habits, appetite, mood, cognitive performance, and anthropometrics will be completed along with measurements of breakfast waste.
2844544|NCT03636997|Active Comparator|Draining seton|Draining seton is placed through the fistula track and internal and external anal sphicnters
2844545|NCT03636997|Active Comparator|Rerouting of track|The seton and the fistula track are rerouted to include the internal anal sphincter only and spare the external anal sphincter
2844546|NCT03636984||rheumatoid arthritis patients|subjects with rheumatoid arthritis would be administered with recombinant TNF-α receptor: IgG Fc fusion protein （Anbainuo）50 mg peer week for 3 to 6 months until reaching clinical remission or low disease activity. Then the application of Anbainuo would be continued for 6 months. If the subjects did not reach clinical remission or low disease activity in 6 months, the treatment should be considered as invalid.
2844547|NCT03636984||ankylosing spondylitis patients|subjects with ankylosing spondylitis would be administered with recombinant TNF-α receptor: IgG Fc fusion protein （Anbainuo）50 mg peer week for 3 to 6 months until reaching clinical remission or low disease activity. Then the application of Anbainuo would be continued for 6 months. If the subjects did not reach clinical remission or low disease activity in 6 months, the treatment should be considered as invalid.
2844548|NCT03636971|Experimental|hyaluronic acid with mannitol|
2844549|NCT03636971|Experimental|hyaluronic acid with sorbitol|
2844550|NCT03636971|Active Comparator|saline|
2844551|NCT03636958|Active Comparator|control group|they will receive conventional antiepileptic treatment (antiepileptic combination therapy) without perampanel
2844552|NCT03636958|Experimental|experimental group|they will receive conventional antiepileptic treatment (antiepileptic combination therapy) with perampanel
2844553|NCT03636945|Experimental|Medullary thyroid carcinoma|Patients with MTC who have serum calcitonin> 150 pg / ml at initial diagnosis and have performed baseline imaging examinations within the last 3 months will be included in the study A PET at 18F-FDOPA will be performed according to a very powerful acquisition protocol
2844554|NCT03636932|Active Comparator|N-acetylcysteine (NAC) group|
2844555|NCT03636932|Placebo Comparator|Placebo group|
2844556|NCT03636919||experimental group|patient with pollen allergic rhinitis patients will filled an e-BOOK included questionnaires of life
2844557|NCT03636906|Experimental|1 Dose GSK3389245A + Bexsero Group|Subjects, males or females between and including 6 and 7 months of age will receive 1 dose of the experimental GSK3389245A vaccine followed by placebo and Bexsero vaccine
2844558|NCT03636906|Experimental|2 Dose GSK3389245A + Bexsero Group|Subjects, males or females between and including 6 and 7 months of age will receive 2 doses of the experimental GSK3389245A vaccine followed by Bexsero vaccine
2844559|NCT03636906|Active Comparator|Bexsero Group|Subjects, males or females between and including 6 and 7 months of age will receive the Bexsero vaccine comparator and placebo
2844560|NCT03636906|Experimental|1 Dose GSK3389245A + Nimenrix Group|Subjects, males or females between and including 6 and 7 months of age will receive 1 dose of the experimental GSK3389245A vaccine followed by placebo and Nimenrix vaccine
2844561|NCT03636906|Experimental|2 Dose GSK3389245A + Nimenrix Group|Subjects, males or females between and including 6 and 7 months of age will receive 2 doses of the experimental GSK3389245A vaccine followed by Nimenrix vaccine
2844562|NCT03636906|Active Comparator|Nimenrix Group|Subjects, males or females between and including 6 and 7 months of age will receive the Nimenrix comparator vaccine and placebo.
2844563|NCT03636906|Experimental|1 Dose GSK3389245A + Menveo Group|Subjects, males or females between and including 6 and 7 months of age will receive 1 dose of the experimental GSK3389245A vaccine followed by placebo and Menveo vaccine
2844564|NCT03636906|Experimental|2 Dose GSK3389245A + Menveo Group|Subjects, males or females between and including 6 and 7 months of age will receive 2 doses of the experimental GSK3389245A vaccine followed by Menveo vaccine
2844565|NCT03636906|Active Comparator|Menveo Group|Subjects, males or females between and including 6 and 7 months of age will receive the Menveo comparator vaccine and placebo.
2844566|NCT03636906|Experimental|1 dose GSK3389245A + Synflorix Group|Subjects, males or females between and including 6 and 7 months of age will receive1 dose of the experimental GSK3389245A vaccine followed by placebo and Synflorix vaccine
2844567|NCT03636906|Experimental|2 dose GSK3389245A + Synflorix Group|Subjects, males or females between and including 6 and 7 months of age will receive2 doses of the experimental GSK3389245A vaccine followed by Synflorix vaccine
2844568|NCT03636906|Active Comparator|Synflorix Group|Subjects, males or females between and including 6 and 7 months of age will receive the Synflorix comparator vaccine and placebo
2844569|NCT03636906|Experimental|1 dose GSK3389245A + Placebo|Subjects, males or females between and including 6 and 7 months of age will receive the 1 dose of the GSK3389245A experimental vaccine followed by placebo.
2844570|NCT03636906|Experimental|2 dose GSK3389245A + Placebo|Subjects, males or females between and including 6 and 7 months of age will receive the 2 doses of the GSK3389245A experimental vaccine followed by placebo.
2844571|NCT03636906|Placebo Comparator|Placebo Group|Subjects, males or females between and including 6 and 7 months of age will receive the Placebo vaccine
2844572|NCT03636893|Experimental|FLOT Chemotherpy regimen|"A total of four preoperative and four postoperative cycles of FLOT chemotherapy administered~A cycle consist of Day 1 5-FU 2600mg/M2 administered via intravenous PICC for 24 hour Leucovorin 200mg/M2 intravenous Oxaliplatin 85mg/ M2 intravenous Docetaxel 50mg/M2 intravenous~Repeated every 15th day"
2844573|NCT03636893|Active Comparator|SOX Chemotherapy regimen|"Three preoperative cycles and eight postoperative cycles of SOX chemotherapy administered~A cycle consist of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily)~Repeated every 21st day"
2844574|NCT03636880|Experimental|Brief treatment for insomnia|Brief Behavioral Treatment for Insomnia (BBTI) is a manualized, individual intervention designed to modify sleep patterns to reduce insomnia and improve sleep quality and efficiency. Participants complete two in-person meetings and two booster telephone calls over a four-week period.
2844575|NCT03636880|Active Comparator|Sleep Monitoring|Sleep Monitoring is an active comparator condition where participants track their sleep patterns for two weeks prior to the baseline and post-intervention assessments. They receive no contact from study staff during the intervening four-week period, except for a reminder call to begin completing the second sleep diary and to schedule the post-intervention assessment.
2844576|NCT03636867||data and specimen collection|consecutive diabetic patients admitted to Maria Cecilia Hospital for critical limb ischemia
2844577|NCT03636854|Experimental|Concentric Exercises|2 different concentric exercises will be done 3 times a week for 8 weeks.
2844578|NCT03636854|Experimental|Eccentric Exercises|2 different eccentric exercises will be done 3 times a week for 8 weeks.
2844579|NCT03636841|Experimental|EXPERIMENTAL GROUP|A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch on
2844580|NCT03636841|Active Comparator|CONTROL GROUP|A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch off
2844581|NCT03636802||EXPERIMENTAL GROUP|Patient with respiratory failure and on a lung transplant waiting list
2844582|NCT03636789|Experimental|Neurological consultation group|
2844583|NCT03636776|Experimental|quality of life in metastatic BC|"Patients benefit from a longitudinal follow-up determined according to the treatments.~Each type of treatment has its own schedule based on medical consultation times. At each change of treatment, from chemotherapy to hormone therapy or vice versa, the assessment times are determined according to the nature of the treatment.~The rhythm of the evaluation visits will therefore be defined by the doctor, according to the habits of the centre.~The evaluation times used to collect the questionnaires (QLQ-C30, BR23, PDS, STAI, BDI II)."
2844584|NCT03636763||Bullous pemphigoid and diabetes 2|patients with Bullous pemphigoid and diabete type 2 data report about gliptin exposure will be performed
2844585|NCT03636763||diabete type 2|patients with diabetes type 2 data report about gliptin exposure will be performed
2844586|NCT03636750|Experimental|HB002.1T 2mg/kg|Participants received a 2mg/kg dose of HB002.1T via intravenous injection.
2844593|NCT03636724|Experimental|Intervention group|Patients will receive the interventions on both PA and FVI simultaneously.
2844594|NCT03636724|No Intervention|Waiting control group|Patients will not receive any supportive interventions on PA or FVI during the intervention period but will be provided with the same intervention at follow-up six-month after the intervention.
2844595|NCT03636711||experimental group|• Patient admitted to emergency for infectious syndrome Description of antibiotic protocol, according to a syndromic approach will be performed
2844596|NCT03636698||Chorioamnionitis Group|preterm infants were born to mothers with chorioamnionitis
2844597|NCT03636698||Control Group|preterm infants were born to mothers without chorioamnionitis
2844598|NCT03636685|Experimental|Non-squamous cell lung cancer|"Anlotinib combined with pemetrexed and carboplatin, phase I~Anlotinib combined with pemetrexed and carboplatin, phase II"
2844599|NCT03636685|Experimental|Squamous cell lung cancer|"Anlotinib combined with paclitaxel and carboplatin, phase I~Anlotinib combined with paclitaxel and carboplatin, phase II"
2844600|NCT03636672|Experimental|experimental|Perturbation training during stationary bicycle riding
2844601|NCT03636672|Active Comparator|control|stationary bicycle riding training
2844602|NCT03636659|Experimental|Amphotericin B Liposome|Amphotericin B Liposome for Injection 50 mg/vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days
2844603|NCT03636659|Active Comparator|AmBisome Liposome|AmBisome Liposome for Injection 50 mg/ vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days
2844604|NCT03636633|Active Comparator|Control Group|"Standard respiratory physiotherapy~Patients in this group will receive standard respiratory physiotherapy two times a day, 7 days a week for 4 weeks. During hospitalization, sessions will be performed by a respiratory physiotherapist. After discharge, other sessions will be performed at home by themselves."
2844605|NCT03636633|Experimental|Training Group|"Standard respiratory physiotherapy and inspiratory muscle train~In addition to the standard respiratory physiotherapy program, patients in this group will receive 3 sets of inspiratory muscle training with 10 repetitions twice a day for 4 weeks. During hospitalization, sessions will be performed by a respiratory physiotherapist. After discharge, other sessions will be performed at home by themselves."
2844606|NCT03636620|Active Comparator|TACE group|Transcatheter arterial chemoembolization
2844607|NCT03636620|Experimental|TACE+RFA/MV group|Transcatheter arterial chemoembolization and radiofrequency /microwave ablation
2844608|NCT03636607|Experimental|Non-metastatic group|PET/CT dynamic scan
2844609|NCT03636607|Experimental|Metastatic group|PET/CT dynamic scan
2844610|NCT03636594|Experimental|Dance|This was a single arm study with all participants receiving the same intervention.
2844611|NCT03636581|Experimental|Intervention|This group will receive a smart watch to track activity and diet. This group will also receive education on nutrition and exercise.
2844612|NCT03636581|No Intervention|Control|This group will receive a smart watch to track activity only with no intervention.
2844613|NCT03636568|Experimental|Fluid restricted|
2844614|NCT03636568|No Intervention|Non Fluid Restricted|
2844615|NCT03636555|Active Comparator|Oxytocin|Syntocinon Spray (intranasal oxytocin spray). Each dose is 10 intranasal insufflations totaling 1.0 mL of Syntocinon Spray containing 40 IU of oxytocin. Subjects self-administer doses twice daily (before breakfast and before dinner) for 12 consecutive weeks.
2844616|NCT03636555|Placebo Comparator|Placebo|Each dose is 10 intranasal insufflations totaling 1.0 mL of a solution containing all ingredients in Syntocinon Spray except oxytocin. Subjects self-administer doses twice daily (before breakfast and before dinner) for 12 consecutive weeks.
2844617|NCT03636542|Experimental|liposomal bupivacaine|These patients receive an interscalene block with liposomal bupivacaine.
2844618|NCT03636542|Active Comparator|bupivacaine|These patients receive an interscalene block with bupivacaine.
2844619|NCT03636529|Active Comparator|Tart cherry juice (TCJ)|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
2844620|NCT03636529|Placebo Comparator|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
2844621|NCT03636516|Active Comparator|jj stent yes|
2844622|NCT03636516|Active Comparator|jj stent no|
2844623|NCT03636503|Experimental|Rituximab +Utomilumab+Avelumab|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only~Utomilumab is administered intravenously over 1 hour once every 4 weeks~Avelumab is administered intravenously over 1 hour once every 2 weeks"
2844624|NCT03636503|Experimental|Rituximab+Utomilumab+PF04518600|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only~Utomilumab is administered intravenously over 1 hour once every 4 weeks~PF-04518600 is administered intravenously over 1 hour on day 1 and day 15"
2844625|NCT03636503|Experimental|Rituximab+Avelumab+PF04518600|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only~Avelumab is administered intravenously over 1 hour once every 2 weeks~PF-04518600 is administered intravenously over 1 hour on day 1 and day 15"
2844626|NCT03636490|Experimental|Psychological Stress|All participants will undergo stress-inducing tasks (psychological stress intervention) using cognitive research tools.
2844627|NCT03636477|Experimental|Ad-RTS-hIL-12 + veledimex in combination with nivolumab|Intratumoral Ad-RTS-hIL-12 and varying doses of oral veledimex (activator ligand) given in combination with nivolumab via infusion.
2844628|NCT03636451|Experimental|40cc 0.5% Lidocaine|Prior to cervical dilation, paracervical block will be placed one time containing 38mL of 0.5% lidocaine buffered with 2mL 8.4% sodium bicarbonate and 2 units Vasopressin
2844629|NCT03636451|Active Comparator|20cc 1% Lidocaine|Prior to cervical dilation, paracervical block will be placed one time containing 18mL of 1% lidocaine buffered with 2mL 8.4% sodium bicarbonate in and 2 units Vasopressin
2844716|NCT03635866|Experimental|prior negative MRFTB of PI-RADS 4 and 5 lesions|Diagnosed withing 12 months of initial diagnostic cancer biopsy
2844717|NCT03635853|Experimental|patients with palmar arsenical keratosis|patients are given an ointment containing extract from cock's comb twice daily for three months
2976565|NCT02719860|Experimental|Black tea|
2844630|NCT03636412|Experimental|Ambulatory Intervention|Patients who score greater than or equal to 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will be enrolled in an ambulatory intervention. Care technicians will ambulate patients three times per day at their level of physical ability. They will also receive physical therapy standard of care.
2844631|NCT03636412|No Intervention|No Ambulator|Patients who score less than 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will not be enrolled in the ambulatory intervention. They will receive physical therapy standard of care.
2844632|NCT03636399|Experimental|Standard GIST|Standard Group Interactive Structured Treatment.
2844633|NCT03636399|Experimental|Intensive GIST|Intensive Group Interactive Structured Treatment.
2844634|NCT03636386|Experimental|Percutaneous Microelectrolysis Group|Group exposed to a Direct Current application using an acupuncture needle with intensities in microamps (μA) in the PGm of the upper trapezius muscle. The acupuncture needle will correspond to the negative electrode or cathode.This group will also be treated with conventional Ultrasound (US) on PGm before the application of MEP. The treatment parameters will include; a frequency of treatment 1MHz, intensity of 1.5W / cm2, ERA 5cm2, Duty Cycle 100%, treatment time 6 minutes.
2844635|NCT03636386|Active Comparator|Ultrasound therapy|Group treated only with conventional Ultrasound (US) on PGm with a frequency of treatment 1MHz, Intensity of 1.5W / cm2, ERA 5cm2, Duty Cycle 100%, treatment time 6 minutes.
2844636|NCT03636373|Experimental|Etanercept|Subjects will be administered etanercept 50 mg subcutaneously and a placebo intramuscularly
2844637|NCT03636373|Active Comparator|Triamcinolone acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly and a placebo subcutaneously
2844638|NCT03636360|Experimental|LED|LED lighting with spectral pattern similar to that of sunlight
2844639|NCT03636360|Active Comparator|Fluorescent|Fluorescent light at same illuminance (lux) as LED light
2844640|NCT03636360|Placebo Comparator|Dim|"Dim fluorescent light with same spectrum as Fluorescent condition"
2844641|NCT03636347|Placebo Comparator|Placebo oral tablet|
2844642|NCT03636347|Active Comparator|Alvelestat oral tablet - dose 1|MPH966
2844643|NCT03636347|Active Comparator|Alvelestat oral tablet - dose 2|MPH966
2844644|NCT03636334|Experimental|Computer-based decision support system|Computer-based decision support system for BP management, with appropriate training of local PHC doctors.
2844645|NCT03636334|No Intervention|Control|After site randomization, physicians at the control sites will manage their patients with hypertension by usual care.
2844646|NCT03636321|Experimental|intraductal stent|in this group ,patients candidate for living donor liver transplantation duct to duct biliary anastomosis will done on intraductal custom made stent
2844647|NCT03636321|Active Comparator|stentless|in this group ,patients candidate for living donor liver transplantation duct to duct biliary anastomosis will done without stent
2844648|NCT03636308|Experimental|AS：Nanoparticle albumin-bound paclitaxel，S-1|"Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle.~S-1 is orally administered (BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle."
2844649|NCT03636308|Active Comparator|AG：Nanoparticle albumin-bound paclitaxel，Gemcitabine|"Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 and 8 of each 21 day cycle.~Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21 day cycle."
2844650|NCT03636295|Experimental|Reduced INR Target|Warfarin therapy will be titrated to a target INR in the range of 1.5 to 2.5.
2844651|NCT03636295|Active Comparator|Standard INR Target|"Warfarin therapy will be titrated to a standard of care target INR range."
2844652|NCT03636282|Experimental|Hockey FIT Program (Immediate Delivery)|Hockey FIT Program: A gender-sensitized, weight loss and healthy lifestyle program that engages men using the power of being a sports fan.
2844653|NCT03636282|No Intervention|Wait-List Control (Delayed Delivery)|No intervention for 12 months. After 12 months, Hockey FIT program is offered.
2844654|NCT03636269|Active Comparator|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
2844655|NCT03636269|Placebo Comparator|Placebo|IV Placebo administered after each dialysis session (3 times/week)
2844656|NCT03636256|Experimental|Non-Muscle Invasive Bladder Cancer|Subjects will be enrolled in sequential, dose escalating cohorts of NanoDoce direct injection (0.75 1.5, 2.5, or 3.75 mg/mL) and will also receive NanoDoce intravesical instillations at 3.0 mg/mL.
2844657|NCT03636256|Experimental|Muscle Invasive Bladder Cancer|Subjects will be enrolled in sequential, dose escalating cohorts of NanoDoce direct injection (0.75 1.5, 2.5, or 3.75 mg/mL) and will also receive institutional standard of care therapy and NanoDoce intravesical instillations at 3.0 mg/mL.
2844658|NCT03636243|Other|Group of obese patients with type-2 diabetes|
2844659|NCT03636243|Other|Group of non-diabetic obese patients|
2844660|NCT03636230|Active Comparator|Remote Patient Management|Remote monitoring only
2844661|NCT03636230|Placebo Comparator|Standard of Care|In-clinic visits
2844662|NCT03636217|Experimental|LGI-Milk Breakfast|Low glycemic index and milk content (LGI-Milk) breakfast as a test meal
2844663|NCT03636217|Experimental|LGI-Kefir Breakfast|Low glycemic index and kefir content (LGI-Kefir) breakfast as a test meal
2844664|NCT03636217|Experimental|HGI-Kefir Breakfast|High glycemic index and kefir content (HGI-Kefir) breakfast as a test meal
2844665|NCT03636204|Experimental|AL001|Up to five single ascending dosed of AL001.
2844666|NCT03636204|Placebo Comparator|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects
2844667|NCT03636191|Experimental|Probiotic|
2844668|NCT03636191|Placebo Comparator|Placebo|
2844669|NCT03636178|Other|1st group|20 patients out of 40 will be enrolled into the study including males and females above 18 years old
2844670|NCT03636178|Other|2nd group|20 patients out of 40 will be enrolled in the study including males and females above 18 years old
2844718|NCT03635840|No Intervention|Control|Group of patients not receiving IABP
2844719|NCT03635840|Experimental|Intra Aortic Balloon Pump|Group of patients receiving Intra Aortic Balloon Pump prior to revascularization
2844720|NCT03635827|Active Comparator|NBTX-001|
2844671|NCT03636165|Experimental|M plus R group|Participates received peri-incisional scalp infiltration of miscible liquid of 1.25mg methylprednisolone and 2mg ropivacaine per milliliter. The miscible liquid will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by the investigator.
2844672|NCT03636165|Active Comparator|R group|Participates received peri-incisional scalp infiltration of 2mg/mL ropivacaine. The local infiltration solution will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by the investigator.
2844673|NCT03636152|Active Comparator|Hydroxychloroquine (HCQ) Group|These patients will receive HCQ for 18 months
2844674|NCT03636152|Placebo Comparator|Placebo Group|These patients will receive a matching placebo for 18 months
2844675|NCT03636139|Experimental|Anodal stimulation|transcranial DC stimulation : anodal
2844676|NCT03636139|Sham Comparator|Sham stimulation|transcranial DC stimulation : sham
2844677|NCT03636126|Experimental|VR + TACS|"Complete one chapter of the virtual reality game Land's End while simultaneously using the tACS system (chapters range in length from approximately 5-20 minutes) after waking up each day (or prior to beginning a work shift).~Use the tACS system without the VR for 20 minutes just before sleep (or at the end of a work shift, whichever time point is most convenient). Table 1. Timeline of Study Treatment"
2844678|NCT03636126|No Intervention|No Intervention for 2 Weeks|For 2 weeks of the 4 week study, each group (Group A and Group B) will continue work shifts as usual with no intervention.
2844679|NCT03636113||ICU nurses -manual|Standard method of Urine Output monitoring
2844680|NCT03636113||ICU nurses -automated|Device- Clarity RMS Electronic sensor
2844681|NCT03636087|Active Comparator|Conventional|Access cavity preparation Working length determination Root canal instrumentation and chemo-mechanical preparation Root canal obturation Coronal restoration build up Cone Beam Computed Tomography scanning (CBCT) Radiographic imaging using periapical radiographs
2844682|NCT03636087|Experimental|Enhanced sterile protocol|Access cavity preparation Working length determination Root canal instrumentation and chemo-mechanical preparation Root canal obturation Coronal restoration build up Changing gloves before obturation Disinfecting rubber dam The use of new instruments at time of obturation Cone Beam Computed Tomography scanning (CBCT) Radiographic imaging using periapical radiographs
2844683|NCT03636074||Hearth-valve surgery|
2844684|NCT03636074||Hearth bypass surgery|
2844685|NCT03636061|Active Comparator|OC-01 Low Dose|
2844686|NCT03636061|Active Comparator|OC-01 Mid Dose|
2844687|NCT03636061|Active Comparator|OC-01 High Dose|
2844688|NCT03636061|Placebo Comparator|Placebo|
2844689|NCT03636048|Experimental|Spinal anesthesia group|Spinal anesthesia is used for operation with epidural patient-controlled device for pain control. Bupivacaine Hcl 0.5% Inj. 9-10mg is injected into intrathecal space for anesthesia. 0.2% ropivacaine is used for postoperative pain control with continuous infusion into epidural space.
2844690|NCT03636048|Active Comparator|General anesthesia group|General anesthesia is used for operation with wound patient-controlled device for pain control. propofol (10milligram/ML) 1.5-2 mg/ml is used as bolus intravascular injection for induction of anesthesia. 0.5% ropivacaine is used for postoperative pain control with continous infusion through wound catheter.
2844691|NCT03636035|Experimental|Tregocel® supplementation|Tregocel® coated tablets (2/day) orally for 36 weeks
2844692|NCT03636022|Experimental|Virtual Reality|Virtual Reality exposure therapy system to deliver homework and in-office exposures.
2844693|NCT03636022|Other|Traditional therapy|Traditional treatment using exposure therapy
2844694|NCT03636009|Experimental|Experimental group|Participants will receive concurrent traction and neuromobilizations. While on cervical traction in supine, the therapist will perform an neuromobilization technique to the involved arm.
2844695|NCT03636009|Active Comparator|control group|Participants will receive sequential traction and neuromobilizations
2844696|NCT03635996|Experimental|Etripamil NS 70 mg|The dose of etripamil to be evaluated in NODE-302 is 70 mg.
2844697|NCT03635983|Experimental|Combination|NKTR-214 + Nivolumab
2844698|NCT03635983|Experimental|Monotherapy|Nivolumab
2844699|NCT03635970|Placebo Comparator|conventional treatment|receive the best conventional therapy
2844700|NCT03635970|Active Comparator|experimental treatment|The best medical treatment possible plus celular therapy
2844701|NCT03635957|Experimental|KRYSTEXXA® with methotrexate (MTX)|All participants will receive dual therapy MTX and KRYSTEXXA®
2844702|NCT03635944||Group A|Infants born in Lyon (France)
2844703|NCT03635944||Group B|Infants born in Stockholm (Sweden)
2844704|NCT03635931|Active Comparator|Concentrated Growth Factor|plaque control, scaling and root planing if required, surgical application of CGF
2844705|NCT03635931|No Intervention|Control Group|plaque control, scaling and root planing if required
2844706|NCT03635918|Other|NightOwl HSAT|Patient undergoes a NightOwl sleep apnea test whilst simultaneously undergoing a sleep study with a Type I sleep monitor (Lab-PSG) and optionally a benchmark HSAT monitor.
2844707|NCT03635905|Experimental|Gabapentin|Gabapentin (Neurontin)- 600 mg oral administered pre-operatively at the time of cervical preparation
2844708|NCT03635905|Placebo Comparator|Placebo|
2844709|NCT03635892|Experimental|cabozantinib in combination with nivolumab|Cycle length will be defined as 28 days. Treatment will include cabozantinib 40mg, self administered orally once daily on a continuous schedule (days 1-28), and nivolumab 3mg/kg, administered intravenously on days 1 and 15 of each cycle ± 3 days. Treatment will be continued until confirmed disease progression, major toxicity, or withdrawal from the study for any reason.
2844710|NCT03635879|Active Comparator|MCTprocal medical food|Vitaflo MCTprocal, single dose (20 g MCT)
2844711|NCT03635879|Active Comparator|Milk/tricaprilin oil blend|Lactose-free milk and tricaprilin oil, blended,single dose (20 g tricaprilin)
2844712|NCT03635879|Active Comparator|AC-1207|AC-1207 liquid, single dose (20 g tricaprilin)
2844713|NCT03635879|Active Comparator|AC-1205|AC-1205 liquid, single dose (20 g tricaprilin)
2844714|NCT03635879|Active Comparator|AC-1206|AC-1206 liquid, single dose (20 g tricaprilin)
2844722|NCT03635814|Experimental|YD312 drug treatment|From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
2844723|NCT03635814|Placebo Comparator|YD312 placebo drug treatment|From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
2844724|NCT03635801||MyoVista 12 Lead (ECG) NSTEMI|"Patients enrolling in this clinical investigation will undergo a standard 12-lead ECG using the MyoVista 12-lead hs ECG device. An ECG is a quick, safe and painless test. No electricity is put into the body while it's carried out.~There may be some slight discomfort when the electrodes are removed from the skin - similar to removing a sticking plaster - and some people may develop a mild rash where the electrodes were attached.~An ECG is performed under controlled conditions."
2844725|NCT03635788|Experimental|Arm A: LA ART|In Step 1, participants will receive SOC oral ART regimen for 24 weeks. In Step 2, participants will receive oral RPV once daily and oral CAB once daily for 4 weeks, followed by a RPV-LA loading dose and a CAB-LA loading dose, followed in 4 weeks by a RPV-LA maintenance dose and a CAB-LA maintenance dose every 4 weeks for 44 weeks. In Step 3, participants will receive a RPV-LA maintenance dose and a CAB-LA maintenance dose every 4 weeks for 52 weeks. In Step 4, eligible participants will be followed until they complete 52 weeks on locally sourced oral ART.
2844726|NCT03635788|Active Comparator|Arm B: SOC Oral ART|In Step 1, participants will receive SOC oral ART regimen for 24 weeks. In Step 2, participants will continue SOC oral ART regimen for 52 weeks. In Step 3, participants will receive oral RPV once daily and oral CAB once daily for 4 weeks, followed by a RPV-LA loading dose and a CAB-LA loading dose, followed in 4 weeks by a RPV-LA maintenance dose and CAB-LA maintenance dose every 4 weeks for 44 weeks. In Step 4, eligible participants will be followed until they complete 52 weeks on locally sourced oral ART.
2844727|NCT03635775|Experimental|Anodal ipsilesional Active tDCS|Anodal tDCS (excitatory) applied to the lesioned hemisphere. Participant must have lesioned hemisphere MEP.
2844728|NCT03635775|Experimental|Cathodal contralesional Active tDCS|Cathodal tDCS (inhibitory) applied to the non-lesioned hemisphere. Participant must have lesioned hemisphere MEP.
2844729|NCT03635775|Experimental|Anodal contralesional Active tDCS|Anodal tDCS (excitatory) applied to the non-lesioned hemisphere. Participant must not have lesioned hemisphere MEP.
2844730|NCT03635775|Sham Comparator|Sham tDCS|Sham tDCS applied in one of the above configurations
2844731|NCT03635762|Experimental|Be In Charge|behavioral + nutrition education program
2844732|NCT03635749|Active Comparator|DAPT + early intensive statin|This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); active atorvastatin calcium with high dosage in the early phase.
2844733|NCT03635749|Other|DAPT + delayed intensive statin|This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the ealy phase.
2844734|NCT03635749|Other|Aspirin+early intensive statin|This group will receive active aspirin and clopidogrel placebo; active atorvastatin calcium with high dosage in the early phase.
2844735|NCT03635749|Placebo Comparator|Aspirin+delayed intensive statin|This group will receive active aspirin and clopidogrel placebo; atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the early phase.
2844736|NCT03635736||Severe brain injury|ICU-patients suspect to severe brain injury, measurement with multiple-spectral-sonography as acustocerebrography (ACG
2844737|NCT03635697|Experimental|Mindfulness Intervention Group|Participants in this group will listen to a short mindfulness audio clip during 6 of their NST appointments.
2844738|NCT03635697|No Intervention|Control Group|Participants in this group will have the regular standard of care for their NST appointments.
2844739|NCT03635684|Experimental|SC Acetaminophen|Palliative Care Patients who receive subcutaneous Acetaminophen for pain or fever relief
2844740|NCT03635671||Intensified blood glucose control|Patients with diabetes mellitus type 2 and poor blood sugar control that are introduced to insulin or GLP-1 therapy
2844741|NCT03635671||Nephropathy|Patients that are introduced to hemodialysis or renal transplantation secondary to renal failure
2844742|NCT03635658|Active Comparator|titanium mesh|using non resorbable titanium mesh to fix and cover the onlay bone graft mixture to the atrophic maxillary ridge.
2844743|NCT03635658|Experimental|collagen membrane(Sausage technique)|using resorbable collagen membrane with the sausage technique to fix the onlay bone graft mixture to the resorbed atrophic maxillary ridge
2844744|NCT03635645|Experimental|Retinal stimulation|Alternative stimulus patterns will be tested (vs. baseline). The intervention is the alternative stimulus pattern. The intervention will be tested only in the clinic vs. baseline. The subject will go home with baseline settings. The two alternative stimulus patterns to be tested are asymmetric waveforms and bipolar stimulus.
2844745|NCT03635632|Experimental|C7R-GD2.CART cells|This is a single arm study. Patients will be treated at 4 dose levels. At the dose level 0, patients will only receive C7R-GD2.CART cells without lymphodepletion chemotherapy. Three patients will be evaluated and if safety is confirmed patients will be treated with lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by C7R.GD2.CART cell infusion at 3 dose levels.
2844746|NCT03635593|Active Comparator|CBD|
2844747|NCT03635593|Active Comparator|CBD+THC|
2844748|NCT03635593|Placebo Comparator|Placebo|
2844749|NCT03635580|Experimental|rhGH/Jintropin AQ|Jintropin AQ, injection, 30IU/10mg/3ml/cartridge, 0.05mg /kg/d in phase 1 and 0.05-0.07mg/kg/d in phase 2.
2844750|NCT03635567|Experimental|Pembrolizumab+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of pembrolizumab 200 mg PLUS Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH or WITHOUT bevacizumab 15 mg/kg OR paclitaxel 175 mg/m^2 PLUS carboplatin Area Under the Curve (AUC) 5, WITH or WITHOUT bevacizumab 15 mg/kg). All treatments are administered until disease progression or toxicity, for up to 35 cycles (up to approximately 2 years).
2844751|NCT03635567|Placebo Comparator|Placebo+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an IV infusion of placebo (Normal Saline or Dextrose solution) PLUS Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH or WITHOUT bevacizumab 15 mg/kg OR paclitaxel 175 mg/m^2 PLUS carboplatin AUC 5, WITH or WITHOUT bevacizumab 15 mg/kg). All treatments are administered until disease progression or toxicity, for up to 35 cycles (up to approximately 2 years).
2844752|NCT03635541||NAFLD|Liver biopsy proved NAFLD patients, observational study. Oral advice on lifestyle would be given at each visit.
2844753|NCT03635515|Active Comparator|Standard Protocol (Control) Group|Patients will be given a VAS scale to record their highest level of pain 6 hrs prior to treatment. The standard endodontic protocol will be followed. The same VAS scale from pretreatment will be used to record pain level at 6, 24, 72, and 168 hours post-treatment.
2844754|NCT03635515|Active Comparator|Gentlewave Treatment Group|Patients will be given a VAS scale to record their highest level of pain 6 hrs prior to treatment. The standard endodontic protocol will be followed through working length verification. For the Gentlewave treatment group, each canal will be shaped to a canal size of 20.06 and to 0.5 - 1mm short of the apical terminus. An occlusal platform will be prepared using the Kool-dam material recommended by Sonendo. The Gentlewave system will be held on the tooth by the clinician and will cycle through five minutes of 3% sodium hypochlorite, two minutes of 8% EDTA, and a final rinse of distilled water. Canals will be obturated with root canal sealer and gutta-percha. The same VAS scale from pretreatment to take home and asked to record their level of pain at 6, 24, 72, and 168 hours post-treatment.
2844755|NCT03635502||Stroke Group|
2844756|NCT03635502||Healthy Group|
2844757|NCT03635489|Experimental|Bevacizumab + Paclitaxel + Carboplatin|Participants will receive paclitaxel, carboplatin intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting from Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab for a total of 21 cycles of bevacizumab in the absence of disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.
2844758|NCT03635489|Placebo Comparator|Placebo + Paclitaxel + Carboplatin|Participants will receive paclitaxel, carboplatin IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and placebo IV infusion starting from Cycle 2 for a total of 5 cycles, followed by maintenance therapy placebo for a total of 21 cycles of placebo in the absence of disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.
2844759|NCT03635463|Experimental|twin block appliance|this group will receive conventional twin block appliance and followed up every month for 9 months.
2844760|NCT03635463|Experimental|modified twin block appliance group|modified twin block appliance group , this group will receive the modified appliance and followed up every month for 9 months
2844761|NCT03635450|Experimental|First cohort of 3 subjects enrolled|The first cohort of three patients will receive a single dose in the first 48 postnatal hours.
2844762|NCT03635450|Experimental|Second cohort of 3 subjects enrolled|If there are no safety concerns after the first cohort of 3 subjects are infused then the second cohort of three patients will receive two doses, with the first dose given in the first 48 postnatal hours and the second dose given approximately two months after the first dose.
2844763|NCT03635437|Experimental|Low dose gamma-aminobutyric acid (GABA)|Oral GABA treatment 200 mg daily for 6 months
2844764|NCT03635437|Experimental|High dose gamma-aminobutyric acid (GABA)|Oral GABA treatment 600 mg daily for 6 months
2844765|NCT03635424|Experimental|Medtronic TAVR Systems|Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
2844766|NCT03635411|Experimental|Basis|Nicotinamide riboside 500 mg and pterostilbene 100 mg given twice daily in divided doses for 90 days
2844767|NCT03635411|Placebo Comparator|Placebo|Placebo given twice daily for 90 days
2844768|NCT03635398|Experimental|Intranasal Midazolam by SipNose device|
2844769|NCT03635398|Active Comparator|Intranasal Midazolam by MAD (Mucosal Atomization Device)|
2844770|NCT03635398|Active Comparator|oral administration of midazolam|
2844771|NCT03635385|Active Comparator|Plasma exchange (PE) technic patient group|
2844772|NCT03635385|Active Comparator|Immunoadsorption technic patient group|
2844773|NCT03635372|Experimental|Alginate|10 cc of Alginate peroral
2844774|NCT03635372|Experimental|Sucralfate|10 cc of Sucralfate peroral
2844775|NCT03635372|Experimental|Hydrotalcite|10 cc of Hydrotalcite peroral
2844776|NCT03635359||positive for fetal aneuploidy|
2844777|NCT03635359||negative for fetal aneuploidy|
2844778|NCT03635333|Experimental|Low nicotine, tobacco|6 mg nicotine combined with tobacco flavored e-juice
2844779|NCT03635333|Experimental|Low nicotine, menthol|6 mg nicotine combined with menthol flavored e-juice
2844780|NCT03635333|Experimental|Low nicotine, strawberry|6 mg nicotine combined with strawberry flavored e-juice
2844781|NCT03635333|Experimental|High nicotine, tobacco|18 mg nicotine combined with tobacco flavored e-juice
2844782|NCT03635333|Experimental|High nicotine, menthol|18 mg nicotine combined with menthol flavored e-juice
2844783|NCT03635333|Experimental|Hign Nicotine, strawberry|18 mg nicotine combined with strawberry flavored e-juice
2844784|NCT03635320|Experimental|investigational group|using Trochanteric Fixation Nail Advanced to treat the fracture
2844785|NCT03635320|Active Comparator|the control group|Using Proximal Femoral Nail Antirotation to treat the fracture
2844786|NCT03635307||Operated patients with volume expansion|
2844787|NCT03635294|Experimental|Blood sample|Blood sample for analyses
2844788|NCT03635281|Experimental|PEEP group|In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached)
2844789|NCT03635281|Experimental|RM+PEEP group|"Recruitment maneuvers will be performed as follow Recruitment maneuvers~set FIO2 at 1.0~Ppeak limit at 45 cmH2O~Respiratory rate set at 6~I:E set at 1:1~Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O~If the maximum VT is set without rasing the Pplat, raise PEEP~Allow three respiratory cycles with Pplat between 30 and 40 cmH2O~End of RM~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached)."
2844790|NCT03635242|Active Comparator|Control. no therapeutic program|The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
2844864|NCT03634774|Experimental|Step 1 CHOICE+|Receives the intervention first
2844791|NCT03635242|Experimental|Experimental. Therapeutic program|"People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform"
2844792|NCT03635190|Experimental|Interventional|Orbital Circumferential Atherectomy
2844793|NCT03635177|Experimental|Remote ischemic conditioning|The participant will conduct remote ischemic preconditioning by use of an automated cuff device placed on the upper arm which inflates to 200 mmHg and occludes blood flow. The procedure is conducted on one arm 4 x 5 min per day. Each 5 min occlusion period is interspersed by 5 min.
2844794|NCT03635177|Sham Comparator|Sham occlusion|The participant will conduct a sham procedure of remote ischemic preconditioning by use of an automated cuff device placed on the upper arm which inflates minimally and does not occlude blood flow. The procedure is conducted on one arm 4 x 5 min per day. Each 5 min of sham occlusion is interspersed by 5 min.
2844795|NCT03635164|Experimental|Dose Escalation and Expansion|"Part 1 of this trial will use a traditional 3+3 design will be used for this trial (i.e. cohort sizes of 3 patients for the first and second cohort at each dose level). Dose escalation will occur as long as there are minimal dose limiting toxicities.The expectation is that 9 patients will be enrolled to the trial during part 1.This is based on the expectation that all dose levels are safe (i.e. patients will not experience DLTs at all dose levels). The range of patients needed will be 6-12 patients.~Part 2 of this trial will be an expansion cohort. A total of 8 additional patients will be enrolled at the dose level determined to be the MTD in part 1 of the study. These 8 patients will be used to confirm that the MTD is a safe combination, as well as provide additional patients to investigate the efficacy for the treatment combination.~Note: Standard of care surgery will follow 3-6 weeks after medication and radiation treatment."
2844796|NCT03635151|Experimental|TASK III Group|The Telephone Assessment and Skill-Building Kit (TASK III) group
2844797|NCT03635151|Active Comparator|ISR Group|The Information, Support, and Referral (ISR) group
2844798|NCT03635138|Experimental|Adhesives Cu/Zn nanoparticles doped|Adhesive dopped with Zn Oxide + Cu nanoparticles in a ( 5% / 0.2% concentration )
2844799|NCT03635138|Active Comparator|Adhesive control|Adhesive conventional
2844800|NCT03635125|No Intervention|Background treatment phase|A 12- week Amlodipine 10 mg background treatment phase
2844801|NCT03635125|Active Comparator|Low Dose Treatment Phase-Nebivolol I|4-week low dose Nebivolol10 mg/Metoprolol 50 mg treatment phase
2844802|NCT03635125|Active Comparator|High dose treatment Phase-Nebivolol II|4-week High dose Nebivolol 20 mg/Metoprolol 100mg treatment phase
2844803|NCT03635125|Other|Baseline Washout Phase|2 to 4 week Baseline Washout Phase
2844804|NCT03635112|Active Comparator|Active Treatment TD-1473 with Dose A|"1 oral Dose A daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD.~Subjects who complete Induction will continue to receive TD-1473 at Dose A in the Active Treatment Arm for up to 24 additional weeks."
2844805|NCT03635112|Active Comparator|Active Treatment TD-1473 with Dose B|"1 oral Dose B daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD.~Subjects who complete Induction will continue to receive TD-1473 at Dose B in the Active Treatment Arm for up to 24 additional weeks."
2844806|NCT03635112|Placebo Comparator|Placebo|"1 oral dose daily of placebo for 12 weeks in subjects with moderately to-severely active CD.~Subjects who complete Induction will receive TD-1473 at Dose A in the Active Treatment Arm for up to 24 additional weeks."
2844807|NCT03635099|Experimental|Dose group A|
2844808|NCT03635099|Experimental|Dose group B|
2844809|NCT03635099|Experimental|Dose group C|
2844810|NCT03635099|Experimental|Dose group D|
2844811|NCT03635099|Placebo Comparator|Dose group E|
2844812|NCT03635086|Placebo Comparator|Treatment group A|"MV-CHIK lyophilised formulation, low dose, treatment group A:~12 subjects will receive two low dose treatments with MV-CHIK 5x10^4 (+/- 0.5 log) TCID50 /dose on day 0 and 28"
2844813|NCT03635086|Placebo Comparator|Treatment group B|MV-CHIK liquid frozen formulation, low dose, treatment group B: 12 subjects will receive two low dose treatments with MV-CHIK 1x10^5 (+/-0.5 log) TCID50 /dose on day 0 and 28
2844814|NCT03635086|Placebo Comparator|Treatment group C|MV-CHIK SPS® formulation, low dose, treatment group C: 12 subjects will receive two low dose treatments with MV-CHIK 1x10^5 (+/-0.5 log) TCID50 /dose on day 0 and 28
2844815|NCT03635086|Placebo Comparator|Treatment group D|MV-CHIK liquid frozen formulation, high dose, treatment group D: 12 subjects will receive two high dose treatments with MV-CHIK 1x10^6 (+/-0.5 log) TCID50 /dose on day 0 and 28
2844816|NCT03635086|Placebo Comparator|Treatment group E|MV-CHIK liquid frozen formulation, high dose and placebo, treatment group E: 12 subjects will receive one high dose treatment with MV-CHIK 1x10^6 (+/-0.5 log) TCID50 /dose on day 0 and placebo on day 28
2844817|NCT03635073|Experimental|TAK-935|treatment: two-weeks titration followed by 102 weeks maintenance period
2844818|NCT03635060|Active Comparator|Dorsal Bridge Plating|The intervention is surgery with dorsal distraction plating with or without any additional fragment specific fixation.
2844819|NCT03635060|Active Comparator|Volar Locking Plating|The intervention is surgery with open reduction and internal fixation with non-spanning fixation.
2844820|NCT03635047|Active Comparator|AL002|AL002 by intravenous (IV) infusion
2844821|NCT03635047|Placebo Comparator|Saline Solution|placebo by intravenous (IV) infusion
2844822|NCT03635034|Experimental|No Bladder catheter|"Subjects will not have bladder catheter inserted during their ablation procedure.~Intervention: No catheter"
2844823|NCT03635034|Active Comparator|Bladder catheter inserted|"Bladder catheter will be inserted prior to starting ablation procedure after the subject is under general anesthesia.~Intervention: bladder catheter inserted"
2844824|NCT03635021|Experimental|Sequence 1|FOLFOX regimen panitumumab FOLFIRI regimen bevacizumab
2844825|NCT03635021|Experimental|Sequence 2|FOLFOX regimen bevacizumab FOLFIRI regimen panitumumab
2844865|NCT03634774|Other|Step 2 CHOICE+|Received intervention four months after baseline
2844866|NCT03634774|Other|Step 3 CHOICE+|Receives intervention eight months after baseline
2844897|NCT03634514|Active Comparator|Application of Hormotrop|A single dose of Recombinant Human Somatropin - Hormotrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
2844826|NCT03635008|Experimental|Anodal tDCS|"This group will receive the 30 mins of the tDCS (Yrain, Korea) over the contralesional premotor area simultaneously with 30 mins of the robotic arm training using Armeo Power (Hocoma, Switzerland), per day. Additional 30 mins of occupational therapy focusing on the arm motor recovery will be provided per day. These interventions will be provided for 10 weekdays. Other conventional rehabilitation (e.g. gait training, speech therapy) will be permitted.~Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA."
2844827|NCT03635008|Placebo Comparator|sham tDCS|"This group will receive the 30 mins of the tDCS (Yrain, Korea) over the contralesional premotor area simultaneously with 30 mins of the robotic arm training using Armeo Power (Hocoma, Switzerland), per day. Additional 30 mins of occupational therapy focusing on the arm motor recovery will be provided per day. These interventions will be provided for 10 weekdays. Other conventional rehabilitation (e.g. gait training, speech therapy) will be permitted.~Regard to the sham tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be started but the intensity will decrease and stop in 30 seconds."
2844828|NCT03634995|Experimental|Single Dose|Ascending single doses of BMS-986256
2844829|NCT03634995|Experimental|Multiple Dose|Ascending multiple doses of BMS-986256
2844830|NCT03634995|Experimental|Sequential Dose|Sequential multiple doses of BMS-986256
2844831|NCT03634982|Experimental|RMC-4630|RMC-4630 for oral administration
2844832|NCT03634969|Experimental|Normal Renal Function|
2844833|NCT03634969|Experimental|Mild Renal Impairment|
2844834|NCT03634969|Experimental|Moderate Renal Impairment|
2844835|NCT03634969|Experimental|Severe Renal Impairment|
2844836|NCT03634969|Experimental|End-Stage Renal Disease (ESRD)|ESRD participants and are on chronic hemodialysis
2844837|NCT03634956|Experimental|Group I.IONM in thyroid surgery|Group I.IONM in thyroid surgery.Once the vagus has been detected,nerve conduction data will be detected with IONM. If the muscle relaxant effect is not detected, it will be detected with TOF device.
2844838|NCT03634943||Patients with Nutritional Support|Patients expected to be admitted >72h at the Intensive Care Unit with the need of artificial Nutritional Support
2844839|NCT03634930||EBF exclusive breast fed children at 16 weeks|observation of 24 hours drinking volume, weight, length, body composition, biomarker and satiety cues, as well as eating- and feeding behaviour and nutritional status of exklusiv breastfed children at the age of 8 and 16 weeks, and at 1 and 2 Years
2844840|NCT03634930||EFF exclusive formula fed children at 16 week|observation of 24 hours drinking volume, weight, length, body composition, biomarker and satiety cues, as well as eating- and feeding behaviour and nutritional status of exklusiv formula fed children at the age of 8 and 16 weeks, and at 1 and 2 Years
2844841|NCT03634917|Active Comparator|Acamprosate|"1 capsule with Acamprosate calcium~oral use~3 times / day (morning, noon, evening)~666 mg per capsule~14 - 19 days"
2844842|NCT03634917|Active Comparator|Calcium Citrate|"1 capsule with Calcium citrate tetrahydrate~oral use~3 times / day (morning, noon, evening)~950 mg per capsule (= 200 mg Calcium 2+)~14 - 19 days"
2844843|NCT03634917|Placebo Comparator|Placebo|"1 capsule placebo,~oral use~3 times / day (morning, noon, evening)~14 - 19 days"
2844844|NCT03634904|Experimental|Drug Blood sampling|"Drug Blood sampling~Pharmacokinetic study measuring total and free ceftazidime concentrations"
2844845|NCT03634878|Experimental|Perineal ultrasound to visualize the strips and their position|
2844846|NCT03634852|Active Comparator|Topical|Moxifloxacin hydrochloride 0.5% eye drops and dexamethasone 0.1% eye drops were prescribed four times a day for 1 month postoperatively.
2844847|NCT03634852|Active Comparator|Intracameral - Subconjunctival|Intracameral Moxifloxacin 0.1% with Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml had been administered at the conclusion of the surgery
2844848|NCT03634839|Placebo Comparator|Nicotine 0 mg, Sweet non-menthol|Nicotine 0 mg combined with sweet non-menthol flavor
2844849|NCT03634839|Active Comparator|Nicotine 3 mg, Sweet non-menthol|Nicotine 3 mg combined with sweet non-menthol flavor
2844850|NCT03634839|Active Comparator|Nicotine 12 mg, Sweet non-menthol|Nicotine 12 mg combined with sweet non-menthol flavor
2844851|NCT03634839|Placebo Comparator|Nicotine 0 mg, Sweet menthol|Nicotine 0 mg combined with sweet menthol flavor
2844852|NCT03634839|Active Comparator|Nicotine 3 mg, Sweet menthol|Nicotine 3 mg combined with sweet menthol flavor
2844853|NCT03634839|Active Comparator|Nicotine 12 mg, Sweet menthol|Nicotine 12 mg combined with sweet menthol flavor
2844854|NCT03634839|Placebo Comparator|Nicotine 0 mg, Tobacco non-menthol|Nicotine 0 mg combined with tobacco non-menthol flavor
2844855|NCT03634839|Active Comparator|Nicotine 3 mg, Tobacco non-menthol|Nicotine 3 mg combined with tobacco non-menthol flavor
2844856|NCT03634839|Active Comparator|Nicotine 12 mg, Tobacco non-menthol|Nicotine 12 mg combined with tobacco non-menthol flavor
2844857|NCT03634839|Placebo Comparator|Nicotine 0 mg, Tobacco menthol|Nicotine 0 mg with tobacco menthol flavor
2844858|NCT03634839|Active Comparator|Nicotine 3 mg, Tobacco menthol|Nicotine 3 mg combined with tobacco menthol flavor
2844859|NCT03634839|Active Comparator|Nicotine 12 mg, Tobacco menthol|Nicotine 12 mg combined with tobacco menthol flavor
2844860|NCT03634813|Experimental|High Blood Pressure Monitoring and Counseling|"Enrolled patients will be fitted with a HBPM device and instructed in its use. Patients will be asked to return the HBPM device on the morning of surgery. At the same time they receive the HBPM device, they will also be provided with the National Institutes of Health (NIH) booklet called Your guide on lowering blood pressure, which has several guidelines regarding diet, exercise and lifestyle changes that can be implemented to improve blood pressure control."
2844861|NCT03634813|Active Comparator|Usual Care|The usual care group will receive brief counseling after the PAT visit which will review their blood pressure readings taken at the clinic and how they compare with the American Heart Association (AHA) blood pressure guidelines. They will be offered the suggestion that they should follow up with their primary care doctor 2-4 weeks after their surgical episode is completed, or at their earliest convenience.
2844862|NCT03634787||Acute pancreatitis|First time acute pancreatitis. No later than 2 days since the clinical symptoms started.
2844867|NCT03634761|Experimental|Experimental group|Preschools/Children in this group will receive EIBI supervised by an external expert from the habilitation center on a regular basis. In addition, preschool staff in this group are provided with in-service training consisting of a one full day (onset of project) and a half day (middle of project) on autism, applied behavior analysis, evidence-based practices, engagement, participation, inclusion and overall quality factors when working with Children with autism in preschool settings. Preschool staff are also provided with monthly on-site coaching in implementing evidence based practices, goal setting and working with overall intervention setting, through coaching from the habilitation center.
2844868|NCT03634761|Active Comparator|Comparison group|"Preschools/Children are in this group receive treatment as usual, which is EIBI supervised by an external expert from the habilitation center at the habilitation center directed toward the paraprofessional. At the offset of the project preschool staff are offered to participate in a one-day learning course/workshop on autism, applied behavior analysis, evidence-based practices, engagement, participation, inclusion and overall quality factors when working with children with autism in preschool settings."
2844869|NCT03634735|Active Comparator|Thiamin|Oral thiamine: 600 - 1800 mg/day in 4 weeks. Dose is depending on gender and age. Tablet contains 300 mg Thiamine each.
2844870|NCT03634735|Placebo Comparator|Placebo|Placebo: same number of tablets as in the active comparator arm, in 4 weeks
2844871|NCT03634722|Experimental|The intervention group|the transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
2844872|NCT03634722|No Intervention|The observational group|routine nursing
2844873|NCT03634709|Experimental|Memory Flexibility Training (MemFlex)|The MemFlex programme has been adapted from the initial format addressing depression-related memory distortions to facilitate completion with individuals experiencing posttraumatic stress. The workbook and associated materials have also been translated from English to Farsi. The programme consists of one researcher-facilitated session and eight self-guided workbook-based sessions that train memory retrieval skills and are completed over a one month period.
2844874|NCT03634709|No Intervention|Waitlist control|After randomisation, the waitlist control group will be informed that they have been placed on a waiting list for the intervention. The participants will complete the baseline assessment and receive no further contact from the researcher until the post assessment one month later, followed by the follow-up assessment three months later. After the three month assessment, wait listed participants will receive the intervention. No further assessments will be completed.
2844875|NCT03634696|Experimental|Field test participants|Late-stage adult cancer patients seeking care at Ocean Road Cancer Center, consenting to participate in mPCL application field test
2844876|NCT03634696|Active Comparator|Control participants|Late-stage adult cancer patients seeking care at Ocean Road Cancer Center, consenting to serve as controls for mPCL field test
2844877|NCT03634683|Experimental|LioCyx|"This is a single-arm study.~Patients will receive escalating doses of LioCyx on Day 1, Day 8, Day 15 and Day 22 of the first 28-day treatment cycle, followed by every 2-week dosing on Day 1, Day 15, Day 29 and Day 43 of repeated cycle. A 21-day treatment break will be given between each cycle."
2844878|NCT03634657|Active Comparator|Plain X-ray protection shield|
2844879|NCT03634657|Experimental|Protection shield & X-ray protective strips|
2844880|NCT03634657|Experimental|Protection shield & protective strips & patient cut-outs|
2844881|NCT03634644|Active Comparator|Omega-3 fatty acid capsule|1g per capsule(EPA400mg，DHA320mg)
2844882|NCT03634644|Placebo Comparator|Placebo capsule|The placebo capsule has same appearance and packing with the Omega-3 fatty acid capsule
2844883|NCT03634618|Experimental|Mirror Therapy|Mirror Therapy program for 2 weeks and convantional physiotherapy for 4 weeks. Exercises Frequency: 5 days/week; 2 days with the physiotherapist, other days as home program; 2 weeks in total. Exercises Duration: 20 minutes. Exercises Repetation: 20 repetation for each exercise.
2844884|NCT03634618|Experimental|Convantional Physiotherapy|Convantional physiotherapy for 6 weeks. Exercises Frequency: 3 times a day, 4 weeks in total. Exercises Duration: 15-20 minutes. Exercises Repetation: 10 repetation for each exercise.
2844885|NCT03634605|Experimental|Case Group|Chemical pleurodesis for the this group was done using 2 grams of tetracycline 3% ointment (Aerotex®, Sina Daru, Tehran, Iran), 5 milliliter of lidocaine 2% and 50 milliliter normal saline that was injected through embedded thoracostomy tube
2844886|NCT03634605|Placebo Comparator|Control Group|Chemical pleurodesis for this group was done using 5 milliliter of lidocaine 2% and 50 milliliter normal saline that was injected through embedded thoracostomy tube
2844887|NCT03634579|Experimental|MRI-guided focal laser ablation|Subjects will undergo MRI Guided Focal Laser Interstitial Thermal Ablation of localized low and intermediate risk prostate cancer.
2844888|NCT03634566|Active Comparator|NAC group|Group NC received NAC 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
2844889|NCT03634566|Placebo Comparator|Control group|Group C (Control group) will receive ringer acetate continuous infusion at same rate for 2 days.
2844890|NCT03634553|Experimental|Intervention|Training with e-health product The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
2844891|NCT03634553|Active Comparator|Control|usual care, i.e. participates in regular training regime at the physiotherapy department
2844892|NCT03634540|Experimental|Cohort 1: PT2977 and cabozantinib|Cohort 1: Patients must not have received prior systemic therapy for advanced or metastatic ccRCC
2844893|NCT03634540|Experimental|Cohort 2: PT2977 and cabozantinib|Cohort 2: Patients must have received prior immunotherapy and no more than two prior treatments for advanced or metastatic ccRCC
2844894|NCT03634527|Experimental|Auricular Point Acupressure|Auricular points related to Chemotherapy-induced peripheral neuropathy (CINP) will be used for the intervention.
2844895|NCT03634527|Sham Comparator|Control Auricular Point Acupressure|Auricular points not related to CINP will be used for the intervention.
2844896|NCT03634514|Experimental|Application of Biomatrop|A single dose of Recombinant Human Somatropin - Biomatrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
2844898|NCT03634501|Experimental|NK cells|Activated NK from peripheral blood and/or umbilical cord blood（UCB）
2844899|NCT03634488||Children with SCD AND malnutrition|Children between 5-12 years of age with SCD with moderate or severe acute malnutrition will be treated per local protocols
2844900|NCT03634488||Children without SCD AND malnutrition|Children who are 5-12 years of age without SCD with moderate of severe acute malnutrition will be treated per local protocols
2844901|NCT03634488||Children with SCD but no malnutrition|Children who are 5-12 years of age with SCD without signs of malnutrition will be followed for at least 24 months
2844902|NCT03634475|Experimental|PP-001|Single intravitreal injection of 3 up to 4 doses of PP-001
2844903|NCT03634462|Experimental|Patients with Lipedema|Females with lipedema who meet the inclusion and exclusion criteria for lipedema and this study requirements. The intervention in this arm is a course of CDT with graded negative pressure.
2844904|NCT03634462|Experimental|Patients with secondary leg lymphedema|Patients with secondary leg lymphedema following cancer therapies will be limited to the female gender since the comparison group of patients have lipedema which is a condition predominantly effecting females. These patient subjects will consist of those who meet the inclusion and exclusion criteria for secondary leg lymphedema and this study requirements. The intervention in this arm is a course of CDT with graded negative pressure.
2844905|NCT03634449|Experimental|i-gel|After anesthetic durg given, i-gel, a supraglottic airway devices with a gastric suction channel, will be inserted into the patients' airway.
2844906|NCT03634449|Active Comparator|endotracheal tube|After anesthetic durg given, the endotracheal tube, traditional use for protect airway during the laparoscopic surgery, will be inserted into the patients' airway.
2844907|NCT03634436|Experimental|Cohort 1|A single subcutaneous injection of SHR-1209 dose 1 versus placebo
2844908|NCT03634436|Experimental|Cohort 2|A single subcutaneous injection of SHR-1209 dose 2 versus placebo
2844909|NCT03634436|Experimental|Cohort 3|A single subcutaneous injection of SHR-1209 dose 3 versus placebo
2844910|NCT03634436|Experimental|Cohort 4|A single subcutaneous injection of SHR-1209 dose 4 versus placebo
2844911|NCT03634423|Experimental|Sweet Spot: Flexible high incentive condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 490 points if they make a gym visit at any other time. 7000 points convert to $25
2844912|NCT03634423|Experimental|Sweet Spot: Flexible low incentive condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 290 points if they make a gym visit at any other time. 7000 points convert to $25
2844913|NCT03634423|Experimental|Sweet Spot: Rigid high incentive condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. 7000 points convert to $25
2844914|NCT03634423|Experimental|Sweet Spot: Rigid low incentive condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. 7000 points convert to $25
2844915|NCT03634423|Experimental|FOTW: High incentive control condition|Participants will receive 750 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. 7000 points convert to $5
2844916|NCT03634423|Experimental|FOTW: Low incentive control condition|Participants will receive 450 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. 7000 points convert to $5
2844917|NCT03634423|Experimental|FOTW: High incentive treatment condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. Additionally, if a participant misses a scheduled gym visit, they will receive 750 points the next time they visit the gym within the pre-specified window. 7000 points convert to $5
2844918|NCT03634423|Experimental|FOTW: Low incentive treatment condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. Additionally, if a participant misses a scheduled gym visit, they will receive 450 points the next time they visit the gym within the pre-specified window. 7000 points convert to $5
2844919|NCT03634423|Experimental|Think Twice: Control condition|Participants get 300 points per gym visit. 7000 points convert to $5
2844920|NCT03634423|Experimental|Think Twice: Treatment condition|Participants get 300 points per gym visit and are taught about the planning fallacy. 7000 points convert to $5
2844921|NCT03634423|Experimental|WDR: Control condition|Participants get 300 points per gym visit and are allowed to vary their gym schedules in different days. 7000 points convert to $5
2844922|NCT03634423|Experimental|WDR: Treatment condition|Participants get 300 points per gym visit. Participants are required to select a single exercise time for the weekdays (Monday - Friday) and a single exercise time for the weekends (Saturday - Sunday). 7000 points convert to $5
2844923|NCT03634410||Employed|people aged +50 and currently employed
2844924|NCT03634410||Unemployed|people aged +50 and currently unemployed
2844925|NCT03634410||Early retirement|people aged +50 and currently on early retirement
2844926|NCT03634410||Disability pension|people aged +50 and currently on disability pension
2844927|NCT03634397|Experimental|Non-Paretic Arm Intervention|Intervention condition includes therapy of the non-paretic arm.
2844928|NCT03634397|Sham Comparator|Comparison Intervention|Comparison control condition includes therapy of the paretic arm.
2844929|NCT03634384||Derivation cohort|"We include eligible patients presenting with chest pain suggestive of myocardial infarction to the emergency department (see eligibility).~For the primary study patients will be divided into two groups: 500 patients will serve as derivation cohort."
2844930|NCT03634384||Validation cohort|"We include eligible patients presenting with chest pain suggestive of myocardial infarction to the emergency department (see eligibility).~For the primary study patients will be divided into two groups: 500 patients will serve as validation cohort."
2844931|NCT03634371|Experimental|Test Formulation of Levothyroxine|Levothyroxine sodium tablets 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2
2844932|NCT03634371|Active Comparator|Reference formulation of Levothyroxine|Eutirox 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2
2844933|NCT03634358|Active Comparator|Bipolar scissors group|Group of male infants undergoing circumcision using bipolar scissors to separate the foreskin
2844934|NCT03634358|Active Comparator|Classic scalpel group|Group of male infants undergoing circumcision using classic scalpel to separate the foreskin, and sutures to control bleeding
2844935|NCT03634345|Experimental|PF-04965842|investigational drug
2844936|NCT03634332|Experimental|PEGPH20 plus Pembrolizumab|All patients will receive treatment with PEGPH20 3 micrograms/kg IV weekly x 3, and pembrolizumab 200 mg IV every 3 weeks, in 3-week cycles.
2844937|NCT03634306|Active Comparator|ARM 1|Use of Ultravision System
2844938|NCT03634306|Placebo Comparator|ARM 2|Standard of Care/no Ultravision System (Arm 2)
2844939|NCT03634306|Active Comparator|ARM 3|Patients enrolling in study arm 3 who are undergoing a myomectomy will have their procedure conducted with the Ultravision System.
2844940|NCT03634293|Placebo Comparator|control group|The group will receive 2 ml' saline subcutaneous injection upon randomization when admitted to the ICU with the diagnosis of sepsis or septic shock
2844941|NCT03634293|Active Comparator|treatment group|The group will receive a 2 ml' subcutaneous injection of the study drug Alirocumab 150 mg', upon randomization when admitted to the ICU with the diagnosis of sepsis or septic shock.
2844942|NCT03634280|Placebo Comparator|Splinting|Splinting was applied to the patients' ankle in the second group(n=20). Splint were kept on the patients for 5 days for 23 hours a day. In patients in the splint group, 16-18 layers of cotton gauze (15-cm cast gauze) were applied from the tip of the toes to the beginning of the fibula. Following the gauze application, short leg splint application was performed in a neutral ankle position.
2844943|NCT03634280|Experimental|Kinesio taping|In this study, Kinesio Tape Tex Gold® kinesio tape over lateral ankle (5cm*5m) is used. 20 participants were taped for a lateral ankle sprain. 50-mm wide and 0.5-mm thick KT was applied to the tendinomuscular meridian around the ankle with three I-shaped tapes. Initially, one I-shaped tape was applied along the course of the tibialis anterior muscle, and another I-shaped tape was then applied to the peroneus longus and brevis muscles. The third I-shaped tape was applied from the abductor digiti minimi muscle and wrapped around the ankle in a figure-of-eight shape to the abductor hallucis muscle, surrounding the ankle over the medial and lateral malleoli. The tape was applied to the skin by applying zero tension, and skin problems were avoided.
2844944|NCT03634267|Experimental|Treatment (MRI, internal radiation therapy)|Participants undergo MRI scan during internal radiation therapy applicator placement.
2844945|NCT03634254||primary caregivers of AAC users in New Taipei City|Satisfaction level of communication quality
2844946|NCT03634241|Active Comparator|Arm A (standard of care)|Participants receive standard of care.
2844947|NCT03634241|Experimental|Arm B (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2844948|NCT03634228|Experimental|Treatment (low dose cytarabine, MDM2 inhibitor DS-3032b)|Participants receive low dose cytarabine SC BID on days 1-7 and receive MDM2 inhibitor DS-3032b PO QD on days 8-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2844949|NCT03634215||Multiple Trauma patients|
2844950|NCT03634202|Experimental|IMRT + oral chemotherapy|Radiotherapy = IMRT with SIB. The overall duration of irradiation is 5 to 7 weeks Chemotherapy = oral capecitabine. Chemotherapy is taken in concomitance as radiotherapy days
2844951|NCT03634189|Experimental|HF- ACC/AHA stage A-C + CBD|Patients with HF stages A-C + Cannabidiol
2844952|NCT03634176||Group M|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received 0.5gr/kg 20% mannitol
2844953|NCT03634176||Group H|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received 1.5 ml/kg 7.5% NaCl solution
2844954|NCT03634176||Group F|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after Furosemide 1 mg/kg intravenously.
2844955|NCT03634176||Group S|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received dexamethasone 16 mg intravenously
2844956|NCT03634176||Group P|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after patients were positioned on reverse Trendelenburg position 30 degrees higher than the feet
2844957|NCT03634163|Experimental|Immediate|Quality of Life Assessment plus facilitated implementation of neighbourhood exchange and personal care support
2844958|NCT03634163|Active Comparator|Delayed|Quality of Life Assessment
2844959|NCT03634150|Experimental|Single arm Nerofe followed by Doxorubicin|IV treatment of Nerofe 96 mg\m2 followed by IV Doxorubicin 10mg\m2 Once weekly
2844960|NCT03634137|Experimental|Afamelanotide Group 1|A 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
2844961|NCT03634137|Experimental|Afamelanotide Group 2|A 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
2844962|NCT03634124|Experimental|interventional group|
2844963|NCT03634111|Active Comparator|T group|The TAP block group was called T group. The participants were performed TAP block under guidance at the end of surgery.
2844964|NCT03634111|Placebo Comparator|C group|The controlled group was called C group. The participants has not TAP block and were treated postoperative analgesia with intravenous morphine to patients controlled analgesia
2844965|NCT03634098|Experimental|Volunteers|"Exams performed on volunteers with other purpose than liver disease or diabetes in two centers:~MRI~Ultrasound AixPlorer These examinations are carried out in 2 differents centers at 1month intervals"
2844966|NCT03634098|Experimental|T2D liver test abnormalities's participants|"Exams performed on type 2 diabetic patients with liver test abnormalities :~sample for analysis and biocollection~MRI~Ultrasound AixPlorer"
2844967|NCT03634098|No Intervention|T2D participants without liver test abnormality|type 2 diabetic participants without liver test abnormality and not undergoing liver biopsy
2844968|NCT03634085|Experimental|Cohort A|"Ascending doses of BDM-2 in Bottle (50 mg - 3600 mg); oral suspension or placebo will be orally administered and will be investigated, alternately dosed in Cohort A of 8 healthy male subjects under fasted conditions. For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo.~The last session for the subjects in Cohort A will be under fed conditions where the same treatment allocation as in the session of the selected dose (administered under fasted conditions) will be used."
2845106|NCT03633084|Experimental|RBM-007 Injectable Solution - Dose 2|No additional information.
2844969|NCT03634085|Experimental|Cohort B|Ascending doses of BDM-2 in Bottle (50 mg - 3600 mg); oral suspension or placebo will be orally administered and will be investigated, alternately dosed in Cohort B of 8 healthy male subjects under fasted conditions. For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo.
2844970|NCT03634072|Other|PVR Arm|PVR arm will undergo PVR via catheter or surgery
2844971|NCT03634072|No Intervention|No PVR|No PVR group will continue with medical management
2844972|NCT03634059|Experimental|apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
2844973|NCT03634046|Experimental|PTED group|Percutaneous transforaminal endoscopic discectomy (PTED). Use German Joimax company production of intervertebral foramen mirror operation system, the prone position, by preoperative X-ray locating the skin into the needle point, intervertebral level away from the spine line 8 ~ 10 cm, 18 g needle insertion, the Kambin security triangle directly through the middle of pathological changes of intervertebral disc. After the success of the puncture, remove the needle core, injection of contrast agent, methylene blue (9:1) mixture disk imaging, replace the godet, slight rotation step by step to insert the expansion sleeve, X-ray perspective to determine work under the correct position. Radiofrequency ablation is used to form nucleus pulposus and fibrous ring and stop bleeding.
2844974|NCT03634046|Active Comparator|RA group|Radiofrequency ablation (RA). Patients in prone position, local infiltration anesthesia, the puncture point for lesion clearance level, is apart from the spine line distance is 8 to 10 cm, in the perspective of the C-shaped arm X-ray machine; After the puncture needle was reached, the needle core was removed and the radiofrequency head was pierced through the puncture channel to the nucleus pulposus. In accordance with the method of melt into the shrinking exit, the intensity of the treatment by band 2, increased to 3 file again, according to the needle round mouth of 2, 4, 6, 8, 10, 12 o'clock to this process is repeated six times.
2844975|NCT03634033|Experimental|MiCAP with IF|MiCAP with Internal Facilitation will receive MiCAP (implementation strategies). Internal facilitators will be waiver site clinicians with exemplary clinical practice and/or supervisory experience, who are expected to be early adopters of CAPABLE; and will be selected by their supervisors.
2844976|NCT03634033|Experimental|MiCAP with IF and EF|MiCAP with Internal Facilitation and External Facilitation will receive MiCAP (implementation strategies) and the addition of external facilitation. The external facilitators will be Super-Champion waiver program site clinicians from prior work who were trained and early adopters of CAPABLE; and will be selected by the research team to perform external facilitation.
2844977|NCT03634020|Experimental|DynamX Sirolimus-eluting Coronary Bioadaptor System|2.5 - 3.5mm 14mm, 18mm and 28mm
2844978|NCT03634007|Experimental|Cohort I: 8.0 x 10^10 gc/kg|Subjects will receive 8.0 x 10^10 gc/kg of AAVrh.10hAPOE2.
2844979|NCT03634007|Experimental|Cohort II: 2.5 x 10^11 gc/kg|Subjects will receive 2.5 x 10^11 gc/kg of AAVrh.10hAPOE2.
2844980|NCT03634007|Experimental|Cohort III: 8.0 x 10^11 gc/kg|Subjects will receive 8.0 x 10^11 gc/kg of AAVrh.10hAPOE2.
2844981|NCT03633994|Experimental|Heparin Bladder Instillation|At the completion of the scheduled benign hysterectomy, intravesicular bladder instillation containing 40,000U of heparin (40mL of 10,000U heparin/10mL) will be administered be introduced in a retrograde fashion by gravity via Foley catheter. The Foley catheter will be clamped for 30 minutes approximately 1cm from the vaginal opening.
2844982|NCT03633994|Placebo Comparator|Normal Saline Bladder Instillation|Patients randomized to the control group will undergo intravesical instillation with 40mL of normal saline. The Foley catheter will be clamped for 30 minutes approximately 1cm from the vaginal opening.
2844983|NCT03633968|Active Comparator|maxillary sinus lift small antrostomy|"local anaesthesia will be given flap will be reflected to expose sinus lateral wall. round diamond bur will be used to make small antrostomy and expose schneiderian membrane.~maxillary sinus lift by using antral membrane balloon elevation without using graft material with simultaneous implant placement"
2844984|NCT03633968|Active Comparator|maxillary sinus lift large antrostomy|"local anaesthesia will be given flap will be reflected to expose sinus lateral wall round diamond bur will be used to make large antrostomy and expose schneiderian membrane.~maxillary sinus lift by using antral membrane balloon elevation without using graft material with simultaneous implant placement"
2844985|NCT03633955||Standard therapy|This Arm will accrue patients receiving standard therapy (e.g. chemotherapy for leukemia).
2844986|NCT03633955||Immunotherapy|The other Arm will include patients receiving immunotherapy
2844987|NCT03633942||Observational: LMA Supreme|"An appropriately sized LMA Supreme will be prepared by removing all air from the cuff while applying manual pressure. A water soluble non-local anesthetic containing lubricant gel will be applied to the fully deflated airway before insertion. A 1 cm column of the gel will be preloaded into the gastric port of the LMA Supreme for the Gel Test.~The cuff will be inflated with a manometer to a pressure of approximately 30cm H2O. If a significant leak is detected, the cuff will be inflated in increments of 5cm H2O until a satisfactory seal is obtained. The final cuff pressure will be recorded. The lungs will then be gently inflated by applying manual pressure to the anesthesia circuit bag while observing the gel column in the LMA Supreme gastric port for movement."
2844988|NCT03633929||KIOS OUD|
2844989|NCT03633916|Experimental|Classroom sensitization session|"The experimental intervention is a one-off classroom information and engagement session delivered in addition to school-level sensitization activities. Individual classroom sessions will be conducted by a 'lay' counselor with facilitatory support from a researcher.~Each session will be conducted with the aid of a video with an aim of providing information to adolescents about common mental health problems, self-care and availability of a school counselling service. The session will be conducted during a class period lasting about 30 minutes. A brief self-screening form will be further distributed in the class for the use of the students and encourage the self-referral to the school counselling program.~This will be implemented in the classes from the same schools already receiving the school level sensitization activities."
2845028|NCT03633630|Placebo Comparator|Placebo|1000 mg dose per day. Two capsules of 500 mg, one in the morning before breakfast and the other before dinner during 90 days
2845029|NCT03633617|Experimental|Part A: Dupilumab or Placebo|Part A consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab or placebo. At the end of the double-blind treatment visit (week 24), eligible participants will enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
2844990|NCT03633916|Active Comparator|School level sensitization activities|"The control arm intervention will comprise sensitization activities conducted at the whole school level. These activities will include:~Display of posters targeting student and parents with information about the school counselling program and referral pathways in an easy and readable format.~A drop-box for student self-referral slips, set up in a prominent place (Preferably outside the counsellor's room or in a main hallway).~A series of meetings with school teachers will be conducted by the counsellor at the beginning of the trial.~A meeting with the school principal will be conducted by the Intervention Coordinators at the beginning of the trial."
2844991|NCT03633903|Active Comparator|Mindfulness|Mindfulness: Eight sessions, twice per week over four weeks
2844992|NCT03633903|No Intervention|Control|
2844993|NCT03633890|Experimental|DaZhu Rhodiola Rosea Capsule|
2844994|NCT03633890|Placebo Comparator|DaZhu Rhodiola Rosea Simulation Capsule|
2844995|NCT03633877|Experimental|DuraporeTM on R, Hy-Tape ® on L|DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia
2844996|NCT03633877|Experimental|DuraporeTM on L, Hy-Tape ® on R|DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia
2844997|NCT03633864|Experimental|FMT treatment|FMT treatment arm: Accept fecal microbiota transplantation without changing the ongoing treatment strategy.
2844998|NCT03633851|Experimental|Toric intraocular MX60T lens|one eye will receive toric MX60T lens
2844999|NCT03633851|Other|Standard MX60 plus corneal incisions|the other eye will receive standard MX60 lens with corneal incisions
2845000|NCT03633825|No Intervention|Control|
2845001|NCT03633825|Experimental|Intervention|
2845002|NCT03633812||Beta blocker group|ESLD recipients who had beta blocker during more than 1 month before the liver transplantation
2845003|NCT03633812||Non-Beta blocker group|ESLD recipients who had not taken beta blocker more than 3 month before the liver transplantation
2845004|NCT03633799|Experimental|VeraCept|VeraCept™ Intrauterine Contraceptive
2845005|NCT03633786|Other|Group A: standard laparoscopic surgery|patients affected by deep infiltrating endometriosis undergoing standard laparoscopic surgery; assessment of sexual function; assessment of bowel symptoms; assessment of urinary symptoms
2845006|NCT03633786|Other|Group B: robot-assisted surgery|patients affected by deep infiltrating endometriosis undergoing robot-assisted surgery; assessment of sexual function; assessment of bowel symptoms; assessment of urinary symptoms
2845007|NCT03633773|Experimental|MUC-1 CART|Patients are given fludarabine and cyclophosphamide as pretreatment before MUC-1 CART immunotherapy. After treatment, specific antibodies, CART cells and serum levels of cytokines will be assessed.
2845008|NCT03633760|Experimental|Bilastine 40mg single dose|12 eligible subjects will be allocated to this arm and receive a single dose of 40 mg of bilastine
2845009|NCT03633760|Experimental|Bilastine 20mg multiple dose|12 eligible subjects will be allocated to this arm and receive a single dose of bilastine 20 mg on Day 1 and six doses of bilastine 20 mg from Day 4 to Day 9
2845010|NCT03633747|Experimental|propranolol|Propranolol hydrochloride tablets were taken orally three times a day at an initial dose of 30 mg/day, doubled one week later until the daily dose was 1.5 mg/kg. If the dose was unable to increase due to side effects, the maximum dose tolerable was maintained for 6 months.
2845011|NCT03633734|Experimental|Sequential treatment|"One cycle of sequential treatment lasts for 56 days.~Stage 1(28 days): AG regimen. Nab-paclitaxel (Abraxane) 125mg/m^2 + gemcitabine 1000mg/m^2 (days 1, 8, 15, 28)~Stage 2(28 days)：mFolfirinox regimen. Fluorouracil 2400 mg/m^2 continuous intravenous drip 46h + calcium folinate 400 mg/m^2 + irinotecan 135 mg/m^2 + oxaliplatin 68 mg/m^2 (day 1, 15, a total of 28 days).~Repeat the cycle above until progression or intolerance of toxicity."
2845012|NCT03633721|Active Comparator|HIV positive; cannabis|HIV positive women will be given cannabis and tested
2845013|NCT03633721|Active Comparator|HIV positive; placebo|HIV positive women will be given placebo and tested
2845014|NCT03633721|Active Comparator|HIV negative; cannabis|HIV negative women will be given cannabis and tested
2845015|NCT03633721|Active Comparator|HIV negative; placebo|HIV negative women will be given placebo and tested
2845016|NCT03633708|Experimental|Etelcalcetide|Randomized in a 3:1 ratio to receive etelcalcetide in addition to standard of care
2845017|NCT03633708|Active Comparator|Control|Randomized in a 3:1 ratio to receive etelcalcetide in addition standard of care alone (control arm)
2845018|NCT03633695|Experimental|IC-8 IOL|The AcuFocus IC-8 intraocular lens will be surgically implanted in one eye of each subject. A monofocal or monofocal toric intraocular lens will be surgically implanted in the fellow eye of each subject.
2845019|NCT03633695|Active Comparator|Monofocal|A monofocal or monofocal toric intraocular lens will be surgically implanted in both eyes of each subject.
2845020|NCT03633682|Experimental|Engagement Support|In the engagement support group, participants will be sent text messages that will encourage use of the app through tips, reminders, and encouraging messages.
2845021|NCT03633682|Other|No Engagement Support|Participants in this group will receive no text message support.
2845022|NCT03633669|Active Comparator|Tight control|Group that will receive fecal calprotectin testing every 3 months
2845023|NCT03633669|Placebo Comparator|Standard care|Routine clinical care
2845024|NCT03633656|Experimental|Treatment|Model predictive control recommendation of iron dosing in combination with an erythropoietic stimulating agent.
2845025|NCT03633643|Placebo Comparator|Group A|"Single-dose TMP/sulfamethoxazole (SMX, i.e. Cotrimoxazole) perioperative as two ampoules of TMP/SMX 400/80 mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion followed by five oral applications of placebo (lactose tablet; Fagron Gesellschaft mit beschränkter Haftung (GmbH) & Co.~KG) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital."
2845026|NCT03633643|Active Comparator|Group B|3-day application with TMP/SMX (i.e. Cotrimoxazole): Preoperatively as two ampoules of TMP/SMX 400/80mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion, followed by five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
2845027|NCT03633630|Experimental|Amla (Emblica Officinalis)|1000 mg dose per day. Two capsules of 500 mg, one in the morning before breakfast and the other before dinner during 90 days.
2845030|NCT03633617|Experimental|Part B: Dupilumab or Placebo|Part B consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab dosing regimen 1, dupilumab dosing regimen 2 or placebo. At the end of the double-blind treatment visit (week 24), eligible participants will enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
2845031|NCT03633617|Experimental|Part C: Dupilumab or Placebo|Part C is a 28-week treatment period. Participants will receive dupilumab dosing regimen 1, dupilumab dosing regimen 2 or placebo. At the end of the treatment period (week 52), participants will enter a 12-week follow-up period.
2845032|NCT03633591|Experimental|Modified Release Prototypes of Tolcapone|
2845033|NCT03633578|Experimental|Interventional group|Patients are asked to walk ont a treadmill in four conditions: with and without distraction (virtual environment) and at different speed (comfortable vs high).
2845034|NCT03633565|Active Comparator|Steroid|prednisolone 20 mg tablet by mouth taken once daily for 10 days each month for 2 years
2845035|NCT03633565|Active Comparator|Phosphodiestrase inhibitors|sildenafil 25 mg tablet by mouth once daily for 2 years
2845036|NCT03633565|Experimental|Mesenchymal stem cell transplantation|The cells can be injected intramuscular in several points in the muscle alternatively they can be injected in the motor point of the muscle. A motor point is the point at which the motor branch of the innervating nerve enters the muscle). This injection is repeated every 6 month up to 2 years.
2845037|NCT03633552|Experimental|12-cycle arm|After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters body surface per day for the first 5 days of every 28 days).
2845038|NCT03633552|Active Comparator|6-cycle arm|After completion of chemoradiation, the participants will receive 6 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters body surface per day for the first 5 days of every 28 days).
2845039|NCT03633539|Active Comparator|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（multi-ports）.
2845040|NCT03633539|Experimental|Single-incision Laparoscopic Surgery|Patients with colorectal cancer undergo single-incision laparoscopic surgery.
2845041|NCT03633526|Experimental|Part A: Triple Combination|Subjects will receive 120 mg VX-659/ 50 mg TEZ/ 75 mg IVA as an FDC tablet in the morning and 75 mg IVA as mono tablet in the evening.
2845042|NCT03633526|Experimental|Part B: Triple Combination|Subjects will receive VX-659/TEZ/IVA as an FDC tablet in the morning and IVA as mono tablet in the evening, with the dose to be based on the outcome of Part A.
2845043|NCT03633513||Patients|Clinical diagnosed Parkinson's disease patients
2845044|NCT03633513||Caregivers|Environmentally matched healthy control subjects
2845045|NCT03633500|Placebo Comparator|Sterile water|Sterile water: Started by six hours of age, In the control arm, 0.2 ml of sterile water is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The liquid is given time to get absorbed, any pooled liquid is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
2845046|NCT03633500|Experimental|Breastmilk|Breastmilk. This is started at 6 hours of age at the earliest; breast milk: 0.2 ml of mothers' own colostrum/ breast milk is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The colostrum is given time to get absorbed, any pooled milk is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
2845047|NCT03633487|Experimental|Mucinex® 1200 mg|Mucinex® 1200 mg Extended-Release (ER) Bi-Layer tablet (single dose)
2845048|NCT03633474|Experimental|N. Lactamica in PBS|Wild-type Neisseria lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) will be used for this human challenge experiment. This strain is identical to that utilised in our previous challenge experiments (>350 volunteers to date).
2845049|NCT03633474|Placebo Comparator|PBS Control|PBS only control. Volunteers randomized to this arm will receive a PBS only solution which contains no bacteria.
2845050|NCT03633461|Active Comparator|OC-02|
2845051|NCT03633461|Placebo Comparator|Placebo|
2845052|NCT03633448|Experimental|Mucinex® 1 x 200 mg (10 mL)|1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
2845053|NCT03633448|Experimental|Mucinex® 1 x 400 mg (20 mL)|1 x 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
2845054|NCT03633435|Experimental|assisted home hemodialysis patients|all patients starting assisted home hemodialysis during the study period
2845055|NCT03633409||IBD patients and healthy volunteers|We will recruit IBD patients and healthy volunteers
2845056|NCT03633396|Placebo Comparator|Placebo|Placebo as subcutaneous (SC) injection every 4 weeks
2845057|NCT03633396|Experimental|Group 1|ANB019 subcutaneous (SC) injection every 4 weeks
2845058|NCT03633383||Transfemoral Approach|
2845059|NCT03633383||Transapical Approach|
2845060|NCT03633370|No Intervention|Control Group|Usual management of patients according to international guidelines. Protocols of call acceptance, phone advice and sending of emergency services are not modified
2845061|NCT03633370|Other|Test Group|"Multifaceted intervention~Training using distance learning for medical regulation assistants to recognise cardiac arrest on phone~Activation of the location-software application to send bystanders on cardiac arrest location before the arrival of emergency medical services (EMS)~Motivation feed-back Volunteers will received feed-back regarding CPR initiated before EMS arrival and survival"
2845062|NCT03633357|Experimental|JNJ-18038683 first|One week of JNJ-18038683, followed by one week of Placebo after a two week-washout period,
2845063|NCT03633357|Placebo Comparator|Placebo first|One week of Placebo followed by one week of JNJ-18038683 after a two week-washout period,
2845064|NCT03633344|Active Comparator|Carbowhite|3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
2845065|NCT03633344|Placebo Comparator|Carbowhite placebo|3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
2845066|NCT03633331|Experimental|Treatment (palbociclib, letrozole or fulvestrant)|Patients receive palbociclib PO QD on days 1-21. Patients also receive letrozole PO QD on days 1-28 or fulvestrant IM on days 1 and 15 of course 1 and on day 1 of subsequent courses per MD discretion. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2845067|NCT03633318|Active Comparator|IBM Group|Participants in this arm will have Inclusion Body Myositis (IBM).
2845068|NCT03633318|Other|Control Group|Participants in this arm will be healthy controls.
2845069|NCT03633305|Active Comparator|Treatment as usual|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks
2845070|NCT03633305|Experimental|Online cognitive behavior therapy|Online CBT- Internet self-help program for insomnia with 6 cores
2845071|NCT03633305|Experimental|Treatment as usual + Online CBT|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks Online CBT- Internet self-help program for insomnia with 6 cores
2845072|NCT03633305|Experimental|Medication|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks (arms 1, 3, 4)
2845073|NCT03633305|Experimental|In-person cognitive behavior therapy|Face-to-face CBT- Face-to-face therapy with 3 to 4 individual sessions in a period of 6 to 8 weeks.
2845074|NCT03633305|No Intervention|No additional treatment|
2845075|NCT03633292|Active Comparator|Clorhexidine|- Clorhexidine Gel (LACER®, Barcelona, Spain) 0.12%, application 2 times / days for 1 month. The gel will be applied two times/day each 12 hours to the gingiva and mucosa.
2845076|NCT03633292|Experimental|Aloe Vera|"- 80% Aloe vera gel, application 2 times / day for 1 month~Master formula of 80% aloe vera gel Aloe Vera extract, obtained from the central part of the caudal leaves of plants with more than 8 years of life, eliminating its bark. Formulated with carbopol, hydrophilic crosslinked polymer of acrylic acid and vitamin C. The mixture is presented in containers that serve as a container for preparation and will be dispensed in the canister format with applicator tube."
2845077|NCT03633279|Experimental|Branched Chain Amino Acid|Branched Chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg). one packet at 6pm and two at 9pm.
2845078|NCT03633279|Placebo Comparator|Placebo|Equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
2845079|NCT03633266|Experimental|anti-VEGF|experimental group: vitreoretinal surgery combined with intraoperative anti-VEGF
2845080|NCT03633266|Active Comparator|PRP|Control group: vitreoretinal surgery combined with intraoperative PRP
2845081|NCT03633253||MCR syndroms|
2845082|NCT03633253||Non MCR syndroms|
2845083|NCT03633227|Experimental|Obeticholic Acid (OCA) 5 mg to 10 mg|
2845084|NCT03633227|Placebo Comparator|Placebo|
2845085|NCT03633214|Active Comparator|Training module (Intervention)|Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later
2845086|NCT03633214|No Intervention|No training module (Control)|
2845087|NCT03633201|Active Comparator|Cruciate Retaining|
2845088|NCT03633201|Active Comparator|Medial Congruent|
2845089|NCT03633201|No Intervention|Healthy Controls|
2845090|NCT03633188|Experimental|Patients treated by antibiotherapy|35 Patients treated by antibiotherapy for acute and subacute post-operative implant-associated BJI infections and among them 10 patients with Staphylococcus. aureus treated with antibiotics as part of their standard treatment procedure for metagenomic procedure.
2845091|NCT03633175|Active Comparator|Vaginal progesterone group|Women will receive vaginal progesterone 400 mg [Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt], once at bed time starting from 26-28 weeks of gestation and till 36 weeks of gestation or delivery (which is closer).
2845092|NCT03633175|No Intervention|Control group|Women with gestational age from 26-28 weeks diagnosed with placenta previa who will not receive vaginal progesterone.
2845093|NCT03633149|Experimental|Computer tablet-delivered C4H|Two session CHOICES4Health intervention delivered by a computer tablet to address no use or ineffective use of contraception, and risky alcohol use, or cigarette smoking, or marijuana use.
2845094|NCT03633149|Experimental|Person-delivered C4H|Two session CHOICES4Health intervention delivered by a counselor to address no use or ineffective use of contraception, and risky alcohol use, or cigarette smoking, or marijuana use.
2845095|NCT03633149|Active Comparator|Brief Advice|Women will receive advice and educational material from a research assistant about risk drinking, smoking, marijuana, and contraception, depending on their specific risk behaviors, as well as information about women's health. In addition, the women will receive referrals to the Harris Health System's SBIRT clinic if needed.
2845096|NCT03633136|No Intervention|standard education|Standard of care education provided at each transplant center
2845097|NCT03633136|Experimental|electronic video education|Standard education along with home-based video education. The videos will be initially viewed in the following order: Video 1: Introduction; Video 2: The Kidney; Video 3: Assessment and Waitlist; Video 4: Operation and Recovery; Video 5: Medications; Video 6: Your New Life. After the series has been viewed in its entirety one time, participants will be able to replay a specific video as often as desired.
2845098|NCT03633123|Other|Standard of Care (SoC)|SOC prophylactic treatment pre-operation will be as per Israeli Ministry of Health and international guidelines: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.
2845099|NCT03633123|Experimental|D-PLEX + SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
2845100|NCT03633110|Experimental|Part A|"Participants in Part A have no evidence of disease when they begin receiving GEN-009 Adjuvanted Vaccine, and have completed treatment with curative intent for their disease (eg, surgical resection, neoadjuvant and/or adjuvant chemotherapy, and/or radiation therapy).~Part A will consist of approximately 9 participants."
2845101|NCT03633110|Experimental|Part B|"Participants in Part B have advanced or metastatic solid tumors, and will receive GEN-009 Adjuvanted Vaccine in combination with nivolumab.~Part B will consist of up to 75 participants."
2845102|NCT03633110|Experimental|Part C|"Participants in Part C have relapsed or refractory solid tumors, have received at least 1 line of standard systemic therapy that included a PD-1 or PD-L1 inhibitor for advanced, recurrent, or metastatic disease, and will receive GEN-009 Adjuvanted Vaccine as a monotherapy.~Part C will consist of up to 40 participants."
2845103|NCT03633097|Experimental|Acupuncture + Usual care|Acupuncture with Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet
2845104|NCT03633097|Active Comparator|Usual care|Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet
2845105|NCT03633084|Experimental|RBM-007 Injectable Solution - Dose 1|No additional information.
2845107|NCT03633084|Experimental|RBM-007 Injectable Solution - Dose 3|No additional information.
2845108|NCT03633058|Experimental|0.75 mg/kg|ketamine will be dosed orally twice daily for 5 days at 0.75 mg/kg, in addition to 5 days of placebo
2845109|NCT03633058|Experimental|1.5 mg/kg|ketamine will be dosed orally twice daily for 5 days at 0.75 mg/kg, in addition to 5 days of placebo
2845110|NCT03633058|Experimental|3.0 mg/kg|ketamine will be dosed orally twice daily for 5 days at 3.0 mg/kg, in addition to 5 days of placebo
2845111|NCT03633058|Experimental|4.5 mg/kg|ketamine will be dosed orally twice daily for 5 days at 4.5 mg/kg, in addition to 5 days of placebo
2845112|NCT03633019|Experimental|high-dose rhTPO|rhTPO (300-600U/kg/day), ih, until the platelets increased by 50 x 109/L compared to the baseline or above 100 x 109/L
2845113|NCT03633006||Pulmonary Nodules|"Subject with pulmonary nodules will be enrolled, provide a blood sample and may be followed up to 2 years for nodule resolution.~A second blood draw will be collected at 12 months."
2845114|NCT03633006||CT Suspicion of Cancer|"Subject with suspicion of lung cancer will provide a blood sample.~Diagnostic information will be collected to confirm the final diagnosis."
2845115|NCT03633006||Pathologically Confirmed Cancer|"Subject has pathologically confirmed lung cancer and is treatment naïve.~Subject will be enrolled and provide a blood sample."
2845116|NCT03632993|Active Comparator|Treatment I: EN3835 Shallow Injection, 3 Aliquots|"In Treatment I, EN3835 will be injected subcutaneously while the subject lies in a prone position. Each injection will consist of a single skin injection of study drug administered as three 0.1 mL aliquots (for a total injection volume of 0.3 mL).~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of EN3835 (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of EN3835 (0.84 mg in each treatment area)."
2845117|NCT03632993|Active Comparator|Treatment II: EN3835 Shallow Injection, 1 Aliquot|"In Treatment II, EN3835 will be injected subcutaneously while the subject is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single shallow injection of a 0.3 mL aliquot.~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of EN3835 (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of EN3835 (0.84 mg in each treatment area)."
2845118|NCT03632993|Active Comparator|Treatment III: EN3835 Deep Injection, 1 Aliquot|"In Treatment III, EN3835 will be injected subcutaneously while the subject is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single deep injection of a 0.3 mL study drug aliquot.~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of EN3835 (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of EN3835 (0.84 mg in each treatment area)."
2845119|NCT03632993|Active Comparator|Treatment IV: EN3835 Deep and Shallow Injections, 5 Aliquots|"In Treatment IV, EN3835 will be injected subcutaneously while the subject lies in a prone position. Each injection will consist of a single skin injection of study drug administered as five 0.3 mL (for a total injection volume of 1.5 mL).~During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.5mL of EN3835 (5 aliquots of 0.3 mL, for each injection, in each syringe). Dose per subject per treatment visit = up to 1.68 mg of EN3835 (0.84 mg in each treatment area)."
2845120|NCT03632993|Active Comparator|Treatment V: EN3835 Shallow Injections, 4 Aliquots|"In Treatment V, EN3835 will be injected subcutaneously while the subject lies in a prone position. Each injection will receive a single skin injection of study drug administered as four 0.3 mL aliquots (for a total injection volume of 1.2 mL).~During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.2mL of EN3835(4 aliquots of 0.3mL each). Dose per subject per treatment visit = up to 1.68 mg of EN3835 (0.84 mg in each treatment area)."
2845121|NCT03632980|Experimental|HIFU prostate treatment|"The HIFU intervention will concern Primary care patients or Secondary care patients (salvage).~Intervention with Ablatherm Foc/Dyn or Focal One HIFU treatment devices~HIFU intervention will be administered with Ablatherm Foc/Dyn or Focal One - First line to Patients suffering from localized prostate cancer that has not been previously treated or Salvage HIFU intervention will be administered with Ablatherm Foc/Dyn or Focal One - Post radiotherapy to subjects harboring prostate cancer recurrency after radiotherapy"
2845122|NCT03632954||ACell Arm|"Cytal® Wound Matrix and/or MicroMatrix®~Cytal® Wound Matrix 1-Layer is composed of porcine-derived extracellular matrix also known as urinary bladder matrix. It is intended for the management of a variety of wounds. The individual device is intended for one time use.~MicroMatrix® is composed of a porcine-derived extracellular matrix known as urinary bladder matrix and is intended for the management of a variety of wounds. The devices are supplied in particle form in masses up to 1000mg. It is intended for one-time use."
2845123|NCT03632941|Active Comparator|VRP-HER2 Vaccine|VRP-HER2 Vaccine 4 x 10EE8 IU given as a single injection every 2 weeks for 3 injections total (Cycle 1: Day 1 and Day 15 Cycle 2: Day 8)
2845124|NCT03632941|Active Comparator|Pembrolizumab|5 administrations of Pembrolizumab 200 mg every 3 weeks for 5 total IV infusions (Day 1 of each 3 week cycle x 5 cycles)
2845125|NCT03632941|Experimental|VRP-HER2 Vaccine + Pembrolizumab|VRP-HER2 Vaccine 4 x 10EE8 IU given as a single injection every 2 weeks for 3 injections total (Cycle 1: Day 1 and Day 15 Cycle 2: Day 8)+ 5 administrations of Pembrolizumab 200 mg every 3 weeks for 5 total IV infusions (Day 1 of each 3 week cycle x 5 cycles)
2845126|NCT03632928||Migraine patients|"Migraine patients, who do not have any other diseases except from tension type headache.~No intervention, but daily measurements of muscle hardness (Ultrasound Elastography) and tenderness (Pressure pain threshold)"
2845127|NCT03632889|No Intervention|Control Arm|Subjects randomized to the control group will receive a sleep hygiene handout .
2845128|NCT03632889|Other|Computerized Group|Subjects randomized to GoToSleep program will receive a sleep hygiene handout and a unique code for home access to the GoToSleep program.
2845129|NCT03632876|Active Comparator|Lower Dose Vitamin A|Subjects with SCD-SS in the lower dose Vitamin A arm receive 3000IU of retinyl palmitate daily for 8 weeks.
2845130|NCT03632876|Active Comparator|Higher Dose Vitamin A|Subjects with SCD-SS in the higher dose Vitamin A arm receive 6000IU of retinyl palmitate daily for 8 weeks.
2845131|NCT03632876|No Intervention|Healthy Comparison Arm|Healthy subjects receive no intervention and undergo comparisons to the two vitamin A supplementation arms at baseline.
2845132|NCT03632863|Experimental|Electronic Patient Decision Aid|Participants login to a website where they access the interactive PDA as well as access standard published information and resources.
2845133|NCT03632863|Sham Comparator|Standard Resource Sheet|Participants login to a website where they access standard published information and resources.
2845134|NCT03632850||Doctors|This is a group of oncologists who have experience in treatment deliberations with patients of advanced cancer.
2845135|NCT03632850||Nurses|This is a group of clinical nurse specialists who have experience in treatment deliberations with patients of advanced cancer
2845136|NCT03632850||Patients|this is a group of adult patients who have been diagnosed with advanced pancreatic cancer
2845137|NCT03632850||Relatives|this is a group of adults who are involved in providing support for their loved ones who are diagnosed with advanced pancreatic cancer
2845138|NCT03632837|Experimental|Treatment|Inclusion of an extracorporal in line adsorbing cartridge for 48h (with a cartridge exchange at 24h) post establishing ECMO in addition to standard post resuscitation intensive care
2845139|NCT03632837|No Intervention|Control|ECMO and standard post resuscitation intensive care without any additional module in extracorporal circulation
2845140|NCT03632824|Experimental|interventional arm|Tranexamic acid applied intravenously for 2 days followed by oral tranexamic acid
2845141|NCT03632798|Active Comparator|Physician Choice treatment|"Participants will be treated with control chemotherapy treatment (Bevacizumab plus standard-of-care chemotherapy chosen by the Physician from the provided list).~Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin;~Docetaxel;~Paclitaxel;~Carboplatin;~Cisplatin;~Gemcitabine;~Topotecan;~Carboplatin, Gemcitabine;~Cisplatin, Gemcitabine;~Carboplatin, Liposomal Doxorubicin;~Carboplatin, Paclitaxel;~Carboplatin, Docetaxel.~The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
2845142|NCT03632798|Experimental|ChemoID-guided treatment|"Participants will be treated with Bevacizumab plus ChemoID-guided standard-of-care chemotherapy drugs from the provided list.~ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin;~Docetaxel;~Paclitaxel;~Carboplatin;~Cisplatin;~Gemcitabine;~Topotecan;~Carboplatin, Gemcitabine;~Cisplatin, Gemcitabine;~Carboplatin, Liposomal Doxorubicin;~Carboplatin, Paclitaxel;~Carboplatin, Docetaxel.~The treating physician will receive the ChemoID assay results from the ChemoID lab."
2845143|NCT03632772|Experimental|Solifenacin 5 mg for 4 weeks|Solifenacin 5 mg once-daily for 4 weeks.
2845144|NCT03632772|Experimental|Mirabegron 50 mg for 4 weeks|Mirabegron 50 mg once-daily for 4 weeks.
2845145|NCT03632772|No Intervention|Control: non treatment|Control: non treatment.
2845146|NCT03632759|Experimental|Liraglutide|Participants will receive subcutaneous (SC) liraglutide for 8 weeks
2845147|NCT03632759|Experimental|Golimumab|Participants will receive subcutaneous (SC) golimumab for 8 weeks
2845148|NCT03632733|Active Comparator|Tetracycline group|Tetracycline cream twice daily for three months
2845149|NCT03632733|Active Comparator|Clotrimazole group|Clotrimazole cream twice daily for three months
2845150|NCT03632733|Active Comparator|Combination drug group|Tetracycline and Clotrimazole combination cream twice daily for three months
2845151|NCT03632733|Placebo Comparator|Placebo group|participants will be provided a cream containing no active drug ingredients
2845152|NCT03632720|Experimental|Group 1|MenACYW conjugate vaccine at 3 months and at 12 to 13 months of age; meningococcal Group B vaccine at 2, 4, and 12 to 13 months of age; routine pediatric vaccines
2845153|NCT03632720|Experimental|Group 2|MenACYW conjugate vaccine at 3 months and at 12 to 13 months of age; meningococcal Group B vaccine at 2 and 4 months of age; routine pediatric vaccines
2845154|NCT03632720|Active Comparator|Group 3|Meningococcal Group B vaccine at 2, 4, and 12 to 13 months of age; routine pediatric vaccines
2845155|NCT03632707|Other|Magnetic resonance imaging of the knee|Patients complain of painful knee with clinical suspicious of medial meniscus posterior root tear of the knee will be examined by all Magnetic Resonance Imaging sequences including sagittal, coronal and axial T1,T2 and STAR weighted images and correlate the results with Knee Arthroscopy
2845156|NCT03632694|Experimental|Health Coaching and Tech Support|"Participants receive tech support for using the Jawbone UP2 activity monitor and smartphone app, and education materials and health coaching to achieve their goals to reduce sedentary time and increase their daily steps."
2845157|NCT03632694|Active Comparator|Tech Support Only|"Participants receive tech support for using the Jawbone UP2 activity monitor and smartphone app and education materials on reducing sedentary behavior."
2845158|NCT03632694|No Intervention|Waitlist Control|"Participants are instructed to maintain their regular activities. Upon completion of the 16-week intervention, participants receive the Jawbone UP2 activity monitor, education materials, and one session of tech support/health coaching."
2845159|NCT03632681|Active Comparator|Insulin|In this arm a single-dose of (160 IU/1.6ml) intranasal insulin will be administrated
2845160|NCT03632681|Placebo Comparator|Placebo|In this arm a single-dose intranasal placebo will be administrated
2845161|NCT03632668|Experimental|Sequence 1|Period 1: AD-2071 10/20mg QD Period 2: AD-2072 80/5mg QD and AD-2071 10/20mg + AD-2072 80/5mg QD
2845162|NCT03632655|Active Comparator|Transrectal Ultrasound Guided Biopsy (TRUS)|Patients will receive a transrectal guided prostate biopsy
2845163|NCT03632655|Active Comparator|Transperineal Prostate Biopsy|Patients will receive a transperineal prostate biopsy
2845164|NCT03632642|Active Comparator|Benzylpenicillin arm|Patients randomised to benzylpenicillin will be treated according to Therapeutic Guidelines 15th Edition. During hospitalisation, the standard dose will be 1.8g Q4H IVI for uncomplicated BSIs and 2.4g Q4H for deep-seated or critical illness infections.
2845165|NCT03632642|Active Comparator|Flucloxacillin arm|Patients randomised to flucloxacillin will be treated according to Therapeutic Guidelines 15th Edition. During hospitalisation, the standard dose will be 2g Q6H IVI or 2g Q4H for deep-seated or criticial illness infections.
2845166|NCT03632629|Active Comparator|study group|3 months of individualized interactive cognitive training, 2 times per week, 15 min per session, a total of 24 sessions, in addition to traditional rehabilitation programs.
2845167|NCT03632629|No Intervention|control group|3 months of traditional rehabilitation programs, without individualized interactive cognitive training.
2845168|NCT03632603|Experimental|Radiotherapy 20 Gy / 4 F|Radiotherapy 20 Gy / 4 F
2845169|NCT03632603|Active Comparator|Radiotherapy 30 Gy/ 10 F|Radiotherapy 30 Gy/ 10 F
2845170|NCT03632590|Experimental|Magnesium Citrate|450 mg of Magnesium Citrate per day
2845171|NCT03632590|Experimental|Magnesium Sulfate|450 mg of Magnesium Sulfate per day
2845172|NCT03632590|Experimental|Magnesium Oxide|450 mg of Magnesium Oxide per day
2845173|NCT03632590|Placebo Comparator|Placebo|
2845174|NCT03632577|Experimental|High Flow Oxygen (HFO)|HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
2845175|NCT03632577|Active Comparator|Non Invasive Ventilation (NIV)|NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers
2845176|NCT03632564|Experimental|Stimulation Arm|REVIVIEW dichoptic audio-visual stimulation
2845177|NCT03632551|Active Comparator|Symmetrical hearing|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
2845178|NCT03632551|Experimental|Single-sided deafness|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
2845179|NCT03632551|Experimental|Bilateral profound hearing loss treated|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
2845180|NCT03632538||Male|"20 male adult patients after cardiac surgery. Drawing of patients blood for measurement of biomarkers (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide) for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours)."
2845181|NCT03632538||Female|"20 female adult patients after cardiac surgery. Drawing of patients blood for measurement of biomarkers (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide) for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours)."
2845182|NCT03632525|Experimental|Intravenous iron|All participants will receive a single dose of intravenous ferric carboxymaltose
2845183|NCT03632512|Experimental|Hericium honey bolus|Dosage form: honey bolus Dosage : Hericium erinaceus mycelium 250mg/day Frequency: 8 bolus/ day Duration: 8 months
2845184|NCT03632512|Placebo Comparator|Control group|Dosage form: Placebo honey bolus Dosage : maize starch Frequency: 8 bolus/ day Duration: 8 months
2845185|NCT03632486||Suspected Dengue|Children with fever and two of the following criteria: anorexia and nausea, rash, aches and pains, warning signs, leukopenia, positive tourniquet test will all receive a diagnostic bedside ultrasound.
2845186|NCT03632473||clinically isolated syndrome (CIS)|"Multiple sclerosis (MS) with a clinically isolated syndrome (CIS) within six months of first clinical event.~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
2845187|NCT03632473||early relapsing-remitting late disease course (RRMS)|"MS with relapsing-remitting early disease course (RRMS) </= 10 years, Expanded Disability Status Scale (EDSS) </=3.5~EDSS:~1.0: No disability, minimal signs in 1 functional System (FS) 1.5: No disability, minimal signs in more than one FS 2.0: Minimal disability in one FS 2.5: Mild disability in one FS or minimal disability in two FS 3.0: Moderate disability in one FS, or mild disability in three or four FS. No impairment to Walking 3.5: Moderate disability in one FS and more than minimal disability in several others. No impairment to Walking.~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
2845188|NCT03632473||late relapsing-remitting late disease course (RRMS)|"MS with relapsing-remitting late disease course (late RRMS) of 5 to 15 years, EDSS: 2.0-5.5 inclusive~EDSS:~4.0: Significant disability but self-sufficient and up and about some 12 hours a day. Able to walk without aid or rest for 500m 4.5: Significant disability but up and about much of the day, able to work a full day, may otherwise have some limitation of full activity or require minimal assistance. Able to walk without aid or rest for 300m 5.0: Disability severe enough to impair full daily activities and ability to work a full day without special provisions. Able to walk without aid or rest for 200m 5.5: Disability severe enough to preclude full daily activities. Able to walk without aid or rest for 100m.~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
2845189|NCT03632473||primary progressive disease course (PPMS)|"MS with a primary progressive disease course (PPMS) up to 15 years, EDSS: 2.0-6.5 inclusive~EDSS:~6.0: Requires a walking aid - cane, crutch, etc. - to walk about 100m with or without resting 6.5: Requires two walking aids - pair of canes, crutches, etc. - to walk about 20m without resting.~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
2845190|NCT03632460|Active Comparator|Dexmedetomidine|1 mcg/kg dexmedetomidine added to 8 ml 0.375% ropivacaine
2845191|NCT03632460|Active Comparator|Dexamethasone|8 mg dexamethasone added to 8 ml 0,375% ropivacaine
2845192|NCT03632447|Experimental|Leva Arm|Subjects will undergo pelvic floor muscle training using the leva device (a vaginal probe) which provides immediate visual feedback via smartphone regarding the motion of pelvic floor muscles. Subjects will perform exercises 2 1/2 minutes twice daily for 8 weeks. At the beginning of the study, four weeks later, and eight weeks later subjects will undergo pelvic floor muscle testing using the PFDx device and surveys to document response to training. After eight weeks, subjects may pursue any additional treatments they wish, but may continue to use the device. They will be further randomized to receive reminder text messages or no messages over 10 months. Subjects will be asked to complete follow up surveys at 6- and 12-months.
2845246|NCT03632018|Active Comparator|Standard Cardiac Rehabilitation|Participants in the STANDARD condition will receive the standard of care cardiac rehabilitation, consisting of 36 sessions across 12 weeks of prescribed, supervised exercise sessions.
2845351|NCT03631199|Experimental|canakinumab|canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy
2845193|NCT03632447|Active Comparator|Kegel Arm|Subjects in this arm will perform pelvic floor muscle exercises (Kegels) for the treatment of stress or mixed urinary incontinence. Subjects will be asked to perform exercises three times daily for 8 weeks. At the beginning of the study, four weeks later, and eight weeks later, subjects will undergo pelvic floor muscle testing (using the PFDx device) and surveys to document response to training. After eight weeks, subjects may pursue any additional treatments they wish, but may continue to use the device.
2845194|NCT03632434|Experimental|tDCS|6-week course of active tDCS treatment, consisting of 5 sessions per week for the first 3 weeks followed by 2 sessions per week for 3 weeks, for a total of 21 tDCS sessions. The duration of each session is 30 minutes.
2845195|NCT03632421|Experimental|Intervention group|
2845196|NCT03632421|Active Comparator|Control group|
2845197|NCT03632382|Other|OSA diagnosis with 3D acquisition|OSA diagnosis with 3D acquisition
2845198|NCT03632369||Optimization Group|The primary objective of this study is to determine an optimized set of scan parameters for HP 129Xe MR diffusion-weighted imaging, HP 129Xe MR ventilation imaging, HP 129Xe Chemical Shift Saturation Recovery (CSSR) and Xenon polarization Transfer Contrast (XTC) MRI that will produce clear, anatomically and clinically relevant images of the lungs in up to 10 healthy participants and up to 10 participants with NSCLC. The primary objective will be completed before moving onto the secondary objective.
2845199|NCT03632369||Delineate Functional vs. non-functional lung tissue|The secondary objective of this study is to delineate functional versus non-functional lung tissue and the effects of radiotherapy. This objective will be explored by performing these five optimized techniques with up to 10 participants with NSCLC at three time points: before radiotherapy begins, at the end of radiotherapy, and at least 10-weeks post-radiation treatment. These results will be correlated with those from PFTs and CT scans performed at corresponding time points.
2845200|NCT03632356|Experimental|Stepped Care Intervention (STEP)|In a stepped-care model, all patients start with an evidence-based intervention of low intensity as a first treatment step. Progress is monitored and patients who do not respond adequately can subsequently be 'stepped up' to a higher intensity treatment. This model is now being recommended as the best strategy for treating panic attacks and panic disorder.
2845201|NCT03632356|Active Comparator|Screening only|Screening only for panic attacks and panic disorder using a gold standard clinical interview that provides coverage of the core symptoms of panic attacks and panic disorder.
2845202|NCT03632343|Experimental|Experimental Group A|Participants in this arm will receive the Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain >3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
2845203|NCT03632343|Experimental|Experimental Group B|Participants in this arm will receive the Pain Squad+ smartphone app with algorithm-driven pain management advice but without nurse (RN)-initiated pain support.
2845204|NCT03632343|No Intervention|Waitlist Control|Participants in this arm will be waitlisted to receive their choice of experimental group condition within 1 month of completing all post-study outcome measures.
2845205|NCT03632330||Dexmedetomidine|Dexmedetomidine group
2845206|NCT03632330||Midazolam|Midazolam group
2845207|NCT03632330||propofol|propofol group
2845208|NCT03632330||Midazolam/Propofol|Midazolam and Propofol group
2845209|NCT03632317|Experimental|Panobinostat and Everolimus|Panobinostat daily M, W, F for 2 weeks every 28 days for the first cycle (28 days). After first cycle Panobinostat daily M, W, F for 2 weeks every 28 days combined with Everolimus daily.
2845210|NCT03632304|No Intervention|Brachial plexus block (infraclavicular)|The standard of care at our institution. Performed by experienced regional anesthetists.
2845211|NCT03632304|Active Comparator|Local anesthesia with minimal sedation|The comparison group. Performed by the operating surgeon.
2845212|NCT03632291|Experimental|UB-221 (0.3 mg/kg)|Intravenous infusion
2845213|NCT03632291|Experimental|UB-221 (1 mg/kg)|Intravenous infusion
2845214|NCT03632291|Experimental|UB-221 (3 mg/kg)|Intravenous infusion
2845215|NCT03632291|Experimental|UB-221 (6 mg/kg)|Intravenous infusion
2845216|NCT03632291|Experimental|UB-221 (10 mg/kg)|Intravenous infusion
2845217|NCT03632278|Experimental|Mindfulness psychoeducation programme|A MBPP will be conducted for 2 hours for each session, one a week for ten weeks, with 13-15 participants per group. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien & Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).
2845218|NCT03632278|No Intervention|Treatment as usual|"The usual care group will receive routine psychiatric outpatient services, including monthly psychiatric consultation and treatment by a psychiatrist, psychiatric nursing advice and brief education according to the patient's psychosocial needs. There will be community mental health services, social welfare or financial assistance supported by medical social workers, whenever necessary.~Participants in this control may be aware that they are receiving no extra treatment which may result in negative expectancies and inflation of the treatment effect (Stoney & Johnson, 2012). To eliminate the time effect and artificially inflated intervention effect, patients in the control group will receive telephone contact once a week to discuss their disease process and daily issues."
2845219|NCT03632252|Experimental|Powered ankle prosthesis|We will use data from various sensors to optimize the amount of power provided by custom ankle ankle prosthesis. This is a single session study lasting about 4 hours.
2845220|NCT03632239||Patients|who have undergone genome sequencing under separate protocol
2845221|NCT03632226||1|Healthy Volunteers
2845222|NCT03632213|Active Comparator|Losartan|Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
2845223|NCT03632213|Placebo Comparator|Placebo|Placebo group:15 patients, both sexes, will receive oral placebo for 12 months.
2845312|NCT03631498||periodontitis patients|Gingival biopsies of periodontitis patients who were never-smokers and had no systemic disease or condition.
2845313|NCT03631498||Healthy smokers|Gingival biopsies of healthy individuals who were smokers but no systemic or oral disease or condition.
2845224|NCT03632200|Experimental|Experimental group|"The patients with a cancer of the VADS: in preoperative, all the patients will benefit from dietary advice during a multidisciplinary specific consultation (physiotherapist, dietician, nursing staff CMF). The accent will be put on the adaptations of the diet, the complementary nutritional contributions, the assistants in better to eat.~In post-operative, a dietetic consultation will be set up in 7 days at the post hospitalization and rate call phone at M1, M2, M4 and M5.~The undernourished patient will benefit besides a multidisciplinary consultation at the rate of a consultation a month during 6 months according to the same conditions."
2845225|NCT03632200|No Intervention|Control group|The patients will be followed according to the current recommendations of the French Society Clinical Nutrition and Metabolism (SFNEP).
2845226|NCT03632187|Experimental|Experimental group|Subcutaneous abatacept every weeks during 3 months (W0 to W11). Then, at W12, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS≤10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d). Dosage of GCs will be decreased between W16 and W24 (1mg every week) in each arm according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 17 increase to previous dosage, 10 ≤ PMR-AS ≤ 17: stable dose). If PMR-AS ≤10, the patients wont receive any treatment until a flare.
2845227|NCT03632187|Placebo Comparator|Control group|Subcutaneous placebo every week during 3 months (W0 to W11). Then, at week 12, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS≤10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d). Dosage of GCs will be decreased between W16 and W24 (1mg every week) in each arm according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 17 increase to previous dosage, 10 ≤ PMR-AS ≤ 17: stable dose). If PMR-AS ≤10, the patients won't receive any treatment until a flare.
2845228|NCT03632174|Experimental|Ointment A|Adult subjects presenting with mild-moderate Atopic Dermatitis
2845229|NCT03632174|Experimental|Ointment B|Adult subjects presenting with mild-moderate Atopic Dermatitis
2845230|NCT03632161|Active Comparator|Dexmedetomidine|Dexmedetomidine is added to bupivacaine the paravertebral block
2845231|NCT03632161|Other|Bupivacaine|Bupivacaine only in the paravertebral block
2845232|NCT03632135|Active Comparator|Physician Choice treatment|"Participants will be treated with control chemotherapy treatment (standard-of-care chemotherapy chosen by the Physician from the provided list).~Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Carboplatin;~Irinotecan;~Etoposide;~BCNU;~CCNU;~Temozolomide;~Procarbazine;~Vincristine;~Imatinib;~Procarbazine, CCNU, Vincristine;~Carboplatin, Irinotecan;~Carboplatin, Etoposide;~Temozolomide, Etoposide;~Temozolomide, Imatinib. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
2845233|NCT03632135|Experimental|ChemoID-guided treatment|"Participants will be treated with ChemoID-guided standard-of-care chemotherapy drugs from the provided list.~ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:~Carboplatin;~Irinotecan;~Etoposide;~BCNU;~CCNU;~Temozolomide;~Procarbazine;~Vincristine;~Imatinib;~Procarbazine, CCNU, Vincristine;~Carboplatin, Irinotecan;~Carboplatin, Etoposide;~Temozolomide, Etoposide;~Temozolomide, Imatinib.~The treating physician will receive the ChemoID assay results from the ChemoID lab."
2845234|NCT03632122||Bothersome back pain|The investigators will include community-dwelling older adults at Round 1 or 6 of the NHATS cohort, and will include those with bothersome back pain in the past month based on self-report questions at the respective baseline time point. The investigators will exclude participants who are non-ambulatory (requires wheelchair or scooter).
2845235|NCT03632109|Experimental|Single Arm|Men who have sex with men (MSM) with pharyngeal gonorrhea will be treated with 360mg intramuscular gentamicin x 1.
2845236|NCT03632096|Active Comparator|Photobiomodulation group|Patients will receive 3 applications of low intensity light directly in the region of the three pairs of salivary glands already described. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2. The first application will be after the stimulated collection of saliva and the following applications will be given once a week for another 2 weeks.
2845237|NCT03632096|Sham Comparator|Sham group|The placebo group will have a simulation of application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
2845238|NCT03632083|Active Comparator|Hy-Care Contact Lens Solution|Each subject will wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Hy-Care contact lens solution. Patient will wear as an unmatched pair, per predetermined randomization schedule (to determine which eye receives fanfilcon A/comfilcon A lens).
2845239|NCT03632083|Active Comparator|Lite Contact Lens Solution|Each subject will wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Lite contact lens solution. Patient will wear as an unmatched pair, per predetermined randomization schedule (to determine which eye receives fanfilcon A/comfilcon A lens).
2845240|NCT03632070||Stroke|Patients with stroke who participated in previous studies.
2845241|NCT03632057|Active Comparator|Fixed Tilt (65%)|This is the control group, so device programming for shock energy is the default setting
2845242|NCT03632057|Active Comparator|Fixed Pulse Width|This is the Study group.
2845243|NCT03632044|Experimental|Suprazygomatic maxillary nerve blockade|A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia.
2845244|NCT03632044|Sham Comparator|25 Gauge needle|Subcutaneous placement of a 25 Gauge needle as a sham comparator after the induction of general anesthesia. Nothing will be injected.
2845245|NCT03632031|Experimental|Oasis Extracellular Matrix|Application of Oasis ECM on non-healing ulcers of any etiology present for at least 1 month
2845314|NCT03631498||Smokers with periodontitis|Gingival biopsies of periodontitis patients who were smokers but no systemic disease or condition.
2845315|NCT03631485||parents having children with cancer|No intervention.
2845247|NCT03632018|Experimental|HEART-PLAY|Participants in the HEART-PLAY will receive standard CR and additionally receive pedometers, resistance bands, and the National Institute of Aging (NIA) exercise guide. They will further receive counseling from peer health coaches, social support from group education sessions, and supplemental educational materials. After the 12 weeks of prescribed, supervised exercise sessions, HEART-PLAY group participants will continue to receive support from peers and clinic staff with check-in calls, feedback on pedometer goals, and twice weekly group events including walks and/or resistance band group exercise classes.
2845248|NCT03632005|Other|Sterile Dressing|Standard of care treatment - Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
2845249|NCT03632005|Active Comparator|Vacuum Assisted Closure|The Prevena™ System, a type of vacuum assisted closure, is indicated for use over clean, closed incisions that continue to drain following sutured or stapled closure. It acts by removing exudate, helping hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment.
2845250|NCT03631992|Experimental|Low Sweet|"Children in intervention group will be provided with daily snacks lower in added sugar and sweetness and their mothers will receive educational lessons on dental care, reading food labels, and nutrition that support the goals of reducing sweet exposure and added sugar intake."
2845251|NCT03631992|Sham Comparator|Regular Sweet|Children in the regular sweet control group will be provided with common snacks fed to children of this age and mothers will be given education lessons on portion size, physical activity, sleep, screen time and, at the end of the trial, dental care.
2845252|NCT03631979|Experimental|Intervention group|Regular intestinal lavage with normal saline twice per day, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. The intervention will be applied at a maximum of 2 weeks from birth.
2845253|NCT03631979|No Intervention|Control group|Current routine for extremely preterm infants that do not defecate adequately will be applied.
2845254|NCT03631966|Experimental|BTX-A injection|
2845255|NCT03631953|Experimental|Alpelisib in combination with Trametinib administered|A panel of 3 doses of Alpelisib could be tested in combination with fixed dose of Trametinib (1.5 mg every day).
2845256|NCT03631940|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk the entire length of umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC as we have demonstrated in our previous trials.
2845257|NCT03631940|Active Comparator|Early Cord Clamping|This will occur by clamping the umbilical cord as soon as possible. Since both ECC and UCM will occur after a brief assessment, it is important to note that the cord clamping time will be longer than in previously conducted preterm trials (average 20 seconds) which performed the intervention on all subjects regardless of whether or not they were vigorous. In all cases, the cord clamping time will be documented to ensure consistency.
2845258|NCT03631914|Active Comparator|Active needle tip tracking|A needle tip tracking system is used when performing an ultrasound guided infraclavicular brachial plexus block.
2845259|NCT03631914|Other|Inactive needle tip tracking|No needle tip tracking system is used when performing an ultrasound guided infraclavicular brachial plexus block.
2845260|NCT03631901|Active Comparator|Melatonin|melatonin 0.3mg/kg/8 hours, orally. Given only during the febrile illness.
2845261|NCT03631901|Active Comparator|Diazepam|oral diazepam 1mg/kg/day divided into 3 doses. Given only during the febrile illness.
2845262|NCT03631888||patients scheduled for elective laparoscopic surgery|
2845263|NCT03631875|Placebo Comparator|P (propofol),|normal saline is injected 01 min before induction with propofol 3 mg/kg. After 60 seconds, an experimented anesthesiologist evaluated the LMA conditions insertion.
2845264|NCT03631875|Active Comparator|PK (propofol-ketamine)|we inject 0.5 mg/kg of ketamine 01 min before induction with 03 mg/kg of propofol .Sixty seconds after, an experimented anesthesiologist evaluated the LMA conditions insertion.
2845265|NCT03631862|Experimental|Apatinib combined with CHOP regimen|Apatinib: 250mg/d d1-21 po CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
2845266|NCT03631862|Experimental|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
2845267|NCT03631849|Experimental|Peri implantitis patients|
2845268|NCT03631849|Active Comparator|not peri implantitis patient|
2845269|NCT03631836|Experimental|Combinaton monoclonal therapeutic antibody and bevacizumab|Determine the safety profile and tolerability of monoclonal therapeutic antibody given in combination with a fixed dose of bevacizumab in patients with recurrent glioblastoma in terms of Dose-Limiting Toxicities
2845270|NCT03631823||Radio/Chemotherapy group|The participants in this group receive the concurren radio/chemotrherapy
2845271|NCT03631823||Radio/ without chemotherapy group|The participants in this group receive the radiotherapy but without chemotrherapy
2845272|NCT03631823||Healthy volunteer group|The volunteers for control group
2845273|NCT03631797|Experimental|Microvascular reactivity evaluation|"Patients referred for a preoperative arterial palmar arches assessment before cardiac valvular or coronary surgery.~Intervention is measurement of microvascular reactivity with a laser speckle contrast imaging before surgery."
2845316|NCT03631472|Experimental|GATS Treatment|Gala Airway Treatment System (GATS)
2845317|NCT03631459||Kanglaite Injection/Capsules|Kanglaite injection 200ml, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
2845318|NCT03631446||Patients administered Picoprep® for bowel cleansing|
2845380|NCT03630952|Experimental|0.5 mg Conbercept|
2845274|NCT03631784|Experimental|Cohort A|Participants will receive 1 cycle of carboplatin area under the curve (AUC)6 with paclitaxel 200 mg/m^2 and pembrolizumab 200 mg on Day 1. Approximately 3 weeks later, participants will receive carboplatin AUC2 with paclitaxel 45 mg/m^2 administered weekly for 6 weeks along with 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) in conjunction with standard thoracic radiotherapy. To conclude the study treatments, participants will receive 14 additional cycles of pembrolizumab 200 mg administered Q3W.
2845275|NCT03631784|Experimental|Cohort B|Participants will receive 3 cycles of cisplatin 75 mg/m^2 with pemetrexed 500 mg/m^2 and pembrolizumab 200 mg on Day 1 of each 3- week cycle. Treatment will be given in conjunction with standard thoracic radiotherapy in Cycles 2 and 3. To conclude the study treatments, participants will receive 14 additional cycles of pembrolizumab 200 mg administered Q3W.
2845276|NCT03631771|Experimental|Iodixanol, iohexol, or iopromide|Investigational medicinal product administered intravascularly per usual clinical practice at each participating institution. Doses will be per usual practice. The dose of ICM, timing of ICM administration in relation to the diagnostic procedure, rate of ICM administration, and route of ICM administration will be determined by the physician performing the enhanced radiologic procedure per medical need and local clinical practice.
2845277|NCT03631758|Experimental|Experimental: Evidence + PDA|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources), plus a blog post on PDAs and the relevant decision aid from the Portal database
2845278|NCT03631758|Experimental|Evidence only|The same evidence-based information as group 1 (Evidence + PDA), but without the PDA to quantify the effect of accessing evidence through the Portal alone
2845279|NCT03631758|Sham Comparator|Attention control|Information on how to distinguish high from low-quality health information, not specific to cancer screening or PDAs
2845280|NCT03631745|Experimental|NAMI Mental Health 101 and NAMI FaithNet|Mental Health 101 and FaithNet
2845281|NCT03631745|No Intervention|Wait-list Control|After the 12-month follow-up, wait-list control churches will be provided with the opportunity to receive Mental Health 101 and NAMI FaithNet interventions.
2845282|NCT03631732|Experimental|B/F/TAF|Participants will receive B/F/TAF FDC.
2845283|NCT03631732|Active Comparator|Stay on Baseline Regimen|Participants will stay on 2 NRTIs and a third agent until Week 24, with a delayed switch to B/F/TAF FDC at Week 24.
2845284|NCT03631719||Early-release|Resident in areas that receive early Wolbachia deployments.
2845285|NCT03631719||Late-release|Resident in areas that receive late Wolbachia deployments.
2845286|NCT03631706|Experimental|M7824|
2845287|NCT03631706|Active Comparator|Pembrolizumab|
2845288|NCT03631693|Active Comparator|Simplified papilla preservation flap|PERIODONTAL SURGICAL INTERVENTION:The first arm is the simplified papilla preservation flap (SPPF) surgery.At visit 3, the SPPF surgery is performed. 2D and 3D imaging on surgical site will be carried out pre and post surgery. 2D and 3D imaging performed on surgical site for all post operative visits.
2845289|NCT03631693|Active Comparator|Resective flap with osseous recontouring|PERIODONTAL SURGICAL INTERVENTION: The second arm is the Resective periodontal flap with osseous recontouring (RPFO). At visit 3, the RPFO surgery is performed. 2D and 3D imaging on surgical site will be carried out pre and post surgery. 2D and 3D imaging performed on surgical site for all post operative visits.
2845290|NCT03631680||'Bilateral Oophorectomy Surgery' Group|Premenopausal women planning to undergo a laparoscopic, elective bilateral oophorectomy surgery.
2845291|NCT03631680||'Comparative (Control)' Group|Premenopausal women with normal menstrual cycles from a previously completed study at Pennington Biomedical Research Center [NCT01748994] will serve as a comparator (control) group.
2845292|NCT03631667|Experimental|50 ng dose|Capsule containing 50 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
2845293|NCT03631667|Experimental|50 ng dose plus 1250 ng phenanthrene|Capsule containing 50 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP) and 1250 phenanthrene
2845294|NCT03631654|Placebo Comparator|Control|
2845295|NCT03631654|Experimental|Intervention|
2845296|NCT03631641|Experimental|Treatment (nivolumab)|Participants receive nivolumab intravenously IV over 60 minutes on day 1. Treatment repeats every 3 months for a total of 8 courses in the absence of disease progression or unacceptable toxicity.
2845297|NCT03631628|Experimental|MT+TENS|All subjects will undergo 16 sessions of treatment (2 times per week, for 8 weeks). Subjects will receive 1.5 hours rehabilitation program per visit to the Rehabilitation Clinic: 30 minutes of TENS + MT and 1 hour conventional training.
2845298|NCT03631628|Placebo Comparator|sham-MT+TENS|All subjects will undergo 16 sessions of treatment (2 times per week, for 8 weeks). Subjects will receive 1.5 hours rehabilitation program per visit to the Rehabilitation Clinic: 30 minutes of TENS + sham-MT and 1-hour conventional training.
2845299|NCT03631615|Experimental|Neoadjuvant therpy|neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)
2845300|NCT03631602|Experimental|Arm 1|posaconazole oral suspension
2845301|NCT03631602|Active Comparator|Arm 2|itraconazole oral solution
2845302|NCT03631589|Experimental|MSCs treated|
2845303|NCT03631576|Experimental|Arm 1|CD123/CLL1 CAR-T Cells treat
2845304|NCT03631563|Experimental|Arm 1|ATG-F treated
2845305|NCT03631563|Active Comparator|Arm 2|ATG treated
2845306|NCT03631537|Experimental|NST group|Nutrition support team gives the dietary supplement or other nutritional support during the period of chemotherapy
2845307|NCT03631537|No Intervention|routine group|clinicians decide whether to give and how to give the dietary supplement and other nutritional support
2845308|NCT03631524|No Intervention|Conventional therapy|The control arm will be subject to the same assessments as the treatment arm at the start and end of the two week period. They will receive standard care in the ward including physiotherapy as prescribed by the managing team
2845309|NCT03631524|Experimental|Intervention arm|The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period. They will be evaluated for motor strength, activity of daily living performance, mood and perceived level of health.
2845310|NCT03631511|Experimental|RetroMTA|Direct pulp capping with RetroMTA (BioMTA, Daejeon, Korea)
2845311|NCT03631498||Healthy individuals|Gingival biopsies of healthy individuals who were never-smokers and had no systemic or oral disease or condition.
2845319|NCT03631433|Active Comparator|ibuprofen|A registered pharmacist compounded identical appearing tablets of 200 mg ibuprofen and tablets of 200 mg ibuprofen/216.7 mg acetaminophen. The tablets were placed in identical-appearing bottles (60 tabs of 200 mg ibuprofen or 60 tabs of a combination of 200 mg ibuprofen/216.7 mg acetaminophen). At the end of the debridement appointment, the patient received either a bottle containing 60 tabs of 200 mg ibuprofen or 60 tabs of 200 mg ibuprofen/216.7 mg acetaminophen. The patients were instructed to take 3 tablets every 6 hours as needed for pain.
2845320|NCT03631433|Experimental|ibuprofen/acetaminophen combination|A registered pharmacist compounded identical appearing tablets of 200 mg ibuprofen and tablets of 200 mg ibuprofen/216.7 mg acetaminophen. The tablets were placed in identical-appearing bottles (60 tabs of 200 mg ibuprofen or 60 tabs of a combination of 200 mg ibuprofen/216.7 mg acetaminophen). At the end of the debridement appointment, the patient received either a bottle containing 60 tabs of 200 mg ibuprofen or 60 tabs of 200 mg ibuprofen/216.7 mg acetaminophen. The patients were instructed to take 3 tablets every 6 hours as needed for pain.
2845321|NCT03631420|Experimental|UMC119-01|
2845322|NCT03631407|Experimental|Vicriviroc QD at Dose Level 1 + Pembrolizumab|Participants vicriviroc (dosed orally; once daily [QD]) at dose level 1 in combination with 200 mg pembrolizumab (intravenous [IV] infusion; every 3 weeks [Q3W]) for up to 35 cycles (cycle length: 3 weeks).
2845323|NCT03631407|Experimental|Vicriviroc QD at Dose Level 2 + Pembrolizumab|Participants receive vicriviroc (dosed orally; QD) at dose level 2 in combination with 200 mg pembrolizumab (IV infusion; Q3W) for up to 35 cycles (cycle length: 3 weeks).
2845324|NCT03631394|Experimental|beetroot and anthocyanin|A compound pharmacy will formulate capsules with nitrates extracted from beetroot and anthocyanins from tart cherries. A daily dose of the capsules will be taken for 7 days after the washout period. Each dose will comprise 500 mg of nitrates and 450 mg of anthocyanins. In a meta-review by Dominguez and colleagues, 6-8 mmol of nitrates from beetroot was associated with increased exercise performance. Another review by Kelley et al., showed that marathon runners and resistance trainers ingesting between 450-480 mg of anthocyanins had reduced muscle soreness and decreased oxidative stress. Subject will consume each supplement orally with only water 2 hours pre-prandial.
2845325|NCT03631394|Placebo Comparator|beetroot and placebo|The same compound pharmacy will formulate capsules with nitrate extracted from beetroot and a placebo element made of starch. This product will taste the same as the nitrate and anthocyanin supplementation. A daily dose of the capsules will be taken for 7 days after the washout period. Each supplementation will have 500 mg of nitrate and 450 mg of placebo. Subjects will consume each supplement orally with only water 2 hours pre-prandial.
2845326|NCT03631368|Experimental|Botox|
2845327|NCT03631355|Active Comparator|high tibial osteotomy (HTO)|with or without medial patello-femoral ligament (MPFL)
2845328|NCT03631355|Active Comparator|tibial tubercle osteotomy (TTO)|with or without medial patello-femoral ligament (MPFL)
2845329|NCT03631342|Experimental|VCV20|Volume-controlled ventilation mode under constant flow of 20 Lpm. The inspired volume was progressively increased until the maximum pressure reached 40cmH2O.
2845330|NCT03631342|Experimental|VCV40|Volume controlled ventilation mode under constant flow of 40 Lpm. The inspired volume was progressively increased until the maximum pressure reached 40cmH2O.
2845331|NCT03631342|Experimental|PCV|Pressure controlled ventilation mode, inspiratory time of 1 second. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
2845332|NCT03631342|Experimental|PCV+Tins|Pressure controlled ventilation mode and inspiratory pressure was increased every 5cmH2O, until the maximum pressure of 40 cmH2O was reached. The inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP.
2845333|NCT03631342|Experimental|PSV|Pressure support ventilation mode, with progressive increases of 5 cmH2O at inspiratory pressure, until reaching Pmax of 40 cmH2O. The expiratory sensitivity was adjusted by 25% for all patients.
2845334|NCT03631329||Uncomplicated cesarean delivery|Uncomplicated singleton full-term parturients undergoing cesarean delivery
2845335|NCT03631316|Experimental|Generic valganciclovir|Participants will receive generic formulation (Pisa) of valganciclovir, 450 mg tablets, total dosage 900 mg daily for 4 days.
2845336|NCT03631316|Active Comparator|Innovative valganciclovir|The same participant will receive innovative drug valcyte (roche), 450 mg tablets, total dosage 900 mg daily during 4 days.
2845337|NCT03631303||ICD patients with ATP/shock|10 primary prevention 2-chamber ICD patients (LVEF <35 percent) who received appropriate ICD therapy during follow-up.
2845338|NCT03631303||ICD patients without ATP/Shock|10 primary prevention 2-chamber ICD patients (LVEF <35 percent) who were free from appropriate ICD therapy during follow-up.
2845339|NCT03631303||Pacemaker-patients|10 2-chamber pacemaker-patients (LVEF >50%).
2845340|NCT03631290|Experimental|Deprescribing Intervention|
2845341|NCT03631277|Experimental|photo-activated oral disinfection|photo-activated oral disinfection is an advanced technology utilizing two non-toxic components, a photo-activating liquid and a LED light source that selectively target and abolish cariogenic bacteria and periodontal pathogens
2845342|NCT03631277|Active Comparator|calcium hydroxide|Calcium hydroxide is the gold standard for pulp capping, it permits reparative dentin bridge formation, maintains pulp vitality, protects the pulp against harmful stimuli and has antimicrobial effect
2845343|NCT03631264|Experimental|Kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
2845344|NCT03631264|No Intervention|Control|In this group the late preterm infants won't be applied kinesiotaping to suck and swallow muscles.
2845345|NCT03631251|Experimental|Open Placebo|Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
2845346|NCT03631238||Apparently normal participants|Participants are not complaining from any cognitive decline are subjected to cognitive and cholesterol and homocysteine levels assessment.
2845347|NCT03631225||Guided-Care Arm|Physicians will use the reported Vectra score to guide treatment decisions
2845348|NCT03631225||Usual Care Arm|Physicians will treat patient per standard of care without the use of the Vectra score
2845349|NCT03631212|No Intervention|Waitlist control|Wait-list control group
2845350|NCT03631212|Experimental|Flexiquit|Digital ACT-based intervention for smoking cessation
2845352|NCT03631199|Other|canakinumab matching-placebo|canakinumab matching-placebo in combination with pembrolizumab and platinum-based doublet chemotherapy
2845353|NCT03631186||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
2845354|NCT03631173|Active Comparator|Patient with microdialysis|Intervention group - Patients will receive an intraperitoneal microdialysis catheter and will be monitored consecutively by microdialysis. The surgeon is familiar with the current microdialysis results at any time during the study period. The surgeon may intervene based on traditional symptoms and signs plus predetermined values of the microdialysis results.
2845355|NCT03631173|No Intervention|Patient without microdialysis|The control group - The patients will not receive a microdialysis catheter. The patients are monitored according to current standards of care and the surgeon may intervene based only on traditional symptoms and signs.
2845356|NCT03631160|Experimental|TAES treatment|"Patients in the treatment group receive Transcutaneous Acupoint Electrical Stimulation (TAES) at Zhongji ( CV3),Guanyuan ( CV4), bilaterally Sanyinjiao ( SP6) and bilaterally Ciliao ( BL32) points by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected and maintained until the end of treatment."
2845357|NCT03631160|Sham Comparator|Sham TAES treatment|"Participants in the control group receive shallow TAES at SP6, BL32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the acuponit is shamed without manual stimulation and Deqi and the stimulation apparatus is inefficiency without actual current output."
2845358|NCT03631147|Experimental|Rifaximin treatment group|Rifaximin 400mg bid for 8 weeks
2845359|NCT03631147|No Intervention|The control group|
2845360|NCT03631134|Experimental|SGLT2i treatment|The patients who are using basal insulin therapy with or without oral hypoglycemic drugs will be added SGLT2 inhibitor treatment
2845361|NCT03631121|Experimental|Basalin to Lantus|the patients who are using Basalin treatment will use isodose of Lantus instead
2845362|NCT03631108||Normal Population|"Normal population with different gender, different age different, different blood pressure, different ocular pressure, etc.~All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens."
2845363|NCT03631108||Patients with common ophthalmic diseases|"(1) conjunctivitis; (2) glaucoma; (3) childhood myopia; (4) uveitis; (5) diabetic retinopathy; (6) retinal detachment; (7) fundus neovascularization.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens."
2845364|NCT03631108||Patients using eye drops|"(1) conjunctivitis patients treated with levofloxacin antibiotics; (2) glaucoma patients treated with prostaglandins, adrenaline or receptor blockers drugs; (3) childhood myopia patients treated with atropine drugs; (4) uveitis patients treated with hormones treatment. (5) diabetic retinopathy patients treated with vasodilator.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens before and after eyedrops."
2845365|NCT03631108||Ocular surgery patients|"(1) cataract, phacoemulsification + intraocular lens implantation; (2) glaucoma, iridectomy; (3) fundus neovascularization, intraocular injection of anti-VEGF; (4) diabetic retinopathy, vitrectomy.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens before and after surgery."
2845366|NCT03631082|Experimental|Slump stretching group|"Slump stretching will be performed with the patient in the long sitting position. The position will be held for 30 seconds. A total of 5 repetitions will be completed.~Patients will also complete a standardized exercise program consisting of pelvic tilts, bridging, wall squats, and quadruped alternate arms/legs activities as described by Cleland et al.~Patients will perform 10 repetitions of each exercise."
2845367|NCT03631082|Active Comparator|Lumbar mobilization group|"Maitland Grade 1 - 2 Posterior to anterior lumbar spine mobilization will be applied for 30 - 45 seconds for all segments through L1 to L5 at rate of 1 oscillation per 2 seconds.~Patients will also complete a standardized exercise program consisting of pelvic tilts, bridging, wall squats, quadruped alternate arms/legs activities as described by Cleland et al.~Patients will perform 10 repetitions of each exercise."
2845368|NCT03631069||Dementia|People with hospital episode statistics labels of dementia
2845369|NCT03631069||Normal|
2845370|NCT03631043|Experimental|Treatment (personalized vaccine)|Participants undergo collection of blood and bone marrow for making the vaccine. Participants then receive personalized vaccine SC on days 1 and 15 of courses 1-2 and on day 1 of courses 3-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2845371|NCT03631030|Other|Cooled radiofrequency ablation|This is a single arm study. Patients who will be undergoing cooled radiofrequency ablation for the treatment of arthritis in the cervical facet joints, thoracic facet joints, lumbar facet joints, sacroiliac (SI) region, hip and knee.
2845372|NCT03631017|Experimental|[18 F]-PARPi and PET/CT Scans|The intervention of this study is the injection of a microdose (< 10 0 ug) of [18 F]- PARPi followed by 3 PET/CT studies to determine the biodistribution of this imaging agent in normal organs as well as the kinetics of uptake in squamous cell carcinomas of the head and neck.
2845373|NCT03631004|Experimental|olanzapine|PATIENT WILL TAKE OLANZAPINE 10 MG BERFORE SURGERY
2845374|NCT03631004|Placebo Comparator|placebo|PATIENT WILL TAKE PLACEBO BEFORE SURGERY
2845375|NCT03630991|Experimental|Ca-EDTA Group|"Participants receive Ca-EDTA by vein over about 30 minutes before dose of chemotherapy.~Participants given a daily multivitamin (which is made up of Vitamins C, E, K, B6, and B12 and thiamin, riboflavin, niacin, pantothenic acid, folate, biotin, choline, inositol, rubidium, selenium, zinc, and magnesium) and/or standard drugs while on study. Participants take up to 12 multivitamin capsules every day while on study."
2845376|NCT03630991|Experimental|DMSA Group|"Participants take DMSA by mouth every day for 8 days as directed by the study doctor.~Participants given a daily multivitamin (which is made up of Vitamins C, E, K, B6, and B12 and thiamin, riboflavin, niacin, pantothenic acid, folate, biotin, choline, inositol, rubidium, selenium, zinc, and magnesium) and/or standard drugs while on study. Participants take up to 12 multivitamin capsules every day while on study."
2845377|NCT03630978||Liver resection|
2845378|NCT03630965|No Intervention|Group A|No CPR video
2845379|NCT03630965|Experimental|Group B|CPR video
2845381|NCT03630952|Experimental|1.0 mg Conbercept|
2845382|NCT03630952|Active Comparator|Aflibercept|
2845383|NCT03630939|Experimental|ESR-114 1.5%|ESR-114 1.5% Topical Gel BID for 6 weeks
2845384|NCT03630939|Experimental|ESR-114 5.0%|ESR-114 5.0% Topical Gel BID for 6 weeks
2845385|NCT03630939|Placebo Comparator|Vehicle Gel|Placebo Topical Gel BID for 6 weeks
2845386|NCT03630926||Prostate Cancer (PCa)|Comprised of men with biopsy-confirmed PCa who are scheduled for prostatectomy.
2845387|NCT03630926||Benign Prostatic Hypertrophy (BPH)|comprosed of men with benign prostatic hypertrophy (BPH) who are scheduled for transurethral resection of the prostate (TURP).
2845388|NCT03630926||Bladder/kidney stone|Comprised of men or women with bladder/kidney stones who are scheduled for a cystoscopy.
2845389|NCT03630913|Experimental|Tagged axillary metastatic node|"Patients undergo axillary sonography assessment routinely performed to seek suspicious nodes. A cytological examination (biopsy is optional) of the suspicious node is performed.~The involved node is then tagged with a metal clip under sonography. Then, patients receive NAC before surgery. Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC."
2845390|NCT03630900|Experimental|Sequential O2 culture (5% then 2.5%)|Embryo culture from day 0 to 3 in 5% O2 then split to either 5% or 2.5% O2 until Day 5 or 6.
2845391|NCT03630900|No Intervention|5% O2 culture|
2845392|NCT03630887|No Intervention|Control|Non-active prewarming. Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
2845393|NCT03630887|Experimental|Prewarming during 15 minutes|Active Prewarming will be performed during 15 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
2845394|NCT03630887|Experimental|Prewarming during 30 minutes|Active Prewarming will be performed during 30 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
2845395|NCT03630887|Experimental|Prewarming during 45 minutes|Active Prewarming will be performed during 45 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
2845396|NCT03630874|Experimental|Experimental arm|
2845397|NCT03630874|No Intervention|Control arm|
2845398|NCT03630861||GBM|Primary glioblastoma (GBM)
2845399|NCT03630861||PCNSL|Primary CNS lymphomas (PCNSL)
2845400|NCT03630861||Brain metastases|Brain metastases (BM)
2845401|NCT03630861||Cerebral Stroke|Cerebral Stroke (CS)
2845402|NCT03630861||Healthy Volunteers|Healthy Volunteers (HV)
2845403|NCT03630848|Experimental|10% protein concentration in Embryo Culture Media|
2845404|NCT03630848|No Intervention|5% protein concentration in Embryo Culture Media|
2845405|NCT03630835|Experimental|99mTc-Annexin-V-128 uptake on scintigraphy|
2845406|NCT03630822|Experimental|beneficiary of the advance directive program|
2845407|NCT03630822|Active Comparator|beneficiary of standard Support|
2845408|NCT03630809|Experimental|HER2 DC1 Vaccine|HER2 DC1 vaccine given in 3 booster injections administered every 3 months for the treatment of participants with nonmetastatic HER2pos breast cancer (BC) with low HER2 immunity and history of prior treatment with HER2 DC1 vaccines.
2845409|NCT03630796|Active Comparator|Sevoflurane|"Anesthetic induction with sevoflurane by mask 3-8% and fresh gas flow 2-8 l/min (FiO2 50-100%) followed by ketamine 1-2 mg/kg, midazolam 0,1-0,5 mg/kg, fentanyl 2-4 mcg/kg and pancuronium 0,1 mg/kg.~After orotracheal intubation, anesthesia is maintained with fentanyl 10 - 30 mcg/kg according to clinical needs and sevoflurane 1-3% (end-tidal concentration) before and after cardiopulmonary bypass. Specifically during cardiopulmonary bypass extra fentanyl 1-5 mcg/kg and pancuronium 0,1 mg/kg will be administered and the sevoflurane sustained 1-3% in a specific sevoflurane vaporizer included in the CPB machine.~Pressure-controlled ventilation will be applied to both groups objectifying normocarbia and normoxia.~Ringer`s lactate (RL) will be used as crystalloid solution for fluid therapy."
2845410|NCT03630796|Other|Intravenous anesthetics (TIVA)|"Anesthetic induction with ketamine 1-3 mg/kg, midazolam 0,1-0,5 mg/kg, fentanyl 2-4 mcg/kg and pancuronium 0,1 mg/kg after preoxygenation with FiO2 between 50-100% and fresh gas flow 4-8 l/min.~After orotracheal intubation, anesthesia is maintained with fentanyl 10 - 30 mcg/kg according to clinical needs and continuous infusion of midazolam and ketamine 0,2-0,8 mg/kg/h and 1-2 mg/kg/h respectively before and after cardiopulmonary bypass. Specifically during cardiopulmonary bypass extra fentanyl 1-5 mcg/kg, midazolam 0,1-0,5 mg/kg and pancuronium 0,1 mg/kg will be administered.~Pressure-controlled ventilation will be applied to both groups objectifying normocarbia and normoxia.~Ringer`s lactate (RL) will be used as crystalloid solution for fluid therapy."
2845411|NCT03630783|Experimental|Cognitive Bias Modification (Group-E)|Participants were subjected to Combined Cognitive Bias Modification in each session. During the attentional bias modification phase, photographs of neutral or threatening (disgusted) faces were used. In each trial, a pair was shown for 500 ms. Then, a sign of arrow appeared and participants were asked to indicate the direction of the arrow. In %80 of the trials, the arrow was in the same area with the neutral photograph. During the interpretational bias modification phase a threatening or positive word, as the interpretation of a sentence, appeared, then, a relevant sentence with ambiguous meaning appeared, and later, participants were asked to indicate if the word and the sentence were related. After their response a feedback (right/wrong) was given and the next trial was started.
2845694|NCT03628924|Experimental|Group 2: Guselkumab Regimen 2|Participants will receive guselkumab dose 2 subcutaneously.
2845412|NCT03630783|Placebo Comparator|Placebo Control (Group-C)|Participants in this group were subjected to the same procedure as the experimental group. However, during the Combined Cognitive Bias Modification process, the sign of arrow appeared at even rates (%50 - %50) after neutral and disgusted facial impressions; and during the interpretational bias modification, sentences and relevant words were superficially related or were not related at all.
2845413|NCT03630770|No Intervention|Control|This group receives no feeding supplement.
2845414|NCT03630770|Experimental|MCT Oil|This group is supplemented with MCT oil
2845415|NCT03630757|Experimental|Treatment|While holding the patient's head with the therapist's hands,the cervical spinous processes with the fingertips palpitate to the occipital condyle towards the proximal.Then the fingers of both hands applied pressure to the axis in the space between the occipital condyle and the spinous process
2845416|NCT03630757|Placebo Comparator|Group 2|reaching to the feet while sitting together with warming and cooling periods
2845417|NCT03630744||Adult patients undergoing surgery|Patients over 18 years surgically treated with fluid therapy during the 24 hours of the day study
2845418|NCT03630718|No Intervention|Control Group (CG)|Patients assigned to no intervention
2845419|NCT03630718|Active Comparator|Psychoeducational Intervention Group (EG-EDU)|Patients assigned to psychoeducational intervention
2845420|NCT03630718|Active Comparator|Hypnosis intervention Group (EG-HYP)|Patients assigned to hypnosis intervention
2845421|NCT03630705|Experimental|Group 1 (Mexico)|MenACYW conjugate vaccine at 2, 6, and 12 months of age administered concomitantly with routine pediatric vaccines (at 2, 4, 6, and 12 months of age)
2845422|NCT03630705|Active Comparator|Group 2 (Mexico)|Menveo® at 2, 4, 6, and 12 months of age administered concomitantly with routine pediatric vaccines (at 2, 4, 6, and 12 months of age)
2845423|NCT03630705|Experimental|Group 3 (Russian Federation)|MenACYW conjugate vaccine at 3, 6, and 12 months of age administered concomitantly with routine pediatric vaccines (at 2, 3, 4.5, 6, and 12 months of age)
2845424|NCT03630705|Active Comparator|Group 4 (Russian Federation)|Menveo® at 2, 4, 6, and 12 months of age administered concomitantly with routine pediatric vaccines (at 2, 3, 4.5, 6, and 12 months of age)
2845425|NCT03630705|Experimental|Group 5 (Philippines)|MenACYW conjugate vaccine at 6 to 8 weeks, 18 to 24 weeks, and 12 to 15 months of age administered concomitantly with routine pediatric vaccines (at 6 to 8 weeks, 10 to 16 weeks, 18 to 24 weeks, and 12 to 15 months of age)
2845426|NCT03630705|Active Comparator|Group 6 (Philippines)|Menveo® at 8 weeks, 16 weeks, 24 weeks and 12 months of age administered concomitantly with routine pediatric vaccines (at 8 weeks, 16 weeks, 24 weeks, and 12 months of age)
2845427|NCT03630692||observance of oral drug treatment|Study of observant or nonobservant patient behavior for their oral drug treatment
2845428|NCT03630679||Preterm|born at <37 weeks of gestation
2845429|NCT03630679||Full term Term|born at >/= 37 weeks of gestation
2845430|NCT03630666|Active Comparator|IADT|one injection of IADT. The overall duration of IADT will be six months.
2845431|NCT03630666|Experimental|IADT+ radiotherapy|One injection of IADT. The overall duration of IADT will be six months. Irradiation three months after injection of IADT. The overall duration of radiotherapy will be three months.
2845432|NCT03630653|Experimental|Sentinel LN in breast cancer recurrence|"Patients with a biopsy assessing an ipsilateral breast tumor recurrence, and a diagnosis of invasive carcinoma after a previous diagnosis of breast cancer that has been treated by breast conservative surgery at least one year before.~Before the SLNB procedure, each patient will have a lymphoscintigraphy to evaluate axillary and extra axillary lymphatic mapping.~Patients will be operated by breast conservative surgery (BCS) or mastectomy. Each patient will have a second SLND followed by a systematic complete ALND."
2845433|NCT03630640|Experimental|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant for 12 months
2845434|NCT03630627|Experimental|SB26 for Part 1|SB26: various single doses, administered to various cohorts
2845435|NCT03630627|Experimental|SB26 for Part 2|SB26: various multiple doses, administered to various cohorts
2845436|NCT03630627|Placebo Comparator|Placebo for Part 1|SB26 matching placebo: various single doses, administered to various cohorts
2845437|NCT03630627|Placebo Comparator|Placebo for Part 2|SB26 matching placebo: various multiple doses, administered to various cohorts
2845438|NCT03630614|Experimental|Electronic cigarette condition|Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline
2845439|NCT03630614|Active Comparator|Varenicline condition|Reference group: Electronic cigarette without nicotine (ECwoN) plus active varenicline tablets
2845440|NCT03630614|Placebo Comparator|Placebo condition|Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline
2845441|NCT03630601|Experimental|Diagnostic (photoacoustic imaging)|Participants undergo PAI on different parts of the body over 20 minutes for up to 5 imaging sessions for 6 months.
2845442|NCT03630588|Placebo Comparator|Placebo|
2845443|NCT03630588|Experimental|Surimi intervention|
2845444|NCT03630575|Experimental|Newborns exposed in-utero to psychoactive substances|
2845445|NCT03630562|Other|Patients with exudative AMD|
2845446|NCT03630549|Active Comparator|Standard of Care|"Offer of home-based same-day ART initiation~Clinic-based ART visit/refill Who: Nurse Where: Nurse-led health facility When: Follow-up interval of max. 3 months What: TB screening, Screening for other opportunistic infections, Screening for ART-related toxicities, adherence assessment, assessment whether patient visited any medical facility since last appointment, addressing basic psychosocial problems, ART (+CTX/IPT) dispensing~No SMS intervention"
2845447|NCT03630549|Experimental|Village-based ART refill|"Offer of home-based same-day ART initiation~Offer of Village-based ART visit/refill Who: VHW Where: At VHW's home* When: Follow-up interval of max. 3 months What: TB screening, Screening for other opportunistic infections, Screening for ART-related toxicities, adherence assessment, assessment whether patient visited any medical facility since last appointment, addressing basic psychosocial problems, ART (+CTX/IPT) dispensing~*Except at 6 and 12 months follow-up: visit at health facility for laboratory assessment (viral load)~Offer of Individually customized SMS~Monthly reminder SMS: to pick up ART~SMS communicating VL result"
2845448|NCT03630523|Other|Vaccination|Arm contains all subjects; vaccination with Influvac Tetra will be administered at start of study, response will be measured in 7 and 21 days.
2845449|NCT03630510|Experimental|mechanical ventilator hyperinflation|The VHI maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
2845450|NCT03630510|No Intervention|Control|To perform the control (CTRL), the patients were only positioned and aspirated, without alteration in ventilatory parameters.
2845451|NCT03630497|Experimental|Period 1 Single Dose SD1 (first dose)|"Period 1 Group SD1 a single IV infusion of first single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
2845452|NCT03630497|Experimental|Period 1 Single Dose SD2 (second dose)|"Period 1 Group SD2 a single IV infusion of second single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
2845453|NCT03630497|Experimental|Period 1 Single Dose SD3 (third dose)|"Period 1 Group SD3 a single IV infusion of third single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
2845454|NCT03630497|Experimental|Period 1 Single Dose SD4 (fourth dose)|"Period 1 Group SD4 a single IV infusion of fourth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
2845455|NCT03630497|Experimental|Period 2 Single Dose SD1 (fifth dose)|"Period 2 Group SD1 a single IV infusion of fifth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
2845456|NCT03630497|Experimental|Period 2 Single Dose SD2 (sixth dose)|"Period 2 Group SD2 a single IV infusion of sixth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
2845457|NCT03630497|Experimental|Period 2 Single Dose SD3 (seventh dose)|"Period 2 Group SD3 a single IV infusion of seventh single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
2845458|NCT03630497|Experimental|Period 2 Single Dose SD4 (Optional)|"(Optional) Period 2 Group SD4 a single IV infusion of eighth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
2845459|NCT03630497|Experimental|Multiple Dose MD1|"MD1 once daily IV infusions of first multiple dose BN201 (n=6) or placebo (n=2) for 5 consecutive days~Comparison of BN201 treatment with Placebo"
2845460|NCT03630497|Experimental|Multiple Dose MD2|"MD2 once daily IV infusions of second multiple dose BN201 (n=6) or placebo (n=2) for 5 consecutive days~Comparison of BN201 treatment with Placebo"
2845461|NCT03630484|Active Comparator|Expiratory Rib Cage Compression|Expiratory rib cage compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.
2845462|NCT03630484|Active Comparator|Compression + Ventilator Hyperinflation|Expiratory rib cage compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same.
2845463|NCT03630471|Active Comparator|Enhanced usual care|Enhanced usual care (problem-solving booklets only).
2845464|NCT03630471|Experimental|Intervention|PRIDE 'Step 1' problem-solving intervention.
2845465|NCT03630458|Experimental|Pearl millet couscous - made in Senegal|Steamed pearl millet couscous - commercially produced in Senegal
2845466|NCT03630458|Experimental|Pearl millet couscous - made in USA|Steamed pearl millet couscous - pearl millet obtained from Senegal but processed and prepared in USA
2845467|NCT03630458|Experimental|Pearl millet thick porridge|Thick porridge prepared according to traditional West African methods with pearl millet obtained from Senegal but processed and prepared in USA
2845468|NCT03630458|Experimental|Wheat couscous|Steamed wheat couscous - wheat flour processed and prepared in USA
2845469|NCT03630458|Active Comparator|White rice|White rice - medium-grain prepared using a rice cooker
2845470|NCT03630445|Experimental|Isomaltooligosaccharides (IMOs)|"Isomaltooligosaccharides (IMOs) incorporated into a yogurt test meal.~IMOs are a mixture of short-chain carbohydrates with a purported slow digestion property."
2845471|NCT03630445|Experimental|Xtend® sucromalt|"Xtend® sucromalt incorporated into a yogurt test meal.~Sucromalt is derived from a combination of sucrose (cane or beet sugar) and maltose (corn sugar), yet it has been found to be slowly digested."
2845472|NCT03630445|Experimental|Combination of IMOs and Xtend® sucromalt|Combination of IMOs and Xtend® sucromalt incorporated into a yogurt test meal.
2845473|NCT03630445|Experimental|Raw corn starch|"Raw corn starch incorporated into a yogurt test meal.~Raw corn starch is uncooked starch from corn. Because it is not cooked, it has a slow digestion property."
2845474|NCT03630445|Experimental|Maltodextrin|"Maltodextrin incorporated into a yogurt test meal.~Maltodextrin is a type of starchy carbohydrate (polysaccharide) composed of units of D-glucose (simple sugars). The maltodextrin used for this study had a fast digestion property."
2845475|NCT03630432|Active Comparator|Group A|Immediate 8 week course of pulmonary rehabilitation
2845476|NCT03630432|Placebo Comparator|Group B|Initial 8 weeks of usual care
2845477|NCT03630419|Experimental|Mito-Food Plan and Cellular Repair|Mito-Food Plan with adjunctive Cellular Repair Therapy
2845478|NCT03630406||Laser treatment|Female patients with either SUI of vaginal wall weakness and prolapse refered for an attempt at laser treatment.
2845479|NCT03630393|Experimental|Pressure 6 mmHg|Pneumoperitoneum Pressure 6 mmHg
2845480|NCT03630393|Active Comparator|Pressure 15 mmHg|Pneumoperitoneum Pressure 15 mmHg
2845481|NCT03630380||Single Arm|All children under five years of age with clinical suspicion of pneumonia (fever or respiratory complaints) who have a chest radiograph ordered will be consented. Clinical history, physical exam findings (temperature, respiratory rate, oxygen saturation, and lung auscultation findings), laboratory findings (white blood cell count, differential, and CRP) will be recorded. Lung ultrasound will be performed on all patients.
2845482|NCT03630367|Experimental|study group|women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of L-carnitine 1 gm slow intravenous
2845483|NCT03630367|Active Comparator|control group|women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of saline 1 gm slow intravenous
2848158|NCT03611608|Experimental|LY3316531 Dose 1|LY3316531 administered IV
2845484|NCT03630354|Experimental|Exercising Together supervised|Couples will attend group exercise classes for survivors and their spouse/partner twice weekly for 6 months. Both partners will be expected to attend the same exercise class. All couples will be followed for an additional 6 months after formal training stops. Questionnaire Administration: Participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner.
2845485|NCT03630354|Active Comparator|Exercising separately, supervised|Participants will attend separate group exercise classes for each survivors and for spouses twice weekly for 6 months. All couples will be followed for an additional 6 months after formal training stops. Questionnaire Administration: Participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner.
2845486|NCT03630354|Active Comparator|Exercising at home, unsupervised|Participants will be given an exercise program to do twice a week at home for 6 months. There is no requirement that partners exercise at the same time. All couples will be followed for an additional 6 months after formal training stops. Questionnaire Administration: Participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner.
2845487|NCT03630341|Experimental|study group|This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral carnitine 1g tablet, three times per day from the third day until the day of the pregnancy test.
2845488|NCT03630341|Active Comparator|control group|This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral placebo tablet, three times per day from the third day until the day of the pregnancy test.
2845489|NCT03630328|Experimental|Cogni.Q|800 mg per day (Two 200 mg capsules in the morning and two 200 mg capsules in the evening) for 21 days
2845490|NCT03630328|Placebo Comparator|Placebo|Two capsules in the morning and two capsules in the evening for 21 days
2845491|NCT03630315|Experimental|Dose 1 (Low Dose)|Dose 1 will be a low dose of OTX-TKI.
2845492|NCT03630315|Experimental|Dose 2 (High Dose)|Dose 2 will be a high dose of OTX-TKI.
2845493|NCT03630315|Experimental|Cohort Expansion|This cohort will expand to include more subjects.
2845494|NCT03630289|Experimental|Surgical tissue autograft: TPF flap/pericranial flap|Use of a pedicled autologous piece of tissue called the temporoparietal fascial (TPF) flap or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients
2845495|NCT03630276|Other|Neutrophil/lymphocyte ratio|
2845496|NCT03630276|Other|Platelet/lymphocyte ratio|
2845497|NCT03630276|Other|CRP|
2845498|NCT03630263|Experimental|Raw Corn Starch|Vehicle (apple sauce) will be spiked with 30 g of slowly digestible carbohydrate (raw corn starch)
2845499|NCT03630263|Placebo Comparator|No Raw Corn Starch|Vehicle (apple sauce) will not be spiked with 30 g of slowly digestible carbohydrate (raw corn starch)
2845500|NCT03630250|Experimental|Challenge Volunteer - 4BN1|"Volunteers will be given a choice of which version of the GM N. lactamica they would like to be given (4BN1 or 4YB2).~On Day 0 Challenge volunteers will be asked to lie on their back, 0.5 mL of fluid containing a carefully measured amount of 4BN1 will be dripped slowly into each nostril. The volunteer will be able to breathe through their mouth during the procedure. Volunteers will be asked to remain lying down for 15 minutes. This will be performed only once.~Volunteers will then be admitted to the NIHR Southampton CRF for 5 days. Challenge volunteers will then be asked to return for follow up visits on Day 7, 10, 14, 28, 56 90 & 92.~A single dose of an antibiotic (Ciprofloxacin) will be administered on day 90 regardless of colonisation with modified N. lactamica 4BN1."
2845501|NCT03630250|No Intervention|Contact Volunteer|Contact volunteers are those volunteers whose partner/spouse is a Challenge volunteer. Investigators will monitor Contact volunteers to collect information about transmission. A single dose of an antibiotic (Ciprofloxacin) will be administered on Day 90 regardless of colonisation with modified N. lactamica.
2845502|NCT03630250|Experimental|Challenge Volunteer - 4YB2|"Volunteers will be given a choice of which version of the GM N. lactamica they would like to be given (4BN1 or 4YB2).~On Day 0 Challenge volunteers will be asked to lie on their back, 0.5 mL of fluid containing a carefully measured amount of 4YB2 will be dripped slowly into each nostril. The volunteer will be able to breathe through their mouth during the procedure. Volunteers will be asked to remain lying down for 15 minutes. This will be performed only once.~Volunteers will then be admitted to the NIHR Southampton CRF for 5 days. Challenge volunteers will then be asked to return for follow up visits on Day 7, 10, 14, 28, 56 90 & 92.~A single dose of an antibiotic (Ciprofloxacin) will be administered on day 90 regardless of colonisation with modified N. lactamica 4YB2"
2845503|NCT03630237||Intensive care population|All patients admitted to any of the three adult intensive care units (general, cardiac & neurosciences) at a large teaching hospital. These patients will have a high sensitivity troponin added onto biochemistry samples requested by the clinical team.
2845504|NCT03630224|Experimental|Plasmalyte Viaflo|Intervention type: drug (Plasmalyte Viaflo) Intervention name: plasmalyte Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
2845505|NCT03630224|Active Comparator|NaCl 0.9%|Intervention type: drug (NaCl 0.9%) Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
2845506|NCT03630211|Experimental|Autologous Stem Cell Transplantation|CD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 30 days, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
2845507|NCT03630198|Active Comparator|Corticosteroid with lidocaine|This arm will include an injection mixture of corticosteroid and lidocaine
2845508|NCT03630198|Experimental|Corticosteroid with normal saline|This arm will include a mixture of corticosteroid and normal saline. The purpose of normal saline is to keep the volume and concentration similar when compared to the injections containing lidocaine.
2845509|NCT03630185|Experimental|Custom-manufactured compression hosiery (Isobar)|The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
2845632|NCT03629288|Experimental|Periodontal treatment, Antibiotic|Periodontal treatment (scaling and root planning) and one tablet containing 500 milligrams (mg) of Azithromycin once a day for three days immediately after the scaling and root planning.
2845510|NCT03630185|Active Comparator|Off-the-rack stockings (Sigvaris)|Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
2845511|NCT03630172|Experimental|Dry Needling Group|"Dry needles will be sterile, and 0.30 x 60mm in gauge and length. Needles will be placed using an inferomedial approach with the subject positioned in prone. The needle is inserted perpendicular to the skin and then is guided inferiorly and medially until it reaches the lamina. Needles will be manipulated in a pistoning fashion for 15 seconds."
2845512|NCT03630172|Sham Comparator|Sham Needling Group|Non-penetrating needles were constructed by cutting 100mm needles where the handle meets the shaft, and sanding down any rough edges. Guide tubes from 40mm needles will be used. These needles will be place in the same location and manipulated in the same fashion as in the dry needling group, except the needles will not have penetrated the skin.
2845513|NCT03630159|Experimental|Tisagenlecleucel+Pembrolizumab|
2845514|NCT03630146|Experimental|iPeer2Peer Mentorship|10 sessions of 20-30 minute Skype video calls conducted over 5-12 weeks.
2845515|NCT03630146|Active Comparator|Waitlist Control Group|The control group will receive standard care but without the iPeer2Peer program.
2845516|NCT03630133|Experimental|Intracept System Ablation|
2845517|NCT03630120|Active Comparator|Standard of Care: DTC|Standard of Care (SOC) TKI Therapy for Differentiated Thyroid Cancer (DTC): Lenvatinib + Sorafenib.
2845518|NCT03630120|Experimental|Adaptive Care: DTC|SOC followed by Adaptive Care TKI Therapy for DTC Participants with >=50% drop: Lenvatinib + Sorafenib.
2845519|NCT03630120|Active Comparator|Standard of Care: MTC|Standard of Care (SOC) TKI Therapy for Medullary Thyroid Cancer: Cabozantinib + Vandetanib.
2845520|NCT03630120|Experimental|Adaptive Care: MTC|SOC followed by Adaptive Care TKI Therapy for MTC Participants with >=50% drop: Cabozantinib + Vandetanib.
2845521|NCT03630107|Experimental|WO 5101 Shampoo for Scalp and Hair|WO 5101 is used in subjects with chronically itchy scalp
2845522|NCT03630094|Experimental|FEP-ZID via intravenous|total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
2845523|NCT03630081|Experimental|FEP-TAZ 4 g|FEP-TAZ Pharmaceutical dosage form: Intravenous infusion Dosage: 4 g (2 g FEP and 2 g TAZ) IV q8h, infused over 90 min
2845524|NCT03630081|Active Comparator|Meropenem|Meropenem Pharmaceutical dosage form: Intravenous infusion Dosage: 1 g IV q8h, infused over 45 min
2845525|NCT03630068||Patients with hepatocellular carcinoma treated with microwave|
2845526|NCT03630055|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg tablet to be taken orally once daily for 7 days. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
2845527|NCT03630055|No Intervention|Standard of Care|Participants will not receive any anticoagulation. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
2845528|NCT03630042|Experimental|Pembrolizumab and Rituximab|
2845529|NCT03630029|Other|Administer a dose 12mgFeS/9mg SnPP|12 healthy volunteers will be administered a single dose of 12 mg Iron Sucrose and 9 mg of Tin Protoporphyrin and followed for seven days.
2845530|NCT03630029|Other|Administer a dose 60mgFeS/45 mg SnPP|12 healthy volunteers will be administered a single dose of 60 mg of Iron Sucrose and 45 mg of Tin Protoporphyrin and followed for seven days.
2845531|NCT03630029|Other|Administer a dose 120mgFeS/90mg SnPP|12 healthy volunteers will be administered a single dose of 120 mg of Iron Sucrose and 90 mg of Tin Protoporphyrin and followed for seven days.
2845532|NCT03630029|Other|Administer a dose 180mgFeS/135mg SnPP|12 healthy volunteers will be administered a single dose of 180 mg and 135 mg of Tin Protoporphyrin and followed for seven days.
2845533|NCT03630029|Other|Administer a dose of FeS/SnPP CKD Arm|12 subjects with stage 3 or 4 CKD will be administered a single dose of Iron Sucrose and Tin Protoporphyrin selected from the highest dose from the prior arm that evidences the best safety profile. The subjects will be followed for seven days.
2845534|NCT03630016|Active Comparator|Reference CO-Oximetry|
2845535|NCT03630016|Experimental|Owlet BabySat v1.0|
2845536|NCT03630016|Experimental|Owlet Smart Sock V2 v1.1|
2845537|NCT03630003|Experimental|Use of MOCS with post-use interview|"The patients in this arm will be asked to utilize the Manually Operated Communication System (MOCS) device and will then be asked to provide feedback on their experiences.~Subjects will be asked to complete up to 3 sessions using the device. Each session is expected to last between 10 and 30 minutes. If the subject is interested in continuing, the session may last up to one hour.~The study team will perform post-study interviews with each subject to ask about their experience with MOCS. The data collection forms will be filled out during the session by a member of the research team."
2845538|NCT03629990|Experimental|Active ABM + CBT/MET|"Participants in the Active ABM condition will receive approach bias modification (ABM) training sessions aimed at reducing cognitive bias for cannabis cues.~All participants will receive MET/CBT therapy."
2845539|NCT03629990|Sham Comparator|Sham ABM + CBT/MET|"Participants in the Sham ABM condition will undergo similar computerized tasks without the manipulation of response contingencies that target modification of approach bias.~All participants will receive MET/CBT therapy."
2845540|NCT03629977||early RRT|A patient where initiation of RRT is started without the absolute indications
2845541|NCT03629977||late RRT|"CRRT based on absolute indications.~Absolute indications:~hyperkalemia (serum potassium≥6 mEq/L),~severe acidosis (pH≤7.15),~plasma urea>36 mmol/L (equals BUN=100.8 mg/dl),~oliguria or anuria (urine output<0.3 ml/kg per hour for ≥24 hours or anuria for ≥12 hours), and~fluid overload with pulmonary edema as defined by the presence of all the following factors: (a) >10% fluid accumulation (cumulative fluid balance/baseline weight>10%), (b) oliguria (urine output<0.5 ml/kg per hour for ≥12 hours), and (c) severely impaired oxygenation (PaO2/FiO2<200 indicated by respiratory Sequential Organ Failure Assessment [SOFA] score≥3)"
2845542|NCT03629977||never RRT|RRT is never started, matched against early RRT group.
2845633|NCT03629275|Experimental|CTX0E03 Drug Product and delivery device|20 million neural stem cells
2845634|NCT03629275|Sham Comparator|Placebo|Sham Surgery
2845722|NCT03628716|Experimental|CV301 + Atezolizumab|Subject receiving combination treatment with CV301 + Atezolizumab
2845543|NCT03629964|Experimental|Head stabilizer group|Patients will be receiving standard brain radiation. The experimental head holder device (called the Wiersma Head Stabilizer) will be attached to treatment table and will make small movements to adjust the position of the head in response to movement by the patient. In addition, the AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the patient's head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
2845544|NCT03629951||Participants with Schizophrenia|Participants will not receive any intervention as a part of this study. Participants with a diagnosis of schizophrenia or schizoaffective disorder receiving oral antipsychotics (OAP) for example, risperidone (1 to 6 milligram [mg] once daily [OD] to twice a day [BID]), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to thrice a day [TID]) etc, per their treating physician/clinician instruction will be observed. The primary data source for this study will be the clinical assessments by the treating physician of each participant conducted as a part of routine clinical practice.
2845545|NCT03629925|Experimental|Sintilimab+ gemcitabine plus platinum|Experimental: Sintilimab Injection (Dosage form:10ml:100mg; Frequency: 200mg Q3W; Duration: until first documented tumor progression per RECIST v1.1 criteria) Sintilimab 200mg + gemcitabine plus platinum for 4 cycles followed by Sintilimab 200mg Q3W until first documented tumor progression per RECIST v1.1 criteria
2845546|NCT03629925|Placebo Comparator|Placebo+gemcitabine plus platinum|Placebo + gemcitabine plus platinum Q3W for 4 cycles followed by placebo (Conditional crossover to sintilimab 200mg Q3W)
2845547|NCT03629912|Experimental|Exercise + Health Education + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating exercises AND health information on fall risks + diet/nutrition.
2845548|NCT03629912|Active Comparator|Exercise + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating exercises ONLY.
2845549|NCT03629912|Active Comparator|Health Education + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating health information on fall risks + diet/nutrition ONLY.
2845550|NCT03629912|No Intervention|Bingo Only|Participants use the Bingocize app to play bingo only.
2845551|NCT03629899|Experimental|RETINA IMPLANT Alpha AMS|"After implantation surgery, every single sub-test will be performed with randomized implant activation (ON or OFF). During every trial of each sub-test there will be a study coordinator and a technician. The study coordinator will have a set randomization examination schedule while the technician will record patient response without knowledge of the randomization examination schedule. The patient, technician and investigator will all be masked to the testing conditions."
2845552|NCT03629886|No Intervention|Vaccinated-HPV-039 Group|Healthy Chinese female subjects, who previously received Cervarix vaccine in HPV-039 study (NCT00779766), will undergo cervical sample collection in the current study.
2845553|NCT03629886|Experimental|Cervarix Group|Healthy Chinese female subjects, above 26 years of age at study entry, who previously received control vaccine in HPV-039 study (NCT00779766), will undergo cervical sample collection before vaccination and will receive Cervarix vaccine in the current study.
2845554|NCT03629860|Active Comparator|ascending ramus group|"Local anesthesia will be given to the patient~flap will be reflected to expose the facial wall of the maxilla then The ascending ramus is accessed.~A disc bur will be used to make a rectangular osteotomy~The block bone graft is removed from ascending ramus to recipient site the fixed by mini screws~Doner site flap is closed by using interrupted internal sutures.~after atrophic maxillary alveolar ridge augmentation,sub mucosal periosteal releasing cuts is done~Post-operative medications will be prescribed as follows: amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, metronidazole 5 mg/kg every 8 hours for 7 days"
2845555|NCT03629860|Active Comparator|Chin Group|"Local anesthesia will be given to the patient~flap will be reflected to expose the facial wall of the maxilla then The chin is accessed.~A disc bur will be used to make a rectangular osteotomy~The block bone graft is removed from chin to recipient site the fixed by mini screws~Doner site flap is closed by using interrupted internal sutures~after atrophic maxillary alveolar ridge augmentation,submucosal periosteal releasing cuts is done~Post-operative medications will be prescribed as follows: amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, metronidazole 5 mg/kg every 8 hours for 7days"
2845556|NCT03629847|Experimental|Everolimus & Radiolabeled Lu-177|Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
2845557|NCT03629821|Experimental|Ballet|Subjects who will receive the experimental protocol.
2845558|NCT03629821|No Intervention|Control|Subjects who will not receive the experimental protocol, only will be on a wait list.
2845559|NCT03629808||Group1: 4-6cm from starting point of gastrectomy to pylorus|
2845560|NCT03629808||Group2: 2-4cm from starting point of gastrectomy to pylorus|
2845561|NCT03629769|Experimental|Patients with prostatitis-like symptoms|Cohort of patients with CP/CPPS (abacterial prostatitis)
2845562|NCT03629756|Experimental|Dose Escalation|3+3 design, including a DLT evaluation period. Varying doses of AB928 in combination with the selected dose of AB122
2845563|NCT03629743||ECOG and EEG Sensor|Study subjects are neurosurgical patients with medically refractory epilepsy who will have implanted with intracranial ECoG electrodes. The electrodes will be used during a period of inpatient monitoring to identify resectable seizure foci.
2845564|NCT03629730|Experimental|High dose|Will receive the greatest duration of coordination intervention training.
2845565|NCT03629730|Experimental|Intermediate dose|Will receive a moderate duration of coordination intervention training.
2845566|NCT03629730|Experimental|Low dose|Will receive a short duration of coordination intervention training.
2845567|NCT03629730|Active Comparator|Active control|Will perform the same number and duration of physical exercises as the High Dose group, but while moving one body segment at a time.
2845568|NCT03629717|Experimental|Denosumab|An ultrasound-guided core needle breast biopsy will be performed on day 1 prior to the intervention. A single dose of subcutaneous denosumab 60mg will be administered immediately after the core biopsy on day 1. This will take place on an outpatient basis. Repeat core-needle biopsy will take place on Day 60 (+/-10 days). Blood samples will also be collected at the time of core-needle biopsy to allow for biomarker assay. Gene expression analyses will be done using NanoString nCounter gene expression system.
2845861|NCT03627780||no PONV|Patients not presenting with postoperative nausea and vomiting
2845569|NCT03629691||gastric cancer lung metastatic|One of the study tumors.Between February 1, 2015 and May 19, 2018, 356adult patients with gastric adenocarcinoma, multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University, of them, 110 patients with lung metastasis. 28 patients with lung cavitation
2845570|NCT03629691||NSCLC|One of the study tumors.Between February 1, 2015 and May 19, 2018, 77 adult patients with primary lung cancer, multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University. 30 of 77 were squamous cell carcinoma and 47 of 77 were adenocarcinoma. 28 patients with lung cavitation.
2845571|NCT03629678|No Intervention|Control group (Booklets)|Group 1 will receive the control arm with a paper booklet of the patient-centered SCD-guidelines with education by a health care provider at a single visit
2845572|NCT03629678|Active Comparator|mobile health application|Group 2 will receive continuous access to technology-based patient-centered SCD-specific guidelines using a user-driven technological platform, plus a paper booklet of the guidelines with education by a health care provider at a single visit. The mobile app will include interactive content and a fully searchable collection of the SCD-specific guidelines that are age- and health literacy-appropriate. Through the mobile app, the investigators will reinforce important points of guideline content; motivate patient engagement through quizzes and reminders; and facilitate peer support, for instance by forming teams to compete against each other to attain goals.
2845573|NCT03629665|Active Comparator|rTMS and naming combined with ILAT|Interventions: Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
2845574|NCT03629665|Sham Comparator|sham rTMS and naming combined with ILAT|Interventions: sham Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
2845575|NCT03629652|Experimental|Head down position|head-down position treatment combined with conventional rehabilitation.
2845576|NCT03629652|Sham Comparator|Conventional Rehabilitation|Conventional rehabilitation treatment
2845577|NCT03629639|Experimental|Metformin|the distributed subjects will be orally administered Metformin 500mg bid lasting for 12 weeks.
2845578|NCT03629639|Placebo Comparator|Placebo|the distributed subjects will be orally administered Metformin-like placebo 500mg bid lasting for 12 weeks.
2845579|NCT03629626|No Intervention|Conventional Perioperative (SP) care|Conventional Perioperative (SP) care
2845580|NCT03629626|Experimental|ERAS protocol|preoperative / intraoperative/ postoperative management
2845581|NCT03629613|Sham Comparator|Baseline|"Subjects will be tested on one day. Baseline testing will take place and will be followed by oral antioxidant cocktail intake. Oral antioxidant cocktail testing will take place ~2 hours after antioxidant intake.~During baseline testing, no supplement or placebo intake will be used."
2845582|NCT03629613|Experimental|Oral antioxidant cocktail|"Subjects will be tested on one day. Baseline testing will take place and will be followed by oral antioxidant cocktail intake. Oral antioxidant cocktail testing will take place ~2 hours after antioxidant intake.~Dose 1:(immediately after baseline) 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2: (30 minutes after dose 1) 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E"
2845583|NCT03629600|Experimental|Aggressive Hydration|Patients randomized to the aggressive intravenous hydration group received Lactated Ringers solution (LR) [COMPOUND SODIUM LACTATE INJECTION I.P.,INVEN PHARMACEUTICALS PVT.LTD,MP,INDIA] intravenously (IV) at 3 mL/kg/hr during the ERCP, a 20cc/kg IV bolus immediately afterward, and then at 3 mL/kg/hr for 8 hours following the procedure.
2845584|NCT03629600|Active Comparator|Rectal Indomethacin|Patients randomised to Rectal Indomethacin were administered a suppository of 100 mg of indomethacin [Indomethacin Suppository 100 Mg B.P, GALEN PHARMACEUTICAL LTD, GUJRAT, INDIA] just after the completion of ERCP procedure.
2845585|NCT03629587||Patients presented H pylori positive|Upper endoscopy, Gastric biopsy, CBC, VITAMIN B12 level, iron studys, folic acid level, bone marrow aspirate
2845586|NCT03629587||Patients with H pylori negative|Upper endoscopy, Gastric biopsy, CBC, VITAMIN B12 level, iron studys, folic acid level, bone marrow aspirate
2845587|NCT03629574|Experimental|Ventilated Group|This group will receive a protective mechanical ventilation during cardiopulmonary byass. No drugs will be administered.
2845588|NCT03629574|No Intervention|Not-ventilated group|This group will not receive any kind of mechanical ventilation during cardiopulmonary byass. The ventilator will be switched off.
2845589|NCT03629548|Active Comparator|early amniotomy plus dinoprostone|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix. Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
2845590|NCT03629548|Experimental|foley balloon catheter plus dinoprostone|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix and an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix
2845591|NCT03629535|Experimental|Patients in SICU|Patients in the SICU with an intra-arterial blood pressure monitor already in place will be considered as subjects.
2845592|NCT03629522|Active Comparator|ondansetron group|Ondansetron 8Mg/4mL Injection: administration of a bolus of 8 mg intravenous Ondansetron diluted in 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia
2845593|NCT03629522|Placebo Comparator|control group|administration of 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia
2845594|NCT03629509|Other|Pre-Intervention|"The BEFORE decision aid will be available for use on the RUBY communication portals (Twitter, Facebook and study portal)~Data will be collected 6 weeks before the implementation of the BEFORE decision aid in RUBY sites to establish a baseline"
2845595|NCT03629509|Experimental|BEFORE Decision Aid Intervention|"Evaluate more intensive strategies to promote use of the BEFORE decision aid through:~We will advertise the availability of the BEFORE decision aid with posters placed in clinic areas at each RUBY site, and will have small handouts available to be distributed in clinic.~We will conduct an educational intervention describing and promoting the use of the BEFORE decision aid and general oncofertility information to nurses and support staff at each RUBY site. This will include an optional 1hr informational webinar, direct outreach and training of nurses/support staff on the use of the tool."
2845596|NCT03629509|Other|Post-Intervention|Data will be collected after the BEFORE decision aid has been implemented in each RUBY site regarding the recommendation of fertility resources, most useful/least useful tool, and use of the BEFORE decision aid.
2845597|NCT03629496|Experimental|Arts-based intervention|Participants will participate in 6x1 hourly art sessions over a period of 3 weeks while they receive their haemodialysis treatment. This will involve 1:1 facilitation with a student and will involve visual arts including sketching, water colour painting and pen and ink, and creative writing activities. Participants will be provided with their own art supplies for infection control purposes and these will be kept on the unit in between sessions. Participants will have an option of displaying completed work in the reception area of the unit during their sessions.
2845598|NCT03629496|No Intervention|Control|Participants will receive usual care during their haemodialysis sessions and will be asked not to engage in any creative writing or visual arts during their haemodialysis sessions for the duration of the study. Once data collection has been completed the participants in the control group will receive art supplies and a single facilitated session on haemodialysis for the purpose of equity.
2845599|NCT03629483|Experimental|Dexmedetomidine group|For patients in the dexmedetomidine group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and 3.75 ug/kg dexmedetomidine. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours (equivalent to dexmedetomidine infusion at a rate of 0.075 ug/kg/h).
2845600|NCT03629483|Placebo Comparator|Control group|For patients in the control group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and placebo (normal saline). The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours.
2845601|NCT03629470|Active Comparator|Group 1|standard conservative treatment
2845602|NCT03629470|Experimental|Group 2|nerve gliding exercises along with the standard conservative treatment.
2845603|NCT03629457|Experimental|Intervention group 4s (mindfulness)|Abbreviated program of 4 weeks: will consist of 4 weekly sessions of 2.5 hours. Participants must practice at home for 15 minutes a day
2845604|NCT03629457|Experimental|Intervention group 8s (mindfulness)|Program of 8 weeks: The format will be 8 weekly sessions of 2.5 hours. Participants must practice at home for 30 minutes a day
2845605|NCT03629457|No Intervention|Control group|The participants will only receive a one-hour information session and will be invited to complete the questionnaires provided in two moments of the time (coinciding with the interventions in the experimental groups)
2845606|NCT03629431|Active Comparator|postoperative standard care|Standard care after surgery in postoperative unit
2845607|NCT03629431|Experimental|Prophylactic non-invasive ventilation|Prophylactic noninvasive ventilation in postoperative and intensive care unit
2845608|NCT03629418|Experimental|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started at the beginning of anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher during surgery.
2845609|NCT03629418|Active Comparator|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
2845610|NCT03629405|No Intervention|A - Negative control (untreated) for product C|On the forearms four test areas were located, which were labeled from A-D. Test area A contralateral to product C
2845611|NCT03629405|No Intervention|B - Negative control (untreated) for product D|On the forearms four test areas were located, which were labeled from A-D. Test area B contralateral to product D
2845612|NCT03629405|Experimental|C - Cosmetic Product WO 3741 with pH 4|On the forearms four test areas were located, which were labeled from A-D. Test area C on the same arm like product D.
2845613|NCT03629405|Experimental|D - Cosmetic Product WO 4081-1 with pH 5.8|On the forearms four test areas were located, which were labeled from A-D.
2845614|NCT03629392|Experimental|Low met/cys diet|Dietary intervention
2845615|NCT03629392|Experimental|Moderate met/cys diet|Dietary intervention
2845616|NCT03629392|Active Comparator|High met/cys diet|Dietary intervention
2845617|NCT03629379|Active Comparator|ustekinumab arm|First 10 patients who are switched from anti-TNF to ustekinumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
2845618|NCT03629379|Active Comparator|vedolizumab arm|First 10 patients who are switched from anti-TNF to vedolizumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
2845619|NCT03629366|Experimental|Supported Employment (SE)|Follow-up with Supported Employment (SE), provided by a job specialist trained in the eight evidence-based principles of Individual Placement and Support (IPS). The SE intervention is provided in addition to the mandatory introduction program for refugees in Norway (treatment as usual).
2845620|NCT03629366|Active Comparator|Treatment as usual (TAU)|Follow-up with treatment as usual, which involves participation in the mandatory introduction program provided for all refugees in Norway. The program includes training in Norwegian language and culture, as well as the various traditional employment schemes offered by the Norwegian labor and welfare Administration.
2845621|NCT03629353|Experimental|intubation group|The enrolled patients will be oxygenated by endotracheal tube during operation.
2845622|NCT03629353|Experimental|THRIVE group|The enrolled patients will be oxygenated by intubationless high flow nasal cannula during operation.
2845623|NCT03629340|Experimental|Drug: Metformin|500mg PO (by mouth) BID (two times daily) x 1 week then increase to 1000mg PO BID x 11 weeks
2845624|NCT03629340|Placebo Comparator|Placebo Oral Capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
2845625|NCT03629327|Active Comparator|ASA 300mg|Daily uptake of 300mg ASA
2845626|NCT03629327|Placebo Comparator|placebo|daily uptake of a placebo
2845627|NCT03629327|Active Comparator|ASA 100mg|daily uptake of 100mg ASA
2845628|NCT03629314|Experimental|Educational Pamphlet arm|Educational Pamphlet will be provided to all participants to review, questionnaire will be provided to complete before and after review of the pamphlets
2845629|NCT03629301|Experimental|ID-DPP group|Internet-delivered intervention based on the DPP
2845630|NCT03629301|Other|Wait-list Group|
2845631|NCT03629288|Placebo Comparator|Periodontal treatment, lactose tab|Periodontal treatment (scaling and root planning) and one tablet containing lactose once a day for three days immediately after the scaling and root planning.
2848159|NCT03611608|Experimental|LY3316531 Dose 2|LY3316531 administered IV
2845635|NCT03629262|Experimental|Dexmedetomidine group|For patients in the dexmedetomidine group, postoperative analgesia is provided in the form of patient-controlled intravenous analgesia. The formula contains a mixture of sufentanil (1.25 ug/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a patient-controlled bolus of 2 ml each time and a lockout interval of 8 minutes.
2845636|NCT03629262|Placebo Comparator|Control group|For patients in the control group, postoperative analgesia is provided in the form of patient-controlled intravenous analgesia. The formula contains a mixture of placebo and sufentanil (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a patient-controlled bolus of 2 ml each time and a lockout interval of 8 minutes.
2845637|NCT03629249|Experimental|QAW039 Dose 1|QAW039 Dose 1 once daily orally
2845638|NCT03629249|Experimental|QAW039 Dose 2|QAW039 Dose 2 once daily orally
2845639|NCT03629249|Placebo Comparator|Placebo|Placebo to QAW039 once daily orally
2845640|NCT03629236|Experimental|GrafixPL|
2845641|NCT03629236|Active Comparator|Control|
2845642|NCT03629223|Experimental|Part A, Stage 1: First Tepotinib TF2 then TF3|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
2845643|NCT03629223|Experimental|Part A, Stage 1: First Tepotinib TF3 then TF2|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
2845644|NCT03629223|Experimental|Part A, Stage 2 (Optional): First Tepotinib TF2 then TF3|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
2845645|NCT03629223|Experimental|Part A, Stage 2 (Optional): First Tepotinib TF3 then TF2|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
2845646|NCT03629223|Experimental|Part B: First Tepotinib TF2 Fasted then TF2 Fed|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 under fasting conditions followed by single oral dose of Tepotinib TF2 in treatment period 2 under fed conditions. Two treatment periods will be separated by a washout period of 21 days.
2845647|NCT03629223|Experimental|Part B: First Tepotinib TF2 Fed then TF2 Fasted|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 under fed conditions followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
2845648|NCT03629223|Experimental|Part C: First Tepotinib TF3 Fasted then TF3 Fed|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 under fasting conditions followed by single oral dose of Tepotinib TF3 in treatment period 2 under fed conditions. Two treatment periods will be separated by a washout period of 21 days.
2845649|NCT03629223|Experimental|Part C: First Tepotinib TF3 Fed then TF3 Fasted|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 under fed conditions followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
2845650|NCT03629210|Experimental|Combination Treatment|Combination treatment: Participants will receive intravitreal Eylea (AFL, 2.0 mg) injection and OZURDEX implant (0.7 mg) injection within 0 to 8 days of each other.
2845651|NCT03629210|Active Comparator|Monotherapy|Monotherapy treatment: Participants will receive OZURDEX implant (0.7 mg) injection.
2845652|NCT03629197|Experimental|Communication skills training|Intervention clinicians will receive 2 standardized patient visits. The first visit will consist of an 8 minute video on the development of 5 key communication skills, a 10-12 minute role-play session to practice using these skills, and 8-10 minutes of constructive feedback. The 2nd visit will include only the role-play and feedback components. Clinicians will also get a printed pocket card and pamphlet explaining the targeted communication skills in more detail.
2845653|NCT03629197|Active Comparator|Control|Control clinicians will receive a written summary of the 2016 CDC opioid prescribing guidelines, which include recommendations for best practices for use of opioids to treat chronic non-cancer pain. CDC guidelines will serve as an attention control.
2845654|NCT03629184|Experimental|Baloxavir Marboxil|Participants will receive a single oral dose of baloxavir marboxil on Day 1 (based on body weight). Oseltamivir matching placebo will also be administered orally twice daily (BID) for 5 days.
2845655|NCT03629184|Active Comparator|Oseltamivir|Participants will receive oseltamivir orally BID for 5 days (based on body weight). Baloxavir marboxil matching placebo will also be administered orally on Day 1
2845656|NCT03629171|Experimental|CPX-351 + Venetoclax)|"INDUCTION: Participants receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 of course 1 and on days 1 and 3 of course 2. Participants also receive venetoclax PO QD on days 2-21. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Participants receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 and venetoclax PO QD on days 2-21. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
2845657|NCT03629158|Experimental|CLIMB intervention|"The intervention group will receive the Cardiac Lifestyle Intervention for Maintaining healthy Behaviors (CLIMB) intervention. Participants will participate in a 3-session, one-on-one intervention that takes place over the course of two weeks."
2845658|NCT03629158|No Intervention|Treatment as usual (TAU)|The TAU group will continue to receive their regular medical care.
2845659|NCT03629145|Experimental|Live Music Therapy|Twenty minutes of live, preferred music played on guitar and voice
2845660|NCT03629145|Placebo Comparator|Recorded Music|Twenty minutes of recorded music, also on guitar and voice, previously recorded by investigator
2845661|NCT03629132|Experimental|PRP|Platelet-rich plasma
2845662|NCT03629132|Sham Comparator|Gel|Self-crosslinking sodium hyaluronate gel
2845663|NCT03629119|Experimental|Dietary Fiber Supplement|Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet.
2845664|NCT03629106|Experimental|Contingent Reinforcement|The Contingent Reinforcement (CR) group (n=26) will be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence verified by self-report and urinary THC-COOH level <20 ng/ml.
2845665|NCT03629106|Experimental|No Contingent Reinforcement|The Non-Contingent Reinforcement (NCR) group (n=26) will not be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence.
2845666|NCT03629093||Long-time anesthesia exposure|Infants receive general anesthetics longer than 3 hours in total.
2845667|NCT03629093||Short-time anesthesia exposure|Infants receive general anesthetics shorter than 3 hours in total.
2845668|NCT03629080|Experimental|HB-101 vaccine preemptive|Three doses of HB-101 vaccine will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.
2845669|NCT03629080|Placebo Comparator|Placebo preemptive|Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.
2845670|NCT03629080|Experimental|HB-101 vaccine prophylactic|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
2845671|NCT03629080|Placebo Comparator|Placebo prophylactic|Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
2845672|NCT03629067|Experimental|Sequence A|"Period 1(Treatment R) - Period 2(Treatment R) - Period 3(Treatment T)~There will be a 14 washout of days between the each period."
2845673|NCT03629067|Experimental|Sequence B|"Period 1(Treatment R) - Period 2(Treatment T) - Period 3(Treatment R)~There will be a 14 washout of days between the each period."
2845674|NCT03629067|Experimental|Sequence C|"Period 1(Treatment T) - Period 2(Treatment R) - Period 3(Treatment R)~There will be a 14 washout of days between the each period."
2845675|NCT03629054|Experimental|Test treatment (T)|Low strength empagliflozin/linagliptin/metformin XR fixed dose combination tablet
2845676|NCT03629054|Experimental|Reference treatment (R)|Single tablets of empagliflozin + linagliptin + metformin XR
2845677|NCT03629041|Experimental|Treatment A - Microneedle patch|The application of a 5% topical lidocaine gel to one of the identified areas within the participants mouth using a microneedle patch. The microneedle patch will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
2845678|NCT03629041|Sham Comparator|Treatment B - Patch with no microneedles|The application of a 5% topical lidocaine gel to one of the identified sites within the participants mouth using a patch with no microneedles. The patch with no microneedles will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
2845679|NCT03629028|Active Comparator|Single Layer|Diagnostic Test: Residual myometrium thickness 6th months Diagnostic Test: Total myometrium thickness Diagnostic Test: Niche Presence 6th months Diagnostic Test: Niche Measurements in 3D
2845680|NCT03629028|Active Comparator|Double Layer|Diagnostic Test: Residual myometrium thickness 6th months Diagnostic Test: Total myometrium thickness Diagnostic Test: Niche Presence 6th months Diagnostic Test: Niche Measurements in 3D
2845681|NCT03629015|Experimental|Stemchymal®|Biological: Stemchymal® ALF/ ACLF patients will receive low (0.5 x 10^6 cells/kg) or high (2 x 10^6 cells/kg) dose of Stemchymal® through intravenous infusion
2845682|NCT03629002||patients with systemic scleroderma|Use of the biological collection of the vascualire stromal fraction of the SCLERADEC 2 clinical trial.
2845683|NCT03629002||healthy volunteers|Recovery of a sample of adipose tissue during a liposuction operation in a context of routine cosmetic surgery.
2845684|NCT03628989|Experimental|Technology Arm (i.e Virtual Reality, Augmented Reality)|
2845685|NCT03628976|Sham Comparator|Sham-tVNS to ear lobe|Sham-tVNS will be applied to the ear lobe.
2845686|NCT03628976|Active Comparator|tVNS to tragus|tVNS will be applied to the tragus.
2845687|NCT03628963|Experimental|Concerto+ (Intervention group)|Patients with two or more targeted chronic diseases (diabetes, hypertension, dyslipidemia) and who had three or more visits in the last 12 months will use Concerto+ application during 6 months.
2845688|NCT03628963|No Intervention|Usual care (Control group)|Patients with two or more targeted chronic diseases (diabetes, hypertension, dyslipidemia) and who had three or more visits in the last 12 months will not use the application Concerto+ but receive usual care from FMG.
2845689|NCT03628950|Active Comparator|ICSSB group|infraclavicular suprascapular nerve block administered group
2845690|NCT03628950|Active Comparator|ISB group|interscalene nerve block administered group
2845691|NCT03628937|Experimental|Intervention group|"Interventions: Decaffeinated green tea polyphenol capsule (400 mg, EGCG accounted for 50%) will be given to participants in intervention group, and they need take it once a day after breakfast for 12 weeks.~Decaffeinated green tea polyphenol: 400mg/capsule, 1 capsule/d, qd, 12 weeks"
2845692|NCT03628937|Placebo Comparator|Control group|The placebo control group will be given placebo capsules, and participants need take it once a day after breakfast for 12 weeks.
2845693|NCT03628924|Experimental|Group 1: Guselkumab Regimen 1|Participants will receive guselkumab dose 1 administered Intravenously (IV) followed by guselkumab dose 2 administered subcutaneously.
2848160|NCT03611608|Placebo Comparator|Placebo|Placebo administered IV
2845695|NCT03628924|Experimental|Group 3: Placebo then Guselkumab|Participants will receive placebo IV and SC and an additional SC placebo dose at Week 12 then cross over at Week 16 to receive guselkumab dose 2 and dose 3 SC and placebo SC.
2845696|NCT03628885|No Intervention|General Vaccine Information|Brief (47 second) animated informational video about vaccines recommended for all young adolescents.
2845697|NCT03628885|Experimental|Top Concern Tailored Intervention|"Intervention includes the General Vaccine Information video plus a brief (< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns: 1. I need more information about the vaccine; 2. My child is too young; 3. I am concerned about the long-term health effects or safety of the vaccine; 4. My child's health care provider did not recommend it or said my child could wait; 5. The vaccine is not required for school; 6. Other / none of the above. For those indicating #6, they will receive the same video as those indicating #1 (need more information)."
2845698|NCT03628885|Experimental|All Concerns Tailored Intervention|"Intervention includes the General Vaccine Information video plus one or more brief (< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns: 1. I need more information about the vaccine; 2. My child is too young; 3. I am concerned about the long-term health effects or safety of the vaccine; 4. My child's health care provider did not recommend it or said my child could wait; 5. The vaccine is not required for school; 6. Other / none of the above."
2845699|NCT03628872|Active Comparator|Cleaning with hand instruments|Patients will undergo scaling and root planing with hand instruments in half of their mouth (the right side or the left side).
2845700|NCT03628872|Experimental|Cleaning with Er:YAG Laser|Patients will undergo scaling and root planing with Er:YAG Laser on the other half of their mouth that was not treated with the conventional approach (the right side or the left side).
2845701|NCT03628833|Experimental|Incontinence Management system|
2845702|NCT03628820|Experimental|Therapy Dog|"This group is exposed to the therapy dog and handler. On a convenience sample of shifts, a dog will be available. Participants will not know when dogs will be present and will not be informed of whether or not they will see a dog on any given shift. The dog and handler will be kept out of site of other providers. Participants who agree to participate will be approached by study personnel between 3 and 7 hours into his or her shift and asked would now be a good time to see a therapy dog? If the physician answers yes, then the physician will be escorted to a separate private, quiet room away from the usual work area to interact with a therapy dog and handler. We will ask the physician to spend approximately 5 minutes with the therapy dog, but will not specify or mandate any time. Study personnel will record the time spent. Only the handler and dog will be present in the room."
2845703|NCT03628820|Experimental|Mandala Coloring|This group is not exposed to the therapy dog or handler. At 3-7 hours into the shift, study personnel will encourage providers to take a 5 min period of mindfulness, achieved by coloring mandalas. Participants will be escorted out of the work area to the same private, quiet room where the interaction occurs with the dog and handler in the therapy dog group. Participants will have their choice of one of three mandalas to color and will be provided a full palette of colored pencils. When the provider's time is up, study personnel will notify them of the five minute period. Study personnel will not be present in the room but will photograph the work when the participant is done with the session and record the image in REDcap. The original art work will be returned to the provider.
2845704|NCT03628807||Retrospective 1|Retrospective Bare Metal Stent Cohort that received TIPS from 01/01/1996 to 12/31/2003.
2845705|NCT03628807||Retrospective 2|Retrospective Covered Stent Cohort that received TIPS from 01/01/2004 to 12/31/2012.
2845706|NCT03628807||Prospective|Prospective cohort that received TIPS from 01/01/2013 onwards
2845707|NCT03628794|Other|Intervention|Subjects in the intervention group will receive the D-SCAN mobile application
2845708|NCT03628794|Other|Control|Subjects randomized into the control group will receive standard of care which includes the routine provision of information about supportive care services by nurses and other staff in the DCI clinics, as part of the standard nurse-driven distress screening and management process
2845709|NCT03628781|Experimental|mehealth portal with integrated behavioral tools|Patients in this arm will continue to use the mehealth for ADHD web-based software for ADHD care but will also have access to a module that allows parents and teachers to develop and implement behavioral interventions such as daily report cards online.
2845710|NCT03628781|Other|mehealth portal with no integrated behavioral tools|Patients in this arm will continue to use the mehealth for ADHD web-based software for ADHD care but will wait one year before getting access to the behavioral intervention features.
2845711|NCT03628768||Healthy / Non fallers|Older cognitively healthy individuals Non fallers
2845712|NCT03628768||Healthy / Fallers without injuries|Older cognitively healthy individuals Fallers without injuries
2845713|NCT03628768||Healthy / Fallers with injuries|Older cognitively healthy individuals Fallers with injuries
2845714|NCT03628768||MCI / Non fallers|Older individuals with MCI and mild dementia Non fallers
2845715|NCT03628768||MCI / Fallers without injury|Older individuals with MCI and mild dementia Fallers without injuries
2845716|NCT03628768||MCI / Fallers with injury|Older individuals with MCI and mild dementia Fallers with injuries
2845717|NCT03628755|Active Comparator|Digital Manipulation|Digital manipulation of thyroid cartilage (DMT) Duration: Each child was given 15-20 minute session. Frequency: Twice in a week. Total 24 sessions were performed. The aim of DMT was to reduce the severity of stuttering and improve the fluency.
2845718|NCT03628755|Active Comparator|fluency shaping Therapy|"Fluency Shaping Therapy Duration:Each child was given 30-minute session. Fluency Shaping Therapy (FST) Frequency: Twice in a week Total 24 sessions were performed.~The aim of DMT was to reduce the severity of stuttering and improve the fluency"
2845719|NCT03628755|Experimental|combination Group|Combination Group (DMT+FST) Duration:Each subject was given 45-Minute session Frequency: Twice in a week Total 24 sessions were performed combination group was more significant option for reducing the severity of stuttering and improve fluency than practice the single DMT or FST
2845720|NCT03628729|Experimental|Embrace™ WetBond™ Pit & Fissure Sealant.|pits and fissures will be sealed with bioactive pits-and-fissure sealant
2845721|NCT03628729|Active Comparator|Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA|Pits and fissures will be sealed by fluoride releasing resin based pits and fissures sealant
2845723|NCT03628703|Experimental|Repetitive TMS|Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation
2845724|NCT03628690|Experimental|BandGrip|Topical skin closure device
2845725|NCT03628690|Active Comparator|Standard Suture|Standard sutures will be used for wound closure
2845726|NCT03628677|Experimental|AB154 Monotherapy|Varying Doses of AB154 Monotherapy
2845727|NCT03628677|Experimental|AB154 + AB122 Combination Therapy|Varying Doses of AB154 in Combination With the Selected Dose of AB122
2845728|NCT03628664|Active Comparator|CT planned total knee arthroplasty|Surgeon will follow the CT plan
2845729|NCT03628664|No Intervention|Non CT planned total knee arthroplasty|Surgeon will not follow the CT plan
2845730|NCT03628651||HCC Surveillance|Approximately 1000 HCC surveillance subjects (controls) will be enrolled.
2845731|NCT03628651||HCC|Approximately 500 subjects with untreated clinically diagnosed HCC will be enrolled.
2845732|NCT03628638||Lung Cancer Screening Patients - No Nodules|Subjects in an low dose CT screening program that present no nodules.
2845733|NCT03628638||Lung Cancer Screening Patients - Nodules|Subjects in an low dose CT screening program that present nodules. Additional follow-up data will be collected for up to 12 months and an additional blood sample collected
2845734|NCT03628625|Experimental|Study group|3 tablets of Letrozole 2.5 mg will be given as single daily dose, 7.5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
2845735|NCT03628625|Placebo Comparator|Control group|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
2845736|NCT03628612|Experimental|AUTO CAR T cell therapy|Patients who received previous treatment with AUTO CAR T Cell Therapy
2845737|NCT03628599|Experimental|TOTAL1|Delefilcon A contact lenses worn bilaterally (in both eyes) for 4 weeks in a daily disposable modality
2845738|NCT03628599|Active Comparator|1-DAY|Senofilcon A contact lenses worn bilaterally for 4 weeks in a daily disposable modality
2845739|NCT03628573|Other|Intermittent Theta burst stimulation.|Procedure: repetitive transcranial magnetic stimulation (iTBS) to the left Dorsolateral Prefrontal Cortex; 3 sessions per day, for 20 days.
2845740|NCT03628560|Experimental|RespirAct Step-Wise Normocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% in approximate 5% steps.
2845741|NCT03628560|Experimental|RespirAct Slope Normocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% as gradual slope.
2845742|NCT03628560|Experimental|RespirAct Step-Wise Hypocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% in approximate 5% steps.
2845743|NCT03628560|Experimental|RespirAct Slope Hypocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% as gradual slope.
2845744|NCT03628560|Active Comparator|ROBD Step-Wise desaturation sequence|ROBD = Reduced Oxygen Breathing Device. Reduction in oxygen saturation 100 to 70% in approximate 5% steps. This represents the standard type of desaturation sequence for pulse oximeter accuracy testing.
2845745|NCT03628547||soccer players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur soccer players and10 professional soccer players.
2845746|NCT03628547||basketball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur basketball players and10 professional basketball players.
2845747|NCT03628547||volleyball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur volleyball players and10 professional volleyball players.
2845748|NCT03628547||runners|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur runners and 10 professional runners.
2845749|NCT03628547||table tennis athlete|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur table tennis athlete and 10 professional table tennis athlete.
2845750|NCT03628547||field tennis athlete|10 amateur field tennis athlete 10 professional field tennis athlete
2845751|NCT03628547||kickboxers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur kickboxers and 10 professional kickboxers.
2845752|NCT03628547||archers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur archers and 10 professional archers.
2845753|NCT03628534|Experimental|single arm|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
2845754|NCT03628521|Other|arm A|Anlotinib combined with erlotinib. Anlotinib will be given at a dose of 10mg once daily on days 1-14 of a 21-day cycle. Erlotinib will be given at a dose of 150mg once daily.
2845755|NCT03628521|Other|arm B|Anlotinib combined with chemotherapy. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. Pemetrexed (just for adenocarcinoma) will be given intravenously at a dose of 500mg per square meter of body surface area every 3 weeks; gemcitabine (just for squamous carcinoma) will be given intravenously at a dose of 1000mg per square meter of body surface area every 3 weeks; carboplatin will be given intravenously with a target area under the curve of 5 mg per milliliter per minute every 3 weeks.
2845756|NCT03628521|Other|arm C|Anlotinib combined with IBI308. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. IBI308 will be given intravenously at a dose of 200mg every 3 weeks.
2845757|NCT03628508|Experimental|Exercise|Six-week exercise including stretching, strengthening, endurance and gait modification
2845758|NCT03628495|Experimental|SSCP + SPMS|
2845759|NCT03628495|Active Comparator|PG|
2845760|NCT03628482|Active Comparator|CRF group|Patients were assigned to receive continuous radiofrequency (CRF) treatment of genicular nerves
2845761|NCT03628482|Experimental|PRF group|Patients were assigned to receive pulsed radiofrequency (CRF) treatment of genicular nerves
2845787|NCT03628261|Other|physical therapy then serious games|Children will receive four weeks of treatment with EMG-based serious games in addition to the conventional physiotherapy
2845862|NCT03627767|Experimental|PF-04965842 100 mg QD|Double-blind randomized treatment following open label run-in period.
2845762|NCT03628469|Experimental|Active Patient Support|The purpose of the intervention is to enhance patients' self-management strategies and thereby enable patients to cope with illness at home and prevent the development of those conditions, that are sensitive to preventive efforts.The intervention includes active listening, coaching and counselling and elements from case management such as assessing the need for healthcare services. Emphasis is on supporting and empowering the patient to make the necessary contacts to healthcare professionals.
2845763|NCT03628469|No Intervention|Usual care|Usual care
2845764|NCT03628456|Experimental|AffloVest Monarch Arm|Devices placed on highest intensity / highest frequency
2845765|NCT03628443||Heart Failure without Chronic Kidney Disease|This group has patients managed with all types of heart failure without concomitant chronic kidney disease.
2845766|NCT03628443||Heart Failure with Chronic Kidney Disease|This group has patients managed with all types of heart failure with concomitant chronic kidney disease, without evidence of sustained hyperphosphatemia.
2845767|NCT03628430|Placebo Comparator|Group C|"For patients of this group, the intervention was a Local Anesthesia with:~10 mL of 2% lidocaine with epinephrine 0.005mg/ml~and 5 mL of 0.9% NaCl"
2845768|NCT03628430|Active Comparator|Group A|"For patients of this group, the intervention was a Local Anesthesia with:~10 mL of 2% lidocaine with epinephrine 0.005mg/ml~and 5 mL of 4.2 % sodium bicarbonate"
2845769|NCT03628417|Experimental|Calcium Electroporation|"Calcium~Calcium chloride 220 mmol/L (9 mg/ml):~Tumor < 0.5 cm³ - 1 ml/cm³ tumor volume~Tumor > 0.5 cm³ - 0,5 ml/cm³ tumor volume Tumor volume = ab²π/6 (a = longest diameter, b = longest diameter perpendicular to a)"
2845770|NCT03628417|Experimental|Bleomycin based electrochemotherapy|"Bleomycin~Bleomycin 1000 IU/ml:~Tumor < 0.5 cm³ - 1 ml/cm³ tumor volume~Tumor > 0.5 cm³ - 0,5 ml/cm³ tumor volume Tumor volume = ab²π/6 (a = longest diameter, b = longest diameter perpendicular to a)~Maximum of injected bleomycin per tumor will be 1500 IU and total dose per treatment 7500 IU. Normal maximum limit for bleomycin is 15.000 IU/m² body surface area."
2845771|NCT03628391|Active Comparator|haloperidol|"study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations)."
2845772|NCT03628391|Placebo Comparator|placebo|"study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations)."
2845773|NCT03628378|No Intervention|Non-Sensor Group|Patients will undergo standard total knee replacement surgery without Verasense assisted balancing technology.
2845774|NCT03628378|Experimental|Sensor Group|Patients will undergo total knee replacement surgery with Verasense assisted balancing technology.
2845775|NCT03628365|Active Comparator|HMB (beta-hydroxy beta-methylbutyrate)|HMB, 1.5 g b.i.d., from day 4 to day 30 after ICU admission
2845776|NCT03628365|Placebo Comparator|Placebo|Maltodextrin, 1.5 g b.i.d., from day 4 to day 30 after ICU admission
2845777|NCT03628352|Experimental|Tricaprilin|Approximately 5 mL liquid of tricaprilin using various flavoring agents (swish and expectorate) up to 20 times. Dose will not be ingested.
2845778|NCT03628339|Experimental|Midazolam, then tepotinib followed by midazolam + tepotinib|Participants will receive a single oral dose of midazolam on Day 1 of treatment period 1 followed by daily single oral dose of tepotinib from Day 1 to Day 10 of treatment period 2 and then co-administration of tepotinib and midazolam on Day 11 of treatment period 2.
2845779|NCT03628326||right lung resection|The investigators sought to identify anatomic variations of the pulmonary arterial tree and assess their respective frequencies.
2845780|NCT03628326||left lung resection|The investigators sought to identify anatomic variations of the pulmonary arterial tree and assess their respective frequencies.
2845781|NCT03628313||Aortic valve stenosis|The participants will be identified from the Transthoracic ultrasound echocardiography reports of the echocardiography laboratory of the University Hospital of Amiens and CH Philibert for the retrospective part. They are analyzed during echocardiography at the echocardiography laboratory of two participating centers when a diagnosis of aortic stenosis is made. Patients are informed by newsletter.
2845782|NCT03628300||piperacillin serum measurement|patient that underwent at least one piperacillin serum concentration monitoring
2845783|NCT03628300||included for analysis|patient that have been included for analysis according to previously described criteria
2845784|NCT03628287|Active Comparator|Original Care Coordination Program|Specific intervention components include: 1) outreach for initial case finding and after any missed appointment; 2) case management, including social services and benefits assessments; 3) multidisciplinary care team communication and decision-making via case conferences; 4) patient navigation, including appointment reminders, assistance with scheduling appointments, transportation resources, and accompaniment to primary care visits; 5) antiretroviral treatment adherence support, including directly observed therapy for individuals with greatest need; and 6) structured health promotion, for which clients are assigned to program tracks (determining their frequency of health promotion visits: weekly, monthly or quarterly), depending on their level of assessed need.
2845785|NCT03628287|Experimental|Revised Care Coordination Program|The revised model includes the original intervention components without program track assignments. Specific differences include: (1) more focused recruitment/eligibility criteria (based on findings that newly diagnosed and previously unsuppressed PLWH experience a CCP benefit above that of usual care); (2) greater flexibility of delivery, with (a) tailored/differentiated care allowing continual need-based adjustment of the intensity and content of service and (b) options to meet by video chat; and (3) incentives for desired service delivery (e.g., reimbursement encouraging outreach, and covering new components such as immediate ART initiation; and (4) a standard protocol for regularly assessing clients' current HIV self-management capacity, within specific task areas.
2845786|NCT03628274|Experimental|Magnetic Resonance Imaging (RMI) 7 Tesla|
2845858|NCT03627793|Experimental|high load frail|Frail participants who will receive resistance training at 70% of their maximal strength
2845788|NCT03628261|Other|serious games then physical therapy|Children will receive four weeks of treatment with EMG-based serious games in addition to the conventional physiotherapy
2845789|NCT03628248|Experimental|embolization|
2845790|NCT03628248|Other|No embolization|
2845791|NCT03628235||Early stage HDGECs|CAG length ≥ 40; DCL = 4, 7 ≤ TFC ≤ 10
2845792|NCT03628235||Middle stage HDGECs|CAG length ≥ 40; DCL = 4, TFC ≥ 11
2845793|NCT03628235||Late stage HDGECs|CAG length ≥ 40; DCL = 4, 0 ≤ TFC ≤ 6
2845794|NCT03628235||Companions of early stage HDGECs|
2845795|NCT03628235||Companions of middle stage HDGECs|
2845796|NCT03628235||Companions of late stage HDGECs|
2845797|NCT03628222|Experimental|ENB-TBLB|Under ENB guidance, the Location Catheter and Guide Catheter reach the lesion. After confirmation by X-ray, biopsy tools are introduced and specimens are obtained.
2845798|NCT03628222|Active Comparator|X-ray-TBLB|Based on chest CT, the physician determines the lesion location. Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and specimens are obtained.
2845799|NCT03628209|Experimental|Dose Escalation, Resection, Dose Expansion|Participants will receive 1 cycle of neoadjuvant Nivolumab or Nivolumab + Azacitidine, followed by surgery to render them in surgical remission. Subsequently they will continue to receive Nivolumab or Nivolumab + Azacitidine for 12 additional cycles or until recurrence, whichever occurs first. Once the recommended Phase II dose (RP2D) is identified during Phase I, the Dose Expansion Phase II will be opened at this dose level. The Phase II portion of the study will consist of a maximum 33 evaluable patients (27-30 in addition to the 3-6 enrolled at RP2D on the Phase I portion).
2845800|NCT03628196||Pre-Quality Improvement Program Comparison Group|Patients that meet the eligibility criteria and receive standard of care at participating clinics.
2845801|NCT03628196||Post Quality Improvement Program Study Group|Patients that meet the eligibility criteria and are enrolled from participating clinics to receive systematic nutrition screening, education and oral nutrition supplementation recommendations, and follow up.
2845802|NCT03628183|Active Comparator|Hydrolysate Infant Formula 1|Ready to feed infant formula in can
2845803|NCT03628183|Experimental|Hydrolysate Infant Formula 2|Ready to feed infant formula in bottle
2845804|NCT03628170|Experimental|PRF (Platelet -rich fibrin) group|Extraction of the tooth followed by Platelet rich fibrin placed in the socket covered bu platelet rich fibrin membrane for socket preservation.
2845805|NCT03628170|Active Comparator|Free gingival graft group|Extraction of the tooth followed by using free gingival graft to cover the socket for socket preservation.
2845806|NCT03628157|Experimental|intervention|using a bio-oss bovine bone alone
2845807|NCT03628157|Active Comparator|control|using a bio-oss bovine bone with autogenous bone ratio 1:1
2845808|NCT03628144|Experimental|A: Intervention Group - Impact®|A: Intervention Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Impact® Advanced Recovery: Three times daily for the 5 days just prior to the start of each cycle of chemotherapy. Participants will undergo pre- and post-treatment assessments.
2845809|NCT03628144|Active Comparator|B: Control Group - Boost®|B: Control Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Boost® High Protein: Identical schedule of a supplement with similar calorie and protein content, Boost® High Protein. Participants will undergo pre- and post-treatment assessments.
2845810|NCT03628131|Experimental|Pazopanib + conventional chemotherapy|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
2845811|NCT03628118||open radical hysterectomy|"The patients who would undergo open radical hysterectomy procedure."
2845812|NCT03628105|Experimental|CR Before Exposure|Participants in this arm will receive 15 minutes of CR (preparation) before engaging in exposure and will complete the 15-minute questionnaire filler task after exposure.
2845813|NCT03628105|Experimental|CR After Exposure|Participants in this arm will complete the 15-minute questionnaire filler task before exposure and receive 15 minutes of CR (consolidation) after engaging in exposure.
2845814|NCT03628092|Active Comparator|CO2 Fractional Ablative Laser|3 treatments approximately 4 weeks apart with vaginal/vulval laser
2845815|NCT03628092|Placebo Comparator|Placebo|"3 treatments approximately 4 weeks apart with sham laser"
2845816|NCT03628079|Experimental|Single arm study|"ReposMBZ 100 mg capsule by mouth followed by 8h PK sampling to decide the initial daily dose.~Treatment: Repos MBZ capsules by mouth twice daily for 16 weeks, daily dose 50mg-4g, based on the serum level of mebendazole."
2845817|NCT03628066|Experimental|Arm 1|"Oncotype DX Breast recurrence score on diagnostic tissue~Daily Letrozole for 24 weeks + Palbociclib daily for 24 weeks + Goserelin weekly for 24 weeks"
2845818|NCT03628053|Experimental|Tisagenlecleucel arm|Patient to receive tisagenlecleucel after optional bridging therapy and lymphodepleting chemotherapy.
2845819|NCT03628053|Active Comparator|Control arm|blinatumomab or inotuzumab per investigator's discretion after optional bridging chemotherapy
2845820|NCT03628040|Sham Comparator|Sham Block|Patient will receive a single shot of normal saline 20 mL injected at the erector spinae plane
2845821|NCT03628040|Active Comparator|Erector Spinae Block|Patient will receive a single shot of Ropivacaine Injection [Naropin] 0.5% 20 mL injected at the erector spinae plane
2845822|NCT03628027|Experimental|Treatment Algorithm|The treatment algorithm arm will be the experimental arm in which GPs use the computerised decision support tool to guide their prescribing of antidepressants.
2845823|NCT03628027|No Intervention|Treatment-as-usual|The treatment-as-usual arm will comprise GPs prescribing antidepressants and providing care as they typically would.
2845824|NCT03628014|Other|Interventional|The HELP Program is a comprehensive inpatient-care program that ensures optimal care for older adults in the hospital by using trained volunteers that do specific activities to help prevent or maintain functional decline.
2845825|NCT03628001|Other|A|ERCP with (Group A) ES before biliary SEMS placement
2845826|NCT03628001|Other|B|ERCP without (Group B) ES before biliary SEMS placement
2845827|NCT03627988|Experimental|Patients with breast cancer|
2845859|NCT03627793|Experimental|low load frail|Frail participants who will receive resistance training at 30% of their maximal strength
2845860|NCT03627780||PONV|Patients presenting with postoperative nausea and vomiting
2845828|NCT03627975|No Intervention|Conservative treatment|Conservative treatment. The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, the prevention and treatment of secondary epilepsy, the control of intracranial hypertension(including the application of mannitol and glycerol fructose, etc.), and the corresponding symptomatic and neurotrophic treatment. Non-specific treatment is mainly deal with intracranial hematoma, including intraventricular drainage, intracranial hematoma evacuation, and ventriculoperitoneal shunt.
2845829|NCT03627975|Experimental|Indirect vascular reconstruction surgery|Indirect vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) is performed. The surgery is performed according to the procedures described by Matsushima.
2845830|NCT03627975|Experimental|direct vascular reconstruction surgery|Direct vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) bypass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And if necessary, the STA may not be preserved. The bone flap should be large enough to select the right recipient blood vessel.
2845831|NCT03627962|Experimental|gaze-directed oculomotor training|device: Tobii PCEye Treatment group went through the oculomotor training with a gaze-pointer interface (Tobii PC Eye) in reading in Chinese.
2845832|NCT03627962|No Intervention|control|No intervention: participants in control read ordinary Chinese textbooks.
2845833|NCT03627949|Experimental|Intervention group 1|Students in the intervention group 1 received first 4-week treatment on physical activity followed by 4-week treatment on healthy dietary behaviour.
2845834|NCT03627949|Experimental|Intervention group 2|Students in the intervention group 2 received first 4-week treatment on healthy dietary behaviour followed by 4-week treatment on physical activity.
2845835|NCT03627949|No Intervention|Control group|Students in the control group were not provided with any supportive treatments on physical activity or healthy dietary behaviour.
2845836|NCT03627936|Experimental|Lorcaserin 20 mg manufactured at: Zofingen (A) + Kawashima (B)|Participants will receive a single oral dose of lorcaserin 20 milligram (mg) XR tablets manufactured at Zofingen (A) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Kawashima (B) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.
2845837|NCT03627936|Experimental|Lorcaserin 20 mg manufactured at: Kawashima (B) + Zofingen (A)|Participants will receive a single oral dose of lorcaserin 20 mg XR tablets manufactured at Kawashima (B) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Zofingen (A) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.
2845838|NCT03627910|Experimental|Treatment group|Participants assigned to the treatment group will be administered a commercial symbiotic (Probinul Ca.Di.GROUP S.r.l.) for the entire duration of the study (90 days) plus an enteral nutrition formula rich in zinc and arginine
2845839|NCT03627910|Active Comparator|Control group|Control group will be administered only an enteral nutrition formula rich in zinc and arginine
2845840|NCT03627897|Experimental|Regional analgesia group|ESP block at bilateral side will be performed in the lateral decubitis position and at T5 transverse process level by using 10-MHz liner ultrasound probe. The probe will be located 1 cm lateral to T5 spinous process in longitudinal parasagittal orientation. Simplex A 50mm (B.Braun, Germany) will be inserted by using out of plane technique. The ESP blocks proceed with 0,5 ml/kg of 0,25% bupivacaine
2845841|NCT03627897|Sham Comparator|Control group|ESP block at bilateral side will be performed in the lateral decubitis position and at T5 transverse process level by using 10-MHz liner ultrasound probe. The probe will be located 1 cm lateral to T5 spinous process in longitudinal parasagittal orientation. Simplex A 50mm (B.Braun, Germany) will be inserted by using out of plane technique. The ESP blocks proceed with 0,5 mlt/kg salin (Group S).
2845842|NCT03627884|Active Comparator|Normal Saline Catheter Lock Solution Group|Patients receiving normal saline catheter locking solution
2845843|NCT03627884|Active Comparator|Sodium Bicarbonate Catheter Lock Solution|Patients receiving sodium bicarbonate catheter locking solution
2845844|NCT03627871|Experimental|Trending majority norm|Participants receive information about exercise-related norms that apply to the majority of the population and are told this norm has been increasing recently.
2845845|NCT03627871|Experimental|Non-trending majority norm|Participants receive information about exercise-related norms that apply to the majority of the population but are not told about recent trends.
2845846|NCT03627871|Experimental|Trending minority norm|Participants receive information about exercise-related norms that apply to a minority of the population and are told this norm has been increasing recently
2845847|NCT03627871|Experimental|Non-trending minority norm|Participants receive information about exercise-related norms that apply to a minority of the population but are not told about recent trends.
2845848|NCT03627871|Experimental|Control|Participants receive information about exercise unrelated to social norms or recent trends.
2845849|NCT03627845|Experimental|Experimental|PHP-303, single oral dose, up to 6 ascending dose cohorts
2845850|NCT03627845|Placebo Comparator|Placebo|Placebo, single oral dose, up to 6 ascending dose cohorts
2845851|NCT03627832|Experimental|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for 6 weeks
2845852|NCT03627832|Active Comparator|Sleep Hygiene|Sleep hygiene handout delivered once to all participants
2845853|NCT03627819|Active Comparator|Plant sterol-enriched margarine|Intake of 20 gram margarine with added plant sterol esters, providing 3 gram plant sterols per day for 1 year
2845854|NCT03627819|Active Comparator|Plant stanol-enriched margarine|Intake of 20 gram margarine with added plant stanol esters, 3 gram plant stanols per day for 1 year
2845855|NCT03627819|Placebo Comparator|Control margarine|Intake of 20 gram margarine without any addition, every day for 1 year
2845856|NCT03627793|Active Comparator|High load non-frail|Non-frail participants who will receive resistance training at 70% of their maximal strength
2845857|NCT03627793|Active Comparator|low load non-frail|Non-frail participants who will receive resistance training at 30% of their maximal strength
2849745|NCT03599960|Experimental|Chemotherapy|
2845863|NCT03627767|Experimental|PF-04965842 200 mg QD|Double-blind randomized treatment following open label run-in period.
2845864|NCT03627767|Placebo Comparator|Placebo QD|Double-blind randomized treatment following open label run-in period.
2845865|NCT03627754|Experimental|Moderate Hepatic Impairment Group|Subjects with Child-Pugh Classification B (score 7-9)
2845866|NCT03627754|Experimental|Severe Hepatic Impairment Group|Subjects with Child-Pugh Classification C (score 10-15)
2845867|NCT03627754|Experimental|Normal Hepatic Function Group|Healthy subjects with normal hepatic function
2845868|NCT03627741|Experimental|Triamcinolone arm|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
2845869|NCT03627728|Experimental|regorafenib|Regorafenib 160 mg, 4 tablets once daily on days 1-21, every 4 weeks, until intolerance or progression disease
2845870|NCT03627728|Placebo Comparator|placebo|Placebo 4 tablets once daily on day 1-21, every 4 weeks, until intolerance or progression disease
2845871|NCT03627715|Experimental|Propagermanium then Placebo|"Propagermanium one capsule orally twice daily for 12 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 12 weeks propagermanium and 12 weeks placebo separated by a 6 week washout period."
2845872|NCT03627715|Experimental|Placebo then Propagermanium|"Propagermanium one capsule orally twice daily for 12 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 12 weeks placebo and 12 weeks propagermanium separated by a 6 week washout period."
2845873|NCT03627702||Study group|All bedsores were irradiated with a Bioptron lamp. Photo and measurement of bedsores size and Torrance score, were made: on the first, 9,18 and 36 day of therapy.
2845874|NCT03627689|Experimental|Active air purifier arm|Active portable air purifier for 1 month at bedside
2845875|NCT03627689|Sham Comparator|Sham air purifier arm|Placebo portable air purifier for 1 month at bedside
2845876|NCT03627676|Experimental|Intervention|
2845877|NCT03627663|Experimental|Intervention|Receiving treatment with Dialectic Behavior Therapy - Skills System + Treatment As Usual
2845878|NCT03627650|Experimental|1 group of 15 patients|procedure/surgery: fat grafting injection of scar
2845879|NCT03627650|Experimental|Same group of 15 patients|procedure/surgery: placebo injection of scar
2845880|NCT03627637|Experimental|Experimental: Soy nuts|
2845881|NCT03627637|No Intervention|Control - no soy nuts|
2845882|NCT03627611|Active Comparator|T4|
2845883|NCT03627611|Experimental|T3|
2845884|NCT03627598|Active Comparator|standard group|NIV alternating with low oxygen therapy at 1 to 4 liters per minute to obtain SpO2 between 88% and 94%.
2845885|NCT03627598|Experimental|HFNC group|NIV alternating with HFNC delivering the equivalent inspired fraction of oxygen (FiO2) with a flow at 30 to 60 liters/min through an Optiflow nasal interface.
2845886|NCT03627585|No Intervention|Usual Care|Patients received echocardiogram but no pacemaker reprogramming or personalisation.
2845887|NCT03627585|Active Comparator|Personalised programming|Patient will have tailored pacemaker programming based on echocardiographic findings, blood results, and symptoms in an attempt to minimise right ventricular pacing and extend battery longevity.
2845888|NCT03627572||Active cohort (N=1000)|Participants in this group will complete questionnaires at baseline (birth) and after 1-2-3 years. At baseline samples will be collected (blood/nasopharyngeal/urine/feces/buccal). During the RSV season(Oct-May) active sampling for RSV will be done when infants experience a respiratory infection.
2845889|NCT03627572||Passive cohort (N=9000)|Parents who agree with participation in the study will be asked to fill out a questionnaire at inclusion in the first week(s) after birth and at age one year. Only children who were admitted to the hospital for ARTI during the first year of life will be followed up to the age of maximum 3 years by yearly questionnaires.
2845890|NCT03627559||Pancreaticoduodenectomy patients|All patients undergoing pancreaticoduodenectomy receive a microdialysis catheter before skin closure and will be monitored postoperatively for lactate, pyruvate, glucose and glycerol in the microdialysate at certain timepoints
2845891|NCT03627546|Experimental|Rapid Treatment with sofosbuvir/velpatasvir (Intervention arm)|"The intervention arm receives same‐day medical evaluation and treatment for hepatitis C. They receive medical evaluation, laboratory assessment , baseline questionnaire/interview, and distribution of a medication (sofosbuvir/velpatasvir) starter pack on the day of enrollment. Participants who are HCV RNA negative are discontinued from the study. Other participants start medications and receive weekly text messages during treatment to record adherence. They have follow up visits for laboratory tests, medication distribution, and counseling for prevention of reinfection. They have HCV testing at end of treatment and 12 weeks post treatment, and at 48 weeks to assess for reinfection. Each study visit will include a brief questionnaire and qualitative interview."
2845892|NCT03627546|No Intervention|Usual Care (Control arm)|Participants in the control arm will be provided facilitated referral to community HCV providers by an on‐site care coordinator already facilitating care at the community site. HCV RNA negative participants will be called to inform them of these results, and then discontinued from the study. HCV RNA positive participants will be asked during the semi‐structured interviews as at 12, 24, 36 and 48 week if they engaged in HCV treatment to assess whether their HCV referral has been filled, and to record their current HCV treatment status. They will also receive repeat HCV RNA testing at week 12, 24, and 48. Participants that have started treatment will be asked to sign consent for release of medical records pertaining to HCV‐related laboratory testing to determine achievement of treatment response.
2845893|NCT03627533|Experimental|Electroacupuncture|Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on endocrine ear points, GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
2845894|NCT03627533|Sham Comparator|Sham electroacupuncture|Sham electroacupuncture are done at same electroacupuncture point location but puncture are not done, also electro stimulator are turned off.
2848193|NCT03611413||conventional care|Patients who have been treated under an conventional care
2845895|NCT03627520|Other|[14C]Sulfatinib|This is a single center and single dose in 6 volunteers. Subject would take a suspension containing 300 mg of Sulfatinib (containing about 100 μCi of radioactivity) within 1 hour after standard breakfast.
2845896|NCT03627507|Experimental|Hepa B|79 participant will be randomly assigned to the test group for receiving the locally produced 'Hepa-B' vaccine.
2845897|NCT03627507|Active Comparator|Engerix B|79 participant will be randomly assigned to the comparator group for receiving 'Engerix-B' vaccine.
2845898|NCT03627494|Experimental|Part A: P1,PBO/GSK3439171A Dose 2/GSK3439171A Dose 3|Subjects will administer oral solution with doses 0.5 milligram (mg) up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence placebo (PBO) followed by Dose 2 of GSK3439171A followed by Dose 3 of GSK3439171A in period 1 (P1). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
2845899|NCT03627494|Experimental|Part A: P1, GSK3439171A Dose 1/ PBO/GSK3439171A Dose 3|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and PBO as per randomized sequence: Dose 1 of GSK3439171A followed by PBO followed by Dose 3 of GSK3439171A in P1. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
2845900|NCT03627494|Experimental|Part A: P1, GSK3439171A Dose 1/ GSK3439171A Dose 2/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 1 of GSK3439171A followed by Dose 2 of GSK3439171A followed by PBO in P1. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
2845901|NCT03627494|Experimental|Part A: P2, PBO/GSK3439171A Dose 5/GSK3439171A Dose 6|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: PBO followed by Dose 5 of GSK3439171A followed by Dose 6 of GSK3439171A in period 2 (P2). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
2845902|NCT03627494|Experimental|Part A: P2, GSK3439171A Dose 4/ PBO/GSK3439171A Dose 6|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 4 of GSK3439171A followed by PBO followed by Dose 6 of GSK3439171A in P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
2845903|NCT03627494|Experimental|Part A: P2, GSK3439171A Dose 4/ GSK3439171A Dose 5/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 4 of GSK3439171A followed by Dose 5 of GSK3439171A followed by PBO in P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
2845904|NCT03627494|Experimental|Part A: P3, PBO/GSK3439171A Dose 8/GSK3439171A Dose 9|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: PBO followed by Dose 8 of GSK3439171A followed by Dose 9 of GSK3439171A in Period 3 (P3). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
2845905|NCT03627494|Experimental|Part A: P3, GSK3439171A Dose 7/ PBO/GSK3439171A Dose 9|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 7 of GSK3439171A followed by PBO followed by Dose 9 of GSK3439171A in P3. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
2845906|NCT03627494|Experimental|Part A: P3, GSK3439171A Dose 7/ GSK3439171A Dose 8/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 7 of GSK3439171A followed by Dose 8 of GSK3439171A followed by PBO in P3. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
2845907|NCT03627494|Experimental|Part B: GSK3439171A|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A in part B
2845908|NCT03627494|Placebo Comparator|Part B: Placebo|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of Placebo in part B
2845909|NCT03627494|Experimental|Part C: GSK3439171A fed followed by GSK3439171A fasted|Subjects will administer GSK3439171A in Fed condition in Part C P1 followed by GSK3439171A in fasted condition in Part C P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
2845910|NCT03627494|Experimental|Part C: GSK3439171A fasted followed by GSK3439171A fed|Subjects will administer GSK3439171A in fasted condition in Part C P1 followed by GSK3439171A in fed condition in Part C P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
2845911|NCT03627481|Experimental|AERD patients|Patients managed with Endoscopic sinus surgery for treatment of AERD.
2845912|NCT03627468|Experimental|Gel, 5%|Sofpironium Bromide Gel, 5%, q.d. for 48 weeks
2845913|NCT03627468|Experimental|Gel, 15%|Sofpironium Bromide Gel, 15%, q.d. for 48 weeks
2845914|NCT03627455||Male, with DM|
2845915|NCT03627455||Male, without DM|
2845916|NCT03627455||Female, with DM|
2845917|NCT03627455||Female, without DM|
2845918|NCT03627442|Active Comparator|Mastectomy with PhotonBlade|Patients undergoing double mastectomy with immediate reconstruction with expanders. One breast will be randomly selected to be operated with PhotonBlade
2845919|NCT03627442|Active Comparator|Mastectomy with Bovie|Patients undergoing double mastectomy with immediate reconstruction with expanders. One breast will be randomly selected to be operated with Bovie.
2845920|NCT03627416|Experimental|active rTMS|10 hertz (Hz) rTMS will be administered over bilateral primary motor areas for the muscles of lower extremities. Therapy will include five daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
2845921|NCT03627416|Sham Comparator|Sham rTMS|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
2845922|NCT03627403|Experimental|Selinexor, all patients|Single Arm Study, all patients will get selinexor
2845923|NCT03627390|Experimental|BP-C1|Patients will be treated with BP-C1 for 32 consecutive days
2849782|NCT03599622|Experimental|BMS-986165 Dose 3|
2845924|NCT03627390|Experimental|BP-C1+BP-C2|Patients will be treated with BP-C1 and BP-C2 for 32 consecutive days
2845925|NCT03627377|No Intervention|Control Phase|3-month initial control phase (no intervention, month 1-3)
2845926|NCT03627377|Experimental|Intervention Phase|6-month intervention phase - MIDAS Intervention Delivered. Followed by 6-month follow-up phase (no intervention, months 10-15).
2845927|NCT03627364||Post stroke patients|will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals.
2845928|NCT03627364||Control group|will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in post stroke patients.
2845929|NCT03627351||Healthy Women and Men|Group of healthy women and men
2845930|NCT03627338||Norfloxacin|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
2845931|NCT03627338||Non-selective beta blockers|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
2845932|NCT03627338||diuretics|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
2845933|NCT03627312|Experimental|Omega-3|this group receives a fruit juice drink containing omega-3
2845934|NCT03627312|Placebo Comparator|Placebo|this group receives the same fruit juice drink as in the experimental group, but it does not contain omega-3
2845935|NCT03627312|Other|Treatment as Usual|this group do not receive a fruit juice drink
2845936|NCT03627299|Experimental|Deceased donor HCV RNA PCR+|Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks
2845937|NCT03627286|Active Comparator|Active Drug|
2845938|NCT03627286|Placebo Comparator|Placebo|
2845939|NCT03627273|Experimental|walker|
2845940|NCT03627273|Active Comparator|no walker|
2845941|NCT03627247|Experimental|Cognitive Behavioral Stress Management|Women randomized to CBSM participated in an eight-week prenatal course called SMART Moms (Stress Management and Relaxation Training for Moms) aimed at teaching coping and relaxation skills that address stressors and daily challenges experienced during pregnancy and motherhood.
2845942|NCT03627247|No Intervention|Attention Control Group|"Women randomized to the AC group participated in an eight-week program where they received printed materials (offered in Spanish and English) by mail once per week, on common prenatal health information topics (e.g., common discomforts of pregnancy, labor and delivery) chosen from the March of Dimes Foundation's Becoming a Mom handouts (March of Dimes, 2011). Women in this group were contacted once per week by phone by a research staff member to make sure that they received their mailed prenatal health information and to see if they had any questions."
2845943|NCT03627234|Experimental|Same Day Discharge|Same day discharge after hysterectomy is the standard of care at George Washington University Hospital.
2845944|NCT03627234|Experimental|Overnight stay|Overnight stay is not the standard of care at George Washington University Hospital. It is being used as an experimental condition.
2845945|NCT03627221|Experimental|music listening and social network|The intervention group will receive music listening at sleep time and will be invited to join a social network for 12 weeks. But their sleep quality , sleep knowledge, sleep hygiene, daytime fatigue, and daytime sleepy will be collected for 12 months (at baseline, 3 month, 6 month, and the 12th month).
2845946|NCT03627221|No Intervention|Control group|The control group will not receive music listening at sleep time and will not be invited to join a social network for 12 weeks. But their sleep quality, sleep knowledge, sleep hygiene, daytime fatigue, and daytime sleepy will be collected for 12 months (at baseline, 3 month, 6 month, and the 12th month).
2845947|NCT03627208||1|Retrospective chart review of children and young adults with ALL/LBL enrolled on treatment protocols in the POB
2845948|NCT03627195|Experimental|DSP-1349M|Lurasidone injection suspension (30 mg, 75 mg, 150 mg, 300 mg, and 450 mg)
2845949|NCT03627195|Placebo Comparator|Placbo|placebo injection
2845950|NCT03627182|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
2845951|NCT03627182|Placebo Comparator|Placebo|Placebo
2845952|NCT03627169||MATRx plus/PSG group|Healthy individuals, individuals suspected of having OSA, and individuals with a previous diagnosis of OSA will spend a single night in a sleep laboratory and undergo a standard polysomnogram simultaneously with a Level III sleep study using the MATRx plus device. There is no interventional aspect to the study.
2845953|NCT03627156|Experimental|Intervention|Intervention Arm is an arm to which community-based guided counseling using Health Belief Model and Theory of Planned Behavior will be given.
2845954|NCT03627156|No Intervention|Control|Control Arm is an arm to which the intervention will not be implemented.
2845955|NCT03627143|Other|Local implementation of AAFF guidelines|The study intervention will support local implementation of the CAEP AAFF Guidelines during the intervention periods of the trial. The investigators will identify behaviour change techniques and organization/system level strategies that could likely address identified barriers or enhance enablers.
2845956|NCT03627130|Active Comparator|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
2845957|NCT03627130|Placebo Comparator|Potassium Chloride|Potassium Chloride
2845958|NCT03627117|Experimental|Verum/Placebo|This group will start with CBD and after washout will receive placebo.
2845959|NCT03627117|Experimental|Placebo/Verum|This group will start with placebo and will receive CBD after washout.
2845960|NCT03627104|Other|Normoprotein diet with animal protein|The patient will intake the diet assigned for a month
2845961|NCT03627104|Other|Normoprotein diet with vegetable protein|The patient will intake the diet assigned for a month
2845962|NCT03627104|Other|High-protein diet with animal protein|The patient will intake the diet assigned for a month
2845963|NCT03627104|Other|High-protein diet with vegetable protein|The patient will intake the diet assigned for a month
2845964|NCT03627091|Experimental|SHP647 25 mg|Participants will receive 25 mg of SHP647 subcutaneous (SC) injection using a prefilled syringe every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 [NCT03559517] or SHP647-306 [NCT03566823]).
2845965|NCT03627091|Experimental|SHP647 75 mg|Participants will receive 75 mg of SHP647 subcutaneous injection using a prefilled syringe every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 [NCT03559517] or SHP647-306 [NCT03566823]).
2845966|NCT03627091|Placebo Comparator|Placebo|Participants will receive placebo matching with SHP647 subcutaneous injection using prefilled syringe every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 [NCT03559517] or SHP647-306 [NCT03566823]).
2845967|NCT03627078|Experimental|Motor Interference Therapy|Initial interview applying the Spanish version of the PTSD Symptom Severity Scale-Revised (EGS-R), the visual analogue scale (EQ-VAS) from EuroQol 5D (EQ-5D), and a simple visual-analogue scale (VAS). After that, patients will listen to an audio track twice and follow the instructions. The first four minutes of the audio track instruct the subjects to tap their fingers in response to specific sounds. During the remaining ten minutes, the patients will be asked to recall a traumatic memory while simultaneously are tapping their fingers. Patients must complete at least 80% of the motor task in order to be included. We will reassess a week, a month and six months after the intervention, using all three scales.
2845968|NCT03627078|Sham Comparator|Relaxation Exercise|Initial interview applying the Spanish version of the PTSD Symptom Severity Scale-Revised (EGS-R), the visual analogue scale (EQ-VAS) from EuroQol 5D (EQ-5D), and a simple visual-analogue scale (VAS). After that, patients will listen to an audio track twice and follow the instructions. The first four minutes of the audio track instruct the subjects in how to do the exercises. During the remaining 10 minutes will hear commands for performing progressive muscle tension-relaxation exercises while the patient evoked the traumatic memory. Patients must complete at least 80% of the motor task in order to be included. We will reassess a week, a month and six months after the intervention, using all three scales.
2845969|NCT03627065|Experimental|INCB050465|
2845970|NCT03627052|Experimental|Itacitinib|
2845971|NCT03627052|Placebo Comparator|Placebo|
2845972|NCT03627039||Truven|NOTE: In the case there are not enough patients/events data will be included from other databases (e.g., Optum, Medicare)
2845973|NCT03627026|Other|Patients treated with immune checkpoint inhibitor|
2845974|NCT03627013|Experimental|Kidney Custodiol-N|
2845975|NCT03627013|Active Comparator|Kidney Custodiol|
2845976|NCT03627013|Experimental|Liver Custodiol-N|
2845977|NCT03627013|Active Comparator|Liver Custodiol|
2845978|NCT03627013|Experimental|Kidney/Pancreas Custodiol-N|
2845979|NCT03627013|Active Comparator|Kidney/Pancreas Custodiol|
2845980|NCT03627000||failure after reimplantation|description of the failure at the reimplantation
2845981|NCT03626987||Bacterial identification|Describe the MALDI-TOF spectrum to identify peaks that may be associated with epidemiological and clinical characteristics of bacterial strains
2845982|NCT03626974|Experimental|Venipuncture with vanilla odor|the venipuncture will be performed on the neonate in the presence of a diffuser spreading the vanilla odor and ingestion of water
2845983|NCT03626974|Placebo Comparator|Venipuncture without odor|the venipuncture will be performed with an odorless diffuser and ingestion of sucrose
2845984|NCT03626961||discharge|patients discharge from icu
2845985|NCT03626961||readmission|patients readmitted icu in 48 hours after icu discharge
2845986|NCT03626948|Experimental|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
2845987|NCT03626935|Experimental|3D-printed customized guide plate|3D-printed customized guide plate will be used to guide the Kirschner wires in ankle arthrodesis.
2845988|NCT03626922|Experimental|Cohort 1|"Pembrolizumab + Pemetrexed every 21 days. Folic Acid 5 days prior to first dose of pemetrexed and daily including 21 days after last dose of pemetrexed.~Dexamethasone twice daily on the day before, the day of, and the day after each dose of pemetrexed.~Vitamin B-12 7 days prior to first dose of pemetrexed, every 9 weeks, continue until 3 weeks after last dose of pemetrexed."
2845989|NCT03626922|Experimental|Cohort 2|"Pembrolizumab + Pemetrexed + Oxaliplatin every 21 days. Folic Acid 5 days prior to first dose of pemetrexed and daily including 21 days after last dose of pemetrexed.~Dexamethasone twice daily on the day before, the day of, and the day after each dose of pemetrexed.~Vitamin B-12 7 days prior to first dose of pemetrexed, every 9 weeks, continue until 3 weeks after last dose of pemetrexed."
2845990|NCT03626896|Experimental|NaviFUS System|NaviFUS System: dose escalation focus ultrasound to transiently disrupt BBB
2845991|NCT03626883|Experimental|1 hamstring|Patients will receive the intervention of 'single-bundle, single-hamstring ACL reconstruction'.
2845992|NCT03626883|Active Comparator|2 hamstrings|Patients will receive the intervention of 'single-bundle, double-hamstring ACL reconstruction'.
2845993|NCT03626857|Experimental|NMES+ECC|Neuromuscular electrical stimulation (NMES) and Eccentric Exercise (ECC). Patients randomized to the NMES+ECC group will first receive NMES for 2x/week for 8 weeks, beginning at the first post-operative visit. Beginning at 9 weeks after anterior cruciate ligament reconstruction (ACLR) patients will begin to receive eccentric exercise 2x/week for an additional 8 weeks. For NMES, patients will have electrical stimulation delivered to their quadriceps. Fifteen isometric actions lasting 10 seconds each will be elicited during each session. For eccentric exercise, patients will train for 4 sets of 10 repetitions. This group will also receive standard of care ACL rehabilitation alongside the study interventions.
2845994|NCT03626857|Other|NMES placebo +ECC|"Neuromuscular electrical stimulation (NMES) placebo + Eccentric Exercise (ECC) arm. Participants randomized to NMES placebo+ECC will receive an NMES placebo to their quadriceps 2x/week for 8 weeks beginning at the first post-operative visit. Beginning at 9 weeks after anterior cruciate ligament reconstruction (ACLR) patients will begin to receive an eccentric exercise placebo 2x/week for 8 weeks.~For the NMES placebo, patients will have electrical stimulation delivered to their quadriceps. Fifteen isometric actions lasting 10 seconds each will be elicited during each session. For the eccentric exercise, patients will train for 4 sets of 10 repetitions. This group will also receive standard of care ACL rehabilitation alongside the study interventions."
2846052|NCT03626441|Experimental|Ginger|Two coloured capsules containing 0.5g ginger powder, flavoured with non-active essence of ginger, given 2 hours before the scheduled start of surgery.
2846053|NCT03626415|Experimental|PF-04965842|PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
2849783|NCT03599622|Placebo Comparator|Placebo|
2845995|NCT03626857|Other|NMES+ECC placebo|"Neuromuscular electrical stimulation (NMES) + Eccentric Exercise (ECC) placebo arm. Patients randomized to the NMES + ECC placebo group will first receive NMES for 2x/week for 8 weeks, beginning at the first post-operative visit. Beginning at 9 weeks after anterior cruciate ligament reconstruction (ACLR) patients will begin to receive an eccentric exercise placebo 2x/week for 8 weeks.~For the NMES intervention, patients will have electrical stimulation delivered to their quadriceps. Fifteen isometric actions lasting 10 seconds each will be elicited during each session. For the eccentric exercise placebo, patients will begin to receive eccentric exercise 2x/week for 8 weeks. Patients will train 4 sets of 10 repetitions."
2845996|NCT03626857|Placebo Comparator|NMES placebo + ECC placebo|"Neuromuscular electrical stimulation (NMES) placebo + Eccentric Exercise (ECC)placebo arm. Patients randomized to the NMES placebo + ECC placebo group will first receive NMES placebo for 2x/week for 8 weeks, beginning at the first post-operative physical therapy visit. Beginning at 9 weeks after anterior cruciate ligament reconstruction (ACLR) patients will begin to receive an eccentric exercise placebo 2x/week for 8 weeks.~For the NMES placebo, patients will have NMES placebo delivered to their quadriceps 2x/week for 8 weeks beginning at the first post-operative visit. Fifteen isometric actions lasting 10 seconds each will be elicited during each session.~For the eccentric exercise placebo, patients will begin to receive eccentric exercise two times per week for 8 weeks. Patients will train for 4 sets of 10 repetitions."
2845997|NCT03626844|Experimental|Manual Lysis after 15 minutes (Intervention)|Manual Lysis of Placenta 15 minutes after Delivery.
2845998|NCT03626844|Active Comparator|Manual lysis after 30 minutes (Control)|Waiting 30 minutes after delivery and then manual lysis of the placenta.
2845999|NCT03626831|Active Comparator|Treatment|Baseline vascular function parameters will be obtained and the patient will be given an SC injection of the study drug by Evolocumab Prefilled Syringe
2846000|NCT03626831|Placebo Comparator|Placebo|Baseline vascular function parameters will be obtained and the patient will be given an SC injection of placebos
2846001|NCT03626818||NCF group|The patients have received 10 daily fractions of 3 Gy WBRT. Following WBRT treatment, subjects were assessed at each visit for NCT according to the Hopkins Verbal Learning Test-Revised(HVLT-R),Mini-Mental Status Examination(MMSE) and Quality Of Life measurements(QOL,Questionnaire-QLQC30).These tests was administered by trained and certified nurses or clinical research associates at baseline,6th week, 3rd, 6th, 9th, 12th month, and every 6 months until PS> 2 or intracranial tumor progression.
2846002|NCT03626805||Migraine patients|Migraine patients attending the Danish Headache Centre
2846003|NCT03626805||Healthy Controls|Age and sex matched
2846004|NCT03626792|Other|Hypertensive group|The Mat Pilates session was held lasting 50 minutes of exercises with the first 5 minutes heating and in each exercise performing 10 repetitions with 45 seconds of rest between one exercise and another. For practice, are used only mats, and alternative devices such as the Swiss ball and the flexible ring, as well as body weight and the force of gravity as resistance factors and Borg's subjective perception of effort scale for intensity parameters. The 20 exercises were chosen through the classic exercises thus classified by the creator of the Joseph Pilates method.During the sessions, volunteers were instructed on correct breathing without performing the valsalva maneuver.
2846005|NCT03626792|Other|Normotensive group|The Mat Pilates session was held lasting 50 minutes of exercises with the first 5 minutes heating and in each exercise performing 10 repetitions with 45 seconds of rest between one exercise and another. For practice, are used only mats, and alternative devices such as the Swiss ball and the flexible ring, as well as body weight and the force of gravity as resistance factors and Borg's subjective perception of effort scale for intensity parameters. The 20 exercises were chosen through the classic exercises thus classified by the creator of the Joseph Pilates method.During the sessions, volunteers were instructed on correct breathing without performing the valsalva maneuver.
2846006|NCT03626779|Other|immediate placment and loading with prf|Immediat placment and loading with prf
2846007|NCT03626779|No Intervention|immediate implant placment and loading|Immediate implant placment and loading without prf
2846008|NCT03626766|Active Comparator|Photo in Verification Alert|Patient photo displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
2846009|NCT03626766|Active Comparator|Photo in Banner|Patient photo displayed in the banner (at the top of the screen).
2846010|NCT03626766|Active Comparator|Photo in Banner and Verification Alert|Patient photograph displayed in the banner (at the top of the screen) AND patient photo displayed in a verification alert when placing electronic orders.
2846011|NCT03626766|No Intervention|No Photo|No patient photographs displayed in the electronic health record.
2846012|NCT03626753|Active Comparator|Oral Group|"received in post operative period oral analgesia ( nefopam (Acupan) 20mg/6h, piroxicam (piroxan) 40mg/24h, Acetaminophen (paracetamol) 1g/6h)"
2846013|NCT03626753|Active Comparator|Intravenous group|"received in post operative period intravenous analgesia ( nefopam (Acupan) 20mg/6h, piroxicam (piroxan) 40mg/24h, Acetaminophen (paracetamol) 1g/6h)"
2846014|NCT03626740|Experimental|TheraCal|Indirect pulp capping with TheraCal
2846015|NCT03626740|Active Comparator|Mineral trioxide aggregate (MTA)|Indirect pulp capping with MTA
2846016|NCT03626727|Experimental|Sodium Oxybate Oral Solution (Xyrem®)|4.5g of oral solution Xyrem will be given as a starting dose. This will be titrated up weekly to the final treatment dose of 9.0g. Participants will be on this final dose for 8 weeks.
2846017|NCT03626701|Experimental|RECELL® Autologous Cell Harvesting Device|"RECELL + Telfa™ Clear and Xeroform™ dressings~Conventional autografting (only when indicated)"
2846018|NCT03626701|Active Comparator|Mepilex® Wound Dressing|"Mepilex® Wound Dressing~Conventional autografting (only when indicated)"
2846019|NCT03626688|Placebo Comparator|Placebo|Placebo once per day plus standard of care or PAH-specific background therapy
2846020|NCT03626688|Active Comparator|Ralinepag|Ralinepag once daily, initiated at 50 mcg and titrated to the highest tolerated dose (maximum dose of 1450 mcg) plus standard of care or PAH-specific background therapy
2846054|NCT03626402|Experimental|Intervention|"These patients will be exposed to the educational intervention, including viewing the video, Planning for the Care You Want, and meeting with a lay health advisor to discuss advance care planning and initiate plans, as patients wish."
2846129|NCT03625908|Active Comparator|12-month DAPT following angiography-guided PCI|Patients will receive dual antiplatelet therapy for 12 months after PCI under OCT-guidance.
2846021|NCT03626675|Other|study group|"They will be subjected to:~Preoperative A-complete ophthalmic examination will be done for every patient; B- Biometric parameters measured with the AS‑OCT C- Medical fitness for all patients D- Informed consent will be obtained from all patients after through explanation of operation and its potential benefits and risks.~Surgery combined Phaco trabeculectomy~Post operative:~-Follow-up examinations will be performed for every patient at 1day, 1 week, 1 and 3 months postoperatively.~and biometric parameters measured with the AS‑OCT before and after the surgery will be used to collect the data.~-The data will be managed and analysed with confidentiality by scientifically qualified persons"
2846022|NCT03626662|Placebo Comparator|Placebo|Single Ascending Dose cohorts, Multiple Ascending Dose cohorts
2846023|NCT03626662|Experimental|AMG 890|Single Ascending Dose Cohorts and Multiple Ascending Dose Cohorts
2846024|NCT03626649|Experimental|DiamondTemp Cardiac Ablation System|Cardiac ablation procedure
2846025|NCT03626636|Active Comparator|Active Group|Treatment Group 1: 25 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be injected intravitreally with 1.0mg of Luminate®
2846026|NCT03626636|Placebo Comparator|Placebo Group|Treatment Group 2: 15 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be treated with a sham injection
2846027|NCT03626623|Placebo Comparator|Standard of Care (SOC)|The usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds.
2846028|NCT03626623|Active Comparator|Cytal Wound Matrix 1-Layer|The application of the Cytal Wound Matrix 1-Layer device according to the Cytal Wound Matrix 1-Layer instructions for use (IFU).
2846029|NCT03626610|Experimental|Interventional|Participants will be given a monitored exercise program during their treatment starting before chemotherapy
2846030|NCT03626610|No Intervention|Non-interventional|Patients will have standard care.
2846031|NCT03626597|Active Comparator|CHV-provided post-test counseling & referral|The CHV will provide the woman with the urine pregnancy test and collect baseline information. If the woman desires enrollment in Arm 1 (CHV-provided post-test counseling and referral), the CHV will provide all post-test counseling and referral based on training provided. This may occur at the time of enrollment or at a later time, as preferred by the woman.
2846032|NCT03626597|Active Comparator|Phone-based post-test counseling & referral|The CHV will provide the woman with the urine pregnancy test and collect baseline information. If the woman desires enrollment in Arm 2 (phone-based post-test counseling and referral), the CHV will provide the woman with a phone number which she may call or short message service (SMS) to receive post-test counseling and referral. If the study team does not receive a call or SMS from the woman within one week, our research assistant will phone and/or SMS the participant to provide phone-based post-test counseling and referral.
2846033|NCT03626584||Cardiac Amyloidosis Patients|Patients with established diagnosis of cardiac amyloidosis.
2846034|NCT03626584||Healthy Volunteers|Healthy volunteer subjects of similar age and gender to patient cohort.
2846035|NCT03626571||Native valve infective endocarditis|Patients with infective endocarditis of native valves of the heart with no contraindications to MRI scanning.
2846036|NCT03626571||Prosthetic endocarditis|Patients with endocarditis of prosthetic heart valves or device-related infections.
2846037|NCT03626571||Non-infective post-operative|Patients who have recently undergone valve or device implantation with no evidence of post-operative infection.
2846038|NCT03626558|Experimental|Distroke patients|"For every patient include in the study, ultrasound measures at the admission/discharge of hospitalization will be realized.~All the patients will see each other suggested participating in a new collection of remote ultrasound measures of the stroke (around 2-3 months). These measures will be made during the usual consultation proposed by the department of neurology. This medical consultation is a part of the follow-up post--stroke recommended by the High Authority of Health. These measures will allow us to highlight the kinetics of recovery of the diaphragmatic function except any intervention of reeducation of muscles inspirers."
2846039|NCT03626545|Experimental|Canakinumab|Blinded Canakinumab administered at the recommended Phase III regimen (defined in the safety run-in part). Canakinumab will be given in combination with docetaxel (standard of care)
2846040|NCT03626545|Placebo Comparator|Placebo|Matching placebo, administered at the recommended Phase III regimen (defined in the safety run-in part), in combination with docetaxel (standard of care)
2846041|NCT03626532|Experimental|Mindfulness-Based Stress Reduction|Participants will meet once a week for 8 weeks (2.5 hours per session), plus a 4-hour retreat day, to engage in mindfulness meditation exercises. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will require participants to engage in guided practices for 30 minutes a day for 5 days a week.
2846042|NCT03626532|Active Comparator|Lifestyle Education|Participants will meet once a week for 2.5 hours for 8 weeks, plus a 4-hour retreat day, to engage in light stretching exercises and interactive discussions on health topics, such as physical activity, nutrition, sleep, stress, etc. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will ask participants to engage in stretching, read or watch informational content, and answer reflection questions for 30 minutes a day for 5 days a week.
2846043|NCT03626519|Experimental|Test with Menthol|Patients will chew a menthol flavored chewing gum 5 minutes before perform one Six-minute Walk Test
2846044|NCT03626519|Placebo Comparator|Test with placebo|Patients will chew a strawberry flavored chewing gum 5 minutes before perform one Six-minute Walk Test
2846045|NCT03626506|Experimental|spironolactone|Subjects will take spironolactone 20~40mg once daily on top of amlodipine 5~10mg once daily.
2846046|NCT03626506|Active Comparator|indapamide|Subjects will take indapamide 1.5~3.0mg once daily on top of amlodipine 5~10mg once daily.
2846047|NCT03626493||LSRH|patients who undergo laparoendoscopic single-site radical hysterectomy with pelvic lymphadenectomy
2846048|NCT03626467|Experimental|Arm 1|Men infected by HIV who have sex with men
2846049|NCT03626454|Active Comparator|group B|'Norepinephrine bolus' of 6 µg plus Normal Saline 0.9% Infusion Solution
2846050|NCT03626454|Active Comparator|group I|'Norepinephrine infusion' 6 µg/kg/h plus 'Normal Saline Flush, 0.9% Injectable Solution
2846051|NCT03626441|Placebo Comparator|Placebo|Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger, given 2 hours before the scheduled start of surgery.
2849784|NCT03599609|Experimental|Treatment|Treatment: Simvastatin 40mg/day
2846055|NCT03626402|No Intervention|Control - Usual Care|These patients will not be exposed to the educational intervention and will receive usual care. All patients will be mailed an informational brochure about advance care planning with a reminder letter two weeks after completing their baseline survey.
2846056|NCT03626389||Patients receiving physiotherapy|Physiotherapy, without predetermined selection of specific modalities
2846057|NCT03626376|Placebo Comparator|Control|suppressive antiviral treatment
2846058|NCT03626376|Active Comparator|Study Arm|oral acyclovir or oral valacyclovir
2846059|NCT03626363|Experimental|Mindfulness-Based Stress Reduction|
2846060|NCT03626363|Active Comparator|Stress Management Education|
2846061|NCT03626337||Hospital-based cohort|50 mg thiamine provided via intramuscular injection (Thiamine 100 MG/ML)
2846062|NCT03626337||Community-based cohort|Sex-, age- and regionally matched control group
2846063|NCT03626324|Experimental|C2P Study|Clinical Evaluation of Connected Catheter 2P Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
2846064|NCT03626311|Experimental|AKBM-3031|4g/day (2 capsules BID)
2846065|NCT03626311|Placebo Comparator|Placebo|4g/day (2 capsules BID)
2846066|NCT03626298|Placebo Comparator|Adapalene and placebo (ADAP)|
2846067|NCT03626298|Experimental|Adapalene, Nicotinamide, ABA, Zinc PCA (ANAZ)|
2846068|NCT03626285|Experimental|Treatment (BMT with CD34 peripheral blood stem cells)|Donor stem cells undergo CD34 selection ex vivo using the CliniMACS CD34 Reagent System using SOPs from the manufacturer. Recipients undergo standard of care preparative regimen, bone marrow transplantation with CD34-selected peripheral blood stem cells via infusion over 1 to 2 hours on day 0, and then receive standard of care GVHD prophylaxis.
2846069|NCT03626272|Active Comparator|8-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 8 months.
2846070|NCT03626272|Active Comparator|4-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 4 months.
2846071|NCT03626272|Active Comparator|2-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 2 months.
2846072|NCT03626259|Other|losartan and amlodipine|Individuals with SAH grade 1 or 2 without triple pharmacological therapy.
2846073|NCT03626259|Active Comparator|Losartan|Individuals with SAH grade 1 or 2 without triple pharmacological therapy.
2846074|NCT03626246||Kidney disease|Patients who participate in our study are 40 years old or older and have a Chronic kidney disease stage 3, 4 or 5.
2846075|NCT03626233||Vascular group|Pregnant women with vascular pathology
2846076|NCT03626233||Control group|"Pregnancy without any vascular complication~Delivery before or after 37 weeks of gestation (GW)~In case of delivery after 37GW: birth by cesarean delivery"
2846077|NCT03626220||acupuncture group|acupuncture with de-chi sensation
2846078|NCT03626220||sham acupuncture group|skin-deep acupuncture without de-chi sensation
2846079|NCT03626207||Retinitis pigmentosa|Retinitis pigmentosa patients with severe visual impairment
2846080|NCT03626181|Experimental|Active TBS-DLPFC|There is only one arm. All participants will receive Theta Burst Stimulation (transcranial magnetic stimulation) of the dorsolateral prefrontal cortex.
2846081|NCT03626168|Active Comparator|Consumption of 100% watermelon juice|Consumption of two 12-ounce doses of pasteurized 100% watermelon juice for a four-week period
2846082|NCT03626168|Placebo Comparator|Consumption of a placebo beverage|Consumption of a placebo beverage with comparable sugar content, pH, taste, texture, and color for a four-week period
2846083|NCT03626155|Experimental|Seated Control|
2846084|NCT03626155|Experimental|Morning Exercise (walking)|
2846085|NCT03626155|Experimental|Afternoon Exercise (walking)|
2846086|NCT03626155|Experimental|Evening Exercise (walking)|
2846087|NCT03626142||Left DLPFC aTBS stimulation|Patients who have received accelerated theta burst stimulation delivered to the left dorsolateral prefrontal cortex on the inpatient unit at Stanford
2846088|NCT03626142||ACC aTBS stimulation|Patients who have received accelerated theta burst stimulation delivered to the anterior cingulate cortex on the inpatient unit at Stanford
2846089|NCT03626142||Ketamine|Patients who have received ketamine on the inpatient unit at Stanford
2846090|NCT03626142||ECT|Patients who have received ECT on the inpatient unit at Stanford
2846091|NCT03626129|No Intervention|Traditional rapid deflation|"Group A: At time of sheath removal 15 ml. air is inflated in the TR-band. The sheath is removed. Air is deflated until bleeding, and 1-2 ml. air is then re-inflated to achieve hemostasis, and the volume air inflated is registered (Initial inflated air volume). Every 20 minutes 1/3 of the initial inflated air volume is deflated. If bleeding occurs then air is re-inflated until hemostasis and then additional 1-2 ml. air is inflated. This routine is repeated until hemostasis is achieved (TR-band fully deflated without bleeding)."
2846092|NCT03626129|Experimental|Oximetry guided deflation|"Group B: Initial step with sheath removal as in group A. Before departure from the cath.lab. a Patent hemostasis test (see description in Interventions below) is performed. Further action as described in Interventions below."
2846093|NCT03626103|Experimental|+ Brief ED Intervention (BI), + Text|Participants receive both the Brief ED Intervention component (a 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant) and the Text Message Intervention component (8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills).
2846094|NCT03626103|Experimental|+ Brief ED Intervention (BI), no Text|Participants receive the Brief ED Intervention component only (which is a 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant).
2846095|NCT03626103|Experimental|No Brief ED Intervention (BI), + Text|Participants receive the Text Message Intervention component only (8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills). Participants receive a brochure containing online and community resources for violence and depression prevention instead of the Brief ED Intervention component.
2846128|NCT03625908|Active Comparator|3-month DAPT following angiography-guided PCI|Patients will receive dual antiplatelet therapy for 3 months after PCI under OCT-guidance.
2846096|NCT03626103|No Intervention|No Brief ED Intervention (BI), no Text|Participants receive neither the Brief ED Intervention component, nor the Text Message Intervention component. Participants receive a brochure containing online and community resources for violence and depression prevention, instead of the Brief ED Intervention component.
2846097|NCT03626090|Experimental|Treatment Arm|A single dose of 0.5 to 1 x 10^6/kg autologous BM MSCs (Total volume: 30 - 50 ml) will be infused via peripheral venous access.
2846098|NCT03626077|Active Comparator|group A|Group (A) physical therapy program for 60 minutes per session, three times a week for three consecutive months
2846099|NCT03626077|Active Comparator|group B|Group (B) E-Link Upper Limb Exerciser (augmented biofeedback training)for 60 minutes per session, three times a week for three consecutive months
2846100|NCT03626077|Experimental|group C|group (C) physical therapy program and E-Link Upper Limb Exerciser
2846101|NCT03626064|Other|PROMPT Participants|80 participants who are homeless or at-risk for homelessness, smoke tobacco, and identify as People Who Use Drugs in Ottawa.
2846102|NCT03626051|Active Comparator|rigid tape group|
2846103|NCT03626051|Experimental|fibular tape group|
2846104|NCT03626038|Experimental|Patients who receive the A.L.P.S. Prox. Humerus Plating Sys.|"Subjects in need of proximal humerus fracture fixation who met the inclusion/exclusion criteria and received the A.L.P.S. Proximal Humerus Plating System.~Subjects can be enrolled prospectively or retrospectively as indicated in the protocol."
2846105|NCT03626025|No Intervention|Mass Learning Group|Participants underwent an eight-hour microsurgery training course in a single session under the mass-learning format.
2846106|NCT03626025|Other|Spaced Learning Group|Participants underwent two-hour microsurgery training sessions every week for a total of 4 sessions under the spaced learning format.
2846107|NCT03626012|Experimental|Cohort 1: BIIB078 First Dosage|BIIB078 will be administered as a loading regimen of 3 doses on Day 1, and two later days, followed by two maintenance doses for each cohort on two later days.
2846108|NCT03626012|Experimental|Cohort 2: BIIB078 Second Dosage|BIIB078 will be administered as a loading regimen of 3 doses on Day 1, and two later days, followed by two maintenance doses for each cohort on two later days.
2846109|NCT03626012|Experimental|Cohort 3: BIIB078 Third Dosage|BIIB078 will be administered as a loading regimen of 3 doses on Day 1, and two later days, followed by two maintenance doses for each cohort on two later days.
2846110|NCT03626012|Experimental|Cohort 4: BIIB078 Fourth Dosage|BIIB078 will be administered as a loading regimen of 3 doses on Day 1, and two later days, followed by two maintenance doses for each cohort on two later days.
2846111|NCT03626012|Placebo Comparator|Cohorts 1-4: Placebo|Matching placebo will be administered as a loading regimen of 3 doses on Day 1, and two later days, followed by two maintenance doses for each cohort on two later days.
2846112|NCT03625999|Experimental|Training Group|Parents and children selected for the Training group will be lent an iPad if they do not have one and wish to use one, but they can use a smart phone instead if they prefer. They will be assisted in downloading and installing the video game training exercise. Parents and children will be shown the game's operation and controls, including a home visit to the family's house to help them establish the game as part of routine. Parents will be asked to engage their children in the video game training exercise (on tablet or smart phone) for a minimum of 20 minutes, 3 times a week, for 4 weeks. The app will log all responses as well as time spent playing.
2846113|NCT03625999|No Intervention|Wait-List Control|The families assigned to the wait-list control group will not receive access to the game until after 4 weeks and completion of the secondary round of testing at the lab. After the second lab visit and completion of the testing, families will be given access to the video game training exercise (on their own tablet or smart phone), walked through the game's operation and controls, and encouraged to use it as often as they or their child like.
2846114|NCT03625986|Experimental|Nicotine-Containing Electronic Cigarette|The experimental group will be provided with and encouraged to use a Standardized Research Electronic Cigarette (SREC) with liquid containing 15 mg/ml nicotine for the duration of 6 weeks.
2846115|NCT03625986|Placebo Comparator|Non-Nicotine Electronic Cigarette|The placebo group will be provided with and encouraged to use a Standardized Research Electronic Cigarette (SREC) with liquid containing 0 mg/ml nicotine for the duration of 6 weeks.
2846116|NCT03625973|Experimental|16 Weeks of 3D-RT|Participants will receive 16 weeks of Reminiscence Therapy using 3D printed objects as stimuli.
2846117|NCT03625973|Experimental|8 Weeks of 3D-RT|Participants will receive 8weeks of Reminiscence Therapy using 3D printed objects as stimuli and 8 weeks of RT using verbal stimuli.
2846118|NCT03625973|Active Comparator|16 Weeks of RT using Verbal Stimuli|Participants will receive 16 weeks of RT using verbal stimuli to reminiscence.
2846119|NCT03625960|Experimental|Cantharidine group|Application of cantharidine to perenial warts
2846120|NCT03625960|Active Comparator|trichloroacetic acid group|application of trichloroacetic acid to perenial warts
2846121|NCT03625947||Hemoptysis patients|Hemoptysis patients caused by endobronchial malignancies
2846122|NCT03625934|Experimental|VVX001 (20 micrograms)|Subjects will receive 5 injections of 20 micrograms each over a period of 4 months
2846123|NCT03625934|Placebo Comparator|Placebo|Subjects will receive 5 s.c. injections of matching placebo over a period of 4 months
2846124|NCT03625921|Experimental|Powered device with physical therapy|Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided an intensive device-specific physical therapy (PT) intervention. The subjects will complete, on average, 8 PT training sessions lasting 30 - 45 minutes each. The subjects will also be provided with a home exercise program.
2846125|NCT03625921|Active Comparator|Powered device with standard of practice|Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided the current standard of practice training for use of this powered prosthesis. The prosthetist will confirm a stable and comfortable alignment and educate the subject on proper home usage. Next, the subject will undergo a 45 - 60 minute training with a physical therapist that is characteristic of the current standard of practice.
2846126|NCT03625908|Active Comparator|3-month DAPT following OCT-guided PCI|Patients will receive dual antiplatelet therapy for 3 months after PCI under OCT-guidance.
2846127|NCT03625908|Active Comparator|12-month DAPT following OCT-guided PCI|Patients will receive dual antiplatelet therapy for 12 months after PCI under OCT-guidance.
2850213|NCT03596684|Experimental|citrulline|citrulline 5g/d
2846130|NCT03625895||Agrylin|Participants who received treatment with Agrylin will be evaluated for this study.
2846131|NCT03625882||Gaucher Disease Participants Treated With VPRIV|Participants with Gaucher disease will be enrolled in this survey, who are in VPRIV treatment-naïve therapy or have been switched from another therapeutic agent for Gaucher disease.
2846132|NCT03625869|No Intervention|Conventional therapy|This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.
2846133|NCT03625869|Experimental|PICSO in adjunct to conventional therapy|This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).
2846134|NCT03625856|Experimental|Intervention|1500 mg Chlorella Vulgaris capsule
2846135|NCT03625856|Placebo Comparator|Control|1500 mg placebo (starch)
2846136|NCT03625843|Experimental|Mindfullness exercises|Participate in mindfulness exercises prior to urodynamic studies (UDS). As a participant, you will be guided through a mindfulness meditation exercise by a licensed professional. During this exercise you will be asked to focus your attention on your breathing, physical sensations, and thoughts. This exercise will last for approximately 10 minutes.
2846137|NCT03625843|No Intervention|Control|Sitting quietly in a room alone.
2846138|NCT03625830|Experimental|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|
2846139|NCT03625830|Active Comparator|Rapid exchange PTCA Balloon Catheter (SeQuent® Neo)|
2846140|NCT03625817|No Intervention|Urban setting|The participants will be staying in their permanent house in an urban area in Cyprus for at least 7 days. On the 7th day, they will be wearing 2 temperature sensors, for skin and air temperature. They will also collect the urine samples of the day and note in an activity diary, the names and times of activities.
2846141|NCT03625817|Experimental|Mountainous setting|The intervention is the short stay in the mountainous area of Troodos for atleast 7 consecutive days. The participants will be staying in their holiday house in the mountainous-rural area of Troodos, Cyprus for at least 7 days. On the 7th day, they will wear 2 temperature sensors, for skin and personal air temperature monitoring (every minute data points). They will also collect the urine samples of the day and note in an activity diary, the names and times of activities.
2846142|NCT03625804|Experimental|PNS+AO+Training|"adopted PNS+AO+Training as the intervention"
2846143|NCT03625804|Experimental|PNS+AOsham+Training|"adopted PNS+AOsham+Training as the intervention"
2846144|NCT03625804|Placebo Comparator|PNSsham+AOsham+Training|"adopted PNSsham+AOsham+Training as the intervention"
2846145|NCT03625791||radiation-induced sarcomas|
2846146|NCT03625791||radiotherapy for at least 5 years and without sarcomas|
2846147|NCT03625791||primary sarcomas|
2846148|NCT03625778|Experimental|MEDI0382|MEDI0382 administered subcutaneously
2846149|NCT03625778|Placebo Comparator|Placebo|Placebo administered subcutaneously
2846150|NCT03625765|Experimental|SmartGoggles|The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. Investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nanomolar (nM) concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with optical density (OD) 6 level cut-off. The SmartGoggles is a non-invasive imaging system that does not require contact with patients.
2846151|NCT03625752|Active Comparator|Active Comparator: Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
2846152|NCT03625752|Sham Comparator|Sham|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
2846153|NCT03625726|Experimental|patients with cirrhosis|pathophysiology study, blood sample
2846154|NCT03625726|Placebo Comparator|healthy volunteers|pathophysiology study, blood sample
2846155|NCT03625726|Placebo Comparator|patients with hepatocellular carcinoma|pathophysiology study, blood sample
2846156|NCT03625700||Hypoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation <94 % irrespective of supplemental oxygen~Patients with chronic obstructive pulmonary disease: blood oxygen saturation <88% irrespective of supplemental oxygen"
2846157|NCT03625700||Normoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation 94-98% in combination with supplemental oxygen OR blood oxygen saturation ≥94% without supplemental oxygen.~Patients with chronic obstructive pulmonary disease: blood oxygen saturation 88-92% in combination with supplemental oxygen OR blood oxygen saturation ≥88% without supplemental oxygen."
2846158|NCT03625700||Hyperoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation >98% in combination with supplemental oxygen~Patients with chronic obstructive pulmonary disease: blood oxygen saturation >92% in combination with supplemental oxygen"
2846159|NCT03625687|Experimental|Treatment with Direct Acting Antiviral for HCV|12 weeks of treatment with HCV Direct Acting Antiviral tablet (Mavyret or Epclusa)
2846160|NCT03625674|Other|psychological and GI mechanisms|The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Psychoactive medicine relieves FD symptoms through both psychological and GI mechanisms.
2846161|NCT03625674|Other|psychological mechanism|The patients in Group 2 were told that: GI symptoms in FD are attributable to psychological mechanisms. Psychoactive medicine relieves FD symptoms through psychological mechanisms.
2846162|NCT03625674|Other|GI mechanism|The patients in Group 3 were told that: GI symptoms in FD are attributable to GI mechanisms. Psychoactive medicine relieves FD symptoms through GI mechanisms.
2846163|NCT03625674|Other|no explanation|The patients in Group 4 were not explained with the detailed mechanism of FD and psychoactive medicine
2846164|NCT03625661|Experimental|Arm with Ferinject|Ferinject will be administered once at inclusion
2846165|NCT03625648|Experimental|PTX|Active drug
2846166|NCT03625648|Placebo Comparator|Placebo|Placebo
2846271|NCT03624959|Experimental|Treatment Group E - Ozanimod plus Rifampin|Rifampin 600 mg QD on Days 1 through 21. On Day 8, a single dose of ozanimod 0.92 mg will be coadministered with rifampin
2846167|NCT03625635|Experimental|Nutrition diagnosis and intervention|At baseline and 6-mo after, a nutrition diagnosis will be done by measuring body composition components with DXA and basic anthropometric measurements. Based on the results, an individualized food-based intervention will be prescribed for each patient according to her diagnosis, food preferences, cultural and socioeconomic status. Follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed and initial measurements are repeated.
2846168|NCT03625622|Placebo Comparator|Placebo|Placebo, orally administered once daily for 26 weeks.
2846169|NCT03625622|Active Comparator|AR1001 - 10 mg|Active, AR1001 - 10 mg, orally administered once daily for 26 weeks.
2846170|NCT03625622|Active Comparator|AR1001 - 30 mg|Active, AR1001 - 30 mg, orally administered once daily for 26 weeks.
2846171|NCT03625596|Active Comparator|High L-arginine|During this experimental day, men will receive a high-fat shake with a high dose of L-arginine.
2846172|NCT03625596|Experimental|Medium L-arginine + Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with a medium dose of L-arginine enriched with nitrate and nitrite.
2846173|NCT03625596|Experimental|Low L-arginine + Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with a low dose of L-arginine enriched with nitrate and nitrite.
2846174|NCT03625596|Experimental|Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with nitrate and nitrite.
2846175|NCT03625596|Placebo Comparator|Placebo|During this experimental day, men will receive a high-fat shake without supplement.
2846176|NCT03625583||chronic myeloid leukaemia|chronic myeloid leukaemia diagnosed from 2007 - 2017
2846177|NCT03625570|Experimental|PT³|Power Training combined with interval treadmill training
2846178|NCT03625570|Active Comparator|Traditional training|Strength training combined with traditional treadmill training
2846179|NCT03625544|Experimental|MagnetOs™ Granules|MagnetOs™ Granules
2846180|NCT03625544|Active Comparator|Autograft|Autologous bone graft
2846181|NCT03625531|Experimental|Personalized acupuncture|Two sets of acupoints will be selected for the two types.The basic acupoint-prescription includes the conception vessel (CV) 3, CV6, CV12 and spleen (SP) 6, stomach (ST) 25 and extra-meridian (EX) CA1 bilaterally. Auxiliary points of ST40, SP9 bilaterally and CV8 will be added for the type of yang deficiency of spleen and kidney, as well as kidney (K)13 and liver (LR) 3 bilaterally for the type of yin deficiency of liver and kidney. All acupoints except CV8 will be inserted with disposable needles. The points SP6 and EXCA1 of both types will be connected to electrical stimulator. Moreover, the points CV6, CV12 and ST25 for yang deficiency of spleen and kidney will receive moxibustion with needles, and CV8 will only receive ginger-salt-indirect moxibustion without acupuncture.
2846182|NCT03625531|Experimental|Standardized acupuncture|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV 3, CV 6, ST 29 bilaterally, SP 6 bilaterally, SP 9 bilaterally, GV 20 and LI 4 bilaterally. The second set consists of 13 needles: ST 25 bilaterally, ST 29 bilaterally, CV 3, CV 6, SP 6 bilaterally, LR 3 bilaterally, PC 6 bilaterally and GV 20. The following points will be connected to an electrical stimulator: ST25 bilaterally, ST29 bilaterally, SP6 bilaterally, LR3 bilaterally.
2846183|NCT03625531|Active Comparator|Letrozole|Letrozole will be started on day 3-5 after a spontaneous period or a withdrawal bleeding following progestin. They will be instructed to have intercourse on a regular basis during the cycles, and a serum progesterone level test will be performed in the local laboratory during the third week of the ovulation cycle.
2846184|NCT03625531|Placebo Comparator|Placebo|Women will receive placebo letrozole with no acupuncture. Placebo will be started on day 3-5 after a spontaneous period or a withdrawal bleeding following progestin. They will be instructed to have regular intercourse every 2 to 3 days and will be monitored weekly by serum progesterone level and urinary human chorionic gonadotropin test to document ovulation and pregnancy.
2846185|NCT03625518|Active Comparator|prostaglandins|vaginal prostaglandins insertion (PGE2) for cervical ripening and induction
2846186|NCT03625518|Active Comparator|intracervical balloon catheter with pitocin|insertion of intra cervical balloon catheter combined with intravenous pitocin for ripening and induction of labor
2846187|NCT03625505|Experimental|Venetoclax + Gilteritinib|Venetoclax and gilteritinib will be administered in combination. Different combinations of dose levels for venetoclax and gilteritinib will be explored.
2846188|NCT03625492|Experimental|Reduce Potentially Irritating Beverages|This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.
2846189|NCT03625492|Active Comparator|Adopt Healthy Eating Habits|This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
2846190|NCT03625466|Experimental|Part 1: Double Blind Period|Subjects will receive LUM/IVA as FDC granules dependent upon weight or matched placebo at Day 1.
2846191|NCT03625466|Experimental|Part 2: Open Label Period|Subjects will receive LUM/IVA as FDC tablets or granules dependent upon weight at Day 1.
2846192|NCT03625453|Experimental|ABX-1431|Oral use of hard capsule (10 milligrams), maximum dose per day: 40 milligrams
2846193|NCT03625453|Placebo Comparator|Placebo|Oral use of hard capsule
2846194|NCT03625440|Other|study group - Waterpipe Smoking|"The Digit span test and Paced Auditory Serial Addition Test (PASAT) performed at baseline and 30minutes after waterpipe smoking.~The Digit span test and PASAT with waterpipe smoking"
2846195|NCT03625440|Other|control group|"The Digit span test and Paced Auditory Serial Addition Test (PASAT) without waterpipe smoking, performed at 30minures apart.~The Digit span test and PASAT without waterpipe smoking"
2846196|NCT03625427|Placebo Comparator|Placebo|The placebo is olive oil, stripped of polyphenols, 70% oleic acid, and will be administered at two 1 gram capsules per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
2846197|NCT03625427|Experimental|Palmitoleic acid, 500 mg (Dose 1)|POA Dose 1 is a 1 gram capsule containing 500 mg POA and one placebo capsule containing 500 mg olive oil per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
2846272|NCT03624946|Experimental|Zika Virus Immune Globulin (ZIKV-IG)|Single dose of 50 mL Zika Virus Immune Globulin (ZIKV-IG) will be administered intravenously over 33 minutes.
2846198|NCT03625427|Experimental|Palmitoleic acid, 1,000 mg (Dose 2)|POA Dose 2 is two, 1 gram capsules containing 500 mg POA, totaling 1,000 mg POA per day for twelve weeks.The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
2846199|NCT03625414||Healthy individuals|Gingival biopsies of healthy individuals who had no systemic or oral disease or condition.
2846200|NCT03625414||Unaffected sites of CP|Chronic periodontitis patients had teeth affected from destruction and some teeth were unaffected. Gingival biopsies of chronic periodontitis patients were taken from sites which were not affected by periodontal destruction.
2846201|NCT03625414||Affected sites of CP|Chronic periodontitis patients had teeth affected from destruction and some teeth were unaffected. Gingival biopsies of chronic periodontitis patients were taken from sites which were affected by periodontal destruction.
2846202|NCT03625414||Unaffected sites of LAgP|Like chronic periodontitis, aggressive periodontitis patients had also teeth affected by destruction and some teeth were unaffected. Gingival biopsies of aggressive periodontitis patients were taken from sites which were not affected by the periodontal destruction.
2846203|NCT03625414||Affected sites of LAgP|Like chronic periodontitis, aggressive periodontitis patients had also teeth affected by destruction and some teeth were unaffected. Gingival biopsies of aggressive periodontitis patients were taken from sites which were affected by the periodontal destruction.
2846204|NCT03625401|Experimental|AD-35 60 mg|AD-35 60 mg group: 2 AD-35 30 mg tablets and 1 placebo tablet
2846205|NCT03625401|Experimental|AD-35 90 mg|AD-35 90 mg group: 3 AD-35 30 mg tablets
2846206|NCT03625401|Placebo Comparator|Placebo of AD-35 30 mg|Placebo group: 3 placebo tablets
2846207|NCT03625388|Other|Dasatinib 50 mg|Dasatinib 50 mg orally once daily
2846208|NCT03625388|Other|Dasatinib 100 mg|Dasatinib 100 mg orally once daily
2846209|NCT03625375|Experimental|Treatment Group|Individuals will perform exercises 3 times a week.
2846210|NCT03625375|No Intervention|Control Group|Individuals will not perform exercises
2846211|NCT03625362|Experimental|Hydrogen|1 L of hydrogen-rich water
2846212|NCT03625362|Placebo Comparator|Placebo|1 L of tap water
2846213|NCT03625349||PLM participants|Participants who undergo passive leg movement, with and without LNMMA.
2846214|NCT03625336||Prostate Calcifications|Men with prostate calcifications
2846215|NCT03625323|Experimental|1st line NSCLC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).~Pembrolizumab: 200 mg every 3 weeks."
2846216|NCT03625323|Experimental|2nd line NSCLC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).~Pembrolizumab: 200 mg every 3 weeks."
2846217|NCT03625323|Experimental|HNSCC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).~Pembrolizumab: 200 mg every 3 weeks."
2846218|NCT03625310|Active Comparator|Sodium Fluoride|Varnish containing 5% Sodium Fluoride, was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
2846219|NCT03625310|Experimental|Sodium Fluoride with TCP|Varnish containing 5% Sodium Fluoride with tricalcium phosphate (TCP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
2846220|NCT03625310|Experimental|Sodium Fluoride with CXP|Varnish containing 5% Sodium Fluoride with Xylitol-coated Calcium and Phosphate (CXP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
2846221|NCT03625310|Experimental|Sodium Fluoride with CPP-ACP|Varnish containing 5% Sodium Fluoride with casein phosphopeptide amorphous calcium phosphate (CPP-ACP), varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
2846222|NCT03625297|No Intervention|Shelter cat adoption control group|Families of children with autism will complete a control period with no intervention, then adopt a shelter cat after completion of the control period
2846223|NCT03625297|Experimental|shelter cat adoption|Families of children with autism will adopt a shelter cat
2846224|NCT03625284|Experimental|Fucovital|capsules of a dietary supplement rich with fucoxanthin from microalgae extract
2846225|NCT03625284|Placebo Comparator|Placebo|capsules of an edible oil
2846226|NCT03625271|No Intervention|Control|All subjects will undergo same study procedures. Subjects in the Control Arm will receive treatment as usual by the prescribing clinician/investigator. The prescribing clinician/investigator will not receive the PEER Report of probable medication response for a control arm subject.
2846227|NCT03625271|Experimental|Experimental|All subjects will undergo same study procedures. Subjects in the Experimental Arm will receive treatment as usual by the prescribing clinician/investigator. However, the prescribing clinician/investigator will receive the PEER Report of probable medication response for an experimental arm subject. The report will provide additional data/information regarding probable medication response for an experimental arm subject to the prescriber .
2846228|NCT03625245|Placebo Comparator|Control Yogurt|Control yogurt
2846229|NCT03625245|Experimental|Yogurt Variety 1|Experimental Yogurt 1: Dextrin, wheat bran, whole oatmeal
2846230|NCT03625245|Experimental|Yogurt Variety 2|Experimental Yogurt 2: Pea protein, oatmeal
2846231|NCT03625219|Active Comparator|Prednisone|Cohort B only: Subjects will take 40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.
2846232|NCT03625219|Placebo Comparator|Placebo|Cohort B only: 8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
2846233|NCT03625206|Experimental|Cognitive bias modification training|Participants will receive 5 training sessions, each session including attention bias modification and interpretation bias modification training modules
2846234|NCT03625206|Placebo Comparator|Control training|Participants will receive 5 sessions that involve exercises that are matched to the task demands of the attention bias modification and interpretation bias modification training modules
2846273|NCT03624946|Placebo Comparator|Placebo (Saline Solution)|Single dose of 50 mL placebo will be administered intravenously over 33 minutes.
2852337|NCT03581773|Placebo Comparator|Placebo arm|PLACEBO (1 tablet) per day for 12 weeks.
2846235|NCT03625193||Ambulatory patients with SCI|"Age at least 18 years~Body mass index (BMI) between 18.5 - 29.9 kg/m2~Having an incomplete SCI from traumatic or non-traumatic causes~Ability of independent standing up from a chair with or without hand support~Ability of independent walking with or without walking device over at least 10 meters continuously.~Ability to follow commands used in the studies"
2846236|NCT03625180||Treatment|NAMIC technique
2846237|NCT03625167|Experimental|Treatment with petrolatum|In each healthy volunteer, one of the two forearms is randomly assigned to the intervention. This forearm is treated with petrolatum for 4 respectively 8 weeks.
2846238|NCT03625167|No Intervention|Control|The control forearm will remain untreated throughout the study.
2846239|NCT03625154|Active Comparator|non operative control group|Patients with negative gravity stress (non-operative treatment/observational control group)
2846240|NCT03625154|Active Comparator|non operative experimental group|Patients with positive gravity stress (medial clear space > 4 mm on initial injury pre-reduction x-rays, who undergo a reduction with closing of the medial clear space to <4mm. Plan for nonoperative treatment of all these patients with splint and subsequent walker boot.
2846241|NCT03625154|Active Comparator|operative observational group|Patients with positive gravity stress (medial clear space > 4 mm) who undergo a reduction with closing of the medial clear space to <4mm who declined non-operative treatment but agree to be observed. These patients will undergo ORIF (Open Reduction and Internal Fixation) with plates and screws and function as a second observation group
2846242|NCT03625141|Experimental|Cohort 1- cobimetinib and atezolizumab|Participants with BRAFV600 wild-type disease will be administered cobimetinib on Days 1−21 of each 28-day cycle; and atezolizumab on Days 1 and 15 of each treatment cycle.
2846243|NCT03625141|Experimental|Cohort 2 - cobimetinib, atezolizumab and vemurafenib|Participants with BRAFV600 mutation-positive disease will be administered cobimetinib, atezolizumab and vemurafenib in 28-day treatment cycles. Treatment includes a 28-day run-in period where participants will receive cobimetinib and vemurafenib only. Upon completion of the 28-day run-in period, atezolizumab will be added to their treatment regimen.
2846244|NCT03625128|Experimental|F-18 PMPBB3|F-18 PMPBB3 imaging
2846245|NCT03625115|No Intervention|Usual Care (Control)|Dyads randomized into this control arm will continue with usual care consisting of information about early intervention services and routine Child Find procedures.
2846246|NCT03625115|Experimental|Family Navigator (Intervention)|Dyads randomized to the Intervention arm with be assigned a designated Family Navigator (FN) who will engage, inform, and assist the participating parents to follow-through with the process of EI referrals and services.
2846247|NCT03625102|Experimental|Antroquinonol 100 mg PO BID|Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol, twice a day.
2846248|NCT03625102|Experimental|Antroquinonol 50 mg PO BID|Antroquinonol (Hocena) 50mg/capsule. 1 capsule antroquinonol and 1 capsule placebo,twice a day.
2846249|NCT03625102|Placebo Comparator|Placebo|Placebo capsule, 2 capsules placebo, twice a day
2846250|NCT03625089|Active Comparator|Group 1 - FRS arm|Both group will participate in the nurse-led programme on CV risk screening and carotid ultrasound for carotid plaque assessment. Subjects in group 1 will initiate Atorvastatin treatment (20mg daily per oral) if their Franminham Risk Score >10%
2846251|NCT03625089|Experimental|Group 2 USG arm|Subjects in group 2 will initiate Atorvastatin treatment (20mg daily per oral) if they had carotid plaque upon carotid ultrasound findings..
2846252|NCT03625076|Experimental|Intra-articular Lidocaine|20 mL of 1% lidocaine injected into the joint of the dislocated shoulder
2846253|NCT03625076|Active Comparator|Procedural Sedation|Intravenous etomidate or propofol
2846254|NCT03625063|Active Comparator|Exercise training group|Inspiratory muscle, upper extremity aerobic exercise and progressive resistance trainings
2846255|NCT03625063|Sham Comparator|Control training group|Upper extremity aerobic exercise and progressive resistance trainings
2846256|NCT03625050|Experimental|Chuna + Usual care|
2846257|NCT03625050|Active Comparator|Usual care|
2846258|NCT03625037|Experimental|GEN3013 (DuoBody®-CD3xCD20)|Open label, single arm trial where GEN3013 will be administered
2846259|NCT03625011|Placebo Comparator|Placebo Group|Participants will be randomized to either Control Group or Gabapentin Group
2846260|NCT03625011|Active Comparator|Gabapentin Group|Participants will be randomized to either Control Group or Gabapentin Group
2846261|NCT03624998|Experimental|THA Patients|Orthopedic patients submitted to elective surgery (THA - Total Hip Arthroplasty)
2846262|NCT03624985|Experimental|Intravenous Lidocaine Infusion|Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
2846263|NCT03624985|Placebo Comparator|Placebo Infusion|Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose.
2846264|NCT03624972|Active Comparator|Resources Only|Patients will receive a list of resources on sexual and menopausal health in breast cancer. They will be asked to review the resources before their next clinic visit.
2846265|NCT03624972|Experimental|Resources + Video|"Patients will receive a list of web resources on sexual and menopausal health in breast cancer. In addition to the resources, patients will be asked to view an online video called Starting the Conversation and to complete an accompanying workbook. Patients in this arm will be asked to review the resource list, watch the Starting the Conversation video, and complete the workbook before their next clinic visit."
2846266|NCT03624972|No Intervention|Clinician Arm|Seven clinicians will be consented to this study in order to have their clinic visits with the participating patients audio recorded. Only demographic information will be collected from the clinicians via self-report.
2846267|NCT03624959|Experimental|Treatment Group A - Ozanimod 0.46mg|A single dose of ozanimod 0.46 mg on Day 1
2846268|NCT03624959|Experimental|Treatment Group B - Ozanimod plus Gemfibrozil|Gemfibrozil 600 mg twice daily (BID) on Days 1 through 17. On Day 4, a single dose of ozanimod 0.46 mg will be coadministered with the morning dose of gemfibrozil.
2846269|NCT03624959|Experimental|Treatment Group C - Ozanimod 0.92mg|A single dose of ozanimod 0.92 mg on Day 1.
2846270|NCT03624959|Experimental|Treatment Group D - Ozanimod plus Itraconazole|Itraconazole 200 mg once daily (QD) on Days 1 through 17. On Day 4, a single dose of ozanimod 0.92 mg will be co-administered with itraconazole.
2852579|NCT03580161||99mTc MDP Bone Scan|Patients receiving routine diagnostic scan
2846274|NCT03624933|Experimental|28-Day Cannabis Abstinence|The study will assess the changes that occur after a 28-day abstinence period in patients with Major Depressive Disorder (MDD) and comorbid Cannabis Use Disorder (CUD). Patients will be instructed to initiate abstinence 12 hours prior to the baseline session and will come in for weekly visits involving a series of clinical, cognitive, and substance use assessments.
2846275|NCT03624920|Placebo Comparator|THN102 Dosage A|THN102 Dosage A is a Placebo
2846276|NCT03624920|Experimental|THN102 Dosage B|THN102 Dosage B : 200 mg/2 mg THN102 is a combination of modafinil 100mg and flecainide 1 mg daily dosage is 200 mg of modafinil and 2 mg of flecainide
2846277|NCT03624920|Experimental|THN102 Dosage C|THN102 Dosage C : 200 mg/18 mg THN102 is a combination of modafinil 100mg and flecainide 9 mg daily dosage is 200 mg of modafinil and 18 mg of flecainide
2846278|NCT03624907|Other|Consecutive Daily Treatment|Participant will receive daily stereotactic body radiotherapy at a dose of 48-50 Gy in 4-5 fractions with treatment occurring over 4-5 days
2846279|NCT03624907|Other|Non-Consecutive Daily Treatment|Participant will receive non-daily stereotactic body radiotherapy at a dose of 48-50 Gy in 4-5 fractions with treatment occurring over 8-12 days
2846280|NCT03624894||Patients that undergo a dental restorations|Patients that undergo a dental restorations independently from the present study
2846281|NCT03624881|Experimental|VISITAG SURPOINT Module with EPU|Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
2846282|NCT03624868|Experimental|Tai Chi|A Tai Chi protocol designed for use with older veterans will be used. In each class, the instructor will explain exercise theory and procedures of Tai Chi and review printed materials. Every session will include the following components: (1) warm-up and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture. The Tai Chi instructor will also encourage patients to practice for at least 30 minutes a day at home and to complete daily logs indicating the amount of time that they spent engaged in Tai Chi exercise. Discussion of goal-setting regarding home practice and solutions to potential barriers will be included.
2846283|NCT03624868|Active Comparator|Wellness Education|The wellness education intervention will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives). The Whole Health program focuses on teaching mindful awareness to promote behavioral changes that are consistent with an individual's health goals. Components of the Whole Health model include working the body, surroundings, personal development, food and drink, recharge, family, friends and coworkers, spirit and soul, and power of the mind. Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. Goal-setting using the SMART goals model, with regards to health and wellness, and discussions about ways to address potential barriers will be included in this condition.
2846284|NCT03624855||Description of BJI due to Pseudomonas aeruginosa|patients having bone and joint infection on implant due to Pseudomonas aeruginosa
2846285|NCT03624829||Exp: Patients of GPs with shared care|All patients 16-65 years old who during 12 months have been in contact with a GP in any of the three GP centers that are randomized to shared care before the 12 months.
2846286|NCT03624829||Con: Patients of GPs without shared care|All patients 16-65 years old who during 12 months have been in contact with a GP in any of the three GP centers that are not randomized to shared care before the 12 months, and all patients 16-65 years old who during 12 months have been in contact with a GP in any of the six GP center before the randomization and implementation of shared care.
2846287|NCT03624816|Experimental|Restylane Defyne|injection with Restylane Defyne
2846288|NCT03624816|No Intervention|Control|no-treatment control
2846289|NCT03624790|Experimental|Group 1: rRSV A/Maryland/001/11|Participants will receive a single dose of rRSV A/Maryland/001/11 at study entry (Day 0).
2846290|NCT03624777|Experimental|Stroll Safe Program|
2846291|NCT03624777|Active Comparator|Outdoor Fall Prevention Brochure|
2846292|NCT03624764|Experimental|Promontofixation using glue|Patients in this arm will have a laparoscopic promontofixation using a biocompatible cyanoacrylate adhesive replacing some sutures to maintain the strips.
2846293|NCT03624764|Active Comparator|Promontofixation using threads|Patients in this arm will have a laparoscopic promontofixation using sutures with threads to maintain the strips.
2846294|NCT03624738|Active Comparator|Patients with redo cardiac surgery 1|Procedure: the patients will undergo femorofemoral bypass
2846295|NCT03624738|Active Comparator|Patients with redo cardiac surgery 2|Procedure: the patients will undergo conventional Aortobicaval cannulation
2846296|NCT03624725|Active Comparator|modified BII+Braun|The jejunum of the input segment is properly ligated with double line 7 at 3-5cm from the anastomotic site, and the jejunum of the output segment is extended to 30cm
2846297|NCT03624725|No Intervention|traditional BII+Braun|traditional BII+Braun digestive tract reconstruct
2846298|NCT03624712||uterine neoplasms|Women with operable and inoperable uterine malignomas (cervical cancer, endometrial cancer, uterine sarcoma)
2846299|NCT03624699|Experimental|Glaukos iStent inject®|Patients suffering from cataract and open-angle glaucoma. Glaukos iStent inject® is implanted during routine cataract surgery. The effect on IOP/glaucoma medications is monitored.
2846300|NCT03624686||healthy volunteer|
2846301|NCT03624686||luekemia patient|
2846302|NCT03624673|Experimental|endoscopic robot-assisted simple enucleation|Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.
2846303|NCT03624673|Active Comparator|standard robot-assisted partial nephrectomy|Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.
2846304|NCT03624660|Experimental|HR-A (High-risk A)|"Prostate and proximal seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent."
2846339|NCT03624400|Experimental|Internet-based CBT-I|N= 120 participants are offered Internet-based Cognitive behaviour therapy for insomnia (CBT-I)
2846305|NCT03624660|Experimental|HR-B (High-risk B)|"Prostate, proximal seminal vesicles, and pelvic nodes: 2 cobalt gray equivalent per fraction to a total does of 46 cobalt gray equivalent.~Prostate and proximal seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 32 cobalt gray equivalent.~Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent."
2846306|NCT03624660|Experimental|HR-C (High-risk C)|"Prostate, entire seminal vesicles, and pelvic nodes: 2 cobalt gray equivalent per fraction to a total dose of 46 cobalt gray equivalent.~Prostate and entire involved seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 14 cobalt gray equivalent.~Prostate, entire involved seminal vesicle, and at least the proximal seminal vesicle on uninvolved side: 2 cobalt gray equivalent per fraction to a total dose of 18 cobalt gray equivalent.~Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent."
2846307|NCT03624647|Experimental|Power toothbrush|
2846308|NCT03624647|Placebo Comparator|Manual toothbrush|
2846309|NCT03624621|Experimental|Functional Remediation + CCT|12 sessions (1 per week) of group functional remediation program (90 min/session) plus 20 min of tailored computerized cognitive training (CCT)
2846310|NCT03624621|Placebo Comparator|Psychoeducation + Online Games|12 sessions (1 per week) of psychoeducation for major depression (90 min/session) plus 20 min of playing freely with online games (pre-selected by investigators)
2846311|NCT03624621|No Intervention|Treatment as usual|Usual intervention supervised by their psychiatrist
2846312|NCT03624608|Experimental|Auryzon-Processed Ear/Nose|Patients in this category underwent reconstruction and implantation of a completed ear/nose cartilaginous graft that was processed using the AuryzoN device.
2846313|NCT03624595|Experimental|Dexmedetomidine group|Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery; and will repeated for a maxium of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
2846314|NCT03624595|Placebo Comparator|Placebo group|Placebo (normal saline) infusion is administered from 16:00 to 08:00 in the same speed for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
2846315|NCT03624569|Sham Comparator|Bagel diet|Bagel consumed daily for 2 weeks
2846316|NCT03624569|Experimental|Potato diet|Potato consumed daily for 2 weeks
2846317|NCT03624556|Experimental|Experimental group DS and FXS|Cohort 1: a 35 DS children group taking EGCG FontUp. Cohort 2: a 6 FXS children group taking EGCG FontUp. (Experimental open-label)
2846318|NCT03624556|Placebo Comparator|Control group DS|Cohort 1: a 35 DS children group taking placebo FontUp.
2846319|NCT03624543|Experimental|Cohort 1: TNBC|CFI-400945; 64mg, oral, cycle1: day 1-7; 14 day cycle. cycle 2: daily; 28 day cycle N=9 to 24 patients
2846320|NCT03624543|Experimental|Cohort 2: PTEN-null, ER+ and/or PR+, HER2-|CFI-400945; 64mg, oral, cycle1: day 1-7; 14 day cycle. cycle 2: daily; 28 day cycle N=9 to 24 patients
2846321|NCT03624543|Experimental|Cohort 3: Not PTEN-null, ER+ and/or PR+, HER2-|CFI-400945; 64mg, oral, cycle1: day 1-7; 14 day cycle. cycle 2: daily; 28 day cycle N=9 to 24 patients
2846322|NCT03624530|Experimental|Prophylactic TKI Therapy|Treatment with prophylactic TKI will be initiated from day +30 to +60 post-transplants. TKI was selected according to the mutation results of ABL kinase region.
2846323|NCT03624530|No Intervention|No TKI therapy|Prophylactic TKI will not be given.
2846324|NCT03624517|Experimental|24-hour octreotide infusion|Patients will receive octreotide infusion over 24 hours
2846325|NCT03624517|Active Comparator|72-hour octreotide infusion|Patients will receive octreotide infusion over 72 hours
2846326|NCT03624504|Experimental|Micra Implant Group|Subjects implanted with the Micra Transcatheter Pacing System (TPS)
2846327|NCT03624491|No Intervention|Standard of care mechanical ventilation|Anesthesia and surgical procedures will be performed following standard of care for mechanical ventilation during surgery.
2846328|NCT03624491|Active Comparator|Transpulmonary pressure guided mechanical ventilation|Same treatment as the control group with the addition of esophageal pressure measurements used to guide mechanical ventilation during surgery.
2846329|NCT03624478|Experimental|Treatment (hypofractionated radiation therapy)|Participants undergo hypofractionated radiation therapy daily for 5 days, then undergo standard of care surgery 4-16 weeks after radiation therapy.
2846330|NCT03624465|Experimental|Levita Magnetic Surgical System|Levita Magnetic Surgical System use of surgical tool
2846331|NCT03624452|Experimental|rIPC and exercise training|Those in the rIPC + exercise group will attend three 50 minute exercise sessions per week for 8 weeks at Liverpool John Moores University and 3 bouts of IPC per week at home at a time of their choice
2846332|NCT03624452|Experimental|rIPC only|Those randomly allocated into the rIPC group will self administer 3 bouts of IPC per week at home at a time of their choice.
2846333|NCT03624439|Experimental|Normal airway|normal airway. the language has not been inflated. the instructor assessed the difficulty of intubation based on the Cormack - Lehane scale to the first degree
2846334|NCT03624439|Experimental|Difficult airway|dofficult airway. Difficult airways were obtained by means of language inflation using a simulator control panel, so as to obtain the degree of intubation difficulty assessed by an independent anesthesiologist to the third degree according to the Cormack-Lehane scale
2846335|NCT03624426|Experimental|Automated SSEP Monitored Group|SSEP monitored group: When a nerve alert is signaled by the automated SSEP device, the surgeon will be informed with the aim to reverse the signal changes. Possible surgical interventions include repositioning the operative arm into a more neutral position, avoidance of excessive traction, removal of retractors, and using a smaller implant to avoid over-correction/traction.
2846336|NCT03624426|No Intervention|Standard Group|The automated SSEP device will be connected and will be blinded to the surgeon. The screens of the automated SSEP device will be covered by an opaque plastic bag and the alarms will be turned off. No intervention is planned for this group.
2846337|NCT03624413|Experimental|Receives social media intervention|40 adolescents receiving the social media intervention
2846338|NCT03624413|No Intervention|Receives standard of care|40 adolescents receiving standard of care
2846340|NCT03624400|Active Comparator|Internet-based psychoeducation|N= 120 participants are offered Internet-based psychoeducation about sleep problems in ASD.
2846341|NCT03624387|No Intervention|Control Group( No Painting Sessions)|No Geriatric Inclusive Art session.
2846342|NCT03624387|Experimental|Intervention Group( Painting Session)|Painting sessions for participants
2846343|NCT03624361|Experimental|Stand-alone|"Patients will receive MINIject Glaucoma implant in a stand-alone procedure.~MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention."
2846344|NCT03624348|Experimental|Meditation Group|Participants in the intervention group will assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
2846345|NCT03624348|No Intervention|Wait list control group|Waitlist control group participants will continue their normal activities and not add any form of meditation during the study period.
2846346|NCT03624335|Experimental|Group 1: ECC|"In the ECC group, the cord was clamped immediately after delivery, before the first minute of life.~Blood test 6hours after clamping Blood test 24hours after clamping Blood test 48hours after clamping Blood test 28days after clamping"
2846347|NCT03624335|Experimental|Group 2: DCC|In the DCC group, the cord was clamped when it stops beating. Blood test 6hours after clamping Blood test 24hours after clamping Blood test 48hours after clamping Blood test 28days after clamping
2846348|NCT03624322|Active Comparator|Period 1|Period 1 (n=36) assignment to 1 of 2 reference therapy treatment groups (Zyprexa 5mg IM or Zydis 10mg orally disintegrating wafer, 10mg) over 3 cohorts (single dose)
2846349|NCT03624322|Experimental|Period 2|Period 2 (n=36) assignment to 1 of 3 IP treatment groups (INP105 of 5, 10, or 20mg or placebo) administered with the I231 POD® Device) over 3 cohorts (single dose)
2846350|NCT03624309|Experimental|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
2846351|NCT03624309|Active Comparator|Docetaxel|Docetaxel (75mg/m2 IV d1)
2846352|NCT03624296|Experimental|patient with multiple sclerosis (MS)|
2846353|NCT03624283|Experimental|Group A|Group A will be provided with Exercise-based vestibular rehabilitation (VR) twice per day for a period of 4 weeks;
2846354|NCT03624283|Experimental|Group B|Group B will be prescribed with Betahistine 12mg, twice daily for 7 days;
2846355|NCT03624283|Experimental|Group C|Group C will receive an combination of Exercise-based VR plus Betahistine.
2846356|NCT03624270|Experimental|Oral arsenic trioxide|"Induction:~Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses) and Ascorbic acid 1g daily for 42 days~Daunorubicin at 50mg/m2 daily for 3 days (omitted if WBC at diagnosis < 10 x 10^9/L; or age ≥ 65 years; or cardiac function impairment)~Consolidation:~- Daunorubicin 50mg/m2 per day for 2 days + cytarabine 100mg/m2 per day for 5 days every 4 to 6 weeks for 2 cycles~Consolidation (if WBC at diagnosis < 10 x 10^9/L; or aged ≥ 65 years; or cardiac function impairment):~- Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses) and ascorbic acid 1g daily for 14 days every 28 days for 2 cycles~Maintenance (for all patients):~- Oral Arsenic trioxide 10mg daily, ATRA (45mg/m2 per day in divided doses) and ascorbic acid 1g daily for 2 weeks every 2 months for 24 months."
2846357|NCT03624257|Experimental|Scaling and root planning + Laser treatment|
2846358|NCT03624257|Active Comparator|Mucosal flap surgery|
2846359|NCT03624244|Experimental|Interruption of aromatase inhibitors|Interruption of aromatase inhibitors until progression disease. At disease progression, AI can be reintroduced.
2846360|NCT03624244|Other|Maintenance of aromatase inhibitors|Maintenance of aromatase inhibitors
2846361|NCT03624231|Experimental|Arm 1|"Patients in arm 1 will receive a single dose of durvalumab of 1500 mg administered on day 1, 14 days prior to initiation of the radiotherapy.~Radiotherapy with 35 fractions over 7 weeks (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks) will start on day 14. On week 5, 9, 13 and 17 patients will receive durvalumab (1500 mg) and tremelimumab (75 mg) for up to 4 doses/cycles and then continue 1500 mg durvalumab q4w starting on week 21 to complete a total of 12 months of therapy (overall 9 single doses durvalumab including the initial dose on day 1)."
2846362|NCT03624231|Experimental|Arm 2|"Patients in arm 2 will receive durvalumab (1500 mg) q4w starting on day 1. Radiotherapy with 35 fractions over 7 weeks (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks) will start on day 14.~Overall patients will recieve treatment with durvalumab mono up to a total of 12 months (up to 13 doses in total)."
2846363|NCT03624218|No Intervention|Treatment as Usual|Participants in the control arm will not receive the PE therapy, but they will rather receive the standard clinical treatment receive by all SCI patients at BIR. This includes an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. This therapy does not consist of trauma-focused therapy and will be summarized in the analysis as a part of standard of care. TAU participants will have a posttreatment assessment, as well as follow-up assessments at one and 6 months
2846364|NCT03624218|Experimental|Intervention|Participants randomized to the PE intervention will receive 2-3, 60-minute sessions each week for 4-6 weeks (12 total sessions). Treatment is manualized, and includes education about common reactions to trauma, breathing retraining, prolonged (repeated) imaginal exposure to trauma memories, repeated in vivo exposure to situations that participants are avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises.
2846365|NCT03624192|Experimental|RECELL® Autologous Cell Harvesting Device|RECELL + Telfa™ Clear and Xeroform™ dressings
2846366|NCT03624192|Active Comparator|Telfa™ Clear and Xeroform™ dressings|Telfa™ Clear and Xeroform™ dressings
2846367|NCT03624179||Rheumatoid arthritis patients|complete blood count, Erythrocyte sedimentation rate, C reactive protien ,rheumatoid factor,Anti cyclic citrullinated peptide antibody
2846368|NCT03624179||healthy control|complete blood count, Erythrocyte sedimentation rate, C reactive protien ,rheumatoid factor,Anti cyclic citrullinated peptide antibody
2846369|NCT03624166|Active Comparator|Ketamine|sub- anesthetic dose of ketamine 0.5 mg/kg will be given in 3 ml volume
2846370|NCT03624166|Placebo Comparator|isotonic saline|isotonic saline 3 ml volume will be given
2846393|NCT03623958|Experimental|iVATS resection|Image guided Video-assisted thoracoscopic surgery (VATS) in either one of two hybrid operating rooms and Fine Needle Aspiration (FNA) under fluoroscopy.
2846371|NCT03624153|Experimental|Robotic-assisted training|Participants in robotic-assisted training group will receive 1.5 hours/ day, 3 days a week, for 4 continuous weeks at the clinical setting. Participants will receive 10-minute of muscle tone normalization preparation and passive range of motion, then an 80-minute robotic-assisted training. After the end of the robotic-assisted training, a four-week wash-out period followed. Then, patients will receive the clinic-based training for 4 continuous weeks.Before and after the treatment, the evaluations were conducted. One month after the end of the treatment course, a follow-up evaluation will be assessed.
2846372|NCT03624153|Active Comparator|Clinic-based therapy|"Participants in clinic-based training group will receive 1.5 hours/ day, 3 days a week, for 4 continuous weeks at the clinical setting. Participants will receive traditional occupational therapy for 90 minutes. After the end of the clinic-based training, a four-week wash-out period followed. Then, patients will receive the Robot-assisted training for 4 continuous weeks.~Before and after the treatment, the evaluations were conducted. One month after the end of the treatment course, a follow-up evaluation will be assessed."
2846373|NCT03624140|Experimental|Hemoglobin monitoring|3 different techniques will be used for hemoglobine monitoring : hemocue, pulse co-oxymeter (SpHb) and blood measurement
2846374|NCT03624127|Experimental|BMS-986165|BMS-986165 oral administration
2846375|NCT03624127|Placebo Comparator|Placebo|Placebo oral administration
2846376|NCT03624127|Active Comparator|Active comparator|Active comparator oral administration
2846377|NCT03624101|Experimental|tezacaftor/ivacaftor|After a 4-week screening period to confirm eligibility based on study inclusion and exclusion criteria subjects will receive Symdeko in 3 intermittent four-week intervals, followed by a 4-week follow-up period (for safety and to detect efficacy changes upon washout) Symdeko (Ivacaftor (150 mg daily) Tezacaftor (100 mg daily) will be administered at the approved dose in combination pill, and alternated with ivacaftor.
2846378|NCT03624088|Experimental|Single-Arm Intervention|Participants will complete a baseline questionnaire. They will then self-administer the web-based decision aid, RealRisks. Upon completion, they will complete two more surveys: one within 1 month of completing RealRisks and one six months after completing RealRisks.
2846379|NCT03624075|No Intervention|control group|The control group had a protocol of a health education / self-gestation session lasting 60 minutes. This session should include topics such as definition of knee OA, guidance on knee anatomy and physiology, prayer over articulation, rehabilitation and practice of exercises, and as volunteer to receive an educational and self explanatory primer with all the content that is exposed during a lesson .
2846380|NCT03624075|Placebo Comparator|Placebo group|The placebo group will simultaneously receive two techniques of applying tensionless KT. The first technique that will be applied is inverted 'Y' on the rectus femoris. In the second technique to be applied, the tape body will be divided lengthwise into four narrow strips. The two pieces intersect the front of the knee. For this application, the volunteer will be positioned in the dorsal position without knee flexion and the tape will be applied by a trained researcher. In the case of bilateral OA, in both techniques of application, the most affected member based on the VAS score will be the one that will undergo the intervention. All volunteers will remain with the tape for 72 hours.
2846381|NCT03624075|Experimental|intervention group|The intervention group will receive the same protocol as the placebo group, differing only in relation to the tension of the bandage. According to Kase et al (2003), the techniques recommend the relief of pain and edema and performance. In the second technique to be applied, the tape body will be divided lengthwise into four narrow strips. The two pieces intersect the front of the knee. For this application, the volunteer will be positioned in the dorsal position without knee flexion and the tape will be applied by a trained researcher. In the case of bilateral OA, in both techniques of application, the most affected member based on the VAS score will be the one that will undergo the intervention. All volunteers will remain with the tape for 72 hours.
2846382|NCT03624062|Other|33 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 33 ug IBC dose in 0.25 mL MAS-1 emulsion
2846383|NCT03624062|Other|109 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 109 ug IBC dose in 0.25 mL MAS-1 emulsion
2846384|NCT03624062|Other|327 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 327 ug IBC dose in 0.25 mL MAS-1 emulsion
2846385|NCT03624062|Other|TBD ug IBC in 0.5 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with the maximum safe IBC dose selected from the first 3 groups (either 33 µg, or 109 µg, or 327 µg IBC) in 0.5 mL MAS-1 emulsion
2846386|NCT03624049|Other|Community Exercise Program|Participation in Health Class including: Arthritis Exercise Foundation Exercise Class, Tai Chi for Arthritis, EnhanceFitness Class, or Healthier Living Class.
2846387|NCT03624036|Experimental|KTE-C19|Participants will receive conditioning chemotherapy (fludarabine and cyclophosphamide), followed by the investigational treatment, KTE-C19.
2846388|NCT03624023|Experimental|TWB-103|(Mixture of TWB-102 cell and TWB-103 hydrogel)
2846389|NCT03624010|Experimental|Levosimendan|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
2846390|NCT03623997||Stable isotope labeled iron II sulfate|All subjects will go through two iron absorption study cycles. In one cycle they get 100mg oral iron labeled with stable isotopes on two consecutive and on one alternate day and in another cycle they get 200mg oral iron labeled with stable isotopes on two consecutive and on one alternate day. Half of the subjects start with the 100mg cycle whereas the other half starts with the 200mg cycle.
2846391|NCT03623984|Experimental|Gallium Dotatate|All patients in the study will be undergoing both a 68Gallium-DOTATATE scan for tumor localization and planned surgical resection. Both of these maneuvers are clinically indicated and the standard of care in the care of these patients. Following induction of general endotracheal anesthesia (as required for the surgery portion of treatment), the patients will receive an additional injection of 68Gallium-DOTATATE in the operating room itself. A probe that can detect 68Gallium will be used to identify tumors in the OR within the patient's abdominal cavity for targeted resection.
2846392|NCT03623971|Experimental|Artificial Intelligence|A universal diagnostic system. An artificial intelligence to make comprehensive evaluation and treatment decision of cataract.
2846454|NCT03623503||first group|Observational study of 25 newborn with a likely EOS
2846394|NCT03623958|Active Comparator|Standard VATS resection|Standard video-assisted thoracoscopic surgery (VATS) in operating room and Fine Needle Aspiration (FNA) in pathology frozen section room.
2846395|NCT03623945||Cohort A|Patients who have recently had an abnormal mammogram, followed by a breast biopsy and an initial diagnosis of Stage I, II, III or IV invasive breast cancer, will be invited to participate. Stage I, II and III participants will be further categorized into high-risk and low-risk. For the purposes of this study, participants with at least one of the following will be considered high-risk; any triple negative cancer, any grade III cancer, lymph node involvement, tumor greater than 2cm, or any patient receiving cytotoxic chemotherapy.
2846396|NCT03623945||Cohort B|Patients who have recently had an abnormal mammogram, followed by a breast biopsy and diagnosed with a benign but high-risk pathology, will be invited to participate. This includes, but is not limited to, atypical ductal hyperplasia, atypical lobular hyperplasia, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), flat epithelia atypia or phylloides.
2846397|NCT03623945||Cohort C|Patients who have recently had an abnormal mammogram, followed by a breast biopsy and diagnosed with a benign tumor, will be invited to participate. This includes, but is not limited to, fibroadenoma, papilloma, fibrocystic changes and Pseudoangiomatous stromal hyperplasia (PASH).
2846398|NCT03623945||Cohort D|Patients who have had a normal screening mammogram within the last 6 months will be invited to participate.
2846399|NCT03623932|Active Comparator|immunosuppressor/TNFalpha|Standard treatment with immunosuppressor and/or anti-TNFalpha treatment.
2846400|NCT03623932|Experimental|Hypnosis + Standard Treatment|Standard treatment with immunosuppressor and/or anti-TNFalpha treatment in addition to hypnosis parallel treatment.
2846401|NCT03623919|Experimental|Exercise group|"Group games, including two teams of seniors aged 50 years or older. The FallSensing games software include 3 mini-games to be played by two teams with up to 3 players each will compete against each other alternately.~The players will perform an initial evaluation with FallSensing screening tool, 16 sessions of group games (2 times a week/8weeks) with FallSensing multiplayer games and a final evaluation also with FallSensing screening tool.~Both initial and final evaluation include six functional tests (Grip Strength, Timed Up and Go, 30 seconds Sit-to-Stand, Step test, 4 Stage Balance test modified and 10 meters Walking Speed) and a questionnaire concerning self-efficacy for Exercise."
2846402|NCT03623906|Experimental|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
2846403|NCT03623906|Active Comparator|Air insufflation colonoscopy|Room air insufflation colonoscopy
2846404|NCT03623893|Other|Intervention group|Unilateral inguinal hernia repair with contralateral exploration.
2846405|NCT03623893|No Intervention|Control group|Unilateral inguinal hernia repair.
2846406|NCT03623880|Experimental|Unified Protocol|This is a type of CBT for emotional distress.
2846407|NCT03623880|Active Comparator|Supportive Therapy|This is a commonly-used form of all-purpose psychotherapy, often used as a comparator in CBT clinical trials.
2846408|NCT03623867|Experimental|Secukinumab|Subject will received secukinumab 150mg at week 0-4, and once monthly till week 52
2846409|NCT03623867|Placebo Comparator|Placebo|Subject will received placebo 150mg at week 0-4, and once monthly till week 52
2846410|NCT03623854|Experimental|Treatment (nivolumab and relatlimab)|Participants receive nivolumab intravenously (IV) over 60 minutes and relatlimab via infusion over 60 minutes on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2846411|NCT03623841|Experimental|Dual-task training group|Participants in dual-task training group will execute dual-task training via exer-game which combined with treadmill, 3 times per week, least 8 weeks.
2846412|NCT03623841|Active Comparator|Treadmill training group|Participants in treadmill training group will do treadmill training only, 3 times per week, least 8 weeks.
2846413|NCT03623828|Experimental|Apomorphine treatment|"Treatment by apomorphine hydrochloride subcutaneous infusion 12 hours per day during 30 days: 5-days titration phase (increasing doses from 0 to 4 mg/h), 7 days of maintenance at 4 mg/h and 18 days of maintenance phase with possible increase up to 6 mg/h if well tolerated.~Two days before the initiation of apomorphine, domperidone 20mg t.i.d per os (or via gastric tube) will be initiated to reduce common side effects. It will be maintained at least 7 days before an optional tapering off in the absence of nausea of vomiting."
2846414|NCT03623815|Other|Sham tDCS followed by active tDCS|Within subjects design. This group received sham (placebo) transcranial direct current stimulation (tDCS) for 20 minutes in session one. At least one month later this group received 2mA of active tDCS for 20 minutes in session two.
2846415|NCT03623815|Other|Active tDCS followed by sham tDCS|Within subjects design. This group received 2mA of active transcranial direct current stimulation (tDCS) for 20 minutes in session one. At least one month later this group received sham (placebo) tDCS for 20 minutes in session two.
2846416|NCT03623802|Experimental|Local Movement Therapy|Group receiving treatment in form of Local Movement Therapy Program.
2846417|NCT03623802|Experimental|Integral Movement Therapy|Group receiving treatment in form of Integral Movement Therapy Program.
2846418|NCT03623789|Active Comparator|Group I|Primary total hip replacement with application of Floseal hemostatic matrix on potential bleeding sites after prosthesis implantation, and intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later
2846419|NCT03623789|Active Comparator|Group II|Primary total hip replacement with intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later
2846420|NCT03623789|Placebo Comparator|Group III|Control group, neither TXA nor Floseal® will be used. Equivalent volume of normal saline injection pre- and post-operatively
2846421|NCT03623776|Experimental|SHR-1210+chemotherapy or SHR-1210 alone|Subjects receive SHR-1210 200mg and pemetrexed of 500 mg/m^2 and carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles; or SHR-1210 was given 200 mg i.v. infusion on days Day 1 of each 14-day cycle for 3 cycles
2846422|NCT03623763||Healthy individuals|Individuals without any complaints and chronic diseases
2846423|NCT03623763||Swimmers|Elite athletes - swimmers to distance of national team of Uzbekistan
2846424|NCT03623763||Synchronized swimmers|Elite athletes - swimmers of national team of Uzbekistan
2846455|NCT03623503||second group|Observational study of v33 newborn with a possible EOS
2846425|NCT03623750|Experimental|EGFR-TK Inhibitor plus EGF-PTI|Elegile patients will receive a single pre-treatment low dose of intravenous cyclophosphamide 200mg/m2 before experimental treatment starts. Daily oral therapy with afatinib according to the SmPC of the product in nominal treatment cycles of 21 days followed by immunisation with EGF-PTI.
2846426|NCT03623737|Experimental|paclitaxel plus cisplatin|A. T: Paclitaxel 50 mg/m2, 1h IVF, weekly, week 1 to week 5 during CRT. B. P: Cisplatin 30 mg/m2, 2 h IVF, weekly following paclitaxel, week 1 to week 5 during CRT.
2846427|NCT03623737|Active Comparator|cisplatin plus 5-fluorouracil|A. P: Cisplatin 75 mg/m2, 2 h IVF, on day 1 of week 1 and week 5 during CRT. B. F: 5-FU 1,000 mg/m2, 24 h IVF, on day 1, 2, 3, 4 of week 1 and week 5 during CRT.
2846428|NCT03623724|Experimental|blended Cognitive-behavioral Therapy|The experimental condition refers to a blended treatment that integrates empirically-supported face-to-face cognitive-behavioral psychotherapy with a mobile phone application and a web platform - blended cognitive-behavioral therapy (bCBT). The intervention includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on the self-help treatment modules of the Moodbuster (psychoeducation, exercise therapy, behavioral activation, problem solving, cognitive restructuring and relapse prevention) delivered over a period of 16 weeks. 50 patients will be integrated in this experimental condition.
2846429|NCT03623724|Active Comparator|Treatment-As-Usual|The control condition concerns the treatment-as-usual (TAU) that consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial). 50 patients will be integrated in this condition.
2846430|NCT03623711|Experimental|Escitalopram group|including 50 patients, dosage:start 10mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 20mg/day and last to the end of 12 week. but if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week.
2846431|NCT03623711|Experimental|Duloxetine group|including 50 patients, dosage:start 30mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 60mg/day and last to the end of 12 week. but if the reduction rate of HAMD more than 20% relative to baseline,the investigators will continue to use current dosage until the end of 12 week.
2846432|NCT03623711|Experimental|Bupropion group|including 50 patients, dosage:start 75mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week.if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 150mg/day and last 2 weeks, the investigators assess the HAMD score again, if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week, but if the reduction rate of HAMD still less than 20% relative to baseline, the participants would withdraw.
2846433|NCT03623711|Placebo Comparator|Healthy control|50 age-, gender-,education level- and handedness matched healthy control would recruit by an advertisement in the local community and school, and excluding ① with a severe physical disease and/or neurological disease, ②with substance abuse, ③ with a history of brain injury, ④ inability to undergo a MRI scan.
2846434|NCT03623698||Neuromuscular disease|"Children and young people with neuromuscular disease that have been on treatment with nebulised hypertonic saline for at least 12 months.~2 questionnaires will be applied to their parent or legal guardian and one questionnaire will be applied to children aged 10 years or older."
2846435|NCT03623698||Cerebral Palsy|"Children and young people with cerebral palsy that have been on treatment with nebulised hypertonic saline for at least 12 months.~2 questionnaires will be applied to their parent or legal guardian."
2846436|NCT03623685|Experimental|voluson 8|
2846437|NCT03623659|Active Comparator|AH group|Subjects whose vitrified/warmed blastocysts will be subjected to the treatment of laser assisted hatching
2846438|NCT03623659|No Intervention|Control group|Subjects whose vitrified/warmed blastocysts will be subjected to the same procedures except for the treatment of laser assisted hatching
2846439|NCT03623646|Other|Arm A (standard arm): Chemoradiotherapy arm|
2846440|NCT03623646|Experimental|Arm B (Experimental arm): Immunotherapy + Radiotherapy arm|
2846441|NCT03623633|Active Comparator|Denosumab and Raloxifene|denosumab and raloxifene
2846442|NCT03623633|Active Comparator|Denosumab and Alendronate|denosumab and alendronate
2846443|NCT03623620|Experimental|Digital delivery of MBCT (Mindful Mood Balance for Moms)|Subjects will receive digital delivery of mindfulness-based cognitive therapy (Mindful Mood Balance for Moms) for 12 weeks, along with the usual care they would receive from their provider.
2846444|NCT03623620|No Intervention|Usual Care|Subjects will receive only usual care, the care they would normally receive from their community provider, for 12 weeks.
2846445|NCT03623594|Experimental|Surgical repair of the diastasis|Repair of the diastasis with a double row plication using absorbable Quill suture
2846446|NCT03623581|Experimental|GB226 3mg/kg every 2 weeks|GB226 3mg/kg every 2 weeks
2846447|NCT03623568|Experimental|Treatment with Mavyret (glecaprevir/pibrentasvir) for HCV|12 weeks of treatment with Mavyret
2846448|NCT03623555||E-IPV|"Women who have been exposed to intimate partner violence. Half of this group will also have a history of childhood maltreatment.~Women will be assessed for behavioral performance during the Trier Social Stress Test, and salivary cortisol will be collected."
2846449|NCT03623555||NE-IPV|"Women who have never been exposed to intimate partner violence. Half of this group will also present a diagnosis of Major Depressive Disorder.~Women will be assessed for behavioral performance during the Trier Social Stress Test, and salivary cortisol will be collected."
2846450|NCT03623542||Dementia or alzheimer dementia|All patients presenting with dementia syndrome and whose admission was unplanned between May 2010 and November 2011 were consecutively included in the study.
2846451|NCT03623529|Experimental|Active Comparator: LJPC-501|LJPC-501 Angiotensin II Solution for infusion
2846452|NCT03623529|Placebo Comparator|Placebo Comparator: Placebo|0.9% sodium chloride solution
2846453|NCT03623516||Thyroid cancer|All subjects living in the Marne or Ardennes Departments of France and who were diagnosed with papillary thyroid cancer between 1975 and 2014.
2846456|NCT03623490|Experimental|accented follow-up|Initial consultation with a trio oncologist / pharmacist / nurse; weekly telephone follow-up with a nurse between each treatment and follow-up visit with the oncologist at each renewal of treatment.
2846457|NCT03623490|No Intervention|standard follow-up|Initial consultation with the oncologist and follow-up visit with the oncologist
2846458|NCT03623477|Active Comparator|Cognitive Remediation (CRT)|Participants assigned to CRT alone will complete 24 hours of neurocognitive training activities and 12 hours of control computer activities.
2846459|NCT03623477|Experimental|CRT+ Social Cognition Training|Participants assigned to the combination of CRT and SCT will complete 24 hours of computerized neurocognitive training in memory, attention, and processing speed, and 12 hours of computerized social cognition training focused on improving emotion recognition, social perspective taking, and mentalizing abilities.
2846460|NCT03623464|Active Comparator|Mobile app and Fitbit + Standard of care|Mobile health application and Fitbit + standard of care: Participants will utilize mobile app and Fitbit and standard of care. Mobility data will be generated using a mobile health tracker designed for smartphone devices.
2846461|NCT03623464|Other|Standard of care|Participants will receive standard of care
2846462|NCT03623451|Experimental|Chinese Medicine Formula|All 100 patients were treated with Chinese Medicine Formula(CMF) for six menstrual cycles.
2846463|NCT03623438|Experimental|Self-administered acupressure group|Subjects will attend two weekly 120-minute of self-administered acupressure training
2846464|NCT03623438|Active Comparator|Sleep hygiene education (SHE) group|Subjects will attend two weekly 120-minute of sleep hygiene education
2846465|NCT03623425|Experimental|68Ga-PSMA-11 PET before 18F-FCH PET|Crossover design
2846466|NCT03623425|Experimental|18F-FCH PET before 68Ga-PSMA-11 PET|Crossover design
2846467|NCT03623412|Experimental|One abnormal value|Women with only one abnormal value on OGTT (Oral Glucose Tolerance Test) during pregnancy
2846468|NCT03623412|Active Comparator|GDM|Women with two abnormal values on OGTT during pregnancy - diagnosis=GDM
2846469|NCT03623399|No Intervention|15 mmhg-15mmhg|Abdominal entrance pressure will be set to 15 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 15 mmhg.
2846470|NCT03623399|Other|15 mmhg-12 mmhg|"Abdominal entrance pressure will be set to 15 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 12 mmhg.~Low gas pressure laparoscopy"
2846471|NCT03623399|Other|12 mmhg-12 mmhg|"Abdominal entrance pressure will be set to 12 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 12 mmhg.~Low gas pressure laparoscopy"
2846472|NCT03623386|Experimental|Patients with PD neurofeedback training|Patients will receive neurofeedback training.
2846473|NCT03623386|Active Comparator|Patients with PD control|Patients will not receive neurofeedback training.
2846474|NCT03623373|Experimental|Bendamustine/Rituximab/Acalabrutinib/Cytarabine|"Patients will receive (6) 28 day cycles~Odd-numbered cycles (1, 3, and 5) will consist of bendamustine on Days 1 and 2, rituximab on Day 1, and acalabrutinib twice per day (BID) on Days 1 through 28.~Even-numbered cycles (2, 4, and 6) will consist of rituximab on Day 1, cytarabine every 12 hours on Days 1 and 2, acalabrutinib BID on Days 1 through 7 and 22 through 28 (one week on, two weeks off, one week on), and growth factors as per institutional standard~After Cycle 6, patients will undergo leukapheresis"
2846475|NCT03623360||Patients with liver cirrhosis|"The cohort includes patients who encompass the full clinical spectrum of liver function within cirrhosis.~The participants will undergo a full MRI protocol for liver screening including morphological imaging, fibrosis scoring tests based on relaxometry and diffusion maps, and our novel functional technique based on free breathing DCE-MRI."
2846476|NCT03623334|Other|Image Guided Radiation Therapy|Image-guided radiation therapy (IGRT) is a process of using various imaging technologies to locate a tumor target prior to each treatment with radiation therapy.As a result, the amount of healthy tissue exposed to radiation can be reduced, minimizing the incidence of side effects. An example of three-dimensional (3D) IGRT is localization of a cone-beam computed tomography (CBCT) dataset with the planning computed tomography (CT) dataset from planning.
2846477|NCT03623321|Experimental|Drug - pimavanserin|Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
2846478|NCT03623308|Experimental|Fiber Intervention I|Participants will be asked to consume two ½ cup servings of fiber cereal daily (equivalent to 28 g fiber) for 14 days, one in the morning and one in the evening.
2846479|NCT03623308|Experimental|Fiber Intervention II|Participants will be asked to consume two ¼ cup servings of fiber cereal daily (equivalent to 14 g fiber) for 14 days, one in the morning and one in the evening.
2846480|NCT03623295||Cohort study population|For the main cohort study, we will include 500 patients with moderate or mild hemophilia A and 500 patients with moderate or mild hemophilia B.
2846481|NCT03623295||Sub study population|A subset of 200 patients of the cohort study population will be investigated in more detail by longitudinal data collection.
2846482|NCT03623282|Experimental|Synatura® 15 mL|Synatura syrup single arm
2846483|NCT03623256|Active Comparator|Spinal Fentanyl|Spinal dose of preservative-free fentanyl 25 mcg (Volume 0.5 mL)
2846484|NCT03623256|Active Comparator|Spinal Bupivacaine|Spinal dose of preservative-free 0.25% bupivacaine (Volume 0.5 mL)
2846485|NCT03623256|Active Comparator|Spinal Fentanyl and Bupivacaine|Spinal combination of preservative-free 0.25% bupivacaine (0.5 mL) and fentanyl 25 mcg (0.5 mL). (Total Volume 1 mL).
2846486|NCT03623256|Experimental|Epidural fentanyl /spinal bupivacaine|Spinal preservative-free 0.25% bupivacaine (Volume 0.5 mL) and epidural fentanyl 100 mcg (Volume 2 mL).
2846487|NCT03623243|Experimental|Arm 1 (BAF312)|Siponimod 2mg
2846488|NCT03623230|Sham Comparator|GCont|Only dressing will be applied to patients without actually nerve block performed
2846489|NCT03623230|Active Comparator|G125 Block|"Ultrasound Guided Femoral Nerve Block: 20ml Bupivacaine 0.125% Injectable Solution will be administered for femoral nerve block.~5ml %0,5 Bupivacaine will be diluted with 15ml Saline solution."
2846490|NCT03623230|Active Comparator|G25 Block|"Ultrasound Guided Femoral Nerve Block: 10ml Bupivacaine 0.25% Injectable Solution will be administered for femoral nerve block.~5ml %0,5 Bupivacaine will be diluted with 5ml Saline solution."
2846491|NCT03623217||Kidney transplant participants receiving tacrolimus|Transplant participants who have received tacrolimus twice daily for a minimum of 6 months to a maximum of 12 months after the surgery, and who are within 1 month of switching to the once daily regimen of modified release tacrolimus.
2846492|NCT03623204||Patients with bariatric surgery for obesity|
2846493|NCT03623191||Patients with erosive pustular dermatosis of the leg|
2846494|NCT03623178||Assertive Community Treatment|"patients with DSM-5 Diagnosis of SUD and one of the following criteria (1) present important functional difficulties, in at least one of the following areas: everyday life activities and maintaining a supportive social network, for minimum two years.~or (2) difficulties to attend their health care appointments, during the last 3 months."
2846495|NCT03623178||Treatment As Usual|patients with DSM-5 Diagnosis of SUD which do not respond to ACT inclusion criteria
2846496|NCT03623165||Arm|Cordella™ Heart Failure System
2846497|NCT03623139|Active Comparator|Standard nutritional education|Control group
2846498|NCT03623139|Experimental|BCC|Education and training i basic carbohydrate counting (BCC) plus standard nutritional education
2846499|NCT03623113|Experimental|BCC intervention|The BCC program consists of three group sessions and is delivered by two trained dietitians. In addition to the BCC program, the participants receive regular medical care in the diabetes clinic
2846500|NCT03623113|Experimental|ABC-ACC intervention|The ABC-ACC program consists of one group session and two individual follow-up sessions and is delivered by trained dietitians with supervision by a medical doctor. In addition to the ABC-ACC program, the participants receive regular medical care in the diabetes clinic
2846501|NCT03623113|Active Comparator|Standard dietary education|The routine outpatient dietary care consists of three individual consultations delivered by a trained dietitian. The individual guidance is based on the overall treatment goal(s), the defined personal dietary goals for behavioral change which will be in accordance with the patient's needs and preferences. In addition to the dietary counselling, the participants receive regular medical care in the diabetes clinic
2846502|NCT03623100|Experimental|Speech Treatment|Half of the children will be assigned to the traditional speech treatment program which will focus on how to produce sounds in academic vocabulary words.
2846503|NCT03623100|Experimental|Speech Treatment & Perception|Half of the children will be assigned to the traditional speech treatment program and speech perception training program combination. This treatment program will teach children not only how to produce sounds in academic vocabulary words, but to also identify correctly and incorrectly produced sounds in words.
2846504|NCT03623087|Experimental|SIMPLE|cisplatin, gemcitabine, ifosfamide, etoposide (VP-16), L-asparaginase, dexamethasone
2846505|NCT03623074|Experimental|Test Arm 1|Single vision, impact-resistant spectacle lenses
2846506|NCT03623074|Experimental|Test Arm 2|Single vision, impact-resistant spectacle lenses
2846507|NCT03623074|Other|Test Arm 3|Single vision, impact-resistant spectacle lenses
2846508|NCT03623061||Low Fibrinogen Level|Anonymised low fibrinogen adult samples from the laboratory (Low fibrinogen concentrations). Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
2846509|NCT03623061||Normal Fibrinogen Level|Healthy non pregnant females presenting for elective gynaecology surgery (Normal non pregnant fibrinogen concentrations) Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
2846510|NCT03623061||High Fibrinogen Level|Healthy pregnant females presenting for elective caesarean section (Normal term pregnancy fibrinogen levels) Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
2846511|NCT03623048|Experimental|Propolis extract|intervention
2846512|NCT03623048|Experimental|Pomegranate extract|intervention
2846513|NCT03623048|Active Comparator|Chlorhexidine|comparator
2846514|NCT03623048|Placebo Comparator|Saline|comparator
2846515|NCT03623035||Lumbar Plexus block Group|This group includes participants that received Lumbar Plexus blocks (LPB) as the regional analgesic technique in a direct anterior approach (DAA) Total Hip Arthroplasty.
2846516|NCT03623022|Experimental|Endotoxin, then Normal Saline|"Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The Clinical Center Reference Endotoxin (CCRE) will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).~Following a washout of 2 weeks to 3 months the participant will undergo a Saline Challenge: Subjects will undergo inhalation of 0.9% sodium chloride. The Normal saline will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes)."
2846517|NCT03623022|Experimental|Normal Saline, then Endotoxin|"Saline Challenge: Subjects will undergo inhalation of 0.9% sodium chloride. The Normal saline will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).~Following a washout of 2 weeks to 3 months the participant will undergo an Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes)."
2846518|NCT03623009|Experimental|Intervention|An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
2846519|NCT03623009|Sham Comparator|Control|The control arm will receive a neutral article prior to completing the assessment.
2846520|NCT03622983||Collection of sample and data|Collection of biological samples and clinical data
2846521|NCT03622970|Experimental|VGBT with Nintendo® Wii and LMC games|"VGBT with Nintendo® Wii and LMC games:~In order to improve the elbow and shoulder functions, Tennis and boxing, the games of Nintendo Wii® Fit WiiSports package that includes shoulder and elbow movements will be used for VGBT with Nintendo® Wii and Leap Motion Controller (LMC) games. In both of the games, the activities are carried out by providing feedback in the context of remote control and sound and vibration notifications."
2846522|NCT03622970|Active Comparator|NDT-based upper limb rehabilitation|"NDT-based upper limb rehabilitation:~NDT-based upper limb rehabilitation aims to facilitate normal movement for upper extremity activities such as getting dressed and eating etc by using real materials (clothes, spoons, pencils, buttons, rope, etc.). The target activities were practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools."
2846523|NCT03622957||Type 2 diabetes subjects|Type 2 diabetes subjects consecutively referring to Santa Chiara, Pisa diabetes outpatients clinic
2846524|NCT03622944|Active Comparator|Muscle energy technic|post isometric relaxation technics were used as muscle energy technics.
2846525|NCT03622944|Active Comparator|Deep Friction Massage|Painful areas palpated and deep friction massage was applied.
2846526|NCT03622944|Active Comparator|exercise|Physiotherapist guided Spinal stabilization exercises were applied.
2846527|NCT03622931|Experimental|the experimental arm|standard chemotherapy at 3/4-weekly intervals (cf. inclusion criteria) + romiplostim 750 μg sc once per week for up to 4 cycles
2846528|NCT03622931|Placebo Comparator|the placebo arm|standard chemotherapy at 3/4-weekly intervals (cf. inclusion criteria) + placebo once per week for up to 4 cycles
2846529|NCT03622918|Sham Comparator|colistin monotherapy|The subjects will be treated with colistin monotherapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
2846530|NCT03622918|Experimental|colistin-rifampin combination|The subjects will be treated with colistin and rifampin combination therapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
2846531|NCT03622905|Experimental|DBS On|DBS system On
2846532|NCT03622905|Sham Comparator|DBS Off|DBS System Off
2846533|NCT03622879|Experimental|MT + TENS|The subject will adopt a semi-seated position on a bed while the mirror board is positioned between the legs perpendicular to the subject's midline. The paretic leg will be positioned behind the mirror, with the intact leg facing the reflective surface. All subjects will be reminded to focus on the image in the mirror during MT training. All subjects will receive concurrent TENS stimulation over the common peroneal nerve while practising bilateral lower limb exercises. After 15 minutes of priming with TENS + MT, all subjects will perform 60 minutes of lower limb task-oriented training.
2846534|NCT03622879|Placebo Comparator|Placebo-MT+TENS|In the Placebo-MT+TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group, except that the reflecting surface of the angle-adjustable mirror was covered with paper. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
2846535|NCT03622879|Placebo Comparator|MT+placebo-TENS|In the MT+placebo-TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group. The only difference is that placebo stimulation will be applied to the paretic limb from identical-looking TENS devices with the electrical circuit disconnected inside. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
2846536|NCT03622879|Sham Comparator|control training|All subjects will perform 60 minutes of lower limb task-oriented training only.
2846537|NCT03622866|Active Comparator|Ultra-high pulse width|Ultra-high pulse width stimulation using the Algovita System
2846538|NCT03622866|Active Comparator|Low (traditional) pulse width|Low (traditional) pulse width stimulation using the Algovita System
2846539|NCT03622853|Experimental|intraarticular steroid injection|intraarticular steroid hydrodilatation (shincort 40mg )
2846540|NCT03622840|Experimental|Parkinson's disease patients with cognitive impairment|
2846541|NCT03622827|Experimental|Chemoradiotherapy + Endostar|"Chemoradiotherapy with Endostar：~Chemoradiotherapy: pelvic radiotherapy with concurrent chemotherapy that consisted of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day,civ, day 1-4) for 2 cycles every 3 weeks.~Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the chemotherapy every 3 weeks, total of two cycles during chemoradiotherapy course."
2846542|NCT03622814|Experimental|Treatment - Partners at Meals (PAM)|People with dementia (PWD) often lose weight and suffer subsequent health issues: the goal of this intervention is to improve or maintain weight of a PWD, and to improve or maintain food intake. A train-the-trainer intervention is used with volunteers in Respite Care Centers who partner with family caregivers of PWD. Designed to be personalized to the PWD and focusing on his/her existing strengths and compensating for his/her deficits in mealtime management, sessions occur initially (1 hr) and every month (~30 mins) to reinforce key areas of behavioral or environmental change. Samsung tablets are used initially and then monthly (x5) to record mealtimes in the home, and are reviewed by the volunteer with the family member at the monthly session to discuss areas where changes could be made.
2846543|NCT03622814|Placebo Comparator|Enhanced Usual Condition (EUC)|In the non-treatment respite care centers, an Enhanced Usual Condition will be delivered to caregivers of People with Dementia (PWD). This program consists of enhanced training in caregiving using components from a module of the evidence-based Savvy Caregiver program (K. Hepburn) given in a group setting with opportunity for a question and answer period; the program is given for new enrollees and every 6 months. The PI (EJA), the nutritionist (KM) or the Program Manager (MCP) will lead these groups. Weight of the PWD is measured initially and monthly (x5); amount of food consumed will be measured using the Samsung tablets, also initially and monthly (x5).
2846544|NCT03622801||Intra-arterial administration|Patients with intra-arterial administration of Iopromide
2846545|NCT03622801||Intravenous administration|Patients with intravenous administration of Iopromide
2846546|NCT03622788|Experimental|Treatment (chemotherapy, PBSCT, cytokine-treated veto cells)|"CONDITIONING REGIMEN: Participants receive ATG IV over 4 hours on days -9 to -7, and fludarabine IV over 1 hour on days -6 to -3, then undergo TBI on day -1.~TRANSPLANT: Participants undergo PBSCT IV over 30-60 minutes on day 0.~GVHD PROPHYLAXIS: Participants receive cyclophosphamide IV over 3 hours on days +3 and +4 and cytokine-treated veto cells IV over 30-60 minutes on day +7."
2846547|NCT03622775|Experimental|Treatment (daratumumab)|Beginning 60-120 days after transplant, participants receive daratumumab IV over 4-8 hours on days 1, 8, 15 and 22 of courses 1 and 2 and days 1 and 15 of courses 3-6, then on day 1 of subsequent courses. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
2846682|NCT03621865|Experimental|subject sequence 6|subject allocation sequence 6. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2846548|NCT03622762|Experimental|Green tea extract|In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
2846549|NCT03622762|Placebo Comparator|Placebo|In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
2846550|NCT03622749|Active Comparator|Patients|Individuals with Bipolar 1 Disorder
2846551|NCT03622749|No Intervention|Controls|Healthy controls
2846552|NCT03622710|Experimental|Different surfaces|Subjects are trained to walk over a walking track with different surfaces (WTDS) for 5 days over 4 weeks.
2846553|NCT03622710|Active Comparator|overground|Subjects are trained to walk overground for 5 days over 4 weeks.
2846554|NCT03622697|Experimental|Mindfulness Meditation Arm|Mindfulness meditation intervention: patients will be asked to complete a guided mindfulness meditation phone application intervention.
2846555|NCT03622697|No Intervention|Non-Intervention Arm|Patients assigned to the non-intervention arm will be instructed to use a phone application unrelated to mindfulness meditation.
2846556|NCT03622684|Experimental|Muscle relaxation according to Jacobson|. Does the use of the method of progressive relaxation according to Jacobson will be beneficial to reduce pain and improve the functioning of the stomatognathic system being evaluated in clinical trials?
2846557|NCT03622671|Active Comparator|Skeletonized LIMA|In patients in this arm the left internal mammary artery will be skeletonized without opening of the left pleural cavity during CABG.
2846558|NCT03622671|Active Comparator|Pedicled LIMA|In patients in this arm the left internal mammary artery will be harvested as a pedicled graft with wide opening of left pleural cavity.
2846559|NCT03622658|Placebo Comparator|Placebo|Placebo solution administered by subcutaneous injection on 4 occasions over 10 weeksx
2846560|NCT03622658|Experimental|Namilumab|Namilumab (150 mg) administered by subcutaneous injection on 4 occasions over 10 weeksx
2846561|NCT03622645|Experimental|Range of motion in hand|Assessment of Wrist flexion/extension, radial/ulnar deviation, supination/pronation, 1.-5. DIP, PIP and MCP flexion/extension ROM measurements of the fingers with universal goniometer and Leap motion sensor
2846562|NCT03622619|Experimental|Manuka eye drops|
2846563|NCT03622619|Active Comparator|Systane Ultra|
2846564|NCT03622606|Experimental|Acute and subacute phase of right stroke|"The intervention will be the passation of Right Language Screening Test (R-LAST).~Patients in acute phase of right hemispheric stroke will be used for the internal validation and the integrated reliability of the Right Language screening test.~Patients in subacute phase of right hemispheric stroke will be used for the external validation of the Right Language screening test."
2846565|NCT03622593|Experimental|A: RO6867461 Q8W|
2846566|NCT03622593|Experimental|B: RO6867461 As Specified in Protocol|
2846567|NCT03622593|Active Comparator|C: Aflibercept Q8W|
2846568|NCT03622580|Experimental|A: RO6867461 Q8W|
2846569|NCT03622580|Experimental|B: RO6867461 As Specified in Protocol|
2846570|NCT03622580|Active Comparator|C: Aflibercept Q8W|
2846571|NCT03622567|Other|Push Notifications|Push notification number (0, 1, 3, 5) will be counter balanced within-subjects.
2846572|NCT03622554|No Intervention|Control arm|Curist taking a spa treatment of 3 weeks in the usual conditions for each Center
2846573|NCT03622554|Experimental|Intervention|"Addition to the usual cure: -12 adapted physical activity (APA) sessions of 60 minutes to improve the balance , muscular strength, endurance and suppleness without creating additional fatigue for the curists~- personalized therapeutic patient education (ETP) with an individual assessment at the beginning of the treatment (1h), 3 group sessions (1h30) and an end-of-cure interview (1h) and an educational follow-up by phone at 3, 6 and 12 months"
2846574|NCT03622528||Lung Cancer Screening Cohort|Patients who are seen in the UIHC lung cancer screening clinic will be asked to undergo an additional standard chest CT scan during their UIHC clinical lung cancer screening CT scan. Additionally, data from that clinical scan and all medical records associated with nodules that were discovered by the Lung Cancer Screening, will also be collected.
2846575|NCT03622515|Experimental|Group S|Sedline monitoring Adjust the depth of anesthesia by adjusting the amount of anesthesia, and adjust the cerebral perfusion pressure by adjusting blood pressure
2846576|NCT03622515|No Intervention|Group C|Bispectral index (BIS)
2846577|NCT03622502|Experimental|Dexmedetomidine|Dexmedetomidine was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
2846578|NCT03622502|Active Comparator|Remifentanil|Normal saline was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
2846579|NCT03622489|Experimental|Tab ibuprofen + IV acetaminophen|"All women will receive immediately after surgery, in the recovery room:~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3~IV Tramal 100 mg, once~After Admitted to Maternity ward:~- Scheduled doses: 08:00 hr, Tab. Ibuprofen 400 mg, and IV Acetaminophen 1 gr 14:00 hr, IV Acetaminophen 1 gr 19:00 hr, Tab. Ibuprofen 400 mg 00:00 hr, IV Acetaminophen 1 gr~-Additional analgesia if needed according to VNS scale: PO drops Dipyrone 1 gr, for VNS>4, up to 4 times a day, at least 6 hours between doses.~Tab Tramadex 100 mg, for VNS>6, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 4 hours between doses."
2846580|NCT03622489|Experimental|Tab Ibuprofen + Tab acetaminophen|"All women will receive immediately after surgery, in the recovery room:~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3~IV Tramal 100 mg, once~After Admitted to Maternity ward:~- Scheduled doses: 08:00 hr, Tab. Ibuprofen 400 mg, and PO Acetaminophen 1 gr 14:00 hr, PO Acetaminophen 1 gr 19:00 hr, Tab. Ibuprofen 400 mg 00:00 hr, PO Acetaminophen 1 gr~- Additional analgesia if needed according to VNS scale: PO drops Dipyrone 1 gr, for VNS>4, up to 4 times a day, at least 6 hours between doses.~Tab Tramadex 100 mg, for VNS>6, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 4 hours between doses."
2846611|NCT03622255|Other|MINST|Minimally invasive non-surgical technique (MINST): Root instrumentation under local anesthesia using specific hand instruments (micro- curettes) and delicate piezon ultrasonic instruments in the area of intraosseous defect.
2847466|NCT03616314||stepping verticalization + FES|in ICU they received conventional physiotherapy + stepping verticalization sessions with FES using ErigoPro
2846581|NCT03622489|Experimental|"On demand analgesia"|"All women will receive immediately after surgery, in the recovery room:~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3~IV Tramal 100 mg, once~After Admitted to Mternity ward:~Will not receive scheduled pain medication, but offered some only upon patients' request according to VNS score:~Tab. Acetaminophen 1 gr, for VNS 1-3, up to 4 times a day, at east 6 hours between doses.~PO drops Dipyrone 1 gr, for VNS 4-7, or if pain persists for 1 hour after receiving Acetaminophen, up to 4 times a day, at least 6 hours between doses.~Tab Ibuprofen 400 mg, for VNS 8-10, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 8 hours between doses."
2846582|NCT03622476|Experimental|PK research|Interventional studies were performed in the 1-7 year old subgroup, and the children received a comprehensive assessment and PK test every 3 months. After the 72-hour washout period, 50 IU/kg of concentrated FVIII was administered in a single dose, and blood was taken within half an hour before the infusion and 1 h, 9 h, 24 h, and 48 h after the infusion, and the samples were centrifuged. If the assessment considers that the treatment is inadequate, then the valley concentration target is upgraded.
2846583|NCT03622463|Experimental|Antroquinonol 100 mg PO QD|Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol,once a day.
2846584|NCT03622463|Experimental|Antroquinonol 50 mg PO QD|Antroquinonol (Hocena) 50mg/capsule. 1 capsules antroquinonol and 1 capsule placebo, once a day.
2846585|NCT03622463|Placebo Comparator|Placebo|Placebo capsule, 2 capsules placebo, once a day
2846586|NCT03622450|Experimental|Medication arm|Colistin to be given as 2 millions three times daily in the inhalation form from 5 to 7 days in addition to another antipseudomonal antibiotic according to infectious disease society of antimicrobials (IDSA) guidelines from day 1 of incidence of ventilator associated pneumonia
2846587|NCT03622450|Active Comparator|Control arm|Patients receive antipseudomonal antibiotics IV as carbapenem and quinolone or aminoglycoside according to IDSA guidelines from day 1 of incidence of Ventilator associated pneumonia carbapenem as 1g three times daily + tavanic 750mg once daily or ciprofloxacin 500mg twice daily or aminoglycoside according to renal function
2846588|NCT03622437|Experimental|Patient-led follow-up|Participants in the experimental arm are enrolled in a patient-led follow-up program, based on patient-education and self-referral, in addition to recommendations from national guidelines for follow-up.
2846589|NCT03622437|Active Comparator|Standard follow-up|Participants in this control group follow standard care for follow-up after rectal cancer treatment, as described in local and national guidelines.
2846590|NCT03622424|Active Comparator|Gelesis200|Subjects on this ARM will receive Gelesis200
2846591|NCT03622424|Placebo Comparator|Placebo|Subjects on this ARM will receive a placebo device
2846592|NCT03622424|Active Comparator|Gelesis200 and Placebo|Subejcts on this ARM will receive both Gelesis200 and placebo.
2846593|NCT03622411|Experimental|aphasia therapy + speech app|3 hours per week of conventional aphasia therapy during 3 weeks + 5 hours per week during 3 weeks independent practice via the speech app
2846594|NCT03622411|Active Comparator|aphasia therapy + brain games|3 hours per week of conventional aphasia therapy during 3 weeks + 5 hours per week during 3 weeks of recreational tables use (brain games)
2846595|NCT03622411|Active Comparator|aphasia therapy|3 hours per week of conventional aphasia therapy during 3 weeks
2846596|NCT03622398|Experimental|HXLPE|"This side of knee implanted with HXLPE(highly crosslinked polyethylene) liner while undergoing total knee arthroplasty. This group will receive the intervention, Total knee arthroplasty with HXLPE liner."
2846597|NCT03622398|Active Comparator|Conventional|"This side of knee implanted with conventional polyethylene while undergoing standard total knee arthroplasty. This group will receive the intervention, Total knee arthroplasty with conventional polyethylene liner."
2846598|NCT03622385||Patients diagnosed with Serous Epithelial Ovarian Cancer|"Discovery Cohort: patients who were diagnosed with serous epithelial ovarian cancer whose tissue specimens were previously collected.~Validation Cohort: patients who are scheduled for a diagnostic laparoscopic biopsy for an undiagnosed pelvic mass that is determined to be cancerous."
2846599|NCT03622385||Normal patients|"Discovery Cohort: patients who were determined to have normal ovarian tissue specimens that were previously collected.~Validation Cohort: patients who are scheduled for a diagnostic laparoscopic biopsy for an undiagnosed pelvic mass that is determined to not be cancerous."
2846600|NCT03622372|Experimental|CoNextions TR Implant|Operative repair of Zone 2 FDP tendon lacerations will be performed using the CoNextions TR Implant System
2846601|NCT03622372|Active Comparator|Suture Repair|Operative repair of Zone 2 FDP tendon lacerations will be performed using a 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture
2846602|NCT03622359||Diabetic patients with PAD|Patients with peripheral arterial disease, critical limb ischemia in the form of a non-healing wound, and previously diagnosed diabetes mellitus. Patients will have already been scheduled for clinically indicated revascularization procedures of the lower extremity.
2846603|NCT03622333|Experimental|Familial Carcinoid Tumors|All patients with proven Familial Carcinoid Tumors
2846604|NCT03622320||Vitiligo patients|Vitiligo patients (100 NSV and 50 segmental) who will be further classified according to age of onset and blood sample will be taken
2846605|NCT03622320||controls|Matching will be done taking into consideration age, sex, education and socio economic status, blood sample will be taken
2846606|NCT03622307|Experimental|S-ICD therapy combined with VT Ablation|To evaluate the feasibility and safety of a management approach that incorporates VT-ablation and S-ICD implantation in secondary prevention patients
2846607|NCT03622294|Experimental|Right Breast Mammogram Measurements and Survey|"A right breast screening mammogram will be performed with Bella Blankets protective coverlets on the imaging receptor plate, then removed from the equipment.~The screening mammogram continues with a left breast and second right breast screening mammogram on a bare imaging receptor plate.~Clinical image quality measurements for the right breast mammograms will automatically be captured by VolparaEnterprise for a comparative analysis.~A patient satisfaction survey will be completed by each participant and the results will be analyzed."
2846608|NCT03622281|Experimental|Colonoscopists who received quality intervention|
2846609|NCT03622281|No Intervention|Colonoscopists who did not received quality intervention|
2846610|NCT03622268||Indirect calorimetry measurement|Using indirect calorimetry for measure resting energy expenditure
2847467|NCT03616314||conventional physiotherapy|in ICU they received only conventional physiotherapy
2846612|NCT03622255|Active Comparator|MINST with EMD|Minimally invasive non-surgical technique (MINST) with application of Enamel Matrix Derivative (EMD): Root instrumentation under local anesthesia using micro- curettes and delicate piezon ultrasonic instruments in the area of intraosseous defect. Experimental intervention by application of EDTA gel for 2 minutes on the root surface of the involved tooth, followed by rinsing with saline, drying and application of Enamel Matrix Derivative gel, to fill the defect.
2846613|NCT03622242|Experimental|Pain threshold index group|Adjust infusion rate of remifentanil and propofol according to pain threshold index and wavelet index in 'pain threshold index group'.
2846614|NCT03622242|Active Comparator|Control group|As conventional management, adjust infusion rate of remifentanil and propofol according to wavelet index and conventional vital signs
2846615|NCT03622229|Active Comparator|EUS-FNB with side-fenestrated needle|"Before randomization, the endosonographer chooses the needle gauge to perform biopsy preferring the 25 gauge caliber for difficult lesions. The needle advances inside the lesion and the operator will perform some needle movements back and forth into the lesion while slowly withdrawn the stylet (slow-pull technique). If possible the direction of the needle inside the lesion will be changed during the movements (fanning technique) to sample different areas of the lesion. Three needle passes will be performed and the material acquired at each pass will be placed directly in formalin in a single vial.~Diagnostic Test: Histologic evaluation"
2846616|NCT03622229|Active Comparator|EUS-FNB with fork-tip needle|"Intervention: like above.~Diagnostic Test: Histologic evaluation."
2846617|NCT03622216|Experimental|Bradanicline QD|Randomized crossover design of 3 different doses of bradanicline (film-coated tablets) to be administered orally QD
2846618|NCT03622216|Placebo Comparator|Placebo|Randomized crossover design of matching placebo tablets to be administered orally QD
2846619|NCT03622203||Real life patients|Patients who are often offered a Biofreedom in real life, that is those with active cancer or needing major surgery or on OAT (Oral Anticoagulation)
2846620|NCT03622203||Difficult coronary lesions|Patients with bifurcation and multivessel disease, that is those with an increased risk of ST
2846621|NCT03622203||STEMI|Patients with STEMI
2846622|NCT03622190||Cohort 1|Music students who are free of pain, PRMDs and/or MSK problems at baseline data collection
2846623|NCT03622190||Cohort 2|Music students who aren't free of pain, PRMDs and/or MSK problems at baseline data collection
2846624|NCT03622177||HIV+|
2846625|NCT03622177||HIV- STI+|
2846626|NCT03622177||HIV- STI-|
2846627|NCT03622164|Active Comparator|Non-experimental intervention|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck).
2846628|NCT03622164|Experimental|Experimental intervention|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck).
2846629|NCT03622151|Experimental|Intervention group|Primer la Llar Program (housing first model): to live in permanent and individual housing and receiving weekly visits from a multidisciplinary team.
2846630|NCT03622151|No Intervention|Control group|"Treatment as usual:~attention from the resources of the homeless network in Barcelona."
2846631|NCT03622138|Experimental|Naive EBP Providers|Naive Providers (providers with no prior experience implementing the EBP) will attend a one-hour orientation meeting via web-based meeting software (e.g., WebEx) or in person to receive training on research procedures and implementation methods for the study. Participants will complete online surveys via 3C's secure system for any measures not collected directly via Impact. Providers will receive secure login information to the survey system and automatic email alerts with links to surveys to prompt completion. Surveys will be completed at PRE and POST time points to assess feasibility, usability, and value. 3C research staff will be available to assist providers (via email and phone) throughout the pilot field study.
2846632|NCT03622138|Experimental|Experienced EBP Providers|Experienced EBP Providers (providers with prior experience implementing the EBP) will attend a one-hour orientation meeting via web-based meeting software (e.g., WebEx) or in person to receive training on research procedures and implementation methods for the study. Participants will complete online surveys via 3C's secure system for any measures not collected directly via Impact. Providers will receive secure login information to the survey system and automatic email alerts with links to surveys to prompt completion. Surveys will be completed at PRE and POST time points to assess feasibility, usability, and value. 3C research staff will be available to assist providers (via email and phone) throughout the pilot field study.
2846633|NCT03622125||1|Patients who apply anti-scorpion venom serum Birmex at the discretion of the attending physician were given vital signs.
2846634|NCT03622125||2|Patients who apply anti-scorpion venom serum Alacramyn at the discretion of the attending physician were given vital signs.
2846635|NCT03622112|Experimental|AZD7594 Dose 1|The randomized subjects will receive AZD7594 55 μg/50 μg (nominal/delivered dose), oral inhalation via dry powder inhaler (DPI) once daily.
2846636|NCT03622112|Experimental|AZD7594 Dose 2|The randomized subjects will receive AZD7594 99 µg/90 µg, oral inhalation via DPI once daily.
2846637|NCT03622112|Experimental|AZD7594 Dose 3|The randomized subjects will receive treatment with AZD7594 198 µg/180 µg, oral inhalation via DPI once daily.
2846638|NCT03622112|Experimental|AZD7594 Dose 4|The randomized subjects will receive treatment with AZD7594 396 µg/360 µg, oral inhalation via DPI once daily.
2846639|NCT03622112|Experimental|AZD7594 Dose 5|The randomized subjects will receive treatment with AZD7594 792 µg/720 µg, oral inhalation via DPI once daily.
2846640|NCT03622112|Placebo Comparator|Placebo|The randomized subjects will receive AZD7594 matching placebo oral inhalation via DPI once daily.
2846641|NCT03622112|Active Comparator|Fluticasone Furoate|The randomized subjects will receive treatment with fluticasone furoate (FF) oral inhalation via DPI, 100 µg per nominal dose, once daily (open-label).
2846642|NCT03622099||The study group|As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
2847725|NCT03614624|Experimental|Comparison of two devices|Patients receive clinical examination, electrocardiogramm and echocardiography.
2846643|NCT03622086|Experimental|7-10 years old|Children-caregiver pairs will participate in a 24-week pilot that includes 2 phases, 12 weeks of usual care, followed by 12 weeks of Foundations of Fitness Program.
2846644|NCT03622086|Experimental|11-13 years old|Children-caregiver pairs will participate in a 24-week pilot that includes 2 phases, 12 weeks of usual care, followed by 12 weeks of Foundations of Fitness Program.
2846645|NCT03622073|Experimental|Misoprostol treatment by Midwife|Administration of misoprostol by the midwife and assessment for the primary outcome.
2846646|NCT03622073|Active Comparator|Misoprostol treatment by Doctor|Administration of misoprostol by the doctor and assessment for the primary outcome.
2846647|NCT03622060|Active Comparator|Nitroglycerin|500 microgram intraarterial Nitroglycerin
2846648|NCT03622060|Placebo Comparator|Nicardipine|200 microgram intraraterial Nicardipine
2846649|NCT03622047|Experimental|dexmedetomidine ropivacaine|Observing 0.5 μ g / ml dexmedetomidine + 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
2846650|NCT03622047|Experimental|sufentanil ropivacaine|compare the analgesic effects of dexmedetomidine or sufentanil combined with ropivacaine in epidural labor.
2846651|NCT03622047|Experimental|No analgesia labor|Observing with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
2846652|NCT03622021|Experimental|AK111 30mg|Single dose of 30mg AK111 or placebo is administered subcutaneously to healthy subjects
2846653|NCT03622021|Experimental|AK111 75mg|Single dose of 75mg AK111 or placebo is administered subcutaneously to healthy subjects
2846654|NCT03622021|Experimental|AK111 150mg|Single dose of 150mg AK111 or placebo is administered subcutaneously to healthy subjects
2846655|NCT03622021|Experimental|AK111 300mg|Single dose of 300mg AK111 or placebo is administered subcutaneously to healthy subjects
2846656|NCT03622021|Experimental|AK111 450mg|Single dose of 450mg AK111 or placebo is administered subcutaneously to healthy subjects
2846657|NCT03622008|Experimental|FEP-TAZ 4 g|FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
2846658|NCT03622008|Placebo Comparator|Placebo|placebo IV
2846659|NCT03621995||Obstructive azoospermia|Malondialdehyde and Catalase level measurement before and after cryopreservation
2846660|NCT03621995||Non obstructive azoospermia|Malondialdehyde and Catalase level measurement before and after cryopreservation
2846661|NCT03621995||Negative group|Malondialdehyde and Catalase level measurement without cryopreservation
2846662|NCT03621982|Experimental|ADCT-301|"In Part 1 (dose-escalation), patients will receive a 1-hour intravenous infusion of ADCT-301 on Day 1 every 3 weeks (21-day cycle). at escalating doses. Part 1 will continue until the maximum tolerated dose or the recommended dose(s) and schedule(s) for expansion are determined.~In Part 2 (expansion), patients will be assigned to receive the recommended dose(s) of ADCT-301 as determined by the Dose Escalation Steering Committee (DESC).~This study will investigate dose levels between 20 μg/kg and 300 μg/kg Q3W."
2846663|NCT03621969|Experimental|Group 1|"Group 1 will receive:~Medical History and Brief Physical Exam~Diagnostic Assessments~Patient Instruction and use of RePlay Device~two weeks of RePlay device therapy twice per week at REACT (weeks 1-2), followed by re-assessment,~then will rest for 2 weeks (weeks 3-4),~then will take the RePlay devices and tablets home for two weeks (weeks 5-6) for daily RePlay device therapy, followed by re-assessment."
2846664|NCT03621969|Experimental|Group 2|"Group 2 will receive:~Medical History and Brief Physical Exam~Diagnostic Assessments~Patient Instruction and use of RePlay Device~two weeks of RePlay device therapy daily at home (they will take the RePlay devices and tablets home) (weeks 1-2), followed by re-assessment,~then will rest for 2 weeks (weeks 3-4),~then will receive two weeks of RePlay device therapy twice per week at REACT (weeks 5-6), and then will undergo re-assessment."
2846665|NCT03621956|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
2846666|NCT03621956|Active Comparator|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
2846667|NCT03621943|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
2846668|NCT03621943|Active Comparator|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
2846669|NCT03621904||EC patients with HT|Patients with advanced stage or recurrent endometrial cancer treated with hormonal therapy
2846670|NCT03621891||healthy individuals|Orally and systemically healthy individuals who has no hypo-functional teeth, hyper-occlusion or occlusal trauma
2846671|NCT03621891||periodontitis patients|Systemically healthy individuals who has chronic periodontitis but no hypo-functional teeth, hyper-occlusion or occlusal trauma
2846672|NCT03621891||healthy-occlusal trauma|Orally and systemically healthy individuals who has occlusal trauma caused by bruxism
2846673|NCT03621891||periodontitis-occlusal trauma|Systemically healthy individuals who has both chronic periodontitis and occlusal trauma caused by bruxism
2846674|NCT03621878|Active Comparator|Control group|
2846675|NCT03621878|Experimental|Tensioner Group|
2846676|NCT03621878|Experimental|Slider Group|
2846677|NCT03621865|Experimental|subject sequence 1|subject allocation sequence 1. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2846678|NCT03621865|Experimental|subject sequence 2|subject allocation sequence 2. IIntervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2846679|NCT03621865|Experimental|subject sequence 3|subject allocation sequence 3. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2846680|NCT03621865|Experimental|subject sequence 4|subject allocation sequence 4. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2846681|NCT03621865|Experimental|subject sequence 5|subject allocation sequence 5. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2847811|NCT03614078|Experimental|PRCL-02 Dose 2|Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
2846683|NCT03621865|Experimental|subject sequence 7|subject allocation sequence 7. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2846684|NCT03621865|Experimental|subject sequence 8|subject allocation sequence 8. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2846685|NCT03621865|Experimental|subject sequence 9|subject allocation sequence 9. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2846686|NCT03621865|Experimental|subject sequence 10|subject allocation sequence 10. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2846687|NCT03621852||Endoultrasound guided FNB|Patients with tumors of the pancreas, submucosal tumors or lymphnode disease of the upper gastrointestinal tract, which have to undergo EUS guided FNB.
2846688|NCT03621826||Children with Sickle Cell Anemia|Data from patients with sickle cell anemia will be entered into a retrospective database for evaluation of implementation rates of TCD (stroke) screening). A small number of these children/parents/stakeholders will be selected by convenience sampling to participate in a survey and/or interview to assess barriers and enablers to stroke prevention therapy.
2846689|NCT03621813|Other|Control|Participants maintain their current activity level.
2846690|NCT03621813|Active Comparator|Exercise Rehabilitation|Participants will exercise 2x/week at training facilities and at home one day a week.
2846691|NCT03621800|Experimental|Menthol popsicle|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This was performed by a researcher who did not participate in the data collection. The intensity of the initial thirst was measured by Visual Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After 20 minutes of the intervention (menthol popsicle), the final intensity and discomfort were measured using the same scales.
2846692|NCT03621800|No Intervention|Usual care (maintenance of fasting)|When allocated in the control group, the intensity of the initial thirst was measured by Visual Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After maintaining the usual care, that is, reaffirming the need for absolute fasting of food and drinks for 20 minutes, the final intensity and discomfort were measured using the same scales.
2846693|NCT03621787|Experimental|Single arm study: implant insertion|Participants in trial will be within a single study arm. All participants will have a placebo subcutaneous implant inserted with the device being studied. The implant accuracy will be assess through palpation and ultrasound depth measurements. The implant will then be removed. Safety will be assessed by measuring bruising and bleeding. A follow-up questionnaire will assess bruising and infection risk. A final visit will assess bruising and infection risk by a physician.
2846694|NCT03621774|Experimental|Mobile-assisted CBT-informed Skills Training|Psychosocial intervention combining in-person and smartphone-based CBT-informed skills training for experiential negative symptoms in schizophrenia, called Mobile-assisted Cognitive-Behavioral Therapy for Negative symptoms (mCBTn).
2846695|NCT03621774|Placebo Comparator|Supportive Contact|An active group leader- and device-contact control group.
2846696|NCT03621761|Active Comparator|Cognitive Behavioral Therapy|8 weekly telephone-based sessions and 2 booster sessions
2846697|NCT03621761|Active Comparator|Modafinil|50-400 mg per day (oral)
2846698|NCT03621761|Active Comparator|Cognitive Behavioral Therapy + Modafinil|Telephone-based cognitive behavioral therapy (8 weekly therapy sessions and 2 booster sessions) + Modafinil 50-400 mg per day (oral)
2846699|NCT03621748|Active Comparator|Non-Awake Cohort|Cohort undergoing craniotomy utilizing general anesthesia protocol
2846700|NCT03621748|Experimental|Awake Cohort|Cohort undergoing craniotomy utilizing awake anesthesia protocol
2846701|NCT03621735|Other|Sham then Active|"Active: Bimodal auditory-somatosensory stimulation~Sham: Sham Bimodal auditory-somatosensory stimulation~Subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
2846702|NCT03621735|Other|Active then Sham|"Active: Bimodal auditory-somatosensory stimulation~Sham: Sham Bimodal auditory-somatosensory stimulation~Subjects receive both an active treatment and a sham treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
2846703|NCT03621722|Experimental|Anxiety Arm (Treatment)|Patient will receive Elequil Aromatabs
2846704|NCT03621722|Experimental|Nausea/Vomiting Arm (Treatment)|Patient will receive Elequil Aromatabs
2846705|NCT03621722|No Intervention|Nausea/Vomiting Arm (Control)|Patient will not receive Elequil Aromatabs
2846706|NCT03621722|No Intervention|Anxiety Arm (Control)|Patient will not receive Elequil Aromatabs
2846707|NCT03621709||CoreValve™ Evolut R™ 34mm|All consecutive real-world patients with aortic stenosis selected for TAVI as part of routine clinical care, using a CoreValve™ Evolut R™ 34mm during the inclusion period will be entered the registry.
2846708|NCT03621696|Experimental|Arm 1: POAmCRT|"Patients with extracapsular extension (ECE) or positive margin but not clinical or pathologic T4 or clinical N3 disease~Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes~Treated with post-operative adjuvant modified chemoradiation therapy (POAmCRT) which is 42 Gy radiation therapy in 21 doses and 1 dose of cisplatin.~It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection~Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
2846741|NCT03621475|Experimental|Novel restraint first, then traditional restraint|Participants will be randomized to wear the novel arm restraint bilaterally for 4 hours on study day #1, followed by traditional soft bilateral wrist restraints for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
2848266|NCT03610867|Experimental|Furaprevir capsule (SAD)|single ascending oral dose (100 mg, 200 mg, 400 mg, and 600 mg) of TG-2349 (Furaprevir capsule)
2846709|NCT03621696|Experimental|Arm 2: POAmRT|"Patients with no extracapsular extension (ECE) and no positive margins~Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes~Treated with post-operative adjuvant modified radiation therapy (POAmRT) which is 42 Gy radiation therapy in 21 doses~It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection~Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
2846710|NCT03621696|Experimental|Arm 3: POACRT|"Patients with clinical or pathologic T4 or clinical N3 disease~Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes~Treated with post-operative adjuvant chemoradiation therapy (POACRT) which is 60 Gy radiation therapy in 30 doses and 3 doses of cisplatin~The first dose of cisplatin will given on one of the days during the initial 5 days of radiation therapy, the 2nd dose on the day of radiation dose 16, and the 3rd dose on the day of radiation dose 26.~It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection~Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
2846711|NCT03621683|Experimental|ovarian bio-stimulation|"Intervention:~ovarian bio-stimulation: blood rich plasma platelets"
2846712|NCT03621683|Active Comparator|Antioxidant therapy|"Intervention:~antioxidants: Q10, DHEA, Vitamin E, Vitamin C, omega 3"
2846713|NCT03621670|Experimental|MenB+PCV Group|Approximately 1800 subjects enrolled in this group will receive rMenB+OMV NZ (Bexsero) concomitantly with PCV13 (Prevnar13) and other RIV (Pediarix, Hiberix, Rotarix, M-M-R II, Varivax) at 2, 4, 6 and 12 months of age
2846714|NCT03621670|Placebo Comparator|Placebo+PCV Group|Approximately 900 subjects enrolled in this group will receive PCV13 concomitantly with placebo and other RIV at 2, 4, 6 and 12 months of age.
2846715|NCT03621657|Active Comparator|Low dose FMT Capsule double-encapsulate (DE)|FMT Capsule DE by mouth, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic
2846716|NCT03621657|Active Comparator|Single dose FMT Capsule DE|FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.
2846717|NCT03621657|Placebo Comparator|Placebo Oral Capsule|Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic
2846718|NCT03621631|Experimental|optimized Tai Chi intervention|
2846719|NCT03621631|Active Comparator|traditional Tai Chi intervention|
2846720|NCT03621618|Other|dobutamine|Cardiac failure
2846721|NCT03621618|Other|norepinephrine|Sepsis
2846722|NCT03621605|Experimental|VIB9600|"Single dose of VIB9600 administered by IV infusion or SC injection.~Multiple dose VIB9600 administered by IV infusion every 2 weeks for 4 weeks."
2846723|NCT03621605|Placebo Comparator|Placebo|Placebo comparator administered by slow IV infusion or SC injection.
2846724|NCT03621592|Experimental|Cutimed® Sorbact®|
2846725|NCT03621592|Active Comparator|Acticoat®|
2846726|NCT03621579|Other|the RNFLT and CMT|the retinal nerve fiber layer (RNFLT) and macular thickness (CMT)
2846727|NCT03621566||Central Sleep Apnea|Subjects with an apnea/hypopnea index ≥ 15/h of sleep and proportion of non-obstructive events > 50%, derived from polysomnography (diagnostic or during positive airway pressure treatment)
2846728|NCT03621553|Experimental|Low vit-D, Ergocalciferol|"Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Vitamin D2 (Ergocalciferol) 50,000 units will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
2846729|NCT03621553|Placebo Comparator|Low vit-D, Placebo|"Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Placebo capsules of identical size and appearance will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
2846730|NCT03621553|Other|Normal vit-D, control|"Normal serum vitamin D level, split by use or non-use of systemic corticosteroid.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
2846731|NCT03621540|Active Comparator|Verum arm|25 min anodal tDCS + adaptive working memory training
2846732|NCT03621540|Sham Comparator|Sham arm|sham tDCS + adaptive working memory training
2846733|NCT03621527|Active Comparator|Standard group|"For each vertebra treated: 10 ml of lidocaine hydrochloride 1% are applied to the skin and the lower structures including the periosteum.~An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure"
2846734|NCT03621527|Experimental|Epidural group|"Fluoroscopy-guided epidural anesthesiaI is the identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air.~According to patient's height, 10-15 ml of lidocaine hydrochloride 1% are injected by the radiologist into the epidural space.~An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure"
2846735|NCT03621514|Other|painless indwelling catheter|This group of patients underwent catheterization after anesthesia. At the end of the operation, the patient was removed from the catheter before anesthesia was awakened.
2846736|NCT03621514|Other|indwelling catheter|This group of patients underwent catheterization after anesthesia,and the catheter was indwelled. The patient was routinely removed for 24 to 72 hours after surgery.
2846737|NCT03621501|Placebo Comparator|Staged complete revascularization|• Culprit only + staged (within six weeks after index procedure) complete revascularization in all vessels ≥ 2.5mm with ≥ 50% stenosis by visual estimation or QCA (Control arm). Functional assessment with FFR/iFR will be at operator's discretion
2846738|NCT03621501|Active Comparator|Immediate complete revascularization|• Immediate complete revascularization in all vessels ≥ 2.5mm with ≥ 50% stenosis by visual estimation or QCA (Experimental arm). Functional assessment with FFR/iFR will be at operator's discretion
2846739|NCT03621488|Experimental|Efficacy of Behavioral Self-Activation with virtual reality|
2846740|NCT03621488|Sham Comparator|Efficacy of Behavioral Self-Activation without virtual reality|
2848267|NCT03610867|Placebo Comparator|Placebo (SAD)|Single ascending oral dose of Furaprevir similar capsule.
2846742|NCT03621475|Experimental|Traditional restraint first, then novel restraint|Participants will be randomized to wear traditional soft bilateral wrist restraints for 4 hours on study day #1, followed by the novel arm restraint bilaterally for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
2846743|NCT03621462|Experimental|Acquisition of Lesion Images with AIDA|Subjects presenting with atypical skin lesions referred for biopsy will have their lesion imaged using the Artificial Intelligence Dermatology Assistant (AIDA™) study device
2846744|NCT03621436|Experimental|TRVD Therapy|
2846745|NCT03621410|Experimental|T89 (225 mg) group|Low dose group. 225 mg will be taken for duration of study
2846746|NCT03621410|Experimental|T89 (300 mg) group|High dose group. This group will take a placebo for 12 days before going to altitude and will switch to 300 mg 2 days before being at altitude and will continue the 300 mg dose at altitude.
2846747|NCT03621410|Placebo Comparator|Placebo controlled group|
2846748|NCT03621397|Experimental|Cognitive Intervention Group|Research participants in the cognitive intervention group will undergo a baseline neuropsychological evaluation. One week later, they will receive the online training program (brainHQ by Posit Science) three times a week for 45 minutes for a total of 12 weeks. This group will return one week after completing the online intervention program for their follow-up neuropsychological evaluation. They will then return again one year later for another follow-up neuropsychological evaluation.
2846749|NCT03621397|No Intervention|Wait-List Control Group|Research participants in the Wait-List group will undergo a baseline neuropsychological evaluation. They will then return 13 weeks after their baseline neuropsychological evaluation for a follow-up neuropsychological evaluation and again one year later.
2846750|NCT03621384||Bb Genotype|Subjects with Bb genotype of BsmI polymorphisms in vitamin D receptor gene
2846751|NCT03621384||bb Genotype|Subjects with bb genotype of BsmI polymorphisms in vitamin D receptor gene
2846752|NCT03621371|Experimental|Metacognitive therapy|
2846753|NCT03621371|Experimental|Intolerance of uncertainty therapy|
2846754|NCT03621358|Placebo Comparator|Control Gummy|Control gummy with free flavour (without encapsulating)
2846755|NCT03621358|Experimental|Gummy Variety 1|Experimental gummy with 50% free/50% encapsulated flavour
2846756|NCT03621358|Experimental|Gummy Variety 2|Experimental gummy with 100% encapsulated flavour
2846757|NCT03621345|Active Comparator|ESP block group|"The bilateral erector spine plane (ESP) block will be performed with ultrasound guided, preoperatively. Following antiseptic preparation of block site with povidone iodine, ultrasound probe will be placed 3 cm lateral to spine at T5 level. After identifying the erector spinae muscle and transverse process, the overlying skin will be infiltrated with local anesthetics and 20 mL local anesthetics (10 mL 0.5% bupivacaine + 10 mL 1% lidocaine) will be injected deep to the erector spinae muscle. The same procedure will be performed on the other side. Also, patients will receive intravenous patient controlled analgesia with morphine, and 1 g acetaminophen for supplemental analgesia if pain score raises over 5/10 on NRS and 50 mg meperidine for rescue analgesic for persistent pain.~Interventions:~Procedure: Ultrasound guided erector spinae plane block Other: Standard Pain Followup and Monitorization"
2846758|NCT03621345|Sham Comparator|sham block|"A sham block will be performed while looking for intended location for ESP block placement. Skin will be infiltrated with local anesthetics but ESP block will not be performed, instead of ESP block 2 mL subcutaneous saline injection will be applied.~Intervention: Sham block Other: Standard Pain Followup and Monitorization"
2846759|NCT03621332||Questionnaire adminstration|All patients who participate will complete questionnaires
2846760|NCT03621319|Active Comparator|Hybrid argon plasma ablation (HAPC)|Eligible participants will be randomized to receive ablation of dysplasia with Hybrid argon plasma coagulation (HAPC) after EMR of visible lesions (if present) has been performed as per standard of care.
2846761|NCT03621319|Active Comparator|Radiofrequency ablation (RFA)|Eligible participants will be randomized to receive treatment of dysplasia with RFA after EMR of visible lesions (if present) has been performed as per standard of care.
2846762|NCT03621306||Men and women aged 18+|Men and women over the age of 18
2846763|NCT03621293|Active Comparator|Liberal Oxygenation (LO) group|"A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 90 to 105 mmHg that will be checked on arterial blood gases (ABG). Between these measurements, SpO2 will be kept more or equal to 96 percent. Alarms will be set at 95 percent for SpO2.~Intervention: Drug: Modulation of Inspired Fraction of Oxygen (FiO2)"
2846764|NCT03621293|Experimental|Conservative Oxygenation (CO) group|"A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 55 to 70 mmHg that will be checked on arterial blood gases. Between these measurements, SpO2 will be kept between 88 and 92 percent. Alarms will be set between 87 and 93 percent for SpO2.~Intervention: Drug: Modulation of Inspired Fraction of Oxygen (FiO2)"
2846765|NCT03621280|Experimental|Levoketoconazole|Levoketoconazole taken twice daily up to 1200 mg daily
2846766|NCT03621267|Experimental|Interactive Stepping Exercise|"Interactive Stepping Exercise (1 hour, 3 times/week, 12 weeks)~The 1-hour training program will start with10 minutes warm-up session, after that 40 minutes of ISE, and ended with 10 minutes of cool down session.~Interactive Stepping Exercise (ISE) will perform on a thin mat that was partitioned into 24 squares. The ISE program included forward, backward, lateral and oblique steps, and step patterns were progressively made more complicated."
2846767|NCT03621267|Active Comparator|Home exercise program|60 minutes, 3 times/week, 12 weeks of home exercise
2846768|NCT03621254|Experimental|[HI-SHORT]|High-intensity interval training modality of exercise using FES-evoked leg cycling. Three times weekly over 6 weeks. The programme is 10 x 2-min exercise intervals with 1-2 min of recovery between intervals. High intensity is achieved by high FES current amplitude (120-150 milliampere, patient dependent)
2846769|NCT03621254|Active Comparator|[LO-LONG]|Low-moderate intensity continuous training modality of exercise using FES-evoked leg cycling. Three times weekly over 6 weeks. The programme is 20+ min continuous exercise. Lower intensity is achieved by lower FES current amplitude (< 90-100 milliampere, patient dependent)
2846770|NCT03621228|Experimental|MindfulGarden|Standard care + exposure to an interactive digital device
2846771|NCT03621228|No Intervention|Control|Standard care only
2846838|NCT03620799|No Intervention|Control group|10 participants will be assigned to the control group in order to the inclusion criteria for the study. Control group
2846772|NCT03621215|Experimental|Tart cherry juice|30 mL tart cherry concentrate (CherryActive, UK) diluted with 220 mL of water once per day (250 mL total volume per day). According to available manufacturers data, this is equivalent to consuming 90-100 fresh cherries per day.
2846773|NCT03621215|Placebo Comparator|Fruit-flavoured placebo drink|"Matched for sensory characteristics and energy (with the addition of glucose).~once per day (250 mL total volume per day)"
2846774|NCT03621189|Active Comparator|posterior superior temporal sulcus|iTBS 1200
2846775|NCT03621189|Sham Comparator|Sham control|iTBS 1200
2846776|NCT03621176|Experimental|Home-based exercise|Home-based intervention in the advanced chronic kidney disease group, hemodialysis or peritoneal dialysis group
2846777|NCT03621163|Experimental|bleaching agent|intervention : bleaching agent ( Boost 40%)
2846778|NCT03621163|Active Comparator|laminate veneers|laminate veneers ( monolithic lithium - silicate)
2846779|NCT03621150||Cases|Patients complaining of ankle pain, swelling or dysfunction underwent ultrasound examination and then MRI as a reference to compare the diagnostic accuracy of ultrasonography in the assessment of tendino-ligamentous injuries around the ankle joint
2846780|NCT03621137||Patients with moderate-to-severe atopic eczema|Adult and pediatric patients that start treatment with phototherapy or systemic immunomodulating therapy for their atopic eczema
2846781|NCT03621124|Other|Brown Adipose Tissue Positive patients|Patients with known malignancy and incidental finding of positron emission tomography/ computerized tomography (PET/CT) scans positive for brown adipose tissue (BAT). After obtaining informed consent and all initial screening visit procedures, patients will participate in two four-hour recording sessions in the whole room indirect calorimeter to assess resting energy expenditure, and patient's thermal (comfort) response to the temperature of the room.
2846782|NCT03621124|Other|Brown Adipose Tissue Negative Patients|Patients with known malignancy and no evidence of brown adipose tissue BAT activity positron emission tomography/ computerized tomography (PET/CT) scans to be matched to group 1 for primary tumor and stage, sex, age (±5 years), BMI (±3 Kg/m2). After obtaining informed consent and all initial screening visit procedures, patients will participate in two four-hour recording sessions in the whole room indirect calorimeter to assess resting energy expenditure, and patient's thermal (comfort) response to the temperature of the room.
2846783|NCT03621111|Experimental|Adherence plan|At the discharge, the hospital pharmacist will complete the medication reconciliation and assess the patient's medications. All patients enrolled will undergo three interventions in order to improve medication adherence: counseling, pill counts and self-questionnaire. The adherence plan concerns 6 classes of drugs recommended by the European Society of Cardiology in acute myocardial infarction. The adherence plan is performed by the community pharmacists. The hospital pharmacist will complete the discharge care form for the community pharmacist who has in charge the patient. Each patient will be scheduled for the first meeting with his community pharmacist within one month from the hospital discharge; afterward the adherence plan will be submitted every 3 months.
2846784|NCT03621111|No Intervention|Control group|All the patients discharged from the cardiological ward between September 2017 and February 2018 with a primary diagnosis of acute myocardial infarction has been enrolled in the control arm. These patients have been discharged with the current standard therapy and without any adherence plan performed by the community pharmacists. The investigators will collect the data from the administrative pharmaceutical databases throughout 12 months from the hospital discharge.
2846785|NCT03621098||Diet+Exercise|Diet with structured exercise (mostly walking) at a moderate-intensity level This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)
2846786|NCT03621098||Diet+Daily Activity|"Diet with increased light-intensity physical activity and decreased sedentary behavior throughout the day.~This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)"
2846787|NCT03621098||Diet+Exercise+Daily Activity|Diet with structured exercise and increased daily activity. This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)
2846788|NCT03621085|Experimental|Ketamine|Subjects will receive up to 20 mg Ketamine Hydrochloride while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
2846789|NCT03621085|Placebo Comparator|Placebo|Subjects will receive placebo while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
2846790|NCT03621072|Other|Reference|Fluconazole 150mg Capsule Originator
2846791|NCT03621072|Experimental|Experimental|Fluconazole 150mg Capsule Localized Originator
2846792|NCT03621059|Experimental|Behavioral Therapy with TS|habit reversal training (HRT)
2846793|NCT03621059|No Intervention|observational|observational and usual care Pyridoxine(50mg)
2846794|NCT03621046|Experimental|Zolpidem|A single oral zolpidem tablet (5 mg) administered in clinic and then each day for the following 3 days
2846795|NCT03621046|Placebo Comparator|Placebo|A single oral placebo administered in clinic and then each day for the following 3 days
2846796|NCT03621033|Other|non-transparent cap-assisted endoscopic intubation|we do not use transparent cap-assisted endoscopic intubation.
2846797|NCT03621033|Other|transparent cap-assisted endoscopic intubation|we use transparent cap-assisted endoscopic intubation in the second insertion.
2846798|NCT03621020||Healthy controls|Subjects not taking medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
2846799|NCT03621020||Aspirin monotherapy|Subjects taking 325 mg daily aspirin and no additional medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
2846800|NCT03621020||von Willebrand Disease|Subjects diagnosed with vWD (all types except Type 2N), not taking medications with antiplatelet effects, and history of clinically significant bleeding.
2846801|NCT03621020||Glanzmann's Thrombasthenia|Subjects diagnosed with Glanzmann's Thrombasthenia, not taking medications with antiplatelet effects, and history of clinically significant bleeding.
2846802|NCT03621007||POMC deficiency obesity|
2846803|NCT03621007||LEPR deficiency obesity|
2846804|NCT03621007||PCSK1 deficiency obesity|
2846805|NCT03620994||Irritable Bowel Syndrome|All patients who were satisfied with the inclusion criteria and exclusion criteria in the department of the second affiliated hospital of Xi'an JiaoTong University received investigation. Patients who participate in the study are determined on their own initiative, with full understanding and informedness.
2846806|NCT03620981|Experimental|Brexpiprazole, 1mg/day|Drug: 1mg/day Once daily for 10 weeks
2846807|NCT03620981|Experimental|Brexpiprazole, 2mg/day|Drug: 2mg/day Once daily for 10 weeks
2846808|NCT03620981|Placebo Comparator|Placebo|Drug: Placebo (0mg/day) Once daily for 10 weeks
2846809|NCT03620968|No Intervention|Group 1|Control, no intervention
2846810|NCT03620968|Experimental|Group 2|Intervention before surgery (cognitive training)
2846811|NCT03620968|Experimental|Group 3|Intervention Before and after surgery (cognitive training)
2846812|NCT03620955||Risk stratification|Risk stratification based on cytogenetic and molecular and MRD level after two courses of induction.
2846813|NCT03620942|Experimental|ADIVA system|Vasopressor delivery automated system administering phenylephrine and ephedrine using a three-step algorithm vasopressor delivery technique
2846814|NCT03620942|Active Comparator|DIVA system|Vasopressor delivery automated system administering phenylephrine and ephedrine using a two-step algorithm vasopressor delivery technique
2846815|NCT03620929|Experimental|Experiment group|Having estrogen(Estradiol Valerate) after hysteroscopic adhesiolysis three months, all patients in this group will be treated with hormone therapy for 3 cycles; each cycle consists of estradiol 4mg per day for 21 days with addition of progestogen in the form of dydrogesterone 10mg per day for the last 7 days;
2846816|NCT03620929|No Intervention|Control group|Control group without estrogen treatment. A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery.
2846817|NCT03620916|Experimental|Intrathecal morphine|Intrathecal morphine (0,4 mg) immediately before operation
2846818|NCT03620916|Active Comparator|Intravenous morphine|Intravenous morphine (0,15 mg/kg body mass) immediately after the operation
2846819|NCT03620903|Experimental|Bortezomib-Rituximab-Ibrutinib|"Cycle 1:~Rituximab: 375 mg/m2 intravenously (i.v) day 1 Bortezomib:1.6 mg/ m2 subcutanously (SC) day 1,8,15 Ibrutinib: 420 mg orally (p.o.) day 1-28~Cycle 2-6 Rituximab: 1400 mg absolute SC day 1 Bortezomib:1.6 mg/ m2 SC day 1,8,15 Ibrutinib: 420 mg p.o. day 1-28~Maintenance:~Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject Rituximab 1400 mg absolute SC day 1, every second month for 24 months (month 7-30)"
2846820|NCT03620890|Active Comparator|Neutral Protamine Hagedorn (NPH)|NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
2846821|NCT03620890|Active Comparator|Detemir|Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)
2846822|NCT03620877|Experimental|personalized intervention|Personalized intervention by a preventive nurse, relying on validated prevention models, in improving participation in the colonoscopic screening of siblings
2846823|NCT03620864|Active Comparator|Motor control exercise|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling.
2846824|NCT03620864|Experimental|Motor control exercise plus neurodynamic intervention|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling. In addition, participants allocated to the neurodynamic group will also receive a nerve neurodynamic slider intervention targeting the main trunk of the sciatic nerve of the affected side during al treatment sessions (n=8).
2846825|NCT03620851||elderly patients (≥70 yo) vs. younger patients (<70 yo)|elderly patients (≥ 70 yo) and younger patients (< 70 yo)
2846826|NCT03620838||Group 1|Patients with endometrioma who had at least one endometrioma >3 cm and who will not need hormonal or surgical treatment at the time of diagnosis and who will be expectantly managed
2846827|NCT03620838||Group 2|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with OCP during the study period
2846828|NCT03620838||Group 3|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with oral progesterone during the study period
2846829|NCT03620838||Group 4|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with surgery short after recruitment
2846830|NCT03620838||Group 5|The control group, who do not have endometrioma and any gynecological disorder
2846831|NCT03620825|Experimental|Dehydration by sauna exposure|Participants dehydrate using sauna exposure until they lose 3% of their body weight.
2846832|NCT03620825|Active Comparator|Indomethacin - Positive control|Indomethacin is administered to induce increased intestinal permeability
2846833|NCT03620825|No Intervention|Negative control|No intervention is performed
2846834|NCT03620812|Experimental|rapeseed protein|Three interventions are planned, in which the subjects will eat a test meal with added rape protein isolate (arm 1), a test meal with added soy protein isolate (arm 2) and a test meal without additional protein (arm 3) in random order on 3 days. The subjects are randomly assigned to one of the 3 treatment arms, ultimately resulting in 6 sequences (cross-over)
2846835|NCT03620812|Active Comparator|soy protein|
2846836|NCT03620812|Placebo Comparator|no protein|
2846837|NCT03620799|Experimental|Intervention group|10 participants will be assigned to the intervention group in order to the inclusion criteria for the study. Experimental group. Manual therapy intervention
2846839|NCT03620786||HIFU Study Participants|Subjects who have biopsy-proven adenocarcinoma of the prostate, who have met all study inclusion and exclusion criteria, and have elected to receive or have already received the HIFU procedure as part of their routine prostate cancer treatment, will be invited to participate in this observational registry study. The HIFU device currently used in this standard-of-care procedure at UCLA is the Sonablate 450 HIFU System.
2846840|NCT03620773|Other|Clinical Investigation|"Participants will include youth who are scheduled for, and will undergo, vertical sleeve gastrectomy (VSG) surgery at the Bariatric Surgery Clinic at Children's Hospital of Colorado.~To understand how bariatric surgery affects renal function, all participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI."
2846841|NCT03620760|Experimental|Lower dose ticagrelor|Subjects will be treated with ticagrelor 45 mg twice daily in combination with aspirin 100mg one daily.
2846842|NCT03620760|Active Comparator|Standard dose ticagrelor|Subjects will be treated with ticagrelor 90 mg twice daily in combination with aspirin 100mg once daily.
2846843|NCT03620747|Experimental|Dupilumab|One dose administered every two weeks. A loading dose may be administered at the start of treatment for some patients (e.g., due to previous Dupilumab treatment discontinuation for more than 6 weeks).
2846844|NCT03620734||GAHT and PrEP|HIV-negative TGW will have HIV testing using the 4th generation immunoassays/nucleic acid testing (NAT) in acute HIV testing algorithm currently used at the Thai Red Cross Anonymous Clinic at week 5, 8, and 15. Creatinine clearance will be performed at week 15.
2846845|NCT03620734||GAHT and ART|HIV-positive TGW on ART will have their plasma HIV RNA measured at the same day ART is initiated and at week 15 (12 weeks after ART provision). CD4 count will be measure at week 15.
2846846|NCT03620721|Experimental|M-Body|mindfulness group intervention
2846847|NCT03620721|No Intervention|Usual Care|treatment as usual
2846848|NCT03620708|Experimental|Motivational Interviewing|35 minute individual motivational interviewing intervention concluding with a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line
2846849|NCT03620708|Active Comparator|Nicotine Replacement Therapy Sampling|Participants are provided with a 2-week supply of nicotine patches and a 2 week supply of nicotine lozenges with a recommendation to try them and are also given a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line.
2846850|NCT03620708|Other|Referral Only|Participants are provided with a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line.
2846851|NCT03620682|Experimental|Mobile mental health intervention|Participants will receive emotional support and problem-solving / stress-management skills via over-the-phone coaching sessions and mobile applications.
2846852|NCT03620669|Experimental|Durvalumab|Durvalumab until progression or unacceptable toxicity
2846853|NCT03620656||The smartphone group|Patients recruited from the cardiology ward where 10 different smartphone devices will be used for the recording of PPG signals with the FibriCheck application. These recordings will be compared with single-lead ECG recorded with an AliveCor Smartphone devices and gold-standard 12-lead ECG to determine the diagnostic accuracy.
2846854|NCT03620656||The smartwatch group|Patients recruited from the cardiology ward where 2 different wearable devices will be used for the recording of PPG signals with the FibriCheck application. These recordings will be compared with single-lead ECG recorded with an AliveCor wearable and gold-standard 12-lead ECG to determine the diagnostic accuracy.
2846855|NCT03620643|Active Comparator|Crizotinib Oral Capsule [Xalkori] monotherapy|Arm 1 - Gastric cancer cohort (n=29 participants) will be treated with monotherapy called Crizotinib Oral Capsule [Xalkori] (250 mg b.d) taken on a continuous dosing schedule. One treatment cycle for Crizotinib is 28 days long.
2846856|NCT03620643|Active Comparator|Crizotinib Oral Capsule [Xalkori] plus Fulvestrant injection|Arm 2 - Lobular Breast Cancer cohort (n=29 participants) will be treated with combination therapy. The combination therapy includes; Crizotinib Oral Capsule [Xalkori] (250mg b.d.) plus Fulvestrant 50 mg/mL Prefilled Syringe [Faslodex] intramuscular (IM) injection (500 mg per 1 cycle (q28 days, plus loading dose on day 15).
2846857|NCT03620630|No Intervention|Usual Care|Patients allocated to usual care will continue with their current NHS management in line with national and local guidelines.
2846858|NCT03620630|Active Comparator|myCOPD|Patients allocated to the myCOPD arm will receive access to a web based application called myCOPD
2846859|NCT03620617|Experimental|Experimental: Raspberry supplementation|Dietary Supplement: 280g of frozen raspberries, taken daily for 8 weeks. Subjects will consume frozen raspberry to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and control group (without raspberry).
2846860|NCT03620617|No Intervention|Control|Control: follow their usual diet (control group). Subjects will follow their usual diet and not consume raspberry to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the experimental group (with raspberry).
2846861|NCT03620604||Stress urinary incontinence surgery|This is a single observational study were all patients had stress urinary incontinence. All of them underwent surgery performing a single incision sling type ALTIS
2846862|NCT03620591|Active Comparator|Lidocaine|"Intraoperative administration of lidocaine to patients undergo laparoscopic cholecystectomy.~Prior induction to anesthesia, lidocaine bolus 1.5 mg / kg will be administered to the lidocaine group and then patients will be connected to a continuous 2 mg / kg / h administration of lidocaine until the end of the procedure."
2846863|NCT03620591|Placebo Comparator|Placebo|Intraoperative administration of normal saline to patients undergo laparoscopic cholecystectomy.
2846864|NCT03620578|Experimental|DA-EPOCH-R followed by Nivolumab|5 cycles of DA-EPOCH-R protocol induction, followed with one year Nivolumab consolidation for end-of-induction patients who are in complete metabolic response
2846865|NCT03620565||Laparoscopic sacrocolpopexy(LSC)|Patients who prefer to accept laparoscopic sacrocolpopexy after hysterectomy. For patients who has desire of uterine-preservation,laparoscopic sacrocervicopexy or sacrohysteropexy is carried.
2846866|NCT03620565||Reconstruction with transvaginal mesh(TVM)|Patients who undertake pelvic reconstruction with tran-vaginal mesh(commercial mesh kits or self-cut synthesized mesh).
2846867|NCT03620565||Reconstruction with native tissue(NT)|Patients who prefer to accept reconstruction with native tissue,mainly including high uterosacral ligament suspension, sacrospinous ligament fixation,ischial spinous fascia fixation,the Lefort operation.
2846868|NCT03620565||Tension-free vaginal tape surgery(TVT)|Patients who undertake anti-incontinence surgeries(tension-free vaginal tape procedure).
2846869|NCT03620552|Experimental|18F-S16 injection and PET/CT scan|The subjects were intravenously injected with 370MBq 18F-S16 and underwent PET/CT scan immediately after the injection.
2846870|NCT03620539|No Intervention|Control|Participants randomized to the control condition will be asked to maintain their normal daily habits.
2846871|NCT03620539|Experimental|Sauna|The sauna intervention will consist of 20 to 30 minute sauna bathing sessions within a dry Finnish sauna, performed 4 times per week.
2846872|NCT03620526|Experimental|Iloprost|patients received inhaled iloprost 10 mcg/mL x 1 dose after baseline and exercise test and then received measurements for hemodynamic data again for both baseline and after exercise test.
2846873|NCT03620526|Placebo Comparator|Placebo|patients received inhaled normal saline with the same amount x 1 dose after baseline and exercise test and then received measurements for hemodynamic data again for both baseline and after exercise test.
2846874|NCT03620513|No Intervention|No pre-medication|No pre-medication prior to fiberoptic procedure
2846875|NCT03620513|Placebo Comparator|Normal Saline nasal spray|Two spray (via atomizer) of normal saline in each nostril five minutes prior to fiberoptic procedure
2846876|NCT03620513|Experimental|Decongestant (Oxymetazoline 0.05%)|Two sprays via atomizer (about 0.18 ml) of oxymetazoline 0.05% (Nasivion) in each nasal cavity five minutes prior to fiberoptic procedure. Two sprays will be given at the gap of ten seconds.
2846877|NCT03620513|Experimental|Anesthesia (lidocaine 15%, Nummit)|Two sprays of 15% lidocaine (Nummit) will be give in each nasal cavity five minutes prior to fiber optic procedure. Two sprays will be given at the gap of ten seconds.
2846878|NCT03620513|Experimental|Decongestant and Anesthesia|In this group decongestants and anesthesia (oxymetazoline and lidocaine) sprays will be used. Decongestant (Oxymetazoline 0.05%) will be give as described above. After two minutes, lidocaine 15% (Nummit) spray will be given as described above. Procedure will be done after five minutes of decongestant.
2846879|NCT03620500||Children with Cochlear Implants|Children with sensory neural hearing loss who undergo cochlear implantation will be monitored to see if balance develops normally in this population
2846880|NCT03620474|Experimental|PRI-724|"Dose: 140, 280, 380 mg / m 2/4 hr~Administration method:~【Phase I Phase】 (Level 1) 140 mg / m 2/4 hr (Level 2) 280 mg / m 2/4 hr (Level 3) 380 mg / m 2/4 hr Twice weekly, continuous 4-hour intravenous administration (tolerance of administration time: ± 15 minutes). This is one cycle and 12 cycles (12 weeks in total) are carried out. However, in Phase I phase, single dose is administered on Day - 7 (tolerance: - 7 days).~【Phase IIa phase】 Continuous intravenous administration for 4 hours twice a week at the recommended dose determined in Phase I. This is one cycle and 12 cycles (12 weeks in total) are carried out."
2846881|NCT03620448|Experimental|bCPAP Arm.|"Babies randomized to receive bCPAP were started (by principle investigator assisted by a clinician) on bCPAP (Rice 360◦c low cost bCPAP device) consisting of 3 components:~(i) An oxygen concentrator with a gas flow fate of 3-4L/min, (ii) A nasal interface (short nasal prongs) connecting the baby`s airway to a two limb circuit i.e the inspiratory limb connected to the bCPAP machine and the expiratory limb connected to the water bottle and (iii) An expiratory limb with the distal end submerged 6cm in water to generate an end expiratory pressure as seen in appendix 7. adopted from suppliers of the pumani bCPAP machine in Kenya."
2846882|NCT03620448|Other|Oxygen Arm|Preterms on the control arm and those whose parents didn't consent received the standard treatment for RDS i.e pure oxygen via nasal prongs from the oxygen cylinders.
2846883|NCT03620435|Experimental|atezolizumab|Atezolizumab will be given during trimodal therapy, and every 3 weeks for 16 cycles or until disease progression or unacceptable toxicity.
2846884|NCT03620422|Other|Healthy Controls|Mannitol-Induced Cough Challenges on Visit 2 and 3. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
2846885|NCT03620422|Placebo Comparator|Mild Allergic Asthmatics (Saline)|Mannitol-Induced Cough Challenges on Visit 2, 3 and 4. Nebulized placebo (Sodium Chloride 0.9% Inhl 3Ml) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
2846886|NCT03620422|Active Comparator|Mild Allergic Asthmatics (Salbutamol)|Mannitol-Induced Cough Challenges on Visit 2, 3 and 4. Nebulized salbutamol (5mg/mL) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
2846887|NCT03620409||Sepsis|Patients with and without diagnosis septic cardiomyopathy
2846888|NCT03620409||Cardiomyopathy without infection|Patients without operation and patients with scheduled LVAD-Implantation
2846889|NCT03620409||Healthy subjects|Healthy controls
2846890|NCT03620396|Experimental|Experimental: Interventional|Group A patients consists of Gingivitis patients whose serum is collected at base line and treated with Scaling and root planing and after three months serum is collected for assessment of Trefoil factor 3.
2846891|NCT03620396|Experimental|Experimental Interventional|Group B patients consists of Periodontitis patients whose serum is collected at base line and treated with Scaling and Root Planing and after three months serum is collected for assessment of Trefoil factor 3.
2846892|NCT03620383|Experimental|Heat|Distal topical heat application
2846893|NCT03620383|No Intervention|No Heat|Inactive heat pack to blind the investigator.
2846894|NCT03620370|Experimental|NBO group|Normobaric oxygen therapy is the delivery of high-flow oxygen (10L/min) via oxygen storage facemask. This therapy should start in the pre-hospital or emergency room as soon as possible (within 1 hours) after diagnosis of ischemic stroke and last for 4 hours. All participant will receive mechanical thrombectomy and a standard clinical therapy.
2846895|NCT03620370|No Intervention|Control group|The participants receive mechanical thrombectomy therapy after diagnosed ischemic. All participants receive a standard clinical therapy.
2846896|NCT03620357|Experimental|Continuous Glucose Monitor (CGM) Group|
2846897|NCT03620357|Active Comparator|SMBG Group|
2848300|NCT03610646|Active Comparator|Eylea|Eylea
2846898|NCT03620344|Experimental|ADH-Me Book|"Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure. Families assigned to this condition will also receive the ADH-Me! book. Written by a pediatrician and health literacy expert, ADH-Me! is an accessible, rhyming narrative that describes an empathetic journey from the perspective of a child learning to live and succeed with ADHD. The book is intended to help families know what to expect from diagnosis through all stages of treatment, while attempting to foster love and support."
2846899|NCT03620344|Sham Comparator|No ADH-Me Book|"Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure."
2846900|NCT03620331|Active Comparator|Non Surgical + Surgical|Non surgical approach (NS) followed by surgical treatment (S) of peri-implantitis
2846901|NCT03620331|Experimental|Immediate Surgery|Direct surgical approach (S), without a previous non surgical approach
2846902|NCT03620305||Description of treatment of septic pseudarthrosis|chirurgical and medical treatment
2846903|NCT03620292|Experimental|Intraoperative NIR fluorescence imaging|"A non-randomized, non-blinded, prospective, single center pilot dose escalation study with bevacizumab-800CW for NIR fluorescence image guided surgery in hilar cholangiocarcinoma~IV-administration of 10, 25 or 50 mg of the fluorescent tracer bevacizumab-800CW to a total of 15 patients with resectable hilar cholangiocarcinoma 3 days prior to surgery.~Peroperative open air NIR fluorescence imaging~Ex vivo endoscopic and histopathological NIR fluorescence imaging"
2846904|NCT03620279|Experimental|Magic camp intervention|These children are diagnosed with cerebral palsy and we will provide motor control training.
2846905|NCT03620266|Experimental|Bilberry|Dietary supplement with dried bilberry 3 times daily for 3 months
2846906|NCT03620266|Placebo Comparator|Placebo|Dietary supplement with no active bilberry 3 times daily for 3 months
2846907|NCT03620253|Experimental|Modafinil|Participants will be administered 100 mg modafinil tablets, that will be over-encapsulated, for one week. If the drug is well tolerated, the dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
2846908|NCT03620253|Placebo Comparator|Placebo|Participants will be administered 100 mg placebo capsule. This capsule will have all the same ingredients as the modafinil tablets, minus the active ingredient. After 1 week, participants' dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
2846909|NCT03620240|Experimental|Sleep Education|Half of the participants are randomly assigned to the Sleep Education group. These participants will undergo 4 weekly class-based lesson, during which they are educated about sleep.
2846910|NCT03620240|No Intervention|Control|Half of the participants are randomly assigned to the Control group. These participants undergo 4 weekly class-based lessons, during which they are educated about health-related topics, but not about sleep.
2846911|NCT03620227|Experimental|Beetroot juice|ingestion of beetroot juice before an exercise session.
2846912|NCT03620227|Placebo Comparator|Placebo|ingestion of placebo before an exercise session.
2846913|NCT03620214||healthy children|Healthy children consulting at the odontology department of Reims CHU for carious screening or orthodontic diagnosis; excluding research
2846914|NCT03620201|Experimental|M7824|Participants receive M7824 by vein over 1 hour on Days 1 and 15 of the study.
2846915|NCT03620175|Active Comparator|5 Percent TolaSure Topical Gel|
2846916|NCT03620175|Active Comparator|1.5 Percent TolaSure Topical Gel|
2846917|NCT03620175|Active Comparator|0.5 Percent TolaSure Topical Gel|
2846918|NCT03620175|Placebo Comparator|Topical Vehicle Gel|
2846919|NCT03620162|Active Comparator|Group 1: Prevnar 13™|Participants will receive a single 0.5 mL intramuscular (IM) injection of double-blind Prevnar 13™ at approximately 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13). Other licensed pediatric vaccines will be administered open-label concomitantly with the study vaccines according to the recommended schedule: RotaTeq™, Pentacel™, and Recombivax HB™ at approximately 2, 4, and 6 months of age (Study Day 1, Month 2, and Month 4), and Hiberix™, M-M-R™ II, and Varivax™ at approximately 12-15 months of age (Study Month 10-13).
2846920|NCT03620162|Experimental|Group 2: Prevnar 13™ Switch to V114 at Dose 4|Participants will receive a single 0.5 mL IM injection of double-blind Prevnar 13™ at approximately 2, 4, and 6 months of age (Study Day 1, Month 2, and Month 4) and double-blind V114 at approximately 12-15 months of age (Study Month 10-13). Other licensed pediatric vaccines will be administered open-label concomitantly with the study vaccines according to the recommended schedule: RotaTeq™, Pentacel™, and Recombivax HB™ at approximately 2, 4, and 6 months of age (Study Day 1, Month 2, and Month 4), and Hiberix™, M-M-R™ II, and Varivax™ at approximately 12-15 months of age (Study Month 10-13).
2846921|NCT03620162|Experimental|Group 3: Prevnar 13™ Switch to V114 at Dose 3|Participants will receive a single 0.5 mL IM injection of double-blind Prevnar 13™ at approximately 2 and 4 months of age (Study Day 1 and Month 2) and double-blind V114 at approximately 6 and 12-15 months of age (Study Month 4 and 10-13). Other licensed pediatric vaccines will be administered open-label concomitantly with the study vaccines according to the recommended schedule: RotaTeq™, Pentacel™, and Recombivax HB™ at approximately 2, 4, and 6 months of age (Study Day 1, Month 2, and Month 4), and Hiberix™, M-M-R™ II, and Varivax™ at approximately 12-15 months of age (Study Month 10-13).
2846922|NCT03620162|Experimental|Group 4: Prevnar 13™ Switch to V114 at Dose 2|Participants will receive a single 0.5 mL IM injection of double-blind Prevnar 13™ at approximately 2 months of age (Study Day 1) and double-blind V114 at approximately 4, 6 and 12-15 months of age (Study Month 2, 4 and 10-13). Other licensed pediatric vaccines will be administered open-label concomitantly with the study vaccines according to the recommended schedule: RotaTeq™, Pentacel™, and Recombivax HB™ at approximately 2, 4, and 6 months of age (Study Day 1, Month 2, and Month 4), and Hiberix™, M-M-R™ II, and Varivax™ at approximately 12-15 months of age (Study Month 10-13).
2846956|NCT03619876|Active Comparator|Non-TNF inhibitor arm|Treatment with abatacept will consist of weekly subcutaneous (SQ) injections at a dose of 125mg.
2848582|NCT03608592|Placebo Comparator|control group|Intravenous infusion of 100ml normal saline, infusion duration 30-60min.
2846923|NCT03620162|Experimental|Group 5: V114|Participants will receive a single 0.5 mL IM injection of double-blind V114 at approximately 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13). Other licensed pediatric vaccines will be administered open-label concomitantly with the study vaccines according to the recommended schedule: RotaTeq™, Pentacel™, and Recombivax HB™ at approximately 2, 4, and 6 months of age (Study Day 1, Month 2, and Month 4), and Hiberix™, M-M-R™ II, and Varivax™ at approximately 12-15 months of age (Study Month 10-13).
2846924|NCT03620149|Experimental|Denosumab|denosumab at reduced dose
2846925|NCT03620136|Experimental|locoregional analgesia by a block on the adductor channel|
2846926|NCT03620136|Experimental|locoregional analgesia by periarticular local infiltrations|
2846927|NCT03620123|Experimental|Nivolumab and Ipilimumab|Nivolumab 3 mg/kg of body weight intravenous infusion every two weeks and ipilimumab 1 mg/kg of body weight intravenous infusion every six weeks
2846928|NCT03620123|Other|Docetaxel|docetaxel 75 mg/m² intravenous infusion every three weeks
2846929|NCT03620097|Experimental|Experimental Arm|30 subjects will receive 800mg of DHA (Dietary Supplement: EuPoly-3 DHA Infant) per day.
2846930|NCT03620097|Placebo Comparator|Control Arm|30 children will take a placebo with similar lipid characteristics
2846931|NCT03620084|Experimental|Expiratory Muscle Strength Training (EMST)|Participants will be taught how to use the EMST-150 device. The device has a one-way spring-loaded valve calibrated at different resistances that the user can select. The valve will open when expiratory pressure exceeds the threshold set by the user on the device. This threshold is set at 75% of the individual's maximum expiratory pressure for the session.
2846932|NCT03620071|Experimental|Intervention|Receipt of a novel mobile-health tool, GoalKeeper Plus Standard Care
2846933|NCT03620071|Experimental|Control|Standard Care
2846934|NCT03620058|Experimental|CART22-65s monotherapy|
2846935|NCT03620058|Experimental|CART22-65s in combination with huCART19|
2846936|NCT03620045|Experimental|Acute moderate physical activity|Participants will walk at a moderate intensity for 20 minutes on a treadmill
2846937|NCT03620045|No Intervention|Sedentary activity|Participants will be permitted to read books and/or draw for 20 minutes
2846938|NCT03620032|Other|Standard treatment|Nimotuzumab 150 mg /mq/d as iv weekly and Vinorelbine 20 mg/mq/d weekly, in week 1-12 (Induction phase).If not progression Nimotuzumab 150 mg/m2 as iv and Vinorelbine 25 mg/m²/d as iv until progression or maximum at week 108; in case of non-progressive disease re-irradiation 1 for a total of 19.8 Gy from week 26 to week 28; in case of non-progressive disease: re-irradiation 2 for a total of 19.8 Gy from week 46 to week 48. Irradiation will be scheduled to begin in the 3rd week after starting the nimotuzumab and vinorelbine treatment. For the first course, a total dose of 36 Gy will be delivered, in 1.8 Gy daily fractions 5 days a week.
2846939|NCT03620032|Experimental|Experimental treatment|Nimotuzumab 150 mg /mq/d as iv weekly and Vinorelbine 20 mg/mq/d weekly, in week 1-12 (Induction phase).If not progression Nimotuzumab 150 mg/m2 as iv and Vinorelbine 25 mg/m²/d as iv until progression or maximum at week 108; in case of non-progressive disease re-irradiation 1 for a total of 19.8 Gy from week 26 to week 28; in case of non-progressive disease: re-irradiation 2 for a total of 19.8 Gy from week 46 to week 48. Irradiation will be scheduled to begin in the 3rd week after starting the nimotuzumab and vinorelbine treatment. For the first course, a total dose of 36 Gy will be delivered, in 1.8 Gy daily fractions 5 days a week.
2846940|NCT03620019|Experimental|Single Arm: Denosumab+ Pembrolizumab|Subjects in this trial will be given denosumab q4 weeks, starting on day 1 of study treatment. An additional loading dose of denosumab will be administered on day 8. Pembrolizumab will be administered intravenously (IV) every 3 weeks and initiated 21 days after the first dose of denosumab is given. Combination therapy with both agents will continue as long as subjects benefit from therapy for up to 1 year.
2846941|NCT03619993|Experimental|Arm A: Start with On-body injector|4 consecutive cycles of treatment in total, with 2 cycles of treatment with pegfilgrastim pre-filled syringe (PS) and 2 cycles of treatment with On-body injector (OBI) for pegfilgrastim in an alternating sequence (OBI-PS-OBI-PS)
2846942|NCT03619993|Experimental|Arm B: Start with pre-filled syringe|4 consecutive cycles of treatment in total, with 2 cycles of treatment with pegfilgrastim pre-filled syringe (PS) and 2 cycles of treatment with On-body injector (OBI) for pegfilgrastim in an alternating sequence (PS-OBI-PS-OBI)
2846943|NCT03619980||Participants with prostate cancer|This is a retrospective registry based study to collect real world data on participants with different disease stages of prostate cancer in Sweden.
2846944|NCT03619967|Experimental|Multispectral imaging device|Bio-inspired multispectral imaging device will be used to record fluorescence signals emited by dyes (Indocyanine green and methylene blue) routinely used for visual identification of sentinel lymph nodes per current standard of care worldwide.
2846945|NCT03619954|Experimental|NK cells infusion|
2846946|NCT03619941|Placebo Comparator|Placebo|
2846947|NCT03619941|Experimental|Montmorency Tart Cherry Juice|
2846948|NCT03619928|Experimental|Dry needling|Procedure in which a thin needle is used to penetrate the skin, subcutaneous tissues and muscle with the intention of mechanically stimulating the tissue without the use of an anesthetic. The physiological mechanism supporting the effects of dry needling remains to be clarified. It has been suggested that the needle works according to the pain gate control theory, indicating that one type of sensory input could be inhibited in the Central nervous system by another input
2846949|NCT03619928|Active Comparator|Massotherapy|Among the therapeutic approaches for DOMS is massage therapy. Several authors have examined the effects of DOMS massage and indirect markers of muscle damage, such as impaired muscle function, edema and muscle changes in blood proteins.
2846950|NCT03619915||Greater dependence|
2846951|NCT03619915||Less dependence|
2846952|NCT03619915||Independent|
2846953|NCT03619902|Experimental|ANB019 Biological/Vaccine|ANB019 subcutaneous (SC) injection every 4 weeks
2846954|NCT03619889|Sham Comparator|Control group|A simulation of the pressure release technique, applying a soft pressure or contact in the same muscles sites or trigger points than in the intervention group.
2846955|NCT03619889|Experimental|Intervention group|The release pressure technique is applied in the trigger points of masticatory and neck muscles (upper trapezius, sternal and clavicular sternocleidomastoid, deep and superficial masseter, posterior, medium and anterior temporalis.
2847024|NCT03619369|Placebo Comparator|Routine Circumcision|
2846957|NCT03619876|Active Comparator|TNF inhibitor arm|Treatment with a adalimumab, as the TNF-inhibitor arm, will consist of every 2 weeks SQ injections at a dose of 40mg.
2846958|NCT03619850|Experimental|Ferumoxytol|
2846959|NCT03619850|Active Comparator|Iron sucrose|
2846960|NCT03619837|Experimental|Treatment Arm|"Single Arm: Sofosbuvir/Velpatasvir~Dosage: 400mg/100mg. Once daily for 12 weeks."
2846961|NCT03619824|Experimental|Intervention arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 66-70Gy will be given in six to seven weeks. Concurrent cisplatin 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Sintilimab 200mg will be given every 3 weeks for 6 cycles, started on day 1 of induction chemotherapy.
2846962|NCT03619811|No Intervention|Healthy Subject|This research study is looking at the diagnosis and treatment of Reflux associated laryngeal symptoms. In order to do this, healthy subjects are needed to act as the baseline to compare with people who have Reflux associated laryngeal symptoms
2846963|NCT03619811|Experimental|Symptomatic|This study examines the efficacy of the upper esophageal sphincter assist device as an adjunct to Proton-pump inhibitors (PPI) therapy in symptomatic subjects. (Reza Band® Upper Esophageal Sphincter (UES) Assist Device)
2846964|NCT03619785|Experimental|Experimental (SAPB)|Patients randomized to the experimental arm receive an ultrasound-guided serratus anterior plane block for their rib fracture pain.
2846965|NCT03619785|Active Comparator|Control|Patients randomized to the control arm receive usual pain control treatment in the emergency department.
2846966|NCT03619772|Experimental|Bilateral|Participants will control game using EMG from both upper limbs.
2846967|NCT03619772|Active Comparator|Unilateral|Participants will control game using the more impaired upper limb.
2846968|NCT03619759||Sugammadex|Patients who used sugammadex Sugammadex 1 vial (200mg) intravenous, at the end surgery, before extubation
2846969|NCT03619759||Non-sugammadex|Patients who didn't use sugammadex Pyridostigmine 15~20mg intravenous, at the end of surgery, before extubation
2846970|NCT03619746|No Intervention|Pre-Intervention|Current practice (unchanged). This arm of patients will cared for by physicians who have NOT received the POCUS Educational Intervention.
2846971|NCT03619746|Experimental|Post-Intervention|This arm of patients will cared for by physicians who have received the POCUS Educational Intervention.
2846972|NCT03619720|Experimental|Participants|
2846973|NCT03619707|Experimental|Oral Dydrogesterone|Oral dydrogesterone (Duphaston 10 mg) will be given orally four times daily : will be continued till the pregnancy test, and till at least 12 weeks of gestation in case of a positive pregnancy test.
2846974|NCT03619707|Experimental|Vaginal microprogesterone|Vaginal progesterone (Utrogestan 200 mg) will be given vaginally four times daily: will be continued till the pregnancy test, and till at least 12 weeks of gestation in case of a positive pregnancy test
2846975|NCT03619681|Experimental|KN026|
2846976|NCT03619655|Experimental|"Cohort A - SPECT CT and NaF PET"|Intervention 1: SPECT CT Intervention 2: NaF PET
2846977|NCT03619655|Experimental|"Cohort B - SPECT CT and 18F-DCFPyL PET/CT"|Intervention 1: SPECT CT Intervention 2: 18F-DCFPyL PET/CT
2846978|NCT03619655|Experimental|"Cohort C - SPECT CT and WB-MRI"|Intervention 1: SPECT CT Intervention 2: WB-MRI
2846979|NCT03619642|Other|persons with Multiple Sclerosis (MS)|25 persons with MS Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
2846980|NCT03619642|Other|stroke patients|25 stroke patients Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
2846981|NCT03619642|Other|healthy controls|50 healthy controls Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
2846982|NCT03619629|Experimental|Kinesio-taping|Kinesiotape will be applied both ankles.
2846983|NCT03619629|Experimental|Mulligan's mobilization with movement|'Posterolateral glide mobilization with movement' will be applied both ankles.
2846984|NCT03619629|Sham Comparator|Sham Kinesio-taping|Sham kinesio-taping technique will be applied both ankles.
2846985|NCT03619629|Sham Comparator|Sham Mulligan's mobilization with movement|Sham Mulligan's mobilization with movement will be applied both ankles.
2846986|NCT03619616|Experimental|ZSP1603 (single dose)-7.5 mg (Cohort 1)|Subject adminsitered at a dose of ZSP1603 7.5 mg on day 1 under fasted condition.
2846987|NCT03619616|Experimental|ZSP1603 (single dose)-12.5mg (Cohort 2)|"Subject adminsitered at a dose of ZSP1603 12.5 mg or placebo on day 1 under fasted condition.~Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1."
2846988|NCT03619616|Experimental|ZSP1603 (single dose)-25 mg (Cohort 3)|"Subject adminsitered at a dose of ZSP1603 25 mg or placebo on day 1 under fasted condition.~Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2."
2846989|NCT03619616|Experimental|ZSP1603 (single dose)-50 mg (Cohort 4)|"Subject adminsitered at a dose of ZSP1603 50 mg or placebo on day 1 under fasted condition.~Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3."
2846990|NCT03619590||Exposure Group|Pregnant women who were exposed to Twinrix within 28 days prior to conception or at any time during pregnancy. Reporting of exposed pregnancies is voluntary and prospective.
2846991|NCT03619577|Experimental|Sequential training-high frequency|The participants of HF will receive a total of 36 training sessions, and each session will contain 120 minutes of training. The participants in this group will first perform 60 minutes of physical exercise followed by 60 minutes of cognitive training. The participants in this group participate in multimodel exercise programs including aerobic exercise, balance, and strength training. The entire program will contain 10 minutes of warm-up, 40 minutes of physical exercise, and 10 minutes of cool-down. Then, the participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions for 1 hour.
2847025|NCT03619369|Active Comparator|Delayed Circumcision|
2847026|NCT03619343|Experimental|No ETOIMS arm|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography.
2847069|NCT03619096|Active Comparator|Test Group (tunnel technique)|It Will be performed root coverage of multiple recessions using porcine collagen matrix with a tunnel Technique
2853266|NCT03575364||Registry|Patients with iliac and/or femoral DVT
2846992|NCT03619577|Experimental|Sequential training-low frequency|The participants of LF will receive a total of 12 training sessions, and each session will contain 120 minutes of training. The participants in this group will first perform 60 minutes of physical exercise followed by 60 minutes of cognitive training. The participants in this group participate in multimodel exercise programs including aerobic exercise, balance, and strength training. The entire program will contain 10 minutes of warm-up, 40 minutes of physical exercise, and 10 minutes of cool-down. Then, the participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions for 1 hour.
2846993|NCT03619564||No protein restriction|No protein restriction
2846994|NCT03619564||Low protein diet (LPD)|LPD: < 0.8 g/kg bodyweight
2846995|NCT03619564||Ketoanalogue suppl. very LPD|sVLPD: 0.3-0.4 g/kg bodyweight + keotanalogues
2846996|NCT03619551|Experimental|Low Dose Busulfan|"Busulfan based preparative regimen targeted at area-under-the-curve (cAUC) exposure of 25-35 mg*h/L .~Randomization between the two dose levels will be done separately in each genotype stratum (RAG1/RAG2 and IL2RG/JAK3), using permuted blocks."
2846997|NCT03619551|Experimental|Medium Dose Busulfan|"Busulfan based preparative regimen targeted at area-under-the-curve (cAUC) exposure of 55-65 mg*h/L.~Randomization between the two dose levels will be done separately in each genotype stratum (RAG1/RAG2 and IL2RG/JAK3), using permuted blocks."
2846998|NCT03619538|Placebo Comparator|control group|
2846999|NCT03619538|Experimental|Nefopam group|
2847000|NCT03619525|Active Comparator|recruitment group|will receive intermittent lung recruitment during CPB
2847001|NCT03619525|No Intervention|control group|will recieve no intervention
2847002|NCT03619512||Richter Syndrom at diagnosis|patients diagnosed with Richter Syndrom, for whom a suitable lymph node biopsy at diagnosis is available.
2847003|NCT03619512||Primitive Diffuse Large B-Cell Lymphoma|patients diagnosed with a primitive Large B-Cell Lymphoma, for whom a suitable lymph node biopsy at diagnosis is available.
2847004|NCT03619512||Other secundary Diffuse Large B-Cell Lymphoma|patients diagnosed with a secundary Large B-Cell Lymphoma (different from Richter Syndrom), for whom a suitable lymph node biopsy at diagnosis is available.
2847005|NCT03619512||Control group with no tumor involvment of lymph nodes|patients for whom a diagnostic lymph node biopsy has been performed, which did not conclude to any tumoral lymph node involvment.
2847006|NCT03619499|Experimental|non invasive|infants who fulfill criteria of severe bronchiolitis will be connected to non invasive ventilation
2847007|NCT03619499|No Intervention|invasive|infants who were connected to invasive mechanical ventilation
2847008|NCT03619486|Placebo Comparator|Placebo|Placebo treatment (shock wave probe w/o energy)
2847009|NCT03619486|Experimental|Low energy shock wave|Low energy shock wave treatment (shock wave probe w/ energy)
2847010|NCT03619473|Experimental|intervention|"the group~assessed for proper helmet usage (type, chinstrap, standard helmet usage)~evaluated for the behavioral of helmet usage~underwent the educational session under helmet initiative program~received one standard motorcycle child safety helmet per family~assessed for proper helmet usage (type, chinstrap, standard helmet usage) 3 months after educational session and after received standard motorcycle child safety helmet~evaluated for the behavioral of helmet usage 3 months after educational session and after received standard motorcycle child safety helmet"
2847011|NCT03619473|No Intervention|control|"the group~assessed for proper helmet usage (type, chinstrap, standard helmet usage)~evaluated for the behavioral of helmet usage~assessed for proper helmet usage after 3 months 4 evaluated for the behavioral of helmet usage after 3 months~do not receive any educational session or standard motorcycle child safety helmet"
2847012|NCT03619460|Experimental|piezoelectric extraction|The flap will be raised using a Piezoelectric elevator, the eventual bone around the third molar crown will be removed with the same piezoelectric lever used for luxation and root extraction. The eventual rizectomy will be performed using a piezoelectric saw.
2847013|NCT03619460|Active Comparator|conventional extraction|The flap will be raised using a manual elevator and the eventual bone around the third molar crown will be removed with a bone bur with a straight handpiece while the eventual rizectomy will be performed using a bone bur. Manual levers will be used for luxation and tooth extraction
2847014|NCT03619447|Active Comparator|ESP block group|Under general anaesthesia, Ultrasound guided ESP block will perform at the T6 level with15 ml bupivacain+ 5ml lidocaine, bilaterally. Morphine 0.1 mg/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with morphine will apply to the all patients. Postoperative pain assessment and morphine consumption will record till the postoperative 24 th hours.
2847015|NCT03619447|Active Comparator|serratus block group|Under general anaesthesia, Ultrasound guided SAP block will perform at the T6 level with15 ml bupivacain+ 5ml lidocaine, bilaterally. Morphine 0.1 mg/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with morphine will apply to the all patients. Postoperative pain assessment and morphine consumption will record till the postoperative 24 th hours.
2847016|NCT03619434|Active Comparator|Conventional keratoplasty group (Control)|This group will undergo conventional penetrating keratoplasty with a trephine blade.
2847017|NCT03619434|Experimental|Femtolaser group|This group will undergo femtosecond laser-assisted penetrating keratoplasty.
2847018|NCT03619421|Experimental|Supplement with food|Zinc supplement to be taken at time of breakfast consumption
2847019|NCT03619421|Experimental|supplement prior to food|Zinc supplement to be taken 30-min before breakfast consumption
2847020|NCT03619408||No/Mild Esophagitis|All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have no or mild histologic esophagitis, no erosive esophagitis, and reflux index <3% on pH-metry. Antacid therapy will be discontinued.
2847021|NCT03619408||Moderate/Severe Esophagitis|"All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have moderate or severe histologic esophagitis, and/or erosive esophagitis, and/or reflux index > 3% on pH-metry.~Antacid therapy with PPI (omeprazole 1mg/kg/dose BID) will be initiated. For patients already taking PPI at therapeutic dosing, an H2 blocker (ranitidine 3mg/kg/dose BID) will be added."
2847022|NCT03619382||Healthy|Subjects identified to have a healthy foot/ankle
2847023|NCT03619369|Active Comparator|Early Circumcision|
2847027|NCT03619343|Active Comparator|ETOIMS arm|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
2847028|NCT03619330|Active Comparator|liraglutide|In the LIRA group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
2847029|NCT03619330|Active Comparator|testosterone|In the ANDRO group testosterone was initiated at a dose of 50 mg in a gel form once daily.
2847030|NCT03619317||Cancer esophagus and gastroesophageal junction|EGEJ cancer patients referred to combined therapy of chemoRT and surgery can be included.
2847031|NCT03619304|Experimental|no coffee|oral squamous cell carcinoma cell line without intervention
2847032|NCT03619304|Active Comparator|green coffee|oral squamous cell carcinoma cell line with application of green coffee
2847033|NCT03619304|Active Comparator|roasted coffee|oral squamous cell carcinoma cell line with application of roasted coffee
2847034|NCT03619304|Active Comparator|decaffeinated coffee|oral squamous cell carcinoma cell line with application of decaffeinated coffee
2847035|NCT03619291|Experimental|High-intensity functional training|all-out exercise
2847036|NCT03619291|Active Comparator|Aerobic exercise|walking
2847037|NCT03619291|Sham Comparator|control|sitting
2847038|NCT03619278|Experimental|Boosted iHIVARNA|Participants will receive 3 vaccines of HIVARNA01.3 prime, 2 MVA-vectored vaccine boosts, 1 dose of 10-1074 antibodies and 3 doses of romidepsin
2847039|NCT03619278|Experimental|iHIVARNA|Participants will receive 5 vaccines of HIVARNA01.3, 1 dose of 10-1074 antibodies and 3 doses of romidepsin
2847040|NCT03619278|Experimental|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 1 dose of 10-1074 antibodies and 3 doses of romidepsin
2847041|NCT03619278|Experimental|only antibody|Participants will receive 1 dose of 10-1074 antibodies and 3 doses of romidepsin
2847042|NCT03619265|Experimental|Prickly pear juice|Prickly pear juice, 3 oz daily for 8 weeks.
2847043|NCT03619265|Placebo Comparator|Pear-flavored juice|Pear-flavored juice, 3 oz daily for 8 weeks.
2847044|NCT03619252|Experimental|Vaccination group|Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and enrolled in vaccination by pneumococcal conjugate vaccine (PCV13): 3 doses with 1 month interval, and fourth dose planned to be administered 6 months later.
2847045|NCT03619252|Active Comparator|Standard prophylaxis|Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and receiving standard institutional antibacterial prophylaxis by Levofloxacin 500 mg daily during the median four cycles of treatment by novel agents
2847046|NCT03619239|Experimental|Cohort 1|Patients will receive treatment with GX-I7 at a pre-determined dose (Level I) on Day1 of each cycle.
2847047|NCT03619239|Experimental|Cohort 2|Patients will receive treatment with GX-I7 at a pre-determined dose (Level II) on Day1 of each cycle.
2847048|NCT03619239|Experimental|Cohort 3|Patients will receive treatment with GX-I7 at a pre-determined dose (Level III) on Day1 of each cycle.
2847049|NCT03619239|Experimental|Cohort 4|Patients will receive treatment with GX-I7 at a pre-determined dose (Level IV) on Day1 of each cycle.
2847050|NCT03619239|Experimental|Cohort 5(Dose-expansion)|Optimal fixed dose of GX-I7 from Dose-escalation stage on Day1 of each cycle (Maximum tolerable dose or Maximum efficacious dose or Maximum administered dose level or consecutive lower or upper dose level which does not exceed Maximum tolerable dose based on Safety Monitoring Committee(SMC) decision)
2847051|NCT03619226|Experimental|test patch|two adhesive patches are applied to the abdominal area
2847052|NCT03619213|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
2847053|NCT03619213|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
2847054|NCT03619200||Fallers|"Participants who reported at least one fall in the 12-months follow-up period were categorized as fallers."
2847055|NCT03619200||Non-Fallers|"Participants who did not report any fall in the 12-months follow-up period were categorized as non-fallers."
2847056|NCT03619187|Experimental|Single Arm|Study Product
2847057|NCT03619174|Active Comparator|Active Treatment|Treatment dose
2847058|NCT03619174|Placebo Comparator|Sham Treatment|Sub-therapeutic dose
2847059|NCT03619161|No Intervention|No cleaning (control)|Patients will have a bacterial culture taken from their bathtub and then continue regular care. We will offer to clean their bathrooms after the 4 week intervention period ends.
2847060|NCT03619161|Experimental|Bubbles|Patients will have a bacterial culture taken from their bathtub and have their bathrooms cleaned by the investigators
2847061|NCT03619161|Active Comparator|Bleach and Bubbles|Patients will have a bacterial culture taken from their bathtub, have their bathrooms cleaned by the investigators, and be given instructions to perform bleach baths twice weekly.
2847062|NCT03619148|Other|High-Flow Humidified Nasal Oxygen - TOE partipajnts|High-Flow Humidified Nasal Oxygen - standard care
2847063|NCT03619148|Active Comparator|High-Flow Humidified Nasal Oxygen|High-Flow Humidified Nasal Oxygen - staff volunteers
2847064|NCT03619135|Experimental|Use of Buzzy Device|The Buzzy device was used for IV access for this arm.
2847065|NCT03619135|Placebo Comparator|Control|No Buzzy device was used - standard IV access for this arm.
2847066|NCT03619122|Experimental|Second Examination|Eligible patients who consent to participate undergo planned colonoscopy by endoscopists performing procedures that day per normal standard of care. The colonoscope is passed to the cecum and then withdrawn to the hepatic flexure with washing and aspirating of colonic contents as needed to optimize visualization of colonic mucosa. Then, the colonoscope is inserted to the cecum and withdrawn to the hepatic flexure again for second examination.
2847067|NCT03619122|No Intervention|Traditional Examinaiton|Eligible patients who consent to participate undergo planned colonoscopy by endoscopists performing procedures that day per normal standard of care. The colonoscope is passed to the cecum and then withdrawn to the hepatic flexure with washing and aspirating of colonic contents as needed to optimize visualization of colonic mucosa. Then, the colonoscope is withdrawn to the anus directly.
2847068|NCT03619109||Healthy Volunteers|No real intervention since samples from volunteers are not tested on Nanōmix eLab™ System near any volunteers. Leftover samples are stored at Sponsor for potential future analysis/ projects.
2847070|NCT03619096|Placebo Comparator|Control Group (extended flap technique)|It Will be performed root coverage of multiple recessions using porcine collagen matrix with a extended flap technique
2847071|NCT03619083||Breast cancer patients treated with chemotherapy|
2847072|NCT03619083||patients not exposed to chemotherapy|
2847073|NCT03619083||healthy controls|
2847074|NCT03619070|Experimental|Lower load resistance training (LL)|In the LL group, postmenopausal women will perform the resistance training with moderate volume (i.e. three sets per exercise performed until or close to failure) and low load (i.e. 30% of 1RM)
2847075|NCT03619070|Experimental|Higher load resistance training (HL)|In the HL group, postmenopausal women will perform the resistance training with moderate volume (i.e. three sets per exercise performed until or close to failure) and high load (i.e. 80% of 1RM)
2847076|NCT03619070|Experimental|Higher volume resistance training (HVHL)|In the HVHL group, postmenopausal women will perform the resistance training with high volume (i.e. six sets per exercise performed until or close to failure) and high load (i.e. 80% of 1RM)
2847077|NCT03619070|Other|Control group, (CG)|In CG, the postmenopausal women group will not perform exercise
2847078|NCT03619057||> 18 years|
2847079|NCT03619057||10 to 18 years|
2847080|NCT03619044|Other|Patients with metastatic breast cancer|Patients with metastatic breast cancer treated with trastuzumab + pertuzumab + taxane in the metastatic first line.
2847081|NCT03619031|Experimental|LONG LEAVENING|Acute test meal
2847082|NCT03619031|Experimental|SHORT LEAVENING|Acute test meal
2847083|NCT03619031|Active Comparator|TRADITIONAL|Acute test meal
2847084|NCT03619018||Single arm|Subjects who are scheduled to undergo ablation due to arrhythmia will be enrolled in the study for Data collection to develop specific therapy (PSOT)
2847085|NCT03619005|Placebo Comparator|Placebo|
2847086|NCT03619005|Active Comparator|Prasterone|
2847087|NCT03618992|Active Comparator|Cohort 1|Subjects will be provided with containers of topical cholesterol-containing moisturizers to be applied to the skin and hair, identical except for labels designating left and right. Topical formulations will be purchased by Skin Actives Scientific (www.skinactives.com), and will consist of one container of intervention and one of vehicle only (see ingredients below), to be applied to the left or right arm as indicated by pre-randomization assignment. Patients will be instructed to begin a 1-week washout period in which they will stop all topicals, and will then begin daily application of the topical intervention products to the indicated sites. Patients will return for follow-up visits at 2, 6, 10, and 14 weeks after starting intervention.
2847088|NCT03618992|No Intervention|Cohort 2|Pre-study randomization will assign patients to have measurements obtained from either the left or right side of the body. Baseline skin barrier measurements of the skin and lips will be obtained, including transepidermal water loss (TEWL), hydration, pH and sebum (oil). Photos of the skin, lips, eyebrows, eyelashes and scalp will be taken. On each side, samples of scalp (pluck 1), eyebrow (trim 1), and eyelash (trim 1) hairs will be obtained only at baseline and the final visit. Patients will return for follow-up visits at 1, 2, and 3 months after discontinuation of oral antifungal therapy.
2847089|NCT03618992|No Intervention|Cohort 3|Pre-study randomization will assign patients to have measurements obtained from either the left or right side of the body. Baseline skin barrier measurements of the skin and lips will be obtained, including transepidermal water loss (TEWL), hydration, pH and sebum (oil). Photos of the skin, lips, eyebrows, eyelashes and scalp will be taken. On each side of the body, samples of scalp (pluck 1, trim 1), eyebrow (pluck 1, trim 1), and eyelash (trim 1) hairs will be obtained at the baseline and final visit. Patients will return for follow-up visits at monthly intervals after initiation of oral antifungal therapy for up to 12 months.
2847090|NCT03618979|Experimental|PPP with ECM treatment|Platelet Poor Plasma (PPP) mixed with extracellular matrix (ECM) into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
2847091|NCT03618979|Experimental|PRP treatment|5x concentration Platelet Rich Plasma (PRP) injected into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
2847092|NCT03618979|Experimental|PRP and PL Combo treatment|5x concentration PRP injected into the multifidus, along with a facet joint injection with 14x PRP into each joint and capsule, and transforaminal epidural injection with of 3x concentrated platelet lysate (PL) and 0.5% ropivacaine on each side and at each level 1 time every 2 weeks for 6 weeks total (series of 3 injections)
2847093|NCT03618966|Experimental|Right-real NMMS Group|It will receive a real stimulation (rNMMS) of the right arm and a sham stimulation (sNMMS) of the left arm
2847094|NCT03618966|Active Comparator|Left-real NMMS Group|It will receive a rNMMS of the left arm and a sNMMS of the right arm
2847095|NCT03618953|Experimental|Arm 1 (Intravenous dosing)|"Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-E6E7 administered as 4 infusion (IV) doses over 2 weeks starting at study day 15.~Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43."
2847096|NCT03618953|Experimental|Arm 2 (Intravenous and Intra-tumoral injection dosing)|"Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 2 dose levels (escalation) of MG1-E6E7 administered as 1 IV dose, starting at study day 15, followed by 2 intratumoral (IT) doses administered on study days 18 & 29.~Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43."
2847097|NCT03618940|Experimental|School-based educational intervention|"assessed for knowledge and attitude on burn injury prevention~underwent the School-based educational intervention~impact evaluation~Output evaluation 3 months after School-based educational intervention"
2847098|NCT03618927|Experimental|Daily physical activity intervention|The intervention consisted of a DPA program designed by a national organization with expertise in school-based physical activity programming and delivered in school by teachers. The program was offered to students in grades 4 through 8 and consisted of 20 minutes of structured DPA in school for 20 consecutive weeks. The DPA activities included jumping jacks, squats, running and other body weight exercises.
2847099|NCT03618927|No Intervention|Control - treatment as usual|Participants in control classes completed regular school activities as per the Ontario curriculum.
2847100|NCT03618914||Non-anemic women|
2847101|NCT03618914||anemic women|anemia due to iron deficiency
2847102|NCT03618901|Experimental|Rock Steady Boxing|Non-contact boxing program.
2847103|NCT03618901|Active Comparator|PD SAFEx|Sensory attention focused exercise.
2847104|NCT03618888|Active Comparator|Instructor-led training|Instructor-led training contents a supervised practical training for BLS, facilitated by a certified instructor.
2847105|NCT03618888|Experimental|Self-learning training|Self-learning training is self-directed and contents practical training for BLS
2847106|NCT03618875|Active Comparator|ice|Patients were randomly assigned to receive an ice 5 minutes prior the IViT
2847107|NCT03618875|Placebo Comparator|placebo|Patients were randomly assigned to a room temperature patch (placebo) 5 minutes prior the IViT
2847108|NCT03618849|Experimental|Sham tDCS|Post initial screening and baseline data collection, all study participants (a single cohort of patients) will receive a single dose of sham tDCS for 20 minutes over the left dorsolateral prefrontal cortex (DLPFC) in conjunction with Mozart piano sonata. For sham tDCS, the current will be ramped up and immediately ramped down for 30 seconds. The sham tDCS session will be preceded and followed by behavioral assessments and EEG recording.
2847109|NCT03618849|Experimental|1-mA tDCS|Post sham-tDCS, we will determine the eligibility of the participant to receive 1 mA of real tDCS based on the occurrence of adverse events and seizures occurring within 5 days of the sham session. After a minimum of 5 days post-sham stimulation (and typically around 7 days later), the participant will receive a single dose of 1-mA current over left DLPFC in conjunction with Mozart piano sonata. The participant will receive 1-mA current for 20 minutes; the current will be ramped up for 30 seconds, will held constant at the determined intensity for 20 minutes, and then ramped down for 30 seconds. The 1-mA tDCS session will be preceded and followed by behavioral assessments and EEG recording.
2847110|NCT03618849|Experimental|2-mA tDCS|Post 1-mA tDCS, we will again determine the eligibility of the participant to receive 2 mA current. After a minimum of 5 days post-1 mA stimulation (typically 7 days), the participant will receive a single dose of 2-mA current over left DLPFC in conjunction with Mozart piano sonata. The participant will receive 2-mA current for 20 minutes; the current will be ramped up for 30 seconds, will held constant at the determined intensity for 20 minutes, and then ramped down for 30 seconds. The 2-mA tDCS session will be preceded and followed by behavioral assessments and EEG recording.
2847111|NCT03618836||Cases. Preterm Births|Microbiological and biological patterns on vaginal samples in the first trimester of pregnancy among spontaneous preterm births between 22 and 36 weeks
2847112|NCT03618836||Controls. Term Births|Microbiological and biological patterns on vaginal samples in the first trimester of pregnancy among deliveries over ≥ 37 weeks
2847113|NCT03618823|Experimental|Opioid pain control|Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the diary as well as any unused opioids.
2847114|NCT03618823|Active Comparator|Non-opioid pain control|Patients in this group will be receiving therapy for pain control with acetaminophen and ibuprofen only. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the diary.
2847115|NCT03618810|Experimental|PEGCSF first level prophylactic use|The first level prophylactic use of PEG-rhG-CSF. The Prophylactic use of PEG-rh-CSF in all cycles of chemotherapy.
2847116|NCT03618810|Active Comparator|PEGCSF second level prophylactic use|The second level prophylactic use of PEG-rhG-CSF. The Prophylactic use of PEG-rh-CSF in the next cycle until FN or 4 grade neutropenia happened.
2847117|NCT03618797|Experimental|HL-PIF cap.160/2mg + Placebo|"Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg~once a day"
2847118|NCT03618797|Active Comparator|Livalo tab. 2mg + Placebo|"Pitavastatin ca 2mg~once a day"
2847119|NCT03618784|Experimental|FURESTEM-RA Inj.|
2847120|NCT03618784|Placebo Comparator|Placebo Comparator: Placebo|
2847121|NCT03618771|Experimental|Medacta GMK Sphere|Half of the patients will be implanted with the Medacta GMK Sphere total knee arthroplasty
2847122|NCT03618771|Experimental|DePuy Synthes Attune|Half of the patients will be implanted with the DePuy Attune total knee arthroplasty
2847123|NCT03618758|Experimental|Gastric Cancer with Peritoneal Carcinomatosis|Intraperitoneal Chemotherapy (Paclitaxel) + Systemic mFOLFOX6(5-FU, Oxaliplatin, Leucovorin)
2847124|NCT03618732|Experimental|Bilateral movement-based computer training|"All subjects underwent 16 sessions of assigned treatment (2 times per week; for 8 weeks; 3 hours standardized rehabilitation program per visit) There was 1.5 hours standardized conventional physiotherapy training a 1.5 hours multi-disciplinary program which consisted of standardized occupational therapy, speech therapy and nursing care.~Subjects in Intervention Group will be assigned an additional 30 minutes bilateral movement-based computer games(Able-X) training program of upper limb."
2847125|NCT03618732|Other|Video-directed conventional training|All subjects underwent 16 sessions of assigned treatment (2 times per week; for 8 weeks; 3 hours standardized rehabilitation program per visit) There was 1.5 hours standardized conventional physiotherapy training a 1.5 hours multi-disciplinary program which consisted of standardized occupational therapy, speech therapy and nursing care.
2847126|NCT03618719||Obstructive sleep apnea|Patients with treatment-naive obstructive sleep apnea (OSA) who need continuous positive airway pressure (CPAP) therapy on clinical basis
2847127|NCT03618719||Control|Healthy controls without OSA
2847128|NCT03618706|Experimental|involved-field RT + standard salvage treatment|Patients receiving involved-field RT on recurred lesions + standard salvage treatment for recurrent ovarian cancer
2847129|NCT03618693|Experimental|spinal analgesia SSS|"Patients will receive a spinal analgesia (group SSS) with a single shot of bupivacaine 0.5% combined with fentanyl intrathecally during induction of anaesthesia. The technique used is referred to daily practice.~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3* per day for 48 hours intravenously and 1 gr 4* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets (per oral administration).~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
2847130|NCT03618693|Experimental|TAP block|"Patients will receive a TAP block with a single shot of ropivacaine 0.375% combined with clonidine bilaterally. The technique used is referred to daily practice. The blocks will be performed under ultrasound guidance.~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3* per day for 48 hours intravenously and 1 gr 4* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets (per oral administration).~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
2847131|NCT03618693|Active Comparator|Standard|"Standard care for prostatectomy in the investigators institution consists in the concomitant systemic administration of lidocaine to standard general anaesthesia. Lidocaine will administered initially during induction with a bolus of 1.5 mg per kgBW, followed by an infusion of 1.5 mg per kgBW per hour for 24 hours.~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3* per day for 48 hours and 1 gr 4* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets.~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
2847132|NCT03618667|Experimental|single group|GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycle) up to 6 cycles, or till progression or uncontrolled toxicity.
2847133|NCT03618654|Experimental|Arm A (durvalumab, metformin)|"Patients will take Metformin 500mg/day for 3 days. From day 4, 500mg twice daily and then in 3 days (day 7) dose escalation to 1000mg twice daily will be achieved. This will be taken until the day before surgery after dinner.~Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion"
2847134|NCT03618654|Experimental|Arm B (durvalumab)|Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion. Participants receive durvalumab as in Arm A in the absence of disease progression or unacceptable toxicity.
2847135|NCT03618641|Experimental|Nivolumab and CMP-001 Combination|"Prime Phase -Nivolumab 240mg, IV Infusion, every two weeks starting with Cycle 2 ( Cycles 2, 4, 6) for 6 weeks in combination with CMP-001, 5mg, Injection, at Week 1 and the remaining injections, 3-10 mg depending on the size of the tumor will be administered Weeks 2 -7.~Boost Phase -Nivolumab 240mg, IV Infusion, every two weeks, over a 46 week period in combination with CMP-001, 5mg, administered every 4 weeks for 1 year."
2847136|NCT03618628|Experimental|People using a CFO|People who are currently wearing a carbon fiber off loading orthosis (CFO) will have a new CFO fabricated for them based on the results of our finite element (FE) model. We will then test both CFOs ability to reduce peak plantar compared to barefoot and the peak plantarflexor power of both braces.
2847137|NCT03618602|Experimental|100mg Bisthianostat|100mg starting dose taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
2847138|NCT03618602|Experimental|200mg Bisthianostat|200mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
2847139|NCT03618602|Experimental|400mg Bisthianostat|400mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
2847140|NCT03618602|Experimental|600mg Bisthianostat|600mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
2847141|NCT03618589|Placebo Comparator|opioid only|Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
2847142|NCT03618589|Experimental|pregabalin add-on|Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.
2847143|NCT03618576|Experimental|Balance exercise group|During the 2-week postoperative intervention period, patients will participate in the hospital's exercise program beginning 5-7 days after HFS. All participants will follow the computer-based balance specific exercise (BSE) program.
2847144|NCT03618550|Experimental|pembrolizumab plus GVD|Patients will receive 2-4 cycles of pembrolizumab plus GVD
2847145|NCT03618537|Experimental|ixazomib|"Enrolled patients will receive ixazomib at a fixed dose of 4mg on days~1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle. Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue. Treatment cycles will be repeated until disease progression for up to 24 cycles or until development of significant treatment-related toxicities."
2847146|NCT03618524|Experimental|Experimental|Lower limb hot water immersion
2847147|NCT03618511|Experimental|Financial Incentive Group|
2847148|NCT03618511|Experimental|Reminders Group|
2847149|NCT03618511|Experimental|Financial Incentive and Reminders Group|
2847150|NCT03618511|No Intervention|Control Group|
2847151|NCT03618498|Other|Patient accept surgery|Proliferative diabetic retinopathy suffering from MH with RD who were treated with vitrectomy combined with inverted epiretinal ILM flap,inverted ILM flaps insertion techniques, or free ILM flaps.
2847152|NCT03618472|Experimental|metformin|The participant will be eat metformin 850 mg 1 tab daily,4 weeks prior to hysterectomy
2847153|NCT03618472|Placebo Comparator|placebo|The participant will be eat placebo (same shape, size, color)1 tab daily ,4 weeks prior to hysterectomy
2847154|NCT03618459||Breast-surgery patients|A consecutive cohort of adult patients undergoing breast surgery with a combined anesthesia technique, employing a thoracic single-shot paravertebral block performed before surgery. Operations performed were in all cases unilateral tumor resections, lumpectomies and mastectomies without axillary lymphadenectomy.
2847155|NCT03618446||Survivors|Patients whose pelvic fracture and survived till time of discharge from the hospital.
2847156|NCT03618446||Non-Survivors|Patients whose pelvic fracture and died while in hospital.
2847157|NCT03618433|Experimental|Study group|"Standart exercise protocol and KİNECT® video based physiotherapy~The treatment protocol of the study group will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises.In total, a 25-minute Kincet® video game program will be applied in addition to the 15-minute basic and standart exercise program."
2847158|NCT03618433|Active Comparator|Control group|"Standart exercise protocol and Upper extremity rehabilitation~The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol"
2847159|NCT03618420|Other|Clinical Investigation|All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.
2847160|NCT03618407||Oral oseltamivir group|Patients with influenza virus positive and early oral oseltamivir capsules
2847161|NCT03618407||Oral Lotus Capsules group|Patients with positive influenza virus and early oral administration of lotus extract capsules
2847162|NCT03618407||other group|Influenza virus positive patients who were not treated with oral lotus capsule or oseltamivir capsules early
2847163|NCT03618394||Smoflipid|premature neonates receiving MCT/ω-3-PUFA-containing lipid emulsion
2847164|NCT03618394||Intralipid|premature neonates receiving Soybean Based lipid emulsion
2847165|NCT03618381|Experimental|EGFR 806CAR(2G) -EGFRt|Autologous CD4+ and CD8+ T cells that have been genetically modified to express the EGFR 806CAR(2G) -EGFRt
2847166|NCT03618381|Experimental|EGFR806CAR(2G)-EGFRt and CD19CAR(2G)-T2A-HER2tG|Autologous CD4+ and CD8+ T cells that have been genetically modified to express the EGFR806CAR(2G)-EGFRt and CD19CAR(2G)-T2A-HER2tG
2847167|NCT03618368|Experimental|Blinded THERANOVA-500 dialyzer|This group of 25 subjects is dialyzed with masked THERANOVA-500 dialyzer which is an improved version of REVACLEAR-400 dialyzer.
2847168|NCT03618368|Placebo Comparator|Blinded REVACLEAR-400 dialyzer|This group of 25 subjects is dialyzed with masked REVACLEAR-400 dialyzer which is their usual dialyzer.
2847169|NCT03618368|Experimental|Unblinded THERANOVA-500 dialyzer|This group of 10 subjects is dialyzed with unmasked THERANOVA-500 dialyzer which is an improved version of REVACLEAR-400 dialyzer.
2847170|NCT03618368|Placebo Comparator|Unblinded REVACLEAR-400 dialyzer|This group of 10 subjects is dialyzed with unmasked REVACLEAR-400 dialyzer which is their usual dialyzer.
2847171|NCT03618355|Experimental|Cohort 1: 0.5 mg weekly|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 0.5 mg every week."
2847172|NCT03618355|Experimental|Cohort 2: 1 mg weekly|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 1 mg every week."
2847173|NCT03618355|Experimental|Cohort 3: 0.5 mg daily|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 0.5 mg daily."
2847174|NCT03618355|Experimental|Cohort 4: 1 mg daily|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 1 mg daily."
2847175|NCT03618342||PCOS|PCOS women
2847176|NCT03618342||Healthy controls|Healthy control women
2847177|NCT03618329|Active Comparator|Prehabilitation|exercise, nutrition and anxiety reduction in the preoperative period
2847178|NCT03618329|No Intervention|No Prehabilitation|Not: exercise, nutrition and anxiety reduction in the preoperative period
2847179|NCT03618316|Experimental|Open-label imeglimin + cimetidine|Day 1: single oral dose of 1,500 mg imeglimin Day 5 to Day 10 inclusive: repeated doses of 400 mg cimetidine twice daily Day 8: second 1,500 mg dose of imeglimin together with the morning dose of cimetidine
2847180|NCT03618303|Experimental|Interventional|All patients will undergo the same intervention of having a PET-MRI scan and optical coherence tomography.
2847181|NCT03618290||Acute ischemic stroke group|50 patients (expected) - Acute ischemic stroke (AIS)
2847182|NCT03618290||Non-neurological pathologies group|25 control subjects with non-neurological pathologies (Congestive heart failure (CHF), Chronic obstructive pulmonary disease ( COPD ) etc.)
2847183|NCT03618290||Non AIS-related brain injuries group|25 control subjects with traumatic or other non AIS-related brain injuries. These will include: Traumatic Brain Injury (TBI), migraine, subdural hematomas or patients after neurosurgical interventions on brain tissue.
2847184|NCT03618264|Experimental|Dexamethasone plus Ropivacaine group|Participates received peri-incisional scalp infiltration of a miscible liquid of dexamethasone and ropivacaine. The local infiltration miscible liquid containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter
2847185|NCT03618264|Active Comparator|Ropivacaine group|Participates received peri-incisional scalp infiltration of 5mg/mL ropivacaine.
2847186|NCT03618251||ischemic stroke|all patients with a suspicion of ischemic stroke
2847187|NCT03618238|Experimental|Anlotinib|patients will be given anlotinib 12 mg daily for continus 14 days every 21 days until disease progression.
2847188|NCT03618225|Active Comparator|duloxetine group|duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure.
2847189|NCT03618225|Placebo Comparator|placebo pill group|placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure.
2847190|NCT03618212||Myeloma patients|
2847191|NCT03618199|Experimental|Efficacy of vibrating system on healthy volunteers|
2847192|NCT03618199|Experimental|Efficacy of vibrating system on vestibular patients|
2847193|NCT03618186|Experimental|Normal control|Cognitively normal volunteers
2847194|NCT03618186|Experimental|Mild Cogntive impairment|Person with cognitive impairment that meet Peterson Criteria
2847195|NCT03618186|Experimental|Demented|Patient's that meet dementia criteria
2847196|NCT03618173|Experimental|dexamethasone|IV dexamethasone group : dexamethasone administrated at the induction of general anesthesia, at the dose of 0,2mg/kg (= 0,2mL/kg of a syringe with a 1mg/mL concentration) maximum 8mg (=8mL).
2847216|NCT03618030|Placebo Comparator|Placebo Treatment|
2854534|NCT03566719|Experimental|Intervention group|
2847197|NCT03618173|Placebo Comparator|Placebos|IV placebo group : saline serum is administrated at the induction of general anesthesia, at the dose of 0,2mL/kg, maximum 8mL.
2847198|NCT03618160|Experimental|Part 1: SAD (Cohort 1 to 3)|Participants in Cohorts 1 to 3 will receive a single Subcutaneous (SC) low, medium, and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety, tolerability review to determine safe and maximum well tolerated dose.
2847199|NCT03618160|Experimental|Part 2: MAD (Cohort 4 to 6)|Participants in Cohorts 4 to 5 will receive weekly multiple SC low and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. If multiple high dose is judged as not tolerable, additional optional Cohort 6 will be added to Part 2 to investigate the safety, tolerability and PK after administration of multiple medium dose of JNJ-64565111 in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety and tolerability review to determine safe and maximum well tolerated dose.
2847200|NCT03618160|Experimental|Part 3: Single Dose (Cohort 7)|Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 which may be started (as early as) in parallel with Cohort 3 in Part 1 on Day 1, under fasted conditions in healthy Caucasian male participants. Based on the results from Cohort 1 to 3 in Part 1, the dose of Cohort 7 may be reduced to low dose or increased to high dose.
2847201|NCT03618134|Experimental|Cohort I (SBRT, durvalumab, TORS, neck dissection)|Beginning day 0 of course 1, participants undergo stereotactic body radiation therapy 5 days a week for 1 week and receive durvalumab IV over 1 hour on days 0 and 27 in the absence of disease progression or unacceptable toxicity. Participants then undergo transoral robotic surgery and modified radical neck dissection between weeks 6-8. Beginning week 12, participants then receive durvalumab IV over 1 hour every 4 weeks. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2847202|NCT03618134|Experimental|Cohort II (SBRT, durvalumab,tremelimumab,TORS,neck dissection)|Beginning day 0 of course 1, participants undergo stereotactic body radiation therapy 5 days a week for 1 week and receive tremelimumab IV and durvalumab IV over 1 hour on days 0 and 27 in the absence of disease progression or unacceptable toxicity. Participants then undergo transoral robotic surgery and modified radical neck dissection between weeks 6-8. Beginning week 12, participants then receive durvalumab IV over 1 hour every 4 weeks. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2847203|NCT03618121|Experimental|Biofeedback plus gaming (Nevermind)|1) Group A is a biofeedback plus gaming group. Participants in this group play a horror videogame called Nevermind, while also wearing a chest strap heart rate monitor. The object of the videogame is to assist a patient by entering his/her mind and helping him/her work through some trauma memories. The way the game works is that the more anxious players are, the faster their heart beats, and the faster the heart beats, the harder and scarier the game gets. Thus, in order for one to do well in the game, he or she has to learn how to control the heartbeat and stress through relaxation. A therapist will help people in this group to learn relaxation techniques to help calm their body and finish the game.
2847204|NCT03618121|Active Comparator|Gaming only|2) Group B is a gaming only group. Like Group A, participants in this group play a Nevermind, but this time they do not wear a heart rate monitor. A therapist will still be present to help people in this group to learn relaxation techniques to help calm themselves during game play, but in this case the game does not change based on heart rate.
2847205|NCT03618121|Active Comparator|Biofeedback only (The Pip)|3) Group C is a biofeedback only group. In Group C, participants use a device called The Pip that measures Galvanic Skin Response. The Pip interacts with a few basic apps used in this study to teach relaxation. In one app, players control flying dragons. The more relaxed players are (as measured by GSR), the higher and faster their dragon flies. In another app, players control the changing of seasons. The more relaxed players are, the faster they can make seasons change from winter to spring. In another app, players can watch a simple graph of their stress over a period of time. Participants can learn to decrease stress by learning to make the line on the graph go down. In Group C, a therapist will also be present with participants to help them learn techniques to reduce stress.
2847206|NCT03618121|Active Comparator|Relaxation training only|4) Group D is a relaxation training only group. In Group D, participants receive relaxation training from a trained therapist. Participants in this group learn and practice with their therapist different techniques to help them relax and reduce stress.
2847207|NCT03618108|Active Comparator|Active|Subjects will be given oral capsules containing the active comparators 50mg oral capsule doxycycline, 250mg oral capsule azithromycin and 150mg oral capsule rifabutin daily (days 1 to 7). From days 8 to 90 subjects will be given 50mg oral capsule doxycycline, 250mg oral capsule azithromycin and 150mg oral capsule rifabutin twice daily.
2847208|NCT03618108|Placebo Comparator|Placebo|subjects will be given sugar capsules identical in form and size to the active comparators, 1 capsule of each bottle (3 separate capsules) daily (days 1 to 7), 1 capsule of each bottle (3 separate capsules) twice daily (days 8 to 90).
2847209|NCT03618082|Active Comparator|usual practice|control group (usual practice): patients receiving a general anesthesia with propofol, ketamine and remifentanil with or without curare for the induction, and desflurane and remifentanil (with or without curare) for the maintenance. The dosage of the anesthetic agent, as well as the prophylactic administration of morphine at the end of the intervention, will be decided by the anesthesiologist.
2847210|NCT03618082|Experimental|targeted analgesia to ANI|"experimental group: patients receiving a general anesthesia with propofol, ketamine and remifentanil with or without curare for the induction, and desflurane and remifentanil (with or without curare) for the maintenance, as well as the prophylactic administration of morphine at the end of the intervention, will be administered according to the ANI.~- In addition, desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC)."
2847211|NCT03618069|No Intervention|routine investigation|
2847212|NCT03618069|Active Comparator|study protocol CCI (CTA, cardiac CT) and MRI scans|
2847213|NCT03618056|Experimental|AIDSVAX® B/E|Participants will receive 600 mcg/mL of AIDSVAX® B/E at Months 0, 1, and 6.
2847214|NCT03618043|Experimental|SH-1028|Oral Once-Daily Administration of SH-1028
2847215|NCT03618030|Experimental|Active Treatment|PRC-063 25, 35, 45, 55, 70, 85, or 100 mg
2847217|NCT03618017|Experimental|CCC Website|The intervention, ContinuingCancerCare (CCC) Website is a personalized, navigation tool that is tailored to patients' preferences for provider roles in follow-up care, their satisfaction with their current primary care provider, and their worry about cancer recurrence. It involves a personalized, patient-facing website which includes a baseline survey, tailored educational modules, and a guide for their survivorship care, as well as a text or email based reminder system. The intervention also includes a provider-facing summary document, which will be faxed to both the oncology and primary care teams.
2847218|NCT03618017|Other|Static care plan|"The control arm will receive is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as standard of care."
2847219|NCT03618004|Experimental|Experimental group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects of the experimental group made use of the restriction of blood flow, using a pressure cuff coupled in the most proximal region of the arm, 10 cm wide. The pressure was calculated based on the initial systolic pressure of the subjects."
2847220|NCT03618004|Active Comparator|Control group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects in the control group did not use pressure cuffs."
2847221|NCT03617991|Experimental|Exercise Group|Participants will be provided an 8-week home exercise program that they will complete. The participants will also be provided all of the equipment. An investigator will contact them weekly to ensure compliance and send You Tube videos with new Phases.
2847222|NCT03617991|No Intervention|Control Group|The control group will be contacted weekly to check on health status.
2847223|NCT03617978|Experimental|None Elevation|Participant placed on a flat surface. Study participant connected to the measuring hemodynamic parameters device
2847224|NCT03617978|Experimental|Elevation angle of 20 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 20 degrees. Study participant connected to the measuring hemodynamic parameters device
2847225|NCT03617978|Experimental|Elevation angle of 30 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 30 degrees. Study participant connected to the measuring hemodynamic parameters device
2847226|NCT03617978|Experimental|Elevation angle of 45 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 45 degrees. Study participant connected to the measuring hemodynamic parameters device
2847227|NCT03617965||Mild thrombocytopenia|Patients with a platelet count of 100 × 10e9 to 149 × 10e9/L.
2847228|NCT03617965||Moderate thrombocytopenia|Patients with a platelet count of 50 × 10e9 to 99 × 10e9/L
2847229|NCT03617965||Severe thrombocytopenia|Patients with a platelet count<50 × 10e9/L
2847230|NCT03617965||Control group|Patients with normal platelet count (i.e.150 × 10e9 to 399 × 10e9/L)
2847231|NCT03617952|Experimental|S1 (Peer) group|"S1 group households located in 25 clusters that were included in a prior cookstove study: selected households are nearest neighbors (peers) of households who received free stoves in that prior study. This group is used to represent a potentially high peer influence on the adoption of improved cookstoves.~The P3 Bio Intervention is implemented in this group."
2847232|NCT03617952|Experimental|S2 (Non-Peer) Group|"S2 group households are located in 25 clusters randomly selected from the area of the K-N Districts more than 1 km from the S1 clusters. This group will have minimal prior knowledge of the cookstoves through peers.~The P3 Bio Intervention is implemented in this group."
2847233|NCT03617939||Biospeciman and Data Collection|Patients with cancer or who are at risk of having cancer who have given consent to have blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected and stored for the advancement of medicine.
2847234|NCT03617926|Experimental|Test product|Water-based lotion (internal code (X92001666)
2847235|NCT03617926|Active Comparator|Reference|Commercial, pyrethrin-based shampoo (RID shampoo)
2847236|NCT03617913|Experimental|Treatment (avelumab, chemotherapy, radiation therapy)|Participants receive avelumab IV over 60 minutes every 14 days for a total of 10 courses in the absence of disease progression or unacceptable toxicity. Beginning 29 days after the first dose of avelumab, participants receive either fluorouracil IV on days 1-5 and 16-20 during RT and mitomycin IV on day 1 of course 3, or cisplatin IV starting on day 1 of courses 3-5 for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
2847237|NCT03617900|Placebo Comparator|Placebo|
2847238|NCT03617900|Experimental|Ginger|
2847239|NCT03617900|Active Comparator|Paracetamol|
2847240|NCT03617887|Experimental|Experimental group|Plank exercise, Lateral plank exercise, Bird dog exercise, Pelvic drop exercise, and Stabilization of the middle gluteus in the knee valgus:
2847241|NCT03617887|Experimental|Control group|Plank exercise, Lateral plank exercise and Bird dog exercise
2847242|NCT03617874|Active Comparator|PC4PrEP- Intervention Clinics|Intervention clinics will receive the PC4PrEP intervention. The intervention includes Montefiore PrEP policy awareness, provider and patient education, pre-screening to identify PrEP eligible patients, and identifying high risk individuals in the community and providing referral and linkage to primary care.
2847243|NCT03617874|Placebo Comparator|Standard of Care Clinics|These clinics will not receive the PC4PrEP intervention but will continue with their standard of care model.
2847244|NCT03617861|Active Comparator|Treatment|Human Secretin 0.2 mcg/kg IV over 1 min
2847245|NCT03617861|Placebo Comparator|Placebo|Normal Saline over 1 min
2847246|NCT03617848||Cohort|A cohort of participants with suspected stable HFpEF will be recruited from the primary care setting. HFpEF diagnosis will be confirmed as per the 2016 European Society of Cardiology (ESC) guidelines for diagnosing HFpEF. All participants will undergo a series of assessments including but not limited to pulse wave velocity, 6 minute walk test, blood tests including natriuretic peptides (NT-Pro-BNP), ECG, physical assessments and a series of questionnaires. Those with confirmed HFpEF will be followed up at 6 and 12 months.
2847247|NCT03617835|Experimental|BI 655130|
2847248|NCT03617809||Prewarming|Active Prewarming will be performed using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be warmed using a surgical blanket during the intraoperative period. Esophageal thermometer will be used to measure the temperature throughout the intraoperative period.
2847249|NCT03617809||Control|Non-active prewarming. Patients will be warmed using a surgical blanket during the intraoperative period. Esophageal thermometer will be used to measure the temperature throughout the intraoperative period.
2847250|NCT03617783|Active Comparator|Prebiotin|
2847251|NCT03617783|Placebo Comparator|Placebo|
2847252|NCT03617770|Experimental|Sleep-Opt-In|Sleep optimization intervention
2847253|NCT03617770|Active Comparator|Healthy Living|Health education
2847254|NCT03617757|Experimental|All recruited patients|Blood taking procedure, oral glucose tolerance test and questionnaire will be included.
2847255|NCT03617744|Experimental|Surgical Intervention|Open Sleeve gastrectomy procedure will be performed immediately following liver transplantation (as a single surgery) or within 2 weeks of transplantation (as a second open surgery)
2847256|NCT03617744|No Intervention|No Surgical Intervention|Liver transplantation will proceed as per routine practice
2847257|NCT03617731|Active Comparator|IA|Patients in arm IA are treated with 3 cycles RVd (lenalidomide 25 mg/d p.o. d1 - 14 and d22 - 35; bortezomib 1.3 mg/m2 s.c. d1, 4, 8, 11, 22, 25, 29, 32; dexamethasone p.o. 20 mg/d d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33).Treatment repeats every 42 days (d43 = cycle 2 d1). Standard intensification: For all patients, stem cells are mobilized by GMMG Standard protocols (CAD: cyclophosphamide, doxorubicin, dexamethasone) and G-CSF. At least 7.5x106 CD34+ cells/kg body weight are harvested. High dose treatment (melphalan 200mg/m², HDT) followed by autologous stem cell transplantation (ASCT) is started 4 - 6 weeks after CAD. For patients not in CR after HDT1, a second HDT is performed within 3 months.
2847258|NCT03617731|Experimental|IB|Patients in arm IB are treated with 3 cycles RVd + Isatuximab (lenalidomide 25 mg/d p.o. d1 - 14 and d22 - 35; bortezomib 1.3 mg/m2 s.c. d1, 4, 8, 11, 22, 25, 29, 32;dexamethasone p.o. 20 mg/d d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33).Isatuximab (10 mg/kg i.v. C1: d 1, 8, 15, 22, 29; C2-3: d 1, 15, 29).Treatment repeats every 42 days (d43 = cycle 2 d1). Standard intensification: For all patients, stem cells are mobilized by GMMG Standard protocols (CAD: cyclophosphamide, doxorubicin, dexamethasone) and G-CSF. At least 7.5x106 CD34+ cells/kg body weight are harvested. High dose treatment (melphalan 200mg/m², HDT) followed by autologous stem cell transplantation (ASCT) is started 4 - 6 weeks after CAD. For patients not in CR after HDT1, a second HDT is performed within 3 months.
2847259|NCT03617731|Active Comparator|IIA|maintenance treatment with Lenalidomide 10mg/d (increased to 15mg/d after 3 months) repeated every 28d. Maintenance treatment is planned for up to 36 months or until progression if progression occurs first.
2847260|NCT03617731|Experimental|IIB|maintenance treatment with Lenalidomide 10mg/d (increased to 15mg/d after 3 months) + Isatuximab (10 mg/kg; C1: d1, 8, 15, 22; C2-C3: d1 + 15; C4-39:d1, repeated every 28d). Within the trial, maintenance treatment is planned for up to 36 months or until progression if progression occurs first.
2847261|NCT03617718|Experimental|Glycine Buffer|All participants will be asked to inhale a glycine buffer at visit 2 prior to the research bronchoscopy that is performed at visit 3.
2847262|NCT03617705|Active Comparator|HIV+ drinkers|Participants will wear the BACtrack Skyn Alcohol Monitoring Device throughout Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA and Skyn Monitor Lab Session 2 to compare the device readings collected with breath alcohol concentration (BrAC) tests.
2847263|NCT03617705|Active Comparator|HIV- drinkers|Participants will wear the BACtrack Skyn Alcohol Monitoring Device throughout Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA and Skyn Monitor Lab Session 2 to compare the device readings collected with breath alcohol concentration (BrAC) tests.
2847264|NCT03617692||Oral Cannabis|This is an observational study of individuals who have already decided to try cannabis for their cancer treatment-related symptoms. A research assistant will provide information on the range of edible cannabis products and basic information about their various cannabinoid profiles, approximate prices, and nearby locations where participants may choose to purchase their product. Participants will then initiate use of an orally administered product they have selected and obtained. Participants will take the product as they see fit, without any frequency or dosing instructions from study staff, for two weeks.
2847265|NCT03617679|Active Comparator|Active Ingredient|1:1 Randomization. Participants in this arm receive the active ingredient medication.
2847266|NCT03617679|Placebo Comparator|Placebo|1:1 Randomization. Participants in this arm receive the placebo medication. (Placebos do not contain active ingredients).
2847267|NCT03617666|Experimental|Avelumab|Patients with newly diagnosed cHL will receive single agent avelumab in 2 cycles
2847268|NCT03617653|Other|Group A - Intervention|Baseline procedure, Bio specimen collection , Six minute walk, Musculoskeletal Analysis, Exercise intervention from Visit 2 to Visit 13, End of 3 month assessment.
2847269|NCT03617653|Other|Group B- Control|Baseline procedure, Bio specimen collection , Six minute walk, Musculoskeletal Analysis & End of 3 month assessment.
2847270|NCT03617640||Hirschsprung's disease patients|Children diagnosed with Hirschsprung's disease or Hirschsprung's disease associated enterocolitis
2847271|NCT03617640||control patients|Children diagnosed and treated for miscellaneous bowel diseases
2847272|NCT03617627|Experimental|Experimental group|Patients will be included in a self-management intervention.
2847273|NCT03617627|No Intervention|Control group|Patients will receive a booklet with information.
2847274|NCT03617614||Collaborative Care Model|Participants who received care from the Medical Psychiatry Alliance Seniors Outpatient Collaborative Care Program at Trillium Health Partners.
2847275|NCT03617614||Mood Consult|Participants who received a one time mood consultation at the Centre for Addiction and Mental Health.
2847276|NCT03617601||> 4 MET|Patients with functional capacity over 4 MET
2847277|NCT03617601||< 4 MET|Patients with functional capacity under 4 MET
2847278|NCT03617588|Experimental|Gallium-68 THP-PSMA|Single intravenous administration of Gallium-68 THP-PSMA
2847279|NCT03617575|Placebo Comparator|apo-Lactoferrin|unsaturated (= no iron) form of Lactoferrin Lactoferrin is a human milk protein Test Meal A1
2853568|NCT03573297|Placebo Comparator|Placebo|Matching placebo capsules, oral administration, once daily
2847280|NCT03617575|Placebo Comparator|holo-Lactoferrin|saturated (= contains a certain amount of iron) form of Lactoferrin Lactoferrin is a human milk protein Test Meal B1
2847281|NCT03617575|Placebo Comparator|FeSO4|Ferrous sulfate = FeSO4 acting as the reference Test Meal C1
2847282|NCT03617575|Placebo Comparator|1. FeSO4|Ferrous sulfate = FeSO4 Test Meal A2
2847283|NCT03617575|Placebo Comparator|FeSO4 after 1 day break|Ferrous sulfate = FeSO4 Test Meal B2
2847284|NCT03617575|Placebo Comparator|FeSO4 after 2 day break|Ferrous sulfate = FeSO4 Test Meal C2
2847285|NCT03617562|Experimental|Superior Capsule Reconstruction|Patients will be treated with the new technique of superior capsule reconstruction with dermal allograft.
2847286|NCT03617562|Active Comparator|Partial Repair|Patients will have a partial repair with residual defect as an established standard procedure.
2847287|NCT03617549||All Participants|Mothers of singleton moderate preterm appropriate for Gestational Age (AGA) infants (29-32+6 weeks gestation in the neonatal intensive care unit at the Golisano Children's Hospital
2847288|NCT03617536|Experimental|CR845 0.25 mg Oral Tablet|Oral CR845 0.25 mg to be taken orally once daily for 12 weeks
2847289|NCT03617536|Experimental|CR845 0.5 mg Oral Tablet|Oral CR845 0.5 mg to be taken orally once daily for 12 weeks
2847290|NCT03617536|Experimental|CR845 1 mg Oral Tablet|Oral CR845 1 mg to be taken orally once daily for 12 weeks
2847291|NCT03617536|Placebo Comparator|Placebo Oral Tablet|Oral Placebo to be taken orally once daily
2847292|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 1: 6 to < 36 months|Fluzone Quadrivalent vaccine: pediatric dose containing 7.5 µg/HA of each antigen per 0.25-mL dose. For participants for whom 2 doses of influenza vaccine are recommended, a second dose will be administered on Day 28.
2847293|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 2: 3 to < 9 years|Fluzone Quadrivalent vaccine: 15 µg/HA of each antigen per 0.5-mL dose. For participants for whom 2 doses of influenza vaccine are recommended, a second dose will be administered on Day 28.
2847294|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 3: 18 to < 65 years|Fluzone Quadrivalent vaccine. 15 µg/HA of each antigen per 0.5-mL dose
2847295|NCT03617523|Experimental|Flublok Quadrivalent vaccine Group 4: 18 to < 65 years|Flublok Quadrivalent vaccine. 45 µg/HA of each antigen per 0.5-mL dose
2847296|NCT03617523|Experimental|Fluzone High-Dose vaccine Group 5: ≥ 65 years|Fluzone High-Dose vaccine (subjects ≥ 65 years of age): 60 µg/HA of each antigen per 0.5-mL dose
2847297|NCT03617510|Experimental|group1|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:47.13mg Volume:2.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
2847298|NCT03617510|Experimental|group2|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:94.25mg Volume:4.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
2847299|NCT03617510|Experimental|group3|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:188.50mg Volume:8.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
2847300|NCT03617510|Experimental|group4|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:259.16mg Volume:11.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
2847301|NCT03617497|Active Comparator|Healthy control participants|Age- and gender matched healthy participant (n=30) with no cognitive problems and normal amyloid PET scan will undergo 48 hour scalp EEG and polysomnography
2847302|NCT03617497|Active Comparator|Alzheimer disease|Participants with Alzheimer disease (n=100) will undergo 48 hour scalp EEG and polysomnography
2847303|NCT03617497|Experimental|Alzheimer disease with high seizure risk|Selected participants with Alzheimer disease, with higher risk for silent hippocampal seizures after 48 hour scalp EEG and polysomnography (e.g. presence of interictal spikes or frequent nocturnal awakenings) (n=15) will undergo scalp EEG with foramen ovale electrodes with polysomnography
2847304|NCT03617484|Experimental|Bortezomib + Ibrutinib|"Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.~Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m^2 on days 1, 4, 8, and 11 of each 21-day cycle."
2847305|NCT03617471|Experimental|Paracetamol oral tablets 1g tid|Patients received paracetamol one gram three times daily. Venopuncture for PK profiling
2847306|NCT03617471|Experimental|Paracetamol oral granules 1g tid|Patients received paracetamol one gram three times daily. Venopuncture for PK profiling
2847307|NCT03617458|Active Comparator|Metformin + mHealth Intervention|"Patients will receive active ingredient medicine with mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.~Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po twice a day (BID) x 5 days, 500mg po three times a day (TID) x 5 days,1000mg po BID x 69 days (12 weeks total)."
2847308|NCT03617458|Placebo Comparator|Placebo + Usual Care|Patient will receive non active medicine and routine medical care.
2847309|NCT03617458|Active Comparator|Metformin + Usual Care|"Patient will receive active ingredient medicine with routine medical care.~Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po BID x 5 days, 500mg po TID x 5 days,1000mg po BID x 69 days (12 weeks total)."
2847310|NCT03617458|Placebo Comparator|Placebo + mHealth Intervention|Patient will receive non active medicine and the mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
2847311|NCT03617445|Active Comparator|FMT enema/ oral vancomycin placebo|FMT plus placebo vancomycin
2847312|NCT03617445|Active Comparator|Placebo FMT/ Active oral vancomycin|Vancomycin plus FMT enema placebo
2847313|NCT03617432|Experimental|Experimental group|Experimental group will be treated by Chidamide combined CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
2847314|NCT03617432|Experimental|Control group|Control group will be treated by CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
2848676|NCT03607929|Experimental|optimal and hydration|Physiological Saline Solution 300 ml/h AND drink freely mineral water during labor
2847315|NCT03617419|Other|VScan Access R2 Ultrasound System|"Pre-market: Vscan Access R2 Ultrasound System~The following post-market products will be used on label:~GE Corometrics 170 Series Fetal Monitor - as a reference for value of fetal heart rate GE Voluson P8 Ultrasound System - for verification of fetal location during measurement"
2847316|NCT03617406|Other|Arm Volume Challenge|A standard LDDSE will be performed. The stroke volume (SV) will be recorded. The addition of VC with the passive leg raise method at peak dobutamine dose will be performed. A TEE with low dose dobutamine and a bolus of normal saline will be performed as a validation method.
2847317|NCT03617393||Pulmonary Infection with DM group|Patients with diabetes and pulmonary infection.
2847318|NCT03617393||Pulmonary Infection group|Patients with pulmonary infection while the fasting blood-glucose in the normal range.
2847319|NCT03617393||DM group|Patients without pulmonary infection while the fasting blood-glucose > 8 mmol/L.
2847320|NCT03617393||Control group: normal people|Patients without pulmonary infection while the fasting blood-glucose in the normal range.
2847321|NCT03617380|Experimental|PHARMD-TOC i|PharmD Follow-Up Post Discharge
2847322|NCT03617380|Active Comparator|USUAL CARE|Usual Post Discharge Procedures
2847323|NCT03617367|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
2847324|NCT03617354||Trainee Gynaecologists|"RANZCOG accredited O&G specialists who are proficient in RANZCOG laparoscopic skills level 3 or higher;~Surgical capabilities will be assessed using The Global Operative Assessment of Laparoscopic Skills (GOALS) Tool which is an adapted GOALS tool for hysterectomy. GOALS measures depth perception, bimanual dexterity, efficiency, tissue handling and surgeon autonomy each on a 5 point Likert scale. An experienced mentor will assess each surgeon using this scale and skills will be validated against objective outcomes (surgical adverse events recorded in the baseline period).~Will be able to attend each of the 10 training days."
2847325|NCT03617341||Brain MRI|Regular brain MRI can detect early brain metastases in metastatic Breast cancer with high risk subgroups, such as HER2-positive and triple negative.
2847326|NCT03617328|Experimental|Arm A: 6MHP/Montanide ISA-51 + polyICLC + mCy + CDX-1127|"200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously/intradermally on days 1, 8, 15, 36, 57 and 78. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:~Day -6 (Cycle 1)~Day 8 (Cycle 2)~Day 22 (Cycle 3)~Day 36 (Cycle 4)~Day 50 (Cycle 5)~CDX-1127 (3mg/kg) will be administered intravenously on days -6, 36, and 78."
2847327|NCT03617328|Experimental|Arm B: 6MHP/Montanide ISA-51 + polyICLC + mCy|"200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously/intradermally on days 1, 8, 15, 36, 57 and 78. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:~Day -6 (Cycle 1)~Day 8 (Cycle 2)~Day 22 (Cycle 3)~Day 36 (Cycle 4)~Day 50 (Cycle 5)"
2847328|NCT03617315|Experimental|Hyaluronic Acid|One drop application of Hyaluronic acid + Galact-Xyloglucan with a dosage of 3 times a day for 45 days
2847329|NCT03617315|Experimental|CrossLinked Hyalurnic Acid|One drop application of Crosslinked Hylauronic Acid + Liposomes with a dosage of 3 times a day for 45 days
2847330|NCT03617302|Experimental|Beetroot juice|10-grams of nitrate-containing beetroot concentrate diluted in 120-180 milliliters of water.
2847331|NCT03617302|Placebo Comparator|Placebo Beetroot juice|10 grams of nitrate-depleted beetroot concentrate balanced for anti-oxidant content diluted in 120-180 milliliters of water.
2847332|NCT03617289|Experimental|Treatment|Receiving Magnesium Sulfate
2847333|NCT03617289|Placebo Comparator|Placebo|Receiving D5W
2847334|NCT03617276||Outcome measurement|Each participant will be asked to complete each standardised outcome measure (SOM) three times and each trial will be videotaped by the researcher. The selected SOM's are the modified nine-hole peg test, the four square step test and the modified clinical test of sensory integration and balance. A doctor will watch the video on 2 separate occasions to evaluate intra-rater reliability. Inter-rater reliability will be assessed through asking three other neurofibromatosis specialist professionals (two NF2 consultants and one NF2 specialist nurse) to review the video and to score each measure completed. Once the filmed sessions have been analysed by the relevant clinician's the data will be destroyed in line with Trust policy. Each participant will also be required to complete the INFI-QOL questionnaire, the dynamic visual acuity test and provide information about the number of falls/near misses they have had over the past 12 months
2847335|NCT03617263|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium once daily in the morning before breakfast
2847336|NCT03617263|Placebo Comparator|Placebo|Placebo tablet once daily in the morning before breakfast
2847337|NCT03617250||Active patients|50 rheumatoid patients with active disease according to Disease Activity Score-28
2847338|NCT03617250||patients with remission|50 patients with remission according to Disease Activity Score-28
2847339|NCT03617224|Experimental|TSEBT and pembrolizumab|Dose regimens are sequential therapy of TSEBT with Pembrolizumab.
2847340|NCT03617198|Experimental|Cohort 1|Cohort 1 subjects will begin treatment interruption approximately 24 hours after they receive the modified T-cells. All other study procedures are the same as Cohort 2.
2847341|NCT03617198|Experimental|Cohort 2|Cohort 2 subjects will begin treatment interruption approximately 8 weeks after they receive the modified T-cells. All other study procedures are the same as Cohort 1.
2847342|NCT03617185|Active Comparator|Bariatric Surgery/HIIT|Patients who have undergone bariatric surgery will be randomized to this arm and will follow a high intensity interval training (HIIT) protocol for 24 months. Patients will complete 2 supervised HIIT sessions and 1 unsupervised HIIT session a week.
2847343|NCT03617185|Active Comparator|Bariatric Surgery/Routine Exercise|Patients who have undergone bariatric surgery will be randomized to this arm and will follow a standard routine exercise regimen for 24 months.
2847344|NCT03617185|Active Comparator|No Bariatric Surgery/HIIT|Patients who have not undergone bariatric surgery will be randomized to this arm and will follow a high intensity interval training (HIIT) protocol for 24 months. Patients will complete 2 supervised HIIT sessions and 1 unsupervised HIIT session a week.
2847345|NCT03617185|Active Comparator|No Bariatric Surgery/Routine Exercise|Patients who have not undergone bariatric surgery will be randomized to this arm and will follow a standard routine exercise regimen for 24 months.
2847346|NCT03617172|Experimental|Study Drug (Misoprostol)|
2847347|NCT03617172|Placebo Comparator|Placebo|
2847348|NCT03617146|Experimental|Intervention Arm|"Participants in the intervention arm will receive the following interventions:~Month 1: Diabetes Distress-specific Education.~Months 1 to 3: Six 30 to 45-minute telephone-based health coaching sessions targeting diabetes distress reduction and self-care improvement.~Month 3: Follow up distress-specific education.~Months 4 and 5: Two 30 to 45 minute telephone-based health coaching sessions targeting diabetes distress reduction and self-care improvement."
2847349|NCT03617146|Active Comparator|Control Arm|"Participants in the control arm will receive the following interventions:~Month 1: Diabetes Distress-specific Education (same as for the intervention arm).~Month 3: Follow up distress-specific education (same as for the intervention arm)."
2847350|NCT03617133|Other|Standard arm|General and specific aims of EMBRACEII as well as the multiple quantitative hypotheses are based on technical data, dose volume parameters and clinical results of the prospective observational study EMBRACEI (NCT00920920, 3 year data 2015) and the retrospective RetroEMBRACE (3/5 year data 2015). The performance of EMBRACE II interventions and clinical outcome in terms of disease- (local, nodal, systemic control, OS, CSS) and morbidity-outcome (various organs and endpoints) is thus based on recent clinical evidence with radiochemotherapy and image guided adaptive brachytherapy. The expected effect of EMBRACE II interventions on clinical outcome is estimated from comparative analyses of interventions in subgroups of Retro-/EMBRACE (partly published). Based on the Retro-/EMBRACE benchmark, the estimated outcome including a confidence interval is quantified for each clinical endpoint in the overall cohort as well as different subgroups for an overall expected patient number of 1000.
2847351|NCT03617120|Experimental|Ergonomic Brace vs hard brace|"Ergonomic Brace is a new design of scoliosis brace, which consists of a knit bodice as base and also resin bones, paddings, straps and a pelvic belt as auxiliaries for spinal correction. The purpose of the bones is to keep the posture of patient upright. Paddings are placed at the convex regions of the spine while straps are used to input directional force onto the paddings. Pelvic belt, on the other hand, is for stabilizing the pelvis in order to achieve an effective spinal correction. The biomechanical principles for the correction of spine has considered both the frontal and sagittal planes, where the overall brace mechanism follows the Rigo classification.~Hard brace is the brace which the participants are currently using for their ongoing conservative treatment."
2847352|NCT03617094|Experimental|Early percutaneous vertebroplasty (EPV)|Surgical procedure of percutaneous vertebroplasty.
2847353|NCT03617094|Active Comparator|Standard Conservative treatment (CT)|Thoracolumbar corset.
2847354|NCT03617081|Experimental|NNC0113-2023|Participants will receive increasing doses of NNC0113-2023 on day 1. Each participant will receive only a single dose.
2847355|NCT03617081|Placebo Comparator|Placebo|Participants will receive placebo (NNC0113-2023)
2847356|NCT03617068|Active Comparator|Coconut Oil Cream|This group consist of batik traditional workers who use coconut oil cream for 2 weeks.
2847357|NCT03617068|Placebo Comparator|Placebo Cream|This group consist of batik traditional workers who use placebo cream which contained the vehiculum of the cream; using for 2 weeks.
2847358|NCT03617042|Experimental|Cohort 1|One dose of intravenous dalbavancin infusion 22.5 mg/kg in young infants aged greater than 28 days to 3 months
2847359|NCT03617042|Experimental|Cohort 2|One dose of intravenous dalbavancin infusion 22.5 mg/kg in term neonates (defined as gestational age at or greater than 37 weeks) aged up to 28 days
2847360|NCT03617042|Experimental|Cohort 3|One dose of intravenous dalbavancin infusion 22.5 mg/kg in preterm neonates (defined as gestational age of 32 weeks, up to 37 weeks) aged no more than 28 days
2847361|NCT03617029|Experimental|Microcoil|Needle localization for deep-seated lung nodules with microcoil placement
2847362|NCT03617029|Active Comparator|Contrast|Needle localization for deep-seated lung nodules with contrast injection
2847363|NCT03617016|Experimental|Domperidone|Participants will receive domperidone 10 milligram (mg) tablets orally thrice in a day from Day 1 to Day 14.
2847364|NCT03617016|Placebo Comparator|Placebo|Participants will receive matching placebo corresponding to domperidone orally thrice in a day from Day 1 to Day 14.
2847365|NCT03617003|Experimental|phototherapy with WST11|Patients with urothelial cancer that includes involvement of the upper urinary tract and have failed prior endoscopic treatment, refuse standard treatment, or are ineligible for curative surgical resection of the kidney or ureter will be offered WST11 VTP treatment to be provided at the time of scheduled endoscopic procedure. At the time of endoscopy, patients will be treated with VTP therapy applied to the site of the tumor.
2847366|NCT03616990|Active Comparator|Usual Care (Control)|"Usual care. These individuals will receive linkages to community-based services only. These linkages will be made while in the Discharge Area of the Cook County Jail. Individuals randomized on days Heartland Alliance Health recruits at SRC for non-SRC study are excluded from population.~Receives: TASC Service Linkages - Discharge Area Only"
2847367|NCT03616990|Experimental|Supportive Release Center (Treatment)|"These individuals will receive SRC services: an overnight stay at the SRC, linkages to community-based services made at the SRC or in the discharge area of the CCJ if they choose not to visit the SRC facility, and access to an Advanced Practice Nurse. Individuals randomized on days Heartland Alliance Health recruits at SRC for non-SRC study are excluded from population.~Receives: TASC Service Linkages - Discharge Area Only -OR- SRC Overnight Stay, TASC Services Linkages - SRC Onsite, APN Appointment"
2847368|NCT03616977|Experimental|LY900014 U-200|Single subcutaneous (SC) dose of LY900014 U-200 in two of four study periods.
2847369|NCT03616977|Experimental|LY900014 U-100|Single SC dose of LY900014 U-100 in two of four study periods.
2847370|NCT03616964|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2847371|NCT03616964|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2847372|NCT03616964|Placebo Comparator|Placebo|Placebo administered orally.
2847373|NCT03616938|Experimental|the two finger chest compression technique|Two finger technique (TFT): the pediatric thorax is compressed with the tips of two fingers and is recommended for lone rescuer during infant cardiopulmonary resuscitation by international resuscitation guidelines
2847374|NCT03616938|Experimental|the two thumb chest compression technique|Two thumb technique (TTHT): the two thumbs of the rescuer are placed over the lower third of the sternum, with the fingers encircling the torso and supporting the back. This technique is recommended for two rescuers during infant CPR by international CPR guidelines
2847375|NCT03616938|Experimental|the new two thumb chest compression technique|'new two-thumb technique' (nTTT): this technique consists in using two thumbs directed at the angle of 90° to the chest while closing the fingers of both hands in a fist
2847376|NCT03616925|Experimental|Platelet rich fibrin matrix|surgical open flap debridement with Application of Platelet rich fibrin matrix using Platelet Rich Fibrin Matrix kit in 15 intrabony defect sites
2847377|NCT03616925|Active Comparator|surgical open flap debridement|only surgical open flap debridement was done without application of Platelet rich fibrin matrix in 15 intrabony defect sites
2847378|NCT03616912|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2847379|NCT03616912|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2847380|NCT03616912|Placebo Comparator|Placebo|Placebo administered orally.
2847381|NCT03616899|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
2847382|NCT03616899|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
2847383|NCT03616886|Experimental|Phase I and Phase II Arm A|Patients are treated with paclitaxel, carboplatin, durvalumab and oleclumab.
2847384|NCT03616886|Active Comparator|Phase II Arm B|Patients are treated with paclitaxel, carboplatin and durvalumab.
2847385|NCT03616873||Adults aged 60 or older|
2847386|NCT03616860|Experimental|Focused Ultrasound (FUS) BBB Disruption|The Exablate Model 4000 Type 2.0 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing standard of care chemotherapy.
2847387|NCT03616860|No Intervention|Maintenance chemotherapy|Patients with glioblastoma undergoing standard of care chemotherapy
2847388|NCT03616847|Experimental|Standard care|Participants will have hallux valgus/hallux rigidus surgery using a calf tourniquet which will remain inflated until the wound is closed.
2847389|NCT03616847|Experimental|Tourniquet release|Participants will have hallux valgus/hallux rigidus surgery using a calf tourniquet which will be removed. There will be a five minute delay before the wound is closed.
2847390|NCT03616834|Experimental|eFT508|eFT508 will be taken at 200 mg twice daily (bid). Subjects will continue their anti-PD-1/anti-PD-L1 therapy, which they had already initiated per standard of care according to the package insert.
2847391|NCT03616821|Experimental|Brazikumab Dose 1|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning at day 71
2847392|NCT03616821|Experimental|Brazikumab Dose 2|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning at day 71.
2847393|NCT03616821|Experimental|Brazikumab Dose 3|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning at day 71.
2847394|NCT03616821|Active Comparator|Vedolizumab|Intravenous vedolizumab on day 1, day 15, and day 43 followed by IV vedolizumab every 8 weeks beginning at day 99.
2847395|NCT03616821|Placebo Comparator|Placebo|Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous every 4 weeks beginning at day 71.
2847396|NCT03616808|No Intervention|Conventional therapy|Intraoperative haemostatic treatment is based on conventional coagulation assays.
2847397|NCT03616808|Active Comparator|Goal-directed therapy|Thromboelastometry-guided haemostatic treatment is provided intraoperatively.
2847398|NCT03616795|Experimental|LY3154207 and [14C]-LY3154207|A single dose of LY3154207 and [14C]-LY3154207administered orally.
2847399|NCT03616782|Experimental|Ixazomib|Ixazomib 3mg on day a, 8, 15 q 4 weeks for 24 months or until to progression
2847400|NCT03616769||quantiles of serum uric acid level|quantiles according to the patient's serum uric acid level
2847401|NCT03616756|Experimental|Intervention group|
2847402|NCT03616756|Active Comparator|Control group|
2847403|NCT03616743|Experimental|Brief pain and smoking arm|The experimental arm incorporated a novel psychoeducational component that addressed associations between cigarette smoking and chronic pain
2847404|NCT03616743|Active Comparator|Brief smoking control arm|"The brief smoking control arm was comprised of the 5A's of smoking cessation."
2847405|NCT03616730||Heart Disease in pregnancy group|Fifty women will be recruited with structurally and functionally abnormal hearts without a history of chronic hypertension, pre-gestational diabetes, multiple gestations, preeclampsia, autoimmune disease, and anyone with a history of cardiomyopathy but currently normal ejection fraction. Women who are unable to give informed consent will not be included.
2847406|NCT03616730||Control Group|Fifty women will be recruited with structurally normal hearts without a history of chronic hypertension, pre-gestational diabetes, multiple gestations, preeclampsia, autoimmune disease, and anyone with a history of cardiomyopathy but currently normal ejection fraction. Any woman on cardiac or antihypertensive medications (beta blockers, calcium channel blockers, hydralazine) will be excluded. Women who are unable to give informed consent will not be included.
2847407|NCT03616717|Active Comparator|dextroamphetamine 10 mg|"Drug: Dexedrine, dextroamphetamine, d-amphetamine.~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
2847408|NCT03616717|Active Comparator|dextroamphetamine 20 mg|"Drug: Dexedrine, dextroamphetamine, d-amphetamine.~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
2847409|NCT03616717|Placebo Comparator|placebo|"Drug: Dexedrine, dextroamphetamine, d-amphetamine~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
2847410|NCT03616691|Experimental|Atezolizumab|The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)
2847411|NCT03616691|Experimental|Atezolimab+Bevacizumab|Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy (stage 2). Both of drugs are administered via intravenous infusion every 3 weeks.
2847412|NCT03616678|Experimental|VenTouch System Implant|"The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is indicated for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable to annular and/or ventricular dilation. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is intended to provide ventricular support that will encourage beneficial remodeling of the heart and, with adjustable inflatable chambers, it is intended to reduce annular dilation, correct papillary muscle displacement, and restore mitral valve leaflet coaptation, allowing proper closure of the valve, and reducing or eliminating MR. The VenTouch System is indicated for patients who have moderately severe or severe mitral regurgitation (grade 3 or 4 MR)."
2847413|NCT03616665|Experimental|CBASPersonalized|Within the psychotherapy CBASPersonalized, the original specific six interpersonal CBASP strategies are augmented with intrapersonal evidence-based strategies. According to the frequently diagnosed comorbid disorders of PDD the following modules have been added: a) treatment of anxiety disorders and treatment of traumatic experiences, b) regulating intensive emotions, c) coping with resistant problems like pain, and d) relapse prevention. In addition, therapists adjust their strategies and therapeutic relationship according to the impairment in personality functioning and maladaptive personality traits of the patient.
2847414|NCT03616665|No Intervention|Waiting List Control (WLC)|Patients being randomized to the waiting list control (WLC) group have to wait six weeks before start of inpatient treatment. During this waiting period, the study-patients could continue their current treatments (naturalistic waiting period) which will be monitored.
2847415|NCT03616665|Active Comparator|CBIntegrative|Patients assigned to this group receive the established and evidence-based psychotherapy cognitive behavioral therapy (CBT) whereas strategies of Acceptance and Commitment Therapy (ACT) are integrated. Basic CBT techniques will be applied in this group (e.g. psychoeducation, behavior analyses, behavioral activation, cognitive strategies, exposure sessions). Further, therapists are allowed to apply social competence training and euthymic techniques, self-management, relaxation techniques, and biofeedback. In addition, techniques from ACT will be integrated. Therapists are explicitly instructed not to use the original six interpersonal CBASP techniques or methods from schema therapy.
2847416|NCT03616652|Experimental|Non-deceptive placebo group (additional information)|Participants receive a placebo pill and are told that it is placebo. They receive additional information about the power of placebo effects via a film sequence before they take the placebo.
2847417|NCT03616652|Placebo Comparator|Non-deceptive placebo group (no additional information)|Participants receive a placebo pill and are told that it is placebo. They do not receive additional information about placebo effects. Instead, they watch a neutral film sequence about sleep.
2847418|NCT03616639|Experimental|Oxycodone|Continuous subcutaneous infusion (CSCI) of oxycodone.
2847419|NCT03616639|Active Comparator|Morphine|Continuous subcutaneous infusion (CSCI) of morphine.
2847420|NCT03616626|Active Comparator|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
2847421|NCT03616626|Experimental|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
2847422|NCT03616626|Experimental|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
2847423|NCT03616613||Men|Men born in 1952 in Barcelona in health areas depending from Hospital de la Santa Creu i Sant Pau.
2847424|NCT03616613||Women|Aleatory sample of women born in 1952 in Barcelona in health areas depending from Hospital de la Santa Creu i Sant Pau.
2847425|NCT03616600|Experimental|Treatment|Wearing the orthokeratology lenses for 3 months
2847426|NCT03616600|No Intervention|Control|Not wearing any contact lenses
2847427|NCT03616587|Experimental|AZD9833 monotherapy dose escalation|
2847428|NCT03616587|Experimental|AZD9833 monotherapy dose expansion|
2847429|NCT03616587|Experimental|AZD9833 with palbociclib dose escalation|
2847430|NCT03616587|Experimental|AZD9833 with palbociclib dose expansion|
2847431|NCT03616574|Experimental|Dose Escalation - CA102N Monotherapy|0.36, 0.54, and 0.72 mg/kg of nimesulide equivalents of CA102N on Days 1 and 15 of a 28-day cycle
2847432|NCT03616574|Experimental|Dose Escalation - CA102N plus LONSURF|0.36, 0.54, and 0.72 mg/kg of nimesulide equivalents of CA102N on Days 1 and 15 in combination with 35 mg/m2/dose of LONSURF orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle
2847433|NCT03616574|Experimental|Dose Expansion - CA102N plus LONSURF|The preliminary RP2D of CA102N on Days 1 and 15 in combination with 35 mg/m2/dose of LONSURF orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle
2847434|NCT03616561||ultrasound|The cohort will be recruited in Hospital General de Granollers and Hospital Moises Broggi
2847435|NCT03616548|Other|Intestinal transplantation|Magnifying endoscopy under NBI system via chimney ileostomy after intestinal transplantation using a novel VENCH scoring system
2847436|NCT03616535|Active Comparator|Cognitive training|"Participants randomized to CT will play brain games on a tablet. They will be asked to engage in the activity for a minimum of 30 minutes during each hemodialysis session for 6 months. At each HD session, participants will have 10 different brain games to play and the games will vary for each session."
2847437|NCT03616535|Active Comparator|Exercise training|"Participants randomized to the ET arm will be given a stationary foot peddler and will be asked to engage in the activity for a minimum of 30 minutes at each hemodialysis session for 6 months. ET will start with a 2 minute warm up, then the resistance will be adjusted so that participants are working at perceived exertion of somewhat strong, using the Borg scale (87) (~50 rpm). Resistance will be increased when the rating falls below somewhat hard."
2847438|NCT03616535|Active Comparator|Combined cognitive and exercise training|"Participants in the CT+ET arm will start with 30 minutes of CT (playing brain games on tablet) with a 15-minute break, and then, 30 minutes of ET (stationary foot peddler)."
2847439|NCT03616535|No Intervention|Standard of Care|Participants in this arm will receive standard of care
2847440|NCT03616509|Experimental|Placebo and Growth Hormone|2 months on placebo followed by 12 months on GH
2847441|NCT03616496|Experimental|ATTR amyloidosis patients|Intervention by this arm: PET with injection of Neuraceq 300MBq/ml, blood and urine sampling for protein electrophoresis, bone scintigraphy
2847442|NCT03616496|Experimental|AL amyloidosis patients|Intervention by this arm: PET with injection of Neuraceq 300MBq/ml, blood and urine sampling for protein electrophoresis, bone scintigraphy
2847443|NCT03616496|Active Comparator|control subjects|"Intervention by this arm: PET with injection of Neuraceq 300MBq/ml, blood and urine sampling for protein electrophoresis, bone scintigraphy.~Control subjects are patients with left ventricular hypertrophy"
2847444|NCT03616470|Experimental|Uproleselan (GMI-1271)|Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)
2847445|NCT03616470|Placebo Comparator|Placebo (Saline, 0.9% Sodium Chloride)|Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)
2847446|NCT03616457||All Study Participants|All study participants will undergo the same study procedures, including Automated Breast Ultrasound (ABUS).
2847447|NCT03616444|Experimental|TCM—Xiaoai Jiedu Decoction|Xiaoai Jiedu Decoction：Oldenlandia 20g,kuh-seng 9g,Codonopsis pilosula 15g,bighead atractylodes rhizome 12g,smoked plum 9g,the rhizome of Chinese goldthread 3g,RHIZOMA ZINGIBERIS PREPARATA 6g,Semen Coicis 20g. Take one pack a day, divided into twice one day, 28 days for each course of treatment, 2 days rest, followed by the second course of treatment, 3 consecutive courses of treatment in every year， last two years.
2847448|NCT03616444|Placebo Comparator|TCM—Xiaoai Jiedu Decoction Placebo|The control group took placebo twice a day, 28 days for each course of treatment, 2 days rest, followed by the second course of treatment, 3 consecutive courses of treatment in every year，last two years.
2847449|NCT03616431||Demographic cohort|A prospective cross-sectional assessment of the prevalence of PEI-related symptoms in up to n=150 patients with pancreatic malignancy.
2847450|NCT03616431||Diagnosis cohort|"A sub-set (up to n=50) of the Demographic cohort patients will be tested to elucidate the most efficient diagnostic panel for PEI in pancreatic malignancy.~An extra assessment for PEI diagnosis consisting of a breath test (Pancreo-KIT breath test) will be carried out during the following 1-2 weeks after the first appointment (which takes around six hours to complete and involves the administration of bread spread with 13C butter followed by collection of the patient's breath in small plastic vials at timed intervals. The vials will subsequently be analyzed for 13C quantity; details in Appendix 6). Following these diagnostic tests, patients will complete an acceptability questionnaire to assess their opinion regarding the burden that these diagnostic tests may add."
2847451|NCT03616431||Follow-up cohort|Validation of the diagnostic panel designed and tested in Step-1 of this study and evaluation of dietician intervention (including Pancreatic Enzyme Replacement Therapy; PERT) and its impact in weight loss, symptom evolution, chemotherapy receiving rate, quality of life and overall survival.
2847452|NCT03616405|Experimental|14-day modified sequential therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment.~Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.~Drugs: 1. esomeprazole 40mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the firs 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
2847453|NCT03616392|Experimental|Part 1: Group 1(Treatment A/Treatment B)|Period 1: Treatment A (D308 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO
2847454|NCT03616392|Experimental|Part 1: Group 2(Treatment B/Treatment A)|Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment A (D308 1T)/day for 5days, QD, PO
2847455|NCT03616392|Experimental|Part 2: Group 1(Treatment C/Treatment B)|Period 1: Treatment C (CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO
2847456|NCT03616392|Experimental|Part 2: Group 2(Treatment B/Treatment C)|Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment C (CKD-501 1T)/day for 5days, QD, PO
2847457|NCT03616379|Placebo Comparator|Psychoeducational Control|
2847458|NCT03616379|Experimental|Affect Regulation Condition|
2847459|NCT03616379|Experimental|Affect Labelling Condition|
2847460|NCT03616353|Experimental|Group 1: Corticosteroid Injection|Patients in this group will undergo an injection of corticosteroid into the carpal tunnel as per current treatment practices.
2847461|NCT03616353|Experimental|Group 2: Perineural Hydrodissection|Patients in this group will undergo a perineural hydrodissection plus an injection of corticosteroid into the carpal tunnel, as a novel technique.
2847462|NCT03616340|Experimental|Ketorolac|
2847463|NCT03616340|Experimental|Kenalog|
2847464|NCT03616327|Other|MATRx in-lab or MATRx plus test|Participants will undergo the MATRx in-lab or MATRx plus home test to determine adequacy for mandibular repositioning oral appliance therapy. The tests only differ in their setting (i.e., in the sleep lab or at home). All participants will receive the same treatment protocol preceding and following the MATRx/MATRx plus test.
2847465|NCT03616314||stepping verticalization|in ICU they received conventional physiotherapy + stepping verticalization sessions with Erigo
2847468|NCT03616301|Experimental|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml is the test product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) will be given single oral dose (5 ml containing 400 mg of amoxicillin and 57 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
2847469|NCT03616301|Active Comparator|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml is the reference product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) will be given single oral dose (5 ml containing 400 mg of amoxicillin and 57 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
2847470|NCT03616288|Placebo Comparator|Negative Control|placebo; 0 mg thiamine
2847471|NCT03616288|Experimental|EAR Group|1.2 mg thiamine as thiamine hydrochloride
2847472|NCT03616288|Experimental|Double EAR Group|2.4 mg thiamine as thiamine hydrochloride
2847473|NCT03616288|Experimental|Positive Control|10 mg thiamine as thiamine hydrochloride
2847474|NCT03616275|Experimental|HRV biofeedback group|8 once-a-week, individual, 30-min sessions of HRV biofeedback and 1 session of healthy lifestyle education
2847475|NCT03616275|No Intervention|control group|1 session of healthy lifestyle education
2847476|NCT03616262|Active Comparator|Phase 1|In Phase 1, subjects will receive either Treatment A (Lidocaine alone) or Treatment B (Botox+Lidocaine )
2847477|NCT03616262|Active Comparator|Phase 2|In Phase 2, subjects will receive either Treatment B (Botox+Lidocaine) or Treatment A (Lidocaine alone) -- the opposite of what was administered in Phase 1
2847478|NCT03616249|Experimental|Sleep quality|To compare if elderly sartcopics present sleep losses at higher levels than non-sarcopenic elderly
2847479|NCT03616249|Experimental|sleep-wake cycle.|To compare if elderly sarcopenics present sleep-wake cycle. disorders at higher levels than non-sarcopenic elderly
2847480|NCT03616249|Active Comparator|Exercise And Sleep quality|Comparing resistance training in the sarcopenician elderly showed improvements in sleep patterns.
2847481|NCT03616249|Active Comparator|Exercise And sleep-wake cycle.|Comparing resistance training in the elderly with sarcopenia presents better sleep-wake cycle.
2847482|NCT03616236|Active Comparator|TAU|Participants will receive a referral to buprenorphine treatment in the community.
2847483|NCT03616236|Experimental|BBT|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
2847484|NCT03616223|Experimental|FX-322 Low Dose|Single intratympanic injection of a hydrogel formulation
2847485|NCT03616223|Experimental|FX-322 High Dose|Single intratympanic injection of a hydrogel formulation
2847486|NCT03616223|Placebo Comparator|Placebo|Single intratympanic injection of a hydrogel formulation
2847487|NCT03616210|Experimental|Protective ventilation|Protective ventilation strategy (tidal volume of 6 to 7 ml.kg-1 of predicted body weight and PEEP of 6 to 8 cmH2O)
2847488|NCT03616210|No Intervention|Conventional ventilation|Conventional mechanical ventilation (tidal volume between 9 to 10 ml.kg-1 of predicted body weight and PEEP between 3 and 5 cmH2O)
2847489|NCT03616197|Active Comparator|Group 1|"Thin Biotype group has described as Group 1. The biotypes of the terminal teeth adjacent to the free gingival graft region were determined by the Probe transparency method.~The mesial terminal tooth (MTT) was defined as the first tooth adjacent to the mesial side of the tooth / teeth to which the FGG will be applied. The distal terminal tooth (DTT) was defined as the first tooth adjacent to the distal side of the tooth / teeth to which the FGG will be applied. If MTT and DTT had thin biotype, the patient was assigned to the thin biotype group."
2847490|NCT03616197|Active Comparator|Group 2|"Thick biotype group has described as Group 2. The biotypes of the terminal teeth adjacent to the free gingival graft region were determined by the Probe transparency method.~The mesial terminal tooth (MTT) was defined as the first tooth adjacent to the mesial side of the tooth / teeth to which the FGG will be applied. The distal terminal tooth (DTT) was defined as the first tooth adjacent to the distal side of the tooth / teeth to which the FGG will be applied. If MTT and DTT had thick biotype, the patient was assigned to the thick biotype group."
2847491|NCT03616184|Experimental|Ruxolitinib|Patients will receive oral ruxolitinib at a dose of 10 mg twice daily.
2847492|NCT03616171|Experimental|Interventional Group|"Intervention Group (SLEEP-Extend intervention): The SLEEP-Extend intervention consists of two components:~One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep (an investigator-developed brochure and information based on recommendations from the American Academy of Sleep Medicine and the National Sleep Foundation will be given and reviewed with the subject)~Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later (subject will decide what works best for them)."
2847493|NCT03616171|Other|Control Group|Control group: consists of One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
2847494|NCT03616158||Pre-RA|"Subjects with interstitial lung disease (ILD) or airways disease, no rheumatoid arthritis (RA), and positive antibodies will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
2847495|NCT03616158||RA without LD|"Subjects with rheumatoid arthritis (RA), and no interstitial lung disease (ILD) or airways disease, will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
2854535|NCT03566719|No Intervention|Control group|
2847496|NCT03616158||RA-LD|"Subjects with rheumatoid arthritis (RA) and interstitial lung disease (ILD) or airways disease, will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
2847497|NCT03616158||LD Controls|"Subjects with interstitial lung disease (ILD) or airways disease, no rheumatoid arthritis (RA), and negative antibodies will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
2847498|NCT03616145|Experimental|Osteopathic Manipulative Treatment (OMT)|Participants assigned to the OMT arm will receive 6 weekly sessions. The provider will perform the following 14 osteopathic procedures 1) lateral (and anteroposterior) translation of vertebrae in the thoracic/lumbar spine; 2) active myofascial stretch to the thoracic spine; 3) occipito-atlanto release; 4) translation of cervical spine; 5) muscle energy techniques of the cervical spine; 6) Spencer technique applied to the shoulder bilaterally; 7) supination/pronation of the forearm; 8) circumduction of the wrist; 9) sacroiliac joint gapping; 10) muscle energy technique applied to adductor muscles of lower extremity; 11) psoas muscle energy technique; 12) hamstring muscle energy technique; 13) articulatory technique applied to the ankle; 14) and muscle energy technique applied to the ankle in dorsi and plantar flexion. Further, each subject will receive cranial assessment and treatment emphasizing the venous sinus techniques and compression of the fourth ventricle (CV-4).
2847499|NCT03616145|Sham Comparator|Light Touch|Participants assigned to the light touch comparator arm will receive 30 minutes of light touch procedures designed to be credible but minimally effective. The procedures for the light touch arm are adapted from the methodology established in the North Texas Chronic Low Back Pain Trial, and have been used successfully by the PI as a comparator arm numerous times in the past (e.g., in the OSTEPAThic Trial). Subjects assigned to receive light touch will be treated in positions similar to subjects receiving OMT. Light touch will target each of the 15+ anatomic regions for approximately 1 ½ to 2 minutes each to appropriately control for time, attention, and physical contact. Light touch hand placement will be over the same areas of the body contacted in the OMT protocol, but involve virtually no motion of a meaningful nature, such a range of motion testing which could have therapeutic effect.
2847500|NCT03616145|No Intervention|Standard of Care Only|Subjects will continue their usual care and will visit the UCSD for the 4 assessment sessions only, during their course of study participation.
2847501|NCT03616132|Experimental|IBS implantation|Implantation of IBS in patients with coronary artery lesions.
2847502|NCT03616106|Experimental|Intervention Group|Participants in the intervention group will receive health education using infographics (Infographic Intervention) during their regularly scheduled clinic visits.
2847503|NCT03616093|Experimental|Test Beet shot|Active supplement containing 6.2 mmol nitrate
2847504|NCT03616093|Placebo Comparator|Placebo beverage|Placebo supplement containing negligible nitrate
2847505|NCT03616080|Experimental|experimental|children who participated in soccer play program usual activity and therapy + soccer play program (once a week for eight weeks)
2847506|NCT03616080|No Intervention|control|children without soccer paly program usual activity and therapy
2847507|NCT03616067|Experimental|Botox® injection arm|Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars).
2847508|NCT03616067|Active Comparator|Scopoderm® patches arm|Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear
2847509|NCT03616041||Colon capsule endoscopy|Participant who meet the eligible criteria undergo an evaluation for severe hematochezia with a second-generation colon capsule endoscopy system in addition to standard diagnostic tests including tagged RBC scan, and/or computerized tomographic angiography (CTA), and/or conventional angiography.
2847510|NCT03616028|Experimental|Non-valvular AF adults|Left atrial appendage closure (LAAC) with the CLAAS device will be performed according to the device Instructions for Use, based on TEE, ICE and angiographic guidance, femoral venous access and inter-atrial septum crossing.
2847511|NCT03616015|Experimental|Patient|"For all patients included in the study, the following interventions will be performed :~several blood samples (quantity collected requiring classification of this study as interventional according to French law)~several fecal samples~anxiety tests~stress tests"
2847512|NCT03616002|Experimental|Hookah smoking|Healthy habitual Hookah smokers will undergo brachial artery flow mediated dilation, reactive hyperemia peripheral arterial tonometry or pulse tonometry before and after Hookah smoking.
2847513|NCT03615989|Placebo Comparator|Exercise and Carbohydrate (CHO)|Participants will have a fasted, baseline blood sample (10ml) taken upon arrival to the lab. They will then complete a supervised resistance and plyometric exercise bout. Immediately following exercise, 51g of carbohydrate (maltodextrin) + water will be consumed. Two more blood samples will follow the exercise bout at 5 minutes post (10ml) and 1 hour post (10ml). An additional 51g of carbohydrate will be consumed with water 1 hour post exercise. Two more fasting blood samples (10ml) will be taken 24 and 48 hours later.
2847514|NCT03615989|Experimental|Exercise and Milk (Milk)|Participants will have a fasted, baseline blood sample (10ml) taken upon arrival to the lab. They will then complete a supervised resistance and plyometric exercise bout. Immediately following exercise, 555 ml of skim milk will be consumed. Two more blood samples will follow the exercise bout at 5 minutes post (10ml) and 1 hour post (10ml). An additional 555 ml of skim milk will be consumed 1 hour post exercise. Two more fasting blood samples (10ml) will be taken 24 and 48 hours later.
2847551|NCT03615755|Active Comparator|Combination Therapy|Standard Therapy with adjuvant Hyperbaric Oxygen Therapy (Total 10 sessions, each session used pressure 2.4 ATA for 90 minutes per day)
2847756|NCT03614468|Active Comparator|Formula B|A Commercially available Infant Formula, for healthy term infants 0 to 6 months of age (Enfamil TM, Milk-Based Powder with Iron)
2847515|NCT03615989|Experimental|Exercise, Milk and Creatine (Cre)|Participants will complete a 6-day creatine loading phase (5 grams x 4 times/day) before they come in for the exercise bout. Participants will have a fasted, baseline blood sample (10ml) taken upon arrival to the lab. Before the exercise bout, 5 grams of creatine will be taken. They will then complete a supervised resistance and plyometric exercise bout. Immediately following exercise, 555 ml of skim milk + 5g of creatine will be consumed. Two more blood samples will follow the exercise bout at 5 minutes post (10ml) and 1 hour post (10ml). An additional 555ml of skim milk will be consumed 1 hour post exercise without creatine. 5g of creatine will then be consumed with the participant's last meal of the day. Two more fasting blood samples (10ml) will be taken 24 and 48 hours later. On the day after exercise, participants will consume a 5g maintenance dose of creatine with their last meal of the day (between the 24 and 48h blood sample).
2847516|NCT03615976|Experimental|pre operative group|pre operative group with patellofemoral pain resistant to medical and physiotherapy assessment by pre operative knee score arthroscopic circumpatellar denervation with or without lat. Patellar facetectomy
2847517|NCT03615963||normal|patient complains of anginal chest pain but coronary angiography is normal
2847518|NCT03615963||coronary artery disease|patient complains of chest pain with coronary angiography showing atherosclerotic plaques causing luminal obstruction
2847519|NCT03615950||Intervention Group|30 Children with eosinophilic esophagitis who are started on swallowed corticosteroids by their clinical provider.
2847520|NCT03615950||Control Group|30 children, 5-12 years of age, not taking swallowed corticosteroids. Age and sex matched 1:1 with intervention group.
2847521|NCT03615937|Experimental|Comprehensive Intervention|"This is a holistic package of interventions, including:~Child interactive intervention (dialogic reading and play intervention)~Family Empowerment (positive parenting and grandparenting)~Access to Community Hub and its services~Enhancement to the kindergartens~Health education, screening, and support"
2847522|NCT03615937|Active Comparator|Health Support|"This is a control arm with only health components.~1. Health education, screening, and support"
2847523|NCT03615924|Experimental|Ticagrelor|"The double-blinded study drug dose will be weight dependent:~≥12 to ≤24kg: Ticagrelor 15 mg, twice a day~>24 to ≤48 kg: Ticagrelor 30 mg, twice a day~>48 kg: Ticagrelor 45 mg, twice a day."
2847524|NCT03615924|Placebo Comparator|Placebo|"The double-blinded study drug dose will be weight dependent:~≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~>48 kg: Placebo to match ticagrelor 45 mg, twice a day."
2847525|NCT03615911|Experimental|Vaccination with 10^7 PFU MVA-MERS-S|Vaccinations occur on days 0 and 28
2847526|NCT03615911|Experimental|Vaccination with 10^8 PFU MVA-MERS-S|Vaccinations occur on days 0 and 28
2847527|NCT03615885|Placebo Comparator|Placebo Drink|Placebo drink attempted to match for total energy, appearance and taste of Montmorency tart cherry juice.
2847528|NCT03615885|Experimental|Montmorency Tart Cherry Capsules|10 capsules consumed to match total anthocyanin content to Montmorency tart cherry juice.
2847529|NCT03615885|Experimental|Montmorency Tart Cherry Juice|Single-bolus of Montmorency tart cherry juice (130 mL)
2847530|NCT03615859||Healthy volunteers|Healthy volunteers whose data represents a negative control
2847531|NCT03615859||Prednisolone replacement group|Participants with adrenal insufficiency who are treated with replacement doses of prednisolone
2847532|NCT03615859||Hydrocortisone replacement group|Participants with adrenal insufficiency who are treated with replacement doses of hydrocortisone
2847533|NCT03615859||New adrenal insufficiency group|Participants who have recently been given a new diagnosis of adrenal insufficiency
2847534|NCT03615859||High dose steroids groups|Participants who are treated with high dose steroids for management of any medical condition to serve as a positive control
2847535|NCT03615846||All Patients|"Whole blood from patients who are currently receiving Dual Anti-Platelet Therapy (DAPT) Clopidogrel and aspirin (ASA) or receiving either ASA or Clopidogrel alone for a minimum of 4 weeks (on-drug) will be used to conduct antiplatelet reactivity tests using VerifyNow assay and LTA with AggRAM Aggregometer with and without PGE1.~There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care."
2847536|NCT03615833|Experimental|Patients with Vitamin D deficency|Patients with Vitamin D deficency, Administration of Cholecalciferol 2.5 mg (100 000 UI), once a month for 3 months
2847537|NCT03615820|Experimental|Niosomal PPE oromucoadhesive film|Niosomal PPE oromucoadhesive film in which PPE entrapped in niosomes then incorporated in oromucoadhesive films
2847538|NCT03615820|Placebo Comparator|Oromucoadhesive film|Oromucoadhesive film that has no niosomal PPE in its content
2847539|NCT03615807|Experimental|Short antibiotic arm|10 days for soft tissue infections 3 weeks for osteomyelitis
2847540|NCT03615807|Active Comparator|Standard antibiotic arm|20 days for soft tissue infections 6 weeks for osteomyelitis
2847541|NCT03615794||Pregnant women with Mood Disorders|Pregnant women with a history or current diagnosis of Major Depressive Disorder or Bipolar Disorder
2847542|NCT03615794||Healthy controls|Pregnant women without a history or current diagnosis of a mood disorder.
2847543|NCT03615781|Experimental|Two week's arm - surgery|The investigators perform a surgical drainage and removal of the infected orthopedic implant.
2847544|NCT03615781|Active Comparator|Four week's arm - surgery|The investigators surgically remove the infected implant.
2847545|NCT03615781|Experimental|Two week's arm - drugs|The investigators perform a surgical drainage and removal of the infected orthopedic implant. They start an empirical antibiotic treatment based on patient's history and co-morbidities, such as vancomycin or amoxicillin/clavulanic acid. The adapt later on the targeted antibiotic therapy according to the causative pathogens and their antibiotic susceptibility testing.
2847546|NCT03615781|Active Comparator|Four week's arm - drugs|The investigators surgically remove the infected implant and all soft tissue infection. Instead of a total of 2 week's of antibiotic therapy, they administer a total of 4 weeks of systemic antibiotic therapy targeted to the pathogen(s).
2847547|NCT03615768|Experimental|Adapalene-Clindamycin Combination Gel|
2847548|NCT03615768|Active Comparator|Adapalene Gel|
2847549|NCT03615768|Active Comparator|Clindamycin Gel|
2847550|NCT03615755|No Intervention|Standard Therapy|Standard Therapy (controlling blood sugar, antibiotic drug, ulcer debridement, wound care, offloading)
2847552|NCT03615742|Placebo Comparator|Placebo and Filtered Air|Volunteers will use an inhaler that does not contain any medication, before sitting in a booth and being exposed to high-efficiency particulate air (HEPA) filtered air for 2 hours.
2847553|NCT03615742|Active Comparator|Budesonide and Filtered Air|Volunteers will inhale 1.6mg of budesonide before sitting in a booth and being exposed to HEPA filtered air for 2 hours.
2847554|NCT03615742|Active Comparator|Placebo and Diesel Exhaust|Volunteers will use an inhaler that does not contain any medication, before sitting in a booth and being exposed to 300µg/m³ concentration of diesel exhaust for 2 hours.
2847555|NCT03615742|Experimental|Budesonide and Diesel Exhaust|Volunteers will inhale 1.6mg of budesonide before sitting in a booth and being exposed to 300µg/m³ concentration of diesel exhaust for 2 hours.
2847556|NCT03615729||Rheumatoid arthritis patients|A total of 55 rheumatoid arthritis patients diagnosed according to 2010 ACR / EULAR Rheumatoid Arthritis Classification Criteria recruited from Clinical Rheumatology unit, Internal Medicine, Assiut University Hospitals
2847557|NCT03615729||controls|A total of 33 age and sex matched healthy controls randomly selected from healthy volunteers
2847558|NCT03615716|Experimental|Multi-level Violence Prevention Intervention - Boys|A study examining middle school boys who have a high potential of violence based on where they live. This arm will measure outcomes in the boys. as the result of the intervention, from the perspectives of the boys.
2847559|NCT03615716|Experimental|Multi-level Violence Prevention Intervention - Caregivers|In this study examining middle school boys who have a high potential of violence based on where they live, this arm will measure caregivers' perspectives of the boys ' outcomes. Caregivers will be surveyed pre-intervention and 4- and 6-month post intervention to explore the impact of the boys' intervention.
2847560|NCT03615690|Experimental|Fasting Mimicking Diet|Either one cycle of 5 day of reduced calorie diet over one month, or optional three cycles of reduced calorie diet over three months.
2847561|NCT03615677|Experimental|LXI-15028 50mg group (n=130)|
2847562|NCT03615677|Active Comparator|Esomeprazole 40mg group (n=130)|
2847563|NCT03615664|Experimental|BGD therapy|Bendamustine, Gemcitabine, Dexamethasone
2847564|NCT03615651|Placebo Comparator|Placebo|All study participants will receive the study product and the placebo in a randomized, double-blind crossover fashion. Probiotic and placebo products have similar appearance and taste.
2847565|NCT03615651|Experimental|Probiotic|All study participants will receive the study product and the placebo in a randomized, double-blind crossover fashion. Probiotic and placebo products have similar appearance and taste.
2847566|NCT03615638|Experimental|Fall prevention group|Fall prevention program
2847567|NCT03615638|No Intervention|Usual care group|Usual postoperative care
2847568|NCT03615638|No Intervention|Asymptomatic control|No intervention
2847569|NCT03615625|No Intervention|Control session|Control session without any exercise. The participants remain in seated rest throughout 40 min
2847570|NCT03615625|Experimental|Power Training Session|The power training session will last 40 min, in which the participants will perform a resistance exercise session using high velocity contractions during the exercises characterizing a power training session
2847571|NCT03615612|Other|OR Eyeglasses, then SR|Objective Refraction (OR) Eyeglasses, then Subjective Refraction (SR)
2847572|NCT03615612|Other|SR Eyeglasses, then OR|Subjective Refraction (SR) Eyeglasses, then Objective Refraction (OR)
2847573|NCT03615599||Seventh-day Adventists|This is a prospective cohort study of 96,000 members of the Seventh-day Adventists Church in the United States and Canada age 30 and older at the time of enrollment who are proficient in English language.
2847574|NCT03615586|Active Comparator|With Chaperone|Female patients examined by male physicians in the presence of a female (nurse) chaperone. The intervention consists of the presence of a female chaperone.
2847575|NCT03615586|Active Comparator|Without Chaperone|Female patients examined by male physicians without a chaperone. The intervention is the absence of a female chaperone.
2847576|NCT03615560||Preeclampsia (mild)|
2847577|NCT03615560||Preeclampsia (severe)|
2847578|NCT03615560||Gestational hypertension|
2847579|NCT03615560||Control group|
2847580|NCT03615547|Experimental|Clomifene citrate group|a daily dose of 50mg of Clomifene Citrate per os during 9 months
2847581|NCT03615547|Experimental|Placebo group|a daily dose of 50mg per os of placebo (lactose monohydrate) during 9 months.
2847582|NCT03615534|Placebo Comparator|Placebo|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch daily single placebo capsule for eight weeks.
2847583|NCT03615534|Active Comparator|Fenofibrate Monotherapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate (Lipanthyl® 200 mg micronized fenofibrate capsule, Abbott Laboratories Fournier) for eight weeks.
2847584|NCT03615534|Active Comparator|WMER Niacin Monotherapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive a night-time 500 mg daily single dose of Wax Matrix Extended Release Niacin (WMER Niacin, ENDUR-ACIN®500mg, Endurance Products Company, Oregon USA) for one week, titrated up to 1000 mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
2847585|NCT03615534|Active Comparator|Combination Therapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate for eight weeks, in combination with a night-time 500 mg daily single dose of WMER Niacin for one week, titrated up to 1000mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
2847586|NCT03615521|Experimental|Repeated Contraction Exercise Group|Repeated Contractions Exercise Group, Hotpack apply for knee 20 minute, Ultrasound is a termal ajan which use for 10 minute and Repeated Stretch (Repeated Contractions) exercise. Repeated Contractions exercise is type of Proprioceptive Neuromusculer Facilititation Exercise. 3 session for 6 weeks.
2847587|NCT03615521|Experimental|Combine Exercise Group|"Combination of Isotonics Exercise Group, Hotpack apply for knee 20 minute, Ultrasound is a termal ajan which use for 10 minute Combination of Isotonics Exercise. Combination of Isotonics Exercise is type of PNF. Combined concentric, eccentric, and stabilizing contractions of one group of muscles (agonists) without relaxation.~3 Session for 6 weeks."
2847642|NCT03615131||MRI-TRUS fusion prostate biopsy|Single Arm Study, MRI and Prostate-Biopsy on same patient, individual patient acts as own control for intervention
2847588|NCT03615521|Experimental|Standart Exercise Therapy|"Classic Physiotherapy: Hotpack, Ultrasound, Standart exercise program to improve Quadriceps, Hamstring and hip muscle strength.~3 session for 6 weeks."
2847589|NCT03615508|Other|10% phenylephrine|All patients will receive 10% phenylephrine at their eye examination as the drug to dilate the pupil. After pupil dilation, pupil size will be measured.
2847590|NCT03615495||Flourish device|The Flourish Pediatric Esophageal Atresia device is indicated for use in lengthening atretic esophageal ends and creating an anastomosis with a non-surgical procedure in pediatric patients.
2847591|NCT03615482|Experimental|Concomitant Vaccination|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 and a single 0.5 mL IM injection of QIV on Day 1 and a single 0.5 mL injection of placebo on Day 30
2847592|NCT03615482|Experimental|Non-concomitant Vaccination|Participants will receive a single 0.5 mL IM injection of QIV and a single 0.5 mL IM injection of placebo on Day 1 and a single 0.5 mL injection of V114 on Day 30
2847593|NCT03615469|Active Comparator|Neuromusclar electrical stimulation|"NMES will be set up with the machine on simultaneous large muscle atrophy setting with 500 ohm with peak of 50 volts, the self-adhesive electrodes positioned on the thighs approximately 5 cm below the inguinal fold and 3 cm above the upper patella border as described by Gobbo. When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality. It is expected that tolerance will develop and intensity will increase over time."
2847594|NCT03615469|Sham Comparator|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation
2847595|NCT03615456|Active Comparator|Conventional thyroidectomy|Thyroidectomy with ligation and division of thyroid vessels
2847596|NCT03615456|Active Comparator|Harmonic scalpel thyroidectomy|Thyroidectomy with sealing of thyroid vessels using harmonic scalpel
2847597|NCT03615443|Other|Treatment-naive metastatic non-squamous NSCLC|
2847598|NCT03615430|Placebo Comparator|Control group|saline control group, 15 mL of the saline was administered to superficial and deep surface of serratus anterior in Control group via ultrasound before the surgery
2847599|NCT03615430|Experimental|SPB group|Serratus plane block group, 15ml of 0.25% ropivacaine, a widely used local anesthetic for peripheral nerve block, was administered to superficial and deep surface of serratus anterior in SPB group via ultrasound before the surgery
2847600|NCT03615417|Experimental|HFNC - High Flow Nasal Cannula|Participants are preoxygenated by High Flow Nasal Cannula (HFNC) OptiFlow.
2847601|NCT03615417|Active Comparator|FM - FaceMask|Participants are preoxygenated by standard anesthesia FaceMask.
2847602|NCT03615404|Experimental|CMV-DCs with GM-CSF and Td (tetanus toxoid)|CMV-DCs are autologous dendritic cells derived from peripheral blood mononuclear cells (PBMCs) loaded with ribonucleic acid (RNA) encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF and Td vaccine as adjuvants.
2847603|NCT03615378|Placebo Comparator|Placebo|
2847604|NCT03615378|Active Comparator|Vitamin D 1000 IU D3 daily|
2847605|NCT03615378|Active Comparator|Vitamin D 5000 IU D3 daily|
2847606|NCT03615365||Patients with moderate-to-severe COPD.|"Patients will be identified from the Cambridge COPD Centre. This unit sees patients following emergency admissions, GP referrals and has a regional referral base for complex COPD. Patients' medical records will be reviewed and classified according to GOLD criteria.~Patients will undergo a clinical assessment of COPD during screening at Addenbrooke's Hospital. All patients will be assessed five times: at the start, 2 weeks, 10 weeks, 18 weeks and at the end of the 26 week study period. A brief follow-up telephone review will be conducted approximately 2 weeks after the end of the monitoring period. At each assessment, capnometry measurements will be taken in addition to vital signs and pulse oximetry."
2847607|NCT03615352|Experimental|ovarian cystectomy|laparoscopic ovarian cystectomy in endometrioma
2847608|NCT03615352|Experimental|ovarian cyst aspiration and coagulation|laparoscopic ovarian endometrioma aspiration and coagulation
2847609|NCT03615339|Experimental|Molkosan|"Consumption of Molkosan (fermented whey) 20ml to be diluted in 200ml water prior to use twice a day (morning & evening).~Total duration was 6 weeks."
2847610|NCT03615326|Experimental|Pembrolizumab +Trastuzumab + Chemotherapy|Participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy (Global Cohort) or SOX chemotherapy (Japan cohort).
2847611|NCT03615326|Active Comparator|Placebo +Trastuzumab + Chemotherapy|Participants receive matched placebo to pembrolizumab IV Q3W plus trastuzumab (8mg/kg loading dose, 6mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy (Global Cohort) or SOX chemotherapy (Japan cohort).
2847612|NCT03615313|Experimental|PD-1 antibody expressing mesoCAR-T cells|Patients will receive two cycles of PD-1 antibody expressing mesoCAR-T cells treatment. Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day -18, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of PD-1 antibody expressing mesoCAR-T cells from day 1 to day 3 (±3days).
2847613|NCT03615300||good neurologic outcome|Patients with good neurological prognosis after 6 months (CPC 1, 2). serum NGAL is collected.
2847614|NCT03615300||poor neurologic outcome|Patients with poor neurological prognosis after 6 months (CPC 3, 4, 5). serum NGAL is collected.
2847615|NCT03615287||Group A|40 subjects undergoing Medical Treatment
2847616|NCT03615287||Group B|40 subjects undergoing Surgical Treatment
2847617|NCT03615287||Group C|40 control subjects
2847618|NCT03615274|Experimental|Experimental|Children in the training group must complete home-based executive function training by iPad. At the same time, they are asked to learn basic psychoeducational contents and send pictures of their daily meals. Furthermore, physical activity and sleep patterns are registered over the training period.
2847721|NCT03614663|Placebo Comparator|Placebo transdermal gel|Matching ZYN002 placebo supplied as a transdermal gel.
2854536|NCT03566706|Experimental|Unhealthy Eating|
2847619|NCT03615274|Active Comparator|Placebo non-adaptive training|Children in the control group must complete cognitive control tasks. They are also asked to learn basic psychoeducational contents and send pictures of their daily meals. Furthermore, physical activity and sleep patterns are registered over the training period.
2847620|NCT03615261|Experimental|Mothers and Babies (Enhanced)|"The course is a manualized stress-reduction intervention with an integrated tech suite designed for timely detection and response to stress. Based on Cognitive-Behavioral Therapy & attachment theory, MB is divided into 3 sections: Pleasant Activities; Thoughts; Contact with Others. Each module has been enhanced with mindfulness as a strategy to help center participants and facilitate practice of skills. Participants receive skills training in each of the three sections as tools to improve and manage their mood. The MB course emphasizes developing & strengthening the bond with the baby. The technology enhancement includes wearing a BioStamp sensor, and text message-based extra intervention content. Participants get worksheets linked to the 12 sessions."
2847621|NCT03615248|Experimental|Primary Arm -|"30 Subjects will be approached in Asthma Clinics at the Janeway Children's Health and Rehabilitation Centre by the research nurse, and if selected to the study, will use the BreatheSuite device for 3-6 months.~Inclusion criteria: Age 10-18, diagnosis of asthma by the pediatrician, regular access to a smartphone, parental consent, ongoing need for regular use of a medication delivered by metered dose inhaler as deemed by the pediatrician, ability to demonstrate proper technique of metered dose inhaler use in the clinic while supervised by research nurse or pediatrician without parent or caregiver intervention;"
2847622|NCT03615235||Recipients of a Kidney Transplant|APOLLO will prospectively assess transplant outcomes in recipients of kidneys from eligible living and deceased donors at all transplant programs in the United States including Puerto Rico.
2847623|NCT03615235||Living Kidney Donors|APOLLO will prospectively assess post-donation renal outcomes in eligible living kidney donors at all transplant programs in the United States including Puerto Rico.
2847624|NCT03615222|Experimental|ACT-FX|Acceptance and Commitment Therapy to promote functional recovery in war veterans (ACT-FX) will be an individually-tailored intervention to reduce functional impairment associated with any combination of the most common mental and physical wounds of war. ACT is an evidence-based, mindfulness-based behavioral treatment. The ACT model posits that low levels of psychological flexibility leads to functional impairment across a range of mental and physical health problems; thus, ACT is aimed at increasing psychological flexibility. ACT-FX will be a 12-session, individual, outpatient treatment, with sessions occurring approximately weekly. Each session includes: 1) mindfulness training; 2) review of between-session mindfulness practice and behavioral assignments; 3) new content and experiential exercises; and 4) development of values-consistent behavioral assignments to improve functioning. Daily mindfulness practice will be assigned.
2847625|NCT03615222|Active Comparator|Treatment as usual (TAU)|Among Veterans randomized to TAU, those already receiving TAU will continue in TAU. Those who are not already receiving TAU will be offered a clinical referral to address the Veterans' most pressing mental or behavioral health concern (e.g., to the PTSD clinic or to primary care-behavioral health for pain management). Offering such referrals has been the investigators' procedure throughout the SERVE research program. Because of the complexity of the target population, TAU will involve a variety of interventions. In accordance with recommendations, a brief (5 minute) weekly phone will be conducted with TAU participants to closely track their use of VA and non-VA mental health services.
2847626|NCT03615209|Active Comparator|Transauricular vagus nerve stimulation|Non invasive vagus nerve stimulation will be conducted with Cerbomed NEMOS via the left ear.
2847627|NCT03615209|Sham Comparator|Transauricular sham stimulation|Non invasive sham stimulation will be conducted with Cerbomed NEMOS via the left ear lobe.
2847628|NCT03615196|Experimental|USB005 0.03%|USB005 (aclerastide) Ophthalmic Solution 0.03%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
2847629|NCT03615196|Experimental|USB005 0.1%|USB005 (aclerastide) Ophthalmic Solution 0.1%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
2847630|NCT03615196|Experimental|USB005 0.3%|USB005 (aclerastide) Ophthalmic Solution 0.3%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
2847631|NCT03615196|Experimental|USB005 0.45%|USB005 (aclerastide) Ophthalmic Solution 0.45%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
2847632|NCT03615196|Placebo Comparator|USB005 Placebo|USB005 Ophthalmic Solution Placebo; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
2847633|NCT03615183|Experimental|Panel A|Single oral dose of 10 mg MK-8527 capsule after an 8-hour fast
2847634|NCT03615183|Experimental|Panel B|Single oral dose of 25 mg MK-8527 capsule after an 8-hour fast
2847635|NCT03615183|Experimental|Panel C|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
2847636|NCT03615183|Experimental|Panel D|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
2847637|NCT03615183|Experimental|Panel E|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
2847638|NCT03615157|Experimental|Home-based exercise rehabilitation|Patients will be submitted to a 12-weeks training program, with walking at 60-70% of heart rate reserve monitored by a heart rate monitor (30 minutes/session for 5 days/week) and peripheral muscle training including upper and lower limbs (50% of the 1-maximum repetition test)
2847639|NCT03615157|Active Comparator|Supervised exercise rehabilitation|Patients will be submitted to a 12-weeks training program, with sessions (3 days/week) supervised by a physiotherapist, including cycling at 60-70% of heart rate reserve and peripheral muscle training of upper and lower limbs (50% of the 1-maximum repetition test)
2847640|NCT03615144|Active Comparator|Melphalan/Thiotepa/Clofarabine|Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
2847641|NCT03615144|Active Comparator|Melphalan/Thiotepa/ Fludarabine|Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
2847722|NCT03614650|Experimental|EIE cells to treat cancer|EIE cells to treat cancer
2847643|NCT03615118|Experimental|Intervention|Patients randomized to the intervention group will receive the AniMóvil intervention, including: the Sentirse Mejor manual that patients can refer to for information about CBT and skill practice, weekly IVR depression symptom assessments and psychoeducational messages, daily SMS mood monitoring and CBT reinforcement messages, and CHW telephone CBT sessions in the event of elevated PHQ-9 scores during the study. CHWs will use information from patients' IVR/SMS monitoring to support intervention-group patients' depression self-management under close supervision from their mental health specialist supervisor. Intervention patients will be part of a 'stepped' intervention based on the severity of their depression upon entry into the program and assessment throughout the intervention.
2847644|NCT03615118|Active Comparator|Enhanced Usual Care|Enhanced usual care patients will receive usual care, including the Sentirse Mejor manual developed by the research team in conjunction with local Ministries of Mental Health and tailored by the study team, emphasizing CBT principles, and daily SMS messages asking participants to report their mood on a 1 to 9 scale. Enhanced usual care group patients who report mood scores of 1 or 2 (worst scores) for at least 3 days per week and 3 consecutive weeks will be called by the Community health worker and referred to the national program office for depression services support - a free service available to all citizens diagnosed with depression. Enhanced usual care patients will be part of a 'stepped' program based on the severity of their depression upon entry into the program and assessment throughout the intervention.
2847645|NCT03615105|Experimental|Radiation, Thiotepa & Cyclophosphamide|
2847646|NCT03615105|Experimental|Busulfan, Fludarabine & Melphalan|
2847647|NCT03615105|Experimental|Clofarabine, Thiotepa & Melphalan|
2847648|NCT03615092|Active Comparator|Test Group|"Active Comparator: gingival recession with a previous restored cervical lesion~the aim of this study is to compare if the acellular dermal matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions with non carious cervical lesions."
2847649|NCT03615092|Placebo Comparator|Control Group|the aim of this study is to compare if the acellular dermal matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions with non carious cervical lesions. The control group had no cervical lesion, and was treated with the same technique as the acelular dermal matrix graft
2847650|NCT03615079|Other|Cognitive Behavioral Therapy (CBT) program|
2847651|NCT03615066|Experimental|Placebo (Cohort 1)|HBeAg-positive participants will receive tenofovir alafenamide (TAF) and GS-9888 placebo.
2847652|NCT03615066|Experimental|GS-9688 1.5 mg (Cohort 1)|HBeAg-positive participants will receive TAF and GS-9688 1.5 mg.
2847653|NCT03615066|Experimental|GS-9688 3 mg (Cohort 1)|HBeAg-positive participants will receive TAF and GS-9688 3 mg.
2847654|NCT03615066|Experimental|Placebo (Cohort 2)|HBeAg-negative participants will receive TAF and GS-9888 placebo.
2847655|NCT03615066|Experimental|GS-9688 1.5 mg (Cohort 2)|HBeAg-negative participants will receive TAF and GS-9688 1.5 mg.
2847656|NCT03615066|Experimental|GS-9688 3 mg (Cohort 2)|HBeAg-negative participants will receive TAF and GS-9688 3 mg.
2847657|NCT03615053|Other|Tailored Regimen|Implementation of WAPPS-Hemo personalized dosing regimen.
2847658|NCT03615040|Experimental|Anti-ST2|Anti-ST2 (MSTT1041A) Received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period
2847659|NCT03615040|Placebo Comparator|Placebo|Placebo (no active component) Received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period
2847660|NCT03615027|Experimental|Intervention|see detailed description
2847661|NCT03615014|Other|Patients having trauma|Adults patients having trauma in the month before visiting emergency will fill questionnaires
2847662|NCT03615001|Experimental|Urodynamics Arm|
2847663|NCT03614988|Active Comparator|Morning Levothyroxine Intake First|Randomized patients to receive levothyroxine in the morning and after crossover to Evening Levothyroxine Administration.
2847664|NCT03614988|Experimental|Evening Levothyroxine Intake First|Randomized patients to receive levothyroxine in the morning and after crossover to Morning Levothyroxine Administration.
2847665|NCT03614975|Active Comparator|Flucelvax inactivated influenza vaccine|Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly
2847666|NCT03614975|Active Comparator|Fluzone inactivated influenza vaccine|Participants receiving inactivated Fluzone influenza vaccine will receive 0.5 mL given intramuscularly
2847667|NCT03614962|Experimental|Warmth + TENS group|All participants will be offered a hat device that elicits warmth and TENS.
2847668|NCT03614962|Active Comparator|Warmth + placebo-TENS group|All participants will be offered a hat device that elicits warmth and placebo-TENS.
2847669|NCT03614962|Active Comparator|Warmth group|All participants will be offered a hat device that elicits warmth only.
2847670|NCT03614962|Active Comparator|TENS group|All participants will be offered a hat device that elicits TENS only.
2847671|NCT03614962|Sham Comparator|control group|All participants will be offered a hat device that without warmth or TENS output.
2847672|NCT03614949|Experimental|Combination Therapy|Stereotactic body radiation therapy (SBRT) followed by atezolizumab, 1 week later.
2847673|NCT03614936||Inoperable squamous cell cancer of the head and neck|patients 70 years of age or older with ENT carcinoma
2847674|NCT03614923|Active Comparator|Dose 1|SC administration, Q4W
2847675|NCT03614923|Active Comparator|Dose 2|SC administration, Q8W
2847676|NCT03614923|Placebo Comparator|Placebo|SC administration, Q4W
2847677|NCT03614910||Locally Advanced Pancreatic Cancer|"Patients with locally advanced unresectable pancreatic cancer. Unresectable tumors as defined by:~occlusion, thrombosis or several centimeters of encasement of the superior mesenteric vein or portal vein~tumor abutment greater than 180 degrees of the superior mesenteric artery or thrombosis of the artery~abutment or encasement of the celiac axis~involvement of lymph nodes outside the area of resection"
2847678|NCT03614897|Experimental|Education|Providers participating in education related to guidelines for treating patients at risk of falling
2847679|NCT03614884|Experimental|Gambling and Smoking Treatment|Participants in this arm will be given access to the online integrated treatment for gambling and smoking.
2847680|NCT03614884|Active Comparator|Gambling Only Treatment|Participants in this arm will be given access to the online gambling only treatment.
2847681|NCT03614871||No arms|There are no interventions
2847682|NCT03614858|Experimental|Cohort 1|Experimental: Cohort 1 Intervention: Biological: CART-19/22 This cohort will determine the safety and efficacy of targeted CD19/CD22 chimeric Antigen Receptor Engineered T Cell Immunotherapy (CART) in the Treatment of CD19/CD22 Positive Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
2847683|NCT03614845|Active Comparator|VCV-Lung Ultrasonography|patients undergoing laparoscopic surgery will be performed pre and postoperatively lung ultrasonography. after induction of anesthesia patients will be supported by mechanical ventilation on volume controlled ventilation mode.
2847684|NCT03614845|Active Comparator|PCV-VG- Lung Ultrasonography|patients undergoing laparoscopic surgery will be performed pre and postoperatively lung ultrasonography.after induction of anesthesia patients will be supported by mechanical ventilation on pressure controlled volume guaranteed mode
2847685|NCT03614832|Experimental|Ticagrelor 90 mg|To observe low-dose of ticagrelor（90 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
2847686|NCT03614832|Active Comparator|Clopidogrel 150 mg|To observe double standard-dose clopidogrel （150 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
2847687|NCT03614819|Experimental|Diode laser group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying, followed by application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W (energy of 70 mJ) and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2. The FieldMaxII-TOP power meter (Coherent, Inc, USA) will be used prior to and after the applications. The laser will be applied in a sweeping motion throughout the affected surface, the fiber being maintained positioned perpendicular to the occlusal surface throughout the movement. The irradiation time will be standardized in 30 seconds.
2847688|NCT03614819|Active Comparator|Glass Ionomer Sealing Group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying with cotton balls, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material, removal of the excess, checking the occlusion with carbon paper, occlusal adjustments if necessary, superficial protection with petroleum jelly.
2847689|NCT03614806|Experimental|Patients tested for hyperventilation|Simultaneous Transcutaneous and End-tidal CO2 measurements. Eligible patients will be first invited to fill in the Nijmegen questionnaire. Then, in an hyperventilation test, transcutaneous Carbon Dioxide Pressure will be recorded simultaneously with the standard End-tidal Carbon Dioxide Pressure measurement.
2847690|NCT03614793|Active Comparator|Cooled Radiofrequency Ablation Procedure|
2847691|NCT03614793|Active Comparator|Facet Joint Inject Procedure|
2847692|NCT03614780|Experimental|30 additional minutes outdoors|Participants were asked to go about their normal activities during the first 2 baseline days of participation. Participants were asked to spend an additional 30 minutes outdoors per day for the next 5 days of participation.
2847693|NCT03614767||Successes|Patients with >50% improvement during test procedure of sacral neuromodulation.
2847694|NCT03614767||Failures|Patients with <50% improvement during test procedure of sacral neuromodulation.
2847695|NCT03614754||Successes|Patients with reduction of symptoms >50% during the test procedure for sacral neuromodulation.
2847696|NCT03614754||Failures|Patients with reduction of symptoms <50% during the test procedure for sacral neuromodulation.
2847697|NCT03614741|Active Comparator|Control group|Bolus of 4500 IU tinzaparin
2847698|NCT03614741|Active Comparator|Study group|Bolus of 4500 IU tinzaparin and continuous infusion of 4500 IU tinzaparin
2847699|NCT03614728|Experimental|Part 1: GSK3326595|Subjects will receive GSK3326595 400 mg oral capsule once a day. The dose may be reduced due to toxicity in the myeloid population, or escalated if required.
2847700|NCT03614728|Experimental|Part 2A: GSK3326595|Subjects in this treatment arm will start at the dose identified as the myeloid monotherapy dose in Part 1 of the study.
2847701|NCT03614728|Experimental|Part 2A: Best available care|Best available care will be the treatment of choice as considered by the investigator.
2847702|NCT03614728|Experimental|Part2B:GSK3326595+5-azacitidine(dose escalation and expansion)|Subjects will receive GSK3326595 oral capsule once a day along with 5-azacitidine administered at a dose of 75 mg/meter square (m^2) seven days in a 28-day cycle. The initial dose of GSK3326595 administered in Part 2B of this study will be reduced by two dose levels from the recommended myeloid monotherapy dose, as determined in Part 1, and escalate up to the Recommended Myeloid Monotherapy Dose.
2847703|NCT03614728|Experimental|Part 2C: GSK3326595|Subjects in this treatment arm will receive GSK3326595 oral capsule at the dose identified as the myeloid monotherapy dose in Part 1 of the study, until progression, unacceptable toxicity, or withdrawal of consent.
2847704|NCT03614715|Experimental|CinnaGen interferon beta-1a|CinnoVex® (IFNβ-1a, Prefilled syringe produced by CinnaGen Company) in prefilled syringe in healthy volunteers. (Stage 1: 30 µg or 60 µg)(Stage 2: 30 µg)
2847705|NCT03614715|Active Comparator|Biogen interferon beta-1a|Avonex® (IFNβ-1a, Prefilled syringe produced by Biogen Company) in prefilled syringe in healthy volunteers. (Stage 1: 30 µg or 60 µg)(Stage 2: 30 µg)
2847706|NCT03614702|Experimental|1-dose cIPV + 2-doses bOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences . 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
2847723|NCT03614637||Cannabis User Group|Forty eight participants who are regular Cannabis users with a self-reported frequency of at least once weekly over the past 6 months of screening visit.
2847724|NCT03614637||Non-Cannabis User Group|Twenty four participants who self-report no Cannabis use in the past 6 months of screening visit and fewer than 10 times during their lifetime
2848677|NCT03607929|Active Comparator|variability and hydration|Other Solutions >o < 300 ml/h AND uncontrolled drink during labor
2847707|NCT03614702|Experimental|1-dose sIPV + 2-doses bOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time;each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
2847708|NCT03614702|Experimental|2-doses cIPV + 1-dose bOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50"
2847709|NCT03614702|Experimental|2-doses sIPV + 1-dose bOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50"
2847710|NCT03614702|Experimental|2-doses cIPV + 1-dose tOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine（Vero） Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd. 1g/pill,10 pills/pach;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 2 polio virus ≥4.8lgCCID50，type 3 polio virus ≥5.3lgCCID50"
2847711|NCT03614702|Experimental|2-doses sIPV + 1-dose tOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose~tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd.1g/pill,10 pills/pach,one pills each time;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 2 polio virus ≥4.8lgCCID50，type 3 polio virus ≥5.3lgCCID50"
2847712|NCT03614702|Experimental|1-dose cIPV + 2-doses bOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine（Vero） Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
2847713|NCT03614702|Experimental|1-dose sIPV + 2-doses bOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
2847714|NCT03614702|Experimental|2-doses cIPV + 1-dose bOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
2847715|NCT03614702|Experimental|2-doses sIPV + 1-dose bOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle,total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
2847716|NCT03614702|Experimental|2-doses cIPV + 1-dose tOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~tOPV(Liquid) Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml，type1 polio virus≥ 7.0 lgCCID50/ml，type2 polio virus ≥ 6.0lgCCID50/ml，type 3 polio virus≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
2847717|NCT03614702|Experimental|2-doses sIPV + 1-dose tOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.0.5ml/dose~Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 2 polio virus ≥ 6.0lgCCID50/ml，type 3 polio virus ≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
2847718|NCT03614676|Other|Pregnant Women/Mothers Group|Subjects, 18 to 40 years of age, enrolled in the study in view of determining pregnancy outcomes and related events of interest, as well as the occurrence of lower respiratory tract infection (LRTI) associated with respiratory syncytial virus (RSV). Collection of maternal blood samples and cord blood samples at delivery are planned for determination of antibody titers.
2847719|NCT03614676|Other|Neonates/Infants Group|Infants born to mothers aged 18-40 years old, enrolled for the collection of infant events of interest, nasal swabs and the incidence of RSV LRTI and RSV hospitalization
2847720|NCT03614663|Experimental|ZYN002 - CBD transdermal gel|"ZYN002 supplied as a transdermal gel. Patients weighing less than or equal to 35 kg will be randomized to receive either 125 mg CBD Q12H or placebo.~Patients weighing greater than 35 kg will be randomized to receive 250 mg CBD Q12H or placebo."
2847726|NCT03614611|Experimental|Contiform pessary|Enrolled participants will be part of the intervention arm. They will use of the Contiform Intravaginal pessary for the treatment of stress urinary incontinence, for a period of 3 months.
2847727|NCT03614598|Active Comparator|LMA-UNIQUE™|
2847728|NCT03614598|Active Comparator|LMA-SUPREME™|
2847729|NCT03614598|Active Comparator|I-GEL®|
2847730|NCT03614585|Experimental|High-intensity interval training|Intensity will be determined using a percentage of the workload associated with VO2peak (pVO2peak) from the graded exercise test and ratings of perceived exertion (RPE). The protocol will involve 10 30-second intervals of high intensity interspersed with 8 60-second low-intensity intervals. The workload during the high intensity intervals will start at 70% of the pVO2peak (RPE=14-17) and progressed by 10% every 4 weeks. Low intensity intervals will be performed at 30% pVO2peak (RPE=9-11). Three-minute warm-up and 2-minute cool-down periods will be performed at 30% pVO2peak. Total HIIT time including warm-up and cool-down is 18 minutes.
2847731|NCT03614585|Experimental|Moderate-intensity continuous training|Intensity will be determined using a combination of heart rate reserve (HRR, calculated as HRR= [max HR - resting HR] x [% training] + [resting HR]) and ratings of perceived exertion (RPE). The MICT protocol will be increased using a progression schedule previously used (initial intensity at 40% HRR (RPE=9-11), and progressed by 10% HRR every 4 weeks up to 60% HRR (RPE=13-14) will be maintained until the end of the intervention). A 3-minute warm-up and 2-minute cool-down will be performed at 30% HRR (RPE=9-11). The total duration of MICT, including warm-up and cool-down, will be 35 minutes.
2847732|NCT03614572|Experimental|Group MI|The structure and content of the active intervention programme will be developed and adopted on the basis of previous research on sleep educational programme and motivational interviewing techniques. The whole treatment package consists of 4 sessions of group therapy (n=6-8) followed by 3 week daily text reminders.
2847733|NCT03614572|No Intervention|Control group|Control group will no receive any intervention
2847734|NCT03614559||CTO PCI group and non CTO PCI group|CTO PCI group： Succession of CTO revascularization non CTO PCI group： Failure or not tried to revascularization
2847735|NCT03614559||Initially attempted and re-attempted|PCI initially attempted group： First time to try to revascularization PCI re-attempted group: Second or more time to try to revascularization
2847736|NCT03614559||PCI during China Club or not|PCI during Chronic Total Occlusion Club， China Club : CAG in 2016.11.04 Another group: CAG in other time
2847737|NCT03614559||Morning，Afternoon，Night|Morning group:（8:00-12:59） Afternoon group：（13:00-17:59） Night group：（after 18:00）
2847738|NCT03614546|Other|A（surgery） group|Hepatectomy
2847739|NCT03614546|Experimental|B1（SBRT） group|Stereotactic Body Radiation Therapy(SBRT), 40-55Gy/5-6F
2847740|NCT03614546|Experimental|B2a（TACE+ IMRT ） group|First，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W, 4 weeks after IMRT，treat with transcatheter arterial chemoembolization（TACE） 2-4 times
2847741|NCT03614546|Experimental|B2b（TACE+ IMRT ） group|First，treat with transcatheter arterial chemoembolization（TACE） 2-4 times，4 weeks after TACE，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W
2847742|NCT03614546|Experimental|C1（SBRT） group|Stereotactic Body Radiation Therapy, 40-55Gy/5-6F
2847743|NCT03614546|Experimental|C2a（TACE+ IMRT ） group|First，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W, 4 weeks after IMRT，treat with transcatheter arterial chemoembolization（TACE） 2-4 times
2847744|NCT03614546|Experimental|C2b（TACE+ IMRT ） group|First，treat with transcatheter arterial chemoembolization（TACE） 2-4 times，4 weeks after TACE，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W
2847745|NCT03614533|Experimental|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Children will receive a single 0.5-ml dose of Vi-TCV administered by the intramuscular route.
2847746|NCT03614533|Active Comparator|Inactivated Poliovirus Vaccine (IPV)|Children will receive a single 0.5-ml dose of Inactivated Poliovirus Vaccine (IPV) by the intramuscular route.
2847747|NCT03614520|Experimental|Sub-study A : olive oil, wine, both, or water (placebo).|After being selected, subjects will do 4 experimental sessions (each separated by 3 days minimum) in which ones they will drink olive oil, red wine, red wine and olive oil, or water (placebo). The order of the experimental sessions will be drawn.
2847748|NCT03614520|Experimental|Sub-study B : three types of beer, and wine|The subjects will do 4 experimental sessions (each separated by 3 days minimum) in wich ones they will drink a beer (250mL) or wine (150mL). The order of the experimental sessions will be drawn.
2847749|NCT03614507|Experimental|FreeO2 Arm|Automatic adjustment of oxygen
2847750|NCT03614507|Active Comparator|Manual Arm|Manual adjustment of oxygen
2847751|NCT03614494|Active Comparator|Piroxicam|Piroxicam 40 mg (in 2 tablets) + levonorgestrel 1.5 mg single oral dose
2847752|NCT03614494|Placebo Comparator|Placebo|Placebo (2 tablets) + levonorgestrel 1.5 mg single oral dose
2847753|NCT03614481||AMD patient|"During the AMD consultation, patients have their imaging exams including OCT, retinophotography, and fluorescein angiography.~After the interview with the doctor on pathology diagnosis and follow-up, they will meet the clinical research associate nurse to complete the questionnaire and perform anthropometric measurements (weight, height, abdominal perimeter measurement and blood pressure measurement). Patients recruited at Créteil will benefit from a venous blood sample (20 mL) in 2 EDTA tubes for DNA extraction after light reading and signature of consent. For patients recruited from other ophthalmic centers, the Clinical Research Associate will perform salivary sampling for DNA extraction after light reading and signature of consent."
2847754|NCT03614481||control without AMD|"898/5000 Given the observation of a mutation in an unaffected control individual, it is not excluded that this individual may be suffering from AMD at a later age. The observation of the mutation could thus be considered as a pre-clinical test. None of the teams were able to obtain a control population of the same age and sex ratio, which could have benefited from fluorescein angiography or at least a fundus examination, to ensure the absence of warning signs of AMD. This requires cooperation from healthy elderly volunteers not only for blood sampling but also for pupillary dilatation.~The controls may be the accompanying persons or spouses of AMD patients. It may also be people seen in general consultation without maculopathy or retinopathy with an age greater than 55 years."
2847755|NCT03614468|Experimental|Formula A|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 6 months of age.
2854537|NCT03566706|Experimental|Marijuana Use|
2847757|NCT03614455|Experimental|Milademetan alone (A)|During Period 1, participants receive a single 100 mg milademetan oral dose on Study Day 1, with PK sampling to 168 hours post-dose (during the following 7-day washout period)
2847758|NCT03614455|Other|Milademetan with itraconazole (AB)|During Period 2, participants receive itraconazole, 200 mg twice daily (BID) on Study day 8 and 200 mg once daily (QD) on Study Days 9 through 20, along with a single 100 mg milademetan dose on Day 14
2847759|NCT03614455|Other|Milademetan with posaconazole (AC)|During Period 2, participants receive 200 mg posaconazole three times daily (TID) on Study Days 8 through 20, along with a single 100 mg milademetan dose on Day 14
2847760|NCT03614442|Experimental|slopped shoulder implant|The osteotomy site will be prepared using appropriate drill sizes with flapless approach, The implant (conventional neck implant design )will be inserted till the platform will be flushed with the crestal bone, The primary stability will be checked using torque wrench
2847761|NCT03614442|Active Comparator|conventional implant with flat platform|inserted implant will be bone leveled implant (crestal maxi z) implant (conventional implant with platform). The primary stability will be checked using torque wrench
2847762|NCT03614429|No Intervention|Control|"Group 1: control group, n=50 Male patients undergoing aseptic surgery (regardless the procedure)~Inclusion criteria Male patients aged 20-50 years-old or older undergoing a sterile surgical procedure.~Exclusion criteria Unwilling patient for this procedure Patients with history of urethral surgery, urinary calculi, urethral structure, or ongoing pyospermia, prostatitis or pyuria will be excluded, and so will be patients undergoing non-sterile surgeries such as abscess drainage."
2847763|NCT03614429|Experimental|Ch group|"Group 2: Chlorhexidine group (Ch group), n=50 Male patients undergoing aseptic surgery (regardless the procedure)~Inclusion criteria Male patients aged 20-50 years-old or older undergoing a sterile surgical procedure.~Exclusion criteria Unwilling patient for this procedure Patients with history of urethral surgery, urinary calculi, urethral structure, or ongoing pyospermia, prostatitis or pyuria will be excluded, and so will be patients undergoing non-sterile surgeries such as abscess drainage."
2847764|NCT03614416|Experimental|EOXY device and Gold standard oximter and SaO2 measures|Heart rate and SPO2 measures provided from EOXY device Heart rate measures provided from gold standard oximeter. SaO2 measures provided from blood sampling There is only one arm: all subjects have simultaneously three interventions (as required in the European standard ISO 80601-2-61), to qualify a pulse oximeter
2847765|NCT03614403|Experimental|Vitamin D|Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection
2847766|NCT03614403|No Intervention|control|Control patients will not be received any intervention
2847767|NCT03614390|Other|MBCT group|"There is only 1 arm in the study.~The MBCT will be conducted according to the treatment manual. The program consists of eight weekly sessions. In between sessions, participants are advised to practice mindfulness meditations for 40-50 minutes every day.~The teachers of the program will teach on voluntary basis. The teachers must have attended the 1-year foundation course to teach mindfulness (available in the United Kingdom and Hong Kong), regular mindfulness practice and must have at least yearly mindfulness retreat. This is in accordance to the good practice guidelines developed in the UK for mindfulness teachers"
2847768|NCT03614377||Patients with low burden of sleep-disordered breathing|
2847769|NCT03614377||Patients with high burden of sleep-disordered breathing|
2847770|NCT03614364|Experimental|nanoxel and herzuma|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
2847771|NCT03614351|Experimental|Physical Therapy plus Protein Supplement|Participants will be randomized to the protein supplementation group, PROT, and will receive education from a dietary counselor on how to monitor protein intake using a smartphone app.
2847772|NCT03614351|Active Comparator|Physical Therapy Control|Participants will be randomized to the enhanced-care control group, CONT, and will receive education from a dietary counselor on how to monitor protein intake using a smartphone app.
2847773|NCT03614338|Experimental|Core Participants Weight Loss Program|Small changes weight loss program
2847774|NCT03614325|Experimental|Virtual Reality Immersive Relaxation|"Patients in the experimental group will wear a headset and be immersed in a virtual reality environment during their surgery. There are various short videos and environments such as sitting on a beach that are designed to promote relaxation and calmness.~Throughout their surgery patients will be monitored according to current anesthesia standards. The relaxation programming will run for the duration of the operative procedure. At the end of the procedure the headset will be removed and standard postoperative care will commence."
2847775|NCT03614325|No Intervention|Usual Anesthesia Care|Patients in the usual care arm will undergo the current standard of care for hand/wrist surgery and postoperative recovery. They will be asked to refrain from using a virtual reality headset during their surgery.
2847776|NCT03614312||BMI 18-25 Pregnant Women|BMI 18-25 less than 36 weeks pregnant
2847777|NCT03614299||pSS cohort|Patients with pSS included in the study
2847778|NCT03614273|Active Comparator|Group 1 (HS)|Nebulized with 4 ml of 3% hypertonic saline for a duration of 20 minutes
2847779|NCT03614273|Active Comparator|Group 2 (Adr)|Nebulized with 0.1 mg/kg of adrenaline (non-racemic solution, 1:1000 concentration), which was diluted in normal saline to make it a 4 ml solution, for a duration of 20 minutes
2847780|NCT03614260|Experimental|Renal Denervation|Renal Angiogram and Renal Denervation (Paradise Renal Denervation System)
2847781|NCT03614260|Sham Comparator|Sham Control|Renal Angiogram
2847782|NCT03614247|Active Comparator|RIRS|Patients underwent retrograde intrarenal surgery for lower calyceal stone between 1cm and 2cm in size
2847783|NCT03614247|Active Comparator|Micro-PNL|Patients underwent micro percutaneous nephrolithotomy (tract size <10 F) for lower calyceal stone between 1cm and 2cm in size
2847784|NCT03614247|Active Comparator|Ultramini-PNL|Patients underwent ultra-mini percutaneous nephrolithotomy (tract size <15 F) for lower calyceal stone between 1cm and 2cm in size
2847785|NCT03614247|Active Comparator|Mini-PNL|Patients underwent mini percutaneous nephrolithotomy (tract size <20 F) for lower calyceal stone between 1cm and 2cm in size
2847786|NCT03614247|Active Comparator|Standard PNL|Patients underwent standard percutaneous nephrolithotomy (tract size >25 F) for lower calyceal stone between 1cm and 2cm in size
2847787|NCT03614234|Experimental|Experimental open label|Pegunigalsidase alfa
2847788|NCT03614221|Experimental|Lindioil|Lindioil ointment is applied twice daily for 6 weeks, followed by a washout period of 1 to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2. If relapse to IGA ≥ 2 is achieved, the patient is using Protopic ointment 0.1% twice daily for another 6 weeks. If relapse to IGA ≥ 2 is not achievable within 8 weeks after the first treatment period, the subject will terminate participation in this trial.
2847789|NCT03614221|Active Comparator|Protopic|Protopic ointment 0.1% is applied twice daily for 6 weeks, followed by a washout period of 1 to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2. If relapse to IGA ≥ 2 is achieved, the patient is using Lindioil ointment twice daily for another 6 weeks. If relapse to IGA ≥ 2 is not achievable within 8 weeks after the first treatment period, the subject will terminate participation in this trial.
2847790|NCT03614208|Experimental|Home-care rehabilitation group (HCRG)|"The home-based exercise program consists of aerobic exercise on a stationary bike, muscular endurance training of the upper limb and stretching exercises for finger joint motion. The exercise on the stationary bike and muscular endurance training will be performed on alternate days, three times a week. For finger stretching the patients will be directed to perform it every day, both in the morning and in the evening.~During the rehabilitation period, the patients will report each day on a diary for each type of exercise. They received a phone call monthly, only for the first 3 months, to encourage them about the adherence and investigate any problems with the exercise program."
2847791|NCT03614208|No Intervention|Control group|Control group was encouraged to perform the generic aerobic physical activity at the baseline. Also, they received a monthly phone call, only for the first 3 months, to encourage them about the importance of doing aerobic exercise.
2847792|NCT03614195|Experimental|MCDTT|The MCDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
2847793|NCT03614195|Active Comparator|MDTT|The MDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
2847794|NCT03614195|Active Comparator|CDTT|The CDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
2847795|NCT03614182|Experimental|physical training concurrent with cognitive training|The physical training concurrent with cognitive training group (the P+C group) will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
2847796|NCT03614182|Active Comparator|physical training followed by cognitive training|The physical training followed by cognitive training will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
2847797|NCT03614182|Active Comparator|physical training without cognitive training|The physical training without cognitive training group will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
2847798|NCT03614169|Experimental|Direct HIS-pacing|In this arm a right ventricular (RV) lead or implantable cardioverter defibrillator (ICD) lead is placed first and then implantation of a HIS-pacing lead is attempted. If it is not possible to find and pace HIS or it is not possible to correct the LBBB, a left ventricular (LV) lead is implanted instead.
2847799|NCT03614169|Active Comparator|Biventricular pacing|In this arm an RV-lead or ICD-lead is placed first and then implantation of a LV-pacing lead is attempted. If this is not possible due to anatomical difficulties (no coronary sinus (CS) access, no available branches other than v cordis anterior or v cordis media) or electrical difficulties (no capture below 4 V at 1.0 msec or phrenic nerve stimulation < 2x pacing threshold)
2847800|NCT03614156|Experimental|Rapastinel weekly|Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration)
2847801|NCT03614156|Experimental|Rapastinel clinically driven schedule|Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
2847802|NCT03614156|Placebo Comparator|Placebo weekly|Placebo (prefilled syringe, weekly IV administration)
2847803|NCT03614117|Active Comparator|L.salivarius PS7 6-months|Lactobacillus salivarius PS7 during 6-months; approximately 1*10E9 colony forming unit (CFU) of L. salivarius PS7 in 1 sachet per day to be diluted in water by mouth for 6-months.
2847804|NCT03614117|Active Comparator|L. salivarius PS7 + placebo (3+3)|Lactobacillus salivarius PS7 during 3 months; approximately 1*10E9 CFU of L. salivarius PS7 in 1 sachet per day to be diluted in water by mouth for 3-months followed by 3 months oral administration of 1sachet per day of placebo supplement to be diluted in water.
2847805|NCT03614117|Placebo Comparator|Control group|Placebo supplement in 1 sachet per day to be diluted in water by mouth for 6-months.
2847806|NCT03614104|Sham Comparator|mobile health technology|Health education mobile health technology
2847807|NCT03614104|Sham Comparator|Without mobile health technology|Health education without mobile health technology
2847808|NCT03614091|Active Comparator|Paravertebral plane block group|The TPVB will be administered at the T4 level with the patient in the sitting position.The ultrasound probe will be placed 5 cm from the midline in the craniocaudal direction and moved medially to identify the transverse process and parietal pleura. The superior costotransverse ligament was identified as a collection of homogeneous linear echogenic bands alternating with echo-poor areas running from one transverse process to the next. Bubivacaine0.5%, 20 ml will be deposited in the space between the pleura and the costotransverse ligament.
2847809|NCT03614091|Active Comparator|Erector spinae plane block group|the transducer will be placed in a transverse orientation to identify the spinous process, lamina,and transverse process.The tip of the transverse process will be centered on the ultrasound screen, and the transducer will be rotated 90 degrees into a longitudinal orientation to obtain a parasagittal view. Depending on the level imaged, 2 or 3 hypoechoic muscle layers were identiﬁed overlying the tip of the transverse processes. From T1 to T5 the erector spinae, rhomboid major and trapezius muscles are visible posterior and superfacial to the transverse processes. An 8cm 22-gauge block needle will be Inserted in-plane to the ultrasound beam in a cephalad-to-caudad Direction to place the needle tip between the posterior fascia of Erector spinae and the tip of the targeted transverse process.following which a total of 20 mL of 0.5%bupivacaine will be injected.
2847810|NCT03614078|Experimental|PRCL-02 Dose 1|Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
2847812|NCT03614078|Placebo Comparator|Placebo|Loading dose followed by a once daily maintenance dose at matching treatment levels, commencing on Day 2 and continuing for 12 weeks
2847813|NCT03614065|Placebo Comparator|arm a|This group is a placebo control group, and we will use radiation therapy plus Placebos as the control group for the study
2847814|NCT03614065|Experimental|arm b|This group belongs to the experimental group. We will use radiotherapy combined with endostar for treatment, so as to judge the efficacy of the medicine
2847815|NCT03614052|Experimental|tamsulosin hydrochloride|Tamsulosin hydrochloride 0,4 mg tablets by mouth per day for 5 days before ureteroscopy
2847816|NCT03614052|Placebo Comparator|Placebo oral tablet|Placebo oral tablets by mouth per day for 5 days before ureteroscopy
2847817|NCT03614039|Active Comparator|probiotic-smectite|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
2847818|NCT03614039|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
2847819|NCT03614026|Experimental|Teachers and Parents as Partners Intervention|Teachers and Parents as Partners will occur in a series of stages comprised of approximately four structured meetings over approximately 8 weeks. A Teachers and Parents as Partners consultant will meet together with a student's parent(s), teachers, other school personnel (as appropriate), and the student (as appropriate). The Teachers and Parents as Partners team will collaboratively address behavior problem solving objectives. Specific objectives include: identifying strengths and specific behaviors of concern, specifying alternative prosocial behaviors, creating measurable behavior goals, co-constructing behavior intervention/support plans to address the target concerns, creating sustainable conditions to support plan implementation at home and school, and evaluating the plan to assess progress toward goals.
2847820|NCT03614026|No Intervention|Business as usual control|In the business-as-usual control condition, participants will have access to any services that a school would routinely provide (e.g., develop and implement a behavior support plan) as well as services families can access in the community (e.g., mental health support).
2847821|NCT03614013||Immunotherapy responders/non-responders|paraffin samples and relevant clinical data including RECIST 1.1 will be obtained from metastatic gastric cancer patients
2847822|NCT03614000|Experimental|positive screenings|
2847823|NCT03613987|No Intervention|NIPPV|non synchronized non invasive positive pressure ventilation
2847824|NCT03613987|Experimental|NAVA-NIPPV|synchronized non invasive positive pressure ventilation with NAVA
2847825|NCT03613974|Experimental|lidocaine concentraion|the popliteal block will be performed (once) in all patients using 20 ml of lidoacine. The response of a patient determined the lidocaine concentration given to the next patient (a biased-coin design up-down sequential method). If a patient had a negative response (failed block), the lidocaine concentration was increased by 0.1% w/v in the next patient. If a patient had a positive response (successful block), the next patient was randomized to receive the same lidocaine concentration (with probability of 0.89), or to receive a concentration 0.1% w/v less (with probability of 0.11).
2847826|NCT03613935|Placebo Comparator|Product 1|Normal glucose, isosweet, homogeneous: 43 g glucose beverage, with a 43 g glucose equivalent sweetness homogenously delivered
2847827|NCT03613935|Active Comparator|Product 2|Low glucose, isosweet, heterogeneous: 30 g glucose beverage with 43 g glucose equivalent sweetness heterogeneously delivered
2847828|NCT03613935|Active Comparator|Product 3|Low glucose, less sweet, homogeneous: 30 g glucose beverage with a 30 g glucose equivalent sweetness homogenously delivered
2847829|NCT03613935|Active Comparator|Product 4|Low glucose+sucralose, isosweet, homogeneous: 30 g glucose + 18 mg sucralose beverage with a 43 g glucose equivalent sweetness homogenously delivered
2847830|NCT03613922|Experimental|Early Manual Therapy Group|Routine physiotherapy program plus Mulligan's Mobilization with Movement technique were applied.
2847831|NCT03613922|Active Comparator|Routine Physiotherapy Group|Only routine physiotherapy program was applied
2847832|NCT03613909|Experimental|CP950|CP950 Off The Ear (OTE) sound processor
2847833|NCT03613909|Active Comparator|BTE|Behind the Ear (BTE) sound processor (either a CP810 or CP900 series)
2847834|NCT03613896|Placebo Comparator|conventional dentures|a complete denture made through conventional processing technique
2847835|NCT03613896|Active Comparator|3D printed dentures|a complete denture made through 3d printing
2847836|NCT03613883|Experimental|Primary Study Arm|The intervention is done to those patients that are managed by endovascular stent that is inserted in the parent artery to induce slowness in the blood flow thus initiate thrombosis in the aneurysmal sac.
2847837|NCT03613883|Experimental|Expanded Selection Arm|The intervention is done to the expanded selection arm and is managed by embolic materials (coils / glue) that occlude the aneurysm by proximal occlusion, proximal and distal occlusion or sac packing
2847838|NCT03613870|Active Comparator|PermeaDerm|Participants receive PermeaDerm dressing for wound treatment until wounds have healed completely
2847839|NCT03613870|Active Comparator|Mepilex Ag|Participants receive Mepilex Ag dressing for wound treatment until wounds have healed completely
2847840|NCT03613857||Clopidogrel group|Anterior myocardial infarction patients undergoing percutaneous coronary intervention take loading dose 600 mg oral clopidogrel (plavix) tablets before the procedure.
2847841|NCT03613857||Ticagrelor group|Anterior myocardial infarction patients undergoing percutaneous coronary intervention take loading dose180 mg oral ticagrelor (brilique) tablets before the procedure.
2847842|NCT03613844|Experimental|DHA|oral DHA supplementation at 2 grams per day
2847843|NCT03613844|Placebo Comparator|Placebo|Placebo for DHA
2847844|NCT03613818|Experimental|eCHECKUP TO GO|Brief, web-based alcohol intervention
2847845|NCT03613818|No Intervention|Control|Assessment only
2847846|NCT03613805|Active Comparator|Dexcom G5 - Eversense|Patients will wear first Dexcom G5 (Dexcom San Diego, CA, USA) transcutaneous sensor for 3 months, then Eversnese(Senseonics Inc, MD, USA) implantable sensor for 3 months Accuracy and efficacy will be evaluated
2847847|NCT03613805|Experimental|Eversense- Dexcom G5|Patients will wear first Eversense (Senseonics Inc, MD, USA) implantable sensor for 3 months, then Dexcom G5 (Dexcom San Diego, CA, USA) transcutaneous sensor for 3 months accuracy and efficacy will be evaluated
2847937|NCT03613220|Experimental|ribociclib + letrozole|Ribociclib oral (3 weeks on/1 week off) in combination with oral once daily letrozole: 600 mg ribociclib QD + 2.5 mg letrozole QD
2847848|NCT03613792|Active Comparator|Remifentanil and Ketamine Group|Patients in Group 1 will receive remifentanil and ketamine. Remifentanil will be administered initially with a 1mcg/kg IV bolus followed by a continuous infusion, 0.1 to 0.15 mcg/kg/min IV (using ideal body weight) with titration to a maximum dose of 0.2 to 0.4 mcg/kg/min IV. Total dose of ketamine will be titrated from 10 to 40 mg, based on clinical judgment, and it will be recorded. Ketamine will be delivered using 2mL syringes, previously filled with ketamine in normal saline at a 10mg/mL concentration.
2847849|NCT03613792|Active Comparator|Fentanyl and Midazolam|The patients in this group will receive fentanyl doses that range between 0.5 to 2 mcg/kg (25 - 50 mcg) IV bolus in combination with midazolam 1-5 mg bolus over at least 2 minutes as determined by attending anesthesiologist (not to exceed 2.5 mg / 2 min per package insert). Total dosing of fentanyl and midazolam may be titrated, based on clinical judgment, and it will be recorded. Maintenance, additional midazolam doses of 25% of total initial dose required to achieved desired sedation may be administered IV if additional sedation is considered necessary
2847850|NCT03613779|Experimental|LUS-guided therapy group|"LUS-guided therapy group. Patients randomly allocated to this arm will receive standard of care + LUS examination accessible to treating physician in every visit. Depending on the results of LUS examination, a low dose or high dose of diuretics will be administered.~A standardized algorithm will be provided to ensure compliance to guideline-recommended medical therapy for heart failure."
2847851|NCT03613779|Active Comparator|Control group.|"Control group. Patients randomly allocated to this arm will receive standard of care + LUS examination blinded to the treating physician in every visit. Diuretic titration will be based on standard practice (physical examination, symptoms and lab results).~A standardized algorithm will be provided to ensure compliance to guideline-recommended medical therapy for heart failure."
2847852|NCT03613766|Experimental|Physical activity program|Before 3 to 6 months before the expected date of surgery, the experimental group, performed a 12-week monitored and supervised concurrent exercise program. Before and after of this period, body composition, anthropometric measures, physical fitness, cardiovascular risk, blood samples, Basal Metabolic Rate and health-related quality of life were measured in a laboratory under controlled conditions.
2847853|NCT03613766|No Intervention|Habitual care prescription|Before 3 to 6 months before the expected date of surgery, the control group, followed the habitual care prescriptions until the surgery
2847854|NCT03613753|Experimental|Arm A|Chemotherapy:irinotecan plus lobaplatin
2847855|NCT03613753|Active Comparator|Arm B|Chemotherapy:irinotecan
2847856|NCT03613740|Experimental|Fucoxanthin|12 mg Fucoxanthin capsule, once a day before breakfast during 90 days.
2847857|NCT03613740|Placebo Comparator|Magnesium Sterate|Homologated magnesium sterate capsule, once a day before breakfast during 90 days.
2847858|NCT03613727|Experimental|IV Vitamin C followed by oral Vitamin C|All study participants will receive the same treatment. Each participant will be given intravenous, which means by vein (IV), vitamin C three times a day for 14 days. Then participants will take vitamin C orally (by mouth in pill form) twice a day each day until 6 months after transplant. The treatment is IV vitamin C 50 mg/kg/day. After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day.
2847859|NCT03613714|Active Comparator|Intervention Group|At-home blood pressure monitoring at 2-5 days post-discharge from the hospital using a digital blood pressure cuff. Participants will receive text message reminders to check blood pressure. Contacted by clinic staff to review blood pressure log.
2847860|NCT03613714|No Intervention|Usual Care|Blood pressure monitoring assessment will be done at 2-5 days post-discharge in the office. Participants will be given high blood pressure information hand-outs and instructed to follow-up in obstetric clinic for blood pressure check within 5 days after discharge from the hospital.
2847861|NCT03613701||Moyamoya disease patients|Moyamoya disease patients/Healthy volunteers
2847862|NCT03613688|Experimental|Deepure Group A|Visit 3: Warm water without Deepure; Visit 4: Warm water with 1 g Deepure; Visit 5: Warm water with 1.5 g Deepure; Visit 6: Warm water with 2 g Deepure.
2847863|NCT03613688|Experimental|Deepure Group B|Visit 3: Warm water with 1 g Deepure; Visit 4: Warm water with 1.5 g Deepure; Visit 5: Warm water with 2 g Deepure; Visit 6: Warm water without Deepure.
2847864|NCT03613688|Experimental|Deepure Group C|Visit 3: Warm water with 1.5 g Deepure; Visit 4: Warm water with 2 g Deepure; Visit 5: Warm water without Deepure; Visit 6: Warm water with 1 g Deepure.
2847865|NCT03613688|Experimental|Deepure Group D|Visit 3: Warm water with 2 g Deepure; Visit 4: Warm water without Deepure; Visit 5: Warm water with 1 g Deepure; Visit 6: Warm water with 1.5 g Deepure.
2847866|NCT03613675|Experimental|Video games|All participants will be asked to play 4 video games.
2847867|NCT03613662|Experimental|SP-102|SP-102
2847868|NCT03613649|Experimental|Treatment A|2 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72
2847869|NCT03613649|Experimental|Treatment B|4 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72
2847870|NCT03613649|Placebo Comparator|Treatment C|Placebo for zoliflodacin administered orally on Day 1 of each dosing period, n=72
2847871|NCT03613649|Active Comparator|Treatment D|400 mg of moxifloxacin administered orally on Day 1 of each dosing period, n=72
2847872|NCT03613636||CAP cohort|"Children of age 3 to 16 years;~In- and outpatients;~Clinically diagnosed community-acquired pneumonia (CAP)."
2847873|NCT03613636||Healthy control cohort|"Healthy asymptomatic children of age 3 to 16 years;~undergoing an elective surgical procedure."
2847874|NCT03613636||Family control cohort|- Family members of index CAP patients.
2847875|NCT03613623||Patients|Patients diagnosed with acromegaly and currently taking long-acting somatostatin analogues for treatment.
2847876|NCT03613623||Physicians|Physicians for those treating the patients enrolled in the study.
2847877|NCT03613610|Active Comparator|Three needles group|
2847878|NCT03613610|Active Comparator|Single needle group|
2847879|NCT03613597|Experimental|Etoposide plus Lobaplatin group|Chemotherapy:etoposide plus lobaplatin (EL)
2847880|NCT03613597|Active Comparator|Etoposide plus Cisplatin group|Chemotherapy:etoposide plus cisplatin (EP)
2847881|NCT03613584|Active Comparator|Group W (von Willebrand factor concentrate)|The patient receives von Willebrand factor concentrate (vWFC) as a bolus of 25 IU/kg followed by a continuous infusion of 50 IU/kg/24h until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the administration of the Investigational Medicinal Product (IMP) will be stopped on the 7th day.
2847882|NCT03613584|Placebo Comparator|Group S (standard therapy with saline solution)|The patient receives the standard therapy plus an additional volume of saline solution equivalent to the amount of von Willebrand factor concentrate (vWFC) the patient would receive in Group W to keep the blind. The volume is given according to the VWFC-solution (0.25 ml/kg BW) what would be resulting from the patient's weight followed by a continuous saline infusion (0.50 ml/kg BW) until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the Investigational Medicinal Product (IMP) administration is stopped on the 7th day.
2847883|NCT03613571|Experimental|ILB|ILB treatment
2847884|NCT03613558|Experimental|Dexmedetomidine Sedation|This group will receive 1mcg/kg bolus of dexmedetomidine over 15 minutes after intubation followed by an infusion of dexmedetomidine at 0.5mcg/kg/hr until approximately 30 minutes before the end of surgery.
2847885|NCT03613558|Placebo Comparator|Placebo|This group will receive a colorless, odorless liquid (i.e. normal saline) in order to resemble Dexmedetomidine.
2847886|NCT03613545|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
2847887|NCT03613545|Sham Comparator|placebo fecal microbiota transplantation|Infusion of sham
2847888|NCT03613545|Sham Comparator|Traditional treatments|Traditional treatments according to associated guidelines such as probiotics, antibiotics or antidepressants
2847889|NCT03613532|Experimental|Venetoclax|"This trial can be divided into three periods: 1) Screening, 2) Treatment including venetoclax + FluBu2 and transplantation; and 3) Post-Transplant follow up.~Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Venetoclax: 6-7 total doses depending on dose level assigned~FLuBu2~Busulfan: given twice daily for 4 days~Fludarabine : given once daily for 4 days"
2847890|NCT03613519|Placebo Comparator|Usual care (sleep hygiene)|Participants randomized to usual care will receive an emailed PDF copy of the standardized sleep hygiene handout and will be mailed a paper copy of the same document.
2847891|NCT03613519|Active Comparator|Sleep Healthy Using the Internet (SHUTi)|SHUTi is a publicly available standard web-based cognitive-behavioral therapy instrument for insomnia (CBT-I)
2847892|NCT03613519|Active Comparator|SHUTi for Black women (SHUTi-BW)|The CBT-I instrument tailored for Black women.
2847893|NCT03613506|Experimental|Peripheral blood TGF-β content before and after radiotherapy|
2847894|NCT03613493|Other|HPV self-sampling kit + Interview|Participants will receive an HPV self-sampling kit to screen for HPV and then are interviewed about their experience using the tool.
2847895|NCT03613493|Experimental|Culturally-targeted Fear appeal message HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV, accompanied by a culturally-targeted fear appeal message
2847896|NCT03613493|Experimental|Fear appeal message HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV, accompanied by a culturally-targeted fear appeal message
2847897|NCT03613493|Active Comparator|HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV
2847898|NCT03613480|Experimental|Motivational Interviewing|Patients will receive 6 brief (20-30mins) counseling sessions based on the principles of Motivational Interviewing by a trained member (psychiatrist) of the research team. The first session will take place at 2 weeks after baseline and the following 5 sessions will be conducted at a monthly basis.
2847899|NCT03613480|No Intervention|Care as usual|Patients will be followed-up by the hepatologists of the Outpatient Department at regular time intervals and will be re-evaluated after 6 months from baseline
2847900|NCT03613467||VATS lobectomy|Pathologic N2 NSCLC patients who received lobectomy by video-assisted thoracoscopic surgery
2847901|NCT03613467||Thoracotomy lobectomy|Pathologic N2 NSCLC patients who received lobectomy by thoracotomy
2847902|NCT03613454|Active Comparator|Splenic artery embolization with vascular embolic coils|
2847903|NCT03613454|Active Comparator|Splenic artery embolization with vascular embolic plugs|
2847904|NCT03613441|Experimental|Mindful Awareness Practices (MAPs)|Mindful Awareness Practices is a mindfulness-based intervention developed at UCLA's Mindful Awareness Research Center. It is a weekly 2-hour, 6-session, group-based course in mindfulness meditation that is available in-person or online.
2847905|NCT03613441|No Intervention|Control|Waitlist control (intervention will be available to this group at the end of the study period)
2847906|NCT03613428|Experimental|ruxolitinib, vincristine, prednisone|Open label dosing cohorts will evaluate oral ruxolitinib (doses ranging from 10 - 80 mg) in combination with vincristine (1.4 mg/m2) and oral prednisone (1 mg/kg, 5 days a week for 4 weeks).
2847907|NCT03613415|Experimental|Expansion by Densah bur|"Scrubbing and draping of the patient in a standard fashion for intra oral procedures followed by local anesthesia administration to the patient.~A mid crestal flap will be reflected.~For both groups the implant manufacturer's pilot drill will be used to perform a standard osteotomy of 10 mm depth.~Sequential use of Densah bur under copious irrigation.~An implant of 3.9*10 mm will be inserted.~Smart peg will be placed on implant and Osstell will be used to record ISQ.~Healing collars will be placed on implants.~Flap will be prepared for closure and suturing."
2847908|NCT03613415|Active Comparator|Expander|"Scrubbing and draping of the patient in a standard fashion for intra oral procedures followed by local anesthesia administration to the patient.~A mid crestal flap will be reflected.~For both groups the implant manufacturer's pilot drill will be used to perform a standard osteotomy of 10 mm depth.~Sequential use of screw expanders.~An implant of 3.9*10 mm will be inserted.~Smart peg will be placed on implant and Osstell will be used to record ISQ.~Healing collars will be placed on implants.~Flap will be prepared for closure and suturing."
2847909|NCT03613402||Cohort 1|Patients at risk of VTE who are prescribed betrixaban to prevent VTE
2847910|NCT03613402||Cohort 2|Patients at risk of VTE who are prescribed betrixaban or other VTE prophylaxis
2847911|NCT03613389|Experimental|oral topical vitamin E|
2847912|NCT03613389|No Intervention|voriconazole and levofloxacin|
2847913|NCT03613376|No Intervention|No Compression|Patients in this group will not receive any compression after treatment
2847914|NCT03613376|Active Comparator|Compression|Patients in this group will use class II compression stockings continuously until next evening and then next 4 days during daytime.
2847936|NCT03613233|Active Comparator|microinvasive glaucoma surgery (MIGS)|glaucoma procedures such as : canaloplasty (traditional, ABiC, modified), iStent, XEN, Cypass,Hydrus- and with any other microinvasive IOP reducing device
2847915|NCT03613350||Urodynamic stress incontinence|Urodynamic study incontinence Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.
2847916|NCT03613350||USI+BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.BO was defined as <300 mL of the volume at strong desire to void during filling cystometry. Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at a cystometric capacity that usually results in voiding.
2847917|NCT03613350||BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. BO was defined as <300 mL of the volume at strong desire to void during filling cystometry. Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at a cystometric capacity that usually results in voiding.
2847918|NCT03613350||No demonstrated USI+BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. No urodynamic stress incontinence, no bladder oversensitivity nor detrusor overactivity was noted in this group.
2847919|NCT03613337||current smokers|Current smokers are those who continued smoking cigarettes more than 1 cigarette pre month after first percutaneous coronary intervention (PCI) .
2847920|NCT03613337||nonsmokers|Nonsmokers are those who never smoked in their lifetime.
2847921|NCT03613337||former smokers|Former smokers are those who had quit smoking after percutaneous coronary intervention (PCI) , and smoked less than 1 cigarette pre month after first percutaneous coronary intervention (PCI)
2847922|NCT03613324||Bladder outlet obstruction (BOO)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having BOO when Qmax was <12 mL/s and PdetQmax was ≥25 cmH2O with sustained detrusor contraction during voiding cystometry.
2847923|NCT03613324||Detrusor underactivity (DU)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having DU when Qmax was <12 mL/s and PdetQmax was <10 cmH2O during voiding cystometry.
2847924|NCT03613324||ND BOO/DU|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. This group revealed no demonstrated bladder outlet obstruction nor detrusor underactivity.
2847925|NCT03613311||Evident urodynamic stress incontinence(USI)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. USI is noted during filling cystometry and is defined as the involuntary leakage of urine during increased abdominal pressure, in the absence of a detrusor contraction.
2847926|NCT03613311||Occult USI|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. USI is noted during filling cystometry and is defined as the involuntary leakage of urine during increased abdominal pressure, in the absence of a detrusor contraction after prolapse reduction by vaginal gauze.
2847927|NCT03613311||ND USI|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. No USI was noted in this group.
2847928|NCT03613298|Experimental|HIFU (Focal One®) Treatment|"Subjects harboring an isolated recto-sigmoid deep invasive endometriosis (DIE) lesion with a persistence of symptoms despite hormonal treatment will be installed on the Focal One® device to:~Evaluate its ability to locate and assess the volume of the endometriosic lesion~Treat the targeted lesion by HIFU energy application. Real-time guided ultrasonography will be used to determine the location of the endometriosic nodule.~Patients will fill-out questionnaires on gynecological and intestinal symptoms and on quality of life before treatment and 1 and 6 months after HIFU. Imaging follow-up scans will be organized at 1 and 6 months and by a pelvic MRI scan at 3/6 months."
2847929|NCT03613285|Active Comparator|conventional brackets|Conventional brackets with Mac Laughin bennette Trevisi (MBT) prescription
2847930|NCT03613285|Active Comparator|Smart clip passive self ligating brackets|Smart clip passive self ligating brackets with Mac Laughin bennette Trevisi (MBT) prescription
2847931|NCT03613285|Active Comparator|Empower active self ligating brackets|Empower active self ligating brackets with Mac Laughin bennette Trevisi (MBT) prescription
2847932|NCT03613272|Experimental|Subxiphoid approach|The patients in subxiphoid group will get subxiphoid approach extended thymectomy by VATS. Whole dissection was performed through a 4 to 7cm transverse subxiphoid incision, and a single 5-mm port was inserted into the right chest cavity for the video thoracoscope and subsequently for the chest tube. The sternum was elevated with two hooks connected to the sternal frame. The lower hook was inserted through the subxiphoid incision, and the superior hook was inserted percutaneously after the mediastinal tissue including the major mediastinal vessels was dissected from the inner surface of the sternum. The thymus and fatty tissue of the anterior mediastinum and the aorta-pulmonary window was completely removed.
2847933|NCT03613272|Experimental|Intercostal approach|The patients in intercostal group will get intercostal approach extended thymectomy by VATS.
2847934|NCT03613259|Experimental|Diagnostic (fluorothymidine F-18 PET)|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes 21 or less days prior to standard of care radiation therapy and 14 or less days prior to the standard of care surgery.
2847935|NCT03613233|Active Comparator|traditional glaucoma surgery|glaucoma procedures such as trabeculectomy, iridencleisis, non - penetrating deep sclerectomy
2848075|NCT03612154|Experimental|Lorlatinib|Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
2847938|NCT03613207|Experimental|Dermal pharmacokinetic measurement|"Measurement of dermal pharmacokinetic (PK) parameters (AUC, Cmax) within each subject.~For dermal PK measurement cutaneous interstitial fluid will be sampled using dermal open flow microperfusion (dOFM). Additionally 8 blood samples will be drawn to rule out systemic appearance of lidocaine/prilocaine.~Each subject will have 9 test sites in total which are treated with:~2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~test sites: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)~2 test sites: untreated test site"
2847939|NCT03613194|Other|Patients with metastatic colorectal cancer|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~Peritoneal liquid~none tumoral peritoneum~Portal blood~Peripheral blood~Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
2847940|NCT03613181|Experimental|ANG1005|ANG1005 Investigational Drug
2847941|NCT03613181|Active Comparator|Physician's Best Choice|One of the protocol specified Physician's Best Choice therapies, assigned by the Investigator prior to randomization: capecitabine or eribulin or high-dose intravenous (IV) methotrexate.
2847942|NCT03613168|Experimental|Trastuzumab plus Gem/Cis|Gemcitabine 1,000 mg/m2 Day 1 and Day 8, every 3 weeks Cisplatin 25 mg/m2 Day 1 and Day 8, every 3 weeks Trastuzumab, every 3 weeks, 8 mg/kg at first cycle then, 6 mg/kg
2847943|NCT03613142|Experimental|Double tract anatomosis|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.
2847944|NCT03613142|Active Comparator|Esophagogastrostomy|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. Next, end-to-end or side to end esophagogastrostomy is performed with a circular stapler.
2847945|NCT03613129|Active Comparator|Low Dose CT38|A low dose of CT38 will be subcutaneously infused for 3 hours over each of 2 days
2847946|NCT03613129|Active Comparator|Intermediate Dose CT38|An intermediate dose of CT38 will be subcutaneously infused for 3 hours over each of 2 days
2847947|NCT03613129|Active Comparator|High Dose CT38|A high dose of CT38 will be subcutaneously infused for 3 hours over each of 2 days
2847948|NCT03613116|Experimental|High Dose Vitamin D3|Receives 4000 IU daily Vitamin D3 tablets.
2847949|NCT03613116|Active Comparator|Standard Dose Vitamin D3|Receives 600 IU Vitamin D3 tablets.
2847950|NCT03613103|Active Comparator|Direct laryngoscopy|Intubation with direct laryngoscopy (Conventional Intubation)
2847951|NCT03613103|Experimental|Videolaryngoscopy|Intubation with videolaryngoscopy (Assisted video intubation)
2847952|NCT03613090|Experimental|Collagen-hydroxyapatite Scaffold (Syn-Oss)|Placement of a collagen-hydroxyapatite scaffold (Syn-Oss), placement of a tricalcium silicate barrier (mineral trioxide aggregate), placement of a composite occlusal restoration (standard dental material).
2847953|NCT03613090|Active Comparator|Collagen Scaffold (Colla-Plug)|Placement of a collagen scaffold (Colla-Plug) over a blood clot, placement of a tricalcium silicate barrier (mineral trioxide aggregate), placement of a composite occlusal restoration (standard dental material). The Colla-Plug material is placed adjacent to the blood clot that has formed inside the root canal space. It act as a matrix for the subsequent placement of the mineral trioxide aggregate material. It has been used as the standard of care in regenerative endodontics since 2004.
2847954|NCT03613064|Experimental|Congestive Heart Failure (CHF)|The CHF arm will include adults hospitalized with CHF who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the CHF arm will receive the Socially Enhanced Transitional Care Intervention.
2847955|NCT03613064|Experimental|Ischemic Heart Disease (IHD)|The IHD arm will include adults hospitalized with IHD who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the IHD arm will receive the Socially Enhanced Transitional Care Intervention.
2847956|NCT03613051||age band one|age band one ( from 3 to 6 years ) we test manual dexterity by posting coins with prefered hand and non prefered hand test balance by jumping on mats
2847957|NCT03613051||age band two|age band two ( from 7 to 10 years ) test manual dexterity by threading lace
2847958|NCT03613051||age band three|age band three ( from 11 to 18 years ) test manual dexterity by turning pegs test balance by zigzag hopping
2847959|NCT03613038|Other|Phonetic complexity effects|Conduct a comprehensive kinematic assessment using state-of-the art 3D speech tracking technology on individuals with ALS and PD as well as healthy talkers to identify articulatory motor disturbances as a function of phonetic complexity and dysarthria severity. Phonetic complexity will be experimentally manipulated using the consonant and vowel complexity classification system proposed by Kent (1992) that takes into account the underlying articulatory motor adjustments required to produce various speech sounds.
2847960|NCT03613025|Other|Case : confirmed PCP diagnosis|Sampling of non-invasive and/or non-targeted respiratory tract specimens
2847961|NCT03613025|Other|Control : non confirmed PCP diagnosis|Sampling of non-invasive and/or non-targeted respiratory tract specimens
2847962|NCT03613012||Pain index|Pain index will be extracted from the EEG of chronic pain patients before and after pain treatments
2848076|NCT03612128|Other|control group|Children continued their traditional physiotherapy
2847963|NCT03612999|Experimental|CGM and Activity Tracker|Subjects receive a continuous glucose monitor (CGM) and activity tracker and are instructed to record daily activities and psychological data.
2847964|NCT03612986|Active Comparator|A: Active comparator SYALOX® 300 Plus|"Active Nutraceutical containing HA and AKBA (SYALOX® 300 Plus)~1 tablet/day, oral administration"
2847965|NCT03612986|Placebo Comparator|B: Placebo|"Placebo~1 tablet/day, oral administration"
2847966|NCT03612973|Active Comparator|non cirrhotic HCV patients|"complete blood picture~Liver and renal function tests~Prothrombin time and concentration~HCV quantitative polymerase chain reaction~Hepatitis B surface Ag~lipid profile~fasting blood glucose level~fasting insulin level~homeostasis model for the assessment of insulin resistance (HOMA-IR)~fibrosis (FIB- 4) index~Aspartate aminotransferase (AST)/platelet ratio index (APRI)~Abdominal ultrasound to assess liver and spleen~Fibroscan/transient elastography to grade hepatic fibrosis all these investigations will be done before and after receiving direct acting antiviral therapy (sofosbuvir 400 mg once daily + daclatasvir 60 mg once daily) for 12 weeks"
2847967|NCT03612973|Active Comparator|cirrhotic HCV patients|"complete blood picture~Liver and renal function tests~Prothrombin time and concentration~HCV quantitative polymerase chain reaction~Hepatitis B surface Ag~lipid profile~fasting blood glucose level~fasting insulin level~homeostasis model for the assessment of insulin resistance (HOMA-IR)~Fibrosis (FIB- 4) index~Aspartate aminotransferase (AST)/platelet ratio index (APRI)~Abdominal ultrasound to assess liver and spleen~Fibroscan/transient elastography to grade hepatic fibrosis all these investigations will be done before and after receiving direct acting antiviral therapy (sofosbuvir 400 mg once daily + daclatasvir 60 mg once daily) for 12 weeks"
2847968|NCT03612960|Experimental|Very low nicotine content cigarettes|Research cigarettes with very low nicotine content (0.03 mg/cigarette) compared to usual brand cigarettes.
2847969|NCT03612960|Placebo Comparator|Normal nicotine content cigarettes|Research cigarettes with normal nicotine content (0.8 mg/cigarette) similar to usual brand cigarettes.
2847970|NCT03612947|Active Comparator|Bupivacaine +magnesium sulphate|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4.
2847971|NCT03612947|Placebo Comparator|Bupivacaine only|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
2847972|NCT03612934||patients under the age of 65 years|patients under the age of 65 years
2847973|NCT03612934||patients at the age of 65 years and over|patients at the age of 65 years and over
2847974|NCT03612921|Active Comparator|oral group|the patients will receive oral amantadine sulfate using the dose 100 mg 90 minute prior to the surgery and infusion of100cm I.V saline
2847975|NCT03612921|Active Comparator|I.V group|the patients will receive 100 mg I.V amantadine sulfate infusion over 60minute prior to the surgery and placebo tablet 90 minute prior to the surgery
2847976|NCT03612921|Placebo Comparator|control group (group C)|the patients will receive placebo tablet 90 minute prior to the surgery and infusion of 100cm I.V saline over 60minute prior to the surgery
2847977|NCT03612908||Normothyroid pregnant women|Healthy pregnant women with the TSH serum values within the recommended ranged per trimester of pregnancy.
2847978|NCT03612908||Patients with a thyroid disease|Patients with a thyroid disease named hypothyroidism or hyperthyroidism.
2847979|NCT03612895|Experimental|Internal Care Coordination|The smoker will be connected to a Tobacco Care Coordinator who is based centrally within the health care system but has ready access via EHR, email, and telephone with staff in each primary care practice.
2847980|NCT03612895|Experimental|External Community Referral|"This intervention will connect the smoker directly via warm transfer to a the Massachusetts Smokers Helpline operated by National Jewish Health, which will provide its standard services to smokers."
2847981|NCT03612895|Other|Usual Care|Passive referral to quitline and referral to primary care physician.
2847982|NCT03612882||Western University Students|Online questionnaire
2847983|NCT03612869|Experimental|AAV SGSH gene therapy (LYS-SAF302)|One-time intracerebral administration of adeno-associated viral vector serotype rh10 containing the human N-sulfoglucosamine sulfohydrolase (SGSH) cDNA.
2847984|NCT03612856|Experimental|AB023 (xisomab 3G3)|
2847985|NCT03612856|Placebo Comparator|placebo|
2847986|NCT03612843||Dry needle|Dry needling is provided as a part of a comprehensive treatment program by a physical therapist. The patient and the therapist will record any adverse events that occur.
2847987|NCT03612830|Experimental|LECS|Laparoscopic and Endoscopic cooperative surgery,LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .
2847988|NCT03612830|Experimental|RECS|Robotic and Endoscopic cooperative surgery,RECS resects the tumor completely by Dan Vinchi robot with the help of the precise positioning and guidance of endoscopy .
2847989|NCT03612817|Active Comparator|Tafluprost/timolol with PM dosing|Therapy with Tafluprost/timolol fixed combination drops dosed PM (20:00)
2847990|NCT03612817|Active Comparator|Tafluprost/timolol with AM dosing|Therapy with Tafluprost/timolol fixed combination drops dosed AM (08:00)
2847991|NCT03612804|No Intervention|Unstructured care|Providers in this arm will continue to provide care as usual during lung cancer screening, with no intervention from the study team.
2847992|NCT03612804|Experimental|Proactive care|Providers in this arm will receive guidance from the study team about offering lung cancer screening patients proactive cessation care, including cessation medications and behavioral telephone counseling.
2847993|NCT03612791|Active Comparator|Standard Treatment Arm|"Radiotherapy (RT):~Pelvic +/- para-aortic EBRT (IMRT): 45 Gy in 25 fractions over 5 weeks (Weeks 1-5, with simultaneously integrated boosts to macroscopically involved lymph nodes, if any, in order to deliver a total dose of 60 Gy to macroscopic lymph nodes (including the dose delivered by brachytherapy).~Uterovaginal brachytherapy (Week 7; maximum interval between EBRT and brachytherapy: 14 days). If appropriate and feasible, dose escalation will be assumed, particularly for advanced disease, with the objective to deliver a total dose of 85 Gy (equivalent dose in 2-Gy fractions with α/β=10 Gy) to 80% of the High Risk-Clinical Target Volume (HR-CTV), including 45 Gy through EBRT. The total dose might be lower in case of close proximity to organs at risk (OARs).~Total duration of RT (including brachytherapy) should be ≤ 55 days.~Chemotherapy:~- Cisplatin infused 40 mg/m2 (maximum 70 mg) weekly IV during EBRT (Weeks 1-5)."
2848077|NCT03612128|Active Comparator|intervention group|We applied mirror therapy in addition to traditional physiotherapy
2847994|NCT03612791|Experimental|Experimental Treatment Arm|"Same treatment as described above (CRT, followed by uterovaginal brachytherapy), plus~atezolizumab administered IV 1200 mg Q3W, starting one week before EBRT (Week -1) and continued as an adjuvant for a total maximum of 20 cycles."
2847995|NCT03612778|Experimental|Plant-based diet|Participants will receive a meal plan based on unrefined plant-based foods with the following macronutrient composition: approximately 15% of calories from vegetable protein, <15% from fat, and 70-75% from carbohydrates. Additionally, to ensure adequate intake of n-3 polyunsaturated fatty acids, they will receive a supplement in the form of one 840 mg n-3 acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily. Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.
2847996|NCT03612778|Active Comparator|Mediterranean diet|Participants will receive a meal plan, based on the recommendations by the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology and European Atherosclerosis Society, based on Mediterranean diet pattern with the following macronutrient composition: approximately 15% of calories from animal and vegetable protein, up to 30% of calories from fat, 50-65% from carbohydrates. Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.
2847997|NCT03612765|Experimental|Intervention group|Participants in the intervention group will receive face-to-face intervention sessions that include interviews, discussions and didactic teaching.
2847998|NCT03612765|No Intervention|Control group|Participants in the control group will receive usual care that normally includes three monthly outpatient doctor consultations and when necessary, heart failure nurse referral.
2847999|NCT03612752|Experimental|Active arm|CMI-168
2848000|NCT03612752|Placebo Comparator|Placebo arm|Placebo
2848001|NCT03612739|Experimental|Cohort 1|5-azacytidine + 1x10^8 NKR-2 CAR-T Cells
2848002|NCT03612739|Experimental|Cohort 2|5-azacytidine + 3x10^8 NKR-2 CAR-T Cells
2848003|NCT03612739|Experimental|Cohort 3|5-azacytidine + 1x10^9 NKR-2 CAR-T Cells
2848004|NCT03612713|Active Comparator|Oxycodone Medication First|one hour before fMRI scan participants will be given a single dose 15mg immediate release oxycodone
2848005|NCT03612713|Placebo Comparator|Placebo First|one hour before fMRI scan participants will be given a single dose placebo.
2848006|NCT03612700|Experimental|CPFA-rich diet|Free living diet controlled in CPFA intake
2848007|NCT03612687||Laparoscopic Liver Surgery|Laparoscopic Liver Surgical Procedures with minimally invasive hemodynamic monitoring
2848008|NCT03612687||Laparoscopic Pancreas Surgery|Laparoscopic Pancreas Surgical Procedures with minimally invasive hemodynamic monitoring
2848009|NCT03612687||Open Liver Surgery|Open Liver Surgical Procedures with minimally invasive hemodynamic monitoring
2848010|NCT03612687||Open Pancreas Surgery|Open Pancreas Surgical Procedures with minimally invasive hemodynamic monitoring
2848011|NCT03612674|Active Comparator|Standard colonoscopy (S)|A standard colonoscopy will be performed.
2848012|NCT03612674|Experimental|AEV assisted colonoscopy (E)|Colonoscopy with ARC Endocuff Vision attached to the top of the scope will be performed.
2848013|NCT03612661|Experimental|Intuitive Eating Group Intervention|Intuitive eating intervention delivered in a group format with 8-10 women, led by 2 facilitators.
2848014|NCT03612661|Experimental|Intuitive Eating Guided Self-Help|Participants in this condition engage in 8 weeks of self-study of the intuitive eating intervention have ~20 minute weekly phone call with a study interventionist.
2848015|NCT03612648|Experimental|TRI-APBI|"Brachytherapy TRI-APBI the PTV is prescribed 7.5 Gy x three fractions given over two to three days OR~External beam TRI-APBI the PTV is prescribed 8.5 Gy x three fractions given over two to three days"
2848016|NCT03612622|Active Comparator|Transcranial Magnetic Stimulation-Real|Participants will receive active TMS once daily for two weeks
2848017|NCT03612622|Placebo Comparator|Transcranial Magnetic Stimulation-Sham|Participants will receive sham TMS once daily for two weeks
2848018|NCT03612609|Other|blood, urine and semen sample|15 patients, with acute dengue virus infection and a positive RNA detection in blood or/and urines
2848019|NCT03612596|Experimental|Narrative visualization|Wearable activity monitor, app, and enhanced motivational scrapbook materials (instant camera, stickers, markers, enhanced content)
2848020|NCT03612596|Active Comparator|Standard self-regulation|Wearable activity monitor, app, and standard workbook materials (markers, a workbook with a calendar log to keep track of steps over time)
2848021|NCT03612583|Experimental|Lower PEEP|Lung- and Diaphragm-Protective Ventilation - PEEP will be set at 8 cm H2O
2848022|NCT03612583|Experimental|Higher PEEP|Lung- and Diaphragm-Protective Ventilation - PEEP will be titrated to achieve end-expiratory PL = 2-3 cm H20 and at least 5 cm H2O greater than the level applied in the lower PEEP arm
2848023|NCT03612570|Experimental|NPS Treated SH Lesion|Nano-Pulse Stimulation Device using pre-defined energy protocol
2848024|NCT03612557|Experimental|active treatment arm|penicillin G benzathine treatment
2848025|NCT03612544|Experimental|Intervention group|
2848026|NCT03612544|Active Comparator|Control group|
2848027|NCT03612531|Experimental|Supportive Care (manual therapy)|Participants receive 10 manual therapy sessions performed by a speech pathologist during weeks 1-6. After completion of 6 weeks of therapy, participants perform manual therapy at home daily for 6 weeks.
2848028|NCT03612518|Experimental|Text and Voice Messages|Participants will receive text messages and voice messages
2848029|NCT03612518|Experimental|Interactive Phone Call|Participants will receive interactive phone calls
2848030|NCT03612518|No Intervention|Control|Participants in this arm will not be exposed to any intervention.
2848031|NCT03612505|Active Comparator|Intervention|
2848032|NCT03612505|No Intervention|Control|
2848033|NCT03612492|Active Comparator|Esmolol Group|Patients will receive esmolol during induction of anesthesia
2848034|NCT03612492|Active Comparator|Lidocaine Group|Patients will receive lidocaine during induction of anesthesia
2848035|NCT03612479|Experimental|KIDFIT Healthy|
2848036|NCT03612479|Active Comparator|KIDFIT Safe|
2848078|NCT03612115|Experimental|Neuromuscular electrical stimulation intervention|Neuromuscular electrical stimulation treatment
2848079|NCT03612115|No Intervention|Control|No additional intervention
2853724|NCT03572140||group A|RAVS IN resistent cases after daclatasvir plus sofosbuvir treatment
2848037|NCT03612466|Experimental|Dose Escalation Arm|"Dose Levels 1-3 will consist of treatment with radiopharmaceutical (153Sm-DOTMP) alone. If the maximally tolerated dose (MTD) has not been reached at Level 3, external beam radiotherapy will be added to each of Levels 4-6. Participants enrolled on Dose Levels 4-6 will be treated with external beam radiotherapy to all radiographically evident sites of disease. If an MTD has not been determined at Level 6, the study will end and Dose Level 6 will be declared the Recommended Phase 2 Dose.~Participants will be given prophylactic / supportive treatment protocols including Calcium Carbonate, mozobil, and neupogen injectable product."
2848038|NCT03612453|Experimental|Intervention group|
2848039|NCT03612453|Active Comparator|Control group|
2848040|NCT03612440|Experimental|Group D|40 patients receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
2848041|NCT03612440|Placebo Comparator|Group C|40 patients receive matching placebo (normal saline)
2848042|NCT03612427||Breastfed infants|Infants depending on breastfeeding S. Cholesterol S. Triglycerides S. HDL Cholesterol
2848043|NCT03612427||Formula-fed infants|Infants have formula feeding S. Cholesterol S. Triglycerides S. HDL Cholesterol
2848044|NCT03612414|Experimental|Aqualief® tablets|400 mg mucoadhesive tablets; three times per day just
2848045|NCT03612414|Placebo Comparator|Placebo tablets|400 mg mucoadhesive placebo tablets, three times per day just
2848046|NCT03612401|Other|Neurogenic Bladder|Spinal Cord Injury patients with known neurogenic bladder on treatment with Anticholinergic Agents at baseline switched to mirabegron as the study intervention
2848047|NCT03612388||cardioplegia with MPS® (Myocardial protection system)|cardioplegic formula with MPS® (Myocardial protection system); use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation
2848048|NCT03612388||cardioplegia with Cardioplexol ®|cardioplegic formula with Cardioplexol ® (colloid solution with Procaine, magnesium and potassium)
2848049|NCT03612375|Experimental|Intervention group|
2848050|NCT03612375|Active Comparator|Control group|
2848051|NCT03612362|Experimental|"Improved Injera Baking Biomass Stove"|"2750 eligible households with in 50 randomly selected clusters/Gotes are allocated into the improved Injera backing stove intervention arm."
2848052|NCT03612362|No Intervention|Control arm|"Similarly 2750 eligible households with in 50 randomly selected clusters/Gotes will continue to use the traditional Injera baking biomass stove and will be used as control arm."
2848053|NCT03612349|Other|Condition 1: All Products|Experimental Tobacco Marketplace Task is a behavioral economics task. During the task, participants purchase products from an online tobacco marketplace. In this condition, all tobacco products are available in menthol and non-menthol flavors.
2848054|NCT03612349|Other|Condition 2: No menthol LCCs|Experimental Tobacco Marketplace Task is a behavioral economics task. During the task, participants purchase products from an online tobacco marketplace. In this condition, the online tobacco marketplace does not include menthol flavored little cigars and cigarillos.
2848055|NCT03612336|Experimental|Intervention group|
2848056|NCT03612336|Active Comparator|Control group|
2848057|NCT03612323|Experimental|Intra-ligamentary Piroxicam|Piroxicam is a long acting potent Non steroidal anti-inflammatory drug (NSAID)with half life of 50 hours in plasma, is given as intervention to assess the pain,will be administered by intra-ligamentary technique by injecting 0.4 milliliter (mL) of 20 milligram (Mg) piroxicam.
2848058|NCT03612323|Active Comparator|Intra-ligamentary Articaine|Articaine is a local anesthetic agent, will be administered by intraligamentary technique by injecting 0.4 milliliter (mL) of 4% articaine
2848059|NCT03612297||ATOUTBIO|Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults.
2848060|NCT03612297||EVOLAB|Complete reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults.
2848061|NCT03612284|Experimental|Device Feasibility|"Scleral lens insertion solution study. This is not an interventional study, but a study to test a new contact lens solution. Primary FDA Classification: 21 CFR 886.5928 Soft (Hydrophilic) Contact Lens Care Products Product Code: LPN~Secondary FDA Classification: 21 CFR 886.5918 - Rigid gas permeable contact lens care products Product Code: MRC~The FDA has previously made risk determinations (class II, non-significant risk) for devices classified under 21 CFR 886.5928 and 21 CFR 886.5918. As a non-significant risk device, the GatorFil Contact Lens Saline Solution is exempt from the IDE regulation (21 CFR 812)."
2848062|NCT03612271|Experimental|mGlide Intervention|Participants will be educated on HTN and taught to self-monitor their BP. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice.
2848063|NCT03612271|No Intervention|Clinical Care Comparison|Patients will be educated similar to intervention and taught self-monitoring of BP. Then they will be asked to follow up with primary care as usual.
2848064|NCT03612258|Experimental|Functional Magnetic Resonance Imaging|
2848065|NCT03612232|Experimental|Cabozantinib|oral cabozantinib as tablets continuosly (60 mg single dose, tablets)
2848066|NCT03612219|Experimental|IMRT with CC+Adjuvant Apatinib|Treat with Apatinib mesylate tablet for adjuvant treatment(the dose was 250 mg,orally,qd,28 days for an observation period,Six cycles)of local advanced nasopharyngeal carcinoma after Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy(cisplatin).
2848067|NCT03612219|Active Comparator|IMRT with CC|Only obeservation after Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy(cisplatin).
2848068|NCT03612193||Study A: Chronic >1 year|
2848069|NCT03612193||Study A: Acute <1 year|
2848070|NCT03612193||Study A: Household Control|
2848071|NCT03612193||Study B: Newly Diagnosed <6 months|
2848072|NCT03612193||Study B: Household Controls|
2848073|NCT03612167|Experimental|multi-modal cognitive intervention|a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.
2848074|NCT03612167|Active Comparator|nutritional group|A quasi-experimental design with nonequivalent control was adopted in a senior center. The intervention for control group was a 12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
2848080|NCT03612102|Active Comparator|Treatment|The treatment consists of a 5-day intensive group behavioral treatment program (IGBT)
2848081|NCT03612102|No Intervention|Waitlist|The waitlist consists of a 4-week waitlist period where parents will be provided with psychoeducational materials about their child's condition (i.e., selective mutism). After the 4-week waitlist period, families will be provided with the opportunity to participate in IGBT.
2848082|NCT03612089||Low back pain group|Individuals with non-specific chronic low back pain
2848083|NCT03612089||Healthy control group|Healthy individuals without low back pain
2848084|NCT03612076||Global cost of management of PJI|
2848085|NCT03612063|Experimental|Fitbit Iconic HR and Garmin Vivosmart HR|
2848086|NCT03612063|Experimental|Fitbit Iconic HR and TomTom Spark 3|
2848087|NCT03612063|Experimental|Garmin Vivosmart HR and TomTom Spark 3|
2848088|NCT03612063|Experimental|Fitbit Iconic HR and Apple Watch III|
2848089|NCT03612063|Experimental|Apple Watch III and Garmin Vivosmart HR|
2848090|NCT03612063|Experimental|Apple Watch III and TomTom Spark 3|
2848091|NCT03612050|Placebo Comparator|Enhanced Usual Care|facilitate any clinical interventions
2848092|NCT03612050|Experimental|Meaning Centered Psychotherapy|raise patients' sense of meaning/purpose
2848093|NCT03612037|Placebo Comparator|Control Phase|cellulose (600 mg)
2848094|NCT03612037|Experimental|Experimental Phase|alpha lipoic acid (600 mg)
2848095|NCT03612024||request for organ donation approved|
2848096|NCT03612024||request for organ donation rejected|
2848097|NCT03612011|Experimental|Onco-Repair|Onco-Repair tube of 150 ml
2848098|NCT03612011|Placebo Comparator|Placebo|Placebo tube of 150 ml
2848099|NCT03611998|Experimental|Survivors of Sex Trafficking|Survivors of sex trafficking (SST) who were living in a residential facility participated in this project by receiving occupation-based programming to address limitations in executive function skills over the course of the 8-month project. Sessions were held twice-monthly for an hour duration at each session.
2848100|NCT03611985|Experimental|Epidiferphane + taxane chemotherapy|
2848101|NCT03611972|Experimental|Sugar-sweetened beverage (SSB)|SSB provided at 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 2 weeks
2848102|NCT03611946|Experimental|rZIKV/D4Δ30-713|Participants will receive a single dose of rZIKV/D4Δ30-713 at study entry (Day 0).
2848103|NCT03611946|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
2848104|NCT03611933|No Intervention|Control group (CG)|Patients in the CG were provided with routine nursing care, as practiced in the clinic, including restricted bed rest. For this purpose, patients were given supine position in which the HOB was elevated 15° for 6-10 h; the patient's leg on the of the side of intervention was kept straight.
2848105|NCT03611933|Experimental|Experimental group (EG)|Patients in the EG were applied position changes between the first minute and sixth hour. During the initial six hours a supportive, thin pillow, 4 x 40 x 100 cm in size, was placed between the patient's shoulders and gluteals; this reduced the pressure on local tissues and muscle groups.
2848106|NCT03611920||Tetracycline|Teeth were soaked in topical tetracycline 5% for 5 minutes before replantation
2848107|NCT03611920||Dexamethasone|Teeth were soaked in dexamethasone (60μ ml-1) for 20 minutes before replantation
2848108|NCT03611907|Active Comparator|SL1(Cook® Single Lumen)|Oocyte retrieval with only aspiration system
2848109|NCT03611907|Active Comparator|SL2 ( Kitazato® Single Lumen 327350)|Oocyte retrieval with only aspiration system
2848110|NCT03611907|Active Comparator|DL1 (Cook® EchoTip® Double Lumen)|Oocyte retrieval with aspiration and flushing system
2848111|NCT03611907|Active Comparator|DL2 ( Kitazato® Single flushing Lumen)|Oocyte retrieval with aspiration and flushing system
2848112|NCT03611894||hemorrhagic ischemia|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
2848113|NCT03611894||nonhemorrhagic ischemia|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
2848114|NCT03611894||intracerebral hematoma|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
2848115|NCT03611881|Experimental|Short, Short, Present|4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.
2848116|NCT03611881|Experimental|Short, Long, Present|4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.
2848117|NCT03611881|Experimental|Long, Short, Present|8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.
2848118|NCT03611881|Experimental|Long, Long, Present|8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.
2848119|NCT03611881|Experimental|Short, Short, Absent|4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.
2848120|NCT03611881|Experimental|Short, Long, Absent|4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.
2848121|NCT03611881|Experimental|Long, Short, Absent|8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.
2848122|NCT03611881|Experimental|Long, Long, Absent|8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.
2848123|NCT03611868|Experimental|APG-115+Pembrolizumab open label, two-part phase Ib/II|single arm dose escalation and dose expansion
2848124|NCT03611855|Experimental|BCI Rehabilitation|Patients trained on use of BCI-controlled orthotic device are given a device for home use. Patients are asked to use the device an hour per day, 5 days per week, for 12 weeks. During device use, patients are instructed via pre-programmed instructions on a tablet paired with the device to either rest or vividly imagine moving their affected hand. The device receives signals from a scalp electrodes within a headset the patient dons prior to use. The device interprets these signals and closes the patient's hand during a successful rest trial, and opens the patient's hand during a successful move trial.
2848156|NCT03611647|Placebo Comparator|Placebo|
2848157|NCT03611634||BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|The aim of this study is just to constitute a biological collection from samples from the GUT microbiote in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
2848125|NCT03611855|Active Comparator|Range of Motion Therapy|Active and Passive Range-of-Motion (AROM, PROM) therapy strategies are commonly prescribed by physical therapists for at-home post-stroke motor deficit rehabilitation that can be performed independently. Patients practice movement with joints and limbs affected by the stroke, either by using the unaffected limb (or the assistance of a caretaker) to stretch the affected limb (PROM) or by actively moving the affected limb (AROM). Patients are asked to perform this therapy one hour per day, 5 days per week, for 12 weeks.
2848126|NCT03611842||Healthy eardrum|OME (otitis media with effusion)with normal tympanic membrane
2848127|NCT03611842||Atrophic eardrum|OME (otitis media with effusion) with atrophic membrane : thinning of the membrane, retraction pocket
2848128|NCT03611829|Active Comparator|Standard Care|Participants in the standard care condition were provided with diet and exercise counselling and psychoeducation from their physicians over the course of 8 sessions, as was routinely done at the clinic. Standard care did not involve any targeted intervention to reduce emotional eating.
2848129|NCT03611829|Experimental|ACT Intervention|In addition to receiving standard care, participants in the ACT condition were taught techniques to reduce their emotional eating. Three overarching skills were taught over the course of the ACT intervention: (1) values clarification and commitment, (2) metacognitive awareness, and (3) distress tolerance. Throughout the sessions, physicians formed if-then plans with the patients to specify how to habitually use the ACT techniques to reduce emotional eating in their everyday lives. At the end of each session, participants were given a one-page homework sheet that asked them to monitor their behavior and their use of the ACT techniques during the week.
2848130|NCT03611816||Group 1a|Patient with atrial fibrillation and without stroke history.
2848131|NCT03611816||Group 1b|Patient with atrial fibrillation with scheduled electrophysiology exploration or ablation.
2848132|NCT03611816||Group 1c|Patient with atrial fibrillation and with stroke history.
2848133|NCT03611816||Group 2|Patients aged over 80 years old and without history of atrial fibrillation.
2848134|NCT03611816||Group 3|Patient with cryptogenic stroke history before the age of 50.
2848135|NCT03611803|Experimental|Ekso Group|
2848136|NCT03611803|Active Comparator|Control|
2848137|NCT03611777||subjects with Pulmonary Disease, Chronic Obstructive|
2848138|NCT03611764|Experimental|Arm 1: Body Scan|"The mindfulness-based intervention (MBI) of the Body Scan is expected to take 20 minutes~Participants will then be guided through the Body Scan. Beginning with awareness of sensations of the left toe, patients will be asked to observe these sensations without judgment, simply noticing and allowing them. Awareness of sensations will continue up through the left leg, then from the right toe up the right leg, then abdomen and chest, then fingertips to arms, then neck, and finally the head. After completing the Body Scan, participants will be given several minutes of quiet to reflect upon how they feel. After opening their eyes, participants will be given the opportunity to discuss and ask questions.~Caregivers will be encouraged to practice with the patient or on their own, in an additional space on the floor called the Zen Den"
2848139|NCT03611751|Experimental|BMS-986165|BMS-986165 oral administration
2848140|NCT03611751|Placebo Comparator|Placebo|Placebo oral administration
2848141|NCT03611751|Active Comparator|Active comparator|Active comparator oral administration
2848142|NCT03611738|Experimental|Phase I Dose Escalation|"The design will recruit participants in cohorts of three patients each and will not allow for dose-skipping during escalation. A maximum of 18 participants will be enrolled for the phase I dose escalation. Three ceritinib dose levels have been identified for dose escalation (150 mg, 300 mg, and 450 mg), plus docetaxel at 75 mg. A backup dose (ceritinib 150 mg with docetaxel at 60 mg) is also prepared in case the three dose levels are too toxic. Therefore, four potential dose levels will be used for determination of maximum tolerated dose (MTD). The first cohort will start at dose level 1 (ceritinib 150 mg with docetaxel at 75 mg).~Level -1 Backup Cohort: 150 mg ceritinib; 60 mg/m^2 docetaxel Level 1 Starting Cohort: 150 mg ceritinib; 75 mg/m^2 docetaxel Level 2 Cohort: 300 mg ceritinib; 75 mg/m^2 docetaxel Level 3 Cohort: 450 mg ceritinib; 75 mg/m^2 docetaxel"
2848143|NCT03611738|Experimental|Phase Ib Dose Expansion|Treatment at recommended dose. Investigators plan to have 30 patients for the expansion cohort. This will include participants from the dose escalation portion receiving the recommended dose.
2848144|NCT03611725|Active Comparator|Distal radial artery|"After subcutaneous injection of lidocaine, the distal radial artery around the bony surface area is punctured with a 20-gauge venipuncture catheter needle or steel needle according to the operator's discretion. After successful puncture, flexible, straight plastic 0.025 mini-guidewire is inserted through the hole of the puncture needle. Then, Radifocus® introducer sheath (Terumo, Tokyo, Japan) is inserted into the distal radial artery."
2848145|NCT03611725|Placebo Comparator|Radial artery|"After subcutaneous injection of lidocaine, the radial artery is punctured with a 20-gauge venipuncture catheter needle or steel needle according to the operator's discretion. After successful puncture, flexible, straight plastic 0.025 mini-guidewire is inserted through the hole of the puncture needle. Then, Radifocus® introducer sheath (Terumo, Tokyo, Japan) is inserted into the radial artery."
2848146|NCT03611712|Experimental|CCRT-PG2 arm|Astragalus Polysaccharides 500 mg
2848147|NCT03611712|No Intervention|CCRT alone arm|
2848148|NCT03611699|Active Comparator|Umeclidinium bromide/vilanterol|Umeclidinium bromide/vilanterol (umeclidinium bromide 62.5 mcg; vilanterol 25mcg inhalation powder; trade name Anoro Ellipta) is a combination long-acting bronchodilator that acts to reduce the amount of air trapped in the lungs at the end of of expiration.
2848149|NCT03611699|Placebo Comparator|Placebo|A placebo inhaler will be administered to serve as a control comparator to the umeclidinium bromide/vilanterol inhaler.
2848150|NCT03611686||patient followed for metastatic prostate adenocarcinoma|patient wil be followed for metastatic prostate adenocarcinoma during 3 years
2848151|NCT03611673|Experimental|Group A: 15 Scents|Participants will be asked to inhale 15 different scents two times a day.
2848152|NCT03611673|Active Comparator|Group B: 4 Scents|Participants will be asked to inhale 4 different scents two times a day.
2848153|NCT03611660|Active Comparator|Traditional Lifestyle Program ONLY|Participants will receive an evidence-based 12-week family-based pediatric obesity program.
2848154|NCT03611660|Experimental|Traditional Lifestyle Program PLUS Mindfulness|Participants will receive an evidence-based 12-week family-based pediatric obesity program plus 6 sessions of mindfulness meditation instruction.
2848155|NCT03611647|Active Comparator|Probiotic|
2848161|NCT03611595|Experimental|Cabozantinib and 13-cis-retinoic acid|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles, combined with 13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
2848162|NCT03611582|Experimental|Semaglutide|Participants will receive semaglutide 2.4 mg during 68-week treatment period in addition to intensive behavioural therapy.
2848163|NCT03611582|Placebo Comparator|Semaglutide placebo|Participants will receive semaglutide placebo during 68-week treatment period in addition to intensive behavioural therapy.
2848164|NCT03611569|Experimental|Lu AF82422|"Part A:~Cohorts A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4: 12 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects (aiming for an equal number of men and women)~Part B:~Cohort B1: 8 patients with Parkinson's disease"
2848165|NCT03611569|Placebo Comparator|Placebo|"Part A:~Cohorts A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4: 12 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects (aiming for an equal number of men and women)~Part B:~Cohort B1: 8 patients with Parkinson's disease"
2848166|NCT03611556|Active Comparator|Arm A1|gemcitabine and nab-paclitaxel
2848167|NCT03611556|Experimental|Arm A2|oleclumab (MEDI9447), gemcitabine and nab-paclitaxel
2848168|NCT03611556|Experimental|Arm A3|oleclumab (MEDI9447), durvalumab (MEDI4736), and gemcitabine/nab-paclitaxel
2848169|NCT03611556|Active Comparator|Arm B1|mFOLFOX (oxaliplatin, leucovorin, 5-FU)
2848170|NCT03611556|Experimental|Arm B2|oleclumab (MEDI9447) and mFOLFOX (oxaliplatin, leucovorin, 5-FU)
2848171|NCT03611556|Experimental|Arm B3|oleclumab (MEDI9447), durvalumab (MEDI4736), and mFOLFOX (oxaliplatin, leucovorin, 5-FU)
2848172|NCT03611543||Screening Patients|100 Patients. Each patient who agrees to participate and is consented and is undergoing a routine screening mammogram will receive her normal 4 view 2D plus 3D combination imaging (Left Cranial Caudal (LCC), Left Mediolateral-Oblique (LMO), Right Cranial Caudal (RCC), Right Mediolateral-Oblique (RMLO)) mammogram, with the current standard paddle. In addition she will also receive a CC and a MLO in one of her breasts as determined by a randomization scheme with the new investigational curved paddle. The amount of compression applied to both mammograms will be that to achieve tautness.
2848173|NCT03611543||Diagnostic Patients|400 Patients. Patients who agree to participate, are consented and are undergoing a diagnostic exam will have her prescribed diagnostic 2D plus 3D combination imaging as well as a CC or MLO with both the standard paddle and the new investigational curved paddle compressed to tautness on the breast of interest. The order of the paddles will be randomized and the view (CC or MLO) will be based in the visibility of the area of interest for which the diagnostic imaging was ordered. (It is possible that one of the views is superior to assess the area of interest).
2848174|NCT03611530|Experimental|Arm A|Patients in Arm A will be randomized to receive Prostaglandin analogue (PGA) monotherapy + CoQun®. CoQun® ophthalmic solution will be administered two times daily. CoQun® will be administered in addition to hypotensive therapy. Dose modifications for CoQun® are not permitted.
2848175|NCT03611530|Placebo Comparator|Arm B|Patients in Arm B will be randomized to receive Prostaglandin analogue (PGA) monotherapy +Placebo. Placebo ophthalmic solution will be administered two times daily. Placebo will be administered in addition to hypotensive therapy. Dose modifications for Placebo are not permitted.
2848176|NCT03611517|Experimental|Sexual rehabilitation programme|The intervention exists of a nurse-led sexual rehabilitation programme, which is provided in addition to the care as usual. The intervention consists of four one-hour sessions at 1 month, 3, 6, and 12 months after RT. Women treated with RTBT will receive an additional appointment with the nurse (2 months after RTBT). Furthermore, the latter group receives a vaginal dilator set.
2848177|NCT03611517|No Intervention|Care as usual|The control group receives the optimal care as usual, according to each participating hospital's guidelines. Additionally, all patients receive an information booklet including information concerning sexuality after RT for GC. Patients who underwent RTBT also receive a vaginal dilator set.
2848178|NCT03611504||Hemospray® group|Patients with gastrointestinal bleeding treated with Hemospray®.
2848179|NCT03611491|Experimental|Princess® FILLER Lidocaine|Princess FILLER Lidocaine injections up to 10 ml given to the patients at baseline time point
2848180|NCT03611478|Experimental|Probiotic formulation|Contains a probiotic formulation. One capsule to be taken by mouth once daily for 28 days.
2848181|NCT03611478|Placebo Comparator|Placebo|Matching placebo to be taken once daily by mouth for 28 days.
2848182|NCT03611465|Other|VT ablation group|patients presenting history of myocardial infarction and ventricular tachycardia undergoing a VT ablation
2848183|NCT03611465|Experimental|pre implantation group|patients presenting history of myocardial infarction but without history of ventricular tachycardia. Patients schedulded for a cardiac defibrillator implantation in primary prevention.
2848184|NCT03611465|Experimental|control group|patients without history of myocardial infarction and without history of ventricular tachycardia, undergoing an ablation in the left atrium for an atrial fibrillation or an accessory pathway ablation.
2848185|NCT03611452|Experimental|Simple continuous|the sutures will be taken continuously by simple method
2848186|NCT03611452|Active Comparator|subcuticular|the sutures will be taken subcuticular
2848187|NCT03611452|Active Comparator|interrupted|the sutures will be taken interrupted method
2848188|NCT03611439|Active Comparator|ReBuilder Actives|Subjects take one 650 mg capsule by mouth twice a day for 12 months.
2848189|NCT03611439|Placebo Comparator|ReBuilder Placebo|Subjects take one placebo capsule by mouth twice a day for 12 months.
2848190|NCT03611426|Experimental|rhThrombin ( Topical )|The first part:rhThrombin ( Topical ) 500IU /ml、1000IU/m and 2000IU/ml During segmental hepatectomy; The second part:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml with absorbable collagen sponge During segmental hepatectomy; The third part:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml used directly sprayed on hemorrhagic point During segmental hepatectomy;
2848191|NCT03611426|Placebo Comparator|placebo|The first part: the same volume of saline during segmental hepatectomy; The second part:the same volume of saline used withabsorbable collagen sponge during segmental hepatectomy; The third part:the same volume of saline during segmental hepatectomy;
2848192|NCT03611413||ERAS programme|Patients who have been treated under an ERAS programm
2848194|NCT03611400|Experimental|Probiotic|2 capsules daily for 3 weeks, containing 3.8 x 10^9 CFU (colony forming units)/capsule of Lactobacillus rhamnosus strain R011and 0.2 x 10^9 CFU/capsule of L. helveticus strain R0052 (group is unknown, double blinded)
2848195|NCT03611400|Placebo Comparator|Placebo|2 capsules daily for 3 weeks containing the same carrier material and is similar in size, shape and taste to probiotic (group is unknown, double blinded)
2848196|NCT03611387||Normal|Patients without any type of glaucoma
2848197|NCT03611387||Primary angle closure glaucoma|Patients with primary angle closure glaucoma
2848198|NCT03611387||Primary open-angle glaucoma|Patients with primary open-angle glaucoma
2848199|NCT03611374|Experimental|Erector Spinae Plane Block|All participants will get the Erector Spinae Plane block (ESPB) as a prospective cohort study. After anesthesia induction all enrolled patients will have bilateral ESPB catheters placed at the T7 spine level prior to surgery. The surgery is a sternotomy for congenital heart repair in high risk children and adults.
2848200|NCT03611348|Active Comparator|Microneedling + latanoprost|patient will receive topical application of latanoprost 0.005% eye drops solution twice daily for 3 months preceded by microneeding in sessions by dermapen every 2 weeks for 3 months (totally 6 sessions).
2848201|NCT03611348|Active Comparator|latanoprost|Patient will receive topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months (active control side).
2848202|NCT03611335|Active Comparator|Site 1 H+H|Bellevue Hospital
2848203|NCT03611335|Active Comparator|Site 2 H+H|Coney Island Hospital
2848204|NCT03611335|Active Comparator|Site 3 H+H|Lincoln Medical and Mental Health Center
2848205|NCT03611335|Active Comparator|Site 4 H+H|Metropolitan Hospital
2848206|NCT03611322|Experimental|DV3372 device|Participants will receive semaglutide on day 1, 8, 15, 22 and 29. The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
2848207|NCT03611322|Active Comparator|PDS290 semaglutide pen-injector|Participants will receive semaglutide on day 1, 8, 15, 22 and 29. The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
2848208|NCT03611309|Experimental|Surgeon-palliative care team co management|In Surgeon-palliative care team co management arm all patients will receive the surgical care of surgeon alone management which includes surgeon and the surgical team. In addition to this surgeon alone care, palliative care will be provided by a specialist team consistent with the doctor palliative care team co management. For patients in this arm, patients and/or family members will be seen by the palliative care team: (1) in an outpatient setting prior to surgery, (2) in the hospital within 72 hours of their initial surgery and as needed afterwards, and (3) via phone on in-clinic (per patient preference) on an at least monthly basis and/or as needed 12 weeks following surgery.
2848209|NCT03611309|No Intervention|Surgeon alone management|The surgeon and surgical team will manage symptoms, psychosocial support, and prognostic related communication. The surgeon and surgical team care for the patient and their family both prior to and following surgery.
2848210|NCT03611283|Experimental|Test group|"Patients had to use:~Mouthwash treatment (250 ml): Aqua, Betaine, Glycerin, PEG-40, Hydrogenated Castor Oil, Propylene Glycol, Xylitol, Aroma, Potassium Phosphate, Diazolidinyl Urea, Allantoin, Olea Europaea Fruit Oil, Sodium Methylparaben, Sodium Propylparaben, Sodium Fluoride, CI75810, Panthenol, Tocopheryl Acetate, Sucralose, Carum Petroselinum Seed Oil, Limonene.~Toothpaste treatment (50 ml): Glycerin, Aqua, Hydrated Silica, Xylitol, Betine, Tetrapotassium Pyrophosphate, Olea Europaea Fruti Oil, Xanthan Gum, Titanium Dioxide, Potassium Phosphate, Aroma, Sodium Fluoride, Diazolidinyl Urea, Papain, Carum Petroselinum Seed Oil, Panthenol, Tocopheryl Acetate, Limonene"
2848211|NCT03611283|Placebo Comparator|Placebo group|"Patients had to use:~Mouthwash placebo(250 ml): Aqua, Glycerin, PEG-40 Hydrogenated Castor Oil, Propylene Glycol, flavoring, Potassium Phospate, Diazolidinyl Urea, Sodium Methylparaben, Sodium Propylparaben, Sodium Fluoride, CI75810, Tocopheryl Acetate, Sucralose, LImonene.~Toothpaste placebo (50 ml): Aqua, Sorbitol, Hydrated Silica, Glycerin, Tetrapotassium Pyrophosphate, Xanthan Gum Titanium Dioxide, Sodium Lauryl Sulphate, Potassium Phosphate, flavoring, Sodium Fluoride, Diazolidinyl Urea, Sucralose, Limonene"
2848212|NCT03611257|Experimental|dRAST|"Hematologic patients with bacteremia will receive antibiotics based on dRAST results."
2848213|NCT03611257|Active Comparator|Current standard method|Hematologic patients with bacteremia will receive antibiotics based on current standard method results.
2848214|NCT03611244|Experimental|Experimental group|When loss of ambulation was observed in patients with Duchenne muscular dystrophy, portable seat device devised to maintain lumbar lordosis were applied within 1 year, and then compliance with the the device were evaluated at 6-month intervals for 5 years.
2848215|NCT03611244|No Intervention|Control group|Analysis of retrospective medical records who had not been applied portable seat device devised to maintain lumbar lordosis
2848216|NCT03611231|Experimental|Experimental|chidamide
2848217|NCT03611218|Other|Hemodiafiltration HDF|Three consecutive treatment weeks and on follow-up week per patient. Each treatment week includes three hemodiafiltration HDFsessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Nipro: Sureflux-17UX and comparator Baxter/Gambro: Polyflux 170 H.
2848218|NCT03611205|Experimental|Diagnostic (dPET/CT)|Participants receive radiotracer injection and undergo dPET/CT over 20-75 minutes at baseline, during the 2nd and 4th week of radiotherapy, and 3 months after the completion of chemoradiation therapy.
2848219|NCT03611192|Experimental|Multicomponent exercise group|
2848220|NCT03611192|Active Comparator|Home-program exercise group|
2848221|NCT03611179|Experimental|advanced ovarian cancer cases|patients with advanced ovarian cancer will receive Bevacizumab 15 mg/kg every 21 days with chemotherapy (Paclitaxel 175 mg/m2 & Carboplatin AUC 5 every 21 days)
2848222|NCT03611153|Experimental|Oral myeloperoxidase inhibitor|Patient may take 30 mg of oral myeloperoxidase inhibitor following baseline right heart catheterization.
2848223|NCT03611153|Placebo Comparator|Placebo|Patient may take 30 mg of placebo oral capsule following baseline right heart catheterization.
2848224|NCT03611140|Experimental|Dietary portfolio (DP)|The dietary portfolio was given daily at the breakfast and dinner for 2 months. The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein, oat, and inulin) that was provided in a dehydrated form in packages of 30 g dissolved in 250 ml water for breakfast and 30 g in 250ml water for dinner.
2853725|NCT03572140||group B|RAVS IN relapsed cases after daclatasvir plus sofosbuvir treatment
2848225|NCT03611140|Placebo Comparator|placebo (P)|The placebo (P) was given daily at the breakfast and dinner for 2 months. The placebo intervention consisted of a mixture of calcium caseinate, maltodextrins, sweetener and of artificial flavoring that was provided in a dehydrated form in packages of 30 g dissolved in 250 ml water for breakfast and 30 g in 250ml water for dinner.
2848226|NCT03611127|Experimental|early pulmonary rehabilitation (EPR)|early pulmonary rehabilitation started shortly after hospital discharge for COPD exacerbation.
2848227|NCT03611127|No Intervention|Usual care (UC)|No pulmonary rehabilitation for this group
2848228|NCT03611114|Experimental|Blood orange juice|Subjects will be asked to consume blood orange juice (400 ml/day) for 2 weeks.
2848229|NCT03611114|Placebo Comparator|Control drink|Subjects will be asked to consume a control drink (400 ml/day) for 2 weeks.
2848230|NCT03611088|Experimental|Newborns submitted to Kangaroo Position.|
2848231|NCT03611088|No Intervention|Newborns not submitted to Kangaroo Position.|
2848232|NCT03611075||Low-Functioning Autism Spectrum Disorder (ASD) Children|Participants will be 5-12 years old, with Intelligence Quotient (IQ) scores between 50-70
2848233|NCT03611075||High-Functioning ASD Children|Participants will be 5-12 years old, with IQ scores of 70 or above
2848234|NCT03611075||Low-Functioning ASD Adolescents|Participants will be 13-17 years old, with IQ scores between 50-70
2848235|NCT03611075||High-Functioning ASD Adolescents|Participants will be 13-17 years old, with IQ scores of 70 or above
2848236|NCT03611075||Low-Functioning ASD Adults|Participants will be 18-45 years old, with IQ scores between 50-70
2848237|NCT03611075||High-Functioning ASD Adults|Participants will be 18-45 years old, with IQ scores of 70 or above
2848238|NCT03611075||Healthy Participants|Participants will be 5-12 years old
2848239|NCT03611062|Experimental|VR Executive Functions Training|Participants will receive training of executive functions in a virtual reality environment.
2848240|NCT03611062|Placebo Comparator|Control|Participants will play a virtual reality game using the same hardware and similar environments, but without the training of executive functions.
2848241|NCT03611049|Placebo Comparator|Low dose Vitamin D intervention|intervention includes 800 IU Vitamin D3 replacement
2848242|NCT03611049|Active Comparator|High dose Vitamin D intervention|Intervention includes 5000 IU Vitamin D3 replacement
2848243|NCT03611036|Experimental|Strength|Patients will follow the pulmonary rehabilitation program associated with upper limbs strength training for a duration of 4 weeks
2848244|NCT03611036|Active Comparator|Endurance|Patients will follow the pulmonary rehabilitation program associated with upper limbs endurance training for a duration of 4 weeks
2848245|NCT03611010|Experimental|10 mg oral atorvastatin|Subjects taking 10 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
2848246|NCT03611010|Experimental|20 mg oral atorvastatin|Subjects taking 20 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
2848247|NCT03611010|Experimental|40 mg oral atorvastatin|Subjects taking 40 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
2848248|NCT03611010|Experimental|80 mg oral atorvastatin|Subjects taking 80 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
2848249|NCT03610997|Other|Photorefractive keratectomy|The children will undergo PRK in the affected eye(s) using previously derived formulas for PRK.
2848250|NCT03610984||Intensive structured education group|Regular outpatient visit in every 3 months to these patients. The glucose control and diabetes complication screening will be evaluated in visit. Patients will also be evaluated by specialized psychologists, dietitians and therapists. Diabetes self-management education will be regularly exposed to patients
2848251|NCT03610984||Conventional education group|Outpatients visit to endocrinologists when necessary in a conventional way.
2848252|NCT03610971|Experimental|Combination Therapy + Remission Phase|"Combination therapy followed by treatment free remission (TFR) phase.~Combination Therapy: Ruxolitinib plus BCR-ABL Tyrosine Kinase Inhibitors (TKIs).~All eligible patients will begin ruxolitinib in combination with their BCR-ABL TKI on cycle 1 day 1 of the combination phase. They will continue combination therapy for a total of 12 cycles. Each cycle will be 28 days. At the end of 12 cycles ruxolitinib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase. Once in the TFR phase, participants will discontinue their BCR-ABL TKI and be monitored off treatment."
2848253|NCT03610958|Experimental|Epitomee Device arm|"A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety. The Device is composed of a 000 size standard capsule and the Tulip's proprietary Device, encapsulated within it.~The Device components are produced from approved pharmaceutical excipients / food additives / generally recognized as safe (GRAS )/ food contact materials which are used at high grade"
2848254|NCT03610945|Experimental|EDP-305 and fluconazole interaction (Part 1)|
2848255|NCT03610945|Experimental|EDP-305 and quinidine interaction (Part 2)|
2848256|NCT03610932|Experimental|Vitamin C|Participants will ingest 3 (500 mg) capsules of Vitamin C each day for 2 weeks.
2848257|NCT03610932|Active Comparator|Placebo|Participants will ingest a matched capsule for size and color to the Vitamin C supplement.
2848258|NCT03610919|Experimental|Oxytocin nasal spray(5 doses)|Oxytocin nasal spray for 5 days, 24 IU per day
2848259|NCT03610919|Experimental|Oxytocin nasal spray(3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day.
2848260|NCT03610919|Placebo Comparator|Placebo nasal spray(control group)|Placebo nasal spray for 5 days,24 IU per day.
2848261|NCT03610906||Pediatrics with Tumors|Pediatrics who have a tumor specimen that is suspected to be craniopharyngioma, but is deemed superfluous to the clinical care of the patient (e.g. pathological diagnosis).
2848262|NCT03610893|Active Comparator|Perineural dexamethasone|addition of dexamethasone to local anesthetics in infraclavicular brachial plexus block
2848263|NCT03610893|Active Comparator|Perineural dexmedetomidine|addition of dexmedetomidine to local anesthetics in infraclavicular brachial plexus block
2848264|NCT03610880|Experimental|TG-2349 (400 mg) plus DAG181 (200 mg)|Dosing period 1 (Day 1 to 7): TG-2349 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181
2848265|NCT03610880|Experimental|DAG181 (200 mg) plus TG-2349 (400 mg)|Dosing period 1 (Day 1 to 7): DAG181 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181
2848268|NCT03610867|Experimental|Furaprevir capsule (MAD)|multiple ascending oral doses (200 mg, 400 mg, and 600 mg) of TG-2349 (Furaprevir capsule)
2848269|NCT03610867|Placebo Comparator|Placebo (MAD)|Multiple ascending oral doses of Furaprevir similar capsule
2848270|NCT03610854|Experimental|Fitness tracker Arm|Patients will be wearing a commercially available fitness tracker during radiotherapy or chemotherapy and four weeks after the end of treatment.
2848271|NCT03610841||preterm labor|Workgroup consists of patients which diagnosed with preterm labor between the age of 21 and 34
2848272|NCT03610841||healthy|24-36 6/7 weeks of pregnant between the age of 21 and 34
2848273|NCT03610815|Experimental|mSBIRT|Mobile Screening, Brief Intervention, Referral to Treatment (mSBIRT)
2848274|NCT03610815|Active Comparator|SBIRT-CTS),|Screening, Brief Intervention, Referral to Treatment Conventional Training and Supervision strategy
2848275|NCT03610802||Patients|Patients (ages 0-99 years) with known or suspected primary immunodeficiency disorder (PID) or immunodysregulation;
2848276|NCT03610802||Healthy Volunteers|Patients' relatives (ages 0-99 years) that are unaffected
2848277|NCT03610789||REDAPT Revision Femoral System|REDAPT Revision Femoral System Monolithic Sleeveless Stems and/or Acetabular Components
2848278|NCT03610776|Experimental|Portion control plate|Portion control plate first (50% of subjects experiment with this plate first)
2848279|NCT03610776|Active Comparator|Conventional plate|Conventional plate first (50% of subjects experiment with this plate first)
2848280|NCT03610763|Active Comparator|Transplantation/Replantation Patients|Can plateaued hand function in hand transplantation patients/hand replantation patients in the chronic stage of recovery be facilitated by use of bi-hemispheric transcranial direct current stimulation (tDCS) combined with modified Constraint Induced Movement Therapy (CIMT)?
2848281|NCT03610763|Active Comparator|Nerve Injury Patients active|Can plateaued hand function in peripheral nervous system injuries in the chronic stage of recovery be facilitated by use of bi-hemispheric transcranial direct current stimulation (tDCS) combined with modified Constraint Induced Movement Therapy (CIMT)?
2848282|NCT03610763|Sham Comparator|Nerve Injury Patients sham|Can plateaued hand function in peripheral nervous system injuries in the chronic stage of recovery be facilitated by use of sham bi-hemispheric transcranial direct current stimulation (tDCS) combined with modified Constraint Induced Movement Therapy (CIMT)?
2848283|NCT03610763|No Intervention|Actigraphy Testing|We will acquire a set of actigraphy data from a group of hand transplant/replant patients and unilateral, adult amputees in order to evaluate typical patterns of limb use prior to hand transplantation and to investigate prosthesis utilization.
2848284|NCT03610750|Active Comparator|Specialty Care|Psychiatric medications and evidence-based psychotherapies to be provided at a specialty mental clinic facilitated by psychiatric technicians, the mental health specialty workforce already in place in Mozambique.
2848285|NCT03610750|Experimental|Integrated Care|Psychiatric medications and evidence-based psychotherapies to be provided by primary care providers.
2848286|NCT03610750|Experimental|Community Clinic Stepped Care|Psychiatric medications and evidence-based psychotherapies to be provided by primary care providers and community health workers, respectively.
2848287|NCT03610737|Active Comparator|MILD with CMM|The MILD procedure is an image-guided minimally-invasive lumbar decompression with conventional medical managment
2848288|NCT03610737|Active Comparator|CMM alone|Patient in the CMM alone group can have physical therapy, home exercise, pain medication, epidural steroid injections, nerve blocks, and other lumbar steroid injections.
2848289|NCT03610724|Experimental|Tisagenlecleucel|CAR-positive viable T cells infusion
2848290|NCT03610711|Experimental|Arm A Nivolumab Only|stereotactic body radiation (SBRT) 8G x 3 followed by Nivolumab 240mg administered IV over 30 minutes every 2 weeks for one year or until evidence of disease progression or unresolved toxicity. Oligometastatic progression can be treated with additional SBRT if not previously radiated.
2848291|NCT03610711|Experimental|Arm B Nivolumab + Relatlimab|stereotactic body radiation (SBRT) 8G x 3 followed by Nivolumab 240mg administered IV over 30 minutes every 2 weeks and Relatlimab (anti-LAG3) every 2 weeks for one year or until evidence of disease progression or unresolved toxicity. Oligometastatic progression can be treated with additional SBRT if not previously radiated.
2848292|NCT03610698|Experimental|Facilitated Intervention|Intervention arm facilitated by a trained team member, delivering the 8 positive emotion skills over 5 weeks.
2848293|NCT03610698|Experimental|Self-Guided Intervention|Intervention arm that is self-guided on an online platform, delivering the 8 positive emotion skills over 5 weeks.
2848294|NCT03610698|Active Comparator|Emotion Reporting Control|Participants in the emotion reporting control condition will be reporting their emotions daily for the same length as the intervention.
2848295|NCT03610685|Placebo Comparator|Placebo|Participants will be given 2 weeks of placebo treatment. The placebo capsules will be taken once a day orally. The daily dose of placebo treatment will match the Prednisone dose for each participant.
2848296|NCT03610685|Active Comparator|Prednisolone|Participants will be given 2 weeks of prednisolone treatment. This is administered orally once a day. The daily dose is calculated according to 0.5mg/kg with a maximum dose of 40mg per day.
2848297|NCT03610672|Active Comparator|OD prevention/response training|Immediately following the baseline assessment, trained research staff will conduct a brief (20 min.) OD training with each participant. Participants will be asked to view the NYC Department of Health and Mental Hygiene's 13-minute OD prevention and response training video (available online free-of-charge). Following the video, research staff will review key information, answer any questions participants may have, demonstrate assembly of the intranasal naloxone atomizer and ensure participants are able to execute this assembly procedure. A prescription for naloxone, as well as a standard naloxone kit containing two doses of the medication and atomizers for intranasal administration, will be given to participants, along with printed literature reviewing key training information.
2848298|NCT03610672|Experimental|OD training + mobile PI intervention|Participants will complete the same baseline assessment and OD training (plus naloxone) as those in the first condition. Participants also will receive mobile phones pre-loaded with the PI App and will be sent daily prompts. As part of the PI App, participants will be asked to share information about avoiding problems associated with opioid use with peers in their social network, and to encourage their peers to download the PI App for their own use.
2848299|NCT03610646|Experimental|MYL-1701P|MYL-1701P
2848301|NCT03610633|Experimental|Oxytocin/alcohol use disorder|Participants will receive 24 IU of oxytocin prior to completing fMRI scanning procedures.
2848302|NCT03610633|Placebo Comparator|Placebo/Alcohol use disorder|Participants will receive placebo (saline solution) prior to completing fMRI scanning procedures.
2848303|NCT03610620|Experimental|ARM A|Vivascope 2500 ex-vivo fluorescent confocal microscope
2848304|NCT03610607|Active Comparator|intense education of periodontal health maintenance|
2848305|NCT03610607|Placebo Comparator|No intense education of periodontal health maintenance|
2848306|NCT03610594|Experimental|kalaripayattu|The experimental groups will treated with kalaripayattu exercises for the period of 12 weeks
2848307|NCT03610594|No Intervention|Wait list control|Control group will not be given any intervention. After the treatment period is over, all the subjects will be given Kalaripayattu training.
2848308|NCT03610581|Experimental|Regimen 1: Single Ad26.HPV16 or Ad26.HPV18 and MVA.HPV16/18|Participants will receive a dose of adenovirus serotype 26 (Ad26)-human papillomavirus (HPV)16 or HPV18 (Ad26.HPV16 or Ad26.HPV18) as prime immunization and a dose of Modified Vaccinia Ankara (MVA)-HPV16/18 (MVA.HPV16/18) as boost immunization.
2848309|NCT03610581|Experimental|Regimen 2: Double Ad26.HPV16 or Ad26.HPV18 and MVA.HPV16/18|Participants will receive a double dose of Ad26.HPV16 or Ad26.HPV18 as prime immunization and a dose of MVA.HPV16/18 as boost immunization.
2848310|NCT03610581|Experimental|Regimen 3: Ad26.HPV16/Ad26.HPV18 mix and MVA.HPV16/18|Participants will receive a mix of Ad26.HPV16/Ad26.HPV18 as prime immunization and a dose of MVA.HPV16/18 as boost immunization.
2848311|NCT03610581|Placebo Comparator|Control: Placebo|Participants will receive matched placebo as prime and boost immunizations.
2848312|NCT03610568|Experimental|Growing up GREAT! Intervention|
2848313|NCT03610568|No Intervention|Control|
2848314|NCT03610555|No Intervention|Current website|
2848315|NCT03610555|Active Comparator|New patient centered website|
2848316|NCT03610542|Experimental|Face to Face Cognitive Behaviour Therapy|Cognitive behaviour therapy conducted in groups of 6-8 persons.One forty-five minute session per week for 6 weeks: Triggers for anxiety, identifying and challenging negative thoughts, relaxation and goal setting
2848317|NCT03610542|Experimental|Computerised Cognitive Behaviour Therapy|Cognitive behaviour therapy, individually accessed from a webpage by static or mobile computerised devices (e.g., a smart-phone). 60 five minute modules accessed over a 6 week period: Triggers for anxiety, identifying and challenging negative thoughts, relaxation and goal setting
2848318|NCT03610542|No Intervention|Control|This is a no intervention control arm
2848319|NCT03610529|Experimental|ECG monitoring system CardioSenseSystem group|
2848320|NCT03610529|Active Comparator|ECG monitoring system Philips Intellivue|
2848321|NCT03610516|Experimental|CFZ533|Investigational drug CFZ533 will be administred as multiple doses
2848322|NCT03610516|Placebo Comparator|Placebo|Investigational drug matching placebo will be administered as multiple doses
2848323|NCT03610503|Experimental|Music|Patients listen to music during EMG test
2848324|NCT03610503|No Intervention|Control (Standard Care)|Patients do not listen to music during EMG test (ie. Standard of care)
2848325|NCT03610490|Experimental|Treatment (autologous tumor infiltrating lymphocytes MDA-TIL)|"LYMPHODEPLETION REGIMEN: Participants receive cyclophosphamide IV over 2 hours on days -7 and -6, and fludarabine IV over 30 minutes on days -5 to -1 in the absence of disease progression or unacceptable toxicity.~T-CELL INFUSION: Participants receive autologous tumor infiltrating lymphocytes MDA-TIL IV over 45 minutes on day 0. Participants then receive IL-2 IV over 30 minutes on days 1-4 for up to 6 doses in the absence of disease progression or unacceptable toxicity."
2848326|NCT03610477|Active Comparator|Medium Chain Triglyceride|Participants will be randomized to consume 5% of total energy intake from medium chain triglycerides.
2848327|NCT03610477|Placebo Comparator|Long Chain Triglyceride|Participants will be randomized to consume 5% of total energy intake from long chain triglycerides.
2848328|NCT03610464|Experimental|Study patients (AMPH EROS)|All patients treated with extended-release oral suspension (AMPH EROS) that contains 2.5 mg/mL amphetamine base
2848329|NCT03610451|Experimental|Floatation-REST|Participants will float supine in a pool of water saturated with epsom salt, in a light and sound attenuated chamber, for up to 60 minutes, on 8 separate occasions. Ratings of the experience will be collected before and after each float.
2848330|NCT03610451|Other|Usual care|Participants will be assessed along the same time periods, i.e., before and after a 60 minute window, on 8 separate occasions. Ratings of the experience will be collected before and after each time period.
2848331|NCT03610438|Experimental|Cohort 1|Cohort 1 will entroll 38 Ph+ patients
2848332|NCT03610438|Experimental|Cohort 2|Cohort 2 will enroll 38 Ph- patients
2848333|NCT03610425||Post-op evidence based bundle w/ Pre-op education|25 patients undergoing hysterectomy from October 1, 2017 to December 31, 2017 will receive the post-operative evidence based bundle/standard pre-operative education.
2848334|NCT03610425||Standard pre-operative education alone|25 patients undergoing hysterectomy from October 1, 2017 to December 31, 2017 will receive the standard pre-operative education alone.
2848335|NCT03610412|Active Comparator|Cinnamomum Cassia|A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of cinnamomum cassia orally every 8 hours, for 90 days.
2848336|NCT03610412|Placebo Comparator|Placebo|A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of placebo (calcined magnesia) orally every 8 hours, for 90 days.
2848337|NCT03610399|Other|Primaquine Regular Dose Unsupervised|This is the regular primaquine dose Brazil without directly observed therapy.
2848338|NCT03610399|Active Comparator|Primaquine Regular Dose Supervised|This is the regular primaquine dose in Brazil but with directly observed therapy.
2848339|NCT03610399|Active Comparator|Primaquine Double Dose Unsupervised|This is the double total primaquine dose (14 days) in Brazil with directly observed therapy.
2848340|NCT03610386|Active Comparator|Control|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …).One of two biopsies will be left in culture for 24 hours and then the biopsy will be cut in half: half will be used for immunohistochemical analyzes, the second half for transcriptomic analyzes .
2848341|NCT03610386|Experimental|Treatment with menthoxypropanediol|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. Thy will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …).One of two biopsies will be left in culture for 24 hours. Then the menthoxypropanediol (200 µM) will be applied topically on this explant and left for 6 hours. Then the biopsy will be cut in half: half will be used for immunohistochemical analyzes, the second half for transcriptomic analyzes.
2848342|NCT03610373|Experimental|Shared Decision Making|In this arm, parents and children will participate in a shared decision-making protocol with the clinician to plan their treatment. The treatment options available are established, evidence-based treatment techniques. The shared decision-making protocol was developed for this research project.
2848343|NCT03610373|Active Comparator|Clinician Guided|In this arm, the clinician will plan the treatment in consultation with their supervisor, and share the treatment plan with the parent and child. The parent and child will have the opportunity to ask questions about the treatment plan (and, if they do not agree, reject the treatment plan), but they are not actively involved in making each decision. This is more typical of usual care.
2848344|NCT03610360|Active Comparator|Arm A|Arm A will receive the study drug MesoPher plus best supportive care
2848345|NCT03610360|No Intervention|Arm B|Arm B will follow best supportive care as deemed appropriate by the investigator.
2848346|NCT03610347|Experimental|Bare metal Stent plus Paclitaxel Balloon|Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux®)
2848347|NCT03610347|Active Comparator|Drug-Eluting Stent (DES)|Sirolimus Eluting Stent (Orsiro®)
2848348|NCT03610334|Experimental|IFB-088|"IFB-088 oral capsule:~In SAD phase: single daily dose of IFB-088 will be administered to 6 successive cohorts while increasing dose exposure.~In MAD phase: multiple doses of IFB-088 will be administered daily during 14 days to 3 succesive cohorts while increasing dose exposure."
2848349|NCT03610334|Placebo Comparator|Placebo|"Placebo oral capsule:~In SAD phase: single daily dose of placebo (cellulose microcrystalline) will be administered in equivalent-weight.~In MAD phase: multiple doses of placebo (cellulose microcrystalline) will be administered daily during 14 days."
2848350|NCT03610321|Active Comparator|Statin group|Receiving statin treatment only
2848351|NCT03610321|Experimental|Gefarnate group|Combined treatment with statins and gefarnate
2848352|NCT03610295|Experimental|PPI group|cataract extraction surgery with prophylactic peripheral iridectomy
2848353|NCT03610295|Active Comparator|historical control group|cataract extraction surgery
2848354|NCT03610282|Experimental|EEG Dynamics|EEG data will be collected on patients receiving propofol and IV methylphenidate together.
2848355|NCT03610282|Placebo Comparator|Propofol EEG Dynamics|EEG data will be collected on patients receiving propofol and a saline placebo.
2848356|NCT03610256|Experimental|SADI-S|"This corresponds to obese patients (BMI ≥40 kg/m2 or BMI ≥35 kg/m2 +/- co-morbidities (high blood pressure, dyslipidemia, obstructive sleep apnea, type 2 diabetes mellitus, arthrosis)) benefiting from a laparoscopic SADI-S (laparoscopic Single-anastomosis duodeno ileal bypass with Sleeve gastrectomy).~SADI-S will be performed as a primary procedure or after failure of sleeve gastrectomy, defined as insufficient weight loss at 18 months after surgery (EWL% <50), or as weight regain (+ 20% of nadir weight)."
2848357|NCT03610256|Active Comparator|RYGB|"This corresponds to obese patients (BMI ≥40 kg/m2 or BMI ≥35 kg/m2 +/- co-morbidities (high blood pressure, dyslipidemia, obstructive sleep apnea, type 2 diabetes mellitus, arthrosis)) benefiting from a laparoscopic RYGB (laparoscopic Roux-en-Y Gastric ByPass).~Similarly to the experimental group, RYGB will be performed as a primary procedure or after failure of sleeve gastrectomy, which is defined as insufficient weight loss at 18 months after surgery (EWL% <50), or as weight regain (+ 20% of nadir weight)."
2848358|NCT03610243|Experimental|Self-administered acupressure|"The proposed self-administered acupressure intervention is patient-centered comprising four pre-selected acupoints that should be applied pressure on by all patients and a list of additional acupoints from which patients can choose two for self-administration according to the personalized recommendations of trainers. In this way, each patient will receive an individualized protocol (four pre-selected and two self-selected acupoints).~The intervention consists of: individual participant training (Two 2-hour one-on-one training sessions in week 1), self-practice (15 minutes of self-administered acupressure twice a day), and follow-up visits (a 1-hour follow-up visit at weeks 2, 3, and 4)."
2848359|NCT03610243|No Intervention|Wait-list control|The wait-list control group will be contacted in the third week to attend a health talk unrelated to symptom management.
2848360|NCT03610230|Experimental|Monofer|Iron Isomaltoside as a single intravenous dose 1000mg over 60 minutes
2848361|NCT03610230|Active Comparator|Venofer|Iron Sucrose 200mg weekly intravenous infusions over 2 hours for 5 weeks
2848362|NCT03610217|Experimental|Interstitial lung disease induction|
2848363|NCT03610217|Experimental|Pulmonary arterial hypertension|
2848364|NCT03610217|Experimental|Raynaud's phenomenon|
2848365|NCT03610217|Experimental|Digital ulcers|
2848366|NCT03610217|Experimental|Inflammatory arthritis|
2848367|NCT03610217|Experimental|Gastroesophageal reflux|
2848368|NCT03610217|Experimental|Bacterial overgrowth|
2848369|NCT03610217|Experimental|Constipation|
2848370|NCT03610217|Experimental|Skin involvement|
2848371|NCT03610217|Experimental|Pain|
2848372|NCT03610204|Experimental|Deep massage (DM) group|"The therapist performs the deep massage with buffalo horn technique. A small rod with a cone-like end was used in the technique. By pressuring the rod end against the body surface of the participant, it produces higher pressure that may release the deep-layer fascia of muscles. Thus this technique features a deep massage."
2848373|NCT03610204|Active Comparator|Superficial massage (SM) group|"The therapist performs the superficial massage with buffalo horn technique. A small rod that has an end in a larger surface area (5 times as that used in the DM group). By pressuring the rod end against the body surface of the participant, it produces lower pressure. Thus this intervention features a superficial massage."
2848410|NCT03609957|Experimental|Interval Training|High intensity (95% heart rate reserve) cycling exercise for 20 minutes, 3 days per week for 5 weeks
2848411|NCT03609957|No Intervention|Control|Control (no exercise intervention) group
2849059|NCT03605212|Experimental|Cohort 3|Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)
2848374|NCT03610191||Surgery|Patients aged over 18 scheduled for elective cardiac surgery under CPB and general anesthesia. This group will later be divided in to two sub groups based on their neuropsychological battery tests results before surgery and one day before discharge. Blood sample will be collected before, immediately after surgery and at 24h after surgery for serum biomarker tests: MD2, CysC as well as DNA methylation markers of neural system origin.
2848375|NCT03610191||non-surgical control|Age and sex matched volunteers from the community were included for neuropsychological battery tests and set as controls for the diagnosis of POCd in surgical patients.
2848376|NCT03610178|Active Comparator|very tight glycemic targets|
2848377|NCT03610178|Active Comparator|tight-moderate glycemic targets|
2848378|NCT03610178|No Intervention|Control group|Only observation in women with normal glucose tolerance
2848379|NCT03610165|Placebo Comparator|Arterial line - Control|Arterial line waveform and pressure
2848380|NCT03610165|Experimental|Acumen HPI-enabled EV1000 screen|Arterial line waveform and pressure + HPI alert from EV1000 monitor
2848381|NCT03610152|No Intervention|Control|Hospitals made aware of Choosing Wisely Canada recommendations and Health Quality Ontario data.
2848382|NCT03610152|Experimental|Hospital wide policy|A hospital-wide policy will be implemented whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologists based on their clinical assessment of the patient.
2848383|NCT03610139|Active Comparator|low dose vitamin D3 supplementation|Patients in this group will take 800 IU daily dose of vitamin D supplementation. They will be kept on 800 IU for 6 months. If they still had low vitamin D at 3 months, they will be asked about their adherence to the supplement, the investigators will remind them to take it as prescribed, and the investigators will keep the 800 IU vitamin D supplement dose for another 3 months. If they were still deficient at 6 months, the investigators will switch them to 10,000 IU weekly dose.
2848384|NCT03610139|Experimental|high dose vitamin D3 supplementation|"Patients in this group will take 50,000 IU weekly dose of vitamin D supplementation. Patients who will reach normal serum vitamin D level, between 40-80 ng/ml, at 3 or 6 months will be asked to decrease their Vitamin D3 supplementation as follows: Those who will reach levels between 40-60ng/ml will be switched to 10,000 IU three times per week, and those who reach levels between 60-80 ng/ml will be switched to 10,000 IU once weekly.~If they did not have any improvement in their levels of vitamin D at 3 or 6 months, they will be asked about their adherence to the supplement and the investigators will remind them to take it as prescribed and the investigators will keep them at the 50,000 IU weekly dose."
2848385|NCT03610126||volume controlled ventilation|after induction of anesthesia and insertion of BASKA laryngeal mask airway mechanical ventilation of patients will be maintained with volume controlled ventilation mode
2848386|NCT03610126||pressure controlled ventilation|after induction of anesthesia and insertion of BASKA laryngeal mask airway and mechanical ventilation of patients will be maintained with pressure controlled ventilation mode
2848387|NCT03610113|No Intervention|CONSERVATIVE TREATMENT|Conservative treatment is conceived to the use of sling for three weeks, followed by rehabilitation protocol
2848388|NCT03610113|Experimental|REVERSE ARTHROPLASTY TREATMENT|"This group receives a surgical intervention by the use of reverse shoulder arthroplasty through deltopectoral approach and tuberosities reattachment.~It is followed by the same rehabilitation protocol than conservative treatment"
2848389|NCT03610100|Experimental|Acelarin (NUC-1031)|"825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle.~Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression."
2848390|NCT03610100|Active Comparator|Gemcitabine|"Gemcitabine: 1000mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle.~Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression."
2848391|NCT03610087|Other|Low Intensity Intervention|Participants receive service as usual and NAVIGATE self-help modules.
2848392|NCT03610087|Experimental|High Intensity Intervention|Participants receive TECC enabled support.
2848393|NCT03610074|Experimental|Mint ice cubes|"Physician applies 3 mint ice cubes in mouth of highly dehydrated patient. Patient undergoes an additional blood test at 5 min from mint ice cubes application.~Physician performs patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application."
2848394|NCT03610061|Experimental|Radiotherapy plus Durvalumab|"A minimum of 3 patients will initially be enrolled in each cohort of this arm. Patients will be allocated to a radiotherapy dose and site cohort from the schedule at registration. There will be no intra-patient dose or site escalations.~Cohorts will escalate in number of anatomical sites of radiotherapy and dose of radiotherapy given subject to safety. Durvalumab will be administered at a fixed dose every 4 weeks IV."
2848395|NCT03610048|Experimental|ALKS 5461|Sublingual tablets
2848396|NCT03610035|Experimental|Experimental|NPT189
2848397|NCT03610035|Placebo Comparator|Placebo Comparator|Placebo
2848398|NCT03610022|Experimental|Patients with BCC and annexial carcinoma|Patients with BCC and annexial carcinoma histologically proven under treatment or new patients under vismodegib
2848399|NCT03610009|Active Comparator|2D ultrasound|Two-dimensional (2D) ultrasound is used to identify number and size of ovarian follicles, to select optimal day for triggering final oocyte maturation.
2848400|NCT03610009|Active Comparator|SonoAVC|SonoAVC is used to identify number and size of ovarian follicles, to select optimal day for triggering final oocyte maturation.
2848401|NCT03609996||PDR treated with Laser|
2848402|NCT03609996||PDR treated with Lucentis|
2848403|NCT03609983|Experimental|Daily Weighing|Participants will weigh themselves daily and receive feedback daily.
2848404|NCT03609983|Experimental|Weekly Weighing|Participants will weigh themselves weekly and receive feedback weekly.
2848405|NCT03609983|No Intervention|No Weighing|Participants will refrain from weighing themselves.
2848406|NCT03609970|No Intervention|Control|No intervention
2848407|NCT03609970|Experimental|UVR (Solar simulated radiation)|Twice weekly 1.25 SED (sub-erythemal) (4 weeks)
2848408|NCT03609970|Experimental|Vitamin D3 supplementation|4X 1000IU cholecalciferol tablets daily (28 days)
2848409|NCT03609957|Experimental|Aerobic Exercise Training|Moderate intensity (75% heart rate reserve) cycling exercise for 32 minutes, 3 days per week for 5 weeks
2848412|NCT03609944|Sham Comparator|EUS + Sham|Subjects randomized to EUS + sham will undergo a diagnostic endoscopic ultrasound (EUS) under sedation. The physician investigator will not make any attempts to achieve minor papilla cannulation, but photo document the minor papilla using a duodenoscope. Diluted dye will be injected into the duodenum. A small caliber prophylactic pancreatic duct stent will be deposited into the duodenal lumen. These maneuvers are performed to minimize the risk of unmasking.
2848413|NCT03609944|Experimental|EUS + ERCP with miES|Subjects randomized to EUS + ERCP with miES will undergo the procedure at the same time as endoscopic ultrasound (EUS), under sedation. Indomethacin (100 mg) will be administered rectally at the onset of the ERCP procedure in patients with no known allergy to indomethacin. The techniques used to perform the endoscopic retrograde cholangiopancreatography (ERCP)with miES (minor papilla endoscopic sphincterotomy) will be left to the discretion of the study endoscopist. The extent of sphincterotomy will be per the discretion of the treating endoscopist. Unless methylene blue (or similar chromoendoscopy agent such as indigo carmine) has already been used to facilitate minor papilla cannulation, diluted dye will be injected into the duodenum.
2848414|NCT03609931||Mitral Valve repair|Patients undergoing mitral valve repair
2848415|NCT03609905|Experimental|Intervention group|interventions: The MSCs of 5×10*7 will be given in different sites within colonic submucosa at a total 100 ml with the use of the colonoscope. Once every week，a total of two times. Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used
2848416|NCT03609905|Other|Control group|interventions:Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used
2848417|NCT03609892|Experimental|berberine plus amoxicillin quadruple therapy|Berberine 500mg three time daily for 14days, amoxicillin 1000 mg, esomeprazole 20 mg, and Bismuth 200mg by mouth, twice daily for 14 days.
2848418|NCT03609892|Active Comparator|tetracycline plus furazolidone quadruple therapy|Tetracycline 500mg three time daily for 14days，furazolidone 100 mg, esomeprazole 20 mg, and Bismuth 200mg by mouth, twice daily for 14 days.
2848419|NCT03609879|No Intervention|without cervical collar|baseline - without cervical collar
2848420|NCT03609879|Experimental|with cervical collar|scenarios with cervicall collars
2848421|NCT03609866|Active Comparator|control|will be performed ankle passive mobilization
2848422|NCT03609866|Experimental|experimental|abdominal thoracic compression technique will be applied
2848423|NCT03609853|Placebo Comparator|Placebo|Placebo (5mL distilled water)
2848424|NCT03609853|Experimental|Vaporized low THC|15mg of pure THC
2848425|NCT03609853|Experimental|Vaporized high THC|30mg of pure THC
2848426|NCT03609853|Experimental|Vaporized low d-limonene|1mg of d-limonene
2848427|NCT03609853|Experimental|Vaporized high d-limonene|5mg of d-limonene
2848428|NCT03609853|Experimental|Low THC and low d-limonene|15mg of THC paired with 1mg of d-limonene
2848429|NCT03609853|Experimental|High THC and low d-limonene|30mg of THC paired with 1mg of d-limonene
2848430|NCT03609853|Experimental|Low THC and high d-limonene|15mg of THC paired with 5mg of d-limonene
2848431|NCT03609853|Experimental|High THC and high d-limonene|30mg of THC paired with 5mg of d-limonene
2848432|NCT03609801|Experimental|ACTV|"Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new Batterers Intervention Program (BIP) for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is an innovative BIP in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming."
2848433|NCT03609801|Active Comparator|The Duluth Model|The Duluth Model Men's Nonviolence Classes is the most widely used BIP. The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model's Men's Nonviolence Classes (The Duluth Model for short) help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
2848434|NCT03609775|Experimental|Treatment A (ethanol + ACT-541468)|5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of ACT-541468 (50 mg)
2848435|NCT03609775|Experimental|Treatment B (ethanol placebo + ACT-541468)|5 h i.v. placebo clamp in combination with a single oral dose of ACT-541468 (50 mg)
2848436|NCT03609775|Experimental|Treatment C (ethanol + ACT-541468 placebo)|5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of matching ACT-541468 placebo
2848437|NCT03609775|Experimental|Treatment D (ethanol placebo + ACT-541468 placebo)|5 h i.v. placebo clamp in combination with a single oral dose of matching ACT-541468 placebo
2848438|NCT03609762|Experimental|Intervention group|EQ-5D-5L HRQOL results be available to the attending doctor
2848439|NCT03609762|No Intervention|Control group|usual care, EQ-5D-5L HRQOL results will not be available to the attending doctor
2848440|NCT03609749|Experimental|Mindfulness Training for Primary Care|"Experimental: Mindfulness Training for Primary Care For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3). For the Mindfulness Training for Primary Care (MTPC) fMRI - arm, the investigators acquire pre-/post-intervention neuroimaging measures from subjects enrolled in this additional fMRI study."
2848441|NCT03609723||MPS® in patients with CABG|Patients undergoing coronary artery bypass grafting with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC)
2848442|NCT03609723||OPCABG in patients with CABG|Patients undergoing coronary artery bypass grafting without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
2848443|NCT03609710|Experimental|PSTLAR|Combined application of left colic artery preservation, anastomotic reinforcing sutures and postoperative transanal tube placement in robotic low anterior resection for rectal cancer
2848444|NCT03609710|Active Comparator|NORLAR|Traditional robotic low anterior resection for rectal cancer without left colic artery preservation, anastomotic reinforcing sutures or postoperative transanal tube placement
2848579|NCT03608618|Experimental|Cohort 3|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks
2848445|NCT03609697|Experimental|Community-based lifestyle intervention|Participants will attend 7 community-based group intervention sessions plus 2 individual face-to-face dietician consultation sessions during the first 6 months, followed by a 6-month maintenance phase which they will receive monthly phone support from the research team.
2848446|NCT03609697|Other|Minimal intervention (SMS intervention)|Participants will receive one SMS per month during the first 6 months, followed by a 6-month maintenance phase which participants will receive one SMS every 2 months.
2848447|NCT03609684|Experimental|Gymnastic and Core Stabilization|This group consist people who regularly do gymnastics and also do 30-45 minutes core stabilization exercises.
2848448|NCT03609684|Experimental|Only Gymnastic Training|People can do gymnastics twice a week during 8 weeks but can't do core stabilization exercise.
2848449|NCT03609684|Active Comparator|Sedentary Group|This group consist individuals who are not interested in any sports and don't do any exercises during 8 weeks.
2848450|NCT03609671|Experimental|Standard of Care + Intervention (Individualized Therapy)|Intervention (individualized therapy) plus Standard of Care, and the completion of a psychological questionnaire at chemotherapy start and at the end, approximately four to six months later.
2848451|NCT03609671|Other|Control Group: Standard of Care|Standard of Care plus the completion of a psychological questionnaire at the beginning of the chemotherapy and at the end, approximately four to six months later.
2848452|NCT03609658|Experimental|Nurse Navigator Pathway Group|Participants in this Nurse Navigator led ACP pathway group will participate in ACP discussions, surveys, and participant visit(s) for duration of the study (12 months)
2848453|NCT03609658|Sham Comparator|Usual Care Group|Participants in the Usual Care group will follow usual daily living activities for the duration of the study (12 months).
2848454|NCT03609645|Active Comparator|Fascia iliaca block (FIB)|Group will receive Fascia iliaca block (FIB) with local anesthetic and femoral articular branch block (FAB) with normal saline (Placebo).
2848455|NCT03609645|Experimental|Femoral articular branches block(FAB)|Group will receive Fascia iliaca block (FIB) with normal saline (Placebo) and Femoral AON articular branch block (FAB) with local anesthetic.
2848456|NCT03609632|Experimental|OGTT with 13C-labelled leucine|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
2848457|NCT03609619|Experimental|AEVI-001|
2848458|NCT03609619|Placebo Comparator|Placebo|
2848459|NCT03609606|Experimental|Part A, Sequence1|"Period 1: Treatment of D013, D326 and D337 on Day1~Day7~Period 2: Treatment of D013 on Day22~Day28"
2848460|NCT03609606|Experimental|Part A, Sequence 2|"Period 1: Treatment of D013 on Day1~Day7~Period 2: Treatment of D013, D326 and D337 on Day22~Day28"
2848461|NCT03609606|Experimental|Part B, Sequence 1|"Period 1: Treatment of D013, D326 and D337 on Day1~Day7~Period 2: Treatment of D326 and D337 on Day22~Day28"
2848462|NCT03609606|Experimental|Part B, Sequence 2|"Period 1: Treatment of D326 and D337 on Day1~Day7~Period 2: Treatment of D013, D326 and D337 on Day22~Day28"
2848463|NCT03609593|Experimental|BR followed by venetoclax and rituximab|Subjects will be on Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days, and Rituximab 375 mg/m2 on day 1 or days 1-2 for three cycles with each cycle being 28 days. Venetoclax will then be started in a step-wise fashion per the package insert.
2848464|NCT03609567|Experimental|Aromatherapy|Aromatherapy using essential oils
2848465|NCT03609567|Placebo Comparator|Placebo|Aromatherapy using odorless placebo
2848466|NCT03609554|Experimental|Pilates|The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session).
2848467|NCT03609554|No Intervention|Control|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
2848468|NCT03609541||Patient with stable COPD|Evaluation of serum amlyoid A, lipoxin A4, CRP and fibrinogen
2848469|NCT03609541||Patient with COPD exacerbation|Evaluation of serum amlyoid A, lipoxin A4, CRP and Fibrinogen at beginning and at the end of COPD exacerbation
2848470|NCT03609528|Experimental|CamPROBE biopsy method|To be completed
2848471|NCT03609515|Experimental|Patients with contract about patient-controlled admissions|Patients have a contract about short self-referred inpatient admissions in mental health services without approval by clinicians, for a maximum of 5 days and with a minimum of three weeks between such stays
2848472|NCT03609502|Experimental|behavioral|Adults with and without language impairment will be given three different types of behavioral training, and assessments of learning through those trainings, at two time points.
2848473|NCT03609502|Experimental|neuroimaging|Following speech sound behavioral training, adults with and without language impairment will undergo post-training perceptual assessments in an MRI scanner before and after post-training sleep.
2848474|NCT03609489|Experimental|Test Group|Apatinib combined with Capetabine
2848475|NCT03609489|Active Comparator|Control Group|Capecitabine
2848476|NCT03609476|Active Comparator|Standard of care group|No saline instillation
2848477|NCT03609476|Active Comparator|Room temperature saline group|room temperature saline instillation
2848478|NCT03609476|Active Comparator|Warmed saline group|warmed saline instillation
2848479|NCT03609463|Experimental|Well-being and small change|Participants will be randomized to receive 4 individual 1-hour weekly sessions of the well-being intervention before starting the 12 individual 1-hour weekly sessions of the small change intervention in addition to the treatment as usual.
2848480|NCT03609463|Active Comparator|Small change|Participants will be randomized to receive 12 individual 1-hour weekly sessions of the small change intervention in addition to the treatment as usual.
2848481|NCT03609450|Active Comparator|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
2848525|NCT03609125|Experimental|CBS eyedrop|The product is prepared from cord blood serum (CBS) analyzed in advance with regard to the content of specific neurotrophic growth factors.
2848580|NCT03608618|Experimental|Cohort 4|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks
2848581|NCT03608592|Experimental|UCMSCs group|Intravenous infusion of 60million UCMSCs suspended in 100ml normal saline, infusion duration 30-60min.
2848482|NCT03609450|Other|Low-Dose Comparator|Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group, but are allowed to receive behavioral, psychiatric, and medical treatments that are consistent with treatment as usual. All participants complete an action planning protocol during Week 7.
2848483|NCT03609437||ESUS patients|Acute ischemic stroke patients satisfying embolic stroke of undetermined source (ESUS) diagnostic criteria.
2848484|NCT03609437||Controls|Healthy volunteers (colleagues, friends, relatives and others).
2848485|NCT03609424|Experimental|PDR001 plus Imatinib|
2848486|NCT03609411||Splenectomy|Patients undergoing liver transplantation with simultaneous splenectomy
2848487|NCT03609411||Liver transplantation|Patients undergoing liver transplantation only
2848488|NCT03609398|Experimental|RVF Vaccine|1.0 mL dose given SQ in upper arm
2848489|NCT03609385||Stroke patients with elevated troponin|Patients with acute ischemic stroke (confirmed by cerebral imaging) and cardiac troponin values > 52 ng/l or troponin values > 14 ng/l and dynamic change > 20% will undergo coronary angiography
2848490|NCT03609372|Experimental|Single arm|These practices, which previously received the addition of performance feedback and provider prompts in the presence of communication skills training, will receive The STOP-HPV Trial 6: Maintenance
2848491|NCT03609359|Experimental|Lenvatinib + Pembrolizumab|Lenvatinib and Pembrolizumab will be administrated simultaneously for advanced gastric cancer patients.
2848492|NCT03609346||STEMI|Arm: STEMI Intervention: PCI with 1 or more BioFreedom stents in patients presenting with a STEMI. Medication according to hospital practice.
2848493|NCT03609320|Experimental|Single Arm|These practices, which previously received standard of care, will receive The STOP-HPV Trial 5: Bundle Intervention
2848494|NCT03609307|Active Comparator|injection Combined Intravitreal bevacizumab and propranolol|patients receive two injections at each session Bavacizumab
2848495|NCT03609307|Active Comparator|injection Intravitreal bevacizumab|patients receive only Bevacizumab
2848496|NCT03609294|Experimental|Sequence A|"Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)~There will be a washout of 35 days between the each period."
2848497|NCT03609294|Experimental|Sequence B|"Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)~There will be a washout of 35 days between the each period."
2848498|NCT03609294|Experimental|Sequency C|"Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)~There will be a washout of 35 days between the each period."
2848499|NCT03609281||Scheduled cesaren group|Patient delivered by elective cesarean section without labour pains
2848500|NCT03609281||Emergency cesarean group|Patients delivered by cesarean section due to an emergency
2848501|NCT03609268|Active Comparator|MWA|Patients receive microwave ablation (MWA)
2848502|NCT03609268|Experimental|SBRT|Patients receive stereotactic body radiotherapy (SBRT)
2848503|NCT03609255|Active Comparator|Control group (C)|
2848504|NCT03609255|Experimental|Sedentary behavior group (SB)|
2848505|NCT03609255|Experimental|Stress management group (SR)|
2848506|NCT03609242|Experimental|Intervention|Arm 1 will receive the STOP-HPV bundle intervention
2848507|NCT03609242|No Intervention|Control|Arm 2 will receive standard of care
2848508|NCT03609229|Experimental|Study group|Abdominal Sacrocolpopexy with burch technique
2848509|NCT03609229|Active Comparator|control group|Abdominal Sacrocolpopexy without burch technique
2848510|NCT03609216|Experimental|Arm I (gemcitabine, cisplatin, bladder sparing)|Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage < cT1 undergo bladder sparing.
2848511|NCT03609216|Experimental|Arm II (gemcitabine, cisplatin, cystectomy, chemoradiotherapy)|Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage >= cT1 or participants without DDR gene alteration undergo radical cystectomy or chemoradiotherapy.
2848512|NCT03609203||Patients|
2848513|NCT03609203||Controls|
2848514|NCT03609190|Experimental|Ketamine|i.v. infusion of 0.25 mg/kg S-ketamine over 40 min
2848515|NCT03609190|Placebo Comparator|Placebo|i.v. infusion of NaCl over 40 min
2848516|NCT03609177|Experimental|Advance Care Planning|"-In Person Survey:~A subgroup of older patients with advanced cancer (N=450) will have an in-person survey over the course of the 36 months of recruitment.~Participants will be provided written copies of the questions to follow along during the in-person interviews"
2848517|NCT03609177|Experimental|Advance Care Planning-Video Declaration|"Video Declaration:~From among this group of 450 participants, the video declaration of preferences activity will be conducted with 240 patients.~For those participants that agree to the video declaration, they will proceed with recording of their video declarations~The RA will begin by reading a standardized introduction to aid the subject do the video"
2848518|NCT03609177|Other|Comprehensive Record Review of ACP|"A review of Medical orders for resuscitation preferences in the electronic health record~A review of Medical orders for Palliative care consultations preferences in the electronic health record~A review of Medical orders for Hospice use preferences in the electronic health record"
2848519|NCT03609177|Experimental|Main Study Arm|Patients with cancer being seen at the 36 oncology clinics will be exposed to clinicians who have had communication skills training (Vital Talk) and who are using video decision aids (ACP Decisions). Our main outcome is advance care planning documentation.
2848520|NCT03609164|Experimental|Suture-spanning augmentation of single-row repair|
2848521|NCT03609164|Active Comparator|single-row repair|
2848522|NCT03609151|Active Comparator|group A|laparoscopic hepatectomy (surgery)
2848523|NCT03609151|Experimental|group B|stereotactic body radiotherapy (SBRT)
2848524|NCT03609138||Study Cohort|
2853726|NCT03572127|Experimental|Non-animal derived diet|High protein diet derived from non-animal sources.
2848526|NCT03609112||Patients treated for a brain tumor|As part of their usual follow-up, these patients have neuropsychological evaluations following their treatment. A complete neuropsychological evaluation will therefore be performed as part of their usual follow-up during the inclusion period of this study and only the data from this evaluation will be taken into account for the statistical analysis of this study.
2848527|NCT03609112||Patients treated for a non-cerebral tumor|A single neuropsychological assessment will be proposed to these patients after the end of treatment and during the inclusion period of this study. This evaluation will be carried out during a visit to Gustave Roussy as part of their usual follow-up. If on the occasion of this evaluation, cognitive disorders or psychological disorders were highlighted, a neuropsychological and / or psychological follow-up would be proposed.
2848528|NCT03609112||Patients who received Methotrexate|"Methotrexate is used in the treatment of certain brain tumors as in that of non-cerebral tumors. Some of these patients, particularly those who have had neurological complications with methotrexate, will already have longitudinal neuropsychological follow-up as part of their usual follow-up. For these patients, only one complete neuropsychological assessment will be performed during the inclusion period and will be considered for statistical analysis.~For patients in the course of treatment with methotrexate, during the period of inclusion of this study, a longitudinal follow-up will be carried out with neuropsychological evaluations close and successive at the time of their coming to Gustave Roussy within the usual framework of their care."
2848529|NCT03609099|Active Comparator|Moxifloxacin|Active treatment to patients treated during the 5 previous days.
2848530|NCT03609099|Experimental|Placebo|Placebo treatment to patients treated during the 5 previous days.
2848531|NCT03609073|Experimental|Intervention|
2848532|NCT03609060|Experimental|DEXAML|"Induction therapy:~Idarubicin 8 mg/m²/day, IV over 15 minutes, D1 to D5 + Cytarabine 100 mg/m²/d, IV continuous 24h-infusion D1 to D7 + Lomustine 200 mg/m²/d, orally at D1 + Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3. Addition of midostaurin in patients with Fms-like tyrosine kinase 3-internal tandem ( FLT3-ITD) or Fms-like tyrosine kinase 3-tyrosine kinase domain (FLT3-TKD) mutations is allowed.~Post remission therapy:~Idarubicin 8 mg/m², IV over 15 minutes, D1 + Cytarabine 50 mg/m²/12h, subcutaneous, D1 to D5 + Dexamethasone 20 mg/d, IV over 30 minutes, D1. Addition of midostaurin in patients with FLT3-ITD or FLT3-TKD mutations is allowed. Intermediate dose cytarabine is allowed for patients with Core Binding Factor AML (CBF-AML).~Allogeneic stem-cell transplantation allowed after 2 to 4 cycles"
2848533|NCT03609047|Experimental|experimental palbociclib arm|Standard adjuvant endocrine therapy for a duration of at least 5 years + palbociclib (one capsule 125mg QD, orally, for 21 days followed by 7 days off treatment) for a total duration of up to 2 years.
2848534|NCT03609047|Active Comparator|control chemotherapy arm|"Adjuvant chemotherapy:~4 cycles docetaxel 75 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles doxorubicin 60 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles epirubicin 90 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles weekly paclitaxel 80 mg/m2 D1, D8, and D15 q3w~Followed by standard adjuvant endocrine therapy for a duration of at least 5 years."
2848535|NCT03609021||Observational (bilateral screening mammogram)|Participants provide bilateral screening mammogram taken prior to all cancer treatment and within 8 weeks prior to registration to A011502 and an annual bilateral mammogram as near as possible to 1 year post-registration to A011502 and as near as possible to 2 years post-registration to A011502. Participants also undergo collection of blood sample and menstrual cycle data within 2 weeks after registration and at 1 and 2 years after registration to A011502.
2848536|NCT03609008|Active Comparator|Levcromakalim|18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)
2848537|NCT03609008|Placebo Comparator|Saline|18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)
2848538|NCT03608995|Experimental|Premaquick©|
2848539|NCT03608995|Other|Quikcheck|
2848540|NCT03608982|Experimental|Simulated patient|The materials in this course are standardized, and consist of lectures with a slide show, questions & answers conversations, and practical exercises on fellow-students. The courses are being taught by professional first aid tutors from the Belgian Red Cross. During the practical exercises, a simulated patient will unexpectedly enter the room requiring treatment.
2848541|NCT03608982|Active Comparator|No simulated patient|The course materials in the control courses are also standardized. Instead of using simulated patients, however, video clips will be shown to demonstrate the first aid techniques.
2848542|NCT03608969||Study Group|Children with cerebral palsy aged 3-16 years will be evaluated in terms of the orofacial function using the Nordic Orofacial test- screening (NOT-S). Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS) level and Communication Function Scale (CFS) of child will be recorded. Oral health related quality of life will be assessed using the Parental- Caregiver Perceptions Questionnaire. Caries experience will be measured by identifying decayed, missing, and filled teeth for deciduous and permanent teeth (dmft)
2848543|NCT03608943||Adrenal insufficiency|"Individuals who are in the process of changing their treatment from:~hydrocortisone to prednisolone or;~prednisolone to hydrocortisone"
2848544|NCT03608930|Experimental|rotary polypectomy snare|All colorectal polyps found are removed using a rotary polypectomy snare (Disposable Polypectomy Snare). The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is used after hot snare polypectomy if removing a flat polyp or bleeding on the wound after treatment.
2848576|NCT03608631|Experimental|Treatment (iExosomes)|Participants receive mesenchymal stromal cells-derived exosomes with KrasG12D siRNA IV over 15-20 minutes on days 1, 4, and 10. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Participants who respond may continue 3 additional courses.
2848577|NCT03608618|Experimental|Cohort 1|3-6 subjects will receive a starting dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks
2848578|NCT03608618|Experimental|Cohort 2|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks
2848545|NCT03608930|No Intervention|regular polypectomy snare|All colorectal polyps found are removed using a regular polypectomy snare (polypectomy snare, symmetrical). The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the bending section angulation of the colonoscopy as required, advance the snare until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is performed after hot snare polypectomy if a flat polyp or bleeding on the wound after treatment.
2848546|NCT03608917|Experimental|Treatment group|"Drug:Total Glucosides of Paeony (TGP)~Time Frame: Week0-week8 The 1st Week, TGP 0.6g , Bid, orally; 2nd to Week8 , TGP 0.6g , Tid, orally combined with NB-UVB phototherapy( 1 time every other day)~Time Frame: Week9-Week24 TGP, 0.6g, Tid, orally."
2848547|NCT03608917|Placebo Comparator|Control group|"Drug:Total Glucosides of Paeony (TGP) analogue~Time Frame:Week0-week8 The 1st Week, TGP analogue 0.6g , Bid, orally; 2nd to Week8, TGP analogue (0.6g , Tid, orally) combined with NB-UVB phototherapy( 1 time every other day)~Time Frame: Week9-Week24 TGP analogue, 0.6g, Tid, orally."
2848548|NCT03608904|Experimental|Music Listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
2848549|NCT03608904|Placebo Comparator|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
2848550|NCT03608891|Active Comparator|Control Arm|Conventional titanium miniplates
2848551|NCT03608891|Experimental|Intervention arm|Patient specific 3D plates
2848552|NCT03608878|Active Comparator|TACE alone arm|TACE (Transarterial Chemoembolization)
2848553|NCT03608878|Experimental|adagloxad simolenin arm|TACE plus adagloxad simolenin/OBI-821 adjuvant therapy
2848554|NCT03608865|Experimental|experimental group|Drug:Durvalumab + tremelimumab Dose/Potency:Durvalumab 1500mg(up to 4cycle) / tremelimumab 75mg(up to 13 cycle) Dose Frequency:Q4W Route of Administration:IV infusion Regimen/Treatment Period:Day 1 of each 4 week cycle Use:Experimental
2848555|NCT03608852||Banked-money group|This group will have $50 placed in a 'bank account' for every clinic visit where their tests reveal abstinence from smoking. As a modified commitment contract, the Banked-Money Group can only withdraw the accrued money at the end of the trial if they complete the trial by quitting smoking for the entire 6 months.
2848556|NCT03608852||Reward group|This group will directly receive $50 for every clinic visit where their tests reveal abstinence from smoking.
2848557|NCT03608839|Experimental|Dexamethasone 0,01 ml intravitreal group|Patients who received a single intravitreal injection of 0,01 ml dexamethasone solution 4 mg/ml.
2848558|NCT03608839|Experimental|Dexamethasone 0,03 ml intravitreal group|Patients who received a single intravitreal injection of 0,03 ml dexamethasone solution 4 mg/ml.
2848559|NCT03608839|Experimental|Dexamethasone 0,05 ml intravitreal group|Patients who received a single intravitreal injection of 0,05 ml dexamethasone solution 4 mg/ml.
2848560|NCT03608826|Experimental|Single Arm Study|Invesigational RAMware will be downloaded onto the LINQ device.
2848561|NCT03608813||Controls|Healthy subjects
2848562|NCT03608813||Case|PCOS affected subjects
2848563|NCT03608800|Experimental|Intermittent fasting|two inconsecutive days of 75% energy restriction per week for 8 weeks, followed by 8 weeks of wash-out
2848564|NCT03608787|Experimental|Cohort 1-Early Intervention|Following baseline, participating outlets in this arm will receive the S-STOP program consisting of Pseudo-Intoxicated Mystery Shops (P-I/MS) with performance feedback for 3 months. After 3 months they will receive no further intervention, but will continue to receive Pseudo-Intoxicated Mystery Shops (P-I/MS).
2848565|NCT03608787|Experimental|Cohort 2-Delayed Intervention|Following baseline, participating outlets in this arm will receive receive Pseudo-Intoxicated Mystery Shops (P-I/MS) with no feedback. After 3 months they will receive the S-STOP program consisting of Pseudo-Intoxicated Mystery Shops (P-I/MS) with performance feedback.
2848566|NCT03608774|Experimental|Arm 1|1 gram of Azithromycin (4 capsules of 250 mg) administered orally as a single dose on Day 1, and Doxycycline placebo (1 capsule) administered orally twice daily for 7 days starting on Day 1. N=221
2848567|NCT03608774|Experimental|Arm 2|100 mg of Doxycycline (1 capsule) administered orally twice daily for 7 days starting on Day 1, and Azithromycin placebo (4 capsules) administered orally as a single dose on Day 1. N=221
2848568|NCT03608761|Experimental|Rebamipide 2%|"- wash-out: 2 weeks~- rebamipide 2% four times a day for 3 months~- controls will be taken at day zero, 30 and 90.~- wash-out: 2 weeks~- autologous serum for 3 months"
2848569|NCT03608761|Experimental|Autologous serum|"- wash-out: 2 weeks~- autologous serum four times a day for 3 months~- controls will be taken at day zero, 30 and 90.~- wash-out: 2 weeks~- rebamipe 2% for 3 months"
2848570|NCT03608761|Experimental|autologous serum and rebamipide 2%|rebamipide 2% and autologous serum four times a day for 3 months separately by 1 minute between each other controls will be taken at day zero, 30 and 90. this group will not be crossed
2848571|NCT03608722|Experimental|BrainCheck vs Pen and paper tests|Compare patient performance on BrainCheck neurocognitive test vs pen and paper dementia tests (SLUMS, MMSE, MoCA), as well as an exploratory analysis comparing BrainCheck performance to aid in identifying patients with MCI and dementia vs physician diagnosis
2848572|NCT03608722|Experimental|BrainCheck performance in ESRD patients|Assess BrainCheck test performance in patients with ESRD and how undergoing hemodialysis treatment can impact cognitive performance.
2848573|NCT03608696|Experimental|buprenorphine|"Buprenorphine 0.075 mg ml sublingual solution~Initial daily dose 24 mcg/kg/day Initial unit dose 8 mcg/kg q8 hours Maximum daily dose 75 mcg/kg/day Maximum unit dose 25 mcg/kg q8 hours Up-titration rate 33% Maximum # of up-titrations 4 Weaning rate 15% Cessation (bottom) dose < Initial dose Dosing interval until bottom dose (hrs) 8 Dose interval extension #1 at bottom dose (hrs) 12 Dose interval extension #2 at bottom dose (hrs) 24"
2848574|NCT03608670|Experimental|Experimental|Patients will be implanted with an extravascular ICD and undergo requisite electrical testing.
2848575|NCT03608657||Psoriatic Arthritis patients treated with Apremilast|Active PsA as per the CASPAR criteria, based on the investigator's clinical judgement with access to commercially available Otezla
2848583|NCT03608579|Experimental|Single Injection|Single administration of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip by single ultrasound guided injection
2848584|NCT03608579|Experimental|Two Injections|Two-dose administration (2 x ultrasound guided injections) of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip with one month interval between doses
2848585|NCT03608553|Experimental|Transcranial ExAblate MR Guided Focused Ultrasoun|
2848586|NCT03608540|Experimental|Intervention|Suturing system with suture apposition then bulging formation then cutting the lesion
2848587|NCT03608527|Experimental|Active motor treatment (AMT) group|15 people with multiple sclerosis performing a 8 week rehabilitative treatment based on task-oriented voluntary exercises (3 sessions/week).
2848588|NCT03608527|Active Comparator|Passive motor treatment (PMT) group|15 people with multiple sclerosis performing a 8 week passive mobilization delivered by a physical therapist (3 sessions/week).
2848589|NCT03608514|Active Comparator|nor-epinephrine+/- epinephrine infusion|"Intravenous infusion of Nor-epinephrine in an initial dose of 0.01µg/kg/min. which can be increased every 15-30 minutes to maximum 3µg/kg/min. ± intravenous infusion of epinephrine with an initial dose 0.05µg/kg/min. & can be titrated every 15-30 minutes up to 2µg/Kg/min.~The end point is to achieve mean arterial pressure ≥ 65 mmHg & normalized lactate ≤ 2 mmol/L or lactate clearance ≥ 10% within 6 hours.~Patients will be followed for 48 hours."
2848590|NCT03608514|Other|Terlipressin infusion|"Intravenous infusion of terlipressin by rate 1-2µg/kg/min. The end point is to achieve mean arterial pressure ≥ 65 mmHg & normalized lactate ≤ 2mmol/L or lactate clearance ≥ 10% within 6 hours.~Patients will be followed for 48 hours."
2848591|NCT03608501|Experimental|Ixazomib 4 mg + Thalidomide 100 mg + Dexamethasone 40 mg|Ixazomib 4 milligram (mg), capsule, orally, once on Days 1, 8 and 15 along with thalidomide 100 mg, tablet, orally, once daily on Days 1 to 28 and dexamethasone 40 mg, tablet, orally, once on Days 1, 8, 15 and 22 in a 28-day treatment cycle for up to 9 cycles or until withdrawal from the study in the treatment phase. Participants who complete treatment phase will be eligible to continue on to the maintenance phase of the study to receive ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of a 28-day treatment cycle for up to 24 months or until withdrawal from the study.
2848592|NCT03608488|Experimental|Vitamin D<10 ng/ml; Vitamin D replacement|
2848593|NCT03608488|Experimental|Vitamin D<10 ng/ml; Vitamin D replacement and exercise|
2848594|NCT03608488|Experimental|Vitamin D<10 ng/ml; exercise|
2848595|NCT03608488|Active Comparator|Vitamin D>30ng/ml; exercise|
2848596|NCT03608475|Active Comparator|Comprehensive Ultrasound Group|Children in the comprehensive ultrasound protocol group will follow the current standardized treatment protocol used at the Hospital for Sick Children in Toronto, Canada. For children presenting with stable hip dysplasia, Pavlik harness (PH) treatment is initiated at the initial visit (week 0) and runs for a total of 12 weeks. Children return to clinic at weeks 2, 5, 8 and 12 for clinical and ultrasound examinations to ensure that the harness is fitting correctly, to screen for PH complications and to monitor acetabular development.
2848597|NCT03608475|Experimental|Limited Ultrasound Group|Children in the limited ultrasound protocol group will receive the same treatment as described for the comprehensive ultrasound group above, except the ultrasound imaging conducted at weeks 2, 5 and 8 will be omitted. Children will still return to clinic at 2, 5, and 8 weeks for clinical examination, which includes the assessment of the Pavlik harness fit and screening for complications.
2848598|NCT03608462|Sham Comparator|left DLPFC rTMS treatment|60 patients will be randomly allocated into this group,half of them will receive rTMS(20Hz) on left DLPFC,while the other half will receive sham stimulation.
2848599|NCT03608462|Sham Comparator|left LPC rTMS treatment|60 patients will be randomly allocated into this group,half of them will receive rTMS(20Hz) on left LPC,while the other half will receive sham stimulation.
2848600|NCT03608462|No Intervention|observation group|investigate the abnormalities of hippocampal neurogenesis in patients with early schizophrenia(n=30) compared to healthy controls(n=30)
2848601|NCT03608449|Active Comparator|study group|after monitoring treatment outcomes for 4 weeks, treatment plan or psychotherpist will be changed according to scoring by the director of department.
2848602|NCT03608449|Placebo Comparator|control group|treatment as usual. treatment counitunes as usual without depending on monitoring treatment outcomes.
2848603|NCT03608436|Experimental|Low pressure PNP, deep NMB|Low pressure pneumoperitoneum of 8 mmHg with deep neuromuscular block (post tetanic count of 1-2) reached by titration with continuous infusion of Rocuronium bromide.
2848604|NCT03608436|Active Comparator|Normal pressure PNP, moderate NMB|Normal pressure pneumoperitoneum of 12 mmHg with moderate neuromuscular block (TOF count of 1-2) reached by titration with bolus or continuous infusion of a low dose of Rocuronium bromide.
2848605|NCT03608423|Experimental|Surgical treatment|Minimally-invasive endoscopy-guided surgery or hematoma aspiration, additional to standard medical treatment.
2848606|NCT03608423|No Intervention|Standard medical management|Standard medical treatment (treatment of bloodpressure, admission to stroke unit and supportive care, surgical treatment if necessary in case of deterioration)
2848607|NCT03608410|Experimental|PRO intervention|Weekly PRO questionnaires Quality of life every 3 months
2848608|NCT03608410|No Intervention|Standard of care|Quality of life every 3 months
2848609|NCT03608397|Experimental|DAXI for injection low dose|Low Dose Group
2848610|NCT03608397|Experimental|DAXI for injection high dose|High Dose Group
2848611|NCT03608397|Placebo Comparator|Placebo|Placebo Group
2848612|NCT03608371|Experimental|BTRX-246040 Cohort 1|BTRX-246040 will be administered orally 40 mg (1capsule) in Cohort 1
2848613|NCT03608371|Experimental|BTRX-246040 Cohort 2|BTRX-246040 will be administered orally 80 mg (2 capsules) in Cohort 2
2848614|NCT03608371|Experimental|BTRX-246040 Cohort 3|BTRX-246040 will be administered orally120 mg (3 capsules) in Cohort 3
2848615|NCT03608371|Experimental|BTRX-246040 Cohort 4|BTRX-246040 will be administered orally160 mg (4 capsules) in Cohort 4
2848616|NCT03608371|Placebo Comparator|Placebo Cohorts 1-4|Placebo will be administered orally at the same number of capsules as active drug at each Cohort. Placebo capsules will consist of inactive ingredients and look identical to BTRX-246040.
2848617|NCT03608358|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg and dapagliflozin 5 mg placebo to match added to saxagliptin 5 mg and metformin
2854538|NCT03566706|Experimental|Sedentary Behavior|
2848618|NCT03608358|Experimental|Dapagliflozin 5 mg|Dapagliflozin 5 mg and dapagliflozin 10 mg placebo to match added to saxagliptin 5 mg and metformin
2848619|NCT03608358|Placebo Comparator|Placebo|Dapagliflozin 5 mg placebo to match and dapagliflozin 10 mg placebo to match added to saxagliptin 5 mg and metformin
2848620|NCT03608332|No Intervention|Group S|"weaning readiness will be evaluated with the standard criteria :- A) Clinical assessment:-~Resolution of acute phase of disease for which patient was intubated~Adequate cough~Absence of excessive tracheobronchial secretions~B) Objective criteria:-~Adequate oxygenation:PaO2>60mmHg with PEEP<8,SaO2>90%,FIO2 <0.5,PaO2/FIO2>200~Respiratory rate <30~PH and PaCO2 appropriate for patients' baseline respiratory status~Hemodynamically stable :minimal or no vasopressor/inotropes,no evidence of myocardial ischemia~HR<140 beats/minute~Patient is arousable or Glasgow coma scale (GCS)>13"
2848621|NCT03608332|Experimental|Group SD|"weaning readiness will be evaluated with the following criteria:- A) Clinical assessment:-~Resolution of acute phase of disease for which patient was intubated~Adequate cough~Absence of excessive tracheobronchial secretions~B) Objective criteria:-~Adequate oxygenation:PaO2>60mmHg with PEEP<8,SaO2>90%,FIO2 <0.5,PaO2/FIO2>200~Respiratory rate <30~PH and PaCO2 appropriate for patients' baseline respiratory status~Hemodynamically stable :minimal or no vasopressor/inotropes,no evidence of myocardial ischemia~HR<140 beats/minute~Patient is arousable or Glasgow coma scale (GCS)>13~C) Ultrasound criteria:-~DTF> 30%~DE>11 mm"
2848622|NCT03608319|Experimental|Single dose following overnight fast|
2848623|NCT03608319|Experimental|Single dose following high fat breakfast|
2848624|NCT03608319|Experimental|Single dose sprinkled on applesauce following overnight fast|
2848625|NCT03608306|Experimental|Resin-modified glass ionomer|Activa Bioactive-Restorative is an enhanced resin modified glass ionomer (RMGI) with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
2848626|NCT03608306|Active Comparator|Bulk-fill glass hybrid restorative|EQUIA Forte is a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
2848627|NCT03608293|Experimental|Smokers|Smokers outpatients at the Pneumology service from the HôpitalSaint-Philibert (Lomme, France) to whom a bronchoalveolar lavage will be performed
2848628|NCT03608293|Active Comparator|Non smokers|Non smokers outpatients at the Pneumology service from the HôpitalSaint-Philibert (Lomme, France) to whom a bronchoalveolar lavage will be performed
2848629|NCT03608280|Active Comparator|Autograft|Reconstructive surgery by autologous bone graft (bone autograft). It is the gold standard strategy.
2848630|NCT03608280|Experimental|3D implant|"Orbital reconstruction by 3D-printed porous titanium implant (PorousiTi®, laboratoire OBL/MATERIALISE).~The device is a custom-made porous titanium implant processed by selective laser melting (SLM technique)"
2848631|NCT03608267|Experimental|Intervention|
2848632|NCT03608241|Experimental|Treatment sequence 1|Treatment sequence 1 will receive a single dose of an oral contraceptive during the first period of the study (period 1) and then continue to the second period (Period 2) of the study where they will receive PF-06651600 every day for 11 days and a single dose of an oral contraceptive towards the end of the period.
2848633|NCT03608241|Experimental|Treatment Sequence 2|Treatment sequence 2 will receive PF-06651600 every day for 11 days during the first period of the study (period 1) and a single dose of an oral contraceptive towards the end of this period. After completion of Period 1, there will be a washout period of at least 10 days before starting the second period of the study (period 2). During period 2, a single dose of an oral contraceptive will be received.
2848634|NCT03608228||Parkinson's Disease|
2848635|NCT03608215|Experimental|Active tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). Active stimulation consists of 2 mA current applied continuously for 20 minutes.
2848636|NCT03608215|Sham Comparator|Sham tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). The 2 mA current will be applied for 30 seconds at the beginning of the session.
2848637|NCT03608202|Experimental|POCUS protocol group|"POCUS protocol group~It will be submitted to an ultrasound protocol which consists in performing the following ultrasound studies in each patient:~Measurement of the diameter of the optic nerve. Neck. Pulmonary ultrasound (LUS score). Echocardiogram (function and volemia). Abdomen. Femoral vascular package. Eco-guided interventionism. Central venous accesses (controlling positioning with saline injection under ultrasound), arterial, pleural or abdominal drainage and percutaneous tracheotomy will be performed under ultrasound."
2848638|NCT03608202|Active Comparator|Control group|The usual handling will be followed. The studies will only be performed if the medical team-treating team considers it, requesting a radiologist specialist the same, as is done routinely.
2848639|NCT03608189||ACL injury subjects|Subjects with anterior cruciate ligament injuries.
2848640|NCT03608176|Experimental|PASO diet group|
2848641|NCT03608176|Active Comparator|Low-fat diet group|
2848642|NCT03608176|Other|Waiting list group|
2848643|NCT03608163|No Intervention|No intervention (Susceptibility to HAAF evaluation)|Susceptibility to HAAF evaluation: No medication will be given during the first or second episodes of hypoglycemia.
2848644|NCT03608163|Experimental|Naloxone|Naloxone evaluation: Intranasal naloxone (4 mg NARCAN Nasal Spray) in one nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Intranasal naloxone (4 mg NARCAN Nasal Spray) will again be given in one nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
2848645|NCT03608163|Placebo Comparator|Placebo (for Naloxone)|Naloxone evaluation: Placebo (for naloxone) nasal spray in one nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Placebo (for naloxone) nasal spray will again be given in one nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
2848646|NCT03608163|Experimental|Naloxone + diazoxide|Naloxone/Diazoxide evaluation: Up to 7 mg/kg oral diazoxide 3 hours before the first hypoglycemic episode. Intranasal naloxone (4 mg NARCAN Nasal Spray) in one nostril twice during each hypoglycemia episode; once at the start of insulin administration and again after one hour.
2848647|NCT03608163|Active Comparator|Diazoxide + placebo (for naloxone)|Naloxone/Diazoxide evaluation: Up to 7 mg/kg oral diazoxide 3 hours before the first hypoglycemic episode. Placebo (for naloxone) nasal spray in one nostril twice during each hypoglycemia episode; once at the start of insulin administration and again after one hour.
2848648|NCT03608163|Active Comparator|Naloxone + placebo (for diazoxide)|Naloxone/Diazoxide evaluation: Oral placebo (for diazoxide) 3 hours before the first hypoglycemic episode. Intranasal naloxone (4 mg NARCAN Nasal Spray) in one nostril twice during each hypoglycemia episode; once at the start of insulin administration and again after one hour.
2848649|NCT03608163|Placebo Comparator|Placebo (for naloxone) + placebo (for diazoxide)|Naloxone/Diazoxide evaluation: Oral placebo (for diazoxide) 3 hours before the first hypoglycemic episode. Placebo (for naloxone) nasal spray in one nostril twice during each hypoglycemia episode; once at the start of insulin administration and again after one hour.
2848650|NCT03608137|Experimental|Cannabis users|Subjects of this group have to meet the DSM-5 criteria for schizophrenia and smoke cannabis at least two days per week for every week of the past month. They have to exhibit negative urine screen for any substance except benzodiazepines and cannabis.
2848651|NCT03608137|Active Comparator|Non- cannabis users (control group)|Subjects of this group have to meet the DSM-5 criteria for schizophrenia and have to report no cannabis use over the previous month, and exhibit negative urine screen for any substance except benzodiazepines.
2848652|NCT03608111|Active Comparator|single task balance training|
2848653|NCT03608111|Active Comparator|dual task balance training|
2848654|NCT03608098|Active Comparator|Short Pulse Duration Group|A short pulse duration (300 μs or 350 μs) will be used in this group.
2848655|NCT03608098|Active Comparator|Long Pulse Duration Group|A long laser pulse duration (700 μs or 1500 μs) will be used in this group.
2848656|NCT03608085|Experimental|Pharmacist Heart failure MTM training|Community pharmacist who will receive heart failure medication therapy management training
2848657|NCT03608085|Experimental|Patient Heart failure MTM intervention|Independently living community dwelling subjects who are prescribed at least 1 cardiovascular medication for HF and 3 additional chronic medications after discharge from the Hospital for an MTM consultation by a pharmacist trained in heart failure medication therapy management.
2848658|NCT03608072|Experimental|Dose group 1|
2848659|NCT03608072|Experimental|Dose group 2|
2848660|NCT03608072|Experimental|Dose group 3|
2848661|NCT03608059|Experimental|ATG/PTCy|The GvHD prophylaxis consisted of ATG 2.5mg/kg administered on day -2 to -1 and cyclophosphamide (Cy) 50 mg/kg on day +3, cyclosporine A (CsA) and mycophenolate mofetil (MMF) initiating on day +4. CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 3 times per day (maximum dose 3g per day) until day +34 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
2848662|NCT03608059|Active Comparator|standard ATG|The GvHD prophylaxis consisted of ATG 2.5mg/kg administered on day -4 to -1 , cyclosporine A (CsA) initiating on day -5 and mycophenolate mofetil (MMF) initiating on day +1 . CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 2 times per day (maximum dose 2g per day) until day +30 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
2848663|NCT03608059|Active Comparator|standard PTCy|The GvHD prophylaxis consisted of cyclophosphamide (Cy) 50 mg/kg on day +3, +4,cyclosporine A (CsA) and mycophenolate mofetil (MMF) initiating on day +5. CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 3 times per day (maximum dose 3g per day) until day +35 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
2848664|NCT03608046|Experimental|Avelumab, Cetuximab, Irinotecan|"Avelumab : administrated at a fixed dose of 10 mg/kg once every 2- week. Cetuximab: administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3.~Irinotecan: administrated every 2 weeks (180 mg/m2)."
2848665|NCT03608033|Experimental|OMS721|Administration of OMS721
2848666|NCT03608033|Placebo Comparator|Placebo|Administration of Vehicle (D5W or Saline Solution)
2848667|NCT03608020|Active Comparator|WBRT + BMX-001|Whole brain radiation therapy in combination with BMX-001 (subcutaneous injection of 28 mg loading dose, followed by subsequent 14 mg twice per week for 2 weeks).
2848668|NCT03608020|No Intervention|Whole Brain Radiation Therapy|Whole brain radiation therapy per standard of care.
2848669|NCT03608007|Experimental|X-396 Capsule|Single-arm trial whereby all consented, enrolled, eligible patients receive X-396 capsule, 225 mg once daily.
2848670|NCT03607994|Active Comparator|HIRREM-SOP (BCC|Acoustic stimulation linked to brainwave activity and continued current care.
2848671|NCT03607994|Other|NCC|Continued current care and acoustic stimulation that is not linked to brainwave activity.
2848672|NCT03607968||All women in this study|All women with POP and concomitant overt or occult USI, who underwent the novel anterior TVM surgeries, were enrolled in this study. Medical records, including urodynamic studies, questionnaires and 3-day bladder diaries, were retrospectively reviewed. Linear regress analysis was used to identify factors that were responsible for the changes in pad weights from baseline [i.e., 100 * (postoperative pad weight - baseline pad weight)/baseline pad weight].
2848673|NCT03607955|Experimental|AVB-S6-500 + Paclitaxel + Carboplatin|"Paclitaxel will be given intravenously at a dose of 175 mg/m^2 on an outpatient basis over 3 hours on Day 1 of each 21-day cycle~Carboplatin will be given intravenously at a dose of AUC 6 over 30 minutes on Day 1 of each cycle of chemotherapy~AVB-S6-500 will be given at doses based on the dose escalation schema~The investigators will continue dosing AVB-S6-500 until 1 week prior to surgery and continuing after surgery. Maintenance dosing q2 weeks will begin with Cycle 7A/7B and be given every 2 weeks for 12 months through Cycle 19 (total of 13 maintenance cycles)."
2848674|NCT03607942|Experimental|Experimental Formula|The experimental group will receive a liquid supplement containing 2 specific HMOs
2848675|NCT03607942|Placebo Comparator|Control Formula|The control group will receive a liquid placebo
2848678|NCT03607916|Experimental|Cohort 1 : HB Prilocaine 2%,(60mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2848679|NCT03607916|Experimental|Cohort 2 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2848680|NCT03607916|Experimental|Cohort 3 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2848681|NCT03607916|Experimental|Cohort 4 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2848682|NCT03607916|Experimental|Cohort 5 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2848683|NCT03607916|Experimental|Cohort 6 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2848684|NCT03607916|Experimental|Cohort 7 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2848685|NCT03607916|Experimental|Cohort 8 : HB Prilocaïne 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2848686|NCT03607916|Experimental|Cohort 9 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2848687|NCT03607916|Experimental|Cohort 10 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2848688|NCT03607903|Active Comparator|Subcutaneous adalimumab and placebo|adalimumab SC (40 mg in 0.4 mL) and saline ID (0.9%, 0.4 mL)
2848689|NCT03607903|Active Comparator|PLacebo and subcutaneous adalimumab|saline ID (0.9%, 0.4 mL) and adalimumab SC (40 mg in 0.4 mL)
2848690|NCT03607903|Experimental|Placebo and intradermal adalimumab|saline SC (0.9%, 0.4 mL) and adalimumab ID (40 mg in 0.4 mL)
2848691|NCT03607903|Experimental|Intradermal adalimumab and placebo|adalimumab ID (40 mg in 0.4 mL) and saline SC (0.9%, 0.4 mL)
2848692|NCT03607890|Experimental|Nivolumab and Relatlimab|
2848693|NCT03607877|Active Comparator|pedometer walking (PW)|15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down for 3 months.
2848694|NCT03607877|Active Comparator|pedometer walking with training (PWT)|15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down. Exercise intensity for the first four weeks was 50-55% heart rate reserve (HRR) with training for 3 months.
2848695|NCT03607877|Experimental|positive education and walking (PEPWT)|PEPWT: 15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down for 3 months and six sessions of positive education.
2848696|NCT03607864|Experimental|coral bone graft and xenograft|Extraction of upper anterior badly broken teeth with immediate implant placement with the use of coral bone and xenograft as grafting material between the implant and the labial socket bone
2848697|NCT03607851|Active Comparator|Conventional titration group|
2848698|NCT03607851|Experimental|Rapid titration group 1|
2848699|NCT03607851|Experimental|Rapid titration group 2|
2848700|NCT03607838|Experimental|SI-6603|
2848701|NCT03607838|Sham Comparator|Sham injection|
2848702|NCT03607799|Experimental|Dietary Intervention|"A dietitian develops personalized diet advice for each intervention group participant. She sets 2-4 SMART goals according to the following principles: 1) Replace fried foods and meat with vegetable protein, raw and cooked vegetables; 2) Reduce refined carbohydrate intake; 3) Improve carbohydrate quality (replace high glycemic index, refined grain foods with lower glycemic index, whole-grain foods; 4) Reduce trans fats; 5) Schedule regular mealtimes, 3-4 hours apart; 6) Reduce high-carbohydrate snacks; 7) Reduce desserts and/or drinks high in starch and sugar. Participants review 6 simple messages at the baseline visit, aimed at increasing walking, with reinforcement text messages sent weekly."
2853727|NCT03572127|Active Comparator|Animal derived diet|High protein diet derived from animal sources.
2848703|NCT03607799|Active Comparator|Control|"Control group participants will be provided with paper copies and website links to The Sensible Guide to a Healthy Pregnancy, which provides advice on healthy eating, physical activity, and other lifestyle factors during pregnancy plus additional materials adapted specifically for the SA community. Participants review 6 simple messages at the baseline visit, aimed at increasing walking, with reinforcement text messages sent weekly."
2848704|NCT03607786|Active Comparator|RIVP group|After total cardiopulmonary bypass was initiated, the patient is cooled slowly to induce moderate hypothermia(28-30℃). The combination of selective antegrade cerebral perfusion and retrograde inferior vena caval perfusion is performed. The antegrade perfusion flow rate was is maintained at 6-12 mL/min/kg.Pump pressure of retrograde perfusion was is maintained at 20-30 mmHg, and blood flow was is maintained at 8-12 mL/min/kg.
2848705|NCT03607786|Active Comparator|ACP group|After total cardiopulmonary bypass was initiated, the patient is cooled slowly to induce moderate hypothermia(26-28℃). Only select antegrade cerebral perfusion is performed by maintaining the flow rate at 6-12 mL/min/kg.
2848706|NCT03607773|Active Comparator|Mindfulness Behavioural Intervention (MBI) group|10 one-hour mindfulness sessions
2848707|NCT03607773|No Intervention|Control group|Standard of care.
2848708|NCT03607760||ECMO|severe respiratory failure with ECMO
2848709|NCT03607760||conventional mechanical ventilation|severe respiratory failure with conventional mechanical ventilation
2848710|NCT03607734|Other|Group 1 - Interventional Treatment|"A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:~50mg amoxicillin (10% total dose)~250mg amoxicillin (50% total dose)~200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available."
2848711|NCT03607721|Experimental|DBS Patients Group|Body Motion Evaluation DARI
2848712|NCT03607721|Active Comparator|Control Group|Body Motion Evaluation DARI
2848713|NCT03607708|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).
2848714|NCT03607708|Active Comparator|Health Enhancement Program (HEP)|Health Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
2848715|NCT03607695|Experimental|Gait training|1 hour walking exercise on a treadmill
2848716|NCT03607669||Healthy Controls|Healthy volunteers of similar age and gender
2848717|NCT03607669||Ischaemic Cardiomyopathy|Patients with ischaemic cardiomyopathy and NYHA II-III heart failure
2848718|NCT03607669||Hypertrophic Cardiomyopathy|Patients with hypertrophic cardiomyopathy and NYHA II-III heart failure
2848719|NCT03607669||Dilated Cardiomyopathy|Patients with dilated cardiomyopathy and NYHA II-III heart failure
2848720|NCT03607656|Experimental|TCM & Oxaliplatin & Capecitabine|Traditional Chinese Medicine oral taken twice a day for at least 3 months combined with intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21-28 days)
2848721|NCT03607656|Active Comparator|Oxaliplatin & Capecitabine|intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21-28 days
2848722|NCT03607643|Placebo Comparator|Colon: Chemo + Placebo|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
2848723|NCT03607643|Experimental|Colon: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
2848724|NCT03607643|Placebo Comparator|Rectal: Chemo + Placebo|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
2848725|NCT03607643|Experimental|Rectal: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
2848726|NCT03607643|Placebo Comparator|Multiple myeloma: Chemo + Placebo|Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 & 11 schedule to be repeated every 21 days.
2848727|NCT03607643|Experimental|Multiple myeloma: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 & 11 schedule to be repeated every 21 days.
2848728|NCT03607643|Placebo Comparator|Pancreatic: Chemo + Placebo|Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
2848729|NCT03607643|Experimental|Pancreatic: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
2848730|NCT03607643|Placebo Comparator|GBM: Chemo + Placebo|Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
2853801|NCT03571737|Active Comparator|Ibuprofen|Ibuprofen 800mg every 8 hours for 3 days
2848731|NCT03607643|Experimental|GBM: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
2848732|NCT03607630|No Intervention|Waiting Pre-Intervention Control|Participant completes measures for 1-3 weeks (randomly chosen) before they complete the intervention. Participants act as their own controls
2848733|NCT03607630|Experimental|Imagery Rescripting|3 Sessions of Imagery Rescripting
2848734|NCT03607617||Wedge 1|Five randomized clinics will implement SDH tool.
2848735|NCT03607617||Wedge 2|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
2848736|NCT03607617||Wedge 3|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
2848737|NCT03607617||Wedge 4|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
2848738|NCT03607617||Wedge 5|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
2848739|NCT03607617||Wedge 6|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
2848740|NCT03607604||Autoantibody Negative|"Patients who are autoantibody negative (could potentially be either MODY or type 2 diabetes patients)~Suspected MODY patients will be candidates for next generation sequencing (NGS)"
2848741|NCT03607604||Diabetes Mellitus, Type 1|"Patients diagnosed with type 1 diabetes mellitus~Patients with positive UCPCR and negative autoantibodies results will be suspected with MODY and will be candidates for next generation sequencing (NGS)"
2848742|NCT03607604||Non Diabetic|Individuals not diagnosed with any type of diabetes (but could be diagnosed with IFG and/or IGT)
2848743|NCT03607591|Active Comparator|Active rTMS group|One daily session: active 15Hz frequency, pulse intensity 100% of the rTMS, 60 pulses per train, inter-train pause of 15 sec, 40 stimulation trains for a total of 2400 pulses in 13 min of stimulation). 15 sessions (3 weeks of 5 consecutive daily sessions and 2 days of rest)
2848744|NCT03607591|Placebo Comparator|Placebo rTMS group|One daily session: inactive 15Hz frequency, pulse intensity 100% of the rTMS, 60 pulses per train, inter-train pause of 15 sec, 40 stimulation trains for a total of 2400 pulses in 13 min of stimulation). 15 sessions (3 weeks of 5 consecutive daily sessions and 2 days of rest)
2848745|NCT03607578|Other|Control Group - Minimal Intervention|Minimal intervention
2848746|NCT03607578|Experimental|Protection Routine 1|
2848747|NCT03607578|Experimental|Protection Routine 2|
2848748|NCT03607578|Experimental|Protection Routine 1+2|
2848749|NCT03607565||good perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in middle cerebral artery (MCA) territory in anterior cerebral ischemia.(good perfusion)
2848750|NCT03607565||middle perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in middle cerebral artery (MCA) territory in anterior cerebral ischemia.(middle perfusion)
2848751|NCT03607565||poor perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in middle cerebral artery (MCA) territory in anterior cerebral ischemia.(poor perfusion)
2848752|NCT03607552||Phase 1: Pilot Study Phase|Optimize DWI sequences to maximize spatial resolution, reduce distortion, and increase lesion contrast.
2848753|NCT03607552||Phase 2: Development Phase|Develop interpretation tools to optimize diagnostic performance for detecting cx on DWI.
2848754|NCT03607552||Phase 3: Reader Performance Phase|Test the performance of the optimized DWI approach for detecting clinically and mammographically-occult cancer in women with dense breasts.
2848755|NCT03607539|Experimental|Sintilimab in combination with pemetrexed and platinum|Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria Sintilimab 200mg + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains
2848756|NCT03607539|Placebo Comparator|Sitilimab Placebo Comparator|placebo 200mg + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains
2848757|NCT03607526||Barriers to Vegetable Consumption|Four groups of participants will meet for NGT sessions, identifying barriers to meeting the DGA recommendation for vegetable consumption.
2848758|NCT03607526||Facilitators to Vegetable Consumption|Four groups of participants will meet for NGT sessions, identifying facilitators to meeting the DGA recommendation for vegetable consumption.
2848759|NCT03607513|Experimental|Single Ascending Dose (SAD)|The SAD part will consist of 6 escalating dose cohorts and 1 fed cohort of healthy male participants and 2 dose escalating cohorts of healthy female participants. Participants in each cohort will receive JNJ-64264681 or Placebo on Day 1, orally. Doses for the female cohorts and fed cohort will be selected based on safety, tolerability, and pharmacokinetics (PK) data from preceding cohorts.
2848760|NCT03607513|Experimental|Multiple Ascending Dose (MAD)|The MAD part will consist of 3 dose escalation cohorts of males and females. Participants will receive once-daily oral doses of JNJ-64264681 or placebo for 10 consecutive days.
2848761|NCT03607500|Experimental|Caloric Intake Reduction|The intervention group will be seen by the kidney disease dietician at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3). During months 2 and 3, in the weeks that the patients are not in clinic, they will receive telephone calls from the dietician. Thus the intervention involves weekly assessment for the first 3 months (in person or over the telephone). After 3 months, the patient will not receive any further active dietary intervention from the dieticians unless the patient wishes to continue using the dieticians advice per clinic protocol.
2848762|NCT03607500|No Intervention|Standard of care|The standard of care arm will receive dietary guidance per current University of Michigan Transplant Center policy, where a one time face-to-face visit is provided in the first month after kidney transplant and then as requested by the patient or referred by physician.
2848763|NCT03607487|Experimental|Cohort 1|INCB054707 at the Cohort 1 dose or placebo.
2848764|NCT03607487|Experimental|Cohort 2|INCB054707 at the Cohort 2 dose or placebo.
2848765|NCT03607487|Experimental|Cohort 3|INCB054707 at the Cohort 3 dose or placebo.
2848917|NCT03606395|Experimental|Single ascending dose_healthy subjects|"NV-5138:~Single dose of 150, 300, 600, 1000, 1600 or 2400 mg single dose of placebo"
2848766|NCT03607474||Couple (Patients and caregivers)|"Patient in remission of hypercortisolism Caregivers will be the spouse or, failing that, a person close to the patient, who has been in regular contact with the patient since taking care of him.~Questionnaires of life quality for patients Questionnaires of life quality for caregivers"
2848767|NCT03607461|Experimental|Smartphone App Users|Smartphone App Users will receive important information and prescriptive exercise via a smartphone app upon returning home from the hospital following total knee arthroplasty
2848768|NCT03607461|Active Comparator|Home Health Users|Home Health Users will have already undergone traditional home health physical therapy and/or skilled nursing for the purpose of comparing outcomes
2848769|NCT03607448||Diabetes Mellitus Type 1 and Type 2|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and expected to perform at least 8 capillary BG test per day. Site Staff will determine when subject will undergo either a hypoglycemia induction or a hyperglycemia induction. Study staff will perform IV blood draw to obtain blood plasma for YSI sampling every 15 min when glucose as measured by YSI is above 70mg/dL and below 240 mg/dL.
2848770|NCT03607435|Experimental|Test Article Scanning|Spectroscopy for Analyte Quantification
2848771|NCT03607422|Experimental|Arm A|Upadacitinib Dose A is administered once daily.
2848772|NCT03607422|Experimental|Arm B|Upadacitinib Dose B is administered once daily.
2848773|NCT03607422|Experimental|Arm C|Placebo administered once daily followed by Upadacitinib Dose A once daily.
2848774|NCT03607422|Experimental|Arm D|Placebo administered once daily followed by Upadacitinib Dose B once daily.
2848775|NCT03607383|Experimental|Red rice yeast group|Red rice yeast based product will be provided under the brand name Molval Fort, one pill a day, for 8 weeks, for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions
2848776|NCT03607383|Active Comparator|Statin group|Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
2848777|NCT03607370|No Intervention|Group 1|The cancer surgery is practice 8 weeks after neoadjuvant chemoradiotherapy
2848778|NCT03607370|Experimental|Group 2|The cancer surgery will be performed in 12 weeks after neoadjuvant chemoradiotherapy
2848779|NCT03607357|Experimental|HFNO group/Group A|The patients should receive the treatment of high flow nasal oxygen immediately after extubation.
2848780|NCT03607357|Placebo Comparator|NIV group/Group B|The patients should receive the treatment of non-invasive Ventilation immediately after extubation.
2848781|NCT03607331|Experimental|Auricular vagus nerve stimulation|Auricular Concha Electro-acupuncture: twice a day at home as required, once in the morning and once in the evening, with 5 consecutive days per week for two months
2848782|NCT03607331|Active Comparator|Citalopram|citalopram for oral administration; 10mg for the first 1-3 days, 20mg for the following 4-7 days；40mg for the left days within two months
2848783|NCT03607318|Experimental|iASIST|iASIST, involves 1) an individual intervention with the adolescent in which motivational enhancement techniques are used to explore alcohol use as a risk factor for continued suicide-related thoughts and behaviors and to create a change plan, 2) a subsequent family intervention using motivational enhancement techniques to align the parent with the adolescent to strengthen the adolescent's self-efficacy and commitment to the change plan as well as the parent's ability to support the adolescent in their plan to reduce or stop drinking, and 3) a post-discharge mHealth booster to adolescents focused on strengthening their commitment to the change plan, and to parents focused on their commitment, confidence, and ability related to supporting the adolescent in reducing or stopping drinking.
2848784|NCT03607318|Active Comparator|Attention-Matched Comparison|The attention-matched comparison condition involves one psychoeducation session focused on the role of a healthy lifestyle in mental health and an additional family intervention, in which the adolescent will review handouts from the session with the parent, facilitated by the interventionist. In addition, adolescents and parents assigned to the comparison will receive a post-discharge mHealth control about the maintenance of a healthy lifestyle with the same frequency and type of interaction as the iASIST mHealth booster.
2848785|NCT03607305|Active Comparator|BP limb 70cm|Patients underwent a RYGB with a biliopancreatic limb of 70cm
2848786|NCT03607305|Experimental|BP limb 120cm|Patients underwent a RYGB with a biliopancreatic limb of 120cm
2848787|NCT03607292|Experimental|Group A|Anterior sciatic nerve block
2848788|NCT03607292|Experimental|Group P|Posterior sciatic nerve block
2848789|NCT03607279||NGAL - retropubic radical prostatectomy|Plasma NGAL was determined at baseline, 6 and 12 hrs after induction of anaesthesia
2848790|NCT03607279||NGAL - robotic radical prostatectomy|Plasma NGAL was determined at baseline, 6 and 12 hrs after induction of anaesthesia
2848791|NCT03607266||Group I (Ibuprofen)|Ibuprofen Group will receive 800 mg iv ibuprofen in 100 cc of isotonic solution within 30 min before the procedure
2848792|NCT03607266||Group D (Dexketoprofen|Dexketoprofen Group will receive 50 mg iv dexketoprofen in addition to 100 cc of isotonic solution within 30 min before the procedure
2848793|NCT03607266||Placebo Group|will receive 100 cc of isotonic solution within 30 min before the procedure
2848794|NCT03607253|Other|Men|Healthy young men aged between 18-25 years
2848795|NCT03607253|Other|Women|Healthy young women aged between 18-25 years
2848796|NCT03607240|Experimental|LUS-guided alveolar recruitment|Lung ultrasound-guided alveolar recruitment maneuver will be performed
2848797|NCT03607240|Active Comparator|conventional alveolar recruitment|Alveolar recruitment maneuver will be provided with positive pressure of 30 cmH2O for 10 seconds.
2848798|NCT03607227|Active Comparator|Local anesthetic|Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
2848799|NCT03607227|Placebo Comparator|Saline|Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as in the active substance arm.
2848800|NCT03607214|Experimental|Positive Expectations Group|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from experiencing negative emotions and generally improves their mood. They take the nasal spay in the laboratory and on seven consecutive days. Participants watch two film sequences that are supposed to induce sadness.
2848801|NCT03607214|No Intervention|No-treatment control group|Participants do not receive the nasal spray. Participants watch two film sequences that are supposed to induce sadness.
2848802|NCT03607201||Diabetic|History of diabetes prior to Acute Coronary Syndrome
2848803|NCT03607201||Non-diabetic|No documented history of diabetes prior to Acute Coronary Syndrome
2848804|NCT03607188|Experimental|ZG0418 200mg QD|
2848805|NCT03607188|Experimental|ZG0418 300mg QD|
2848806|NCT03607188|Experimental|ZG0418 400mg QD|
2848807|NCT03607188|Experimental|ZG0418 500mg QD|
2848808|NCT03607188|Experimental|ZG0418 600mg QD|
2848809|NCT03607175|Active Comparator|Steroid-eluting implant (Propel)|Mometasone furoate implant. 370ug of mometasone furoate with each application. One application to be used at the conclusion of surgery and left in place for 1 month or less depending on if it requires removal during office debridement.
2848810|NCT03607175|Experimental|Triamcinolone-impregnated CMC foam|Applied to one nostril at end of case through randomization. Experimental drug is triamcinolone-acetonide 40mg/mL. 2mL will be combined with 5mL sterile water and mixed with carboxymethylcellulose foam and placed in the nares at the conclusion of the surgery. This will only be applied once and will remain in the nares until it dissolves or 7 days.
2848811|NCT03607162|No Intervention|Usual care|Local usual management of FWS (pragmatic approach)
2848812|NCT03607162|Experimental|DIAFEVER algorithm|New DIAFEVER sequential algorithm PCT rapid test-based will be applied
2848813|NCT03607149|Active Comparator|STANDARD ARM|Calculation of the dose of pemetrexed as a function of body surface area
2848814|NCT03607149|Experimental|EXPERIMENTAL ARM|Calculation of the pemetrexed dose as a function of the Clearance of creatine (CrCLCG)
2848815|NCT03607136|Experimental|exercise training|Participants in the exercise training group received a 12-week exercise training.
2848816|NCT03607136|No Intervention|control|Participants in the control group did not receive any specific training programs instead of maintaining their usual activities of daily living.
2848817|NCT03607123||Baseline|After implantation of pacemaker, the pacing mode and the lower rate of pacemaker will be set as VDD and 50/45 bpm respectively, to get the baseline burden of atrial fibrillation without atrial pacing. Except for beta-blockers digoxin, and CCB to control heart rate, anti-arrhythmic drugs (AAD) will not be prescribed. Patients who can not tolerate will drop out. After follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group / stage (Atrial Pacing, Step1).
2848818|NCT03607123||Atrial Pacing (Step 1)|After Baseline and after follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group /stage (Atrial Pacing). At this stage, the pacing mode and the lower rate of pacemaker will be set as DDD and 70/60 bpm respectively, to perform relatively high-rate atrial pacing. Except for beta-blockers digoxin, and CCB to control heart rate, anti-arrhythmic drugs (AAD) will not be prescribed. After follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group/stage (AAD, Step1).
2848819|NCT03607123||AAD (Step 2)|After Step 1, and after follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group/stage. Anti-arrhythmic drugs including propafenone, amiodarone and dronedarone will be prescribed. After follow-up of at least 6 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group/stage (RFCA, Step3).
2848820|NCT03607123||RFCA (Step 3)|After Step 2, and after follow-up of at least 6 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group/stage (RFCA, Step3). Patients will receive catheter ablation of AF, up to patients' willingness. After follow-up of at least 12 month, patients without AF lasting longer than one minute detected by pacemaker will go to next group/stage (SAFE PAF-SND II).
2848821|NCT03607123||SAFE PAF-SND II|After RFCA, and after follow-up of at least 12 month, patients without AF lasting longer than one minute detected by pacemaker will come to this group/stage (SAFE PAF-SND II). At this stage, the pacing mode and the lower rate of pacemaker will be set as VDD and 40 bpm respectively. If the patient can not tolerate, the the pacing mode and the lower rate of pacemaker will be set as DDD/DDDR and 60 bpm. If the patient has no symptom related to bradycardia, he/she will be followed up until the end of this study.
2848822|NCT03607110||ketamine|ketamine used
2848823|NCT03607110||fentanyl|fentanyl used
2848824|NCT03607097|Experimental|Secondary prevention of DRPs (medication code) (intervention)|The intervention consists of :1)Patient-centred prescription Espaulella-Panicot J model (review model that includes different strategies in a single intervention. It is performed by a multidisciplinary team, and allows them to adapt the pharmacological plan of patients with clinical complexity). 2)strategies to improve medication adherence
2848825|NCT03607097|No Intervention|Usual care (control group)|
2848826|NCT03607084|Experimental|Intervention|The intervention group receives a school health program that has two components: the training of selected teachers to become school Health Workers and bi-annual health screenings of all students.
2848827|NCT03607084|No Intervention|Control|The control group receives regular school programming.
2848828|NCT03607071|Experimental|Prednisolone|The patient who has detected myocardial inflammation from cardiac MRI from baseline is given prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
2848829|NCT03607058|Active Comparator|Kinect + Exercise Training|Xbox Kinect and exercise training will be applied together for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. A treatment session in this arm will consist of Kinect games for 40 minutes and exercise training for 20 minutes. In this arm, patients will play each game as two repetitions. Each game lasts about 3-4 minutes, and patients will be seated for resting between the games. After 1 week washout period only exercise training will be applied for 8 weeks.
2848830|NCT03607058|Active Comparator|Exercise Training|Exercise training will be applied for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. After 1 week washout period exercise training and Xbox Kinect will be applied together for 8 weeks.
2848831|NCT03607045|Placebo Comparator|control group|bouquet technique
2848832|NCT03607045|Active Comparator|test group|headless screw
2848833|NCT03607032|Experimental|RespinPad and usual treatment|
2848834|NCT03607032|Active Comparator|only usual treatment|
2854539|NCT03566693|Experimental|CGM|
2854540|NCT03566693|Active Comparator|SMBG|
2848835|NCT03607006|Experimental|Patient specific PEEK sheets|Patient specific PEEK sheets will be fixed with titanium screws and act as containment system for the mixed autogenous/xenogenic bone graft that will fill the gap between the sheets and the ridge .
2848836|NCT03607006|Active Comparator|Autogenous bone shell technique|Bone shells will be fixed with titanium screws to the ridge and mixed autogenous/xenogenic bone graft will fill the gap between the shells and the ridge .
2848837|NCT03606993|Experimental|Lucky Iron Fish™ (LIF)|For Mother-infant dyads enrolled into the LIF arm, mother receives a cooking supplement: one ~ 200g iron ingot.
2848838|NCT03606993|No Intervention|Enhanced standard of care (eSOC)|For mother-infant dyads in the eSOC arm, families are not provided iron supplementation (consistent with standard of care) but have additional visits and laboratory monitoring beyond well-child care (enhanced).
2848839|NCT03606980|Experimental|Iontophoresis with Dexamethasone|Iontophoresis is a non-invasive delivery mechanism for transmitting a medication to a local area of the body. The I-Bresis™ System and I-Bresis™ Patch will be the delivery system used for this study. The I-Bresis™ Patch is an adhesive patch. 1.5 ml of the dexamethasone sodium phosphate (4ml/1mL) will be placed on one side and 1.5 ml of 0.9% sodium chloride (saline) solution will be placed on the other. Duration of exposure: 123 minutes. Frequency of exposure: twice per week for a total of 12 sessions over a maximum of 8 weeks or until Return to Sport Criteria are met, whichever is sooner. Participants will also receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
2848840|NCT03606980|Placebo Comparator|Iontophoresis with Sodium Chloride|Iontophoresis is a non-invasive delivery mechanism for transmitting a medication to a local area of the body. The I-Bresis™ System and I-Bresis™ Patch will be the delivery system used for this study. The I-Bresis™ Patch is an adhesive patch. 1.5 ml of 0.9% sodium chloride (saline) solution will be placed on one side and 1.5 ml of 0.9% saline solution will be placed on the other. Duration of exposure: 123 minutes. Frequency of exposure: twice per week for a total of 12 sessions over a maximum of 8 weeks or until Return to Sport Criteria are met, whichever is sooner. Participants will also receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
2848841|NCT03606980|Active Comparator|Physical Therapy alone|Participants will only receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
2848842|NCT03606967|Active Comparator|Arm II (durvalumab, nab-paclitaxel)|"PART A: Participants receive gemcitabine hydrochloride IV over 30 minutes and carboplatin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants with progression of disease within the first 18 weeks may switch and receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 of each remaining course.~PART B: Participants receive durvalumab IV over 60 minutes on day 1 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2848843|NCT03606967|Experimental|Treatment (neoantigen vaccine, durvalumab, nab-paclitaxel)|"PART A: Participants receive gemcitabine hydrochloride IV over 30 minutes and carboplatin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants with progression of disease within the first 18 weeks may switch and receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 of each remaining course.~PART B: Participants receive personalized synthetic long peptide vaccine and poly-ICLC SC on days 1, 4, 8, 15, 22, 50, and 78 in the absence of disease progression or unacceptable toxicity. Participants also receive durvalumab IV over 60 minutes on day 1 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2848844|NCT03606954|Active Comparator|Combination topical corticosteroid|"The combination topical corticosteroid will be applied to specific and marked sites on the forearms (on the flexor side of the forearm- 5*5 cm with a distance of 3 cm) - two sites on both forearms of every subject (4 sites in total). The nature of this application method will enable the measurement of the level of potency of each drug, in a manner that is comparative, neutralizing thus the influence of inter-subject variability.~The drugs will be topically applied (50 microliter on each site) for 16 hours, utilizing an occlusive dressing bandage such as Tegaderm. The vasoconstriction test will be preformed both before and after drug application. The vasoconstriction in each subject will be graded on the Olsen scale"
2848845|NCT03606954|Active Comparator|Non-combination topical corticosteroid|"The non-combination topical corticosteroid will be applied to specific and marked sites on the forearms (on the flexor side of the forearm- 5*5 cm with a distance of 3 cm) - two sites on both forearms of every subject (4 sites in total). The nature of this application method will enable the measurement of the level of potency of each drug, in a manner that is comparative, neutralizing thus the influence of inter-subject variability.~The drugs will be topically applied (50 microliter on each site) for 16 hours, utilizing an occlusive dressing bandage such as Tegaderm. The vasoconstriction test will be preformed both before and after drug application. The vasoconstriction in each subject will be graded on the Olsen scale"
2848846|NCT03606941|Experimental|electroacupuncture treatment|"Participants in the treatment group received acupuncture (0.30mm×70mm) at bilaterally Shenmen (HT7) acupoints (0.3-0.5 inch), Neiguan (PC6) acupoints (0.5-1 inch), Baihui (DU20) acupoint (0.5-0.8 inch) and Yintang (EX-HN3) acupoint (0.3-0.5 inch) 30 minutes before anesthesia induction. After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected and maintained the end of operation."
2848847|NCT03606941|Sham Comparator|sham electroacupuncture treatment|"Participants in the control group received shallow needling (0.30mm×25mm) at bilateral sham HT7, PC6, DU20 and EX-HN3 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output."
2848848|NCT03606928|Experimental|modified FLOT|modified FLOT Docetaxel 40mg/m2 ivgtt day 1 over 1 hour Oxaliplatin 65mg/m2 ivgtt day 1 over 2hours Dose escalation will be performed. Leucovorin 200mg/m2 ivgtt day 1 over 2 hours 5-FU 2200mg/m2 civ over 24 hours
2848849|NCT03606915||no pain|pain evaluation for patients performed surgery without painful condition (bleeding or others)
2848850|NCT03606915||acute pain|pain evaluation for patients performed surgery with painful condition within several days
2848851|NCT03606915||chronic pain|pain evaluation for patients performed surgery with the painful condition for over months
2848918|NCT03606395|Experimental|Single dose in subjects with TRD|NV-5138 oral solution single dose (dose to be determined from Part A) single dose of placebo
2848852|NCT03606902|Active Comparator|(Group f):|"Intervention:~Procedure: Epidural catheter insertion~Drug: Epidural 15 ml of 0.0625%bupivacaine with 1 µg /Kg Fentanyl ,then continuous epidural infusion of fixed volume 10 ml of 0.0625% bupivacaine +1 µg/Kg/h Fentanyl for the next 6 hours ."
2848853|NCT03606902|Active Comparator|(Group Lf):|"Intervention:~Procedure:Epidural catheter insertion~Drug: Epidural injection 15 ml of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then 1st hour continuous IV infusion of 10ml of 0.0625%bupivacaine +1 µg/Kg/h Fentanyl ,2nd hour 10ml of 0.0625%bupivacaine + 0.5 µg/Kg/h Fentanyl , then next 4 hours10 ml of 0.0625%bupivacaine with + 0.25 µ g/Kg/h Fentanyl."
2848854|NCT03606889|Experimental|Quadratus Lumborum block group|Quadratus Lumborum block group (QL) patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
2848855|NCT03606889|Experimental|Transversus abdominis plane block group|Transversus abdominis plane block (TAP) patients will receive a bilateral TAP block using Bupivicaine 0.125%
2848856|NCT03606876|Experimental|BAT1806 injection|BAT1806 injection: 4 mg/kg, intravenous infusion over 60 min
2848857|NCT03606876|Active Comparator|Actemra(EU-licensed)|Actemra(EU-licensed): 4 mg/kg, intravenous infusion over 60 min
2848858|NCT03606876|Active Comparator|Actemra(US-licensed)|Actemra(US-licensed): 4 mg/kg, intravenous infusion over 60 min
2848859|NCT03606863|Experimental|Perioperative peripheral parenteral nutrition|Perioperative peripheral parenteral nutrition during 4 days
2848860|NCT03606863|No Intervention|Standard fluid therapy|Standard fluid therap
2848861|NCT03606850|Experimental|Treatment by citalopram|The patients will receive a treatment by citalopram at 20mg/day. If patients respond by at least 20% on the HAMD-21 scale at day 14 : continuation at 20 mg/day. If patients do not respond by at least 20% at day 14 : increase the dose at 40 mg/day. The patients who will not respond by at least 50% on the HAMD-21 scale at day 28 will be excluded of the study and will undergo a new treatment plan. The patients who will respond by at least 50% on HAMD-21 at day 28 will continue citalopram at the same dose and will be reappraised at day 60. The patients will be assessed for the markers of neuroexcitability at day 1, day 3, day 7, day 14, day 28 and day 60.
2848862|NCT03606837|Experimental|PET/CT Imaging|
2848863|NCT03606824|Active Comparator|Monotherapy group|After randomization, patients in monotherapy will receive pitavastatin as the only lipid-lowering therapy.
2848864|NCT03606824|Experimental|Combination group|After randomization, patients in combination group will receive pitavastatin as the lipid-lowering therapy and take levothyroxine as the thyroid hormone supplement.
2848865|NCT03606811|Active Comparator|fluroscopic guided block|
2848866|NCT03606811|Experimental|double modality guided block|
2848867|NCT03606798|Experimental|Multidisciplinary and personalized care|Personalized care and proposals bring by a team of experts : neurologists ; geriatrician ; psychologist.
2848868|NCT03606798|No Intervention|Reference care|Standard clinical evaluations of patient with Frontotemporal Lobar Degeneration.
2848869|NCT03606785|Active Comparator|tranexamic acid group|
2848870|NCT03606785|Placebo Comparator|placebo group|
2848871|NCT03606772||Total abdominal hysterextomy|Patients operated abdominal by removal of uterus, cervix, without removal of tubes and ovaries
2848872|NCT03606772||Total abdominal hysterectomy with bilateral slapingoophrectomy|Patients operated abdominal by removal of uterus, cervix, with removal of tubes and ovaries
2848873|NCT03606772||supracervical hysterectomy|Patients operated abdominal by removal of uterus, with removal of tubes and ovaries and retaining of cervix
2848874|NCT03606772||Total laparoscopic hysterectomy|Patients operated laparoscopically by removal of uterus, cervix, with removal of tubes and ovaries
2848875|NCT03606772||vaginal hysterectomy|Patients operated vaginally by removal of uterus, cervix, without removal of tubes and ovaries
2848876|NCT03606759|Experimental|Group 1|Assessments with a multidisciplinary team (doctors, nurses, psychologists, psychiatrists, social workers) once a week during 3 months.
2848877|NCT03606759|Active Comparator|Group 2|Assessments with a multidisciplinary team (doctors, nurses, psychologists, psychiatrists, social workers) once a week during 3 months.
2848878|NCT03606746|Experimental|Investigational Arm|A low-dose Total Lymphoid Irradiation (TLI) and anti-thymocyte globulin (ATG) combined with a single IV infusion of MDR-103 and standard anti-rejection medications in past recipients of HLA Zero-mismatch living donor kidney transplants.
2848879|NCT03606733|Experimental|M&M SCS needle for macular diseases|
2848880|NCT03606720|Active Comparator|group(A) low level laser therapy|composed of 30 patients who received pelvic stabilization exercises and low level laser therapy For 12 sessions over six week's period by 2 sessions per week.
2848881|NCT03606720|Active Comparator|group(B) pelvic stabilization exercises|composed of 30 patients who pelvic stabilization exercises only For 12 sessions over six week's period by 2 sessions per week.
2848882|NCT03606707|Experimental|corticosteroid|steroid group, received intra-articular steroid injection for atlantoaxial joint. , in addition to methotrexate and chloroquine 400 mg per day.
2848883|NCT03606707|No Intervention|oral steroid|systemic group, received systemic steroid 20 mg/d , in addition to methotrexate and chloroquine 400 mg per day.
2848884|NCT03606694|Experimental|Dihydromyricetin|Dihydromyricetin capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
2848885|NCT03606694|Experimental|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
2848886|NCT03606681|Active Comparator|Calcium Hydroxide (Dycal)|Indirect pulp capping treatment with Calcium Hydroxide
2848887|NCT03606681|Experimental|Mineral Trioxide Aggregate (ProRoot MTA)|Indirect pulp capping treatment with Mineral Trioxide Aggregate
2848888|NCT03606681|Experimental|Theracal LC|Indirect pulp capping treatment with Theracal LC
2848889|NCT03606668|Experimental|Virtual Reality Therapy|eligible participants will receive a full session of VR therapy that may extend as long as an hour in length.
2848890|NCT03606655|Experimental|Kava|This is a double-blind, randomized, placebo-controlled pilot study. A total of 40 subjects will be enrolled on this study. Following screening, subjects will be randomized to receive either kava supplement or placebo. 20 subjects will be assigned to each treatment arm. The SAS procedure PROC PLAN will be used to assign subjects to one of the two study arms. Subjects will take either 75 mg of kava supplement or placebo orally three times daily. Study treatment is scheduled for 14 days.
2854915|NCT03564158|Placebo Comparator|Normal Saline (placebo)|Placebo
2848891|NCT03606655|Placebo Comparator|Control|This is a double-blind, randomized, placebo-controlled pilot study. A total of 40 subjects will be enrolled on this study. Following screening, subjects will be randomized to receive either kava supplement or placebo. 20 subjects will be assigned to each treatment arm. The SAS procedure PROC PLAN will be used to assign subjects to one of the two study arms. Subjects will take either 75 mg of kava supplement or placebo orally three times daily. Study treatment is scheduled for 14 days.
2848892|NCT03606642|Experimental|PCI with 30 day DAPT Therapy|Single group of patients undergoing IVUS stent placement for PCI with 30 day DAPT therapy regimen. DAPT therapy consists of Aspirin (325 mg loading dose [if applicable] and 81 mg for maintenance dose) and P2Y12 Inhibitor (INFO ABOUT THE DRUGS)
2848893|NCT03606629||Endoprosthesis implantation|Device implantation
2848894|NCT03606616||ACOSOG Z0011 no further ALND arm|patients meeting the criteria for ACOSOG Z0011 trial inclusion：histologically confirmed invasive breast cancer;clinical T1/T2;breast conserving surgery；1 or 2 positive sentinel lymph nodes; Whole-breast RT planned; no preoperative chemotherapy
2848895|NCT03606603||Surgical patients|Adult patients after elective major abdominal gastrointestinal surgery with pre-existing malnutrition or who are at significant risk for malnutrition or nutrition-related complications, with indications for nutritional support
2848896|NCT03606590|Experimental|TTFields in combination with sorafenib|Patients will be treated continuously with TTFields, in addition to sorafenib
2848897|NCT03606577|Experimental|Carfilzomib, Daratumumab, Lenalidomide and Dexaméthasone|
2848898|NCT03606564||paediatric patients undergoing day care surgery|
2848899|NCT03606551||New Orthodontic Patients|"New patient subjects who are just initiating full orthodontic treatment will have their premolars, canines, and incisors bonded with the EXD-959 Bracket System, using the related EXD-961 instruments, according to the manufacturer's IFU.~Their remaining teeth will be bonded with the brackets of the orthodontist's choice. Three of the 5 new patients recruited may be patients that the orthodontist will choose to initiate treatment with the EXD-959 study brackets being applied to the upper teeth only. Having this option will allow the investigators to recruit subjects with deeper over-bites where their standard of care would be to apply esthetic brackets on the upper teeth and metal brackets on the lower teeth."
2848900|NCT03606551||Intercept Orthodontic Patients-Progress|This group will include a minimum of three, and up to 5 patients at each study site who have moved into rectangular wires; and in whom, the orthodontist- investigator believes they will be able to evaluate rotation corrections using the EXD-959 Bracket System. For example, rotation correction of the upper central incisor which will test the width of the bracket's holding points in situations that have wide teeth and greater inter-bracket distance.
2848901|NCT03606551||Intercept Orthodontic Patients-Finishing|This group will include a minimum of three, and up to 5 patients per study site who are estimated to be within 4 months of completing their orthodontic treatment; and in whom, the orthodontist-investigator believes they will be able to evaluate both torque control and debonding experiences using the EXD-959 Bracket System.
2848902|NCT03606538|Experimental|Moderate hepatic impairment|Eight participants with moderate hepatic impairment receive a single dose of 80 mg MDMA.
2848903|NCT03606538|Experimental|Normal hepatic function|Eight participants, each matched on age, weight and gender to a participant with moderate hepatic impairment, receive a single dose of 80 mg MDMA.
2848904|NCT03606512|Experimental|Group 1: RSV Seronegative Toddlers (Ad26.RSV.preF)|Respiratory syncytial virus (RSV) seronegative toddlers will receive intramuscular (IM) injection of 2.5*10^10 viral particles (vp) of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F-protein on Days 1, 29, and 57.
2848905|NCT03606512|Placebo Comparator|Group 2: RSV Seronegative Toddlers (Placebo)|RSV seronegative toddlers will receive IM injection of placebo on Days 1, 29, and 57.
2848906|NCT03606499||CD Participants with EIMs and/or IMIDs|Crohn's Disease (CD) participants with suspected extra-intestinal manifestations (EIMs) and/or immune-mediated inflammatory diseases (IMIDs) will be enrolled into the study to assess effectiveness of ustekinumab on each type of CD associated with EIMs and/or IMIDs. Participants will receive ustekinumab at study entry (Week 0) as treatment for CD according to standard clinical practice and will be followed up to 24 weeks (+/- 3 weeks). Only data available per clinical practice will be collected within this study.
2848907|NCT03606486|Experimental|Diagnostic (pap smear, uterine lavage, tumor sample)|Participants undergo pap smear, uterine lavage, and collection of tumor sample during a planned surgery. DNA is then extracted from the samples and sequenced for TP53 mutations using Crispr-Duplex sequencing.
2848908|NCT03606473|Experimental|Prenatal cocaine exposed subjects|[C-11]NPA PET at baseline and post d-amphetamine
2848909|NCT03606473|Experimental|Comparison subjects|[C-11]NPA PET at baseline and post d-amphetamine
2848910|NCT03606460|Experimental|Cohort 1|This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for Dose 2 or Dose 3. Participants who have already received one or two doses of ocrelizumab according to the approved infusion protocol and have reported no serious infusion-related reactions (IRRs) will be enrolled. They will then receive the next infusion of ocrelizumab (Dose 2 or Dose 3) at a dosage of 600 milligram (mg) over the course of approximately 2 hours. Dose 2 is administered at Week 24, Dose 3 is administered at Week 48 after initial infusion.
2848911|NCT03606460|Experimental|Cohort 2|This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for the second infusion of Dose 1. Ocrelizumab-naïve participants will be enrolled who, after receiving Dose 1 of ocrelizumab at the approved rate have no reported serious IRRs, will then receive the second 300-mg shorter infusion over approximately 1.5 hours.
2848912|NCT03606447|Experimental|Single IV administration of [14C]-Uproleselan|
2848913|NCT03606434|Experimental|Hypoxic Exposure|Men, and women in early or late follicular phase of menstrual cycle will be exposed to acute and intermittent hypoxic episodes.
2848914|NCT03606421||Arm A|Patients in Arm A will be treated with stereotactic radiosurgery (SRS) which is a modern method of treating brain lesions that delivers a high amount of radiation to a small volume of the brain affected by a tumour; and is the standard of care for patients with a limited number of brain metastases.
2848915|NCT03606421||Arm B.|Patients in Arm B will be treated with whole brain radiotherapy, due to the number of lesions in their brain.
2848916|NCT03606408|Other|osilodrostat|open label, with patients receiving same dose as provided in the parent study
2854916|NCT03564145|Experimental|S5G4T-1|Topical cream
2848919|NCT03606369|Experimental|Palonosetron|"Early emesis: Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV.~Delayed emesis: Dexamethasone 8 mg orally on days 2, 3 and 4."
2848920|NCT03606369|Active Comparator|Ondansetron|"Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV.~Delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs."
2848921|NCT03606343|Experimental|Open Trial|Group based treatment targeting academic executive functioning skills such as organization, planning, and study skills. Likely to be 7 90-minute sessions attended weekly by parents and teens
2848922|NCT03606330||VP-SG 01|Study subjects that present MACE at the 36 months follow-up
2848923|NCT03606330||VP-SG 02|Study subjects that do not present MACE at the 36 months follow-up
2848924|NCT03606304|Experimental|Problem-solving therapy|The intervention is based on an established PST protocol for medical patients, with an additional focus on HF to link depressed mood to impaired HF self-care. Seven steps are included: 1) select and define the problem; 2) establish realistic and achievable goals for problem resolutions; 3) generate multiple solution alternatives (brainstorming); 4) implement decision-making guidelines (pros and cons); 5) evaluate and choose the solutions; 6) implement the preferred solution(s); and 7) evaluate the outcome.
2848925|NCT03606291|Experimental|isotoxic hypofractionation group|"1. Hypofractionated radiation: 3Gy/f. 2,Individualized prescriptions for different patients:~(1) Spinal cord: 0%>45 Gy, and ≤2 Gy each time Lung: V20≤30%, V5≤65%, MLD≤16Gy Esophagus: highest dose ≤ 72Gy 3. Maximum limit: If the limit of any A is not reached, the maximum radiation dose is 72 Gy. The lowest radiation dose: 45Gy."
2848926|NCT03606278|Experimental|Structured debriefing assisted by video|In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required.
2848927|NCT03606278|Active Comparator|Structured oral debriefing|In the structured oral debriefing, the process was based by the mental search of their memories of what occurred.
2848928|NCT03606265|Experimental|App+Web|Treatment as usual + app Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
2848929|NCT03606265|Active Comparator|Treatment as usual|Treatment as usual (waiting list) Patients at this condition will receive the usual medical treatment at the pain unit, but they will not be monitored daily using the app.
2848930|NCT03606252|Other|pneumocystosis with favourable evolution|patients with a favourable pneumocystosis outcome
2848931|NCT03606252|Other|pneumocystosis with unfavourable outcome|patients with unfavourable pneumocystosis outcome
2848932|NCT03606252|Other|Pneumocystis colonization|subject colonized by Pneumocystis jirovecii
2848933|NCT03606239|Experimental|isotoxic hypofractionated group|"Hypofractionated radiation:~1. Split mode: 3Gy/f. 2,Individualized prescriptions for different patients:~(1) Spinal cord: 0%>45 Gy, and ≤2 Gy each time Lung: V20≤30%, V5≤65%, MLD≤16Gy Esophagus: highest dose ≤ 72Gy 3. Maximum limit: If the limit of any A is not reached, the maximum radiation dose is 72 Gy. The lowest radiation dose: 45Gy.~Chemotherapy:~Platinum-containing two-drug regimen: docetaxel + lobaplatin: Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1; repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.~The same chemotherapy regimen is used up to 4 cycles as consolidation after the completion of radiotherapy."
2848934|NCT03606213|Placebo Comparator|Cohort A - Arm 1|Placebo will be administered by electoporation at Day 0 and Weeks 4, 8 and 12
2848935|NCT03606213|Active Comparator|Cohort A - Arm 2|Active gag/pol, env and IL-12 plasmids (PENNVAX-GP and INO-9102)) administered by electoporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.
2848936|NCT03606213|Active Comparator|Cohort A - Arm 3|Active gag/pol and IL-12 plasmids (INO-6145 INO-9012) will be administered by electroporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.
2848937|NCT03606213|Active Comparator|Cohort B - Arm 1|A single arm study of gag/pol/env/IL-12 DNA plasmids PENNVAX-GP and INO-9102) administered by electoporation (CELLECTRA-2000) will be performed in HIV-infected adults for whom ART was initiated during acute HIV infection.
2848938|NCT03606187|Experimental|Test Arm|Subjects randomized to this arm will receive test treatment
2848939|NCT03606187|Active Comparator|Control Arm|Subjects randomized to this arm will receive control treatment
2848940|NCT03606174|Experimental|Sitravatinib and Nivolumab|Sitravatinib oral capsule administered daily in combination with nivolumab administered as 240 mg IV every 2 weeks
2848941|NCT03606161|Experimental|Supportive care (nrTMS)|Between 1-7 days after standard of care surgery, participants undergo 10 nrTMS sessions over 30 minutes each over 3 weeks.
2848942|NCT03606148||SurePathTM|"The subjects are randomly assigned to SurePathTM/Conventional test group at a ratio of 1: 1.~In SurePathTM group, subjects who underwent SurePathTM liquid-phase cytology test with the first sample subjected to the conventional smear test with the second sample."
2848943|NCT03606148||Conventional|"The subjects are randomly assigned to SurePathTM/Conventional test group at a ratio of 1: 1.~In conventional test group, those who subjected to the conventional smear test with the first sample, will undergo the SurePathTM liquid cell test with the second obtained sample."
2848944|NCT03606135||The Pneumonia Group|Subjects with chest images (x-ray or CT scan) indicating pneumonia.
2848945|NCT03606135||The Control Group|Healthy subjects
2848946|NCT03606122|Experimental|PD P 506 A-PDT|The study medication will be applied to each study lesion for 4 hours. After removal of the study medication the study lesions will be illuminated with red light of defined wavelength (PDT). Second PDT of the lesions will be performed 6-14 days after the first PDT.
2848947|NCT03606109|Active Comparator|High tibial osteotomy (HTO)|Patients indicated and scheduled for a high tibial osteotomy or tibial tubercle osteotomy with or without medial patello-femoral ligament reconstruction will be identified from faculty surgeon case logs at the NYU Langone Health, Langone Orthopedic Hospital Sports Medicine Division.
2848948|NCT03606109|Active Comparator|Tibial tubercle osteotomy (TTO)|Patients indicated and scheduled for a high tibial osteotomy or tibial tubercle osteotomy with or without medial patello-femoral ligament reconstruction will be identified from faculty surgeon case logs at the NYU Langone Health, Langone Orthopedic Hospital Sports Medicine Division.
2849058|NCT03605212|Experimental|Cohort 2|Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days
2848949|NCT03606096|Experimental|Boostrix IPV - infant acellular Pertussis (TdaP-aP)|vaccination of the mother with Boostrix-IPV vaccine which includes the infant acellular pertussis
2848950|NCT03606096|Experimental|Boostrix IPV - infant whole Pertussis (Tdap-wP )|vaccination of mother with Boostrix -IPV which includes infant whole cell pertussis
2848951|NCT03606096|Active Comparator|TT - infant acellular Pertussis (T-ap )|vaccination of mother with TT-which includes infant acellular pertussis
2848952|NCT03606096|Active Comparator|TT - infant whole Pertussis (T-wP)|vaccination of mother with T which includes infant whole cell pertussis
2848953|NCT03606070|Other|Patients with NSCLC|"Characterization of tumor heterogeneity by multiparametric regional mapping PET-MRI.~Patients will realize:~a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)~a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI)."
2848954|NCT03606057|Experimental|Treatment Group 1: JNJ-64565111+Moxifloxacin Placebo|Participant will receive JNJ-64565111 on days 2, 9, 16, and 23 and moxifloxacin-matching placebo on days 1 and 27.
2848955|NCT03606057|Active Comparator|Treatment Group 2: JNJ-64565111 Matching Placebo+Moxifloxacin|Participant will receive JNJ-64565111-matching placebo on days 2, 9, 16, and 23. Participants will also receive moxifloxacin on day 1 and moxifloxacin-matching placebo on day 27 (sequence 2a) or moxifloxacin-matching placebo on day 1 and moxifloxacin on day 27 (sequence 2b) in a nested crossover manner.
2848956|NCT03606044||MIS-PN|Participants approved for elective robot-assisted partial nephrectomy with T1a or T1b renal tumours.
2848957|NCT03606018|Experimental|Insulin Lispro Mix 25|Single subcutaneous administration of Insulin Lispro Mix 25 in dose 0.4 IU / kg
2848958|NCT03606018|Active Comparator|Humalog® Mix 25|Single subcutaneous administration of Humalog® Mix 25 in dose 0.4 IU / kg
2848959|NCT03606005||Group 1: Allogeneic-HSCT recipients|Dyspnea [Modified Medical Research Council dyspnea scale (MMRC)], submaximal exercise capacity [6-minute walk test (6-MWT)], physical activity level [metabolic holter], quality of life [European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)] and pulmonary functions [spirometry] were evaluated in allogeneic-HSCT recipients (.Vital signs, dyspnea and fatigue perception [Modified Borg Scale] were recorded as pre-post measurements of 6-MWT.
2848960|NCT03606005||Group 2: Healthy individuals|Healthy individuals were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
2848961|NCT03605992|Experimental|TeleRehabilitation|Home-based cardiac rehabilitation that includes the components of education and physical exercises mainly unsupervised and oriented by telephone.
2848962|NCT03605992|Active Comparator|CentreRehabilitation|Traditional cardiac rehabilitation offered at the outpatient centre including components of education and physical exercises mainly supervised.
2848963|NCT03605979||diabetes group|Patient with hypoglycemia unawareness
2848964|NCT03605940|Experimental|Experimental group|corticosteroids + ECP
2848965|NCT03605940|Active Comparator|Contrôl group|corticosteroids alone
2848966|NCT03605927|Experimental|Combination Therapy|"BMS-986004: From day 13, intravenously (IV) every 2 week through day 100 post HCT.~Tacrolimus: From day -3 as standard of care. Sirolimus: From day -1 as standard of care."
2848967|NCT03605914|Experimental|NSAID|The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
2848968|NCT03605914|Active Comparator|opioid|The Opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
2848969|NCT03605901|Active Comparator|Standard dosing of methadone|Receive 0.2 mg/kg based on ideal body weight of methadone after the intubation and before positioning.
2848970|NCT03605901|Experimental|Aliquots of methadone titrated to apnea|Receive incremental aliquots of methadone up to 0.5 mg/Kg based on ideal body weight titrated to apnea. Each subject will receive a 10 mg loading dose then aliquots of 5mg each, given at 3 to 5 minute time intervals. The practitioner will continue to coach patient to take deep breaths. After reaching the apnea threshold as determined by respiratory rate less than 4 breaths/min, induction of general anesthesia and intubation will proceed.
2848971|NCT03605888|Experimental|RCT Intervention|Overweight or obese (BMI ≥ 25 kg/m2) participants randomized to the Koa Family. intervention
2848972|NCT03605888|No Intervention|RCT Control|Overweight or obese (BMI ≥ 25 kg/m2) participants randomized to the control group.
2848973|NCT03605888|Other|Exploratory|Normal-weight mothers (BMI 18.5-24.9 kg/m2) assigned to the Koa Family intervention.
2848974|NCT03605875|Experimental|Web-App|A customized web-app tool to be used by patients to communicate concerns to their nephrologist
2848975|NCT03605875|Active Comparator|Paper|A customized paper tool to be used by patients to communicate concerns to their nephrologist
2848976|NCT03605862|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily for 5 days
2848977|NCT03605862|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 5 days
2848978|NCT03605849|Experimental|Centanafadine|400 mg total daily dose
2848979|NCT03605836|Experimental|Centanafadine Treatment 1|Total daily dose of 200 mg
2848980|NCT03605836|Experimental|Centanafadine Treatment 2|Total daily dose of 400 mg
2848981|NCT03605836|Placebo Comparator|Placebo|
2848982|NCT03605810||eGFR-population|To be included in the eGFR-population, patients have to have at least one recorded eGFR value in the OPTUM CDM database between January 1, 2007 and December 31, 2016, be adults (>18 years of age at the time of eGFR test) and have at least 370/180 days (180 days serves as sensitivity analysis) of continuous enrollment in medical and pharmacy insurance plans since eGFR test date.
2848983|NCT03605810||Atrial fibrillation (AF) sub-population|"To be included in the AF sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have two inpatient or outpatient diagnoses for AF or atrial flutter on two different days within the study period irrespective of time points when eGFR is measured.~Patients with at least one inpatient or outpatient diagnosis or procedure code for mitral stenosis and prosthetic valves within the study period will be excluded."
2848984|NCT03605810||Coronary artery disease (CAD) sub-population|To be included in the CAD sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have at least one inpatient CAD diagnosis within the study period irrespective of time points when eGFR is measured.
2848985|NCT03605810||Type 2 diabetes mellitus (T2DM) sub-population|To be included in the T2DM sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have at least two inpatient or outpatient diagnosis of T2DM on two different days within the study period irrespective of time points when eGFR is measured.
2848986|NCT03605797||No intervention|To study the indication and results of fixing the sacral fracture by tension band plating
2848987|NCT03605771||Advanced Melanoma|"Patients of legal age with stage III, metastatic, or unresectable melanoma at first diagnosis after January 8, 2018. First diagnosis is understood as:~Disease onset as metastatic or unresectable disease.~First metastatic or unresectable relapse in the pre-established dates (after January 8, 2018) in a patient with previous localised melanoma and completely resected on dates before the pre-inclusion period."
2848988|NCT03605758|Active Comparator|Ivermectin on Days 1 and 2|Participants will receive 200 µg/kg of ivermectin daily for two consecutive days with breakfast.
2848989|NCT03605758|Active Comparator|Ivermectin on Days 1 and 14|Participants will receive 200 µg/kg of ivermectin on day one and day 14 with breakfast.
2848990|NCT03605745|Experimental|Treatment|Prostatic Vapor Ablation with Rezum
2848991|NCT03605732|Experimental|intervention|Intervention group: They will receive an educational app designed to improve sleep, and will receive self-help training in a six-week training package.
2848992|NCT03605732|Active Comparator|Usual care|Control group: Participants in the control group perform routine activities
2848993|NCT03605719|Experimental|Arm I|Participants receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2848994|NCT03605719|Experimental|Arm II|Participants receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, wild-type reovirus IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2848995|NCT03605719|Experimental|Arm III|Participants receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, wild-type reovirus IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, nivolumab IV over 30 minutes on days 1 and 15, and pomalidomide PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2848996|NCT03605706|Experimental|SHR-1210|SHR-1210+FOLFOX4
2848997|NCT03605706|Experimental|CONTROL|FOLFOX4 or sorafenib
2848998|NCT03605693|Active Comparator|Early Psychological Intervention|Those assigned to Early Psychological Intervention will receive Written Exposure Therapy, a 5 session treatment in which participants write about their trauma event in a specified manner.
2848999|NCT03605693|No Intervention|Usual care|Those assigned to usual care will complete study assessments but will not be referred to any psychological treatment
2849000|NCT03605680|Experimental|Centanafadine Treatment 1|Total daily dose of 200 mg
2849001|NCT03605680|Experimental|Centanafadine Treatment 2|Total daily dose of 400 mg
2849002|NCT03605680|Placebo Comparator|Placebo|
2849003|NCT03605667|Experimental|BHV-4157|trigriluzole, 280 mg capsules, QD
2849004|NCT03605667|Placebo Comparator|Placebo|matching 280 mg placebo capsules, QD
2849005|NCT03605654|Experimental|Investigational Arm|A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102 post-kidney transplant and standard anti-rejection medications in recipients of 1, 2, or 3 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants
2849006|NCT03605654|Active Comparator|Active Control Arm|Standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study
2849007|NCT03605654|Experimental|Non-Randomized Exploratory Arm|A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102 post-kidney transplant and standard anti-rejection medications in recipients of 4, 5, or 6 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants
2849008|NCT03605641|Experimental|JUUL electronic cigarette|JUUL electronic cigarette. Virginia Tobacco 5% tobacco-derived nicotine.
2849009|NCT03605641|Active Comparator|VUSE Solo electronic cigarette|Reynolds American International VUSE Solo electronic cigarette. Original flavor 4.8% tobacco-derived nicotine.
2849010|NCT03605641|Active Comparator|Conventional cigarette|Canadian purchased, store bought (not hand-rolled) conventional full-flavored cigarettes of subjects' preference.
2849011|NCT03605628|Other|abdominal wall length|Measurement of abdominal wall length during neuromuscular block with a measuring tape
2849012|NCT03605615|No Intervention|CONTROL|In this group parturients will be attended in standardized manner, which in our hospital means a humanized approach with choice of position in socond stage and without routine episiotomy.
2849013|NCT03605615|Experimental|VOCALIZATION|In this group parturients will besides being be attended with our standar care, will receive training to vocalize during second stage.
2849014|NCT03605589|Experimental|Blinatumomab and Pembrolizumab|"Blinatumomab and Pembrolizumab will be given for 2 cycles (each cycle lasts 35 days).~Blinatumomab administered as a continuous IV infusion. Patient Weight Greater Than or Equal to 45 kg (Fixed dose) Patient Weight Less Than 45 kg (BSA-based dose)~Cycle 1 (Days 1-7):~Patient Weight Greater Than or Equal to 45 kg: 9 mcg/day Patient Weight Less Than 45 kg: 5 mcg/m2/day~Cycle 1(Days 8-28):~Patient Weight Greater Than or Equal to 45 kg: 28 mcg/day Patient Weight Less Than 45 kg: 15 mcg/m2/day~Cycle 2 (Days 1-28):~Patient Weight Greater Than or Equal to 45 kg: 28 mcg/day Patient Weight Less Than 45 kg: 15 mcg/m2/day~Pembrolizumab: 2 mg/kg (max dose 200 mg) administered as a 30 minute IV infusion on day 12 of cycle 1 and day 5 of cycle 2."
2849015|NCT03605576|Experimental|Fu's subcutaneous needling|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
2849016|NCT03605576|Active Comparator|Transcutaneous electrical nerve stimulation|In this arm, the subjects will receive the intervention of TENS on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
2849017|NCT03605563|Experimental|FSN: Fu's subcutaneous needling|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
2849018|NCT03605563|Active Comparator|TENS: Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of TENS on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
2849019|NCT03605550|Experimental|Treatment (PTC596)|PTC596 administered orally twice weekly (M/Th or T/F schedule) concomitantly with radiotherapy. One cycle is defined as 28 days. Post RT patients will continue to receive PTC596 twice weekly for up to 26 cycles.
2849020|NCT03605537|Experimental|Stent|"Subjects will undergo repair of the choanal atresia in the operating room with a drug eluting stent placed at the end of the surgical procedure. They will return to the operating room in 3-5 weeks for repeat nasal endoscopy with possible balloon dilation, which is standard of care within our institution. At this time in the operating room the intervention arm will have the stent removed. Following removal of the stent, photodocumentation of the posterior nasal cavity and nasopharynx will take place to assess the size (standard of care).~Subjects will then follow up and undergo a bedside or outpatient nasal endoscopy and nasopharyngoscopy (standard of care) at the following approximate intervals 1 month, 6 months, 12 months (these are not exact time periods as clinic scheduling can sometimes be 2-3 months on either side of these time stamps)."
2849021|NCT03605537|No Intervention|No Stent|"Subjects will undergo repair of the choanal atresia in the operating room with no stent placed at the end of the surgical procedure. They will return to the operating room in 3-5 weeks for repeat nasal endoscopy with possible balloon dilation, which is standard of care within our institution. Photodocumentation of the posterior nasal cavity and nasopharynx will take place to assess the size (standard of care).~Subjects will then follow up and undergo a bedside or outpatient nasal endoscopy and nasopharyngoscopy (standard of care) at the following approximate intervals 1 month, 6 months, 12 months (these are not exact time periods as clinic scheduling can sometimes be 2-3 months on either side of these time stamps)."
2849022|NCT03605524|Other|Sensory training|"Sensory (Olfactory or visual) training will be done at home for 12 weeks.~The effect of the training will be evaluated using an experimental protocol includes (i) clinical and psychometric evaluations, (ii) the study of olfactory perception using Sniffin' Sticks Test and (iii) the study of the emotional perception using the subjective Sense'n Feel method and the objective measurement of the spontaneous pupillary dilatation."
2849023|NCT03605485|Experimental|Trial Continuous Positive Airway Pressure (CPAP) mask|Trial nasal pillows CPAP mask
2849024|NCT03605472|Experimental|Patients|
2849025|NCT03605459|Experimental|Device use|"Only one treatment arm; the Comfort Plug™ is a device designed to control urinary incontinence in male subjects by being placed in the urethra to stop urine leakage."
2849026|NCT03605446|Experimental|Animal 12%|Animal based protein biscuit containing 12% of total energy as protein
2849027|NCT03605446|Experimental|Animal 20%|Animal based protein biscuit containing 20% of total energy as protein
2849028|NCT03605446|Experimental|Plant 12%|Plant based protein biscuit containing 12% of total energy as protein
2849029|NCT03605446|Experimental|Plant 20%|Plant based protein biscuit containing 20% of total energy as protein
2849030|NCT03605446|Placebo Comparator|Wheat biscuit|
2849031|NCT03605433|Experimental|Oral Anticoagulation+Antiplatelet|Rivaroxaban 2.5 mg twice daily and Aspirin 100 mg once daily.
2849032|NCT03605433|Experimental|Oral Anticoagulation|Rivaroxaban 20 mg once daily
2849033|NCT03605433|Active Comparator|Antiplatet|Aspirin 100 mg once daily
2849034|NCT03605420|Experimental|Experimental group|Receiving one family visit prior to hospital admission
2849035|NCT03605420|No Intervention|Control group|Without receiving one family visit prior to hospital admission
2849036|NCT03605407|Experimental|Experimental group|Patient receiving one visit prior to hospital admission
2849037|NCT03605407|No Intervention|Control group|Patient without receiving one visit prior to hospital admission
2849038|NCT03605368|Active Comparator|Video Modeling|
2849039|NCT03605368|Experimental|Virtual Reality Intervention|
2849040|NCT03605342|Active Comparator|Buprenorphine + CPT-C|Buprenorphine induction and stabilization for all participants (x1 week). Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, then CPT-C for 12 weeks.
2849041|NCT03605342|Active Comparator|Buprenorphine + IDC|Buprenorphine induction and stabilization for all participants (x1 week). Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, then IDC for 12 weeks
2849042|NCT03605329|Other|Type 1 diabetic patients with OSAS|to explore the severity of NAC in case of OSAS
2849043|NCT03605290|Active Comparator|Mechanically aligned TKR|patients were operated using the standard mechanically aligned technique
2849044|NCT03605290|Experimental|Kinematically aligned TKR|patients were operated using the newer mechanically aligned technique
2849045|NCT03605277|Experimental|Normal renal function|healthy volunteers with normal renal function
2849046|NCT03605277|Experimental|Severe renal impairment|subjects with severe renal impairment
2849047|NCT03605277|Experimental|Moderate renal impairment|subject with moderate renal impairment
2849048|NCT03605277|Experimental|Mild renal impairment|subjects with mild renal impairment
2849049|NCT03605264||Slow Graft Function|Slow Graft function(SGF) is defined as a failure of serum creatinine to fall by 70% at postoperative day 7 after renal transplantation.
2849050|NCT03605264||Immediate Graft Function|Immediate graft function(IGF) is defined as a fall of serum creatinine of 70% at postoperative day 7 after renal transplantation.
2849051|NCT03605251|Experimental|TAS5315 low dose group|TAS5315 low dose and Methotrexate as specified
2849052|NCT03605251|Experimental|TAS5315 high dose group|TAS5315 high dose and Methotrexate as specified
2849053|NCT03605251|Placebo Comparator|Placebo group|Placebo and Methotrexate as specified
2849054|NCT03605238|Experimental|Corticosteroids & tanCART19/20|Twelve days of high-dose IV methylprednisolone to reduce acute inflammation, then infuse anti-CD19/20-CAR retroviral vector-transduced autologous derived T cells only once.
2849055|NCT03605225|Experimental|Cellphone application|Train of Four (TOF) ratio displayed by the Cellphone Application
2849056|NCT03605225|Active Comparator|Draeger TOF Scan|Train of Four (TOF) ratio displayed by the Draeger TOF Scan
2849057|NCT03605212|Experimental|Cohort 1|Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days
2849060|NCT03605212|Experimental|Cohort 4|Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)
2849061|NCT03605212|Active Comparator|Adults|Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)
2849062|NCT03605199|Experimental|Denosumab active treatment|Denosumab active treatment
2849063|NCT03605186|Experimental|Chamomile oral cryotherapy|"The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs).~Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.~Patient will receive a cup of ice cubes which is continuously replenished before being emptied.~Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session."
2849064|NCT03605186|Active Comparator|Oral cryotherapy|"The plain icecubes will be prepared in the clinic with 400 mL of distilled water.~Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.~Patient will receive a cup of ice cubes which is continuously replenished before being emptied.~Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session."
2849065|NCT03605173|Experimental|free vitamin d|free vitamin is directly measured from blood serum using an ELISA kit
2849066|NCT03605173|Experimental|total vitamin d|Total vitamin d is measured routinely from blood serum
2849067|NCT03605160|Active Comparator|traditional group|
2849068|NCT03605160|Experimental|fluid-jet group|
2849069|NCT03605147|Experimental|CaHMB|CaHMB Group (n=60) will receive CaHMB twice a day and a late evening snack every night for 12 weeks. A specialized, ready-to-drink liquid with 34 kcal, 8.5 g carbohydrate, 1.5g calcium-HMB. The late evening snack is a drink with low-Glycemic Index carbohydrate with 112 kcal.
2849070|NCT03605147|Active Comparator|Control|Control Group (n=60) will receive placebo twice a day and placebo every night for 12 weeks with similar composition but without HMB. The late evening snack is a drink with low-Glycemic Index carbohydrate with 112 kcal.
2849071|NCT03605134||study group|level of cardiac troponin and diastolic function assessment by means of transthoracic echocardiography
2849072|NCT03605108|Active Comparator|Probiotic|"• Probiotic fomula per capsule:~2 Billion CFUs HU36 - 30 mg HU58 - 20 mg Bacillus clausii -25 mg Bacillus coagulans 10B - 35 mg Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose."
2849073|NCT03605108|Placebo Comparator|Placebo|Rice flour only
2849074|NCT03605095|Active Comparator|8 mg/ml nitroglycerin|Higher concentration of NO donor (Nitromint) vs dilution
2849075|NCT03605095|Active Comparator|1 mg/ml nitroglycerin|Lower concentration of NO donor (Nitropohl) vs physiological saline
2849076|NCT03605082|Experimental|UCB0107|Subjects will be randomized to receive a predefined dosage of UCB0107 in order to maintain the blinding.
2849077|NCT03605082|Placebo Comparator|Placebo|Subjects will be randomized and receive a placebo in order to maintain the blinding.
2849078|NCT03605069|Other|First TWA (A)|"In each subject up to two target wound areas (TWA) are randomized, one each to active treatment or placebo.~In the first arm; randomization of the first selected TWA to active treatment or placebo"
2849079|NCT03605069|Other|Second TWA (B)|In each subject, in the second arm; allocation of the second selected target wound area (TWA) to the alternative treatment. Second arm in the same subject as the first arm.
2849080|NCT03605056|Experimental|CRD regimen|CRD is a new 3-drug regimen adding a HDACi named chidamide to a novel 2-drug combination of lenalidomide and dexamethasone (RD)
2849081|NCT03605043||Overall cohort|All Persons Living with HIV who enlisted in any one of three high-volume HIV clinics in Tororo District of Eastern Uganda between 2014 and 2017.
2849082|NCT03605030|Active Comparator|Novel Lead Based Armboard|
2849083|NCT03605030|Placebo Comparator|Standard Armboard|
2849084|NCT03605017|Experimental|VREFT: Wonderkin Treatment|Administered by computer
2849085|NCT03605017|Active Comparator|VREFT: Attention Control|Administered by computer
2849086|NCT03605004||VUS|Adult patients with undiagnosed conditions who have received one or more variants ofuncertain significance from exome sequence.
2849087|NCT03605004||Negative|Adult patients with undiagnosed conditions who have received an uninformative negative result from exome sequence.
2849088|NCT03604991|Experimental|Arm A (carboplatin, paclitaxel, radiation therapy)|Participants receive carboplatin IV and paclitaxel IV and undergo radiation therapy once a week beginning on day 1. Courses repeat every week for up to 5 weeks in the absence of disease progression or unacceptable toxicity.
2849089|NCT03604991|Experimental|Arm B (carboplatin, paclitaxel, radiation therapy, nivolumab)|Participants receive carboplatin, paclitaxel, and radiation therapy as in Arm A. Participants also receive nivolumab IV over 60 minutes on days 1 and 15. Courses repeat every week for up to 5 weeks in the absence of disease progression or unacceptable toxicity.
2849090|NCT03604991|Experimental|Arm C (nivolumab)|Participants receive nivolumab IV over 60 minutes on day 1. Courses repeat every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2849091|NCT03604991|Experimental|Arm D (nivolumab, ipilimumab)|Participants receive nivolumab as in Arm C and receive ipilimumab IV over 90 minutes on day 1 of courses 1, 4, 7, and 10. Courses repeat every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2849092|NCT03604978|Experimental|Cohort A (nivolumab, radiosurgery)|Participants receive nivolumab IV over 60 minutes on day 1. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Participants also undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5.
2849093|NCT03604978|Experimental|Cohort B (nivolumab, ipilimumab, radiosurgery)|Participants receive nivolumab IV over 60 minutes every 2 weeks for 12 doses (6 months) and then every 4 weeks for additional 6 months. Participants also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 6 weeks for 4 doses in the absence of disease progression or unacceptable toxicity. Participants undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5.
2849094|NCT03604965|Experimental|GP+CCRT|GP neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
2849095|NCT03604965|Active Comparator|TPF+CCRT|TPF neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
2849096|NCT03604926||chemo-naive patients|
2849097|NCT03604926||pre-treated patients with systemic chemotherapy +/- a targeted|
2849098|NCT03604913|Active Comparator|A(aortic valve sparing operation)|Undergo aortic valve sparing root replacement operation
2849099|NCT03604913|Active Comparator|B(Bentall operation)|Undergo Bentall operation
2849100|NCT03604887||study group|All pregnant women who will attend the labor unit during the study period will be invited to participate in the study.
2849101|NCT03604874|Active Comparator|low dose oxytocin|patients will receive intravenous infusion of 5 Units of oxytocin/500 mL lactated ringer solution. Starting rate will be 2 mU/min, incrementally increase by 2 mU/min every 30 minutes until achievement of adequate uterine contractions.
2849102|NCT03604874|Experimental|high dose oxytocin|patients will receive intravenous infusion of 5 Units of oxytocin/500 mL lactated ringer solution. Starting rate will be 4 mU/min, incrementally increase by 4 mU/min every 30 minutes until achievement of adequate uterine contractions
2849103|NCT03604848|Experimental|NGS-guided regimen: Regimen A|Regimen A: 9-month regimen for simple MDR-TB patients 4 months of pyrazinamide, amikacin ,moxifloxacin, prothionamide, and cycloserine , followed by 5months of pyrazinamide,moxifloxacin, prothionamide, and cycloserine
2849104|NCT03604848|Experimental|NGS-guided regimen: Regimen B|Regimen B: 12-month simple MDR-TB regimen for simple MDR-TB patients 6 months of pyrazinamide, amikacin ,moxifloxacin, prothionamide, and cycloserine , followed by 6 months of pyrazinamide,moxifloxacin, prothionamide, and cycloserine
2849105|NCT03604848|Experimental|NGS-guided regimen: Regimen C|"Regimen C : for complicated MDR-TB patients In regimen C, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol based on the drug susceptibility test results. The duration of treatment in the complicated MDR-TB group is consistent with control group, with 6 months of intensive phase and 18 months of consolidation phase."
2849106|NCT03604848|Active Comparator|WHO-approved MDR-TB regimen|6 months of pyrazinamide, amikacin,moxifloxacin, prothionamide , and cycloserine , followed by 18 months of pyrazinamide, moxifloxacin, prothionamide , and cycloserine
2849107|NCT03604835||Patients with MPS VII receiving vestronidase-alfa|via prescription, or early access/ compassionate use program
2849108|NCT03604835||Patients with MPS VII not receiving vestronidase-alfa|no treatment or treatment other than vestronidase alfa
2849109|NCT03604822|Experimental|Music therapy protocol|Each participant received 12 home-based music therapy treatment sessions over 6-week time period.
2849110|NCT03604809|Experimental|OT Guided Cognitive Interventions|Occupational Therapy interventions will be adjusted according to the patient's Richmond Agitation and Sedation Scale (RASS).
2849111|NCT03604809|No Intervention|Usual Care|This will be the standard of care currently provided for delirium prevention within the Department of Critical Care Medicine in Calgary using the ABCDEF bundled approach.
2849112|NCT03604796|Active Comparator|Continuous IV Acetaminophen|Intravenous Infusion
2849113|NCT03604796|Active Comparator|Rectal Acetaminophen|Rectal Solution
2849114|NCT03604783|Experimental|Single Arm TP-1287|Twice Daily dose of TP-1287 by oral administration
2849115|NCT03604770||Women seeking fertility treatment|Women aged 18-45 who are seeking fertility treatment at Bethesda Fertility Center will be provided a survey and food diary to complete.
2849116|NCT03604757|Experimental|PET/CT Imaging|
2849117|NCT03604744|Placebo Comparator|LSD-100, LSD-200, Psilocybin-15, Psilocybin-30, Placebo|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2849118|NCT03604744|Placebo Comparator|LSD-200, Psilocybin-15, Psilocybin-30, Placebo, LSD-100|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2849119|NCT03604744|Placebo Comparator|Psilocybin-15, Psilocybin-30, Placebo, LSD-100, LSD-200|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2849120|NCT03604744|Placebo Comparator|Psilocybin-30, Placebo, LSD-100, LSD-200, Psilocybin-15|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2849121|NCT03604744|Placebo Comparator|Placebo, LSD-100, LSD-200, Psilocybin-15, Psilocybin-30|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2849122|NCT03604731||Uncomplicated cardiac surgery patients|Patients after schedulled cardiac surgery procedures
2849123|NCT03604731||Complicated cardiac surgery patients|Patients after schedulled cardiac surgery procedures complicated by multiorgan failure
2849124|NCT03604705|Experimental|APX001 Treatment|
2849125|NCT03604692|Experimental|5 cohorts of escalating dose levels of SNDX-6352|"5 cohorts of escalating dose levels of SNDX-6352 to establish the optimal biologic dose (OBD) and recommended Phase 2 dose (RP2D).~IV infusion; SNDX-6352 at a dose of 0.15 mg/kg to 3 mg/kg."
2849126|NCT03604679|Experimental|SyB C-0501|"SyB C-0501 (Oral Bendamustine) will be administered orally once a day (specified dose). The treatment period of 21 days (Cohort 1; 7 days of administration + 14 days of observation or Cohort 2; 14 days of administration + 7 days of observation or Cohort 3; 21 days of administration) constitutes 1 cycle.~Part 1: dose escalation to determine MTD, RD and dosing schedule Part 2: dose expansion at RD"
2849127|NCT03604666||Health care process with Nurse Navigator|"A Nurse Navigator will:~Be present at the announcement consultation~Give information on the outpatient circuit~Offer assistance for patients over 75 years~Complete onco-geriatric orientation questionnaires~Take care of patients on the ambulatory circuit"
2849128|NCT03604666||Health care process|Health care process
2849129|NCT03604653||Stomach|Heated Intraperitoneal Chemotherapy with Mitomycin C 30mg at time 0, 10mg at time 45 minutes, CDDP Cisplatin 50mg/m2@ time 0
2849130|NCT03604653||Colorectal, Appendiceal, Pseudomyxoma Peritonei|Heated Intraperitoneal Chemotherapy with Mitomycin C 30mg at time 0, 10mg at time 45 minutes
2849131|NCT03604653||Primary Peritoneal|Heated Intraperitoneal Chemotherapy with CDDP Cisplatin 50mg/m2 at time 0, Doxorubicin 15mg/m2 at time 0
2849132|NCT03604653||Ovarian, Cervical, Uterine, Fallopian Tube|Heated Intraperitoneal Chemotherapy with CDDP Cisplatin 75mg/m2 at time 0
2849133|NCT03604640|No Intervention|standard care|
2849134|NCT03604640|Experimental|Physical and educational program|
2856569|NCT03552445|Active Comparator|PCV13 alone|
2849135|NCT03604627|Other|Patients treated for cancer during childhood or adolescence|Patients over the age of 18 treated during childhood or adolescence for cancer with irradiation affecting the heart area (≥20% of ≥5Gy heart volume) and / or anthracyclines (≥ 300mg / m²)
2849136|NCT03604614|Experimental|HIPEC and chemotherapy|Hyperthermic Intraperitoneal Chemotherapy and SOX（Tiggio+Oxaliplatin ）
2849137|NCT03604614|Sham Comparator|Without HIPEC|Without Hyperthermic Intraperitoneal Chemotherapy，Only SOX（Tiggio+Oxaliplatin ）
2849138|NCT03604588|Other|Patients with oropharyngeal cancer|"Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test.~Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results."
2849139|NCT03604575|Experimental|Insulin Lispro|Single subcutaneous administration of Insulin Lispro in dose 0.3 IU / kg
2849140|NCT03604575|Active Comparator|Humalog®|Single subcutaneous administration of Humalog® in dose 0.3 IU / kg
2849141|NCT03604549|Placebo Comparator|Saline|Women in this arm will receive a flush with saline after normal saline Sono HSG.
2849142|NCT03604549|Experimental|Lipiodol UF|Women in this arm will receive a flush with Lipiodol UF after normal saline Sono HSG.
2849143|NCT03604523|Active Comparator|Dilation by Balloon|Esophageal dilation by balloon device.
2849144|NCT03604523|Active Comparator|Dilation by Semi-rigid Savary|Esophageal dilation by semi-rigid savary device.
2849145|NCT03604510|Experimental|Electroencephalographic recordings|Electroencephalographic recordings
2849146|NCT03604497|Experimental|beacon alerts|active intervention - participants are receiving alerts to warn them about distracted pedestrian behavior near intersections
2849147|NCT03604497|No Intervention|no alerts baseline|baseline - participants do not receive any alerts on their mobile smartphone when near intersections
2849148|NCT03604497|Other|no alerts retention|retention phase - alerts have stopped after active intervention and behavior is monitored to test retention of learned behavior
2849149|NCT03604484|Active Comparator|Tricuspid annuloplasty|Patient treated with tricuspid annuloplasty at the moment of the mitral valve surgery
2849150|NCT03604484|No Intervention|No Tricuspid annuloplasty|Control patients
2849151|NCT03604471|Other|Atorvastatin|All patients using atorvastatin at any dose (usually ranging from 5 to 80 mg once-daily).
2849152|NCT03604445|Experimental|BI 905677|Schedule A: 3 week cycle (treatment every 3 weeks). Schedule B: 4 week cycle (treatment every 2 weeks). Recruitment into Schedule B will start after the MTD of Schedule A is reached.
2849153|NCT03604419|Experimental|PB-119 100 μg|PB-119 100 μg subcutaneous (SC) once weekly (QW) + Metformin oral (p.o.) Glucophage® (stable dosage)
2849154|NCT03604419|Experimental|PB-119 150 μg|PB-119 150 μg SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
2849155|NCT03604419|Experimental|PB-119 200 μg|PB-119 200 μg SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
2849156|NCT03604419|Placebo Comparator|PB-119 Placebo|PB-119 Placebo SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
2849157|NCT03604406|Experimental|Varicella Zoster Vaccine|Live zoster vaccine injection will be administered as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
2849158|NCT03604406|Placebo Comparator|Placebo Injection|Saline injection will be administered as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
2849159|NCT03604393|Experimental|Practice Facilitation, Cluster 1|Intervention Cluster 1 is the first intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
2849160|NCT03604393|Experimental|Practice Facilitation, Cluster 2|Intervention Cluster 2 is the second intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
2849161|NCT03604393|Experimental|Practice Facilitation, Cluster 3|Intervention Cluster 3 is the third intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
2849162|NCT03604393|Experimental|Practice Facilitation, Cluster 4|Intervention Cluster 4 is the fourth intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
2849163|NCT03604393|Experimental|Practice Facilitation, Cluster 5|Intervention Cluster 5 is the final intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
2849164|NCT03604380|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
2849165|NCT03604380|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
2849166|NCT03604367|Experimental|GAITRite assessment|Subjects will undergo the GAITRite assessment of functional walking and then complete the Functional MRI Bipedal paradigm followed by questionnaires and assessments regarding the virtual environment.
2849167|NCT03604354|Active Comparator|Pregabalin|Pregabalin 150mg oral tablets before one hour before undergoing unilateral total knee arthroplasty
2849168|NCT03604354|Experimental|Tapentadol|tapentadol 100mg oral tablets before one hour before undergoing unilateral total knee arthroplasty
2849169|NCT03604341|Experimental|Gestational age up to 10w0d - Dronabinol|Women with gestational age up to 10 weeks 0 days will be randomized to Dronabinol 5mg Cap or placebo
2849170|NCT03604341|Placebo Comparator|Gestational age up to 10w0d - Placebo|Women with gestational age up to 10 weeks 0 days will be randomized to Dronabinol 5mg Cap or placebo
2856570|NCT03552445|Active Comparator|Td alone|
2849171|NCT03604328|Experimental|PA5108|PA5108 ocular implant (study eye) and topical prostaglandin analogue therapy (non-study eye)
2849172|NCT03604315|Experimental|Treatment (FDG PET/CT, [18F]FTT PET/CT)|Participants receive FDG IV and undergo FDG PET/CT scan over 20-30 minutes if they have not already had one per standard of care. At least 20-24 hours later, participants receive fluorine F 18 fluorthanatrace IV and undergo [18F]FTT PET/CT over 1 hour.
2849173|NCT03604302|Experimental|Functional Magnetic Resonance Imaging (fMRI)|The interventions for this study are non-invasive. For patients, routine pre-operative MRI that includes task based fMRI and perfusion data acquisition will be performed on a 3T scanner. Patients who participate in this study, will have approximately 5 minutes added to their scan time for the below described breath holding fMRI (BH fMRI) paradigm, which will be done for research purposes. For healthy volunteers, participation will involve having a high resolution anatomical MRI done with the same paradigms which patients will have, listed below. the total scanner time will be approximately 25 minutes, and the scan will not be billed to the healthy volunteer.
2849174|NCT03604289|Experimental|Angiotensin-(1-7)|Participants receive intravenous angiotensin-(1-7) at one study visit for 100 minutes total. Angiotensin-(1-7) will be given in escalating doses of 2ng/kg/min, 4ng/kg/min, and 8ng/kg/min. Each of these doses will be infused for 10 minutes. Following the dose escalation, angiotensin-(1-7) will be given at 8ng/kg/min for an additional 70 minutes. Infusion rates will be calculated for each patient based on body mass.
2849175|NCT03604289|Placebo Comparator|Saline|Participants receive intravenous saline at one study visit for 100 minutes total. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each patient based on body mass. Saline will be given in escalating doses for 10 minutes each and then held for 70 minutes at the highest dose.
2849176|NCT03604263|Experimental|Treatment Arm|Subjects enrolled and treated with ArcticLine Cardiac Cryoablation Catheter
2849177|NCT03604250|Experimental|Lifestyle plus prebiotics|Research participants will be asked to wear health monitoring devices, including a continuous glucose monitoring device and an Apple watch. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
2849178|NCT03604237|Experimental|Targeted forceps biopsy|In this group, an endoscopist takes a forceps biopsy at depressed mucosa or large nodular area of large colorectal tumors after meticulous surface evaluation.
2849179|NCT03604237|No Intervention|Conventional forceps biopsy|In this group, an endoscopist takes a forceps biopsy at the most convenient area of large colorectal tumors.
2849180|NCT03604224||Canagliflozin Containing Treatment Regimens|No intervention will be administered as a part of this study. Participants with type 2 diabetes mellitus (T2DM) who were initiated on canagliflozin 300 milligram (mg) treatment 12 weeks back and meeting the inclusion criteria will be observed.
2849181|NCT03604198|Experimental|relacorilant (CORT125134)|
2849182|NCT03604185|Experimental|Choir Singing Group|Choir participants will take part in weekly two-hour group choral sessions over the course of fourteen weeks, during which time they will receive pitch training and vocal direction. In addition to the weekly group choir sessions, participants will be offered optional individual online musical and vocal training exercises (up to one hour weekly).
2849183|NCT03604185|Active Comparator|Music Appreciation Group|Participants assigned to the music appreciation class will take part in a fourteen week course which will emphasize analytic listening to musical excerpts, which will match the choir class in terms of duration, homework demands, and instructor - both classes will be taught by the same person.
2849184|NCT03604185|No Intervention|Do-Nothing Control Group|The do-nothing control group will not receive any active training.
2849185|NCT03604172|Experimental|Cognitive behavioral therapy|16-week cognitive behavioral therapy intervention for binge eating disorder
2849186|NCT03604172|Other|Waitlist control|16-weeks on waitlist then participants will be provided with 16-weeks of cognitive behavioral therapy
2849187|NCT03604159|Experimental|Buprenorphine Extended-Release|XRB is a 300mg pre-mixed subcutaneous injectable formulation to be administered monthly. XRB is for abdominal subcutaneous injection only. Participants in the XRB treatment arm will be given 1 or more XRB injections prior to release from jail and one more at week 5 post-release, depending on their release date.
2849188|NCT03604159|Experimental|Sublingual Buprenorphine|SLB (SUBOXONE, Zubsolv, or generic tablets) is a daily sublingual film or tablet ranging from 8-24mg/day or equivalent (Zubsolv is dosed 5.7-17.1 mg/day). The film or tablet is placed under the tongue for 5 to 10 minutes until dissolved completely. Participants in the SLB treatment arm will be provided SLB daily by observed dosing in-jail (controlled substances are not self-administered in-jail) and provided to the participant by the Bellevue pharmacy in weekly, bi-weekly, or monthly quantities for unobserved, daily, self-administration through week 5.
2849189|NCT03604146||control group|Doctors and nurses were trained to treat chronic obstructive pulmonary disease according to the GOLD guidelines.Hospital patient cohort and outpatient cohort will be setted. Subjects were interviewed and received pulmonary function tests.
2849190|NCT03604146||Quality control group|Doctors and nurses will not receive any training from research team. Hospital patient cohort and outpatient cohort will be setted. Subjects were interviewed and received pulmonary function tests.
2849191|NCT03604133||Patients receiving ICD devices|
2849192|NCT03604120|Experimental|Preoxygenation with high flow therapy by nasal cannula|High flow oxygen therapy by nasal cannula.
2849193|NCT03604120|Active Comparator|Preoxygenation by standard Facial mask|"Patients randomized in STANDARD FACIAL MASK group will receive a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction or Fiber-optic intubation under spontaneous ventilation."
2849194|NCT03604094||Group I|0-1 month old newborns
2849195|NCT03604094||Group II|1 month-2 year-old pediatric patients
2849196|NCT03604081|Experimental|Intervention Group|One hour of intense massed practice of lower extremity either in the form of shaping or task practice
2849197|NCT03604081|Placebo Comparator|Control Group|Conventional physical therapy for 1 hour as per current standard of care that follows stroke clinical practice guideline.
2849198|NCT03604068|Active Comparator|Active Group|Patients in this group will be treated with the currently used standard protocol for the control of post-operative pain as well as an active RecoveryRx Pulsed Short Wave Therapy device.
2849199|NCT03604068|Sham Comparator|Control Group|Patients in this group will be treated with the currently used standard protocol for the control of post-operative pain as well as a sham RecoveryRx Pulsed Short Wave Therapy device.
2849200|NCT03604055|Other|Endobronchial hamartomas treatment|After removal of endobronchial lesions, cryotherapy is applied to the area of origin. Recurrences are followed. Recurrences are recorded as poor results, compared with good results.
2849201|NCT03604042|Active Comparator|Weight-driven protein fortification|Individualized protein fortification based on weight gain
2849202|NCT03604042|Experimental|BUN-driven protein fortification|Individualized protein fortification based on BUN concentrations
2849203|NCT03604029||Qualifying Subjects|Qualifying subjects who are high risk for ACS.
2849204|NCT03604029||Qualifying Subjects with ACS|Qualifying subjects who are diagnosed with ACS
2849205|NCT03604016|Experimental|Besifovir dipivoxil+L-carnitine|Besifovir dipivoxil 150 mg and L-carnitine 330 mg
2849206|NCT03604016|Active Comparator|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
2849207|NCT03604003|Experimental|bedtime dosing ARB for hypertension|bedtime administration of potassium losartan has benefit for the isolated nocturnal hypertension
2849208|NCT03604003|Experimental|bedtime dosing ARB for the prognosis|bedtime administration of potassium losartan has benefit for the prognosis of CKD patients
2849209|NCT03603990|Experimental|Eye with vitrectomy|Eye with standard pars plana vitrectomy
2849210|NCT03603990|Active Comparator|Eye with usual care|Eye with usual care according to the investigator choice
2849211|NCT03603977||Lpv/r+3TC|These cases were given simplified therapy regimen including lopinavir(200mg) and ritonavir(50mg)500 mg,oral,bid) combined with lamivudine (300 mg,oral,qd).
2849212|NCT03603964|Experimental|Guadecitabine|Subjects will receive guadecitabine treatment at the same dose that they were receiving in the last cycle of their prior study or at a different dose as guided by the dose adjustment guidelines in the prior study protocol. Treatment may continue as long as the subject continues to benefit based on investigator judgment.
2849213|NCT03603951|Experimental|SHR2554 treated group|treated with escalated doses of EZH2 inhibitor SHR2554 respectively
2849214|NCT03603938|Experimental|bedtime dosing ARB for hypertension|potassium losartan has benefit for the nondipping BP pattern
2849215|NCT03603938|Experimental|bedtime dosing ARB for the prognosis|bedtime administration of potassium losartan has benefit for the prognosis of CKD patients
2849216|NCT03603925||PET/MR + PET/CT|The interventions for participating in this research are centered around steps needed to safely and ethically collect a research PET/MR scan following a standard-of-care PET/CT scan. The patient will be imaged in at least one of several standard anatomic areas: head/neck, thorax, abdomen, pelvis or whole-body.
2849217|NCT03603912|No Intervention|Control|Written educational literature on healthy eating and exercise guideline
2849218|NCT03603912|Experimental|Metformin|Metformin ER up to 750 mg twice daily
2849219|NCT03603912|Experimental|Lifestyle/Risk Factor Modification|Lifestyle/Risk Factor Modification (LRFM): Diet/nutrition, exercise, and risk factor modification
2849220|NCT03603912|Experimental|Metformin + LRFM|Metformin ER up to 750 mg twice daily + Lifestyle/Risk Factor Modification (LRFM) diet/nutrition, exercise, and risk factor modification
2849221|NCT03603912|No Intervention|No Atrial Fibrillation|Written educational literature on healthy eating and exercise guideline
2849222|NCT03603899|Experimental|Hp 129Xenon|Participants will inhale up to 4 doses of Hp129Xenon; each dose will be no more than 1 liter.
2849223|NCT03603886|Experimental|Telemedicine Pain Management|
2849224|NCT03603886|Other|Waitlist Control|Treatment as usual comparator
2849225|NCT03603873||Patients|
2849226|NCT03603834|Experimental|mFOLFOXIRI|"mFOLFOXIRI consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours Leucovorin, 400 mg/m2, IV over 2 hours Irinotecan, 150 mg/m2, IV over 90 minutes 5 FU, 400 mg/m2, IV bolus 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles"
2849227|NCT03603821||LUTS male|Clinical assesment of males older than 50 years with lower urinary tract symptoms presumably related to benign prostate enlargement
2849228|NCT03603808|Experimental|Treatment (VGX-3100, electroporation)|Patients receive HPV DNA plasmids therapeutic vaccine VGX-3100 IM and then undergo electroporation over 10 seconds for 4 doses in week 0, 4, 12, and 24 in the absence of disease progression or unacceptable toxicity.
2849229|NCT03603795|Experimental|A|"55 patients will be randomized in the experimental arm A. If platelets counts < 100 x 10 Giga/L, patients will be treated with Eltrombopag 200 mg/day per os from day 11 of induction chemotherapy to platelets counts > 100 x 10 Giga/L or maximum to day 45. If platelets counts ≥ 100 x 10 Giga/L on day 11, the start of IP will be delayed until platelets < 100 x 10 Giga/L.~Chemotherapy administration would be performed among standard practice:~Daunorubicin: 60 mg/m² D1 to D3~Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7~Lomustine (CCNU): 200 mg/m² per os, at D1.~200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.~Investigational Product (IP) will be taken at the same time daily on an empty stomach 1 hour before or 2 hours after a meal or preferably no calcium or dairy products."
2849230|NCT03603795|Placebo Comparator|B|"55 patients will be randomized in the comparator arm B and will received: Placebo once daily from day 11 of induction chemotherapy to AML response evaluation or platelets count > 100 x 10 Giga/L (maximum day 45)~Placebo 200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.~Chemotherapy administration would be performed among standard practice:~Daunorubicin: 60 mg/m² D1 to D3~Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7~Lomustine (CCNU): 200 mg/m² per os, at D1."
2849231|NCT03603782|Experimental|1|
2849232|NCT03603782|Experimental|2|
2849233|NCT03603782|Experimental|3|
2849234|NCT03603782|Experimental|4|
2849261|NCT03603639|Experimental|E2730 120 mg, E2730 40 mg, Placebo|Participants will receive a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 1 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 2 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
2849262|NCT03603626|Experimental|Preemptive pregabalin|
2849235|NCT03603769|Experimental|Group A: Food Supplement (Salmon Polar Lipids) Intervention|"Experimental: After fasting overnight, subjects will come to our metabolic unit where in a randomized and double blinded way they will be provided several versions of the food supplement either of stomach resistant (intestine release) or stomach non-resistant (stomach release) each containing either 0.25 (Low Dose) or 0.50 g (High Dose) of Salmon Polar Lipids (SPL)~Assessment & outcome measured: Blood samples will be taken from each subject at baseline (0 hours) and after 1-4 hours of the SPL-food supplement intervention. Aggregation of platelets will be assessed in these samples as previously described (see references 1-4), in order to evaluate the postprandial effects of this supplement on platelet aggregation.~Other blood coagulation parameters will also be evaluated, such as prothrombin time, fibrinogen, Activated partial thromboplastin time Plasma lipid profile (levels of plasma Total Cholesterol, LDL, HDL and Triglycerides) and serum CRP levels will also be assessed."
2849236|NCT03603769|Placebo Comparator|Group B: Consumption of Placebo Comparator|"Experimental: After fasting overnight subjects will come to the metabolic unit in UL at 08.00 am where in a randomized and double blinded way they will be provided a placebo capsule containing only glycerin.~Assessment & outcome measured: Blood samples will be taken from each subject at baseline (0 hours) and after 1-4 hours of the placebo administration. Aggregation of their platelets will be assessed as previously described (see references 1-4), in order to evaluate the postprandial effects of this supplement on platelet aggregation.~Other blood coagulation parameters will also be evaluated, such as prothrombin time, fibrinogen, Activated partial thromboplastin time Plasma lipid profile (levels of plasma Total Cholesterol, LDL, HDL and Triglycerides) and serum CRP levels will also be assessed."
2849237|NCT03603756|Experimental|Cohort 1|Patients with advanced or metastatic esophageal squamous cell carcinoma are to receive SHR-1210 with apatinib and irinotecan injection in cohort 1.
2849238|NCT03603756|Experimental|Cohort 2|Patients with advanced or metastatic esophageal squamous cell carcinoma are to receive SHR-1210 with apatinib and paclitaxel liposome plus nedaplatin in cohort 2.
2849239|NCT03603743|Experimental|high intensity interval training|high intensity interval training: two sets of 8-min intervals at 100% of peak power output (PPO). Each interval set was composed of repeated bouts of 30 s at 100% of PPO interspersed by 30 s of passive recovery in the seated position. Four minutes of passive recovery were allowed between the two sets.
2849240|NCT03603743|Active Comparator|moderate intensity and continuous exercise|moderate intensity and continuous exercise: 30 minutes at 60% of PPO.
2849241|NCT03603730|Experimental|taVNS|Active or inactive taVNS
2849242|NCT03603717|Experimental|CBT-I|Four individual sessions that will last approximately 15-30 minutes each across a 6-week time period, with the option to deliver sessions over the telephone as necessary.
2849243|NCT03603717|Active Comparator|SH|Four individual sessions that will last 15-30 minutes each across a 6-week time period, with the option to deliver sessions over the telephone as necessary.
2849244|NCT03603704|Experimental|LY3209590|LY3209590 administered subcutaneously (SC).
2849245|NCT03603704|Active Comparator|Placebo|Placebo administered SC.
2849246|NCT03603691|Active Comparator|Modified Manual Muscle Test|The MMMT will be tested in a test-retest design
2849247|NCT03603691|Active Comparator|Neurostatus BMRC|The Neurostatus BMRC measures Strength and will be used in a test-retest design
2849248|NCT03603691|Active Comparator|MicroFET2|The MicroFET2 is a hand held dynamometer to measure strength
2849249|NCT03603678|Experimental|Part A single dose BAY2253651|Single dose BAY2253651
2849250|NCT03603678|Placebo Comparator|Part A single dose Placebo|Single dose matching placebo
2849251|NCT03603678|Experimental|Part B multiple dose BAY2253651|Multiple dose BAY2253651 on 5 consecutive nights
2849252|NCT03603665|Experimental|Arm A|Single intravenous (IV) infusion of 0.033 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
2849253|NCT03603665|Experimental|Arm B|Single IV infusion of 0.165 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
2849254|NCT03603665|Experimental|Arm C|Single IV infusion of 0.330 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
2849255|NCT03603652|Experimental|Microwave Ablation|Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon.
2849256|NCT03603639|Experimental|Placebo, E2730 40 mg, E2730 120 mg|Participants will receive a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 1 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 2 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
2849257|NCT03603639|Experimental|E2730 40 mg, E2730 120 mg, Placebo|Participants will receive a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 1 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 2 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
2849258|NCT03603639|Experimental|E2730 120 mg, Placebo, E2730 40 mg|Participants will receive a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 1 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 2 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
2849259|NCT03603639|Experimental|Placebo, E2730 120 mg, E2730 40 mg|Participants will receive a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 1 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 2 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
2849260|NCT03603639|Experimental|E2730 40 mg, Placebo, E2730 120 mg|Participants will receive a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 1 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 2 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
2849263|NCT03603626|Placebo Comparator|Placebo|
2849614|NCT03600974||impedance-I（-）|Subjects with total reflux number ＜ 80 in 24h pH-impedance monitoring.
2849264|NCT03603613|Experimental|EPP: Entrepreneurship Programme|EPP: Entrepreneurship Programme: Youth randomized into the EPP-only arm will receive GIZ's employment programming within two weeks after the completion of the baseline assessments. The GIZ-supported EPP program includes six training modules. The modules include skills related to entrepreneurship, financial literacy, and skills building.
2849265|NCT03603613|Experimental|EPP+YRI|EPP+YRI: Youth randomized into the EPP+YRI arm will begin the Entrepreneurship programme within two weeks of baseline assessments. The entrepreneurship modules will occur for 15 days for 5 hours each day, 5 days per week. Immediately following the EPP, youth will begin receiving the YRI. The YRI curriculum (12 modules), will be delivered twice weekly over the course of 6 weeks. Each session lasts approximately 90-minutes, with additional time taken as needed. These sessions assume a peer-to-peer group learning format deemed culturally appropriate for a setting like Sierra Leone where limited resources for mental health services exist. Once youth complete the YRI they will complete a post-intervention quantitative assessment.
2849266|NCT03603613|No Intervention|Control|Control: Youth randomized into the control arm will be quantitatively assessed at the same time points as youth randomized into the two treatment arms (baseline and post-intervention). Due to access to funding and feasibility, youth in the control arm will not have the opportunity to receive the YRI once the study period concludes. However, GIZ is conducting a phased roll out of their EPP programming, meaning they will offer their EPP throughout 2018 past their participation in Youth FORWARD. The list of youth from the control group will be provided to GIZ so they can participate in the future phases. Youth will also be compensated for their participation in our quantitative assessments.
2849267|NCT03603600|Experimental|enVista MX60EF|enVista MX60EF (trifocal) multifocal IOL (MIOL)
2849268|NCT03603600|Sham Comparator|enVista MX60E|enVista MX60E monofocal IOL
2849269|NCT03603587|Experimental|Patients who will benefit from the removal of a scalp tumour|"Patients who will benefit from the removal of a scalp tumour in the alopecic zone will be recruited in the dermatology department of the St-Etienne University Hospital.~They will have biopsy, blood sample, examination of the scalp, questionnaire on sun exposure, Norwood scale, scinexa score, questionnaire of clinicals signs and questionnaire of the history of the hair loss."
2849270|NCT03603574|Experimental|EWA through the needle|EWA through the needle group, 5 mL of normal saline are injected through the epidural needle after the occurrence of LOR. The needle is subsequently connected to the pressure transducer (leveled with the heart) via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations.
2849271|NCT03603574|Experimental|EWA through the catheter|EWA through the catheter group, the epidural catheter is advanced 5 cm beyond the needle tip after the occurrence of LOR. Subsequently, the operator injects 5 mL of normal saline through the catheter and the latter is connected to the pressure transducer via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations.
2849272|NCT03603561|Active Comparator|Active cTBS|
2849273|NCT03603561|Sham Comparator|Sham cTBS|
2849274|NCT03603548|Active Comparator|Advagraf|
2849275|NCT03603548|Experimental|Envarsus|
2849276|NCT03603522|Experimental|BioGaia-DSM17938 then Placebo Comparator|28 days treatment with BioGaia-DSM17938, followed by 28 days washout and then crossover to 28 days placebo comparator treatment.
2849277|NCT03603522|Placebo Comparator|Placebo Comparator then BioGaia DSM17938|28 days treatment with placebo comparator treatment, followed by 28 days washout and then crossover to 28 days treatment with BioGaia DSM17938.
2849278|NCT03603509|Active Comparator|Fluad vaccine|110 subjects will receive a single dose of the Fluad influenza vaccine.
2849279|NCT03603509|Active Comparator|Fluzone vaccine|110 subjects will receive a single dose of the Fluzone High-Dose influenza vaccine.
2849280|NCT03603496|Experimental|Personalized Tobacco Care Management|PTCM will provide 8 weeks of nicotine replacement therapy at hospital discharge and proactive contacts over 3 months delivered by automated IVR call +/- text messaging +/- email. At each contact the patient is offered a return call from the hospital-based tobacco coach forcounseling, medication advice, and coordination of care with the patient's outpatient health care team.
2849281|NCT03603496|Active Comparator|eReferral to State Tobacco Quitline|Referral from hospital to the state Quitline will be made by the research team on behalf of each enrolled patient. Feedback from the quitline will be included in the patient's medical chart.
2849282|NCT03603483|Active Comparator|Patients with sever aortic stenosis 1|Procedure: the patients will undergo aortic valve replacement with aortic root enlargement.
2849283|NCT03603483|Active Comparator|Patients with sever aortic stenosis 2|Procedure: the patients will undergo conventional aortic valve replacement
2849284|NCT03603470|Other|Patients with previous prothesis instability|
2849285|NCT03603470|Other|Patients without prothesis instability|
2849286|NCT03603444||First study group: patients with PHPT|"Patients aged between 18-90 years old with primary hyperparathyroidism who had been diagnosed in the Unit of Endocrinology of the University of Modena and Reggio Emilia.~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
2849287|NCT03603444||Second study group: patients with HypoP|"Subjects with reduced serum P, but normal serum Ca, will be enrolled among HIV-infected patients on HAART treatment from the Modena cohort.~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
2849288|NCT03603444||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their calcium-phosphorus metabolism state with normal results.~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
2849289|NCT03603431|Experimental|Single Ascending Dose - MRG-110|Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites
2849290|NCT03603431|Placebo Comparator|Single Ascending Dose - Placebo|Intradermal injection of placebo at four wound sites
2849291|NCT03603431|Experimental|Multiple Ascending Dose - MRG-110|Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites
2849292|NCT03603431|Placebo Comparator|Multiple Ascending Dose - Placebo|Intradermal injection of placebo at four wound sites
2849293|NCT03603418|Experimental|Group D (Study group-Dexamethasone group)|Forty patients undergoing induction of labor will receive 8 mg (2ml) of the product dexamethasone sodium phosphate intramuscular one hour before the initiation of labor induction in the form of epidrone ampoules which is a dexamethasone product from Epico-Egypt, and labor induction will be performed according to the American College of Obstetricians and Gynecologists protocol, i.e, starting by 25 mcg of PGE1 vaginally, in the form of Vagiprost, every 3-6 hours according to patient response, Dexamethasone will be given one hour before the first dose of Vagiprost, when bishop score reaches 6 to 8, oxytocin will be added by 5 drops/minute of 500 cc saline + 5 units of oxytocin with the dose increasing by 5-10 drops / minute every 30 minute till optimal contractions are reached which are three uterine contractions in 10 minutes and each lasting for 40-50 seconds
2849294|NCT03603418|Placebo Comparator|Group C (Control group)|Forty patients undergoing induction of labor will receive 2ml of distilled water intramuscular one hour before the initiation of labor induction, and labor induction will be performed by the same protocol as above.
2849295|NCT03603405|Experimental|Experimental: ADV/HSV-tk (gene therapy)|"Experimental: ADV/HSV-tk (gene therapy)~The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 30 sessions (over 6 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent with the radiotherapy dependent on patient status based on best clinical judgment following the Stupp protocol."
2849296|NCT03603392|Experimental|Physical activity program|Before and after a 5-months of a supervised exercise program were performed in post bariatric patients, body composition, physical fitness and cardiovascular risk factors were measured.
2849297|NCT03603379|Experimental|C225-ILs-dox i.v.|C225-ILs-dox administered intravenously
2849298|NCT03603366||Primary prevention|"Patients in Italy who are eligible to use low-dose aspirin for primary prevention of CVD and CRC.~Subgroups:~Patients eligible for and using low-dose aspirin who are at 20% ten-year CVD risk for primary prevention of CVD~Patients eligible for and not using low-dose aspirin who are at 20% ten-year CVD risk for primary prevention of CVD"
2849299|NCT03603366||Secondary prevention|"Patients in Italy who are eligible to use low-dose aspirin for secondary prevention of CVD and CRC.~Subgroups:~Patients eligible for and using low-dose aspirin for secondary prevention of CVD~Patients eligible for and not using low-dose aspirin for secondary prevention of CVD"
2849300|NCT03603366||Physicians|Physicians from Italy with experience recommending low-dose aspirin for primary and/or secondary prevention of CVD and CRC.
2849301|NCT03603353|Experimental|Intervention group|
2849302|NCT03603353|Active Comparator|Control group|
2849303|NCT03603340|Experimental|Intervention group|
2849304|NCT03603340|Active Comparator|Control group|
2849305|NCT03603327|Other|Treatment|All subjects will receive a standard of care treatment- Direct acting anti-viral agents Drugs
2849306|NCT03603314|Experimental|29 mg dose group|Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
2849307|NCT03603314|Experimental|43.5 mg dose group|Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
2849308|NCT03603314|Placebo Comparator|placebo oral tablet|Patients will receive the study drug (placebo) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
2849309|NCT03603288|Experimental|idebenone 150 mg film-coated tablets|900 mg idebenone/day (2 tablets to be taken 3 times a day with meal)
2849310|NCT03603275||Patient/caregiver of Kovaltry (BAY81-8973)|Patients who are switching factor replacement products to Kovaltry and patients who have switched factor replacement products to Kovaltry previously
2849311|NCT03603275||Physician Group|Physicians participating in the study are associated with US hemophilia treatment centers that are affiliated with the ATHN hemophilia treatment center network
2849312|NCT03603262|Experimental|SH-1028|Oral Once-Daily Administration of SH-1028
2849313|NCT03603249|Experimental|Clopidogrel and Trimetazidine Arm|Patients on DAPT for at least 6 months will be tested for platelet function testing with the P2Y12 VerifyNow assay at baseline. The patients will then undergo at least a 2-week course of Trimetazidine 35 mg/q12h, followed thereafter by platelet function testing.
2849314|NCT03603236||preeclampsia|18-40 aged diagnosed with preeclampsia
2849315|NCT03603236||control|18- 40 aged healthy females over 37. weeks of pregnant with no history of preeclampsia
2849316|NCT03603223|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
2849351|NCT03602950|Active Comparator|study group|50 diabetic ladies will undergo elective CS at full term and autologous PRP will be injected subcutaneously before skin closure.
2849352|NCT03602937|Experimental|Renastep|All participants to incorporate Renastep into their usual dietary regime.
2849353|NCT03602911|Other|Proof of Concept|The isotope 68Ga, available as NETSPOT and 18F-FDG-PET/CT per established protocol will both be administered
2849317|NCT03603210||Patients treated with DCB angioplasty|"Patient cohort is comprised of all patients who received drug coated balloon angioplasty at NNUH during the above period. Within this cohort there will be two main groups which are drug coated balloon (DCB) angioplasty for de novo coronary artery disease (CAD) and DCB angioplasty for ISR/ST. Graft cases will be reported as a small third group.~Outcomes will also be reported for three sub groups of de novo disease group, namely, dcb-only angioplasty for de novo disease, dcb-only angioplasty as primary percutaneous coronary intervention (PPCI) and dcb-only angioplasty group using a DCB with a diameter of 3mm or more in de novo disease."
2849318|NCT03603197|Experimental|BP-C1|Patients allocated to BP-C1 arm will be treated for 32 consecutive days. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they will be offered to continue treatment with BP-C1.
2849319|NCT03603197|Placebo Comparator|Placebo|Patients allocated to Placebo arm will be treated for 32 consecutive days. Thereafter the patients will cross over to 32-day treatment with BP-C1. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they will be offered to continue treatment with BP-C1.
2849320|NCT03603184|Experimental|Experimental arm|paclitaxel 175 mg/m2 + carboplatin AUC 5 or 6 will be administered every 21 days for 6-8 cycles or PD. Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.
2849321|NCT03603184|Placebo Comparator|Control arm|paclitaxel 175 mg/m2 + carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or PD. Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.
2849322|NCT03603171||DM2 group|Patients with Myotonic Dystrophy type 2 genetically confirmed, without limitation regarding age or disease onset.
2849323|NCT03603171||Healthy controls group|A group of gender and age-matched healthy controls.
2849324|NCT03603145|Experimental|Immediate insertion|Randomized to insertion within 48 hours of medical abortion
2849325|NCT03603145|No Intervention|Standard Insertion|Insertion at 2-4 weeks post medical abortion
2849326|NCT03603132|Active Comparator|Hetrombopag Olamine A|health subjects received 7.5 mg Hetrombopag Olamine while fasting.
2849327|NCT03603132|Active Comparator|Hetrombopag Olamine B|health subjects received a high-fat meal one hour after taking7.5 mg Hetrombopag Olamine
2849328|NCT03603132|Active Comparator|Hetrombopag Olamine C|health subjects received a high-fat meal two hours after taking7.5 mg Hetrombopag Olamine
2849329|NCT03603119|Active Comparator|Group A|Dexamethasone-ondansetron
2849330|NCT03603119|Experimental|Group B|Midazolam
2849331|NCT03603106|Experimental|Part I (Phase I)|In each dose group (0.025, 0.05, 0.075, 0.1, 0.2 and 0.3 mmol/kg), 9 healthy subjects were to be included: 6 subjects received P03277 and 3 subjects received placebo in one single intravenous administration.
2849332|NCT03603106|Experimental|Part II (Phase IIA)|In each dose group (0.05, 0.075, 0.1 and 0.2 mmol/kg), all 3 patients received one single intravenous administration of P03277.
2849333|NCT03603080|Experimental|Medication arm|
2849334|NCT03603080|No Intervention|No medication arm|
2849335|NCT03603067||monophthalmic group|The BCVA of the worse eye is less than 0.05 or CFOV is less than 5°. The better eye need to receive ocular surgery.
2849336|NCT03603067||Normal group|The BCVA of the worse eye is more than 0.3 and CFOV is more than 10°. One of two eyes need to receive ocular surgery.
2849337|NCT03603054|Active Comparator|Active neck mobilization|The subjects, who were randomly allocated to group active neurodynamic mobilization group, will receive the active sciatic nerve mobilization intervention. The subject will be instructed to do a a modification of the slump. The procedure will be performed 1 minute with each leg, two times, the subjects will rest one minute between each mobilization and between series.
2849338|NCT03603054|Experimental|Active Mobilization of the Sciatic nerve|The subjects, who were randomly allocated to group active neurodynamic mobilization group, will receive the active sciatic nerve mobilization intervention. The subject will be instructed to do a a modification of the slump. The procedure will be performed 1 minute with each leg, two times, the subjects will rest one minute between each mobilization and between series.
2849339|NCT03603041|No Intervention|Control|These participants will maintain their daily food and exercise routine and will receive no intervention.
2849340|NCT03603041|Experimental|Whey Protein Supplementation|Participants will receive protein supplementation daily for 16 weeks.
2849341|NCT03603041|Experimental|Omega-3 Fatty Acids (O3FA)|Participants will receive O3FA supplementation daily for 16 weeks.
2849342|NCT03603041|Experimental|Whey Protein and O3FA|Participants will receive protein and O3FA supplementation daily for 16 weeks.
2849343|NCT03603041|Placebo Comparator|Whey Protein and Placebo Fat Source|Participants will receive protein and placebo fat source supplementation daily for 16 weeks.
2849344|NCT03603028|Experimental|Exergaming|
2849345|NCT03603015|Other|Pilot group: urodynamics and cuff test|Single-arm study with all participants undergoing cystometrogram, then cystometrogram with simultaneous penile cuff test, then penile cuff test alone
2849346|NCT03603002|Experimental|Stage I NSCLC with SABR Therapy|Participants receive stereotactic ablative radiotherapy (SABR) and pre-SABR biopsy as part of standard of care and then receive a post-SABR biopsy after receiving SABR.
2849347|NCT03602976|No Intervention|Observation|
2849348|NCT03602976|Experimental|UDCA at Month 6|
2849349|NCT03602963||Dexcom G5 mobile CGM system|Children (6 to 18 years) with type 1 diabetes mellitus treated with insulin injections and wearing a FreeStyle Libre Flash glucose sensor that will switch to the Dexcom G5 mobile glucose monitoring system.
2849350|NCT03602950|No Intervention|Control group|50 diabetic ladies at full term will undergo elective CS and will receive the usual surgical care routinely done at our hospital
2849354|NCT03602898|Experimental|Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive anti-thymocyte globulin IV over 4-6 hours on days -3 to -1. Beginning day -1, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease progression or unacceptable toxicity.
2849355|NCT03602898|Experimental|Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning day 5, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50 in the absence of disease progression or unacceptable toxicity.
2849356|NCT03602898|Experimental|Arm 3 (tacrolimus or cyclosporine, methotrexate)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Beginning day -1, participants receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11.
2849357|NCT03602885|Experimental|Chemotherapy education intervention arm|Patients randomized to the chemotherapy education intervention (CEI) arm will be given regimen specific written and video chemotherapy educational materials developed by the study team. The treating oncologist will identify which chemotherapy regimen(s) are being considered, in order to select the appropriate chemotherapy educational tool(s) to give the patient. The patient may be given more than one CEI tool if they are considering more than one regimen. Patients randomized to the intervention arm may receive the intervention in addition to OR in place of the standard institutionally approved chemotherapy information sheets (both are acceptable); this is at the discretion of the treating site or the treating physician.
2849358|NCT03602885|Active Comparator|Usual chemotherapy education arm|Patients randomized to the usual chemotherapy education (CE) arm will undergo the standard institutional practice of chemotherapy education. The oncologist may also choose to give the patient the institutionally approved chemotherapy information sheets according to site-specific policies and clinical practice.
2849359|NCT03602872|Experimental|Group 1|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
2849360|NCT03602872|Experimental|Group 2|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
2849361|NCT03602872|Experimental|Group 3|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
2849362|NCT03602859|Placebo Comparator|Arm 1|Standard of care chemotherapy treatment with TSR-042 Placebo, and maintenance treatment of Niraparib Placebo and TSR-042 Placebo.
2849363|NCT03602859|Active Comparator|Arm 2|Standard of care chemotherapy treatment with TSR-042 Placebo, and maintenance treatment of Niraparib and TSR-042 Placebo.
2849364|NCT03602859|Experimental|Arm 3|Standard of care chemotherapy treatment with TSR-042, and maintenance treatment of Niraparib and TSR-042.
2849365|NCT03602846||Good Outcome|Good outcome is defined as the safe delivery of the newborn.
2849366|NCT03602846||Poor Outcome|Poor outcome is defined as the incidence of fetal demise during pregnancy.
2849367|NCT03602833|Experimental|Compound 451238|To assess the safety and tolerability of combining radiotherapy with compound 451238, treating advanced STS.
2849368|NCT03602807|Experimental|Active treatment|
2849369|NCT03602794|Active Comparator|PECs Block|"Total local anaesthetic dose: 30ml ropivacaine 0.5%~•Pecs block will be performed by anaesthetist using ultrasound guidance in plane approach: 10ml ropivacaine 0.5% will be delivered at the plane between pectoralis major and pectoralis minor, another 20ml ropivacaine 0.5% will be delivered in the plane between the pectoralis minor and serratus anterior muscles at the level of the third and fourth ribs"
2849370|NCT03602794|Placebo Comparator|Local Infiltration|LIA will be performed by surgeon during the operation. The upper skin flap will be raised in the standard manner for mastectomy. The lateral border of the major pectoralis muscle will then be visualised. A volume of 10 ml ropivacaine 0.5% will be delivered between the inter-fascial planes of the pectoral muscles. The lower skin flap will then be raised in the standard manner for mastectomy and the breast is raised off the pectoralis muscle exposing the serratus anterior muscle. A volume of 20 ml ropivacaine 0.5% will be delivered between the muscle planes of the serratus anterior and pectoralis minor muscles.
2849371|NCT03602781|Placebo Comparator|Cohort 1: Placebo 99.999% Nitrogen|"Randomized Withdrawal Treatment Period Week 1-8:~Placebo at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day~Long Term Open Label Extension Period:~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day"
2849372|NCT03602781|Active Comparator|Cohort 2: iNO 75 mcg/kg IBW/hr|"Randomized Withdrawal Treatment Period Week 1-8:~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day~Long Term Open Label Extension Period:~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day"
2849373|NCT03602768|Experimental|Goal Management Training|The online version of GMT with a therapist on the back-end monitoring progress and giving feedback throughout the program. Online GMT takes 5-9 weeks (self-paced) to complete 9 modules involving instructional video with interactive content, practice of cognitive strategies through games, and between-module exercises.
2849374|NCT03602768|Experimental|Memory & Aging Program|The online version of MAP with a therapist moderator on the course discussion pages. MAP takes 5-9 weeks (self-paced) to complete 8 modules involving instructional video with interactive content and practice of memory strategies through various exercises.
2849375|NCT03602768|Placebo Comparator|BrainHQ Training|This is a commercial brain training platform, with a course designed for memory and attention that can be completed at participants' own pace. Involves a number of short games that are advertised to train cognitive faculties.
2849376|NCT03602768|No Intervention|Waitlist|Participants randomized to this arm will receive no additional information or access to intervention programs until after the follow up testing measures are collected, at which point they will be given access to the intervention of their choosing.
2849377|NCT03602755||Patients with newly diagnosed transplant-ineligible MM|Adult Patients with newly diagnosed MM who were not suitable candidates for ASCT who started first-line treatment for the study disease in a routine clinical practice setting between 2012 and 2016, inclusive.
2849548|NCT03601559|Placebo Comparator|Placebo|Inert placebo
2849378|NCT03602742|Other|24-hour Holter and 14-day EZYPRO®|This is an open-label study to investigate the functional features of prolonged monitoring by 14-day EZYPRO® to improve the medical care and/or diagnosis for the patient with arrhythmia. One arm included.
2849379|NCT03602729|No Intervention|Group 1|No study related education given
2849380|NCT03602729|Experimental|Group 2|Written BF education
2849381|NCT03602729|Experimental|Group 3|Verbal BF education
2849382|NCT03602729|Experimental|Group 4|Video BF education
2849383|NCT03602716|Experimental|HD-tDCS group|This HD-tDCS group will be stimulated by active HD-tDCS.
2849384|NCT03602716|Sham Comparator|Sham HD-tDCS group|This sham HD-tDCS group will have a sham stimulation with HD-tDCS.
2849385|NCT03602703||chronic HCV|chronic HCV either treated or not with DAAs.Flow cytometry and Western Blot analysis for each subgroup
2849386|NCT03602703||Liver cirrhosis without HCC|Liver cirrhosis without HCC either received treatment or not.Flow cytometry and Western Blot analysis for each subgroup
2849387|NCT03602703||Liver cirrhosis with HCC|Liver cirrhosis with HCC either received treatment or not.Flow cytometry and Western Blot analysis for each subgroup
2849388|NCT03602690|Experimental|Dolutegravir + Darunavir/ritonavir + optimized NRTI|"All patients will receive ART regimen every day including:~Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)"
2849389|NCT03602677|Experimental|ICG fluorescence imaging|Colorectal surgery and anastomosis will be performed according to standard practice with the addition of intraoperative indocyanine green fluorescence imaging.
2849390|NCT03602677|No Intervention|Standard procedure|Standard colorectal surgery and anastomosis.
2849391|NCT03602664||Thoracic surgery|Patients undergoing thoracic surgery
2849392|NCT03602651||MAGZEN®|All patient will be treated with MAGZEN® and will be evaluated with the Hamilton-anxiety scale (HAM-A)
2849393|NCT03602638|Experimental|Sitagliptin|
2849394|NCT03602638|Active Comparator|CONTROL|Acarbose
2849395|NCT03602625||Preterm group|All the live-born infants with gestational age less than 37weeks and more than 20weeks born in the cooperative hospital every day or every two or three days.
2849396|NCT03602625||Term group|The one next-live-born infants with gestational age at 37weeks or more than 37weeks.
2849397|NCT03602612|Experimental|1/Arm 1|Patients will receive escalating doses (up to 5 planned) of CAR+ T cells infused on day 0 + Cyclophosphamide: 300 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg /m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
2849398|NCT03602612|Experimental|2/ Arm 2|MTD dose of CAR T Cells + Cyclophosphamide: 300 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
2849399|NCT03602599||New Transplant Cohort|"(Cohort NT; approximate n=300) consists of patients who are scheduled to undergo allogeneic HSCT (under another protocol at the NIH)."
2849400|NCT03602599||Prior Transplant Cohort|"(Cohort PT; approximate n=100) consists of patients who have already undergone allogeneic HSCT."
2849401|NCT03602599||Healthy-controls Longitudinal Cohort|"(Cohort HL; approximate n=20) includes subjects who will participate in up to the full set of 8 study visits across 3 years."
2849402|NCT03602599||Healthy-controls Short-term Cohort|"(Cohort HS; approximate n=80) will participate in a single baseline visit."
2849403|NCT03602586|Experimental|Treatment (epacadostat, pembrolizumab)|Participants receive epacadostat PO BID and pembrolizumab IV over 30 minutes Q3W. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2849404|NCT03602573||pre-menopause|
2849405|NCT03602573||post-menopause|
2849406|NCT03602560|Experimental|Seladelpar 5-10 mg|
2849407|NCT03602560|Experimental|Seladelpar 10 mg|
2849408|NCT03602560|Placebo Comparator|Placebo|
2849409|NCT03602547|Experimental|CM082 plus JS001|Patients who meet the enrollment criteria will receive CM082 tablets 200mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks, q2w), every 28 days A treatment cycle until the disease progresses, the toxicity is intolerable, the investigator or subject decides to withdraw, loses to follow up, starts using other anti-tumor treatments or dies.
2849410|NCT03602534||cases with variable acne severity scores|"group will include 50 females~Clinical examination including acne grade assessment using Global Acne Grading Scale (GAGS)~Assessment of body mass index (BMI)~blood serum samples will be collected from all patients to do thyroid function test"
2849411|NCT03602534||healthy controls|"group will include 29 females~Assessment of body mass index (BMI)~blood serum samples will be collected from all healthy controls to do thyroid function test"
2849412|NCT03602521|Experimental|BPD|Blood sample After simulating an interpersonal stress, the evolution of plama neuropeptides level (OXT, vasopressin and opioid) of patients with a BPD
2849413|NCT03602521|Active Comparator|HC|Blood sample After simulating an interpersonal stress, the evolution of plama neuropeptides level (OXT, vasopressin and opioid) of healthy controls (HC) patients .without any history of psychopathology
2849414|NCT03602508||mirabegron|Patients on mirabegron as prescribed by a physician in routine clinical practice.
2849415|NCT03602508||antimuscarinics|Patients on one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine as prescribed by a physician in routine clinical practice.
2849416|NCT03602495|Experimental|Donafenib|Donafenib 300mg bid for each 28 days cycle.
2849417|NCT03602495|Placebo Comparator|Placebo|Placebo 300mg bid for each 28 days cycle.
2849418|NCT03602482|Experimental|Standing|Participants will complete cognitive testing while standing.
2849419|NCT03602482|Active Comparator|Supine|Participants will complete cognitive testing while supine.
2849420|NCT03602469|Experimental|Bupivacaine|Ultrasound-guided suprascapular nerve block using bupivacaine will be performed before induction of general anesthesia
2849421|NCT03602469|Active Comparator|Bupivacaine-magnesium|Ultrasound-guided suprascapular nerve block using bupivacaine in conjunction of magnesium sulfate will be performed before induction of general anesthesia
2849549|NCT03601546||Patients with HCV infection|
2858189|NCT03540940|Experimental|zero positive end expiratory pressure|
2849422|NCT03602456||Kentucky HEALTH|This group will consist of 90% of eligible beneficiaries who will receive Kentucky HEALTH benefits throughout the 5-year demonstration waiver.
2849423|NCT03602456||Traditional Medicaid (control)|This group will consist of 10% of eligible beneficiaries who will continue receiving traditional Medicaid benefits as in place before July 1, 2018 throughout the 5-year demonstration waiver.
2849424|NCT03602443|Experimental|Experimental|This group will receive the LSVT(R)BIG Intervention first (4 weeks) and then cross over to the Waitlist Control (no intervention for 4 weeks).
2849425|NCT03602443|Other|Waitlist Control|This group will receive the Waitlist Control (4 weeks) and then cross over to receive the LSVT(R)BIG Intervention (4 weeks).
2849426|NCT03602430|Experimental|Drug Group|twenty-five patients will receive 200.000 IU/month native vitamin D; (Cholecalciferol) orally in addition to their standard treatment for 3 months period
2849427|NCT03602430|Placebo Comparator|Placebo Group|twenty-five patients will receive a placebo ampule with their standard treatment for 3 months period.
2849428|NCT03602417|Experimental|Flare type stent|Flare type stent (Taewoong medical) has a wide diameter at proximal end to prevent stent migration.
2849429|NCT03602417|Active Comparator|Conventional D-type stent|Conventional D-type (Taewoong medical) stent has a same diameter at both ends.
2849430|NCT03602404||St. Petersburg: School aged children|Generally healthy 9 to 12 years old children
2849431|NCT03602404||St. Petersburg: Women of reproductive age|Generally healthy non-pregnant, non-lactating women between 18 and 44 years of age
2849432|NCT03602404||Marrakesh: School aged children|Generally healthy 9 to 12 years old children
2849433|NCT03602404||Marrakesh: Women of reproductive age|Generally healthy non-pregnant, non-lactating women between 18 and 44 years of age
2849434|NCT03602391|Experimental|SCP Plus|
2849435|NCT03602391|No Intervention|Services as usual|
2849436|NCT03602378||Parents of children with disability|parents of children with developmental disabilities (Down syndrome, autism spectrum disorder, pervasive developmental disorder, cerebral palsy), age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
2849437|NCT03602378||Parents of children with chronic disease|parents of children chronic disease (diabetes mellitus type 1, epilepsy, asthma), age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
2849438|NCT03602378||Parents of healthy children|parents of healthy children, age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
2849439|NCT03602365|Experimental|OXYGEN CONSUMPTION SINGLE ARM|Single arm Study Volunteer will h lie in supine posture for 20 min and oxygen consumption(VO2) will be measured in duplicate. Gentle Jogger (GJ) will be started in supine posture for 20 min and VO2 measured again in duplicate. The subject will be asked to sit in a chair for 20 min and VO2 will be measured in duplicate. Gentle Jogger (GJ) will be started in seated posture for 20 min and VO2 measured again in duplicate.
2849440|NCT03602339|Experimental|Arm 1_Suspected CNS-lesion|Patients with suspected or confirmed CNS-lesions will undergo unenhanced MRI, and contrast-enhanced MRI after gadoterate injection.
2849441|NCT03602339|Experimental|Arm 2_Confirmed CNS-lesion|Patients with gadoterate-confirmed CNS-lesions (subgroup of Arm 1) will undergo a second unenhanced MRI, and contrast-enhanced MRI after gadobutrol injection.
2849442|NCT03602326|Experimental|Neurodevelopmental Therapy-Bobath group|Bobath Approach Principles and exercises will be performed 5 days a week with physical therapists and everyday with caregivers. Physiotherapy will be initiated as early as possible according to the principles of the method by experienced NDT-B therapists. Exercises will be implemented according to the patients' status and will be used to maintain and improve muscle strength and endurance. Both the unaffected and affected side will be included in rehabilitation. The exercises given are designed to be simple, understandable, task-oriented and repetitive, in accordance with the Bobath approach and the functional state of the patient at that time. In order to prevent motor amnesia and neglect of the affected side, correct positioning and sensory input will be provided since the first session.
2849443|NCT03602326|Active Comparator|Standart Rehabilitation Group (SR group)|Patients will be included in standard rehabilitation sessions, 5 days per week. The rehabilitation sessions will be performed by standard clinical physiotherapists according to the hospital routine. The rehabilitation program will consist of in-bed joint range of motion exercises and bedside mobilization applications. The patients will be included in the rehabilitation program as early as possible and the program will continue until the patients are discharged
2849444|NCT03602313|Active Comparator|Traditional Gait Training|The Traditional Gait Training group will receive gait training as presently performed without additional modalities.
2849445|NCT03602313|Experimental|Body Weight Support Training|The Body Weight Support group will received body weight support gait training in lieu of traditional gait training.
2849446|NCT03602300|Active Comparator|Ravidasvir reference formulation|Ravidasvir 200 mg oral single dose manufactured by EEPI
2849447|NCT03602300|Experimental|Ravidasvir test formulation|Ravidasvir 200 mg oral single dose manufactured by Doppel
2849448|NCT03602287|Active Comparator|2% lignocaine|In the Lignocaine group, 2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the Merocel pack 15 minutes before removal of the pack. Nothing will be done to the opposite nostril, which would act as a control.
2849449|NCT03602287|Placebo Comparator|Normal saline|In the Normal saline group, 5 ml of normal saline was injected into the Merocel pack 15 minutes before removal of the pack. Nothing will be done to the opposite nostril.
2849450|NCT03602274||orthopedic and visceral surgery patients|patient having been subjected to an intervention from the orthopedic or visceral surgery department being prescribed 4 g paracetamol / day
2849451|NCT03602274||Overdosed patients|Patent admitted to hospital with paracetamol overdoses
2849452|NCT03602261|Active Comparator|CTAP101 Capsules 300mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 300mcg/weekly for 26 weeks
2849453|NCT03602261|Active Comparator|CTAP101 Capsules 600mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 600mcg/weekly for 26 weeks
2849454|NCT03602261|Active Comparator|CTAP101 Capsules 900mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 900mcg/weekly for 26 weeks
2849455|NCT03602261|Placebo Comparator|Placebo Capsules weekly|Placebo Oral Capsules/weekly for 26 weeks
2854612|NCT03566186|Other|non-treatment control group|(n=13) Phase 2 training + control group
2849456|NCT03602248|Experimental|Speed endurance training protocol A|"Performance of two different speed endurance training protocols:~Speed endurance training protocol A will consist of 1 set of 8 repetitions interspersed by 2,5 minutes of recovery with a work to rest ratio of 1:5 (25-30 seconds all out work)."
2849457|NCT03602248|Experimental|Speed endurance training protocol B|Speed endurance training protocol B will consist of 1 set of 8 repetitions interspersed by 4 minutes of recovery with a work to rest ratio of 1:8 (25-30 seconds all out work)
2849458|NCT03602248|No Intervention|Control condition|No training protocol will be performed, the participants will perform only the measurements for performance and muscle damage and neuromuscular fatigue
2849459|NCT03602235|Experimental|Low dose melphalan + high dose ascorbate acid (HDAA)|"Patients will receive a test dose of 15g of HDAA prior to starting treatment dose. This will be mainly to rule out allergic reactions.~HDAA + Melphalan:~HDAA on day 1 and day 4 in combination with melphalan 12.5 mg/m2, followed by 2 additional doses of HDAA on day 2 and day 5.~A 3 + 3 cohort method will be used for this study. After successfully completing the test dose, subjects will receive 50gms, 75gms and 100gms of ascorbate per infusion in 3 different cohorts. Dose modifications are not made for weight or body surface area."
2849460|NCT03602222|Active Comparator|In-person training LGBT mental health|In-person training LGBT mental health: Participants randomized to the in-person condition will receive training in LGBT-affirmative mental health counseling face-to-face.
2849461|NCT03602222|Experimental|Mobile training LGBT mental health|Mobile training LGBT mental health: Participants randomized to the mobile training condition will receive training in LGBT-affirmative mental health counseling while on the web.
2849462|NCT03602209|Experimental|4 weeks of treatment|
2849463|NCT03602209|Active Comparator|6 weeks of treatment|
2849464|NCT03602196|Experimental|pregnant women|pregnant women with one visit per trimester of pregnancy (14-18 weeks, 24-28 weeks and 34-38 weeks)
2849465|NCT03602183|Experimental|Normal airway without chest compressions|intubation without chest compressions during procedure
2849466|NCT03602183|Experimental|Normal airway with uninterrupted chest compressions|intubation with uninterrupted chest compressions. Chest compressions will be performed using mechanical chest compression device with the chest compressions rate 100-120/min and depth - 5cm in the continous mode.
2849467|NCT03602170|Experimental|High-Intensity Interval Training|8 weeks of high-intensity interval training. Three sessions per week will be performed (24 total sessions).
2849468|NCT03602170|Active Comparator|Moderate-Intensity Continuous Training|8 weeks of moderate-intensity continuous training. Three sessions per week will be performed (24 total sessions).
2849469|NCT03602157|Experimental|ATLCAR.CD30.CCR4 & ATLCAR.CD30|A 3+3 design in adult subjects. Subjects in the first dose level will receive ATLCAR.CD30.CCR4 cells alone, once safety has been established, the initial dose of ATLCAR.CD30.CCR4 will be combined with a fixed dose of ATLCAR.CD30 cells in the next dose level. Every time the dose of ATLCAR.CD30.CCR4 is escalated, subjects in that dose level will receive ATLCAR.CD30.CCR4 alone prior to subsequent dose level enrolling subjects to receive a combination of fixed dose ATLCAR.CD30 and the selected dose level of ATLCAR.CD30.CCR4. The six dose levels will consist of: dose level 1 = 2 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 2 = 1 × 10^8 ATLCAR.CD30 cells/m2 and 2 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 3 = 5 × 10^7/m2 ATLCAR.CD30.CCR4 cells/m2; dose level 4 = 1 × 10^8 ATLCAR.CD30 cells/m2 and 5 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 5 = 1 × 10^8/m2 ATLCAR.CD30.CCR4 cells/m2; dose level 6 = 1 × 108 ATLCAR.CD30 cells/m2 and 1 × 108 ATLCAR.CD30.CCR4 cells/m2.
2849470|NCT03602144|Active Comparator|Carbohydrate|Participants will receive a carbohydrate-based smoothie every morning for 6 weeks (42 days).
2849471|NCT03602144|Experimental|Protein|Participants will receive a protein-based smoothie every morning for 6 weeks (42 days).
2849472|NCT03602131|Experimental|ChiCGB|Treated with chidamide, cladribine, gemcitabine and busulfan(ChiCGB) therapy followed by autologous hematopoietic stem cell transplantation.
2849473|NCT03602118|Active Comparator|Phenobarbital Sodium Injection 20 mg|Once participants are deemed to be eligible for participation in the study and randomized to the lower dose they will be given a loading dose of phenobarbital 20 mg/kg administered intravenously over the course of 30 minutes.
2849474|NCT03602118|Active Comparator|Phenobarbital Sodium Injection 40 mg|Once participants are deemed to be eligible for participation in the study and randomized to the higher dose they will be given a loading dose of phenobarbital 20 mg/kg administered intravenously over the course of 30 minutes. ministered intravenously over the course of 30 minutes.
2849475|NCT03602105|Active Comparator|Intervention group|Exercise interventions for 6-12 weeks. Adherence is monitored with day journals
2849476|NCT03602105|No Intervention|Control group|Care as usual
2849477|NCT03602079|Experimental|Phase I: Dose Escalation|Six dose levels have been selected for evaluation in the Phase I part of the study: 0.3, 0.6, 1.2, 2.4, 3.6, and 4.8 mg/kg of A166
2849478|NCT03602079|Experimental|Phase II: • Cohort 1|HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) breast cancer. Treatment with A166 at recommended Phase II dose.
2849479|NCT03602079|Experimental|Phase II: • Cohort 2|HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) gastric cancer. Treatment with A166 at recommended Phase II dose.
2849480|NCT03602079|Experimental|Phase II: • Cohort 3|HER2 low expressing (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) breast cancer. Treatment with A166 at recommended Phase II dose.
2849481|NCT03602079|Experimental|Phase II: • Cohort 4|All cancers other than breast cancer with low HER2 expression (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) and HER2 positive (IHC2+ with FISH confirmation and Immunohistochemistry (IHC) 3+) cancers other than breast and gastric cancer. Treatment with A166 at recommended Phase II dose.
2849482|NCT03602066|Experimental|Arm I (chlorine dioxide sterilization)|Patients receive chlorine dioxide sterilization oral rinse over 30 seconds BID from the start of RT to the evening prior to the 1 month RT follow-up appointment.
2849483|NCT03602066|Placebo Comparator|Arm II (placebo)|Patients receive placebo oral rinse over 30 seconds BID from the start of RT to the evening prior to the 1 month RT follow-up appointment.
2849550|NCT03601533|Other|Phenol|Patients will undergo neurolysis of genicular nerves with 1,5 mL of 7% phenol in each of the genicular nerves (superior, medial and lateral).
2849484|NCT03602053|Experimental|ROTAVAC 5CM|Bharat Biotech International Ltd's new Rotavirus vaccine, ROTAVAC 5CM is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. 5CM is in liquid form.
2849485|NCT03602053|Experimental|ROTAVAC®|Bharat Biotech International Ltd's licensed rotavirus vaccine, ROTAVAC® is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. ROTAVAC® is in frozen form and is thawed till fully liquid prior to administration.
2849486|NCT03602053|Active Comparator|Rotarix®|GSK Biologicals' licensed rotavirus vaccine, Rotarix® is a live attenuated RIX4414 strain of human rotavirus of the G1P[8] type containing not less than 106.0 CCID50 (cell culture infectious dose 50%) of the RIX 4414 strain of human rotavirus.
2849487|NCT03602040|Experimental|PISICC group|Psychoeducational intervention
2849488|NCT03602027|Experimental|Anlotinib Plus Gefitinib|"This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day and Gefitinib. middle-dose groups: Anlotinib 10mg per day and Gefitinib. high-dose groups: Anlotinib 12mg per day and Gefitinib.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any dose group, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any dose group, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
2849489|NCT03602014|Experimental|Study 1: Dose Optimization of Northera|Subjects will be administered oral droxidopa in a dose escalation, open-label manner beginning with 200 mg. The dose will be adjusted upwards by 100 mg on subsequent visits until average Systolic Blood Pressure (SBP) recorded 60-120 minutes after dose administration is 111-139 mmHg in males and 101-139 mmHg in females, sustained elevation (≥ 30 consecutive minutes) in seated SBP ≥ 140/100 mmHg, maximum dose of 800 mg is reached without adequate SBP response. Subjects will visit the testing laboratory on as few as 1 (200 mg) and as many as 7 (800 mg) days. Seated cardiovascular assessments will be monitored and recorded at 15-minute intervals for 4-hours, and the side effects questionnaire will be administered hourly during the 4-hour study. Each study visit will take about 5 hours.
2849490|NCT03602014|Placebo Comparator|Study 2: Blinded Placebo & Northera|Participants will then be administered either oral optimal dose of Northera (Droxidopa) or matching placebo in a double-blinded manner and will remain in the supine position for 60 minutes. Subjects will remain in their wheelchair for instrumentation, which will include: 1) ECG, 2) brachial BP, 3) finger arteriolar BP and 4) Cerebral Blood Flow velocity (CBFv).
2849491|NCT03602001|Experimental|attentive eating smartphone app group|Participant's received the intervention 'Attentive eating smartphone application'. This is a smartphone application that encourages a more attentive eating style. Participants also received the 'Standard dietary advice and text tips' intervention. This consists of a standard dietary advice booklet, and weekly dietary advice tips by text message.
2849492|NCT03602001|Active Comparator|control group|Participants received the 'Standard dietary advice and text tips' intervention. This consists of a standard dietary advice booklet, and weekly dietary advice tips by text message.
2849493|NCT03601988|Active Comparator|Chemotherapy|Adjuvant chemotherapy group receive 8 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1,capecitabine 1000mg po, Bid, D1-14, Q21D)
2849494|NCT03601988|Experimental|Chemo-radiotherapy|Adjuvant chemo-radiotherapy group receive 6 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1, capecitabine 1000mg po, Bid, D1-14, Q21D) and concurrent chemo-radiotherapy (capecitabine 825mg po, Bid, d1-5, QW)
2849495|NCT03601975|Experimental|anlotinib plus Gemcitabine/Cisplatin|patients receive anlotinib at 12mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
2849496|NCT03601975|Placebo Comparator|placebo plus Gemcitabine/Cisplatin|patients receive pacebo at 0mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
2849497|NCT03601962|Experimental|Aqualief® tablets|oral mucoadesive tablets
2849498|NCT03601962|Placebo Comparator|Placebo tablets|oral mucoadesive tablets
2849499|NCT03601949|Experimental|SInergy Cooled Radiofrequency|Halyard Health SInergy Cooled Radiofrequency in addition to standard medical management
2849500|NCT03601949|Active Comparator|Medical Management|Standard Medical Management
2849501|NCT03601936|Other|Infants less than 6 months of age|The Evivo Infant Gut Bifidobacterium Screening Test study is a single-group interventional study of 600 female and male infants who are less than 6 months of age and generally healthy.
2849502|NCT03601923|Experimental|Niraparib|"Niraparib will be administered orally once daily~Palliative radiation therapy to a small field >1 week prior to Day 1 of study treatment"
2849503|NCT03601910|Experimental|A group|"Period 1: D308 10mg Tab. 1T~Period 2: CKD-380 10mg Tab. 1T"
2849504|NCT03601910|Experimental|B group|"Period 1: CKD-380 10mg Tab. 1T~Period 2: D308 10mg Tab. 1T"
2849505|NCT03601897|Experimental|50 mg rebastinib Arm|50 mg BID of rebastinib orally (PO) in combination with paclitaxel administered by IV infusion at 80 mg/m2 in repeated 28-day cycles.
2849506|NCT03601897|Experimental|100 mg rebastinib Arm|100 mg BID of rebastinib orally (PO) in combination with paclitaxel administered by IV infusion at 80 mg/m2 in repeated 28-day cycles. If 100 mg BID is deemed intolerable, a cohort of 75 mg BID in combination with paclitaxel will be initiated
2849507|NCT03601884|Experimental|OHP and Treatment as usual (TAU)|"Optimal Health Program (OHP) A self-management program that promotes patients to be actively involved in their own healthcare and overall well-being through enhancing self-efficacy.~Treatment is delivered by a trained facilitator in OHP. The OHP is delivered in groups of 8 to 10 participants It consists of 5 weekly, 1.5 hour sessions and an additional booster session post-program at 3 months a The group facilitator will contact the participants by phone at 8 weeks and 16 weeks.~Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
2849508|NCT03601884|Other|TAU Alone|"Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
2849509|NCT03601871|Active Comparator|Control group|Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.
2849510|NCT03601871|Experimental|Thalidomide group|Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.
2849511|NCT03601845|Other|MRE-IA (no stimuli)|Additional sequencing only
2849512|NCT03601845|Active Comparator|MRE-IA with stimuli|Visual stimulation while using additional sequencing
2849513|NCT03601832|Experimental|4-D navigated stereotactic radiosurgical ablation|The patients enroled to this arm of the study will undergo 4-D navigated stereotactic radiosurgical ablation.
2849514|NCT03601819|Experimental|Pacritinib|200 mg twice daily
2849515|NCT03601806|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2849516|NCT03601793|Experimental|Internet intervention with assistance|This arm is given access to the internet intervention Alcohol Help Center with email assistance from a health educator during the first two weeks after randomization.
2849517|NCT03601793|Active Comparator|Internet intervention without assistance|This arm is given access to the internet intervention Alcohol Help Center without any assistance from a health educator.
2849518|NCT03601780|Active Comparator|Local wound infiltration|local wound infiltration plus usual care
2849519|NCT03601780|Placebo Comparator|Control|usual care only
2849520|NCT03601754|Experimental|Closed Loop Stimulation (CLS)|Prior to enrollment, the patient would have received Biotronik pacemaker with His bundle lead placement for at least 30 days and CLS will be programmed ON for at least 7 days as part of routine care.
2849521|NCT03601741|Active Comparator|Antimicrobial Stethoscope Diaphragm Covers|
2849522|NCT03601741|Active Comparator|Uncovered Stethoscopes|
2849523|NCT03601728|Experimental|Enhanced Monitoring Program|Four weeks prior to the scheduled (elective) surgery, participants will receive a 60-minute in person education session how to increase the level of physical activity. This will be followed by 4 weeks of keeping this level of physical activity, which will be monitored and supported by personalized interactive prompts delivered by a smartwatch. This approach is called personalized prehabilitation.
2849524|NCT03601728|No Intervention|Regular Monitoring Program|Participants randomized to this arm will receive standard perioperative care.
2849525|NCT03601715|Active Comparator|Coplanar|Electrode placed side by side on the same aspect of the right tight.
2849526|NCT03601715|Active Comparator|Contraplanar|Electrode placed over opposite aspects of the right tight.
2849527|NCT03601715|Active Comparator|Longitudinal|One electrode is placed at each end of the limb in opposite aspects of the tight.
2849528|NCT03601702||EmboTrap ® II Device|The study group consists of the patients with acute ischemic stroke from large vessel occlusion treated with EmboTrap ® II Device (Neuravi)
2849529|NCT03601676|Active Comparator|Intervention|
2849530|NCT03601676|No Intervention|Control|
2849531|NCT03601663|Experimental|Group 1|Participants in the main experimental group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity, a wearable activity tracker to support self-monitoring, and autonomy-support delivered through weekly emails to help enhance motivation for physical activity.
2849532|NCT03601663|Active Comparator|Group 2|Participants in this comparison group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity, and a wearable activity tracker to support self-monitoring. They will not receive any specific support to enhance motivation for physical activity.
2849533|NCT03601663|Active Comparator|Group 3|Participants in this information-only comparison group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity.
2849534|NCT03601650|Experimental|Mindful eating|Participants will be encouraged to focus on the sensory properties of their food every time they eat. This will be achieved via an audio recording that they will listen to in the laboratory at their first appointment and that they will have access to over the three-day intervention period. They will also receive a pack of envelopes to open over the intervention period that will also contain reminders to focus on the sensory properties of their food every time they eat.
2849535|NCT03601650|Active Comparator|Eating without distractions|Participants will be encouraged to eat their food without distractions every time they eat. This will be achieved via an audio recording that they will listen to in the laboratory at their first appointment and that they will have access to over the three-day intervention period. They will also receive a pack of envelopes to open over the intervention period that will also contain reminders to eat their food without distractions every time they eat.
2849536|NCT03601650|No Intervention|No strategy control|Participants will simply complete the measures
2849537|NCT03601637|Experimental|Part A Cohort 1 [aged 18 to <24 months]|Subjects will receive LUM/IVA as FDC granules dependent upon weight at Day 1.
2849538|NCT03601637|Experimental|Part A Cohort 2 [12 to <18months]|Subjects will receive LUM/IVA as FDC granules dependent upon weight at Day 1.
2849539|NCT03601637|Experimental|Part B|Subjects will receive LUM/IVA as FDC granules dependent upon weight at Day 1.
2849540|NCT03601624|Experimental|Experimental|"Pomalidomide at 4 mg orally on days 1-21 of a 28 day cycle~Cyclophosphamide 300 mg IV on days 1 and 15 of a 28 day cycle.~Dexamethasone 40 mg PO weekly.(Or 20 mg if patients are older than 75 years )"
2849541|NCT03601611|Experimental|Experimental|Tocilizumab 8 mg/kg is to be given as an IV infusion over 60 minutes every 4 weeks (Q4W).
2849542|NCT03601598|Experimental|SHR-1210 + SHR6390|SHR-1210 was administered 200mg iv every 2 weeks in combination with SHR6390 150mg or 100mg oral daily with 3 weeks on and 1 week off
2849543|NCT03601585|Experimental|Rolly Brush|Chew for 1 minute
2849544|NCT03601585|Experimental|Chewing gum|Chew for 1 minute
2849545|NCT03601585|Experimental|Apple|Chew for 1 minute
2849546|NCT03601585|Active Comparator|Brush|brush for 1 minute
2849547|NCT03601559|Active Comparator|Lactobacillus paracasei Lpc-37|Probiotic
2849551|NCT03601507|Experimental|Treatment (Alpelisib)|Participants receive Alpelisib PO QD for 14-21 days in the absence of disease progression of unacceptable toxicity and then undergo surgery. Participants may receive Alpelisib for up to 28 days if surgery is delayed.
2849552|NCT03601494|Active Comparator|Intervention|peri-neural platelet rich plasma injection under ultrasound guidance in addition to medical treatment.
2849553|NCT03601494|Placebo Comparator|Control|medical treatment only
2849554|NCT03601455|Experimental|Regimen A (radiation therapy and durvalumab)|Participants receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Participants also undergo EBRT for 5 fractions beginning on day 8 of course 1.
2849555|NCT03601455|Experimental|Regimen B (radiation therapy, durvalumab, tremelimumab)|Participants receive tremelimumab IV over 60 minutes on day 1 for up to 2 courses and durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression of unacceptable toxicity. Participants also receive undergo EBRT for 5 fractions beginning on day 8 of course 1.
2849556|NCT03601429|Experimental|Lactogyn|1 capsule of Lactogyn 2 times daily for the first 7 days then 1 time daily for 4 months
2849557|NCT03601429|Placebo Comparator|Placebo|1 capsule of Placebo Comparator 2 times daily for the first 7 days then 1 time daily for 4 months
2849558|NCT03601416|Experimental|Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be given to participants with refractory pulmonary diseases.
2849559|NCT03601416|Active Comparator|No Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be not given to participants with refractory pulmonary diseases.
2849560|NCT03601403|No Intervention|CONTROL GROUP|Received the standard medical and pharmacological care provided by the hospital
2849561|NCT03601403|Experimental|Inhaler technique|The intervention group received the standard medical and pharmacological care provided by the hospital. In addition, a tablet-assisted training on the use of inhalers, which included an explanation of the use of inhalers together with a ventilatory re-education program.
2849562|NCT03601390||PET/CT and EBV DNA|NPC patients after chemoradiotherapy (induction and/or Concurrent chemoradiotherapy). PET/CT and EBV DNA will be proformed 12 weeks after IMRT
2849563|NCT03601390||control group|NPC patients after chemoradiotherapy (induction and/or Concurrent chemoradiotherapy). MR, X-ray, B-ultrasonography will be proformed 24 weeks after IMRT
2849564|NCT03601377|Experimental|Training away from threat|"Experiment 1 and 2: In the intervention group -training away from threat-, in all angry-neutral faces presentation the probe is presented only after neutral face. Probe type (< or >) is not factorially counterbalanced but there is equal possibility of presentation for each of the following: angry-face location, probe location, or actor.~Experiment 1: received 8 times (2 times per week for 4 weeks) Experiment 2: received 4 times (2 times for 2 weeks)"
2849565|NCT03601377|Experimental|Training towards threat|"Only for Experiment 2: The second ABMT condition -training towards threat- is identical to the first one with the exception that in all angry-neutral face presentations the symbol is presented only after threat face. In addition, at the beginning of every session participants will be informed that a random number of participants will have to repeat their speech. They will also be informed that this instruction will be given right after the dot probe task completion. This will be done in order for the participants to maintain their state anxiety but repetition of the speech task will not actually happen at this stage.~Experiment 2: received 4 times (2 times for 2 weeks)"
2849566|NCT03601377|Placebo Comparator|Placebo|"Experiment 1 and 2: In the placebo group, angry-face location, probe location and actor are fully counterbalanced with regards to their presentation.~Experiment 1: received 8 times (2 times per week for 4 weeks) Experiment 2: received 4 times (2 times for 2 weeks)"
2849567|NCT03601364||Group 1|"Mechanical ventilator closed group (Mechanical ventilator off)~FiO2; 50%, Flow: 2 L / min."
2849568|NCT03601364||Group 2|"Tidal Voltage 3-4ml / kg (TV),~FIO2 50%, Flow: 2L / min,~Frequency; 10-12 applied group."
2849569|NCT03601364||Group 3|"1. PEEP: 5 cm H2O basınç,~Tidal Voltage 3-4ml / kg (TV),~FIO2 50%, Flow: 2L / min,~Frequency; 10-12 applied group."
2849570|NCT03601351||TT|Tumor Tissue. Colon or rectum neoplasia stage II and III tumor tissue.
2849571|NCT03601351||NTT|Nontumorous Tissue. Colon or rectum neoplasia stage II and III adjacent nontumorous tissue.
2849572|NCT03601338|Active Comparator|Bemiparin group|"Women with high resistant index of umbilical artery received the intervention Bemiparin Sodium 2,500 IU anti Xa/0.2 ml solution for injection in pre-filled syringe provided for each woman . The injections were received daily since 20 weeks gestation and up to 24 hours before delivery~Other Name: Hibor; Laboratories Rovi pharmaceuticals"
2849573|NCT03601338|Placebo Comparator|control group|Normal umbilical arty resistant index group received only multivitamins and routine antenatal follow up
2849574|NCT03601312|Active Comparator|Treatment-As-Usual|Individuals receiving treatment as usual will be receiving exposure and response prevention (ERP), the standard of care for pediatric OCD.
2849575|NCT03601312|Experimental|OC-Go|Individuals in the OC-Go group will be receiving exposure and response prevention (ERP) augmented by the OC-Go application.
2849576|NCT03601299|Experimental|Traditional food arm|Traditional food-focused menu
2849577|NCT03601299|No Intervention|Non-intervention arm|Standard RurAL CAP menu
2849578|NCT03601286|Experimental|Lentiviral vector transduced CD34+ cells|Single arm, non-randomised cohort of up to 5 patients with X-linked Severe Combined Immunodeficiency. CD34+ cells will be collected via bone marrow harvest or leukapheresis. The collected cells will then be purified, cultured and transduced with the G2SCID lentiviral vector. Transduced cells will be frozen. A minimum of 2.5 x 106/kg CD34+ cells after transduction with a minimum transduction efficiency of 0.7 copies/cell is required for infusion into the patient. The patient will receive non-myeloablative conditioning with intravenous busulfan the two or three days prior to cell infusion. The frozen cells will be thawed on the day of infusion and the cells administered according to hospital procedures. The patient will remain in hospital until sufficient cover of the patient's immune system
2849579|NCT03601260|Other|Gout Patients|Allopurinol 100 mg-300mg/day as secondary treatment in gout patients
2849580|NCT03601247|Other|All patients|Split-face study: patients undergoing bilateral eye surgery will have the sides of their face randomized to receive either placebo or silicone gel.
2849581|NCT03601234|Experimental|laparoscopic surgery|This is a kind of traditional surgical method.only use laparoscopy to resect the GIST.
2849582|NCT03601234|Experimental|laparoscopic and endoscopic combined surgery|LECS resects the GIST completely by laparoscopy with the help of the precise positioning and guidance of endoscopy.
2849583|NCT03601208|Experimental|Blood sample|Venepuncture vs fingerprick test using Mitra volumetric absorptive microsampling (VAMs)
2849584|NCT03601195||Subjects|Chinese women carrying multiple pregnancies
2849585|NCT03601169|Experimental|Low Dose MMFS-205-SR|Low dose, oral MMFS-205-SR twice daily (1,000 or 1,500 mg/day total, depending on lean body mass: ~22mg/kg LBM/day) for 6 weeks
2849586|NCT03601169|Experimental|High Dose MMFS-205-SR|High dose, oral MMFS-205-SR twice daily (1,500 or 2,000 mg/day total, depending on lean body mass: ~33mg/kg LBM/day) for 6 weeks
2849587|NCT03601169|Placebo Comparator|Placebo|Oral inactive placebo twice daily for 6 weeks
2849588|NCT03601156|Experimental|NATACE-RT|Patients receive Oxaliplatin 130mg/m2 intraarterial chemoembolization on day1, and then radiation ( 44 Gy/20 fractions/4 weeks, from day 7 to day 11, day14 to day 18, day 21 to day 25, day 28 to day 32) plus oral S-1 (BSA < 1.25 mm2 receive 80 mg/day; 1.25 mm2 < BSA < 1.5mm2 recive 100 mg/day, BSA>1.5mm2 receive120 mg/day, twice daily, from day 1 to day 28, every 4 weeks)
2849589|NCT03601156|Active Comparator|NACT-RT|Patients receive Oxaliplatin 130mg/m2 intravenous chemotherapy on day1, and then radiation ( 44 Gy/20 fractions/4 weeks, from day 7 to day 11, day14 to day 18, day 21 to day 25, day 28 to day 32) plus oral S-1 (BSA < 1.25 mm2 receive 80 mg/day; 1.25 mm2 < BSA < 1.5mm2 recive 100 mg/day, BSA>1.5mm2 receive120 mg/day, twice daily, from day 1 to day 28, every 4 weeks)
2849590|NCT03601130|Other|No Bone Graft|Open Wedge High Tibial Osteotomy with medial plate fixation (without bone grafting)
2849591|NCT03601130|Active Comparator|HydroxyColl Bone Graft Substitute|Open Wedge High Tibial Osteotomy with medial plate fixation (with bone grafting) using Hydroxycoll bone graft substitute.
2849592|NCT03601117|Active Comparator|Dorsolateral prefrontal cortex|The accelerated theta burst stimulation protocol will be applied to the dorsolateral prefrontal cortex (dlPFC)
2849593|NCT03601117|Active Comparator|Anterior cingulate cortex|The accelerated theta burst stimulation protocol will be applied to the anterior cingulate cortex(ACC)
2849594|NCT03601104|Active Comparator|HIET (n = 15)|High intensity eccentric training: A high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
2849595|NCT03601104|Experimental|HIET-BFR (n= 15)|High intensity eccentric training with blood flow restriction (BFR): A high intensity eccentric (80% isometric peak) training of the knee extensors in isokinetic will be performed, associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) for 6 weeks, 3 times a week.
2849596|NCT03601104|Experimental|LIET-BFR (n = 15)|Low intensity eccentric training with blood flow restriction (BFR): A low intensity eccentric (40% isometric peak) training of the knee extensors in isokinetic will be performed associated with a pressure cuff placed in the proximal thigh (40% absolute occlusion pressure) for 6 weeks, 3 times a week.
2849597|NCT03601091|Active Comparator|PR|PRECEDEX 200 mcg 2 ml,0,3 mcg/kg/h, intravenous continue infusion, 4 hours.
2849598|NCT03601091|Active Comparator|DO|DORMICUM 5MG/5 ML, 0,1 mg/kh/h, intravenous continue infusion for 4 hours
2849599|NCT03601078|Experimental|bb2121 in relapsed and refractory multiple myeloma patients|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
2849600|NCT03601065||Routine colonoscopy Cohort|
2849601|NCT03601052|Experimental|Cohort 1 - MRG-201 (L) vs. Placebo (R)|Six doses MRG-201 (5.3 mg) over a period of 2 weeks at the site of one excisional skin wound (left side) and six doses Placebo over a period of 2 weeks at the site of a second excisional skin wound (right side). Each subject will serve as their own control.
2849602|NCT03601052|Experimental|Cohort 1 - MRG-201 (R) vs. Placebo (L)|Six doses MRG-201 (5.3 mg) over a period of 2 weeks at the site of one excisional skin wound (right side) and six doses Placebo over a period of 2 weeks at the site of a second excisional skin wound (left side). Each subject will serve as their own control.
2849603|NCT03601039|Experimental|Absnow Absorbable ASD Closure System|All subjects are implanted with Absnow Absorbable ASD Occluder
2849604|NCT03601026|Experimental|Genetic counselling|Eligible participants who are randomized will be contacted and offered an invitation to attend the intervention. Genetic counselling will be provided to participants who accept the intervention as a single 1-2 hour session by a board-certified genetic counsellor. During the genetic counselling session, participants will have the option to receive their genotype at rs2494732. Participants will be counselled regarding their individualized risk of developing and of NOT developing SMI based on family history, whether or not they choose to use cannabis, and genotype (if they accept the genetic test results). Approximately 1 month after the intervention, participants will receive a follow-up interview.
2849605|NCT03601026|No Intervention|Control group|Eligible participants who are not randomized to be offered the intervention will continue with their annual assessments as part of the parent study. These participants will receive the current standard of care (no intervention), and will not be offered or informed of the intervention.
2849606|NCT03601000|Experimental|Yi-Zhi-An-Shen|Yi-Zhi-An-Shen Granules given three times every day for 16 weeks.
2849607|NCT03601000|Placebo Comparator|Placebo|Placebo given three times every day for 16 weeks.
2849608|NCT03600987|Experimental|Music and reading lyrics|A single-subject adapted alternating treatment design will be used to compare two music conditions, using music with sung lyrics simultaneously with silent reading of the lyrics, and priming with music and sung lyrics followed by reading of the lyrics, with a control condition using reading materials without music.
2849609|NCT03600974||Endoscopy-E(+)|Subjects with positive endoscopy finding:erosive esophagitis or Barrett esophagus.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.
2849610|NCT03600974||Endoscopy-E(-)|Subjects with negative endoscopy finding:NERD.
2849611|NCT03600974||Acid-A(+)|Subjects with DeMeester scores>14.72.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.
2849612|NCT03600974||Acid-A(-)|Subjects with DeMeester scores＜14.72
2849613|NCT03600974||impedance-I（+）W/S|Subjects with total reflux number ＞ 80 in 24h pH-impedance monitoring. W means weakly acid reflux account for above 50% in total reflux number. G means gas reflux account for above 50% in total reflux number.For subjects of this group,probiotic agent is considered.
2849615|NCT03600974||Reflux-symptom association-S(+)|Subjects with positive reflux-symptom association.For subjects of this group, PPIs, Stretta, neuromodulators are considered.
2849616|NCT03600974||Reflux-symptom association-S(-)|Subjects with negative reflux-symptom association
2849617|NCT03600974||motility-M(+)|Subjects with motility disorders according to Chicago v3.0.For subjects of this group, prokinetic motility agents are considered.
2849618|NCT03600974||motility-M(-)|Subjects without motility disorders according to Chicago v3.0
2849619|NCT03600974||lower oesophageal sphincter-L(+)|Subjects with abnormal LES pressure or EGJ type III or hiatus hernia.For subjects of this group, Stretta,Laparoscopic Nissen fundoplication is considered.
2849620|NCT03600974||lower oesophageal sphincter-L(-)|Subjects with normal LES pressure and EGJ type I~II
2849621|NCT03600974||psychology-P(+)|Subjects with normal psychology condition.For subjects of this group,neuromodulators are considered.
2849622|NCT03600974||psychology-P(-)|Subjects with abnormal psychology condition
2849623|NCT03600935|Experimental|Vancouver Clinical Pathway|The Vancouver Clinical Pathway utilizes objective anatomical and functional screening criteria as well as strict peri-procedural guidelines to determine if next day discharge home is appropriate.
2849624|NCT03600922|Experimental|Intervention group|
2849625|NCT03600909|Experimental|Good Risk Patients|Patients 18 years old or younger with marrow aplasia or single lineage cytopenias (Arm A) will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.6-0.8 mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
2849626|NCT03600909|Experimental|Intermediate risk patients|Patients 18 years old or younger with MDS or AML will be will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8-1.0mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
2849627|NCT03600909|Experimental|High risk patients|Patients 19 years old or older with marrow aplasia or MDS or AML will be will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.4mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
2849628|NCT03600896|Experimental|Phase 1: Recombinant Human Interleukin-7 (CYT107)|"In Part 1 of the study, 3 dose levels of CYT107 will be tested in this study. Up to 3 participants will be enrolled in each dose level. The first group of participants will receive the lowest dose level. The next group will receive a higher dose than the first group, if no intolerable side effects were seen. The third group will receive an even higher dose than the second, if no intolerable side effects were seen. Based on the results seen, 1 of the 3 doses will be selected as the recommended dose.~In Part 2 of the study, an additional 25 participants will be enrolled to receive CYT107 at the recommended dose found in Part 1."
2849629|NCT03600896|Experimental|Phase 2: Recombinant Human Interleukin-7 (CYT107)|In Part 2 of the study, an additional 25 participants will be enrolled to receive CYT107 at the recommended dose found in Part 1.
2849630|NCT03600883|Experimental|Dose Exploration Part 1|Enrollment into the dose exploration cohorts may be from any eligible solid tumor type. Dose escalation will begin with 2-4 subjects treated with AMG 510 at the lowest planned dose level of 180 mg.
2849631|NCT03600883|Experimental|Dose Expansion Part 2|Upon completing the dose exploration part of the study and depending on data obtained, dose expansion at the maximum tolerated dose determined in the escalation may proceed with three groups consisting of subjects with KRAS p.G12C mutant solid tumors Dose expansion in all three groups may be done concurrently.
2849632|NCT03600870|Experimental|Open Label|All subjects enrolled will be assigned to receive midodrine. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
2849633|NCT03600857|Experimental|Home administration|Home administration of 0.8 mg misoprostol pv
2849634|NCT03600857|No Intervention|Hospital administration|Hospital administration of 0.8 mg misoprostol pv
2849635|NCT03600844|Experimental|Phase 1 Intervention|Phase 1 intervention communities will be offered Community distribution of SP for IPTp in addition to routine ANC IPTp distribution throughout the project.
2849636|NCT03600844|Active Comparator|Phase 1 Comparison/Phase 2 Intervention|During Phase 1 (intervention months 1 through 12), these communities will be offered only usual treatment--SP for IPTp at in facilities during routine ANC. During Phase 2 (intervention month 13 through the end of the project), these communities will be offered Community distribution of SP for IPTp, in addition to routine ANC IPTp distribution.
2849637|NCT03600831|Experimental|concurrent chemoradiotherapy group|All patients in this group will receive concurrent chemoradiotherapy with DP regimen (docetaxel plus cisplatin).
2849638|NCT03600831|Active Comparator|radiotherapy group|All patients in this group will receive radiotherapy alone 50Gy (2.0 Gy/fraction, 5 days a week).
2849639|NCT03600818|Experimental|Group 1|Sarilumab once every 2 weeks plus prednisone taper regimen of 14 weeks
2849640|NCT03600818|Placebo Comparator|Group 2|Placebo matching sarilumab once every 2 weeks plus prednisone taper regimen of 52 weeks
2849641|NCT03600805|Experimental|Group A|Sarilumab dose 1, once every 2 weeks plus 26-week prednisone taper regimen
2849642|NCT03600805|Experimental|Group B|Sarilumab dose 2, once every 2 weeks plus 26-week prednisone taper regimen
2849643|NCT03600805|Placebo Comparator|Group C|Sarilumab matching placebo once every 2 weeks plus prednisone regimen 26 weeks
2849644|NCT03600805|Placebo Comparator|Group D|Sarilumab matching placebo once every 2 weeks plus prednisone regimen 52 weeks
2849645|NCT03600779|Experimental|experimental group 1.5T|Population of patients with myelin syndrome (MS) at the the disease onset with active lesions inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed.
2849646|NCT03600779|Active Comparator|control group 1.5 T|healthy volunteers matched in sex and age inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed.
2849647|NCT03600779|Experimental|experimental group 3T|Population of patients with myelin syndrome (MS) at the the disease onset with active lesions inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T will be performed.
2849648|NCT03600779|Active Comparator|control group 3T|inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed. inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T will be performed.
2849649|NCT03600766|Active Comparator|Mirabegron|oral mirabegron 50 gm plus tamsulosin 0.4 mg once daily for 8 weeks
2849650|NCT03600766|Active Comparator|Placebo|oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
2849651|NCT03600753|Experimental|symptomatic patients|symptomatic patients with viral respiratory infection harboring positive qPCR for respiratory virus (influenza A or B, RSV, rhinovirus, metapneumovirus) A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
2849652|NCT03600753|Active Comparator|asymptomatic patients|"symptomatic patients with viral respiratory infection with positive qPCR for respiratory virus.~A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed"
2849653|NCT03600753|Other|healthy subjects|Control group of healthy patients. A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
2849654|NCT03600740|Experimental|GPi DBS|Patients selected to undergo GPi DBS placement will be eligible for enrollment in the study. In addition to standard-of-care tests, subjects will undergo an MRI consisting of the proposed novel imaging protocol prior to placement of DBS. The patient will subsequently undergo standard-of-care therapy for DBS placement. Once the stimulator has been programmed post-operatively, the stimulation parameters and corresponding clinical changes will be collected and used to model the volume of activated tissue. The patient will additionally undergo a follow-up MRI used to localize the electrode within the brain to further localize the volume of activated tissue.
2849655|NCT03600727|Experimental|Propofol group|Patients in this arm will be sedated by propofol.
2849656|NCT03600727|Experimental|Dexmedetomidine group|Patients in this arm will be sedated by dexmedetomidine.
2849657|NCT03600714|Experimental|1|Triple Therapy
2849658|NCT03600701|Experimental|Treatment (atezolizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 14 and cobimetinib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
2849659|NCT03600675||South Asian Indians|No intervention will be applied for any group
2849660|NCT03600675||Caucasians|No intervention will be applied for any group
2849661|NCT03600662|Experimental|TriRec|Trileaflet Reconstruction of the Aortic Valve
2849662|NCT03600662|Experimental|Aortic valve replacement|Biological prosthesis, Device: St. Jude Medical Trifecta GT
2849663|NCT03600649|Experimental|SP-2577|
2849664|NCT03600636|Other|Control|
2849665|NCT03600636|Other|antiphospholipid syndrome patients|
2849666|NCT03600623|Experimental|Folfirinox + SBRT|Folfirinox comprises the following: Fluorouracil 2,400 mg/m2 intravenously over 48 hours Days 1-3 and 15-17 every 4 weeks; Folinic acid 400 mg intravenously on Days 1 and 15 every 4 weeks; Oxaliplatin 85 mg/m2 intravenously on Days 1 and 15 every 4 weeks; and Irinotecan 180 mg/m2 intravenously on Days 1 and 15 every 4 weeks. Radiation will begin at the completion of cycle 2 if chemotherapy toxicity permits and will last over a period of 5 days.
2849667|NCT03600623|Experimental|Gemcitabine-nab Paclitaxel + SBRT|Gemcitabine-nab Paclitaxel comprises the following: Gemcitabine 1000 mg/m2 on Days 1, 8, and 15 every 4 weeks; nab Paclitaxel 125 mg/m2 on Days 1, 8, and 15 every 4 weeks. Radiation will begin at the completion of cycle 2 if chemotherapy toxicity permits and will last over a period of 5 days.
2849668|NCT03600610|Experimental|patient group|malnourished patients with anorexia nervosa gadolinium-enhanced cardiac MRI will be performed
2849669|NCT03600610|Active Comparator|control group|age- and sex- matched, normal weight, healthy volunteers gadolinium-enhanced cardiac MRI will be performed
2849670|NCT03600584|Experimental|One-layer duct-to-mucosa Group|Modified one-layer duct-to-mucosa pancreaticojejunostomy is used after pancreaticoduodenectomy.
2849671|NCT03600584|Active Comparator|Invagination Group|Invagination pancreaticojejunostomy is used after pancreaticoduodenectomy.
2849672|NCT03600571|Experimental|AM groups in cadavers study|32 osteoarthritic knees of cadavers were randomly assigned to the AM group (injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion). Hyaluronic acid (HA) traced by methylene blue was injected into the knee, and the intra-articular distribution of HA was assessed using a five-point scale.
2849673|NCT03600571|Experimental|MMP groups in cadavers study|32 osteoarthritic knees of cadavers were randomly assigned to the MMP group (injection medial under horizontal patella midline was administrated with the lower limb extension). Hyaluronic acid (HA) traced by methylene blue was injected into the knee, and the intra-articular distribution of HA was assessed using a five-point scale.
2849674|NCT03600571|Experimental|AM groups in random controlled trial|50 patients with unilateral mKOA were enrolled and randomly into the AM group (injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion).The clinical outcomes of 5-weekly injections of HA were evaluated by WOMAC and Lequesne index. The follow-up times were at weeks 1, 2, 3, 4, 5, 14, and 24 after the injections.
2849675|NCT03600571|Experimental|MMP groups in random controlled trial|50 patients with unilateral mKOA were enrolled and randomly into the MMP group (injection medial under horizontal patella midline was administrated with the lower limb extension).The clinical outcomes of 5-weekly injections of HA were evaluated by WOMAC and Lequesne index. The follow-up times were at weeks 1, 2, 3, 4, 5, 14, and 24 after the injections.
2849676|NCT03600545|Experimental|Active|4 weeks daily practice of the brain exercises
2849677|NCT03600545|Placebo Comparator|control|no brain exercises
2849678|NCT03600532|Experimental|Teachable Moment Brief Intervention|The TMBI is informed by evidence based strategies to collaboratively identify 1) drivers of suicidal ideation, 2) functional aspects of the recent suicide attempt, 3) the patient's relationship with the concept of suicide, 4) what has been lost and gained as a result of the suicide attempt, 5) short term management suicide prevention management strategies, and 6) documentation of factors to address in a suicide-specific treatment plan.
2849679|NCT03600532|No Intervention|Treatment as Usual (TAU)|Usual care at Laureate Psychiatric Clinic and Hospital Adult Stabilization Unit who have attempted suicide involves psychiatric evaluation/treatment and ongoing medical stabilization. Patients will engage in usual care or a rest period before completing the post-assessment.
2849680|NCT03600532|No Intervention|Community Control Group (CCG)|Patients will engage in a rest period before completing the post-assessment.
2849681|NCT03600519|Experimental|AMD Patients|OCT scan
2849682|NCT03600506|Active Comparator|Dexmedetomidine|Intervention drug of the study
2849683|NCT03600506|Placebo Comparator|Placebo|Normal Saline (Placebo)
2849684|NCT03600493|Active Comparator|Dexemetomidine|Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.
2849685|NCT03600493|Active Comparator|Lidocaine|Lidocaine prepared in a syringe with the same volume of Dexmedetomidine to assure blinding given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
2849686|NCT03600480|Experimental|NNC0174-0833+Semaglutide|Participants will receive increasing doses of NNC0174-0833 along with semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks.
2849687|NCT03600480|Active Comparator|Placebo (NNC0174-0833)+Semaglutide|Participants will receive placebo (NNC0174-0833) along with semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks
2849688|NCT03600467|Experimental|Adrogen Postive Solid Tumours|
2849689|NCT03600454|Experimental|Hip surgery: spinal anesthesia|Patients scheduled to undergo elective total hip arthroplasty will receive spinal anesthesia in combination with monitored anesthesia care (MAC).
2849690|NCT03600454|Experimental|Hip surgery: general anesthesia|Patients scheduled to undergo elective total hip arthroplasty will receive general anesthesia
2849691|NCT03600454|Experimental|Colectomy: general anesthesia and epidural analgesia|Patients scheduled to undergo elective laparoscopic hemicolectomy will receive general anesthesia combined with epidural analgesia (EA).
2849692|NCT03600454|Experimental|Colectomy: general anesthesia|Patients will receive general anesthesia.
2849693|NCT03600441|Experimental|Abexinostat|"Abexinostat tablets will be administered orally at 80 mg (4 × 20 mg tablets) BID (twice a day) 4 hours apart for 7 days in a one week on, one week off schedule (on Days 1 to 7 and Days 15 to 21 of each 28-day cycle)."
2849694|NCT03600428|Experimental|Live Attenuated Influenza Vaccine (LAIV)|Participants will receive one dose of live attenuated influenza vaccine via intranasal spray (administer approximately one half of the contents of the single-dose intranasal sprayer into each nostril, each sprayer contains 0.2 mL of vaccine)).
2849695|NCT03600428|Active Comparator|Inactivated Influenza Vaccine (IIV)|Participants will receive one dose of inactivated influenza vaccine via intramuscular injection (0.5 mL).
2849696|NCT03600415|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
2849697|NCT03600415|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
2849698|NCT03600402|Experimental|Experimental Group|
2849699|NCT03600402|Other|Control Group|
2849700|NCT03600389|Experimental|Intervention Arm (Implementing Patient Priorities Care)|Aligning healthcare recommendations to achieve patients' specific health outcome goals within the context of what patients are willing and able to do.
2849701|NCT03600389|No Intervention|Control Arm (Not Implementing Patient Priorities Care)|Routine Care
2849702|NCT03600376|Experimental|Ryanodex and Standard of Care|In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered.
2849703|NCT03600376|Other|Standard of Care only (SOC)|Standard of Care treatment will consist of the immediate start of cooling measures.
2849704|NCT03600363|Experimental|metformin arm|
2849705|NCT03600363|Placebo Comparator|control arm|
2849706|NCT03600350|Experimental|Treatment Group|"Nivolumab 240 mg IV every two weeks x 6 beginning day 1, then every four weeks x 9 beginning week 12~pTVG-HP (100 µg) administered intradermally (i.d.) every two weeks x 6 beginning day 1, then every four weeks x 9 beginning week 12~rhGM-CSF (208 µg) administered intradermally (i.d.) every two weeks x 4 beginning week 4, then every four weeks x 9 beginning week 12 NOTE: Only administered to patients for whom serum PSA obtained week 4 > serum PSA obtained at day 1."
2849707|NCT03600337|Experimental|Experimental Condition|Working to Optimize Wellness in Teens with PCOS
2849708|NCT03600337|No Intervention|Control Condition|Participants in this arm will receive treatment as usual and will be given the intervention after 1 month assessments are completed for the intervention group
2849709|NCT03600324|Experimental|Low Intensity/Low Frequency|Participants will be assigned T-REV with low intensity (30% of perceived effort) and low frequency (exercises performed 1x/day)
2849710|NCT03600324|Experimental|Low Intensity/ High Frequency|Participants will be assigned T-REV with low intensity (30% of perceived effort) and high frequency (exercises performed 2x/day)
2849711|NCT03600324|Experimental|High Intensity/Low Frequency|Participants will be assigned T-REV with high intensity (70% of perceived effort) and low frequency (exercises performed 1x/day)
2849712|NCT03600324|Experimental|High Intensity/High Frequency|Participants will be assigned T-REV with high intensity (70% of perceived effort) and high frequency (exercises performed 2x/day)
2849713|NCT03600311|Placebo Comparator|Energy Balance|Participants will be in energy balance and consume 1.2 g/kg BW protein. They will be provided 30 g of maltodextrin following exercise.
2849714|NCT03600311|Active Comparator|Caloric Restriction and CHO Supp|Participants will be calorie restricted to 15 kcal/kg FFM/day and consume 1.2 g/kg BW protein. They will be provided 30 g of maltodextrin following exercise.
2849715|NCT03600311|Experimental|Caloric Restriction and PRO Supp|Participants will be calorie restricted to 15 kcal/kg FFM/day and consume 1.2 g/kg BW protein. They will be provided 30 g of whey protein following exercise.
2849716|NCT03600298|Other|Pediatric intensive care unit-nurses|"Phase I: During the month leading up to the simulation two trained observers / raters will observe the rate of Closed-Loop Communication in the pediatric intensive care unit (PICU) among study participants.~Intervention phase: Study participants will be subjected to on-site simulation training focusing on communication, including CRM and non-technical skills in the PICU setting.~Phase II + III: During the follow up phase, trained raters will again observe the study-participating PICU staff relative to their communication behaviour in the month following simulation training (Phase II) and again three months later (Phase III)."
2849743|NCT03600012|Active Comparator|control group|"control group: Physiotherapy~Children with cp in control group were taken physiotherapy program including weight shifting, knee and hip strenging and gait training for 8 weeks, 3 times in a week, 45 min per session."
2849744|NCT03599973|Other|Patient|One-arm study, where all patients are given the same standard fluidotherapy and anesthetic conditions to compare measures of Aortic VTI before and after the IV fluid.
2849717|NCT03600272|Experimental|Combined spinal-epidural analgesia|The combined spinal epidural analgesia technique was used to maintain analgesia for parturients in the combined spinal-epidural analgesia group. First, the investigator injected a dose of 5 ug sufentanil into cerebrospinal fluid. If no adverse effects were observed 10 minutes after the first dose, the parturient then received mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate through a patient-controlled epidural analgesia (PCA) pump, which provided patients themixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
2849718|NCT03600272|Other|Epidural analgesia|The epidural analgesia technique was used to maintain analgesia for parturients in the epidural analgesia group, which involved placing a thin catheter through a needle inserted into the epidural space. First, the investigator injected a test dose of 5ml 1% lidocaine through it. If not adverse effects were observed 10 minutes after the test dose, the parturient then received a bolus injection of an initial dose of 8-10 ml mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate. We then connected the catheter with a patient-controlled epidural analgesia (PCA) pump, which provided patients the same mixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
2849719|NCT03600259||Acute Myocardial Infarction|
2849720|NCT03600233|Experimental|CVM-1118|CVM-1118 200mg or 300mg Bis In Die (BID) daily/ Cycle (28 days per cycle)
2849721|NCT03600220|No Intervention|drug use|routine drug use, each patient was using 1-3 antihypertensive drug of a heterogeneous pharmacological group ranging from ACE inhibitors, diuretics, and beta blockers
2849722|NCT03600220|Experimental|drug combine acupuncture|routine drug use combine acupuncture twice a week for 3 months
2849723|NCT03600207|Active Comparator|Control group -complex training|complex training
2849724|NCT03600207|Active Comparator|Experimental group -diaphragm training|diaphragm training
2849725|NCT03600181||orotracheal intubation|Patients admitted in ICU and planned to be intubated. Non-invasive sensor capable of measuring ORI (RAD - 97 pulse co-oximeter; Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.
2849726|NCT03600155|Experimental|Arm A (nivolumab)|Beginning at least 6 weeks post-stem cell transplant, participants receive nivolumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2849727|NCT03600155|Experimental|Arm B (ipilimumab)|Beginning at least 6 weeks post-stem cell transplant, participants receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2849728|NCT03600155|Experimental|Arm C (nivolumab and ipilimumab)|Beginning at least 6 weeks post-stem cell transplant, participants receive nivolumab IV over 60 minutes on days 1, 14, and 28, and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2849729|NCT03600142|No Intervention|Standard of Care (SoC)|Participants randomized to the control condition will receive the standard HIV counseling protocol in the clinic, which is administered by clinic nurses. According to the Tanzania PMTCT guidelines, HIV pre-test counseling should provide education about HIV and prepare women for HIV testing. For anyone who tests positive for HIV, counseling should help her to accept her HIV test result and discuss implications for treatment.
2849730|NCT03600142|Experimental|SoC + stigma counseling (Maisha)|Participants randomized to the intervention condition will receive the SoC counseling plus Maisha, a brief, scalable, theory-based counseling intervention that addresses HIV stigma at entry into antenatal care. Maisha involves a video delivered to all women prior to HIV testing, and, if a woman tests positive for HIV, two counseling sessions.
2849731|NCT03600129|Experimental|QLB with 0,375% ropivacaine|
2849732|NCT03600129|Placebo Comparator|QLB with 0,9% NaCl|
2849733|NCT03600116|Other|Study Visit|Subjects will arrive to the study visit having fasted the night before. Subjects will be given an insulin injection based on their meal to carbohydrate ratio for their breakfast meal as well as a correction bolus to correct their current plasma glucose value down to 40 mg/dL. Following the insulin injection, subjects will eat breakfast. Blood, breath, and sweat samples will be collected throughout the study visit with increased frequency of collection during hypoglycemia. After subjects reach the hypoglycemia threshold, they will be allowed to eat and drink and their blood sugar will be monitored for stability prior to discharge.
2849734|NCT03600103|No Intervention|Control|Participants will receive standard of care.
2849735|NCT03600103|Experimental|Intervention|TECH2CHECK involves field visits by a CHN trained in disease intervention protocols, including clinical assessment, case management, counseling, and a behavioral intervention coupled with text messaging support for medication and self-care reminders.
2849736|NCT03600090|Experimental|Arm EOC202 + Paclitaxol|"Biological: EOC202 This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).~Two EOC202 dose levels (6 mg and 30 mg) will be evaluated in two cohorts of 18 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 48 weeks (12 s.c. injections in total), separated by 13-day intervals free of EOC202 administration.~The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy."
2849737|NCT03600064|Other|Misoprostol group|
2849738|NCT03600064|No Intervention|NO intervention|
2849739|NCT03600038|Experimental|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smoking cessation smartphone app. Therapy description of experimental app withheld to protect the integrity of the study.
2849740|NCT03600038|Active Comparator|Control|This is the control arm of the study. This includes receiving the standard of care smoking cessation smartphone app. Therapy description of standard of care app withheld to protect the integrity of the study.
2849741|NCT03600025|Other|non-randomized|Responses will be compared before and after vaccination
2849742|NCT03600012|Experimental|intervention group|"intervention group: Cycling Functional Electrical Stimulation & Physiotherapy~Children in intervention group were taken in a therapy program withRT 300 SLSA FES system for cycling functional electrical stimulation training additionly to physiotherapy program including weight shifting, knee and hip strenging and gait training for 8 weeks, 3 sessions in a week and 45 min per session."
2849746|NCT03599934|Experimental|LiFE training and home safety assessment|The participants will receive Lifestyle Integrated Functional Exercise Program and Home safety assessment
2849747|NCT03599934|No Intervention|Control group|The control group will continue their usual daily routine.
2849748|NCT03599921||Family-based Treatment|Participants will receive family-based treatment.
2849749|NCT03599921||Enhanced Cognitive behavioral therapy|Participants will receive enhance cognitive behavioral therapy.
2849750|NCT03599895|Experimental|3D printing group|the radical gastrectomy for gastric cancer of Davinci robotic surgery with the assistance of 3D printing model
2849751|NCT03599895|Experimental|non 3D printing group|the radical gastrectomy for gastric cancer of Davinci robotic surgery without the assistance of 3D printing model
2849752|NCT03599856|No Intervention|"Before control group"|Control group with observation of current local standard of care with paper checklist available at the bedside during the ICU rounds of the ICU physicians (as usual)
2849753|NCT03599856|Experimental|"After Intervention group"|An mini Ipad providing TraceBook' intelligent dynamic clinical checklists during the ICU rounds of the ICU physicians.
2849754|NCT03599843|Experimental|ACCESS|Individuals that consent to the study will be assigned to a 12-week exercise program (ACCESS)
2849755|NCT03599830|Other|Cognitive test passations|3 neuropsychological passations over a period of 6 months.
2849756|NCT03599817|Experimental|Healthy lifestyle promotion program|All the participants of the intervention program will be offered group sessions focused on healthy eating, promotion of physical activity and behavioral changes. In this way, the loss of body weight and the increase of physical activity will be promoted. Translating into an improvement in obesity parameters and cardiovascular and metabolic risk factors, to reduce the risk of developing type 2 diabetes.
2849757|NCT03599791|Experimental|Azelastine Hydrochl. + Fluticasone Prop.|Drug: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT Nasal Spray, consists of a fixed-dose combination of azelastine hydrochloride and fluticasone propionate; 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
2849758|NCT03599791|Active Comparator|Azelastine hydrochloride|Drug: Azelastine Hydrochloride 0.137 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
2849759|NCT03599791|Active Comparator|Fluticasone propionate|Drug: Fluticasone Propionate 0.05 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
2849760|NCT03599778|Experimental|treatment group|8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w) + apatinib'MTD(maximum tolerated dose)
2849761|NCT03599778|Active Comparator|Control group|8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w)
2849762|NCT03599765|Experimental|Arm I (LCT, routine therapy)|Participants receive up-front standard of care LCT including but not limited to surgical resection, cryotherapy, and radiofrequency ablation. Participants then receive routine drug therapy.
2849763|NCT03599765|Experimental|Arm II (routine therapy)|Participants receive routine drug therapy. Participants may later receive LCT at the discretion of doctor.
2849764|NCT03599752|Experimental|Group 1A (chemotherapy, metastasectomy)|Low risk participants receive standard of care chemotherapy for 3 months prior to and 3 months after undergoing metastasectomy in the absence of disease progression or unacceptable toxicity.
2849765|NCT03599752|Experimental|Group 1B (metastasectomy)|Low risk participants undergo metastasectomy.
2849766|NCT03599752|Experimental|Group 2A (metastasectomy)|High risk participants undergo metastasectomy.
2849767|NCT03599752|Experimental|Group 2B (chemotherapy)|High risk participants continue standard of care chemotherapy for 6 months in the absence of disease progression or unacceptable toxicity. Participants with stable disease or radiographic response after 6 months may then cross over to Group 2A.
2849768|NCT03599739||Follow-On Cohort|We will survey 823 nursing facilities who participated in the aTIV Influenza Vaccination and Morbitiy and Mortality in U.S. Nursing Homes study in 2016-2017. We anticipate a 70% response rate from this sample for participation.
2849769|NCT03599739||Parallel Cohort|We will survey an additional 1000 facilities (i.e., facilities not participating in the original 2016-2017 study, but meeting the same entry criteria, except prior use of high dose vaccine will be allowed) in order to capture a cohort that used a wide range of self-selected vaccine choices. We anticipate a 50% response rate from this sample.
2849770|NCT03599726|Experimental|Active study drug: Donepezil|Donepezil 5 mg per day for week 1-2 or 5-6
2849771|NCT03599726|Placebo Comparator|Placebo study drug: Placebo|Placebo 5 mg per day for week 1-2 or 5-6
2849772|NCT03599713|Experimental|INCMGA00012|
2849773|NCT03599700||myeloproliferative neoplasms|"history taking~physical examination~laboratory investigations: Complete blood counts Bone marrow examination JAK2 V617F mutation. High-sensitivity C-reactive protein ESR Uric acid level LDH GGT BCR- ABL fusion gene IL-8 , TNF-Alpha Serum ferritin Serum albumin, transferrin, alpha feto protein Complement system: C3, C4."
2849774|NCT03599674|Experimental|Family Bridge Program|Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
2849775|NCT03599661|Experimental|Fertilit-e|Participants review Fertilit-e content, undergo interviews about issues of content, functionality, and ease of use, and complete questionnaires over 45-60 minutes.
2849776|NCT03599648|Experimental|BPT-E|"Behavioral parent training (BPT) plus a psychoeducation program.~Includes a 10-week standard BPT, plus a 6-week psychoeducation program delivered prior to the standard BPT."
2849777|NCT03599648|Experimental|BPT-M|"Behavioral parent training (BPT) plus mindfulness-based stress reduction (MBSR).~Includes a 10-week standard BPT, plus a 6-week MBSR delivered prior to the standard BPT."
2849778|NCT03599635|Experimental|liposomal bupivacaine|These patients will receive liposomal bupivacaine for a pectoralis block infiltration by the anesthesiologist.
2849779|NCT03599635|Active Comparator|bupivacaine|These patients will receive incisional bupivacaine infiltration by the surgeon.
2849780|NCT03599622|Experimental|BMS-986165 Dose 1|
2849781|NCT03599622|Experimental|BMS-986165 Dose 2|
2849785|NCT03599596|Active Comparator|Two doses of sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken twice before delivery
2849786|NCT03599596|Active Comparator|Monthly doses of sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken monthly delivery
2849787|NCT03599583|Experimental|Intervention|Arm 1 will receive the STOP-HPV prompts intervention
2849788|NCT03599583|No Intervention|Control|Arm 2 will receive standard of care
2849789|NCT03599570|Experimental|Intervention|Arm 1 will receive the STOP-HPV performance feedback intervention
2849790|NCT03599570|No Intervention|Control|Arm 2 will receive standard of care
2849791|NCT03599557|Experimental|Intervention|Arm 1 will receive the STOP-HPV communication intervention
2849792|NCT03599557|No Intervention|Control|Arm 2 will receive standard of care
2849793|NCT03599544|Active Comparator|Robot-Assisted Therapy (RT)|Armeo & Amadeo robot-assisted intensive upper limb therapy 1 hour sessions 3x week for 6 weeks.
2849794|NCT03599544|Experimental|Robot + Active Learning Program(RT-ALPS)|Armeo & Amadeo robot-assisted intensive upper limb therapy 1 hour sessions 3x week for 6 weeks plus training in active problem solving, analysis of performance, and goal-setting focused on the transfer of acquired motor skills to daily activities in the home and community.
2849795|NCT03599518|Experimental|DS-1205c with Gefitinib|Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 600 mg, 800 mg) in combination with daily 250 mg oral dose of gefitinib
2849796|NCT03599492||Cirrhosis Patients|10 Patients with body mass index (BMI) etiology of cirrhosis
2849797|NCT03599479|Experimental|Virtual reality group|"After experiencing the VR machine in the transfer bed for 5 minutes, the subject moves to the operating room.~After the subject moves to the surgical bed, he/she takes the appropriate position for the fluoroscopic pain intervention, and wears the virtual reality device (headset, headphone, smartphone).~After the subject starts the VR program, the practitioner starts the fluoroscopic pain intervention.~Lidocaine skin infiltration and description of the practitioner during the intervention are performed with the intervention when necessary."
2849798|NCT03599479|No Intervention|Conventional group|The fluoroscopic pain intervention is performed using only local anesthetics and description of the practitioner during the intervention as in the conventional cases.
2849799|NCT03599466|Experimental|BF-Lisinopril Tablets 20mg|During the study session, the subjects will be administered a single dose of BF-Lisinopril Tablet 20mg after an overnight fast of approximately 10 hours.
2849800|NCT03599466|Active Comparator|Zestril Tab 20mg|During the study session, the subjects will be administered a single dose of Zestril Tab 20mg after an overnight fast of approximately 10 hours.
2849801|NCT03599453|Experimental|Treatment (chemokine modulation therapy)|Participants undergo pre-treatment biopsy. Participants then undergo chemokine modulation therapy consisting of celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV over 30-60 minutes on days -11 to -9, and -4 to -2. Participants then undergo additional biopsy. Following biopsy and chemokine modulation therapy, participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
2849802|NCT03599440||Pulse contour disturbance|Patients with an arterial catheter and pressure line extensions.
2849803|NCT03599427|Active Comparator|systemic lidocaine|Lidocaine 2% IV bolus: 1.5 mg/kg at induction of anesthesia and at the end of surgery.
2849804|NCT03599427|Placebo Comparator|Placebo|Saline 0.9% IV bolus: 0.075 ml/kg at induction of anesthesia and at the end of surgery.
2849805|NCT03599401|Active Comparator|Aspirin Group (Group I)|14 Patients in Group I underwent scaling and root planing using ultrasonic scalers after which 75 mgms of Aspirin was administered orally, once daily for 3 months
2849806|NCT03599401|Active Comparator|Omega 3 Fatty acid Group (Group II)|14 Patients in Group II were given 500 mgms of Omega 3 Fatty Acid orally, twice daily for 3 months after scaling and root planing using ultrasonic scalers.
2849807|NCT03599401|Placebo Comparator|Placebo Group (Group III)|14 Patients in Group III was given Placebo, which was administered orally, twice daily for 3 months after scaling and root planing using ultrasonic scalers.
2849808|NCT03599388|Experimental|SASI|"Sleep Diaries (daily)~Fitbit 24/7~Phone/videoconference (weekly with study team)~Epworth Sleepiness Scale (weekly)~PROMIS fatigue scale-morning (weekly)~PROMIS fatigue scale-evening (weekly)"
2849809|NCT03599375|Experimental|B-ALL treated with CD19 CART cell|The qualified CD19-targeted CART cells will be transferred to patient for 3 days as follow:D1,10% fraction;D2,30%;D3 60%. The number of CART cells for each course will be about 1×106/kg. If complete response (CR) or complete response with incomplete hemogram recovery (CRi) in hemogram is achieved after the first course of treatment, further treatment will be decided according to the clinical assessment and the wishes of the patient.If partial response (PR) is achieved after the first course, 1 or 2 courses of treatment will be continued. If there is no response (NR) after the first course, the treatment will be ceased or restarted based on the clinical assessment or patients' wishes. Treatent may be discontinued due to any severe toxicity, such as cytokine release syndrom.
2849810|NCT03599362|Experimental|Multi Agent Chemotherapy Cancer Patients|Subjects will be enrolled into this study following completion of 2-6 months of multi agent chemotherapy with documentation of stable or responsive disease.
2849811|NCT03599349|Experimental|Microfocused ultrasound w/ visualization|Each subject to receive a full face and neck area treatment using a standard 800 line treatment with set energy levels (0.90 joules for the 4-4.5mm transducer, 0.30 joules for the 7-3.0mm/7-3.0N transducers and 07.5 joules for the 7-4.5mm transducer)
2849812|NCT03599336|Other|Nonoperative Treatment|
2849813|NCT03599336|Other|Operative Course for rTSA|
2849814|NCT03599323||Clotrimazole 1% (Empecid L Cream, BAYB5097)|Patients who self-selected Empecid L Cream, and who will have pharmacist intervention prior to purchase.
2849815|NCT03599310|Experimental|Advance care planning|The intervention is a facilitator-based ACP process with a structured guide as a communication tool to aid the interventionists in broaching end-of-life care issues and eliciting patients' values and preferences in a consistent manner.
2849816|NCT03599310|Placebo Comparator|Usual care|A leaflet covering the concept of ACP and advance directives (AD), purposes and potential benefits will be distributed to all participants as part of usual information support to standardize the information provided. The health care team will encourage patients to discuss the matters with their family carers and/or significant others.
2849817|NCT03599297|Experimental|Bilateral synchronous simultaneous stone surgery|Patients who will be operated for kidney stones at both their kidneys in a single surgery session will be included in the study. Patients will undergo percutaneous nephrolithotomy for one side and flexible ureteroscopy for the other side.
2849818|NCT03599284|Experimental|Experimental group 1|Experimental group 1: Vicagrel 20mg loading followed by 5mg/day for 28 days
2849819|NCT03599284|Experimental|Experimental group 2|Experimental group 2: Vicagrel 24mg loading followed by6mg/day for 28 days
2849820|NCT03599284|Experimental|Experimental group 3|Experimental group 3: Vicagrel 30mg loading followed by 7.5mg/day for 28 days
2849821|NCT03599284|Active Comparator|Control group|Control group: Clopidogrel 300mg loading followed by 75mg/day for 28 days
2849822|NCT03599258|Other|Arm 1|Skylife device
2849823|NCT03599258|Active Comparator|Arm 2|Standard therapy
2849824|NCT03599245|Experimental|Ocrelizumab single-dose|Participants will receive a single 600-mg infusion of Ocrelizumab every 24 weeks
2849825|NCT03599232|Active Comparator|intervention( formative OSCE)|"students attended a formative objective structured clinical examination (OSCE) on the first day of their pediatric module to assess the competencies they gained from previous modules. the formative OSCE composed of 8 stations, which were both interactive and static. The interactive stations include history taking, examination, communication (counseling about breastfeeding), and procedural skills (pediatric basic life support) while non-interactive stations include data interpretation, management (linked-station) and a video-station (emergency).~assessed at end of the module(7 weeks) through summative OSCE"
2849826|NCT03599232|No Intervention|control|students in this group have attended pediatric module without formative OSCE and assessed at end of the module(7 weeks) through summative OSCE
2849827|NCT03599219|Other|case|donors with an hemorrhagic score >2 and / or hematoma (more than 4 cm) that occurred during blood donation
2849828|NCT03599219|Other|control|donors with an hemorrhagic score <2.
2849829|NCT03599206|Experimental|Ozone|
2849830|NCT03599206|Placebo Comparator|Filtered Air|
2849831|NCT03599193|Experimental|DFD-03 Lotion|DFD-03 Lotion will be applied to the affected areas twice daily for 1 minute and rinsed off. 29 subjects will be enrolled into this arm.
2849832|NCT03599193|Active Comparator|Tazorac Cream|Tazorac Cream will be applied to the affected areas once daily and left on for ~12 hours. 29 subjects will be enrolled into this arm.
2849833|NCT03599180||Knee Osteoarthritis group|KOA patients without accept treat in the past month
2849834|NCT03599180||Control group|Heathly volunteers
2849835|NCT03599141|Active Comparator|Depression Management|8 weekly group sessions
2849836|NCT03599141|Experimental|Trust-building Self-management Together|8 weekly group sessions
2849837|NCT03599128|Placebo Comparator|Placebo|Placebo
2849838|NCT03599128|Experimental|43.3 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
2849839|NCT03599128|Experimental|86.6 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
2849840|NCT03599128|Experimental|173 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
2849841|NCT03599115|Experimental|Inhibitory Control Training to Food Items|Participants complete a 10 minute training task once a day, 4 days a week, for 4 weeks. Task is administered using a mobile app (Paradigm mobile) that is installed on an iPhone or iPad. Participants receive an instruction text/email at 9am on their chosen weekdays with instructions on what task to complete and a reminder text/email at 5pm if the task has not yet been completed. Research team receives an email when the task has been completed. When the task is administered, participants see a picture for 1250ms with an inter-stimulus interval of 1250ms and have to indicate which side of the screen the picture appears (go trials). Participants are instructed to not make a response when the picture is surrounded by a black box (no-go trials). There are 6 blocks with 36 trials each, half being go and half being no-go trials. High-calorie foods are always no-go trials and low-calorie foods are always go trials.
2849842|NCT03599115|Active Comparator|Inhibitory Control Training to Neutral Items|Participants complete a 10 minute training task once a day, 4 days a week, for 4 weeks. Task is administered using a mobile app (Paradigm mobile) that is installed on an iPhone or iPad. Participants receive an instruction text/email at 9am on their chosen weekdays with instructions on what task to complete and a reminder text/email at 5pm if the task has not yet been completed. Research team receives an email when the task has been completed. When the task is administered, participants see a picture for 1250ms with an inter-stimulus interval of 1250ms and have to indicate which side of the screen the picture appears (go trials). Participants are instructed to not make a response when the picture is surrounded by a black box (no-go trials). There are 6 blocks with 36 trials each, half being go and half being no-go trials. All pictures are of household items.
2849843|NCT03599102|Experimental|LOVED intervention|Intervention group receives the LOVED program, an 8-week program where participants receive video education modules, and weekly video chat sessions with other end-stage renal disease patients and a prior living kidney African American recipient. The program aims to increase knowledge and skills on how to promote individual strategies on how to ask for a kidney from others.
2849844|NCT03599102|No Intervention|Standard Care|Standard interaction with transplant center and physician care.
2849845|NCT03599089|Active Comparator|CA-008 2.5 mg|Each patient will receive a single dose of 2.5 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
2849846|NCT03599089|Active Comparator|CA-008 7.5 mg|Each patient will receive a single dose of 7.5 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
2849847|NCT03599089|Active Comparator|CA-008 15 mg|Each patient will receive a single dose of 15 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
2849848|NCT03599089|Placebo Comparator|Placebo|Each patient will receive a single dose of CA-008 vehicle (identical to active treatment but without CA-008) injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
2849849|NCT03599076||Manifest HD|
2849850|NCT03599076||Premanifest HD|
2849851|NCT03599076||Control|
2849852|NCT03599063|Experimental|Cohort 1|Single subcutaneous administration of PF-06946860 at planned dose level 0.1 mg, or placebo
2849853|NCT03599063|Experimental|Cohort 2|Single subcutaneous administration of PF-06946860 at planned dose level 0.3 mg, or placebo
2849854|NCT03599063|Experimental|Cohort 3|Single subcutaneous administration of PF-06946860 at planned dose level 1 mg, or placebo
2849855|NCT03599063|Experimental|Cohort 4|Single subcutaneous administration of PF-06946860 at planned dose level 3 mg, or placebo
2849856|NCT03599063|Experimental|Cohort 5|Single subcutaneous administration of PF-06946860 at planned dose level 10 mg, or placebo
2849857|NCT03599063|Experimental|Cohort 6|Single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo
2849858|NCT03599063|Experimental|Cohort 7|Single subcutaneous administration of PF-06946860 at planned dose level 100 mg, or placebo
2849859|NCT03599063|Experimental|Optional: Cohort 8|Optional: single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo in healthy Japanese subjects
2849860|NCT03599050|Experimental|Communication Simulation|Nurses will use simulation over 12 weeks while fidelity is monitored using the NIH Behavior Change Consortium Treatment Fidelity Guidelines.
2849861|NCT03599037|Experimental|ICOUGH Recovery App|The ICOUGH Recovery app v2.0 will be downloaded to participants who have a smartphone and want to use the app after their surgery. These participants will be instructed to use the app daily after their surgery until discharge and to select a care coach. Prior to discharge subjects will complete a questionnaire to assess usability and will participate in a brief recorded interview of their experience using the app. Inpatient post operative complications will be abstracted from medical records.
2849862|NCT03599037|No Intervention|Standard of care|Participants who either do not have a smartphone or have a smartphone but don't want to use the app will receive the standard of care after surgery which includes an ICOUGH protocol checklist. Inpatient post operative complications will be abstracted from medical records.
2849863|NCT03599024|Experimental|PCEA Group|The patients randomized into this arm were able to control the administration of analgesics, according to their subjective condition.
2849864|NCT03599024|Active Comparator|Non-PCEA Group|The patients randomized into this arm were receiving analgesics according to the physician's prescription.
2849865|NCT03599011||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
2849866|NCT03599011||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
2849867|NCT03599011||Non exposure|Non-pharmacological treatment (psychotherapy)
2849868|NCT03598998|Experimental|Treatment (pralatrexate and pembrolizumab)|Participants receive pralatrexate IV over 3-5 minutes on days 1 and 8 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
2849869|NCT03598985||Patients with CAI|"Patients referred with a confirmed diagnosis of CAI, with a Cumberland Ankle Instability tool score lower than 27 points. Patients should have had a recurrent sprain within the previous year.~Patients will have their balance assessed using the Myankle smartphone application simultaneously with Biodex balance system assessment."
2849870|NCT03598985||Healthy participants|"Healthy participants who are not complaining of pain and have not be exposed to trauma, injury or undergone surgery for the lower quadrant of the body.~Participants will have their balance assessed using the MyAnkle smartphone application simultaneously with Biodex balance system assessment."
2849871|NCT03598972||control|teeth of children of non vitamin taking mother
2849872|NCT03598972||intervention|children teeth of vitamin taking mother
2849873|NCT03598959|Experimental|Treatment|Treated with tofacitinib and chidamide for 4 cycles.
2849874|NCT03598946|Experimental|Human Papilloma Virus Test urinary|Urinary Test by a kit which is send to the woman's house
2849875|NCT03598920||AspireAssist|Patients undergoing the endoscopic bariatric procedure using the AsspireAssist device
2849876|NCT03598920||Nutritional consulting|Patients undergoing nutritional consulting
2849877|NCT03598907||Standard management of coagulopathy|"The first group of existing ,,standard care - the approach to bleeding patient will be based on clinical experience of the anaesthetist, practically meaning administering crystalloids, colloids (hydroxyethyl starch or gelatin), fresh frozen plasma and erythrocytes to restore normovolemia and platelets, fibrinogen, prothrombin complex concentrate, von Willebrand factor, tranexamic acid, all products giving ,,blindly when it comes to diagnosis and treatment of coagulopathy."
2849878|NCT03598907||POC management of coagulopathy|"group of ,,point-of-care approach to the diagnosis and treatment of perioperative bleeding and coagulopathy will be conducted on the basis of the results of the POC methods ROTEM, PFA 200 and Multiplate (prothrombin complex concentrate, fibrinogen, platelets, von Willebrand factor, tranexamic acid). A solution of 5% albumin and erythrocytes (to keep haemoglobin level over 100 g/l as it is critical for normal primary haemostasis) will be used to keep normal circulating volume and to compensate for perioperative blood loss."
2849879|NCT03598894||Case NDHT|Healthy non-dipping hypertensives 'NDHT' (24h mean wake SBP >145mmHg at baseline and a decline of <10% between mean day time and night time systolic pressures)
2849880|NCT03598894||Control NT|matched healthy normotensives 'NT' (24h mean wake SBP <120mmHg)
2849881|NCT03598894||Control DHT|matched dipping hypertensives 'DHT' (24h mean wake SBP >145mmHg and a decline of >10% between mean day time and night time systolic pressures)
2849882|NCT03598881|Experimental|Treatment|Toothpaste containing 0.32%NaF and no sodium lauryl sulphate (SLS)
2849883|NCT03598881|Active Comparator|Comparator|Toothpaste containing 0.8% sodium monofluorophosphate (SMFP) and sodium lauryl sulphate (SLS)
2849884|NCT03598868|Experimental|Vortioxetine|Vortioxetine 5-20 mg
2849885|NCT03598868|Placebo Comparator|Placebo|Placebo augmentation
2849886|NCT03598855|Experimental|IPC intervention|Participants will self administer IPC of the upper arm daily for 7 days.
2849887|NCT03598855|No Intervention|Control|
2849912|NCT03598686|No Intervention|HOSENG Control|"Standard of care during a door-to-door HIV testing campaign:~For present household members: blood-based HIV testing~For absent household members or household members who refuse testing: They are encouraged to get tested by the Village Health Worker (VHW) or the nearby health facility"
2849888|NCT03598842|Experimental|Malnourished without lung parasites|Thirty study participants, household contacts of an index TB case, who are malnourished and do not have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and have the choice of a vegan, lacto-vegetarian, or non-vegan/vegetarian meal plan option. The consented household contact will also receive a daily multivitamin.
2849889|NCT03598842|Experimental|Malnourished with lung parasites|Thirty study participants, household contacts of an index TB case, who are malnourished and have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and have the choice of a vegan, lacto-vegetarian, or non-vegan/vegetarian meal plan option. The consented household contact will also receive a daily multivitamin. These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.
2849890|NCT03598842|Active Comparator|Well-nourished with lung parasites|These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.
2849891|NCT03598842|No Intervention|Well-nourished without lung parasites|These thirty study participants will serve as the control.These participants will be well-nourished and not have a parasite infection; therefore, they will not receive the nutritional supplementation or treatment for parasite infection.
2849892|NCT03598816|Experimental|Arm 1: Durvalumab + Tremelimumab + Neoantigen DNA Vaccine|"All patients will receive durvalumab intravenous (IV) at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses~All patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles~The first vaccination will take place two weeks after confirmed disease progression on targeted therapy. This will be Day 1 of the first 28-day cycle of treatment with durvalumab and tremelimumab~The schedule of vaccination is Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, and Cycle 5 Day 1 (for a total of 6 doses)"
2849893|NCT03598816|Experimental|Arm 2: Durvalumab + Tremelimumab|"All patients will receive durvalumab IV at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses~All patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles."
2849894|NCT03598790|Experimental|Bimekizumab dose regimen 1|Subjects will receive bimekizumab dose regimen 1.
2849895|NCT03598790|Experimental|Bimekizumab dose regimen 2|Subjects will receive bimekizumab dose regimen 2.
2849896|NCT03598777|Experimental|Dysport - Dose Escalation stage 1|Intramuscular injection of Dysport on day 1 of each cycle.
2849897|NCT03598777|Placebo Comparator|Placebo - Dose Escalation stage 1 and Dose Expansion stage 2|Intramuscular injection on day 1 of cycle 1.
2849898|NCT03598777|Active Comparator|Dysport - Dose Expansion stage 2|Depending upon the results from Stage 1 one or two doses of Dysport will be selected. Intramuscular injection of Dysport on day 1 of each cycle.
2849899|NCT03598764|Other|Classic head extraction group|
2849900|NCT03598764|Other|External Pop out group|
2849901|NCT03598751|Experimental|BCD-085|"Blinded period:~BCD-085 120 mg at weeks 0, 1, 2, 4, 6, 8, 10, 14, 18, 22~Open-label period:~BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54"
2849902|NCT03598751|Placebo Comparator|Placebo|"Blinded period:~Placebo at weeks 0, 1, 2, 4, 6, 8, 10, 14~patients who don't achieve ACR 20 at week 16 will receive BCD-085 at weeks 18 and 22~patients who achieve ACR 20 at week 16 will continue placebo at weeks 18 and 22~Open-label period:~BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54"
2849903|NCT03598738|Active Comparator|Esomeprazole 40mg Group|Intervention group consisted of 16 diabetic subjects that had various degrees of symptoms for functional dyspepsia, gastro-oesophageal reflux, gastritis or duodenitis. All of them were prescribed 40 mg of esomeprazole treatment for three months.
2849904|NCT03598738|No Intervention|Control Group|The control group consisted of without gastric complaints, thus who did not receive PPI drugs. This group was followed-up without any intervention for three months.
2849905|NCT03598725|Experimental|ITI strategy|The low-dose ITI was Coagulation Factor VIII (50IU/kg, every other day) alone or combined with prednisone (2mg Kg-1/day, one month, then taper in three months) depending on the tendency of inhibitor, and Rituximab (375mg/square meter every week for 4 weeks) when the inhibitor titer ≥40BU/ml before or during ITI.Inhibitor and hemorrhage should be retested and recorded periodically.
2849906|NCT03598712|Experimental|Compression by chest bandage urgo K2®|"After the second puncture, the local compression by thoracic bandage will be put in place.~The system being effective 7 days, it will be left in place between each visit. A visit will be made for all patients 7 days after the installation of the device. However, if necessary, an intermediate visit may be carried out.~During these visits, a puncture will be made according to the criteria mentioned above. The bandage will be renewed after each visit.~The device will be removed after 15 days without indication of a new puncture. The patient will be seen again between 10 and 15 days after the bandage is removed for a final evaluation."
2849907|NCT03598712|Active Comparator|punctures|"After the second puncture, the patient will be seen at the same frequency as in the experimental arm.~The decision to perform a puncture will be made according to the same criteria and the follow-up conditions will be identical."
2849908|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 3 mg/mL|AXR-159 Low Dose
2849909|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 30 mg/mL|AXR-159 Mid Dose
2849910|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 50 mg/mL|AXR-159 High Dose
2849911|NCT03598699|Placebo Comparator|AXR-159 Ophthalmic Solution Vehicle|Control Group
2849948|NCT03598478|No Intervention|Control group|Usual medical care is allowed.
2850086|NCT03597516|Placebo Comparator|Placebos|maltodextrin, powder for reconstitution for oral administration, 7.5 grams 2 times per day
2849913|NCT03598686|Experimental|HOSENG Intervention|"HOSENG Intervention during a door-to-door HIV testing campaign:~For present household members: blood-based HIV testing~a) If any absent person in the household: One of the present household members is tested and trained using the oral HIVST (OraQuick©)~For absent household members or household members who refuse testing: One oral HIVST (OraQuick©) is left behind and has to be brought back to the VHW after usage. Otherwise it will be collected by the VHW after two weeks."
2849914|NCT03598673||Hypertensives to receiving Nevibolol|Patients to receive Nevibolol
2849915|NCT03598660||Breast cancer patients|"The present study will be carried on 50 breast cancer patients before surgery.~The followings markers must be estimated:~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using enzyme linked immuno sorbent assay (ELISA)."
2849916|NCT03598660||Healthy controls|"The present study will be carried on 15 age and sex matched controls.~The followings markers must be estimated:~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA."
2849917|NCT03598660||Benign breast diseases|"The present study will be carried on 15 patients with benign breast diseases.~The followings markers must be estimated:~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA."
2849918|NCT03598647|Active Comparator|Physical activity information|Non-exercisers randomized to this condition will receive basic information about physical activity. This includes the national physical activity guidelines,clarification of 'moderate-intensity', exercise safety, and the progression of physical activity within the weight loss program.
2849919|NCT03598647|Experimental|Memories and feelings about exercise|Non-exercisers randomized to this condition will receive the same basic information about physical activity as described above, but they will also receive a brief intervention in which they are taught cognitive strategies designed to make their affective recall more positive.
2849920|NCT03598634|Active Comparator|Epi-on cross-linking|Intervention: Drug: Riboflavin 0.15 in 20% dextran solution
2849921|NCT03598634|Active Comparator|Epi-off cross-linking|intervention: Drug: Riboflavin 0.15 in 15% dextran solution supplemented with Tris-hydroxymethylaminomethane and sodium ethylenediaminetetraacetic acid
2849922|NCT03598621|Experimental|Cohort 1: Semaglutide 0.25 mg|Participants will receive a single dose of semaglutide 0.5 mg/mL using DV3372 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
2849923|NCT03598621|Experimental|Cohort 2: Semaglutide 0.5 mg|Participants will receive a single dose of semaglutide 1.0 mg/mL using DV3372 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
2849924|NCT03598621|Experimental|Cohort 3: Semaglutide 0.5 mg|Participants will receive a single dose of semaglutide 2.0 mg/mL using NovoPen®4 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
2849925|NCT03598608|Experimental|Part A: MK-4280 Dose A+pembrolizumab|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion followed by MK-4280 Dose A by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
2849926|NCT03598608|Experimental|Part A: MK-4280 Dose B+pembrolizumab|Participants receive 200 mg pembrolizumab by IV infusion followed by MK-4280 Dose B by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
2849927|NCT03598608|Experimental|Part A: MK-4280 Dose C+Pembrolizumab|Participants receive 200 mg pembrolizumab by IV infusion followed by MK-4280 Dose C by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
2849928|NCT03598608|Experimental|Part B: cHL|Participants with cHL receive 200 mg pembrolizumab by IV infusion followed by the RPTD of MK-4280 by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
2849929|NCT03598608|Experimental|Part B: DLBCL|Participants with DLBCL receive 200 mg pembrolizumab by IV infusion followed by the RPTD of MK-4280 by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
2849930|NCT03598608|Experimental|Part B: iNHL|Participants with iNHL receive 200 mg pembrolizumab by IV infusion followed by the RPTD of MK-4280 by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
2849931|NCT03598595|Experimental|Treatment (hydroxychloroquine, gemcitabine, docetaxel)|Participants receive hydroxychloroquine PO QD or BID on days 1-21, gemcitabine IV over 90 minutes on days 1 and 8, and docetaxel IV over 1 hours on day 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2849932|NCT03598582|Other|epoetin zeta|Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.
2849933|NCT03598569||lung cancer|
2849934|NCT03598569||other lung diseases|
2849935|NCT03598556|Experimental|Vitamin D3 Supplementation Arm|This arm will receive 180,000IU vitamin D3 every 3 months from baseline through week 96.
2849936|NCT03598556|Placebo Comparator|Placebo Arm|This arm will receive placebo every 3 months from baseline through week 48, followed by 180,000IU vitamin D3 every 3 months from week 48 through week 96.
2849937|NCT03598543||Carbapenem-Sensitive K. pneumoniae|Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.
2849938|NCT03598543||Carbapenem-Resistant K. pneumoniae|Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
2849939|NCT03598530||Tibial Shaft Fracture|Patients sustaining a tibial shaft fracture (AO/OTA type 42) that requires surgery
2849940|NCT03598517|Experimental|high dose chemoradiotherapy|all eligible patients receive image-guided intensity-modulated radiotherapy 60 Gy in 30 fractions over 6 weeks and concurrent weekly paclitaxel and cisplatin，followed by hyperfractionated intensity-modulated radiotherapy boost to residual metabolic disease concurrent with the same chemotherapy regimen, followed by adjuvant chemotherapy 6 weeks after completion of radiation therapy.
2849941|NCT03598504|Active Comparator|Healthy Controls Group|
2849942|NCT03598504|Active Comparator|Spinal Cord Injury Group|
2849943|NCT03598491||Iohexol|Iohexol was applied in video-fluoroscopic-swallowing study
2849944|NCT03598491||Barium|Barium was applied in video-fluoroscopic-swallowing study
2849945|NCT03598478|Experimental|TC-MPT group|Tai Chi-muscle power training group
2849946|NCT03598478|Active Comparator|TC group|Tai Chi group
2849947|NCT03598478|Active Comparator|MPT group|Muscle power training group
2849949|NCT03598465||PHLF Group|The investigators will define PHLF as a postoperatively acquired deterioration in synthetic, excretory, and detoxifying functions of liver. According to the PHLF definition and grading criteria established by International Liver Group of Liver Surgery (ISGLS) in 2011 (Surgery,2011,149(5):713-724), PHLF will be diagnosed by an increased PT-INR and concomitant hyperbilirubinemia on or after postoperative day 5.
2849950|NCT03598465||Non-PHLF Group|Non-PHLF will be defined as normal liver function in terms of normal PT-INR and bilirubin levels after hepatectomy on or after postoperative day 5.
2849951|NCT03598452|Experimental|High dose of ganciclovir group|IVG was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
2849952|NCT03598439|Experimental|Recombinant (RIV4) Influenza Vaccine|A single dose of licensed recombinant influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20.
2849953|NCT03598439|Experimental|Cell-culture (ccIIV4) Influenza Vaccine|A single dose of licensed cell-culture influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20
2849954|NCT03598439|Active Comparator|Standard (IIV4) Influenza Vaccine|A single dose of licensed standard influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20.
2849955|NCT03598426|Active Comparator|Conventional|Oral dexamethasone (20 mg) at home, 12 hours and 6 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
2849956|NCT03598426|Active Comparator|Short-Course|Intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
2849957|NCT03598426|Active Comparator|Combined|Oral dexamethasone (20 mg) at home, 12 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an additional intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
2849958|NCT03598413|No Intervention|Control|Patients undergoing standard laparoscopic colorectal resection with no omega-3 enriched peri-operative nutritional support
2849959|NCT03598413|Experimental|Omega-3|Patients in this group will receive 7 days pre and 7 days post surgery of a nutritional supplement enriched with 1.42g/dose of the fish oils EPA and DHA. The supplement is pre-mixed and will be taken twice daily for a total of 14 days.
2849960|NCT03598400|No Intervention|Control|Participants will continue with their habitual lifestyle but perform no exercise for 2 weeks
2849961|NCT03598400|Active Comparator|Moderate intensity continous training|Participants will complete moderate intensity continous training during a 2 week intervention period
2849962|NCT03598400|Experimental|high intensity interval training|Participants will complete high intensity interval training during a 2 week intervention period
2849963|NCT03598387|Experimental|APD group|Subjects will receive PD catheter placement and subsequent automated peritoneal dialysis treatment.
2849964|NCT03598387|Active Comparator|IHD group|Subjects will receive un-tunneled hemodialysis catheter placement and subsequent intermittent hemodialysis.
2849965|NCT03598374|Experimental|Inositol + Folic acid|"Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid for 6 months.~Couples are required to have regular intercourse with the aim to achieve a spontaneous conception."
2849966|NCT03598374|Placebo Comparator|Folic acid|"Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid for 6 months.~Couples are required to have regular intercourse with the aim to achieve a spontaneous conception."
2849967|NCT03598348|Experimental|Maintenance Treatment Group A|Maintenance Treatment with Capecitabine plus Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
2849968|NCT03598348|No Intervention|Observation Group|Observation after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
2849969|NCT03598348|Experimental|Maintenance Treatment Group B|Maintenance Treatment with Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
2849970|NCT03598335||Women with malignant tumor|Women with malignant tumor in reproductive system
2849971|NCT03598335||Women with benign tumor|Women with benign tumor in reproductive system
2849972|NCT03598335||Women with no observed tumor|Women with no observed tumor in reproductive system
2849973|NCT03598322|Active Comparator|Dextrose 1mL|Dextrose injection, Dextrose 1mL, active comparator
2849974|NCT03598322|Experimental|Dextrose 2mL|Dextrose injection, Dextrose 2mL
2849975|NCT03598322|Experimental|Dextrose 4mL|'Dextrose injection, Dextrose 4mL
2849976|NCT03598309|Active Comparator|Curcumin C3 complex® +Lovaza®|"Group A:~4 grams Lovaza®, 2 grams twice a day (BID). 8,000 mgs CUR Curcumin C3 complex® tablets, 4,000 mgs BID."
2849977|NCT03598309|Active Comparator|Curcumin C3 complex® +Lovaza® +Placebo|"Group B:~2 grams Lovaza®, 1 gram BID. 4,000 mgs CUR Curcumin C3 complex® tablets, 2,000 mgs BID.~1 placebo capsule BID."
2849978|NCT03598309|Active Comparator|Placebo only|Placebo: Two matching placebo capsules twice a day (BID).
2849979|NCT03598296|Experimental|Group A:Group Tube|Implanted the big-bore tube (32F).Patients undergo upper lobectomy were implanted one additional big-bore tube(we named this tube upper tube).This group is planned to enroll 30 patients.
2849980|NCT03598296|Experimental|Group B:Group Ball|Implanted the small-bore tube connects with a negative pressure ball.Patients undergo upper lobectomy were implanted one additional big-bore tube(we named this tube upper tube).This group is planned to enroll 30 patients.
2849999|NCT03598127||sepsis group|patients of sepsis group are diagnosed with sepsis according to International Pediatric Sepsis Consensus Conference:Definitions for sepsis and organ dysfunction in pediatrics.
2850000|NCT03598127||control group|A gender- and age- matched control group are recruited from among non-sepsis children from Pediatric Intensive Care Unit of West China Hospital.
2850087|NCT03597503|Experimental|Flexible dose of SPN-810|Subjects will be treated with flexible dose of SPN-810
2849981|NCT03598283||Severely burned patients|In this prospective study, the extent to which severe burn injuries affect the morphology and function of liver, pancreas and thyroid. The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.
2849982|NCT03598270|Placebo Comparator|Arm A (Control Arm)|"Placebo of atezolizumab in combination with one of the platinum based regimens below (investigator's choice) followed by maintenance niraparib with placebo:~Carboplatin plus paclitaxel and placebo every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks~Carboplatin plus gemcitabine and placebo every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks.~Carboplatin plus pegylated liposomal doxorubicin (PLD) and placebo every 4 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks."
2849983|NCT03598270|Experimental|Arm B (experimental arm)|"Atezolizumab in combination with one of the platinum based regimens below (investigator's choice) followed by maintenance niraparib with atezolizumab:~Carboplatin plus paclitaxel and atezolizumab every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks.~Carboplatin plus gemcitabine and atezolizumab every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks.~Carboplatin plus pegylated liposomal doxorubicin (PLD) and atezolizumab every 4 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks."
2849984|NCT03598257|Experimental|Group I (olaparib, radiation therapy)|Participants receive olaparib PO BID the day before standard RT commences (Day 0) and throughout the RT course until the last day of RT administration. Olaparib is also continued on weekends (routine days without RT) throughout the RT course. Participants undergo standard radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unaccepted toxicity.
2849985|NCT03598257|Active Comparator|Group II (radiation therapy)|Participants undergo standard radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unaccepted toxicity
2849986|NCT03598244|Experimental|Treatment (volitinib)|Participants receive volitinib PO QD. Treatment repeats every 28 days for up to 39 courses in the absence of disease progression or unacceptable toxicity.
2849987|NCT03598231|Sham Comparator|Arm OFF-ON|"Patients are subjected to a test phase by stimulation with an external temporal generator and, if there is improvement in their symptomatology, a subcutaneous impulse generator for sacral neuromodulation is implanted.~Once the generator is placed it will be disconnected for 4 weeks. Then it will be continued to be turned OFF for 2 weeks as a wash-out period. Then, the stimulator will be turn ON for 4 weeks and will be left on afterwards at the maximum subsensory stimulus.~Specific scales will be passed after each sequence crossing."
2849988|NCT03598231|Active Comparator|Arm ON-OFF|"Patients are subjected to a test phase by stimulation with an external temporal generator and, if there is improvement in their symptomatology, a subcutaneous impulse generator sacral neuromodulation is implanted.~Once the generator is placed it will be turned ON for 4 weeks at the maximum subsensory stimulus. Then it will be turned OFF for 2 weeks as a wash-out period. Then, the stimulator will be kept OFF for 4 weeks. After this sequence it will be turned on again and will be left on afterwards at the maximum subsensory stimulus.~Specific scales will be passed after each sequence crossing."
2849989|NCT03598218|Experimental|Hypofractionated dose IMRT|Patients receive hypofractionated with a low total dose radiation with induced chemotherapy and adjuvant chemotherapy.
2849990|NCT03598218|Experimental|Standard-dose IMRT|Patients receive standard-dose radiation therapy with induced chemotherapy and adjuvant chemotherapy..
2849991|NCT03598205|Experimental|DIABEC plus intravitreal dexamethazone|Intervention:Curmin formulation (DIABEC) plus dexamethazone intravitreal injection. Oral curcumin formulation (DIABEC 2 tablets/die) in combination with Dexamethazone (0,7 mg) intravitral injection for diabetic macular edema treatment
2849992|NCT03598205|No Intervention|dexamethazone intravitreal injection|Intervention: dexamethazone intravitreal injection (0,7 mg) in PRN for diabetic macular edema treatment monotherapy.
2849993|NCT03598192|Experimental|TAP group|"The TAP block is performed under the ultrasound guidance at four points: at subcostal and lateral abdominal wall at right-side and left-side.~Drug: ropivacaine 0.375% 40 ml (maximum dose <= 3 mg/kg). Maintenance: ropivacaine 0.375% 8 ml/hour during 48 hours."
2849994|NCT03598192|Experimental|PVB group|The paravertebral block is performed under the ultrasound guidance at T7. Drug: ropivacaine 0.5% 20 ml (maximum dose <= 3 mg/kg). Maintenance: ropivacaine 0.25% 8 ml/hour during 48 hours.
2849995|NCT03598166|No Intervention|Control|"Patients will receive a letter noting that they are not up-to-date on screening and encouraging them to contact a study number if they choose to screen with colonoscopy or FIT. Patients who call will speak to a research assistant who is trained in patient navigation and can facilitate referrals for colonoscopy or FIT. Patients will receive a follow-up telephone call that reiterates information in the letter.~Patients will also be asked to complete a questionnaire about their beliefs and attitudes regarding CRC screening. The questionnaire will be mailed with the invitation letter and will also be administered over the telephone by the research assistant."
2849996|NCT03598166|Experimental|Septin9|"Patients will receive a letter noting that they are not up-to-date on screening and encouraging them to contact a study number if they choose to screen with colonoscopy or FIT. Letters will also include an option to participate in the blood test, with instructions to call the study number to schedule the blood draw. This option will not appear in the letters sent to the control group. Patients will also receive a follow-up telephone call and a questionnaire.~Participants who choose to the blood test (Septin9) will undergo phlebotomy. The blood sample will be run by an off-site commercial laboratory. The study team will notify patients and their primary care physicians of blood test results and will facilitate a colonoscopy referral for those with positive tests."
2849997|NCT03598140|Placebo Comparator|Placebo oral capsule|If randomized to placebo, the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
2849998|NCT03598140|Active Comparator|Sildenafil Citrate|If randomized to sildenafil (60mg), the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
2850001|NCT03598114|Experimental|Program Sustainability Training|Selected publicly funded tobacco control programs receive the intervention in the form of custom training curricula designed to identify and enable sustainable tobacco control programming at a state-organizational level. Sustainability is assessed at t=12 months and 1=24 months to capture potential impact of the training and curricula.
2850002|NCT03598114|No Intervention|Control Condition|In this condition, publicly funded tobacco control programs do not receive the designated program sustainability training and proceed with standard operations. Sustainability is assessed at t=12 months and t=24 months to compare against tobacco control programs receiving sustainability training.
2850003|NCT03598101|Experimental|Test group|
2850004|NCT03598088|Other|Healthy Sexually Active Women|Healthy, sexually active women who are not at risk for pregnancy due to previous female tubal sterilization will receive both Ovaprene and the Caya diaphragm throughout the course of the trial. The purpose of the Caya PCT cycle is to ensure that in this study population and at these sites, results that are expected to be observed in a PCT cycle with an approved vaginal barrier can be replicated.
2850005|NCT03598075|Other|Amylin (Pramlintide)|Pramlintide intravenous infusion 30 micrograms/mL over 20 minutes
2850006|NCT03598075|Other|CGRP|CGRP intravenous infusion 30 micrograms/mL over 20 minutes
2850007|NCT03598049|Experimental|densah burs drilling group|implant osteotomy site drilling using the densah burs osseo densification drills
2850008|NCT03598049|Active Comparator|surgical burs drilling group|implant osteotomy site drilling using conventional surgical burs drilling
2850009|NCT03598036|Experimental|Voclosporin|"Cohort 1:~Maximum dose of 3 capsules (7.9mg) BID~Cohort 2~Dosing to be decided based on the safety from the first 6 subjects in Cohort 1."
2850010|NCT03598023|Active Comparator|Group 1|Cytal® Burn Matrix
2850011|NCT03598023|Active Comparator|Group 2|EZ-Derm® Porcine Xenograft
2850012|NCT03598010|Experimental|Lenodiar|"Lenodiar on top of Oral Rehydration Therapy.~LenoDiar Pediatric acts thanks to Actitan-F, a plant-based molecular complex resulting from Aboca research which reduces attacks of diarrhoea and normalises the consistency of stools, helping to rapidly restore a balanced intestinal function.~Actitan-F counteracts the inflammation of the intestinal mucous membrane, always present in the case of diarrhoea, through two action mechanisms:~a protective action, achieved by forming a barrier-effect film to limit contact with microorganisms and irritants;~an antioxidant action on the free radicals which counteracts the irritation of the mucous membrane."
2850013|NCT03598010|Active Comparator|Codex|Codex on top of Oral Rehydration Therapy.
2850014|NCT03597997|Experimental|Group P|The patients in group (P) will be anaesthetized using total intravenous propofol.
2850015|NCT03597997|Sham Comparator|Group S|Patients in group (S) will be anaesthetized by inhalational anaesthesia using sevoflurane.
2850016|NCT03597984|No Intervention|Arm A|Standard Radiotherapy: 4 Gy x 5 fractions (fr) to Whole vertebra
2850017|NCT03597984|Experimental|Arm B|"Intervention: Radiotherapy with Simultaneous Integrated Boost-SIB on macroscopic metastases~Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:~- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)"
2850018|NCT03597971|Experimental|Part A: experimental|Subjects will receive HMPL004-6599 or matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule. Dose levels may be repeated, or reduced if deemed appropriate by the Safety Monitoring Committee (SMC).
2850019|NCT03597971|Placebo Comparator|Part A: placebo|Subjects will receive matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule.
2850020|NCT03597958||Hypercholesterolaemia|"Individuals attending Imperial College London Diabetes Centre (ICLDC) and with LDL-C ≥5.0 mmol/L, for children <18 years LDL-C>95th centile by age and gender for country, and possible evidence of known premature CHD.~Individuals with a high probability of disease according to the Dutch Lipid Network Criteria, score of ≥6 points, will be identified as possible probands (individual serving as our starting point for the genetic study of the family) and will be selected for further screening.~Patients will be tested for known and/or suspected FH genes, using next generation sequencing (NGS) panel, whole exome and/or whole genome sequencing (WES/WGS) in cases where FH is highly suspected despite negative results from panel testing, and transcriptomic analysis of RNA blood samples."
2850021|NCT03597945|Placebo Comparator|Group Placebo|"For patients of this group, the intervention was a femoral nerve block with:~15 ml of lidocaine with epinephrine (300 mg)~and 3 ml of normal saline as adjuvant."
2850022|NCT03597945|Active Comparator|Group Magnesium|"For patients of this group, the intervention was a femoral nerve block with:~15 ml of lidocaine with epinephrine (300 mg)~and 3 ml of Magnesium sulfate 15% (450 mg) as adjuvant."
2850023|NCT03597932||baseline or control group|All participant anesthesiologists do intraoperative handover of anesthesia care according to a usual process or without checklist for 2-week to 1-month baseline data collection.
2850024|NCT03597932||Checklist group|All participant anesthesiologists do intraoperative handover of anesthesia care by using a standardized handover checklist for another 2-week to 1-month data collection.
2850025|NCT03597919|Active Comparator|Three-dose schedule for Sabin IPV|Subjects vaccinate Sabin IPV at 2, 3, and 4 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 3rd dose of IPV.
2850026|NCT03597919|Experimental|Two-dose schedule for Sabin IPV|Subjects vaccinate first dose IPV at 4 months, and the second dose IPV given between 8 and 11 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 2nd dose of IPV.
2850027|NCT03597906|Experimental|Group A: Manifest|20 eyes will be treated using Contoura, topography guided ablation vision with the standard manifest refraction.
2850028|NCT03597906|Experimental|Group B: partial TMR|20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and without change in the spherical power (using the same spherical power as the manifest refraction).
2850029|NCT03597906|Experimental|Group C: Full TMR|20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and modifying the spherical power to obtain the same spherical equivalent as the manifest refraction. This is done by subtracting half of the difference between topographic astigmatic power and the manifest astigmatic power from the spherical power (topography-modified treatment refraction).
2850030|NCT03597893|Experimental|Oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland) .
2850031|NCT03597893|Placebo Comparator|Placebo|Placebo contains all ingredients except for the peptide in three puffs of 3.99 IU per 6.72mg nostril.
2850032|NCT03597880|Other|obese patient|BMI>30 kg/m2 and underwent bariatric surgery
2850033|NCT03597867|Placebo Comparator|Placebo|Placebo using single-use vials of hyaluronic acid 0.2% preservative-free lubricating tear drops three days before surgery.
2850034|NCT03597867|Experimental|Dicloftil|"Diclofenac Na 0.1% Oph Soln, Dicloftil®, NSAID eyedrops administered three days before surgery"
2850035|NCT03597867|Experimental|Nevanac|"Nepafenac 0.3% Ophthalmic Suspension, Nevanac 3mg/ml®, NSAID eyedrops administered three days before surgery"
2850036|NCT03597867|Experimental|Indom|"Indomethacin 5 MG/ML Ophthalmic Suspension, Indom ®, NSAID eyedrops administered three days before surgery"
2850037|NCT03597867|Experimental|Yellox|"Bromfenac 0.09 % Ophthalmic Solution, Yellox®, NSAID eyedrops administered three days before surgery"
2850038|NCT03597841||Patients with CRKp BSI:Combination therapy|
2850039|NCT03597841||Patients with CRKp BSI: Monotherapy|
2850040|NCT03597828||DEXMEDETOMIDINE|Dexmedetomidine infusion for pleuroscopy sedation. Rescue drugs will be midazolam for inadequate sedation and fentanyl for pain control
2850041|NCT03597828||MIDAZOLAM/FENTANYL|Midazolam for sedation and fentanyl for pain will be used for pleuroscopy monitored anesthesia care
2850042|NCT03597815||DME positive, OSA positive|Visit 1: Baseline DME Treatment. Includes first EYELEA(aflibercept) injection. (DME positive patients will receive a minimum of 6 injections with the first five occurring at 1-month intervals and the sixth occurring two months after the fifth. Further injections will be provided at the discretion of the ophthalmologist in according to the treat and extend protocol of Eylea to ensure the DME is resolved by the end of the study.) Each injection is 2 mg (0.05 mL). Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 1 month follow up post-CPAP initiation Visit 4: 6-month visit post DME initial treatment Visit 5: 2-3 month follow up - titration study (at sleep lab) Visit 6: 12-month visit post DME initial treatment in the OSA- group and at least 3 months post CPAP initiation in the OSA+ group Visit 7: 12-month sleep apnea follow up
2850043|NCT03597815||DME positive, OSA negative|Visit 1: Baseline DME Treatment Includes first EYELEA(aflibercept) injection. (DME positive patients will receive a minimum of 6 injections with the first five occurring at 1-month intervals and the sixth occurring two months after the fifth. Further injections will be provided at the discretion of the ophthalmologist in according to the treat and extend protocol of Eylea to ensure the DME is resolved by the end of the study.) Each injections is 2 mg (0.05 mL). Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 6-month visit post DME initial treatment Visit 4: 12-month visit post DME initial treatment in the OSA- group and at least 3 months post CPAP initiation in the OSA+ group
2850044|NCT03597815||DME negative (NPDR positive), OSA positive|no injections needed. Visit 1: Baseline NPDR diagnosis Sleep lab visits Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 1 month follow up post-CPAP initiation Visit 4: 2-3 month follow up - titration study Visit 5: 12-month sleep apnea follow up
2850045|NCT03597815||DME negative (NPDR positive), OSA negative|no injections needed. Visit 1: Baseline NPDR diagnosis Visit 2: Diagnosis of OSA - Overnight sleep study
2850046|NCT03597802|No Intervention|Control Group|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance).
2850047|NCT03597802|Active Comparator|Intervention group 1|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance), and will perform exercise at workplace three times per week, during 15 minutes
2850048|NCT03597802|Active Comparator|Intervention group 2|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance) and and will perform exercise at workplace four times per week, during 15 minutes.
2850049|NCT03597789|Other|Helping the NonCompliant Child Treatment|"Families will participate in an average of 8 to 12 weeks of Behavioral Parent Training (BPT), by way of the standard-of-care training program Helping the Noncompliant Child (HNC) via weekly sessions and mid-week calls."
2850050|NCT03597776|Experimental|Lidocaine Group|Bolus of intravenous lidocaine of 2mg/kg over 5 mins will be given before skin incision.
2850051|NCT03597776|Placebo Comparator|Placebo Group|Normal Saline of 2mg/kg over 5 mins will be given as bolus before skin incision
2850052|NCT03597763||Moderate to severe traumatic brain injury|Patients who have suffered a moderate to severe traumatic brain injury, with confirmed intracranial damage.
2850053|NCT03597750|Experimental|Static air support devices (Repose®)|"Alternating-pressure devices will be replaced by static air support devices (Repose®) during 14 days:~Repose® Mattress~Repose® Cushion~Repose® Wedge or Foot Protectors~The frequency of repositioning remains unchanged."
2850054|NCT03597750|No Intervention|Alternating-pressure devices|"Instead of replacing the alternating-pressure devices by static air support devices (Repose®), the residents remain on their alternating-pressure devices.~The frequency of repositioning remains unchanged."
2850055|NCT03597737|Active Comparator|Treatment as usual (waiting list)|Patients at this condition will receive the usual medical treatment at the pain unit, but they will not be monitored daily using the app
2850056|NCT03597737|Experimental|Treatment as usual + APP|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor APP. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
2850057|NCT03597724||Patient suffering from sarcopenia|Subjects aged 65 years or older suffering from sarcopenia (diagnosis performed with a valid definition and valid cut-off points) and they will respond to the Questionnaire composed of 13 choice questions.
2850058|NCT03597711|Active Comparator|IVCannulation 24G non-safety cannula|Peripheral Intravenous cannulation using 24G non-safety cannula
2850059|NCT03597711|Active Comparator|IVCannulation 26G safety cannula|Peripheral Intravenous cannulation using 26G safety cannula
2850060|NCT03597711|Active Comparator|IVCannulation 24G safety cannula|Peripheral Intravenous cannulation using 24G safety cannula
2850088|NCT03597503|Placebo Comparator|Placebo|Subjects will be treated with Placebo
2850061|NCT03597659||BioVU-Emerge EHR cohort|"A primary EHR population derived from the eMERGE Phase I & II Network (n=16,924), a consortium of medical centers using EHRs as a tool for genomic research, and from Vanderbilt University Medical Center's (VUMC) BioVU resource (n=20,230).~BioVU is VUMC's de-identified collection of patients whose DNA was extracted from discarded blood and linked to phenotypes through a de-identified EHR.~All subjects were born prior to 1990 and fell within 4 standard deviations for each of the first 2 principal components based on common single nucleotide variants (SNVs) for the subset of subjects self-identified as White, non-Hispanic."
2850062|NCT03597646|Experimental|Kinesio Taping|Kinesio Taping group consisted of 19 patients. Kinesio Tape was applied 2 times a week for a period of 4 weeks. Kinesio Taping was applied for musculus diaphragmaticus, musculus externus obliquus abdominis and internus obliquus abdominis.
2850063|NCT03597646|Active Comparator|Inspiratory Muscle Training (IMT)|Inspiratory Muscle Training (IMT) group consisted of 19 patients. IMT sessions were applied 2 sessions/everyday for a period of 4 weeks and 15 minutes for each session. Every session patients performed 5 breathing circles, then rested and continued again. By this way they used the device for 15 minutes each session. The patients visited the clinic every week and the therapist adjusted the IMT device in terms of their maximal inspiratory pressures.
2850064|NCT03597646|No Intervention|Control|Control group also consisted of 19 CHF patients. No interventions were applied for them. Pharmacological treatment of control group continued and they were advised for using their medication properly.
2850065|NCT03597620|Experimental|Patients with plaque psoriasis 3-10% BSA|Metaderm cream will be applied topically twice a day to all active lesions.
2850066|NCT03597620|Experimental|Patients with stable dose of biologic treatment & 3-10% BSA|Metaderm cream will be applied topically twice a day to all active lesions. The metaderm scalp spray will be applied daily to the affected areas on the scalp.
2850067|NCT03597620|Experimental|Patients with Scalp Psoriasis|For the subgroup for scalp psoriasis, patient will use the shampoo Head & Shoulders formula with 1% Pyrithione Zinc as the active ingredient
2850068|NCT03597607|Experimental|Intensive Smoking Cessation Group|This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have session ranging from 15 mins to 1 hour. Follow-up sessions will occur during quit week(week 1) and at weeks 2, 3, 4, 6, 8, 10, 12 and at 6 months.
2850069|NCT03597607|Experimental|Abbreviated Smoking Cessation Group|This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have brief sessions (15-30 mins) at the end of week 1, week 4, week 12 and at 6 months.
2850070|NCT03597607|No Intervention|Usual care group|The usual care group will be given a package of independent resources that could aid them to quit smoking on their own. They will not receive intervention by a clinic pharmacist.
2850071|NCT03597594|Active Comparator|TCRα/β/CD19-depleted SCT|"A preparative regimen based on the type of SCID will be given followed by infusion of donor cells. Cells for infusion are prepared using the CliniMACS System~Regimen 1 - IL2RG, JAK 3 (Haplocompatible) and all MSD~ATG (rabbit) IV Days -9 -8 and -7, Rest Days -6 and -5, Busulfan IV Days -4, -3, and -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0~Regimen 2 - RAG1, RAG2 (Haplocompatible)~ATG (rabbit) IV Days -9 -8 and -7, Fludarabine IV Days -7, -6, -5 and -4, Busulfan IV Days -5, -4 and -3, Thiotepa IV twice daily, Day -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0~Regimen 3 - ADA, IL7R, CD45 deficiency, CD3 subunits (Haplocompatible)~ATG (rabbit) IV Days -9 -8 and -7, Fludarabine IV Days -7, -6, -5 and -4, Busulfan: IV Days -4, -3 and -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0"
2850072|NCT03597594|Experimental|Donor Lymphocyte Infusions|"Phase I:~On the Phase I portion of the study, up to 4 different dose levels will be evaluated: Dose level -1, Dose ≥0.1 to ≤0.3; Dose level 1, Dose >0.3 to ≤0.56; Dose level 2, Dose >0.56 to ≤1.8; Dose level 3, Dose >1.80 to ≤3.0~Dosing is determined based on the number of CD3+CD45RA-cells/kg and the patient weight in kilograms.~Phase II:~Participants will receive the Phase I determined maximum tolerated dose (MTD) of DLI.~Cells for infusion are prepared using the CliniMACS System."
2850073|NCT03597581|Experimental|Single agent RGX-202-01|RGX-201-01 is administered orally twice daily on days 1-28 of each 28-day cycle. The dose regimen is dependent on the cohort in which the patient is enrolled.
2850074|NCT03597581|Experimental|RGX-202-01 in combination with FOLFIRI|"RGX-201-01 is administered orally twice daily on days 1-28 of each 28-day cycle. The dose regimen is dependent on the cohort in which the patient is enrolled.~FOLFIRI is administered as follows: irinotecan 180 mg/m2 intravenously over 90 minutes concurrently with folinic acid (leucovorin) 400 mg/m2 intravenously over 2 hours, followed by 5-FU 400 mg/m2 intravenous bolus and then 5-FU 2400 mg/m2 intravenous infusion over 46 hours, on Days 1 and 15 of each 28-day cycle."
2850075|NCT03597568|Experimental|Resveratrol|Patients will receive resveratrol 500 mg PO once a day
2850076|NCT03597568|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
2850077|NCT03597555|Experimental|Xyrem|"Xyrem (Sodium Oxybate), oral solution 500mg/mL First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
2850078|NCT03597555|Placebo Comparator|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
2850079|NCT03597542|Experimental|Maltodextrin|Participants will consume 56g of maltodextrin dissolved in 500mL of water.
2850080|NCT03597542|Experimental|Egg|Participants will consume 36g of spray-dried egg powder (equivalent to 3 eggs) dissolved in 500mL of water.
2850081|NCT03597529|Experimental|melatonin 2mg (equal to or over 40kg)|melatonin 2mg (equal to or over 40kg)
2850082|NCT03597529|Experimental|melatonin 8mg (equal to or over 40kg)|melatonin 8mg (equal to or over 40kg)
2850083|NCT03597529|Experimental|melatonin 1mg (under 40kg)|melatonin 1mg (under 40kg)
2850084|NCT03597529|Experimental|melatonin 4mg (under 40kg)|melatonin 4mg (under 40kg)
2850085|NCT03597516|Experimental|RP-G28|galacto-oligosaccharide, spray-dried powder for reconstitution for oral administration, 7.5 grams 2 times per day
2850089|NCT03597490||Partial thickness rotator cuff tear|Patients with symptomatic non-traumatic partial thickness rotator cuff tear treated with multimodal physical therapy with exercise
2850090|NCT03597477||Autism Spectrum Disorder|Patients with a diagnosis of autism spectrum disorder
2850091|NCT03597477||Control|Patients with no developmental diagnoses
2850092|NCT03597464|Experimental|Voclosporin|Voclosporin
2850093|NCT03597464|Placebo Comparator|Placebo Oral Capsule|Placebo
2850094|NCT03597451||Multiple sclerosis|Patients with MS between 0-5,5 score according to the Extended Disability Status Scale (EDSS)
2850095|NCT03597451||Control|Healthy individuals of similar age and sex to patients
2850096|NCT03597438||Patient|patients scheduled for elective surgery who are patients either as an inpatient or arriving to the hospital on the day of scheduled surgery
2850097|NCT03597438||Volunteer|Volunteers who are employees, trainees and students at the Children's Hospital of Philadelphia (CHOP) will be introduced to the study via an informational study flyer to determine eligibility and desire to participate in the study
2850098|NCT03597412|Experimental|Rosuvamibe Tab|Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks
2850099|NCT03597412|Active Comparator|Monorova Tab|Rosuvastatin 20mg qd for 24 weeks
2850100|NCT03597386||All Participants|
2850101|NCT03597373||reintubation|Reestablish of invasive mechanical ventilation
2850102|NCT03597373||not reintubation|Favourable respiratory function
2850103|NCT03597360|Experimental|CT scan subjects|Three participants with severe Alzheimer's dementia will be studied
2850104|NCT03597347|Experimental|Inhaled molgramostim|Molgramostim nebulizer solution (300 µg/dose) administered once daily for 48 weeks utilizing the PARI eFlow nebulizer system
2850105|NCT03597334||critical ill patients|critical ill patients who admit to ICU
2850106|NCT03597321|Experimental|Arm A-DLI|Patients will be planned to receive prophylactic Donor Lymphocyte Injection
2850107|NCT03597321|No Intervention|Arm B- No intervention|
2850108|NCT03597308|Active Comparator|Opioid Group|
2850109|NCT03597308|Active Comparator|NSAID group|
2850110|NCT03597308|Active Comparator|Acetaminophen|
2850111|NCT03597295|Experimental|INCMGA00012|
2850112|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously.
2850113|NCT03597282|Experimental|Nivolumab + adjuvant|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive Poly-ICLC (adjuvant) administered subcutaneously.
2850114|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab on alternate schedule|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant, administered on an alternative schedule, subcutaneously.
2850115|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab + APX005M|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously. Patients on this arm will also receive APX005M at a dose of 0.1 mg/kg administered by IV infusion at Week 12, Week 15, and Week 19.
2850116|NCT03597282|Experimental|Nivolumab + APX005M|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, Week 15, and Week 19, all patients, regardless of their disease status, will receive APX005M at a dose of 0.1 mg/kg administered by IV infusion.
2850117|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab + ipilimumab|Nivolumab at a dose of 240 mg administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously. Patients on this arm will also receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion at Week 12 and Week 19.
2850118|NCT03597282|Experimental|Nivolumab + ipilimumab|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12 and Week 19, all patients, regardless of their disease status, will receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion.
2850119|NCT03597256|Experimental|Treatment Group|Single injection and optional touch-up injection with Restylane Defyne in chin
2850120|NCT03597256|No Intervention|Control Group|No treatment
2850121|NCT03597243|Experimental|Intervention|AGYW in the standard Sauti cash transfer (Arm I) will receive unconditional cash transfer (UCT) in the presence of behavioral and biomedical interventions in quarterly installments of 70,000 TSH. The first installment will take place after completion of 10 hours of BCC sessions and the AGYW has registered into CTP.
2850122|NCT03597243|No Intervention|Control|AGYW in the control group (Arm II) will not receive cash payment but will receive behavioral and biomedical interventions. The behavioral and biomedical interventions are provided by Sauti program to all project beneficiaries.
2850123|NCT03597230|Experimental|patients operated on for pancreatic resection|All consecutive patients operated on for pancreatic resection
2850124|NCT03597217|Experimental|Cohort A_Active|3 single doses treatment of PF-05221304
2850125|NCT03597217|Experimental|Cohort B_Active|Repeated doses of PF-05221304
2850126|NCT03597217|Placebo Comparator|Cohort B_Placebo|Repeated doses of placebo
2850127|NCT03597204|Other|fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for selected high risk individuals to undergo CRC screening. And colonoscopy for those with FIT positive result
2850128|NCT03597191|Experimental|Spinal Stabilization Exercise Program|"Participants in the spinal stabilization exercise group will be instructed to perform four exercises in total, one exercise from each of the following four categories: (a) abdominal bracing, (b) quadruped, (c) prone plank, and (d) side plank exercises. Each exercise will be progressed and advanced in difficulty by increasing repetitions, hold times, and/or extremity movements.~The progression of exercises will be based on the participants' performance at each supervised physical therapy session based on pre-established criteria by Hicks et al. (2005)."
2850173|NCT03596905|Experimental|1.5 mg plecanatide|Plecanatide 1.5 mg Taken orally once daily for 4 weeks Group B: 12 to < 18 years old
2850129|NCT03597191|Placebo Comparator|General Exercises Program|Participants in the general exercise group will perform a range of motion (ROM) and flexibility exercises of low back and lower extremities. Each participant will be instructed to perform four exercises in total, one exercise from each of the following four categories: (a) knee to chest, (b) lower trunk rotation, (c) prone press-ups, and (d) hamstring stretch exercises. These exercises will be progressed by increasing repetitions and pain-free ROM.
2850130|NCT03597178|Experimental|senofilcon A|Subjects that are of at least 60 years of age and non-habitual contact lens wearers will receive instructions to insert and remove a contact lens from each eye.
2850131|NCT03597165|Experimental|Incidental Genomic Sequencing Results|"Patients in Intervention will receive GS results related to primary indication (cancer) and will be offered the option learning their incidental results, categorized into five bins based on a framework by Berg et al."
2850132|NCT03597165|Active Comparator|Primary Indication only|Patients in the control will receive the intervention GS results for Primary Indications only.
2850133|NCT03597152|Experimental|Treatment|WelTract
2850134|NCT03597152|Placebo Comparator|Control|Inert Placebo
2850135|NCT03597139|Experimental|Voclosporin ophthalmic solution (VOS)|0.2% VOS, Twicw Daily (BID), both eyes for 28 days
2850136|NCT03597139|Active Comparator|Comparator|0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days
2850137|NCT03597126|Active Comparator|robot-assisted ISR|Patients with low rectal cancer undergo intersphincteric resection assisted by Robotic
2850138|NCT03597126|Active Comparator|laparoscopic ISR|Patients with low rectal cancer undergo laparosocopic intersphincteric resection
2850139|NCT03597087|Experimental|General anesthesia|Group of general anesthesia before transurethral resection of the bladder tumor anesthesia: propopol
2850140|NCT03597087|Experimental|Spinal anesthesia|Group of spinal anesthesia before transurethral resection of the bladder tumor anesthesia: bupibacaine
2850141|NCT03597074||1|Patients without AKI progression Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
2850142|NCT03597074||2|Patients with Transient AKI Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
2850143|NCT03597074||3|Patients with Persistent AKI Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
2850144|NCT03597061|Experimental|Healthy Start to Feeding Intervention|Participants and their parents will participate in a 3 session intervention targeting healthy introduction of complementary foods. Intervention sessions will occur when the infant is 4, 6, and 9 months of age.
2850145|NCT03597061|No Intervention|Control|Participants and their parents will complete pre- and post-treatment period study visits to assess study outcomes. They will receive no intervention.
2850146|NCT03597048|Experimental|Curriculum|Participants received only the curriculum intervention
2850147|NCT03597048|Active Comparator|Contact|Participants received only the contact intervention
2850148|NCT03597048|Active Comparator|Materials|Participants received only the materials intervention
2850149|NCT03597048|Experimental|Curriculum and Contact|Participants received both curriculum and contact interventions
2850150|NCT03597048|Experimental|Curriculum and Materials|Participants received curriculum and materials interventions
2850151|NCT03597048|Active Comparator|Contact and Materials|Participants received contact and materials intervention
2850152|NCT03597048|Active Comparator|Curriculum, Contact and Materials|Participants received curriculum, contact and materials interventions
2850153|NCT03597048|No Intervention|No intervention|Participants received no intervention
2850154|NCT03597035|Experimental|Patiromer Add-On|Single arm experimental study in 50 diabetic patients with chronic kidney disease and hyperkalemia.
2850155|NCT03597022|Experimental|Hemophilia patients_Arm 1|Patients receive a dose of 100 mg of BAY1093884.
2850156|NCT03597022|Experimental|Hemophilia patients_Arm 2|Patients receive a dose of >100 mg and <400 mg of BAY1093884.
2850157|NCT03597022|Experimental|Hemophilia patients_Arm 3|Patients receive a dose of BAY1093884 that is between the dose of Arm 2 and 400 mg.
2850158|NCT03597009|Experimental|Open-label, single-arm Phase I|Talimogene laherparepvec (TVEC) administered into the intrapleural space of subjects with malignant pleural effusion (MPE) via a pleurX catheter with or without nivolumab
2850159|NCT03596996|Experimental|Ferrous Sulfate|Children 6 to 23 months of age will receive a tablet that contains the equivalent of 12.5 mg of elemental iron. Children over 24 months will receive a tablet that contains the equivalent of 30 mg of elemental iron.
2850160|NCT03596996|Placebo Comparator|Placebo|
2850161|NCT03596983|Experimental|Short Sleep Patients|
2850162|NCT03596970|Experimental|Everolimus with MMF (TAC-withdrawal)|Everolimus (RAD001) with MMF and Steroids
2850163|NCT03596970|Active Comparator|Everolimus with reduced TAC|Everolimus (RAD001) with reduced TAC and Steroids
2850164|NCT03596957|Active Comparator|Tolvaptan group|Treatment with tolvaptan for six weeks followed by six weeks observation without trial medication
2850165|NCT03596957|No Intervention|Control group|No tolvaptan treatment but following the same visit and investigation plan as the subjects in the tolvaptan group
2850166|NCT03596944||Statin|History of statin use for primary prevention
2850167|NCT03596944||Non-Statin|No documented history of statin use prior to Acute Coronary Syndrome
2850168|NCT03596931||Statin|History of statin use prior to Acute Coronary Syndrome
2850169|NCT03596931||Non-Statin|No documented history of statin use prior to Acute Coronary Syndrome
2850170|NCT03596918|Experimental|Supportive care (vincristine sulfate, bleomycin sulfate)|Patients receive vincristine sulfate IV over 1-2 minutes and bleomycin sulfate IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2850171|NCT03596905|Experimental|0.5 mg plecanatide|Plecanatide 0.5 mg Taken orally once daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old
2850172|NCT03596905|Experimental|1.0 mg plecanatide|Plecanatide 1.0 mg Taken orally once daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old
2850174|NCT03596905|Placebo Comparator|Matching placebo|Matching placebo Taken orally once daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old
2850175|NCT03596892|Experimental|Decitabine + BUCY|For MLL+ acute leukemia undergoing allo-HSCT，Decitabine+BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
2850176|NCT03596892|Active Comparator|BUCY|For MLL+ acute leukemia undergoing allo-HSCT，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
2850177|NCT03596879|Experimental|dCBTI|Online access to the digital CBTI program Sleepio.
2850178|NCT03596879|Placebo Comparator|Sleep Education|Weekly email messages with sleep hygiene recommendations.
2850179|NCT03596866|Experimental|Brigatinib|Brigatinib 90 mg, tablets, orally, once daily 7 days, followed by Brigatinib 180 mg, tablets, orally, once daily for until objective disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by the investigator, or intolerable toxicity.
2850180|NCT03596866|Active Comparator|Alectinib|Alectinib 600 mg, capsules, orally twice daily until objective disease progression per RECIST version 1.1, as assessed by the investigator, or intolerable toxicity.
2850181|NCT03596853|Experimental|Experimental: Mobilization|These patients will receive standard rehabilitation delivered by non-study physiotherapist. In addition, the patients will undergo a protocol of progressive mobilization with individualized dose control and training load stratified according to functional levels and performance.
2850182|NCT03596853|Sham Comparator|Control: Usual care|These patients will receive standard rehabilitation delivered by non-study physiotherapist.
2850183|NCT03596827|Active Comparator|1E10 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
2850184|NCT03596827|Experimental|1E9 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E9 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
2850185|NCT03596827|Experimental|1E8 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E8 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
2850186|NCT03596827|Experimental|1E7 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E7 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
2850187|NCT03596827|Experimental|1E6 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E6 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
2850188|NCT03596801|Experimental|Group 1: RSV 6120/∆NS1 Vaccine|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of 10^6.0 plaque-forming units (PFUs) of RSV 6120/∆NS1 vaccine at Day 0.
2850189|NCT03596801|Experimental|Group 1: RSV 6120/F1/G2/∆NS1 Vaccine|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of 10^5.8 PFUs of RSV 6120/F1/G2/∆NS1 vaccine at Day 0.
2850190|NCT03596801|Placebo Comparator|Group 1: Placebo|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of placebo at Day 0.
2850191|NCT03596801|Experimental|Group 2: RSV 6120/∆NS1 Vaccine|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of 10^5.0 PFUs of RSV 6120/∆NS1 vaccine at Day 0.
2850192|NCT03596801|Experimental|Group 2: RSV 6120/F1/G2/∆NS1|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of 10^5.0 PFUs of RSV 6120/F1/G2/∆NS1 vaccine at Day 0.
2850193|NCT03596801|Placebo Comparator|Group 2: Placebo|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of placebo at Day 0.
2850194|NCT03596788|Experimental|Carbohydrate Beverage|A glucose-fructose beverage mixture supplying 100 grams of carbohydrate per day for 5 days
2850195|NCT03596788|Placebo Comparator|Placebo Beverage|An artificially-sweetened beverage containing aspartame
2850196|NCT03596775|Experimental|Dexmedetomidine group|the children received 0.5 μg/kg of intravenous dexmedetomidine over 10 minutes after induction of anesthesia
2850197|NCT03596775|Placebo Comparator|Control Comparator group|the children received 10ml saline over 10 minutes after induction of anesthesia
2850198|NCT03596762|Experimental|NT-814 160mg|160mg NT-814 capsules once daily
2850199|NCT03596762|Experimental|NT-814 120mg|120mg NT-814 capsules once daily
2850200|NCT03596762|Experimental|NT-814 80mg|80mg NT-814 capsules once daily
2850201|NCT03596762|Experimental|NT-814 40mg|40mg NT-814 capsules once daily
2850202|NCT03596762|Placebo Comparator|Placebo|Placebo capsules to match, once daily
2850203|NCT03596749|Experimental|Sevelamer Carbonate|Sevelamer carbonate will be given with fixed dose of 1600mg (p.o. b.i.d) with meals
2850204|NCT03596749|No Intervention|Control|blank-control
2850205|NCT03596736|Experimental|Elbow Hemiarthroplasty|
2850206|NCT03596736|Active Comparator|Total Elbow Arthroplasty|
2850207|NCT03596723|Experimental|KPI-121 1% BID|
2850208|NCT03596723|Active Comparator|Prednisolone acetate QID|
2850209|NCT03596710|Experimental|Diagnostic (image-guided biopsy)|Participants undergo image-guided biopsy over 45 minutes prior to first RLT course and 1-2 days after the third RLT course.
2850210|NCT03596697|Experimental|CRV431|
2850211|NCT03596697|Placebo Comparator|Placebo|
2850212|NCT03596697|Experimental|CRV431 and TDF|
2850214|NCT03596684|Placebo Comparator|Placebo|pure mixture of amino acids: alanine, aspartate, glycine, proline, serine, histidine
2850215|NCT03596671|Experimental|Treatment arm|RENOVA iStim™ System implanted patients
2850216|NCT03596658|Experimental|SHR9549 dose escalation and expansion(s)|Escalating dose of SHR9549 with intensive safety monitoring to ensure the safety of patients
2850217|NCT03596645|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab through Week 50. Doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.
2850218|NCT03596645|Experimental|Group 2: Infliximab|Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
2850219|NCT03596632|Experimental|Single Oral Solution Dose|Single 200-mg (approximately 100-µCi) oral solution dose of [14C/12C]-fenebrutinib under fasted conditions.
2850220|NCT03596619|Experimental|PBN-ALA-PDT Group|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation [SD] of 10 nm; 100-200 J/cm2).
2850221|NCT03596619|No Intervention|ALA-PDT Group|The ALA-PDT group received ALA cream and irradiation only.
2850222|NCT03596606|Experimental|Myofunctional Motor Control Exercises|"Both groups will be treated with Osteopathic treatment and in one of them the myofunctional motor control treatment will be added as intervention. The experimental group will be the one that will receive the combined treatment.~The patient will receive five sessions, one session every week."
2850223|NCT03596606|Active Comparator|Osteopathic Treatment|The control group will receive only osteopathic treatment (TO). The patient will receive five sessions, one session every week.
2850224|NCT03596593|Experimental|Experimental group|A total of 8-10 mL of blood will be collected from this group of patients and used for blood-MSI testing.
2850225|NCT03596580||Dehydrated participants|125 participants ≥ 65 years of age at the moment of the interviews; hospitalized in General Medicine; osmolarity ≥ 296 mOsm/L
2850226|NCT03596580||Hydrated participants|97 participants ≥ 65 years of age at the moment of the interviews; hospitalized in General Medicine; osmolarity < 296 mOsm/L
2850227|NCT03596567|Experimental|Normal Renal Function Group|Subjects with estimated glomerular filtration rate (eGFR) of => 90 ml/min
2850228|NCT03596567|Experimental|Moderate Renal Impairment Group|Subjects with estimated glomerular filtration rate (eGFR) of => 30ml/min and < 60 ml/min
2850229|NCT03596567|Experimental|Severe Renal Impairment Group|Subjects with estimated glomerular filtration rate (eGFR) of < 30 ml/min and not requiring dialysis
2850230|NCT03596541|Experimental|An open real-time tele-stethoscopy system|EHAS-Fundatel digital stethoscope is an open real-time tele-stethoscopy system. The interventions in this arm will be to make a respiratory and heart auscultation with this tele-stethoscope. After that, we will do the comparison or agreetment between the auscultation of two protocols: tele-stethoscopy system and conventional stethoscope.
2850231|NCT03596541|Active Comparator|Conventional stethoscope|Conventional stethoscope used is the 3M Littmann Classic II S.E. stethoscope. The interventions in this arm will be to make a respiratory and heart auscultation with this conventional stethoscope. After that we will do the comparison or agreetment between the ascultation of two protocols: conventional stethoscope and tele-stethoscopy system.
2850232|NCT03596528|Other|Lung biopsy|Lung biopsy
2850233|NCT03596515|Experimental|Received sensory integration therapy|Participants in the experimental group received 16 sessions (45 minutes each) of individualized Ayres Sensory Integration intervention.
2850234|NCT03596515|No Intervention|Waitlist control group|Participants in the control group received Ayres Sensory Integration according to the usual clinical scheduling. It is after the post- assessment outcome at the same time of the experimental group.
2850235|NCT03596502||Direct oral anticoagulants (DOACs)|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with a DOAC (apixaban, dabigatran or rivaroxaban) at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
2850236|NCT03596502||Warfarin|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with warfarin at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
2850237|NCT03596476|Experimental|Patients with persistent GERD|Patients with persistent GERD suggestive symptoms despite PPI therapy. All the patients will undergo an upper gastrointestinal (GI) endoscopy, a wireless pH monitoring and a post prandial esophageal High Resolution Impedance Manometry (HRIM). Optional: 24-h pH-impedance monitoring on PPI
2850238|NCT03596463||Group A|Patients treated according to suggestions of tumor board
2850239|NCT03596463||Group B|Patients not treated according to suggestions of tumor board
2850240|NCT03596450|Experimental|Semaglutide|Participants will receive semaglutide in addition to metformin monotherapy as treatment intensification in the course of routine clinical practice. Participants will be followed for 2 years, regardless of changes in antidiabetic treatment over the course of the study.
2850241|NCT03596450|Active Comparator|Standard of care|Participants will receive standard of care in addition to metformin monotherapy as treatment intensification in the course of routine clinical practice. Participants will be followed for 2 years, regardless of changes in antidiabetic treatment over the course of the study.
2850242|NCT03596437|Experimental|Ehlers-Danlos Syndrome|Intima-media thickness by ultrahigh frequency vs standard ultrasound
2850243|NCT03596437|Experimental|Fibromuscular Dysplasia|Triple signal by ultrahigh frequency vs standard ultrasound
2850244|NCT03596424|Active Comparator|Ketamine hydrochloride|Intraoperative bolus (0.25 mg/kg) and infusion (0.25mg/kg/h) of ketamine plus an intraoperative bolus (over 20 min) and infusion of normal saline;
2850245|NCT03596424|Active Comparator|dexmedetomidine hydrochloride|Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5µg/kg/h) of dexmedetomidine plus an intraoperative bolus and infusion of normal saline
2850282|NCT03596099|Experimental|Mizkan rice vinegar with acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.
2850246|NCT03596424|Active Comparator|dexmedetomidine hydrochloride and ketamine hydrochloride|Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5 µg/g/h) of dexmedetomidine plus an intraoperative bolus (0.25mg/kg) and infusion (0.25mg/kg/h) of ketamine
2850247|NCT03596398||Young stroke|Patients with acute stroke aged 20 or over, and under 56 years old (Not included 56) .
2850248|NCT03596385|Experimental|Beta-blocker therapy|"This is a strategy (pragmatic) trial. In patients allocated to Beta-blocker therapy, beta blocker agent and dose are decided by treating physician.~betablocker therapy chosen might be any of the following: atenolol bisoprolol carvedilol metoprolol nebivolol"
2850249|NCT03596385|No Intervention|Control (no beta-blocker therapy).|Do not receive beta -blocker therapy
2850250|NCT03596372|Experimental|Patients with Solid tumors|"Escalation cohorts:~Patients receive escalating doses of BAY1834942 intravenously for 1 hour once every 21 days"
2850251|NCT03596372|Experimental|Patients with Gastric cancer|Expansion cohort with patients having gastric and/or gastroesophageal adenocarcinoma; Patients receive BAY1834942 intravenously for 1 hour every 21 days
2850252|NCT03596372|Experimental|Patients with Colorectal cancer|Expansion cohort with patients having colorectal cancer; Patients receive BAY1834942 intravenously for 1 hour every 21 days
2850253|NCT03596372|Experimental|Patients with Non-small-cell-lung cancer|Expansion cohort with patients having adeno Non-small-cell-lung cancer; Patients receive BAY1834942 intravenously for 1 hour every 21 days
2850254|NCT03596359|Experimental|Test group|Self-care behaviors training with Teach-Back method within 15 to 45 minutes was done on the Test group
2850255|NCT03596359|Active Comparator|Control group|The control group received routine treatment
2850256|NCT03596346|Active Comparator|Test group|20 g of rapeseed ingredient (RI) daily
2850257|NCT03596346|Placebo Comparator|Control group|0 g of rapeseed ingredient (RI) daily
2850258|NCT03596307|Experimental|Ashwagandha extract|180 mg Shoden once daily before breakfast for 2 days in Acute Phase and 16 days in Short Term Phase.
2850259|NCT03596307|Placebo Comparator|Placebo|180 mg identical placebo once daily before breakfast for 2 days in Acute Phase and 16 days in Short Term Phase.
2850260|NCT03596294|Experimental|Treatment sequence AB|"Period A:~Saline + clazosentan~Period B:~Rifampicin + clazosentan"
2850261|NCT03596294|Experimental|Treatment sequence BA|"Period B:~Rifampicin + clazosentan~Period A:~Saline + clazosentan"
2850262|NCT03596281|Experimental|Cohort A|
2850263|NCT03596281|Experimental|Cohort B|
2850264|NCT03596268||Persons Living with HIV (PLWH)|Persons 20-80 years old with a documented HIV infection for at least 1 year, who are on a stable cART medication regimen for at least 1 year, and have an undetectable plasma HIV RNA (<50 copies/ml).
2850265|NCT03596268||HIV- Controls|Persons 20-80 years old with confirmed HIV- status matched to PLWH cohort with similar age, sex, education, and race.
2850266|NCT03596255||Patients|All public dental clinics in the region of Östergötland, Sweden, were asked to consecutively recruit adult patients returning for their annual examination
2850267|NCT03596255||Dental personnel|All public dental clinics in the region of Östergötland, Sweden were contacted and asked to participate in the study
2850268|NCT03596242|Experimental|High Blood Pressure Monitoring by SMS|Participants will have their high blood pressure monitored by a SMS system
2850269|NCT03596216|Experimental|Percutaneous Electrial Stimulation (PES group).|"This intervention consisted in the application of an asymmetric biphasic rectangular current. The subject lay prone with her feet outside the table. The FHL muscle was located at 50% of the distance between the fibular head and inferior border of the lateral malleolus on the posterior aspect of the fibular by ultrasound machine (cross-section) (Logiq, GE Healthcare, USA) and then, a needle (0.30mm x 0.40mm) was inserted, perpendicular to the surface of the skin, until the muscle belly. Prior to inserting a neddle, the underlying skin was cleaned with isopropyl alcohol. The intensity of the current was necessary to cause an exacerbated muscle contraction, during 1.5 min acording to the Valera and Minaya protocol´s.~This intervention was performed once in each participant, on one leg only (stance limb), It's only once, it was not a treatment"
2850270|NCT03596216|Experimental|Transcutaneous Electrial Stimulation (TENS group)|"This intervention consisted in the application of an asymmetric biphasic rectangular current. The subject lay prone with her feet outside the table. The FHL muscle was located at 50% of the distance between the fibular head and inferior border of the lateral malleolus on the posterior aspect of the fibular by ultrasound machine (cross-section) (Logiq, GE Healthcare, USA),and then, one self-adhesive electrode was placed on the back of the leg and the other on the sole of the foot. The intensity of the current was necessary to cause an exacerbated muscle contraction, during 1.5 min.~This intervention was performed once in each participant, on one leg only (stance limb), It's only once, it was not a treatment"
2850271|NCT03596216|Active Comparator|Eccentric Group.|Dancers in this group performed eccentric exercise of the FHL muscle.
2850272|NCT03596203|Experimental|Treatment group|
2850273|NCT03596190|Other|Assessment arm|
2850274|NCT03596177|Experimental|MEDI0382|MEDI0382 administered subcutaneously
2850275|NCT03596177|Placebo Comparator|Placebo|Placebo administered subcutaneously
2850276|NCT03596164|Experimental|Teduglutide 0.05 mg|Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm until Teduglutide is commercially available, the participant's participation in this study is discontinued, or the study is discontinued.
2850277|NCT03596151|Experimental|Click Device|One self collected vaginal swab for Click Device testing. Three health care provider collected vaginal swabs for comparator testing.
2850278|NCT03596125|Experimental|N-acetylcysteine (NAC)|"High risk of prematurity: 9g intravenously then 6g (per os) a day until day 7, then 1,8g (per os) a day until 37 weeks of gestational age.~Moderate risk of prematurity: 6g (per os) a day until day 7 then 1,8g ( per os) a day until 37 weeks of gestational age."
2850279|NCT03596125|Placebo Comparator|Placebo|"High risk of prematurity: 9g intravenously then 6g (per os) a day until day 7, then 1,8g (per os) a day until 37 weeks of gestational age.~Moderate risk of prematurity: 6g (per os) a day until day 7 then 1,8g ( per os) a day until 37 weeks of gestational age."
2850280|NCT03596112|Experimental|polyacrylate wound pad|Use of cellulose and distinct layers of sodium-polyacrylate pad for wound care; frequency: twice a week
2850281|NCT03596112|Active Comparator|hydrocellular foam pad|Use of standard foam pad for wound care; frequency: twice a week
2850283|NCT03596099|Placebo Comparator|Mizkan rice vinegar without acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid
2850284|NCT03596086|Experimental|ADV/HSV-tk (gene therapy)|The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 10 sessions (over 2 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent or after completion of the radiotherapy dependent on patient status based on best clinical judgment.
2850285|NCT03596073|Experimental|Topical Calcipotriene Ointment|-Topical Calcipotriene Ointment will be administered by the participants to their upper extremities twice a day for the period between core biopsy and surgical removal of their breast lesion
2850286|NCT03596073|Placebo Comparator|Topical Vaseline|-Topical Vaseline will be administered by the participants to their upper extremities twice a day for the period between core biopsy and surgical removal of their breast lesion
2850287|NCT03596060|Active Comparator|General anesthesia|Hip fracture patients older or equal to 65 years of age, who receive clopidogrel, will be randomly assigned to undertake surgery under general anesthesia in the first 48 hours. Anesthetics to be used are propofol, fentanyl and rocuronium. Maintenance will be achieved with remifentanyl and propofol (TIVA) and the depth of anesthesia will be monitored by BIS. Morphine will be administered bolus IV immediately postoperatively.
2850288|NCT03596060|Active Comparator|Regional anesthesia|Hip fracture patients older or equal to 65 years of age, who receive clopidogrel, will will be randomly assigned undertake surgery under regional anesthesia (spinal) at least 5 days after the discontinuation of clopidogrel. Anesthetics to be used are chirochaine 0.5% and fentanyl.
2850289|NCT03596047|Experimental|Standard treatment + Radial wave therapy|Sildenafil according to the degree of patient involvement + 6 sessions of radial waves.
2850290|NCT03596047|Placebo Comparator|Standard treatment + Placebo therapy|Sildenafil according to the patient's degree of affectation + 6 sessions of placebo therapy.
2850291|NCT03596034|Experimental|JUUL 5%, Virginia Tobacco, ENDS product|Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and combustibles per day (CPD) throughout the 15 day product use period.
2850292|NCT03596008|Experimental|Active1|freeze-dried strawberry powder (25 g) in active drink
2850293|NCT03596008|Placebo Comparator|Placebo|Placebo drink
2850294|NCT03595995|Experimental|Cohort 1|
2850295|NCT03595995|Experimental|Cohort 2|
2850296|NCT03595982|Experimental|Procardia XL 30 mg|Procardia XL 30 mg XL Q 12h - When a patient's BP is persistently elevated after a dose of 30 mg of Procardia XL, the dose is increased to 60 mg Procardia XL divided in 2 doses of 30 mg given 12h apart.
2850297|NCT03595982|Active Comparator|Procardia XL 60 mg|Procardia XL 60 mg Q 24h - When a patient's BP is persistently elevated after a dose of 30 mg of Procardia XL, the dose is increased to 60 mg Procardia given once a day.
2850298|NCT03595969||chronic lymphoblastic leukemia group|150 patients were recruited, who have diagnosed with chronic lymphoblastic leukemia by bone marrow biopsy
2850299|NCT03595969||Control group|The 50 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
2850300|NCT03595956||Medical Gender Affirmation (MGA) Cohort|Patients engaged in gender-affirming care.
2850301|NCT03595943|Experimental|Low glycemic index diet|Low glycemic index pulse-based diet (i.e. beans, peas, lentils, chickpeas)
2850302|NCT03595943|Active Comparator|Regular hospital diet|Moderate glycemic index diet based on hospital menus
2850303|NCT03595930||Subjects who received ARNUITY|This PMS will be conducted with subjects who were administered ARNUITY in accordance with the approved label.
2850304|NCT03595917|Experimental|ABL001, Dasatinib, Prednisone|"- Dose escalation will occur conventional Fibonocci 3+3 dose escalation scheme to determine a recommended phase 2 dose (RP2D)~Dasatinib-Fixed doses oral once a day per cycle~ABL001 is administered orally daily per cycle~Prednisone-Fixed doses oral once a day per cycle. --- Prednisone will be tapered and stop during cycle 2."
2850305|NCT03595904|Experimental|E-Motivate group|Participants complete a 20-minute tablet app, called e-Motivate, and receive usual care.
2850306|NCT03595904|Active Comparator|Usual Care Group|Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy
2850307|NCT03595891||Adult with acute PE before the introduction of apixaban|
2850308|NCT03595891||Adult with acute PE after the introduction of apixaban|
2850309|NCT03595878|Active Comparator|Randomized Arm - Control Group|Patients randomized to this group will receive standard WBRT.
2850310|NCT03595878|Experimental|Randomized Arm - Intervention Group|Patients randomized to this group will receive parotid sparing WBRT.
2850311|NCT03595878|No Intervention|Observational Arm|Patients enrolled in this arm will be treated per their treating physician's choice.
2850312|NCT03595865|Experimental|residual primary open angle glaucoma|Each eye will be preformed tafluprostin 0.0015% at 9 PM, 1 time daily for 6months
2850313|NCT03595865|Experimental|residual primary angle-closure glaucoma|Each eye will be preformed tafluprostin 0.0015% at 9 PM, 1 time daily for 6months
2850314|NCT03595852|Experimental|Prophylaxis|The intervention will be a single dose of prophylactic antibiotic (cefazolin): 2 gr in adults or 3 gr for patients weighing >120Kg or 30mg/kg in children given within 30-60 minutes prior to skin incision.
2850315|NCT03595852|Placebo Comparator|No prophylaxis|The control group will receive a similarly looking prepared placebo injection (normal saline placebos for injection) 30-60 minutes prior to incision.
2850316|NCT03595839|Active Comparator|Fistulotomy with Marsupialization|Lay open and Marsupialization of the fistula track
2850317|NCT03595839|Active Comparator|Fistulotomy without Marsupialization|lay open of the fistula track
2850318|NCT03595826|Experimental|1. Neurostimulant pharmaceutical drugs..|1.Participants receiving medicinal drugs, such as methylphenidate/Ritalin, administered by a medical practitioner, in dosages prescribed by the practitioner, to suit the child.
2850383|NCT03595397|Active Comparator|Group III|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125 bupivacaine and 2 mcg/ml fentanyl, followed by continuous infusion of 8 ml/hour
2850319|NCT03595826|Experimental|2. Exercise Intervention|Participants receiving a minimum of 8 sessions of exercise intervention, for the duration of an hour each session. Exercises will be to build muscle tone, improve core stability, enhance balance, improve fine and gross motor skills and visual motor integration.
2850320|NCT03595826|Experimental|3. Neurostimulants + Exercise intervention|See Arms 1 and 2 above. Both interventions administered together: Pharmaceutical drugs plus exercise intervention
2850321|NCT03595826|Experimental|4. Control Group|Participants will not receive any intervention during the research process. They will be given an intervention after the research is completed.
2850322|NCT03595813|Experimental|Patients treated with Immune Checkpoint Blockade|
2850323|NCT03595800|Experimental|haploidentical related donors|
2850324|NCT03595800|Active Comparator|Matched unrelated donor|
2850325|NCT03595787|Experimental|Prehabilitation program|Program based on nutritional support, physical activity program and coaching. Home-based monitoring will be done thanks to connected watches (step counter pedometer) and a connected body fat weight scale
2850326|NCT03595774|Placebo Comparator|Placebo|3.3 mL/kg concentrated beet root juice *depleted of nitrate* Other names: Beet It Sport Nitrate 400 placebo
2850327|NCT03595774|Active Comparator|low nitrate|"1.55 mL/kg concentrated beet root juice depleted of nitrate + 1.55 mL/kg concentrated beet root juice *depleted of nitrate*~Other names: Beet It Sport Nitrate 400 placebo + Beet It Sport Nitrate 400"
2850328|NCT03595774|Active Comparator|high nitrate|"3.3 mL/kg concentrated beet root juice containing nitrate~Other names:Beet It Sport Nitrate 400"
2850329|NCT03595748|Experimental|Peer mentorship intervention|
2850330|NCT03595748|No Intervention|Usual Care|
2850331|NCT03595735|Experimental|Treatment Group|Receives treatment with the Zenflow Spring System
2850332|NCT03595722|Experimental|Early rectal cancer|Patients with early rectal cancer undergoing a treat and resect pathway - patients will be treated with high intensity focused ultrasound 7-10 days prior to the surgical resection of their rectal cancer
2850333|NCT03595722|Experimental|Late pelvic cancer|Patients with late pelvic (rectal, endometrial, cervical) cancer will undergo a treat and observe pathway - patients will be treated with high intensity focused ultrasound and their response will be observed
2850334|NCT03595709|Experimental|combined tablet(EFV 400,TDF 300, 3TC 300)|Participant receive the combined tablet(EFV 400,TDF 300, 3TC 300) for 24 weeks
2850335|NCT03595696|Experimental|Core Strengthening Exercise Intervention|All subjects will participate in the study for a total of 24 consecutive weeks. During the first 12 weeks, subjects will participate in weekly online exercise classes and will be asked to perform daily homework assignments. Following completion of the 12-week intervention, subjects will be asked to continue the exercises on their own.
2850336|NCT03595696|Active Comparator|Control+Core Strengthening Exercise|All subjects will participate in the study for a total of 24 weeks. During the first 12 weeks, subjects will serve as the control group, and they will be advised to continue their baseline level of exercise and lifestyle. During the subsequent 12 weeks, subjects will participate in the exact same program as Group A performed during the first 12 weeks.
2850337|NCT03595683|Experimental|Cohort 1: Anti-PD1 naive|Participants that have not received prior anti-PD1 therapy for their cancer will be enrolled to this arm.
2850338|NCT03595683|Experimental|Cohort 2: Anti-PD1 refractory|Participants that have received prior anti-PD1 therapy for their cancer will be enrolled to this arm.
2850339|NCT03595670||experimental group|"• Patients diagnosed bipolar in mania, depression or euthymic phases according DSM-IV critiera by psychiatrist~standardized questionnaires and interview will be performed"
2850340|NCT03595657|Experimental|CS1001|Participants will receive CS1001 1200 mg by intravenous infusion every 3 weeks
2850341|NCT03595644|Experimental|SBRT+TKI|SBRT with photon and dose is 40-50Gy/5F after three months after EGFR-TKI treatment
2850342|NCT03595644|Active Comparator|TKI|Standard EGFR-TKI(Gefitinib, erlotinib or icotinib) Gefitinib: 250mg po Qd Erlotinib: 150mg po Qd Icotinib: 125mg po tid
2850343|NCT03595631|Active Comparator|Physical Therapy|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
2850344|NCT03595631|Experimental|Physical Therapy plus neurodynamic|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week. In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
2850345|NCT03595618|Experimental|GLPG1972 Dose A|A daily dose of 1 film-coated tablet of GLPG1972 for oral use.
2850346|NCT03595618|Experimental|GLPG1972 Dose B|A daily dose of 2 film-coated tablets of GLPG1972 for oral use.
2850347|NCT03595618|Experimental|GLPG1972 Dose C|A daily dose of 4 film-coated tablets of GLPG1972 for oral use.
2850348|NCT03595618|Placebo Comparator|Placebo|A daily dose of film-coated tablets for oral use.
2850349|NCT03595605|Experimental|FitBit Group|Will receive a wearable device (FitBit) designed to track number of steps for the duration of their hospital stay. They will receive nudges twice/day to ambulate
2850350|NCT03595605|Active Comparator|Control Group-Standard of Care|300 subjects who will receive usual standard of care on a general inpatient medicine unit with the addition of a wearable device (FitBit) to track usual mobility in this setting. will complete their admission without push for increased activity (although having the device may influence their steps taken).
2850351|NCT03595592|Active Comparator|HPCT|Patients will receive a combination of trastuzumab, pertuzumab, carboplatin and paclitaxel as neoadjuvant therapy for 6 cycles every 3 weeks. Trastuzumab (H) will be delivered on day 1 at the dose of 8 mg/kg loading dose i.v., then 6 mg/kg i.v. Pertuzumab (P) will be delivered on day 1 at the dose of 840 mg loading dose i.v., then 420 mg i.v. Carboplatin (C) will be administered at AUC 2 i.v. on day 1 and day 8. Paclitaxel (T) will be given at 90 mg/m2 i.v. on day 1 and day 8. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab and pertuzumab will then be delivered for 12 additional cycles as adjuvant therapy.
2850382|NCT03595397|Active Comparator|Group II|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml mixture of 0.125% bupivacaine and 30 mg/kg magnesium sulfate, followed by continuous infusion of 8 ml/hour of a mixture of 0.125% bupivacaine and 20% magnesium sulfate
2850352|NCT03595592|Experimental|ACy followed by HPCT and atezolizumab|Patients will receive a combination of doxorubicin (A, 60 mg/m2 i.v.), cyclophosphamide (C, 600 mg/m2 i.v.) and atezolizumab (1200 mg i.v.) on day 1 every 3 week for 3 cycles. Subsequently they will be given trastuzumab on day 1 (H, at the loading dose of 8 mg/kg i.v. then 6 mg/kg i.v.), pertuzumab on day 1 (P, at the loading dose of 840 mg .v., then 420 mg i.v.), carboplatin (C) at AUC 2 i.v. on day 1 and day 8, paclitaxel (T) at 90 mg/m2 i.v. on day 1 and day 8, and atezolizumab 1200 mg i.v. on day 1 for 3 cycles every 3 weeks. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab and pertuzumab will then be delivered for 15 additional cycles and atezolizumab for 12 additional cycles as adjuvant therapy.
2850353|NCT03595592|Experimental|HPCT and atezolizumab|Patients will receive a combination of trastuzumab, pertuzumab, carboplatin, paclitaxel and atezolizumab as neoadjuvant therapy for 6 cycles every 3 weeks. Trastuzumab (H) will be delivered on day 1 at the dose of 8 mg/kg loading dose i.v., then 6 mg/kg i.v. Pertuzumab (P) will be delivered on day 1 at the dose of 840 mg loading dose i.v., then 420 mg i.v. Carboplatin (C) will be administered at AUC 2 i.v. on day 1 and day 8; paclitaxel (T) will be given at 90 mg/m2 i.v. on day 1 and day 8; atezolizumab at the dose of 1200 mg i.v. on day 1. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab, pertuzumab and atezolizumab will then be delivered for 12 additional cycles as adjuvant therapy.
2850354|NCT03595579|Experimental|AXS-05|
2850355|NCT03595579|Active Comparator|Bupropion|
2850356|NCT03595566|Experimental|ridinilazole|
2850357|NCT03595566|Active Comparator|vancomycin|
2850358|NCT03595553|Experimental|ridinilazole|
2850359|NCT03595553|Active Comparator|vancomycin|
2850360|NCT03595540|Experimental|Prolon - FMD|Patients undergoing active cancer treatment are assigned monthly cycles of the fasting-mimicking diet Prolon
2850361|NCT03595527|Experimental|Patients consulting in the emergency room|
2850362|NCT03595514|Active Comparator|Single Injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus
2850363|NCT03595514|Experimental|Double Injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus as well as at the intersection of the subclavian artery and the medial cord.
2850364|NCT03595501||Hematology Analyzer - OLO|The investigational device is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening capillary or venous whole blood samples.
2850365|NCT03595501||Hematology Analyzer - Predicate|The predicate device is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening patient populations found in clinical and reference laboratories.
2850366|NCT03595488|Experimental|Treatment arm|"Single-blinded, Dupilumab or matching placebo will be administered to the patients at the study visits. At each study visit, a single dose of dupilumab or placebo will be dispensed to the patients to be administered at home.~300 mg/2 ml solution in a single-dose pre-filled syringe with needle shield given once every 2 weeks in a subcutaneous injection"
2850367|NCT03595475||Psychiatric RBD cases|"Concurrent psychiatric illnesses according to the Mini International Neuropsychiatric Interview( M.I.N.I);~The onset of mental symptoms preceded the onset of RBD:~Onset of RBD symptom was younger than 50 years old (as most patients with pRBD tended to be younger at mid-40s with an earlier age onset than typical iRBD)."
2850368|NCT03595475||Psychiatric cases|"Age- and sex- matched with pRBD proband;~Concurrent psychiatric illnesses according to the Mini International Neuropsychiatric Interview( M.I.N.I);~Free of narcolepsy and other neurological diseases;~Absence of any RBD features as based on REM sleep behavior disorder questionnaire (RBDQ-HK) and v-PSG;~Free of neurodegenerative diseases."
2850369|NCT03595475||Age- & sex-matched health control|"Age- and sex- matched with pRBD proband;~Without lifetime psychiatric disorder according to Mini International Neuropsychiatric Interview( M.I.N.I);~Free of narcolepsy and other neurological diseases;~Absence of any RBD features as based on RBDQ-HK and v-PSG;~Free of neurodegenerative diseases."
2850370|NCT03595462|Experimental|Snack|The study participants will be provided with a snack to consume every day of the week. The energy content of the snacks will be standardized to ~240 kcal. The snacks will have different levels of protein, fat, carbohydrates, sugar, and fiber.
2850371|NCT03595462|Placebo Comparator|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
2850372|NCT03595449|Active Comparator|Lidocaine jelly|This is the group that will have lidocaine jelly applied during Mohs surgery
2850373|NCT03595449|Sham Comparator|Surgilube|This is the group that will have surgilube (placebo) applied during Mohs surgery
2850374|NCT03595436|Experimental|Pea Protein Breakfast Preload|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preloads will be standardized to ~325 kcal. The preloads will include the same fat content but will vary in protein and carbohydrate amounts. All ingredients are GRAS listed and approved.
2850375|NCT03595436|Placebo Comparator|Carbohydrate Control Breakfast Preload|The study participants will be provided with a control breakfast preload to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. The preload will include the same fat content (as the Experimental Preloads) but will vary in protein and carbohydrate amounts. All ingredients are GRAS listed and approved.
2850376|NCT03595436|Active Comparator|Whey Protein|The study participants will be provided with an active control breakfast preload to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. The preload will include the same fat content (as the Experimental Preloads) but will vary in protein amount and type and carbohydrate amount. All ingredients are GRAS listed and approved.
2850377|NCT03595423||Bioprosthesis|All patients operated on of isolated AVR with a bioprosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
2850378|NCT03595423||Mechanical prosthesis|All patients operated on of isolated AVR with a Mechanical prosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
2850379|NCT03595410||Recurrence laryngeal cancer|
2850380|NCT03595410||No recurrence laryngeal cancer|
2850381|NCT03595397|Active Comparator|Group I|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125% bupivacaine, followed by continuous infusion of 8 ml/hour
2850384|NCT03595384|Experimental|Soccer-based adaptation to the DPP|Participants taking part in a 24 week soccer program as part of diabetes prevention.
2850385|NCT03595371|Experimental|dapansutrile capsules|Hard gelatin capsules containing 100 mg of dapansutrile (API)
2850386|NCT03595358|Experimental|Arm|"Ellume Home Flu Test and ellume.lab Flu A+B Test~Upper respiratory tract samples from participants will be tested with:~Ellume Home Flu Test; ellume.lab Flu A+B Test; Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and viral culture."
2850387|NCT03595345||Training set|2200 HCC cases from East and West centres enlisted for LT and then delisted or transplanted
2850388|NCT03595345||West validation set|630 HCC cases from a Western centre enlisted for LT and then delisted or transplanted
2850389|NCT03595345||East validation set|300 HCC cases from a Eastern centre enlisted for LT and then delisted or transplanted
2850390|NCT03595332|Experimental|Immediate intervention|Summer activity program: Children will receive the summer scorecard program during the first summer of the 2-year study.
2850391|NCT03595332|Experimental|Delayed intervention|Summer activity program: Children will receive the summer scorecard program during the second summer of the 2-year study.
2850392|NCT03595319|Experimental|Young patients|Patients between 19 and 40 years-old
2850393|NCT03595319|Experimental|Elder patients|Older than 65
2850394|NCT03595306|Experimental|Prebiotic A|
2850395|NCT03595306|Experimental|Prebiotic B|
2850396|NCT03595306|Experimental|Prebiotic C|
2850397|NCT03595293|Experimental|Experimental Group for AUD Patients|Patients will undergo six NFB sessions from the rDLPFC using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with an alcohol image, blocking them from progressing through the maze. When patients encounter the alcohol image and they increase activity in their rDLPFC, the image in the maze will decrease in size and vice versa. The size of the alcohol image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the rDLPFC will be sampled every 500 milliseconds using COBI studio software.
2850398|NCT03595293|Sham Comparator|Sham Feedback Group for AUD Patients|Patients will undergo six sham feedback sessions from the skin over the zygomatic arch using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with an alcohol image, blocking them from progressing through the maze. When participants encounter the alcohol image and they increase blood supply over the zygomatic area, the image will decrease in size and vice versa. The size of the alcohol image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the zygomatic area will be sampled every 500 milliseconds using COBI studio software.
2850399|NCT03595293|Experimental|Experimental Group for pOUD Patients|Patients will undergo six NFB sessions from the rDLPFC using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with a pill image, blocking them from progressing through the maze. When patients encounter the pill image and they increase activity in their rDLPFC, the image in the maze will decrease in size and vice versa. The size of the pill image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the rDLPFC will be sampled every 500 milliseconds using COBI studio software.
2850400|NCT03595293|Sham Comparator|Sham Feedback Group for pOUD Patients|Patients will undergo six sham feedback sessions from the skin over the zygomatic arch using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with a pill image, blocking them from progressing through the maze. When participants encounter the pill image and they increase blood supply over the zygomatic area, the image will decrease in size and vice versa. The size of the pill image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the zygomatic area will be sampled every 500 milliseconds using COBI studio software.
2850401|NCT03595280|No Intervention|Control|Participants in the control group receive no study messages
2850402|NCT03595280|Experimental|Untailored Messages|Participants in the untailored message group receive mobile multimedia service messages conveying the risks of hookah tobacco on their mobile phones.
2850403|NCT03595280|Experimental|Tailored Messages|Participants in the tailored message group receive mobile multimedia service messages conveying the risks of hookah tobacco on their mobile phones that are personalized to their hookah tobacco use behavior and beliefs.
2850404|NCT03595267||Rural and Remote Indigenous Communities|Point-of-care screening for Chronic Kidney Disease, Diabetes, and Hypertension will be administered in rural and remote communities in Manitoba, British Columbia, Alberta, Saskatchewan, and Ontario.
2850405|NCT03595254|Experimental|Thrive Intervention|Online cognitive behavior therapy program
2850406|NCT03595254|Active Comparator|Waitlist Control|Wait 8 weeks before receiving program access
2850407|NCT03595241|Experimental|Group A - active treatment|
2850408|NCT03595241|No Intervention|Group B - conservative management|
2850409|NCT03595228|Experimental|BN-Brachyury plus radiation|MVA-BN-Brachyury then treatment of the tumor(s) with radiation followed by FPV-Brachyury
2850410|NCT03595215|Experimental|Single Treatment Arm|This study is an early feasibility study which will be treating all patients at least 3 times per week, for 8 weeks, using the device.
2850411|NCT03595202|Other|Step1:4㎎ TID|TS-143 12mg total dose/day or Placebo
2850412|NCT03595202|Other|Step2:11㎎ TID|TS-143 33mg total dose/day or Placebo
2850413|NCT03595189|Experimental|Cilastatin Dose 1|Starting dose (3g of Cilastatin) Single intravenous administration during 3 hours.
2850414|NCT03595189|Experimental|Cilastatin Dose 2|Dose escalation Single intravenous administration during 3 hours.
2850415|NCT03595189|Experimental|Cilastatin Dose 3|Dose escalation Single intravenous administration during 3 hours.
2850416|NCT03595189|Placebo Comparator|Placebo|Saline solution for infusion
2854917|NCT03564132|Experimental|Yigansan|2.5g of Yigansan granules by mouth, three times a day for 4 weeks
2850417|NCT03595163|Experimental|Group S|Children aged 1 month to 3 years who were scheduled to undergo cochlear implant surgery under general anesthesia were enrolled in this study.Children were treated with an infusion bolus of 2.0mg/kg propofol during anesthesia induction and maintained with 2.0-2.5vol% sevoflurane, with the dosage adjusted to achieve loss of consciousness.The bispectral index of EEG was maintained between 50 and 60 in all groups.The homocysteine and folic acid concentrations were measured after anesthesia induction and at the end of surgery separately .
2850418|NCT03595163|Active Comparator|Group P|Children aged 1 month to 3 years who were scheduled to undergo cochlear implant surgery under general anesthesia were enrolled in this study.Children were treated with an infusion bolus of 2.0mg/kg propofol during anesthesia induction and continuous infusion of 7 to 8mg/kg/hour, with the dosage adjusted to achieve loss of consciousness.The bispectral index of EEG was maintained between 50 and 60 in all groups.The homocysteine and folic acid concentrations were measured after anesthesia induction and at the end of surgery separately .
2850419|NCT03595150|Active Comparator|Diclofenac|100 mg Diclofenac rectally prior to the ERCP
2850420|NCT03595150|No Intervention|No prophylaxis|No prophylaxis
2850421|NCT03595137|Experimental|sono with simple needle guide device group (Group D)|sono with simple needle guide device Simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
2850422|NCT03595137|Placebo Comparator|sono only group (Group S)|sono only group After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
2850423|NCT03595124|Experimental|Arm A (axitinib, nivolumab)|Participants receive axitinib PO BID on days 1-28 and nivolumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity.
2850424|NCT03595124|Experimental|Arm B (axitinib)|Participants receive axitinib PO BID on days 1-28. Treatment repeats every 28 days for up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity.
2850425|NCT03595124|Experimental|Arm C (nivolumab)|Participants receive nivolumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity.
2850426|NCT03595111|Experimental|Myocardial biopsy|The specimens were classified into three categories: normal, focal hydropic change and diffuse hydropic change.
2850427|NCT03595098|Experimental|FCBT|The Family Based Cognitive Behavioural Therapy (FCBT)
2850428|NCT03595098|Active Comparator|FPRT|Family-based Psychoeducation /Relaxation Training (FPRT)
2850429|NCT03595085|Experimental|catheter directed interventions|Those patients will undergo catheter directed fragmentation followed by local thrombolysis using streptokinase
2850430|NCT03595085|Active Comparator|systemic thrombolysis|Those patients will receive systemic streptokinase
2850431|NCT03595072||Stimulation|patient ECOG recordings during active VNS stimulation
2850432|NCT03595072||interstimulation|the same patient ECOG during inter-stimulation periods
2850433|NCT03595059|Experimental|Escalation 1a: ABBV-155|Subjects will be administered ABBV-155 (various doses).
2850434|NCT03595059|Experimental|Escalation 1b: ABBV-155 + paclitaxel|Subjects will be administered ABBV-155 (various doses) in combination with paclitaxel.
2850435|NCT03595059|Experimental|Expansion 2a: ABBV-155 in SCLC|Description: Subjects with small cell lung cancer (SCLC) will administer ABBV-155 (at the recommended Phase 2 dose).
2850436|NCT03595059|Experimental|Expansion 2b: ABBV-155 + paclitaxel in Breast Cancer|Subjects with breast cancer will be administered ABBV-155 (at the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with paclitaxel.
2850437|NCT03595059|Experimental|Expansion 2b: ABBV-155 + docetaxel in NSCLC|Subjects with non-small cell lung cancer (NSCLC) will be administered ABBV-155 (at or near the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with docetaxel.
2850438|NCT03595046|Experimental|erector spinae plane block group (group E)|ultrasound-guided erector spinae plane block
2850439|NCT03595046|Active Comparator|thoracic paravertebral block group (group P)|ultrasound-guided thoracic paravertebral block
2850440|NCT03595033|Experimental|Intervention Phase|Throughout the intervention phase, participants will attend weekly intervention visits. During these visits, an occupational therapist (OT) will educate the participant and their caregiver on the therapy plan which includes the iPad apps to be completed during the week. The participants will be asked to complete their therapy plan for 1 hour per day at home, 4 days per week.
2850441|NCT03595020||MDD group|The major depression group (MDD group) received antidepressant treatment but did not interfere with drug selection.
2850442|NCT03595020||HC group|The healthy control group (HC group) don't accept intervention and treatment.
2850443|NCT03595007|Experimental|Phase 1|
2850444|NCT03595007|Experimental|Phase 2|
2850445|NCT03595007|Experimental|Phase 3|
2850446|NCT03594994|No Intervention|Control|Normal sleep habits < 6h
2850447|NCT03594994|Experimental|Sleep Extension|Extend time-in-bed to 8 hours
2850448|NCT03594981|Experimental|CMV/AdV /EBV/BKV specific T cells|CMV/AdV /EBV/BKV specific T cells will be thawed or thawed and diluted into a total volume of 10 mL of Plasmalyte A and given by slow intravenous injection over 1-2 minutes. Three dose levels will be explored. The lowest dose level will be 1x107cells/m2 and the highest will be 5x107/m2.
2850449|NCT03594968||polycystic ovary syndrome (PCOS)|"Presence of ≥2 of the following:~oligomenorrhea and/or anovulation~Hyperandrogenism (clinical and/or biochemical) One of the signs for clinical hyperandrogenism is hirsutism, which represents hair growth in a male pattern on a female with four different degrees of severity in 11 different body parts: 1) upper lip; 2) chin; 3) chest; 4) upper back; 5) lower back; 6) upper abdomen; 7) lower abdomen; 8) arm; 9) forearm; 10) thigh; and 11) lower leg. The Ferriman-Gallwey scoring system is used to score the degree of excess male-pattern body hair to indicate hirsutism."
2850450|NCT03594968||healthy|healthy patients who had no polycystic ovary
2850451|NCT03594955|Experimental|SAR440234|SAR440234 as weekly intravenous injection; a cycle is defined as 6 weeks of study treatment; (Additionally infusion on day 4 is planned for dose level ≥ 3). Two dose escalation schemes will be used. Treatment may be continued as long as it is clinically beneficial.
2850452|NCT03594929|Active Comparator|Active RIC|Active RIC using a manual BP cuff to inflate to 200mmHg.
2850453|NCT03594929|Sham Comparator|Sham Control|A sham control using a manual blood pressure cuff visually identical to that used in the RIC protocol will be placed on the upper arm and a simulated RIC protocol will be administered.
2850454|NCT03594916|Experimental|Active tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). Active stimulation consists of 2 mA current applied continuously for 20 minutes.
2850455|NCT03594916|Sham Comparator|Sham tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). The 2 mA current will be applied for 30 seconds at the beginning of the session.
2850456|NCT03594903|Experimental|Expectation violation (positive outcome of therapy)|Experimental: patients` report about therapy outcome Video with patients giving information about (mostly) positive therapy outcome
2850457|NCT03594903|Other|Control group (symptoms + expectation)|"Control group: patient´s report about symptoms and therapy expectations~Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome."
2850458|NCT03594890|Experimental|OVX836 (Intramuscular)|"OVX836 is a recombinant Influenza vaccine based on the NP of the Influenza virus. OVX836 vaccine is a ready to use sterile liquid clear and colourless solution, presented in 2 mL glass vials filled with 1.2 mL solution. It contains 300 µg/mL of OVX836 vaccine and is formulated without adjuvant.~3 Dose levels tested: 30µg, 90 µg and 180 µg."
2850459|NCT03594890|Placebo Comparator|Placebo (Intramuscular)|The Placebo, is Sodium Chloride 0.9 % ready to use sterile solution. The volume of placebo to be administered will be similar to the one of the experimental vaccine.
2850460|NCT03594890|Experimental|OVX836 (Intranasal)|"OVX836 is a recombinant Influenza vaccine based on the NP of the Influenza virus. OVX836 vaccine is a ready to use sterile liquid clear and colourless solution, presented in 2 mL glass vials filled with 1.2 mL solution. It contains 300 µg/mL of OVX836 vaccine and is formulated without adjuvant.~3 Dose levels tested: 30µg, 90 µg and 180 µg."
2850461|NCT03594890|Placebo Comparator|Placebo (Intranasal)|The Placebo, is Sodium Chloride 0.9 % ready to use sterile solution. The volume of placebo to be administered will be similar to the one of the experimental vaccine.
2850462|NCT03594877|Experimental|Psoriasis patients|Patients with verified diagnosis of psoriasis would be given standard treatment for the first 3 months, and then followed with the standard therapy accompanied with the sublimated mare milk supplement for additional 3 months.
2850463|NCT03594877|No Intervention|Healthy volunteers|Healthy patients will be enrolled in this study, and their gut microbiota composition as well as immune system indicators will be used for comparison with the psoriasis group.
2850464|NCT03594864||Hyper-reduced liver recipients.|Low-weight children who underwent live donor liver transplantation with ultrasound-guided in situ left lateral segment graft hyper-reduction.
2850465|NCT03594851|Experimental|Administration of individualized advice|"Administration of individualized advice to improve the quality of older people's sleep, based on the following interventions :~Pittsburgh Sleep Quality Index, Sleep diary, Mini Mental State Examination, Autonomy assessment (Katz Index of Independence in Activities of Daily Living~& Lawton Instrumental Activities of Daily Living), Neuropsychiatric Inventory (Cummings) for the caregiver, if applicable, Mini Zarit Caregiver Burden Scale, for the caregiver, if applicable, Cornell Scale for Depression in Dementia, Quality of Life in Alzheimer's Disease, Neuropsychiatric Inventory"
2850466|NCT03594838|Experimental|Decentralized testing approach|Harm reduction site HCV viremia testing approach A. Four HRS will conduct blood draw and point-of-service (decentralized) HCV RNA testing, and results will be provided at the HRS on the same or the following day.
2850467|NCT03594838|Experimental|Centralized testing approach|Harm reduction site HCV viremia testing approach B. Two sites will collect blood samples on site and transport them to a reference (centralized) laboratory for HCV viremia testing. Results will be provided at a follow-up visit to the HRS as soon as results are available.
2850468|NCT03594838|No Intervention|Standard of Care|Current standard of care. Patients who screen anti-HCV positive at HRS will be referred to HCV treatment centers for HCV RNA testing, and results will be provided at a follow-up visit to the treatment center.
2850469|NCT03594825|Experimental|nighttime group|patients with nocturnal hypertension taking valsartan at nighttime
2850470|NCT03594825|Active Comparator|daytime group|patients with nocturnal hypertension taking valsartan at daytime
2850471|NCT03594812|Experimental|Experimental group|This group performed aerobic exercise just after radiofrequency therapy in the abdominal region.
2850472|NCT03594812|Placebo Comparator|Placebo group|This group performed aerobic exercise just after radiofrequency therapy in the abdominal region but the radiofrequency device was switched off- Radiofrequency without power.
2850473|NCT03594799|Experimental|Bed Rest Control Group|60 days of strict head-down tilt bed rest
2850474|NCT03594799|Experimental|Cocktail intervention|60 days of strict head-down tilt bed rest along with a Cocktail supplementation composed of natural antioxidants XXS-2A-BR2 comprising vitamin E, Selenium and coupled with omega-3
2850475|NCT03594786|Experimental|endovascular aneurysm repair (EVAR) arm|every patients are in the same arm and have EVAR with supra-renal fixation
2850476|NCT03594773|Experimental|Interpersonal Psychotherapy|Participants randomized to this arm will be treated with 8 sessions over the course of 8 to 12 weeks by a therapist trained in IPT. Participants will complete brief questionnaires before and after treatment sessions. Before each session, they will report on their psychological distress. Following each session, participants and therapists will both complete assessments of the working alliance and rate their own and the other person's affective and interpersonal behavior.
2850477|NCT03594773|Experimental|Cognitive Behavioral Therapy|Participants randomized to this arm will be treated with 8 sessions over the course of 8 to 12 weeks by a therapist trained in CBT. Participants will complete brief questionnaires before and after treatment sessions. Before each session, they will report on their psychological distress. Following each session, participants and therapists will both complete assessments of the working alliance and rate their own and the other person's affective and interpersonal behavior.
2850478|NCT03594760|Experimental|Main arm|PET-CT imaging following 18F-DCFPyL injection, 1 injection, IV, 10 mCi
2850479|NCT03594747|Experimental|Tislelizumab combined with carboplatin and paclitaxel|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) Q3W. Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Paclitaxel 175 mg/m2, D1 of each cycle, administered as an IV infusion over 1 to 3 hours, for 4 to 6 cycles
2850480|NCT03594747|Experimental|Tislelizumab combined with carboplatin and nab-paclitaxel|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) Q3W. Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Nab-paclitaxel 100 mg/m2, D1, D8, and D15 of each cycle, administered as an IV infusion over 30 minutes, for 4 to 6 cycles
2850481|NCT03594747|Active Comparator|Carboplatin and paclitaxel|Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Paclitaxel 175 mg/m2, D1 of each cycle, administered as an IV infusion over 1 to 3 hours, for 4 to 6 cycles
2850482|NCT03594734|Experimental|GLB Weight-Loss Intervention|The GLB program, adapted for individuals with TBI, will be delivered to participants over a 12-month period, divided into 22 in-person, group sessions. The intervention promotes 5-7% weight-loss by reducing calories and increasing exercise (150 minutes of moderate physical activity per week).
2850483|NCT03594734|Active Comparator|Attention Control Group|The attention control group will meet at the same frequency as the GLB-TBI group over a 12-month period. The attention control group will receive education composed of the content from the TBI Model Systems Knowledge Translation Center's factsheets. No education on weight-loss strategies will be provided.
2850484|NCT03594721|Experimental|Fitzpatrick Skin Types I-III|Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
2850485|NCT03594721|Experimental|Fitzpatrick Skin Types IV-V|Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
2850486|NCT03594708|Placebo Comparator|Placebo|placebo consisting of rice starch, light olive oil, and vegetable oil
2850487|NCT03594708|Active Comparator|Supplement|active supplement consisting of a fermentable fiber, omega-3 polyunsaturated fatty acid, vitamin D3, vitamin E, and zinc
2850488|NCT03594695||Group G|Patients undergoing general anesthesia HSCRP and NLR measurement
2850489|NCT03594695||Group R|Patients undergoing spinal anesthesia HSCRP and NLR measurement
2850490|NCT03594682|Experimental|dose titration group|First of all, according to the patient's weight and ECOG score, patients were divided into three groups（the initial dose of 250 mg qd,250 mg/500 mg qd by turns, 500 mg qd）. in two weeks, if the patient who is intolerant of the initial dose,250mg qod,250mg qd ,250mg qd was selected. if the patient can tolerate the dose well,a high-dose was given,and the maximum dose does not exceeding 750mg qd.
2850491|NCT03594682|Active Comparator|non-titration group|Patients were given 750mg qd apatinib until disease progression or intolerance
2850492|NCT03594669|Experimental|Intervention|"When enrolled into the study, the participants will be asked to join a group in WhatsApp for purposes of the research study. The application will be used to: deliver reminders for each treatment session; deliver daily prompts for the home exercise program; and present a web-link to the home exercise program (HEP).~Participants will receive physical therapist delivered multi-modal sensorimotor training interventions. The exercises delivered at each intervention will be delivered in a group format, using a circuit of exercises that each athlete will complete in a session. Subsequent sessions will build upon previous sessions to work the sensorimotor control system in progressively more challenging and sport-specific scenarios. This present study will complete 8 sessions over 4 weeks."
2850493|NCT03594656|Experimental|Early-start Group|Receiving Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 72 weeks
2850494|NCT03594656|Placebo Comparator|Delayed-start Group|Receiving placebo for 24 weeks followed by Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 48 weeks
2850495|NCT03594643||electronic cigarette|patient using electronic device, electronic cigarette
2850496|NCT03594643||control|patient not smoking nor using electronic cigarette
2850497|NCT03594630|Active Comparator|Group I (surgical resection)|Participants who have achieved clinical complete response undergo standard surgical resection.
2850498|NCT03594630|Experimental|Group II (active surveillance)|Participants who have achieved clinical complete response receive active surveillance and consolidated chemotherapy for up to 4 months in the absence of disease progression or unacceptable toxicity. Participants with incomplete response or regrowth of tumor, undergo surgical resection as in Group I.
2850499|NCT03594617|Experimental|ICC-C|Intervention: Interaction Competencies with children - for Caregivers (ICC-C) 11 days with 8 hours of training for caregivers. Core training components include caregiver-child interactions, maltreatment prevention, effective discipline strategies, child-centered institutional care, identifying and supporting burdened children and implementation of the training materials into the daily working
2850500|NCT03594617|No Intervention|Control institutions|The control institutions do not receive any intervention.
2850501|NCT03594604|Experimental|Norethindrone|Delaying menstruation using Norethindrone 5mg three times daily in women who desire postponement of their period for social or personal reasons.
2850502|NCT03594604|Active Comparator|Oral Contraceptive Pills|Women who desire postponing their periods are typically treated with oral contraceptive pills, the current standard of care.
2850503|NCT03594578|Experimental|Episodic future thinking|"Participants will complete a guided interview designed to elicit a number of personalized events that are likely to occur during various future time frames (e.g., 1 day, 1 week, 3 months, 1 year, etc.), as well as text cues designed to prompt episodic future thinking (e.g., In 3 months, I will be at my daughter's wedding). Text cues will be presented during subsequent behavioral tasks and participants will be asked to think vividly about these events."
2850590|NCT03593941||Alzheimer's dementia and challenging behaviour symptoms|Care home residents >65y No interventions as this is a pilot project
2850504|NCT03594578|Sham Comparator|Episodic recent thinking (control)|"Participants will complete a guided interview designed to elicit a number of personalized events that occurred in the recent past (e.g., earlier today, yesterday), as well as text cues designed to prompt episodic thinking (e.g., Earlier today, I was playing tennis with my wife.). Text cues will be presented during subsequent behavioral tasks and participants will be asked to think vividly about these events."
2850505|NCT03594565|Experimental|Local steroids prior to CGMS insertion|"topical spraying of fluticasone propionate nasal spray (nsFP) on the skin area of CGMS placement prior to sensor insertion in a group of pediatric T1D patients who had mild to severe local skin reactions to CGMS adhesives.~Dosage: 2 puffs."
2850506|NCT03594552|Experimental|Placebo, Arbaclofen_15, Arbaclofen_30|Dose order: Placebo, Arbaclofen 15mg, Arbaclofen 30mg
2850507|NCT03594552|Experimental|Placebo, Arbaclofen_30, Arbaclofen_15|Dose order: Placebo, Arbaclofen 30mg, Arbaclofen 15 mg
2850508|NCT03594552|Experimental|Arbaclofen_30, Placebo, Arbaclofen_15|Dose order: Arbaclofen 30mg, Placebo, Arbaclofen 15mg
2850509|NCT03594552|Experimental|Arbaclofen_15, Placebo, Arbaclofen_30|Dose order: Arbaclofen 15mg, Placebo, Arbaclofen 30mg
2850510|NCT03594552|Experimental|Arbaclofen_15, Arbaclofen_30, Placebo|Dose order: Arbaclofen 15mg, Arbaclofen 30mg, Placebo
2850511|NCT03594552|Experimental|Arbaclofen_30, Arbaclofen_15, Placebo|Dose order: Arbaclofen 30mg, Arbaclofen 15mg, Placebo
2850512|NCT03594539|No Intervention|Standard|Participants will have their hyperphosphatemia managed with lanthanum carbonate 1 g with meals and 500 mg with snacks as per typical care, for 2 weeks.
2850513|NCT03594539|Placebo Comparator|Intervention|Participants will take a placebo instead of standard care with a phosphate binder, for 2 weeks.
2850514|NCT03594526|Experimental|Maternal support to become mother|"Maternal support to become mother: is an intervention based on the mid-range nursing theory of Ramona Mercer, whose purpose is to empower first-time mothers in their new maternal role, favoring the mother-child bond, strengthening social support and maternal self-efficacy, consists of:~Four Home visits , in the first week; first month of baby life; at three months; and the fourth postpartum month.~Four Educational sessions and support sessions for maternal empowerment in each home visit.~Telephone follow-up: at 15 days; a month and a half; at two and a half months; and three and a half months postpartum."
2850515|NCT03594526|Active Comparator|Control group: usual Care|The participants will receive the usual education about the care of the mother during the puerperium, the care of the newborn, including breastfeeding.
2850516|NCT03594513|Active Comparator|MCAF+PR+CTG|The partial restoration of the NCCL will be performed prior the surgeries and will be carried out with composite resin.The surgical procedure for root coverage will be carried out by means modified coronally advanced flap and will be performed by starting with oblique incisions in the interdental areas, which continued with the intrasulcular incision at the recession defects.Each surgical papilla will be dissected in a split-thickness and the envelope flap will be raised with a split-full-split thickness in the coronal-apical direction. Additionally, this group will receive the connective tissue graft harvested from the palate on the recessed area before the sutures.Then, the flap will be coronally positioned and sutured to completely cover the graft.
2850517|NCT03594513|Experimental|MCAF+PR+XMD(Mucoderm®)|The partial restoration of the NCCL will be performed prior the surgeries and will be carried out with composite resin.The surgical procedure for root coverage will be carried out by means modified coronally advanced flap and will be performed by starting with oblique incisions in the interdental areas, which continued with the intrasulcular incision at the recession defects.Each surgical papilla will be dissected in a split-thickness and the envelope flap will be raised with a split-full-split thickness in the coronal-apical direction. Additionally, this group will receive a porcine acellular dermal matrix on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
2850518|NCT03594500|Experimental|Intervention: PockeTalker|Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department
2850519|NCT03594500|Other|Control: No PockeTalker|Consenting participants will be randomly assigned to the control group while receiving care in the emergency department
2850520|NCT03594487|Experimental|Interventional FMT Treatment Arm|"After providing written informed consent, subjects will undergo screening and baseline assessments of stool and blood sampling, questionnaires, physical examination, MS rating scales, and MRI. Subjects will then initiate an oral antibiotic regimen for 5 days to precondition the gut for the Fecal Microbiota Transplantation (FMT) of FMP30 donor stool and optimize engraftment of the FMP30 donor stool microbiome. Following standard bowel preparation for colonoscopy, subjects will undergo the FMT procedure by an experienced gastroenterologist. Subjects will return for scheduled assessments and follow-up MRI for 12 weeks, with additional safety and biomarker follow-up for 36 weeks.~The active study time is designed to be short (12 weeks active phase) to minimize time not on other MS disease modifying therapy (DMT). This arm of the study will last for approximately 52 weeks total (4 weeks of screening + 12 weeks active treatment phase + 36 weeks of safety follow up)."
2850521|NCT03594487|Active Comparator|Observational Control Arm|"Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.~After providing written informed consent, subjects will undergo screening and baseline assessments, including collection of blood and stool samples, demographic data collection, concomitant medication review, and an MS Relapse assessment. At week 2, subjects will mail in stool samples with a prepaid air bill and packaging. Weeks 4, 8, and 12 assessments will include concomitant medication review, relapse assessment, and blood and stool collection.~The duration of the study for the observational control arm will last for 12 weeks. All study procedures will be performed at the University of California, San Francisco."
2850522|NCT03594474|No Intervention|control group|Begins treatment with 0.5 g/kg per day of 20% Intravenous Lipid Emulsion (IVLE) after birth if the birth weight is less or equal 1000g or 1 g/kg per day if birth weight is more than 1000g. The IVLE dose in this group will be increased by 0.5 g/kg per day daily until reaching 3 g/kg per day.
2850523|NCT03594474|Experimental|experimental group|"The experimental group will begin treatment with 2 g/kg per day of 20% Intravenous Lipid Emulsion after birth.~The dose of IVLE will be increased directly from 2 to 3 g/kg per day the next day in this group."
2850591|NCT03593941||Alzheimer's dementia and no challenging behavioural symptoms|Care home residents >65y No interventions as this is a pilot project
2850524|NCT03594461|Experimental|2mg IAI q2w|2mg Intravitreal Aflibercept injection will be given every 2 weeks starting at baseline and then at weeks 2, 4, 6, 8, 10 and 12. Patients will then be seen at week 16 (4 weeks following the end of the intensive dosing period), and a treat and extend regimen will be initiated through week 52.
2850525|NCT03594461|Experimental|2mg IAI q3w|2mg Intravitreal Aflibercept injection will be given every 3 weeks starting at baseline and then at weeks 3, 6, 9 and 12. Patients will then be seen at week 16 (4 weeks following the end of the intensive dosing period), and a treat and extend regimen will be initiated through week 52.
2850526|NCT03594448||Ancillary-correlative (Specimen collection)|Participants undergo collection of blood samples in addition to the usual amount collected when they come in for their regular cancer treatments or doctor?s appointment every 6-8 weeks until disease progression or stopping at 9 months.
2850527|NCT03594435|Experimental|Ibudilast|10mg delayed-release capsules, target dose 50mg BID (5 x 10mg capsules twice daily) for 12 weeks
2850528|NCT03594435|Placebo Comparator|Placebo Oral Capsule|matched to experimental drug
2850529|NCT03594422|Experimental|HQP1351|The starting dose for this study was 20 mg .The sequence dose would be 30mg, 40mg, 50mg and 60mg.Doses can be modified depending on emerging toxicity data and PK results after the discussions between the Investigators and Sponsor.
2850530|NCT03594396|Experimental|MEDIOLA|"Prior to the start of study medication, tumor tissue and blood will be collected as baseline. Olaparib 300mg bid will be started after the collection of tumor and blood. Olaparib will be given on days 1-28 days without rest.~Tumor tissue and blood will be collected on day 14 before administration of durvalumab, to see the change in biomarkers after 2 weeks of olaparib treatment. After the acquisition of tumor and blood, durvalumab will be given in a fixed one dose of 1.5 gram on day 15.~On day 29, there will be a third acquisition of tumor and blood, to see the change in biomarkers after combination treatment of olaparib and durvalumab. Tumor response will also be evaluated according to RECIST criteria version 1.1 based on CT."
2850531|NCT03594370||control|Limbal image by OCT in normal subjects.
2850532|NCT03594370||Advancing wave-like epitheliopathy|Limbal image by OCT in subjects with advancing wave-like epitheliopathy.
2850533|NCT03594370||Ocular rosacea or phlyctenulosis|Limbal image by OCT in subjects with ocular rosacea or phlyctenulosis
2850534|NCT03594357||Multiple sclerosis|MS patients (EDSS: 0-5,5)
2850535|NCT03594357||Control|Healthy individuals without chronic disease
2850536|NCT03594344|Experimental|Hyperbaric oxygen therapy|30 sessions of Hyperbaric oxygen therapy, 90min treatment at 2,4 ATA(atmosphere absolute) with 100% oxygen.First session must be given within 7 days after initial amputation. Treatment is given as outpatient treatment after discharge from hospital.
2850537|NCT03594344|No Intervention|Control group|Control group will be given standard of care with follow up at the outpatient clinic after discharge from hospital.
2850538|NCT03594331|Experimental|Gluten Exposure Group 1|This group will ingest the drug and then consume a study meal containing a low level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding as to at which visit placebo is given.
2850539|NCT03594331|Experimental|Gluten Exposure Group 2|This group will ingest the drug and then consume a study meal containing a medium level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding as to at which visit placebo is given.
2850540|NCT03594331|Experimental|Gluten Exposure Group 3|This group will ingest the drug and then consume a study meal containing a high level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding as to at which visit placebo is given.
2850541|NCT03594305|Experimental|Educational Intervention Arm|Villages randomized to this arm will receive a one-day educational seminar, which their religious leaders of all denominations will be invited to attend. The seminar will address religious, cultural, and medical aspects of family planning. Leaders who attend will also have the opportunity to participate in mentorship group discussions after the intervention. In addition, both villages will have standard teaching provided by nurses at dispensaries about family planning, and a continual supply of contraceptive options at dispensaries in all villages will be ensured.
2850542|NCT03594305|No Intervention|Control arm|Villages randomized to this arm will not receive the educational seminar. These villages will have standard teaching provided by nurses at dispensaries about family planning, and a continual supply of contraceptive options at dispensaries in all villages will be ensured.
2850543|NCT03594292|Experimental|FASTFORWARDTM Bunion|The participants are treated with FASTFORWARDTM Bunion Correction system. The FASTFORWARDTM Bunion Correction system employed 3D printed titanium bone tether plate at second metatarsal. Due to the merit of 3D printing technology, the plate is designed to broadly distribute forces across bone to secure mechanical integrity of the bone. The FASTFORWARDTM Bunion Correction system has been cleared by the United States Food and Drug Administration.
2850544|NCT03594292|Active Comparator|Conventional Surgery|The participants are treated with fusion surgery. This procedures is a standard treatment for 1st metatarsal hallux valgus by cutting, realigning and fusing the 1st metatarsal or fusing the metatarsal-cuneiform joint.
2850545|NCT03594279|Experimental|Community Mobilization|This arm will receive specific messages regarding the prevention and management of childhood diarrhea and pneumonia. The investigators will form village committees (VC) consisting of prominent members of the community (6-8 in a group) to carry out awareness and motivational activities for the uptake of the identified interventions.
2850546|NCT03594279|Experimental|Community Mobilization and Community Incentive|In this arm, along with the interventions in the community mobilization arm, community based incentives will also be provided. The clusters which improve the practices for preventive and curative strategies for diarrhea and pneumonia will receive community-based incentive including structural benefits linked to health including tube wells, water supply, toilets in community/schools, water storage facility or any other incentive as decided with the respective village committees.
2850547|NCT03594279|No Intervention|Control|This arm will receive the routine standard of care.
2850548|NCT03594266|Experimental|Therapy A Spinal Cord Stimulation Parameter Set|
2850549|NCT03594266|Experimental|Therapy B Spinal Cord Stimulation Parameter Set|
2850592|NCT03593941||Older adults without dementia|Care home residents >65y No interventions as this is a pilot project
2858190|NCT03540940|Experimental|Positive end expiratory pressure|
2850550|NCT03594253|Experimental|RFP-C|Regulation Focused Psychotherapy for Children (RFP-C; Hoffman & Rice with Prout, 2015) is a novel, manualized, time-limited psychodynamic treatment approach for children who manifest disruptive behaviors and emotional dysregulation. Throughout the 16 sessions of play therapy and four parent meetings, the clinician works with the parents and the child to increase understanding that all behavior, even disruptive behavior, has meaning in the service of emotional and behavioral regulation. This insight leads to a decreased need and reliance to act on the distressing emotions (e.g. less need for disruptive behaviors) and an increased ability to tolerate, work through, and talk about the feelings that previously needed to be warded off.
2850551|NCT03594253|No Intervention|Wait List control|Participants assigned to this condition will receive no intervention. They may continue on current medication regimens (no major changes) but may not be enrolled in psychological treatments. They will be evaluated weekly via phone call with primary caregiver. At the conclusion of this 10-week wait list period all participants assigned to this condition will receive RFP-C treatment.
2850552|NCT03594240|Active Comparator|intervention group|Intervention group included pediatric patients with diabetic nephropathy receiving oral vitamin B complex tablets( Neurorubine TM -Forte Lactab TM ) once daily.
2850553|NCT03594240|Placebo Comparator|Control group|Placebo group or control patients received placebo that were similar in appearance to vitamin B complex tablets and the administered dose was as the same schedule as vitamin B complex .
2850554|NCT03594227|Active Comparator|Low dose|ATI-501 low dose
2850555|NCT03594227|Active Comparator|Mid dose|ATI-501 mid dose
2850556|NCT03594227|Active Comparator|High dose|ATI-501 high dose
2850557|NCT03594227|Placebo Comparator|Vehicle|Vehicle
2850558|NCT03594214||Single arm|pre-treatment serum vitamin d level measured by ELISA kit in patients confirmed for diagnosis with invasive breast cancer and before receiving any treatment for breast cancer
2850559|NCT03594201||group1|A+B grade sperm count after treatment=0
2850560|NCT03594201||group2|0＜A+B grade sperm count after treatment≤10^6
2850561|NCT03594201||group3|10^6＜A+B grade sperm count after treatment＜2*10^6
2850562|NCT03594201||group4|A+B grade sperm count after treatment≥2*10^6
2850563|NCT03594188|Experimental|general anesthesia|Patients in this group will have RF ablation for treatment of HCC under general anesthesia.
2850564|NCT03594188|Active Comparator|local anesthesia|Patients in this group will have RF ablation for treatment of HCC under local anesthesia.
2850565|NCT03594175|Experimental|CUSA-081|Participants will receive 1 or 2 doses of CUSA-081, 0.7 milligrams (mg) (0.4 units) per 2 milliliter (mL) directly into the catheter lumen. Participants will receive the first dose at minute (min) 0, and the second dose, if needed, at min 90.
2850566|NCT03594175|Placebo Comparator|Placebo|Participants will receive 1 or 2 doses of placebo (normal saline) directly into the catheter lumen. Participants will receive the first dose at min 0, and the second dose, if needed, at min 90.
2850567|NCT03594175|Active Comparator|Alteplase|Participants will receive 1 or 2 doses of alteplase, 2 mg/mL, directly into the catheter lumen. Participants will receive the first dose at min 0, and the second dose, if needed, at min 90.
2850568|NCT03594149|Experimental|antibacterial prophylaxis|Levofloxacin 500 mg/d p.o. during the first 3 cycles of azacytidine
2850569|NCT03594149|No Intervention|control|No levofloxacin will be given.
2850570|NCT03594136|Experimental|Telemetric intracranial pressure implant|A telemetric intracranial pressure monitoring sensor is inserted into the brain parenchyma at the end of an uncomplicated surgery for an unruptured aneurysm
2850571|NCT03594123|Experimental|Brexpiprazole Arm 1|Oral tablet; taken once daily. Total daily dose of 2 mg/day
2850572|NCT03594123|Experimental|Brexpiprazole Arm 2|Oral tablet; taken once daily. Total daily dose of 3 mg/day
2850573|NCT03594110|Experimental|Empagliflozin|
2850574|NCT03594110|Placebo Comparator|Placebo|
2850575|NCT03594097|Experimental|Treatment cookies|
2850576|NCT03594097|Active Comparator|Control cookies|
2850577|NCT03594058|Experimental|Solabegron modified release tablets low dose|
2850578|NCT03594058|Experimental|Solabegron modified release tablets high dose|
2850579|NCT03594058|Placebo Comparator|Placebo Comparator|
2850580|NCT03594045|Experimental|Apixaban for HIT|Patients with Heparin Induced Thrombocytopenia (HIT) will receive Apixaban, at an initial dose of 10 mg orally twice a day for 7 days followed by 5 mg twice a day for a total of 30 days.
2850581|NCT03594045|Experimental|Apixaban for HITT|Patients with Heparin Induced Thrombocytopenia with Thrombosis (HITT) will receive Apixaban, at an initial dose of 10 mg orally twice a day for 7 days followed by 5 mg twice a day for a total of 3 months.
2850582|NCT03594019|Placebo Comparator|Control Group|Patients in the control group will follow the conventional treatment protocol. Briefly, hopeless tooth will be extracted atraumatically. Implant will be placed in the palatal side and grafting materials will be filled in the buccal gap. Healing abutment will placed and collegan sponge will be used to seal the wound. After 4 months, implant impression and crown delivery will be finished.
2850583|NCT03594019|Experimental|Test Group|Patients in the test group will receive conventional immediate implant placement combined with connective tissue graft. After 4 months, implant impression and crown delivery will be finished.
2850584|NCT03594006|Other|Cancer patients on active therapy|
2850585|NCT03593993||Surgical Cohort|Blood, cerebrospinal fluid, and tumor tissue will be obtained from each participant on this arm.
2850586|NCT03593980|Experimental|400ml cranberry juice|Patients will be given 400ml of cranberry juice to drink 3 hours prior to cesarean delivery.
2850587|NCT03593967|Experimental|Intervention Group|Youths and seniors in the intervention group will be paired to receive a novel five-week (3 hours/ week) bilingual (English/ Mandarin), intergenerational arts programme which includes guided museum tours, collaborative art-making and story telling as well as reflective writing. These sessions will be held at the National Museum, and facilitated by experienced artists and trained art therapists.
2850588|NCT03593967|Experimental|Waitlist Control Group|Participants will serve as a waitlist control group before receiving the intervention that the intervention group receives at the end of 5 weeks.
2850589|NCT03593954|Experimental|JNJ-61393215 2 mg + Ritonavir 100 mg|Participants will receive suspension of JNJ-61393215 2 mg (Day 1 and 5) orally and tablet of Ritonavir 100 mg twice a Day (Day 4-14) orally.
2850593|NCT03593915|Experimental|Ph 1b and 2: Pts w/ previously untreated MDS|"Patients with previously untreated MDS~Patients with MDS who have received <6 cycles of HMAs~Patients with de novo (cause unknown) or secondary MDS (treatment-related) who are not eligible for intensive induction chemotherapy or stem cell transplant~All French-American-British (FAB) subtypes~Intermediate and above per IPSS-R groups"
2850594|NCT03593902|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, fludarabine, cyclophosphamide, Mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
2850595|NCT03593889|Experimental|Intervention group|The intervention group will receive a collaborative stepped care programme provided by registered social workers and trained peer supporters from elderly or mental health service units (NGOs) according to level of risks, symptom severity, and intervention response. Home visits or other format of contact will be delivered by trained peer supporters employed by NGOs to detect and engage hidden cases.
2850596|NCT03593889|Other|Control group|The control group will receive treatment as usual, which will be determined by the responsible worker from NGO units.
2850597|NCT03593876|Experimental|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
2850598|NCT03593863|No Intervention|"PE as Usual Control Group"|The Control Group will be asked to continue with their normal PE lessons
2850599|NCT03593863|Experimental|Intervention Group|Physical Education (PE) Programme
2850600|NCT03593850|Experimental|Music group|"Patients in this arm listened through headphones to a song of 29 minutes and 32 seconds duration. The song was composed entirely by investigator Juan Martin-Saavedra and registered to copyright and authorship regulatory entities from Colombia under the name Occasio adolore (Musical piece No. 5-559-355 and Phonogram No. 12-105-295 of Colombia's Copyright authorship agency). Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Silence group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise."
2850601|NCT03593850|Active Comparator|Silence group|Patients on the silence group listened to a 29 minute and 32 second audio file that produced no sounds with headphones on. Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Music group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise.
2850602|NCT03593837|Experimental|Experimental group|Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg).
2850603|NCT03593837|Placebo Comparator|Placebo group|Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg).
2850604|NCT03593824|Experimental|dense cataract group|
2850605|NCT03593824|Experimental|non-dense nuclear cataract group|
2850606|NCT03593811|Active Comparator|Healthy Controls|Healthy Volunteers with no known gastrointestinal complications will be given questionnaires and testing by electrogastrogram (EGG) and/or magnetogastrogram (MGG) after an overnight fast to determine nausea parameters. They will also have a electrocardiogram (EKG) and do some testing after being fed a protein bar.
2850607|NCT03593811|Active Comparator|Non-nauseated|Functional nausea patients with a score of 0-2 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
2850608|NCT03593811|Active Comparator|Mildly nauseated|Functional nausea patients with a score of 3-4 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
2850609|NCT03593811|Active Comparator|Moderately nauseated|Functional nausea patients with a score of 5-6 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
2850610|NCT03593811|Active Comparator|Severely nauseated|Functional nausea patients with a score of 7-9 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar. Some patients will also be tested after receiving a one time dose of a 8mg disintegrating tablet of ondansetron followed by a 2 day washout period prior to testing again after a 5 day maintenance dose of oral cyproheptadine (0.04-0.62 mg/kg/day).
2850611|NCT03593785|Experimental|Cohort 1|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 1 injection (6 subjects) or matching placebo (2 subjects).
2850612|NCT03593785|Experimental|Cohort 2|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 2 injection (6 subjects) or matching placebo (2 subjects).
2850613|NCT03593785|Experimental|Cohort 3|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 3 injection (6 subjects) or matching placebo (2 subjects).
2850614|NCT03593785|Experimental|Cohort 4|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 4 injection (6 subjects) or matching placebo (2 subjects).
2850615|NCT03593785|Experimental|Cohort 5|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 5 injection (6 subjects) or matching placebo (2 subjects).
2850616|NCT03593772|Active Comparator|Treatment arm|Treatment Arm: MR is an user-driven, dyadic, self-care management program developed with NIMH funding (R43/44) for use by Veterans and their selected partners, individually or together, to reduce pain and distress and support physical, mental, and relationship health. MR was designed for Veterans who face obstacles accessing formal mental health services. It can also be used to complement formal services. MR is a patient-centered intervention, allowing users to determine the pace at which to proceed in each program component. MR Content. The program provides video and audio instruction in a set of 11 evidence-based wellness.
2850756|NCT03592862|Experimental|HTL0018318 low dose|oral capsule, once daily
2850617|NCT03593772|Placebo Comparator|Control arm|Usual Care Waitlist Control Arm: For ethical reasons, this study will use a waitlist control arm to ultimately provide all participants exposure to the MR intervention. Dyads in the control arm will participate in all assessments like those in the treatment group, however, they will be asked to agree to not access the public web site during their participation. Wait-list control participants will be instructed to seek advice about treatment from their providers. Other than this initial advice, there will be no attempt by study personnel to influence condition management unless an issue (i.e., suicidal ideation) arises. The control condition will account for potential temporal effects that occur from passage of time (brief), and expectation effects associated with anticipation of MR participation. The control group will receive access to MR after they complete data collection.
2850618|NCT03593759|Active Comparator|Prednisone|Prednisone 0.5 mg kg/day for 6 months (max dose 30 mg)
2850619|NCT03593759|Experimental|Methotrexate|Methotrexate 15-20 mg orally, sc, or IM once a week for 6 months + prednisone 20 mg po daily for one month then 10 mg po daily for one month then 5 mg po daily for one month and then stop. Also Folic Acid 2 mg po daily for 6 months.
2850620|NCT03593746|Experimental|HIIT and LED therapy|Light-Emitting Diode (LED) therapy followed by physical training with high intensity interval training (HIIT)
2850621|NCT03593746|Sham Comparator|High intensity interval training (HIIT)|Light-Emitting Diode (LED) therapy simulation followed by physical training with high intensity interval training (HIIT)
2850622|NCT03593746|Experimental|Combined training and LED therapy|Light-Emitting Diode (LED) therapy followed by physical training with combined training
2850623|NCT03593746|Sham Comparator|Combined training|Light-Emitting Diode (LED) therapy simulation followed by physical training with combined training.
2850624|NCT03593733|Experimental|Cold Water Immersion|Cold Water Immersion
2850625|NCT03593733|Experimental|Photobiomodulation Therapy|Photobiomodulation Therapy
2850626|NCT03593720||Hypospadius|Patients with hypospadias
2850627|NCT03593720||Control|Patients without hypospadias
2850628|NCT03593707|Experimental|Metformin Alone|Metformin alone
2850629|NCT03593707|Experimental|Metformin + PF-06865571|Co-administer metformin and PF-06865571
2850630|NCT03593694|Other|Group 1|"Arm: Other: Group 1 Participants in this group will receive the culturally tailored education booklet titled Your Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session as detailed above."
2850631|NCT03593694|Active Comparator|Group 2|"Arm: Active Comparator: Group 2 Participants in this group will receive as detailed above, the culturally tailored education booklet titled My Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session. Patients will also be assigned the FORA Test-n-Go Series Blood Glucose and Blood Pressure monitors and provided glucose test strips to allow testing at least once a day during the initial face-to-face session."
2850632|NCT03593694|Experimental|Group 3|Arm: Experimental: Group 3 The intervention has 3 components: 1) diabetes education; 2) home telemonitoring; and 3) diabetes modified behavioral activation, delivered by nurses via smartphones. Trained nurses will deliver the TECH DM-BAT intervention via videoconferencing technology on smartphones.
2850633|NCT03593668|Active Comparator|Metformin|Metformin Hydrochloride Tablet 500mg po by month,three times a day for 12 weeks
2850634|NCT03593668|Active Comparator|Benaglutide|Benaglutide Injection 0.2mg, iH,po, three times a day for 3 12 weeks
2850635|NCT03593655|Experimental|Sequence A: Dapivirine vaginal ring + FTC/TDF|Participants will receive one 25 mg dapivirine vaginal ring inserted vaginally each month for 24 weeks, followed by one FTC/TDF oral tablet taken by mouth daily for 24 weeks, followed by participant's choice of either or neither study product for 24 weeks.
2850636|NCT03593655|Experimental|Sequence B: FTC/TDF + Dapivirine vaginal ring|Participants will receive one FTC/TDF oral tablet taken by mouth daily for 24 weeks, followed by one 25 mg dapivirine vaginal ring inserted vaginally each month for 24 weeks, followed by participant's choice of either or neither study product for 24 weeks.
2850637|NCT03593642|Placebo Comparator|Control Group|Erector spinae bilateral catheters with continuous infusion iso saline during 48h after surgery Day 0 to day 2
2850638|NCT03593642|Experimental|Regional analgesia group|Erector spinae bilateral catheters with continuous infusion Ropivacaine 0.1 or 0.2%, depending on age, infusion during 48h after surgeryDay 0 to day 2
2850639|NCT03593629|No Intervention|Standard of Care|Participants receive standard of care for PrEP, including 3-months of PrEP supply and HIV testing at clinic every three months
2850640|NCT03593629|Experimental|Blood-based HIV self-testing|Participants receive 6-months of PrEP supply and blood-based HIV self-tests for quarterly HIV testing.
2850641|NCT03593629|Experimental|Oral fluid HIV self-testing|Participants receive 6-months of PrEP supply and oral fluid HIV self-tests for quarterly HIV testing.
2850642|NCT03593616||Lens Phacoemulsification Group|insertion of intra-ocular lens
2850643|NCT03593603||Nellcor™ Bedside Respiratory Monitoring System|Patients on the general care floor who are prescribed non-invasive respiratory monitoring via spot check vital signs at least every 4 hours
2850644|NCT03593590||Ocrelizumab|Participants with relapsing or primary progressive MS receiving ocrelizumab under routine clinical care.
2850645|NCT03593564|Experimental|KINDER|The intervention will be provided with a 12-part psychoeducational intervention delivered online on a weekly basis. Online modules will be comprised of a short (approximately 3 minute) videos followed by more specific text-based information and links to additional resources. At the end of the module, participants will complete a short quiz, followed by a reflexive exercise to reinforce learning. Each model, participants will be asked to select a goal to complete a pleasurable activity and receive an option to set a text or email reminder to do so.
2850646|NCT03593564|No Intervention|Waitlist control group|"The waitlist control group is referred as no intervention since the intervention will be provided after all data points are collected for participants in this arm. While the investigators will recommend these caregivers access another online program, called CareJourney, they will not follow whether these caregivers actually accessed this program."
2850647|NCT03593551|Experimental|relaxation and control|All participants will attend five relaxation treatments and one control. The order of treatments and control will be randomised allocated to participants.
2850757|NCT03592862|Placebo Comparator|Placebo|oral capsule, once daily
2850648|NCT03593538|Experimental|Low Dose Metformin|Days 1-7: Metformin 500 mg capsule 1x/day; Days 8-14: Metformin 500 mg capsule 1x/day and Placebo capsule 1x/day; Days 15-23: Metformin 500 mg capsule 1x/day and Placebo capsule 2x/day
2850649|NCT03593538|Experimental|High Dose Metformin|Days 1-7: Metformin 500 mg capsule 1x/day; Days 8-14: Metformin 500 mg capsule 2x/day; Days 15-23: Metformin 500 mg capsule 3x/day
2850650|NCT03593538|Placebo Comparator|Placebo|Days 1-7: Placebo 500 mg capsule 1x/day; Days 8-14: Placebo capsule 2x/day; Days 15-23: Placebo capsule 3x/day
2850651|NCT03593525|Experimental|SPARK Intervention|"Participants will complete symptom screening using SPARK once daily on a study-supplied iPad. For inpatients, daily reminders to complete SSPedi will appear on the iPad. Reports will be available to the child at any time. For outpatients, clinical research associates will provide the iPad in person daily and reports may be viewed at those encounters. The intervention is daily symptom screening with provision of reports to the healthcare team. Severe symptoms will result in email alerts. More specifically, SSPedi reports will be printed daily and provided in the patient chart. On days 1 and 3, an alert will be emailed to the physician providing direct medical care if any symptom is a lot or extremely bothersome (score 3 or 4 on 0-4 scale). Reports and alerts will have links to SPARK-housed CPGs."
2850652|NCT03593525|No Intervention|Standard of Care Arm|Participants randomized to the control arm will not complete daily symptom screening. They will complete SSPedi on days 1 and 5 to obtain the primary outcome. Health care providers will not be notified of their SSPedi scores and no symptom reports or symptom alerts will be generated.
2850653|NCT03593512|Experimental|PPN DBS|All patients will undergo bilateral PPN DBS
2850654|NCT03593486|Experimental|Active Stimulation|Participants will receive active EMF stimulation through the study device for 60 minutes during the procedure.
2850655|NCT03593486|Sham Comparator|Sham Stimulation|The participant will be positioned in the stimulator, but no EMF stimulation will be delivered.
2850656|NCT03593473|Experimental|Intranasal Oxytocin|Participants block randomized to Oxytocin intranasal spray by risk status at enrollment in the Mood, Mother and Infant (MMI) study and as verified by structured clinical diagnostic interview (no history of depression or anxiety, past depression or anxiety, current depression or anxiety).
2850657|NCT03593473|Placebo Comparator|Placebo|Participants block randomized to placebo Intranasal spray with all equivalent ingredients except oxytocin. Blocks will be stratified by risk status at enrollment in the Mood, Mother and Infant (MMI) study and as verified by structured clinical diagnostic interview (no history of depression or anxiety, past depression or anxiety, current depression or anxiety).
2850658|NCT03593460|Experimental|sPIF 1 mg/kg (Starting Dose)|Patients will be administered a starting dose of sPIF 1mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
2850659|NCT03593460|Experimental|sPIF 2 mg/kg|Patients will be dosed at 2mg/kg sPIF for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels.
2850660|NCT03593460|Experimental|sPIF 3 mg/kg|Patients will be administered a starting dose of sPIF 3mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
2850661|NCT03593460|Experimental|sPIF 4 mg/kg|Patients will be administered a starting dose of sPIF 4mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
2850662|NCT03593460|Experimental|sPIF 5 mg/kg|Patients will be administered a starting dose of sPIF 5mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels.
2850663|NCT03593447|Experimental|non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181+Ribavirin
2850664|NCT03593447|Experimental|non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin
2850665|NCT03593447|Experimental|non-cirrhotic subjects. low TG-2349+ low DAG181|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181
2850666|NCT03593447|Experimental|non-cirrhotic subjects. high TG-2349+ high DAG181|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181
2850667|NCT03593447|Experimental|cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin
2850668|NCT03593447|Experimental|cirrhotic subjects. high TG-2349+ high DAG181|HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181
2850669|NCT03593421|Experimental|synthetic preImplantation factor 1 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
2850670|NCT03593421|Experimental|synthetic preImplantation factor 2 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
2850671|NCT03593421|Experimental|synthetic preImplantation factor 3 mg/kg|Patients will be dosed SQ 14 doses
2850672|NCT03593421|Experimental|synthetic preImplantation factor 4 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
2850673|NCT03593421|Experimental|synthetic preImplantation factor 5 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
2850674|NCT03593408||Pediatric Patients on ECMO Support|
2850675|NCT03593395|Active Comparator|Arm 1-A|Small sized Program Structured Education Based Transition Program [STE]
2850676|NCT03593395|Experimental|Arm 1-B|Small sized program Structured Education Based Transition Program [STE] + Peer Mentoring [PM]
2850677|NCT03593395|Active Comparator|Arm 2-A|Large sized program Structured Education Based Transition Program [STE]
2850678|NCT03593395|Experimental|2-B|Large sized program Structured Education Based Transition Program [STE] + Peer Mentoring [PM]
2850679|NCT03593382||Female endurance athletes|Female endurance athletes recruited from Swedish and Danish national teams and competitive sport clubs
2850680|NCT03593369|Experimental|KLOX BioPhotonic System (single treatment)+SOC|KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered twice weekly in association with SOC (10 patients)
2850681|NCT03593369|Experimental|KLOX BioPhotonic System (consecutive treatments)+SOC|KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered in two consecutive treatments (twice weekly on the first two weeks then once weekly) in association with SOC (10 patients)
2850682|NCT03593369|Active Comparator|Standard of Care|SOC only (5 patients)
2850683|NCT03593356|Experimental|$333 monthly cash gift payments|These subjects receive $333 each month for 40 months via debit card.
2850684|NCT03593356|Placebo Comparator|$20 monthly cash gift payments|"These subjects receive $20 each month for 40 months via debit card. Although receiving the money and the debit card do not meet the formal definition of a placebo, the condition is better described as placebo comparator than either active comparator or no intervention."
2850685|NCT03593343|Experimental|Short overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 11 pm and stay overnight fasted afterwards for (9.5h).
2850686|NCT03593343|Experimental|Long overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 4.30 pm and stay overnight fasted afterwards for (16h).
2850687|NCT03593330|Experimental|Transitional Care Programme|The primary intervention of the Transitional Care Programme (TCP) will be additional patient education, framing of expectations for the hospital course and length of stay, coordinated team preparation for discharge, a dedicated discharge appointment, and a follow up phone call.
2850688|NCT03593330|No Intervention|Standard of Care|Patients are admitted without a pre-determined discharge date. They do not receive a dedicated discharge appointment, and will not receive a follow up phone call 48 hours after discharge.
2850689|NCT03593317|Experimental|Ramipril group|
2850690|NCT03593317|Placebo Comparator|Placebo group|
2850691|NCT03593304|Active Comparator|Experimental:Mecobalamin and Pyridoxine hydrochloride|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
2850692|NCT03593304|Placebo Comparator|Placebo: normal saline and Oral placebo|Injection normal saline (1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.Oral placebo pill 2 tablets thrice daily for 5 weeks.
2850693|NCT03593278|Experimental|Treatment and observation period|On Day 1, the subjects will receive a single s.c. dose of 16 mg 14C-radiolabeled ACT-246475 in the fasted state. Subjects will be followed by an observation period of 3 days (72 h) during which blood, urine, and feces samples will be collected.
2850694|NCT03593265|Experimental|Healthy group|healthy subjects MUNIX will be performed
2850695|NCT03593252|Experimental|Combination bowel prep|Patients will received mechanical bowel preparation (age appropriate dose, starting 2 days before surgery) and prophylactic oral antibiotics (3 doses, 1 day before surgery). The standard care will also be delivered (NPO for anesthesia and intravenous antibiotics on induction) Patients/parents will be provided with stool diary to document the adequacy of preparation. This will include frequency and character of stool according to Bristol grade.
2850696|NCT03593252|Active Comparator|Oral antibiotics|The patients will receive prophylactic oral antibiotics (3 doses, 1 day before surgery)as well as standard care (NPO for anesthesia and intravenous antibiotics on induction).
2850697|NCT03593252|Placebo Comparator|No prep|Patients will receive no pre-operative bowel prep. The will receive the standard care only.
2850698|NCT03593239|Experimental|Tobacco flavored JUUL 1.7% ENDS|Tobacco flavored JUUL 1.7% ENDS (10 puffs)
2850699|NCT03593239|Experimental|Tobacco flavored JUUL 5% ENDS|Tobacco flavored JUUL 5% ENDS (10 puffs)
2850700|NCT03593239|Experimental|Mint flavored JUUL 1.7% ENDS|Mint flavored JUUL 1.7% ENDS (10 puffs);
2850701|NCT03593239|Experimental|Mint flavored JUUL 5% ENDS|Mint flavored JUUL 5% ENDS (10 puffs)
2850702|NCT03593239|Experimental|Fruit Medley flavored JUUL 1.7% ENDS|Fruit Medley flavored JUUL 1.7% ENDS (10 puffs)
2850703|NCT03593239|Experimental|Fruit Medley flavored JUUL 5% ENDS|Fruit Medley flavored JUUL 5% ENDS (10 puffs)
2850704|NCT03593239|Experimental|Crème brulee flavored JUUL 1.7% ENDS|Crème brulee flavored JUUL 1.7% ENDS (10 puffs)
2850705|NCT03593239|Experimental|Crème brulee flavored JUUL 5% ENDS|Crème brulee flavored JUUL 5% ENDS (10 puffs)
2850706|NCT03593239|Experimental|JUUL 1.7% ENDS 10 puffs vs. ad lib puffs|Tobacco flavoured JUUL 1.7% ENDS products 10 puffs versus ad libitum puffs
2850707|NCT03593239|Experimental|JUUL 5% ENDS 10 puffs vs. ad lib puffs|Tobacco flavoured JUUL 5% ENDS products 10 puffs versus ad libitum puffs
2850708|NCT03593226|Experimental|AGI-134|AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
2850709|NCT03593226|Experimental|AGI-134 + Pembrolizumab|AGI-134 every three weeks for 4 cycles in combination with Pembrolizumab. Pembrolizumab will continue to be administered IV for a total of up to 17 cycles (one year of treatment).
2850710|NCT03593213|Experimental|Cariprazine 3.0 mg/day|Cariprazine capsules, oral administration, once daily.
2850711|NCT03593213|Experimental|Cariprazine 4.5 mg/day|Cariprazine capsules, oral administration, once daily.
2850712|NCT03593213|Placebo Comparator|Placebo|Matching placebo capsules, oral administration, once daily.
2850713|NCT03593200|Experimental|Experimental: Cohort 1|270 mg/day (up to 360 mg/day from Day 29) from Day 1 to Day 364*
2850714|NCT03593187|Experimental|Cal-1( LVsh5/C46) drug product|
2850715|NCT03593174|Experimental|Ossur Rigid Dressing|Use of ORD, which is a type of Removable Rigid Dressing (RRD), as a post tibial amputation dressing modality.
2850716|NCT03593174|Active Comparator|Elastic bandage|Use of the elastic bandage as a post amputation dressing modality.
2850717|NCT03593161|Experimental|Humor therapy|After baseline assessment (before start of conditioning), patients assigned to the experimental study arm will receive the standard psychosocial care plus weekly clown visits over the course of their inpatient stay for allogeneic stem cell transplantation.
2850718|NCT03593161|No Intervention|Treatment as usual|Patients assigned to the control arm will receive the standard psychosocial care over the course of their inpatient stay for allogeneic stem cell transplantation.
2850719|NCT03593148|Other|Lifestyle treatment|Patients will be included in the Lifestyle treatment that is a existing treatment program at Vestfold Hospital Trust.
2850720|NCT03593135|Experimental|Intervention group|Intervention group taking their diet according to their original meal pattern only dietary guideline were given regarding high glycaemic and low glycaemic diet. Medical treatments continued (including tablet Tagipment 50mg/1000mg twice a day)(Metformin + Sitagliptin group). 15ml apple cider vinegar (American garden organic vinegar) (containing 5% acetic acid) mixed in 200ml water during meal at night time was prescribed.
2856669|NCT03551769|Experimental|Cohort 1, Period 4|Study drug administered after an overnight fast
2850721|NCT03593135|Placebo Comparator|Comparison group|Control group also taking their diet according to their original meal pattern only dietary guideline were given regarding high glycaemic and low glycaemic diet. Medical treatment continued (including tablet Tagipmet 50mg/1000mg twice a day)( Metformin + Sitagliptin group). Flavor of apple cider vinegar used as placebo, mixed in 200ml plain water during meal at night time.
2850722|NCT03593122|Experimental|WO 2085 Moisturising Cream|"WO2085 is a hormone-free Moisturizing Cream and is used to treat vulvovaginal dryness symptoms."
2850723|NCT03593109|Experimental|LCAR-L10D treatment group|In LCAR-L10D treatment group, patients will be treated with dual specificity CD19 and CD22 CAR-T cells with a escalation approach, 4 CAR-T dosage will be tested in this study: 0.5×10^6, 1.5×10^6, 5.0×10^6, 15.0×10^6 CAR-T cells/kg.
2850724|NCT03593096|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
2850725|NCT03593096|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
2850726|NCT03593083|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
2850727|NCT03593083|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
2850728|NCT03593070|Experimental|CGMI-V|Caregivers in the Chronic Grief Management Intervention-Video (CGMI-V) condition will participate in eight weekly professionally led, real-time, live-streaming video online group sessions.
2850729|NCT03593070|No Intervention|Minimal Treatment (MT)|Those caregivers in the MT condition will receive written information materials about late-stage Alzheimer's disease or a related dementia at baseline.
2850730|NCT03593057|Experimental|Manual therapy protocol|Manual therapy protocol and self-care advice and body awareness. Three sessions of manual therapy will be applied, one every 15 days.
2850731|NCT03593057|Active Comparator|Control group.|Advice on self-care and body awareness.
2850732|NCT03593044|Experimental|One Week Atropine|0.01% concentration atropine drops
2850733|NCT03593031|Active Comparator|CI OBVAT|Patients with Convergence Insufficiency in Active Vision Therapy
2850734|NCT03593031|Sham Comparator|CI Sham therapy|CI Sham therapy
2850735|NCT03593031|Active Comparator|Controls OBVAT|Control receive active therapy
2850736|NCT03593031|Sham Comparator|Controls Sham|Subjects with Normal Binocular Vision will receive a therapy that appears to be therapeutic but does not have any binocular coordination benefits.
2850737|NCT03593018|Experimental|Oral Azacitidine|Oral azacitidine 300mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacitidine 200mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)
2850738|NCT03593018|Active Comparator|Investigator's choice therapy|Romidepsin 14mg/m² on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity) or Bendamustine 120mg/m² on days 1 and 2 of a 21-days cycle (during 6 cycles) or Gemcitabine 1200mg/m² on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)
2850739|NCT03593005|Experimental|Order A|The participants will be tested in the following order: Zurich (Low altitude: 470m above sea level) and consecutively High Altitude (Säntis; 2500m above sea Level)
2850740|NCT03593005|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
2850741|NCT03592992|Experimental|Spinal Hydromorphone|For the intervention group, 75 mcg of hydromorphone will be added to the spinal anesthetic mixture as a one-time injection prior to cesarean delivery.
2850742|NCT03592992|Active Comparator|Spinal Morphine|For the control group,150 mcg of preservative-free morphine will be added to the spinal anesthetic mixture as a one-time injection prior to cesarean delivery.
2850743|NCT03592979|Experimental|Order A|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
2850744|NCT03592979|Experimental|Order B|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
2850745|NCT03592966|Placebo Comparator|Placebo|Freeze-dried placebo powder
2850746|NCT03592966|Active Comparator|Wild Blueberry powder|Freeze-dried whole fruit blueberry drink.
2850747|NCT03592953|Experimental|Serious game Control group|The participants spend on three different scenarios from the game PerinatSims; basic scenarios designed to train Technical Skills (management of post partum hemorrhage according to the algorithm).
2850748|NCT03592953|Experimental|Serious game Experimental group|"The participants spend on three PerinatSims scenarios in which critical situations have been implemented, aiming to mobilize some of the non-technical skills of the learners: situation awareness, decision making, communication..."
2850749|NCT03592953|No Intervention|Classical teaching group|the students received the classical teaching of postpartum hemorrhage management and a reminder of the algorithm before the high fidelity simulation session.
2850750|NCT03592927|Experimental|Order A|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
2850751|NCT03592927|Experimental|Order B|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
2850752|NCT03592901||BPA Patients|Participants that are receiving brachial plexus anesthesia for a previously planned shoulder surgery.
2850753|NCT03592875||Professional nurses|A semi-structured interview will be used for data collection with 16 guiding questions addressing aspects related to Nursing Care Systematization knowledge and practices.
2850754|NCT03592862|Experimental|HTL0018318 high dose|oral capsule, once daily
2850755|NCT03592862|Experimental|HTL0018318 mid dose|oral capsule, once daily
2850758|NCT03592849|Experimental|UC-MSCs therapy|transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by thin endometrium or endometrial scarring
2850759|NCT03592836|Active Comparator|Continuous infusion of loop diuretics|Furosemide continuous infusion: 125 or 250 mg die
2850760|NCT03592836|Active Comparator|Intermittent infusion of loop diuretics|Furosemide bolus intermittent: 125 or 250 mg die
2850761|NCT03592823|No Intervention|control|receiving radiofrequency ablation and anticoagulant therapy
2850762|NCT03592823|Experimental|hydrochloroquine|receiving radiofrequency ablation, anticoagulant therapy and hydrochloroquine treatment (200 mg,bidpo)
2850763|NCT03592810||ECPR|All patients who received ECMO placement during cardiopulmonary resuscitation (ECPR)
2850764|NCT03592797|Experimental|Laser acupuncture therapy group|Each subject in the experimental group will receive laser acupuncture therapy using Handylaser Trion device (RJ Laser, Germany) to stimulate acupuncture points with laser beam irradiation.
2850765|NCT03592797|Sham Comparator|Sham laser acupuncture therapy group|Each subject in the sham control group will receive laser acupuncture therapy using Handylaser Trion device (RJ Laser, Germany). The laser device in the sham group will be deactivated and won't produce any laser beam irradiation on acupuncture points
2850766|NCT03592784|Experimental|Food Order Therapy + Medical Nutrition Therapy|
2850767|NCT03592784|Active Comparator|Medical Nutrition Therapy Alone|
2850768|NCT03592771|No Intervention|Usual Care|Participants will complete a survey at baseline, and then once every 6 months until March 2022 and agree to use an electronic pill monitoring device with their AET medication.
2850769|NCT03592771|Active Comparator|App|"Participants in this group will be asked to use a web-based app to report their AET use in the previous 7 days and any treatment-related symptoms or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week during the 6-month intervention phase.~Participants will complete a survey at baseline, and then once every 6 months until March 2022 and agree to use an electronic pill monitoring device with their AET medication."
2850770|NCT03592771|Active Comparator|App+Feedback|"Participants in this group will be asked to use a web-based app to report their AET use in the previous 7 days and any treatment-related symptoms or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week during the 6-month intervention phase.~In addition, participants in this group will also receive weekly tailored feedback text messages or images during the 6-month intervention phase.~Participants will complete a survey at baseline, and then once every 6 months until March 2022 and agree to use an electronic pill monitoring device with their AET medication."
2850771|NCT03592758||ultrasound assessment|all patient are evaluated by an ultrasound assessment before general anaesthesia
2850772|NCT03592745|Experimental|active tVNS + robotic arm therapy|Transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting ~60 minutes, 3x per week for 3 weeks.
2850773|NCT03592745|Sham Comparator|sham tVNS + robotic arm therapy|Sham (placebo) transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting ~60 minutes, 3x per week for 3 weeks.
2850774|NCT03592732||A|Patients with atrial fibrillation
2850775|NCT03592732||B|Patients without atrial fibrillation
2850776|NCT03592719|Experimental|MI-PrEP|"Participants in this arm will receive the manualized two-session intervention entitled Motivational Interviewing to Increase PrEP Uptake"
2850777|NCT03592719|Active Comparator|Enhanced Treatment as Usual (E-TAU)|Participants in this arm will receive two sessions which entail psychoeducation on PrEP.
2850778|NCT03592706|Experimental|IKC and TACE|IKC (Immune Killer Cells) and TACE(Transcatheter Arterial Chemoembolization)
2850779|NCT03592706|Active Comparator|TACE|TACE (Transcatheter Arterial Chemoembolization)
2850780|NCT03592693|Experimental|Vitamin-Steroid|"Combined Vitamin C and Stress-Dose Hydrocortisone: Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization."
2850781|NCT03592693|Placebo Comparator|Control|"Placebo plus placebo: Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization."
2850782|NCT03592680|Active Comparator|Vitamin C|Vitamin C 1000mg PO from 5 days before surgery until 10 days after surgery
2850783|NCT03592680|Placebo Comparator|Placebo|Placebo as an alternative for Vitamin C tablets
2850784|NCT03592667|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
2850785|NCT03592667|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
2850786|NCT03592654|Experimental|infant telehelp condition|caregiver coaching to improve infant behaviors that indicate they are at risk for autism spectrum disorder
2850787|NCT03592641|Experimental|Treatment (volitinib)|Participants receive volitinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2850788|NCT03592628|Placebo Comparator|Standard Instructions|Subjects enrolled in this arm received standardized teach-back regarding discharge instructions as well as the standard printed discharge instructions regarding post-cesarean wound care.
2850789|NCT03592628|Experimental|Enhanced Instruction|Subjects enrolled in this arm received standardized teach-back regarding discharge instructions as well as the standard printed discharge instructions regarding post-cesarean wound care AND they received an additional printed visual diagram.
2850790|NCT03592615|Experimental|Cataract group|All participants in this arm undergo cataract surgery for the purpose of vision correction.
2850791|NCT03592615|Experimental|Refractive error group|All participants in this arm undergo corneal refractive surgery for the purpose of vision correction.
2850792|NCT03592602|Experimental|arm movement|Male or female patients, age ≥ 18, who meet the indication of PICC placement and be able to move the arm (abducted and adducted) with compliance will be studied.
2850793|NCT03592589|No Intervention|control group|standard general anesthesia using sevoflurane delivered by a pediatric high concentration mask
2850794|NCT03592589|Experimental|Intervention group|sevoflurane will be deliver by a pediatric high flow nasal canula (2L/KG/min)
2850795|NCT03592563||Red group|"Those participants who had established diagnosis of one or more neurological and/or psychiatric conditions~Baseline: The participants' medical history, signs, symptoms and diagnoses of neurological and/or psychiatric disorders would be recorded. Neuro-QoL questionnaire plus an additional subset of questions based on their clinical diagnosis should be done."
2850796|NCT03592563||Yellow group|"Those participants who are high-risk to develop one or more neurological and/or psychiatric conditions, for example:~family history (first degree relative) one or more neurological and/or psychiatric conditions;~examination, imaging or laboratory findings consistent with pre-symptomatic stages of one or more neurological and/or psychiatric disorders.~Baseline: The participants' medical history, signs, symptoms and diagnoses of neurological and/or psychiatric disorders would be recorded. Neuro-QoL questionnaire should be done."
2850797|NCT03592563||Green group|"Those participants who are not meeting criteria for Red or Yellow groups, but interested in longitudinal research on maintenance and/or improvement of their brain health.~Baseline: The participants' medical history would be recorded and Neuro-QoL questionnaire should be done."
2850798|NCT03592550||Group A|Volunteers will be asked to receive ultrasound imaging in repeat voluntary breath hold and during free-breathing.
2850799|NCT03592550||Group B|Volunteers will be asked to receive ultrasound imaging in repeat voluntary breath hold and during free-breathing and in repeat spirometer assisted breath hold.
2850800|NCT03592537|Active Comparator|fentanyl|Group F: will receive 0.2 mic/kg of fentanyl intrathecally
2850801|NCT03592537|Active Comparator|midazolam|Group M: will receive 0.5 mg of midazolam intrathecally
2850802|NCT03592511|Experimental|Intervention|WGPF-burger group
2850803|NCT03592511|Placebo Comparator|Control|Control-burger group
2850804|NCT03592498|Active Comparator|Sulfadiazine, Silver|Intervention: Treatment with silver sulfadiazine ointment. Procedures: wound washing, application of silver sulfadiazine ointment, bandage covered with gauze and bandage. These patients undergone the change of dressings on alternate days.
2850805|NCT03592498|Experimental|Skin of Nile tilapia|"Intervention: treatment with skin of Nile tilapia (Oreochromis niloticus), as a biological occlusive dressing.~Procedures: wound washing, application of tilapia skin and dressing with gauze and bandage. These dressings were changed if the skin of the tilapia was loose (not adhered)."
2850806|NCT03592485|Experimental|ESP|Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
2850807|NCT03592485|Experimental|PECS|Before the induction of general anesthesia, Erector Spinae Plane (ESP) block and Pectoral fascia type I and II will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
2850808|NCT03592472|Experimental|Pazopanib plus abexinostat|Randomized patients will receive a combination of pazopanib plus abexinostat. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat p.o twice daily (BID) on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of abexinostat at the same time each day.
2850809|NCT03592472|Placebo Comparator|Pazopanib plus placebo|Randomized patients will receive a combination of pazopanib plus abexinostat matching placebo. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat matching placebo p.o BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of placebo at the same time each day.
2850810|NCT03592459|Experimental|Device feasibility (Macy catheter, opioids)|Participants undergo placement of rectal catheter and receive opioids through the Macy catheter.
2850811|NCT03592446|Experimental|Active-raVNS|Transcutaneous electrical vagus nerve stimulation at ear.
2850812|NCT03592446|Sham Comparator|Sham-raVNS|Sham vagus nerve stimulation at ear.
2850813|NCT03592433|Experimental|I Can PIC|The I Can PIC website will be provided to participants randomized to the experimental/intervention group.
2850814|NCT03592433|No Intervention|Attention Control|Participants randomized to the attention control group will be provided a link to a website developed by the American Cancer Society Cancer Action Network.
2850815|NCT03592420|Experimental|Interdisciplinary interventions|"Multicomponent interventions~On-site supervised group exercise program (11 weeks)~Educational / behavioral sessions addressing specific behavioral and environmental risk factors for falls delivered by trained health professionals (11 sessions in total)~Home visits for suggestion and implementations of safety interventions aiming at reducing environmental hazards~Home-based exercise program: Personalized multi-factorial interventions: patients will have geriatric, neurology and physiatrist outpatient referrals to assess and treat individual risk factors.~Personalized multi-factorial interventions. Patients will have geriatric, neurology and physiatrist outpatient referrals to assess and treat individual risk factors"
2850816|NCT03592420|Active Comparator|Usual care|Usual care: after pre-test assessment and randomization, participants in the control group will be given a structured booklet with detailed information about participant's own personal risk factors (fall risk profile) to be given to the family doctor, together with an information booklet on fall risk factors and their prevention.
2850817|NCT03592407|Experimental|Treatment (epacadostat, pembrolizumab)|Starting 14 days after completion of standard of care chemoradiotherapy, participants receive epacadostat PO BID during weeks 3-8 and pembrolizumab IV over 30 minutes on day 1 of weeks 3 and 6 in the absence of disease progression or unacceptable toxicity.
2850818|NCT03592394|Active Comparator|Somatic IVR (s-IVR)|This group will use an Immersive Virtual Reality (Gear VR) device to focus on encouraging disassociation between pain and visualization and movement of the affected limbs. Subjects in this group will be exposed to an IVR environment that cycles them through a series of stretching and mobility exercises for the affected limbs bilaterally.
2850819|NCT03592394|Active Comparator|Distractive IVR (d-IVR)|This group will use an Immersive Virtual Reality (Gear VR) device to focus on distracting the subject from the pain. Subjects in this group will be exposed to a variety of engaging landscape IVR environments, without the ability to visualize their own body.
2850820|NCT03592381|Experimental|Ridge expansion by osseodensification|Ridge expansion and osteotomy drilling by osseodensification in conjunction with simultaneous implant placement in narrow ridges.
2850821|NCT03592381|Active Comparator|Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
2850822|NCT03592368|Active Comparator|Active IBT, Out of MRI|
2850823|NCT03592368|Sham Comparator|Sham IBT, Out of MRI|
2850824|NCT03592368|Active Comparator|Active IBT, In MRI|
2850825|NCT03592368|Sham Comparator|Sham IBT, In MRI|
2850826|NCT03592355|Experimental|Intervention|"If enrolled in the intervention arm, the following steps will occur:~The Brigham Health Virtual Care team will work with the clinician toward immediate on-boarding (software training, hardware setup, technical support) as per their usual process.~The clinician will schedule virtual visits as s/he and/or her/his department see fit. Virtual visits occur on an already-in-use Partners- and Brigham-approved video platform."
2850827|NCT03592355|No Intervention|Control|"If enrolled in the control arm, the following steps will occur:~Three months from the time of the follow-up email, the Brigham Health Virtual Care team will work with the clinician toward immediate on-boarding (software training, hardware setup, technical support) as per their usual process.~The clinician will schedule virtual visits as s/he and/or her/his department see fit. Virtual visits occur on an already-in-use Partners- and Brigham-approved video platform."
2850828|NCT03592342|Placebo Comparator|Rivelin® plain patches|Dosing is two times per day (morning and evening) with Rivelin® plain patches (placebo).
2850829|NCT03592342|Experimental|Rivelin®-CLO patch 1µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 1µg Clobetasol propionate per patch.
2850830|NCT03592342|Experimental|Rivelin®-CLO patch 5µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 5µg Clobetasol propionate per patch.
2850831|NCT03592342|Experimental|Rivelin®-CLO patch 20µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 20µg Clobetasol propionate per patch.
2850832|NCT03592329|Experimental|active tVNS + SRT A|active tVNS and Stress Reduction Training A
2850833|NCT03592329|Experimental|active tVNS + SRT B|active tVNS and Stress Reduction Training B
2850834|NCT03592329|Other|sham tVNS + SRT A|sham stimulation and Stress Reduction Training A
2850835|NCT03592329|Other|sham tVNS + SRT B|sham tVNS and Stress Reduction Training B
2850836|NCT03592316|Experimental|Lower Extremity Amputation Pathway|Patients will follow the Lower Extremity Amputation Pathway, which will include pre-operative consultations and earlier progression with physical therapy post-operatively.
2850837|NCT03592303||Control|Any pregnant patient with a normal pregnancy is eligible for possible participation in the study.
2850838|NCT03592303||PPH group|Women with PPH requiring biological evaluation of hemostasis
2850839|NCT03592277|Experimental|Intervention Arm|Patients in this arm will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum). In addition, they will receive 200 mg IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
2850840|NCT03592277|No Intervention|Control Arm|Patients in the control arm will receive the 100 mL of 0.9% sodium chloride every six hours and 50 mL of 0.9% sodium chloride every 12 hours to act as placebos for the vitamins C and B1 respectively.
2850841|NCT03592264|Experimental|Dose escalation phase|OBI-3424 (1.0 mg/m^2 to 24.0 mg/m^2) will be administered by IV infusion on Days 1 and 8 of each 21-day cycle to determine the MTD and RP2D.
2850842|NCT03592264|Experimental|Cohort expansion phase|Once the MTD and RP2D is determined then OBI-3424 (dosage TBD) will be administered by IV infusion on Days 1 and 8 of each 21-day cycle.
2850843|NCT03592251|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
2850844|NCT03592251|Active Comparator|EPA-rich|3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA
2850845|NCT03592251|Active Comparator|DHA-Rich|3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA
2850846|NCT03592238|Experimental|Aerobic Exercise Intervention|Participants will exercise on a motor-driven treadmill at a constant speed during the 23-min period.
2850847|NCT03592238|Active Comparator|Trier Social Stress Test for Children|The Trier Social Stress Test for Children consists of a speech task in which children must finish a story and a mental arithmetic task, completed in front of a camera and two neutral observers.
2850848|NCT03592238|Placebo Comparator|Seated Rest|Participants will sit in a comfortable chair, placed in the same room as the motor-driven treadmill, for a period of 25-min.
2850849|NCT03592225|Other|Educational workshop intervention arm|The group of general practitioners (GP) from Lyon (France), about 300, that will be invited to attend the 3 hours educational workshop about HPV vaccination. After the workshop, the GPs will return to their normal health care practice.
2850850|NCT03592225|No Intervention|Control arm|The group of general practitioners (GP) from Lyon (France), about 300, that will NOT be invited to attend the 3 hours educational workshop about HPV vaccination. These GPs perform their normal health care practice.
2850851|NCT03592199|Experimental|1st Line Sunitinib and 2nd Line Axitinib|1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
2850852|NCT03592186|Experimental|Parenting Wisely+|Parenting Wisely+ consists of access to the Parenting Wisely computer program (www.parentingwisely.com), paired with engagement strategies: up to four in-person coaching sessions, daily text messages, and access to an online networking forum.
2850853|NCT03592186|Active Comparator|Treatment as Usual|The active comparator is defined as residential treatment services as usual.
2850854|NCT03592173|Experimental|SAS20|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 20ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
2850855|NCT03592173|Active Comparator|SAS0|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 0ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
2851031|NCT03590886||total response Group|The PBC patients show biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
2857305|NCT03547323|Experimental|Theranova 400 Dialyzer|One treatment session in an in-center setting.
2850856|NCT03592173|Active Comparator|SAS50|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 50ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
2850857|NCT03592160|Experimental|Experimental group|"The therapy lasted two months, at a rate of two sessions per week, with a duration of 45 minutes per session. The program consisted of pelvic floor exercises assisted by manometric biofeedback, which were performed in supine position for 20 minutes. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.~Together with the treatment at the clinic, patients were asked to perform a series of exercises at home, consisting in: 8-12 sustained contractions of 6 seconds, with a subsequent rest period of double the work-time, followed by 3-5 fast contractions of 2 seconds with maximum intensity, resting double the work-time. Domiciliary exercises were performed in supine, siting and standing position."
2850858|NCT03592160|No Intervention|Control group|The control group received an information brochure with recommendations, including the same program of pelvic floor exercises taught to the patients in the experimental group, but without carrying out any kind of supervision by the physiotherapist.
2850859|NCT03592147|Other|Relaxation|This is a within-subject pilot study, where each participant received, in random order, five different relaxation therapies (Guided Imagery Relaxation Tape, Music Listening, Relaxation Lighting, Meditation and Relaxation Light, and Music and Relaxation Light) and one Control/Silence state spanning across 3-6 weeks.
2850860|NCT03592134||Clinical settings|Infants with the choice of the non respiratory support and settings of the non respiratory support defined by clinical practice (nocturnal gas exchange, apneas, bradycardia, oxygen desaturation)
2850861|NCT03592134||Physiological settings|Infants with the choice of the non respiratory support and settings of the non respiratory support defined by the measurement of work of breathing
2850862|NCT03592121|Experimental|AB-101|Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
2850863|NCT03592121|Placebo Comparator|Placebo|Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
2850864|NCT03592108|Experimental|CSR remote monitoring|The remote monitoring of CPAP treatment will be modified in order to detect the presence of CSR as soon as any significant increase of the apnea-hypopnea index occurs.
2850865|NCT03592095|Experimental|DN group|The Intervention group underwent dry needling (DN) (fast in and fast out needling technique) in a MTP within upper trapezius muscle.
2850866|NCT03592095|Placebo Comparator|Placebo needle|A sham needle will be used as placebo. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin.
2850867|NCT03592082|Active Comparator|Standard care alone|Participants will receive standard antibiotic therapy for Clostridium Difficile (CDiff) infection without additional adjuvant therapy.
2850868|NCT03592082|Experimental|Standard care with Bismuth subsalicylate (BSS)|Participants will receive BSS524 mg ((2) 262 mg tablets) four times per day for 14 days in addition to standard antibiotic therapy.
2850869|NCT03592069|Active Comparator|10 day concomitant|"After the confirmation of H. pylori infection, eligible patients randomly assigned to either concomitant or hybrid treatment group will receive:~- Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid."
2850870|NCT03592069|Active Comparator|14 day hybrid|"After the confirmation of H. pylori infection, eligible patients randomly assigned to either concomitant or hybrid treatment group will receive:~Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days."
2850871|NCT03592043||MitraClip|All patients who have undergone percutaneous mitral valve repair with the MitraClip system in Canada
2850872|NCT03592017|Experimental|Patients with various retinal diseases|Patients with various retinal diseases will be examined using long-wavelength autofluorescence imaging to assess the performance compared to conventional imaging methods and to quantify the signal compared to a normative database
2850873|NCT03592017|Experimental|Healthy participants|Healthy participants will be examined using long-wavelength autofluorescence imaging to optimize the signal with additional laser sources and device settings and to compile a normative database for the quantification of the signal.
2850874|NCT03592004||Guangdong General Hospital|
2850875|NCT03592004||Cancer Hospital Chinese Academy Of Medical Sciences|
2850876|NCT03592004||Beijing Friendship Hospital|
2850877|NCT03592004||Yunnan Cancer Hospital|
2850878|NCT03592004||Liaoning Cancer Hospital|
2850879|NCT03592004||The First Hospital Of China Medical University|
2850880|NCT03592004||Affiliated Hospital Of Hebei University|
2850881|NCT03591991|Active Comparator|treatment group|Patients will be randomized into two groups after enrolled. In Empagliflozin Group, the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin .After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths. The procedure will double blind to patients and investigators.
2850882|NCT03591991|Placebo Comparator|Placebo group|Patients will be randomized into two groups after enrolled. In Placebo Group, the treatment started 30 minutes before PCI with a dose of 10 mg Placebo .After admission, patients were treated with 10 mg Placebo once daily for 3 mouths. The procedure will double blind to patients and investigators.
2850883|NCT03591978||Healthy non smokers|Healthy subjects with no respiratory disease and never smokers
2850884|NCT03591978||Healthy smokers|Healthy subjects without respiratory disease and at least a cumulative tobacco consumption history of <10 pack-years
2850885|NCT03591978||COPD|COPD patients (diagnosed as recommended by GOLD 2017 strategy) former or current smokers with at least >10 pack-years
2850886|NCT03591965|Experimental|A|The starting dose of ATG-008 will be 15 mg daily for 28 days each cycle for the first 6 fully evaluable (including PK outcomes) subjects. Providing DLTs occur in less than 2 of 6 subjects who complete Cycle 1, additional 24 subjects will be enrolled at the starting dose of 30 mg daily.
2850887|NCT03591952|Active Comparator|Suction|The pleural fluid will be drained by the syringe system with a one-way valve tubing system provided in the kit. Selection of the vacuum pressure will be at the discretion of the proceduralist, as per standard of care.
2850888|NCT03591952|Experimental|Gravity|The pleural fluid will be drained using gravity drainage to a bag positioned approximately 100 cm (approximately 40 inches) below the catheter entry point (see picture below) using the 40 inch tubing provided in the thoracentesis kit (CareFusion or Arrow).
2850889|NCT03591939||1|cases of Diabetic type two nephropathy
2850890|NCT03591939||2|controls of normal subjects
2850891|NCT03591926|Experimental|"BAL Arm"|Subjects in this arm will undergo a bronchoalveolar lavage (BAL) procedure at baseline and after two weeks of treatment.
2850892|NCT03591926|Experimental|"Non-BAL Arm"|Subjects in this arm will not undergo any BAL procedures.
2850893|NCT03591913|Experimental|study group|will receive sublingual misoprostol immediately after urinary catheterization and before skin incision
2850894|NCT03591913|Active Comparator|control group|will receive sublingual misoprostol immediately after skin closure
2850895|NCT03591900|Active Comparator|daibetic thalassemic patients on SC insulin|"A pilot study will be done on 20 patients with abnormal glucose tolerance which will include:~A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be put on sc insulin"
2850896|NCT03591900|Active Comparator|daibetic thalassemic patients on insulin pump|"A pilot study will be done on 20 patients with abnormal glucose tolerance which will include:~A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be put on insulin pump"
2850897|NCT03591887|Experimental|ABY-035 2 mg|2 mg ABY-035 SC
2850898|NCT03591887|Experimental|ABY-035 20 mg|20 mg ABY-035 SC
2850899|NCT03591887|Experimental|ABY-035 80 mg|80 mg ABY-035 SC
2850900|NCT03591887|Experimental|ABY-035 160 mg|160 mg ABY-035 SC
2850901|NCT03591887|Placebo Comparator|Placebo|Placebo, switching to 80 mg ABY-035 after 12 weeks
2850902|NCT03591874|Experimental|OCU-300|Brimonidine Tartrate Nanoemulsion Eye Drops 0.18% given 2 times a day for 12 weeks.
2850903|NCT03591874|Placebo Comparator|Placebos|Placebo - Ophthalmic buffered saline Eye Drops given 2 times a day for 12 weeks.
2850904|NCT03591861|Experimental|Ketogenic Diet|"Caregivers (and participating children) attend intro ketogenic diet class (4 - 30 min lectures)~Clinic visit with neurologist, nurse, and dietitian prior to hospital admission and then once every 3 months~Laboratory studies prior to hospital admission and then at each follow-up visit~Hospital admission (3-4 day) to start the ketogenic diet~Standard of care chemotherapy with BCNU for up to 2 years~Ketogenic diet can continue for up to 2 years"
2850905|NCT03591848|Experimental|DECISIF|Exposed to an online support decision tool, in addition of the standard oral information
2850906|NCT03591848|Active Comparator|IRIS|Exposed to a standard oral information
2850907|NCT03591835|Active Comparator|Weight+6|For the Tochen formula in Group 1, ETT depth will be calculated by taking the infant's actual weight within the last 24 h and adding 6 cm.
2850908|NCT03591835|Active Comparator|NTL+1|The infants in Group 2 will be intubated by measuring the NTL, the distance from the basement of the nasal septum to the the tragus of the ear.
2850909|NCT03591822|Other|Arm AB : Intervention under study x Control intervention|Subjects receive intervention A during which they will benefit from a systemic pain assessment and from the PARO robot as a therapeutic mediator, followed by intervention B during which patients will benefit from a systemic pain assessment without the PARO robot.
2850910|NCT03591822|Other|Arm BA: Control intervention x Intervention under study|Subjects receive intervention B during which they will benefit from a systemic pain assessment without the PARO robot, followed by intervention A during which patients will benefit from a systemic pain assessment and from the PARO robot as a therapeutic mediator.
2850911|NCT03591809|Experimental|combined exercise training group|The combined exercise training group will be given combined exercise training, consisting of Pilates and aerobic exercise, three times during 8 weeks.
2850912|NCT03591809|No Intervention|Control group|The patients in the control group will not apply an exercise training.
2850913|NCT03591796|Experimental|HFOV|Ventilated infants were randomized to HFOV.
2850914|NCT03591796|Active Comparator|CMV|Ventilated infants were randomized to CMV.
2850915|NCT03591783||study group|All patients will be subjected to: Baseline investigations, end of treatment investigations and 3 months after treatment investigations.
2850916|NCT03591770|Experimental|UC patients on tofacitinib monotherapy|Ulcerative Colitis patients on Tofacitinib monotherapy, all patients will be treated with the standard Tofacitinib and will receive Shingrix vaccine.
2850917|NCT03591770|Active Comparator|UC patients on anti-TNF monotherapy|Ulcerative Colitis patients on anti-TNF monotherapy, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab)and will receive Shingrix vaccine.
2850918|NCT03591770|Active Comparator|UC patients on anti-TNF and a thiopurine|Ulcerative Colitis patients on anti-TNF and a thiopurine, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab) and thiopurine (6-mercaptopurine, azathioprine) and will receive Shingrix vaccine.
2850919|NCT03591770|Active Comparator|UC pts. on aminosalicylates or off immunomodulatory therapy|Ulcerative Colitis patients on non-immunosuppressive therapy or 5-aminosalicylates, all patients will be treated with the standard non-immunosuppressive therapy or 5-aminosalicylates and will receive Shingrix vaccine.
2850920|NCT03591757|Experimental|Tolcapone|Tolcapone will be administered to assess the short-term (4 weeks) effects on plasma and CSF TTR tetramer stability in subjects with TTR CNS Amyloidosis. Tolcapone is currently licensed for the treatment of Parkinson's disease in combination with levodopa/carbidopa. It is an immediate release product and is currently used at either 100 mg or 200 mg three times a day during waking hours. During this trial, participants will be taking 100mg for 14 days, and then 200mg for 14 days.
2850957|NCT03591484|Active Comparator|G3 dentate older bronchiectasis|Treatment with tongue scraper (n = 20). The dentate participants with bronchiectasis will received periodontal treatment. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
2858392|NCT03539679|No Intervention|CONTROL GROUP|No intervention.
2850921|NCT03591744|Experimental|Treatment (daratumumab, bortezomib, chemotherapy)|Participants receive daratumumab IV on days 1, 8, 15, and 22, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 1 and 2. Participants then receive daratumumab IV on days 1, and 15, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 3 and 4. Courses repeat every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants may receive up to 8 courses at the discretion of treating physician.
2850922|NCT03591731|Experimental|Arm A : monotherapy arm|Nivolumab administered IV
2850923|NCT03591731|Experimental|Arm B : combination arm|Nivolumab administered IV followed by ipilimumab administered IV
2850924|NCT03591718|Experimental|BI 456906|
2850925|NCT03591718|Experimental|Placebo|
2850926|NCT03591705|Experimental|TACE-HAIC|chemo-lipiodolization with EADM, followed by mFOLFOX6-based chemotherapy artery infusion
2850927|NCT03591705|Active Comparator|TACE|chemo-lipiodolization with EADM/CBP/FUDR
2850928|NCT03591692|Experimental|ACAF surgery|Underwent anterior controllable antedisplacement and fusion
2850929|NCT03591692|Placebo Comparator|ACCF surgery|Underwentanterior controllable antedisplacement and fusion
2850930|NCT03591679|Experimental|study group|248 patients at risk of uterine atony undergoing cesarean section underwent bilateral uterine artery ligation and received oxytocin.
2850931|NCT03591679|Active Comparator|control group|248 patients at risk of uterine atony undergoing cesarean section received oxytocin only.
2850932|NCT03591666|Experimental|Study Group|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2850933|NCT03591653|Experimental|LXI-15028 50mg group|
2850934|NCT03591653|Placebo Comparator|Placebo group|
2850935|NCT03591640|Active Comparator|Pregnant with hemoglobinopathy|Standard of care with blood test before active labor
2850936|NCT03591640|Active Comparator|Pregnant without known hemoglobinopathy|Standard of care with blood test before active labor
2850937|NCT03591627||AF or AFl patients|Patients with AF or AFl in whom TEE will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period.
2850938|NCT03591614|Experimental|Dendritic cell DKK1 vaccine|5-10x106 DKK1 loaded dendritic cells. Three doses will be given two weeks apart, followed by 11 months of observations.
2850939|NCT03591601|Active Comparator|Manual therapy protocol|Treatment based on manual therapy with proven evidence.
2850940|NCT03591601|Experimental|Foam Rolling protocol|Treatment based on massage with a Foam Rolling
2850941|NCT03591601|Placebo Comparator|Placebo Control|Placebo treatment based on the placement of the hands on the head without intention to treat.
2850942|NCT03591588|Active Comparator|high-saturated fat diet|Diet high in saturated fat (~50% calorie from fat, ~25% from saturated fat)
2850943|NCT03591588|Active Comparator|low-fat diet|Diet with low fat (~25% calorie from fat)
2850944|NCT03591588|Active Comparator|Mediterranean diet|Diet high in monounsaturated fat (~50% calorie from fat, ~25% from monounsaturated diet).
2850945|NCT03591575|Experimental|Deferiprone|Subjects in this group will receive deferiprone oral solution at a dosage up to 75 milligrams per kilogram of body weight (mg/kg) per day, divided into 3 equal doses
2850946|NCT03591575|Placebo Comparator|Placebo|Subjects in this group will receive placebo solution at a volume equal to what they would receive if they were in the active arm, divided into 3 equal doses
2850947|NCT03591562||COSYCONET COPD Subcohort|"MRI and CT of the lung will be performed in a multi-centre subcohort of 370 patients having already participated in the precursor trial  Image-Based Structural and Functional Phenotyping of the COSYCONET Cohort Using MRI and CT (MR-COPD), NCT 02629432."
2850948|NCT03591549|Experimental|fulvestrant arm|patients will receive fulvestrant + zoladex intramuscular monthly with an assessment every three months to assess the response and progression
2850949|NCT03591536|Other|pentoxifylline oral|50 adult patient underwent elective CABG intervention to be administered will be receiving main drug (pentoxifylline )oral 400 mg' every 8 hours from three days before surgery and on the day of surgery effect of intervention regarding antioxidant
2850950|NCT03591536|Placebo Comparator|placebo|50 adult patient underwent elective CABG received oral placebo pill resembling completely to pentoxifylline 400 mg, every 8 hours from three days before surgery and on the day of surgery
2850951|NCT03591523||Suspicion of vascular pathology|Subjects indicated to quantitative MR angiography and duplex sonography for suspicion of cervical or intracranial vascular pathology
2850952|NCT03591510|Experimental|Chemotherapy followed by Midostaurin|Midostaurin with standard induction (Block 1 induction according to local practice, Block 2 induction containing Fludarabine, cytarabine, daunorubicin/daunorubicin liposomal(idarubicin ) and consolidation (Block 3: cytarabine+ mitoxantrone, Block 4:cytarabine + etoposide, Block 5:Cytarabine) chemotherapy followed by single agent midostaurin post-consolidation therapy
2850953|NCT03591497|Experimental|Intervention Group|"Instrument to be used:~Software Neuro@home (semi immersive virtual reality system for neurological rehabilitation) was used. In each of the sessions, an avatar on screen that representing the patient was regulated by the patient to perform a virtual task that focused on the training of a specific body part.~Programme schedule:~Each session of virtual reality therapy lasted for thirty minutes. Day 0 included an orientation to the machine with five minutes of gaming. This was followed by virtual reality therapy for five days a week at the same time of the day for three consecutive weeks."
2850954|NCT03591497|No Intervention|Control Group|Virtual reality sessions were not provided.
2850955|NCT03591484|Experimental|G1 dentate healthy older|Treatment with Photodynamic therapy (n = 20). The dentate participants will received periodontal treatment. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
2850956|NCT03591484|Experimental|G2 healthy older/dentures|Treatment with Photodynamic therapy (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
2851028|NCT03590912|Experimental|Oral histaminics and oxymetazoline drops|Standard dose of oral cetirizine for a month plus oxymetazoline nasal drops for two weeks
2850958|NCT03591484|Active Comparator|G4 older bronchiectasis /dentures|Treatment with tongue scraper (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
2850959|NCT03591471|Experimental|TCM multistep therapy|"Light HSPN:1.Glycosides Of Tripterygium Wilfordii Hook(GTW): initial dosage is 1.5mg/kg/d(4 weeks),continued with 1mg/kg/d(8 weeks),12weeks in total. Severe HSPN:1.GTW:the initial dosage is 2mg/kg/d(2 weeks), continued with 1.5mg/kg/d(2 weeks) and 1mg/kg/d(8 weeks); 12weeks in total.~On the above base,Sulfotanshinone Sodium Injection(1mg/kg/d,2weeks) and Qingrezhixue granules(a nosocomial preparation) combined with Chinese herbs(12weeks) based on TCM syndrome differentiation are taken at the same time."
2850960|NCT03591471|Active Comparator|Routine medicine|"Light HSPN:1.Lotensin: 5-10mg/d,12weeks; 2.Low Molecular Weight Heparin(LMWH):100u/kg,2weeks;3.Dipyridamole:3mg/kg/d,Tid,12weeks.4.Chinese medicine placebo,12weeks.~Severe HSPN:Add pednisone on the treatment of Light HSPN,and gradually reduce the dosage in 12 weeks,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）"
2850961|NCT03591458|Experimental|Amitriptyline|Participants will be initiated on 25 mg Amitriptyline daily for two weeks during the Titration Period. Amitriptyline dose will be increased to 50 mg daily for 8 weeks during the Intervention Period. Finally, the dose of Amitriptyline will be reduced to 25 mg daily during the two week Taper Period.
2850962|NCT03591458|Placebo Comparator|Placebo|Participants will be initiated on a daily Placebo capsule matching the 25 mg Amitriptyline during the Titration Period. The daily dose will be changed to the Placebo capsule matching the 50 mg Amitriptyline for 8 weeks during the Intervention Period. Finally, the daily dose will be changed back to the Placebo capsule matching the 25 mg Amitriptyline during the two week Taper period.
2850963|NCT03591445|Experimental|Experimental：Bronchoscopy|Patients with GGO lung cancer perform the bronchoscopy
2850964|NCT03591432|Experimental|THRIVE|Using transnasal humidified rapid insufflation ventilatory exchange (THRIVE) oxygenation technique in elderly patients undergoing induction of anesthesia.
2850965|NCT03591432|Active Comparator|Facemask|Using facemask technique in elderly patients undergoing induction of anesthesia.
2850966|NCT03591419|Experimental|polymer clip|polymer clips will be used to ligate the appendicular stump. and time and ease of appliction and cost of clips will be calculated
2850967|NCT03591419|Active Comparator|endoloop|endoloops will be used to ligate the appendicular stump an time and ease of application and cost of loops will be calculated
2850968|NCT03591406|Experimental|Ferric carboxymaltose (FCM)|Subjects treated with FCM given by IV injection or drip infusion
2850969|NCT03591406|Active Comparator|Iron sucrose (IS)|Subjects treated with IS given by IV injection or drip infusion
2850970|NCT03591393|Experimental|Pregnant women|"questionnaire at 1st and 3rd trimester, 10-12 weeks postpartum and 12 months postpartum~pelvic floor ultrasound at 1st trimester and at 3rd trimester"
2850971|NCT03591380|Experimental|Experimental: Belimumab|Belimumab 10mg/kg will be administered IV at the following intervals: at the time of transplant (Day 0), then post-transplant at 2, 4, 8, 12, 16, and 20 weeks.
2850972|NCT03591367|Other|Hematuria due to suspicious superficial bladder tumor|MicroRNAs-155 (miRNAs-155) and Human telomerase reverse transcriptase (hTERT)
2850973|NCT03591354|Experimental|Closed Loop Control (CLC)|"Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 3 months.~OBJ1: This arm is participants who had 6 months of CLC in DCLP3 Pivotal Trial (Phase 1)~OBJ2: This arm is participants who had 6 months of SAP in DCLP3 Pivotal Trial (Phase 1)"
2850974|NCT03591354|Active Comparator|Sensor-augmented pump (SAP)|"Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 3 months.~OBJ1 and OBJ2: This arm is participants who had 6 months of CLC in DCLP3 Pivotal Trial (Phase 1)"
2850975|NCT03591341||nursing women|women who gave birth and are breast feeding their baby- melatonin level in pumped breast milk have been checked
2850976|NCT03591328||Culprit|Plaques which is related with acute coronary syndrome
2850977|NCT03591328||Non-culprit|Plaques which is not related with acute coronary syndrome
2850978|NCT03591315||TG group|Patients with visual impairment caused by chiasma compression from sellar area tumors will undergo the following examinations: resting state fMRI, visual tasking state fMRI, diffusion tensor imaging (DTI), visual acuity and automated visual field test.
2850979|NCT03591315||HC group|Volunteers with no visual impairment(visual acuity of both eyes >1.0) or Nervous System disease will undergo the following examinations: resting state fMRI, visual tasking state fMRI, diffusion tensor imaging (DTI), visual acuity and automated visual field test.
2850980|NCT03591302|Experimental|Immune tolerance, Kidney transplantation|Intervention: HLA matched living donor recipients of a functioning kidney transplant graft at one year will receive hematopoietic cell transplantation and Total lymphoid irradiation. The intervention is intended to induce immune tolerance such as to allow withdrawal of the immunosuppressive drugs. Immune tolerance is achieved through the development of donor/recipient mixed chimerism following combined kidney and hematopoietic stem cell transplantation from the living donor.
2850981|NCT03591289|Active Comparator|Deep NMB|Deep NMB: Intervention: Rocuronium will be given as a continuous infusion for deep block. TOF will be maintained at 0 (zero) with at least one PTC. Patients' paralysis will be continued through the anesthesia period. At the end of surgery, patients will receive 4 mg/kg sugammadex and the patient's trachea will be extubated according to routine extubation criteria.
2850982|NCT03591289|Active Comparator|Moderate NMB|Moderate NMB: Intervention: Rocuronium will be used as bolus doses to achieve a moderate block. TOF will be maintained between 1 to 3 twitches. PTC will not be counted. Paralysis will be continued throughout the anesthesia period. At the end of surgery, patients will receive 2 mg/kg sugammadex and the patient's trachea will be extubated according to routine extubation criteria.
2850983|NCT03591276|Experimental|Pembrolizumab and PLD|"Cohort S1: IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 every 3 weeks.~Reduced Dose Cohort (R1)*: IV pembrolizumab 200 mg flat dose with IV PLD 24 mg/m2 every 3 weeks.~*Subjects will be recruited into the R1 cohort only if DLT is reported in 2 or more subjects during the first 2 cycles of treatment in the first 6 patients of the S1 cohort."
2851029|NCT03590912|Experimental|Oral steroid|1mg/kg oral prednisolone for 10 days
2851030|NCT03590899||Healthy patients|
2850984|NCT03591263||Chronic obstructive pulmonary disease|Subjects with the diagnosis of chronic respiratory disease, such as chronic obstructive pulmonary disease, bronchiectasis, idiopathic pulmonary fibrosis that referred for evaluation as routine care at Physical Therapy Center (National Taiwan University)
2850985|NCT03591237|Experimental|MBCT|As patients with significant pain are identified and accept the offer of receiving 'Mindfulness-Based Cognitive Therapy' (MBCT) for pain, they will be consecutively included in groups of 12-20 participants. The patients will participate in eight weekly two hour group sessions and will be asked to do an additional 45 minutes of daily training at home.
2850986|NCT03591224|Active Comparator|Intervention|Pharmacist optimizing antidepressant therapy using the patient's personalized pharmacogenomic report to make recommendations.
2850987|NCT03591224|Placebo Comparator|Control|Pharmacist optimizing antidepressant therapy based on standard of care
2850988|NCT03591211|Experimental|Qigong Training|
2850989|NCT03591211|Active Comparator|Cognitive Training|
2850990|NCT03591198|Experimental|Qigong Training|
2850991|NCT03591198|Active Comparator|Cognitive Training|
2850992|NCT03591185|Experimental|Exercise group|Exercise group, including community-dwelling adults aged 50 years or over, will perform an initial evaluation, 24 intervention sessions with FallSensing clinical tool (2 or 3 sessions per week) and a final evaluation.
2850993|NCT03591172|Experimental|propolis|natural antibacterial, anti-inflammatory irrigation solution
2850994|NCT03591172|Experimental|Nano-propolis|natural antibacterial, anti-inflammatory irrigation solution
2850995|NCT03591172|Active Comparator|saline|sodium chloride irrigation solution
2850996|NCT03591159|Active Comparator|Membrane Sweeping Group|
2850997|NCT03591159|No Intervention|Control Group|
2850998|NCT03591146|Experimental|TLC590|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
2850999|NCT03591146|Active Comparator|Naropin|Naronpin injection contains ropivacaine HCl. Strength: 150mg/ 30mL (5 mg/mL) Size: 30mL fill, in a 30mL single dose vial
2851000|NCT03591133|Other|Step1:3㎎ QD|Drug: TS-143 3mg Drug: Placebo
2851001|NCT03591133|Other|Step2:6㎎ QD|Drug: TS-143 6mg Drug: Placebo
2851002|NCT03591133|Other|Step3-1:11㎎ QD|Drug: TS-143 11mg Drug: Placebo
2851003|NCT03591133|Other|Step3-2:11㎎ QD（Fed)|Drug: TS-143 11mg Drug: Placebo
2851004|NCT03591133|Other|Step4:20㎎ QD|Drug: TS-143 20mg Drug: Placebo
2851005|NCT03591133|Other|Step5:36㎎ QD|Drug: TS-143 36mg Drug: Placebo
2851006|NCT03591120|Placebo Comparator|Control|Subject will receive anesthesia
2851007|NCT03591120|Experimental|Preventative Delirium Protocol|"Consider regional block if applicable~Minimized fentanyl usage intraoperatively~Intubation + general anesthesia adjunct total: 1-2 mcg/kg fentanyl~Sedation: 0-0.24 mcg/kg fentanyl~Post-operative: 0.5 - 1 mcg/kg fentanyl~Avoid morphine~Avoid ketamine~Avoid diphenhydramine, dexamethasone, scopolamine, metoclopramide, and promethazine~Avoid H2-blockers (cimetidine, ranitidine, famotidine)~Avoid polypharmacy intraoperatively if possible (i.e. > 5 new medications)~Fluid repletion based on maintenance and losses"
2851008|NCT03591107|Experimental|PTSD Care Management (PCM)|In addition to the education and feedback components for both conditions the PCM intervention provides access to a trained Care Manager (CM) who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist.
2851009|NCT03591107|Active Comparator|Minimally Enhanced Usual Care (MEU)|The MEU condition will consist of only clinician education, patient education (Information Sheet) and feedback about having a probably diagnosis of PTSD to both the clinician and patient.
2851010|NCT03591094|Active Comparator|PTI-428 dose level 1|
2851011|NCT03591094|Active Comparator|PTI-428 dose level 2|
2851012|NCT03591094|Placebo Comparator|Placebo PTI-428|
2851013|NCT03591081|Other|Intellin smart phone application|Participants will download a smart phone app, the platform will give the patients daily hints and tips on how to look after their feet.
2851014|NCT03591068|Experimental|OPN-375|
2851015|NCT03591055|Experimental|Intervention Group|Patients in the intervention group will be first derived to a nurse case manager for initial application of a comprehensive geriatric assessment. Then patient-centered interventions will be prescribed, according to the different target areas identified in the geriatric assessment. All participants in the intervention group will undergo a medication review and will also perform an aerobics exercise plan in the primary care centre, 60-minute session twice a week on non-consecutive days for 6 weeks (12 sessions of 60 minutes each) and memory workshops (10 sessions).
2851016|NCT03591055|No Intervention|Control group|Participants in the control group will receive the usual standard care and regular referrals.
2851017|NCT03591042|Experimental|cervical length screening|cervical length screening
2851018|NCT03591042|No Intervention|no screening|no screening
2851019|NCT03591016||Difficult intravenous access|Recording number of IV attempts in the operating room prior to surgery start.
2851020|NCT03591003||HIV-infected patients|HIV-infected patients vaccinated at least once in their life against yellow fever
2851021|NCT03590977|Experimental|licorice extract mouthwash|administration of a mouthwash containing licorice as a preventive measure to high caries risk patients (faculty of pharmacy, cairo university)
2851022|NCT03590977|Placebo Comparator|chlorohexidine mouthwash|administration of chlorohexidine 0.2% in 1:1 diluation mouthwash that is broad spectrum antimicrobial activity to high caries risk patients
2851023|NCT03590964|Active Comparator|Open sinus lift using chin bone graft|Patients with atrophied posterior maxilla will undergo open sinus lift with chin bone graft according to standardized surgical approach.
2851024|NCT03590964|Experimental|Sinus lift using bone ring containing the implant|Patients with atrophied posterior maxilla will undergo sinus lift using bone ring containing the implant.
2851025|NCT03590925||new screening and referring system of ICD|Non-randomized, non-blinded, multi-center study receiving new screening and referring system of ICD
2851026|NCT03590912|No Intervention|Wait and watch|Wait and watch for 1 month
2851027|NCT03590912|Experimental|Fluticasone spray|Standard dose of fluticasone nasal spray daily for one month
2860894|NCT03522441|Experimental|Clindamycin 1% gel (Akorn Pharmaceuticals)|
2851032|NCT03590886||poor response group|The PBC patients show poor biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
2851033|NCT03590873|No Intervention|Control group|Intraoperative fluid management: administration of 6-10 ml/kg/hr of crystalloid solution.
2851034|NCT03590873|Experimental|Restrictive group|"Intervention: administration of vasopressin 0.01 - 0.04 U/min after induction of anesthesia.~Intraoperative fluid management: administration of 2-4 ml/kg/hr of crystalloid solution."
2851035|NCT03590860|Experimental|LY3322207 (Part A)|LY3322207 administered subcutaneously (SC)
2851036|NCT03590860|Placebo Comparator|Placebo (Part A)|Placebo matching LY3322207 administered SC
2851037|NCT03590860|Experimental|LY3322207 (Part B)|LY3322207 administered SC once weekly
2851038|NCT03590860|Placebo Comparator|Placebo (Part B)|Placebo matching LY3322207 administered SC once weekly
2851039|NCT03590860|Experimental|LY3322207 (Part C)|LY3322207 administered SC in participants with hypertension
2851040|NCT03590847|Experimental|Intermittent fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks.
2851041|NCT03590834|Experimental|Center-based intervention|In-person, child-focused intervention taking place only at the Head Start centers
2851042|NCT03590834|Experimental|Center-and-home-based intervention|In-person, child-focused intervention taking place only at the Head Start centers. Delivered in-person at Head Start centers and the family home.
2851043|NCT03590834|Active Comparator|Active Control|Active comparison group
2851044|NCT03590821|Experimental|Aspirin 81 mg/Placebo|Participants will receive aspirin in Phase 1 followed by matched placebo in Phase 2, or vice versa, over 14 days. The order will be randomized and aspirin/placebo will be double-blinded.
2851045|NCT03590821|Experimental|Celecoxib 200mg capsule|Participants will receive celecoxib in Phase 1 and Phase 2 over 7 days. This is open, meaning participant and investigator will recognize celecoxib capsules.
2851046|NCT03590808|Experimental|Immune checkpoint inhibitor|"Solid cancer patients who receiving immune checkpoint inhibitor patients~will be undergone Influenza vaccination using purified inactivated influenza virus antigen (Green Cross Corp.) 0.5 mL IM once"
2851047|NCT03590808|Active Comparator|Cytotoxic chemotherapy|"Solid cancer patients who receiving conventional cytotoxic chemotherapy~will be undergone Influenza vaccination using purified inactivated influenza virus antigen (Green Cross Corp.) 0.5 mL IM once"
2851048|NCT03590795||Problem Sleepers|Those individuals that have self identified as having a unspecified sleep problem will take the sleep survey.
2851049|NCT03590769|Experimental|PET/MR using FDG-18 radiotracer|Using FDG-18 radiotracer, subject undergoes PET/MR scan which detects the uptake of the tracer.
2851050|NCT03590756|Experimental|High mango group|250g (1.5 cup) of mango intake per day, 4 days a week for 16 weeks
2851051|NCT03590756|Other|Low mango group|85g (0.5 cup) of mango intake per day, 4 days a week for 16 weeks
2851052|NCT03590743|Active Comparator|Apixaban|Apixaban 5mg (10 mg twice daily for 7 days followed by 5 mg twice daily for 3 months).
2851053|NCT03590743|Placebo Comparator|Placebo|Patients will receive matching placebo.
2851054|NCT03590730||Valvular heart disease|Patients with left ventricular dysfunction due to valvular heart disease who received ICD implantation for primary prevention of sudden cardiac death.
2851055|NCT03590717|Other|BCC-Only|Intervention: Households in the 'BCC-only' arm receive SBCC but do not receive vouchers.
2851056|NCT03590717|Experimental|Small-voucher|Intervention: Households in the 'Small-voucher' arm receive a voucher (~$12-17) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
2851057|NCT03590717|Experimental|Large-voucher|Intervention: Households in the 'Large-voucher' arm receive a larger voucher (~$21-23) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
2851058|NCT03590704|Experimental|Intervention Vitaltape® bandage|The neuromuscular bandage will be applied after skin antisepsis with 70% alcohol. A 5 cm width Vitaltape® bandage will be used. For the bandage application, a distal base (anchor) with two centimeters of diameter will be maintained with maximum stretching on the seroma and finalized with another base no stretching, of 2 cm, in the proximal region. How many bundles of bandages are required according to the patient's body characteristics and aspect of the flotation region. The bandage will not be applied on the scar. If there are any complications such as itching, redness, discomfort and / or others, the patients will remove the material at home and communicate on return to the institution. They will remain four days approximately for revaluation and intervention suspension.
2851059|NCT03590691|Active Comparator|Comparison group|Vietnam National Hypertension Program: a training program for health care workers and a health educational program for general public.
2851060|NCT03590691|Experimental|Intervention group|"Vietnam National Hypertension Program including training program for health care workers and an health educational program for general public.~PLUS~Three selected enhancements integrated into routine clinical care:~expanded community health worker services;~home blood pressure self-monitoring; and~a storytelling intervention."
2851061|NCT03590678||1|Subject is scheduled for an invasive procedure and did not have NIPT testing in current pregnancy
2851062|NCT03590678||2|Subject is scheduled for an invasive procedure and has a known positive or no-call result from a targeted NIPT in the current pregnancy
2851063|NCT03590665|Other|Individuals with Down syndrome|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
2851095|NCT03590470|Experimental|Experimental_INTERCARE intervention|Implementation of a nurse-led model of care adapted to the Swiss context, comprising a geriatric nurse expert with specific training in multidimensional clinical assessment and quality improvement tools.
2851064|NCT03590665|Other|Individuals without Down syndrome|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
2851065|NCT03590652|Experimental|ixazomib, daratumumab, pomalidomide and dexamethasone|Daratumumab will be administered at 16mg/kg IV weekly x 8 weeks, biweekly x 8 weeks, then monthly. Pomalidomide 4mg will be administered orally daily for days 1-21. Patients ≤ age 75 will receive a 40mg dose of dexamethasone, and those over the age of 75 may receive a 20mg dose of dexamethasone orally on days 1, 8, 15, and 22 (weekly). Ixazomib will be administered 4mg orally on days 1, 8 and 15.
2851066|NCT03590626|Experimental|Dulaglutide group|receive dulaglutide 0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks plus standard treatment for type 2 diabetes
2851067|NCT03590626|No Intervention|Control group|receive standard treatment for type 2 diabetes and up titration of treatment will be done by anti-diabetic medicines other than the GLP-1 receptor agonist
2851068|NCT03590613|Experimental|Sequence 1: Placebo TID then 60 TID then 120 TID then 240 TID|The eligible subjects in this arm will receive placebo TID in TP1, GSK2982772 60 mg TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
2851069|NCT03590613|Experimental|Sequence 2: 60 TID then Placebo TID then 120 TID then 240 TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, placebo TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
2851070|NCT03590613|Experimental|Sequence 3: 60 TID then 120 TID then Placebo TID then 240 TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, placebo TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
2851071|NCT03590613|Experimental|Sequence 4: 60 TID then 120 TID then 240 TID then Placebo TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, GSK2982772 240 mg TID in TP3 and placebo TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
2851072|NCT03590600|Experimental|Cohort 1: 125 mg BTZ-043 fasting|N=8, 125 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
2851073|NCT03590600|Placebo Comparator|Cohort 1: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
2851074|NCT03590600|Experimental|Cohort 2: 250 mg BTZ-043 fasting|N=8, 250 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
2851075|NCT03590600|Placebo Comparator|Cohort 2: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
2851076|NCT03590600|Experimental|Cohort 3: 500 mg BTZ-043 fasting|N=8, 500 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
2851077|NCT03590600|Placebo Comparator|Cohort 3: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
2851078|NCT03590600|Experimental|Cohort 4: 1000 mg BTZ-043 fasting|N=8, 1000 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
2851079|NCT03590600|Placebo Comparator|Cohort 4: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
2851080|NCT03590600|Experimental|Cohort 5: 2000mg BTZ-043 fasting|N=8, 2000 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
2851081|NCT03590600|Placebo Comparator|Cohort 5: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
2851082|NCT03590587||1|patients treated with 0.19 mg fluocinolone acetonide (FAc) implant for 12 months
2851083|NCT03590574|Experimental|AUTO4|Relapsed or refractory T cell non-Hodgkin Lymphoma patients
2851084|NCT03590561|Experimental|High caloric diet|Participants will eat 1500 kcal more than their usual diet for five days.
2851085|NCT03590548||gausher disease in children|• Inclusion criteria: All cases with confirmed diagnosis of Gaucher disease type 1 and type 3 receiving enzyme replacement therapy at Assuit University Children's Hospital.
2851086|NCT03590535||Patients with Possible ACS|Adult patients presenting to the Emergency Department with symptoms that maybe be caused by acute coronary syndrome, who are clinically considered to be at enough risk for ACS to send a cardiac enzyme as part of the diagnostic evaluation.
2851087|NCT03590522||Group I:|Thirty heart failure patients
2851088|NCT03590522||Group II:|Twenty healthy controls
2851089|NCT03590509|Experimental|Telemedicine and home visitation|Integrated Telemedicine-Home Visitation Program
2851090|NCT03590509|Active Comparator|Control|Usual Comprehensive Care
2851091|NCT03590496|Active Comparator|Arm 1|31 patients will be treated with 500mg Calcium-Propionate capsules (twice a day) in addition to their basic cholesterol lowering therapy with 10mg Atorvastatin (once per day) for 8 weeks.
2851092|NCT03590496|Placebo Comparator|Arm 2|31 patients will be treated with placebo capsules (twice a day) in addition to their basic cholesterol lowering therapy with 10mg Atorvastatin (once per day) for 8 weeks.
2851093|NCT03590496|Active Comparator|Arm 3|31 patients will be treated with 500mg Calcium-Propionate capsules (twice a day) for 8 weeks.
2851094|NCT03590496|Placebo Comparator|Arm 4|31 patients will be treated with placebo capsules (twice a day) for 8 weeks.
2851259|NCT03589365|Other|Preterm group|young adults born preterm will performed an Magnetic resonance imaging (MRI)
2851096|NCT03590470|No Intervention|Control|The design used for the INTERCARE intervention is a non-randomized stepped wedge design, therefore all nursing homes will receive the intervention but at different time points. All nursing homes will be in a control phase before receiving the intervention, and switch to the intervention phase, once the intervention is implemented.
2851097|NCT03590457|Other|High-Flow/Swallow|All participants will be subjected to all three flows randomly. All participants will be asked swallow water and applesauce
2851098|NCT03590444|Active Comparator|Prompt laser group|"Eyes of eligible patients will be randomized (ratio 1:1) and receive ranibizumab and focal/grid laser on the same day (prompt' group, 25 eyes, 50%).~Interventions: ranibizumab and focal/grid laser on the same day [Ranibizumab (Ranibizumab 0.5 MG/0.05 ML Intraocular Solution]"
2851099|NCT03590444|Active Comparator|Deferred laser group|"Eyes of eligible patients will be randomized (ratio 1:1) and receive ranibizumab and focal/grid laser on one week prior to laser treatment (deferred' group, 25 eyes, 50%).~Interventions: ranibizumab and focal/grid laser on one week prior to laser treatment [Ranibizumab 0.5 MG/0.05 ML Intraocular Solution]"
2851100|NCT03590431|Other|bioavailability iodine milk (extrinsic)|300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine in milk, low protein-bound fraction)
2851101|NCT03590431|Other|bioavailability iodine milk (intrinsic)|300 ml whole cow's milk delivering ≈ 200 µg iodine (intrinsic iodine in milk, high protein-bound fraction)
2851102|NCT03590431|Other|bioavailability water iodine solution|300 ml water iodine solution delivering ≈ 200 µg iodine (water iodine solution)
2851103|NCT03590418||Intestinal stoma output|No interventions.
2851104|NCT03590418||Colonic feaces|No interventions.
2851105|NCT03590418||Healthy Control|No interventions.
2851106|NCT03590405|Experimental|uterus transplantation|uterus transplantation from living donor with the donor being close relative
2851107|NCT03590392|Experimental|Group 1|Group 1 volunteers (n= 6) will be administered ChAdOx1 Chik, 5 x 10^9 vp through intramuscular route.
2851108|NCT03590392|Experimental|Group 2|Group 2 volunteers (n= 9) will be administered ChAdOx1 Chik, 2.5 x 10^10 vp through intramuscular route.
2851109|NCT03590392|Experimental|Group 3|Group 3 volunteers (n= 9) will be administered ChAdOx1 Chik, 5 x 10^10 vp through intramuscular route.
2851110|NCT03590379|Experimental|CHF 5993 DPI|BDP/FF/GB DPI 100/6/12,5 mcg
2851111|NCT03590379|Active Comparator|CHF 5993 pMDI|BDP/FF/GB pMDI 100/6/12,5 mcg
2851112|NCT03590379|Active Comparator|CHF 1535 pMDI|BDP/FF pMDI 100/6 mcg
2851113|NCT03590366|Active Comparator|B244|"B244 suspension in 30ml/bottle~Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day."
2851114|NCT03590366|Placebo Comparator|Vehicle|"Vehicle, 30ml/bottle~Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day."
2851115|NCT03590353|Active Comparator|Dual chamber pacemaker|"Patients with sinus node disfunction: sinus node disfunction with obvious clinical symptoms, including sinus pause; patients with chronotropismus disfunction; patients have to take some medicine due to some diseases, but the medicine may result to sinus bradycardia.~Adult Acquired Atrioventricular Block (AVB): (1). Third degree or advanced atrioventricular block in any block part with symptomatic bradycardia (2). Patients taking other antiarrhythmic drugs in long term, which could result in third degree or advanced AVB (in any block part) and symptomatic bradycardia;~Patients with acute myocardial infarction (AMI) and AVB:~(1). Patients with His-Purkinje system persistent second degree AVB and retardant or third degree AVB after STEMI; (2). Patients with temporary severe second degree AVB or third degree AVB (block part under atrioventricular node) and retardant; 4. Patients with carotid sinus hypersensitivity or neurogenic syncope of the heart;"
2851116|NCT03590353|Experimental|His bundle pacemaker|His Bundle Pacemaker: All of the Criteria Inclusion of dual chamber pacemaker excluding patients with block part under the his bundle;
2851117|NCT03590340|Experimental|Group 1a (PfSPZ Vaccine)|"Group 1a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 113.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
2851118|NCT03590340|Experimental|Group 2a (PfSPZ Vaccine)|"Group 2a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last prime dose by DVI injection."
2851119|NCT03590340|Experimental|Group 3a (PfSPZ Vaccine)|"Group 3a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 29.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
2851120|NCT03590340|Experimental|Group 4a (PfSPZ Vaccine)|"Group 4a: subjects (n=21) will receive two doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1 and 8 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 29.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
2851121|NCT03590340|Placebo Comparator|Group 1b (NS)|"Group 1b: subjects (n=5) will receive normal saline (NS) placebo on Days 1, 3, 5, 7, and 113.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
2851122|NCT03590340|Placebo Comparator|Group 2b (NS)|"Group 2b: subjects (n=5) will receive NS placebo on Days 1, 3, 5, and 7.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
2851123|NCT03590340|Placebo Comparator|Group 3b (NS)|"Group 3b: subjects (n=5) will receive NS placebo on Days 1, 3, 5, 7, and 29.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
2851124|NCT03590340|Placebo Comparator|Group 4b (NS)|"Group 4b: subjects (n=5) will receive NS placebo on Days 1 and 8.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
2851125|NCT03590327|No Intervention|Apathy +, rTMS -|This arm will be followed without intervention
2851126|NCT03590327|Active Comparator|rTMS|This group will be randomized to receive rTMS treatment
2851127|NCT03590327|Sham Comparator|Sham|This group will be randomized to receive sham treatment
2851128|NCT03590314|Experimental|Experimental group|The experimental group was treated using a robot assisted arm training, Armotion (Reha Technology, Olten, Switzerland).
2851129|NCT03590314|Active Comparator|Control group|The control group was treated using a conventional training, without end effector robot.
2851130|NCT03590301|Experimental|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup will enable and inspire parents to encourage their children to improve their diet and activity behaviors through general authoritative parenting, structured feeding practices, and a healthy home environment. Parents and toddlers will participate in the FUNPALs Playgroup together where they will be led through a series of open but structured activities including free play, exercise, snack preparation, discussion, singing, and yoga stretches.
2851131|NCT03590301|Active Comparator|Healthy Toddlers Parent Group|The goal of the Healthy Toddlers Parent Group is to deliver the same nutrition and activity messages to parents as those delivered in the FUNPALs Playgroup. In the Healthy Toddlers Parent Group, parents (without children) will meet in groups to receive information on nutrition and activity as it relates to their toddlers and they will engage in a discussion around how they do or can implement these behaviors. No experiential learning, children, play, or parenting instruction will be included in this control condition.
2851132|NCT03590288||TIPS group|Pressure gradient were measured in consecutive cirrhotic patients undergoing TIPS.
2851133|NCT03590262|Experimental|metformin|patients take metformin 500mg twice or three times a day as add-on therapy to insulin for 3 months ,using self-control method.
2851134|NCT03590249|Experimental|Osteopathic Manipulative Treatment (OMT)|Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
2851135|NCT03590249|No Intervention|No Intervention|Participants in the No Intervention arm will undergo the planned assessments, but not receive any intervention.
2851136|NCT03590236|Experimental|Graded exposure therapy|Patients in this group received graded exposure therapy added to physiotherapy
2851137|NCT03590236|Active Comparator|Physiotherapy|Patients included in this group received the standard treatment based on a physiotherapy approach.
2851138|NCT03590236|No Intervention|Control group|Waiting list patients
2851139|NCT03590210|Experimental|Group A - L-sarcoma|Patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen will receive drug treatment with trabectedin (3 cycles mono-therapy) followed by trabectedin/nivolumab combination (up to 13 additional cycles)
2851140|NCT03590210|Experimental|Group B - non-L-sarcoma|Patients with unresectable or metastatic soft tissue sarcoma other than liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen (GIST excluded) will receive drug treatment with trabectedin (3 cycles mono-therapy) followed by trabectedin/nivolumab combination (up to 13 additional cycles)
2851141|NCT03590197|Placebo Comparator|Control Arm|The patients in Control Arm will receive placebo with valproate (20 mg/kg).
2851142|NCT03590197|Experimental|Melatonin Arm|The Experimental Arm will receive tablet melatonin as an add-on to valproate. Melatonin will be prescribed 3 mg/day to the patients and will be advised to take 30 minutes before bedtime.
2851143|NCT03590184||patients with a biological prosthesis|patients who have received a biological prosthesis
2851144|NCT03590184||patients with a biosynthetic resorbable prosthesis|patients who have received a biosynthetic resorbable prosthesis
2851145|NCT03590171|No Intervention|Arm HR-A|Induction: Backbone ALL R3
2851146|NCT03590171|Experimental|Arm HR-B|Induction: Backbone ALL R3 + Bortezomib
2851147|NCT03590158|Experimental|TRF|Participants will be instructed to eat only within a 10-hour time frame each day for 8 weeks. Participants may self-select the precise window that best suits their lifestyles, however any food and drink must be consumed at least 3 hours prior to their usual bedtime.
2851148|NCT03590145||Qatari athletes|Participants meeting general criteria and included from site 1 in Doha, Qatar.
2851149|NCT03590145||Irish athletes|Participants meeting general criteria and included from site 2 in Dublin, Ireland.
2851150|NCT03590132|Experimental|SAAF|participants in this arm receive the SAAF intervention at age 11-12.
2851151|NCT03590132|Experimental|SAAF-T|participants in this arm receive the SAAF-Teen intervention at age 14-15.
2851152|NCT03590132|Experimental|SAAF SAAF-T|participants in this arm receive SAAF at age 11-12 and later receive SAAF-Teen at age 14-15
2851153|NCT03590132|No Intervention|Control|These participants receive no interventions.
2851154|NCT03590119|Experimental|Intra-arterially treated liver lobe|Depending on the allocation after randomization, Lu-177-dotatate will be infused in either the left or the right hepatic artery, following catheterization using the Seldinger-technique.
2851155|NCT03590119|Active Comparator|'Intravenously' treated liver lobe|The lobe that is not treated intra-arterially, will act as the intravenously treated lobe, due to the first-pass effect.
2851156|NCT03590106|Experimental|Peer Recovery Support Program|"Patients enrolled in the Peer Recovery Support Program will:~Actively engage in the program as defined by meeting with a Peer Support Volunteer at least two times prior to discharge, and or use of resilience journal, and or review of NA book.~Demonstrate negative drug screens done randomly during their hospitalization.~Actively contact at least one outpatient recovery program that they might enroll in prior to discharge (information about recovery programs to be provided by unit SW).~Demonstrate appropriate changes in their SOCRATES 8D survey scores from admission to program to post discharge.~Participate in follow up phone call with completion of SOCRATES 8D survey at 30 and 60 days post discharge."
2851157|NCT03590093|Experimental|Periodontal Surgery with EMD|A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed. After carefully cleaning root dental surfaces, EMD was placed inside the infrabony periodontal defect. Suture were placed to maintain wound stability.
2851158|NCT03590093|Active Comparator|Periodontal Surgery|A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed. Suture were placed to maintain wound stability.
2851260|NCT03589365|Other|control group|young adults born at term will performed an Magnetic resonance imaging (MRI)
2851159|NCT03590080||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
2851160|NCT03590067||Heamodialysis group|
2851161|NCT03590067||Kidney transplantation group|
2851162|NCT03590054|Experimental|Treatment (abexinostat, pembrolizumab)|Participants receive abexinostat PO BID on days 1-21 and pembrolizumab IV on over 30 minutes day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2851163|NCT03590041|Active Comparator|Standardized SMA|The standardized SMA model includes the same TTIM curriculum as in the patient-driven model, but it is delivered in a standardized way (order of and time spent on topics are set) across all participating practices.
2851164|NCT03590041|Active Comparator|Patient-driven SMA|In the patient-driven SMA model, patients receive the same TTIM curriculum, but patients at each practice are able to set the order of the curriculum and dictate how long to spend on each topic.
2851165|NCT03590028|Experimental|Early Nephrology Consult (ENC)|The ENC will be a structured consultative note that will provide detailed recommendations around issues such as Differential Diagnosis, Drug Dosing and Volume Status. The research ENC will have a daily follow-up with documented recommendations.
2851166|NCT03590028|Active Comparator|Standard of Care (SOC)|Subjects will receive nephrology consultation at the typical timepoint after symptoms of AKI appear.
2851167|NCT03590015|Other|old letter of invitation|"Old invitation letter written by researchers/doctors in The coronary project sent to patients in order to recruit to an ongoing project"
2851168|NCT03590015|Other|New letter of invitation|New invitation Letter written with consideration of impaired language comprehension and has therefore been written in simple sentences with a sequential structure of basic information sent to patients in an ongoing project.
2851169|NCT03590002|Experimental|Electronic ICU Medical Transfer Tool|ICUs allocated to the experimental arm will have access to the electronic Medical Transfer of Care Documentation Tool within the clinical information system (CIS) in order to prepare ICU transfer of care documents for the receiving medical care team.
2851170|NCT03590002|No Intervention|Dictated ICU Medical Transfer|Usual Care, ICUs in the control group will only have access to the dictation documentation system as the standard method to prepare ICU medical transfer documents. New ICU medical staff responsible for preparing transfer documents will receive the usual training on the dictation system.
2851171|NCT03589989|Experimental|Intervention group|
2851172|NCT03589989|Active Comparator|Control group|
2851173|NCT03589976|Experimental|Sirolimus|2 mg/day (one 2-mg tablet/day). The dose of sirolimus will be adjusted throughout the trial based on sirolimus plasma levels and the presence of drug-related adverse events. The maximum dose of sirolimus will be6 mg/day (three 2-mg tablets/day).
2851174|NCT03589976|Placebo Comparator|Placebo|Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.
2851175|NCT03589963|No Intervention|Pre-intervention|regular CPNP programming
2851176|NCT03589963|Experimental|Post-intervention|regular CPNP programming plus access to postnatal lactation support
2851177|NCT03589950|Experimental|Anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle) + Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
2851178|NCT03589950|Active Comparator|Chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
2851179|NCT03589924|Experimental|One step method|Immediate implant reconstruction following mastectomy using TiLoop®Bra (one step method) n=225
2851180|NCT03589924|Active Comparator|Two step method|Immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra (two step method) n=225
2851181|NCT03589898|Experimental|Gabapentin|Single dose of gabapentin 900 mg will be given and neuroimaging markers will be measured before and after administration of gabapentin
2851182|NCT03589885|Placebo Comparator|Placebo 2 mL auto-injector|Placebo to secukinumab s.c., provided in 2 mL auto-injector form
2851183|NCT03589885|Placebo Comparator|Placebo 1 mL prefilled syringe|Placebo to secukinumab s.c., provided in 2 * 1 ml prefilled syringe form
2851184|NCT03589885|Experimental|Secukinumab 2 mL auto-injector|Secukinumab 300 mg provided in 2 mL auto-injector form
2851185|NCT03589885|Active Comparator|Secukinumab 1 mL prefilled syringe|Secukinumab 300 mg provided as 2x 1 mL prefilled syringe of 150 mg/mL
2851186|NCT03589872||Study Group|patients with parkinson disease
2851187|NCT03589872||Control Group|healthy subjects
2851188|NCT03589859||Normal Volunteers|Testing motor learning
2851189|NCT03589859||Vestibular hypofunction|Testing feasibility of rehabilitation game
2851190|NCT03589846|Experimental|Muscle stimulation|Consented participants who meet eligibility will have a drug induced sleep endoscopy (DISE) and the Grass S88 muscle stimulator.
2851191|NCT03589833|Placebo Comparator|MTX|Treated with oral methotrexate and two placebos.
2851192|NCT03589833|Placebo Comparator|Tripterygium Wilfordii|Treated with oral Tripterygium Wilfordii and two placebos.
2851193|NCT03589833|Active Comparator|Yisaipu + MTX|Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
2851194|NCT03589833|Experimental|Yisaipu + Tripterygium Wilfordii|Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
2851195|NCT03589820|Active Comparator|Artificial liver support system group|30 patients will receive treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine.
2851196|NCT03589820|No Intervention|Control group|30 patients will receive treatment of internal medicine.
2851197|NCT03589807|Experimental|Heterologous Arm 1|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 and 3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + ASO3 adjuvant administered intramuscularly on Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=30
2851198|NCT03589807|Experimental|Heterologous Arm 2|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and 3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + ASO3 adjuvant administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
2851199|NCT03589807|Experimental|Heterologous Arm 3|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and 15 mcg per 0.5 ml dose of 2017 A/H7N9 IIV administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
2851200|NCT03589807|Experimental|Homologous Arm 1|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and Day 22. PBS diluent may be used to achieve targeted dosages. N=30
2851201|NCT03589807|Experimental|Homologous Arm 2|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and Day 121. PBS diluent may be used to achieve targeted dosages. N=30
2851202|NCT03589807|Experimental|Homologous Arm 3|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 Adjuvant administered intramuscularly on Day 1 and 15 mcg per 0.5 ml dose of 2017 A/H7N9 IIV administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
2851203|NCT03589794|Experimental|Group 1|10 subjects receive 10 mcg rCSP + 5mcg AP 10-602 [GLA-LSQ] intramuscularly (IM) on days 1, 29 and 85
2851204|NCT03589794|Experimental|Group 2|10 subjects receive 30 mcg rCSP + 5mcg AP 10-602 [GLA-LSQ] intramuscularly (IM) on days 1, 29 and 85
2851205|NCT03589794|Experimental|Group 3|10 subjects receive 30 mcg rCSP intramuscularly (IM) on days 1, 29 and 85
2851206|NCT03589794|Experimental|Group 4|10 subjects receive 60 mcg rCSP + 5 mcg AP 10-602 [GLA-LSQ] intramuscularly (IM) on days 1, 29 and 85. Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
2851207|NCT03589794|Experimental|Group 5|10 subjects receive 30mcg rCSP + 5 mcg AP 10-602 [GLA-LSQ] intramuscularly (IM) on days 1, 29 and 85 if immunogenicity analysis conducted 28 days post-2nd dose in Groups 2 and 3 show promise (at least fourfold increase in geometric mean anti-CSP antibody or geometric mean anti-CSP titer of 20). Otherwise, Group 5 will receive 60 mcg rCSP + 5 mcg AP 10-602 [GLA-LSQ]. Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
2851208|NCT03589794|Other|Group 6|6 subjects receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain
2851209|NCT03589781|Experimental|Mikei Red Reishi Essence EX|
2851210|NCT03589781|Placebo Comparator|Placebo|
2851211|NCT03589768|Experimental|Group 1|"0.5 ml single dose of Tdap (Tetanus, Diphtheria, Acellular Pertussis Vaccine), BOOSTRIX administered intramuscularly to pregnant women at 14 0/7 weeks through 26 6/7 weeks estimated Gestational Age (GA).~N=133"
2851212|NCT03589768|Active Comparator|Group 2|"0.5 ml single dose of Td (Tetanus, Diphtheria Toxoid) administered intramuscularly to pregnant women at 14 0/7 weeks through 26 6/7 weeks estimated GA.~N=67"
2851213|NCT03589755|Active Comparator|mindful meditation|Behavioral intervention, providing meditation
2851214|NCT03589755|No Intervention|Waiting list|Patient on a waiting list
2851215|NCT03589742|Experimental|Radiofrequency ablation patients|Single-Arm study, all patients included will undergo RF ablation using AblaView® Ablation Catheter
2851216|NCT03589729|Experimental|Supportive care (dexrazoxane hydrochloride, chemotherapy)|See detailed description.
2851217|NCT03589716|Other|Participants with Vital Signs Within Normal Range|All participants will be asked to have an arm and finger measurement conducted and undergo vital sign measurements using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiration rate, blood oxygen saturation, and temperature. Participants with vital signs within the normal physiological range will also be asked to perform an optional exercise testing and/or undergo arterial blood gas measurement.
2851218|NCT03589716|Other|Participants with Vital Signs Outside of Normal Range|All participants will be asked to have an arm and finger measurement conducted and undergo vital sign measurements using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiration rate, blood oxygen saturation, and temperature. Participants with vital signs outside of the normal physiological range would be documented.
2851219|NCT03589703|Active Comparator|APA|Patients with active points related to cLBP. Will receive acupressure within the two zones for cLBP located on the front and back of the ear and three points known for alleviating stress and pain.
2851220|NCT03589703|Sham Comparator|Comparison Group (CG-1)|"The same procedure for APA will be applied but the tapes/seeds will be placed on five different ear points, comprising mouth, stomach, duodenum, internal ear, and tonsil.~These points are chosen for the sham APA treatment for two reasons. First, they are distinct from the zones of the ear (and the points therein) associated with the lower back, and correspond to body regions in which the participant is usually pain-free. Second, they are equivalent in number to those points used in the APA treatment group."
2851221|NCT03589703|Other|Enhanced Educational Control Group (CG-2)|Participants in the enhanced educational control group will be given the cLBP educational booklet and visit the office weekly for assessment (i.e., blood draws and questionnaires), which is the same schedule as that for the APA groups.
2851222|NCT03589690|Experimental|Alpha Lipoic acid|Alpha lipoic acid capsules (600 mg/day)
2851223|NCT03589690|Placebo Comparator|Placebo|Starch-filled capsules (600 mg/day)
2851224|NCT03589677||Myotonic dystrophy type 1|"Subjects of both sexes with a diagnosis of Steinert's disease (DM1), de novo or with the previous diagnosis that shows significant worsening detectable during the follow-up foreseen by the normal cure procedure with clinical presentation indicating a CNS compromise will be evaluated for:~quality of life evaluation~exam of neuroimaging~study of myomiRNAs before and after rehabilitation"
2851225|NCT03589664||Non-Sternotomy Group|Subjects who have no prior sternotomy
2851226|NCT03589664||Sternotomy Group|Subjects who previously underwent a sternotomy procedure.
2851227|NCT03589651|Experimental|Group A|INCMGA00012 with epacadostat.
2851228|NCT03589651|Experimental|Group B|INCMGA00012 with INCB050465.
2851229|NCT03589638|Active Comparator|direct laryngoscope|Endotracheal intubation was applied by anesthesiologist with direct laryngoscope.
2851230|NCT03589638|Active Comparator|C-MAC videolaryngoscope|Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
2851231|NCT03589638|Active Comparator|McGrath videolaryngoscope|Endotracheal intubation was applied by anesthesiologist with McGrath videolaryngoscope.
2851232|NCT03589625|Experimental|Solar Suitcase Installation First Group|Facilities will receive the installation of the Solar Suitcase shortly after baseline data collection.
2851261|NCT03589339|Experimental|NBTXR3 activated by SABR|
2851677|NCT03586427|Experimental|AGN-241751 Dose 4|AGN-241751 Dose 4 administered as 1 tablet taken orally every day
2851233|NCT03589625|Experimental|Solar Suitcase Installation Second Group|Facilities will act as a comparator for experimental group 1 and then will receive the installation of the Solar Suitcase shortly after midline data collection.
2851234|NCT03589599|Experimental|Flavored tobacco|All participants will be completing a lab visit where they smoke flavored waterpipe tobacco ad lib for up to 45 min.
2851235|NCT03589599|Experimental|Non-flavored tobacco|All participants will be completing a lab visit where they smoke non-flavored waterpipe tobacco ad lib for up to 45 min.
2851236|NCT03589586|Experimental|DermACELL AWM + Conventional Care|DermACELL AWM, acellular dermal matrix, plus conventional wound care- DermACELL AWM will be applied at the Baseline visit. Conventional wound care will include advanced wound dressings and multilayer compression.
2851237|NCT03589586|No Intervention|Conventional Care|Conventional wound care will include advanced wound dressings and multilayer compression.
2851238|NCT03589560|Experimental|Biodentine|3-4 mm of Biodentine (Septodont, St. Maur-des-Fosses, France) was applied over the clot carefully in group I by using amalgam carrier. material was packed lightly with a moistened cotton pellet and Periapical radiograph was taken to confirm coronal seal in the second visit of dental pulp revascularization.
2851239|NCT03589560|Active Comparator|Mineral Trioxide Aggregate|3-4 mm of white Mineral Trioxide Aggregate (Angelus, Londrina, Brazil) was applied over the clot in group II by using amalgam carrier. material was packed lightly with a moistened cotton pellet and Periapical radiograph was taken to confirm coronal seal in the second visit of dental pulp revascularization.
2851240|NCT03589547|Experimental|Durvalumab and SBRT|"Durvalumab 10mg/kg x 1 day, dose #1 to occur > 3 weeks and <7 weeks after last chemo/RT and prior to SBRT dose 1 (5-10 day time frame between Durvalumab and SBRT).~SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab (see above for time frames). The dose will consist of 20Gy (2 fractions of 10Gy). 3 fractions are allowed for centrally located tumors~Dose # 2 of durvalumab, (post SBRT) to be given 1-10 days post last SBRT. Durvalumab then to be given at 10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)"
2851241|NCT03589534|Other|pregnancy test|pregnancy tests
2851242|NCT03589521|Experimental|ABCT_Military|ABCT_Military manual will address alcohol use, couple issues and military specific issues. Required interventions include: routine interventions, overview of treatment, reintegration issues, motivational techniques, patient-focused interventions for abstinence, partner-related interventions for abstinence, couple interventions, general coping skills, social skills and relapse prevention. In addition, to personalize each treatment plan, interventions from optional modules (e.g., intimate partner violence (IPV), depression, trauma, and traumatic brain injury (TBI)) will be integrated into each couple's treatment plan depending on clinical presentation.
2851243|NCT03589508|Experimental|In-Person Sessions: ABCP_P|In-person therapy sessions: 6 Weekly Prevention Session conducted in person (half of participants will attend alone, half of participants will attend with a significant other)
2851244|NCT03589508|Experimental|Video conference sessions: ABCP_T|Video conference therapy sessions: 6 Weekly Prevention Session conducted using videoconference (half of participants will attend alone, half of participants will attend with a significant other)
2851245|NCT03589495|Active Comparator|N acetylcysteine group|N Acetyl L Cysteine IV bolus (100 mg/kg dissolved in dextrose5%) infused over 15 minutes, followed by continuous infusion of 50mg/kg/day dissolved in dextrose 5% starting 1hr before induction of anesthesia, and continued for 48 hours after operation
2851246|NCT03589495|Placebo Comparator|placebo group|received equal volume of dextrose 5% administrated at the same rate and duration as in the study group as a placebo
2851247|NCT03589482|Experimental|EIT algorithm|Patients randomized to this arm will be ventilated at the PEEP level selected by the EIT algorithm, which selects a PEEP at which both collapse and hyperdistention are minimized.
2851248|NCT03589482|Active Comparator|ExPRESS algorithm|Patients randomized to this arm will be ventilated at the PEEP level selected by the ExPRESS algorithm, which is a method that targets a tidal volume of 6 ml/kg predicted body weight and then titrates PEEP until plateau airway pressure reaches 28 cm H2O.
2851249|NCT03589469|Experimental|Loncastuximab tesirine|Participants will receive loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurs first.
2851250|NCT03589443|Experimental|Multiplexed heptapeptides|QRH & KSP sprayed onto area of interest and imaged before and after application
2851251|NCT03589430||1 child A|child A liver cirrhosis
2851252|NCT03589430||2 child B|child B liver cirrhosis
2851253|NCT03589430||3 child C|child C liver cirrhosis
2851254|NCT03589404|Experimental|rso2|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
2851255|NCT03589391|Experimental|Procedures with the use of device for LOR monitoring|Patients enrolled suffered from chronic back pain and underwent epidural infiltration. The device is used.
2851256|NCT03589391|No Intervention|Procedures without the use of device for LOR monitoring|Patients enrolled suffered from chronic back pain and underwent epidural infiltration
2851257|NCT03589378|Experimental|PEAF|Intervention group:the patient will receive treatment with PEAF immediately after randomization.PEAF that is TPE (20ml/kg/d Fresh frozen plasma, Blood pump: 120ml/min, replacement pump 20ml/kg/min, dialysate pump 0ml/kg/min, waste pump 20ml/kg/min, plasma exchange 1 hour) plus plasma-filtration adsorption(PFA) (Blood pump: 120ml/min, Plasma separation rate 25-30%, PFA with acute multitherapeutic system (AMPLYA™ Italy) ≥30ml/min) and High volume plasma diafiltration (HVPDF) with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) , Blood pump same as PFA , replacement fluid pump 2000ml/h, dialysate pump 2000ml/h, waste pump 4000ml/h),with PFA and HVPDF for 15 hours in the first 3 days. If hemodynamically unstable or acute kidney injury(AKI) stage 2or 3,continue High volume hemofiltration(HVHF).Same protocol with control group after 3days.
2851258|NCT03589378|No Intervention|Control group|HVHF for septic shock with MODS is permitted in Control group routinely（Blood pump: 200ml/min, replacement fluid pump 45ml/kg/min, dialysate pump 45ml/kg/min, waste pump 90ml/kg/min, and high-volume hemofiltration for 16 hours with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) in the first 3 days after randomization.If hemodynamically unstable or AKI stage 2or 3,continue HVHF.
2851262|NCT03589326|Experimental|Cohort A: Ponatinib 30 mg|Ponatinib 30 mg, tablets, orally, once daily, along with vincristine 1.4 mg/m^2 (max 2 mg) intravenous (IV), on Days 1 and 14 and dexamethasone 40 mg (<60 years [yrs]) and 20 mg (≥60 yrs), orally, once on Days 1 through 4 and Days 11 through 14 in each 28-day cycle for up to 3 cycles in induction phase followed by ponatinib 30 mg, tablets, orally, once daily, along with cytarabine, 1000 mg/m^2 every 12 hours as a 2-hour IV infusion (≤60 yrs) and 250 mg/m^2 every 12 hours (>60 yrs), IV on Days 1, 3 and 5 of each even cycles (cycles 2, 4 and 6) and methotrexate, 1000 mg/m^2 (≤60 yrs) and 250 mg/m^2 (>60 yrs), IV infusion, on Day 1 of each odd cycles (cycle 1, 3 and 5) in consolidation phase followed by ponatinib 30 mg, tablets, orally, once daily, along with vincristine 1.4 mg/m^2,(max 2 mg) IV, on Day 1 and prednisone 200 mg (<60 yrs), 100 mg (≥60-69 yrs) and 50 mg (≥70 yrs) on Days 1 through 5 in each cycle from Cycle 10 to 20 in maintenance phase.
2851263|NCT03589326|Active Comparator|Cohort B: Imatinib|Imatinib 600 mg, tablets, orally, once daily, along with vincristine 1.4 mg/m^2 (max 2 mg) IV, on Days 1 and 14 and dexamethasone 40 mg (<60 years [yrs]) and 20 mg (≥60 yrs), orally, once on Days 1 through 4 and Days 11 through 14 in each cycle 28-day for up to 3 cycles in induction phase followed by imatinib 600 mg, tablets, orally, once daily, along with cytarabine, 1000 mg/m^2 every 12 hours as a 2-hour-IV infusion (≤60 yrs) and 250 mg/m^2 every 12 hours (>60 yrs), IV on Days 1, 3 and 5 of each even cycles (cycles 2, 4 and 6) and methotrexate, 1000 mg/m^2 (≤60 yrs) and 250 mg/m^2 (>60 yrs), IV infusion, on Day 1 of each odd cycles (cycle 1, 3 and 5) in consolidation phase followed by imatinib 600 mg, tablets, orally, once daily, along with vincristine 1.4 mg/m^2, (max 2 mg) IV, on Day 1 and prednisone 200 mg (<60 yrs), 100 mg (≥60-69 yrs) and 50 mg (≥70 yrs) on Days 1 through 5 in each cycle from Cycle 10 to 20 in maintenance phase.
2851264|NCT03589313|Experimental|GLPG3067 single dose.|Single Dose of GLPG3067 film coated tablets.
2851265|NCT03589300|Other|Persona TM Tibia subjects|Subjects that receive the Persona TM Tibia implant
2851266|NCT03589287|Experimental|Chondrochymal® 1 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
2851267|NCT03589287|Experimental|Chondrochymal® 5 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
2851268|NCT03589287|Experimental|Chondrochymal® 10 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
2851269|NCT03589274|Experimental|I-FS-CBT|In I-FS-CBT each participant saw a therapist weekly. The first session was 90 minutes long, and subsequent sessions were 60 minutes long. The I-FS-CBT manual included core CBT, motivational enhancement, and relapse prevention components. Two core thematic women's issues were integrated into each session via discussion and illustrative material: (a) self-confidence, and (b) self-care.
2851270|NCT03589274|Experimental|G-FS-CBT|The G-FS-CBT manual included core CBT, motivational enhancement, and relapse prevention components. Two core thematic women's issues were integrated into each session via discussion and illustrative material: (a) self-confidence, and (b) self-care. The session organization was modified for a closed group format. The group treatment was designed to provide didactic presentation of coping skills and motivational enhancement material, and group discussion and rehearsal of new skills within a supportive atmosphere that facilitated mutual emotional support and support for abstinence.
2851271|NCT03589261|Other|Portal blood flow measure by MRI|Hepatic blood flow baseline will be measured using MRI. Fluid challenge of 500 ml of NaCl 0.9% will be administered during 10 minutes. Before and After fluid challenge, MRI will be performed to compare flow changes.
2851272|NCT03589248||GIF score|assess the AGI by gastrointestinal failure(GIF) score
2851273|NCT03589248||US score|assess the AGI by ultrasonography(US) score
2851274|NCT03589235|Experimental|A Platelet-Rich Fibrin dressing|A Platelet-Rich Fibrin dressing (PRF) will be used in both donor and receiving sites after a free gingival graft.
2851275|NCT03589235|Experimental|A non-eugenol-based dressing|A non-eugenol-based dressing (Coe-Pak™) will be used in both donor and receiving sites after a free gingival graft.
2851276|NCT03589222|Experimental|Selinexor, Daratumumab, Bortezomib and dexamethasone|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle plus dexamethasone 40 or 20 mg mg orally with each dose of selinexor in combination with daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter and bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9. Each cycle is of 4 weeks of duration
2851277|NCT03589196|Active Comparator|Photoselective Vaporization|
2851278|NCT03589196|Active Comparator|Plasma Kinetic Vaporization|
2851279|NCT03589196|Active Comparator|Transurethral Resection Of The Prostate|
2851280|NCT03589170||People over 60 years of age|People over 60 years of age without previous known atrial fibrillation
2851281|NCT03589157|Experimental|Drug-coated balloon group|
2851282|NCT03589157|Active Comparator|second-generation drug-eluting stent group|
2851283|NCT03589131|Active Comparator|Robotic-assisted Surgery Group|In this arm the investigators use a robotic system to perform resection of the rectum harboring the tumor trying to do that while being oncologically safe. The robotic system that we use is the da Vinci Si (Intuitive Surgical, Inc.,Sunnyvale,CA) Interventions used are total operative time, margin assessment, conversion rate to open surgery, baseline demographics, preoperative data and postoperative data
2851284|NCT03589131|Active Comparator|Laparoscopic Surgery Group|"In this arm the investigators use a Laparoscopy system to perform resection of the rectum harboring the tumor trying to do that while being oncologically safe.~Interventions used are total operative time, margin assessment, conversion rate to open surgery, baseline demographics, preoperative data and postoperative data"
2851285|NCT03589118|Experimental|Qi Gong|Qi gong sessions added to usual well defined medical and psychological support
2851286|NCT03589118|No Intervention|Control|Usual well defined medical and psychological support
2851287|NCT03589105|Experimental|Ocrelizumab Treatment Cycles|Each participant will receive an initial dose of two 300 mg infusions of Ocrelizumab each separated by 14 days followed by one single dose of 600 mg 24 weeks after the initial dose.
2851288|NCT03589092||GDM Current|"Currently pregnant women diagnosed with GDM.~Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes."
2851390|NCT03588364|No Intervention|Waitlist Control|Six-week waiting period.
2860895|NCT03522441|Active Comparator|Clindamycin 1% gel (Greenstone LLC)|
2851289|NCT03589092||GDM History|"Women with history of GDM (with negative GAD/IA2 antibodies if results available).~Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes."
2851290|NCT03589079||Monogenic Disorder|Participants exhibiting clinical phenotypes suggestive of an underlying novel monogenic disorder, with/without the presence of familial recurrence of the phenotype and/or parental consanguinity will be included. Sanger and/or Next generation Sequencing (NGS) - Panel/WES/WGS approaches will be used to facilitate identification of de novo/inherited variants in the child/proband.
2851291|NCT03589066|Experimental|Formulation A|LY03003 28 mg intramuscular suspension, single dose, 1 day duration
2851292|NCT03589066|Experimental|Formulation B|LY03003 28 mg intramuscular suspension, single dose, 1 day duration
2851293|NCT03589053|Experimental|LRIC group|Participants in the experimental group receive both LRIC and standard clinical therapy. The LRIC treatment is composed of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion (Patent No.CN200820123637.X, China).
2851294|NCT03589053|Sham Comparator|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
2851295|NCT03589040|Other|Ripivirine arm|All subjects will be administered oral ripilvirine 25mg once daily together with the rest of their oral antiretroviral combination and an etonogestrel single-rod subdermal implant (68mg/rod). Study participants will have both interventions for a period of one year.
2851296|NCT03589040|Other|Darunavir arm|All subjects will be administered oral DRV/r 600/100mg twice daily together with the rest of their oral antiretroviral combination and an etonogestrel single-rod subdermal implant (68mg/rod). Study participants will have both interventions for a period of one year.
2851297|NCT03589027|Experimental|Rilpivirine arm|All subjects will be administered oral rilpivirine 25mg once daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
2851298|NCT03589027|Experimental|Darunavir arm|All subjects will be administered oral darunavir/ritonavir 600/100mg twice daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
2851299|NCT03589014|No Intervention|Control|Standard Treatments recommended for CCM
2851300|NCT03589014|Experimental|￼Propranolol|Initial oral dose 40 mg bid, uptitrated to 80mg bid
2851301|NCT03589001||OSD|51 adolescents with Osgood Schlatter who participated in an activity modification intervention.
2851302|NCT03588988|Experimental|Dexmedetomidine group|
2851303|NCT03588988|Placebo Comparator|Control group|
2851304|NCT03588975|Experimental|MACI|autologous cultured chondrocytes on porcine collagen membrane
2851305|NCT03588975|Active Comparator|microfracture|surgical procedure
2851306|NCT03588962|Experimental|Metal allergy driven restenosis|Patients with angiographically proven in-stent restenosis developed after technically correct implantation. Patch tests for the metals used in stent production will be applicated. The tests will be applicated during the hospitalisation, then read after 48 hours and 72 hours, and subsequently interpreted by the skilled dermatologist, during the hospital stay or afterwards. Possible correlation between allergy to metals utilised during the stent manufacturing (nickel, cobalt, chromium, molybdenum, tungsten) and in-stent restenosis occurence.
2851307|NCT03588962|Placebo Comparator|Looking for allergic restenosis|Patients with (technically correctly) implanted stent. Patch tests will be applicated to identify cases with contact allergy. The tests will be applicated during the hospitalisation, then read after 48 hours and 72 hours, and subsequently interpreted by the skilled dermatologist, during the hospital stay or afterwards.The patients will then be monitored for a 12 months follow-up period in purpose of evaluating the dependance between in-stent restenosis and contact allergy. Possible correlation between allergy to metals utilised during the stent manufacturing (nickel, cobalt, chromium, molybdenum, tungsten) and in-stent restenosis occurence.
2851308|NCT03588949|Experimental|Active Dietary Supplement|Dietary Supplement with L-carnitine (FertilHom)
2851309|NCT03588949|Placebo Comparator|Control Dietary Supplement|Dietary Supplement with 50% RDA of beta-carotene
2851310|NCT03588936|Experimental|Nivolumab and Tocilizumab|
2851311|NCT03588923|Active Comparator|Cohort 1|SH229 (400 mg) or matching placebo, once daily
2851312|NCT03588923|Active Comparator|Cohort 2|SH229 (600 mg) or matching placebo, once daily
2851313|NCT03588923|Active Comparator|Cohort 3|SH229 (800 mg) or matching placebo, once daily
2851314|NCT03588910|Active Comparator|Number of oxycodone tablets typically prescribed|Participants will receive a prescription for 10 tablets of 5 mg oxycodone (1 tablet every 6 hours as needed) as well as 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed) and 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed).
2851315|NCT03588910|Experimental|Half the number of oxycodone tablets typically prescribed|Participants will receive 5 tablets of 5mg oxycodone as well as 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed) and 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed).
2851316|NCT03588897|No Intervention|Normal Diet|Elderly patients receiving normal diet
2851317|NCT03588897|Experimental|Nutritional Support|Elderly patients receiving normal diet with nutritional support (Nutridrink Multi Fibre 2x100 ml per day)
2851318|NCT03588884|Active Comparator|CTAP101|CTAP101/Calcifediol Capsules 60 mcg once daily at bedtime, except on Days 1 and 29 when dosing will occur in the morning before breakfast
2851319|NCT03588884|Experimental|Immediate-release (IR) calcifediol|Immediate-release (IR) calcifediol/266 mcg capsule before breakfast on the mornings of Day 1 and Day 29
2851320|NCT03588884|Experimental|Cholecalciferol|Cholecalciferol/Capsules 300,000 IU (high-dose) before breakfast on the mornings of Day 1 and Day 29
2851321|NCT03588884|Active Comparator|Paricalcitol|Paricalcitol/Capsules 1 mcg plus cholecalciferol capsules 800 IU (low-dose) once daily in the morning before breakfast, except on Days 1 and 29 when dosing will occur before breakfast
2851322|NCT03588871|Experimental|Group A|Dental bleaching with PaintOn Plus, HP 6%, 6x10min, two sessions
2851323|NCT03588871|Experimental|Group B|Dental bleaching with Opalescence GO, HP 6%, 10x60min
2851324|NCT03588871|Experimental|Group C|Dental bleaching with Opalescence PF, CP 16%, 14x60h
2851325|NCT03588845|Other|Protocol Treatment|"If a score on the GSS is > 5, the computer will send an automatic notice to the office of the doctor and to the doctor him/herself telling them of this.~Upon receipt of the notice, the protocol doctors will be expected to make an appointment within the timeframe outline in the protocol. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess the timeliness of the first visit after notification, about the adherence of protocol doctors to protocol treatment."
2851326|NCT03588845|Other|Standard of Care|Standard care doctors, who will not know the details of this protocol, will decide on their own if and when to see the patient. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess types of medications and general pattern of treatment of the standard of care doctors.
2851327|NCT03588819|Experimental|2-fraction SABR|
2851328|NCT03588806|Experimental|Xtampza ER (oxycodone) Treatment|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study. A standard conversion table will be used to calculate the dose of Xtampza ER that is equivalent to the subject's current opioid medication dosage. Subjects will be converted to 75% of the calculated dose for the first 7-10 days and then to 100% of the calculated dose for the remaining 3 weeks of the study. The Xtampza ER dosage may be modified at the discretion of the PI to ensure the safety of the subject. As per manufacturer recommendations, subjects will be instructed to open the capsules, sprinkle the microspheres onto soft food such as pudding or applesauce, and then consume the food.
2851329|NCT03588767|Experimental|Vitamin D3 + anabolic substance|Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
2851330|NCT03588767|Active Comparator|Retrospective analysis|Retrospectively analyzed patients, no vitamin D3 + anabolic substance administration.
2851331|NCT03588754|Experimental|Propranolol|Propranolol extended release (160mg/day). Administered orally once daily at 10:00PM. Titration schedule Days 1-3 60mg, Days 4-7 80mg, Days 8-11 120mg, and Days 12-14 160mg until steady state.
2851332|NCT03588754|Placebo Comparator|Placebo|Administered orally once daily at 10:00PM
2851333|NCT03588741|Experimental|Turoctocog alfa|
2851334|NCT03588728|Experimental|CR + tDCS|Cognitive Remediation (CR) and Transcranial Direct Current Stimulation (tDCS)
2851335|NCT03588728|Sham Comparator|CR + sham tDCS|Cognitive Remediation (CR) and Sham Transcranial Direct Current Stimulation (tDCS)
2851336|NCT03588728|Sham Comparator|control CR + tDCS|Control Cognitive Remediation (CR) and Transcranial Direct Current Stimulation (tDCS)
2851337|NCT03588728|No Intervention|control CR + sham tDCS|Control Cognitive Remediation (CR) and Sham Transcranial Direct Current Stimulation (tDCS)
2851338|NCT03588715|Experimental|Pegylated Interferon alpha 2b + bNAbs|Pegylated Interferon alpha 2b (peg-IFN-α2b) + bNAbs (3BNC117 + 10-1074)
2851339|NCT03588715|Experimental|bNAb only|bNAb (3BNC117 + 10-10-74) only
2851340|NCT03588702|Experimental|Venus Legacy LB2 Body applicator group|Liposuction area is divided into 2 equal sections. One section receives RF and PEMF treatment.
2851341|NCT03588689|No Intervention|Standard Treatment|Patients in this group will receive standard treatment orders which include a combination of opioids, NSAIDs, acetaminophen, and other adjuncts for analgesia.
2851342|NCT03588689|Experimental|Continuous fascia iliaca block|"The cFIB group will receive an ultrasound guided cFIB and standard treatment orders as backup in the event of block failure.~The cFIB group will receive an initial bolus of 40 cc of 0.25% Ropivacaine followed by an infusion of 8 cc/hr until the time of surgery. Immediately pre-operatively, the anesthesiologist performing the case will bolus the catheter 40 cc of 0.25% ropivacaine and discontinue the catheter."
2851343|NCT03588676|No Intervention|Normoxia|Participants will sleep in room air and receive no melatonin.
2851344|NCT03588676|Placebo Comparator|Hypoxia and Placebo|5mg placebo before sleep study
2851345|NCT03588676|Experimental|Hypoxia and Melatonin|5mg melatonin before sleep study
2851346|NCT03588663|Experimental|Bionic Leg|Participants will wear the Bionic Leg during a series of different activities including a timed-up-and-go, balance tests, 6-min walk test and sit-to-stand exercises.
2851347|NCT03588663|Active Comparator|Control|Participants will complete a series of different activities including a timed-up-and-go, balance tests, 6-min walk test and sit-to-stand exercises without wearing the bionic leg (control condition).
2851348|NCT03588650|Experimental|HLX20, in patients with solid tumors|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX20 once every two weeks. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 1, 3, 10 and 20 mg/kg, starting from 1 mg/kg.
2851349|NCT03588637||Study population|Patient who receive at least one dose of daptomycin
2851350|NCT03588624|Experimental|TearCare|All subjects in the study will undergo the TearCare procedure one time at the baseline visit. They will then be followed out to one month.
2851351|NCT03588611|Experimental|Low dose group with eGFR ≥60ml/min|This arm, we will choose the patients who's eGFR ≥60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.
2851352|NCT03588611|Active Comparator|Standard dose group with eGFR ≥ 60ml/min|This arm, we will choose the patients who's eGFR ≥60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .
2851353|NCT03588611|Active Comparator|Standard dose group with eGFR <60ml/min|This arm, we will choose the patients who's eGFR ＜60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .
2851354|NCT03588611|Experimental|Low dose group with eGFR <60ml/min|This arm, we will choose the patients who's eGFR ＜60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.
2851355|NCT03588598|Experimental|SHC014748M treatment|SHC014748M capsule， 50, 100, 150, 200, 250 mg, QD, 28 days for each cycle
2851356|NCT03588585|Active Comparator|Tension|foley balloon will be placed on tension and taped to thigh at 10 cm. Misoprostil will be placed in posterior vaginal vault.
2851357|NCT03588585|Active Comparator|No tension|The foley balloon will be loosely taped without tension to the patient's thigh. Misoprostil will be placed in the posterior vaginal vault.
2851358|NCT03588572|Experimental|Venlafaxine Group|The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation ( each containing venlafaxine 75mg), 1 capsule per day, until 4 weeks after randomization.
2851359|NCT03588572|No Intervention|Controlled group|the patients in controlled group do not use the drug during the experiment, and the other treatments are same as the venlafaxine group.
2851360|NCT03588559|Experimental|BPM, TMB-1591-A-002 and Reference Device|DUT: Transtek Blood Pressure Monitor TMB-1591-A-002 Reference Device: Baumanometer Desk Mercury Sphygmomanometer. Blood Pressure Measurement with the Transtek BPM TMB-1591-A-002 and with reference device.
2851361|NCT03588533|Experimental|Herzuma-capecitabine/cisplatin(XP)|"Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)~Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle~ ) every 3 weeks~Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks~Cisplatin 60~100mg/m2 i.v. D1 every 3 weeks"
2851362|NCT03588520|Experimental|Home BP Monitoring Group|Patients allocated to this group will receive a home blood pressure monitoring device and decisions to modify the hypertension treatment will be based on the results of the home blood pressure monitoring in accordance with the current guidelines of the European Society for Hypertension for the Treatment of Hypertension.
2851363|NCT03588520|No Intervention|Office BP Monitoring Group|Patients allocated to this group will act as controls. They will receive no home blood pressure monitoring device and decisions to modify the hypertension treatment will be based exclusively on blood pressure measurements in office visits.
2851364|NCT03588507|No Intervention|Papilla preservation flap techniques|Papilla preservation flap techniques will be conducted to gain access to the intrabony defects. In the narrow interproximal spaces (≤2 mm), incision with the preservation of the buccal papilla according to the simplified papilla preservation technique will be applied. Whereas, in the wide interdental spaces (>2 mm), the modified papilla preservation technique will be applied. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
2851365|NCT03588507|Active Comparator|PPF+NCHA bone graft substitute|intervention: papilla preservation flap techniques + nanocrystalline hydroxyapatite bone graft substitute Same surgical techniques and procedures will be performed. Before suturing the flap, nanocrystalline hydroxyapatite bone graft substitute(Dentaurum, Germany) will be placed within the defect up to the existing level of the alveolar crest and care will be taken not to overfill the defect. The mucoperiosteal flaps will be repositioned and secured in place using non-resorbable # 6-0-suturing material. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
2851366|NCT03588494|Active Comparator|concurrent chemoradiotherapy (CCRT)|"Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
2851367|NCT03588494|Experimental|W1-CCRT|"Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first chemoradiotherapy cycle(days -5～-1).~Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
2851368|NCT03588494|Experimental|W2-CCRT|"Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).~Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
2851369|NCT03588481||Coronary stenosis|
2851370|NCT03588468|Sham Comparator|healthy|will be defined as persons without pathological mutation of the TTR gene Electrophysiological biomarkers and MRI biomarkers will be performed
2851371|NCT03588468|Active Comparator|Asymptomatic carriers|"will be defined as persons with a known pathological mutation of the TTR gene but with no clinical complain, normal clinical examination, and normal renal and cardiac investigations.~Electrophysiological biomarkers and MRI biomarkers will be performed"
2851372|NCT03588468|Experimental|Symptomatic carriers|"will be defined as persons with a known pathological mutation of the TTR gene with clinical complain, abnormal clinical examination, and abnormal renal and cardiac investigations.~Electrophysiological biomarkers and MRI biomarkers will be performed"
2851373|NCT03588442||Cirrhosis cohort|Patients with liver cirrhosis.
2851374|NCT03588442||HBV infection cohort|Patients with seropositivity of HBsAg.
2851375|NCT03588429|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
2851376|NCT03588429|Experimental|Isoflurane|Anesthesia was maintained with isoflurane.
2851377|NCT03588403||Arm A:Tomotherapy|Patients with non-disseminated nasopharyngeal carcinoma receiving Tomotherapy.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.
2851378|NCT03588403||Arm B: IMRT|Patients with non-disseminated nasopharyngeal carcinoma receiving IMRT.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.
2851379|NCT03588390|Experimental|Dose Group 1|
2851380|NCT03588390|Experimental|Dose Group 2|
2851381|NCT03588390|Experimental|Dose Group 3|
2851382|NCT03588390|Experimental|Dose Group 4|
2851383|NCT03588390|Experimental|Dose Group 5|
2851384|NCT03588390|Experimental|Dose Group 6|
2851385|NCT03588390|Experimental|Dose Group 7|
2851386|NCT03588390|Experimental|Dose Group 8|
2851387|NCT03588377|Active Comparator|Intervention Cluster|Signs and symptoms of severe pneumonia Pulse Oximetry
2851388|NCT03588377|No Intervention|Non-Intervention Cluster|Signs and symptoms of severe pneumonia
2851389|NCT03588364|Experimental|Osteopathic Manipulation|Twelve weekly sessions using the techniques of osteopathy in the cranial field.
2851391|NCT03588351|Active Comparator|chlorhexidine gluconate|GROUP I: - 15 teeth will be treated with specially prepared gel containing chlorhexidine gluconate as intracanal medicament .
2851392|NCT03588351|Experimental|chitosan nanoparticles gel|GROUP II: - 15 teeth will be treated with specially prepared gel containing chitosan nanoparticles that ready to use as intracanal medicament.
2851393|NCT03588351|Experimental|chitosan gel|Group III: 15teeth will be treated with specially prepared gell containing chitosan that ready to use as intra medicament .
2851394|NCT03588338|Active Comparator|Perfalgan|1.5 mg/kg intravenous, intraoperative (20 min before end of the surgery)
2851395|NCT03588338|Active Comparator|Metoclopramide|0.2 mg/kg intravenous, intraoperative (20 min before end of the surgery)
2851396|NCT03588312||simple heart defects|Newborns with hypoplastic aortic arch in simple congenital heart defects requiring aortoplasty
2851397|NCT03588312||complex heart defects.|Newborns with hypoplastic aortic arch in complex congenital heart defects requiring aortoplasty
2851398|NCT03588299|Experimental|BAY2599023 / (DTX201)|Adult patients with severe hemophilia A, who have been previously treated with FVIII products
2851399|NCT03588286|Experimental|Intervention Arm (Early EPS)|"The intervention group all undergo electrophysiologic study early after myocardial infarction (within 40 days of MI).~If the study is positive (inducible monomorphic ventricular tachycardia of cycle length greater than or equal to 200ms) participants have an ICD implanted. Participants with a negative study (no inducible arrhythmia or induced ventricular fibrillation/ ventricular flutter cycle length <200ms) are discharged without an ICD.~A proportion of trial patients from both the intervention and control arms at >48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury."
2851400|NCT03588286|Active Comparator|Control Arm (Standard Care)|"The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).~A proportion of trial patients from both the intervention and control arms at >48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury."
2851401|NCT03588273|Other|Amoxil 500 mg Oral Capsule Time 0|In each period (before the surgery and 2 months after the bariatric surgery) the obese volunteers received a single oral dose of amoxicillin 500 mg capsule (Amoxil®, GlaxoSmithKline Brazil Ltda.) with 200 mL water after an overnight fast (approximately 8 h).
2851402|NCT03588260||Idiopathic pulmonary fibrosis|The patients who have agreed to participate in the study from patients diagnosed with idiopathic pulmonary fibrosis referred to the center of pulmonary rehabilitation from the interstitial lung disease polyclinic.
2851403|NCT03588260||Healthy subjects|The healthy adults without additional disease
2851404|NCT03588234||Type 1 diabetes|Individuals with type 1 diabetes (18-29 years old). They must complete a questionnaire. This group has approximately 26 extra questions to respond to compared to controls. The extra questions pertain to their diabetes history as well as their knowledge regarding diabetes.
2851405|NCT03588234||Matched controls without Type 1 diabetes|Individuals without type 1 diabetes (18-29 years old). They must complete the same questionnaire as the individuals with diabetes (without the diabetes-specific questions).
2851406|NCT03588221|Other|Six-step hand hygiene technique with application time of 30|
2851407|NCT03588221|Other|Six-step hand hygiene technique with application time of 15|
2851408|NCT03588221|Other|Three-step hand hygiene technique with application time of 3|
2851409|NCT03588221|Other|Three-step hand hygiene technique with application time of 1|
2851410|NCT03588208|Experimental|Intervention Group|
2851411|NCT03588208|Active Comparator|Control Group|
2851412|NCT03588195|Experimental|Education Group|
2851413|NCT03588195|Active Comparator|Control Group|
2851414|NCT03588182|Experimental|Group VR|Virtual reality (VR) experience VR visualization of a 3-dimensional relaxing nature scene with the accompanying audio. The patient will be offered a selection of scenes from which to choose, played continuously on a Samsung Gear VRTM(San Jose, CA) headset and headphones. The goal is for the patient to use the intervention for the entire duration of the external cephalic version procedure (ECV), which typically lasts 15 - 30 minutes.The patient will also receive verbal reassurance and coaching as needed. The obstetrician will communicate as usual with the patient.
2851415|NCT03588182|No Intervention|Group No VR|No intervention will be provided for the control group, who will receive usual management at CUMC, which involves provision of no analgesia or sedation for the procedure, which typically lasts 15 - 30 minutes. Verbal reassurance and coaching is routinely provided by caregivers, including encouraging deep breathing, particularly during painful manipulation of the abdomen, for the duration of the procedure. The obstetrician will communicate as usual with the patient - for example advising that he/she is about to begin the procedure and giving updates as to the degree of success.
2851416|NCT03588169||patients hospitalized at the Dijon University Hospital|Patients hospitalized in the endocrinology, digestive surgery, pneumology and geriatric units of the Dijon University Hospital with a prescription for ONS
2851417|NCT03588156|Experimental|Benapenem|Investigatial Product: Benapenem: 11 group : 62.5mg one dose; 125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
2851418|NCT03588156|Placebo Comparator|Placebo|Placebo control 11 group : 62.5mg one dose;125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
2851419|NCT03588143|Active Comparator|Electrical stimulation with TENS|TENS with 100 Hz frequency, 65 microseconds pulse duration, in continuous pattern
2851420|NCT03588143|Experimental|Electrical stimulation with HVPS|HVPS with twin spiked monophasic current at 100 pps frequency, in continuous pattern
2851421|NCT03588143|Placebo Comparator|Placebo electrical stimulation|same electrode placement with other interventions, using the same electrotherapy device, without activating the device except its time unit.
2851422|NCT03588130|Active Comparator|EscharEx (5% EX-02 formulation)|Debridement will be performed with 5% EX-02 for 24±3 hours, up to 8 applications
2851423|NCT03588130|Placebo Comparator|Gel Vehicle|Debridement will be performed with Gel vehicle for 24±3 hours, up to 8 applications
2851424|NCT03588117||Participants of a weight management program|Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
2851425|NCT03588104|Experimental|POWER2DM support group|Participants in this group will receive access to the POWER2DM system as an adjunct to usual care. The participants have three intervention visits in which they will use the Shared Decision Making Dashboard to set self-management goals and will use the Self-Management Support system for trying to reach those goals in the periods after the intervention visits.
2851426|NCT03588104|Active Comparator|Usual care group|Participants in this group will follow their usual diabetes care with their own diabetes care team.
2851427|NCT03588091|Experimental|arm1|Pyrotinib Plus trastuzumab and docetaxel
2851428|NCT03588091|Placebo Comparator|arm2|placebo plus trastuzumab and docetaxel
2851429|NCT03588078|Experimental|combination of APR246 and azacitidine|Following completion of the Dose Finding Phase, we will conduct a dose expansion, whereby patients will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing as in Phase 1b
2851430|NCT03588065|Experimental|attend education for TICS|The educational activities were directed to soccer players belonging to Equidad, Bogotá-Colombia. Computerized media were used within the reach of footballers, applied with professionals of physical activity sciences under blind study methodology, using the new tendencies of Information and Communication Technologies (ICT) in Health Education. The investigators counted on the advice of the group manager of knowledge of the secretary of the district of the city of Bogotá. In the educational intervention seven aspects were addressed, distributed in four weekly modules for a total of four months
2851431|NCT03588065|Active Comparator|attend education for conference|"The intervention arm descriptionTHE CONFERENCE include face-to-face sessions focused on the four aspects mentioned above for ICT. To this end, the theoretical elements of the concepts under study were taken into account: human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing.~The face-to-face sessions focused on the four aspects mentioned above for ICT. To this end, the theoretical elements of the concepts under study were taken into account: human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing."
2851432|NCT03588065|Sham Comparator|attend for FMS|The FMS test was applied in two moments with three blind evaluators physiotherapists with specialization in therapeutic physical activity and master in Physical Activity and Sports, with an experience of more than 5 years in the field of assessment of sport condition and clinical experience in sport greater than 6 years in sports clubs in the region.
2851433|NCT03588052|Experimental|VISTA using PRF|"Vestibular incision subperiosteal tunnel access combined with Platelets-Rich Fibrin~An intravenous blood will be drawn from the patient in a glass-coated plastic tubes, centrifuged at 3000 rpm for 10-12 min. A Platelets rich fibrin membrane will then be obtained"
2851434|NCT03588052|Active Comparator|VISTA using SCTG|"vestibular incision subperiosteal tunnel access combined with subepithelial connective tissue graft~Subepithelial connective tissue graft will be harvested from the palate, secured in the tunnel to cover the root dehiscence then sutured"
2851435|NCT03588039|Experimental|Dose escalation-Arm 1|During the dose escalation period Oraxol will be administered once daily for 2 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2851436|NCT03588039|Experimental|Dose escalation-Arm 2|During the dose escalation period Oraxol will be administered once daily for 3 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2851437|NCT03588039|Experimental|Dose escalation-Arm 3|During the dose escalation period Oraxol will be administered once daily for 4 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2851438|NCT03588039|Experimental|Dose escalation-Arm 4|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2851439|NCT03588039|Experimental|Dose escalation-Arm 5|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2851440|NCT03588039|Experimental|Dose escalation-Arm 6|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2851441|NCT03588039|Experimental|Dose expansion-Gastric/GE|The dose expansion period will enroll subjects with gastric/gastro-esophageal cancer to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2851442|NCT03588039|Experimental|Dose expansion-NSCLC cancer|The dose expansion period will enroll subjects with NSCLC to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2851678|NCT03586427|Placebo Comparator|Placebo|Placebo administered as 1 tablet taken orally every day
2860896|NCT03522441|Placebo Comparator|Placebo|
2851443|NCT03588039|Experimental|Dose expansion-Urothelial cancer|The dose expansion period will enroll subjects with advanced/metastatic urothelial to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2851444|NCT03588026|Experimental|Arm 1 - 9 months of treatment (rVA576 plus SOC)|6 months (SOC plus rVA576), Followed by a further 3 months of (SOC plus rVA576).
2851445|NCT03588026|Experimental|Arm 2 - 6 months on SOC|6 months on SOC only. Followed by 3 months (SOC plus rVA576).
2851446|NCT03588013|Experimental|Moderate/severe malnourishment|Pakistani children from age 0 to 6 months with weight for height Z score (WHZ) < -2 at the time of enrollment. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth. Those participants who remain WHZ < -2 despite interventions are eligible for medical evaluation for more advanced workup of malnutrition, including UGI endoscopy and biopsy.
2851447|NCT03588013|Active Comparator|Well nourished children|Pakistani children from age 0 to 6 months who would be growing normally, with WHZ > 0, to serve as controls. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth.
2851448|NCT03588013|No Intervention|US children with celiac disease|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. Environmental Enteropathy and celiac disease have some shared features therefore we plan to enroll children under the age of 6 years with newly diagnosed celiac disease per endoscopy at CCHMC to assess the extent to which gene signatures and associated biologic pathways for children with celiac disease or environmental enteropathy overlap or differ.
2851449|NCT03588013|No Intervention|US children with Crohn's disease|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. As some differentially expressed ileal gene signatures for Crohn's disease bear remarkable similarities to individual gene expression patterns previously reported for EE, children under the age of 10 years with newly diagnosed Crohn's disease per endoscopy at CCHMC will be enrolled to study these similarities and any differences
2851450|NCT03588013|No Intervention|Healthy age-matched US children|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. Number of upper gastrointestinal endoscopies performed in children less than 2 years old are limited in Pakistan, therefore US age-matched controls will be used; healthy children < 3 years old will be enrolled, who will undergo endoscopy at CCHMC as part of a diagnostic workup for digestive symptoms, but whose biopsies and diagnoses are not supportive of eosinophilic esophagitis, celiac disease, or inflammatory bowel disease, and who were not treated with antibiotics ≤ 4 weeks prior to endoscopy.
2851451|NCT03588000|Experimental|Strength group|Strengthen self-monitoring of blood glucose by Internet mobile terminal (APP)
2851452|NCT03588000|No Intervention|Control group|Voluntary self-monitoring of blood glucose
2851453|NCT03587987|Active Comparator|Neopuff|neopuff
2851454|NCT03587987|Experimental|r PAP|rPap device
2851455|NCT03587974|Experimental|REACH-VN|In-home psychosocial intervention to enhance caregiver knowledge and skills and to reduce stress delivered in 4-6 sessions over the course of 2-3 months
2851456|NCT03587974|No Intervention|Enhanced control|Single session with education about nature of dementia
2851457|NCT03587961|Experimental|Symdeko|Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Symdeko, depending on the in vitro response pattern
2851458|NCT03587961|Experimental|Ivacaftor|Patients who have mutation response to a potentiator of CFTR function will be given Ivacaftor monotherapy.. Patients with a mutation equivalent to wild type will be given Ivacaftor.
2851459|NCT03587961|Experimental|Orkambi|Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Orkambi, depending on the in vitro response pattern
2851460|NCT03587948||Case group|Children and adolescents with diabetes mellitus
2851461|NCT03587948||Control group|Children and adolescents without diabetes mellitus
2851462|NCT03587922|Experimental|Treatment Arm|Single arm study with treatment of Fantom scaffold
2851463|NCT03587909|Active Comparator|Phacoemulsification Cataract Surgery|Procedure / Surgery : Phacoemulsification Surgery
2851464|NCT03587909|Active Comparator|Femtosecond Cataract Surgery|Procedure / SUrgery - Femtosecond Laser Cataract surgery
2851465|NCT03587896|Experimental|Self Help Plus|SH+ programme has been developed by WHO and collaborators working in the humanitarian field, with expertise in global mental health and psychosocial interventions. SH+ programme consists of a pre-recorded audio course, complemented with bibliotherapy, and thanks to this format not requiring much time from experts for implementation. SH+ consists of 5 sessions.
2851466|NCT03587896|No Intervention|Enhanced Treatment As Usual|Control arm participants will receive routine social support and/or care according to ordinary practice and following local regulations. Additionally, they will receive baseline and follow-up assessments according to the study schedule, and information about freely available mental health services, social services and community networks providing support to asylum seekers and refugees, and NGOs' contact details.
2851467|NCT03587883|Experimental|Cocoa Flavanol intervention|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 300 mg of cocoa flavanols per capsule: 900 mg of cocoa flavanols consumed daily for 2 weeks; 2 intervention periods: Cocoa flavanols I and cocoa flavanols II.
2851468|NCT03587883|Placebo Comparator|Control intervention|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks; 2 intervention periods: control I and control II.
2851469|NCT03587870|Experimental|Bolus enteral nutrition with Fresubin Intensive|Bolus nutrition over 30-40 minutes every 4 hours with Fresubin Intensive
2851470|NCT03587870|Active Comparator|Continuous enteral nutrition with Fresubin Intensive|Continuous nutrition over 20 hours per day with Fresubin Intensive (standard)
2851471|NCT03587857|Experimental|Arm 1: Intervention|In the first phase, the investigators will randomize 78 YLWH to receive the mobile health application (i.e., WYZ 2.0) versus a wait-list control. The intervention arm will use the app for 6 months, at which the investigators will asses feasibility, acceptability and preliminary clinical impact of WYZ at 6 months. Based on this initial data, the investigators will refine and release a new version of the app (WYZ 3.0).
2851716|NCT03586141|Other|noninvasive measurement of hemoglobin|All participating patients are measured by the Pronto® hemoglobin measurement tool
2851717|NCT03586128||HIV serodiscordant couples|
2851472|NCT03587857|Other|Arm 2: Wait-list control|In the second phase, the wait-list control arm will use the latest version of the mobile health application (WYZ 3.0) for 6 months and will evaluate the acceptability, feasibility and preliminary clinical impacts at 14 months. Participants in the intervention arm (i.e., Arm 1) will be able to continue to use the app during months 6-14. Finally, based on acceptability, feasibility and preliminary clinical impact data from participants between 6-14 months, the investigator will refine and release a new version of the app (WYZ 4.0).
2851473|NCT03587844|Experimental|not been previously treated with brentuximab vedotin.|Patients with MF who have not been previously treated with brentuximab vedotin.
2851474|NCT03587844|Experimental|treated with reduced dose brentuximab vedotin|Patients with MF who were previously treated with brentuximab vedotin. Up to 10 patients will be enrolled onto this cohort. Following identification of a promising dose after the completion of the full Cohort 1 Simon two stage design, enrollment will initiate onto cohort 2 at the dose found to be promising in cohort 1. If neither dose is found promising, cohort 2 will not start.
2851475|NCT03587844|Experimental|who have not been previously treated with brentuximab vedotin.|Patients with LyP who have not been previously treated with brentuximab vedotin. Patients with lymphomatoid papulosis will receive brentuximab vedotin 0.9 mg/kg as an intravenous infusion over 30 minutes every three weeks. Cohort 3 will enroll patients concurrently with Cohort 1
2851476|NCT03587831|Experimental|VSG + LSM|"Procedure/Surgery: Vertical Sleeve Gastrectomy will be performed using five laparoscopic ports. The short gastric and epiploic vessels will be taken down With a 40 French Bougie in place, the greater curvature will be excised starting 6 cm proximal to the pylorus.~Behavioral: Lifestyle Modification Counseling - The intensive lifestyle intervention will align with methods listed in the LSM arm description. However, participants assigned to the VSG will not have calorie ceilings during the first 6 months of rapid weight loss, and they will receive additional instruction regarding food volume and adequate protein intake."
2851477|NCT03587831|Active Comparator|LSM|Behavioral: Lifestyle Modification Counseling - The intensive lifestyle intervention is modeled after the LookAHEAD trial, with modules modified for participants undergoing surgery, and designed to produce maximum achievable weight loss. Both groups will increase their level of moderate-intensity physical activity (such as walking) to a total of 325 minutes per week. All lifestyle-medical management participants will be given calorie intake targets of 1200, 1500, or 1800 kilocalories per day, depending on body weight, with the goal of producing a weight loss of 1 to 2 pounds per week. There will be 24 weekly counseling meetings during the first 6 months, bi-weekly meetings between months 7 and 9, and monthly meetings between months 10 and 12.
2851478|NCT03587818|No Intervention|Control group|"Conventional care. Patients were receiving several written patient education materials (PEMs), mostly related to specific parts or procedures related to the surgery and the recovery.~Communication between patients and professionals during consultations occurred according to conventional care practice."
2851479|NCT03587818|Experimental|Intervention group|"I. Written interactive PEM structured into chapters/phases of the care process. Designed to serve three purposes:~generic information of the surgery and recovery process on a group level to promote high readability, suitability and comprehensibility~arena of dialogues between patient and professionals; voicing concerns, share perspectives~for the patient to personally reflect on generic information.~II. Person-centred communication in dialogues using the PEM as a supportive tool, facilitated by four communication strategies:~professionals guiding the patient through the care process~communicating an introduction, agenda and closing~being sensitive to the patient's questions, beliefs, experiences and resources~dialogue based on story, posing open-ended questions, and following up."
2851480|NCT03587805|Experimental|Tralokinumab, all subjects|"Week 0: subcutaneous (SC) injection of tralokinumab loading dose.~From Week 2 up to Week 140*: SC injection of tralokinumab maintenance dose.~* The length of treatment for each subject will depend on when they enter the trial."
2851481|NCT03587779|Experimental|Sevoflurane|Anesthesia is maintained with sevoflurane.
2851482|NCT03587779|Experimental|Desflurane|Anesthesia is maintained with desflurane.
2851483|NCT03587766|Experimental|Group A|Fexinidazole (FEXI) 600 mg x 10 days in a single daily dose orally (1 fexinidazole 600 mg tablet and 1 fexinidazole matching placebo oral tablet administered in a single daily dose) (total dose: 6.0 g).
2851484|NCT03587766|Experimental|Group B|Fexinidazole (FEXI) 1200 mg x 3 days orally (2 fexinidazole 600 mg tablets administered in a single daily dose for 3 days), to be followed by matching placebo oral tablet for 7 days (2 fexinidazole matching placebo oral tablets administered once daily for 7 days) (total dose: 3.6 g).
2851485|NCT03587766|Experimental|Group C|Fexinidazole (FEXI) 600 mg for 3 days, followed by 1200 mg in a single daily dose orally for 4 days (1 fexinidazole 600 mg tablet AND 1 fexinidazole matching placebo oral tablet administered in a single daily dose for 3 days, to be followed by 2 fexinidazole 600 mg tablets for 4 days), then followed by matching placebo oral tablet for 3 days (2 fexinidazole matching placebo tablets administered once daily for 3 days) (total dose: 6.6 g).
2851486|NCT03587753|Active Comparator|Unsaturated|A test meal containing a unsaturated fatty acid labelled with 13C to measure hepatic fatty acid partitioning.
2851487|NCT03587753|Active Comparator|Saturated|A test meal containing a saturated fatty acid labelled with 13C to measure hepatic fatty acid partitioning
2851488|NCT03587740|Experimental|T-DM1|T-DM1 will be administered every 3 weeks intravenously, with 21 consecutive days defined as a treatment.
2851489|NCT03587701|Experimental|Group A|This group will be randomized to receive intervention of 42 consecutive days of anakinra (100mg/0.67ml) in period 1 followed by an additional 42 consecutive days of anakinra (100mg/0.67ml) in period 2
2851490|NCT03587701|Experimental|Group B|This group will be randomized to receive intervention of 42 consecutive days of anakinra (100 mg/0.67ml) in period 1 followed by 42 consecutive days of placebo in period 2
2851491|NCT03587701|Experimental|Group C|This group will be randomized to receive intervention of placebo for 42 consecutive days in period 1 followed by 42 consecutive days of anakinra (100mg/0.67ml) in period 2
2851492|NCT03587675|Other|EVH in high-school elite athletes|EVH-test, skin prick test, sputum induction in all subjects Interventional but no drug or device tested
2851525|NCT03587467||chronic hepatitis b|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~Meet diagnostic criteria of chronic hepatitis B in EASL 2017 Clinical Practice Guidelines on the management"
2851828|NCT03585309|Experimental|Laparascopy comper with coagulation and without coagulation|
2851493|NCT03587662|Experimental|Treatment (ixazomib, gemcitabine, doxorubicin)|"INDUCTION: Participants receive ixazomib PO, gemcitabine IV over 90 minutes, and doxorubicin IV over 15-30 minutes on day 1. Treatment repeats every 14 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Participants receive ixazomib PO and gemcitabine IV over 90 minutes. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
2851494|NCT03587649|Experimental|[18F]MNI-1126|To measure the dynamic uptake and washout of [18F]MNI-1126 in the brain using positron emission tomography (PET) in subjects with AD, PD, and healthy volunteers.
2851495|NCT03587636|Experimental|Liposome bupivacaine interscalene block|10 mL of liposome bupivacaine and 10 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance
2851496|NCT03587636|Active Comparator|bupivacaine interscalene block|20 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance.
2851497|NCT03587610|Active Comparator|Intervention arm|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
2851498|NCT03587610|No Intervention|Standard care|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~if the patients vaccinations are not up to date: the patient will be informed that a remedial vaccination is necessary and that he should contact his primary care provider after hospital discharge."
2851499|NCT03587597|Experimental|socket shield technique|socket shield technique with immediate temporization
2851500|NCT03587597|Active Comparator|conventional immediate implant|conventional implant placement with immediate temporization
2851501|NCT03587584|Experimental|liposomal bupivacaine|These patients receive an interscalene block with liposomal bupivacaine.
2851502|NCT03587584|Active Comparator|bupivacaine|These patients receive an interscalene block with bupivacaine.
2851503|NCT03587571|Active Comparator|Surgical intervention|Open reduction and osteosynthesis by plating is done. Further after treatment is similar to conservative treatment arm.
2851504|NCT03587571|No Intervention|Conservative treatment|At the first visit a split cast is applied. Afterwards physiotherapy and weightbearing as tolerated is allowed.
2851505|NCT03587558|Experimental|Carvedilol group|Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT. Dilatrend® sustained release form of Chong Kun Dang Pharmaceutical will be used (initial dose: 8 mg sustained release form). Outpatient follow-up will be performed every 2 weeks and the dose is increased from the initial dose to a maximal tolerable dose, at the discretion of the investigator.
2851506|NCT03587558|Active Comparator|Flecainide group|Patients in this group are taking flecainide to inhibit outflow tract PVC/VT. Tambocor® of JW Pharmaceutical will be used. Outpatient follow-up will be performed every 2 weeks and the dose is increased from the initial dose to a maximal tolerable dose, at the discretion of the investigator.
2851507|NCT03587545|Experimental|Healthy probiotic group LGG|Daily intake by healthy volunteers of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.
2851508|NCT03587545|Experimental|Healthy probiotic group LAMBR2|Daily intake by healthy volunteers of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.
2851509|NCT03587545|Placebo Comparator|Healthy placebo group|"Daily intake by healthy volunteers of 2 dosages of placebo spray during 2 weeks.~Placebo nasal spray."
2851510|NCT03587545|Experimental|CRS probiotic group LGG|Daily intake by CRS patients of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.
2851511|NCT03587545|Experimental|CRS probiotic group LAMBR2|Daily intake by CRS patients of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.
2851512|NCT03587545|Placebo Comparator|CRS placebo group|Daily intake by CRS patients of 2 dosages of placebo spray during 2 weeks. Placebo nasal spray.
2851513|NCT03587532|Experimental|Indocyanine Green Angiography|ICG based angiography after creation of the stomach graft and after thoracic pull-up of the graft. Dynamic digital images will be obtained starting immediately after intravenous bolus administration of 0.5 mg/kg of ICG.
2851514|NCT03587519|Experimental|Early ileostomy closure|Early ileostomy closure will be performed 7 to 12 days after with ileal j-pouch anal anastomosis (IPAA) and loop ileostomy (IPAA).
2851515|NCT03587519|Active Comparator|Late ileostomy closure|Late ileostomy closure will be performed 8 - 12 weeks after IPAA.
2851516|NCT03587506||Patients: group|Group I (n=10) included patients who did not develop any major or minor seizure during the follow-up period and their follow up EEG was free of any epileptiform discharge
2851517|NCT03587506||Patients: group II|Group II (n=11) included patients who developed only minor seizures and their follow up EEG showed epileptiform discharge
2851518|NCT03587506||Patients: group III|Group III (n=9) were patients who developed one or more major seizures during the follow-up period whatever their EEG findings.
2851519|NCT03587506||Controls|healthy volunteers (n=30) who were not related to the patients and had no family history of epilepsy.
2851520|NCT03587493|Experimental|EXPERIMENTAL GROUP|"110 adults, on national waiting list for a first lung transplantation in the centers of Marseille and Strasbourg, whatever the lung disease, and who will be transplanted and benefit immunosuppressive induction therapy that specifically targets T lymphocytes will be included.~Blood sample analysis will be performed"
2851521|NCT03587480|Other|TME+LLDD group|Total Mesorectal Excision With Lateral Lymph Node Dissection for low rectal cancer with regional lymph node metastasis.
2851522|NCT03587480|Other|TME+nCRT|Total Mesorectal Excision After Neoadjuvant Chemo-radiotherapy for low rectal cancer with regional lymph node metastasis.
2851523|NCT03587467||health|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~smooth and soft stool like sausage or snake~Voluntary participate in this study"
2851524|NCT03587467||chronic hepatitis b carrier|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~Meet diagnostic criteria of chronic HBV infection in EASL 2017 Clinical Practice Guidelines on the management"
2851558|NCT03587246||non-pregnant women|
2851829|NCT03585296|Experimental|ATI-502|ATI-502 topical solution applied daily for four weeks.
2851526|NCT03587467||decompensated cirrhosis|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~Meet diagnostic criteria of chronic hepatitis B in EASL 2017 Clinical Practice Guidelines on the management"
2851527|NCT03587441|Active Comparator|The Intervention Group (N)|Neostigmine Methylsulfate intervention : A one milliliter syringe will contain 20 µg of Neostigmine methyl sulfate. 0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 µg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
2851528|NCT03587441|Placebo Comparator|The Control Group (P)|Dextrose 5% in water intervention : an equal volume (0.2 ml) of dextrose 5% will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
2851529|NCT03587428|Experimental|Zinc-A toothpaste|In this arm, participants received Zinc-A toothpaste (test product 1) in the form of slurry.
2851530|NCT03587428|Experimental|Zinc-B toothpaste|In this arm, participants received Zinc-B toothpaste (test product 2) in the form of slurry.
2851531|NCT03587428|Other|Mineral water|In this arm, participants received mineral water.
2851532|NCT03587415||Polycyctic ovary sendrome (PCOS)|these women who have PCOS, we will use their blood samples
2851533|NCT03587415||Healty groups|These women who have reguler menstrual cycle, no akne or hirsutism, we will use their boold samples
2851534|NCT03587402|Experimental|Transcutaneous perineal stimulation|Patient is asked to lie down with legs slightly bend and two adhesive electrodes are attached transcutaneous on base of penis and on perineum. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
2851535|NCT03587402|Active Comparator|Anal stimulation|Patient is asked to lie down with legs slightly bend and an electrical probe is inserted into the anus. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
2851536|NCT03587389|Experimental|Rotavirus vaccine|"The Rotarix vaccine package consist of 1.5 ml of oral suspension in a pre-filled oral applicator (type I glass) with a plunger stopper (rubber butyl) and a protective tip cap (rubber butyl) in pack sizes of 1.~The vaccination course consists of two doses. The first dose may be administered from the age of 6 weeks. There should be an interval of at least 4 weeks between doses. The vaccination course should preferably be given before 16 weeks of age, but must be completed by the age of 24 weeks. Rotarix is for oral use only and should under no circumstancies be injected.~All participating infants will receive two doses of Rotarix vaccine following the standard Rotarix immunization protocol."
2851537|NCT03587376|Experimental|Participants with Elevated Liver Enzymes|Blood samples will be collected on Day 1 from participants previously treated with atabecestat and who had elevated liver enzymes while on atabecestat.
2851538|NCT03587376|Active Comparator|Participants Without Elevated Liver Enzymes|Blood samples will be collected on Day 1 from participants who completed at least 3 months of dosing with atabecestat and who did not have the elevated liver enzymes (adverse event) while on atabecestat.
2851539|NCT03587363|Experimental|Cohort 1: Normal Hepatic Function|Participants with normal hepatic function will receive 6 milligram (mg) erdafitinib as a single oral dose under fasted conditions on Day 1.
2851540|NCT03587363|Experimental|Cohort 2: Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh score of 5 or 6) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
2851541|NCT03587363|Experimental|Cohort 3: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh score of 7 to 9) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
2851542|NCT03587363|Experimental|Cohort 4: Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh score of 10 to 15) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
2851543|NCT03587350|Active Comparator|Interventional Treatment|
2851544|NCT03587350|No Intervention|Usual care|
2851545|NCT03587337||Prophylaxis|
2851546|NCT03587337||Antibiotic tp|
2851547|NCT03587324|Experimental|Experimental: aspirin, clopidogrel|Perioperative measurement of ASA and clopidogrel resistance in patients undergoing vascular treatment
2851548|NCT03587311|Experimental|GROUP I (anetumab ravtansine, bevacizumab)|Participants receive anetumab ravtansine IV over 1 hour on days 1, 8, 15, and 22 and bevacizumab over 30-90 minutes IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2851549|NCT03587311|Experimental|GROUP II (paclitaxel, bevacizumab)|Participants receive paclitaxel on days 1, 8, 15, and 22 and bevacizumab over 30-90 minutes IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2851550|NCT03587298||Group 1|NAFLK criteria met (by definition: sonographic fatty liver)
2851551|NCT03587298||Group 2|Control group: matched age; no NAFKL
2851552|NCT03587285|Experimental|Arm 1|metastatic hormone-sensitive prostate cancer (mHSPC):After diagnosis of mHSPC, patients receive infusions of autologous Tcm cells intravenously on Day 1 and Day 42, followed by hormonal therapy of maximal androgen blockade (LHRH-a + Anti-androgen).
2851553|NCT03587285|Experimental|Arm 2|metastatic castration-resistant prostate cancer (mCRPC):After diagnosis of mCRPC, patients receive infusions of autologous Tcm cells intravenously on Day 1 and Day 42, followed by goserelin acetate monthly. Abiraterone acetate 1000 mg orally daily plus prednisone 5 mg orally twice daily will be also administered continuously during the duration of the trial.
2851554|NCT03587272|Experimental|SUN regimen|"Alemtuzumab intravenously, low dose total body irradiation, Sirolimus~HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, SUN) can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD)."
2851555|NCT03587259|Active Comparator|2D mammography|45-46 years old women are invited to attend the usual screening examination (2D mammography). The next year they will be invited to make a 2D mammography, according to screening protocol.
2851556|NCT03587259|Experimental|Tomosynthesis|45-46 years old women are invited to attend the Digital Breast Tomosynthesis (DBT) in adjunct to synthetic mammograms (sDM). The next year they will be invited to make a 2D mammography, according to screening protocol.
2851557|NCT03587246||Pregnant women|
2851559|NCT03587233|Active Comparator|Women with higher professional status|"Women with higher professional status working in the Universities as academicians will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of women with higher professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
2851560|NCT03587233|Active Comparator|Women with lower professional status|"Women with lower professional status in the cleaning companies will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of women with lower professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
2851561|NCT03587233|Active Comparator|Men with higher professional status|"Men with higher professional status working in the Universities as academicians will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of men with higher professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
2851562|NCT03587233|Active Comparator|Men with lower professional status|"Men with lower professional status working in the cleaning companies will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form' and the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of men with lower professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
2851563|NCT03587220|Experimental|Capsaicin+UVB group|All subjects will be treated with capsaicin, placebo + UVB, or Capsaicin+UVB.
2851564|NCT03587220|Experimental|Capsaicin + EMLA group|All subjects will be pre-treated with lidocain cream before capsaicin application
2851565|NCT03587207|Experimental|MenABCWY Group|Approximately 100 subjects (50 subjects aged 10 to 17 years and 50 subjects aged 18 to 25 years) will receive one dose of MenABCWY twice, 2 months apart (Day 1 and Day 61).
2851566|NCT03587207|Active Comparator|rMenBOMV+ACWY_S Group|Approximately 100 subjects (50 subjects aged 10 to 17 years and 50 subjects aged 18 to 25 years) will concomitantly receive one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in the same arm twice, 2 months apart (Day 1 and Day 61).
2851567|NCT03587207|Active Comparator|rMenBOMV+ACWY_D Group|Approximately 100 subjects (50 subjects aged 10 to 17 years and 50 subjects aged 18 to 25 years) will concomitantly receive one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in 2 different arms twice, 2 months apart (Day 1 and Day 61).
2851568|NCT03587207|Active Comparator|rMenBOMV Group|Approximately 100 subjects (50 subjects aged 10 to 17 years and 50 subjects aged 18 to 25 years) will receive one dose of rMenB+OMV NZ (Bexsero) twice, 2 months apart (Day 1 and Day 61).
2851569|NCT03587207|Active Comparator|MenACWY Group|Approximately 100 subjects (50 subjects aged 10 to 17 years and 50 subjects aged 18 to 25 years) will receive one dose of MenACWY (Menveo) once (Day 1).
2851570|NCT03587194|Experimental|Otezla|Otezla BID
2851571|NCT03587168||Patients with Parkinson's Disease|Patients with Parkinson's Disease Parkinson's Disease (Hoehn and Yahr stage 1-4)
2851572|NCT03587168||Healthy Controls|Healthy People
2851573|NCT03587155||Mutation|Embryo or infant with ASNS mutation.
2851574|NCT03587155||Control|Embryo or infant without ASNS mutation.
2851575|NCT03587142|Active Comparator|Buspirone|Buspirone HCl 10 mg capsule orally three times daily, 30 minutes before each meal, for 4-weeks
2851576|NCT03587142|Placebo Comparator|Placebo|Placebo capsule orally three times daily, 30 minutes before each meal, for 4-weeks; manufactured to look identical to buspirone capsule
2851577|NCT03587129|Experimental|apatinib|1 times a day, atapinib, 500 mg, is taken orally
2851578|NCT03587116|Other|Standarad of Care FIX replacement therapy|
2851579|NCT03587103|Experimental|Protocol initiate with A|Eligible participants will be randomized to receive one of the protocols initiated with A, or the protocols initiated with two-drug combination therapy with full dose A.
2851580|NCT03587103|Experimental|Protocol initiate with C|Eligible participants will be randomized to receive one of the protocols initiated with C, or the protocols initiated with two-drug combination therapy with full dose C.
2851581|NCT03587103|Experimental|Protocol initiate with D|Eligible participants will be randomized to receive one of the protocols initiated with D, or the protocols initiated with two-drug combination therapy with full dose D.
2851582|NCT03587077|Experimental|study group|Women will receive vaginally one tablet misoprostol 200 mcg(Misotac; Sigma Pharma, SAE, EGYPT) plus one tablet isosorbide mononitrate 40 mg(Effox 40 mg; Minapharm). A trained clinical nurse will introduce the tablets, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position.
2851583|NCT03587077|Placebo Comparator|control group|Women will receive vaginally one tablet misoprostol 200 mcg Plus one tablet placebo.A trained clinical nurse will introduce the tablets, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position.
2851584|NCT03587064|Active Comparator|3-lead CRT implantation (CRT-D)|In the 3-lead CRT implantation (CRT-D) group, conventional 3-lead CRT defibrillator system implantation will be performed. The CRT-D system is composed by three leads, one in atrium and two in both ventricles
2851676|NCT03586427|Experimental|AGN-241751 Dose 3|AGN-241751 Dose 3 administered as 1 tablet taken orally every day
2861840|NCT03516084|Experimental|ZL-2306(nirapairb)|
2851585|NCT03587064|Experimental|2-lead CRT implantation (CRT-DX)|In the 2-lead CRT implantation (CRT-DX) group, 2-lead CRT defibrillator system implantation will be performed. The CRT-DX system is composed by two ventricular leads, the right one is provided with a dipole for atrial sensing
2851586|NCT03587051|Experimental|Low glycemic index post-exercise diet|Lentil-based post-exercise meal
2851587|NCT03587051|Active Comparator|High glycemic index post-exercise diet|Instant potato, white bread, and egg white post-exercise meal
2851588|NCT03587038|Experimental|OKN-007 3 days per week plus temozolomide|OKN-007: 60 mg/kg, IV, 3 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
2851589|NCT03587038|Experimental|OKN-007 5 days per week and temozolomide|OKN-007: 60 mg/kg, IV, 5 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
2851590|NCT03587025|Active Comparator|Amitryptyline|Patients who will be take amitryptyline, 75mg, only use, 30min before surgery.
2851591|NCT03587025|Placebo Comparator|Placebo|Patients who will be take placebo 30min before surgery.
2851592|NCT03587012|Experimental|exercising|practicing with the brain exercises
2851593|NCT03586999|Experimental|Nivolumab and EPOCH|Patients will all receive nivolumab in combination with standard dose adjusted EPOCH for a planned 6 cycles, unless treatment is stopped early for disease progression or toxicity. Patients that have already received up to 1 cycle of standard of care chemotherapy will receive 5 cycles of experimental nivolumab + DA-EPOCH (dose adjusted, continuous infusion etoposide, prednisone, vincristine, doxorubicin, and bolus dosing of cyclophosphamide) for a total of 6 cycles of chemotherapy.
2851594|NCT03586986||FDR with abnormal brain MRI|First degree relatives fulfilling lesions disseminated in space on MRI
2851595|NCT03586986||FDR with normal brain MRI|First degree relatives not fulfilling lesions disseminated in space on MRI
2851596|NCT03586986||Non-FDR|Age and sex-matched controls to FDRs noted above
2851597|NCT03586973|Experimental|Cohort A: Cabozantinib 60 mg|Cabozantinib 60 milligrams (mg), tablet, orally, once daily in the fasted state. Participants who have received first/second line anticancer therapy with sorafenib before this study will be assigned to Cohort A.
2851598|NCT03586973|Experimental|Cohort B: Cabozantinib 60 mg|Cabozantinib 60 mg, tablet orally, once daily in the fasted state. Participants who have not received first/second line anticancer therapy with sorafenib before this study will be assigned to Cohort B..
2851599|NCT03586960|Experimental|Experimental Group|Peak tension will be measured with a calibrated force gauge (Series 3 Digital Force Gauge; Mark-10 Corporation; Copiague, NY) until the wound edges touch. A clamp will be used to secure the sutures on top of the device between measurements. At each time point (5, 10 and 30 minutes), the clamps will be loosened and the wound allowed to relax. Photographs and measurements will be taken to document the wound size after stress-reduction. The suture will be re-tensioned while measurements of peak tension (as outlined above) are recorded with the force gauge.
2851600|NCT03586947|Experimental|Vitamin D3 Drops group|Patients in this group would take Vitamin D3 400 UNT Oral Capsule.
2851601|NCT03586947|No Intervention|Non-Vitamin D3 Drops group|Patients in this group would take nothing.
2851602|NCT03586934|Other|Traditional (Standard) Protocol|Preoperative Single shot interscalene block (30 mL 0.5 ropivacaine), postoperative morphine patient controlled analgesia (1 mg/10 min/30 mg) with Hydrocodone-Acetaminophen (oral, 5/325 mg, 1 tab q4h pro re nata (PRN) for pain score of 1-3), Hydrocodone-Acetaminophen (oral, 10/325 mg, 1 tab q4h PRN for pain score of 4-6) Morphine injectable solution (2 mg IV q3h PRN for pain score 7-10), and oxycodone hydrochloride (oral, 10 mg q12h x2 doses) through postoperative day one. Discharged from hospital with hydrocodone bitartrate and acetaminophen (Norco) (5/325 mg or 10/325 mg, 1-2 oral tabs q4-6h PRN pain) script.
2851603|NCT03586934|Experimental|Multimodal Anesthesia and Analgesia|"Under age 75: Preop: acetaminophen 1000 mg oral, celecoxib 400 mg oral. Interscalene block (30 ml 0.5% ropivacaine with 1:200,000 epinephrine). Intraop: ketorolac 15 mg IV, acetaminophen injectable product. Postop: acetaminophen 500 mg oral, oxycontin 10 mg oral. Breakthrough: ketorolac 15 mg IV, oxycodone 10 mg oral. Floor: tramadol 100 mg q6h oral, acetaminophen 1 g q8h oral, celecoxib 200 mg q12h oral, ketorolac 15 mg IV q6h. Breakthrough: Pain scores 4-6: oxycodone 5 mg q4h PRN oral, pain scores 7-10: oxycodone 10 mg q4h PRN oral. Discharge: acetaminophen 1 g q8h oral, tramadol 100 mg q8h oral, celecoxib 200 mg q12h oral or meloxicam 15 mg daily oral, oxycodone 5 mg q4h PRN oral.~75 or older: Same except: Preop: celecoxib 200 mg oral. PACU meds: acetaminophen 500 mg oral. No OxyER."
2851604|NCT03586921|Experimental|Enhanced usual care + group intervention|Intervention patients received enhanced primary care plus a 9-session group intervention. The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party. The patients from the intervention arm also received additional outreach from the Family Health Teams, including home delivery of psychotropic medication when needed and active outreach and engagement by community workers if patients missed group sessions.
2851605|NCT03586921|Active Comparator|Enhanced Usual Care|All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
2851606|NCT03586908|Experimental|PHP-201 0.5%|PHP-201 0.5%, ophthalmic solution, topical eye drop, OU
2851607|NCT03586895|Experimental|Wave 1|First County implements e-Connect
2851608|NCT03586895|Experimental|Wave 2|Second County implements e-Connect
2851609|NCT03586895|Experimental|Wave 3|Third County implements e-Connect
2851610|NCT03586882|Experimental|Spinal Cord Stimulation Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
2851611|NCT03586882|No Intervention|Control Group|Gait and balance testing to be administered once in healthy subjects
2851612|NCT03586869|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011 (CEA), ETBX-021 (HER2), ETBX-051 (Brachyury), ETBX-061 (MUC1), GI-4000, GI-6207, GI-6301, haNK for infusion, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, oxaliplatin, and Stereotactic Body Radiation Therapy (SBRT).
2851613|NCT03586856|Active Comparator|Nasal mask interface|The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
2851614|NCT03586856|Active Comparator|Nasal prongs interface|The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
2851615|NCT03586843|Experimental|Treatment Sequence ABC: JNJ-64565111|Participants will receive Treatment A (JNJ-64565111 subcutaneous [SC] administration in the upper arm in fasted condition) on Day 1 of Treatment Period 1; followed by Treatment B (JNJ-64565111 SC administration in the thigh in fasted condition) on Day 1 of Treatment Period 2 and then Treatment C (JNJ-64565111 SC administration in the abdomen in fasted condition) on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last pharmacokinetic (PK) sample collection and dosing on Day 1 of subsequent treatment period.
2851616|NCT03586843|Experimental|Treatment Sequence ACB: JNJ-64565111|Participants will receive Treatment A on Day 1 of Treatment Period 1; followed by Treatment C on Day 1 of Treatment Period 2 and then Treatment B on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
2851617|NCT03586843|Experimental|Treatment Sequence BAC: JNJ-64565111|Participants will receive Treatment B on Day 1 of Treatment Period 1; followed by Treatment A on Day 1 of Treatment Period 2 and then Treatment C on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
2851618|NCT03586843|Experimental|Treatment Sequence BCA: JNJ-64565111|Participants will receive Treatment B on Day 1 of Treatment Period 1; followed by Treatment C on Day 1 of Treatment Period 2 and then Treatment A on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
2851619|NCT03586843|Experimental|Treatment Sequence CAB: JNJ-64565111|Participants will receive Treatment C on Day 1 of Treatment Period 1; followed by Treatment A on Day 1 of Treatment Period 2 and then Treatment B on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
2851620|NCT03586843|Experimental|Treatment Sequence CBA: JNJ-64565111|Participants will receive Treatment C on Day 1 of Treatment Period 1; followed by Treatment B on Day 1 of Treatment Period 2 and then Treatment A on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
2851621|NCT03586830|Experimental|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 12-week treatment phase.
2851622|NCT03586830|Experimental|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly for 12-week treatment phase.
2851623|NCT03586830|Experimental|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly for 12-week treatment phase.
2851624|NCT03586830|Placebo Comparator|Placebo|Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 12-week treatment phase.
2851625|NCT03586817|Active Comparator|Palonosetrona|Palonosetron 75 mcg during the anesthesia
2851626|NCT03586817|Active Comparator|Fosaprepitant|Fosaprepitant 150 mg during the anesthesia
2851627|NCT03586804||women without dysmenorrheal syndrome|women without dysmenorrheal syndrome
2851628|NCT03586804||women with dysmenorrheal syndrome|women with dysmenorrheal syndrome
2851629|NCT03586791|Experimental|Pupillometry group|In this group, anesthesia is performed using Pupillometry guided anesthesia.
2851630|NCT03586791|Active Comparator|SPI group|In this group, anesthesia is performed using SPI guided anesthesia.
2851631|NCT03586791|Sham Comparator|Control group|In this group, remifentanil concentration is controlled by the discretion of the anesthesiologist in charge of the patients (Standard management).
2851632|NCT03586778|Experimental|MTEX-DN|dry needling, manual therapy, and therapeutic exercise
2851633|NCT03586778|Active Comparator|MTEX|manual therapy and therapeutic exercise
2851634|NCT03586765||Experimental group|Assess prevalence of urinary functional disorders in women of 40 and more, visiting a general practitioner, occupational medicine or health examination center in Puy-de-Dôme. Study conducted for a month using a self-filled survey distributed by secretaries or nurses.
2851635|NCT03586752|Experimental|On-line group|On-line program course
2851636|NCT03586752|Active Comparator|Standard group|Standard program course
2851637|NCT03586739|Experimental|"Covered stents strategy"|
2851638|NCT03586739|Active Comparator|"Bare metal stents strategy"|
2851639|NCT03586726|Experimental|Balovaptan + Rifampicin|Participants will receive the study drugs in 2 periods. There will be a minimum of a 14-day to a maximum of a 21-day washout between the last dose in Period 1 and the first dose in Period 2.
2851640|NCT03586713|Other|ICDAS-II|According to the international caries detection and assessment system (ICDAS-II). The visual examination was performed using the ICDAS-II criteria, which provides a standardized method of lesion detection. The ICDAS-II detection codes for coronal categories the score will be 0 =surface not restored or sealant then according to caries categories range from 0 to 6 depending on the severity of the lesion with the corresponding clinical views.
2851641|NCT03586700|Experimental|Xiao zhong fang granules|Xiao zhong fang granules were made from Smilax glabra 20g, Paris polyphylla 10g, Alisma orientale15g, Plantago15g, Peach kernel 10g, safflower 10g, radices cyathulae10g,fructus chaenomeles lagenaria 10g, corydalis tuber 10g, radix clematis 10g, radices paeoniae alba 10g, glycyrrhiza 10g. Granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
2851642|NCT03586700|Placebo Comparator|Placebo Xiao zhong fang granules|Placebo Xiao zhong fang granules were made by the same institution. Placebo granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
2851643|NCT03586687|Active Comparator|20 mg|20mg Triamcinolone with 3cc of 1% Lidocaine
2851644|NCT03586687|Active Comparator|40 mg|40mg Triamcinolone with 3cc of 1% Lidocaine
2851645|NCT03586687|Active Comparator|80 mg|80mg Triamcinolone with 3cc of 1% Lidocaine
2851646|NCT03586674|Active Comparator|Ursogal|Control group : Ursogal 10-20 mg/kg/d on 2 divided dose for four months with regular follow up.
2851647|NCT03586674|Experimental|Lipanthyl + Ursogal|Therapy group: Ursogal 10-20 mg/kg/d by mouth, on 2 divided dose, and lipanthyl 10-20 mg/kg/d by mouth,once per day, for four months with regular follow up.
2851648|NCT03586661|Experimental|Treatment (niraparib, copanlisib)|Participants receive niraparib PO daily on days 1-28 and copanlisib IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2851649|NCT03586635||Patients with Multiple Sclerosis|
2851650|NCT03586622|Experimental|Low FODMAP diet|Low FODMAP diet (LFD) Each IBS patient randomized to the Australian exclusion diet, Low FODMAP diet (LFD) group (n=52) will when allocated to LFD group have a one-hour counseling to the LFD by a nutritionist at the hospital. Within this one hour a diet anamnesis of the patient will be made in order to register the High FODMAP foods the patient is consuming (important that one find good low FODMAP substitutions). Based on the diet anamnesis optimization of the low FODMAP diet counseling can be made. They will receive hands-out with recipes, tips, meal plans, list of suitable low FODMAP foods and folder of foods they should avoid- most of information in the LFD folder patients will also find in the app 'Low FODMAP diet' which they will receive free of charge.
2851651|NCT03586622|Experimental|VSL#3®|Each IBS patient randomized to the probiotic VSL#3 arm (n=52) will at randomization be given VSL#3 for 4 weeks (56 sachets) together with a leaflet on VSL#3 - holding information on the product from the manufacture regarding storage, nutritional information etc. If the patients have any questions regarding the treatment, they can ask the project investigator handing out the VSL#3 to them. They will be instructed in taking their VSL#3 (2 sachets a day) as described by the manufacturer
2851652|NCT03586609|Experimental|Treatment (cladribine, cytarabine, venetoclax, azacitidine)|See Detailed Description.
2851653|NCT03586596|Experimental|The Decídetext program|Participants will receive a tablet-based interactive educational session, 6 months of text-messaging based counseling, which includes prompts to access free pharmacotherapy.
2851654|NCT03586596|Active Comparator|Standard Care Control|Participants will receive an adapted version of standard printed smoking cessation educational materials from the American Cancer Society and, the National Cancer Institute, which include information about the health risks of smoking, benefits & strategies for quitting and access to free pharmacotherapy by calling a free number.
2851655|NCT03586583|Active Comparator|FBP (old processing)|Filtered back projection; old processing.
2851656|NCT03586583|Experimental|ISR (new processing)|Iterative super resolution; new processing.
2851657|NCT03586570|Experimental|Aprocitentan|
2851658|NCT03586570|Placebo Comparator|Placebo|
2851659|NCT03586557|Experimental|Corticosteroid & Plasma Exchange|1000mg intravenous methylprednisolone daily for 3~5 days and subsequent taper, combined with plasma exchange every other day for five times in all
2851660|NCT03586557|Active Comparator|Corticosteroid|1000mg intravenous methylprednisolone daily for 3~5 days, and subsequent corticosteroid decrement.
2851661|NCT03586544|Experimental|Experimental|Children will complete an exercise induced bronchoconstriction test preceded by: 1) pretreatment with 'Albuterol' 2) interval warm-up exercise and 3) Control
2851662|NCT03586505|Experimental|Light exposure|"The keratitis eye of the patient is exposed to 6 lights with increasing intensity according to a constant speed.~The patients switch off the light when the discomfort is too elevated"
2851663|NCT03586492|Other|Patient with myocardial ischemia|
2851664|NCT03586479|Experimental|Low Testing|Children will receive 0 testing (talking) exposures and 6 listening exposures for a total of 6 exposures to each word. This is a listening only condition with minimal testing.
2851665|NCT03586479|Experimental|Mid Testing|Children will receive 2 testing (talking) exposures and 4 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly listening.
2851666|NCT03586479|Experimental|High Testing|Children will receive 4 testing (talking) exposures and 2 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly talking.
2851667|NCT03586466|Experimental|BupreCare|The BupreCare system is an integrated medication management and patient monitoring system, consisting of a smart medication-tracking dispenser and online platform. The dispensing component is a portable smart dispenser and secure pill cartridges that is programmed with an individualized treatment plan for each patient. This arm will be assigned a MedicaSafe device that will have their buprenorphine/naloxone securely stored. Treatment reports of their dispensation history will be collated and available to the treatment team.
2851668|NCT03586466|Active Comparator|Treatment as Usual|This arm represents an active comparator for the experimental group. Subjects in this group will undergo TAU, with no changes to the way that they receive their medication. They will have pill counts bi-weekly to examine adherence.
2851669|NCT03586466|Active Comparator|Treatment as Usual with MEMS|This arm represents a second active comparator for the experimental group. Subjects in this group will receive their medication in a MEMS pill bottle, but otherwise will undergo TAU.
2851670|NCT03586453|Experimental|Osimertinib|Osimertinib: Oral, once a day, dosage determined per protocol
2851671|NCT03586440||Rounded shoulder posture group|-distance between the on table and posterior aspect of lateral part of acromion process ≥ 2.5 cm
2851672|NCT03586440||forward head rounded shoulder posture|"craniovertebral angle (CVA) ≤ 50 degree~distance between on table and acromion ≥ 2.5 cm"
2851673|NCT03586440||normal posture group|"Craniovertebral angle> 50 degree~distance between on table and acromion < 2.5 cm"
2851674|NCT03586427|Experimental|AGN-241751 Dose 1|AGN-241751 Dose 1 administered as 1 tablet taken orally every day
2851675|NCT03586427|Experimental|AGN-241751 Dose 2|AGN-241751 Dose 2 administered as 1 tablet taken orally every day
2851679|NCT03586414|Experimental|A: 'MITOQUINOL MESYLATE then placebo|'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
2851680|NCT03586414|Experimental|B: Placebo then 'MITOQUINOL MESYLATE'|Placebo capsule administered twice daily for 4 weeks followed by a washout period, then 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'
2851681|NCT03586401||Childhood Cancer Survivors|"The study will be attended by 1000 families with children who have completed treatment for cancer at least 6 months before the start of the trial and undergo rehabilitation courses at the Medical and Rehabilitation Research Center Russkoe pole at least twice a year."
2851682|NCT03586388|Experimental|Oral immunotherapy protocol|Eligible children receive the oral food challenge (OCD) protocol
2851683|NCT03586362||Treatment Group A|Patients admitted for pneumonia whose MRSA nasal swab is negative for MRSA, and empiric vancomycin is discontinued within 24 hours of the MRSA nasal swab results being documented in the electronic health record.
2851684|NCT03586362||Treatment Group B|Patients admitted for pneumonia whose empiric vancomycin is continued for ≥24 hours after electronic health record documentation of negative MRSA nasal swab results.
2851685|NCT03586336|Experimental|ReDS-Guided|Patients in the intervention arm will undergo daily measurements of lung fluid content at the bedside with the ReDS vest. The values will be shared with the treating clinicians, who can use the measurements in addition to other standard data to guide diuresis. Patients should be discharged only once their lung fluid content falls within the normal range of 20-35%.
2851686|NCT03586336|Sham Comparator|Control|Patients in the control arm will also undergo daily measurements of lung fluid content at the beside with the ReDS vest. However, the values will not be shared with the treating clinicians, who will direct management based on standard clinical tools
2851687|NCT03586323|Experimental|L-SLNB|performed a superior laryngeal nerve block with lidocaine
2851688|NCT03586323|Placebo Comparator|S-SLNB|performed a superior laryngeal nerve block with saline
2851689|NCT03586310|Other|4 nights with PSG|For all subjects: 4 nights with polysomnography and ear-EEG
2851690|NCT03586310|Other|12 nights with ear-EEG|"For a subset of the subjects in arm the '4 nights with PSG', a second phase follows in which each subject sleeps 12 nights with only ear-EEG.~If a night's recording is unsuccessful, for whatever reason, up to 6 additional nights may be attempted."
2851691|NCT03586284|Active Comparator|Oral Valganciclovir|Oral Valganciclovir 900mg PO BID Topical placebo solution, 1 drop applied 6 times daily
2851692|NCT03586284|Active Comparator|Topical Ganciclovir 2%|Topical Ganciclovir 2% solution, 1 drop applied 6 times daily Placebo pills PO BID
2851693|NCT03586284|Placebo Comparator|Placebo|Topical placebo solution, 1 drop applied 6 times daily Placebo pills PO BID
2851694|NCT03586271||trifocal lens|trifocal lens implantation(AT Lisa tri 839MP)
2851695|NCT03586271||bifocal lens 1|bifocal lens implantation(Diff-aay)
2851696|NCT03586271||bifocal lens 2|bifocal lens implantation(ReSTOR +3.0D)
2851697|NCT03586271||bifocal lens 3|bifocal lens implantation(ReSTOR +2.5D)
2851698|NCT03586258|Experimental|Brain Damaged Subjects|Patients with circumscribed brain injury, developmental pathology or degenerative pathology responsible for selective cognitive disorders
2851699|NCT03586258|Sham Comparator|Healthy Volunteers|Healthy Controls
2851700|NCT03586245|Active Comparator|Ferric pyrophosphate|"Study I group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds.~57FePP (95.8%) 3.49 mg~Aspergillus oryzae (unenriched) 0.025 mg~FePP natural abundance 0.685 mg.~Subjects received iron fortificants in a meal composed of zucchini, cabbage, carrot (42g each), onion (24g), corn oil (6.3 g), jasmine rice (75g dw), and flavored granulated chicken bouillon (6.6g). All meals were consumed in a fasted state with nothing to eat or drink (besides water) for 3 hours following consumption."
2851701|NCT03586245|Experimental|Aspiron|"The Aspiron group was required to follow the same protocol as the 57Fe as FePP, with the exception of consuming 58Fe ASP.~ASP-p (8% Fe; natural abundance) 3.516 mg~58ASP-p (5% Fe; 99.5% enrichment) 0.68 mg~4.2 total mg of Fe"
2851702|NCT03586245|Other|Ferrous sulfate|"The FeSO4 study group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds. .~Aspergillus oryzae (unenriched) 0.027 mg~57FeSO4 (95.4%) 3.18 mg~4.2 total mg of Fe"
2851703|NCT03586232|Placebo Comparator|Control|Participants will take two placebo pills q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
2851704|NCT03586232|Experimental|Arnica Montana|Participants will take Arnica Montana, 30C oral, pill and a placebo pill q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
2851705|NCT03586232|Experimental|Arnica Montana and Bromelain|Participants will take Bromelain, 500mg oral pill + Arnica Montana, 30C oral, q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
2851706|NCT03586219|No Intervention|Control Arm|Standard preoperative and postoperative instructions will be provided to the study subjects
2851707|NCT03586219|Experimental|Intervention Arm|Intervention: Study subjects will receive opioid-specific educational patient pamphlets in addition to standard preoperative and postoperative instructions
2851708|NCT03586206||Mild-moderate C.difficile infection|
2851709|NCT03586206||severe C.difficile infection|
2851710|NCT03586206||severe complicated/fulminant C.difficile infection|
2851711|NCT03586193||patients with HMF|Patients who are diagnosed as high myopic macular schisis and agree to receive pars plana vitrectomy as the treatment are planned to allocated in this group
2851712|NCT03586180||children and their parents|aged 4-18 children with cancer/blood disease and their parents
2851713|NCT03586180||Dr. Clowns|they will perform shows for children and parents
2851714|NCT03586154|Other|Group A|patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml
2851715|NCT03586154|Active Comparator|Group B|patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml plus posterior approach shoulder injection with PRP.
2851942|NCT03584555|Active Comparator|120 μm group|The subjects underwent SMILE using 120 μm cap.
2851718|NCT03586115||Patients with Hereditary telangectasia|In addition to all laboratory analyses and imaging studies required to evaluate the disease, hepatic elastometry and critical flicker frequency assessment will be performed.
2851719|NCT03586102|Experimental|High protein supplementation|Infants will receive a diet that consists of mother's own milk or donor human milk and bovine-based human milk fortifier plus a fixed amount of commercially available hydrolyzed bovine protein. The study intervention will begin the day after fortification is ordered and will be continued until postnatal day 50 or 32 weeks postmenstrual age, whichever occurs first.
2851720|NCT03586102|Active Comparator|Standard protein supplementation|Infants will receive a standard diet that consists of mother's own milk or donor human milk (DHM) and bovine-based human milk fortifier. The study intervention will be continued until postnatal day 50 or 32 weeks postmenstrual age, whichever occurs first.
2851721|NCT03586089|Experimental|Phenobarbital|Patients will receive a single dose of phenobarbital (7.5 mg/kg IBW, IV) in addition to usual therapy.
2851722|NCT03586089|Placebo Comparator|Placebo|Patients will receive an inactive placebo (IV).
2851723|NCT03586076|Experimental|JHL1922|
2851724|NCT03586076|Active Comparator|Pulmozyme|
2851725|NCT03586050|Experimental|Microwave Ablation|All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories
2851726|NCT03586037|Experimental|Sequence 1|Period 1: AD-2011 10/20mg QD Period 2: AD-2012 80mg QD Period 3: AD-2011 10/20mg + AD-2012 80mg QD
2851727|NCT03586037|Experimental|Sequence 2|Period 1: AD-2011 10/20mg QD Period 2: AD-2011 10/20mg + AD-2012 80mg QD Period 3: AD-2012 80mg QD
2851728|NCT03586037|Experimental|Sequence 3|Period 1: AD-2012 80mg QD Period 2: AD-2011 10/20mg + AD-2012 80mg QD Period 3: AD-2011 10/20mg QD
2851729|NCT03586037|Experimental|Sequence 4|Period 1: AD-2012 80mg QD Period 2: AD-2011 10/20mg QD Period 3: AD-2011 10/20mg + AD-2012 80mg QD
2851730|NCT03586037|Experimental|Sequence 5|Period 1: AD-2011 10/20mg + AD-2012 80mg QD Period 2: AD-2011 10/20mg QD Period 3: AD-2012 80mg QD
2851731|NCT03586037|Experimental|Sequence 6|Period 1: AD-2011 10/20mg + AD-2012 80mg QD Period 2: AD-2012 80mg QD Period 3: AD-2011 10/20mg QD
2851732|NCT03586024|Experimental|Cohort 1|cohort 1: NK/T-cell lymphoma;
2851733|NCT03586024|Experimental|Cohort 2|EBV-associated diffuse large B cell lymphomas
2851734|NCT03585998|Experimental|Study arm|Concurrent radiotherapy with chemotherapy (Etoposide/Cisplatin) with durvalumab, and followed by consolidation durvalumab
2851735|NCT03585985||Group 1|10 patients aged above 70 years with typical geriatric multimorbidity or aged above 80 years otherwise, patient in the hospital Franziskushospital Aachen on the ward of geriatric medicine
2851736|NCT03585985||Group 2|10 healthy elderly people above 70 years, healthy
2851737|NCT03585972|Experimental|Frailty Prevention Program|4 face-to-face sessions, with a licensed and registered occupational therapist over 4 months
2851738|NCT03585972|No Intervention|Educational materials|Participants receive publicly available educational materials
2851739|NCT03585959|Experimental|superDimension™ Navigation System 7.2|superDimension™ Navigation System Version 7.2
2851740|NCT03585946||Cyclosporine|
2851741|NCT03585946||Intravenous Immunoglobulin|
2851742|NCT03585946||Etanercept|
2851743|NCT03585946||Steroids|
2851744|NCT03585920|Active Comparator|Positive Control (standard fat)|Expanded Corn Snack. Positive control (13 g oil per 40 g snack portion)
2851745|NCT03585920|Experimental|Negative Control (reduced fat)|Expanded Corn Snack. Negative control (<8 g oil per 40 g snack)
2851746|NCT03585920|Experimental|Reduced Fat Sensory Matched|Expanded Corn Snack. Reduced fat optimised (<8 g oil, matched sensory signals)
2851747|NCT03585907|Experimental|Modified Atkins Diet (MAD)|A diet that can produce ketones
2851748|NCT03585907|Active Comparator|MIND diet|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND). A diet that has been indicated to be helpful in preventing or decreasing cognitive decline.
2851749|NCT03585894|Other|Sumatriptan|Sumatriptan 4 mg/mL I.V will be administrated over 10 min
2851750|NCT03585894|Active Comparator|Ketorolac|Ketorolac 30 mg/mL I.V will be administrated over 10 min
2851751|NCT03585881|Experimental|window bracket positioning tray|
2851752|NCT03585881|No Intervention|conventional indirect boning tray|
2851753|NCT03585868|Placebo Comparator|Placebo|Beverage without flavonoids
2851754|NCT03585868|Sham Comparator|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
2851755|NCT03585868|Experimental|Flavonoids|Beverage with a flavonoid rich mixture
2851756|NCT03585855|No Intervention|Historic control|historic cohort of patients with ABMR treated with standard of care therapy
2851757|NCT03585855|Experimental|MSC transplantation|patients with ABMR treated with MSC transplantation
2851758|NCT03585842||Pre-test group|Patients from CMP B coming for consultation or day hospital
2851759|NCT03585842||Test group|Patients suffering from DSMV substance use disorder with one or more psychiatric comorbidities
2851760|NCT03585829|Active Comparator|hydrocortisone|hydrocortisone 20 mg per day: 15 mg at pre-dawn meal and 5 mg at dinner
2851761|NCT03585829|Active Comparator|prednisolone|Prednisolone 5 mg at pre-dawn meal and a placebo (starch) at dinner
2851762|NCT03585803|Other|KMRC011 5μg or Placebo|Cohort 1
2851763|NCT03585803|Other|KMRC011 10μg or Placebo|Cohort 2
2851764|NCT03585803|Other|KMRC011 20μg or Placebo|Cohort 3
2851765|NCT03585803|Other|KMRC011 30μg or Placebo|Cohort 4
2851766|NCT03585803|Other|KMRC011 45μg or Placebo|Cohort 5
2851767|NCT03585803|Other|KMRC011 60μg or Placebo|Cohort 6
2851768|NCT03585803|Other|KMRC011 75μg or Placebo|Cohort 7
2851769|NCT03585790|Experimental|Arm A|
2851770|NCT03585790|Placebo Comparator|Arm B|
2851771|NCT03585777||Group 1|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking metformin
2851772|NCT03585777||Group 2|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking linagliptin
2851773|NCT03585777||Group 3|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking impaglifluzin
2851943|NCT03584555|Active Comparator|140 μm group|The subjects underwent SMILE using 140 μm cap.
2851774|NCT03585764|Experimental|Cohort 1: MOv19-BBz CAR T cells without chemo|Cohort 1: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy.
2851775|NCT03585764|Experimental|Cohort 2: MOv19-BBz CAR T cells after chemo|Cohort 2: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
2851776|NCT03585764|Experimental|Cohort 3: MOv19-BBz CAR T cells after chemo|Cohort 3: (n=3 to 6 subjects): Single infusion of 1-3x108 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
2851777|NCT03585764|Experimental|Cohort-1: without chemo;only if dose de-escalation required|Cohort -1: (n= 3 to 6 subjects): Single Infusion of 1-3x106 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy. Up to 6 subjects will be infused in Cohort -1 with ≤ 1 DLT/6 subjects to establish the MTD.
2851778|NCT03585751|Active Comparator|Triple antibiotic paste|Pulpectomy for primary molars, triple antibiotic mix is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
2851779|NCT03585751|Experimental|3mixstatin|Pulpectomy for primary molars, 3 Mixstatin ( mix of simvastatin and triple antibiotic mix ) is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
2851780|NCT03585751|Experimental|simvastatin|Pulpectomy for primary molars, simvastatin is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
2851781|NCT03585738|Experimental|Inositol + Folic acid|Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid before spontaneous conception until delivery.
2851782|NCT03585738|Placebo Comparator|Folic acid|Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid before spontaneous conception until delivery.
2851783|NCT03585725|Experimental|Ribavirin|Ribavirin 1000 mg will be administered orally twice daily continuously in 28 day cycles for up to 6 cycles.
2851784|NCT03585712|Other|Arm A: Delayed then Missed Pill|Treatment period 2, visit 2R: 6 hour delayed intake of Norgestrel 75 mcg Treatment period 3, visit V3R: missed pill of Norgestrel 75 mcg
2851785|NCT03585712|Other|Arm B: Missed then Delayed Pill|Treatment period 2, visit 2R: missed pill of Norgestrel 75 mcg Treatment period 3, visit V3R: 6 hour delayed intake of the pill of Norgestrel 75 mcg
2851786|NCT03585699|Active Comparator|Fluoroscopy Guided Spinal Biopsy Arm|Fluoroscopy guided spinal biopsies were done by spine surgeons in the operation theatre using C-Arm fluoroscopy device (OECFluorostar7900Compact - GE®). C-arm image intensiﬁer was positioned until fluoroscopic beam was collinear with the corresponding vertebral body on AP view prior to insertion of biopsy needle
2851787|NCT03585699|Active Comparator|CT guided Spinal Biopsy Arm|CT guided spinal biopsies were done by radiologist under guidance of 128-slice CT scanner (SOMATOM Definition AS+, Siemens Medical Solutions USA, Inc.). Preliminary axial CT scanning was done in bone window (window width, WW:2500; window level, WL:500) at the pre-selected levels decided from previous imaging to plan the needle access. Biopsy was then performed under sequential CT-fluoroscopy scan.
2851788|NCT03585686|Experimental|vemurafenib|vemurafenib, Cytarabine, 2-chlorodeoxyadenosine
2851789|NCT03585673|Experimental|Docetaxel-PM+Oxaliplatin|"Docetaxel-PM 35mg/m2 D1, 8 I.V.~Oxaliplatin 120mg/m2 D1 I.V. Every 3 weeks till progression"
2851790|NCT03585660|Experimental|Interventional Arm|Participants will undergo diagnostic MRI exam followed by clinical biopsies of suspected prostate cancer tumors.
2851791|NCT03585647||GA-group|Patients undergoing elective hip arthroplasty included in the GA-group received general anesthesia. GA was induced by intravenous fentanyl (1 mcg/kg) and propofol (2 mg/kg), followed by vecuronium bromide (0.1 mg/kg) to facilitate tracheal intubation, then GA was maintained using a 50% air/oxygen mixture and sevoflurane.The end-tidal concentration of sevoflurane was adjusted to maintain heart rate and blood pressure values within 20% of baseline. Mechanical ventilation was regulated to maintain the end-tidal carbon dioxide partial pressure ranging between 4.3 and 5.1 kilopascal.
2851792|NCT03585647||RA-group|"Patients undergoing elective hip arthroplasty included in the RA-group received regional anesthesia. Regional anaesthesia included continuous lumbar plexus block, performed by or under supervision of an experienced operator using a nerve stimulator (Stimulax, B. Braun) and Continued Peripheral Nerve Block Set.~A total dose of 20 ml of 0.5% Levobupivacaine was administered at the time of catheter placement. Dural puncture was performed at the L3-L4 interspace using a 25-Gauge whitaker spinal needle (Becton-Dickinson, New Jersey, USA) with the midline approach using 3 ml of 0.5% Levobupivacaine."
2851793|NCT03585647||IA-group|Patients undergoing elective hip arthroplasty included in the IA-group received integrated anesthesia. The patients received regional anaesthesia (lumbar plexus block + spinal anaesthesia) as described protocol. General anaesthesia was induced by propofol 1% and a laryngeal mask airway of appropriate size was inserted. General anaesthesia and mechanical ventilation were maintained as standard protocol.
2851794|NCT03585634|Other|Dads in Gear Program|An 8 week group program to support men's smoking cessation efforts.
2851795|NCT03585621|Experimental|SBRT to the Primary Breast Tumour|SBRT to the breast using 4 sequentially escalating dose levels from 9Gy to 12 Gy.
2851796|NCT03585595|Experimental|Intensive treatment group|Systolic BP target <120 mmHg for the intensive treatment group
2851797|NCT03585595|Active Comparator|Standard treatment group|Systolic BP <140 mmHg for the standard treatment group
2851798|NCT03585582||PARDS survivors|"Children <18 years~diagnosed with PARDS, as defined by PALICC~admitted to the ICU at the CHUSJ, a pediatric tertiary care center"
2851799|NCT03585556|Experimental|AAVCAGsCD59 Treated Arm|An anti-VEGF injection will be given at Day 0 followed by an intravitreal injection of AAVCAGsCD59 at Day 7. All eyes will then be treated with intravitreal anti-VEGF monthly as needed based on disease activity.
2851800|NCT03585530|Experimental|treatment group|
2851801|NCT03585517|Experimental|IM23 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD123 CAR will be infused 24-96 hours later.
2851802|NCT03585504|Experimental|Intervention group|Patients will undergo etonogestrel contraceptive implant insertion prior to hospital discharge per package instructions.
2851803|NCT03585504|Active Comparator|Control Group|These patients will receive an appointment to undergo etonogestrel contraceptive implant insertion at the postpartum visit occuring approximately six weeks after delivery as is standard care in our institution.
2851804|NCT03585491|Experimental|Bankart Procedure|Bankart Procedure: the participant will be placed in the lateral decubitus or beach chair position. Standard diagnostic arthroscopy will be performed. The anterior capsulolabral complex will be freed from the anterior aspect of the scapular neck. The anterior aspect of the scapular neck will be decorticated using a motorized burr. A capsuloligamentous repair will be performed with the capsule shifted from inferior to superior and repaired on the glenoid face. The number of anchors used for the repair will be left to the discretion of the surgeon. Patients will be given a sling for 4 weeks, and participation in sports will not be allowed for 6 months.
2851805|NCT03585491|Experimental|Latarjet Procedure|Open or Arthroscopic coracoid transfer (Latarjet Procedure): This procedure may be performed through small incisions (minimally invasive) but may require a larger incision in some cases. It involves the transfer of a nearby bony structure (the coracoid process) to the front of the shoulder joint (glenoid). This bone will then provide support to prevent the shoulder joint from dislocating.
2851806|NCT03585478|Active Comparator|Latiglutenase|IMGX003
2851807|NCT03585478|Placebo Comparator|Placebo|Placebo
2851808|NCT03585465|Experimental|A: Cyclophosphamide Vinblastine Nivolumab|First stage
2851809|NCT03585465|Experimental|B: Capecitabine Nivolumab|First stage
2851810|NCT03585465|Experimental|C: Cyclophosphamide Vinblastine Capecitabine|First stage
2851811|NCT03585465|Experimental|Metronomic Arm (Second stage)|Arm retained at first stage (A, B or C)
2851812|NCT03585465|Experimental|Metronomic + Nivolumab Arm (Second stage)|Nivolumab + Arm retained at the end of first stage (A, B or C)
2851813|NCT03585452||Group C|Patients with typical anesthetic regimen: premedication: 2 mg estazolam p.o. and 10 mg morphine s.c. - 1 hour before procedure. Preoxygenation and induction of anaesthesia: remifentanyl 1 µg/kg, etomidate 0.3 mg/kg, pancuronium 0.1 mg/kg and intubation. Maintenance of the anesthesia: remifentanyl 0.2-0.5 µg/kg/min and propofol 2-4 mg/kg/min infusions. Ventilation with Air/O2. Additionally: nitroglycerine infusion or phenylephrine 0.05-0.1 mg boluses will be used for normotension maintenance at demanding doses. Subsequently typical CABG procedure with normothermic CPB will be performed. Weaning from CPB will be performed with inotropic support (dobutamine) and vasodilator (nitroglycerine) administration - with patients dependent doses. Routine recovery after surgery.
2851814|NCT03585452||Group D|Regimen will be the same with additional dexmedetomidine infusion: with loading dose: 0.5 µg/kg/h through 1 hour and then dose will be reduced to 0.25 µg/kg/h and infusion will be continued during surgery and postoperative period to the total dose of 200 µg. Anesthetics and opioids doses will be adjusted under hemodynamic and eeg sensor - SedLine Masimo.
2851815|NCT03585439||Single cohort of operated patients|One group of patients: isthmic spondylolisthesis operated in our center using a double approach technique
2851816|NCT03585426|Experimental|Vancomycin 1g q12h|
2851817|NCT03585426|Experimental|Vancomycin 1g q8h|
2851818|NCT03585413|Active Comparator|Specific Micronutrient-probiotic-combination|"Intake of one micronutrient capsule three times daily and probiotic powder twice daily starting on the first day after hospital discharge until 12 weeks postoperatively.~The micronutrient capsules consist of vitamins, minerals, phytochemicals and bioactive substances. The probiotic supplement is a powder of 10 different species of probiotic bacteria."
2851819|NCT03585413|Placebo Comparator|Micronutrient-placebo-combination|"Intake of one micronutrient capsule three times daily and placebo powder twice daily starting on the first day after hospital discharge until 12 weeks postoperatively.~The micronutrient-control-combination consists of a micronutrient capsule (vitamins and minerals) but without phytochemicals and bioactive substances, and a placebo powder manufactured to mimic the probiotic powder."
2851820|NCT03585400||Observational Study|Observational Study: Not Applicable for Observational Studies
2851821|NCT03585387||Main|Each subjects in this group will be its own control for the two navigation mehtods.
2851822|NCT03585374|Experimental|A_test drug_Methoxyflurane (Penthrox®)|Pain from moderate to severe (NRS score 4-10). 3 ml of methoxyflurane vaporized through the Penthrox® inhaler. The drug is self administered under the supervision of investigators/study nurse. The treatment duration is about 25 minutes. The patient is instructed to breath normally and to close the diluter aperture via his/her forefinger to increase the analgesic effect, if needed. In case of pain increase or insufficient pain relief the investigator is allowed to administer a rescue medication as per local routine practice.
2851823|NCT03585374|Active Comparator|B_comparator_Morphine/Paracetamol/Ketoprofen|"The comparator to be administered will vary according to pain intensity and local clinical practice.~In case of severe pain (NRS score ≥ 7), morphine will be administered at a dose of 0.10 mg/kg body weight.~In case of moderate pain (NRS score 4-6) paracetamol or ketoprofen will be administered respectively at a 1 g and 100 mg dose.~All comparator will be administered by intravenous drip in a maximum 10 minutes time of infusion. .~Maximum time of infusion 10 minutes."
2851824|NCT03585361|Experimental|Intervention|Health centers provide PPFP counseling and services, implementing current Government of Ethiopia policy and standard of care (including still experimental screening and intra-facility referrals of women bringing infants for immunization). Also, health centers conduct data reviews of PPFP counseling, intra-facility referrals and uptake data. At community level, HEWs provide PPFP counseling and services throughout continuum of care, volunteers (Development Army) promote PPFP, and HEWs and volunteers track PPFP method choice and uptake.
2851825|NCT03585361|Active Comparator|Comparison|Health centers provide PPFP counseling and services, implementing current Government of Ethiopia policy and standard of care (including still experimental screening and intra-facility referrals of women bringing infants for immunization). Health centers conduct data reviews.
2851826|NCT03585348||Study cohort|The estimated cohort consists of 250.000 adult patients who are intubated for a non-cardiac surgery and extubated at the end of the case at Beth Israel Deaconess Medical Center (150.000) as well as Massachusetts General Hospital (100.000) and received treatment by anesthesia providers who have completed at least one hundred anesthesia procedures at their respective institution.
2851827|NCT03585322|Experimental|APG-1387 for Injection|APG-1387 will be explored sequentially using a escalation scheme at the dose escalation phase.
2851830|NCT03585283|Experimental|Myofascial Group|Myofascial release will be applied by physiotherapist two times a week for four weeks which is a manual therapy technique includes stretching and compression of soft tissues according to fascial chains.Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
2851831|NCT03585283|Sham Comparator|Sham Group|Sham application will be applied two times a week for four weeks. Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
2851832|NCT03585270|Experimental|Clazosentan|
2851833|NCT03585270|Placebo Comparator|Placebo|
2851834|NCT03585257|Experimental|IV albumin|25% IV albutein (albumin) formulation will be infused 1.5g/kg IV over one hour weekly for 4 weeks
2851835|NCT03585257|Placebo Comparator|Placebo|Normal saline will be infused 1.5g/kg IV over one hour weekly for 4 weeks
2851836|NCT03585244||Individuals with Prader-Willi Syndrome|Individuals with Prader-Willi Syndrome aged 12 and over will be recruited to gather data on weekly weight over six months
2851837|NCT03585231|Experimental|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smoking cessation conversational agent. Therapy description withheld to protect the integrity of the study.
2851838|NCT03585231|Active Comparator|Control|This is the control arm of the study. This includes receiving the standard of care smoking cessation text messaging program. Therapy description withheld to protect the integrity of the study.
2851839|NCT03585218|Experimental|Experimental Group|The Experimental Group participants will be submitted to the inhalation of the hedonic aroma during the chemotherapeutic treatment, this being the intervention of the study.The control group is not subject to intervention.
2851840|NCT03585218|No Intervention|Control Group|The control group is not subject to intervention.
2851841|NCT03585205|Experimental|Stress and cognitive load Induction|Participants will engage in a computerized task which induces cognitive load. Each participant will perform the task once under a stress condition and once under a neutral (non-stress) condition.
2851842|NCT03585192|Experimental|Skin Group|Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to skin group, neonate will initiate skin-to-skin contact after umbilical cord is cut and dried with warm blankets on Mother's abdomen. Length of monitoring will be for first hour of life.
2851843|NCT03585192|Active Comparator|Warmer Group|Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to warmer group, neonate will initiate skin-to-skin contact after 20 minutes of observation under the radiant warmer. Length of monitoring will be for first hour of life.
2851844|NCT03585179|Experimental|Oral tranexamic acid|250 mg of tranexamic acid bid orally
2851845|NCT03585179|Experimental|Topical tranexamic acid|5% topical tranexamic acid bid
2851846|NCT03585179|Active Comparator|Topical hydroquinone|4% hydroquinone once daily at night
2851847|NCT03585166||laparoscopic hepatectomy|laparoscopic hepatectomy for primary liver cancer
2851848|NCT03585166||open hepatectomy|open hepatectomy for primary liver cancer
2851849|NCT03585153||T1D|Individuals with type 1 diabetes and some other forms of diabetes
2851850|NCT03585153||Control|Individuals without type 1 diabetes
2851851|NCT03585153||Aab+|Individuals without type 1 diabetes who possess 2+ type 1 diabetes-related autoantibodies
2851852|NCT03585140|Active Comparator|Normal Diet|Participants will receive a normal diet according to their metabolic status.
2851853|NCT03585140|Experimental|Low glycemic diet|Participants will receive a low-glycemic index and load diet according to their metabolic status. Milk and vitamin supplements will be eliminated from the diet.
2851854|NCT03585127|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy comprises of nine weekly sessions of an hour.
2851855|NCT03585127|Experimental|Avatar Therapy|Avatar Therapy consists of 9 weekly sessions: one avatar creation session and 8 therapeutic sessions of one hour.
2851856|NCT03585114|Experimental|PyL-PET|Male participants diagnosed with metastatic castrate resistant prostate cancer (mCRPC) and are scheduled to start a new treatment will receive [F-18] DCFPyL PET/CT imaging before starting new treatment and after 6 weeks on treatment.
2851857|NCT03585101|Experimental|All participants|Intervention: Elbasvir/grazoprevir
2851858|NCT03585088|Other|SPI Group|All patients who received the liver resection surgery will receive surgical pleth index
2851859|NCT03585062|Experimental|S-1 combined with Paclitaxel-albumin|S-1 combined with Paclitaxel-albumin S-1:40~60mg bid, day 1~14 (S-1: BSA <1.25m2, 40mg bid , 1.25m2 ≤ BSA ≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid， for 2 weeks, rest a week) Paclitaxel-albumin: 125 mg/m2, intravenous infusion for 30 minutes, Day1 and Day 8.
2851860|NCT03585036|Active Comparator|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
2851861|NCT03585036|Active Comparator|tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
2851862|NCT03585036|Placebo Comparator|placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
2851863|NCT03585023||Spontaneous miscarriage|The study group will be recruited at admission for uterine cavity revision planned for spontaneous abortion.
2851864|NCT03585023||Voluntary pregnancy interruption|The control group will be recruited at admission for uterine cavity revision planned for voluntary pregnancy interruption.
2851865|NCT03585010|Experimental|Supportive Parenting for Anxious Childhood Emotions|Parent-based treatment for childhood anxiety disorders
2851866|NCT03585010|Active Comparator|Parent Educational Support or CBT|Parent-based intervention for childhood anxiety disorders (phase 1) or child based treatment for childhood anxiety disorders (phase 2)
2851867|NCT03584997|Experimental|PRF , ABB & Autogenous Particulate|Platelets rich fibrin + anorganic bovine bone + autogenous particulate graft
2851868|NCT03584997|Active Comparator|ABB And Autogenous Particulate|anorganic bovine bone +autogenous particulate graft
2851944|NCT03584542||Patients in general practitioners' offices|No interventional study. Only one questionnaire will be done
2851869|NCT03584984|Experimental|Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)|socket preservation with a mixture of autogenous bone graft acquired at the time of extraction mixed with a 50:50 ratio of Anorganic bovine bone
2851870|NCT03584984|Active Comparator|Anorganic bovine bone graft (ABB)|filling the extraction socket with ABB graft
2851871|NCT03584984|Active Comparator|Absorbable gelatin Sponge|Filling the socket with an absorbable gelatin sponge
2851872|NCT03584971||female patients|women in fertility treatment according to Long GnRH Agonist Protocol
2851873|NCT03584971||control group|random sample of male students
2851874|NCT03584958||Ab interno goniotomy surgery|Gonioscopy-assisted transluminal trabeculotomy (GATT) surgery to decrease intraocular pressure.
2851875|NCT03584958||Gelatin stent surgery|Subconjunctival stent (Xen) surgery to decrease intraocular pressure.
2851876|NCT03584958||Suprachoroid stent and cataract surgery|Suprachoroidal stent (Cypass) to decrease intraocular pressure in combination with cataract surgery.
2851877|NCT03584958||Trabeculectomy surgery|Glaucoma filtering surgery to decrease intraocular pressure.
2851878|NCT03584958||Cataract surgery|Cataract surgery with no glaucoma procedure.
2851879|NCT03584945|Experimental|Obsessive Compulsive Disorder|
2851880|NCT03584945|Other|Subclinical Obsessive-Compulsive symptoms (OCS)|
2851881|NCT03584945|No Intervention|Healthy Control|
2851882|NCT03584932|Experimental|Intervention arm|Subjects participate in a youth service navigation intervention and are eligible to receive contingency management incentives.
2851883|NCT03584932|No Intervention|Control arm|Standard of care as set forth by the national HIV care guidelines.
2851884|NCT03584919|Active Comparator|EM doxycycline|patients with EM who received doxycycline
2851885|NCT03584919|Active Comparator|EM cefuroxime axetil|patients with EM who received cefuroxime axetil
2851886|NCT03584919|Placebo Comparator|controls|control subjects without history of Lyme disease
2851887|NCT03584906|Experimental|De-epithelialized gingival graft (DGG)|A harvesting approach where the a graft is obtained from the superficial palate and then extra-orally de-epithelialized in order to obtain a connective tissue graft (DGG harvesting approach) Then the DGG is used for treating gingival recessions (root coverage procedure)
2851888|NCT03584906|Experimental|Envelope technique (ET)|"A harvesting approach where only one horizontal incision is performed on the palate (ET harvesting approach) for harvesting a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
2851889|NCT03584906|Experimental|Trap door technique (TDT)|"A harvesting approach where one horizontal and two vertical incisions are performed on the palate (TDT harvesting approach) for harvesting a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
2851890|NCT03584906|Experimental|Maxillary tuberosity (MT)|"A harvesting approach that obtains an epithelialized gingival graft from the maxillary tuberosity (MT harvesting approach) which is then extra-orally de-epithelialized in order to obtain a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
2851891|NCT03584893||Epidemiologic observational study cohort|All patients over 2 and below 20 years old diagnosed as idiopathic bilateral juvenile cataracts will be included in the study at the study sites.
2851892|NCT03584880|Experimental|Diode Laser disinfection|Diode laser disinfection Laser type: 940 nm diode laser Power: 1 Watt Tip: 200 micrometer fibre tip
2851893|NCT03584880|Placebo Comparator|Pseudo Diode Laser Disinfection|Inactivated Diode laser application in root canal
2851894|NCT03584867|Experimental|study Group|refresher CPR
2851895|NCT03584867|No Intervention|control|NO refresher
2851896|NCT03584854|Active Comparator|15-methyl prostaglandin F2α|IM Carboprost followed by Methylergonovine if needed.
2851897|NCT03584854|Active Comparator|Methylergonovine Maleate|IM Methylergonovine followed by Carboprost if needed.
2851898|NCT03584841|Experimental|Patients with mucoviscidosis|For patients with cystic fibrosis: clinically stable, all genotypes included.
2851899|NCT03584841|Experimental|Parents of patients with confirmed diagnosis of mucoviscidosis|The parents are heterozygous subjects
2851900|NCT03584841|Active Comparator|Healthy volunteers|
2851901|NCT03584828|Experimental|Tele-Rehabilitation - intervention|Following the standard rehabilitation intake process the subjects in the Tele-rehaab arm will receive physiologic consultation based on clinical stress tests and clinical data passed from the physician. The Tele-rehab arm will receive an exercise prescription and execution will be assessed and periodically adjusted in accordance to data received from the wearable device. Intensity and type of exercise will be moderate and will comply with exercise recommendations provided by ESC guidelines. A dedicated application will be installed on the mobile phone for patients in the research group and they will receive a smart sports watch.
2851902|NCT03584828|No Intervention|Usual care|The usual care arm will receive general recommendations for a healthy and active lifestyle and community cardiologist and primary care physician according to local guidelines.
2851903|NCT03584815|Active Comparator|Surgery/fasciotomy|"Fasciotomy of the anterior and lateral compartments in the lower legs:~Two linear longitudinal skin incisions, each approximately 4 cm, are made allowing for excision of the fascia in full length. Sharp dissection to the level of the subcutaneous tissues down to the layer of the overlying fascia is performed, and using a finger or blunt instrument, the subcutaneous tissue is swept away from the fascia, so that an unobstructed cut of the fascia can be performed. The fascia overlying the anterior and lateral compartment is meticulously dissected under direct visualization, the fascia is released approximately as far proximal and distal as the muscle belly is. The perimysium is spared."
2851904|NCT03584815|Active Comparator|Physiotherapy|"Change the running pattern to decrease load on the affected muscles of the lower leg including the eccentric work performed by the tibialis anterior during the rear-foot strike.~Strengthen the major muscles of all lower leg compartments in order address any muscular imbalance/instability around the ankle joint, and to strengthen the main muscle groups responsible for alignment of the hip and knee."
2851945|NCT03584542||Patients of specialized centers for drug addict patients|No interventional study Only one questionnaire will be done
2851946|NCT03584542||General practitioners|No interventional study Only one questionnaire will be done
2852369|NCT03581513|Active Comparator|IMR≥40 and immediately PCI|Patients whose IMR≥40 undergo immediately stent implantation
2851905|NCT03584802|Experimental|Experimental treatment of AE-IPF|The experimental group will receive a combination of: 1- Methylprednisolone bolus of 1g IV day 1, then 20 mg/day (or oral prednisolone equivalent) for 21 days; 2- Nine therapeutic plasma exchanges of 1,5x the estimated plasma volumes using albumin: saline (3:1) or fresh frozen plasma in case of an INR superior to 1,5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100mg/kg) 3, Rituximab 1g IV on days 7 and 15 (after therapeutic plasma exchange and premedication) 4, Intravenous immunoglobulin 0,5g/kg/d on days 16 to 19,
2851906|NCT03584802|Active Comparator|Conventional treatment of AE-IPF|Intravenous methylprednisolone bolus of 10mg/kg on day1, 2 and 3, then 1mg/kg/d for 1 week, and 0,75 mg/kg/d for 1 week, then 0,5 mg/kg/d for 1 week, and 0,25 mg/kg/d for 1 week, and 0,125 mg/kg/d until day 90. Shift to oral prednisone as soon as the oral route is available.
2851907|NCT03584789|No Intervention|Standard Practice|
2851908|NCT03584789|Experimental|Clinical Decision Support|
2851909|NCT03584789|Experimental|Clinical Decision Support + Education|
2851910|NCT03584776|Experimental|Virtual Reality Post Spinal Fusion|Patients randomized to the VR group will have the opportunity to utilize VR during the post operative period, and will also experience VR during research visits each day following surgery.
2851911|NCT03584776|No Intervention|Standard of Care|Patients randomized to the non-VR condition will experience the usual standard of care following spinal fusion surgery.
2851912|NCT03584763|Active Comparator|Bi-Weekly Umbilical Artery Doppler|will undergo Doppler every other week
2851913|NCT03584763|Experimental|Weekly Umbilical Artery Doppler|will undergo Doppler every week
2851914|NCT03584750|Active Comparator|Intervention group|Floating
2851915|NCT03584750|Placebo Comparator|Control group|Placebo floating
2851916|NCT03584750|No Intervention|No-treatment group|Waiting list
2851917|NCT03584737||Symptomatic for bacterial sinusitis|Samples from participants showing symptoms of bacterial sinusitis tested by rapid in vitro diagnostic test, bacterial culture, and PCR assay
2851918|NCT03584737||Healthy - no symptoms of sinusitis|Samples from healthy participants showing no symptoms of sinusitis tested by rapid in vitro diagnostic test, bacterial culture, and PCR assay
2851919|NCT03584724|Experimental|Norflo Oro|Box of 30 packets of Norflo Oro. The study subject will take the entire content of one packet with meal twice per day. The study subject will be evaluated in a total of three visits.
2851920|NCT03584724|Placebo Comparator|Placebo for Norflo Oro|Box of 30 packets of Placebo. The study subject will take the entire content of one packet with meal twice per day. The study subject will be evaluated in a total of three visits.
2851921|NCT03584711|Experimental|FOLFOX + panitumumab|"1 cylce every 14 days : Panitumumab : 6 mg/kg en IV (J1) during 60 minutes for 1st infusion followed by 30 to 60 minutes Oxaliplatine : 85 mg/m² inG5% orNaCl 0.9% in IV (D1) during 2 hours Acide folinique : 400 mg/m² (or200 mg/m² if Elvorine) in IV (D1) 5Fu bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours~LV5FU2 : 1 cycle every 14 days Acide folinique : 400 mg/m² (or 200 mg/m² ifElvorine) in IV (D1) during 2 hours 5FU bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours"
2851922|NCT03584698|Experimental|study group|Misoprostol + Evening primrose oil group
2851923|NCT03584698|Active Comparator|control group|Misoprostol only group
2851924|NCT03584685|Experimental|With Mask|Use of the surgical mask in one routine wound treatment appointment.
2851925|NCT03584685|Active Comparator|Without Mask|Routine wound treatment appointment without nurses wearing the surgical mask.
2851926|NCT03584672||Patients with Multiple Sclerosis|Patients with Multiple Sclerosis (Expanded Disability Status Scale (EDSS) score < 7)
2851927|NCT03584672||Healthy Controls|Healthy people
2851928|NCT03584659|No Intervention|Standard of care|This arm will continue standard procedure regarding side effect registration and handling
2851929|NCT03584659|Experimental|PRO|This arm will be assigned to intervention by weekly electronic reporting of side effects and quality of life. A specifically developed alert-algorithm will in real-time guide both patient and alert clinical staff if symptoms are increasing or quality of life is deteriorating.
2851930|NCT03584646|Experimental|Arm 1 - Control Arm|Usual care, nutrition and exercise counseling at baseline, use of the Nokia GO wearable step tracker device and end-of-study assessment at the end of the 14-week study period. Participants will receive the Nokia GO wearable step tracker to monitor daily step counts, but they will not be provided with personalized walking goals or automated feedback on goal attainment via text message.
2851931|NCT03584646|Experimental|Arm 2 - Intervention arm|Physical activity program supported by financial incentives for meeting walking goals and participating in weekly check-in appointments with study team members via telephone calls. Participants in the intervention arm will also receive twice-daily medication reminders via bidirectional text messages to promote medication adherence. Participants in Arm 2 will also receive personalized nutrition and exercise counseling, daily feedback on step counts via the Nokia GO wearable step tracker and their smartphones, and an end-of-study assessment.
2851932|NCT03584633|Other|Lymphedema|The subjects with lymphedema will be exercising on a Nu-Step exercise machine that will exercise their arms and legs simultaneously for ten minute intervals. Every ten minutes their limbs will be imaged with Indocyanine Green Lymphography.
2851933|NCT03584620|Experimental|IMT+PR Group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training. In addition standard pulmonary rehabilitation, patients received inspiratory muscle training.
2851934|NCT03584620|Experimental|PR group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training.
2851935|NCT03584607||Idiopathic Pulmonary Arterial Hypertension patients|Blood sampling Insulin resistance-measurement
2851936|NCT03584607||Healthy controls|Blood sampling Insulin resistance-measurement
2851937|NCT03584594||Presepsin assessment|Residual blood samples after performing all necessary blood examinations and analyses will be used to determine the level of presepsin, as the potential new biomarker of infection.
2851938|NCT03584581|Experimental|Olive polyphenols|
2851939|NCT03584581|Placebo Comparator|Control|
2851940|NCT03584568|Experimental|Perspective Taking Reappraisal|This arm focuses on reappraisals with perspective taking with a limited amount of basic skill building
2851941|NCT03584568|Other|Basic Skill Building|This arm focuses on basic skill building only.
2851947|NCT03584529|Experimental|vitamin D deficiency treatment group|patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 < 20 ng/ml)and uterine fibroids receive 1600 IU/day of vitamin D3 oral capsule for two years
2851948|NCT03584529|No Intervention|vitamin D deficiency control group|patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 < 20 ng/ml)and uterine fibroids receive regular follow-up.
2851949|NCT03584529|Experimental|vitamin D insufficiency treatment group|patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 < 30 ng/ml) and uterine fibroids receive 800 IU/d of vitamin D3
2851950|NCT03584529|No Intervention|vitamin D insufficiency control group|patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 < 30 ng/ml)and uterine fibroids receive regular follow-up.
2851951|NCT03584516|Experimental|Itacitinib + corticosteroids|Itacitinib administered in combination with corticosteroids.
2851952|NCT03584516|Placebo Comparator|Placebo + corticosteroids|Placebo administered in combination with corticosteroids.
2851953|NCT03584503|Active Comparator|Group SA|Group SA intubated with Suction Above Cuff Endotracheal Tube
2851954|NCT03584503|No Intervention|Group C|Group C intubated with classic endotracheal tube
2851955|NCT03584490|No Intervention|Pen-and-paper format|Based on randomization, participants in this group will receive traditional pen-and-paper questionnaires about health.
2851956|NCT03584490|Experimental|Computerized Talking Touchscreen|"This group will receive the Computerized Talking Touchscreen intervention.~Based on randomization, participants in this group will receive a computerized talking touchscreen version of our health questionnaires, which allows the participant to have questions and answer choices read aloud to them by the computer."
2851957|NCT03584477|Active Comparator|Conventional rehabilitation|5 sessions / week of 1 hour of occupational therapy
2851958|NCT03584477|Active Comparator|Robotic rehabilitation with assistance|5 sessions / week of 1 hour of rehabilitation of the upper limb with 30 min of conventional rehabilitation and 30 min of robotic rehabilitation with assistance.
2851959|NCT03584477|Active Comparator|Non-assistance robotic rehabilitation|5 sessions / week of 1 hour of rehabilitation of the upper limb including 30 min of conventional rehabilitation and 30 min of robotic rehabilitation without assistance.
2851960|NCT03584464|Other|Bifurcation Cohort|Subjects receiving stents 2.0 mm - 5.0 mm in diameter will be included in the Bifurcation Cohort.
2851961|NCT03584451|Active Comparator|with rehabilitation sport|rehabilitation sport over 52 weeks after THA, start 6 weeks postoperatively
2851962|NCT03584451|No Intervention|without rehabilitation sport|no further rehabilitation program after THA
2851963|NCT03584438|Experimental|Hanlon Real iTBS Protocol 1|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. 600 pulses of iTBS over the motor cortex (C3), 3600 pulses are delivered over 19 minutes.
2851964|NCT03584438|Experimental|Hanlon Real iTBS Protocol 2|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. 600 pulses of iTBS over the motor cortex (C3), 1800 pulses are delivered over 9 minutes and 30 seconds.
2851965|NCT03584438|Experimental|Huang Real iTBS Protocol|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. (2 sec trains of tbs every 10 sec) was applied over the left motor cortex (C3) for 190 seconds (a total of 600 TMS pulses).
2851966|NCT03584438|Experimental|Gamboa Real iTBS Protocol|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. (2 sec trains of tbs every 10 sec) was applied over the left motor cortex (C3) for 380 seconds (a total of 1200 TMS pulses).
2851967|NCT03584438|Sham Comparator|Sham iTBS protocol|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin over the left motor cortex (C3) and beneath the coil.
2851968|NCT03584425|Experimental|Healthy Controls|Subjects will undergo the following diagnostic tasks and assessments: Rasch Modified Version of the Fugl-Meyer Motor Assessment, Anatomical Image Acquisition, and the Functional MRI Task and Acquisition
2851969|NCT03584425|Experimental|Stroke Participants|Subjects will undergo the following diagnostic tasks and assessments: Rasch Modified Version of the Fugl-Meyer Motor Assessment, Anatomical Image Acquisition, and the Functional MRI Task and Acquisition
2851970|NCT03584412|Experimental|ACT OPEN|Acceptance and Commitment Therapy Online for Painful Peripheral Neuropathy (ACT OPEN).
2851971|NCT03584412|Other|Waiting List Control|Participants in this condition will not receive any change to their usual treatment for a period of 5 months, after which they will be given access to complete the ACT OPEN treatment.
2851972|NCT03584386|Experimental|V-CAMS|"In Phase I (formative), all enrolled participants are asked to provide feedback on the V-CAMS prototype as it is being refined. Feedback will be gathered via survey measure and interview.~In Phase II (summative), enrolled patient participants will be randomly assigned to this arm and will be given access to the V-CAMS tools as part of their treatment in the ED. Baseline assessment surveys will be administered in the ED, and three follow up assessments after discharge at 7 days, 30 days, and 90 days."
2851973|NCT03584386|No Intervention|Care As Usual|In Phase II (summative), enrolled patient participants will be randomly assigned to this arm so there is an even number of participants in the experimental condition and this condition. Those assigned to this condition will be treated as usual in the ED. Same as the experimental condition, those in the Care As Usual condition will be asked to complete baseline assessment surveys while they are waiting in the ED, and then three subsequent assessments after discharge at 7 days, 30 days, and 90 days).
2851974|NCT03584373|Experimental|Non-Opioid Analgesia|"Ketorolac - Oral; 10 mg tablet: 1 tablet every 6 hours, or as needed. (20 tablets prescribed).~Acetaminophen - Oral; patient directed as needed. Not prescribed.~Ketorolac and Acetaminophen administered post surgery to compare pain outcomes to that of Percocet."
2851975|NCT03584373|Active Comparator|Opioid Analgesia|"Percocet - Oral; 5 mg tablet: 1 tablet every 4-6 hours, or as needed. (10 tablets prescribed).~Percocet administered post surgery to compare pain outcomes to that of the non-opioid analgesia."
2851976|NCT03584360|Experimental|betamethasone-calcipotriol versus placebo|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a placebo foam in an other area during 4 weeks.
2852136|NCT03583229|Other|Aspirin - single arm|1 tablet of Aspirin 75 mg administered x 1 daily for 7 days.
2851977|NCT03584360|Experimental|betamethasone-calcipotriol versus betamethasone|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a betamethasone pomade in an other area during 4 weeks.
2851978|NCT03584360|Experimental|betamethasone-calcipotriol versus propionate of clobetasol|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a propionate of clobetasol pomade in an other area during 4 weeks.
2851979|NCT03584334|Other|18FDG PET|Diagnostic performance of 18FDG PET for identification of early tumor escape to immunotherapy in patients with unresectable melanoma or Broncho-Pulmonary Carcinoma No to Advanced or Metastatic Small Cells
2851980|NCT03584321||Participants with Coronary Artery Disease|Participants with suspected or confirmed coronary artery disease who underwent coronary angiography during 01 Jan 2013 and 31 Dec 2015 will be observed in the study.
2851981|NCT03584308|Experimental|Viusid® + Glizigen®|The experimental arm will receive nutritional supplements Viusid + Glizigen
2851982|NCT03584308|Placebo Comparator|Placebo|The control group will receive a placebo of both (Viusid and Glizigen).
2851983|NCT03584295|Active Comparator|Conventional care|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
2851984|NCT03584295|Experimental|Extracorporeal carbon dioxide Removal|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R (Extracorporeal carbon dioxide Removal) to facilitate early extubation. ECCO2R is used in a standard configuration with either double lumen cannula (20-22Fr) or two small single vessel cannulas (15-19 Fr), allowing a blood flow rate between 1-2 L/min.
2851985|NCT03584282|No Intervention|Standard of Care|Participants in this group will receive the standard of care for PrEP follow-up and no additional research interventions.
2851986|NCT03584282|Active Comparator|Text Messaging|Participants in this group will receive the text messaging intervention.
2851987|NCT03584282|Active Comparator|Peer Navigation|Participants in this group will receive the peer navigator intervention.
2851988|NCT03584282|Active Comparator|Text Messaging and Peer Navigation|Participants in this group will receive both the text messaging and peer navigation interventions.
2851989|NCT03584269|Experimental|NIV Device + LTOT|administration of ventilary support, without using an invasive artificial airway
2851990|NCT03584269|Active Comparator|LTOT|standard treatment, without NIV
2851991|NCT03584256||gymnasts|Female gymnasts, older than 13 years, with status of ineternational or national level,
2851992|NCT03584256||swimmers|Female swimmers, older than 12 years, with status of ineternational or national level,
2851993|NCT03584243|Experimental|Patient with progressive keratoconus|"Patient with progressive keratoconus will be included after providing their consent.~The intervention administrated is a cross-linking with oxygen treatment"
2851994|NCT03584230|Experimental|Positive Condition|"Students will be assigned to a group that receives positive nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs positive nonverbal behaviors to students in the same t-shirt color and negative nonverbal behaviors to students in another t-shirt color.~Intervention: Assigned to positive group"
2851995|NCT03584230|Experimental|Negative Condition|"Students will be assigned to a group that receives negative nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs negative nonverbal behaviors to students in the same t-shirt color and positive nonverbal behaviors to students in another t-shirt color.~Intervention: Assigned to negative group"
2851996|NCT03584230|No Intervention|No Cues Condition|Students will be assigned to a group that receives no nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs positive nonverbal behaviors to students in a different t-shirt color and negative nonverbal behaviors to students in a different t-shirt color. Students wearing the same t-shirt color as the participant never interact with the teacher.
2851997|NCT03584217|Other|Clinical Investigation|All participants will undergo GFR (Iohexol Inj 300 MG/ML), ERPF (Aminohippurate Sodium Inj 20%) in addition to renal BOLD and ASL MRI.
2851998|NCT03584191||People with Obesity|General population - potential participants will be recruited using various and numerous general population as appropriate in each country.
2851999|NCT03584191||Health Care Professionals|Health Care Professionals include primary care physicians and specialists who treat patients with obesity.
2852000|NCT03584178|Experimental|Mucosal Atomization Device|Budesonide via MAD Device
2852001|NCT03584178|Experimental|Intranasals Saline Irrigation|Budesonide via Intranasals Saline Irrigation
2852002|NCT03584152|Active Comparator|DRUG ARM A|Norco 5Mg-325Mg Tablet, administered orally every 4 hours for 5 days total
2852003|NCT03584152|Active Comparator|DRUG ARM B|Tylenol 325Mg Caplet, administered orally every 4 hours for 5 days total. Ibuprofen 200 mg administered orally every 4 hours for 5 days total.
2852004|NCT03584139|Experimental|IRIS HOOK|iris hook assisted maneuver in phacoemulsification
2852005|NCT03584139|Active Comparator|TRADITION|traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
2852006|NCT03584126||Patients with AF|Patients with atrial fibrillation visiting the outpatient clinic; examined by general examination, electrocardiography, ecocardiography and MRI.
2852007|NCT03584126||Control|Healthy adult volunteers; examined by the study physicians by general examination, electrocardiography, ecocardiography and MRI.
2852008|NCT03584113|Active Comparator|IR guided chest tube insertion with fibrinolytics|Image guided chest tube insertion by interventional radiology along with MIST 2 trial fibrinolysis which includes intrapleural dornase (5mg) and Alteplase (10mg) every twelve hours for a total of six doses as primary intervention for empyema.
2852009|NCT03584113|Active Comparator|VATS Decortication|Video assisted thorascopic surgery decortication (VATS) as primary intervention for empyema.
2852010|NCT03584100|Experimental|Patients with prior axillary lymph node dissection|Participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. Hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.
2852011|NCT03584100|Active Comparator|Healthy Volunteers|Participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. Hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.
2852012|NCT03584087|Placebo Comparator|TG 0 (0Hr)|TG0 will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly in place of Terlipressin therapy after EVL.
2852013|NCT03584087|Active Comparator|TG 2 (48Hr)|TG2 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 48 hours after EVL .
2852014|NCT03584087|Active Comparator|TG 5 (120Hr)|TG5 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 120 hours after EVL .
2852015|NCT03584074|Experimental|Pregabalin and COX-2 inhibitor|Pregabalin 75mg BID + Celecoxib 200mg qd
2852016|NCT03584074|Active Comparator|COX-2 inhibitor|Celecoxib 200mg qd
2852017|NCT03584061|Experimental|Fat grafting/fat transplant.|Each patient receives fat grafting to the site of dermal pain. Fat is to be harvested for either the abdomen or the thigh.
2852018|NCT03584048||HIV-1|HIV-1+, males, females, transgender, ≥18 years of age, residing in the Charlotte Metropolitan Area and with at least a single entry in the EHR in the last 2 years.
2852019|NCT03584035|Experimental|Sensory motor integration group|Sensory-motor integration exercises with 3 progressive steps, 30 minutes per sessions, 3 sessions per week for 6 weeks.
2852020|NCT03584035|Active Comparator|Conventional group|Conventional exercises include simple passive and active exercises and lower extremities strengthening exercises for balance and ambulation. The exercise session will last 30 minutes for 3 sessions per week. The total intervention period is 6 weeks.
2852021|NCT03584022|Experimental|Biopsy + Nerve Repair|Subjects will undergo standard sural nerve biopsy plus repair of the 6 cm nerve defect using a synthetic polymer (PCLF) nerve tube.
2852022|NCT03584022|Sham Comparator|Biopsy Only|Subjects will undergo the same standard sural nerve biopsy procedure as the Experimental Group, but will not include the nerve repair.
2852023|NCT03584009|Experimental|Venetoclax + Fulvestrant|Participants in the venetoclax arm will receive venetoclax, taken orally and fulvestrant administered as IM injections until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined end of the study (2 years after the last patient is enrolled) which ever occur first.
2852024|NCT03584009|Active Comparator|Fulvestrant|Participants will receive fulvestrant administered as IM (intramuscular) injections. No crossover to the venetoclax arm is permitted. Study treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined end of the study (2 years after the last patient is enrolled) which ever occur first.
2852025|NCT03583996|Other|Open Label|All subjects receive 20mg of 13C Cholate mixed with Albumin via IV push, and 40mg of d4 Cholate mixed with juice orally, both doses given simultaneously one time.
2852026|NCT03583983|Other|Personalized Health Recommendations|
2852027|NCT03583983|Other|No Health Recommendations|
2852028|NCT03583957||Entire Study|
2852029|NCT03583944|Experimental|Eribulin Mesylate 1.23 mg|Participants will receive eribulin mesylate 1.23 mg intravenous (IV) infusion, given over 2 - 5 minutes on Days 1 and 8 of 21 days cycle for a total of 6 cycles.
2852030|NCT03583931|Active Comparator|Operative VATS decortication|Operative group that will undergo early VATS decortication of complicated parapneumonic effusion/empyema
2852031|NCT03583931|Active Comparator|Non-operative Fibrinolytic Therapy|Non-operative group that will undergo instillation of the drugs DNAse and tPA (tissue plasminogen activator) together i.e. 5mg DNAse and 10mg tPA twice a day for up to six doses, through chest tube as treatment of the patient's complicated parapneumonic effusion/empyema. Fibrinolytic therapy = DNAse + tPA; these medications are not mutually exclusive.
2852032|NCT03583918|Experimental|Highthroughput Micro Coring Device|Skin excision and removal with with Highthroughput Micro Coring device
2852033|NCT03583905|Experimental|Experimental Group 1|Patients assigned to this group are treated with CKD-330, D086
2852034|NCT03583905|Placebo Comparator|Placebo Group 1|Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the D086)
2852035|NCT03583905|Placebo Comparator|Placebo Group 2|Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the CKD-330)
2852036|NCT03583892||Group A|In the Group A, a single-dose of 600mg gabapentin was used as part of a multimodal analgesic technique.
2852037|NCT03583892||Group B|In the group B gabapentin was not administered.
2852038|NCT03583879|Experimental|Exoskeleton exercise|8-week exercise program using the exoskeleton
2852039|NCT03583879|Active Comparator|Standard exercise|8-week exercise program not using the exoskeleton
2852040|NCT03583879|Placebo Comparator|No exercise|8-weeks of no treatment (wait-list control)
2852041|NCT03583866|Experimental|Candesartan|Sub chronic (7 days) Candesartan (16 mg/day)
2852042|NCT03583866|Placebo Comparator|Placebo|Endothelial function will be determined following a seven day treatment of placebo
2852043|NCT03583853||patients|take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of Ribonucleic acid (RNA) to determine the expression of autophagy genes by real time polymerase chain reaction (real time PCR)
2852044|NCT03583853||control|take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of RNA to determine the expression of autophagy genes real time polymerase chain reaction
2852045|NCT03583840|No Intervention|Control group|Participants which are not given the link to the ScreenMen website
2852046|NCT03583840|Experimental|Intervention group|Participants will be given the link to the ScreenMen website
2852047|NCT03583827|Experimental|Experimental Group|Experimental group patients will be submitted to conventional therapy for 30 minutes and training of the affected upper limb using virtual reality, which will last 20 minutes over twelve sessions (4 weeks).
2852048|NCT03583827|Active Comparator|Control Group|The control group will undergo 30 minutes of Conventional physical therapy in twelve sessions (4 weeks).
2852049|NCT03583814|Active Comparator|CASE Program only|"During the Active Trial Phase, families of children with asthma status defined as not well controlled will complete the CASE program. Outcomes for participants assigned to the CASE program will be compared in a pre-post within subject comparison. Regardless of intervention arm assignment, children are expected show improvement in asthma outcomes. The stepped wedge trial design of the overall study allows for comparison of outcomes of communities in the pre-active trial baseline control period, active trial phase, and post-active trial phase follow-up period."
2852050|NCT03583814|Active Comparator|CASE and HARP Programs|"During the Active Trial Phase, families of children with asthma status that is defined as poorly controlled will complete the CASE and HARP programs. Outcomes for participants assigned to this arm (CASE and HARP) will be compared in a pre-post within subject comparison. Regardless of intervention arm assignment, children are expected show improvement in asthma outcomes. The stepped wedge trial design of the overall study allows for comparison of outcomes of communities in the pre-active trial baseline control period, active trial phase, and post-active trial phase follow-up period."
2852051|NCT03583814|No Intervention|Standard Care|Cluster-based randomization in the Stepped Wedge Trial allows for comparison of Community Based Outcomes for clusters (communities defined by school catchment areas) who are not yet in the active trial phase and are receiving Standard of Care at that time.
2852052|NCT03583801|Experimental|aromatherapy group|"The patient has to choose an essential oil among the 3 proposed :~sweet orange (Citrus sinensis L. Persoon)~fine lavender (Lavandula angustifolia P. Miller)~little seed from the mandarin tree (Citrus reticulata blanco)"
2852053|NCT03583801|Placebo Comparator|without aromatherapy|
2852054|NCT03583788|Experimental|Hypnotherapy group|The intervention consisted of individual hypnotherapy of 5 hourly sessions (60 minutes) over 5 weeks, a total of five hours. The hypnotherapy treatment method was Erickson`s (permissive) hypnosis (17). It began with a conversation about patient`s past life events, present situation, alcohol problem and his or her thoughts about it. The hypnotherapy Group did not receive any treatment of motivational interviewing.
2852055|NCT03583788|Active Comparator|Motivational interviewing group|The comparator patient group received individual therapy as motivational interviewing (MI) for 5 hourly sessions over 5 weeks, a total of five hours. The patients in the experimental group did not receive this.
2852056|NCT03583775||Patients with congenital heart disease|Patients with congenital heart disease who are greater than 40 kg and are referred for a clinically indicated 2D CMR exam with a gadolinium-based contrast agent.
2852057|NCT03583762|Experimental|Pre-intervention group|100 participants received empiric antibiotic by ID physician, bacterial identification by Mass spectrometry technique
2852058|NCT03583762|Experimental|Post-intervention group|100 participants received empiric antibiotic therapy by ID physician, bacterial identification by Microarray assay from blood culture and confirm with Mass spectrometry technique
2852059|NCT03583749||amoxicillin-clavulanate|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
2852060|NCT03583749||ceftriaxone|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
2852061|NCT03583749||piperacillin-tazobactam|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
2852062|NCT03583736|Active Comparator|Rapid first contact virtual visit|Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed. Subjects will be randomized after accepting offer of a virtual visit.
2852063|NCT03583736|Placebo Comparator|First contact in person office visit|Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed. Subjects will be randomized after accepting offer of a virtual visit.
2852064|NCT03583723|Experimental|Radiotherapy Group|Patients with LA NSCLC treated with concurrent chemoradiation will be enrolled. During treatment all patients will undergo weekly chest CT simulations without intravenous contrast to assess acute toxicity and tumor shrinkage, and they will be all visualized by two radiation oncologists independently. For all CT simulations, each physician will be able to judge whether reduction will be (1) present and clinically significant, (2) present and clinically non significant, or (3) absent. In the case of physician agreement for the first category, a contrast-enhanced CT will be performed to better visualize node reduction, a new target volume will be delineated, and a new treatment plan (replanning study) performed. Patients will be treated without any time break.
2852065|NCT03583710|Experimental|Arm A (mitotane)|Participants receive mitotane PO daily on days 1-21. Courses repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
2852066|NCT03583710|Experimental|Arm B (mitotane, etoposide, cisplatin)|Participants receive mitotane as in Arm A. Participants also receive cisplatin IV over 2 hours on day 1 and etoposide IV over 2 hours on days 1-3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2852067|NCT03583697|Experimental|Active BMN111|Daily subcutaneous injection of 15 micrograms per kilogram BMN111
2852068|NCT03583697|Placebo Comparator|Placebo|Daily subcutaneous injection of placebo
2852069|NCT03583684|Experimental|Pivotal Response Treatment Program (PRT-P)|The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
2852070|NCT03583684|No Intervention|Delayed Treatment Group (DTG)|Child continues stable treatments as usual in the community.
2852071|NCT03583658|Active Comparator|Ambroxol hydrochloride (BIH1526)|One lozenge 20 mg on as-needed basis, up to 6 times per day
2852072|NCT03583658|Placebo Comparator|Placebo|One lozenge on as-needed basis, up to 6 times per day
2852073|NCT03583645|Experimental|Incremental theory of personality|1 hour behavioral intervention (based on ITP) consisting on several tasks to be completed on paper individually.
2852074|NCT03583645|Other|Educational intervention|1 hour educational intervention (about the human brain) consisting on several tasks to be completed on paper individually.
2857306|NCT03547323|Active Comparator|FX80 Dialyzer|One treatment session in an in-center setting.
2852075|NCT03583619|Experimental|APBI|Patients receive accelerated partial breast irradiation to tumour bed to a total dose of 40Gy, 4.0Gy per fraction, 5 fractions a week, within 2 weeks.
2852076|NCT03583619|Active Comparator|WBI|Patients receive whole breast irradiation to a total dose of 43.5Gy, at 2.9Gy per fraction, 5 fractions a week, within 3 weeks.
2852077|NCT03583606|Experimental|ChAd3-EBO-Z + ChAd3-EBO-Z|ChAd3-EBO-Z (1 x 10^11 particle units (pu)) intramuscularly into the deltoid on Day 1 and ChAd3-EBO-Z (1 x 10^11 pu) intramuscularly into the opposite arm on Day 8, n = 20
2852078|NCT03583606|Experimental|ChAd3-EBO-Z + Placebo|ChAd3-EBO-Z (1 x 10^11 particle units (pu)) intramuscularly into the deltoid on Day 1 and placebo intramuscularly into the opposite arm on Day 8, n = 20
2852079|NCT03583606|Experimental|ChAd3-EBO-Z + MVA- BN-Filo|ChAd3-EBO-Z (1 x 10^11 particle units (pu)) intramuscularly into the deltoid on Day 1 and MVA-BN-Filo (1 x 10^8 Infectious Units (IU)) intramuscularly into the opposite arm on Day 8, n = 20
2852080|NCT03583593|Experimental|DIAMEL|Study group that receives the active product.
2852081|NCT03583593|Placebo Comparator|Placebo|Control group receiving double-blind placebo.
2852082|NCT03583580|Experimental|Accelerated Partial Breast Irradiation|Accelerated partial breast irradiation (APBI) to the region of tumour bed
2852083|NCT03583567|Placebo Comparator|Normal Saline Flush, 0.9% Injectable Solution|Syringe No 1 contain normal saline 1 mL Syringe No 2 contain normal saline 2 mL
2852084|NCT03583567|Experimental|Chlorpheniramine and ranitidine|Syringe No 1 contain chlorpheniramine 10 mg (1 mL) Syringe No 2 contain ranitidine 50 mg (2 mL)
2852085|NCT03583554|Placebo Comparator|Placebo|Placebo
2852086|NCT03583554|Active Comparator|AV-101 720 mg|One time 720 mg L-4-Chlorokynurenine
2852087|NCT03583554|Active Comparator|AV-101 1440 mg|One time 1440 mg L-4-Chlorokynurenine
2852088|NCT03583541|Experimental|Control arm: Bolstered treatment|Women in the control condition (and in the treatment arms) will receive treatment as usual (TAU) for FSW in the study area. Provided by RHSP, TAU includes: health education, HIV testing services, STI screening and treatment in a session that lasts about 2 hours, provided on a quarterly basis. This will be bolstered with 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention
2852089|NCT03583541|Experimental|Treatment arm: HIVRR+S|Women in this arm will receive TAU for FSW and the 4 HIVRR sessions (described above) and a single session following HIVRR specifically describing bank account opening, the matching process, and how to interact with banks. In this session our partnering banks will open up matched savings accounts for women in the two treatment arms. Women in both arms will save money in their matched savings accounts over a 10-month period post HIVRR. The study team will monitor the accounts using the statements received directly from the banks holding the accounts. Participants will receive monthly bank statements indicating their own savings and the associated match (1:1 match rate).
2852090|NCT03583541|Experimental|Treatment arm: HIVRR+S+FLM|Women in this arm will receive TAU and the 4 HIVRR sessions (as above). Next, they will receive the savings session (described above) and 6 financial literacy (FL) sessions provided twice a week for 3 weeks, followed by 8 mentorship (M) sessions supporting transition to vocational, educational training, employment or business development, and receipt of a matched savings account to be used on short-term and/or long term consumption and skills development per participants own discretion/choice.
2852091|NCT03583528||PET/CT Diagnostic Imaging|Each subject will have two PET/CT scans, one using 68Ga-DOTATOC and the other using 18F-FDG. The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 18F-FDG is considered standard care and has been approved by Health Canada.
2852092|NCT03583515|Experimental|Alcohol-Specific Personalized Normative Feedback|Participants will receive feedback about their average number of days on which alcohol was consumed, average drinks per occasion, and average number of drinks per week. This feedback will include the participant's averages reported at baseline, the participant's descriptive norm of others' averages (what they think others drank), and actual others' drinking. Feedback will be about other students at their university of the same sex.
2852093|NCT03583515|Placebo Comparator|Social Media Personalized Normative Feedback|Participants will receive feedback about their number of hours texting, on social media websites, and playing video games. This feedback will include the participant's averages reported at baseline, the participant's descriptive norm of others' averages (what they think others did), and actual others' behavior. Feedback will be about other students at their university of the same sex.
2852094|NCT03583502|Experimental|Supplemented|krill oil and fish oil supplement
2852095|NCT03583502|No Intervention|Controls|The control group did not receive any supplementation.
2852096|NCT03583489|Placebo Comparator|Placebo|
2852097|NCT03583489|Experimental|APD421|
2852098|NCT03583489|Experimental|APD421 + ondansetron|
2852099|NCT03583476||CLA triple therapy|Patients with clarithromycin-containing triple therapy
2852100|NCT03583476||MET triple therapy|Patients with metronidazole-containing triple therapy
2852101|NCT03583476||Concomitant therapy|Patients with concomitant therapy
2852102|NCT03583476||Sequential therapy|Patients with sequential therapy
2852103|NCT03583450|Experimental|Perioperative virtual reality headset|Perioperative virtual reality headset with mobile app
2852104|NCT03583450|No Intervention|Control|Control
2852105|NCT03583424|Experimental|Treatment (venetoclax, BEAM)|Participants receive venetoclax PO QD on days -10 to -1, carmustine IV on day -6, etoposide IV BID on days -5 to -2, cytarabine IV BID on days -5 to -2, and melphalan IV on day -1. Participants then undergo hematopoietic cell transplantation on day 0.
2852106|NCT03583411||acute coronary syndrome (ACS) patients|ACS subjects hospitalized in the Cardiology 1 - UTIC department of ASST Grande Ospedale Metropolitano Niguarda between 2014 and 2017
2852107|NCT03583398||TAVI TAo|
2852108|NCT03583398||TAVI TF|
2852109|NCT03583398||AVR|
2852110|NCT03583385|Experimental|First Test, Then Comparator Drug|Participants will receive single oral dose of Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) followed by single oral dose of Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) under fasted conditions. The two doses will be separated by a 7-day wash-out period.
2852137|NCT03583229|Experimental|Extracorporeal photopheresis|All patients with HLA antibodies receive 4 ECP-treatments in 2 months.
2852111|NCT03583385|Experimental|First Comparator, Then Test Drug|Participants will receive single oral dose of Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) followed by single oral dose of Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) under fasted conditions. The two doses will be separated by a 7-day wash-out period.
2852112|NCT03583372|Experimental|Vibegron + Placebo to match Tolterodine|
2852113|NCT03583372|Active Comparator|Tolterodine + Placebo to match vibegron|
2852114|NCT03583359|Experimental|Treatment with Radiesse (+)|Enrolled subjects will be randomized (2:1 allocation ratio) to either receive treatment with Radiesse (+) or delayed treatment with Radiesse (+).
2852115|NCT03583359|Other|Delayed Treatment with Radiesse (+)|Enrolled subjects will be randomized (2:1 allocation ratio) to either receive treatment with Radiesse (+) or delayed treatment with Radiesse (+).
2852116|NCT03583346|Experimental|M6495|
2852117|NCT03583346|Placebo Comparator|Placebo|
2852118|NCT03583333|Experimental|IMI/REL FDC|Imipenem/cilastatin/relebactam (IMI/REL) administered intravenously (IV) as a fixed-dose combination (FDC) at a dosage of 500 mg IMI/250 mg REL/500 mg Cilastatin, once every 6 hours for a minimum 7 days, up to 14 days. At the start of IMI/REL treatment, participants will be treated empirically with 600 mg open-label linezolid administered IV every 12 hours until methicillin-resistant Staphylococcus aureus (MRSA) is ruled out. Participants with confirmed MRSA infection will continue to receive 600 mg linezolid every 12 hours for a minimum of 7 days, up to 14 days total.
2852119|NCT03583333|Active Comparator|PIP/TAZ FDC|Piperacillin/tazobactam (PIP/TAZ ) administered IV as a FDC at a dosage of 4000 mg PIP/500 mg TAZ once every 6 hours for a minimum 7 days, up to 14 days. At the start of PIP/TAZ treatment, participants will be treated empirically with 600 mg open-label linezolid administered IV every 12 hours until methicillin-resistant Staphylococcus aureus (MRSA) is ruled out. Participants with confirmed MRSA infection will continue to receive 600 mg linezolid every 12 hours for a minimum of 7 days, up to 14 days total.
2852120|NCT03583320|Experimental|Arm A (Cardiac CT)|Patients randomised to Arm A i.e. the intervention arm will under go standard of care patient hospital management but will also have cardiac CT angiogram (CTCA) carried out. Their subsequent clinical management will be left to clinician discretion in light of the additional CTCA results.
2852121|NCT03583320|No Intervention|Arm B (Standard of care arm)|"Patients randomised to Arm B will receive usual standard of care management guided by serial troponin blood tests. These patients will also under go cardiac CT angiogram (CTCA) but these scans will not be used for the patients' in-hospital care.~Furthermore, unlike Arm A, CTCA interpretation followed by reporting will not take place in the acute hospital setting and therefore will be carried out within the following three weeks. Should the CTCA be found to have significant high risk CAD e.g. >50% stenosis in the left main (LM) coronary artery, and/or >50% stenosis in the proximal left anterior descending (LAD) coronary artery, they will be un-blinded and kept in a separate registry. Their results will be discussed with the hospital care team and if they have not had any invasive coronary imaging during the preceding hospital admission, an urgent cardiology out-patient referral will be made to enable further clinical management."
2852122|NCT03583307|Experimental|Sirolimus|
2852123|NCT03583294|Experimental|irradiation regimen before 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed
2852124|NCT03583294|Experimental|busulfan regimen before 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed
2852125|NCT03583294|Experimental|irradiation regimen after 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed
2852126|NCT03583294|Experimental|busulfan regimen after 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed
2852127|NCT03583281|Active Comparator|Flax oil|Participants will consume capsules containing flax oil (4 grams alpha-linolenic acid [ALA] per day) for 4 weeks
2852128|NCT03583281|Active Comparator|Fish oil|Participants will consume capsules containing DHA-enriched fish oil (4 grams DHA per day + 0.8 grams EPA per day) for 4 weeks
2852129|NCT03583268|Active Comparator|Moderate Intensity Exercise Alone|45 minutes of moderate intensity exercise at 45-55% of maximum aerobic capacity (active participants) or heart rate reserve (sedentary participants) used as a control condition. Participants will consume a glucerna bar at 10pm following this session.
2852130|NCT03583268|Experimental|70% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 70% heart rate reserve every 4 minutes. Note: this session is not included for the active participants. Participants will consume a glucerna bar at 10pm following this session.
2852131|NCT03583268|Experimental|80% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 80% of heart rate reserve every 4 minutes. Note: this session is not included for the active participants. Participants will consume a glucerna bar at 10pm following this session.
2852132|NCT03583268|Experimental|90% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 90% of maximum aerobic capacity (active participants every two minutes) or heart rate reserve (sedentary participants every 4 minutes). Participants will consume a glucerna bar at 10pm following this session.
2852133|NCT03583255|Experimental|Arm I (dexamethasone, exercise)|Participants receive dexamethasone PO BID for 7 days. Participants also complete resistance training and moderate intensity walking at home for minimum 5 days per week over 4 weeks.
2852134|NCT03583255|Active Comparator|Arm II (placebo, exercise)|Participants receive placebo PO BID for 7 days. Participants also complete resistance training and moderate intensity walking as in Arm I.
2852135|NCT03583242||DME treat with antiangiogenic|"3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.~1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process."
2861841|NCT03516084|Placebo Comparator|Placebo|
2852138|NCT03583229|No Intervention|Control group|The control group does not receive ECP-treatments, but blood samples are drawn at the same intervals as treatment group and CAG+OCT are also performed at baseline and 12 months follow up as the treatment group.
2852139|NCT03583216||Diabetic pregnancy|Pregnant patients with a diagnosis of Type I, Type II or gestational diabetes will be included in this arm. Blood will be drawn from each patient when they are hospitalized and before they deliver either vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will contain 4 ml blood.
2852140|NCT03583216||Non-diabetic pregnancy|Healthy non-diabetic pregnant patients will be included in this arm. Blood will be drawn from each patient when they are hospitalized and before they deliver either vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will contain 4 ml blood.
2852141|NCT03583203|Experimental|Experimental Group|This group will include personalized information about lung damage. After evaluating their COPD, the patients will be informed about its existence it so and staging. Depending on the damage found, the generation of motivation will focus on the different prevention methods. Likewise, after the motivation level is set, the patients will be offered the option of treatment and regular follow-up. The intervention will be strengthened by motivational messages, half of which are linked to the possibilities of preventing respiratory damage, sent to the patient's mobile phone via SMS during the 3 months after the face-to-face intervention. Patients without mobile phones will receive a call on their phone to convey the same messages.
2852142|NCT03583203|No Intervention|Control Group|The control intervention lasts 30 minutes and will be structured around the 5 A's technique (Ask, Advice, Assess, Assist and Arrange).
2852143|NCT03583190|Experimental|Cervical-cranial dry needling|Patients randomized to this arm will receive cervical-cranial dry needling, thoracic manipulation, and exercise.
2852144|NCT03583190|Active Comparator|Orthopedic Manual Therapy|Patients randomized to this arm will receive orthopedic manual therapy to cervical spine, thoracic manipulation, and exercise.
2852145|NCT03583177||healthy volunteers|
2852146|NCT03583177||cancer patients|
2852147|NCT03583177||undergoing chronic hemodialysis patients|
2852148|NCT03583164|Experimental|F901318|open-label single-arm of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi which are susceptible to F901318 in patients with limited treatment options.
2852149|NCT03583151|Active Comparator|Steroid injection|1 mL Solu-medrol mixed with 0.5mL marcaine and 0.5 mL of lidocaine
2852150|NCT03583151|Experimental|Amniotic fluid injection|1 mL amniotic fluid mixed with 0.5mL marcaine and 0.5 mL of lidocaine
2852151|NCT03583138|Active Comparator|Buprenorphine|Participants are eligible for the study if they are 18 years of age or older, HIV+, meet DSM-IV criteria for opioid dependence, have health insurance accepted at Lab Corp, are able to read and understand English, and live in Washington, DC and plan to remain in DC. The intervention is to provide buprenorphine for 12 months for those who are interested in receiving it.
2852152|NCT03583138|No Intervention|No buprenorphine|No buprenorphine
2852153|NCT03583125|Experimental|EOC 317|"Dose-escalation part: the enrolled 20 subjects will be given EOC 317 tablet one dose on Day 1, paused for 2 days, and then given EOC 317 tablet one dose every day during Day 4 to Day 24.~Dose-extension: the enrolled 120 subjects will be given EOC 317 tablet one dose every day during Day 1 to Day 21."
2852154|NCT03583112|Active Comparator|Dapoxetine|In this group, patients received one dapoxetine hydrochloride tablet before MRI scan.
2852155|NCT03583112|Placebo Comparator|Placebo|In this group, patients received placebo tablet before MRI scan.
2852156|NCT03583099|Experimental|CAPTURE + COPD Education|Practice clinicians will receive basic COPD education, and patient-level CAPTURE information with CAPTURE interpretation education. As the second aim address the optimal format for delivering practice CAPTURE education this will be incorporated at the sites randomized to this arm.
2852157|NCT03583099|Active Comparator|COPD Education|Practice clinicians will receive basic COPD education only.
2852158|NCT03583086|Experimental|Treatment (vorolanib, nivolumab)|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 60 minutes every 2 weeks on days 1, 15, 29, and 43. Courses repeat every 56 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2852159|NCT03583073|Active Comparator|Standard Care/Baseline Control|Standard care is the typical process of referral to mental health services for Juvenile Justice (JJ) youth who screen positive for mental heath concerns at intake. For this study, baseline control participants will be referred to the Coordinated Specialty Care (CSC) clinic due to their endorsement of psychosis-spectrum symptoms.
2852160|NCT03583073|Experimental|Enhanced Referral/Linkage to Care|"The experimental condition will include a psychoeducational and motivational enhancement protocol completed at the JJS intake appointment, paired with a warm hand-off referral to the CSC for evaluation and initiation of mental health services."
2852161|NCT03583060|Experimental|MABT|Receive 8 weekly sessions of Mindful Awareness in Body-oriented Therapy (MABT).
2852162|NCT03583060|No Intervention|Control|
2852163|NCT03583021|Experimental|sugammadex group|Sugammadex group receives the intravenous sugammadex of 3 mg/kg.
2852164|NCT03583021|Placebo Comparator|neostigmine group|Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.
2852165|NCT03583008|Experimental|Anticoagulation (AC) Intervention|Providers in this arm will receive supportive tools including Anticoagulation (AC) Intervention--Prescribing Practices and Anticoagulation (AC) Intervention--Academic Detailing to help them assess their Anticoagulant (AC) prescribing practices and will also meet with the study investigators for academic detailing.
2852166|NCT03583008|No Intervention|Control|Providers in this arm will not receive any intervention.
2852167|NCT03582995|Active Comparator|Flap Surgery for root coverage with Alloderm and xenograft|Root coverage surgery using a flap technique
2852168|NCT03582995|Experimental|Tunnel Surgery for root coverage with Alloderm and xenograft|Root coverage surgery using a tunnel technique
2852169|NCT03582982|Experimental|Eccentric overload exercise|
2852170|NCT03582969|Experimental|Fecal transplantation|Fecal transplantation of feces from healthy donor via capsules. Oral application.
2852171|NCT03582969|Placebo Comparator|Placebo|Placebo capsules
2852370|NCT03581513|Experimental|IMR≥40 and defer PCI|Patients whose IMR≥40 undergo anticoagulation and antiplatelet therapy for stent implantation one week later
2852172|NCT03582956|Other|Adolescent Overweight|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D that will receive a euglycemic hyperinsulinemic clamp with tracer enhancement.
2852173|NCT03582956|Other|Adolescent Typical|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement.
2852174|NCT03582956|Other|Young Adult|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement
2852175|NCT03582943|Experimental|Remote limb ischemic conditioning (RLIC)|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the dominant arm. RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
2852176|NCT03582943|Sham Comparator|Sham conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-7.
2852177|NCT03582917|Experimental|Alphacalscidol|0,5mg tablet by mouth, one each day for one year
2852178|NCT03582917|No Intervention|No treatment|
2852179|NCT03582904|Experimental|Real tDCS|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered via saline-soaked sponge electrodes (anode, 8 cm^2; cathode 38.4 cm^2) at an intensity of 1.5 milliamperes over < 30 minutes.
2852180|NCT03582904|Sham Comparator|Control|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered via saline-soaked sponge electrodes (anode, 8 cm^2; cathode 38.4 cm^2) at an intensity of 1.5 milliamperes over 2 minutes.
2852181|NCT03582891|Experimental|Closed-loop trial at 11 months|This group receives closed loop stimulation for a 1 month trial at 11 months into the study. This group will receive open-loop stimulation at month 12 of the study. Both groups receive the same treatment but during this blinded portion, the subject may either be in closed or open loop stimulation first.
2852182|NCT03582891|Experimental|Closed-loop trial at 12 months|This group receives closed loop stimulation for a 1 month trial at 12 months into the study. This group will receive open-loop stimulation at month 11 of the study. Both groups receive the same treatment but during this blinded portion, the subject may either be in closed or open loop stimulation first.
2852183|NCT03582878|Active Comparator|mycophenolate mofetil|mycophenolate mofetil dosing 1g before transplantation and 1g bid afterwards
2852184|NCT03582878|Experimental|Sirolimus|Sirolimus oral product Dosing 5mg orally 2-6h before transplantation Target trough levels between 5-10ng/ml
2852185|NCT03582865||responding|patients who received Tamoxifen 20 mg daily for at least 3 years with good response (no relapse) to tamoxifen. Both genotyping assessment and TDM of tamoxifen and its metabolites will be performed and correlated with the records. Follow up for these patients for further assessment of tamoxifen effectiveness will be carried out for 1- 2 years.
2852186|NCT03582865||relapse|patients who received Tamoxifen 20 mg daily for at least 3 years who were good responder to the drug but then the response has been diminished (relapse) and they have been shifted to another therapy. They will be exposed to genotyping study of CYP 2D6 to recognize the phenotyping style of that patient that may explain diminishing of response to tamoxifen therapy.
2852187|NCT03582865||tamoxifen resistant|patients who received Tamoxifen 20 mg daily for not more than 1 year with poor response to tamoxifen (early relapse) and clinically will be shifted to use another medication as they were diagnosed as tamoxifen resistant. Like the second group, they will be exposed to genotyping study of CYP2D6 with the same concept.
2852188|NCT03582852|Active Comparator|promontory|Laparoscopic sacrocolpopexy, which consist in fixing a mesh between vaginal anterior wall
2852189|NCT03582852|Active Comparator|laparoscopic lateral suspension|The procedure consists in spreading out bilaterally, a subperitoneal T-shaped mesh in the anterior abdominal wall
2852190|NCT03582839|Experimental|PROTECT+|The PROTECT+ intervention group is a self-selected sample, which receives the PROTECT+ group therapy (4 modules in 4 subsequent weeks à 100 min). Participants are assessed at T1 (baseline), T2 (post treatment, 1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
2852191|NCT03582826|Experimental|Study Participants|Nutrition counselling and stress-management counselling behavioral interventions will be given to minimize subjects symptoms and observe corresponding changes in their microbiomes
2852192|NCT03582813|Experimental|Self-directed care|Subjects receive traditional behavioral health and non-traditional services via a self-directed care model in which they develop a person-directed plan and create a budget for the purchase of medically necessary goods and services. Program staff acting as service brokers help them secure needed goods and services from within or outside the public behavioral health provider system. A fiscal intermediary manages financial resources to pay providers and enable the purchase of approved goods..
2852193|NCT03582813|Active Comparator|Services as usual|Subjects receive traditional behavioral health services as usual via the traditional service delivery system and its network of providers.
2852194|NCT03582800|Experimental|Treated|M0-M6: run-in phase (control) M6-M12: STS treatment phase
2852195|NCT03582787|Experimental|Mcgrath group|Orotracheal intubation with McGrath MAC videolaryngoscopy
2852196|NCT03582787|Placebo Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscopy
2852197|NCT03582774|No Intervention|Arm 1|Patient does not undergo 68Ga-PSMA-11 PET/CT for SRT planning.
2852198|NCT03582774|Active Comparator|Arm 2|Patient undergoes 68Ga-PSMA-11 PET/CT for SRT planning.
2852199|NCT03582761|Experimental|320U /0.5ml in children|EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28
2852200|NCT03582748||New surgical subjects|This group will be consist of 150 consecutively consented subjects who are scheduled to have sleeve gastrectomy at the Hartford Hospital Surgical Weight Loss Center.
2852201|NCT03582748||Carry over surgical subjects|This group will include 45 subjects who participated in the pilot study and who will be contacted and consented into the present study.
2852333|NCT03581799|Other|Oral dispersible tablet|5 mm calcium carbonate based ODT will be administered by placing it in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
2852202|NCT03582748||Non-surgical subjects|This group will include 15 non-surgical patients who will be group-matched to Group A on pertinent characteristics. These patients will be non-surgical in that they will have been evaluated for bariatric surgery by the SWLC but deemed ineligible for any of a number of reasons.
2852203|NCT03582735|Experimental|Nerve gliding exercise|Three series of 15 daily repetition of the rehabilitation exercise targetting nerve excursion
2852204|NCT03582735|No Intervention|Control|No intervention according to current practice.
2852205|NCT03582722|Experimental|Weight loss aid|One-month supply of orlistat capsules (60mg) to be taken up to 3x daily with meals containing fat, daily multivitamins, and instructions for dietary modification and exercise for six months.
2852206|NCT03582722|Placebo Comparator|Placebo|One-month supply of placebo capsules to be taken up to 3x daily with meals containing fat, daily multivitamins, and instructions for dietary modification and exercise for six months.
2852207|NCT03582696|Other|No Arms|Participants are not assigned to randomized study arms or groups.
2852208|NCT03582683|Experimental|CPSMP Intervention|Participants randomly assigned to this arm will, following a baseline assessment, immediately begin attending a 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
2852209|NCT03582683|Active Comparator|Wait-list Control Group|Participants assigned to this arm will wait six months after a baseline assessment and then attend the 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
2852210|NCT03582670|Experimental|Strategy Training Intervention|Study participants receive specific memory strategy training with training games, as well as feedback on accuracy and performance.
2852211|NCT03582670|Active Comparator|Process Training|Study participants attend training sessions and complete training games, but receive no specific strategy training
2852212|NCT03582670|Other|Control Group|Study participants do not attend any strategy training sessions.
2852213|NCT03582644|Experimental|CRYOTHERAPY INTERVENTION|Patients with end stage knee osteoarthritis, both sexes, 60 years or higher
2852214|NCT03582618|Experimental|Sorafenib + CVM-1118|"Cycle 0 (at least 3 weeks): sorafenib tolerability assessment period (sorafenib alone)~400mg BID daily (starting dose); The subject will be assessed for the need for a dose reduction in sorafenib during this period.~Cycle 1+ (28-day cycles): combination period (sorafenib+CVM-1118)~Tolerable dose of sorafenib and CVM-1118 150 (starting dose) or 200 mg BID will be administered continuously for a 28-day cycle until progressive disease, unacceptable toxicity, or consent withdrawal."
2852215|NCT03582605|Placebo Comparator|Control Group|All participants will be weighed. This group will receive a placebo (glucose) 1 hour prior to insertion of mini-screw implants.
2852216|NCT03582605|Experimental|Experimental Group|All participants will be weighed so that appropriate dosing can be ensured and will receive 2 grams of Amoxicillin 1 hour prior to mini-screw insertion. Patients weighing less than 40 kg will be given 50mg/kg of Amoxicillin.
2852217|NCT03582592|Experimental|Fluid Distribution Timetable (FDT) Group|It is the fluid distribution timetable. It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
2852218|NCT03582592|No Intervention|Comparison Group|It is the standard of care that served as the intervention. The control group received the standard care for patients on hemodialysis. The standard care involves a 10 -15-minute face-to-face health teaching of their treatment regimen including pharmacologic management, dialysis schedule, dietary and fluid restrictions or nutritional therapy, care for vascular access, and other necessary lifestyle modifications.
2852219|NCT03582579|Experimental|Control in VR|Adults ages 18 to 35 who will be training in Virtual Reality.
2852220|NCT03582579|Experimental|Control Non-VR|Adults ages 18 to 35 who will be training on a computer screen.
2852221|NCT03582579|Experimental|College Athletes with TBI Group|Adults ages 18 to 35 with mild TBI who will be training in Virtual Reality
2852222|NCT03582579|Experimental|Older Adult Group|Older Adults over the age of 65 who will be training in Virtual Reality
2852223|NCT03582566|Experimental|Phonological Awareness|Children will play games to practice their rhyming, sound sequencing, and letter-sound knowledge. These games are all implemented in the Earobics program.
2852224|NCT03582566|Experimental|Working Memory|Children will play games designed to help them hold and manipulate objects in memory. These games are implemented in Cogmed.
2852225|NCT03582566|Experimental|Phonological Awareness + Working Memory|Children will practice both their sound skills (Earobics) and their memory skills (Cogmed).
2852226|NCT03582566|Active Comparator|Active Control|Children will play games to practice their addition and subtraction skills (Splashmath).
2852227|NCT03582553|Experimental|150 mg dose|Blood will be drawn at at 0, 2, 3, 3.5, 4, 4.5, 6, 8,12, and 24 hours to measure serum naringenin concentrations in response to a single 150 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
2852228|NCT03582553|Experimental|300 mg dose|Blood will be drawn at at 0, and 4 hours to measure serum naringenin concentrations in response to a single 300 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
2852229|NCT03582553|Experimental|600 mg dose|Blood will be drawn at at 0, 2, 3, 3.5, 4, 4.5, 6, 8,12, and 24 hours to measure serum naringenin concentrations in response to a single 600 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
2852230|NCT03582553|Experimental|900 mg dose|Blood will be drawn at at 0, and 4 hours to measure serum naringenin concentrations in response to a single 900 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
2852231|NCT03582553|Placebo Comparator|Placebo|Subjects in the first cohort will receive 150 mg and 300 mg ascending doses of naringenin and subjects in the second cohort will receive 600 mg and 900 mg ascending doses of naringenin. Each cohort will also have a placebo group.
2852334|NCT03581786|Placebo Comparator|placebo combine with chemotherapy|
2852232|NCT03582540|Active Comparator|early double-guidewire technique (DGT)|First arm: early double-guidewire technique The early arm attempts biliary cannulation using the DGT immediately once the guidewire is inserted in the pancreatic duct in cases of difficult biliary cannulation.
2852233|NCT03582540|Active Comparator|delayed double-guidewire technique (DGT)|In the delayed arm, once the guidewire is inserted in the pancreatic duct, the operator continues to attempt biliary cannulation with conventional technique (contrast- or guidewire-assisted). DGT is used only if 10 more minutes of conventional cannulation technique does not allow biliary access.
2852234|NCT03582527||observation group|All these patients who have been tested will be observed for further treatment and been recorded for toxicity.
2852235|NCT03582514|Experimental|Dose or volume radiation escalation|"Patients with a biopsy proven GBM referred to our hospital or patients who are diagnosed with GBM based on the MRI (judged by the neuro-oncology multidisciplinary team) are to be considered for this study.~This GBM study assesses the feasibility, safety and efficacy of a preoperative single fraction. The phase-I part has a 3+3 dose or volume escalation design. The choice of dose or volume escalation is based on tumor volume and location. After the single fraction of radiotherapy, patients will receive the standard treatment."
2852236|NCT03582501|Experimental|Healthy volunteers|All volunteers will be studied at rest and during experimental condition (lower body negative pressure)
2852237|NCT03582488|Experimental|Dementia with Lewy Bodies|18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology
2852238|NCT03582475|Experimental|Treatment (pembrolizumab, platinum-based chemotherapy)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising either etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1 (Cohort 1), or etoposide IV on days 1-3, carboplatin IV on day 1, and docetaxel IV on day 1 (Cohort 2). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2852239|NCT03582462|Experimental|IONIS FXI-LRx|Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection.
2852240|NCT03582462|Placebo Comparator|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator.
2852241|NCT03582449||Elaprase|Participants with Hunter syndrome (Mucopolysaccharydosis II) being treated with Elaprase will be evaluated for this study.
2852242|NCT03582436||Prospective cohort|Kidney transplantation
2852243|NCT03582423|Experimental|electro-acupuncture group|Eight acupoints are chosen: he gu (LI4), nei guan(PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
2852244|NCT03582423|Placebo Comparator|sham-acupuncture group|"Streitberger's non-invasive acupuncture needles (Gauge 8 × 1.2/ 0.30 × 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin by a small plastic ring instead of being inserted and the stimulation will be a pseudo-stimulation"
2852245|NCT03582410|Active Comparator|Absorbable suture|laparoscopic sacral colpopexy with absorbable suture
2852246|NCT03582410|Active Comparator|Non absorbable suture|laparoscopic sacral colpopexy with non absorbable suture
2852247|NCT03582397|Experimental|Experimental|Subjects to receive virtual reality mirror therapy via WiseMind Software (Realiteer) 3x/week for 4 weeks.
2852248|NCT03582384|Experimental|Treatment|
2852249|NCT03582371|Experimental|Aqua SUP|Patients in the Aqua SUP group will benefit from a 1 hour Aqua SUP session, twice a week, for 8 weeks in a therapeutic pool.
2852250|NCT03582371|Active Comparator|Physiotherapy|Patients in the control group will receive a conventional physiotherapy session of 1 hour, twice a week, for 8 weeks.
2852251|NCT03582358||Verrine|Patients served verrines
2852252|NCT03582358||CNO|Patients served wrapped supplements
2852253|NCT03582345|Experimental|EEG/fMRI|The presented project will include only one arm constituted by patients affected by pharmacoresistant epilepsies elegible for respective surgery. Patients will be identified by RU1 and RU2. The definition of drug-resistant epilepsy requires: (a) the failure of at least two first-line AEDs; (b) the occurrence of an average of one seizure per month for > 18 months; (c) no more than 3-month seizure free hiatus during those 18 months (Berg et al., 2006).
2852254|NCT03582332|Active Comparator|Group A in phase 1|Indomethacin 75 mg, extended release capsule twice daily
2852255|NCT03582332|Active Comparator|Group B in phase 1|Indomethacin 25 mg capsule, 2 capsule twice daily
2852256|NCT03582332|Active Comparator|Group A in phase 2|Etoricoxib 90 mg once daily
2852257|NCT03582332|Active Comparator|Group B in phase 2|Etoricoxib 60 mg once daily
2852258|NCT03582319|Experimental|Biodentine|Regenerative material for pulp therapy
2852259|NCT03582319|Active Comparator|Formocresol|Fixative agent for pulp therapy
2852260|NCT03582306|Experimental|High chlorophyll diet - intervention 1st|Participants will complete the 4 week intervention, 4 week washout, then 4 week control period (monitor only)
2852261|NCT03582306|Experimental|High chlorophyll diet - control 1st|Participants will complete the 4 week control period (monitor only), 4 week washout, then 4 week intervention
2852262|NCT03582293|Active Comparator|Tranexamic Acid|Tranexamic acid 500mg two times a day orally for a total of 28 days
2852263|NCT03582293|Placebo Comparator|PLACEBO|Placebo capsules two times a day orally for a total of 28 days
2852264|NCT03582280|Experimental|Amorous Calcium Carbonate (ACC) - Amor|"The investigational product will include:~Amor powder, each eppendorf contains 200mg Calcium~Amor Inhaled Double Pack - 1% ACC in 8 ml suspension"
2852265|NCT03582267|Experimental|Dietary Supplement|Docosahexaenoic Acid (DHA)
2852266|NCT03582267|No Intervention|No Intervention|No Docosahexaenoic Acid supplementation
2852267|NCT03582254|Experimental|[18F]-FDG PET/MR|[18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital
2852268|NCT03582228|Experimental|Virtual Envrionment for Social Communication|"Once the intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~15 minutes- Social support group (guided discussion of experiences related to weekly topic)~20 minutes- Didactic instruction~15 minutes- Role playing~10 minutes- Debriefing and group feedback"
2852269|NCT03582215|Experimental|Part 1: Product #1|
2852270|NCT03582215|Experimental|Part 1: Product #2|
2852271|NCT03582215|Experimental|Part 1: Product #3|
2852272|NCT03582215|Experimental|Part 1: Product #4|
2852273|NCT03582215|Experimental|Part 2|One sunscreen product with the highest avobenzone exposure will be selected for the second part of the study. If there is no quantifiable exposure of avobenzone for any of the sunscreen products, the formulation with the highest oxybenzone exposure will be selected for Part 2.
2852274|NCT03582202|Active Comparator|Dietetic service|Nutritional assessment and therapy by dietitian throughout the hospital stay
2852275|NCT03582202|Placebo Comparator|standard care|Nutritional handling by nurses supported by a dietician if needed
2852276|NCT03582189||Pancreatic Cancer|Approximately 10 patients with pancreatic cancer will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
2852277|NCT03582189||Liver Metastases|Approximately 10 patients with liver mets will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
2852278|NCT03582189||Hepatocellular carcinoma|Approximately 10 patients with HCC will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
2852279|NCT03582176|Placebo Comparator|Lactose Placebo|Lactose Placebo by mouth twice per day
2852280|NCT03582176|Active Comparator|Ketotifen Fumarate - 2mg|Ketotifen Fumarate 2 mg by mouth twice per day
2852281|NCT03582176|Active Comparator|Ketotifen Fumarate - 5mg|Ketotifen Fumarate 5 mg by mouth twice per day
2852282|NCT03582163||STN|Patients with Parkinson's disease who have undergone subthalamic nucleus (STN) DBS.
2852283|NCT03582163||GPi|Patients with Parkinson's disease who have undergone GPi (GPi) DBS.
2852284|NCT03582150|Experimental|Receiving Soberlink Device|
2852285|NCT03582137|Experimental|CBD Cannabis extract oral solution|Cannabidiol (CBD) Cannabis extract oral solution
2852286|NCT03582137|Placebo Comparator|placebo|Placebo oral solution
2852287|NCT03582124|Experimental|Diagnostic (panitumumab-IRDye800, surgery, NIR)|Participants receive panitumumab- IRDye800 IV over 60 minutes on day 0, and then undergo NIR and surgery within 1-5 days.
2852288|NCT03582111||Pregnant women who have a foetus with a cleft lip/palate|Pregnant women who have a foetus with a cleft lip/palate
2852289|NCT03582098||Idelalisib and Rituximab|Individuals who received treatment for CLL with at least one dose of idelalisib and rituximab in accordance with the marketing authorisation.
2852290|NCT03582085|Experimental|Bacillus Calmette-Guerin (BCG)|3 BCG vaccinations spaced 1 year apart.
2852291|NCT03582085|Placebo Comparator|Placebo Comparator: Saline injections|3 saline injections spaced 1 year apart.
2852292|NCT03582072|Experimental|letter|letter from the CMO: practice outside the top 20% of prescribers whose prescribing increased by > 4%, where GPs in the practice were sent a letter informing them their prescribing had increased
2852293|NCT03582072|No Intervention|control|practice outside of the top 20% of prescribers whose prescribing increase by >4%, GPs were not sent a letter
2852294|NCT03582059|Other|Patient group meeting inclusion criteria group 1|Patients meeting the inclusion criteria in the first 10 days of entering trial and are randomised to first intervention.
2852295|NCT03582059|Other|Patient group meeting inclusion criteria group 2|Patient group meeting inclusion criteria after 10 days and are allocated second intervention.
2852296|NCT03582046|No Intervention|Monitoring Group|Patients will be monitored and given sepsis standard of care.
2852297|NCT03582046|No Intervention|MAP Group|For patients with elevated IAP, Patients will be treated with sepsis standard of care, maintaining MAP level.
2852298|NCT03582046|Experimental|APP Group|For patients with elevated IAP, Patients will be treated by adjusting MAP to target and maintain APP levels
2852299|NCT03582033|Experimental|SGN-BCMA|SGN-BCMA
2852300|NCT03582020|Placebo Comparator|Traditional Western Diet|Intervention: Menu plans and recommendations for persons who consume a traditional Western diet (daily consumption of meat and sausage)
2852301|NCT03582020|Active Comparator|Flexitarians|Intervention: Menu plans and recommendations for persons, who rarely consume meat and meat products (predominantly high-quality products; ≤ 2 times / week) = flexitarians
2852302|NCT03582020|Active Comparator|Vegetarians|Intervention: Menu plans and recommendations for persons who do not eat meat and sausage (vegetarians)
2852303|NCT03582020|Active Comparator|Vegans|Intervention: Menu plans and recommendations for persons who do not eat products from animal origin (vegans)
2852304|NCT03582007|Experimental|Murepavadin|Murepavadin + ertapenem
2852305|NCT03582007|Active Comparator|Anti-pseudomonal antibiotic|One anti-pseudomonal-β-lactam-based antibiotic (either meropenem or piperacillin-tazobactam)
2852306|NCT03581994|No Intervention|Control|Not receiving any intervention/educational materials on drug-drug interaction testing
2852307|NCT03581994|Experimental|Intervention 1|Receiving educational materials on drug-drug interaction testing and a sample test report when caring for patient cases.
2852308|NCT03581994|Experimental|Intervention 2|Receiving educational materials on drug-drug interaction testing and given a sample test report if ordered when caring for patient cases.
2852309|NCT03581981|Experimental|Prolonged Exposure for Primary Care (PE-PC)|Brief version of PE provided in 30 minute sessions in PC
2852310|NCT03581981|Active Comparator|Treatment as Usual (TAU)|Veterans assigned to PCMHI-TAU will receive standard PCMHI care for PTSD in PC that does not include any PTSD-specific therapy in PCMHI but may include referral for specialty care (including specialty MH), medication management or general supportive contact while awaiting referral. All PTSD care received during the study will be collected and monitored as TAU.
2852335|NCT03581786|Experimental|JS001 combine with chemotherapy|
2852336|NCT03581773|Active Comparator|Treatment arm|5 mg of folic acid (1 tablet) per day for 12 weeks.
2852311|NCT03581968|Experimental|Closed-loop therapy|Participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be determined by the camp's physicians. The research staff will update the pump's settings to reflect the physician's recommendations at the beginning of the closed-loop therapy, and each time the physicians update the study parameters. The closed-loop therapy will last 2 days (48 hours).
2852312|NCT03581968|Experimental|Closed-loop therapy with learning module|participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be computed by the learning algorithm and updated daily. The learning algorithm runs on a computer of the research staff members and requires patient data to calculate the optimal basal rates and ICR. Each day, the research staff members will upload patient data onto the computer, run the leaning algorithm, and update the pump parameters to reflect the recommendations computed by the learning algorithm. The closed-loop therapy with the learning module will last 8 days (192 hours).
2852313|NCT03581955|Experimental|Banana Cavendish|240g of fruit plus 150ml of Fresubin ® 2kcal fiber neutral flavor
2852314|NCT03581955|Experimental|Control drink|250ml of Fresubin ® 2kcal fiber neutral flavor
2852315|NCT03581955|Experimental|Tomato|300g of tomato plus of Fresubin ® 2kcal fiber neutral flavor plus 12g of refined sunflower oil.
2852316|NCT03581942|Experimental|Copanlisib in combination with Ibrutinib|"The 3+3 design will be applied in the phase Ib portion of the trial. Participants will be assigned to the following dose levels: Dose level 1: Ibrutinib 560 mg daily + Copanlisib 60 mg weekly (3w on/1w off) Dose level 2: Ibrutinib 840 mg daily + Copanlisib 60 mg weekly (3w on/1w off) Dose level -1: Ibrutinib 560 mg daily + Copanlisib 45 mg weekly (3w on/1w off).In the phase II portion a Simon two-stage design will be used. At the first stage, 14 patients will be enrolled at the MTD. If at least 11 patients respond then an additional 19 patients will be accrued to the second stage. Participants will remain on treatment until tumor progression, as long as there are no unacceptable toxicities."
2852317|NCT03581929|Experimental|Memormax|2 vials / day of Memormax from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360.
2852318|NCT03581929|Placebo Comparator|Placebo|2 vials / day of Placebo from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360.
2852319|NCT03581916|Experimental|18F-JNJ-64326067|Participants will receive single intravenous (IV) bolus injection of 18F-JNJ-64326067 on Day 1.
2852320|NCT03581903|Experimental|H7N3 pLAIV + H7N9 pIIV|Participants will receive H7N3 pLAIV on Days 0 and 28, followed by H7N9 pIIV on Day 84.
2852321|NCT03581890||Danish Colorectal Cancer Group (DCCG.dk) database|The DCCG.dk database is a national population-based, clinical database with a completeness proportion of 99% of all colorectal cancer patients in Denmark. Patients are included in the database if treated for or diagnosed with colorectal cancer at a public surgical department in Denmark. No patients underwent treatment for colorectal cancer at private hospitals in Denmark. Metachronous cancers, recurrence, and tumors of other histological origin than primary adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, or undifferentiated carcinoma are not registered in the DCCG.dk database. The surgeon prospectively registers perioperative variables such as surgical priority, stent insertion and type of colectomy, and patient related variables. Information on postoperative mortality is imported to the database from the Danish Central Civil Registration Registry linking all Danish residents with a unique identification number.
2852322|NCT03581877|Experimental|Peripheral low dose thrombolysis|Peripheral low dose thrombolysis will use a peripheral vein into an arm as in routine intravenous therapy. This is the experimental arm. Alteplate (R-tpa) belong to thrombolytic or fibrnolytic drug class. Routine hospital policies for peripheral venous therapy will be used. A fixed dose of 24 mg of Activase (Atleplase) over 12 hours or 2.0 mg/hr will be administered peripherally. Simultaneously, intravenous unfractionated heparin will be given with a target partial thromboplastin time of 40 to 60 secs.
2852323|NCT03581877|Active Comparator|Catheter directed acoustic thrombolysis|For ACDT, routine hospital protocols and EKOS(generic) will be used. EKOS is made up of 3 parts which include the drug delivery pulmonary artery catheter, a removable microsonic device, and a reusable Eko-Sonic control unit. Venous access will be obtained by ultrasound guidance in the internal jugular vein or femoral vein. After catheter placement, the right heart pressures will be measured. R-tpa will be directly given into the pulmonary catheter. A fixed dose of 24 mg of tpa over 12 hours or 2.0mg/hr will be given. For unilateral PE, a single catheter will be used with infusion rate of 2 mg//hr and two catheters will be used for bilateral PEs each with 1 mg /hr infusion rate. Intravenous unfractionated heparin will be given with a target partial thromboplastin time of 40 to 60 secs.
2852324|NCT03581864||Group of 14 patients with post-traumatic complete anirirdia|14 eyes with post-traumatic complete aniridia and aphakia treated withscleral fixation of BD IOL with measurements included ophthalmological comorbidities, best corrected visual acuity (BCVA), complications, and postoperative interventions.
2852325|NCT03581851|Experimental|Order Sham/Hypoxia|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
2852326|NCT03581851|Experimental|Order Hypoxia/Sham|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
2852327|NCT03581838||Acitve EoE|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals who have EoE who have not been treated or have not achieved remission from treatment.
2852328|NCT03581838||Remission EoE|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals who have EoE who are have achieved remission from treatment.
2852329|NCT03581838||Controls|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals without EoE.
2852330|NCT03581812|Active Comparator|Intervention snack 1|Snack food believed to selectively promote the growth of beneficial bacterial strains in the human colon.
2852331|NCT03581812|Active Comparator|Intervention snack 2|Snack food believed to selectively promote the growth of beneficial bacterial strains in the human colon.
2852332|NCT03581812|Placebo Comparator|Control snack|Control snack food reflecting the macro-nutrient profile of a typical UK snack.
2852338|NCT03581760|Experimental|Cycling Exercise|Patients randomized into this arm will undergo cycling exercise once a day while on mechanical ventilation at intensive care unit.
2852339|NCT03581760|Active Comparator|Conventional Physiotherapy|Patients randomized into this arm will undergo conventional physiotherapy twice a day while on mechanical ventilation at intensive care unit.
2852340|NCT03581747||Subjects with atopic dermatitis|
2852341|NCT03581747||Controls|
2852342|NCT03581734|Active Comparator|OPV only|The vaccine will be available in prefilled vials containing 10 doses. Each vial will be labelled with the study ID of the participant. Therefore, for participants randomized to arm A and arm C, there will be 3 vials per participant for the 3 doses of the bOPV vaccine to be given 28 weeks apart. Any remaining, non-used doses of vaccine in the vial will be discarded.
2852343|NCT03581734|Active Comparator|Shanchol only|Each dose of vaccine is 1.5ml in volume. Each vial will be labelled with the study ID of the participant. One vial will be used per participant per study visit. OCV was studied in a double-blind, randomized, placebo-controlled trial in Kolkata, India. Participants were 1 year and above in age. In these studies, 100 children aged 1-17 were administered 2-doses of OCV or placebo separated by an interval of two weeks, with 80% of vaccinated showing over 4 fold rise in serum V. cholerae O1 antibody titers, showing that the 2-dose regimen was well-tolerated, safe and immunogenic
2852344|NCT03581734|Experimental|OPV-OCV co-administered|"Our primary analysis will be to compare seroconversion (defined as a change of status from seronegative to seropositive titers, or a ≥4-fold rise in antibody titer) for OPV1 and OPV 3 antibodies between Arm A and Arm C, to determine whether seroconversion to bOPV when administered with Shanchol is non-inferior to seroconversion to bOPV when bOPV is administered alone.~Our second objective will be to compare vibriocidal antibody seroconversion (also, ≥4-fold rise in antibody titers) to Shanchol when co-administered with OPV or when Shanchol is administered alone, Arm B compared to Arm C"
2852345|NCT03581721|No Intervention|The control group|"Control group according to usual practices: no active warming (no fluid warming). The enFlow® device will be set up but not activated. The control group will receive IV fluid coload at room temperature through the fluid warmer set to off. The device is hidden"
2852346|NCT03581721|Experimental|The warming group|"IV fluid warming with the enFlow® IV fluid warmer : Women will receive IV fluid coload warmed to 40°C through the enFlow® device. The box will be also hidden. The enFlow® will be turned off at the end of surgery, just before transfer to the PACU."
2852347|NCT03581708||advanced lung cancer|Patients diagnosed with advanced lung cancer
2852348|NCT03581695||Pulmonary Hypertension and Congenital Heart Disease|Pulmonary Hypertension and Congenital Heart Disease
2852349|NCT03581695||Congenital Heart Disease|Congenital Heart Disease
2852350|NCT03581695||Healthy Controls|Healthy Controls
2852351|NCT03581669||THA + cerclage acetabulum|
2852352|NCT03581656|Experimental|Arm|The ChordArt System is intended for chordal replacement in patients with mitral valve insufficiency due to leaflet prolapse or flail delivered through a catheter based technology for mitral chordal replacement via a small incision in the thorax.
2852353|NCT03581630|Experimental|Breast cancer subjects-naltrexone/bupropion+Mediterranean Diet|
2852354|NCT03581630|Experimental|Breast cancer subjects-Mediterranean Diet|
2852355|NCT03581630|Active Comparator|Healthy subjects-naltrexone/bupropion+Mediterranean Diet|
2852356|NCT03581617||Infertile women|Inclusion criteria for the study group will be as follows: 21-38 years old, primary infertility (no live birth), regular menstrual cycle (24-35 days), body mass index (BMI) ≤ 25, FSH <10 mUI/mL, E2 < 50 pg/ml on day 2-3 of the menstrual cycle. They will be recruited at admission for tubal patency assessment.
2852357|NCT03581617||Fertile women|Inclusion criteria for control group will be as follows: 21-35 years old, almost one live birth, regular menstrual cycle (24-35 days), BMI ≤ 25, FSH <10 mUI/mL, E2 < 50 pg/mL on day 2-3 of the menstrual cycle. Women with endometritis, endometriosis, tubal factor, ovulatory dysfunction, anatomical uterine pathologies will be excluded.
2852358|NCT03581604|Other|Patients labeled as penicillin allergic|Patients labeled as penicillin allergic will be allergologically investigated to confirm/exclude the diagnosis. Allergy work-up will be performed. Blood samples and Microbiological samples will be obtained.Questionnaire to evaluate the effectiveness of the intervention.
2852359|NCT03581604|Other|Healthy Controls|Healthy Controls, blood samples and microbiological samples.Clinical history
2852360|NCT03581591|Experimental|Primary; open label|Injection of Burosumab every two weeks based on Serum Phosphorus level of subject. Initial dose to be 0.3 mg/kg. Subsequent dosing will be titrated up or down depending on Serum Phosphorus level for that time period.
2852361|NCT03581565|Active Comparator|Technique I|"Loading of a zinc polycarboxylate (with the requirements of ISO 9917) cement to fulfill the crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): placement of mixture into crown using a heidemann Spatula Setting Time (intraoral): 2-8 minutes"
2852362|NCT03581565|Active Comparator|Technique II|"Loading of a zinc polycarboxylate (with the requirements of ISO 9917) to fill the coronal half of the crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): placement of mixture into crown using a heidemann Spatula Setting Time (intraoral): 2-8 minutes"
2852363|NCT03581565|Active Comparator|Technique III|"Application of a zinc polycarboxylate (with the requirements of ISO 9917) to the axial walls of internal surface of crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): application of mixture into crown using a bonding applicator tip Setting Time (intraoral): 2-8 minutes"
2852364|NCT03581539|Active Comparator|Group #1|Transverses Abdominis Plane (TAP) block
2852365|NCT03581539|Active Comparator|Group #2|Quadratus Lumborum (QL) block
2852366|NCT03581539|Active Comparator|Group #3|Surgeon Infiltration using Exparel
2852367|NCT03581513|Experimental|IMR＜40 and defer PCI|Patients whose IMR＜40 undergo anticoagulation and antiplatelet therapy for stent implantation one week later
2852368|NCT03581513|Active Comparator|IMR＜40 and immediately PCI|Patients whose IMR＜40 undergo immediately stent implantation
2857383|NCT03546790|Experimental|Flavor 3|Tobacco flavored tobacco cigar wrapper
2852371|NCT03581500|Experimental|Diagnostic (hyperpolarized carbon C 13 pyruvate MRSI)|Participants receive hyperpolarized carbon C 13 pyruvate IV over 10-20 seconds and undergo MRSI over 2-3 minutes at 6 and 8 weeks.
2852372|NCT03581487|Experimental|Arm I (intermittent selumetinib, durvalumab, tremelimumab)|Participants receive selumetinib PO BID on days 1-7 and 15-21 and durvalumab intravenously (IV) over 60 minutes on day 1. Participants also receive tremelimumab IV over 60 minutes on day 1 for courses 1-4. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2852373|NCT03581487|Experimental|Arm II (continuous selumetinib, durvalumab, tremelimumab)|Participants receive selumetinib PO BID on days 1-28 and durvalumab IV over 60 minutes on day 1. Participants also receive tremelimumab IV over 60 minutes on day 1 for courses 1-4. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2852374|NCT03581474|Other|aScope 3 Large|Bronchoscopic procedure
2852375|NCT03581461|Experimental|Trauma-Informed Mindfulness-Based Yoga|The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
2852376|NCT03581448|Experimental|Nerve Growth During Prosthesis Control|"Determine the optimum conditions that promote sensory restoration in limb-absent people, with an adaptive haptic feedback control law that mimics the experience of neural plasticity.~The intervention Sensory Restoration During Prosthesis Control will be used."
2852377|NCT03581435||gallbladder carcinoma patients|Cases will be the patients with newly-diagnosed gallbladder carcinoma.
2852378|NCT03581435||The controls|The controls will be matched （1：1）by sex，race and age which will be selected from the patients receiving cholecystectomy due to gallstones from the same hospital with the cases.
2852379|NCT03581422||NC-FET|pure natural cycle frozen-thawed embryo transfer
2852380|NCT03581422||mNC-FET|modified natural cycle frozen-thawed embryo transfer by hCG administration
2852381|NCT03581409|Experimental|dual-antiplatelet|Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received prasugrel 20mg. After that, dual-antiplatelet (aspirin 100mg & prasugrel 5mg) treatment continued for 3 months through study completion.
2852382|NCT03581409|Experimental|triple-antiplatelet|Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received cilostazol 200mg. After that, triple-antiplatelet (aspirin 100mg, clopidogrel 75mg, and cilostazol 200mg) treatment continued for 3 months through study completion.
2852383|NCT03581383|No Intervention|Current Care Model (Control)|The Current Care Model will not have any intervention beyond the standard of care for Hepatitis C provided by an interdisciplinary team at the University of Kentucky.
2852384|NCT03581383|Experimental|PREP-C Model|The PREP-C care model will provide Hepatitis C care with the standard interdisciplinary team expanded by a social worker and a patient navigator team. The social worker/ patient navigator team will use the standardized Psychosocial Readiness Evaluation and Preparation for hepatitis C treatment (PREP-C) tool and will guide PREP-C related interventions to overcome barriers to HCV treatment uptake and completion.
2852385|NCT03581383|Experimental|Modified ECHO Model|The modified Extension for Community Healthcare Outcomes (ECHO) Model will provide patient care through collaboration of the expanded interdisciplinary team (including social worker patient navigator team) with community providers.
2852386|NCT03581370|Active Comparator|1 hour infusion|"The first group corresponds to 1-hour infusion : First administration of ceftolozane-tazobactam with 2000 mg by infusion for 60 minutes every 8 hours.~24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48."
2852387|NCT03581370|Experimental|4 hours infusion|The second group corresponds to 4-hours infusion: First administration of ceftolozane-tazobactam with 2000 mg by infusion for 4 hours every 8 hours. 24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48.
2852388|NCT03581357|Active Comparator|Online Mindful Meditation (standard)|
2852389|NCT03581357|Active Comparator|Online Mindful Meditation (app)|
2852390|NCT03581357|No Intervention|Control|
2852391|NCT03581344|No Intervention|Control arm|Patients undergoing surgery 9-11 weeks after the end of chemoradiotherapy, whose major/complete response has to be assessed with clinical-instrumental exams to be performed 7-8 weeks after the end of chemoradiotherapy.
2852392|NCT03581344|Experimental|Experimental arm|Patients undergoing surgery 13-16 weeks after the end of chemoradiotherapy, (length of surgical interval ) showing a major/complete response at the clinical-instrumental exams to be performed 7-8 weeks after the end of chemoradiotherapy. These patients will undergo a repetition of re-staging (a second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy.)
2852393|NCT03581331|Experimental|acute unilateral vestibular loss|patients with acute unilateral vestibular loss by surgical deafferentation will performed an orthoptic balance
2852394|NCT03581318||Healthy adults|Subjects will be used as controls for adults with cardiac disease
2852395|NCT03581318||Adults with cardiac disease|Subjects will undergo MRI scans
2852396|NCT03581318||Healthy children|Healthy children will be used as controls for children with cardiac disease
2852397|NCT03581318||Children with cardiac disease|Subjects will undergo MRI scans
2852398|NCT03581305||Dopaminergic arm: Group A, HIV-positive subjects|Dopaminergic arm: Group A, HIV-positive subjects
2852399|NCT03581305||Dopaminergic arm: Group B, HIV-negative subjects with co-morbi|Dopaminergic arm: Group B, HIV-negative subjects with co-morbidities
2852400|NCT03581305||Dopaminergic arm: Group C, HIV-negative subjects without co-mo|Dopaminergic arm: Group C, HIV-negative subjects without co-morbidities
2852401|NCT03581305||Serotonergic arm: Group D, HIV-positive subjects|Serotonergic arm: Group D, HIV-positive subjects
2852402|NCT03581305||Serotonergic arm: Group E, HIV-negative subjects|Serotonergic arm: Group E, HIV-negative subjects
2852443|NCT03581032||A-Active reprogram follwed by sham|This arm will be randomized to have PACING device reprogramming followed by sham reprogramming
2852403|NCT03581292|Experimental|Treatment (veliparib, radiation therapy, temozolomide)|"CHEMORADIOTHERAPY PHASE: Participants receive veliparib PO BID and undergo 30 daily fractions of radiation therapy 5 days per week for 6-7 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CHEMOTHERAPY: Beginning 4 weeks after chemoradiotherapy phase, participants receive veliparib PO BID and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 10 courses in the absence of disease progression or unacceptable toxicity."
2852404|NCT03581279|Active Comparator|EM present|All patients must display signs/symptoms of Lyme disease as well as exhibit an EM lesion.
2852405|NCT03581279|Active Comparator|No EM present|All patients must display signs/symptoms of Lyme disease but do not have an EM lesion.
2852406|NCT03581266|Experimental|Rye|A breakfast consisting of whole slices of wholemeal rye bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
2852407|NCT03581266|Experimental|Wheat|A breakfast consisting of whole slices of refined wheat bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
2852408|NCT03581253|Experimental|peripheral facial palsy patients|"peripheral facial palsy patients will performed questionnaires of quality of life (Facial disability Index (FDi) and Facial Clinimetric Evaluation (FaCE)"
2852409|NCT03581227||Participants without a diagnosis of COPD|Men and women aged 45 to 80, who have not been diagnosed with Chronic Obstructive Pulmonary Disease (COPD)
2852410|NCT03581214|Active Comparator|Room air|Room air (no mask)
2852411|NCT03581214|Placebo Comparator|Oxygen|10L/min Oxygen by facemask
2852412|NCT03581201||Oral contraception|Healthy females at childbearing age with oral contraception.
2852413|NCT03581201||No contraception|Healthy females without any contraception at all.
2852414|NCT03581188|Experimental|Self-examination of the skin|Participants will perform self-surveillance of the skin using a dermatoscope device. They will receive guidance from the ASICA skin checker and receive reminders every 2 months to perform self-examination. They will receive an educational booklet 'Your guide to early melanoma' and scheduled visits to their clinician as required.
2852415|NCT03581188|No Intervention|Control|Participants will receive an educational booklet 'Your guide to early melanoma'and scheduled visits to their clinician as required.
2852416|NCT03581175||Cycle1|Patients undergoing colonoscopy with full bowel cleansing before the improvement phase
2852417|NCT03581175||Cycle2|Patients undergoing colonoscopy with full bowel cleansing after the improvement phase
2852418|NCT03581162||Patients|Patients with diagnosis of Juvenile Mixed Connective Tissue Disease
2852419|NCT03581162||Controls|Healthy, age-and sex-matched controls
2852420|NCT03581149|Active Comparator|Citrafleet®|Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
2852421|NCT03581149|Active Comparator|MoviPrep®|Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet.
2852422|NCT03581136|Experimental|Prescription Isodose Surface Coverage|"The dose fractionation to the CTV (1cm expansion on cavity) will be 40Gy/ 5 fractions and the PTV (3 mm expansion of CTV) will be a minimum dose of 30Gy/5 fractions.~Isodose value to which treatment dose is prescribed is usually between 65-85%, but should be greater than 50%.Optional and up to investigator -If PTV >125cc can prescribe CTV (1.0cm) to 35Gy/5 fractions and PTV (3mm) to 30Gy/5 fractions. This is to potentially reduce risk of fat necrosis"
2852423|NCT03581123|Experimental|Supported-Self management (SSM)|Supported-Self management
2852424|NCT03581123|Experimental|Spinal Manipulation Therapy (SMT)|Spinal Manipulation Therapy
2852425|NCT03581123|Experimental|SMT + SSM|Spinal Manipulation Therapy + Supported Self-Management
2852426|NCT03581123|Active Comparator|Standard Medical Care (SMC)|Standard Medical Care
2852427|NCT03581110||16-slice CT scanner|1426 patients that have received a noncontrast-enhanced chest CT on our 16-slice clinical routine CT scanner in inspiration only.
2852428|NCT03581110||2nd generation dual-source CT|320 patients that have received a noncontrast-enhanced chest CT on our second generation dual-source CT scanner in inspiration only.
2852429|NCT03581110||3rd generation dual-source CT|211 patients that have received a noncontrast-enhanced chest CT on our third generation dual-source CT scanner in inspiration and expiration.
2852430|NCT03581097|Experimental|Video Group|Patients in the film group watched the film using a laptop computer equipped with headphones, and VAS score was repeated after the movie. Video was recorded by the Anaesthesiology department team, in order to explain and show in a detailed way on a model, the sequence of events, which occurs between the arrival of patients in the operating room and the performance of intravenous regional anesthesia
2852431|NCT03581097|No Intervention|Control Group|Patients assigned to this control group were not shown the video and underwent an otherwise identical preoperative preparation procedure.
2852432|NCT03581084|Experimental|N-acetylcysteine|"This study will look at the effects of a medication, called n-acetylcysteine or NAC, on lung function. NAC is already approved for use in people with chronic airway conditions, including asthma. However, it is not known who this medication works best in. We believe this medication will likely have the most benefit in people with asthma that have mucus in their airways or mucus plugging. Initial study procedures will include lung function measurements, a low dose CT scan, a blood draw, and a sputum induction. The CT lung imaging will identify asthmatics with mucus plugs."
2852433|NCT03581071|Experimental|Step1:1mg in non-dialysis subject|
2852434|NCT03581071|Experimental|Step2-1:1mg in hemodialysis subjects|
2852435|NCT03581071|Experimental|Step2-2:6mg in non-dialysis subject|
2852436|NCT03581071|Experimental|Step3-1:11㎎ in hemodialysis subjects|
2852437|NCT03581071|Experimental|Step3-2:11㎎ in non-dialysis subject|
2852438|NCT03581058|Experimental|Cannabis - Jean Guy|A participant will be administered 1g of Jean Guy strain of cannabis.
2852439|NCT03581058|Experimental|Cannabis - Churchill|A participant will be administered 1g of Churchill strain of cannabis.
2852440|NCT03581058|No Intervention|Sober|All participants will complete same tasks sober.
2852441|NCT03581045||ALL Survivors|Adult survivors of Acute Lymphoblastic Leukemia (ALL) enrolled on the SJLIFE protocol
2852442|NCT03581045||Control Group|Healthy Individuals with no history of childhood or adult onset cancer, matched on age- and sex
2852540|NCT03580330|Experimental|Intervention Group|
2852444|NCT03581032||B-Sham followed by active reprogram|This arm will be randomized to have sham reprogramming followed by active pacing reprogramming
2852445|NCT03581019|Experimental|Uterus transplantation|Uterus transplantation
2852446|NCT03581006||Exposed Workers with Lung Injury (LI)|This observational cohort study will follow firefighters enrolled in Monitoring and Treatment Program. Investigators will include firefighters in the validation cohort who were present at the WTC site within 3 days of 9/11, have consent, and have abnormal pre-9/11 lung function
2852447|NCT03581006||Exposed Workers without Lung Injury (LI)|This observational cohort study will follow firefighters enrolled in Monitoring and Treatment Program. Investigators will include firefighters in the validation cohort who were present at the WTC site within 3 days of 9/11, have consent, and have normal pre-9/11 lung function
2852448|NCT03580993||SBT Completers|Those patients who successfully complete a spontaneous breathing trial of 2 hours.
2852449|NCT03580993||SBT Non-completers|Those patients who fail to complete a spontaneous breathing trial of 2 hours.
2852450|NCT03580980|Active Comparator|Drug: Morphine|Morphine Group C (n=30) was the control group who received IV morphine in a dose of 0.1 mg/kg after induction of anesthesia
2852451|NCT03580980|Active Comparator|Procedure/surgery:Caudal levobupivacaine|In Caudal Group (n=30), patients were placed in the lateral position and received caudal epidural block after induction of anesthesia with levobupivacaine 0.125% , 1.1 ml/kg and morphine 0.02 mg/kg with maximum 20ml.
2852452|NCT03580980|Active Comparator|Drug: Paracetamol and ketamine|The patients of Multimodal Group (n=30) received paracetamol infusion 10 mg/kg over 10 minutes and ketamine 0.5 mg/kg IV bolus followed by ketorolac 1 mg/kg infusion over 10 minutes.
2852453|NCT03580967|Other|Drug: Vortioxetine|
2852454|NCT03580954|Experimental|Repetitive TMS (estimulation)|
2852455|NCT03580954|Active Comparator|Repetitive TMS (inhibition)|
2852456|NCT03580928|Experimental|Acalabrutinib/Venetoclax/Obinutuzumab|"Acalabrutinib will be administered orally twice daily at 100 mg bid~Venetoclax will be administered orally once daily, with dose ramp-up from 20 mg up to a final dose of 400 mg~Obinutuzumab will be administered as per standard of care for 6 months with dosing at 100 mg on cycle 1 day 1, 900 mg on cycle 1 day 2, and then 1,000 mg on cycle 1 days 8, 15, and day 1 of cycles 2-6"
2852457|NCT03580915|Experimental|Functional Literacy Intervention|The intervention group will receive the functional literacy program in which, in small groups, participants learn literacy skills in the context of daily life activities such as shopping, meal preparation, and transportation use.
2852458|NCT03580915|Active Comparator|Functional Literacy Control|The control group will not receive intervention but the Usual Care Management Services.
2852459|NCT03580902|Active Comparator|Standard Buprenorphine|Participants assigned to this arm will received buprenorphine treatment consistent with standard practice at the study site. This includes induction by a physician, regular meetings with a physician for medical management, urine monitoring, and prescription of buprenorphine, with access to behavioral support services.
2852460|NCT03580902|Experimental|Standard Buprenorphine plus CBT4CBT-Buprenorphine|Participants in this condition will receive Standard Buprenorphine as described above, with the addition of access to the CBT4CBT-Buprenorphine program, which is a web-based program that covers basic knowledge about buprenorphine treatment as well as teaches cognitive and behavioral coping skills.
2852461|NCT03580889|Active Comparator|Atropine sulphate|Atropine 5 mcg/kg diluted in normal saline to total volume of 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blood pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly
2852462|NCT03580889|Active Comparator|Glycopyrrolate|Glycopyrrolate 2.5 mcg / kg diluted in normal saline to total volume of 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blold pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly.
2852463|NCT03580889|Active Comparator|Normal Saline|Normal saline 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blold pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly.
2852464|NCT03580876|Other|switch to anti-TNF alone|"Switch to the second anti-TNF drug alone (infliximab or adalimumab)~Loss of response under Infliximab: 10 mg/kg IV every 8 weeks Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC OR Loss of response under Adalimumab: 40mg EW SC Randomization to: Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks."
2852465|NCT03580876|Other|switch to anti-TNF with addition of azathioprine|"Switch to anti-TNF (infliximab or adalimumab) with addition of azathioprine~Loss of response under Infliximab: 10 mg/kg IV every 8 weeks Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC with azathioprine 2.5 mg/kg/day OR~Loss of response under Adalimumab: 40mg EW SC Randomization to:~Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks with azathioprine 2.5 mg/kg/day."
2852466|NCT03580824|Experimental|Group 1|Group 1 adults (n=20) will be administered 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the non-dominant arm).
2852467|NCT03580824|Experimental|Group 2|"Group 2A children 1-5 years (n=3) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 2B children 1-5 years (n=17) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid)."
2852541|NCT03580330|No Intervention|Control Group|
2852542|NCT03580317|Experimental|EA + Carbamazepine Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including electroacupuncture(EA) treatment and combined with Carbamazepine (0.1g each time, thrice daily). The follow-up period is 6 months.
2852618|NCT03579901|Other|Primary Breast Augmentation|Subjects age 22 and over, indicated to increase breast size
2852468|NCT03580824|Experimental|Group 3|"Group 3A infants 5-<12 months (n=3) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3B infants 5-<12 months (n=3) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3C infants 5-<12 months (n=15) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3D infants 5-<12 months (n=15) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3E infants 5-<12 months (n=15) will be receiving 5mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid)."
2852469|NCT03580811|Active Comparator|Dental Implant & ADMG|Dental implant placed with simultaneous grafting using one layer of ADMG
2852470|NCT03580811|Experimental|Dental implant & ADMG & BDX|Dental implant placed plus simultaneous grafting using ADMG with BDX
2852471|NCT03580798|Experimental|Delayed Grafting|8 weeks after extraction implant placement and simultaneous osseous grafting.
2852472|NCT03580798|Active Comparator|Simultaneous Grafting|At the time of extraction the socket will be grafted and implant placed 4 months later.
2852473|NCT03580772||Persona TKR|Patients will have undergone a medial congruent Persona total knee replacement
2852474|NCT03580772||Attune TKR|Patients will have undergone a Attune total knee replacement
2852475|NCT03580772||Control participants|Patients will not have recieved a primary TKR
2852476|NCT03580759|Experimental|Exergaming|Subjects in the exergaming group will participate in three exergaming training sessions with the Wii Fit U exergaming system. The Wii Fit U will then be left in the subjects' homes for a minimum of four weeks prior to left ventricular assist device implantation or heart transplant.
2852477|NCT03580759|No Intervention|Usual Care|Subjects in the usual care group will be encouraged to partake in physical activity as recommended in the 2017 AHA/ACC/HFSA guidelines for heart failure.
2852478|NCT03580746||Taping and posteromedial release|Children with clubfoots are treated by taping and posteromedial release
2852479|NCT03580746||Treatment by Ponseti|Children with clubfoots are treated by Ponseti
2852480|NCT03580733|Placebo Comparator|placebo|placebo
2852481|NCT03580733|Experimental|antifungal therapy|caspofungin
2852482|NCT03580720|Experimental|Intervention|Intervention group, receiving Inspiratory threshold loading protocol.
2852483|NCT03580707|Active Comparator|Part 1|Compare rapidity of CNS effects of levetiracetam (LEV) & brivaracetam (BRV) within same pt-(randomized, two-way crossover, dbl-blind in total 16 pts w/epilepsy. Pt 1: IV infusion over 15 min BRV will also be administered as 15-min.infusion. BRV vs LEV in randomized double blinded, crossover fashion.
2852484|NCT03580707|Active Comparator|Part 2|Pt 2 Op I:Assuming statistically signify. diff. in rapidity of CNS action has been observed from an analysis of data set in Pt 1,will proceed w/ Pt 2Opt I. Levetiracetam (LEV) or brivaracetam (BRV administered in randomized, two-way crossover, dbl-blind design as IV infusion over 5 min. to another cohort of 8 pts w/photosensitive epilepsy OR Pt 2,Opt II: Assuming no statistically signif. diff. in rapidity of CNS action has been observed from an analysis of data set in Pt 1, will proceed w/Pt 2,Opt II. LEV or BRV will be administered, in randomized, two-way crossover, dbl-blind design as IV infusion over again 15 min. to another cohort of 8 pts w/ photosensitive epilepsy. LEV will be given as 500 mg dose & BRV as 25 mg dose. BRV vs LEV in randomized double blinded, crossover fashion.
2852485|NCT03580694|Experimental|Cemiplimab Monotherapy|In a single dose escalation cohort, participants will receive cemiplimab alone.
2852486|NCT03580694|Experimental|Combination Therapy|"Dose Escalation cohorts:~In 3 dose escalation cohorts, participants will receive a lead-in dose of REGN4659 followed by REGN4659 and cemiplimab in combination.~In 4 dose escalation cohorts, participants will receive REGN4659 with cemiplimab in combination.~Dose Expansion cohorts:~In dose expansion cohorts, participants will receive combination regimens of REGN4659 and cemiplimab."
2852487|NCT03580681|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
2852488|NCT03580681|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
2852489|NCT03580668||B/F/TAF|Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) therapy in HIV-1 infected adults who initiate B/F/TAF therapy
2852490|NCT03580655|Experimental|Avapritinib|Avapritinib will be administered as an immediate release tablet, orally, at a dose of 200 mg QD, continuously, in 28-day cycles
2852491|NCT03580642|Experimental|eHealth Technologies|eHealth Technologies is a messure of diferent paramenters of the patient; heart rate, blood pressure, weight, thermometer, daily activity.
2852492|NCT03580642|No Intervention|Control|Habitual treatment.
2852493|NCT03580629|Experimental|Liver Live Donor Champion|The Liver Live Donor Champion program (LLDC) is the sole educational intervention for this trial. LLDC consists of 2 or 3 monthly sessions (depending on cohort) of approximately 2 or 3 hours each. Each LLDC session is led by a transplant physician or clinical coordinator. The sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LLDC session topics are as follows: 1) education about End-Stage Liver Disease (ESLD), liver transplantation, and living donation 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) surgeon and hepatologist panel 6) Program Recap.
2852494|NCT03580616|Experimental|L-Serine|L-Serine 15 grams orally twice a day as tolerated for 6 months
2852495|NCT03580603|Experimental|Antibiotic visualization tool|Provider will answer microbiological sensitivity questions using a new antibiotic visualization tool.
2852496|NCT03580603|No Intervention|Standard practice|Provider will answer microbiological sensitivity questions using standard medical record tools.
2852497|NCT03580590|Experimental|1st group|20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative
2852498|NCT03580590|Experimental|2nd group|20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative+ 10 mg/kg IV Tranexamic Acid slow infusion with saline half an hour before the induction of anesthesia
2852499|NCT03580590|Placebo Comparator|3rd group|20 patients will receive oral placebo tablet 3 hours pre-operative
2852577|NCT03580161||99mTc DMSA(III) Renal Scan|Patients receiving routine diagnostic scan
2852578|NCT03580161||99mTc MAG3 Renal Scan|Patients receiving routine diagnostic scan
2852500|NCT03580577||Cirrhotic with venous thromboembolism|"cirrhotic patients with a venous thromboembolic event (including deep venous thrombosis, pulmonary embolism, acute non-malignant portal vein thrombosis, splenic vein, inferior vena cava thrombosis or mesenteric vascular occlusion).~Each patient will subjected to through history taking and careful examination to detect and risk factors also laboratory work to detect thrombocytopenia, disease severity, coagulation status thrombelastography before starting anticoagulants.~Patients will start treatment with anticoagulants therapy after liaise with the specialized physician.~Protein C, protein S and antithrombin III level will be assessed 3 months after the acute thrombotic event and 1 month of vitamin K antagonist (VKA) withdrawal."
2852501|NCT03580577||Cirrhotic without venous thromboembolism|"cirrhotic patients without any thrombotic events Each patient will subjected to through history taking and careful examination to detect and risk factors.~- Protein C, protein S and antithrombin III level will be assessed at baseline."
2852502|NCT03580564|Experimental|Experimental|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
2852503|NCT03580551|Experimental|Intervention Group|Ten participants from each racial group (Black/White) will be assigned to the Intervention, which will receive the home-based DVD Chair Exercise Program. This is the group that will receive the chair exercise intervention upon enrollment.
2852504|NCT03580551|Active Comparator|Waitlist Control Group|Ten participants from each racial group (Black/White) will be assigned to the Waitlist Control Group, which will receive the home-based DVD Chair Exercise Program at the end of 8 weeks.
2852505|NCT03580538|Experimental|elastic tube group|
2852506|NCT03580525|Experimental|nicotine saline infusion 0.00mcg/kg/s|0.00 mcg/kg/s The day order will be randomized per day
2852507|NCT03580525|Experimental|nicotine infusion 0.24mcg/kg/s|0.24mcg/kg/s The day order will be randomized per day
2852508|NCT03580525|Experimental|nicotine infusion 0.096mcg/kg/s|0.096mcg/kg/s The day order will be randomized per day
2852509|NCT03580525|Experimental|nicotine infusion 0.048mcg/kg/s|0.048mcg/kg/s The day order will be randomized per day
2852510|NCT03580525|Experimental|nicotine infusion 0.024mcg/kg/s|0.048mcg/kg/s The day order will be randomized per day
2852511|NCT03580512||Group 1|- 800 existing clients who already received PrEP
2852512|NCT03580512||Group 2|"800 new clients who present for HIV testing and are HIV-negative. All will be offered PrEP~600 clients who will refuse PrEP~200 clients who will receive PrEP"
2852513|NCT03580512||Group 3|- 400 new clients who are HIV-positive or new clients who present for HIV testing and are HIV-positive
2852514|NCT03580499|Experimental|Supportive Care (vitamin B6)|Participants receive vitamin B6 PO daily for 12 weeks.
2852515|NCT03580486||Patients with Parkinson's Disease|Parkinson's Disease (Hoehn and Yahr stage 1-4)
2852516|NCT03580486||Healthy controls|Healthy people
2852517|NCT03580473|Experimental|SATURNO II|1 drop, 4 times a day, in the eye to be operated, 1 day before surgery until 15 days after surgery
2852518|NCT03580473|Active Comparator|Vigadexa®|1 drop, 4 times a day, in the eye to be operated, 1 day before surgery until 15 days after surgery
2852519|NCT03580460|No Intervention|Waitlist control|After 8 weeks, individuals randomized to this arm receives the computer-delivered smoking cessation counseling intervention
2852520|NCT03580460|Experimental|Computer Delivered Intervention|Individuals receive a 15-20 minute computer delivered smoking cessation counseling intervention
2852521|NCT03580447|Experimental|Citrus extract|During this period participants receive daily citrus extract supplements for four weeks
2852522|NCT03580447|Placebo Comparator|Placebo|During this period participants receive daily maltodextrin supplements for four week
2852523|NCT03580434|Experimental|V-STRUT|V-STRUT implantation
2852524|NCT03580421|Active Comparator|standard pathway group|this group will benefit from standard care including: one surgical consultation, one anesthesia consultation, surgery followed by 2-4 days of hospitalization and 3 post-operative consultations (M1, M6, M12) during the first operative year
2852525|NCT03580421|Experimental|ambulatory pathway group|Preoperative and postoperative protocols will be applied for optimizing same-day discharge. Gynaecologists, anaesthetists, and nursing staff will work as a team. A specific anesthesia consultation will focus on ambulatory surgery management. A geriatric evaluation will be offered to women over 70 years old with a score ≤14 according to G8 screening tool. A dietetic evaluation will be offered to women with BMI ≥ 35. A nursing consultation will be offered, as patient and their family preparation prior to ambulatory surgery is important.
2852526|NCT03580408|Experimental|Experimental|"Induction treatment :Nivolumab will be given alone at 240 mg flat dose every 2 weeks (i.e. one cycle) Patients will be assessed after 3 months of therapy (after 6 injections of Nivolumab)~Consolidation treatment:~It depends on the induction evaluation by PET-CT and CT-scan (Lugano 2014 criteria) :~For patients achieving CMR according to Lugano Classification : treatment by nivolumab 240 mg every 2 weeks for 9 months.~Patients who reach PMR and NMR after 3 months (according to Lugano Classification) will be treated by the Nivolumab+Vinblastin regimen every 2 weeks for 9 additional months: Vinblastin(6 mg/m2 (IV) + Nivolumab 240 mg (IV)~In case of progressive disease , patients will be considered in treatment failure."
2852527|NCT03580395|Experimental|apatinib+TP|TP neoadjuvant chemotherapy (paclitaxel 165mg/m2 day 1, cisplatin 40mg, day 1-3) combined with apatinib (received TP concurrently with apatinib 500mg, day1-21).
2852528|NCT03580395|Sham Comparator|TP|TP neoadjuvant chemotherapy alone (paclitaxel 165mg/m2 day 1, cisplatin 40mg, day 1-3).
2852529|NCT03580382|Experimental|NRAS mutant melanoma|C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
2852530|NCT03580382|Experimental|WT melanoma|C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
2852531|NCT03580369|Experimental|Ligelizumab Dose A|Ligelizumab Dose A q4w
2852532|NCT03580369|Experimental|Ligelizumab Dose B|Ligelizumab Dose B q4w
2852533|NCT03580369|Active Comparator|Omalizumab 300 mg|Omalizumab 300 mg q4w
2852534|NCT03580369|Placebo Comparator|Placebo|Placebo q4w from randomization to week 20. Ligelizumab Dose B from week 24 to week 48.
2852535|NCT03580356|Experimental|Ligelizumab Dose A|Ligelizumab Dose A q4w
2852536|NCT03580356|Experimental|Ligelizumab Dose B|Ligelizumab Dose B q4w
2852537|NCT03580356|Active Comparator|Omalizumab 300 mg|Omalizumab 300 mg q4w
2852538|NCT03580356|Placebo Comparator|Placebo|Placebo q4w from randomization to week 20. Ligelizumab Dose B from week 24 to week 48.
2852539|NCT03580343|Experimental|Tofacitinib Treatment|
2852543|NCT03580317|Placebo Comparator|EA + Placebo Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including EA treatment and combined with placebo of carbamazepine. The follow-up period is 6 months.
2852544|NCT03580317|Active Comparator|Sham EA+ Carbamazepine Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham electroacupuncture(sham EA) intervention and combined with carbamazepine. The follow-up period is 6 months.
2852545|NCT03580317|Sham Comparator|Sham EA+ Placebo Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham EA intervention and combined with placebo took orally. The follow-up period is 6 months.
2852546|NCT03580304|Experimental|industrial-physical-cognitive|
2852547|NCT03580304|Experimental|industrial- cognitive-physical|
2852548|NCT03580304|Experimental|physical- industrial- cognitive|
2852549|NCT03580304|Experimental|physical-cognitive- industrial|
2852550|NCT03580304|Experimental|cognitive- industrial-physical|
2852551|NCT03580304|Experimental|cognitive-physical-industrial|
2852552|NCT03580291|Experimental|Mesenchymal stem cells|"The group receive pulse infusion of MSCs and placebo of oral Mycophenolate Mofetil (MMF). The cells of 2 x 10^6/kg body weight are suspended in 100ml saline and infused intravenously.~Dexamethasone of 10mg is intravenously injected before 30 minutes of cells infusion.~A sterile blood transfusion device is used during the venous transfusion, and it is washed with saline before infusion. Take a slow infusion of about 20 drops per minute in the first 15 minutes. Increase to about 60 drops per minute if the patient had no complaints of discomfort."
2852553|NCT03580291|Active Comparator|Mycophenolate Mofetil|The group receive placebo of MSCs and oral Mycophenolate Mofetil of 2.0g/d. .
2852554|NCT03580278|Experimental|Cohort 1: 25 mg ABY-035/AFO2|Cohort 1: 25 mg ABY-035/AFO2 once daily for 14 days
2852555|NCT03580278|Experimental|Cohort 2:75 mg ABY-035/AFO2|Cohort 2: 75 mg ABY-035/AFO2, once daily for 14 days
2852556|NCT03580278|Experimental|Cohort 3: 150 mg ABY-035/AFO2|Cohort 3: 150 mg ABY-035/AFO2 once daily for up to 28 days
2852557|NCT03580265|Experimental|Six-sessions of laser acupuncture|Laser acupuncture was given three times a week for 2 weeks.
2852558|NCT03580265|Sham Comparator|Six-sessions of sham laser acupuncture|Sham laser acupuncture was given three times a week for 2 weeks.
2852559|NCT03580252||Preterm Infant Neurological Follow-Up|"Preterm infants <37 weeks' gestational age (GA) at birth admitted to the neonatal nurseries at the Abha Private Hospital in Kingdom of Saudi Arabia. This project aims to recruit 50 infants <37weeks at birth over a 1-year stating from march 2018.~A Correlation analyses for the outcomes with initial regular medical practice of MRI/Ultrasound and Hammersmith assessment."
2852560|NCT03580239|Experimental|Everolimus & Best Supportive Care|Everolimus will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
2852561|NCT03580239|Placebo Comparator|Placebo & Best Supportive Care|Placebo will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
2852562|NCT03580226||Good glycemic control|Good glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c < 7.0.
2852563|NCT03580226||Poor glycemic control|Poor glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c >= 7.0.
2852564|NCT03580213|Experimental|Hand therapy MCPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected, receiving hand therapy after collagenase injection and extension treatment.~Hand therapy: edema control, wound and scar treatment, splinting, exercises for hand, exercise through activities of daily living."
2852565|NCT03580213|Experimental|Hand therapy PIPJ affected|"40 participants With Dupuytren's contracture with the proximal interphalangeal joint involved, receiving hand therapy after collagenase injection and extension treatment.~Hand therapy: edema control, wound and scar treatment, splinting, exercises for hand, exercise through activities of daily living. Possible additional splint and exercises specifically for the PIPJ extension."
2852566|NCT03580213|No Intervention|Control group MCPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected.~No treatment after the collagenase injection and extension treatment."
2852567|NCT03580213|No Intervention|Control group PIPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected.~No treatment after the collagenase injection and extension treatment."
2852568|NCT03580200|Experimental|Intervention Side|Each participant is to be randomly assigned an intervention side (side of the body that will receive trigger point dry needling) and a control side (side of the body that will not receive trigger point dry needling).
2852569|NCT03580200|No Intervention|Control Side|Each participant is to be randomly assigned an intervention side (side of the body that will receive trigger point dry needling) and a control side (side of the body that will not receive trigger point dry needling).
2852570|NCT03580187|Other|morphine +|"We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success.~morphine (+) group: good response to morphine in nebulization after 30 min if VAS > than 4 we conclude to morhine (-)"
2852571|NCT03580174|Active Comparator|Goal directed physiotherapy group|Ten children with CP will receive structural, comprehensive activity based, goal directed physiotherapy
2852572|NCT03580174|Active Comparator|Routine physiotherapy group|Ten children with CP will receive conventional, traditional physiotherapy
2852573|NCT03580161||18-F FDG PET/CT|Patients receiving routine diagnostic scan
2852574|NCT03580161||Ga-68 PSMA PET/CT|Patients receiving routine diagnostic scan
2852575|NCT03580161||68-Ga Dotatate PET/CT|Patients receiving routine diagnostic scan
2852576|NCT03580161||99mTc Pertechnetate Thyroid Scan|Patients receiving routine diagnostic scan
2861842|NCT03516071|Experimental|Brivanib 800 mg, QD + BSC|
2852580|NCT03580148|Active Comparator|Cortisone|Patients randomized to this arm will receive one (1) ultrasound guided injection of 80mg Depo Medrol cortisone in the glenohumeral joint of the affected shoulder. Procedure time of approximately 10 minutes
2852581|NCT03580148|Active Comparator|Bone Marrow Aspirate|Patients randomized to this arm will receive one (1) ultrasound injection of bone marrow aspirate, harvested from the posterior superior iliac spine, and injected into the glenohumeral joint of the affected shoulder. Procedure time of approximately 45 minutes
2852582|NCT03580135|Experimental|Propolis powder|"resin (50%),~vegetable Balsam, wax~essential aromatic oils (30%)~salivary secretions (10%)~pollen(5%)~other substances (5%) including amino acids~,ethanol vitamin A, B complex, and E, minerals, steroids~ﬂavonoids. The most important pharmacologically active constituents in propolis are ﬂavonoids, which are well-known compounds which have antioxidant, anti-bacterial, antifungal, antiviral, and anti-inﬂammatory properties.~Other ingredients: carob powder (free flow agent). Contains no yeast, salt, sugar, starch, milk, preservatives or colors."
2852583|NCT03580135|Active Comparator|Mineral Tri Oxide|"Consists of calcium oxide and silicon dioxide.When these raw materials are blended, they produce tricalcium silicate, dicalcium silicate, tricalcium aluminate, and tetracalcium aluminoferrite.~A radiopacifier (bismuth oxide) is added to the cement for dental radiological diagnosis."
2852584|NCT03580122|Experimental|Asparten|Asparten (arginine aspartate) 5000mg/10mL 3x/day
2852585|NCT03580109|Active Comparator|Immediate spa treatment|Spa treatment linked with education therapeutic during 18 days just after randomization : common to all of spa resorts
2852586|NCT03580109|Sham Comparator|Late spa treatment|Spa treatment linked with education therapeutic during 18 days 6 months visit after randomization
2852587|NCT03580096|Experimental|Experimental group|Patients were included in a core stability intervention. It will be done with different stages and increasing gradually.
2852588|NCT03580096|Active Comparator|Control group|Standard intervention consisting of exercises aimed at improving balance.
2852589|NCT03580083|Experimental|Dose 1; 2x10^9 GC/g brain mass of RGX-111|
2852590|NCT03580083|Experimental|Dose 2; 1x10^10 GC/g brain mass of RGX-111|
2852591|NCT03580057|Experimental|Breastfeeding promotion intervention (BPI)|
2852592|NCT03580057|Experimental|Diet- and weight loss intervention (D)|
2852593|NCT03580057|Experimental|BPI and D|Both interventions.
2852594|NCT03580057|No Intervention|Control|
2852595|NCT03580044|Experimental|ATM- AVI|Aztreonam- Avibactam (ATM-AVI) Active Treatment Arm
2852596|NCT03580044|Active Comparator|BAT|Best Available Therapy (BAT) Comparator Treatment Arm
2852597|NCT03580031|Experimental|Study group|HCG IM 10,000 IU Im 48 hours after first triggering dose
2852598|NCT03580031|Placebo Comparator|Control group|Saline 2m Injection im 48 hours after the first triggering dose
2852599|NCT03580018|Experimental|Tranexamic Acid group|Ten mL of TXA (100 mg/mL) was injected into the joint at the end of the index operation and the drain was clamped for 2 h.
2852600|NCT03580018|Placebo Comparator|Control Group|The control group patients only received ACLRs without TXA injections.
2852601|NCT03580005|Other|methylphenidate HCl ERCT|methylphenidate HCl ERCT
2852602|NCT03579992|Experimental|60-minute Isometric|60-min Isometric MyCI training: EMG-controlled game training for 60-minutes per session
2852603|NCT03579992|Experimental|90-minute Isometric|90-min Isometric MyCI training: EMG-controlled game training for 90-minutes per session
2852604|NCT03579992|Experimental|90-minute Movement|90-min movement MyCI training: EMG-controlled game training for 90-minutes per session
2852605|NCT03579979|Experimental|Self control|"During the operation, with the fluorescent molecular imaging instrument, the imaging agent (indocyanine green) is illuminated by the probe distance to the tissue surface 10-30cm, and is excited to produce the near infrared fluorescence of the specific wavelength (the human eye is not visible). The system uses a photoelectric coupler to collect the light of the specific spectrum, and the image is collected by the method of correction. The operation was performed to achieve real-time display of lesions.~The injection points were selected subcutaneously around the areola or the periphery of the tumor. 1% methylene blue 0.5ml was injected at each point, with a total of 2-3 points. Within 5 minutes, 2.5mg/ml ICG 0.5ml was injected at each point, with a total of 2-3 points."
2852606|NCT03579966|Experimental|amifampridine phosphate|tablets equivalent to 10mg amifampridine, 3 to 4 times per day
2852607|NCT03579953|Experimental|Real cTBS to MPFC|One session of real cTBS treatment delivered to the medial prefrontal cortex (MPFC) (2 trains of stimulation over the MPFC as defined by EEG coordinates (FP1); each train: 120 sec, 3 pulse bursts presented at 5Hz, 15 pulses/sec, 1800 pulses/train, 60 sec intertrain interval; 110% RMT, MagPro X100 Cool Coil; 3600 pulses total).
2852608|NCT03579953|Sham Comparator|Sham cTBS to MPFC|One session of sham cTBS treatment delivered to the medial prefrontal cortex (MPFC) (2 trains of stimulation over the MPFC as defined by EEG coordinates (FP1); each train: 120 sec, 3 pulse bursts presented at 5Hz, 15 pulses/sec, 1800 pulses/train, 60 sec intertrain interval; 110% RMT, MagPro X100 Cool Coil; 3600 pulses total).
2852609|NCT03579940|Experimental|Lasmiditan - Japanese|Lasmiditan administered orally in up to three of three study periods.
2852610|NCT03579940|Placebo Comparator|Placebo - Japanese|Placebo administered orally in up to one of three study periods.
2852611|NCT03579940|Experimental|Lasmiditan - Caucasian|Lasmiditan administered orally in up to three of three study periods.
2852612|NCT03579940|Placebo Comparator|Placebo - Caucasian|Placebo administered orally in up to one of three study periods.
2852613|NCT03579927|Experimental|Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT)|Participants receive rituximab IV over 3 hours on days -14 and -8, carmustine IV over 2 hours on day -13, etoposide IV over 3 hours BID on days -12 to -9, cytarabine IV over 1 hour BID on days -12 to -9, melphalan IV over 30 minutes on day -8, CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV over 1 hour on day -5. Participants undergo ASCT on day 0. Beginning day 0, participants receive filgrastim SC QD until evidence of an ANC of 0.5 x 10^9/L per 3 consecutive days.
2852614|NCT03579914|Placebo Comparator|Placebo group|Patients receive intravenous placebo injection.
2852615|NCT03579914|Experimental|Intravenous metoprolol group|Patients receive intravenous metoprolol injection.
2852616|NCT03579914|Experimental|RIPC group|Patients receive RIPC treatment.
2852617|NCT03579914|Experimental|Intravenous metoprolol and RIPC group|Patients receive intravenous metoprolol injection and RIPC treatment.
2852619|NCT03579901|Other|Primary Breast Reconstruction|Surgery to replace breast tissue that has been removed due to cancer, prophylactic mastectomy, breast trauma or that has failed to develop properly due to a severe breast anomaly.
2852620|NCT03579901|Other|Revision Augmentation|Revision surgery to correct or improve the results of a previous breast augmentation
2852621|NCT03579901|Other|Revision Reconstruction|Revision surgery to correct or improve the results of a previous breast reconstruction.
2852622|NCT03579888|Experimental|Treatment (fludarabine, cyclophosphamide, T cell infusion)|"CHEMOTHERAPY: Participants receive fludarabine IV over 1 hour and cyclophosphamide IV over 3 hours on days -5, -4, and -3 in the absence of disease progression or unacceptable toxicity.~T CELL INFUSION: Participants receive CD19+ specific chimeric antigen receptor T cells IV over 15-30 minutes on day 0 in the absence of disease progression or unacceptable toxicity."
2852623|NCT03579862||Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|
2852624|NCT03579862||Pulmonary Embolism (PE)|
2852625|NCT03579862||Pulmonary Arterial Hypertension (PAH)|
2852626|NCT03579849|Experimental|Perfusion SPECT|"Included patients with a diagnosis of acute PE on CTPA and who had a subtraction iodine mapping CT will undergo a SPECT/CT within 24 hours.~Each lung subtraction iodine mapping CT will be interpreted blindly by 3 radiologists. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused.~Each perfusion SPECT will be interpreted blindly by 3 nuclear medicine physicians. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused."
2852627|NCT03579836|Experimental|Phase I-1, cohort 1|BEY1107(25mg) in monotherapy (cycle 1, 4 weeks)
2852628|NCT03579836|Experimental|Phase I-1, cohort 2|BEY1107(50mg) in monotherapy (cycle 1, 4 weeks)
2852629|NCT03579836|Experimental|Phase I-1, cohort 3|BEY1107(100mg) in monotherapy (cycle 1, 4 weeks)
2852630|NCT03579836|Experimental|Phase I-1, cohort 4|BEY1107(150mg) in monotherapy (cycle 1, 4 weeks)
2852631|NCT03579836|Experimental|Phase I-2, cohort 1|BEY1107(50mg) in combination with Gemcitabine (cycle 1, 4 weeks)
2852632|NCT03579836|Experimental|Phase I-2, cohort 2|BEY1107(100mg) in combination with Gemcitabine (cycle 1, 4 weeks)
2852633|NCT03579836|Experimental|Phase I-2, cohort 3|BEY1107(150mg) in combination with Gemcitabine (cycle 1, 4 weeks)
2852634|NCT03579836|Experimental|Phase II|BEY1107(RP2D) in combination with Gemcitabine (cycle 6, 24 weeks)
2852635|NCT03579823|Experimental|AVT02 100 MG/ML|Single subcutaneous injection of 40 mg of AVT02 (100MG/ML)
2852636|NCT03579823|Active Comparator|Adalimumab 100 MG/ML [HUMIRA]|Single subcutaneous injection of 40 mg of Adalimumab (100MG/ML) [HUMIRA]
2852637|NCT03579810|Experimental|Investigational|"An education intervention was implemented in 5 schools including 516 children, 360 parents and 240 teachers.~The Pedagogical Intervention last two and a half years. In children, the intervention included class activities (1/week) and the use of educational materials for the development of pedagogical activities (posters and educative guide).~In parents included 3 workshops/year (2 hours each) about the areas of the intervention; sending healthy notes (1/month) and celebration of healthy family day (1/year).~In teachers included 3 workshops/year (2 hours each) about the areas of the intervention; planning and realization of pedagogical activities to develop with the students (1/week) and follow-up visits to school (1/month)."
2852638|NCT03579810|Active Comparator|Control|"The control group consisted of 4 schools including 354 children, 305 parents and 110 teachers.~The activities in control group last two and a half years. Children received the standard curriculum in health and physical activity of the national Ministry of Education.~In parents and teachers included 3 workshops/year (2 hours each) about the first aid and accident prevention."
2852639|NCT03579784|Experimental|Durvalumab+Olaparib+Paclitaxel|"st cycle : Paclitaxel+Olaparib~Olaparib 150mg bid on D1-28~Paclitaxel 80 mg/m2 mg iv on D1, D8, D15~nd cycle and thereafter: Durvalumab+Olaparib+Paclitaxel :~Olaparib 150mg bid on D1-28~Durvalumab 1.5 g iv on D1~Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks~During first 4 weeks, palictaxel/olaparib dual combination will be used. Since 2nd cycle, palictaxel/olaparib/Durvalumab combination will be used."
2852640|NCT03579771|Experimental|Gemcitabine, cisplatin, nab-paclitaxel|Participants receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants with stable disease (SD), partial response (PR), or complete response (CR) then undergo standard of care hepatectomy with portal lymphadenectomy.
2852641|NCT03579758|Active Comparator|Arm I (capecitabine)|Participants undergo re-resection (including partial liver resection and portal lymph node dissection). Participants then receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
2852642|NCT03579758|Experimental|Arm II (chemotherapy, capecitabine)|Participants receive cisplatin IV over 1 hour and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Within 10 weeks of chemotherapy, participants undergo re-resection (including partial liver resection and portal lymph node dissection). Participants then receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
2852643|NCT03579745|Active Comparator|Conventional lingual mechanics|
2852644|NCT03579745|Experimental|Lever arm lingual mechanics|
2852645|NCT03579732||Long-term users|Adults using low-dose aspirin for > 3 years
2852646|NCT03579732||Episodic users|Adults using low-dose aspirin inconsistently, or consistently but < 3 years
2852647|NCT03579732||Former users|Subset of adult Episodic users of aspirin who discontinued the drug for at least 1 year before case/ control date
2852648|NCT03579732||Non-consumers|Adults who did not use low-dose aspirin
2852649|NCT03579719|Experimental|Balovaptan + Itraconzole|Dosing in Period 1 will be separated by at least a 7 day washout period before dosing starts in Period 2. Participants will receive the study drugs in 2 periods over a total of 37 days.
2852650|NCT03579706|Experimental|Intervention|The intervention condition will involve participants completing baseline measures, the Cognitive Anxiety Sensitivity Treatment, post measures, and a 4 month follow up assessment.
2852651|NCT03579706|Placebo Comparator|Control|The control condition will involve participants completing baseline measures, the Physical Health Education Training, post measures, and a 4 month follow up assessment.
2852652|NCT03579693|Active Comparator|CoQ10|Coenzyme Q10, 2 - 250 mg tablets twice a day (1000 mg total daily dose) for 6 weeks
2852653|NCT03579693|Active Comparator|Nicotinamide riboside|Nicotinamide riboside, 1 - 600 mg tablet twice a day (1200 mg total daily dose) for 6 weeks
2852654|NCT03579693|Placebo Comparator|Placebo|Placebo, inactive sugar pill for 6 weeks
2852655|NCT03579680||Providers|Urologists and other providers who have experience caring for more than 10 prostate cancer patients on ADT and express interest in prostate cancer care for prostate cancer will be eligible to participate. Providers will engage in a 30-45 minute interview to identify key preferences and de-implementation barriers, as well as facilitators, for reducing low value ADT as prostate cancer (PC) treatment.
2852656|NCT03579680||Patients|Patients receiving ADT as primary prostate cancer treatment will engage in a 30-45 minute interview regarding to better understand patient perspectives into not initiating or stopping castration with ADT
2852657|NCT03579667|Experimental|Diet intervention|
2852658|NCT03579667|No Intervention|Control|
2852659|NCT03579654|Experimental|Arm 1 - Proscavax vaccine treatment|In this arm, during the first 4 months of induction treatment, 6 doses of the Proscavax vaccine will be administered intradermally at weeks 1, 2, 3, 7, 11, and 15, followed by maintenance booster injections once every month which will alternate between low dose IL-2 alone (at weeks 19, 27 and 35) and Proscavax vaccine (at weeks 23, 31, 39) for 6 months.
2852660|NCT03579654|No Intervention|Arm 2 - Active Surveillance|In this arm, patients will undergo active surveillance and will not receive any Proscavax vaccine treatment.
2852661|NCT03579641||BSC ICD or CRT-D with HeartLogic™|Patients with Heart Failure, implanted with BSC ICD or CRT-D inclusive of the HeartLogic™ feature
2852662|NCT03579628|Experimental|AsiDNA|"This phase 1 will follow a dose escalation 3 + 3 cohort design (with 6 dose levels).~All patients will receive a loading dose of AsiDNA for 3 consecutive days as iv infusion at Day 1 (D1), Day 2 (D2) and Day 3 (D3), followed by iv infusion once a week (at D8 and D15 of a 21 days treatment period (1 cycle = 21 days). Each subsequent cycle will be administered on a weekly basis (D1, D8, D15) of a 21 days treatment period."
2852663|NCT03579615|Experimental|FIASP + closed loop device|Subjects randomised to FIASP and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using FIASP + closed loop intervention for 24 hours. Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
2852664|NCT03579615|Active Comparator|Insulin aspart (standard of care insulin) + closed loop device|Subjects randomised to insulin aspart (standard of care insulin) and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using insulin aspart (standard of care insulin) + closed loop intervention for 24 hours.Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
2852665|NCT03579602|Active Comparator|Arm 1 (no tozuleristide)|Subjects randomized to Arm 1 (~9% of subjects) will not receive tozuleristide but will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.
2852666|NCT03579602|Experimental|Arm 2 (tozuleristide treated)|Subjects randomized to Arm 2 (~ 91% of subjects) will be administered tozuleristide at a dose of 15 mg/m^2 at least 1 hour and no more than 36 hours prior to surgery. They will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.
2852667|NCT03579589|Active Comparator|Sugammadex|"If spontaneous recovery has reached second twitch after TOF: 2 mg/kg~If spontaneous recovery has reached between 1-2 post-tetanic counts but no twitch responses to TOF: 4 mg/kg~When there is a clinical need to reverse NMB within 3 min of a single dose of rocuronium (1.2 mg/kg): 16 mg/kg"
2852668|NCT03579589|Active Comparator|Neostigmine|50 µg. Kg-1 will be administered after spontaneous recovery has reached fourth twitch after TOF in accordance with our institutional standard procedures and published literature.
2852669|NCT03579576||HCV infected patients|All participants found HCV infected with or without HIV will be initiated treatment and followed up until 24 weeks ( 12 weeks after treatment)
2852670|NCT03579563|Active Comparator|AUD (audiologist-based)|In this group, the audiologist-based fitting will be used to provide hearing aids.
2852671|NCT03579563|Experimental|OTC (over-the-counter)|In this group, the over-the-counter fitting will be used to provide hearing aids.
2852672|NCT03579563|Experimental|OTC-Plus|In this group, the hybrid fitting will be used to provide hearing aids.
2852673|NCT03579550|Active Comparator|Hysterocopy group|Office hyteroscopic metroplasty will be performed. After oparetion 9 months spontaneous conception
2852674|NCT03579550|No Intervention|Spontaneous cycles plus COH/IUI|Six months spontaneous coitus cycles plus 3 cycles of Clomiphene citrate and intrauterine insemination (COH/IUI)
2852675|NCT03579537|Experimental|Hemodyalisis patients|group of patients in hemodialysis who performs the exercise program
2852676|NCT03579524|Active Comparator|ESPB group|Erector Spinae Plane Block administered group
2852677|NCT03579524|Active Comparator|SAPB group|Serratus Anterior Plane Block administered group
2852678|NCT03579498||Patient group|Patients who have suffered a cardiac arrest at Uppsala University Hospital or who were admitted to this hospital after the event.
2852679|NCT03579498||Control group|The control group will, as far as it is possible, match the patient group regarding mean age, age distribution, sex and educational attainments.
2852680|NCT03579485||aging HIV positive patients|HIV-1 infected patients, aged ≥ 60 years old, naive patients receiving raltegravir based-regimen, including Nuc-sparing regimens or experienced patients with virological suppression (HIV-1 RNA<50 copies) who had switched from any antiretroviral drug to raltegravir-based regimens (including Nuc-sparing regimens) because of toxicity, convenience or other reasons.
2852744|NCT03578991|No Intervention|Arm 1|"Control group - Treatment as usual:~Type 2 diabetic patients with mild cognitive impairment who will receive the standard clinical treatment recommended by their primary care physician/endocrinologist."
2852681|NCT03579472|Experimental|Treatment (M7824, eribulin mesylate)|Participants receive anti-PD-L1/TGFbetaRII fusion protein M7824 IV over 50-80 minutes on days 1, 15, and 29, and eribulin mesylate IV over 2-5 minutes on days 1, 8, 22, and 29. Treatment repeats every 42 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
2852682|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 1|
2852683|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 2|
2852684|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 3|
2852685|NCT03579459|Placebo Comparator|Placebo|Normal saline solution (0.9% sodium chloride)
2852686|NCT03579446|Experimental|Supportive care (levorphanol, opioid regimen)|Participants receive levorphanol PO every 8 or 12 hours for 30 days. Participants may receive opioid regimen including hydrocodone, morphine sulfate, hydromorphone hydrochloride, oxycodone, and oxymorphone hydrochloride for breakthrough pain.
2852687|NCT03579433|Experimental|ORA System with VerifEye+|Acrysof® IQ Toric IOL, with lens power selected preoperatively by ORA System with VerifEye+ and Alcon Toric Calculator
2852688|NCT03579420|Experimental|Brief lifestyle program|3-session lifestyle group intervention program focussed on physical activity and eating habits, using interactive methods and a behavioral approach
2852689|NCT03579420|Active Comparator|Traditional lifestyle longer program|6-session lifestyle group intervention program focussed on physical activity and eating habits, using traditional lessons and interactive methods
2852690|NCT03579407|Active Comparator|Traditional Open Ended Trocar|Patients will undergo bone marrow aspiration using the Jamshidi bone marrow aspiration needle. This needle is the traditional trocar with an open end. 50-60 mL will be collected and concentrated with a centrifuge.
2852691|NCT03579407|Experimental|Fenestrated Blunt Trocar|Patients will undergo bone marrow aspiration using the Marrow Cellution bone marrow aspiration needle. This needle has several fenestrations along the trocar through which the bone marrow is aspirated. Approximately 8-10 mL of high concentrate bone marrow will be collected, which will not be concentrated.
2852692|NCT03579394|Active Comparator|Interval Debulking Surgery (IDS)|Complete surgery after 3 courses of neoadjuvant chemotherapy (NACT)
2852693|NCT03579394|Experimental|Retarded Interval Debulking Surgery (IDS)|Complete surgery after 6 courses of neoadjuvant chemotherapy (NACT)
2852694|NCT03579381||Immune Controllers|Patients with very low or undetectable levels of viremia without treatment
2852695|NCT03579381||Acute Infection|Early infection, i.e. within 2 weeks of infection
2852696|NCT03579368|Other|Symfony Implantation|Patients undergoing bilateral IOL implantation with the Tecnis Symfony Extended Range of Vision IOL at a single surgical site
2852697|NCT03579355|Experimental|DFND Program|"Dentist Fighting Nicotine Dependence, (DFND) intervention program consisted primarily of a 10-session curriculum, each session lasting about an hour. The curriculum was comprehensive and incorporated information about tobacco and its adverse health effects, social influences, and social competence skills. DFND was administered over 5 weeks, at a rate of 2 sessions per week. Each session lasts an hour. Fourteen classrooms in four schools represented the experimental arm and received DFND."
2852698|NCT03579355|No Intervention|Informational Booklet|Fourteen classrooms in four schools represented the No Intervention arm (control). They received only an informational booklet about tobacco adverse health effects.
2852699|NCT03579342|Experimental|App technology and coaching|Participants in the intervention group with app technology and coaching participate in a first meeting with the coach and will thereafter receive active support from the coach every 4 weeks for the duration of the intervention.
2852700|NCT03579342|Experimental|App technology only|Participants in the intervention group with only app technology participate in a first meeting with the coach but do not get any additional support during follow-up.
2852701|NCT03579342|No Intervention|Control group|Participants in the control group participate in baseline assessments. The control group will get access to the app and will have a meeting with a coach after 12 weeks of follow-up.
2852702|NCT03579316|Active Comparator|Arm I (adavosertib)|Participants receive adavosertib PO QD on days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2852703|NCT03579316|Experimental|Arm II (olaparib, adavosertib)|Participants receive olaparib PO BID on days 1-21 and adavosertib PO QD on days 1-3 and 8-10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2852704|NCT03579303|Active Comparator|Homoeopathic remedies in PCOS|Homoeopathic treatment for menstrual disorders in females with PCOS
2852705|NCT03579303|Active Comparator|Homoeopathic remedies and yoga in PCOS|Homoeopathic treatment integrated with yoga therapy for menstrual disorders in females with PCOS
2852706|NCT03579290|Experimental|CBT4CBT program|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:~Understanding and changing patterns of drug use, Coping with craving, Substance refusal skills, Seemingly irrelevant decisions, Planning for emergencies, and Problem-solving skills. Staying Safe"
2852707|NCT03579277|Active Comparator|Radial forearm free flap|Subjects in this arm will receive a radial forearm free flap.
2852708|NCT03579277|Active Comparator|Ulnar forearm free flap|Subjects in this arm will receive an ulnar forearm free flap.
2852709|NCT03579264|No Intervention|Standard Arm|No use of My Viva Plan.
2852710|NCT03579264|Experimental|Intervention Arm|Use of My Viva Plan.
2852711|NCT03579251|Other|Pilot test|12 weeks of behavioral intervention (Black Men's Care), including an in-person session and two-way SMS, with a three-month follow-up period post-intervention.
2852712|NCT03579238|No Intervention|Distant|The clinician sits quietly 3 feet away from participant who is lying on a soft table at rest.This position is held for 5 minutes without moving.
2852713|NCT03579238|No Intervention|close|The clinician sits at the head of the table with his arms on the table alongside the participant's head but not touching the resting patient who is lying at rest on the table. This position is held for 5 minutes without moving.
2852745|NCT03578991|Experimental|Arm 2|"Intervention - Smart pillbox:~Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox."
2852943|NCT03577587|No Intervention|Reference group|Non-randomized healthy volunteering mothers after term birth receiving no intervention
2852714|NCT03579238|Sham Comparator|touching|"The clinician lifts the patient's head passively off the table in order to place his hands underneath the participant's head, palms facing upwards and in contact with the back of the head of the participant. The participant's head is gently lowered to rest upon the clinician's hands. No external force is provided by the clinician upon the participant's head as the head rests in the clinician's palms on the table. This position is held for 5 minutes without moving. This is called a touching intervention and is meant to be a sham. A five minute rest period follows in which the clinician removes his hands from underneath the participant's head and places them next to the patient on the table, but not in contact with the patient."
2852715|NCT03579238|Experimental|Occipital motion inhibition|"The clinician gently inhibits motion of the participant's occiput into flexion phase of the primary respiratory mechanism, and allows extension phase only. Upon sensing a still point, where no further flexion motion is palpated, the clinician will state to the research assistant now to indicate he feels a still point. This position is held for 5 minutes without moving. This is called a CV4 or modified CV4 intervention. A five minute rest period follows in which the clinician removes his hands from underneath the participant's head and places them next to the patient on the table, but not in contact with the patient."
2852716|NCT03579225||MATRx plus test|
2852717|NCT03579199|Experimental|exploration of abdominal cavity using a NIR/ICG camera|
2852718|NCT03579186|Experimental|Gait|Patients undergoing a routine clinical gait assessment at the Brain Fit Club at BIDMC will have their posture and gait measured before and during optokinetic stimulation (OKS).
2852719|NCT03579173||Nutrition and Infant PFT|To examine the relationship between nutritional status (weight-for-age (WFA) and weight-for-length (WFL)) at 6 months of age and lung function at 1-2 years of age in infants with CF.
2852720|NCT03579173||Nutrition and Lung Clearance Index|To examine the relationship between nutritional status (WFA and WFL) in infants with CF at 12 months of age and the lung clearance index (LCI) at 3-5 years of age.
2852721|NCT03579173||Passive Pulmonary Function and Infant Pulmonary Testing|To delineate the relationship between non-sedated tidal breathing parameters in infants with CF at 4-8 weeks of age and subsequent lung function at 6-12 months of age.
2852722|NCT03579160|Experimental|0.25% Timolol gel applied to full-thickness skin graft|"During surgery: application of 0.25% timolol gel (2 drops per cm2) on wound bed before FTSG is placed~During surgery: application of 0.25% timolol gel (2 drops per cm2) over FTSG after insetting of the graft~After bolster removal (7 days): daily cleansing and daily 0.25% timolol (2 drops per cm2) application for 4 weeks"
2852723|NCT03579160|Active Comparator|Standard of Care dressings|"FTSG surgery as per SOC~After bolster removal (7 days): daily cleansing and daily Vaseline application for 4 weeks"
2852724|NCT03579147|Experimental|Treatment Group|Treatment with the investigational device BTL EMSCULPT.
2852725|NCT03579134|Experimental|partial overlay denture|removable partial denture with a metal extension over the remaining posterior teeth raising their height to the newly proposed vertical dimension and occlusal plane
2852726|NCT03579134|Active Comparator|fixed temporary crowns|fixed crowns made from temporary material placed on the prepared posterior teeth to the new occlusal plane level elevating the vertical dimension to the newly proposed level
2852727|NCT03579121|Experimental|Pharmacogenomic (PGx) guided|Subjects will have Pharmacogenomic (PGx) testing preoperatively. The pharmacists will review results and make recommendations to the anesthesia and orthopedic teams for perioperative anesthesia and analgesia. The teams will use this information to drive clinical decisions as they see fit.
2852728|NCT03579121|Active Comparator|Control|Subjects will undergo Pharmacogenomic (PGx) preoperatively but the results will be sealed until completion of treatment and clinicians will not have access to this information. These patients will undergo standard treatment dosing and medication selection.
2852729|NCT03579095|Experimental|American ginseng|200mg Cereboost and Maltodextrin
2852730|NCT03579095|Placebo Comparator|Placebo|Placebo
2852731|NCT03579082|Experimental|Arm A|"R-ESHAP + decitabine:~decitabine:10mg/d,ivgtt,d1-5;R-ESHAP:rituximab,375mg/m2,ivgtt,d6;etoposide,100mg,ivgtt,d7-11;cytarabine,150mg,ivgtt,d7-11;cisplatin,25mg/m2,ivgtt,d7-9;dexamethasone,20mg,ivgtt,d7-11.21 days for one cycle."
2852732|NCT03579082|No Intervention|Arm B|R-ESHAP:rituximab,375mg/m2,d1,ivgtt;etoposide,100mg,d2-6,ivgtt;cytarabine,150mg,d2-6,ivgtt;cisplatin,25mg/m2,d2-4,ivgtt;dexamethasone,20mg,d2-6,ivgtt.21 days for one cycle.
2852733|NCT03579069||Ductus venosus Doppler realized|Ductus venosus Doppler realized
2852734|NCT03579069||Ductus venosus Doppler unrealized|Ductus venosus Doppler unrealized
2852735|NCT03579043|Experimental|Nutritive Sweetener|Participants will consume 36 ounces of Coke daily for three consecutive days.
2852736|NCT03579043|Experimental|Non-Nutritive Sweetener|Participants will consume 36 ounces of Diet Coke daily for three consecutive days.
2852737|NCT03579043|Experimental|Carbonated Water|Participants will consume 36 ounces of carbonated water daily for three consecutive days.
2852738|NCT03579030|Experimental|Single Dose of RTA 1701 or Placebo|"RTA 1701 capsules or placebo taken orally in a single dose.~Group 1: RTA 1701 10 mg or matching placebo Group 2: RTA 1701 ≤ 20 mg or matching placebo Group 3: RTA 1701 ≤ 40 mg or matching placebo Group 4: RTA 1701 ≤ 80 mg or matching placebo Group 5: RTA 1701 ≤ 160 mg or matching placebo Group 6: RTA 1701 ≤ 320 mg or matching placebo Group 7: RTA 1701 ≤ 640 mg or matching placebo"
2852739|NCT03579030|Experimental|Multiple Dose of RTA 1701 or Placebo|"RTA 1701 capsules, Dose TBD mg or placebo taken orally once daily for 14 weeks.~Group 8: RTA 1701 ≤40 mg or matching placebo Group 9: RTA 1701 ≤160 mg or matching placebo Group 10: RTA 1701 ≤640 mg or matching placebo"
2852740|NCT03579017||Patients with ALS|Patients with ALS will be tested by two independent testers with the ECAS-N at 4 months (baseline) and 8 months (follow-up), and the MoCA at 4 months (baseline) by one tester
2852741|NCT03579017||Healthy controls|Persons with no cognitive impairment will be tested with the ECAS-N once, by one tester
2852742|NCT03579017||Controls with dementia|Persons with cognitive impairment due to other disorders will be tested with the ECAS-N once, by one tester
2852743|NCT03579004|Experimental|Trimodality approach|"2 cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/м2 iv day 1, cisplatin 75 mg/м2 iv day 1, fluorouracil 750 mg/m2/day continuous infusion, day 1-4 every 3 weeks). 3-4 weeks later - preoperative chemoradiotherapy (paclitaxel 50 mg/m2 + cisplatin 20 mg/m2 weekly + radiotherapy 44 Gray (Gy) for 4 weeks).~4-6 weeks after completion of chemoradiation patients undergo Ivor Lewis esophagogastrectomy."
2852746|NCT03578991|Experimental|Arm 3|"Intervention - Smart pillbox & Interactive digital platform:~Description: Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox and an interactive digital platform."
2852747|NCT03578978||Neonates with suspected LONS and/or NEC|A group of 150 neonates with suspected LONS and/or NEC will be recruited. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
2852748|NCT03578978||Healthy neonates|A group of 50 neonates who are clinically well, admitted to the NICU for reasons other than neonatal sepsis or NEC will be recruited into the study to explore the kinetics and concentrations of the panel of biomarkers in healthy subjects comparing to subjects with suspected LONS/NEC. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
2852749|NCT03578965|Experimental|Arm 1: Antibiotic prophylaxis prior to skin incision|-Women randomized to prophylactic antibiotics will receive a cefazolin as per ACOG guidelines.
2852750|NCT03578965|No Intervention|Arm 1: No antibiotic prophylaxis prior to skin incision|-Women randomized to no antibiotic prophylaxis will not receive any antibiotics prior to skin incision.
2852751|NCT03578952|Experimental|Pure AR|Patients with symptomatic severe aortic valve regurgitation without severe aortic stenosis requiring aortic valve replacement.
2852752|NCT03578926|Experimental|fanfilcon A toric lens|Randomized participants will wear fanfilcon A toric contact lenses bilaterally for two weeks then switch to senofilcon A toric contact lenses for another two weeks.
2852753|NCT03578926|Active Comparator|senofilcon A toric lens|Randomized participants will wear senofilcon A toric contact lenses bilaterally for two weeks then switch to fanfilcon A toric contact lenses for another two weeks.
2852754|NCT03578913|Active Comparator|porcelain fused to metal crown|Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
2852755|NCT03578913|Experimental|PEEK crown|The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading
2852756|NCT03578900|Experimental|Xeros Group - Lozenge|"Application of Xeros system for 15 days. Lozenge (Malic acid 28.56 mg, Xylitol 421,98 mg, Sodium fluoride 0.55 mg) or Spray (Malic acid 1%, Xylitol 10%, Sodium fluoride 0.05%) 4 times a day. Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires.~Effects of lozenge on hyposalivation and pH variation determined by saliva collection with pre-weighed falcon and a ph electrode at predetermined times during a 20 minute period."
2852757|NCT03578900|Active Comparator|Mouthwash group|"Application of citric acid based Mouthwash (0,33% citric acid) for 15 days four times a day. Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires.~Effects of mouthwash on hyposalivation and pH variation determined by saliva collection with pre-weighed falcon and a pH electrode at predetermined times during a 20 minute period."
2852758|NCT03578900|Experimental|Xeros Group - Mouthwash|"Application of Xeros system for 15 days. Mouthwash (Betaine 1.33%, Xylitol 3.30%, Sodium fluoride 0.05%, Allantoin 0.10%) 2 times a day.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
2852759|NCT03578900|Experimental|Xeros Group - Gel|"Application of Xeros system for 15 days. Gel (Betaine 1%, Aloe Vera 0.05%, Xylitol 10%, Sodium Fluoride 0.0033%) before bed.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
2852760|NCT03578900|Experimental|Xeros Group - Toothpaste|"Application of Xeros system for 15 days. Toothpaste (Betaine 4%, Xylitol 10%, Sodium Fluoride 0.33%, Allantoin 0.10%) 3 times a day.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
2852761|NCT03578887|Active Comparator|Lifestyle Cohort|Participants Undergoing Behavioral Weight Loss Program
2852762|NCT03578887|Active Comparator|Surgical Cohort|Participants Scheduled for Roux-en-Y Gastric Bypass Surgery
2852763|NCT03578887|No Intervention|Healthy Weight Control Cohort|Healthy Weight Controls With No Intervention
2852764|NCT03578874|Experimental|SECOX|Sorafenib 400 mg twice daily from Day 1 to 14, Capecitabine 850 mg/m2 twice daily from Day 1 to 7, Oxaliplatin 85 mg/m2 on Day 1
2852765|NCT03578861|Experimental|Dementia related mobility and counseling|"The DESKK mobility program is based on the already existing day structure of the RC facility with two slots a day for physical activation activities (1 ½ hours forenoon and 1 ½ hours afternoon). The program structures these activities based on specific developed exercises, which are focused on the individual mobility level of every PwD and his/her mobility level.~The DESKK counseling program is an effort to structure and systemize counseling processes focused on the respite care setting by different documents and assessments."
2852766|NCT03578848|Active Comparator|uAOBP & Home BP|On the scheduled visits, the uAOBP and Home BP will be measured before meeting doctors and provided for clinicians to adjust patients' medication according to practice guideline.
2852767|NCT03578848|Experimental|CBP & Home BP|On the scheduled visits, the CBP and Home BP will be measured before meeting doctors and provided for clinicians to adjust patients' medication according to practice guideline.
2852768|NCT03578835||Multi-center BSI cohort|Patients from six German study centers suffering from bloodstream infection caused by specific target organisms.
2852769|NCT03578822|Experimental|Group A(Recombinant human urokinase,rhPro-UK)|
2852770|NCT03578822|Other|Group B(Basic treatment)|
2852771|NCT03578809|Experimental|Cohort A|MEDI6012
2852772|NCT03578809|Experimental|Cohort B|MEDI6012
2852773|NCT03578809|Placebo Comparator|Placebo|
2852774|NCT03578796||Persons with ALS|Persons With possible ALS-specific cognitive impairment will be tested With ECAS-N, MoCA, CDR and a questionnaire at 4 months (baseline) and 8 months (1. follow-up). Further evaluation will be with the questionnaire and CDR at each follow-up until 3 years or use of permanent ventilation support or Death. Information about use of advanced life-prolonging therapy will be collected from patient journal.
2852775|NCT03578783|Experimental|PSD502|PSD502 spray contains a eutectic-like mixture of lidocaine and prilocaine, and a propellant (norflurane) which also serves as a solvent. Each spray contains 7.5 mg lidocaine and 2.5 mg prilocaine. A single dose consists of 3 sprays applied to the glans penis.
2852776|NCT03578783|Placebo Comparator|Placebo|The placebo is a metered dose spray, identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine (instead it contains PEG600 and Povidone).
2852777|NCT03578757|Experimental|intervention group|stress management program and the same usual practice (restrictive diet, physical activity and thermal spa treatment)
2852778|NCT03578757|Active Comparator|usual practice group|Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders
2852779|NCT03578744|Experimental|Interventional|Group A patients will be treated with conventional flap surgery. The furcation defects will be debrided and autologous platelet-rich fibrin will be paced as a graft and membrane. Later the flap will be sutured.
2852780|NCT03578744|Experimental|Interventional Comparator|Group B patients will be treated with conventional flap surgery. The furcation defects will be debrided and Hyaluronic acid (Gengigel) will be placed as a graft. Amniotic membrane (Tata Memorial Hospital Mumbai) will be placed over the graft and later the flap will be sutured.
2852781|NCT03578731||Consilium-APP|Patietns with oncological, medical treatment for brastcancer, colo-rectal-cancer, prostatcancer, lung cancer or hematological malignancies.
2852782|NCT03578692||Surgery group|The protocol for patients assigned to surgery group was as follows. ASUC patients were admitted in, estimated their baseline situations and tested their blood and fecal indicators including PCT, IL-6 and FC on admission. All patients were treated according to the ECCO guideline 2012. Patients who showed bad response to medicine (glucocorticoid for 5 days and rescue therapy for 3 days) were recommended and classified in the surgery group. Their baseline manifestations were collected and compared with the medical group, to exploit the baseline indicators with great sensitive and specificity predicting the high risk for surgery.
2852783|NCT03578692||Medical group|The protocol for patients assigned to medical group was as follows. ASUC patients were admitted in, estimated their baseline situations and tested their blood and fecal indicators including PCT, IL-6 and FC on admission. All patients were treated according to the ECCO guideline 2012. Patients who showed response to medicine (glucocorticoid for 5 days or rescue therapy for 3 days) were classified in the medical group. Their baseline manifestations were collected and compared with the surgery group.
2852784|NCT03578679|Experimental|HEGOR/AZICUR shampoo solution|At D1, shampoo AZICUR liquid formulation in infested persons aged 0 to 6 years and / or less than 15 kg, also apply the combination HEGOR / AZICUR solution shampoo in women pregnant or lactating women not eligible for treatment with Ivermectin, to prevent them from contaminate treated participants who are very close to them or share the same bed or same bench table at school.
2852785|NCT03578666|Experimental|Massage Group|Recreational active runners recruited from local running clubs (n= 16) will receive 40 minutes of massage therapy.
2852786|NCT03578666|Experimental|Cold water immersion group|Recreational active runners recruited from local running clubs(n= 16) will immerse for 10 minutes in a cold water bath
2852787|NCT03578666|No Intervention|Control group|Recreational active runners recruited from local running clubs will rest passively in a sitting position for 30-min period
2852788|NCT03578653|Experimental|Merging Yoga and Occupational Therapy for Parkinson disease|The group participates in three assessment periods: August, October, and December. Then in October-December the group will receive group occupational therapy and recommended community adaptive yoga programming 2x/week for 8 weeks.
2852789|NCT03578640|Experimental|Treatment arm|Elbasvir, Grazoprevir 50-100Mg Oral Tablet
2852790|NCT03578627|No Intervention|Assessment-only|
2852791|NCT03578627|Experimental|Intervention|
2852792|NCT03578614|No Intervention|Control Group|There is no intervention for Control Group
2852793|NCT03578614|Experimental|Intervention Group|Intervention Group will be submitted to three physical activity sessions (two supervised and one nonsupervised) conducted over 6 months
2852794|NCT03578601||Thyroid surgery|Patient undergoing thyroid surgery
2852795|NCT03578588|Experimental|Banapenem B1 group|Dose in the 1st period 250mg; Dose in the 2nd period 500mg; Dose in the 3rd period 1000mg
2852796|NCT03578588|Experimental|Banapenem B2group|Dose in the 1st period 500mg; Dose in the 2nd period 1000mg; Dose in the 3rd period 250mg
2852797|NCT03578588|Experimental|Banapenem B3group|Dose in the 1st period 1000mg; Dose in the 2nd period 250mg; Dose in the 3rd period 500mg
2852798|NCT03578588|Experimental|Banapenem C1group|250mg Once daily for 7 consecutive days
2852799|NCT03578588|Experimental|Banapenem C2group|500mg Once daily for 7 consecutive days
2852800|NCT03578575|Experimental|Danggui Buxue Tang group|Use Danggui Buxue Tang 5g/time, 3 times a day, for 12 weeks.
2852801|NCT03578575|Placebo Comparator|Placebo group|Use Placebo 5g/time, 3 times a day, for 12 weeks.
2852802|NCT03578562|Experimental|Targeted training intervention|An 8-week progressive homebased training intervention with supervised booster-sessions
2852803|NCT03578549|Experimental|Oximetry testing of healthy teeth and those requiring removal|"To assess the ability of pulse oximeter to assess the presence of pulse in teeth and to correlate pulse oximeter readings with conventional pulp testing measures including cold test, electrical pulp test, percussion and palpation testings, pulse oximeter will be used with a special holding frame, for 15-30 seconds.~Note: the reading will not affect clinical practice; it is simply to gather data to see if pulse oximetry can facilitate diagnostic practices in the future"
2852837|NCT03578315|Experimental|Solar lentigo|25 Patients with Solar lentigo
2852838|NCT03578315|Experimental|Nevus zygomaticus|25 Patients with Nevus zygomaticus
2852839|NCT03578289|Experimental|Experimental Group (telemental health_|The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
2852944|NCT03577574|Active Comparator|retrobulbar anesthesia group|2% lidocaine 4ml injected into retrobulbar space
2852804|NCT03578536|Experimental|CIT with Recovery Rapids|"This project will develop a therapeutic model that promotes use of the impaired arm and hand. Researchers often call this type of therapy constraint induced therapy. In this study, participants focus on using the impaired limb rather than the unaffected limb. Study participants will only be able to play the game using the impaired limb.~A small group of patients will participate in a question and answer session about preferences for activities which make up transfer tasks. Patients will also receive automated reminders to use the impaired arm throughout the day. Twelve (12) Veterans will be recruited annually from the inpatient Stroke Specialty Program. Six (6) patients will be assigned to the Treatment group and receive the intervention. The remaining six (6) will receive the current standard of care. Outcome measures will include motor function tests that evaluate upper extremity function."
2852805|NCT03578536|No Intervention|Standard of Care|As part of standard care, participants will receive a minimum of daily OT, PT and Speech for a total of three hours. Current occupational therapy intervention options for inpatient stroke rehab patients with UE neuromotor impairments include active assisted range of motion exercise, morning bedside ADL sessions, high-repetition task-specific training, mirror therapy, Digi-flex, theraputty, theraband, free weights, weighted therapy bars for strengthening exercises in clinic and use with home exercise programs (HEP). Additional tools used as determined by therapist include FES modalities to assist with upper extremity neuromotor re-education, unweighted reaching tasks via the ArmeoSpring, and functional work task training/strengthening. They also participate in recreation therapy as appropriate.
2852806|NCT03578523||Chronic Kidney Disease|"CKD stage 3-4 eGFR 59-20mls/min/1.73 '3 Tesla multiparametric MR: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion).~Each patient will have 3 renal MRI scans. renal histopathology scoring: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication) Iohexol clearance test: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel.~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis.~Iohexol clearance to measure GFR within 1 week of the scan session"
2852807|NCT03578523||Acute Kidney Injury|"AKI stage 2-3 '3 Tesla multiparametric MR: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion).~Each patient will have 3 renal MRI scans. Iohexol clearance test: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel.~renal histopathology scoring: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication) urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis.~Iohexol clearance to measure GFR within 1 week of the scan session"
2852808|NCT03578510|Active Comparator|SHD|Standard hemodialysis
2852809|NCT03578510|Experimental|HHD|Hemocontrol hemodialysis
2852810|NCT03578497|Experimental|IL-1 receptor antagonist Anakinra 100 mg|Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Anakinra/Kineret® is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colorless-to-white, preservative free solution for daily s.c. administration over a time period of 28 days.
2852811|NCT03578484||Volunteer female subjects|Females age 18-35 years of age. 3D breast scan will be performed and followed over 15 years. No therapeutic interventions will be performed.
2852812|NCT03578471|Active Comparator|Hearing Aid without NR and BF|Hearing Aid without Noise Reduction (NR) or beam forming (BF) enabled serves as reference condition.
2852813|NCT03578471|Experimental|Hearing Aid with NR|Hearing Aid with Noise Reduction (NR) enabled.
2852814|NCT03578471|Experimental|Hearing Aid with BF|Hearing Aid with beam forming (BF) enabled.
2852815|NCT03578458|Other|US Healthy diet|Subjects will install a mobile app for use and will be randomly assigned to a healthy diet.
2852816|NCT03578458|Other|Vegetarian diet|Subjects will install a mobile app for use and will be randomly assigned to a vegetarian diet.
2852817|NCT03578458|Other|Mediterranean diet|Subjects will install a mobile app for use and will be randomly assigned to a Mediterranean diet.
2852818|NCT03578445|Experimental|Patients with a pancreatic cystic lesion|
2852819|NCT03578432|Experimental|Supportive care (everolimus, saliva output testing)|Participants receive everolimus PO QD for 5 days beginning 2 weeks after radiation treatment. Participants also undergo saliva output testing at baseline prior to radiation or chemoradiation treatment, after 3 weeks of RT/chemoRT, after 6 weeks of RT/chemoRT, prior to everolimus administration, at completion of the 5 day everolimus course, and at 1, 3, and 6 months after the completion of radiation or chemoradiation therapy.
2852820|NCT03578419|Active Comparator|Control Period|Standard-Volume Blood Collection Tubes
2852821|NCT03578419|Experimental|Intervention Period|"Small-Volume Blood Collection Tubes (soft-draw)"
2852822|NCT03578406|Experimental|HPV TCR-T|HPV E6-specific TCR-T cell
2852823|NCT03578393|Experimental|Intervention|Will visualize an Educational Virtual Reality video in preoperative period to reduce perioperative anxiety.
2852824|NCT03578393|No Intervention|Usual treatment|Will be applied the usual treatment (provide information on the anaesthetic-surgical process).
2852825|NCT03578380|Experimental|Surgery|Lymphovenous anastomosis
2852826|NCT03578380|Active Comparator|Compression|Conservative treatment with physiotherapy and compression
2852827|NCT03578367|Experimental|Asciminib 60mg QD + Imatinib 400mg QD|Asciminib 60 mg taken once daily in combination with Imatinib 400 mg taken once daily
2852828|NCT03578367|Experimental|Asciminib 40mg QD + Imatinib 400mg QD|Asciminib 40 mg taken once daily in combination with Imatinib 400 mg taken once daily
2852829|NCT03578367|Active Comparator|Imatinib 400mg QD|Imatinib 400 mg taken once daily
2852830|NCT03578367|Active Comparator|Nilotinib 300mg BID|Nilotinib 300 mg taken twice daily
2852831|NCT03578354|Experimental|4-AP|15 mg 4-aminopyridine twice daily
2852832|NCT03578354|Experimental|Atenolol|25 mg atenolol twice daily
2852833|NCT03578354|Placebo Comparator|Placebo|Masked placebo twice daily
2852834|NCT03578341|Experimental|Colostrum|Group 1:(Colostrum): Preterm infants under 32 SDG will receive orally colostrum 0.3 mL every 4 h during three days.
2852835|NCT03578341|Placebo Comparator|Placebo|Group 2: (Placebo): Preterm newborns under 32 SDG who will receive orally sterile water 0.3 mL every 4 h during three days.
2852836|NCT03578328||Cardiac arrest with targeted temperature management|
2852840|NCT03578289|Experimental|Waiting Control Group (usual care)|Participants randomly assigned to the control group will receive routine care for three months followed by the 8-week CBT intervention
2852841|NCT03578276|Active Comparator|LessDrops|Compounded eye drop containing Gatifloxacin (antibiotic), bromfenac (non-steroidal anti-inflammatory), and prednisolone acetate 1% used three times a day (TID) starting 1 day prior to surgery and continuing after surgery for 2 weeks then twice a day for a week and once a day for another week.
2852842|NCT03578276|Active Comparator|Standard of Care|"Gatifoxacin 0.5%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.~Bromfenac 0.07%: 1 drop QD starting 3 days before surgery, continue QD for 4 weeks after surgery and then discontinue.~Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinue."
2852843|NCT03578263|Experimental|carbetocin arm|carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after the birth of the baby
2852844|NCT03578263|Active Comparator|oxytocin and ergometrine arm|oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist plus intramuscular ergometrine 0.2 mg after the birth of the baby
2852845|NCT03578250|Experimental|Study Group|"Training of the upper extremity on a robotic device. Participants will carry out hand reaching movement for multiple directions in 3 dimensions, while grasping the robotic handle according to assignments given by the robotic device.~During training the robotic device will apply error augmentation force-field to perturbate the arm of the participant away from the straight trajectory line."
2852846|NCT03578250|Experimental|Control group|"Training of the upper extremity on a robotic device. Participants will carry out hand reaching movement for multiple directions in 3 dimensions, while grasping the robotic handle according to assignments given by the robotic device.~During training the robotic device will not apply any perturbations on the participant's arm."
2852847|NCT03578237|Experimental|Treatment|Receiving active cryoneurolysis
2852848|NCT03578237|Sham Comparator|Sham|Receiving sham cryoneurolysis procedure
2852849|NCT03578224|Experimental|Diagnostic (EUS, FNA, perflubutane microbubble)|Participants undergo standard of care unenhanced endoscopic ultrasound (EUS) and fine needle aspiration (FNA) of identified lymph nodes. Participants then receive perflubutane microbubble peri- or intratumorally and undergo contrast-enhanced EUS followed by FNA of identified lymph nodes.
2852850|NCT03578211|Experimental|DAs group|Shared decision making using decision aids
2852851|NCT03578211|No Intervention|Control group|Standard oral explanation guided with booklets
2852852|NCT03578198|Experimental|Rituximab + MG4101|
2852853|NCT03578172|Experimental|Experimental-HMG stimulation group|Women will be subjected to ovarian stimulation for endometrial preparation using human menopausal gonadotrophin before blastocyst transfer
2852854|NCT03578172|Active Comparator|Control-HRT group|Women will be subjected to hormone replacement therapy for endometrial preparation before blastocyst transfer
2852855|NCT03578159||Arsha Vidya Chhatralaya|Chhatralaya is residential setting for children 8 to 16 years old. It provides residence,food and education opportunities along with regular practice of Yoga, Spiritual sessions and vedic practices to learn and follow.
2852856|NCT03578146|Experimental|Apixaban (90 mg bolus)|90 mg PRT064445/saline or vehicle control given as a single IV bolus
2852857|NCT03578146|Experimental|Apixaban (210 mg bolus)|210 mg PRT064445/saline or vehicle control given as a single IV bolus
2852858|NCT03578146|Experimental|Apixaban (420 mg bolus)|420 mg PRT064445/saline or vehicle control given as a single IV bolus
2852859|NCT03578146|Experimental|Apixaban (420 mg bolus + 180 mg infusion) 4 mg/min|600 mg PRT064445/saline or vehicle control given as follows: 420 mg IV over ~14 minutes (~30 mg/min), followed by a continuous infusion of 180 mg (4 mg/min over 45 minutes);
2852860|NCT03578146|Experimental|Apixaban (420 mg bolus + 180 mg bolus) 30mg/min|600 mg PRT064445/saline or vehicle control given as follows: up to 420 mg IV over ~14 minutes (~30 mg/min), followed by a second bolus of 180 mg IV over ~6 minutes (~30 mg/min), 45 minutes after completion of the bolus
2852861|NCT03578146|Experimental|Apixaban (420 mg bolus + 480 mg infusion) 4mg/min|900 mg PRT064445/saline or vehicle control given as follows: 420 mg IV, followed by a continuous infusion of 480 mg (4 mg/min over 120 minutes
2852862|NCT03578146|Experimental|Rivaroxaban (210 mg bolus)|210 mg PRT064445/saline or vehicle control given as a single IV bolus
2852863|NCT03578146|Experimental|Rivaroxaban (420 mg bolus)|420 mg PRT064445/saline or vehicle control given as a single IV bolus
2852864|NCT03578146|Experimental|Rivaroxaban (600 mg bolus)|600 mg PRT064445/saline or vehicle control given as a single IV bolus
2852865|NCT03578146|Experimental|Rivaroxaban (720 mg bolus + 240 mg infusion) 4mg/min|960 mg PRT064445/saline or vehicle control given as follows: 720 mg IV at ~30 mg/min, followed by a continuous infusion of 240 mg (4 mg /min over 60 minutes)
2852866|NCT03578146|Experimental|Rivaroxaban (800 mg bolus + 960 mg infusion) 8mg/min|1760 mg PRT064445/saline or vehicle control given as follows: 800 mg IV at ~30 mg/min, followed by a continuous infusion of 960 mg (8 mg/min over 120 minutes)
2852867|NCT03578146|Experimental|Enoxaparin (210 mg bolus) original|210 mg PRT064445/saline or vehicle control given as a single IV bolus
2852868|NCT03578146|Experimental|Enoxaparin (420 mg bolus) original|420 mg PRT064445/saline or vehicle control given as a single IV bolus
2852869|NCT03578146|Experimental|Enoxaparin (210 mg) lyophilized|210 mg PRT064445/vehicle control (lyophilized formulation) given as a single IV bolus
2852870|NCT03578146|Experimental|Edoxaban (600 mg bolus)|600 mg PRT064445/vehicle control given as a single IV bolus
2852871|NCT03578146|Experimental|Edoxaban (800 mg bolus + 480 mg infusion) 8mg/min|1280 mg PRT064445/saline or vehicle control given as follows: 800 mg IV at ~30 mg/min, followed by a continuous infusion of 480 mg (4 mg /min over 60 minutes).
2852872|NCT03578146|Experimental|Edoxaban (800 mg bolus)|800 mg PRT064445/vehicle control given as a single IV bolus
2852873|NCT03578120||iMAP2 participants where their mothers received REPEVAX|Children who participated in iMAP2 study whose mothers received a pertussis-containing vaccine during pregnancy called REPEVAX
2852874|NCT03578120||iMAP2 participants where their mothers received BOOSTRIX-IPV|Children who participated in iMAP2 study whose mothers receives a pertussis-containing vaccine during pregnancy called BOOSTRIX-IPV
2852941|NCT03577587|Experimental|Verum|Silitidil for 21 days
2852875|NCT03578120||iMAP2 participants where their mothers received no vaccine|Children who participated in iMAP2 study whose mothers did not receive a pertussis-containing vaccine during pregnancy
2852876|NCT03578107|Other|Improvement intervention1|receive the following improvement intervention for 18 months：
2852877|NCT03578107|Other|Improvement intervention2|receive the following improvement intervention for 12 months：
2852878|NCT03578107|Other|Improvement intervention3|receive the following improvement intervention for 6 months：
2852879|NCT03578081|Experimental|Arm I (fosaprepitant dimeglumine, olanzapine)|Patients receive palonosetron hydrochloride IV over 30 seconds or ondansetron hydrochloride IV over 2-5 minutes or PO on day 1, dexamethasone PO on days 1-4, fosaprepitant dimeglumine IV over 20-30 minutes on day 1, and olanzapine PO on days 1-4. Treatment may repeat every 4 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
2852880|NCT03578081|Active Comparator|Arm II (placebo, olanzapine)|Patients receive palonosetron hydrochloride IV over 30 seconds or ondansetron hydrochloride IV over 2-5 minutes or PO on day 1, dexamethasone PO on days 1-4, placebo IV over 20-30 minutes on day 1, and olanzapine PO on days 1-4. Treatment (with no placebo) may repeat every 4 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
2852881|NCT03578055|Active Comparator|BDD with UDCA|Postoperative BDD with UDCA treatment
2852882|NCT03578055|Placebo Comparator|Placebo|Placebo
2852883|NCT03578042|Active Comparator|LosanetAMplus|Patients taking the fixed triple combination
2852884|NCT03578042|Other|standard of care|Patients taking 2 or 3 free combinations containing 3 drugs for hypertension as decided by the treating physician
2852885|NCT03578029|Experimental|RGN-137|It is formulated as a gel for topical administration.
2852886|NCT03578029|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-137 formulation without the active ingredient.
2852887|NCT03578016|Experimental|Circle of Security-Parenting|10 weekly, manualized group sessions at the clinic
2852888|NCT03578016|Other|Treatment as Usual (TAU)|TAU consists of clinical assessment and treatment.
2852889|NCT03578003|Experimental|Morning Bright Light Therapy|Subjects who engage in morning bight light therapy
2852890|NCT03578003|No Intervention|Control|Subjects who do not engage in morning bright light therapy
2852891|NCT03577990|Experimental|Treatment Arm|Twine Health Monitoring will include blood pressure, weight measurements, daily food intake, self-report medication-taking, and physical activity plus interactive technology-enhanced coaching (ITEC) for 3 months and then monitor another 3 months with no ITEC to assess for sustainability for a total 6 months.
2852892|NCT03577990|Sham Comparator|Control Arm|The same intervention will be used in the control arm with the exception of interactive technology-enhanced coaching (ITEC). Twine Health Monitoring will include blood pressure, weight measurements, daily food intake, self-report medication-taking, and physical activity plus limited sham coaching for 3 months and then monitor another 3 months with no sham coaching to assess for sustainability for a total 6 months.
2852893|NCT03577977||Patients treated with Betaferon|Patients with very early onset of MS, who received at least one injection of interferon beta-1b as prescribed by the treating physician, before the age of 18.
2852894|NCT03577951|Experimental|high position space group|The left and right Trocar meet at the level of the sternum angle and begin to establish the operating space.
2852895|NCT03577951|Experimental|low position space group|The left and right Trocar meet under the sternum angle and begin to establish the operating space.
2852896|NCT03577938|Experimental|Chinese herbal medicine|One dosage of Chinese herbal medicine by oral administration per day for 8 weeks. For patients who cannot take oral medicine can be switched to colon route by the colonic therapy system（IMS-100A produced by Sunny Medical in Beijing China).
2852897|NCT03577938|Other|Control (blank)|Patients in the control group only receive the standard medical treatment (SMT), no control drug with CHM.
2852898|NCT03577925||HSIL|the patients with HSIL
2852899|NCT03577925||stage IA1 cervical squamous cancer|the patients with stage IA1 cervical squamous cancer
2852900|NCT03577912|Active Comparator|TAP block administered by Surgery|transversus abdominis (TAP) plane block is performed by the surgeon at the conclusion of the surgery, still under general anesthesia, prior to removing the trocars a single dose 60 cc of 0.5%bupivicaine is delivered into the TAP under direct surgeon observed laparoscopic visualization. (Split dose 30cc/side)
2852901|NCT03577912|Active Comparator|TAP block administered by Anesthesia|transversus abdominis (TAP) plane block is performed by the anesthesiologist at the conclusion of the surgery after incisions are closed and dressing are on, prior to emergence from general anesthesia, a single dose 60 cc of 0.5%bupivicaine is delivered into the TAP under by the anesthesiologist using ultrasound visualization. (Split dose 30cc/side)
2852902|NCT03577899|Experimental|0.5 mg Conbercept|
2852903|NCT03577899|Experimental|1.0 mg Conbercept|
2852904|NCT03577899|Active Comparator|Aflibercept|
2852905|NCT03577886|Experimental|CDX-6114|0.225, 0.75, 2.25 and 7.5 g
2852906|NCT03577886|Placebo Comparator|Placebo|Phosphate Buffer Diluent solution
2852907|NCT03577873|Placebo Comparator|gallbladder preserved|Patients with stones in their bile ducts and gallbladders will keep gallbladders in stay after clearance of bile duct stones with ERCP.
2852908|NCT03577873|Experimental|cholecystectomy|Patients with stones in their bile ducts and gallbladders will undergo cholecystectomy after clearance of bile duct stones with ERCP.
2852909|NCT03577860|Active Comparator|Bupivacaine 4ml|The interscalene brachial plexus block is performed with 4ml at level of C5-6 roots
2852910|NCT03577860|Active Comparator|Bupivacaine 15ml|The interscalene brachial plexus block is performed with 15ml at level of C5-6
2852911|NCT03577847||1|Intervention group: Stroke patients investigated with rural CT examination and treated with, if indicated, thrombolysis at HSS, Ål. Patients living in the municipalities of Hol, Ål, Gol, Hemsedal and Nes.
2852912|NCT03577847||2|Control-group: Stroke patients with similar transportation time to hospital, but no access to rural CT or thrombolytic treatment. Patients living in the municipalities of Nore- and Uvdal, Vang, Øystre and Vestre Slidre, Lesja, Vågå, Lom, Dovre, Skjåk and Sel.
2852913|NCT03577834|Experimental|Liquid vinegar|Participants in this arm were instructed to drink 2 tablespoons of red wine vinegar (provided) mixed with water twice each day for weeks 1 to 8 of the trial.
2852942|NCT03577587|Placebo Comparator|Placebo|Placebo for 21 days
2852914|NCT03577834|Placebo Comparator|Vinegar pill|Participants in the control group were instructed to take one vinegar pill (provided) each day for weeks 1-8 of the trial.
2852915|NCT03577808||Arm|Patients with locally advanced rectal cancer will receive neoadjuvant chemoradiation. The radiation procedure and concurrent chemotherapy drugs will base on clinical practice. Organoids bio-bank of pre-treatment tumor biopsies will be established and exposed to irradiation and the same chemotherapy drugs as the corresponding patient.
2852916|NCT03577782|Experimental|Single group|HIV-infected subjects with no previous ART will begin ART together with Vedolizumab infusions at week 0, 4, 8, 12, 16, 20 and 24 weeks. At this time point ART and Vedolizumab treatment will be interrupted. Patients will be followed up until week 48. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).
2852917|NCT03577756||Infants with cystic fibrosis|Twelve months infants with cystic fibrosis will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Rough Motor Function Measure.
2852918|NCT03577756||Healthy infants|Twelve months healthy infants will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Rough Motor Function Measure.
2852919|NCT03577743|Experimental|experimental arm|bevacizumab and chemotherapy given every 21 day untill disease progression or unacceptable toxicity
2852920|NCT03577730|Experimental|Experimental|Prepared intravenous piggyback solution of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.
2852921|NCT03577730|Placebo Comparator|Control|Prepared intravenous piggyback solution of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.
2852922|NCT03577717|Experimental|computerized cognitive training|"participants will be trained by the Cookies for the brainy day, including memory, attention, calculation, executive functions, and language training."
2852923|NCT03577717|Active Comparator|occupational therapy|participants will receive craft activities of occupational therapy, such as weaving, origami etc.
2852924|NCT03577704|Experimental|HLX07+Gemcitabine+Cisplatin arm|"HLX07 is given on D1,D8,D15 combine with Gemcitabine (1000 mg/m2) and Cisplatin (75 mg/m2) in 3 weeks- cycles for 4-6 cycles .Gemcitabine was administered on the D1 and D8 and cisplatin 75 mg/m2 was administered on the D1. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
2852925|NCT03577704|Experimental|HLX07+Paclitaxel+Carboplatin arm|"HLX07 is given on D1,D8,D15 combine with Paclitaxel (80 mg/m2) and carboplatin (AUC=2) in 3 weeks-cycle for 4-6 cycles .Paclitaxel and carboplatin were administered on D1, D8 and D15. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
2852926|NCT03577704|Experimental|HLX07+mFOLFOX6 arm|"HLX07 is given on D1,D8 combine with mFOLFOX6 ( oxaliplatin (85 mg/m2), leucovorin (400 mg/m2), and 5-FU (400 mg/m2, followed by 2400 mg/m2) in 2 weeks-cycles for 6-12 cycles . Oxaliplatin, leucovorin and 5-FU were administered on D1. After 6-12 cycles of combination therapy,once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
2852927|NCT03577691|Experimental|Training for use of web based Decision Aid|Subjects will be provided access to the decision aid website and will receive a log-in identification, user password and url at time of consent and will be guided during a 30 minutes training session to use the website. They will ben be asked to continue to peruse the website at home to learn more about hydroxyurea. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
2852928|NCT03577691|Placebo Comparator|No training for use of web based Decision Aid|Subjects will receive a log-in identification, user password and url at time of scheduled appointment for web access. They will not receive training but will be instructed to maneuver through the website and access the information pertaining to hydroxyurea and access the videos for the purposes of learning. Participants will be asked to peruse the website for 30 minutes at time of consent then to continue to access the website at home to learn about hydroxyurea treatment. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
2852929|NCT03577678|Experimental|observational|orthopaedic Surgery to fix lateral half prosthesis for clavicle
2852930|NCT03577665|Experimental|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
2852931|NCT03577652|Experimental|Ticagrelor, 90mg, 12h|
2852932|NCT03577652|Experimental|Ticagrelor, 90mg, 24h|
2852933|NCT03577652|Experimental|Ticagrelor, 180mg, 24h|
2852934|NCT03577626|Experimental|Hemay005 Fast|
2852935|NCT03577626|Experimental|Hemay005 Fed|
2852936|NCT03577613||Early stage Cervical Cancer- Open Radical Hysterectomy(RH)|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a open RH at our institution as primary treatment were included in the study
2852937|NCT03577613||Early stage Cervical Cancer- Laparoscopic Radical Hysterectomy|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a laparoscopic RH at our institution as primary treatment were included in the study
2852938|NCT03577613||Early stage Cervical Cancer- Robotic radical Hysterectomy(RRH)|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a robotically assisted RH at our institution as primary treatment were included in the study
2852939|NCT03577600|Experimental|with FQMR treatment|Patients diagnosed with cerebral palsy between 1 and 6 years of age whose parents agree to participate in the study and have signed informed consent.
2852940|NCT03577600|Placebo Comparator|without FQMR treatment|Patients diagnosed with cerebral palsy between 1 and 6 years of age whose parents agree to participate in the study and have signed informed consent.
2852945|NCT03577574|Active Comparator|peribulbar anesthesia group|2% lidocaine 4 to 8ml injected into peribulbar space
2852946|NCT03577574|Experimental|two step anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
2852947|NCT03577561|No Intervention|Control group A|Control group A: 1 -year historical data (2016/2017) The blood sampling error rate in the interns receiving proficiency based progression training in 2018 will be compared to historical data on doctors who would have received whatever training they would normally undergo as a part of their existing training program. It will not differ from what they would normally receive at that institution.
2852948|NCT03577561|Active Comparator|Control Group B|Control group B (2017/2018) In a pilot project in July 2017, 46 interns received the phlebotomy proficiency based progression training at CUH. The error rates in the interns in 2017 will be compared to the newly trained interns in 2018 to determine the effectiveness of the training over time. The intervention is the proficiency based progression training programme in phlebotomy.
2852949|NCT03577561|Active Comparator|Interventional Group|"The blood sampling error rate of doctors in training provided with the intervention i.e. improved proficiency based progression training programme will be analysed from July 10th 2018 until the study ends.~The proficiency based progression training will consist of an online eLearning module to teach the doctors the correct process to take blood in the hospital. The doctors will then have to attend a face to face training day on a simulation ward where they will be asked to take blood according to a metric of 77 steps with less than 13 errors and no critical errors. Finally, the doctors will be observed taking blood on the ward and again must take it to a proficient standard."
2852950|NCT03577535|Experimental|Oncoxin®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN
2852951|NCT03577535|No Intervention|No Oncoxin Treatment®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment.
2852952|NCT03577522|Active Comparator|Avenir cementless hip stem|Total hip arthroplasty: Avenir vs Corail
2852953|NCT03577522|Active Comparator|Corail HA-coated hip stem|Total hip arthroplasty: Corail vs Avenir
2852954|NCT03577509|Experimental|ABCD|Group1: 0.5mg/kg Group2: 1.0mg/kg Group3: 1.5mg/kg
2852955|NCT03577496|Experimental|Peppermint oil|A cotton ball with three drops of peppermint oil will be waved under the patient's nares upon arrival to the recovery room. The patients will be assessed for PONV for up to an hour in the post anesthesia care unit (PACU) or until their discharge, whichever is first.
2852956|NCT03577483|Other|Parkinson's disease|Diagnosis of idiopathic Parkinson's disease (PD) according to criteria
2852957|NCT03577483|Other|Multiple system atrophy|Diagnosis of Multiple Atrophy System (MSA) Parkinsonian form possible or probable according to Gilman et coll 's criteria (2008)
2852958|NCT03577483|Other|Healthy volunteer|Absence of neurologic and oto-rhino-laryngologic disease
2852959|NCT03577470||Group 1|Participants will not receive any intervention as a part of this study. This group will include participants in treatment with Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF), who were always being treated with boosted-darunavir (DRV)-based regimen. The primary data source will be the medical records of each participant participating in this study.
2852960|NCT03577470||Group 2|Participants will not receive any intervention as a part of this study. This group will include participants who started their antiretroviral (ARV) treatment with any combination excluding DRV before starting D/C/F/TAF treatments, who were always being treated with ARV treatment with any combination excluding DRV before starting D/C/F/TAF treatments. The primary data source will be the medical records of each participant participating in this study.
2852961|NCT03577470||Group 3|Participants will not receive any intervention as a part of this study. This group will include participants started with D/C/F/TAF as naive. The primary data source will be the medical records of each participant participating in this study.
2852962|NCT03577457|Experimental|male oxytocin and ATD group|male subjects receiving oxytocin and ATD treatment
2852963|NCT03577457|Experimental|male oxytocin and placebo group|male subjects receiving oxytocin and ATD-placebo treatment
2852964|NCT03577457|Experimental|male placebo and ATD group|male subjects receiving oxytocin placebo and ATD treatment
2852965|NCT03577457|Placebo Comparator|male placebo group|male subjects receiving oxytocin placebo and ATD placebo treatment
2852966|NCT03577444||Dysphagia patients|Patients who had been diagnosed with neurogenic dysphagia related to either stroke or traumatic brain injury at two university affiliated hospitals
2852967|NCT03577431|Experimental|arTreg-CSB|"arTreg CSB: alloantigen-reactive T regulatory cells costimulatory blockade per protocol.~The investigational product is donor alloantigen-specific T regulatory cells (arTreg-CSB). Supportive regimen for receipt of arTregs-CSB includes everolimus, leukapheresis, cyclophosphamide, and mesna.~Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 500 x 10^6 total cells. arTreg-CSB will be administered as a single peripheral intravenous (IV) infusion over approximately 15 to 30 minutes.~Note: Participants who receive at least the minimum Treg product (arTreg-CSB) dose of 1 to < 2.5 x 10^6 cells will be included in intent-to-treat analysis."
2852968|NCT03577418|Experimental|Clinician-facilitated educational intervention|
2852969|NCT03577418|Active Comparator|Enhanced usual care|
2852970|NCT03577392|Experimental|XELOX chemotherapy with recombinant human endotatin|Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
2852971|NCT03577392|Active Comparator|XELOX chemotherapy without recombinant human endotatin|Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
2852972|NCT03577379|No Intervention|Control|Patients in the control arm will receive standard of care for their rotator cuff tear, and will not receive the additional whole blood fibrin clot.
2852973|NCT03577379|Experimental|Treatment|Patients in the control arm will receive standard of care for their rotator cuff tear, in addition to, the whole blood fibrin clot.
2853038|NCT03576898|Placebo Comparator|Placebo|
2861843|NCT03516071|Experimental|Brivanib 400 mg, BID + BSC|
2852974|NCT03577353|Experimental|experimental-DTW|The intervention of the experimental group was based on dual-task treadmill walking while using the Virtual Reality (VR) tool.
2852975|NCT03577353|Active Comparator|Control- TMW|The intervention of the control group was based on single-task treadmill walking.
2852976|NCT03577340||Novices|Novices: Trainee cardiologists implanting cardiac devices as per guidelines under supervision
2852977|NCT03577340||Experts|Experts: Device implanting cardiologists implanting cardiac devices as per guidelines
2852978|NCT03577327||Adults with vitiligo|
2852979|NCT03577327||Healthy adults|
2852980|NCT03577314||miscarriage|Patients were aged from 18 to 35 years, 50 females who have history of at least two unexplained recurrent miscarriage below 20th week of pregnancy
2852981|NCT03577314||healthy|50 systemically healthy females with at least two normal births and no poor obstetric history such as preeclampsia and premature birth
2852982|NCT03577301|Active Comparator|Clinic-based Delivery|Participants will receive the intervention in person following HIV counseling and testing. The intervention involves completion of the 4 YMHP sessions and the delivery of pre-exposure prophylaxis (PrEP) information and navigation services to interested participants.
2852983|NCT03577301|Active Comparator|Remote Delivery|Participants will receive the intervention by remote delivery following HIV counseling and testing. Just as the clinic-based participants, he intervention involves completion of the 4 YMHP sessions and the delivery of pre-exposure prophylaxis (PrEP) information and navigation services to interested participants.
2852984|NCT03577288|Experimental|Experiment 1 A, B - Level of realism of EVR|Participants (30 children and 30 young adults for part A, and 30 other children and 30 other young adults) will be exposed to virtual experience having different level of realism. In one condition the realism will be high (very close to the real word) and in the second condition the realism will be low (comparable to cartoon). The stimuli of interest included in virtual experience will be of three emotional categories : negative, positive and neutral.
2852985|NCT03577288|Experimental|Experiment 4 - Presence of avatar|Participants (30 children and 30 young adults) will be exposed to virtual experiences in which in one condition they will be part of the virtual environment in a body of an avatar and in another condition the avatar will not be present.
2852986|NCT03577288|Experimental|Experiment 1 - Interaction in virtual experience|Participants (30 children and 30 young adults) will be submitted to two conditions of virtual experience, one condition in which it is possible to interact with the stimuli presented in the virtual environment and another condition in which it is not possible to interact. In addition, the stimuli of interest will be of one of three emotional categories : negative, positive and neutral. Thus participants will be exposed to six short virtual experiences.
2852987|NCT03577288|Experimental|Experiment 2 - Animate/Inanimate nature of interactive objects|Participants (30 children and 30 young adults) will be exposed to the virtual experience during which they will be able to interact in one condition with animated (e.g., dog, bird) stimuli and in another condition with inanimate (e.g., book, jacket) stimuli. The animate and inanimate stimuli of interest will be of three emotional categories : negative, positive and neutral.
2852988|NCT03577275|Placebo Comparator|Placebo oral capsule|Single dose of placebo to match NST-4016
2852989|NCT03577275|Active Comparator|Moxifloxacin 400mg|Single 400mg dose of active comparator moxifloxacin (open label)
2852990|NCT03577275|Experimental|NST-4016 600mg|Likely therapeutic dose of NST-4016
2852991|NCT03577275|Experimental|NST-4016 2000mg|Supratherapeutic dose of NST-4016
2852992|NCT03577262|Experimental|Healthy subjects [11C]-UCB-J|Net dose of approximately 370 megabecquerel (MBq) of [11C]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28
2852993|NCT03577262|Experimental|AD patients [11C]-UCB-J|Net dose of approximately 370 megabecquerel (MBq) of [11C]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28
2852994|NCT03577249|Experimental|Single arm|
2852995|NCT03577236|Experimental|Zenflow Spring System|Receives treatment with the investigational device
2852996|NCT03577223|Experimental|Whole Eggs|
2852997|NCT03577223|Active Comparator|Egg White-Based Egg Substitute|
2852998|NCT03577210|Other|computer-guided augmentation genioplasty|patient-specific PEEK implant
2852999|NCT03577171|Experimental|ABI-H0731 & SOC NUC|Participants with chronic HBV who are currently not being treated will receive ABI-H0731 along with SOC NUC (entecavir [ETV]) tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.
2853000|NCT03577171|Experimental|Placebo & SOC NUC|Participants with chronic HBV who are currently not being treated will receive matching placebo along with SOC NUC (entecavir [ETV]) tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.
2853001|NCT03577158|Experimental|Closed-loop controller with exercise mitigation module|"Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with mitigation module.~Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFEAP with mitigation module) based on blood glucose estimations from CGM."
2853002|NCT03577158|Experimental|Closed-loop controller without exercise mitigation module|Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFEAP without mitigation module) based on blood glucose estimations from CGM.
2853003|NCT03577158|Active Comparator|Open-loop insulin infusion system|Standard Open-loop intensive insulin treatment with continuous subcutaneous insulin infusion (CSII). Commercially available insulin infusion systems will be used.
2853004|NCT03577145|Experimental|Tomato, onion & lovage soup with inulin|One dose of tomato (300g), onion (100g) & lovage (20g) with 10g inulin will be given to subjects in the form of a soup
2853005|NCT03577145|Experimental|Tomato, onion & lovage soup|One dose of tomato (300g), onion (100g) & lovage (20g) will be given to subjects in the form of a soup
2853006|NCT03577145|Experimental|Inulin|One dose of 10g inulin will be given to subjects in the form of a drink
2853155|NCT03576144|Experimental|BI 1265162|
2853007|NCT03577132|Experimental|Luminal type|Luminal type in previous transurethral resection of bladder tumor pathology. Luminal type in Immunohistochemistry (KRT5/6-KRT14-FOXA1+GATA3+)
2853008|NCT03577132|Experimental|Basal typr|Basal type in previous transurethral resection of bladder tumor pathology. Basal type in Immunohistochemistry (KRT5/6+KRT14+FOXA1-GATA3-)
2853009|NCT03577119|Experimental|Full-fat yogurt|Participants will receive a 21-day controlled diet that includes three daily servings of whole (3.25% fat) yogurt (38% of energy from fat, 44% of energy from carbohydrates, and 18% of energy from protein).
2853010|NCT03577119|Experimental|Non-fat yogurt (Control)|Participants will receive a 21-day controlled diet that includes three daily servings of fat-free yogurt (28% of energy from fat, 54% of energy from carbohydrates, and 18% of energy from protein).
2853011|NCT03577106|Experimental|Transcranial magnetic stimulation (TMS)|
2853012|NCT03577093||ischemic stroke|acute ischemic stroke patients within 6h after stroke onset
2853013|NCT03577093||control|healthy controls
2853014|NCT03577080|Active Comparator|ET+RT+ NMES|neuromuscular electrical training NMES
2853015|NCT03577080|Placebo Comparator|ET+RT|placebo neuromuscular electrical training NMES
2853016|NCT03577067||Patients submitted to liver resection|Patients underwent liver resection for primary and secondary disease
2853017|NCT03577054|Experimental|HBB Prompt|"The investigators will train frontline health providers in Helping Babies Breathe (HBB) 2.0 and Essential Care for Every Baby (ECEB). Providers will undergo ECEB training in addition to HBB as these training programs are recommended by the Uganda Ministry of Health to be offered together.~Providers at this hospital will have access to the most updated version of HBB Prompt (beta) after HBB training.~Participants in will be asked to achieve a minimum practice target of once per day (low-dose high frequency training). The recommended frequency to use the app will be once per shift."
2853018|NCT03577054|Placebo Comparator|Control|"The investigators will train frontline health providers in Helping Babies Breathe (HBB) 2.0 and Essential Care for Every Baby (ECEB). Providers will undergo ECEB training in addition to HBB as these training programs are recommended by the Uganda Ministry of Health to be offered together.~The control group will not have exposure to the HBB Prompt app post training. Participants in will be asked to achieve a minimum practice target of once per day (low-dose high frequency training)."
2853019|NCT03577028|Experimental|Experimental: HPN424-1001|"In Part 1 (Dose Escalation), HPN424 will be administered once weekly via IV infusion with dose escalation until an estimated therapeutic dose level has been reached.~In Part 2 (Dose Expansion), patients will receive HPN424 at the recommended phase 2 dose(s) established in Part 1 of the study. Study procedures will be the same in Part 1 and Part 2 of the study. Additional expansion cohorts of up to 18 patients per expansion cohort may be added."
2853020|NCT03577015||critically ill patients at risk for DIC|patients 18 years or older with a condition potentially associated with DIC, admitted to intensive care: severe infection/sepsis, solid tumor, hematologic malignancies, trauma, obstetric complications, acute pancreatitis
2853021|NCT03577002|Active Comparator|Clinician SICP|Advance care planning between primary care clinician and the patient/family using the Serious Illness Care Program (SICP)
2853022|NCT03577002|Active Comparator|Team SICP|Advance care planning between team members and the patient/family using the Serious Illness Care Program (SICP)
2853023|NCT03576989|Experimental|EPA+DHA Group|12 weeks of daily oral therapy with EPA+DHA (four opaque softgels to provide a total daily intake of 2.5 g of EPA + 0.5 g of DHA)
2853024|NCT03576989|Placebo Comparator|Placebo Group|12 weeks of daily oral therapy with placebo (four opaque softgels to provide a total daily intake of 2.5 mL of mineral oil)
2853025|NCT03576976|Active Comparator|Clinic-based Cognitive Remediation|Clinic-based cognitive remediation is the current standard of care in NY State outpatient programs. It consists of twice weekly group-based and clinician-led sessions.
2853026|NCT03576976|Experimental|Hybrid Cognitive Remediation|Hybrid cognitive remediation consists of one weekly group-based, clinician-led session plus independent cognitive practice.
2853027|NCT03576963|Experimental|Treatment (guadecitabine, nivolumab)|This study consists of an initial dose escalation followed by an expansion cohort. Dose escalation of guadecitabine starts from 30 mg/m^2 given SC on days 1-5 every 28 days in combination with fixed dose of nivolumab at 240 mg given IV on days 8 and 22 every 28 days. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered.
2853028|NCT03576950||Uterine rupture|Women with uterine rupture occurred during pregnancy.
2853029|NCT03576937||Cohort 1|Patients with advanced (incurable stage IIIB or IV), histologically proven, non-squamous NSCLC who are never- or light-smokers (≤10 pack year smoking history) and are being considered for systemic therapy in the first line setting are eligible. Blood will be collected prior to first line treatment for testing cfDNA with the GUARDANT360 assay. Testing of available diagnostic tissue for genomic abnormalities will be performed in all patients per standard of care at the participating sites.
2853030|NCT03576937||Cohort 2|Patients with advanced non-squamous NSCLC with known oncogenic drivers (such as EGFR, ALK, ROS-1, BRAF) that have failed tyrosine kinase inhibitor (TKI) therapy, and are being considered for subsequent therapy. Blood will be collected from patients at time of progression on TKI therapy for cfDNA testing with the GUARDANT360 assay. Testing of available diagnostic tissue for genomic abnormalities will be performed in all patients per standard of care at the participating sites.
2853031|NCT03576924|Active Comparator|Imposed-MICT|Continuous exercise for 30 minutes per session at 60-65% of heart rate max for five times per week, consistent with physical activity guidelines that advocate 150 minutes per week of moderate activity.
2853032|NCT03576924|Active Comparator|Imposed-HIIT|Five repeated vigorous intervals of 1-min duration at 85-90% of heart rate max with 1-min recovery periods, with 3-min warm-up and 2-min cool-down, making the total session duration 15 min for five times/week, equated to match the guidelines of 75 min of vigorous exercise per week.
2853033|NCT03576924|Experimental|CHOICE|Participants will always self-select the exercise type that they will do, either the IM-HIIT or the IM-MICT protocols, which will be matched to the parallel imposed conditions.
2853034|NCT03576911|Experimental|Coenzyme Q10|100mg CoQ10 capsule taken orally three times per day for 6 months
2853035|NCT03576911|Placebo Comparator|Placebo|Placebo capsule taken orally three times per day for 6 months
2853036|NCT03576898|Active Comparator|Topical ganciclovir 2%|
2853037|NCT03576898|Active Comparator|Oral valganciclovir 900 mg PO BID|
2853039|NCT03576885|Active Comparator|Treatment group - active|inhaled nitric oxide treatment will start at 20 ppm and continue for 2 weeks or until resolution of pulmonary hypertension, whichever comes first.
2853040|NCT03576885|Placebo Comparator|Treatment group - placebo|Placebo treatment will start at 20 ppm and continue for 2 weeks or until resolution of pulmonary hypertension, whichever comes first.
2853041|NCT03576885|No Intervention|Control group|Enrolled infants with no evidence of pulmonary hypertension will serve as the control group for incidence of death or bronchopulmonary hypertension
2853042|NCT03576872|Experimental|Psychoeducational intervention|"Psychoeducational will be conducted prior to chemotherapy.~Teach session will occur prior and during administration of chemo~A small quiz will be conducted to asses understanding of the educational binder"
2853043|NCT03576859|Other|cirrhotic patients with chronic liver failure|
2853044|NCT03576859|Other|cirrhotic patients without chronic liver failure|
2853045|NCT03576846|Experimental|Intervention|Stretching and Spinal Manipulative Therapy
2853046|NCT03576846|Active Comparator|Comparator|Stretching
2853047|NCT03576833|Experimental|Balloon|
2853048|NCT03576820|Experimental|Lidocaine|Subjects will receive a one time dose of 20mg of 2% lidocaine (1 mL) via nasal mucosal atomizer
2853049|NCT03576820|Placebo Comparator|Placebo|Subjects will receive a one time dose of 1 mL of 0.9% sodium chloride solution via nasal mucosal atomizer.
2853050|NCT03576807|Experimental|CD20 CAR-T cells|Experimental: CD20 CAR-T cells
2853051|NCT03576794|Active Comparator|Leflunomide treatment|Patients will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27. During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day in order to prevent early drug withdrawal due to side effects. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
2853052|NCT03576794|Placebo Comparator|Placebo control|Patients will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27. During the first 2 weeks after randomization patients will receive placebo 20 mg every other day in order to prevent early drug withdrawal due to side effects. After 2 weeks placebo will be increased to 20 mg once daily and this therapy will be continued during 12 months.
2853053|NCT03576781|Experimental|Real iTBS to the DLPFC|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
2853054|NCT03576781|Sham Comparator|Sham iTBS to the DLPFC|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
2853055|NCT03576781|Experimental|Real cTBS to the MPFC|One session of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
2853056|NCT03576781|Sham Comparator|Sham cTBS to the MPFC|One session of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
2853057|NCT03576768|Experimental|Real cTBS to the vmPFC|Ten sessions of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
2853058|NCT03576768|Sham Comparator|Sham cTBS to the vmPFC|Ten sessions of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
2853059|NCT03576768|Experimental|Real iTBS to the dlPFC|Ten sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
2853060|NCT03576768|Sham Comparator|Sham iTBS to the dlPFC|Ten sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
2853061|NCT03576755|Experimental|spironolactone|spironolactone, 100 mg capsule administered orally once daily for 12 months
2853062|NCT03576755|Placebo Comparator|placebo|matching placebo capsule administered orally once daily for 12 months
2853063|NCT03576742||patients|all who fulfil inclusion criteria and consent to participation; potential biomarkers will be documented
2853064|NCT03576729||Hurler syndrome participants|Participants who have MPS IH, also called Hurler syndrome
2853065|NCT03576729||Hurler-Scheie/Scheie participants|Participants who have either MPS IHS or MPS IS. MPS IHS is also called Hurler-Scheie syndrome. MPS IS is also called Scheie syndrome.
2853066|NCT03576729||Healthy Controls|Age-matched healthy controls
2853067|NCT03576716|Experimental|Study Population|D6-25-hydroxyvitamin D3 with vitamin D3
2853068|NCT03576703|Experimental|EX+H2O|Exercise and diet that did not include SSB
2853069|NCT03576703|Experimental|EX+SSB|Exercise and diet that includes SSB
2853070|NCT03576703|No Intervention|CONTROL|No exercise and diet that did not include SSB
2853071|NCT03576677|Active Comparator|Levosimendan|Study participants in this arm will receive a 6 hours infusion of levosimendan 0.2 µg/kg/min.
2853156|NCT03576144|Placebo Comparator|Placebo|
2862137|NCT03514277|Active Comparator|Local infiltration of Exparel|
2853072|NCT03576677|Placebo Comparator|Placebo|Study participants in this arm will receive a 6 hours infusion of placebo (sterile isotonic sodium chloride + 5% dextrose + vitamin B)
2853073|NCT03576664|Experimental|Carvedilol first|Carvedilol (25 mg) followed by Placebo oral capsule is administered in a crossover manner.
2853074|NCT03576664|Experimental|Placebo first|Placebo oral capsule followed by Carvedilol (25 mg) is administered in a crossover manner.
2853075|NCT03576651|Experimental|JHL1149|
2853076|NCT03576651|Active Comparator|US-sourced-Avastin™|
2853077|NCT03576651|Active Comparator|EU-sourced Avastin™|
2853078|NCT03576638|Active Comparator|Sinemet|Controlled Release 25/100
2853079|NCT03576638|Experimental|AP CD/LD|
2853080|NCT03576625|Placebo Comparator|High oleic sunflower oil (HOSO)|30 ml HOSO emulsion (equivalent to 9.9 ml oil) in a single dose, 56 days
2853081|NCT03576625|Experimental|Buglossoides oil emulsion|30 ml Buglossoides oil emulsion (equivalent to 9.9 ml oil) in a single dose, 56 days
2853082|NCT03576612|Experimental|Cohort 1: MGMT Unmethylated Patients|After confirmation of high grade glioma, AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8 and continues for 6 weeks. Temozolomide started after complete valacyclovir and stop when MGMT unmethylated result obtained. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.
2853083|NCT03576612|Experimental|Cohort 2: MGMT Methylated & undetermined Patients|After confirmation of high grade glioma, AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8. Temozolomide started after complete valacyclovir and continue during radiation then 5 week break and then begin adjuvant temozolomide dosing. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.
2853084|NCT03576599|Active Comparator|Zoledronic Acid Injectable Product|Patients randomized to treatment with Zoledronic Acid 5mg infusion, repeated after 3 months
2853085|NCT03576599|Placebo Comparator|Placebo|Patients randomized to Placebo infusion (saline), repeated after 3 months
2853086|NCT03576586|Experimental|Intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department"
2853087|NCT03576586|Placebo Comparator|Control|Attention placebo control (cognitive task for same amount of time) plus usual care in the maternity department
2853088|NCT03576573||Primary Total Hip Arthroplasty|Single arm study of subjects previously implanted with PROFEMUR® Xm Femoral Stems or PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® C Acetabular Components
2853089|NCT03576547|Experimental|Venetoclax + Ponatinib|
2853090|NCT03576534|No Intervention|Control|Standard of care
2853091|NCT03576534|Active Comparator|Study|PBUF used prior to Cardiopulmonary bypass
2853092|NCT03576521|Experimental|Ocoxin-Viusid®|The CT with Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles + OV nutritional supplement.
2853093|NCT03576521|Placebo Comparator|Placebo|The QT Adriamycin scheme 60 mg per m2 of Body Surface (SC) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles + a placebo of the OV nutritional supplement.
2853094|NCT03576508|Experimental|CNTX-4975-05 Intra-Articular (IA) Injection|Receives IA injection into the most painful OA knee.
2853095|NCT03576508|Active Comparator|Topical 8% Capsaicin Patch|Receives Capsaicin Patch on posterior rib cage.
2853096|NCT03576495|Experimental|Early Intervention / Retention Group|"We will assess the residents' knowledge, attitudes, and skills prior to and after the PACTS curriculum administration at half the sites (Early Intervention/Retention Group).~We plan to conduct follow-up testing after one year to evaluate learner retention.~Further, we will test post-exposure effect retention in the Early Intervention Group at the end of year 2."
2853097|NCT03576495|Active Comparator|Delayed Intervention Group|"We will conduct baseline testing prior to the standard residency curriculum, and administer the PACTS curriculum the following year.~We will examine both between- and within-group differences based on curriculum exposure in intervention year 1 as well as within-group differences for the Delayed Intervention Group at the end of year 2."
2853098|NCT03576482||Transport on foot|Patients go to operating room walking with their families and with their normal clothes
2853099|NCT03576482||Transport by stretcher on wheels|Patients go to operating room by stretcher on wheels and with hospital clothes. Normal routine of our hospital.
2853100|NCT03576469|Experimental|C1-esterase inhibitor [recombinant] (C1-INH-R)|"Single-site, open-label arm to evaluate the benefit of C1-INH-R in subjects with CVID who experience ADRs related to IVIG. The study will have 2 periods:~6 - 8 weeks - subjects will receive 2 infusions of IVIG every 3 - 4 weeks~9 - 12 weeks - subjects will receive 3 infusions of C1-INH-R prior to IVIG infusion every 3 - 4 weeks"
2853101|NCT03576456|Active Comparator|Alprazolam|Patients receive alprazolam 0.5 mg 1 hour prior to coronary angiography.
2853102|NCT03576456|Placebo Comparator|Placebo Oral Tablet|Patients receive placebo 1 hour prior to coronary angiography.
2853103|NCT03576443|Experimental|Treatment arm|Idelalisib 150 mg x 2 p o, until progression
2853104|NCT03576430|Active Comparator|active|active stress handling
2853105|NCT03576430|No Intervention|control|no stress handling
2853106|NCT03576417|Active Comparator|RT+ cisplatin|100 mg/m2 of cisplatin on days 1, 22,43 of RT
2853107|NCT03576417|Experimental|RT+ cisplatin + nivolumab|"360 mg of nivolumab 3 weeks before RT-Cisplatin~360 mg of novolumab on days 1, 22,43 of -RT-cisplatin"
2853108|NCT03576404|Experimental|Eligible participants|The intervention of patient-centered pharmacist care included a comprehensive interview patients conducted at month 3 and 5 ,which included and reviewing all their medications using concepts of MTM and MI All study participants were assessed at baseline and on monthly basis for the changes in the study outcomes.
2853109|NCT03576391|Experimental|Control condition|Control condition to assess whether the repetition of a RAM task without fatiguing task in between 2 repetitions affects trunk motor control and cortical movement preparation.
2853110|NCT03576391|Experimental|Physical Fatigue condition|Fatigue condition to assess whether a physical fatiguing task in between 2 RAM tasks affects trunk motor control and cortical movement preparation for the 2nd RAM.
2853157|NCT03576131|Experimental|GEN1029 (HexaBody®-DR5/DR5)|Open label, single arm trial where GEN1029 will be administered
2853111|NCT03576391|Experimental|Cognitive Fatigue condition|Fatigue condition to assess whether a cognitive fatiguing task in between 2 RAM tasks affects trunk motor control and cortical movement preparation for the 2nd RAM.
2853112|NCT03576378|Experimental|Experimental: Brentuximab vedotin plus EPEM|Brentuximab Vedotin dose will start at 1.2 mg/kg by intravenous (IV) infusion on Day1 and Day15 plus Cyclophosphamide 500mg/m2 IV on Day1 plus Procarbazine 100mg/m2 by mouth (OR) on Day1 through 5 plus Etoposide 60mg/m2 OR on Day15 through 19 plus Mitoxantrone 6mg/m2 IV on Day15 and Prednisone 30mg/m2 on Day1 through 5 of each 28-day treatment cycles for up to 6 total treatment cycles (approximately 24 weeks or 6 months)
2853113|NCT03576365|Experimental|VOICE Intervention Arm|Participants participate in the online VOICE program to learn about perceived control and stress reduction to improve voice outcomes.
2853114|NCT03576365|Sham Comparator|Information-Only Arm|Participants participate in the information only program to learn about voice problems, anatomy and physiology.
2853115|NCT03576352|Experimental|Pediatric anesthesiologist|10 rapid sequence tracheostomy (RST) on rabbit cadaver
2853116|NCT03576352|Experimental|Pediatric intensivists|10 rapid sequence tracheostomy (RST) on rabbit cadaver
2853117|NCT03576352|Experimental|Pediatric surgeons|10 rapid sequence tracheostomy (RST) on rabbit cadaver
2853118|NCT03576352|Experimental|Pediatric emergency physicians|10 rapid sequence tracheostomy (RST) on rabbit cadaver
2853119|NCT03576339|Sham Comparator|Sham Group - Free Gingival Graft + Sham Electric Stimulation|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 9 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Patient randomized to the SHAW Group will receive the simulation of the electrical stimulation process, thus non current will be applied.
2853120|NCT03576339|Experimental|Test Group - Free Gingival Graft + Electric Stimulation|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 9 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Conductive electrodes for electrical current application will be applied to the palatal donor area on each side of the wound at a distance of 3 mm from the wound edge. An alternating current of 100 microamperes (μA) at 9 kilohertz (kHz), will be distributed in order to traverse the operated area. A single application of electrical stimulation will be given for 120 seconds, five consecutive days.
2853121|NCT03576326|Experimental|Incentive Drawing|Eligible to earn a weekly drawing entry with different winning probabilities during the 6-month incentive intervention period. Possible winnings depend on toothbrushing performance: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will have an 18% chance of winning $25 and a 1% chance of winning $50 (expected $5 payout); high adherence threshold (brushing twice per day for 14 days in a week) will have a 34% chance of winning $25 and a 3% chance of winning $50 (expected $10 payout).
2853122|NCT03576326|No Intervention|Control - Delayed Incentive|No rewards during the first 12 months, but information on toothbrushing performance. After the Month 12 follow-up visit, may opt to participate in a delayed 6-month open label extension to earn the same monetary rewards the intervention group could earn Baseline through Month 6. Not a formal part of this trial, but rather a necessary condition to assure all participating parents/caregivers have the chance to earn the same monetary incentives.
2853123|NCT03576313|Experimental|intervention: IVM and DP|Mass Drug Administration with ivermectin (IVM) and dihydroartemisinin-piperaquine (DP) will be given to participants in the intervention villages plus the NMCP standard malaria control intervention
2853124|NCT03576313|Active Comparator|control: standard malaria control intervetions|Participants in the control clusters will receive only standard malaria control interventions such as Artemether Lumefantrine, LLINs, IRS, SMC and IPTp as implemented by the National Malaria Control Program (NMCP) of the Gambia
2853125|NCT03576300||control|subjects without dry eye and diabetes
2853126|NCT03576300||patients with diabetes and dry eye|diabetic patients with dry eye
2853127|NCT03576300||diabetics without dry eye syndrome|diabetic patients without dry eye
2853128|NCT03576300||dry eye syndrome patients without diabetes|non-diabetic patients with dry eye
2853129|NCT03576287|Experimental|apremilast|apremilast standard doses
2853130|NCT03576274|Experimental|TEHE only|"Participants in TEHE group will receive a combined technology and home exercise program.~During study visit: Participants will be trained to set weekly goal and discuss the progress (20 min), 2) Walking exercise (30 min); and 3) Exercise safety and body alignment (10 min).~At home: Participants will be instructed to walk at home to achieve the goal of 5,000 steps in week 1 and increase 1,000 steps/week until achieving 10,000 steps at 6 weeks. The reminding message will be sent to the patient 2 times a day (morning and evening). On each weekly visit (week 2-6), participants will spend 15 min review the daily step count and list barriers to exercise and possible solution."
2853131|NCT03576274|Experimental|TEHE+APA|"In additional to the TEHE program, participants will receive auricular point acupressure (APA) right before each weekly group exercise training.~During the study visit: Participants will be trained to evenly press the tape and seeds covering each ear point without rubbing.~At home: : Participants will be instructed to press the tape and seeds covering each ear point for 3 minutes per time with a 2-second pause in between pressing, three times daily (morning, afternoon and evening: 9 minutes total), even when they do not experience fatigue.~The tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day and will receive a new treatment before the group exercise training."
2853132|NCT03576274|Experimental|TEHE+ 14 min mindfulness body scan|"In addition to the TEHE program, the TEHE+MBI group will receive a audio-recording of a mindfulness-based body scan.~During the weekly study visit: Participants will be instructed to listen to the recorded mindfulness-based body scan in the morning and before bedtime.~At home: Participants will be asked to listen to this audiotape daily in the morning and before bedtime."
2853133|NCT03576274|No Intervention|Control (usual care)|The control group will receive instructions on how to use the physical activity tracker and mEMA application. Participants will be asked to meet with a research team member weekly to discuss their fatigue experience and receive general information about fatigue management.
2853134|NCT03576261|Experimental|Preoperative echo + fluids|20 individuals investigated by preoperative transthoracic echocardiography. Preoperative colloid fluid bolus (Gelofusine, Fresenius Kabi AB, Sweden) 6 ml/kg lean body weight, is infused intravenously immediately before anesthesia induction.
2853135|NCT03576261|Active Comparator|Preoperative echo, control|20 individuals investigated by preoperative transthoracic echocardiography. No intravenous fluids are infused before anesthesia induction.
2853136|NCT03576248|Experimental|In-phase 6 Hz prefronto-parietal tACS|6 Hz stimulation (1000 μA) with transcranial Alternative Current Stimulation (tACS) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3 of the 10-20 international scalp EEG system, with a return electrode in Cz) for 20 minutes. The phase difference between the two stimulation sites will be 0°.
2853137|NCT03576248|Sham Comparator|Sham prefronto-parietal tACS|The same stimulation as in in-phase transcranial Alternative Current Stimulation tACS (6 Hz F3 and P3 stimulation with 0° phase difference) will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation. The whole session duration is 20 minutes.
2853138|NCT03576248|Experimental|2 mA left prefrontal tDCS|2000 μA anodal trancranial Direct Current Stimulation (tDCS) will be applied over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system with a right supraoribtal return electrode (Fp2 of the 10-20 international scalp EEG system) during 20 minutes.
2853139|NCT03576248|Sham Comparator|Sham left prefrontal tDCS|The same stimulation as active trancranial Direct Current Stimulation (tDCS) (anodal F3 and return in Fp2) will start at 2 mA intensity for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation. The whole session duration is 20 minutes.
2853140|NCT03576235|Experimental|a treatment group|PG102P 1.5 g/day
2853141|NCT03576235|Placebo Comparator|a control group|placebo
2853142|NCT03576222|Active Comparator|patients with preventive PICO|PICO dressing is used in patients with incisional hernia intraoperatively
2853143|NCT03576222|Placebo Comparator|patients with preventive MEPORE|MEPORE dressing is used in patients with incisional hernia intraoperatively
2853144|NCT03576209|Active Comparator|Intervention Group|12 week Walking intervention
2853145|NCT03576209|No Intervention|Control Group|No walking program
2853146|NCT03576196|Experimental|Pain Neuroscience Education|"Single session of pain neuroscience education a week prior to surgery, of an individual character, lasting approximately 30 minutes, performed by a physiotherapist trained. The main contents addressed in the educational session were: neurophysiological aspects of pain, biopsychosocial aspects of pain, concept of peripheral and central sensitization, using audio-visual support, examples and metaphors for a better understanding by the patient, as reported in previous studies.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
2853147|NCT03576196|Other|Usual Care|"Patients in the control group received usual care, which consists of an educational session prior to surgery, based on medical, anatomical and pathological aspects of the syndrome.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
2853148|NCT03576183|Active Comparator|VLA1701|"VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)~The vaccine is administered orally in 2 doses about 1 week apart."
2853149|NCT03576183|Placebo Comparator|Placebo|"The buffer component of VLA1701 will be used as Placebo.~The vaccine is administered orally in 2 doses about 1 week apart."
2853150|NCT03576170|Active Comparator|aromatherapy-scent|
2853151|NCT03576170|Active Comparator|aromatherapy-touch|
2853152|NCT03576170|No Intervention|wait-list control|
2853153|NCT03576157|Experimental|Kilkari|Pregnant and postpartum women randomized to the Kilkari arm will receive health information messages over their mobile phone during pregnancy and up to 1 year postpartum.
2853154|NCT03576157|No Intervention|Comparison|Existing standard of care; no new health messages
2853158|NCT03576118|Experimental|Deep neuromuscular block|Deep neuromuscular relaxation and low pressure pneumoperitoneum
2853159|NCT03576118|Active Comparator|Moderate neuromuscular block|Moderate neuromuscular relaxation and standard pressure pneumoperitoneum
2853160|NCT03576105|Experimental|experimental group|G1 - 32 patients Photodynamic therapy with convention methylene blue as photosesintizer irrigation /sterile saline Conventional methylene blue as photosensitizer -Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes Photodynamic therapy -Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
2853161|NCT03576105|Active Comparator|positive control group|G2 - 32 patients Photodynamic therapy with oral formula of methylene blue as photosesintizer, treatment identical to G1, however methylene blue will be delivered in a new formulation for oral use (patent aplicattion INPI BR1020170253902) irrigation /sterile saline Photodynamic therapy -Methylene blue for oral use as photosensitizer-Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
2853162|NCT03576092||Normal Pregnancy|Healthy gestational age-matched pregnant patients from 32 - 41 weeks without a diagnosis of preeclampsia.
2853163|NCT03576092||Preeclampsia Pregnancy|Pregnant patients from 32 - 41 weeks with a diagnosis of preeclampsia based on standard criteria as outlined by the American Congress of Obstetrics and Gynecology (ACOG).
2853164|NCT03576079|Experimental|Laser therapy|12 laser sessions over 3 months
2853165|NCT03576079|Active Comparator|anterior re-positioning splint therapy|anterior re-positioning splint worn for 8 hours during night time for 3 months
2853166|NCT03576079|Placebo Comparator|inactive laser therapy|placebo laser for 12 sessions over 3 months
2853167|NCT03576066|Experimental|ABI-H0731 & SOC NUC|Virologically suppressed participants will receive ABI-H0731 along with SOC NUC (ETV, TDF or TAF) tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.
2853168|NCT03576066|Active Comparator|Placebo & SOC NUC|Virologically suppressed participants will receive matching placebo tablets and continue their SOC NUC (ETV, TDF or TAF) for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.
2853169|NCT03576053|Experimental|Histamine+cowhage+heat|
2853170|NCT03576053|Experimental|Histamine+cowhage+serotonin+pre-heating|
2853171|NCT03576053|Placebo Comparator|lidocaine and saline+heat|
2853172|NCT03576027|Experimental|Hyperbaric oxygen therapy|
2853173|NCT03576014|Experimental|BD03|"This study will be comprised of 3+3 dose escalation design with three dose levels, 0.6mg (cohort1), 2mg(cohort2), 6mg(cohort3).~Decision to increase dose will be guided by occurrence of DLT (dose limiting toxicity) evaluated 1week after the second injection (5weeks after first injection)"
2853174|NCT03576001|Experimental|Multi-modality intervention group|Hybrid exercise (functional electrical stimulation - leg cycling, FES LC plus arm ergometry) plus selective androgen receptor modulator (SARM)
2853175|NCT03576001|Placebo Comparator|Placebo group|Hybrid exercise plus placebo medication
2853176|NCT03575988||Diabetes group|
2853177|NCT03575988||Control group|
2853178|NCT03575975||Mobile-bearing ankle prosthesis user|Users of the Stryker Scandinavian Total Ankle Replacement (STAR) mobile-bearing prosthesis.
2853179|NCT03575975||Control|Healthy individual age- and gender-matched to a participant in the mobile-bearing prosthesis user group.
2853180|NCT03575975||Fixed-bearing ankle prosthesis user|Users of the INBONE II Total Ankle Replacement fixed-bearing prosthesis.
2853181|NCT03575962|Experimental|GSK3640254 Bis-hydrochloride followed by GSK3640254 mesylate|The subjects in this arm will receive an oral administration of 200 mg, as 2 GSK3640254 bis-hydrochloride salt Capsules(reference), as single oral dose, on the morning of Day 1 during Period 1 of the study. This will be followed by an oral administration of 200 mg, as 2 GSK3640254 Mesylate salt capsule (test), as single oral dose, on the morning of Day 1, during Period 2 of the study. The drug will be administered following a moderate calorie and fat meal. There will be a minimum washout of 7 days between each dose of study treatment.
2853182|NCT03575962|Experimental|GSK3640254 Mesylate followed by GSK3640254 Bis-hydrochloride|The subjects in this arm will receive an oral administration of 200 mg as 2 GSK3640254 Mesylate salt capsule (test), as single oral dose, on the morning of Day 1 during Period 1 of the study. This will be followed by an oral administration of 200 mg, as 2 GSK3640254 bis-hydrochloride salt Capsule, 100 mg (reference), as single oral dose, on the morning of Day 1 during Period 2, of the study. The drug, will be administered following a moderate calorie and fat meal. There will be a minimum washout of 7 days between each dose of study treatment.
2853183|NCT03575949|Experimental|FDG PET/CT|
2853184|NCT03575936|Active Comparator|Standard of Care Group|Standard of Care arm. Pharmacist intervention in clinic
2853185|NCT03575936|Experimental|Home Monitoring Group|Pharmacist intervention with home INR monitoring
2853186|NCT03575923||Intervention site 1|2 planted trees; bulb planting
2853187|NCT03575923||Comparison site 1A|
2853188|NCT03575923||Comparison site 1B|
2853189|NCT03575923||Intervention site 2|12 planted trees; bulb planting; artificial tree decorations (string lights)
2853190|NCT03575923||Comparison site 2A|
2853191|NCT03575923||Comparison site 2B|
2853192|NCT03575923||Intervention site 3|3 planted trees; artificial tree decorations (string lights, tree socks)
2853193|NCT03575923||Comparison site 3A|
2853194|NCT03575923||Comparison site 3B|
2853195|NCT03575923||Intervention site 4|8 planted trees; bulb planting; artificial tree decorations (string lights, tree socks)
2853196|NCT03575923||Comparison site 4A|
2853197|NCT03575923||Comparison site 4B|
2853198|NCT03575910||Acute Rejection (AR)|Heart transplant patients diagnosed with an ISHLT grade 2R or 3R via endomyocardial biopsy.
2853199|NCT03575910||Mild Rejection (MR)|Heart transplant patients diagnosed with an ISHLT grade 1R via endomyocardial biopsy.
2853200|NCT03575910||Non-Rejection (NR)|Heart transplant patients diagnosed with an ISHLT grade 0R via endomyocardial biopsy.
2853264|NCT03575377|No Intervention|Control|These families will receive routine postoperative instructions only.
2853201|NCT03575897|Experimental|Intervention Group|Infants randomly assigned to the intervention group will undergo serial measurements of infant body composition during their hospitalization. This information about infant body composition will be known to the clinicians caring for them (including reference data).
2853202|NCT03575897|Active Comparator|Control Group|Infants randomly assigned to the control group will also undergo serial measurements of infant body composition during their hospitalization, but this information will not be available to the clinicians caring for them.
2853203|NCT03575884|Experimental|Screen Time Reduction Curriculum|Fit5Kids curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices.
2853204|NCT03575884|No Intervention|Control|Students will be taught the standard preschool curriculum.
2853205|NCT03575871|Experimental|PF-04965842 100 mg|
2853206|NCT03575871|Experimental|PF-04965842 200 mg|
2853207|NCT03575871|Placebo Comparator|Placebo|
2853208|NCT03575858|Experimental|Barrel shaped interdental brushes|test group
2853209|NCT03575858|Active Comparator|Tapered interdental brushes|control group
2853210|NCT03575845|Experimental|Occupational therapy informed yoga|Occupational therapists adapted postures to meet the abilities and rehabilitation needs of individual breast cancer survivors engaging in group-delivered yoga sessions
2853211|NCT03575832|Experimental|Prostate Cancer Patients + Partners|
2853212|NCT03575819|Experimental|FOR46 (Dose Escalation)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
2853213|NCT03575819|Experimental|FOR46 (Dose Expansion)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
2853214|NCT03575806|Experimental|TACE+Tcm group|Experimental arm: TACE plus autologous Tcm immunotherapy to treat HCC.
2853215|NCT03575806|Active Comparator|TACE group|Active comparator: TACE to treat HCC.
2853216|NCT03575793|Experimental|Phase I: nivolumab, ipilimumab and plinabulin|"On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV) and plinabulin (escalating cohorts, IV).~After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment criteria occur.~Plinabulin escalation is as follows:~Level -1 : 13.5mg/m^2~Level 1 (start) : 20mg/m^2~Level 2 : 30mg/m^2"
2853217|NCT03575793|Experimental|Phase II Arm A: nivolumab and ipilimumab|"On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV).~After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with nivolumab 240 mg (maintenance period) until one of the end of treatment criteria occur ."
2853218|NCT03575793|Experimental|Phase II Arm B: nivolumab, ipilimumab, and plinabulin|"On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV) and plinabulin (MTD from Phase I).~After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment criteria occur ."
2853219|NCT03575780|Experimental|KX2-391 Ointment|KX2-391 ointment 1% will be administered once daily over 5 consecutive days
2853220|NCT03575741||Patients|After suffering from a concussion patients will be investigated 48 h, 72 h, 120 h, 360 h and 720 h after sustaining the injury. Postural control will be measured using 7 different easy balance tests.
2853221|NCT03575741||Control|Healthy children will be measured in the very same way to collect data of possible matched controls.
2853222|NCT03575728|Other|Mood disorder|Participants who screen positive for a history of mood disorders
2853223|NCT03575728|Other|Other|Participants who do not screen positive for a history of mood disorders
2853224|NCT03575715|Experimental|EBUS group|EBUS and guide sheath (GS) are inserted into bronchi in the assistance of navigation bronchoscopy. The EBUS probe and GS are confirmed to reach the lesion by EBUS images, cytologic and pathologic specimens are obtained with or without fluoroscopic guidance.
2853225|NCT03575702|Experimental|Uritos®|one tablet orally twice a day (after breakfast and dinner) for 12 weeks
2853226|NCT03575702|Active Comparator|Urotol®|one tablet orally twice a day (after breakfast and dinner) for 12 weeks
2853227|NCT03575689|Experimental|Splint|A. The Doyle splint will be places in both nostrils of the patient after septoplasty. The doyle splints will be removed 6 days after surgery as per standard of care. No other procedures will be changed during the surgery.
2853228|NCT03575689|No Intervention|No Splint|B. No Doyle splints will be placed in the nostrils of the patient after septoplasty. All standart of care visits will remain the same.
2853229|NCT03575676|Experimental|Group A|Administration of SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks, SOM3355 100mg BID for 6 weeks and placebo BID for 6 weeks.
2853230|NCT03575676|Experimental|Group B|Administration of placebo BID for 6 weeks, SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks and SOM3355 100mg BID for 6 weeks.
2853231|NCT03575650||Cardiac imaging modalities|Repeat echocardiography (cECHO), cardiac MRI (cMRI) scans and cardiac CT (cCT) scans will be performed to evaluate myocardial dysfunction and deformation; myocardium inclusing tissue abnormalities, cardiac morphology and function and; coronary artery lesions and coronary artery calcium score.
2853232|NCT03575637|Experimental|Olanzapine intervention group|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
2853233|NCT03575637|No Intervention|Control group|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen.
2853234|NCT03575624|Experimental|Nutrition, goal-setting, yoga|Behavioral: Nutritional and goal-setting education, yoga to promote achievement of change in health behaviors. SMART goal setting was used to guide nutritional and physical activity change to decrease disease risk and promote well-being.
2853235|NCT03575611|Experimental|Radiation Therapy|Study doctor discusses with participant the dose and schedule of radiation that participant receives, based on the disease site. It can take 1 day to 3 weeks.
2853265|NCT03575364||Primary Analytic|Patients with unilateral acute and/or chronic DVT of less than six weeks' duration.
2853236|NCT03575598|Experimental|Sitravatinib and Nivolumab|"Patients will start therapy with sitravatinib within 10 days of study enrollment. Sitravatinib will be given at 120mg once daily on a continuous basis until 48 hours before planned surgery, or for a maximum period of 28 days.~Nivolumab will be given as a single infusion at a dose of 240mg, over a period of 30 minutes on Day 15 of the study."
2853237|NCT03575585|Experimental|Comparator: No Feedback, Standard Counselor|Patient assigned to a Standard Training counselor, completed the BEST assessment, but did NOT receive a feedback report.
2853238|NCT03575585|Experimental|Active1: Feedback, Standard Counselor|Patient assigned to a Standard Training counselor, completed the BEST assessment, and received a personalized feedback report.
2853239|NCT03575585|Experimental|Active2: No feedback, Enhanced Counselor|Patient assigned to a Enhanced Training counselor, completed the BEST assessment, but did NOT receive a feedback report.
2853240|NCT03575585|Experimental|Active3: Feedback, Enhanced Counselor|Patient assigned to a Enhanced Training counselor, completed the BEST assessment, and received a personalized feedback report.
2853241|NCT03575572|Experimental|Colchicine|Colchicine will be given at 0.6 mg once daily for the duration of chest tube output plus 24 hours after chest tube removal with a maximum of 4 weeks duration.
2853242|NCT03575559|Experimental|Individual planning|An education and general motivational treatment is provided to each participant. Afterwards, participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form up to three own individual plans. They are not allowed to speak to each other. The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, problem solving (coping planning). Interventions: Behavioral: Individual planning. Behavioral: Education and motivation. Active Comparator: No planning intervention, individual distraction task.
2853243|NCT03575559|Experimental|Collaborative planning|An education and general motivational treatment is provided to each participant. Afterwards, participants are filling in the planning forms together, referring to their joint physical activity. The friendship dyad forms up to three joint plans about engaging in PA together. The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, problem solving (coping planning). Interventions: Behavioral: Collaborative planning. Behavioral: Education and motivation. Active Comparator: No planning intervention, collaborative distraction task.
2853244|NCT03575559|Active Comparator|Individual distraction task|An education and general motivational treatment is provided to each participant. Afterwards, participants have to interpret a short video showing scenes of two different superhero movies. Several questions will be asked about characteristics of the two super heroes in the movie and whether these heroes are comparable. Each participant watches the movie alone and answers all questions by him/herself. Both members of the dyad are not allowed to speak to each other.
2853245|NCT03575559|Active Comparator|Collaborative distraction task|An education and general motivational treatment is provided to each participant. Afterwards, participants have to interpret a short video showing scenes of two different superhero movies together. Several questions ask about the characteristics of the two super heroes in the movie and whether these heroes are comparable. Both members of the dyad watch the movie together and answer the questions conjointly.
2853246|NCT03575520|Experimental|Peg group|
2853247|NCT03575507|Experimental|Treatment Group|Treatment with the investigational device BTL EMSCULPT.
2853248|NCT03575494||female infertility|Women who had regular menses and can't conceive despite a long-term regular sexual intercourse for more than 12 months
2853249|NCT03575494||healthy|healthy patients who had minimum two normal pregnancies
2853250|NCT03575481||Post stroke patients|
2853251|NCT03575468|Experimental|Enhanced E-cigarette Coaching (EEC) Intervention|
2853252|NCT03575468|Active Comparator|Quitline treatment as usual (TAU)|
2853253|NCT03575455|Experimental|Exercise|"Concussed participants will participate in a single 20' bout of treadmill walking at either 40% or 60% of the age-predicted HRmax.~Healthy participants will participate in a single 20' bout of treadmill walking at either 40% or 60% of the age-predicted HRmax."
2853254|NCT03575455|No Intervention|Seated Control|"Concussed participants will participate in a single 20' treatment session of seated rest.~Healthy participants will participate in a single 20' treatment session of seated rest."
2853255|NCT03575442|Other|"3 session program of art therapy"|Development of the program applied as a group, during three weeks, one session a week, each lasting approximately 90 minutes and assisted by a specialist in plastic expression. Each session was held in an occupational therapy room, including all the material deemed necessary for the execution of some of the techniques introduced by the technician. After each session, a semi-structured interview was conducted with each participant in order to analyze the meanings attributed.
2853256|NCT03575429|Active Comparator|Engagement Intervention|Family navigators will engage families to access resources and support when they first learn their child has signs of autism spectrum disorder (ASD) using an intervention that integrates motivational interviewing (MI) and problem-solving education (PSE). The family navigator will meet with parents for up to 6 individual MI+PSE sessions for each 3-month stage of intervention.
2853257|NCT03575429|Active Comparator|Engagement + Coaching Intervention|Family navigators will engage families to access resources and support when they first learn their child has signs of autism spectrum disorder (ASD) using an intervention that integrates MI+PSE. Family navigators will also coach families to embed intervention strategies for toddlers with ASD in everyday activities using the Early Social Interaction (ESI) model. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places. The family navigator will meet with parents for 12 weekly home visits for each 3-month stage of intervention.
2853258|NCT03575403|Placebo Comparator|Placebo|Subjects will receive oral placebo capsules one time daily.
2853259|NCT03575403|Experimental|Low Dose Duloxetine|Subjects will receive 30 mg oral duloxetine one time daily.
2853260|NCT03575403|Experimental|High Dose Duloxetine|Subjects will receive 60 mg oral duloxetine one time daily.
2853261|NCT03575390|Placebo Comparator|control group|Control group will receive placebo medication therapy
2853262|NCT03575390|Experimental|test group|pomegranate group will receive oral pomegranate (500 mg, twice per day)
2853263|NCT03575377|Experimental|Deterra Bag|These families will receive a Deterra® bag (a drug Disposal Aid) and instructions on its use by a research team member.
2853267|NCT03575351|Active Comparator|Arm A - Standard of Care (SOC)|Subjects should receive SOC (R-DHAP, R-ICE or R-GDP) followed by HDCT (BEAM) and HSCT. Standard of care regimen will be administered as per investigator decision.
2853268|NCT03575351|Experimental|Arm B - JCAR017|Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently followed by JCAR017 infusion.
2853269|NCT03575338|Active Comparator|Open Scarf Osteotomy|This group of patients will undergo surgery performing an open scarf osteotomy
2853270|NCT03575338|Experimental|Minimally invasive scarf Osteotomy|This group of patients will undergo surgery performing a Minimally invasive scarf osteotomy
2853271|NCT03575325|Experimental|CPX-351 Treatment|"Participants will receive induction with CPX-351 at a dose of 100 u/m^2 administered intravenously over 90 minutes on days 1, 3 and 5 of a 28 day cycle.~This may be followed by consolidation with CPX-351 at a dose of 65 u/m^2 administered intravenously over 90 minutes on days 1 and 3 of a 28 day cycle (up to 3 cycles)."
2853272|NCT03575312|Experimental|Enrofloxacin|enrofloxacin by dermal route, by inhalation, oral adminstration
2853273|NCT03575299|Experimental|Study group|Patients will be treated with anti-tuberculosis drugs, and meanwhile will be treated with Allogeneic γδT cells.
2853274|NCT03575299|Placebo Comparator|Control Group|Patients will be treated with anti-tuberculosis drugs, and meanwhile will not be treated with allogeneic γδT cells.
2853275|NCT03575286||Pregnant female|Patient has been determined pregnant with a urine pregnancy test and, if applicable, a serum pregnancy test performed at Northwestern University.
2853276|NCT03575286||Non-pregnant female|Patient has been determined not pregnant with a urine pregnancy test and, if applicable, a serum pregnancy test performed at Northwestern University.
2853277|NCT03575273|Experimental|Opioid dependence receiving methadone|Patients with a history of opioid dependence receiving methadone maintenance therapy will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
2853278|NCT03575273|Experimental|Opioid dependence not on methadone|Patients with a history of opioid dependence not current receiving methadone maintenance therapy will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
2853279|NCT03575273|Active Comparator|Healthy controls|Healthy controls without history of opioid use will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
2853280|NCT03575260||Fulvestrant|Fulvestrant 500 mg on days 0, 14, and 28, and every 28 days thereafter
2853281|NCT03575260||Exemestane|Exemestane 25mg per day
2853282|NCT03575234|Experimental|Cohort 1: HPV-Related Oropharynx SCC|HPV-positive oropharynx cancer patients receive nivolumab IV over 60 minutes on days 1 and 15, cyclophosphamide IV on day 1, and IRX-2 SC over 10 consecutive days between days 4-21 in the absence of disease progression or unacceptable toxicity. Beginning days 25-30, patients undergo surgery.
2853283|NCT03575234|Experimental|Cohort 2: HPV-Negative Oral Cavity SCC|HPV-negative oral cavity cancer patients receive nivolumab IV over 60 minutes on days 1 and 15, cyclophosphamide IV on day 1, and IRX-2 SC over 10 consecutive days between days 4-21 in the absence of disease progression or unacceptable toxicity. Beginning days 25-30, patients undergo surgery.
2853284|NCT03575221||Patients|Patients
2853285|NCT03575208|Experimental|Arm 1|HBIg x 12 weeks followed by peginterferon alfa-2a 180ug x 24 weeks
2853286|NCT03575208|Experimental|Arm 2|peginterferon alfa-2a 180ug x 24 weeks
2853287|NCT03575195|Experimental|Intervention|Rifaximin
2853288|NCT03575195|Placebo Comparator|Placebo|Matching placebo
2853289|NCT03575182|Experimental|Gait retraining program|
2853290|NCT03575182|No Intervention|Physical therapy standard care|
2853291|NCT03575169||Patients with TBI|Admitted to Aberdeen ICU with diagnosis of TBI and expected to require greater than 24 hours sedation.
2853292|NCT03575156|Experimental|Systemic lupus erythematosus (SLE)|
2853293|NCT03575156|Experimental|systemic scleroderma (SSc)|
2853294|NCT03575143||PLWH+OSA|Subjects diagnosed with both Human Immunodeficiency Virus and Obstructive Sleep Apnea
2853295|NCT03575143||PLWH-OSA|Subjects diagnosed with both Human Immunodeficiency Virus without Obstructive Sleep Apnea
2853296|NCT03575130|Experimental|Glanatec|
2853297|NCT03575130|Placebo Comparator|Placebo|
2853298|NCT03575117|Experimental|NCI HYT--GA + CSM--Be Well|"Participants who view the Common Sense Model (CSM) Be Well text and image communication will be invited to receive two sets of daily text messages: (1) one text message and one image per day and (2) National Cancer Institute (NCI) HealthyYouTXT-Get Active (HYT-GA) program that is delivered 2-5 times daily for 6 weeks. After baseline and at timepoint 2, participants will view a slide presentation with imagery and text related to colorectal cancer risk and sedentary lifestyle. The same messages will be delivered as a drip campaign alongside the NCI HYT-GA text messaging program."
2853299|NCT03575117|Other|NCI HYT--GA + ACS usual messages|Adapted American Cancer Society (ACS) informational messages about colorectal cancer risk and lifestyle will be invited to receive one set of daily text messages, NCI HealthyYouTXT-Get Active (HYT-GA) program that is delivered 2-5 times daily for 6 weeks. After baseline and at timepoint 2, participants will view an informational slide presentation that is based on adapted language from American Cancer Guidelines related to cancer prevention and physical activity (https://www.cancer.org/healthy/eat-healthy-get-active/acs-guidelines-nutrition-physical-activity-cancer-prevention.html).
2853300|NCT03575104|Experimental|ACT-541468 10 mg|ACT-541468 will be administered as tablets, orally, once daily in the evening.
2853301|NCT03575104|Experimental|ACT-541468 25 mg|ACT-541468 will be administered as tablets, orally, once daily in the evening.
2853302|NCT03575104|Placebo Comparator|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
2853303|NCT03575091|No Intervention|control group|The infants will receive the standard care at the ward.
2853304|NCT03575091|Experimental|Changing positions|The parents will be guided manually and receive written information of how to change body positions of their child regularly.
2853305|NCT03575091|Experimental|Physiotherapy|The child will be given physiotherapy including light chest compressions, change of body positions and stimulation to deep breathing.
2853306|NCT03575078|Experimental|Maximum tolerated dose of ARQ761 in combination with Olaparib.|ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
2853307|NCT03575065|Experimental|TNBC|Locally advanced or metastatic TNBC with confirmed either deleterious or suspected deleterious germline BRCA1/2 mutation.
2853308|NCT03575065|Experimental|HR(+)/HER2(-) breast cancer|Locally advanced or metastatic HR(+)/HER2(-) breast cancer with confirmed either deleterious or suspected deleterious germline BRCA1/2 mutation.
2853309|NCT03575052|Experimental|Drug - Pimavanserin|
2853310|NCT03575052|Placebo Comparator|Placebo|
2853311|NCT03575039|Experimental|Single arm clinical investigation|Subjects in experimental group will be implanted the VitaFlow II Transcatheter Aortic Valve System.
2853312|NCT03575026|Experimental|Intervention|Subjects will receive 12-week music-with-movement intervention at home by their trained caregivers for 12 weeks, at least 3 sessions per week and 30 minutes for each session.
2853313|NCT03575026|Placebo Comparator|Wait-list control|Subjects will receive 12-week usual care (social activity) at home. Dose is similar to intervention arm. After the completion of 12-week usual care, subjects will receive the same music intervention as intervention arm.
2853314|NCT03575013|Experimental|Avelumab and Docetaxel|"Induction phase:~Avelumab (10 mg/kg) + Docetaxel (75 mg/m2) every 3 weeks for 6 cycles~Maintenance phase:~Avelumab (10 mg/kg) every 2 weeks until disease progression or toxicity"
2853315|NCT03575000|Experimental|Bromocriptine|This is an open-label study, so there is no comparator group. As such there is only one arm. Subjects will receive bromocriptine at a starting dose of 2.5mg daily which will be increased, if tolerated, to 5mg daily after one week. Bromocriptine will be continued for a total of 6 weeks. Laboratory investigations, telephonic interviews, and face to face visits with subjects will be conducted before, during, and after the time period that bromocriptine will be used as detailed in the study design section.
2853316|NCT03574987|Active Comparator|CONTROL|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
2853317|NCT03574987|Experimental|LOW SUG|Diet consisting of 50% carbohydrate (<5% sugar), 15% protein, 35% fat
2853318|NCT03574987|Experimental|LOW CHO|Diet consisting of <8% carbohydrate (<5% sugar), 15% protein, >77% fat
2853319|NCT03574974|Experimental|Experimental Feedback Intervention|Participants receive real-time feedback during fMRI scans that the investigators believe may help them learn to control their PTSD symptoms.
2853320|NCT03574974|Placebo Comparator|Control Feedback Intervention|Participants receive real-time feedback during fMRI scans that the investigators do not believe can help their PTSD symptoms.
2853321|NCT03574961|Experimental|e-Support Group|Participants in this arm will receive the treatment, 12 weeks of 1-hr weekly moderated e-Support sessions.
2853322|NCT03574961|Placebo Comparator|e-Journaling Placebo|Participants in this arm will complete 12 weeks of 1-hr weekly online journaling activities.
2853323|NCT03574948|Experimental|5-HTP|8 weeks active substance 5-HTP (2 x 100 mg per day)
2853324|NCT03574948|Placebo Comparator|placebo oral capsule|8 weeks placebo (2 x 1 capsule per day)
2853325|NCT03574935|Experimental|External Chinese medicine|"External Chinese medicine include 3 kinds of formula，including:~Qin, Hua and Bu will be applied to cover the participants' lesions in wet dressing form. Dosage form:5g/ml; frequency:qd; duration:2months."
2853326|NCT03574935|Active Comparator|External Western medicine|Ethacridine Lactate Solution, 1% Sulfadiazine Silver Cream and rb-bFGF will be applied to cover the participants' lesions. Dosage form:3g/ml; frequency:qd; duration: 2months.
2853327|NCT03574922|Active Comparator|Balance Exercises|Balance Exercises
2853328|NCT03574922|Active Comparator|Core Stabilization Exercises|Balance and core stabilization exercises
2853329|NCT03574909|Experimental|Treatment Arm|"Treatment Arms: Tromalyt® 150mg prolong release capsule for oral ingestion. The capsule contains 150mg of anti-platelet agent acetylsalicylic acid, maize starch and Sucrose 20:80. The capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethylcellulose and Triacetin. The capsule is made with gelatin, erythrosine, quinoline yellow, titanium dioxide. Tromalyt® is trademark of Meda Pharma SL (Reg 59.210).~There is no requirement for the first dose to be administered in the clinic under observation.~The dosing frequency is once daily. Subjects will be instructed to take the study medication at the same time each day.~No specific precautions are required in relation to concomitant food intake."
2853330|NCT03574909|Placebo Comparator|Control Arm|"Placebos to be used are hard gelatin capsules (Sanitatis®) for patients randomized to the placebo arm. These capsules are externally identical to Tromalyt capsule. The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate (Sanitatis®) Placebo: There is no requirement for the first dose to be administered in the clinic under observation.~The dosing frequency is once daily. Subjects will be instructed to take the study medication at the same time each day.~No specific precautions are required in relation to concomitant food intake."
2853331|NCT03574883|Experimental|In-phase tACS|6 Hz stimulation (1000 μA) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator. The phase difference between the two stimulation sites will be 0°.
2853332|NCT03574883|Active Comparator|Anti-phase tACS|6 Hz stimulation (1000 μA) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator. The phase difference will be 180°,
2853333|NCT03574883|Sham Comparator|Sham tACS|The stimulation (anti-phase) will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation.
2853334|NCT03574883|Experimental|Active tDCS|1000 μA tDCS stimulation will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator
2853335|NCT03574883|Sham Comparator|Sham tDCS|The stimulation will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation.
2853423|NCT03574350|Experimental|KS in Kangaroo Position (KSKP)|KS is performed while the infant is in Kangaroo Position using a lycra band to maintain the position.
2853336|NCT03574870|Experimental|Chemoraditherapy|"Patients with head and neck cancer require chemo and radiation therapy (Cohort A):~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from the time of their radiation simulation through one week following the end of radiation treatment"
2853337|NCT03574870|Experimental|Primary surgery w/o radiotherapy|"Patients with head and neck cancer require primary surgery alone (Cohort B-SA)~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from one week before surgery through 1 month following surgery~Patients with head and neck cancer require primary surgery and postoperative radiotherapy (Cohort B-RT)~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from one week before surgery to one week following the end of radiation treatment ."
2853338|NCT03574857|Active Comparator|Metolazone|Metolazone 5 mg by mouth once daily for 2 days
2853339|NCT03574857|Active Comparator|Chlorothiazide|Chlorothiazide 500 mg IV once daily for 2 days
2853340|NCT03574844|Experimental|Saccharomyces cerevisiae, dose 500|Saccharomyces cerevisiae CNCM I-3856, 500 mg per day (2 capsules), for 4 weeks
2853341|NCT03574844|Experimental|Saccharomyces cerevisiae, dose 1000|Saccharomyces cerevisiae CNCM I-3856, 1 g per day (2 capsules), for 4 weeks
2853342|NCT03574844|Placebo Comparator|Placebo|Maize starch and magnesium stearate, 1 g per day (2 capsules), for 4 weeks
2853343|NCT03574831||Stretta|Radio Frequency Ablation (RFA) using a Stretta device.
2853344|NCT03574818|Experimental|Arm 1|"Chemotherapy and Necitumumab Regimen Gemcitabine 1250mg/m2 IV over 30 minutes, days 1 and 8 following necitumumab, Cisplatin 75mg/m2 IV over 60 minutes, day 1, immediately following gemcitabine,each cycle is 3 weeks (21 days).~Necitumumab 800mg absolute dose IV over a minimum of 60 minutes, days 1 and 8 prior to chemotherapy regimen Each cycle is 3 weeks (21 days).~The regimen will be given for a total of 3 cycles.~The regimen will be given for a total of 3 cycles."
2853345|NCT03574805|Active Comparator|PRS-060|PRS-060 or equivalent Placebo administered BID for study days 1-10
2853346|NCT03574805|Placebo Comparator|Placebo|PRS-060 or equivalent Placebo administered BID for study days 1-10
2853347|NCT03574792|Active Comparator|Arm I (gabapentin, methadone, oxycodone)|Participants receive gabapentin PO daily or TID. Participants may also receive methadone PO TID and oxycodone PO every 8 hours as needed. Treatment continues for up to 12 months in the absence of disease progression or unacceptable toxicity.
2853348|NCT03574792|Experimental|Arm II (gabapentin, methadone, oxycodone, venlafaxine)|Participants receive gabapentin, methadone, and oxycodone as in Arm I and venlafaxine PO BID or venlafaxine hydrochloride extended release daily for up to 12 months in the absence of disease progression or unacceptable toxicity.
2853349|NCT03574779|Experimental|Cohort A: 1-2 prior lines of therapy|PARP Inhibitor-Naive Platinum-Resistant Ovarian Cancer Treatment Cohort with TSR-042, Bevacizumab, and Niraparib. TSR-042 administered 500mg every 3 weeks for 4 cycles, followed by 1,000 mg every 6 weeks thereafter. Bevacizumab administered 15 mg/kg every 3 weeks for up to 15 months. Niraparib 200 or 300 mg per day.
2853350|NCT03574766|Experimental|Meditation Group|Twenty minutes of daily meditation for 7 days. Routine lactation support.
2853351|NCT03574766|No Intervention|Control Group|Routine lactation support.
2853352|NCT03574753|Experimental|ABBV-399|"C-MET overexpression is seen in 30% of patients with lung squamous cell carcinoma (SCCA). ABBV-399 (Process II) is a first-in-class antibody-drug conjugate (ADC) comprised of ABT-700, an anti-c-Met monoclonal antibody linked to monomethyl auristatin E (MMAE), which is a potent microtubule inhibitor. This delivers a direct anti-mitotic effect without relying on MET pathway inhibition.~ABBV-399 will be administered intravenously on day 1 of each 21-day cycle. Treatment will continue in consenting patients until disease progression or intolerable toxicity."
2853353|NCT03574740||Entire population|All patients included in this retrospective study. These patients were analyzed following their tobacco smoking habits.
2853354|NCT03574701|Experimental|A: Vitamin A and Olfactory Retraining|Group A: This study group will receive intranasal vitamin A at 10,000 I.U. per day and olfactory retraining using scented oils in addition to their standard of care.
2853355|NCT03574701|Experimental|B: Vitamin A|Group B: This study group will receive Vitamin A in addition to their standard of care. They will not receive olfactory retraining.
2853356|NCT03574701|No Intervention|C: Standard of Care|Group C: This study group will receive only standard of care .
2853357|NCT03574688|Experimental|Water intervention|The participants increase their habitual daily water intake with 1.5 Liters of tap water per day during 6 weeks.
2853358|NCT03574675|Experimental|Order Sham/Hypoxia|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
2853359|NCT03574675|Experimental|Order Hypoxia/Sham|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
2853360|NCT03574662|Experimental|Frailty assessment in Advanced heart failure|Subjects with advanced heart failure defined as current or recent (within the last 3 months) New York Heart Association (NYHA) class III or IV symptoms.
2853361|NCT03574649|Experimental|NANT NSCLC Combination Immunotherapy regimen|
2853362|NCT03574649|Active Comparator|Standard of Care|
2853363|NCT03574636|Active Comparator|OCT guidance|"Before Firehawk stent implantation, high-speed rotational will be performed with Optical Coherence Tomography guidance.~At the end of the procedure, a final DSA imaging run must be performed. At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
2853364|NCT03574636|Active Comparator|IVUS guidance|"Before Firehawk stent implantation, high-speed rotational will be performed with Intravascular Ultrasound guidance.~At the end of the procedure, a final DSA imaging run must be performed. At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
2853424|NCT03574350|Active Comparator|KS in incubator (KSI)|The infant is in the incubator, unclothed with diaper.
2858112|NCT03541525||Non affected relatives|Biological samples of blood for all relatives.
2853365|NCT03574636|Active Comparator|Coronary PCI guided by Angiography|"stenting will be performed with angiography guidance according to standard practice.~At the end of the procedure, a final DSA imaging run must be performed. At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
2853366|NCT03574623|Experimental|CCFES|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses an electrical stimulator and surface electrodes placed over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. During the lab visits, participants in the CCFES group will use CCFES to assist hand opening during occupational therapy task practice. During their home sessions, participants in the CCFES group will use CCFES to perform hand opening exercise.
2853367|NCT03574623|Active Comparator|cNMES|Cyclic Neuromuscular Electrical Stimulation (cNMES) uses an electrical stimulator and surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation to open the weak hand. The stimulation automatically turns on and off causing the weak hand to open repetitively for several seconds at a time. During the lab visits, participants in the cNMES group will receive occupational therapy task practice. During their home sessions, participants in the cNMES group will use cNMES to perform hand opening exercise.
2853368|NCT03574623|Active Comparator|Task Oriented Therapy|Task Oriented Therapy (TOT) focuses on practicing using the weak hand to practice activities of daily living tasks. During the clinic visits, participants in the TOT group will receive occupational therapy task practice. During their home sessions, participants in the TOT group will practice using their hand to complete a list of tasks given to them by the therapist to ensure that the participant receives a high dose of task practice.
2853369|NCT03574610||Subjects with Multiple Sclerosis and Voiding Dysfunction|Subjects with Multiple Sclerosis (MS) and voiding dysfunction (VD). In this group 'Transcranial Rotating Permanent Magnet Stimulator (TRPMS)' device will be used.
2853370|NCT03574610||Subjects with other causes of Voiding Dysfunctions|Subjects in this group have other causes of neurogenic voiding dysfunction, VD (such as stroke)
2853371|NCT03574597|Experimental|Semaglutide|Participants will receive semaglutide as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
2853372|NCT03574597|Placebo Comparator|Placebo (semaglutide)|Participants will receive placebo (semaglutide) as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
2853373|NCT03574584|Experimental|NNC0165-1562 + Semaglutide|Participants will receive NNC0165-1562 and semaglutide once weekly for 20 weeks.
2853374|NCT03574584|Experimental|Placebo (NNC0165-1562) + Semaglutide|Participants will receive placebo (NNC0165-1562) and semaglutide once weekly for 20 weeks.
2853375|NCT03574571|Experimental|Docetaxel|Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses. Prednisone will be given at a dose of 5mg orally twice daily.
2853376|NCT03574571|Experimental|Docetaxel with Radium-223|Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses. Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
2853377|NCT03574558|Experimental|MD-Logic Switch Advisor|MD-Logic Switch Advisor Algorithm for pesonalized automated determination of insulin pump settings for subjects with type 1 diabetes switching from MDI to pump therapy and vice versa
2853378|NCT03574545|Active Comparator|Reference VAY736 Drug Product|Powder for solution for injection / infusion
2853379|NCT03574545|Experimental|Test VAY736 Drug Product|Solution for injection
2853380|NCT03574532||Hospitalized adults with RSV, hMPV and influenza A infections|Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) and Influenza A Infected adults that required hospitalization due to the ARTI during the prespecified recent past season(s) will be retrospectively observed to describe the proportion and burden of the different types of respiratory pathogens. The primary data source for this study will be the medical records of each participating patient.
2853381|NCT03574532||Hospitalized infants/children with RSV or hMPV infection|Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) and Infected Infants/Children that required hospitalization due to the ARTI during the prespecified recent past season(s) will be retrospectively observed to describe the proportion and burden of the different types of respiratory pathogens. The primary data source for this study will be the medical records of each participating patient.
2853382|NCT03574519|Experimental|Non-contingent incentives and weekly feedback|Participants will receive payment for participating in the study (regardless of goal attainment) and will receive weekly updates about their performance.
2853383|NCT03574519|Experimental|Non-contingent incentives and daily feedback|Participants will receive payment for participating in the study (regardless of goal attainment) and will receive daily updates about their performance.
2853384|NCT03574519|Experimental|Contingent incentives and weekly feedback|Participants will receive payment for meeting their daily goals and will receive weekly updates about their performance.
2853385|NCT03574519|Experimental|Contingent incentives and daily feedback|Participants will receive payment for meeting their daily goals and will receive daily updates about their performance.
2853386|NCT03574493||Open laparotomy|A surgical procedure involving a large incision through the abdominal wall to gain access into the abdominal cavity.
2853387|NCT03574493||Laparoscopic surgery|A minimally-invasive technique in which operations are performed via small incisions (usually 0.5-1.5 cm) at a location distant to the site of interest.
2853388|NCT03574493||Robot-assisted surgery using the da Vinci® Surgical System|A minimally-invasive approach that allows good precision, flexibility, and control.
2853389|NCT03574493||Transanal surgery through the anus|Where the protectomy is performed down to up until the Douglas pouch
2853390|NCT03574480|Experimental|Control|Advice on healthy diet and physical activity recommendations
2853391|NCT03574480|Experimental|Intervention|"Advice on healthy diet and physical activity recommendations~Training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary."
2853392|NCT03574467||Bobath Approach Applied to Patient with Brain Tumors|
2853393|NCT03574467||Bobath Approach Applied to Patient with Stroke|
2853563|NCT03573323|Experimental|Ixekizumab|Ixekizumab administered subcutaneously (SC).
2862138|NCT03514277|Active Comparator|Local infiltration of Bupivacaine|
2853394|NCT03574454|Other|Phase 1 - Mixed Scan Data Training Set|Machine learning (ML): A mixed data set of 200 WB-MRI scans comprising scans obtained from 40 healthy volunteers (scanned for the purposes of the study), 40 previously acquired inactive myeloma WB-MRI scans and 120 previously acquired active myeloma WB-MRI scans, in which machine learning and convolutional neural networks will be trained to recognise healthy marrow, treated inactive previous myeloma and active myeloma. An algorithm will be developed for testing in phase 2.
2853395|NCT03574454|Other|Phase 2 - Mixed Scan Data Validation Set|Machine Learning (ML): A mixed data set of 353 WB-MRI scans as that comprising 50 healthy volunteers (scanned for the purposes of the study), and previously acquired scans from 303 myeloma patients, 100 of whom have inactive disease and 203 of whom have active myeloma. The scans will be read by radiologists in random order either with or without the support of for the detection of active myeloma. The diagnostic performance of the radiology reads with or without the machine learning support will be measured against an expert panel reference standard.
2853396|NCT03574454|Other|Phase 3 - Disease Burden Paired Data Set|Machine Learning (ML): Approximately 200 paired WB-MRI scans from 100 patients (scanned at baseline with active disease and then post treatment) will be used to develop a machine learning tool to quantify the burden of disease. The machine learning algorithm will then be tested on a further additional set of 60 patients who previously had two WB-MRI scans comprising paired baseline (with active disease) and post treatment scans. The agreement of radiology readers to evaluate the burden of disease will be measured against the reference standard (expert panel) with and without machine learning support.
2853397|NCT03574441|Active Comparator|TegadermTM only|
2853398|NCT03574441|Active Comparator|Dressing with TegadermTM plus Steri-StripTM bands|
2853399|NCT03574441|Experimental|Dressing with TegadermTM plus catheter support pad.|
2853400|NCT03574428|Active Comparator|Cohort 1|GNbAC1 36 mg/kg single i.v. dose or GNbAC1 placebo
2853401|NCT03574428|Active Comparator|Cohort 2|GNbAC1 60 mg/kg single i.v. dose or GNbAC1 placebo
2853402|NCT03574428|Active Comparator|Cohort 3|GNbAC1 85 mg/kg single i.v. dose or GNbAC1 placebo
2853403|NCT03574428|Active Comparator|Cohort 4|GNbAC1 110 mg/kg single i.v. dose or GNbAC1 placebo
2853404|NCT03574415|Experimental|Japanese_DWP14012 Amg|DWP14012 Amg, tablets, orally, single and multiple administration
2853405|NCT03574415|Experimental|Japanese_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
2853406|NCT03574415|Experimental|Japanese_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
2853407|NCT03574415|Experimental|Caucasian_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
2853408|NCT03574415|Experimental|Caucasian_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
2853409|NCT03574415|Experimental|Korean_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
2853410|NCT03574415|Experimental|Korean_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
2853411|NCT03574415|Placebo Comparator|Placebo|DWP14012 placebo-matching tablets
2853412|NCT03574402|Experimental|Arm1: Avitinib Maleate|Patients with EGFR de novo T790m mutation receive Avitinib 300mg orally (PO) twice daily (BID) on day 1-28.
2853413|NCT03574402|Experimental|Arm2: Chidamide plus Afatinib|"Patients with EGFR sensitive mutation with BIM deletion polymorphism receive Afatinib plus Chidamide.~Chidamide will be administered 30mg orally twice weekly, 28 days as one cycle. Afatinib will be administered 40mg orally once a day, 28 days as one cycle."
2853414|NCT03574402|Experimental|Arm3: crizotinib|Patients with MET 14 exon mutation receive crizotinib 250mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
2853415|NCT03574402|Experimental|Arm4: X396|Patients with MET amplification receive X396 225mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
2853416|NCT03574389|Experimental|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|"Participants in cohort 1 will receive each dose of 13vPnC in months 2, 4 and 6, and then a booster dose during months 12-15.~Participants in cohort 2 will receive first dose dose 13vPnC at the age of months 7(included) to months 12 (less than months 12), and the second dose will be given at least 28 days after first dose, and the third dose will be months 12 to 15 (and at least 56 days after the second dose).~Participants in cohort 3 will receive the first dose of 13vPnC during 1 (included) to 2 years (less than 2 years of age) of age, and the second dose will be given at least 56 days after first dose.~Participants in cohort 4 will receive only one dose at the age of 2 (included) to 6 (less than 6 years of age) years of age."
2853417|NCT03574389|Active Comparator|Haemophilus influenzae type b (Hib)|"No participants in cohort 1 will receive Hib vaccine.~Participants in cohort 2 will receive the first dose of Hib vaccine at the age of months 7 (included) to 12 (less than 12 months), and the second dose will be given at least 28 days after the first dose, the third dose will following local practice or national recommendation at the discretion of the investigator.~Participants in cohorts 3 and 4 will receive the only one dose Hib vaccine at the age of 1 (included) to 6 (less than 6 years) years of age."
2853418|NCT03574376|Active Comparator|Bupivacaine Liposome Injection [Exparel]|Patients will receive a nerve block with a medication called liposomal bupivacaine, also called Exparel. Once assigned, a University of Illinois surgeon, or resident surgeon, will administer the nerve block. The nerve block is expected to provide pain relief from 72 to 96 hours. During this time, patients may request oral or intravenous pain medication for breakthrough pain. Patients will remain in the hospital until discharged by the attending physician.
2853419|NCT03574376|Active Comparator|Epidural 0.125% bupivicaine|"Patients will receive pain relief through a 0.125% bupivacaine epidural in the upper back by an assigned anesthesiologist. This epidural will remain in place for an uncertain amount of time. The decision to remove the epidural will be determined by the physicians and will be based on level of pain and injury.~However, pain data will only be recorded by the research team for no longer than 96 hours after the epidural is placed. Patients are able to request intravenous and oral pain medications for breakthrough pain. After the epidural is removed, they will remain in the hospital until discharged by the attending physician."
2853420|NCT03574363|Experimental|KBP-5074 0.25 mg tablet|KBP-5074 0.25 mg tablet QD orally, 84 days
2853421|NCT03574363|Experimental|KBP-5074 0.5 mg tablet|KBP-5074 0.5 mg tablet QD orally, 84 days
2853422|NCT03574363|Placebo Comparator|Placebo tablet|Placebo tablet QD orally, 84 days
2862194|NCT03513874|Experimental|Metformin + Insulin|
2853425|NCT03574337|Active Comparator|Sugammadex|Patient's will receive sugammadex at the end of the case for reversal of neuromuscular blockade. The dosing will be determined based on the patient's weight and TOF ratio by the pharmacy. It will be a one time dose at the end of the case
2853426|NCT03574337|Active Comparator|Neostigmine/glycopyrrolate|Patient's will receive neostigmine/glycopyrrolate at the end of the case for reversal of neuromuscular blockade. The dosing will be determined based on the patient's weight (50mcg/kg of neostigmine with an equivalent volume to volume ratio of glycopyrrolate). It will be a one time dose at the end of the case
2853427|NCT03574337|No Intervention|No reversal administered|No reversal administered at the end of the case
2853428|NCT03574324|Experimental|TPF+CCRT|TPF neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
2853429|NCT03574324|Other|CCRE+PF|Cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy followed by PF adjuvant chemotherapy
2853430|NCT03574311|Experimental|Ferric carboxymaltose|Preoperative 1000 mg intravenous single dose as 30 minute infusion
2853431|NCT03574311|Placebo Comparator|Placebo|Preoperative 100 ml saline as 30 minute infusion
2853432|NCT03574285|Experimental|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
2853433|NCT03574285|Active Comparator|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
2853434|NCT03574272|Experimental|Patient Transfer Monitoring System|
2853435|NCT03574246|Experimental|CHXBNZ|Pharyngeal pack moisturized with chlorhexidine gluconate %0,12 benzydamine hydrochloride %0,15 and placed to oropharynx
2853436|NCT03574246|Active Comparator|SF|Pharyngeal pack moisturized with %0,9 NaCl and placed to oropharynx
2853437|NCT03574233||patients who are ready to wean ventilator off|
2853438|NCT03574220|Experimental|Pembrolizumab + Stereotactic Body Radiotherapy|"Lung SBRT 50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-15 days.~Adjuvant Therapy:~Pembrolizumab 200mg IV every 21 days for 6 months"
2853439|NCT03574207|Other|Arm A: Stimulation then Sham|All procedures are identical in both arms with the exception of the order of stimulation administration. In Arm A, transcranial magnetic stimulation (TMS) will be applied in the first week of participation, and sham stimulation will be applied in the second week of participation.
2853440|NCT03574207|Other|Arm B: Sham then Stimulation|All procedures are identical in both arms with the exception of the order of stimulation administration. In Arm B, sham stimulation will be applied in the first week of participation, and transcranial magnetic stimulation (TMS) will be applied in the second week of participation.
2853441|NCT03574194|Experimental|Methionine-restricted diet|6 weeks methionine-restricted diet (MRD) with 3-5 fraction SBRT to the lung tumor
2853442|NCT03574168|Experimental|CD19-CAR-T Cells|Subjects will receive CD19-CAR-T Cells on Day 0 : 100% of total dose.
2853443|NCT03574155|No Intervention|Control- group|"It is composed of patients scheduled for surgical treatment by tumors of the uterine cervix, vulva, ovary or endometrium, who will receive preoperative and postoperative guidelines according to the usual routine for the perioperative period of the present institution. Patients and their followers of the control group will participate in a preoperative consultation with the surgeon to discuss the indication of the procedure and its risks, benefits and alternatives to the procedure being indicated, if any.~Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)"
2853444|NCT03574155|Experimental|Experimental Group|"Composed of patients scheduled for surgical treatment by tumors of the uterine cervix, vulva, ovary or endometrium who will receive preoperative counseling and education through a pre-defined protocol after preoperative consultation with the surgeon. The counseling session will take place with at least one companion. The purpose of this session is to supplement, re-emphasize and strengthen the perioperative guidelines. An illustration (explanatory folder) will be used to demonstrate the location of the surgery, how the scar will be and on which sites of the abdomen and organs the surgery will cover. All this counseling and education will be applied at the same time to the patient and her companion. At the end of the intervention, a space will be left open for both the patient and the companion to ask questions and questions.~Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)"
2853445|NCT03574142|Experimental|Epanova|Epanova® capsule, per oral
2853446|NCT03574129|Experimental|Adolescent transition package|Adolescent transition package
2853447|NCT03574129|No Intervention|Standard of care|Standard of care adolescent services
2853448|NCT03574103|Active Comparator|Caloric restriction only|Participants in this group will receive a eating plan with caloric restriction as dietary weight loss strategy.
2853449|NCT03574103|Experimental|Caloric restriction plus TRF morning|Participants in this group will receive a eating plan with caloric and time restriction as dietary weight loss strategy.
2853450|NCT03574103|Experimental|Caloric restriction plus TRF night|Participants in this group will receive a eating plan with caloric and time restriction as dietary weight loss strategy.
2853451|NCT03574090|Experimental|amoxicillin clavulanate|1000 mg amoxicillin and potassium clavulanate equivalent to 200mg of clavulanic acid. administered topically and dissolved in 500 ml 0.9% Physiological Serum.
2853452|NCT03574090|Active Comparator|Physiological Saline|500 milliliters of 0.9% Physiological Serum.
2853453|NCT03574077|Experimental|Instant messaging|AWARD advice + NRT sampling + Active referral + Instant Messaging (IM)
2853454|NCT03574077|Active Comparator|SMS messaging|AWARD advice + NRT sampling + Active referral + SMS messaging
2853455|NCT03574064|Experimental|GLP-2|Glucagon-Like Peptide-2 (GLP-2)
2853456|NCT03574064|Experimental|GIP|Glucose-dependent Insulinotropic polypeptide (GIP)
2853457|NCT03574064|Experimental|GLP-2+GIP|GLP-2+GIP
2853458|NCT03574064|Placebo Comparator|Placebo|Placebo
2853459|NCT03574051|Experimental|Probiotic|Taking probiotics containing Bifidobacterium infantis, Lactobacillus acidophilus and Enterococcus faecalis for 30 days
2853460|NCT03574038|Active Comparator|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation
2853461|NCT03574038|Sham Comparator|Sham Stimulation|Sham Stimulation
2853462|NCT03574025||Cardiac Arrest Questionnaire|Children who will survive 3 months after Cardiac Arrest
2853564|NCT03573323|Experimental|Guselkumab|Guselkumab administered SC. Placebo administered SC to maintain the blind.
2853463|NCT03574012|Active Comparator|Control Group (general health information, fitness tracker)|Participants receive general information about physical activity and diet, and access to Fitbit and Healthwatch.
2853464|NCT03574012|Experimental|Intervention Group (individualized information, tracker)|Participants receive individualized goal-setting and coaching in relation to physical activity and diet, supplemented with peer support through the study's social media platform, over 4 months. They also have access to mHealth apps including Fitbit and Healthwatch that provide feedback on physical activity and diet.
2853465|NCT03573999|Active Comparator|Mannitol 20%|Mannitol 20% (4.6ml/kg) will be administered 20 minutes before dura matter opening.
2853466|NCT03573999|Experimental|Hypertonic saline 7.5%|Hypertonic saline 7.5% (2ml/kg) will be administered 20 minutes before dura matter opening
2853467|NCT03573986|Experimental|Arm A|
2853468|NCT03573973|Experimental|Fresh fruit and vegetable placement intervention|The intervention is a store refurbishment programme that includes the creation of a new fresh fruit and vegetable section at the store entrance with expanded range thus improving the availability and position of fresh fruit and vegetables.
2853469|NCT03573973|Sham Comparator|Control|The control condition is the existing store layout with a limited range of fresh fruit and vegetables that are placed at the back of the store.
2853470|NCT03573960|Experimental|Lenvatinib 24 mg|Participants will receive 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily with or without food in 28-day cycles until disease progression or until unacceptable toxicity occurs.
2853471|NCT03573947|Experimental|nivolumab, ipilimumab and paclitaxel|
2853472|NCT03573934|Experimental|GLP-2|Glucagon-Like Peptide-2 (GLP-2) injection
2853473|NCT03573934|Experimental|GIP|Glucose-dependent Insulinotropic polypeptide (GIP) injection
2853474|NCT03573934|Experimental|GLP-2+GIP|GLP-2+GIP injection
2853475|NCT03573934|Placebo Comparator|Placebo|Placebo injection
2853476|NCT03573921|Experimental|Gastrografin Arm|Patients will receive a single dose of undiluted Gastrografin via the nasogastric tube at 24 hours after admission for small bowel obstruction. The dose of Gastrografin will be proportional to the patient's weight and age and will be based off of the recommendations from the drug manufacturer. Dosages will range from 30 ml for infants to children less than 5 years old and 60 ml for children 5-18 years and will not be diluted.
2853477|NCT03573921|Experimental|Control Arm|Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after admission for small bowel obstruction. The volume of saline solution will be proportional to the volume of Gastrografin patients of similar weight and age would receive.
2853478|NCT03573908|Experimental|Linaclotide 290 µg|
2853479|NCT03573908|Placebo Comparator|Placebo|
2853480|NCT03573895|Experimental|Foam-Roller|
2853481|NCT03573895|Experimental|Neuromuscular Stretching|
2853482|NCT03573895|Experimental|Pasive stretching|
2853483|NCT03573895|No Intervention|Control|
2853484|NCT03573882|Active Comparator|900 mg|Voxelotor (GBT440) 900 mg
2853485|NCT03573882|Active Comparator|1500 mg|Voxelotor (GBT440) 1500 mg
2853486|NCT03573869|Experimental|Cryoballoon ablation|A 28-mm cryoballoon (Arctic Front Advance™ Cardiac CryoAblation Catheter, Medtronic, Minneapolis, MN) will be employed. The cryoballoon catheter will be introduced into the left atrium, following a single transeptal puncture, through a 12F FlexCath steerable sheath (Medtronic), constantly flushed with heparinized saline. A circular mapping catheter (Achieve, Medtronic) will be advanced through the cryoballoon to the PV orifice and positioned as proximally as possible inside the vessel to record the PV potentials at baseline and monitor the isolation procedure in real time.
2853487|NCT03573869|No Intervention|Standard treatment|Standard treatment, including at least one rhythm control medication, on top of optimized rate control and HF treatment
2853488|NCT03573856|Active Comparator|Active Living|Three component behavioral intervention consisting of group-based classes, individual motivational interviewing-based sessions, and resource toolbox
2853489|NCT03573856|Placebo Comparator|Health and Safety|One component health and safety program consisting of group classes
2853490|NCT03573843|Placebo Comparator|Control|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the Control group: They will continue to receive the standard prevention measures: delirium detection, treatment health team education and the patient's family, sleep hygiene plan, early mobilization , resolve sensorial deterioration, and delivery of information of temporal-spatial reorientation in a continuous manner, plus the use of a mobile device without installed delirium prevention software (placebo).
2853491|NCT03573843|Experimental|Experimental|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the experimental group:They will continue to receive standard prevention measures: Detection of delirium, education of health care team and the patient's family, sleep hygiene plan, early mobilization, resolve sensory impairments, and delivery of information of temporal-spatial reorientation in continuously, plus the use of software installed on a mobile device designed to support the prevention of delirium (Prevention software).
2853492|NCT03573830|Active Comparator|Current material|Participants in this arm will be shown the online Transport Canada Material that is currently available at: https://www.tc.gc.ca/en/services/road/child-car-seat-safety/installing-using-child-car-seat-booster-seat-seat-belt/stage-3-booster-seats.html
2853493|NCT03573830|Experimental|Enhanced material|Participants in this arm will be shown an enhanced version of the online Transport Canada Material, which includes an introduction explaining how booster seats prevent injuries caused by seat belts.
2853494|NCT03573817|Experimental|Revefenacin+Formoterol (Sequential)|Days 1 to 21: revefenacin and formoterol sequentially administered via nebulizer in the morning. Formoterol will be administered again in the evening.
2853495|NCT03573817|Experimental|Revefenacin+Formoterol (Combo Solution)|Days 22 to 42: After a 21 day period subjects on revefenacin and formoterol will be dosed for 21 days with a combination of revefenacin and formoterol administered as a combined solution via a single nebulization. Formoterol will be administered again in the evening.
2853496|NCT03573817|Placebo Comparator|Placebo+Formoterol (Sequential)|Days 1 to 21: Placebo revefenacin and formoterol sequentially administered via nebulizer in the morning. Formoterol will be administered again in the evening.
2853802|NCT03571737|Experimental|Ibuprofen & Lidocaine Patch 4%|Ibuprofen 800mg every 8 hours for 3 days and Lidocaine patch 4% 1 patch applied for 12 hours then removed for 12 hours, for 3 days
2853497|NCT03573817|Placebo Comparator|Placebo+Formoterol (Combo Solution)|Days 22 to 42: After a 21 day period subjects on placebo revefenacin and formoterol will be dosed for 21 days with a combination of placebo revefenacin and formoterol administered as a combined solution via a single nebulization. Formoterol will be administered again in the evening.
2853498|NCT03573804|Experimental|Prone to Supine MRI|The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
2853499|NCT03573791||Complete response|After neoadjuvant therapy, postoperative pathological examination will be performed to evaluate the efficacy of the therapy. Define postoperative staging ypT0N0 as complete response.
2853500|NCT03573791||Poor response|After neoadjuvant therapy, postoperative pathological examination will be performed to evaluate the efficacy of the therapy. Define postoperative staging >ypT1-2N0 as poor response.
2853501|NCT03573778|Experimental|iHEAL|10-18 visits (over 6 months) with a Registered Nurse
2853502|NCT03573778|Active Comparator|Usual Care|Information about Community Services
2853503|NCT03573739|Experimental|Low group|"Patients randomized in the low group will receive a low-calorie low-protein nutrition regimen during the acute phase."
2853504|NCT03573739|Active Comparator|Standard group|"Patients randomized in the standard group will receive a standard-calorie/standard-protein nutrition regimen during the acute phase."
2853505|NCT03573726|Other|Technically N/A, Crossover Design|Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
2853506|NCT03573713|Experimental|IPT-G (Treatment arm)|This arm will receive IPT-G for 12 weeks. Following IPT-G, this arm will go on to receive the Care Group intervention parallel to the control arm.
2853507|NCT03573713|Other|Control arm (Treatment as usual - Care Group)|This arm will receive assessment only at the beginning of the study (parallel to the start of IPT-G) and then receive the Care Group intervention after 12 weeks together with the IPT-G arm.
2853508|NCT03573700|Experimental|SJCAR19 Therapy|"Patients in both the Phase I and Phase II portion of the study will receive lymphodepleting chemotherapy (unless determined by PI that lymphodepletion is not necessary), followed by a single infusion of the patient-derived SJCAR19 cellular product. The most commonly used lymphodepleting chemotherapy regimen will consist of the agents: Fludarabine and Cyclophosphamide. They will also receive Mesna. Dosing of SJCAR19 on the Phase I study will follow a dose escalation schema, with dose changes based on dose-limiting toxicities. In the Phase II study, SJCAR19 dosing with follow the maximum tolerated dose, as determined in the Phase I portion.~Cells for infusion are prepared using the CliniMACS System."
2853509|NCT03573687|Experimental|RT on Fat Metabolism|Determine the extent to which a full-body acute RT protocol will affect intra-RT and post-RT SCAAT lipolytic rate, and post-RT whole-body substrate utilization in RT women compared to baseline measures (independent of Aims 2 and 3).
2853510|NCT03573687|Experimental|PRO Timing on Fat Metabolism|Assess the differences in overnight and next morning SCAAT lipolytic rate and next-morning whole-body substrate utilization compared to baseline between acute NP and DP consumption trials after a RT bout in RT women.
2853511|NCT03573687|Experimental|PRO Timing on Markers of Fat Metabolism|Assess the differences in overnight and next morning metabolic biomarkers of fat metabolism compared to baseline between acute nighttime PRO (NP) consumption versus daytime PRO (DP) consumption trials after a RT bout in RT women.
2853512|NCT03573674|Experimental|Cognitive ergonomics Intervention|
2853513|NCT03573674|Active Comparator|Stress management Intervention|
2853514|NCT03573674|No Intervention|Passive control|"Passive Control groups receive no intervention at all."
2853515|NCT03573661|Experimental|Breast Cancer Locator (BCL)|The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
2853516|NCT03573648|Active Comparator|Tamoxifen|Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive tamoxifen (T) versus tamoxifen with palbociclib (PT) in a 1:1 ratio. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
2853517|NCT03573648|Active Comparator|Tamoxifen with Palbociclib|Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive tamoxifen (T) versus tamoxifen with palbociclib (PT) in a 1:1 ratio. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
2853518|NCT03573635|Other|Supratube|Patient with orotracheal intubation and supratube device
2853519|NCT03573622|Experimental|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
2853520|NCT03573622|Active Comparator|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
2853521|NCT03573609|No Intervention|Control|Usual respiratory care
2853522|NCT03573609|Active Comparator|Supranav|"Respiratory care with supranav which is a continuous supraglottic suction device"
2853523|NCT03573596|Other|dasatinib|2 years of dasatinib treatment before discontinuation if MR 4 is achieved for at least 1 year
2853524|NCT03573583|Experimental|Resistance Training group (RT)|The resistance training intervention will include a full body, high-intensity resistance training performed three days per week.
2853525|NCT03573583|Active Comparator|Successful Aging|The comparator group will meet for stretching and health education classes every 2 weeks.
2853565|NCT03573310|Experimental|JNJ-64619178|Participants will receive JNJ-64619178 orally as per the assigned sequential cohorts and doses will be escalated based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and clinical activity.
2853566|NCT03573297|Experimental|Cariprazine 3 mg/day|Cariprazine capsules, oral administration, once daily
2853567|NCT03573297|Experimental|Cariprazine 1.5 mg/day|Cariprazine capsules, oral administration, once daily
2853526|NCT03573570|Experimental|Treatment|110 Fair Price Shops (FPS) in Chidambaram, Tamil Nadu, India will be assigned randomly to receive rice fortified. Rice will be fortified using Fortified Rice Kernels (FRKs) containing iron, zinc, vitamin A and vitamins B1, B3, B6, B9 and B12. All households receiving rice from the PDS will receive fortified rice instead of conventional PDS rice, and members of households sampled for baseline will have blood samples and demographic surveys taken at a baseline visit, and another visit at 12-15 months after the baseline visit. Because a given FPS only receives rice from a single upstream distributor (godown) it should be straightforward to ensure that fortified rice reaches the appropriate treatment FPS and only those FPS.
2853527|NCT03573570|No Intervention|Control|The control arm, i.e. FPS not a part of the treatment shops, will continue to receive the regular rice supplied by the Public Distribution System (PDS), and members of households sampled for baseline will have blood samples and demographic surveys taken at a baseline visit, and another visit at 12-15 months after the baseline visit. It therefore represents the status quo and serves as a control group against which any improvements observed in the treatment group will be gauged.
2853528|NCT03573557|Active Comparator|Pink Pad|The Pink Pad will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg to determine how much slipping is happening during the procedure.
2853529|NCT03573557|Active Comparator|Bean Bag|The Bean Bag will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg to determine how much slipping is happening during the procedure.
2853530|NCT03573557|Active Comparator|Gel Pad|The Gel Pad will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg determine how much slipping is happening during the procedure.
2853531|NCT03573544|Experimental|OBI-888 Escalation Phase|Three cohorts of escalating dose levels of OBI-888 5, 10, and 20 mg/kg liquid form for intravenous infusion to establish maximum tolerated dose (MTD).
2853532|NCT03573544|Experimental|OBI-888 Expansion Phase|Part B will be initiated with the MTD determined to be safe.
2853533|NCT03573531||Donor Human Milk|Donor Human Milk (processed by a human milk bank) Sampled at two different neonatal units in the United Kingdom Collection of 5 ml of otherwise routinely discarded donor human milk
2853534|NCT03573531||Preterm Milk|Preterm transitional or mature breast milk Sampled from healthy mothers of preterm babies (born , 37 weeks gestational age) at a neonatal unit in the United Kingdom Collection of 5 ml at a time point of routine expression
2853535|NCT03573531||Term Milk|Term mature breast milk Sampled from healthy mothers of term babies in the community (e.g. Baby Cafes). Collection of 5 ml expressed for this study
2853536|NCT03573518|Experimental|BTX 1503 Dose 1 BID|BTX 1503 Dose 1 twice daily
2853537|NCT03573518|Experimental|BTX 1503 Dose 1 QD|BTX 1503 Dose 1 once daily
2853538|NCT03573518|Experimental|BTX 1503 Dose 2 QD|BTX 1502 Dose 2 once daily
2853539|NCT03573518|Placebo Comparator|Vehicle BID|Vehicle twice daily
2853540|NCT03573518|Placebo Comparator|Vehicle QD|Vehicle once daily
2853541|NCT03573505|Experimental|BG00011|Participants will receive BG00011 56 mg once weekly by subcutaneous (SC) injection for 52 weeks.
2853542|NCT03573505|Placebo Comparator|Placebo|Participants will receive placebo once weekly by (SC) injection for 52 weeks.
2853543|NCT03573492|Active Comparator|In-Person Education by Ultrasonographer|In-person education of the DVT scanning technique by an RDMS-certified ultrasonographer
2853544|NCT03573492|Active Comparator|Online Education (EM Sono)|Online lectures of DVT scanning technique by an Emergency Ultrasound fellowship director
2853545|NCT03573479||Pre-implementation cohort|This is the pre-implementation phase where a baseline documentation will take place about usual clinical practice, perceptions and attitudes of PICU staff and clinicians
2853546|NCT03573479||PICU Liber8 bundle|After the implementation of the bundle (the PICU Liber8 components) same measurements will be captured and analyzed comparatively.
2853547|NCT03573466|Experimental|Amyotrophic Lateral Sclerosis|
2853548|NCT03573453|Experimental|Intermittent|enteral nutrition will be administered via enteral feeding pump as 30-60minutes lasting bolus 6 times per day volume of initial bolus will be 80ml. The volume of bolus will be increased gradually according to tolerance, till the estimated target rate will be reached
2853549|NCT03573453|Experimental|Continuous|enteral nutrition will be administered via enteral feeding pump for at least 16 hours par day initial rate will be 25ml/hour. The rate will be increased gradually according to tolerance, till the estimated target rate will be reached
2853550|NCT03573440|No Intervention|no mindful eating education|"Subject will be asked to eat their meal with an investigator present.~They will inform the investigator verbally when they are feeling full.~After they have decided to end their meal, they will be asked to fill out a questionnaire"
2853551|NCT03573440|Experimental|mindful eating education|"After receiving a brief education session on mindful eating, subject will be asked to eat their meal with an investigator present.~They will inform the investigator verbally when they are feeling full.~After they have decided to end their meal, they will be asked to fill out a questionnaire"
2853552|NCT03573414|Experimental|Health overweight men and women|
2853553|NCT03573401|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~Photodynamic therapy (PDT)"
2853554|NCT03573401|Placebo Comparator|Vehicle|Topical application of vehicle to BF-200 ALA containing no active ingredient. Photodynamic therapy (PDT)
2853555|NCT03573388||Optical coherence tomography (OCT)|
2853556|NCT03573375|Experimental|Cancer Patients in Supportive Care Clinic (SCC)|
2853557|NCT03573362|Experimental|Vizishot Flexneedle 19G|Mediastinal and hilar lymph node sampling using the Vizishot Flexneedle19G EBUS-TBNA needle
2853558|NCT03573362|Active Comparator|Vizishot 22G|Mediastinal and hilar lymph node sampling using a standard Vizishot 22G EBUS-TBNA needle
2853559|NCT03573349|Other|Ketamine|
2853560|NCT03573336|Experimental|Treatment group 1: Vilaprisan (BAY1002670)|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 2 mg
2853561|NCT03573336|Experimental|Treatment group 2: Vilaprisan (BAY1002670)|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 4 mg
2853562|NCT03573336|Placebo Comparator|Placebo group|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1
2862195|NCT03513874|Active Comparator|Insulin alone|
2853569|NCT03573284|Experimental|Asthma group|Patients with chronic nonproductive cough for more than 8 weeks based on physician's opinion will be subjected to FeNO, impulse oscillometry(IOS) and pulmonary function. Receiver operating characteristic (ROC) curves to evaluate the clinical value of FeNO and small airways indices in CVA diagnosis. The optimal cutoff point for the level of FeNO and IOS is also determined.
2853570|NCT03573271|Experimental|Micro-coring of facial/neck skin with MCD|Micro coring of facial and neck skin will be conducted in up to 2 treatments and followed 90 days post treatment with MCD
2853571|NCT03573258|Experimental|Fiber|"300 ml of orange juice plus Intervention~6 g of oat beta glucan = FIBER (study A) or~25 g inulin/FOS = FIBER (study B)"
2853572|NCT03573258|Placebo Comparator|Placebo|"300 ml of orange juice plus Placebo:~13.5 g maltodextrin = PLACEBO (study A) or~15.5 g maltodextrin = PLACEBO (study B)"
2853573|NCT03573245||intra-op single dose|intra-operative single dose of tranexamic acid
2853574|NCT03573245||intra-op dose and additional dose|intra-operative dose of tranexamic acid and additional dose 3 hours after
2853575|NCT03573245||intra-op dose and perfusion|intra-operative dose of tranexamic acid followed by a continuous infusion during 6 hours.
2853576|NCT03573219|Experimental|Healthy participant|Healthy volunteers that fulfill the inclusion criteria. Intervention: Short-wave diathermy (Radiation)
2853577|NCT03573206|Experimental|Treatment Arm|Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
2853578|NCT03573193|Active Comparator|study group:|ridge preservation alveolar ridge socket preserved using alloplastic material beta tri calcium phosphate type
2853579|NCT03573193|Other|control group|ridge preservation (alveolar ridge socket preserved using xenograft material Bio-oss type
2853580|NCT03573167|Active Comparator|In-Person Motivational Interviewing|In-Person Motivational Interviewing (MI) is the standard form of MI treatment delivered in person face to face at the primary care office. MI is a type of brief intervention that uses open-ended questions, affirmations, reflective listening, and summarizing as key tools and has been shown to treat a range of problem behaviors, including alcohol use disorders, by helping participants to identify and address ambivalence towards changing the behavior. MI is delivered in a communicative style that promotes individual autonomy and improves self-efficacy. The investigator provides counseling in-person with the participant for one session of MI lasting approximately 30 minutes.
2853581|NCT03573167|Experimental|Mobile MI|Mobile Motivational Interviewing (MI) is delivered by a counselor over the mobile phone, rather than in-person (face-to-face). MI is a type of brief intervention that uses open-ended questions, affirmations, reflective listening, and summarizing as key tools and has been shown to treat a range of problem behaviors, including alcohol use disorders, by helping the patient to identify and address ambivalence towards changing the behavior. MI is delivered in a communicative style that promotes individual autonomy and improves self-efficacy. The investigator provides counseling over the mobile phone with the participant for one session of mobile MI lasting approximately 30 minutes.
2853582|NCT03573167|No Intervention|Waitlist Control|After consenting to participate in the study, the Waitlist control participants receive no intervention for one (1) month, and then the Waitlist control participants are contacted by the investigators for follow up..
2853583|NCT03573154|Other|e-liquid 1|
2853584|NCT03573154|Other|e-liquid 2|
2853585|NCT03573141||Knee OA patients receiving Physical Therapy|Only 1 group was included in this study. Subject's physical activity and sleep quality were assessed at baseline, prior to treatment. Follow up data was collected immediately after a course of physical therapy then again 8 weeks later.
2853586|NCT03573128|Experimental|Intervention|Students with Autism Accessing General Education (SAAGE). Teaching staff work with a study team coach to identify areas of concern for individual students, create goals and implement a modular behavioral intervention using an active teaching/feedback loop model.
2853587|NCT03573128|Active Comparator|Enhanced Services As Usual|Teaching staff access in-service training sessions hosted by study team and are provided with print materials from which the modules for the active intervention were created.
2853588|NCT03573115|Experimental|Acne patients|
2853589|NCT03573102|Active Comparator|control|ACE inhibitor , aspirin , statins will be given once daily
2853590|NCT03573102|Experimental|cases|SGLT2 inhibitors will be given with classic antiproteinuric drugs
2853591|NCT03573089|Active Comparator|Intensive phosphate target|Intensive serum phosphate target of ≤1.50 mmol/L.
2853592|NCT03573089|Experimental|Liberal phosphate target|Liberal serum phosphate target of 2.0 to 2.5 mmol/L.
2853593|NCT03573076|Experimental|Thulium laser + photodynamic therapy|Non-ablative Thulium laser (NAFL) + Photodynamic therapy combination treatment
2853594|NCT03573076|Experimental|RF microneedles + photodynamic therapy|Radio-frequency microneedles (RF-MN) + Photodynamic therapy combination treatment
2853595|NCT03573076|Active Comparator|Non-ablative Thulium laser|Non-ablative Thulium laser (NAFL) single treatment
2853596|NCT03573076|Active Comparator|RF microneedles|Radio-frequency microneedles (RF-MN) single treatment
2853597|NCT03573076|No Intervention|Control|Control receiving no intervention
2853598|NCT03573063|Other|Androgen metabolism after starvation|Metabolism changes after 48 hours starvation in healthy women
2853599|NCT03573050|Experimental|RIV-TDS 13.3 mg/24 h (Test)|5 consecutive patch applications of Test (each patch to be applied for 24 hours)
2853600|NCT03573050|Active Comparator|Exelon® 13.3 mg/24 hours transdermal patch (Reference)|5 consecutive patch applications of Reference (each patch to be applied for 24 hours)
2853601|NCT03573037|Experimental|1-month anticoagulation group|Anticoagulation using warfarin or non-VKA oral anticoagulant for 1 month after radiofrequency catheter ablation of paroxismal atrial fibrillation and then stop anticoagulation.
2853602|NCT03573037|Active Comparator|2-month anticoagulation group|Anticoagulation using warfarin or non-VKA oral anticoagulant for 2 months after radiofrequency catheter ablation of paroxismal atrial fibrillation and then stop anticoagulation
2853603|NCT03573024|Experimental|Azacitidine and Venetoclax|Azacitidine will be given intravenously for 7 days. Venetoclax will be given orally. The patient will start out with 100mg and progress to 600mg. Once 600mg is reached, the patient will stay at this dose until the 28 day cycle is finished.
2853636|NCT03572777|Active Comparator|Hybrid therapy|Amoxicillin ('Amoksicilin') 1 g bid and esomeprazole ('Emanera') 40 mg bid for 14 days, with metronidazole ('Medazol')500 bid and clarithromycin ('Makcin') 500 mg bid for the last 7 days.
2853604|NCT03573011|Experimental|2.0 ± 0.2 MBq/kg [18F]PSMA-11 dosing group|"To define the optimal [18F]PSMA-11 scan protocol, the quality of the PET images from patients that received 2.0 ± 0.2 MBq/kg will be compared to the images from patients that received 4.0 ± 0.4 MBq/kg.~Patients in this study arm will receive 2.0 ± 0.2 MBq/kg for acquiring the [18F]PSMA-11 scan. All other study parameters and procedures are identical to those in the other study arm.~As for the use of radiopharmaceuticals, the ALARA ('as low as reasonably achievable') principle must be applied, this study arm is considered to be the reference."
2853605|NCT03573011|Experimental|4.0 ± 0.4 MBq/kg [18F]PSMA-11 dosing group|Concerning the dose of [18F]PSMA-11, the patients in this study arm will receive 4.0 ± 0.4 MBq/kg for the [18F]PSMA-11 scan. All other study parameters and procedures are identical to those in the other study arm
2853606|NCT03572998|Other|Breast cancer patients|study subject
2853607|NCT03572985|Other|Blood alcohol concentration (BAC) level 0.025 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.025%
2853608|NCT03572985|Other|BAC level 0.05 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.05%
2853609|NCT03572985|Other|BAC level 0.09 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.09%
2853610|NCT03572985|Other|BAC level 0 %|Drink beverages containing non alcohol
2853611|NCT03572972||Patients prescribed apixaban|
2853612|NCT03572972||Patients prescribed dabigatran|
2853613|NCT03572972||Patients prescribed rivaroxaban|
2853614|NCT03572972||Patients prescribed warfarin|
2853615|NCT03572972||Patients prescribed antiplatelet|
2853616|NCT03572959|Active Comparator|comparison group (active control)|0.1 % topical triamcinolone acetonide preparation (Kenacourt-A Orabase Pomad, DEVA HOLDINGS A.S., Istanbul, Turkey) was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application. Patients used the medication for 4 weeks , and if extension of treatment was required after that period , patients were instructed to apply miconazole oral gel (JANSSEN-CILAG Pty Ltd 1-5 Khartoum Road North Ryde NSW 2113 Australia) four times a day for one week to protect from superimposed fungal infections.15
2853617|NCT03572959|Experimental|experimental group|"OLP lesions were irradiated with a 970-nm diode laser (SIRO Laser Advance class III b, SIRONA, Germany) with a 2 W irradiation power in a continuous non-contact mode. The laser beam was delivered using a fiber-optic tip with a 320 µm diameter with defocused mode directed at the lesions plus 0.5 cm peri- lesional tissues with a slight overlapping in order to evenly distribute energy covering all the lesional and peri-lesional tissues until blanching of the area was observed.14 Diode laser was calibrated to an output power of 3W, frequency of 30 Hz, energy of 180 joule and time interval of 8 minutes divided into 4 sessions , two min each with one minute rest in between to allow for tissue relaxation.~Irradiation was done twice weekly for two months until the resolution of signs for a maximum of ten sessions.11 After each session, patients were advised to have a cold diet and use chlorhexidine oral gel postoperatively twice a day to the lesion for one week."
2853618|NCT03572946|Experimental|mpMRI group|mpMRI examination and/or targeted prostate biopsy
2853619|NCT03572946|Active Comparator|standard group|Standard prostate biopsy
2853620|NCT03572933|Experimental|Ganaxolone|ganaxolone suspension (50 mg/ml) 3x's /day or ganaxolone 225 mg capsules 2x's/day for 17 weeks
2853621|NCT03572933|Placebo Comparator|Placebo|placebo suspension 3x's /day or placebo capsules 2x's/day for 17 weeks
2853622|NCT03572920||Patients with hip/knee arthroplasty.|Objective sleep evaluation by actigraphy. Pittsburgh Sleep Quality Index (PSQI). Epworth Sleepiness Scale (ESS).
2853623|NCT03572881|Experimental|Asymptomatic|
2853624|NCT03572881|Experimental|Symptomatic|
2853625|NCT03572855|Experimental|Scoliosis Brace|The Peak Scoliosis Brace designed to alleviate pain in adult patients with chronic pain secondary to scoliosis.
2853626|NCT03572842|Other|quantiferon monitor|Test measuring interferon gamma production after T cells and Natural Killers (NK) in vitro stimulation : QuantiFERON Monitor® (QFM)
2853627|NCT03572829|Experimental|Aprepitant|Aprepitant combined with ondansetron and dexamethasone
2853628|NCT03572816|No Intervention|Current standard|"mobilization without weight bearing for 6 weeks starting with the day of either decision-making for non-operative therapy or open reduction and internal fixation, if needed a cast or another kind of orthosis as a Static Walker are applied, then 4 weeks 15-20 kg, 2 weeks 35-45 kg, after that transition to full-weight bearing (always only if possible)~X-ray after 6 and 12 weeks; depending on the results, the schedule for weight bearing may be adjusted to the need in case of delayed healing or complications related to implants"
2853629|NCT03572816|Experimental|Intervention|"mobilization with the custom-made heel-unloading orthosis ('Settner shoe') without pads for 6 weeks, then 2 weeks one pad, 2 weeks 2 pads, 2 weeks 3 pads, after that full-weight bearing without any support (always only if possible)~X-ray after 6 and 12 weeks; depending on the results, the schedule for weight bearing may be adjusted to the need in case of delayed healing or complications related to implants"
2853630|NCT03572803|Active Comparator|Group of Dry Needling|"They will receive a treatment of dry needling, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.~The needle will get in the relevant zone of treatment. The punction will be realized using Hong's technique (fast in-out). Three needle insertions will be carried out in the target area during 3 seconds"
2853631|NCT03572803|Active Comparator|Group of electrolysis|"They will receive a treatment of Intratissue Percutaneous Electrolysis, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.~The needle will get in the relevant zone of treatment. The punction will be realized simulating Hong's technique (fast in-out). Three needle insertions will be carried out in the target area during 3 seconds and 3mA each one."
2853632|NCT03572803|Sham Comparator|Control Group|They will receive a treatment of punction sham, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.
2853633|NCT03572790|Experimental|Prucalopride|
2853634|NCT03572790|Placebo Comparator|Placebo|
2853635|NCT03572777|Active Comparator|Concomitant therapy|Amoxicillin ('Amoksicilin') 1 g bid, metronidazole ('Medazol')500 mg bid, clarithromycin ('Makcin')500 mg bid and esomeprazole ('Emanera')40 mg bid for 14 days.
2853803|NCT03571724|Experimental|Non-Menthol Very Low Nicotine Cigarettes|Subjects will be switched from their usual brand to smoke Very Low Nicotine king size cigarettes
2853637|NCT03572764|Experimental|CPX-351|"CPX-351 will be given according to the assigned dose level as a 90-minute IV infusion on Days 1, 3, and 5 of the first induction~A second induction may be considered for patients in the absence of a chemoablated, hypocellular marrow on the Day 14 bone marrow assessment, if the patient has failed to achieve a marrow CR, and it is deemed safe to administer by the treating physician. The second induction uses a modified schedule in which CPX-351 will be given according to the assigned dose level on Days 1 and 3~In the absence of disease progression or unacceptable toxicity, the patient may continue to consolidation at the discretion of the treating physician or the patient may proceed to alloHCT after induction at the discretion of the treating physician"
2853638|NCT03572751||Vascular surgical patients|"Patient subjects are recruited from patients referred for vascular surgical procedure in Tampere University Hospital.~Bed-, wrist- and ECG-sensor monitoring"
2853639|NCT03572751||Healthy volunteers|"Healthy volunteer subjects will be recruited mainly from the students of Tampere University of Technology.~Bed-, wrist- and ECG-sensor monitoring"
2853640|NCT03572738||Patients with HS|The set of all Hidradenitis Suppurativa patients (ICD-10 code: L73.2) who visited Wake Forest Baptist Medical Center's dermatology clinic during the last 5 years will either be recruited in person or be mailed the HS Severity Self-Assessment tool and a survey about their demographics, symptoms, treatments, psychological aspects, and lifestyle.
2853641|NCT03572725|Active Comparator|Gas tamponade|Gas as intraocular tamponade.
2853642|NCT03572725|Experimental|Air tamponade|Air as intraocular tamponade.
2853643|NCT03572686|Sham Comparator|Group Ropivacaine High (RH)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.5% 20ml + N/S 1.6mL.
2853644|NCT03572686|Placebo Comparator|Group Ropivacaine Low (RL)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.25% 20ml + N/S 1.6mL.
2853645|NCT03572686|Experimental|Group Ropivacaine Low + Dexamethasone (RLD)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.25% 20ml + Dexamethasone 8mg (1.6mL).
2853646|NCT03572673|Active Comparator|Flexima 3S|Flexima 3S is a 2-piece ostomy appliance composed with an adhesive base plate and a drainable pouch for collecting stools (1 base plate for 5 days and 1 pouch for 5 days)
2853647|NCT03572673|Experimental|New 2-piece ostomy appliance|New 2-piece appliance is a 2-piece ostomy appliance composed with an adhesive base plate and a drainable pouch for collecting stools (1 base plate for 5 days and 1 pouch for 5 days)
2853648|NCT03572660|Other|BMMNC intervention arm|Bone marrow derived mononuclear cells and G-CSF
2853649|NCT03572647|Experimental|Test ERITROMAX|Blausiegel Industria e Comercio Ltda. Recombinant Human Erythropoietin (ERITROMAX)
2853650|NCT03572647|Active Comparator|EPREX|Janssen-Cilag Recombinant Human Erythropoietin (EPREX)
2853651|NCT03572634|Experimental|Group 1-TP 0903 monotherapy|"Adult patients with CLL/SLL who:~are intolerant to, or have had progressive disease on B-cell receptor antagonists, BCL-2 antagonists or other investigational treatments for CLL/SLL"
2853652|NCT03572634|Experimental|Group 2-TP-0903 and ibrutinib combination therapy|"Adult patients with CLL/SLL who:~have progression of disease on ibrutinib, yet the treating provider considers continuation of ibrutinib therapy to be in the best interest of the patient"
2853653|NCT03572621|Experimental|Experimental group|Patients in the experimental group are offered to participate in a 6-session therapeutic education program on sexuality, ranging from 15 days before surgery to approximately 3 months after. This in addition to the current care by the teams of care about sexual rehabilitation (information and medication prescriptions).
2853654|NCT03572621|Sham Comparator|Control group|Patient without therapeutic education.
2853655|NCT03572621|Other|Partner|Patient's partner.
2853656|NCT03572608|Experimental|Acupuncture Treatment|Acupuncture group will receive 3 acupuncture sessions. The first session will be one week before embryo transfer. The second session will be 30 minute before embryo transfer. And the last session will be 30 minute after embryo transfer.
2853657|NCT03572608|No Intervention|Control Group|Control Group will not receive any acupuncture session before or after embryo transfer.
2853658|NCT03572595||Staging|Patients with pathologically proven colorectal cancer presented for pre-operative staging, underwent standard routine conventional radiological imaging i.e MRI , then will be subjected to be imaged by F-18 FDG-PET/CT from skullbase to midthigh, then interpretating the results of the hybrid PET/CT by two nuclear physicians then comparing with other conventional images.
2853659|NCT03572595||Recurrent|"Patients with treated colorectal cancer, suspecting of recurrence , will be subjected to be imaged by F-18 FDG-PET/CT from skull base to midthigh, interpretating the results of the hybrid PET/CT by two nuclear physicians.~Then refer back to the treating physicians , another biopsy will be taken from the suspected recurrence and then results will be compared with hybrid PET/CT images.~comparing the results with histopathology ."
2853660|NCT03572582|Experimental|TACE in combination with nivolumab|Treatment will be divided into 4-week cycles from the starting date of TACE. The second TACE will be repeated on day 1 (± 4 days) of cycle 3 (after 8 weeks ± 4 days). Nivolumab will be initiated on day 2-3 after the first TACE session. Nivolumab will be administered every two weeks (240mg fixed dose IV) until disease progression for up to two years.
2853661|NCT03572569||Index patients|Patients ≤18 years with primary cardiomyopathy
2853662|NCT03572569||First-degree family members|Parents and siblings of index patients
2853663|NCT03572556||Patients|Hereditary hemorrhagic telangiectasia patients
2853664|NCT03572556||Controls|Matched for age (+/- 5 ans) and sex.
2853665|NCT03572543|Experimental|Active tDCS|Active-tDCS targeting the mPFC. 20-minutes of multifocal-tDCS (30 seconds ramp in/out) at 1.5mA, with the anode placed over the frontal pole and five cathodes in a circumferential array surrounding the anode.
2853666|NCT03572543|Sham Comparator|Sham tDCS|Sham-tDCS over the mPFC. A multifocal-tDCS electrode montage with the anode placed over the frontal pole and five cathodes in a circumferential array surrounding the anode will be used for sham stimulation. Current will be ramped in/out at the beginning and end of a 20-minute period.
2853667|NCT03572530|Experimental|group 1|5-Azacytidine (5-AZA) group 1: Enrolled patients will undergo surgical placement of a ventricular catheter into the fourth ventricle that will be attached to a subcutaneously placed reservoir. Patients will be divided into 3 dose groups and receive 8 weeks of intraventricular 5-AZA (20 mg) into the fourth ventricle. Patients in Group 1 will receive two 5-AZA infusions every week.
2858784|NCT03537105|Experimental|Sclerodermic patients|Sclerodermic patients presenting cutaneous fibrosis
2853668|NCT03572530|Experimental|group 2|5-Azacytidine (5-AZA) group 2: Enrolled patients will undergo surgical placement of a ventricular catheter into the fourth ventricle that will be attached to a subcutaneously placed reservoir. Patients will be divided into 3 dose groups and receive 8 weeks of intraventricular 5-AZA (20 mg) into the fourth ventricle. Patients in Group 2 will receive three 5-AZA infusions every week.
2853669|NCT03572530|Experimental|group 3|5-Azacytidine (5-AZA) group 3: Enrolled patients will undergo surgical placement of a ventricular catheter into the fourth ventricle that will be attached to a subcutaneously placed reservoir. Patients will be divided into 3 dose groups and receive 8 weeks of intraventricular 5-AZA (20 mg) into the fourth ventricle. Patients in Group 3 will receive four 5-AZA infusions every week.
2853670|NCT03572517|Active Comparator|Subarachnoid block|"Subarachnoid block with hyperbaric bupivacaine 0,5% 3ml associate with morphine 50 mcg.~A general anesthetic with fentanyl 3 mcg / kg + propofol 2 mg / kg + rocuronium 0.6 mg / kg will be performed.~Anesthesia will be maintained with remifentanil (ng / ml) through Minto's pharmacokinetic model (BBraun infusion syringe - Perfusor® Space model) and desflurane (Fe%)."
2853671|NCT03572517|Active Comparator|Spinal morphine|"Spinal morphine with morphine 50 mcg. A general anesthetic with fentanyl 3 mcg / kg + propofol 2 mg / kg + rocuronium 0.6 mg / kg will be performed.~Anesthesia will be maintained with remifentanil (ng / ml) through Minto's pharmacokinetic model (BBraun infusion syringe - Perfusor® Space model) and desflurane (Fe%)."
2853672|NCT03572491|Experimental|Allantoic split inactivated seasonal influenza vaccine|A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NYMC X-275 (A/PR/8/34 (M, PB2, PA, NS, NP genes) и A/Michigan/45/2015 (PB1, HA, NA genes)), NYMC X-263В (A/PR/8/34 (PB1, PB2, PA, NS, NP, М genes) и A/Hong Kong/4801/2014 (HA, NA genes)), NYMC BX-35 (B/Lee/40 (NP gene), B/Panama/45/90 (PB2, М genes) и B/Brisbane/60/2008 (HA, NA PB1, PA, NS genes)).
2853673|NCT03572478|Experimental|Combination Therapy (Phase 1b Cohort)|Participants will receive rucaparib plus nivolumab in 4 week cycles.
2853674|NCT03572478|Experimental|Rucaparib (Phase 2b Randomized Cohort)|Participants randomized to receive rucaparib alone in 4 week cycles.
2853675|NCT03572478|Experimental|Nivolumab (Phase 2b Randomized Cohort)|Participants randomized to receive nivolumab alone in 4 week cycles.
2853676|NCT03572478|Experimental|Combination Therapy (Phase 2b Randomized Cohort)|Participants randomized to receive rucaparib plus nivolumab in 4 week cycles. Participants will receive rucaparib alone in cycle 1 and begin nivolumab on day 1 of Cycle 2.
2853677|NCT03572465||NAFLD, NASH patients|"All patients enrolled will undergo:~Acoustic Radiation Force Impulse (ARFI)~Magnetic Resonance Elastography (MRE)"
2853678|NCT03572465||Non-obese volunteers|"All patients enrolled will undergo:~Acoustic Radiation Force Impulse (ARFI)~Magnetic Resonance Elastography (MRE)"
2853679|NCT03572452|Experimental|McKenzie - method group|Participants will be sent to an experienced MDT therapist for therapy. They are 1) assessed clinically, 2) treated according the MDT-approach which includes home exercise program, consisting i) an educational component, and ii) an active therapy component with directional preference exercises, several times a day with sustained end range positions according to symptom response, and with avoiding aggravating positions. Participants have a maximum of 7 treatment visits. They will also have physiotherapy counselling at study entry about the good prognosis of sciatica.
2853680|NCT03572452|Active Comparator|Advice to stay active group|"Participants enrolled into this group will receive physiotherapist's counselling at study entry for at least 60 minutes time about the good prognosis of sciatica, the spontaneous regression of the intervertebral disc herniation and pain tolerance (natural healing). In addition, they will get ergonomic advice and advice to stay normally active. The participants are also told to avoid bed rest and advised to continue their normal routines as actively as possible including exercise activities with limits permitted by their signs and symptoms. A two-page summary booklet related to these items will be given to them."
2853681|NCT03572439|Active Comparator|Cephalad to caudal|Sensory block level check using ice, moving from cephalad to caudal
2853682|NCT03572439|Active Comparator|Caudal to cephalad|Sensory block level check using ice, moving from caudal to cephalad
2853683|NCT03572426||Bipolar|Diagnosed as having at least 1 lifetime manic episode by the MINI
2853684|NCT03572426||Depression|Diagnosed as having at least 1 Major Depressive Episode by the MINI
2853685|NCT03572426||Healthy Controls|Does not meet Criteria for any mood disorder diagnosis (MDD, BD, dysthymia)
2853686|NCT03572413|Experimental|Low pressure PNP, deep NMB|Low pressure pneumoperitoneum of 8 mmHg with deep neuromuscular block (post tetanic count of 1-2) reached by titration with continuous infusion of Rocuronium bromide.
2853687|NCT03572413|Active Comparator|Normal pressure PNP, moderate NMB|Normal pressure pneumoperitoneum of 12 mmHg with moderate neuromuscular block (TOF count of 1-2) reached by titration with bolus or continuous infusion of a low dose of Rocuronium bromide.
2853688|NCT03572400|Experimental|Gemcitbine/Durvalumab|"Neoadjuvant CCRT with Gemcitbine/Durvalumab~+Adjuvant Gemcitabine/Durvalumab Total 6 cycles, after that, Durvalumab q4wks up to total 1 year"
2853689|NCT03572387|Experimental|(5-AZA) + (ATRA) combination|Combination of 5-Azacitidine (5-AZA) + all trans retinoic acid (ATRA) group after one month of Lupron, group will receive treatment on a 28-day cycle, in the absence of prohibitive toxicities, for 3 cycles.
2853690|NCT03572387|Active Comparator|Lupron only|No treatment after one month of Lupron
2853691|NCT03572374|Experimental|TEAMWork App|"The 2-pronged approach of the intervention is operationalized through 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu has a list of features from which participants can choose to learn about a particular topic. A My notes button allows participants to take notes directly on the app. These notes will not be available to the research team, such that participants may use the tool without concerns about privacy. The workplace accommodations menu includes sample videos using trained actors to demonstrate how to approach an employer to request accommodations. Additional features include suggestions for accommodations that may be helpful, templates for letters participants can use when requesting accommodations, links to relevant websites, information about legal protections, and contact information for lawyers and firms that provide pro bono assistance."
2853723|NCT03572153|Active Comparator|Self-Administered White Noise Hypnosis|Self-administered white noise hypnosis will be practiced daily using a white noise recording. Participants will practice hypnosis at home after completing the two consent and education sessions.
2853692|NCT03572374|Active Comparator|Information Booklet (control)|Participants will receive a booklet that includes the information in the app that can practicably be converted to paper. These participants will not have access to the multimedia aspects of the intervention, such as the videos, but they will have all of the relevant information in the app described above, including suggestions for accommodations, written templates for letters, links to websites, information about legal protections, and contact information for pro bono legal assistance. The booklet will also contain information about chemotherapy, radiation therapy and surgery, recommendations for management of common symptoms, and advice for communicating with the clinic team. The information booklet will be provided entirely on paper, although participants may independently access websites recommended in the booklet. The booklet content will mirror the app with regard to cultural responsiveness and appropriateness for different job types and characteristics.
2853693|NCT03572361|Experimental|V3-MOMMO|Oral once daily pill of tableted vaccine (V3-MOMMO) containing pooled breast cancer antigens administered for 3 months in 20 volunteers with breast cancer
2853694|NCT03572348|Active Comparator|Transecting anastomotic repair (tAR)|Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.
2853695|NCT03572348|Active Comparator|Vessel-sparing anastomotic repair (vsAR)|Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
2853696|NCT03572335||HIV positive with normal PFT's|HIV positive with normal baseline DLco. Subjects with DLco>80% predicted after adjustments for Hgb and Co
2853697|NCT03572335||HIV positive with mild DLco impairment|HIV positive with mild DLco impairment DLco <80% predicted after adjustments for Hgb and Co.
2853698|NCT03572322||Doctors|
2853699|NCT03572322||Patients|
2853700|NCT03572296|Placebo Comparator|Placebo|No polyphenols or fibre will be delivered in a low sugar drink.
2853701|NCT03572296|Experimental|Polyphenol and fibre|Blackcurrant extract (800 mg total polyphenols) and pulp (source of fibre) will be delivered in a low sugar drink.
2853702|NCT03572296|Experimental|Fibre|Pulp (source of fibre) will be delivered in a low sugar drink.
2853703|NCT03572283|Experimental|Bethanechol|Patients with pancreatic adenocarcinoma will receive bethanechol prior to pancreatic surgery
2853704|NCT03572270|Experimental|case|PLWH
2853705|NCT03572270|Other|control|HIV negative women, going to medically assisted procreation consultation for male infertility
2853706|NCT03572257|Experimental|Quetiapine (0.5 mg/kg TID x 10 days)|This study group will receive treatment with quetiapine after diagnosis of pediatric delirium. Group assignment will be blinded.
2853707|NCT03572257|Placebo Comparator|Placebo|This study group will receive a placebo treatment after diagnosis of pediatric delirium. Group assignment will be blinded.
2853708|NCT03572244|Experimental|Laser-Lok|A Laser-Lok microgrooved implant will be placed.
2853709|NCT03572244|Active Comparator|Machine|A machined implant will be placed.
2853710|NCT03572231||mirabegron|Participants will commence the OAB treatment with mirabegron that is prescribed by a physician in routine clinical practice.
2853711|NCT03572231||Antimuscarinics|Participants will commence the OAB treatment with one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine. The antimuscarinic is prescribed by a physician in routine clinical practice.
2853712|NCT03572218|Experimental|BWL + BIAS|The behavioral weight loss (BWL) + weight bias internalization and stigma (BIAS) group will include standard BWL treatment (described in more detail in Intervention section) combined with a weight stigma-reduction intervention. During the initial 12 weeks, the weekly 60-minute BWL sessions will be followed by 30 minutes devoted to stigma-related content. In the every-other-week and monthly weight loss maintenance sessions from weeks 13-26, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies specifically in the context of weight management.
2853713|NCT03572218|Active Comparator|Standard BWL|The Standard BWL group will receive weekly BWL sessions (described in more detail in Intervention section) for 12 weeks, followed by every-other-week and monthly weight loss maintenance sessions from weeks 13-26. BWL content will last for 60 minutes, with an additional 30 minutes in this group devoted to discussing recipes and food preparation.
2853714|NCT03572205|Experimental|CC genotype LA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of sunflower oil (source of LA: linoleic acid) daily, depending on body weight. The same diet will be instructed for both genotypes.
2853715|NCT03572205|Experimental|TT genotype LA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of sunflower oil (source of LA: linoleic acid) daily, depending on body weight. The same diet will be instructed for both genotypes.
2853716|NCT03572205|Experimental|CC genotype ALA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of camelina oil (source of alpha-linolenic acid: ALA) daily, depending on body weight. The same diet will be instructed for both genotypes.
2853717|NCT03572205|Experimental|TT genotype ALA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of camelina oil (source of alpha-linolenic acid: ALA) daily, depending on body weight. The same diet will be instructed for both genotypes.
2853718|NCT03572179|Active Comparator|Treatment Group|After finishing orthodontic treatment, all patient will receive a modified indirect technique for bonding fixed mandibular retainer and the key of modification is the fabrication of 3D printed digital positioning tray for placement of retainer with holes for composite pads for its direct application using 3 shape Ortho analyser Software ® instead of conventional indirect retainer fabrication method
2853719|NCT03572179|No Intervention|Control Group|All patients of this group will follow conventional steps of direct bonding procedure of fixed mandibular retainer
2853720|NCT03572166|Experimental|Arginine Infusion|Arginine Stimulation Test
2853721|NCT03572166|Active Comparator|Hypertonic saline infusion|Hypertonic Saline Infusion Test
2853722|NCT03572153|Experimental|Self-Administered Hypnosis|Self-administered hypnosis will be practiced daily using different audio recordings using the researcher's voice. Participants will practice hypnosis at home after completing the two study sessions.
2853728|NCT03572114||Sporadic Dystonia|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
2853729|NCT03572114||Familial Dystonia|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
2853730|NCT03572114||Parkinson´s disease, juvenile|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
2853731|NCT03572114||Neurodegeneration with brain iron acc.|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
2853732|NCT03572114||mitochondrial disease|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
2853733|NCT03572114||Healthy Controls|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
2853734|NCT03572101||Calgary Patient Cohort|Patients with advanced colorectal cancer who are recruited from Calgary, Canada before, during, and after an early palliative care pathway becomes the new standard of care in Calgary.
2853735|NCT03572101||Calgary Caregiver Cohort|Caregivers of patients with advanced colorectal cancer who are recruited from Calgary, Canada before, during, and after an early palliative care pathway becomes the new standard of care in Calgary.
2853736|NCT03572101||Edmonton Patient Cohort|Patients with advanced colorectal cancer who are recruited from Edmonton, Canada during the same time period (no palliative care pathway introduced).
2853737|NCT03572101||Edmonton Caregiver Cohort|Caregivers of patients with advanced colorectal cancer who are recruited from Edmonton, Canada during the same time period (no palliative care pathway introduced).
2853738|NCT03572088|Active Comparator|Terlipresssin|Terlipressin was started at the beginning of surgery, just after exposure of the portal vein and getting a basal portal pressure reading, as an initial bolus dose of 1 mg over 30 minutes (1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
2853739|NCT03572088|Placebo Comparator|Control|patients received the same volume of normal saline for the same duration (50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours)
2853740|NCT03572075|Experimental|Group A|assessment of symptoms at the first medical examination; standard care protocol; pelvic floor physiotherapy; assessment of symptoms after four months
2853741|NCT03572075|Experimental|Group B|assessment of symptoms at the first medical examination; standard care protocol; assessment of symptoms after four months
2853742|NCT03572062|Experimental|Sentinel Arm 1|Low dose formulation A
2853743|NCT03572062|Experimental|Sentinel Arm 2|Low dose formulation B
2853744|NCT03572062|Experimental|Sentinel Arm 3|Mid dose formulation A
2853745|NCT03572062|Experimental|Sentinel Arm 4|Mid dose formulation B
2853746|NCT03572062|Experimental|Sentinel Arm 5|High dose formulation A
2853747|NCT03572062|Experimental|Sentinel Arm 6|High dose formulation B
2853748|NCT03572062|Placebo Comparator|Sentinel Arm 7|Placebo
2853749|NCT03572062|Experimental|Expanded Arm 8|Low dose formulation A and SIIV
2853750|NCT03572062|Experimental|Expanded Arm 9|Low dose formulation B and placebo
2853751|NCT03572062|Experimental|Expanded Arm 10|Low dose formulation B and SIIV
2853752|NCT03572062|Experimental|Expanded Arm 11|Mid dose formulation A and SIIV
2853753|NCT03572062|Experimental|Expanded Arm 12|Mid dose formulation B and placebo
2853754|NCT03572062|Experimental|Expanded Arm 13|Mid dose formulation B and SIIV
2853755|NCT03572062|Experimental|Expanded Arm 14|High dose formulation A and SIIV
2853756|NCT03572062|Experimental|Expanded Arm 15|High dose formulation B and placebo
2853757|NCT03572062|Experimental|Expanded Arm 16|High dose formulation B and SIIV
2853758|NCT03572062|Experimental|Expanded Arm 17|Placebo and Placebo
2853759|NCT03572049|Experimental|SUBA itraconazole|"Stage 1: Day 1-3 two 65 mg capsules three times daily with food. Days 4-42 two 65 mg capsules twice daily with food.~Stage 2 : Days 43-180 two 65 mg capsules twice daily with food"
2853760|NCT03572049|Active Comparator|Conventional itraconazole|"Stage 1: Day 1-3 two 100 mg capsules three times daily with food. Days 4-42 two 100 mg capsules twice daily with food.~Stage 2 : Days 43-180 two 100 mg capsules twice daily with food"
2853761|NCT03572036||Arm 1|aged 18 and older, participated in 001-H-0088 and 04-H-0161 and 1) a diagnosis of SCD 2) a diagnosis of PH 3) prescribed and/ or reported taking PDE5-I therapy for a duration of >16 weeks.
2853762|NCT03572023|Other|MI without obstructive CAD, with OCT and CMR,SPECT|MSCT CMR Single-Photon Emission Computed Tomography
2853763|NCT03572010|Placebo Comparator|FeFum fortified maize test meal|
2853764|NCT03572010|Placebo Comparator|FeSO4 fortified LNS|
2853765|NCT03572010|Placebo Comparator|FeSO4 supplement|
2853766|NCT03572010|Placebo Comparator|FeSO4 fortified fruit juice|
2853767|NCT03571984|Experimental|Moving on ABC Plus Group|Moving on ABC Plus is combination of two interventions. The culturally adapted Positive Health Program (PHP) and Moving on ABC. PHP is a psychological intervention based on the principles of CBT intervention. The PHP will be integrated with The Moving on After Breast Cancer (ABC), which has been developed by Dr Anneela Saleem who suffered from breast cancer. The integrated intervention will consist of 12 sessions (60-90 minutes). The first 8 sessions will be delivered weekly and the last four sessions will be delivered fortnightly
2853768|NCT03571984|No Intervention|Routine Care|This will consist of routine assessment and management as usually conducted by oncology clinics and general practice. GP's will be informed about the psychiatric diagnosis.
2853769|NCT03571971|Experimental|Load modification education|Load modification education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities, but will also include education on common daily postures and movement patterns that may increase load and stress on the muscles and tendons around the hip.
2859187|NCT03534115|Experimental|Experimental Arm|solution containing NAC with buffers
2853770|NCT03571971|Active Comparator|Standard exercise education|Standard exercise education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities.
2853771|NCT03571958|No Intervention|Traditional OHI (Control)|"Advice giving method of OHI known as tell-show-do to inform, demonstrate, and expect patient compliance."
2853772|NCT03571958|Experimental|BMI (Test)|A derivative of motivational interviewing (MI), which is a patient-centered, collaborative counseling approach to strengthen an individual's intrinsic motivation towards a positive behavior change. BMI is intended for healthcare providers with limited time (5-10 minutes) to support a positive behavior change.
2853773|NCT03571945|Active Comparator|BIS Guided Group|GA will be monitored and controlled with Bi-spectral index (BIS) monitoring.The anaesthesiologist will be blinded to ETAG and MAC readings.
2853774|NCT03571945|Active Comparator|ETAG Guided Group|GA will be monitored and controlled with end-tidal anaesthesia gas (ETAG) monitoring.The anaesthesiologist will be blinded to the BIS readings.
2853775|NCT03571932||Intervention Facilities|Includes 18 health facilities
2853776|NCT03571932||Comparison facilities|Infludes 18 health facilities
2853777|NCT03571919|Placebo Comparator|Control|Will receive normal saline bolus and infusion and have sham lab draws every 8 hours.
2853778|NCT03571919|Active Comparator|Lidocaine|Will receive lidocaine bolus and infusion and have lidocaine lab draws every 8 hours.
2853779|NCT03571906|Experimental|Pre-rehab intervention|"Subjects in the prehab arm will receive an exercise prescription and execution will be assessed and periodically adjusted in accordance to data received from the wearable device. Intensity and type of exercise will be moderate and will comply with exercise recommendations provided by ESC guidelines. A dedicated application will be installed on the mobile phone for patients in the research group and they will receive a smart sports watch.~Periodic encouragements and consultations will be provided by exercise trainer, physiologist and nurse from the cardiac rehabilitation center. A physician will be available for consultations.~In addition to monitored physical activity, patients will receive nutritional and psychological counseling. This is part of a multi-professional rehabilitation program accepted by the rehabilitation center."
2853780|NCT03571906|No Intervention|pre-operative usual care arm|"The control group will receive recommendations for a healthy and active lifestyle and physician follow-up~All subjects will undergo a stress test at baseline (post enrollment), and again prior to cardiac surgery."
2853781|NCT03571893|Experimental|Weight Watchers Freestyle (Flex)|Participate in Commercially Available behavioral weight loss program delivered by Weight Watchers International in the community
2853782|NCT03571893|Active Comparator|DIY Personal Plan|Receive informational resources for healthy lifestyle change to promote weight loss
2853783|NCT03571880|Experimental|CNSLBP group|
2853784|NCT03571880|Active Comparator|Healthy control group|
2853785|NCT03571867||group Sugammadex|After surgery, while the TOF count was 2/4, the residual muscle relaxation was antagonized with 2 mg/kg iv sugammadex + 0.01 ml/kg saline in Group S
2853786|NCT03571867||group Neostigmine|After surgery, while the TOF count was 2/4, the residual muscle relaxation was antagonized with 0.02 mg/kg neostigmin+0.01 mg/kg atropine in Group N.
2853787|NCT03571854|Experimental|Group PCV-VG|Pressure controlled ventilation-volume guaranteed
2853788|NCT03571854|Active Comparator|Group VCV|Volume controlled ventilation
2853789|NCT03571841|Experimental|Educational Intervention|"For breast cancer survivors currently on chemical ovarian suppression who are experiencing sexual dysfunction.~Group Session~Telephone Booster Session"
2853790|NCT03571828|Experimental|Part 1: Dose Exploration|Dose exploration cohorts to estimate the MTD, safety, tolerability, PK, and PD of different doses of AMG 562 in subjects with relapsed/refractory DLBCL, MCL or FL using a Bayesian logistic regression model (BLRM; Neuenschwander et al, 2008).
2853791|NCT03571828|Experimental|Part 2: Dose Expansion|dose expansion part to gain further clinical experience, safety and efficacy data for AMG 562 in subjects with relapsed / refractory DLBCL. The dose to be evaluated will be at or below the MTD estimated in the dose exploration cohorts.
2853792|NCT03571815|Experimental|fluoride varnish application|intervention; fluoride varnish application (with 5% Sodium fluoride varnish application on teeth)
2853793|NCT03571815|Placebo Comparator|control group|application of water on teeth in the control group
2853794|NCT03571802|Experimental|intervention arm|simvastatin 20mg once
2853795|NCT03571789|Experimental|Vine™ implantation bilaterally in the common carotid arteries|Vine™ is a permanent carotid filter made from a single nitinol wire. It is configured to capture emboli exceeding 1.2mm in size, which originate in the heart and large arteries below the neck. Vine™ has a helical structure, with leading and supporting coils interposed by a filter section.
2853796|NCT03571776|Active Comparator|Surgery|Laparoscopic ovarian cystectomy
2853797|NCT03571776|Active Comparator|Sclerotherapy|US-aspiration and alcohol sclerosis
2853798|NCT03571763||acute ischemic stroke patient|acute ischemic stroke patient acute ischemic stroke patient Patient age ≥18 years .Acute ischemic stroke patient confirmed by imaging(SWI sequence) .Time of onset: within 3 months
2853799|NCT03571750|Experimental|Building Stronger Allies Condition|"BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness."
2853800|NCT03571750|Placebo Comparator|Health Education Training Condition|In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
2853804|NCT03571724|Experimental|Menthol Very Low Nicotine Cigarettes|Subjects will be switched from their usual brand to smoke Very Low Nicotine king size Menthol cigarettes
2853805|NCT03571711||Meropenem therapy in SBP|Patients in a tertiary care Hospital with meropenem injection due to spontaneous bacterial Peritonitis.
2853806|NCT03571698|No Intervention|Exercise programme only|The treatment group received only exercise programme. The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
2853807|NCT03571698|Active Comparator|Exercise with NMES standard electrodes|The treatment group received exercise programme with simultaneously active contraction with NMES with standard electrodes.The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
2853808|NCT03571698|Active Comparator|Exercise with NMES large electrodes|The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
2853809|NCT03571685|Experimental|Intervention, Sustainable Early Episode Clinic Model of Care|The model of care given in the sustainable early episode clinic study, provides early intense intervention, with an ongoing maintenance phase in an outpatient setting
2853810|NCT03571685|Other|Control Arm|Usual Care - Insurance Database
2853811|NCT03571672|Experimental|DEFINITY|Each patient will undergo an unenhanced ultrasound examination and a DEFINITY contrast-enhanced ultrasound
2853812|NCT03571659||two subthreshold parameters|5% and 15% duty cycle (DC)
2853813|NCT03571659||standard ETDRS|early treatment of diabetic retinopathy study
2853814|NCT03571646|Other|Capnostream 20|Continuous monitoring of CO2
2853815|NCT03571646|Other|PM1000N-RR|Continuous monitoring of SpO2
2853816|NCT03571633|Experimental|Paclitaxel+Trastuzumab+Pegfilgrastim|"NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC) + Pegfilgrastim (6 mg, Q3W, subcutaneously, the day after the trastuzumab + paclitaxel infusion (i.e. Day 2 of each cycle)).~ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)"
2853817|NCT03571633|Active Comparator|Paclitaxel+Trastuzumab|"NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC).~ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)"
2853818|NCT03571620|Placebo Comparator|Vehicle|
2853819|NCT03571620|Experimental|1.0% Q301 Cream|
2853820|NCT03571620|Experimental|1.4% Q301 Cream|
2853821|NCT03571607|Experimental|13-valent pneumococcal conjugate vaccine|
2853822|NCT03571594|Experimental|ONO-5788 Part A1|Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group
2853823|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part A1|Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group
2853824|NCT03571594|Experimental|ONO-5788 Part A2|Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group
2853825|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part A2|Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group
2853826|NCT03571594|Experimental|ONO-5788 Part B|Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group
2853827|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part B|Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group
2853828|NCT03571594|Experimental|ONO-5788 Part C|Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group
2853829|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part C|Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group
2853830|NCT03571594|Experimental|ONO-5788 Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
2853831|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
2853832|NCT03571594|Active Comparator|Octreotide Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
2853833|NCT03571594|Placebo Comparator|Octreotide Placebo Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
2853834|NCT03571581|Experimental|Mindfulness Training (MT)|Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
2853835|NCT03571568|Experimental|BI-1206|BI-1206 IV Standard 3+3 Dose-Escalation Design
2853836|NCT03571555||Young people with perinatally acquired HIV|Residential interventions (camps) and community based support (clubs)
2853837|NCT03571555||Caregivers of young people with perinatally acquired HIV|Community based support (clubs)
2853838|NCT03571529|Active Comparator|Robotic rehabilitation|"Active Comparator: Robotic rehabilitation~Protocol with EMG-driven hand exoskeleton (Hand of Hope):~Warm-up: 10 min passive mode 2 min resting~Training: According to residual muscle power:~10 min active-assistive, 2 min resting, 10 min Active-assistive or~5 min active, 2 min resting, 15 min active assistive or~10 min active, 2 min resting, 10 min active and~10 min window cleaning game Robotic rehabilitation will be applied 5 times a week; Totally 15 sessions (3 weeks). Conventional physiotherapy also will be performed to the robotic rehabilitation group."
2853839|NCT03571529|Active Comparator|conventional physiotherapy|"Conventional Physiotherapy will be performed to the both group 5 sessions a week and totally 15 sessions (3 weeks).~Conventional physiotherapy will include neurophysiological approaches. Each session will last around 1,5 hours."
2853898|NCT03571087|Experimental|HL140 20/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)
2853840|NCT03571516|Experimental|Teduglutide|Participants will receive 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection of teduglutide into abdomen or into either the thigh or arm once daily (QD) in addition to standard medical therapy for 24 weeks.
2853841|NCT03571516|Other|Standard of Care (SOC)|Participants will receive standard medical therapy for 24 weeks.
2853842|NCT03571503||Integrative Korean medicine treatment|Herniated lumbar disc (HLD) patients with radiating leg pain in the integrative Korean medicine treatment group will be administered integrative Korean medicine treatment consisting of 2 sessions/day of acupuncture, and herbal medicine, Chuna manual therapy, bee venom pharmacopuncture and pharmacopuncture, electroacupuncture, cupping, and other interventions, as needed.
2853843|NCT03571503||Doin with integrative Korean medicine|Herniated lumbar disc (HLD) patients with radiating leg pain in the Doin (conduction exercise) with integrative Korean medicine treatment group will be administered integrative Korean medicine treatment consisting of 2 sessions/day of acupuncture, and herbal medicine, Chuna manual therapy, bee venom pharmacopuncture and pharmacopuncture, electroacupuncture, cupping, and other interventions, as needed, plus Doin (conduction exercise) for 1 session of the 2 sessions/day of acupuncture.
2853844|NCT03571490|Active Comparator|TQL Ropivacaine(active)|Bilateral Single shot of ropivacaine 0.325% 30 mL. In total 60 mL of 0.325% ropivacaine
2853845|NCT03571490|Placebo Comparator|TQL saline (placebo)|Bilateral single shot of saline 0.9% 30 mL. in Total 60 mL of saline 0.9%
2853846|NCT03571464|Experimental|Immediate use GGRO Mobile App|The group starts using the GGRO Mobile App immediately after the first assessment (T1) for 15 days.
2853847|NCT03571464|Active Comparator|Delayed use GGRO Mobile App|Delayed use GGRO Mobile App group started using the App 15 days after the first assessment (T2).
2853848|NCT03571438|Experimental|CK2(CX4945) and ATM(Ku 60019)|Treatment of cell culture with a combination of CK2 and ATM inhibitors serine/ threonin Kinase combination
2853849|NCT03571438|Active Comparator|Sunitinib|Treatment of cell culture with Sunitinib
2853850|NCT03571438|Active Comparator|Pazopanib|Treatment of cell culture with Pazopanib
2853851|NCT03571438|Active Comparator|Temsirolimus|Treatment of cell culture with Temsirolimus
2853852|NCT03571425|Placebo Comparator|Oral Placebo|Placebo drink
2853853|NCT03571425|Active Comparator|Oral Protein|Protein drink, ingested orally
2853854|NCT03571425|Active Comparator|Enteral Protein|Protein drink, administered via enteral tube
2853855|NCT03571412|Experimental|5Hz Left Dorsolateral Prefrontal Cortex|This group will receive 5Hz Left Dorsolateral Prefrontal Cortex repetitive Transcranial Magnetic Stimulation. Once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
2853856|NCT03571412|Experimental|5Hz Dorsomedial Prefrontal Cortex|This group will receive 5Hz Dorsomedial Prefrontal Cortex Transcranial Magnetic Stimulation, once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
2853857|NCT03571386||Mild to Moderate Depression|Patients who currently have mild to moderate severity of depression symptoms are who are receiving Mindfulness-Based Cognitive Therapy (MBCT) in a group setting as standard of care will be recruited for this arm.
2853858|NCT03571386||Mild to Moderate Anxiety|Patients who currently have mild to moderate severity of anxiety symptoms are who are receiving Mindfulness-Based Cognitive Therapy (MBCT) in a group setting as standard of care will be recruited for this arm.
2853859|NCT03571386||High Stress|Patients with a history of reported stress who are receiving Mindfulness-Based Stress Reduction (MBSR) in a group setting as standard of care will be recruited for this study. All patients are eligible.
2853860|NCT03571360|Other|Pembrolizumab|Pembrolizumab 200 mg i.v., every 3 weeks, maximum of 2 years
2853861|NCT03571347|Experimental|Self Help Plus|SH+ programme has been developed by WHO and collaborators working in the humanitarian field, with expertise in global mental health and psychosocial interventions. SH+ programme consists of a pre-recorded audio course, complemented with bibliotherapy, and thanks to this format not requiring much time from experts for implementation. SH+ consists of 5 sessions.
2853862|NCT03571347|Other|Enhanced Treatment As Usual|Control arm participants will receive routine social support and/or care according to ordinary practice and following local regulations. Additionally, they will receive baseline and follow-up assessments according to the study schedule, and information about freely available mental health services, social services and community networks providing support to asylum seekers and refugees, and NGOs' contact details.
2853863|NCT03571334|Experimental|onabotulinumtoxinA|"onabotulinumtoxinA ((Botox®, Allergan, CA, USA) (ONA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units.~Study participants in this arm will receive 50u ONA (total volume 2.5mL) injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.)~Hands: ONA will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site).~Feet: ONA will be injected across the dorsal surface of the feet also in a grid like pattern covering a total of 25 sites per limb (0.1mL/site)."
2853864|NCT03571334|Placebo Comparator|saline control|"Study participants in this arm will 2.5mL normal saline injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.)~Hands: saline will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site).~Feet: Saline will be injected across the dorsal surface of the feet also in a grid like pattern covering a total of 25 sites per limb (0.1mL/site)."
2853865|NCT03571321|Experimental|Ruxolitinib|"Participants will receive ruxolitinib in addition to standard chemotherapy.~Standard Chemotherapy Consists of:~Remission consolidation therapy (lasting 8 weeks)~Interim Maintenance (lasting 8 weeks)~Delayed Intensification (lasting 8 weeks~Maintenance Therapy (12 week courses/84 day cycles lasting 2-3 years)~Prior to study entry, patients must have completed a 4-drug induction therapy regimen with intrathecal chemotherapy (modified Berlin-Frankfurt-Münster (aBFM) regimen or equivalent) as per the institution standard of care."
2853866|NCT03571308|Other|Open Label Trial|Open-label non-randomised phase Ib/II study conducted in two stages. Stage 1 will be dose escalation in a modified classical 6+6 design. Stage 2 will be an expansion cohort to gain additional information on safety and efficacy at the recommended phase II dose of acalabrutinib
2853867|NCT03571295|Experimental|videolaryngoscopy|
2853868|NCT03571295|Experimental|direct laryngoscopy|
2863156|NCT03507296||Chronic low back pain patients|
2853869|NCT03571282|Experimental|treatment group|The patients in the treatment group receive three monthly intravitreal injection of conbercept followed by PRN rescue treatments such as intravitreal injection of conbercept, laser photocoagulation (when outside the macular) or photodynamic therapy (when in the macular).
2853870|NCT03571269||OCT-guided group|OCT examination methods and precautions are the same as above. The operator judges the lesion according to the feature of culprit lesions from OCT. If a stent is implanted, postoperative OCT examination is performed. Based on the operator's experience, it is judged whether post-dilatation is necessary. Patients undergoing stent implantation should be treated with aspirin for at least 12 months.
2853871|NCT03571269||angiography-guided group|CAG examination methods and precautions are the same as above. Patients undergoing conventional angiography and/or thrombus aspiration do not undergo OCT. The operator judges the lesion according to the current treatment standard and decides whether to implant the stent. If a stent is implanted, postoperative angiography (also required to meet the above body position requirements) is performed. Based on the operator's experience, it is judged whether post-dilatation is necessary. Patients undergoing stent implantation should be treated with aspirin for at least 12 months.
2853872|NCT03571256|Experimental|TEV-50717 [high]|The target dose for each patient receiving TEV-50717 will be based on the group to which they are randomized, body weight at baseline, and cytochrome P450 2D6 (CYP2D6) impairment status.
2853873|NCT03571256|Experimental|TEV-50717 [low]|The target dose for each patient receiving TEV-50717 will be based on the group to which they are randomized, body weight at baseline, and cytochrome P450 2D6 (CYP2D6) impairment status.
2853874|NCT03571256|Placebo Comparator|Placebo|Placebo Comparator
2853875|NCT03571243||smokers|no intervention
2853876|NCT03571243||never-smokers|no intervention
2853877|NCT03571230|Experimental|Antimicrobial susceptibility testing guided therapy|"Patients in this group will receive a 10-day triple therapy for the Helicobacter pylori eradication. The regimen contains one proton pump inhibitor and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 10d 2.two sensitive antibiotics: amoxicillin 1000mg bid for 10d, clarithromycin 500mg bid for 10d, metronidazole 500mg tid for 10d, tinidazole 500mg tid for 10d, levofloxacin 500mg qd for 10d, furazolidone 100mg bid for 10d, tetracycline 750mg bid for 10d."
2853878|NCT03571230|Experimental|Empirical tailored therapy|"Patients in this group will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and clarithromycin 500mg bid for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
2853879|NCT03571230|Other|Salvage therapy for negative culture|"When the culture results are negative, patients will receive 14-day empirical tailored therapy based on personal medication history.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and clarithromycin 500mg bid for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
2853880|NCT03571230|Other|Salvage therapy for failed eradication|"If patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics for rescue therapy: tetracycline 750mg bid and furazolidone 100mg bid for 14d."
2853881|NCT03571217||Diabetic retinopathy cohort|
2853882|NCT03571217||Mild visual impairment cohort|
2853883|NCT03571204|Active Comparator|Group-1 active treatment|Group 1, 15 individuals who began ART during primary HIV-1 infection will be randomized to treatment with 3BNC117 plus 10-1074. Study staff and participants will be blinded to Group 1 treatment assignments.
2853884|NCT03571204|Placebo Comparator|Group-1 placebo|Group 1, 15 individuals who began ART during primary HIV-1 infection will be randomized to treatment with normal saline placebo. Study staff and participants willbe blinded to Group 1 treatment assignments.
2853885|NCT03571204|Experimental|Group-2 active treatment|Group 2, up to 15 viremic individuals not taking ARTwill receive 3BNC117 combined with 10-1074.
2853886|NCT03571178|Experimental|Treatment|Patients who will receive physical therapy
2853887|NCT03571165|Experimental|Intervention|The intervention group received information on accessing My Tools 4 Care - In Care for 2 months.
2853888|NCT03571152|Experimental|Educational videos|Subjects allocated in this arms will receive the educational videos.
2853889|NCT03571139||Diabetics type 2 with and without diabetic retinopathy|Patients with diabetes mellitus type 2 with and without diabetic retinopathy who needs cataract surgery by phacoemulsification. All patients will undergo OCT angiography examination prior to their cataract surgery and 4 weeks after the cataract surgery.
2853890|NCT03571126|Placebo Comparator|Placebos group|Patients will be administered with placebos, dexamethasone plus tropisetron /granisetron from D1 to D3.
2853891|NCT03571126|Experimental|Experimental group|Patients will receive regimen with dexamethasone plus tropisetron/granisetron from D1-D3. Patients will also be administrated with olanzapine from D1-D5.
2853892|NCT03571113||Development|The study population was divided into two parts by random: development dataset (5,775) and validation dataset (1,457)
2853893|NCT03571113||Validation|The study population was divided into two parts by random: development dataset (5,775) and validation dataset (1,457)
2853894|NCT03571100|Active Comparator|Povidine-Iodine|Bilateral injections patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye
2853895|NCT03571100|Active Comparator|Chlorhexidine|Bilateral injections patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye
2853896|NCT03571087|Experimental|HL140 5/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)
2853897|NCT03571087|Experimental|HL140 10/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)
2860086|NCT03528044|No Intervention|Control group|Healthy controls with normal BMI.
2853899|NCT03571087|Experimental|Rosuvastatin 5mg → HL140 5/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 5mg~Extension period(W9~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)"
2853900|NCT03571087|Experimental|Rosuvastatin 10mg → HL140 10/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 10mg~Extension period(W9~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)"
2853901|NCT03571087|Experimental|Rosuvastatin 20mg → HL140 20/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 20mg~Extension period(W9~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)"
2853902|NCT03571074||Hypoxia|"Defined as a group of patients with oxygen saturation <94 % irrespective of supplemental oxygen.~If COPD, defined as oxygen saturation <88 % irrespective of supplemental oxygen."
2853903|NCT03571074||Normoxia|"Defined as a group of patients with oxygen saturation 94 % - 98 % in combination of supplemental oxygen, or oxygen saturation >94 % without supplemental oxygen.~If COPD, defined as oxygen saturation 88 % - 92 % in combination of supplemental oxygen, or oxygen saturation >88 % without supplemental oxygen."
2853904|NCT03571074||Hyperoxia|"Defined as a group of patients with oxygen saturation >98 % in combination of supplemental oxygen.~If COPD, defined as oxygen saturation >92 % in combination of supplemental oxygen."
2853905|NCT03571061|Active Comparator|whole colon water immersion group|whole colon water immersion group: the air supply was turn off until the cecum was reached. For adequate lumen distention to advance the colonoscope tip, warm water which stored in 1L bottles and maintained 37°C with a water bath, was instilled intermittently into the colon through the auxiliary working channel of colonoscope using a footswitch-controlled flushing pump
2853906|NCT03571061|Experimental|sigmoid water immersion group|sigmoid water immersion group: air pump would be turned off and the procedure would be switched from water immersion method to air insufflation method after successful passage through the descending sigmoid junction.
2853907|NCT03571061|Placebo Comparator|air insufflation|air insufflation group: air was insufflated through out the whole procedure for advancement and inspection when needed.
2853908|NCT03571048|Active Comparator|Reduced Calorie Diet (RCD)|Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.
2853909|NCT03571048|Experimental|Time Restricted Feeding (TRF)|Participants in this group will focus on time restricted feeding in addition to daily calorie restriction as their dietary weight loss strategy.
2853910|NCT03571035|Experimental|Example|Mandibular movements recordings by a mono vision system.
2853911|NCT03571022|Active Comparator|USE-MI System|Immediate use of the USE-MI smartwatch and smartphone app.
2853912|NCT03571022|Active Comparator|USE-MI System after 6 Months Follow-Up|After 6 months of follow-up, subjects will begin using the USE-MI smartwatch and smartphone app.
2853913|NCT03571009|Experimental|utilization of PAAS|conventional treatment utilization of PAAS
2853914|NCT03571009|No Intervention|Conventional care|conventional treatment only
2853915|NCT03570996|Active Comparator|Transversus abdominis plane catheter|Transversus abdominis plane catheter (TAP) for pain control in esophagectomy operations. TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine.
2853916|NCT03570996|Active Comparator|epidural|Epidural pain control for pain control in esophagectomy operation. Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
2853917|NCT03570983|Experimental|BEAM Regimen- Experimental Arm|"Allopurinol Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.~BCNU (Carmustine) Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.~Etoposide (VP-16, Vepesid) Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.~Cytarabine (Ara-C) Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3."
2853918|NCT03570983|Active Comparator|Melphalan Regimen- Control Arm|"Melphalan Dosage: Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.~Allopurinol Dosage: Allopurinol 200 mg/m2/day starts on the day prior to melphalan (day -3) and stops on day -1."
2853919|NCT03570970|Experimental|Banapenem C1 group|250mg Once daily for 7
2853920|NCT03570970|Experimental|Banapenem C2group|500mg Once daily for 7
2853921|NCT03570970|Experimental|Banapenem C3group|1000mg Once daily for 7
2853922|NCT03570957|Experimental|MT-2990, Low dose|Single intravenous dose
2853923|NCT03570957|Experimental|MT-2990, Low-middle dose|Single intravenous dose
2853924|NCT03570957|Experimental|MT-2990, High-middle dose|Single intravenous dose
2853925|NCT03570957|Experimental|MT-2990, High dose|Single intravenous dose
2853926|NCT03570957|Placebo Comparator|Placebo|Single intravenous dose
2853927|NCT03570944||Patients undergoing elective HRS or KRS|Adult patients undergoing elective HRS or KNS
2853928|NCT03570931|Experimental|RT001|RT001, oral, 3.84 g/day
2853929|NCT03570918|Experimental|MGD014|HIV-1 x CD3 bispecific DART molecule
2853930|NCT03570905|Experimental|Sugartong Splint|
2853931|NCT03570905|Experimental|Clam Shell Splint|
2853932|NCT03570892|Experimental|Tisagenlecleucel treatment strategy|Patients will receive investigator's choice of optional platinum-based immunochemotherapy followed by lymphodepleting chemotherapy and a single dose of tisagenlecleucel
2853933|NCT03570892|Active Comparator|Standard of care treatment strategy|Patients will receive investigator's choice of platinum-based immunochemotherapy followed in responding patients by high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT). Patients who do not respond to initial immunochemotherapy may switch to a different regimen or to lenalidomide or ibrutinib
2853934|NCT03570879||Power morcellation|Women that underwent laparoscopic myomectomy with subsequent power morcellation of the surgical specimens.
2863157|NCT03507296||Asymptomatic subjects|
2853935|NCT03570879||Transvaginal extraction|Women that underwent laparoscopic myomectomy with subsequent transvaginal extraction of the surgical specimens.
2853936|NCT03570866||Early stage endometrial cancer|Women with diagnosis of intermediate and high-risk early stage endometrial cancer.
2853937|NCT03570853|Experimental|Immediate Intervention|Participants will receive the 8-week SMART-3RP intervention within a few weeks of enrolling in the study.
2853938|NCT03570853|Experimental|Delayed Intervention|Participants will receive the 8-week SMART-3RP intervention following completion of the immediate intervention groups (approximately 2-4 months after enrolling in the study).
2853939|NCT03570853|No Intervention|No Intervention|Participants will not receive the SMART-3RP program and will only complete study questionnaires..
2853940|NCT03570840||obese children and adolescents|
2853941|NCT03570827|Experimental|Group I (hypofractionated radiation therapy)|Participants undergo hypofractionated radiation therapy over 15-30 minutes every other day over 2 weeks, for 5 treatments.
2853942|NCT03570827|Experimental|Group II (radiation therapy, androgen suppression therapy)|Beginning 8-10 weeks before radiation therapy, participants receive androgen suppression therapy SC or IM for up to 6 months (at the discretion of the treating physician). Participants then undergo hypofractionated radiation therapy as Group I.
2853943|NCT03570827|Experimental|Group III (radiation therapy, androgen suppression therapy)|Participants receive androgen suppression therapy as Group II for up to 18 months (at the discretion of the treating physician), then undergo hypofractionated radiation therapy over 15-30 minutes every other day over 1-2 weeks, for 1-5 treatments.
2853944|NCT03570814|Active Comparator|Separate Administration|Standard administration of Albendazole/Ivermectin separated from administration of azithromycin
2853945|NCT03570814|Experimental|Co-administration|Combined administration of Albendazole/Ivermectin/Azithromycin at a single time point
2853946|NCT03570801|Experimental|Expert Panel Review|"For patients who are randomized to receive an expert panel review, de-identified lumbar MRI (sagittal and key axial images), 36-inch standing plain radiographs (if available), and flexion and extension radiographs will be uploaded into a web-based platform and reviewed. These will be submitted for an Expert Panel Review.~Images will be reviewed through a Spine Expert's Network, consisting of physicians involved in this study who will each offer their opinion as to which of two surgical treatment groups (decompression alone or decompression with fusion) they would choose for the patient. The results of this review will be discussed between the patient and the patient's physician. Together, they will determine the best surgical approach."
2853947|NCT03570801|No Intervention|No Expert Panel Review|For patients not receiving the expert panel review, they will discuss with their surgeon the best surgical option and proceed as they would in standard of care.
2853948|NCT03570775|Experimental|"Neomedlight Sleeping bag phototherapy"|Phototherapy device with LED light + fiber optic mesh
2853949|NCT03570775|Active Comparator|Conventional phototherapy|LU-6T model: phototherapy device with six fluorescent tubes, four white and two blue, with adjustment of inclination and height incorporated.
2853950|NCT03570749|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2853951|NCT03570749|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2853952|NCT03570749|Placebo Comparator|Placebo|Placebo administered orally.
2853953|NCT03570736|Experimental|Minimal Invasive Surgical Technique|
2853954|NCT03570736|Active Comparator|Open Flap Debridement|
2853955|NCT03570723|Active Comparator|stepwise uterine devascularization|"Uterine hemostatic sutures, through examination of the placental bed, may use some hemostasis at the placental bed,overswing was commenced using endo-uterine sutures. If there is still significant bleeding, bilateral uterine artery ligation, and internal iliac artery ligation when needed.BUAL started immediately through blunt dissection downwards and laterally of the peritoneum covering the uterine isthmus and cervix. The peritoneum is mobilized freely at the uterine angles to expose both uterine arteries and avoid inclusion of the ureters in the ligation. The uterine artery pulsations were palpated digitally at the level of the internal os."
2853956|NCT03570723|Experimental|A glove-loaded Foley's catheter|A glove-loaded Foley's catheter tamponade, the internal os of the cervix was identified and a double-way 20 Fr Foley's catheter with a 30-50-ml balloon was inserted through the cervix to be handled by an assistant through the vagina and fixed to the patient's lower limb after inflation of the catheter balloon by 300 ml warm saline and pulling it against the lower uterine segment between the two transverse sutures. Only one glove-loaded Foley's catheter was used for tamponade.
2853957|NCT03570710|Placebo Comparator|normal saline arm group|110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
2853958|NCT03570710|Active Comparator|intravenous tranexamic acid group|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
2853959|NCT03570710|Active Comparator|Topical tranexamic acid group|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
2853960|NCT03570697|Experimental|Evolucumab|Participants receive Evolocumab subcutaneous injection once every month (QM=every 4 weeks + 3 days) for 48 weeks. As prescribed and provided by the investigator, participants will be treated with maximally tolerated statin therapy and not expected to change for the duration of the study participation.
2853961|NCT03570697|Placebo Comparator|Placebo|Participants receive placebo subcutaneous injection once every month (QM=every 4 weeks + 3 days) for 48 weeks. As prescribed and provided by the Investigator, participants will be treated with maximally tolerated statin therapy and not expected to change for the duration of the study participation.
2854279|NCT03568500|Experimental|Aripiprazole|A CoEncapsulated (CoE) aripiprazole, DMS patch & associated smartphone application.
2853962|NCT03570684|Experimental|tie group|During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was much easier as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum.
2853963|NCT03570684|No Intervention|non-tie group|
2853964|NCT03570671|Experimental|Spasm positive|Ergonovine-induced coronary spasm provocation test positive: defined as transient, total, or sub-total occlusion (>90% stenosis) of a coronary artery with symptoms of myocardial ischemia (angina pain and ischemic ECG change).
2853965|NCT03570671|Placebo Comparator|Spasm negative|Suspected vasospastic angina subjects with negative ergonovine provocation test are considered as reference modality.
2853966|NCT03570658|Experimental|Single-Ascending Dose (SAD)|Participants will receive a single dose of RO7049389.
2853967|NCT03570658|Experimental|Multiple-Ascending Dose (MAD)|Participants will receive multiple doses of RO7049389.
2853968|NCT03570658|Placebo Comparator|Placebo|Participants will receive either a single dose (SAD cohorts) or multiple doses (MAD cohorts) of placebo matched to RO7049389.
2853969|NCT03570645|Experimental|dexmedetomidine group|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography ;general anesthesia combined with 0.5 μg/kg dexmedetomidine infusion before induction
2853970|NCT03570645|Experimental|Paravertebral Block Group|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography ;general anesthesia combined with paravertebral block
2853971|NCT03570645|Experimental|Epidural Block Group|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography ;general anesthesia combined with epidural block
2853972|NCT03570632|No Intervention|Usual care|
2853973|NCT03570632|Experimental|Metformin|
2853974|NCT03570619|Experimental|Metastatic CRPC|Patients with metastatic castration resistant prostate cancer (mCRPC) will be enrolled in cohort A.
2853975|NCT03570619|Experimental|Solid Tumors (non-prostate)|Patients with all other metastatic subtypes will be enrolled in cohort B
2853976|NCT03570606||HA Paste in Spinal|"Evaluation of HA Paste in spinal fusion procedures~o Spinal cage filling"
2853977|NCT03570606||HA Paste in long bone & extremities|"Evaluation of HA Paste in long bone and extremity group:~Filling bone defects after cyst removal~Filling distal radius fractures~Filling defects such as tibial plateau fractures~Filling defects created by osteotomy procedures"
2853978|NCT03570606||Granulated Paste in Spine|"Evaluation of Granulated Paste in spinal fusion procedures~o Spinal cage filling"
2853979|NCT03570606||Granulated Paste in long bone & extremities|"Evaluation of Granulated Paste in long bone and extremity group:~Filling bone defects after cyst removal~Filling distal radius fractures~Filling defects such as tibial plateau fractures~Filling defects created by osteotomy procedures"
2853980|NCT03570606||Granules in Spine|"Evaluation of Granules in spinal fusion procedures~o Spinal cage filling"
2853981|NCT03570606||Granules in long bone & extremities|"Evaluation of Granules in long bone and extremity group:~Filling bone defects after cyst removal~Filling distal radius fractures~Filling defects such as tibial plateau fractures~Filling defects created by osteotomy procedures"
2853982|NCT03570606||Block in long bone & extremities|"Evaluation of Blocks in long bone and extremity group:~o High tibial osteotomies with fixation"
2853983|NCT03570593|No Intervention|Retrospective Group|
2853984|NCT03570593|Experimental|Prospective Group|
2853985|NCT03570580||Main Group - OSA Scoring|All patients include in this study for whom the four OSA scoring will be evaluated
2853986|NCT03570567|Other|Piranha Treatment|The food impaction will be treated using the Piranha endoscopic device.
2853987|NCT03570554|Experimental|Osteoarthritis A-B-D-C|Patients with knee osteoarthritis receive treatments in order A, B, C and D. Treatment periods will be separated by a washout of 3 to 7 days.
2853988|NCT03570554|Active Comparator|Osteoarthritis B-C-A-D|Patients with knee osteoarthritis receive treatments in order B, C, A and D. Treatment periods will be separated by a washout of 3 to 7 days.
2853989|NCT03570554|Active Comparator|Osteoarthritis C-D-B-A|Patients with knee osteoarthritis receive treatments in order C, D, B and A. Treatment periods will be separated by a washout of 3 to 7 days.
2853990|NCT03570554|Placebo Comparator|Osteoarthritis D-A-C-B|Patients with knee osteoarthritis receive treatments in order D, A, C and B.Treatment periods will be separated by a washout of 3 to 7 days.
2853991|NCT03570541|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0,375% single shot.~Every six hours postoperative, all patients are administered 1 g of acetaminophen.~In both arms morphine will be administered IV as part of a patient controlled analgesia (PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment.~On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis.~On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a Quality of recovery-15 questionaire.~Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension."
2853992|NCT03570541|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL saline single shot.~Every six hours postoperative, all patients are administered 1 g of acetaminophen.~In both arms morphine will be administered IV as part of a patient controlled analgesia (PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment.~On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis.~On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a Quality of recovery-15 questionaire.~Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension."
2853993|NCT03570528||Maxillary Retrusion|CT
2853994|NCT03570528||Healthy Patients|
2853995|NCT03570515|Experimental|Yoga|Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days.
2853996|NCT03570515|Active Comparator|Educational Film|Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
2860128|NCT03527797|No Intervention|Control|Standard of care
2853997|NCT03570489|Active Comparator|Exercise|Use of an ergometric bicycle where patients will bicycle 5 Days a week for 20 minutes at a predetermine level
2853998|NCT03570489|Sham Comparator|Relaxation|Patients will listen to a relaxation exercise involving muscle relaxation. This takes about 20 minutes and will be performed 5 Days/week
2853999|NCT03570476|Experimental|Treatment (olaparib, radical prostatectomy)|Participants receive olaparib PO BID for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.
2854000|NCT03570463||GLA:D Back|Two 1-hour group sessions of patient education 8 weeks of twice-weekly 1-hour supervised group exercise sessions
2854001|NCT03570450|Experimental|Adipose derived Stem Cells - 1.10^6cells/kg|ADSC, single, IV, 1.10^6cells/kg
2854002|NCT03570450|Experimental|Adipose derived Stem Cells - 2.10^6cells/kg|ADSC, single, IV, 2.10^6cells/kg
2854003|NCT03570450|Experimental|Adipose derived Stem Cells - 2,5.10^6cells/kg|ADSC, single, IV, 2,5.10^6cells/kg
2854004|NCT03570450|Experimental|Adipose derived Stem Cells - 3.10^6cells/kg|ADSC, single, IV, 3.10^6cells/kg
2854005|NCT03570450|Placebo Comparator|placebo|Placebo
2854006|NCT03570437|Active Comparator|Arm 1: Paclitaxel|Paclitaxel 80 mg/m2 administered on days 1, 8 and 15 of a 28-day cycle for up to 6 cycles.
2854007|NCT03570437|Experimental|Arm 2: Cediranib and paclitaxel|Cediranib 20 mg once daily for 28 days given with weekly paclitaxel 80 mg/m2 administered on days 1, 8 and 15 of a 28-day cycle for up to 6 cycles. Participants with stable disease or better will be able to continue cediranib once daily until disease progression.
2854008|NCT03570437|Experimental|Arm 3: Cediranib and olaparib|Cediranib 20 mg once daily with olaparib 300 mg twice daily, continuously on a 28 day cycle for up to 6 cycles. Participants with stable disease or better will be ableto continue with olaparib and cediranib until disease progression.
2854009|NCT03570424|Placebo Comparator|Placebo|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass of artificially flavoured and textured placebo 45 minutes prior to HIIT exercise
2854010|NCT03570424|Experimental|Whey Protein|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass intact whey protein 45 minutes prior to HIIT exercise
2854011|NCT03570424|Experimental|Whey Protein Hydrolysate|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass hydrolysed whey protein 45 minutes prior to HIIT exercise
2854012|NCT03570411||HCT Recipient|"All participants who meet eligibility criteria and consent to enrollment on study.~Blood specimens will be collected for the T-SPOT.CMV blood test from HCT recipients over the course of 6 months, starting weekly at Day +1, biweekly starting at Day +45, and monthly starting at day +120.~The amount of blood collected at each visit will be based on age."
2854013|NCT03570411||HCT Donor|"Approved allogeneic HCT donor for a HCT recipient enrolled on the SPOTCMV protocol~A blood sample for the T-SPOT.CMV blood test will be collected from the HCT donor prior to transplant"
2854014|NCT03570398|Other|Abdominal CT|
2854015|NCT03570398|Other|Abdominal Ultrasound|
2854016|NCT03570385|Experimental|Patient with Optic Neuritis|
2854017|NCT03570372|Experimental|Intervention group|36 week internet-based CBT with therapist support. Regular online group discussions.
2854018|NCT03570372|Active Comparator|Control group|Reads 2 books about Autism Spectrum Disorder (ASD)
2854019|NCT03570359|Active Comparator|Interferon beta 1a|"Part 1- Interferon beta 1a once a day for 3 days via inhalation~Part 2 - Interferon beta 1a once a day for 14 days via inhalation"
2854020|NCT03570359|Placebo Comparator|Placebo|"Part 1- placebo once a day for 3 days via inhalation~Part 2 - placebo once a day for 14 days via inhalation"
2854021|NCT03570346|Experimental|Hemay005|6 subjects in each cohort(15mg, 30mg, 60mg) will receive Hemay005
2854022|NCT03570346|Placebo Comparator|Placebo|2 subjects in each cohort(15mg, 30mg, 60mg) will receive placebo
2854023|NCT03570333|Experimental|Progenitor Potential at Molar site|Harvested tissue from the back (molar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.
2854024|NCT03570333|Experimental|Progenitor Potential at Premolar site|Harvested tissue from the front (premolar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.
2854025|NCT03570320|No Intervention|Control group|The first treatment group will be our control arm. On discharge following their surgery, these patients will receive a single prescription for 225 Morphine Milligram Equivalents (MMEs). This corresponds to #30 pills of 5mg oxycodone/acetaminophen, #45 pills of 5mg hydrocodone/acetaminophen, or #30 pills of 7.5mg Morphine.
2854026|NCT03570320|Experimental|Interventional Arm|Patients who are randomized into the second group will also receive prescriptions for 225 MME's on discharge following their surgery, however their medications will be broken up equally into 3 separate scripts, each for 75 MME's. This corresponds to 3 scripts for #10 pills of 5mg oxycodone/acetaminophen, 3 scripts for #15 pills of 5mg hydrocodone/acetaminophen, or 3 scripts for #10 pills of 7.5mg Morphine. Each script will be post-dated to ensure that patients wait the appropriate amount of time between filling their scripts, and that they cannot fill multiple scripts on the same day or at the same time.
2854027|NCT03570307|Other|drug treatment|Misoprostol for uterine evacuation
2854028|NCT03570307|Other|surgical treatment|dilatation and curettage for uterine evacuation
2854029|NCT03570294|Other|Atosiban|Total oxidant status (TOS), total antioxidant status (TAS) and oxidative stress index (OSI) values as well as 3-nitrotyrosine, carbonyl and thiol groups levels weill be measure using ELISA test in serum and plasma of 64 pregnant women before and after 48 hours of continuous administration of Atosiban.
2854030|NCT03570281|Experimental|Edoxaban group|Edoxaban, per oral, 60mg qd (may consider reduced dose to 30mg qd in patients with proper clinical reason by attending physician, estimated creatinine clearance of 30 to 50 ml per minute, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine), for 90 days.
2854031|NCT03570281|Active Comparator|Enoxaparin group|Enoxaparin, subcutaneous injection, 1mg/kg BID (may consider reduced dose to 1mg/kg qd in patients with proper clinical reason by attending physician, Creatinine clearance <30 mL/min), for 90 days.
2854064|NCT03569982|Experimental|Intervention|Patients receiving integrative care (including acupuncture) in addition to best supportive care
2860129|NCT03527797|Experimental|Intervention|Titration of support level
2854032|NCT03570268|Experimental|Experimental group: Education group|Participants in the experimental intervention group (education group) received an educational program and tailored home exercises. This intervention consist of multiple, interacting components supported by a handbook and audio-video material designed to teach people the skills, techniques, and strategies for preventing falls, and increase social participation and engagement in inactivity of daily living. . After the educational session, two one hour sessions were spent to teach safe balance exercises that were developed in preceding studies, the patient was invited to perform at home for 2 months.
2854033|NCT03570268|Active Comparator|Control Group: Usual care|Participants allocated to the control group received ongoing usual treatments. In addition, two one hour lessons were spent to teach stretching exercises that the patient was invited to perform at home for 2 months.
2854034|NCT03570242|No Intervention|Control group (palliative treatment)|"usual care control group (includes patients undergoing palliative Treatment) receives individualized nutritional support (dietary advices: daily protein intake1,2 - 1,5 g/kg bodyweight)"
2854035|NCT03570242|Experimental|WB-EMS group (palliative treatment)|"physical exercise group (includes patients undergoing palliative Treatment) receives regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1,2-1,5 g/kg bodyweight)"
2854036|NCT03570242|No Intervention|Control group (curative treatment)|"usual care control group (includes patients undergoing curative treatment 3-4 weeks before surgery) receives individualized nutritional support (dietary advices: daily protein intake1,2 - 1,5 g/kg bodyweight)"
2854037|NCT03570242|Experimental|WB-EMS group (curative treatment)|"physical exercise group (includes patients undergoing adjuvant treatment 3-4 weeks before surgery) receives regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1,2-1,5 g/kg bodyweight)"
2854038|NCT03570216|Experimental|Exercise|All participants will perform 2 exercise sessions: one session on moderate-intensity continuous exercise and one session of high-intensity interval exercise
2854039|NCT03570203||Retrospective Cohort|Supratentorial/Suprasellar brain tumor patients with Glasgow Coma Score > 3 at time of admission.
2854040|NCT03570203||Prospective Cohort|Supratentorial/Suprasellar brain tumor patients with Glasgow Coma Score > 3 at time of recruitment.
2854041|NCT03570190||TAVI patients|elective patients with a diagnosis of sAS and admitted for TAVI attending one of the participating centers for commercially available balloon expandable valve implantation that will be managed by a coordinator
2854042|NCT03570177||all subject|the all population (described in eligibility criteria)
2854043|NCT03570164|Experimental|Sevoflurane|Anesthesia is maintained with sevoflurane.
2854044|NCT03570164|Experimental|Desflurane|Anesthesia is maintained with desflurane.
2854045|NCT03570138|Experimental|Flash continuous glucose monitoring system|Participants will wear the FREESTYLE LIBRE device and receive a specific therapeutic education for its use.
2854046|NCT03570138|Active Comparator|Standard self monitoring blood glucose system|Participants will use their own usual self monitoring blood glucose system and receive a C They will wear a masked FREESTYLE LIBRE Pro system.
2854047|NCT03570125|Experimental|Dietary intervention arm|"group will follow an ad libitum diet but, every two months, will follow a 5 day of fasting mimicking diet (PROLON). The diet consists of natural ingredients, which are Generally Regarded As Safe (GRAS).~Prolon will be provided for free by L-nutra or in case of unforeseeable budget constraint at one fifth of its commercial value."
2854048|NCT03570125|No Intervention|no intervention|Control/Placebo with multivitamin supplementation
2854049|NCT03570112||Pregnant Women with Hep C|SOF/VEL Therapy-sofosbuvir 400mg, velpatasvir 100mg, once daily for 12 weeks at 24 weeks post partum
2854050|NCT03570099||Prospective Naloxone cohort|The prospective cohort consists of study subjects receiving Naloxone nasal spray in the distribution program.
2854051|NCT03570099||Historical control cohort|Data from the historical control cohort will be collected from national registries years 2013-2017.
2854052|NCT03570086||migraineurs without aura|
2854053|NCT03570086||health controls|
2854054|NCT03570073|Active Comparator|Manual vitrification|
2854055|NCT03570073|Experimental|Automatic vitrification|
2854056|NCT03570034||Obalon Balloon System|Obalon Balloon System with moderate intensity Weight Loss Behavioral Modification Program
2854057|NCT03570021|Active Comparator|Group 1|total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association [American Thyroid Association Surgery Working Group, Thyroid 2009]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery [French Society of Otolaryngology Head and Neck Sugery].
2854058|NCT03570021|Experimental|Group 2|total thyroidectomy alone without neck dissection. This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
2854059|NCT03570008|Experimental|Sp-Ex|a 9 days spa residential program including physical activity. 3 sessions of 10 minutes per day of physical exercise for bone health improvements supervised by a professional of adapted physical activity. Participants will benefit advices from national plan for physical activity and nutrition (NPPN)
2854060|NCT03570008|Active Comparator|Sp-alone|Participants will benefit a short term spa residential program of 9 days. In addition they will benefit advices from national plan for physical activity and nutrition (NPPN)
2854061|NCT03570008|Active Comparator|Ex-alone|Participants will benefit 3 sessions of 10 minutes per day of physical exercise for bone health improvements supervised by a professional of adapted physical activity. Participants will benefit advices from national plan for physical activity and nutrition (NPPN)
2854062|NCT03569995|Experimental|Induction+Consolidation chemotherapy|"[Induction phase]~① After induction therapy (Rituximab-Methotrexate) 2 times, first evaluation~Complete, partial response or stable disease-> next step~Progressive disease-> eliminated~② After Induction therapy (Rituximab-Methotrexate) was added 3 times (total 5 times), 2nd evaluation~Complete response -> consolidation therapy(Rituximab-Cytarabine) progress~Partial response or stable disease-> Rituximab-Methotrexate 2 additional administrations~Progressive disease-> eliminated~③ After Induction therapy (Rituximab-Methotrexate) was added twice (7 times in total), 3rd evaluation~Complete, partial response or stable disease-> consolidation therapy(Rituximab-Cytarabine)~Progressive disease-> eliminated"
2854063|NCT03569982|No Intervention|Control|Patients receiving best supportive care
2854065|NCT03569969|Experimental|control group|Step1. Under local anesthesia and sedation , the temporal muscle fascia was removed, Step2. After the preparation on the tympanic membrane embedded , foam gel smeary with Dexamethasone was worn.Step3. Then the wound dressing was done with a gas number and a Surgifix. Step4. Patients were discharge from the operating room with an oral administration of Cephalexin capsules.
2854066|NCT03569969|Experimental|Test group|Step1. After sedation and conducting local anesthesia with Lidocaine 2% and inserting the edges of the tympanic membrane and inserting the foam gel into the middle ear, amniotic membranes (produced in Iran tissue product) with a thickness of 100 microns on the tympanic membrane and the foam gel embedded. Step2. Under-layered and short-lived foam gel (manufactured by Ethicon Company) smeary with dexamethasone was covered.
2854067|NCT03569956|Active Comparator|Razor Group|Subject will use the 556 razor with regular shaving products, and shave at least 5 or more times per week
2854068|NCT03569956|Experimental|Regimen|Subject will use the 556 razor with the Pre-shave Gel, Cleaning Brush, and Shaving Gel and shave at least 5 or more times per week.
2854069|NCT03569943|Experimental|Robotol|
2854070|NCT03569930|Experimental|Standard|standard of care (diet rich in water and vegetable fibers, hygienic)
2854071|NCT03569930|Experimental|ProtFlav|oral supplements (flavonoid-based supplements - ProtFlav) will be added to standard of care
2854072|NCT03569930|Experimental|ProtCent|anal application of a Centella based cream (Centella asiatica - ProtCent) will be added to standard of care
2854073|NCT03569917|Experimental|patient under Ceftriaxone treatment|
2854074|NCT03569891|Experimental|AMT-061|"Single infusion of AMT-061~Subjects will receive a single infusion of AAV5-hFIXco-Padua (AMT- 061) at baseline. After study drug administration (post study drug), subjects will be monitored for tolerance to the study drug and detection of potential immediate AEs at the clinical trial site for a few hours after dosing."
2854075|NCT03569878|Experimental|Peer-Integrated Multidisciplinary Collaborative Care|The peer-integrated collaborative care intervention includes front-line trauma center staff (e.g., nursing and masters in social work), joined by injured peer interventionists and supervised by an MD (psychiatrist). The collaborative care team will provide case management, behavioral intervention elements, psychopharmacologic medication recommendations as well as 24/7 cell phone coverage for approximately 6 months post-injury. The intervention will be supported by a novel emergency department health information technology platform.
2854076|NCT03569878|Active Comparator|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with recommendation for mental health inpatient consultation will be the comparator condition.
2854077|NCT03569865|Experimental|Active AVS-1|Active AVS-1 consists of a 30-minute pulsing lights (red, green, blue) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
2854078|NCT03569865|Experimental|Active AVS-2|Active AVS-2 consists of a 30-minute pulsing lights (red, green) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
2854079|NCT03569865|Placebo Comparator|Placebo AVS|The placebo control AVS program consists of 30 minutes of constant dim light that slowly changes in color, and a steady monotone at ultra-low (<1 Hz) frequency (outside of the entrainment range).
2854080|NCT03569852|Experimental|Experimental Group 1|Order of treatment, time restrictive feeding (16 hours fasting and 8 hours eating) followed by traditional eating pattern (12 hours fasted and 12 hours eating).
2854081|NCT03569852|Experimental|Experimental Group 2|Order of treatment, traditional eating pattern (12 hours fasted and 12 hours eating) followed by time restrictive feeding (16 hours fasting and 8 hours eating).
2854082|NCT03569839||Patients undergoing surgery|Patients subject to TIVA
2854083|NCT03569826||Observational|There is no intervention being administered. This registry only observes patients through their regular standard of care visits.
2854084|NCT03569813|Experimental|PrEP@Home System|The experimental group will be assigned to the remote care system for one year of follow-up PrEP care to include home test kits and behavioral surveillance, and telemedicine visits as needed.
2854085|NCT03569813|Active Comparator|Standard of Care|The comparator group will receive active linkage to a local PrEP provider for clinic-based PrEP follow-up. Participants in this study arm will be seen quarterly by a health care provider, per standard of care when taking PrEP.
2854086|NCT03569787||Patients with hyperprolactinaemia|Patients undergoing subfertility studies with at least one high prolactin reading (>500mU/L).
2854087|NCT03569774|Experimental|Individualized PEEP|Individualized PEEP will be identified by performing a decremental PEEP protocol which will determine the level of PEEP that correlates with maximal lung compliance in each subject. Subjects will receive one-lung ventilation with individualized PEEP
2854088|NCT03569774|Active Comparator|Low PEEP|Subjects will receive One-lung ventilation with low PEEP (5 cmH2O)
2854089|NCT03569761|Experimental|Decision Aid Video Intervention|Participants randomized to the intervention group will view the AI culturally-adapted CRC screening decision aid in a private room at a RHCC clinic. The video will be viewed on an electronic tablet or laptop computer.
2854090|NCT03569761|Active Comparator|Control|Participants randomized to the control group will view an attention-control video about food safety in a private room at a RHCC clinic. The video will be viewed on an electronic tablet or laptop computer. The investigators chose the attention-control video so that the structure of the control arm mirrors the intervention arm. The food safety topic was chosen to provide information that is reasonably salient to the control arm participants but that would not be likely to affect encounters with healthcare providers.
2854091|NCT03569748|Experimental|IQOS|HEAT NOT BURN REDUCED RISK PRODUCT
2854092|NCT03569748|Active Comparator|E-CIG|ELECTRONIC CIGARETTE REDUCED RISK PRODUCT
2854093|NCT03569722||Older adults|Older adults, ages 65+
2854094|NCT03569709|Active Comparator|Aerobic Exercise|Sub-threshold aerobic exercise.
2854095|NCT03569709|Placebo Comparator|Stretching|Stretching program that will not raise heart rate.
2854096|NCT03569709|Placebo Comparator|Rest|Relative rest. Avoid all structured exercise.
2854097|NCT03569696|Experimental|Nivolumab|Nivolumab will be administered intravenously every 2 weeks in a dose of 240mg over 30 minutes for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
2854135|NCT03569449|Experimental|Standard FN, Enhanced Technology, and Community Visits|Participants randomized into this arm will receive the usual Standard Family Navigation (FN), Enhanced Technology, and Community Visits
2854098|NCT03569683|Experimental|Interventional Single arm|"Group A- Diode laser biostimulation on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery.~Group B- Hyaluronic acid (Gengigel) topical application on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery.~Group C- Herbal gel (Hiora SG) topical application on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery."
2854099|NCT03569670|Experimental|Posterior Stabilized|A posterior stabilized, all-polyethylene tibial component will be used during surgery.
2854100|NCT03569670|Active Comparator|Cruciate Retaining|A cruciate retaining, all-polyethylene tibial component will be used during surgery.
2854101|NCT03569657|Other|A positive psychology workshop|The group intervention implements a manualized treatment protocol outlining the content of each of the four 90 minute sessions. The sessions will include topics such as mindfulness, self-compassion, gratitude and forgiveness, grief and growth, utilizing one's strengths, and resilience; with each session including homework exercises to be practiced between sessions. To assess the outcome measures, participants complete a baseline survey, a survey after the second session (2 weeks), a survey after the final session (4 weeks), and a follow-up survey 3 months after the workshop has ended (4 months).
2854102|NCT03569644|Other|qualitative study|heterogeneous group of patients
2854103|NCT03569631|Experimental|BPN14770|25mg BPN14770 capsules, one capsule taken twice daily for 12 weeks
2854104|NCT03569631|Placebo Comparator|Placebo|Matching placebo capsules, one capsule taken twice daily for 12 weeks
2854105|NCT03569618|Active Comparator|Game 1|Tablet-based Game 1.
2854106|NCT03569618|Placebo Comparator|Game 2|Tablet-based Game 2.
2854107|NCT03569605|Active Comparator|Self-help|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group.
2854108|NCT03569605|Experimental|Intervention|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group, behavioral lessons, adaptive physical activity goals, tailored feedback summaries, and text messages.
2854109|NCT03569592|Experimental|Overdose Prevention Intervention|The experimental group will receive a brief overdose prevention education intervention and be issues naloxone upon discharge from jail.
2854110|NCT03569579|Experimental|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Memantine Tab. 10mg)*2T, QD, PO.~Period 2: Treatment B(Memantine Tab. 10mg)*2T + Donepezil Tab. 10mg)*1T, QD, PO.~Each treatment period was separated by a washout period of at least 21 dyas."
2854111|NCT03569579|Experimental|Group 1(Treatment B/Treatment A)|"Period 1: Treatment B(Memantine Tab. 10mg)*2T + Donepezil Tab. 10mg)*1T, QD, PO.~Period 2: Treatment A(Memantine Tab. 10mg)*1T, QD, PO.~Each treatment period was separated by a washout period of at least 21 dyas."
2854112|NCT03569566||Elite endurance athletes|Cross-country skiers at high national level
2854113|NCT03569553||AIGIV|Inhalational anthrax patients who have been administered AIGIV (ANTHRASIL®) as per licensed US prescribing information.
2854114|NCT03569540|Experimental|Treated Patients|Patients who will receive Glibenclamide 05mg daily for 21 days, orally or by nasogastric tube.
2854115|NCT03569540|Placebo Comparator|Control Group|Patients who will receive amylum 05mg daily for 21 days, orally or by nasogastric tube.
2854116|NCT03569527|Active Comparator|Kiwifruit|Treating chronic constipation with 2 kiwifruit (6g fiber) per day
2854117|NCT03569527|Active Comparator|Psyllium fiber|Treating chronic constipation with 24g psyllium fiber (6g fiber) per day
2854118|NCT03569527|Active Comparator|Prune|Treating chronic constipation with 100g dried plums (6g fiber) per day
2854119|NCT03569514||AIGIV|Anthrax patients who have been administered AIGIV (ANTHRASIL®) as per licensed US prescribing information.
2854120|NCT03569501|No Intervention|nutritional guidance|routine care (all arms with nutritional guidance per routine care)
2854121|NCT03569501|Active Comparator|oat grains|90 mg oat, per day.
2854122|NCT03569501|Experimental|oat grains and DHA tablets|90 mg oat and 500 mg DHA oral tablets, per day.
2854123|NCT03569501|Active Comparator|DHA tablets|500 mg DHA oral tablets, per day.
2854124|NCT03569475|Experimental|Levomilnacipran ER|patients will take levomilnacipran 10 mg/day on Days 1-3, 20 mg/day on Days 4-7, and 40 mg/day during weeks 2 through 8 of the double blinded treatment and 40 mg/day for 2 days, and then levomilnacipran 20 mg/day for 5 days in the down-taper period. Based on therapeutic response and tolerability, an additional dose increase to 80 mg/day is permitted at Week 3 through 8 of the double blinded treatment. in the down-taper period. the patient will take levomilnacipran 40 mg/day for 2 days, and then levomilnacipran 20 mg/day for 5 days
2854125|NCT03569475|Active Comparator|Fluoxetine 20 mg|Patients randomized to the Fluoxetine 20 mg arm will take Week 1, 10mg/day; week 2 through week 8, 20 mg/day
2854126|NCT03569475|Placebo Comparator|Placebo|Patients randomized to the placebo arm will take placebo capsules once daily through week 8
2854127|NCT03569462|Experimental|"Mobile WeChat intervention"|Participants will watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile health application that delivers content to promote HIV-self testing and reduce HIV-related risk behavior.
2854128|NCT03569462|Active Comparator|Control condition|Participants will watch a demonstration of HIV self-testing and receive HIV self-testing kits.
2854129|NCT03569449|Active Comparator|Standard FN (Family Navigation)|Participants randomized into this arm will receive the usual Standard Family Navigation (FN)
2854130|NCT03569449|Experimental|Standard FN & Enhanced Monitoring|Participants randomized into this arm will receive the usual Standard Family Navigation (FN) and Enhanced Monitoring
2854131|NCT03569449|Experimental|Standard FN & Community Visits|Participants randomized into this arm will receive the usual Standard Family Navigation (FN) and Community Visits
2854132|NCT03569449|Experimental|Standard FN & Enhanced Technology|Participants randomized into this arm will receive the usual Standard Family Navigation (FN) and Enhanced Technology
2854133|NCT03569449|Experimental|Standard FN, Enhanced Monitoring, & Community Visits|Participants randomized into this arm will receive the usual Standard Family Navigation (FN), Enhanced Monitoring, and Community Visits
2854134|NCT03569449|Experimental|Standard FN, Enhanced Monitoring, & Enhanced Technology|Participants randomized into this arm will receive the usual Standard Family Navigation (FN), Enhanced Monitoring and Enhanced Technology
2860130|NCT03527784|Active Comparator|Parietene Macro|Parietene Macro is a macroporous synthetic mesh.
2854136|NCT03569449|Experimental|Enhanced Monitoring, Enhanced Technology, & Community Visits|Participants randomized into this arm will receive Enhanced Monitoring, Enhanced Technology, and Community Visits
2854137|NCT03569436||Metastatic head and neck participants in Japan|Study in Japan targeting recurrent/metastatic HNC patients who are treated with nivolumab
2854138|NCT03569423|Experimental|Transepithelial PRK|Transepithelial photorefractive keratectomy was done in 100 right eyes of 100 patients included in the study.
2854139|NCT03569423|Active Comparator|Alcohol assisted PRK|Alcohol assisted photorefractive keratectomy was done in 100 left eyes of the same 100 patients included in the study.
2854140|NCT03569410|Active Comparator|Supplement Group|The protein supplement group was instructed by their dietician in how many protein supplements to consume in addition to their natural food intake in order to reach their goal protein intake.
2854141|NCT03569410|Experimental|Natural Food Group|The Natural food group was instructed by their dietician in how much additional protein rich foods to eat in order to reach their goal protein intake.
2854142|NCT03569397|Experimental|Music Therapy|Administer music therapy during the operation
2854143|NCT03569397|No Intervention|Non-Music Therapy|No headphones or music therapy during the operation
2854144|NCT03569384|Experimental|"Intervention group tele-rehabilitation"|"Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist. Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system. Workout Sessions with a Virtual Physiotherapist Agent (VPA):~The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time."
2854145|NCT03569384|Active Comparator|Control|COPD patients in the control group will undergo the conventional standardized rehabilitation program as implemented at the Department of Respiratory Medicine and Allergy, Aarhus University Hospital. The program is an 8 weeks program consisting of 2 weekly group training sessions at the hospital with instruction by a physiotherapists and 6 hours of education about COPD and its treatment.
2854146|NCT03569371|Experimental|INCB054707|
2854147|NCT03569358|Experimental|Virtual Reality and EEG Interventions|In the interventional arm, 20 subjects will receive twice daily sessions of immersive virtual reality for a maximum of 15 minutes, with EEG headband recording starting 5 minutes prior to and 5 minutes after the intervention, for a maximum of 4 consecutive days.
2854148|NCT03569358|Active Comparator|EEG Intervention group|In the control arm, 10 subjects would have EEG recorded for 25 mins twice daily, with a minimum of 4 hours intervening, for 3 consecutive days, with the EEG headband. There would be no immersive virtual reality sessions.
2854149|NCT03569358|Active Comparator|Healthy Volunteers|At the completion of the above intensive care study recruitment, demographic data of the interventional immersive virtual reality arm would analysed to recuit 10 age-matched healthy volunteers with no known cognitive disorders or visual impairment. This is to compare study data with healthy controls. A 25 minute session consisting of 15 minutes of immersive virtual reality and 5 minutes of EEG recording with the EEG headband before and after the intervention would be performed. Eye-tracking and EEG data from these groups of patients would be compared against subjects in both arms of the study performed in the intensive care unit to investigate for exploratory differences.
2854150|NCT03569345|Experimental|Arm|Basal cell carcinoma (BCC) patients Patients (>18 pr) with histologically-verified superficial or nodular basal cell carcinoma (<20 mm on face/scalp, <50 mm on trunk/extremities)
2854151|NCT03569332|Experimental|Test Group|Participants will receive the mobile self-input tool providing alarm on tablet, and their practicing rate will be sent to Nurse's Dashboard.
2854152|NCT03569332|No Intervention|Control Group|Participants will receive the mobile self-input tool on tablet (to compare the rate with Test group). But it won't contain alarm function and their practicing rate won't be sent to Nurse's Dashboard, either.
2854153|NCT03569319|Experimental|"Group 1: THINK-MED resource (baseline)"|"The THINK-MED resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline (n=10)"
2854154|NCT03569319|Experimental|"Group 2: THINK-MED resource (staged)"|"This group of participants will receive the THINK-MED resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian (n=10)"
2854155|NCT03569319|Placebo Comparator|Group 3: Control|"Participants will receive the THINK-MED resource after their final 6 month study visit (i.e. delayed intervention) (n=10)"
2854156|NCT03569306|Experimental|ENB-EBUS-GS group|ENB is used in this group.EBUS and GS are inserted into bronchi in the assistance of ENB. The EBUS probe and GS are confirmed to reach the lesion by EBUS images.
2854157|NCT03569306|Active Comparator|EBUS-GS group|ENB isn't used in this group.EBUS and GS are inserted into bronchi according to the chest CT that judged by the doctor. The EBUS probe and GS are confirmed to reach the lesion by EBUS images.
2854158|NCT03569293|Experimental|Arm A|Upadacitinib Dose A is administered once daily.
2854159|NCT03569293|Experimental|Arm B|Upadacitinib Dose B is administered once daily.
2854160|NCT03569293|Experimental|Arm C|Placebo administered once daily followed by Upadacitinib Dose A once daily.
2854161|NCT03569293|Experimental|Arm D|Placebo administered once daily followed by Upadacitinib Dose B once daily.
2854162|NCT03569280|Experimental|KPG-121 dose escalation + Enzalutamide|Antitumor Activity of KPG-121 capsules 1.5, 2.5, 5.0, 10, 20, and 30 mg/day daily for 21 days
2854163|NCT03569267|Experimental|OLX10010|OLX10010, an siRNA therapeutic, with four different doses by Groups (dose ascending manner with 1, 4, 10, 20 mg)
2854164|NCT03569267|Placebo Comparator|Placebo|placebo
2854165|NCT03569254|Experimental|Neomedlight Phototherapy Blanket|Phototherapy with a fiber-optic device based on LED light administered intermittently for a total of 6 hours with periods of 2 hours in kangaroo position and pauses of 1 hour at the end of each period.
2854166|NCT03569254|Active Comparator|Ohmeda-Fiber Optic Phototherapy Blanket|Phototherapy with a fiber-optic device: the Ohmeda fiber optic Phototherapy blanket
2854167|NCT03569241|Other|MDT + ADT|Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + 6 months androgen deprivation therapy
2854168|NCT03569241|Experimental|MDT + WPRT + ADT|Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + whole pelvic radiotherapy + 6 months androgen deprivation therapy
2854169|NCT03569228|Experimental|Study 1 (In-the-Ear) Group|Experienced users of in-the-ear (ITE) hearing aids will receive replacement ITE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
2854170|NCT03569228|Experimental|Study 1 (Behind-the-Ear) Group|Experienced users of behind-the-ear (BTE) hearing aids will receive replacement BTE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
2854171|NCT03569228|No Intervention|Study 2 (Open-Fit corrections)|Participants with hearing loss will be fitted monaurally with 12 stock non-custom, receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids using the standard in-situ approach and test box measures will be made of each fitting to develop correction factors for these styles.
2854172|NCT03569228|Active Comparator|Study 3 (open-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling using the standard of care approach, then undergoing a 4-week field trial.
2854173|NCT03569228|Active Comparator|Study 3 (closed-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling using the standard of care approach, then undergoing a 4-week field trial.
2854174|NCT03569228|Experimental|Study 3 (experimental open-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
2854175|NCT03569228|Experimental|Study 3 (experimental closed-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
2854176|NCT03569215||IVF/ICSI failure|These patients had prolonged infertility with one or more failure of IVF/ICSI cycles
2854177|NCT03569215||Prolonged infertility only|These patients had prolonged infertility without any trials of IVF/ICSI cycles
2854178|NCT03569202|Experimental|Emulsion Eye Drops|Daily treatment with Piiloset Trehalose Emulsion Eye Drops
2854179|NCT03569202|Active Comparator|Control Eye Drops|Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
2854180|NCT03569189|Experimental|High Fat Diet|Participants will consume a high-fat, high-calorie diet for 7 days (i.e. westernised diet) following a 3-day weight maintenance diet. Measurements will be made pre- and post-high fat diet intervention.
2854181|NCT03569176|Experimental|Autism Glass Intervention|Participants in the experimental group will receive the autism glass for 6 weeks once they are assigned to the experimental condition. Participants will be asked to use the glasses at least 3 times a week for 20 minutes sessions in addition to continuing Applied Behavior Analysis (ABA) therapy.
2854182|NCT03569176|Other|Crossover Control for Autism Glass|Participants randomized to the control arm, will continue treatment as usual (receiving ABA twice a week) while the intervention participants will receive the Autism Glass intervention (while continuing to receive ABA therapy). After 6 weeks, control participants will receive the Autism Glass intervention after which, they will be asked to come in for a second round of follow-up testing following 6 weeks of use (at week 18).
2854183|NCT03569150|Other|Intervention (Rosebud)|The intervention is: Native Americans patients with a serious life-limiting illness will have an advance care planning discussion with an interdisciplinary healthcare professional trained in the culturally-adapted COMFORT Communication Curriculum.
2854184|NCT03569150|No Intervention|Control (Pine Ridge)|In the control group, Native American patients with a serious life-limiting illness will receive usual care. The healthcare professionals have not undergone training in the culturally-adapted COMFORT Communication Curriculum.
2854185|NCT03569124||Training group|
2854186|NCT03569124||Non-Training group|
2854187|NCT03569098|Experimental|Dysport Dose 1|Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
2854188|NCT03569098|Experimental|Dysport Dose 2|Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
2854189|NCT03569098|Placebo Comparator|Placebo|Intramuscular injection of Placebo on day 1 of cycle 1 (double-blind period)
2854190|NCT03569085|Experimental|Sevoflurane then isoflurane|
2854191|NCT03569059|Experimental|Early Robotic/VR Therapy (EVR)|Subjects in this group will receive state-of-art inpatient usual care therapy plus 10 days of extra 1-hour/day of intensive therapy focusing on the hand using haptic robots integrated with complex gaming and virtual environments and initiated 5-30 days post stroke.
2854192|NCT03569059|Experimental|Delayed Robotic/VR Therapy (DVR)|Subjects in this group will receive state-of-art usual care therapy (inpatient and outpatient) plus 10 days of extra 1-hour/day of intensive therapy focusing on the hand using haptic robots integrated with complex gaming and virtual environments and initiated within 31-60 days post stroke.
2854193|NCT03569059|No Intervention|Usual Physical Therapy Care|Subjects in this group will receive state-of-art usual physical therapy/occupational therapy care.
2854194|NCT03569059|Experimental|Dose-Matched Usual Physical Therapy Care|Subjects in this group will receive state-of-art usual physical therapy/occupational therapy care plus an extra hour of state-of-art usual care.
2854195|NCT03569046|Active Comparator|group l|ear block by local anaesthetic injection 0.25% bupivacaine. general anesthetic by: midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 µg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air. hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
2854231|NCT03568812|Placebo Comparator|Placebo|Placebo: Chewing tablet with identical flavour, colour, smell, and size as investigational drug Dosage: 1 chewing tablet Frequency: once daily every night Duration: 12 weeks
2860232|NCT03527108|Experimental|Immuno-Oncology experienced patients|
2854196|NCT03569046|Placebo Comparator|Group II|ear block by Normal Saline Flush, 0.9% Injectable Solution . general anesthetic by: midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 µg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air. hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
2854197|NCT03569033|Experimental|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg film-coated tablet twice daily (BID) for 7 days.
2854198|NCT03569033|Experimental|Placebo BID|Participants will receive a matching placebo tablet BID for 7 days.
2854199|NCT03569020|Experimental|Dietitian-Directed Diet|Participants will be provided $105/week ($15/day) to purchase foods in servings that correspond to the DASH diet and thus include fruits, vegetables, lean meat, low fat dairy, and high fiber foods. Participants will also be asked to restrict red meat, sweets, and sugary beverages during this intervention period. A dietitian will help participants order foods from a digital supermarket. Foods will be delivered to the Johns Hopkins ProHealth Research Clinic for weekly pick-up. This study period will last 4 weeks.
2854200|NCT03569020|No Intervention|Self-Directed Diet|Participants will be asked to consume their typical diet for 4 weeks. There will be no subsidy during this period.
2854201|NCT03569007|Active Comparator|Larazotide Acetate 0.25 mg|Larazotide acetate 0.25 mg capsules TID for up to 16 weeks
2854202|NCT03569007|Active Comparator|Larazotide Acetate 0.50 mg|Larazotide acetate 0.50 mg capsules TID for up to 16 weeks
2854203|NCT03569007|Placebo Comparator|Placebo|Matching placebo capsules TID for up to 16 weeks
2854204|NCT03568994|Experimental|ADE 10+3+5 plus Atovaquone (AQ)|Induction I ADE: cytarabine, daunorubicin, etoposide 10+3+5, atovaquone daily
2854205|NCT03568994|Experimental|DA 3+10 with GO plus AQ|Induction I DA: daunorubicin, cytarabine 3+10 with GO: gemtuzumab ozogamicin, atovaquone daily
2854206|NCT03568981||Partial Breast Irradiation (PBI)|Patients receiving 5-fraction stereotactic partial breast irradiation for breast cancer
2854207|NCT03568981||Whole Breast Irradiation (WBI)|Patients receiving whole breast irradiation for breast cancer
2854208|NCT03568968|Experimental|Nicotinamide Riboside|nicotinamide riboside, 1000mg daily for the duration of the trial (52 weeks). Dosage form is tablets.
2854209|NCT03568968|Placebo Comparator|Placebo Comparator|Placebo tablets, no active ingredients.
2854210|NCT03568955||Swiss Bereaved|Adults from the Swiss population who have lost a loved one at least 6 months to 10 years prior to testing
2854211|NCT03568955||Japanese Bereaved|Adults from the Japanese population who have lost a loved one at least 6 months to 10 years prior to testing
2854212|NCT03568955||Chinese Bereaved|Adults from the Chinese population who have lost a loved one at least 6 months to 10 years prior to testing
2854213|NCT03568942|Experimental|Female subjects with acute cystitis|Adult female subjects with suspected acute cystitis based on clinical presentation and pyuria (>=10 WBC/mm^3 or presence of leukocyte esterase) and/or nitrite will be included. Subjects will be administered 1500 mg gepotidacin BID for 5 days via the oral route.
2854214|NCT03568929||Idelalisib|Participants who have been or are currently being treated with 100 or 150 mg of idelalisib
2854215|NCT03568916||Rivaroxaban vs dabigatran|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with rivaroxaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
2854216|NCT03568916||Apixaban vs dabigatran|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
2854217|NCT03568916||Apixaban vs rivaroxaban|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or rivaroxaban at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
2854218|NCT03568903|Experimental|Intervention group|Comprehensive physical therapy intervention in small groups (3 members), altogether 16 sessions were performed during a period of 8 weeks (twice a week). Each session lasted 1 hour.
2854219|NCT03568903|No Intervention|Control group|Control group members did not receive any specific intervention during study period, but if needed, medical treatment (medication, it`s dosage etc) of Parkinson Disease was changed during study period. They were assigned to individual therapy after the study period.
2854220|NCT03568890|Active Comparator|Anticoagulation therapy|Direct oral anticoagulants (rivaroxaban, dabigatran, apixaban, or edoxaban; with dosage according to guideline recommendations) for 8 weeks.
2854221|NCT03568890|Active Comparator|Antiplatelet therapy|Dual antiplatelet therapy with clopidogrel -75 mg/day- and low dose aspirin -80 to 125 mg/day for 8 weeks.
2854222|NCT03568877|Placebo Comparator|Placebo Control|2 capsules per day, each with 400 mg Cellulose microcrystalline, for 8 weeks
2854223|NCT03568877|Experimental|Dietetic Supplement Group|2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 8 weeks
2854224|NCT03568864|Placebo Comparator|Low nucleotide meal|Mixed meal containing mycoprotein with a reduced nucleotide content (~ 2% nucleotides)
2854225|NCT03568864|Experimental|High nucleotide meal|Mixed meal containing mycoprotein with a high nucleotide content (~ 10% nucleotides)
2854226|NCT03568838|Experimental|Enoxaparin|Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin.
2854227|NCT03568838|No Intervention|Standard Therapy|Patients randomised to the standard therapy arm will receive treatment as guided by the treating cardiologist in line with the local standard-of-care, usually consisting of UFH and a GPI.
2854228|NCT03568825|Experimental|Number of Osteopatic Manual Therapy|Intervention: OMT. Osteopatic Manual treatment consisting of Thoracic spine, Diaphragm mobilisation, Traction of the cardia and posture correction.
2854229|NCT03568825|Experimental|Interval in days between each OMT|Intervention: OMT. The time between each OMT's is calculated by the study design. Each OMT intervantion consists of Thoracic spine and Diaphragm mobilisation, Traction of the cardia and Posture correction.
2854230|NCT03568812|Experimental|Probiotics Rillus®|Rillus®, Chewing tablet containing viable cell 1.0 x 10^9 colony forming unit (Lactobacillus plantarum 8.55 mg, Streptococcus thermophilus 8.55 mg, Bifidobacterium bifidum 2.55 mg, fructooligosaccharide 480 mg), isomalt, xylitol, milk flavour, vanilla flavour Dosage: 1 chewing tablet Frequency: once daily every night Duration: 12 weeks
2854232|NCT03568799|Experimental|4-[18F]Fluoroglutamine|Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-[18F]Fluoroglutamine IV and 60 minutes after injection, undergo 4-[18F]Fluoroglutamine PET/CT before the start of therapy.
2854233|NCT03568786|Experimental|End-inspiratory pause (EIP) 10%|Once the patient is intubated and after initiating ventilation in a volume control mode using a tidal volume of 7 ml/kg of predicted body weight (PBW) with an inspiration: expiration ratio of 1:2; a respiratory rate of 12-14 breaths per minute to maintain the etCO2 at 35-40 mmHg and an initial PEEP of 5 cmH2O, the investigators will apply an alveolar recruitment maneuver (ARM) with estimation of the open lung PEEP using an end-inspiratory pause (EIP) corresponding with a of 10% of the total inspiratory time. Volume control ventilation will be restored after ARM maintaining the same ventilatory parameters except the EIP, which in this group will be of 10% of total inspiratory time.
2854234|NCT03568786|Experimental|End-inspiratory pause (EIP) 30%|Once the patient is intubated and after initiating ventilation in a volume control mode using a tidal volume of 7 ml/kg of predicted body weight (PBW) with an inspiration: expiration ratio of 1:2; a respiratory rate of 12-14 breaths per minute to maintain the etCO2 at 35-40 mmHg and an initial PEEP of 5 cmH2O, the investigators will apply an alveolar recruitment maneuver (ARM) with estimation of the open lung PEEP using an end-inspiratory pause (EIP) corresponding with a 30 % of the total inspiratory time. Volume control ventilation will be restored after ARM maintaining the same ventilatory parameters except the EIP, which in this group will be of 30 % of total inspiratory time.
2854235|NCT03568773|Experimental|High-intensity interval training|"The HIIT protocol is being performed with the cycling mode. The program consists of repeated intense explosions alternating with recovery intervals.~The adaptation period consists of 4 shots of 20 seconds interspersed by 180 seconds interval (active recovery). From the first to the fourth week the volunteers performed from four to six race shots from 30 to 45s with intervals from 180s to 120s. From the fifth week until the end of the intervention, training takes place with six shots of 60s with a 120s interval between running shots. The work intensity for all sessions is above 95% of VO2max, with 30W of recovery. In addition, participants refer to number 19 on the Borg Scale. Sessions range from 12 to 36 minutes without heating and recovery. In total there are 12 weeks of training."
2854236|NCT03568773|Experimental|Aerobic exercise moderate intensity|The training protocol was started, with the sessions held in the open air. From the first to the fourth week, the volunteers gave sessions of 40 to 60 minutes, intensity in L1, three sessions / week. In the fifth week, the intensity was increased to the midpoint between L1 and half of L2, maintaining 60 minutes per session and frequency three times per week. From the sixth week, the weekly frequency increased to five days, with three supervised sessions and two unsupervised sessions, but with a smartphone application that recorded distance traveled and intensity. From the ninth week on, the weekly frequency was maintained and the intensity increased for L2. In supervised sessions, training intensity is also monitored by heart rate using a Polar heart rate monitor.
2854237|NCT03568773|Experimental|Control Group|The control group attends stretching classes once a week and sessions lasting 60 minutes. At the end of the fifteen weeks (three weeks of adaptation and twelve weeks of training) of the study, these volunteers will be invited to engage in the aerobic training program regardless of their participation in the research.
2854238|NCT03568760|Experimental|SFA treatment|Semantic feature analysis
2854239|NCT03568760|Placebo Comparator|Comprehension training|Comprehension training
2854240|NCT03568747|Experimental|NIV plus oxygen therapy|noninvasive ventilation (dual-limb NIV) is given at peak exercise until the borg scale reaches it's baseline point
2854241|NCT03568747|Experimental|oxygen therapy|oxygen therapy is given at peak exercise until the borg scale reaches it's baseline point
2854242|NCT03568734|Experimental|Transplant arm|Fecal transplant sample given to child at delivery
2854243|NCT03568721|Experimental|ibuprofen|ibuprofen (400 mg) immediately after insertion of the initial archwire and 6/6 hs for a week if there is any orthodontic pain.
2854244|NCT03568721|Experimental|acetaminophen|acetaminophen (500 mg) immediately after insertion of the initial archwire and 6/6 hs for a week if there is any orthodontic pain.
2854245|NCT03568721|Experimental|chewing gum|chewing gum (01 tablet) immediately after insertion of the initial archwire and 6/6 hs of chewing gum for a week if there is any orthodontic pain.
2854246|NCT03568721|No Intervention|control|control (no reliever for orthodontic pain)
2854247|NCT03568708|No Intervention|Control Participants|The control group will reflect a comparison group similar to the POI patient group. As bone density, body composition, and cognitive domains continue to mature throughout the teenage years, this comparison group will provide an important metric of normal growth and development.
2854248|NCT03568708|Experimental|POI Participants|This group will be participants who have been recently diagnosed with POI. In an open-label fashion, participants with POI will receive Transdermal Estrogen(beginning at a dose of 25 μg/patch applied weekly), with the dose increased at 3, 6 and 12 months (to 37.5, 50, and 75 μg/patch).
2854249|NCT03568695|Other|Detected patients|If they agree to participate in the study, the patients detected for one or the other of the STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium) on one site, will have on day of result return, two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
2854250|NCT03568682|Experimental|Nutritional counseling + urban gardening|Participants in the intervention clinic will receive: 1) nutritional counseling from peer counselors in their clinic (approximately 4-5 sessions administered monthly); 2) training from the Ministry of Agriculture on how to plant and maintain a garden in their home (training workshop and monthly follow-up); and 3) a cooking and nutrition workshop facilitated by project nutritionists once garden produce are available.
2854251|NCT03568682|No Intervention|Usual care control|Participants in the control clinic will receive their usual care from the clinic. After 12 month follow-up, they will be offered the opportunity to receive the intervention.
2854252|NCT03568656|Experimental|CCS1477 Dose Escalation|Dose escalation of CCS1477 in patients with mCRPC
2854253|NCT03568656|Experimental|CCS1477 Monotherapy - Prostate|CCS1477 expansion phase in patients with mCRPC
2854254|NCT03568656|Experimental|CCS1477 and Abiraterone|CCS1477 plus abiraterone acetate in patients with mCRPC
2854255|NCT03568656|Experimental|CCS1477 and Enzalutamide|CCS1477 plus enzalutamide in patients with mCRPC
2860233|NCT03527095|Experimental|Regimen A|FDL169 200 mg reference tablet
2854256|NCT03568656|Experimental|CCS1477 Monotherapy - Solid tumours|CCS1477 expansion phase in patients with advanced solid tumours with a mutation in p300/CBP
2854257|NCT03568643|Experimental|Azithromycin|
2854258|NCT03568643|Active Comparator|Amoxicillin|
2854259|NCT03568630||New Onset Diabetes/High-Risk Prediabetes|"Must meet one of the following criteria:~New onset type 2 diabetes diagnosed within the past 3 years, defined as Hemoglobin A1c ≥ 6.5%*, fasting blood glucose >126mg/dL confirmed on a subsequent day or as diagnosed by a physician~High-risk pre-diabetes: Hemoglobin A1c >6.3% or A1c >6.0% with fasting blood glucose >110 or 2 hour oral glucose tolerance test between 140-200mg/dL; subjects who have been on metformin <3 years are eligible"
2854260|NCT03568630||Pancreatic Cystic Neoplasm/Pancreatitis|"Must meet one of the following criteria:~Pancreatic cystic neoplasm for which resection, endoscopic ultrasound or serial imaging has been recommended~Chronic pancreatitis as defined by cross-sectional imaging, endoscopic ultrasound, functional testing abnormalities OR as diagnosed by a gastroenterologist"
2854261|NCT03568630||Inherited Risk|"Must meet one of the following criteria:~Two or more blood relatives with PDAC (includes 1st-3rd degree relatives as defined in Table 2)~One 1st degree relative with PDAC diagnosed before age 60~Germline mutation associated with a higher than average risk of PDAC including but not limited to the following: Hereditary breast and ovarian cancer syndromes BRCA1, BRCA2, PALB2 Hereditary nonpolyposis colon cancer (Lynch) syndrome MLH1, MSH2, MSH6, PMS2 Familial adenomatous polyposis (APC) Familial atypical multiple melanoma and mole syndrome CKDN2a, p16 Peutz-Jeghers syndrome STK11 Ataxia-telangiectasia ATM Juvenile polyposis syndromes SMAD4, BMPR1A Li Fraumeni TP53 Cystic fibrosis and unaffected carriers CFTR~Personal or family history which meets clinical criteria for a hereditary cancer syndrome and includes a relative with PDAC"
2854262|NCT03568617|Experimental|rTMS group|
2854263|NCT03568604|Experimental|Prasterone|6.5 mg vaginal inserts of prasterone will be used daily once the patient meets inclusion and exclusion for 20 weeks.
2854264|NCT03568591|Experimental|Intervention Group (Treatment)|A treatment group cohort who have self-referred for the psychosensory therapy intervention (Havening Techniques).
2854265|NCT03568591|No Intervention|Control Group (Waiting List)|Self-referral waiting list cohort (usual care).
2854266|NCT03568578|Active Comparator|Entecavir Group|Patients in this arm will be given Entecavir 0.5 mg a day for 2 years.
2854267|NCT03568578|Experimental|Entecavir and Anluohuaxian Group|Patients in this arm will be given Entecavir 0.5 mg and Anluohuaxian Pill 12 g a day for 2 years.
2854268|NCT03568565|Experimental|ePREP Program|The ePREP program is based on the in-person Prevention and Relationship Enhancement Program. The ePREP program consists of six sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour. Participants who do not complete activities in a timely manner will be re-randomized to either continue without a coach or to receive a coach.
2854269|NCT03568565|Experimental|ePREP Program plus Coach|The ePREP program is based on the in-person Prevention and Relationship Enhancement Program. The ePREP program consists of six sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour. Couples also have four, brief video or phone calls with a coach throughout the program.
2854270|NCT03568565|Experimental|OurRelationship Program|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner.Participants who do not complete activities in a timely manner will be re-randomized to either continue without a coach or to receive a coach.
2854271|NCT03568565|Experimental|OurRelationship Program plus Coach|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner. The first conversation between partners centers on discussing possible core relationship issues and jointly deciding on the problem(s) to focus on during the program. During the second conversation, both partners' previous written responses are displayed on the screen and conversation is encouraged. During the final conversation, couples share their strategies to decrease stress, improve patterns of communication, and engage in problem-solving exercises specific to their core issue(s). Couples also have four, brief video or phone calls with a coach throughout the program.
2854272|NCT03568565|No Intervention|Waitlist|Participants are assessed at 1, 2, 4, and 6 months after randomization; however, no active intervention is given during the waitlist period.
2854273|NCT03568552|Experimental|Patient Decision Aid|Participating clinics (and their patients) will be randomly selected to implement the intervention, at which time their patients will receive Patient Decision Aid for Medication Assisted Treatment for opioid use disorder.
2854274|NCT03568552|No Intervention|Prior to intervention|All participating clinics will start with a baseline period without the intervention. The clinics and their patients will remain in the no intervention condition until randomly selected to crossover to receive the intervention.
2854275|NCT03568539|Experimental|IBI308|
2854276|NCT03568526|Experimental|Supportive Care (sensorimotor rehabilitation program)|Patients attend 1 therapy session to receive education and training in the use of the home program. Patients then complete exercises over 90 minutes per week for 6 weeks.
2854277|NCT03568513|Experimental|Treatment|Patients in the treatment arm with weight between 35 kg to 50 kg will receive 50 mg capsule of curcumin twice a day (maximum dose 2.8 mg/kg/day, which is within the GRAS approved dose) and those over 50 kg in weight will receive three curcumin capsules a day (maximum dose 3 mg/kg/day, within GRAS recommended dose). Study duration will be 8 weeks.
2854278|NCT03568513|Placebo Comparator|Placebo|Patients in the placebo arm will receive a capsule which has similar size, shape and color of the curcumin capsule. The placebo capsule will contain inert food powder. Study duration will be 8 weeks.
2854280|NCT03568500|Experimental|Olanzapine|A CoEncapsulated (CoE) olanzapine, DMS patch & associated smartphone application.
2854281|NCT03568500|Experimental|Quetiapine|A CoEncapsulated (CoE) quetiapine, DMS patch & associated smartphone application.
2854282|NCT03568500|Experimental|Risperidone|A CoEncapsulated (CoE) risperidone, DMS patch & associated smartphone application.
2854283|NCT03568487|Experimental|Intensive scapula-focused approach|
2854284|NCT03568487|Active Comparator|Control therapy|
2854285|NCT03568474|Experimental|Silver Diamine Fluoride|Silver Diamine fluoride will be applied after after minimal caries removal then glass ionomer over it followed by composite resin restoration.
2854286|NCT03568474|Active Comparator|Glass Ionomer|Glass ionomer will be applied after minimal caries removal followed by composite resin restoration.
2854287|NCT03568461|Experimental|CTL019|tisagenlecleucel infusion
2854288|NCT03568435||Participants with metastatic RCC taking nivolumab|Specified dose on specified day
2854289|NCT03568422|Experimental|CFI-402257 + Paclitaxel|Oral CFI-402257 on intermittent schedule:* days 1, 2, 8, 9, 15 & 16 q4w Plus Paclitaxel 80 mg/m2 IV days 1, 8 & 15 every 28 days
2854290|NCT03568409|Experimental|Group A: ABO-GLYC|Libramed
2854291|NCT03568409|Placebo Comparator|Group B: Placebo|
2854292|NCT03568396||Pupillometry|The relationship between the target effect site concentration of remifentanil and the pupil diameter and reactivity in response to a standard noxious stimulus.
2854293|NCT03568383|Experimental|Arm A: Delamanid (DLM)|HHCs will receive delamanid (DLM) for 26 weeks.
2854294|NCT03568383|Experimental|Arm B: Isoniazid (INH)|HHCs will receive isoniazid (INH) and pyridoxine (vitamin B6) for 26 weeks.
2854295|NCT03568370|Experimental|olive oil|use one drop olive oil on each nipple after each feeding
2854296|NCT03568370|No Intervention|breast milk|use breast milk on each nipple after each feeding
2854297|NCT03568357||Reoxygenation|After one minute of full bypass, fraction of inspired oxygen (FiO2) in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 40%-80% adjusted reoxygenation to maintain PO2 in the range of 250mm Hg-300 mm Hg or more during the bypass.
2854298|NCT03568344||Community based tx seeking: baseline|Children <5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including CHWs and primary health facilities during baseline period (no QA RAS administration).
2854299|NCT03568344||tx seeking @ referral facility: baseline|Children <5 years of age seeking care for a severe febrile illness episode directly at the referral facility during baseline period (no QA RAS administration).
2854300|NCT03568344||Community based tx seeking: Post RAS|Children <5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including CHWs and primary health facilities after QA RAS roll-out (after pre-referral QA RAS administration).
2854301|NCT03568344||tx seeking @ referral facility: Post RAS|Children <5 years of age seeking care for a severe febrile illness episode directly at the referral facility after QA RAS roll-out ( no QA RAS administration).
2854302|NCT03568331|Experimental|Tradipitant|
2854303|NCT03568331|Placebo Comparator|Placebo|
2854304|NCT03568318|Experimental|Arm A|Upadacitinib Dose A is administered once daily along with topical corticosteroids (TCS).
2854305|NCT03568318|Experimental|Arm B|Upadacitinib Dose B is administered once daily along with topical corticosteroids (TCS).
2854306|NCT03568318|Experimental|Arm C|Placebo administered once daily and TCS followed by Upadacitinib Dose A once daily along with TCS.
2854307|NCT03568318|Experimental|Arm D|Placebo administered once daily and TCS followed by Upadacitinib Dose B once daily along with TCS.
2854308|NCT03568292|Experimental|Arm I: Virtual Reality|Participants receive the VR intervention during bone marrow biopsy or lumbar puncture lasting until completion of the procedure. Participants will be trained to use VR equipment prior to the bone marrow biopsy or lumbar puncture. The headset will cover both eyes with a strap along the back to hold the headset in place. The headset will be attached by a wire to a laptop which will power the headset and provide content. A remote control will be available for assistance in setting up or stopping the content in the case of an event. The VR content will consist of meditation and relaxing techniques through visual and auditory input which can last up to one hour. There will be minimal stimulatory effort to decrease excess movement for the procedure.
2854309|NCT03568292|Active Comparator|Arm II: No Virtual Reality|Participants receive standard of care during bone marrow biopsy or lumbar puncture.
2854310|NCT03568279|Active Comparator|Control|The attending anesthesiologist provided intubation without two-handed jaw thrust.
2854311|NCT03568279|Experimental|Two-hand|The attending anesthesiologist provided intubation with two-handed jaw thrust.
2854312|NCT03568266||Biospecimen Collection|Buccal swabs of prospective participants' saliva will be collected when participant achieves complete remission (during regular clinical visit) from their asparaginase treatment.
2854313|NCT03568253|Active Comparator|Bulk fil composite|
2854314|NCT03568253|Active Comparator|High viscosity glass ionomer|
2854315|NCT03568240||30 men suffering from apnea|
2854316|NCT03568240||15 men defined as snorers|
2854317|NCT03568240||15 men without complaints|
2854318|NCT03568227|Experimental|Healthy Subjects|"The study has a 2 (Intervention: Hypnosis, Control) x 2 (State: 1 & 2) factorial within-subjects design, resulting in a total of 4 conditions. All volunteers participate at the 4 conditions in the same session.The order of the interventions is counterbalanced resulting in two possible sequences:~Sequence 1: Hypnosis State 1, Hypnosis State 2, Control State 1, Control State 2~Sequence 2: Control State 1, Control State2, Hypnosis State 1, Hypnosis State 2~Volunteers will be randomly allocated to the two sequence types."
2854319|NCT03568214|Experimental|Individualized moderate + high-intensity|"12 weeks of moderate-intensity continuous training (MICT) combined with high-intensity interval training (HIIT)~4 days per week of MICT for 50 minutes per session~1 day per week of HIIT for 35 minutes per session~Exercise intensity for MICT will be established according to ventilatory thresholds one and two (VT1 and VT2)~The HIIT protocol will consist of eight, 60 second intervals at 100% maximal oxygen uptake (VO2max), separated by 150 seconds active recovery"
2854414|NCT03567551||Women w/ Preeclampsia w/ Visual Disturbances or Headaches|Preeclampsia With either Visual Disturbances or Headaches Blood Pressure: >Systolic 160 or Diastolic 110
2854320|NCT03568214|Experimental|Standardized moderate-intensity|"12 weeks of MICT~5 days per week of MICT for 50 minutes per session~Exercise intensity for MICT will be established according to 40-65% heart rate reserve (HRR)"
2854321|NCT03568214|No Intervention|Control|non-exercise control group testing at baseline and post-program (12 weeks)
2854322|NCT03568201|Experimental|patients|Patients suspected of iliac kinking will have a transcutaneous oximetry test during hip flexion
2854323|NCT03568201|Sham Comparator|controls|Healthy asymptomatic athletes will have a transcutaneous oximetry test during hip flexion
2854324|NCT03568188|Experimental|HIFU treatment|170 patients with prostate cancer of intermediate risk receive the immediate treatment with focal HIFU. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed. Patients will also have PSA (Prostate-Specific Antigen) dosage, MRI (Magnetic Resonance Imaging) exam, questionnaires and prostatic biopsies during their follow up. If the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) and a urine test (for PCA3 (The prostate cancer antigen 3 gene) test) will be performed during their follow up.
2854325|NCT03568175|Experimental|JR-141 2.0 mg/kg/week|
2854326|NCT03568162|Experimental|GBR 830 - Group 1|Subcutaneous (SC) administration of GBR 830 as a loading dose, followed by SC maintenance dose of GBR 830.
2854327|NCT03568162|Experimental|GBR 830 - Group 2|Subcutaneous (SC) administration of GBR 830 as a loading dose, followed by SC maintenance dose of GBR 830.
2854328|NCT03568162|Experimental|GBR 830 - Group 3|Subcutaneous (SC) administration of GBR 830 as a loading dose, followed by SC maintenance dose of GBR 830.
2854329|NCT03568162|Placebo Comparator|Placebo - Group 4|Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
2854330|NCT03568149||Group A: endometriosis|assessment of pain symptoms at first medical examination; assessment of pelvic vascular insufficiency signs.
2854331|NCT03568149||Group B: no endometriosis|assessment of pain symptoms at first medical examination; assessment of pelvic vascular insufficiency signs.
2854332|NCT03568136|Experimental|Treatment Arm A|Patients in treatment arm A receive 300 mg Secukinumab administered as 2 subcutaneous injections of 150 mg (i.e. 2x 150 mg) at baseline day 1 and week 1, 2, 3, 4, 8, 12 and injections with placebo at week 5, 6, 7 and 16. For assessments of the study endpoints were followed up visits at week 20 and 24. Placebo will be administered as 2 subcutaneous injections.
2854333|NCT03568136|Placebo Comparator|Treatment Arm B|Patients in treatment arm B receive placebo until visit 3 (week 3) and will switch to Secukinumab 300 mg s.c. up from visit 4 (week 4), visit 5, 6, 7, 8, 12 and16. For assessments of the study endpoints were followed up visits at week 20 and 24.
2854334|NCT03568123|Experimental|MC polyethylene bearing|Persona Total Knee System with MC polyethylene bearing
2854335|NCT03568123|Active Comparator|CR polyethylene bearing|Persona Total Knee System with a CR polyethylene liner.
2854336|NCT03568097|Experimental|Avelumab + Standard 1st line Chemotherapy|Administration of cisplatin or carboplatin + etoposide every 3 weeks with phased avelumab administered every 2 weeks until disease progression.
2854337|NCT03568084|Experimental|MEFAP|MEFAP (multicomponent physical activity program) for 12 weekly sessions of an hour and a half which includes 1) briefing 2) exercises for improving aerobic resistance, muscle strength, proprioception-balance and flexibility and 3) delivery of exercise chart to do at home (two times per week).
2854338|NCT03568084|Active Comparator|Control: usual practice|No intervention. Individuals allocated to this arm, will be look after as usual in their health Centers.
2854339|NCT03568071|Experimental|Cohort A - dose regimen A|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen A) will be administered on Day 1.
2854340|NCT03568071|Experimental|Cohort B - dose regimen B|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen B) will be administered on Day 1.
2854341|NCT03568071|Experimental|Cohort C - dose regimen C|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen C) will be administered on Day 1.
2854342|NCT03568071|Experimental|Cohort D - dose regimen D|MOR106 will be administered as IV infusion. Subjects will receive alternating repeated doses of MOR106 or placebo over a 12-week treatment period. A loading dose (dose regimen D) will be administered on Day 1.
2854343|NCT03568071|Experimental|Cohort E - dose regimen E|MOR106 will be administered as IV infusion.Subjects will receive alternating repeated doses of MOR106 or placebo over a 12-week treatment period.. A loading dose (dose regimen E) will be administered on Day 1.
2854344|NCT03568071|Placebo Comparator|Placebo|Subjects will receive repeated doses of placebo over a 12-week treatment period.
2854345|NCT03568058|Experimental|vaccine and anti-PD-1|personalized vaccine and anti-PD-1 administered concurrently at the start of study therapy
2854346|NCT03568058|Experimental|anti-PD1 before vaccine|anti-PD-1 antibody for 6 weeks followed by personalized vaccine therapy
2854347|NCT03568045|Active Comparator|Usual care, standard light|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), but otherwise have usual care."
2854348|NCT03568045|Experimental|10,000 lux bright light, 4 hours|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 8am to noon starting on study day 2 and continuing through study day 5. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor if the patient is transferred.~Feasibility metrics will be collected."
2854415|NCT03567551||Women w/o Preeclampsia|Normal Pregnancy Blood Pressure: <140/90
2854416|NCT03567525|Active Comparator|Standard surgical approach|standard lymphadenectomy using clips and bipolar cautery to seal lymphatic vessels
2854349|NCT03568045|Experimental|10,000 lux bright light, 8 hours|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 8am to 4pm starting on study day 2 and continuing through study day 5. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor if the patient is transferred.~Feasibility metrics will be collected."
2854350|NCT03568032||the post-radiation group|patients diagnosed as non-metastatic nasopharyngeal carcinoma who received definitive IMRT more than 3 years ago
2854351|NCT03568032||the pre-radiation group|untreated patients diagnosed as non-metastatic nasopharyngeal carcinoma
2854352|NCT03568006|Experimental|Intervention|"Intervention will consist of passive joint mobilization (caudal and dorsal gliding) grade II in the glenohumeral joint.~Besides, participants will receive a standardized treatment consisting of infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene."
2854353|NCT03568006|Active Comparator|Control|Control treatment will consist of a standardized treatment consisting of infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene.
2854354|NCT03567993|Active Comparator|Comparison|The comparison condition is designed as a minimal intervention, and allows for blinding of the patients to randomization group.
2854355|NCT03567993|Experimental|Intervention|The intervention is designed to encourage and remind smokers of the availability of the Quitline services. In addition to the one-way motivational messages, the investigators will use two-way assessments. Two-way automated texting is the ability to push out a question, have the user respond with a brief, numeric or one-word answer, and based on that answer, provide immediate feedback. The goal of these brief assessments is two-fold: 1) to assess behavior (abstinence) and motivation to use services, and 2) to return feedback tailored to each individual smoker based on the answers of the user.
2854356|NCT03567980|Experimental|topical crisaborole 2%|
2854357|NCT03567967|Experimental|San Francisco|Each study participant will receive four paper vouchers per month for a total of six months. Each of these vouchers can be redeemed for fresh or frozen fruits and vegetables at a number of specified local corner stores, supermarkets, or farmer's markets. The San Francisco participants will receive and spend these vouchers in an environment which has implemented a sugar-sweetened beverage tax.
2854358|NCT03567967|Active Comparator|Los Angeles|Each study participant will receive four paper vouchers per month for a total of six months. Each of these vouchers can be redeemed for fresh or frozen fruits and vegetables at a number of specified local corner stores, supermarkets, or farmer's markets. The Los Angeles participants will receive and spend these vouchers in an environment which has NOT implemented a sugar-sweetened beverage tax.
2854359|NCT03567941|Placebo Comparator|Placebo|Single dose
2854360|NCT03567941|Experimental|Hydrocodon bitartrate-acetaminophen arm 1|Single dose
2854361|NCT03567941|Experimental|Hydrocodon bitartrate-acetaminophen arm 2|Single dose
2854362|NCT03567941|Active Comparator|Reference|Single dose
2854363|NCT03567928|Active Comparator|Standard Treatment|Standard Treatment Sedation with propofol target controlled infusion (TCI) and no airway devices (mandatory spontaneous breathe)
2854364|NCT03567928|Experimental|Interventional Treatment|Interventional Treatment Sedation with propofol target controlled infusion (TCI) and Gastro Cuff Pilot Laryngeal Mask (possibility to use a pressure-support ventilation)
2854365|NCT03567915||Rice|Group that healthy volunteers eat rice.
2854366|NCT03567915||Noodle|Group that healthy volunteers eat noodle.
2854367|NCT03567902|Experimental|Group A|C-MAC videolaryngoscope intubation -> Direct laryngoscope intubation
2854368|NCT03567902|Experimental|Group B|Direct laryngoscope intubation -> C-MAC videolaryngoscope intubation
2854369|NCT03567889|Experimental|Daromun and Surgery (Arm 1)|Two-weeks screening period and a 4-weeks open-label treatment period, followed by surgery within a maximum of another 4 weeks (Arm 1).
2854370|NCT03567889|Active Comparator|Surgery alone (Arm 2)|Patients in control arm (Arm 2) will receive direct surgery within 4 weeks from randomization.
2854371|NCT03567876|Experimental|V-RBAC (RBAC followed by Venetoclax)|"Induction phase: RBAC --> up to 6 cycles for low risk (LR) patients and up to 4 cycles for high risk (HR) patients.~Patients proceeding to Venetoclax treatment will receive consolidation with single agent Venetoclax 800 mg/die x 4 28d cycles (with initial ramp-up dose) of each consolidation cycle. Consolidation will be followed by maintenance with single agent Venetoclax 400 mg/die (V maint ) for a total of 2 years (4 months consolidation+20 months maintenance)."
2854372|NCT03567863|Active Comparator|Group A|"The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)~20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®"
2854373|NCT03567863|Active Comparator|Group B|"The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)~22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®"
2854374|NCT03567850|Experimental|Intervention|Participants assigned to the intervention arm will receive Problem Solving Skills Training (PSST) consisting of eight one-hour individual weekly sessions.
2854375|NCT03567850|Active Comparator|Control Arm|Care As Usual Group (CAU): Participants randomized to the CAU group will be observed under naturalistic conditions. Both PSST and CAU participants and their clinicians (PCP and oncology providers) will be allowed to use any clinically appropriate medical and behavioral care without restriction (e.g., care management, rehabilitation, behavioral therapy, palliative care) or refer patients to social and community services (e.g., peer support, county cancer services program or aging services). The CAU participants will undergo the same evaluation protocol as the PSST group
2854376|NCT03567837|Active Comparator|Obese Metabolically Healthy|Intervention: Oral challenge of Fructose+Glucose Beverage 1:1, 3g/kg
2854377|NCT03567837|Experimental|Obese Pre-diabetes|Intervention: Oral challenge of Fructose+Glucose Beverage 1:1, 3g/kg
2854378|NCT03567824|Experimental|Open label phase|MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months, all subjects.
2854379|NCT03567824|Other|Random off phase|MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months or Placebo
2854417|NCT03567525|Experimental|Experimental approach|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels
2854380|NCT03567811|Other|Chronic Fatigue Syndrome|"Inclusion and exclusion criteria based on 1994 Center for Disease Control (Fukuda) criteria of persistent, disabling, moderate to severe fatigue that was relieved by rest, plus at least 4 of the 8 following ancillary features: cognitive dysfunction affecting short term memory or concentration, sore throat, sore lymph nodes, sore muscles, sore joints, headache, sleep disturbance, and exertional exhaustion (post-exertional malaise). Intervention: Procedure/Surgery: Submaximal bicycle exercise stress test on Days 1 and 2"
2854381|NCT03567811|Other|Sedentary Control|Subjects who lived a sedentary lifestyle, did not meet Chronic Fatigue Syndrome criteria, and did not have any exclusionary chronic medical, psychiatric or other conditions were our Sedentary Control subjects. By design, this control group included controlled Type II diabetes and thyroid disease, chronic idiopathic fatigue, hypertension (other heart disease excluded) and other stable medical conditions. This variety of subjects were included to prevent ceiling (CFS) vs. floor (control) effects if the control group had totally pristine subjects with zero health issues. Intervention: Procedure/Surgery: Submaximal bicycle exercise stress test on Days 1 and 2
2854382|NCT03567798|Experimental|A|"UPLAT® (Carica papaya leaf Extract + Tinospora cardifolia Extract~Take 4 units daily (2 in morning and 2 in evening) for 10 days"
2854383|NCT03567798|Placebo Comparator|B|"Placebo~Take 4 units daily (2 in morning and 2 in evening) for 10 days"
2854384|NCT03567772|Experimental|Wiifit Nintendo video game|Pulmonary rehabilitation program using video games exercise from Nintendo
2854385|NCT03567772|Active Comparator|Pulmonary rehabilitation program|Pulmonary rehabilitation program with ergometer cycle
2854386|NCT03567746|Experimental|Underwater EMR|The patients randomized in this arm will be treated by endoscopic resection assisted by the filling of the colonic lumen using water instead of air and avoiding the formation of a submucosal cushion
2854387|NCT03567746|Active Comparator|Conventional EMR|The patients randomized in this arm will be treated by endoscopic resection following the traditional technique. It means, by assistance of selective submucosal saline injection to create a submucosal cushion below the polyp.
2854388|NCT03567733||Coronary Artery Disease|Drug- eluting Stent
2854389|NCT03567720|Experimental|intratumoral tavo-EP plus IV pembrolizumab|intratumoral tavo-EP plus IV pembrolizumab
2854390|NCT03567707|Experimental|C-section -Vaginal seeding|"Pregnant women who undergo C-section and (neonate) vaginal seeding.~Infants that are scheduled to be born in a hospital by standard C-section procedure (e.g., elective, unlabored C-section) will be wiped with gauze containing their mother's vaginal microbiota just after delivery."
2854391|NCT03567707|Experimental|C-section - Placebo Seeding|"Pregnant women who undergo C-section and (neonate) placebo seeding.~Infants that are scheduled to be born in a hospital by standard C-section procedure (e.g., elective, unlabored C-section) will be wiped with sterile gauze (placebo)."
2854392|NCT03567707|Active Comparator|standard care|"Pregnant women who undergo spontaneous vaginal delivery (of neonate) .~Pregnant women who undergo spontaneous vaginal delivery and (neonate) receives standard care."
2854393|NCT03567694|Experimental|SAD/Food effect|This is the SAD / Food effect arm. For SAD, a total of 80 subjects will be enrolled into 8 groups of 10 subjects each; within each group, 8 will receive HA115 at a single ascending dose 10, 25, 50, 100, 200, 400, 800, 1200 mg, and 2 subjects will be placebo control. For food effect study,10 participants will be administered HA115 at a single dose to be selected based on SAD results.
2854394|NCT03567694|Experimental|MAD|For the MAD portion, 3 dose levels will be selected based on SAD results.
2854395|NCT03567681|Experimental|Extended release oxcarbazepine|Six week of open treatment with extended release oxcarbazepine (Oxtellar XR)
2854396|NCT03567681|Experimental|Immediate release oxcarbazepine|Six week of open treatment with Immediate release oxcarbazepine ( Trileptal)
2854397|NCT03567655|Experimental|Single group|Farlutal tab. 500mg/ Pfizer to be administered
2854398|NCT03567642|Experimental|Osimertinib, Platinum (cisplatin or carboplatin) and Etoposide|Initially, 6 patients will be enrolled and will begin treatment with osimertinib 80mg orally daily (3 who will be receiving cisplatin and 3 who will be receiving carboplatin). Cisplatin or carboplatin treatment will be decided by the treating physician prior to study registration. After 9 weeks (+/- 1 week)( 3 cycles) on osimertinib alone, carboplatin or cisplatin and etoposide will be added. Carboplatin is doses at an AUC of 5 or cisplatin at 60mg/m2 will be given on C4D1. Etoposide is dosed at 100mg/m2 given on Days 1-3 of C4. Only patients on osimertinib 80mg orally daily at the start of cycle 4 will be included in the 3+3 dose de-escalation portion of the study. Chemotherapy and osimertinib will be administered concurrently during cycles 4-7, and from cycle 8 onward, osimertinib monotherapy will be continued.
2854399|NCT03567629|Experimental|Irinotecan-based chemotherapy|
2854400|NCT03567629|Active Comparator|Oxaliplatin-based chemotherapy|
2854401|NCT03567616|Experimental|Dose-Escalation Phase|Dose-Escalation Phase subjects will administer venetoclax (various doses) + pomalidomide + dexamethasone.
2854402|NCT03567616|Experimental|Expansion Phase: Arm A t(11;14) Positive|Expansion Phase Arm A in subjects positive for t(11;14) translocation will administer venetoclax + pomalidomide + dexamethasone .
2854403|NCT03567616|Experimental|Expansion Phase: Arm B t(11;14) Negative|Expansion Phase Arm B in subjects negative for t(11;14) translocation will administer venetoclax + pomalidomide + dexamethasone.
2854404|NCT03567603||opioid exposed neonates|
2854405|NCT03567603||non-opioid exposed neonates|
2854406|NCT03567590|Experimental|Pulsed Radiofrequency Group|This group will undergo pulsed radiofrequency treatment.
2854407|NCT03567590|Active Comparator|Nerve Block Group|This group will undergo nerve block treatment.
2854408|NCT03567577|Experimental|Solnatide 5mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 5mg administered
2854409|NCT03567577|Experimental|Solnatide 60mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 60mg administered
2854410|NCT03567577|Experimental|Solnatide 125mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 125mg administered
2854411|NCT03567577|Placebo Comparator|Placebo|0,9% saline solution
2854412|NCT03567564||Mechanically ventilated patients|Abdominal muscles ultrasound
2854413|NCT03567551||Women w/ Preeclampsia w/o Visual Disturbances or Headache|Preeclampsia Without either Visual Disturbances or Headaches Blood Pressure: >Systolic 160 or Diastolic 110
2854532|NCT03566745||Control|Patients without mutation in AhR gene - presumed normal Blood for protein activity
2854418|NCT03567512|Experimental|Intervention group|The Intervention administered to this group will focus on Quit Smoking of parental and household smokers and Reduction of Secondhand Smoke Exposure among the Children.
2854419|NCT03567512|Placebo Comparator|Control group|The placebo intervention will be administered in this group.
2854420|NCT03567499|Experimental|Part A: Sequence 1|Subjects in sequence 1 will receive matching placebo in period 1 followed by GSK3039294 200 milligrams (mg) in Period 2 followed by GSK3039294 600 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
2854421|NCT03567499|Experimental|Part A:Sequence 2|Subjects in sequence 2 will receive GSK3039294 600 mg in period 1 followed by matching placebo in Period 2 followed by GSK3039294 200 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
2854422|NCT03567499|Experimental|Part A: Sequence 3|Subjects in sequence 3 will receive GSK3039294 200 mg in period 1 followed by GSK3039294 600 mg in Period 2 followed by matching placebo in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session
2854423|NCT03567499|Experimental|Part A: Sequence 4|Subjects in sequence 4 will receive GSK3039294 600 mg in period 1 followed by GSK3039294 200 mg in Period 2 followed by matching placebo in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
2854424|NCT03567499|Experimental|Part A: Sequence 5|Subjects in sequence 5 will receive GSK3039294 200 mg in period 1 followed by matching placebo in Period 2 followed by GSK3039294 600 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
2854425|NCT03567499|Experimental|Part A: Sequence 6|Subjects in sequence 6 will receive matching placebo in period 1 followed by GSK3039294 600 mg in Period 2 followed by GSK3039294 200 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
2854426|NCT03567499|Experimental|Part B: Sequence 1|Subjects in sequence 1 will receive matching placebo in period 1 followed by GSK3039294 (dose level to be decided on results of Part 1) in Period 2 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
2854427|NCT03567499|Experimental|Part B: Sequence 2|Subjects in sequence 2 will receive GSK3039294 (dose level to be decided on results of Part 1) in period 1 followed by matching placebo in Period 2 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing
2854428|NCT03567486||Tuberculum sellae meningiomas|Adult patient suffering from tuberculum sellae meningiomas with surgical treatment
2854429|NCT03567473|Experimental|Active Intervention Arm|Oral dexamethasone and nebulized epinephrine
2854430|NCT03567473|Placebo Comparator|Control Arm|Oral placebo (OraBlendTM in Canada and a compounded oral placebo solution at New Zealand/Australia sites) and nebulized saline.
2854431|NCT03567447|Experimental|Treatment group|This group will receive droxidopa 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
2854432|NCT03567447|Placebo Comparator|Non treatment group|This group will receive placebo appearing to be 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
2854433|NCT03567408|Experimental|Selective PCI with bivalirudin|Before PCI, bivalirudin is intravenously injected with 0.75 mg/kg, 1.75 mg/(kg.h) through continuous intravenous drip to finish surgery (no more than 4 hours), if necessary, after the surgery, with a low dose of 0.2 mg/(kg.h) intravenous drip less than 20 hours.
2854434|NCT03567408|Placebo Comparator|Unfractionated heparin|Before PCI, unfractionated heparin sodium is intravenously injected with 70-100 U/kg, and if the operation time exceeded 1h, an additional 1000 U/h would be added.
2854435|NCT03567395|Active Comparator|Melatonin|Melatonin (5 mg sublingual tablet)
2854436|NCT03567395|Experimental|Honey|raw honey (1.5 tablespoons)
2854437|NCT03567382|Experimental|High-risk HBV dyads|Mothers with high-risk HBV (defined as viral load >10^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of vertical transmission of HBV. All HBV-exposed infants (regardless of mother's status of high- or low-risk HBV) will receive monovalent HBV vaccine within 24 hours of life.
2854438|NCT03567382|Experimental|Low-risk HBV dyads|Mothers with low risk HBV (defined as a viral load <10^6 and negative HBeAg) will not receive tenofovir disoproxil fumarate therapy during or after pregnancy. Their infants will still receive monovalent HBV vaccine within 24 hours of life.
2854439|NCT03567369|Experimental|Dexamethasone|Dexamethasone 4,0 mg / mL
2854440|NCT03567369|Experimental|Traumeel S|Traumeel 2,2 mg / mL
2854441|NCT03567356|No Intervention|Treatment as Usual|TAU will contain patients who will be receiving treatment for opioid use disorder through their usual venues without the family engagement, assertive outreach, and home delivery of XRNTX doses.
2854442|NCT03567356|Experimental|MAT-Plus Intervention|"The intervention group will receive the multi-component MAT-PLUS treatment: 1) Significant other engagement through the Helping Hands approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing."
2854498|NCT03566966||Non-organ-specific Ab negative|Patients who did not have detectable circulating autoantibodies before treatment with antivirals.
2854530|NCT03566771|Active Comparator|CLOSS|Usual care plus using a web-based support system for self-monitoring weight, physical activity and communication with the clinic during 6 months
2854443|NCT03567343|Active Comparator|Proprietary Spearmint Extract Blend|"Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the Proprietary Spearmint Extract Blend blend by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.~A subset of this group will undergo 2 overnight polysomnography studies"
2854444|NCT03567343|Placebo Comparator|Control|"Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the excipient, microcrystalline cellulose by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.~A subset of this group will undergo 2 overnight polysomnography studies"
2854445|NCT03567343|Active Comparator|Proprietary Blend And Melatonin|Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the proprietary spearmint extract blend and 1 Mg of melatonin by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.
2854446|NCT03567343|Active Comparator|Melatonin|Subjects randomized into the active treatment group will be asked to consume 1 Mg of melatonin by mouth every night 30 mins before bed and complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.
2854447|NCT03567330|Experimental|Experimental|Family-based attachment-focused intervention for families where parent/caregiver is within 12 months of first diagnosis of a stage I-III solid tumor cancer.
2854448|NCT03567330|Active Comparator|Psychoeducation|Provides equivalent number of American Cancer Society psychoeducational sessions.
2854449|NCT03567317|No Intervention|CPAP|According to study design, patients will be randomized to remain on CPAP during the initial study visit or withdraw CPAP one week before. If randomized to withdraw CPAP during the initial study visit, patients will resume CPAP use for one week before the second study visit.
2854450|NCT03567317|Experimental|CPAP withdrawal|According to study design, patients will be randomized to remain on CPAP during the initial study visit or withdraw CPAP one week before. If randomized to withdraw CPAP at the second study visit, patients will withdraw CPAP one week before.
2854451|NCT03567304|No Intervention|EFV-based|"HIV-infected patients, who has been taking efavirenz (EFV)-based regimen for at least 1 year and is diagnosed with asymptomatic neurocognitive impairment (ANI) or mild neurocognitive disease (MND) by neurocognitive battery tests, is randomized to continue EFV-based regimen.~EFV based regimen defines as efavirenz 600 mg per oral once daily (OD) + 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)."
2854452|NCT03567304|Experimental|RPV-based|"HIV-infected patients, who has been taking efavirenz-based regimen for at least 1 year and is diagnosed with asymptomatic neurocognitive impairment (ANI) or mild neurocognitive disease (MND) by neurocognitive battery tests, is randomized to switch antiretroviral therapy to rilpivirine (RPV)-based regimen.~RPV based regimen defines as rilpivirine 25 mg PO OD + 2 NRTIs."
2854453|NCT03567291|Experimental|TEV-50717|All patients will undergo TEV-50717 dose titration in this study. Patients will receive 6 mg of TEV-50717 with food on the evening of day 1. The titration scheme and maximum dose will be determined by body weight and cytochrome P450 2D6 (CYP2D6) impairment status from the parent study.
2854454|NCT03567291|Placebo Comparator|Placebo|Matching Placebo
2854455|NCT03567278|Experimental|ACURATE TA™|Patients implanted with ACURATE TA™ Bioprosthesis
2854456|NCT03567252|Experimental|Walking Group|Participants in this group will join an established walking group and travel by foot 1 kilometer to a local Farmer's Market. They will also receive handouts about nutrition information and nutritional choices.
2854457|NCT03567252|No Intervention|Non-Walking Group|Participants in this group will have no walking requirement. They will receive handouts about nutrition information and nutritional choices.
2854458|NCT03567239|Experimental|Using adaptive device|Participants will use a non-commercially available device, designed to meet their needs.
2854459|NCT03567226|Experimental|Intervention Group|The intervention group will be enrolled into a WeChat Group to receive reminders to exercise and health education materials.
2854460|NCT03567226|Active Comparator|Control Group|Controls will receive a handout telling them to increase walking and that walking may be helpful for the eye at the return visit.
2854461|NCT03567213|Experimental|Surgical implantation of the CortiCom system|
2854462|NCT03567200|Experimental|Single-Arm Feasibility|9-week, 1x/week, 90-minute face-to-face sessions.
2854463|NCT03567187|Experimental|Iovera|"The iovera° device consists of a reusable, portable hand-piece, along with a single-patient use sterile smart Tip (aka cryoprobe) and disposable nitrous oxide (N2O) cartridges. The smart tip is composed of three 6.9mm 27-gauge needles made of stainless steel, each of them closed-tip, thereby fully enclosing the cryogen. The cryogen is provided in a nitrous oxide cylinder attached to a custom filter, known as the cartridge. An integrated skin warmer is located at the base of the smart tip.~The iovera° device produces the desired effect through the initiation of a cooling cycle that lasts for 60 seconds. Each cooling cycle is initiated by fully inserting the smart tip into the selected procedure site and activating the cryogen flow. As the cryogen gas travels through the length of the needle, an ice ball develops around the needle causing the surrounding tissue to be frozen."
2854464|NCT03567174|Experimental|Integrated care van (ICV)|ICV visits neighborhoods served by the mobile syringe service program weekly. ICV provides a range of services targeted to people who inject drugs - HIV testing, HCV testing, PrEP, MAT, wound care, case work services, on-site medical management and linkage.
2854465|NCT03567174|No Intervention|Control|No additional services provided.
2854466|NCT03567161|Experimental|Cavitron ultrasonic surgical aspirator|"Patients.with periodontitis.~Inclusion criteria:~Having received a diagnosis of chronic periodontitis (Armitage 1999)~Being treated by full mouth debridement, and supportive periodontal treatment (SPT) in the last year (at least three sessions)~Having at least one residual pocket ≥ 5 mm with and intra bony component at least ≥ 2 mm~Exclusion criteria:~Smoking more than ten cigarettes per day~Pregnancy~Irregular compliance during SPT in the last year; and systemic conditions or therapies known to affect the healing potential of periodontal tissues (e.g., uncontrolled diabetes, oncological conditions, immunosuppressant drugs)."
2854467|NCT03567148|Active Comparator|PRF group|Four layers of PRF membranes were placed in the palatal wound and sutured with 5/0 resorbable sutures
2854468|NCT03567148|Active Comparator|Essix retainer group|An impression of palatal region was taken and the Essix retainer was prepared before the patients underwent surgery.
2854469|NCT03567148|Active Comparator|Ozone therapy group|Ozone was applied to the donor sites at five different points (four corner-points and a center point) at a fixed concentration of 2100 p.p.m. through a connected hand-piece, using a sterile, specially-formed perio-tip with 80% oxygen for 30 seconds. The applications were performed immediately after surgery and on the 1st, 3rd, and 7th days following the operation.
2854470|NCT03567148|Active Comparator|LLLT group|Irradiation was performed at the same points described above using a diode laser (λ=970±15 nm, 14-W source power) (SIROLaser Xtend; Sirona Dental Systems GmbH, Bensheim, Germany) that continuously emitted a wavelength with 320µm fiberoptic; the power was 2W and the tissue dose was 35 J/cm2. Total irradiation time was 30 seconds. The applications were performed immediately after surgery, and on the 1st, 3rd and 7th, days following the operation.
2854471|NCT03567148|Active Comparator|Collagen fleece group|Collagen fleece (BEGO Collagen Fleece, Bremen, Germany) was sutured with 5/0 resorbable sutures (Pegesorb, Istanbul, Turkey) on the open wound with the aid of vertical mattress sutures.
2854472|NCT03567148|No Intervention|Control group|Palatal wounds were left for spontaneous healing
2854473|NCT03567135||glioblastoma patients|"Subjects received anti-angiogenesis drugs simultaneous accompanied with radio-and chemotherapy in Fuzhou General Hospital since October, 2017;~Age: 18-70 years;~The first surgical pathology was diagnosed as glioblastoma, WHO grade IV;~Patients who have previously received no more than one surgical treatment;~ECOG performance status: 0-2;~Survival expectation≥3 months."
2854474|NCT03567122|Experimental|Internal Focus of Attention|30 subjects will be randomized to this arm. Only internal focus of attention feedback instructions will be given during the execution and training performing the Cranio-Cervical Flexion Test. The subjects allocated to this arm will not be allowed to use the visual feedback traditionally provided during the Cranio-cervical Flexion Test.
2854475|NCT03567122|Experimental|External Focus of Attention|30 subjects will be randomized to this arm. Only external focus of attention feedback instructions will be given during the execution and training performing the Cranio-Cervical Flexion Test. The subjects allocated to this arm will not be allowed to use the visual feedback traditionally provided during the Cranio-cervical Flexion Test. In addition, they will use just a laser point attached to the head to guide their cranio-cervical flexion.
2854476|NCT03567122|Active Comparator|Control|30 subjects will be randomized to this arm. The participants allocated to this arm will be instructed as traditionally during the Cranio-Cervical Flexion Test. They will be given visual feedback while have their attention guided to the inner neck movement.
2854477|NCT03567109||Shoulder rotator cuff tendinopathy|unilateral rotator cuff tendinopathy, 3 months or more duration, confirmed by imagery,
2854478|NCT03567109||chronic low back pain|non specific chronic (3 months) low back pain
2854479|NCT03567109||carpal tunnel syndrome|unilateral carpal tunnel syndrome, confirmed by electromyogram, 3 months or more duration
2854480|NCT03567109||control|healthy subjects
2854481|NCT03567096|Active Comparator|BiV+MPP|"Patients randomized to the BiV pacing with MPP and SyncAV study arm will have CRT programming to biventricular pacing with MPP activated. RV-LV pacing delay set to 5 ms, LV1 & LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration)."
2854482|NCT03567096|Experimental|LV-only + MPP|"Patients randomized to the  LV only pacing with MPP and SyncAV study arm will have CRT programming to left ventricular only pacing with MPP activated. LV1 & LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration)"
2854483|NCT03567083|Experimental|E-CAU with Problem Management Plus (PM+)|30 participants will be randomly assigned to E-CAU with PM+ group. The PM+ is developed by the World Health Organization (WHO) especially for the communities who are exposed to adversity. PM+ (Dawson et al., 2015) belongs to a set of programs which are low-intensity, shorter, less expensive and trans-diagnostic (i.e., not condition-specific, but targeted at a broader set of symptoms of common mental disorders) programs to reduce common mental health symptoms (including depression, anxiety and stress symptoms) and improve psychosocial functioning.
2854484|NCT03567083|No Intervention|Enhanced care as usual (E-CAU) only|30 participants will be randomly assigned to E-CAU group. CAU ranges from the free health services government provides to Refugee and Asylum Seekers Assistance and Solidarity Association's (RASASA) mental health services which are provided by the Psychological Support Unit (MHPSS Support Unit) which includes counselling as well. The enhanced care arm (CAU, with the addition of a referral document), is to be used as a benchmark for measuring the effectiveness of STRENGTHS's intervention, which is Problem Management Plus (PM+).
2854485|NCT03567070|Other|qualitative study based on an individual clinical interview|
2854486|NCT03567057|Experimental|ADS-5102|
2854487|NCT03567044|Experimental|Blood Collection|Patients will be asked to have blood draws at specific time points during their whole breast irradiation.
2854488|NCT03567031|Experimental|Main Arm|In each patient, under ongoing standard general anesthesia in a stable state, EtCO2 is manually modified to reach predefined values, and after waiting until cerebral blood flow has reached steady state, NIRS and DTC values are noted.
2854489|NCT03567018|Experimental|Healthy volunteer population|We plan to enroll 25 healthy volunteers.
2854490|NCT03567018|Experimental|Patient population|We plan to enroll 50 clinical patients who are receiving flap procedures at the Ohio State Medical Center.
2854491|NCT03566992|Active Comparator|Gastric Tube Placement|Nasoenteric tube placed in the stomach.
2854492|NCT03566992|Experimental|Small bowel|Nasoenteric tube placed in the small bowel.
2854493|NCT03566979|Experimental|Test naproxen sodium tablet|Single dose of 440 mg of naproxen sodium administered as two Test Naproxen Sodium 220 mg tablets (Test NPX)
2854494|NCT03566979|Active Comparator|Commercial naproxen sodium tablet|Single dose of 440 mg of naproxen sodium administered as two commercial naproxen sodium 220 mg tablets
2854495|NCT03566979|Active Comparator|Commercial naproxen sodium liquid gels capsule|Single dose of 440 mg of naproxen sodium administered as two 220 mg commercial liquid gels capsules
2854496|NCT03566979|Placebo Comparator|Placebo tablet|Single dose of two Placebo tablets
2854497|NCT03566966||Non-organ-specific Ab positive|Patients who had detectable circulating autoantibodies before treatment with antivirals.
2854533|NCT03566732||Bereaved relatives|Bereaved relatives after cancer deaths in hospitals
2854499|NCT03566940|Experimental|Group 1: Low Dose IPV Based on Sabin Strains (sIPV)|Participants will receive intramuscular (IM) injection of the low dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of conventional Salk IPV (cIPV) at approximately 24 weeks after the third vaccination (38 weeks of age).
2854500|NCT03566940|Experimental|Group 2: Intermediate Dose sIPV|Participants will receive IM injection of the intermediate dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
2854501|NCT03566940|Experimental|Group 3: High Dose sIPV|Participants will receive IM injection of the high dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
2854502|NCT03566940|Active Comparator|Group 4: Conventional Salk IPV (cIPV)|Participants will receive IM injection of cIPV (3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
2854503|NCT03566927|Experimental|FLEX Scoring Catheter plus DCB|This is a single-arm study. All patients will be treated with the FLEX Scoring Catheter, then a standard balloon angioplasty, followed by a Lutonix® drug-coated balloon (DCB).
2854504|NCT03566914|Experimental|Tadalafil|Tadalafil 10 mg once daily per oral for 3 months
2854505|NCT03566914|Placebo Comparator|Placebo|Tablet placebo once daily per oral for 3 months
2854506|NCT03566901|Experimental|Robot-Assisted Stair Climbing Training|Each session will consist of the G-EO System training and stretching exercises. Total net treatment time/session: 50 minutes. Physiotherapists will alter constraints to grade tasks according to patient ability. The training complexity will be increased, as the patient will improve in performance (i.e. increasing gait speed, reducing body weight support, increasing the number of repetition). Heart rate during training sessions will be monitored using a Polar V800. Heart rate will not exceed the threshold of 120 bpm.
2854507|NCT03566901|Active Comparator|Conventional Physiotherapy|50 min of overground walking training and stair climbing up/down and lower limb mobilization and stretching exercise.
2854508|NCT03566888||Single Group|85 eligible study participants
2854509|NCT03566875|Experimental|Total knee arthroplasty with the Stryker's MAKO™ system|The total knee arthroplasty is performed with Stryker's MAKO™ robotic system. It allows to place precisely the prosthetic implants.
2854510|NCT03566875|Active Comparator|Total knee arthroplasty with mechanical ancillary|The total knee arthroplasty is performed using a mechanical ancillary. It's the conventional method.
2854511|NCT03566862||Lung cancer|Individuals with confirmed diagnosis of lung cancer including disease in the lungs and an active cough.
2854512|NCT03566862||COPD|Individuals with a confirmed diagnosis of COPD according to established criteria.
2854513|NCT03566862||Other (non-COPD) chronic lung disease|Individuals with a confirmed diagnosis of non-COPD chronic lung disease (e.g. pulmonary fibrosis, asthma).
2854514|NCT03566862||Normal smokers|Individuals who have presented with cough but who appear to have 'healthy' lungs (i.e. COPD, other chronic lung disease and lung cancer have been excluded after clinical assessment).
2854515|NCT03566849|Experimental|KC group|It mainly involve all segment in kinetic chain, not only shoulder girdle, include exercise training 3 times a week for a total 4 weeks.
2854516|NCT03566849|Experimental|CT group|It involve shoulder girdle only, include exercise training 3 times a week for a total 4 weeks.
2854517|NCT03566836||AF Detection|Participants will be asked to wear the Garmin smart watch and Garmin chest band. Both are commercially available. The devices will collect information about heart rates before and after a cardioversion procedure.
2854518|NCT03566823|Experimental|SHP647 25 mg|Participants will receive 25 mg of SHP647 subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
2854519|NCT03566823|Experimental|SHP647 75 mg|Participants will receive 75 mg of SHP647 subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
2854520|NCT03566823|Placebo Comparator|Placebo|Participants will receive placebo matching with SHP647 subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
2854521|NCT03566810|Experimental|First Test GXR (Fasting), Then Reference GXR (Fasting)|Participants will receive single oral dose of GXR tablet manufactured in Merck Nantong China (Test Drug) in fasting state in Treatment Period 1 followed by GXR tablet manufactured in Merck Darmstadt Germany (Reference Drug) in fasting state in Treatment Period 2. The two doses will be separated by a 7-day wash-out period.
2854522|NCT03566810|Experimental|First Reference GXR (Fasting), Then Test GXR (Fasting)|Participants will receive single oral dose of GXR tablet manufactured in Merck Darmstadt Germany (Reference Drug) in fasting state in Treatment Period 1 followed by GXR tablet manufactured in Merck Nantong China (Test Drug) in fasting state in Treatment Period 2. The two doses will be separated by a 7-day wash-out period.
2854523|NCT03566810|Experimental|First Test GXR (Fed), Then Reference GXR (Fed)|Participants will receive single oral dose of GXR tablet manufactured in Merck Nantong China (Test Drug) in fed state in Treatment Period 1 followed by GXR tablet manufactured in Merck Darmstadt Germany (Reference Drug) in fed state in Treatment Period 2. The two doses will be separated by a 7-day wash-out period.
2854524|NCT03566810|Experimental|First Reference GXR (Fed), Then Test GXR (Fed)|Participants will receive single oral dose of GXR tablet manufactured in Merck Darmstadt Germany (Reference Drug) in fed state in Treatment Period 1 followed by GXR tablet manufactured in Merck Nantong China (Test Drug) in fed state in Treatment Period 2. The two doses will be separated by a 7-day wash-out period.
2854525|NCT03566797||SC-CIP|Patients developing SC-CIP
2854526|NCT03566797||noSC-CIP|Patients with similar severity of critical illness not developing SC-CIP
2854527|NCT03566784||Electrocoagulation|Patients will undergo a standard procedure for inguinal hernia repair, with the use of electrocoagulation.
2854528|NCT03566784||No electrocoagulation|Patients will undergo a standard procedure for inguinal hernia repair, without the use of electrocoagulation.
2854529|NCT03566771|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic during 6 months
2854531|NCT03566745||Study group|Patients with mutation in AhR gene - presumed low Blood for protein activity
2854541|NCT03566680|Experimental|Orthokeratology Group|All subjects will be fit in orthokeratology contact lenses.
2854542|NCT03566667|Active Comparator|Metoprolol|Metoprolol at an aimed dose of 100 mg in addition to usual standard care
2854543|NCT03566667|Other|Standard care|Usual standard care
2854544|NCT03566654|Experimental|remote ischemic conditioning|Receiving remote ischemic conditioning (RIC) treatment with pressure set at 200 mmHg.
2854545|NCT03566654|Sham Comparator|placebo remote ischemic conditioning|Receiving sham RIC treatment with pressure set at 50~60 mmHg
2854546|NCT03566641|Experimental|Negative pressure wound therapy|This group of patients will receive negative pressure wound therapy (prevena) as their postoperative wound care method.
2854547|NCT03566641|Active Comparator|standard care dressing|This group of patients will receive standard care dressing as their postoperative wound care method.
2854548|NCT03566628|Experimental|Warmed Saline|Patients allocated to this arm will receive a warmed (39ºC) solution of up to 500mL of isotonic saline. This solution will be administered directly to the cerebral vasculature as part of the angiography.
2854549|NCT03566628|Active Comparator|Room-Temperature Saline|Patients allocated to this arm will receive isotonic saline at room temperature. This solution will be administered directly to the cerebral vasculature as part of the angiography.
2854550|NCT03566615|Active Comparator|Water|Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
2854551|NCT03566615|Experimental|CAP-straight|A straight transparent cap was fitted to the colonoscope per manufacturer instruction.Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
2854552|NCT03566615|Experimental|CAP-daisy|A daisy cap transparent cap was fitted to the colonoscope per manufacturer instruction.Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
2854553|NCT03566602|Other|Dura Sealant Path|Application of Dura Sealant Patch after closure of the dura mater
2854554|NCT03566589|Experimental|PS128|daily ingestion of Lactobacillus plantarum PS128 capsules
2854555|NCT03566576|Experimental|Anlotinib Plus Pemetrexed|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: Anlotinib 8mg per day and Pemetrexed. Cohort 2: Anlotinib 10mg per day and Pemetrexed. Cohort 3: Anlotinib 12mg per day and Pemetrexed.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
2854556|NCT03566576|Experimental|Anlotinib Plus Docetaxel|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: Anlotinib 8mg per day and Pemetrexed. Cohort 2: Anlotinib 10mg per day and Pemetrexed. Cohort 3: Anlotinib 12mg per day and Pemetrexed.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
2854557|NCT03566563||Ex-Drug Users|These are ex drug users residing at halfway houses
2854558|NCT03566550||CF|people with cystic fibrosis
2854559|NCT03566550||Control|people without cystic fibrosis
2854560|NCT03566537||Cases|Patients who are going to undergo a thyroid surgery due to symptomatic non-toxic multinodular goiter, uncontrolled thyrotoxicosis or suspicious FNA
2854561|NCT03566537||Controls|Patients with benign thyroid disease, not undergoing thyroidectomy
2854562|NCT03566524|Experimental|Arginine|In this experimental arm, 13 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary arginine for 21 days. Arginine will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The arginine will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
2854563|NCT03566524|Active Comparator|Citrulline|In this arm, 13 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary citrulline for 21 days. Citrulline will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The citrulline will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
2854564|NCT03566524|Placebo Comparator|alanine|In this arm, 13 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary alanine for 21 days. Alanine will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The alanine will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
2854565|NCT03566511|Experimental|Healthy (Diazoxide)|Proglycem, oral suspension (4-6 mg/kg). Healthy participants will receive diazoxide between MRI scans.
2854566|NCT03566511|Placebo Comparator|Healthy (Placebo)|Taste-matched placebo. Healthy participants will receive placebo between MRI scans.
2854567|NCT03566511|Experimental|T2D (Diazoxide)|Proglycem, oral suspension (4-6 mg/kg). Type 2 diabetic (T2D) participants will receive diazoxide between MRI scans.
2854568|NCT03566511|Placebo Comparator|T2D (Placebo)|Taste-matched placebo. T2D participants will receive placebo between MRI scans.
2854569|NCT03566498|Experimental|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements.
2854790|NCT03564990|Sham Comparator|conventional approach|conventional follow-up with oral healthy education
2854570|NCT03566498|Active Comparator|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
2854571|NCT03566485|Experimental|Arm I (atezolizumab, cobimetinib)|Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2854572|NCT03566485|Experimental|Arm II (atezolizumab, idasanutlin)|Participants without TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and idasanutlin PO daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2854573|NCT03566459||MAT|Veteran with opioid use disorder (OUD) receiving MAT using telemedicine
2854574|NCT03566459||No MAT|Veteran with opioid use disorder receiving other tx
2854575|NCT03566446|Experimental|36 aminoacid CALR exon 9 mutated peptide|15 vaccines, over the course of 1 year
2854576|NCT03566433|Active Comparator|TEP|Routine total extraperitoneal technique surgery for inguinal hernia
2854577|NCT03566433|Active Comparator|Lichtenstein|Routine lichtenstein surgery for inguinal hernia
2854578|NCT03566407|Other|Single Group|This is a prospective, longitudinal descriptive study of subjects with diagnosed Crohn's disease. Blood samples for measurement of protein biomarkers (serology), fresh whole blood for detection of gene polymorphisms, and stool samples for detection and assessment of microbiome and host DNA will be collected, and colonoscopy will be performed.
2854579|NCT03566394|Experimental|Prophylactic Gabapentin|Gabapentin at a dose of 300mg three times a day for 2 days before and 5 days after each taxane infusion. Administered orally.
2854580|NCT03566394|No Intervention|Observation|
2854581|NCT03566381||Healthy adults|Healthy adults without a history of medical or surgical problems
2854582|NCT03566368||Study Group|Isolated Traumatic Brain Injury Patients requiring emergency surgical intervention.
2854583|NCT03566355|Experimental|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
2854584|NCT03566342||GROUP A|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 8ml Lockout ( number of doses per hour) 2 Lock out interval 30 minutes
2854585|NCT03566342||GROUP B|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 5ml Lockout ( number of doses per hour) 4 Lock out interval 15 minutes
2854586|NCT03566342||GROUP C|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 3ml Lockout ( number of doses per hour) 6 Lock out interval 10 minutes
2854587|NCT03566342||GROUP D|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 14 ml/hour Demand dose 0 ml Lockout ( number of doses per hour) 0 Lock out interval 0 minutes
2854588|NCT03566342||GROUP E|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 7ml Lockout ( number of doses per hour) 3 Lock out interval 20 minutes
2854589|NCT03566329|Active Comparator|Magnesium sulphate|50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion
2854590|NCT03566329|Active Comparator|lidocaine hydrochloride|1.5mg/kg loading followed by 2mg/kg/hr infusion
2854591|NCT03566329|Placebo Comparator|NaCl 0.9% normal saline|Normal saline infusion with the same rate as the study drugs
2854592|NCT03566316|Experimental|Telmisartan/Amlodipine+Rosuvastatin|Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin 20mg1tab. and Telmisartan placebo 1tab.
2854593|NCT03566316|Active Comparator|Telmisartan/Amlodipine|Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin placebo 1tab. and Telmisartan placebo 1tab.
2854594|NCT03566316|Active Comparator|Telmisartan +Rosuvastatin|Telmisartan/Amlodipine placebo 2tab., Rosuvastatin 80mg 1tab. and Telmisartan 20mg 1tab.
2854595|NCT03566303|Active Comparator|Rivaroxaban|Rivaroxaban 15mg BID
2854596|NCT03566303|Placebo Comparator|Warfarin|Warfarin dose adjusted
2854597|NCT03566290|Experimental|Open-Label Extension, 3 mg GTx-024|Eligible subjects from G201002
2854598|NCT03566277|Experimental|Single-arm trial|All participants will undergo each of three conditions during the study.
2854599|NCT03566264||Participants hospitalized with ADHF|
2854600|NCT03566251|Experimental|Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS, Expanded Sisability Status Scale range of 0.5-4 who are able to walk independently.
2854601|NCT03566251|No Intervention|Healthy individuals|29 healthy volunteers with matching ages and genders
2854602|NCT03566238|Experimental|A4250 low dose|Capsules for oral administration (40 ug/kg) once daily for 24 weeks
2854603|NCT03566238|Experimental|A4250 high dose|Capsules for oral administration (120 ug/kg) once daily for 24 weeks
2854604|NCT03566238|Placebo Comparator|Placebo|Capsules for oral administration (to match active) once daily for 24 weeks
2854605|NCT03566225|Active Comparator|Group A|Pioglitazone in adose 30 mg tablet will be administered dialy+ clomiphene citrate as ovulation induction
2854606|NCT03566225|Placebo Comparator|Group B|Metformin in adose 1500 mg dialy will be administered + clomiphene citrate
2854607|NCT03566212||conventional syringe|Individuals requiring local anesthesia for dental treatment were treated in first group by using conventional syringe.
2854608|NCT03566212||camouflaged syringe|Individuals requiring local anesthesia for dental treatment were treated in second group by using camouflage syringe.
2854609|NCT03566199|Experimental|Treatment (MTX110)|Participants receive panobinostat nanoparticle formulation MTX110 IT by CED infusion on day 1 or days 1 and 2 as determined by dose level. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
2854610|NCT03566186|Experimental|Active phototherapy group|(n=12) Phase 2 training + active phototherapy Dosage applied was 30J per site (180J per muscle) to six sites on the quadriceps The MR4 LaserShower 50 4D emitter (MultiRadiance Medical, USA). The optical power was calibrated before irradiationin each participant using a Thorlabs thermal power meter(Model S322C, Thorlabs, Newton, NJ, USA).
2854611|NCT03566186|Placebo Comparator|Placebo group|(n=14) Phase 2 training + placebo phototherapy group
2854613|NCT03566160|Experimental|Cryobiopsy probe as a tool for biopsy|'Cryobiopsy probe, administered to study participants' . Testing the efficacy of a novel cryobiopsy probe in acquiring tissue samples.
2854614|NCT03566147|Experimental|low dose group|300,000 HuRPE cells
2854615|NCT03566147|Experimental|middle dose group|500,000 HuRPE cells
2854616|NCT03566147|Experimental|high dose group|1,000,000 HuRPE cells
2854617|NCT03566134|Placebo Comparator|Placebo|DA-8010 placebo + Solifenacin succinate placebo
2854618|NCT03566134|Experimental|DA-8010 2.5mg|DA-8010 2.5mg + Solifenacin succinate placebo
2854619|NCT03566134|Experimental|DA-8010 5mg|DA-8010 5mg + Solifenacin succinate placebo
2854620|NCT03566134|Active Comparator|Solifenacin 5mg|DA-8010 placebo + Solifenacin succinate 5mg
2854621|NCT03566121|Other|Continent women|Women with ICI-Q=0 Pelvic ultrasound / Urodynamic ultrasound
2854622|NCT03566121|Experimental|Incontinent women|Women with ICI-Q≥1 Pelvic ultrasound / Urodynamic ultrasound
2854623|NCT03566108|Active Comparator|Vestibular incision supraperiosteal tunnel access (VISTA)|VISTA incision to allow for coronally advanced flap and placement of acellular dermal matrix (ADM) graft
2854624|NCT03566108|Active Comparator|Sulcular Tunnell access|Sulcular tunnel access incision to allow for coronally advanced flap and placement of acellular dermal matrix (ADM) graft
2854625|NCT03566095|Active Comparator|Coaching and Voices for Food Kit|The treatment communities received community coaching from an Extension Professional or Educator in the use of the Voices for Food kit.
2854626|NCT03566095|Sham Comparator|Voices for Food Kit|The comparison community received the Voices for Food kit.
2854627|NCT03566082||Post Approval Study|"The PAS cohort consisted of 137 subjects who were implanted with the R3 delta Ceramic Acetabular System (DoD) in the pivotal study. These patients will continue to be followed to 10 years post-operatively.~The primary endpoint for the PAS study is implant survivorship at 10 years post study procedure."
2854628|NCT03566069|Experimental|Experimental Group|After a double-blind rabdomization, patients allocated to the experimental group will be followed for four weeks beginning at the start of their hospitalization, after signing a consent form. After completing baseline self-report measurements, they will be assessed for the severity of their symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal OT will be administered twice a day (at 08:00 a.m. and at 17:00 p.m.). The experimental group will receive - 32IU (16IU*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water. OT will be inhaled in two sprays, one in each nostril.The substance for both study groups will be prepared in the hospital pharmacy, (in identical bottles), after randomization that will be conducted by the pharmacist. A month post intervention, patients will complete self-report measurements as part of a follow-up evaluation.
2854629|NCT03566069|Placebo Comparator|Placebo Group|After a double-blind rabdomization, patients allocated to the placebo group will be followed for four weeks beginning at the start of their hospitalization, after signing a consent form. After completing baseline self-report measurements, they will be assessed for the severity of their symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal Placebo will be administered twice a day (at 08:00 a.m. and at 17:00 p.m.). The placebo group will receive - 32IU (16IU*2) of Sorbitol, Benzyl, alcohol glycerol, distilled water, meaning all ingredients except for the OT and will be inhaled in two sprays, one in each nostril.The substance for both study groups will be prepared in the hospital pharmacy, (in identical bottles), after randomization that will be conducted by the pharmacist. A month post intervention, patients will complete self-report measurements as part of a follow-up evaluation.
2854630|NCT03566043|Experimental|Dose 1|1.3x10^10 GC/g brain mass of RGX-121
2854631|NCT03566043|Experimental|Dose 2|6.5x10^10 GC/g brain mass of RGX-121
2854632|NCT03566030||Tenofovir Disoproxil Fumarate 300 mg QD|Administered Tenofovir Disoproxil Fumarate 300 mg QD
2854633|NCT03566030||Tenofovir Alafenamide|Administered Tenofovir Alafenamide 25 mg QD
2854634|NCT03566017|Experimental|Experimental open label|pegunigalsidase alfa
2854635|NCT03566004|Other|endoscoped patients|Patients addressed for endoscopy with indication of biopsies for H. pylori detection will be enroled to provide stool specimen
2854636|NCT03565991|Experimental|Combination of avelumab and talazoparib|Single arm open label
2854637|NCT03565978|Experimental|BAMA solution|This group will use BAMA solution. This is an digital solution used for cardiac post-discharge management. It is an application installed on a tablet. This arm will use this application and also have usual outpatient follow up.
2854638|NCT03565978|No Intervention|Usual care|Not using the application installed on the tablet. Usual outpatient follow up.
2854639|NCT03565965|Experimental|Experimental Group (EG)|The Experimental training (ET) consists of 10 sessions with 4 blocks of MP (GMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
2854640|NCT03565965|Active Comparator|Control Group (CG)|The Control training (CT) consists of 10 sessions with 4 blocks of MP (nGMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
2854641|NCT03565952|Experimental|Cranial massage|Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.
2854642|NCT03565952|Active Comparator|Control Group|The control group does not receive treatment.
2854643|NCT03565939|Active Comparator|Trichuris suis ova (TSO)|7500 TSO suspension, orally every second week for 24 weeks.
2854644|NCT03565939|Placebo Comparator|Placebo|Solution without TSO orally every second week for 24 weeks
2854645|NCT03565926|Active Comparator|Manual Therapy|"Manual Therapy Protocol~Articulation technique L4-S1~Lumbar neuromuscular technique~Fascial technique of crossed hands~Posteroanterior mobilizations of the lumbar vertebrae"
2854646|NCT03565926|Experimental|Hypopressive exercises|Protocol of 5 Hypopressive Exercises
2854647|NCT03565913|Experimental|EffCaMgCit|Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
2854648|NCT03565913|Active Comparator|CaAcS|Patients in the CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate) per day.
2854791|NCT03564977|Experimental|CD19-targeted CAR-T cells|
2854649|NCT03565900|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1, Day 30 and Day 60 and a single 0.5 mL IM injection of PNEUMOVAX™23 at 12 months after HSCT. Participants will have received HSCT 90 to 180 days prior to Day 1. Those who develop chronic graft-versus-host-disease (GVHD) during the first year after HSCT will receive V114 instead of PNEUMOVAX™23 as their fourth dose.
2854650|NCT03565900|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1, Day 30 and Day 60 and a single 0.5 mL IM injection of PNEUMOVAX™23 at 12 months after HSCT. Participants will have received HSCT 90 to 180 days prior to Day 1. Those who develop chronic GVHD during the first year after HSCT will receive Prevnar 13™ instead of PNEUMOVAX™23 as their fourth dose.
2854651|NCT03565887|Experimental|RVL-1201 ophthalmic solution 0.1%|RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
2854652|NCT03565887|Placebo Comparator|Vehicle ophthalmic solution|Vehicle placebo ophthalmic Solution
2854653|NCT03565874|Experimental|Heart Rate Variability Biofeedback|HRVB program conducted over the course of 2 weeks of individual daily exercises for 20 minutes per day.
2854654|NCT03565861|Placebo Comparator|Placebo|Placebo intravenous 30 minute infusion on day 1
2854655|NCT03565861|Experimental|NP10679 5 mg|NP10679 5 mg intravenous infusion on day 1
2854656|NCT03565861|Experimental|NP10679 15 mg|NP10679 15 mg intravenous infusion on day 1
2854657|NCT03565861|Experimental|NP10679 50 mg|NP10679 50 mg intravenous infusion on day 1
2854658|NCT03565861|Experimental|NP10679 100 mg|NP10679 100 mg intravenous infusion on day 1
2854659|NCT03565861|Experimental|NP10679 200 mg|NP10679 200 mg intravenous infusion on day 1
2854660|NCT03565861|Experimental|NP10679 300 mg|NP10679 300 mg intravenous infusion on day 1
2854661|NCT03565848||Women underwent colorectal resection for endometriosis|Women referred for colorectal resection for deep infiltrating endometriosis that underwent laparoscopic segmental colorectal resection performed with mesenteric vascular and nerve sparing surgery.
2854662|NCT03565835|Experimental|Abiraterone and Prednisone without a GnRH Analogue|Abiraterone (1000 mg daily) with Prednisone (5 mg) with Discontinuation of GnRH Analogue Injection
2854663|NCT03565822|Other|interview|There are two data collection phases (individual interviews +/- focus groups) with parents of children with esophageal atresia, congenital diaphragmatic hernia or short bowel syndrome.
2854664|NCT03565809||Case : ADRS group|"Incidence analysis in ADRS group defined by the first recording of one of the following criteria: (i) LTD registration for ADRS (ICD-10 codes: F00-F03, G30, or G31), (ii) hospital stay reporting a diagnosis code of ADRS (similar ICD-10 codes) or (iii) reimbursement for at least one acetylcholinesterase inhibitor (rivastigmine, galantamine or donepezil) or memantine."
2854665|NCT03565809||Control : non ADRS Group|Incidence analysis in non ADRS group. Each incident ADRS case was paired (1:1) to a beneficiary without any ADRS criteria, matched on age (same birth year), sex, residence area (based on of the 100 administrative 'départements') and insurance scheme.
2854666|NCT03565796|Experimental|Group A|Personalized active referral plus financial incentive+ AWARD advice + referral card + warning leaflet+ COSH booklet
2854667|NCT03565796|Experimental|Group B|AWARD advice + COSH booklet
2854668|NCT03565783|Experimental|REGN2810|
2854669|NCT03565770|Experimental|standard care + coaching|minor patients with a type 1 diabetes, having therapy adjustment difficulties, receiving individual coaching and usual standard care
2854670|NCT03565770|Sham Comparator|Standard care|minor patients with a type 1 diabetes, having therapy adjustment difficulties, receiving usual standard care only.
2854671|NCT03565757|Experimental|SMART intervention|90-minute SMART small group session
2854672|NCT03565744|Experimental|Group 1 - B'N Fit POWER|Participants enrolling in B'N Fit POWER afterschool program will be assigned to Group 1.
2854673|NCT03565744|No Intervention|Group 2 - Standard of Care|All other PS/MS-95 participants who completed the screening (approximately 50) will be in comparison Group 2
2854674|NCT03565744|No Intervention|Group 3 - Standard of Care|Participants at an additional school site completing the screening (approximately 100) will be in an additional comparison Group 3.
2854675|NCT03565731|Experimental|ACT-PA Intervention|The primary goal of the intervention is to increase values-based autonomous motivation to increase bout-related MVPA using a single workshop. Participants will engage in basic and advanced values clarification exercise to help clarify (1) the relative importance of major values domains (e.g. social, vocational, recreational), and (2) the potential role of PA in empowering functioning in these domains. Participants will generate their own activity goals and additional values-based goals. In addition, acceptance strategies will be taught to reduce cognitive and emotional barriers to meeting values-based goals. Participants will be asked to report progress on goals each week via an automated email survey from a secure project website. Upon completing the survey, participants will receive standardized responses via email. Monthly phone calls will be brief, semi-structured, and designed to review key principles and trouble-shoot specific barriers identified by the participant.
2854676|NCT03565718|Active Comparator|Standard Group|Participants in this group will receive counseling, informational materials, and recipes for following a vegan diet. Participants in this group will receive gift cards to go shopping at their local supermarkets and follow the diet for 3 weeks. At the end of the 3 week period each participant will have a follow-up meeting and provide feedback to the study personnel. The Dietary Intervention: Standard/Grocery includes intervention meetings and dietary counseling.
2854677|NCT03565718|Experimental|Restaurant Group|"Participants in this group will receive counseling, informational materials, and recipes for following a vegan diet. Participants in this group will receive gift cards to go and eat out a few times a week at local vegan soul food restaurants and follow the diet for 3 weeks. At the end of the 3 week period each participant will have a follow-up meeting and provide feedback to the study personnel.~The Dietary Intervention: Restaurant condition includes intervention meetings and dietary counseling."
2854678|NCT03565705||Spinal anesthesia with propofol sedation|Patients receive spinal anesthesia for analgesia to undergo open abdominal prostatectomy. Ventilation is secured via a laryngeal mask under propofol sedation and no muscular blocking is necessary.
2854679|NCT03565705||General anesthesia|General anesthesia is conducted with a combination of intravenous opioid (sufentanil) and neuromuscular blocking agent for open abdominal prostatectomy. Patients receive an induction bolus of propofol, undergo tracheal intubation and maintenance of sedation by sevoflurane.
2854680|NCT03565692||Patients treated by LUMACAFTOR-IVACAFTOR|Patients over 12 years with double p.Phe508del mutations, who are currently able to benefit from LUMACAFTOR-IVACAFTOR and for whom conventional microbiological analysis of sputum samples will be collected during their follow-up once they will be treated by LUMACAFTOR-IVACAFTOR
2854681|NCT03565679|Experimental|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|Reference sensors from the reprocessed oximeter device will be placed on each subject to evaluate the SpO2 accuracy and performance.
2854682|NCT03565679|Sham Comparator|Reference CO-oximetery sensor|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
2854683|NCT03565666|Experimental|Test-Run Period|Eight adult participants (age ≥18 years) will use the iLet in the insulin-only configuration with Humalog or Novolog (using the iLet pigtail adapter, the iLet ready-to-fill insulin cartridge, the Contact Detach infusion set, and the Dexcom G5 CGM) for 7 days at a single site. The uncontrolled Test-Run Period will be completed and data reviewed to verify safety before proceeding with Transitional Study and with Adult RCT Period.
2854684|NCT03565666|Other|Adult RCT: Usual care|36 adult patients with type 1 diabetes will complete 3 arms in a random-order crossover fashion. Participants in the usual care arm (UC) will manage their diabetes with either multiple daily injections or continuous subcutaneous insulin infusion (pump therapy). All ubjects will wear Dexcom G5 continuous glucose monitor (CGM) and half of all subjects will also wear a senseonics CGM.
2854685|NCT03565666|Experimental|Adult RCT: closed-loop control with iLet Humalog or Novolog|Adult subjects will cross-over to the iLet in the insulin-only configuration with the iLet pigtail adapter and the iLet ready-to-fill insulin cartridge, the Contact Detach infusion set, the Dexcom G5 CGM, and the insulin analog that they use for their usual care (either Humalog or Novolog. Half of all subjects will also wear a senseonics CGM.
2854686|NCT03565666|Experimental|Adult RCT: closed-loop control with iLet using Fiasp|Adult subjects will cross-over to the iLet in the insulin-only configuration using the iLet pigtail adapter, the Contact Detach infusion set, the Dexcom G5 CGM, and faster insulin aspart (Fiasp) in PumpCart, where the pharmacokinetic (PK) parameter for tmax used by the insulin-dosing algorithm will be set to the same value as is used for Humalog and Novolog (65 minutes). Half of all subjects will also wear a senseonics CGM.
2854687|NCT03565666|Other|Pediatric Transitional Study: Usual Care arm|"The Pediatric Transitional Study Session will consist of a two-period, random-order, cross-over, pilot study in 20 pediatric participants 6-17 years old with T1D ~ 10 adolescent participants 12-17 years old and~ 10 pre-adolescent participants at 6-11 years old with type 1 diabetes. ). The two experimental periods will each span 5 days, including 4 nights (e.g. Monday-Friday). A washout period of ~ 3 days in duration will separate the two experimental periods of the Pediatric Transitional Study Session~In the usual care arm, participant's will manage their diabetes via their usual insulin regimen and will wear a Dexcom G5 CGM,"
2854688|NCT03565666|Experimental|Pediatric Transitional Study :iLet insulin only|Participants in this arm will be under closed-loop control with the iLet in the insulin-only configuration with the iLet pigtail adapter and the iLet ready-to-fill insulin cartridge, the Contact Detach infusion set, the Dexcom G5 CGM, and the insulin analog that they use for their usual care (either Humalog or Novolog).
2854689|NCT03565666|Other|Pediatric RCT Usual Care|"The Pediatric RCT Period will consist of a two-period, random-order, cross-over, study in 20 pediatric participants 6-17 years old with type 1 diabetes. The two experimental periods will each have a duration of 7 days. A washout period of approximately 7 days in duration will separate the two experimental periods of the Pediatric RCT Period. The washout period could be as short as 5 days or as long as 9 days depending on scheduling of study visits.~In the usual care period participants will manage their diabetes own usual care and will wear a Dexcom G5 CGM."
2854690|NCT03565666|Experimental|Pediatric RCT iLet Insulin only|Durring the iLet closed-loop period patients will use the iLet in the insulin-only configuration with the iLet pigtail adapter and the iLet ready-to-fill insulin cartridge, the Contact Detach infusion set, the Dexcom G5 CGM, and the insulin analog that they use for their usual care (either Humalog or Novolog).
2854691|NCT03565666|Experimental|Post-Study Transition to Usual Diabetes Management|For 48 hours after the last period of the RCT Period in both adults and pediatric participants is completed, there will be a small Post-Study Transition period. All adult and pediatric participants who complete the RCT Period on an intervention period will transition to their usual care (CSII or MDI) regimen following the recommendations of the bionic pancreas for 48 hours.
2854692|NCT03565653|Experimental|High dietary salt|For 10 days each, participants will be asked to eat a recommended sodium diets (2300 mg Na+/d) while taking unmarked pills containing uniodized table salt. On the 10th day, participants will report to the lab to complete 60 minutes of cycling exercise. Following exercise, participants will rest for 60 minutes while undergoing serial blood pressure measurements. Participants will then be outfitted with ambulatory blood pressure cuffs for assessment of blood pressure over the following 24 hours.
2854693|NCT03565653|Experimental|Placebo|For 10 days each, participants will be asked to eat a recommended sodium diets (2300 mg Na+/d) while taking unmarked pills containing a placebo (dextrose). Participants will complete both interventions in random order. On the 10th day, participants will report to the lab to complete 60 minutes of cycling exercise. Following exercise, participants will rest for 60 minutes while undergoing serial blood pressure measurements. Participants will then be outfitted with ambulatory blood pressure cuffs for assessment of blood pressure over the following 24 hours.
2854694|NCT03565640|Active Comparator|Capio Slim Device|Participants will be randomized to the sacrospinous ligament fixation with use of Capio Slim Device
2854695|NCT03565640|Experimental|Anchorsure Device|Participants will be randomized to the sacrospinous ligament fixation with use of Anchorsure Device
2854696|NCT03565627|Experimental|Exercise app|7 Minute Workout Challenge by Fitness Guide Inc.
2854697|NCT03565627|Experimental|Running App|One You Couch to 5K by Public Health England
2854698|NCT03565614|Experimental|Reablement rehabilitation|Reablement rehabilitation to maintain or increase the participants' physical, psychological and social functional abilities.
2854699|NCT03565614|Active Comparator|Traditional home care|The traditional home care and required rehabilitation efforts as by the municipality's current practice.
2854700|NCT03565601||Connective tissue disease patients with anti-Ro52|
2854789|NCT03564990|Experimental|interactive, multifaceted approach|A health education module consisting of a lecture and workshop was incorporated into a health-care course.
2854701|NCT03565588|Experimental|Education session with fixed incentive|Education sessions offered by a circumcised health worker and contribution towards transport costs to the health facility with payments conditional on being circumcised.
2854702|NCT03565588|Experimental|Education session with lottery incentive|Education sessions offered by a circumcised health worker and contribution towards transport costs but with conditional lottery financial incentives.
2854703|NCT03565588|No Intervention|Control arm|No intervention will be administered to the control arm
2854704|NCT03565575|Experimental|Interactive tablet-based quiz|Individuals participate in an interactive tablet-based risk perception and PrEP counselling information session.
2854705|NCT03565575|No Intervention|Control arm|No intervention will be administered to the control arm
2854706|NCT03565562|No Intervention|Control group|Local authorities allocated to this group won't implement any promotion of the e-health tool for the nine first months. Free access to StopBlues.
2854707|NCT03565562|Active Comparator|Group experimental 1 promotion|Local authorities allocated to this group will have to implement the promotion of the e-health tool: the promotion at the local authority level. They will promote the e-health tool using their usual communication methods (local newspapers, local website, bulletin and billboards, posters in the local shops and in the bus stops…). Free access to StopBlues.
2854708|NCT03565562|Active Comparator|Group experimental 2 promotion|Local authorities allocated to this group will have to implement promotion of the e-health tool: the promotion at local authority and GPs' waiting room level. Local authorities will promote the e-health tool using their usual communication methods (local newspapers, local website, bulletin and billboards, posters in the local shops and in the bus stops...). (similarly to group experimental1) as well as leaflets and posters in GPs' waiting room. Free access to StopBlues.
2854709|NCT03565549|Experimental|Mnemonic|Intervention group will receive a mnemonic aid to remember the CCHR
2854710|NCT03565549|Active Comparator|CCHR rule|The control group will receive the CCHR only
2854711|NCT03565536|Experimental|Nexavar neoadjuvant treatment group|"After the patient had diagnosed as anaplastic thyroid cancer, Nexavar was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.~operation for possible surgical treatment,with complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.~then External radiation therapy after surgery."
2854712|NCT03565523|Experimental|Test Beet shot|Containing 385 mg nitrate
2854713|NCT03565523|Placebo Comparator|Placebo beverage|<0.1 mmol nitrate in sucrose solution with beet coloring
2854714|NCT03565510|No Intervention|Control|Those assigned to the Control group will receive a diet composed of 55% of carbohydrate, 15% of protein, and 30% of lipid (similar to the North American dietary pattern).
2854715|NCT03565510|Experimental|High-Protein Diet|Those assigned to the High-Protein Diet group will receive a diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement.
2854716|NCT03565497|Placebo Comparator|Wellness Education Control Condition|The wellness education control condition (CC) is modeled after that used in our studies of exercise for smoking cessation, but delivered in an individual format. Content focuses on discussions of a variety of healthy lifestyle topics, such as healthy eating, time management, recommended health screenings, and cancer and cardiovascular prevention. Content is delivered using a combination of lectures, videos, handouts, and discussions while allowing participants to set their own realistic wellness goals, which they can gradually incorporate into their lives.
2854717|NCT03565497|Experimental|Mindfulness Training (MT)|Mindfulness training will be adapted for 6 individual sessions;elements include: (1) a body scan designed to teach participants to pay attention to specific parts of their bodies as a strategy to increase attentional capacities/reduce habitual mind-wandering; (2) non-judgmental awareness, and (3) 'awareness of breath' meditation, with an additional focus on helping participants become more aware of the present moment and refrain from habitually engaging in self-related pre-occupations concerning the future or the past.
2854718|NCT03565497|Experimental|Mindfulness Training Plus IE (MT+IE)|This condition will mirror the MT condition for the first 4 individual sessions, then for the final 2 individual sessions, MT will be rehearsed under conditions of sensations of anxiety/tension induced by interoceptive exposure procedures (IE).
2854719|NCT03565484|Experimental|Antimicrobial susceptibility testing guided therapy|"Patients in this group will receive a 14-day triple therapy for the Helicobacter pylori eradication. The regimen contains one proton pump inhibitor and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.two sensitive antibiotics: amoxicillin 1000mg bid for 14d, clarithromycin 500mg bid for 14d, metronidazole 500mg tid for 14d, tinidazole 500mg tid for 14d, levofloxacin 500mg qd for 14d, furazolidone 100mg bid for 14d, tetracycline 750mg bid for 14d."
2854720|NCT03565484|Experimental|Empirical tailored therapy|"Patients in this group will receive a 14-day bismuth based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and clarithromycin 500mg bid for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
2854721|NCT03565484|Other|Salvage therapy for negative culture|"When the culture results are negative, patients will receive 14-day empirical tailored therapy based on personal medication history.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and clarithromycin 500mg bid for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
2854722|NCT03565484|Other|Salvage therapy for failed eradication|"If patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 220mg bid for 14d 3.two antibiotics for second rescue therapy: tetracycline 500mg qid and furazolidone 100mg bid for 14d"
2860234|NCT03527095|Experimental|Regimen B|FDL169 200 mg testing tablet 1
2854723|NCT03565471||ASD patients with surgical closure|"Patients diagnosed with an ASD who have had a surgical closure of the defect more than 3 years ago.~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
2854724|NCT03565471||ASD patients with transcatheter closure|"Patients diagnosed with an ASD who have had a transcatheter closure of the defect more than 3 years ago.~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
2854725|NCT03565471||Controls|"Controls who do not have any cardiac or pulmonary diagnoses nor use prescription drugs that may affect the cardiopulmonary function.~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
2854726|NCT03565458|Experimental|gemigliptin|gemigliptin single dose
2854727|NCT03565458|Experimental|dapagliflozin|dapagliflozin single dose
2854728|NCT03565458|Experimental|gemigliptin and dapagliflozin|co-administration of gemigliptin and dapagliflozin
2854729|NCT03565458|Experimental|empagliflozin|empagliflozin single dose
2854730|NCT03565458|Experimental|gemigliptin and empagliflozin|co-administration of gemigliptin and empagliflozin
2854731|NCT03565445|Experimental|ASP1948 Dose Escalation|The monotherapy escalation cohort will evaluate escalating dose levels of ASP1948. Each dose level will enroll approximately 3 or 4 participants. Dose escalation to the next level will be made based on the Bayesian Continual Reassessment Method (CRM).
2854732|NCT03565445|Experimental|ASP1948 Dose Expansion|If a confirmed response (iRECIST partial response (iPR) or iRECIST confirmed response (iCR)) per iRECIST occurs in a monotherapy escalation cohort, a tumor specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been cleared. Up to 5 expansion cohorts may be opened.
2854733|NCT03565445|Experimental|ASP1948 Optional Retreatment Period|Participants may reinitiate study drug treatment after confirmation that they meet all the re-treatment eligibility criteria.
2854734|NCT03565432||IBD in KHUH|Registered patients with Inflammatory bowel disease at Kyung Hee University Hospital
2854735|NCT03565419|No Intervention|Control|Participants conduct the ultrasound-guided peripheral cannulation while they confirm real-time images displayed on the viewer next to the phantom.
2854736|NCT03565419|Experimental|Intervention|Participants conduct the ultrasound-guided peripheral cannulation wearing smart glasses. They confirm real-time images displayed on the viewer of smart glasses.
2854737|NCT03565406|Experimental|Unresectable Stage III or Stage IV Melanoma|
2854738|NCT03565393|Placebo Comparator|Fibersol-2|Receive Fibersol-2 twice daily
2854739|NCT03565393|Placebo Comparator|Placebo|Receive placebo twice daily
2854740|NCT03565380|Experimental|Patients with intervention|12-week community-based Tai Chi rehabilitation program starting at 12 weeks after TKA
2854741|NCT03565380|Experimental|Patients without intervention|usual post-operative care without outpatient physiotherapy,
2854742|NCT03565380|Experimental|Asymptomatic controls|untreated asymptomatic controls
2854743|NCT03565367|Experimental|Diagnostic (MRI, hyperpolarized carbon C 13 pyruvate MRSI)|Participants undergo MRI over 45 minutes at baseline. Participants then receive hyperpolarized carbon C 13 pyruvate IV over 30-40 seconds. Within 1 minute, participants undergo MRSI over 3 minutes and MRI over 10 minutes (participants may receive gadolinium at the discretion of the protocol director).
2854744|NCT03565354|Active Comparator|Treatment arm|intravenous iron isomaltose 3-10 weeks before operation date. The dose will be determined by the patient's body weight: > 50kg: 1000mg; <50kg: 20mg/kg body weight, to be infused over 30 minutes. 2 weeks after intravenous iron isomaltoside administration, blood test for hemoglobin level and iron profile would be repeated. Subjects with hemoglobin level less than 10g/dL will receive a second dose of intravenous iron isomaltoside. The second dose would be identical to the first dose
2854745|NCT03565354|No Intervention|Control arm|Patient randomized to the control arm will follow the standard perioperative care and the perioperative management they received will be identical to the treatment arm except no intravenous iron isomaltoside will be given.
2854746|NCT03565341|Experimental|Melasma|Treatment of Melasma Using PiQo4 Laser System
2854747|NCT03565328|Experimental|1|
2854748|NCT03565315|Experimental|Group 1|5 mg/kg SC; Day 0
2854749|NCT03565315|Experimental|Group 2|5 mg/kg SC; Day 0, Week 12, Week 24
2854750|NCT03565315|Experimental|Group 3|5 mg/kg SC; Day 0
2854751|NCT03565315|Experimental|Group 4|5 mg/kg SC; Day 0, Week 12, Week 24
2854752|NCT03565302|Placebo Comparator|Control|Subjects receive placebo treatment
2854753|NCT03565302|Experimental|Long acting beta2-agonist|Subjects are treated with long-acting beta2-agonist formoterol
2854754|NCT03565302|Experimental|Short acting beta2-agonist|Subjects are treated with short-acting beta2-agonist terbutaline
2854755|NCT03565289||All patients|All
2854756|NCT03565276|Experimental|Experimental: TXA|Intravenous Tranexamic Acid beginning at 5mg/kg administered as part of a dose-escalation design.
2854757|NCT03565263||FGID-IBD|"Patients aged 9-18 years~with inflammatory bowel disease (Crohns, ulcerative colitis or indeterminate colitis)~in remission (defined as: Physician's global assessment = remission, no nocturnal stools, no blood in stools, < or = 3 stools/day, C-reactive-protein < 10 mg/L, Erythrocyte sedimentation rate < 20 mm, no flare of disease or change of treatment in the last 3 months, no ongoing corticosteroid therapy~followed for IBD for at least 1 year~with at least one Functional Gastrointestinal disorder according to the Fr-qPGS questionnaire (Rome III criteria)"
2854758|NCT03565263||No FGID-IBD|"Patients aged 9-18 years~with inflammatory bowel disease (Crohns, ulcerative colitis or indeterminate colitis)~in remission (defined as: Physician's global assessment = remission, no nocturnal stools, no blood in stools, < or = 3 stools/day, C-reactive-protein < 10 mg/L, Erythrocyte sedimentation rate < 20 mm, no flare of disease or change of treatment in the last 3 months, no ongoing corticosteroid therapy~followed for IBD for at least 1 year~not a single Functional Gastrointestinal disorder according to the Fr-qPGS questionnaire (Rome III criteria)"
2854759|NCT03565250|Experimental|ADHD patients|children aged 8-12 ans with ADHD
2854760|NCT03565250|Active Comparator|control|children aged 8-12 ans without ADHD
2854761|NCT03565237|Experimental|All Study Participants|Study participants with Hemophilia B in India receiving Rixubis
2860235|NCT03527095|Experimental|Regimen C|FDL169 200 mg testing tablet 2
2854762|NCT03565224||Cespace|The patients have been operated with Cespace Titanium Coated PEEK Cage for Degenerative Disc Disease between 2014 and 2017. All patients are invited to the Hospital for Follow-Up. Depending on the date of Initial Intervention the timeframe of follow-up for the individual Patient is 1 to 4 years.
2854763|NCT03565211|Experimental|Progesterone vaginal ring (PVR)|
2854764|NCT03565185||End-effector|"For stroke rehabilitation 5 days a week in addition to conventional treatment methods robot-assisted gait training(end-effector type-Lokohelp) will be taken with 45 minutes a day for 3 days a week for 4 weeks.~Patients will be assessed with PASS, Rivermead mobility index, Barthel index and FAC in terms of baseline and ending for posture, mobility, daily life activities and ambulance level."
2854765|NCT03565185||Exoskeleton|"For stroke rehabilitation 5 days a week in addition to conventional treatment methods robot-assisted gait training (exoskeleton type-Robogait) will be taken with 45 minutes a day for 3 days a week for 4 weeks.~Patients will be assessed with PASS, Rivermead mobility index, Barthel index and FAC in terms of baseline and ending for posture, mobility, daily life activities and ambulance level."
2854766|NCT03565172|Experimental|Children with spastic cerebral palsy|"Children with spastic cerebral palsy will be included. They will have 3 phases:~Baseline: 4, 5 or 6 evaluations~Intervention: 9 evaluations before and after every stretching session~Follow-up: 4, 5 or 6 evaluations~The evaluation part will be composed of isokinetic dynamometer with ultrasound and Visual Analog Scale (VAS). The number of evaluations at baseline and follow-up will be randomized before the study by Single Case Experimental Design (SCED) methodology."
2854767|NCT03565159|Active Comparator|Prevenar 13|A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.
2854768|NCT03565159|Placebo Comparator|Sodium chloride 0.9%|A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.
2854769|NCT03565146|Experimental|Pigmentation|Treatment of Pigmented Lesions Using PiQo4 Laser System
2854770|NCT03565133|Experimental|Oral quinine, gastric placebo|Oral sham feeding of quinine and a gastric capsule containing placebo (cellulose)
2854771|NCT03565133|Experimental|Oral placebo, gastric quinine|Oral sham feeding of placebo (tap water) and a gastric capsule containing quinine
2854772|NCT03565133|Experimental|Oral quinine, gastric quinine|Oral sham feeding of quinine and a gastric capsule containing quinine
2854773|NCT03565133|Placebo Comparator|Oral placebo, gastric placebo|Oral sham feeding of placebo (tap water) and a gastric capsule containing placebo (cellulose)
2854774|NCT03565120|Experimental|Arm-R|patients in this arm will receive aggressive thoracic radiotherapy.
2854775|NCT03565107||Female Patients|ICSI treatment because of male subfertility
2854776|NCT03565094|Experimental|Lu AF28996|"Lu AF28996 solution, cohort depending dose~Cohort 1: single oral dose of Lu AF28996~Cohorts 2-6: two single ascending oral doses of Lu AF28996 with a washout in between~Possibility of 4 additional cohorts (Cohorts 7 to 10), allowing for the investigation of a potential 12 additional subjects"
2854777|NCT03565081|Experimental|PWS elastic band training group|Genetically confirmed diagnosis of PWS participants were recruited. The PWS participants needed to have sufficient command of the Mandarin language to understand the study information and motivated to conduct the training program.
2854778|NCT03565068|Experimental|Panel A (Healthy Participants): MK-8189|Healthy participants receive MK-8189 (4 mg oral tablet; once daily[QD]), titrated from 4 mg to 24 mg over the course of an 18-day treatment period as follows: Days 1-3: 1 tablet (4 mg total); Days 4-6: 2 tablets (8 mg total); Days 7-9: 3 tablets (12 mg total); Days 10-12: 4 tablets (16 mg total); Days 13-15: 5 tablets (20 mg total); Days 16-18: 6 tablets (24 mg total).
2854779|NCT03565068|Placebo Comparator|Panel A (Healthy Participants): Placebo|Healthy participants receive placebo (oral tablet; QD) over the course of an 18-day treatment period as follows: Days 1-3: 1 tablet; Days 4-6: 2 tablets; Days 7-9: 3 tablets; Days 10-12: 4 tablets; Days 13-15: 5 tablets; Days 16-18: 6 tablets.
2854780|NCT03565068|Experimental|Panel B (Schizophrenia Participants): MK-8189 Monotherapy|Participants with schizophrenia receive MK-8189 (4 mg oral tablet; QD) as a monotherapy, titrated from 4 mg to 24 mg over the course of an 18-day treatment period as follows: Days 1-3: 1 tablet (4 mg total); Days 4-6: 2 tablets (8 mg total); Days 7-9: 3 tablets (12 mg total); Days 10-12: 4 tablets (16 mg total); Days 13-15: 5 tablets (20 mg total); Days 16-18: 6 tablets (24 mg total).
2854781|NCT03565068|Placebo Comparator|Panel B (Schizophrenia Participants): Placebo Monotherapy|Participants with schizophrenia receive placebo (oral tablet; QD) as a monotherapy over the course of an 18-day treatment period as follows: Days 1-3: 1 tablet; Days 4-6: 2 tablets; Days 7-9: 3 tablets; Days 10-12: 4 tablets; Days 13-15: 5 tablets; Days 16-18: 6 tablets.
2854782|NCT03565068|Experimental|Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy|In combination with background atypical antipsychotic (AAP) treatment, participants with schizophrenia receive MK-8189 (4 mg oral tablet; QD) as add-on therapy, titrated from 4 mg to 24 mg over the course of an 18-day treatment period as follows: Days 1-3: 1 tablet (4 mg total); Days 4-6: 2 tablets (8 mg total); Days 7-9: 3 tablets (12 mg total); Days 10-12: 4 tablets (16 mg total); Days 13-15: 5 tablets (20 mg total); Days 16-18: 6 tablets (24 mg total).
2854783|NCT03565068|Placebo Comparator|Panel C (Schizophrenia Participants): Placebo Add-on Therapy|In combination with background AAP treatment, participants with schizophrenia receive placebo (oral tablet; QD) as add-on therapy over the course of an 18-day treatment period as follows: Days 1-3: 1 tablet; Days 4-6: 2 tablets; Days 7-9: 3 tablets; Days 10-12: 4 tablets; Days 13-15: 5 tablets; Days 16-18: 6 tablets.
2854784|NCT03565055|Experimental|IPCST|Intervention = Patients that participate in IPCST programme
2854785|NCT03565055|Active Comparator|E.A.S.Y|Treatment as usual = Patients of E.A.S.Y Programme in HK Kwai Chung Hospital
2854786|NCT03565042||MoA ustekinumab|Patients with a diagnosis of psoriatic arthritis according to the CASPAR criteria with at least one swollen knee or ankle joint who are planning to receive treatment with ustekinumab at the outpatient clinic. An arthroscopy will be done in the swollen knee/ankle at week 0, 12 and 24.
2854787|NCT03565029|Experimental|Medium/low locally advanced rectal cancer|Patients with Stage II (cT3-4 N0) or Stage III (cT1-4, N1-3) locally advanced rectal cancer amenable to Total Mesorectal Excision (TME)/Abdominal-Perineal Amputation
2854788|NCT03565003|Experimental|JAB-3068|JAB-3068 will be administered orally in the morning following a fast of approximately 6 hours before on PK collection. Patients will continue to fast for approximately 2 hours after the administration of JAB-3068. On non-PK days patients will fast approximately 2 hours before JAB-3068 and continue to fast for approximately 2 hours afterwards.
2854792|NCT03564951|Active Comparator|Control|ablation of Atrial fibrillation using spatio-temporal dispersion
2854793|NCT03564951|Experimental|Isochrone|ablation of concordance zones using isochrone and voltage maps
2854794|NCT03564938|Experimental|Regorafenib (Stivarga, BAY 73-4506)|Patients with metastatic colorectal cancer
2854795|NCT03564925|Active Comparator|Wide area circumferential ablation|Device:Smart Touch® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
2854796|NCT03564925|Experimental|Cryoballoon ablation|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
2854797|NCT03564912|Experimental|2 week group|
2854798|NCT03564912|Active Comparator|3 week group|
2854799|NCT03564899|No Intervention|control|Receive no physical activity intervention (maintain baseline physical activity participation)
2854800|NCT03564899|Experimental|Lighter intensity physical activity|Receive an intervention of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve for 12 weeks.
2854801|NCT03564899|Active Comparator|Higher intensity physical activity|Receive an intervention of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve for 12 weeks.
2854802|NCT03564886|Experimental|Hyperosmolar Saline|The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
2854803|NCT03564886|Placebo Comparator|Normal Saline|Lactate Ringer's (LR, 273mOsm/L) is commonly used at our facility as our isotonic standard irrigation solution and will serve as the control to be evaluated against a hyperosmolar (1.9%, 600mOsm) solution.
2854804|NCT03564873|Experimental|Phase I|Up to 18 patients will be enrolled to one of three cohorts to receive various doses of omacetaxine over a 28 day cycle. Azacitidine will be given at the standard dose over a 28 day cycle.
2854805|NCT03564873|Experimental|Phase II|Up to 33 patients will be enrolled to receive the maximum tolerated dose (determined in phase I) over a 28 day cycle. Azacitidine will be given at the standard dose over a 28 day cycle.
2854806|NCT03564860||HBP device data collection group|Device electrograms and 12-lead ECG will be collected from patients over the age of 18 years who have been previously implanted with a permanent His Bundle pacing lead and an Abbott pacemaker, defibrillator, or cardiac resynchronization therapy device during a standard-of-care device follow-up visit.
2854807|NCT03564847|Experimental|LTP Plus|LTP Plus Participants will receive the intervention over 4 months Weekly sessions for 2 months and fortnightly for next two months by trained non-specialists/community health workers.
2854808|NCT03564847|No Intervention|Treatment As Usual (TAU)|Treatment as Usual (TAU) group will receive routine care and their follow up will be done at 4th and 6th month post randomization.
2854809|NCT03564834|Experimental|Laparoscopic gastrectomy|A standard laparoscopic gastrectomy with D2 lymphadenectomy will be performed by two experienced surgeons, according to the Japanese Gastric Cancer Treatment Guidelines 2014 (version 4) and the Japanese Classification of Gastric Carcinoma (3rd English edition).
2854810|NCT03564834|Active Comparator|Open gastrectomy|A standard open gastrectomy with D2 lymphadenectomy will be performed by two experienced surgeons, according to the Japanese Gastric Cancer Treatment Guidelines 2014 (version 4) and the Japanese Classification of Gastric Carcinoma (3rd English edition).
2854811|NCT03564821|Experimental|Ivosidenib (500mg/day)|-Ivosidenib will be administered orally every day
2854812|NCT03564821|Experimental|Ivosidenib (250mg/day)|-Ivosidenib will be administered orally every day
2854813|NCT03564808|Experimental|Fat graft enriched with MSCs|Adipose tisse derrived MSCs
2854814|NCT03564808|Experimental|Fat graft only|Fat graft withiut enrichment with MSCs
2854815|NCT03564795|Experimental|KeraStat Gel|Each enrolled subject will have at least one eligible burn randomized to the KeraStat Gel arm. This burn will be dressed with KeraStat Gel and covered by a secondary dressing. Subjects will be instructed to change the dressing and re-apply the KeraStat Gel per the instructions for use (at least every 3 days).
2854816|NCT03564795|Active Comparator|Silver Sulfadiazine|Each enrolled subject will have at least one eligible burn randomized to the Silver Sulfadiazine arm. This burn will be dressed with the Silver Sulfadiazine and covered by a secondary dressing. Subjects will be instructed to change the dressing and re-apply the Silver Sulfadiazine per the institution's Standard of Care instructions.
2854817|NCT03564782|Experimental|PVSRIPO|Polio vaccine booster will be administered 1 week prior to PVSRIPO injection. On the day of PVSRIPO injection (Day 0), a pre-treatment biopsy is obtained. PVSRIPO in injected into the tumor mass at a dose of 1x10^8 TCID50. On day 14, women will undergo standard-of-care surgical resection of PVSRIPO-treated tumor.
2854818|NCT03564769|Experimental|Intervention Arm 1|Individuals randomized to intervention group 1 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 AND will receive additional skin cancer screening educational materials.
2854819|NCT03564769|Experimental|Intervention Arm 2|Individuals randomized to intervention group 2 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 only.
2854820|NCT03564756|Experimental|Iron + Vitamin C|One iron tablet once a day plus a 500 mg vitamin C tablet twice a day until delivery.
2854821|NCT03564756|No Intervention|Iron + Placebo|One iron tablet once a day plus a placebo tablet twice a day until delivery.
2854822|NCT03564730|Active Comparator|Total Knee Arthroplasty (TKA)|Patient will have complete replacement - Simultaneous vs Staged
2854823|NCT03564730|Active Comparator|Unicompartmental Knee Arthroplasty (UKA)|Patient will have half-knee replacement (partial) - Simultaneous vs Staged
2854824|NCT03564717|Experimental|Segmented Three dimensionally printed transfer tray|
2854825|NCT03564717|No Intervention|Full arch three dimensionally printed transfer tray|
2854906|NCT03564184|Experimental|MT during and after NICU|Consists of music therapy during NICU hospitalization, and music therapy after discharge from initial NICU hospitalization, along with standard care.
2854907|NCT03564184|Experimental|MT during NICU|Consists of music music therapy during NICU hospitalization, along with standard care.
2854826|NCT03564704|Experimental|PDT-ALL-LBL|The intervention of PDT-ALL-LBL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy (methotrexate, cytarabine, dexamethasone), radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
2854827|NCT03564691|Experimental|Part A: MK-4830 Monotherapy|MK-4830 monotherapy (with MK-4830 doses determined by an accelerated titration design [ATD]) will be administered intravenously (IV), every 3 weeks (Q3W), starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days.
2854828|NCT03564691|Experimental|Part B: MK-4830 Monotherapy|MK-4830 monotherapy (with MK 4830 doses determined by a modified toxicity probability interval [mTPI] method) will be administered IV, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days.
2854829|NCT03564691|Experimental|Part C: MK-4830 and Pembrolizumab|Combination therapy with MK-4830 and pembrolizumab (with MK-4830 doses determined by an mTPI design). MK-4830 will be administered IV, Q3W, starting with Cycle 1 following pembrolizumab infusion, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
2854830|NCT03564678|Experimental|Previously Treated with PEG-asparaginase Group|"Participants receive Levocarnitine by vein 4 times a day.~Participants take Vitamin B complex capsules by mouth 2 times a day.~Participants may receive Levocarnitine and Vitamin B complex until the hyperbilirubinemia has improved or for up to 30 days after last dose of PEG-asparaginase or Inotuzumab."
2854831|NCT03564678|Experimental|Previously Treated with Inotuzumab Group|"Participants receive Levocarnitine by vein 4 times a day.~Participants take Vitamin B complex capsules by mouth 2 times a day.~Participants may receive Levocarnitine and Vitamin B complex until the hyperbilirubinemia has improved or for up to 30 days after last dose of PEG-asparaginase or Inotuzumab."
2854832|NCT03564665|Experimental|400mg Magnesium Glycinate BID Arm|Prescription for an 8 week supply (+/- 4 days) of Magnesium Glycinate will be sent to the pharmacy for patient pick up. Study Coordinator will then dispense study diaries (Supplementation Diary and Hot Flash Diary) with instructions on how to complete for the eight week study duration. Study Coordinator will discuss upcoming phone calls on Weeks 2-8 to complete the MDASI by phone and the best times to do so with the patient. Coordinator will schedule a return visit with the Patient approximately 9 weeks after the start of the study for follow-up. At follow-up, Coordinator will retrieve Patient Diaries (Hot Flash Diary and Medication Diary), perform supplement reconciliation, and exit Patient from the study.
2854833|NCT03564665|Placebo Comparator|Control Arm|Prescription for an 8 week supply (+/- 4 days) of placebo will be sent to the pharmacy for patient pick up. Study Coordinator will then dispense study diaries (Supplementation Diary and Hot Flash Diary) with instructions on how to complete for the eight week study duration. Study Coordinator will discuss upcoming phone calls on Weeks 2-8 to complete the MDASI by phone and the best times to do so with the patient. Coordinator will schedule a return visit with the Patient approximately 9 weeks after the start of the study for follow-up. At follow-up, Coordinator will retrieve Patient Diaries (Hot Flash Diary and Medication Diary), perform supplement reconciliation, and exit Patient from the study.
2854834|NCT03564652|No Intervention|Control Arm A|Lactating women (LW) randomized in this arm will only receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
2854835|NCT03564652|Experimental|Intervention Arm B|Lactating women (LW) randomized in this arm will receive Maamta product for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
2854836|NCT03564652|Experimental|Intervention Arm C|Lactating women (LW) randomized in this arm will receive Maamta product for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, the same infant of LW will receive a single dose of Azithromycin (20mg/kilogram) at day 42 of age. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
2854837|NCT03564639||Injection drug users with HCV|People who inject drugs who were confirmed positive for HCV and initiated treatment in the parent study beginning in September 2017.
2854838|NCT03564626|No Intervention|Control Group|Standard of care counseling and discharge instructions per local hospital policy. Standard of care follow up phone calls and visits at baseline and at 30 days. Follow-up will be for 30 days
2854839|NCT03564626|Experimental|Health IT only|Subjects and caregivers will be given individual phones loaded with the Patient Buddy App and the EncephalApp that will be used to enter medications, issues and orientation questions daily. There will be messages and phone calls as needed per the App and visits will be at baseline and at 30 days.Follow-up will be for 30 days
2854840|NCT03564626|Experimental|Health IT + Scheduled Follow Up|Subjects and caregivers will be given individual phones loaded with the Patient Buddy App and the EncephalApp that will be used to enter medications, issues and orientation questions daily. There will be messages and phone calls as needed per the App and visits will be at baseline, scheduled at 15 days and at 30 days. In addition, scheduled phone calls will be performed at days 7 and 21.Follow-up will be for 30 days
2854841|NCT03564613||HIV positive pregnant women|Data from approximately 250 HIV positive pregnant women with exposure to DTG from potential investigational sites across Europe will be included.
2854842|NCT03564600||ABC Group|Veterans with back pain for at least the past 6 months.
2854843|NCT03564587|Experimental|AWAKE|The AWAKE intervention is an 8 week program including a mobile app and phone-based coaching, focused on improving hope in order to increase quality of life and health-promoting behaviors in young adult cancer survivors.
2854844|NCT03564587|No Intervention|No treatment|Control participants will receive the surveys to complete only; however, they may opt to receive the intervention after the 4-month assessment.
2854908|NCT03564184|Experimental|MT after NICU|Consists of music therapy after discharge from initial NICU hospitalization, along with standard care.
2854845|NCT03564574|Experimental|Study group|"Inclusion criteria~History of consumption of OP compound.~Symptom complex consistent with OP poisoning~Age > 18 years~Informed consent from the patient or next kin.~Exclusion criteria~History of combined poisoning with a non OP compound.~All other patients not fitting in the organophosphate symptom complex.~Patients with underlying liver and kidney disease.~History suggestive of acute pancreatitis in the past.~All patients with history and clinical features of OP compound poisoning admitted to the emergency department in PGIMER during the study period, meeting the inclusion, exclusion criteria and who gave consent were enrolled in the study.~Intervention : Administration of 100mL of 20% Lipid emulsion to all patients in the study group"
2854846|NCT03564574|No Intervention|Historic controls|The control arm The study group was compared with data of patients admitted for OP poisoning between the years 2013 and 2014 ( 2 calendar years), fulfilling the inclusion and exclusion criteria as stated above.
2854847|NCT03564548|Experimental|Inhaled medical cannabis (PPP001)|"280 mg dried cannabis pellet -(9% THC / 2% CBD per pellet)~THC: Δ-9-tetrahydrocannabinol CBD: Cannabidiol"
2854848|NCT03564548|Active Comparator|Fentora Buccal Tablets (FBT)|Fentora Buccal Product are composed of a potent opioid analgesic, intended for buccal mucosal administration. The tablets contain fentanyl citrate equivalent to fentanyl base and will be given in low-dose (100 mcg) or high-dose (200 mcg).
2854849|NCT03564548|Experimental|Active PPP001 with FBT Placebo|Fentanyl Placebo tablets will have no fentanyl and will look identical to the active FBT. For these tablets there will also be low-dose tablets and high-dose tablets which will look identical to the active FBT 100 mcg and 200 mcg tablets.
2854850|NCT03564548|Active Comparator|Active FBT with PPP001 Placebo|The placebo is designed to contain 0% Δ-9-tetrahydrocannabinol (THC) and as per the placebo specifications < 0.9% total Cannabidiol (CBD).
2854851|NCT03564535|Experimental|SELF FIXATING GROUP|Monofilament polyester mesh with polylactic acid (PLA) microgrips of size 11*15 will be used. It is an isoelastic large-pore knitted fabric with a density of 73g/m2 at implantation and 38g/m2 after microgrips absorption which will be at 18 months. The resorbable micro grips provide immediate adherence to surrounding muscle and adipose tissue during the initial days post hernia surgery, serving as an alternate method of fixation to traditional sutures, tacks, staples, or fibrin sealants. No additional tacks, staples, sutures, or fibrin sealant will be used.
2854852|NCT03564535|Active Comparator|TACKER FIXATION GROUP|Patients will be undergoing mesh ﬁxation with non-absorbable tacks. The tacks would be used such that they avoid bony prominences and vascular and neural structures. One or two tacks will be put at the Cooper's ligament and another applied laterally superior to the iliopubic tract in the anterior abdominal wall. In any patient, the maximum number of tacks applied will not exceed three.
2854853|NCT03564522||Pulmonary Hypertension|Participants diagnosed with pulmonary hypertension that will undergo a clinically indicated cardiac catheterization and cMRI.
2854854|NCT03564522||Heart Transplant|Successful cardiac transplant recipient without evidence of pulmonary hypertension, that will undergo clinically indicated cardiac catheterization.
2854855|NCT03564509|Experimental|FE 999302 (dose 1) and follitropin delta|
2854856|NCT03564509|Experimental|FE 999302 (dose 2) and follitropin delta|
2854857|NCT03564509|Experimental|FE 999302 (dose 3) and follitropin delta|
2854858|NCT03564509|Experimental|FE 999302 (dose 4) and follitropin delta|
2854859|NCT03564509|Experimental|FE 999302 (dose 5) and follitropin delta|
2854860|NCT03564509|Placebo Comparator|Placebo and follitropin delta|
2854861|NCT03564496|Active Comparator|Healthy Controls|20 Healthy Controls
2854862|NCT03564496|Experimental|MS Patients|40 individuals diagnosed with MS recruited from the MS Center/ Neurology Department at NYULMC
2854863|NCT03564483||Registry Observational Study|
2854864|NCT03564470|Experimental|Chidamide|Chidamide will be added to chidamide arm Ph-like ALL(CRLF2 high-expression, CRLF2/EPO/JAK2 rearrangement, JAK/IL-7R/SH2B3 mutation, etc).
2854865|NCT03564470|Experimental|Dasatinib|Dasatinib at a dose of 100mg/day will be added to Dasatinib arm of Ph-like ALL (CRKL high-expression, ABL1 or ABL2 or CSFR1 or PRGFRB rearrangement, etc).
2854866|NCT03564457||One group of 20.000 patients|No interventions will take place as this is an observational study
2854867|NCT03564444|Experimental|Bivalent influenza vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) strain of bivalent influenza vaccine will be administered as intranasal spray on Day 1
2854868|NCT03564444|Placebo Comparator|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
2854869|NCT03564431||controls|
2854870|NCT03564431||T2DM patients|
2854871|NCT03564431||depression patients|
2854872|NCT03564431||T2DM with depression patients|
2854873|NCT03564418|Active Comparator|Ultrasound-Guided Thermocoagulation of Lumbar facet joints|Prone position: Thanks to a high-resolution ultrasound and a 5 MHz curved probe, we will use the ultrasound technique described by Greher et al to reach the target points. Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol) to observe them using the standard Fluoroscopic method. Wrongly positioned needles will be correctly repositioned and these patients will be excluded from ODI and VAS scale statistics.
2854874|NCT03564418|Active Comparator|Fluoroscopy-Guided Thermocoagulation of Lumbar facet joints|Prone position: We will use the standard fluoroscopic method to reach the target points. (maximum three levels, same side). Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol). The correct location being the superolateral edge of the lateral facet and the diffusion of the contrast material at the level of the medial branch observed thanks to an anteroposterior radioscopic view. Then the location of the needles is confirmed by a lateral radioscopic view.
2854875|NCT03564405|Experimental|UNI-DEB|
2854909|NCT03564184|Experimental|No MT|Consists of standard care.
2854910|NCT03564171|No Intervention|Standard of Care|Patients will receive standard treatment without added intervention.
2854911|NCT03564171|Experimental|Intervention|"These patients will receive standard treatment plus multimodal intervention (prehabilitation program) including :~exercise, nutritional counseling, stress counseling, smoking cessation) before starting chemotherapy."
2854912|NCT03564158|Experimental|meropenem 2 g- vaborbactam 2 g|Approved Dose
2863764|NCT03502798|Experimental|scanning a/LCI|
2854876|NCT03564392|Experimental|Treatment|Ten weekly modules will be delivered through an e-learning platform (i.e., Coursesites). Each module includes a video presentation of material synchronized with a slideshow illustrating session material with interactive features, and directed assignments to be completed throughout the week. At the end of every two weeks, a brief (i.e., 20 min) telephone call with a member of the study team will be scheduled to discuss and clarify the content of the session, discuss how the participant utilized skills demonstrated in the session, problem-solve difficulties in utilizing the skills, and review homework. Participants will be required to weigh themselves weekly (data will be transferred wirelessly to the laboratory) and feedback regarding weight losses will be provided during the phone call. The interventionist will provide individualized feedback on food records via email.
2854877|NCT03564392|No Intervention|Wait List Control|The Wait-List Control (WLC) condition does not receive any intervention during the study period. They receive the intervention after completing the study.
2854878|NCT03564379|Experimental|Part 1: Single Dose Part|Participants will receive a single oral dose of 25 mg JNJ-42165279 or placebo tablet under fasted condition in the morning on Day 1.
2854879|NCT03564379|Experimental|Part 2: Multiple Dose Part|After a washout period of at least 10 days, same participants from Part 1 will receive multiple daily dosing of 25 mg JNJ-42165279 or placebo tablet for 10 days.
2854880|NCT03564353|Experimental|memory task with tDCS location 1|memory task paired with tDCS targeting location 1
2854881|NCT03564353|Experimental|memory task with tDCS location 2|memory task paired with tDCS targeting location 2
2854882|NCT03564353|Experimental|memory task with tDCS location 3|memory task paired with tDCS targeting location 3
2854883|NCT03564353|Experimental|memory task with tDCS location 4|memory task paired with tDCS targeting location 4
2854884|NCT03564340|Experimental|Monotherapy|
2854885|NCT03564340|Experimental|Combination Therapy|
2854886|NCT03564327||Patients with sinus rhythm|
2854887|NCT03564327||patients with atrial fibrillation|
2854888|NCT03564314|Experimental|SUPPORT AKI Clinical Decision Support|Multidimensional clinical decision support intervention consisting of education and tools to support early recognition and management of AKI, including guidance on fluid therapies, medication management, investigation, and consultation with specialists.
2854889|NCT03564314|No Intervention|Control|Usual care provided to patients with AKI on surgical units.
2854890|NCT03564301|Active Comparator|Metronidazole 250mg|Systemic antibiotic: Metronidazole 250mg , 2 capsules three times a day, for 7 days.
2854891|NCT03564301|Placebo Comparator|Placebo|Placebo: same shape, size and dosis as test
2854892|NCT03564288|Experimental|Dose Escalation Cohort|To identify the recommended phase 2 dose (RP2D) of SKI-G-801 in patients with relapsed or refractory AML (Acute Myeloid Leukemia)
2854893|NCT03564275|Experimental|Prospective Treatment Group|Proton Boost
2854894|NCT03564275|No Intervention|Retrospective Comparison Group|Retrospective patients previously treated with standard of care photon therapy. There is no patient interaction with this group. Data collection from medical records only.
2854895|NCT03564262|Experimental|Cerebrovascular Reactivity|"Cerebrovascular reactivity (CVR) will be assessed using transcranial Doppler ultrasound with carbon dioxide as the vasoactive stimuli.~The intervention is to provide subjects with either a low sodium meal (138 mg sodium) and high sodium meal (1,495 mg sodium), in a randomized order. The CVR test will be performed prior to soup consumption as well as after soup consumption."
2854896|NCT03564262|Experimental|Blood Pressure Reactivity|Blood pressure responses during dynamic exercise will be assessed. The intervention is to provide subjects with either a low sodium meal (138 mg sodium) and high sodium meal (1,495 mg sodium), in a randomized order. Blood pressure reactivity during dynamic exercise will be assessed after soup consumption.
2854897|NCT03564249|Experimental|Group 1 Young patients with constipation|25 young patients that present at secondary or tertiary care with intractable constipation. They will undergo the new MRI gastrointestinal transit test (MiniCap) once before standard treatment for constipation and once after the treatment.
2854898|NCT03564249|Experimental|Group 2 Healthy participants|25 young healthy controls matched for gender. They will undergo the new MRI gastrointestinal transit test (MiniCap) once.
2854899|NCT03564236|Active Comparator|Standard Care|"Standard care is provided according to our local COPD exacerbation protocol. All patients are treated with:~oral prednisolone 40 mg/day for 5 days;~antibiotics prescribed according to the following criteria: fever (body temperature > 38.5 degrees Celsius), elevated C-reactive protein (CRP) >50, change in sputum colour, and/or according to the physician's decision of severe illness, and/or in all patients with a FEV1 <30% of predicted;~high dose inhaled corticosteroids, beta-agonists and or anticholinergics.~Oxygen will be prescribed in all patients through a standard low flow system in order to maintain an adequate arterial oxygen saturation (Sa,O2) Patients will be discharged with regular low flow oxygen once they fulfil the criteria for long-term oxygen therapy."
2854900|NCT03564236|Experimental|Nasal High Flow Therapy|"In addition to the standard care described above, patients in the intervention group will be treated with:~nHFT, set at 30-50 L/min flow with oxygen to achieve an adequate oxygen saturation. nHFT is prescribed for at least 6 hours, but patients are stimulated to use the device as much as possible during the hospital stay.~During periods without HFT through a standard low flow system, to maintain an adequate arterial oxygen saturation (Sa,O2) (between 90-92% if patients are concomitantly hypercapnic, and between 90-95% if patients are normocapnic). Flow rates are titrated accordingly.~After discharge patients in the nHFT arm will continue the prescribed therapy at home for 90 subsequent days."
2854901|NCT03564223||Parents/Guardians|"Parents/Guardians aged over 18, attending Great Ormond Street Hospital Outpatients.~Intervention: Administer questionnaire to review and decide on significance of each of 30 child health concerns"
2854902|NCT03564223||Paediatricians|"Paediatricians working at Great Ormond Street Hospital NHS Foundation Trust.~Intervention: Administer questionnaire to review and decide on significance of each of 30 child health concerns"
2854903|NCT03564210|Active Comparator|Screen time permitted|Concussion sufferers permitted screen time for first 48 hours of recovery
2854904|NCT03564210|Active Comparator|Screen time abstain|Concussion sufferers asked to abstain from screen time for first 48 hours of recovery
2854905|NCT03564197|Other|Nivolumab|nivolumab treatment according to label
2854913|NCT03564158|Experimental|meropenem-vaborbactam (dose TBD)|Supratherapeutic Dose
2854914|NCT03564158|Active Comparator|Moxifloxacin 400 mg|Active Control
2854918|NCT03564132|Placebo Comparator|Placebo|2.5g of Placebo(contained one-tenth Yigansan) granules by mouth, three times a day for 4 weeks
2854919|NCT03564119|Experimental|S5G4T-1|topical cream
2854920|NCT03564119|Placebo Comparator|S5G4T-2|topical cream
2854921|NCT03564106|Experimental|group A|receive intraarticular radiofrequency + methylprednisolone (30 mg)
2854922|NCT03564106|Experimental|group C|receive intraarticular methylprednisolone (30 mg)
2854923|NCT03564093|Experimental|Dexmedetomidine|1µg/kg intranasal dexmedetomidine
2854924|NCT03564093|Placebo Comparator|Placebo|0,01ml/kg intranasal 4,5% saline
2854925|NCT03564080|No Intervention|Control - PAD|This group of patients will complete the 'standard care' of supervised exercise as recommended by NICE.
2854926|NCT03564080|Experimental|Combined - PAD and CAD|This group of PAD patients will exercise alongside CAD patients in an established supervised exercise programme (Cardiac Rehabilitation).
2854927|NCT03564067|Other|tDCS + cCBT|After baseline assessments are complete, participants will be provided with a tDCS device (Soterix Medical tDCS mini-Clinical Trials system (mini-CT)), which is deactivated until a code is provided by the research staff. Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
2854928|NCT03564054|Experimental|Photodynamic Therapy|Photodynamic therapy (PDT) uses activation of a photosensitizer by light of a specific wavelength to generate reactive oxygen species and singlet oxygen that causes direct cell damage and death, apoptosis, tumor vasculature damage and thrombosis, and inflammation leading to an immunological response.Following randomization, subjects will undergo treatment with either PDT or APC. Subjects will then have six additional study visits at 30, 45, 60, 90, and 180 days after their last PDT or APC treatment
2854929|NCT03564054|Experimental|Argon Plasma Coagulation|Argon plasma coagulation (APC) is a noncontact form of electrocautery. Following randomization, subjects will undergo treatment with either DPT or APC. Subjects will then have six additional study visits at 30, 45, 60, 90, and 180 days after their last PDT or APC treatment.
2854930|NCT03564041|Experimental|Sahaj Samadhi Meditation (SSM)|SSM will be taught to participants over 4 consecutive days, for 2 hours each day. Participants will initially learn about the nature of meditation and will be taken through a guided meditation. Afterwards, participants will undergo training which includes understanding the nature of the mind and the thoughts arising from it, guided meditation by the instructor, and a discussion of what is correct and incorrect meditation. Follow-ups will be conducted once every week for the following 11 weeks, each including guided meditation. Participants will be encouraged to practice the meditation at home for 20 minutes per session and will be given weekly practice logs to complete.
2854931|NCT03564041|Other|Health Enhancement Program (HEP)|"Arm type: Active control group~HEP controls for several non-specific factors found in a meditation group such as Sahaj Samadhi, including: group support and morale, behavioral activation, reduction of stigma, facilitator attention, treatment duration, and time spent on at-home practice. HEP has been tailored to be structurally equivalent to a SSM intervention, with similar-sized groups, meeting for 4 days for 2 hours, and then a one-hour follow up session weekly for the subsequent 11 weeks, and completing the same amount of home practice (20 minutes twice daily, every day), and will be asked to complete weekly practice logs."
2854932|NCT03564028|Experimental|energy conservation technique|Patients will perform one session of stair climbing of 108 steps (corresponding to 6 floors).
2854933|NCT03564028|Other|Control session|Patients will perform one session of stair climbing of 108 steps (corresponding to 6 floors).
2854934|NCT03564015|Experimental|Smartphone app|The smartphone group will not be given paper-based discharge instructions in the ED. They will download onto their smartphone device an Intervention App that will allow recording of the above mentioned study outcomes and contains an interactive educational component encompassing the identical information outlined in the paper handout. The app will provide educational guidance towards recovery using a feedback algorithm that will recommend on a daily basis, the use of ice, elevation, range of motion exercises, and/or analgesics based on the participant's report of their pain using the FPS-R.
2854935|NCT03564015|Active Comparator|Paper handout|The paper handout group will be asked to read the paper-based discharge instructions in the ED, outlining pharmacological and non-pharmacological pain management and return to activity. They will download onto their smartphone device a Recording App that will only allow them to record the following study outcome measures: daily use of ice, analgesia, range of motion exercises, elevation, pain using the Faces Pain Scale - Revised (FPS-R), and ASKp scores on days 5, 7, 10, and 12.
2854936|NCT03564002||obese subjects|
2854937|NCT03564002||lean subjects|
2854938|NCT03563989|Experimental|Stentys Xposition S Self-Apposing stent|STENTYS Xposition S Sirolimus Eluting Self-Apposing Coronary Stent System
2854939|NCT03563989|Active Comparator|Conventional Balloon-expandable stent|Conventional Balloon-expandable drug eluting stents in effect at the time of the study, in compliance with applicable contracts made between Hospital and suppliers.
2854940|NCT03563963|Active Comparator|Lidocaine 2% in Endotracheal Tube cuff|2ml of lidocaine 2% will used to inflate the endotracheal tube cuff for the duration of the subjects' surgery. If there is an air leak around the endotracheal tube, additional lidocaine will be added to obtain an endotracheal cuff pressure of no more than 30cmH20.
2854941|NCT03563963|Experimental|Ropivacaine 0.5% Endotracheal Tube cuff|2ml of ropivacaine 0.5% will used to inflate the endotracheal tube cuff for the duration of the subjects' surgery. If there is an air leak around the endotracheal tube, additional ropivacaine will be added to obtain an endotracheal cuff pressure of no more than 30cmH20.
2854942|NCT03563963|Active Comparator|Air in the Endotracheal Tube cuff|Air will used to inflate the endotracheal tube cuff for the duration of the subjects' surgery, to obtain a endotracheal cuff pressure of no more than 30cmH20.
2854943|NCT03563950|Experimental|Rifampin + BMS-986224|Oral administration
2854944|NCT03563937||Phenprocoumon|Patients with NVAF who initiated the treatment of Phenprocoumon.
2854945|NCT03563937||Apixaban|Patients with NVAF who initiated the treatment of Apixaban.
2854946|NCT03563937||Rivaroxaban (Xarelto, BAY59-7939)|Patients with NVAF who initiated the treatment of Rivaroxaban.
2854947|NCT03563937||Edoxaban|Patients with NVAF who initiated the treatment of Edoxaban.
2854948|NCT03563924||Historical cohort|Patients with venous thromboembolism and cancer who follow traditional management of venous thromboembolism
2854949|NCT03563924||AlloTC cohort|"Patients with venous thromboembolism and cancer who follow AlloTC specific management. AlloTC specific care path way develop a personalized care plan (PPS) and ensure the transmission of data (to all the interlocutors: patients and caregivers) at each step of the patient care path."
2854950|NCT03563911|Experimental|Brief Mindfulness-Based Intervention|Those assigned to the Brief Mindfulness-Based Intervention (BMBI) Arm will receive BMBI.
2854951|NCT03563911|Active Comparator|Control/Nutrition Education|Those assigned to the Control/Nutrition Education Arm will receive the nutrition education intervention.
2854952|NCT03563885|Experimental|RYGB or SG|Baseline testing followed by subject's already scheduled RYGB or SG surgery, and then post-testing.
2854953|NCT03563885|No Intervention|Lean|Lean control subjects doing baseline testing only.
2854954|NCT03563872|Active Comparator|Active Comparator|Team-based care
2854955|NCT03563872|Experimental|Intervention|Enhanced team-based care
2854956|NCT03563846|Experimental|RP-G28 administered in the fasted state|RP-G28, 15 g dissolved in water, administered in the fasted state
2854957|NCT03563846|Experimental|RP-G28 administered in the fed state|RP-G28, 15 g dissolved in water, administered immediately following the consumption of a standard non-dairy meal
2854958|NCT03563833|Other|Minimal Flow Anesthesia|"Minimal Flow Anesthesia (50% O2, 50% air), Desflurane (MAC = 4,5). In hypotensive anesthesia application; Remifentanil will be used at infusion rates of 0.025-0.1μg / kg / min after a loading dose of 1 μg / kg / min, with mean Arterial Pressure 55-65 mmHg.~Before the induction of anesthesia and 30 minutes of anesthesia, 2 ml of venous blood sample will be taken from the patients and simultaneous tissue oxygen saturation will be recorded. Serum thiol disulfide levels obtained from the blood sample of the recipient will be studied in the biochemistry research laboratory using the method developed by Erel et al."
2854959|NCT03563833|Other|High Flow Anesthesia|"High Flow Anesthesia (50% O2, 50% air), Desflurane (MAC = 4,5) In hypotensive anesthesia application; Remifentanil will be used at infusion rates of 0.025-0.1μg / kg / min after a loading dose of 1 μg / kg / min, with mean Arterial Pressure 55-65 mmHg.~Before the induction of anesthesia and 30 minutes of anesthesia, 2 ml of venous blood sample will be taken from the patients and simultaneous tissue oxygen saturation will be recorded. Serum thiol disulfide levels obtained from the blood sample of the recipient will be studied in the biochemistry research laboratory using the method developed by Erel et al."
2854960|NCT03563807|Experimental|Golf|Group golf lessons will be led by professional golf instructors.
2854961|NCT03563807|Active Comparator|Tai Chi|Group Tai Chi classes led by a certified Tai Chi instructor.
2854962|NCT03563794|Experimental|CSII(insulin Lispro)+Vildagliptin|Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
2854963|NCT03563794|Active Comparator|CSII(insulin Lispro)|T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
2854964|NCT03563781|Other|SENTINEL NODE|Patients with ovarian cancer will receive sentinel node identification and they will be then submitted to complete pelvic and para-aortic lymphadenectomy (as per the present guidelines)
2854965|NCT03563768|Experimental|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
2854966|NCT03563768|No Intervention|Staging strategy group|PCI will be performed several days after EVAR
2854967|NCT03563755|Experimental|Cognitive Bias Modification (CBM) + Treatment as usual|Participants will receive access to a 3-week online training programme alongside their usual treatment.
2854968|NCT03563755|No Intervention|Treatment as usual|Participants will continue to receive their usual treatment.
2854969|NCT03563742|Experimental|Treatment: Rilpivirine+Combination Therapy (TDF/3TC)|The participants will receive antiretroviral treatment of rilpivirine 25 milligram (mg) tablet orally once daily from Day 1 for 48 weeks with a meal to improve absorption. The participants will also receive background combination therapy of 1 tablet orally once daily containing 300 mg tenofovir disoproxil fumarate (TDF) and 300 mg lamivudine (3TC).
2854970|NCT03563729|Experimental|A: Pembrolizumab (Prednisolone 11-25 mg)|Intravenous infusion of pembrolizumab 2 mg/kg every third week for up to two years.
2854971|NCT03563729|Experimental|B: Pembrolizumab (Prednisolone >25 mg)|Intravenous infusion of pembrolizumab 2 mg/kg every third week for up to two years.
2854972|NCT03563729|Experimental|C: Ipilimumab/nivolumab (Prednisolone 11-25 mg)|Intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
2854973|NCT03563729|Experimental|D: Ipilimumab/nivolumab (Prednisolone >25 mg)|Intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
2854974|NCT03563716|Experimental|MTIG7192A + atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle and MTIG7192A at a dose of 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
2854975|NCT03563716|Placebo Comparator|Placebo + atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
2854976|NCT03563703|Experimental|Ultrasound imaging|Ultrasonography offers visual information about the size and depth of blood vessels, potentially facilitating intravenous placement of the needle in real time.
2854977|NCT03563703|Experimental|Near-infrared imaging|Near-infrared imaging devices project near-infrared light onto the skin, which is absorbed by deoxygenated hemoglobin. The invisible image of the underlying vascular pattern is captured by the device, processed and projected, in real time, back onto the patient's skin using visible green light. This technology allows hands-free visualization of a vascular map to guide catheter placement.
2854978|NCT03563703|No Intervention|Standard approach|The standard approach for detection and selection of a new venous access includes the use of a tourniquet, applied at an appropriate proximal location to promote venous distention, followed by the palpation and observation of the selected insertion site.
2855163|NCT03562429|Experimental|TGF group (study group)|Use TGF to treat osteoarthritis of the knee, 5g/time, 3 times a day, for 12 weeks.
2854979|NCT03563690|Experimental|Acupuncture group|When recruited from six centers,the participant will be randomized to six groups .In acupuncture group participant will receive four-week acupuncture treatment(three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
2854980|NCT03563690|Experimental|Electro-acupuncture group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week electro-acupuncture treatment(three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
2854981|NCT03563690|Experimental|Moxibustion group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week moxibustion treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
2854982|NCT03563690|Experimental|Warm-needling group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week warm-needling treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
2854983|NCT03563690|Sham Comparator|Sham-needle group|When recruited from six centers,the participant will be randomized to six groups.In this group participant receive four-week sham acupuncture treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
2854984|NCT03563690|Active Comparator|Celebrex group|When recruited from six centers,the participant will be randomized to six groups . In this group participant will receive Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd)treatment, which will be applied 1 time daily(one time oral 0.2g) for 4 weeks. The follow-up period is six months.
2854985|NCT03563677|No Intervention|Usual care|Standard evaluation process for patients approaching a center for rare diseases with an unclear diagnosis. The process includes the evaluation of complete medical records byan experienced physician, an outpatient visit to the center, and case discussion between experts. The process may also include an inpatient stay, a local case conference and a case conference between centers for rare diseases from different cities
2854986|NCT03563677|Experimental|New Innovative Care|The innovative evaluation process includes the additional involvement of a psychiatrists/psychosomatic expert in all of the processes described for the usual care arm plus the option to use telemedicine in the process of evaluation in addition to outpatient and inpatient visits and to transfer the patient back into standard care (i.e., primary care physician, rehabilitation, psychological/psychosomatic specialized care, etc.)
2854987|NCT03563664|Experimental|Study group|38 ovulatory patients with unexplained recurrent implantation failure were recruited. Pre-treatment endometrial biopsy and immunohistochemical examination for endometrial αvβ3 integrin expression (using immunohistochemically stained endometrial biopsy) was done. After treatment with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in daily dosage of 400 mg for 12 weeks, post-treatment endometrial biopsy and immunohistochemical examination was repeated and compared with previous results.
2854988|NCT03563651||Ancillary-Correlative (biospecimen collection, biopsy)|Participants undergo collection of blood and urine at baseline, on day 1 of courses 1, 2, and 3, at restaging, and at disease progression. Participants may undergo collection of stool at baseline, on day 1 of course 2, and at disease progression. Participants also undergo biopsy within 4 weeks of disease progression.
2854989|NCT03563638||GDM group|Women with maternal age ≥ 18 years, singleton pregnancy, primipara, no smoking, confirmed gestation≤20 weeks and spontaneous conception were invited to participate in the study,and excluded if they had multiple pregnancy, pre-gestational diabetes mellitus, hypertensive disorders, preterm delivery, cardiovascular disease, immunological disease, glucocorticoid therapy, or other severe illness,and fetal abnormalities occurred during pregnancy were also excluded from the study.GDM was verified on the 75gOGTT at 24-28 gestational weeks.The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: FPG≥5.1 mmol/L and/or 1h-PG ≥10.0 mmol/L and/or 2h-PG ≥8.5 mmol/ L.
2854990|NCT03563638||NGT group|Women with maternal age ≥ 18 years, singleton pregnancy, primipara, no smoking, confirmed gestation≤20 weeks and spontaneous conception were invited to participate in the study. Women were excluded if they had multiple pregnancy, pre-gestational diabetes mellitus (PGDM), hypertensive disorders, preterm delivery, cardiovascular disease, immunological disease, glucocorticoid therapy, or other severe illness. if there were fetal abnormalities including chromosomally abnormal fetuses and/or structural defects and fetal growth restriction occurred during pregnancy were also excluded from the study.GDM was verified on the 75gOGTT at 24-28 gestational weeks.those who not met the criteria were the NCT group.
2854991|NCT03563625|Active Comparator|Caudal block|Caudal block with 1mg/kg bupivacaine 0.25%.
2854992|NCT03563625|Active Comparator|Wound infiltration|Local wound infiltration with 1mg/kg bupivacaine 0.25%.
2854993|NCT03563612|Active Comparator|cpap first, differential ventilation later|
2854994|NCT03563612|Active Comparator|differential ventilation first, cpap late|
2854995|NCT03563599|Experimental|Telacebec (Q203) tablet|
2854996|NCT03563599|Active Comparator|Rifafour e-275|
2854997|NCT03563586|Active Comparator|Bowel Preparation plus antibiotics|Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
2854998|NCT03563586|Other|Bowel Preparation|Preoperative mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
2854999|NCT03563573|Active Comparator|Lidocaine-effective ADHD: Intervention|Single-dose potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is effective
2855000|NCT03563573|Placebo Comparator|Lidocaine-effective ADHD: Placebo|Single-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is effective
2855001|NCT03563573|Active Comparator|Lidocaine-ineffective ADHD: Intervention|Single-dose potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is ineffective
2855002|NCT03563573|Placebo Comparator|Lidocaine-ineffective ADHD: placebo|Single-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is ineffective
2855003|NCT03563560|Experimental|ACM regimen|ACM regimen is for Japanese patients with relapsed or refractory AML.
2855004|NCT03563560|Experimental|A+7+3 regimen|A+7+3 regimen is for Japanese newly diagnosed AML patients.
2855164|NCT03562429|Placebo Comparator|TGFP group (placebo group)|Use TGFP to treat osteoarthritis of the knee, 5g/time, 3 times a day, for 12 weeks.
2855005|NCT03563547|Active Comparator|Fat modified diet|Subjects in this arm had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
2855006|NCT03563547|Experimental|Fat modifed diet enriched with soy protein|"Subjects in this arm had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.~Subjects in this arm were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target."
2855007|NCT03563534|Active Comparator|silver diamine fluoride|38% silver diamine fluoride applied to cavitated primary molars twice per week to arrest caries
2855008|NCT03563534|Active Comparator|interim restorative therapy|Resin modified glass ionomer applied to cavitated primary molars
2855009|NCT03563521||Atopic, eosinophilic|
2855010|NCT03563521||Atopic, non-eosinophilic|
2855011|NCT03563521||Non-atopic, eosinophilic|
2855012|NCT03563521||Chronic rhinosinusitis with/without nasal polyposis|
2855013|NCT03563521||Non-atopic, non-eosinophilic|
2855014|NCT03563521||Control|Without asthma, atopy and eosinophilia
2855015|NCT03563508||CBCT of Egyptian subpopulation|Cone-beam computed tomography (CBCT) of a sample of Egyptian subpopulation containing maxillary premolars for image assessment.
2855016|NCT03563495|Active Comparator|tissue engineered group|autogenous bone marrow derived and cultured stem cells loaded on collagen matrix was implanted in the alveolar cleft in the study group (1st arm)
2855017|NCT03563495|Active Comparator|autogenous bone graft group|autogenous cortico-cancellous bone graft harvested from the anterior iliac crest was implanted in the alveolar cleft of the control group (2nd arm)
2855018|NCT03563482|Experimental|Experimental|Biopsy and PET scan
2855019|NCT03563456|Experimental|EXPERIMENT (EXP)|Subjects conduct the structured combined exercise in form of combination of High Intensity Interval Training and Resistance Training
2855020|NCT03563456|Active Comparator|CONTROL (KTR)|Subjects conduct structured exercise of cardiorespiratory training in form of lower-volume continuous cardiorespiratory exercise.
2855021|NCT03563443||Bladder cancer patients|Diagnosed bladder cancer patients who are being monitored will be the experimental group to develop the LOI panel, and subsequent cohort will be used to confirm the sensitivity and specificity of this urinary analysis.
2855022|NCT03563443||Non-cancer participants|Patients being treated for other diseases but without any tumor or healthy participants will provide a negative control to provide data for developing the LOI diagnostic panel
2855023|NCT03563430|Experimental|Active Recovery Group|Participants in this group will exercise for 15 minutes, for a range of 65 to 70% of the maximum heart rate.
2855024|NCT03563430|Experimental|Self-Massage with Foam Roller Group|This group will perform 15 minutes self-massage with foam roller following the exercise session.
2855025|NCT03563430|Experimental|Neuromuscular Electrical Stimulation|Participants of this group will be applied electrical stimulation on quadriceps femoris and hamstring muscles for 15 minutes while they are comfortable lying position.
2855026|NCT03563417|Active Comparator|PCI|
2855027|NCT03563417|Other|OMT|
2855028|NCT03563404||Portal Blood Flush|participants that receive the portal blood flush
2855029|NCT03563404||No Portal Blood Flush|participants that don't receive the portal blood flush
2855030|NCT03563391|Experimental|Evaluation of a new infant formula|To evaluate the effects of a new formula on the growth, safety and tolerance of infants with growth failure
2855031|NCT03563378|Experimental|Lactated ringers solution|Participants in this group will receive Lactated Ringer's solution during the intraoperative period.
2855032|NCT03563378|Experimental|Normal saline solution|Participants in this group will receive Normal saline solution during the intraoperative period.
2855033|NCT03563365|Experimental|Replenix|Replenix power of 3 cream with Resveratrol applied twice daily
2855034|NCT03563365|Experimental|Replenix and Adapalene and Benzoyl Peroxide gel|Replenix power of 3 cream with Resveratrol applied twice daily and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily
2855035|NCT03563365|Active Comparator|Adapalene and Benzoyl Peroxide gel|Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily
2855036|NCT03563352||Observational (interview, survey)|Participants attend an interview over 15 minutes and complete surveys.
2855037|NCT03563339|Experimental|P-POD|All participants will complete the prevention for postpartum onset distress (P-POD)
2855038|NCT03563326|Experimental|CAR-T cell and chemotherapy|Biological: CAR-T cells targeting EpCAM Chemotherapy: determined by medical Oncologist
2855039|NCT03563326|Active Comparator|chemotherapy|Chemotherapy: determined by medical Oncologist
2855040|NCT03563313|Experimental|Closed Loop Control (CLC)|Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 6 months.
2855041|NCT03563313|Active Comparator|Sensor-Augmented Pump (SAP)|Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
2855042|NCT03563300|Active Comparator|Wheat flour|Wheat flour will be administered blindly versus placebo for 7 days
2855043|NCT03563300|Placebo Comparator|Rice flour|Placebo will be administered blindly versus wheat flour for 7 days
2855044|NCT03563287|Experimental|Phenotyping cocktail of 9 CYP probe drugs before surgery|
2855045|NCT03563287|Experimental|Phenotyping cocktail of 9 CYP probe drugs 1 year after surgery|
2855046|NCT03563261|Active Comparator|Collagen supplement group|Participants assigned in the collagen supplement group will drink the active product every morning before breakfast.
2855047|NCT03563261|Placebo Comparator|Placebo supplement group|Participants assigned in the placebo supplement group will drink the placebo every morning before breakfast.
2855048|NCT03563248|Active Comparator|FOLFIRINOX: SBRT: Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~SBRT should be administered 2-6 weeks after completing chemotherapy~All participants will undergo an attempt at definitive surgical resection following SBRT"
2855049|NCT03563248|Experimental|FOLFIRINOX+Losartan:SBRT+Losartan:Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~Losartan will be administered orally as a tablet to be taken by the patient at home every day~SBRT should be administered 2-6 weeks after completing chemotherapy~All participants will undergo an attempt at definitive surgical resection following SBRT"
2855050|NCT03563248|Experimental|FOLFIRINOX+Losartan:SBRT+Nivolumab+Losartan:Sur|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~Losartan will be administered orally as a tablet to be taken by the patient at home every day~SBRT should be administered 2-6 weeks after completing chemotherapy~Participants will receive nivolumab during SBRT~All participants will undergo an attempt at definitive surgical resection following SBRT"
2855051|NCT03563248|Experimental|FOLFIRINOX x 8 : SBRT + Nivolumab : Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~SBRT should be administered 2-6 weeks after completing chemotherapy~Participants will receive nivolumab during SBRT~All participants will undergo an attempt at definitive surgical resection following SBRT"
2855052|NCT03563235|Experimental|Xulin Jiangu granules|Xulin Jiangu granule 15g tablet by mouth every 6 hour for 6 months
2855053|NCT03563235|Active Comparator|Calcitriol capsules|Calcitriol capsules tablets 0.25 ug by mouth every 6 hour for 6 months
2855054|NCT03563222|Experimental|Smoflipid|"Smoflipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of Smoflipid is 0.20 g/mL, and comprises a mixture of soybean oil, medium chain triglycerides, olive oil, and fish oil. Smoflipid is indicated as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.~The mean essential fatty acid content of Smoflipid is 35 mg/mL linoleic acid (omega-6) and 4.5 mg/mL α-linolenic acid (omega-3)."
2855055|NCT03563222|Active Comparator|Intralipid, 20%|Intralipid 20% is a sterile, non‑pyrogenic fat emulsion intended as a source of calories and essential fatty acids. Intralipid 20% is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time and as a source of essential fatty acids for prevention of essential fatty acid deficiency. The major component fatty acids are linoleic acid, oleic acid, palmitic acid, α-linolenic acid and stearic acid.
2855056|NCT03563196||Chest Radiograph|All the patients will undergo routine chest radiogram on day 1 after operation
2855057|NCT03563196||Lung Ultrasound|The same patient will undergo ultrasound evaluation of lungs on day 1 after operation
2855058|NCT03563183||Zoster-064 GSK1437173A Group|Subjects who have received herpes zoster subunit vaccine (gE/AS01B vaccine) in the ZOSTER-006 and Zoster-022 studies. SF-36 and EQ-5D questionnaires will be encoded to evaluate frailty Thereafter, efficacy/safety / immune responses will be assessed by frailty status.
2855059|NCT03563183||Zoster-064 Placebo Group|Subjects who have received saline solution (NaCl solution) as control in the ZOSTER-006 and Zoster-022 studies. SF-36 and EQ-5D questionnaires will be encoded to evaluate frailty Thereafter, efficacy/safety / immune responses will be assessed by frailty status.
2855060|NCT03563170|Experimental|NANT Hepatocellular Carcinoma Vaccine|Phase 1b and 2: The following combination of agents will be administered to subjects assigned to this treatment: Aldoxorubicin HCl, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK™, avelumab, capecitabine, cetuximab, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, sorafenib, SBRT.
2855061|NCT03563170|Active Comparator|Sorafenib Monotherapy|Phase 2: Sorafenib monotherapy will be administered to subjects with advanced, unresectable, and untransplantable HCC, who have not previously received sorafenib, and who are randomly assigned to receive SoC treatment.
2855062|NCT03563157|Experimental|NANT Colorectal Cancer (CRC) Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin Hydrochloride HCI, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, avelumab, capecitabine, cetuximab, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, oxaliplatin, regorafenib, SBRT, trastuzumab.
2855063|NCT03563157|Active Comparator|Regorafenib|In subjects with metastatic CRC who have been previously treated with standard-of-care (SoC) therapy.
2855064|NCT03563144|Experimental|NANT Pancreatic Cancer Vaccine|"in subjects with ECOG=2 or subjects with ECOG=0 or 1~A combination of agents will be administered to subjects in this study:~cyclophosphamide, bevacizumab, oxaliplatin, capecitabine, 5-fluorouracil, leucovorin, nab-paclitaxel, aldoxorubicin HCl, avelumab, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-021, ETBX-051, ETBX-061."
2855065|NCT03563144|Active Comparator|Gemcitabine and Nab-paclitaxel|Gemcitabine plus Nab-paclitaxel will be administered to subjects with ECOG=2
2855066|NCT03563144|Active Comparator|Gemcitabine|Gemcitabine will be administered to subjects with ECOG=0 or 1
2855067|NCT03563131|Active Comparator|Uncemented Persona® total knee arthroplasty|Uncemented TM Zimmer Persona® TKA. It is a relatively new implant that is now in routine clinical use. Implants are approved by FDA and CE marked. Patella will be resurfaced with the cemented Zimmer 3-Peg All Polyethylene Patella.
2855068|NCT03563131|Active Comparator|Cemented Persona® total knee arthroplasty|Cemented Zimmer Persona® TKA. It is a relatively new implant that is now in routine clinical use. Implants are approved by FDA and CE marked. Patella will be resurfaced with the cemented Zimmer 3-Peg All Polyethylene Patella.
2855069|NCT03563118||Group OSAS|We included 56 with OSAS [13 subjects 23.2% mild, 19 subjects 33.9% moderate, 24 subjects 42.8% severe
2855070|NCT03563118||control group|simple snoring
2855071|NCT03563105|Experimental|Desaturation|Vascular Occlusion Test
2855072|NCT03563092|Experimental|Lap Inguinal Hernia repair with Drain|A (14 French sizes) closed suction drain will be placed in preperitoneal space after laparoscopic inguinal hernia (TEP/TAPP) surgery.
2855073|NCT03563092|Active Comparator|Lap Inguinal Hernia repair without Drain|No drain will be placed after laparoscopic inguinal hernia (TEP/TAPP) surgery.
2855130|NCT03562663|Sham Comparator|Sham tDCS|Participants in this group received 20 minutes of sham 2 mA transcranial direct current stimulation over the motor cortex of the affected arm prior to robotic training.
2866160|NCT03486262||Lung carcinoma on IPF|Lung carcinoma on IPF
2855074|NCT03563079|Experimental|trial group|The treatment will be performed using two pieces of Instrument Assisted Soft Tissue Mobilization (IASTM) stainless steel in the neck, bilaterally, which comprise the following muscles: Upper Trapezius, Splenius, scalenes and Sternocleidomastoid. An established time of 3 minutes will be used in each region, using an angle of 30 to 60º with the instrument. As it is observed, through the instrument, regions of greater adhesion, the researcher will use most of this time to release this condition.
2855075|NCT03563079|Active Comparator|group control|Treatment will be performed using manual Myofascial Release techniques. Release the upper Trapezius muscle bilaterally, sliding using roller with the dorsum of the fingers and ending with myofascial release. Sternocleidomastoid, sliding using roller with the dorsum of the fingers, ending with myofascial release. Afterwards the release of the scalenes muscles will be performed, with the fingers sliding and ending with the myofascial release. Soon afterwards techniques will be performed for the Splenius muscles, using finger slips and ending with posterior cervicothoracic release. The same time of 3 min will be used for the treatment bilaterally in each region.
2855076|NCT03563066|Experimental|Benralizumab|Fixed dose 30mg benralizumab.
2855077|NCT03563066|Placebo Comparator|Placebo Control|Will appear identical in form to benralizumab arm.
2855078|NCT03563053|Experimental|active drug|~14-22 mg dexamethasone sodium phosphate (DSP)
2855079|NCT03563040|Experimental|Methoxsalen with the THERAKOS CELLEX Photopheresis System|Treatment will be performed according to a predefined protocol based on the consensus guidelines in patients with MF/SS. Treatment should be administered for one year unless confirmed disease progression or unless other criteria for treatment discontinuation are met as specified in the protocol.
2855080|NCT03563027|No Intervention|Control|This arm serves as control and uses a wearable device to track daily step counts
2855081|NCT03563027|Experimental|Social Incentive Gamification|This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, and selects a support sponsor
2855082|NCT03563027|Experimental|Social Incentive Gamification and Financial Incentive|This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, selects a support sponsor, and receives a financial incentive
2855083|NCT03563014||Radium-223 (Xofigo, Bay88-8223)|Belgium patients with a diagnosis of mCRPC (no known visceral metastases) and who were treated with Radium-223 for this indication
2855084|NCT03563001|Experimental|Chronic Obstructive Pulmonary Disease Group|Patients with diagnosis of chronic obstructive pulmonary disease according to Global Initiative for Chronic Obstructive Disease(GOLD 2018) are recruited.Small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months` treatment.
2855085|NCT03563001|Experimental|Asthma-Chronic Obstructive Pulmonary Disease Overlap Group|Patients with diagnosis of asthma-chronic obstructive pulmonary disease overlap according to Global Initiative for Chronic Obstructive Disease(GOLD 2018),Global Initiative for Asthma(GINA 2018) and Spanish COPD Guidelines(GesEPOC 2017) are recruited.Small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months` treatment.
2855086|NCT03562988|Experimental|vitafusion Power C gummy|A single oral dose of gummy vitamin C to monitor vitamin C blood levels
2855087|NCT03562988|Active Comparator|Nature Made vitamin C caplet|A single oral dose of gummy vitamin C to monitor vitamin C blood levels
2855088|NCT03562962|Other|Functional Analytic Psychotherapy|"Within the baseline (A), Supportive Listening (SL) will be provided, which has been widely utilized in randomized control trials (Cuijpers et al., 2012), including the only Randomized Control Trial (RCT) conducted in FAP (Maitland & Gaynor, 2016), as a control condition. SL is defined as a psychological treatment in which therapists do not engage in any therapeutic strategies other than active listening and offering support, focusing on participants' problems and concerns (Cuijpers et al., 2012, p. 281). In this therapy, the therapist reflects on clients' experiences and encourage them to share emotional experiences. Therapists are prohibited from giving advice, making interpretations, and providing feedback to clients (Cuijpers et al., 2012).~FAP will be introduced at phase B, where contingent reinforcement will be administered for increasing clients' alternative behaviors (CRB2) and differential reinforcement will be utilized to reduce clients' problem behaviors (CRB1)."
2855089|NCT03562949|Experimental|Test Product|Test Product, 40 mcg, 2 x daily
2855090|NCT03562949|Active Comparator|Reference Product|Reference Product, 40 mcg, 2 x daily
2855091|NCT03562949|Placebo Comparator|Placebo|Placebo Product 2 x daily
2855092|NCT03562923|Experimental|Test Product|Test Product, 100/50 mcg, 2 x daily
2855093|NCT03562923|Active Comparator|Reference Product|Reference Product, 100/50 mcg, 2 x daily
2855094|NCT03562923|Placebo Comparator|Placebo|Placebo Product 2 x daily
2855095|NCT03562910|Experimental|Intervention|All enrolled subjects will be given access to the HelpSteps application, either via their personal cell phone or to a provided tablet.
2855096|NCT03562897|Experimental|Ocoxin-Viusid®|Ocoxin-Viusid® before, during and after the Chemotherapy treatment.
2855097|NCT03562884|Experimental|BLI800|BLI800 given orally as a split-dose: 1st dose the evening before colonoscopy (e.g. at 6:00 p.m.- 8:00 p.m.) and 2nd dose on the morning of colonoscopy, 10 to 12 hours after the evening dose (e.g. at 5:00 a.m.-7:00 a.m.)
2855098|NCT03562884|Active Comparator|Fortrans®|Fortrans® given orally as a split dose: 1st dose the evening before colonoscopy (e.g. at 6:00 p.m - 8:00 p.m.) and 2nd dose on the morning of colonoscopy, 10 to 12 hours after the evening dose (e.g. at 5:00 a.m.-7:00 a.m.)
2855099|NCT03562871|Experimental|Cohort A1|Drug: IO102 100µg administered subcutaneously (SC) on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg intravenous (IV) infusion on Day 1 of each 3 week cycle
2855100|NCT03562871|Active Comparator|Cohort A2|Drug: pembrolizumab (Keytruda) 200 mg IV infusion on Day 1 of each 3 week cycle
2855101|NCT03562871|Experimental|Cohort B1|Drug: IO102 100µg SC on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle
2855162|NCT03562442|No Intervention|Never-Smokers|Healthy caucasian volunteers who never smoked are investigated once only (Visit 1)
2855102|NCT03562871|Active Comparator|Cohort B2|Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle
2855103|NCT03562858|Active Comparator|Delayed dentine sealing|
2855104|NCT03562858|Experimental|Immediate dentin sealing|
2855105|NCT03562845||ARM 1-Bad vs Good Clinical Evolution|"This arm is intended to evaluate the correlation of Immunobiogram® sensitivity/resistance patterns with clinical prognosis as it may be judged at this moment considering clinical outcomes and immune-biomarker evolution in the past 12 to 18 months. Thus, it may confirm the BH-Pilot study findings. Renal transplant patients of two types will be included:~Patients who, over previous months, have had a bad clinical evolution, in which rejection mechanisms were involved~Patients with a good and stable clinical evolution~IMBG sensitivity/resistance profiles will be compared amongst the two groups to evaluate the differences."
2855106|NCT03562845||ARM 2-Stable Renal Transplant Patients|This arm is intended to evaluate robustness of Immunobiogram® as an IVD test. Thus, it will be performed intrasubject comparisons and inter-time evaluation of two sets of Immunobiogram® separated by 30+/- 10 days, each including three IMBG determinations (IMBGx3 - IMBGx3, the two sets separated by 30+/- 10 days). The intended evaluation will be to analyse the similarities between all IMBG tests performed, both between the same set and also between the two sets planned.
2855107|NCT03562832|Experimental|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
2855108|NCT03562819||NSCLC|Non-small cell lung cancer
2855109|NCT03562806|Experimental|PET/MR (single arm)|PET and MR sequence acquisition on SIGNA PET/MR device
2855110|NCT03562793|Experimental|COOPERATE Intervention Arm|Intervention patients will focus on 1) goal clarification/prioritization; 2) communication skills. There are 6 total sessions delivered individually over 12 weeks: 4 sessions teaching skills (30 min each) and 2 booster sessions delivered once/month for the next 2 months. Intervention will be delivered by telephone.
2855111|NCT03562793|No Intervention|Attention Control Arm|Veterans randomized to the control group will receive phone calls on the same schedule as intervention Veterans. During these phone calls, study staff will ask Veterans a series of questions about their pain, self-management activities, and any changes they have experienced since the last call. These phone calls are designed to control for attention only, and Veterans will not be offered specific information or advice about their pain or its management (with the exception of suggesting a doctor visit if warranted).
2855112|NCT03562780|Experimental|Fortolin Tab 500mg|During the study session, healthy subjects will be administered a single oral dose of Fortolin Tab 500mg after an overnight fast of approximately 10 hours.
2855113|NCT03562780|Active Comparator|Panadol Caplet 500mg|During the study session, healthy subjects will be administered a single oral dose of Panadol Caplet 500mg after an overnight fast of approximately 10 hours.
2855114|NCT03562767|Experimental|Group-based Cognitive Behavioral Intervention|Subjects receiving the group-based CT-CB intervention
2855115|NCT03562767|Experimental|Web-based Cognitive Behavioral Intervention|Subjects receiving the web based CT-CB intervention
2855116|NCT03562767|Placebo Comparator|Usual Care|Subjects receiving usual care from their primary care providers
2855117|NCT03562754|Active Comparator|Control|
2855118|NCT03562754|Experimental|Prometheus System|
2855119|NCT03562741|Experimental|Fecal Microbiota Transplantation|Subjects receive intervention of stool transplanted to the colon via colonoscopy.
2855120|NCT03562728|Active Comparator|ECMO- Bridge to Transplant|Interventions: MRP+MNES(neuromuscular electric stimulation).Patients in the treatment arm will receive additional physical therapy(arm and leg exercises, using light weight machines, hand weights, or rubber bands, exercise machines such as portable arm or seated bikes) as well as therapy with an electric stimulator device. This device uses weak electric impulses to involuntarily exercise the muscles(one-two sessions a day).Four muscle groups(quadriceps and dorsiflexors bilaterally) will be stimulated using surface electrodes .In addition, patients in the experimental group will receive nutrition supplementation with essential amino acids 3 times a day in their feeding to prevent muscle breakdown and promote positive nitrogen balance.
2855121|NCT03562728|Other|ECMO- Bridge to Transplant Control Group|"Interventions: standard of care~Patients are not going to receive any additional intervention."
2855122|NCT03562728|Active Comparator|Transplant|Interventions: MRP+MNES(neuromuscular electric stimulation).Patients in the treatment arm will receive additional physical therapy(arm and leg exercises, using light weight machines, hand weights, or rubber bands, exercise machines such as portable arm or seated bikes) as well as therapy with an electric stimulator device. This device uses weak electric impulses to involuntarily exercise the muscles(one-two sessions a day).Four muscle groups(quadriceps and dorsiflexors bilaterally) will be stimulated using surface electrodes .In addition, patients in the experimental group will receive nutrition supplementation with essential amino acids 3 times a day in their feeding to prevent muscle breakdown and promote positive nitrogen balance.
2855123|NCT03562728|Other|Transplant Control Group|"Interventions: standard of care.~Patients are not going to receive any additional intervention."
2855124|NCT03562715||Control group|Blood samples were collected from 100 control with normal pregnancies. Thirty fresh umbilical cord samples of women with healthy pregnancies (n=15) were retrieved during caesarean deliveries and umibilical cord mesenchymal stem cells (UCMSCs) were isolated from Wharton jelly.
2855125|NCT03562715||Preeclampsia group|Blood samples were collected from 100 patients with PE. Thirty fresh umbilical cord samples of PE patients (n=15) were retrieved during caesarean deliveries and UCMSCs were isolated from Wharton jelly.
2855126|NCT03562702|Active Comparator|Standard IV Rehydration Therapy|Patients randomized into the IV rehydration group will receive a Normal Saline bolus of IVF (usually 20 mL/kg) which is the standard therapy up to 24 hrs or as needed depending on patient's weight
2855127|NCT03562702|Experimental|Oral Rehydration Therapy (ORT)|Patients randomized into the oral rehydration group will receive the oral Speedlyte product instead of the IV rehydration therapy.
2855128|NCT03562676|Experimental|weightlessness|
2855129|NCT03562663|Experimental|Active tDCS|Participants in this group received 20 minutes of active 2 mA transcranial direct current stimulation over the motor cortex of the affected arm prior to robotic intervention.
2855165|NCT03562416|Experimental|Nintedanib|Nintedanib 150 mg tablet by mouth twice daily for 24 months.
2855131|NCT03562650|Experimental|Safety Behavior Fading|Participants are asked to pick their three most common safety behaviors from a list and then receive texts every other day for a month reminding them to fade those behaviors.
2855132|NCT03562650|Active Comparator|Present Centered|Participants receive texts every other day for a month asking them to try to focus on the present that day.
2855133|NCT03562637|Experimental|Adagloxad simolenin + OBI-821|Participants will be administered adagloxad simolenin combined with OBI-821 for up to a total of 21 subcutaneous injections at week 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 36, 44, 52, 60, 68, 76, 84, 92, and 100.
2855134|NCT03562637|Active Comparator|Placebo|Participants will be administered placebo for up to a total of 21 subcutaneous injections at week 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 36, 44, 52, 60, 68, 76, 84, 92, and 100.
2855135|NCT03562624|Experimental|BAY98-7443 (low IND dose)|Combi IUS Treatment, LNG (Levonorgestrel) with lowest dose of IND (indomethacin)
2855136|NCT03562624|Experimental|BAY98-7443 (middle IND dose)|Combi IUS Treatment, LNG with medium dose of IND
2855137|NCT03562624|Experimental|BAY98-7443 (high IND dose)|Combi IUS Treatment, LNG with highest dose of IND
2855138|NCT03562624|Active Comparator|Marketed comparator|Marketed comparator IUS
2855139|NCT03562611|Active Comparator|flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg
2855140|NCT03562611|Experimental|nalbuphine|nalbuphine intraoperative administration 0.1mg/kg
2855141|NCT03562611|Experimental|nalbuphine and flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg and nalbuphine intraoperative administration 0.1mg/kg
2855142|NCT03562585||Efficacy of immunoassay in liver fibrosis|efficacy of immunoassay in liver fibrosis in patients with CHB
2855143|NCT03562572|Experimental|Ischemia driven revascularization|In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload, which may lead to deterioration of cardiac and renal function of the patient.
2855144|NCT03562572|Active Comparator|Usual care group|In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
2855145|NCT03562559||TKA Patients|
2855146|NCT03562546|Experimental|Structured Resistance Exercise|12 week at home structured resistance exercise programme ('Strength From Within') using resistance bands. Under the supervision of an experienced exercise specialist.
2855147|NCT03562533||pegylated liposomal doxorubicin + carboplatin|carboplatin area under the curve [AUC] 5 plus pegylated liposomal doxorubicin (PLD) 30 mg/m2 every 4 weeks
2855148|NCT03562533||paclitaxel + carboplatin|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks
2855149|NCT03562520|Experimental|Adolescents with bipolar disorder|Forty adolescents (aged 13-21) with BD (type I, II, or not otherwise specified/other specified and related disorder) will be enrolled in the behavior change counseling intervention.
2855150|NCT03562507|Experimental|ESK981 Monotherapy|ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4 week cycles
2855151|NCT03562507|Experimental|ESK981 and Nivolumab|"ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4 week cycles~Nivolumab: 240 mg/dose IV, Day 1 and day 15"
2855152|NCT03562494|Experimental|VY-AADC02|Single dose of up to 2.5 x 10^12 vector genomes(vg) of VY-AADC02
2855153|NCT03562494|Placebo Comparator|Placebo (Sham)|Partial burr/twist hole without dura penetration
2855154|NCT03562481|Experimental|Buffered Anesthetic, then Unbuffered Anesthetic|Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.
2855155|NCT03562481|Experimental|Unbuffered Anesthetic, then Buffered Anesthetic|Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.
2855156|NCT03562468|Placebo Comparator|Placebo|Each subject will be randomly assigned to receive placebo for an 8-week treatment period. Subjects will be instructed to take two capsules (placebo) in the morning with breakfast and two capsules (placebo) in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
2855157|NCT03562468|Experimental|TRU NIAGEN (nicotinamide riboside) 300 mg/day|Each subject will be randomly assigned to receive 300 mg/day of TRU NIAGEN (nicotinamide riboside) for an 8-week treatment period. Subjects will be instructed to take two capsules of TRU NIAGEN in the morning with breakfast and two capsules of TRU NIAGEN in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
2855158|NCT03562468|Experimental|TRU NIAGEN (nicotinamide riboside) 1000 mg/day|Each subject will be randomly assigned to receive 1000 mg/day of TRU NIAGEN (nicotinamide riboside) for an 8-week treatment period. Subjects will be instructed to take two capsules of TRU NIAGEN in the morning with breakfast and two capsules of TRU NIAGEN in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
2855159|NCT03562455|Experimental|Virtual Reality Training|Participants will receive virtual reality power wheelchair training using VRSim 3.0 in this group.
2855160|NCT03562455|Active Comparator|In-person Therapist Training|Participants will receive in-person wheelchair training by a therapist in this group.
2855161|NCT03562442|Experimental|Smokers|"Healthy caucasian smokers who are willing to quit smoking are investigated before cessation (Visit 1) and 6 weeks after cessation (Visit 2).~Intervention: Smoking cessation"
2855166|NCT03562416|Placebo Comparator|Placebo|Placebo tablet by mouth twice daily for 24 months
2855167|NCT03562403|Experimental|DBS on patients with abnormal movement disorders|16 patients with intractable abnormal movement disorders (Parkinson's disease, Essential tremors and Dystonia)
2855168|NCT03562390|Experimental|Experimental group|124 women with locally recurrent or metastatic breast cancer who will receive treatment at 17 research centers in Liaoning Province and Heilongjiang Province of China. Irinotecan is administered intravenously on days 1 and 8 of each 3-week cycle.
2855169|NCT03562377|Experimental|Tralokinumab|"Week 0 to 16:~Tralokinumab will be given as subcutaneous injections.~Subjects will receive a tralokinumab loading dose at Day 0 followed by tralokinumab injection regimen A. The last administration will occur at Week 14."
2855170|NCT03562377|Placebo Comparator|Placebo|"Placebo (dummy treatment) will be given as subcutaneous injections.~Subjects will receive a placebo loading dose at Day 0 followed by placebo injection regimen A. The last administration will occur at Week 14."
2855171|NCT03562364|No Intervention|Standard of Care|Participants in the standard of care group will remain non weight bearing for at least 10 weeks. They will be given a standardized set of exercises to be completed at home or in the presence of a licensed PT
2855172|NCT03562364|Experimental|Early Advanced Weight Bearing (EAWB)|Participants randomized to the EAWB group will complete standardized home exercises, in addition to weight bearing therapy using the AlterG treadmill up to 3 times per week
2855173|NCT03562351|Experimental|Verbal Instructions on use of RM|Caregivers will undergo an educational intervention with typical training with verbal instructions and use of a rectal diazepam trainer.
2855174|NCT03562351|Experimental|Video on use of RM|Caregivers will undergo an educational intervention with training by watching an instructional video regarding rescue medication administration
2855175|NCT03562351|Experimental|Mannequin on use of RM|Caregivers will undergo an educational intervention with training by use of a mannequin to practice administering the rescue medication
2855176|NCT03562338|Experimental|Manual Therapy and Exercise|
2855177|NCT03562338|Active Comparator|Usual Care|
2855178|NCT03562325|Other|ACT|Acceptance & Commitment Therapy (ACT)
2855179|NCT03562312|Experimental|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
2855180|NCT03562312|Placebo Comparator|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
2855181|NCT03562299|Experimental|Experimental|Reconstruction of the Anterior Cruciate Ligament (ACL) using OrthoPure™ XT in patients with a partial or complete tear of the Anterior Cruciate Ligament (ACL)
2855182|NCT03562286|Experimental|Experimental Fetoscopy|All participants will undergo fetoscopic repair of open spina bifida
2855183|NCT03562273|Other|GammaPod Quality of Life Evaluations|This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.
2855184|NCT03562260|Experimental|children who had bipolar release|children who had bipolar release are included
2855185|NCT03562247|Active Comparator|Usual Care of IPF|Newly diagnosed patients will continue to receive excellent healthcare as currently given in management of the lung disease
2855186|NCT03562247|Experimental|Telenursing|Patients will receive usual care with structured phone calls from the nurse practitioner and/or case manager occuring more frequently earlier in the diagnosis to help the patient and care giver understand all aspects of the disease and it time will evolve to managing symptoms outside of out-patient clinic visits.
2855187|NCT03562247|Experimental|Telenursing and Remote Monitoring|Patients will receive usual care with telenursing and will be given a hand held spirometer and puse oximeter and be asked to take daily measurements and report these via an electronic HIPAA approved secured platform for evaluation by the telenursing team.
2855188|NCT03562234||Pre-op Chemotherapy for CLM: MR & LiMAx|"Patients undergoing pre-operative chemotherapy for colorectal liver metastases being treated at the Christie NHS (National Health Service) Foundation Trust.~No intervention - participants will continue with standard care. Observation of changes in liver fat and liver function measured by MR (Magnetic Resonance) scan and LiMAx test (Maximum liver capacity)."
2855189|NCT03562221|Experimental|Gluten free diet|Gluten free diet
2855190|NCT03562221|Active Comparator|Probiotics|Capsules with a combination of two probiotic bacteria with maize starch as excipient and at a total dose of 10(10) colony forming units (CFU)/capsule.
2855191|NCT03562221|Placebo Comparator|Placebo|Placebo capsules with maize starch and without any bacteria.
2855192|NCT03562195|Experimental|Subjects receiving Mepolizumab 100 milligrams|Eligible subjects will receive Mepolizumab 100 milligrams administered subcutaneously into the upper arm or thigh after every 4 weeks during the total treatment period of 52 weeks along with the standard care of therapy. Subjects will be provided with salbutamol metered dose inhalers (MDIs) as a rescue medication to be used on an as needed basis in this study.
2855193|NCT03562195|Placebo Comparator|Subjects receiving Placebo|Eligible subjects will receive placebo (0.9 percent sodium chloride) matching to Mepolizumab administered subcutaneously into the upper arm or thigh after every 4 weeks during the total treatment period of 52 weeks. Subjects will be provided with salbutamol MDIs as a rescue medication to be used on an as needed basis in this study.
2855194|NCT03562182||Women Receiving Antenatal Steroids|Group 2: Determine how (and if) serum hLPCAT1 mRNA changes with administration of a course of steroids by measuring its plasma levels before, 24hrs after the first dose and 24hrs after the second dose of bethamethasone as well as one and two week after the first dose. This is accomplished through a simple blood draw. We seek to understand the effects of the 2nd dose of steroids and determine if, once the hLPCAT1 expression begins, does it continue or does it turn off again after some time from steroid administration.
2855195|NCT03562182||Normal Pregnancy Controls|1) Group 1: Determine the plasma levels of hLPCAT1 mRNA in pregnant women from 32- 36+6/7 weeks gestation. This is accomplished through a simple blood draw. More specifically, we seek to find out, at what moment in gestation, expression spontaneously begins.
2855196|NCT03562169|Active Comparator|Conventional Autologous Stem Cell Transplant (ASCT)|Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0
2860236|NCT03527095|Experimental|Regimen D|FDL169 200 mg testing tablet 1 or 2 with high fat diet
2855197|NCT03562169|Experimental|Augmented Autologous Stem Cell Transplant (ASCT)|Melphalan 100mg/m2 IV infusion on Day -3 and -2 plus ixazomib 4mg capsules on Day -4 and -1. ASCT will then be given on Day 0.
2855198|NCT03562156|Experimental|VT-1161 150mg capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
2855199|NCT03562156|Placebo Comparator|Control capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
2855200|NCT03562143|Experimental|Alternate-day iron supplementation|Patients taking iron supplementation given as 2 tabs of 325 mg ferrous sulfate (equivalent to 130 mg of elemental iron) for 6 weeks.
2855201|NCT03562143|Active Comparator|Daily iron supplementation|Patients taking iron supplementation given as 1 tab of 325 mg ferrous sulfate (equivalent to 65 mg of elemental iron) for 6 weeks.
2855202|NCT03562130|Experimental|Revestive|Revestive® (teduglutide)is administered in children sub cutaneous injection at 0.05 mg/kg body weight once daily
2855203|NCT03562117|Experimental|Normal Hepatic function, Part 1 (Group D)|The eligible subjects, with normal hepatic function, in this arm will receive a single oral dose of gepotidacin as 1500 milligram (mg), administered as 2 × 750 mg tablets on Day 1.
2855204|NCT03562117|Experimental|Moderate hepatic impairment, Part 1 (Group B)|The subjects in this arm, will be the one's with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1.
2855205|NCT03562117|Experimental|Mild hepatic impairment, Part 2 (Group A)|The subjects in this arm, will be the one's with a Child-Pugh score of 5 to 6, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1. This will be optional arm.
2855206|NCT03562117|Experimental|Severe hepatic impairment, Part 2 (Group C)|The subjects in this arm, will be the one's, with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets, on Day 1.
2855207|NCT03562117|Experimental|Normal Hepatic function, Part 2 (Group E)|The eligible subjects, with normal hepatic function, will be matching with those enrolled in Part1, and will receive a single oral dose of gepotidacin as 1500 mg, administered as 2 × 750 mg tablets on Day 1.
2855208|NCT03562104|Experimental|Minimally consciousness Patient|Wessex Head Injury Matrix scale and Videofluoroscopy for characterization of swallowing disorders in Minimally consciousness Patient
2855209|NCT03562078|Experimental|Tai Chi Quan for Type 2 Diabetes|diabetic patients care education and Tai Chi Quan training, including 10-minute warm-up, 40-minute Tai Chi lesson, and 10-minute cool-down exercise in the training, twice a week for 12 weeks.
2855210|NCT03562078|No Intervention|Control Group for Type 2 Diabetes|diabetic patients care education
2855211|NCT03562065|Experimental|mesenchymal stem cells|"Phase I-II, Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:~1.10^6 CSM / kg~2.10^6 CSM / kg~4.10^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion"
2855212|NCT03562039|Experimental|M-MIST (group A)|M-MIST(incomplete granulation tissue removal)
2855213|NCT03562039|Active Comparator|M-MIST (group B)|conventional M-MIST.
2855214|NCT03562000|Experimental|Intervention group on cough and ventilation assistance|Mechanical cough assistance during physiotherapy post-extubation in ICU and systematic indication of NIV.
2855215|NCT03562000|Other|Control group on cough and ventilation assistance|Control group of extubated patients receiving the current gold standard strategy during physiotherapy after extubation in ICU and with selected indications of NIV.
2855216|NCT03561987||Obese patients and bariatric surgery|"The investigators include men and women, over 18 years old, with morbid obesity and candidates for bariatric surgery, under the routine of the treating service, with signature of acceptance of your participation, by informed consent.~The investigators exclude patients with medication with potential effect on adipose tissue or cardiovascular risk in the last month, also with severe infections in the last month or clinically unstable conditions.~Patients are eliminated in the study if they dont have the desire to continue in the study, and if the samples or the information are insufficient for an adequate analysis."
2855217|NCT03561987||No obese patients and abdominal surgery|"The investigators include men and women, over 18 years old, without obesity and candidates for abdominal surgery (hernioplasty, cholecystectomy, fundoplication), under the routine of the treating service, with signature of acceptance of your participation, by informed consent.~The investigators exclude patients with medication with potential effect on adipose tissue or cardiovascular risk in the last month, also with severe infections in the last month or clinically unstable conditions.~Patients are eliminated in the study if they dont have the desire to continue in the study, and if the samples or the information are insufficient for an adequate analysis."
2855218|NCT03561974|Experimental|Humidification|
2855219|NCT03561974|No Intervention|Control group without humidification|
2855220|NCT03561961|Active Comparator|Moderate Hypo-fractionation|In arm 1 of the study, patients who are randomized to receive moderately hypo-fractionated RT will receive a total dose of 66-68 Gy in 25# to the primary over 5 weeks, with treatment being delivered daily. Patients with node positive disease will receive a dose of 50 Gy in 25# to the pelvis. Boost to gross nodal disease will be considered based on the response to hormonal therapy to a dose of 60-66 Gy/25# as a simultaneous integrated boost(SIB).
2855221|NCT03561961|Experimental|Extreme Hypo-fractionation|In Arm 2 of the study, patients who are scheduled to receive SBRT will receive a course of 5 fractions of radiation; each fraction size will be 7.00-7.25 Gy. The total dose will be 35-36.5 Gy. Patients with node positive disease will receive a dose of 25 Gy in 5 # to the pelvis. Boost to gross nodal disease will be considered based on the response to hormonal therapy to a dose of 30-35 Gy/5# as a simultaneous integrated boost(SIB).The 5 treatments will be scheduled to be delivered alternate day over approximately 7-10 days. An option of equivalent biological dose using 35-36.5 Gy in 5 weekly fractions may be allowed for multicentric accrual in the future.
2855222|NCT03561948|Experimental|Experimental group|Surgery and Intraperitoneal Chemotherapy
2855223|NCT03561948|Placebo Comparator|Control group|only surgery
2855224|NCT03561935|Experimental|Propafenone group|Prescribtion of propafenone for the management of premature ventricular complex
2855225|NCT03561935|Active Comparator|Indenol group|Prescribtion of indenol for the management of premature ventricular complex
2855226|NCT03561922|Experimental|RETINA IMPLANT Alpha AMS|All participants receive the subretinal device RETINA IMPLANT Alpha AMS
2855227|NCT03561909|Other|Platelet transfusion|HLA-A2 and/or HLA A9 negative healthy study subjects will be transfused with a small dose of platelets from an HLA-A2 and/or HLA-A9 positive donor.
2855228|NCT03561896|Experimental|IGRT|Image-Guided Hypofractionated Stereotactic Radiation Therapy (IGRT) of the resection cavity
2855229|NCT03561896|Experimental|SRS|Stereotactic Radiosurgery of the resection cavity (SRS)
2855230|NCT03561883|Experimental|1500 mg IW-3718 BID|Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals.
2855231|NCT03561883|Placebo Comparator|Placebo|Three placebo tablets administered BID immediately after the morning and evening meals.
2855232|NCT03561870|Experimental|Olaparib|
2855233|NCT03561857|Experimental|Confocal Laser Endomicroscopy|All included patients will undergo probe-based Confocal Laser Endomicroscopy during Robotic-Assisted Radical Prostatectomy (RARP) or Laparoscopic Radical Prostatectomy (LRP)
2855234|NCT03561844|Active Comparator|aromatherapy-scent|
2855235|NCT03561844|Active Comparator|aromatherapy-touch|
2855236|NCT03561844|No Intervention|waiting-list control|
2855237|NCT03561831|Active Comparator|propofol group|patients who anesthesized by propofol
2855238|NCT03561831|Active Comparator|sevoflurane group|patients who anesthesized by sevoflurane
2855239|NCT03561818|Experimental|Hospital-based group|2 months hospital-based pulmonary rehabilitation program
2855240|NCT03561818|Experimental|Home-based group|2 months home-based pulmonary rehabilitation program
2855241|NCT03561805|Other|Prolonged continuous ECG monitoring|Patients will undergo a prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure. The duration of the ECG monitoring will be of 1 week.
2855242|NCT03561792|No Intervention|traditional RSBI|the decision to continue SBT depends on the traditional RSBI (RSBI < 105 predicts successful weaning)
2855243|NCT03561792|Experimental|Diaphragmatic RSBI|diaphragm ultrasound was done to measure diaphragmatic displacement which is used to calculate DRSBI and The investigator takes the decision about SBT continuation based on the result of DRSBI (DRSBI < 1.3 predicts successful weaning)
2855244|NCT03561779|Experimental|YYD302|YYD302 (2ml)
2855245|NCT03561779|Active Comparator|Synovian Inj.|Synovian Inj. (3ml)
2855246|NCT03561753|Active Comparator|Group A (the standard 2HRZE/4HR regimen)|Group A, Standard Regimen (2EHRZ/4HR): Control group, use the standard six-month regimen with eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
2855247|NCT03561753|Experimental|Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)|Group B, PRS Regimen (4EZ [high dose] Cfz Pto): Experience group，use the PRS regimen is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.
2855248|NCT03561740|Experimental|Metronomic Capecitabine Group|Patients in experimental group (also Metronomic Capecitabine Group) will receive additional metronomic chemotherapy of capecitabine (500mg TID po), begin after the completion of standard adjuvant chemotherapy or surgery if neoadjuvant chemotherapy were administrated, until three weeks after the last cycle of trastuzumab (6mg/kg every 3 weeks).
2855249|NCT03561740|No Intervention|Control Group|Patients in control group will receive standard therapy only, as per the guidelines.
2855250|NCT03561727|Experimental|Mass closure technique|Abdominal cavity will be closed by a single layer of 2 continuous sutures beginning on the opposite ends of the wound towards the median line and involving peritoneum, transversalis fascia, posterior and anterior layer of rectus abdominis muscle fascia and, in case of incisions beyond the lateral border of rectus abdominis muscle, also the oblique abdominal muscles fascia.
2855251|NCT03561727|Active Comparator|Layered closure technique|Abdominal cavity will be closed with two separate layers of continuous sutures. The first layer will include peritoneum, transversalis fascia and posterior layer of the rectus abdominis muscle fascia. In case of incisions not exceeding the lateral border of rectus abdominis muscle, the second layer will involve only the anterior layer of the rectus abdominis muscle fascia. In case of incisions exceeding the lateral border of rectus abdominis muscle, the second layer will include internal oblique abdominal muscle fascia, external oblique abdominal muscle fascia and anterior layer of the rectus abdominis muscle fascia.
2855252|NCT03561714||CMC-TI|Cardiometabolic Care Team Intervention
2855253|NCT03561714||Non-Intervention Comparator site|Non intervention comparator site with usual care
2855254|NCT03561701|Experimental|VT-1161 150mg capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
2855255|NCT03561701|Placebo Comparator|Control capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
2855256|NCT03561688|Sham Comparator|Standard insole|a flat insole
2855257|NCT03561688|Experimental|Foot orthotics|Custom-made foot orthoses
2855258|NCT03561675|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2855259|NCT03561675|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.
2855260|NCT03561662|Active Comparator|Low isoflavone|Alpro soya drinks containing 10 mg isoflavones per day
2855261|NCT03561662|Active Comparator|Medium isoflavone|Alpro soya drinks containing 35 mg isoflavones per day
2855262|NCT03561662|Active Comparator|High isoflavone|Alpro soya drinks containing 60 mg isoflavones per day
2855263|NCT03561649|Experimental|Adalimumab|"Adalimumab is not the experimental study drug. This treatment justifies the inclusion of patients and is used in accordance with its marketing authorization.~The patients will be seen as part of their follow-up consultation in Rheumatology.~Modality of administration: The baseline visit should take place no more than 4 weeks before the start of adalimumab treatment, 40mg every 2 weeks, subcutaneously, in accordance with Summary of Product Characteristics.~At baseline and 6 months follow-up visits, a single blood draw for the biomarker dosage will be added to the standard patient health care follow-up. The clinical examination will also be performed at these two visits, and the clinical response will be assessed after 6 months of adalimumab treatment at M6 follow-up visit."
2855340|NCT03560973|Experimental|Gemcitabine + Ramucirumab|Gemcitabine 1000 mg/m2 iv D1, D8 plus Ramucirumab 10 mg/kg iv (21 days cycles)
2855264|NCT03561623||Patients with Post Polio Syndrome|Post Polio syndrome diagnosed according to March of Dimes Criteria; 'magnetic resonance (MR) Imaging' will be performed including a 'quantitative muscle force assessment'
2855265|NCT03561623||Healthy controls|subjects age- and sex-matched; 'magnetic resonance (MR) Imaging' will be performed including a 'quantitative muscle force assessment'
2855266|NCT03561610|Active Comparator|Study group 1|normal Nutrition + sip feed (covers individual energy and nutrient demands)
2855267|NCT03561610|Experimental|Study group 2|normal Nutrition + gumdrops (covers individual energy and nutrient demands)
2855268|NCT03561597|Experimental|Mobile health application|Participants will undergo Kurbo program, a Mobile health application, for more detailed dietary and physical activity recommendations and implementation of behavioural changes. The patient's progress will be reviewed by the nurse clinician at one month post intervention to determine whether the BMI percentile has shown a reduction through the Kurbo Program. Patients that declined Kurbo intervention, has a BMI of more than 99th percentile or continue to have increase in their BMI percentile in Kurbo program, will be offered the high risk weight management clinic appointment for a more detailed multidisciplinary evaluation for targeted intervention. Patients that are able to engage with Kurbo intervention and showed a decrease in BMI percentile over 4 sessions of Kurbo will be offered the low risk weight management clinic (WMC). There will be a month 3 and month 6 visit for study measurements in this study.
2855269|NCT03561584|Active Comparator|Active Drug (Sulfasalazine)|
2855270|NCT03561584|Placebo Comparator|Placebo|
2855271|NCT03561571|Active Comparator|Butter based breakfast|
2855272|NCT03561571|Active Comparator|Chocolate spread based breakfast|
2855273|NCT03561558|Experimental|Ibuprofen D, oral suspension|Ibuprofen oral suspension, 200 mg/ 5 ml is the test product. In period 1 and period 2, 15 of 30 subjects will be given single oral dose (5 ml containing 200 mg of ibuprofen) of suspension.
2855274|NCT03561558|Active Comparator|Nurofen® for Children, oral suspension|Nurofen® for Children oral suspension, 100 mg/ 5 ml is the reference product. In period 1 and period 2, 15 of 30 subjects will be given single oral dose (10 ml containing 200 mg of ibuprofen) of suspension.
2855275|NCT03561545|Experimental|Functional capillary density|Functional capillary density during weightlessness
2855276|NCT03561532|Active Comparator|FMT|50% of the participants will receive fecal suspension of a healthy donor administered in colonoscopy into the cecum
2855277|NCT03561532|Placebo Comparator|Placebo|50% of the participants will receive fecal suspension made of their own feces administered in colonoscopy into the cecum.
2855278|NCT03561519|Active Comparator|FMT|IBS patients randomized to receive FMT from a healthy donor.
2855279|NCT03561519|Placebo Comparator|Placebo|IBS patients randomized to receive autologous FMT (fecal suspension made of their own feces) as a placebo.
2855280|NCT03561506|Experimental|Ferric carboxymaltose group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg .
2855281|NCT03561506|Active Comparator|Placebo group|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight <50 Kg.
2855282|NCT03561493|Experimental|zumba exercise group|Participants will engage in 16 classes of 60-minute Zumba® fitness for two consecutive menstrual cycles (an 8-week period, twice weekly). Each class was one h in length and a recovery period of at least 48 h was taken between classes.
2855283|NCT03561493|No Intervention|non zumba exercise group|The participants in the control group did not receive any intervention.
2855284|NCT03561480|Experimental|Ferric carboxymaltose group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with postoperative anemia after total knee arthroplasty.
2855285|NCT03561480|Active Comparator|Placebo group|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with postoperative anemia after total knee arthroplasty.
2855286|NCT03561441|Active Comparator|Tailored standard hydration|Patients will be randomly allocated to tailored standard hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 1.5 milliliter(mL)/kg/hr during and after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.
2855287|NCT03561441|Experimental|Tailored aggressive hydration|Patients will be randomly allocated to tailored aggressive hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg over 1 hour after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.
2855288|NCT03561415|Experimental|Universal posaconazole prophylaxis|Universal posaconazole prophylaxis: All patients will start posaconazole modified release tablet (300mg daily ) between Day 4 and Day 14 post lung or heart-lung transplantation for 3 months.
2855289|NCT03561415|Experimental|Pre-emptive posaconazole therapy|Pre-emptive posaconazole therapy: Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease and given for 3 months.
2855290|NCT03561402||Patients with active disease|From the cohort of patients receiving teriflunomide - 1 tablet (14 mg) daily, the investigators will identify patients that have active disease..
2855291|NCT03561402||Patients with stable disease|From the cohort of patients receiving teriflunomide (as above), the investigators will identify patients that have stable disease.
2855292|NCT03561376|Other|Single arm - split scar study|Surgical closures, at least 7 cm in length, will be split and zinc oxide ointment applied to half and petrolatum ointment to the other half
2855293|NCT03561363|Experimental|Saturated high-fat diet|"In this intervention group, subjects ingest a saturated eucaloric high-fat diet (64 E%) with total fat content being similar to the polyunsaturated high-fat diet.~The diet is enriched in saturated fat (36 E%). The main saturated fatty acids in the diet are primarily palmitic acid (C16:0) and stearic acid (C18:0). The main food sources are milk products, high-fat meat and vegetables.~Carbohydrate comprise 20 E% and protein 15 E%."
2855531|NCT03559621|Other|intervention group|A mobile-based lifestyle intervention
2855294|NCT03561363|Experimental|polyunsaturated high-fat diet|In this intervention group, subjects ingest a polyunsaturated eucaloric high-fat diet (64 E%), with total fat content being similar to the saturated high-fat diet. The diet is enriched in polyunsaturated fat (32 E%). The main polyunsaturated fatty acids in the diet are primarily linoleic acid (C18:2 n-6) and alpha-linoleic acid (C18:3 n-3). The main food sources are vegetable oils, nuts and high-fat fish (e.g. salmon). Carbohydrate comprise 20 E% and protein 15 E%.
2855295|NCT03561337|Experimental|PROTEIN-CARBOHYDRATE|Intervention group receiving protein and carbohydrate supplement
2855296|NCT03561337|Placebo Comparator|CARBOHYDRATE|Intervention groups receiving carbohydrate supplement
2855297|NCT03561324|Experimental|Use of IntraOperative Imaging Probe|The sterilized (Imaging Beta Probe) IBP will be used intraoperatively in surgical wounds for localization of tumor sites and detecting completeness of excision vs. positive margins.
2855298|NCT03561311|Experimental|Remote ischemic conditioning group|
2855299|NCT03561311|Sham Comparator|Sham remote ischemic conditioning group|
2855300|NCT03561298|Experimental|Single Arm: BGB-3111 + Drug Cocktail|BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)
2855301|NCT03561285||Stroke with antiphospholipid|
2855302|NCT03561285||stroke without antiphospholipid|
2855303|NCT03561272|No Intervention|Standard Patient Reported Adherence|Adherence assessment via phone call or in person
2855304|NCT03561272|Active Comparator|Smart Phone Application|Adherence assessment via phone app
2855305|NCT03561272|Experimental|POD and Smart Phone Application|"Adherence assessment via phone app partnered with an automated dispensing machine, a Pod."
2855306|NCT03561259|Experimental|131I-MIBG|131I-MIBG
2855307|NCT03561246|Active Comparator|Personalized training effect on SSWS|"Determine the efficacy of motor control deficit guided personalized training on SSWS compared to non-personalized and CONTROL interventions.~Incline treadmill walking Decline treadmill walking"
2855308|NCT03561246|Active Comparator|Personalized training effect on Pp|"Determine the efficacy of motor control deficit guided personalized training on increasing symmetry of Pp compared to non-personalized and CONTROL interventions.~Incline treadmill walking Decline treadmill walking"
2855309|NCT03561246|Active Comparator|Positive response|"Determine if the personalized intervention increase the positive response rate compared to non-personalized and CONTROL interventions, and to further advance personalize interventions by identifying factors that predict response.~Incline treadmill walking Decline treadmill walking"
2855310|NCT03561233|Experimental|proton pump inhibitor|omeprazole 20 mg twice daily
2855311|NCT03561220|Active Comparator|IMRT (Photon)|As this trial is pragmatic, all treatment will be standard of care.
2855312|NCT03561220|Active Comparator|Proton Therapy Standard of Care|As this trial is pragmatic, all treatment will be standard of care.
2855313|NCT03561220|Experimental|Standard Proton Therapy|78.0 Gy (RBE) in 39 fractions. This is Arm 1 of the embedded randomized trial.
2855314|NCT03561220|Experimental|Hypofractionated Proton therapy|60.0 Gy (RBE) in 20 fractions This is Arm 2 of the embedded randomized trial.
2855315|NCT03561207||Tumor tissue tested with EV3D Assay|Cancer tissue from multiple sites in the body, to include ovarian, brain, breast and other rare tumors.
2855316|NCT03561181|Experimental|High dose Group|Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
2855317|NCT03561181|Experimental|low dose Group|Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,5μg/dose
2855318|NCT03561168||Developmental Delay|Children under age 3 who underwent MRI brain with anesthesia for the indication of Developmental Delay (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
2855319|NCT03561168||Seizure|Children under age 3 who underwent MRI brain with anesthesia for the indication of Seizure (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
2855320|NCT03561168||Developmental Delay and Seizure|Children under age 3 who underwent MRI brain with anesthesia for the indication of Developmental Delay and Seizure (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
2855321|NCT03561155|Experimental|Robot assisted treatment|The experimental group (EG) will undergo a robot-assisted arm training using Amadeo® (Tyromotion-Austria).
2855322|NCT03561155|Active Comparator|Conventional treatment|The conventional group (CG) will undergo robot unassisted treatment (Conventional treatment).
2855323|NCT03561142|Experimental|Radiochemotherapy -> chemotherapy.|Radiochemotherapy followed by consolidation chemotherapy. Deep regional hyperthermia can additionally be performed at the centers in Tübingen and Erlangen.
2855324|NCT03561116|Experimental|XAN|XAN (1 sachet of 12 mg/day)
2855325|NCT03561116|Placebo Comparator|Placebo|Placebo (1 sachet with excipient)
2855326|NCT03561103|Experimental|Intervention|Participants in the intervention arm will receive client-centered representative payee services in addition to the standard of care.
2855327|NCT03561103|No Intervention|Control|Participants in the control group will receive the standard of care.
2855328|NCT03561090|Experimental|1500 mg IW-3718 BID|Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals.
2855329|NCT03561090|Placebo Comparator|Placebo|Three placebo tablets administered BID immediately after the morning and evening meals.
2855330|NCT03561077|Experimental|Mindfulness program|To study the feasibility in France of a mindfulness program with mindfulness-based interventions (MBI's) dedicated for adolescents with chronic pain.
2855331|NCT03561064|Experimental|Receiving CBT-I|This is a single arm study. All participants will receive CBT-I (cognitive behavioral therapy for insomnia).
2855332|NCT03561038|Active Comparator|Franseen Needle|2 strokes within the mass with Franseen Needle, and then 2 strokes with the Fork-tip Needle
2855333|NCT03561038|Active Comparator|Fork-tip Needle|2 strokes within the mass with Fork-Tip needle, and then 2 strokes with the Franseen Needle
2855334|NCT03561025|Active Comparator|18F-FDG-PET/MRI|
2855335|NCT03561025|Experimental|18F-GE180-PET/MRI|
2855336|NCT03561012|Experimental|Intervention arm|
2855337|NCT03561012|Active Comparator|Control Arm|
2855338|NCT03560986|Experimental|Neridronic acid|Neridronic acid administered by 4 intravenous infusions within 10 Days
2855339|NCT03560986|Placebo Comparator|Placebo|Matching placebo administered by 4 intravenous infusions within 10 Days
2855341|NCT03560973|Placebo Comparator|Gemcitabine + Placebo|Gemcitabine 1000 mg/m2 iv D1, D8 plus placebo (21 days cycles)
2855342|NCT03560960|Experimental|Probable AD|Participants with probable AD with positive imaging AD pathology will receive the pramlintide challenge test.
2855343|NCT03560960|Active Comparator|Amnestic MCI|Participants with amnestic MCI with or without positive AD imaging pathology will receive the pramlintide challenge test.
2855344|NCT03560960|Active Comparator|Control- Normal Cognition|Participants with normal cognition without any memory complaints will receive the pramlintide challenge test.
2855345|NCT03560947|Experimental|Manual Therapy and Exercise|
2855346|NCT03560947|Active Comparator|Usual Care|
2855347|NCT03560934|Experimental|Frequent Cannabis Users|"Subjects categorized as frequent cannabis users (>3x/week for 3 months) will receive a single dose of 20-30mg dronabinol on the third night of their stay in the clinical laboratory (following an acclimation and baseline night), one hour prior to bedtime and five minutes after completion of a study snack.~Dronabinol is an orally active, synthetic THC currently indicated for weight loss in patients with acquired immune deficiency syndrome (AIDS) or anorexia and for nausea and vomiting associated with cancer. Dronabinol is nearly absorbed (90%-95%) after a single oral dose of the capsule formulation with 10-20% of the administered dose researching the systemic circulation due to extensive first-pass hepatic metabolism and high lipid solubility. The onset of action is ~30 to 60 minutes with peak effects from 2-4-h following dose (Fig. 2) (34). The 20-30 mg of dronabinol will be administered by OHSU's research pharmacy services."
2855348|NCT03560934|Experimental|Non Cannabis Users|Non-cannabis users (who have never used cannabis or not more than 10 times in their lifetime) will undergo the same single dose administration of 20-30mg dronabinol as the frequent cannabis user arm, under the identical study procedure.
2855349|NCT03560921||Stored blood transfusion|measurement of urinary NGAL
2855350|NCT03560921||Fresh blood transfusion|measurement of urinary NGAL
2855351|NCT03560908|Experimental|Dasatinib plus chemotherapy|Dasatinib combined with chemotherapy for relapsed t(8;21) AML with D816 mutation
2855352|NCT03560895|Active Comparator|Group I|Patients will be anesthetized using low-volume cuffed Kimberly-Clark * MICROCUFF * endotracheal tube (Microcuff, Halyard Health Inc., Atlanta, GA, USA), with its outer diameter determined by ultrasonography.
2855353|NCT03560895|Active Comparator|Group II|Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube (Mallinckrodt Medical, Athlone, Ireland) with its outer diameter determined by ultrasonography.
2855354|NCT03560895|Active Comparator|Group III|Patients will be anesthetized using uncuffed endotracheal tube (Mallinckrodt Medical, Athlone, Ireland) with its outer diameter determined by ultrasonography.
2855355|NCT03560882|Experimental|Atorvastatin|Atorvastatin 80 milligrams (mg) per day, orally for 1 - 4 weeks before surgery (surgery not part of clinical trial)
2855356|NCT03560869|Active Comparator|Normal Hydration|Participants will consume water to maintain proper hydration for three days prior to testing.
2855357|NCT03560869|Experimental|Dehydration|Participants will reduce water intake over three days and abstain from any water for the final 16 hours prior to testing.
2855358|NCT03560856|Other|Fulvestrant 500mg + palbociclib 125 mg|Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
2855359|NCT03560843|Experimental|MBSR treatment|MBSR will be administered over 8 week period.
2855360|NCT03560843|No Intervention|Control group|Usual care will continue for this group.
2855361|NCT03560830||Control|Sedentary control subjects with no medical or psychiatric disorder
2855362|NCT03560830||POTS GWI|GWI with Postural Orthostatic Tachycardia Syndrome (POTS) GWI veterans who had postural orthostatic tachycardia before exercise and after 2 submaximal exercise stress tests. Postural orthostatic tachycardia was defined by 2015 Consensus as an increase in heart rate of greater than or equal to 30 beats per minute between recumbent (after 5 minutes of rest) and standing up. Standing heart rates were measured every minute for 5 minutes. Postural orthostatic tachycardia was defined if the change in heart rate was more than 30 beats per minute at at least 2 of the 5 standing time points. The average change in heart rate did not have to be above 30. There were 11 GWI POTS subjects.
2855363|NCT03560830||START|"START = Stress Test Activated Reversible Tachycardia One third of GWI veterans were found to have normal changes in heart rate between recumbent and standing (usual change ~10 to 15 beats per minute) BEFORE EXERCISE, but AFTER EXERCISE (submaximal exercise stress tests) they developed postural orthostatic tachycardia with changes in heart rate of 30 or more between recumbent and standing. The effect was transient as it lasted about 36 to 48 hr.~The START group had brainstem atrophy and reduced brain activation during a cognitive task compared to sedentary control and other GWI subjects."
2855364|NCT03560830||STOPP|"STOPP = Stress Test Originated Phantom Perception Two thirds of GWI veterans were found to have normal changes in heart rate between recumbent and standing (usual change ~10 to 15 beats per minute) both before and after 2 submaximal exercise stress tests. STOPP did not develop postural orthostatic tachycardia. their changes were equivalent to the sedentary control group.~The STOPP group increased brain activation of the basal ganglia and anterior insula during a cognitive task compared to sedentary control subjects."
2855365|NCT03560817||breast cancer|No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.
2855366|NCT03560817||colorectal cancer|No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.
2855367|NCT03560804|Active Comparator|Olmesartan|ARB administration (OLMESARTAN) at a starting dose and titrating at 15 weeks according to reach blood pressure target
2855368|NCT03560804|Active Comparator|Chlorthalidone|Diuretic administration (chlorthalidone) at a starting dose and titrating at 15 weeks according to reach blood pressure target
2855369|NCT03560765|Experimental|Using MED assigned buddy|Participant has been randomly assigned a student volunteer buddy, and has chosen to purchase an MED following training
2855370|NCT03560765|Active Comparator|Using MED training only|Participant has been randomly assigned to not have a student volunteer buddy, and has chosen to purchase an MED following training
2855371|NCT03560765|Active Comparator|No MED, assigned buddy|Participant has been randomly assigned a student volunteer buddy, and has chosen not to purchase an MED following training
2855372|NCT03560765|No Intervention|No MED, no buddy|Participant has been randomly assigned to not have a student volunteer buddy, and has chosen not to purchase an MED following training
2855373|NCT03560752|Experimental|Prevention(multi-peptide CMV-modified vaccinia Ankara vaccine)|Donors receive multi-peptide CMV-modified vaccinia Ankara vaccine injection between days -60 and -14 prior to granulocyte colony stimulating factor mobilization. Participants undergo hematopoietic cell transplantation on day 0.
2855374|NCT03560739|Other|PFS (abdomen)|ofatumumab 20 mg sc. injection with PFS administrated on abdomen
2855375|NCT03560739|Other|AI (abdomen)|ofatumumab 20 mg sc. injection with AI administrated on abdomen
2855376|NCT03560739|Other|PFS (thigh)|ofatumumab 20 mg sc. injection with PFS administrated on thigh
2855377|NCT03560739|Other|AI (thigh)|ofatumumab 20 mg sc. injection with AI administrated on thigh
2855378|NCT03560726|Experimental|Telehealth|Participants randomized into the telehealth arm will receive up to 7 one-hour telehealth visits with the study psychologist. The first six sessions will focus on cognitive behavioral stress management topics and the seventh session is optional, focusing on lung transplant readiness. Participants will fill out questionnaires every other week (baseline, week 2, week 4, week 6, week 8) and during a 3-month follow-up (week 20). Participants will wear an actigraphy watch to track sleep and movement for one week at a time during baseline, week 8, and week 20.
2855379|NCT03560726|No Intervention|Treatment-As-Usual (TAU)|"Participants randomized into the TAU arm will not receive any telehealth visits during the 8-week intervention phase. Participants will fill out questionnaires every other week (baseline, week 2, week 4, week 6, week 8) and during a 3-month follow-up (week 20).~Participants will wear an actigraphy watch to track sleep and movement for one week at a time during baseline, week 8, and week 20."
2855380|NCT03560713|Experimental|FES + combined exercise|The Functional Electrical Stimulation (FES) + combined exercise group will receive 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant) and receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
2855381|NCT03560713|Sham Comparator|FES sham|The Functional Electrical Stimulation (FES) sham + combined exercise group will receive 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes and receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
2855382|NCT03560700|Experimental|lactobacillus probiotic strain|60 billion CFU/day
2855383|NCT03560700|Placebo Comparator|placebo|
2855384|NCT03560687|Experimental|CardioSIDERAL|Adminsitration of 2 pills per day of CArdiosideral from 30 days before operation to time of operation
2855385|NCT03560687|No Intervention|Control|
2855386|NCT03560661||Amyotrophic lateral sclerosis (ALS) patients|
2855387|NCT03560661||Primitive Lateral Sclerosis (PLS) patients|
2855388|NCT03560661||Kennedy's disease (KD) patients|
2855389|NCT03560648|Other|Reference group|To define the normal muscle aging from HD-sEMG and accelerometer signals correlated to muscular parameters obtained from Dual Energy X-ray Absorptiometry (DEXA), handgrip strength and muscular echography. Data will be collected in healthy volunteers, aged 25 to 75 years old, physically active on IPAQ questionnaire.
2855390|NCT03560648|Other|Test group|"To evaluate the capacity of MFA to detect early muscle aging in  tests  individuals, sedentary volunteers within the same age group (45-55 years old)."
2855391|NCT03560635|Active Comparator|Control|Participants randomized to the CON condition will be informed of their estimated weight maintenance calorie needs (determined by multiplying their resting energy expenditure (REE) obtained from indirect calorimetry by an appropriate activity factor and advised to adhere to this calorie target, as is standard weight maintenance advice. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the diet protocol.
2855392|NCT03560635|Experimental|Reverse Diet|Participants randomized to the reverse diet condition will receive specific caloric intake goals. The initial caloric goal will be set at 2-3% above the level participants ended their weight loss diet at (via self-report). Participants' caloric goals will increase at a rate of 2-3% per week. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the reverse diet protocol.
2855393|NCT03560622|Active Comparator|ET cohort|Ten adults with refractory ET (ET cohort) will undergo multi-modality neuroimaging (structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI)). In addition the ET cohort will also undergo imaging with the identical protocol immediately after and 24 hours after FUS-T.
2855394|NCT03560622|Experimental|control cohort|Twenty adult healthy controls (control cohort) will undergo multi-modality neuroimaging (structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI)).
2855395|NCT03560609|Active Comparator|Subjects With Keratoconus|
2855396|NCT03560609|Active Comparator|Subjects with Glaucoma|
2855397|NCT03560596|Experimental|High Risk Latino Patients Adherence Intervention|74 high risk Latinos with uncontrolled hypertension
2855398|NCT03560596|Active Comparator|High Risk Latinos Usual Care|74 high risk Latinos with uncontrolled hypertension
2855399|NCT03560583|Experimental|Metoclopramide 10 mg BID|
2855400|NCT03560583|Placebo Comparator|Placebo 10 mg BID|
2855401|NCT03560570||Event group|CDG with antecedent of stroke-like, thrombosis or haemorrhages
2855402|NCT03560570||Non event group|CDG without antecedent of stroke-like, thrombosis or haemorrhages
2855403|NCT03560570||Control|Healthy subject
2855404|NCT03560544|Experimental|Breaking up sitting time|A behaviour-change intervention to break up prolonged sitting in the workplace
2855405|NCT03560544|No Intervention|Control|The participants in the control group will continue their daily activities as normal without any form of information about the intervention.
2855406|NCT03560531|Experimental|ZN-c5 monotherapy|Sequential dose escalation cohorts are planned to determine maximum tolerated dose(MTD) or recommended phase 2 dose (RP2D) of ZN-c5, followed by expansion cohorts at each dose level.
2855532|NCT03559595|Experimental|Intervention group|All study participants will be exposed to the intervention
2855407|NCT03560531|Experimental|ZN-c5 + palbociclib combination therapy|After the MTD/RP2D of ZN-c5 as monotherapy has been determined, the combination cohort dose escalation will begin enrollment.The expansion cohorts are planned at each dose level.
2855408|NCT03560518|Experimental|Rapastinel 450mg|Rapastinel (prefilled syringe, weekly intravenous IV administration)
2855409|NCT03560518|Experimental|Rapastinel 900mg|Rapastinel 900 mg (prefilled syringe, weekly intravenous IV administration)
2855410|NCT03560518|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration)
2855411|NCT03560505||Common fibular compression neuropathy|"Patients referred for electrophysiological assessment of common fibular compression neuropathy with subsequent confirmation of referral diagnosis.~Intervention: Ultrasound protocol."
2855412|NCT03560505||Type 2 diabetes polyneuropathy|"Patients with type 2 diabetes referred for polyneuropathy involving the common fibular nerve with subsequent confirmation of referral diagnosis.~Intervention: Ultrasound protocol."
2855413|NCT03560492|Experimental|Posture Plus Force|Participants are provided with the posture garment. They have to wear it 2 to 4 h per day for a 3 month period. Participants receive a logbook that should be filled every day.
2855414|NCT03560492|Active Comparator|Exercise|A physiotherapist teaches exercises to participants (5 sessions of 20 minutes each of stretching and strengthening exercises). Exercises are focused on cervical and dorsal areas, Participants receive instructions to continue at home on a daily basis for 3 months. Participants receive a logbook that should be filled every day.
2855415|NCT03560479|Experimental|alpha1H|alpha1H (7.4 mg/mL), solution for instillation, 30 mL
2855416|NCT03560479|Placebo Comparator|placebo|Placebo, 0.9% NaCl (sodium chloride), 30 mL
2855417|NCT03560466|Experimental|Dupilumab|1 year treatment of Dupilumab on top of asthma conventional treatment
2855418|NCT03560453|No Intervention|Control|Attend assigned high school for 9 months
2855419|NCT03560453|Experimental|Project SEARCH plus ASD Supports|Attend Project SEARCH plus ASD Supports for 9 months
2855420|NCT03560440||Plasma exposure vancomycin|Pediatric patients treated with vancomycin
2855421|NCT03560427|Experimental|duloxetine+morphine|
2855422|NCT03560427|Placebo Comparator|placebo+morphine|
2855423|NCT03560414|Experimental|simple plasma exchange group|The mode is CVVH in CRRT machine, the treatment duration is 2h-3h, the application plasma volume is 40ml/Kg, the replacement fluid flow rate is 1000ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0ml/h.
2855424|NCT03560414|Active Comparator|conventional PDF treatment group|The mode of conventional PDF treatment group is CVVHDF in CRRT machine, and the duration of treatment is 3 hours. the application plasma volume 1500 ml . The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
2855425|NCT03560414|Active Comparator|less plasma PDF treatment group|The mode of conventional PDF treatment group is also CVVHDF in CRRT machine, and the duration of treatment is 3h. All patients are required to apply plasma 1000ml. Use plasma substitutes: 300ml NS+200ml 5% albumin. The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
2855426|NCT03560401|Experimental|Brace group|After spinal surgery, patients in the brace group were instructed to wear a rigid brace (Knight-Taylor [chairback] brace) full-time for 12 weeks, except when bathing or lying in bed.
2855427|NCT03560401|No Intervention|No brace group|After spinal surgery, patients in the no brace group were instructed to wear a soft corset for 2 weeks, after which it was weaned off.
2855428|NCT03560388|No Intervention|Control|Control group include participants randomly allocated to supportive care (with no added integrative care or acupuncture)
2855429|NCT03560388|Experimental|Touch/relaxation|Touch/relaxation treatment (pre-operative)
2855430|NCT03560388|Experimental|Acupuncture and touch/relaxation|Acupuncture (intra operative) and touch-relaxation treatment (pre-operative)
2855431|NCT03560375|Experimental|Circuit resistance training (CRT)|2-3 circuits * 10 exercises * 3 times per week
2855432|NCT03560375|Experimental|Empagliflozin 10 MG|10 mg once daily
2855433|NCT03560375|Experimental|Vegeterranean diet (V-Med diet)|The modified V-Med diet will be considered as ad-libitum (using fat sources), aimed for sufficient protein from animal and mainly plant-based sources with carbohydrates limitation.
2855434|NCT03560362|Active Comparator|Bupivacaine with epinephrine|Patients will receive intraoperative intercostal nerve block with bupivacaine
2855435|NCT03560362|Experimental|Lipossomal extended release bupivacaine|Patients will receive intraoperative intercostal nerve block with lipossomal extended release bupivacaine
2855436|NCT03560349|Experimental|Lidocaine|Transnasal blockade of SPG approach involving the application of 2 cc (approximately the size of a pea) of 2% lidocaine jelly on a cotton swab directed posteriorly towards the SPG in the nasal passage bilaterally. Cotton swab will be inserted to the back of the nasal passage until it can no longer be inserted any further. The cotton swab should remain in place for 15 minutes on both sides simultaneously. The patient will be instructed on how to perform this procedure on themselves, and they will be given supplies for a 7-day supply of medication to be administered two times per day at approximately 12 hour intervals.
2855437|NCT03560349|Placebo Comparator|Placebo|Transnasal blockade of SPG approach involving the application of 2 cc (approximately the size of a pea) of nasal saline jelly on a cotton swab directed posteriorly towards the SPG in the nasal passage bilaterally. Cotton swab will be inserted to the back of the nasal passage until it can no longer be inserted any further. The cotton swab should remain in place for 15 minutes. The patient will be instructed on how to perform this procedure on themselves, and they will be given supplies for a 7-day supply of medication to be administered up to two times per day at approximately 12 hour intervals.
2855438|NCT03560336||Overall Population|Patients will be treated with commercially available liraglutide 3.0 mg according to routine clinical practice at the discretion of the treating physician
2855439|NCT03560323|Active Comparator|Group I Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 0.4 mg/kg.min for 20 minutes and then at a constant rate of 0.2 mg/kg.min until study end
2855440|NCT03560323|Active Comparator|Group II Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 1.5 mg/kg.min for 20 minutes and then at a constant rate of 0.75 mg/kg.min until study end
2855581|NCT03559205|Active Comparator|MSK-Tracker (after)|Use of the MSK-Tracker in clinic consultations
2855441|NCT03560323|Active Comparator|Group III Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 4.0 mg/kg.min for 20 minutes and then at a constant rate of 2.0 mg/kg.min until study end
2855442|NCT03560310|Experimental|Dual antiplatelet therapy|Ticagrelor 90 mg twice daily and ASA 75 mg daily for 12 months
2855443|NCT03560310|Active Comparator|Acetylsalicylic acid|ASA 75-160 mg daily for 12 months
2855444|NCT03560297|Experimental|SeRenade Program|Parent-Child Music Class Program (parent training, peer inclusion, musical play)
2855445|NCT03560297|Experimental|Delayed/Waitlist Program|Participants do not participate in the program for a time period
2855446|NCT03560271|Experimental|Dose A|Cyclo-Z containing 23 mg zinc plus 6 mg CHP
2855447|NCT03560271|Experimental|Dose B|Cyclo-Z containing 23 mg zinc plus 15 mg CHP
2855448|NCT03560271|Placebo Comparator|Dose C|Placebo
2855449|NCT03560258|Experimental|Arm 1: p24CE1/2 pDNA + full-length p55^gag pDNA vaccine|Participants will receive p24CE1/2 pDNA vaccine at Weeks 0 and 4, followed by p24CE1/2 pDNA admixed with full-length p55^gag pDNA vaccine at Weeks 12 and 24.
2855450|NCT03560258|Experimental|Arm 2: Full-length p55^gag pDNA vaccine|Participants will receive full-length p55^gag pDNA vaccine at Weeks 0, 4, 12, and 24.
2855451|NCT03560258|Placebo Comparator|Arm 3: Placebo|Participants will receive placebo at Weeks 0, 4, 12, and 24.
2855452|NCT03560245|Experimental|Bryostatin 20µg|20µg Bryostatin administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
2855453|NCT03560245|Placebo Comparator|Placebo|"Placebo administered IV over 45 minutes every other weekafter 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.~The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution."
2855454|NCT03560232|Active Comparator|Cefazolin + Gentamicin|"[Cefazolin]~Initial dose:~Cefazolin 2g IV x1 dose (patient weight < 120kg)~Cefazolin 3g IV x1 dose (patient weight >/= 120kg)~Subsequent dose:~Cefazolin 2g IV every 8 hrs (CrCl >/= 40 mL/min)~Cefazolin 2g IV every 12 hrs (CrCl 20-39 mL/min)~Cefazolin 2g IV every 24 hrs (CrCl < 20 mL/min)~Duration:~24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first~[Gentamicin]~Initial dose:~If Patient age </= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg)~If Patient age >80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg)~Subsequent dose:~Pharmacy Consult to dose gentamicin~Duration:~24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first"
2855455|NCT03560232|Active Comparator|Ceftriaxone|"Initial dose:~Ceftriaxone 2g IV x1 dose~Subsequent dose:~Ceftriaxone 2g IV every 24 hours~Duration:~One dose post-op after soft tissue coverage or total of 72 hours, whichever comes first"
2855456|NCT03560232|Active Comparator|Ampicillin/Sulbactam|"Initial dose:~Ampicillin/Sulbactam 3g IV x1 dose~Subsequent dose:~Ampicillin/Sulbactam 3g IV every 6 hours (CrCl >/= 30 mL/min)~Ampicillin/Sulbactam 3g IV every 12 hours (CrCl 15-29 mL/min)~Ampicillin/Sulbactam 3g IV every 24 hours (CrCl <15 mL/min)~Duration:~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
2855457|NCT03560232|Active Comparator|Piperacillin/Tazobactam|"Initial dose:~Piperacillin/Tazobactam 4.5g IV x1 dose over 30 minutes~Subsequent dose:~Piperacillin/Tazobactam 3.375g IV every 8 hours over 4 hours (CrCl >/= 20 mL/min)~Piperacillin/Tazobactam 3.375g IV every 12 hours over 4 hours (CrCl < 20 mL/min)~Duration:~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
2855458|NCT03560232|Other|Clindamycin + Gentamicin|"Patients with known Penicillin allergy will receive:~[Clindamycin]~Initial dose:~Clindamycin 900mg IV x1 dose~Subsequent dose:~Clindamycin 600mg IV every 8 hours~Duration:~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first~[Gentamicin]~Initial dose:~If Patient age </= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg)~If Patient age >80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg)~Subsequent dose:~Pharmacy Consult to dose gentamicin~Duration:~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
2855459|NCT03560206|Experimental|Family SWaP intervention with mini iPad|an educational-behavioral intervention consisting of 6 weekly education sessions (45 minutes) followed by 5 bi-weekly sessions (15-20 minutes) that will be held at the dyad's preferred time delivered to their homes using a video conferencing program through a mini iPad.
2855460|NCT03560206|Active Comparator|Usual Care|The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
2855461|NCT03560193|Experimental|Chlorhexidine Group|
2855462|NCT03560193|Active Comparator|Povidone Iodine Group|
2855463|NCT03560167|Experimental|AccuCinch® Ventricular Repair System|
2855464|NCT03560154|Experimental|Whole Body Vibration Training|whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. In TVT training; Eight kinds of exercises will be provided, including 3 sessions per week for 4 weeks. The duration of each session will vary between 8-30 minutes. The frequency, amplitude, and duration of the TVT will be gradually increased from the lowest intensity to the level that the patient can tolerate. 8 exercises will be applied: for lower extremity; high squat, deep squat, right/left lunge, calf raise, for upper extremity; front raise, bent over lateral, biceps curl, and cross over. Before TVT application, 5-8 min. warm-up exercises will be applied. If desaturation (<88%) develops during the training in the patient, an oxygen mask will be used to ensure adequate oxygenation. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
2855465|NCT03560154|No Intervention|Home respiratory exercises|Respiratory exercises will be taught to the patient. Duration of the respiratory exercises is at least 10 minute per session, 7 days a week for 4 weeks. A weekly phone call will be provided and exercise will be followed.
2855466|NCT03560128|Experimental|Endocuff Vision Arm|Colonoscopy with Endocuff Vision device attached to the distal end of the scope.
2855467|NCT03560128|Experimental|AmplifEYE Arm|Colonoscopy with AmplifEYE device attached to the distal end of the scope.
2855468|NCT03560102|Experimental|MR-HIFU treatment|Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat& resect model
2855650|NCT03558893|Experimental|Forced Desynchrony|All participants will undergo a forced desynchrony protocol.
2855469|NCT03560089|Active Comparator|Rehabilitation with active serious game|25 patients will perform motor rehabilitation programme using the serious game
2855470|NCT03560089|Placebo Comparator|No active serious game|25 patients will not perform motor rehabilitation programme using the serious game
2855471|NCT03560076||Group 1|One medical surgical unit in seven acute care facilities in which nurses have received SBIRT training and implementation strategies and are randomized to Group 1 implementation
2855472|NCT03560076||Group 2|One medical surgical unit in seven acute care facilities in which nurses have received SBIRT training and implementation strategies and are randomized to Group 2 (delayed) implementation
2855473|NCT03560063|Experimental|Corin OPS arm|Total hip replacement with use of Corin Optimised Positioning System to guide implant positioning
2855474|NCT03560063|Active Comparator|Standard care arm|Total hip replacement with standard templating to guide implant positioning
2855475|NCT03560050|Experimental|Behavioral: Nutrition assistance|three encounters with Intervention team over three months: two home-based visits for 90 minutes each scheduled at the convenience of the provider and a 3- hour group class session with other providers.
2855476|NCT03560050|Experimental|Behavioral: Children's environmental health|three encounters with Intervention team over three months: two home-based visits for 90 minutes each scheduled at the convenience of the provider and a 3- hour group class session with other providers.
2855477|NCT03560037|No Intervention|Standard Colonoscopy|Patients randomly assigned to this group will receive standard colonoscopy without the use of a distal attachment.
2855478|NCT03560037|Experimental|Endocuff Vision Assisted Colonoscopy|Patients randomly assigned to this group will receive colonoscopy with the use of the Endocuff Vision distal attachment.
2855479|NCT03560024|Active Comparator|PACAP27|12 healthy volunteers will receive PACAP27 (10 picomole/kg/min) over 20 min
2855480|NCT03560024|Placebo Comparator|Placebo|6 healthy volunteers will receive placebo (Saline) over 20 min
2855481|NCT03560011|No Intervention|Rituximab (375 mg/m²)|Single infusion of rituximab (375 mg/m²)
2855482|NCT03560011|Experimental|Rituximab followed by 5 injections of immunoglobulin IV|Rituximab (375 mg/m²) followed by 5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g). Treatment duration : 6 months
2855483|NCT03559985|Other|Paracetamol and placebo comparator (Group 1)|Neuropathic pain patients taking either paracetamol or placebo according to the randomization plan
2855484|NCT03559985|Other|Paracetamol and placebo comparator (Group 2)|Neuropathic pain patients taking either paracetamol (if during period 1 they received placebo) or placebo (if during period 1 they received paracetamol)
2855485|NCT03559972|Experimental|Treatment Group #1|"Subject in Treatment group 1 will apply the following products in the morning and evening.~SkinMedica Facial Cleanser~Hulk (cosmetic investigational)~Marvel AM (cosmetic investigational)~Marvel PM (cosmetic investigational)~SkinMedica HA5 Rejuvenating Hydrator~SkinMedica Rejuvenative Moisturizer~SkinMedica Essential Defense Mineral Shield SPF 35 Sunscreen"
2855486|NCT03559972|Experimental|Treatment group #2|"Subject in Treatment group 2 will apply the following products in the morning and evening.~SkinMedica Facial Cleanser~SkinMedica TNS Essential Serum~Marvel AM (cosmetic investigational)~Marvel PM (cosmetic investigational)~SkinMedica HA5 Rejuvenating Hydrator~SkinMedica Rejuvenative Moisturizer~SkinMedica Essential Defense Mineral Shield SPF 35 Sunscreen"
2855487|NCT03559959|Experimental|$0 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to redeem an HIV self-testing kit free of charge.
2855488|NCT03559959|Experimental|$0.5 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $0.5.
2855489|NCT03559959|Experimental|$1 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $1.
2855490|NCT03559959|Experimental|$2 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $2.
2855491|NCT03559959|Experimental|$3 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $3.
2855492|NCT03559946|Sham Comparator|Standard Protocol (SP) group|The patients in the SP group will receive one PTNS treatment and one sham treatment per week for 12 weeks
2855493|NCT03559946|Experimental|Condensed Protocol (CP) group|The patients in the CP group will receive 2 PTNS treatments per week for 12 weeks.
2855494|NCT03559920|Experimental|Naso-tracheal group|Patients who are sedated using sevoflurane with the naso-tracheal intubation
2855495|NCT03559920|Active Comparator|Tracheostomy group|Patients who are sedated using sevoflurane with the tracheostomy
2855496|NCT03559907|Experimental|Cooking Matters for Parents|Trained instructors with a background in nutrition or culinary arts will lead six weekly, two-hour sessions to groups of 10 parent participants at local Family Support Centers.
2855497|NCT03559907|Experimental|Mealtime PREP|Trained group leaders with experience in pediatric occupational therapy will lead six weekly, two-hour, Mealtime PREP sessions to groups of 10 parent participants at local Family Support Centers.
2855498|NCT03559907|Experimental|Cooking Matters + Mealtime PREP|Parents will receive both programs in succession. They will attend Cooking Matters for Parents followed by Mealtime PREP. In total, this will equal 12 weekly, two-hour sessions delivered to groups of 10 parent participants at a local Family Support Center.
2855499|NCT03559881|No Intervention|Observation|Participants with a habitual protein intake >1.2 g/kg body weight/day will be allocated to the observational arm of the study
2855500|NCT03559881|Experimental|Intervention|Participants with a habitual protein intake <1.2 g/kg body weight/day will be allocated to the interventional arm of the study
2855501|NCT03559868|Active Comparator|patients receiving digoxin 3mcg|Patients receiving digoxin 3 mcg/Kg/day
2855502|NCT03559868|Active Comparator|Patients receiving digoxin 0.3 mcg|Patients receiving digoxin 0.3 mcg/Kg/day
2855503|NCT03559868|Active Comparator|Patients receiving digoxin 0.15 mcg|Patients receiving digoxin 0.15 mcg/Kg/day
2855504|NCT03559868|Placebo Comparator|placebo|placebo
2855505|NCT03559855|Experimental|Real Essentials|The Real Essentials curriculum is delivered in class to students by the Center for Relationship Education staff. It consists of 5 to 6 hours of healthy relationship education.
2855506|NCT03559855|No Intervention|Class as Usual|For the Class-as-Usual condition, there is no change in class content. Teachers offer what they typically offer.
2855507|NCT03559842||Obese patients|
2855508|NCT03559842||Lean patients|
2855509|NCT03559829|Experimental|Single Arm - Intervention arm|RAPAEL Smart Glove Arm The participant will be issued a Smart Glove and a tablet preloaded with the game software. The available games provide various kinds of motion tasks such as ADL-related tasks presented in an entertaining manner. The learning schedule algorithm automatically adjusts to the optimal level of difficulty to balance challenge and motivation. The participant will be expected to use the Smart Glove at home for 60 min per day for at least 5 days per week.
2855510|NCT03559816||Selective use of Episiotomy|Vaginal delivery assisted with selective use of episiotomy and prospective classification of perineal laceration with a sub-classification of second-degree tears. Data of subclassifications are registered with data usually recorded in delivery ward register.
2855511|NCT03559816||Not selective use of Episiotomy|Vaginal delivery assisted without a selective use of episiotomy. Data retrospectively retrieved by delivery ward register that were usually recorded.
2855512|NCT03559803|Experimental|Cisplatin|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
2855513|NCT03559777|Active Comparator|closed sinus lifting by Osteotome|"Local anesthesia will be injected intra-orally~A full thickness flap will be elevated~A pilot drill will be used to start the osteotomy preparation, which should be ended 1mm short of sinus floor.~The widening drills can be sequentially used to widen the osteotomy site to the same level~An osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level.~The osteotome will be tapped gently to fracture up the sinus floor.~Xenograft will be added to the osteotomy as the grafting material.~Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~Smart peg will be placed on implant and Ostell will be used to record ISQ.~Healing collar will be placed on implant.~Suturing the flab around healing collar."
2855514|NCT03559777|Experimental|closed sinus lifting by Densah bur|"Local anesthesia will be injected intra-orally~A full thickness flap will be elevated~A pilot drill will be used to start the osteotomy , which should be ended 1mm short of sinus floor.~Change the drill motor to reverse- densifying Mode~Begin with the densah bur (2.5mm) until 1 mm short of the sinus floor.~Use the next wider Densah Bur (3.0) in densifying-mode until feeling the haptic feedback of the bur reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments.~densah burs (3.5mm) advance in the osteotomy.~Xenograft will be added to the osteotomy .~Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~Smart peg will be placed on implant and Ostell will be used to record ISQ.~Healing collar will be placed on implant.~Suturing the flab around healing collar."
2855515|NCT03559764|Experimental|Anti-BCMA CAR T cells|Total dose of 0.5-6 millions /kg cells will be administered at day -2, day -1 and day 0 by split dose (30%, 30% and 40% respectively).
2855516|NCT03559751|Experimental|VLN Cigarettes (A)|Subjects will smoke VLN cigarettes
2855517|NCT03559751|Experimental|Usual Brand Cigarettes (B)|Subjects will smoke their usual brand cigarettes
2855518|NCT03559751|Experimental|Nicotine Gum (C)|Subjects will chew nicotine gum
2855519|NCT03559738||Patients With Upper Ureteric Stones|Patients with upper ureteral stones more than 1cm and 1000 HU
2855520|NCT03559725|Experimental|VLN Menthol Cigarettes (A)|Subjects will smoke VLN menthol cigarettes
2855521|NCT03559725|Experimental|Usual Brand Menthol Cigarettes (B)|Subjects will smoke their usual brand menthol cigarettes
2855522|NCT03559725|Experimental|Nicotine Gum (C)|Subjects will chew nicotine gum
2855523|NCT03559712|Experimental|Telemedicine|Participants in this arm will be treated by the trained primary health care physicians in the primary health care centers, who will be having weekly supervisions with the specialists for case management.
2855524|NCT03559712|No Intervention|Control|Participants in this arm will experience treatment as usual, which means referral to a specialist.
2855525|NCT03559699|Experimental|Part 1: Dose Optimization AG-348|"Part 1 (Dose Optimization Period): Participants will receive AG-348 for approximately 16 to 24 weeks.~Part 2 (Fixed Dose Period): Participants will receive their optimized dose of AG-348 as determined by the individual participant's transfusion cycle and response to AG-348 in Part 1."
2855526|NCT03559647||Cohort 1|Participants who have demonstrated a lack of Clinical Benefit from Atezolizumab
2855527|NCT03559647||Cohort 2|Participants who demonstrated durability of Clinical Benefit and Tumor Response to Atezolizumab
2855528|NCT03559634|Other|A - Electronic App Limited Offering|Using an electronic application, participants will answer survey questions about their health and sexual history. Patients will watch a video that overviews the types of hormonal contraception with brief pros and cons of each method. Then, if participants qualify based on their survey questions they will be able to watch a more in-depth counseling and educational video on medroxyprogesterone acetate contraceptive injection. The participant will then be given the opportunity to start this method in the ED that day. If participants would like other forms of contraception, choose not to start contraception during their ED visit, or do not qualify based on health history questions, they would be referred for outpatient contraceptive services.
2855529|NCT03559634|Other|B - Electronic App Comprehensive Offering|Using an electronic application, participants answer survey questions about their health and sexual history. They will watch a video that overviews the types of hormonal contraception with brief pros and cons of each method. Then, based on participants survey answers they will be able to watch more in-depth counseling and educational videos on contraceptive methods that they qualify for. Participants will only be offered methods that are considered low risk and without any contraindication based upon responses to health history screening. This may include, contraceptive implant, medroxyprogesterone acetate injection, microgestin pills, xulane patch, or intravaginal ring. The participant will then be given the opportunity to start contraception either in the ED or given a script. If they would like other forms of contraception, choose not to start contraception that day, or do not qualify, they would be referred for outpatient contraceptive services.
2855530|NCT03559621|No Intervention|control group|Women in the control group will receive follow-up as in normal routine with referral to primary care. They will receive an OGTT after 1 year as part of the trial.
2855533|NCT03559569||Patients with circulatory shock|500 patients with circulatory shock hospitalize in ICU will be prospectively included to assess the effect of this pathology on the senescence phenotype
2855534|NCT03559569||Healthy volunteers|20 healthy volunteers will be included to assess the effect of no pathology on the senescence phenotype.
2855535|NCT03559556|Experimental|Patient with AVM requiring radiotherapy|Patients on this protocol will still get treated based on target generated by interventional cerebral arteriography but also receive CT angiography.
2855536|NCT03559543|Experimental|Ocoxin-Viusid®|
2855537|NCT03559530||Patients|Patients with microbiologically proven A. baumannii-related osteomyelitis
2855538|NCT03559517|Experimental|SHP647 25 mg|Participants will receive 25 mg of SHP647 subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
2855539|NCT03559517|Experimental|SHP647 75 mg|Participants will receive 75 mg of SHP647 subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
2855540|NCT03559517|Placebo Comparator|Placebo|Participants will receive placebo matching with SHP647 subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
2855541|NCT03559504||Group 1|Infant period: 1 month-1 year old
2855542|NCT03559504||Group 2|Toddler period:1-3 years old
2855543|NCT03559504||Group 3|Preschool age period:3-6 years old
2855544|NCT03559504||Group 4|School age period:7-18 years old
2855545|NCT03559504||Group 5|Adults:18-65 years old
2855546|NCT03559504||Group 6|Elderly:65-80 years old
2855547|NCT03559491||Macular Edema Patients|Patients affected by cystoid macular edema (CME) due to retinal vein occlusion of recent onset (less than three months) will be enrolled.
2855548|NCT03559478|Active Comparator|Treatment Group 1|Sharp dissection with scalpel plus electrocautery to vessels
2855549|NCT03559478|Active Comparator|Treatment Group 2|Electrocautery for all dissection
2855550|NCT03559465|Experimental|patient with Scs|patients with SSc, (10 diffuse forms and 20 limited forms)
2855551|NCT03559465|Sham Comparator|healthy subject|
2855552|NCT03559452|Experimental|Muscle damage|
2855553|NCT03559439|Experimental|CD19 CAR T|CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion.
2855554|NCT03559426|Active Comparator|Maintenance|Participants continue to receive antipsychotic treatment at the original dose for the 24month duration of the trial.
2855555|NCT03559426|Experimental|Reduction/discontinuation|Antipsychotic medication is gradually reduced and discontinued if possible. The reduction is flexible, and is done over approximately 12 months. During this time participants see their psychiatrist roughly every 2 months.
2855556|NCT03559413|Experimental|Intervention group|
2855557|NCT03559400|Experimental|local gentamicin injection|Subjects with an open tibia fracture who receive aqueous gentamicin administered after closure at the time of initial debridement.
2855558|NCT03559400|Active Comparator|debridement alone|Subjects with an open tibia fracture who receive debridement alone.
2855559|NCT03559387|Experimental|ANF-RHO™|Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg as a subcutaneous injection.
2855560|NCT03559387|Active Comparator|Neulasta®|Neulasta® will be administered to the subjects at a dose of 6.0 mg in 0.6 ml as a subcutaneous injection.
2855561|NCT03559374||Pregnant women|Consenting women will provide samples to be tested with Vanadis NIPT system.
2855562|NCT03559361|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
2855563|NCT03559361|Active Comparator|EPA-rich|3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA
2855564|NCT03559361|Active Comparator|DHA-Rich|3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA
2855565|NCT03559348|Experimental|Biweekly TS-1, Leucovorin and Gemcitabine (GSL)|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 to 7 Leucovorin 60 mg/d, orally twice daily on day 1 to 7 Every 14 days as one cycle
2855566|NCT03559335||Patients after colorectal cancer surgery|
2855567|NCT03559309|Other|Alirocumab|Medical Treatment (Clinical Routine)
2855568|NCT03559296||Study Group|patients with postmastectomy lymphedema who will undergo ultrasonographic assessment of postmastectomy lymphedema and circumferential tape measurement of arm
2855569|NCT03559283|Experimental|Walking and Record Cortical Activity|A sensor placement will be performed on the patient's forehead to record brain activity when walking, when performing a mental task, and when performing both tasks at the same time. In parallel, walking will be on a carpet that will record the spatio-temporal parameters of walking.
2855570|NCT03559270|Experimental|Baricitinib|Baricitinib administered orally.
2855571|NCT03559257|Experimental|Galcanezumab|Galcanezumab administered subcutaneously (SC).
2855572|NCT03559257|Placebo Comparator|Placebo|Placebo administered SC.
2855573|NCT03559244|Experimental|Dynamic compression brace 8 hours|Children with pectus carinatum who will wear dynamic compression brace 8 hours a day plus exercises for three weeks
2855574|NCT03559244|Experimental|Dynamic compression brace 23 hours|Children with pectus carinatum who will wear dynamic compression brace 23 hours (except for bathing and sports activities) a day plus exercises for three weeks
2855575|NCT03559244|Active Comparator|Only exercises|The children who are in wait in list for dynamic compression brace will receive only posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises for three weeks
2855576|NCT03559231|Experimental|dFTRD|Endoscopic full-thickness resection of the duodenal adenoma with the 'duodenal Full-Thickness resection device' (dFTRD).
2855577|NCT03559231|Active Comparator|EMR|Endoscopic Mucosal Resection (EMR) of the duodenal adenoma (=standard therapy).
2855578|NCT03559218|Other|Standard of care|Patients undergoing radiation therapy for breast cancer will be provided instructions for radiation dermatitis per institutional standard of care
2855579|NCT03559218|Experimental|KeraStat Cream|Patients undergoing radiation therapy for breast cancer will be provided KeraStat Cream for twice daily application.
2855580|NCT03559205|No Intervention|MSK-Tracker (before)|Usual Care in clinic consultations
2869828|NCT03460977|Experimental|DL 4|PF-06821497 375 mg BID
2855582|NCT03559192|Placebo Comparator|Lead-in Period: Placebo|Participants will receive matching placebo for the entire duration of the lead-in period.
2855583|NCT03559192|Experimental|Treatment Period: JNJ-67953964 or Placebo|Participants who respond or do not respond (based on reduction from lead-in baseline in MADRS) in the placebo lead-in period will receive either matching placebo or 10 (2*5) milligram (mg) JNJ-67953964 capsules in a 1:1 ratio for 6 weeks.
2855584|NCT03559192|Placebo Comparator|Withdrawal Period: Placebo|Participants who complete the double-blind treatment period prior to the end of Week 11 will receive matching placebo for the remaining time of the treatment phase of the study.
2855585|NCT03559179|Experimental|Receives the Opioid Wizard|These providers will receive the OUD clinical decision support tool (Opioid Wizard).
2855586|NCT03559179|No Intervention|Does not Receive the Opioid Wizard|These providers will continue to treat their patients as usual.
2855587|NCT03559166|Placebo Comparator|cohort 1 a-starting dose|Single oral dose of BLD-2660 or placebo capsule administered to healthy volunteers
2855588|NCT03559166|Placebo Comparator|cohort 1b- first SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (1st dose escalation)
2855589|NCT03559166|Placebo Comparator|cohort 1c-2nd SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (2nd dose escalation) in fasting state, followed by washout period and then single oral dose of BLD-2660 or placebo administered to healthy volunteers in fed state.
2855590|NCT03559166|Placebo Comparator|cohort 1d-3rd SAD escalation|Single oral dose of BLD-2660 or placebo capsules(s) administered to healthy volunteers (3rd dose escalation)
2855591|NCT03559166|Placebo Comparator|cohort 1e (optional cohort)|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (final dose escalation if assessed as safe).
2855592|NCT03559166|Placebo Comparator|cohort 2 a-1st MAD cohort|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers
2855593|NCT03559166|Placebo Comparator|cohort 2b- 2nd MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
2855594|NCT03559166|Placebo Comparator|cohort 2c-3rd MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
2855595|NCT03559166|Placebo Comparator|cohort 3a|Therapeutic oral dose (as determined by SAD and MAD data) of BLD-2660 or placebo capsule(s) administered to participants with lung fibrosis
2855596|NCT03559166|Placebo Comparator|cohort 3 b|Therapeutic oral dose (as determined by SAD and MAD data) of BLD-2660 or placebo capsule(s) administered to participants with liver fibrosis
2855597|NCT03559153|No Intervention|Control group|All workers will receive ergonomics instructions. Instruction for rest break.
2855598|NCT03559153|Experimental|Passive rest break - Shiatsu massage|"All workers will receive ergonomics instructions. The workers will be receive quick massage using shiatsu techniques."
2855599|NCT03559153|Active Comparator|Active rest break - Physical Exercise Program|All workers will receive ergonomics instructions. The workers will be receive exercises during the rest break.
2855600|NCT03559140|Experimental|Group A|"The R25 (size 25/ .08) instrument was used in thin and curved root canals, and R40 files (40/ .06) were used in wide root canals. Three in-and-out pecking motions were used with an amplitude of not more than 3 mm until reaching the estimated working length.~After the procedure cryotherapy will be applied as follows:~Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes"
2855601|NCT03559140|Experimental|Group B|"Canals were prepared as in group A, Patients assigned to this group receive (application of criotherapy)~A final irrigation will be applied with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes. was applied. as follows:~Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes"
2855602|NCT03559140|Experimental|Control Group (CG)|"The R25 (size 25/ .08) instrument was used in thin and curved root canals, and R40 files (40/ .06) were used in wide root canals. Three in-and-out pecking motions were used with an amplitude of not more than 3 mm until reaching the estimated working length. Reciproc instruments were used in one tooth only (single use).~The group will receive the irrigant solution at room temperature. as follows:~they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes."
2855603|NCT03559127|Experimental|Group A. Cold Protocol with 6 oC|"Use of 20 mL cold (6 oC) sterile saline solution.~After the clinical procedure cryotherapy was applied. 5 mL cold (6 oC) 17% EDTA followed with 20 mL cold (6 oC) sterile saline solution dispensed to the WL using a cold (6 oC) metallic micro-cannula included in the Endo Vac System for five minutes."
2855604|NCT03559127|Experimental|Group B. Cold Protocol with 2.5 oC|"Use of 20 mL cold (2.5 oC) sterile saline solution~After the procedure cryotherapy was applied. 5 mL cold (2.5 oC) 17% EDTA followed with 20 mL cold (2.5 oC) sterile saline solution dispensed to the WL using a cold (2.5 oC) metallic micro-cannula included in the Endo Vac System for five minutes."
2855605|NCT03559127|Experimental|CG. Room temperature Protocol|"Use of 20 mL (at room temperature) sterile saline solution~The group will receive irrigant at room temperature. 5mL of 17% EDTA and 20 mL of sterile saline usingmetallic micro-cannula included in the Endo Vac System for five minutes."
2855606|NCT03559114|Active Comparator|Anticoagulant|Dalteparin sodium (at a dose of 5000 IU once daily by subcutaneous injection) for 7 days upon randomization after hospital admission.
2855607|NCT03559114|Placebo Comparator|Saline|Saline (0.2 mL) once daily by subcutaneous injection for 7 days upon hospital admission.
2855608|NCT03559101|Active Comparator|Beverage 1 - Control|Distilled Water
2855609|NCT03559101|Experimental|Beverage 2|Medical Food 1 (8 amino acids, 60 mmol/L Na, 20 mmol/L K + citrate, Cl)
2855610|NCT03559101|Experimental|Beverage 3|Medical Food 2 (8 amino acids, 30 mmol/L Na, 10 mmol/L K + citrate, Cl)
2855611|NCT03559101|Experimental|Beverage 4|Pedialyte
2855612|NCT03559101|Experimental|Beverage 5|Gatorade
2855613|NCT03559088|Experimental|Migraine Participants Using Application (App)|Participants with migraine history or a recent prescription for a common migraine medication will use a migraine app linked to their electronic health record (EHR) with results reported in their EHR.
2855614|NCT03559088|No Intervention|Controls Not Using App|Observational history on contemporaneous matched controls at similar sites without migraine app linked to their EHR.
2855615|NCT03559075||Group 1|Participants will be randomized into group 1 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
2855616|NCT03559075||Group 2|Participants will be randomized into group 2 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
2855617|NCT03559075||Group 3|Participants will be randomized into group 3 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
2855618|NCT03559075||Group 4|Participants will be randomized into group 4 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
2855619|NCT03559075||Group 5|Participants will be randomized into group 5 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
2855620|NCT03559075||Group 6|Participants will be randomized into group 6 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
2855621|NCT03559075||Group 7|Participants will be randomized into group 7 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
2855622|NCT03559075||Group 8|Participants will be randomized into group 8 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
2855623|NCT03559062|Experimental|F/F Subjects: TEZ + IVA|
2855624|NCT03559062|Experimental|F/F Subjects: Placebo|
2855625|NCT03559062|Experimental|F/RF Subjects: TEZ + IVA|
2855626|NCT03559062|Experimental|F/RF Subjects: IVA + Placebo|
2855627|NCT03559049|Experimental|Rucaparib and Pembrolizumab Maintenance|"All patients will receive induction therapy with Pembrolizumab (200mg IV on day 1 of every 21 days), Pemetrexed (500mg/m^2 IV on day 1 of every 21 days), and Carboplatin (AUC5 IV on day 1 of every 21 days).~This will be followed by maintenance therapy with Pembrolizumab (200mg IV on day 1 of every 21 days) and Rucaparib (600mg PO BID days 1-21 of each 21 day cycle)."
2855628|NCT03559036||Locomotor Training|Assessments for bladder function will be conducted pre-training and following 80 sessions of locomotor training. Locomotor training consists of body-weight supported stepping on a treadmill for one hour.
2855629|NCT03559023|Active Comparator|Ultrasound Only|Ultrasound assisted epidural placement
2855630|NCT03559023|Active Comparator|Manometry Only|Manometry confirmation in epidural placement
2855631|NCT03559023|Active Comparator|Ultrasound Plus Manometry|Ultrasound Plus Manometry confirmation in epidural placement
2855632|NCT03559023|Sham Comparator|Usual Care/Management|Usual epidural technique placement
2855633|NCT03559010|Experimental|Use Phase Norgestrel 0.075 mg|Norgestrel 0.075 mg tablets to be taken orally, one tablet daily at the same time everyday for up to 16 weeks
2855634|NCT03558997|Experimental|Dupilumab + Timothy Grass SCIT|
2855635|NCT03558997|Experimental|Placebo matching dupilumab + Timothy Grass SCIT|
2855636|NCT03558997|Experimental|Dupilumab + Placebo matching SCIT|
2855637|NCT03558997|Experimental|Placebo matching dupilumab + Placebo matching SCIT|
2855638|NCT03558984|Experimental|D-PLEX + SOC|For subjects randomized to the investigational treatment arm, D-PLEX treatment will be applied at the end of the index surgery just before closing the chest, as an adjunct to the SOC prophylactic antibiotic treatment.
2855639|NCT03558984|No Intervention|Standard of Care|For subjects randomized to the control arm, the surgical treatment will be as per the SOC.
2855640|NCT03558971|Experimental|Patient self-administration of cortisol|Intervention is patient self-administration of cortisol.
2855641|NCT03558958|Experimental|P-188 NF|P-188 NF, 5 mg/Kg administered subcutaneously daily for 1 year
2855642|NCT03558945|Experimental|Personalized neoantigen vaccine|"Patients will receive radical surgery and at least one circle of post-operative chemotherapy.~Personalized neoantigen vaccines will be injected on day 1 of weeks 1, 3, 5, 7, 9, short interval or 1-2 months after the end of their post-operative chemotherapy, and two boosts will be on day 1 of weeks 12, 20.~Vaccines will be given in a total volume of up to 1.0ml/shot consisting of 0.3mg peptide+0.5mg ployICLC injected subcutaneously into two to four separate sites of the subject's thighs.~Patients will be called 2 times by study staff in the 6 months after last dose of vaccine and asked about any side effects experienced since the end-of-study visit."
2855643|NCT03558945|No Intervention|Conventional treatment|Patients will receive radical surgery and conventional post-operative chemotherapy.
2855644|NCT03558919|Experimental|Mirabegron|Mirabegron 25mg will give daily at night for 12 weeks
2855645|NCT03558919|Active Comparator|Solifenacin|Solifenacin Succinate 5mg will give daily at night for 12 weeks
2855646|NCT03558906||Aggressive Periodontitis|These individuals had minimum PD ≥6 mm and CAL ≥5 mm on eight or more teeth; at least three of these were other than central incisors or first molars. Radiographic alveolar bone loss was ≥30% of root length affecting at least three permanent teeth other than first molars and incisors. The severe destruction pattern was not commensurate with amount of plaque accumulation.
2855647|NCT03558906||Chronic periodontitis|These individuals had at least four non-adjacent teeth with sites with PD ≥6 mm and CAL ≥5 mm. They had also ≥50% alveolar bone loss in at least two quadrants that was commensurate with amount of plaque accumulation. BOP was >50% in the whole mouth.
2855648|NCT03558906||Gingivitis|Gingivitis patients exhibited no sites with CAL >2 mm and no detectable alveolar bone loss in the radiography. BOP was >50% in the whole mouth.
2855649|NCT03558906||Healthy|Periodontally healthy volunteers exhibited no sites with PD >3 mm and CAL >2 mm as well as no radiographic evidence of alveolar bone loss. BOP was <15% in the whole mouth.
2869829|NCT03460977|Experimental|DL 5|PF-06821497 500 mg BID
2855651|NCT03558880|Active Comparator|Erector Spinae Plane Block|Before the general anesthesia Erector Spinae Plane Block was performed.
2855652|NCT03558880|Active Comparator|Tumescent Anesthesia|After the general anesthesia was given, 1 mL of 0.1% adrenaline (1/1000) and as 20 mL of 0.5% bupivacaine solution of tumescent in a total of 1000 mL Ringer's lactate applied by the surgeon applied equally to both breasts
2855653|NCT03558867|Placebo Comparator|Metformin + Healthy diet|Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
2855654|NCT03558867|Active Comparator|Metformin + Personalized diet|Metformin (1500 mg/d, Extended Release) + Personalized diet based on an algorithm developed at the Weizmann Institute of Science (Zeevi et al, Cell 2015)
2855655|NCT03558854|Active Comparator|ASA group|Pill containing 100 mg of acetylsalicylic acid, taken once daily for 04 weeks
2855656|NCT03558854|Placebo Comparator|Placebo oral capsule group|Identical pill containing placebo, taken once daily for 04 weeks
2855657|NCT03558841|Experimental|Intervention Group|Gait training with the THERA-Trainer Lyra (3x/week) in addition to conventional geriatric rehabilitation physical therapy (6x/week) during inpatient period. After discharge home, continuation of Lyra gait training (3x/week), discontinuation of physical therapy.
2855658|NCT03558841|Active Comparator|Control Group|Conventional geriatric rehabilitation physical therapy (6x/week) during inpatient period. After discharge home, discontinuation of physical therapy.
2855659|NCT03558828|Experimental|Step1: Initial Treatment|Participants will be randomly assigned to one of the two initial treatment components: a) enhanced physical activity monitor only (physical activity monitor with goal setting and a physical activity prescription) treatment, or b) enhanced physical activity monitor+ motivational text messaging treatment for 8 weeks (early adoption phase). All participants will be given a physical activity step goal The initial treatment time period is from Weeks 1-8.
2855660|NCT03558828|Experimental|Step 2: Augmented Treatment|"At Week 8, it will be determined if a women has met her physical activity step goal. If she has, then she will be classified as a responder, and will continue with the same initial treatment component for weeks 9-34 (later adoption).~If a woman has not met her physical activity step goal she will be classified as a non-responder. In addition to the initial treatment component non-responders to initial treatments will be randomly assigned to one of two augmented treatment components: a) personal calls, or b) group meetings for Weeks 9-34 (later adoption phase)."
2855661|NCT03558828|Experimental|Step 3: Maintenance|At Weeks 35-50 (maintenance phase) all participants in the study return to an enhanced physical activity monitor only treatment component.
2855662|NCT03558815||Adults with mild, moderate, severe or profound ID|
2855663|NCT03558789||MT|patients complaining about metallic taste before, during or after treatment of head and neck cancer.
2855664|NCT03558789||No-MT|patients not complaining about metallic taste before, during or after treatment of head and neck cancer.
2855665|NCT03558776|Active Comparator|Linseed oil plus defined background diet (high linolec acid)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: A) 7 ± 2 En% linoleic acid (n = 37)
2855666|NCT03558776|Active Comparator|Linseed oil plus defined background diet (low linolec acid)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: B) < 2.5 En% linoleic acid (n = 37)
2855667|NCT03558776|Active Comparator|Linseed oil plus defined background diet (high milk)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: C) 15 ± 2 En% milk fat (n = 37)
2855668|NCT03558776|Placebo Comparator|Linseed oil without defined background diet|Linseed oil (LO) without defined menu plans (D) Western diet, n = 37)
2855669|NCT03558763|Active Comparator|Normal Care|During normal care the subjects will get the possibility to call the COPD-center via telephone on their own initiative e g with worsening symptoms as usual.
2855670|NCT03558763|Active Comparator|Telemonitoring|"Twice a week subject will perform additional vital functions:~Blood pressure and heart rate will be measured using the Electronic Sphygmomanometers Track.~Weight will be taken using the Scale lite Oxygen saturation will be measured using Pulse Oximeter Air And~Complete two PRO´s (integrated in the application):~CAT MRC All this is estimated to take approximately 20-30 min each time.~For the first 4 weeks there will be weekly video calls with a COPD-center nurse discussing health condition and vital parameters.~Thereafter there will be monthly video calls with a COPD-center nurse for the remaining 5 months, i.e. 4 further calls. The video calls will take approximately 15 min."
2855671|NCT03558750|Experimental|Treatment (nivolumab, rituximab, lenalidomide)|Nivolumab give by IV over 60 minutes on days 1 and 15, rituximab IV on day 1, and lenalidomide by mouth once per day on days 1-21. Repeats every 28 days for up to of 8 courses in the absence of disease progression or unacceptable toxicity. Patients with partial response or stable disease at the end of 8 cycles will be offered lenalidomide and nivolumab maintenance for up to 12 courses.
2855672|NCT03558737|Active Comparator|Nasal high-frequency jet ventilation (nHFJV)|
2855673|NCT03558737|Active Comparator|Nasal intermittent positive pressure ventilation (NIPPV)|
2855674|NCT03558724|Experimental|NIR endoscopy with bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.~IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to a total of 25 patients with locally advanced esophageal cancer~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
2855675|NCT03558711|Experimental|study group|
2855676|NCT03558698|Other|Group 1|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
2855677|NCT03558698|Other|Group 2|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
2855678|NCT03558698|Other|Group 3|"One night of good ventilation with High CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
2855868|NCT03557372|Experimental|Mathematical Model-Adapted Radiation|Mathematical Model-Adapted Radiation Fractionation Schedule
2855679|NCT03558698|Other|Group 4|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
2855680|NCT03558698|Other|Group 5|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
2855681|NCT03558698|Other|Group 6|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
2855682|NCT03558685|Experimental|Diet|Nutritional recommendation consisted of moderate caloric restriction, set at 25% to 30% less than calories needed for resting metabolic rate. We applied a high protein Mediterranean diet with the following food group distribution: 30% as protein (> 0.8 g/kg/d); 40% as carbohydrates with medium/low glycemic index; 30% as fat (≥10%monounsaturated fatty acid, ≤7% saturated fatty acid, no trans fats, and 1.6 g omega-3 for men and 1.1 g omega-3 for women). Diet was rich in olive oil, fish, chicken, nuts, white milk products, fruits, and vegetables but low in artificial sugars, commercial sweets, pastries, butter, margarine, and red meat. Dietary fiber content ≥25 g/day
2855683|NCT03558659|Experimental|Positional Therapy Belt|Use of positional therapy belt (SlumberBUMP) during sleep.
2855684|NCT03558659|No Intervention|Standard Care|No positional therapy belt provided for use during sleep.
2855685|NCT03558620|Experimental|Group 1O2|A fitting mask is held by one hand without mouth open -> one hand with mouth open -> held by two hands
2855686|NCT03558620|Experimental|Group 12O|By one hand without mouth open -> held by two hands-> one hand with mouth open
2855687|NCT03558620|Experimental|Group O12|One hand with mouth open ->by one hand without mouth open -> by two hands
2855688|NCT03558620|Experimental|Group O21|By one hand with mouth open -> by two hands-> one hand without mouth open
2855689|NCT03558620|Experimental|Group 21O|By two hands -> one hand without mouth open -> one hand with mouth open
2855690|NCT03558620|Experimental|Group 2O1|By two hands ->one hand with mouth open -> by one hand without mouth open
2855691|NCT03558607|Experimental|Experimental arm|
2855692|NCT03558594|Experimental|Hypnosis|Participant will have one brief meeting with a clinician in which they will learn about hypnosis and be provided with an informational booklet and with audiorecordings of hypnosis exercises. Participants will be encouraged to listen to the hypnosis recordings as much as they would like, whenever they would like to listen. The recordings are short inductions followed by therapeutic suggestions, including post-hypnotic suggestions. Participants will relax in a comfortable position with their eyes closed and will simply listen to the audio recordings that will include an induction followed by suggestions for decreased pain and improvement in co-morbid symptoms (e.g., improved mood and optimism, relaxation, sleep quality).
2855693|NCT03558594|Experimental|Mindfulness|Participant will have one brief meeting with a clinician in which they will learn about mindfulness meditation and be provided with an informational booklet and with audio recordings of mindfulness exercises. Participants will learn Vipassana meditation by listening to audio recordings, which is the specific form of mindfulness meditation (MM) typically implemented in mindfulness research. The emphasis is placed upon developing focused attention on an object of awareness, such as the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.Participants will be encouraged to listen to the meditation recordings as much as they would like, whenever they would like to listen.
2855694|NCT03558594|No Intervention|No intervention|Participants will enroll in the study, but do not select a study intervention. They will complete study assessments on the same schedule as those participants who select either experimental arm.
2855695|NCT03558581|No Intervention|Control|Patients have not received any special intervention, the follow up care was the standard care for the specific clinic
2855696|NCT03558581|Experimental|Intervention|After initial allocation the select patient received six educational interventions selected from Nursing Intervention Classification (NIC)
2855697|NCT03558568|Active Comparator|DBS off|
2855698|NCT03558568|Active Comparator|DBS on 60 Hz.|
2855699|NCT03558568|Active Comparator|DBS on 99 Hz.|
2855700|NCT03558568|Active Comparator|DBS on 130 Hz.|
2855701|NCT03558568|Active Comparator|DBS on 230 Hz.|
2855702|NCT03558555|Active Comparator|Oral Acetaminophen|Patients who are randomized to have oral acetaminophen will take oral acetaminophen preoperatively and receive saline intraoperatively.
2855703|NCT03558555|Active Comparator|Acetaminophen IV Soln|Patients randomized to IV acetaminophen will receive IV acetaminophen after induction of general anesthesia and will take placebo pills preoperatively.
2855704|NCT03558542|Experimental|Study Group|cardiopulmonary rehabilitation plus neurorehabilitation
2855705|NCT03558516|Experimental|Magnesium group|The patient will receive magnesium sulfate injection 40 mg/kg infuse over 30 min started at skin incision and continuous drip 10 mg/kg/hr until the dura is closed
2855706|NCT03558516|Placebo Comparator|Normal saline group|The patient will receive 0.9% sodium chloride the same amount of magnesium sulphate infuse over 30 min started at skin incision and continuous drip until the dura is closed
2855707|NCT03558503|Experimental|UGN-102|75 mg Mitomycin C (MMC) in 56 mL admixture (1.33 mg MMC per 1 mL of admixture).
2855708|NCT03558490|Experimental|ZEMY software|
2855709|NCT03558477|Experimental|Set 1(YYD601 1 & Nexium)|Set 1: YYD601 1 & Nexium
2855710|NCT03558477|Experimental|Set 2(YYD601 2 & Nexium)|Set 2: YYD601 2 & Nexium
2855711|NCT03558477|Experimental|Set 3(YYD601 3 & Nexium)|Set 3:YYD601 3 & Nexium
2855712|NCT03558464|Experimental|Intervention|"Intervention (agriculture-focused package~+ nutrition-sensitive and nutrition-specific interventions=integrated package)"
2855713|NCT03558464|Active Comparator|Control|(agriculture-focused package)
2855714|NCT03558451|Experimental|EXIMe intervention|In addition to the usual assistance, women will receive a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.
2869830|NCT03460977|Experimental|DL 6|PF-06821497 625 mg BID
2855715|NCT03558451|Active Comparator|Usual care|Usual care according to available protocols applicable to the women and the health service standardized portfolio
2855716|NCT03558438||HIV patients older than 50 years|Spanish cohort of patients with HIV infection older tha 50 years old.
2855717|NCT03558425|Experimental|TR group|Period 1: Test drug(CKD-381) Period 2: Reference drug(D026)
2855718|NCT03558425|Experimental|RT group|Period 1: Reference drug(D026) Period 2: Test drug(CKD-381)
2855719|NCT03558412|Experimental|Arm A|"Decitabine+BMF-90 for patients with relapse or refractory T-lymphoblastic lymphoma who used Hyper-CVAD as first-line therapy:Reduction regimen :VDLP(prednison,vincristine,daunorubicin,pegasparaginase),CAT(cyclophosphamide,cytarabine,bleomycin,6-mercaptopurine).Consolidation regimen:HD-MTX(Methotrexate,6-mercaptopurine).Decitabine,10mg,ivgtt,used for 5 days before VDLP,CAT and HD-MTX.~Decitabine+CODOX-M/IVAC for patients with relapse or refractory T-lymphoblastic lymphoma who used BMF-90 as first-line therapy:regimen A:CODOX-M:cyclophosphamide,epirubicin,vincristine,methotrexate.Regimen B :IVAC:ifosfamide,etoposide，cytarabine.Decitabine,10mg,ivgtt,used for 5 days before A+B."
2855720|NCT03558399|Experimental|FET according to ERA|In preparation for frozen embryo transfer (FET), estradiol will be administered for approximately 10 to 14 days or until endometrial criteria are met. These endometrial criteria will be assessed with transvaginal ultrasound and serum estradiol levels. Women will then begin intramuscular progesterone injection and if assigned to the study arm, a single euploid embryo will be transferred at the time indicated by the ERA test results. Merely the timing of embryo transfer will distinguish the study from the control group.
2855721|NCT03558399|Active Comparator|FET according to standard protocol|In preparation for frozen embryo transfer (FET), estradiol will be administered for approximately 10 to 14 days or until endometrial criteria are met. These endometrial criteria will be assessed with transvaginal ultrasound and serum estradiol levels. Women will then begin intramuscular progesterone injection and if assigned to the control arm, a single euploid embryo will be transferred according to our standard FET protocol.
2855722|NCT03558386||Patients between 55-64 years of age|"Patients between 55-64 years who have had a transplant at the following time points:~6 months to 1 year ago~1 year to 3 years ago~3 years ago or more"
2855723|NCT03558386||Patients 65+ years of age|"Patients 65+ years of age who have had a transplant at the following time points:~6 months to 1 year ago~1 year to 3 years ago~3 years ago or more"
2855724|NCT03558360||Bariatric surger|Bariatric surgery and impedance measurement
2855725|NCT03558347|Experimental|short implants with splinted crowns|Patients of that group received splinted crowns on the two adjacent implants Intervention: short implants with splinted crowns
2855726|NCT03558347|Experimental|short implants with non-splinted crowns|Patients of that group received single crowns on the two adjacent implants Intervention: short implants with non-splinted crowns
2855727|NCT03558334|Experimental|Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be given to preterm infants with BPD.
2855728|NCT03558334|Active Comparator|No Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be not given to preterm infants with BPD.
2855729|NCT03558321|Experimental|post menopausal bleeding|women with postmenopausal bleeding and endometrial thickness more than 5 mm
2855730|NCT03558308|Experimental|Brain+ with clinical support|This group will train with the programme 'Brain+' and receive continuous support from a clinician during the intervention period.
2855731|NCT03558308|Experimental|Cogmed with continuous support|This group will train with the programme 'Cogmed' and receive continuous support from a clinician during the intervention period.
2855732|NCT03558308|Experimental|Brain+ without support|This group will train with the programme 'Brain+' but receive no support during the intervention period.
2855733|NCT03558308|Sham Comparator|Sham-training group|This group will train computerized solitaire and other computerized games which are thought to be generally cognitive stimulating but with a very limit load on executive functions. This group will receive continuous support during the intervention period.
2855734|NCT03558282||Maxillary Anterior Implant|Subjects who have a single implant restoration in the maxillary anterior position with sufficient baseline data. Recession observation and crown contour observation of the implant will be completed.
2855735|NCT03558269|Experimental|Study group|This group will receive UCB after the first palliative surgery
2855736|NCT03558269|No Intervention|Control group|This group will not receive any treatment
2855737|NCT03558256|Experimental|Mindfulness-based Cognitive Therapy|MBCT group is a treatment group used mindfulness- based cognitive therapy added to the usual medication treatment, and guided by two therapists for 8 sessions. Every group of 6 people can form a closed structural group. Each session lasts 2 hours once a week, and has daily homework assignments.
2855738|NCT03558256|Active Comparator|Medication|Medication group is a control group that can choose to use the serotonin reuptake inhibitors (SSRIs) approved by China food and Drug Administration (SFDA) for the treatment of depression (fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram and escitalopram).
2855739|NCT03558243|Active Comparator|Patent Hemostasis Arm|The TR Band (Terumo medical) will be placed on the sheath entry site, the air bladder of the TR Band will be filled with 18 mL of air to achieve initial hemostasis. The sheath will be removed, air will be withdrawn slowly until a pulsatile bleeding is observed through the sheath's orifice, once this phenomenon occurs, 2 ml of air will be added to the air bladder and the absence of bleeding will be corroborated, immediately afterwards a pulse oximeter will be placed on the index finger of the patient and transient manual compression of the ipsilateral ulnar artery will be performed, patency of the radial artery will be corroborated by means of oxygen saturation and adequate pulse curve (Barbeau reverse test), if it is not possible to achieve patent hemostasis, it will be retried deflating 1-2 ml of the TR Band every 15 minutes until a positive reverse Barbeau test with absence of bleeding is achieved. TR Band removal will be attempted 2 hours after the procedure.
2855740|NCT03558243|Experimental|ULTRA Arm|The TR Band will be placed at the sheath entry site, the ipsilateral ulnar artery will be compressed at the Guyon's canal by placing a cylindrical composite made by wrapping 4 inch x 4 inch gauze around a 1-inch plastic needle cap, and compressing it using a circumferentially applied Hemoband. After occlusive compression of ulnar artery is confirmed by means of plethysmography, patent hemostasis protocol will be used for radial artery hemostasis as described at the patent hemostasis arm. The needle cap and hemoband that compresses the ulnar artery will be removed 1 hour after the procedure. TR Band removal will be attempted 2 hours after the procedure.
2855741|NCT03558243|Experimental|Hemostatic Disc Arm|The StatSeal hemostatic disc will be placed above sheath entry site, the TR Band will be placed above the disc, according to the manufacturer's specifications the air bladder will be filled with 8 ml of air, the sheath will be then removed, corroborating the absence of bleeding, 20 minutes later 3 ml of air will be removed, 20 minutes after that 5 ml of air will be removed, finally the investigators will try to remove the deflated TR Band 60 minutes after the procedure.
2855742|NCT03558230|Experimental|Vibration|The experimental group will receive the wrist stimulation during standardized Constraint-Induced Movement Therapy.
2855743|NCT03558230|Placebo Comparator|No Vibration|"The control group will wear the vibration device with no vibration during standardized Constraint-Induced Movement Therapy.~The vibration device is a generic, commercially-available, vibrator, not particularly used for this peripheral skin stimulation purpose."
2855744|NCT03558217|Experimental|Collared Femoral Implant|Participants will have the Corail collared femoral implant used during their surgery.
2855745|NCT03558217|Active Comparator|Collarless Femoral Implant|Participants will have the Corail collarless femoral implant used during their surgery.
2855746|NCT03558204||CMC denervation|Patients will undergo denervation of the thumb CMC joint
2855747|NCT03558204||trapeziectomy with ligament reconstruction (LRTI)|Patients will undergo excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
2855748|NCT03558191|Experimental|Injection SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion over 30 minutes.
2855749|NCT03558178|Experimental|Doin with Acupuncture|An acupuncture physician will administer acupuncture at a total 6-12 acupoints in the upper and middle trapezius areas (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels). Cervical Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise as indicated.
2855750|NCT03558178|Active Comparator|Acupuncture|An acupuncture physician will administer acupuncture at a total 6-12 acupoints in the upper and middle trapezius areas (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels).
2855751|NCT03558165||Stage IV Lung Adenocarcinoma|
2855752|NCT03558152|Experimental|Arm 1a: UTTR1147A Dose Level 1 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 1 and Vedolizumab Placebo.~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
2855753|NCT03558152|Experimental|Arm 1b: UTTR1147A Dose Level 1 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 1 and Vedolizumab Placebo.~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
2855754|NCT03558152|Experimental|Arm 2a: UTTR1147A Dose Level 2 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 2 and Vedolizumab Placebo.~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
2855755|NCT03558152|Experimental|Arm 2b: UTTR1147A Dose Level 2 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 2 and Vedolizumab Placebo.~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
2855756|NCT03558152|Experimental|Arm 3a: UTTR1147A Dose Level 3 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 3 and Vedolizumab Placebo.~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
2855757|NCT03558152|Experimental|Arm 3b: UTTR1147A Dose Level 3 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 3 and Vedolizumab Placebo.~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
2855758|NCT03558152|Active Comparator|Arm 4: Vedolizumab|Parts A and B: Vedolizumab and UTTR1147A Placebo.
2855759|NCT03558152|Placebo Comparator|Arm 5: Placebo|Parts A and B: UTTR1147A Placebo and Vedolizumab Placebo.
2855760|NCT03558139|Experimental|Treatment|Combination of Hu5F9-G4 and avelumab.
2855761|NCT03558113|Other|visual tactile method|visual tactile method using the modified USHPS critiria
2855762|NCT03558100|Experimental|Reducing Fall Risks in Obesity|Adults with obesity will be asked to perform the obstacle crossing intervention for adults with obesity for reducing falls risk. This will involve crossing obstacles of different heights under five conditions: initial baseline walking on flat ground, crossing three obstacle heights, and final baseline walking on flat ground for a total of 25 trials. Spatio-temporal gait parameters will be collected using a gait carpet and body-worn sensors.
2855763|NCT03558087|Experimental|Gemcitabine, Cisplatin and Nivolumab|Combination Therapy: Nivolumab 360mg IV, Gemcitabine 100mg/m^2 IV ,Cisplatin 70mg/m^2 IV for four 21-day cycles. At restaging, subjects with cT0 or cTa status may undergo cystectomy or continue maintenance Nivolumab 240mg IV for up to 8 14-day cycles. Subjects with > cTa status will undergo cystectomy.
2855764|NCT03558074|Experimental|Active|ALK4290 800 mg daily (400 mg tablet twice a day)
2855765|NCT03558061|Experimental|Active|ALK4290 800 mg daily (400 mg tablet twice a day)
2855766|NCT03558048||Men with Inflammatory Bowel Disease|Men with a confirmed diagnosis of IBD between the ages of 40-69 years old. These subjects will have their prostate specific antigen checked via a blood draw during clinic visits over the course of the study period.
2855767|NCT03558035|Experimental|Induction CT+ CRT group|Patients receive 2 cycles of TPF chemotherapy followed by Surgery or Chemo-radiotherapy according to the response status after induction chemo.
2855768|NCT03558035|Active Comparator|Concurrent CRT group|Patients receive single-agent Chemotherapy concurrent with Radiotherapy
2855769|NCT03558022|Experimental|Salt Pills|One week on low salt diet plus salt pills
2855770|NCT03558022|Placebo Comparator|Placebo Pills|One week on low salt diet plus placebo pills
2855771|NCT03558009||Observation|Patients with repetitive abdominal pain at-tacks of undetermined etiology aged between 2-60 years
2855772|NCT03557996|Experimental|Group 1|38% silver diamine fluoride liquid will be applied twice annually and patients will be followed up as 0,1,3,6,9 and 12 SDF is brush on liquid
2855773|NCT03557996|Active Comparator|Group 2|5% Sodium fluoride varnish will be applied four times annually and patient will be followed up at 0,1,3,6,9 and 12
2855774|NCT03557983|Experimental|fenofibrate|Fenofibrate should be topically spread three times per day at the irradiated areas, with a concentration of 400 μg/mL for week.
2855775|NCT03557983|Placebo Comparator|Saline|Saline is topically spread three times per day for one week.
2855776|NCT03557970|Experimental|Treatment (FMS inhibitor JNJ-40346527)|Participants receive FMS inhibitor JNJ-40346527 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2855777|NCT03557957|Experimental|Standard care plus targeted correction of hyponatremia|Diagnosis and treatment of hyponatremia will be standardized according to the European Clinical Practice Guidelines (ECPG). Treatment response and adherence will be evaluated daily and treatment adapted if treatment goals are not reached.Targeted correction of plasma sodium Levels.
2855778|NCT03557957|Active Comparator|Standard care|Diagnosis and treatment of hyponatremia will be solely at the discretion of the attending physicians who are in no way involved in the trial. The study team will not intervene with the treatment in any way. Diagnostic and treatment decisions as well as course of the plasma sodium level will only be recorded after patient is discharged from hospital using the medical records and patient charts. It will be generally recommended to measure plasma sodium levels 3x weekly or more frequently if clinically indicated, at discharge and after 30 days.
2855779|NCT03557944|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:~Medication reconciliation~Identification of patient priorities for care~Identification of medications that are potentially appropriate for discontinuation/dose reduction~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~Identification of medications for trial of discontinuation/dose reduction (shared decision making)~Pause of medication and clinical monitoring"
2855780|NCT03557944|No Intervention|Control|Standard of Care as wait list control. Control group will be offered intervention as part of usual clinical care at 6 months.
2855781|NCT03557931|Experimental|ASP4345 low dose|daily dose of ASP4345 in patients with cognitive impairment associated with schizophrenia on stable doses of antipsychotic medication
2855782|NCT03557931|Experimental|ASP4345 high dose|daily dose of ASP4345 in patients with cognitive impairment associated with schizophrenia on stable doses of antipsychotic medication
2855783|NCT03557931|Placebo Comparator|Placebo|daily dose in patients with cognitive impairment associated with schizophrenia on stable doses of antipsychotic medication
2855784|NCT03557918|Experimental|Tremelimumab|Tremelimumab 750 mg IV Day 1 of each 28 day cycle. Up to 7 cycles.
2855785|NCT03557905|Active Comparator|Group I|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse.
2855786|NCT03557905|Active Comparator|Group II|The patient will be ventilated with volume control mode with tidal volume 6 ml/kg, PEEP 3 cmH2O, an inspiratory expiratory ratio of 1:1.5, respiratory rate 20-25 breaths per minute depending on the patient's age and FiO2 of 0.5.
2855787|NCT03557892|Experimental|CSII+CGM|
2855788|NCT03557892|Active Comparator|MDI with degludec|
2855789|NCT03557879||Hearing impaired families|Samples from families presenting with familial hearing impairment, underlying the genetic basis, for whom 74 deafness genes have already been excluded (no evidence of pathogenic genotype)
2855790|NCT03557866|Experimental|pronated group|individuals with pronated foot
2855791|NCT03557866|Active Comparator|control group|individuals with normal foot posture
2855792|NCT03557853||Golimumab injection|Patients with ankylosing spondylitis and coxitis being treated with Simponi (golimumab) according to local clinical practice and label.
2855793|NCT03557840|Experimental|Temocillin treatment|Patients treated with temocillin and sampled as per the protocol
2855794|NCT03557827|Sham Comparator|control|Mechanical debridement by periodontal curets alone
2855795|NCT03557827|Active Comparator|Photodynamic Therapy|Mechanical debridement by periodontal curets and supplement with photodynamic appliance
2855796|NCT03557814|Active Comparator|LED01|Conventional non-surgical periodontal therapy plus LED light irradiation from T0-T1
2855797|NCT03557814|Active Comparator|LED02|Conventional non-surgical periodontal therapy plus LED light irradiation from T1-T2
2855798|NCT03557814|Sham Comparator|Control|Conventional non-surgical periodontal therapy without LED light irradiation
2855799|NCT03557801|Active Comparator|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard of care protocol.
2855800|NCT03557801|Experimental|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, women in the intervention arm 1 will participate in a 20-30 minute educational session alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
2855801|NCT03557801|Experimental|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
2855802|NCT03557788|Experimental|Rifaximin|Patients who receive PO Rifaximin 500mg TDS for 2 weeks. All patients will receive treatment to evaluate the effect of the intervention. This is a single-arm study.
2855803|NCT03557775|Experimental|Inspiratory Muscle Strength Training|"The participants in the IMST arm will receive, in addition to standard of care voice therapy, inspiratory muscle strength training (IMST).~The IMST intervention will consist of 5 sets of 5 breaths in the inspiratory threshold device every day during four weeks, with a loading dose set at 75% of the participants' maximal inspiratory pressure (MIP). MIP will be measured once a week during the weekly supervised session to adjust the inspiratory trainer."
2855804|NCT03557775|Experimental|Expiratory Muscle Strength Training|"The participants in the EMST arm will receive, in addition to standard of care voice therapy, expiratory muscle strength training (EMST).~The EMST intervention will consist of 5 sets of 5 breaths in the expiratory threshold device every day during four weeks, with a loading dose set at 75% of the participants' maximal expiratory pressure (MEP). MEP will be measured once a week during the weekly supervised session to adjust the inspiratory trainer."
2856332|NCT03554122|Placebo Comparator|Placebo Group|Patients spinal injections were performed without Shotblocker
2855805|NCT03557775|Active Comparator|Voice Exercises|The participants in the voice exercises group will receive standard of care voice therapy with a speech language pathologist, once a week during four weeks, plus daily practices.
2855806|NCT03557762|Experimental|Immediate Mindfulness|A 4 week smartphone app-based mindfulness intervention program with in-app activities for 20-30 minutes every day, with a minimum of 4 days of activity in a week.
2855807|NCT03557762|Other|Waitlist Control Mindfulness|No intervention for 4 weeks, after which there will be assessments immediately post-waiting and at 3 months post-baseline. After this, participants will get the same 4 week smartphone app-based mindfulness intervention program.
2855808|NCT03557749||Immune and Microbial Reconstitution|
2855809|NCT03557749||Immune Response Triggered by Severe, Systemic Viral Infection|
2855810|NCT03557749||Immune Response Triggered by Acute Graft-versus-Host Disease|
2855811|NCT03557749||Immune Response Triggered by Chronic Graft-versus-Host Disease|
2855812|NCT03557749||Immune Response Triggered by Relapse|
2855813|NCT03557749||Immune Response Triggered by Cytokine Release Syndrome|
2855814|NCT03557749||Allogeneic Related Donor Samples|
2855815|NCT03557749||Cellular Therapy Products|
2855816|NCT03557736|Experimental|Home-HIT|Home-based high-intensity interval training: participants performed 12 weeks of simple body weight exercises in a place of their own choosing 3x/week
2855817|NCT03557736|Experimental|Home-MICT|Home-based moderate-intensity interval training: participants performed 12 weeks of continuous exercise (running, swimming or cycling) in a place of their own choosing 3x/week
2855818|NCT03557736|Experimental|Lab-HIT|Laboratory-based high-intensity interval training: participants performed supervised cycle exercise under laboratory conditions 3x/week for 12 weeks
2855819|NCT03557710|Experimental|Behavioral Response Training|In Arm 1 of Devaluing energy-dense foods for cancer-control, participants will complete computer delivered versions of the stop-signal, go/no-go, and dot-probe training tasks in 8 30-min biweekly visits to the lab, with breaks between training blocks in which participants sit with their eyes closed to allow consolidation of learning. Participants will also complete a weekly 15-min training task online from home. Total training time = 345 min. Training will involve 100 images of cancer risk foods that participants regularly eat, including red and processed meats; high-sugar foods; heavily salted, smoked, and pickled foods; fries, chips, and snacks with trans-fats, and 100 images of healthy foods that participants rate as palatable, including vegetables, fruits, nuts, and whole grains.
2855820|NCT03557710|Experimental|Cognitive Reappraisal Training|Arm 2 of the Devaluing energy-dense foods for cancer-control intervention will be delivered via computer-assisted in-person training. Between baseline and endpoint sessions, participants will practice reappraisal on a computer, under close supervision of a facilitator, in 8 30-min twice-weekly individual sessions. During sessions, participants will practice cognitive reappraisal to reduce the value of cancer risk foods. Participants will also practice reappraisal of cancer risk foods on a computer at home, twice weekly for 15 minutes, for a total intervention time of contact of 345 minutes. The facilitator will review homework completed by participants and offer corrective feedback. The home practice is intended to promote generalization of use of this skill in the natural environment.
2855821|NCT03557710|Active Comparator|Generic Response Training|In Arm 3 (active control) of the Devaluing energy-dense foods for cancer-control intervention will be identical in duration and contact time to the behavioral response training described above (345 min total), but will involve nonfood images (birds and flowers), as described in the pilot trial. Participants will be informed that this intervention is designed to improve response inhibition, which should lead to eating change and weight loss given that impulsivity increases the risk for overeating, ensuring the credibility of the control arm.
2855822|NCT03557697|Active Comparator|wait-list control|3 measurement visits, baseline, 3, and 6 months
2855823|NCT03557697|Active Comparator|SMS intervention|3 measurement visits, baseline, 3, and 6 months
2855824|NCT03557684|Experimental|PO leucine & IV LPS|Oral (PO) leucine 6 g twice a day for 2 weeks followed by a single intravenous (IV) bolus of lipopolysaccharide (LPS) 0.8 ng/kg of body weight
2855825|NCT03557684|Experimental|PO placebo & IV LPS|PO maltodextrin (placebo) twice a day for 2 weeks followed by a single IV bolus of LPS 0.8 ng/kg of body weight
2855826|NCT03557684|Experimental|PO leucine & IV placebo|PO leucine 6 g twice a day for 2 weeks followed by a single IV bolus of 0.9% saline
2855827|NCT03557684|Placebo Comparator|PO placebo & IV placebo|PO maltodextrin (placebo) twice a day for 2 weeks followed by a single IV bolus of 0.9% saline
2855828|NCT03557671|Experimental|TRHF - Placebo|Each subjects will receive both TRHF and placebo formula during the 1st part of the study
2855829|NCT03557671|Placebo Comparator|Placebo - TRHF|Each subjects will receive both TRHF and placebo formula during the 1st part of the study
2855830|NCT03557658|Experimental|Hepatic Impaired|
2855831|NCT03557658|Experimental|Healthy Volunteer|
2855832|NCT03557645|Sham Comparator|Baseline Mechanical Ventilation|The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow = 60Lpm and tidal volume = 6mL/IBW. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
2855833|NCT03557645|Experimental|VHI With Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow will be set at 20Lpm, the tidal volume will be increased in steps of 200mL until the peak airway pressure of 40cmH2O is achieved, and an inspiratory pause will be applied at the end of inspiration. After achieving the target pressure, this ventilatory regimen will last 15 minutes. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
2855834|NCT03557645|Experimental|VHI Without Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow will be set at 20Lpm and the tidal volume will be increased in steps of 200mL until the peak airway pressure of 40cmH2O is achieved. After achieving the target pressure, this ventilatory regimen will last 15 minutes. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
2855898|NCT03557112|Active Comparator|the control group|TPF regimen induction chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
2855899|NCT03557099|Experimental|Hetrombopag Olamine|Hetrombopag will be started at 7.5 mg/day and uptitrated according to the platelet count.
2855835|NCT03557632|Experimental|TREATMENT:Virtual Reality Cue Exposure Therapy (VRCET)|Virtual Reality Cue Exposure Therapy (VRCET) - Active Intervention - comprised of exposure to VR based heroin cues, such as heroin use paraphernalia and scenes of people using injection heroin or snorting heroin. Exposure will be supplemented by the use of a standardized CBT based skills coping protocol teaching relapse prevention skills such as urge surfing, thought stopping and reframing. Lab based reactivity will be measured by self-reported craving on a scale from 0 (none) to 100 (highest ever), heart rate, galvanic skin response, and muscle tension. Secondary outcome measures are number of times of self-reported drug use in vivo as recorded by a cell phone app based Ecological Momentary Assessment Device (EMA).
2855836|NCT03557632|Active Comparator|Control: Relapse Prevention Drug Education|Relapse Prevention Drug Education (RPDE) is our Active Comparator. Comprised of watching a series of videos on the health risks of heroin use as well as information about relapse prevention. Lab based reactivity will be measured by self-reported craving on a scale from 0 (none) to 100 (highest ever), heart rate, galvanic skin response, and muscle tension. Secondary outcome measures are number of times of self-reported drug use in vivo as recorded by a cell phone app based Ecological Momentary Assessment Device (EMA).
2855837|NCT03557619|Experimental|Ethinyl estradiol/Levonorgestrel and Venetoclax|Ethinyl estradiol/Levonorgestrel administered once daily (QD) on Period 1 Day 1 and QD on Period 3 Day 1. Daily doses of venetoclax is administered for at least 54 days, starting on Period 2 Day 1.
2855838|NCT03557606||Alar treatment with BMC|Patients with CCJ instability that receive Alar treatment with BMC using anterior approach.
2855839|NCT03557580|Active Comparator|IS-5-MN R|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
2855840|NCT03557580|Experimental|IS-5-MN T1|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
2855841|NCT03557580|Experimental|IS-5-MN T2|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
2855842|NCT03557567||MO patients|
2855843|NCT03557567||OI patients|
2855844|NCT03557554|Experimental|Massage Therapy|Subjects who are planning treatment with paclitaxel as part of their standard of care treatment will receive a 20 minute massage prior to each paclitaxel infusion.
2855845|NCT03557541|Experimental|Sardine group|
2855846|NCT03557541|Active Comparator|Control group|
2855847|NCT03557528||Group 1|High Ligation of Inferior mesenteric artery
2855848|NCT03557528||Group 2|Low ligation of inferior mesenteric artery with skeletonization at its origin
2855849|NCT03557515|Experimental|CBT Telephonic Sessions|All participants will receive four stress management sessions. Then, the participant is randomly assigned to receive 4 weekly additional CBT telephonic sessions. Participants will be given weekly assignments to practice the skills learned in the sessions. Sessions will last 45 minutes to 1 hour. Optional grief and loss telephonic session will be offered.
2855850|NCT03557515|Experimental|Metta-Meditation Telephonic Sessions|All participants will receive four stress management sessions. Then, the participant is randomly assigned to receive 4 weekly additional Metta-meditation sessions. Participants will be given weekly assignments to practice the skills learned in the sessions. Sessions will last 45 minutes to 1 hour. Optional grief and loss telephonic session will be offered.
2855851|NCT03557502|Experimental|Heat Therapy Group|Group will undergo 30 sessions of heat therapy over approximately 10 weeks. Sessions will require subjects to be immersed in hot water for up to 45 minutes per session.
2855852|NCT03557502|Experimental|Aerobic Exercise Group|Group will undergo 30 sessions of aerobic exercise training over approximately 10 weeks. Sessions will require subjects to exercise on a cycle ergometer for up to 45 minutes per session.
2855853|NCT03557489|Experimental|Experimental group|Patients use gel pad(in usual) in addition to(Mepilex Border Sacrum)foam pad during surgery.
2855854|NCT03557489|No Intervention|Control group|patients use gel pad(in usual) during surgery.
2855855|NCT03557476|Experimental|Octacosanol|Two capsules (20-mg x 2) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed daily by the octacosanol group for six days, one capsule 30 minutes after morning and afternoon meals.
2855856|NCT03557476|Placebo Comparator|Placebo|A placebo pill was taken twice daily in replacement of the octacosanol supplement
2855857|NCT03557463|Active Comparator|Soy protein|Low isoflavone soy protein powder: Each participant was required to consume a total of 112 servings for the 8-week duration of the study. A 4-week supply was provided at baseline (week 0) and at the time of vaccine administration (week 4).
2855858|NCT03557463|Experimental|Dairy protein|UV-C treated raw milk protein supplement (TruActiv MPC 85). Each participant was required to consume a total of 112 servings for the 8-week duration of the study. A 4-week supply was provided at baseline (week 0) and at the time of vaccine administration (week 4).
2855859|NCT03557450|Experimental|PET/CT scanning with sodium fluoride|Subjects will received PET/CT scanning with sodium fluoride
2855860|NCT03557437|Active Comparator|Triple Therapy|Esomeprazole 20mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
2855861|NCT03557437|Experimental|Bismuth Plus Triple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
2855862|NCT03557424|Experimental|Polyglucosamine Glucomannan normal dose|Patients received the single dose Polyglucosamine und Glucomannan (0,5 g resp. 1 g per Stick) three times per day over 65 days. The drug is administered as a powder which is dissolved in water. The solution is taken orally.
2855863|NCT03557424|Experimental|Polyglucosamine Glucomannan high dose|Patients received the higher dose of Polyglucosamine und Glucomannan (1 g resp. 1,34 g per Stick) three times per day over 65 days. The drug is administered as a powder which is dissolved in water. The solution is taken orally.
2855864|NCT03557424|Placebo Comparator|Placebo|Patients received Placebo three times per day over 65 days. The Placebo is administered according to the respective Intervention (Drug: Placebo Comparator: Placebo) as a powder which is dissolved in water. The solution is taken orally.
2855865|NCT03557411|Experimental|SHR-1210 +Hypofraction radiotherapy|SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy
2855866|NCT03557398|Experimental|Hydeal-D vaginal pessaries|Vaginal application of Hydeal-D vaginal pessaries
2855867|NCT03557385|Other|aFFR vs cFFR|All subjects will receive Fractional Flow Reserve Measurements with both adenosine (aFFR) and contrast (Iopamidol) (cFFR) using the Navvus® Catheter and CVi® Contrast Delivery System
2869944|NCT03460054||Membranous Nephropathy (MGN)|Biopsy-Proven MGN
2855869|NCT03557359|Experimental|Nivolumab|Nivolumab 240 mg will be given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg will be given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab will be administered as a 30-minute infusion. A finite treatment duration with immune therapies in this participant population remains an area of ongoing research; therefore the treatment duration chosen was 2 years.
2855870|NCT03557333|Experimental|INP104|24-week treatment period for all participants followed by a 28-week treatment extension period for a subset of participants
2855871|NCT03557307|Experimental|Benralizumab|Benralizumab subcutaneous injection
2855872|NCT03557294|Experimental|1.0mg varenicline b.i.d.|Days 1 through 3: 0.5mg, once daily; days 4 through 7: 0.5mg, twice daily; days 8 through end of treatment: 1mg, twice daily.
2855873|NCT03557294|Experimental|0.5mg varenicline b.i.d.|Days 1 through 3: 0.5mg, once daily; 0.5 mg b.i.d. dose starting at day 4 through the end of the study
2855874|NCT03557294|Placebo Comparator|0.0mg placebo varenicline b.i.d.|Days 1 through 3: 0.0mg placebo once daily; days 4 through 7: 0.0mg placebo twice daily; days 8 through end of treatment: 0.0 mg placebo twice daily.
2855875|NCT03557281|Experimental|Subjects receiving GSK3036656|Eligible subjects will receive sequential doses of GSK3036656 at a starting dose of 5 milligrams given orally during treatment period.
2855876|NCT03557281|Active Comparator|Subjects receiving RIFAFOUR e-275|Eligible subjects will receive RIFAFOUR e-275 tablet given daily orally as standard-of-care therapy.
2855877|NCT03557268||On a GnRHa|Half of subjects will be on a puberty blocker or gonadotropin-releasing hormone analogue
2855878|NCT03557268||Not on GnRHa|Half of subjects will NOT be on a puberty blocker or gonadotropin-releasing hormone analogue
2855879|NCT03557255|Active Comparator|levosimendan|Levosimendan was prepared in a concentration of 25 µg/ml and infusion was commenced at a rate of 0.1 µg/kg/minute without loading and continued for 24 hours before surgery.The dose was doubled if an increase of > 20 mmHg in systolic blood pressure (SBP) could not be obtained within 2 hours after starting the infusion. Indications for dose reduction were the development of hypotension (SBP < 80 mmHg) or tachycardia (heart rate > 120 beats/min) persisting for more than 10 minute or (premature beats in a frequency exceeding 6/min or occurrence of a significant arrhythmia occurring in runs). The infusion medication would be discontinued should such occurrences persist despite dose reduction.
2855880|NCT03557255|Active Comparator|control|In the control group ,an identical saline infusion regimen was employed instead of levosimendan . Both patient and care giver were blinded for the study.
2855881|NCT03557242|Other|Warfarin plus Aspirin|100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to warfarin plus low dose aspirin for 30-45 days
2855882|NCT03557242|Other|Aspirin Monotherapy|100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to low dose aspirin monotherapy for 30-45 days
2855883|NCT03557242|Other|Registry Arm|Upto an additional 100 subjects with preexisting indication for anti coagulation (e.g. atrial fibrillation, deep venous thrombosis, pulmonary embolism) or who are not eligible for randomization after TAVR due to development of a new indication for anti coagulation will be enrolled in the registry arm of the study.
2855884|NCT03557229|Experimental|Melatonin|
2855885|NCT03557229|Experimental|Vitamin C|
2855886|NCT03557229|Experimental|Vitamin E|
2855887|NCT03557229|Experimental|N-acetylcysteine|
2855888|NCT03557229|No Intervention|Control|
2855889|NCT03557216|Experimental|Complicated diverticulitis|Patients with complicated diverticulitis diagnosed by computed tomography. Colonoscopy, Fecal immunochemical and occult blood test (FIT) and fecal calprotectin test wil be performed.
2855890|NCT03557216|Experimental|Uncomplicated diverticulitis|Patients with uncomplicated diverticulitis diagnosed by computed tomography. Colonoscopy, Fecal immunochemical and occult blood test (FIT) and fecal calprotectin test wil be performed.
2855891|NCT03557151|Active Comparator|Usual Care|Usual Care participants will receive the same excellent multidisciplinary Care they would receive at the same center were they not enrolled in the trial. In clinic visits scheduled at approximately 3-month intervals, they will see subspecialty board certified or eligible pediatric endocrinologists, supplemented as needed with involvement of certified diabetes educators, dietitians, social workers or psychologists. HbA1c target is < 7.5% with no severe hypoglycemia and acceptable quality of life. About half are expected to be on insulin pumps and carbohydrate counting, while the great majority of others are following basal-bolus multiple daily injection regimens, also based on carbohydrate counting. A rising proportion of patients use continuous glucose monitors and this trend is likely to accelerate during the study.
2855892|NCT03557151|Experimental|Transdisciplinary Care-In Person|In addition to all elements of Usual Care, TC-IP participants will have follow-up clinic visits in-person at approximately 3 month intervals during the study that will consist of simultaneous involvement of an advanced practice nurse, dietitian and psychologist who will see the parent and adolescent together. TC team members will have passed a competency exam following completion of a training course on each of the TC team professional disciplines.
2855893|NCT03557151|Experimental|Transdisciplinary Care-Telehealth|This treatment arm is the same as TC-In Person except that follow-up visits with the TC team will occur via Telehealth communication using the Vidyo video conference platform.
2855894|NCT03557138|Experimental|Me4FDG|Intravenous injection of alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me4FDG) and FDG for evaluation the kidney kinetic model of FDG and Me4FDG in type 2 diabetic patients with SGLT2-inhibitor therapies.
2855895|NCT03557125|Active Comparator|Receives QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
2855896|NCT03557125|Placebo Comparator|Receives Saline Skin Wheel No Block|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
2855897|NCT03557112|Experimental|the treatment group|TPF regimen induction chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy
2855900|NCT03557086|Experimental|Advanced Care Planning Video Decision Support Tool|We designed a 3-minute advance care planning video to provide patients with advanced liver disease general understanding of the types of medical care patients may receive at the end of life (EOL) and a description of medical interventions such as hospitalizations, intensive care unit (ICU) admission, cardiopulmonary resuscitation (CPR), and intubation. The video begins by addressing the importance of the patient's personal goals and perspectives by asking the viewer to reflect on their concerns about getting sick and their overall goals for their EOL care. The physician narrator then introduces a framework for choices of medical care at the EOL including: 1) life-prolonging care; 2) limited medical care; and 3) comfort care followed by visual images illustrating each of these EOL care choices. All three sequences of video images accompanying the narration attempt to help the viewer imagine the experience and likely outcomes of receiving these medical interventions at the EOL.
2855901|NCT03557086|Active Comparator|Verbal Narrative Control|Immediately after completing baseline assessments and randomization, patients assigned to the verbal narrative control arm will listen to the same description of the 3 goals of care used in the video arm read out by a research assistant
2855902|NCT03557073|Experimental|Phone Call|Subjects in this study arm receive a post-operative phone call by a physician.
2855903|NCT03557073|No Intervention|No Phone call|Subjects in this study arm do not receive an additional post-operative phone call by a physician.
2855904|NCT03557060||Subjects receiving NUCALA|Subjects with a diagnosis of EPGA, for which NUCALA is indicated will be included.
2855905|NCT03557034|No Intervention|Standard of Care Monitoring|
2855906|NCT03557034|Experimental|Kardia Monitoring|
2855907|NCT03557021|Experimental|Individualized therapy arm|HIV Treatment failure patients will undergo an HIV Drug resistance testing and the followed therapy will be adjusted with in this setting available medications to the outcome of the resistance profile
2855908|NCT03557021|Active Comparator|standard therapy arm|HIV Treatment failure patients will undergo an HIV Drug resistance testing and the national defined standard therapy will be applied as second line treatment.
2855909|NCT03557008|Active Comparator|Rabies Vaccine with Antibiotics|Participants in this group will receive the rabies vaccines as well as an antibiotic regimen consisting of metronidazole, vancomycin, and neomycin sulfate.
2855910|NCT03557008|Active Comparator|Rabies Vaccine|Participants in this group will receive the rabies vaccine.
2855911|NCT03556995||Bariatric surgery patients|All patients above 18 that underwent bariatric surgery
2855912|NCT03556982|Experimental|CART-123|The relapsed/refractory AML patients will receive allogenic or autologous CD123-Targeted CAR-T cells infusion after FC chemotherapy.
2855913|NCT03556969||Sedation after SA|Participants who undergo sedation after spinal anesthesia
2855914|NCT03556956|Experimental|Masitinib plus FOLFIRI|"Masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid).~Masitinib will be prescribed until disease progression (or treatment switch to next line of treatment), death, limiting toxicity or patient consent withdrawal."
2855915|NCT03556956|No Intervention|Best Supportive Care|Best Supportive Care (BSC) includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
2855916|NCT03556943|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
2855917|NCT03556943|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
2855918|NCT03556930|Experimental|Movie Induced Sedation Effect|Pediatric Radiation Oncology with Movie Induced Sedation Effect monitored by an AlignRT system (VisionRT LTD, UK).
2855919|NCT03556917|Active Comparator|group 1|topical gel base + caffeine.
2855920|NCT03556917|Active Comparator|group 2|iontophoresis + caffeine
2855921|NCT03556917|Active Comparator|Group 3|iontophoresis
2855922|NCT03556904|Active Comparator|Standard of Care|The choice of agent will be up to the treating medical oncologist and is not the study intervention. Current first line systemic therapy is most commonly a second generation androgen pathway inhibitor, including enzalutamide or abiraterone, although docetaxel is allowed. Patients will begin systemic treatment within 3 weeks of randomization.
2855923|NCT03556904|Experimental|Standard of Care + Radiotherapy|"Standard of care therapy will be up to the treating medical oncologist and is not the study intervention. Current first line systemic therapy is most commonly a second generation androgen pathway inhibitor, including enzalutamide or abiraterone, although docetaxel is allowed.~Radiotherapy will be delivered to a total EQD2 (Equivalent dose in 2Gy fractions) that ranges between conventional 30 Gy in 10 fractions, to SBRT (Stereotactic Body Radiation Therapy) with 50 Gy in 5 fractions. Patients must start systemic therapy within 3 weeks of randomization (unless radiation is begun within 3 weeks and the provider may hold systemic therapy until completion of radiation) and receive radiotherapy within 8 weeks of randomization."
2855924|NCT03556878|Experimental|Fitted TranS-C|Fitted TranS-C involves 4 x 20-30 minute sessions. It involves selected cross-cutting, core and optional modules from Standard TranS-C.
2855925|NCT03556852|Active Comparator|CARBETOCIN|received 1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby.
2855926|NCT03556852|Active Comparator|MISOPROSTOL|received 4 rectal misoprostol tablets (800 μg) after the delivery of the baby.
2855927|NCT03556839|Active Comparator|Arm A|Cisplatin 50mg/m2 + paclitaxel 175mg/m2+ bevacizumab 15mg/kg i.v D1 Q3W. Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologic therapy, namely bevacizumab, upon investigator discussion.
2855928|NCT03556839|Experimental|Arm B|cisplatin 50mg/m2 + paclitaxel 175mg/m2 + bevacizumab 15mg/kg + atezolizumab 1200mg i.v, D1 Q3W.Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologics therapy, namely bevacizumab plus atezolizumab, upon investigator discussion.
2855960|NCT03556605|Other|Control Arm.|A target of 50 subjects will be enrolled in the Control intervention arm. Subjects continue to use their current Blood Glucose Monitor without connection to mobile diabetes apps.
2856157|NCT03555292|Experimental|healthy control|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
2855929|NCT03556826|Experimental|Social Value Learning|For each child, two faces, randomly selected from the pool of four faces, will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display. Effects of training will be tested one day (efficacy) and one month (maintenance) after training. During each of the follow-up assessments, each child will first undergo the Laboratory Selective Attention (LSA) task to assess if they retained value-face associations from the training sessions, followed by the Real-World Selective Attention (RWSA) task to evaluate generalization.
2855930|NCT03556813||Group Vik|women over the age of 18 with breast cancer or remission
2855931|NCT03556813||Group physicians|women over the age of 18 with breast cancer or remission
2855932|NCT03556800|Experimental|0.5 gm of EstroCream (VML-0203)|
2855933|NCT03556800|Experimental|0.75 gm of EstroCream (VML-0203)|
2855934|NCT03556800|Experimental|1.25 gm of EstroCream (VML-0203)|
2855935|NCT03556800|Active Comparator|1.25 EstroGel|
2855936|NCT03556787|Experimental|Patients with knee pain|Adults patients suffering from osteoarthritis pain or general knee pain
2855937|NCT03556774|Experimental|With smoking cessation training|Participants who allocate to the intervention group will receive regular smoking cessation training program messages by professional team. One to six messages will be sent per day for 8 weeks. Hand copy of behavioral and pharmacotherapy interventions manual will send to each HSP by mail after randomization. One to three messages will be sent per week until the end of the 1-year follow-up. They will also be encouraged to communicate the experience of using behavioral and pharmacotherapy interventions in their group.
2855938|NCT03556774|No Intervention|Without smoking cessation training|Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until 52-week follow-up. One to six messages will be sent per week for 8 weeks. They will be encouraged to communicate the experience of helping patients quit smoking in their group.
2855939|NCT03556761|Experimental|Oral furosemide|Oral furosemide 20 mg/day for a total of 5 consecutive doses.
2855940|NCT03556761|Placebo Comparator|Placebo Oral Tablet|Placebo once per day for a total of 5 consecutive doses.
2855941|NCT03556748|No Intervention|Control group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake 1.2-1.5 g/kg bodyweight),~active exercise therapy is optionally provided (bicycle ergometers at room) during the in-Patient stay"
2855942|NCT03556748|Experimental|WB-EMS group|"physical exercise group regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1.2-1.5 g/kg bodyweight)~active exercise therapy is optionally provided (bicycle ergometers at room) during the in-Patient stay"
2855943|NCT03556735|Other|PEMF treatment|No sham group (placebo) was chosen. Treatment consisted of one active group in a multicenter study.
2855944|NCT03556722|Active Comparator|Active rTMS|Active rTMS on left dorsolateral prefrontal cortex.
2855945|NCT03556722|Sham Comparator|Sham rTMS|Placebo rTMS on left dorsolateral prefrontal cortex
2855946|NCT03556709|Experimental|Treadmill Ankle Robot Training|
2855947|NCT03556696|Experimental|ANI-loop|arm 1 : remifentanil is automatically administered by a medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index (MDMS, Loos, France)
2855948|NCT03556696|Active Comparator|std_practice|arm 2: remifentanil is administered by a target control device using Minto's remifentanil pK/pD model. This is standard practice for this type of surgery at the Burn Center of the University Hospital of Lille, France.
2855949|NCT03556683|Experimental|7% Hypertonic Saline|Subjects will inhale 4 mL of 7% hypertonic saline before having a Mucociliary Clearance (MCC) scan
2855950|NCT03556670|Experimental|Total Worker Health Intervention|
2855951|NCT03556670|Active Comparator|Control|
2855952|NCT03556657|Experimental|Music Therapy Group|Patient receives 6 sessions of music therapy with a board-certified music therapist. Patient will learn various music interventions for pain management that he/she will utilize at home.
2855953|NCT03556657|No Intervention|Wait-List Control Group|Patient receives standard care alone. Patient will receive music therapy sessions following completion of the post-test.
2855954|NCT03556644|Other|Single arm study|70 patients with coronary artery disease will have CTCA imaging and 3 vessel intravascular imaging with NIRS-IVUS during percutaneous coronary intervention and the obtained imaging data will be used to assess the efficacy of CTCA in detecting plaque morphology and shear stress distribution.
2855955|NCT03556631|Experimental|probiotics group|live combined Bifidobacterium and Lactobacillus tablets were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months
2855956|NCT03556631|Placebo Comparator|placebo group|placebo were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months
2855957|NCT03556618|Experimental|Youth Aftercare Reentry Program|"In partnership with LA County Health Agency, Dr. Barnert is adapting the successful Transitions Clinic model developed for reentry adults, to assist recently incarcerated youth link to needed health services and reduce substance use disorder relapse and recidivism. This adaption is informed by Dr. Barnert's prior research on the needs of incarcerated adolescents. The intervention, called the Youth Aftercare Reentry Program (YARP) will consist of network coaches who are formerly incarcerated and formally trained in care coordination and social network coaching, who interact with justice-involved youth and their families pre- and post-release to increase youths' engagement in community SUD and mental health services."
2855958|NCT03556618|No Intervention|Control|Participants in the control arm will receive usual care reentry healthcare planning, including correctional health provider and court-referred SUD and mental health treatment recommendations, medication prescriptions, written instructions for reinstating Medicaid, and written health discharge summaries. Participants in the intervention arm will receive usual care plus YARP.
2855959|NCT03556605|Other|Intervention Arm|A target of 100 subjects will be enrolled in the Intervention arm using the OneTouch Reveal® Mobile APP system
2856126|NCT03555513||living kidney transplanted patients|Any patients over 18 who received kidney transplantation from living donor
2855961|NCT03556592|Experimental|All subjects|"Tralokinumab - investigational medicinal product:~Week 0: subcutaneous (SC) injection of tralokinumab loading dose.~Week 2 to Week 14: SC injection of tralokinumab maintenance dose.~CYP substrates - non-investigational medicinal products:~Week -1, Week 1, and Week 15: oral administration of caffeine 100 mg, warfarin sodium 5 mg x2, omeprazole 20 mg, metoprolol tartrate 100 mg, and midazolam hydrochloride 2 mg."
2855962|NCT03556579|Experimental|Test/Control|For Visit 1, subjects will be randomly assigned to 1 of 2 contralateral lens sequences (Right: Test, Left: Control) OR (Right: Control, Left: Test). Then for visit 2, subjects will be randomly assigned to the same 1 of 2 contralateral lens sequences again.
2855963|NCT03556579|Experimental|Control/Test|For Visit 1, subjects will be randomly assigned to 1 of 2 contralateral lens sequences (Right: Test, Left: Control) OR (Right: Control, Left: Test). Then for visit 2, subjects will be randomly assigned to the same 1 of 2 contralateral lens sequences again.
2855964|NCT03556566|Experimental|V3-OVA treatment arm|Oral once daily pill of tableted vaccine (V3-OVA) containing ovarian cancer antigens administered for 3 months in 20 volunteers with ovarian cancer
2855965|NCT03556553|Experimental|Vertise Flow|Superficial Class I cavities restored with Vertise Flow
2855966|NCT03556553|Experimental|LuxaFlow|Superficial Class I cavities restored with LuxaFlow
2855967|NCT03556540|Placebo Comparator|Control|The volunteers without performing exercise during hemodialysis. Autonomic heart rate modulation, quality of life, physical fitness and safety level of exercise will be evaluated.
2855968|NCT03556540|Experimental|Experimental|The volunteers will perform physical exercise during hemodialysis. Autonomic heart rate modulation, quality of life, physical fitness and safety level of exercise will be evaluated.
2855969|NCT03556488||Pediatric CAP|Patients with a clinical diagnosis of CAP and radiographic evidence of lung consolidation, hospitalized in the Pediatric Unit.
2855970|NCT03556475||Disease 1|Moderate to severe COPD Patients(n=60)
2855971|NCT03556475||Disease type 2-1)|"Patients with AECOPD :~Mild: GOLD I-II, n=60"
2855972|NCT03556475||Disease type 2-2)|"Patients with AECOPD :~Moderate: GOLD I-II, n=60"
2855973|NCT03556475||Disease type 2-3)|"Patients with AECOPD :~Severe: GOLD I-II, n=60"
2855974|NCT03556475||Disease type 3|Non-COPD Patients with high risk factors (n=60)
2855975|NCT03556462|Experimental|Sleep Health Interventions|"Sleep Health Interventions:~Parents- a) invited to 1 hour workshop about healthy sleep, b) invited to attend a brief (app. 20 minute) Sleep Health Flipchart education either 1-on-1 or in a small group.~Children: exposed to 2 week 40min/day healthy sleep curriculum in the classroom.Agency: Video and print material"
2855976|NCT03556462|No Intervention|Control Period|No Intervention, but data collection
2855977|NCT03556449||Patients|High resolution ultrasound
2855978|NCT03556449||Healthy subjects|High resolution ultrasound
2855979|NCT03556436|Experimental|Group 1|YH25448 240mg single dose in korean
2855980|NCT03556436|Experimental|Group 2|YH25448 240mg single dose in caucasian
2855981|NCT03556410|Placebo Comparator|sleep|Subject will undergo 5 days of shortened sleep and then 2 days of ad libitum sleep.
2855982|NCT03556410|Experimental|sleep+exercise|Subject will undergo 5 days of shortened sleep but also have 45 min of moderate exercise/day and then 2 days of ad libitum sleep
2855983|NCT03556397|Experimental|cN0 before and after neoadjuvant th., SLNB - negative, no AD|Patients with cN0 before and after neoadjuvant therapy, SLNB - negative, without AD
2855984|NCT03556397|Experimental|cN0 before and after neoadjuvant th., SLNB - posit., AD|Patients with cN0 before and after neoadjuvant therapy, SLNB - positive, AD (separated histological examination of lymph nodes in levels I and II)
2855985|NCT03556397|Experimental|cN1 before neoadj. th., cN0 after neoadj. th., SLNB, AD|Patients with cN1 before neoadjuvant th., cN0 after neoadjuvant therapy, SLNB, AD (separated histological examination of lymph nodes in levels I and II)
2855986|NCT03556397|Experimental|cN1 after neoadjuvant therapy, SLNB, AD|Patients with cN1 after neoadjuvant therapy, SLNB, AD.
2855987|NCT03556384|Experimental|TMZ 85 mg/m2 mg orally|"TMZ 85 mg/m2 mg orally once for 21 days followed by 7 days without treatment in 28 day cycles.~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters. Temozolomide dose may be held and/or modified for the management of adverse treatment effects according to pre-specified criteria. Patients will have radiographic imaging (CT or MRI) every 8 weeks to assess tumor resection.~An end of treatment visit for clinical evaluations and safety assessments will be performed approximately 28 days after the last dose of study drug. Patients discontinuing study treatment will be followed every 3-6 months for disease recurrence and survival."
2855988|NCT03556371|Experimental|N-acetylcysteine Treatment|Oral administration of two capsules, containing 600 milligrams (mg) of N-acetylcysteine each one, twice day (10.00 and 20.00 hours; Total = 2400 mg/day) for four weeks.
2855989|NCT03556371|Placebo Comparator|Placebo oral capsules|Oral administration of two capsules, containing 600 milligrams (mg) of Placebo each one, twice day (10.00 and 20.00 hours; Total = 2400 mg/day) for four weeks.
2855990|NCT03556358|Experimental|TX05 (trastuzumab)|"• Intravenous (IV) epirubicin, 75 mg/m^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles~Followed by:~• IV TX05 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles"
2855991|NCT03556358|Active Comparator|Herceptin®|"• Intravenous (IV) epirubicin, 75 mg/m^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles~Followed by:~• IV Herceptin 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles"
2855992|NCT03556345|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
2855993|NCT03556332|Experimental|Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab & HCT|After receiving four 28-day cycles of Dara-CRd, eligible patients will then undergo HCT with high dose melphalan conditioning. Sixty to ninety days after HCT, patients will receive another 4 cycles of Dara-CRd.
2855994|NCT03556319|Placebo Comparator|Placebo|Placebo
2855995|NCT03556319|Experimental|2-HOBA Low Dose|2-Hydroxybenzylamine acetate: 500mg dose
2855996|NCT03556319|Experimental|2-HOBA High Dose|2-Hydroxybenzylamine acetate: 750mg dose
2870249|NCT03457935||Non-IPF ILD|non-IPF ILD diagnosis
2855997|NCT03556293|Active Comparator|Technical Assistance (No ASR)|Technical Assistance (TA). Intervention: TA will be offered to the 4 teams randomized to the TA condition without automated surveillance reporting and will receive the AKI Prevention Toolkit plus monthly technical calls independently
2855998|NCT03556293|Active Comparator|Virtual Learning Collaborative (No ASR)|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams without automated surveillance reportingand will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator [CAC] and Systems Redesign).
2855999|NCT03556293|Active Comparator|Technical Assistance with ASR|Technical Assistance (TA). Intervention: TA will be offered to the 4 teams randomized to the TA condition with automated surveillance reporting (ASR) and will receive the AKI Prevention Toolkit plus monthly technical calls independently and monthly ASR dashboard.
2856000|NCT03556293|Active Comparator|Virtual Learning Collaborative with ASR|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams with automated surveillance reporting (ASR) and will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites with the and monthly ASR dashboard. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator [CAC] and Systems Redesign).
2856001|NCT03556280|Experimental|Treatment Group|Will use the Active GammaSense Stimulation System.
2856002|NCT03556280|Sham Comparator|Control Group|Will use the Sham GammaSense Stimulation System.
2856003|NCT03556267|Other|spinal needle 27 gauqge|It is a device used to penetrate the dura to take CSF sample before injecting the drugs used for spinal anesthesia for cesarean section.
2856004|NCT03556267|Other|spinal needle 25 gauage|It is a device used to penetrate the dura to take CSF sample before injecting the drugs used for spinal anesthesia for cesarean section.
2856005|NCT03556254|Experimental|Genotypic resistance guided therapy|In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given.
2856006|NCT03556254|Active Comparator|Susceptibility testing guided therapy|Tailored therapy according to the minimum inhibitory concentration result (susceptibility testing, E-test)
2856007|NCT03556241|Experimental|Intervention: No change group|Case management consists keeping patient's current pacemaker mode during surgery
2856008|NCT03556241|No Intervention|Control: Mode change group|Usual care consists changing pacemaker mode to VOO before surgery
2856009|NCT03556228|Experimental|VMD-928 300 mg|VMD-928 300-mg Capsules
2856010|NCT03556215|Experimental|Effusion, Eustachian tube dilatation device and myringotomy|Patients with chronic Eustachian tube dysfunction and recurrence of chronic otitis media with effusion after tympanostomy tube exclusion, intervention: balloon Eustachian tuboplasty, and myringotomy
2856011|NCT03556215|Experimental|Effusion, Eustachian tube dilatation device|Patients with chronic Eustachian tube dysfunction and recurrence of chronic otitis media with effusion after tympanostomy tube exclusion, intervention: balloon Eustachian tuboplasty only (no myringotomy)
2856012|NCT03556215|Experimental|No effusion, Eustachian tube dilatation device|Patients with chronic Eustachian tube dysfunction and airy middle ear (without otitis media with effusion), Eustachian tube dilatation device, no myringotomy
2856013|NCT03556202|Experimental|Mirikizumab Dose 1|Mirikizumab administered subcutaneously (SC).
2856014|NCT03556202|Experimental|Mirikizumab Dose 2|Mirikizumab administered SC.
2856015|NCT03556189|Experimental|Experimental|case management consists adjusting AV delay of pacemaker to achieve best cardiac output measured by trans-thoracic echocardiogram
2856016|NCT03556189|No Intervention|Control: Usual care|Usual care is provided with routine pacemaker interrogation.
2856017|NCT03556176|Active Comparator|5-HTTLPR or BDNF polymorphisms|
2856018|NCT03556176|Active Comparator|Control ( without 5-HTTLPR or BDNF polymorphisms )|
2856019|NCT03556163|Experimental|Test Group|Modified vertical internal mattress sutures + MWF surgery.
2856020|NCT03556163|Active Comparator|Control Group|Simple loop interrupted sutures + MWF surgery.
2856021|NCT03556150|Experimental|Manual Therapy protocol|Massages, mobilisation and stretching techniques in the most painful joint
2856022|NCT03556150|Active Comparator|Effleurage|Superficial massage in the most painful joint.
2856023|NCT03556137|Experimental|Pain Patients|Individuals suffering from nociceptive pain, neuropathic pain, and mixed pain (pain that appears to be both nociceptive and neuropathic) and undergo a [18F]FTC-146 PET/MRI scan.
2856024|NCT03556137|Experimental|Healthy Volunteers|Individuals who do not have pain and undergo a [18F]FTC-146 PET/MRI scan.
2856025|NCT03556124|Experimental|Active - HD tDCS|Participants randomized to this arm will receive 12 sessions of high definition tDCS (HD-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
2856026|NCT03556124|Experimental|Active - Conventional tDCS|Participants randomized to this arm will receive 12 sessions of conventional tDCS (C-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
2856027|NCT03556124|Sham Comparator|Sham - HD tDCS|Participants randomized to this arm will receive 12 sessions of sham HD tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
2856028|NCT03556124|Sham Comparator|Sham - Conventional tDCS|Participants randomized to this arm will receive 12 sessions of sham conventional tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
2856127|NCT03555500|No Intervention|Fasting Group|Clear fluids up to the time of the procedure and no food for at least 2 hours before the procedure.
2870250|NCT03457935||IPF|Naive patients with no IPF treatment
2856029|NCT03556111|Experimental|anterior knife-edge maxilla graft (Without Xenograft Usage)|"The intervention will be a Sticky bone augmentation of defect. It is prepared using particulate autologous graft only along with fibrin glue and growth factors obtained from the patients' blood.~The sample is withdrawn and placed in plastic tubes which are spun twice in a centrifuge at a certain speed and time. The first spin to obtain the fibrin glue and the second to obtain the growth factors. The mixture is added to the harvested autogenous bone to form a semi-solid bone graft that is easily manipulated in the recipient site."
2856030|NCT03556111|Experimental|anterior knife edge maxilla graft (With Xenograft Usage)|"The intervention will be the sticky bone augmentation of the defect using both particulate autogenous and xenograft bovine bone.~The bone will be harvested from the donor, coupled with the bovine bone, the growth factors and the fibrin glue that is obtained from the patient's own blood sample.~The venous blood sample is placed in plastic tubes to be centrifuged at a certain speed and time to obtain the fibrin glue and growth factors.~The mixture is prepared until the bone is sticky and ready to be placed in the recipient defective maxilla"
2856031|NCT03556098|Active Comparator|GIP|Infusion of Glucose-dependent insulinotropic peptide
2856032|NCT03556098|Active Comparator|GIP[3-30]|Infusion of GIP[3-30]
2856033|NCT03556098|Placebo Comparator|Saline|Infusion of saline
2856034|NCT03556085|Experimental|Venous sinus stenting|Subjects will have stenting of the transverse-sigmoid sinus
2856035|NCT03556072||Intradiverticular papilla (IDP) group|Routine ERCP, recording the endoscopic procedures and observing the intra- and post-operative parameters
2856036|NCT03556072||Juxtapapillary diverticulum (JPD) group|Routine ERCP, recording the endoscopic procedures and observing the intra- and post-operative parameters
2856037|NCT03556059|Active Comparator|RNYGB|The role of EOSS for the surgical intervention: Roux-en-Y gastric bypass for severe obesity
2856038|NCT03556059|Active Comparator|Sleeve|The role of EOSS for the surgical intervention: Sleeve Gastrectomy for severe obesity
2856039|NCT03556059|Active Comparator|MGB/OAGB|The role of EOSS for the surgical intervention: Mini/One anastomosis gastric bypass for severe obesity
2856040|NCT03556046|Experimental|89Zr-girentuximab|A single administration of 37 MBq (+/-10%) 89Zr-girentuximab, containing a mass dose of 5 mg of girentuximab
2856041|NCT03556033|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg capsule once daily for 8 weeks
2856042|NCT03556033|Placebo Comparator|Placebo oral capsule|Placebo matched to dapagliflozin 10 mg capsule once daily for 8 weeks
2856043|NCT03556020|Experimental|High Dose Group|Maximally tolerated dose Drug: PB1046, Once Weekly Subcutaneous Injection
2856044|NCT03556020|Experimental|Low Dose Group|Minimally effective dose Drug: PB1046, Once Weekly Subcutaneous Injection
2856045|NCT03556007|Experimental|NKTR-358|SLE patients in each cohort will receive multiple subcutaneous doses of NKTR-358.
2856046|NCT03556007|Placebo Comparator|Placebo|SLE patients in each cohort will receive the Placebo comparator.
2856047|NCT03555994|Experimental|MEDI0382 (Part A)|MEDI0382 administered subcutaneously (Part A)
2856048|NCT03555994|Placebo Comparator|Placebo (Part A)|Placebo comparator administered subcutaneously (Part A)
2856049|NCT03555994|Active Comparator|Liraglutide (Part B)|Active comparator administered subcutaneously (Part B)
2856050|NCT03555994|Experimental|MEDI0382 (Part B)|MEDI0382 administered subcutaneously (Part B)
2856051|NCT03555994|Placebo Comparator|Placebo (Part B)|Placebo comparator administered subcutaneously (Part B)
2856052|NCT03555981|Experimental|Early KMC|Continuous kangaroo mother care started within 24h of hospital admission, aiming for minimum 18h/day and until hospital discharge with encouragement of KMC at home
2856053|NCT03555981|Active Comparator|Standard care|Standard care under radiant heater or incubator until clinical stability criteria are met then intermittent or continuous Kangaroo mother care started at >24h of hospital admission until hospital discharge with encouragement of KMC at home
2856054|NCT03555968|Placebo Comparator|THC 0 + BAC 0|Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .000%.
2856055|NCT03555968|Experimental|THC 125 + BAC 0|Participants will receive 125 µg/kg of THC in combination with blood alcohol concentrations of .000%.
2856056|NCT03555968|Experimental|THC 250 + BAC 0|Participants will receive 250 µg/kg of THC in combination with blood alcohol concentrations of .000%.
2856057|NCT03555968|Experimental|THC 0 + BAC .025|Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .025%.
2856058|NCT03555968|Experimental|THC 125 + BAC .025|Participants will receive 125 µg/kg of THC in combination with blood alcohol concentrations of .025%.
2856059|NCT03555968|Experimental|THC 250 + BAC .025|Participants will receive 250 µg/kg of THC in combination with blood alcohol concentrations of .025%.
2856060|NCT03555968|Experimental|THC 0 + BAC .049|Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .049%.
2856061|NCT03555968|Experimental|THC 125 + BAC .049|Participants will receive 125 µg/kg of THC in combination with blood alcohol concentrations of .049%.
2856062|NCT03555968|Experimental|THC 250 + BAC .049|Participants will receive 250 µg/kg of THC in combination with blood alcohol concentrations of .049%.
2856063|NCT03555955|Experimental|Cohort 1|Normal renal function
2856064|NCT03555955|Experimental|Cohort 2|Moderate renal impairment
2856065|NCT03555955|Experimental|Cohort 3|Severe renal impairment
2856066|NCT03555942|Active Comparator|Early follicular phase protocol|On day 2 or 3 of the menstrual cycle, following baseline blood sampling, a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.
2856128|NCT03555500|Experimental|Non fasting group|Clear fluids and food up to the time of the procedure.
2856129|NCT03555487|Experimental|18F-choline PET|PET/CT
2856158|NCT03555279|Experimental|Probation Staff (PS) Facilitator|The PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm intervention is delivered by Probation Staff working at the intervention site. Dosage is 8 2-hour sessions delivered over two weeks.
2856331|NCT03554122|Active Comparator|Shotblocker Group|Patients spinal injections were performed with Shotblocker placed onto injection site
2856067|NCT03555942|Experimental|Luteal phase protocol|Following baseline blood sampling on cycle day 2 of 3 of the menstrual cycle, patients will be followed up with blood and ultrasound from cycle day 10 onwards till the detection of serum LH peak. LH peak will be defined as an increase in serum LH above 20IU/LH. Five (5) days after the LH peak a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.
2856068|NCT03555929|Experimental|Dexamethasone|Dexamethasone 8 mg/2cc I.V. 90 minutes after axillary block
2856069|NCT03555929|Placebo Comparator|Normal saline|Normal saline 2cc I.V., 90 minutes after axillary block
2856070|NCT03555916|Experimental|Drug|BOTOX®, Allergan treatment in 2 mL of saline solution (0.9% NaCl) treatment
2856071|NCT03555916|Placebo Comparator|Placebo|2 mL of saline solution (0.9% NaCl) treatment
2856072|NCT03555903||Endometriosis cohort|The aim of the study is to advance the scientific knowledge of deep infiltrating endometriosis (DIE) and to evaluate the impact of surgery on the quality of life and the fertility of affected women.
2856073|NCT03555890|Experimental|Subjects of Group A: Part 1|Subjects in Group A will be randomized to receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine ODT 5 mg with 150 mL water in fasted state in Period 2.
2856074|NCT03555890|Experimental|Subjects of Group B: Part 1|Subjects in Group B will be randomized to receive levocetirizine ODT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 2.
2856075|NCT03555890|Experimental|Subjects of Group C: Part 2|Subjects in Group C will be randomized to receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine ODT 5 mg without water in fasted state in Period 2.
2856076|NCT03555890|Experimental|Subjects of Group D: Part 2|Subjects in Group D will be randomized to receive levocetirizine ODT 5 mg without water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 2.
2856077|NCT03555877|Experimental|Anti-hormonal treatment + ribociclib|In the experimental arm ribociclib will be dosed on a flat scale of 600mg/day (corresponding to three 200mg tablets once daily, 3 week on, one week off). Anti-hormonal/endocrine treatment of choice of investigator: anastrozole, exemestane, letrozole, fulvestrant, tamoxifen.
2856078|NCT03555877|Active Comparator|Anti-hormonal treatment|In the control arm patients will receive endocrine treatment only (of choise of investigator). Anti-hormonal/endocrine treatment of choice of investigator: anastrozole, exemestane, letrozole, fulvestrant, tamoxifen.
2856079|NCT03555864||Obese|Patients need two intravenous access with infra red
2856080|NCT03555851|Experimental|Recipient|Cyclophosphamide
2856081|NCT03555851|Other|Donor|Specimen collection
2856082|NCT03555838|Experimental|Active tDCS|Participants in this arm will receive 20 minutes of 2 mA transcranial direct current stimulation over the primary motor cortex of the more affected arm prior to robotic training.
2856083|NCT03555838|Sham Comparator|Sham tDCS|Participants in this arm will receive 20 minutes of sham transcranial direct current stimulation over the primary motor cortex of the more affected arm prior to robotic training.
2856084|NCT03555825|Active Comparator|60 Minutes ArmeoSpring (1:1)|60 minutes of therapy 3x per week for 6 weeks working one-on-one with a clinician for duration of session.
2856085|NCT03555825|Experimental|60 Minutes ArmeoSpring (2:1)|60 minutes of therapy 3x per week for 6 weeks with one clinician supervising 2 participants.
2856086|NCT03555825|Active Comparator|30 Minutes ArmeoSpring (1:1)|30 minutes of therapy 3x per week for 6 weeks working one-on-one with a clinician for duration of session.
2856087|NCT03555825|Experimental|30 Minutes ArmeoSpring (2:1)|30 minutes of therapy 3x per week for 6 weeks with one clinician supervising 2 participants.
2856088|NCT03555812|Experimental|Healthy volunteers|"a medical examination~10 measurements of pelvic tilt in sitting position, 10 measurements of pelvic tilt in supine position and 10 measurements of pelvic tilt in standing position, each performed by three different operators. These measurements will be done by ultrasound."
2856089|NCT03555812|Experimental|Patients|"a consultation the day before surgery, and a consultation 2 months after surgery, each including:~a medical examination~3 pelvic tilt measurements (1 standing, 1 sitting and 1 lying down). These measurements will be done by ultrasound."
2856090|NCT03555799||Labor analgesia patients|Patients with clinical indication of labor epidural will have IVC diameter measurement with ultrasound before and after the epidural placement
2856091|NCT03555773|Experimental|Lipogems|Lipogems injection into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract
2856092|NCT03555760||Surgery patient|Observation of informed consent form readings of all patients who are scheduled for surgery
2856093|NCT03555747|Other|Canine distalization by 75 g force|Canine was distalized using a continuous force of 75 g with nickel-titanium closed coil springs.
2856094|NCT03555747|Other|Canine distalization by 150 g force|Canine was distalized using a continuous force of 150 g with nickel-titanium closed coil springs.
2856095|NCT03555721||Oral examination followed by biopsy, CytID, and hpvID|Identification of oral lesions with oral examination with both incandescent light and fluorescent light (OralID), and subsequent testing of suspicious oral lesions with biopsy, CytID, and hpvID
2856096|NCT03555708|Experimental|High-Velocity Power Training|Training will consist of unilateral and bilateral leg presses (Total Gym GTS, San Diego CA), which will primarily target the quadriceps followed by the hip extensors and plantarflexors. Target load will be 40% to 80% of 1-repetition maximum (1RM) with progression toward 80%. Each participant will perform 3 to 5 sub-maximal efforts followed by 6 sets of 5 maximum-effort repetitions at the predetermined percentage of 1RM for each leg separately. Following the unilateral leg presses, 6 sets of 5 repetitions of bilateral leg presses will be performed at the predetermined percentage of 1RM. To minimize fatigue, 1-2 minutes of rest will be given between sets.
2856328|NCT03554161|Experimental|Tocilizumab for refractory BDU|This study is a self-control study and all the participants will be enrolled in the interventional arm.
2856097|NCT03555708|Experimental|Perception-Action Physical Therapy|The therapy includes: activities of adequate intensity that promote gait adaptation and gait speed sustainment, exploratory activities that enhance the somatosensory experience through rich/novel movement, and optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints. This includes a 15-minutes of sustaining and adapting gait speed while walking along a 40-meter hallway. Participants will alter their gait through exploratory movements. During the following 20 minutes participants will perform discrete problem solving activities including: waling backward sand stair negotiation.
2856098|NCT03555708|Experimental|Body Weight Supported Treadmill Training|The child will walk on the treadmill for 35-minutes, while the body weight is supported with an overhead system at 30 percent of the child's body weight, reducing every other week by 10 percent until no support is provided during the final 2 weeks. Treadmill speed will be set at 90% of the child's over ground walking speed, gradually increasing each session. Speed adjustments depend on the child's ability to control their steps and achieve: activities that promote symmetry of the leg kinematics, activities that promote maintaining an upright lower limb posture and clearing the tow during the swing, and activities that promote pushing off with ankle at terminal stance.
2856099|NCT03555695|Experimental|Karate Class Participants|Eligible subjects will engage in twice-weekly karate classes for 10 weeks, specifically designed for individuals with early to middle stage PD. Subjects will also complete an in-person pre-intervention focus group and post-intervention focus group, as well as a 6 month post-intervention follow up phone call.
2856100|NCT03555682|Placebo Comparator|Placebo|Placebo
2856101|NCT03555682|Experimental|2-HOBA Low Dose|2-Hydroxybenzylamine acetate: 500mg dose
2856102|NCT03555682|Experimental|2-HOBA High Dose|2-Hydroxybenzylamine acetate: 750mg dose
2856103|NCT03555669|No Intervention|Screening Phase (Pre) Group|"Patients who screen positive on the PHQ-9 for depression during the pre period will comprise the comparison group. Participants will receive standard of care depression treatment at the providers discretion."
2856104|NCT03555669|Experimental|Treatment Phase (Post) Group|"Patients who screen positive during on the PHQ-9 for depression during the post period will comprise the active group. Participants will receive the depression treatment intervention in the form of anti-depressants and/or problem solving therapy (PST) based on their PHQ-9 score."
2856105|NCT03555656|Experimental|Repeated educational intervention|Repetition every 6 months of a group educational session
2856106|NCT03555656|Active Comparator|Control group|Initial single group educational session, with no repetition
2856107|NCT03555643||transient ischemic attack (TIA)|Patients with transient ischemic attack
2856108|NCT03555643||transient neurological attack (TNA)|Patients with transient neurological attack
2856109|NCT03555630||Post-cesarean preeclampsia|
2856110|NCT03555630||Post spontaneous vaginal delivery preeclampsia|
2856111|NCT03555617|Experimental|TD-1473 formulation bridging & food effect|Subjects will receive, on Day 1 of each period, a single 100 mg oral dose of the tablet formulation of TD-1473 in the fed or fasted state, or the PIC formulation of TD-1473 in the fasted state, as part of a 3-period, crossover design.
2856112|NCT03555617|Experimental|TD-1473 with Itraconazole|Subjects will receive a single 100 mg oral dose of the tablet formulation of TD-1473 in the fasted state on Day 1 of Period 1. In Period 2, subjects will receive, in the fasted state, single oral doses of 200 mg itraconazole solution on Days -4 through 7 for a total of 11 days, with a single 100 mg oral dose of the tablet formulation of TD-1473 co-administered on Day 1.
2856113|NCT03555617|Experimental|TD-1473 without Itraconazole|Subjects will receive a single 100 mg oral dose of the tablet formulation of TD-1473 in the fasted state on Day 1 of Period 1.
2856114|NCT03555604||Scheduled cesarean section|Gastric ultrasound in term pregnant patients to correlate with NPO time in relation to body mass index
2856115|NCT03555591||Trelagliptin 100 mg|Trelagliptin 100 mg tablet, orally, once weekly for up to 36 months. Participants received interventions as part of routine medical care.
2856116|NCT03555578||Leuprorelin Acetate 11.25 mg|Leuprorelin Acetate Injection Kit 11.25 mg, every 12 weeks subcutaneously, for up to at most 8 years. Participants received interventions as part of routine medical care.
2856117|NCT03555565||Alogliptin and Metformin hydrochloride|Alogliptin 25 mg and metformin hydrochloride 500 mg, combination tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
2856118|NCT03555552|Experimental|Anticoagulation and Thrombosis Point of Care Test (AT-POCT)|
2856119|NCT03555552|Active Comparator|Duke Central Automated Laboratory (DCAL)|
2856120|NCT03555539|Experimental|Part 1: Healthy Match|Single 200 mg dose of ACH-0144471 on Day 1 in healthy participants (matched control group with normal hepatic function)
2856121|NCT03555539|Experimental|Part 1: Moderate HI|Single 200 mg dose of ACH-0144471 on Day 1 in participants with moderate HI
2856122|NCT03555539|Experimental|Part 2: Severe HI|Single 200 mg dose of ACH-0144471 on Day 1 in participants with severe HI
2856123|NCT03555539|Experimental|Part 2: Mild HI|Single 200 mg dose of ACH-0144471 on Day 1 in participants with mild HI
2856124|NCT03555526|Experimental|Genotypic resistance guided therapy|The regimen will be chosen according to the genotyping of 23S rRNA and gyrase A of H. pylori. In the absence of gyrase A mutation, esomeprazole (Nexium), amoxicillin (Amoxicillin), levofloxacin (Cravit), metronidazole (Flagyl) for 14 days will be given. In the presence of gyrase A mutation but in the absence of 23S rRNA mutation, esomeprazole (Nexium), amoxicillin (Amoxicillin), clarithromycin (Klaricid), metronidazole (Flagyl) for 14 days will be given. In the presence of both gyrase A and 23S rRNA mutation, bismuth quadruple therapy including esomeprazole (Nexium), bismuth (KCB), tetracycline, and metronidazole (Flagyl) for 10 days will be given.
2856125|NCT03555526|Active Comparator|Phenotypic resistance guided therapy|The regimen will be chosen according to the susceptibility testing result. In the absence of levofloxacin resistance, esomeprazole (Nexium), amoxicillin (Amoxicillin), levofloxacin (Cravit), metronidazole (Flagyl) for 14 days will be given. In the presence of levofloxacin resistance but in the absence of clarithromycin resistance, esomeprazole (Nexium), amoxicillin (Amoxicillin), clarithromycin (Klaricid), metronidazole (Flagyl) for 14 days will be given. In the presence of both levofloxacin and clarithromycin resistance, bismuth quadruple therapy including esomeprazole (Nexium), bismuth (KCB), tetracycline, and metronidazole (Flagyl) for 10 days will be given.
2870340|NCT03457272|Experimental|New risk assessment|New risk assesment
2856130|NCT03555474|Experimental|Theta burst stimulation & Physiotherapy|"Patients were given theta burst stimulation (intermittent TBS (iTBS) to the affected hemisphere and continuous TBS (cTBS) to the unaffected hemisphere) along with physiotherapy. TBS was delivered for 3 times in a week for 4 weeks.The stimulation was given with an intensity of 60% of RMT. The iTBS protocol of 10 bursts of high-frequency stimulation (3 pulses at 50 Hz) was applied at 5 Hz every 10 second for a total of 600 pulses.~Continuous TBS (inhibitory) was delivered to the unaffected hemisphere at the hot-spot with an intensity of 60% of RMT, 3 pulses at 50 Hz, repeated every 200 ms for a total of 600 pluses."
2856131|NCT03555474|Experimental|Functional stimulation & Physiotherapy|"Patients in the functional electrical stimulation (FES) group received the electrical stimulation with electrodes positioned according to pattern 3 [Grasp/Flexion/Extension, PATT (pattern movement)] of the FES (F) mode of the instrument. The electrodes were connected to a stimulator controller unit that delivers alternating current at a frequency of 35 Hz and a pulse width of 200 µs, intensity 10~50 mA.~The FES group stimulation session was given for 30 minutes for each day 3 times in a week (alternate days) for 4 weeks and it was concurrently synchronized with the physiotherapy."
2856132|NCT03555474|Active Comparator|Physiotherapy|"The following different physiotherapy regimens were followed for all the patients in the study.~Passive/Active Range of Motion (ROM); Weight bearing and supportive reaction; Reaching activities; Grasping, holding and release; Upper extremity activities of daily living (ADL). Physiotherapy intervention was given to all the patients 5 days per week for 1 month. In addition, all patients continued to receive in-home physiotherapy 1 to 2 times per week by a home physiotherapist who was guided by the research physiotherapist."
2856133|NCT03555448|Active Comparator|Once daily regimen|Once daily medication regimen (Envarsus and azathioprine)
2856134|NCT03555448|Active Comparator|Twice daily regimen|Twice daily medication regimen (Tacrolimus and mycophenolic acid)
2856135|NCT03555435|Experimental|On Your Own|Participants in this group will use the online program on their own for 6 weeks.
2856136|NCT03555435|Experimental|Peer Support|Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
2856137|NCT03555435|Placebo Comparator|Wait|Participants in this group will wait 6 weeks.
2856138|NCT03555422|Experimental|Selinexor|oral selinexor 80 mg once weekly
2856139|NCT03555422|Placebo Comparator|Placebo|oral placebo once weekly
2856140|NCT03555396|Experimental|Intervention|The investigators anticipate the intervention will consist of 4 sessions over the course of two months. The intervention is based off of current evidence-based practices and will consist of activities designed to strengthen support within the couple to improve adherence to antiretroviral therapy.
2856141|NCT03555396|Active Comparator|Standard of Care|Standard of Care consists of an appointment with an AIDS Center nurse at baseline and two months later. Under current Standard of Care in Almaty, no behavioral intervention is provided. Participants obtain prescription refills and give blood for viral load and CD4 tests once every 6 months.
2856142|NCT03555370|Experimental|Standard of Care Group|"Standard of Care:~The standard of care protocol consists of standardized in office and at home behavioral management to include sleep, hydration, nutrition, and stress management interventions. Participants will also be assigned physical activity that they will complete during their visits and at home. Physical activity for the standard of care group will include 15 minutes of flexibility/range of motion exercises, and 10 minutes of aerobic-based daily physical activity (e.g.,walking, stationary cycle)."
2856143|NCT03555370|Experimental|Vestibular Exercise Intervention Group|The vestibular group will complete the behavioral management activities described above, as well as prescribed in-office and at home vestibular exercises from each of four groups: 1) gaze stability training (i.e., integrated eye and head movements on fixed target), 2) visual motion training (i.e., integrated eye and head movements with busy visual background), 3) standing balance (i.e., standing in different stances), and 4) dynamic gait (i.e., walking with head turns). Participants will be prescribed to one of four levels of these four exercise groups based on presentation of symptoms/impairment as indicated on the VOMS. Progression through the four levels will be based on symptom tolerance and successful completion of all exercises at the current level.
2856144|NCT03555357|Active Comparator|PRP|Platelet Rich Plasma (PRP) injections into one half of the scar will be preformed. PRP is already considered an effective treatment for scar therapy.This will be randomly assigned by the clinical research coordinator .
2856145|NCT03555357|Experimental|PRF|Platelet Rich Fibrin (PRF) injections will be preformed the other half of the scar that is not treated with PRP. PRF has not been established as an effective scar treatment. The PRF will be considered experimental as this study seeks to evaluate if it is more effective than PRP.
2856146|NCT03555344|Experimental|Mantra Chikitsa|Mantra chanting for 15 mins
2856147|NCT03555344|No Intervention|Wait list control|Rest for 15 Mins
2856148|NCT03555331||INSIGHT participants|Mother-child dyads who enrolled in the INSIGHT Study and participated from early infancy to age 3 years will be followed through age 9 years.
2856149|NCT03555318|Experimental|Geriatrician + Cardiologist|Patients randomized to a combined ambulatory follow up with a cardiologist and a geriatrician.
2856150|NCT03555318|Active Comparator|Cardiologist|Patients randomized to usual care (ambulatory follow up with a cardiologist).
2856151|NCT03555305|Experimental|LY2963016|LY2963016 administered subcutaneously (SC) in one of two study periods.
2856152|NCT03555305|Active Comparator|Insulin Glargine (Lantus)|Insulin glargine administered SC in one of two study periods.
2856153|NCT03555292|Experimental|PD without dementia|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
2856154|NCT03555292|Experimental|PD with MCI|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
2856155|NCT03555292|Experimental|PD with dementia|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
2856156|NCT03555292|Experimental|dementia with Lewy bodies|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
2860237|NCT03527095|Experimental|Regimen E|FDL169 200 mg testing tablet 1 or 2, fasted
2856159|NCT03555279|Experimental|Youth Representative (YR) Facilitator|The PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm intervention is delivered by young adults who were formally in the juvenile justice system. Dosage is 8 2-hour sessions delivered over two weeks.
2856160|NCT03555266|Experimental|NSS-2 Bridge and ERAS Protocol|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
2856161|NCT03555266|Sham Comparator|Sham NSS-2 BRIDGE and ERAS Protocol|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal. This arm will contain an inactive sham NSS-2 BRIDGE device plus standard of care for abdominal oncological surgeries. Rescue analgesia will be permitted as per the approved ERAS multi-modal anesthetic protocol
2856162|NCT03555253|Experimental|PwMS and their Support Partner|Support Partners will participate in six resilience coaching Program Sessions conducted weekly by a study resilience coach. PwMS will participate in the initial and final coaching Program Sessions with their Support Partners.
2856163|NCT03555240||Patient with Rheumatoid Arthritis|Patient with Rheumatoid Arthritis living in the Emilia Romagna Italian region whom samples will be collected for the Biobank creation and Pharmacogenetic analysis
2856164|NCT03555227|Active Comparator|Group X|"PECS group~USG PECS2 with Drug A (active) Wound infiltration with Drug P (placebo)"
2856165|NCT03555227|Active Comparator|Group Y|"LA (local anaesthetic) infiltration group~USG PECS2 with Drug P (placebo) Wound infiltration with Drug A (active)"
2856166|NCT03555214|Experimental|Manual Therapy|Experimental group that will receive combined treatment of soft tissues with techniques evidenced independently.
2856167|NCT03555214|Placebo Comparator|Control Group|Grupo control placebo.
2856168|NCT03555201|Experimental|Manual therapy|Protocol of soft tissue techniques
2856169|NCT03555201|Active Comparator|Regular treatment control.|Regular treatment control.
2856170|NCT03555188|Experimental|Ondansetron|Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
2856171|NCT03555188|Placebo Comparator|Placebo|Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
2856172|NCT03555175|Other|Group one|This participants group must do eccentric exercise for 12 weeks
2856173|NCT03555175|Other|Group two|This participants group must do proprioception exercise for 12 weeks
2856174|NCT03555175|Other|Group 3|This participants group mustn't do exercise extra
2856175|NCT03555162|Other|Tool Use|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when using tools. Here only the fMRI experimental session is necessary. Tasks proposed to the participants within the fMRI scanner will be related to tool use. They will have to solve mechanical problems, to judge the appropriateness of hand postures for using tools, and to judge if tools presented share the same context of use, the same functional goals, the same hand postures for using them.These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use tools.
2856176|NCT03555162|Other|Tool Evolution|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when we improve tools. Here the fMRI experimental session will be complemented by a cognitive psychology experiment, where participants will be given a tool to improve. Tasks proposed to the participants within the fMRI scanner will be related to cognitive functions that could be implicated in improving tools : creativity, technical reasinoning, logic, empathy. The BOLD measures realted to these experimental condfitions will be related to the ability of the participant to improve a tool, through General Linear Modeling.
2856177|NCT03555149|Active Comparator|Regorafenib (Control)|Participants will continue to receive treatment until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria
2856178|NCT03555149|Experimental|Atezolizumab + Imprime PGG + Bevacizumab|Participants will continue to receive treatment until unacceptable toxicity or disease progression per RECIST V1.1. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria.
2856179|NCT03555149|Experimental|Atezolizumab + Isatuximab|Participants will continue to receive treatment until unacceptable toxicity or disease progression per RECIST V1.1. Participants who progress on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria
2856180|NCT03555136||Patients initiating vortioxetine treatment|Patients with major depressive disorder initiating treatment with vortioxetine
2856181|NCT03555123|Experimental|SIMDAX|Levosimendan2.5mg/mL
2856182|NCT03555123|Placebo Comparator|SIMDAX Placebo|Water for injection
2856183|NCT03555110|Active Comparator|Controlled Group|30 morbid obese patients, 30 to 55 years old, submitted to Personality Factor Battery Test (PFB Test) during the study with the same frequency and criteria of the group of EMDR .
2856184|NCT03555110|Active Comparator|EMDR Group|"30 morbid obese patients, 30 to 55 years old, submitted to Eye Movement Desensitization and Reprocessing Therapy (EMDR) during the study with the frequency of Twelve sessions, including:~Three evaluation and preparation sessions,~Eight EMDR sessions weekly with variable length of 60 minutes and~One closing session. The total intervention time will be about 3 (three) months. After the end of the 12 sessions of EMDR therapy, the patient will be evaluated again individually to verify the existence of change in PFB test results about the 5 big factors. The instrument will also be reapplied three months, twelve months and thirty-six months after bariatric surgery."
2856185|NCT03555097|Experimental|COPD Group|incremental pressure support
2856186|NCT03555084|Experimental|Device: Extension of Phonak Virto B-Titanium|The extension of Phonak Virto B-Titanium will be fitted to the participants individual Hearing loss.
2856187|NCT03555084|Active Comparator|Device: Phonak Virto B-Titanium|The Phonak Virto B-Titanium will be fitted to the participants individual Hearing loss.
2856188|NCT03555071|Experimental|Experimental Group1|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
2856189|NCT03555071|Experimental|Experimental Group2|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
2856190|NCT03555071|Experimental|Experimental Group3|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
2856191|NCT03555071|Active Comparator|Control Group|"The control vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at trial-scale.~Intervention: Live attenuated varicella vaccine manufactured at trial-scale"
2856192|NCT03555058|Other|High risk- TDM|Treatment escalation per TDM and physician's decision.
2856193|NCT03555058|No Intervention|High risk- Follow Up|Patients randomized to this arm will keep with the follow-up regime. Treatment escalation will occur only upon worsening of symptoms.
2856194|NCT03555058|No Intervention|Low risk|Control group. Patients will be assigned to this group based on VCE results and will not undergo randomization.
2856195|NCT03555045|Active Comparator|conducting the slanted recession technique|conducting the slanted recession technique on the superior and inferior poles of the muscle based on far and near deviations.
2856196|NCT03555045|Active Comparator|conducting the augmented recession technique on the muscle|conducting the augmented recession technique on the muscle for 1 to 1.50 mm more compared with the standard method.
2856197|NCT03555032|Experimental|All patients|All patients will receive two pre-operative doses of T-VEC administered by intratumoural injection prior to a 3rd intratumoural dose given at the time of Isolated Limb Perfusion (ILP). No further treatment will be given.
2856198|NCT03555019|Experimental|Formulaid|The intervention group will receive enteral supplementation with Formulaid containing ARA and DHA at a ratio of 2:1, from birth until 36 weeks PMA
2856199|NCT03555019|Active Comparator|MCT-oil|The control group will receive enteral supplementation with MCT oil containing coconut and/or palm kern oil, from birth until 36 weeks PMA
2856200|NCT03555006|Other|Local vs remote group|The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation
2856201|NCT03555006|Other|Local vs local group|The examination will be interpreted by two department's radiologists
2856202|NCT03554993|Experimental|CC-99677 Under Fasted Conditions|CC-99677 Under Fasted Conditions
2856203|NCT03554993|Experimental|Placebo|Placebo under fasted conditions
2856204|NCT03554993|Experimental|CC-99677 Under Fed Conditions|CC-99677 Under Fed Conditions
2856205|NCT03554980|Experimental|Group 1|"38% silver diamine fluoride liquid will be applied twice annually and patients will be followed up at 0,1,3,6, 9 and 12.~SDF is a brush-on liquid."
2856206|NCT03554980|Active Comparator|Group 2|5% sodium fluoride varnish will be applied four times annually and patients will be followed up at 0,1,3,6,9 and 12.
2856207|NCT03554941|Experimental|noise stimulation|noise stimulation
2856208|NCT03554928||Cocaine Dependent|Individuals with cocaine dependence
2856209|NCT03554928||Not Cocaine Dependent|Individuals without cocaine dependence
2856210|NCT03554915||Ketamine-based Protocol|The first 6 month period of the study will employ a ketamine-based protocol for prehospital agitation. There will be a tiered dosing protocol based on degree of agitation.
2856211|NCT03554915||Midazolam-based Protocol|The second 6 month period of the study will employ a midazolam-based protocol for prehospital agitation. There will again be a tiered dosing protocol based on degree of agitation.
2856212|NCT03554902||Endoscopic gastric tubulization|Endoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
2856213|NCT03554889|Experimental|Experimental Group|Peripheral blood lymphocytes will be collected. The NK cell will be selected and expanded ex vivo, then adaptive transfer back into patients. A total of 5.0 x 10^8/L NK cells will be infused in one cycle.To avoid allergic reactions, 50 mg hydrocortisone was intramuscularly injected into patient 30 min before cells infusion every time. Best supportive care was also provided for patients. Nimotuzumab will be used 24 hours before infusion. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT and PET-CT or they withdrew consent.
2856214|NCT03554876|Active Comparator|Multi-Im Machined|Multi-Im Machined
2856215|NCT03554876|Experimental|Multi-Im® nanogolden|Multi-Im® nanogolden
2856216|NCT03554876|Experimental|Multi-Im T-Golden|Multi-Im T-Golden
2856217|NCT03554863|Active Comparator|Facial mask|
2856218|NCT03554863|Experimental|Optiflow anesthesia|
2856219|NCT03554824||Pre-Transfer Adolescents aged 10-16 years|
2856220|NCT03554824||Post-Transfer Young Adults aged 16-25 years|
2856221|NCT03554824||Parents/Guardians of Pre-Transfer Patients|
2856222|NCT03554811|Experimental|Functional electrical stimulation assisted supine cycling|Patients will start functional electrical stimulation assisted supine cycling (FESC) within 48 hours of ICU admission and will undergo up to 1 hour of supine cycling daily, 5 days per week for 28 days, or until discharge from ICU.
2856223|NCT03554811|Active Comparator|Conventional early exercise and mobility interventions|Patients will undergo standard ICU exercise and mobility interventions.
2856224|NCT03554798|Experimental|mOPV1 (monovalent oral poliovirus type1)|"IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1.~6 weeks Infants vaccinated with 3 doses of bOPV and 1 dose of IPV, followed with 1 dose of candidate 1."
2856225|NCT03554798|Experimental|mOPV2 (monovalent oral poliovirus type2)|"IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 2.~Infants vaccinated with 3 doses of bOPV and 1 dose of IPV, followed with 1 dose of candidate 2."
2856226|NCT03554785|No Intervention|Control/Usual Care|"Readiness Assessment (web survey for CHC leadership and providers)~Patient web surveys (10 total per site; 5 SGM and 5 cisgendered)~Option to view 60 minute online webinar Do Ask, Do Tell: Collecting Data on Sexual Orientation and Gender Identity at Health Centers"
2856329|NCT03554148||SSI|This group receives an additional swab of the surgical site infection. Follow up is terminated at the occurence of SSI.
2856227|NCT03554785|Active Comparator|Intervention|"Readiness Assessment (web survey for CHC leadership and providers)~Patient web surveys (10 total per site; 5 SGM and 5 cisgendered)~CHC staff leadership key informant interviews (up to 5 at each site)~Tailored Educational Clinician and Non-clinician staff training intervention and technical assistance follow-up"
2856228|NCT03554772|Experimental|DFN-15 Active Dose A|Single dose
2856229|NCT03554772|Experimental|DFN-15 Active Dose B|Single dose
2856230|NCT03554772|Experimental|DFN-15 Active Dose C|Single dose
2856231|NCT03554772|Placebo Comparator|Placebo|Single dose
2856232|NCT03554746|Experimental|GC group|It mainly involve core stability exercise, stretching exercise and gluteal control training. All of above will be arranged 3 times a week for a total 6 weeks.
2856233|NCT03554746|Experimental|CG group|It involve core stability exercise and stretching exercise. All of above will be arranged 3 times a week for a total 6 weeks.
2856234|NCT03554733|Experimental|Treatment|Re-Inventing Yourself after SCI protocol - 6-week educational sessions
2856235|NCT03554733|No Intervention|Control|No intervention during course of study; participants offered the option of receiving the study intervention after completion of study.
2856236|NCT03554720|Active Comparator|Standard implants|ATTUNE PS Knee
2856237|NCT03554720|Active Comparator|Enhanced-Fixation|ATTUNE S+ PS Knee
2856238|NCT03554707|Experimental|SGT-53 with radiation or drugs|"Radiation phase: SGT-53 will be given at 2.1 mg DNA/m2 twice weekly for the first week of radiation therapy, and then increase to 2.8 mg DNA/m2 twice weekly. Radiation therapy will be administered as per clinical care, with a target of fifteen (15) fractions, but patients with other clinically-determined radiation plans will be allowed.~Chemotherapy phase: SGT-53 will be administered at the highest tolerated dose given during radiation phase. Irinotecan will be given at a dose of 50mg/m2/dose IV daily for five days in a 4-week cycle. Temozolomide will be given at a dose of 100mg/m2 PO daily for five days in a 4-week cycle and bevacizumab will be given at a dose of 10mg/kg IV every two weeks in a 4-week cycle."
2856239|NCT03554694|Experimental|Start with prebiotics|Half of the participants start with prebiotics, followed by a testing period. After a wash-out period they will continue with placebo followed by a testing period.
2856240|NCT03554694|Experimental|Start with placebo|Half of the participants start with placebo, followed by a testing period. After a wash-out period they will continue with prebiotics followed by a testing period.
2856241|NCT03554668||1|Post total knee replacement patients
2856242|NCT03554655|Experimental|Intervention: Momentum app|Intervention Group will receive treatment as usual together with the Momentum app.
2856243|NCT03554655|No Intervention|Control|Control Group will receive treatment as usual without the Momentum app.
2856244|NCT03554642|Experimental|Walkbot Training|This group will receive usual inpatient care that includes at least one 60-minute session of physical therapy and an additional 30-minute session of Walkbot with Augmented Reality 5-days per week during the duration of their stay (14 days).
2856245|NCT03554642|Active Comparator|Physical Therapy|This group will receive usual inpatient care including at least one 60-minute session of physical therapy per day, and an additional 30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
2856246|NCT03554642|No Intervention|Usual Care Physical Therapy|Participants in this group will receive usual inpatient care including at least one 60-minute session of physical therapy per day.
2856247|NCT03554629|Other|Capnography CO2 Sampling Filterline|Change capnography CO2 sampling Filterline by code name for scripted activities
2856248|NCT03554616|Experimental|Pyriproxyfen LLIN|Royal Guard® (Disease Control Technologies, LLC) is a Long Lasting Insecticidal Net made of polyethylene incorporating a mixture of 225 mg/m2 pyriproxyfen and 261mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
2856249|NCT03554616|Experimental|Chlorfenapyr LLIN|Interceptor® G2 (BASF corporation) is a LLIN made of polyester coated with a wash-resistant formulation of 200 mg/m2 chlorfenapyr and 100 mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
2856250|NCT03554616|Experimental|Piperonyl butoxide LLIN|Olyset® Plus (Sumitomo Chemicals) is a LLIN combining Piperonyl butoxide (400mg/m2) and the repellent pyrethroid permethrin (800 mg/m2) incorporated into the polyethylene fibres. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
2856251|NCT03554616|Active Comparator|Standard LLIN|Interceptor® (BASF Corporation) is a single pyrethroid-treated LLIN with alpha-cypermethrin (coated onto filaments) at a target dose of 200 mg/m2 of polyester fabric. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
2856252|NCT03554603|Experimental|Modified Reporting|"Microbiology laboratory will report Positive urine cultures may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call 777-xxxx (researcher mobile phone) for identification and susceptibility results"
2856253|NCT03554603|No Intervention|Standard Reporting|Microbiology laboratory will report identification and susceptibility results
2856254|NCT03554590|Experimental|carbo-counters|carbohydrate counting: patients attending a structured carbohydrate-counting training and practicing this tecnique to manage insulin therapy
2856255|NCT03554590|Active Comparator|control group|insulin therapy according to standard care. patients who don't practice carbohydrate-counting to manage insulin therapy
2856256|NCT03554577|Active Comparator|Hearing Aid without NR|Hearing Aid without Noise Reduction (NR) serves as reference condition.
2856257|NCT03554577|Experimental|Hearing Aid with NR_A|NR_A: Noise Reduction principle A
2856258|NCT03554577|Experimental|Hearing Aid with NR_B|NR_B: Noise Reduction principle B.
2856259|NCT03554577|Experimental|Hearing Aid with NR_C|NR_C: Noise Reduction principle C.
2856260|NCT03554564|Experimental|VOICE/Fitbit|VOICE enrollment with Fitbit walking activity tracking. During the VOICE phase, participants will use the digital health platform that integrates PAD-specific educational content, surveys, and Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase).
2856330|NCT03554148||No SSI|This group is systematically followed up until 30 days after surgery (one year if a implant is implanted, e.g. mesh) by a third party (www.swissnoso.ch).
2856261|NCT03554564|Other|Daily self-reported exercise adherence|Usual care prescribed by physician (walking exercise instructions). During the Usual Care control phase, participants will conduct walking exercise based on instructions received in clinic. Walking exercise will be tracked and self-reported by participants, using a written calendar log. Participants will not have access to the VOICE platform, or use of Fitbit technology during this phase.
2856262|NCT03554551||Patients with Parkinsons disease|Disease duration > 4 years, Hoehn & Yahr stage 2-3, 50-85 years old
2856263|NCT03554551||Healthy controls|50-85 years
2856264|NCT03554538|Experimental|Web app exercises|An evidence based exercise program for the shoulder pain. Web application with multimedia animations with the tailored exercise program for each patient in this group.
2856265|NCT03554538|Active Comparator|Exercises|An evidence based exercise program for the shoulder pain.
2856266|NCT03554525|Experimental|Experimental product : FAT-BINDER DAMM|3 sticks of the dietary supplement (1.4 grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner.
2856267|NCT03554525|Placebo Comparator|Control product : PLACEBO|3 sticks of the dietary supplement (1.4grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner.
2856268|NCT03554512|No Intervention|Standard of Care|No Intervention
2856269|NCT03554512|Experimental|Telehealth|Telehealth virtual appointment
2856270|NCT03554499|Experimental|Hydrodissection|Bichectomy with hydrodissection = infiltration of 15ml per side of a special solution (250ml of saline 0.9% + 1mg of epinephrine + 20ml of 2% Lidocaine, equivalent to 0.0555mg of epinephrine and 22.2mg of Lidocaine per side), prior to the incision with the following distribution: 1ml in the form of a wheal in the oral mucosa with a 22G needle 1cm behind the Stenon canal opening that corresponds to the incision site and 14 ml on the virtual space where the buccal fat pad is located.
2856271|NCT03554499|Active Comparator|Control|Bichectomy without hydrodissection = infiltration with 3ml per side of 2% Lidocaine with 1: 200,000 epinephrine ( equivalent to 0.015mg of epinephrine and 60mg of Lidocaine per side) at the operative site.
2856272|NCT03554486|Experimental|Group 1|Group 1 will use Fiasp insulin for 2 weeks, followed by Novolog insulin for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
2856273|NCT03554486|Experimental|Group 2|Group 2 will use Novolog insulin for 2 weeks, followed by Fiasp for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
2856274|NCT03554473|Experimental|Arm A/M7824 Monotherapy|M7824 (IV) monotherapy once every 21 days on a21-day cycle.
2856275|NCT03554473|Experimental|Arm B/M7824 plus topotecan|M7824 plus topotecan: At least 6 subjects randomizedto receive M7824 plus topotecan to determine safety. 4 more patients enrolled at initial or lower dose forefficacy. If efficacious, an additional 12 subjects enrolled.
2856276|NCT03554473|Experimental|Arm C/M7824 plus temozolomide safety|M7824 plus temozolomide: At least 6 subjects randomized to receive M7824 plus temozolomide todetermine safety. 4 more patients enrolled at initial orlower dose for efficacy. If efficacious, an additional 12 subjects enrolled.
2856277|NCT03554460|Experimental|dual-limb NIV|A maximal cycle exercise test with the participants assisted by BiPAP (Servo i, Maquet, Siemens) receiving 10 cmH2O pressure support in addition to oxygen therapy. During the test, breathing pattern, inspiratory flow of the inhalation limb and expiratory flow of the exhalation limb, fractional concentration of inspired CO2 (FiCO2) of the inspiratory line was measured for each breath were recorded.
2856278|NCT03554447|Experimental|Pentoxifylline group|Escitalopram 20 mg tablet once daily for 12 week plus Pentoxifylline 400 mg tablet twice daily for 12 weeks
2856279|NCT03554447|Placebo Comparator|Control group|Escitalopram 20 mg tablet once daily for 12 week plus placebo tablet twice daily for 12 weeks
2856280|NCT03554421|Experimental|Posterior tibial nerve stimulation|Percutaneous tibial nerve stimulation. Stimulation av posterior tibial nerve via neuromodulator for 30 minutes. 10 sessions
2856281|NCT03554408|Experimental|Group 1A|HIV-uninfected individuals will be administered one 1 mL (approximately 150 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
2856282|NCT03554408|Experimental|Group 1B|HIV-uninfected individuals will be administered one 2 mL (approximately 300 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
2856283|NCT03554408|Experimental|Group 2A|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 3 mg/kg.
2856284|NCT03554408|Experimental|Group 2B|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg.
2856285|NCT03554408|Experimental|Group 2C|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
2856286|NCT03554408|Experimental|Group 3B|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg
2856287|NCT03554408|Experimental|Group 3C|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
2856288|NCT03554408|Experimental|Group 4A|HIV-uninfected individuals will be administered one 2 mL (approximately 150 mg of each mAb) subcutaneous injection of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
2856289|NCT03554408|Experimental|Group 4B|HIV-uninfected individuals will be administered two 2 mL (approximately 300 mg of each mAb) subcutaneous injections of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
2856290|NCT03554408|Experimental|Group 5|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
2856291|NCT03554408|Experimental|Group 6A|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
2856292|NCT03554408|Experimental|Group 6B|HIV-infected individuals (off ART) will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion 3BNC117-LS, each dosed at 30 mg/kg.
2856293|NCT03554395|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
2856294|NCT03554395|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
2856295|NCT03554395|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2856296|NCT03554382|Experimental|intervention|Daily use of interactive mobile phone-based system to support self-management of hypertension: a) relevant items on drug side effects related to patient's drug regimen; and b) blood pressure.
2856297|NCT03554382|No Intervention|Control|"No study intervention will be made in the control group; they will receive treatment as usual."
2856298|NCT03554369|Experimental|Intervention/Treatment|Prostate SBRT will be delivered in 5 fractions using intensity-modulated radiotherapy planning techniques.
2856299|NCT03554356|Experimental|Cryoballoon Focal Ablation System (CbFAS) Treatment|Subjects undergoing CbFAS treatment as part of their clinical care for their condition.
2856300|NCT03554343||All newborn from Southern Belgium|All newborns except newborns for which parents refuse newborn screening will be tested for exon 7 deletion in SMN1
2856301|NCT03554330|Active Comparator|control group|Only graded balloon atrial septostomy is carried out, and no radiofrequency catheter ablation is performed.
2856302|NCT03554330|Experimental|single-RFA group|After graded balloon atrial septostomy procedure identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration.
2856303|NCT03554330|Experimental|double-RFA group|The first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (graded balloon atrial septostomy and radiofrequency catheter ablation around the rim of fenestration).
2856304|NCT03554317|Experimental|Bipolar Androgen Therapy + Nivolumab|All participants must have a rising PSA and/or radiographic progression and prior treatment with at least one novel androgen receptor (AR) targeted therapy (i.e. abiraterone acetate, enzalutamide). Up to one taxane agent for metastatic castration-resistant prostate cancer is permitted. Patients will be treated with testosterone cypionate 400mg IM every 4 weeks for a lead-in period of 12 weeks. After the lead-in period, all patients will be treated with nivolumab 480mg IV every 4 weeks and maintained on testosterone cypionate 400mg IM every 4 weeks. Treatment [with a minimum drug exposure of 12 weeks] will be continued until PSA progression (PCGW3 criteria) or clinical/radiographic progression (whichever comes first), or until unmanageable toxicity requiring drug cessation.
2856305|NCT03554304|Experimental|WCK 5222|WCK 5222 IV solution administered as either a 30- or 60-minute IV infusion)
2856306|NCT03554304|Placebo Comparator|Placebo (IV placebo matched toWCK 5222IV solution)|placebo capsule matched to moxifloxacin overencapsulated tablet IV placebo matched to WCK 5222 IV solution
2856307|NCT03554304|Active Comparator|Moxifloxacin 400-mg|positive control
2856308|NCT03554291|Experimental|Famotidine|"20mg of oral famotidine (pill) daily~Other names: Pepcid"
2856309|NCT03554291|Placebo Comparator|Placebo|Daily oral placebo (pill)
2856310|NCT03554278||Anemia|Stool samples from infants with anemia. Severe anemia defined as hematocrit less than 25%. Anemia defined as hematocrit greater than or equal to 25% and less than 30%.
2856311|NCT03554278||No Anemia|Stool samples from infants without anemia. No anemia defined as hematocrit equal to or greater than 30%.
2856312|NCT03554265|Experimental|mTBI subjects|"mTBI subjects will receive recombinant human growth hormone replacement therapy daily for 6 months.~Drug: recombinant human growth hormone (rhgH); somatropin, Genotropin~Dose: month 0 - month 1 will be dosed at 0.4 mg / day month 1 - month 6 will be dosed at 0.6 mg / day"
2856313|NCT03554265|No Intervention|Household Control Subjects|household control subjects will not receive any intervention.
2856314|NCT03554252|Experimental|Frequencies|
2856315|NCT03554252|Experimental|Percentages|
2856316|NCT03554239|Other|Voriconazole treatment|Patients who start voriconazole treatment and receive benefits of genotyping
2856317|NCT03554226|Experimental|AD Patients with NeuroPsychiatric Inventory Clinician (NPI-C)|The investigation aims to study the natural evolution of type A / A SPCDs in patients with AD. In this study, patients will receive optimized management based on existing best practice recommendations (HAS Recommendations 2009). It will therefore be a standard care study, since this survey applies the current recommendations on tools for the evaluation of SPCDs and the management of behavioral disorders in Alzheimer's disease (Recommendations HAS 2009).
2856318|NCT03554213||Phase 1: TCV in 2018|Children receiving TCV (typhoid conjugate vaccine) in 2018 vaccination campaign by NMMC.
2856319|NCT03554213||Phase 2: TCV in 2019|Children receiving TCV (typhoid conjugate vaccine) in 2019 vaccination campaign by NMMC.
2856320|NCT03554200|Experimental|Empagliflozin|Patients will receive empagliflozin 10 mg qd for a period of 30 days.
2856321|NCT03554200|Placebo Comparator|Placebo|Patients of the placebo arm will receive placebo tablets qd for a period of 30 days.
2856322|NCT03554187|Experimental|Lactibiane Buccodental, probiotics|"For one tablet : Lactobacillus paracasei LA 802 (109 UFC), Vitamine D3 (1,5 µg), Vitamine C (24 mg) Dosage : 2 tablets daily for 6 weeks tablet to suck after the meal and brushing teeth (one in the morning and one in the evening)~Interventions :~Ultrasonic periodontal debridement, with appropriate device : D+1 / Analyzes of periodontopathogenic bacteria : D-14, D+1, D+45, D+90 / IL1B test : D-14 / Salivary sampling : D+1, D+45, D+90 / Halitosis measure : D+1, D+45, D+90"
2856323|NCT03554187|Placebo Comparator|Placebo|"With no metabolic action ; identical in appearance to experimental probiotics Dosage : 2 placebo tablets daily for 6 weeks tablet to suck after the meal and brushing teeth (one in the morning and one in the evening)~Intervention(s) :~Ultrasonic periodontal debridement, with appropriate device : D+1 / Analyzes of periodontopathogenic bacteria : D-14, D+1, D+45, D+90 / IL1B test : D-14 / Salivary sampling : D+1, D+45, D+90 / Halitosis measure : D+1, D+45, D+90"
2856324|NCT03554174|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
2856325|NCT03554174|Experimental|Placebo/Medium Dose Psilocybin|Subjects in this arm receive placebo in the first session and medium dose psilocybin in the second session.
2856326|NCT03554174|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
2856327|NCT03554174|Experimental|Medium Dose Psilocybin/Placebo|Subjects in this arm receive medium dose psilocybin in the first session and placebo in the second session.
2860238|NCT03527095|Experimental|Regimen F|FDL169 200 mg testing tablet 1 or 2, with standard diet
2856333|NCT03554109|Experimental|Group A|"NANT Neoadjuvant Triple Negative Breast Cancer Vaccine~A combination of agents will be administered to subjects in this study:~cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, avelumab, aldoxorubicin HCl, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-051 and ETBX-061"
2856334|NCT03554109|Active Comparator|Group B|Standard treatment with a combination of doxorubicin, cyclophosphamide and paclitaxel.
2856335|NCT03554096|Experimental|2-HOBA|2-Hydroxybenzylamine acetate: 550mg dose
2856336|NCT03554083|Experimental|Arm A (vemurafenib, cobimetinib, atezolizumab)|"Participants receive vemurafenib PO BID on days 1-28, cobimetinib PO QD on days 1-21, and atezolizumab IV over 30-60 minutes on days 1 and 15 of courses 2 and 3. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Within 2-4 weeks after treatment, participants undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
2856337|NCT03554083|Experimental|Arm B (cobimetinib, atezolizumab)|Participants receive cobimetinib as in Arm A, and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Within 2-4 weeks after treatment, participants undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
2856338|NCT03554070|Experimental|Infravesical Obstruction|Patients with infravesical obstruction due to BPH (IPSS > 20, Qmax < 10), who underwent Thulium Fiber Laser Enucleation of the Prostate.
2856339|NCT03554057||Intervention Group|All low-risk patients referred for invasive coronary angiography through the Hamilton General Hospital's Heart Investigation Unit Triage will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification with CCTA at HHS and NHS as an alternative to upfront invasive angiography.
2856340|NCT03554057||Control Group|Intervention sites will act as their own controls: outcomes of all eligible patients in the 24-months prior to the implementation of the intervention will be assessed from a routinely collected health administrative database. Eligible patients not undergoing CCTA (patient or physician refusal, or CCTA not available) will be captured and included in the control group as part of a sensitivity analysis during the intervention period
2856341|NCT03554044|Experimental|Cohort I (talimogene laherparepvec, paclitaxel)|Participants receive talimogene laherparepvec IT every 2 weeks for the first 12 weeks and then every 3 weeks thereafter. Participants also receive paclitaxel IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2856342|NCT03554044|Experimental|Cohort II (talimogene laherparepvec, endocrine therapy)|Participants receive talimogene laherparepvec IT every 2 weeks for the first 12 weeks and then every 3 weeks thereafter. Participants also receive letrozole PO, anastrazole PO, exemestane PO, tamoxifen PO on days 1-28 or fulvestrant IM every 2 weeks for 3 doses then every 4 weeks for the subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2856343|NCT03554031|Experimental|rhGH injection/Jintropin AQ|Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.No control.
2856344|NCT03554018|Experimental|Acetaminophen|Acetaminophen 500-1000mg every 6 hours for 7 days Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention.
2856345|NCT03554018|Active Comparator|Placebo|Placebo Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention.
2856346|NCT03554005|Experimental|PEG Interferon Alfa-2b 0.75 mcg/kg Once Weekly (OW)|Participants receive PEG interferon alfa-2b 0.75 mcg/kg by subcutaneous (SC) injection once weekly (OW) for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
2856347|NCT03554005|Experimental|PEG Interferon Alfa-2b 1.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 1.25 mcg/kg by SC injection once weekly for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
2856348|NCT03554005|Experimental|PEG Interferon Alfa-2b 3 mcg/kg OW|Participants receive PEG interferon alfa-2b 3 mcg/kg by SC injection once weekly for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
2856349|NCT03554005|Experimental|PEG Interferon Alfa-2b 4.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 4.5 mcg/kg by SC injection once weekly for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
2856350|NCT03554005|Experimental|PEG Interferon Alfa-2b 6 mcg/kg OW|Participants receive PEG interferon alfa-2b 6 mcg/kg by SC injection once a week for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
2856351|NCT03554005|Experimental|PEG Interferon Alfa-2b 7.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 7.5 mcg/kg by SC injection once a week for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
2856352|NCT03553992|Experimental|The Put It Out Project (POP-6):|a culturally tailored intervention developed for sexual and gender minority (SGM) young adults on Facebook
2856353|NCT03553992|Experimental|Tobacco Status Project (TSP-6):|the original TSP intervention (non-tailored) delivered to groups of only SGM participants on Facebook
2856383|NCT03553797|Experimental|Arm 1 : Sequential Boost|"Whole Breast Irradiation with Sequential Boost~Breast : 50 Gy in 25 fractions of 2 Gy.~Optional : 42.7 Gy in 16 fractions of 2.67 Gy Lumpectomy Cavity: Total dose will be 12 Gy in 6 fractions or 14 Gy in 7 fractions per institutional discretion."
2856354|NCT03553979|Experimental|Stress management program (SM)|The stress management program (SM) is a program which has been tailored to meet the specific needs of low-SES participants. The SM consists of 4-weekly sessions (1.5hours/session) and a follow-up session 8 weeks later. A core element of SM is its group-based format in which psycho-educative topics on stress responses and coping and motivation to stop smoking link up with cognitive and behavioural technique activities.
2856355|NCT03553979|Experimental|Stress management + Buddy program (SM-B)|The stress management + buddy program (SM-B) includes the same psycho-educative topics and exercises, cognitive and behavioural technique activities as the SM condition. The SM-B in addition to SM utilises one-to-one support through a buddy selected by a participant. A buddy, 18 year or older is a student or a volunteer who is recruited and trained by Indigo Rijnmond. The buddy pairs up with a participant and provides the following: supports participant in managing and filling in tax/welfare papers; 2) helps a participant to get a grip over his/her personal finances; and 3) helps a participant to overcome daily barriers (eg. arranging childcare). Over the duration of the course, the buddy meets up 6 times with a participant every second week in a public area.
2856356|NCT03553979|No Intervention|Control|Participants in the control condition are instructed to continue with their normal daily behaviour. They will be invited to complete the questionnaires and objective measurements at the equivalent times as the intervention groups, thus at baseline, 4 weeks after baseline and 12 weeks after baseline. After the control period, participants in the control condition will be offered the intervention.
2856357|NCT03553966|Experimental|Tooth Brushing HAP+Restorative dentistry|"Arm Intervention: HA-Toothpaste Tooth Brushing HA Prophylactic cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated toothpaste containing microcrystalline hydroxylapatite 3x daily over the duration of the study (336 days).~Procedure: Tooth Brushing HA"
2856358|NCT03553966|Active Comparator|Tooth Brushing F+Restorative dentistry|"Cleaning teeth using a standardized electric tooth brush and a fluoridated tooth paste containing amino fluoride (500 ppm F-), (three times daily over the duration of the study (336 days).~Intervention:~Procedure: Tooth Brushing F 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated toothpaste."
2856359|NCT03553953||Patients with recording from BIS device|One hundred screened adult patients and no more than 60 valid cases who undergo elective surgery under general anesthesia with recording from the BIS device at the same time and comply with the inclusions criteria
2856360|NCT03553940|Experimental|Arm 1|A single dose of monovalent live attenuated influenza H3N2 M2SR vaccine (M2SR) administered intranasally on Day 1, and a single dose of licensed quadrivalent influenza vaccine (QIV) administered intramuscularly on Day 92. N=25
2856361|NCT03553940|Placebo Comparator|Arm 2|A single dose of Placebo administered intranasally on Day 1, and a single dose of licensed QIV administered intramuscularly on Day 92. N=25
2856362|NCT03553927|Other|Low Energy Diet|Commercially available diet products
2856363|NCT03553927|Other|NHS advice on healthy eating|Dietary / lifestyle advice programme
2856364|NCT03553914|Experimental|12 mg/m^2 dose group|Subjects will receive PLM60 at 12 mg/m^2 dose.
2856365|NCT03553914|Experimental|16 mg/m^2 dose group|Subjects will receive PLM60 at 16 mg/m^2 dose.
2856366|NCT03553914|Experimental|20 mg/m^2 dose group|Subjects will receive PLM60 at 20 mg/m^2 dose.
2856367|NCT03553901|Experimental|Acupressure|Acupressure is applied before injection
2856368|NCT03553901|No Intervention|Control group|acupressure is not applied before injection
2856369|NCT03553888||HS patient|patients with HS
2856370|NCT03553888||no HS patients|patients without HS
2856371|NCT03553875|Active Comparator|Memantine|Memantine administered in tablet form twice daily titrated to a maximum dose of 20 mg for 12 weeks.
2856372|NCT03553875|Placebo Comparator|Placebo|Subjects in the placebo control group will receive a matched placebo pill with no active ingredients. This will be administered twice daily for 12 weeks.
2856373|NCT03553862|No Intervention|Control|Patients randomly assigned to the control arm will receive the usual or conventional care not interfered by the study team.
2856374|NCT03553862|Experimental|Intervention|The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.
2856375|NCT03553849|Experimental|Very Low Calorie Diet|If they are randomized into the treatment arm, they will be prescribed with a 2-week VLCD that will begin 2 weeks prior to the scheduled elective surgery. Patients will be required to pay for the meal replacements.
2856376|NCT03553849|No Intervention|Standard Preop Diet|The control group will continue a regular diet until the day before surgery.
2856377|NCT03553836|Experimental|Pembrolizumab|Pediatric participants receive up to 17 cycles of 2 mg/kg (200 mg maximum) pembrolizumab by intravenous (IV) infusion every 3 weeks (Q3W) in a double-blind design in Part 1. Adult participants receive up to 17 cycles of 200 mg pembrolizumab by IV infusion Q3W in a double-blind design in Part 1. Participants that complete 17 cycles of pembrolizumab and experience disease recurrence may be eligible to receive additional cycles of pembrolizumab in Part 2 in an open-label design. In Part 2, participants will receive up to 17 cycles of pembrolizumab for local/distant recurrence following resection of disease or up to 35 cycles of pembrolizumab for disease that cannot be resected or metastatic disease.
2856378|NCT03553836|Placebo Comparator|Placebo|Participants receive up to 17 cycles of saline placebo by IV infusion Q3W in a double-blind design in Part 1. Participants that complete 17 cycles of placebo and experience disease recurrence may be eligible to receive pembrolizumab in Part 2 in an open-label design. In Part 2, participants will receive up to 17 cycles of pembrolizumab for local/distant recurrence following resection of disease or up to 35 cycles of pembrolizumab for disease that cannot be resected or metastatic disease.
2856379|NCT03553823|Experimental|secukinumab|20 subjects with plaque psoriasis with an inadequate response to ustekinumab will self-administer 300 mg secukinumab as two 150-mg s.c. injections at Baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 12 inclusive
2856380|NCT03553823|Active Comparator|Guselkumab|20 subjects with plaque psoriasis with an inadequate response to ustekinumab will self-administer guselkumab as 100 mg s.c. injections at Baseline, Weeks 4, and 12.
2856381|NCT03553810|Experimental|Treatment Arm|Entresto (valsartan/sacubitril) 100mg once a day
2856382|NCT03553810|Active Comparator|Controlled Arm|Valsartan 40mg once a day
2856384|NCT03553797|Experimental|Arm 2 : Concurrent Boost|"Hypofractionated Whole Breast Irradiation with Concurrent Boost~- Breast : 40 Gy in 15 fractions of 2.67 Gy fractions per day. Lumpectomy Cavity: Total dose of 48.0 Gy in 15 fractions of 3.2 Gy fractions per day."
2856385|NCT03553784|Experimental|Intervention Group|Group delivered Low Intensity Cognitive Behavioural Therapy (CBT).
2856386|NCT03553784|No Intervention|Control Group|No intervention.
2856387|NCT03553758|Experimental|Ketamine EEG Dynamics|EEG recordings will be obtained from 15 subjects undergoing ketamine general anesthesia.
2856388|NCT03553745|Experimental|Gentle Yoga Program|Program will meet twice a week for a 10-week period. Participants will be a part of gentle yoga sessions led by instructors specializing in the area.
2856389|NCT03553745|Experimental|Rigorous Yoga Program|Program will meet twice a week for a 10-week period. Participants will be a part of rigorous yoga sessions led by instructors specializing in the area.
2856390|NCT03553745|Experimental|Cardiovascular Exercise Program|Program will meet twice a week for a 10-week period. Participants will be a part of cardiovascular exercise sessions led by instructors specializing in the area.
2856391|NCT03553732||Active Surveillance Patients|Patients who elect to be monitored by an Active Surveillance protocol for prostate cancer
2856392|NCT03553719||One day point-prevalence analysis 1|Data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 288 patients per point-prevalence analysis will be collected.
2856393|NCT03553719||One day point-prevalence analysis 2|"Before the start of the second one day point-prevalence analysis a training package is conducted at each study center. This contains online lectures, instructional videos, educational handouts, and a bedside teaching component over the course of 6 weeks. The effect of a training block for intensive care unit staff on routine delirium screening rate and the change of the other outcome measures will be assessed.~During the one day point-prevalence analysis 2 data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 288 patients per point-prevalence analysis will be collected."
2856394|NCT03553719||One day point-prevalence analysis 3|Data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 288 patients per point-prevalence analysis will be collected.
2856395|NCT03553693|Experimental|Intervention Clinics|RAPID-VL study intervention testing and counseling package, which includes near point-of-care viral load (VL) testing at local testing hubs, structured VL counseling, forms to track VL ordering and testing, with feedback and performance evaluations at regular intervals.
2856396|NCT03553693|No Intervention|Control Clinics|Standard of care VL testing and counseling procedures consistent with country guidelines.
2856397|NCT03553680|Experimental|Emotion-Focused CBT|Ten CBT sessions with a therapist.
2856398|NCT03553680|No Intervention|Wait List|Three visits for assessments only over the same time period of the Experimental Arm.
2856399|NCT03553667|Active Comparator|Standard group|Adult patients, Creatinine clearance >= 30ml/min, with limb lymphedema, receiving lymphatic venous anastomosis
2856400|NCT03553667|Experimental|ClearSight|Adult patients, Creatinine clearance >= 30ml/min, with limb lymphedema, receiving lymphatic venous anastomosis
2856401|NCT03553654|Experimental|CT monitoring arm|18-75 year old patients with newly-diagnosed cancer, scheduled to undergo anthracycline-based chemotherapy.
2856402|NCT03553628|Active Comparator|Chlorhexidine Once Daily|Chlorhexidine HCL 0.12% mouthwash to be used once daily for one week each month for six months
2856403|NCT03553628|Active Comparator|Chlorhexidine Twice Daily|Chlorhexidine HCL 0.12% mouthwash to be used twice daily for one week each month for six months
2856404|NCT03553628|Experimental|Propolis Once Daily|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash to be used once daily for one week each month for six months
2856405|NCT03553628|Experimental|Propolis Twice Daily|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash to be used twice daily for one week each month for six months
2856406|NCT03553615|Experimental|Oral treatment|12mg oral ivermectin treatment taken once a week for four weeks
2856407|NCT03553602|Experimental|HDR Brachytherapy + EBRT + STAD|"Day 1: HDR Brachytherapy implant: 2 fractions of 12 Gy to prostate/ proximal SV.~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET positive lesions.~6 months hormonal therapy(LHRH agonist and antiandrogen [until the end of radiotherapy])"
2856408|NCT03553589||Cases|Women older than 18 years and diagnosed with endometrial cancer will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
2856409|NCT03553589||controls|Women older than 18 years and with a benign endometrial disturbance will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
2856410|NCT03553576|Experimental|Low volume bolus|6.25 mL administration at 250 ml per hour of a greater density solution (0.1% bupivacaine with fentanyl 1.95 mcg/mL)
2856411|NCT03553576|Experimental|High volume bolus|10 mL administration of a lower density local anesthetic (0.0625% bupivacaine with fentanyl 1.95 mcg/mL).
2856412|NCT03553563|Experimental|Group1|Initial healing phase (8 weeks), D961H 10 mg once-daily; Maintenance phase (24 or 44 weeks), D961H 10 mg once-daily
2856413|NCT03553563|Experimental|Group2|Initial healing phase (8 weeks), D961H 20 mg once-daily; Maintenance phase (24 or 44 weeks) starts with D961H 10 mg once-daily and may be increased to 20 mg once-daily based on investigator's discretion
2856414|NCT03553563|Experimental|Group3|D961H 10 mg once-daily (32 or 52 weeks)
2856415|NCT03553563|Experimental|Group4|D961H starts with 10 mg once-daily, and may be increased to 20 mg once-daily based on investigator's discretion (32 or 52 weeks)
2856416|NCT03553537|Experimental|Decitabine + CHOP regimen|decitabine plus CHOP (D-CHOP) administered in 4 week cycles for 6 cycles
2856417|NCT03553537|Active Comparator|CHOP regimen|cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles
2856418|NCT03553524|Experimental|Morning first|"Both arms of the study will perform the baseline measurements during visit 1. Arm 1 of the study will perform HIIT at 08:30 during visit 2, and after a 1-week washout period will perform HIIT at 19:30 during visit 3.~HIIT bout will consist of 3 minutes of warm-up followed by 6 1-minute intervals of full exertion cycling on a cycle ergometer, interspersed by a 1-minute recovery periods and ending with a 3-minute cooldown."
2870341|NCT03457272|No Intervention|Standard|Standard risk assessment
2856419|NCT03553524|Experimental|Afternoon first|"Both arms of the study will perform the baseline measurements during visit 1. Arm 2 of the study will perform HIIT at 19:30 during visit 2, and after a 1-week washout period will perform HIIT at 08:30 during visit 3.~HIIT bout will consist of 3 minutes of warm-up followed by 6 1-minute intervals of full exertion cycling on a cycle ergometer, interspersed by a 1-minute recovery periods and ending with a 3-minute cooldown."
2856420|NCT03553511|Experimental|Uterosacral ligaments suspension|Women affected by stage II-III pelvic organ prolapse undergoing total laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments.
2856421|NCT03553511|Active Comparator|McCall culdoplasty|Women affected by stage II-III pelvic organ prolapse undergoing vaginal hysterectomy with McCall culdoplasty.
2856422|NCT03553498|Experimental|Hydromorphone plus Acetaminophen|1000 mg IV acetaminophen will be administered over 5-10 minutes following administration of 1 mg of IV hydromorphone
2856423|NCT03553498|Placebo Comparator|Hydromorphone plus Placebo|100 ml normal saline administered over 5-10 minutes following administration of 1 mg IV hydromorphone.
2856424|NCT03553485|Experimental|taVNS|Treatment will be carried out twice a day (once before the RT session and 8h later) during 7 weeks. Each treatment takes 30 minutes.
2856425|NCT03553485|Sham Comparator|Control|Treatment will be carried out twice a day (once before the RT session and 8h later) during 7 weeks. Each treatment takes 30 minutes.
2856426|NCT03553472||Non-immunosuppressed IBD patients|24 IBD patients on mesalamine therapy or no IBD therapy
2856427|NCT03553472||Thiopurine group|12 IBD patients on azathioprine at least 2.0mg/kg or 6MP 1.0mg/kg
2856428|NCT03553472||Anti-TNF therapy|12 IBD patients on maintenance therapy infliximab (at least 8 every 8 weeks), golilumab (at least monthly), adalilumab (at least every 2 weeks), or certolizumab (at least monthly)
2856429|NCT03553472||Combination therapy|12 IBD patients on anti-TNF therapy as described in group along with either 15mg of methotrexate or azathioprine at least 1.0mg/kg or 6MP 0.5mg/kg
2856430|NCT03553472||Healthy Control|"The control group with consist of 12 individuals who meet the following inclusion and exclusion criteria.~Individuals will be obtained from patients without an IBD diagnosis, chronic liver disease, celiac disease or other chronic health condition coming to Digestive Health Center for endoscopic procedures or clinic visits."
2856431|NCT03553459|Experimental|Trendelenburg Maneuver|Trendelenburg maneuver is performed to predict fluid responsiveness. Responders are defined by an increase in stroke volume over 15% after infusion of 500ml of crystalloid solution.
2856432|NCT03553446|Experimental|children receiving sevoflurane|Children receiving pre-determined sevoflurane concentration using modified Dixon's up-and-down method
2856433|NCT03553433|Experimental|Verum|Apremilast 30mg bd
2856434|NCT03553433|Placebo Comparator|Placebo Oral Tablet|Excipiens
2856435|NCT03553407|Experimental|Low Level Laser - Pulse|In this group the patient will receive the following laser protocol: 880nm, 30mW, 3.6 J / cm², 25 Hz
2856436|NCT03553407|Experimental|Low Level Laser - continuous|In this group the patient will receive the following laser protocol: 880nm, 30mW, 3.6 J / cm²
2856437|NCT03553407|Placebo Comparator|Low Level Laser - Placebo|In this group the patient will receive the protocol with the equipment turned off.
2856438|NCT03553394|Active Comparator|Standard of care group|Will receive a fluid bolus 5 ml/kg Ringer's Acetate infusion immediately if oliguric/anuric for two consecutive hours (standard of care).
2856439|NCT03553394|No Intervention|Expectant management group|Await fluid therapy for 2 hours. Will NOT receive a fluid bolus if oliguric/anuric for two consecutive hours and a now assessment will be made after two more hours.
2856440|NCT03553381||obese without MS|BMI 25- 35 Kg/mq without metabolic syndrome (MS) submitted to hypocaloric balanced diet
2856441|NCT03553381||obese with MS|BMI 25- 35 Kg/mq with metabolic syndrome submitted to hypocaloric balanced diet
2856442|NCT03553368|Experimental|Step 1: Healthy volunteers|"Experimental intervention:~MRI data will be acquired with the use of HF-NIV (HF-NIV-MR).~Control intervention:~MRI data will be acquired without the use of HF-NIV, as a reference (MR)."
2856443|NCT03553368|Experimental|Step 2: Patients (arm A)|"Experimental intervention:~MRI data will be acquired with the use of HF-NIV (HF-NIV-MR).~Control intervention:~MRI data will also be acquired without the use of HF-NIV, as a reference (MR). The clinically prescribed CT will be the gold standard."
2856444|NCT03553368|Experimental|Step 2: Patients (arm B)|"Experimental intervention:~PET/CT data will be acquired with the use of HF-NIV (HF-NIV-PET). MRI data will be acquired with the use of HF-NIV (HF-NIV-MR). PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV (PET/CT breath hold).~Control intervention:~Data from the clinically indicated PET/CT acquisition will be used as reference.~MRI data will also be acquired without the use of HF-NIV, as a reference (MR). Histological data will be used when available."
2856445|NCT03553355|Experimental|Infrared Laser Moxibustion Therapy|Each patient will receive this treatment twice per week for six weeks (12 sessions total).
2856446|NCT03553355|Sham Comparator|Sham Infrared Laser Moxibustion Therapy|The patients will receive treatment from sham laser moxibustion instrument.
2856447|NCT03553355|No Intervention|Waitlist Controls|The patients maintain their usual treatment and self-care,
2856448|NCT03553342|Experimental|Corticoids|
2856449|NCT03553342|Placebo Comparator|Placebo|
2856450|NCT03553316|Experimental|Sequence (1)|"Number of Subject: 24~Wash out Period: over 7 days (between each period)~Investigators Products(IPs) for Period1: A (Single)= PK101-002~IPs for Period2: B (Combination)= PK101-001, PK101-002"
2856451|NCT03553316|Experimental|Sequence (2)|"Number of Subject: 24~Wash out Period: over 7 days (between each period)~IPs for Period1: B (Combination)= PK101-001, PK101-002~IPs for Period2: A (Single)= PK101-002"
2856452|NCT03553303|Experimental|Intervention|Increasing doses of Sacubitril/Valsartan
2856453|NCT03553290|Sham Comparator|control|Mechanical debridement alone
2856454|NCT03553290|Active Comparator|lower-level laser Therapy|"Mechanical debridement with lower-level laser therapy~Device: A.R.C. FOX Laser-FOX Q-810nm Mechanical debridement with lower-level laser therapy"
2856455|NCT03553277|Experimental|Transfluthrin|transfluthrin
2856456|NCT03553277|Placebo Comparator|Placebo|inert ingredients
2856479|NCT03553095|Active Comparator|Chronic Periodontitis|Patients without depression, not taking any antidepressants and with chronic periodontitis
2871261|NCT03450733||Control (Group 2)|Control, non-implanted subjects
2856457|NCT03553264|Experimental|Head Mounted Device|"In addition to the Vestibular Rehabilitation protocol, each HMD group patient will perform Virtual Reality Rehabilitation by means of the game protocol Track Speed Racing 3D uninterruptedly for 20min/day, while sitting on a chair or sofa, after the smartphone accommodation into the HMD 'Revelation' 3D VR Headset. The game consists of a point-of-view race in which the car is steered from the cockpit by tilting the head to the left and to the right to avoid swerving off the road and to achieve all the goals before finishing the lap. During this real car experience, the visual background and the scenario change perspective according to the patients' left or right tilted head movements, possibly emulating eye-head exercises that induce visual-vestibular conflicts."
2856458|NCT03553264|Active Comparator|Vestibular Rehabilitation|Patients will be actively involved in adapting the exercise program to suit their symptoms, capabilities, and lifestyle. Following previous protocols, the home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises, and all chronic unilateral vestibular hypofunction patients will be seen twice a week for 4 weeks for 30-45 min and monitored for adherence. Between supervised sessions, patients will perform a twice-daily home exercise program for a total of 30-40min/day.
2856459|NCT03553238|Experimental|ETP-ALL|Chidamide at a dose of 10mg/day will be added to PDT-ETP-ALL protocol. The intervention of PDT-ETP-ALL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, Karyotyping ，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy, radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
2856460|NCT03553225|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsules regimen (1g)
2856461|NCT03553225|Active Comparator|Concord Grape Extract 1|1 g Concord Grape Extract in 2 capsules
2856462|NCT03553225|Active Comparator|Concord Grape Extract 2|500 mg Concord Grape Extract in 2 capsules
2856463|NCT03553212|Experimental|High dose external beam Radiotherapy|Image-guided tomotherapy
2856464|NCT03553199|Experimental|TRS|TRS, Tissue resection system
2856465|NCT03553186|Experimental|ivTXA + topical TXA|"4 sponge lap pads will be soaked in TXA lavage solution (70 cc sterile normal saline + 3 g tranexamic acid 100mg/ml (30cc)) and placed 2 on each side longitudinally into the surgical field and left in contact for five minutes. This will occur after instrumentation and prior to grafting. Excess solution will be suctioned away using a non-cell saver suction and the wound grafted and closed without further deep irrigation.~IV txa will be given as (5mg/ml) loading dose (20mg/kg) over 15 minutes followed by 2 mg/kg/hr maintenance dosing as per hospital protocol"
2856466|NCT03553186|Placebo Comparator|IV TXA + topical placebo|"4 sponge lap pads will be soaked in placebo solution (70 cc sterile normal saline + placebo TXA ampule (normal saline) (30cc)) and placed 2 on each side longitudinally into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation and prior to grafting. Excess solution will be suctioned away using a non-cell saver suction and the wound grafted and closed without further deep irrigation.~IV txa will be given as (5mg/ml) loading dose (20mg/kg) over 15 minutes followed by 2mg/kg/hr maintenance dosing as per hospital protocol"
2856467|NCT03553173|Active Comparator|Control|"Subjects undergoing usual psycho-pharmacological treatment for smoking cessation.~Prescribed treatments:~Bupropion pills + Psychological advice~Varenicline pills + Psychological advice"
2856468|NCT03553173|Experimental|Intervention|"Subjects undergoing usual psycho-pharmacological treatment for smoking cessation plus a smart phone App.~Prescribed treatments:~Bupropion pills + Psychological advice + So-Lo-Mo~Varenicline pills + Psychological advice + So-Lo-Mo"
2856469|NCT03553160|Other|Frequent Self-Weighing|Study examined the effectiveness of daily self-weighing to prevent age related weight gain.
2856470|NCT03553147|Experimental|Group/Cohort 1|all patient SARC-F score, handgrip test and impedancemetry
2856471|NCT03553121|Active Comparator|Walk preoperativelying|Patients will be operated gynecologic cancers and have American Society of Anesthesia score 1 or 2. Subjects will walk during one hour with average speed 3 km/hour 12 hour before surgery.
2856472|NCT03553121|Active Comparator|not walking preoperatively|Patients will be operated gynecologic cancers and have American Society of Anesthesia score 1 or 2. Subjects will not walk preoperatively.
2856473|NCT03553108|Experimental|Olaparib Treatment Sequence ABCD|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~A - Olaparib Tablet 25 mg B - Olaparib Tablet 100 mg C - Olaparib Tablet 150 mg D - Olaparib Tablet 250 mg"
2856474|NCT03553108|Experimental|Olaparib Treatment Sequence BDAC|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~B - Olaparib Tablet 100 mg D - Olaparib Tablet 250 mg A - Olaparib Tablet 25 mg C - Olaparib Tablet 150 mg"
2856475|NCT03553108|Experimental|Olaparib Treatment Sequence CADB|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~C - Olaparib Tablet 150 mg A - Olaparib Tablet 25 mg D - Olaparib Tablet 250 mg B - Olaparib Tablet 100 mg"
2856476|NCT03553108|Experimental|Olaparib Treatment Sequence DCBA|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~D - Olaparib Tablet 250 mg C - Olaparib Tablet 150 mg B - Olaparib Tablet 100 mg A - Olaparib Tablet 25 mg"
2856477|NCT03553095|Active Comparator|Chronic Periodontitis and Depression Medications|Patients with clinically diagnosed depression taking (SSRIs, NDRIs, SNRIs, tricyclic antidepressants) and with chronic periodontitis
2856478|NCT03553095|Active Comparator|Chronic Periodontitis without Depression Medications|Patients with clinically diagnosed depression not taking any antidepressants (SSRIs NDRIs, SNRIs and Tricyclic antidepressants) and with chronic periodontitis
2856480|NCT03553082|Active Comparator|Total intravenous anesthsia|Patients in this group will receive Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance.
2856481|NCT03553082|Active Comparator|Sevoflurane|Patients in this group will receive sevoflurane 8% and fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance.
2856482|NCT03553056|Experimental|Intervention|NZ Step Away app
2856483|NCT03553056|Active Comparator|Control|Modified NZ Step Away app
2856484|NCT03553043|Experimental|Energy Label 1|Alcoholic beverage displayed with Energy label 1
2856485|NCT03553043|Experimental|Energy Label 2|Alcoholic beverage displayed with Energy Label 2
2856486|NCT03553043|Experimental|Energy Label 3|Alcoholic beverage displayed with Energy Label 3
2856487|NCT03553043|Placebo Comparator|Unlabelled|Alcohol beverage displayed unlabelled.
2856488|NCT03553030||prediabetics|patients with diagnosed of prediabetes.
2856489|NCT03553030||normo glycemics (controls)|patients without diagnosed of prediabetes.
2856490|NCT03553017||Participants with eye disease|A maximum of 200 participants with various eye diseases will be recruited from appropriate eye clinics at Moorfields Eye Hospital. Eye conditions will include both anterior segment disease such as corneal disease and ocular inflammatory disease, retinal vascular and macular diseases, and optic nerve disease such as glaucoma.
2856491|NCT03553004|Experimental|Niraparib Treatment|"Niraparib 300 milligrams (mg) by mouth daily for 28 days (1 cycle = 28 days)~(Dose reduced to 200mg dose for participants whose baseline weight is less than 77 kilograms (kg) [169.756 pounds (lbs)] or baseline platelet count is less than 150,000 microliters (µL))."
2856492|NCT03552991|Other|Agio arm|It is a pilot study based on the proof-of-concept that dietary fiber helps glucose control in patients with type 2 diabetes. As a single-arm study, 'Agiocur Pregranules' (dietary fiber) is administered for 28 days and stopped for next 28 days, in patients with type 2 diabetes.
2856493|NCT03552978|Experimental|Tech-facilitated IC intervention|"Complete an initial 2-hour screening visit that includes a series of questionnaires assessing eligibility criteria and meeting with the study physician to review medical history.~Be offered nicotine replacement therapy (NRT) at baseline (Week 0), per VA prescribing guidelines, nicotine dependence levels, and participant preference.~Receive 8 telephone counseling sessions for smoking cessation. The first session lasts 45-60 min, and the remaining 7 sessions last 20-30 min.~Be asked to use the Stay Quit Coach (SQC) app between sessions. SQC is a public domain, no-cost mobile app designed to complement the IC protocol with evidence-based tools to support smoking cessation.~Be asked to use the Covita Bedfont iCO Smokerlyzer, a mobile carbon monoxide (CO) monitor that provides CO readings in order to self-monitor progress in quitting. The Covita mobile app (compatible with iOS and Android) is used with the iCO Smokerlyzer to display CO readings."
2856494|NCT03552978|Active Comparator|Treatment as usual (VA Quitline)|"Complete an initial 2-hour screening visit that includes a series of questionnaires assessing eligibility criteria and meeting with the study physician to review medical history.~Be offered nicotine replacement therapy (NRT) at baseline (Week 0), per VA prescribing guidelines, nicotine dependence levels, and participant preference.~Receive weekly proactive telephone sessions through the VA telephone Quitline, a proactive telephone quitline available to all veterans for up to eight weeks. Participants will initiate the first call and subsequent calls will be made by the Quitline counselor."
2856495|NCT03552965|Active Comparator|Margin-Based Radiotherapy Planning|This arm will receive Intensity-Modulated Radiation Therapy (IMRT) that was calculated by introducing a margin to the target area.
2856496|NCT03552965|Active Comparator|Robust Radiotherapy Planning|This arm will receive Intensity-Modulated Radiation Therapy (IMRT) that was calculated to minimize the dose of radiation to normal tissue.
2856497|NCT03552952||Preterm infants|100 preterm infants
2856498|NCT03552952||Term infants|100 term healthy infants
2856499|NCT03552913||2015 Total knee arthroplasty, hysterectomy or left colectomy|Group of patients having a total knee arthroplasty, hysterectomy or left colectomy in 2015
2856500|NCT03552913||2017 Total knee arthroplasty, hysterectomy or left colectomy|Group of patients having a total knee arthroplasty, hysterectomy or left colectomy in 2017
2856501|NCT03552913||2015 Total hip prosthesis, ovariectomy or gastrectomy|Group of patients having total hip prosthesis, ovariectomy or gastrectomy in 2015
2856502|NCT03552913||2017 Total hip prosthesis, ovariectomy or gastrectomy|Group of patients having total hip prosthesis, ovariectomy or gastrectomy in 2017
2856503|NCT03552900|Active Comparator|App 1 Study group (7 Cups)|"Participants assigned to this group will be assigned a behavioral intervention, the mobile app (7 Cups) which allows participants access to direct online social support via the app."
2856504|NCT03552900|Active Comparator|App 2 Study Group (Bliss)|"Participants assigned to this group will be assigned to a behavioral intervention, the mobile app (Bliss) which provides participants an informational app about mental health resources at Harvard."
2856505|NCT03552887||Postoperative patients|Cohort of patients undergoing cardiac surgery, aged ≥ 18 years old, who had received any physiotherapy intervention
2856506|NCT03552874||Patient Group|Children whose ages between 5-10 years with Duchenne Muscular Dystrophy.
2856507|NCT03552874||Healthy Group|Healthy peers
2856508|NCT03552861|Active Comparator|left and right DLPFC active treatment|Intervention: repetitive transcranial stimulation (rTMS) Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface.
2856509|NCT03552861|Active Comparator|left DLPFC active and right DLPFC sham treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
2856568|NCT03552445|Active Comparator|Tetanus-diphtheria (Td) and PCV13|
2856510|NCT03552861|Active Comparator|left DLPFC sham and right DLPFC active treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
2856511|NCT03552861|Sham Comparator|left DLPFC sham and right DLPFC sham treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks,the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
2856512|NCT03552848|Experimental|Mesenchymal stem cell|Patients in MSC arm will be given MSC, i.v., 1000000 cells per kilogram of body weight.
2856513|NCT03552835|Experimental|no caries removal|mandibular occlusal caries will be treated with placement of stainless steel crown with no caries removal
2856514|NCT03552835|Experimental|partial caries removal upto soft dentine|mandibular occlusal caries will be treated by partial caries removal upto soft dentine
2856515|NCT03552835|Experimental|partial caries removal upto firm dentine|mandibular occlusal caries will be treated by partial caries removal upto firm dentine
2856516|NCT03552822||ERAS Implemented Group|Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
2856517|NCT03552822||Pre-ERAS - Non-ERAS Implemented Group|Non-Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
2856518|NCT03552809|Active Comparator|Conventional Frenectomy|For the conventional surgery, after application of local infiltration anesthesia of articaine HCL associated with epinephrine 1:100,000, the frenulum was grasped with a straight haemostat inserted into the depth of the vestibule; the tissue adjacent to the upper and lower surfaces of the haemostat was incised with a no.15 scalpel. After the diamond shaped resected portion of the frenulum was removed with the haemostat, muscle dilatations were excised on the submucosa of the lateral walls of the cavity. Horizontal incision was made on the periosteum with the help of a scalpel following the procedure. At the end of the operation, the wound was closed with absorbable sutures (4-0, Pegelak®, Doğsan Turkey).
2856519|NCT03552809|Experimental|Diode Laser Frenectomy|For the laser frenectomy, a diode laser device (λ = 810 nm, W: 4, GIGA Cheese II, China) was used to perform the procedure. The procedure was performed under local infiltration anesthesia with articaine HCL associated with epinephrine 1:100,000. The frenlum was held by a haemostat inserted into the depth of the vestibule while laser energy was applied to the upper and lower parts of the frenulum adjacent to the haemostat via a fibre tip (400 µm diameter, plain-ended, optical ﬁbre). The laser was carefully applied to the tissue and care was taken to avoid local necrosis of the periosteum or any bone structure.Following the bleeding control, the wound site was left to secondary healing. No sutures were necessary after procedure.
2856520|NCT03552809|Experimental|Laser Frenectomy with Incision|For the laser frenectomy, a diode laser device (λ = 810 nm, W: 4, GIGA Cheese II, China) was used to perform the procedure. The procedure was performed under local infiltration anesthesia with articaine HCL associated with epinephrine 1:100,000. The frenulum was held by a haemostat inserted into the depth of the vestibule while laser energy was applied to the upper and lower parts of the frenulum adjacent to the haemostat via a fibre tip (400 µm diameter, plain-ended, optical ﬁbre). The laser was carefully applied to the tissue and care was taken to avoid local necrosis of the periosteum. Horizontal incision was made on the periosteum with the help of a scalpel, additionally. No sutures were necessary after procedure.
2856521|NCT03552796|Experimental|sEphB4-HSA|Cohorts of at least 3 participants each will be treated with escalating doses of sEphB4-HAS at 25mg, 50 mg, 75mg, 100 mg, and 125 mg administered intravesically over 2 hours once a week for 6 consecutive weeks to determine the maximum tolerated dose (MTD) and recommended phase II dosing (RP2D). Cycle repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
2856522|NCT03552783|Active Comparator|Fathers for a Lifetime (FFL) only|The participants in the comparison arm will receive the standard, 12-week program curriculum of Father For a Lifetime.
2856523|NCT03552783|Experimental|FFL + Cognitive Behavioral Therapy|The participants in the intervention will receive will the standard, 12-week program curriculum of Father For a Lifetime and the Cognitive Behavioral Therapy. The intervention will be delivered by a gender and culturally-matched Licensed Mental Health Professional (LIMHP). In addition, the men will receive three one-on-one therapy sessions with a Charles Drew LIMHP that will be completed by the end of the FFL program.
2856524|NCT03552770|Active Comparator|IVIBx1|Patients treated with a single intra-vitreous injection of bevacizumab (1.25 mg in 0.05 ml of solution) pro-re-nata repeated after monthly periodic monitoring of each patient
2856525|NCT03552770|Active Comparator|IVIBx2|Patients treated with two combined intra-vitreous injections of bevacizumab, (1.25 mg in 0.05 ml of solution) spaced 30 ± 10 days apart and pro-re-nata repeated after periodic monitoring of each patient
2856526|NCT03552757|Experimental|Semaglutide 1.0 mg|Participants will receive semaglutide 1.0 mg and semaglutide placebo I during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
2856527|NCT03552757|Experimental|Semaglutide 2.4 mg|Participants will receive semaglutide 2.4 mg and semaglutide placebo II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
2856528|NCT03552757|Placebo Comparator|Semaglutide placebo I/II|Participants will receive semaglutide placebo I and II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
2856529|NCT03552744|Experimental|Intervention group|
2856530|NCT03552744|No Intervention|Control group|
2856531|NCT03552731||Subsequent|Patients who have been receiving chemotherapy more than once. A intervention survey will be administered.
2856532|NCT03552731||First Time|Patients who have been receiving chemotherapy first time. A intervention survey will be administered.
2856533|NCT03552718|Experimental|Experimental: NANT Neoepitope Yeast Vaccine (YE-NEO-001)|
2856534|NCT03552705|Experimental|Tranexamic Acid|5-day course of standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
2856535|NCT03552705|Placebo Comparator|Placebo|5-day course of placebo and intravenous saline during ACL reconstruction surgery
2856536|NCT03552692|Experimental|ARM1 - Venetoclax (ABT-199)|"Venetoclax (ABT-199) will be administered orally at the dose of 800 mg once daily.~Response evaluation will be performed initially after 3 cycles from the beginning of treatment with ABT-199 and then every 3 cycles during the first 12 cycles, every 4 cycles from cycle 13 to 24; for those patients still on therapy after 24 cycles, the response evaluation, after this time, will be performed every 6 cycles."
2856537|NCT03552679||LVAD recipients|Consecutive patients accepted for elective LVAD implantation in the context of routine care, will undergo routinely scheduled echocardiography before, within 1 week, 1 month, 3 months and 1 year after LVAD implantation. Echocardiography will be performed using ultrasound machines that are capable of acquisition of two-, three-dimensional and Multiplane Echocardiography of the right ventricle. Invasive hemodynamic data will be collected in the perioperative period.
2856538|NCT03552666|Experimental|Vitafusion Extra Strength Vitamin D3 Gummy|A single oral dose of gummy vitamin D3 to monitor Vitamin D blood levels
2856539|NCT03552666|Active Comparator|Nature Made Vitamin D3 Tablet|A single oral dose of tablet vitamin D3 to monitor Vitamin D blood levels
2856540|NCT03552653|Experimental|Vitafusion Extra Strength Vitamin D3 Gummy|Single oral dose of gummy vitamin D3 to monitor vitamin D blood levels
2856541|NCT03552653|Active Comparator|Nature Made Vitamin D3 Tablet|Single oral dose of tablet vitamin D3 to monitor vitamin D blood levels
2856542|NCT03552627|Active Comparator|80% Oxygen|Patients will receive 80% oxygen throughout anaesthesia in accordance with current World Health Organisation Recommendations
2856543|NCT03552627|Active Comparator|55% Oxygen|Patients will receive 55% oxygen throughout anaesthesia in accordance with current UK clinical practice
2856544|NCT03552627|Experimental|30% Oxygen|Patients will receive 30% oxygen throughout anaesthesia in accordance with this research's hypothesis that lowering intraoperative oxygen concentrations may benefit patients
2856545|NCT03552614||children with brain damage|Patients undergo physiotherapy + Upper limb robot-assisted rehabilitation
2856546|NCT03552601|Other|traditional speed|The target amount of every day's net negative fluid balance for the first three days is 1000mL.
2856547|NCT03552601|Other|faster speed|The target amount of every day's net negative fluid balance for the first three days is 1500mL.
2856548|NCT03552575|Experimental|Sacubitril/valsartan|24mg/26mg (dose level 1), 49mg/51mg (dose level 2) and 97mg/103mg (dose level 3) twice daily
2856549|NCT03552575|Experimental|Valsartan|40mg (dose level 1), 80mg (dose level 2) and 160mg (dose level 3) twice daily.
2856550|NCT03552562|Other|30 patients with no signs of diabetic retinopathy|
2856551|NCT03552562|Other|30 patients with mild diabetic retinopathy|
2856552|NCT03552562|Other|30 patients with moderate to severe diabetic retinopathy|
2856553|NCT03552562|Other|30 healthy age-and sex- matched control subjects|
2856554|NCT03552549|Experimental|PEG-Intron|Participants with node positive cutaneous melanoma will receive subcutaneous PEG-Intron (6.0 ug/kg weekly) for 2 years.
2856555|NCT03552549|Experimental|INTRON A|Participants with node positive cutaneous melanoma will receive intravenous INTRON A (20 million international units [MIU]/m^2/day, 5 days a week) for 4 weeks followed by subcutaneous INTRON A (10 MIU/m^2 three times per week) for 48 weeks.
2856556|NCT03552536|Experimental|A: MK-8583 100mg|After fasting, a single oral dose of 100 mg MK-8583 in capsule form.
2856557|NCT03552536|Experimental|B: MK-8583 ≤ 150 mg|After fasting, a single oral dose of ≤ 150 mg MK-8583 in capsule form, with the dose based on the results from earlier treatments
2856558|NCT03552536|Experimental|C: MK-8583 ≤ 150 mg|After fasting, a single oral dose of ≤ 150 mg MK-8583 in capsule form, with the dose based on the results from earlier treatments
2856559|NCT03552523|Other|Usual Care|Subject will wear a continuous glucose monitoring device (the Dexcom G5) and use the study provided glucose meter.. Subject will not change their prescribed home insulin therapy regimen during this arm whether that be an insulin pump or multiple daily injections.
2856560|NCT03552523|Experimental|Bionic Pancreas|During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.
2856561|NCT03552510|Active Comparator|Initial OPAMM|"At the start of the study, infants will receive mother's milk (to the maximum of 0.2 ml) to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding), and the remaining amount will be given by regular gavage feeding for 24 hours.~Then, infants will receive regular gavage feeding only for the next 24 hours."
2856562|NCT03552510|Active Comparator|Initial Gavage|"At the start of the study, infants will receive regular gavage feeding only for 24 hours.~Then, infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding), and the remaining amount will be given by regular gavage feeding for the next 24 hours."
2856563|NCT03552484|Active Comparator|Home Visit Arm|"Participants and their caregivers, when available, will be asked to participate in four study visits, which will involve in-home clinical assessments, a needs assessment, and completion of some questionnaires. Additional information will be obtained from patients' routine medical records: their medical and medication history, family history, neurological examination findings, and office visit records.~[Completion of Home Visit Program]"
2856564|NCT03552484|Active Comparator|Usual Care Arm|"Participants and their caregivers, when available, will be asked to complete an initial online survey. Twelve months later, patients (and caregivers, if available) will be asked to complete an online follow-up survey.~[Completion of Usual Care/Online Survey]"
2856565|NCT03552471|Experimental|Treatment (mirvetuximab soravtansine, rucaparib)|Participants receive mirvetuximab soravtansine IV on day 1 and rucaparib PO BID on days 1 through 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2856566|NCT03552458|Experimental|LR group|Lactobacillus Reuteri Oral Solution [BioGaia]
2856567|NCT03552458|Placebo Comparator|Placebo group|Placebos: The control agent will not contain the active agent
2856571|NCT03552432|Experimental|Alirocumab therapy group|start with alirocumab 75mg per 2weeks and rosuvastatin 10mg per day
2856572|NCT03552432|No Intervention|standard statin therapy group|start with only rosuvastatin 10mg per day
2856573|NCT03552419||Level Red|A level red refers to a case with an immediate threat to the life of the fetus or mother and may not be delayed under any circumstance.
2856574|NCT03552419||Level Orange|A level orange case requires the patient to arrive in the OR within 30 minutes from the time of decision with the approximate estimated time of arrival determined by the obstetrician.
2856575|NCT03552419||Level Yellow|A level yellow case requires operative intervention, but there is no maternal and/or fetal compromise at the time of evaluation. Timing to the OR is agreed upon by both the anesthesiology and obstetrical providers. The case may be delayed if a level red or orange case is identified. Possible
2856576|NCT03552419||Level Green|A level green case is most dependent on the acuity of the OR suite and unit. The patient and/or fetus are stable with no threat to the health of either.
2856577|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 1)|1 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
2856578|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 2)|3 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
2856579|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 3)|5 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
2856580|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 4)|10 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
2856581|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 5)|20 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
2856582|NCT03552406|Experimental|Dose-Expansion of ISU104|Selected dose during Dose-Escalation Part; Administered once weekly in a 28-days Cycle
2856583|NCT03552393|Experimental|Mircera|Mircera will be administered subcutaneously once every 4 weeks
2856584|NCT03552380|Experimental|Entinostat, Nivolumab and Ipilimumab|"Entinostat: 5mg, 3mg, or 2mg orally (PO) on D1, 8, 15 plus Nivolumab: 3 mg/kg IV D1 and Ipilimumab 1 mg/kg IV D1~Each cycle is 21 days"
2856585|NCT03552367|Experimental|Personalized structured exercise|"This group will be enrolled in a multicomponent program for obese children (8-12 years old) that includes intervention workshops concerning nutrition, emotional factors, cognitive therapy and personalized structured exercise prescription that will be offered on-site and online and monitored through the use of heart rate monitoring devices. The type of exercise offered to patients in this arm is precisely designed for obese patients according to age and physical fitness parameters.~Intervention: Non-personalized non-structured exercise"
2856586|NCT03552367|Active Comparator|Non-personalized non-structured exercise|This group will be enrolled in a multicomponent program for obese children (8-12 years old) that includes intervention workshops concerning nutrition, emotional factors, cognitive therapy and non-personalized non-structured exercise prescription Intervention: Non-personalized non-structured exercise
2856587|NCT03552354|Experimental|Argatroban combined with antiplatelet|
2856588|NCT03552328|Experimental|Intervention|Seniors receiving daily meals from Meals on Wheels. Intervention: Lunch with Medical Student.
2856589|NCT03552328|Placebo Comparator|Control|Seniors receiving daily meals from Meals on Wheels
2856590|NCT03552315|Active Comparator|Water with amino acids and chromium|The carbonated water with a proprietary blend of five amino acids and chromium picolinate is consumed with a standardized test meal to study its effects on glucose and insulin responses.
2856591|NCT03552315|Placebo Comparator|Carbonated water|The placebo carbonated water is consumed with a standardized test meal to study its effects on glucose and insulin responses.
2856592|NCT03552302||Cases|Yoga exercise for 12 weeks
2856593|NCT03552289|Active Comparator|Cook Enforcer balloon catheter|The Enforcer balloon will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.
2856594|NCT03552289|Active Comparator|Conventional angioplasty balloon catheters|Commercial available angioplasty balloon devices will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.
2856595|NCT03552276|Experimental|tildrakizumab 200 mg q4 weeks|Psoriatic arthritis subjects
2856596|NCT03552276|Experimental|tildrakizumab 200 mg q12 weeks|Psoriatic arthritis subjects
2856597|NCT03552276|Experimental|100 mg q12 weeks|Psoriatic arthritis (PsA) subjects
2856598|NCT03552276|Experimental|tildrakizumab 200 mg|Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis (AS/nr-axSpA) subjects
2856599|NCT03552263|Experimental|T89 low-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.~Subjects in this group will use three T89 capsules and one Placebo capsule each time by oral administration twice daily for 19 days."
2856600|NCT03552263|Experimental|T89 high-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.~Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 12 days followed by using four T89 capsules each time by oral administration twice daily for 7 days"
2856601|NCT03552263|Placebo Comparator|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 19 days.
2856602|NCT03552250|Other|Parenting for Lifelong Health|"Parenting Programme Parenting for Lifelong Health for Young Children (PLH) for parents of children aged 2-9, 12 sessions"
2856603|NCT03552237|Experimental|dietary fiber intervention group|
2856604|NCT03552224|Experimental|Subjects with no hearing loss|Subjects referred for cerebellopontine angle surgery with no hearing loss with recording of auditory nerve activity by contact electrode
2856605|NCT03552224|Experimental|Subjects with hearing loss|Subjects referred for cerebellopontine angle surgery with hearing loss with recording of auditory nerve activity by contact electrode
2856670|NCT03551769|Experimental|Cohort 2, Period 1|Study drug administered 30 minutes after a standard meal (Asian)
2871293|NCT03450434|Experimental|XC8 2 mg|XC8 2mg orally
2856606|NCT03552211||Patients treated with biotin|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat
2856607|NCT03552211||Control patients|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat
2856608|NCT03552198|No Intervention|General public/usual health advice|Healthy participants with a self-reported existing health condition were randomised to receive the usual UK Air Quality Indices health advice.
2856609|NCT03552198|Experimental|General public/alternative health advice|Generally healthy participants were randomised to receive targeted health advice about the adoption of protective behaviours in an alternative format.
2856610|NCT03552198|No Intervention|At risk group/usual health advice|Participants with a self-reported pre-existing health condition were randomised to receive the usual UK Air Quality Indices health advice.
2856611|NCT03552198|Experimental|At risk group/alternative health advice|Participants with a self-reported existing health conditions were randomised to receive targeted health advice (based on their health condition) about the adoption of protective behaviours in an alternative format.
2856612|NCT03552172||Prescription physical activity|
2856613|NCT03552172||No prescription for physical activity or suspension|
2856614|NCT03552159|Experimental|Behavioral Activation|For the first 4 weeks,participants received psychoeducation about the symptoms and associated behavioral changes of dementia and the possible effects on the caregivers, t the physical, social and psychological consequences of stress, event scheduling and communication skills. After psychoeducation, eight bi-weekly behavioral activation sessions were administered, focusing pleasant event scheduling and effective communications.
2856615|NCT03552159|Active Comparator|Psychoeducation|For the first 4 weeks, participants were taught about the symptoms and associated behavioral changes of dementia and the possible effects on the caregivers, the physical, social and psychological consequences of stress, event scheduling and communication skills. After psychoeducation, eight biweekly phone sessions of general support but not behavioral activation.
2856616|NCT03552146||Sedation Group 1|Patients will receive standard of care dose of Propofol, based on the provider's assessment, prior to radiologic procedure.
2856617|NCT03552146||Sedation Group 2|Patients will receive standard of care dose of dexmedetomidine, based on the provider's assessment, prior to radiologic procedure.
2856618|NCT03552133|Experimental|Smart CO2|Effects of rebreathe device over two sleep nights on sleep apnea, hypoxemia, sleep state, and blood pressure.
2856619|NCT03552133|No Intervention|No intervention|Effects of control night, i.e. no intervention on sleep apnea, hypoxemia, sleep state, and blood pressure.
2856620|NCT03552120|Experimental|Mindfulness-Oriented Recovery Enhancement|
2856621|NCT03552120|Active Comparator|Supportive Psychotherapy|
2856622|NCT03552107||Observational Group - Lorcaserin Treated|The group in this study will be all patients who initiated therapy with Lorcaserin during the review period.
2856623|NCT03552094||Hemochromatosis or polycythemia patients|"Blood samples from hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.~Blood bag (volume of blood: from 450 to 500 mL)."
2856624|NCT03552094||Healthy donors|Blood samples from healthy donors. Blood bag (volume of blood: from 450 to 500 mL).
2856625|NCT03552081|Experimental|fragmented DNA evaluation in blood and semen samples|20 men followed for smoking cessation will be included in the study in order to evaluate the time required for the repair of the sperm abnormalities and in particular the DNA of the gametes generated by the smoking
2856626|NCT03552068|Placebo Comparator|Patients under placebo|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. The usual antiparkinsonian treatment of the patient should remain stable throughout the 8 weeks.
2856627|NCT03552068|Active Comparator|Patient under clonidine|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. The usual antiparkinsonian treatment of the patient should remain stable throughout the 8 weeks.
2856628|NCT03552042|Experimental|Counterclockwise Program|"Subjects will participate in an 6-day Counterclockwise Retreat in a retrofitted physical environment circa 1989, which helps the participant psychologically return to a time before diagnosis to re-experience their younger self. Groups will be composed of 10-12 participants plus 3 research assistants/facilitators. Participants will live during the week as if they were in 1989, talking about 1989 events as if they were in the present, and avoiding talking about post-1989 events. Everybody will be invited to participate in conversations and discussions about 1989 in the present tense (presente). Furniture, posters, music, television, newspapers, and technological instruments will all reflect what was available in 1989. Participants will be told not merely to reminisce about this earlier era, but to inhabit life in that era, making a psychological leap to be the person they were at the end of the 1980s."
2856629|NCT03552042|Active Comparator|Active control group|Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
2856630|NCT03552042|No Intervention|No-treatment control group|Non-treated participants will be assessed with the same timeline followed by the other groups. Participants will receive three coupons, for each assessment after the baseline (at T2, T3, and T4) for a two-night break in a location of their choice (among a selection of commercial services).
2856631|NCT03552029|Experimental|Part 1: Quizartinib + Milademetan|Participants receive quizartinib + milademetan at increasing and/or decreasing doses and schedules
2856632|NCT03552029|Experimental|Part 2: Cohort 1|Participants with relapsed/refractory AML receive the recommended dose of quizartinib + milademetan determined by Part 1
2856633|NCT03552029|Experimental|Part 2: Cohort 2|Participants with newly diagnosed AML unfit for chemotherapy receive the recommended dose of quizartinib + milademetan determined by Part 1
2856671|NCT03551769|Experimental|Cohort 2, Period 2|Study drug administered after an overnight fast (Asian)
2856634|NCT03552016|Experimental|200 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 200 mg oral riboflavin each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
2856635|NCT03552016|Experimental|400 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 400 mg oral riboflavin each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
2856636|NCT03552016|Placebo Comparator|0 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 0 mg oral riboflavin (placebo) each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
2856637|NCT03552003||Newly diagnosed elderly cHL patients|Newly diagnosed elderly cHL patients undergoing CGA before any therapy (treatment for clinical practise) with the use of ADL, IADL and CIRS-G. Patients who will be considered not eligible to receive treatment or to be given only palliative therapy after CGA assessment are eligible for the study
2856638|NCT03551990|No Intervention|Control group; patients without a tumor disease, surgery|Control group with patients without a tumor disease but with indication for surgery in close proximity to the M. rectus abdominis
2856639|NCT03551990|No Intervention|Control group; tumor patients, surgery|Control group with patients with solid tumors; patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
2856640|NCT03551990|Experimental|Intervention group; tumor patients, WB-EMS, surgery|Intervention group with patients with solid tumors who do perform an 8-week physical training in form of whole-body electromyostimulation (WB-EMS); patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
2856641|NCT03551977|Experimental|Intervention group|The intervention group will receive the iCanCope with Pain app with all five components: (I) symptom trackers for pain, sleep, mood, physical, and social function; (II) goal setting to improve pain and function; (III) coping toolbox of pain self-management strategies; (IV) social support; (V) age-appropriate pain education
2856642|NCT03551977|Active Comparator|Control group|The control group will receive the iCanCope with Pain control app with only the first self-registration component (I) symptom trackers for pain, sleep, mood, physical, and social function.
2856643|NCT03551964|Experimental|Cangrelor therapy|Initiation of iv Cangrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study.
2856644|NCT03551964|Active Comparator|Ticagrelor therapy|Initial dose Ticagrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study. In patients with a disorder of consciousness, initial dose of Ticagrelor will be administered immediately after nasogastric tube insertion.
2856645|NCT03551951||Patients having surgery|Cancer patients undergoing surgery will have test for circulating tumor cells, DNA alterations
2856646|NCT03551951||Patients not having surgery|"Cancer patients not undergoing surgery (but potentially other treatments) will have test for circulating tumor cells, DNA alterations.~Lung cancer screening subjects"
2856647|NCT03551951||Healthy subjects|Healthy control subjects will have test for circulating tumor cells, DNA alterations
2856648|NCT03551938|No Intervention|Control|Receive only the standard Couples HIV Testing and Counseling (CHTC) Session.
2856649|NCT03551938|Experimental|Intervention|Receive one 45-minute Relationship skills session for YMSM couples (the intervention) before receiving the standard Couples HIV Testing and Counseling (CHTC) Session.
2856650|NCT03551925|Experimental|Treatment as Usual Plus Occupational Therapy|The occupational therapy intervention will be guided by the Integrative Medication Self-Management Intervention (IMedS).The IMedS process guides the occupational therapist and client through an initial evaluation process and a three-step intervention plan to improve medication management.
2856651|NCT03551925|Active Comparator|Treatment as Usual (TAU)|Participants will receive only the TAU intervention which is provided by a clinical pharmacist and is the protocol at Jordan Valley Community Health Center. The intervention seeks to improve medication adherence in individuals with hypertension.
2856652|NCT03551886|Experimental|Experimental app|This is the Advanced Emotion App that we initially developed in phase 1 and are now enhancing in phase 2.
2856653|NCT03551886|Active Comparator|Comparison app|This is the Basic Emotion App, which is an alternative intervention app that controls for time and attention.
2856654|NCT03551860|Experimental|TQL Group|Administration of a single shot transmuscular quadratus lumborum (TQL) peripheral nerve block following spinal neuraxial blockade.
2856655|NCT03551860|Active Comparator|FIB Group|Administration of a single shot fascia iliac (FIB) peripheral nerve block following spinal neuraxial blockade.
2856656|NCT03551847|Experimental|Oral antibiotic therapy group|This group will receive preoperative oral antibiotic therapy tailored to the infecting organism (if identified) for two weeks before the time of revision surgery
2856657|NCT03551847|Active Comparator|No antibiotic therapy group|This group will not receive preoperative oral antibiotic therapy.
2856658|NCT03551834|Active Comparator|doing scleral patch graft glaucoma implantation|
2856659|NCT03551834|Active Comparator|Using short tunnel small flap technique|
2856660|NCT03551821|Experimental|ATI-50002 Topical Solution|ATI-50002 Topical Solution
2856661|NCT03551808|Active Comparator|installation of Ketorolac Tromethamine Eye Drop|
2856662|NCT03551808|No Intervention|not receiving placebo|
2856663|NCT03551795|Experimental|treatment|The eligible patient receive the experimental infusion of iNKT cells.
2856664|NCT03551782|Experimental|Cohort 1|Participants who progressed after abiraterone acetate plus prednisone/prednisolone (AA-P) will be enrolled in this cohort. Participants will receive JNJ-63723283 480 milligram (mg) plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
2856665|NCT03551782|Experimental|Cohort 2|Participants who progressed after apalutamide or enzalutamide will be enrolled in this cohort. Participants will receive JNJ-63723283 480 mg plus apalutamide 240 mg daily starting Cycle 1.
2856666|NCT03551769|Experimental|Cohort 1, Period 1|Study drug administered concurrently with a standard meal
2856667|NCT03551769|Experimental|Cohort 1, Period 2|Study drug administered 30 minutes after a standard meal
2856668|NCT03551769|Experimental|Cohort 1, Period 3|Study drug administered 30 minutes after a high-fat meal
2856672|NCT03551756||Heart Failure & Coronary Artery Disease|Biomarker assessment in adults with decompensated heart failure and significant underlying coronary artery disease
2856673|NCT03551756||Healthy Adult|Biomarker assessment in 20 healthy age-matched subjects
2856674|NCT03551743|Experimental|Module 4 (600 mg bolus)|600 mg PRT064445 given as a single IV bolus
2856675|NCT03551743|Experimental|Module 4 (800 mg bolus + 480 mg infusion) 8mg/min|1280 mg PRT064445: 800 mg IV at ~30 mg/min, followed by a continuous infusion of 480 mg (4 mg /min over 60 minutes)
2856676|NCT03551743|Experimental|Module 4 (800 mg bolus)|800 mg PRT064445 as a single IV bolus
2856677|NCT03551743|Placebo Comparator|Module 4 Placebo|Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous infusion.
2856678|NCT03551730|Experimental|Module 3 (210 mg bolus) original|210 mg PRT064445 given as a single IV bolus
2856679|NCT03551730|Experimental|Module 3 (420 mg bolus) original|420 mg PRT064445 given as a single IV bolus
2856680|NCT03551730|Experimental|Module 3 (210 mg) lyophilized|210 mg PRT064445 (lyophilized formulation) given as a single IV bolus
2856681|NCT03551730|Placebo Comparator|Module 3 Placebo|Placebo administered intravenously (IV) as a bolus.
2856682|NCT03551717||High cardiovascular risk patients|Adult patients hospitalized in the Cardiology Department of the University Hospital of Dijon Burgundy for acute coronary syndrome, patients between D1 and D5 of acute coronary syndrome, who can be moved for an ophthalmology consultation where the retinal imaging is done (heart monitoring in the presence of an experienced cardiologist if necessary)
2856683|NCT03551717||Low cardiovascular risk patients|"Adult patients recruited in the Ophthalmology Department of the University Hospital of Dijon Burgundy following a standard consultation for cataract surgery.~The age balance of the patients included in the two groups will be checked regularly."
2856684|NCT03551704|Active Comparator|CBT + EFT|"The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices."
2856685|NCT03551704|Experimental|CBT + EFT + CM|This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on biochemical verification. The schedule will incorporate an increasing magnitude of reinforcement.
2856686|NCT03551691|Active Comparator|Treatment Arm|Subjects will take omeprazole 40mg daily for 28 days, then undergo assessments of fat absorption.
2856687|NCT03551691|Placebo Comparator|Placebo Arm|Subjects will take a placebo daily for 28 days, then undergo assessments of fat absorption.
2856688|NCT03551678|Experimental|Gait retraining|Eight weeks of active-feedback gait retraining. The gait retraining device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
2856689|NCT03551665|Experimental|Step training|This group will undergo a baseline control period, as well as an intervention period. As such, they will serve as their own control subjects.
2856690|NCT03551652||Young patients|Patients aged 18 - 50 years
2856691|NCT03551652||Geriatric patients|Patients aged ≥ 80 years
2856692|NCT03551626|Experimental|Dabrafenib and trametinib combination therapy|Subjects will receive dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.
2856693|NCT03551613|Active Comparator|honey group|malnourished children supplemented with honey in dose of 2ml/kg
2856694|NCT03551613|Placebo Comparator|malnourished control group|no honey supplementation only nutrition rehabilitation
2856695|NCT03551613|No Intervention|healthy children|healthy children with no suplementation
2856696|NCT03551600||Preterm, no PDA|"Babies </= 32 weeks gestation at birth with no symptoms of a patent ductus arteriosus (PDA) or echocardiogram confirmation of no PDA~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic and cranial regions, minimum of 8 feedings need to be recorded"
2856697|NCT03551600||Preterm, moderate to large PDA|Babies </= 32 weeks gestation at birth with confirmed moderate to large PDA on echocardiogram Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic and cranial regions, minimum of 8 feedings need to be recorded
2856698|NCT03551600||>/= 34 wk infants, no CHD|"Babies >/= to 34 weeks gestation at birth with no evidence of ductal dependent congenital heart disease (CHD)~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic, renal and cranial regions, minimum of 8 feedings need to be recorded"
2856699|NCT03551600||>/= 34 week infants, CHD|"Babies >/= to 34 weeks gestation at birth with ductal dependent CHD~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic, renal and cranial regions, minimum of 8 feedings need to be recorded"
2856700|NCT03551587|Experimental|Irrigant delivered by the Vibringe|"Experimental group:~The irrigant will be delivered and sonically activated with the Vibringe system."
2856701|NCT03551587|No Intervention|Irrigation by Conventional needle|"Control group:~Irrigation procedures will br performed with a conventional method using conventional gauge 24 needle."
2856702|NCT03551574||Macular involving retinal detachment|Patients with retinal detachments that have developed PVR when the macula has been involved
2856703|NCT03551561|Active Comparator|CSAAC group|The CSAAC group (chlorhexidine-based soap + ethyl alcohol + alcoholic chlorhexidine): skin preparation process with 4% chlorhexidine-based soap for a period of 5 minutes, followed by a sterile and soaked with 70% alcohol compress. After removing the chlorhexidine-based soap excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns. Cultures were performed in the mannitol and EMB (Eosin Methylene Blue) media after being collected at the pre-skin preparation, post-skin preparation process and end of the surgical procedure.
2856891|NCT03550118|Experimental|Adjustable Socket - Researcher Controls|An adjustable socket is tested where researchers control the adjustments. This arm focuses on socket size adjustments while walking.
2856704|NCT03551561|Active Comparator|CSAC group|The CSAC group (chlorhexidine-based soap + alcoholic chlorhexidine): skin preparation process with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns. Cultures were performed in the mannitol and EMB media after being collected at the pre-skin preparation, post-skin preparation process and end of the surgical procedure.
2856705|NCT03551548|Placebo Comparator|Reference treatment|
2856706|NCT03551548|Experimental|experimental treatment|Spironolactone 25 mg
2856707|NCT03551535|Experimental|Physical Activity Intervention|Patients will be allocated to a physical activity intervention to be performed 3-5 days per week
2856708|NCT03551535|No Intervention|Control|Patients will receive standard counseling regarding activity recommendations in pregnancy
2856709|NCT03551522|Experimental|Seladelpar 10 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
2856710|NCT03551522|Experimental|Seladelpar 20 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
2856711|NCT03551522|Experimental|Seladelpar 50 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
2856712|NCT03551522|Placebo Comparator|Placebo|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
2856713|NCT03551509|No Intervention|Control Group|Patients randomly assigned into the control group will undergo open or arthroscopic rotator cuff repair using the surgeon's standard practice. No ECM graft will be used.
2856714|NCT03551509|Active Comparator|Treatment Group|Patients randomly assigned into the treatment group will undergo open or arthroscopic rotator cuff repair and the surgeon will use the ArthroFLEX® ECM graft to augment the repair. ECM scaffold grafts are indicated for the reinforcement of soft tissues repaired by sutures or suture anchors during tendon repair surgery, including rotator cuff.
2856715|NCT03551509|Other|Crossover Group|Patients initially randomized to the control arm who cannot be repaired without an augmented graft will be followed for safety and remain in the study and put into a group for the intention to treat.
2856716|NCT03551496|Experimental|DES BTK|Treatment with DES BTK
2856717|NCT03551496|Active Comparator|Conventional PTA|Treatment with standard PTA
2856718|NCT03551483|Experimental|ArtontheBrain|ArtontheBrain application for about 30 to 45 minutes twice per week, over 6 weeks.
2856719|NCT03551483|Active Comparator|Seniors Online Victoria|Senior Online Victoria games for about 30 to 45 minutes twice per week, over 6 weeks (https://www.seniorsonline.vic.gov.au/services-information/games), after which they will participate in the ArtontheBrain intervention.
2856720|NCT03551483|Other|Waitlist Control|The waitlist control group will no treatment for 6 weeks, after which they will six weeks of the ArtontheBrain intervention.
2856721|NCT03551470||Synchronous colorectal cancer and liver metastases|Robotic (Da Vinci) one-stage colorectal and liver resection
2856722|NCT03551444|Active Comparator|Administration of DAA-based treatment (Arm 1)|"Arm 1 will be divided into 2 groups by randomization according to a 1:1 ratio into:~Group A: Administration of DAA-based treatment after 3 months of complete remission of HCC.~Group B: Administration of DAA-based treatment after 6 months of complete remission of HCC."
2856723|NCT03551444|Experimental|Control arm (Arm 2)|Not receiving DAAs after complete remission of HCC and to be kept on follow-up
2856724|NCT03551431|Experimental|Video EEG with verbal suggestion|
2856725|NCT03551431|Experimental|video EEG with verbal suggestion and tuning fork|
2856726|NCT03551431|Experimental|video EEG with verbal suggestion and cotton swab|
2856727|NCT03551418|Experimental|Repetitive video watching|Repetitively watching a video of an adult with Down Syndrome washing his hands
2856728|NCT03551405||Intensity accuracy|"The difference of the HU values in corresponding ROIs in the two image sets will be compared with zero using one sample t-test.~In addition, we will also use these patient cases to test the computational efficiency of our algorithm. Based on our preliminary study, it is expected that the computation time will be 5~10 sec per phase. The reconstruction time will be recorded in these patient cases and will be assessed."
2856729|NCT03551392|Active Comparator|NIR -Older Adult|Older adult participants receive the Vielight NeuroGamma system and the Vielight 810 intranasal stand alone unit. These interventions occur during 10 lab sessions (1 hour each) during an 8 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
2856730|NCT03551392|Sham Comparator|No Dose NIR-Older Adult|Older adult participants receive the sham Vielight NeuroGamma system and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 10 lab sessions (1 hour each) during an 8 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
2856731|NCT03551392|Active Comparator|NIR -Parkinson|Participants with Parkinson disease receive the Vielight NeuroGamma system and the Vielight 810 intranasal stand alone unit. These interventions occur during 10 lab sessions (1 hour each) during an 8 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
2856732|NCT03551392|Sham Comparator|No Dose NIR-Parkinson|Participants with Parkinson disease receive the sham Vielight NeuroGamma system and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 10 lab sessions (1 hour each) during an 8 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
2856733|NCT03551366|No Intervention|Control|Subjects in this group will continue with their usual PE curriculum for 15 weeks.
2856734|NCT03551366|Experimental|Linear|Subjects in this group will receive a linear PE curriculum for 15 weeks. Linear Pedagogy is underpinned by neuro-computation approach to motor learning such as information processing theory and prescribes that an ideal movement pattern exists for each task and that the teacher's role is to help learners recreate that pattern. Furthermore, theorists have suggested that learning is a gradual, linear process. This linear pedagogy is supported by a teaching and learning approach that includes both prescriptive and repetitive actions, utilising technical demonstrations that provide learners with a 'visual template or criterion model' for the desired skill . As a consequence, a PE pedagogy has developed whereby the teacher's role is to make all the decisions, and the learner's role is to follow their instructions on cue - a teacher-led approach to PE.
2860809|NCT03522909||Control|A matched controlled group patients not seen at the CPO clinic
2856735|NCT03551366|Experimental|Nonlinear|Subjects in this group will receive a nonlinear PE curriculum for 15 weeks. Nonlinear pedagogy is grounded in Ecological Dynamics theory. Ecological dynamics regards learners as complex adaptive systems which afford opportunities for action from their environment and generate movement solutions to satisfy the combination of personal, environmental and task constraints imposed upon them. According to nonlinear pedagogy, the teacher's role is to design learning experiences that create behavioural symmetry between learning and the performance environment. The teacher is a facilitator and manipulates constraints to channel the learner's physical development, while learners are left free to experiment and select the movement solutions that best answer their individual needs. This child-focused, less prescriptive approach may enhance a child's intrinsic motivation by offering freedom to choose, and an emphasis on exploration and problem solving.
2856736|NCT03551353||Group before Video-assisted feedback|Ten anesthesia residents will be included in this group. Preoperative evaluation in terms of general anesthesia will be completed for a patient before anesthesia induction. After receiving informed consent from the patient resident will complete the preparations by checking the above-mentioned list (anesthesia machine, operating room desk, monitorization methods, aspirator systems, operating room gas systems, waste systems and other anesthesia equipment) then induction will be started. All these steps will be recorded with a camera system. Once the anesthetic application is completed and all stages are recorded, the video records will be evaluated in terms of ASA guideline
2856737|NCT03551353||Group after Video-assisted feedback|Before the second phase of the study, the resident will be informed about the guideline (checkout procedure) by a staff. Then induction of general anesthesia in another patient will be recorded at all stages. Once the anesthesia application is complete, the camera record will be monitored. Differences and developments or possible similar mistakes between the records will be discussed.
2856738|NCT03551340||Traditional methods|Patients, who consulted for gastro-intestinal symptoms between July 2016 and May 2017, and were investigated by traditional methods (stool microscopy and/or culture).
2856739|NCT03551340||Gastro-intestinal panel by PCR|Patients, who consulted for gastro-intestinal symptoms between July 2017 and May 2018,and were investigated by a gastro-intestinal panel by PCR
2856740|NCT03551327|Experimental|Intervention plus information|Participants in this arm will receive 6 telephone therapy sessions and 1 booster session. Participants will be followed up at 4 months and 6 months.
2856741|NCT03551327|Other|Information only|Participants in this arm will receive information only. Participants will be followed up at 4 months and 6 months.
2856742|NCT03551314|Active Comparator|Nasal Intermittent Positive Pressure|"In this group, soon after extubation, the newborns will be studied initially in NIPPV for one hour. Infants will be studied in supine while in their incubator.~NIPPV: Nasal Intermittent Positive Pressure Ventilation"
2856743|NCT03551314|Active Comparator|Continuous Positive Airway Pressure|"In this group, soon after extubation, the newborns will be studied initially in CPAP for one hour. Infants will be studied in supine while in their incubator.~CPAP: Continuous Positive Airway Pressure"
2856744|NCT03551288|Experimental|Food Effect Cohort|Twelve healthy male subjects 18 to 45 years of age, inclusive, will be administered a single oral dose of SUVN-911 on Day 1 (Period 1) and Day 8 (Period 2) with and without food in a crossover manner.
2856745|NCT03551288|Experimental|Gender Effect Cohort|Eight healthy female subjects 18 to 45 years of age, inclusive, will be administered a single dose of SUVN-911.
2856746|NCT03551288|Experimental|Age Effect Cohort|Eight healthy male subjects ≥ 65 years of age will be administered a single oral dose of SUVN-911.
2856747|NCT03551275|Experimental|Cohort no. 1, BCD-132, 100 mg, IV|"Cohort no. 1, Group #1 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 100 mg.~Cohort no. 1, Group #2 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 50 mg and second dose of 50 mg IV after 14 days period after first infusion.~If there is no DLT within the first 14 days after infusion then Cohort no.2 is included."
2856748|NCT03551275|Experimental|Cohort no. 2, BCD-132, 250 mg, IV|"Cohort no. 2, Group #3 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 250 mg.~Cohort no. 2, Group #4 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 125 mg and second dose of 125 mg IV after 14 days period after first infusion.~If there is no DLT within the first 14 days after infusion then Cohort no.3 is included."
2856749|NCT03551275|Experimental|Cohort no. 3, BCD-132, 500 mg, IV|"Cohort no. 3, Group #5 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 500 mg.~Cohort no. 3, Group #6 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 250 mg and second dose of 250 mg IV after 14 days period after first infusion.~If there is no DLT within the first 14 days after infusion then Cohort no.4 is included."
2856750|NCT03551275|Experimental|Cohort no. 4, BCD-132, 1000 mg, IV|"Cohort no. 4, Group #7 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 1000 mg.~Cohort no. 4, Group #8 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 500 mg and second dose of 500 mg IV after 14 days period after first infusion."
2856751|NCT03551262|Experimental|OTSC|Use of OTSC to treat high-risk peptic ulcers (gastric and duodenal), i.e. Forrest Ia, Ib, IIa, IIb, in first-line endoscopic haemostatic treatment.
2856752|NCT03551262|Active Comparator|TTS clip|Use of TTS clip to treat high-risk peptic ulcers (gastric and duodenal), i.e. Forrest Ia, Ib, IIa, IIb in first-line endoscopic haemostatic treatment
2856753|NCT03551249|Experimental|Focused Ultrasound (FUS)|The ExAblate Model 4000 Type 2.0 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing initial standard of care chemotherapy.
2856754|NCT03551223||Women undergoing cesarean delivery with general anesthesia|Preeclamptic parturients undergoing cesarean delivery under general anesthesia
2856755|NCT03551223||Women undergoing cesarean delivery with spinal anesth|Preeclamptic parturients undergoing cesarean delivery under regional-spinal anesthesia
2856756|NCT03551210|Experimental|Nemonoxacin|"Nemonoxacin solution for infusion, 500 mg (250 ml), daily, as single intravenous infusion over 90-110 minutes followed by infusion of Placebo (100 ml), solution for infusion, over a minimum duration of 60 minutes.~Then will be switched to oral therapy with Nemonoxacin capsules, 500 mg once daily (two 250 mg capsules)."
2857132|NCT03548363|Active Comparator|Gingest High|200 mg/d Gingest (powdered extract obtained from Ginger rhizomes) for 4-weeks
2856757|NCT03551210|Active Comparator|Tavanic®|"Tavanic® solution for infusion, 500 mg (100 ml), daily, as single intravenous infusion over a minimum duration of 60 minutes with previous infusion of Placebo (250 ml), solution for infusion, over 90-110 minutes.~Then will be switched to oral therapy with Tavanic®, over-encapsulated film coated tablets, 500 mg once daily (two capsules each containing 250 mg film coated tablet)."
2856758|NCT03551197|Experimental|Budesonide and formoterol bid|At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months` treatment.
2856759|NCT03551184|Active Comparator|Endotoxin|Endotoxin 0.6 ng/kg body weight injection
2856760|NCT03551184|Placebo Comparator|Placebo|Saline injection
2856761|NCT03551171|Experimental|ZL-2306 (niraparib)|Subjects will be randomised into 100mg, 200mg, 300mg dose group at the first day of the first cycle.
2856762|NCT03551158|Other|Atrial fibrillation patients|Patients with atrial fibrillation who underwent cryoballoon ablation
2856763|NCT03551145|Experimental|Acellular collagen matrix|In a test group, partial thickness-flap will be elevation will be performed, in order to create the vascular recipient bed for the randomized graft. Implant surface will be treated with ultrasound device, glycine powder and implantoplasty in case of the exposure of the rough surface. Acellular collagen matrix will be adapted and suture to the vascular bed.
2856764|NCT03551145|Active Comparator|Autogenous free gingival graft|In a control group, partial thickness-flap will be elevation will be performed, in order to create the vascular recipient bed for the randomized graft. Implant surface will be treated with ultrasound device, glycine powder and implantoplasty in case of the exposure of the rough surface. Free gingival graft will be harvested from the zone of the posterior palate, and then adapted and sutured to the vascular bed.
2856765|NCT03551132|Experimental|Group 1|"Experimental group A supervised progressive moderate-to-high RTC program designed to induce muscular hypertrophy was performed. EG followed a progressive moderate-to-high RTC program for 12-weeks. The training program incorporated resistance exercise of six major regions and consisted of 3 training sessions per week on non-consecutive days (Monday, Wednesday and Friday).~All subjects performed the sets with moderate-intensity (8 to 12 repetitions) in each exercise and 30-60 seconds rest between sets. The load was increased during the 12 weeks from 60% 1-RM to high-intensity 80% 1-RM. The training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions) followed the OMNI-RES scale and a hard effort perception level. Rest between sets was 1-2 minutes."
2856766|NCT03551132|No Intervention|Group 2|Control group The CG not participated in the RTC program.
2856767|NCT03551119|Experimental|Exercise|"Personnel experienced in training patients with chronic conditions (exercise specialist) will supervise the exercise training. At each in-center session in phase 1, the patient's exercise will be monitored to assess whether they are achieving target levels. Training intensities will be modified based on the most recent exercise test.~Phase 1: an eight-week program of once weekly-supervised facility-based exercise sessions and twice weekly home-based sessions.~Phase 2: a 16-week home-based exercise program, led by an exercise specialist. During this phase, participants will be progressed through their home-based exercise program from Phase 1 on an individual basis.~i. Frequency. A minimum of three exercise sessions per week. ii. Intensity. A moderate intensity (40-60% heart rate reserve) based on exercise testing.~iii. Time. 150 minutes of exercise per week. iv. Type. We will prescribe aerobic exercise supplemented with isometric resistance exercises."
2856768|NCT03551119|Other|Enhanced usual care|Participants in the control group will also perform accelerometry. This is enhanced usual care because physical activity measurement is not routinely performed in CKD clinics. Control arm participants will only receive their accelerometry data after they have completed the study.
2856769|NCT03551106||Web based learning module|Laboratory prescriptions made by postgraduate students who were enrolled to follow the web based modules
2856770|NCT03551093|Experimental|Study Population|The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa.
2856771|NCT03551080|Active Comparator|Endotoxin|0.8 ng lipopolysaccharide/kg body weight injection
2856772|NCT03551080|Placebo Comparator|Placebo|Saline injection
2856773|NCT03551067|Active Comparator|Dexmedetomidine|Patients received Dexmedetomidine (4 µg/kg) mixed with apple juice to fill the syringe up to 10 ml given orally once.
2856774|NCT03551067|Active Comparator|Midazolam/Ketamine|Patients received Midazolam (0.5 mg/kg) and Ketamine (1 mg/kg) mixed with apple juice to fill the syringe up to 10 ml given orally once.
2856775|NCT03551054|Experimental|Healthy for Two, Healthy for You|Remotely delivered behavioral health coaching in pregnancy and postpartum
2856776|NCT03551054|Active Comparator|Pregnancy Health Education|Single health education visit with study staff member
2856777|NCT03551028|Other|HPV self collection|Pairing self-collection of HPV samples for DNA testing with women seeking mobile mammography.
2856778|NCT03551015|Experimental|Intervention|The intervention arm will have outpatient review at 3 weeks and start 8 sessions of cardiac rehabilitation from 4 weeks, after hospital discharge following CABG.
2856779|NCT03551015|No Intervention|Control|This arm will have outpatient review 6 weeks after hospital discharge and start 8 sessions of cardiac rehabilitation from 8 weeks.
2856780|NCT03551002||Retrospective|
2856781|NCT03551002||Prospective|
2856782|NCT03550989||Non-Smokers|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~Abstinent for at least 12 months from the use of any nicotine and/or tobacco-containing product based on self-reporting.~Must not be exposed to tobacco or nicotine-containing products use in any other substantial way (family, partner, workplace, etc.)."
2856783|NCT03550989||Cigarette Smokers|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~Used at least 100 cigarettes~Smokes cigarettes daily > 1/day~Uses IQOS less than daily~Uses less than 30 HeatSticks/month~Cigarette is > 95% of tobacco/nicotine product (all product use)"
2857133|NCT03548363|Active Comparator|Gingest low|100 mg/d Gingest (powdered extract obtained from Ginger rhizomes) + 100 mg maltodextrin for 4-weeks
2856784|NCT03550989||IQOS Passive Users (not using IQOS)|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~Used at least 100 HeatSticks~Uses IQOS daily > 1/day~Smokes a cigarette less than daily~Smokes less than 30 cigarettes/month~IQOS is > 95% of tobacco/nicotine product (all product use) - excluding other products (e-cig/Ploom/etc.)"
2856785|NCT03550989||IQOS Active Users (using IQOS)|"Each participant can participate in one Exposure Event only.~Used at least 100 HeatSticks~Uses IQOS daily > 1/day~Smokes a cigarette less than daily~Smokes less than 30 cigarettes/month~IQOS is > 95% of tobacco/nicotine product (all product use) - excluding other products (e-cig/Ploom/etc.)"
2856786|NCT03550976|Experimental|High risk intervention group|
2856787|NCT03550976|No Intervention|High risk control group|Dietary evaluation and body composition analysis at 12 and 28 weeks of pregnancy. Receive routine obstetric examinations and routine health education which includes proper diet and exercise advice.Collect birth outcomes.
2856788|NCT03550976|No Intervention|Low risk control group|Dietary evaluation and body composition analysis at 12 and 28 weeks of pregnancy. Receive routine obstetric examinations and routine health education which includes proper diet and exercise advice.Collect birth outcomes.
2856789|NCT03550963|Other|rice-richen meal|All participants included in the study will be randomized assigned into one of two groups in parallel, the rice-richen meal group and wheaten-richen meal group. The intervention of group one is that participants will be provided with rice-richen meal, meaning most of the calculated carbohydrates are from rice.
2856790|NCT03550963|Other|wheaten-richen meal|All participants included in the study will be randomized assigned into one of two groups in parallel, the rice-richen meal group and wheaten-richen meal group.The intervention of group two is that participants will be provided with wheaten-richen meal, meaning most of the calculated carbohydrates are from wheaten.
2856791|NCT03550950|Experimental|Single Ascending Dose (SAD) IV Cohort|Participants will receive single intravenous (IV) dose of JNJ-64232025 or placebo in Cohorts 1 to 6 on Day 1.
2856792|NCT03550950|Experimental|Subcutaneous (SC) Cohort|Participants will receive single dose of JNJ-64232025 or placebo as SC injection.
2856793|NCT03550924|Active Comparator|Low flow Oxygen Group|low flow passive oxygenation during laryngoscopy with 10l/min oxygen via standard nasal prongs
2856794|NCT03550924|Experimental|THRIVE Group|high flow passive oxygenation during laryngoscopy with 120l/min oxygen via THRIVE system
2856795|NCT03550898|Other|Dynamic ultrasonography|Dynamic ultrasonography was performed in all patients who underwent urodynamics, simultaneously.
2856796|NCT03550885|Experimental|High taurine and saturated fat diet|This is a 3-week controlled isocaloric diet containing approximately 125 mg taurine, 40% of calories from fat, 15% of calories from saturated fat, 25% of calories from protein (4:1 animal to plant grams of protein), and 11.5 grams fiber/1000 calories.
2856797|NCT03550885|Experimental|Low in taurine and saturated fat diet|This is a 3-week controlled isocaloric diet containing approximately 7 mg taurine, 36% of calories from fat, 8% of calories from saturated fat, 13% of calories from protein (3:1 plant to animal grams of protein), and 13.5 grams fiber/1000 calories.
2856798|NCT03550872|No Intervention|Control Group|Patients in the group who are continuously guided as the activities of daily living normally avoiding participation in any regular program of physical exercise does not proceed from the study.
2856799|NCT03550872|Experimental|Training Group|the patients randomized to the physical training group will undergo the supervised physical training program
2856800|NCT03550859|Experimental|Duowell Tab. 40/10mg|Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks
2856801|NCT03550859|Active Comparator|Micardis Tab. 40mg|Telmisartan 40mg qd for 48 weeks
2856802|NCT03550833||Rheumatoid Arthritis patients|patients affected by RA according to ACR/EULAR 2010 criteria, with a disease duration less than 2 years
2856803|NCT03550833||control patients|patients with a visceral surgery for less than 2 years (appendectomy, cholecystectomy, bowel obstruction, hernia, eventration…)
2856804|NCT03550794|Experimental|Thiamine|200mg parenterally administered thiamine hydrochloride given twice daily for a 3 days (6 doses)
2856805|NCT03550794|Placebo Comparator|Placebo|Matching placebo (50ml 0.9%NACL) given twice daily for 3 days (6 administrations)
2856806|NCT03550781|Experimental|Anti-inflammatory treatment group|Prednisone and/or cyclophosphamide
2856807|NCT03550781|No Intervention|Control group|No intervention
2856808|NCT03550768||MDP|ERCP was performed by trainees or trainers. Before the cannulation, the photo of major duodenal papilla will be taken carefully to evaluate its size, morphology, orientation and location. All patients initially received wire-guided cannulation with a sphincterotome, If cannulation failed, precut sphincterotomy or the double-wire technique was performed when appropriate. Therapeutic manipulation (eg, sphincterotomy, balloon dilation, stone extraction, and stenting) was done when appropriate. Pancreatic duct stent placement was performed at the discretion of the endoscopists.
2856809|NCT03550755|Experimental|V3-Cervix|Biological: V3-Cervix V3-Cervix is a tableted immunotherapeutic derived from hydrolyzed, heat-inactivated, pooled blood and tumor tissue from women with cervical cancer
2856810|NCT03550742|Experimental|Intervention|Daily administration of 5g of Fuco-N-Tetraose as a bolus for a period of 12 weeks.
2856811|NCT03550729|Experimental|Training|12-weeks of supervised endurance training program.
2856812|NCT03550716|Active Comparator|mTESE|Patients randomized to mTESE
2856813|NCT03550716|Active Comparator|TESA|Patients randomized to TESA
2856814|NCT03550703|Experimental|Single arm receiving V3-Myoma|A single oral pill of V3-Myoma therapeutic vaccine containing pooled antigens circulating in peripheral blood and within myoma tissues
2856815|NCT03550690||Large Volume Paracentesis|Patient has repeated large volume paracentesis for recurrent ascites secondary to cancer
2856816|NCT03550690||Semi-permanent drain|Patient has a semi-permanent drain (Rocket Indwelling Pleural Catheter) placed for recurrent ascites secondary to cancer
2856817|NCT03550677|Experimental|Group General Anesthesia|These group patients will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10 mg-20 mg rocuronium and a proper size laryngeal mask airway will be placed to secure the airway. The lungs will be ventilated with a mixture of 50% and 50% oxygen.
2856892|NCT03550118|Experimental|Adjustable Socket - Participant Controls|An adjustable socket is tested where the study participant controls the adjustments. This arm focuses on socket size adjustments while walking.
2856818|NCT03550677|Experimental|Group Ankle Block|These group patients will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10 mg-20 mg rocuronium and a proper size laryngeal mask airway will be placed to secure the airway. The lungs will be ventilated with a mixture of 50% and 50% oxygen. After than an ankle block will be performed in patient group block patients using a mixture of 5 ml of 2% lidocaine and 10 ml of 0.5 bupivacaine the same amount placebo (saline) in group placebo under the guidance of peripheral nerve stimulator then the anesthesia will be disconnected and LMA will be removed. The patients will be transferred from postoperative care unit toward after they are eligible for discharge according to the modified scoring system.
2856819|NCT03550664|Experimental|Surgical intervention|Patients undergoing a surgical intervention within the CHU Brugmann with utilisation of rocuronium.
2856820|NCT03550651|Experimental|Licorice extract mouthrinse|10ml twice a day for 4 Days.
2856821|NCT03550651|Experimental|Hypertonic salt solution|10ml twice a day for 4 Days.
2856822|NCT03550651|Active Comparator|Essential oil mouthrinse|10ml twice a day for 4 Days.
2856823|NCT03550651|Active Comparator|Chlorhexidine Gluconate mouthrinse|10ml twice a day for 4 Days.
2856824|NCT03550651|Placebo Comparator|Distilled water|10ml twice a day for 4 Days.
2856825|NCT03550638|Experimental|group A|Coil system(Ton-bridgeMT)
2856826|NCT03550638|Active Comparator|group B|Axium Detachable Coil(Medtronic)
2856827|NCT03550625||Routine Colonoscopy Cohort|Photographies of polyps for creation of computer program
2856828|NCT03550612||Neonates with hypoxic ischemic encephalopathy|Cranial ultrasound,Magnetic resonant imaging and amplitude integrated encephalogram performed to All neonates with hypoxic ischemic encephalopathy in period between January 2010 to December 2015.
2856829|NCT03550599||patients accessing to Radiotherapy Unit|patients accessing to Radiotherapy Unit for oncologic treatment
2856830|NCT03550586||Parturients suffering from a PDPH|Parturients suffering form a PDPH following an accidental dural puncture between the years 2007-2017 will be contacted by phone and verbal consent will be obtained for participation in the study. All participants will be requested to answer an IRB approved telephone script. Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS) translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire.Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire
2856831|NCT03550586||Parturients not suffering from a PDPH|This group will consistent of a control group of women receiving epidural analgesia on the same day as those women who suffered an ADP. This participants will be contacted by phone and verbal consent will be obtained for participation in the study. All participants will be requested to answer an IRB approved telephone script. Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS) translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire.Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire
2856832|NCT03550573|Experimental|hypertrophic cardiomyopathy without sudden death history|
2856833|NCT03550573|Experimental|hypertrophic cardiomyopathy with sudden death history|
2856834|NCT03550560||EUS-Guided drainage|Cancer patients in terminal phase with refractory malignant ascites
2856835|NCT03550547|Experimental|7 educational workshops|"Intervention: 7 educational workshops in addition to spa therapy :~Knowledge of the pathology ; Educational physical activity ( 2 workshops); Dietary; Management of pain, fatigue and the medical treatments; Articular hygiene and ergonomics; Technical assistance, an adaptation of the living condition"
2856836|NCT03550547|Active Comparator|spa therapy|Approved Spa therapy
2856837|NCT03550534|Experimental|Calcium Carbonate|Calcium carbonate 3 x 500 mg was given to 23 study participants for 12 weeks
2856838|NCT03550534|Placebo Comparator|Placebo oral capsule|Placebo oral capsule 3 x 1 was given to 23 study participants for 12 weeks
2856839|NCT03550521|Experimental|Mindfulness condition|The brief mindfulness induction will be modeled after basic mindfulness skills commonly used in mindfulness-based interventions and tailored to target distressing thoughts and feelings.
2856840|NCT03550521|No Intervention|Control condition|"Participants assigned to the control task will be instructed to let your mind wander freely without trying to focus on anything in particular."
2856841|NCT03550508|Experimental|Anti-RANKL Monoclonal Antibody|Anti-RANKL Monoclonal Antibody is to be injected subcutaneously 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg or 3.0 mg/kg.
2856842|NCT03550495|No Intervention|Control|Patients will undergo standard of care including the use of the ABCDEF bundle; psychiatry team will not be involved on daily ICU rounds.
2856843|NCT03550495|Experimental|Intervention|Patients will receive standard ICU care, including the use of the ABCDEF bundle, but will also receive the intervention of psychiatry involvement; the psychiatry team will participate in daily ICU rounds with the ICU team to help identify, prevent, and treat ICU delirium and identify other psychiatric disorders which may be otherwise undetected by the ICU team.
2856844|NCT03550482|Experimental|Oncoxin®|
2856845|NCT03550482|No Intervention|Control|
2856846|NCT03550469|Experimental|Computer-assisted Oxygen Weaning|A computer with an adaptive model algorithm will guide oxygen weaning.
2856847|NCT03550469|No Intervention|Manual Oxygen Weaning|Oxygen weaning will be done by staff manually.
2856848|NCT03550456||ECC, ECC with CLE, speech therapy|"After the standard diagnostic (spirometry, body plethysmography, exhaled NO, skin prick test) all patients with dyspnea while exercising undergo exercise challenges in a cold chamber (ECC).~In case of a positive reaction in the ECC the patients get asthma medication (ICS/LABA combination).~Both groups negative and positive should fill out a symptom diary and the next visit will be booked 6 weeks later.~If they still have dyspnea while exercising with ICS/LABA combination or hat a negative ECC the patients undergo an ECC with continuous laryngoscopy. In case of an EILO diagnosis patients will be sent to speech therapy and checked at a follow up visit.~All patients and their parents should complete questionnaires for symptoms and quality of life at every visit."
2856925|NCT03549897|Placebo Comparator|Placebo Product|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
2856849|NCT03550443|Experimental|RTA 402(Bardoxolone methyl)|Patients will receive multiple oral doses of bardoxolone methyl once daily. The starting dose of bardoxolone methyl will be 5 mg. The maximum dose will be 15 mg, and the dose will be increased by 5 mg.
2856850|NCT03550443|Placebo Comparator|Placebo|Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.
2856851|NCT03550430|Experimental|alpha/delta neurofeedback|Ten alpha/delta neurofeedback training sessions, 28 minutes each, two to three weekly sessions over four weeks
2856852|NCT03550430|Active Comparator|beta/theta neurofeedback|Ten beta/theta neurofeedback training sessions, 28 minutes each, two to three weekly sessions over four weeks
2856853|NCT03550430|Active Comparator|Diary Control Group|Daily diary completion for two weeks in the period between baseline and end-point assessments (total period baseline to end-point = four weeks).
2856854|NCT03550417||2011 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010.
2856855|NCT03550417||2013 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010. Comparison of 2011 and 2013 cohorts.
2856856|NCT03550404||Navigators|"AIE Navigators will use the Seasons of Care app in the context of their everyday outreach work with AIEs over two four-month intervention periods (P1 and P2). Their goal will be to facilitate health literacy to shift attitudes, beliefs, and behaviors to create a Culture of Coverage for AIEs at individual, organizational/community, and policy levels. Separated by distance, the AIE Navigators will receive coaching as necessary, using virtual meeting space, to help refine their implementation skills from a member of the research team with experience in AIE health outreach."
2856857|NCT03550404||American Indian Elders (AIEs)|Elders will be exposed to the Seasons of Care app when they reach out to navigators for assistance navigating the healthcare system.
2856858|NCT03550404||Healthcare providers/staff|This cohort will be exposed to the Seasons of Care app via navigators and their patients.
2856859|NCT03550391|Experimental|Whole Brain Radiotherapy (WBRT) plus Memantine|WBRT 3000 cGy in 10 fractions + memantine
2856860|NCT03550391|Experimental|Stereotactic Radiosurgery (SRS)|SRS 18-20 or 22Gy in single fraction
2856861|NCT03550378|Experimental|MEDI0382|MEDI0382 administered subcutaneously
2856862|NCT03550378|Placebo Comparator|Placebo|Placebo administered subcutaneously
2856863|NCT03550365|Experimental|Rye bran bread intervention|4 week rye bran bread diet intervention with dietary fibre intake of 30g
2856864|NCT03550365|Experimental|Rye bread intervention|4 week rye bread diet intervention with dietary fibre intake of 30g
2856865|NCT03550365|Active Comparator|Wheat bread intervention|4 week wheat bread diet intervention with dietary fibre intake of 5-20g prior to two other arms
2856866|NCT03550352|Experimental|Low CBD|Low CBD dose TN-TC11LM oral capsules (THC 2.5 mg / CBD 2.5 mg).
2856867|NCT03550352|Experimental|High CBD|High CBD dose TN-TC19LM oral capsules (THC 5 mg / CBD 45 mg).
2856868|NCT03550339|Active Comparator|SURG|subjects attending bariatric surgery
2856869|NCT03550339|Active Comparator|DIET|subjects attending dietary weight loss program
2856870|NCT03550339|Active Comparator|HAES|subjects attending Health At Every Size weight management program
2856871|NCT03550326||general anesthesia|Patients who undergo general anesthesia and are intubated or inserted airway device will be enrolled. researchers will follow the induction and intubation period and record all the complications due to airway management.
2856872|NCT03550313|Experimental|Group 1 - Coadministration|Multivalent pneumococcal conjugate vaccine coadministered with Prevnar 13
2856873|NCT03550313|Experimental|Group 2 - Staggered Administration|Multivalent pneumococcal conjugate vaccine given 1 month after Prevnar 13
2856874|NCT03550313|Active Comparator|Group 3 - Control with Supplemental Dose|Prevnar 13 with a single dose of multivalent pneumococcal conjugate vaccine
2856875|NCT03550300||Participants with CMT|Participants with CMT1A, CMT1B, CMT2A or CMTX1
2856876|NCT03550300||Control participants|Control participants
2856877|NCT03550287|Experimental|Experimental product|Dietary supplement (Shiitake extract) in a commercial soup at lunch for 8 weeks.
2856878|NCT03550287|Placebo Comparator|Placebo product|Isocaloric placebo (maltodextrin) in a commercial soup at lunch for 8 weeks.
2856879|NCT03550274|Experimental|App-based exercise rehabilitation|Persons with Acute lateral ankle sprain (<48 hours) evaluated by a relevant health specialist in the hospital Emergency Department.
2856880|NCT03550248|Other|Intervention group|Participants will receive the intervention - Healthy Together (HT).
2856881|NCT03550209|Experimental|LCPUFA Oil Supplement|EPA + DHA + GLA + OA oil supplement; twice per day for 90 days at a dose of 50, 100, or 150mg, based on weight of child.
2856882|NCT03550209|Placebo Comparator|Canola Oil|90 days, equal volume, twice per day for 90 days
2856883|NCT03550183|Experimental|mesenchymal stem cells|Selected patients with Parkinson's disease were randomly divided into a therapy group and a control group. Umbilical Cord Derived Mesenchymal Stem Cells(UC-MSCs) at a dose of 10-20 million by intravenous infusion.Patients in the therapy group treated once a week with UC-MSCs. Each course of treatment Lasted 3 weeks.
2856884|NCT03550170|Active Comparator|Teleconference|Teleconference Intervention arm
2856885|NCT03550170|Active Comparator|Internet|Internet Intervention arm
2856886|NCT03550170|Active Comparator|I-to-1, in-person|1-to-1, in-person intervention arm
2856887|NCT03550144|Experimental|Awe Walk Condition|Participants were instructed to take at least one (~15 minute) walk per week for 8 consecutive weeks. Participants were told to seek the experience of feeling awe. Participants were told to keep a fairly light to moderate pace and were encouraged to walk alone and without interruption from a mobile device.
2856888|NCT03550144|Active Comparator|Control Walk Condition|Participants were instructed to take at least one (~15 minute) walk per week for 8 consecutive weeks. Participants were told to keep a fairly light to moderate pace and were encouraged to walk alone and without interruption from a mobile device.
2856889|NCT03550131|Active Comparator|Standard intervention|"Reducing Disabilities in Alzheimer's Disease (RDAD):~9 60-minute face-to-face sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months"
2856890|NCT03550131|Experimental|Personalized intervention|"Innovations in Dementia Empowerment and Action (IDEA):~9 60-minute face-to-face sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months"
2856893|NCT03550118|Experimental|Adjustable Socket - Automatic Controls|An adjustable socket is tested where a control system is used to automatically control the adjustments. This arm focuses on socket size adjustments while walking.
2856894|NCT03550118|Experimental|Stress-Sensing Liner|An adjustable socket is tested in addition to a prosthetic liner with embedded stress sensors to measure mechanical stresses as the socket is adjusted.
2856895|NCT03550118|Experimental|Release/Recovery - Researcher Controls|An adjustable socket is tested where researchers control the adjustments. This arm focuses on a socket release and recovery mechanism that allows for full or partial doffing of the socket while seated.
2856896|NCT03550118|Experimental|Release/Recovery - Participant Controls|An adjustable socket is tested where the study participant controls the adjustments. This arm focuses on a socket release and recovery mechanism that allows for full or partial doffing of the socket while seated.
2856897|NCT03550105|Experimental|GJ-Only|Study Subjects with Baseline Glucose of > 150mg/dl, will have Gentle Jogger Only for 7 days
2856898|NCT03550105|Experimental|GJ-OGTT|Study Subjects with Baseline Glucose of < 150mg/dl, will have Oral Glucose Tolerance Test (OGTT) at baseline and after 7 days of Gentle Jogger
2856899|NCT03550092|Experimental|Aphasia|Abstract Semantic Association Network Training (AbSANT) Each session will be 2 hours long and will occur twice each week for a total of 20 sessions.
2856900|NCT03550079|Experimental|three screws fixation|femoral neck fractures were fixed with three converted screws
2856901|NCT03550079|Experimental|four screws fixation|femoral neck fractures were fixed with four screws
2856902|NCT03550066|Experimental|Values affirmation|
2856903|NCT03550066|Active Comparator|No affirmation|
2856904|NCT03550053|Active Comparator|Intraoperative plate bending|Plate will be bent intraoperatively, which is the standard of care, for this surgery
2856905|NCT03550053|Active Comparator|Preoperative plate bending|A 3D printed model of the patient's mandible will be used to bend the plate preoperatively by the surgeon. The pre-bent plate will be brought into the operating room on the day of surgery.
2856906|NCT03550040|Active Comparator|Robot assisted prostatectomy.|Intervention: radical prostatectomy
2856907|NCT03550040|Experimental|3D laparoscopic prostatectomy|Intervention: radical prostatectomy
2856908|NCT03550027|Experimental|PleurX|Positioning of Pleurx drainage during surgical exploration if lung does not reinflate
2856909|NCT03550027|Experimental|Pleurocath|Positioning of Pleur o cath drainage during surgical exploration if lung does not reinflate
2856910|NCT03550014|Active Comparator|Low Back Only|Participants randomized to the Low Back Only arm will receive physical therapy as directed by the treating physical therapist targeting the lower back.
2856911|NCT03550014|Active Comparator|Low Back+Hip|Participants randomized to the Low Back+Hip arm will receive physical therapy as directed by the treating physical therapist targeting the lower back. In addition to that treatment, participants will received hands-on and exercise physical therapy interventions directed at the hip(s).
2856912|NCT03550001|Experimental|Injection CNP before NAT|Inject carbon nanoparticle as a lymph node tracer before the patient receive neoadjuvant therapy.
2856913|NCT03550001|No Intervention|No injection|Do not inject carbon nanoparticle during the treatment.
2856914|NCT03549988||Control|"The group will receive current standard of care as the usual practice of the attending physician. Basic research data will be collected and participants in this group will be asked to complete the on-line questionnaires (MMAS-8, SIBDQ and EQ-5D 5L) on the baseline visit and month 6, 12 and month 18.~When endoscopy is performed biopsies should be taken and the endoscopic and histologic assessment will be recorded. If a fecal calprotectin is measured, every effort should be made to use the IBDoc with the result being sent to the central primary investigator via the IBDoc Web Portal. However, should a different fecal calprotectin measure be used, this will be recorded as part of the study documentation and will be included in the study data."
2856915|NCT03549988||Intervention: FC measurements with IBDoc|"Fecal Calprotectin (FC) measurements with IBDocTM home kits will be performed by participants in the intervention group every 2 months until final visit.~Basic research data will be collected and participants in this group will be asked to complete the on-line questionnaires (MMAS-8, SIBDQ and EQ-5D 5L) on baseline visit and month 6, 12 and month 18."
2856916|NCT03549975|Experimental|Botulinum toxin type A injection|Botulinum toxin type A injection followed by functional electrical stimulation
2856917|NCT03549936|Active Comparator|Low lactose formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula which arrives from milk lab labeled as formula A or formula B."
2856918|NCT03549936|Active Comparator|Regular formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive regular formula which arrives from milk lab labeled as formula A or formula B"
2856919|NCT03549923|Experimental|Simultaneous CRRT group|CRRT is initiated simultaneously (not late than 24 hours from the initiation of ECMO treatment), regardless of presentation of conventional indication of CRRT. CRRT lasts for 12 hours or more is recommended.The physician can decide when to withdraw CRRT based on the patient's condition.
2856920|NCT03549923|Experimental|Conventional-indication CRRT group|CRRT is not initiated unless conventional indication of CRRT is presented. The conventional indication of CRRT is as follow: KDIGO stage 3 AKI and one of the following criteria is met: severe hyperkalemia (> 6.5 mmol/L), metabolic acidosis (pH < 7.2), pulmonary edema, blood urea nitrogen level >112 mg/dL, or oliguria (urine output < 200 mL/12 h) for more than 72 hours.
2856921|NCT03549923|Experimental|Esmolol group|Patients will receive a continuous esmolol infusion in addition to routine management. The esmolol infusion commences at 25 mg/h and increases by 25 mg/h every 20-minute until the maximal tolerate dosage is reached or the heart rate reduced to 75±5 bpm, or an upper dose limit of 2000 mg/h is reached. Continue infusing esmolol to maintain the heart rate threshold or at the discretion of the physician until either ICU discharge or death. Oral beta-blockers should be considered before the withdrawal of esmolol.
2856922|NCT03549923|Experimental|Control group|All beta-blockers, including esmolol, should not be used during ICU treatment, unless the doctor thinks there's a strong indication.
2856923|NCT03549910|Experimental|Early use of APRVplus protocol in ARDS|physiology-driven APRVplus protocol
2856924|NCT03549910|Other|Low tidal volume ventilation|Low tidal volume lung protective ventilation
2856926|NCT03549897|Active Comparator|90 mcg Reference Product|One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
2856927|NCT03549897|Active Comparator|180 mcg Reference Product|One actuation each from two different Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
2856928|NCT03549897|Experimental|90 mcg Test Product|One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols
2856929|NCT03549884|Experimental|Delayed cord clamping (DCC)|Cord clamping will be performed after 60 seconds of life
2856930|NCT03549884|Active Comparator|Early cord clamping (ECC)|Cord clamping will be performed within 10 seconds of life
2856931|NCT03549871|Experimental|Fitusiran (ALN-AT3SC)|
2856932|NCT03549845|Experimental|CHAP Intervention|The Cardiovascular Health Awareness Program (CHAP) intervention is an on-site drop-in, monthly, cardiovascular risk assessment program run by trained volunteers with community-led group health sessions that deliver education and information about access to community health resources. The education sessions will be delivered by national and provincial and local community organizations utilizing already developed material as much as possible, but maintaining consistency across both provinces. Session topics will include: Physical Activity, Healthy Eating, Stress, Tobacco Use, High Blood Pressure, Role of Pharmacist: How they can assist people, Website/appropriate use of healthcare/medical appointment, Social isolation/loneliness, Anxiety/Depression. This intervention will be held in a common room in selected subsidized housing buildings.
2856933|NCT03549845|No Intervention|Control|The control buildings will receive usual care which will be wellness programs already present in the building prior to the RCT if these are present. Not all control buildings will have wellness programs.
2856934|NCT03549832|Active Comparator|sof/sim/dac|Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin
2856935|NCT03549832|Active Comparator|sof/omb/parit|Sofosbuvir /Ombitasvir/ Paritaprevir /Ritonavir/Ribavirin
2856936|NCT03549819|Experimental|Cannabidiol (CBD) Oil Capsules|Pure CBD in sunflower lecithin oil, flexibly dosed at 200-800 mg per day
2856937|NCT03549819|Placebo Comparator|Sunflower Lecithin Oil in Capsule|1-4 capsules daily
2856938|NCT03549806||Prospective Cohort|No study intervention. Patients referred for ablation of atrial arrhythmias will be treated as per operator preference with no study intervention. Data will be collected in de-identified fashion.
2856939|NCT03549793|Experimental|dance thrapy|4-week Multidisciplinary Rehabilitation Treatment + Dance Therapy Treatment (2 hours par week)
2856940|NCT03549793|Active Comparator|exercises without dance|4-week Multidisciplinary Rehabilitation Treatment + Exercises without music (2 hours par week)
2856941|NCT03549780|Other|Stomal Occlusion|Insertion of a novel stomal occlusion device into patients with Brooke Ileostomy and assess feasibility and patient satisfaction
2856942|NCT03549767|Experimental|Springfusor|Women in this group will have their loading dose (4 gm of 50% Magnesium sulphate in 10 ml syringe administered over 20 minutes) and maintenance therapy (4 gm of 50% Magnesium sulphate in 10 ml syringe administered over 4 hours through an IV infusion administered using a Springfusor pump.. The 4 gm maintenance dose will be repeated every 4 hours for 24 hours.
2856943|NCT03549767|Active Comparator|Standard of care|The control group will have Magnesium sulphate administered using the Pritchard regimen, which involves administration of loading dose of 4 gm of 20% Magnesium sulphate IV over 15-20 minutes, immediately followed by 10 gm of 50% Magnesium sulphate IM (5gm on each buttock). The maintenance dose of 5 gm of 50% Magnesium sulphate IM every 4 hourly in alternate buttocks continued for 24 hours
2856944|NCT03549741|Experimental|study group|will receive a dose of Clomiphene citrate 50 mg tablet , 1 tab twice daily for 5 days from the third day of menses to the seven day and cabergoline 0.25 mg (half tablet) every 3 days (one package) first three months then Clomiphene citrate 50 mg tablet , 2 tabs twice daily for 5 days from the third day of menses to the seven day and cabergoline 0.25 mg (half tablet) every 3 days (one package)
2856945|NCT03549741|Active Comparator|control group|will receive a dose of Clomiphene citrate and placebo tablets with same dose and duration
2856946|NCT03549728|Experimental|Group A|Group A (N=44): women will receive intrauterine infusion of granulocyte colony-stimulating factor on the day of ovum-pick up during IVF cycle.
2856947|NCT03549728|Placebo Comparator|Group B|Group B (N=44): women will receive placebo intrauterine infusion of normal saline on the day of ovum-pick up during IVF cycle.
2856948|NCT03549715|Experimental|ARM A: durvalumab + ddMVAC|Durvalumab + ddMVAC Durvalumab 1500 mg IV D1 every 28 days Durvalumab will be administered at the hospital every 28 days prior to administration of ddMVAC on D1.
2856949|NCT03549715|Experimental|ARM B: durvalumab + tremelimumab+ ddMVAC|"durvalumab + tremelimumab + ddMVAC Tremelimumab 75 mg IV D1 every 28 days Tremelimumab will be administered first, with durvalumab infusion starting approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion.~Infusion of ddMVAC will start approximately 1 hour after completion of durvalumab."
2856950|NCT03549702|Active Comparator|Povidone irrigation Group|Includes the 100 women who will undergo elective caesarian section with subcutaneous tissue irrigation with Povidone iodine 1% solution.
2856951|NCT03549702|No Intervention|Control Group|Includes the 100 women who will undergo elective caesarian section without subcutaneous tissue irrigation with Povidone iodine 1% solution.
2856952|NCT03549689|Experimental|Switch|Dolutegravir (DTG) 50MG/ lamivuidne (3TC) 300MG FIXED_DOSE COMBINATION (FDC) DAILY at randomization for 96 weeks
2856953|NCT03549689|Active Comparator|Continuation|Continue current tenofovir alafenamide (TAF)-containing ART regimen from weeks 0 to 96.
2856954|NCT03549676|Experimental|HSCT patients with refractory GVHD|Patients will accept FilmArray Gastrointestinal (GI) panel test before pre-treatment of HSCT and 28±3 days post-HSCT. Patients will receive 50ml fecal microbiota from unrelated healthy donors through nasojejunal tube and monitored under gastroscopy. Patients receiving FMT treatment will be followed for at least 6 months. The ideal follow up time is 2 year. Stool and blood samples will be serially collected and tested (before pre-treatment, 1/3/6/12 months after FMT).
2856955|NCT03549663|Experimental|Tacrolimus monotherapy|
2856956|NCT03549663|Active Comparator|Tacrolimus combined with hormone therapy|
2856980|NCT03549429|Experimental|TegadermTM on L eye, EyeGard® on R eye|
2871294|NCT03450434|Experimental|XC8 10 mg|XC8 10 mg orally
2856957|NCT03549650|Experimental|Pentosan Polysulfate Na 100Mg Cap|Drug intervention of Pentosan Polysulfate Na 100Mg Cap (ELMIRON) thrice daily PO for 6 weeks, after meeting the eligibility criteria during the the two-week Screening period.
2856958|NCT03549650|Placebo Comparator|Placebo oral capsule|Participants will receive Placebo oral capsule, similar to (ELMIRON 100mg) thrice daily PO for 6 weeks, , after meeting the eligibility criteria during the the two-week Screening period.
2856959|NCT03549637|Experimental|Psychiatric population|"At inclusion: Patients will have A Lipid Panel Test, other biological analyzes and a clinical assessment. In case of a low LDL-C level (≤ 0, 50 g/L), genetic analyzes will be performed to screen for genetic forms of hypobetalipoproteinemia (HBL).~At 2- 4 weeks: for patients with HBL (LDL-C ≤ 0,50 g/L with no secondary cause of LDL-C reduction), another Lipid Panel Test will be performed to confirm the maintenance of the low LDL-C level.~At 6 months : Patients with a HBL will perform a full biological examination, and the LDL-C levels and genetic analyzes will be confirmed. A dietary survey will be performed, together with a psychiatric assessment. The same numbers of matched controls will performed a quick telephone interview to collect the psychiatric characteristics."
2856960|NCT03549624||Intervention group|"All adult (>18y) patients with the need of an acute laparotomy (within 6 hours) at NÄL.~Patients will be treated with an perioperative regime/protocol consisting of:~Early so called NEWS-monitoring (measuring of standard physiological parameters);~Early start of antibiotics;~Rapid (within 6 hours) start of operation;~Goal-directed fluid therapy;~Intensified post-operative monitoring;~The presence of both surgical and anesthesiological specialists in the early care of the patients."
2856961|NCT03549624||Control group|All patients operated with an acute laparotomy at NÄL the years prior to the study will be retrospectively collected using the hospitals operation management database (Orbit©). Medical data will be collected from the patients' medical charts and outcome data (i.e. mortality, length of hospital stay, surgical complications, ICU-management etc.) will be registered
2856962|NCT03549611|Experimental|Multimodel Drug Regimen|"The patients randomized to this arm will receive the following multimodal oral drug regimen administered shortly before induction of general anesthesia~Tylenol, 975mg (3 tabs)~800mg Gabapentin~400mg Celecoxib~10mg Oxycodone"
2856963|NCT03549611|Active Comparator|Acetaminophen Only|"The patients randomized to this arm will receive oral acetaminophen only administered shortly before induction of general anesthesia~1. Tylenol, 975mg (3 tabs)"
2856964|NCT03549598|Experimental|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT and 18FDG PET/CT scan and 13NH3 PET/CT scan will be performed
2856965|NCT03549572||Severe Traumatic Brain Injury|We will administer Coma Recovery Scale-Revised (CRS-R) and the Coma Recovery Scale Revised For Accelerated Standardized Testing (CRSR-FAST) to patients in the intensive care unit who have impaired level of consciousness resulting from a severe traumatic brain injury.
2856966|NCT03549559|Active Comparator|Healthy Subjects|Healthy subjects will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.
2856967|NCT03549559|Active Comparator|Diabetes Patient Subjects|Patient subjects with diabetes will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.
2856968|NCT03549559|Experimental|Aortic Stenosis Patient Subjects|Patient subjects with aortic stenosis will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI before and after transcatheter valve replacement.
2856969|NCT03549546|Other|Patients undergoing lung cancer surgery|Patients undergoing lung cancer surgery will be included. Blood samples will be collected.
2856970|NCT03549533||artificial insemination|Patient who perform his first artificial insemination will be included. Samples of sperm will be analyzed.
2856971|NCT03549520|Experimental|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg may be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 30 minute monitoring period after the first and second injection (if there are two injections of contrast) of the contrast agent.
2856972|NCT03549507|Experimental|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg may be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 30 minute monitoring period after the first and second injection (if there are two injections of contrast) of the contrast agent.
2856973|NCT03549494|Experimental|Ocoxin-Viusid®|
2856974|NCT03549468|Experimental|low level tragus stimulation (LLTS)|Patients with ischemic cardiomyopathy (left ventricular ejection fraction <35%) and heart failure who already have an implantable device with an atrial lead (dual chamber defibrillator or biventricular defibrillator) will undergo sequentially 1. Sham LLTS (5min), 2. Active LLTS at 5Hz (15min) and 20Hz (15min) and 3. Active LLTS group with atrial pacing at 100bpm at 5Hz (15min) and 20Hz (15min).
2856975|NCT03549455|Experimental|Exposure Therapy and Self Distancing|All subjects will have 2 introduction sessions and then receive Exposure therapy with Self-Distancing (2 weeks) following Exposure therapy without Self-Distancing (2 weeks) followed by 2 more weeks of Exposure therapy with Self-Distancing.
2856976|NCT03549442|Experimental|Phase A|Safety Run-in to test the safety of CART-BCMA + huCART19 as split-dose infusions after lymphodepleting chemotherapy with cyclophosphamide + fludarabine in patients who have relapsed/refractory myeloma after two prior regimens but who are responding to their current therapy.
2856977|NCT03549442|Experimental|Phase B|Randomization Phase in which patients responding to first or second-line therapy will receive either CART-BCMA alone (Cohort 1) or CART-BCMA + huCART19 (Cohort 2) as split-doses after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
2856978|NCT03549442|Experimental|Phase C|Single-dose infusion phase to test the safety of single-dose infusion of CART-BCMA alone (Cohort 1) and CART-BCMA + huCART19 (Cohort 2) as single-dose infusions after lymphodepleting chemotherapy with cyclophosphamide + fludarabine in patients responding to first- or second-line therapy.
2856979|NCT03549429|Experimental|TegadermTM on R eye, EyeGard® on L eye|
2856981|NCT03549403|Experimental|Patient-centered telephone education|Patients receive the preoperative call home one week before the day surgery and postoperatively 3-8 days after the day surgery. On the day of surgery patients receive current education.
2856982|NCT03549403|No Intervention|Current education practice|Patient´s education is implemented in accordance with current practice, where day surgery adult patients receive preoperative education over the phone one week prior to day surgery and postoperative education during on the day of surgery.
2856983|NCT03549390|Experimental|Yoga|The yoga session will be held in a room where lighting, temperature and music can be regulated. The session will be led by a trained instructor and involve a combination of body postures, breathing techniques and meditation. There will be a series of progressive breath centred yoga poses named Sun Salutations A & B for participants to complete, which have been chosen based on PPI and current relevant yoga practices. Sun Salutations A & B will be completed in a continuous sequence and aim to be completed with one breath per pose, but can be modified based on participant ability.
2856984|NCT03549390|Experimental|Continuous exercise|The exercise will be 30 minutes of treadmill walking. During the initial stages of walking, participants will gradually be taken up to a speed that registers between 10 and 12 on the Borg Rating of Perceived Exertion (RPE) Scale, up to a maximum of 4.0 km/h. This speed will be fixed for the entire exercise period. This exercise intensity has been chosen as it is the exercise intensity matched to light-moderate physical activity.
2856985|NCT03549390|No Intervention|Control|Participants will remain sitting throughout the test period whilst undertaking typical sedentary behaviours such as watching TV, using a computer, reading and writing. Walking and standing will be restricted.
2856986|NCT03549377||Rested|Based on Pittsburgh Sleep Quality Index, participants scoring in the top 10-20% will be assigned to the rested group and will experience deception as part of the delayed gratification task
2856987|NCT03549377||Sleep-deprived|Based on Pittsburgh Sleep Quality Index, participants scoring in the bottom 10-20% will be assigned to the sleep-deprived group and will experience deception as part of the delayed gratification task
2856988|NCT03549364|Experimental|Endurance race|"baseline investigations with CT and lab tests~the same CT and lab tests < 24h after an endurance race~CT and lab tests again about 1-2weeks after the race"
2856989|NCT03549338|Experimental|Arm A (Sym004)|Sym004 will be administered as a loading dose of 9 mg/kg on Cycle 1/Day 1 (C1D1), followed by weekly doses of 6 mg/kg beginning C1D8.
2856990|NCT03549338|Experimental|Arm B (Futuximab)|"Futuximab will be administered as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8.~At the End of Cycle 2 (EOC2), ongoing patients from Arm B will be crossed-over from futuximab to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of progressive disease (PD).~Upon crossover, Sym004 will be administered at the dose level that contains the corresponding dose level of the individual antibody futuximab as was previously being administered (prior to crossover)."
2856991|NCT03549338|Experimental|Arm C (Modotuximab)|"Modotuximab will be administered as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8.~At the EOC2, ongoing patients from Arm C will be crossed-over from modotuximab to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of PD.~Upon crossover, Sym004 will be administered at the dose level that contains the corresponding dose level of the individual antibody modotuximab as was previously being administered (prior to crossover)."
2856992|NCT03549325|Experimental|Group 1|"Nasal drops containing Neisseria lactamica are administered at Day 0 by the study doctor.~Eradication therapy with the antibiotic Ciprofloxacin given on Day 4, unless required sooner.~Follow up visits occur on Days 5, 14 and 32."
2856993|NCT03549325|Experimental|Group 2|"Nasal drops containing Neisseria lactamica are administered at Day 0 by the study doctor.~Follow up visits on Day 4 and 7 to check for N. lactamica carriage. Eradication therapy with the antibiotic Ciprofloxacin given on Day 14, unless required sooner.~Follow up visits occur on Days 15, 24 and 42."
2856994|NCT03549312|Experimental|Switch to Genvoya Followed By HCV Therapy With Epclusa|Oral Genvoya 150/150/200/10 mg & Epclusa 400/100 mg once daily
2856995|NCT03549299|Experimental|LSC2; 7.5 x 10^4 cells|Single dose of LSC2, 7.5 x 10^4 cells per patient
2856996|NCT03549299|Experimental|LSC2; 3.0 x 10^5 cells|Single dose of LSC2, 3.0 x 10^5 cells per patient
2856997|NCT03549299|Experimental|LSC2; 8.0 x 10^5 cells|Single dose of LSC2, 8.0 x 10^5 cells per patient
2856998|NCT03549299|Experimental|LSC2; 1.2 x 10^6 cells|Single dose of LSC2, 1.2 x 10^6 cells per patient
2856999|NCT03549286||pregnant women in the first trimester ultrasound consultation|Participation in the study will be offered to all pregnant patients, presenting for their first trimester ultrasound consultation in the obstetrics and gynecology department of the University Hospital of Reims. The study includes the consultations of all the certified doctors of the Maternity Department of the Reims University Hospital carrying out the first trimester ultrasounds. It will concern all the ranges of consultation regardless of the doctor who performs the consultation.
2857000|NCT03549273|Experimental|Treatment|Glizigen® spray + Ocoxin-Visuid® oral solution
2857001|NCT03549260|Experimental|LIB003 150 mg or matching placebo|SC LIB003 150 mg or placebo every 4 weeks
2857002|NCT03549260|Experimental|LIB003 300 mg or matching placebo|SC LIB003 300 mg or placebo every 4 weeks
2857003|NCT03549260|Experimental|LIB003 350 mg or matching placebo|SC LIB003 350 mg or placebo every 4 weeks
2857004|NCT03549247||quality of life in periodontal healthy|250 individuals who have teeth pocket depth is at most 3 mm and there is no loss of attachment, no radiological bone loss and no gingival inflammation determeined for their quality of life
2857005|NCT03549247||quality of life in gingivitis|250 individuals who have teeth pocket depth in the mouth is at most 3 mm and there is no loss of attachment, no radiological bone loss and have chronic gingival inflammation with the sign of bleeding determeined for their quality of life
2857006|NCT03549247||quality of life in periodontitis|250 individuals who have more than 30% of teeth in the mouth which have pocket depths equal or more than 4mm and clinical attachment levels equal or more than 5mm and have radiologically detected bone loss determeined for their quality of life
2857007|NCT03549234|Experimental|Erector Spinae (single injection)|
2857008|NCT03549234|Active Comparator|Paravertebral (single injection)|
2857134|NCT03548363|Placebo Comparator|Placebo|200 mg/d maltodextrin for 4-weeks
2860811|NCT03522896|Experimental|test meal 1|orange juice with added hesperidin (low dose)
2857009|NCT03549221|Experimental|MAC with adrenaline|the multimodal anesthetic cocktail (MAC) consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). They were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
2857010|NCT03549221|No Intervention|MAC without adrenaline|the multimodal anesthetic cocktail (MAC) consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). They were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
2857011|NCT03549208|Experimental|LBVE01|Multivalent pneumococcal conjugate vaccine
2857012|NCT03549208|Experimental|LBVE02|Multivalent pneumococcal conjugate vaccine
2857013|NCT03549208|Active Comparator|Prevnar13|Multivalent pneumococcal conjugate vaccine Prevnar13
2857014|NCT03549195|Active Comparator|ICG|
2857015|NCT03549195|Active Comparator|ICG-CP|CP, control peptide
2857016|NCT03549195|Experimental|ICG-TMTP1|also named as TMTP1-ICG
2857017|NCT03549182|Experimental|male TPH2-GG carriers with ATD then placebo group|male TPH2-GG carriers will first receive ATD, then will receive placebo at least 5 weeks later.
2857018|NCT03549182|Experimental|male TPH2-GG carriers with placebo then ATD group|male TPH2-GG carriers will first receive placebo, then will receive ATD at least 5 weeks later.
2857019|NCT03549182|Experimental|male TPH2-TTcarriers with ATD then placebo group|male TPH2-TT carriers will first receive ATD, then will receive placebo at least 5 weeks later.
2857020|NCT03549182|Experimental|male TPH2-TTcarriers with placebo then ATD group|male TPH2-TT carriers will first receive placebo,then will receive ATD at least 5 weeks later.
2857021|NCT03549169|Experimental|TOMAS|Intervention centered on taking decisions for management of symptoms in adults with Heart Failure. Includes 3 doses (self-care maintenance, symptom perception and symptom management) and 4 strategies are developed: knowledge of the situation, experience and abilities in decision taking and compatibility with personal values.
2857022|NCT03549169|Other|Standard or regular attention|Regular attention is centered on education for therapeutic adherence
2857023|NCT03549156|Active Comparator|C-RUSF|Control/Standard RUSF
2857024|NCT03549156|Active Comparator|HIPRO RUSF|New RUSF product
2857025|NCT03549130|Experimental|Active nasal strip group|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
2857026|NCT03549130|Placebo Comparator|Placebo nasal strip group|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
2857027|NCT03549117|Experimental|Active nasal strip group|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
2857028|NCT03549117|Placebo Comparator|Placebo nasal strip group|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH nasal strips placebo nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
2857029|NCT03549104|Experimental|Fear Reduction Efficacy Evaluation (FREE)|The FREE intervention group will participate in eight weekly individual one-hour sessions using CBT and exposure treatment for specific fears.
2857030|NCT03549104|Active Comparator|Attention Control|The attention control group will participate in eight weekly individual one-hour Diabetes Self-Management Education (DSME) sessions.
2857031|NCT03549091|Experimental|Transthoracic echocardiography and MRI|The TransThoracic Echocardiography imaging data are collected exactly as for a standard examination. However, an additional measurement of the flow at the level of the left subclavian artery is performed, resulting in a 10-minute increase in the examination time. A Cardiovascular Magnetic Resonance Imaging 4D Flow is programmed within a maximum of 10 (no change in treatment that could skew the comparison). The usual procedure for MRI is not modified. The examination allows the acquisition of conventional 2D sequences of flow measurements, regurgitant volume and regurgitation fraction obtained at the level of the descending aorta and the sino-tubular junction of the ascending aorta. An additional 4D sequence is acquired increasing the examination time by 10 minutes.
2857032|NCT03549078|Experimental|Intervention|Participants will complete an initial assessment within 2 weeks prior to starting the course or during the first class. The course will include 10 sessions conducted on a weekly basis. Following completion of the course, participants will again complete another assessment during the last class or within 2 weeks of course completion. Participants may be invited to complete assessments at 3- and 6-months following course completion.
2857033|NCT03549065|Active Comparator|20 min active tDCS, and 20 min active rTMS|Applying active tDCS AND active TMS will reduce cue induced craving and opioid use, more than sham TMS AND sham tDCS and also either active TMS OR active tDCS alone. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of 20 minutes active tDCS (anode on F3 EEG positioning and cathode on contra shoulder), followed by 4000 pulses of real rTMS (10Hz over left Dorsolateral Prefrontal Cortex(DLPFC) for 20 minutes at 120%MT). There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS and the groups with only active tDCS OR active TMS.
2857034|NCT03549065|Active Comparator|20 min sham tDCS, and 20 min active rTMS|Applying sham tDCS AND active TMS will reduce cue induced craving and opioid use, more than will sham TMS AND sham tDCS. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes sham tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of real rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
2857035|NCT03549065|Active Comparator|20 min active tDCS, and 20 min sham rTMS|Applying active tDCS AND sham TMS will reduce cue induced craving and opioid use, more than will sham TMS AND sham tDCS. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes active tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of sham rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
2857036|NCT03549065|Sham Comparator|20 min sham tDCS, and 20 min sham rTMS|Applying sham tDCS AND sham TMS will not reduce cue induced craving and opioid use. We will apply 10 sessions of one hour of brain stimulation. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes sham tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of sham rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
2857037|NCT03549026|Experimental|duloxitine group|Patients will receive single oral dose of duloxetine capsule, 60 mg, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
2857038|NCT03549026|Placebo Comparator|placebo group|Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
2857039|NCT03549000|Experimental|NZV930 Monotherapy|Single Agent NZV930
2857040|NCT03549000|Experimental|NZV930 with PDR001 Doublet Therapy|Combination of NZV930 with PDR001
2857041|NCT03549000|Experimental|NZV930 with NIR178 Doublet Therapy|Combination of NZV930 with NIR178
2857042|NCT03549000|Experimental|NZV930 with NIR178 & PDR001 Triplet Therapy|Combination of NZV930 with NIR178 and PDR001
2857043|NCT03548987|Experimental|Semaglutide|"Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.~Maintenance period: Participants will be randomized to receive semaglutide injection for 48 weeks (from week 20 to week 68).~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period."
2857044|NCT03548987|Placebo Comparator|Placebo|"Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.~Maintenance period: Participants will be randomized to receive semaglutide placebo injection for 48 weeks (from week 20 to week 68).~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period."
2857045|NCT03548974|Active Comparator|Interventiongroup1|passive, motor-driven movement therapy followed by intermittent active and passive training
2857046|NCT03548974|Active Comparator|Interventiongroup2|intermittent active and passive training followed by no intervention
2857047|NCT03548961|Experimental|Neoadjuvant chemotherapy|
2857048|NCT03548948|Other|High heme iron diet|
2857049|NCT03548948|Other|Low iron diet|
2857050|NCT03548948|Other|Plant-based high non-heme iron diet|
2857051|NCT03548935|Experimental|Semaglutide s.c. 2.4 mg once weekly|Participants will receive semaglutide for 68 weeks.
2857052|NCT03548935|Placebo Comparator|Semaglutide placebo|Participants will receive semaglutide matching placebo for 68 weeks.
2857053|NCT03548922||Pectus carinatum|Demographic data (age, sex), pressure of correction, Tanner stage, Risser stage, Haller index, pectus carinatum protrusion measurements of patients with pectus carinatum will be recorded and association of them with pressure of correction will be investigated.
2857054|NCT03548909||ED Setting|An acute HF population enrolled at EDs. Testing of clinical samples will be performed with the VITROS Immunodiagnostic Products NT-proBNP II assay.
2857055|NCT03548909||Outpatient Setting|A non-acute population enrolled at outpatient centers.Testing of clinical samples will be performed with the VITROS Immunodiagnostic Products NT-proBNP II assay.
2857056|NCT03548896|Experimental|Dental Implants|Dental implants Titanium SLA treated surface of different dimensions according to the specific needs of the patient
2857057|NCT03548896|Experimental|Resorbable membrane|Resorbable membrane Cross link collagen membrane from porcine animal with a measure of 15 x 25 mm
2857058|NCT03548896|Experimental|Allograft|Allograft Bone from human source that is administered in a dosage of 1 cc per patient
2857059|NCT03548883||Alzheimer subject Group|In phase I, up 50 AD patients will be recruited and screened until we obtain 6 AD subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of standard of care (SOC) medical history, labs, imaging, and cognitive assessment. Recruited subjects will be scheduled for Study Visit #1 (@TRI) and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to rule out other causes of cognitive decline.
2857060|NCT03548883||Control Group|In phase II, up to 50 age, sex, race ethnicity, group matched healthy controls will be recruited and screened until we have 6 healthy control subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of medical history (including a review of past images, current medication and labs if available). Recruited subjects will be scheduled for Study Visit #1 and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to confirm that there are no undiagnosed conditions.
2857165|NCT03548155|Placebo Comparator|control group|
2857283|NCT03547479|Experimental|VDOT + mobile money incentives|Participants receive daily DOTS treatment with video-enabled mobile monitoring supplemented with mobile money incentives, but also maintain regular supervisory checks
2857061|NCT03548883||Type 2 diabetes group|In phase III, up to 50 age, sex, race ethnicity, group matched T2D patients will be recruited and screened until we have 6 T2D subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of medical history (including a review of past images, current medication and labs if available). Recruited subjects will be scheduled for Study Visit #1 and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to confirm that there are no undiagnosed conditions.
2857062|NCT03548870|Experimental|Test with TENS|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with low frequency TENS
2857063|NCT03548870|Sham Comparator|Test with sham-TENS|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with low frequency sham-TENS
2857064|NCT03548857||COPD patients|COPD patients on the waiting list for a lung transplantation
2857065|NCT03548844|Experimental|local excision group|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group)
2857066|NCT03548844|Active Comparator|total mesorectal excision group|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (local excision group)
2857067|NCT03548831||MLH|Minilaparotomy Hysterectomy
2857068|NCT03548831||LAVH|Laparoscopic Assisted Vaginal Hysterectomy
2857069|NCT03548805|Experimental|Trabeculectomy with Ologen|ologen® Collagen Matrix
2857070|NCT03548805|Active Comparator|Trabeculectomy with low dose mitomycin C|Trabeculectomy with low dose MMC (0.02%)
2857071|NCT03548792|Other|RSA radiostereometric analysis|30 patients in each Group Persona or Nexgen will receive tantalus beads to achieve RSA analysis comparing micromevements in radiographs.
2857072|NCT03548792|Other|Clinical comparison|Clinical comarison using different patient reported outcome measures and objective measures (ActivePAL, walking speed)
2857073|NCT03548779|Experimental|Pre-visit prep / usual care + exome seq|"Participants randomized to pre-visit prep will receive a study packet with educational materials and a question prompt list. These participants will be instructed to review the materials, discuss them with family members if desired, use the question prompt list to select questions they would like to ask at clinic visit 1, and bring the list to their clinic visit 1 appointment.~Participants will receive usual care and will be offered research exome sequencing."
2857074|NCT03548779|Experimental|Pre-visit prep / usual care|"Participants randomized to pre-visit prep will receive a study packet with educational materials and a question prompt list. These participants will be instructed to review the materials, discuss them with family members if desired, use the question prompt list to select questions they would like to ask at clinic visit 1, and bring the list to their clinic visit 1 appointment.~Participants will receive usual care."
2857075|NCT03548779|Experimental|No prep / usual care + exome seq|"Participants in the no pre-visit preparation arm will receive a mailed card reminding them about their upcoming clinic visit.~Participants will receive usual care and will be offered research exome sequencing."
2857076|NCT03548779|No Intervention|No prep / usual care|"Participants in the no pre-visit preparation arm will receive a mailed card reminding them about their upcoming clinic visit.~Participants will receive usual care."
2857077|NCT03548766|Experimental|Healthy Subjects|Six healthy subjects will receive an ABT (Autologous Blood Transfusion)
2857078|NCT03548766|Experimental|Anemic Patients|Six patients with anemia will receive a HBT (Homologous Blood Transfusion)
2857079|NCT03548753||Patients with Agatston score > 399|"Coronary computed tomography angiography with FFR-CT~Invasive coronary angiography with FFR"
2857080|NCT03548740||Group A|
2857081|NCT03548740||Group B|
2857082|NCT03548727|Experimental|Repeatability of FLT kinetics|Radiotracer: 18F-FLT Dose: 10 mCi Frequency: Two baseline PET/CT at baseline up to 3 days apart.
2857083|NCT03548727|Experimental|Pseudo-Simultaneous FMISO/FLT PET/CT Imaging|Radiotracer: 18F-FLT and 18F-FLT Dose and Frequency: 8 mCi 18F-FLT and 8 mCi 18F-FLT on Day1, the 8mCi 18F-FLT on Day2
2857084|NCT03548714|Experimental|PT150 with alcohol consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times.
2857085|NCT03548714|Placebo Comparator|PT150 with placebo consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times.
2857086|NCT03548701||Emergency Department|Patients enrolled in the Emergency Department undergoing evaluation for threatened abortion abnormalities.
2857087|NCT03548701||Obstetric Clinic|Patients with normal pregnancies being treated at first obstetric visit in clinic.
2857088|NCT03548675|Experimental|Genotype-guided TCA treatment|Genotype guided dosing of the TCAs in patients with a PM,IM or UM phenotype based on pharmacogenetic test.
2857089|NCT03548675|Active Comparator|Standard TCA treatment (PM,IM or UM)|Standard dosing of TCA in patients with a PM,IM or UM phenotype based on pharmacogenetic test
2857090|NCT03548675|Active Comparator|Standard TCA treatment (EM)|Standard dosing of TCA in patients with EM phenotype based on pharmacogenetic test
2857091|NCT03548662|Experimental|Platelet-Rich Plasma Protein (PRP) Group|Subjects in this group will receive PRP injection into tear site, followed by rehabilitative exercise
2857092|NCT03548662|Active Comparator|Hyaluronic Acid Group|Subjects in this group will receive one injection with hyaluronic acid followed by rehabilitative exercise
2857093|NCT03548649|Experimental|exoskeleton robot training group|subjects will receive exoskeleton robot training for 20 sessions (1 hr/session).
2857094|NCT03548636|Experimental|Single-Arm Feasibility Study|Participant determined 6-month physical activity program
2857130|NCT03548389|No Intervention|Conventional care|In the routine care group, the infant was delivered from the mother by a midwife, wrapped in blankets, taken to be routinely cared under a warmer, and then dried quickly. Afterwards, the Apgar score was determined immediately after the umbilical cord was cut. The infants were provided with all routine care by the midwife working in the delivery room. After the infants were weighed, dressed, and measured, they were handed to their mothers who were encouraged to begin breastfeeding.
2857095|NCT03548610|Experimental|Nanofat-seeded biological scaffold on surgical defect|Nanofat is obtained via lipoaspiration of 10cc of fat from abdomen under moderate local tumescent anesthesia w/ saline. Cannula access point is anesthetized by local lidocaine infiltration. Lipoaspirate is processed into nanofat using the Tonnard method, after 3-minute decantation. Aspiration is performed using a multihole 3mm cannula. Wound margin + bed is treated w/ topical & local injections of nanofat, then covered w/ a biological scaffold, the inferior surface of which is soaked in nanofat; scaffold is fixed w/ external dressings or resorbable sutures; external covering includes polyurethane film & 3 layers of dressings. Topical application creates a fine <1mm nanofat layer. Scaffold (Puracol Plus) is left in place to integrate w/ surrounding skin, while external dressings changed at 7 & 15 days. Lipoaspirate donor site needs mild to moderate compression for 24 hours & suture removal (if not absorbed) at 7 days.
2857096|NCT03548610|No Intervention|Standard of Care dressings|Immediately after surgical resection, each patient will be treated following the SOC, therefore with a local skin flap, rather than with a skin graft, based on surgeon assessment. Sutures, and moulage, if present, will be removed at 7 days and patient instructed to apply a daily silicone cream and sunscreen for 2 months.
2857097|NCT03548584|Experimental|Low Dose Brexpiprazole Arm|Tablet
2857098|NCT03548584|Experimental|High Dose Brexpiprazole Arm|Tablet
2857099|NCT03548584|Placebo Comparator|Placebo|Tablet
2857100|NCT03548571|Experimental|DC immunization|Leukapheresis before start of radiotherapy. Immunization with DCs starting first week after finalizing radiotherapy (2Gy x 30) and concomitant temozolomide.
2857101|NCT03548571|Active Comparator|Standard therapy|Radiotherapy (2 Gy x30) with concomitant and adjuvant temozolomide.
2857102|NCT03548558|Experimental|"Arm 1 (group sessions)"|Group meetings only
2857103|NCT03548558|Experimental|"Arm 2 (group+home sessions)"|Group meetings with a limited number of individual home visits and booster sessions
2857104|NCT03548558|No Intervention|Arm 3|This arm will serve as the control group to identify the effects of a parenting intervention and the most effective mode of delivery, as well as the sustained impacts from the intervention
2857105|NCT03548558|Experimental|Arm B (Father villages)|In one half of Arm 1 and Arm 2 villages above, fathers will be invited to attend the ECD sessions along with mothers.
2857106|NCT03548558|Other|Arm A (Mother-only villages)|In the other half of Arm 1 and Arm 2 villages, only mothers will be invited.
2857107|NCT03548545|Experimental|CBT combined with active tDCS|Subjects allocated to this arm will receive cognitive-behavior therapy combined with active tDCS over the dorsolateral prefrontal cortex.
2857108|NCT03548545|Sham Comparator|CBT combined with sham tDCS|Subjects allocated to this arm will receive cognitive-behavior therapy combined with sham tDCS over the dorsolateral prefrontal cortex.
2857109|NCT03548532|Active Comparator|36.6°C|Embryos of these patients will be cultured at 36.6°C from day 0 after ICSI, untill day 6.
2857110|NCT03548532|Experimental|37.1°C|Embryos of these patients will be cultured at 37.1°C from day 0 after ICSI, untill day 6.
2857111|NCT03548519|Experimental|Attention Training|MCAT-only: An attention training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. The training task is a positively directed Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
2857112|NCT03548519|Active Comparator|Active placebo training|MCAT-sham: An active placebo training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. The training task is an undirected Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
2857113|NCT03548519|Experimental|PSE and Attention Training|MCAT-combo: An online PSE session prior to an attention training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. Content of the PSE will focus on how adaptive functions of automatic and controlled processes may become maladaptive when used inappropriately or excessively. The training task is a positively directed Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
2857114|NCT03548506|Active Comparator|STN_O|Omnidirectional Deep Brain Stimulation of STN
2857115|NCT03548506|Experimental|STN_D|Directional Deep Brain Stimulation of STN
2857116|NCT03548493|Experimental|Magnesium (M) group|Magnesium (M) group (n=15) , in which magnesium sulphate is given as adjuvant to propofol for sedation
2857117|NCT03548493|Active Comparator|Fentanyl (F) group|Fentanyl (F) group (n=15), in which fentanyl is given as adjuvant to propofol for sedation
2857118|NCT03548480|Placebo Comparator|Placebo|
2857119|NCT03548480|Experimental|Probiotic|
2857120|NCT03548467|Experimental|Open-Label|Treatment with individualized VB10.NEO immunotherapy will commence as soon as the patient-specific VB10.NEO vaccine is available and if the patient-specific vaccine meets all pre-specified product release criteria after manufacturing. The vaccinations will be given as intramuscular injection by the study personnel at the study centres.
2857121|NCT03548454|Experimental|Duloxetine|Duloxetine starting at 20 mg per day and increasing to 60 mg per day as tolerated.
2857122|NCT03548454|Experimental|Desipramine|Desipramine starting at 25 mg per day and increasing to 75 mg per day as tolerated.
2857123|NCT03548441||Surgery|Exposed
2857124|NCT03548441||Non-surgical management|Non-exposed
2857125|NCT03548428|Experimental|A|SBRT + Atezolizumab
2857126|NCT03548428|Active Comparator|B|SBRT
2857127|NCT03548415|Experimental|IONIS-GHR-LRx|Single Dose of IONIS GHR-LRx administered subcutaneously once every 4 weeks for 16 weeks
2857128|NCT03548415|Placebo Comparator|Placebo|Placebo (sterile saline 0.9%) Calculated volume to match active comparator administered subcutaneously every 4 weeks for 16 weeks
2857129|NCT03548389|Experimental|Mother and newborn skin to skin contact|By assistance of the researcher, intervention infants were placed undressed in a prone position against their mothers' bare chest between breasts immediately after birth and before placental delivery and suturing of tears or episiotomy. The Apgar score was determined, the infant's nose and mouth were suctioned while on the mother's chest, it was well dried, and both mother and infant were covered with a pre-warmed blanket. To prevent heat loss, the infant's head was covered with a dry cap that was replaced when it became damp. Dressing and measuring of the infant were postponed to an hour after the delivery by registered midwife.
2857131|NCT03548376|Experimental|One-group intervention|Hippotherapy sessions were delivered once a week for 30 minutes, during 6 months.
2857135|NCT03548350|Experimental|Intervention|"The experimental group will participate in a 24 week multi-component programme that includes four strands:~A physical literacy programme focusing on core elements of strength, agility, speed, balance and flexibility. Delivered by external facilitators for one hour per week over 16 weeks of the programme (2 x8week blocks).~'Golden Mile' - pupils and teachers participate 15min walk/run a min of 2 times per week~After schools club (not compulsory) featuring mind-set component delivered by external facilitators~Healthy kidz app with reward system"
2857136|NCT03548350|No Intervention|Control|The control group will continue doing physical activity including physical education as is normal for their school
2857137|NCT03548337|Active Comparator|13vPnC with 2-PE from a MDV|Multi Dose Vial with preservative
2857138|NCT03548337|Active Comparator|13vPnC without 2-PE in a PFS|Pre Filled Syringe without preservative
2857139|NCT03548324|Active Comparator|HHHFNC|Heated Humidified High Flow Nasal Cannulae
2857140|NCT03548324|Active Comparator|NCPAP|Nasal Continuous Positive Air Pressure
2857141|NCT03548311|Placebo Comparator|Placebo|intramuscular injection of saline solution
2857142|NCT03548311|Active Comparator|methylcobalamin|intramuscular injection of methylcobalamin
2857143|NCT03548298|Experimental|GERD without hiatal hernia|Participants with GERD without hernia hiatal will receive ARAT
2857144|NCT03548285|Experimental|patient with low risk|"Low-risk is defined by:~Planning target volume (PTV) less than 10 cc, AND~No reported smoking within 1 month from registration~Radiation Therapy will be delivered twice per week for 5 fractions (total 42.5 Gy)"
2857145|NCT03548285|Experimental|patient with moderate risk|"Moderate-risk is defined by:~Planning target volume (PTV) greater than or equal to 10 cc, OR~Smoking within 1 month from registration (no more than 1 pack per day)~Radiation Therapy will be delivered daily for 16 fraction (total 58.08 Gy)"
2857146|NCT03548272|Experimental|BiOSS LIM C|"Intervention: Percutaneous coronary intervention (PCI) with BiOSS LIM C stent implantation.~The BiOSS LIM C® is a dedicated bifurcation balloon expandable stent made of cobalt-chromium alloy (strut thickness 70 µm) releasing sirolimus (1.4 µg/mm2) from the surface of a biodegradable coating comprised of a copolymer of lactic and glycolic acids (PGLA). The degradation of the polymer lasts approximately 8 weeks. The BiOSS LIM C® stent consists of two main separate parts with different diameters: wider proximally, and distally smaller. The proximal part is always a bit shorter than the distal one (avg. 1 mm)."
2857147|NCT03548272|Active Comparator|regular 2nd generation DES|"Intervention: Percutaneous coronary intervention (PCI) with regular drug-eluting stent implantation (rDES).~rDES well-tested and available on the market. Xience, Orsiro, Resulte Integrity"
2857148|NCT03548259|Experimental|Experimental|Platelet-rich plasma
2857149|NCT03548259|Placebo Comparator|Platelet-poor plasma|Platelet-poor plasma
2857150|NCT03548246|Placebo Comparator|Placebo|Daily placebo, plus usual maintenance treatment with hydrocortisone and fludrocortisone.
2857151|NCT03548246|Experimental|Abiraterone acetate|Abiraterone acetate administered daily in dose determined in Phase 1, plus usual maintenance treatment with hydrocortisone and fludrocortisone..
2857152|NCT03548233|Other|bcg vaccinated|children under five year vaccinated by bcg vaccine
2857153|NCT03548220|Experimental|AG-348|"Part 1 (Dose Optimization Period): Participants will receive AG-348 for 12 weeks. Investigators will assess the need for dose increases every 4 weeks.~Part 2 (Fixed Dose Period): Participants will receive their optimized dose of AG-348 as determined by the individual's response in Part 1."
2857154|NCT03548220|Placebo Comparator|Placebo|"Part 1 (Dose Optimization Period): Participants will receive placebo matching AG-348 for 12 weeks. Investigators will assess the need for dose increases every 4 weeks.~Part 2 (Fixed Dose Period): Participants will receive their optimized dose of placebo matching AG-348 as determined by the individual's response in Part 1."
2857155|NCT03548207|Experimental|JNJ-68284528|After lymphodepletion JNJ-68284528 will be administered as a single infusion.
2857156|NCT03548194|Experimental|BNC210|Administered orally b.i.d. for 5 days.
2857157|NCT03548194|Placebo Comparator|Placebo|Administered orally b.i.d. for 5 days.
2857158|NCT03548181|Experimental|"Intervention group tele-rehabilitation"|"Each patient will have the opportunity to have minimum one Video Consultation (VC) per week the first month, one VC each second week the second month one VC a month the rest of the trial.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Instead of ergometer bike training, the patient will receive some easy training tools such as elastics, weights and a fitness-step that can be used in the different exercises showed by the VPA to reach the same intensity of workout. The VPA will then be animated to motivate and encourage the patient to exercises at home. A digital diary will automatically register the data obtained by the system on patient's performance."
2857159|NCT03548181|Active Comparator|Control|Patients will be followed, but they do not get any other kind of treatment comparable to the intervention group treatment.
2857160|NCT03548168||Healthy Adults|Eligible healthy young adults, aged 18-30 years, will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
2857161|NCT03548168||Low Back Pain|Eligible young adults, aged 18-30 years, with chronic low back pain will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
2857162|NCT03548168||Older Adults|Eligible healthy middle aged and older adults, aged 55 years and older, will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
2857163|NCT03548168||Trunk Experts|Eligible healthy middle aged and older adults, aged 55 years and older, with high levels of trunk muscle control (ie. individuals with expertise in the Pilates Method of exercise) will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
2857164|NCT03548155|Experimental|berberine group|
2857166|NCT03548129|Active Comparator|Fosfomycin group (FG)|"Pre-treatment Urine culture will be done then all patients will receive empirical 3 gm oral phosphomycin fosfomycin will be taken by mouth on an empty stomach i.e. 2-3 hours after meals preferably in the evening before bed time after emptying the bladder.~The contents of 1 packet of Monuril will be dissolved in a glass of water or another non-alcoholic drink and drink immediately. Do not mix with hot water. Do not take fosfomycin in its dry form.~Response to treatment will be assessed by post-treatment urine culture."
2857167|NCT03548129|Active Comparator|Culture specific group (CG):|"Pre-treatment Urine culture and antimicrobial sensitivity testing will be done then all patients will receive oral culture specific antibiotic therapy in the form of five days regimen.~Response to treatment will be assessed by post-treatment urine culture."
2857168|NCT03548116|Sham Comparator|Group 1|Individuals will receive sham non-imaging mode ultrasound (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
2857169|NCT03548116|Experimental|Group 2|Individuals will receive half-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
2857170|NCT03548116|Experimental|Group 3|Individuals will receive full-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
2857171|NCT03548116|Sham Comparator|Group 4|Individuals will receive sham non-imaging mode ultrasound (control group) delivered to the lower, middle, and upper spleen based on the spleen's size.
2857172|NCT03548116|Experimental|Group 5|Individuals will receive half-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
2857173|NCT03548116|Experimental|Group 6|Individuals will receive full-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
2857174|NCT03548103|Experimental|Green Tea Extract|Green Tea Extract 500 mg per capsule
2857175|NCT03548103|Placebo Comparator|Placebo|Identical Placebo capsule
2857176|NCT03548090|Experimental|1|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (control 4-week exercise intervention)
2857177|NCT03548090|Experimental|2|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (control 4-week exercise intervention)
2857178|NCT03548090|Experimental|3|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (control 4-week exercise intervention)
2857179|NCT03548090|Experimental|4|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (control 4-week exercise intervention)
2857180|NCT03548090|Experimental|5|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (control 4-week exercise intervention)
2857181|NCT03548090|Experimental|6|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (control 4-week exercise intervention)
2857182|NCT03548090|Experimental|7|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (control 4-week exercise intervention)
2857183|NCT03548090|Experimental|8|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (control 4-week exercise intervention)
2857184|NCT03548090|Experimental|9|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (control 4-week exercise intervention)
2857185|NCT03548090|Experimental|10|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (control 4-week exercise intervention)
2857186|NCT03548090|Experimental|11|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (control 4-week exercise intervention)
2857187|NCT03548090|Experimental|12|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (control 4-week exercise intervention)
2857188|NCT03548090|Experimental|13|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (experimental 4-week exercise intervention)
2857189|NCT03548090|Experimental|14|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (experimental 4-week exercise intervention)
2857190|NCT03548090|Experimental|15|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (experimental 4-week exercise intervention)
2857191|NCT03548090|Experimental|16|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (experimental 4-week exercise intervention)
2857192|NCT03548090|Experimental|17|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (experimental 4-week exercise intervention)
2857193|NCT03548090|Experimental|18|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (experimental 4-week exercise intervention)
2857194|NCT03548090|Experimental|19|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (experimental 4-week exercise intervention)
2857195|NCT03548090|Experimental|20|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (experimental 4-week exercise intervention)
2857196|NCT03548090|Experimental|21|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (experimental 4-week exercise intervention)
2857197|NCT03548090|Experimental|22|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (experimental 4-week exercise intervention)
2857198|NCT03548090|Experimental|23|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (experimental 4-week exercise intervention)
2857199|NCT03548090|Experimental|24|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (experimental 4-week exercise intervention)
2857200|NCT03548064|Experimental|Regimen A|5 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
2857201|NCT03548064|Experimental|Regimen B|25 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
2857202|NCT03548064|Experimental|Regimen C|5 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
2857203|NCT03548064|Experimental|Regimen D|25 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
2857204|NCT03548064|Experimental|Regimen E|0.3 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
2857205|NCT03548064|Experimental|Regimen F|1.0 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
2857206|NCT03548064|Experimental|Regimen G|50 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
2857207|NCT03548064|Experimental|Regimen H|50 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
2857208|NCT03548064|Experimental|Regimen I|2.0 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
2857209|NCT03548051|Experimental|FMT group|100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1, n=108
2857210|NCT03548051|Experimental|Placebo group|250 ml of saline delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1; if no improvement followed by FMT (100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1) x 2, n=54
2857211|NCT03548038||Bariatric surgery patients|All subjects will be patients scheduled for bariatric surgery. There is only one arm in this study.
2857212|NCT03548025|Experimental|Treatment Group|Treated group of subjects, serves as its own control
2857213|NCT03548012|Experimental|The Carer Support Needs Assessment Tool (CSNAT) intervention|('Standard' basic palliative care +) The Carer Support Needs Assessment Tool (CSNAT) intervention.
2857214|NCT03548012|No Intervention|Control|('Standard' basic palliative care). No intervention offered.
2857215|NCT03547999|Active Comparator|Arm A - Control|mFOLFOX6 and Nivolumab every 2 weeks for 4 cycles. After neoadjuvant therapy, patients will be re-evaluated for surgical resection. Patients still considered resectable will undergo surgical resection with the goal of completely treating all of their disease by either resection and/or ablation. Patients with bilobar disease must have all of their disease treated in a single operation. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6 in addition to Nivolumab. After this, Nivolumab will be given every 4 weeks completing therapy at week 110.
2857216|NCT03547999|Experimental|Arm B - Experimental|Two doses of Nivolumab and MVA-BN-CV301 each given 2 weeks apart (Days -28, -14), followed by four doses of Nivolumab plus FPV-CV301 given 2 weeks apart concurrently with mFOLFOX6, which will again be administered every 2 weeks for 4 cycles (Nivolumab, FPV-CV301 and mFOLFOX6). After neoadjuvant therapy, patients will be re-evaluated for surgical resection. Patients still considered resectable will undergo surgical resection with the goal of completely treating all of their disease by either resection and/or ablation. Patients with bilobar disease must have all of their disease treated in a single operation. Patients in the experimental arm will receive 8 cycles of mFOLFOX6 in addition to Nivolumab and FVP-CV301 boosters with the first two given on Day 0 and 14 and then every 4 weeks. FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.
2857217|NCT03547986|Experimental|Duplex Ultrasound (DUS)|Standard angiography and DUS are performed on the same patients (paired data)
2857218|NCT03547986|Experimental|Intraarterial pressure measurement (IAP)|Standard angiography and Intraarterial pressure (IAP) measurement are performed on the same patients (paired data)
2857219|NCT03547986|Experimental|Intraarterial pressure measurement (IAP) with IVUS|Standard angiography and Intraarterial pressure measurement (IAP) with Intra-Vascular Ultrasound (IVUS) are performed on the same patients (paired data)
2857255|NCT03547674|Experimental|tuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
2871295|NCT03450434|Experimental|XC8 100 mg|XC8 100 mg orally
2857220|NCT03547973|Experimental|Cohort 1 and 2|"All subjects will receive Sacituzumab govitecan (IMMU-132) 10 mg/kg intravenously on Days 1 and 8 of a 21 day cycle.~Cohort 1: Patients in third-line therapy of urothelial cancers, after platinum-based regimen (cisplatin or carboplatin) and anti-PD-1/anti-PD-L1 based therapy.~Cohort 2: Patients in second line therapy of urothelial cancers, ineligible for cisplatin based therapy and after anti-PD-1/anti-PD-L1 based therapy."
2857221|NCT03547960|Experimental|Guar gum in women with early GDM|5 g of Guar gum fibre supplement with meals three times a day (total daily 15 g) for 12 weeks
2857222|NCT03547960|Placebo Comparator|Control/Cellulose in women with early GDM|5 g of Cellulose fibre supplement with meals three times a day (total daily 15 g) for 12 weeks
2857223|NCT03547934|Experimental|Treatment Group|Treatment with the investigated device - High Intensity Focused ElectroMagnetic System
2857224|NCT03547921||operative|operative
2857225|NCT03547921||non operative|non operative
2857226|NCT03547908|Experimental|B/F/TAF|B/F/TAF + placebo to match DTG + placebo to match F/TDF
2857227|NCT03547908|Experimental|DTG+F/TDF|DTG + F/TDF + placebo to match B/F/TAF
2857228|NCT03547895|Active Comparator|cases|"patients with decompensated cirrhosis~treated with Sofosbuvir 400 mg (Sovaldi) + Daclatasvir 60mg (Daklinza) + Ribavirin 200 mg (Rebetol)"
2857229|NCT03547895|Placebo Comparator|control group|the control group treated with liver support including silymarin 140 + phytomenadione 10 mg + lasilactone 50 mg + albumin infusion
2857230|NCT03547882||Other|Target interviewees will be primary care providers at six facilities and their staff (e.g., nurse care managers).
2857231|NCT03547869|Experimental|Active tDCS|Active tDCS
2857232|NCT03547869|Sham Comparator|Sham tDCS|Sham tDCS
2857233|NCT03547843|Experimental|Educational intervention|Patients randomized to the intervention group will start with a group-based educational program immediately after the randomization.
2857234|NCT03547843|Active Comparator|Waiting list|Participants randomized to the waiting list control group receive no educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment, consisting of diagnostic treatment with medication.
2857235|NCT03547830|Experimental|Plerixafor/G-CSF|Plerixafor/G-CSF for HSCT conditioning Myeloablative conditioning regimen with Plerixafor as addition agent before stem cell transplantation in CGD patients
2857236|NCT03547817|Experimental|Optimal negative pulse pressure regime|The equipment for physiological measurements will be attached to the patient, and the foot will then be placed in the pressure chamber of the intermittent negative pressure device. The device induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure. Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels. The order of the different negative pressure levels will be randomized to avoid causal interference.
2857237|NCT03547804|Experimental|experimental arm|apatinib 500 mg qd;Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
2857238|NCT03547791|Active Comparator|ACS (Group 1)|Intramuscular injection of betamethason sodium phosphate 12mg (3ml) twice 24hours apart
2857239|NCT03547791|Placebo Comparator|Placebo (Group 2)|Intramuscular injection of normal saline 3ml twice 24hours apart
2857240|NCT03547778|Experimental|Misoprostol group|Patients in this arm will receive vaginal misoprostol (50 mcg), the night before the procedure (concurrent office hsyteroscopy and endometrial biopsy).
2857241|NCT03547778|Placebo Comparator|Placebo group|Participants in this group will receive placebo (fatty acid), which looks similar to misoprostol and has to be inserted vaginally the night before the procedure.
2857242|NCT03547752|Active Comparator|Effective movement group|Observation of a video of neck movement at 100% range of movement, and imagination of the same observed movement, feeling the realization of the movement but not developing it.
2857243|NCT03547752|Experimental|Ineffective movement group|Observation of a video of neck movement at 40% range of movement, and imagination of the same observed movement, feeling the realization of the movement but not developing it.
2857244|NCT03547739|Active Comparator|Home visits|Participants randomized to intervention arm receive 5 home visits conducted by one female and one male lay health worker.
2857245|NCT03547739|Active Comparator|HIV Self-testing|Women in this study group will receive HIV self-test kits for themselves and their male partner at up to 4 time points.
2857246|NCT03547739|No Intervention|Standard Care|Participants will receive current standard clinic-based services including the option for women and partners to return to the clinic for male partner HIV testing or Couples HIV Counseling and Testing (CHCT).
2857247|NCT03547726|Active Comparator|Physical Therapy|This group of patients will receive a predetermined physical therapy regimen with guidance from a physical therapist.
2857248|NCT03547726|Experimental|Self-Rehab|This group of patients will be provided with a list of actions not to perform during the stages of their rehab (to avoid injury), and allowed to rehab their shoulder at their own pace.
2857249|NCT03547713|Experimental|Study group|social feedback
2857250|NCT03547700|Experimental|Romidepsin plus Ixazomib|The phase I study includes three dose levels (DL) for romidepsin: DL4: 10 mg/m2 on Days 1, 8, 15; DL5: 14 mg/m2 Days 1, 8; DL6: 14 mg/m2 Days 1, 8, 15. Ixazomib is 4 mg PO Days 1, 8, 15. The phase II study will include treatment with ixazomib and romidepsin at the MTD established in the Phase I study. Each cycle is 28 days and patients will receive treatment until progressive disease, unacceptable toxicity, or if any other withdrawal criteria are met.
2857251|NCT03547687|Experimental|Electrical Stimulation Treatment|Patient will receive electrical stimulation to the quadriceps muscle groups on both lower extremities simultaneously for 45 minutes at a time, for a total of 5 treatments each week (Mon-Sun), for up to 14 days or until ICU discharge, whichever comes first.
2857252|NCT03547674|Active Comparator|barefoot|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
2857253|NCT03547674|Active Comparator|shoes only|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
2857254|NCT03547674|Active Comparator|untuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
2857282|NCT03547479|Experimental|VDOT only|Participants receive daily DOTS treatment with video-enabled mobile monitoring, but also maintain regular supervisory checks
2857256|NCT03547661|No Intervention|Treatment as Usual|The treatment as usual (TAU) group will control for regression to the mean, spontaneous remission, natural course of disease, and the participants-provider interaction. Participants of the TAU group are allowed to continue their usual medication intake, given they are already on a stable dose (at least 30 days of intake) and the medication is not listed in the exclusion criteria.
2857257|NCT03547661|Active Comparator|Integrative Open-Label Placebo|"The intervention will encompass an integrative administration of P-Dragees rosa Lichtenstein, which are pink placebo dragées without any active ingredient. Each dragée contents the following substances: lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; highly dispersed silicon dioxide; white clay, macrogol glycerolhydroxy stearate (Ph. Eur.); Arabic gum; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); erythrosine; aluminium salt (E 127); calcium carbonate; sucrose; glucose syrup; maize starch; macrogol 6000.~All participants will be informed that the administered dragées are placebo dragées and participants will be instructed to take one dragée a day for six weeks and during the premenstrual phase until three dragées per day if desired."
2857258|NCT03547661|Active Comparator|Open-Label Placebo|"The intervention will encompass an administration of P-Dragees rosa Lichtenstein, which are pink placebo dragées without any active ingredient. Each dragée contents the following substances: lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; highly dispersed silicon dioxide; white clay, macrogol glycerolhydroxy stearate (Ph. Eur.); Arabic gum; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); erythrosine; aluminium salt (E 127); calcium carbonate; sucrose; glucose syrup; maize starch; macrogol 6000.~All participants will be informed that the administered dragées are placebo dragées and participants will be instructed to take one dragée a day for six weeks and during the premenstrual phase until three dragées per day if desired."
2857259|NCT03547648|Active Comparator|Group I ( 30 cm H2O)|Patients will be applied 30 cm H2O peak airway pressure manually at the end of the surgery
2857260|NCT03547648|Active Comparator|Group II( 40 cm H2O)|Patients will be applied 40 cm H2O peak airway pressure manually at the end of the surgery
2857261|NCT03547648|Active Comparator|Group III(50 cm H2O)|Patients will be applied 50 cm H2O peak airway pressure manually at the end of the surgery
2857262|NCT03547635|Experimental|AMNIOEXCEL Plus Amniotic Membrane|
2857263|NCT03547635|Active Comparator|A Marketed Comparator|
2857264|NCT03547635|Other|Standard of Care|
2857265|NCT03547622|Active Comparator|MAT taper with galantamine|Following initial MAT taper, participants will be given up to 16mg daily of galantamine for up to 10 weeks of the active study
2857266|NCT03547622|Placebo Comparator|MAT taper with placebo|Following initial MAT taper, participants will be given up to 16mg daily of placebo for up to 10 weeks of the active study
2857267|NCT03547583|Experimental|Vericiguat up to 10 mg|Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, with sham titration at week 6.
2857268|NCT03547583|Experimental|Vericiguat up to 15 mg|Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, and to 15 mg at week 6.
2857269|NCT03547583|Placebo Comparator|Placebo|Subject will receive placebo for 24 weeks, once daily, starting sham up-titration at weeks 2, 4, and 6.
2857270|NCT03547570|Experimental|Heavy shoulder resistance training|Progressive heavy shoulder resistance training performed twice a week at the physiotherapy clinic under supervision, while once weekly training at home will be recommended.
2857271|NCT03547557|Experimental|ExAblate MRgFUS|
2857272|NCT03547531|Active Comparator|Natural Tooth Brushing Method|Natural tooth brushing method is the method that is naturally used by the people with horizontal, rotary, or simple up and down motions and any position of the brush without any instruction of particular tooth brushing method.
2857273|NCT03547531|Experimental|Modified Circular Tooth Brushing Method|Modified Circular tooth brushing method is a combination of small circular motion of brushing with the position of the brush slightly reach underneath the gingival that are applied for each jaw in all facial surfaces and posterior lingual of tooth arches.
2857274|NCT03547518|Experimental|Active PTNS treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
2857275|NCT03547518|Sham Comparator|Sham treatment|One-week induction consisting of three sham treatments, each 2 hours long
2857276|NCT03547505|Experimental|R-Pilot®|"R-Pilot® was operated by an endomotor (VDW Silver, Munich, Germany) at Reciproc All setting."
2857277|NCT03547505|Experimental|ProGlider®|ProGlider® was operated by an endodontic motor (X-Smart, Dentsply Sirona, Ballaigues, Switzerland) with 16:1 contra angle at the suggested settings (300 rpm on display, 5 Ncm).
2857278|NCT03547505|Experimental|Manual preparation|"In the manual glide path group, glide path creation was performed with stainless steel #08, 10, 15 K-files used with push and pull motion. Instruments were used with a motion in which the instrument proceeds apically quarterly to the point of resistance, then is pulled out for debris removal. The procedure was repeated with each file until the working length was achieved and confirmed with an electronic apex locator (Root ZX Mini, Morita Corp., Kyoto, Japan)."
2857279|NCT03547492|Experimental|Language Intervention|"1. Baseline LENA recording 2. Review language curriculum and motor curriculum with study personnel 2. Direct linguistic feedback of baseline LENA recording 4. 2nd LENA recording completed and analyzed 5. Direct or mailed linguistic feedback of 2nd LENA recording 6. 16- Weekly text messages 7. 4 month LENA recording with mailed linguistic feedback 8. 12 month LENA recording with mailed linguistic feedback~Assessments:~Ages and Stages Questionnaire at 4 and 12 months~Maternal Peabody Picture Vocabulary test at 4 months~Edinburgh Post-partum Depression Scale at 4 months~MacArthur Bates Communicative Developmental Inventory: Words and Gestures at 12~Participants receive a book at each interaction."
2857280|NCT03547492|Active Comparator|Motor Control|"Baseline LENA recording~Review motor curriculum with study personnel~2nd LENA recording completed and analyzed~4- monthly text messages~4 month LENA recording~12 month LENA recording with mailed linguistic feedback of all recordings~Assessments:~Ages and Stages Questionnaire at 4 and 12 months~Maternal Peabody Picture Vocabulary test at 4 months~Edinburgh Post-partum Depression Scale at 4 months~MacArthur Bates Communicative Developmental Inventory: Words and Gestures at 12~Participants receive a toy at each interaction."
2857281|NCT03547479|No Intervention|Control|Participants receive current standard of care (DOTS)
2871883|NCT03446209|Placebo Comparator|Placebo|0,9% physiological Saline
2857284|NCT03547453||Regular Menstrual Cycles|Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days). Recruitment will be targeted to obtain 20 lean (BMI<25 kg/m2) and 20 overweight or obese (BMI>24.9kg/m2) women in each of the following age groups: 18-24y (early), 25-34y (mid), ≥35y (later adulthood).
2857285|NCT03547453||Polycystic Ovarian Syndrome|Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted to obtain 20 lean (BMI<25kg/m2) and 20 overweight or obese (BMI>24.9kg/m2) women in each of the following age groups: 18-24y (early), 25-34y (mid), ≥35y (later adulthood).
2857286|NCT03547440||type 1 diabetes mellitus|Children with type 1 diabetes mellitus, usually not obese, with diabetic ketoacidosis. They could be with or without stationary metabolic profile. They are recruited at the onset of the T1DM into the Torino and Novara Pediatric Hospitals and then they are divided in relation to the ethnicity.
2857287|NCT03547440||Control healthy|Healthy children without relevant metabolic or systemic co-morbility. They are recruited from orthopedy department of the Torino and Novara Pediatric hospitals and then they are divided in relation to the ethnicity
2857288|NCT03547427|Experimental|Insulin hypoglycemia + pramlintide|Subjects will have a 25% reduction in their standard basal insulin therapy with concurrent basal pramlintide infusion ('Basal pramlintide and reduced basal insulin'). They will receive a Lispro bolus to induce hypoglycemia of ≤55mg/dL ('Insulin-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
2857289|NCT03547427|Active Comparator|Insulin hypoglycemia|Subjects will have their standard basal insulin treatment ('Basal insulin alone') and receive a Lispro bolus to induce hypoglycemia of ≤55mg/dL ('Insulin-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
2857290|NCT03547427|Experimental|Exercise hypoglycemia + pramlintide|Subjects will have a 25% reduction in their standard basal insulin therapy with concurrent basal pramlintide infusion ('Basal pramlintide and reduced basal insulin'). They will have three bouts of exercise to induce hypoglycemia of ≤55mg/dL ('Exercise-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
2857291|NCT03547427|Active Comparator|Exercise hypoglycemia|Subjects will have their standard basal insulin treatment ('Basal insulin alone'). They will have three bouts of exercise to induce hypoglycemia of ≤55mg/dL ('Exercise-induced hypoglycemia' ). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
2857292|NCT03547401||General anesthesia|Patient (15 to 40 years old) undergoing elective surgery requiring general anesthesia in supine position.
2857293|NCT03547375|Experimental|treatment group|Apatinib 500mg/d po,28 days as one cycle
2857294|NCT03547362|Experimental|Casein|Single oral administration
2857295|NCT03547362|Experimental|Dairy protein blend 1|single oral administration
2857296|NCT03547362|Experimental|Whey protein|Single oral administration
2857297|NCT03547362|Experimental|Dairy protein blend 2|Single oral administration
2857298|NCT03547362|Experimental|Dairy protein blend 3|Single oral administration
2857299|NCT03547362|Experimental|Dairy protein blend 4|Single oral administration
2857300|NCT03547349|Active Comparator|Group 1|These study patients will receive a study information/authorization sheet about the study prior to surgery during their pre-operative clinic visit. This subgroup will be provided postoperatively with a digital incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer. Subjects in this group will receive current standard of care with routine surgical and RN encouragement to use the spirometer. The tablet will monitor and record spirometer device utilization.
2857301|NCT03547349|Active Comparator|Group 2|These study patients will be consented by members of the research team prior to surgery at their pre-operative clinic visit. The patient will receive RT or RN education preoperatively as to the importance of incentive spirometry in prevention of post-operative respiratory complications. This subgroup will be provided with a digital incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer, and will set a spirometry goal while collecting usage and pulmonary function data. Subjects in this group will also receive daily intensive education from a study team member during the postoperative time up until 72 hours or until discharge.
2857302|NCT03547349|Experimental|Group 3|These study patients will be consented by a member of the research team prior to surgery at their pre-operative clinic visit. The patients will receive RT or RN education preoperatively as to the importance of incentive spirometry in prevention of post-operative respiratory complications. This subgroup will be provided with both intensive education reinforcement and the Jamboxx Respiratory Therapy Device that also includes multiple gaming programs. The games are meant to encourage incentive spirometry and are programmed to progress in accordance with the patient's personal increasing capacity. Subjects in this group will also receive daily intensive education from a study team member during the postoperative time up until 72 hours or until discharge.
2857303|NCT03547336|Experimental|Theranova 400 Dialyzer|In-center hemodialysis (in HD mode), 3 times a week for 12 week duration. The patient will undergo regular HD treatment on the first treatment of the first week of study, after which, the patient will switch to the randomized dialyzer, from the second treatment to the end of study treatment. Blood sampling will be obtained at the hospital by trained personnel according to local routines.
2857304|NCT03547336|Active Comparator|FX800|In-center hemodialysis (in HDF mode), 3 times a week for 12 week duration. The patient will undergo regular HD treatment on the first treatment of the first week of study, after which, the patient will switch to the randomized dialyzer, from the second treatment to the end of study treatment. Blood sampling will be obtained at the hospital by trained personnel according to local routines.
2857307|NCT03547310|Experimental|MyoBeatz|The intervention consists of playing with the smartphone training program using the muscle signals picked up by surface electrodes. The study will run over a period of 5 weeks, with participants playing with the training program at home for 4 weeks.
2857308|NCT03547284|Active Comparator|81 patients,group 1|81 women will receive 1 stick of sugarless gum for 15 minutes every 2 hours after surgery .
2857309|NCT03547284|No Intervention|81 patients,group 2|81 patients will have traditional management(oral intake of clear fluids after flatus passage and regular diet after passage of stool)
2857310|NCT03547271|Experimental|Group 1|MenACYW conjugate vaccine, 3 doses , co-administered with routine vaccines (10-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and measles, mumps, and rubella [MMR] vaccine) at 2, 4 and 12 to 18 months of age
2857311|NCT03547271|Active Comparator|Group 2|Nimenrix®, 3 doses , co-administered with routine vaccines (10-valent pneumococcal vaccine, DTaP-IPV- HB-Hib vaccine, and MMR vaccine) at 2, 4 and 12 to 18 months of age
2857312|NCT03547271|Experimental|Group 3|MenACYW conjugate vaccine, 3 doses , co-administered with routine vaccines (13-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and MMR vaccine) at 2, 4 and 12 to 18 months of age
2857313|NCT03547271|Experimental|Group 4|MenACYW conjugate vaccine, 4 doses , co-administered with routine vaccines (13-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and MMR vaccine) at 2, 4, and 12 to 18 months of age and administered alone at 6 months of age
2857314|NCT03547258||AML patients|Clinical and Molecular data collection of AML Patients with FLT3 mutations (ITD or TKD)
2857315|NCT03547245|Active Comparator|HIV-uninfected, healthy adults|
2857316|NCT03547245|Placebo Comparator|HIV-uninfected, healthy adults - placebo|
2857317|NCT03547232|Experimental|Indomethacin group|Indomethacin SR 50mg q12h from day1 to day 7 plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.
2857318|NCT03547232|Sham Comparator|Standard group|Similar shape and size suppositories without indomethacin (Placebos) given q12h from admission day 1 to day 7, plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.
2857319|NCT03547219|Experimental|Escitalopram|Participants with depression were treated with escitalopram(ranging from 5mg to 30mg) for 8 weeks. Escitalopram was initiated at 5mg for 1 week, followed by an increase to 10mg at week 2. After week 2, doses of escitalopram were titrated according to symptoms and adverse effects. Specific, indicated psychotherapy for depression was not allowed during the study.
2857320|NCT03547206|Experimental|RPh201|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the Investigational Medical Product (IMP) (20 mg RPh201).
2857321|NCT03547206|Placebo Comparator|Placebo|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the vehicle control.
2857322|NCT03547180|Active Comparator|Cognitive Therapy|The training included four components: (a) educating patients about exacerbating panic symptoms through catastrophic thoughts (vicious cycle), (b) identifying negative cognitions associated with physical sensation triggers of recent panic attacks, (c) practicing replacement of maladaptive cognitions with non catastrophic explanations, and (d) instructing patients in between session exercises during Phase I.
2857323|NCT03547180|Active Comparator|Capnometry-Assisted Respiratory Training|The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
2857324|NCT03547180|Other|In-vivo exposure therapy|In this two-phase intervention, patients were randomized (within each site) to first receive five individual, weekly, 1-hr sessions of respiratory skill training (CART) or cognitive skill training (CT; Phase I, Skill Acquisition Training), followed by three weekly sessions of in-vivo exposure (Phase II, Application Training) plus a fourth session at 2-month follow-up.
2857325|NCT03547167|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)
2857326|NCT03547167|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)
2857327|NCT03547154|Experimental|Interferon alfa-2b|Interferon alfa-2b, recombinant for injection, 5 million international units (MIU)/m^2, administered by subcutaneous (SC) injection
2857328|NCT03547154|Experimental|Pegylated Interferon alfa-2b|Pegylated interferon alfa-2b, 6.0 microg/kg, administered by SC injection
2857329|NCT03547141|Experimental|botulinum toxin 1U|
2857330|NCT03547141|Experimental|botulinum toxin 5U|
2857331|NCT03547141|Experimental|botulinum toxin 15U|
2857332|NCT03547141|Experimental|botulinum toxin 30U|
2857333|NCT03547115|Experimental|Voruciclib|Open-label, 3 + 3 dose escalation study with 5 planned cohorts of Voruciclib which may enroll up to 6 subjects each
2857334|NCT03547102|Active Comparator|Cherry concentrate|8 weeks supplementation with montmorency cherry concentrate
2857335|NCT03547102|Placebo Comparator|Placebo concentrate|8 weeks supplementation with placebo isoenergetic cherry concentrate
2857336|NCT03547089|Experimental|Viveve treatment|Group of women who receive Viveve treatment
2857337|NCT03547076|Experimental|Focused ultrasound diagnostics|"Intervention: Focused ultrasound Diagnostics~All participants will first be examined twice with handheld ultrasound, With separate examinations performed by general practioners and nurses (random order). Both will utilize automatic analyses of left ventricular function and telemedicine support for best possible diagnosis of heart failure. Subsequently, reference imaging and diagnostics will be performed by experts (cardiologists). Handheld ultrasound examinations will be compared to Reference."
2857338|NCT03547063||Sleeve Gastrectomy (SG)|25 participants, male and female, aged 18-50 years, body mass index (BMI) 35-50 kg/m2, due to undergo primary SG
2857339|NCT03547063||Lifestyle Intervention|25 participants, male and female, aged 18-50 years, BMI 35-50 kg/m2
2857340|NCT03547063||Normal Weight|25 participants, aged 18-50 years BMI 18.5-24.9 kg/m2, age and gender matched to group with severe obesity
2857341|NCT03547050||Patients diagnosed with RE|People who meet the eligibility requirements and have been diagnosed with rolandic epilepsy.
2857342|NCT03547050||Controls|People without a lifetime history of seizures.
2857343|NCT03547037|Experimental|Phase 1a: JNJ-63723283 (Monotherapy)|Participants will receive monotherapy of JNJ-63723283 intravenously. The subsequent dose levels of JNJ-63723283 will be escalated using Bayesian logistic regression model (BLRM).
2857344|NCT03547037|Experimental|Phase 1b: Erdafitinib Combination|Participants will receive erdafitinib in combination with JNJ-63723283 which will be escalated using BLRM.
2857345|NCT03547024|Experimental|Part 1: JNJ-55308942 + Drug Cocktail|Participants will receive a single dose of drug cocktail on Day 1 followed by JNJ-55308942 high dose once daily from Day 3 to Day 14 and a single dose of drug cocktail on Day 12.
2857346|NCT03547024|Experimental|Part 2: JNJ-55308942 + Levonorgestrel/Ethinyl Estradiol|Participants will receive a single dose of levonorgestrel/ethinyl estradiol alone on Day 1 followed by JNJ-55308942 high dose once daily on Days 5 to 18 and a single dose of levonorgestrel/ethinyl estradiol on Day 14.
2857347|NCT03547024|Experimental|Part 3: JNJ-55308942 + Drug Cocktail|Participants will receive a single dose of drug cocktail alone on Day 1 followed by JNJ-55308942 low dose once daily on Days 3 to Day 14 and a single dose drug cocktail on Day 12.
2857348|NCT03547011|Active Comparator|US guided Quadratus Lumborum block|Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.
2857349|NCT03547011|Active Comparator|US guided Paravertebral block.|Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
2857350|NCT03546985|Experimental|Group A|
2857351|NCT03546985|Active Comparator|Group B|
2857352|NCT03546972|Experimental|Diabetes Prevention Program (DPP) Group|"Questionnaires completed at baseline, mid-point, and end of study.~Participants take part in a 7-day Self-Monitoring Period at baseline.~Participants receive DPP, a 16 week program which includes 1 training session each week.~Participants take part in a 7-day Self-Monitoring Period at baseline."
2857353|NCT03546972|Experimental|Diabetes Prevention Program (DPP) + Hunger Training Group|"Questionnaires completed at baseline, mid-point, and end of study.~Participants take part in a 7-day Self-Monitoring Period at baseline.~Participants receive DPP, a 16 week program which includes 1 training session each week.~Participants take part in Hunger Training beginning at Week 2 session and lasting until Week 6 session."
2857354|NCT03546959|Experimental|Lycra sleeve after botulinum toxin|8 hours a day lycra sleeve wear plus rehabilitation (for five days a week for three weeks) after botulinum toxin injection for post-stroke spasticity
2857355|NCT03546959|Active Comparator|Rehabilitation after botulinum toxin|Rehabilitation (five days a week for three weeks) after botulinum toxin injection for post-stroke spasticity
2857356|NCT03546946|Experimental|Gaze-Contingent Music Reward Training|GCMRT for eight 20-minute sessions - twice per week over 4 weeks.
2857357|NCT03546946|Placebo Comparator|Control Training|Passive viewing task with continuous music for eight 20-minute sessions - twice per week over 4 weeks.
2857358|NCT03546946|No Intervention|No-Train Group|No active training.
2857359|NCT03546933||Chest pain patients presenting to the ED|All patients that present to the emergency department with chest pain and potentially other symptoms consistent with ACS and meet all eligibility criteria will undergo VitalScan Magnetocardiograph.
2857360|NCT03546920|No Intervention|Control Phase|Usual care for patients admitted to the SNF.
2857361|NCT03546920|Experimental|ALIGN Intervention Phase|ALIGN Intervention delivered by Palliative Care Social Workers in the SNF setting. The intervention consists of aligning patient/caregiver goals of care, completing advance care planning, and connecting to community resources and services to ensure smooth transition from facility to home setting.
2857362|NCT03546907|Experimental|SAR440340|Administration of SAR440340 monotherapy injection
2857363|NCT03546907|Placebo Comparator|Placebo|Administration of matching placebo for injection of SAR440340
2857364|NCT03546894||Brigatinib|The dosage and regimen of brigatinib (ALK inhibitors) will be decided by participant's prescribing physician and will not be determined by participation in the study.
2857365|NCT03546894||Alectinib|The dosage and regimen of alectinib (ALK inhibitors) will be decided by participant's prescribing physician and will not be determined by participation in the study.
2857366|NCT03546894||Ceritinib|The dosage and regimen of ceritinib (ALK inhibitors) will be decided by participant's prescribing physician and will not be determined by participation in the study
2857367|NCT03546894||Other ALK inhibitors|The dosage, regimen and the new ALK inhibitors will be decided by participant's prescribing physician and will not be determined by participation in the study.
2857368|NCT03546881|Experimental|Arm with fusion imaging guidance technology|arm with fusion imaging guidance technology to perform the endovascular surgery, in addition to the traditional 2D X-ray screen system.
2857369|NCT03546881|Active Comparator|Arm without fusion imaging guidance technology|arm without fusion imaging guidance technology, using the traditional 2D X-ray screen system, to perform the endovascular surgery.
2857370|NCT03546868|Experimental|Ulcerative Colitis|Patients with ulcerative colitis undergoing [18F]FSPG PET/CT scan
2857371|NCT03546868|Experimental|Crohn's disease|Patients with Crohn's disease undergoing [18F]FSPG PET/CT scan
2857372|NCT03546855|Experimental|treatment group|apatinib 500mg/d po.28d as one cycle
2857373|NCT03546842|Experimental|V503|V503 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
2857374|NCT03546829|Experimental|Arm 1 - Experimental|
2857375|NCT03546829|Active Comparator|Arm 2 - Control Arm|
2857376|NCT03546816|Experimental|5 mg Serlopitant Tablets|
2857377|NCT03546816|Placebo Comparator|Matching Placebo Tablets|
2857378|NCT03546803||Cohort A|Head and Neck Patients; Photon or Proton Treatment with product
2857379|NCT03546803||Cohort B|Hair/skin fold areas (Axilla, Groin, Perineum); Photon or Proton Treatment with product
2857380|NCT03546803||Cohort C|Misc. (per Rad Onc Physician); Photon or Proton Therapy with routine skin care
2857381|NCT03546790|Experimental|Flavor 1|Grape flavored tobacco cigar wrapper
2857382|NCT03546790|Experimental|Flavor 2|Chocolate flavored tobacco cigar wrapper
2857384|NCT03546764|Experimental|Percutaneous Catheter|14-French Percutaneous catheter (pigtail or non-pigtail) placed at bedside using Seldinger technique
2857385|NCT03546764|Active Comparator|Chest tube|Placement of 28-36F chest tube placed at bedside by an open cut-down technique (traditional)
2857386|NCT03546751|Experimental|CPAP|This arm will consist of patients with obstructive sleep apnea who will be asked to use CPAP nightly to treat their OSA for six months
2857387|NCT03546751|Active Comparator|Diet and Exercise|This arm will consist of patients with obstructive sleep apnea who will be asked to engage in dietary management and regular exercise for six months.
2857388|NCT03546738|Experimental|Burst SCS|Burst Spinal cord stimulation. SCS system implanted and burst stimulation given
2857389|NCT03546738|Sham Comparator|Sham SCS|Sham spinal cord stimulation. SCS system implanted but no stimulation given.
2857390|NCT03546725|Experimental|Leg with compression stocking|Leg wearing compression stocking during the flight
2857391|NCT03546725|No Intervention|Leg without compression stocking|Leg not wearing compression stocking during the flight
2857392|NCT03546686|Experimental|Intervention Arm|Ipilimumab + Nivolumab + Core Biopsy/Cryoablation + Breast Surgery
2857393|NCT03546686|Active Comparator|Control Arm|Breast Surgery
2857394|NCT03546673|No Intervention|Control Condition|Participants in the control group were asked to write for three weeks about facts regarding their cancer and its treatment for three sessions.
2857395|NCT03546673|Experimental|Self-regulation Condition|For the self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; in session two, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
2857396|NCT03546673|Experimental|Emotional Disclosure condition|For the emotional disclosure condition, participants were asked to write about their deepest thoughts and feelings about their cancer experience for three weeks.
2857397|NCT03546660|Experimental|SECM capsule imaging|Subject will swallow the SECM capsule and the imaging of the esophagus will be performed using a SECM optical system
2857398|NCT03546647|Experimental|Toric|Soft toric contact lens
2857399|NCT03546647|Active Comparator|Sphere|Soft sphere contact lens
2857400|NCT03546634|Active Comparator|Three-dose schedule for Sabin IPV|Subjects vaccinate Sabin IPV at 2, 3, and 4 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 3rd dose of IPV.
2857401|NCT03546634|Experimental|Two-dose schedule for Sabin IPV|Subjects first dose IPV vaccinate at 4 months of age, and the second dose IPV given between 8 and 11 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 2nd dose of IPV.
2857402|NCT03546621|Experimental|Arm A|Myrcludex B, 2 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
2857403|NCT03546621|Experimental|Arm B|Myrcludex B, 5 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
2857404|NCT03546621|Experimental|Arm C|Myrcludex B, 10 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
2857405|NCT03546621|Active Comparator|Arm D|tenofovir treatment for 48 weeks
2857406|NCT03546608|Experimental|Part 1, Child-Pugh Class A: Tepotinib|
2857407|NCT03546608|Experimental|Part 1, Child-Pugh Class B: Tepotinib|
2857408|NCT03546608|Experimental|Part 1, Healthy Participants: Tepotinib|Healthy participants matched to Child-Pugh Class B participants.
2857409|NCT03546608|Experimental|Part 2, Child-Pugh Class A or B: Tepotinib|
2857410|NCT03546595|Experimental|Auricular acupressure|
2857411|NCT03546595|Sham Comparator|Sham auricular acupressure|
2857412|NCT03546582|Experimental|Arm I|Patients receive Stereotactic Body Radiation Therapy (SBRT) over 2 weeks and then receive pembrolizumab every 3 weeks for up to 2 years.
2857413|NCT03546582|Other|Arm II|Patients receive Stereotactic Body Radiation Therapy (SBRT) over 2 weeks. Arm II patients who experience progressive disease within 2 years after the start of SBRT will be allowed to cross over to receive pembrolizumab for up to 2 years.
2857414|NCT03546556|Experimental|Allogeneic|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo Fluorothymidine FLT-PET-MRI imaging on two separate occasions.
2857415|NCT03546556|Experimental|Autologous|3 patients undergoing autologous stem cell transplant will also undergo Fluorothymidine FLT-PET-MRI imaging the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
2857416|NCT03546543|Experimental|Supine|
2857417|NCT03546543|Experimental|Prone|
2857418|NCT03546530|Experimental|Interferon|Interferon 1.5ug/kg/week, 48weeks
2857419|NCT03546530|Experimental|Interferon+resveratrol|Interferon 1.5ug/kg/week,resveratrol 1000mg/day, 48weeks
2857420|NCT03546517|Experimental|Intervention with DNHS technique|Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
2857421|NCT03546517|Sham Comparator|Sham Dry Needling|Sham Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
2857422|NCT03546504|Experimental|dental procedures modification and OT|Modifying dental environment and procedures to reduce sensory stimulation. Occupational therapy provides desensitization techniques around the dental visit and home oral hygiene and habit training for oral hygiene activities.
2857423|NCT03546491|Experimental|Preventive Gel|0.4% stannous fluoride
2857424|NCT03546491|Active Comparator|Marketed Control|0.243 % Sodium Fluoride
2857425|NCT03546478|Experimental|99mTc-ABH2 SPECT/CT|The patients were injected with 370±54 MBq of 99mTc-ABH2 in one dose intravenously and underwent SPECT/CT scan 90-270 min later.
2857426|NCT03546465|Experimental|Cohorts 1C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 100 μg
2857427|NCT03546465|Experimental|Cohorts 1J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 100 μg
2857428|NCT03546465|Experimental|Cohorts 2C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 200 μg
2857429|NCT03546465|Experimental|Cohorts 2J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 200 μg
2857430|NCT03546465|Experimental|Cohorts 3C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 300 μg
2857431|NCT03546465|Experimental|Cohorts 3J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 300 μg
2857432|NCT03546465|Experimental|Cohorts 4C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 450 μg
2857433|NCT03546465|Experimental|Cohorts 4J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 450 μg
2857434|NCT03546452||malignant NSCLC hydrothorax|cell free DNA ,which is purified from malignant NSCLC hydrothorax, tested by in vitro NGS-panel
2857435|NCT03546426|Experimental|study treatment|Pembrolizumab in combination with Autologous dendritic cells and Interleukin-2
2857436|NCT03546413||LEAP Participants|LEAP participants are followed during an extended period of ad-libitum peanut consumption and then assessed for peanut allergy and other allergic outcomes. Target accrual is 630.
2857437|NCT03546413||LEAP Siblings|LEAP participant siblings will be randomly assigned to the intervention or control group based on the allocation of their LEAP participants sibling.Target accrual is 746.
2857438|NCT03546413||LEAP Parents|Any parent of a child who enrolled in the LEAP study. Target accrual is 945.
2857439|NCT03546400|Other|methylphenidate HCl ERCT|methylphenidate HCl ERCT
2857440|NCT03546374|Experimental|Primary Cohort|Patients with a history of non-paroxysmal atrial fibrillation (persistent or longstanding persistent) who are undergoing concomitant cardiac surgery
2857441|NCT03546361|Experimental|1 Dose Escalation|three patients will be assigned to the cohort. All three will receive the same Ad-CCL21-DC dose by CT-guided or bronchoscopic intratumoral injection followed by intravenous pembrolizumab 200mg one hour after DC injection on days 0, 21, and 42, and intravenous pembrolizumab 200mg every three weeks thereafter for up to a year. for cohort (1) The Ad-CCL21-DC dose is 1 x 107 cells/injection in the first cohort.
2857442|NCT03546361|Experimental|2 Dose Escalation|three patients will be assigned to the cohort. All three will receive the same Ad-CCL21-DC dose by CT-guided or bronchoscopic intratumoral injection followed by intravenous pembrolizumab 200mg one hour after DC injection on days 0, 21, and 42, and intravenous pembrolizumab 200mg every three weeks thereafter for up to a year. for cohort (2) The Ad-CCL21-DC dose is 3 x 107 cells/injection in the second cohort.
2857443|NCT03546361|Experimental|-1 Dose Escalation|If the dose regimen in cohort 1 (Ad-CCL21-DC 1 x 107 cells/injection) is not well tolerated, de-escalation to Ad-CCL21-DC 0.5 x 107 cells/injection will be allowed (-1). three patients will be assigned to the cohort. All three will receive the same Ad-CCL21-DC dose by CT-guided or bronchoscopic intratumoral injection followed by intravenous pembrolizumab 200mg one hour after DC injection on days 0, 21, and 42, and intravenous pembrolizumab 200mg every three weeks thereafter for up to a year. for cohort (-1) The Ad-CCL21-DC dose is 0.5 x 107 cells/injection in the third cohort.
2857444|NCT03546361|Experimental|Dose Expansion|"After completion of the dose-escalation phase, all safety and tolerability data will be reviewed and the ExD will be determined. A dose expansion cohort of 24 patients will be enrolled and treated at ExD for up to a year (note: only intravenous pembrolizumab is given after day 42).~Ad-CCL21-DC dose at determined maximum tolerated dose (MTD) or maximum administered dose (MAD)"
2857445|NCT03546335|Experimental|1mCi injection of 89Zr-DFO-CZP|The first 2 patients will receive 1mCi of 89Zr-DFO-CZP.
2857446|NCT03546335|Experimental|0.5mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
2857447|NCT03546335|Experimental|1.5mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
2857448|NCT03546335|Experimental|2mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
2857449|NCT03546322||Registry|Head and neck cancer patients monitored on registry
2857450|NCT03546309|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
2857451|NCT03546309|Sham Comparator|sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
2857452|NCT03546283|Placebo Comparator|Control|The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebo group, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
2857453|NCT03546283|Experimental|CEGI treatment|The patients with hypertensive intracerebral hemorrhage will be randomized into giving drug CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
2857454|NCT03546270|Experimental|Swimming|Participants performed SWM training (combination of free style, breast stroke, and backstroke) for 20 weeks. For the first 5 weeks subjects swam 25-30 minutes/day, 3-4 days/week at ~60% of maximal heart rate. As their overall level of fitness and exercise skill improved, the intensity and duration of exercise increased to 40-45 minutes/day, 3-4 days/week at an intensity of 70-75% of the HRmax. Target HR was adjusted based on the observation that maximal heart rate during SWM is approximately 12 beats/min lower than that during running. Each subject was instructed to swim continuously except during the time needed for checking a target heart rate
2857455|NCT03546270|No Intervention|Control|Participants in the non-exercising control group did not participate in a supervised exercise program and visited the laboratory at the same frequency as participants in the swim intervention and underwent recreational activities such as board games
2857456|NCT03546257||EUS|group using conventional WLE and EUS
2857457|NCT03546257||ME-NBI|group using WLE and ME-NBI.
2857458|NCT03546244|Experimental|musical treadmill|4-week daily musical treadmill training, consisting in two session, 20 minute per session
2857459|NCT03546244|Active Comparator|traditional session|4-week daily traditional treadmill training, consisting in two session, 20 minute per session
2857460|NCT03546218|Experimental|Smartphone Application (SPSRS)|Participants watch motion picture using an application that displays positive-word stimuli.
2857461|NCT03546218|Active Comparator|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
2857462|NCT03546205|Experimental|Group 1: JNJ-64565111|Participants with normal renal function and no evidence of kidney damage (estimated glomerular filtration rate [eGFR] greater than or equal to [>=] 90 milliliter/minute [mL/min]) will be enrolled. Participants will receive a single subcutaneous (SC) dose of JNJ-64565111 on Day 1.
2857463|NCT03546205|Experimental|Group 2: JNJ-64565111|Participants with mild renal impairment (eGFR 60 to less than [<] 90 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
2857464|NCT03546205|Experimental|Group 3: JNJ-64565111|Participants with moderate renal impairment (eGFR 30 to <60 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
2857465|NCT03546205|Experimental|Group 4: JNJ-64565111|Participants with severe renal impairment (eGFR <30 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
2857466|NCT03546205|Experimental|Group 5: JNJ-64565111|Participants with end-stage renal disease (requiring hemodialysis 3 times per week for at least 3 months before screening; eGFR will not be calculated) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
2857467|NCT03546192|Experimental|Fluzone Quadrivalent Influenza Vaccine: 18 to 60 Years|Participants aged 18 to 60 years received one 0.5-mL dose of Fluzone Quadrivalent influenza vaccine, intramuscularly, at Day 0.
2857468|NCT03546192|Experimental|Fluzone Quadrivalent Influenza Vaccine: 61 Years or Older|Participants aged 61 years or older received one 0.5-mL dose of Fluzone Quadrivalent influenza vaccine, intramuscularly, at Day 0.
2857469|NCT03546166|Experimental|TREATMENT|
2857470|NCT03546153|Experimental|Aerobic exercise program|Participants will complete 12 week exercise program.
2857471|NCT03546127||STS|Patients with advanced/metastatic soft-tissue sarcoma
2857472|NCT03546127||CCR|Patients with metastatic colorectal carcinoma
2857473|NCT03546114||Patients referring to an osteopathic clinic - CMO, Milan|Adults, age>18 years, first visit at osteopathic clinic, absence of severe psychological or cognitive disability.
2857474|NCT03546101||Department of Kidney Medicine|Primarily transplant recipients undergoing monitoring for EBV and patients suspected for having PTLD.
2857475|NCT03546101||Department of Hematology|Patients diagnosed with PTLD and other kinds of lymphoma. Patients undergoing hematopoietic stem cell transplantation and patients with hemophagocytosis.
2857476|NCT03546101||Department of pediatrics|Children undergoing transplantation. Children diagnosed with hemophagocytic lymphohistiocytosis.
2857477|NCT03546088|Experimental|awake naso-tracheal intubation|The patients with obstructive oro and hypo-pharynx tumours will have their airway secured through awake fiberoptic naso-tracheal intubation with light sedation and topical anaesthesia with lidocaine. The sedation will be provided in small boluses until the desired level will be achieved not exceeding 0.05 mg/kg of midazolam, 3 mcg/kg fentanyl and 2.5 mg of droperidol. The dose of lidocaine will be to a maximum of 7 mg/kg. The reinforced intubating tube will be lubricated with lidocaine gel.
2857478|NCT03546075|Experimental|500 mg Resveratrol|
2857479|NCT03546075|Experimental|250 mg Resveratrol|
2857480|NCT03546075|Placebo Comparator|Placebo|
2857481|NCT03546062||T2DM patients treated by HTx|Authors will include a population of T2DM patients with advanced heart failure and treated by heart transplant.
2857482|NCT03546049|Active Comparator|US-guided percutaneous biliary drainage|The initial percutaneous transhepatic puncture of the bile duct is performed by ultrasound guidance with a Chiba-needle (0.7 mm). After injection of a radiopaque contrast media into the bile duct system, the malignant extrahepatic bile duct stenosis can be visualized by fluoroscopic guidance (digital remote-controlled fluoroscopy device). Then a 0.018 inch guide wire is introduced and proceeded beyond the tumor stenosis into the duodenum. Next, the Chiba needle is exchanged by a 5 F catheter and the 0.018 inch guide wire is exchanged by a 0.035 inch guide wire. After dilatation of the hepatic access route with bougies up to 12 F, a self-expandable metal stent is introduced. The placement of the metal stent is controlled by endoscopic luminal guidance (gastroscope or duodenoscope).
2857483|NCT03546049|Experimental|EUS-guided biliary drainage|The initial transluminal puncture of the bile duct is performed by endoscopic ultrasound guidance (longitudinal echoendoscope) with an 19 G access needle. After injection of a radiopaque contrast media into the bile duct system, the malignant extrahepatic bile duct stenosis can be visualized by fluoroscopic guidance. Then, a 0.035 inch guide wire is introduced into the bile duct. After dilatation of the transluminal access route with a balloon catheter, a self-expandable metal stent is introduced as an antegrade biliary drainage, a transhepatic biliary drainage or a choledochal biliary drainage. The placement of the metal stent is controlled by fluoroscopic and endoscopic luminal guidance.
2857484|NCT03546036|Experimental|Weighted metal chain blanket|As experimental intervention, a weighted metal chain blanket of 8 kg was used during the night. Using a flexible dose protocol, participants who found the 8 kg blanket too heavy were allowed to change to a 6 kg weighted blanket (see below)
2857485|NCT03546036|Sham Comparator|Control plastic chain blanket|As sham comparator, light chain blankets were used, were plastic chains of the same shape and size as the metal chains in the weighted blanket were sewn in. The control blanket has a weight of 1535 grams. When checking the weight of standard blankets for sale in one of the largest stores in Stockholm, weight was ranging from 550 to 2389 grams (average 1332).
2857486|NCT03546010|Experimental|Oculometric and neuropsychological tests|Oculometric tests and neuropsychological tests
2857487|NCT03545997|Experimental|Montelukast|Drug :Montelukast, capsule, 10mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months
2857488|NCT03545997|Placebo Comparator|Placebo|Drug: Mannitol, capsule, 350mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months
2857520|NCT03545854|Experimental|L4 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the L4 vertebral level
2857521|NCT03545854|Experimental|L4 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the L4 vertebral level
2860812|NCT03522896|Experimental|test meal 2|orange juice with added hesperidin (high dose)
2857489|NCT03545984|Experimental|simulation-based training|The simulation-based training during the first week of rotation involves step-by-step instructions on insertion of the CSF drainage catheter including aseptic technique, position of patient (lateral vs. sitting), site of insertion. The simulation training is done on a mannequin to simulate actual conditions. We plan to use a simulation model, which is basically a torso with the ability to palpate the back and spinous processes and use the epidural needle with loss of resistance technique with haptic feedback. The trainees would be able to actually perform the procedure on the manikin.
2857490|NCT03545984|Active Comparator|problem based learning|The residents allocated to the non-simulation group (problem based learning) receives standard educational teaching in the form of a problem based learning discussion during the first week of rotation.
2857491|NCT03545971|Experimental|Ia Cohort A|Low-dose group:Participants will receive IBI310 0.3mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity.
2857492|NCT03545971|Experimental|Ia Cohort B|Middle-dose group:Participants will receive IBI310 1.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
2857493|NCT03545971|Experimental|Ia Cohort C|Middle-dose group:Participants will receive IBI310 2.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
2857494|NCT03545971|Experimental|Ia Cohort D|High-dose group:Participants will receive IBI310 3.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
2857495|NCT03545971|Experimental|Ib Cohort A|3 subjects, low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
2857496|NCT03545971|Experimental|Ib Cohort A2|low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
2857497|NCT03545971|Experimental|Ib Cohort B|3 subjects, low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
2857498|NCT03545971|Experimental|Ib Cohort B2|low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
2857499|NCT03545958|Experimental|High-intensity Interval Training (HIT)|Participants in this groups will receive 15 minutes in the mind-motor training (i.e., Square-Stepping Exercise) followed by a 45-minute HIT intervention.
2857500|NCT03545958|Active Comparator|Moderate-intensity Continuous Training (MCT)|Participants in this groups will receive 15 minutes in the mind-motor training (i.e., Square-Stepping Exercise) followed by a 45-min MCT intervention.
2857501|NCT03545945|Experimental|Study arm|Patients having office diagnostic hysteroscopy and endometrial biopsy
2857502|NCT03545945|Other|Control arm|Patients having only endometrial biopsy
2857503|NCT03545932|Experimental|Hydrogymnastics|Hydrogymnastics Program
2857504|NCT03545906|Experimental|TEAM-UP Intervention Group|
2857505|NCT03545906|Active Comparator|Enhanced Care Comparison Group|
2857506|NCT03545893|Active Comparator|Ibuprofen|
2857507|NCT03545893|Active Comparator|Ibuprofen + Oxycodone|
2857508|NCT03545880|Experimental|Kinesiotaping|A Kinesiotaping will be provided over the upper trapezius muscle after the application of dry needling
2857509|NCT03545880|Placebo Comparator|Placebo|Individuals will not perform any action after the application of trigger point dry needling
2857510|NCT03545867|Experimental|Seated control (CON)|Participants remain seated in their habitual wheel chair for ~45 min (duration of exercise performed in other arms). Following the intervention they are fed.
2857511|NCT03545867|Experimental|Circuit resistance training (CRT)|Participants complete upper extremity resistance maneuvers (lifts) interspersed with low-load/high-speed arm cycling for a combined 30 repetitions of 6 lifts and ~20 min of arm cycling. During this time energy expenditure is measured via open-circuit indirect calorimetry. Following the intervention they are fed.
2857512|NCT03545867|Experimental|Moderate intensity continuous (MICT)|Participants complete continous arm cycling at a steady-state power output (intensity) matched to the energy expenditure (kcal/min) and duration of exercise (min) response during CRT. Following the intervention they are fed.
2857513|NCT03545867|Experimental|High intensity interval training (HIIT)|"Participants complete interval arm cycling at power output that varies between 2 min active and two min recovery periods. This interval exercise is matched to the total energy expenditure (accumulated kcals) response during CRT. Following the intervention they are fed."
2857514|NCT03545854|Experimental|T3 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the T3 vertebral level
2857515|NCT03545854|Experimental|T3 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the T3 vertebral level
2857516|NCT03545854|Experimental|T3 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the T3 vertebral level
2857517|NCT03545854|Experimental|T12 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the T12 vertebral level
2857518|NCT03545854|Experimental|T12 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the T12 vertebral level
2857519|NCT03545854|Experimental|T12 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the T12 vertebral level
2875892|NCT03418831|Active Comparator|Raloxifene|Raloxifene Hydrochloride
2857522|NCT03545854|Experimental|L4 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the L4 vertebral level
2857523|NCT03545841|Experimental|HIT training|6 weeks of high-intensity interval training (HIT)
2857524|NCT03545841|Experimental|Moderate intensity training|6 weeks of moderate-intensity continuous training (MICT)
2857525|NCT03545828||Good neurological outcome|CPC 1 and 2 at 6 month after ROSC
2857526|NCT03545828||Poor neurological outcome|CPC 3 to 5 at 6 month after ROSC
2857527|NCT03545815|Experimental|anti-mesothelin CAR-T cells|"Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de- escalation.~Patients receive anti-mesothelin-CAR T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity."
2857528|NCT03545802|Experimental|Training|6 weeks of home-based high intensity interval training
2857529|NCT03545789|Experimental|[18F]MNI-958|To measure blood metabolites of [18F]MNI-958 and perform kinetic modeling to assess its ability to measure tau protein in brain using the tracer plasma concentration or a reference region as indirect input.
2857530|NCT03545776||Educational program|"Medical and nursing staff will be given a 10-points EEG face-to-face initial training course that will be preceded by a pre-test evaluation and followed by delayed post-test evaluations.~Training will be followed by an online teaching consisting on links to free and open online educational resources dedicated to EEG and to additional questions and answers quizzes based on the 10 educational goals already described elsewhere.~In order to avoid any risk of intrasite contamination, all the learners benefiting from the training in the same department will be trained in a uniform time, with respect to the training schedule regarding post-test evaluations (day-1, day-15 and day-30). A final evaluation will be performed at day-90 after beginning of the training course."
2857531|NCT03545763||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
2857532|NCT03545763||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
2857533|NCT03545750||Regional citrate anticoagulation (RCA)|Those receiving regional citrate anticoagulation for CRRT
2857534|NCT03545750||Systemic heparin anticoagulation (SHA)|Those receiving systemic heparin anticoagulation for CRRT
2857535|NCT03545737||Measurement|The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT.
2857536|NCT03545737||Formula|"The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube.~The depth of intubation = 0.1977* height-4.2423"
2857537|NCT03545724|Experimental|Neofitoroid®|Treatment is made by the application of Neofitoroid® 2 times a day for 10 days.
2857538|NCT03545711|Experimental|Anlotinib plus Irinotecan|
2857539|NCT03545698|Active Comparator|Telehealth Intervention|
2857540|NCT03545698|No Intervention|Non-Telehealth Intervention|
2857541|NCT03545685|Experimental|SMART|The subjects in SMART training group will receive add-on SMART intervention for 3 months. Subjects will play cognitive games for 1 hour per day, five days per week. SMART will track game time, resource use, and text messaging information on a daily basis, which allows researchers/clinicians to monitor subjects' daily SMART activities. Daily end-of-day RedPocket incentives will be delivered to subjects' designated account based on their resource use and game time. Top 5 APS subjects who play the game for the most time in a week will be rewarded
2857542|NCT03545685|Other|Treatment as usual|Participants in this group will receive naturalistic treatment and they will not get the specific memory and attention real-time training
2857543|NCT03545672||PBC group|Patients have a definite PBC diagnosis.
2857544|NCT03545672||Hyperlipidemia group|Patients with hyperlipidemia are diagnosed based on fasting lipid profile.
2857545|NCT03545672||HBV group|Patients with hepatitis B virus (HBV) infection, defined as a positive serum HBsAg for at least 6 months. No evidences indicate hepatocellular carcinoma or end-stage cirrhosis
2857546|NCT03545672||Control group|The healthy volunteers or patients in Renji Hospital whose medical examinations show no systemic disease, and the CMR examinations are normal.
2857547|NCT03545646|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic System
2857548|NCT03545633|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic System
2857549|NCT03545620||Difficult intubation,|Patients who underwent surgery under general anesthesia will be follow up. Patients predicted difficult intubation/airway or established difficult intubation/airway after anesthesia induction will be included. Which rescue technique will be used after unsuccessful direct laryngoscopy will be recorded.
2857550|NCT03545607|Experimental|MultiStem|1.2 billion cells
2857551|NCT03545607|Placebo Comparator|Placebo|
2857552|NCT03545594|Experimental|Patient-centered in home rehabilitation|Eight contacts (six in-home visits of about 2 hours duration each and two telephone contacts) delivered over a 4-month period in three phases:
2857553|NCT03545594|Active Comparator|Control|Usual follow-up assessment and health care and rehabilitation services provided in the municipality
2857554|NCT03545581|Other|Experimental diet Fru rich diet|Enriched fructose diet from day 1 to day 7.
2857555|NCT03545581|Other|Experimental low Fru diet|Low fructose diet from day 1 to day 7.
2857556|NCT03545568|Other|Experimental: sialic acid|
2857557|NCT03545555|Experimental|Kale Powder|"5 capsules with kale preparation kale powder per day for 8 weeks"
2857558|NCT03545555|Experimental|Kale Extract|"5 capsules with kale preparation kale extract per day for 8 weeks"
2857559|NCT03545555|Experimental|Flavonoid Extract|"5 capsules with kale preparation flavonoid extract (from kale) per day for 8 weeks"
2857560|NCT03545555|Placebo Comparator|Placebo|"5 capsules with placebo per day for 8 weeks"
2857600|NCT03545347|Placebo Comparator|Placebo (Sodium Chloride)|Physical therapy with strength training, protein-rich nutritional supplement plus placebo.
2857868|NCT03543163|Active Comparator|subepithelial connective tissue graft|Subepithelial Connective Tissue graft from the hard palate with Coronally Advanced flap at the site of gingival recession.
2857561|NCT03545542|Experimental|Neuroblastoma group|"10 children with neuroblastoma. Inclusion after verification of diagnosis and informed consent.~Sampling of fecal microbiome (Initial microbiome, microbiome under chemotherapy, final microbiome), fecal volatile organic compounds (initial fecal volatile organic compounds, fecal volatile organic compounds under chemotherapy and final fecal volatile organic compounds) and breath organic volatile compounds (initial breath organic compounds, breath volatile organic compounds under chemotherapy and final breath volatile organic compounds).~Samples will be taken after verifying diagnosis before initiation of chemotherapy, 1 week after completion of each cycle and 3 weeks after the end of chemotherapy."
2857562|NCT03545542|Other|Control group|"10 children without gastro-intestinal or pulmonary disease as age and sex matched controls to the neuroblastoma group. Patients will be recruited from paediatric surgery. Inclusion after informed consent.~Sampling of fecal microbiome (initial fecal microbiome), fecal volatile organic compounds (initial fecal volatile organic compounds) and breath organic volatile compounds (initial breath volatile organic compounds).~Samples will be taken as age and sex matched controls for the neuroblastoma group. Sampling will be done once after obtaining informed consent."
2857563|NCT03545529|Experimental|Innovative supported|In addition to usual care, patients benefit from connected tools (telealarm, numeric communication diary...) and from a strong accompaniment with a referent person who help better the patient.
2857564|NCT03545529|No Intervention|conventional supported|Patients benefit from usual care
2857565|NCT03545516|Placebo Comparator|Placebo|Wound infiltration with a placebo
2857566|NCT03545516|Experimental|Bupivacaine|Wound Infiltration with 20 mL (150mg) of 0.75% bupivacaine diluted with 5 mL of normal saline to give a 25 mL
2857567|NCT03545516|Experimental|Bupivacaine and Dexmedetomidine|Wound Infiltration with 20 mL (150mg) of 0.75% bupivacaine and 1.5 mcg/kg of dexmedetomidine will be diluted with normal saline to make 25 mL of solution .
2857568|NCT03545503|Active Comparator|Etomidate|Etomidate will be dosed once at a standard of 0.3 mg/kg via IV Push
2857569|NCT03545503|Active Comparator|Ketamine|Ketamine will be dosed once at a standard 2 mg/kg via IV Push
2857570|NCT03545490|Experimental|Intervention oral or tube feeding group|Ensure 3 times/day
2857571|NCT03545490|No Intervention|Control oral or tube feeding group|Only nutrition education
2857572|NCT03545477|Experimental|Novel treatment, curved-walking training|It consists of 20 sessions of training (three times a week for seven weeks) composed by standard physical therapy and a novel approach to locomotion rehabilitation based on curved-walking training. Each session lasts about 90 minutes.
2857573|NCT03545477|Active Comparator|Usual care|It consists of 20 sessions of training (three times a week for seven weeks) of standard physical therapy and conventional straight-walking training. Each session lasts about 90 minutes.
2857574|NCT03545464|Experimental|Antihistamines + placebo of cortancyl|"- In emergency department : Levocetirizine 5 mg orally. Renewable once if persistence of hives at 30 minutes.~Placebo of Cortancyl : 1mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally~- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).~Placebo of Cortancyl 20 mg x 2 tablets = 40mg once per day for 3 days orally"
2857575|NCT03545464|Active Comparator|Association of antihistamines and cortancyl|"- In emergency department : Levocetirizine 5 mg orally Renewable once if persistence of hives at 30 minutes.~Cortancyl: 1 mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally.~- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).~Cortancyl : 20 mg x 2 tablets = 40 mg per day for 3 days orally"
2857576|NCT03545451|Experimental|Neurofeedback rehabilitation with videogames|Neurofeedback rehabilitation with videogames
2857577|NCT03545438|Placebo Comparator|cohort 1|LIB003 dose 1 SC
2857578|NCT03545438|Placebo Comparator|cohort 2|LIB003 dose 2 SC
2857579|NCT03545438|Placebo Comparator|cohort 3|LIB003 dose 4 SC
2857580|NCT03545438|Placebo Comparator|cohort 4|LIB003 dose 4 SC
2857581|NCT03545438|Placebo Comparator|cohort 5|LIB003 dose 5 SC
2857582|NCT03545438|Placebo Comparator|cohort 6|LIB003 dose 4 IV
2857583|NCT03545438|Placebo Comparator|cohort 7|LIB003 dose 5 IV
2857584|NCT03545438|Placebo Comparator|cohort 8|LIB003 dose 3 SC - statin treated
2857585|NCT03545438|Placebo Comparator|cohort 9|LIB003 dose 4 SC - statin treated
2857586|NCT03545425||Idiopathic Parkinson's Disease patients|Up to 30 Parkinson's Disease patients will be enrolled.
2857587|NCT03545425||Healthy Controls|Up to 30 Healthy Controls will be enrolled.
2857588|NCT03545425||LRRK2 G2019S - Manifesting|Up to 30 LRRK2 G2019S Manifesting carriers will be enrolled.
2857589|NCT03545425||LRRK2 G2019S - Non-Manifesting|Up to 30 LRRK2 G2019s Non-Manifesting carriers will be enrolled.
2857590|NCT03545412|Experimental|Microfocused ultrasound with visualization|
2857591|NCT03545399|Experimental|Ulva Lactuca|The subject is given a capsule containing a concentrated fraction of freeze-dried and crushed hydrosoluble extract of seaweeds. The dose tested of extract of seaweeds is of 6.45mg per kg weight. The daily dose is 3 capsules per day for subjects weighing between 50 and 70kg, 4 capsules per day for subjects weighing between 70 and 90kg and 5 capsules per day for subjects weighing between 90 and 110kg. The duration of the treatment is 12 weeks.
2857592|NCT03545399|Placebo Comparator|Placebo|The subject is given a capsule looking alike that of the active product but containing no extract of seaweeds.The duration of the treatment is 12 weeks.
2857593|NCT03545386|Experimental|FMT|
2857594|NCT03545386|Placebo Comparator|Placebo|
2857595|NCT03545373|Experimental|Azithromycin|Azithromycin 500mg, oral, once daily for 3 days commencing on randomization day.
2857596|NCT03545373|Experimental|Amoxicillin|Amoxicillin 1g, oral, 3 times daily for 5 days commencing on randomization day.
2857597|NCT03545373|No Intervention|Standard of care|The standard of care in current national guidelines for patients presenting with cough and without danger signs (No treatment, re-evaluate with sputum results)
2857598|NCT03545360|Experimental|Treatment Group|Treated group of subjects, serves as its own control
2857599|NCT03545347|Experimental|Nandrolone Decanoate|Physical therapy with strength training, protein-rich nutritional supplement plus Nandrolone decanoate.
2860813|NCT03522896|Experimental|test meal 3|diluted orange juice with added hesperidin
2857601|NCT03545334|Experimental|ICG and VS3-3DHD camera|"After induction of anaesthesia, standard procedures for injection of a single dose Indocyanine green (ICG) intradermally are performed according to product description and hospital SOPs. Dose depending on the length of the lesion/scar, 1-4 ml of ICG was injected intradermally (5 mg/ml). Duration of the whole procedure about 20 - 30 minutes.~After ICG injection the possible draining lymphatic basins from the primary scar (i.e. axillae, inguinal, popliteal and neck regions) are scanned with the VS3-3DHD camera and all transcutaneous fluorescence spots recorded in the CRF. The scanning is discontinued after a maximum of 15 minutes regardless of findings."
2857602|NCT03545321|Experimental|MOON+|MOON+ includes pharmacist online training on opioid safety and naloxone provision, academic detailing of the pharmacy, materials for use at the pharmacy, standardized overdose response safety protocols, and reminder tools for training reinforcement
2857603|NCT03545295|Experimental|QLB 2 10ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 10 ml coloring solution
2857604|NCT03545295|Experimental|QLB 2 20ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 20 ml coloring solution
2857605|NCT03545295|Experimental|QLB 2 30ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 30 ml coloring solution
2857606|NCT03545295|Experimental|QLB 3 10ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 10 ml coloring solution
2857607|NCT03545295|Experimental|QLB 3 20ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 20 ml coloring solution
2857608|NCT03545295|Experimental|QLB 3 30ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 30 ml coloring solution
2857609|NCT03545282|Experimental|ALMA Intervention Group|Amigas Latinas Motivando el Alma (ALMA). This group receives the intervention after baseline assessment.
2857610|NCT03545282|Other|ALMA Delayed Intervention Control Group|Amigas Latinas Motivando el Alma (ALMA). This group receives the intervention five months after the baseline assessment (after the post-intervention, and 3 month assessments have been completed).
2857611|NCT03545269|Experimental|CartiLife®|
2857612|NCT03545269|Active Comparator|Microfracture|
2857613|NCT03545256|Other|T1-N0 or T2-N0 cancers of the oral cavity|outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search
2857614|NCT03545243|Other|Pantoprazole 40mg|Peroral Pantoprazole 40mg once daily for 4 weeks
2857615|NCT03545230|Experimental|"children who recieved Four Not Techniques surgery"|":Four Not Techniques"
2857616|NCT03545217|Experimental|intervention group|
2857617|NCT03545217|No Intervention|control group|
2857618|NCT03545204|Other|Intervention Clusters|Facility Kangaroo Mother Care plus community based Kangaroo Mother Care in low birth weight infants of randomly selected union councils.
2857619|NCT03545204|Other|Control clusters|Facility Kangaroo Mother Care plus routine standard care in low birth weight infants of randomly selected union councils.
2857620|NCT03545191|Experimental|ACT-541468 25 mg|ACT-541468 will be administered as tablets, orally, once daily in the evening.
2857621|NCT03545191|Experimental|ACT-541468 50 mg|ACT-541468 will be administered as tablets, orally, once daily in the evening.
2857622|NCT03545191|Placebo Comparator|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
2857623|NCT03545178||Diabetic patients using CGM/FGM|Evaluation of glucose control and application of hypoglycemia prediction models in diabetic patients wearing CGM and/or FGM devices for at least 50% of the time during the last 4 weeks prior to the medical consultation.
2857624|NCT03545165|Experimental|All Subjects|"177Lu−PSMA−617 [1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration~177Lu−J591 [2.2 GBq or 60 mCi] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration~68Ga−PSMA−HBED−CC [185 ±74MBq or 5 ±2 mCi] intravenous during screening and at 12 weeks (±1 week) with standard imaging"
2857625|NCT03545152|No Intervention|comparison group|No procedure conducted between the pre- and the post-test evaluations, and they received an abridged version of the training after the post-test session.
2857626|NCT03545152|Experimental|exercise group|The exercise program will include instructions on how to read the program, complete the activities, record their sessions, and exercise safely at first day. To promote incorporating exercising in their daily life routine during the 24-week period, we provided 2 group-based (5-8 participants with 2 instructors at community centers, 60' each) and one home-based (with the exercise program VCD and manual to bring home, 30') exercise program.
2857627|NCT03545139|Experimental|NeoMTA (intervention group)|Revascularization with NeoMTA as coronal plug.
2857628|NCT03545139|Active Comparator|White MTA (Control group)|Revascularization with Conventional white mineral trioxide aggregate (White MTA) as coronal plug.
2857629|NCT03545126||Progressive Supranuclear Palsy (PSP)|N=12 Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
2857630|NCT03545126||Corticobasal Degeneration (CBD)|N=8 Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
2857631|NCT03545126||Frontotemporal Dementia: MAPT|N=12 Family members with or at-risk of tau mutations (e.g. P301L) Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
2857632|NCT03545113|Experimental|Upper extremity arteriovenous graft (AVG) - first|
2857633|NCT03545113|Active Comparator|Upper extremity arteriovenous fistula (AVF) - first|
2857634|NCT03545100|Experimental|experimental group|motor control therapy
2857635|NCT03545100|Active Comparator|control group|regular physical therapy
2857636|NCT03545087|Experimental|Lanabecestat Control|Lanabecestat administered orally to participants with normal renal function
2857637|NCT03545087|Experimental|Lanabecestat Severe Renal Impairment|Lanabecestat administered orally to participants with severe renal impairment, not on dialysis
2857869|NCT03543163|Experimental|non pedicled buccal fat pad graft|Non- Pedicled Buccal Fat Pad with Coronally Advanced flap at the site of gingival recession
2857638|NCT03545074|Experimental|Mindfulness Spanish|The MAPs program was developed at UCLA (Winston & Smalley, 2010 and Lopez-Maya, 2016) and provides experiential training in mindfulness-based practices, including mindfulness meditation. UCLA-certified instructors delivered the interventions. Active program components include sitting and walking meditations, body scan and loving-kindness meditation. Participants were provided with audio CDs or digital downloads to complete their daily meditation assignments. Sessions were held once per week for 2 hours per session over a period of six consecutive weeks. Home practice assignments consist of daily mindfulness exercises starting with 5 minutes daily, progressing to 20 minutes daily by the end of the program.
2857639|NCT03545074|Experimental|Mindfulness English|The MAPs program was developed at UCLA (Winston & Smalley, 2010) and provides experiential training in mindfulness-based practices, including mindfulness meditation. UCLA-certified instructors delivered the interventions. Active program components include sitting and walking meditations, body scan and loving-kindness meditation. Participants were provided with audio CDs or digital downloads to complete their daily meditation assignments. Sessions were held once per week for 2 hours per session over a period of six consecutive weeks. Home practice assignments consist of daily mindfulness exercises starting with 5 minutes daily, progressing to 20 minutes daily by the end of the program.
2857640|NCT03545074|Active Comparator|Health Education Spanish|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general. Similar interventions have been described elsewhere (Black, et al., 2014; Irwin, et al., 2014). A trained health educator provided videos and didactic presentations on topics such as: stress, sleep hygiene, diet & nutrition, sexuality, mental health and substance abuse. The health education condition resembled the MAPs intervention in terms of duration, group format and support, attention and participant expectancy regarding health benefits.
2857641|NCT03545074|Active Comparator|Health Education English|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general. Similar interventions have been described elsewhere (Black, et al., 2014; Irwin, et al., 2014). A trained health educator provided videos and didactic presentations on topics such as: stress, sleep hygiene, diet & nutrition, sexuality, mental health and substance abuse. The health education condition resembled the MAPs intervention in terms of duration, group format and support, attention and participant expectancy regarding health benefits.
2857642|NCT03545048|Experimental|Intervention arm|"Interventional groups will have an assessment session with the experienced staff and NRS, QST, WOMAC, MSK-HQ, 30CST, TUG, PSQI, MSK-USS, urine and blood samples will be taken at baseline. Those who consent for aspiration of synovial fluid will go through the USGA procedure.~Interventional group will shortly after that receive a link via email, which will be used to log-in to Joint Academy online portal. After log-in has been achieved, the intervention starts. It consist of a 6-week internet-based physical therapy program. Interventional group will be given actigraphy device (a device to monitor sleeping pattern) which is CE marked. Therefore, their sleeping pattern can be recorded quantitatively.~Once exercises programme is finished in six weeks, the participants will fill in the same questionnaire and perform the physical tests, to enable evaluation."
2857643|NCT03545048|No Intervention|Control arm|Control group will continue with their routine self-management which is offered in the community setup. They will be assessed on NRS, QST, WOMAC, MSK-HQ, PSQI, 30CST, TUG, isometric muscles strengthen of quadriceps, MSK-USS, muscle mass of vastus lateralis, urine and blood samples at baseline. Control group will also get the actigraphy to monitor sleeping pattern of that group. They will be re-assessed after six weeks on the primary objective measures to see if they have made any difference by following self-management strategies in the community.
2857644|NCT03545035||Study group|All patients being observed during the study duration.
2857645|NCT03545022|Active Comparator|Active acupuncture|For both types of treatment, 0.25x30mm stainless steel needles were used (Dux, Brazil).The protocols were differentiated by needle size, in which the placebo needle is not inserted into the patient's skin and has an identical appearance to the active needle.The needle measuring 0.25x30mm was used as an active needle. The needles were inserted partially into an opaque guide tube filled with condensation silicone. This process was used to simulate the needle insertion for the patient and the acupuncturist and for the needle support. The active needle as well as the placebo needle were attached to the skin with an adhesive pedestal to hold the needle in place, even without inserting it into the skin.
2857646|NCT03545022|Placebo Comparator|Placebo acupuncture|For both types of treatment, 0.25x30mm stainless steel needles were used (Dux, Brazil).The protocols were differentiated by needle size, in which the placebo needle is not inserted into the patient's skin and has an identical appearance to the active needle. In the placebo needle, the needles were cut in 5mm, to measure 0.25x25mm. The needles were inserted partially into an opaque guide tube filled with condensation silicone. This process was used to simulate the needle insertion for the patient and the acupuncturist and for the needle support. The active needle, as well as the placebo needle, were attached to the skin with an adhesive pedestal to hold the needle in place, even without inserting it into the skin.
2857647|NCT03545009|Experimental|Beetroot Juice|
2857648|NCT03545009|Active Comparator|Beetroot Juice no Nitrate|
2857649|NCT03545009|Active Comparator|Sodium Nitrate|
2857650|NCT03545009|No Intervention|Control|
2857651|NCT03544996||TD Insulin Pilot|Test of novel transdermal insulin (TD Insulin) formulations
2857652|NCT03544983|Experimental|Proactive Outreach + Web Counseling|Web + Streamlined Telephone Genetic Counseling
2857653|NCT03544983|No Intervention|Usual Care|Participants in the usual care arm will not be provided with access to the web-based intervention nor will they have access to streamlined genetic counseling. They can pursue clinical genetic counseling on their own.
2857654|NCT03544944|Experimental|TJP-008-1|
2857655|NCT03544944|Experimental|TJP-008-2|
2857656|NCT03544944|Active Comparator|Coolprep powder|
2857657|NCT03544931|Experimental|Root Instrumentation + EMD Application|"Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one-stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.~In this group, at the end of the instrumentation enamel matrix derivatives is placed in all sites with a periodontal pocket depth deeper than 5mm."
2857764|NCT03544034|Experimental|Post-intervention|Hometeam toolkit interventions (including improved discharge education, proactive medication safety assessment in daily rounds and handoffs, safety briefings) applied in all hospitalist services.
2857658|NCT03544931|Active Comparator|Root Instrumentation|Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one-stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.
2857659|NCT03544918||Patients with long QT syndrome.|Patents with Long QT syndrome hospitilized. To be followed over time with no intervention. Observational study.
2857660|NCT03544918||Patients in Telemark with normal QT time|Patients in Telemark with normal QT time. To be followed over time with no intervention. Observational study.
2857661|NCT03544905|Experimental|Dose escalation study of CYH33|To determine the maximum tolerated dose (MTD) of CYH33
2857662|NCT03544892|Experimental|Experimental: Low carbohydrate diet|
2857663|NCT03544892|Active Comparator|Experimental: Standard of care diet|
2857664|NCT03544879|Experimental|Yoga|The yoga intervention consisted of 2x weekly 60-minute sessions for 10 weeks. Yoga consists of postures, breathing exercises, movement, and meditation/concentration..
2857665|NCT03544879|Active Comparator|Health Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. Sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion.
2857666|NCT03544853|Experimental|Prosthetic socket evaluation|Intervention: Prosthetic socket for transtibial amputee. A subject's conventional prosthetic socket is compared to a novel prosthetic socket designed as part of the research. For standing and walking exercises the following will be assessed. 1) local skin contact pressures, 2) metabolic power, 3) gait parameters (symmetry indices for joint angles, positions, torques, and also ground reaction forces), and 4) the socket evaluation questionnaire.
2857667|NCT03544840|Experimental|Young Children with Down Syndrome|
2857668|NCT03544827|Experimental|Atropine 0.01% then atropine 0.1%|Participants will be on topical atropine 0.01% ophthalmic solution QD OU for 1 week (7 days) and then topical atropine 0.1% ophthalmic solution QD OU for 1 week (7 days) with a washout period of 4 weeks in between each intervention
2857669|NCT03544827|Experimental|Atropine 0.1% then atropine 0.01%|Participants will be on topical atropine 0.1% ophthalmic solution QD OU for 1 week (7 days) and then topical atropine 0.01% ophthalmic solution QD OU for 1 week (7 days) with a washout period of 4 weeks in between each intervention
2857670|NCT03544814|Experimental|Synchronous therapy group|Icotinib combined with pemetrexed plus cisplatin.
2857671|NCT03544814|Experimental|Sequential therapy group|First icotinib and then pemetrexed plus cisplatin.
2857672|NCT03544801||sample group ,300|CSVD patients after symptomatic stroke
2857673|NCT03544801||control group,100|community population
2857674|NCT03544788|Experimental|Cirvo™ Therapy|
2857675|NCT03544775||Isolated General Anesthesia|Ontario residents, aged 18 years and older, who have undergone elective ambulatory shoulder surgery in Ontario and have not had a nerve block identified using physician billing codes.
2857676|NCT03544775||Peripheral Nerve Block|Ontario residents, aged 18 years and older, who have undergone elective ambulatory shoulder surgery in Ontario and have a nerve block identified using physician billing codes.
2857677|NCT03544762|Experimental|18F-FES PET|PET/CT
2857678|NCT03544749|Experimental|Ambu® AuraGain™ group|
2857679|NCT03544749|Active Comparator|I-gel group|
2857680|NCT03544736|Experimental|Cohort A|"Subjects having palliative radiotherapy towards esophageal tumor will receive concomitant therapy With Nivolumab i.v. 240mg Q2W, 360mg Q3W or 480mg Q4W, treatment to progression or up to 2 years of treatment.~Radiotherapy: 2 Gy / day, (5 fx/week) to a total of 30 - 50 Gy at the decision of the responsible physician."
2857681|NCT03544736|Experimental|Cohort B|"Subjects receiving definitive chemoradiotherapy for esophageal cancer will receive concomitant therapy with Nivolumab 240mg Q2W, 360mg Q3W or 480mg Q4W, treatment to progression or up to 1 year of after radiotherapy.~Chemotherapy: Paclitaxel i.v. 175mg/m2 and Carboplatin AUC5, then after 21 days Radiotherapy 1,8 Gy / day (5 fx/week) to 41,4 Gy and concomitantly Paclitaxel 80mg/m2 and Carboplatin AUC2 Q1W and Nivolumab as described above."
2857682|NCT03544736|Experimental|Cohort C|"Subjects with operable esophageal cancer eligible for neoadjuvant chemoradiotherapy will receive Nivolumab 240mg Q2W, 360mg Q3W or 480mg Q4W, concomitant with neoadjuvant chemoradiotherapy and 1 year adjuvant after surgery.~Neoadjuvant chemotherapy: Concomitantly Paclitaxel 80mg/m2 and Carboplatin AUC2 Q1W and Radiotherapy: 41,4 Gy in 23 fractions."
2857683|NCT03544723|Experimental|Ad-p53 with Nivolumab 100% of patients|Up to 20 patients, all patients treated with intra-tumoral Ad-P53 3 times week 1 of each cycle, dose determined by tumor size, in combination with IV nivolumab (Opdivo) 480 mg, every 4 weeks, on Day 5 of each Cycle.
2857684|NCT03544710|Experimental|Bathing|Intervention was Preoperative bathing with antiseptic. Given warm water and a tablet soap containing chloroxylenol antiseptic. Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team.
2857685|NCT03544710|No Intervention|No bathing|"No intervention done for participants in this arm. They go through the routine ward procedure as below.~Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team."
2857686|NCT03544697||Skin expansion and repair with flaps|The tissue expander was inserted into the scalp in 17 patients and supraclavicular area in two patients.
2857687|NCT03544684|Experimental|Control day with no exercise|glycaemic profile will be assessed using continuous glucose monitors following a single 24-hour period in which participants performed no exercise
2857688|NCT03544684|Experimental|High intensity interval training (HIT)|glycaemic profile will be assessed using continuous glucose monitors following a 24-hour period whereby participants performed a single bout of high-intensity interval training (HIT) in the morning under fasted conditions
2857765|NCT03544021|Experimental|CART-19|The relapsed/refractory ALL patients will receive allogenic or autologous CD19-Targeted CAR-T cells infusion after FC chemotherapy.
2857689|NCT03544684|Experimental|moderate intensity continuous training (MICT)|glycaemic profile will be assessed using continuous glucose monitors following a 24-hour period whereby participants performed a single bout of moderate-intensity continuous training (MICT) in the morning under fasted conditions
2857690|NCT03544671|Experimental|400 IU/d vitamin D2|Children received 1mililiter (dosage applicator) containing 400 IU of vitamin D2 per day. This suplement also contained: iron, vitamin A, C, and E, folic acid, niacin and vitamins B1, B2, B6 y B12. Vitamin D2, dosage form (1 mililiter), frequency (daily) and duration 16 weeks
2857691|NCT03544671|Experimental|800 IU7d vitmin D2|Children received 2 mililiter (dosage applicator) containing 800 IU of vitamin D2 per day. This suplement also contained: iron, vitamin A, C, and E, folic acid, niacin and vitamins B1, B2, B6 y B12. Vitamin D2, dosage form (1 mililiter), frequency (daily) and duration 16 weeks
2857692|NCT03544671|Experimental|1000 IU vitamina D3|Children received 1drop (dosage applicator) containing 1000 IU of vitamin D3 per day. dosage form (1 drop), frequency (daily) and duration 16 weeks
2857693|NCT03544671|Placebo Comparator|Multiple vitamin|Children received 1 mililiter of a supplement with multiple vitamins (dosage applicator) frequency (daily) and duration 16 weeks
2857694|NCT03544658|Experimental|Dental prophylaxis|Visit 1: tooth color assessment (by patient, dentist and spectrophotometer) and professional dental prophylaxis Visit 2: tooth color assessment (by patient, dentist and spectrophotometer)
2857695|NCT03544645|Active Comparator|control group|"This group received a printed material brochure as an educational material"
2857696|NCT03544645|Experimental|intervention group|"This group received an audiovisual material video as an educational material"
2857697|NCT03544632|Experimental|Acellular Adipose Tissue (AAT)|This open-label, phase II, dose-escalation study will be conducted in human subjects seeking repair of modest (approx. 5-30cc) soft tissue defects of the trunk (n=15). All participants will be treated via permanent injection of the study intervention (AAT injection) to restore the defect's contour. All study data will be collected in Case Report Forms (CRFs) and entered into a customized study database, created and maintained in HIPAA-compliant Research Electronic Data Capture (REDCap) software (14).
2857698|NCT03544606|Experimental|isosorbide mononitrate group|isosorbide mononitrate group (study group) 70 patients are induced by Intra vaginal isosorbide mono nitrate at 36, 24 , 12 before induction
2857699|NCT03544606|Placebo Comparator|placebos group|70 patients induced by placebo (pyridoxine) placebo tablet of the same size and shape as the isosorbide mononitrate. administered in the posterior vaginal fornix at 36, 24 , 12 before induction
2857700|NCT03544580|Experimental|immediate implant with dentin chips|using the tooth structure presented in socket either as remaining root or as unrestorable tooth structure remove all periodontal ligaments & scraping all enamel & cementum using a stone also to cut it into slices then putting it in acid to demineralize the dentine ; then using a bone mill to transform dentine into small particles or chips to be used in jumping gap between implant & thin buccal bone
2857701|NCT03544580|Active Comparator|immediate implant with xenograft|after surgical removal of entire badly decayed tooth we immediately put implant and in jumping gap we use xenograft
2857702|NCT03544567|Experimental|Oraxol|Oraxol will be administered once daily for 3 consecutive days every week from Weeks 1 through 25. Subjects who do not have documented disease progression by the end of the Treatment Period will be eligible to receive therapy in the Treatment Extension Period; additional doses of Oraxol may be administered from Week 26 onwards. Subjects may receive Oraxol until they meet 1 of the criteria for withdrawal from the study.
2857703|NCT03544554|Experimental|Intervention group and control group|This research is planned with semi experimental design
2857704|NCT03544528|Experimental|Regeneration|This treatment aims to regenerate pulp-like tissue within the root canal space after inducing an influx of stem cells from the apical papilla that results in reestablishment of pulp protective functions.
2857705|NCT03544528|No Intervention|Apexification|Traditional method. The application of Mineral Trioxide Aggregate (MTA) as an artificial apical barrier; also refer as the MTA apical plug method.
2857706|NCT03544515|Sham Comparator|Scaling and use of inactive Er,Cr:YSGG|Scaling and debridement with hand scalers and ultrasonic unit together with the application of the Er,Cr:YSGG laser in an inactive fashion
2857707|NCT03544515|Experimental|Scaling and use of active Er,Cr:YSGG|Scaling and debridement with hand scalers and ultrasonic unit together with the application of the Er,Cr:YSGG laser in an active fashion
2857708|NCT03544502|Experimental|Music group|Music group (group M, n=35) patients applied CD player. One CDs were prepared with 5 children's songs (classic music) for the study. CD player opened during anesthesia induction and continued until postoperative 15 minute
2857709|NCT03544502|Experimental|Silence group|"silence group (group S, n=35) patients received the independent anesthesiologist applied earplugs into the patients' ears during anesthesia induction and the earplugs were removed immediately before tracheal tube extubation.~During each measurement, noise level recordings were performed using CEL-480 Sound Level Meter Sonometre."
2857710|NCT03544502|Placebo Comparator|Noise group|"noise group (group N, n=35) patients were exposed to the ambient operating room noise.~Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.Postoperatively, Emergence delirium (ED) was assessed as a Pediatric Anesthesia Emergence Delirium (PAED) Score ≥ 10."
2857711|NCT03544489|Experimental|E-ICD Intervention|E-ICD Intervention over 3 months, consists of home walking to achieve the goal of 30 minutes on all or most of the days at moderate level intensity. E-ICD elements are: 1) exercise instructional DVD and manual, 2) exercise monitoring tools (Polar HR monitor, Digi-walker, Borg scale, and exercise logs), and 3) telephone coaching by clinic RNs. Each participant receives an exercise prescription based on the ICD information using HR cut-offs, a minimum of 4 walking sessions/week will be prescribed. Exercise maintenance: At the 3 month conclusion of the E-ICD intervention, each patient will receive an exercise prescription based on the level they were able to achieve, with guidelines about increasing exercise to reach the target of 30 minutes/walking on all or most days over the ensuing 3 months. Participants will record walking sessions each week in the exercise logs that will be collected again at 6 months.
2857766|NCT03543995||Enuresis nocturna|Patients aged 6 to 15 years with at least one night-time wetting weekly
2857767|NCT03543995||Normal population|Patients who were admitted to the urology clinic with a complaint of abdominal or lateral pain, who had no NE and had a direct abdominal x-ray examination
2857768|NCT03543982|Experimental|Oral probiotic product|
2857712|NCT03544489|No Intervention|Usual Care|"Usual Care will receive treatment as usual from their health care clinicians with outcomes measured at baseline, 3 and 6 months. Participants will not be discouraged from physical activity, but will be asked not to change their current level of activity for 6 months while in the study. Usual care involves ICD interrogation and follow-up every 3 months, measured either in-person or with home telephonic transmissions. Because participants in usual care may choose to participate in another exercise program, we will monitor those who participate in exercise programs and use the StepWatch monitor to quantify the amount and timing of physical activity. To control for group differences in attention, investigators will telephone usual care participants requesting information about health care utilization twice during the study at 3 and 6 months."
2857713|NCT03544476|Experimental|Mobile phone TB treatment support app|Daily use of the mobile phone TB treatment support app plus usual care. Participants will be asked to self-report daily TB medication administration, side-effects when applicable, and complete the direct adherence paper-based test randomly on 3-4 days of the week during the intensive treatment phase (first two months) and then 1-2 times per week during the maintenance phase (about month 3-6).
2857714|NCT03544476|Active Comparator|Usual care|Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
2857715|NCT03544463|Experimental|Treated|iNAP® Sleep Therapy System Treatment Intervention
2857716|NCT03544463|No Intervention|Baseline/Control|Self-controlled, pre-treatment baseline condition
2857717|NCT03544450|Experimental|Psychosocial counselling + Enhanced usual care (EUC)|This arm receives psychosocial counselling from the counsellor as well as enhanced usual care from health worker
2857718|NCT03544450|Active Comparator|Enhanced Usual Care (EUC)|This arm receives enhanced usual care from health worker
2857719|NCT03544424||Study cohort|People over 60 years of age with a Medtronic CareLink® compatible CIED in situ recruited from the Manchester University NHS Foundation Trust, England, UK
2857720|NCT03544411|Experimental|Type 2 Diabetes Mellitus group 1|The group supplemented with 15 ml / day of olive oil and 15 ml / day of bran oil
2857721|NCT03544411|Experimental|Type 2 Diabetes Mellitus group 2|this group supplemented with 15 ml / day of olive oil and 15 ml / day of bran oil
2857722|NCT03544398||exoskeleton|We will use exoskeleton type robot assisted gait training for spinal cord injury rehabilitation
2857723|NCT03544398||end-effector|We will use end-effector type robot assisted gait training for spinal cord injury rehabilitation
2857724|NCT03544385|Experimental|Treatment Group|
2857725|NCT03544385|Placebo Comparator|Placebo Group|
2857726|NCT03544346||Retired professional rugby players|"Rugby Players will Provide detailed demographic information Provide detailed overall health information Questionnaires Provide information on athlete's playing career; age of debut, career duration, number of seasons participated in. Provide information on concussion history. Be given a general health screen including- heart rate, blood pressure, body composition and height weight ratio.~Perform a battery of neuropsychological tests (Sound-induced flash illusion and CANTAB, NART) Provide a sample of blood."
2857727|NCT03544346||Retired professional rowers|"Rowers will Provide detailed demographic information Provide detailed overall health information Questionnaires Provide information on athlete's playing career; age of debut, career duration, number of seasons participated in. Provide information on concussion history. Be given a general health screen including- heart rate, blood pressure, body composition and height weight ratio.~Perform a battery of neuropsychological tests (Sound-induced flash illusion and CANTAB, NART) Provide a sample of blood."
2857728|NCT03544333|Experimental|real transcranial magnetic stimulation|In the treatment arm, patients will receive 1Hz of repetitive transcranial magnetic stimulation (rTMS) over the left Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al.,1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
2857729|NCT03544333|Placebo Comparator|sham transcranial magnetic stimulation|In the comparator arm, patients will receive no stimulation. The TMS coil adjusted to the patients head will not be plugged into the TMS machine and can thus not have an effect on the brain. Yet, patients will hear the same noises from a coil that is plugged in, see the TMS machine running, and area Spt localized via baseline structural imaging and our Localite TMS navigation system.
2857730|NCT03544320|Active Comparator|Activity Monitoring-Wrist worn wearable|Participants in the activity monitoring-wrist worn wearable group will be randomly assigned to track their activity using a Fitbit Charge 2 for 6 months.
2857731|NCT03544320|Active Comparator|Activity Monitoring-Waist-worn wearable|Participants in the activity monitoring-waist worn wearable group will be randomly assigned to track their activity using a Fitbit Zip for 6 months.
2857732|NCT03544307|Experimental|Taekwondo Training|Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks.
2857733|NCT03544307|No Intervention|Control|Sedentary control asked not to exercise
2857734|NCT03544294||Group|Consecutive patients treated with very thin stents on ULM and bifurcation
2857735|NCT03544281|Experimental|Arm A, Part 1, GSK2857916 plus lenalidomide plus dexamethasone|Subjects will receive GSK2857916, on Day 1 of each 28-Day cycle, at dose of 2.5 mg/kg, as a 30-minute infusion, followed by 1-hour rest. The dose if well tolerated, will be escalated to 3.4 mg/kg, in next cohort of subjects to determine RP2D dose. If 2.5 mg/kg dose is not tolerated, an additional, lower dose, 1.9 mg/kg may be evaluated. As SOC, subjects will also receive lenalidomide, at dose of 25 mg or 10 mg orally daily, on Days 1-21 of each 28-day cycle with dexamethasone at a dose of 40 mg or 20 mg once weekly, orally on Days 1, 8, 15, and 22 of each cycle.
2857769|NCT03543969|Experimental|BRAF-MEK Inhibitor Therapy|"Vemurafenib twice a day and cobimetinib daily, 3 weeks on / 2 weeks off / 3 weeks on, for an 8-week cycle.~After 8 week cycle, response to these study drugs will be analyzed based on several parameters to determine if participants will proceed in the study.~Participants will be invited for post-treatment follow-up visits for up to 5 years."
2857770|NCT03543956||Systemic Sclerosis patient|patients affected by SSc according to EULAR 2013 criteria
2860814|NCT03522883|Placebo Comparator|group control|the subjects will not take any type of nutrient intake
2857736|NCT03544281|Experimental|Arm B, Part 1, GSK2857916 plus bortezomib plus dexamethasone|Subjects will receive GSK2857916, on Day 1 of each 21-Day cycle, at dose of 2.5 mg/kg, as a 30-minute infusion, followed by 1-hour rest. The dose, if well tolerated, will be escalated to 3.4 mg/kg, in next cohort of subjects to determine RP2D dose. If 2.5 mg/kg, dose is not tolerated, lower dose, 1.9 mg/kg may be evaluated. As SOC, subjects will receive Bortezomib, at a dose of 1.3 mg per meter square (mg/m^2), subcutaneously (SC) or intravenously (IV), given approximately 1 hour post GSK2857916, assuring subjects' stability, on Days 1, 4, 8, and 11 of every 21-day cycle, for 8 cycles with dexamethasone at a dose of 20 mg orally, or IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle. Subjects will also receive Acyclovir, for up to 8-cycles.
2857737|NCT03544281|Experimental|Arm A, Part 2, GSK2857916, RP2D|The subject's in this arm will receive the RP2D dose of treatment A, determined from Part 1 of study, on Day 1 of each 28-Day cycle, as a 30-minute infusion, followed by 1-hour rest. As SOC, subjects will receive lenalidomide, at dose of 25 mg or 10 mg orally daily, on Days 1-21 of each 28-day cycle; with dexamethasone at a dose of 40 mg or 20 mg once weekly, orally on Days 1, 8, 15, and 22 of each cycle.
2857738|NCT03544281|Experimental|Arm B, Part 2, GSK2857916, RP2D|The subjects in this arm will receive the RP2D dose of treatment B, determined from Part 1 of study, on Day 1 of each 21-Day cycle, as a 30-minute infusion, followed by 1-hour rest. As SOC, subjects will receive Bortezomib, at a dose of 1.3 mg/m^2, SC or IV, given approximately 1 hour post GSK2857916, assuring subjects stability, on Days 1, 4, 8, and 11 of every 21-day cycle, for 8 cycles; with dexamethasone at a dose of 20 mg orally, or IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle. Subjects will also receive Acyclovir, for up to 8-cycles.
2857739|NCT03544268|Experimental|Acoustic Angiography|All clinical patients will be included in the experimental group.
2857740|NCT03544268|Experimental|Image Optimization|In addition to clinical patients, 15 participants will be recruited to aid in optimizing the imaging parameters.
2857741|NCT03544242|Active Comparator|Control group|
2857742|NCT03544242|Experimental|Pre-Isolation Infusion|
2857743|NCT03544242|Experimental|Post-Isolation Infusion|
2857744|NCT03544229|Experimental|TAK-906 Maleate 5 mg|TAK-906 maleate 5 mg, capsules, orally, twice daily for up to 12 weeks.
2857745|NCT03544229|Experimental|TAK-906 Maleate 25 mg|TAK-906 maleate 25 mg, capsules, orally, twice daily for up to 12 weeks.
2857746|NCT03544229|Experimental|TAK-906 Maleate 50 mg|TAK-906 maleate 50 mg, capsules, orally, twice daily for up to 12 weeks.
2857747|NCT03544229|Placebo Comparator|Placebo|TAK-906 maleate placebo-matching capsules, orally, twice daily for up to 12 weeks.
2857748|NCT03544216|Experimental|Single Vision First|Subjects in this group will receive the single vision spherical (Bausch + Lomb ULTRA®) lens for the first two weeks and be crossed over to the multifocal (Bausch + Lomb ULTRA® for Presbyopia) lens for the second two weeks.
2857749|NCT03544216|Experimental|Multifocal first|Subjects in this group will receive the multifocal (Bausch + Lomb ULTRA® for Presbyopia) lenses for the first two weeks and be crossed over to the single vision spherical (Bausch + Lomb ULTRA®) lens for the second two weeks.
2857750|NCT03544177|Experimental|BFR-Walking|Interval walking training with blood flow restriction.
2857751|NCT03544177|Active Comparator|Conventional therapy|Conventional therapy
2857752|NCT03544138|Other|Hummingbird Tympanostomy Tube System (H-TTS)|"The Hummingbird Tympanostomy Tube System (H-TTS) is a disposable surgical tool designed to deliver a tympanostomy tube (ear tube) into the tympanic membrane of patients during a tympanostomy tube placement procedure."
2857753|NCT03544125|Experimental|Treatment (olaparib, durvalumab)|Participants receive olaparib PO twice a day BID for 28 days in the absence of disease progression or unacceptable toxicity. Participants then receive olaparib PO BID on days 1-28 and durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Participants may continue on therapy beyond disease progression at the discretion of the investigator.
2857754|NCT03544112||ED and OUD treatment providers and staff|"ED patients will be recruited to participate in interviews or focus groups.~ED patients who are eligible for and willing to receive ED-initiated BUP will be recruited to participate in two research visits.~Administrative and health record data will be examined to assess rates of screening, assessment, eligibility determination, etc."
2857755|NCT03544112||Community Stakeholders|"Community treatment providers/OTP leadership and program staff: Providers, leadership and staff involved in the provision of office-based BUP, community treatment, and/or at opioid treatment programs (OTPs) will be recruited to participate in the formative evaluation and the Implementation Facilitation.~Other Stakeholders: Other community leaders and members (e.g., EMS, fire department, police, local government leadership, community advocacy groups, etc.) may be recruited to participate in qualitative interviews or focus groups."
2857756|NCT03544112||Patients|ED patients will be recruited to participate in interviews or focus groups.
2857757|NCT03544099|Experimental|Pembrolizumab for NPC patients|Pembrolizumab 200 mg Q3W IV infusion, Day 1 of each 3 week cycle, for 35 cycles
2857758|NCT03544086||test group|First group is the first 10 patients
2857759|NCT03544086||study group|following 150 patients
2857760|NCT03544073|Placebo Comparator|Saline Solution for Injection|This arm will receive a one-time subcutaneous injection of 0.4mL normal saline solution at the time of embryo transfer. This arm will continue to receive all the same treatments that everyone routinely receives for the IVF cycle, e.g. estrogen and progesterone supplements.
2857761|NCT03544073|Experimental|Leuprolide Acetate|This arm will receive a one-time subcutaneous injection of 0.4U (0.2mg=0.4mL) Leuprolide acetate at the time of embryo transfer. This arm will continue to receive all the same routine treatments for the IVF cycle, e.g. estrogen and progesterone supplements.
2857762|NCT03544047|Experimental|Experimental arm|Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen) and Herceptin was treated in HER2 amplification patients. After 3 cycles. If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks) and Herceptin was treated in HER2 amplification patients. If the evaluation of the curative effect is SD or PD, according to the result of drug sensitivity of the class organ, combined with the clinical practice, the doctor chooses the most sensitive treatment plan, and continues the 2 cycle treatment (6 weeks).
2857763|NCT03544034|No Intervention|Pre-intervention|Routine/ standard care and retrospective chart review for identifying preventable and ameliorable Adverse drug events as baseline
2857771|NCT03543943|Experimental|Individualized treatment|The ruptured achilles tendon is examined by ultrasonography. If the overlap of the tendon ends is less than 25 % or the tendon is elongated 7 % or more the patient receives conventional open operative treatment. The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below the knee cast after surgery. The ankle is held at maximal plantar flexion. Weight bearing is not allowed. After 3 weeks the cast is removed and the injured leg is transferred to a functional brace with 3 heel wedges. The patient will follow standard functional rehabilitation and the follow-up evaluations.
2857772|NCT03543943|Active Comparator|Control group 1|For the patients allocated to non-operative treatment the injured leg is placed in a circulated below the knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle. The patient will follow standard functional rehabilitation and the follow-up evaluations.
2857773|NCT03543943|Active Comparator|Control group 2|The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below the knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle. The patient will follow standard functional rehabilitation and the follow-up evaluations.
2857774|NCT03543930||Major open vascular surgery|Surgical procedures on the abdominal aorta requiring median abdominal incision
2857775|NCT03543930||Endovascular aortic repair|Abdominal aortic repair with endovascular approach
2857776|NCT03543917|Experimental|New Medication Combination|Intervention: Combination Product: Perfusion with New Combination Medication Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours
2857777|NCT03543904|Experimental|Pre-operative physiotherapy education|Pre-operative education regarding post-operative physiotherapy intervention and post-operative physiotherapy intervention in children with abdominal surgery
2857778|NCT03543904|Experimental|Post-OP PT without Pre-OP education|Post-operative physiotherapy intervention without pre-operative education in children with abdominal surgery
2857779|NCT03543891||Control group|50 healthy volunteers were included in the healthy control group
2857780|NCT03543891||Thyroid cancer group|50 patients of thyroid cancer were included
2857781|NCT03543878|Experimental|Flicker for 8 Weeks|Participants will receive the Flicker exposure during the entire 8-week treatment period
2857782|NCT03543878|Active Comparator|Flicker for 4 Weeks|Participants will receive the Flicker exposure during the second four weeks of the 8-week treatment period
2857783|NCT03543865|Experimental|New Hope (NH)|"The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have experienced suicide ideation, attempt or a binge substance use in the past 30 days.~Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type."
2857784|NCT03543865|Experimental|Elders' Resiliency (ER)|"The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have experienced suicide ideation, attempt or a binge substance use in the past 30 days.~All youth will complete another study assessment after 30 days. The 30-day time frame will allow ample time to complete the NH intervention with participants and assess any changes in youth's mental health status for all study arms. Following another 30-day period, all participants will be re-assessed and re-randomized, using the same blocking and 1:1 ratio to either the Elders' Resilience (ER) intervention plus CM, or CM alone. To track long term outcomes, all youth will complete a final assessment 3 month later (6 months post-enrollment)."
2857785|NCT03543865|Other|Control Condition|"The control condition will only receive Case Management (CM) (n=76).~The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have experienced suicide ideation, attempt or a binge substance use in the past 30 days. Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type."
2857786|NCT03543865|Experimental|New Hope (NH), Elders' Resiliency (ER), Case Management (CM)|The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have experienced suicide ideation, attempt or a binge substance use in the past 30 days. Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type. All youth will complete another study assessment after 30 days.After another 30-days, all participants will be re-assessed/re-randomized, using the same blocking and 1:1 ratio to either the ER intervention plus CM, or CM alone.
2857864|NCT03543202|Sham Comparator|Intravenous patient control analgesia|will not receive any regional anethetic intervention will receive intravenous patient controlled analgesia
2857787|NCT03543852|Experimental|SurvivorLink|Participants receiving treatment at a pediatric cancer survivor clinic randomized to this study arm will receive education on how to use SurvivorLink, late effects of treatment, and survivorship care through the system.
2857788|NCT03543852|No Intervention|Usual care|Participants receiving treatment at a pediatric cancer survivor clinic randomized to the usual care study arm will receive the SurvivorLink intervention beginning at Month 12.
2857789|NCT03543839|Active Comparator|Belimumab|Subjects in this arm will receive 200mg belimumab for self administration subcutaneously weekly for 2 years
2857790|NCT03543839|Experimental|Belimumab/Placebo|Subjects in this arm will receive 200mg belimumab for self administration subcutaneously weekly for 1 year and then placebo injections subcutaneously for 1 year.
2857791|NCT03543839|Placebo Comparator|Placebo|Subjects in this arm will receive placebo for self administration subcutaneously weekly for 2 years
2857792|NCT03543826|Other|Protocol|Patients will have perioperative nuromuscular block managed by protocol. The protocol includes specified appropriate rocuronium dosing and reversal with either neostigmine or sugammadex depending on depth of block as assessed subjectively at adductor pollicis with standard train-of-four stimulation of the ulnar nerve.
2857793|NCT03543813|Experimental|CX-2029 Escalation|CX-2029 Monotherapy
2857794|NCT03543813|Experimental|CX-2029 Biomarker|CX-2029 Monotherapy
2857795|NCT03543813|Experimental|CX-2029 Expansion|CX-2029 Monotherapy
2857796|NCT03543800|Experimental|ABP|(test treatment)
2857797|NCT03543800|Active Comparator|PRP|(active control)
2857798|NCT03543787|Active Comparator|Health IT and Peer Support Intervention|Utilise electronic decision support, tracking of referral list and Peer facilitation for referral completion
2857799|NCT03543787|No Intervention|Non intervention group|2014 - 2018 MoH referral protocol
2857800|NCT03543774|Active Comparator|simvastatin treatment|
2857801|NCT03543774|Sham Comparator|EZE/simvastatin 10/20 mg treatment|
2857802|NCT03543774|Sham Comparator|EZE/simvastatin 10/40 mg treatment|
2857803|NCT03543761|Sham Comparator|A|Sham group
2857804|NCT03543761|Active Comparator|B|LiST active treatment group
2857805|NCT03543761|Active Comparator|C|LiST active treatment group
2857806|NCT03543748|Experimental|TMS|The Transcranial Magnetic Stimulation course consisted of daily sessions of 2,000 stimuli for the left DLPFC (50 trains of 40 stimuli at 10 Hz for 10 days),
2857807|NCT03543748|Sham Comparator|SHAM|The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field.
2857808|NCT03543735|Experimental|Wisepill+SMS|
2857809|NCT03543735|Active Comparator|Wisepill-only|
2857810|NCT03543735|No Intervention|Disulfiram-only|
2857811|NCT03543722|Experimental|National Career Coach Program|This program has four main components: a 4-day in-person introductory seminar held in Alpharetta, GA, up to 18 months of job coaching provided by telephone and Skype, a human capital fund to pay for expenses of securing a job (e.g., travel, clothing, computers, professional organization fees), and an opportunity for two years to earn a bonus for employment earnings above a certain level.
2857812|NCT03543722|Active Comparator|Local Community Resources Program|Consists of referral to three local face-to-face service providers offering veterans training, financial assistance, and paid work experiences: The Department of Veterans Affairs Compensated Work Therapy Program, the state Vocational Rehabilitation program, and the Department of Labor America's Job Center.
2857813|NCT03543709||Behcet and fibromyalgia|Women with Behcet's disease with fibromyalgia
2857814|NCT03543709||Behcet|Women with Behcet's disease without fibromyalgia
2857815|NCT03543696|Experimental|Single Dose Radiotherapy (SDRT)|Single Dose Radiotherapy (SDRT) at a prescription dose of 24 Gy to all detectable metastatic lesions
2857816|NCT03543683|Experimental|osimertinib and aspirin|Osimertinib starting at a dose of 80 mg once a day, orally with meals.The intervention is aspirin which is starting at a dose of 100 mg once a day, orally with meals.Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
2857817|NCT03543670|Experimental|Oncoxin-Viusid|
2857818|NCT03543657|Experimental|Molidustat group|Subjects in the molidustat group will receive molidustat and darbepoetin alfa placebo.
2857819|NCT03543657|Active Comparator|Darbepoetin alfa group|Subjects in the darbepoetin alfa group will receive molidustat placebo and darbepoetin alfa.
2857820|NCT03543644|Active Comparator|Sugar-sweetened beverage (SSB)|"The SSB intervention will consist the participants' consuming their usual serving of cans SSBs (each 355 ml, 42 grams sugar) per day. The calories of the SSB group will not be matched to allow for real-world substitutions using products available on the market."
2857821|NCT03543644|Experimental|Non-nutritive sweetened beverage (NSB)|"The NSB intervention consists of substituting the participants' usual serving of cans SSBs with NSBs (each 355 ml, 0 grams sugar) per day. The calories of the NSB group will not be matched to allow for real-world substitutions using products available on the market."
2857822|NCT03543644|Experimental|Water|"The water intervention consists of substituting the participants' usual serving of cans SSBs with bottles or cans of still or sparkling water (each 355 ml bottle or can, 0 grams sugar) per day. The calories of the water group will not be matched to allow for real-world substitutions using products available on the market."
2857823|NCT03543618|Sham Comparator|Control|Installation of conventional design dental implant
2857824|NCT03543618|Active Comparator|Sloped|Installation of sloped design dental implant
2857865|NCT03543189|Experimental|Combination Therapy|Post androgen deprivation therapy (ADT), participants will receive nivolumab, HDR brachytherapy and external beam radiation therapy, followed by a 2 year follow-up period.
2857866|NCT03543176||UMEC/VI|The subjects in this arm had received, UMEC/VI as 62.5/25 microgram (mcg), which is an approved once-daily single inhaler dual LAMA/LABA therapy, given via Ellipta .
2857867|NCT03543176||FLUT/SAL|The subjects in this arm had received, FLUT/SAL as 250/50 mcg, which is an approved twice-daily single inhaler dual therapy ICS/LABA treatment, given via DISKUS.
2857907|NCT03542929|Active Comparator|healthy elderly|healthy elderly were use the Whole body vibration intervention during 10 minutes
2857825|NCT03543605|Experimental|PROA Experimental|"It consists of the intervention measures described in the general antimicrobial stewardship program (PROA Control) plus clinical advice.~The clinical assessments have been adapted for this project to the unique characteristics of infectious diseases in nursing homes.~These are individual training activities whose main objective is to modify prescribing behaviors when they are inadequate and reinforce them when they are correct.~They are carried out between the medical adviser, an expert in infectious diseases, and the doctor of the nursing home, through the structured review of a case attended by the doctor in the last 24 hours. The recommendations are not compulsory, and do not seek to change the decisions made in that patient, but the future ones in the case that is necessary.~The counseling will be done by video-conference, with an approximate duration of 10 minutes. Each of the doctors will receive two monthly assessments during the intervention period."
2857826|NCT03543605|Other|PROA Control|"The intervention of the general antimicrobial stewardship program (PROA) contains the following set of measures:~Creation of the local team of the PROA: one of the Family Physicians responsible for the patients and the pharmacist of the reference hospital of the center.~Presentation of the project by the local team in its own center.~Choice of the Aljarafe guide as a reference document for the diagnosis and treatment of infectious diseases. It is an accredited guide and widely disseminated among primary care and hospital doctors.~Permanent information of the project (poster with its synthesis, a pocket triptych with the guide for the clinical management of the main clinical syndromes of infections in the residents of the nursing homes).~Feedback of the results that will serve each center to know the evolution of its results, and to stimulate the comparison with the other centers."
2857827|NCT03543592|Active Comparator|3 dimensional ultrasonography and Doppler|80 women suffering post-menopausal bleeding (occurred after at least 12 months of amenorrhea) will be included in the study
2857828|NCT03543579||Multiple myeloma patients|Patients with multiple myeloma and an indication to receive carfilzomib
2857829|NCT03543553||SZ|Individuals with a diagnosis of schizophrenia
2857830|NCT03543553||HC|Healthy control participants
2857831|NCT03543540|Experimental|Nexvax2 (Arm A)|
2857832|NCT03543540|Experimental|Nexvax2 (Arm B)|
2857833|NCT03543540|Placebo Comparator|Nexvax2 Placebo (Arm C)|
2857834|NCT03543540|Placebo Comparator|Nexvax2 Placebo (Arm D)|
2857835|NCT03543527||Takayashu|
2857836|NCT03543514||PREHABILITATION GROUP|Patients affected on Cold-rectal cancer who needs surgery. We made trimodal prehabilitation
2857837|NCT03543501|Experimental|Real-time ultrasound imaging group|See intervention
2857838|NCT03543501|Experimental|PBU group|See intervention
2857839|NCT03543488||Rheumatoid Arthritis Patients|Forty women (range 25-75 years), with a class I and II RA diagnosis according to the American Rheumatism Association's 1987 revised criteria, were recruited from a university hospital's rheumatology clinic. Exclusion criteria included the presence of any cardiovascular, neuromuscular and metabolic diseases or severe limitations in mobility. Five patients were excluded for not attending the inclusion criteria, leading to a final number of 35 RA patients.
2857840|NCT03543488||Healthy Women|Thirty-five healthy women, age- and body size-matched to the RA patients, were recruited as controls (CG).
2857841|NCT03543475|Experimental|Pessary|Silicon device applied on the cervix
2857842|NCT03543475|Active Comparator|No Pessary|standard care, no pessary
2857843|NCT03543462|Sham Comparator|Arm A: Chest tube positioning YES|Patients enrolled for chest tube positioning
2857844|NCT03543462|No Intervention|Arm B: Chest tube positioning NO|Patients enrolled for diaphragm closure without chest tube positioning
2857845|NCT03543436|Experimental|Intravenous temocillin|Intravenous temocillin 2g/intravenously/8h or renally adjusted equivalent (ORAE) in 30-40 min infusion
2857846|NCT03543436|Active Comparator|Intravenous meropenem or imipenem|Intravenous meropenem or imipenem 1g/Intravenously /8h ORAE in 15-30 min infusion. Then switch to oral therapy
2857847|NCT03543423|Experimental|Oral glucose tolerance test|Intervention: oral glucose tolerance test (75 gram glucose supplemented with 5g 3-OMG and 1g paracetamol) ingested over 2 min.
2857848|NCT03543423|Experimental|Liquid mixed meal test|Intervention: Standardised liquid mixed meal (supplemented with 1g paracetamol) ingested over 2min
2857849|NCT03543410|Experimental|SEP-4199 200 mg|SEP-4199 200 mg/day (supplied in two 100mg tablets)
2857850|NCT03543410|Experimental|SEP-4199 400 mg|SEP-4199 400 mg/day (supplied in two 200mg tablets)
2857851|NCT03543410|Placebo Comparator|Placebo|Placebo (supplied in two tablets/day
2857852|NCT03543371||Cardiac Arrest survivors|Cardiac arrest survivors at selected TTM2-sites only.
2857853|NCT03543371||Myocardial Infarction patients|A control group from a cohort of patients with myocardial infarction with performed coronary angiography but no occurrence of cardiac arrest will be recruited at 1:1 ratio.
2857854|NCT03543358|Experimental|Arm A|Arm A includes subjects who enter the extension study while in post-treatment follow-up. This arm includes optional rovalpituzumab tesirine retreatment plus dexamethasone for those who qualify.
2857855|NCT03543358|Experimental|Arm B|Arm B includes subjects who enter the extension study while receiving ongoing rovalpituzumab tesirine treatment plus dexamethasone in the parent study.
2857856|NCT03543332||Cardiac arrest|
2857857|NCT03543332||Myocardial infarction|Myocardial infarction without cardiac arrest
2857858|NCT03543267|Experimental|epilectic Patients|
2857859|NCT03543254|Experimental|BoNT-A injected|BoNT-A (Botulinum toxin A) injected in the head on specific sites and in half the usual concentration
2857860|NCT03543241||MyoStrain|Patients with suspected CAD and scheduled for cardiac catheterization will receive traditional CMR wall motion stress testing with MyoStrain software analysis of myocardial ischemia and viability.
2857861|NCT03543228||MyoStrain|During standard chemotherapy and/or targeted treatment for breast cancer or lymphoma, MyoStrain will be used during standard cardiac magnetic resonance imaging to evaluate the change in myocardial contraction regionally and globally to detect cardiotoxicity and management of myocardial dysfunction.
2857862|NCT03543202|Experimental|Transversus abdominis plane block|will receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia
2857863|NCT03543202|Active Comparator|Local infiltration anesthesia|will receive 20ml bupivacaine for Local infiltration anesthesia and intravenous patient controlled analgesia
2875893|NCT03418831|Placebo Comparator|Placebo|placebo tablet
2857870|NCT03543150||Subjects receiving BOTOX|Subjects with a diagnosis of spasmodic dysphonia, for which BOTOX is indicated, will be included.
2857871|NCT03543137|Experimental|Test Product|Participants will receive a single Nicotine Prototype Mini lozenge (4mg) by oral/buccal route of administration.
2857872|NCT03543137|Active Comparator|Reference Product|Participants will receive a single Nicorette Mini lozenge (4 mg) by oral/buccal route of administration.
2857873|NCT03543124|Active Comparator|Water exchange (WE)|This group will have the air in the colon removed and replaced with water to guide the insertion of the colonoscope.
2857874|NCT03543124|Experimental|WE plus cap(WECAC)|The procedure of this group is similar with WE group, except a cap will be fitted onto the end of the colonoscope.
2857875|NCT03543111|Experimental|Zest|Zest is an internet-based psychological health enhancement program for women with spinal cord injury. The intervention will occur in Second Life (SL), which is an online virtual word simulator with a group of women with spinal cord injury.The Zest program will consist of 10 weekly 2-hour group sessions with approximately 8 women using avatars to represent themselves.
2857876|NCT03543111|No Intervention|Control|No intervention
2857877|NCT03543098|Experimental|Early Surgery & Early Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to early surgery and early rehabilitation.
2857878|NCT03543098|Experimental|Early Surgery & Delayed Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to early surgery and delayed rehabilitation.
2857879|NCT03543098|Experimental|Delayed Surgery & Early Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to delayed surgery and early rehabilitation.
2857880|NCT03543098|Experimental|Delayed Surgery & Delayed Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to delayed surgery and delayed rehabilitation.
2857881|NCT03543098|Experimental|Early Rehab Only|Individuals not eligible for randomization to timing of surgery will be randomized to only early rehabilitation.
2857882|NCT03543098|Experimental|Delayed Rehab Only|Individuals not eligible for randomization to timing of surgery will be randomized to only delayed rehabilitation.
2857883|NCT03543085|Experimental|Ultrahigh Frequency (500 KHz) Stimulation|This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultrahigh frequency spinal cord stimulation in patients with chronic back pain or lower limb pain.
2857884|NCT03543072||exposure group|exposed to some factors
2857885|NCT03543072||control group|not exposed to some factors
2857886|NCT03543059||exposure group|exposed to some factors
2857887|NCT03543059||control group|not exposed to some factors
2857888|NCT03543046|Experimental|Tortle Midliner|The use of the Tortle Midliner will be in addition to the NICU department process guidelines for positioning relevant to the gestational age of the subject. The Tortle Midliner will be applied no later than 3 hours following birth under the supervision of a study investigator. The size/fit and application of the device will be according to the manufacturer's guidelines. The neutral midline head position, supine or slightly side-lying, with a bed elevation between 15° and 30° will be maintained during the first 72 hours of life.
2857889|NCT03543046|No Intervention|Control Group|All clinical care for the control group will be within NICU department process guidelines relevant to the gestational age of the subject and as ordered by physician and/or ARNP providers. The neutral midline head position with the aid of nesting and/or rolls with a bed elevation between 15° and 30° will be maintained throughout position changes during the first 72 hours of life, which is standard practice. Caregivers will document the NICU integrated flowsheet and the Sunrise electronic record with interventions regarding positioning, handling, skin assessment etc. per standard practice requirements.
2857890|NCT03543033|Experimental|Treatment|Patients will receive a corticosteroid epidural injection within 2 weeks of their scheduled lumbar surgery
2857891|NCT03543033|No Intervention|Control|Patients will not receive a corticosteroid injection within 2 weeks of their scheduled lumbar surgery.
2857892|NCT03543020||Patients|Patients undergoing Radiation therapy to brain
2857893|NCT03543007|Active Comparator|Cohort A|Subjects randomized to GrafixPL™ PRIME plus standard compression therapy will receive applications of GrafixPL™ PRIME plus standard compression therapy once weekly for up to 12 weeks.
2857894|NCT03543007|Placebo Comparator|Cohort B|Subjects randomized to standard compression therapy alone will receive standard compression therapy once weekly for up to 12 weeks.
2857895|NCT03542994|Other|Cohort 1|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 66 mg, capsule, once daily, 15 days
2857896|NCT03542994|Other|Cohort 2|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 15 days
2857897|NCT03542994|Other|Cohort 3|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 15 days
2857898|NCT03542994|Other|Cohort 4|12 subjects with mild to moderate psoriasis; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 29 days
2857899|NCT03542994|Other|Cohort 5|24 subjects with mild to moderate psoriasis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days
2857900|NCT03542994|Other|Cohort 6|"24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.~Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days"
2857901|NCT03542981|Active Comparator|Interferential Current Treatment|Interferential Current group received interferential current treatment 30 minutes, 2 times a day for 5 days after the surgery.
2857902|NCT03542981|Sham Comparator|Sham Interferential Current Treatment|In the sham interferential Current treatment, no electrical stimulation was applied to the probes with the same pads for the same time.
2857903|NCT03542968|Experimental|magnetic resonance imaging|MRI, 4D imaging, acquisition and analysis of 4D cardiac MRI images-A single, faster acquisition (8 to 15 minutes).
2857904|NCT03542955|Active Comparator|ActiPatch Group|Subjects in this group will receive an active pulsed shortwave therapy device to wear 24 hours a day for 4 weeks.
2857905|NCT03542955|Placebo Comparator|Control Group|Subjects in this group will take Etoricoxib 60mg, once daily for 4 weeks.
2857906|NCT03542942|Other|treatment with EXIT-target volume|The radiotherapeutic treatment plan is based on an EXIT-target volume in which the non-involved uterus is excluded from the target volume. All other delineations are performed conform standard of care.
2857908|NCT03542929|Experimental|diabetic elderly|diabetic elderly were use the Whole body vibration intervention during 10 minutes
2857909|NCT03542916|Experimental|CJ-40001|CJ-40001 60ug SC, IV injection
2857910|NCT03542916|Active Comparator|NESP|NESP 60ug SC, IV injection
2857911|NCT03542903|Active Comparator|Short ECT arm|In the short arm, bitemporal ECT is administered twice a week during the first 6 weeks. Afterwards, it is administered once a week during 4 weeks. After that, the patients will have one ECT every 3 weeks during 6 weeks. Lastly, patients will receive one ECT each month during 2 months.
2857912|NCT03542903|Active Comparator|Long ECT arm|In the long arm, bitemporal ECT is administered twice a week during the first 12 weeks. Afterwards, it is administered once a week during 8 weeks. After that, the patients will have one ECT every 3 weeks during 12 weeks. Lastly, patients will receive one ECT each month during 4 months.
2857913|NCT03542890|Active Comparator|Baska Mask|It has a non-inflatable cuff, which is moulded to take up the shape of the supraglottic airway, potentially reducing the risk of oropharyngeal tissue and/or nerve damage induced by cuff over inflation, a known complication with other supraglottic airways.
2857914|NCT03542890|Active Comparator|I-gel|The I-gel is a single use (SADs) composed of a soft ,gel-like, non-inflatable cuff made from a thermoplastic elastomer. It has a widened , flattened stem with a rigid bite block that acts as a buccal stabilizer to reduce axial rotation and mal-positioning and a port for gastric tube insertion. It is a latex free device that does not require digital insertion into mouth of patient.
2857915|NCT03542877|Experimental|Stage 1|Up to 16 patients will be enrolled to take 60mg of cabozantinib, by mouth, once a day, every day, for 12 weeks. If less than three patients have Progression Free Survival (PFS) lasting at least 12 weeks, the study will be terminated.
2857916|NCT03542877|Experimental|Stage 2|Up to 28 patients will be enrolled to take 60mg of cabozantinib, by mouth, once a day, every day, for 12 weeks.
2857917|NCT03542864|Experimental|Nasogastroduodenal Protocol|Evaluation of a protocol for the treatment of excess body fat through duodenal nutrition
2857918|NCT03542864|Active Comparator|Controls|Change from Baseline Body Composition values at 1 and 3 months
2857919|NCT03542864|Other|Data analysis|Analysis and publication of data
2857920|NCT03542851|Experimental|Subject Receives BTD001 first|
2857921|NCT03542851|Experimental|Subject Receives Placebo first|
2857922|NCT03542838|Experimental|Resiniferatoxin|Resiniferatoxin is administered as a one-time dose, intra-articularly at dose level of 5ug, 12.5ug, 20ug, 25ug, 30ug
2857923|NCT03542838|Placebo Comparator|Saline|Saline is administered as a one-time dose, intra-articularly.
2857924|NCT03542825|Active Comparator|Iron Sulphate|ferrous sulphate 150 mg iron capsule once daily for 3 consecutive months.
2857925|NCT03542825|Active Comparator|Amino acid Chelated|amino acid chelated iron capsule 15mg for 3 consecutive months.
2857926|NCT03542825|Active Comparator|Lactoferrin|lactoferrin 100 mg sachets once daily for 3 consecutive months.
2857927|NCT03542812|Experimental|Single-dose|"Participants will be enrolled into the two groups, Group 1 (which will consist of 10 participants) and Group 2 (which will consist of 8 participants) in an alternating basis. Both Group 1 and Group 2 participants will receive a single, 150 mg/kg dose of oral L-citrulline. Population PKs will be done for both groups, at up to 3 time points.~Multiple interim time points and following completion of enrollment into Groups 1 and 2, data analysis will be done and results reviewed by the data safety monitoring board (DSMB). After the DSMB review is complete, enrollment into Group 3 will begin."
2857928|NCT03542812|Experimental|Steady-state|To evaluate the tolerability and ability to achieve target trough L-citrulline levels of 100-150 µM, an additional group of 18 infants (group 3) will be given oral L-citrulline doses at intervals over a total of 72 hours. If the participant is not nipple feeding, the dose will be delivered via the participant's indwelling gavage feeding tube. The dose and interval of L-citrulline will be based on results from the studies that assess pharmacokinetic parameters using a maximum daily dose of 3 g/kg/d. Blood draws for PKs will be done at baseline and prior to last dose of L-citrulline. Urine will be collected to measure nitric oxide metabolites.
2857929|NCT03542799|Experimental|3|anti-tumor response of EGFR IL12 CART
2857930|NCT03542786|Experimental|i3.1|This group will have their habitual antiretroviral therapy (integrase inhibitor (INI), protease inhibitor (IP), reverse transcriptase inhibitor (ITINAN)) combined with the research product (probiotic i3.1). The prebiotic will be taken once a day during 6 months.
2857931|NCT03542786|Experimental|i3.1 + ProSeed|This group will have their habitual antiretroviral therapy combined with the probiotic (i3.1) and the prebiotic (ProSheed). The prebiotic and probiotic will be taken once a day during 6 months.
2857932|NCT03542786|Placebo Comparator|Placebo|This group will only have their habitual antiretroviral therapy. The placebo will be taken once a day during 6 months.
2857933|NCT03542773|Experimental|18F-DCFPyL|A bolus of less than or equal to 9 mCi (331 MBq) of IV injection of 18F-DCFPyL
2857934|NCT03542760||Primary Treated Group|Subjects who are administered methylene blue for treatment of acquired methemoglobinemia that is symptomatic (eg, exhibiting sleepiness, cyanosis, dizziness, etc) or with measured methemoglobin levels > 30%.
2857935|NCT03542760||Secondary Treated Group|Subjects who are administered methylene blue for treatment of acquired methemoglobinemia with measured methemoglobin levels ≤ 30 and lack of clinical symptoms
2857936|NCT03542747|Experimental|Time to ventilation with the iLTS|Measuring the time to ventilation (ET) based of insert the iLTS until the chest rise of the simulator in seconds
2857937|NCT03542747|Experimental|Time to ventilation with the Fastrach|Measuring time to ventilation (ET) based of insert the Fastrach until the chest rise of the simulator in seconds
2857938|NCT03542734||Individuals with SVDs|Individuals with at least one following imaging finding: recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, or brain atrophy on baseline brain MRI.
2857939|NCT03542734||Individuals without SVDs|Individuals without any following imaging finding: recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, or brain atrophy on baseline brain MRI.
2857940|NCT03542721|Placebo Comparator|Placebo of DA-5515 Capsule|Placebo of DA-5515 (three times a day)
2857941|NCT03542721|Experimental|DA-5515 Capsule|Garlic oil, Gingko biloba ex.,Crataegus berry ex.,Melissa officinalis ex., (three times a day)
2860815|NCT03522883|Experimental|experimental group 1|carbohydrate intake prior to exercise
2857942|NCT03542708|Experimental|A-PRP|The cortex of selected ovary will be injected with autologous platelet rich plasma.
2857943|NCT03542708|No Intervention|Control|The contralateral ovary will not be injected.
2857944|NCT03542695|Experimental|Diagnostic (64Cu-DOTA-alendronate, PET/CT scan)|Participants receive 64Cu-DOTA-alendronate IV and undergo PET/CT imaging 60 minutes after injection. Participants with sufficient levels of residual radioactivity may undergo repeat imaging on day 1 as determined by the study team.
2857945|NCT03542682|Active Comparator|Individuals given Standard Bolus|Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.
2857946|NCT03542682|Active Comparator|Individuals given Quick bolus|Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.
2857947|NCT03542656|Experimental|amyloid PET|PET/CT
2857948|NCT03542643|Active Comparator|N-3 polyunsaturated fatty acids|n-3 polyunsaturated fatty acids dosage of 1g of Eicosapentaenoic acid(EPA)
2857949|NCT03542643|Placebo Comparator|Placebo|olive oil ethyl esters
2857950|NCT03542630||fertile, without periodontitis|"Women who gave birth to at least one child, without preovious fertility treatments, and who do not have periodontitis.~Interventions:~salivary MMP8 test; periodontal examination; blood tests"
2857951|NCT03542630||fertile, with periodontitis|"Women who gave birth to at least one child, without preovious fertility treatments, and who do have periodontitis.~Interventions:~salivary MMP8 test;periodontal examination;blood tests"
2857952|NCT03542630||infertile, without periodontitis|"Women who are diagnosed with infertility of unknown cause, and who do not have periodontitis.~Interventions:~salivary MMP8 test; periodontal examination;blood tests"
2857953|NCT03542630||infertile, with periodontitis|"Women who are diagnosed with infertility of unknown cause, and who do have periodontitis.~Interventions:~salivary MMP8 test; periodontal examination; blood tests"
2857954|NCT03542617|Placebo Comparator|Normal Saline Solution|The control group receive sterile normal saline solution, as placebo, intravenous immediately prior to induction of spinal anesthesia .
2857955|NCT03542617|Active Comparator|10 mg Dexamethasone|The steroid group will receive Dexamethasone 10 mg IV immediately prior to induction of spinal anesthesia
2857956|NCT03542617|Active Comparator|40 mg Dexamethasone|The steroid group will receive Dexamethasone 40 mg IV immediately prior to induction of spinal anesthesia
2857957|NCT03542604|Experimental|CBT-I + BWL|Cognitive behavioral therapy intervention for insomnia: 6 sessions over 8-week period combining education and behavioral techniques to reduce insomnia. Sleep intervention followed by behavioral weight loss intervention.
2857958|NCT03542604|Placebo Comparator|EDU + BWL|Program will parallel the CBT-I intervention in number and length of sessions. Intended to disseminate basic information about sleep, including behavioral treatment information that is widely available to patients and practitioners.Will be followed by behavioral weight loss intervention.
2857959|NCT03542591||Participants of the VegMed congress (Berlin, April 2018)|
2857960|NCT03542565|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
2857961|NCT03542565|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
2857962|NCT03542552|Active Comparator|Nifidipne|received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
2857963|NCT03542552|Experimental|Magnisum sulphate|Patients in the MgSO4 group received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
2857964|NCT03542500|No Intervention|Control|Youth randomized into the control arm of this study will be quantitatively assessed at the same time points as youth randomized into the two treatment arms (baseline, 3-months, 12-months). Due to access to funding and feasibility, youth in the control arm and EPP-only arm will not have the opportunity to receive the YRI once the study period concludes. However, GIZ is conducting a phased roll out of their EPP programming, meaning they will offer their EPP throughout 2018 past their participation in Youth FORWARD. Youth will also be compensated for their participation in our quantitative assessments.
2857965|NCT03542500|Experimental|Entrepreneurship Training|Youth randomized into the Entrepreneurship Training-only arm will receive GIZ's employment programming approximately three months after the completion of the baseline assessments. The GIZ-supported Entrepreneurship Training program includes six training modules, delivered over three weeks, to include skills development, financial literacy, and other skills necessary to secure employment or engage in livelihood activities.
2857966|NCT03542500|Experimental|YRI+Entrepreneurship Training|Youth randomized into the YRI+Entrepreneurship Training arm will begin the YRI module within two weeks after the completion of baseline assessments. The YRI curriculum (12 modules), will be delivered in 12 weekly 90-minute sessions, with additional time taken as needed. These weekly sessions assume a peer-to-peer group learning format deemed culturally appropriate for a setting like Sierra Leone where limited resources for mental health services exist. Once youth complete the YRI they will complete a post-intervention (3-months) quantitative assessment. Following the completion of the quantitative assessments, youth will receive the Entrepreneurship Training.
2857967|NCT03542487|No Intervention|1: Control|A randomly selected half of primary care practices in the study sample at Inova Health Care Services will not receive any intervention and patients/physicians located at these practices will continue with business as usual.
2857968|NCT03542487|Experimental|2a: Practice Orientation- No Reminder|In the other randomly selected half of primary care practices in the study sample at Inova Health Care Services, practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2a will receive no additional reminder messaging to enter glucose measurements in the electronic flowsheets.
2858113|NCT03541512|Active Comparator|Mindfulness & Education|Mindfulness practice using guided HeadSpace medications plus educational materials
2858114|NCT03541512|Active Comparator|Education only|Educational materials only
2857969|NCT03542487|Experimental|2b: Practice Orientation- Standard Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2b will receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets.
2857970|NCT03542487|Experimental|2c: Practice Orientation- Gift Card Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2c will receive generic biweekly reminders to enter data, addressed from Inova Medical Group, that will also notify that the patient will be entered to win a $50 gift card for each day entering data.
2857971|NCT03542487|Experimental|2d: Practice Orientation- Physician Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2d will receive biweekly reminders, addressed from their physician, encouraging them to enter glucose measurements in the electronic flowsheets (Note that though messages will be addressed from physician, they will be sent by Inova IT).
2857972|NCT03542474|Experimental|Exercise|6 months of high intensity endurance exercise on a treadmill (3 times per week)
2857973|NCT03542461|Experimental|A_Nivolumab|Nivolumab 240 mg IV every 2 weeks until disease progression, unacceptable toxicity, patient refusal or Investigator's decision
2857974|NCT03542461|Other|B_Best Supportive Care|Best Supportive Care until disease progression followed by Nivolumab at a dose of 240 mg IV until further disease progression, unacceptable toxicity, patient refusal or Investigator's decision.
2857975|NCT03542448||Study group|"97 eye of 49 normal Egyptian volunteers were divided into groups according to age, AL, SE of refractive error, minimum corneal thickness (MCT) and mean corneal power as follow:~Age into 3 groups:~Group A: from 18 to 30 years old Group B: from 31 to 40 years old Group C: > 40 years old~Axial length into 3 groups:~Group A: from 22 to less than 24 mm Group B: from 24 to 26 mm Group C: > 26 mm~Spherical equivalent of refractive error into :~Group A : from zero to - 2 D Group B : from - 2 to > - 4 D Group C : from - 4 to > - 6 D Group D: from - 6 to - 8 D~Minimum corneal thickness (MCT) into 3 groups:~Group i: < 500 um Group ii: from 500 to 540 um Group iii: > 540 um~Refractive power of cornea (Mean K) into 3 groups:~Group 1: 41 to less than 44 D Group 2: 44 to 46 D Group 3: > 46 D"
2857976|NCT03542435|Experimental|SXC-2023|Dose Escalation
2857977|NCT03542435|Placebo Comparator|Placebo|Dose Escalation
2857978|NCT03542422|Experimental|Apatinib|Apatinib 500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.
2857979|NCT03542409|Experimental|Group A (contrast enhancing tumor)|Group A patients will undergo standard tumor preoperative imaging and MR perfusion scan prior to surgical resection. Group A patients will undergo standard intraoperative imaging along with MR perfusion scan during surgical resection.
2857980|NCT03542409|Experimental|Group B (non-enhancing tumor)|Group B patients will undergo standard tumor preoperative imaging and 2HG spectroscopy scan prior to surgical resection. Group A patients will undergo standard intraoperative imaging along with 2HG spectroscopy scan during surgical resection.
2857981|NCT03542396|Experimental|Control|
2857982|NCT03542396|Experimental|ImPuls|
2857983|NCT03542383|Active Comparator|Active HD tDCS|Administer 10 20-minute sessions of 1 mA anodal High Definition Transcranial Direct Current Stimulation to the preSMA region over a two week period.
2857984|NCT03542383|Sham Comparator|Sham HD tDCS|Administer 10 20-minute sessions of sham High Definition Transcranial Direct Current Stimulation to the preSMA region over a two week period.
2857985|NCT03542357|Active Comparator|Sumatriptan|headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg as a pre-treatment
2857986|NCT03542357|Placebo Comparator|Placebo|headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of placebo as a pre-treatment
2857987|NCT03542344|Experimental|BI 1015550|
2857988|NCT03542344|Placebo Comparator|Placebo|
2857989|NCT03542331|Other|Control group|The control group wille have a mock catheter introduction between day 6 and 8 of the cycle without any Lipiodol flush
2857990|NCT03542331|Experimental|Intervention group|The intervention group will undergo endometrial flushing with Lipiodol between day 6 and 8 of the cycle
2857991|NCT03542318||Active group (Experimental)|Total of 60 patients were enrolled. All patients were referred for PR from the outpatient clinics of the local general hospital. Pulmonary fibrosis was confirmed through a high resonance computed tomography scan and pulmonary function testing. Participants who required modifications to their drug therapy due to exacerbations were excluded from the study. Each participant was classified according to the modified Medical Research Council dyspnoea scale
2858040|NCT03542058|Experimental|Treatment Group|Study participants will receive carvedilol for a period of 6 month. The initial dosage of carvedilol will be 3.125mg twice daily. Dosage will be titrated up two weekly until the maximum tolerable dose or ceiling dose of 25mg twice daily has been reached.
2858041|NCT03542058|No Intervention|Control Group|Study participant will not receive any cardiac medication, apart from standard cancer care.
2857992|NCT03542318||Inactive control group|A total of 60 patients were enrolled in a control group. All were referred for PR from the outpatient clinics of the local general hospital. In this group patients who requested not to carry out the intervention but participate in the investigations were enrolled. Each participant was classified according to the modified Medical Research Council dyspnoea scale, and placed in one of 5 categories (0 to 4) according to self-perceived breathlessness during daily activities
2857993|NCT03542305|Experimental|Mild|Mild renal impairment
2857994|NCT03542305|Experimental|Moderate|Moderate renal impairment
2857995|NCT03542305|Experimental|Severe|Severe renal impairment
2857996|NCT03542305|Other|Normal|Normal renal function
2857997|NCT03542292|Experimental|placental drainage group|In study group; umbilical cord was clamped from fetal side but unclamped from maternal side. After that unclamped side of umblical cord was left open to drain the blood until the flow ceased. The blood was collected in the metal bowl and measured using a measuring jar. Care was taken not to mix the drained blood from the cord with the blood lost during the third stage.
2857998|NCT03542292|Active Comparator|no placental drainage group|In control group the umblical cord was clamped both sides.
2857999|NCT03542279|Experimental|plasma exchange group|Plasma exchange (PE; 3-5 times in each course) combined with medication immunotherapy (glucocorticoid therapy, intravenous gamma immunoglobulin 0.4 g/kg/d for each course for 5 d)
2858000|NCT03542279|Active Comparator|medication immunotherapy group|medication immunotherapy (glucocorticoid therapy, intravenous gamma immunoglobulin 0.4 g/kg/d for each course for 5 d)
2858001|NCT03542266|Experimental|CC486 +CHOP|CC486 +CHOP
2858002|NCT03542253||Age|
2858003|NCT03542253||Sex|
2858004|NCT03542253||triglyceride|
2858005|NCT03542253||Lipoprotein|
2858006|NCT03542253||CT|Target Reconstruction
2858007|NCT03542253||micorRNA-A Plasma exocrine|
2858008|NCT03542253||micorRNA-A Paracancerous tiusse|
2858009|NCT03542253||pathologic diagnosis|
2858010|NCT03542253||hemolysis|
2858011|NCT03542253||ct-DNA|
2858012|NCT03542253||micorRNA-A in plasma|
2858013|NCT03542253||Sample quality control|
2858014|NCT03542253||positive|
2858015|NCT03542253||negative|
2858016|NCT03542253||micorRNA-R in plasma|
2858017|NCT03542253||micorRNA-R in Plasma exocrine|
2858018|NCT03542253||Surgery|
2858019|NCT03542240|Experimental|Curcumin|
2858020|NCT03542214|Experimental|Calcium electroporation treatment|Experimental treatment with calcium electroporation for inoperabel colorectal cancer
2858021|NCT03542201|Experimental|PLS|Plain abstract about the Cochrane systematic review.
2858022|NCT03542201|Experimental|Blogshot|Blogshot presentation of the results of Cochrane systematic review.
2858023|NCT03542188|Active Comparator|Primary Stroke Center (PSC)|Transport to a primary stroke center for early IV-thrombolysis followed by a secondary transport to a comprehensive stroke center for EVT if needed.
2858024|NCT03542188|Experimental|Comprehensive Stroke Center (CSC)|Direct transport to a comprehensive stroke center for IV-trombolysis and early EVT.
2858025|NCT03542175|Experimental|Rucaparib Administered With Radiation|"Treatment will consist of rucaparib at one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.~Radiotherapy will consist of 50 Gy in 2 Gy per fraction to the breast or chest wall with or without regional nodes plus a 10 Gy boost to the lumpectomy cavity, to a total dose of 60 Gy. A 10 Gy boost to the post-mastectomy scar is allowed at the discretion of the treating physician."
2858026|NCT03542162|Experimental|Healaflow group|The Healaflow group consists of patients with primary RRD, but exclude proliferative vitreoretinopathy grade C or more, dialysis, retinoschisis, eyes with secondary RRD, significant corneal or lens opacity precluding vitrectomy, giant retinal tears, a follow-up period of less than 3 months, and visual loss from causes other than RRD.
2858027|NCT03542149|Experimental|A|"200mg of OZ439 and 480 mgPQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
2858028|NCT03542149|Experimental|B|"200mg of OZ439 and 640 mg PQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
2858029|NCT03542149|Experimental|C|"400mg of OZ439 and 480 mg PQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
2858030|NCT03542149|Experimental|D|"400mg of OZ439 and 640 mg PQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
2858031|NCT03542136|Other|Patients receiving chemotherapy treatment with oxaliplatin.|
2858032|NCT03542123|Experimental|NeuroTronik CANS Therapy® System|
2858033|NCT03542110|Active Comparator|Alirocumab 150 MG/ML subcutaneous injection|Alirocumab 150 mg subcutaneously every 2 weeks
2858034|NCT03542110|Placebo Comparator|Matching Placebo subcutaneous injection|Matching placebo subcutaneously every 2 weeks
2858035|NCT03542097||Temozolomide and Irinotecan treatment|The group include all the patients with histological confirmed diagnosis of Ewing's Sarcoma who received chemotherapic treatment with temozolomide and irinotecan. In this group the MGMT methylation evaluation will be done
2858036|NCT03542084|Experimental|Intervention: Unsolicited e-consult|The PCP of intervention arm patients will receive an unsolicited e-consult by an endocrinologist offering clinical guidance on how to optimize the patients' glycemic control
2858037|NCT03542084|No Intervention|Control|Control arm patients will receive usual care
2858038|NCT03542071|Experimental|Carbohydrate restricted diet|Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.
2858039|NCT03542071|Experimental|Plant-protein based diet|Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.
2858042|NCT03542032|Other|jaw-thrust|"the i-gel was inserted with triple airway maneuver (mouth opening, head extension and jaw thrust) This groups will record the insertion time of i-gel, number of trials, operative time, placement complications.~Recorded complications (blood, laryngospasm, etc.) during insertion and removal of supraglottic airway devices will be assessed.~Patients' postoperative sore throat will be questioned and recorded."
2858043|NCT03542032|No Intervention|classic group|"In the classic group, the index finger used as a guide, pushes the back of i-gel towards the hard palate, inserting it into the pharynx till a resistance is felt and the i-gel is then fixed it its place. This groups will record the insertion time of i-gel, number of trials, operative time, placement complications.~Recorded complications (blood, laryngospasm, etc.) during insertion and removal of supraglottic airway devices will be assessed.~Patients' postoperative sore throat will be questioned and recorded."
2858044|NCT03542019|Active Comparator|Lithium disilicate|Lithium disilicate: a type of ceramic material used to make a dental prosthesis that replaces missing tooth structure following root canal treatment. Other names might include: E-max crowns, computer-aided design and computer-aided manufacturing (CAD CAM) crowns
2858045|NCT03542019|Active Comparator|Monolithic zirconia|Monolithic zirconia: a type of ceramic material used to make a dental prosthesis that replaces the missing tooth structure following root canal treatment. Other names might include: Zolid crown, Bruxzir, Bretau, CAD CAM crowns
2858046|NCT03542019|Active Comparator|Hybrid ceramic|Hybrid ceramic: a type of ceramic material used to make a dental prosthesis that replaces the missing tooth structure following root canal treatment. Other names might include: Enamec, Lava Ultimate, CAD CAM crowns
2858047|NCT03542006|Experimental|Topical brinzolamide|Brinzolamide ophthalmic, given bd for 3 months
2858048|NCT03541993|Experimental|Resveratrol Hypoxia|500 mg of trans-resveratrol, tested at a 12.7% atmospheric oxygen level; the equivalent to 4000m above sea level.
2858049|NCT03541993|Placebo Comparator|Placebo Hypoxia|Pharmaceutical grade fumed silica, tested at a 12.7% atmospheric oxygen level; the equivalent to 4000 m above sea level.
2858050|NCT03541993|Experimental|Resveratrol Normoxia|500 mg of trans-resveratrol, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
2858051|NCT03541993|Placebo Comparator|Placebo Normoxia|Pharmaceutical grade fumed silica, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
2858052|NCT03541980|Active Comparator|Intervention|Patients allocated to receive IV acetaminophen
2858053|NCT03541980|Placebo Comparator|Placebo|Patients allocated to receive IV normal saline placebo
2858054|NCT03541967|Other|ADHEAR-PONTO|The ADHEAR system will be fitted to the patient who will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the ADHEAR system. Then the patient will be fitted with the PONTO 3 SUPER POWER on softband and will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the PONTO 3 SUPER POWER on softband.
2858055|NCT03541967|Other|PONTO-ADHEAR|The PONTO 3 SUPER POWER on softband will be fitted to the patient who will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the PONTO 3 SUPER POWER on softband. Then the patient will be fitted with the ADHEAR system and will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the ADHEAR system.
2858056|NCT03541954|Other|Patient with pelvic or perineal pain with sensitization|Patients with chronic pelvic or perineal pain with sensitization (Convergences PP criteria > 5)
2858057|NCT03541954|Other|Patient with pelvic or perineal pain without sensitization|Patients with chronic pelvic or perineal pain without sensitization (Convergences PP criteria < 5)
2858058|NCT03541941|Experimental|Exparel|Solution of 266mg of Exparel + 150mg Bupivacaine HCL + 40cc normal saline= 120cc administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
2858059|NCT03541941|Active Comparator|Bupivacaine Hcl 0.25% Inj|Solution of 150mg Bupivacaine HCL expanded with 60cc of normal saline=120cc administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
2858060|NCT03541941|Placebo Comparator|Placebo|120 cc of normal saline administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
2858061|NCT03541928|Experimental|Gene Therapy, ADT, RT, and Surgery|"The investigational gene therapy, ADV/HSV-tk, will be administered by injection into the prostate at 5 x 10[11] virus particles (1.25 x 10[11] virus particles per tumor quadrant in 4 quadrants) on day 0 and day 30.~The recommended dose of Valacyclovir for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45).~The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening).~Leuprolide acetate 7.5mg depot injection will be injected monthly for a total of 2 months."
2858062|NCT03541915|Experimental|Mg group|20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.
2858063|NCT03541915|Placebo Comparator|Control group|Same volume of normal saline will be infused after induction of anesthesia. And the same volume of normal saline will be continuously infused at a same rate of magnesium during the operation.
2858064|NCT03541902|Experimental|Cabozantinib Group|"Participants take Cabozantinib 60 mg tablets by mouth 1 time a day.~Each study cycle is 6 weeks."
2858065|NCT03541902|Experimental|Sunitinib Group|Participants take Sunitinib 50 mg tablets by mouth 1 time a day on Days 1-28 and then not take any drug between Days 29-42.
2858066|NCT03541889||Cord and haplo imaging cohort|For all pediatric and adult patients undergoing cord blood HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 9 and 28 after HSCT. For recipients of haplo-HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 5 and 28 after HSCT.
2858067|NCT03541889||Nonengrafted cohort|Pediatric and adult patients who have not engrafted by day 24 after cord or haplo-identical HSCT will undergo a single FLT PET/CT image within one week to determine if this scan can identify graft failure versus delayed engraftment.
2858068|NCT03541876||children with H. pylori infection|
2858069|NCT03541863||Endocrine therapy|use endocrine therapy (ET) after Fulvestrant, include but not limited to: tamoxifen, anastrozole, letrozole, exemestane, exemestane + everolimus
2858070|NCT03541863||Chemotherapy|use Chemotherapy (CT) after Fulvestrant, include but not limited to: capecitabine, docetaxel-based, vinorelbine, paclitaxel-based
2858071|NCT03541850|Experimental|Treatment (SBRT, ADT)|Patients undergo SBRT QOD for 14 days. Patients may also receive ADT comprised of a luteinizing hormone-releasing hormone agonist or a gonadotropin-releasing hormone antagonist, and an oral anti-androgen for 6 months at the discretion of the treating physician.
2858072|NCT03541837|Other|peri operative analgesia|Post operative regional analgesia by Erector Spinae bilateral catheters with infusion of ropivacaine
2858073|NCT03541824|Experimental|Body Acceptance Program|The Body Acceptance Program (BAP) is the active condition. Participants engage in an online intervention during which they complete online and offline activities designed to challenge the appearance-ideal.
2858074|NCT03541824|No Intervention|Waitlist control|Participants in the waitlist control group completed baseline and follow-up assessments with no intervention.
2858075|NCT03541811||patients with hemophilia (16-45y)|not applicable (no intervention administered)
2858076|NCT03541811||peer-matched healthy control|not applicable (no intervention administered)
2858077|NCT03541798|Active Comparator|Traditional sitting position|"Patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion before spinal anesthesia begun.~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
2858078|NCT03541798|Experimental|Harmstring stretch position|"the patients sit up from supine position with the legs remaining on the operating table, knees are maximally extended.~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
2858079|NCT03541798|Experimental|Squatting position|"the patients sit up from supine position with the legs remaining on the operating table, hips and knees are maximally flexed .~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
2858080|NCT03541772|Experimental|Oncoxin-Viusid®|Radiotherapy + Chemotherapy + Oncoxin-viusid®
2858081|NCT03541772|Placebo Comparator|Placebo|Radiotherapy + Chemotherapy + Placebo
2858082|NCT03541759|Active Comparator|Hydromorphone|Hydromorphone Hcl 4 milligram (mg) Tab 2 times after surgery as basic medication. Hydromorphone Hcl 2.6mg maximum 2 per 24h when numeric rating scale (NRS) > 5.
2858083|NCT03541759|Active Comparator|Piritramide|Piritramide 15mg s.c. 2 times after surgery as basic medication. Piritramide 7.5mg s.c. maximum 2 per 24h when numeric rating scale (NRS) > 5.
2858084|NCT03541746|Experimental|Study Group|Platelet Rich Plasma
2858085|NCT03541746|Active Comparator|Control Group|Intrauterine Foley's Catheter
2858086|NCT03541733|Experimental|Tubing-group|mid-gut tubing prior to the MRE examination, administer contrast solution through the mid-gut tube
2858087|NCT03541733|No Intervention|Oral-group|administer contrast solution orally, mid-gut tubing after the MRE examination
2858088|NCT03541720|Experimental|Injection of 18F-DA|18F-DA will be injected into a vein in the arm or leg, or via central venous access line.
2858089|NCT03541707|Active Comparator|Active Therapy|
2858090|NCT03541707|Sham Comparator|"As if Stimulation"|
2858091|NCT03541681|Active Comparator|Glucocorticoid Injections|A series of three cervical transforaminal local anesthetic (0,5 ml Bupivacain) injections with glucocorticoid (1 ml Dexamethasone) within 3 months.
2858092|NCT03541681|Active Comparator|Local Anesthetic Injections|A series of three cervical transforaminal local anesthetic (0,5 ml Bupivacain) injections without glucocorticoid (Dexamethasone) within 3 months.
2858093|NCT03541668|Experimental|Recombinant Human Prourokinase|
2858094|NCT03541668|Active Comparator|Alteplase|
2858095|NCT03541655|Active Comparator|Standard of care analgesia|0.25% Bupivacaine HCl administered following total knee replacement
2858096|NCT03541655|Experimental|F14 (celecoxib)|3.5 mL dose of F14 (celecoxib) concurrent with 0.25% Bupivacaine HCl administered following total knee replacement
2858097|NCT03541642|Experimental|Enhanced Intervention|Women who are eligible and randomized to the Enhanced Intervention will receive targeted PrEP counseling; targeted written/visual materials, follow up supportive text messages, and distribution of PrEP at the syringe exchange
2858098|NCT03541642|Active Comparator|Basic Intervention|"Women who are eligible and randomized to the Basic Intervention will receive usual care with general messaging from medical personnel, reminder text messages, and distribution of PrEP at the syringe exchange"
2858099|NCT03541616||Enrolled Patients|
2858100|NCT03541603|Experimental|Levosimendan 2.5mg/mL Injectable Solution|0.075 - 0.1µg/kg/min for 24 hrs (weekly)
2858101|NCT03541603|Placebo Comparator|Matching Placebo|0.075 - 0.1µg/kg/min for 24 hrs (weekly)
2858102|NCT03541577||Participants|Subjects who meet the inclusion criteria and do not meet the exclusion criteria and undergo FFR measurement with the TruePhysioTM Microcatheter and the Pressure Wire
2858103|NCT03541564|Experimental|BMS-986165 Dose 1 oral administration|BMS-986165 therapeutic single dose
2858104|NCT03541564|Experimental|BMS-986165 Dose 2 oral administration|BMS-986165 supratherapeutic single dose
2858105|NCT03541564|Active Comparator|Moxifloxacin Dose 3 oral administration|Moxifloxacin positive control single dose
2858106|NCT03541564|Placebo Comparator|Placebo Dose 4 oral administration|Placebo single dose
2858107|NCT03541551|Experimental|CTT with ologen® Collagen Matrix|Experimental: Trabeculotomy with trabeculectomy with ologen implant
2858108|NCT03541551|Active Comparator|Trab Trab|Active Comparator: Trabeculotomy with trabeculectomy
2858109|NCT03541538|Active Comparator|Global manipulation|Manual therapy performed in the cervical region in a non-specific way.
2858110|NCT03541538|Experimental|Especific manipulation|manual therapy performed specifically on the C6-7 segment
2858111|NCT03541525||Affected patients|Biological samples of blood for all patients. Biological samples of saliva, surgical remainder (skin, tumor, kidney,....), saliva, urine, hair.
2858115|NCT03541499|Experimental|Group 1|800 microliters (10^7 CFU) of B. pertussis vaccine (BPZE1) administered intranasally with the VaxINator device on Day 1, n=15
2858116|NCT03541499|Experimental|Group 2|800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1, n=15
2858117|NCT03541499|Placebo Comparator|Group 3|800 microliters of Placebo administered intranasally with the VaxINator device on Day 1, n=15
2858118|NCT03541499|Experimental|Group 4|800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1, n=5
2858119|NCT03541486|Experimental|Concomitant Therapy|75 grams of pharmacological ascorbate, daily (M-F) 600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique
2858120|NCT03541473|Active Comparator|Peptamen® 1.5 Vanilla|
2858121|NCT03541473|Placebo Comparator|Boost Plus® Vanilla|
2858122|NCT03541460||Older Cohort|Demographic, health and functional data will be collected from subjects 95 years and older by means of a structured interview. Blood will be collected for laboratory and genetic testing.
2858123|NCT03541460||Younger Controls|Demographic, health and functional data will be collected from the children of the older subjects and other aged-matched controls by means of a structured interview. Blood will be collected for laboratory and genetic testing.
2858124|NCT03541447|Experimental|Tolvaptan plus Octreotide LAR / Tolvaptan plus Placebo|Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of Octreotide LAR (two 20 mg i.m. injections). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of placebo (two i.m. injections of 0.9% NaCl solution)
2858125|NCT03541447|Experimental|Tolvaptan plus placebo/Tolvaptan plus Octreotide LAR|Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of placebo (two i.m. injections of 0.9% NaCl solution). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of Octreotide LAR (two 20 mg i.m. injections).
2858126|NCT03541434||Healthy|Children with no history of adenotonsillar hypertrophy, recurrent tonsillitis, or middle ear effusion. They presented to the clinic for examination or a scheduled procedure.
2858127|NCT03541434||Recurrent tonsillitis|Children with a history of recurret tonsillitis but no adenotonsillar hypertrophy. Diagnosis was based on physical exam and complete blood count. They presented to the clinic for a sceduled tonsillectomy.
2858128|NCT03541434||Middle ear effusion|Children with chronic middle ear effusion but no adenotonsillar hypertrophy. Diagnosis was based on physical exam and tympanometry. They presented to the clinic for scheduled myringotomy with or without adenoidectomy.
2858129|NCT03541434||Adenotonsillar hypertrophy|Children with tonsillar and/or adenoidal hypertrophy. Diagnosis was based on physical exam and partly on x-ray of nasopharynx or nasopharyngoscopy. They presented to the clinic for scheduled tonsillectomy and/or adenoidectomy.
2858130|NCT03541421|Experimental|Intervention|The patients administers own drugs during hospital stay.
2858131|NCT03541421|No Intervention|Control|The patients receive medications from the medicine room dispensed by a nurse (standard care). No intervention
2858132|NCT03541408|Placebo Comparator|Control|Subjects will receive anesthesia
2858133|NCT03541408|Experimental|Preventative Delirium Protocol|"Consider regional block if applicable~Minimized fentanyl usage intraoperatively~Intubation + GA adjunct total: 1-2 mcg/kg~Sedation: 0-0.25 mcg/kg~Post-op: 0.5-1 mcg/kg~Avoid morphine~Avoid ketamine~Avoid diphenhydramine, dexamethasone, scopolamine, metoclopramide, and promethazine~Avoid H2-blockers (cimetidine, ranitidine, famotidine)~Avoid polypharmacy intraoperatively if possible (i.e. >5 new medications)~Fluid repletion based on maintenance and losses"
2858134|NCT03541395|Other|Testosterone|A Gonadotropin releasing hormone agonist (GnRH-agonist) is administered to lower the testosterone to castration levels. After four weeks testosterone undecanoate is administered to increase the testosterone to normal levels.
2858135|NCT03541382|Active Comparator|HIVST campaign arm|"Community representatives will be supported to plan and administer an HIVST campaign linked to HIV care and prevention services in their communities.~Clusters in this arm will also undergo a second stage randomisation with the following arms:~Repeat HIVST campaign arm: Approximately one year after the initial campaign, community representatives will be supported to plan and administer a repeat HIVST campaign linked to HIV care and prevention services in their communities.~Single HIVST campaign arm: Standard HTS will be provided by MoH at health facilities following delivery of a single HIVST campaign in year one."
2858136|NCT03541382|No Intervention|SOC arm|Standard HTS will be provided by MoH at health facilities.
2858137|NCT03541369|Experimental|Dose Escalation Phase|AMG 427 Dose-finding phase of the study
2858138|NCT03541369|Experimental|Dose Expansion Phase|AMG 427 MTD identified in dose escalation phase (or lower) will be administered to subjects.
2858139|NCT03541356|Active Comparator|Experimental: INP103-201 (L-dopa)|Ascending doses of active drug INP103 (L-dopa) delivered via the I231 Precision Olfactory Device (POD)
2858140|NCT03541356|Placebo Comparator|Placebo|Ascending doses of placebo delivered via the I231 Precision Olfactory Device (POD)
2858141|NCT03541343|Experimental|GreenBone|All patients will receive the GreenBone implant instead of bovine xenograft.
2858142|NCT03541330|Other|siblings|Brother or sister of a child has malignant haemopathy and follow-up in the pediatric hematology department
2858143|NCT03541317|Experimental|Step 1: Optimal First Line Implementation Strategy|"All schools enrolled will first be randomized to an optimal first line treatment in order to compare REP vs. REP + Coaching. Schools assigned to Step 1 treatment REP will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; and ongoing technical assistance in CBT implementation. Schools assigned to Step 1 treatment REP + Coaching will receive the REP components plus weekly visits from a CBT expert or Coach, for a minimum of 12 weeks."
2858160|NCT03541174|Experimental|Aprocitentan 25 mg DB|Part 1: Double-blind, randomized (1:1:1 ratio), parallel-group and placebo-controlled and lasts for 4 weeks. Subjects will receive aprocitentan 25 mg
2858161|NCT03541174|Experimental|Aprocitentan 12.5 mg DB|Part 1: Double-blind, randomized (1:1:1 ratio), parallel-group and placebo-controlled and lasts for 4 weeks. Subjects will receive aprocitentan 12.5 mg
2858144|NCT03541317|Experimental|Step 2: Added Value of Providing Facilitation|"After 2 months, schools will be assessed to determine whether they could benefit from augmenting their current strategy with a step-up strategy called Facilitation. Schools identified as potentially benefiting will be re-randomized to compare the added value of augmenting their current strategy with Facilitation, compared to continuing with their same strategy. Step 2 treatment strategy: step-up will include provision of an additional implementation strategy called Facilitation. A full-time Facilitator who is a member of the study team and has expertise in CBT, implementation methods, and use of EBPs in schools will support school professionals in strategic thinking and leadership skills to address organizational barriers. Sites receiving Facilitation will receive regular calls for up to a minimum of 10 weeks from the Facilitator. All schools will also continue to receive their first line treatment (i.e. REP or REP + Coaching)."
2858145|NCT03541291|Experimental|SMART-SYNC LM02|All participants
2858146|NCT03541278|Experimental|IM-SLNB with MIT|The radiotracer was injected with our modified injection technique (MIT) (periareolar intraparenchymal, high volume and ultrasonographic guidance). Internal mammary sentinel lymph node biopsy (IM-SLNB) was performed for patients with internal mammary visualized.
2858147|NCT03541265|Experimental|Adductor block protocol|An ultrasound-guided injection of Subsartorial saphenous nerve using Exparel 266 mg (20 cc vial) via a 21-gauge 4-inch Stimuplex A needle (B. Braun Medical Inc., Melsungen, Germany) was performed at mid-thigh level with a high-frequency linear ultrasound transducer. All regional anesthesia was performed by a trained anesthesiologist. Ultrasound pictures (pre-injection and post-injection) was obtained to verify proper local anesthetic placement.
2858148|NCT03541265|Active Comparator|peri-articular injection|Peri-articular injection included combination of Exparel 266 mg (20 ml vial) with 20 ml of 0.5% bupivacaine, and normal saline to a total volume of 120 ml. The injection was meticulously administered prior and after cementation in the posterior capsule, posteromedial structures, the periarticular synovium, extensor apparatus, pes anserinus, anteromedial capsule, periosteum, iliotibial band, and subcutaneous plane. Injections were performed using 20-mL syringes with 22-gauge needle, minimal leakage. Visible tissue expansion was achieved.
2858149|NCT03541252|Experimental|Basal Cell Carcinoma Patients|Patients (>18 years) with histologically-verified superficial or nodular basal cell carcinoma (<20 mm on the face/scalp, <50mm on the trunk/extremities)
2858150|NCT03541239|No Intervention|non-ischemic conditioning|The participants will have the cuff attached to the arm, however not be inflated for the 4 cycles of remote ischemic conditioning: 1 cycle is 5 minutes of inflation followed by 5 minutes of deflation. The ischemic reperfusion injury was induced by cuff inflation to 200 mmHg in the arm for 20 minutes followed by reperfusion for 15 minutes.
2858151|NCT03541239|Experimental|ischemic conditioning|The blood supply to the distal part of the arm will be occluded by inflation of a single cuff to 200mmHg, by the help of the Tourniquet 8000 device, for 5 minutes separated from 5 minutes of deflation, a cycle that happens 4 times in total. The ischemic reperfusion injury was induced by cuff inflation to 200 mmHg in the arm for 20 minutes followed by reperfusion for 15 minutes.
2858152|NCT03541213|Other|Control group|"Patients with no iron deficiency prior to inclusion and who did not receive intravenous iron prior to inclusion.~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
2858153|NCT03541213|Other|Iron deficiency group|"Patients with iron deficiency who did not receive intravenous iron prior to inclusion.~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
2858154|NCT03541213|Other|Iron treated group|"Patients with iron deficiency who received intravenous iron prior to inclusion (greater than or equal to 1 g ferric carboxymaltose).~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
2858155|NCT03541200|Experimental|Open Label|MT-8554
2858156|NCT03541187|Experimental|G. cockroach allergenic extract - Part A|"Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm. An interim analysis will be conducted when all Part A participants have completed their 12-month NAC. If an effect is seen for the Part A NAC analysis, the study will proceed to Part B.~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. After maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 24 months and up to a maximum of 36 months."
2858157|NCT03541187|Placebo Comparator|Placebo- Part A|"Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm. An interim analysis will be conducted when all Part A participants have completed their 12-month NAC. If an effect is seen for the Part A NAC analysis, the study will proceed to Part B.~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. Once the maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 24 months and up to a maximum of 36 months."
2858158|NCT03541187|Experimental|G. cockroach allergenic extract-Part B|"Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 110 participants 6 to 16 years of age who are sensitized to cockroach and have asthma will be randomized to this treatment arm. In contrast to Part A, a positive NAC will not be required for inclusion into Part B treatment.~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. Once the maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 24 months and up to a maximum of 36 months."
2858159|NCT03541187|Placebo Comparator|Placebo- Part B|"Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 110 participants 6 to 16 years of age who are sensitized to cockroach and have asthma will be randomized to this treatment arm. In contrast to Part A treatment, a positive NAC will not be required for inclusion into Part B treatment.~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. Once the maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 24 months and up to a maximum of 36 months."
2858162|NCT03541174|Placebo Comparator|Placebo DB|Part 1: Double-blind, randomized (1:1:1 ratio), parallel-group and placebo-controlled and lasts for 4 weeks. Subjects will receive placebo
2858163|NCT03541174|Experimental|Aprocitentan 25 mg SB|Part 2: Single-blind and single-arm, lasts for 32 weeks. All subjects will receive aprocitentan 25 mg.
2858164|NCT03541174|Experimental|Aprocitentan 25 mg DB-WD|Part 3: Double-blind withdrawal. Subjects will be re-randomized to aprocitentan 25 mg
2858165|NCT03541174|Placebo Comparator|Placebo DB-WD|Part 3: Double-blind withdrawal. Subjects will be re-randomized to placebo.
2858166|NCT03541161||Early rehabilitation group|Breast cancer patients who underwent reconstructive surgery in samsung medical center from Jan 2017 to August 2017. Following early rehabilitation protocol, patients were educated to undergo a self-exercise program after short-term immobilization of 2 weeks.
2858167|NCT03541161||Conventional protocol group|Breast cancer patients who underwent reconstructive surgery in samsung medical center from May 2016 to Dec 2016. Following conventional protocol, patients were asked to immobilize their shoulder for more than 4 weeks and then undergo self-exercise program.
2858168|NCT03541148|Experimental|Oncoxin-Viusid|Nutritional supplement Oncoxin-Viusid 25 mL in oral solution twice a day
2858169|NCT03541122||Experimental group|Patients will undergo pelvic X-ray examinations. Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads. The investigators will determine the sensitivity and specificity of OFI, MUI and TBOI for the diagnosis of adult acetabular dysplasia, and compare the accuracy of diagnosis between these three indicators and CE angle, sharp angle, and AHI. Further analysis of risk factors for hip function will be implemented.
2858170|NCT03541109|Experimental|Polypill|Polypill available in two forms of tablets with fixed dose combinations of Aspirin (80mg), Atorvastatin (40mg), Metoprolol (50 mg), and Valsartan (40 mg or 80 mg), prescribed once daily by moth for 34 months
2858171|NCT03541109|Active Comparator|Control|Four drugs prescribed separately including Aspirin (80mg), Atorvastatin (40mg), Metoprolol (50 mg), and Valsartan (40 mg or 80 mg), once daily by moth for 34 months.
2858172|NCT03541096|Experimental|Winter Swimmers|4 Months of supervised winter swimming.
2858173|NCT03541096|Placebo Comparator|Control group|No winter swimming activities.
2858174|NCT03541083|Experimental|Blinatumomab|After a 5-day steroid prephase patients will receive two weeks continuous infusion of blinatumomab. Then the first remission-induction course will be given after one week interruption. Subsequent therapy with 4 cycles of chemotherapy and two 4-week courses of blinatumomab will follow, and subsequently depending on risk group, eligibility and a suitable donor either allogeneic stem cell transplantation or 2 year maintenance treatment.
2858175|NCT03541070|Experimental|Kinesiology taping|For tibialis anterior muscle taping, each children's feet were placed at plantar flexion and eversion position while knees were extended, and I-shaped band was applied over tibialis anterior from origin to insertion of muscle with approximately 25-50% tension of the original length of the band. No tension was applied to the first and last 5 cm section of the bands in both applications because it were used as anchor. The tapes were remained for 1 hour on skin of both quadriceps and tibialis anterior muscles, and in this time the children were rested.
2858176|NCT03541044|Experimental|Test Product|Participants will receive a single Nicotine Prototype Mini lozenge (2mg) by oral/buccal route of administration.
2858177|NCT03541044|Active Comparator|Reference Product|Participants will receive a single Nicorette Mini lozenge (2 mg) by oral/buccal route of administration.
2858178|NCT03541031|Experimental|Micronutrient & Fish oil|Fish oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Micronutrient capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day.
2858179|NCT03541031|Placebo Comparator|Olive oil & Safflower oil|Safflower oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Olive oil capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day.
2858180|NCT03541018|Experimental|Posterior canalolithiasis|Type of repositional maneuvre
2858181|NCT03541018|Experimental|Lateral cupulolithiasis|Type of repositional maneuvre
2858182|NCT03541005|Experimental|Obex|a nutritional supplement Obex® 8 g daily by oral route divided into two doses of 4g (between 15 and 20 minutes before lunch and dinner) diluted in water or juice for 6 months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
2858183|NCT03541005|Placebo Comparator|Placebo|Placebo 8 g daily by oral route divided into two doses of 4g (between 15 and 20 minutes before lunch and dinner) diluted in water or juice for 6 months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
2858184|NCT03540979|Active Comparator|Estrogen|Endometrial preparation: Estrogen supplements (Estradiol 6mg/d) will be started at the 2nd-3rd day of the cycle. First US scan will be performed after 10 days. If necessary, adjusting the estradiol doses will be performed according to the physician decision. After achieving trilinear endometrial thickness ≥8mm progesterone supplements (Endometrin 100mg*3/d) will be administrated. Embryo transfer will be performed after completing 5 days of progesterone supplements (at the 6th day after starting the progesterone supplements).
2858185|NCT03540979|Experimental|Letrozole|Women in the Letrozole arm will be treated with Aromatase inhibitors ( Letrozole; 2.5 mg per day) starting at the 3rd day of the cycle for 5 days. US scan,and blood work for serum Estradiol (E2) and progesterone (P) will initially be examined 3-5 days after the last Letrozole pill. Following US scans and serum E2+P will be performed according to the treating physician decision. When US scan demonstrate trilaminar endometrium ≥8 mm and the dominant follicle will be ≥18mm, hCG will be administrated ( recommbinant hCG - Ovitrelle 250 mcg) and 3 days later vaginal Endometrin 100mg*3/d will be started. Single vitrified-warmed blastocyst transfer will be performed after completing 4 days of the progesterone supplements (7 days from hCG administration).
2858186|NCT03540966|Experimental|Group A|complete Chinese version of the vitiligo life quality index, VLQI-C, conventional therapies plus CapulinTM on-demand treatment period
2858187|NCT03540966|Placebo Comparator|Group B|complete Chinese version of the vitiligo life quality index, VLQI-C, conventional therapies on-demand treatment period
2858188|NCT03540953|Other|Endoscopic injection of Mitomycin C|Endoscopy injection of Mitomycin C will be perform to the treatment of pharyngoesophageal stenosis refractory to endoscopic treatment with dilatation in patients with head and neck cancer
2858191|NCT03540927|Experimental|PM+ for entrepreneurs|The intervention arm participants will receive a cash transfer to support them in their businesses PLUS 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement, provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 discusses problem solving technique.Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
2858192|NCT03540927|Active Comparator|Control|The control arm will receive a cash transfer only to support them in their businesses.
2858193|NCT03540914|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2858194|NCT03540914|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.
2858195|NCT03540901|Active Comparator|ACETAZOLAMIDE oral capsule|375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3100m until the morning after the second night at 3100m
2858196|NCT03540901|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3100m until the morning after the second night at 3100m.
2858197|NCT03540888|Experimental|Deep Transverse Friction Massage group|Deep transverse friction massage group. Participants were taught by one of the examiners how to sit and perform pre-exercise self-massages on their tested leg musculotendinous junction (MTJ). The procedure consisted of applying friction massage by fingertips transversely to the hamstrings tendon, in a sitting position. The tendon was located over four finger widths proximal to the medial and lateral epicondyles of the femur. One examiner carefully monitored how the technique was performed to assure the precision of the application. This massage technique was applied over a duration of 30 seconds.
2858198|NCT03540888|Active Comparator|Dynamic stretching intervention|The dynamic stretching intervention was included for its positive effects on agility and muscle strength. Participants in this group, swung their tested leg actively into hip flexion while keeping their knee fully extended and their ankle fully plantar flexed until a stretch was felt in the posterior thigh. This was repeated over 30 seconds and included in the participant's warm-up phase.
2858199|NCT03540888|Active Comparator|Static stretching intervention|In the static stretching intervention, all participants laid on the floor in a supine position with both feet pointing upwards, with the tested limb in full knee extension and the foot in a relaxed position. The tested limb was moved up passively to a point of slight pain or discomfort at the posterior aspect of the thigh. This technique puts the hamstrings muscle at its greatest possible length. This position should be held for 30 seconds and was performed three times for a total of one minute and 30 seconds, 15 minutes after a match or training. The contralateral leg was stabilized by means of another collaborator in order to prevent compensation by rotation or elevation of the pelvis.
2858200|NCT03540875|Experimental|Full automation group|Full automation control of propofol and remifentanil
2858201|NCT03540875|Other|Control group|Manual control of of propofol and remifentanil using TCI system
2858202|NCT03540862||NPV|a hospital-based maintenance NPV program including NPV support, breathing training and an educational program (relaxation techniques, and home pacing walking exercise) in daily clinical practice. Patients received NPV with breathing training via the cuirass ventilator (Philips Respironics Lifecare NEV-100) settings for 60 min. The ventilator was set to control model with frequency of 12 cycles/min, 30% of the ratio of inspiratory time to total breathing cycle time (Ti/Ttot) and delivered negative pressures ranging −20 to −30 cm H2O. In the NPV group, patients underwent the hospital-based NPV once every week as the maintenance program.
2858203|NCT03540862||Control|If patients do not wish to enter the hospital-based NPV program, they are placed in the control group and are trained to perform breathing training, relaxation techniques and home pacing walking exercise.
2858204|NCT03540849|Experimental|BV after allogeneic hematopoietic stem cell transplantation|
2858205|NCT03540836|Experimental|Relacorilant 3x100mg softgel capsules|Relacorilant (3x100 mg softgel capsules)
2858206|NCT03540836|Experimental|Relacorilant 3x100mg hard-shell capsules|Relacorilant (3x100 mg hard-shell capsules)
2858207|NCT03540836|Experimental|Relacorilant 6x50mg hard-shell capsules|Relacorilant (6x50mg hard-shell capsules)
2858208|NCT03540823|Experimental|Patients with rheumatic diseases|Patients with diagnosis of adult and juvenile systemic lupus erythematosus (SLE and JSLE) and Sjogren syndrome (SSp)
2858209|NCT03540823|Other|Healthy controls|Healthy children and adults
2858210|NCT03540810|Active Comparator|Hydroxychloroquine|All patients randomised in this arm will receive hydroxychloroquine with their usual treatment, which is antivitamin K anticoagulants
2858211|NCT03540810|Placebo Comparator|Placebo|All patients randomised in this arm will receive a placebo with their usual treatment, which is antivitamin K anticoagulants
2858212|NCT03540797||Intensive care unit (ICU) patients with sepsis|
2858213|NCT03540784|No Intervention|Control group|usual care treatment
2858214|NCT03540784|Experimental|Nutrition|high-protein nutrition therapy
2858215|NCT03540784|Experimental|EMS+Nutrition|WB-EMS Training (2x/week á 20 min) + high-protein nutrition therapy
2858216|NCT03540771|Active Comparator|Model 1: Consultative Palliative Care|Direct access to Palliative Care provider, who will offer palliative care to patients and caregivers, as guided by a standard PC (palliative care) checklist.
2858217|NCT03540771|Active Comparator|Model 2: Trained Hepatologist- led PC|A hepatologist will receive formal training to deliver Palliative Care (PC) services, and will offer palliative care to patients and caregivers following the same PC checklist as in Model 1
2858218|NCT03540758|Experimental|Healthy (Diazoxide)|"Diazoxide (Proglycem), oral suspension (4-6 mg/kg)~Healthy participants in this arm will receive diazoxide."
2858219|NCT03540758|Placebo Comparator|Healthy (Placebo)|"Taste-matched placebo.~Healthy participants in this arm will receive placebo."
2858220|NCT03540758|Experimental|T2D (Diazoxide)|"Diazoxide (Proglycem), oral suspension (4-6 mg/kg)~Type 2 Diabetic (T2D) participants in this arm will receive diazoxide."
2858221|NCT03540758|Placebo Comparator|T2D (Placebo)|"Taste-matched placebo.~Type 2 Diabetic (T2D) participants in this arm will receive placebo."
2858222|NCT03540758|Experimental|T2D (Diazoxide + Nicotinic Acid)|"Diazoxide (Proglycem), oral suspension (4-6 mg/kg) Nicotinic Acid (Niacin) , infusion~Type 2 Diabetic (T2D) participants in this arm will receive Diazoxide and Nicotinic Acid."
2858223|NCT03540758|Experimental|T2D (Nicotinic Acid Only)|"Nicotinic Acid (Niacin) , infusion~Type 2 Diabetic (T2D) participants in this arm will receive Nicotinic Acid."
2858224|NCT03540745|Experimental|TES Treatment|Where subject is randomized to TES.
2858225|NCT03540745|Placebo Comparator|TES-SHAM Treatment|Where subject is randomized to a SHAM condition
2858226|NCT03540732|No Intervention|1. Control|"Standard physiotherapy~Empiric formula directed feeding (daily caloric requirement calculated by 25 kcal/kg/day)"
2858227|NCT03540732|Active Comparator|2. Intervention|"Up to 60 minutes of cycle ergometry daily in addition to standard physiotherapy sessions.~Indirect calorimetry directed feeding (use of indirect calorimetry to calculate daily caloric requirement)"
2858228|NCT03540706|Experimental|Care with C-reactive protein assay in micro method|During a visit to the general practitioner for a clinical suspicion of respiratory infection, the doctor will practice a C-reactive protein assay in micro method. He will prescribe antibiotics according to the result of the dosage
2858229|NCT03540706|No Intervention|Care without C-reactive protein assay in micro method|Simple management of a patient coming for a suspicion of respiratory infection without dosage of the C-reactive protein in micro method
2858230|NCT03540693||RYGB-longitudinal|Longitudinal group of subjects studied before and after Roux-n-Y gastric bypass surgery
2858231|NCT03540693||SG_longitudinal|Longitudinal group of subjects studied before and after sleeve gastrectomy surgery
2858232|NCT03540693||LAGB_longitudinal|Longitudinal group of subjects studied before and after laparoscopic gastric banding surgery
2858233|NCT03540693||Weight-loss success|Subjects who lost ≥40% body weight by 2-5 years post-surgery
2858234|NCT03540693||Weight-loss failure|Subjects who lost <25% body weight (or lost more but then regain weight so that now are at <25%) by 2-5 years post-surgery
2858235|NCT03540680|Other|Term newborns (≥37GA)|Blood punction on the cordon
2858236|NCT03540680|Other|Premature newborns|Blood punction on the cordon
2858237|NCT03540680|Other|Child between 7 and 15 years old with BPD|Blood punction
2858238|NCT03540680|Other|Child between 7 and 15 years old without BPD|Blood punction
2858239|NCT03540667||Single group study|The study population will include patients presenting for primary elective unilateral total hip and knee arthroplasty.
2858240|NCT03540654||Patients with CML discontinuing TKI treatment|
2858241|NCT03540641|Active Comparator|1500 pulses|This group will receive 1500 pulses of transcranial magnetic stimulation at 5Hz over the left dorsolateral prefrontal cortex, until completing 15 sessions
2858242|NCT03540641|Sham Comparator|1500 pulses sham|this group will receive the sham modality of the protocol of 1500 pulses at 5Hz of transcranial magnetic stimulation during 15 sessions.
2858243|NCT03540641|Active Comparator|5000 pulses|This group will receive 5000 pulses of transcranial magnetic stimulation at 5Hz over the left dorsolateral prefrontal cortex, until completing 15 sessions.
2858244|NCT03540641|Sham Comparator|5000 pulses sham|this group will receive the sham modality of the protocol of 5000 pulses at 5Hz of transcranial magnetic stimulation during 15 sessions.
2858245|NCT03540628|No Intervention|Placebo Arm|The control arm of our randomized trial will receive a second pressor agent, hydrocortisone and standard of care to care for septic shock. The IV bags will be blinded by pharmacy. If the patient needs additional pressor support or therapy, the data will be recorded in the results.
2858246|NCT03540628|Experimental|Thiamine and Vitamin C administration Arm|The experimental arm will receive a second pressor agent and hydrocortisone, plus thiamine and vitamin C along with the standard of care. The IV bags will be blinded by pharmacy. If the patient needs additional pressor support or therapy, the data will be recorded in the results.
2858247|NCT03540615|Experimental|BAY1830839|Single Dose escalations
2858248|NCT03540615|Placebo Comparator|Placebo|Matching Placebo
2858249|NCT03540602|Placebo Comparator|Placebo|Rice flour capsule
2858250|NCT03540602|Active Comparator|Polyphenol Rich Supplement|NordicCherry Tart Cherry Extract Powder 500 mg in capsule form
2858251|NCT03540589|Experimental|Video distraction|A video will be available as soon as the child is randomized to this group, thus enabling the child to become more involved with distraction. A tablet will be delivered to the parents in the reception room to be viewed by the child before entering the vaccine room. After entering the room, the parents will keep the child entertained with the videos. There will be several videos, and it may be optional for the parents to choose according to their preferences.
2858252|NCT03540589|Experimental|Vibration device|Buzzy® specific vibration device will be placed by the professional or caregiver at the application site, 15 to 45 seconds before the procedure.
2858253|NCT03540589|Experimental|Distraction plus vibration|Combination of the two interventions described above
2858254|NCT03540589|No Intervention|Usual care|The vaccine will be carried out according to the routine of the Vaccine Center. Lidocaine plus prilocaine, non-nutritive sucking or breastfeeding may be used.
2858255|NCT03540563|Other|blood draw|Blood and saliva specimens will be taken for ctDNA analysis at baseline, weekly during treatment and at 2 weeks after treatment. During follow up both blood and saliva will be obtained in combination with a CT/MRI scan on the same day at 3 months, 6 months, 1 year and 2 years after treatment.
2858256|NCT03540550|Experimental|Dietary intervention|
2858257|NCT03540537|Other|PCA for Open Hepatectomy|Patient-controlled intravenous analgesia in Open hepatectomy (PCA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing)
2858258|NCT03540537|Experimental|QLB for Open Hepatectomy|Bilateral quadratus lumborum block with 20 ml 0.375% ropivacaine each side(maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
2860816|NCT03522883|Active Comparator|experimental group 2|carbohydrate intake prior to exercise
2858259|NCT03540537|Experimental|TPVB for Open hepatectomy|T6+T8 of thoracic paravertebral block with 15 ml 0.375% ropivacaine each segment (maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
2858260|NCT03540537|Other|PCA for Laparoscopic Hepatectomy|Patient-controlled intravenous analgesia in Laparoscopic hepatectomy (same as PCA for Open hepatectomy Arm)
2858261|NCT03540537|Experimental|QLB for Laparoscopic Hepatectomy|Bilateral quadratus lumborum block 20 ml 0.375% ropivacaine each side(maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
2858262|NCT03540537|Experimental|TPVB for Laparoscopic Hepatectomy|T6+T8 of thoracic paravertebral block with 15 ml 0.375% ropivacaine each segment (maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
2858263|NCT03540524|Experimental|Cohort A - F508del homozygous|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods.( Study Part I)
2858264|NCT03540524|Experimental|Cohort B - F508del heterozygous/potentiator nonresponsive|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods. (study Part II)
2858265|NCT03540524|Experimental|Cohort C - F508del homozygous|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods. (Study Part II)
2858266|NCT03540498|Experimental|Probiotics|The volunteers will follow the assigned treatment for 6 weeks (PROBIOTICS_AB-DENTALAC CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers after 6 weeks.
2858267|NCT03540498|Placebo Comparator|Control|The volunteers will follow the assigned treatment for 6 weeks (PLACEBOS CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers.
2858268|NCT03540485|Experimental|Melatonin|Daily administration of 300 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
2858269|NCT03540485|Placebo Comparator|Control|Daily administration of placebo orally, for 24 months between 10pm to 11pm
2858270|NCT03540472|Experimental|efficiency of tacrolimus on PRCA|"A prospective research of the tacrolimus efficiency on refractory PRCA patients On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study.~Medication time should last at least 6 months."
2858271|NCT03540446|Experimental|Standard stimulation|Group A will be treated with First Relief Treatment at standard stimulation.
2858272|NCT03540446|Experimental|sweep stimulation|Group B will be treated with First Relief Treatment at sweep stimulation.
2858273|NCT03540446|Experimental|Placebo|Group C will be treated with First Relief Treatment, receiving a placebo.(dummy device with no effective electrical stimulation)
2858274|NCT03540433||Study group|Surgical patients aged ≥70 years
2858275|NCT03540433||Control group|Healthy subjects, aged ≥70 years, American Society of Anesthesiologists (ASA) I+II+III, no surgery
2858276|NCT03540420|Experimental|Atezolizumab|atezolizumab after completed chemo-radiotherapy and non-progression
2858277|NCT03540420|No Intervention|Observation|standard care after completed chemo-radiotherapy and non-progression
2858278|NCT03540407|Experimental|Oncoxin-Viusid®|will receive the Oncoxin-Viusid® (oral solution) concomitant to the onco-specific treatment.
2858279|NCT03540407|Placebo Comparator|Placebo|will receive a Placebo concomitant to the onco-specific treatment
2858280|NCT03540381||Identified neoatherosclerosis group|From the patients treated with coronary stents, the investigators functionally evaluated their HDL by measuring the CUC. the investigators also performed follow-up OCT to evaluate the presence of neoatherosclerosis. Consecutive patients were divided into two groups. The patients with neoatherosclerosis were identified neoatherosclerosis group and the remaining were not-identified neoatherosclerosis group. After that, clinical follow-up was performed to assess TLR and the investigators examined the relation between CUC, neoatherosclerosis and TLR.
2858281|NCT03540381||Not-identified neoatherosclerosis group|
2858282|NCT03540368|Experimental|Tranexamic acid injection|Group with tranexamic acid injection
2858283|NCT03540368|Placebo Comparator|Placebo|Group with Placebo
2858284|NCT03540355|Experimental|Cipros 20|"The study is double-masked, the patient will take 2 tablets, as follow:~1 tablet Cipros 20 association; and~1 tablet crestor placebo. Oral, once a day"
2858285|NCT03540355|Active Comparator|Crestor|"The study is double-masked, the patient will take 2 tablets, as follow:~1 tablet Crestor 20 mg; and~1 tablet cipros association placebo. Oral, once a day"
2858286|NCT03540342|Experimental|One stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
2858287|NCT03540342|No Intervention|Staging strategy group|PCI will be performed several days after EVAR
2858288|NCT03540329|Active Comparator|I-A Internal distraction|Internal osteogenesis distractor in congenital mandibular deformities in patients in growing age.
2858289|NCT03540329|Active Comparator|I-A External distraction|External osteogenesis distractor in congenital mandibular deformities in patients in growing age.
2858290|NCT03540329|Active Comparator|I-B Internal distraction|Internal osteogenesis distractor in congenital mandibular deformities in adult patients.
2858291|NCT03540329|Active Comparator|I-B External distraction|External osteogenesis distractor in congenital mandibular deformities in adult patients.
2858292|NCT03540329|Active Comparator|II-A Internal distraction|Internal osteogenesis distractor in acquired mandibular deformities in patients in growing age
2858541|NCT03538691|Placebo Comparator|Placebo & Escitalopram|Placebo: daily oral tablet Escitalopram: oral tablet; 10 or 20 mg/day
2858293|NCT03540329|Active Comparator|II-A External distraction|External osteogenesis distractor in acquired mandibular deformities in patients in growing age
2858294|NCT03540329|Active Comparator|II-B Internal distraction|Internal osteogenesis distractor in acquired mandibular deformities in Adult patients.
2858295|NCT03540329|Active Comparator|II-B External distraction|External osteogenesis distractor in acquired mandibular deformities in Adult patients.
2858296|NCT03540316|Active Comparator|Two short implants and 2 minutes LLLT|Patients receiving 2 short dental implants assisted mandibular over-denture and Low level laser therapy (LLLT) for 2 minutes .
2858297|NCT03540316|Active Comparator|Two short implants and 4 minutes LLLT|Patients receiving 2 short dental implants assisted mandibular over-denture and LLLT for 2 minutes .
2858298|NCT03540316|Active Comparator|Four short implants and 2 minutes LLLT|Patients receiving 4 short dental implants assisted mandibular over-denture and LLLT for 2 minutes .
2858299|NCT03540316|Active Comparator|Four short implants and 4 minutes LLLT|Patients receiving 4 short dental implants assisted mandibular over-denture and LLLT for 4 minutes .
2858300|NCT03540303|Experimental|CAR19 T cells carrying cytoplasmic activated PD-1|patients with refractory/relapsed B-NHL receive a preconditioning before infusion of CAR T cells.
2858301|NCT03540290|Active Comparator|Mechanical instrumentation and oral hygiene instructions|
2858302|NCT03540290|Experimental|Modification of the implant supported prostheses|
2858303|NCT03540277|Experimental|"Prevention Program young In Favor of Myself, active parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents will also participate by a phone app that will pass the parents activities to do with their children, in parallel to the program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
2858304|NCT03540277|Active Comparator|"Prevention Program young In Favor of Myself, passive parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents won't participate in the program, they will get only a brochure about Media literacy, self-esteem, self-image and body image. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
2858305|NCT03540277|No Intervention|control group|The control group will not receive the intervention program. The control group will complete the same self-report questionnaire as the intervention group at baseline, after the program ends, and three months after the completion of the program.
2858306|NCT03540264|Active Comparator|Composite resin|Restoration with composite resin has shown good clinical performance and limited occlusal wear. The Filtek™ supreme Plus will be used in the present study.
2858307|NCT03540264|Active Comparator|Polymer-infiltrated-ceramic-network|This hybrid material seems to be a promising material that imitates natural tooth properties. The VITA-Enamic® will be used in this study.
2858308|NCT03540251|Active Comparator|Therapeutic auricular points treatment|Therapeutic auricular points treatment including auricular points:CO18、TF2、TF4、AT4、CO15（with complaint of sweating）or CO12(with symptom of heart palpitation)in accordance with the position of auricular points Location map of national standard(GBVT13734—2008) Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets. In addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points.
2858309|NCT03540251|Sham Comparator|Placebo auricular points treatment|Placebo auricular points treatment including auricular points AH9、AH11、TG3、AT2、LO4 in accordance with the position of auricular points Location map of national standard(GBVT13734—2008) Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.In addition, both group received 8 treatment sessions of sticking and pressing placebo auricular points treatments.
2858310|NCT03540225|Experimental|Early Low-dose Arm|Start from 11-14 week: 200 mg self-administered vaginal progesterone daily
2858311|NCT03540225|Experimental|Early High-dose Arm|Start from 11-14 week: 400 mg self-administered vaginal progesterone daily
2858312|NCT03540225|Experimental|Late Low-dose Arm|Start from 20-24 week: 200 mg self-administered vaginal progesterone daily
2858313|NCT03540225|Experimental|Late High-dose Arm|Start from 20-24 week: 400 mg self-administered vaginal progesterone daily
2858314|NCT03540212|Experimental|Daclatasvir and sofosbuvir|"Daclatasvir and sofosbuvir~Single arm intervention open label trial for single tablet (Daclatasvir 90 mg and Sofosbuvir 400mg and ) Daclatasvir 90 mg for 12 weeks"
2858315|NCT03540199|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
2858316|NCT03540199|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
2858317|NCT03540199|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2858318|NCT03540186|Experimental|Epigenorm Antivir and acupuncture arm|Epigenorm Antivir is a dietary supplement containing extracts of glycyrrhiza roots, hippophae rhamnoides leaves, curcumin, green tea, and vitamin C. Acupuncture involves inserting needles at certain points of the body.
2858319|NCT03540173||Training Cohort|In the training cohort, we evaluated the impact of patient-related factors on the pain during the colonoscopy. In univariatelogistic regression analysis, All factors associated with the pain during colonoscopy (p<0.1) were included in multivariate analysis.
2858320|NCT03540173||Validation group|The validation cohort was used to verify the intubation discomfort score.
2858321|NCT03540160|Experimental|Experimental: 5 mg Serlopitant Tablets|Serlopitant Tablets
2858322|NCT03540147|Experimental|Exercise with Hokanson cuffs|Participants will walk on the treadmill with Hokanson cuffs inflated.
2858323|NCT03540147|Experimental|Exercise with BStrong Bands|Participants will walk on the treadmill with BStrong bands inflated.
2858324|NCT03540147|Sham Comparator|Exercise without inflated bands/cuffs|Participants will walk on the treadmill with non-inflated BStrong bands.
2858325|NCT03540147|Experimental|Yoga poses with BStrong bands inflated|Participants will perform 15-20 yoga poses with BStrong bands inflated.
2858326|NCT03540147|Sham Comparator|Yoga poses with BStrong bands uninflated|Participants will perform 15-20 yoga poses with uninflated BStrong bands.
2858327|NCT03540134|Experimental|Intracerebral Infusion of Autologous CSF|All subjects will receive the intracerebral infusion of autologous cerebral spinal fluid (CSF) during their deep brain stimulation (DBS) surgery. The DBS surgery will be performed on the targeted nucleus either bilaterally or unilaterally, as previously determined by a multidisciplinary team of neurology, neurosurgery, and neuropsychology. During unilateral DBS surgery, the targeted nucleus will be infused using convection enhanced delivery (CED). The nondominant side will be infused during a bilateral DBS procedure.
2858328|NCT03540121|Experimental|Video education + adherence contract|electronically delivered video education (at transplant discharge) + electronic adherence contract (1 month after enrolment)
2858329|NCT03540121|No Intervention|Standard education|standard of care education provided at each transplant center (control emails will be provided at intervention time points)
2858330|NCT03540108|Experimental|Experimental: L. plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402 equivalent to 2x10^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed twice daily, before breakfast and dinner with 250mL of water.
2858331|NCT03540108|Placebo Comparator|Placebo Comparator: Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed twice daily, before breakfast and dinner with 250mL of water.
2858332|NCT03540095|Experimental|Erector Spinae Plane Block|The patients randomized to the Erector Spinae Plane Block arm will receive this nerve block at the level corresponding to the rib fractures. Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control. Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic. It will be titrated to effect, at maximum 12 mL/hr. Bupivicaine 0.0625% 3mL will be given every hour as a bolus additionally.
2858333|NCT03540095|Experimental|Paravertebral Nerve Block|The patients randomized to the Paravertebral Nerve Block arm will receive this nerve block at the level corresponding to the rib fractures. Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control. Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic. It will be titrated to effect, at maximum 12 mL/hr. Bupivicaine 0.0625% 3mL will be given every hour as a bolus additionally.
2858334|NCT03540082|Active Comparator|Fall Exposure|An instructor will implicitly be exposed to the falling technique. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
2858335|NCT03540082|No Intervention|Control|Written instructions will be provided on the correct way to fall without physical practice.
2858336|NCT03540082|Other|Tuck and Roll Group|An instructor will explicitly verbally and visually demonstrate the falling technique and provide feedback on participant performance. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
2858337|NCT03540069|Experimental|Cervical Cancer Screening Education|Context-specific multi-level peer education cervical cancer screening education curriculum is implemented by Care Groups. This is conducted through a cluster-randomized stepped wedge study. Cluster 1 (randomly selected) crosses to the intervention arm at Period 2, Cluster 2 (randomly selected) crosses over to the intervention arm at Period 3, and so on. By the end of the study, all clusters will cross over to the intervention arm (one-way), though in random order. At the end of the final time period, the outcome of interest is compared between the intervention and control periods within each cluster. Differences in service utilization and recommendation will be compared, whereby clusters serve as their own controls as they cross over from the control to intervention group.
2858338|NCT03540069|No Intervention|Control|No educational program is implemented for each cluster prior to crossover to intervention.
2858339|NCT03540056||Boys without varicocele|Boys thoroughly examined but without diagnose of varicocele
2858340|NCT03540056||Boys with a varicocoele|Boys with a diagnosed varicocele of any stage possible.
2858341|NCT03540043|Placebo Comparator|Placebo|Administration of Placebo
2858342|NCT03540043|Experimental|PUR0110 (Thykamine) 0.05%|Administration of PUR0110 (Thykamine) 0.05%
2858343|NCT03540043|Experimental|PUR0110 (Thykamine) 0.10%|Administration of PUR0110 (Thykamine) 0.10%
2858344|NCT03540043|Experimental|PUR0110 (Thykamine) 0.25%|Administration of PUR0110 (Thykamine) 0.25%
2858345|NCT03540030|No Intervention|Observational|The observational treatment group will not have any changes from your surgeon's normal pain management process. Anesthesia will be utilized in a routine fashion with all routine perioperative medications. You will be discharged on routine postoperative medications including opioids, NSAIDS, and any other modalities typically used by the treating surgeon.
2858346|NCT03540030|Active Comparator|Non-Opioid Intervention|Oral dose of both gabapentin and celecoxib (toradol if sulfa allergy) in the preop area. US-guided interscalene regional block without the aid of opioid co-medication. Intra-op management by anesthesia with non-opioid modalities but should include one dose of IV acetaminophen during the procedure. Anesthetic modalities will include, but not limited to, regional block, propofol, IV lidocaine, rocuronium/vecuronium, and sevoflurane/desflurane. If the attending anesthesiologist deems it necessary to dose with opioids during procedure, it will be recorded and reported. Liposomal bupivacaine will be injected into the peri-articular soft tissues as an adjunct to the block. Post Op, cryotherapy, gabapentin, toradol. Toradol will transition to celecoxib for the duration of the hospitalization (or meloxicam for patients with sulfa allergy). As needed medications will include both oral and IV acetaminophen, as well as up to an additional 15mg of toradol per 6hr, depending on Cr clearance.
2858347|NCT03540017|Experimental|HIPEC|
2858348|NCT03539991|Experimental|Tobacco Counseling|
2858349|NCT03539978||SM-THINk Unit|Two of the three inpatient floors will use the SM-THINk enhanced discharge method. This is part of a clinical practice change and not for research. Parents will complete a questionnaire at the time of the patient's discharge from the hospital.
2858350|NCT03539978||Control Unit|One of the three inpatient floors will use the usual discharge method. Parents will also complete a questionnaire at the time of the patient's discharge from the hospital.
2858351|NCT03539965||Single-arm cohort|Initially, patients will be analyzed in a single group. After determining the status of the biomarkers, the patient sample will be divided into specific groups for comparative purposes.
2858352|NCT03539952|Experimental|TETA 4HCL|Active Treatment
2858353|NCT03539952|Experimental|Penicillamine|Comparator: Penicillamine
2858354|NCT03539939|Experimental|Smoker Group|This group included smoker gingival recession patients.
2858355|NCT03539939|Active Comparator|Non-smoker Group|This group included non-smoker gingival recession patients.
2858356|NCT03539926|Experimental|Lit-control®pH Meter|The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the Lit-control®pH Meter device.
2858357|NCT03539926|Placebo Comparator|Reactive strips|The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the reactive strips.
2858358|NCT03539913|Active Comparator|Saccharomyces boulardii|Floratil, 250 mg sachets, twice daily (1 in the morning and 1 in the evening) during 5 consecutive days.
2858359|NCT03539913|Active Comparator|Bacillus clausii|Enterogermina, 5 ml vials, twice daily (1 in the morning and 1 in the evening) during 5 consecutive days.
2858360|NCT03539900|Experimental|NB Medication|Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
2858361|NCT03539900|Placebo Comparator|Placebo|Placebo will be inactive and taken daily in pill form.
2858362|NCT03539887|Experimental|Intranasal ketamine|Intranasal ketamine
2858363|NCT03539887|Experimental|Intranasal ketamine in alcohol abuse|Intranasal ketamine
2858364|NCT03539887|Placebo Comparator|Placebo|non-active placebo
2858365|NCT03539887|Placebo Comparator|Placebo in alcohol abuse|non-active placebo
2858366|NCT03539874||Confirmed paternity|Sperm sample from men with confirmed paternity
2858367|NCT03539874||Intrauterine insemination|Sperm sample from men in intrauterine insemination process
2858368|NCT03539874||In vitro fertilization|Sperm sample from men in in vitro fertilization process
2858369|NCT03539861|Other|Hemodialysis|"The treatment arm (all participants are in this arm) is done in two phases that are described below:~Treatment 1 will be standard hemodialysis (no device).~Treatment 2 will be hemodialysis with the study device. Of importance, this 5 hour session is planned to ensure adequate solute clearance but with only 4 hour high ultrafiltration to achieve the patients dry weight."
2858370|NCT03539848|Experimental|Subjects with mTBI|Individuals who come to the emergency department or urgent/acute care facility with an mTBI will undergo testing with the I-PAS Goggles.
2858371|NCT03539848|Active Comparator|Subjects with minor injuries|Individuals who come to the emergency department or urgent/acute care facility with minor injuries (such as ankle sprains or knee sprains) will undergo testing with the I-PAS Goggles.
2858372|NCT03539835|Experimental|Resistance training|
2858373|NCT03539835|Active Comparator|Cognitively-based compassion training|
2858374|NCT03539822|Experimental|Cabozantinib combined with Durvalumab|"Cabozantinib~By mouth (PO) once daily on days 1-28 of every 28 day cycle~Starting dose will be 20mg~Dose escalation will follow the dose escalation table~Durvalumab~*Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle"
2858375|NCT03539809|Experimental|BCAA Ratio|Different Branched-chain amino acid (BCAA) ratios will be tested. BCAA are comprised of 3 different amino acids (leucine, isoleucine and valine). The ratios among these 3 amino acids will be tested at 6 different ratios. Each intervention will be for 8hours.
2858376|NCT03539796|Experimental|Dural puncture epidurals (DPE)|Dural puncture epidurals for cesarean section.
2858377|NCT03539796|Active Comparator|Traditional epidurals (EPI)|Traditional epidurals (EPI) for cesarean section.
2858378|NCT03539796|Active Comparator|Combined-spinal epidural technique (CSE)|Combined-spinal epidural technique (CSE) for cesarean section.
2858379|NCT03539783||PARDS|Children >5 kg and <18 years of age with PARDS and expected duration of endotracheal intubation 4 days or greater with 3.5 mm or greater endotracheal tube size.
2858380|NCT03539783||Control|Children >5 kg and <18 years of age without PARDS and expected duration of endotracheal intubation 4 days or greater with 3.5 mm or greater endotracheal tube size.
2858381|NCT03539770||AIS|Adolescent idiopathic scoliosis subjects undergoing posterior spinal fusion.
2858382|NCT03539770||Control|Children without scoliosis
2858383|NCT03539757||Fontan patients|Pediatric and adult Fontan patients will undergo MRI (Magnetic Resonance Imaging) of the liver using novel, non-contrast MRI methods. These MR methods will be used to detect, discriminate and measure liver fibrosis and congestion. The resulting quantitative imaging measurements will be correlated with histopathologic data obtained from a clinically-indicated liver biopsy.
2858384|NCT03539744|Experimental|Arm 1 VenDex|Venetoclax administered orally once daily (QD) plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
2858385|NCT03539744|Active Comparator|Arm 2 PomDex|"Pomalidomide administered orally once daily (QD) on Days 1 - 21 for each 28-day cycle plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.~Subjects randomized to this arm may elect, if eligible, to receive VenDex therapy (venetoclax administered orally QD plus dexamethasone administered orally Q1W for each 28-day cycle) after documented disease progression per IMWG criteria."
2858386|NCT03539731|Active Comparator|Group I ([18F]DASA-23, PET)|Healthy volunteers receive [18F]DASA-23 IV and undergo brain PET scan over 15 minutes and 4 vertex-to-toe PET scans over 30 minutes each.
2858387|NCT03539731|Experimental|Group II ([18F]DASA-23, PET)|Intracranial tumor participants receive [18F]DASA-23 IV and undergo brain PET scan over 60 minutes and 1 vertex-to-toe PET scan over 30 minutes.
2858388|NCT03539731|Experimental|Group III ([18F]DASA-23, PET)|Recurrent glioblastoma participants receive [18F]DASA-23 IV and undergo brain PET scan over 60 minutes and 1 vertex-to-toe PET scan over 30 minutes. Participants undergo second PET scan 7 days after the initiation of therapy.
2858389|NCT03539718|Experimental|cases|Cases, taurolidine heparin 500 will be used at end of session
2858390|NCT03539718|Active Comparator|control|Controls, Heparin Sodium 5000 will be given at end of session
2858391|NCT03539679|Experimental|Encouraging physical activity|Encouraging physical activity by using motion sensor and feedback.
2858393|NCT03539666|Experimental|Pork|Standard American Diet with meat source: lean pork. Diet adheres to 2015-2020 Guidelines for Americans.
2858394|NCT03539666|Experimental|Poultry|Standard American Diet with meat source: chicken. Diet adheres to 2015-2020 Guidelines for Americans.
2858395|NCT03539640|Active Comparator|PEEP level of 5 cmH2O|During second part of the study (MRI) Diaphragm position
2858396|NCT03539640|Active Comparator|PEEP level of 10 cmH2O|During second part of the study (MRI) Diaphragm position
2858397|NCT03539640|Active Comparator|PEEP level of 15 cmH2O|During second part of the study (MRI) Diaphragm position
2858398|NCT03539627||patients with hypertension, CAD and diabetes|Patients with hypertension associated with stable CAD and diabetes on azilsartan medoxomil (Edarbi) therapy
2858399|NCT03539614|Experimental|Open label, blinded discontinuation, prazosin, placebo|"All participants in this study will begin with 8 weeks of active treatment (prazosin), followed by a 4 week blinded discontinuation block where they will take a capsule that will start out as active treatment (prazosin), but will at some point change to placebo. Following these phases of the study, participants will be randomized to two arms. In this first arm, participants will spend 4 weeks on active treatment (prazosin), followed by 4 weeks on placebo."
2858400|NCT03539614|Experimental|Open label, blinded discontinuation, placebo, prazosin|"All participants in this study will begin with 8 weeks of active treatment (prazosin), followed by a 4 week blinded discontinuation block where they will take a capsule that will start out as active treatment (prazosin), but will at some point change to placebo. Following these phases of the study, participants will be randomized to two arms. In this second arm, participants will spend 4 weeks on placebo, followed by 4 weeks on active treatment (prazosin)."
2858401|NCT03539601|Experimental|Crisaborole ointment, 2%|This treatment arm will be administered both in Cohort 1 and Cohort 2.
2858402|NCT03539601|Active Comparator|Hydrocortisone butyrate cream, 0.1%|This treatment arm will be administered in Cohort 1 only.
2858403|NCT03539601|Active Comparator|Pimecrolimus cream, 1%|This treatment arm will be administered in Cohort 2 only.
2858404|NCT03539601|Placebo Comparator|Crisaborole Vehicle|This treatment arm will be administered both in Cohort 1 and Cohort 2.
2858405|NCT03539588|Active Comparator|Treatment group 1|In this group participants will receive trigger point dry needling with electrical stimulation first and receive trigger point needling by itself second. Only MYOTECH dry needles will be used in this study. However we are not studying the equipment.
2858406|NCT03539588|Active Comparator|Treatment Group 2|In this group the participants will receive trigger point dry needling first and receive trigger point dry needling with electrical stimulation second. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
2858407|NCT03539575|Other|Synthetic Psychoactive Cannabinoid Users|Synthetic Psychoactive Cannabinoid dependent subjects who are frequent spice/K2 users will receive the radiotracer [11-C]OMAR.
2858408|NCT03539562||Accepted Morphine Sulfate|Patients accepted morphine and promethazine as a method for pain management in early or prodromal labor.
2858409|NCT03539562||Declined Morphine Sulfate|Patients declined morphine and promethazine as a method for pain management in early or prodromal labor.
2858410|NCT03539549|Experimental|Abicipar pegol|2 mg abicipar administered to the study eye by intravitreal injections
2858411|NCT03539536|Experimental|Telisotuzumab vedotin|Telisotuzumab vedotin administered via intravenous (IV) infusion every 14 days.
2858412|NCT03539510|Experimental|HF-ACP Website|The HF-ACP website leads participants through 4 e-learning modules. Each module contains 3 core elements: (1) educational content which provides information and support to help patients complete the module (2) interactive tools for documenting their thoughts and progress and (3) motivational video clips that encourage behavior change by validating participants ambivalence, suggesting strategies to help participants complete the task and to encourage and reassure participants that they can do this.
2858413|NCT03539510|No Intervention|Usual Care|"The standard of care for advance care planning at our institution is the Speak Up booklet and the Power of Attorney workbook from the Attorney General's Office - Ontario. Patients randomized to the Control arm will be asked to register on a separate research portal where participants will have electronic access to both of the booklets and a link to the Speak Up online Interactive workbook. There is no specific information on HF or HF treatments. Participants in the control arm will be asked to complete the ACP using the interactive workbook. Participants in the control arm will not receive any additional communication from the research team about their progress."
2858414|NCT03539484|Experimental|Part I: Single Participant Cohorts IV/MAD-Escalation|Part I is a multiple-ascending dose-escalation in single participant cohorts. RO7172508 will be administered IV once every 3 weeks (Q3W). The starting dose of RO7172508 will be 65 microgram (mcg) and the maximum dose explored will be 1.6 milligram (mg).
2858415|NCT03539484|Experimental|Part II: Multiple Participant Cohorts IV/MAD-Escalation|Multiple ascending dose-escalation of IV-administered RO7172508 in multiple participant cohorts: The starting-dose for the initiation of the IV dose-escalation will be determined by Part I and RO7172508 will be initially given Q3W. Dose-escalation will be undertaken based on safety until determination of the MTD or the highest safe dose if MTD is not reached. If on-target toxicity is reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.
2858416|NCT03539484|Experimental|Part II: Multiple Participant Cohorts SC/MAD-Escalation (QW)|Multiple ascending dose-escalation of SC-administered RO7172508 in multiple participant cohorts: These will be initiated once the IV schedule has shown RO7172508 preliminary clinical activity or the MTD has been established and is greater than 6 mg. SC dosing will be once a week (QW). The starting-dose for SC administration will be proposed based on the evaluation of the safety and PK data observed following IV administration. Dose escalation in this arm will proceed until the SC MTD/OBD has been determined. If on-target toxicity is reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.
2858417|NCT03539471||psychiatric resident in NTUH|
2858418|NCT03539458|Experimental|Device Arm|All subjects will undergo procedure with the Tendyne Mitral Valve System.
2858419|NCT03539445|Experimental|Butylphthalide|Drug: Butylphthalide Sodium Chloride Injection and Butylphthalide Soft Capsules
2858420|NCT03539445|Placebo Comparator|Placebos|Drug: Butylphthalide Placebo Injection and Butylphthalide Placebo Soft Capsules
2858421|NCT03539432|Experimental|Gemfibrozil|Gemfibrozil 600 mg by mouth twice daily
2858422|NCT03539432|Placebo Comparator|Placebo|Microcrystalline cellulose powder packaged in capsules identical to the experimental condition
2858423|NCT03539419||Patients with plaque psoriasis on apremilast|Adult patients with moderate to severe plaque who have started apremilast treatment for first time 3 months (+/- 4 weeks) before their inclusion in the study, according to the specifications of the drug's prescribing information and under usual clinical practice.
2858424|NCT03539406|Experimental|NK-cells without preparative regimen|NK-cells without preparative regimen
2858425|NCT03539406|Experimental|NK-cells with preparative regimen|NK-cells with preparative regimen
2858426|NCT03539367|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2858427|NCT03539367|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2858428|NCT03539354|Active Comparator|CABG + b-blockers|Standart coronary artery bypass grafting is performed with b-blockers treatment. Continuous ECG during intensive care unit stay, daily ECG, and 24-h Holter monitor recordings will be performed at 7, 14, 21, and 30 days after coronary artery bypass grafting, external loop recorder after discharge from intensive care unit till 30 days after coronary artery bypass grafting.
2858429|NCT03539354|Experimental|CABG + b-blockers + temporary SCS|Before coronary artery bypass grafting in the experimental group, 3 days of temporary spinal cord stimulation is performed than device turned off and coronary artery bypass grafting procedure is made. The device for spinal cord is turned on in intensive care unit for 7 days. Continuous ECG during intensive care unit stay, daily ECG, and 24-h Holter monitor recordings will be performed at 7, 14, 21, and 30 days after coronary artery bypass grafting, external loop recorder after discharge from intensive care unit till 30 days after coronary artery bypass grafting.
2858430|NCT03539341|Experimental|PLH-Thailand parenting programme|Trained facilitators and coaches will deliver the programme over eight weekly sessions at the Udon Thani Regional Hospital during the feasibility pilot and the RCT. During the RCT, the 60 parents/primary caregivers in the intervention group will be divided into 4 groups of 15 participants, with each group overseen by 2 facilitators and 1 coach. Core session activities may include discussion about assigned home activities, core parenting principles, illustrated stories, role-plays, and problem solving. Home visits will be conducted by facilitators to those parents/primary caregivers who miss sessions or require additional support, and SMS/LINE messages will be delivered to all participants twice per week with relevant parenting tips and reminders to attend the upcoming session.
2858431|NCT03539341|Other|Control (care as usual)|The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand. The delivery of services at Parent Schools are guided by the Ministry of Public Health Handbook for Parent Schools, which appear to be open to adaptation at the local level. At Parent Schools, three to five sessions are provided to parents in groups or one-on-one by hospital health personnel.
2858432|NCT03539328|Other|Standard treatment|Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 or Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 or Gemcitabine 1000 mg/mq d 1,8 q 21 or At physician' discretion
2858433|NCT03539328|Experimental|Pembrolizumab|Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 or Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 or Gemcitabine 1000 mg/mq d 1,8 q 21 or At physician' discretion plus Pembrolizumab 200 mg d1 q 21 iv infusion in 30 minutes
2858434|NCT03539315|Experimental|Intervention: ARCHES|All women attending facilities assigned to the intervention arm receive the Addressing Reproductive Coercion within Healthcare Settings (ARCHES) intervention.
2858435|NCT03539315|No Intervention|Control|All women attending facilities assigned to the control arm receive the standard of care (no intervention).
2858436|NCT03539302|Active Comparator|Single dose inhaled flecainide acetate|A single dose of 30 mg of flecainide acetate will be administered once via oral inhalation for 4.5 minutes
2858437|NCT03539302|Placebo Comparator|Single dose matched placebo|A single dose of placebo will be administered once via oral inhalation for 4.5 minutes
2858438|NCT03539302|Active Comparator|Repeat dose inhaled flecainide acetate|Two 30 mg doses of flecainide will be administered via oral inhalation for 4.5 minutes. There will be a 1 minute break before initiation of second inhalation. A new nebulizer will be used for the second dose.
2858439|NCT03539302|Placebo Comparator|Repeat dose matched placebo|Two doses of placebo will be administered via oral inhalation for 4.5 minutes. There will be a 1 minute break before initiation of second inhalation. A new nebulizer will be used for the second dose.
2858440|NCT03539289|Other|MUFA Diet|Monounsaturated Fatty Acids Diet
2858441|NCT03539289|Other|SFA Diet|Saturated Fatty Acids Diet
2858442|NCT03539276|No Intervention|Pre-intervention|Usual care
2858443|NCT03539276|Experimental|Post-intervention|One 90-minute interdisciplinary knowledge exchange including the provision of a validated list of appropriate and inappropriate medications for severe dementia long-term care residents.
2858444|NCT03539263|Experimental|Group 1|the subjects are treated with probiotics: Bifihappy
2858445|NCT03539263|Placebo Comparator|Group 2|the subjects are treated with a placebo
2858446|NCT03539250|Experimental|IMRT with and without chemotherapy|Subdivision of the PTVnx into regions with different prescribed absorbed doses (PTVsv1,PTVsv2, PTVsv2 is the overlaps between PTVnx and temporal lobe) can be used in cases for which the PTVnx overlaps temporal lobe. When the volume of PTVsv2 is less than 0.2 cubic centimeter (cc), the prescribe dose for PTVsv2 is as the same as that of the PTVsv1, D1cc 63.1Gy, Dmax 72.9Gy for TL (32 fractions). When the volume of PTVsv2 is between 0.2 cc and 0.5cc, the prescribe dose for PTVsv2 is 66Gy, D1cc 63.1Gy, Dmax 72.9Gy for TL (32 fractions). When the volume of PTVsv2 is between 0.5 cc and 1cc, the prescribe dose for PTVsv2 is 66Gy, D1cc 65.8Gy, Dmax 75.2Gy for TL (32 fractions).
2858447|NCT03539237|Experimental|"Video-group"|"Video group: Individuals in this group receive the intervention Video demonstration of physical activity intensity levels. They watch a 3-minute-video explaining and visualizing light-, moderate-, and vigorous-intensity levels of physical activity before completing a tablet PC-supported physical activity assessment at the DZHK-examination center.The video can not be skipped."
2876634|NCT03413696||Referred for HCV therapy,did not show up|
2858448|NCT03539237|No Intervention|"No video-group"|"No video group: Individuals in this group do not receive the intervention Video demonstration of physical activity intensity levels. They complete a tablet PC-supported physical activity assessment at the DZHK-examination center without receiving a 3-minute-video explaining and visualizing the different intensity levels of physical activity."
2858449|NCT03539224|Experimental|Dolutegravir (DTG) + Lamivudine (3TC)|Eligible subjects will receive one 50 mg tablet of DTG plus 300 mg 3TC tablet orally once daily upto 48 weeks
2858450|NCT03539211|Experimental|Rotation Exercises|8 minute program of rotation based exercises
2858451|NCT03539211|Active Comparator|Control Exercises|8 minute program of traditional exercises
2858452|NCT03539198||Locoregional|Patients with recurrent locoregional head and neck cancer
2858453|NCT03539198||Metastatic|Patients with recurrent metastatic head and neck cancer
2858454|NCT03539185|Active Comparator|Airtraq|Awake tracheal intubation using airtraq videolaryngoscope.
2858455|NCT03539185|Active Comparator|Fiberoptic|Awake nasotracheal tracheal intubation using flexible fiberoptic bronchoscope.
2858456|NCT03539172|Experimental|Apatinib group|Apatinib Mesylate administered as a daily oral treatment
2858457|NCT03539159|Experimental|Allogeneic conventional sized serum eye drops|
2858458|NCT03539159|Experimental|Allogeneic micro sized serum eye drops|
2858459|NCT03539146|Active Comparator|Control yogurt|Treatment with a control yogurt with cascara but no dietary fiber.
2858460|NCT03539146|Experimental|Yogurt with fiber|Treatment with yogurts containing cascara and 3%, 7% and 13% of dietary fiber.
2858461|NCT03539107|Experimental|Spontaneous void|Subjects will not have retrograde fill of bladder, rather will be required to void 150 mL spontaneously prior to discharge.
2858462|NCT03539107|Active Comparator|Retrograde bladder fill|Subjects will have their bladder retrograde filled with 300mL of fluid prior to a voiding trial.
2858463|NCT03539094|Experimental|Intermittent fasting|The subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.
2858464|NCT03539094|No Intervention|Western diet|The subjects randomized to this group will eat a standard western style diet.
2858465|NCT03539081|Experimental|Subjects with RLS|"Subjects with Restless Leg Syndrome that have recently undergone Spinal Cord Stimulation (SCS) Implantation for chronic pain.~Intervention: Use of epidural spinal cord stimulation."
2858466|NCT03539081|Other|Subjects without RLS|"Subjects without Restless Leg Syndrome that have recently undergone Spinal Cord Stimulation (SCS) Implantation for chronic pain.~Intervention: Use of epidural spinal cord stimulation."
2858467|NCT03539081|Other|Continous BP Monitoring|"This arm consists of subjects from arm Subjects with RLS, Subjects without RLS, and the rest of the qualifying subjects undergoing continuous blood pressure portion of the study only.~Intervention: Use of epidural spinal cord stimulation."
2858468|NCT03539068|No Intervention|WEB-ED Only Control Arm|Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the no intervention control group will receive no further intervention but asked to participate in a subsequent study phase that addresses VA and post-deployment care access
2858469|NCT03539068|Experimental|WEB-ED+ Treatment Arm|"Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the WEB-ED+ Group. WEB-ED+ augments Current WEB-ED in a next step online interface via Pharos. If successful, this enhancement could be integrated into the next iteration of WEB-ED. Enhancements include:~An eHealth interface tailored to Veterans' VA and MHV enrollment needs, links for an electronic interface with VA enrollment, MHV and MHV premium status enrollment, and secure messaging guidance.~Shared decision making (SDM) interface: Veteran SDM-related educational (e.g., existing YouTube videos) and structured questions about treatment concerns, preferences, and questions and can be accessed through postal and email distribution or Pharos portal.~Access to a health coach (the research coordinators) will be available through a toll-free number to assist both Veterans and providers/Transition Patient Advocates."
2858470|NCT03539055|Experimental|Treatment arm|"Dabigatran 75 or 150mg BID x 90 days plus ASA 81mg daily.~Single arm, prospective unblinded study on post Watchman LAA closure device implant anti-coagulation management at a primary center (Vanderbilt Medical Center) and up to 5 additional high volume LAA implant centers. This trial will be designed to evaluate the use of dabigatran for 90 days post implantation of an LAA closure device (Watchman LAA Closure Device, Boston Scientific Inc.)"
2858471|NCT03539029||Control group|age and sex matched healthy control persons
2858472|NCT03539029||Surgery|patients with ankle fracture treated surgically
2858473|NCT03539029||Conservative treatment|patients with ankle fracture treated conservatively
2858474|NCT03539003|Experimental|sevoflurane (Group S)|general anesthesia with sevoflurane
2858475|NCT03539003|Active Comparator|desflurane (Group D)|general anesthesia with desflurane
2858476|NCT03539003|Active Comparator|total intravenous anesthesia (Group T)|general anesthesia with total intravenous anesthesia
2858477|NCT03538990|Other|DASH Eating Pattern|The DASH eating pattern meals prepared for study participants will strictly follow DASH meal planning guidelines published by National Heart, Lung, and Blood Institute of the National Institutes of Health. Participants will exclusively consume prepared meals and provided beverages which will be delivered to participants' homes. Meals will be planned and prepared based on individual participant energy needs and dietary restrictions by a Registered Dietitian at the Georgia Clinical and Translational Science Alliance (CTSA) Bionutrition Unit located at Emory University.
2858478|NCT03538977|Active Comparator|Conventional physiotherapy (GP)|The sample will be evaluated once a day in the morning until they complete at least 11 intervention sessions of conventional physiotherapy in five moments: immediately before therapy, immediately after, 15, 30 and 60 minutes after the intervention.While they are in need of intensive care and hospitalized in the NICU, infants will receive conventional physiotherapy care three times a day. After discharge to the intermediate care unit (ICU), patients will receive care only once a day. Evaluations and interventions will be carried out five days a week (Monday to Friday), according to the logistics of the unit.
2858540|NCT03538691|Experimental|Brexpiprazole & Escitalopram|Brexpiprazole: oral tablet; 2 to 3 mg/day Escitalopram: oral tablet; 10 or 20 mg/day
2858479|NCT03538977|Experimental|GP + hydrotherapy (GH)|The sample will be evaluated once a day in the morning until they complete at least 11 intervention sessions of hydrotherapy in five moments: immediately before therapy, immediately after, 15, 30 and 60 minutes after the intervention. While they are in need of intensive care and hospitalized in the NICU, infants allocated to GH, hydrotherapy will be performed once a day, associated with two sessions of conventional physiotherapy. After discharge to the intermediate care unit (ICU), patients will receive care only once a day, both conventional physiotherapy and hydrotherapy. Evaluations and interventions will be carried out five days a week (Monday to Friday), according to the logistics of the unit.
2858480|NCT03538964|Active Comparator|Toric intraocular lens (IOL)|toric intraocular lens for low astigmatism correction
2858481|NCT03538964|Sham Comparator|Non toric intraocular lens (IOL)|non toric intraocular lens
2858482|NCT03538951|Experimental|Cohort 1|10% VDA-1102
2858483|NCT03538951|Experimental|Cohort 2|20% VDA-1102
2858484|NCT03538938|Experimental|1-Call, Patch, SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement are for completing the counseling call and for staying enrolled in the SmokefreeTXT program for six weeks.
2858485|NCT03538938|Experimental|1-Call, Patch, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
2858486|NCT03538938|Experimental|1-Call, Patch, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement are for completing the counseling call.
2858487|NCT03538938|Experimental|1-Call, Patch, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokeFreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
2858488|NCT03538938|Experimental|1-Call, Patch+Loz, SmokefreeTXT, Financial Incentive|Participants will receive the following: 1-Call Quitline Counseling, 4 weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. Patch treatment will consist of a 4 week supply of over-the-counter nicotine patches (21 mg if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day [TQD] and for 6 weeks following the TQD). The Financial Incentives are for completing the counseling call and for staying enrolled in the SmokefreeTXT program for 6 weeks.
2858489|NCT03538938|Experimental|1-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. Nicotine Patch treatment will consist of a 4-week supply of over-the-counter nicotine patches (21 mg if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a 4-week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
2858490|NCT03538938|Experimental|1-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). No SmokefreeTXT text messaging in support of cessation will be offered proactively. The Financial Incentives for treatment engagement are for completing the counseling call.
2858536|NCT03538704|Experimental|BMI≥25 group with metformin|Patients with BMI≥25kg/m2 in the experimental group are treated with medroxyprogesterone acetate (MPA) 0.25g/d plus metformin and are followed-up of baseline data, hormone levels,
2858491|NCT03538938|Experimental|1-Call, Patch+Loz, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
2858492|NCT03538938|Experimental|4-Call, Patch, SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination:4-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). The Financial Incentives for treatment engagement are for completing each of the four counseling calls and for staying enrolled in the SmokefreeTXT program for six weeks.
2858493|NCT03538938|Experimental|4-Call, Patch, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
2858494|NCT03538938|Experimental|4-Call, Patch, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. The Financial Incentives for treatment engagement are for completing each of the four counseling calls.
2858495|NCT03538938|Experimental|4-Call, Patch, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
2858496|NCT03538938|Experimental|4-Call, Patch+Loz, SmokefreeTXT, Financial Incentive|Participants will receive: 4-Call Quitline Counseling, 4 weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each counseling call will last approximately 20 min. Patch treatment will consist of a 4 week supply of over-the-counter (OTC) nicotine patches (21 mg for if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a 4 week supply of OTC nicotine lozenges (2-mg dose for those who do not smoke within 30 min of waking; 4-mg dose for those who smoke within 30 min of waking). SmokefreeTXT in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day [TQD] and for 6 weeks following the TQD). Financial Incentives are for completing each of the 4 counseling calls and for staying enrolled in SmokefreeTXT for 6 weeks.
2858497|NCT03538938|Experimental|4-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Patch treatment will consist of a 4-week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a 4-week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day and for 6 weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
2858498|NCT03538938|Experimental|4-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenge, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will not be offered proactively. The Financial Incentives for treatment engagement are for completing each of the four counseling calls.
2858537|NCT03538704|No Intervention|BMI≥25 group without metformin|Patients with BMI≥25kg/m2 in the none intervention group are treated with MPA 0.25g/d alone and are followed-up of baseline data, hormone levels, and endometrial pathology every 3 months until 12 months.
2858538|NCT03538691|Experimental|Brexpiprazole & Citalopram Hydrobromide|Brexpiprazole: oral tablet; 2 to 3 mg/day Citalopram hydrobromide: oral tablet; 20 or 40 mg/day
2858499|NCT03538938|Experimental|4-Call, Patch+Loz, No SmokefreeTXT,No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
2858500|NCT03538925|Experimental|Treatment Group|AAC Generative Language Intervention
2858501|NCT03538925|Active Comparator|Business as Usual|Standard of Care / Business as Usual
2858502|NCT03538912|Other|Biomarker group|patient follow the Biomarker strategy
2858503|NCT03538912|Other|Routine group|patient follow the routine strategy
2858504|NCT03538899|Experimental|Gene therapy (AProArt)|Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells. The CliniMACS® CD34 Reagent System sorter device will be used to select CD34 cells. Patients will be conditioned with low dose busulfan prior to transplant.
2858505|NCT03538886|Active Comparator|Percutaneous coronary intervention (PCI)|Currently, percutaneous coronary intervention (PCI) using balloon and drug eluting stents is the treatment of choice for treatment of a proximal LAD lesion.
2858506|NCT03538886|Experimental|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting is a well established treatment with documented excellent long-term results for the treatment of proximal LAD lesion.
2858507|NCT03538873|Active Comparator|Physical activity|"The assessment of physical activity in the prevention of depression. The intervention program being implemented in this study consists of four steps, lasting three months each:~Step 1 - Watchful waiting Step 2 - Physical Activity Intervention 1 Step 3 - Physical Activity Intervention 2 Step 4 - Referral to primary care In the case of the CES-D scores remain high, participants will receive orientation to discuss with their doctors the need to receive a specific medication."
2858508|NCT03538873|No Intervention|Usual care|Participants in the usual care group will have unrestricted access to usual care for depressive and / or anxiety symptoms.
2858509|NCT03538860|Other|Method A first then Method B|Conventional in-person interview with a psychiatrist with a live human interpreter with crossover to asynchronous telepsychiatry
2858510|NCT03538860|Other|Method B first then Method A|Asynchronous telepsychiatry — that is, video-recorded interviews that are subsequently processed with automated speech recognition and machine translation technologies, with crossover to conventional in-person interview with a psychiatrist with a live human interpreter
2858511|NCT03538834|Experimental|Cod meal from residual material|Dietary supplement: cod meal from residual material, 8 g protein daily for 8 weeks
2858512|NCT03538834|Placebo Comparator|Control|Control group receive tablet containing fillers and no protein
2858513|NCT03538821|Experimental|Intact cod protein from fillet|Dietary supplement: intact cod protein from fillet, 8 g protein daily for 8 weeks
2858514|NCT03538821|Experimental|Intact cod protein from residual material|Dietary supplement: intact cod protein from residual material, 8 g protein daily for 8 weeks
2858515|NCT03538821|Experimental|Control|Control group receive tablet containing fillers and no proteins
2858516|NCT03538808|Active Comparator|Therapeutic Dose Truth|told therapeutic dose medication + received therapeutic dose medication
2858517|NCT03538808|Placebo Comparator|Therapeutic Dose Deception|told therapeutic dose medication + received placebo
2858518|NCT03538808|Active Comparator|Low Dose Vareniclince Deception|told low dose medication + received therapeutic dose medication
2858519|NCT03538808|Placebo Comparator|Low Dose Placebo Deception|told low dose medication + received placebo
2858520|NCT03538795|Experimental|iTBS&eCIMT|Participants will first receive baseline testing followed by a no-treatment control period. Participants will then be tested again, receive the combination therapy, i.e., iTBS&eCIMT, and then receive post-treatment testing.
2858521|NCT03538769|No Intervention|Baseline group|This will be the pre and post alert phase where e-alerts will not be sent to providers
2858522|NCT03538769|Other|Alert group|This will be the phase when e-alerts will be sent to the provider
2858523|NCT03538756|Experimental|Group A--walkasins On Then Off|"Subjects will first wear walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a one-hour rest period, they will be retested with walkasins turned off.~After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits."
2858524|NCT03538756|Experimental|Group B--walkasins Off Then On|"Subjects will first wear walkasins turned off and not receive any vibrotactile feedback. Following a one-hour rest period, they will be retested with walkasins turned off.~After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits."
2858525|NCT03538743|Placebo Comparator|Placebo|
2858526|NCT03538743|Experimental|PF-06882961 30 mg|
2858527|NCT03538743|Experimental|PF-06882961 100 mg|
2858528|NCT03538743|Experimental|PF-06882961 300 mg|
2858529|NCT03538743|Experimental|PF-06882961 600 mg|
2858530|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 5|
2858531|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 6|
2858532|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 7|
2858533|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 8|
2858534|NCT03538730|No Intervention|Attention Control|Similar to previous narrative and memory interventions, parents in the control group will receive instructions from a researcher for 20 minutes on how to engage in child-directed play. Importantly, they will not talk about pain or the past surgery experience.
2858535|NCT03538730|Experimental|Memory Reframing Intervention|Parents in the intervention group will spend 20 minutes with a researcher and receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods.
2858539|NCT03538691|Placebo Comparator|Placebo & Citalopram Hydrobromide|Placebo: daily oral tablet Citalopram hydrobromide: oral tablet; 20 or 40 mg/day
2858542|NCT03538691|Experimental|Brexpiprazole & Fluoxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Fluoxetine: oral capsule; 20 or 40 mg/day
2858543|NCT03538691|Placebo Comparator|Placebo & Fluoxetine|Placebo: daily oral tablet Fluoxetine: oral capsule; 20 or 40 mg/day
2858544|NCT03538691|Experimental|Brexpiprazole & Paroxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Paroxetine: oral controlled-release tablet; 37.5 or 50 mg/day
2858545|NCT03538691|Placebo Comparator|Placebo & Paroxetine|Placebo: daily oral tablet Paroxetine: oral controlled-release tablet; 37.5 or 50 mg/day
2858546|NCT03538691|Experimental|Brexpiprazole & Sertraline|Brexpiprazole: oral tablet; 2 to 3 mg/day Sertraline: oral tablet; 100, 150 or 200 mg/day
2858547|NCT03538691|Placebo Comparator|Placebo & Sertraline|Placebo: daily oral tablet Sertraline: oral tablet; 100, 150 or 200 mg/day
2858548|NCT03538691|Experimental|Brexpiprazole & Duloxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Duloxetine: oral delayed-release capsule; 40 or 60 mg/day
2858549|NCT03538691|Placebo Comparator|Placebo & Duloxetine|Placebo: daily oral tablet Duloxetine: oral delayed-release capsule; 40 or 60 mg/day
2858550|NCT03538691|Experimental|Brexpiprazole & Venlafaxine extended-release (XR)|Brexpiprazole: oral tablet; 2 to 3 mg/day Venlafaxine XR: daily extended-release capsule; 75, 150, or 225 mg/day
2858551|NCT03538691|Placebo Comparator|Placebo & Venlafaxine extended-release (XR)|Placebo: daily oral tablet Venlafaxine XR: daily extended-release capsule; 75, 150, or 225 mg/day
2858552|NCT03538678|Experimental|Kwit app|Use of Kwit smartphone app
2858553|NCT03538678|No Intervention|Standard of care|Patient initiated follow-up post discharge
2858554|NCT03538665||Cases|Women undergoing clinically-indicated hysterectomy for endometrial cancer orprecursors
2858555|NCT03538665||Controls|Women undergoing clinically-indicated hysterectomy for benign conditions
2858556|NCT03538652|No Intervention|Formative Interviews|First stage, before content of mobile intervention is finalized
2858557|NCT03538652|Active Comparator|JITAI|Group receiving microrandomized active intervention: JITAI with both CBT and ACT
2858558|NCT03538652|Placebo Comparator|EMA only|Randomized control group undergoing mobile assessment without JITAI
2858559|NCT03538639||1|Adult index cases (affected) and relatives (affected and unaffected)
2858560|NCT03538639||2|Child index cases (affected) and child relatives (affected and unaffected)
2858561|NCT03538639||3|Healthy adult volunteers
2858562|NCT03538626|Experimental|1|5 mg/kg IV
2858563|NCT03538626|Experimental|2|5 mg/kg SC
2858564|NCT03538626|Experimental|3|20 mg/kg IV
2858565|NCT03538626|Experimental|4|40 mg/kg IV
2858566|NCT03538613|Experimental|1/Phase I Arm|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +escalating doses of CISH inactivated TIL + high-dosealdesleukin
2858567|NCT03538613|Experimental|2/Phase II Arm|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +MTD of CISH inactivated TIL
2858568|NCT03538600||1|healthy volunteers
2858569|NCT03538587|Active Comparator|1/EMI Group|Participate in an in-person session followed by a series of at-home assignments, and two booster sessions
2858570|NCT03538587|Active Comparator|2/Control Group|Participants will briefly meet with a member of the research team who will assess parent and child coping, and provide the child- caregiver dyad educational material about coping with cancer
2858571|NCT03538574|Active Comparator|CBT-I|Cognitive behavioral therapy for insomnia (CBT-I), considered the treatment of choice by the American Academy of Sleep Medicine, combines cognitive therapy, stimulus control, sleep restriction, sleep hygiene, and relaxation to improve sleep outcomes, with demonstrated efficacy in adult and older adult populations
2858572|NCT03538574|Experimental|MAP-I|The Mindful Awareness Practices (MAPs) is a validated and curriculum-based meditation similar to Mindfulness Based Stress Reduction, with the exception that MAPs does not include a day-long retreat or yoga and hence takes a more practical and accessible approach that focuses specifically on the practice of mindfulness and its application in everyday life. (http://marc.ucla.edu) MAP for Insomnia (MAP-I) is a modified version of MAPs that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.
2858573|NCT03538548|Experimental|Treatment|Participants receive a standard 12-week course of Cognitive Behavioral Therapy for Relapse Prevention (CBT-RP; Carroll, 1998). The treatment protocol will be implemented over 12 weeks, with two 1-hour sessions per week for the first two weeks and one 1-hour session per week thereafter (i.e., a total of 14 sessions).
2858574|NCT03538535|Experimental|Go/No-Go Active Learning (GOAL)|Adaptation of Behavioral Activation, focused on reinforcement learning strategies.
2858575|NCT03538522|Experimental|Low-dose N-831(Traneurocin)- 10 mg QD|Oral administration of 10 mg of NA-831 (Traneurocin) per day for 24 weeks
2858576|NCT03538522|Experimental|Medium-dose NA-831(Traneurocin)- 20 mg QD|Oral administration of 20 mg of NA-831(Traneurocin) per day for 24 weeks
2858577|NCT03538522|Experimental|High-dose NA-831(Traneurocin)- 40 mg QD|Oral administration of 40 mg of NA-831(Traneurocin) per day for 24 weeks
2858578|NCT03538522|Placebo Comparator|Placebo|Oral administration of placebo per day for 24 weeks
2858579|NCT03538496|Active Comparator|ultrasound guided erector spinae plane block|ultrasound guided erector spinae plane block with 20 ml %0.25 bupivacaine
2858580|NCT03538496|Active Comparator|ultrasound guided paravertebral block|ultrasound guided paravertebral block with 20 ml %0.25 bupivacaine
2858581|NCT03538483|Active Comparator|ultrasound guided serratus plane block|Ultrasound Guided Serratus Plane Block 30 ml %0.25 Bupivacaine
2858582|NCT03538483|Active Comparator|ultrasound guided erector spinae plane block|Ultrasound Guided Erector Spinae Plane Block 20 ml %0.25 Bupivacaine
2858583|NCT03538470|Experimental|Spa treatment|Mineral water cares in Contrexéville thermal cure center, massage, cataplasm.
2858584|NCT03538444|Experimental|Active rTMS|Participants will receive 18 sessions of active repetitive Transcranial Magnetic Stimulation over a period of three days. TMS consists of 3000 pulses of 10Hz stimulation applied to the left DLPFC using the beam F3 method
2858585|NCT03538444|Placebo Comparator|Sham rTMS|Participants will receive 18 sessions of sham rTMS over a period of three days.
2858672|NCT03537859|Experimental|Augmented Reality (AR)|Books with augmented reality plus an electronic tablet.
2861181|NCT03520439|Placebo Comparator|control group|placebo，10mg，One tablet daily, oral treatment
2858586|NCT03538431|Experimental|Buspirone before Simulation 1|These subjects will receive and be instructed to take the buspirone for the 2 days preceding their first driving simulation visit. They will not take buspirone before their 2nd driving simulation visit.
2858587|NCT03538431|Experimental|Buspirone before Simulation 2|These subjects will receive and be instructed to take the buspirone for the 2 days preceding their second driving simulation visit. They will not take buspirone before their 1st driving simulation visit.
2858588|NCT03538418|Experimental|WAT group|The WAT group will receive a 3-month WAT-based exercise training programme, which includes 12 weekly exercise training sessions (an hour each) in addition to 2 face-to-face sessions followed by weekly to monthly telephone sessions offering support on dealing with technical issues and BCTs (7 session in total). The WAT group will be left to use the WAT on their own for 3 months during the follow-up period.
2858589|NCT03538418|No Intervention|Control group|The control group will receive a 3-month exercise training programme without a WAT, which also includes 12 weekly exercise training sessions (an hour each) in addition to 7 face-to-face and telephone sessions offering support for BCTs.
2858590|NCT03538405|Experimental|all participants|All participants received the same interventions, there were no subgroups interventions: supporting cushions and harmonic techniques
2858591|NCT03538392||PAD|
2858592|NCT03538392||AV Fistula|
2858593|NCT03538392||AV Graft|
2858594|NCT03538379|Active Comparator|Combat Application Tourniquet (CAT)|The combat application tourniquet (CAT) is the type of commercial tourniquet taught in the B-Con course as administered by the investigators. It will serve as the control group to which all other types of tourniquets, which are not explicitly taught in the course, are compared to.
2858595|NCT03538379|Active Comparator|Sof Tourniquet (Sof-T)|The Sof-Tourniquet (Sof-T) is a commercial windlass type tourniquet similar to the CAT tourniquet in that it is based on a windlass mechanism. Its application not explicitly taught in the B-Con course.
2858596|NCT03538379|Active Comparator|Stretch-Wrap-And-Tuck (SWAT) Tourniquet|The Stretch-Wrap-And-Tuck (SWAT) Tourniquet is a commercial elastic tourniquet. Its application not explicitly taught in the B-Con course.
2858597|NCT03538379|Active Comparator|Rapid Application Tourniquet (RAT)|The Rapid Application Tourniquet (RAT) is a commercial elastic tourniquet similar to a bungee cord. Its application not explicitly taught in the B-Con course.
2858598|NCT03538379|Active Comparator|Improvised Tourniquet|The improvised tourniquet arm will involve participants being given supplies to enable them to fashion a tourniquet. The supplies will include a leather belt, gauze, shoestring, and a rod to act as a windlass.
2858599|NCT03538366|Experimental|Donor FMT|Fecal transplant from unrelated, healthy volunteers
2858600|NCT03538353|Other|Pain Education Video|Participants will watch a pain education video and then answer several questions.
2858601|NCT03538340|Active Comparator|Control Arm|Control Arm: Surgery without intercostal Cryoanalgesia + Standard of Care (thoracic epidural)
2858602|NCT03538340|Experimental|Study Arm|Study Arm: Surgery with intercostal Cryoanalgesia + Standard of Care (thoracic epidural)
2858603|NCT03538327|Experimental|Silybin|50 Caucasian never-treated hypertensive outpatients, 27 males and 23 women, age range 42-60 years (mean+SD=52+7), showing normal glucose tolerance but 1-h post load plasma glucose >155 mg/dl, during the OGTT.
2858604|NCT03538314|Experimental|Experimental Treatment|UV1/GM-CSF
2858605|NCT03538301|Experimental|ND-L02-s0201 (Dose Level 1)|
2858606|NCT03538301|Experimental|ND-L02-s0201 (Dose Level 2)|
2858607|NCT03538301|Placebo Comparator|Placebo|
2858608|NCT03538288|Experimental|Twenty sessions of rTMS|Twenty sessions of rTMS will be applied to treatment seeking participants.
2858609|NCT03538275||Unipolar depression cohort|
2858610|NCT03538275||Bipolar depression cohort|
2858611|NCT03538275||Healthy Control cohort|
2858612|NCT03538262||former phase 3 PD trial participants|The AT-HOME PD cohort enrolled upon completion of STEADY-PD3 or during completion of SURE-PD3; enrolling 2 to 6 years after diagnosis, and on standard dopaminergic therapy for 0 to 3 years. Former STEADY-PD3 participants had been randomized (1:1) to 3 years of isradipine or placebo treatment; SURE-PD3 participants had been randomized (1:1) to 2 years of inosine or placebo treatment.
2858613|NCT03538249|Experimental|Aerobic training|Patients follow an alternating aerobic training using a treadmill at an intensity of 60% of maximum heart rate, 3 mn and 3 mn working off an alternative way.To ensure progressive overload appropriate, we adjust moderate intensity aerobic exercise every two weeks with an overall 5% increase in heart rate.
2858614|NCT03538249|Experimental|Inspiratory muscle training|The inspiratory muscle training involves a high intensity endurance training to 60% of PI, max. We recalculate the individual SPImax and PImax in each training session. Patients use the driving tool inspiratory muscle.
2858615|NCT03538249|Experimental|Resistance training|The resistance should be measured on 1 RM (Repetition Maximum) for each muscle group. The exercises are performed in three sets of ten repetitions of exercises at 60% of 1RM intensity recalculated every two weeks training.
2858616|NCT03538249|No Intervention|Control|The control group patients were allocated to a non-training time period, during which they were told to continue their life as before enrollment.
2858617|NCT03538249|Experimental|Aerobic and Inspiratory training|Note that the Aerobic and Inspiratory group participant undergone same protocols of inspiratory and aerobic training stated above, with almost a 5 minutes rest in between.
2858618|NCT03538249|Experimental|Combined|Note that the Aerobic, Inspiratory and resistance group participant undergone same protocols of inspiratory and aerobic training stated above, with almost a 5 minutes rest in between.
2858619|NCT03538236|Active Comparator|Lifestyle intervention alone|All patients included in the study will undergo an evaluation by a nutritionist and will undergo diet and lifestyle intervention.
2858620|NCT03538236|Experimental|Intragastric balloon with lifestyle|Patients who do not reach the 10% weight loss with lifestyle intervention alone after 6 months will be offered to have intragastric balloon insertion for 6 months. Regardless of whether an intragastric balloon is inserted, all patients will continue with the same lifestyle changes described above for another 6 months.
2858673|NCT03537859|Other|Non Augmented Reality (NoAR)|Conventional children book. No electronic device will be given to children.
2858674|NCT03537846||Osteoporosis and women|Patient women over thirty years old
2858675|NCT03537833||"PPI-positive or test group"|Patients treated with PPI
2858621|NCT03538223|Experimental|"Melomics-Health Music Listening"|"The musical content is composed by an algorithm (named Melomics-Health) with the purpose of acting psychologically and physiologically on the person: the music follows a constant, melodic trend with a reduced musical density; time is unchanged and there are no significant dynamic and tonal variations. Patients will undergo to music listening for 15 minutes (5 tracks lasting 3 minutes each) before radiotherapy session. Appropriate earphones will be used in order to focus their attention on the musical-sound component and to isolate themselves from the external context."
2858622|NCT03538223|Experimental|Individualized Music Listening|The musical content is based on the patient's preferred music (chosen by patients with the support of the music therapist) with the purpose of acting psychologically and physiologically on the person. Patients will undergo to music listening for 15 minutes before radiotherapy session. Appropriate earphones will be used in order to focus their attention on the musical-sound component and to isolate themselves from the external context.
2858623|NCT03538223|No Intervention|No Music|Patients will undergo the standard treatment (radiotherapy) without music support.
2858624|NCT03538197|Other|SUICID ATTEMPT YOUNG PEOPLE|Suicide Re Attempts in Young Adults after first suicide attempt : socio-demographic, clinical and biological correlates
2858625|NCT03538184|Experimental|Piezosurgery|Osteotomy preparation entirely with piezosurgery tips and equicrestal placement of a 4.1 mm implant in the piezosurgery (test) group were performed as follows: 1.15 mm initial MB1 tip, 1.95 mm MB2 tip, control of depth, diameter and direction of osteotomy with 2.0 mm paralleling pin, 2.5 mm MB3 tip, 2.8 mm MB4 tip, 2.8 mm paralleling pin, 3.05 mm MB5 tip, 3.3 mm MB6 tip, control of final diameter of the osteotomy with 3.5 mm paralleling pin, placement of the 4.1 mm diameter implant and connection of a 4 mm-wide healing abutment.
2858626|NCT03538184|Active Comparator|Drill|Preparation of an implant recipient site entirely with relevant drills were performed as follows: Osteotomy preparation and equicrestal placement of a 4.1 mm diameter implant in the drill (control) group were performed as follows: initial trispade drill, 2.0 mm pilot drill, control of depth, diameter and direction of osteotomy with 2.0 mm paralleling pin, 2.5 mm drill, 2.8 mm drill, 2.8 mm paralleling pin, 3.5 mm drill, control of final diameter of the osteotomy with 3.5 mm paralleling pin, placement of the 4.1 mm diameter implant and connection of a 4 mm wide healing abutment.
2858627|NCT03538171|Active Comparator|ARM Entinostat+Exemestane|Patients receive Exemestane orally (PO) once daily (QD) on days 1-28 and Entinostat PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2858628|NCT03538171|Placebo Comparator|ARM Placebo+Exemestane|Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2858629|NCT03538158|Experimental|Intervention condition - Fittle Senior|Participants will have access to the Fittle Senior System which will provide guided exercises and social support.
2858630|NCT03538158|Placebo Comparator|Control condition - paper and pencil|Participants will have a written booklet with exercises that they may do it on their own.
2858631|NCT03538119|Experimental|HIIT program|Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided into heating, aerobic exercise and recovery.
2858632|NCT03538119|Experimental|Moderate continuous training program|Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided into heating, aerobic exercise and recovery.
2858633|NCT03538119|No Intervention|Control Group|Usual care. The patients will receive nutritional counseling as well as physical activity.
2858634|NCT03538093|Experimental|Local Stabilization Exercise|Experimental: Local Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of the muscles considered as local stabilizers of the core (Transversus Abdominis and Multifidus).
2858635|NCT03538093|Experimental|Global Stabilization Exercise|Experimental: Global Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of the muscles considered as global stabilizers of the core (Erector Spinae, Quadratus Lumborum, Abdominal External Oblique, Abdominal Internal Oblique and Rectus Abdominis).
2858636|NCT03538093|Experimental|Mixed Stabilization Exercise|Experimental: Mixed Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of both local and global core stabilizer muscles.
2858637|NCT03538080|Experimental|ACCUVEIN plus ultrasound|Patients referred for marking of saphenous veins before varicose vein surgery or for saphenectomy for vascular or coronary artery bypass grafting will have marking with Accuvein and ultrasound
2858638|NCT03538080|Sham Comparator|Ultrasound only|Patients referred for marking of saphenous veins before varicose vein surgery or for saphenectomy for vascular or coronary artery bypass grafting will have marking with ultrasound only.
2858639|NCT03538067||Paired sample group|Patients with symptomatic coronary artery disease (stable, NSTEACS) undergoing planned percutaneous coronary intervention with intravascular ultrasound (IVUS) guidance
2858640|NCT03538054|Experimental|Dextromethorphan|Participant will take one dextromethorphan 10mg capsule in the morning and at night.
2858641|NCT03538054|Placebo Comparator|Placebo|Participants will take one placebo capsule in the morning and at night.
2858642|NCT03538041|Experimental|Cohort 1|INCB050465 at the protocol-defined dose for 12 weeks, with a dose-increase option at Week 6 for participants who fulfill dose increase criteria.
2858643|NCT03538041|Experimental|Cohort 2|INCB050465 at the protocol-defined dose for 12 weeks.
2858644|NCT03538028|Experimental|INCAGN02385|Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation to determine the maximum tolerated dose or pharmacologically active dose. Part 2: INCAGN02385 administered Q2W or Q4W at the recommended dose(s) from Part 1.
2858645|NCT03538015|Experimental|Carvedilol 3.125 mg|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of low-dose carvedilol treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
2858676|NCT03537833||"PPI-negative or control group"|Patients not treated with PPI
2861219|NCT03520166|Experimental|Group-B|Medium frequency electrotherapy (interferential currents)
2858646|NCT03538015|Placebo Comparator|Placebo capsule|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of placebo treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
2858647|NCT03538002|No Intervention|Conventional anti-reflection coated spectacle lens|Single vision lenses with correction of distant refraction and conventional anti-reflection coating
2858648|NCT03538002|Experimental|Blue-light filtering spectacle lenses|Single vision lenses with correction of distant refraction and blue-light filtering coating
2858649|NCT03537989|Experimental|Restricted group|"Oral fluid allowed up to 2 h before surgery. Intra-operatively: Glucose 5% (500 ml - volume drunk up to 6 h before) for the fasting; HAES 6% for blood loss volume to volume; IV-medicine in saline 9% for anaesthesia and antibiotics. Blood products after current rules.~Postoperatively: 1000 ml Hypotonic fluid in the recovery room. Free oral intake of fluid and food as well as enteral feeding by tube 500 ml.~In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. If less than 1500 ml fluid pr. mouth supplement with VI-fluid.~Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid. Goal: zero fluid balance with up to 1 kilogram body weight increase.~Urine>5 ml/kg/h with fluid. MAP<60 and hypovolemia treat with fluid."
2858650|NCT03537989|Active Comparator|Standard group|"Oral fluid allowed up to 2 h before surgery. Intra-operatively: Saline 500 ml for fasting; 500 ml HAES 6% for the epidural, Saline for the third space: 7 ml/kg/h first hour, 5 ml/kg/h 2.-3. Hour, 3 ml/kg/h subsequent hours. 1000-1500 ml Saline replaced lost blood up to 500 ml, additional HAES 6% for additional blood loss; IV-medicine in saline.~Postoperatively: 1000-2000 ml isotonic fluid in the recovery room. Free oral fluid and food as well as enteral feeding by tube 500 ml.~In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. Supplemental iv-fluid according to department rules. Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid.~Urine >5 ml/kg/h with fluid. MAP<60 and hypovolemia treat with fluid."
2858651|NCT03537976|Other|Static Images and Facial Videos|2D and 3D still and video images obtained from each patient before surgery.
2858652|NCT03537963|Other|Pre-Intervention Qualitative Interviews|Hematopoietic cell transplant (HCT) survivors, caregivers and clinicians will participate in this part of the study. HCT survivor participants will be asked to nominate and provide contact information for the person who was their primary caregiver before, during, or after their HCT hospitalization. All participants will be asked to participate in either an in-person or telephone interview that will last approximately 1 hour. The interview will be digitally audio-recorded and will ask questions on the trajectory of sleep disturbance in HCT recipients and strategies to manage common barriers to quality sleep, as well as discuss the planned intervention for sleep disturbance in HCT survivors.
2858653|NCT03537963|Experimental|mHealth Stepped-care Intervention|For HCT survivors randomized to this group: Baseline survey, followed by mHealth Stepped-care intervention, post-intervention questionnaire and interview.
2858654|NCT03537963|Active Comparator|Educational Control Condition|For HCT survivors randomized to this group: Baseline survey, followed by Educational Control intervention, post-intervention questionnaire and interview.
2858655|NCT03537950|Experimental|PLC, CBD, CBDV|Dose order: PLC, CBD, CBDV
2858656|NCT03537950|Experimental|PLC, CBDV, CBD|Dose order: PL, CBDV, CBD
2858657|NCT03537950|Experimental|CBD, PLC, CBDV|Dose order: CBD, PLC, CBDV
2858658|NCT03537950|Experimental|CBD, CBDV, PLC|Dose order: CBD, CBDV, PLC
2858659|NCT03537950|Experimental|CBDV, PLC, CBD|Dose order: CBDV, PLC, CBD
2858660|NCT03537950|Experimental|CBDV, CBD, PLC|Dose order: CBDV, CBD, PLC
2858661|NCT03537937|Active Comparator|Lower SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 90% (range 88-92%).
2858662|NCT03537937|Active Comparator|Intermediate SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 94% (range 92-96%).
2858663|NCT03537937|Active Comparator|Higher SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 98% (range 96-100%).
2858664|NCT03537924|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2858665|NCT03537924|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2858666|NCT03537911|Experimental|Cognitive Support Program|Three individual sessions of supportive psychoeducation, mindfulness practice, and strategy training (e.g., strategies to improve memory or concentration), with practice applying program content between sessions.
2858667|NCT03537898|Active Comparator|Lactated Ringer's|Patients in a MICU block randomized to lactated Ringer's will receive lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
2858668|NCT03537898|Active Comparator|Normosol|Patients in a MICU block randomized to Normosol will receive Normosol-R pH 7.4 whenever isotonic intravenous fluid administration is ordered by the treating provider.
2858669|NCT03537885|Experimental|TMS, EEG, and tDCS Group|"Participants will wear a cap fitted with Electroencephalography (EEG) electrodes to detect the brain's activity during the task. Transcranial Magnetic Stimulation will be used to evaluate the brain's responsiveness to Transcranial Direct Current Stimulation.~All study participants will receive the same study procedures - TMS, tDCS, and EEG."
2858670|NCT03537872|Experimental|Miner-Friendly (MF) Cohort|"Subjects will be enrolled over the 9-month enrollment period and will receive additional integrated strategies available at a miner-friendly service venue.~Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies."
2858671|NCT03537872|Active Comparator|Public Sector (PS) Cohort|"Subjects will be enrolled over the 9-month enrollment period and will receive the usual integrated care for the management of TB and HIV at a public sector health facility.~Public Sector (PS) Health Facilities TB/HIV Integration Strategies"
2876635|NCT03413696||Referred,attended HCV therapy evaluation|
2858677|NCT03537820||before nurses formation/installation of a noise warning device|ambulatory or hospitalized patients, who go in post-anesthesia care unit, before nurses formation and installation of a noise warning device
2858678|NCT03537820||after nurses formation/installation of a noise warning device|ambulatory or hospitalized patients, who go in post-anesthesia care unit, after nurses formation and installation of a noise warning device
2858679|NCT03537794||Treatment Resistant Depression|Unmedicated Individuals with Treatment Resistant Depression
2858680|NCT03537794||Major Depressive Disorder|Unmedicated Individuals with Major Depressive Disorder
2858681|NCT03537794||Healthy Control|healthy controls with no previous psychiatric disorders
2858682|NCT03537781|Experimental|Food label available, hungry state|foods will be displayed with food labels present and when participants had nothing to eat
2858683|NCT03537781|Experimental|food label available, satiated|foods will be displayed with food labels present and when participants had already eaten breaksfast
2858684|NCT03537781|Experimental|food label unavailable, hungry state|foods will be displayed without food labels present and when participants had nothing to eat
2858685|NCT03537781|Experimental|food label unavailable, satiated|foods will be displayed without food labels present and when participants had already eaten breakfast
2858686|NCT03537768|Active Comparator|UPA 30mg|
2858687|NCT03537768|Active Comparator|LNG 1.5 mg|
2858688|NCT03537768|Active Comparator|LNG 3.0|
2858689|NCT03537742|Experimental|alirocumab|alirocumab 75mg subcutaneous every other week for one year following transplant
2858690|NCT03537742|Placebo Comparator|placebo|placebo to match alirocumab every other week for one year following transplant
2858691|NCT03537729|No Intervention|Control|There will be no modifications to décor or signage in the existing care community, and no education on wayfinding. However, subjects will receive the same testing that is provided for the other arms at the designated time periods.
2858692|NCT03537729|Experimental|Salient Cues|Special signs and salient cues will be added to the community along the routes being measured for wayfinding. The cues will be comprised of pictures, objects, and signage.
2858693|NCT03537729|Experimental|Spaced retrieval education|This condition will have signage and cues as in Arm 2 added to the care communities. In addition, a spaced retrieval (SR) memory intervention strategy will be implemented individually for each resident participating in the study to help them remember the presence and function of the environmental wayfinding cues.
2858694|NCT03537716|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic system
2858695|NCT03537703|Experimental|Active tDCS + Auditory Training|Cathodal tDCS plus concurrent active auditory training exercise
2858696|NCT03537703|Active Comparator|Active tDCS + Control Condition|Cathodal tDCS plus concurrent control condition
2858697|NCT03537703|Active Comparator|Sham tDCS + Auditory Training|Sham tDCS plus concurrent active auditory training exercise
2858698|NCT03537690|Experimental|Treatment (FID-007)|Participants receive FID-007 IV over 60 minutes on days 1, 8 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2858699|NCT03537677|Experimental|Sedentary Behavior Intervention|A behavioral intervention that targets prolonged sitting and encourages frequent activity breaks.
2858700|NCT03537664|Experimental|Root canal preparation and medication|First endodontic treatment session includes the root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation. The second endodontic treatment includes the intracanal medication with calcium hydroxide paste.
2858701|NCT03537651|Experimental|TEZ + IVA|"Subjects <40 kg will receive 50 mg TEZ/ 75 mg IVA as a FDC tablet in the morning and 75 mg IVA as a mono tablet in the evening.~Subjects >=40 kg will receive 100 mg TEZ/ 150 mg IVA FDC tablet in the morning and 150 mg IVA as a mono tablet in the evening."
2858702|NCT03537638|Experimental|Multicomponent Intervention|Rheumatologist and internist receive a multicomponent intervention
2858703|NCT03537638|No Intervention|Control|Rheumatologist and internist provide the usual care
2858704|NCT03537625|Experimental|Green tea|Green tea extract 2 gram per day
2858705|NCT03537625|Experimental|Fermented green tea|Fermented green tea extract 2 gram per day
2858706|NCT03537625|Placebo Comparator|Placebo|Placebo
2858707|NCT03537612|Experimental|Opt-Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
2858708|NCT03537612|Experimental|Sub-opt-Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
2858709|NCT03537612|Active Comparator|Opt-Morphine|Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
2858710|NCT03537612|Active Comparator|Sub-opt-Morphine|Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
2858711|NCT03537599|Experimental|Treatment (DLI, daratumumab)|Participants receive daratumumab intravenously once a week for 8 weeks and donor lymphocyte infusion in weeks 3 or 4 in the absence of disease progression or unacceptable toxicity.
2858712|NCT03537586|Experimental|Non-Obstructive CAD|After diagnostic coronary angiography, invasive measures of coronary microvascular physiology will be obtained. Blood will be collected for platelet activity, inflammation and isolation of coronary endothelial cells. Evaluation of the sublingual microvasculature with a side stream dark field imaging video microscope will be performed.
2858713|NCT03537573|Active Comparator|Usual Care/Guideline|The Usual Care group (also known as the Guideline group) follows the recent Center for Disease Control (CDC) guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
2858714|NCT03537573|Experimental|Guideline + Opioid Justification (OJ)|"Providers will be required to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition. The provider will be notified that the justification provided will be visible in the Epic EHR and the phrase no justification provided if the provider decides to enter no text and proceed with the prescription. The provider does not need to enter a justification if they choose to cancel the opioid prescription."
2858715|NCT03537573|Experimental|Guideline + Provider Comparison (PC)|Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids f or acute pain who transition to chronic opioid therapy (> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions , unsafe opioid prescribing, and transition to chronic opioid therapy (> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
2858716|NCT03537573|Experimental|Guideline + OJ + PC|This arm will include the guideline, opioid justification, and provider comparison described above.
2858717|NCT03537547|Experimental|GeneSight Psychotropic test|Participants randomized to have their study clinician have access to their pharmacogenetic report (provided through the GeneSight Psychotropic tool) in order to make treatment decisions for the first 12 weeks. At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will continue to be able to use the results to guide treatment options for an additional 12 weeks.
2858718|NCT03537547|Active Comparator|Treatment As Usual|Participants randomized to treatment as usual will receive treatment from study clinicians who do not have access to the participant's report for the first 12 weeks. At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will be unblinded to be able to use the results to guide treatment options for an additional 12 weeks.
2858719|NCT03537534|Experimental|Experiment|Lidocaine jelly (2%) 5mL x 1 dose only
2858720|NCT03537534|Placebo Comparator|Placebo|Surgilube 5mL x 1 dose only
2858721|NCT03537521||DOA|N= 130 patients treated with direct oral anticoagulants (DOAC) with acute bleeding N= 65 patients treated with direct oral anticoagulants (DOAC) with urgent surgical intervention
2858722|NCT03537521||VKA|N= 130 patients treated with vitamin K antagonists (VKA) with acute bleeding N= 65 patients treated with vitamin K antagonists (VKA) with urgent surgical intervention
2858723|NCT03537508|Experimental|Group 1a|MenACYW conjugate vaccine and routine vaccines at 2, 4, 6, and 12 to 15 months of age
2858724|NCT03537508|Experimental|Group 1b|MenACYW conjugate vaccine at 2, 4, 6, and 15 to 18 months of age and routine vaccines at 2, 4, 6, 12 to 15 months of age, and 15 to 18 months of age
2858725|NCT03537508|Active Comparator|Group 2a|MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age
2858726|NCT03537508|Active Comparator|Group 2b|MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age
2858727|NCT03537495|No Intervention|Control arm|Subjects in this arm will only receive rifampicin 1350 mg (~30 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
2858728|NCT03537495|Experimental|Linezolid 600|Subjects in this arm will receive 600 mg linezolid QD along with rifampicin 1350 mg (~30 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
2858729|NCT03537495|Experimental|Linezolid 1200|Subjects in this arm will receive 1200 mg linezolid QD along with rifampicin 1350 mg (~30 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
2858730|NCT03537482|Experimental|single-agent, open-label, Phase I study of APG-2575|The study consists of the dose escalation stage and the dose expansion stage
2858731|NCT03537469|Experimental|CTU Mega 20 real device|A single-session of real CTU Mega 20 on the corresponding primary right-hand motor area, using the real (magnetic field = 2 Tesla; intensity = 90 J; frequency of impulses = 7Hz; duration = 15 minutes) CTU Mega 20 device. This real stimulation provided a Low Frequency-Pulsed Electromagnetic Fields (LF-PEMFs).
2858732|NCT03537469|Sham Comparator|CTU Mega 20 sham device|A single-session of sham CTU Mega 20 on the corresponding primary right-hand motor area (magnetic field = 0 Tesla; intensity = 0 J; frequency of impulses = 7Hz; duration = 15 minutes). The sham stimulation did not provide a Low Frequency-Pulsed Electromagnetic Fields (LF-PEMFs).
2858733|NCT03537456|Experimental|mRDX-02-17|"mRDX-02-17 is a dermal filler recommended for correction and treatment of wrinkles and dermal depressions, which are administered by intradermal injections. It encourages repair and restructuring of skin tissue, reducing the signs of aging and has the following indications:~Hypotrophic tissues~Tissue hypotonicity~Crow's feet~Glogau III - IV~Fiztpatrick I - VI~WSRS (Wrinkle Severity Ranking Scale): 2-5"
2858734|NCT03537430|Other|Tubeless Uniportal Video-assisted Thoracoscopic Surgery|This group of patients underwent tubeless uniportal video-assisted thoracoscopic surgery in total thymectomy.
2858735|NCT03537430|Other|Uniportal Video-assisted Thoracoscopic Surgery|This group of patients underwent uniportal video-assisted thoracoscopic surgery in total thymectomy.
2858736|NCT03537417||Tension pneumothorax group|Patients undergoing intentional pneumothorax for thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
2858737|NCT03537404|Active Comparator|Treatment A (Part 1/ Part 2)|Narlaprevir 200 mg once daily with Ritonavir 100 mg once daily for 5 days
2858738|NCT03537404|Active Comparator|Treatment B (Part 1)|Tenofovir disoproxil fumarate 300 mg once daily for 5 days
2858739|NCT03537404|Active Comparator|Treatment B (Part 2)|Raltegravir 400 mg twice daily for 5 days
2858740|NCT03537404|Experimental|Treatment C (Part 1)|Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and Tenofovir disoproxil fumarate 300 mg once daily for 5 days
2858741|NCT03537404|Experimental|Treatment C (Part 2)|Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and 400 mg raltegravir twice daily for 5 days
2858781|NCT03537131|Active Comparator|arm B2- Dapagliflozin daily administration|Participants who will take a daily dose of Dapagliflozin 10 mg before and after the exercise challenge.
2858782|NCT03537118|Experimental|Fluoroscopic + Ultrasound Guidance|
2858742|NCT03537391|Experimental|Imaging based staging of high risk PC|"Each individual study patient will be imaged for PC metastasis detection with each different imaging modalities as follows:~Traditional imaging (clinical standard imaging);~Whole-body contrast enhanced computer tomography~Planar bone scintigraphy~Novel imaging (investigational imaging);~SPECT/CT (investigational imaging)~18F-PSMA-PET/CT (investigational imaging)~Whole-body MRI (investigational imaging)~In order to define the true nature of the findings from each different imaging modality, comparison with best valuable comparator (BvC) is made. Consensus reading of all imaging modalities and follow-up data of clinical, imaging, histopathological and laboratory results are used to define BvC."
2858743|NCT03537378|Experimental|Hybrid APC Therapy Group|1) Patients are diagnosed as early central lung cancer (severe dysplasia, carcinoma in situ, microinvasive carcinoma) by inquiry of the first doctor, CT test, endoscopy and histopathology. Patients who meet inclusion/exclusion criteria are not suitable for or refuse surgery.
2858744|NCT03537365|Experimental|Bovine Colostrum / intervention group|Preterm infants are supplemented with bovine colostrum (BC) as a fortifier to human milk. BC is the first milk from cows after parturition and is a rich source of protein (80-150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and growth factors. The product is supplied in a sterile, powdered form and consists of unmodified, intact BC.
2858745|NCT03537365|Active Comparator|FM85 / control group|Preterm infants are supplemented with PreNAN FM85 as fortifier to human milk. PreNAN FM85 contains partially hydrolyzed protein and maltodextrin including vitamins and minerals. The product is supplied in a powdered form.
2858746|NCT03537352||Surgical Disorders|
2858747|NCT03537352||Non-Surgical General Medical Disorders|
2858748|NCT03537339||Observation|Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment and so on
2858749|NCT03537326|Experimental|Budesonide|Healthy women, aged between 18 and 45 years old, with weigh between 50 and 75 kg and with IMC included between 19 and 27 kg/m². Patients will be given, on an empty stomach since 10 hours minimum, a single dose of 3 mg of Budesonide, in the form of Entocord ® tablets. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
2858750|NCT03537313|No Intervention|Control-douching group|No preoperative vagina douching
2858751|NCT03537313|No Intervention|Control-painting group|No intra-operative vagina painting
2858752|NCT03537313|Experimental|Vaginal douching group|Preoperative vaginal douches with povidone-iodine solution
2858753|NCT03537313|Experimental|Vaginal painting group|Intra-operative vaginal painting with povidone-iodine solution
2858754|NCT03537300|Experimental|experimental group|
2858755|NCT03537300|Active Comparator|control group|
2858756|NCT03537287|Active Comparator|17 alpha hydroxyprogestrone caproate Group|Patients will receive 250 mg of 17 alpha hydroxyprogestrone caproate intramuscularly once weekly starting from 16 weeks till delivery or 36 weeks.
2858757|NCT03537287|Active Comparator|Vaginal progesterone Group|Patients will receive vaginal progesterone 200 mg once per day starting from 16 weeks till delivery or 36 weeks.
2858758|NCT03537287|Active Comparator|Oral dydrogesterone Group|Patients will receive 2 tablets of oral dydrogesterone daily starting from 16 weeks till delivery or 36 weeks
2858759|NCT03537274|Experimental|PEG-Intron, 0.5 mg/kg|PEG-Intron administered once weekly (QW) for 48 weeks at 0.5 mg/kg by subcutaneous (SC) injection.
2858760|NCT03537274|Experimental|PEG-Intron, 1.0 mg/kg|PEG-Intron administered QW for 48 weeks at 1.0 mg/kg by SC injection.
2858761|NCT03537274|Experimental|PEG-Intron, 1.5 mg/kg|PEG-Intron administered QW for 48 weeks at 1.5 mg/kg by SC injection.
2858762|NCT03537274|Active Comparator|Interferon Alfa-2b|Interferon Alfa-2b administered three times per week (TIW) for 48 weeks at 3 million international units (MIU) by SC injection.
2858763|NCT03537261|Experimental|CPI-Parent Training|Will receive one-day (6-hour) training in P-CPI including the use of nonverbal, paraverbal, verbal, and physical intervention techniques.
2858764|NCT03537261|No Intervention|Waitlist Control|"Will not receive active P-CPI training during the experimental treatment interval.~NOTE: The waitlist group will be offered the P-CPI training session after the treatment group completes their follow-up measures."
2858765|NCT03537248|Experimental|Asepticys investigational ASP-57 Multi-Purpose Solution|ASP-57 Multi-Purpose contact lens care solution used as a rub care regimen (Test)
2858766|NCT03537248|Active Comparator|ReNu® Multiplus Contact Lens Solution|ReNu® Multiplus Contact Lens Solution used as rub care regimen (Control)
2858767|NCT03537235|Experimental|Libramed|3 tablets of Libramed 2 twice a day 15 minutes before meals for 3 months.
2858768|NCT03537235|Placebo Comparator|Placebo|3 tablets of Placebo 2 twice a day 15 minutes before meals for 3 months.
2858769|NCT03537222||MyPOS|
2858770|NCT03537196|Other|Treatment for all patients|All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.
2858771|NCT03537196|Other|Treatment for HIV/HCV co-infected patients|For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day (Sofosbuvir 400 mg and Daclatasvir 90 mg)
2858772|NCT03537196|Other|In case of cirrhosis|In case of cirrhosis : Sofosbuvir 400 mg and Daclatasvir 60 mg and Ribavirin
2858773|NCT03537196|Other|In case of cirrhosis with ribavirin contra-indication|In case of cirrhosis with ribavirin contra-indication : Sofosbuvir 400 mg and Daclatasvir 60 mg for 24 weeks
2858774|NCT03537183|No Intervention|Usual activity level|12 weeks of usual activity level
2858775|NCT03537183|Active Comparator|Exercise training|12 weeks of moderate intensity exercise training, 3 hours a week
2858776|NCT03537157|Experimental|Rifaximin delayed release tablets|Two 400 mg tablets twice a day (total daily dose 1600 mg) for 26 weeks
2858777|NCT03537157|Placebo Comparator|Placebo|Two placebo tablets twice a day for 26 weeks
2858778|NCT03537144|Active Comparator|Indomethacin|Indomethacin as drug to treat PDA.
2858779|NCT03537144|Experimental|Acetaminophen|Acetaminophen as drug to treat PDA.
2858780|NCT03537131|Active Comparator|arm B1- Dapagliflozin once only dose|Participants who will take one tablet of Dapagliflozin 10 mg on the day of the exercise challenge.
2858783|NCT03537118|No Intervention|Fluoroscopic Guidance Alone|
2858785|NCT03537092|Experimental|Vaginal Film|Each participant who inserted a single use placebo vaginal film (Day 0) is randomized to the timing of Visit 3 (Day 3, 7, 10, or 14)
2858786|NCT03537079|Placebo Comparator|normoxia conditioning|exercise training in normoxia and rest conditioning in normoxia
2858787|NCT03537079|Active Comparator|exercise hypoxia|exercise training in hypoxia and rest conditioning in normoxia
2858788|NCT03537079|Active Comparator|rest hypoxia|exercise training in normoxia and rest conditioning in hypoxia
2858789|NCT03537066|Other|CPAP treatment|All included OSA patients are going to be treated by CPAP
2858790|NCT03537053|Experimental|A plan to Move a Little and Often|"The intervention will consist of 3 components: a short video will raise awareness about the impact of sedentary behaviours, a booklet, and an online forum on Facebook to encourage participants to support each other.~At the end of the baseline data collection, participants will be asked to watch the video. They will then be given the booklet and invited to join the Facebook group. A minimum of 5 participants must be recruited prior to running the Facebook group."
2858791|NCT03537040|Other|Method of Levels|Talking therapy- duration and frequency of sessions to be determined by participant
2858792|NCT03537027|Experimental|Vitamin D3|2000 micrograms of vitamin D3 in two doses during one day
2858793|NCT03537014|Experimental|MDMA|Administration of 80 or 120 mg MDMA in combination with psychotherapy and a supplemental dose offered 1.5/2 hrs later of 40 or 60 mg MDMA respectively.
2858794|NCT03537014|Placebo Comparator|Placebo|Administration of inactive placebo in combination with psychotherapy
2858795|NCT03537001||Penthrox|Administration of Penthrox at the beginning of the management of the traumatized adult patient
2858796|NCT03536988|Experimental|TAMIS-IPAA|In TAMIS-IPAA group, transanal minimally invasive surgery of proctectomy with IPAA will be performed.
2858797|NCT03536988|Active Comparator|Lap-IPAA|In Lap-IPAA group, transabdominal minimally invasive surgery of proctectomy with IPAA will be performed.
2858798|NCT03536975|Other|Platform|"Group with access to the web platform CAREGIVERSPRO-MMD"
2858799|NCT03536975|No Intervention|Control|Group without any access to the web platform
2858800|NCT03536949|Experimental|RVL-1201 Ophthalmic Solution, 0.1%|RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
2858801|NCT03536949|Placebo Comparator|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
2858802|NCT03536923|Experimental|Leva Arm|Subjects will use the leva device twice daily to perform pelvic floor muscle exercises
2858803|NCT03536910|Other|General anesthesia|
2858804|NCT03536910|Other|Spinal anesthesia|
2858805|NCT03536897||IORT|All patients will undergo a partial mastectomy with sentinel lymph node biopsy with the goal of achieving a margin-negative resection while maintaining good cosmetic outcome. Immediately following partial mastectomy and frozen section evaluation of the sentinel lymph nodes, IORT is to be delivered. Intraoperative radiation therapy will involve 50 kV xrays to a dose of 20 Gy during breast conserving surgery. After surgery, patients are followed based on the standard schedule determined by their surgeon for 5 years.
2858806|NCT03536884|Experimental|Bimekizumab|Subjects will receive bimekizumab. Placebo will be administered at pre-specified time-points to maintain the blinding.
2858807|NCT03536884|Active Comparator|Secukinumab|Subjects will receive secukinumab.
2858808|NCT03536871|Active Comparator|Multinutrient Supplement|Participants will be allocated in a randomized double-masked manner to receive a multi-nutrient supplement (mitochondrial enhancer + weight loss + protein) or placebo during a 12 week home-based exercise programme and we will assess the influence on the primary and secondary outcomes.
2858809|NCT03536871|No Intervention|Age biological and chronological|The primary and secondary outcomes will be compared between the younger and older age groups as a function of both exercise and nutritional supplementation.
2858810|NCT03536871|No Intervention|Sarcopenia grades|The baseline primary and secondary outcomes will be compared for each of the 3 older adults males groups as a function of muscle mass (healthy active, mild sarcopenia and moderate sarcopenia).
2858811|NCT03536871|No Intervention|Sex differences|For the younger men and women we will asses the response to both exercise +/- nutritional intervention over 12 weeks for both primary and secondary outcomes.
2858812|NCT03536871|Experimental|Exercise - home based programme|Each of the participants will undergo a 12 week home-based exercise program (endurance = increased steps; resistance = body weight and elastic band exercise) to determine the effects on the primary and secondary outcomes.
2858813|NCT03536858|Active Comparator|Centrality|The patients at clinic one who receive hemodialysis on Tuesday, Thursday, Saturday and the patients on the Monday, Wednesday, Friday schedule at clinic two, will be assigned to the Centrality arm. Two patients per hemodialysis shift with the highest centrality will be selected to participate in the COACH (Communicating about Choices in Transplantation) intervention. The patients selected by centrality will have a centrality greater than 1 standard deviation (SD) from the mean of the other patients on their hemodialysis clinic shift and a clustering less than 1 SD from the mean. The investigators will measure the spread of information, attitudes, and behaviors by comparing the targeted patients to the other patients on their shift.
2858814|NCT03536858|Active Comparator|Clustering|The patients at clinic one who receive hemodialysis on Monday, Wednesday, Friday and the patients on the Tuesday, Thursday, Saturday schedule at clinic two, will be assigned to the Clustering arm.Two patients per hemodialysis shift with the highest clustering coefficient will be selected to participate in the COACH (Communicating about Choices in Transplantation) intervention. The patient selected by clustering coefficient, will have a clustering coefficient greater than 1 SD from the mean of the other patients on their hemodialysis clinic shift and centrality 1 SD less than a mean. The investigators will measure the spread of information, attitudes, and behaviors by comparing the targeted patients to the other patients on their shift.
2858815|NCT03536845|Active Comparator|400 IU|
2858816|NCT03536845|Active Comparator|1000 IU|
2858817|NCT03536832|Experimental|cesarean section with Vicryl|Women undergoing cesarean section with low transverse skin incisions will be closed with 3-0 Vicryl.
2858818|NCT03536832|Experimental|cesarean section with prolene|Women undergoing cesarean section with low transverse skin incisions will be closed with 3-0 Prolen.
2858819|NCT03536819|Experimental|Treatment|Participants receive Votiva treatment
2859266|NCT03533595|Active Comparator|Stratafix Barbed Suture|Stratafix Barbed Suture for thoracolumbar fusion will be used.
2858820|NCT03536806|Placebo Comparator|Placebo Comparator: Placebo|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. After drug administration the patient will be observed for 2 hours after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient will depend on clinical condition and will follow appropriate clinical guidelines.
2858821|NCT03536806|Experimental|Experimental: canrenone|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After administration of canrenone: dose 200 mg (1 ampule a 10 ml) within 2-3 minutes the patient will be observed for 2 hours after the dose with exit ECG and BP measure taken at the end of observation.
2858822|NCT03536793||Pancreatic cysts|Samples (urine, serum and cystic fluid) will be taken from 50 patients with pancreatic cysts on follow-up. These will be sent to either the University of Hull or a commercial laboratory for analysis of Endo180 and urinary TF, respectively. Collection will occur on the same day of the participants routinely indicated procedure.
2858823|NCT03536793||Pancreatic cancers|Samples (urine and serum) will be taken from 50 patients diagnosed with pancreatic cancer (resectable and non-resectable).
2858824|NCT03536793||Benign hepatopancreatobiliary conditions|Samples (urine and serum) will be taken from 80 age- and gender-matched control patients - 20 patients with acute pancreatitis, 20 undergoing cholecystectomy for stones, 20 undergoing cholecystectomy for inflammation and 20 patients undergoing their 8-week review subsequent to cholecystectomy (normal control subgroup).
2858825|NCT03536780|Experimental|Avelumab and Gemcitabine|
2858826|NCT03536767|Experimental|Open-Label|
2858827|NCT03536754|Placebo Comparator|Group A|Placebo (N=10)
2858828|NCT03536754|Experimental|Group B|CCX140-B 5 mg once daily (N=10)
2858829|NCT03536754|Experimental|Group C|CCX140-B 10 mg twice daily (N=10)
2858830|NCT03536754|Experimental|Group D|CCX140-B 15 mg twice daily (N=10)
2858831|NCT03536741|Experimental|ALR|
2858832|NCT03536741|Active Comparator|EV|
2858833|NCT03536728|Experimental|Part 1|Dose escalation of AMXT1501 with a fixed low dose of DFMO will follow a 3 + 3 dose escalation design. The AMXT 1501 starting dose administered in the first cohort will be 80 mg (2 capsules); each capsule contains 40 mg of active drug. The dose will be given orally, once daily, fasted state alone for 14 days, and starting on Day 15 AMXT 1501 80 mg given in combination with fixed low-dose oral DFMO at 250mg 2x per day (BID), for an additional 14 days; for a total 28 days of treatment per cycle. Cycle 2 includes AMXT1501 + DFMO that will be administered for 28 days. The patient can be treated for additional 28 day treatment cycles as deemed appropriate by their study investigator. Dose escalation of AMXT1501 alone will increase per Part 1 cohort.
2858834|NCT03536728|Experimental|Part 2|"Dose escalation of DFMO with the Part 1 AMXT1501 RP2D fixed dose will follow a 3 + 3 dose escalation design.~The AMXT 1501 starting dose administered in the first cohort will be one level below the AMXT 1501 Part 1 RP2D with 500 mg DFMO BID. The morning dose will be given orally of both AMXT1501 and DFMO, in a fasted state. The evening dose of DFMO alone will be given prior to bed-time for 28 days per cycle. The patient can be treated for additional 28 day treatment cycles as deemed appropriate by their study investigator. Dose escalation of DFMO alone will increase per Part 2 cohort."
2858835|NCT03536728|Experimental|Expansion|The expansion cohort will include up to 14 evaluable patients at a proposed RP2D level of AMXT1501 and DFMO defined by Part 2 to further characterize safety at proposed RP2D dose level with repeat dosing, and characterize early anti-tumor activity.
2858836|NCT03536702|Experimental|Creative Writing Workshop|The intervention arm will receive a dedicated workshop for one and a half hours every 2 weeks for 3 months.
2858837|NCT03536702|Active Comparator|Independent Writing - Control Group|The control arm will receive a book (i.e., Writing Down Bones by Natalie Goldberg) on creative writing and asked to read and do writing activities for one and a half hours once every two weeks for 3 months.
2858838|NCT03536689|Experimental|Upright maternal position change|The participant will be measured by ultrasonograhy for amniotic fluid index in supine position before maternal position change, then she will do the upright position for 5 minute. After 5 minute of upright position , she will lie down in supine position and she will be measured by ultrasonograhy for amniotic fluid index after upright position.
2858839|NCT03536689|Experimental|Left lateral decubitus maternal position change|the participant will be measured by ultrasonograhy for amniotic fluid index in supine position before maternal position change, then she will do the left lateral decubitus position for 5 minutes. After 5 minutes of left lateral decubitus position , she will lie down in supine position and she will be measured by ultrasonograhy for amniotic fluid index after left lateral decubitus position.
2858840|NCT03536676|Active Comparator|Breakfast in the Classroom|The breakfasts for the 8-week program will adhere to the United States Department of Agriculture nutrition requirements for Grades 6-8.
2858841|NCT03536676|Experimental|'Egg-Cellent' Breakfast in the Classroom|The breakfasts for the 8-week program will adhere to the United States Department of Agriculture nutrition requirements for Grades 6-8 but will include an additional 2 large eggs/breakfast.
2858842|NCT03536663|Experimental|Endexo|Hemodialysis treatments on the dialyzer with Endexo starts at visit 14 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention will be 13 weeks.
2858843|NCT03536650|Experimental|DMR procedure|
2858844|NCT03536637|Experimental|Study Treatment 1|DMT310 Powder mixed with Hydrogen Peroxide
2858845|NCT03536637|Experimental|Study Treatment 2|DMT310 Powder mixed with Placebo Diluent
2858846|NCT03536637|Experimental|Study Treatment 3|Placebo powder mixed with Hydrogen Peroxide
2858847|NCT03536637|Placebo Comparator|Control|Placebo powder mixed with Placebo Diluent
2858848|NCT03536624|Experimental|Experimental group|"Participants will be involved in a short-term spa residential program of 6 days combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.~After the program, participants will be followed for 12 months."
2859267|NCT03533582|Active Comparator|Group A1 (WDF)|Patients undergo observation.
2876739|NCT03412851||A Direct Aspiration First Pass Technique|
2858849|NCT03536611|Experimental|dabigatran|dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months
2858850|NCT03536611|Active Comparator|warfarin|warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
2858851|NCT03536598|Experimental|Test|Amlodipine 10mg + Valsartan 160mg + Rosuvastatin 20mg
2858852|NCT03536598|Active Comparator|Reference 1|Amlodipine 10mg + Valsartan 160mg
2858853|NCT03536598|Active Comparator|Reference 2|Valsartan 160mg + Rosuvastatin 20mg
2858854|NCT03536585|Experimental|Vulvovaginal treatment|Internal vaginal treatment monthly for 3 treatments; External mons pubis treatment monthly for 3 treatments; External labia treatment monthly for 3 treatments.
2858855|NCT03536585|No Intervention|Baseline|Subject's baseline photograph to act as their own control for the one-month and four-month post-treatment photograph of the mons pubis and labia.
2858856|NCT03536572|Active Comparator|Sleep Apnea Self-Management Program|Protocol-based sleep apnea and CPAP education and support
2858857|NCT03536572|Experimental|Individualized Pressure Adjustment|Additional education and support that will allow them to adjust their PAP pressures
2858858|NCT03536559|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
2858859|NCT03536559|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
2858860|NCT03536559|Placebo Comparator|Placebo|The matched placebo to be used in this study will consist of water, sodium bicarbonate, and food coloring to match volume and color of the experimental treatments.
2858861|NCT03536546|Experimental|Alcohol Peer-Mentor Intervention|A Veteran Peer research assistant will have contact with a study participant once in person in the emergency department at enrollment, and up to 6 times after enrollment over the course of 2 months. Participants will receive brief advice from a peer. Brief advice content will be based on strengths-based discussions with participants regarding their drinking and personal goals and preferences. Participants will also receive a resource pamphlet on alcohol and other health issues. Follow-up contact will be made by phone. The content of the follow-up peer intervention will be based on the manual developed by the study team to address strengths-based intervention topics.
2858862|NCT03536546|Active Comparator|Brief Advice|Participants will receive brief substance use advice from a non-peer research staff member in the emergency department. Brief advice content will mirror standard care practices currently provided in VHA when a patient endorses hazardous drinking behaviors. Participants will also receive a resource pamphlet on alcohol and other health issues.
2858863|NCT03536533|Experimental|Exergame|The Senso is a training system (dividat, Schindellegi, Switzerland) for improving physical and cognitive function was used as exergame. With foot pushes participants triggered on a pressure-sensitive plate. The Senso game was projected with a beamer at white wall. To promote head movement during training the direction of the beamer was vertical tilted (± 15°) and horizontal turned (90°) with a remote controlled power panner.
2858864|NCT03536520|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2858865|NCT03536520|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2858866|NCT03536507|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2858867|NCT03536507|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2858868|NCT03536494|Experimental|Mirabegron intervention|Review the use of mirabegron and its discontinuation
2858869|NCT03536494|No Intervention|Control group|Usual care
2858870|NCT03536481|Experimental|T-R cohort under fasted state|Subjects will be administered with one single dose of ensartinib capsules (test product) under fasted state, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (reference product) under fasted state.
2858871|NCT03536481|Experimental|R-T cohort under fasted state|Subjects will be administered with one single dose of ensartinib capsules (reference product) under fasted state, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (test product) under fasted state.
2858872|NCT03536481|Experimental|T-R cohort after meal|Subjects will be administered with one single dose of ensartinib capsules (test product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (reference product) after meal.
2858873|NCT03536481|Experimental|R-T cohort after meal|Subjects will be administered with one single dose of ensartinib capsules (reference product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (test product) after meal.
2858874|NCT03536468||Patients pending complete tooth loss|Will be recruited patients pending tooth loss, ages between 18 and 65 years, whose dental conditions have previously been identified
2858875|NCT03536455|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2858876|NCT03536455|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2858877|NCT03536442||Intervention (CBT)|"As there is only one arm in this trial, this will be described in intervention."
2858878|NCT03536429|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2859293|NCT03533478|Experimental|Group I|32 patients with mild or moderate diabetic macular edema.
2858879|NCT03536429|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2858880|NCT03536416|Experimental|Asthma workshop and theatre group|My Asthma in School. This group will receive the self-management workshops for asthmatic children and the theatre performance for the whole year group.
2858881|NCT03536416|Active Comparator|Theatre only group|My Asthma in School. This group will receive the theatre performance only.
2858882|NCT03536416|No Intervention|Control group|My Asthma in School. The control group will receive usual care for the duration of the intervention.
2858883|NCT03536403|Experimental|healthy volunteers|EOS X-rays is done with et without a kyphosis induced corset and 8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
2858884|NCT03536390|Placebo Comparator|Placebo|one chewable tablet once daily in morning.
2858885|NCT03536390|Experimental|Methylphenidate Hydrochloride Extended Release Chewable Tablet|one chewable tablet once daily in morning.
2858886|NCT03536377|Experimental|very low calorie liquid diet|Phase 1: Caloric restriction Phase 2: Solid diet Phase 3: Transition to independence
2858887|NCT03536364|Experimental|Prediabetes|manipulation of food order during a meal on postprandial in subjects with prediabetes
2858888|NCT03536351|Experimental|Interdisciplinary process drama|Process drama program (3 days/week, 12 weeks, 1-1.5 hours per session) of movement-based activities combining music and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists, and target understanding emotion, intentions and appropriate social interactions.
2858889|NCT03536338|Active Comparator|Control|Sit-to-stand training alone
2858890|NCT03536338|Experimental|Treatment|Sit-to-stand training combined with Spinal Stimulation
2858891|NCT03536325|Experimental|Cohort 1: Guselkumab Dose 1 or Placebo|Participants will receive Dose 1 of guselkumab or matching placebo as an intravenous (IV) infusion on Day 1.
2858892|NCT03536325|Experimental|Cohort 2: Guselkumab Dose 2 or Placebo|Participants will receive Dose 2 of guselkumab or matching placebo as an IV infusion on Day 1.
2858893|NCT03536325|Experimental|Cohort 3: Guselkumab Dose 3 or Placebo|Participants will receive Dose 3 of guselkumab or matching placebo as an IV infusion on Day 1 based on safety data results received from Cohort 1 and 2.
2858894|NCT03536312|No Intervention|Surveillance Arm|Patients in the Non-Operative Registry will be followed in clinic annually with a CT scan to monitor the status of their ascending aortic aneurysm, until the end of the study, the occurrence of an aortic event, or death.
2858895|NCT03536312|Other|Surgery/Treatment Arm|Patients in the Operative Registry will have thoracic aortic surgery
2858896|NCT03536299|Active Comparator|Single-Task Gait|The Single-Task Gait group will be provided with gait training without the Dual-Task cognitive tasks.
2858897|NCT03536299|Experimental|Dual-Task Gait|The Dual-Task Gait group will be provided with gait training AND secondary cognitive tasks during gait training.
2858898|NCT03536286|Experimental|Encouragement Zone 3|"Encouragement households will be randomly sampled based on location, and a team of 2 local community champions/data collectors (hired from within the community) will visit each of the encouragement arm homes. Community champions will be responsible for visiting each home, going door-to-door and speaking with each family individually in order to avoid contamination/cross-over with control households.~The Asili intervention involves membership into a program; households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention."
2858899|NCT03536286|No Intervention|Control Zone 3|Control households will still have equal access to the Asili intervention and can gain membership into a program at any time. Regardless of membership status, households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention.
2858900|NCT03536286|Experimental|Encouragement Zone 4|"Encouragement households will be randomly sampled based on location, and a team of 2 local community champions/data collectors (hired from within the community) will visit each of the encouragement arm homes. Community champions will be responsible for visiting each home, going door-to-door and speaking with each family individually in order to avoid contamination/cross-over with control households.~The Asili intervention involves membership into a program; households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention."
2858901|NCT03536286|No Intervention|Control Zone 4|Control households will still have equal access to the Asili intervention and can gain membership into a program at any time. Regardless of membership status, households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention.
2858902|NCT03536273|Experimental|Functional Movement Screen|
2858903|NCT03536273|Experimental|Posture Analysis|
2858904|NCT03536273|Experimental|Depression Level|
2858905|NCT03536273|Experimental|Quality of Life|
2858906|NCT03536260|Active Comparator|Immediate implant with Xenograft|
2858907|NCT03536260|Active Comparator|Immediate implant with Nanobone|
2858908|NCT03536247|Active Comparator|Laser lithotripsy|Cholangioscopy enables therapeutic intervention including intracorporeal electro-hydraulic and laser lithotripsy for biliary stone disease with favorable efficacy and safety.
2858909|NCT03536247|Active Comparator|Papillary Balloon dilation|Balloon dilation of the Ampulla of Vater after a small sphincterotomy is an alternative technique that allows for removal of large bile duct stones in a safe and effective manner.
2858910|NCT03536234|Experimental|Triptorelin (GnRH analogue)|
2858911|NCT03536234|No Intervention|Control group|
2858912|NCT03536208|Experimental|Warfarin|Patients will be assigned to warfarin by mouth daily on an outpatient basis. Dose level will increase after 5 patients enrolled. Dose 1 = 1 mg warfarin; Dose 2 = 2 mg warfarin; Dose 3 = 2.5 mg warfarin; Dose 4 = 4 mg warfarin and Dose 5 = 5 mg warfarin
2876740|NCT03412851||Stentriever Thrombectomy|
2858913|NCT03536182|Active Comparator|Arm A: Carbon ion radiotherapy|"Arm A (Carbon ion radiotherapy in Japan): 55.2 GyE in 4.6 GyE per fraction in 12 fractions delivered 4 days a week.~Arm A (Carbon ion radiotherapy using the LEM [European] model): The dose calculation algorithms used in Japan and Europe (local effect model, LEM) are different, so the total dose must be modified to ensure consistency 8. Patients treated in Europe should receive 59.4 GyE in 4.95 GyE per fraction in 12 fractions delivered 4 days a week.~Concurrent gemcitabine at 1000 mg/m2 will be delivered during weeks 1-3 of CIRT in Japan and Italy.~Patients treated in Italy and Japan will be treated with 4 cycles of gemcitabine + nab-Paclitaxel following chemoradiotherapy."
2858914|NCT03536182|Active Comparator|Arm B: Photon radiotherapy|"Arm B (Photon radiotherapy): 50.4 Gy in 1.8 Gy per fraction in 28 fractions delivered 5 days a week.~Concurrent gemcitabine at 600 mg/m2 will be delivered during weeks 1-5 of IMRT~Patients treated in United States will be treated with 4 cycles of gemcitabine + nab-Paclitaxel following chemoradiotherapy.~Patients treated in China and Korea will receive 4 cycles of gemcitabine alone, with the exception of para-aortic node positive patients in Korea, who will also receive gemcitabine+nab-Paclitaxel."
2858915|NCT03536143|Experimental|Topical KB103|HSV-1/COLA1 vector (KB103)
2858916|NCT03536130|Experimental|Electronic chest drainage system|Patients in the intervention arm are connected to Drentech Palm Evo with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with digital devices are managed by setting the pump to -20 cmH2O until the morning of postoperative day (POD) 1 and then setting the pump on physiologic mode (0 cmH2O) thereafter.
2858917|NCT03536130|No Intervention|Traditional device|Patients in the no intervention (traditional) arm are connected to traditional drain system with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with traditional devices (requiring connection to wall suction) are managed by applying suction (-20 cmH2O) until the morning of POD 1 and are subsequently disconnected from suction thereafter.
2858918|NCT03536117|Experimental|MTBVAC Group 1|MTBVAC intermediate dose 2.5 x 10E+04 CFU/0.05 mL
2858919|NCT03536117|Experimental|MTBVAC Group 2|MTBVAC high dose 2.5 x 10E+05 CFU/0.05 mL
2858920|NCT03536117|Experimental|MTBVAC Group 3|MTBVAC highest dose 2.5 x 10E+06 CFU/0.05 mL
2858921|NCT03536117|Active Comparator|BCG Group 4|BCG control 2.5 x 10E+05 CFU/0.05 mL
2858922|NCT03536104||Controls|"This group will include healthy person."
2858923|NCT03536104||Parkinson's patient|This group will include Parkinsonian patients
2858924|NCT03536104||patients with a related disease.|This group will include patients with a related disease.
2858925|NCT03536078|No Intervention|Phototherapy at hospital|Newborns with icterus that receive treatment while being admitted to hospital.
2858926|NCT03536078|Experimental|Home phototherapy|Newborns with icterus receiving phototherapy at home.
2858927|NCT03536065|Active Comparator|Pre-Intervention|Current practice (unchanged)
2858928|NCT03536065|Experimental|Post-Intervention|Reduction of opioid prescription based on Pre-Intervention data, implementation of a discharge sheet and nursing education.
2858929|NCT03536052|Experimental|Virtual Heart Guided Ablation|
2858930|NCT03536039|Experimental|NGR-hTNF + R-CHOP|Treatment includes one course of conventional R-CHOP followed by 5 courses of conventional R-CHOP (rituximab, Cyclophosphamide, vincristine, doxorubicin, prednisone) in conjunction with intravenous delivery of NGR-hTNF. Chemoimmunotherapy courses will be delivered every 3 weeks; day 22 is to be considered as day 1 of the subsequent course
2858931|NCT03536026|Experimental|Bronchoscopic evaluation and biopsy|-Bronchoscopy will be performed by pulmonary and/or critical care fellows who have performed fewer than 10 bronchoscopies (inexperienced bronchoscopists) under direct supervision by an attending Interventional Pulmonologist. The inexperienced bronchoscopist will attempt to navigate to the targeted peripheral pulmonary lesion without virtual bronchoscopic navigation, using only standard axial CT images as a reference. The attending physician will directly observe, but will provide no guidance during this period, which will last no longer than 10 minutes. If the lesion is located and confirmed with radial probe endobronchial ultrasound prior to 10 minutes, biopsies will be performed as per routine clinical practice. If the 10 minute time period elapses prior to localization of the peripheral pulmonary lesion, virtual bronchoscopic navigation will be used.
2858932|NCT03536013|Experimental|Treatment|91 patients will undergo a typical lumbar microdiscectomy with the addition of a full-thickness placental allograft after the microdiscectomy has been performed.
2858933|NCT03536013|No Intervention|Control|91 patients will undergo a typical lumbar microdiscectomy without the addition of a full-thickness placental allograft.
2858934|NCT03536000||Healthy women|"200 Pregnant women~Over 18 years~Healthy~With the ability to understand and sign the informed Consent~With the ability to attend the established controls~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
2858935|NCT03536000||Intrauterine Growth restriction|"Pregnant women~Over 18 years~Intrauterine Growth Reestriction(IUGR): fetuses with percentile Growth <p3 or <p10 with vascular Doppler alteration.~With the ability to understand and sign the informed Consent~With the ability to attend the established controls~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
2858936|NCT03536000||Preeclampsia|"Pregnant women~Over 18 years~Preeclampsia: elevated blood pressure + Ratio Prot/Creatinin in urine> 30 mg / mmol creatinin~With the ability to understand and sign the informed Consent~With the ability to attend the established controls~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
2858937|NCT03536000||Diabetes Mellitus type 1|"Pregnant women~Over 18 years~Diabetes mellitus type1~With the ability to understand and sign the informed Consent~With the ability to attend the established controls~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
2858938|NCT03535974|Active Comparator|Preparation with Spirulina|6 weeks bid Preparation with Spirulina
2858939|NCT03535974|Placebo Comparator|Placebo|6 weeks bid Placebo
2858940|NCT03535961|Other|apatinib+oral etoposide|apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle
2858941|NCT03535935|Active Comparator|Standard medical care|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker and oral hypoglycemic agents or insulin
2859294|NCT03533478|Placebo Comparator|Group II|32 patients with mild or moderate diabetic macular edema
2858942|NCT03535935|Experimental|Add on astragalus powder|3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks.
2858943|NCT03535922|Experimental|The disease-specific PROM group|Hemodialysis (HD) units randomized to this PROMs assessment group will administer a disease-specific PROM every 2 months to all patients able to complete the instrument independently or with assistance for a period of 12 months. Patients will receive a copy of their PROM results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the PROM. The disease-specific PROM report will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROM report will be accompanied by treatment aids for all symptoms. The proposed disease-specific PROM is the Edmonton Symptom Assessment Scale modified for renal patients (mESASr)
2858944|NCT03535922|Experimental|The generic PROM group|HD units randomized to this PROMs assessment group will administer a generic PROM every 2 months to all patients able to complete the instrument independently or with assistance for a period of 12 months. Patients will receive a copy of their PROM results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the PROM. The generic PROM report will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROM report will be accompanied by treatment aids for all symptoms. The proposed generic PROM is the EQ-5D-5L.
2858945|NCT03535922|Experimental|Disease-specific and generic PROMs group|HD units randomized to this PROMs assessment group will administer a disease-specific and generic PROM every 2 months to all patients able to complete the instrument for a period of 12 months. Patients will receive a copy of both their PROMs results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the two PROMs. The disease-specific and generic PROMs reports will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROMs reports will be accompanied by treatment aids for all symptoms.
2858946|NCT03535922|No Intervention|The control or 'usual care' group|HD units randomized to this group will follow usual care and patients will not have any PROMs assessment; however, all the treatment aids will be made available for clinicians in this study group during the 12 months trial period.
2858947|NCT03535896|Experimental|HSR and injection|HSR and corticosteroid injection
2858948|NCT03535883||patients taking NOAC's|Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement and are taking Novel Oral Anti-Coagulants (NOAC).
2858949|NCT03535883||patients not taking NOAC's|Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement who are not taking Novel Oral Anti-Coagulants (NOAC).
2858950|NCT03535870|Experimental|Fluticasone propionate/salmeterol|fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) twice a day by inhalation throughout the study
2858951|NCT03535870|Active Comparator|Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder|Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study
2858952|NCT03535870|Placebo Comparator|Placebo|placebo inhaled powder twice a day by inhalation throughout the study
2858953|NCT03535857|Active Comparator|Control|34 gauge needle inserted 3cm above the medial ankle on either ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
2858954|NCT03535857|Experimental|Experimental|Two 34 gauge needle inserted 3cm above the medial ankle on both ankles, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
2858955|NCT03535844|Experimental|Wolfberry with healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet. Subjects will also be provided specific instructions to cook and consume 15 g/day wolfberry as part of a mixed-meal.
2858956|NCT03535844|Active Comparator|Healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet.
2858957|NCT03535831|Experimental|18F-DCFPyL PET/ MR or PET/CT imaging|"Will use a newer technology called PET-MR that combines a Positron Emission Tomography (PET) scan with Magnetic Resonance Imaging (MRI) scan. This new combined imaging test, where PET and MRI data is gathered at one time, will be performed on an integrated PET-MR scanner located at Toronto General Hospital.~Or technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data is gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.~Choice of imaging method (PET/CT or PET/MR) will be made by one of the study PIs, based on clinical judgement taking into account the specific exam indication, prior recent imaging, and suitability for MR imaging."
2858958|NCT03535818|Active Comparator|Redo pulmonary vein isolation|
2858959|NCT03535818|Active Comparator|Ganglionated plexus ablation + redo pulmonary vein isolation|
2858960|NCT03535805|Experimental|Mind My Mind (MMM)|Mind My Mind (MMM)
2858961|NCT03535805|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU)
2858962|NCT03535792|Active Comparator|Fentanyl/Hyperbaric Bupivacaine|"Group F:~Patients will receive intrathecal injection of 2 ml of 0.5% hyperbaric bupivacaine plus 1 ml fentanyl (50μg) and will have Tibial internal fixation."
2858963|NCT03535792|Active Comparator|Nalbuphine/Hyerbaric Bupivacaine|"Group N:~Patients will receive intrathecal injection of 2 ml of 0.5% hyperbaric bupivacaine plus 1ml nalbuphine hydrochloride (1.6 mg); (nalufin 20 mg in 1 ml ampoule, Amoun Pharmaceutical Co. Cairo, Egypt) and will have Tibial internal fixation."
2858964|NCT03535779||Group 1|Healthy volunteers receiving Tetanus (Td/IVP) vaccine were enrolled onto the study for 1 month with no additional follow up visits.
2858965|NCT03535779||Group 2|Healthy volunteers receiving the Hepatitis B (HBsAg) vaccine were enrolled onto the study for 2 months with no additional follow up visits.
2858966|NCT03535753|Experimental|Decitabine and R-GDP|ALL patients will be treated with Decitabine and R-GDP
2858967|NCT03535740|Experimental|Brigatinib|Brigatinib 90 mg, tablets, orally, once daily for 7 days, followed by Brigatinib 180 mg, tablets, orally, once daily for until objective disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by the investigator, or intolerable toxicity.
2858968|NCT03535727|Experimental|Cohort 1|(28 Days) - Nab-paclitaxel ,Gemcitabine, Capecitabine, Cisplatin and Irinotecan
2858969|NCT03535727|Experimental|Cohort 2|(21 Days) - Nab-paclitaxel ,Gemcitabine, Capecitabine, Cisplatin and Irinotecan
2858970|NCT03535714|Active Comparator|MANTR-a group|"Patients who are in the MANTR-a group attend the MANTR-a treatment program, which consists of 20 once-weekly therapy sessions. Caregivers can be invited to 2 sessions. After 20 weeks, therapy continues with four monthly booster-sessions. In sum, each patient (whose bodyweight is above the 3rd BMI percentile) can attend 24 therapy sessions. In patients whose bodyweight is below the 3rd BMI percentile treatment will be extended to 30 once-weekly and 4 monthly booster sessions. Besides therapy the patients are in nutritional consultation by a dietician and under regular medical care to monitor the physical health and weight gain.~Patients who who have already an existing psychotherapy are attached to the control group."
2858971|NCT03535714|No Intervention|control group|Patients of the control group receive treatment as usual (TAU). It consists of medical care and monitoring, psychotherapy in a single or family setting, parents counselling and dietetics.
2858972|NCT03535701|Active Comparator|Arm I (standard of care)|Patients receive standard of care therapy with paclitaxel.
2858973|NCT03535701|Experimental|Arm II (standard of care, ketogenic diet)|Patients receive standard of care with paclitaxel. Patients undergo a controlled feeding period ketogenic diet comprising of meals prepared in the research kitchen for 3 months. Beginning 2 weeks prior to completion of the controlled feeding period, patients also undergo free living ketogenic diet program for 3 months comprising of group format, individual sessions, and online digital content to educate patients to implement a ketogenic eating pattern into their lifestyle.
2858974|NCT03535688|Experimental|D-cycloserine|D-cycloserine 200 mg BID (twice daily)
2858975|NCT03535688|Placebo Comparator|Placebo|Placebo BID (twice daily)
2858976|NCT03535675|Experimental|Arm A|Each treatment cycle consists of once daily oral dosing of 4000 mg Muscadine Plus, every day throughout each 12 week (84 day) cycle. Patients may continue to receive additional cycles of study drug and will be followed every three months with standard visits with their physician until completion of 48 weeks of study treatment, disease progression, or until they wish to discontinue the drug.
2858977|NCT03535675|Experimental|Arm B|Each treatment cycle consists of once daily oral dosing of 4000 mg placebos, every day throughout each 12 week (84 day) cycle. Patients may continue to receive additional cycles of placebo and will be followed every three months with standard visits with their physician until completion of 48 weeks of study treatment, disease progression, or until they wish to discontinue the drug.
2858978|NCT03535662|Experimental|Orvepitant|Orvepitant single 20mg dose
2858979|NCT03535662|Experimental|Orvepitant and itraconazole|Orvepitant single 20mg dose in combination with repeat dose itraconazole
2858980|NCT03535649||Vedolizumab|Participants diagnosed with moderate to severe active UC and having failed tumor necrosis factor alpha (TNF alpha) antagonist therapy and who have initiated vedolizumab intravenous treatment between 01 August 2017 and 30 June 2018 from approximately 15 participating sites will be observed from the date of UC diagnosis until the date when participant is enrolled into the study or until the end of treatment or death of participants or lost-to-follow up.
2858981|NCT03535636||Refugees with PTSD|"Adults over the age of 18. Refugees or family members of refugees that has been reunited. PTSD (ICD-10 criteria) and written consent.~No drug or alcohol abuse and no medication that can affect sleep rhythms, such as antipsychotic drugs, benzodiazepine, opioids, antihistamine or CNS stimulating drugs.~A BMI under 35 and no pregnancy."
2858982|NCT03535636||Healthy controls|Matched on age, sex and BMI and signed written consent. No mental illness, drug or alcohol abuse and medication. No pregnancy.
2858983|NCT03535623|Experimental|RIPC|Remote ischemic preconditioning (RIPC) consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the RIPC group.
2858984|NCT03535623|Sham Comparator|Sham-RIPC|Sham-RIPC consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of < 10 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the Sham-RIPC group.
2858985|NCT03535610|Experimental|Embolization|Uterine Embolization with PVA Microspheres
2858986|NCT03535597|No Intervention|Arm 1|Standard of Care (TR Band)
2858987|NCT03535597|Experimental|Arm 2|Quikclot Radial pad with Coban Bandage to hold the pad in place
2858988|NCT03535597|Experimental|Arm 3|Quikclot Radial Pad with Tegaderm dressing to hold the pad in place
2858989|NCT03535584|Experimental|Exercise Program|All participants will attend a 16-session exercise program based on pulmonary rehabilitation and will complete questionnaires and frailty testing.
2858990|NCT03535571|Experimental|Salmon Protein Hydrolysate (CollaGo)|Dose: 1 sachet of CollaGo will be mixed with 100-300 mL of water and consumed daily at breakfast.
2858991|NCT03535558||Cohort 1: FQ With Uncomplicated Sinusitis or Bronchitis|A target cohort which includes participants exposed to an oral fluoroquinolone (FQ) with an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the treatment groups will be linked to the Truven Health and Productivity Management (HPM) data set.
2858992|NCT03535558||Cohort 2: FQ With Uncomplicated Acute Urinary Tract Infection|A target cohort which includes participants exposed to an oral sulfamethoxazole/trimethoprim (ST) with a qualifying indication of uncomplicated acute urinary tract infection and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the comparator groups will be linked to the Truven HPM data set.
2859030|NCT03535337|Active Comparator|SMS-NRsp-CPS-I|After 3 months of intervention, this group of SMS NRsp will receive 3 months of CPS-I followed by 3 months CPS-T and 3 months SC
2859031|NCT03535337|Active Comparator|SMS-NRsp-I|After 3 months of intervention, this group of SMS NRsp will receive 3 months of SMS-I followed by 3 months of SMS-T and 3 months of SC
2858993|NCT03535558||Cohort 3: AZ with Uncomplicated Acute Sinusitis or Bronchitis|A comparator cohort which includes participants exposed to oral azithromycin (AZ) with a qualifying indication of uncomplicated acute sinusitis or bronchitis and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the comparator groups will be linked to the Truven HPM data set.
2858994|NCT03535558||Cohort 4: ST with Uncomplicated Acute Urinary Tract Infection|A comparator cohort which includes participants exposed to oral sulfamethoxazole/trimethoprim (ST) with a qualifying indication of uncomplicated acute urinary tract infection and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the treatment groups will be linked to the Truven Health and Productivity Management (HPM) data set.
2858995|NCT03535545|Experimental|Healthy Individuals|Healthy volunteers will receive [68Ga]CBP8 and undergo PET imaging.
2858996|NCT03535545|Experimental|Lung Cancer Subjects|Lung cancer patients will receive [68Ga]CBP8 and undergo PET imaging.
2858997|NCT03535545|Experimental|Idiopathic Pulmonary Fibrosis Subjects|Idiopathic Pulmonary Fibrosis patients will receive [68Ga]CBP8 and undergo PET imaging.
2858998|NCT03535532|Experimental|unilateral laparoscopic adrenalectomy|subjects allocated in this group will be given unilateral laparoscopic adrenalectomy as treatment.
2858999|NCT03535532|Active Comparator|standard medical treatment|subjects allocated in standard medical treatment group will be given conservative medicine treatment.
2859000|NCT03535506|Experimental|Group A|Patients enrolled to Group A will receive a 12-day course of Palbociclib before surgery. They will receive Palbociclib 100mg PO daily x 12 days.
2859001|NCT03535506|No Intervention|Group B|These patients will receive no pre-operative treatment. Core biopsies from diagnosis and material from definitive surgery will be collected for translational studies and tissue banking. They will also provide blood samples at screening and prior to definitive surgery.
2859002|NCT03535493|Active Comparator|Acceptance and Commitment Therapy (ACT)|
2859003|NCT03535493|Active Comparator|Float REST|
2859004|NCT03535493|Experimental|ACT + Float REST|
2859005|NCT03535480|Experimental|G-CSF|Only receives G-CSF subcutaneously five days for stem cell mobilization
2859006|NCT03535480|Experimental|ASCOT|Receives G-CSF subcutaneously five days and then plasmapheresis for hematopoietic stem cell collection and catheterism for infusion in ovarian artery
2859007|NCT03535467||Conventional Rehabilitation|
2859008|NCT03535467||Robotic Therapy|
2859009|NCT03535454||Factory workers|
2859010|NCT03535454||Nurses|
2859011|NCT03535454||Janitors|
2859012|NCT03535454||Data automation employees|
2859013|NCT03535441||voluteer group|No treatment, only blood sample collection
2859014|NCT03535441||hemorrhagic shock group|HS was defined as out-of-hospital systolic blood pressure (SBP) of 70 mmHg or less or SBP ranging 71 to 90 mmHg with a heart rate of 108 beats/min or more. Exclusion criteria were pregnancy, <15 years old, more than 2,000 mL of intravenous fluids or blood before enrollment, hypothermia, drowning, asphyxia, burns, isolated penetrating head injury, time of call received by dispatch to study intervention longer than 4 h, known prisoners, and transfer from another hospital
2859015|NCT03535428||VENOUS exploration|
2859016|NCT03535415|Experimental|rhGH Injection|rhGH 0.05mg/kg/d by subcutaneous injection
2859017|NCT03535415|No Intervention|Non-treatment control group|Only follow-up without treatment
2859018|NCT03535402|Other|open label treatment|single arm with patients receiving 200 mg SC twice a week of sarilumab
2859019|NCT03535389|Experimental|Pathologic group|Patients addressed to our imaging department for the realization of a knee scanner as part of routine care and presenting clinical PFI syndrome (Patellofemoral instability diagnosis based on physical examination, history and Kujala score)
2859020|NCT03535389|Active Comparator|Control group|"Patients addressed to our imaging department for osteo-articular pathologies other than patellofemoral instability (non-fracture trauma, vascular pathologies, degenerative or soft tissues).~Does not have any clinical PFI syndrome~Matched (1: 1 ratio) to PFI patients by age (+/- 40 years) and sex"
2859021|NCT03535363|Experimental|Maximum Tolerated Dose of Osimertinib with standard of care|For patients with 1-10 brain metastases, begin daily Osimeritinib 0-7 days prior to stereotactic radiosurgery (SRS), provide daily Osimeritinib concurrently with radiotherapy, followed by maintenance Osimeritinib until disease progression, withdrawal, or unacceptable toxicity. Dose Level 1: 80mg daily. Dose Level -1: 40mg daily
2859022|NCT03535350|Experimental|Unmethylated MGMT Glioblastoma|Every patient gets ibrutinib + radiation over 6 weeks. Patients will undergo a 4-week break and then Ibrutinib treatment will continue until disease progression, intolerable toxicity, or death.
2859023|NCT03535350|Experimental|Methylated MGMT Glioblastoma|Every patient gets ibrutinib + radiation + daily Temozolomide (TMZ) (75mg/m2) for 6 weeks. Patients will undergo a 4-week break and patients will then receive daily ibrutinib and adjuvant Temozolomide for Days 1-5 of a 28-day cycle of temozolomide for 6 cycles. The temozolomide will continue until disease progression, intolerable toxicity, or death or maximum of 6 cycles. Ibrutinib treatment will continue until disease progression, intolerable toxicity, or death.
2859024|NCT03535337|Active Comparator|CPS-Rsp-T|After 3 months of intervention, this group of CPS Rsp will receive 3 months of CPS-T intervention followed by SC.
2859025|NCT03535337|Active Comparator|CPS-Rsp-SC|After 3 months of intervention, this group of CPS Rsp's intervention will discontinue and they'll receive SC only
2859026|NCT03535337|Active Comparator|CPS-NRsp-I|After 3 months of intervention, this group of CPS NRsp will receive 3 months of CPS-I followed by 3 months of CPS-T and 3 months of SC.
2859027|NCT03535337|Active Comparator|CPS-NRsp-SMS-I|After 3 months of intervention, this group of CPS NRsp will receive 3 months of SMS-I followed by 3 months of SMS-T and 3 months of SC
2859028|NCT03535337|Active Comparator|SMS-Rsp-T|After 3 months of intervention, this group of SMS Rsp will receive 3 months of SMS tapered (SMS-T) intervention followed by SC.
2859029|NCT03535337|Active Comparator|SMS-Rsp-SC|After 3 months of intervention, this group of SMS Rsp, intervention will discontinue and they'll receive SC only
2859032|NCT03535324|Experimental|PROA for optimization|Development of a Program for optimizing the use of antibiotics (PROA) in Spanish (Antimicrobial Stewardship Program, ASP, in English), based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations. The intervention will be carried out at the cluster level (group of patients belonging to a specific hospital service that meet the inclusion criteria). The intervention will consist in carrying out the audit with recommendation on days 3 and 5-7 after the extraction of negative blood cultures to assess the possibilities of de-escalation, sequential oral therapy and end of early treatment based on the available evidence.
2859033|NCT03535324|Other|Control|There will be no intervention.
2859034|NCT03535298|Experimental|EHT: Early Highly-effective|"Participants randomized to the EHT: Early Highly-effective arm will receive one of the highly effective MS therapies (Ocrevus, Lemtrada, Tysabri, Rituximab) as their initial disease modifying treatment.~Interventions: one of the highly effective MS therapies~The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group."
2859035|NCT03535298|Experimental|ESC: Escalation|"Participants randomized to the ESC: Escalation arm will receive any other approved MS therapy (not one of the EHT group) as their initial disease modifying treatment.~Interventions: one of the MS therapies NOT in the highly effective group~The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group."
2859036|NCT03535298|No Intervention|OBS: Observational|"Participants will not be restricted to a group of MS therapies.~Participants enter this arm if they are not comfortable with randomization, are not eligible to receive any of the options in a randomized arm, or are not able to secure insurance coverage for any therapy in a randomized arm."
2859037|NCT03535285|Experimental|Surgical modification side|Periodontal ligament distraction without the oblique cuts but with apical horizontal cut
2859038|NCT03535285|Active Comparator|Conventional surgery|Periodontal ligament distraction
2859039|NCT03535272|Active Comparator|Intervention Group|Bismuth subsalicylate 4 tablets po bid (2.1 grams total of BSS)
2859040|NCT03535272|Placebo Comparator|Placebo|Placebo oral tablet 4 bid
2859041|NCT03535259|Experimental|Sorafenib and IMRT|Concurrent sorafenib and IMRT, followed sorafenib maintenance for advanced hepatocellular carcinoma with portal vein or hepatic vein tumor thrombosis or lymph node involved
2859042|NCT03535246|Experimental|Single arm|EIE cells to treat cancer.
2859043|NCT03535233|Active Comparator|Intralesional group|intralesional triamcinolone acetonide 5 mg/ml monthly
2859044|NCT03535233|Active Comparator|Topical therapy group|Minoxidil 5% topical solution applied twice daily and topical clobetasol propionate 0.05% cream applied once daily every night
2859045|NCT03535220||Observational/ Interventional|Hematologic Disease
2859046|NCT03535207|Experimental|high dose chemoradiotherapy|all eligible patients receive intensity-modulated radiotherapy 50 Gy in 25 fractions over 5 weeks and concurrent paclitaxel and cisplatin once weekly for 5 weeks，followed by hyperfractionated intensity-modulated radiotherapy boost to gross tumor volume concurrent with the same chemotherapy
2859047|NCT03535194|Experimental|Mirikizumab|Mirikizumab administered subcutaneously (SC)
2859048|NCT03535194|Placebo Comparator|Placebo|Placebo administered SC
2859049|NCT03535194|Active Comparator|Secukinumab|Secukinumab administered SC
2859050|NCT03535168|Experimental|Dose 1 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 1 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 1 of BAY1902607 will be given only once.
2859051|NCT03535168|Experimental|Dose 2 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 2 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 2 of BAY1902607 will be given only once.
2859052|NCT03535168|Experimental|Dose 3 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 3 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 3 of BAY1902607 will be given only once.
2859053|NCT03535168|Experimental|Dose 4 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 4 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 4 of BAY1902607 will be given only once.
2859054|NCT03535168|Experimental|Matching placebo|Part 1: From Day 1 until Day 12 the matching placebo will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, matching placebo will be given only once.
2859055|NCT03535168|Experimental|BAY1902607+Matching Placebo|"Part 2:~Randomized crossover design in cough patients 4 different doses of BAY1902607+matching placebo"
2859056|NCT03535168|Experimental|Matching Placebo+BAY1902607|"Part 2:~Randomized crossover design in cough patients Matching placebo+4 different doses of BAY1902607"
2859057|NCT03535142|Experimental|Intervention|The intervention is bariatric surgery (Roux en Y gastric bypass or gastric sleeve operation).
2859058|NCT03535142|No Intervention|Control|Age, BMI and co-morbidity matched group who do not undergo surgery.
2859059|NCT03535129||1|Participants both with and without alcohol use disorder.
2859060|NCT03535129||2|Inpatients with alcohol use disorder.
2859061|NCT03535116|Experimental|Patients receiving ketorolac|Patient receives 30mg IV ketorolac(single dose) towards the end of the operation.
2859062|NCT03535116|Placebo Comparator|Control|Patients receive saline intravenously towards the end of the operation.
2859063|NCT03535103|Experimental|ARM A|Gonal-F®
2859064|NCT03535103|Experimental|ARM B|LM001
2859065|NCT03535090||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
2859066|NCT03535077||Suspicious Nevi undergoing biopsy|Subject with suspicious Nevi undergoing biopsy per SOC
2859097|NCT03534882|Experimental|Washout|Discontinuation of topical prostaglandin analogue therapy: Participants are asked to discontinue (washout) their prostaglandin analogue for 42 days. As the experimental group, the purpose of this arm is to determine the lingering IOP-reducing effects following discontinuation of chronic prostaglandin analogue therapy, and to determine if IOP rises back to baseline (pre-treatment values).
2859067|NCT03535064|Experimental|Schools received hand hygiene workshop|Schoolgirls of randomly assigned schools attended one-hour Arabic handwashing workshop conducted by the principal investigator one week after submitting all baseline questionnaires. Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
2859068|NCT03535064|No Intervention|Schools with did not receive hand hygiene workshop|Schoolgirls in control group followed their usual hand washing procedure. When the study ended, schoolgirls of control school were exposed to the same intervention by the same investigator.
2859069|NCT03535051|Experimental|Treatment A|Combination treatment of fractional carbon dioxide laser monthly sessions and topical tacrolimus 0.03% daily application (Tacrolimus Oint 0.03%)
2859070|NCT03535051|Active Comparator|Treatment B|Monotherapy with only topical tacrolimus 0.03% daily intervention: Tacrolimus Oint 0.03%
2859071|NCT03535038|Experimental|Inferior vena cava (IVC) diameter|subjects underwent IVC diameter measurement after VPW measurement
2859072|NCT03535038|Active Comparator|Vascular pedicle width (VPW)|Supine chest x ray was done and the VPW is assessed by radiologists.
2859073|NCT03535012||Reconstruction using an implant|Immediate 2 stage implant based breast reconstruction after mastectomy. All expanders are placed in the subpectoralis muscle using ADM as a sling. After expansion of the tissue expander change to the permanent implant is performed.
2859074|NCT03535012||Reconstruction using abdominal tissue|immediate free DIEP flap breast reconstruction after mastectomy. DIEP(deep inferior epigastric perforator) free flap was prepared and transferred to the breast pocket. Microanastomosis was done under the microscopic magnification. On sitting position, free flap was inset into breast pocket with confirming of satisfactory inflammatory fold.
2859075|NCT03534999|Experimental|TENS|This is intervention Group. Patients in this group received Transcutaneous Electrical Nerve Stimulation (TENS). The VAS and Oxford hip score was administered prior to the treatment to ascertain their pain intensity and hip disability level. The site of intervention (5cm away from incision site) was cleaned properly with cotton wool soaked in methylated spirit in an outward motion. Before the self-adhesive, pre gelled electrodes was placed on the cleansed sites.The TENS unit was switched on and the parameters was adjusted to the required level. For this study, parameters used are: 100µs pulse duration, 100Hz frequency and an intensity comfortable for the patient for a duration of 15 minutes.
2859076|NCT03534999|No Intervention|Control|This was the group with no intervention. Subjects were on their normal analgesic and antibiotic medication for the period of research. The VAS and Oxford hip score were administered on the first day to ascertain pain intensity and hip disability level. The subject continued on the normal analgesics only till the third day and VAS and Oxford hip score was re-administered to assess any change in the pain intensity and hip disability level.
2859077|NCT03534986|Experimental|AffloVest The Vest Arm|Devices placed on highest intensity / highest frequency
2859078|NCT03534986|Experimental|AffloVest inCourage Arm|Devices placed on highest intensity / highest frequency
2859079|NCT03534986|Experimental|AffloVest SmartVest Arm|Devices placed on highest intensity / highest frequency
2859080|NCT03534973|Active Comparator|Caffeine intake|Caffeine is given orally prior to cataract surgery
2859081|NCT03534973|Sham Comparator|No caffeine intake|Caffeine is not given orally prior to cataract surgery
2859082|NCT03534960|Other|High Flow Nasal Oxygen Therapy|Patients are randomized to the high flow nasal oxygen therapy group
2859083|NCT03534960|Other|Nasal CPAP|Patients are randomized to the nasal continuous positive airway pressure treatment group
2859084|NCT03534947|Experimental|Sonidegib followed by imiquimod|Sonidegib 200mg taken orally once a day for 12 weeks. COMPLETE OR PARTIAL RESPONSE WITH SUPERFICAL REMNANT LESION For patients with a complete response or a partial response resulting in a superficial lesion, treatment with topical imiquimod for 5 days a week for 6 weeks will be prescribed.
2859085|NCT03534947|Experimental|Sonidegib followed by surgery|Sonidegib 200mg taken orally once a day for 12 weeks. PARTIAL RESPONSE WITH REMNANT INVASIVE LESION For patients with a no change on BCC size / depth or patients with a partial response but a remaining invasive lesion, will have surgical excscion of the remaining lesion.
2859086|NCT03534947|Other|Sonidegib then best supportive care|Sonidegib 200mg taken orally once a day for 12 weeks. PROGRESSIVE DISEASE Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions.
2859087|NCT03534934|Experimental|Baseline|"Smoker, former smoker and never smoker subjects will participate in the following interventions:~Vital Signs Urine Pregnancy Test on woman of child bearing potential Pre and Post Spirometry Questionnaires Blood Test for Vitamin D level Duel-energy X-ray absorptiometry scan (DXA) Chest Multi-detector computed tomography (MDCT)"
2859088|NCT03534934|Experimental|3 year follow-up|"Smoker and former smoker subjects who completed their baseline visit and it was determined that they did not have vertebral fractures will participate in the following interventions:~Vital Signs Urine Pregnancy Test on woman of child bearing potential Pre and Post Spirometry Questionnaires Blood Test for Vitamin D level Duel-energy X-ray absorptiometry scan (DXA) Chest Multi-detector computed tomography (MDCT)"
2859089|NCT03534921||People with severe mental illness (SMI)|In the study period 01/04/2000-31/03/2016, people with records on the Clinical Practice Research Datalink aged >=18 years with a record of severe mental illness so that at least one event occurs in the study period.
2859090|NCT03534921||People with SMI and type 2 diabetes|Drawn from the first cohort, this group also has a record of type two diabetes mellitus registered during the study period.
2859091|NCT03534921||People with diabetes (matched controls)|This cohort will be matched on a 4:1 ratio by age (+- 2 years), gender and general practitioner practice to the group of people with comorbid SMI and diabetes.
2859092|NCT03534908||NAFLD group|those with NAFLD
2859093|NCT03534908||Control group|those without NAFLD
2859094|NCT03534895|Placebo Comparator|PC1|5mL normal saline intravenous, single-administration, as pre-medication
2859095|NCT03534895|Experimental|PC2|midazolam 0.02mg/Kg in 5mL normal saline, intravenous, single-administration, as pre-medication
2859096|NCT03534895|Experimental|PC3|midazolam 0.06mg/Kg in 5mL normal saline, intravenous, single-administration, as pre-medication
2859098|NCT03534882|No Intervention|Control|Patients are asked to remain on their prostaglandin analogues and continue treatment as prescribed by their ophthalmologist. The purpose of this arm is to minimize bias in intraocular pressure readings.
2859099|NCT03534869|Experimental|Ear Acupuncture and Oral Analgesics|"The acupuncture treatment consisted of three acupuncture needles on the dominant ear according to French auriculotherapy guidelines - internal genital area, external genital area and Shen Men point that is used to increase the anaesthetic effect according to both French and Chinese traditions.~Additional oral analgesics (NSAID) could be supplied at any time upon patients request during hospitalization. Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy."
2859100|NCT03534869|Active Comparator|Oral Analgesics Only|Postoperative standard oral analgesic therapy (NSAID) supplied at any time upon patients request during hospitalization. Oral ibuprofen would be given as first line therapy, while oral paracetamol would be given as second line therapy.
2859101|NCT03534856|Experimental|Mindfulness meditation|Two weeks of short, daily guided mindfulness meditations were provided.
2859102|NCT03534843||Surgical treatment|Patients who received liver resection or palliative surgery, such as microwave coagulation therapy, hepatic artery ligation, or suturing ligation.
2859103|NCT03534843||Non-surgical treatment|Patients who received transcatheter arterial embolization (or transcatheter arterial chemoembolization) or conservative treatment
2859104|NCT03534830||eLASV > 38.5|exposed group of patients with an eLASV at or above 38.5 on a pre-operative MRI.
2859105|NCT03534830||eLASV < 38.5|non-exposed group of patients with an eLASV less than 38.5 of pre-operative MRIs
2859106|NCT03534817|Experimental|Early Access CR|Participants begin cardiac rehabilitation (CR) after 1-week following discharge post-MI.
2859107|NCT03534817|No Intervention|Standard Access CR|Participants begin CR after 7-weeks following discharge post-MI, similar to the average Canadian wait time.
2859108|NCT03534804|Experimental|Cabozantinib and Pembrolizumab, all patients|
2859109|NCT03534791|Experimental|Reminders|Reminders customized for each PLS, containing a name of the PLS indicated in the message. If the participants do not translate PLS within 2 months from PLS assignment, we will stop sending them reminders and we will consider them as dropouts.
2859110|NCT03534791|No Intervention|Control group|Control group will receive no intervention, i.e. standard procedure. Participants in the control group will receive PLSs for translation, in the frequency they indicated, and they will not receive any reminders. They will be assigned new PLSs once they translate the ones that were previously assigned.
2859111|NCT03534778|Other|patients undergoing neck dissection|all patients undergoing neck dissection
2859112|NCT03534765||Retrospective arm|Retrospective multicentre cohort with 1 year outcomes available following emergency surgery for NELA eligible gastrointestinal pathology. Please refer to WP1 inclusion and exclusion criteria for eligibility.
2859113|NCT03534765||Prospective, multicentre arm|10 centre prospective observational arm. Please refer to WP2 inclusion and exclusion criteria for eligibility.
2859114|NCT03534739|Experimental|Pain Inducing Massage|Participants will receive manual pressure applied to one myofascial trigger point.
2859115|NCT03534739|Active Comparator|Light Touch Massage|Participants will receive light touch applied to one myofascial trigger point.
2859116|NCT03534739|Placebo Comparator|Coldpressor|Participants will place hand into water cooled to 6 degrees Celsius (males) or 8 degrees Celsius (females).
2859117|NCT03534726||Patients|Patients with cardiomyopathy
2859118|NCT03534726||Normal subjects|No prior history of heart disease.
2859119|NCT03534713|Experimental|Neoadjuvant chemotherapy+standard therapy|neoadjuvant chemotherapy with carboplatin aera Under curve 5 and paclitaxel 175 mg/m² every 21 days during 3 cycles followed by standard therapy with extended field external radiotherapy and concomitant chemotherapy (Cisplatin 40mg/m2 weekly)
2859120|NCT03534713|Active Comparator|standard therapy alone|standard therapy with extended field external radiotherapy and concomitant chemotherapy (Cisplatin 40mg/m2 weekly)
2859121|NCT03534700|Active Comparator|Open excision|open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
2859122|NCT03534700|Experimental|parasacral flap reconstruction|The parasacral perforator flap has been described. It appears to be a good alternative, offering all the benefits of the reconstruction of the natal cleft in terms of lower rate of recurrence and lower time for complete wound healing. It also gives a better aesthetic result.
2859123|NCT03534687|Experimental|Aerobic Exercise Group|Aerobic Exercise (AE) subjects will come in for supervised, aerobic exercise training sessions 5 days a week for 12 weeks. Training will progress from 55% VO2max for week 1 (40 min session), to 60-65% VO2max for week 2 (50 min session), to ~70% VO2max for all other weeks (50 min session). Subjects will perform a warm-up and cool down (~5 min each) that includes stretching exercises. Subjects will wear heart rate monitors during each training session to provide feedback of target heart rate. Intensity, duration, resting and exercise heart rates, and blood pressures will be recorded for each session. Follow-up VO2max tests will be performed at weeks 4 and 8 to monitor progress and adjust AE training intensity.
2859124|NCT03534687|No Intervention|Control Group|During the 12 week control period, subjects are to maintain their normal, daily-living activities. Control group participants will be given the option to enroll in the AE training group after completion of the original Control group trial period.
2859125|NCT03534674|Experimental|Intervention|Participants assigned to the intervention group will receive a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, with subsequent vitamin D3 2000 IU daily.
2859126|NCT03534674|No Intervention|Control|Participants assigned to the control group will be advised to take our current vitamin D regimen (2000 IU vitamin D3 daily).
2859127|NCT03534661|Placebo Comparator|Teduglutide + Normal Saline|Teguglutide + (L-NMMA control)
2859128|NCT03534661|Active Comparator|Teduglutide + L-NMMA|Tedulgutide + L-NMMA
2859129|NCT03534661|Placebo Comparator|Placebo + L-NMMA|(Teduglutide control) + L-NMMA
2859130|NCT03534648|Experimental|Effect of PF-05221304 on PF-06865571 PK|
2859131|NCT03534648|Experimental|Effect of PF-06865571 on PF-05221304 PK|
2859183|NCT03534141|Experimental|Mild hypothermia & Esophageal cooling/warming device|The target core temperature is 34-35 °C.
2859184|NCT03534141|Active Comparator|Normothermia & Esophageal cooling/warming device|The target core temperature is 36.5-37.5 °C.
2859132|NCT03534635|Experimental|Pembrolizumab|"Pembrolizumab 200 mg will be administered intravenously every 3 weeks, for a maximum of 2 years, until progression, unacceptable toxicity, or withdrawal of consent, whichever happens first.~Patients may be treated for up to one year of additional treatment with pembrolizumab via the Second Course Phase, and according to defined criteria."
2859133|NCT03534622|Experimental|Delafloxacin|"Dosing will be initiated on Day 1. All participants will receive 300-mg delafloxacin as a~1-hour intravenous infusion every 12 hours (± 15 minutes) for a total of 7 doses."
2859134|NCT03534609|Experimental|Genius System Neck Treatment|Lutronic Genius System treatment of lines, wrinkles, and texture concerns on the neck.
2859135|NCT03534583|Active Comparator|Health Enhancement Program (HEP)|The Health-Enhancement Program (HEP) controls for group support and morale, behavioural activation, reduction of stigma, facilitator attention, treatment duration, and time spent on at-home practice. HEP is structurally equivalent to a SKY intervention, with similar-sized groups, meeting for 5 days for 2.5-3 hours, and once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions for the next 8 weeks. Participants will be asked to complete 25 min/day of course homework. Participants will learn about health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation. In HEP, which has been manualized, participants get the support of a group and facilitator, and talk through and try to implement positive health-enhancing life changesHEP will be delivered by a trained social worker (or equivalent).
2859136|NCT03534583|Experimental|Sudarshan Kriya Yoga (SKY)|The SKY PTSD program is a mind-body resilience building program developed for persons with PTSD. Through SKY breathing, interactive discussions, journaling, yoga and guided meditations, the workshop builds a framework for resilience and empowerment, and develops self-awareness, connectedness and community, and a positive outlook. SKY training will take place in group-format (group sizes of 6-8 participants). SKY training involves attending a 5-day course (Mon to Fri) that teaches the basic principles of SKY over 2.5-3 hour daily sessions. This will be followed by once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions (every 2 weeks) for the next 8 weeks. In addition, participants will be asked to practice SKY at home daily (25 min/day) throughout the duration of the study period (up to 26 weeks) and log practice frequency and any other
2859137|NCT03534557||COPD|FEV1/FVC and FEV1/FEV6 will be compared within the same cohort of COPD patients
2859138|NCT03534518|Active Comparator|SCI-patients receiving overground training|
2859139|NCT03534518|Active Comparator|SCI-patients receiving treadmill training|
2859140|NCT03534505|Experimental|Ketorolac injections|Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
2859141|NCT03534505|Active Comparator|bupivacaine|Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
2859142|NCT03534492|Experimental|Durvalumab plus Olaparib|Durvalumab 1500 mg every 4 weeks for up to a maximum of 2 months (up to 2 doses/cycles) plus Olaparib 300 mg b.i.d. up to 56 days (2 cycles of 28 days each cycle).
2859143|NCT03534479|Experimental|CVID-IVIgG, polyclonal IgG i.v. infusion|The patients of the CVID-IVIgG, polyclonal IgG infusion, group are studied five weeks from their last therapeutic polyclonal IgG i.v. infusion (IVIgG). On the mornings of day 0, vascular reactivity of the brachial artery, assessed as Flow mediated dilation (FMD), is measured and blood collected for biochemistry (baseline). Immediately after the FMD measurements and the blood collection, the 24 patients receive half dose of IVIgG necessary to treat their disease (400 mg/kg body weight in 10% solution). Twenty-four hours later, before infusing the second half of the dose of the IVIgG, vascular reactivity is again measured and blood collected. Vascular reactivity is again measured 1, 2, and 3 weeks after the first IVIgG infusion.
2859144|NCT03534466|Experimental|intervention group|Baby treadmill + conventional physical rehabilitation training
2859145|NCT03534466|Active Comparator|positive control group|Conventional physical rehabilitation training only
2859146|NCT03534453|Experimental|Olaparib 300mg tablets|Taken orally twice daily
2859147|NCT03534427|No Intervention|Control group|No exercise intervention
2859148|NCT03534427|Experimental|Jump rope exercise intervention|The jump rope exercise program was performed for 50 minutes with 5 minutes of warm-up and cool-down per day, 5 times a week for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4 and to 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Every subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
2859149|NCT03534414||Intervention|A Portfolio Dietary Pattern involving a combination of 4 cholesterol lowering foods, namely: plant sterols, viscous fibre, plant protein, and nuts.
2859150|NCT03534414||Control|A National Cholesterol Education Program (NCEP) based diet, a diet low in saturated fat and cholesterol.
2859151|NCT03534401|No Intervention|Standard Family Planning Counseling|Clients receive standard FP counseling services.
2859152|NCT03534401|Experimental|ARCHES Kenya Intervention in FP Counseling|Clients receive the ARCHES Kenya intervention in addition to standard FP counseling services.
2859153|NCT03534388|Other|Prospective Subjects|
2859154|NCT03534375||Female Early Adolescents|
2859155|NCT03534375||Male Early Adolescents|
2859156|NCT03534362|Active Comparator|Nasopore Group|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent intervention applied to the post-operative outflow tract.
2859157|NCT03534362|Active Comparator|Propel Stent Group|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement intervention applied to the post-operative outflow tract.
2859185|NCT03534128|Experimental|Spatial navigation evaluation|
2859186|NCT03534115|Placebo Comparator|Placebo|Placebo was prepared by using the same solution containing buffers that were used in the preparation of NAC solution, except it did not contain NAC
2859158|NCT03534336|No Intervention|Control|"Participants are enrolled in a 12-week, self-administered online weight loss program. The program is delivered through 12 weekly sessions; each includes educational videos and a health literacy quiz. Each quiz contains 10 questions, and a quiz is considered passed when at least 7 questions are answered correctly. All participants are encouraged to follow the program, take the quizzes, and lose 5% of their baseline body weight by the end of the program.~No financial incentives are given for losing weight or passing quizzes."
2859159|NCT03534336|Experimental|Incentive for Education|"Same 12-week, self-administered online weight loss program as in the Control arm.~Each participant is also given a $150 Incentive for Education for passing at least nine quizzes by the end of the program."
2859160|NCT03534336|Experimental|Incentive for Weight Loss|"Same 12-week, self-administered online weight loss program as in the Control arm.~Each participant is also given a $150 Incentive for Weight Loss for losing 5% of their baseline body weight."
2859161|NCT03534323|Experimental|Duvelisib +Venetoclax,|"Duvelisib will be given alone for the first seven days. On day 8 Venetoclax will be added.~Duvelisib will be administered orally twice daily~Venetoclax will be administered orally daily~All patients will be admitted for administration of the initial dose of venetoclax at each dose escalation"
2859162|NCT03534310|Active Comparator|Lifestyle modification|1 month of a VLCD with 865 kcal per day followed by a 12 kcal per kg of body weight of a high-protein, high fat diet for 11 months in association with intensive
2859163|NCT03534310|Experimental|Lifestyle modification plus Liraglutide 3 mg|1 month of a VLCD with 865 kcal per day followed by a 12 kcal per kg of body weight of a high-protein, high fat diet for 11 months in association with intensive. The patients will also receive Liraglutide 3 mg daily sc.
2859164|NCT03534310|Active Comparator|Sleeve Gastrectomy|The patients will undergo laparoscopic sleeve gastrectomy
2859165|NCT03534297|Experimental|dapansutrile capsules|"A total of 8 patients in each cohort will receive dapansutrile capsules:~Cohort 1 will receive 5x 100 mg dapansutrile capsules QD for 14 days~Cohort 2 will receive 5x 100 mg dapansutrile capsules BID for 14 days"
2859166|NCT03534297|Placebo Comparator|Placebo Capsules|"A total of 2 patients in each cohort will receive dapansutrile capsules:~Cohort 1 will receive 5 placebo capsules QD for 14 days~Cohort 2 will receive 5 placebo capsules BID for 14 days"
2859167|NCT03534284|Active Comparator|CBT-I|Cognitive Behavioral Therapy for Insomnia sessions: a 30-minute treatment session once weekly for six weeks.
2859168|NCT03534284|Active Comparator|Medication- Trazodone|Trazodone (50-100 mg):
2859169|NCT03534284|Placebo Comparator|Medication- Placebo|Placebo (for trazodone)
2859170|NCT03534245||1|Healthy children aged 2 - 9 years
2859171|NCT03534219|Experimental|Intervention Arm: EarPopper|"All patients in this arm will receive the EarPopper device.~Length of administration: 1 year Dose: Dosing of the EP device will be twice per day, once in the morning and once before bedtime. This is consistent with previous dosing which showed no adverse events and an excellent safety profile. 5, 6~Administration:~Hold nosepiece firmly against nostril opening creating a good, tight seal is crucial. Plug the other nostril closed.~Push button to start the airflow and swallow while the device is running.~Repeat on other nostril. After 5 minutes, repeat steps 1 - 3. This will complete one treatment.~Telephone call survey:~Will be administered monthly by study investigator. Telephone call survey is based on the OMO-22 Form."
2859172|NCT03534219|No Intervention|Control|"All patients in this arm will not receive any intervention. EarPopper device will be given to this group at the end of follow-up period (1 year)~Telephone call survey:~Will be administered monthly by study investigator. Telephone call survey is based on the OMO-22 Form."
2859173|NCT03534206|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
2859174|NCT03534206|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
2859175|NCT03534193|Other|Group 1|Participants randomized to Group 1 will receive Standard Diabetic Education with Registered Nurse and Molly Center Diabetes Care Guide (paper-based)
2859176|NCT03534193|Experimental|Group 2|Participants randomized to Group 2 will receive Molly Center Standard Diabetes Education plus access to Tablet based interactive diabetes education modules
2859177|NCT03534180|Experimental|Treatment (venetoclax)|Participants receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
2859178|NCT03534167|Experimental|TODAY! App and Coaching|RCT participants will be randomized into a 10-week intervention condition during which they will receive the CBT modules through the TODAY! app. In addition to the mobile app, participants will receive coaching from the study Coach who is trained in Motivational Interviewing principles. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks.
2859179|NCT03534167|No Intervention|Referrals|RCT participants will be randomized into a 10-week wait-list control condition and will be provided with and encouraged to use mental health and lesbian, gay, bisexual, queer (LGBQ) referrals and resources in the community. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks. After the 22-week post intervention follow-up, control group participants will have the option to receive the intervention, however they will not be administered follow-up assessments or given coaching.
2859180|NCT03534154||Work Package 1|In a large multi-centre cohort of adult moderate/severe TBI patients we aim to identify the most informative plasma biomarker(s) of the severity of axonal injury. We will characterise their time course, focusing on neurofilament light (NFL) and tau, and relate these to magnetic resonance imaging (MRI) measures of axonal injury. Using logistic regression we will then test whether these measures contribute to the prediction of clinical outcome at twelve months
2859181|NCT03534154||Work Package 2|In a subgroup of the patients recruited to WP1 we will use advanced MRI and longitudinal assessments to provide a more detailed description of the relationship between the plasma biomarkers and outcome after TBI. We will test whether advanced diffusion and myelin integrity measures correlate with plasma biomarkers and whether early plasma biomarker levels predict neurodegeneration measured by progressive atrophy after TBI.
2859182|NCT03534154||Work Package 3|In a second subgroup of patients recruited to WP1 we will combine microdialysis, neuroimaging and plasma sampling of axonal proteins to provide a deeper understanding of the mechanisms of axonal injury progression and use this approach to investigate the axonal origin of the plasma biomarkers.
2877037|NCT03410433|Active Comparator|PG910 5.0|Vicryl suture
2859188|NCT03534102|No Intervention|Standard of Care|Standard instructions from hospital. Subjects talk with hospital staff only when they call the hospital, when RA calls at various benchmarks, and at postoperative clinic visits. Subjects record opioid tapering in diary.
2859189|NCT03534102|Experimental|Improved Instructions|Improved opioid-tapering instructions given upon discharge from hospital. Subjects talk with hospital staff only when they call the hospital, when RA calls at various benchmarks, and at postoperative clinic visits. Subjects record opioid tapering in diary.
2859190|NCT03534102|Experimental|Improved Instructions and Educator|Improved opioid-tapering instructions given upon discharge from hospital. Subject receives regular phone calls from educator for counseling in opioid tapering. Subjects record opioid tapering in diary.
2859191|NCT03534089|Placebo Comparator|Standard infant fomula|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with standard infant formula (without lactoferrin supplementation)
2859192|NCT03534089|Experimental|Low level LF infant formula group|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with infant formula supplemented with low level of lactoferrin (38mg/100g). Lactoferrin:38mg/100g
2859193|NCT03534089|Experimental|High level LF infant formula group|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with infant formula supplemented with high level of lactoferrin (76mg/100g)
2859194|NCT03534063|Active Comparator|genotype-guided opioid therapy|We will collect data on the implementation success metrics, PROs via PROMIS measures, and for opioid utilization measures, we will collect proportion of patients prescribed specific opioids and self-reported opioid use, since patients may not take any or all of the opioid prescribed.
2859195|NCT03534063|No Intervention|usual care|We will collect data on the implementation success metrics, PROs via PROMIS measures, and for opioid utilization measures, we will collect proportion of patients prescribed specific opioids and self-reported opioid use, since patients may not take any or all of the opioid prescribed.
2859196|NCT03534050|Experimental|postoperative adjuvant RT|In this prospective observational study, all potentially eligible patients are clinically indicated for receiving postoperative adjuvant RT. Namely, partial cranial irradiation will be initiated within one month approximately after enrollment. Prescription dose will be 5000 - 6000 cGy in 25 - 30 fraction during 5 - 7 weeks.
2859197|NCT03534037|Experimental|Febuxostat 40mg|Febuxostat 40mg orally per day
2859198|NCT03534037|Active Comparator|Benzbromarone 50mg|Benzbromarone 50mg orally per day
2859199|NCT03534037|Other|Control|Dietary control only
2859200|NCT03534024|Active Comparator|nanomicielle curcumin|
2859201|NCT03534024|Placebo Comparator|plecebo|
2859202|NCT03534011|Experimental|REBOA|Resuscitative Balloon Occlusion of the Aorta after advanced cardiac life support if return of spontaneous circulation is not achieved
2859203|NCT03533985|Experimental|Song of Kin|Voice (with or without guitar)- lullaby/ Holding meter
2859204|NCT03533985|Experimental|Gato box|Simple rhythms using Remo Gato box will be played by the MT-BC using a 3rd to comfort, engage or sedate
2859205|NCT03533985|Experimental|Ocean disc|Creating a consistent womb-like sound soundscape to comfort, engage or sedate
2859206|NCT03533985|Experimental|Contingent singing|"Provision of communicative vocalization-parantese to engage with infants, prosodic responses to infant cues (eye contact, body position)"
2859207|NCT03533985|Experimental|Tonal Vocal holding|Providing a 'blanket of tone' to comfort, engage or sedate
2859208|NCT03533985|Experimental|Muted shaker|If infant is awake, the muted shaker will be used to entrain to the infant's vital signs-to comfort, soothe or sedate
2859209|NCT03533972|Experimental|Test group|subjects will be provided with Ashwagandha capsules 500 mg twice daily, after meals with plain water for 1 month
2859210|NCT03533972|Placebo Comparator|Control group|subjects will be provided with placebo capsules.
2859211|NCT03533959||alirocumab therapy group|patients with 10mg daily rosuvastatin and alirocumab at least 75mg every 2 weaks
2859212|NCT03533959||standard statin therapy group|patient with 10mg daily rosuvastatin and never use alirocumab or other PCSK-9 inhibitor
2859213|NCT03533946|Experimental|Rucaparib, all patients|Single Arm study, all patients will get rucaparib
2859214|NCT03533933|Active Comparator|Autologous connective tissue graft|Soft tissue harvesting from patient palate
2859215|NCT03533933|Experimental|collagen matrix|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland Device: Collagen matrix
2859216|NCT03533920|Experimental|UNI-DEB|
2859217|NCT03533907||treated|The women included were patients of the Humanitas Fertility Center; they all had a diagnosis of infertility and were trying to become pregnant. They received ≥1 month of therapy with UA 5 mg/day
2859218|NCT03533881|Active Comparator|Arom Digest Slim and nutritional changes|Subjects take collagen and follow minimal nutritional changes.
2859219|NCT03533881|Active Comparator|Nutritional changes|Subjects only follow minimal nutritional changes
2859220|NCT03533868|No Intervention|Standard of Care (SOC)|Patients in this arm will have their viral load monitored using the standard of care method, using the Roche Cobas TaqMan HIV-1 v2 (Roche, Branchburg, NJ) assay.
2859221|NCT03533868|Experimental|Point-of-care (POC)|Patients in this arm will have their follow-up viral loads (after baseline) monitored using a Point-of-care viral load monitoring test, the Cepheid Xpert HIV-1 Viral Load assay.
2859222|NCT03533855|Experimental|"CS plus FRFSE"|"we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence"
2859223|NCT03533829|Active Comparator|Buzzy®|Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
2859224|NCT03533829|Active Comparator|Music|Music will be selected and listened to as a distraction before and during vaccination.
2859225|NCT03533829|Active Comparator|Buzzy® and Music|Buzzy® will be applied to the arm prior to and during vaccination and music will be selected and listened to before and during vaccination.
2859264|NCT03533608|Experimental|Group PE|Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
2877462|NCT03407339|Active Comparator|Shared Oral Care Intervention|
2859226|NCT03533816|Experimental|EAGD T-cell infusion (Phase I)|Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at either 1, 3, or 10 x 1,000,000 cells/kg concentrations depending upon the cohort.
2859227|NCT03533816|Experimental|EAGD T-cell infusion (Expansion)|Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at the maximum tolerated dose as determined from Phase I.
2859228|NCT03533803|Active Comparator|Group A (Indomethacin)|All patient had long stimulation protocol and IVF/ICSI. After mock embryo transfer women with any degree of difficulty will receive Indomethacin 100Mg Suppository 1-2 hours before embryo transfer.
2859229|NCT03533803|Placebo Comparator|Group B (Control)|All patient had long stimulation protocol and IVF/ICSI. After mock embryo transfer women with any degree of difficulty will not receive any medications before embryo transfer.
2859230|NCT03533790|Experimental|DEP-Ru|doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2 mg/kg days 1 to 5,then gradually reduce; ruxolitinib 0.3mg/kg/d。This regimen was repeated after 2 weeks.
2859231|NCT03533777|Active Comparator|Antegrade Intravenous Catheter|A 20 gauge 30 millimeter peripheral intravenous catheter will be placed in an upper extremity vein in standard antegrade fashion (with the tip pointed towards the direction of blood flow). Blood draws from this IV catheter will be attempted twice throughout the study. An infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
2859232|NCT03533777|Experimental|Retrograde Intravenous Catheter|A 20 gauge 30 millimeter peripheral intravenous catheter will be placed in an upper extremity vein in a retrograde fashion (with the tip pointed away from the direction of blood flow). Blood draws from this IV catheter will be attempted twice throughout the study. An infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
2859233|NCT03533764|Experimental|Asthma Self-Management for Adolescents|Asthma Self-Management for Adolescents (ASMA) consists of three complementary components: (1) an 8- week intervention for students; (2) caregiver education; and (3) education for students' medical providers.
2859234|NCT03533764|No Intervention|Attention Control|In 3 group sessions and 5 one-on-one sessions, held at school during the school day, students will receive information about asthma and other health topics relevant to adolescents (e.g., nutrition, safety). They will learn to monitor their health by using diaries to record behaviors, such as what they eat, and/or their sleep patterns. Students will be referred to their medical providers for asthma and other health concerns; if they do not have a provider, they are given referrals in their community.
2859235|NCT03533751|Placebo Comparator|Placebo|Placebo
2859236|NCT03533751|Experimental|Group 1|ANB020
2859237|NCT03533751|Experimental|Group 2|ANB020
2859238|NCT03533751|Experimental|Group 3|ANB020
2859239|NCT03533751|Experimental|Group 4|ANB020
2859240|NCT03533738|Experimental|Food selection 1|To consume vegetables followed by meat & rice together
2859241|NCT03533738|Experimental|Food selection 2|To consume meat followed by vegetables & rice together
2859242|NCT03533738|Experimental|Food selection 3|To consume as follows: vegetables, meat, rice
2859243|NCT03533738|Experimental|Food selection 4|To consume vegetables followed by meat and rice together
2859244|NCT03533738|Experimental|Food selection 5|To consume rice followed by vegetables & meat together
2859245|NCT03533725|Experimental|Intervention group|Breastfeeding counseling and education services using mHealth tools
2859246|NCT03533725|No Intervention|Comparative control group|No intervention, only standard of care
2859247|NCT03533712|Experimental|Fortified BEP supplement|Intervention: Dietary Supplement: Fortified balanced energy-protein (BEP) supplement + iron and folic acid supplement.
2859248|NCT03533712|Active Comparator|Fe and folic acid|Dietary Supplement: Fe and folic acid supplement.
2859249|NCT03533699|Active Comparator|Propranolol|101 women with uncomplicated term pregnancy who will be admitted to the Ain Shams University Maternity hospital and will receive syntocinon intravenous infusion for induction or augmentation of labour.
2859250|NCT03533699|Placebo Comparator|placebo|101 women with uncomplicated term pregnancy who will be admitted to the Ain Shams University Maternity hospital and will receive syntocinon intravenous infusion for induction or augmentation of labour.
2859251|NCT03533686|Experimental|Single-Sided Deafness Adult|
2859252|NCT03533686|Experimental|Conductive Hearing Loss Adult|
2859253|NCT03533686|Experimental|Conductive Hearing Loss Child Standard of Care then Adhear|
2859254|NCT03533686|Experimental|Conductive Hearing Loss Child Adhear then Standard of Care|
2859255|NCT03533673|Experimental|Cohort 1|A one-time intravenous infusion of AAV2/8-LSPhGAA (dose level 1)
2859256|NCT03533673|Experimental|Cohort 2|A one-time intravenous infusion of AAV2/8-LSPhGAA (dose level 2)
2859257|NCT03533660|Active Comparator|Feedback|Participant will receive a brief feedback on data downloaded from the ABM and information about treatment resources
2859258|NCT03533660|Active Comparator|Enhanced usual care|Participant will receive information about remaining abstinent and about treatment resources
2859259|NCT03533647||entire cohort (observational)|none (observational study)
2859260|NCT03533634|Experimental|superior group|this group with midshaft clavicle fracture were treated with superior reconstruction plate
2859261|NCT03533634|Experimental|anteroinferior group|this group with midshaft clavicle fracture were treated with anteroinferior reconstruction plate
2859262|NCT03533621|Experimental|Probiotic|1 Probiotic pill, twice a day, for 12 weeks + 20 min weekly support to increase fruit and vegetable consumption
2859263|NCT03533621|Placebo Comparator|Placebo|1 placebo pill (soy protein powder), twice a day, for 12 weeks + 20 min weekly support to increase fruit and vegetable consumption
2859265|NCT03533595|No Intervention|Standard Suture|Standard suture for thoracolumbar fusion will be used per standard of care.
2859268|NCT03533582|Experimental|GROUP A2 (NON-WDF)|Patients receive cisplatin IV over 6 hours on day 1 following surgery. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2859269|NCT03533582|Experimental|GROUP B1 ARM 4-CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2859270|NCT03533582|Experimental|GROUP B1 ARM 6-CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2859271|NCT03533582|Experimental|GROUP B2 (UNRESECTABLE)|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 2 courses. Patients with resectable tumors undergo surgery, then all patients continue with 2 additional courses of cisplatin.
2859272|NCT03533582|Experimental|GROUP C ARM C5VD|Patients receive cisplatin IV over 6 hours on day 1, 5-fluorouracil IV over 1-15 minutes, vincristine sulfate IV over 1 minute on days 1, 8, and 15 and doxorubicin IV over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after course 2.
2859273|NCT03533582|Experimental|GROUP C ARM CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after course 2.
2859274|NCT03533582|Experimental|GROUP D1|"SIOPEL-4 INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for courses 1 and 2) and days 1 and 8 (for course 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients with lung complete remission (either with chemotherapy and/or surgery) receive carboplatin IV over 1 hour on day 1 and doxorubicin IV over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity."
2859275|NCT03533582|Experimental|GROUP D2 ARM CE|"SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for courses 1 and 2) and days 1 and 8 (for course 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients receive carboplatin IV over 1 hour on days 1 and 2, doxorubicin IV over 1-15 minutes on days 1 and 2 during courses 1, 3 and 5, and etoposide IV over 2 hours on day 1 and 2 of courses 2, 4 and 6. Treatments repeat every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
2859276|NCT03533582|Experimental|GROUP D2 ARM VI|"SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for courses 1 and 2) and days 1 and 8 (for course 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients receive carboplatin IV over 1 hour on days 1 and 2 and doxorubicin IV over 1-15 minutes on days 1 and 2 during courses 1, 3 and 5. Patients also receive vincristine sulfate IV over 1 minute on days 1 and 8 and irinotecan IV over 90 minutes QD on days 1 to 5 of courses 2, 4 and 6. Treatments repeat every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
2859277|NCT03533582|Active Comparator|GROUP E1|Patients undergo observation only.
2859278|NCT03533582|Experimental|GROUP E2 (PLADO)|Patients receive cisplatin IV over 6 hours on day 1 and doxorubicin IV over 1-15 minutes on days 1 and 2 following surgery. Treatments repeat every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2859279|NCT03533582|Experimental|GROUP F ARM 1 (PLADO)|Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-21. Treatments repeat every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo surgery, if tumors are resectable, or receive an additional 3 courses of the treatment.
2859280|NCT03533582|Experimental|GROUP F ARM 2 (P/GEMOX)|Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-14 of courses 1 and 3. Patients also receive gemcitabine IV over 90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 and sorafenib PO on days 1-14 of courses 2 and 4. Patients may undergo surgery, if tumors are resectable, or receive an additional 4 courses of the treatment.
2859281|NCT03533569||Osteoarthritis|Participants with an established diagnosis of knee osteoarthritis
2859282|NCT03533569||Rheumatoid arthritis|Participants with an established diagnosis of rheumatoid arthritis
2859283|NCT03533569||Spondyloarthritis or psoriatic arthritis|Participants with an established diagnosis of spondyloarthritis or psoriatic arthritis
2859284|NCT03533569||Case controls|Participants with no arthritis or knee pain as controls
2859285|NCT03533543||New-onset atrial fibrillation|Patients with MI who are free from a medical history of atrial fibrillation (AF) will be recognized as NOAF if they suffer an atrial fibrillation (lasting for at least 30 seconds which are recorded by a 24h cardiac monitoring) incident during hospitalization.
2859286|NCT03533543||Non new-onset atrial fibrillation|Patients with MI who are free from a medical history of AF will be recognized as Non-NOAF if they persist with sinus rhythm (based on 24h cardiac monitoring records) during hospitalization.
2859287|NCT03533530|Active Comparator|No electrical source imaging (ESI)|In all patients, the multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, except for ESI.
2859288|NCT03533530|Experimental|Low-density ESI (LD ESI)|The multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, including ESI using LD EEG recordings.
2859289|NCT03533530|Experimental|High-density ESI (HD ESI)|The multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, including ESI using HD EEG recordings.
2859290|NCT03533517|Experimental|AccuCinch® Ventricular Repair System|
2859291|NCT03533504||Variability in individual PK|Patients with hemophilia A or B, of any severity, who are registered on the web-accessible population pharmacokinetics- hemophilia (WAPPS-Hemo) database, and for whom infusion and/or PK data is available.
2859292|NCT03533491|Experimental|App Evaluation|All 60 teens in The Rewire Study will complete the first 4 modules of the Rewire app. Prior to using the app, they will complete a baseline assessment. Follow up surveys will be completed at 2 weeks and 8 weeks post-baseline.
2877463|NCT03407339|No Intervention|Control|
2859295|NCT03533465|Experimental|Complicated Grief Treatment (CGT)|10 adults with CG who successfully completed Aim 1 and will also participate in open complicated grief treatment (CGT), during which they will complete additional subjective and objective sleep assessments.
2859296|NCT03533452|Active Comparator|PRE-GA|10 mL of 0.5% ropivacaine injection before the start of surgery and 10 ml of normal saline (0.9%) injection at the end of surgery through the interscalene catheter
2859297|NCT03533452|Sham Comparator|POST-GA|10 ml of normal saline (0.9%) injection before the start of surgery and 0.5% ropivacaine injection at the end of surgery through the interscalene catheter
2859298|NCT03533426|Active Comparator|Pump based patient controlled analgesia|"Analgesia is maintained using disposable silicon ballon pump Accufuser containing morphine 0.2 mg/ml, 8mg ondansetron plus and 180 mg ketorolac. The infusion rate is 5 ml / h and lockout interval of 15min. the hourly delivered morphine dose is 1-1.8 mg & the pump is sufficient for about 60 hours according to patient response."
2859299|NCT03533426|Active Comparator|serratus anterior plane catheter block|"Linear ultrasound transducer (superficial) 6-12 MHz is utilized to count the ribs up to 4th or 5 th rib in the mid-axillary line. Musculature of thoracic wall is identified sonographically,an echogenic needle 14-16 G, 100 mm is inserted in plane with the U/S probe towards the plane deep to the serratus anterior muscle. Under real - time U/S, single shot of 20ml contrast medium iohexol = omnipaque 150 mg I2 / ml is injected to check the plane and level (T3-T8/9) of SAPB.A reinforced radiopaque catheter is threaded through the needle and its final position underneath the plane of serratus anterior muscle is confirmed fluoroscopically. 20ml 0.25% levobupivacaine (Chirocaine).Analgesia is maintained using 0.125% levobupivacaine infusion at a rate of 7-12 ml/h according to patient response."
2859300|NCT03533413|Active Comparator|Interventional:Combined CT-fluroscopy|Combined CT-fluroscopic radiofrequency ablation of thoracic dorsal root ganglia.
2859301|NCT03533413|Active Comparator|Interventional: standard fluroscopy|Fluroscopic radiofrequency ablation of thoracic dorsal root ganglia.
2859302|NCT03533400|Active Comparator|Group 1|Group 1 (control group) will be given the standard Jamboxx musical device. They will be trained to use the device during two 20 minute training session with a respiratory therapist, and will be instructed to play the device for a minimum of 30 minutes, 3 times a week. The Jamboxx musical device is a hands-free breath controlled musical device designed for people with quadriplegia. The mouthpiece acts as a transducer, changing air pressure created by the user's lungs to a joystick signal to the computer via a differential pressure sensor. The Jamboxx can produce musical sounds of many instruments (trumpet, drums, etc.) in many different scales and in any key.
2859303|NCT03533400|Experimental|Group 2|Group 2 (treatment group) will be given the Jamboxx musical device plus the Jamboxx respiratory therapy device. The respiratory therapy device is similar to the music device, but with specially designed games that guide the user through breathing exercises intended to strengthen the lungs.
2859304|NCT03533387|Experimental|Extended-release formulation 1 (ER1)|50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.
2859305|NCT03533387|Experimental|Extended-release formulation 2 (ER2)|50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.
2859306|NCT03533387|Active Comparator|Intermediate-release formulation (IR)|10mg MN-166 capsule. This formulation is typically given two or three times daily, hence, the label of intermediate-release.
2859307|NCT03533374||Patients with epileptic seizures|"Electroencephalogram (EEG) and visual evaluation~- Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians)."
2859308|NCT03533374||Patients with non-epileptic seizures|"Electroencephalogram (EEG) and visual evaluation~- Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians)."
2859309|NCT03533348||Fasting arm|Patients will need at least 4 hours of fasting prior to contrast-enhanced CT scans.
2859310|NCT03533348||No fasting|Patients are allowed to eat and drink freely prior to contrast-enhanced CT scans.
2859311|NCT03533335|Active Comparator|Chlorhexidine spray|0.2% chlorhexidine oral spray, once daily
2859312|NCT03533335|Experimental|Chlorine Dioxide spray|0.1% pH-balanced chlorine dioxide oral spray, once daily
2859313|NCT03533335|Placebo Comparator|Sterile water spray|Placebo
2859314|NCT03533309|Experimental|computer guided|Group (A): comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent.
2859315|NCT03533309|Active Comparator|conventional|Group (B) comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique
2859316|NCT03533296|Experimental|Children|Children who receive elective surgery under general anesthesia and are supported by mechanical ventilation
2859317|NCT03533283|Experimental|Dose Escalation and Expansion|Participants will receive RO7082859 in combination with Atezolizumab up to the maximum tolerated dose (MTD).
2859318|NCT03533270||Urethroplasty|Patients with traumatic urethral injury associated with pelvic fractures who underwent urethroplasty
2859319|NCT03533257|Active Comparator|Active (AMX0035)|AMX0035--a combination of TUDCA and Phenylbutyrate
2859320|NCT03533257|Placebo Comparator|Placebo|Taste-matched Placebo
2859321|NCT03533244|Placebo Comparator|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
2859322|NCT03533244|Experimental|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
2859323|NCT03533244|Experimental|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
2859324|NCT03533231|Active Comparator|Triple Antibiotic Paste (TAP)|It consisted of Ciprofloxacin (Ciprocin 250 mg tablets; EPICO, Cairo, Egypt), Metronidazole (Flagyl 500 mg tablets; Sanofi Aventis Pharma, Cairo, Egypt), Doxycycline (Vibramycin 100 mg capsules; Pfizer, Cairo, Egypt). One Doxycycline capsule content was evacuated in a sterile mortar, one tablet of metronidazole and one tablet of ciprofloxacin were crushed and ground in the same mortar using a pestle into homogenous powder. Saline drops (Otrivin baby saline; Novartis, Cairo, Egypt) were added and mixed using the pestle until a creamy paste was achieved (Sabrah et al. 2013, Nagy et al. 2014). TAP was then used for canal disinfection.
2859376|NCT03532945|Active Comparator|Titanium cage|The one-level Posterior Lumbar Interbody Fusion(PLIF) surgery will be carried out with titanium cage.
2859446|NCT03532451|Experimental|Cohort 2: Nivolumab/Lirilumab|Nivolumab 480 mg IV and Lirilumab 240 mg on week 0 and week 4
2859325|NCT03533231|Experimental|Ciprofloxacin + Propolis Paste|Ethanol extract of raw propolis (EEP; ElEzaby Co. Labs, Cairo, Egypt.) was prepared by adding 10 gm of propolis (Imtinan, Cairo, Egypt) to 40 gm of 70% ethanol (ElGomhorya Co., Cairo, Egypt) (for 20% tincture) in a dark container to prevent reduction of propolis. The container was sealed and placed at room temperature for a period of three weeks. The sealed container was manually shaken every 2 days to ensure proper mixing. After 3 weeks, the container was opened and ethanol extract of propolis was obtained. Ethanol-free EEP was made by evaporating the ethanol in a water bath. EEP was then mixed with Ciprofloxacin powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
2859326|NCT03533231|Active Comparator|Ciprofloxacin + Metronidazole Paste|Ciprofloxacin powder was mixed with Metronidazole powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
2859327|NCT03533231|Experimental|Propolis + Metronidazole paste|Ethanol Extract of Propolis (EEP) was mixed with Metronidazole powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
2859328|NCT03533192|Experimental|Receipt of It's Your Game...Keep it Real|It's Your Game...Keep it Real is an HIV, STI, and teen pregnancy prevention program
2859329|NCT03533192|No Intervention|Usual care|Students received their regular health education.
2859330|NCT03533179|Experimental|Esmolol-placebo+glucagon 1 placebo (A)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+ Physiologic saline - glucagon dummy bolus 50 ml at time=0."
2859331|NCT03533179|Experimental|Esmolol+glucagon 1 placebo (B)|"Esmolol intravenous solution (10 mg/ml esmolol hydrochloride) is administered as a loading dose (1.25 mg/kg/min esmolol) at baseline (time= -15 minutes). Continuous infusion (500-750 micrograms/kg/min) of esmolol/placebo is then administered until T=30 minutes.~+ Physiologic saline - glucagon dummy bolus (50 ml) at time=0."
2859332|NCT03533179|Experimental|Esmolol+glucagon 1 (C)|"Esmolol intravenous solution (10 mg/ml esmolol hydrochloride) is administered as a loading dose (1.25 mg/kg/min esmolol) at baseline (time= -15 minutes). Continuous infusion (500-750 micrograms/kg/min) of esmolol/placebo is then administered until T=30 minutes.~+Glukagon 1 (50 μg/kg bolus - over 1-3 min from time=0 min in 50 ml isotonic fluid)"
2859333|NCT03533179|Experimental|Esmolol-placebo+glucagon 2 (D)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+Glukagon 2 (50 μg/kg bolus - over 30 min in 50 ml isotonic fluid from time=0 min)"
2859334|NCT03533179|Experimental|Esmolol-placebo+glucagon 1 (E)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+ Glukagon 1 (50 μg/kg bolus - over 1-3 min from time=0 min in 50 ml isotonic fluid)"
2859335|NCT03533166|Experimental|Chlorhexidine|Mechanical treatment + 0.03% chlorhexidine + 0.05% CPC mouthrinse
2859336|NCT03533166|Placebo Comparator|Placebo|Mechanical treatment + Placebo mouth rinse
2859337|NCT03533153|Experimental|WJ-MSC cells implantation group|"MSC cells (allogeneic transplantation from WJ-MSC primary cells); the frequency: for one time within12h after emergency coronary artery revascularization; dose levels: 1X10^8; method of administration: intravenous injection. Other kinds of treatment are in accordance with the treatment guidelines for MI patients, listed in the column Conventional drug therapy."
2859338|NCT03533153|Placebo Comparator|CTSTMD PBS without WJ-MSC group|"Saline only was injected in the control group. The frequency: for one time 2-12h after emergency coronary artery revascularization. Dose levels: the same dosage given to MSC group. Method of administration: intravenous injection. Other kinds of treatment are in accordance with the treatment guidelines for MI patients, listed in the column Conventional drug therapy."
2859339|NCT03533140|Active Comparator|DUCEST Neurostimulator V Group A|
2859340|NCT03533140|Sham Comparator|DUCEST Neurostimulator V Group B|
2859341|NCT03533127|Experimental|LY01008+Carboplatin/Paclitaxel|Drug: LY01008 15 mg/kg IV every 3 weeks on Day 1 Drug: Carboplatin Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles Drug: Paclitaxel Paclitaxel 175 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
2859342|NCT03533127|Experimental|Bevacizumab + Carboplatin/Paclitaxel|Drug: Bevacizumab Bevacizumab 15 mg/kg IV every 3 weeks on Day 1 Drug: Carboplatin Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles Drug: Paclitaxel Paclitaxel 175 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
2859343|NCT03533114|Experimental|JZP-258|JZP-258 at the stable dose and regimen for 2 weeks.
2859344|NCT03533114|Placebo Comparator|Placebo|Placebo will be administered at a volume and regimen equivalent to the JZP-258 dose and regimen for 2 weeks.
2859345|NCT03533101|Experimental|Tocilizumab 4 mg/kg|Tocilizumab 4 mg/kg IV single dose day -1 prior to haploidentical transplantation
2859346|NCT03533101|Active Comparator|Tocilizumab 8 mg/kg|Tocilizumab 8 mg/kg IV single dose day -1 prior to haploidentical transplantation
2859347|NCT03533088|Experimental|patients|patients with RC repair surgery
2859348|NCT03533075|Experimental|Teachable Moment Brief Intervention|The TMBI is informed by evidence based strategies to collaboratively identify 1) drivers of suicidal ideation, 2) functional aspects of the recent suicide attempt, 3) the patient's relationship with the concept of suicide, 4) what has been lost and gained as a result of the suicide attempt, 5) short term management suicide prevention management strategies, and 6) documentation of factors to address in a suicide-specific treatment plan.
2859349|NCT03533075|No Intervention|Care as Usual|Usual care at Veterans Affairs Medical Centers (VAMC) for Veterans who have attempted suicide involves psychiatric evaluation/treatment and ongoing medical stabilization.
2859350|NCT03533062|Active Comparator|trigonal sparing botox injection|Using a 7 gauge needle injection were allocated uniformly and evenly throughout the designed area excluding trigone in other arm Dilution of BOTOX vial (100 u) in 10 ml normal saline (10 u/ml) and injected in 20 sites (0.5ml /site).•then after 6 months postoperative anticholinergics administration .
2859447|NCT03532438||NTM patient group|NTM lung disease patients living together
2861356|NCT03519360|Experimental|Restricted ultrafiltration rate (UFR)|UFR ≤10 ml/kg/hr
2859351|NCT03533062|Active Comparator|trigonal involved|Using a 7 gauge needle injection were allocated uniformly and evenly throughout the designed area including the trigone .Dilution of BOTOX vial (100 u) in 10 ml normal saline (10 u/ml) and injected in 20 sites (0.5ml /site).then after 6 months postoperative anticholinergics administration .
2859352|NCT03533049|Experimental|myFAMI intervention|"All participants will receive the standard discharge education from their transplant and inpatient care team.~Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge."
2859353|NCT03533049|Active Comparator|Control|Family members assigned to the control group (standard care) will receive standard post-discharge follow-up care consisting of discharge education during the transplant hospitalization and at regularly scheduled appointments instructing families to contact the research nurse with problems or questions.
2859354|NCT03533036|Experimental|Virtual Reality Intervention|VR headsets consist of a Samsung phone dedicated to playing programs designed by the AppliedVR company. The phone is inserted in the front of the headset and can play videos that can be then viewed by the participant while wearing the headset. Participants in the experimental arm will be fitted with VR headsets prior to first trimester abortion and will wear the headset during the procedure. Participants will be able to choose a program of their preference (ex. guided meditation, beautiful scenery). The patient may remove the VR device at any time during the procedure. After the procedure, investigators will carry out a qualitative interview with the participant and ask about the experience of using the VR headset during first trimester abortion. Patients will also complete surveys evaluating procedure-related anxiety. These will be administered before and after the procedure.
2859355|NCT03533036|No Intervention|Control arm|In the control group, participants will not use virtual reality during the procedure. Patients in the control arm will complete surveys evaluating procedure-related anxiety. These will be administered before and after the procedure.
2859356|NCT03533023|Experimental|TRE + SOC|Time Restricted Eating + Standard of Care
2859357|NCT03533023|Other|SOC|Standard of Care
2859358|NCT03533010|Active Comparator|Ca500mg + VitD800IU|Daily Supplementation with 500mg Calcium plus 800IU Vitamin D3
2859359|NCT03533010|Placebo Comparator|Placebo|Dietary Supplement: Placebo
2859360|NCT03532997|Experimental|Intervention|"The investigators aim to introduce patients with advanced cancer to supportive care resources, including specialty palliative care, through a novel app called ELOS (stands for extra layer of support) in a prospective cohort study. The investigators will compare participant acceptance of this new electronic tool to industry standards and follow ultimate referrals to outpatient palliative care compared to historical, matched controls."
2859361|NCT03532984||adults aged 20-29|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
2859362|NCT03532984||adults aged 30-39|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
2859363|NCT03532984||adults aged 40-49|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
2859364|NCT03532984||adults aged 50-59|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
2859365|NCT03532984||adults aged 60-69|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
2859366|NCT03532984||adults aged 70-79|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
2859367|NCT03532984||adults aged 80+|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
2859368|NCT03532984||geriatric patients|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
2859369|NCT03532971||allogeneic hematopoietic-cell transplantation patients|Prospective HCT cohort of patients undergoing allogeneic HCT at DFCI
2859370|NCT03532958|Placebo Comparator|Placebo|Normal saline
2859371|NCT03532958|Experimental|Lowest Dose BNZ-1|
2859372|NCT03532958|Experimental|Low Dose BNZ-1|
2859373|NCT03532958|Experimental|Moderate Dose BNZ-1|
2859374|NCT03532958|Experimental|High Dose BNZ-1|
2859375|NCT03532945|Experimental|Bioactive Glass-Ceramic Spacer|The one-level Posterior Lumbar Interbody Fusion(PLIF) surgery will be carried out with Novomax, which is the bioactive glass ceramic intervertebral spacer.
2861357|NCT03519360|Experimental|Standard of Care/ Unrestricted UFR|UFR as needed
2859377|NCT03532932||UC Participants|Participants diagnosed with moderate to severe UC from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in UC participants particularly on the use of available biological therapies.
2859378|NCT03532932||CD Participants|Participants diagnosed with moderate to severe CD from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in CD participants particularly on the use of available biological therapies.
2859379|NCT03532906|Active Comparator|TAP block|Patients receive the injection of local anaesthetic into the right abdominal wall (TAP block) together with the injection of local anaesthetic into the surgical wounds.
2859380|NCT03532906|Other|Control|Patients receive the injection of local anaesthetic into the surgical wounds only.
2859381|NCT03532880|Experimental|Participants with Small Cell Lung Cancer|
2859382|NCT03532867|Experimental|Healthy volunteers|"After an ophthalmic consultation, the healthy volunteers are summoned to perform the exercise test in the form of an aerobic exercise on an ergometric bicycle with 3 different intensity levels calculated on the theoretical maximum aerobic power.~The OCT examination in the EDI mode, centered on the macular and peri-papillary region, as well as the systolic and diastolic blood pressure and the heart rate.~In healthy patients performing aerobic physical exercise in the Department of Sports Medicine , the investigators will perform the following Intervention :~Examination of pressures before stopping the exercise~Examination of pressure during the exercise~Examination of pressures after stopping the exercise"
2859383|NCT03532854|Experimental|Sequence A|Ezetimibe/Rosuvastatin -> Valsartan -> Valsartan and Ezetimibe/Rosuvastatin
2859384|NCT03532854|Experimental|Sequence B|Valsartan -> Valsartan and Ezetimibe/Rosuvastatin-> Ezetimibe/Rosuvastatin
2859385|NCT03532854|Experimental|Sequence C|Valsartan and Ezetimibe/Rosuvastatin -> Ezetimibe/Rosuvastatin -> Valsartan
2859386|NCT03532854|Experimental|Sequence D|Ezetimibe/Rosuvastatin -> Valsartan and Ezetimibe/Rosuvastatin-> Valsartan
2859387|NCT03532854|Experimental|Sequence E|Valsartan -> Ezetimibe/Rosuvastatin -> Valsartan and Ezetimibe/Rosuvastatin
2859388|NCT03532854|Experimental|Sequence F|Valsartan and Ezetimibe/Rosuvastatin -> Valsartan -> Ezetimibe/Rosuvastatin
2859389|NCT03532841|Experimental|Group I (tramadol group)|Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.
2859390|NCT03532841|Placebo Comparator|Group II (placebo oral tablet group)|group II will receive a placebo one hour before the procedure.the Treatment and placebo will be identical in form and packaging, without any identifying label.
2859391|NCT03532828|Experimental|Polysomnography alone|A polygraphy will be performed in 70 patient to search for obstructive sleep apnea
2859392|NCT03532828|Experimental|Polysomnography and postural assesment|A polygraphy and a postural assesment will be performed in 30 patients
2859393|NCT03532815|Active Comparator|Lifestyle Modification group|
2859394|NCT03532815|No Intervention|Control group|
2859395|NCT03532802|Active Comparator|Metoprolol Succinate|Metoprololsuccinat
2859396|NCT03532802|Placebo Comparator|Placebo oral capsule|Placebo
2859397|NCT03532789|Experimental|herbal patch group|using herbal patch as an intervention
2859398|NCT03532789|Placebo Comparator|placebo patch group|using placebo patch as an intervention
2859399|NCT03532776|Experimental|Podofilox Gel 0.5 %|Podofilox Gel 0.5% twice a day, three days following by four days of discontinuation, up to four cycles
2859400|NCT03532776|Active Comparator|Condylox Topical Gel 0.5%|Condylox Topical Gel 0.5% twice daily, three days following by four days of discontinuation, up to four cycles
2859401|NCT03532776|Placebo Comparator|Placebo Gel|Subjects in this arm will receive a vehicle that matches the test product, except for the inclusion of the active ingredient
2859402|NCT03532763|Experimental|Tocotrienol-rich fraction|
2859403|NCT03532763|Placebo Comparator|Placebo|
2859404|NCT03532750|No Intervention|Control|This arm will undergo no study procedures and continue with best medical management. This entails managing pain and draining excess fluid.
2859405|NCT03532750|Experimental|Particle|Randomized to receive either the Embozene or Embosphere particles
2859406|NCT03532750|Experimental|Coil|Randomized to receive either Ruby or Interlock detachable coils
2859407|NCT03532737|Experimental|Investigational Arm|"All patients will receive radical chemoradiation in addition to the investigational concomitant check point inhibitor CHEMOTHERAPY: Cisplatin: 100 mg/m2 Q21d D1, D22, D43. OR Cetuximab Loading dose 400 mg/m², one week before radiation then maintenance dose 250 mg/m² weekly, D8, D15, D22, D29, D36, D43.~PD-1 inhibitor: Pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks 14 days prior to radiation, then Day 1 of radiation and then every 21 days for total 6 doses~Intensity modulated radiotherapy (IMRT) techniques will be used. A total dose of 66-70 Gy/ 30-35 Fr over 6-7 weeks will be delivered to the primary site and draining lymphatics using simultaneous Integrated Boost (SIB)."
2859408|NCT03532711||Chemotherapy|FOLFOX/XELOX/FOLFIRI
2859409|NCT03532698|Experimental|osimertinib and aspirin|Osimertinib and Aspirin starting at a dose of 80 mg and 100mg once a day, orally with meals. Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
2859410|NCT03532685|Active Comparator|Severe Asthma Obese Patients Surgery|Bariatric surgery
2859411|NCT03532685|No Intervention|Severe Asthma Obese Patients|usual care
2859412|NCT03532685|No Intervention|Severe Obese Patients|usual care
2859413|NCT03532672|Experimental|Acute Fasting|Eutrophic and obese women will fast 10 hours during daily activities after a standardized breakfast.
2859444|NCT03532464|Active Comparator|Patients treated by azithromycin|"The patients in the azithromycin group take 4 tablets of 250 mg in the morning as a single dose.~Antibiotics will be dispensed in their usual packaging with a clinical trial label."
2859445|NCT03532451|Experimental|Cohort 1: Nivolumab|Nivolumab 480 mg IV on week 0 and week 4
2877531|NCT03406806|Experimental|GaitBox|
2859414|NCT03532659|Experimental|Active video game|The adolescents will be submitted to physical activity with active video game for 50 minutes, 3 times a week, for a period of eight weeks. The XBOX360® platform will be used with the Kinect accessory (Microsoft®) and Just Dance will be the selected game. The music used for intervention will be previously selected, including those that can lead to moderate intensity, and assembled in blocks of 10. For each week, a new block and challenges must be elaborated to increase the motivation to carry out the physical activity.
2859415|NCT03532659|No Intervention|control|A follow-up will be done for eight weeks to compare the variables. The adolescents in this group will be interviewed monthly to detect changes in eating habits and lifestyle.
2859416|NCT03532646|Other|group 1: RYGB|All patients who underwent RYGB and were readmitted to upper endoscopy are getting observed
2859417|NCT03532646|Other|group 2:MGB/OAGB|All patients who underwent MGB/OAGB and were readmitted to upper endoscopy are getting observed
2859418|NCT03532633||23-27w|preterm infants 23+0-27+6SSW
2859419|NCT03532633||28-31w|preterm infants 28+0-31+6SSW
2859420|NCT03532633||32-34w|preterm infants 32+0 - 34+6SSW
2859421|NCT03532633||35-36w|preterm infants 35+0-36+6 SSW
2859422|NCT03532633||37-42w|term infants 37+0-42+6
2859423|NCT03532620|Experimental|pitavastatin|Pitavastatin Calcium + lifestyle modification
2859424|NCT03532620|Active Comparator|atorvastatin|Atorvastatin Calcium + lifestyle modification
2859425|NCT03532607|Experimental|Treatment|Participants will be asked to listen to pre-recorded music offered by the research team from an ipod for 30 minutes. After the 30 minutes have elapsed, the research staff will return and ask the patient to turn off the music. The patient then will be escorted to the clinic room to receive the botox injection.
2859426|NCT03532607|No Intervention|Control|After completing the consent form, the participants who are assigned to the control group will be asked to remain in the patient waiting area. The patient then will be escorted to the clinic room to receive the botox injection.
2859427|NCT03532594|Other|Standard Care|At the conclusion of cardiopulmonary bypass, protamine administration will be undertaken at surgical request. For patients in the control group, protamine will be dosed on a 1:1 ratio according to the total dose of heparin initially required to establish a therapeutic activated clotting time (ACT) (i.e. if 30,000 IU were required prior to initiating cardiopulmonary bypass, then the protamine dose will be 300mg).
2859428|NCT03532594|Experimental|Algorithm|For patients in the intervention group, protamine will be administered according to the PRODOSE algorithm, which has been incorporated into an Excel spread sheet for ease of use (Microsoft Corporation).
2859429|NCT03532581|Experimental|Treatment (ICG lymphangiography)|Participants receive indocyanine green solution SC and undergo near-infrared imaging over 1-2 minutes during their standard of care neck surgery.
2859430|NCT03532568|Experimental|CKD-aP patients|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue and their response to narrow band ultraviolet B
2859431|NCT03532568|Experimental|CKD patients without pruritis|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue
2859432|NCT03532568|Experimental|normal healthy participants|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue
2859433|NCT03532555|Active Comparator|Zinc plus standard of care|Infants will receive daily doses of zinc at 2mg/kg from enrollment through 35 6/7 weeks corrected gestational age.
2859434|NCT03532555|Placebo Comparator|Standard of care only|Infants will not receive any doses of zinc through 35 6/7 weeks corrected gestational age
2859435|NCT03532542|Experimental|Casimersen|Patients amenable to exon 45 skipping who have been participating in a clinical trial evaluating casimersen will receive open-label casimersen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks. In the previous clinical trials patients may have been receiving casimersen or matching placebo.
2859436|NCT03532542|Experimental|Golodirsen|Patients amenable to exon 53 skipping who have been participating in a clinical trial evaluating golodirsen will receive open-label golodirsen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks. In the previous clinical trials patients may have been receiving golodirsen or matching placebo.
2859437|NCT03532529||experiencing the composit outcome|"Average values of LV longitudinal strain^ (Midesophageal 4 chamber view) in patients who developed the composite outcome including the following outcomes of interest:~death within 30 days from VA ECMO liberation~the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation~o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal~heart transplantation within 30 days from VA ECMO liberation"
2859438|NCT03532529||not experiencing the composit outcome|"Average values of LV longitudinal strain^ (Midesophageal 4 chamber view) in patients who did not develop the composite outcome including the following outcomes of interest:~death within 30 days from VA ECMO liberation~the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation~o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal~heart transplantation within 30 days from VA ECMO liberation"
2859439|NCT03532503|Active Comparator|Foley catheter filled with 30 ml|The transcervical placement of the foley catheter will be performed and it will be filled with 30 ml saline. A gentle traction will be applied.
2859440|NCT03532503|Active Comparator|Foley catheter filled with 50 ml|The transcervical placement of the foley catheter will be performed and it will be filled with 50 ml saline. A gentle traction will be applied.
2859441|NCT03532490|Active Comparator|Roflumilast 500 mcg oral tablet|500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.
2859442|NCT03532490|Placebo Comparator|Placebo oral tablet|500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.
2859443|NCT03532464|Experimental|Patient treated by doxycycline|"The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.~Antibiotics will be dispensed in their usual packaging with a clinical trial label."
2861566|NCT03517904|Experimental|IVUS-guided group|Intravascular ultrasound-guided intervention group
2859448|NCT03532425|Experimental|B/F/TAF|"B/F/TAF + Atripla Placebo~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks"
2859449|NCT03532425|Active Comparator|Atripla|"Atripla + B/F/TAF Placebo~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks"
2859450|NCT03532412||HF+CSA+PB|Systolic heart failure with predominant central sleep apnea and periodic breathing
2859451|NCT03532399||Pediatric Cardiac Catheterization|
2859452|NCT03532399||Pediatric Cardiac Surgery|
2859453|NCT03532399||Pediatric Extracorporeal Life Support (ECLS)|
2859454|NCT03532386||Study group|Infertile men with oligoasthenospermia with non-tense vaginal hydrocele subjected to ICSI
2859455|NCT03532386||Control group|infertile men with oligoasthenospermia without hydrocele subjected to ICSI
2859456|NCT03532373|No Intervention|Control|None- normal care
2859457|NCT03532373|Experimental|Intervention|Patients will use a preference elicitation tool to determine their preferences for diagnosis and treatment of CTS
2859458|NCT03532360|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
2859459|NCT03532360|Active Comparator|Low-dose|Following randomization, participants in this group will receive escalating doses of the appropriate allergen, up to a dose of 30 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
2859460|NCT03532360|Active Comparator|High-dose|Following randomization, participants in this group will receive escalating doses of the appropriate allergen, up to a dose of 300 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
2859461|NCT03532347|Active Comparator|EUS FNA|Participants will be randomised to an initial 3 passes with Beacon FNA then cross over onto other arm or vice versa. 25g needles will be used for trans duodenal puncture and 22g for trans gastric puncture.
2859462|NCT03532347|Active Comparator|EUS FNB|Participants will be randomised to an initial 3 passes Beacon SharkCore biopsy needles then cross over onto other arm or vice versa. 25g needles will be used for trans duodenal puncture and 22g for trans gastric puncture.
2859463|NCT03532321||Caregivers|Caregivers in the participating hospital departments : medical (doctors, midwives) and paramedical (nurses' aides, registered nurses, specialized nurses and head nurses) staff, working in hospital departments drawn at random among five volunteer hospital centers in Paris, and who will be present at the time of investigator's passage, at a date drawn at random during the inclusion phase.
2859464|NCT03532308|Experimental|Intervention|Daily Fermented Soy (two 12.5g packets/day) (~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
2859465|NCT03532308|Placebo Comparator|Placebo|Daily (matched dose) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
2859466|NCT03532295|Experimental|Safety Run-In|"Epacadostat is an oral medication that will be taken twice a day every day without regard to food during each 21-day cycle~Avelumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle~Bevacizumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle~10 fractions of radiation therapy will be given at a dose of 3.5 Gy per fraction~Dosing of epacadostat will start on the first day of radiation therapy. Avelumab and bevacizumab may be started up to a week before the first day of radiation therapy but must be given no later than the first day of radiation therapy. The first cycle of treatment may be more than 28 days depending on when treatment with avelumab and bevacizumab starts. Cycle 2 will start after the participant has received 28 days of treatment with epacadostat"
2859467|NCT03532295|Experimental|Phase II Cohort A (bevacizumab-naïve patients)|"Epacadostat is an oral medication that will be taken twice a day every day without regard to food during each 21-day cycle~Avelumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle~Bevacizumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle~10 fractions of radiation therapy will be given at a dose of 3.5 Gy per fraction~Dosing of epacadostat will start on the first day of radiation therapy. Avelumab and bevacizumab may be started up to a week before the first day of radiation therapy but must be given no later than the first day of radiation therapy. The first cycle of treatment may be more than 28 days depending on when treatment with avelumab and bevacizumab starts. Cycle 2 will start after the participant has received 28 days of treatment with epacadostat"
2859468|NCT03532295|Experimental|Phase II Cohort B (bevacizumab-refractory patients)|"Epacadostat is an oral medication that will be taken twice a day every day without regard to food during each 21-day cycle~Avelumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle~Bevacizumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle~10 fractions of radiation therapy will be given at a dose of 3.5 Gy per fraction~Dosing of epacadostat will start on the first day of radiation therapy. Avelumab and bevacizumab may be started up to a week before the first day of radiation therapy but must be given no later than the first day of radiation therapy. The first cycle of treatment may be more than 28 days depending on when treatment with avelumab and bevacizumab starts. Cycle 2 will start after the participant has received 28 days of treatment with epacadostat"
2859469|NCT03532282|Active Comparator|ONLINE ONLY|
2859470|NCT03532282|Experimental|STEPPED CARE|
2859471|NCT03532269|Experimental|A: 3rd night with acoustic stimulation|Arm A: PSG (3 nights) with Nightly App - acoustic stimulation during the 3rd night.
2859472|NCT03532269|Experimental|B: 2nd night with acoustic stimulation|Arm B: PSG (3 nights) with Nightly App - acoustic stimulation during the 2nd night.
2859538|NCT03531801||Control group|This group will receive the same intervention than the recovered fracture group
2877532|NCT03406806|Active Comparator|Sprint System device|
2859473|NCT03532256||Surgical Patients|This observational study includes adult patients (age ≥18) undergoing elective surgical procedures within the departments of orthopedics, sports medicine, and neurosurgery, as well as patients undergoing procedures in general surgery and the ED who own a mobile phone and can receive SMS text messaging at the University of Pennsylvania or Penn Presbyterian Medical Center.
2859474|NCT03532243|Experimental|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the threshold loading device with incremental inspiratory load.
2859475|NCT03532243|Experimental|normal respiratory muscle|Patients with normal respiratory muscle are performing the threshold loading device with incremental inspiratory load.
2859476|NCT03532230||Experimental Group|90 new patients seeking treatment for chronic low back pain. This group will receive standard care plus osteopathic manipulative treatment (OMT) for low back pain.
2859477|NCT03532230||Control Group|90 new patients seeking treatment for chronic low back pain. This group will receive only standard care without osteopathic manipulative treatment (OMT) for low back pain.
2859478|NCT03532217|Experimental|PROSTVAC/Ipilimumab/Nivolumab/Neoantigen DNA vaccine|"Within 60 days after the last dose of standard of care docetaxel, patients will start a priming dose of PROSTVAC-V as a single agent, and subsequent doses of PROSTVAC- F in combination with ipilimumab (1mg/kg every 3 weeks for 2 doses), and nivolumab (3 mg/kg every 3 weeks for 6 doses), taking a total of approximately 17 weeks to complete. This is called Treatment A.~Patients will then receive a neoantigen DNA vaccine with continuous nivolumab treatment. The vaccine will be administered by intramuscular injection for a total of 6 treatments every 28 days +/-7 days with at least 21 days between injection days. Each DNA vaccination will be 4 mg vaccine administered intramuscularly using a TriGrid electroporation device. Patients will receive nivolumab at 480 mg every 28 days concurrently with neoantigen DNA vaccine. This is called Treatment B."
2859479|NCT03532204|Experimental|Chemotherapy + SBRT|"Patients will received 2 courses of chemotherapy before SBRT if no hepatic or extra-hepatic progression identified.~All liver metastases will be irradiated. 4 doses prescription are allowed (according to the center, and the technique uded and the dosimetric constraints): 3x15 Gy, 4 x 15 Gy, 5 x10 Gy or 5 x 8 Gy.~The remaining courses of chemotherapy 2 to 3 weeks after completion of SBRT will be administered"
2859480|NCT03532204|No Intervention|Chemotherapy|patients will receive chemotherapy as initially scheduled
2859481|NCT03532191|Experimental|PrEP-OI Intervention|All clinics that have crossed over to initiate the intervention at this time. The order of crossover is determined at random.
2859482|NCT03532191|No Intervention|Control until randomized for intervention|All clinics that have not yet initiated the intervention at this time (i.e., control clinics). Each clinic will cross over to receive the intervention one-by-one every two months, with the order of clinic crossover determined at random.
2859483|NCT03532178|Experimental|Group A|rocuronium + sugammadex / succinylcholine + normal saline
2859484|NCT03532178|Experimental|Group B|succinylcholine + normal saline / rocuronium + sugammadex
2859485|NCT03532165|Other|Positive lower extremity ultrasound|This group found to to have a deep venous thrombosis on lower extremity ultrasound will not have a CT of the chest ordered from the emergency department, and will be treated for the DVT and presumed PE.
2859486|NCT03532165|Other|Negative lower extremity ultrasound|This group that does not have a deep venous thrombosis on lower extremity ultrasound will proceed to get the CT of the chest .
2859487|NCT03532152|Active Comparator|Pure Purr VR technology|"The arm will use the virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen.~The total length of the audio-video sequence is 6 minutes 11 seconds, of which 1 minute 11 seconds is the Pure Purr promotional video, and the duration of the investigational audio-visual sequence itself is 5 minutes."
2859488|NCT03532152|Sham Comparator|Sham VR technology|"The arm will use the headset with audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.~The total length of the audio-video sequence is 6 minutes 11 seconds, of which 1 minute 11 seconds is the Pure Purr promotional video, and the duration of the investigational audio-visual sequence itself is 5 minutes."
2859489|NCT03532139|Experimental|Enoxaparin|-Enoxaparin is administered subcutaneous daily
2859490|NCT03532139|Experimental|Enoxaparin + Rosuvastatin|"Enoxaparin is administered subcutaneous daily.~Rosuvastatin is administered daily orally starting on day 15"
2859491|NCT03532139|Experimental|Thromboprophylaxis|-Thromboprophylaxis is administered per clinician discretion
2859492|NCT03532126||Dermal filler for midface deficit|There will be one group in this study, the actual treatment group.
2859493|NCT03532113|Experimental|Updating|The Updating intervention aims to improve the ability to monitor and quickly add or delete of content of working memory.
2859494|NCT03532113|Experimental|Inhibition|The Inhibition intervention aims to improve the ability to supersede responses that are prepotent or automatic for a given situation.
2859495|NCT03532113|Active Comparator|General Knowledge|The General knowledge intervention allows the learning of information on various topics. It does not involve attentional control but semantic knowledge.
2859496|NCT03532100|Experimental|Straight line walking|All participants will walk in a straight line while wearing the study prosthesis.
2859497|NCT03532100|Experimental|Circle walking with prosthesis inside|All participants will walk around a 1-meter radius circle with their prosthesis on the inside of the circle.
2859498|NCT03532100|Experimental|Circle walking with prosthesis outside|All participants will walk around a 1-meter radius circle with their prosthesis on the outside of the circle.
2859499|NCT03532087|No Intervention|No denosumab|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are not additionally treated with denosumab.
2859500|NCT03532087|Experimental|Denosumab 120 mg|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are additionally treated with denosumab 120 mg every 3 weeks. First denosumab gift is before surgery, last denosumab gift is together with the last cycle of chemotherapy.
2859501|NCT03532087|Experimental|Denosumab 60 mg|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are additionally treated with denosumab 60 mg every 6 months. First denosumab gift is before surgery, last denosumab gift is together with the last cycle of chemotherapy.
2859502|NCT03532074|Other|laparoscopic approach|assessment of bowel symptoms before surgery; assessment of rectosigmoid perfusion using indocyanine green; removal of rectosigmoid endometriosis nodule using a laparoscopic approach; follow up and assessment of bowel symptoms after surgery
2859503|NCT03532074|Other|robot-assisted approach|assessment of bowel symptoms before surgery; assessment of rectosigmoid perfusion using indocyanine green; removal of rectosigmoid endometriosis nodule using a robot-assisted approach; follow up and assessment of bowel symptoms after surgery
2859504|NCT03532061|Experimental|FamCare Group|Family caregivers who receive 6 in-person problem-solving skills training sessions (FamCare Program).
2859505|NCT03532061|Active Comparator|Caregiver Support Group|Family caregivers who receive 6 in-person caregiver support group sessions.
2859506|NCT03532048|Experimental|Intervention Group|The Papás Saludables, Niños Saludables Program
2859507|NCT03532048|Other|Wait-list Control|The Papás Saludables, Niños Saludables Wait-list Control
2859508|NCT03532035|Experimental|Brincidofovir (BCV)|"Cohort 1: BCV 10 mg twice weekly via IV infusion over 2 hours~Cohort 2: BCV 15 mg twice weekly via IV infusion over 2 hours~Cohort 3: BCV In Cohort 3, the actual dose may be higher or lower than doses administered in previous cohorts; the maximum dose of IV BCV will be ≤ 25 mg."
2859509|NCT03532035|Active Comparator|Standard of Care (SoC)|"Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV Cidofovir (CDV), ganciclovir, or ribavirin."
2859510|NCT03532022|Experimental|Chronocort|Hydrocortisone modified release capsules - Chronocort®. 66 subjects will be randomised to this group using an interactive web response system (IWRS).
2859511|NCT03532022|Active Comparator|Standard Care|Subjects participating in this arm will continue to receive their normal, standard care (hydrocortisone, dexamethasone, prednisone, prednisolone) once enrolled on the study. 66 subjects will be randomised to this arm using an interactive web response system (IWRS).
2859512|NCT03532009|Experimental|Sodium Zirconium Cyclosilicate (ZS)|Powder for oral suspension
2859513|NCT03532009|Placebo Comparator|Placebo|Powder for oral suspension
2859514|NCT03531970|Experimental|Dexamethasone|lidocaine & Dexamethasone
2859515|NCT03531970|Placebo Comparator|Non-dexamethasone|lidocaine & Placebo
2859516|NCT03531957|Experimental|ASN002 40 mg|40 mg ASN002
2859517|NCT03531957|Experimental|ASN002 60 mg|60 mg ASN002
2859518|NCT03531957|Experimental|ASN002 80 mg|80 mg ASN002
2859519|NCT03531957|Experimental|Placebo Oral Tablet|Matching placebo for ASN002 doses
2859520|NCT03531944|Experimental|Community pharmacist-involved care|Community pharmacist-involved collaborative care in the management of type 2 diabetes mellitus
2859521|NCT03531944|Placebo Comparator|Usual care|Usual care with physician and as needed referral to nurses
2859522|NCT03531918|Experimental|Treatment (GO, GCLAM)|"INDUCTION THERAPY: Participants receive gemtuzumab ozogamicin IV either as a single dose on day 1, or as three doses on days 1, 4, and 7. Participants also receive G-CSF SC on days 0-5, cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, and mitoxantrone hydrochloride IV on days 1-3. Patients who do not achieve a CR or CRi following the first course of induction are eligible for a second course, which is given without gemtuzumab ozogamicin. Participants with a CR or CRi may then proceed to Post-Remission Therapy.~POST-REMISSION THERAPY: Participants receive G-CSF, cladribine, and cytarabine as in Induction Therapy during course 1, and cytarabine IV every 12 hours on days 1-6 of courses 2-3. Treatment repeats every month for up to 3 courses in the absence of disease progression or unacceptable toxicity."
2859523|NCT03531905|Experimental|Bempedoic acid + Ezetimibe FDC|Bempedoic acid + Ezetimibe FDC Oral Tablet; Placebo oral capsule
2859524|NCT03531905|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10Mg Oral Tablet; Placebo Oral Tablet
2859525|NCT03531905|Placebo Comparator|Placebo|Placebo Oral Tablet, Placebo oral capsul
2859526|NCT03531892|Experimental|AJM300 960mg/dose|Participants will orally receive AJM300 960 mg tablets, three times daily after meals for 8 weeks.
2859527|NCT03531892|Placebo Comparator|Placebo|Participants will orally receive AJM300 placebo-matching tablets, three times daily after meals for 8 weeks.
2859528|NCT03531879||subject with plaques and without plaques|Subject with plaques and without plaques
2859529|NCT03531866|Experimental|Intervention Version A|Youth will be asked to complete a version of DigiKnowIt News that includes investigations, comics, and spotlight videos that focus on four topic areas related to participating in clincial trials. Version A will include an additional topic area.
2859530|NCT03531866|Experimental|Intervention Version B|Youth will be asked to complete a version of DigiKnowIt News that includes investigations, comics, and spotlight videos that focus on four topic areas related to participating in clincial trials. Version B will include an additional topic area (different than in Version A).
2859531|NCT03531866|No Intervention|Wait-List Control|Youth will not have access to DigiKnowIt News until after the post-test timepoint.
2859532|NCT03531853|Experimental|Imaging patients|Get uveitis patients and ER patients to image their eyes
2859533|NCT03531840|Experimental|1/Olaparib|Twice daily oral olaparib
2859534|NCT03531827|Experimental|1/Lead-In Safety|Combination treatment of increasing dose of CRLX101 with enzalutamide
2859535|NCT03531827|Experimental|2/Efficacy|Tolerable dose of CRLX101 in combination with enzalutamide (8 patients, expandable to 21 total patients)
2859536|NCT03531814|Experimental|1/Intervention|Questionnaires and use of the medication event monitoring system (MEMS)
2859537|NCT03531801||Recovered fracture group|The interventions will be conducted on both groups, on two experimental (approximately 45 minutes per session) sessions separated by 24 hours.Pressure algometry consists of measuring pressure pain thresholds at three bilateral muscle sites.Mapping referred pain areas consists of recording on an electronic body chart the area of pain induced by 60s pressure stimulation at 1.2 times the force needed to reach the pressure pain threshold, exerted on the extensor carpi radialis and the infraspinatus muscles.As group-differences can be attenuated at baseline but emerge on a sensitized (exercise-induced soreness) state, these procedures are performed at baseline and 24 hours after evoking exercise-induced muscle soreness. For further clarification see our recent publication PMID:29608510
2859539|NCT03531788|Experimental|Armon Ayura|Participants will trial the Armon Ayura dynamic arm support.
2859540|NCT03531788|Experimental|JAECO WREX|Participants will trial the JAECO Wilmington Robotic EXoskeleton (WREX) dynamic arm support.
2859541|NCT03531775|Other|Upright MRI|All participants will be scanned using an upright MRI in seated/standing position and supine position. They will also be scanned supine using a conventional MRI.
2859542|NCT03531762|Experimental|Sequence 1: Treatment A-B-C|Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib in fed state with omeprazole (Treatment C). Treatment periods will be separated by washout period of at least 14 days.
2859543|NCT03531762|Experimental|Sequence 2: Treatment A-C-B|Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib in fasted state with omeprazole (Treatment B). Treatment periods will be separated by washout period of at least 14 days.
2859544|NCT03531762|Experimental|Sequence 3: Treatment B-A-C|Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fed state with omeprazole (Treatment C). Treatment periods will be separated by washout period of at least 14 days.
2859545|NCT03531762|Experimental|Sequence 4: Treatment B-C-A|Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib alone in fed state (Treatment A). Treatment periods will be separated by washout period of at least 14 days between.
2859546|NCT03531762|Experimental|Sequence 5: Treatment C-A-B|Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fasted state with omeprazole (Treatment B). Treatment periods will be separated by washout period of at least 14 days.
2859547|NCT03531762|Experimental|Sequence 6: Treatment C-B-A|Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib alone in fed state (Treatment A). Treatment periods will be separated by washout period of at least 14 days.
2859548|NCT03531749|Experimental|HIV+ MRPJ|Supplementation with microencapsulated (1g/d) for 90 days
2859549|NCT03531749|Experimental|HIV+ ascorbic acid|Supplementation with ascorbic acid (1g/d) for 90 days
2859550|NCT03531749|Experimental|HIV- MRPJ|Supplementation with microencapsulated (1g/d) for 90 days
2859551|NCT03531749|Experimental|HIV- ascorbic acid|Supplementation with ascorbic acid (1g/d) for 90
2859552|NCT03531749|No Intervention|HIV- Control|Unsupplemented
2859553|NCT03531749|No Intervention|HIV+ Control|Unsupplemented
2859554|NCT03531736|Experimental|Patients with Myeloid Malignancies & Aplastic Anemia|Transplant conditioning will consist of: ATG (2 mg/kg/day IV on days-9 and -7), fludarabine (30 mg/m^2/d on days -5 through -2), TBI 400 cGy (day -1) and high dose cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4). One dose of Rituxan (200 mg/m^2) will be given to reduce the risk of EBV viremia. The donor stem cell product will be derived from the peripheral blood with a target cell infusion of ≥8X10^6 CD34 cells per recipient kg. Patients will receive post-transplant G-CSF starting on day +7. Patients will undergo donor/recipient bone marrow and peripheral chimerism studies at 30, 100 and 180 days, and 12, 18 and 24 months post allo HCT and thereafter, at the discretion of the treating clinician. Immune function and disease restaging will be performed at day 100 and 6, 9, 12, 18, and 24 months and as otherwise clinically indicated by the treating physician.
2859555|NCT03531710|Experimental|3 boosters|Subjects will receive 3 doses of UB-311 and 2 doses of placebo.
2859556|NCT03531710|Experimental|3 priming doses followed by 2 boosters|Subjects will receive 5 doses of UB-311.
2859557|NCT03531697|Experimental|Generic Loteprednol Etabonate - RLD|Period 1: Generic Loteprednol Etabonate - Period 2 (Cross-Over): Reference Listed Drug (RLD)
2859558|NCT03531697|Active Comparator|RLD - Generic Loteprednol Etabonate|Period 1: Reference Listed Drug (RLD) - Period 2 (Cross-Over): Generic Loteprednol Etabonate
2859559|NCT03531684|Experimental|MMFS-205-SR|Oral MMFS-205-SR twice daily (2,000, 3,000, or 4,000 mg/day total, depending on lean body mass and response to initial dose at Week 12) for 24 weeks
2859560|NCT03531684|Placebo Comparator|Placebo|Oral inactive placebo twice daily for 24 weeks
2859561|NCT03531671|Experimental|Presence of age related cataract|Binocular-OCT used to assess the eye pre and post-operatively.
2859562|NCT03531645|Experimental|Fulvestrant + Palbociclib|
2859563|NCT03531632|Experimental|MGD007 + MGA012|MGD007 is a gpA33 x CD3 bi-specific DART antibody; MGA012 is an anti-PD-1 monoclonal antibody.
2859564|NCT03531619||Dizziness|Patients referred to a neuro-otological clinic due to dizziness who answer that they do not suffer from neck pain
2859565|NCT03531619||Dizziness and neck pain|Patients referred to a neuro-otological clinic due to dizziness who answer that they suffer from neck pain
2859566|NCT03531619||Neck pain|Patients referred to a rehabilitation center due to neck pain who answer that they do not suffer from dizziness
2859567|NCT03531619||Neck pain and dizziness|Patients referred to a rehabilitation center due to neck pain who answer that the suffer from dizziness
2859568|NCT03531619||Healthy Control|Healthy Controls without neck pain or dizziness
2859569|NCT03531606|Experimental|Experimental|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
2859570|NCT03531606|Placebo Comparator|Placebo comparator|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into placebo comparator group will take one pack of 'Placebo' which is composed of lactose and simulates a 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
2859571|NCT03531593||US Elastography|All subjects will undergo one ultrasound elastography examination after consent.
2859572|NCT03531580|Experimental|Healthy volunteers|six healthy volunteers: 3 male (age 20-40; 40-60 and 60+) and 3 female (age 20-40; 40-60 and 60+)
2859655|NCT03530969|Active Comparator|Participants with GI/GU/Lymphoma Cancer|Patients of the physicians in group 1
2859573|NCT03531567|Experimental|Virtual Reality Mystic Isle Game|"Subjects in the treatment arm will complete a prescribed 2-month treatment using the virtual reality program Mystic Isle. The OT will follow the Treatment Arm Intervention Protocol, which provides standardized guidelines for grading the intensity, level of challenge, and types of games/activities of the intervention up or down. The OT will complete weekly phone calls with participant to discuss progress, answer any questions, and remotely make updates to the game as necessary. The total time on active treatment for a subject is 8 weeks. The maximum amount of time spent on the intervention will be 7 hours/week. The minimum amount of time spent on the intervention will be 3.5 hours/week."
2859574|NCT03531567|Active Comparator|Standard Home Exercise Program|"Subjects assigned to the control arm will complete the prescribed 2-month treatment. The OT will follow the Control Arm Intervention Protocol to design and prescribe the home exercise program. The OT will complete weekly phone calls with the participant to check on progress, adherence, and update the exercises as necessary. The total time on active treatment for a subject is 8 weeks. The maximum amount of time spent on the control intervention will be 7 hours/week. The minimum amount of time spent on the control intervention will be 3.5 hours/week."
2859575|NCT03531554|Experimental|ketone ester drink|Oral intake of ketone ester drink muscle biopsy exercise muscle biopsy Magnetic Resonance imaging
2859576|NCT03531554|Placebo Comparator|carbohydrate drink|Oral intake of isocaloric carbohydrate drinkmuscle biopsy exercise muscle biopsy Magnetic Resonance imaging
2859577|NCT03531541|Active Comparator|active TENS and CJM|"The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes.~After application of TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation to the tissue barrier to perform a high-velocity low-amplitude manipulation (thrust)."
2859578|NCT03531541|Placebo Comparator|placebos TENS and CJM|"The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value.~Placebo CJM will be performed using an identical position to the active manipulation, however, for only 15 seconds, as proposed by some authors that have used placebo group in their studies[42-44]. The examiner shall not exert tension in the joint capsule of the segment to ensure the placebo effect"
2859579|NCT03531541|Active Comparator|placebo TENS and active CJM|"The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value.~After application of placebo TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation."
2859580|NCT03531541|Active Comparator|active TENS and placebo CJM|"The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes.~After application of placebo TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation."
2859581|NCT03531528|Experimental|Experimental|A 4-week protein-sparing, very low-calorie, ketogenic diet and a subsequent 6-week hypocaloric, low glycemic index, Mediterranean-like diet
2859582|NCT03531502|Active Comparator|Standard medical therapy|Patients who have a positive NIPS study and are randomized to the medical therapy arm will either be initiated on antiarrhythmic therapy or will have their antiarrhythmic therapy intensified. All medication therapy is considered usual standard therapy.
2859583|NCT03531502|Experimental|Ventricular Tachycardia Ablation|Patients who have a positive NIPS study and are randomized to the ablation arm will undergo ventricular tachycardia ablation procedure guided by CardioInsight.
2859584|NCT03531502|Other|Negative NIPS/Non-intervention|Patients who had a negative NIPS study will not be assigned to a treatment group and will be followed according to standard of care.
2859585|NCT03531489|Experimental|Part 1: Feasibility|Patients will perform 6-minute walk test with AIR-AD to allow for observation and real-time feedback.
2859586|NCT03531489|Experimental|Part 2: Crossover|Crossover design where investigator will compare wearing of AIR-AD during exercise to compare distance walked with and without it.
2859587|NCT03531476|Experimental|Online chronic pain management program|There is only one arm. Those who consent to participate in the study and take the online self-directed chronic pain management program with therapist support.
2859588|NCT03531463|Active Comparator|Operative treatment|"Operative treatment of the displaced proximal humeral fracture with a reversed total shoulder prothesis (Delta prosthesis) using a stadardized deltopectoral approach, bone block grafting and thread cerclages of the tubercles.~Rehabilitation with standardized physiotherapy guideline and self exercise protocol"
2859589|NCT03531463|No Intervention|Non-Operative treatment|Rehabilitation with standardized physiotherapy guideline and self exercise protocol
2859590|NCT03531450|Experimental|Cognitive Behavioral Therapy|Patients in the cognitive behavioral therapy group will be asked to undergo a 8-week CBT trial. An online videoconferencing link will be used to deliver CBT virtual sessions that will be approximately 60 minutes in length. Each session will be conducted by a clinical psychology doctoral student, supervised by a licensed psychologist. Patients will also undergo careful phenotyping pre- and post intervention with brain MRI, AFT, WMC, and NDT.
2859591|NCT03531450|No Intervention|Standard Medical Treatment|Patients in the standard medical treatment group will not interact with any therapists and will not receive any education beyond typical clinical exposure. They will be treated by the standard of care.
2859592|NCT03531437|Active Comparator|Zoely|Monophasic combined oral contraceptive pills 24 white active tablets and 4 yellow inactive tablets each active tablet contains 1.5 mg estradiol and 2.5 mg nomegestrol acetate 3 cycles
2859593|NCT03531437|Active Comparator|Minidoz|Monophasic combined oral contraceptive pills 24 active tablets and 4 inactive tablets each active tablet contains ethinylestradiol 15 µg and gestodene 60 µg 3 cycles
2859594|NCT03531424|Active Comparator|Angiographic guided PCI|Angiographic guided PCI is coronary revascularization based on stand-alone angiography.
2859595|NCT03531424|Experimental|CTA guided PCI|CTA guided PCI is coronary revascularization based on systematic use of CTA plus coronary angiography.
2859596|NCT03531398|Experimental|High fat meal|Muffin containing 30g fat
2859597|NCT03531398|Experimental|Medium fat meal|Muffin containing 20g fat
2859598|NCT03531385||Behcet|Patients diagnosed with Behcet disease
2859599|NCT03531385||Healthy controls|Individuals without any chronic disease
2859600|NCT03531372|Experimental|Mipolixin®|Mipolixin® (Advanced Natural Antacid - AdNA)
2859601|NCT03531372|Active Comparator|Poliprotect®|Poliprotect® (Neobianacid)
2859602|NCT03531359|Experimental|TIBD Tablet-based video distraction|Children will receive of tablet-based interctive games in preoperatory room
2859603|NCT03531359|Active Comparator|Midazolam|Children will be premedicated with usual treatmente (midazolam)
2859604|NCT03531346|Experimental|Hyperosmolarity group|Healthy, young, habitual contact lens wearers with initial increased tear osmolarity (hyperosmolarity)
2859605|NCT03531346|Experimental|Normal osmolarity|Healthy, young, habitual contact lens wearers with initial tear osmolarity reported as normal
2859606|NCT03531333|Experimental|Ultrasound|ultrasound navigation guided surgery.
2859607|NCT03531333|No Intervention|Non-ultrasound|standard surgery without ultrasound guidance.
2859608|NCT03531320|Experimental|Part 1:Dose-Escalation Phase|40 mg D07001-softgel capsules 60 mg D07001-softgel capsules 80 mg D07001-softgel capsules 120 mg D07001-softgel capsules 160 mg D07001-softgel capsules
2859609|NCT03531320|Experimental|Part 2: Dose-Expansion Phase (Phase 2)|higher dose-expansion of D07001-softgel capsules lower dose-expansion of D07001-softgel capsules
2859610|NCT03531307||Lactate and Ki 67 levels|Neurosurgical patients between June 2017 and February 2018 for tumoral and non-tumoral craniectomy with lactate levels at the beginning of surgery and Ki-67 index in biopsies.
2859611|NCT03531294|Experimental|Group 1|Treatment based on central reading center reading evaluation of DRSS (diabetic retinopathy severity scale) level based on OPTOS funds photos.
2859612|NCT03531294|Experimental|Group 2|Treatment based on central reading center reading evaluation of DRSS (diabetic retinopathy severity scale) level based leakage index of OPTOS wide field fluorescein angiography.
2859613|NCT03531281|Experimental|Arm I (goat milk, transplant conditioning/prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell infusion on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
2859614|NCT03531281|Active Comparator|Arm II (transplant conditioning/prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell infusion on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
2859615|NCT03531268|Active Comparator|PGx testing has clinical utility|These are subjects whose PGx testing is judged to have clinical utility and whose clinical care may be modified. Modifications may include altering doses or types of drugs given based on metabolic profile of the patient.
2859616|NCT03531268|No Intervention|PGx testing has no clinical utility|"These are subjects whose PGx testing is judged to have no clinical utility. Care as usual is provided, and there are no changes in drug selection or dosing based on the results of PGx testing."
2859617|NCT03531255|Experimental|APL-2 1,080mg twice weekly|1,080mg APL-2 will be administered subcutaneously twice weekly.
2859618|NCT03531255|Experimental|APL-2 1,080mg every three days|1,080mg APL-2 will be administered subcutaneously every three days.
2859619|NCT03531255|Experimental|APL-2 1,080mg twice weekly or every three days|1,080mg APL-2 will be administered subcutaneously twice weekly or 1,080mg APL-2 will be administered subcutaneously every three days.
2859620|NCT03531242|Experimental|Cohort A: Initial Non-responders to VEE TC-83 vaccinations|Venezuelan Equine Encephalomyelitis (VEE) Vaccine, Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1, to be administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area.
2859621|NCT03531242|Experimental|Cohort B: Responders to TC-83 or previous C-84 vaccinations|"Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.~Subjects who were initial non-responders (< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63"
2859622|NCT03531229|Placebo Comparator|Placebo|Placebo to Lu AF76432
2859623|NCT03531229|Experimental|Lu AF76432|Lu AF76432
2859624|NCT03531216|Active Comparator|Topical application of rosemary essential oil|10% Rosemarinus officinalis L. (rosemary) essential oil (manufacturer: Wala Heilmittel GmbH, Bad Boll, Germany)
2859625|NCT03531216|Placebo Comparator|Placebo|Pharmaceutical quality olive oil
2859626|NCT03531203|Experimental|With Soursop|Treatment group (with soursop group) was a group which receive soursop supplementation
2859627|NCT03531203|Placebo Comparator|Without Soursop|Control group (without soursop group) was a group which do not receive any intervention (placebo)
2859628|NCT03531190|Experimental|Nutritional supplement (Protein + MIX)|Patients are given: Nutritional Supplement of protein 2-3 times a day + MIX once daily for 35 days
2859629|NCT03531190|Active Comparator|Nutritional supplement (Protein)|Nutritional Supplement of protein as needed 2-3 times a day for 35 days
2859630|NCT03531177|Experimental|Intervention|HEAL-D diet and lifestyle education and behavioural change intervention, 7 sessions over 14 weeks.
2859631|NCT03531177|Active Comparator|Control|Usual care.
2859632|NCT03531164|Experimental|Kayak ergometer group|Intervention: Training in kayak ergometer: 3 minutes of warming (pre-charge) , 3-5 intervals of training with moderate to high intensity and pauses of 2-4 minutes (charge) and 2 minutes of cooling down (post-charge) to complete 30 minutes.
2859633|NCT03531164|Active Comparator|Control group|Intervention: 30 minutes of proprioceptive neurofacilitation focused on trunk control
2859634|NCT03531138|Experimental|Pulmonary rehabilitation group|All patients will undergo supervised pulmonary rehabilitation program on 2 days per week for 3 months. Apart from that, they will ask to perform the home exercise program which is scheduled as 3 days per week.
2859635|NCT03531112|Experimental|Appetite Awareness Treatment|Participants will receive an 8-week Appetite Awareness Training (AAT) program using a group format, will be provided a smart scale (with bluetooth connection) and instructions to weigh themselves daily. Participants will also be provided with weekly tailored feedback on self-weighing frequency and weight change. Assessment will be conducted at 0, 2, and 6 months.
2859636|NCT03531112|No Intervention|Control|Control group participants will receive no intervention in months 1-6, but will be offered the chance to receive an abbreviated form of AAT (4 weeks) following the 6-month assessment.
2859637|NCT03531099|Experimental|HIFU treatment|"65 patients will receive the immediate treatment with focal HIFU in order to destroy the cancer without causing side effects. HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.~Patients randomized in this arm will also have PSA dosage, MRI exam, questionnaires and prostatic biopsies during their follow up."
2859638|NCT03531099|Active Comparator|Active surveillance|"65 patients will be randomized to active surveillance and will have exactly the same follow-up as treated patients excepting the HIFU treatment.~Active surveillance is a therapeutic option that shifts the eventual moment of curative treatment while remaining within a window of curability of the disease.~Patients randomized in this arm will also have PSA dosage, MRI exam, questionnaires and prostatic biopsies during their follow up."
2859639|NCT03531086||Ioflupane I123|Participants will receive Ioflupane I123 as an adjunct diagnostic tool in combination with single photon emission computer tomography (SPECT) to evaluate striatal dopamine transporter. Patients will serve as their own control longitudinally.
2859640|NCT03531073||Standard care cohort|This study is observational. Patients will receive standard treatment as given in usual clinical practice with no intervention as part of the study. As per current clinical practice guidelines and UK reimbursement rules for biologics in PsA, patients will receive a pragmatic treat to target approach using step up standard therapies. Patients will usually receive methotrexate first line, initially 15mg ow increasing to 25mg ow as tolerated. In case of non-response, an additional DMARD will be used (sulfasalazine up to 3g daily or leflunomide 20mg od). If two DMARDs are failed and patients are eligible for biologic therapy under UK National Institute of Health and Clinical Excellence (NICE) guidance, then biologics will be used.
2859641|NCT03531060|Experimental|IRL790|IRL790 Capsule 10 mg, oral administration
2859642|NCT03531060|Placebo Comparator|Placebo|Placebo capsule, identical appearance, oral administration
2859643|NCT03531047|Experimental|Refractive CXL|Tomography-customised CXL
2859644|NCT03531034|Experimental|Hypertensive Women|Group of hypertensive and controlled women who practiced 10 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
2859645|NCT03531034|Active Comparator|Normotensive Women|Group of normotensive women who practiced 10 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities.
2859646|NCT03531021|Experimental|Heart healthy intervention|The intervention group will receive 2 modules (one in in person and one by video conference) and will receive follow-up phone calls/emails by study staff 3 weeks following each visit to review education and strategies for and barriers to reaching goals. Intervention sessions must include teen; parents may attend if they wish. Participants will be placed on teams and encouraged to complete behavioral challenges to earn points towards a cash reward.
2859647|NCT03531021|No Intervention|Attention Control|There will be a delayed intervention for the control group with study handouts after 3 months. The control group will meet with the RAs for demographic and survey completion and receive reminder phone calls/emails in order to match for attention.
2859648|NCT03531008||Treatment-resistant focal epilepsy|Individuals with treatment-resistant focal epilepsy
2859649|NCT03530995|Experimental|Period 1|Drug: KD025 Subjects will receive KD025 200 mg single dose on Day 1
2859650|NCT03530995|Experimental|Period 2|Drug: itraconazole Subjects will receive itraconazole 200 mg QD on Day 1 through Day 7 Drug: KD025 Subjects will receive KD025 200 mg + itraconazole 200 mg QD on Day 8 Subjects will receive itraconazole 200 mg QD on Day 9
2859651|NCT03530995|Experimental|Period 3|Drug: rabeprazole Subjects will receive rabeprazole 20 mg BID on Day 1 through Day 3 Drug: KD025 Subjects will receive KD025 200 mg + rabeprazole 20 mg QD on Day 4
2859652|NCT03530995|Experimental|Period 4|Drug: rifampicin Subjects will receive rifampicin 600 mg QD on Day 1 through Day 9 Drug: KD025 Subjects will receive KD025 200 mg on Day 10
2859653|NCT03530982|Experimental|Intervention group|Intensive goal training of relevant activities reported by adolescents in the beginning of the study. Therapists will grade the level of complexity of the proposed activities, considering the relevant movements, task demands and contextual factors involved in the performance of each task. Adolescents will be asked to practice these activities at home (1 hour/daily) and to discuss their difficulties and improvements with the therapists. The intervention will be provided in a day-camp model.
2859654|NCT03530969|Experimental|GI/GU/Lymphoma Oncologists|Doctors specializing in treating gastrointestinal cancer (cancer of the stomach, pancreas, colon, etc.), genitourinary cancer (cancer of the genitals and urinary tract), and lymphoma (cancer affecting the blood and lymph nodes)
2859656|NCT03530969|Active Comparator|Caregivers of Participants with GI/GU/Lymphoma Cancer|Family members or caregivers of the patients in group 2
2859657|NCT03530956|Active Comparator|Current prosthesis|A unilateral transtibial amputee will conduct experiments with the current prosthesis
2859658|NCT03530956|Experimental|Novel prosthesis|A unilateral transtibial amputee will conduct experiments with the novel prosthesis
2859659|NCT03530943|Active Comparator|Academic Stress Management|Students assigned to the Academic Stress Management (ASM) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks during which time they will receive 100% exposure to various evidence-based academic stress management tools.
2859660|NCT03530943|Experimental|Human Animal Interaction Enhanced|Students assigned to the Human Animal Interaction - Enhanced (HAI-E) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks. This group receives 50% exposure to structured and unstructured animal assisted activities and 50% exposure to various evidence-based academic stress management tools.
2859661|NCT03530943|Experimental|Human Animal Interaction only|Students assigned to the Human Animal Interaction - only (HAI-O) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks. This group will be receive 100% exposure to structured and semi-structured animal assisted activities.
2859662|NCT03530930|Experimental|Comarum Palustre|Patients taking Comarum Palustre together with conventional treatment for osteoarthritis
2859663|NCT03530917|Experimental|Single Ascending Dose (SAD): Cohort 1|Eight participants will be administered 40 milligram (mg) RO7020531 and two participants will be administered 40 mg matching placebo orally on Day 1.
2859664|NCT03530917|Experimental|SAD: Cohort 2|Eight participants will be administered 100 mg RO7020531 and two participants will be administered 100 mg matching placebo orally on Day 1.
2859665|NCT03530917|Experimental|SAD: Cohort 3|Eight participants will be administered 140 mg RO7020531 and two participants will be administered 140 mg matching placebo orally on Day 1.
2859666|NCT03530917|Experimental|SAD: Cohort 4|Eight participants will be administered 170 mg RO7020531 and two participants will be administered 170 mg matching placebo orally on Day 1. This is an optional cohort.
2859667|NCT03530917|Experimental|Multiple Ascending Dose (MAD): Cohort 1|Eight participants will be administered RO7020531 and two participants will be administered matching placebo orally every other day (QOD) from Day 1 through to Day 13 (total 7 doses will be given). Dose of RO7020531 is to be determined.
2859668|NCT03530917|Experimental|MAD: Cohort 2|Eight participants will be administered RO7020531 and two participants will be administered matching placebo orally every other day (QOD) from Day 1 through to Day 13 (total 7 doses will be given). Dose of RO7020531 is to be determined.
2859669|NCT03530904|Active Comparator|early mobilization after cardiac device implantation|mobilization after 4 hours
2859670|NCT03530904|Active Comparator|Late mobilization after cardiac device implantation|Mobilization after 24 hours
2859671|NCT03530891|Experimental|Computer guided lag screw fixation|Patient specific surgical guided will be used for open reduction and internal fixation for anterior mandibular fracture by lag screws.
2859672|NCT03530891|Active Comparator|Conventional lag screw fixation|Open reduction and internal fixation for anterior mandibular fracture using lag screws.
2859673|NCT03530878|Experimental|Hip Arthroscopy (HA)|This approach addresses intraarticular pathology in the form of labral tears and cartilage that are often concomitant with DDH 3. Furthermore, capsular plication can be performed through HA to reduce instability of the joint.
2859674|NCT03530878|No Intervention|Periacetabular Osteootmy (PAO)|The Bernese periacetabular osteotomy (PAO) remains the gold standard for treatment of symptomatic developmental dysplasia of the hip (DDH) in most patients with closed triradiate cartilage. First developed by Ganz in 1984, this technique utilizes 4 osteotomies to completely mobilize the acetabular fragment 1. Although a technically demanding procedure, it allows optimal correction in all planes and maintains integrity of the posterior column, enabling early weight bearing and mobilization.
2859675|NCT03530852|Experimental|Relizorb treatment|Patients will have tube feeds placed through chamber and evaluate wean from parenteral nutrition
2859676|NCT03530839|Experimental|Arthrodesis|Arthrodesis of the proximal interphalangeal joint by using a threaded K-wire
2859677|NCT03530839|Active Comparator|Resection arthroplasty|Resection arthroplasty of the proximal interphalangeal joint using a normal K-wire
2859678|NCT03530813|Active Comparator|Face-To-Face Group|Asthma First Aid Management in Schools 3 Hour Face to Face Training Group, selected a training session to attend in their local area.
2859679|NCT03530813|Experimental|Ebook Group|Asthma Management in Schools eBook training group were sent a cloudStor link to download and complete training
2859680|NCT03530800|Active Comparator|Dronabinol|Subjects will receive dronabinol 5mg once daily for two weeks, 5mg twice daily for the subsequent two weeks, and 5mg three times daily for the final two weeks.
2859681|NCT03530800|Placebo Comparator|Placebo|Subjects will receive placebo for six weeks.
2859682|NCT03530787|Active Comparator|Acetyl Zingerone Group|This group was given the topical with the active acetyl zingerone agent.
2859683|NCT03530787|Placebo Comparator|Control Group|This group was given the topical without the active acetyl zingerone agent and just the carrier lotion.
2859684|NCT03530774|Experimental|Egg while protein supplement|25 g of powdered egg white protein supplement daily for 6 months
2859685|NCT03530774|Placebo Comparator|Maltodextrin supplement|25 g of powdered maltodextrin supplement daily for 6 months
2859686|NCT03530761||Acute kidney injury|Increase in serum creatinine more than 0.3 mg/dl within 48 hours or a percentage increase serum creatinine more than 50% from baseline.
2859687|NCT03530761||Hepatorenal syndrome|"Diagnosis of cirrhosis and ascites,~Diagnosis of AKI according to ICA-AKI criteria~No response after 2 consecutive days of diuretic withdrawal and plasma volume expansion with albumin 1 g per kg of body weight~Absence of shock~No current or recent use of nephrotoxic drugs (non-steroidal anti-inflammatory drugs, aminoglycosides, iodinated contrast media, etc.)~No macroscopic signs of structural kidney injury, defined as: absence of proteinuria (> 500 mg/day), absence of microhaematuria (> 50 RBCs per high power field), normal findings on renal ultrasonography."
2859688|NCT03530748||Patients with Renal Artery Stenosis|Patients with simple renal artery stenosis or aortic dissection with renal artery obstruction
2859926|NCT03529305|Active Comparator|Physical therapy|Patients receive physical therapy for two weeks.
2859689|NCT03530735|Experimental|Fingerprick Autologous Blood (FAB) for Use in Dry Mouth|"All patients recruited will receive a 10ml saline mouth wash. Half will produce a blood-saline mixture from this mouthwash (preparation details below) and the other half will only use standard saline mouthwash. Each group will use their respective mouthwash 4 times a day for 4 weeks. During the following 4 weeks, participants will use the other mouthwash treatment. In the final 4 weeks, neither group of patients will be using either mouthwash.~Patients will be assessed at week 0, 2, 4, 6, 8, 10 and 12. However only clinic visits 0, 4, 8 and 12 will require clinic visits. During weeks 2, 6, and 10 the patients will fill out the questionnaire at home."
2859690|NCT03530709|Experimental|Experimental|videoconferencing
2859691|NCT03530709|No Intervention|Control|Usual care
2859692|NCT03530696|Experimental|T-DM1 with palbociclib|T-DM1 is given IV every 21 days Palbociclib is administered days 5-18
2859693|NCT03530696|Active Comparator|T-DM1|T-DM1 is given IV every 21 days
2859694|NCT03530683|Experimental|TTI-622 Monotherapy|Escalation Phase will include multiple doses of TTI-622
2859695|NCT03530683|Experimental|TTI-622 + Rituximab|Patients with CD20 positive lymphoma may enter the TTI-622 + rituximab combination cohort; rituximab administered according to the institutional standard of care in accordance with the current FDA-approved package insert.
2859696|NCT03530683|Experimental|TTI-622 + PD-1/PD-L1 Inhibitor|Patients with classic Hodgkin Lymphoma may enroll in this cohort and will receive TTI-622 in combination with either nivolumab administered per institutional standard of care in accordance with the current FDA-approved package insert or pembrolizumab administered per institutional standard of care in accordance with the current FDA-approved package insert.
2859697|NCT03530683|Experimental|TTI-622 + Proteasome-Inhibitor Regimen|Patients with myeloma will receive TTI-622 in addition to a standard NCCN guideline recommended proteasome inhibitor (either bortezomib or carfilzomib) + dexamethasone-containing regimen administered per institutional standard of care in accordance with the current FDA-approved package insert.
2859698|NCT03530670|Active Comparator|oral midazolam (demizolam)|"To prevent preoperative anxiety patient premedicated by 0.5 mg/kg oral midazolam.~In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale"
2859699|NCT03530670|Active Comparator|http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.|To prevent preoperative anxiety by watching a short movie ( at http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.) In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale
2859700|NCT03530670|Active Comparator|playing smartphone game|To prevent preoperative anxiety by playing smartphone game ( angry birds, subway surfers, snail Bob) In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale
2859701|NCT03530644|Experimental|RSP-14|"Comparative study of two Investigational Medical Devices (WM3.4NR and P0.1)~Optical data will be obtained from T1D over a dynamic glycemic range. Data will be paired with references."
2859702|NCT03530631|Experimental|Adderall/Truth|Participants will be told they are receiving Adderall and will actually be administered Adderall.
2859703|NCT03530631|Placebo Comparator|Placebo/Truth|Participants will be told they are receiving placebo and will actually be administered placebo.
2859704|NCT03530631|Experimental|Adderall/Deception|Participants will be told they are receiving Adderall and will actually be administered placebo.
2859705|NCT03530631|Experimental|Placebo/Deception|Participants will be told they are receiving placebo and will actually be administered Adderall.
2859706|NCT03530618|Experimental|Flexible tip straight guidewire|
2859707|NCT03530618|Experimental|J-tip guidewire|
2859708|NCT03530605|Experimental|Optune TTF Device|Optune TTF treatment
2859709|NCT03530605|No Intervention|Historical matched control|age-matched historical controls
2859710|NCT03530592|Experimental|Seated Ankle Robot Training|
2859711|NCT03530579|Experimental|Group 1|Participants will receive 6 two and a half hour educational group trainings over the course of 6 months.
2859712|NCT03530579|Active Comparator|Group 2|A community health worker will answer your questions about diabetes and refer participant if you need one.
2859713|NCT03530566||Pnk group|Patients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities, scheduled bariatric surgery within 3 months will be treated with PnK® Method
2859714|NCT03530566||Control group|Patients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities, treated with standard diet 3 moths prior bariatric surgery
2859715|NCT03530553|Experimental|Treatment arm|The treatment arm will receive the HMS as well as standard of care of the weight management program.
2859716|NCT03530553|No Intervention|Control arm|The control arm will not receive the HMS and will receive standard of care.
2859717|NCT03530540|Experimental|Intervention|Active shockwaves
2859718|NCT03530540|Placebo Comparator|Placebo|Placebo shockwaves
2859719|NCT03530527|Active Comparator|ERCP with biliary stenting|Patient will be undergone ERCP with biliary stenting for biliary decompression to relieve biliary obstruction.
2859720|NCT03530527|Active Comparator|EUS guided biliary drainage|Patient will be undergone EGBD for biliary decompression to relieve biliary obstruction.
2859721|NCT03530514|Experimental|Part A: Single dose cohort 1|Cohort 1 will receive a single IV dose of REGN4461 or matching placebo
2859722|NCT03530514|Experimental|Part A: Single dose cohort 2|Cohort 2 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
2859723|NCT03530514|Experimental|Part A: Single dose cohort 3|Cohort 3 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
2859724|NCT03530514|Experimental|Part A: Single dose cohort 4|Cohort 4 will receive a sequential ascending single SC dose of REGN4461 or matching placebo
2859725|NCT03530514|Experimental|Part A: Single dose cohort 5|Cohort 5 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
2859726|NCT03530514|Experimental|Part A: Single dose cohort 6|Cohort 6 will receive a sequential ascending single SC dose of REGN4461 or matching placebo
2859727|NCT03530514|Experimental|Part A: Single dose cohort 7|Cohort 7 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
2859728|NCT03530514|Experimental|Part A: Single dose cohort 8|Cohort 8 will receive a single IV dose of REGN4461 or matching placebo
2859729|NCT03530514|Experimental|Part A: Single dose cohort 9|Cohort 9 will receive a single IV dose of REGN4461 or matching placebo
2859730|NCT03530514|Experimental|Part B: Repeated dose cohort 10|Cohort 10 will receive repeated IV or SC doses of REGN4461 or matching placebo
2859731|NCT03530501|Placebo Comparator|Placebo|Very low calorie ketogenic diet followed by low calorie diet
2859732|NCT03530501|Experimental|Synbiotic1+synbiotic2|Very low calorie ketogenic diet supplemented with synbiotic 1 followed by low calorie diet supplemented with synbiotic2
2859733|NCT03530501|Experimental|placebo +synbiotic2|Very low calorie ketogenic diet supplemented with placebo followed by low calorie diet supplemented with synbiotic2
2859734|NCT03530488|Active Comparator|Lidocaine group|intrauterine and intracervical instillation of 4 ml of lidocaine 2% diluted in 15 ml normal saline 5 minutes before hystroscopy
2859735|NCT03530488|Placebo Comparator|control group|intrauterine and intracervical instillation of 19 ml normal saline 5 minutes before hystroscopy
2859736|NCT03530475|Active Comparator|placenta previa|cases diagnosed as placenta previa diagnosed by ultrasound and doppler
2859737|NCT03530475|Active Comparator|placenta accreta|placenta previa diagnosed as placenta accreta by ultrasound and doppler
2859738|NCT03530462||patient with first-line and second-line|patients who received intravenous second-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis),in addition to first-line immunotherapy (rituximab, cyclophosphamide)
2859739|NCT03530462||patients with first-line only|patients who received first-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis)only
2859740|NCT03530462||healthy control|healthy individuals without a history of psychiatric or neurologic disease
2859741|NCT03530449||Subjects with Normal Eyes|Color Fundus Photography, Optical Coherence Tomography, and OCT Angiography scans as per protocol in subjects without ophthalmic pathology
2859742|NCT03530449||Subjects with Retinal Vascular Pathology|Color Fundus Photography, Optical Coherence Tomography, and OCT Angiography scans as per protocol in subjects with retinal vascular ophthalmic pathology
2859743|NCT03530436|Other|Native turmeric extract|6 capsules of native curcumin (240 mg curcumin)
2859744|NCT03530436|Experimental|Native turmeric extract with 7-9% volatile turmeric oils|6 capsules of the formulation; dosage normalized to 240 mg curcumin
2859745|NCT03530436|Experimental|Turmeric extract plus mixture of phytochemicals|6 capsules of the formulation; dosage normalized to 240 mg curcumin
2859746|NCT03530436|Experimental|Cyclodextrin complex of curcuminoids|6 capsules of the formulation; dosage normalized to 240 mg curcumin
2859747|NCT03530436|Experimental|Turmeric oleoresin|6 capsules of the formulation; dosage normalized to 240 mg curcumin
2859748|NCT03530436|Experimental|Liposomal curcumin|6 capsules of the formulation; dosage normalized to 240 mg curcumin
2859749|NCT03530436|Experimental|Liposomal turmeric extract|6 capsules of the formulation; dosage normalized to 240 mg curcumin
2859750|NCT03530436|Experimental|Micellar turmeric extract|6 capsules of the formulation; dosage normalized to 240 mg curcumin
2859751|NCT03530436|Experimental|Aqueous turmeric extract with glycerine|6 capsules of the formulation; dosage normalized to 240 mg curcumin
2859752|NCT03530410||Patients with intragastric balloon|Patients who will receive an intragastric balloon placement for weight loss
2859753|NCT03530397|Experimental|Arm A: MEDI5752|MEDI5752
2859754|NCT03530397|Active Comparator|Arm B: durvalumab|durvalumab
2859755|NCT03530397|Experimental|Arm C: MEDI5752 and chemotherapy|MEDI5752, pemetrexed and carboplatin.
2859756|NCT03530397|Active Comparator|Arm D: Pembrolizumab and chemotherapy|pembrolizumab, pemetrexed, and carboplatin
2859757|NCT03530384|Experimental|Cognitive training|Computerized cognitive training program targeting inhibitory control
2859758|NCT03530384|Sham Comparator|Control Training|A sensorial program with similar conditions, but targeting visual acuity, considered as neutral in the addiction field
2859759|NCT03530371|Experimental|sedated auditory brainstem response|sedation of patients to perform auditory test
2859760|NCT03530358|Experimental|Technology-aided rehabilitation|The technology-aided upper limb rehabilitation include reinforced feedback in virtual environment (RFVE), or robotic therapy.
2859761|NCT03530358|Active Comparator|Conventional rehabilitation|The conventional upper limb rehabilitation program will be based on traditional rehabilitation techniques aimed at restoring upper limb motor functions.
2859762|NCT03530345|Experimental|Neridronic acid|Neridronic acid administered by 4 intravenous infusions within 10 Days
2859763|NCT03530345|Placebo Comparator|Placebo|Matching placebo administered by 4 intravenous infusions within 10 Days
2859764|NCT03530332|Experimental|Treatment|
2859765|NCT03530332|No Intervention|Control|
2859766|NCT03530319|Active Comparator|Azithromycin|Azithromycin (10mg/kg/day) is given to children with mycoplasma pneumonia for 3 days.
2859767|NCT03530319|Experimental|Doxycycline|Doxycycline (2-4mg/kg/day) is given to children with mycoplasma pneumonia for 5-10 days.
2859768|NCT03530306|Active Comparator|PS1-PS4|
2859769|NCT03530306|Active Comparator|PS6-PS10|
2859770|NCT03530306|Active Comparator|PS7-PS4|
2859771|NCT03530306|Active Comparator|PS9-PS6|
2859772|NCT03530293|Experimental|Valbenazine|Capsule, administered once daily. Randomization into this arm occurs after open-label treatment with valbenazine once daily for up to 12 weeks. Total treatment up to 36 weeks.
2859773|NCT03530293|Placebo Comparator|Placebo|Capsule, administered once daily. Randomization into this arm occurs after open-label treatment with valbenazine once daily for up to 12 weeks. Total treatment up to 36 weeks.
2859774|NCT03530280|Active Comparator|pregabalin (lyrica)|pregabalin (lyrica) 300 mg preoperative 1 hour before
2859775|NCT03530280|Placebo Comparator|placebo group|a placebo capsule 1 hour before surgery
2859776|NCT03530280|Active Comparator|adductor channel block group|This group will receive adductor channel block including 20 ml of 0.25% bupivacaine
2859927|NCT03529292|Experimental|Modified matrix obtained by the AmeaCell® device|
2859777|NCT03530267|Active Comparator|Arm A (mFOLFOX7)|"Patients in the 5-FU / oxaliplatin arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).~This regimen represents the 80% dosage reduced mFOLFOX 7. The 80% dose reduction was shown to be a tolerable regimen in frail elderly patients in the FOCUS 2 study."
2859778|NCT03530267|Experimental|Arm B (Aflibercept + mLV5FU2)|"Patients in the 5-FU / aflibercept arm receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).~The decision to use reduced doses of 5-FU and folinic acid was made to have comparable doses to the reduced FOLFOX 7."
2859779|NCT03530254|Other|PGT-A without ERA|Patients with PGT-A indication and ET in a Hormone Replacement Therapy (HRT cycle) according to the usual clinical practice (day 5 of progesterone supplementation: P+5/120h).
2859780|NCT03530254|Other|PGT-A and test ERA|"Patients with PGT-A indication and pET in HRT cycle following the ERA test indication (when the WOI is confirmed as Receptive)."
2859781|NCT03530241|Experimental|MRCP positive|
2859782|NCT03530241|Active Comparator|MRCP negative|
2859783|NCT03530228|Experimental|Treatment A: Tegoprazan (C1)|Tegoprazan QD, oral administration
2859784|NCT03530228|Experimental|Treatment B: Tegoprazan (C1)|Tegoprazan QD, oral administration
2859785|NCT03530228|Experimental|Treatment C: Tegoprazan (C1)|Tegoprazan BID, oral administration
2859786|NCT03530228|Experimental|Group 1: Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days
2859787|NCT03530228|Experimental|Group 2: Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days
2859788|NCT03530228|Active Comparator|Group 3: Esomeprazole (C2)|Esomeprazole QD, oral administration, for 7 days
2859789|NCT03530228|Experimental|Tegoprazan (C3)|Tegoprazan QD, oral administration
2859790|NCT03530215||Adverse Events with Antineoplastic and immunomodulating agents|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Antineoplastic and immunomodulating agents, with a chronology compatible with the drug toxicity
2859791|NCT03530202|Experimental|HVRT + Creatine Monohydrate|Participants will perform 8-weeks of high-velocity resistance training, defined as performing the concentric phase of a lift as fast as possible and taking two seconds to perform the eccentric phase of the lift, on six exercises (bilateral legpress, leg extension, leg curl, chest press, triceps extension, and biceps curl) and consume creatine monohydrate powder. The load will be 80% of the participants one-repetition max (1RM; the maximum weight that can be successfully lifted one time with proper form).
2859792|NCT03530202|Placebo Comparator|HVRT + Maltodextrin Powder|Participants will perform 8-weeks of high-velocity resistance training, defined as performing the concentric phase of a lift as fast as possible and taking two seconds to perform the eccentric phase of the lift, on six exercises (bilateral legpress, leg extension, leg curl, chest press, triceps extension, and biceps curl) and consume maltodexterin powder. The load will be 80% of the participants one-repetition max (1RM; the maximum weight that can be successfully lifted one time with proper form).
2859793|NCT03530189||Normoglycemic group|"The infant will enter this group if a single blood glucose concentration is between 2.1 and 2.5 mmol/l (38-45 mg/dL), or a single blood glucose concentration is between 8.6 - 10 mmol/l (155-180 mg/dL) with all other measures between 2.6 and 8.5 mmol/l (47-153 mg/dL).~To all premature infants intravenous 10% dextrose at 60-90 mL/kg/day will be started as soon as possible after birth."
2859794|NCT03530189||Group with impaired glucose|"The infant can be hypoglycemic, hyperglycemic or unstable. The infant will be hypoglycemic if blood glucose concentration is ≤2,5 mmol/l (45 mg/dL) on ≥2 measures >1 hour apart, or any blood glucose concentration is≤2,0 mmol/l (36 mg/dL). Hypoglycemia will be treated with intravenous bolus of 10% dextrose.~The infant will be hyperglycemic if blood glucose concentration is ≥8,6 mmol/l (155 mg/dL) on ≥2 measures >1 hour apart, or any blood glucose concentration ≥10,1 mmol/l (182 mg/dL). Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion.~The infant will be unstable if at least 1 blood glucose concentration is ≤2,5 mmol/l (45 mg/dL) and ≥1 blood glucose concentration is ≥8,6 mmol/l (155 mg/dL)."
2859795|NCT03530176|Experimental|single arm|18F-NaF (sodium Flouride ) is a radio-pharmaceutical used to image skeletal pathology, including primary and secondary neoplasms. Despite US Federal Drug Administration (FDA) approval and 18F-NaF being listed in the US Pharmacopeia, 18F-NaF is not currently approved by Health Canada for use as a cardiac imaging tracer. Therefore, a concurrent Health Canada Clinical Trial Application is being submitted to ensure its availability. Intervention on single arm: A dose of 18F-NaF (200 - 400 MBq) will be injected intravenously at rest. After a 60 minute, an ECG-gated PET acquisition will be performed centered over the heart for 20 minutes. A CT coronary calcium score examination will also be performed on a dedicated CT scanner and the Agatston and volume scores calculated according to standards.
2859796|NCT03530163|Experimental|Respiratory Muscle Training|
2859797|NCT03530163|Sham Comparator|Sham Breathing Training|
2859798|NCT03530150|Active Comparator|Pirfenidone 600 mg|Burn patients randomly allocated to this group will receive pirfenidone 600 mg orally once per day for 21 days additionally to the coverage of the wound with non-adherent gauzes and bandages. The aforementioned coverings will be changed every 3 or 4 days until a complete re-epithelization is achieved.
2859799|NCT03530150|No Intervention|Usual Care|Burn patients randomly allocated to this group will only be treated by the usual care of our hospital which consists in covering the wound with non-adherent gauzes and bandages. These covering will be changed every 3 or 4 days until a complete re-epithelization is achieved.
2859800|NCT03530137|Other|families living at Families Moving Forward (FMF)|
2859801|NCT03530124|Other|Vaccinated|In the study arm, infants will receive PCV13, DTaP, HBV, IPV, and Hib vaccines within 12 hours of randomization. Infants will be monitored from randomization to 48 hours post-vaccination for the occurrence of apnea, bradycardia and desaturation.
2859802|NCT03530124|No Intervention|Unvaccinated|In the study arm, infants will not receive PCV13, DTaP, HBV, IPV, and Hib vaccines during the study. Infants will be monitored from randomization to 48 hours post-randomization for the occurrence of apnea, bradycardia and desaturation.
2859803|NCT03530111||Sedentary|Sedentary individuals will be classified as achieving < 75 minutes of moderate-intensity or < 37 minutes of vigorous-intensity aerobic physical activity per week.
2877533|NCT03406806|Active Comparator|NIH Toolbox 4 meter test|
2859804|NCT03530111||Very Physically Active|Very Physically Active individuals will be classified as achieving > 225 minutes of moderate-intensity or > 112 minutes of vigorous-intensity aerobic physical activity per week.
2859805|NCT03530098|No Intervention|Control|This is the control arm where no intervention is provided; represents current standard of care.
2859806|NCT03530098|Experimental|Experiment|"This is the experiment arm where the intervention, BoneAgeModel, is provided. The participating radiologists in this arm will receive the output of the Artificial Intelligence algorithm. They will be asked to incorporate this new information with their normal workflows to make a diagnosis. The radiologists' diagnosis will be considered final."
2859807|NCT03530085|Experimental|Dec+Flu+Bu Conditioning Regimen|For AML patients older than 60 years in CR, Decitabine+ Fludarabine+Busulfan conditioning regimen was used (Decitabine 20mg/m2/day on days -11 to -7；Fludarabine(Flu) 30mg/m2/day on days -4 to -2；Busulfan (BU) 3.2 mg/kg/day on days -4 to -2).
2859808|NCT03530072||Cases|Subjects with Fever and Neutropenia
2859809|NCT03530046|Experimental|High SID fluid|Group 1: half-normal saline with addition of 75mEq/L sodium bicarbonate
2859810|NCT03530046|Active Comparator|Hartmann's solution|Group 2: Hartmann's Solution
2859811|NCT03530033|No Intervention|Conventional surgery group|Induction of anesthesia according to conventional neuromuscular blockade dose, no neuromuscular blockade drug maintenance during lateral neck dissection.
2859812|NCT03530033|Experimental|Lidocaine group|Anesthesia induction was performed according to conventional nerve monitoring neuromuscular blockade doses and lateral neck dissection was performed. When local muscle tremors occur, lidocaine is injected locally to eliminate muscle tremors.
2859813|NCT03530020|Active Comparator|monolithic zirconia crowns|Monolithic zirconia attracts many dentists worldwide due to its excellent mechanical properties, biocompatibility and appreciate aesthetics
2859814|NCT03530020|Experimental|lithium silicate crowns|A lithium silicate glass ceramic is newly introduced to the market. After crystallization, it exhibits an ideal combination of aesthetics and strength with translucency that mirrors the vitality of natural teeth for fabrication of full anatomic anterior and posterior crowns.
2859815|NCT03530007|Active Comparator|normal saline|patients received normal saline for prevention of shivering during spinal anesthesia
2859816|NCT03530007|Active Comparator|ondansetron 4MG|patients received 4 mg of ondansetron for prevention of spinal shivering
2859817|NCT03530007|Active Comparator|ondansetron 8MG|patients received 8 mg of ondansetron for prevention of spinal shivering
2859818|NCT03529994||Enrollment|
2859819|NCT03529981|Active Comparator|Mindfulness alone|12 minute guided mindfulness meditation
2859820|NCT03529981|Experimental|Mindfulness with TVS|12 minuted guided mindfulness meditation with Tuned Vibroacoustic Stimulation (TVS)
2859821|NCT03529968||Italian Siewert I-II adenocarcinoma|Patients with Siewert type I adenocarcinoma underwent subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Patients with Siewert type II adenocarcinoma underwent total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy. A right anterolateral thoracotomy and an upper midline laparotomy were performed as previously described. Lymphadenectomy included chest stations classified according to the AJCC TNM 7th edition (L/R = left/right; 3, 4R, 7, 2R, 8 and 9 and abdominal stations classified according to the Japanese Classification of Gastric Carcinoma (stations 1-12)
2859822|NCT03529968||Finnish Siewert I-II adenocarcinoma|All Siewert type I/II patients underwent minimally invasive esophagectomy and reconstruction with gastric tube. Laparoscopy and right-sided thoracoscopy in decubitus position were used as previously described. Thoracic lymphadenectomy consisted of stations 7-9 (AJCC TNM 7th edition) and abdominal stations 1-3 and 7-11 according to the Japanese Classification of Gastric carcinoma.
2859823|NCT03529955|Experimental|Dermatomyositis patients with refractory cutaneous disease|Patients with dermatomyositis and refractory skin disease on steroids and one steroid-sparing agent.
2859824|NCT03529942|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
2859825|NCT03529929|Experimental|Methylprednisolone|"Methylprednisolone glucocorticoid Medrol Dose Pack~Medrol is supplied as white tablets, of 4mg each. The tablets come in a commercially produced blister pack with instructions for each day of the 6 day dosing on the packaging. Subjects will receive a standard 6-day, graded dosing regimen of methylprednisolone (24mg, 20mg, 16mg, 12mg, 8mg, and 4 mg on days 1 through 6 respectively)."
2859826|NCT03529916||CVD subjects|CVD will be defined as >50% stenosis of one or more coronary arteries as assessed by coronary angiography.
2859827|NCT03529916||healthy controls|healthy controls defined as not having stenosis of coronary arteries as assessed by coronary angiography.
2859828|NCT03529903|No Intervention|Control Group|*Complete an online survey and intake appointment with a trained Health Coach (HC), who will measure their height, weight, and blood pressure, assess their current health habits (sleep, nutrition, exercise) and work with they to set realistic, achievable health goals. *Wear a Fitbit device daily to track physical activity and weight (members of the MyLife study team can access their data during throughout the program and de-identified, anonymous, data will be shared with Fitbit as part of a research partnership). *Complete another online survey and telephone check-in with their HC at the halfway point to monitor their progress toward reaching their goals. *Complete a final online survey and outtake appointment with their HC to re-check their measurements and discuss their progress.
2859829|NCT03529903|Experimental|Experimental Group|*Complete survey/ intake appointment with a HC, who will measure their height, weight, and blood pressure, assess their health habits and set achievable health goals. *Wear a Fitbit to track their daily physical activity and weight *Set a weekly active minutes goal and record their weight weekly. *Receive motivational text messages 4x per week, one will ask for their weekly active minutes goal and weight and another will ask for goal progression.*Complete photo food diaries biweekly (send pictures of everything they eat/drink to their HC). *Complete surveys/telephone check-ins with their HC every 2 weeks to monitor their progress toward reaching their goals. *Complete final survey/outtake appointment with their HC to for final measurements and to discuss goal progression (about 2 hours).
2859830|NCT03529890|Experimental|Radio-Immunotherapy before cystectomy|Single arm treatment with Nivolumab during a neoadjuvant radiation therapy of the pelvis before radical cystectomy with standardized pelvic lymphadenectomy
2859831|NCT03529877|Experimental|allo-APZ2-EB|intravenous infusion, three doses of allo-APZ2-EB (2 x 10^6 cells/kg)
2877534|NCT03406793|Experimental|1. Standard MNP|
2859832|NCT03529864|Experimental|Exercise therapy|The participants took part in a progressive exercise therapy program for 9 consecutive weeks, once a week. This consisted of group sessions with 8 or 9 students, with each session lasting 60 minutes, supervised by the principal researcher
2859833|NCT03529864|No Intervention|Control|The CG did not receive any type of information or instructions apart from the general information sheet on the progress of the study, attached to the informed consent form
2859834|NCT03529851|Experimental|PRO intervention|Patients included will weekly fill in a 12 item questionaire via the internet during the 3 week study period.
2859835|NCT03529838|Placebo Comparator|No medication|Group of pre-hypertensive women with no medication who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
2859836|NCT03529838|Active Comparator|Angiotensin receptor blockers|Group of hypertensive women taking Angiotensin receptor blockers who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
2859837|NCT03529838|Active Comparator|Beta blockers|Group of hypertensive women taking Beta blockers who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
2859838|NCT03529825|Experimental|Rifaximin|Rifaximin will be administered twice a day orally or by nasogastric tube to patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
2859839|NCT03529825|No Intervention|Retrospective comparison cohort|Thirty six patients who underwent HSCT for hematologic malignancies, and received myeloablative conditioning, without prophylactic antibiotics, between 2013-2017 enrolled in the Aflac biorepository will comprise the comparison arm. Clinical data on transplant and infection characteristics is available and linked to stool microbiome samples already analyzed and described. Stored plasma and peripheral blood mononuclear cells are available for further analysis.
2859840|NCT03529812|Experimental|Early-start group for CBCT-informed training|Hospital chaplain residents receiving the Cognitively-Based Compassion Training (CBCT) education during the first unit of their year-long residency.
2859841|NCT03529812|Active Comparator|Delayed-start group for CBCT-informed training|Hospital chaplain residents receiving the Cognitively-Based Compassion Training (CBCT) education midway through their year-long residency.
2859842|NCT03529799|Experimental|Injured Participants|Participants with mild traumatic brain injury (mTBI) tested using the I-PAS goggles
2859843|NCT03529799|Active Comparator|Uninjured Participants|Participants with no mild traumatic brain injury (mTBI) tested using the I-PAS goggles
2859844|NCT03529786||Retrospective|An observational medical records review study (data collected retrospectively) in subjects with the severe form of MPS II.
2859845|NCT03529773|Experimental|Sentinel Arm 1|Low dose formulation A
2859846|NCT03529773|Experimental|Sentinel Arm 2|Mid dose formulation A
2859847|NCT03529773|Experimental|Sentinel Arm 3|High dose formulation A
2859848|NCT03529773|Experimental|Sentinel Arm 4|Low dose formulation B
2859849|NCT03529773|Experimental|Sentinel Arm 5|Mid dose formulation B
2859850|NCT03529773|Experimental|Sentinel Arm 6|High dose formulation B
2859851|NCT03529773|Placebo Comparator|Sentinel Arm 7|Placebo
2859852|NCT03529773|Experimental|Expanded Arm 8|Low dose formulation A and SIIV
2859853|NCT03529773|Experimental|Expanded Arm 9|Mid dose formulation A and SIIV
2859854|NCT03529773|Experimental|Expanded Arm 10|High dose formulation A and SIIV
2859855|NCT03529773|Experimental|Expanded Arm 11|Low dose formulation B and SIIV
2859856|NCT03529773|Experimental|Expanded Arm 12|Mid dose formulation B and SIIV
2859857|NCT03529773|Experimental|Expanded Arm 13|High dose formulation B and SIIV
2859858|NCT03529773|Experimental|Expanded Arm 14|Low dose formulation A and placebo
2859859|NCT03529773|Experimental|Expanded Arm 15|Mid dose formulation A and placebo
2859860|NCT03529773|Experimental|Expanded Arm 16|High dose formulation A and placebo
2859861|NCT03529773|Experimental|Expanded Arm 17|Low dose formulation B and placebo
2859862|NCT03529773|Experimental|Expanded Arm 18|Mid dose formulation B and placebo
2859863|NCT03529773|Experimental|Expanded Arm 19|High dose formulation B and placebo
2859864|NCT03529773|Placebo Comparator|Expanded Arm 20|placebo and placebo
2859865|NCT03529747|Experimental|Online self-help|A website providing information and psycho-education aimed at parents and carers of children with food allergies.
2859866|NCT03529747|No Intervention|Wait list control|A waiting list control group, who will receive access to the online self-help once the RCT is complete.
2859867|NCT03529734|Experimental|12 min running group|This group will perform a 12 min high intensity running with the goal to cover maximal possible distance.
2859868|NCT03529734|Experimental|Local strengthening exercise group|This group will perform local strengthening exercises (curl-ups, left side trunk flexion, trunk extension, right side trunk flexion). Each participant will have to perform three sets of each exercise with the maximal possible number of repetitions with a slow tempo (1s concentric phase and 2 s eccentric phase). Between sets, minimal rest (15 s) will be administered.
2859869|NCT03529721|Experimental|zumba dance group|females in this group will be instructed to engage into12 classes of 60-minute Zumba® fitness over an 8-week period of continuous dance movements to Latin music with varying intensity level throughout the sessions. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced.
2859870|NCT03529721|Placebo Comparator|non zumba dance group|the control group will be required to carry on doing their normal daily activities throughout the 8-week period.
2859871|NCT03529708|Experimental|SBRT boost|Standard radiotherapy (3D conformal, urgent palliative radiotherapy) plus stereotactic body radiotherapy (SBRT) boost
2861567|NCT03517904|Active Comparator|Angiography-guided group|Angiography-guided intervention group
2859872|NCT03529695|Active Comparator|Standard HVP Curriculum|"Participants will receive the standard Healthy Families America (HFA) home visitation curriculum delivered by trained home visitors. The HFA model meets the Department of Health and Human Services criteria for an evidence-based early childhood home visiting service delivery model. HFA services begin prenatally and continue until children are 2-5yo. The curriculum focuses on strengthening parent-child relationships and family functioning, promoting positive child development, and linkage to community resources. Accredited home visitors are matched to families on cultural background and language, to provide culturally sensitive services. Home visitors receive weekly supervision, ongoing developmental training, and have limited caseloads (10-15 families) to meet their families' needs."
2859873|NCT03529695|Experimental|Obesity Prevention|Participants will receive the standard Healthy Families America home visitation curriculum with the obesity prevention enhancement module, delivered by trained home visitors. Families are matched to home visitors based on their ethnicity/race and language preferences. The obesity prevention program targets 4 key behaviors (physical activity, fruit and vegetable consumption, sugary beverages, fried foods) aimed at reducing obesity risks in mothers and their children. Participants will also be provided opportunities to meet in groups with other participating mothers/infants to enhance social networks that support healthy eating and physical activity.
2859874|NCT03529682|Experimental|Circuit Training Group|Circuit exercise training will be given to the experimental group participants during 10 weeks, 60 minutes in a day and 3 times a week.
2859875|NCT03529682|Other|Control Group|The control group participants will continue to their own previous physiotherapy approaches as the same as minimum 3 times a week and total 3 hours.
2859876|NCT03529669|Experimental|Cytosponge™|All participants will receive the Cytosponge™ device.
2859877|NCT03529656|No Intervention|Pre-ERP|A group of patients who underwent liver transplantation surgery before the early rehabilitation program
2859878|NCT03529656|Experimental|Post-ERP|A group of immediate liver transplant patients who had an early rehabilitation program in ICU care
2859879|NCT03529643|Experimental|Anesthesia with dexmedetomidine|"Anesthesia with sevoflurane-remifentanil-dexmedetomidine~Dexmedetomidine :Continuous infusion of dexmedetomidine with loading dose of 1.0 μg/kg (0.25 ml/kg) for 10 minutes, then followed by maintenance dose of 0.4 µg/kg/hr (0.1 ml/kg/hr)."
2859880|NCT03529643|Placebo Comparator|Anesthesia without dexmedetomidine|"Anesthesia with sevoflurane-remifentanil~Normal saline :Continuous infusion of normal saline with loading dose (0.25 ml/kg) for 10 minutes, then followed by maintenance dose (0.1 ml/kg/hr)."
2859881|NCT03529630|Experimental|Inverted syringe|Participants in this arm will use of the inverted syringe before each breastfeeding starting from the first feed after delivery and continued as long as needed by the mother.
2859882|NCT03529630|No Intervention|Standard of care|Participants in the control group will receive standard medical care as dictated by their obstetricians. Any advice regarding infant nutrition or treatment of inverted nipples will be left to the primary physician, including possible use of the inverted syringe technique. .
2859883|NCT03529617||Critically ill patients|Patients admitted on ICU.
2859884|NCT03529617||Hematology patients|Patients admitted on the hematology ward.
2859885|NCT03529604||Oral Cancer group|Patients with patohistologically diagnosed T1 conventional oral squamous cell carcinoma
2859886|NCT03529604||PMOD group|Patients with clinically diagnosed leukoplakia, erithroplakia and oral lichen planus.
2859887|NCT03529604||Control|Age and sex matched subjects
2859888|NCT03529591|Active Comparator|180 deg selective laser trabeculoplasty|The right eye of a patient is randomized to be treated with either 180 or 360 degrees selective laser trabeculoplasty (SLT). The fellow eye is treated with the opposite treatment, that is, if the right eye is treated with 180 degrees SLT, the left eye is treated with 360 degrees SLT. Intraocular pressure (IOP) response is assessed at 2 weeks, one, three and six months post treatment and compared to the alternative treatment arm, the fellow eye.
2859889|NCT03529591|Active Comparator|360 deg selective laser trabeculoplasty|The right eye of a patient is randomized to be treated with either 180 or 360 degrees selective laser trabeculoplasty (SLT). The fellow eye is treated with the opposite treatment, that is, if the right eye is treated with 180 degrees SLT, the left eye is treated with 360 degrees SLT. Intraocular pressure (IOP) response is assessed at 2 weeks, one, three and six months post treatment and compared to the alternative treatment arm, the fellow eye.
2859890|NCT03529578|Experimental|dHACM|Standard of Care plus Weekly Application of dHACM
2859891|NCT03529565||Ancillary-Correlative (biospecimen collection)|Participants undergo collection of blood samples for histamine level analysis via ELISA.
2859892|NCT03529552|Experimental|Patients with anterior cruciate ligament rupture|
2859893|NCT03529526|Experimental|KN046|
2859894|NCT03529513||Depressed|Subjects currently experiencing a moderate-to-severe major depressive episode are clinically evaluated over approximately 2-week period. 24-hour ECG data recordings are collected during each of the two weeks. Subjects may continue on current treatment regimen.
2859895|NCT03529513||Control|Subjects not currently experiencing a major depressive episode are clinically evaluated over approximately 2-week period. 24-hour ECG data recordings are collected during each of the two weeks. Subjects may continue on current treatment regimen.
2859896|NCT03529500||Adequate nutritional status|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
2859897|NCT03529500||Mild malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
2859928|NCT03529279|Experimental|Experimental Group|The patients in the Experimental Group are allocated to receive CNG staging and CNG chemotherapy strategy and CNG radiation strategy
2859929|NCT03529279|Active Comparator|Controlled Group|The patients in the Controlled Group are allocated to receive the eighth edition of UICC/AJCC staging and NCCN chemotherapy strategy and NCCN radiation strategy
2859898|NCT03529500||Moderate malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
2859899|NCT03529500||Severe malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
2859900|NCT03529487|Experimental|Oxymetazoline applied intra analy|
2859901|NCT03529474|Experimental|Psychology and Physiotherapy group|The psychological program consists of 4 sessions (2 hours each) comprising psychoeducation, training techniques of psychological management of pain and kinesiophobia resources The physiotherapy program consists of 3 domiciliary sessions per week, including physical exercise and stretching
2859902|NCT03529474|Placebo Comparator|Placebo Comparator: Control group|Usual daily activities
2859903|NCT03529461|Other|Control|Intervention: nasal cannula (6L O2) + non invasive positive pressure nasal mask (not connected to machine)
2859904|NCT03529461|Experimental|Experimental|Intervention: Non invasive positive pressure nasal mask (connect to machine once patient is sedated)
2859905|NCT03529448|Experimental|TN-TC11G, radiotherapy and Temozolomide Oral Product|"During Phase Ib, Four to seven weeks after surgical diagnosis, concurrent with radiotherapy (STUPP)~+ temozolomide (75mg/m2/day for 42 days) +TN-TC11G will be evaluated. During radiation therapy, temozolomide and TN-TC11G will be administered. This last, as the dose that have been selected previously, based on dose-titration period. Patient specific dose will remain until progresion of disease, unacceptable toxicity, non-compliance, consent withdrawal up to 2 years."
2859906|NCT03529435|Active Comparator|Massed Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks. If necessary, the treatment window may be extended for another week.
2859907|NCT03529435|Experimental|Intensive Outpatient Prolonged Exposure|The IOP-PE will include the same primary treatment components as the Massed-PE protocol (fifteen weekday 90-minute PE sessions delivered five days a week over a three-week period) plus eight augmentations designed to maximize treatment outcomes. Similar to the Mass-PE, participants will have three consecutive weeks to complete treatment; however, the treatment window may be extended another week if necessary.
2859908|NCT03529422|Other|Open-label, single-arm|Durvalumab in combination with intensity modulated radiotherapy (IMRT) treatments and tremelimumab
2859909|NCT03529409|Experimental|Project Khanya|Those assigned to Project Khanya (the behavioral intervention for substance use and adherence condition) will have approximately 6 sessions (including Life-Steps, behavioral activation, and relapse prevention) delivered by a peer interventionist plus standard of care, which is typically referral to a local outpatient substance use treatment clinic. They will also receive a Wisepill, a wireless, real-time adherence monitoring device.
2859910|NCT03529409|No Intervention|ESOC|Those assigned to the ESOC (enhanced standard of care) condition will receive the standard of care, which is referral to a local substance use treatment clinic. The substance use clinics in the location that this study occurs follow the Matrix, and evidence-based 16-week outpatient program to treat substance use. We will enhance patients' normal referral to Matrix for ESOC participants by promoting facilitating and following up on the referral. Additionally, those in the control group will also receive a Wisepill, a wireless adherence monitoring device.
2859911|NCT03529396|Experimental|1a: Chloroquine + 5th-day Primaquine|Ten G6PD deficient patients. Directly observed therapy.
2859912|NCT03529396|Experimental|1b: Chloroquine + 8-week Primaquine|Ten G6PD deficient patients. Directly observed therapy.
2859913|NCT03529396|Active Comparator|1c: Chloroquine + 12-week Chloroquine|Ten G6PD deficient patients. Control group in terms of safety. Directly observed therapy.
2859914|NCT03529396|Active Comparator|2: Standard chloroquine + primaquine|Thirty G6PD normal patients. Control group in terms of efficacy. Directly observed therapy.
2859915|NCT03529383|Experimental|Connected device|"Women randomized to the connected device arm will follow a 6-month exercise program using a connected device that includes an activity tracker and subscription to an exercise and physical activity management program through a smartphone application and a website. They will also receive international recommendations on physical activity."
2859916|NCT03529383|Experimental|Therapeutic education|"Women randomized to the therapeutic education arm will follow a 6-month program of therapeutic patient education. They will also receive international recommendations on physical activity."
2859917|NCT03529383|Experimental|Combined|"Women will benefit from both the connected device intervention and the therapeutic education intervention and receive international recommendations on physical activity."
2859918|NCT03529383|No Intervention|Control|Women will receive standard care, i.e., international recommendations on physical activity, without further intervention.
2859919|NCT03529344|Active Comparator|Blue whiting protein hydrolysate|Dietary Supplement: Blue whiting protein hydrolysate 6g protein per day for 6wk
2859920|NCT03529344|Placebo Comparator|Placebo Comparator: Control|Control group will receive non-caloric juice without protein supplementation
2859921|NCT03529331|Active Comparator|Morphine Sulfate Immediate Release|ED patients at discharge will receive 15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days.
2859922|NCT03529331|Active Comparator|Oxycodone/Acetaminophen (Percocet),|ED patients at discharge will receive 5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days.
2859923|NCT03529331|Active Comparator|Hydrocodone/Acetaminophen (Vicodin)|ED patients at discharge will receive 5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days.
2859924|NCT03529305|Experimental|Low frequency rTMS|Patients receive low frequency rTMS treatment and physical therapy. rTMS is applied over primary motor (M1) cortex of the unaffected side for two weeks, 5 consecutive days each week.
2859925|NCT03529305|Experimental|High frequency rTMS|Patients receive high frequency rTMS treatment and physical therapy. rTMS is applied over primary motor (M1) cortex of the affected side for two weeks, 5 consecutive days each week.
2859930|NCT03529266|Experimental|A(Surgery+PFS)|Arm A consists of the concurrent application of Porcine Fibrin Sealant (PFS) on the gastroesophageal or coloesophageal anastomosis during Mckeown surgery .
2859931|NCT03529253|Experimental|Intensive therapy group|Alirocumab group is Alirocumab75mg/2week plus Rosuvastatin10mg/daily.
2859932|NCT03529253|Active Comparator|Standard therapy group|The standard therapy group is Rosuvastatin10mg/daily alone.
2859933|NCT03529240|Experimental|Kinesiology taping|After performing the baseline assessments, kinesiology taping with facilitation technique was applied on bilateral quadriceps and tibialis anterior muscles of children. In both applications, the first and last 5 cm section of the bands were used as anchor and no tension was applied.
2859934|NCT03529214|Other|Implemented Health Facility|"Health facility that has piloted the Team Birth Project"
2859935|NCT03529201|Experimental|QLB|At the end of surgery, QLB with ropivacaine will be done on the side of the operation.
2859936|NCT03529201|Experimental|Control|Standard care. No regional blocks.
2859937|NCT03529175|Active Comparator|Concomitant|Intravenous Abraxane125 mg/m2 30-minute infusion followed immediately by intravenous Gemcitabine 1000 mg/m2 30-minute infusion will be administered on days 1, 8 and 15 of a 4-week cycle.
2859938|NCT03529175|Active Comparator|Sequential|Intravenous Abraxane 125 mg/m2 30-minute infusion will be administered on days 1, 8 and 15 of a 4-week cycle. Intravenous Gemcitabine 1000 mg/m2 30-minute infusion will be administered on days 2, 9 and 16 of a 4-week cycle. Gemcitabine must be delivered 24 +/- 2 hours after commencing Abraxane infusion.
2859939|NCT03529162|Active Comparator|Suture Anchor Technique (SA)|If randomized to this group, the patient will receive an open subpectoral long head of biceps tenodesis technique whereby the long head of biceps is re-attached to the humerus using an FDA-approved suture anchor (SA) device for the suture anchor technique. The device to be used will be the Mitek Super Quick Anchor.
2859940|NCT03529162|Active Comparator|Pectoralis Major Technique (PMT)|If randomized to this group, the patient will receive an open subpectoral long head of biceps tenodesis technique whereby the long head of biceps is re-attached by suturing the biceps tendon into the pectoralis major tendon.
2859941|NCT03529149|Experimental|Accurate blood pressure control|Implementing accurate blood pressure management under TCD monitoring
2859942|NCT03529149|Active Comparator|Guideline blood pressure control|Control blood pressure according to guidelines
2859943|NCT03529136|Experimental|MSC group 1|Procedure:UC-MSC infusion via peripheral vein. Four times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 1(once every 4 days).
2859944|NCT03529136|Experimental|MSC group 2|Procedure:UC-MSC infusion via peripheral vein. Two times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 2(once every 7 days).
2859945|NCT03529136|Experimental|Control group|Control group with standard medical care. UC-MSC infusion could be considering in this group after 24 weeks' followed-up.
2859946|NCT03529123|Experimental|Tested Drug|Insulin glargine/lixisenatide fixed ratio combination (FRC)
2859947|NCT03529123|Active Comparator|Control Drug|Insulin glargine (Lantus®)
2859948|NCT03529110|Experimental|Trastuzumab deruxtecan (DS-8201a)|HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane randomized to treatment with DS-8201a
2859949|NCT03529110|Active Comparator|Ado-trastuzumab emtansine (T-DM1)|HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane randomized to treatment with T-DM1
2859950|NCT03529097|Active Comparator|Fluids|Intervention: 2 liters of 0.9% NaCl IV during the ER stay with pain killers. For placebo purposes this arm participants will get an infusion with black cover so they could not tell if it drips or not
2859951|NCT03529097|Placebo Comparator|Placebo|No interventions, Only pain killers. For placebo purposes this arm participants will get an infusion with black cover so they could not tell if it drips or not
2859952|NCT03529084|Experimental|EGF816|Investigational treatment arm of EGF816 (nazartinib).
2859953|NCT03529084|Active Comparator|Investigator's Choice|Investigator's Choice (erlotinib or gefitinib).
2859954|NCT03529071|Experimental|CKD-Question Prompt Sheet|Study participants will receive the CKD-QPS.
2859955|NCT03529071|No Intervention|Control|Individuals will not receive any intervention or surveys.
2859956|NCT03529045||VNS Therapy|Any approved VNS Therapy System (according to local regulations) may be used in this registry.
2859957|NCT03529032|No Intervention|Fentanyl group|Drug: Fentanyl Fentanyl group 3µg/kg to start surgery TIVA: general anesthesia will be based on Fentanyl an Propofol, titrated to achieve bispectral index (BIS) between 40-60.
2859958|NCT03529032|Experimental|methadone group|Drug: methadone methadone group 0.2mg/kg to start surgery TIVA: general anesthesia will be based on Fentanyl an Propofol, titrated to achieve bispectral index (BIS) between 40-60.
2859959|NCT03529019|Experimental|Nutritional Supplement|Administration of Ensure Surgery Immunonutrition Shake and ensure Enlive Advanced Nutrition Shake.
2859960|NCT03529006|Active Comparator|Sequent Please Drug Coated Balloon Group|For Sequent Please Group, PCI (percutaneous coronary intervention) PCI procedure with Sequent Please inflation will be performed - drug eluting balloon will be used in the narrowed part of the artery. This method of treatment is one of the standard ones, which is typically used for treatment patients with diagnosis of in stent restenosis, the exact intervention and anesthesia procedures will be performed according to physician's usual practice. For bailout situation Xience stent implantation is possible.
2859961|NCT03529006|Active Comparator|Absorb Stent Group|Absorb scaffold group will be treated by PCI procedure with Absorb BVS implantation - implantation of bioresorbable vascular scaffold (Absorb). Coronary stent implantation for treatment in stent restenosis is one of the standard method of treatment this disease, but Absorb system has not been investigated in this indication yet.
2859962|NCT03528993|Experimental|Exercise by hippotherapy device group|The experimental group receive conventional rehabilitation for 45 min/day following by use of a hippotherapy device for 15 min/day, 5 times/week for 4 weeks
2859963|NCT03528993|Other|Control group|The control group will receive conventional rehabilitation for 45 min/day, following by postural control exercises 15 min/day 5 times/week for 4 weeks.
2859964|NCT03528980||Bariatric surgery|
2859965|NCT03528980||standard nutritional management|
2861709|NCT03516916||Australia|Patients with a permanent colostomy after curative surgery for rectal cancer
2859966|NCT03528967|Experimental|Arm 1|"Patients going on ASPIRIN 100 mg/day combined with ENOXAPARIN 4000 IU per dat prevention treatment according to randomization:~Administer Aspirin 100 mg Oral Tablet, Enteric Coated once daily~Administer the Enoxaparin preventive dose of 4000 IU as a subcutaneous Enoxaparin 40 mg / 0.4 mL Prefilled Syringe once daily~Start treatment from inclusion visit~Maintain treatment until the day of delivery, or the appearance of a complication (Retroplacental hematoma (RPH), preeclampsia (PE) , In utero fetal death (IUFD), or Intrauterine growth restriction (IUGR) and its complications)"
2859967|NCT03528967|Other|Arm 2|"Patients going on ASPIRIN 100 mg/day prevention treatment alone according to randomization:~Administer only Aspirin 100 mg Oral Tablet, Enteric Coated once daily~Administer orally~Start treatment from inclusion visit~Maintain treatment until 35 Weeks of Amenorrhea (WA)"
2859968|NCT03528954|Active Comparator|Propofol|Received intravenous 0.5mg/kg propofol
2859969|NCT03528954|No Intervention|Control|Do not received intravenous 0.5 mg/kg propofol
2859970|NCT03528941||Lamivudine|Patients who received lamivudine
2859971|NCT03528941||No prophylaxis|Patients who did not receive any prophylaxis
2859972|NCT03528928|Experimental|Surface electrical stimulation|Each subject did a Kegel pelvic floor contraction, had the surface electrical stimulation turned on at highest comfortable intensity, did a Kegel contraction with surface electrical stimulation on, and had second electrical stimulation turned on.
2859973|NCT03528915||Prophylaxis group|Newborns treated with rifamycin eye drops systemically two months before change of practices in delivery room.
2859974|NCT03528915||no-antibiotic group|Newborns not treated with antibiotic prophylaxis in a systemic way, according to the new french guidelines of January 1st, 2015.
2859975|NCT03528902|Experimental|Tamoxifen|20 mg po TID for 24 weeks
2859976|NCT03528902|Placebo Comparator|Placebo|Placebo arm
2859977|NCT03528889|Active Comparator|Goniometer|Extension FDO: classic procedure with goniometer controlled extension and derotation
2859978|NCT03528889|Experimental|EMT|Extension FDO: procedure with electromagnetic tracking (EMT) controlling extension and derotation
2859979|NCT03528876|Other|Single arm intervention study|Biweekly FOLFOX for two cycles alternating with FOLFIRI for two cycles (FOLFOX-FOLFIRI)
2859980|NCT03528863|Experimental|Supportive Care (web-based mindfulness meditation)|Participants practice with web-based mindfulness meditation over 10-15 minute guided audio sessions for 5 days a week for 8 weeks. Participants also attend meditation webinars over 60 minutes once a week, for 8 weeks.
2859981|NCT03528850|Experimental|Telehealth|The Telehealth arm will receive daily biometric measurement of blood pressure, heart rate, oxygen saturation and weight. The Telehealth arm will also have weekly virtual visits for the first month after hospital discharge. The Telehealth arm will answer surveys weekly for the first 30 days.
2859982|NCT03528850|No Intervention|Standard of Care|The Standard of Care will receive no interventions but will conduct surveys at enrollment and at the end of 30 days.
2859983|NCT03528837||Diagnosed as acute kidney injury|Sure diagnosed as acute kidney injury
2859984|NCT03528824|Experimental|Fenugreek wraps|Daily application of fenugreek wraps for 1/2-2 hours per day, 4 weeks application
2859985|NCT03528824|Active Comparator|Diclofenac gel|Daily application of diclofenac gel, 4 weeks application
2859986|NCT03528824|No Intervention|Usual care|no specific intervention
2859987|NCT03528811|Other|Five points test of Tongji university|"We established the evaluatation and follow-up system of diabetes vascular disease based on the method called Five points test of Tongji university ."
2859988|NCT03528785|Experimental|Single Arm|All patients will receive a treatment scheme of Irinotecan Liposomal Injection [Onivyde], oxaliplatin, Levofolinic Acid and 5-fluorouracil (5 -FU) on Day 1 and Day 15 of each 28 day cycles.
2859989|NCT03528772|Active Comparator|Minoxidil|Patients in this arm will receive topical treatment with Minoxidil forte 5% gel three times per days for 4 weeks
2859990|NCT03528772|Active Comparator|Glyceryl trinitrate|Patients in this arm will receive topical treatment with glyceryl trinitrate 0.2% cream three times per days for 4 weeks
2859991|NCT03528746|Experimental|Isometric exercise|Participants will complete isometric quadriceps exercise
2859992|NCT03528746|Active Comparator|Isotonic exercise|Participants will complete dynamic leg extension
2859993|NCT03528733|Experimental|Multi-Energy Detector|Multi-Energy Digital Radiography Detector System
2859994|NCT03528707|Active Comparator|probiotic-omega|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
2859995|NCT03528707|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
2859996|NCT03528694|Experimental|Durvalumab plus BCG (induction + maintenance)|Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy
2859997|NCT03528694|Experimental|Durvalumab plus BCG (induction only)|Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy
2859998|NCT03528694|Active Comparator|BCG treatment (Standard of care therapy)|Bacillus Calmette-Guerrin (BCG) standard of care treatment
2859999|NCT03528681|Experimental|Sodium Zirconium Cyclosilicate 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
2860000|NCT03528681|Experimental|Sodium Zirconium Cyclosilicate 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
2860001|NCT03528681|Placebo Comparator|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
2860002|NCT03528655|Experimental|Decision aid group|Shared decision making using decision aid
2860003|NCT03528655|No Intervention|Controlled group|Standard oral explanation with booklet.
2860004|NCT03528642|Experimental|Treatment (CB-839, temozolomide, RT)|Participants receive CB-839 PO BID 7 days a week, temozolomide PO QD 7 days a week, and undergo RT 5 days a week for up to 5.5 weeks (diffuse astrocytoma) or 6.5 weeks (anaplastic astrocytoma) in the absence of disease progression or unacceptable toxicity.
2860005|NCT03528629|Experimental|Safety Part Arm A (IMAB362 dose-1/2)|Participants will receive a loading dose-1 of IMAB362 on Cycle 1 Day 1 followed by a lower dose-2 in subsequent every 3 weeks.
2860006|NCT03528629|Experimental|Safety Part Arm B (IMAB362 dose-3)|Participants will receive a loading dose-3 of IMAB362 on Day 1 of each cycle (every 3 weeks).
2861710|NCT03516916||Brazil|Patients with a permanent colostomy after curative surgery for rectal cancer
2860007|NCT03528629|Experimental|Expansion Part (IMAB362 dose-1/2)|Participants will receive a loading dose-1 of IMAB362 on Cycle 1 Day 1 followed by a lower dose-2 in subsequent every 3 weeks.
2860008|NCT03528603|Experimental|Oleocanthal-Rich Extra Virgin Olive Oil|Extra Virgin Olive Oil that is high in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Low Extra Virgin Olive Oil
2860009|NCT03528603|Placebo Comparator|Oleocanthal-Low Extra Virgin Olive Oil|Extra Virgin Olive Oil that is low in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Rich Extra Virgin Olive Oil
2860010|NCT03528590|Active Comparator|size 3 i-gel®|size 3 i-gel supraglottic airway device in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
2860011|NCT03528590|Experimental|size 4 i-gel®|size 4 i-gel supraglottic airway device in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
2860012|NCT03528577|Experimental|Test|Albuterol Sulfate Inhalation Aerosol, eq 90 mcg
2860013|NCT03528577|Active Comparator|Reference|PROAIR® HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg
2860014|NCT03528577|Placebo Comparator|Test Placebo|Placebo for Albuterol Sulfate Inhalation Aerosol
2860015|NCT03528577|Placebo Comparator|Reference Placebo|Placebo for Albuterol Sulfate Inhalation Aerosol
2860016|NCT03528564|Experimental|Epoetin alfa|Preoperative treatment of anemia with iron sucrose (Venofer) plus Epoetin Alfa (Eprex)
2860017|NCT03528564|Placebo Comparator|Intravenous Iron|Preoperative treatment of anemia with iron sucrose (Venofer) plus placebo (saline)
2860018|NCT03528551|Experimental|N8-GP, once weekly|All participants will receive turoctocog alfa pegol (N8-GP) once weekly.
2860019|NCT03528551|Experimental|N8-GP, twice weekly|All participants will receive N8-GP twice weekly.
2860020|NCT03528551|Experimental|N8-GP, three times weekly|All participants will receive N8-GP three times weekly.
2860021|NCT03528538|Placebo Comparator|Placebo|
2860022|NCT03528538|Active Comparator|AlphaFen fenugreek 400 mg|This group received 400 mg of fenugreek to be ingested daily for 60 days.
2860023|NCT03528538|Active Comparator|AlphaFen fenugreek 500 mg|This group received 500 mg of fenugreek to be ingested daily.
2860024|NCT03528525||Monogenic diseases cases|
2860025|NCT03528512|Experimental|IN ketamine|Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)
2860026|NCT03528512|Active Comparator|IN midazolam and fentanyl|Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
2860027|NCT03528499|Experimental|Scapular Movement Training|Orientation and scapular exercises, performed twice a week, for 8 weeks.
2860028|NCT03528499|Active Comparator|General Exercises|Scapulothoracic muscle stretching and strengthening exercises, performed twice a week, for 8 weeks.
2860029|NCT03528486|Experimental|Music Training I|Participants will complete a type of music training including listening to music, learning about music, or learning to read music, or play a musical instrument.
2860030|NCT03528486|Active Comparator|Music Training II|Participants will complete a type of music training including listening to music, learning about music, or learning to read music, or play a musical instrument
2860031|NCT03528473|Experimental|Patients|Our study is an interventional, single group assignment study in which subjects are first assigned to control group and, after 3-months interval with no physical training, are shifted into the 6-months exercise intervention group. Thus, subjects act as their own control at the end of the study.
2860032|NCT03528447|Experimental|Pulmonary Rehabilitation|Lung transplantation candidates who refered from Lung Transplantation surgery team will undergo the Pulmonary Rehabilitation program for 3-months (2 days at hospital, 3 days at home). Patient will evaluate at the beginning and end of the program.Cognitive functions and exercise capacities of the patients before and after the program will be evaluated.
2860033|NCT03528434|Experimental|Zinc|Dietary Supplement: Zinc 10mg dispersible zinc sulfate tablet
2860034|NCT03528434|Placebo Comparator|Placebo|Dispersible tablet with inert ingredients, identical to zinc in appearance
2860035|NCT03528421|Experimental|IM19 CAR-T cells|3*10^5/kg，1*10^6/kg，3*10^6/kg IM19 CAR-T cell.Two days before cell infusion, all patients will be treated with fludarabine and Cyclophosphamide for 3 days
2860036|NCT03528408|Experimental|Nivolumab and Ipilimumab|All patients enrolled to the study will be treated with nivolumab 240 mg IV every 2 weeks plus ipilimumab 1mg/kg IV every 6 weeks. 1 cycle = 6 weeks.
2860037|NCT03528395|Experimental|Semi-immersive virtual reality|8 week protocol with semi-immersive virtual reality provided with the XBOX 360º video game console and its Kinect device. The commercial video games used will be: Kinect Sports I ®, Kinect Sport II ®, Kinect Joy Ride ® and Kinect Adventures ®.
2860038|NCT03528395|Active Comparator|Conventional Rehabilitation|Physical therapy and Occupational Therapy based on a task-oriented approach
2860039|NCT03528382|Experimental|period I group|
2860040|NCT03528382|Experimental|period II group|
2860041|NCT03528382|Experimental|period III group|
2860042|NCT03528369|Experimental|CGS-200-1|CGS-200-1 (1% Capsaicin content), a topical analgesic liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
2860043|NCT03528369|Experimental|CGS-200-5|CGS-200-5 (5% Capsaicin content), a topical analgesic liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
2860044|NCT03528369|Sham Comparator|CGS-200 Vehicle|CGS-200 Vehicle (no Capsaicin), a topical liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
2860045|NCT03528356|Placebo Comparator|Regular diet|
2860046|NCT03528356|Experimental|White diet|
2860047|NCT03528343|Experimental|Tylenol/Motrin|Group of patients who will receive instructions to use tylenol and motrin for pain control, and parents will be sent home with a paper prescription with a rescue does of standard of care narcotics. They will be instructed to only use the rescue dose if pain is uncontrolled using over the counter medications.
2860048|NCT03528343|No Intervention|Narcotic|Group of patients who will receive the standard of care narcotic prescription filled upon discharge.
2860085|NCT03528044|Experimental|Patients undergoing bariatric surgery|In this study, patients will undergo sleeve gastrectomy to reduce the size of the stomach to induce weight loss.
2860049|NCT03528330|Active Comparator|Internal hexagon connection|"Small flaps will be elevated to reduce any kind of injury on the periosteum and maintain the blood supply during the healing period.~Patients will receive 2 implants. One implant (assigned randomly) will have internal hexagon connection.~The Internal Hex (IH) implant has a 2.5mm internal hexagon and a 90° cone. The platform diameter is Ø3.5mm."
2860050|NCT03528330|Experimental|Conical connection|"Small flaps will be elevated to reduce any kind of injury on the periosteum and maintain the blood supply during the healing period.~Patients will receive 2 implants. One implant (assigned randomly) will have internal hexagon connection.~The Conical Standard (CS) implant has a 2.5mm internal hexagon and 22° cone. The platform diameter is Ø3.1mm."
2860051|NCT03528317|Experimental|Alternate day fasting|Alternate day fasting with a high protein diet
2860052|NCT03528304|Experimental|Smoking arm|As part of the CM intervention, women attend visits for smoking and weight loss assessment and are rewarded with prizes for abstaining from smoking.
2860053|NCT03528304|Experimental|Weight loss arm|As part of the CM intervention women attend visits for smoking and weight loss assessment and are rewarded with prizes for losing some weight.
2860054|NCT03528304|Experimental|Smoking and weight loss arm|As part of the CM intervention, women attend visits for smoking and weight loss assessment and are rewarded with prizes for abstaining from smoking and for losing some weight.
2860055|NCT03528304|No Intervention|Control|Women attended clinic visits for smoking status and weight loss assessment.
2860056|NCT03528291||Cardiogenic shock treated with medical treatment|Patients with cardiogenic shock treated only by medical treatment
2860057|NCT03528291||Cardiogenic shock treated with transient circulatory support|Patients where transient circulatory support was implanted: veno-arterial extracorporeal circulatory life support (ECLS), Impella
2860058|NCT03528265||Patients with melioidosis-like symptoms admitted to Kapit Hosp|
2860059|NCT03528252|Active Comparator|LDL Cholesterol|Will receive dietary advice effective for reducing LDL cholesterol.
2860060|NCT03528252|Sham Comparator|Triglycerides|Will not be aware that they are in fact Control Group. Will receive dietary advice effective for reducing Triglycerides, but neutral for LDL cholesterol.
2860061|NCT03528226|Experimental|Exercise Training|
2860062|NCT03528226|Other|Control|
2860063|NCT03528213|Sham Comparator|Normal saline|at physician discretion
2860064|NCT03528213|Experimental|Sodium lactate light dose|bolus 2.5ml/kg lactate 60min then 0.25ml/kg/h during 24hrs
2860065|NCT03528213|Experimental|Sodium lactate high dose|bolus 2.5ml/kg lactate 60min then 0.50ml/kg/h during 24hrs
2860066|NCT03528200|Other|Dyna Embo|Contrast dye injected through the IV in their arm which helps to see the blood in the arteries using x-ray pictures
2860067|NCT03528187||Patient Cohort 1|"Age 18 or over~BMI greater than or equal to 30 (greater than or equal to 27.5 for patients of Asian origin)~Due to undergo or referred for a formal treatment intervention for obesity (lifestyle modifications [dietary change, behavioural therapy, increased physical activity], surgical intervention or pharmacological treatment) as part of their usual clinical care~Informed written consent~Able to tolerate MRI"
2860068|NCT03528187||Patient Cohort 2|"Age 18 or over~Attending weight management service at UCLH~Informed written consent~Able to tolerate MRI"
2860069|NCT03528187||Controls|"Age 18 or over~BMI less than 25~Informed written consent~Able to tolerate MRI"
2860070|NCT03528174|Experimental|Single Hormone closed loop|Subjects will have glucose managed using the Artificial Pancreas Control system (APC) using insulin only. Insulin will be infused through the Pacific Diabetes Technologies CGM Insulin Infusion system.
2860071|NCT03528148|Experimental|active cycling group|effect of combine cycling and conventional physical therapy in quality of life, functional activity and ADL, postural control, balance, muscle tone, spasticity, motor functioning, gait of stroke patients.
2860072|NCT03528148|Active Comparator|control group|effect of combine conventional physical therapy in quality of life, functional activity and ADL, postural control, balance, muscle tone, spasticity, motor functioning, gait of stroke patients.
2860073|NCT03528135|Experimental|Project PRIDE|"Those in the Project PRIDE condition will receive 8 weekly sessions, each lasting 2.5 hours and consisting of approximately 10 men (estimated number given expected attrition). Each session will be co-led by two trained group facilitators. The intervention sessions are described in the Detailed Description section. The will complete a pre-test, post-test, and follow-up assessment."
2860074|NCT03528135|No Intervention|Wait-list|Those in the wait-list arm will wait approximately 5 months before receiving the intervention. They will complete the same pre-test, post-test, and follow-up assessments as those in the PRIDE arm. After they have completed the follow-up assessment, they will be offered the intervention.
2860075|NCT03528122|Experimental|Recurrent opened macular hole|Pars plana vitrectomy with internal limiting membrane peel if not peeled in the first surgery and application of amniotic membrane graft
2860076|NCT03528109|Experimental|patient-centered CBT|60 minute office-based exposure therapy with a PhD psychologist once per month and a 90 minute community-based CBT with a mobile exposure coach three times per month for a total of four visits per month (once per week)
2860077|NCT03528109|Active Comparator|Provider-centered|60 minute office-based exposure therapy with a PhD psychologist four times per month (once per week)
2860078|NCT03528096|Experimental|Intervention night|Vestibular stimulation, in the form of gentle rocking movements, is provided using the Somnomat B rocking bed. Stimulation is provided for the first 60 minutes of the night and for 10 minutes upon detection of symptoms. The stimulation frequency is in the range of 0.25-2 Hz.
2860079|NCT03528096|Sham Comparator|Baseline night|The sound of the moving bed is played back to the participant at the right sound intensity level.
2860080|NCT03528083|No Intervention|Retrospective Controls|A retrospective control group of patients with a diagnosis of bronchiolitis and meeting inclusion criteria will be used as a comparison group. These patients received usual care for bronchiolitis at our institution.
2860081|NCT03528083|Experimental|Quality Improvement|All patients diagnosed with bronchiolitis and meeting inclusion criteria will undergo the intervention of a bronchiolitis quality improvement process to improve bronchiolitis care quality at our institution.
2860082|NCT03528070|Experimental|Tranilast|
2860083|NCT03528057|Active Comparator|Group 1|Patients undergoing RALPN with the use of HAs by a surgeon.
2860084|NCT03528057|No Intervention|Group 2|Patients undergoing RALPN without the use of HAs by a surgeon
2860087|NCT03528031|Experimental|Intervention Daily Avocado|Participants will follow their usual diet and lifestyle but also be provided with 1 avocado to consume per day for 6 months. To maximize compliance, participants will be provided with resources on how to choose, store and ripen avocados along with simple usage ideas. Specific nutrition guidance will not be provided. Participants will pick up fresh avocados every 2 weeks with minimal interaction with study personnel. Compliance visits will be conducted monthly.
2860088|NCT03528031|No Intervention|Control Usual Diet and Lifestyle|Participants will be instructed to follow their usual diet and lifestyle. Participants will be allowed to consume up to 2 avocados per month, but avocado consumption will not be encouraged and no avocados will be provided. Compliance visits will be conducted monthly.
2860089|NCT03528018|Other|Control|Conventional physical therapy
2860090|NCT03528018|Experimental|Experimental|Combined tDCS and VR-based intervention
2860091|NCT03528005|No Intervention|Control|A regular health education program was provided by case managers only.
2860092|NCT03528005|Experimental|Intervention|Multi-domain intervention included exercise,cognitive training, diet education, and disease consultation was conducted for two hours twice per week in the first month, once per week in the second month, and once per month since third month.
2860093|NCT03527992|Other|Automated oxygen therapy|An automated oxygen therapy is a system that allows administration of oxygen with a flow that is automatically adjusted to the patient's saturation, which is continuously monitored. Patients will receive O2 automated intervention.
2860094|NCT03527992|Other|Standard Oxygen therapy|Patients will receive O2 standard therapy
2860095|NCT03527979|Active Comparator|PCOS women with history of LOD before IVF/ICSI|
2860096|NCT03527979|Active Comparator|PCOS women without history of drilling|
2860097|NCT03527966|Active Comparator|Intervention group - 5cc Vivigen and local autograft|
2860098|NCT03527966|Active Comparator|Control group - small kit rhBMP-2 with local autograft|
2860099|NCT03527953|Active Comparator|Tetric EvoCeram BulkFill resin|Randomly applied
2860100|NCT03527953|Active Comparator|Surefil SDR Flowable bulk-fill resin|Randomly applied
2860101|NCT03527953|Active Comparator|everX fiber-reinforced resin|Randomly applied
2860102|NCT03527940||Patients with STEMI|
2860103|NCT03527927|Experimental|LABA/LAMA inhaler|Patients on a combination of inhaled corticosteroid (ICS), long acting beta agonist (LABA) and long acting muscarinic antagonist (LAMA) will be taken off their current ICS/LABA/LAMA combination inhalers and will commence on a single LABA/LAMA inhaler (any LABA/LAMA) of their choice.
2860104|NCT03527914|Active Comparator|Treatment as Usual|
2860105|NCT03527914|Experimental|Goal Based Outcomes|
2860106|NCT03527901||Chronic periodontitis|This groups participant has radiographically moderate alveolar bone loss, CAL > 5 mm and PD >6 mm in several sites of each quadrant
2860107|NCT03527901||Generalized aggressive periodontitis|This demonstrated a generalized pattern of severe breakdown and CAL > 5 mm and PD > 6 mm on 8 > teeth; minimum three of those were other than first incisors or first molars
2860108|NCT03527901||Gingivitis|This group has varying degrees of gingival inflammation, with CAL < 2 mm, without any radiographical bone loss due to periodontitis
2860109|NCT03527901||Implant|Implants classified PD < 5 mm, no bleeding on probing, no suppuration and no radiographic bone loss > 0.5 mm
2860110|NCT03527901||Health|Probing depth (PD) < 3mm, no gingival recession due to periodontal disease, and clinical attachment level (CAL) < 2 mm, BOP in < 10% of full-mouth score examination
2860111|NCT03527888|Other|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2860112|NCT03527875|Experimental|PTBD group|Percutaneous Transhepatic Biliary Drainage
2860113|NCT03527875|Experimental|ENBD group|Endoscopic Nasobiliary Biliary Drainage
2860114|NCT03527875|Experimental|EBS group|Endoscopic Biliary Stenting
2860115|NCT03527875|No Intervention|Without PBD group|receive surgery without PBD
2860116|NCT03527862|No Intervention|Control group|No intervention is performed. Lung ultrasonography is performed within 4 hours after surgery for diagnostic purpose.
2860117|NCT03527862|Experimental|lung ultrasonography group|Lung ultrasonography is performed three times; after tracheal intubation, before surgery end, and within 4 hours after surgery. In this group, respiratory management is performed according to diagnosis.
2860118|NCT03527849|Experimental|In-Person MBSR Course|
2860119|NCT03527849|Experimental|Online MBSR Course|
2860120|NCT03527849|Active Comparator|In-Person HEP|
2860121|NCT03527836|Active Comparator|Lidocaine|Lidocaine brachial plexus block 0.4 ml/kg of 0.66% solution
2860122|NCT03527836|Active Comparator|Bupivacaine|Bupivacaine brachial plexus block 0.4 ml/kg of 0.33% solution
2860123|NCT03527836|Active Comparator|Mixture|Mixture brachial plexus block 0.4 ml/kg of 0.33% bupivacaine and 0.33% lidocaine solution
2860124|NCT03527823||LH supplementation|luteinizing hormone administrated microdose flare up GnRH analog protocol in poor ovarian responders undergoing in vitro fertilization.
2860125|NCT03527823||without LH supplementation|microdose flare up GnRH analog protocol in poor ovarian responders
2860126|NCT03527810|Experimental|Sleeve Gastrectomy With Interrogation of Hiatus|In those randomized to interrogation, the hiatus will be opened posteriorly during surgical procedure intervention with preservation of the phreno-esophageal ligament where possible, as per standard described techniques. Dissection into the mediastinum will be stopped if no hernia is seen or when appropriate intra-abdominal length of 2 cm of esophagus is created. Once opened, the Hiatal Surface Area will be measured, calculated and recorded and when possible, a photo taken of the area. Repair of the crura will then be performed around the sizing tube used to create the sleeve with enough space to allow a 5 mm instrument to be easily inserted. Permanent sutures will be placed posterior to the esophagus.
2860127|NCT03527810|Active Comparator|Sleeve Gastrectomy Without Interrogation of Hiatus|In those randomized without interrogation, the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature. The procedure involves a longitudinal resection of the stomach starting from the antrum at the point 5-6 cm from the pylorus and finishing at the fundus close to the cardia.[1] The remaining gastric sleeve is calibrated with a bougie. Most surgeons prefer to use a bougie between 36-40 Fr with the procedure and the ideal approximate remaining size of the stomach after the procedure is about 150 mL.
2860131|NCT03527784|Active Comparator|Parietex Parastomal|Parietex Parastomal is a synthetic mesh with resorbable collagen lining to prevent attachments.
2860132|NCT03527784|Active Comparator|Dynamesh IPST|Dynamesh IPST is synthetic mesh with central tube to accommodate bowel tightly designed to prevent and treat parastomal hernia.
2860133|NCT03527771|No Intervention|unassisted CPR|unassisted CPR
2860134|NCT03527771|Active Comparator|T-CPR|telephone assisted CPR according to ERC Guidelines 2015
2860135|NCT03527771|Experimental|V-CPR|video-assisted CPR according to ERC Guidelines 2015
2860136|NCT03527758|No Intervention|Standard Invasive intraoperative monitoring|
2860137|NCT03527758|Experimental|Flo TracIQ with HPI software|
2860138|NCT03527745|Experimental|200 mg albendazole|against T. trichiura in preschool-aged children or against hookworm infections in preschool-aged children, school-aged children and adults
2860139|NCT03527745|Experimental|400 mg albendazole|against T. trichiura in preschool-aged children, school-aged children and adults or against hookworm infections in preschool-aged children, school-aged children and adults
2860140|NCT03527745|Experimental|600 mg albendazole|against T. trichiura in preschool-aged children, school-aged children and adults or hookworm infections in preschool-aged children, school-aged children and adults
2860141|NCT03527745|Experimental|800 mg albendazole|against T. trichiura in school-aged children and adults or against hookworm infections in school-aged children and adults
2860142|NCT03527745|Placebo Comparator|Placebo|against T. trichiura in preschool-aged children, school-aged children and adults or hookworm infections in preschool-aged children, school-aged children and adults
2860143|NCT03527732|Placebo Comparator|Arm A: albendazole|400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of placebo at day 0 administered orally
2860144|NCT03527732|Experimental|Arm B: albendazole and ivermectin|400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of ivermectin (Stromectol®) at day 0 administered orally
2860145|NCT03527719|Experimental|Experimental Group|"All participants of intervention groups will receive a new comprehensive evidence-based medicine(EBM) management program including nine intervention measures.~Strengthen the performance appraisal system for primary hypertension management~Establishing a chronic disease management system~Simulating medical insurance reform~Enhancing village doctors'ability for standardized diagnosis and treatment of hypertension.~Establishing a supervision mechanism for the effect of hypertension management~Establishing a hierarchical management system for patients~Enhancing the awareness of blood pressure self-management~Establishing a self-management group for patients~Establishing patient encouragement system"
2860146|NCT03527719|No Intervention|Control Group|All participants in the routine management groups will receive the current management program.
2860147|NCT03527680|Experimental|Lactobacillus rhamnosus|received daily one capsule containing 1.6*107 CFU of Lactobacillus Rhamnosus
2860148|NCT03527680|Placebo Comparator|Placebo|received one placebo capsule per day Infant formula after meal for 28 days
2860149|NCT03527667|Experimental|Short term incentives|usual quit smoking treatment (counseling + medication) plus 6-weeks of payments for proof of smoking abstinence
2860150|NCT03527667|Experimental|Long term incentives|usual quit smoking treatment (counseling + medication) plus 12-weeks of payments for proof of smoking abstinence
2860151|NCT03527667|No Intervention|No incentives|usual quit smoking treatment (counseling + medication)
2860152|NCT03527654||Hispanic Immigrants|
2860153|NCT03527641|Experimental|Salud sin Barreras, Health without Barriers|"Salud sin Barreras is a manualized community-delivered program tailored for Latino families and their adolescent children at-risk for type 2 diabetes. Salud sin Barreras is based upon a lifestyle intervention called the Healthy Living Program (HeLP), which includes 6 weekly 2-hour nutrition/cooking sessions and 6 weekly 2-hour Multidisciplinary Sessions that include parent education on nutrition, fitness, goal-setting, parenting, and a brief mindfulness curriculum, a teen group physical fitness class, and a teen mindfulness curriculum called Learning 2 BREATHe. In between sessions, participants are encouraged to practice brief mindfulness skills in their daily lives and to complete the homework assignments, such as an audio-guided body scan. Participants have access to home-practice audio-recordings and will be queried about their completion of home-practice assignments."
2860154|NCT03527641|Active Comparator|La Vida Saludable, Healthy Living|The Health Living Program (HeLP) is a manualized community-delivered program tailored specifically for Latino families and children at-risk for adult obesity. HeLP includes 6 weekly 2-hour nutrition/cooking sessions and 6 weekly 2-hour Multidisciplinary Sessions, that include parent education on nutrition, fitness, goal-setting, and parenting, a teen group physical fitness class, and a teen health knowledge curriculum derived from a health education curriculum called Hey DURHAM.
2860155|NCT03527628|Other|Patients with PET-2 Negative Result|"After 2 ABVD cycles an interim PET-2 will be performed, and treatment will be adapted according to to PET results~PET-2 negative patients will be treated with 4 cycles of ACVD (Adriamycin, Cyclophosphamide, Vinblastine And Dacarbazine)"
2860156|NCT03527628|Other|Patients with PET-2 Positive Result|"After 2 ABVD cycles an interim PET-2 will be performed, and treatment will be adapted according to to PET results~PET-2 positive patients will be treated with 4 cycles of ACVD with addition of Brentuximab Vedotin"
2860157|NCT03527602|Experimental|Intervention|Endodontic treatment will be performed in maxillary anterior teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Foraminal enlargement will be achieved with rotary files in foraminal enlargement group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit.
2860158|NCT03527602|No Intervention|Control|In the control group, no foraminal enlargement will be performed.
2860159|NCT03527589|Experimental|Treated with Embosphere Microspheres|Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres (size of embolic determined at Investigator discretion).
2860160|NCT03527576|Active Comparator|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
2860161|NCT03527576|Placebo Comparator|Placebo|Intravenous injection of NaCl 0,9% before the surgery.
2877535|NCT03406793|Experimental|2. High zinc, low iron MNP|
2860162|NCT03527563|Other|Internet Medical Model|Using Internet blood pressure management model: home blood pressure self-monitoring + Internet diagnosis + Maintained or adjusted anti-hypertension drug(s) treatment.
2860163|NCT03527563|No Intervention|Conventional Medical Model|Using Conventional blood pressure management model: home blood pressure monitoring + face-to-face diagnosis in clinic + Maintained or adjusted anti-hypertension drug(s) treatment.
2860164|NCT03527550|Experimental|Cognitive Training plus Treatment as Usual|Participants in this arm will receive daily computerized cognitive training sessions during partial hospitalization, in addition to treatment as usual. Cognitive training sessions will alternate between response inhibition training and working memory training.
2860165|NCT03527550|No Intervention|Treatment as Usual|Participants in the Treatment As Usual group will receive usual treatment in the partial hospitalization program.
2860166|NCT03527537|Active Comparator|20% cutoff group|Treatment intervention will be initiated with glyburide, metformin, or insulin if 20% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.
2860167|NCT03527537|Active Comparator|40% cutoff group|Treatment intervention will be initiated with glyburide, metformin, or insulin if 40% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.
2860168|NCT03527524|Experimental|exercise with ball|The participant in core stabilization exercise with ball group performed 12 training sessions of the core stabilization exercises, 3 days/week for 4 weeks. Each exercise took 15 times/set and each participant did it repeatedly for 3 sets and rested 1 minute between sets. The total time of core stabilization exercise was 20 minutes and assessment time was 10 minutes.
2860169|NCT03527524|Other|exercise without ball|The participant in core stabilization exercise without ball group performed 12 training sessions of the core stabilization exercises, 3 days/week for 4 weeks. Each exercise took 15 times/set and each participant did it repeatedly for 3 sets and rested 1 minute between sets. The total time of core stabilization exercise was 20 minutes and assessment time was 10 minutes.
2860170|NCT03527498|Experimental|intervention group|Baby treadmill + physical rehabilitation training
2860171|NCT03527498|Active Comparator|positive control group|Physical rehabilitation training only
2860172|NCT03527485|Other|Opiate Use Disorder (OUD)|30 subjects meeting opiate dependence criteria will receive 11UCB-J PET Scan.
2860173|NCT03527485|Other|Cocaine Use Disorder (CUD)|30 subjects meeting cocaine dependence criteria 11UCB-J PET Scan.
2860174|NCT03527485|Other|Healthy Controls (HC)|30 healthy controls; no substance dependence or mental health issues 11UCB-J PET Scan.
2860175|NCT03527472|Experimental|Memantine|At randomization, subjects will receive 5 mg twice per day for one week. They will escalate their dose to 10 mg twice per day for one week, then 10 mg in the morning and 20 mg at night for one week, and finally 20 mg twice per day for three weeks. Maximum tolerated will be determined at this time and this dose will be continued for an additional six weeks.
2860176|NCT03527472|Placebo Comparator|Placebo|At randomization, subjects will receive one matching placebo capsule twice per day for one week. They will also take one matching placebo capsule twice per day for the next week (week 2), then one matching placebo capsule in the morning and two capsules at night for one week (week three), and finally two capsules twice per day for three weeks (weeks 4-6). Maximum tolerated number of capsules will be determined at this time and this dose will be continued for an additional six weeks.
2860177|NCT03527459|Active Comparator|SPARC A|SPARC A is an existing clinical program which has a general focus on negative cognitions.
2860178|NCT03527459|Experimental|SPARC B|SPARC B includes all aspects of the SPARC A clinical program, but targets negative cognitions of perceived burdensomeness in some sessions.
2860179|NCT03527446|Experimental|Normal Weight|BMI ≥ 18.5 < 25.0 km/m2 Sprint Interval Training
2860180|NCT03527446|Experimental|Individuals living with Obesity|BMI ≥ 30.0 km/m2 Sprint Interval Training
2860181|NCT03527433|No Intervention|Standard arm|In the standard arm, an average of one suture will be placed at each cm length of the wound, thus the number of sutures placed should be equal to the length of the wound in cm.
2860182|NCT03527433|Experimental|Intervention arm|The intervention arm will undergo the alternative/new closure technique with small and close fascia sutures, where each suture will be placed only 5 mm away from the fascia edge and 5 mm apart from the adjacent fascia suture.
2860183|NCT03527420|Active Comparator|Exercising|12 weeks of aerobic exercise training
2860184|NCT03527420|No Intervention|Non-exercising|standard of care
2860185|NCT03527394||Families|"We plan to recruit a sample of 100 families (dyads) for this study, which will include 100 youth and 100 parents.~Note: For the sake of transparency, this sample size differs from the original estimate (n=250 families; see Ball et al., BMC Health Serv Res, 2017;17:261). A recent systematic review (Park et al., Int J Nurs Stud, 2018;79:58-69) suggested that sample size estimates for studies that evaluate test-retest reliability (a key psychometric property we will examine) should include ~5 participants for every survey item. Given the design of the interview, and in light of current patient volumes at the clinical recruitment sites, we are confident that a sample of 100 families will be both achievable and satisfactory for psychometric analyses."
2860186|NCT03527381|Experimental|Nitric Oxide|Patients of this group receive treatment with exogenous gaseous nitric oxide supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
2860187|NCT03527381|Placebo Comparator|Standard CPB|Patients of this group receive sham-treatment without supplying nitric oxide to the cardiopulmonary bypass circuit (Standard CPB) during cardiac surgery. Considering dilution of nitric oxide at a high ratio of 1 to 25,000 in the gas mixture of the cardiopulmonary bypass circuit (CPB), no addition of any inert gas to the CPB circuit is required in sham-treatment group.
2860188|NCT03527368|Experimental|Time-restricted feeding|
2860189|NCT03527368|Other|Usual feeding pattern|Comparison
2860190|NCT03527355|Experimental|A (Single dose)|"One dose of Vi-DT (Typhoid conjugate vaccine) 25 µg 0.5 mL is administrated intramuscularly at first dost (Day 0).~One dose of FluQuadri™ 0.25mL is administrated intramuscularly at second dose (Week 24).~One booster dose of Vi-DT 0.5 mL is administrated 2 years apart (Week 96). MMR for age group at 9-12 months."
2860191|NCT03527355|Active Comparator|B (Two dose)|"Two doses of Vi-DT (Typhoid conjugate vaccine) 25 µg 0.5 mL is administrated intramuscularly 6 months apart (Day 0 and Day 168 (Week 24)).~MMR for age group at 9-12 months."
2861711|NCT03516916||China|Patients with a permanent colostomy after curative surgery for rectal cancer
2860192|NCT03527355|Placebo Comparator|C (Placebo/Comparator)|"One dose of Placebo (0.9% sodium chloride isotonic solution) 0.5 mL is administrated intramuscularly at first dost (Day 0).~One dose of FluQuadri™ 0.25mL is administrated intramuscularly at second dose (Day 168; Week 24).~MMR for age group at 9-12 months."
2860193|NCT03527342||Dilated Cardiomyopathy|
2860194|NCT03527342||Myocarditis|
2860195|NCT03527342||Sarcoidosis Heart|
2860196|NCT03527342||Giant Cell Myocarditis|
2860197|NCT03527342||Amyloidosis Heart|
2860198|NCT03527342||Hypertrophic Cardiomyopathies|
2860199|NCT03527342||Left Ventricular Myocardial Noncompaction Cardiomyopathy|
2860200|NCT03527342||Arrhythmogenic Right Ventricular Cardiomyopathies|
2860201|NCT03527329||Prewarming|Active Prewarming will be performed using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be warmed using a surgical blanket during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
2860202|NCT03527329||Control|Non-active prewarming. Patients will be warmed using a surgical blanket during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
2860203|NCT03527316|Placebo Comparator|MDMA, Placebo|Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase
2860204|NCT03527316|Placebo Comparator|Placebo, MDMA|Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase
2860205|NCT03527303|Experimental|Meditation Group|Participants in the intervention group will assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
2860206|NCT03527303|No Intervention|Waitlist Control Group|Waitlist control group participants will continue their normal activities and not add any form of meditation during the study period.
2860207|NCT03527290|Experimental|Time Restricted Eating|Participants will be instructed and counseled to incorporate a 12-hour Time Restricted Eating (TRE) regimen that begins upon waking and concludes within a 12-hour period (e.g. if wake at 6:30 AM then all caloric intake occurs between 6:30 AM and 6:30 PM). Water and non-caloric beverages (e.g. herbal tea) outside the period are encouraged as desired. There are no specific content or energy intake changes to the diet counseled or recommended as the focus of the counseling in this arm is timing of eating with innate circadian patterns and developing plans and approaches to follow this plan.
2860208|NCT03527290|Active Comparator|Standard Cardiometabolic Health Diet|Participants will be instructed and counseled with standard clinical dietary guidance for improving cardiometabolic health, where the focus is on the content, specifically a dietary pattern that emphasizes vegetables, fruits, whole grains, legumes, nuts/seeds, low fat dairy, seafood, lean poultry and meat and avoidance of foods with high levels of sodium, added sugars, saturated fats, and trans fats. There is no prescription to reduce energy intake.
2860209|NCT03527277|Experimental|Naturally-sweetened orange juice|Naturally-sweetened orange juice Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks
2860210|NCT03527277|Active Comparator|Sugar-sweetened beverage|Sugar-sweetened beverage Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks
2860211|NCT03527264|Experimental|Cohort 1A|Nivolumab during Chemo/RT with whole pelvic RT
2860212|NCT03527264|Experimental|Cohort 1B|Nivolumab during Chemo/RT with extended field
2860213|NCT03527264|Experimental|Cohort 2|Chemoradiation followed by Nivolumab Maintenance
2860214|NCT03527264|Experimental|Cohort 3|Nivolumab during chemoradiation and then as maintenance
2860215|NCT03527251|Experimental|Sequential group|intravenous ipilimumab following by intravenous SHR-1210
2860216|NCT03527238|Active Comparator|Standard of Care|Standard of Care Tacrolimus Drug Dosing
2860217|NCT03527238|Experimental|Phenotypic Precision Medicine (PPM)|PPM-based Computation Assisted Drug Dosing
2860218|NCT03527225|Experimental|Music|Patients randomized to the music intervention arm will select a preferred genre of music from an internet based resource.
2860219|NCT03527225|No Intervention|No Music|These patient's will have no music playing during the first radiotherapy session.
2860220|NCT03527212|Experimental|SJP-0035 0.001% (ophthalmic solution)|
2860221|NCT03527212|Placebo Comparator|Placebo (ophthalmic solution)|
2860222|NCT03527186|Experimental|Risperidone ISM 100 mg|A single intramuscular (IM) dose of 100 mg risperidone ISM® will be administered deeply into the gluteal muscle. A total of 4 IM doses will be given; each dose will be separated by 4 weeks
2860223|NCT03527173|Experimental|GSK3536852A Group|Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, receiving 2 doses of the GSK3536852A vaccine at Day 1 and Day 29, intramuscularly into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects will receive the challenge dose.
2860224|NCT03527173|Placebo Comparator|Placebo Group|Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, receiving 2 doses of placebo at Day 1 and Day 29, intramuscularly into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects will receive the challenge dose.
2860225|NCT03527147|Experimental|AZD9150 + Acalabrutinib|AZD9150 given in combination with acalabrutinib
2860226|NCT03527147|Experimental|AZD6738 + Acalabrutinib|AZD6738 in combination with acalabrutinib
2860227|NCT03527134|Experimental|Amantadine treatment|To determine whether amantadine is effective in reducing the occurrence of postoperative cognitive dysfunction.
2860228|NCT03527134|No Intervention|No-treatment|Patients will not receive any treatment.
2860229|NCT03527121|Experimental|R.I.C.E.+ (ESP physiotherapy)|Participants will receive a single session with advice and instructions from an ESP physiotherapist in rest, ice, compression and elevation AND pain guided early weight bearing plus a written home-based exercise program.
2860230|NCT03527121|Active Comparator|R.I.C.E.(Usual care)|A single session with advice and instructions from a physician in rest, ice, compression and elevation.
2860231|NCT03527108|Experimental|Immuno-Oncology naive patients|
2860239|NCT03527082||Women attending gynaecology clinics|"150 women attending gynaecology clinics that fulfil inclusion criteria~Inclusion criteria:~Inclusion criteria~Over the age of 18~attending gynaecology clinics~Able to read and comprehend the details of the study in patient information sheet.~Mentally competent at signing the consent form.~English -speaking, if not then translator available"
2860240|NCT03527069|Experimental|CIPROS 10|"The study is double-Masked, the patient wil take 2 tablets, as follow:~1 tablet Cipros 10 association; and~1 tablet crestor placebo Oral, once a day."
2860241|NCT03527069|Active Comparator|Crestor|"The study is double-Masked, the patient wil take 2 tablets, as follow:~1 tablet Crestor 10mg; and~1 tablet Cipros association placebo Oral, once a day."
2860242|NCT03527056|Experimental|Oral capsule fecal transplantation|Enrolled patients who have screened positive for CRE in the stool will receive fecal transplant via OpenBiome oral capsules. The patient is given 90 minutes to swallow all capsules and does not require any anesthesia or sedation. Stool samples to test for CRE will be taken 10 days and 30 days after the fecal transplant.
2860243|NCT03527056|No Intervention|Observation|Enrolled patients who have screened positive for CRE in the stool will have stool samples to test for CRE taken 10 days and 30 days after initial enrollment.
2860244|NCT03527043|Experimental|Escitalopram|10mg by mouth daily for 6 weeks
2860245|NCT03527043|Placebo Comparator|Placebo|Matched placebo control by mouth for 6 weeks.
2860246|NCT03527030||General Population|Adults living in a registered household in the Greater London area.
2860247|NCT03527030||IQOS users|Adult current IQOS users (at the time of survey) living in the Greater London area who are registered in the UK IQOS User Database and agree to be contacted for research purposes at the time of registration.
2860248|NCT03527017||General Population|Adults living in Germany.
2860249|NCT03527017||IQOS Users|Adult current IQOS users (at the time of survey) living in Germany who are registered in the Germany IQOS User Database and agreed to be contacted for research purposes at the time of registration.
2860250|NCT03527004||General Population|Survey on use of tobacco products in the general population of adults living in Italy.
2860251|NCT03527004||IQOS Users|Survey on use of tobacco products in adult current IQOS Users (at the time of survey) living in Italy who are registered in the Italy IQOS User Database and agreed to be contacted for research purposes at the time of registration.
2860252|NCT03526991|Experimental|Spinal Cord Stimulation (SCS)|The subjects will complete pre-operative visits, spinal cord stimulator placement (device implantation - SCS) and postoperative follow-up visits on an outpatient basis.
2860253|NCT03526978|Experimental|Experimental Group|"The investigational vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd.~Intervention: investigational sIPV"
2860254|NCT03526978|Active Comparator|Control Group|The control vaccine was manufactured by Sanofi Pasteur Company. Intervention: control IPV
2860255|NCT03526965|Experimental|Yoga Chikitsa|YC group were given traditional combination of yoga therapy including loosening movements, physical postures, breathing, relaxation and yoga counselling.
2860256|NCT03526965|Active Comparator|Usual Care|Usual care were given exercise moves of necks, pain medications prescribed by physicians.
2860257|NCT03526952|Experimental|Intervention Group|Couples in this group will receive the Internet-Delivered Intervention for Sexual Re-Adjustment
2860258|NCT03526952|Active Comparator|Educational Comparison Group|Couples in this group will receive only written educational material about sexuality and intimacy with an ostomy.
2860259|NCT03526939||HIV negative from RDS round 1|HIV negative PWID subjects from RDS round 1
2860260|NCT03526939||HIV negative from RDS round 2|HIV negative PWID subjects from RDS round 2
2860261|NCT03526939||HIV negative from RDS round 3|HIV negative PWID subjects from RDS round 3
2860262|NCT03526926||Vyxeos|A minimum of 50 patients who receive at least one infusion of prescribed VYXEOS.
2860263|NCT03526913|Experimental|PRP + STSG|autologous PRP treatments every week prior to graft placement (STSG)
2860264|NCT03526913|Active Comparator|STSG Split Thickness Skin Graft|skin graft (STSG) (intervention)
2860265|NCT03526900|Experimental|Atezolizumab|Induction phase: atezolizumab will be given intravenously (iv) at a dose of 1200 mg/kg for 60 minutes on day 1 of each cycle. Subsequent atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity. Pemetrexed will be administered at a dose of 500 mg/m2 IV for 15 minutes on day 1 of each cycle. In addition, folic acid, vitamin B12, and dexamethasone 4 mg will be given the day before and the day after treatment with pemetrexed. Carboplatin will be given at a dose with an area under the 5 curve for 30 minutes on day 1 of each cycle, approximately 30 minutes after the pemetrexed infusion is complete. After completing 4 to 6 cycles of Carboplatino plus pemetrexed and atezolizumab, patients will continue with pemetrexed in combination with atezolizumab (maintenance phase) until they have an unacceptable toxicity, progression of the disease, decision of the patient/physician or have Completed 2 years of treatment.
2860266|NCT03526887|Experimental|Cohort 1|Patients who experienced progression disease while on treatment progression disease < 12 weeks after stopping treatment. After that the patients took chemotherapy ≥ 4 cycles and progressed again. After the last progression the patient is included in the study to be retreated with Pembrolizumab 200mg
2860267|NCT03526887|Experimental|Cohort 2|Stop treatment and progression > 12 weeks after stopping treatment. After the last progression the patient is included in the study to be retreated with Pembrolizumab 200mg
2860268|NCT03526874|Experimental|Greater Occipital Nerve (GON) Block with Lidocaine|"Subjects randomized to this arm receive 2 mL injection of lidocaine 2% over the right and left greater occipital nerve at the baseline study visit.~All subjects then complete daily headache-related questions through a Headache Diary and other assessments for 28 days."
2860269|NCT03526874|Placebo Comparator|Greater Occipital Nerve (GON) Block with Saline|"Subjects randomized to this arm receive 2 mL injection of preservative-free normal saline over the right and left greater occipital nerve at the baseline study visit.~All subjects then complete daily headache-related questions through a Headache Diary and other assessments for 28 days."
2860270|NCT03526861|Experimental|Tralokinumab(Dose1) initial-> Tralokinumab(Dose1) maintenanceA|"Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 1) maintenance SC injection regimen A."
2860386|NCT03526003||Surgical patients|Adult patient scheduled for laparoscopic surgery under general anesthesia
2860271|NCT03526861|Experimental|Tralokinumab(Dose1) initial-> Tralokinumab(Dose1) maintenanceB|"Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 1) maintenance SC injection regimen B."
2860272|NCT03526861|Experimental|Tralokinumab(Dose2) initial-> Tralokinumab(Dose2) maintenanceA|"Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 2) maintenance SC injection regimen A."
2860273|NCT03526861|Experimental|Tralokinumab(Dose2) initial-> Tralokinumab(Dose2) maintenanceB|"Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 2) maintenance SC injection regimen B."
2860274|NCT03526861|Experimental|Placebo initial-> Placebo maintenance|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 52 (maintenance period):~Placebo continuation SC injection regimen A."
2860275|NCT03526861|Experimental|Tralokinumab (Dose1) initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
2860276|NCT03526861|Experimental|Tralokinumab (Dose2) initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
2860277|NCT03526861|Experimental|Placebo initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
2860278|NCT03526848|Experimental|Group 1|HIV infected participants on ART will undergo analytical treatment interruption 2 days after the first infusion of 3BNC117 and 10-1074, and will receive 6 additional infusions of both antibodies at weeks 2, 4, 8, 12, 16 and 20 (Part A). Participants will remain off ART until week 38, if viral suppression is maintained (Part B).
2860279|NCT03526848|Experimental|Group 2|HIV infected participants on ART will remain on ART and will be administered seven infusions of 3BNC117 and 10-1074 at weeks 0, 2, 4, 8, 12, 16 and 20 (Part A). Analytical treatment interruption will begin at week 26 until week 38, if viral suppression is maintained (Part B).
2860280|NCT03526835|Experimental|MCLA-158|In Part 1, the dose escalation phase, patients with metastatic CRC will receive escalating doses of MCLA-158 (every 2 weeks) until MTD or RP2D is reached. Each Cycle is 28 days. Single agent treatment. In Part 2, the expansion phase, participants with metastatic CRC and certain other solid tumors will receive intravenous infusion of MCLA-158 at the recommended Phase II dose (RP2D) every 2 weeks, at Day 1 and Day 15. The duration of each treatment cycle is 28 days.
2860281|NCT03526822|Experimental|patients with newly diagnosed glioblastoma|
2860282|NCT03526809||Ovarian cancer patients|MRI and FDG-PET imaging
2860283|NCT03526796|Experimental|Hyperbaric oxygen therapy|Patients who recieve hyperbaric oxygen therapy will be maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
2860284|NCT03526783|Other|Failed sleeve gastrectomy - RNYGB|Intervention: Roux en Y gasric bypass (RNYGB)
2860285|NCT03526783|Other|Failed sleeve gastrectomy - MGB/OAGB|Inervention: Mini/One anastomosis gasic bypass (MGB/OAGB)
2860286|NCT03526770|Active Comparator|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test carbonated drink."
2860287|NCT03526770|Experimental|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention"
2860288|NCT03526770|Experimental|Group 3: 0.2% chlorhexidine|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
2860289|NCT03526770|Experimental|Group 4: fluoridated tooth paste|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the tooth paste as an intervention."
2860318|NCT03526510|Active Comparator|Standard Fractionation|Using 2 sequential IMRT plans, the pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent boost to the prostate to a total dose of 78 Gy.
2860319|NCT03526510|Experimental|Hypofractionation|Using a one phase IMRT plan, the pelvic lymph nodes will be treated to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68 Gy in 25 fractions concomitantly (simulataneous integrated boost).
2860290|NCT03526770|Experimental|Group 5: Polyol containing gum|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
2860291|NCT03526770|Experimental|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention"
2860292|NCT03526757|Experimental|Standing Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of Pilates exercises focusing on orthostatic position, for twelve weeks. The following equipment will be used: The Cadillac, Reformer and Chair, emphasizing balance training in the orthostatic position.
2860293|NCT03526757|Active Comparator|Standard Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.
2860294|NCT03526744|Experimental|marine protein hydrolysate|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 and 40 mg per kg bodyweight (i.e. standardized to a 80 kg person, adjusted to the actual weight of the participants) during 1 week, followed by 3 similar cycles with other MPH dosages, with 1-2 wash-out weeks in between. Random sequence of cycles.
2860295|NCT03526731|Experimental|Group A (original QLB):|Local anesthetic will be injected between the quadratus lumborum muscle and the latissimus dorsi muscle guided by ultrasound.
2860296|NCT03526731|Experimental|Group B (trans-muscular OLB)|Local anesthetic will be injected between quadratus lumborum and psoas major after passing through the quadratus lumborum muscle guided by ultrasound.
2860297|NCT03526692|Experimental|Sensorimotor/delta NF training group|"Three interventions will be administered:~An electroencephalography recording (EEG) for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.~The third intervention is the neurofeedback training sensorimotor/delta ratio that will be recorded at channel Cz according to the International 10-20 system."
2860298|NCT03526692|Experimental|Beta1/theta NF training group|"Three interventions will be administered:~An electroencephalography recording (EEG) for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.~The third intervention is the neurofeedback training Beta1/theta ratio that will be recorded at channel Fz according to the International 10-20 system."
2860299|NCT03526692|No Intervention|Control group|"Three interventions will be administered:~An electroencephalography recording for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.~The psychopedagogical care : Each session will be organized using the same video material than for the NF training sessions."
2860300|NCT03526679|Experimental|Experimental arm|The combination of lenvatinib and eribulin
2860301|NCT03526666||AML, MDS, and CMML patients|
2860302|NCT03526653|Other|Intervention 1|exercise on an ergometer or motomed in an environment without other visual stimuli
2860303|NCT03526653|Other|Intervention 2|exercise on an ergometer or motomed while watching the National Geografics channel on television
2860304|NCT03526653|Other|Intervention 3|exercise on an ergometer or motomed with the interactive software program MemoRide with which participants can exercise in real life on a virtual manner
2860305|NCT03526653|No Intervention|Control group|Rest during 30 minutes
2860306|NCT03526640|Experimental|Plug Arm|Participants randomized for plug arm will be treated with a plug after CT guided is conducted.
2860307|NCT03526640|No Intervention|Non Plug arm|No Intervention, i.a. CT guided biopsy without plug.
2860308|NCT03526627||patient with advanced heart failure|we included the patients with advanced heart failure who had the poor cardiac function(LVEF<=30%) and was admitted to the general ward or emergency room within one year.
2860309|NCT03526588|Experimental|Autologous umbilical cord blood|
2860310|NCT03526575|Placebo Comparator|10 mg Zolpidem and 10 mg Zaleplon|Experiment 1 will involve N= 14 subjects randomized to placebo , 10 mg zolpidem for males and 10 mg zaleplon in counterbalanced order. Subjects are nested into group.
2860311|NCT03526575|Placebo Comparator|5 mg Zolpidem and 10 mg Zaleplon|Experiment 2, which will involve N=20 subjects randomized to placebo, 5 mg zolpidem and 10 mg zaleplon. All females will be placed in experiment 2. Subjects are nested into group.
2860312|NCT03526562|Experimental|Single arm phase I trial with 3 exercise dose-escalation arms|exercise dose-escalation: aerobic, resistance and flexibility training
2860313|NCT03526549|Experimental|EN3835 Active|EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)
2860314|NCT03526536|Other|Patients with diabetes and ESRD|
2860315|NCT03526536|Other|Patients with diabetes and no ESRD|
2860316|NCT03526523|Experimental|Active Treatment|Mindfulness-based stress reduction
2860317|NCT03526523|No Intervention|Waitlist control|The active treatment will be received only after the outcomes monitoring period is complete.
2860414|NCT03525782|Experimental|CAR-T|Anti-MUC1 CAR-T cells will be prepared ex vivo and infused back to the patients.
2860320|NCT03526484|Active Comparator|Urinalysis|The control group will have a urine sample taken for a urinalysis prior to their procedure. The results of the urinalysis will be reported to the doctor performing the procedure, who may run a urine culture on the urine sample depending on the results of the analysis. This may require patients to take antibiotics and/or delay their procedure until the results of the urine culture are available.
2860321|NCT03526484|Experimental|Urine Culture|The experimental group will have a urine sample taken for a urine culture. The results of the urine culture will not be available to the doctor before the patient's procedure. If the urine culture results are positive for infection, a member of the study team will call the patient to arrange for treatment.
2860322|NCT03526471|Experimental|Left Atrial Appendage (LAA) Occluder|Left Atrial Appendage (LAA) Occluder
2860323|NCT03526458|Active Comparator|Holmium:YAG laser: 0.2J&15Hz|Patients are assigned to treat stones with 0.2J&15Hz of the holmium laser.
2860324|NCT03526458|Experimental|Holmium:YAG laser: 0.8J&15Hz|Patients are assigned to treat stones with 0.8J&15Hz of the holmium laser.
2860325|NCT03526445|Active Comparator|Glucagon|3 hours i.v. infusion of Glucagon (4 ng/kg/min).
2860326|NCT03526445|Placebo Comparator|Saline|3 hours i.v. infusion of saline
2860327|NCT03526432|Experimental|Bevacizumab + Atezolizumab|
2860328|NCT03526406|Experimental|CP9700|400 mg CP9700 along with modified cellulose (MCC), magnesium stearate, silica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
2860329|NCT03526406|Placebo Comparator|Matched Placebo|Maltodextrin along with modified cellulose (MCC), magnesium stearate, silica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
2860330|NCT03526393|Experimental|Support Equipment|Were selected high performance athletes with various kinds of disabilities found in sitting volleyball functional classification. Three equipment was built to aid high-performance athletes. All the volunteers tested the survey training equipment, attack and serve training equipment and pass training equipment The motor sign captured footage of each athlete, lasted 30 minutes and the data collected provided the data for the construction of the equipment, later there was the interaction of the athletes with the equipment ready to test effectiveness.
2860331|NCT03526380|Experimental|Treatment|Participants receive the OPT-IN Brief Intervention.
2860332|NCT03526380|No Intervention|Control|Participants will only complete the baseline and follow-up surveys.
2860333|NCT03526367|Experimental|hydration plus rosuvastatin therapy|"After randomized，hydration（3ml/kg/h, if patients had LVEF<40%, 1.5 ml/kg/h）last 12 hours;~After randomized，a loading dose of rosuvastatin 20mg then 10 mg daily followed for at least 7 days."
2860334|NCT03526367|Active Comparator|Standard therapy|No statin within 12 h after randomization, hydration at physicians' discretion, but no more than 1ml/kg/h.
2860335|NCT03526354|Experimental|Experimental|Brexpiprazole 4mg daily for 12 weeks
2860336|NCT03526354|Active Comparator|Treatment as Usual|Stay on current antipsychotic medication for 12 weeks
2860337|NCT03526328||DCLK1 post BE treatment|Effects of EMR and RFA on the expression of putative stem cell biomarkers and correlate them with serum/plasma protein expression and disease progression and/or recurrence (Barrett's esophagus/ esophageal adenocarcinoma)
2860338|NCT03526315|Active Comparator|CPP-ACP paste|Casein phosphopeptide amorphous calcium phosphate is a product that contains calcium, phosphate, protein and casein.
2860339|NCT03526315|Active Comparator|Fluoride toothpaste|Fluoride toothpaste
2860340|NCT03526315|Active Comparator|Both (Fluoride and CPP-ACP)|Fluoride toothpaste and CPP-ACP paste
2860341|NCT03526289|Active Comparator|GIP infusion|5 hours of continuously GIP1-42 infusion
2860342|NCT03526289|Placebo Comparator|Saline|5 hours of continuously saline infusion
2860343|NCT03526276|Active Comparator|CPP-ACP paste|Casein phosphopeptide amorphous calcium phosphate is a product that contains calcium, phosphate, protein and casein.
2860344|NCT03526276|Active Comparator|Fluoride toothpaste|Fluoride toothpaste
2860345|NCT03526276|Active Comparator|Both (Fluoride and CPP-ACP)|Fluoride toothpaste and CPP-ACP paste
2860346|NCT03526263|Experimental|Gastric mucosal devitalization arm|"Patients will be enrolled into the study after being scheduled to undergo vertical sleeve gastrectomy as part of routine clinical care at Johns Hopkins Bayview. The cost of the surgery will be covered by the patient's insurance and there will no extra procedural element that would add time to surgery.~The intervention will occur on the excised specimen ex vivo (outside the body) and will involve devitalization of the gastric mucosa using Argon Plasma Coagulation."
2860347|NCT03526250|Experimental|Treatment (palbociclib)|Patients receive palbociclib PO QD on days 1-21. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2860348|NCT03526237|Experimental|The 24-week treatment|The 24-week treatment, Sisters Health And Primary CarE Uniting and Preventing Diabetes (SHAPE UP) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.
2860349|NCT03526237|Other|Wait-list Control|Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.
2860350|NCT03526224||Aubagio|Individuals diagnosed with multiple sclerosis (MS) who have been treated with teriflunomide (Aubagio).
2860351|NCT03526224||Tecfidera|Individuals diagnosed with multiple sclerosis (MS) who have been treated with dimethyl fumarate (Tecfidera) and matched with the teriflunomide (Aubagio) patients on age, sex, disease duration, and disability level
2860352|NCT03526211|Experimental|Experimental|Patients with FES Cycling
2860383|NCT03526055|Experimental|>1000 µS Pulse Width|Intervention includes spinal cord stimulation will be programmed to >1000 µS pulse width and patient will undergo an Algovita Spinal Cord Stimulation System trial procedures. Following the trial procedure, the subject's EPG will be set to the appropriate pulse width, based on the arm assigned, and then programmed to achieve optimal pain relief.
2860353|NCT03526198|Experimental|Group 1 (adult)|Each volunteer stood on the platform. The duration of the tests was standardized at 10 seconds for each angulation variant of the test. The tilt variables occurred every 5 degrees oscillating in the two-dimensional movement of the ankle joint. The test was discontinued when the volunteer failed to remain balanced at the tested angulation for more than 10 seconds (thus shifting the foot (s) from the initial position or supporting with one and / or both arms at the therapist or at the support bars ) or when it reached maximum angulation
2860354|NCT03526198|Experimental|Group 2 (elderly)|Each volunteer stood on the platform. The duration of the tests was standardized at 10 seconds for each angulation variant of the test. The tilt variables occurred every 5 degrees oscillating in the two-dimensional movement of the ankle joint. The test was discontinued when the volunteer failed to remain balanced at the tested angulation for more than 10 seconds (thus shifting the foot (s) from the initial position or supporting with one and / or both arms at the therapist or at the support bars ) or when it reached maximum angulation
2860355|NCT03526185|Experimental|Tumor Infiltrating Lymphocytes|"After consent, subjects will undergo tumor resection for generation of autologous TIL cultures~Full body staging~Study investigators confirm cell product will be ready prior to lymphoablation~Non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide (60 mg/kg/day IV) on days -7 and -6, fludarabine (25 mg/m2/day) on days -5 through -1~On day 0 subjects will receive autologous TIL and then will begin intermediate-dose aldesleukin (IL-2) (72,000 IU/kg IV every 12 hours for up to 10 doses)~Safety monitoring daily during and immediately after lymphoablation~Adverse events assessment as medically indicated and at least 4 weeks and 8 weeks after hospital discharge~Response assessment at 8, 16 and 24 weeks post baseline, then q12w x 2 years or until progression"
2860356|NCT03526172||Control|Patients undergoing HTO without the inclusion of any bone wedge
2860357|NCT03526172||Allograft|Patients undergoing HTO with the inclusion of an allograft bone wedge
2860358|NCT03526159|Experimental|Gentamicin Sulfate|"IV Arm:~7.5 mg/kg gentamicin once daily for 14 days.~Topical Arm:~0.5% gentamicin ointment applied twice daily for 14 days to selected skin sites."
2860359|NCT03526146|Experimental|PLIE|PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
2860360|NCT03526146|No Intervention|Usua Care|Study participants who are randomized to the Usual Care (UC) control group will continue to participate in usual activities at the senior center, which include a combination of daily physical, mental and social activities.
2860361|NCT03526120|Experimental|Pistachio diet|Incorporates 44 g (1 serving) of pistachios into a daily diet
2860362|NCT03526120|No Intervention|Control|No pistachio consumption
2860363|NCT03526107|Active Comparator|CF Control|CF Control: 583 mg of cocoa flavanols, <1 mg caffeine and <1 mg theobromine
2860364|NCT03526107|Experimental|CF-Theobromine|CF-Theobromine: 566 mg of cocoa flavanols, 11 mg caffeine and 93 mg theobromine
2860365|NCT03526107|Experimental|CF-Caffeine|CF-Caffeine: 583 mg of cocoa flavanols, 112 mg caffeine and <1 mg theobromine(Experimental)
2860366|NCT03526094|Active Comparator|Flavanols-capsules|Capsules containing 456 mg cocoa flavanols and 315 g of milk (1% fat)
2860367|NCT03526094|Experimental|Flavanol-banana blend|Fruit blend prepared by mixing 177 g ripe, frozen bananas, 240 g almond milk and a chocolate flavored powder containing 626 mg cocoa flavanols
2860368|NCT03526094|Experimental|Flavanol-high protein drink|Drink prepared by mixing 225 mL of a chocolate flavored high protein dairy drink with a CF powder containing 533 mg cocoa flavanols
2860369|NCT03526094|Experimental|Flavanol-berry blend|Fruit blend prepared by mixing 120 g almond milk, 70 g water, 95 g yogurt, 50 g each strawberries, blueberries, blackberries, raspberries, 105 g crushed ice and a fruit-flavored powder containing 561 mg cocoa flavanols
2860370|NCT03526094|Experimental|Flavanol-sports drink|Drink prepared by mixing 488 g of a sports drink with a CF powder containing 533 mg cocoa flavanols
2860371|NCT03526094|Experimental|Flavanol-peanut butter toast|Prepared by mixing 32 g peanut butter with a chocolate flavored powder containing 602 mg cocoa flavanols and spread on 1 slice toasted bread (50 g) and 50 g sliced strawberries
2860372|NCT03526094|Experimental|Flavanol-oats|Prepared by mixing 40 g quick oats with 237 g boiling water and combined with a chocolate flavored powder containing 602 mg cocoa flavanols
2860373|NCT03526094|Experimental|Flavanol-yogurt|Prepared by 227 g yogurt (0% fat) mixed with a fruit-flavored powder containing 561 mg cocoa flavanols
2860374|NCT03526094|Active Comparator|II- Flavanol drink|Drink prepared by mixing 240 g almond milk with a chocolate flavored powder containing 626 mg cocoa flavanols
2860375|NCT03526094|Experimental|II- Flavanol drink + banana blend|Drink 1 (Flavanol drink): prepared by mixing 120 g almond milk with 626 mg cocoa flavanols Drink 2 (Fruit blend): prepared by mixing 120 g almond milk blended with 177 g ripe, frozen bananas
2860376|NCT03526081|Experimental|Chamomile Tea|Chamomile Tea in 300mL hot water
2860377|NCT03526081|Experimental|Parsley based drink|3.2 g dried parsley in 300mL hot water
2860378|NCT03526081|Experimental|Parsley Yogurt|3.2 g dried parsley in 100g plain yogurt
2860379|NCT03526081|Experimental|Apigenin|Apigenin capsule mixed with 300mL hot water
2860380|NCT03526081|Experimental|Parsley-based drink (II)|3.2 g of dried parsley in 300 ml of hot water
2860381|NCT03526068|Experimental|SafeZoneUVC|Patients were subjected to 90s UV light therapy of 540 mW/cm2 sessions 2 times a week for 2 weeks for a total of 4 sessions. Pre and post UV light therapy swabs were taken after standard wound irrigation
2860382|NCT03526055|Active Comparator|<500 µS Pulse Width|Intervention includes spinal cord stimulation will be programmed to <500 µS pulse width and patient will undergo an Algovita Spinal Cord Stimulation System trial procedures. Following the trial procedure, the subject's EPG will be set to the appropriate pulse width, based on the arm assigned, and then programmed to achieve optimal pain relief.
2860384|NCT03526042|Experimental|Losartan|AT1R-ab effect can be blocked with the use of angiotensin-II receptor blockers. The participants will receive losartan.
2860385|NCT03526042|Active Comparator|Enalapril|Angiotensin converting enzyme inhibitors are indicated in the management of active lupus nephritis but do not block the effect of AT1R-Ab.
2860387|NCT03525990|Active Comparator|Intervention Arm|Quality of life questionnaires (electronic patient reported outcomes) to be filled out by the patients at every visit. Quality of life data is fully available for physicians. Paper-based questionnaire (EORTC QLQ-COMU26) at baseline, after three months and after six months.
2860388|NCT03525990|Placebo Comparator|Control Arm|Quality of life questionnaires (electronic patient reported outcomes) only to filled out by the patients at baseline, after three months and after six months. Quality of life data is hidden for physicians. Paper-based questionnaire (EORTC QLQ-COMU26) at baseline, after three months and after six months.
2860389|NCT03525977|No Intervention|Control|Patients in the control arm will receive pain control via traditional oral and intravenous pain medications such as opioids and non-steroidal anti-inflammatory medication as needed.
2860390|NCT03525977|Experimental|Fascia iliaca block|Patients in the intervention arm will receive the regional fascia iliaca block performed by the anesthesiologists on call.
2860391|NCT03525964|Experimental|Individualized treatment|"The ruptured achilles tendon is examined by ultrasonography. If the overlap of the tendon ends is less than 25 % or the tendon is elongated 7 % or more the patient receives conventional open operative treatment. The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anaesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below-the-knee cast after surgery. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.~The patient will follow standard functional rehabilitation and the follow-up evaluations."
2860392|NCT03525964|Active Comparator|Control group 1|"For the patients allocated to non-operative treatment the injured leg is placed in a circulated below-the-knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.~The patient will follow standard functional rehabilitation and the follow-up evaluations."
2860393|NCT03525964|Active Comparator|Control group 2|"The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anaesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below-the-knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.~The patient will follow standard functional rehabilitation and the follow-up evaluations."
2860394|NCT03525951|Active Comparator|Typically Developing Children|Parent Early Language Stimulation Training
2860395|NCT03525951|Experimental|Children with Dev Language Disorder|Parent Early Language Stimulation Training
2860396|NCT03525951|Experimental|Children with Autism Spectrum Disorders|Parent Early Language Stimulation Training
2860397|NCT03525938|Active Comparator|TAP group|
2860398|NCT03525938|Sham Comparator|SHAM group|
2860399|NCT03525925|Experimental|Treatment (ibrutinib, nivolumab)|Participants receive ibrutinib PO daily for 15 days. After 7 days receiving ibrutinib, participants receive nivolumab IV over 60 minutes on days 1 and 15. Courses with nivolumab repeat every 28 days in the absence of disease progression or unaccepted toxicity.
2860400|NCT03525912|Experimental|Ketamine infusion|postoperative pain in adult population after abdominal, thoracic and orthopedic surgery that received adjuvant analgesia with ketamine 0.1mg/kg/h during 24 to 48 hours in postoperative period.
2860401|NCT03525899||MH after diabetic pars plana vitrectomy|Recruited patients included, the persistent MH group, who had MH before the primary DV, and the newly-developed MH group, who developed MH after a successful primary DV
2860402|NCT03525886|Experimental|NBI-74788 Dose Group 1|NBI-74788 administered orally for 14 consecutive days.
2860403|NCT03525886|Experimental|NBI-74788 Dose Group 2|NBI-74788 administered orally for 14 consecutive days. Dosing will not commence until safety and tolerability data from Dose Group 1 have been reviewed.
2860404|NCT03525873|Experimental|ARM I (methylphenidate, physical activity)|Participants receive methylphenidate PO BID for up to 2 weeks in the absence of disease progression or unacceptable toxicity. Participants also complete physical activity consisting of walking and resistance exercise over 25-40 minutes QD 4 days a week. After 2 weeks, participants may continue methylphenidate at the discretion of the treating physician for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
2860405|NCT03525873|Placebo Comparator|ARM II (placebo, physical activity)|Participants receive a matched placebo PO BID and complete physical activity as in Arm I. Treatment continues for up to 2 weeks in the absence of disease progression or unacceptable toxicity.
2860406|NCT03525860|Experimental|Acupuncture Treatment|"20 subjects will be treated with standard of care and acupuncture.~Will complete Symptom and Pain questionnaire (VAS) and a Was It Worth It (WIWI) questionnaire each day of study participation (3 days)."
2860407|NCT03525860|No Intervention|No Intervention|"20 subjects will be treated with standard of care only.~Will complete Symptom and Pain questionnaire (VAS) each day of study participation (3 days)."
2860408|NCT03525847|Active Comparator|contrast enhanced FNA endosonography|First passage in the solid pancreatic tumor using FNA endosonography then with the contrast enhanced FNA endosonography
2860409|NCT03525847|Active Comparator|FNA standard endosonography|First passage in the solid pancreatic tumor using contrast enhanced FNA endosonography then with the FNA endosonography
2860410|NCT03525834|Experimental|everolimus|Everolimus oral tablets, 10 mg per day
2860411|NCT03525821|Experimental|intranasal administration of ketamine|intranasal adminstration of ketamine combined with nitrous oxide befor reduction of fracture
2860412|NCT03525808|Experimental|AXIOS|Patients will receive the AXIOS stent for the treatment of walled-off pancreatic necrosis.
2860413|NCT03525795|Experimental|CPI-1205 Combination with ipilimumab|
2860415|NCT03525782|Experimental|CAR-T combining PD-1 knockout|Anti-MUC1 CAR-T cells and PD-1 knockout Engineered T cells will be prepared ex vivo and infused back to the patients.
2860416|NCT03525782|Experimental|PD-1 knockout|PD-1 knockout Engineered T cells will be prepared ex vivo and infused back to the patients.
2860417|NCT03525782|Active Comparator|PD-1 mAb|Patients will be treated with a FDA approved monoclonal antibody for an identical course of treatment. This group will serve as PD-1 antibody treated group.
2860418|NCT03525782|Placebo Comparator|Sham Control|Patient's T cells will be separate without genetic or engineered modification ex vivo and infused back to the patients.
2860419|NCT03525769||Type 2 Diabetes Mellitus|
2860420|NCT03525756||Cystogram on Post-Op Day 2|An indwelling Foley catheter is placed intraoperative and continued postoperative. All patients who consent to participate would undergo a cystogram on postoperative day two. The cystogram will be conducted by a radiologist and technician well-trained in the techniques and interpretation of the study. The colorectal surgery enhanced recovery protocol will be followed on all patients with the exception of the cystogram being conducted on post-op day two.
2860421|NCT03525743||Patients undergoing intubation|Adhesive gel pads will be placed on patient to measure continuous cardiac output and to calculate stroke volume variation. Other physiologic data will be analyzed in real time using the NICOM (Non invasive cardiac output monitor) device.
2860422|NCT03525730|No Intervention|Control|This group receives no intervention.
2860423|NCT03525730|Experimental|Valproic acid|This group receives valproic acid (enteric) for 14 days.
2860424|NCT03525730|Experimental|Pyrimethamine|This group receives pyrimethamine for 14 days.
2860425|NCT03525730|Experimental|Valproic acid and Pyrimethamine|This group receives valproic acid and pyrimethamine for 14 days.
2860426|NCT03525717|Active Comparator|Routine Dinner|"Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at routine dinner time (18:00) followed by a sleep study (23:00). Timing of dinner is the sole intervention distinguishing this arm from late dinner. This arm will cross-over to late dinner in random order."
2860427|NCT03525717|Experimental|Late Dinner|"Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (22:00) followed by a sleep study (23:00). Timing of dinner is the sole intervention distinguishing this arm from routine dinner. This arm will cross-over to routine dinner in random order."
2860428|NCT03525691|Experimental|Minimal distension|Tidal volume 4 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)
2860429|NCT03525691|Experimental|Maximal recruitment|Tidal volume 4 ml/kg PBW and PEEP adjusted to maintain a plateau pressure between 23 - 25 cmH2O + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)
2860430|NCT03525691|Active Comparator|Standard|Tidal volume 6 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) without ECCO2R (no sweep gas flow, blood flow = 400 mL/min)
2860431|NCT03525678|Experimental|Subjects receiving frozen 2.5 mg/kg GSK2857916|Subjects will be randomized in 1:1 ratio to receive either 2.5 or 3.4 mg/kg frozen liquid GSK2857916. Subjects will administer frozen liquid GSK2857916 via infusion pump for once in every 3 weeks.
2860432|NCT03525678|Experimental|Subjects receiving frozen 3.4 mg/kg GSK2857916|Subjects will be randomized in 1:1 ratio to receive either 2.5 or 3.4 mg/kg frozen liquid GSK2857916. Subjects will administer frozen liquid GSK2857916 via infusion pump for once in every 3 weeks.
2860433|NCT03525678|Experimental|Subjects receiving lyophilized GSK2857916|Subjects in lyophilized arm will receive lyophilized GSK2857916 once lyophilized configuration becomes available and enrollment has been completed for frozen liquid arms.
2860434|NCT03525652|Active Comparator|Therapeutic vaccine|Therapeutic vaccine will be prepared ex vivo using the peripheral mononuclear cells from the patients and the vaccine (as maturated dendritic cells) will be infused back to the patients in 3 times with a 2-week interval.
2860435|NCT03525652|Experimental|Therapeutic vaccine plus PD-1 knockout|Therapeutic vaccine and PD-1 knockout T cells will be prepared ex vivo using the white cells from the patients and the vaccine (as maturated dendritic cells) and maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
2860436|NCT03525652|Active Comparator|PD-1 knockout T cells|PD-1 knockout T cells will be prepared ex vivo using the white cells from the patients and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
2860437|NCT03525639|Experimental|Patients with Acute Myocarditis|Patients undergoing Cardiac Magnetic Resonance at baseline, 1 month, 1 year.
2860438|NCT03525626|Experimental|Online Mindfulness-based Tic Reduction|
2860439|NCT03525613|Experimental|APL-2 15mg 0.1 mL Monthly for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month
2860440|NCT03525613|Experimental|APL-2 15mg 0.1 mL EOM for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month
2860441|NCT03525613|Experimental|Sham Procedure Monthly for 24 months|Sham Procedure monthly for 24 months
2860442|NCT03525613|Experimental|Sham Procedure Every Other Month for 24 months|Sham Procedure every other month for 24 months
2860443|NCT03525600|Experimental|APL-2 15mg 0.1 mL monthly for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month
2860444|NCT03525600|Experimental|APL-2 15mg 0.1 mL EOM for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month
2860445|NCT03525600|Experimental|Sham Procedure Monthly for 24 months|Sham Procedure for 24 months
2860446|NCT03525600|Experimental|Sham Procedure Every Other Month for 24 months|Sham Procedure every other month for 24 months
2860447|NCT03525587|Active Comparator|Ongoing r-hGH therapy|"Patients on long-term r-hGH therapy.~Intervention: Use of MAGHD App/MAGHD Framework"
2860448|NCT03525587|Active Comparator|Previous r-hGH therapy|"Patients previously treated with r-hGH, who had stopped the treatment for any reason (age, concomitant adverse reactions, contraindications or personal will).~Intervention: Use of MAGHD App/MAGHD Framework"
2860449|NCT03525587|Active Comparator|Never treated|"Patients never treated for any reason (according to age, contraindications or lack of patient's consent).~Intervention: Use of MAGHD App/MAGHD Framework"
2860450|NCT03525574|Experimental|Open-label Triple Combination|"Subjects will receive 200 mg VX-445/ 100 mg TEZ/ 150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening.~Parent studies are Phase 3 Vertex studies investigating VX-445 in combination with TEZ and IVA. This includes, but is not limited to, Studies VX17-445-102 and VX17-445-103."
2860451|NCT03525561|Active Comparator|acetazolamide arm|This is the arm of the study in which the volunteers will take the acetazolamide (Diamox) pill.
2860452|NCT03525561|Placebo Comparator|placebo arm|This is the arm of the study in which volunteers will take the placebo.
2860453|NCT03525548|Experimental|Triple Combination|Subjects will receive 200 mg VX-445/ 100 mg TEZ/ 150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening
2860454|NCT03525548|Active Comparator|TEZ/IVA|Subjects will receive 100 mg TEZ/ 150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening
2860455|NCT03525535||Pulmonary embolism|data from routine care will be collected for patient eligible and willing to participate
2860456|NCT03525522|Experimental|Nd:YAG Laser|Three sessions of Nd:YAG laser (1064 nm) treatment with Dynamis (Fotona, Slovenia)
2860457|NCT03525522|Active Comparator|Topical Corticosteroid Diprosone|Topical corticosteroid betamethasone (Diprosone, Merck Sharp & Dohme, d.o.o.) for 3 months.
2860458|NCT03525509|Experimental|Epidural methadone|A single 4mg epidural bolus of methadone hydrochloride
2860459|NCT03525509|Active Comparator|Epidural morphine|A single 4mg epidural bolus of morphine sulfate
2860460|NCT03525483|Experimental|Patients with ECMO|"Patients with circulatory assistance by ECMO Patients are included 48 hours after ECMO VA or VV therapy and after hemodynamic stabilization defined by blood pressure stability and cardiac output for at least 12 hours without significant changes in amine flow.~When stable they will have an Ultrasound for renal resistivity index measurement"
2860461|NCT03525470|Experimental|Water|Subjects consumed water
2860462|NCT03525470|Experimental|No water|Subjects did not consume water
2860463|NCT03525457|Experimental|Experimental|Non surgical periodontal therapy
2860464|NCT03525444|Experimental|Triple Combination|Subjects will receive 200 mg VX-445/ 100 mg TEZ/ 150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening
2860465|NCT03525444|Placebo Comparator|Placebo|
2860466|NCT03525431|Experimental|Whole Exome Sequencing|Following consent and collection of standardized phenotypic data, probands and biological parents will undergo WES with variant analysis conducted utilizing primary gene lists based on referring clinical indication. After results provision and follow up 6-12 months later, clinical utility will be assessed in those with a positive result (pathogenic or likely pathogenic variant) and those with negative results (no variant returned or a VUS) using specific outcomes at each site to examine effectiveness for both the child and family.
2860467|NCT03525418|Experimental|Cohort A - Phase 1 (Open Label)|10 consecutive HLHS patients will be enrolled and treated with Longeveron Mesenchymal Stem Cells (LMSCs). A single administration of LMSCs will be performed via intramyocardial injections during the Stage II (BDCPA) surgery. Dosing is based on body weight. Each LMSC-treated patient will be given 2.5 x 105 LMSCs per kg of body weight. The entire dose of the cells will be roughly 600 microliters.
2860468|NCT03525418|Experimental|Cohort B - Phase 2 Treatment Group|Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.
2860469|NCT03525418|No Intervention|Cohort C - Phase 2 Control Group|Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.
2860470|NCT03525405|Experimental|Single Dose|
2860471|NCT03525392|Experimental|177Lu-3BP-227|"Screening: 177Lu-IPN01087 - 25 µg 3BP-227 (IPN01087) per 1 GBq of 177Lu. 1 GBq in a total volume of 10 mL.~Treatment phase: 177Lu-IPN01087 - 2.5 to 7.5 GBq escalation dose of 177Lu-3BP-227 (IPN01087) in a total volume of 20 mL for each cycle of administration (2 cycles plus 4 optional additional)."
2860472|NCT03525379|Experimental|Resveratrol|1) Resveratrol- (Transmax) trans- resveratrol (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules. One capsule will be taken orally 2 times per day (BID) for 8 weeks.
2860473|NCT03525379|Placebo Comparator|Placebo|2) Placebo- 500mg (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules. One capsule will be taken orally 2 times per day (BID) for 8 weeks.
2860474|NCT03525353||Patients undergoing ERCP by formally trained Endoscopists|Patients who undergo ERCP (Endoscopic Retrograde Cholangio Pancreatography) performed by Endoscopists who are trained on minimum use of fluoroscopy.
2860475|NCT03525353||Patients undergoing ERCP by Endoscopists not formally trained|Patients who undergo ERCP (Endoscopic Retrograde Cholangio Pancreatography) performed by Endoscopists who have not received formal training on minimum use of fluoroscopy.
2860476|NCT03525340|No Intervention|Standard of Care|Participants in the standard of care arm will receive no navigation assistance to remain in care. They will provide informed consent, respond to baseline and endline surveys, and have clinic record data extracted for the 9 months of their study participation, but no additional services to remain engaged in care other than what is provided as standard by the clinic.
2860477|NCT03525340|Experimental|Peer Navigation|Participants in the peer navigation arm will meet with a peer navigator at least once per month for nine months in-person, and have at least one other navigator contact per month. Like the standard of care arm, they will provide informed consent, respond to baseline and endline surveys, and have clinic record data extracted for the 9 months of their study participation.
2860478|NCT03525327||Line Dance Class participants|The group will be participating in line dance classes as intervention.
2860479|NCT03525301|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fractions
2860480|NCT03525301|Experimental|short course treatment|patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
2860481|NCT03525288|Experimental|PSMA-PETgRT|PSMA-PET/CT imaging is performed during treatment planning. Treating physicians are informed of test results and advised to include up to 5 PSMA-PET avid sites distant to the prostate gland, if present, in the radiotherapy treatment plan.
2860482|NCT03525288|Active Comparator|Standard|Patient`s receive standard care radiotherapy and do not undergo PSMA-PET/CT imaging.
2860483|NCT03525275|Experimental|BFA with Physical Therapy|BFA + post-surgical protocol, intervention = battlefield acupuncture plus post-surgical protocol
2860484|NCT03525275|Active Comparator|Physical Therapy alone|Intervention = Post-surgical protocol
2860485|NCT03525262|No Intervention|SAbR WITHOUT Neurovascular sparing|"GTV represents MR defined gross radiographic disease, if identifiable.~CTV encompasses the full prostate. At physician's discretion, the insertion of the seminal vesicle upon the prostate on slices containing prostate may be included.~PTV1_30Gy will not be used or created on this arm~PTV2_SAbR will be generated by a 3mm expansion on the CTV. PTV2_SAbR will receive 8-9 Gy per fraction for 5 fractions (40-45 Gy)."
2860486|NCT03525262|Experimental|SAbR WITH Neurovascular sparing|"GTV represents MR defined gross radiographic disease, if identifiable.~CTV encompasses the full prostate. At physician's discretion, the insertion of the seminal vesicle upon the prostate on slices containing prostate may be included.~PTV1_30Gy represents a 3mm expansion on the CTV, excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).~PTV2_SAbR will be generated by subtracting a 5mm expansion around the neurovascular elements to be spared (at least one side, left or right) from PTV1. These neurovascular structures consist of the neurovascular bundle, penile bulb, and internal pudendal arteries. PTV2 will receive 8-9 Gy per fraction for 5 fractions (40-45 Gy)."
2860487|NCT03525249|Experimental|Comparator Membraflex 500mg|experimental product one dose
2860488|NCT03525249|Experimental|Comparator Membraflex 300mg|experimental product two doses
2860489|NCT03525249|Placebo Comparator|Placebo Comparator|placebo product
2860490|NCT03525236|Experimental|Taste of 5 flavors|"Each patient will taste 5 products, in sequential-monadic test, randomized, one by one.~Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients)~For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product.~Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes"
2860491|NCT03525223|Active Comparator|dialysate [Na+] 138 mmol/l|Intervention: Change of dialysate [Na+] from 138 mmol/l to 142 mmol/l The dialysate [Na+] will be increased by 2 mmol/l per week and kept constant for 5 weeks (altogether 6 weeks). Before and after intervention tissue [Na+] will be determined by sodium MRI. Additionally body fluid distribution (by bioimpedance spectroscopy) and central arterial pressure wave form, pulse wave velocity as well as flow-mediated vasodilatation will be assessed.
2860492|NCT03525223|Active Comparator|dialysate [Na+] 142 mmol/l|Intervention: Change of dialysate [Na+] from 142 mmol/l to 135 mmol/l The dialysate [Na+] will be decreased by 2 mmol/l per week for 3 weeks and by 1mmol/l for 1 further week. Afterwards the dialysate [Na+] will be kept constant for 5 weeks (altogether 8 weeks). Before and after intervention tissue [Na+] will be determined by sodium MRI. Additionally body fluid distribution (by bioimpedance spectroscopy) and central arterial pressure wave form, pulse wave velocity as well as flow-mediated vasodilatation will be assessed.
2860493|NCT03525210|Other|HIV patients|All HIV patients will receive the study vaccines
2860494|NCT03525210|Other|SOT patients|All SOT patients will receive the study vaccines
2860495|NCT03525197|Experimental|Whey protein-based supplement|Participants in the experimental condition will consume a supplement containing Whey Protein Isolate (20g) and other ingredients
2860496|NCT03525197|Active Comparator|Collagen protein-based supplement|Participants in the experimental condition will consume a supplement containing Collagen protein (20g) and other ingredients
2860497|NCT03525184|Placebo Comparator|Normal sleep|A normal sleep condition and the placebo treatment (0.9 g protein/kg body weight/day + placebo beverage; NS)
2860498|NCT03525184|Placebo Comparator|72-h Sleep restriction with placebo beverage|Sleep restriction (72-h with 2-h of sleep per night) and the placebo treatment (0.9 g protein/kg body weight/day + placebo beverage; SR),
2860499|NCT03525184|Experimental|72-h Sleep restriction with multi-nutrient beverage|Sleep restriction (72-h with 2-h of sleep per night) and the experimental treatment (1.5 g protein/kg body weight/day + multi-nutrient beverage; SR+).
2860500|NCT03525171|Active Comparator|GHD children|23 prepubertal children with isolated GHD consecutively admitted to the Section of Endocrinology of the University of Palermo during treated with GH for at least 12 months underwent full metabolic evaluation including euglycemic hyperinsulinemic clamp
2860501|NCT03525171|Placebo Comparator|controls|12 prepubertal healthy subjects with short stature recruited among children referred for assessment of short stature as a control group at baseline underwent full metabolic evaluation including euglycemic hyperinsulinemic clamp
2860502|NCT03525158|No Intervention|Baseline phase ('A')|Measurements collected in a pen-and-paper diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.
2860503|NCT03525158|Other|Intervention phase ('B')|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game-play) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a pen-and-paper diary four times a day over one week following the intervention for the primary outcome (occurrence of intrusive memories of trauma).
2860504|NCT03525132|Experimental|Healthy subjects|120 healthy subjects in the first session and 30 in the second Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
2860505|NCT03525132|Experimental|Glaucoma|60 subjects with glaucoma Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
2860506|NCT03525132|Experimental|Retinal vein occlusion|80 subjects with retinal vein occlusion including 40 with peripheric occlusion and 40 with central occlusion Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
2860507|NCT03525119|Other|HAV Vaccine 1.0 ml + Placebo|HAV vaccine 1.0 ml, injection, IM, and placebo, injection, SC, once on Day 1 (first dose) followed by placebo, injection, SC on Day 90 (second dose).
2861712|NCT03516916||Denmark|Patients with a permanent colostomy after curative surgery for rectal cancer
2860508|NCT03525119|Experimental|TDV 0.5 ml + Placebo|TDV 0.5 ml, injection, SC, and placebo, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).
2860509|NCT03525119|Experimental|TDV 0.5 ml + HAV Vaccine 1.0 ml|TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).
2860510|NCT03525106|Experimental|Participants: Positive Psychology Intervention|Participants receive a positive psychology exercise manual, complete positive psychology exercises every week, and participate in phone sessions over 30 minutes every week for 8 weeks.
2860511|NCT03525106|Experimental|Caregivers: Positive Psychology Intervention|Caregivers receive a positive psychology exercise manual, complete positive psychology exercises every week, and participate in phone sessions over 30 minutes every week for 8 weeks.
2860512|NCT03525093|Active Comparator|Hypnosis + health education|5 sessions of group hypnosis, each 90 minutes; plus CDs/MP3 recordings to train at home plus health education booklet on coping with stress
2860513|NCT03525093|Other|Health education alone|Patients receive a health education booklet to improve coping with stress
2860514|NCT03525080|Experimental|PET Arm|
2860515|NCT03525067||Patients with Bile Samples|Patients underwent pancreaticoduodenectomy who had intraoperative bile sampling for bacterial examination.
2860516|NCT03525041|Active Comparator|CABG+mitral valve annuloplasty|Participants will undergo CABG and mitral valve annuloplasty.
2860517|NCT03525041|Active Comparator|CABG|Participants will undergo CABG only.
2860518|NCT03525028|Experimental|Metformin group|Oral metformin 500 mg once daily for first week, 500 mg twice daily for next 23 weeks. The follow-up treatment according to the participants' condition.
2860519|NCT03525028|Placebo Comparator|Placebo group|Oral placebo 500 mg once daily for first week, 500 mg twice daily for next 23 weeks. The follow-up treatment according to the participants' condition.
2860520|NCT03525015|Experimental|A decision aid booklet|A decision aid booklet about cataract surgery choice
2860521|NCT03525015|Active Comparator|An usual booklet|An usual booklet about cataract and cataract surgery
2860522|NCT03525002|Placebo Comparator|FTO SNP rs8050136 (AA), Placebo|Participants with FTO SNP rs8050136 AA receiving matching Placebo
2860523|NCT03525002|Active Comparator|FTO SNP rs8050136 (AA), Bromocriptine|Participants with FTO SNP rs8050136 AAreceiving Bromocriptine up to 5 mg
2860524|NCT03525002|Placebo Comparator|FTO SNP rs8050136 (CA), Placebo|Participants with FTO SNP rs8050136 CA receiving matching Placebo
2860525|NCT03525002|Active Comparator|FTO SNP rs8050136 (CA), Bromocriptine|Participants with FTO SNP rs8050136 CA receiving Bromocriptine up to 5 mg
2860526|NCT03525002|Placebo Comparator|FTO SNP rs8050136 (CC), Placebo|Participants with FTO SNP rs8050136 CC receiving matching Placebo
2860527|NCT03525002|Active Comparator|FTO SNP rs8050136 (CC), Bromocriptine|Participants with FTO SNP rs8050136 CC receiving Bromocriptine up to 5 mg
2860528|NCT03524989|Active Comparator|Treatment|Hyperbaric Oxygen Therapy: 2 months of treatment consisting of 40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
2860529|NCT03524989|Sham Comparator|Control/Crossover|SHAM therapy: 2 months of treatment consisting of 40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week
2860530|NCT03524976||Embolization with Squid|All patients with DAVFs are treated with SQUID™ aiming at complete occlusion of the fistula. Each participating center will include patients with DAVFs in whom the liquid embolic agent SQUID™ is planned to be used consecutively in the study. The
2860531|NCT03524963|Experimental|Sequence A|Cilostan CR Tab. in phase 1 and Pletaal SR Cap. in phase 2
2860532|NCT03524963|Experimental|Sequence B|Pletaal SR Cap. in phase 1 and Cilostan CR Tab. in phase 2
2860533|NCT03524950|No Intervention|no dexmedetomidine|
2860534|NCT03524950|Experimental|high dose dexmedetomidine|
2860535|NCT03524950|Experimental|low dose dexmedetomidine|
2860536|NCT03524937|Experimental|MELATONIN (LOW DOSE)|Daily administration of melatonin by enteral route at 0.3 mg/day (low dose arm), up to 14 days.
2860537|NCT03524937|Experimental|MELATONIN (HIGH DOSE)|Daily administration of melatonin by enteral route at 3 mg/day (high dose arm), up to 14 days.
2860538|NCT03524937|Placebo Comparator|PLACEBO|Daily administration of identical placebo up to 14 days.
2860539|NCT03524924||non-frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: < 0.3151361243 Male: < 1.211878526
2860540|NCT03524924||pre-frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: 0.3151361243 to < 2.1301121973 Male: 1.211878526 to < 3.0052612772
2860541|NCT03524924||frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: 2.1301121973 to < 6 Male: 3.0052612772 to < 7
2860542|NCT03524911|Experimental|CHFFF nutrition education|Expanded Food and Nutrition Education (EFNEP) participants in 5 NY counties in 2015
2860543|NCT03524898|Experimental|nab-paclitaxel and gemcitabine|Treatment consists of the combination treatment of nab-paclitaxel and gemcitabine, which is given every 2 weeks during 28-day cycle intervals until disease progression.
2860544|NCT03524885|Active Comparator|Short implants|2 or 3 implant 4-5 mm length and 4 mm diameter (Syra Short, Sweden & Martina, Padua, Italy) will be positioned. The healing cap will be immediately connected and a vycril suture will be done after soft tissue reflection.
2860545|NCT03524885|Experimental|Bone regeneration with longer implants|"A horizontal and vertical regeneration following GBR technique will be performed using not-resorbable PTFE titanium reinforced membrane (Cytoplast Osteogenics, US) fixed by titanium pins or miniscrews to ensure the perfect stability (Pro-fix, Cytoplast Osteogenics, US).~The graft will be composed half autogenous bone harvested with a scraper (Meta, Firenze, Italy) by the same surgical site or by a second tunnel site in the mandibular ramus and half deproteinized bovine bone (Bio Oss Geislicht Pharma, Switzerland). The mucosal flaps will be sutured in a double layer with horizontal mattress and single gore-tex sutures (Cytoplast PTFE sutures 3.0, Cytoplast Osteogenics, US).~2 or 3 implant from 10 to 13 mm length putting the implant platform 2 or 3 mm apical to CEJ of the adjacent tooth will be inserted."
2860546|NCT03524872|Active Comparator|Original CAD/CAM abutment|Patients will be rehabilitated using Sweden&Martina implants and original (Sweden&Martina) CAD/CAM abutments.
2860583|NCT03524586|Active Comparator|Contralateral rotation of head|Head was laterally rotated to the opposite side against fixed tube
2860547|NCT03524872|Experimental|Compatible CAD/CAM abutment|Patients will be rehabilitated using Sweden&Martina implants and compatible (New Ancorvis) CAD/CAM abutments.
2860548|NCT03524859||Cystic fibrosis|Cystic fibrosis participants without experience on endurance or resistance training will be analyzed through a test battery and lung function test.
2860549|NCT03524859||Healthy Subjects|Healthy matched control group without experience on endurance or resistance training will be analyzed through a test battery.
2860550|NCT03524846|Active Comparator|Ascorbic acid 300 mg|Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
2860551|NCT03524846|Active Comparator|Ascorbic acid 600 mg|Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
2860552|NCT03524846|Placebo Comparator|Placebo|Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
2860553|NCT03524833|Other|Intraluminal Metronidazole eradication|Twenty patients receive intraluminal Metronidazole eradication of H. pylori.
2860554|NCT03524833|Other|oral antibiotic triple therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.
2860555|NCT03524820|Experimental|Metastatic colorectal cancer patients|Metastatic colorectal cancer patients receiving third line cetuximab treatment
2860556|NCT03524807|Experimental|Electrophysiologic therapy group|apply electrophysiologic therapy after surgery
2860557|NCT03524807|No Intervention|non-electrophysiologic therapy group|do not apply electrophysiologic therapy after surgery
2860558|NCT03524768||patients presenting with Chagas cardiomyopathy|Evaluation of systemic microvascular reactivity using laser speckle contrast imaging Evaluation of skin capillary density using video-capillaroscopy
2860559|NCT03524768||control group|Evaluation of systemic microvascular reactivity using laser speckle contrast imaging Evaluation of skin capillary density using video-capillaroscopy
2860560|NCT03524755|Experimental|Training Group|Warm up period for 5 minutes on a bicycle ergometer or an upper body cycle with individual selectable wattage. A leg press, a latissimus pull-down and a chest press formed the three equipment supported core exercises. All exercises were performed with 8-12 repetitions and 3 sets. 3 training sessions (30min for each session) per week for during the course of radiotherapy (~6 weeks).
2860561|NCT03524755|No Intervention|Control Group|The control group received usual care.
2860562|NCT03524742|Experimental|Avocado-Mediterranean Diet|Avocado based Mediterranean diet with intake of ½ portion of a Hass avocado per day, during 3 months.
2860563|NCT03524742|Active Comparator|Control-Group Diet|Control-Group Diet consists of a low fat-high complex carbohydrate diet, during 3 months.
2860564|NCT03524729|Active Comparator|Ankle osteoarthritis patients|Ambulatory adult patients (18+) with ankle osteoarthritis.
2860565|NCT03524729|Other|Healthy control subjects|Ambulatory adults (18+) with no known ankle osteoarthritis.
2860566|NCT03524716|Experimental|Fitbit and Text Messages|Participants randomized to this arm receive print materials and a Fitbit Flex 2 at baseline and daily text messages for 12 weeks.
2860567|NCT03524716|No Intervention|Usual Care|Participants randomized to usual care receive print materials at baseline.
2860568|NCT03524703|Experimental|Chewing Gum Group|Patients who receive anterior cervical fusion and have mild or moderate dysphagia postoperatively, will be randomized into two groups. Subjects assigned to the Chewing Gum Group are asked to chew gum four times a day for 5 days (15 minutes each time) after surgery in addition to standard cares. Standard cares include cleaning the wound every 2 days, wearing a collar, pain management, and education.
2860569|NCT03524703|No Intervention|Control Group|Patients who receive anterior cervical fusion and have mild or moderate dysphagia postoperatively, will be randomized into two groups. Subjects assigned to the Control Group receive standard cares and are asked not to chew gum within 5 days after surgery. Standard cares include cleaning the wound every 2 days, wearing a collar, pain management, and education.
2860570|NCT03524690|Active Comparator|SUSOPS Balance|Volunteers provided sufficient food to maintain energy balance.
2860571|NCT03524690|Experimental|SUSOPS Negative Balance|Volunteers provided insufficient food to maintain energy balance resulting in negative energy balance.
2860572|NCT03524677||Non metastatic pancreatic cancer|patients with biopsy or fnac proven ductal adenocarcinoma without any systemic metastatic spread at preoperative imaging
2860573|NCT03524664|No Intervention|"Delayed tuning in to kids intervention"|Children with fetal alcohol spectrum disorder and their parents
2860574|NCT03524664|Experimental|"Tuning in to kids intervention"|Children with fetal alcohol spectrum disorder and their parents
2860575|NCT03524651|Active Comparator|Ferrous sulfate|Patients will take every day for 12 weeks two oral capsules of 150 mg ferrous sulfate delivering 47 mg of active elemental iron. Capsules should be taken orally either two hours before meal or two hours after meal. The same patients will take every day on exactly the same time for 12 weeks two placebo vials of 15 ml volume with excipients contained in the commercially available formulation Fe-Asp Omalin (Uni-Pharma SA).
2860576|NCT03524651|Active Comparator|Fe-ASP|Patients will take every day for 12 weeks two oral placebo capsules. Capsules should be taken orally either two hours before meal or two hours after meal. The same patients will take every day on exactly the same time for 12 weeks two vials of 15 ml volume of the Fe-Asp preparation Omalin (Uni-Pharma SA) delivering 40 mg of elemental iron.
2860577|NCT03524638|Active Comparator|ARM A|Colorectal surgery with administration of VSL3
2860578|NCT03524638|Active Comparator|ARM B|Colorectal Surgery alone
2860579|NCT03524612|Other|eltrombopag|Participants will be treated with eltrombopagto to induce sustained remission to reach a target platelet count of ≥ 100×109/L (CR), after 1st line steroids have failed.
2860580|NCT03524599|Experimental|Intervention municipality|In the intervention municipalities, primary health care providers will receive ongoing training and support in undertaking screening and brief advice for heavy drinking. They will also receive community-based five adoption mechanisms and five support systems.
2860581|NCT03524599|No Intervention|Comparator municipality|In the comparator municipalities, the primary health care providers will be given a summary card of screening and brief advice for heavy drinking, with no instruction
2860582|NCT03524586|Experimental|Ipsilateral rotation of head|Head was laterally rotated to the same side against fixed tube
2860584|NCT03524573|Experimental|Delayed Appendectomy|Patients will undergo appendectomy the morning following the decision to operate. This group will have an anticipated delay between 3 - 14 hours from the decision to operate, with a surgical start time between 0600 - 0900.
2860585|NCT03524573|Active Comparator|Immediate Appendectomy|Patients will undergo appendectomy within 6 hours of the decision to operate. Surgery will take place between 2200 - 0400.
2860586|NCT03524547|Experimental|J-shaped|Endotracheal tube will be molded into a J-shape that is similar to that of Macintosh type blade of a McGrath MAC® videolaryngoscope.
2860587|NCT03524547|Active Comparator|60-degrees|Endotracheal tube will be bent 60 degrees.
2860588|NCT03524534|Active Comparator|Telephone Follow-Up Intervention|
2860589|NCT03524534|Active Comparator|In-person follow-up intervention|
2860590|NCT03524521|Active Comparator|Standard Walking|This arm is prescribed standard of care exercise prescription; 30 minutes of moderate intensity walking, 5 days/week.
2860591|NCT03524521|Experimental|Interval Training|This arm is prescribed body-weight based interval training 3 days per week with progressive increase in exercise intervals and sets.
2860592|NCT03524508|Experimental|5-FU/LV/Onivyde|Onivyde 70 mg/m2 (90 minutes), leucovorin (LV) 400 mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.
2860593|NCT03524508|Active Comparator|5FU/LV|leucovorin (LV) 400 mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.
2860594|NCT03524482|Experimental|Path2Quit|Culturally specific text message intervention
2860595|NCT03524482|Active Comparator|SmokeFreeText|The National Cancer Institute's publicly available, standard text messaging program for tobacco cessation
2860596|NCT03524469||Normal weight|"Normal Weight will be defined as pre-pregnant BMI between 18.5-23.9 kg/m2 and passing the 28 week oral glucose tolerance test."
2860597|NCT03524469||Insulin resistant|"Insulin Resistance will be defined as meeting any of the following:~pre-pregnant BMI ≥ 28 and failed the 28 week oral glucose screening test~pre-pregnant BMI ≥ 28 and diagnosis of either A1 (diet controlled) or A2 (insulin-requiring) gestational diabetes during pregnancy, but insulin therapy discontinued after birth.~pre-pregnant BMI ≥ 28 and diagnosed with type 2 diabetes during pregnancy~pre-pregnant BMI ≥ 30, and unmediated."
2860598|NCT03524456|Experimental|Home blood pressure monitoring|
2860599|NCT03524456|No Intervention|Usual monitoring|
2860600|NCT03524443||Patient suffering from anorexia/bulimia|Each patient will receive standard care: multidisciplinary and corresponding to the HAS recommendations for anorexia nervosa and bulimia nervosa associated with semimonthly or weeklies sessions of art therapy treatment, using all types of art, realized by trained professional, in Toulouse. Each patient will be her own control before art therapy Female patients with anorexia nervosa or bulimia according to DSM-5 criteria, patient will be above 16 years-old
2860601|NCT03524430|Experimental|Single Interventional Study Arm|"There will be one biopsy collection time point if there is no change of drugs, and 2 collection time points if a change is made to a different chemotherapy drug as part of the planned standard of care (SoC) treatment.~2 core needle biopsy specimens will be taken at each biopsy collection time point for RDA analysis during chemotherapy."
2860602|NCT03524417|Experimental|RIG injection|RIG injection on day 7
2860603|NCT03524404|Active Comparator|Diabetes Prevention Program (DPP)|Live stream the first six sessions of the Diabetes Prevention Program (DPP) curriculum to Senior Planet on a weekly basis, The webinars will be about 1 hour long, led by a certified DPP educator, and live-streamed to the senior center. Participants will have weekly weigh-ins and meet with a research assistant led focus group following two out of the six sessions to discuss program acceptability.
2860604|NCT03524391|Experimental|Yoga Counselling Group|Yoga based psychological counselling delivered individually and in group along with conventional care
2860605|NCT03524391|Active Comparator|Usual Care Group|Usual care provided to patients
2860606|NCT03524378|Other|Ergonomic and movement modifications|No group assignment - all participants will self select suitable ergonomic or movement modifications
2860607|NCT03524365|Active Comparator|RYGB plus LM counselling|96 subjects with NASH
2860608|NCT03524365|Active Comparator|SG plus LM counselling|96 subjects with NASH
2860609|NCT03524365|Sham Comparator|ILM|96 subjects with NASH
2860610|NCT03524352|Experimental|fecal microbiota|
2860611|NCT03524352|Placebo Comparator|placebo|
2860612|NCT03524339|Placebo Comparator|Placebo|
2860613|NCT03524339|Experimental|Tamsulosin|
2860614|NCT03524326|Experimental|Head and Neck Squamous or Cutaneous Squamous Cell Carcinoma|A 3+3 dose de-escalation design for three dose levels of lenvatinib combined with cetuximab will be used. A DLT will be defined as any toxicities of grade 3 or higher (per CTCAE v4 criteria) felt to be possibly, probably, or definitely related to lenvatinib, as well as grade 4 toxcities related to cetuximab, which occurs within 28 days following the first dose of lenvatinib in combination with cetuximab.
2860615|NCT03524300|Experimental|Robotic Assisted Total Gastrectomy|Robotic Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
2860616|NCT03524300|Active Comparator|Laparoscopic Assisted Total Gastrectomy|Laparoscopic Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
2860617|NCT03524287|Experimental|No.10 lymph node dissections|Patients with locally advanced upper third gastric carcinoma will performed robotic assisted spleen-preserving No.10 lymph node dissections. After the surgery the patients will be treated with oxaliplatin or platinum-based chemotherapy.
2860618|NCT03524274|Experimental|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
2860619|NCT03524274|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
2860620|NCT03524274|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2860621|NCT03524261|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
2860749|NCT03523403|No Intervention|Chronic phase - control group|Participants will be asked to consume no apples per day for 6 weeks.
2860622|NCT03524261|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
2860623|NCT03524261|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2860624|NCT03524235|Experimental|Subjects|Pre-Transplantation Conditioning (Bendamustine, Fludarabine, and Rituximab + Total Body Irradiation) + Haploidentical Stem Cell Transplantation with CD56-enriched donor lymphocyte infusion
2860625|NCT03524235|No Intervention|Controls|Patients undergoing standard-of-care reduced-intensity peripheral blood allogeneic stem cell transplantation (any indication, donor source, conditioning regimen) using PTCy GVHD prophylaxis.
2860626|NCT03524222|Experimental|Home Hospitalization|Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
2860627|NCT03524209|Other|Surgery|Patients with spondylodiscitis are operated by percutaneous instrumentation and receive an antibiotic treatment according to the bacterium evidenced in the initial diagnostic intervertebral disc puncture (6 weeks to 3 months according to CRP course)
2860628|NCT03524209|Other|Brace|Patients with spondylodiscitis are wearing a thoracolumbar brace for 3 months and receive an antibiotic treatment according to the bacterium evidenced in the initial diagnostic intervertebral disc puncture (6 weeks to 3 months according to CRP course)
2860629|NCT03524196|Experimental|MYLO|"Manage Your Life Online (MYLO) is accessed online using a username and password. Client's type into the MYLO conversation box about a problem they are currently experiencing. MYLO operates by analysing the client's input of text for key terms and themes. It responds with questions about the problem aimed at encouraging higher level awareness.~Participants will decide how often to use the MYLO programme over a two week period. This is likely to be a reasonable length of time to allow at least one use of the programme with no upper limit on usage."
2860630|NCT03524183|Active Comparator|Control|The children will receive the standard of care at their respective afterschool programs. As with the treatment group, all children will be asked to wear their Fitbits for one year following the intervention period, for the mid- and long-term follow up. Fitbit data will be recorded tracked year-round through the automated Fitbit data syncing stations at the afterschool program site. All participants will be assessed for PA and psychosocial variables at the same four measurement points for the treatment group.
2860631|NCT03524183|Experimental|Treatment|The virtual pet functions as a personalized fitness buddy to encourage children to set and meet physical activity goals, promote physical activity self-efficacy, and foster mutually supportive relationships among children, parents, and the virtual pet. Concurrently, the kiosk sends a text message to parents on the child's physical activity progress. Parents are then able to send words of encouragement and communicate with their children via the kiosk, using the text messaging feature of their mobile phones. Parents will also receive text messages from the kiosk with a security code to access a website that provides detailed records of the child's physical activity over time. Participants will be assessed for post-treatment measurements immediately after 3 months, 6 months after, and 12 months after the intervention.
2860632|NCT03524170|Experimental|M7824 + Radiation Therapy|
2860633|NCT03524157|Experimental|PRO-087|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days Active principles: chondroitin sulfate 0.18%, sodium hyaluronate 0.1% ophthalmic solution made by Laboratorios Sophia, S.A. de C.V., transparent solution, free of visible particles in a sterile multi-dose bottle.
2860634|NCT03524157|Active Comparator|Xyel Ofteno|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days, Active principles: Xanthan gum 0.9 mg, sodium chondroitin sulfate 1.0 ophthalmic solution made by Laboratorios Sophia, S.A. de C.V., transparent solution, free of visible particles in a sterile multi-dose bottle.
2860635|NCT03524157|Active Comparator|Systane ultra|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days Active principles: Polyethylene glycol 400 0.4%, propyleneglycol 0.3%, Ophthalmic solution, multi-dose dropper bottle, made by Alcon Laboratories, Inc.
2860636|NCT03524144|Other|adult patients with Crohn's disease|All adult patients(18 years old or older) with Crohn's disease underwent gastroscopy; patients with diagnosed and treated Crohn's disease had gastroscopy performed during the re-examination, and patients diagnosed with Crohn's disease for the first time had gastroscopy performed during the initial consultation.
2860637|NCT03524131|Experimental|risk-framed leaflet|Patients sent 2-sided risk-framed leaflet with NHS Health Check invitation
2860638|NCT03524131|Experimental|benefits-framed leaflet|Patients sent 2-sided benefits-framed leaflet with NHS Health Check invitation
2860639|NCT03524131|Active Comparator|control|Patients sent 4-sided current national leaflet with NHS Health Check invitation
2860640|NCT03524118|Experimental|Panel A: Pre-term MK-1654 Dose 1|Pre-term infants will receive MK-1654 Dose 1 via intramuscular (IM) injection.
2860641|NCT03524118|Experimental|Panel B: Pre-term MK-1654 Dose 2|Pre-term infants will receive MK-1654 Dose 2 via IM injection.
2860642|NCT03524118|Experimental|Panel C: Pre-term MK-1654 Dose 3|Pre-term infants will receive MK-1654 Dose 3 via IM injection.
2860643|NCT03524118|Experimental|Panel D: Pre-term MK-1654 Dose 4|Pre-term infants will receive MK-1654 Dose 4 via IM injection.
2860644|NCT03524118|Experimental|Panel E: Full-term MK-1654 Dose 4|Full-term infants will receive MK-1654 Dose 4 via IM injection.
2860645|NCT03524118|Placebo Comparator|Placebo|Pre-term infants will receive placebo via IM injection.
2860646|NCT03524105|Active Comparator|Thrive Professional Learning plus ParentCorps|
2860647|NCT03524105|Active Comparator|Thrive Professional Learning track|
2860648|NCT03524092|Experimental|Mirikizumab Dose #1|Mirikizumab Dose #1 administered subcutaneously (SC)
2860649|NCT03524092|Experimental|Mirikizumab Dose #2|Mirikizumab Dose #2 administered intravenously (IV)
2860650|NCT03524092|Placebo Comparator|Placebo|Placebo administered SC
2860651|NCT03524079||BrS Group|Ajmaline 17-(Chloroacetate) Monohydrochloride
2860652|NCT03524079||No BrS group|Ajmaline 17-(Chloroacetate) Monohydrochloride
2860750|NCT03523390|Experimental|Avelumab|
2860653|NCT03524066|Experimental|Inhaled + Bronchoscopy|One-time Inhalation of Salbutamol 200 µg, Salmeterol 50µg and Fluticasone 500µg. During two bronchoscopic procedures two pre-specified lung tissue sites (middle lobe and lingula) will be sampled. Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and bronchoalveolar lavage (BAL) samples will be taken from each site.
2860654|NCT03524066|Experimental|Systemic + Bronchoscopy|One-time Salbutamol (8 mg) and Propranolol (40mg) administered orally. During two bronchoscopic procedures two pre-specified lung tissue sites (middle lobe and lingula) will be sampled. Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples will be taken from each site.
2860655|NCT03524053|Experimental|Exercise induced bronchoconstriction|An exercise challenge will then be performed according to international guidelines. The exercise will consist of 8 minutes of cycling on a cycle ergometer while breathing medical grade dry air from a reservoir (Douglas bag) via a two-way non-rebreathing valve. The workload will be increased progressively over the first 2 minutes, and will then be maintained for 6 minutes at a target workload (in Watts) of [53.76 * measured forced expiratory volume in 1 sec (FEV1)-11.07].
2860656|NCT03524053|Active Comparator|Inhibited EIB|An exercise challenge will then be performed according to international guidelines. The exercise will consist of 8 minutes of cycling on a cycle ergometer while warm-humid air from a reservoir (Douglas bag) via a two-way non-rebreathing valve. The workload will be increased progressively over the first 2 minutes, and will then be maintained for 6 minutes at a target workload (in Watts) of [53.76 * measured forced expiratory volume in 1 sec (FEV1)-11.07].
2860657|NCT03524053|No Intervention|Control|Participants will attend the laboratory but no exercise trial will be performed.
2860658|NCT03524040|Experimental|Acne patients|Application of gold microparticles to 2-3 facial areas
2860659|NCT03524040|Experimental|Heatlhy volunteers|Application of gold microparticles to 2 facial areas
2860660|NCT03524027|Experimental|Congenital Thoracolumbar Kyphoscoliosis|Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS) Spinal Deformity by Posterior Vertebral Column Resection (PVCR) Surgical Technique
2860661|NCT03524014||HEV-infected patients with hepatitis|
2860662|NCT03524014||HEV-infected patients with neurological features|
2860663|NCT03524014||HEV-infected patients with kidney features|
2860664|NCT03524001|Active Comparator|Bifocal stimulation|Active comparator is represented by programming bifocal stimulation (bifocal DDD mode). Every patients will undergo crossover randomization (from bifocal DDD mode to VVI and vice versa).
2860665|NCT03524001|Placebo Comparator|VVI 40|Placebo comparator is represented by programming the device in VVI mode 40/mins. Every patients will undergo crossover randomization (from VVI to bifocal DDD mode and vice versa).
2860666|NCT03523988|Active Comparator|Acetaminophen|Acetaminophen 650mg powder in gel capsule taken by mouth before entering appointment
2860667|NCT03523988|Active Comparator|Ibuprofen|Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
2860668|NCT03523988|Experimental|Acetaminophen and Ibuprofen|Acetaminophen 650mg and Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
2860669|NCT03523975|Experimental|Venetoclax, Lenalidomide, Rituximab|Rituximab 375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12 Lenalidomide 10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12. Venetoclax PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
2860670|NCT03523962|Experimental|First pre-op antiseptic skin solution|The PREPARE trial will compare the most common alcohol-based pre-operative antiseptic skin solutions used during extremity fracture surgery. Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all eligible fracture surgeries for a two-month period.
2860671|NCT03523962|Experimental|Crossover - Second pre-op antiseptic skin solution|Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all eligible fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.
2860672|NCT03523949|Experimental|PNE.|Procedure: This educational intervention is based in the latest evidence of pain neuroscience education, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptive thoughts and behaviors.
2860673|NCT03523936|Active Comparator|Prebiotic|
2860674|NCT03523936|Placebo Comparator|Placebo|
2860675|NCT03523923|No Intervention|Usual Care|If assigned to the Usual Care (UC) arm, participants receive the same care as they would normally received from the HMC or UWMC outpatient TBI clinics, which could include similar types of treatment (medication changes, referral to specialists, etc.).
2860676|NCT03523923|Active Comparator|Collaborative Care|If assigned to the Collaborative Care (CC) arm, participants receive up to 12 sessions (45-60 minutes) of scheduled contacts with a Collaborative Care Manager (CCM) over 16 weeks of treatment. The CCM meets weekly for supervision with a team of experts to determine appropriate care.
2860677|NCT03523910|Experimental|Patient|A research MRI scan with exercise will be obtained in conjunction with standard of care cardiopulmonary testing.
2860678|NCT03523897|Active Comparator|Robot Assisted Total Knee Replacement|In addition to expert judgment and hand-eye coordination, the surgeon also relies on a robot in making cuts within the pre-determined diseased areas of the joints and placing the implants. This is made possible by uploading 3-dimensional (3D) images of the knee joints into the robot prior to surgery. The robot uses these 3D images to guide the surgeon during the procedure. The 3D images are obtained from a computerized tomography (CT) scan that combines a series of X-ray images taken from different angles to create cross-sectional images of the bones.
2860679|NCT03523897|Active Comparator|Traditional Total Knee Replacement|The traditional method where the surgeon employs mechanical guides, expert judgment, and natural hand-eye coordination in making the necessary cuts to prepare the bone for the implant as well as in placing the implant.
2860680|NCT03523884|Experimental|Exercise Program plus Education.|Rotator cuff stretching and strengthening exercises outlined in the American Academy of Orthopedic Surgeons (AAOS) guidelines on management of rotator cuff problems.
2860681|NCT03523884|Active Comparator|Educational Program (EP).|An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions
2860682|NCT03523871|Experimental|Post Lung Transplant Patients|The lung transplantation will be performed per standard of care techniques,and all post-transplant management of the transplanted organ, including immunosuppression, will be carried out per standard of care.
2860683|NCT03523858|Experimental|Ocrelizumab|Ocrelizumab will be administered via intravenous (IV) infusion.
2860684|NCT03523845||Test group|Test group (patients diagnosed with early apical peri-implantitis diagnosed)
2860685|NCT03523845||Control group|Control group (patients whose implants had not developed any inflammatory/infectious process and were osseointegrated)
2860686|NCT03523832|Active Comparator|Group 1|celecoxib 400mg and pregabaline 150mg 1 hour before operation
2860687|NCT03523832|Active Comparator|Group 2|celecoxib 200mg and pregabaline 75mg twice daily started from 3 days before operation
2860688|NCT03523832|Placebo Comparator|Group 3|No treatment given
2860689|NCT03523819|Experimental|CS1002|Participants will receive CS1002 intravenously at specified dose on specified days.
2860690|NCT03523806|Experimental|Solution-Focused Coaching Group|Half of the participants (n=15) will be assigned a coach and receive coaching 8 times for up to 1 hour over 6 months. The first session will take place in the home and subsequent session will take place online using an online meeting tool.
2860691|NCT03523806|No Intervention|Control Group|Half of the participants (n=15) will not be receiving coaching
2860692|NCT03523793|Experimental|Physical Therapists - CPG|Cross-sectional stepped wedge design with 16 physical therapy clinics (including approximately 40 physical therapists) being allocated to one of 4 sequences that differ in CPG implementation time (each sequence consisting of 4 clinics). This proposed study will be conducted over 68 weeks, with the initial 12 weeks serving as a baseline washout phase (before any clinic has received training), then 4 clinics crossing over from standard care (control) to CPG and decision support tool implementation (intervention) approximately every 8 weeks until week 44 when all 4 sequences (16 clinics) have completed training.
2860693|NCT03523793|Active Comparator|Physical Therapists - Control|This proposed study will be conducted over 68 weeks, with the initial 12 weeks serving as a baseline washout phase (before any clinic has received training), then 4 clinics crossing over from standard care (control) to CPG and decision support tool implementation (intervention) approximately every 8 weeks until week 44 when all 4 sequences (16 clinics) have completed training.
2860694|NCT03523780||Whole blood|A whole blood transfusion during cesarean delivery
2860695|NCT03523780||Blood component therapy|A blood component transfusion during cesarean delivery
2860696|NCT03523767|Experimental|Typhoid Vaccine, then Normal Saline|0.5 ml of S.typhi injection, then 0.5 ml of normal saline injection
2860697|NCT03523767|Placebo Comparator|Normal Saline, then Typhoid Vaccine|0.5 ml of normal saline injection, then 0.5 ml of S.typhi injection
2860698|NCT03523754|Other|Misoprostol only|This group will receive Intravaginal Misoprostol only.
2860699|NCT03523754|Other|Isosorbide Mononitrate & Misoprostol|This group will reveive intravaginal Isosorbide Mononitrate & Misoprostol.
2860700|NCT03523728|Experimental|GZ/SAR402671 dose 1|Patients will receive GZ/SAR402671 dose 1 once daily for 24 months
2860701|NCT03523728|Experimental|GZ/SAR402671 dose 2|Patients will receive GZ/SAR402671 dose 2 once daily for 24 months
2860702|NCT03523728|Placebo Comparator|placebo|Placebo will be given once daily (Stage 1 and Stage 2) for 24 months
2860703|NCT03523715|Experimental|Prunes|The study group will be instructed to consume 4 oz of prunes as well as docusate sodium twice daily for 3 days after surgery.
2860704|NCT03523715|Placebo Comparator|Control|The placebo group will be instructed to take docusate sodium twice daily for 3 days after surgery.
2860705|NCT03523702|Experimental|PembroRT Cohort|Subjects with PD-L1 expression ≥ 50% Combination of pembrolizumab and dose-painted radiotherapy for locally advanced NSCLC patients with high (≥ 50%) PD-L1 expression.
2860706|NCT03523702|Active Comparator|ChemoRT Cohort|Subjects with PD-L1 expression < 50% Subjects with PD-L1 expression below 50% will be enrolled and treated with standard concurrent chemoradiotherapy.
2860707|NCT03523689||EBUS-TBNA Group|
2860708|NCT03523676||Group A|sepsis patients who did not develop atrial fibrillation during ICU stay
2860709|NCT03523676||Group B|sepsis patients with newly developed atrial fibrillation during ICU stay
2860710|NCT03523663||Control|healthy children without ADHD or other mental health issues
2860711|NCT03523663||ADHD|children diagnosed with ADHD
2860712|NCT03523650|Experimental|Group 1: Propranolol Group|Group 1: Propranolol - group of randomized patients will receive one propranolol pill tid for 36 months.
2860713|NCT03523650|Placebo Comparator|Group 2: Placebo Group|Group 2: Placebo - group of randomized patients will receive one placebo pill tid for 36 months.
2860714|NCT03523637|Experimental|Pain Education/Interoceptive Exposure|This study will evaluate the effects of IE and will briefly comprises of: education session explaining the rationale behind IE practice, teaching of the technique, supervised IE practice and self-monitored home practice twice daily for the period of two weeks.
2860715|NCT03523611||lung resection|Patients with suspected lung cancer undergoing lung resection by anatomic lobectomy
2860716|NCT03523598|Placebo Comparator|Placebo gel + Normal Toothpaste|The patient will receive the application of placebo gel on vestibular surface teeth, for 10 minutes and will use the normal toothpaste (Colgate).
2860717|NCT03523598|Experimental|Placebo Gel + Potassium Nitrate Toothpaste|The patient will receive the application of placebo gel on vestibular surface teeth, for 10 minutes and will use the Potassium nitrate toothpaste (Sensodyne).
2860718|NCT03523598|Experimental|Potassium Nitrate Gel + Normal Toothpaste|The patient will receive the application of 5% Potassium nitrategel on vestibular surface teeth, for 10 minutes and will use the normal toothpaste (Colgate).
2860719|NCT03523585|Experimental|Trastuzumab deruxtecan (DS 8201a)|HER2 positive, unresectable and/or metastatic breast cancer subjects previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T DM1) randomized to treatment with DS 8201a
2860778|NCT03523130||non-HIV-infected|
2860810|NCT03522896|Placebo Comparator|control meal|glucose, fructose, sucrose, malic acid and citric acid in water
2877536|NCT03406793|Experimental|3. High zinc, low/no iron|
2860720|NCT03523585|Active Comparator|Trastuzumab+capecitabine|HER2 positive, unresectable and/or metastatic breast cancer subjects previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T DM1) randomized to investigator's choice treatment with Trastuzumab/capecitabine
2860721|NCT03523585|Active Comparator|Lapatinib+capecitabine|HER2 positive, unresectable and/or metastatic breast cancer subjects previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T DM1) randomized to investigator's choice treatment with Lapatinib/capecitabine
2860722|NCT03523572|Experimental|Dose Escalation|Part 1 will enroll participants meeting the eligibility criteria set up for any of the 4 cohorts of Part 2 specified below using a 3 + 3 + 3 design. Escalating doses of trastuzumab deruxtecan (DS-8201a) in combination with nivolumab will be assessed. DS-8201a and nivolumab will be administered on Day 1 of each 21-day cycle.
2860723|NCT03523572|Experimental|Dose Expansion - Cohort 1|"Cohort 1 (n=30): Advanced HER2-positive breast cancer [as defined by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines 2013] participants who have previously received ado-trastuzumab emtansine (T-DM1) with documented progression.~Participants will receive the Part 1 recommended dose of trastuzumab deruxtecan (DS-8201a) and the same dose of nivolumab as in Part 1."
2860724|NCT03523572|Experimental|Dose Expansion - Cohort 2|"Cohort 2 (n=15): Advanced HER2 low-expressing breast cancer (HER2 IHC 1+ or IHC 2+/ISH-) participants who have exhausted treatments that can confer any clinically meaningful benefit (eg, other therapies such as hormonal therapy for patients who are hormone receptor positive).~Participants will receive the Part 1 recommended dose of trastuzumab deruxtecan (DS-8201a) and the same dose of nivolumab as in Part 1."
2860725|NCT03523572|Experimental|Dose Expansion - Cohort 3|"Cohort 3 (n=30): Advanced HER2 high-expressing urothelial cancer (HER2 IHC 2+ or IHC 3+) participants who received prior platinum-based therapy with documented progression.~Participants will receive the Part 1 recommended dose of trastuzumab deruxtecan (DS-8201a) and the same dose of nivolumab as in Part 1."
2860726|NCT03523572|Experimental|Dose Expansion - Cohort 4|"Cohort 4 (n=15): Advanced HER2 low-expressing urothelial cancer (HER2 IHC 1+) participants who have received prior platinum-based therapy with documented progression.~Participants will receive the Part 1 recommended dose of trastuzumab deruxtecan (DS-8201a) and the same dose of nivolumab as in Part 1."
2860727|NCT03523559||Interstitial Cystitis|
2860728|NCT03523559||normal|
2860729|NCT03523546|Experimental|Episode Payment Model|Oncologists in this arm will be paid for each member's episode of care. The episode of care is 6 months in duration. Oncologists will have the opportunity to receive performance-based payments based upon a set of 6 quality metrics.
2860730|NCT03523546|No Intervention|Fee for Service|Oncologists in this arm will not receive the intervention and will continue to be paid through fee-for-service.
2860731|NCT03523533|Experimental|Peripherally-inserted internal jugular catheter|All enrolled patients will receive a peripheral angiocatheter in the internal jugular vein, under dynamic ultrasound guidance.
2860732|NCT03523520|Active Comparator|Methylnaltrexone oral tablets|"Methylnaltrexone oral tablets (total 450 mg) + subcutaneous water injection~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
2860733|NCT03523520|Active Comparator|Methylnaltrexone subcutaneous injection|"Methylnaltrexone 12mg subcutaneous injection + sugar placebo tablet~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
2860734|NCT03523520|Active Comparator|Naloxegol oral tablets|"Naloxegol oral tablets (total 25 mg) + subcutaneous water injection~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
2860735|NCT03523507|Experimental|Active: rTMS|Participants will receive 20 bilateral treatment sessions provided over approximately a 5-week period. Daily sessions entail approximately 60 minutes of time.
2860736|NCT03523507|Sham Comparator|Sham: rTMS|Sham: Repetitive Transcranial Magnetic Stimulation; Participants will receive sham treatment designed to have similar sound and tactile sensation, without producing active stimulation.
2860737|NCT03523494||Normal limb|Normal
2860738|NCT03523494||Abnormal limb|Lymph Edema
2860739|NCT03523481||NHF use|
2860740|NCT03523468|Experimental|uniportal sleeve lobectomy|locally advanced central lung cancer resection by uniportal VATS sleeve lobectomy
2860741|NCT03523468|Active Comparator|open sleeve lobectomy|locally advanced central lung cancer resection by open chest sleeve lobectomy
2860742|NCT03523455|Placebo Comparator|Sugar Pill|Maltodextrin (matches the weight of the active treatment) Taken once each day after breakfast, but before lunch.
2860743|NCT03523455|Active Comparator|Iron Aid IPS (Iron Protein Succinylate)|IronAid Iron Protein Succinylate 30 mg Taken once each day after breakfast, but before lunch.
2860744|NCT03523442|Experimental|Apalutamide|Participants will receive a single oral dose of apalutamide 240 milligram (mg) during pharmacokinetics (PK) Week Day 1 and will be monitored for one week (that is; PK Week) to assess PK and safety of drug. Subsequently, participants will further receive daily treatment of apalutamide from Cycle 1 Day 1 onwards until disease progression, withdrawal of consent, lost to follow-up, or the occurrence of unacceptable toxicity. Each treatment cycle consists of 28 days.
2860745|NCT03523429|Experimental|blinatumomab|blinatumomab administered during the early consolidation phase in patients ≤ 55 years with high-risk Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukaemia (ALL) with MRD < 0.1% (< 1×10-3) after induction therapy.
2860746|NCT03523403|Experimental|Acute phase - intervention|Participants will be asked to consume 3 whole apples and a high-fat meal (a mixture of commercially available whipping cream and milk, providing 1 g of fat per kg of body weight) within 30 minutes.
2860747|NCT03523403|No Intervention|Acute phase - control|Participants will be asked to consume a high-fat meal (a mixture of commercially available whipping cream and milk, providing 1 g of fat per kg of body weight) within 30 minutes.
2860748|NCT03523403|Experimental|Chronic phase - intervention group|Participants will be asked to consume 3 whole apples per day for 6 weeks.
2860751|NCT03523377|Experimental|prolonged overnight fasting|The purpose of the intervention is to increase the nightly fasting duration to a minimum of 12 hours. Adherence to the intervention will be measured by the proportion of SMS text message-days reflecting 12 or more hours of fasting. The intervention protocol follows an approach using strategies outlined by social cognitive theory that focus on (a) goal setting and (b) building self-efficacy.
2860752|NCT03523351|Active Comparator|Standard of care|Patients randomized to Arm 1 will undergo appropriate therapy as determined by their oncologist. These patients will either continue their current therapy or be transitioned to a new standard of care therapy at the discretion of the treating oncologist. If randomized to Arm 1, these patients may undergo palliative RT for progressive, painful lesions (a skeletal related event) at time of symptom development (not upfront palliative RT).
2860753|NCT03523351|Experimental|Selective radiation to ≤5 highest risk bone metastases|Patients on Arm 2 of the study will undergo selective RT to ≤ 5 high risk bone metastases defined as 1. bulkiest sites of osseous disease ≥ 2cm, 2. disease involving the hip (acetabulum, femoral head, femoral neck), shoulder (acromion, glenoid, humeral head), or sacroiliac joints 3. disease in long bones with1/3-2/3 cortical thickness (humerus, radius, ulna, clavicle, femur, tibia, fibula, metacarpus, phalanges) 4. disease in junctional spine (C7-T1, T12-L1, L5-S1) &/or disease with posterior element involvement.
2860754|NCT03523338|Experimental|Apalutamide (JNJ-56021927)+Androgen Deprivation Therapy (ADT)|Participants will receive apalutamide 240 milligram (mg) as 4 tablets of 60 mg each orally once daily with or without food until disease progression, occurrence of unacceptable toxicity or no longer receiving clinical benefit as determined by the study investigator, or the end of study. All Participants who did not undergo surgical castration, should receive and remain on a stable regimen of ADT according to local standard of care.
2860755|NCT03523312|Experimental|HFA-IMRT|Eligible patients will receive HFA-IMRT to a total dose of 67.5 Gy in 15 fractions or 75Gy in 25 fractions to areas of gross tumor with concurrent capecitabine. Cross-sectional imaging will be repeated 4-6 weeks after the end of CRT to assess for resectability.
2860756|NCT03523299|Experimental|Cryoablation|Participants in this arm will receive cryoablation of their breast tumor two weeks before their routine lumpectomy. They will undergo two blood draws: one before cryoablation (at the time of consent) and one after cryoablation (at the time of surgery).
2860757|NCT03523299|No Intervention|Control|Participants in this arm will undergo a blood draw at the time of consent and then will continue with their scheduled lumpectomy (standard of care).
2860758|NCT03523286|Experimental|RAPID-VT Software guided ablation|The induced VT(s) 12-lead ECG will be acquired by the RAPID-VT software which will provide real time localization of the VT(s) exits from the scar margin. These exits will be targeted by ablation
2860759|NCT03523273|Active Comparator|Liraglutide|Saxenda initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
2860760|NCT03523273|Placebo Comparator|Placebo|Placebo initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
2860761|NCT03523260|Active Comparator|Tunneled dialysis Split-tip catheter|High-flow tunneled Split-tip catheter for hemodialysis will be inserted by standard interventional technique
2860762|NCT03523260|Active Comparator|Tunneled dialysis Step-tip catheter|High-flow tunneled Step-tip catheter for hemodialysis will be inserted by standard interventional technique
2860763|NCT03523260|Active Comparator|Tunneled dialysis Symmetric tip catheter|High-flow tunneled Symmetric tip catheter for hemodialysis will be inserted by standard interventional technique
2860764|NCT03523247|Experimental|Whole Food Plant Based Diet|Single-arm whole-food, plant-based diet will explore the effects on primary prevention in a free-range environment
2860765|NCT03523234|Experimental|surgery group|
2860766|NCT03523234|Placebo Comparator|control group|
2860767|NCT03523221|Active Comparator|Dexamethasone arm|All patients will be Urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of study medication orally, and he /she will observe in the observation room with cardiac monitor and close monitoring by nurse.
2860768|NCT03523221|Placebo Comparator|Placebo arm|All patients will be Urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of study medication orally, and he /she will observe in the observation room with cardiac monitor and close monitoring by nurse.
2860769|NCT03523195|Active Comparator|Arm 0 (written information)|Participants wear Fitbit and receive written information on healthy exercise and diet recommendations.
2860770|NCT03523195|Experimental|Arm I (exercise program)|Participants complete exercise program including aerobic and resistance exercises over 60 minutes 3 times per week for 12 weeks. Exercise is supervised all 3 times during weeks 1-2. During weeks 3-12, exercise is supervised 2 times a week, with home-based coaching for an additional 60 minutes a week.
2860771|NCT03523182|Experimental|Spirulina (SP)|Children in the SP group (n=251) received a soya-maize-based porridge for 12 months with the addition of spirulina.
2860772|NCT03523182|Active Comparator|Control (CON)|Children in the CON group (n=250) received a soya-maize-based porridge for 12 months.
2860773|NCT03523156|Active Comparator|Azithromycin mass treatment|Persons living in regions randomized to this arm will receive mass drug administration (MDA) of azithromycin per the current annual MDA schedule.
2860774|NCT03523156|Experimental|Azithromycin mass treatment plus targeted treatment|In addition to azithromycin administration per the current annual MDA schedule, children in regions randomized to this arm will receive azithromycin targeted treatment.
2860775|NCT03523143|Experimental|Early-screen Group|The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). The time of early screening and intervention will be 6-8 weeks earlier than that of standard screening and intervention.
2860776|NCT03523143|Active Comparator|Standard-screen Group|The standard screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 24-28 weeks of gestational age (GA). The time of standard screening and intervention will be 6-8 weeks later than that of early screening and intervention.
2860777|NCT03523130||HIV-infected|
2860779|NCT03523117|Active Comparator|Ferric Caroboxymaltose|Ferric Carboxymaltose - 2 doses (day 0 and day 7) at 15 mg/kg to a maximum single dose of 750 mg (whichever is smaller) up to a maximum of total dose of 1500 mg administered as either an undiluted IV push at a rate of 100 mg (2mL)/minute OR in no more than 250 mL of normal saline and infused over 15 minutes.
2860780|NCT03523117|Active Comparator|Oral Ferrous Sulfate|Oral Ferrous Sulfate - will receive an age-dependent formulation of oral ferrous sulfate daily for 28 days as follows: participants <12 years of age will receive 6 mg (elemental iron)/kg/day divided into 2 daily doses of an oral liquid formulation, either drops or elixir, and participants ≥12 will receive 2 daily doses of oral tablets. Infants and children (ages 1 to <4 years) will receive oral ferrous sulfate drops, while children (ages ≥4 to <12 years) will receive oral ferrous sulfate elixir. Adolescents (ages ≥12 to 17 years) will receive an oral ferrous sulfate tablet (65 mg of elemental iron/tablet/dose) twice a day (BID). The maximum daily dose for all participants is 130 mg of elemental iron.
2860781|NCT03523091|Experimental|3 Injection Sites|OnabotulinumtoxinA 100Unit injection into 3 sites throughout the bladder
2860782|NCT03523091|Experimental|10 Injection Sites|OnabotulinumtoxinA 100Unit injection into 10 sites throughout the bladder
2860783|NCT03523039|Experimental|Hemoadsorption|Hemoadsorption is performed using a CytoSorb® cartridge.
2860784|NCT03523039|No Intervention|Control|Post-cardiac arrest management will be conducted as per institutional protocols.
2860785|NCT03523026|Experimental|NMES and Peripheral Muscle Training|"Neuromuscular Electrical Stimulation (NMES) and Peripheral Muscle Training~NMES frequency will be 30 Hertz and the application time will be 30 minutes.Treatment will be programmed for 3 days per week.~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks."
2860786|NCT03523026|Experimental|IMT and Peripheral Muscle Training|"Inspirator Muscle Training (IMT) and Peripheral Muscle Training~IMT will be applied 7 days per week, twice a day for 15 minutes.~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week. The program will continue for 6 weeks."
2860787|NCT03523026|Experimental|Peripheral Muscle Training|"Peripheral Muscle Training~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks."
2860788|NCT03523013|Experimental|CPAP pressure (determied by DISE)|
2860789|NCT03523013|Active Comparator|CPAP pressure (determined by physician)|
2860790|NCT03523000|Active Comparator|Active Solution|Continuous intrathecal prognostic infusion test of active solution: intrathecal bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml
2860791|NCT03523000|Placebo Comparator|Inactive Placebo Solution|Continuous intrathecal prognostic infusion test of inactive placebo solution: preservative-free normal saline
2860792|NCT03522987|Experimental|Epileptologist-Driven Treatment|The intervention will consist of initiating a chronic care management plan in the epilepsy clinic and an initial prescription from the epileptologist for escitalopram 10mg daily. Escitalopram dose adjustment will be made based on biweekly repeated screening of anxiety and depression symptoms, as well as side effects identified on biweekly telephone calls or the 6-week advanced practice provider (APP) follow up visit. Escitalopram dose may be titrated up to a maximum of 20mg daily in 5-10mg increments every 2 weeks for treatment effect, or titrated down to 5mg if needed for adverse effects. If a participant is unable to tolerate escitalopram, then venlafaxine XR 37.5mg will be substituted, to be titrated in a similar manner biweekly based on side effects and anxiety and depression symptoms (with 37.5-75mg increment dose changes and maximum dose of 225mg daily).
2860793|NCT03522974|Placebo Comparator|Placebo|40 g/d placebo powder
2860794|NCT03522974|Experimental|Strawberry powder (high dose)|40 g/d freeze dried strawberry powder
2860795|NCT03522974|Active Comparator|Strawberry powder (low dose)|13 g/d freeze dried strawberry powder
2860796|NCT03522961|Active Comparator|Nitrofurantoin prophylaxis/Placebo|Subjects will receive Nitrofurantoin 100mg capsules (Bottle A) once a day until they pass their voiding trial and no longer require transurethral catheterization. Subjects will be switched to Placebo capsules (Bottle B) once a day, starting the day after they pass their voiding trial until the end of the 28 day study period.
2860797|NCT03522961|Active Comparator|Cranberry capsules|Subjects will receive TheraCran® One Cranberry 36mg capsules (Bottle A) once a day until they pass their voiding trial and no longer require transurethral catheterization. Subjects will be switched to another bottle of TheraCran® One Cranberry 36mg capsules (Bottle B) once a day, starting the day after they pass their voiding trial until the end of the 28 day study period.
2860798|NCT03522948|Experimental|Open pilot|The intervention is a brief, in-person motivational intervention followed by 4 weeks of text messaging to reduce heavy episodic drinking and sexual risk behavior (unprotected anal intercourse) among men-who-have-sex-with-men.
2860799|NCT03522935|Experimental|Elafin 0.03 mg/kg|5 subjects will be administered with 0.03 mg/kg of Elafin subcutaneously once daily for 7 days.
2860800|NCT03522935|Experimental|Elafin 0.06 mg/kg|5 subjects will be administered with 0.06 mg/kg of Elafin subcutaneously once daily for 7 days.
2860801|NCT03522935|Experimental|Elafin 0.10 mg/kg|5 subjects will be administered with 0.10 mg/kg of Elafin subcutaneously once daily for 7 days.
2860802|NCT03522935|Experimental|Elafin 0.15 mg/kg|5 subjects will be administered with 0.15 mg/kg of Elafin subcutaneously once daily for 7 days.
2860803|NCT03522935|Experimental|Elafin 0.18 mg/kg|5 subjects will be administered with 0.18 mg/kg of Elafin subcutaneously once daily for 7 days.
2860804|NCT03522935|Placebo Comparator|Placebo Drug|5 subjects will be administered with placebo drug subcutaneously once daily for 7 days.
2860805|NCT03522922|Active Comparator|Dermaroller arm|Patients received a series of six treatments by dermaroller at 4 weeks interval and no topical anti scar treatment in between sessions.
2860806|NCT03522922|Active Comparator|Dermaroller + topical Vit. C arm|Patients received a series of six treatments by dermaroller at 4 weeks interval with the same maneuver and instructions as first group and each session was followed by immediate application of topical vitamin C serum plus once daily application in between sessions.
2860807|NCT03522922|Active Comparator|Topical Vit. C arm|Patients received once daily topical vitamin C serum capsule at night for six months. With monthly evaluation.
2860808|NCT03522909||Study|We will be reviewing records of parturients seen at Johns Hopkins Hospital in the Center for Peripartum Optimization (CPO) clinic between January 2017 to January 2018
2860817|NCT03522870|Experimental|Flash Glucose Monitoring System|People selected to this group will using flash glucose monitoring system continuously on Week 0-12 and Week 14-26.
2860818|NCT03522870|Active Comparator|SMBG|People selected to this group will using SMBG continuously on Week 0-12 and Week 14-26.
2860819|NCT03522857||Teesside University|nursing, midwifery, physiotherapy, occupational therapy, diagnostic radiography, paramedics
2860820|NCT03522857||Glasgow Caledonian University|nursing, midwifery, physiotherapy, occupational therapy, diagnostic radiography, paramedics
2860821|NCT03522857||Northumbria University|nursing, midwifery, physiotherapy, occupational therapy
2860822|NCT03522857||The University of Nottingham|Physiotherapy, nursing and midwifery
2860823|NCT03522844|Experimental|Mindfulness-Based Stress Reduction (MBSR)|
2860824|NCT03522844|Active Comparator|Escitalopram|
2860825|NCT03522831|Active Comparator|Salbutamol meter-dose inhaler|Inhalation of 400 μg salbutamol
2860826|NCT03522831|Placebo Comparator|Placebo meter-dose inhaler|Inhalation of 400 μg placebo
2860827|NCT03522818|Active Comparator|Normal|Group will use the alarm as provided by the manufacture.
2860828|NCT03522818|Experimental|Manual trigger|Group will use the same model but will be instructed to manually trigger the alarm 1-2 hours after the child falls asleep.
2860829|NCT03522805|Experimental|Non-invasive ventilation|Subjects will undergo a baseline night with standard polysomnography, followed by a treatment night using non-invasive ventilation under polysomnography
2860830|NCT03522792|Experimental|Saline + ad libitum meal|This will serve as the placebo / control day for the NT + ad libitum meal study day.
2860831|NCT03522792|Experimental|NT + ad libitum meal|Neurotensin (NT) infusion followed by an ad libitum meal to study the effect of NT on ad libitum food intake.
2860832|NCT03522792|Experimental|Saline + liquid meal + ad libitum meal|Saline infusion followed a standardized liquid mixed meal followed by an ad libitum meal. This will serve as the placebo / control day for the NT + standardized liquid mixed meal + ad libitum meal study day. Investigating the effect of NT on the second meal effect.
2860833|NCT03522792|Experimental|NT + liquid meal + ad libitum meal|NT infusion followed a standardized liquid mixed meal followed by an ad libitum meal. This study day aims to study the effect of NT on the second meal effect.
2860834|NCT03522792|Experimental|Neurotensin|Acclimatization day
2860835|NCT03522779|Placebo Comparator|High-fat meal + placebo|Participants will complete a high-fat meal challenge with a placebo beverage.The placebo will be designed to match the tart cherry juice for volume and macronutrient content, but without the phytonutrient content of the tart cherries.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
2860836|NCT03522779|Experimental|High-fat meal + tart cherry|Participants will complete a high-fat meal challenge with a tart cherry juice concentrate. 60 mL of montmorency tart cherry concentrate will be diluted with 100 mL of water.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
2860837|NCT03522779|Placebo Comparator|Exercise + high-fat meal + placebo|Participants will perform an acute bout of submaximal aerobic exercise 15 hours prior to the high-fat meal test. The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve. The following morning participants will complete a high-fat meal challenge with a placebo beverage.The placebo will be designed to match the tart cherry juice for volume and macronutrient content, but without the phytonutrient content of the tart cherries.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
2860838|NCT03522779|Experimental|Exercise + high-fat meal + tart cherry|Participants will perform an acute bout of submaximal aerobic exercise 15 hours prior to the high-fat meal test. The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.The following morning participants will complete a high-fat meal challenge with a tart cherry juice concentrate. 60 mL of montmorency tart cherry concentrate will be diluted with 100 mL of water.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
2860839|NCT03522766||Healthy volunteers with no urinary tract infections|people who don't experience urinary tract infections
2860840|NCT03522766||Healthy volunteers with urinary tract infections|people who frequently experience urinary tract infections
2860841|NCT03522766||Intermittent catheter users with neurogenic bladder|
2860842|NCT03522766||Intermittent catheter users with enlarged prostate|
2860843|NCT03522753|Experimental|Staples|For short single incisions, these patients will receive superficial closure using only metal skin staples. Closure will be performed by resident or fellow involved in the case.
2860844|NCT03522753|Active Comparator|Suture|For short single incisions, these patients will receive superficial closure using only nylon sutures. No metal skin staples will be used. Closure will be performed by resident or fellow involved in the case.
2860845|NCT03522753|Other|Half Staple Half Suture|Some patients will receive both nylon sutures and metal skin staples for superficial closure. If multiple incisions are involved, each incision will count as 1 in the alternation method (i.e. toe 1 will be all sutures, then toe 2 will be all staples). For long incisions, closure will alternate between nylon sutures and metal skin staples on the part of the incision which is closer (more proximal) or farther away (more distal) from the rest of the body.
2860846|NCT03522740|Active Comparator|Decision Aid for Renal Therapy|Usual Care as in the 'no intervention arm' below plus access to an web-based decision aid, the Decision Aid for Renal Therapy to patients and their care-partners
2860847|NCT03522740|No Intervention|Usual Care|In-person education as would be done at study sites plus 'Choosing a Treatment for Kidney Failure', an educational booklet published by the National Kidney Foundation
2860848|NCT03522727|No Intervention|Control|Participants will be asked to complete a questionnaire.
2860893|NCT03522454|No Intervention|Lifestyle counselling group|Lifestyle counselling group: Recommendation to perform moderate-intensity aerobic activity at least 30 minutes 5 days per week as tolerated and eat a balanced diet based on the AHA/ACC Guideline on Lifestyle Management.
2860849|NCT03522727|Experimental|Intervention 1|"Single self-incentivising implementation intention~After completing a questionnaire, participants will be asked to form a self-incentivising implementation intention:~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself.~Please complete the following sentence with a reward of your own choosing.~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by…~**Drop down menu**~Learning a new skill..."
2860850|NCT03522727|Experimental|Intervention 2|"Multiple self-incentivising implementation intentions~After completing a questionnaire, participants will be asked to form self-incentivising implementation intentions:~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself. You can choose as many rewards as you like! Please complete the following sentence with a reward of your own choosing.~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by… and/or…~**Drop down menu**~Learning a new skill..."
2860851|NCT03522727|Experimental|Intervention 3|"Self-generated self-incentivising implementation intentions~After completing a questionnaire, participants will be asked to form a self-incentivising implementation intention:~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself.~Please complete the following sentence with a reward of your own choosing.~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by…"
2860852|NCT03522714|Active Comparator|Fluid Immersion Simulation System (FIS)|Pressure ulcer patients are assigned to Fluid Immersion Simulation System (Dolphin) after operative debridement and closure.
2860853|NCT03522714|Active Comparator|Air Fluidized Bed System (AFB)|Pressure ulcer patients are assigned to Air Fluidized Bed (Clinitron) after operative debridement and closure
2860854|NCT03522701|Experimental|Group CBTI|Behavioral: Cognitive Behavioural Therapy for Insomnia (CBT-I) The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-I delivered within a 10-week window. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
2860855|NCT03522701|Active Comparator|Email-delivered CBTI|The email delivered self-guided CBT-I consists of 8 weekly learning sessions. Participants will receive an email embedded with session materials each week.
2860856|NCT03522701|No Intervention|Waiting-list control|Participants will not receive any active treatment.
2860857|NCT03522688|No Intervention|control group|
2860858|NCT03522688|Active Comparator|treatment group|
2860859|NCT03522649|Experimental|Napabucasin plus FOLFIRI|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8~12 hours (480 mg total daily dose). FOLFIRI chemotherapy infusion will start at least 2 hours following the first daily dose of Napabucasin and will be administered every 2 weeks. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, at least 2 hours following the first daily dose of Napabucasin. Fluorouracil 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by fluorouracil 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.
2860860|NCT03522649|Other|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8~12 hours (480 mg total daily dose).
2860861|NCT03522636||Treatment|Prehospital blood products resuscitation up to 2 units of blood products as follows: 1 unit of packed human plasma and 1 unit of packed red blood cells
2860862|NCT03522636||Historic control|No prehospital blood products available
2860863|NCT03522623||IBD|Children and families with IBD will be surveyed
2860864|NCT03522610|Experimental|ADAPT|Parents participate in a 14-week in person group based version of ADAPT with web-enhanced online ADAPT materials.
2860865|NCT03522610|No Intervention|Comparison Group|Parents receive services as usual (pamphlets, brochures, etc) on parenting typically found at a VA or Dr.'s office.
2860866|NCT03522597||Normal weight|Normal weight (BMI) women and their infants
2860867|NCT03522597||Obese|Obese (BMI) women and their infants
2860868|NCT03522597||Diabetic|Women with gestational diabetes and their infants
2860869|NCT03522584|Experimental|Treatment (tremelimumab, durvalumab, SBRT)|Participants receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1, week 1. Treatment repeats every 4 weeks for up to 4 courses or every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Participants then receive durvalumab IV over 60 minutes on day 1, week 1. Treatment repeats every 4 weeks for up to 9 courses or every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Participants also undergo SBRT over 3 fractions QOD during week 3.
2860870|NCT03522571|Experimental|Patients with altered passive eruption - APE|3 teeth of the patients with altered passive eruption that will undergo to experimental gingivitis
2860871|NCT03522571|Active Comparator|Patients with normal gingival anatomy - Non APE|3 teeth of the patients with normal gingival anatomy that will undergo to experimental gingivitis
2860872|NCT03522558|Experimental|Standardized Medical Nutrition Therapy|Standardized Medical Nutrition Therapy will include nutrition assessment provided by a registered dietitian (RD) at initial clinic visit or first Well Child Check (WCC) and regularly scheduled nutrition follow-up at each WCC visit thereafter.
2860892|NCT03522454|Experimental|Intervention group|Intervention group: Combination of a protein-rich oral nutritional supplement consumed twice daily for 4 weeks pre-TAVR and 12 weeks after the patient is discharged home post-TAVR, and a home-based supervised exercise program that combines walking and weight-bearing exercises to build strength and balance performed for 12 weeks after the patient is discharged home post-TAVR.
2860873|NCT03522558|Active Comparator|Usual Care|At the primary care provider's discretion, a nutrition consult can be requested for the RD to perform nutrition assessment or discuss the patient's plan without full nutrition assessment, as is current practice. Currently in the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UTHealth, providers consult the RD as deemed appropriate with no established criteria for when to include the RD in patient care. Usual care will not be modified by the study protocol.
2860874|NCT03522545|Experimental|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow
2860875|NCT03522545|Placebo Comparator|Placebo|Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
2860876|NCT03522532|Experimental|Amalgam (Amg)|Amalgam was sealed in 8-K2 patients and 6-K2 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
2860877|NCT03522532|Experimental|Tetric EvoCeram (TEC)|Tetric EvoCeram was sealed in 12-K2 patients and 5-K5 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
2860878|NCT03522532|Experimental|Beautifil (BF)|Beautifil was sealed in 15-K2 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
2860879|NCT03522532|Experimental|Zinc phosphate cement (ZPhC)|"Zinc phosphate cement was sealed in 7-K2 patients, 4-K3 patients, 1-K4 patients and 2-K5 patients.~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
2860880|NCT03522532|Experimental|Zinc polycarboxylate cement (ZPoC)|"Zinc polycarboxylate cement was sealed in 5-K2 patients, 4-K3 patients and 5-K4 patients.~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
2860881|NCT03522532|Experimental|Glass ionomer cement (GIC)|"Glass ionomer cement was sealed in 11-K2 patients, 2-K3 patients and 1-K5 patients.~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
2860882|NCT03522519||Assessment of real world performance|
2860883|NCT03522506|Experimental|TAK-925 Low Dose + Placebo + TAK-925 High Dose + Modafinil|TAK-925 low dose milligram (mg), intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
2860884|NCT03522506|Experimental|TAK-925 High Dose + TAK-925 Low Dose + Modafinil + Placebo|TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
2860885|NCT03522506|Experimental|Modafinil + TAK-925 High Dose + Placebo + TAK-925 Low Dose|Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
2860886|NCT03522506|Experimental|Placebo + Modafinil + TAK-925 Low Dose + TAK-925 High Dose|Placebo orally, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
2860887|NCT03522493|Active Comparator|Young group|This arm include 20 young subjects that will perform the same experiment as the old group for a comparison reasons.
2860888|NCT03522493|Experimental|Old group|This group us the group of interest. This group will wear the mask and is expected to show differences from the younger group.
2860889|NCT03522480|Other|Group A: Education & Gaming|Children will participate in 1 initial training session where they will be taught by a RT to use autogenic drainage (AD). Patients will be sent home & prescribed to practice the technique 15 minutes 3 times / week. At week 8 +/- 1 week patients will return and will be tested by a software program designed to evaluate their ability to perform the AD sequence (percent accuracy). At the 8 week visit, the Jamboxx gaming device will be introduced, which will contain a game to guide them through the proper sequence of breathing for the AD technique. Patients will be sent home with a Jamboxx device and requested to do 15 minutes of AD training 3 times / week. Patients will return at week 16 and again will be tested via software program for ability to perform the AD technique.
2860890|NCT03522480|Experimental|Group B: Gaming Only|Children will participate in an initial training session at Albany Med where they will be taught by a RT to use the Jamboxx respiratory therapy device to guide them through autogenic drainage (AD): a series of controlled breathing exercises that mobilizes mucous without inducing wheezing in patients with reactive airways. Patients will be sent home and prescribed to use the Jamboxx respiratory therapy device 15 minutes three times per week. At week 8 and week 16 +/- 1 week patients will return and will be tested by a software program designed to evaluate their ability to perform AD sequence (percent accuracy).
2860891|NCT03522467|Experimental|MRCP001|MRCP001 administered per protocol dose titration regimen (beginning at 1 capsule daily, titrated to a maximum of 3 capsules BID)
2860897|NCT03522428|Active Comparator|Receiving treatment|Adding vitamin B12 at a dose of 5 μg / 100 days, custom folic acid therapy and iron supplements
2860898|NCT03522428|No Intervention|Control group|Standard prenatal care (custom folic acid therapy and iron supplements)
2860899|NCT03522415|Experimental|HLX01+MTX|
2860900|NCT03522415|Placebo Comparator|Placebo+MTX|
2860901|NCT03522402|Experimental|30 degree rotated lateral position|19 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to the head in 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
2860902|NCT03522402|Active Comparator|neutral position|19 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to the head in the neutral position.The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
2860903|NCT03522389|Experimental|AOT with gait training group|Action observation training with gait training
2860904|NCT03522389|Active Comparator|Gait training group|Gait training
2860905|NCT03522389|Other|Control group|Education
2860906|NCT03522376||Chronic obstructive pulmonary disease|Subjects with the diagnosis of chronic obstructive pulmonary disease, stable clinically, has no infection or acute exacerbation in the previous four weeks, and can cooperate with the measurements of this study, loaded inspiratory muscle test.
2860907|NCT03522363|Experimental|Monodose group|1 vial with 4E10 CFU/g Total dose treatment: 4E10 CFU
2860908|NCT03522363|Experimental|Multidose group|7 vials with 5,5E09 CFU/g Total dose treatment: 4E10 CFU
2860909|NCT03522350|Active Comparator|EmbryoScope|Standard of care embryo incubator.
2860910|NCT03522350|Experimental|EmbryoScope+|New experimental embryo incubator.
2860911|NCT03522337|Placebo Comparator|Control group|The main intervention is conventional leaflets. Tooth-brushing training (toothbrushes and toothpastes provided) and oral health instruction are reinforced by leaflets.
2860912|NCT03522337|Experimental|Test group|The main intervention is visual pedagogy (social stories). Tooth-brushing training (toothbrushes and toothpastes provided) and oral health instruction are reinforced by social stories.
2860913|NCT03522298|Experimental|Dose Escalation and Expansion Cohorts|"This is an open-label study.~Patients in Stage 1 will be enrolled and sequentially assigned to a dose cohort.~The initial cohort will receive an oral dose of 60 mg GDC-0084 QD (4 x 15 mg capsules). Patients of future dose cohorts will receive GDC-0084 at increasing levels with 15 mg steps until a dose-limiting toxicity occurs (DLT) occurs. The dose level where <1/3 of the patients exhibit a DLT will be determined the Maximum Tolerated Dose (MTD).~Dose escalation will occur for three separate dose schedules including QD, every other day (QOD) and 3 times a week on consecutive days (3 days on/4 days off), i.e. an MTD will be established for three different dose schedules.~In stage 2, the expansion phase, patients will receive doses of oral GDC-0084 at the MTD established for each of the three dosing schedules until disease progression or an unacceptable toxicity, whichever occurs first.~Patients will be randomized in a 1:1:1 ratio to one of the three dose schedules."
2860914|NCT03522272|Experimental|Ultrasonic cleaning with cetylpyridinium chloride|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent, and ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) of the denture with 0.07% cetylpyridinium chloride mouthrinse
2860915|NCT03522272|Active Comparator|Ultrasonic cleaning with water|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent, and ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) of the denture with distilled water
2860916|NCT03522272|Active Comparator|Conventional denture hygiene|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent (Control group)
2860917|NCT03522259|Active Comparator|A: Rivaroxaban short arm|7 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.
2860918|NCT03522259|Active Comparator|B: Rivaroxaban long arm|"28 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.~Subgroup: PK/PD parameters are assessed following the last intake of Rivaroxaban at day 28"
2860919|NCT03522246|Experimental|Arm A|oral rucaparib + intravenous (IV) nivolumab
2860920|NCT03522246|Experimental|Arm B|oral rucaparib+IV placebo
2860921|NCT03522246|Experimental|Arm C|oral placebo+ IV nivolumab
2860922|NCT03522246|Placebo Comparator|Arm D|Oral placebo + IV placebo
2860923|NCT03522220|Experimental|3D Super Mario Game Condition|3D navigation video game intervention
2860924|NCT03522220|Active Comparator|2D Super Mario Game Condition|Video game intervention without 3D navigation
2860925|NCT03522220|Active Comparator|Kindle Device|No 3D navigation
2860926|NCT03522207|Experimental|Trazo1|After a baseline polysomnography (PSG), subject will receive 100 mg of trazodone 30 minutes prior to their 2nd PSG and will receive 100mg Placebo 30 minutes prior to their 3rd PSG.
2860927|NCT03522207|Experimental|Trazo2|After a baseline polysomnography (PSG), subject will receive 100 mg of placebo 30 minutes prior to their 2nd PSG and will receive 100mg trazodone 30 minutes prior to their 3rd PSG.
2860928|NCT03522194||Sevoflurane|Anesthesia maintenance
2860929|NCT03522194||Propofol|Anesthesia maintenance
2860930|NCT03522181|Placebo Comparator|control group|saline
2860931|NCT03522181|Experimental|GIK group|glucose-Insulin-Potassium(GIK) infusion
2860932|NCT03522168||Risperidone group|Rispridone, n=350, including 30 children 3 - <6 years old and 320 children 6 - <18 years old. ~50% - ~80% of the entire group will have <90 days of prior treatment with any antipsychotic.
2860933|NCT03522168||Aripiprazole group|Aripiprazole group, n=350, including 30 children 3 - <6 years old and 320 children 6 - <18 years old. ~50% - ~80% of the entire group will have ≤90 days of prior treatment with any antipsychotic.
2860980|NCT03521830|Active Comparator|Previous Systemic Therapy Patients|Arm A: Nivolumab 480mg IV q4weeks for up to 48 weeks (six 8-week cycles)
2860934|NCT03522155|Experimental|Intervention Arm|"Intervention: (1) Subjects will be provided with patient-specific LE estimates, (2) counseling physicians will receive talking points to assist in meaningful communication of life expectancy, and (3) subjects will complete a computer-based conjoint analysis exercise prior to counseling."
2860935|NCT03522155|No Intervention|Standard-of-care Arm|Patients in the standard-of-care arm will not receive an intervention and will receive the usual standard of care for treatment counseling.
2860936|NCT03522142|Experimental|INCB081776|Single-agent INCB081776.
2860937|NCT03522142|Experimental|INCB081776 + Nivolumab|INCB081776 in combination with nivolumab.
2860938|NCT03522129|Active Comparator|Active Treatment- CT1812 560 mg|
2860939|NCT03522129|Active Comparator|Active Treatment- CT1812 280 mg|
2860940|NCT03522129|Active Comparator|Active Treatment- CT1812 90 mg|
2860941|NCT03522129|Placebo Comparator|Placebo Comparator - Placebo|
2860942|NCT03522116||No intervention|
2860943|NCT03522090||No neck CT|Cohort of patients with suspected lung cancer where the lower neck is not routinely included in CT
2860944|NCT03522090||Neck CT|Cohort of patients with suspected lung cancer where the lower neck is routinely included in CT
2860945|NCT03522077|Experimental|SoftSeal®-STF hemostatic pad|The SoftSeal®-STF hemostatic pad will be applied over the radial access site and then will apply constant pressure for a period of 1 minute per French size if ACT < 170, 2 minutes per French size if ACT 170-220, or 15 minutes if ACT >220.
2860946|NCT03522077|Active Comparator|VascBand™ Hemostat|The device will be placed proximal to the puncture site and inflated slowly until hemostasis is obtained.
2860947|NCT03522064|Experimental|High dose testosterone|500mg IM enanthate every 4 weeks in combination with ongoing LHRH agent (unless post-orchidectomy).
2860948|NCT03522051|Experimental|Patients with carious teeth|female or male patients with permanent teeth and deep caries will receive pulpotomy treatment and dressing with calcium silicate based material (Neo MTA plus material) followed by restoration.
2860949|NCT03522025|Active Comparator|GMK-UNI cemented fixation prosthesis|Unicompartmental Knee Arthroplasty (UKA)
2860950|NCT03522025|Experimental|GMK-UNI cementless fixation prosthesis|Unicompartmental Knee Arthroplasty (UKA)
2860951|NCT03522012|Experimental|LusiNex|4 mg/kg, single-dose IV infusion (Mycenax tocilizumab)
2860952|NCT03522012|Active Comparator|RoActemra|4 mg/kg, single-dose IV infusion (RoActemra; tocilizumab marketed in EU )
2860953|NCT03522012|Active Comparator|Actemra|4 mg/kg, single-dose IV infusion (Actemra; tocilizumab marketed in US)
2860954|NCT03521999|Active Comparator|AboutFace|Veterans in the AboutFACe arm will receive access to an online peer-to-peer digital storytelling resource for Veterans with PTSD
2860955|NCT03521999|Placebo Comparator|Enhanced Usual Care (eUC)|Veterans in the Enhanced Usual Care (eUC) arm will receive an education brochure for PTSD
2860956|NCT03521986|Experimental|Subxiphoid uniportal VATS|Standard Subxiphoid single-port video assisted mediastinal thymectomy, no use of rib-spreader.
2860957|NCT03521986|Active Comparator|Intercostal uniportal VATS|Standard Intercostal single-port video assisted mediastinal thymectomy, no use of rib-spreader.
2860958|NCT03521973|Experimental|Group 1- PfSPZ-Vaccine|"Children aged 7-12 years (inclusive) of age will be enrolled in this group.~N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals."
2860959|NCT03521973|Placebo Comparator|Group 2|"Children aged 7-12 years (inclusive) of age will be enrolled in this group.~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals."
2860960|NCT03521973|Experimental|Group 3|"Children aged 3-6 years (inclusive) of age will be enrolled in this group.~N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals."
2860961|NCT03521973|Placebo Comparator|Group 4|"Children aged 3-6 years (inclusive) of age will be enrolled in this group.~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals."
2860962|NCT03521973|Experimental|Group 5|"Children aged 1-2 years (inclusive) of age will be enrolled in this group.~N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals."
2860963|NCT03521973|Placebo Comparator|Group 6|"Children aged 1-2 years (inclusive) of age will be enrolled in this group.~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals."
2860964|NCT03521960|Active Comparator|Buspirone oral capsule|Buspirone (15 milligrams) administered orally three times per day
2860965|NCT03521960|Placebo Comparator|Placebo oral capsule|Placebo administered orally three times per day
2860966|NCT03521947||One group of children below 18 years old|
2860967|NCT03521934|Experimental|Sotagliflozin|Sotagliflozin dose 1, once daily with possible uptitration in the first 8 months to dose 2
2860968|NCT03521934|Placebo Comparator|Placebo|Placebo dose 1, once daily with possible uptitration in the first 8 months to dose 2
2860969|NCT03521908||Participants treated with apixaban|
2860970|NCT03521908||Participants treated with warfarin|
2860971|NCT03521895||Treatment naïve wAMD|Treatment naïve patients with wAMD treated with IVT aflibercept from the two underlying studies PERSEUS and RAINBOW
2860972|NCT03521882||Stroke Symptom Participants|
2860973|NCT03521882||Healthy Controls|
2860974|NCT03521869|Active Comparator|Compression bandage group|
2860975|NCT03521869|Active Comparator|Standard gauze group|
2860976|NCT03521856|Experimental|shoulder exercise intervention|A home exercise intervention for strengthening and stretching the shoulders - Strengthening and Optimal Movement for Painful Shoulders (STOMPS) - performed 3 times per week for 12 weeks.
2860977|NCT03521856|Active Comparator|education-only control|Subjects watched a 1 hour educational video on shoulder anatomy, mechanisms of shoulder injury and pain, and hints for managing shoulder pain
2860978|NCT03521843|Experimental|balloon dilation only|The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.
2860979|NCT03521843|Experimental|balloon dilation+local drug delivery|The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.
2861106|NCT03520959|Experimental|Arm B|CMB305
2860981|NCT03521830|Experimental|Progression after anti-PD-1 therapy|Arm B: ipilimumab 1mg/kg IV q4 weeks x 4 doses + nivolumab 480mg IV q4weeks followed by nivolumab 480mg IV q4weeks for up to 48 total weeks of therapy.
2860982|NCT03521817|Experimental|Alcohol|Etoh will have a 30% reduction in calories from weight maintenance and will consume the same percentage of each traditional macronutrient (20% protein, 50% carbohydrate, and 30% fat; (minus the ~240 kcals from ethanol). The Etoh group will consume a 30% energy restriction diet that will also include ~2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila).
2860983|NCT03521817|Active Comparator|No Alcohol|No Etoh will have a 30% reduction in calories from weight maintenance and will consume the same percentage of each traditional macronutrient (20% protein, 50% carbohydrate, and 30% fat).
2860984|NCT03521804|Other|SoundBite™ Crossing System-Coronary|Crossing of coronary chronic total occlusions.
2860985|NCT03521791|Experimental|PRO-155|Pro-155: 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac for 20 days
2860986|NCT03521791|Placebo Comparator|Placebo|Placebo 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac
2860987|NCT03521778|Experimental|Fascial Distortion Model group|Patients will receive manual treatment complies with Fascial Distortion Model method.
2860988|NCT03521778|Experimental|Mulligan Concept group|Patients will receive manual treatment complies with Mulligan Concept method.
2860989|NCT03521778|Experimental|Traditional physiotherapy group|Patients will receive traditional physiotherapy.
2860990|NCT03521765|Experimental|OT intervention group|The OT intervention group were given a consultation based on a CRC education handbook by an occupational therapist for discharge preparation and on 1-month, 3-month follow-up clinic.
2860991|NCT03521765|No Intervention|non-intervention group|The non-intervention group participants were given a CRC education handbook (the same handbook) only for discharge preparation.
2860992|NCT03521752|Experimental|Experimental|Performed a specific program exercises (resistance training, balance, coordination and flexibility) during 4 weeks.
2860993|NCT03521752|No Intervention|Control|The control group wasn't subjected to any intervention
2860994|NCT03521726|Other|Intraluminal Amoxicillin eradication|20 Patients receive intraluminal Amoxicillin eradication of H. pylori.
2860995|NCT03521726|Other|Rabeprazole, Amoxicillin dual therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole and Amoxicillin) for 14 days.
2860996|NCT03521713|Experimental|EPORON|"<Part 1 Treatment Period> Week 1 to Week 24 Initial Phase (Week 1 to Week 4) : 50 IU/kg of Erythropoietin Alpha, three times a week (3 x 50 IU/kg/week) No dose adjustments will be permitted during the first 4 weeks of the study. Maintenance Phase (Week 5 to Week 24) The dose will be adjusted to maintain Hb levels between 10 and 12 g/dL.~<Part 2 Treatment Period> : Week 25 to Week 52 The dose of Erythropoietin Alpha will be adjusted to maintain hemoglobin levels between 10 and 12 g/dL as subcutaneous administration in accordance with the given dosing algorithm. The further details are the same as those for maintenance phase of Part 1 Treatment Period."
2860997|NCT03521713|Active Comparator|EPREX|"<Part 1 Treatment Period> Week 1 to Week 24 Initial Phase (Week 1 to Week 4) : 50 IU/kg of Erythropoietin Alpha, three times a week (3 x 50 IU/kg/week) No dose adjustments will be permitted during the first 4 weeks of the study. Maintenance Phase (Week 5 to Week 24) The dose will be adjusted to maintain Hb levels between 10 and 12 g/dL.~<Part 2 Treatment Period> : Week 25 to Week 52 The dose of Erythropoietin Alpha will be adjusted to maintain hemoglobin levels between 10 and 12 g/dL as subcutaneous administration in accordance with the given dosing algorithm. The further details are the same as those for maintenance phase of Part 1 Treatment Period."
2860998|NCT03521700|Experimental|Intensive lipid lowering group|10 mg/d rosuvastatin was initially prescribed and target LDL-C was < 1.8mmol/L
2860999|NCT03521700|Other|Conventional lipid lowering group|5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, <3.3mmol/L
2861000|NCT03521687|Experimental|Apremilast|Patients with CCCA
2861001|NCT03521674|Other|Foley catheter|Foley catheter will be inserted through the cervical os and it will be filled with 40 ml saline. After insertion gentle traction will be applied for cervical ripening. Pregnancy termination will be achieved.
2861002|NCT03521674|Other|Double-balloon catheter|Double-balloon catheter will be inserted through the cervical os and both baloons will be filled with 40 ml saline. No traction will be applied. Pregnancy termination will be achieved.
2861003|NCT03521661||Kyphoplasty|Patients underwent kyphoplasty with an intravertebral expander
2861004|NCT03521648||PAE|Men with BPH - LUTS BPE who have opted for PAE and have consented to take part in the Register Study.
2861005|NCT03521648||TURP|Men with BPH - LUTS BPE who have opted for TURP and have consented to take part in the Register Study.
2861006|NCT03521648||Other|Men with BPH - LUTS BPE who have opted for other treatment options (e.g., holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate) and have consented to take part in the Register Study.
2861007|NCT03521635|Experimental|Pramipexole SR|
2861008|NCT03521635|Active Comparator|Pramipexole IR|
2861009|NCT03521622|Experimental|brief counseling interventions|"For smoking patients the brief intervention is 5 As model for motivated patients and 5Rs for not motivated patients.~For risky alcohol drinkers the brief intervention is simple advise for motivated patients and brief intervention for not motivated patients."
2861010|NCT03521622|Placebo Comparator|Control group|written informative material about healthy lifestyles
2861011|NCT03521609|Experimental|Emotional Intelligence Intervention|Patient's emotional abilities will be stimulated by means of a brief intervention in a group format (nine sessions). In these sessions we will use both projective and guided-fantasy techniques for the emotional diagnosis, as well as psychoeducational workshops of both emotional education and emotional intelligence development.
2861012|NCT03521596||Patient enrolled|Part of the patients will be retrospectively enrolled (learning sample) and part prospectively (validation sample)
2861013|NCT03521570|Experimental|Treatment (nivolumab, IMRT)|Participants receive nivolumab IV over 30 minutes on weeks -2, 0, 2, 4, and 6 and undergo IMRT once daily beginning on week 0 for up to 6-6.5 weeks. Beginning week 10, participants receive nivolumab IV over 30 minutes every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
2861014|NCT03521557|Experimental|Gaze and Postural Stability|"The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.~Gaze stability exercise will consist of progressive Vestibular-occular training.~Postural stability exercises will consist of progressive static and dynamic postural training."
2861015|NCT03521557|Active Comparator|Standard Care Control|The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength. The target duration of each in clinic visit will be 90 min (30 min of aerobic exercise, 30 min of lower extremity resistance exercises, and 30 min of rest interspersed throughout the exercise session.
2861016|NCT03521544|Experimental|Plantar Fascia|Self-myofascial release in the plantar fascia.
2861017|NCT03521544|Experimental|Tricep surae fascia|Self-myofascial release in the triceps surae fascia.
2861018|NCT03521544|Experimental|Hamstrings fascia|Self-myofascial release in the hamstrings fascia.
2861019|NCT03521544|Experimental|Spine erectors and lumbar fascia|Self-myofascial release in the spine erectors and lumbar fascia.
2861020|NCT03521544|Experimental|Occipital and suboccipital fascia|Self-myofascial release in the occipital and suboccipital fascia.
2861021|NCT03521544|No Intervention|Control group|Lay on a stretcher.
2861022|NCT03521505|Experimental|Dexmedetomidine arm|Dexmedetomidine will be administrated for sedation of EBUS-TBNA
2861023|NCT03521505|Active Comparator|Propofol arm|Propofol will be administrated for sedation of EBUS-TBNA
2861024|NCT03521492|Experimental|caries group|
2861025|NCT03521492|Experimental|free caries group|
2861026|NCT03521479|Experimental|Group A|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8.
2861027|NCT03521479|Experimental|Group B|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8.
2861028|NCT03521479|Active Comparator|Group C|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0, month 3, and month 6.
2861029|NCT03521479|Active Comparator|Group D|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and month 6.
2861030|NCT03521466|Experimental|Intervention|Smoking Cessation counseling by trained medical students with or without Nicotine Replacement Therapy
2861031|NCT03521466|No Intervention|Control|The control group will receive counseling and/or NRT at the discretion of the treating physician.
2861032|NCT03521453||Before|Conventionnel written information
2861033|NCT03521453||After, with PEPPER|Written information + presence of a robot (PEPPER) in the waiting room, who will give informations.
2861034|NCT03521440|Experimental|Psychomotor Massage|Participants will be randomly allocated to individual sessions, and will receive two 30-minute individual sessions per week, for 8 weeks.
2861035|NCT03521440|Experimental|Progressive Muscle Relaxation|Participants will participate in 30-minute group sessions, twice a week, for 8 weeks.
2861036|NCT03521440|No Intervention|Waiting List|Participants will maintain their daily routines through the experimental intervention period. After finishing all periods of data collection, participants will be invited to participate in one of the interventions previously offered to the experimental groups.
2861037|NCT03521427|Experimental|Intensive bimanual therapy|Ninety hours of intensive bimanual therapy
2861038|NCT03521427|Active Comparator|Neurodevelopmental treatment|Ninety hours of intensive neurodevelopmental therapy
2861039|NCT03521414|Active Comparator|Group I=13-15 mildly injured|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery. use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.~Group I (n=15)=13-15 mildly injured"
2861040|NCT03521414|Active Comparator|Group 2 =9-12 moderately damaged|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery.use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.~Group 2 (n=15)=9-12 moderately damaged"
2861041|NCT03521414|Active Comparator|Group 3=3-8 severely damaged.|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery. use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.~Group 3 (n=15)=3-8 severely damaged."
2861042|NCT03521401|Experimental|ACE - Exercise Group|Participants with ACE scores of 4 or higher who will undergo exercise training for the duration of the study (experimental).
2861043|NCT03521401|No Intervention|ACE - Non-Exercise Group|Participants with ACE scores of 4 or higher who will not undergo exercise training for the duration of the study (+ control).
2861044|NCT03521401|No Intervention|Non-ACE - Non-Exercise Group|Participants with ACE scores of 0 who will not undergo exercise training for the duration of the study (- control).
2861045|NCT03521388|Experimental|Intervention group|"The intervention consists of an Internet-based program. The program will last 3 months, with subsequent monthly reinforcement sessions for other 3 months.~The program is stepped, so that the more depressive symptomatology the more intensive program and consists of more components.~The students will interact with the program via a monitoring and feedback e-mail with 3 questions of the PHQ--9- adolescent version (1st, 2nd & 9th question) that they will receive every 2 weeks and a Website that will allow them to access to psycho-educational videos and information. There will also in the Website sections that will provide emergency information, the possibility of a contact via e-mail, and group chats. Adolescents with more depressive symptoms or suicidal risk will be invited to participate in an online counselling appointment or a face to face assessment with a mental health professional of the program."
2861046|NCT03521388|Other|Control group|The comparison group will receive general psychoeducation of depression in adolescents and will be on the waiting list to receive the intervention in the event that its efficacy is demonstrated.
2861107|NCT03520946|Experimental|Arm A (ramucirumab + TAS102)|Patients randomized to arm A will receive ramucirumab 8 mg/kg iv over 60 min on d1+15, q4w and TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression or intolerance or completion of 6 cycles.
2861047|NCT03521375|Experimental|VATS lobectomy|VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
2861048|NCT03521375|Active Comparator|Open lobectomy|Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.
2861049|NCT03521362|Experimental|MyT1DHero App|Participants in this group will receive use of the MyT1DHero app.
2861050|NCT03521362|Active Comparator|"Other T1D App"|Participants in this group will receive use of a different app with less capabilities.
2861051|NCT03521349|Placebo Comparator|Egg White Snacks|Egg white-based snacks
2861052|NCT03521349|Experimental|Whole Egg Snacks|Whole egg-based snacks
2861053|NCT03521336|Experimental|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months
2861054|NCT03521336|Placebo Comparator|Control|Placebo: Sham operation, 10ml saline, once a month for 4 months
2861055|NCT03521323|Experimental|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months
2861056|NCT03521323|Placebo Comparator|Control|Sham operation and 10ml saline as placebos, once a month for 4 months
2861057|NCT03521310|Experimental|Skin-to-skin Contact group|Neonates in gestational age between 28+0 - 32+6 will get continuous Skin-to-skin contact with one parent/caregiver the first 6 hours after birth and as much as possible the first 72 hours after birth.
2861058|NCT03521310|Active Comparator|Conventional care group|Neonates in gestational age between 28+0 - 32+6 will get Conventional care - incubators, warmers etc - the first 72 hours after birth.
2861059|NCT03521297|No Intervention|single UDCA|0.25g UDCA po third per day for 6 month
2861060|NCT03521297|Experimental|UDCA combined probiotics|0.25g UDCA po third per day and 2g Live Combined Bifidobacterium and Lactobacillus Tablets po third per day for 6 month
2861061|NCT03521284||Mothers with education program during their mat|
2861062|NCT03521284||Mothers without education program during their mat|
2861063|NCT03521258|Experimental|Human Amnion/Chorion Membrane + skin graft|Dehydrated Human Amnion/Chorion Membrane (dHACM) will be placed on wound at the initial debridement to promote granulation tissue at the wound bed. Approximately 5-7 days following debridement, wound will be assessed for suitability of split thickness skin grafting. If an adequate granulation tissue is present, skin grafting will be performed and assessed for take in 5 days.
2861064|NCT03521258|Active Comparator|Flap Reconstruction (Standard of Care)|A negative pressure wound dressing (NPWD) will be applied at the time of debridement until the wound is clean and adequate for flap reconstruction. Flap-based reconstruction is performed. Following flap reconstruction,patient will have 5 days of bed rest to allow proper healing and coverage of the wounds. If flaps are successful, patients starts a limb dangle protocol which gradually increases the dependent position and allows the flap to acclimate to new physiologic demands. Following dangle protocol patient will require inpatient physical and occupational therapy prior to discharge.
2861065|NCT03521245||Trastuzumab monotherapy|Her2-positive breast cancer patients treated with Trastuzumab (monotherapy)
2861066|NCT03521245||Chemotherapy plus Trastuzumab|Her2-positive breast cancer patients treated with Trastuzumab in combination with other regimens of chemotherapy
2861067|NCT03521232|Experimental|150 mg/60 ml|Niclosamide enemas 150 mg/60 ml given twice daily for 6 weeks
2861068|NCT03521232|Experimental|450 mg/60 ml|Niclosamide enemas 450 mg/60 ml given twice daily for 6 weeks
2861069|NCT03521219|Experimental|Apatinib|Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
2861070|NCT03521206|Experimental|Intervention group|"The ACP+ programme aims to improve or establish advance care planning (ACP) in the day-to-day routine of staff working in nursing homes.~The intervention implementation period has a total duration of 8 months and is divided into:~a four-month preparation and training phase. During this phase the ACP reference persons will attend a two-day training given by the ACP trainers. Other staff will receive training by the reference persons on conducting ACP conversation or recognizing triggers for an ACP conversation in nursing home residents.~A four-month follow-up phase in which ACP conversations are held with residents. Additional training sessions will be organized to give more in-depth knowledge to the ACP reference persons."
2861071|NCT03521206|No Intervention|Control group|The staff of nursing homes in the control group will receive no additional training next to any standard education or continuous training. After the intervention and follow-up measures are finished, all nursing homes in the control group will be offered a shortened version of the ACP+ training programme as well as all ACP+ training materials.
2861072|NCT03521193|Experimental|Migraine evaluation in PFO patients|Patients symptomatic for migraine with/o aura and addressed to patent foramen ovale closure (Occlutech Figulla Flex II PFO occluder device) for a previous ischemic event, will receive dual antiplatelet therapy (DAPT) for 2 months after procedure and aspirin alone subsequently. Patients will undergo evaluation of platelet reactivity, serotonin and cytokines before PFO closure with a dedicated device and at 6 months follow-up
2861108|NCT03520946|Active Comparator|Arm B (TAS102 only)|Patients randomized to arm B will receive TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression, intolerance or completion of 6 cycles.
2861427|NCT03518957|No Intervention|Non-exercise|Patients who are randomised to the non-exercise group can continue their daily and physical activities as they normally would.
2861073|NCT03521180||Subjects with Celiac Disease|"Group 1 will start the gluten challenge with 4 slices of white bread once daily for 3 days. Blood will be taken at pre-specified time points for up to 9 days following the start of gluten challenge for biomarker analyses.~Based on data from the first 5 subjects, the 2nd group of 5 subjects may: 1) not be needed if the objectives are met; 2) receive gluten at increased quantity (not to exceed 6 slices of bread once daily for 3 days) or have biomarker samples collected at adjusted time points; 3) same as the first 5 subjects; 4) reducing the duration of gluten free diet for a minimum of 3 months instead of 6 month for the Inclusion Criteria # 5;5) subjects may be re-enrolled once.~The same applies to the 3rd group of subjects. A notification will be provided to the clinical study site for detailed changes."
2861074|NCT03521167|No Intervention|T|traditional opioid based regimen
2861075|NCT03521167|Active Comparator|MD|multimodal group with dexmedetomidine
2861076|NCT03521167|Placebo Comparator|M|multimodal with saline placebo
2861077|NCT03521154|Experimental|Osimertinib|Osimertinib (80mg or 40mg orally, once daily), in accordance with the randomization schedule.
2861078|NCT03521154|Placebo Comparator|Placebo Osimertinib|Matching placebo for Osimertinib (80mg or 40mg orally, once daily), in accordance with the randomization schedule
2861079|NCT03521141|Other|Guideline-Based Care (GBC)|GBC participants are 1) referred to the state quitline, 2) provided the NCI Clearing the Air smoking cessation program, and 3) asked to talk to their healthcare provider about potential lung cancer screening (LCS). Medication assignment is guided by standard guidelines and a conversation between the study tobacco counselor and the participant. Groups 1 and 2 also receive GBC counseling.
2861080|NCT03521141|Active Comparator|Nicotine Metabolite Ratio (PC-NMR)|Group 1, nicotine metabolism. Medication is guided by nicotine metabolism.
2861081|NCT03521141|Active Comparator|Respiragene (PC-Respiragene)|Group 2, genetically-informed lung cancer risk score. Medication assignment is guided by standard guidelines and a conversation between the study nurse and the participant.
2861082|NCT03521128|Experimental|the radiological tubal blockage group|
2861083|NCT03521128|Active Comparator|the laparoscopic salpingectomy group|
2861084|NCT03521115|Experimental|Smart Choices 4 Teens|A web-based intervention consisting of 3 main components (Communication, Alcohol, Relationships) provided to both parents and teens was completed by parents and teens individually. At the end of each component, discussion guidelines were given to promote communications and to offer skill building practices between parent and teen regarding the component topic. Both the parent and teen were required to complete the component and discussion before moving to the next component.
2861085|NCT03521115|No Intervention|Control condition|This group was provided with websites where information was available regarding the same topics.
2861086|NCT03521102|Experimental|Acetaminophen 1000mg IV|NRS pain scores will be obtained at 5, 15, 30, 45, 60, 75, 90, 105 and 120 minutes following completion of intervention. Adverse events will be recorded every 15 minutes for the duration of the study protocol. Participants will be reassessed for the need of additional pain control at 60 minutes.
2861087|NCT03521102|Active Comparator|Hydromorphone 0.5mg IV|NRS score will be checked at 5 minutes and every 15 minutes for 120 minutes. Adverse events will be recorded every 15 minutes for the duration of the study protocol. The need for additional pain control will be assessed at 60 minutes.
2861088|NCT03521089|Active Comparator|Active tDCS|Active tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The active tDCS intervention include stimulation for 15 minutes at 1mA. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
2861089|NCT03521089|Sham Comparator|Sham tDCS|Sham tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The sham tDCS intervention lasts for 15 minutes. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
2861090|NCT03521076|Experimental|Virtual Reality for distraction|The application of VR during the putative painful treatment (botulinum toxin injections) will provide a) active and engaging distraction during the procedure, and will b) block the view and auditory noise related to the procedure.
2861091|NCT03521076|No Intervention|Standard of Care|Patients will receive the standard of care for the putative painful treatment (botulinum toxin injections).
2861092|NCT03521063|Experimental|Poractant alfa/budesonide|A mixture of poractant (200mg/kg) and budesonide (0.25 mg/kg) will be instilled intratracheal
2861093|NCT03521063|Active Comparator|Poractant alfa/saline|A mixture of poractant (200mg/kg) and saline (1 ml/kg) will be instilled intratracheal
2861094|NCT03521050||implanted defibrillator lead|patients having an ICD implanted and having follow-up at the investigators center
2861095|NCT03521037|Experimental|no name|Group 1: patients with normal hepatic function Group 2: patients who have moderate hepatic impairment
2861096|NCT03521024|Active Comparator|lithium disilicate crowns|lithium disilicate crowns are well documented in the literatures as successful restoration modality.
2861097|NCT03521024|Experimental|poly ether ketone ketone crowns|pekkton
2861098|NCT03520998|Experimental|GRF6019 Low Dose|Subjects will receive a low dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.
2861099|NCT03520998|Experimental|GRF6019 High Dose|Subjects will receive a high dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.
2861100|NCT03520985|Experimental|Pomalidomide|The treatment in this trial consists of oral pomalidomide on alternate days (ad) plus Low-Dose Dexamethasone (adPOM + LD-DEX)
2861101|NCT03520972|Experimental|PB-119 75ug|PB-119 injection 75ug subcutaneously injected once-weekly for 12 weeks
2861102|NCT03520972|Experimental|PB-119 150ug|PB-119 injection 150ug subcutaneously injected once-weekly for 12 weeks
2861103|NCT03520972|Experimental|PB-119 200ug|PB-119 injection 200ug subcutaneously injected once-weekly for 12 weeks
2861104|NCT03520972|Placebo Comparator|placebo|placebo injection subcutaneously injected once-weekly for 12 weeks
2861105|NCT03520959|Placebo Comparator|Arm A|CMB305 Placebo
2861109|NCT03520933||Embryos undergoing PGT-A / niPGT-A|Embryos from IVF patients between 20 and 44 years of age, undergoing PGT-A for any medical indication, with own oocytes or ovum donation cycles and with single embryo transfer (SET)
2861110|NCT03520920|Experimental|cohort 1 and cohort 2|BGB-3111 in combination with Rituximab in relapsed/refractory non-GCB DLBCL and relapsed/refractory follicular (FL) or marginal zone lymphoma (MZL)
2861111|NCT03520907|Experimental|Transversalis Fascia Plane Block|receive transversalis fascia plane block with 0.4 ml/kg of 0.25% levobupivacaine after establishment of general anesthesia.
2861112|NCT03520907|Active Comparator|Ilioinguinal/iliohypogastric Nerve Block|receive ilioinguinal/iliohypogastric nerve block with 0.1 ml/kg of 0.25% levobupivacaine after establishment of general anesthesia.
2861113|NCT03520894|Experimental|Neoadjuvant radiotherapy arm|Early breast cancer patients eligible for breast conservative surgery will undergo neoadjuvant radiotherapy with Cyberknife robotic system
2861114|NCT03520881|Experimental|Pediatric ASTHMA-Educator arm|This arm corresponds to the pediatric version of the ASTHMA-Educator mobile application.
2861115|NCT03520868||Coumadin|Coumadin patients with undergo standard procedure with monitoring of Anti-Factor Xa assay before and during the procedure. Heparin bolus given will be based on 70 U/kg
2861116|NCT03520868||Dabigatran|Dabigatran patients with undergo standard procedure with monitoring of Anti-Factor Xa assay before and during the procedure. Heparin bolus given will be based on 110 U/kg
2861117|NCT03520868||Rivaroxiban|Rivaroxiban patients with undergo standard procedure with monitoring of Anti-Factor Xa assay before and during the procedure. Heparin bolus given will be based on 110 U/kg
2861118|NCT03520868||Apixaban|Apixaban patients with undergo standard procedure with monitoring of Anti-Factor Xa assay before and during the procedure. Heparin bolus given will be based on 10 U/kg
2861119|NCT03520855|Experimental|ETP + Serious game|patients receiving the serious game additionally to the classic therapeutic education
2861120|NCT03520855|Active Comparator|ETP|patients under classic therapeutic education
2861121|NCT03520842|Experimental|Treatment (regorafenib, methotrexate)|Participants receive regorafenib PO QD on days 1-21, and methotrexate PO twice weekly with 2-3 days apart on a 3 week on/ 1 week off cycle. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2861122|NCT03520829||Patient treated for Gamma Knife|
2861123|NCT03520816|Experimental|Burn Physiotherapy Protocol Group|Patients in the treatment group have been received to the physiotherapy programme from the first day of their stay in the hospital.
2861124|NCT03520816|No Intervention|Control Group|The control group consisted of patients who could not receive physiotherapy due to various reasons.
2861125|NCT03520803|Experimental|Experimental|ERAS protocol
2861126|NCT03520803|No Intervention|Control|Standard of care
2861127|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Placebo|"Gemcitabine is administered intravenously 4 times a cycle.~Nap-paclitaxel is administered intravenously 4 times a cycle.~Placebo is administered orally on a daily basis"
2861128|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Paricalcitol IV|"Gemcitabine is administered intravenously 4 times a cycle.~Nap-paclitaxel is administered intravenously 4 times a cycle.~Paricalcitol is administered intravenously 3 times a week"
2861129|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Paricalcitol oral|"Gemcitabine is administered intravenously 4 times a cycle.~Nap-paclitaxel is administered intravenously 4 times a cycle.~Paricalcitol is administered orally on a daily basis"
2861130|NCT03520777|Other|Artist Intervention|One of the three artists (visual artist, music therapist, creative writer) will work with subjects for up to 90 minutes.
2861131|NCT03520764|Experimental|New infant formula with synbiotics|
2861132|NCT03520764|Active Comparator|Standard infant formula with prebiotics|
2861133|NCT03520764|No Intervention|human milk|
2861134|NCT03520751|Experimental|Low dose (2e12 vg/kg)|Three patients age 18-35 will receive intramuscular injection of recombinant AAV1 carrying a human NFT3 gene under the control of the tMCK promoter (scAAV1.tMCK.NTF3) distributed bilaterally between both limbs at low dose (2e12 vg/kg).
2861135|NCT03520751|Experimental|Dose escalation (6e12 vg/kg)|Six patients age 15-35 will receive Intramuscular injection of recombinant AAV1 carrying a human NFT3 gene under the control of the tMCK promoter (scAAV1.tMCK.NTF3) distributed bilaterally between both limbs in a 3-fold dose escalation (6e12 vg/kg)
2861136|NCT03520738|Other|Chronic Kidney Disease|"Blood and urinary samples on the following patients:~10 Stage 1 and 2 CKD patients 10 patients 6 weeks after graft 10 patients on maintenance dialysis."
2861137|NCT03520738|Other|Pseudoxanthoma elasticum (PXE)|"Blood and urinary samples on the following patients:~10 patients with pseudoxanthoma elasticum (PXE) with low PPi levels and vascular calcifications and patients with hypophosphatasia (HPP) with high PPi levels and bone decalcification."
2861138|NCT03520738|Other|Hypophosphatasia (HPP)|"Blood and urinary samples on the following patients:~4 patients with hypophosphatasia (HPP) with high PPi levels and bone decalcification."
2861139|NCT03520725|Experimental|No Intervention|This group did not have an intervention
2861140|NCT03520725|Experimental|Intervention pineapple|Daily consumption of 30 g of pineapple snack bar for 4 weeks.
2861141|NCT03520725|Experimental|Intervention mango|Daily consumption of 30 g of mango snack bar for 4 weeks.
2861142|NCT03520712|Experimental|valoctocogene roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg
2861143|NCT03520686|Experimental|Group A|
2861144|NCT03520686|Active Comparator|Group B|
2861145|NCT03520673|Other|Development of Clinical Decision Support Tool|All men will receive the same series of simple index tests which will be compared with the results of the urodynamics reference test to identify which index tests give the best prediction of the urodynamic results. The data from the first cohort will develop the clinical decision support tool.
2861146|NCT03520660||1|patients with chronic HCV infection
2861147|NCT03520647|Experimental|Transplant recipients|haplo-identical transplantation
2861177|NCT03520452|Experimental|302 mg green coffee extract|Green coffee extract
2861178|NCT03520452|Experimental|604 mg green coffee extract|Green coffee extract
2861179|NCT03520452|Experimental|906 mg green coffee extract|Green coffee extract
2861180|NCT03520439|Experimental|study group|mifepristone tablets ，10mg，One tablet daily, oral treatment
2861148|NCT03520634|Experimental|PD-L1 PET imaging in melanoma patients|The main intervention of this study is a [18F]PD-L1 PET scan. In both phase one and phase two a scan sequence will be performed both at baseline and 6 weeks after initiation of nivolumab treatment. The PET scans will be combined with either a low dose or diagnostic CT scan of chest, abdomen and pelvis and a MRI of the brain. In phase two, a biopsy of at least one accessible lesion will be performed to analyze PD-L1 expression using immunohistochemical staining after each PET scan.
2861149|NCT03520621||High Prevalence Population|Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is >2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo
2861150|NCT03520621||Low Prevalence Population|Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is <2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo
2861151|NCT03520595|Active Comparator|Arnica Group|Study group 1 CLP with ostectomy Arnica 200 drug 3 pills,3 times daily for 3 days
2861152|NCT03520595|Active Comparator|Diclofenac Sodium group|Study group 2 CLP with ostectomy Diclofenac Sodium 50mg twice daily after meals with plain water
2861153|NCT03520595|Placebo Comparator|Placebo Group|Study group 3 CLP with ostectomy Placebo pills and distilled water 3 pills,3 times daily
2861154|NCT03520582||Volunteers|Cohort of 10 healthy subjects. The tube will be placed and removed by a gastroenterologist experienced in performing endoscopic postpyloric tube placement. Secondly, a second tube will be placed and removed.
2861155|NCT03520582||Mechanically ventilated ICU|Cohort of 20 mechanically ventilated intensive care patients requiring a placement of a postpyloric feeding tube on clinical indications.
2861156|NCT03520569|Active Comparator|Octreotide- Euglycemia|octreotide is 30 ng/kg/min x 240 min insulin 0.15mU/kg/min x 240 min Dextrose 20% at variable rate to maintain euglycemia for 240 min
2861157|NCT03520569|Active Comparator|Octreotide - Euglycemia- insulin clamp|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 210 min insulin 1.0mU/kg/min x 120 min Dextrose 20% at variable rate to maintain euglycemia for 330 min
2861158|NCT03520569|Active Comparator|Octreotide- hyperglycemia|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 330 min Dextrose 20% at variable rate to maintain euglycemia for 90 min Dextrose 20% at variable rate to maintain hyperglycemia for 240 min
2861159|NCT03520569|Active Comparator|Octreotide- hyperglycemia - insulin clamp|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 210 min insulin 1.0mU/kg/min x 120 min Dextrose 20% at variable rate to maintain euglycemia for 90 min Dextrose 20% at variable rate to maintain hyperglycemia for 240 min
2861160|NCT03520556||docosahexaenoic acid (DHA)|Adults supplemented with DHA in a randomized controlled trial of ≥7 days duration
2861161|NCT03520556||eicosapentaenoic acid (EPA)|Adults supplemented with EPA in a randomized controlled trial of ≥7 days duration
2861162|NCT03520556||control|Adults supplemented with control fatty acids in a randomized controlled trial of ≥7 days duration assessing the effects of EPA and/or DHA
2861163|NCT03520543|Experimental|Part A : Imput function|Compartmental model of the volume of distribution of [11C]Yohimbine in Brain by PET
2861164|NCT03520543|Experimental|Part B : validity of the measure|Part B1 : Test Retest Variability in the distribution of [11C]Yohimbine Part B2 : Percentage of alpha2-adrenergic receptor occupancy
2861165|NCT03520530|Experimental|Mouth Guard|Patients will push in the second stage of labor without use of mouth guard
2861166|NCT03520530|No Intervention|Control|Patients will push in the second stage of labor without use of mouth guard
2861167|NCT03520517|Experimental|BHV-0223|riluzole 40 mg sublingual tablet
2861168|NCT03520504|Experimental|Proton Radiation|"Patients will be enrolled to receive 30Gy (RBE) in 3Gy (RBE) or 25Gy (RBE) in 2.5Gy (RBE) fractions course of proton CSI.~The first 3 patients will be enrolled at dose level 30Gy (RBE) in 3Gy(RBE) fractions. If 1 or fewer patients develop dose-limiting toxicity (DLT), 3 additional patients will be enrolled. If 1 or fewer of the 6 patients experiences a DLT, the trial will proceed to the dose expansion cohort at 30Gy (RBE) . In contrast, if 2 or more patients experience a treatment DLT, 3 patients will be enrolled at dose level 25Gy (RBE) in 2.5Gy(RBE) fractions. If 1 or fewer patients develop a DLT, an additional three patients will be enrolled. If 2 or more patients experience a DLT at 25Gy, the study will be stopped. If 1 or fewer patients develop a DLT in these 6 patients, the trial will proceed to the dose expansion cohort at 25Gy (RBE) and the 6 patients who were treated in Phase Ib will be included in full assessment of safety and efficacy."
2861169|NCT03520491|Experimental|Cohort 1|Nivolumab 3 mg/kg on day 1 of each cycle for a total of 5 cycles. Each cycle will be two weeks long and treatment will occur during weeks 0, 2, 4, 6, and 8.
2861170|NCT03520491|Experimental|Cohort 2|Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1 of each cycle, followed by Nivolumab 3 mg/kg on day 22 of each cycle for a total of 2 cycles. Each cycle will be six weeks long. Ipilimumab and Nivolumab will occur on weeks 0 and 6 while Nivolumab alone will occur on weeks 3 and 9.
2861171|NCT03520491|Experimental|Cohort 3|Ipilimumab 3 mg/kg on day 1 each cycle and Nivolumab 1 mg/kg on day 1 of each cycle for a total of 3 cycles. Each cycle will be three weeks long and treatment will occur during weeks 0, 3, and 6.
2861172|NCT03520478|Experimental|SHR3680|Participants will receive SHR3680 orally
2861173|NCT03520478|Active Comparator|bicalutamide|Participants will receive bicalutamide orally
2861174|NCT03520465|Experimental|Supraaponeurotic mesh|"Patients with laparotomy closure by conventional approach of aponeurosis (continuous suture with monofilament of slow absorption), and posterior placement of supraaponeurotic mesh of polyvinylidene fluoride (PVDF) medium / low density and wide pore. The mesh has a longitudinal measurement that exceeds about 3 cm the upper and lower ends of the wound and width should not be less than 10 cm, therefore the mesh selected is DynaMesh®-CICAT longitudinal measure 10x35 cm.~The mesh is fixed to the aponeurosis with a crown of loose stitches and points to the midline. A prolene 2/0 non-reabsorbable monofilament suture of cylindrical needle is used.~A 10 Fr suction drainage is placed in the supraaponeurotic plane, with an exit to the exterior beyond the edges of the prosthesis. Drainage will be preserved for a minimum of 48 hours after surgery, and will be withdrawn when a debit of less than 50 ml is presented in 24 h."
2861175|NCT03520465|No Intervention|Monofilament|Patients with conventional closure of the middle laparotomy with approach of aponeurosis in a plane by continuous suture with monofilament of slow absorption. In this study, the suture used in all patients will be poly-4-hydroxybutyrate or Mono-max loop®.
2861176|NCT03520452|Placebo Comparator|Placebo|Placebo
2861182|NCT03520426|Experimental|Votiva RF|Patients will undergo radiofrequency treatment using the Votiva FormaV and FractoraV hand pieces, using the device's standard protocol. Patients will have 3 treatments spaced 3-4 weeks apart and two follow-up visits. Duration of each treatment visit is approximately 1-1.5 hours. Prior to treatment and follow-up visit, each patient will be assessed using standardized photos, perineometry, and validated questionnaires.
2861183|NCT03520426|Sham Comparator|Votiva RF Sham|Patients will undergo the acts of receiving radiofrequency treatment with the Votiva FormaV and FractoraV hand pieces, but no direct energy will be applied. Patients will have 3 treatments spaced 3-4 weeks apart and 2 follow-up visits. Duration of each treatment visit is approximately 1-1.5 hours. Prior to treatment and follow-up visit, each patient will be assessed using standardized photos, perineometry, and validated questionnaires.
2861184|NCT03520413|Experimental|PRACTICE-DM|PRACTICE-DM is a comprehensive telemedicine intervention that bundles telemonitoring, self-management support, diet/activity support, medication management, and depression support - each of which targets a critical factor underlying PPDM - into a single, comprehensive program specifically developed for practical delivery using existing VHA Home Telehealth (HT) workforce, infrastructure, and technical resources.
2861185|NCT03520413|Active Comparator|Standard VA Home Telehealth|Standard VA HT care coordination and telemonitoring.
2861186|NCT03520400|Experimental|Exercise Intervention Group|Group receives one year of exercise and lifestyle intervention
2861187|NCT03520400|No Intervention|PCI group (usual care)|Group receives standard clinical care with no intervention
2861188|NCT03520387|Experimental|Lumbar medial branch nerve radiofrequency ablation (LRFA)|Radiofrequency ablation of the dorsal rami of the lumbar spinal nerves
2861189|NCT03520387|Active Comparator|Simulated lumbar radiofrequency ablation (simulated LRFA)|Simulated radiofrequency ablation of the dorsal rami of the lumbar spinal nerves(simulated LRFA), with targeted steroid injections
2861190|NCT03520387|Experimental|AcTIVE-CBT|Activity-Tracker Informed Video-enabled Cognitive Behavioral Therapy (AcTIVE-CBT)
2861191|NCT03520387|Active Comparator|TBSCE|Telephone-based supportive contact and education (TBSCE)
2861192|NCT03520374|Other|Ultrasonography- Novices|Novice ultrasonographers will be taught to assess gastric contents with a short and simple educational program. These results will be compared to the evaluation of experts in ultrasonography i.e interventional radiologists.
2861193|NCT03520374|Other|Ultrasonography-Expert Interventional Radiologists|Physician assessment i.e interventional radiologist evaluation of gastric contents using ultrasonography.
2861194|NCT03520361|Experimental|Oral sulfate solution (OSS) taking group|On the evening before colonoscopy, drink 177ml of OSS (Suclear®) (473ml including water in container), additionally allow another 946 ml of water. On the day of colonoscopy, drink 177ml of OSS (473ml including water in container), additionally allow another 946 ml of water.
2861195|NCT03520361|Active Comparator|2L PEG/Asc taking group|On the evening before colonoscopy, drink 1L of 2L PEG/Asc (Haprep®) solution, additionally allow another 500 ml of water. On the day of colonoscopy, drink 1L of 2L PEG/Asc solution, additionally allow another 500 ml of water.
2861196|NCT03520348|Experimental|PRO-167|Dose: a strip approximately 1 cm long, 4 times a day during the period of vigil, in the bottom
2861197|NCT03520348|Active Comparator|Corneregel®|Dose: a strip approximately 1 cm long, 4 times a day during the period of vigil, in the bottom of the right eye sac.
2861198|NCT03520322|Experimental|Mastoid Oscillator|patients with Menieres Disease
2861199|NCT03520322|Placebo Comparator|Control device|patients with Menieres Disease
2861200|NCT03520309|Active Comparator|International Dental Federation|Diagnosis and treatment decision of the restorations based on the International Dental Federation (FDI) criteria
2861201|NCT03520309|Experimental|Caries Around Restorations System|Diagnosis and treatment decision of the restorations based on the Caries Around Restorations System (CARS) and treatment decision proposed by the International Caries Classification and Management System (ICCMS)
2861202|NCT03520296||Patients hospitalized in the cardiology unit|
2861203|NCT03520296||Patients hospitalized in the orthopedic surgery unit|
2861204|NCT03520296||Patients hospitalized in the endocrinology unit|
2861205|NCT03520283|Experimental|Supportive Care (MAP)|Participants complete MAP in-clinic over 60-90 minutes.
2861206|NCT03520257|Experimental|Apatinib Plus Radiotherapy|
2861207|NCT03520257|Other|Apatinib|
2861208|NCT03520244|Experimental|Exercise + Holistic Education|A 12-week exercise program with 6 bi-weekly education sessions.
2861209|NCT03520244|No Intervention|Wait list control|Participants in the control group will be offered the exercise + education sessions after the study is complete.
2861210|NCT03520231|Experimental|Denosumab and Standard Chemotherapy|"Denosumab, given subcutaneously at a dose of 120 mg, every 4 weeks.~Gemcitabine, given intravenously at standard doses, on Days 1 and 8 of every 21 day cycle, for 3-4 cycles.~Carboplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~OR Cisplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~Calcium, orally at a dose of 1000 mg, once daily.~Vitamin D, orally at a dose of 400 IU, once daily."
2861211|NCT03520231|Placebo Comparator|Denosumab Placebo and Standard Chemotherapy|"Denosumab placebo, given subcutaneously, every 4 weeks.~Gemcitabine, given intravenously at standard doses, on Days 1 and 8 of every 21 day cycle, for 3-4 cycles.~Carboplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~OR Cisplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~Calcium, orally at a dose of 1000 mg, once daily.~Vitamin D, orally at a dose of 400 IU, once daily."
2861212|NCT03520218|Experimental|Performance of R-PEM|"5miCi of F-18 FDG will be injected and patients will wait for uptake of FDG before proceeding with first set of R-PEM scans. Additional optional R-PEM scans may be performed 4 hours after injection, and then possibly 7 hours after injection.~These R-PEM images will be compared to standard diagnostic breast work-up using DBT and MRI"
2861213|NCT03520205|Active Comparator|Quadratus Lumborum Block|Patient will receive quadratus lumborum block
2861214|NCT03520205|Active Comparator|Epidural|Patient will receive epidural anesthesia
2861215|NCT03520179||SMA TYPE 1|genetically confirmed SMA
2861216|NCT03520179||SMA TYPE 2|genetically confirmed SMA
2861217|NCT03520179||SMA TYPE 3|genetically confirmed SMA, Ambulant and non-ambulant
2861218|NCT03520166|Placebo Comparator|Group-A|No treatment
2861220|NCT03520153||FD/MAS with diabetes mellitus|"Fibrous Dysplasia/McCune-Albright Syndrome with diabetes mellitus.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
2861221|NCT03520153||FD/MAS without diabetes mellitus|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
2861222|NCT03520153||FD/MAS without diabetes and without IPMN|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus and without intraductal papillary mucinous neoplasms.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
2861223|NCT03520153||FD/MAS without diabetes and with IPMN|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus and with intraductal papillary mucinous neoplasms.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
2861224|NCT03520153||Healthy Controls|Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test.
2861225|NCT03520127||Females, 18 years of age or older|Females, 18 years of age or older, who will undergo the Intact procedure
2861226|NCT03520114|Experimental|RP sling group|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure.
2861227|NCT03520114|Experimental|SIS group|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure.
2861228|NCT03520101|Other|SAPIEN|Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received an Edwards (SAPIEN XT or SAPIEN 3) valve.
2861229|NCT03520101|Other|COREVALVE|Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received the CoreValve Evolut R or Evolut PRO valve system.
2861230|NCT03520088|Experimental|Inferior mesenteric Vein dissection|To improve and preserve the rectal nerve in the total mesorectal excision, its starts the dissection from the inferior mesenteric vein to the inferior mesenteric artery and through the pelvis
2861231|NCT03520088|Active Comparator|Inferior mesenteric Artery dissection|As standard, the dissection starts straight in the inferior mesenteric artery and through the pelvis
2861232|NCT03520075|Experimental|Phase 1 Regimen 1|"Dose escalation and expansion:~Regimen 1: ASTX029 orally once a day for 21 days of each 21-day cycle."
2861233|NCT03520075|Experimental|Phase 1 Regimen 2|"Dose escalation and expansion:~Regimen 2: ASTX029 orally once a day for 14 days of each 21-day cycle."
2861234|NCT03520075|Experimental|Phase 2|ASTX029 at the RP2D of the selected dosing regimen identified in Phase 1 to subjects with tumors characterized by gene aberrations in the MAPK signal pathway that may confer sensitivity to ASTX029.
2861235|NCT03520062|Experimental|GLP-1 Receptor Agonist (Liraglutide)|3.0mg daily dose
2861236|NCT03520049|Experimental|Oseltamivir|Oseltamivir capsule administered orally at 75 mg twice daily for five consecutive days.
2861237|NCT03520049|Placebo Comparator|Placebo|Placebo capsule administered orally twice daily for five consecutive days.
2861238|NCT03520036|Experimental|MT-7117 low dose|
2861239|NCT03520036|Experimental|MT-7117 high dose|
2861240|NCT03520036|Placebo Comparator|Placebo|
2861241|NCT03520023|No Intervention|Standard Care|Standard care with consultant discretion regarding consult of palliative care medicine
2861242|NCT03520023|Experimental|Experimental|Early palliative care consult based upon meeting study inclusion criteria
2861243|NCT03520010|Active Comparator|Internally-driven implementation|
2861244|NCT03520010|Experimental|Externally-facilitated implementation|
2861245|NCT03519997|Experimental|Pembro + Bavi|Pembrolizumab 200 mg IV every 3 weeks plus, Bavituximab 3mg/kg IV weekly
2861246|NCT03519984|Experimental|Arm A (sEPHB4-HSA, cytarabine)|Participants receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, 15, and 22 and cytarabine IV over 4 hours on days 1-5. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2861247|NCT03519984|Experimental|Arm B (sEPHB4-HSA, vincristine liposomal)|Participants receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, 15, and 22 and vincristine liposomal IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2861248|NCT03519971|Experimental|Arm 1: Durvalumab + platinum-based chemotherapy and radiation|"Durvalumab ((MEDI4736) in concurrence with platinum-based chemo-radiation therapy.~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:~cisplatin/etoposide~carboplatin/paclitaxel~pemetrexed/cisplatin~pemetrexed/carboplatin~At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive durvalumab as consolidation treatment."
2861249|NCT03519971|Placebo Comparator|Arm 2: Placebo + platinum-based chemotherapy and radiation|"Placebo in concurrence with platinum-based chemo-radiation therapy.~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:~cisplatin/etoposide~carboplatin/paclitaxel~pemetrexed/cisplatin~pemetrexed/carboplatin~At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive placebo as consolidation treatment."
2861250|NCT03519958||EGFR NSCLC Progressed on EGFR TKI|Patients with EGFR NSCLC who have progressed following EGFR TKI therapy will undergo plasma-tissue testing
2861251|NCT03519945|Experimental|Mirikizumab|Mirikizumab administered subcutaneously (SC).
2861252|NCT03519932|Experimental|comfilcon A toric lens|Subjects who wear comfilcon A toric lens either as first or second pair during this cross-over study.
2861253|NCT03519932|Active Comparator|samfilcon A toric lens|Subjects who wear samfilcon A toric lens either as first or second pair during this cross-over study.
2861254|NCT03519919|Experimental|Somofilcon A multifocal lens|Habitual wearers of multifocal contact lenses will be refit to somofilcon A multifocal lens and provide a subjective assessment.
2861255|NCT03519880|Experimental|Custom Mask Interface|Patients use a custom mask interface for one month with an option to use for a year if it performs better than a commercial mask.
2861256|NCT03519867|Experimental|1) Zemuron® 0.6 mg/kg + MK-8616 0.5 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
2861257|NCT03519867|Experimental|2) Zemuron® 1.2 mg/kg + MK-8616 0.5 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
2861258|NCT03519867|Experimental|3) Zemuron® 0.6 mg/kg + MK-8616 1.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
2861259|NCT03519867|Experimental|4) Zemuron® 1.2 mg/kg + MK-8616 1.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
2861260|NCT03519867|Experimental|5) Zemuron® 0.6 mg/kg + MK-8616 2.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
2861261|NCT03519867|Experimental|6) Zemuron® 1.2 mg/kg + MK-8616 2.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
2861262|NCT03519867|Experimental|7) Zemuron® 0.6 mg/kg + MK-8616 4.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
2861263|NCT03519867|Experimental|8) Zemuron® 1.2 mg/kg + MK-8616 4.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
2861264|NCT03519867|Experimental|9) Zemuron® 0.6 mg/kg + MK-8616 8.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
2861265|NCT03519867|Experimental|10) Zemuron® 1.2 mg/kg + MK-8616 8.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
2861266|NCT03519854|Placebo Comparator|Placebo; given 3 minutes after Esmeron®|Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861267|NCT03519854|Experimental|MK-8616 (1 mg/kg); given 3 minutes after Esmeron®|MK-8616 (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861268|NCT03519854|Experimental|MK-8616 (2 mg/kg); given 3 minutes after Esmeron®|MK-8616 (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861269|NCT03519854|Experimental|MK-8616 (4 mg/kg); given 3 minutes after Esmeron®|MK-8616 (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861270|NCT03519854|Experimental|MK-8616 (6 mg/kg); given 3 minutes after Esmeron®|MK-8616 (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861271|NCT03519854|Experimental|MK-8616 (8 mg/kg); given 3 minutes after Esmeron®|MK-8616 (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861272|NCT03519854|Placebo Comparator|Placebo; given 5 minutes after Esmeron®|Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861273|NCT03519854|Experimental|MK-8616 (1 mg/kg); given 5 minutes after Esmeron®|MK-8616 (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861274|NCT03519854|Experimental|MK-8616 (2 mg/kg); given 5 minutes after Esmeron®|MK-8616 (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861275|NCT03519854|Experimental|MK-8616 (4 mg/kg); given 5 minutes after Esmeron®|MK-8616 (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861276|NCT03519854|Experimental|MK-8616 (6 mg/kg); given 5 minutes after Esmeron®|MK-8616 (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861277|NCT03519854|Experimental|MK-8616 (8 mg/kg); given 5 minutes after Esmeron®|MK-8616 (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861278|NCT03519854|Placebo Comparator|Placebo; given 15 minutes after Esmeron®|Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861279|NCT03519854|Experimental|MK-8616 (1 mg/kg); given 15 minutes after Esmeron®|MK-8616 (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861280|NCT03519854|Experimental|MK-8616 (2 mg/kg); given 15 minutes after Esmeron®|MK-8616 (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861281|NCT03519854|Experimental|MK-8616 (4 mg/kg); given 15 minutes after Esmeron®|MK-8616 (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861282|NCT03519854|Experimental|MK-8616 (6 mg/kg); given 15 minutes after Esmeron®|MK-8616 (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861283|NCT03519854|Experimental|MK-8616 (8 mg/kg); given 15 minutes after Esmeron®|MK-8616 (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
2861284|NCT03519841|Experimental|RSP-13-01|Experimental: IMD data collection Subjects will intensively collect spectral Raman data in a home-based setting for 5 days using P0.1 and comparators
2861285|NCT03519841|Experimental|RSP-13-02|Experimental: IMD data collection Subjects will collect spectral Raman data on P0.1 four times a day for 30 days distributed over a time period of 60 days. Each timepoints are conducted in duplicate. Spectral data will be compared to standard BG measurements.
2861286|NCT03519828||Patients with post-stroke cognitive impairment|
2861287|NCT03519828||Patients without post-stroke cognitive impairment|
2861288|NCT03519815|Active Comparator|Ectoin Eye Spray|"Eye Spray to be applied 3 times per day for the duration of 10 +/-3 days Ectoin® Eye Spray - Colloidal (EES09; bitop AG) - CE marked medical device~Ingredients: Ectoin®, Soy-Lecithin, Vitamin A, Vitamin E, water, physiological buffer system Indication: to treat mild to moderate dry eye disease"
2861289|NCT03519815|Active Comparator|Liponit Eye Spray|"Eye Spray to be applied 3 times per day for the duration of 10 +/-3 days~Liposomal eye spray: Tears Again® (TA, Optima Medical Swiss AG) - CE marked medical device Ingredients: Soy-Lecithin, Sodium Chloride, Ethanol, Phenoxyethanol, Vitamin A-Palmitate, Vitamin E, Aqua purificata Indication: to treat mild to moderate dry eye disease"
2861290|NCT03519789||Post-Traumatic Stress Disorders (PTSD)|30 patients with PTSD (diagnosis based on the standard DSM criteria)
2861291|NCT03519789||Controls|30 healthy controls without any psychiatric or neurological diagnosis
2861292|NCT03519763||Control group|Fifteen patients without isthmocele
2861293|NCT03519763||Study subgroup1|15 patients with 1 previous C-Section
2861294|NCT03519763||Study subgroup2|15 patients with 2 or more previous C-Section.
2861295|NCT03519750|Active Comparator|Intravenous melatonin|Intravenous administration, making it possible to calculate bioavailability for other routes of administration
2861296|NCT03519750|Experimental|Rectal melatonin|Rectal administration of melatonin
2861297|NCT03519750|Experimental|Intravesical melatonin|Intravesical administration of melatonin
2861298|NCT03519750|Experimental|Vaginal melatonin|Vaginal administration of melatonin
2861299|NCT03519750|Experimental|Transdermal melatonin|Transdermal administration of melatonin
2861300|NCT03519737|Sham Comparator|Control group (tPA + sham TUS)|Control group (tPA + sham TUS) During the primary phase of the study, subjects will be randomized 1:1
2861301|NCT03519737|Active Comparator|Treatment group (tPA + TUS)|Treatment group (tPA + TUS): Lead-in phase and Primary phase
2861302|NCT03519724|Experimental|SUG|
2861303|NCT03519724|Active Comparator|NEO|
2861304|NCT03519711|Experimental|Cohort 1|Patients will receive CNSA-001 2.5 mg/kg/day for 7 days in Period 1, undergo a 3- to 4-day washout period, then escalate to 10 mg/kg/day for 7 days in Period 2 (14 days total treatment).
2861305|NCT03519711|Experimental|Cohort 2|Patients will receive CNSA-001 5 mg/kg/day for 7 days in Period 1, undergo a 3- to 4-day washout period, then escalate to 20 mg/kg/day for 7 days in Period 2 (14 days total treatment).
2861306|NCT03519698|Placebo Comparator|Warm water|12 l footbath with warm water (40 °C)
2861307|NCT03519698|Experimental|Warm water & Mustard|12 l footbath with warm water (40 °C) and 80 g mustard flour
2861308|NCT03519698|Experimental|Warm water & Ginger|12 l footbath with warm water (40 °C) and 80 g ginger flour
2861309|NCT03519685|Experimental|Contraceptive Training and Education|Colleges assigned to this arm receive a one-day UCSF Continuing Medical Education (CME # MMC18087) accredited training on contraceptives and technical assistance. The training is for staff at the student health center and local health centers where they refer for contraceptive services. Students attending colleges assigned to this arm receive education about contraceptive methods and how to access services.
2861310|NCT03519685|Placebo Comparator|Nutrition Education|Students attending colleges assigned to this arm receive nutrition education about the impacts of sugar on health.
2861311|NCT03519672||Participants with cTTP - adolescents|Adolescents aged 12 to 17 years
2861312|NCT03519672||Participants with cTTP - adults|Adults aged ≥18 years
2861313|NCT03519659|Experimental|Sub-Study A|Patients receive PET/CT scan on Gemini Astonish PET/CT
2861314|NCT03519659|Experimental|Sub-Study B|Patients receive PET/CT scan on Biograph mCT
2861315|NCT03519659|Experimental|Sub-Study C|Patients receive PET/CT scan on Discovery PET/CT
2861316|NCT03519659|Experimental|Sub-Study D|Patients receive PET/CT scan on Vereos 128 digital PET/CT
2861317|NCT03519659|Experimental|Sub-Study E|Patients receive lower radiation dose on Vereos 128 digital PET/CT
2861318|NCT03519659|Experimental|Sub-Study F|Patients receive PET/SCAN using system that did not show equivalence in Sub-Study A-C
2861319|NCT03519646|Experimental|Experimental Case_Eiglustat|Besides regular ERT, patients also need to take Eiglustat for 24 months.
2861320|NCT03519633|Experimental|SUG|
2861321|NCT03519633|Active Comparator|NEO|
2861322|NCT03519620|Experimental|SWWSV|Spirometric Values: Forced Vital Capacity; Forced Expiratory Volume in 1 second; Peak Expiratory Flow
2861323|NCT03519607|Active Comparator|Treatment Group|Participants who are in the intervention group will receive the FertiStrong app downloading instructions as soon as they have been randomized. They will have access to this app for a period of 30 days during the intervention phase of the study.
2861324|NCT03519607|No Intervention|Control Group|Participants in the control group will not have access to the FertiStrong app for the first 30 days. After a period of 30 days, participants will be provided downloading instructions to this app.
2861325|NCT03519594||Embolization group|The group that underwent embolization after pelvic injury.
2861326|NCT03519594||Non-embolization group|The observed group of pelvic injuries without embolization
2861327|NCT03519581|Active Comparator|Micropulse Laser Treatment|"Subjects assigned to the micropulse laser arm of the trial will undergo the following procedures:~Confirmation of the subject's identity and eye to be treated~Subject's eye will be dilated~Subject will be positioned at the slit lamp for treatment~Application of subthreshold micropulse laser using the Iridex IQ577 laser unit. (intermittent pulsed energy) in a 7 X 7 grid pattern surrounding the fovea."
2861328|NCT03519581|Placebo Comparator|Sham Treatment|"Subjects assigned to the sham arm of the trial will undergo the following procedures:~Confirmation of the subject's identity and eye to be treated~Subject's eye will be dilated~Subject will be positioned at the slit lamp for treatment~No Actual laser treatment will occur"
2861329|NCT03519568|Experimental|Combination inoculation group|GroupⅠ: HepB:3 and EV71 were injected at 6 months old, EV71 second dose was injected at 7 months old GroupⅡ: MPSV-A:1 and EV71 were injected at 6 months old, EV71 second dose was injected at 7 months old, MPSV-A:1 second dose was injected at 9 months old GroupⅢ: MR and EV71 were injected at 8 months old, EV71 second dose was injected at 9 months old GroupⅣ: JE-Land EV71 were injected at 8 months old, EV71 second dose was injected at 9 months old
2861428|NCT03518944||occult premature ovarian insufficiency|Serum FSH levels ≥10mIU/ml/ serum AMH levels ≤1.0pg/ml/ AFC ≤5, on at least two occasion ＞4 weeks apart
2861330|NCT03519568|Active Comparator|Separate inoculation control group|GroupⅠ: HepB:3 third dose was injected at 6 months old GroupⅡ: MPSV-A:1 was injected at 6 months old, then MPSV-A:1 second dose was injected at 9 months old GroupⅢ: MR was injected at 8 months old GroupⅣ: JE-L was injected at 8 months old
2861331|NCT03519568|Active Comparator|EV71 inoculation control group|GroupⅠ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅡ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅢ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅣ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old
2861332|NCT03519542||Metastatic clear cell renal carcinoma (mRCC) patients|Metastatic clear cell renal carcinoma (mRCC) patients cadidates to receive Sunitinib 50 mg/day 4/2 schedule or Pazopanib 800mg/day until unaccetable toxicity or progression or death under standar clinical practice.
2861333|NCT03519516|Experimental|PRO-174|"Active ingredient: Levofloxacin 0.5%~o Dosage: 1 drop in both eyes, 8 times a day during the waking period"
2861334|NCT03519516|Active Comparator|Sophixín Ofteno®|o Dosage: 1 drop in both eyes, 8 times a day during the waking period
2861335|NCT03519490|Placebo Comparator|Single Vision Hybrid Contact Lens|Subjects will wear the Duette single vision hybrid contact lens.
2861336|NCT03519490|Experimental|Multifocal Hybrid Contact Lens|Subjects will wear the Duette hybrid multifocal contact lens with the near center design in one eye and the distance center design in the other eye with a crossover at every six months.
2861337|NCT03519477|Experimental|Heart failure care with Sano test|Scheduled outpatient care for patients at high risk of admission for heart failure, supplemented with the Sano Patient Medication Profile
2861338|NCT03519477|No Intervention|Heart failure care as-usual|Scheduled outpatient care for patients at high risk of admission for heart failure, care as-usual (i.e. without the Sano Patient Medication Profile).
2861339|NCT03519464|Experimental|1|A 0.5-mL intramuscular injection in the deltoid region of the upper arm or in the anterolateral area of the thigh, 3-dose regimen of injections given at month 0, month 2, and month 6.
2861340|NCT03519451|Experimental|KickAsh Group|
2861341|NCT03519451|Experimental|Breathe2Relax Group|
2861342|NCT03519438||Lateral 3/4 of treatment field|placement of Mepitel on the lateral ¾ of the treatment field
2861343|NCT03519438||Medial 3/4 of treatment field|placement of Mepitel on the medial ¾ of the treatment field
2861344|NCT03519425|No Intervention|Group 1 (Standard of care)|"Participants will be directed to the clinic waiting area to be seen by facility health workers who will direct all further care without any further input from the study team. Available to facility health workers will be:~Routine HIV testing and counselling, provided by Facility HIV Testers using a rapid fingerprick kit-based algorithm.~Routine TB screening, with both sputum smear microscopy and Xpert MTB/Rif testing available onsite.~Routine linkage to the onsite HIV clinic, where patients are registered and assessed for initiation onto antiretroviral therapy by facility HIV Care Clinic health workers. Malawi guidelines recommend universal treatment for HIV. HIV Care Clinic health workers will additionally have access to TB screening tests as described above.~Routine linkage to the onsite TB clinic, where patients are registered and initiated onto anti-TB treatment. Malawi guidelines recommend universal HIV testing for all patients with confirmed TB."
2861345|NCT03519425|Active Comparator|Group 2 (Optimised HIV screening and linkage to care)|"Participants will be directed to the study room located in a separate building. After identity validation participants will be offered a supervised HIV self-testing intervention. Participants will be given brief pre-test instructions and will be asked to self-test in a private area using the OraQuick 1/2 (OraSure Technologies) oral fluid HIV kit. Participants will be supported to read their HIV test result by study Research Assistants, and provided with confirmatory HIV testing by the trained Research Assistants.~HIV-positive participants will be supported by Research Assistants to register at the onsite HIV care clinic, and all further care (including TB screening) will be directed by facility health workers without any further study input.~HIV-negative participants will be referred to the clinic waiting area (with a copy of their HIV test results) to be seen by the facility health workers who will direct all further investigations without further study input."
2861346|NCT03519425|Active Comparator|Group 3 (Optimised HIV and TB screening and linkage to care)|"Participants will be directed to the Study Room. After identity validation, they will be offered the HIV self-testing and linkage intervention as described above for Group 2. Additionally, they will be offered a TB screening intervention comprising of:~A digital chest x-ray using the study MinXray unit.~Chest x-rays will be immediately classified by the CAD4TB software running on the MinXray unit laptop as either high probability of TB, or low probability of TB.~Participants whose chest x-rays have a low probability of TB will be referred to facility health workers (at either the onsite HIV care clinic if HIV-positive, or the clinic waiting area), with copies of their results for further routine care, and without further study input.~Participants whose chest x-ray x-ray show a high probability of TB will submit a single spot sputum sample for Xpert testing (done in the clinic). Those with confirmed TB will be linked to register at the onsite TB clinic."
2861347|NCT03519412|Experimental|MMR-proficient (MMRp)|MGMT-IHC-negative, MGMT promoter methylation-positive patient population is selected for treatment with temozolomide (induction) orally until disease progression or unacceptable toxicity whichever comes first, followed by pembrolizumab IV if Tumor Mutational Burden post Temozolomide is > 20 Muts/Mb
2861348|NCT03519412|Other|MMR-deficient (MMRd)|Patients receive Pembrolizumab (treatment) IV until disease progression or unacceptable toxicity or 35 cycles, whichever comes first
2861349|NCT03519399||Cases and Controls|"Cases - Pregnant women with ICP defined as pruritus in pregnancy in association with raised serum bile acids (using hospital threshold for diagnosis), and in the absence of an alternative cause.~Controls - Pregnant women not affected by ICP, or other liver, cardiac or hypertensive disorders."
2861350|NCT03519386|Experimental|Implant Group 1|G2TR intraocular implant containing travoprost 78 mcg with high elution rate, plus postoperative placebo eye drops.
2861351|NCT03519386|Experimental|Implant Group 2|G2TR intraocular implant containing travoprost 78 mcg with low elution rate, plus postoperative placebo eye drops.
2861352|NCT03519386|Active Comparator|Control Group|Sham surgery + active-comparator eye drops
2861353|NCT03519373||PER001|HIV 1-infected pregnant women
2861354|NCT03519373||PER002|HIV 1-uninfected pregnant women
2861355|NCT03519373||PER003|HIV 1-uninfected non-pregnant women
2861358|NCT03519347|Experimental|Potassium Removal Maximization Strategy|Dialysate potassium will be adjusted according to the results of point of care testing in order to maximize potassium removal and avoid hyperkalemia.
2861359|NCT03519347|Experimental|Potassium Gradient Minimization Strategy|Dialysate potassium will be adjusted according to the results of point of care testing in order to minimize the flux of potassium.
2861360|NCT03519347|Experimental|Alkalosis Avoidance Strategy|Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding alkalosis.
2861361|NCT03519347|Experimental|Acidosis Avoidance Strategy|Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding acidosis.
2861362|NCT03519334||Chronic health condition group/study|People with any of the following chronic health conditions: Diabetes, Chronic obstructive Pulmonary Disease, Major Depression, Dysthymia, Migraine, Back & Neck Pain, Cancer, Ischemic Heart Disease
2861363|NCT03519334||Expert consultation group/study|Relevant contacts from advocacy organizations operating at European level for the professional integration of people with chronic health conditions.
2861364|NCT03519321|Experimental|Treatment|MID-C EOS implant will be implanted for the correction of the spine deformity in children found eligible for the study
2861365|NCT03519308|Experimental|Arm A|
2861366|NCT03519308|Experimental|Arm B|
2861367|NCT03519295|Experimental|ARM A - mDCF + Atezolizumab|"MPDL3280A (atezolizumab) will be administered every 2 weeks at 800 mg for 12 months.~Patients will receive 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5FU at 1200 mg/m2/day for 2 days) every 2 weeks"
2861368|NCT03519295|Active Comparator|ARM B - mDCF|Patients will receive 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5FU at 1200 mg/m2/day for 2 days) every 2 weeks.
2861369|NCT03519269|No Intervention|Non robotics-assisted Surgical System|Conventional, non-robotics-assisted total knee surgical system
2861370|NCT03519269|Experimental|Navio™ Robotics-assisted Surgical System|Navio™ Robotics-assisted Surgical System
2861371|NCT03519256|Experimental|Nivolumab monotherapy|
2861372|NCT03519256|Experimental|Nivolumab + BCG|
2861373|NCT03519256|Experimental|Nivolumab + BMS-986205|
2861374|NCT03519256|Experimental|Nivolumab + BMS-986205 + BCG|
2861375|NCT03519243|Experimental|BCD-131 1,05 mcg/kg * conversion ratio|subcutaneously monthly
2861376|NCT03519243|Experimental|BCD-131 1,7 mcg/kg * conversion ratio|subcutaneously monthly
2861377|NCT03519243|Experimental|BCD-131 2,75 mcg/kg * conversion ratio|Subcutaneously monthly
2861378|NCT03519243|Active Comparator|Mircera|subcutaneously monthly
2861379|NCT03519230|Experimental|Treatment arm|
2861380|NCT03519230|Placebo Comparator|Placebo arm|
2861381|NCT03519217||Diabetic patients under the age of one year|All cases which are diagnosed with diabetes mellitus under the age of one year will be subjected for blood glucose level, glycated haemoglobin, fasting C-peptide, anti-insulin and anti-islets auto-antibodies, and who have negative tests for anti-insulin and anti-islets auto-antibodies, will be subjected to do genetic study for KCJN11 and ABCC8
2861382|NCT03519204|Experimental|JUVÉDERM VOLBELLA with Lidocaine|Juvederm Volbella XC with lidocaine injected into lips at Day 1
2861383|NCT03519204|Experimental|No-treatment control|No-treatment control
2861384|NCT03519191|Other|Healthy Relationships Education (HRE)|Social-behavioral intervention Participants will receive employment support services and Healthy Relationships Education interventions.
2861385|NCT03519191|Other|HRE+Technology Bootcamp|Social-behavioral intervention + technology bootcamp (associated economic pathways for participants) Participants will receive employment support services, Healthy Relationships Education, and Technology Bootcamp interventions.
2861386|NCT03519178|Experimental|Dose Escalation|Single Agent Dose Escalation
2861387|NCT03519178|Experimental|Dose Finding Endocrine Therapy 1 Combination|Part 1B PF-06873600 plus Endocrine Therapy 1
2861388|NCT03519178|Experimental|Dose Finding Endocrine Therapy 2 Combination|Part 1B PF-06873600 plus Endocrine Therapy 2
2861389|NCT03519178|Experimental|Dose Expansion Arm A|PF-06873600 as a Single Agent
2861390|NCT03519178|Experimental|Dose Expansion Arm B|PF-06873600 as a Single Agent in Various Tumor Types
2861391|NCT03519178|Experimental|Dose Expansion Arm C|PF-06873600 in Combination with Endocrine Therapy 1
2861392|NCT03519178|Experimental|Dose Expansion Arm D|PF-06873600 in Combination with Endocrine Therapy 1
2861393|NCT03519178|Experimental|Dose Expansion Arm E|PF-06873600 in Combination with Endocrine Therapy 2
2861394|NCT03519165|No Intervention|Control group (Group C)|"Conventional Fluid therapy guided by clinical parameter~Intraoperative fluid therapy will include maintenance fluid and replacement of the surgical loss. Aim to maintain MAP > 65 mmHg, CVP 8-12 cm H2O and urine output > 0.5 ml/kg/h."
2861395|NCT03519165|Active Comparator|Goal directed group (Group G)|"Intervention: Machine guided fluid therapy using EV1000 (FloTrac System 4.0 Edward Lifesciences, Irvine, CA, USA)~Intraoperative fluid therapy will be targeted to SVV <13%, SVI > 35ml/m2/ beat, SVRI more than equal to 1900 dynes-sec/cm-5/m2 using EV1000 floTrac monitor in addition to clinical parameters like MAP, CVP and urine output"
2861396|NCT03519152|Experimental|study group one side|All patients were scheduled for open flap debridement surgery on at least two quadrants ≥1 weeks apart.One group will receive Low Dose Diclofenac tablets (25mg Diclofeanc and 325 mg paracetamol), BID for 3 days. The patients who are diagnosed with generalized moderate/severe chronic periodontitis will be included in study. For each quadrant, a flap was raised under local anesthesia (2% lignocaine with 1:80,000 epinephrine). In both the quadrants same technique of anesthesia will be employed. The location and the extent of surgery, volume of the local anesthesia given, and time required to perform the surgical procedure will be recorded in the patient file. Patients will be instructed to complete a pain diary chart for 3 days.
2861429|NCT03518931|No Intervention|Control|This arm included individuals randomized to receiving fitness information only.
2861430|NCT03518931|Experimental|Intervention|This arm included individuals randomized to having fitness assessments performed.
2861431|NCT03518905|Sham Comparator|sham-treatment|Patients with symptomatic large heterotopic gastric mucosa receive an esophagoscopy without radiofrequency ablation under sedation
2861713|NCT03516916||Egypt|Patients with a permanent colostomy after curative surgery for rectal cancer
2861397|NCT03519152|Placebo Comparator|study group second side|Other group will receive Diclofeanc (50mg Diclofenac and 325mg paracetamol), BID for 3 days. The patients who are diagnosed with generalized moderate/severe chronic periodontitis were included in study. For each quadrant, aperiodontal flap was raised under local anesthesia (2% lignocaine with 1:80,000 epinephrine). In both the quadrants same technique of anesthesia will be employed. The location and the extent of surgery, volume of the local anesthesia given, and time required to perform the surgical procedure was recorded in the patient file. Patients were instructed to complete a pain diary chart for 3 days.
2861398|NCT03519139|Experimental|individual dietary counselling|three individual dietary counsellings. The first at the hospital by discharge, then in week 1 and week 3 at the subject's home/the respite care after discharge and, if necessary, telephone follow-up in weeks 2 and 4 after discharge
2861399|NCT03519139|No Intervention|Control|standard counselling provided by the hospital at discharge. The standard counselling may include nutritional prescription and nutritional plan, but no follow-up to the nutrition plan after the discharge.
2861400|NCT03519126|Experimental|vaginal|Group of volunteers who will be treated with vaginal electrostimulation
2861401|NCT03519126|Experimental|posterior tibial nerve|Group treated with transcutaneous electrostimulation of the posterior tibial nerve
2861402|NCT03519126|No Intervention|control|Group of volunteers who will not be treated
2861403|NCT03519113|Experimental|Test group 1|GC1102 80,000 IU
2861404|NCT03519113|Experimental|Test group 2|GC1102 100,000 IU
2861405|NCT03519113|Active Comparator|Control group|I.V HBIG
2861406|NCT03519087|Experimental|Interdisciplinary Evaluation|Participants will receive an Interdisciplinary Evaluation for Nonarthritic Hip Disease from a hip arthroscopist, followed by an examination from a physical therapist, and then will participate in a shared decision-making process with both providers to determine a plan of care.
2861407|NCT03519087|No Intervention|Standard Evaluation|Participants will receive a standard-of-care evaluation from a hip arthroscopist who will then determine the plan of care with the participant.
2861408|NCT03519087|Experimental|Posture and Movement Training|Participants will receive six training sessions with a physical therapist over a 3-week period.
2861409|NCT03519087|No Intervention|3-week Wait Period|Participants will undergo a 3-week wait period. They will be instructed to not receive any treatment (e.g. chiropractic services, physical therapy, medication, surgery, injections) for their hip symptoms during this time.
2861410|NCT03519087|Other|Observational Arm|Participants who refuse randomization to receive posture and movement training may continue participation in an observational group. These participants complete the same baseline and follow-up testing but proceed with their treatment-of-choice during the 3-week intervention period.
2861411|NCT03519074|Experimental|TS-1 combined with cisplatin|Eligible patients will be stratified by degree of liver dysfunction into 4 cohorts, in accordance to the National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria
2861412|NCT03519061|Experimental|Treatment|This is the group of enrollees who receive budesonide
2861413|NCT03519048|Active Comparator|Conventional follow-up|clinical examination with nasofibroscopy every 1-3 months first year post-treatment, every 2-4 months second year, every 4-6 months third year (mean of around 13 visits) and every 6 months thereafter. Low Dose Chest CTscan every year in patients with tobacco consumption history of > 20 pack-year. Panendoscopy plus CT-scan are performed in case of clinical symptoms or abnormal clinical exam.
2861414|NCT03519048|Experimental|Intensive follow-up strategy|adding to the conventional follow-up strategy , an annual head&neck and thoracic injected CT-scan and Lugol upper gastrointestinal endoscopy (the first performed 12 months after inclusion), annual whole body PET-CT (the first at 6 months after inclusion). These 3 exams are performed every year during 3 years after inclusion (i.e. 3 CT-scan, 3 digestive endoscopies and 3 PET-CT per patient). Clinical follow up will be conducted as in the conventional follow up group and panendoscopy or bronchoscopy will be performed if needed. After 3 years, patients will be followed by conventional follow-up.
2861415|NCT03519035||Borderline personality disorder Patient|"Patients will be recruited in the different services. They have to respect inclusion criteria which are : patient with BPD (clinical diagnosis), patients 18 years of age or older, patients who can give their consent.~In this study, patients will have to pass different questionnaires (DIB-R, DES II, THQ, PCL-S, PSAS, qualitative questionnaire) in order to compare the characteristics between BDL patients with and without hallucinations."
2861416|NCT03519022|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
2861417|NCT03519022|Active Comparator|Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Cocaine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.
2861418|NCT03519009|Experimental|IPS Plus Abstinence-Contingent Wage Supplement|Abstinence-contingent wage supplements are provided for obtaining and maintaining competitive employment.
2861419|NCT03519009|No Intervention|Usual Care Control|Counseling and referrals to employment and treatment programs.
2861420|NCT03518996|Experimental|TMS/tACS|Subjects will receive 5 days of 3x daily rTMS (intermittent theta burst stimulation) or tACS (transcranial alternating current stimulation) targeted over the cerebellum.
2861421|NCT03518996|Sham Comparator|Sham TMS/tACS|Subjects will receive 5 days of 3x daily sham stimulation of the cerebellum.
2861422|NCT03518983|Sham Comparator|Sham Group|The subjects of this group will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks) by the sham probe.
2861423|NCT03518983|Active Comparator|Active Group|The subjects of this group will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks) at energy level 7.
2861424|NCT03518970|Experimental|Nursing intervention|The experimental group will receive the Nursing intervention to reduce uncertainty in illness and increase quality of life in family caregivers of patients with cancer in palliative care
2861425|NCT03518970|No Intervention|Conventional care|The control group will receive the nursing care conventionally given in the health care institution
2861426|NCT03518957|Experimental|Exercise intervention|Patients who are randomised to this arm will be enrolled to the exercise programme.
2861432|NCT03518905|Active Comparator|treatment arm|Patients with symptomatic large hetertotopic gastric mucosa receive an esophagoscopy with radiofrequency ablation (12J/cm2) using the Barrx channel RFA endoscopic catheter (Medtronic)
2861433|NCT03518892||Spinal Cord Injury Group|Body Composition, Resting Metabolic Rate, and dietary assessment
2861434|NCT03518892||Healthy Controls|Body Composition, Resting Metabolic Rate, and dietary assessment
2861435|NCT03518879|Experimental|ASTHMA-Educator arm|The ASTHMA-Educator mobile application for patient-centered asthma education. The application is administered via on-site iPad (tablet).
2861436|NCT03518853|Experimental|Short-course Radiation Therapy|Short-course Hypofractionated Once-weekly Radiation Therapy: 35Gy in 5 fractions delivered once a week.
2861437|NCT03518840|Other|Sacroiliac Joint Belt|All patients will receive and be fitted by the PI with an SIJ belt.
2861438|NCT03518827||Athletes|For Asymmetry measurement, the group will consist of 200 athletes of different sports (the proportion not strictly predefined) - track and field, racket sports, ball sports, other team sports, swimming, running, cycling, dancing, ice skating, etc.
2861439|NCT03518814||Multimetastatic melanoma in remission|Questionnaires
2861440|NCT03518801|Experimental|Prolonged Exposure + Cannabidiol|Psychotherapy plus active medication
2861441|NCT03518801|Active Comparator|Prolonged Exposure + Placebo|Psychotherapy plus placebo medication
2861442|NCT03518788|Experimental|Pleur-X|Placement of a permanent drainage under local anesthesia
2861443|NCT03518788|Experimental|pleurodesis|Pleurodesis with talc in VATS
2861444|NCT03518775||Normal Eyes|Eyes with best-corrected visual acuity of 20/20 or better, and lens opacities of 1.0 or less in the study eye using the LOCS III system, and no prior Laser Vision Correction.
2861445|NCT03518775||Cataract Eyes|Cataract in the study eye greater than Grade 1 using the LOCS III system for one or more: nuclear opacity, nuclear color, cortical opacity, or PSC.
2861446|NCT03518775||Post LVC Eyes|History of Laser Vision Correction (LVC)
2861447|NCT03518762|Experimental|Sustained lung inflation|"Participants in this arm (n=80) received:~Sustained lung inflation (SLI) manoeuvre(s) was applied once or twice, based on the protocol algorithm.~Within the first 60 seconds of life, assessment for the need of advanced resuscitation (defined as the need for more than oxygen and tactile stimulation during resuscitation) was done;~Infants who needed advanced resuscitation were considered to receive SLI as a rescue approach.~Infants who needed only oxygen and tactile stimulation were considered to receive SLI as a prophylactic approach.~Then Continuous positive airway pressure (CPAP). Intermittent positive pressure ventilation (IPPV) was given through an ETT, if intubation was needed."
2861448|NCT03518762|Other|Control|"Participants in this arm (n=80) received:~Resuscitation according to the American academy of pediatrics guidelines.~Then Continuous positive airway pressure (CPAP). Intermittent positive pressure ventilation (IPPV) was given through an ETT, if intubation was needed."
2861449|NCT03518749|Active Comparator|1mA anodal tDCS + cognitive control training|1 mA anodal tDCS will be administered to the left dlPFC (F3) for 23 mins during the performance of a cognitive control training.
2861450|NCT03518749|Active Comparator|2mA tDCS + cognitive control training|2 mA anodal tDCS will be administered to the left dlPFC (F3) for 23 mins during the performance of a cognitive control training.
2861451|NCT03518749|Placebo Comparator|sham tDCS + cognitive control training|Sham tDCS (30 secs of tDCS) will be administered to the left dlPFC (F3) with 2mA at the beginning of a cognitive control training.
2861452|NCT03518736|No Intervention|Usual Care|Infants randomly assigned to this arm will not receive any study intervention but will continue with any intervention in the community recommended by their health care team.
2861453|NCT03518736|Experimental|SPEEDI_Early|"Infants randomly assigned to this arm will participate in the SPEEDI intervention starting in the hospital and lasting for 4 months. This intervention includes 10 visits with a physical therapist and parent working together to advance an intervention program and 12 weeks of parent daily intervention.~In addition they will continue with any intervention in the community recommended by their health care team."
2861454|NCT03518736|Experimental|SPEEDI_Late|"Infants randomly assigned to this arm will participate in the SPEEDI intervention starting at 4 months post baseline or approximately 3 months after discharge from the hospital. This intervention includes 10 visits with a physical therapist and parent working together to advance an intervention program and 12 weeks of parent daily intervention.~In addition they will continue with any intervention in the community recommended by their health care team."
2861455|NCT03518723|Experimental|Non-linear Periodized Resistance Training|"The objective of the Non-linear Periodized Resistance Training (NLPRT) program is to increase muscle strength as well as muscle endurance. The NLPRT program will over the 8 week intervention period target several different aspects of limb muscle function, by alternating the intensity and volume of the exercises.~Progression of exercise is symptom dependent and will be based on Borg CR-10 ratings (dyspnea, muscle fatigue and exertion).~All exercises will be performed using exercise equipment that are available at each included center.~All sessions are supervised and conducted by local professionals using a group format, with approximately 2-4 participants per group."
2861456|NCT03518723|Active Comparator|Resistance Training|"The primary objective of the Resistance training (RT) group is to increase muscular strength. The RT program will be performed in line with current guidelines that are recommended for increasing muscular strength in patients with COPD.~Progression of exercise is performance dependent and will be based on the previous 2 sessions.~All exercises will be performed using exercise equipment that are available at each included center.~All sessions are supervised and conducted by local professionals using a group format, with approximately 2-4 participants per group."
2861457|NCT03518710|Experimental|Children with NF1|"One experimental group of NF1 children with 3 reading levels (1st grade, 2nd grade and 3rd grade). For this research they will pass :~Neuropsychological evaluation~Evaluation of the reading assistance technique"
2861458|NCT03518697|Experimental|Exercise Group|"First 6 months supervised exercise program with telephone contact every two weeks~Second 6 months exercise program without telephone contact~Patients should increase habitual daily physical activity for 10-20 minutes per day 5 times per week~Activities were chosen according to the preferences, interests, and severity of disease of the patients~Activites should improve endurance, strength, coordination and flexibility~Every three month regular vistit at the CF care center (medical examination, lung function, exercise testing, counselling and evaluation of activities by acceleometry and if appropirate adaption of exercise program)"
2861459|NCT03518697|No Intervention|Control-Group|"12 months usual routine care and habitual exercise in daily life.~At start and after 12 month assessment of habitual exercise with accelerometry (Actigraph GTX3)"
2861460|NCT03518684|No Intervention|Group 1|Group 1 in which they will receive the standard care during labor and delivery without the use of the obstetrical gel
2861461|NCT03518684|Experimental|Group 2|Group 2 in which they will have the standard care during labor and delivery with the vaginal application of the obstetrical gel according to the study protocol. Those 2 groups will be further divided into 4 subgroups where the parity will be accounted for (nulliparous [never delivered beyond 20 weeks of gestation in a previous pregnancy] or primiparous or more)
2861462|NCT03518671|Experimental|CBT|Self-limited cognitive behavioral therapy delivered via 5 weekly sessions, either face-face or via telemedicine
2861463|NCT03518658||Evaluation Group|Patients implanted with a pacemaker or CRT-P device who will be using remote monitoring via the MyCareLink Heart App
2861464|NCT03518658||Control Group|Patients with low power implantable devices and CareLink Monitor 2490 (Excluding wireless model 2490C)
2861465|NCT03518645|Experimental|OPN strategy|The OPN NC Super High Pressure PTCA Balloon will be used as the study device for lesion preparation for BVS Absorb implantation - OPN strategy of lesion preparation. This balloon has a twin layer balloon construction, which allows a very high pressure resistance of 35 bar. The balloon has a 0.016`` lesion entry profile and is available in sizes between 1.5 and 4.5 mm and lengths of 10, 15 and 20 mm.
2861466|NCT03518645|Active Comparator|standard strategy|Predilatation with standard coronary balloon will be performed for lesion preparation for BVS Absorb implantation - standard strategy of lesion preparation.
2861467|NCT03518632|Active Comparator|Control group|
2861468|NCT03518632|Experimental|Interval training 1|
2861469|NCT03518632|Experimental|Interval training 2|
2861470|NCT03518619|Experimental|PFIcope+EMI|This will include: 1) an in-person personalized feedback session to present normative information and feedback on problems associated with drinking to cope, to discuss the individual's use of alcohol to cope, and to generate relapse prevention coping skills messages to be used in the EMI text intervention; 2) EMA to monitor affect and intention to drink after discharge; 3) tailored text messages (EMI) based on EMA responses (i.e., individualized coping skills messages when individuals report negative affect and intention to drink); and 4) additional EMA to monitor coping skills usage, alcohol use, and drinking to cope.
2861471|NCT03518606|Experimental|Breast cancer cohort|Patients presenting advanced refractory breast cancer
2861472|NCT03518606|Experimental|Head and neck cohort|Patients presenting advanced refractory head and neck cancer
2861473|NCT03518606|Experimental|Cervix cohort|Patients presenting advanced refractory cervix cancer
2861474|NCT03518606|Experimental|Prostate cohorte|Patients presenting advanced refractory prostate cancer
2861475|NCT03518606|Experimental|Miscellaneous cohorte|Patients presenting advanced refractory solid tumour with high mutational load
2861476|NCT03518593|Experimental|Intervention|Additional cash transfer and nutritional counselling
2861477|NCT03518593|No Intervention|Control|Existing cash transfer only
2861478|NCT03518567|Experimental|High THC dose (6% THC)|Smoked marijuana cigarettes (High THC dose [6% THC])
2861479|NCT03518554|Experimental|JAB-3068|Daily oral administration of JAB-3068
2861480|NCT03518541|Active Comparator|Goniometer|FDO: classic procedure with goniometer controlled derotation
2861481|NCT03518541|Experimental|EMT|FDO: procedure with electromagnetic tracking (EMT) controlling derotation
2861482|NCT03518528||transdermal|transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
2861483|NCT03518528||vaginal|Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks
2861484|NCT03518515|Experimental|White potato (French fries)|Participants will be asked to consume 1 serving of French fries each day for 30 days.
2861485|NCT03518515|Experimental|White potato (French fries), +seasoning|Participants will be asked to consume 1 serving of French fries with added seasoning each day for 30 days.
2861486|NCT03518515|Active Comparator|Almond|Participants will be asked to consume 1 serving of almonds (calorie-matched to other arms) day for 30 days.
2861487|NCT03518502|Active Comparator|Sorafenib monotherapy arm|The sorafenib monotherapy group receives sorafenib immediately after randomization.
2861488|NCT03518502|Experimental|TACE-sorafenib sequential therapy arm|TACE(transarterial chemoembolization )-sorafenib group receives 2~4 times of TACE before starting sorafenib.
2861489|NCT03518489|Experimental|Experimental|Lappaconitine Adhesive Patch Lappaconitine Adhesive Patch is administered every radiation day, until the end of radiotherapy.
2861490|NCT03518489|Active Comparator|Control|Patients will be given standard care when oral pain is reported
2861491|NCT03518476|Experimental|Intervention arm|Participants in the intervention group will participate in an intensive education program delivered by a multi-disciplinary group of educators, researchers, and clinicians with expertise in tobacco control and tobacco dependence treatment. The program will be delivered over 4 days (run over 2 weekends) with an average of eight contact hours per day (a total of 32 contact hours) at Qatar University.
2861492|NCT03518476|Active Comparator|Control arm|Non-tobacco related training or education sessions will delivered to pharmacists in the control group.
2861493|NCT03518463|Experimental|Intervention|"ERAS arm received;~Preoperative:1. Intravenous (IV) cefazoline 1g 2. IV metoclopromide 10mg, dexamethasone 8mg, ranitidine 150mg~Intraoperative: 1. Hyperbaric bupivacaine 10-15mg plus intrathecal morphine 100mcg 2. Adrenaline 100mcg in 500ml of ringers lactate 3. Individualized goal directed fluid therapy 4. Reinforced counseling and education 5. wound infiltration with isobaric bupivacaine 2mg/kg 6. Rectal diclofenac 100mg and misoprostol 400mcg stat~Postoperative:~Feeding within 1 hour~urethral catheter removal at 6-8 hours~Mobilization at 8-10 hours~A single fixed dose combination of ibuprofen 400 mg and paracetamol 500 mg 8 hourly~Tablets Amoxicillin-clavulunate 850mg 12 hourly"
2861562|NCT03517943|Active Comparator|Reference treatment|Healthy adult subjects under fed conditions
2861563|NCT03517930|Experimental|Test treatment|Healthy adult subjects under fasted conditions
2861564|NCT03517930|Active Comparator|Reference treatment|Healthy adult subjects under fasted conditions
2861494|NCT03518463|Active Comparator|Control|"Standard care arm received;~IV ceftriaxone 2g or ampiclox 2g~Anesthetists administered IV fluids, vasopressors, and managed hypothermia based on their clinical impressions.~Oral feeding and breastfeeding were allowed any time after transfer to postnatal ward.~Urethral catheters were removed between 12-24 hours after surgery.~Ward nurses and obstetricians made decisions regarding treatment without study staff input or oversight."
2861495|NCT03518450|Active Comparator|Femoral Nerve Block|Ultrasound guided femoral nerve block, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
2861496|NCT03518450|Active Comparator|Adductor Canal Block|Ultrasound guided adductor canal block, at the proximal third of the canal, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
2861497|NCT03518450|Experimental|Apex Femoral Triangle Block|Ultrasound guided femoral triangle block, at the distal third of the triangle, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
2861498|NCT03518411|Experimental|Medical Students|Cognitive Behavioral Therapy Protocol
2861499|NCT03518398|Experimental|IPL group|IPL 9-13 J/cm2 according to Fitzpatrick's skin type on day 0, 15, 45
2861500|NCT03518398|Sham Comparator|sham-IPL group|IPL 0 J/cm2 according to Fitzpatrick's skin type on day 0, 15, 45
2861501|NCT03518385||Patients with intracavitary fluid|to evaluate the correlation between the presence of intracavitary fluid during hormonal stimulation for IVF depending on the position of C-section-scar and the presence of an isthmocele, this group patients will have intracavitary fluid.
2861502|NCT03518385||Patients without intracavitary fluid|to evaluate the correlation between the presence of intracavitary fluid during hormonal stimulation for IVF depending on the position of C-section-scar and the presence of an isthmocele, in this group patients will not have intracavitary fluid.
2861503|NCT03518359|Experimental|Mental Training for Residents|The intervention will be the modified form of Mindfulness-Based Stress Reduction (MBSR). For this study investigator named the experimental arm Enhanced Stress Resilience Training (ESRT).
2861504|NCT03518359|Active Comparator|Active Control|"Active control that emphasizes externalized attention via the shared reading and listening model."
2861505|NCT03518346|Experimental|Virtual Reality Group|Participants may be randomized to the virtual reality, VR, group or the standard of care group. For the VR group, we are using the Samsung VR Go (VR head set), Samsung S7 (phone) and programmed distraction (Spaceburgers, Pebbles the Penguin, and/or Happy Place). Spaceburgers and Pebbles the Penguin were designed by the Department of Anesthesiology at Lucile Packard Children's Hospital Stanford through the Stanford Chariot Program (Childhood Anxiety Reduction Through Innovation and Technology). Happy Place is a nongame immersive experience that will be offered to children uninterested in the previously mentioned game. Happy Place was designed by a Swedish Pharmacy Chain, Apotek Hjartat, aimed to distract patients from their pain with a peaceful, interactive environment. Each of the video games runs for the length of time needed to complete the venipuncture.
2861506|NCT03518346|Active Comparator|Standard of Care Group|Participants may be randomized to the virtual reality, VR, group or the standard of care group. The standard of care group will use various distractions. Distraction tools include books and movies using a wall mounted TV as standard practice.
2861507|NCT03518333|Experimental|ARM 1|Injection of adipose derived cells into penis followed six months later with sham control saline injection procedure
2861508|NCT03518333|Experimental|ARM 2|Sham control saline injection procedure followed six months later by injection of adipose derived cells into penis
2861509|NCT03518320|Experimental|TAR-200 and Nivolumab Combination|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 is placed into the bladder through an Inserter and gradually releases gemcitabine during the 21-day indwelling period before being removed. In combination, subjects are dosed intravenously with a Nivolumab Injection [Opdivo] within 3 days of TAR-200 placement. Subjects will receive four consecutive 21-day dosing cycles of the combination of TAR-200 and Nivolumab prior to radical cystectomy.
2861510|NCT03518294|No Intervention|Standard of Care|Subjects in the control condition will be instructed to continue their medical care at the discretion of their treating medical professional. They will be informed to maintain their current physical activity level. Weekly phone calls will be performed by study personnel to ensure adherence to the protocol (no changes in activity). Subjects will report to Penn State on a monthly basis for anthropometric assessment to confirm their self-reports and study investigators will perform and interim history and physical examination at that time.
2861511|NCT03518294|Experimental|Aerobic Exercise|Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
2861512|NCT03518281|Placebo Comparator|Placebo|
2861513|NCT03518281|Experimental|Treatment|Whole Cell Euglena delivering βeta Glucan
2861514|NCT03518268|Active Comparator|Dietary supplement Vivomixx|Vivomixx sachets contains a mixture of 450 billion viable lyophilized bacteria from 8 strains: Lactobacillus paracasei DSM 24733, Lactobacillus plantarum DSM 24730, Lactobacillus acidophilus DSM 24735, Lactobacillus delbrueckii subspecies bulgaricus DSM 24734, Bifidobacterium longum DSM 3 24736, Bifidobacterium infantis DSM 24737, Bifidobacterium breve DSM 24732, and Streptococcus thermophilus DSM 24731
2861515|NCT03518268|Placebo Comparator|Placebo|The placebo sachets contain the inactive ingredients maltose and silicon dioxides
2861516|NCT03518255|No Intervention|Control group|This control group will not receive an intervention.
2861517|NCT03518255|Experimental|Nature video|A pre-validated nature images video will be shown to the patient during their chemotherapy session. After thirty minutes of the start of the chemotherapy session, the patient you will receive a notebook (specific to the study and blocked for other functions) that he can watch a presentation of nature images. It will be four videos with fifteen minutes each one.
2861518|NCT03518242|Experimental|Oral Treatment|oral CMF [Cyclophosphamide 60 mg/m2 daily on days 1-21, Methotrexate 15 mg/m2 on days 1, 8 and 15, and Capecitabine 1500 mg twice daily on days 1-14] on a 21 day schedule
2861519|NCT03518229|Experimental|Intervention|Microsoft Band 2 application with UV messaging activated
2861520|NCT03518229|Active Comparator|Control|Microsoft Band 2 application (UV messaging not active)
2861565|NCT03517917||Arm 1|Tumour tissue collection and blood collection to enable a manufacturing process for immunotherapies to be developed.
2861521|NCT03518216|Experimental|ADAPT|Participants randomized to ADAPT will complete Aim to Decrease Anxiety and Pain Treatment (ADAPT),a tailored intervention that integrates mindfulness meditation with cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions are in person with a trained psychological provider and the following 4 sessions are web-based. Each web-based session is followed by therapist phone support.
2861522|NCT03518216|No Intervention|Waitlist Control|Participants randomized to waitlist control will receive medical treatment as usual. These participants will be given the opportunity to complete ADAPT upon completion of the post assessment.
2861523|NCT03518203|Experimental|Eculizumab|All patients will receive eculizumab based on their weight for 24 weeks.
2861524|NCT03518190|Experimental|Suspected pressure injury|Patients evaluated with high-risk for pressure injury
2861525|NCT03518177|Experimental|Hospital-based PR group|The patient will receive an 8-week supervised Pulmonary Rehabilitation Exercise Program at hospital
2861526|NCT03518177|Experimental|Home-based PR group|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program at home
2861527|NCT03518164|Other|Allograft Bone|Subjects in this arm will receive allograft bone for use in 2 level anterior cervical discectomy and fusion surgery (ACDF surgery).
2861528|NCT03518164|Other|Autograft Iliac Crest Bone|Subjects in this arm will have bone from their iliac crest harvested for use in 2 level anterior cervical discectomy and fusion surgery (ACDF surgery).
2861529|NCT03518151|Experimental|Intervention|The intervention includes 3 components: i) creation of a new fresh fruit and vegetable section at store entrance; ii) placing frozen fruit and vegetables in the first aisle and iii) removal of all cakes, confectionary and sugar sweetened beverages from checkouts (replaced with non-food items, fruit and bottled water).
2861530|NCT03518151|Sham Comparator|Control|The control condition is provision of a limited range of fresh fruit and vegetables, all placed at the back of the store, frozen vegetables in a middle aisle and confectionery sold at checkouts.
2861531|NCT03518138|Experimental|Group 1, study drug|65 patients treated with Q-122, 100 mg BID
2861532|NCT03518138|Placebo Comparator|Group 2, placebo|65 patients treated with placebo
2861533|NCT03518125|Experimental|Age ≥ 66, BioThrax (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL BioThrax.
2861534|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL AV7909.
2861535|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1 and 15)|Subjects dosed on Days 1 and 15 with 0.5 mL AV7909 and on Day 29 with 0.5 mL placebo.
2861536|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1 and 29)|Subjects dosed on Days 1 and 29 with 0.5 mL AV7909 and on Day 15 with 0.5 mL placebo.
2861537|NCT03518125|Active Comparator|Age18-50, BioThrax (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL BioThrax.
2861538|NCT03518125|Active Comparator|Age 18-50, AV7909 (Days 1 and 15)|Subjects dosed on Days 1 and 15 with 0.5 mL AV7909 and on Day 29 with 0.5 mL placebo.
2861539|NCT03518112|Experimental|Blinatumomab + Mini-Hyper-CVD|"Blinatumomab given in combination with mini-hyper-CVD. Each cycle of induction and consolidation is 42 days.~Mini-hyper-CVD chemotherapy regimen consists of a total of 8 cycles with mini-hyper-CVD alternating with high-dose methotrexate and cytarabine administered approximately every 21 days. A total of 4 cycles of blinatumomab are planned in induction/consolidation and 2 additional cycles during maintenance. Blinatumomab given by continuous infusion for 4 weeks, followed by a 2 week treatment-free period. Patients then receive 2 years of maintenance therapy with POMP (6-mercaptopurine [6-MP], vincristine, methotrexate and prednisone) and blinatumomab single agent given in cycles 6 and 12 of the first year and vincristine and prednisone alone for an additional year."
2861540|NCT03518099|Experimental|Patient|Any patient admitted for acute abdomen condition with or without ischemic causes.
2861541|NCT03518099|Experimental|witness|
2861542|NCT03518086|Experimental|Mirikizumab|Mirikizumab administered intravenously (IV).
2861543|NCT03518086|Placebo Comparator|Placebo|Placebo administered IV.
2861544|NCT03518073|Experimental|LY3303560 Dose 1|LY3303560 administered intravenously (IV).
2861545|NCT03518073|Experimental|LY3303560 Dose 2|LY3303560 administered IV.
2861546|NCT03518073|Placebo Comparator|Placebo|Placebo administered IV.
2861547|NCT03518060||Subjects receiving Juluca|Approximately 250 virologically suppressed HIV positive subjects on a stable antiretroviral regimen as indicated in local SmPC of Juluca will be included in the study. The subjects will be followed for approximately 3 years during routine clinical practice.
2861548|NCT03518047|Placebo Comparator|Placebo|Placebo for risankizumab by subcutaneous (SC) injection.
2861549|NCT03518047|Experimental|Risankizumab|Risankizumab by subcutaneous (SC) injection.
2861550|NCT03518034|Active Comparator|Arm A|Participants receiving topical testosterone
2861551|NCT03518034|Placebo Comparator|Arm B|Participants receiving placebo
2861552|NCT03518021|Experimental|Naloxone, intranasal|
2861553|NCT03518021|Active Comparator|Naloxone, intramuscular|
2861554|NCT03518021|Placebo Comparator|placebo, intranasal|
2861555|NCT03518021|Placebo Comparator|placebo, intramuscular|
2861556|NCT03517995|Active Comparator|Sulforaphane Plus Surgery|Sulforaphane Administration prior to bladder cancer surgery.
2861557|NCT03517995|Placebo Comparator|Placebo Plus Surgery|Placebo Administration prior to bladder cancer surgery.
2861558|NCT03517969|Experimental|Arm A (docetaxel, carboplatin)|Participants receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes, or carboplatin alone on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants who have PSA progression or radiographic progression may crossover to Arm B.
2861559|NCT03517969|Experimental|Arm B (carboplatin, ATR kinase inhibitor VX-970)|Participants receive carboplatin IV over 30 minutes on day 1 and ATR kinase inhibitor VX-970 IV over 60 minutes on days 2 and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2861560|NCT03517956|Experimental|Patients with FGFR1-4 - positive solid tumors|"Dose escalation:~The starting dose of the combination will be escalated in a stepwise fashion, escalating one drug at a time.~Dose expansion (urothelial cancer):~Patients in the dose expansion will be treated with the combination identified in the dose escalation part of the study."
2861561|NCT03517943|Experimental|Test treatment|Healthy adult subjects under fed conditions
2861568|NCT03517891|Experimental|WIC +|"The intervention consist in the implementation of an enhanced nutritional education and services model through the use of a combination of modalities to disseminate messages and educational materials framed in the health empowerment model. Each component of the intervention has been developed to provide the information consistent with the theoretical framework of the modality being used.~The intervention targets the following behaviors: Infant activation, Healthy sleep patterns, Screen time, Healthy feeding practices."
2861569|NCT03517891|No Intervention|WIC Standard of care (Control)|Participants recruited in randomly assigned control clinics will receive the WIC program standard of care. This includes the projected implementation of a web page for the nutritional education contacts. We will update our definition of the PR WIC program standard of care upon recruitment initiation and throughout the study implementation phase. We will also document the utilization rate of the web base platform provided by WIC among the control participants to determine baseline use of distance learning platforms.
2861570|NCT03517878||Comprehensive CHW Cohort|Pregnant women who become mothers and their infants living in areas served by the comprehensive CHW program. These are areas around two primary health care clinics and matched to the Control Cohort clinic areas.
2861571|NCT03517878||Control Cohort|Pregnant women who become mothers and their infants living in areas that are not served by the comprehensive CHW program. These are areas around two primary health care clinics and matched to the Comprehensive CHW Cohort clinic areas.
2861572|NCT03517852|Experimental|Arm 1|Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with peritoneal carcinomatosis during standard course of treatment (cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, or CRS-HIPEC).
2861573|NCT03517839|Experimental|Training Group|
2861574|NCT03517839|Sham Comparator|Control Group|
2861575|NCT03517813||Cohort 1|"Asymptomatic women at increased risk of breast cancer referred clinically for high risk screening breast MRI or women with newly diagnosed primary unilateral breast cancer referred for evaluation of extent of disease (EOD) in the index breast and screening of the contralateral breast.~All women enrolled on study will complete a clinical breast MRI and research contrast enhanced mammogram. Abbreviated MRI images will be extracted from the standard breast MRI exam."
2861576|NCT03517813||Cohort 2|"Women receiving MRI for any indication and for whom percutaneous biopsy with ultrasound or MRI guidance has been recommended.~All women enrolled on study will complete a standard breast MRI and research contrast enhanced mammogram. Abbreviated MRI images will be extracted from the standard breast MRI exam."
2861577|NCT03517787|Experimental|FES+TE|Participants receiving Functional electrical stimulation (FES) combined with therapeutic exercise (TE)
2861578|NCT03517787|Active Comparator|TE|Participants receiving only therapeutic exercise
2861579|NCT03517787|Other|REF-FES+TE|Healthy adults (reference group REF) that participate only in 1 session and receive FES and therapeutic exercise
2861580|NCT03517787|Other|REF-TE|Healthy adults that participate only in 1 session and receive only therapeutic exercise
2861581|NCT03517774|Experimental|3D Printed Socket|All participants will received a 3D Printed Prosthetic
2861582|NCT03517761|Experimental|Bone Marrow Concentrate treatment|Bone marrow concentrate subjects will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow nucleated cell layer. Injectate will then be used to treat the ligaments in the CCJ.
2861583|NCT03517761|Sham Comparator|Sham Control|Control subjects will also undergo a bone marrow aspiration of 30-60 cc to maintain blinding. Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia.
2861584|NCT03517748|Experimental|the investigational device: DM05|DM05 eye drops, multidose sterile emulsion, will be administered in the DM05 Arm at one to two drops instilled in each eye from 4 to 6 times per day during 84 days
2861585|NCT03517748|Active Comparator|The comparative device : Optive™|Optive™ eye drops, multidose sterile solution, will be administered in the Optive Arm at one to two drops instilled in each eye from 4 to 6 times per day during 84 days
2861586|NCT03517735|Experimental|Automated postoperative sedation|Automated administration of Propofol and Remifentanil.
2861587|NCT03517735|Active Comparator|Manual postoperative sedation|Manual administration of Propofol and Remifentanil.
2861588|NCT03517722|Experimental|Ustekinumab|Participants will receive ustekinumab approximately 6 milligram per kilogram (mg/kg) intravenously (IV) based on body weight-range at Week 0 followed by 90 mg ustekinumab subcutaneously (SC) at Week 8 and every 8 weeks (q8w) thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will continue to receive 90 mg ustekinumab SC q8w through Week 160.
2861589|NCT03517722|Experimental|Placebo|Participants will receive matching placebo to ustekinumab IV at Week 0, followed by matching placebo to ustekinumab SC at Week 8 and q8w thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will cross-over to receive 90 mg ustekinumab SC q8w through Week 160.
2861590|NCT03517709|Other|Conventional|
2861591|NCT03517709|Other|Blood Pressure Monitor|
2861592|NCT03517696|Active Comparator|Membrane Sweeping|Membrane sweeping
2861593|NCT03517696|No Intervention|Control|Routine vaginal exam
2861594|NCT03517683|Experimental|Low speed|Patients will receive intrathecal injection of the anesthetic mixture in a slow speed (1ml in 15 seconds)
2861595|NCT03517683|Active Comparator|High speed|Patients will receive intrathecal injection of the anesthetic mixture in a high speed (1ml in 5 seconds)
2861596|NCT03517657|Experimental|Bilateral motor priming + Task specific training (BMP + TST)|A combination of bilateral motor priming (BMP) plus task specific training (TST) for 30 hours over 5 weeks.
2861597|NCT03517657|Active Comparator|Control Priming + TST (CP + TST)|The control priming is transcutaneous electric stimulation (TENS) set at a low threshold followed by the same task specific training protocol for 30 hours over 5 weeks.
2861598|NCT03517644|Experimental|Deceptive Placebo (DP)|After pretreatment heat pain assessment, participants are informed that they are about to receive an effective analgesic cream. In fact, they receive a placebo cream. Next, the posttreatment pain assessment is conducted.
2861707|NCT03516929|Active Comparator|high risk group|history of stroke or TIA, carotid bruit, left main stem disease, other peripheral vascular disease
2861599|NCT03517644|Experimental|OLP with Hope (OLP Hope)|After pretreatment heat pain assessment, participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, using verbal instructions, the investigator aims to induce hope among the participants that the cream could have a positive effect. Next, the posttreatment pain assessment is conducted.
2861600|NCT03517644|Experimental|OLP with Expectations (OLP Expectation)|After pretreatment heat pain assessment, participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, using verbal instructions, the investigator aims to raise expectations among the participants that the cream will have a positive effect. Next, the posttreatment pain assessment is conducted.
2861601|NCT03517644|Experimental|Control|After pretreatment heat pain assessment, this group does not receive an intervention targeting pain sensation prior to the posttreatment pain assessment.
2861602|NCT03517631|Experimental|No busulfan preconditioning|shRNA-modified CD34+ cells without busulfan preconditioning.
2861603|NCT03517631|Experimental|Low dose busulfan preconditioning|shRNA-modified CD34+ cells, with a single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.
2861604|NCT03517631|Experimental|High dose busulfan preconditioning|shRNA-modified CD34+ cells, with a single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.
2861605|NCT03517618|Experimental|S-1 + leucovorin|Single arm
2861606|NCT03517605|Experimental|Exercise for cardiac rehabilitation|Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided into heating, aerobic exercise and recovery.
2861607|NCT03517592|Experimental|EMDR Therapy|EMDR: 20 individual sessions 60 minutes each for 6 months
2861608|NCT03517592|Other|Treatment as Usual|The TAU condition includes follow-up visits with the psychiatry, psychology and with the nursing service. Visits with the psychiatrist consist to evaluate clinical status and readjust the pharmacological treatment if necessary while visits with the psychologist consist to assess and detect risk situations and to prevent relapses using a cognitive behavioral approach. Finally, the nursing service will provide health and care habits and will carry out the abstinence controls.
2861609|NCT03517579|Experimental|Pilot Project|It is a Pilot study of 10 persons
2861610|NCT03517566|Placebo Comparator|placebo|Placebo
2861611|NCT03517566|Experimental|ZPL389 Dose 1|Dose 1 of ZPL389
2861612|NCT03517566|Experimental|ZPL389 Dose 2|Dose 2 of ZPL389
2861613|NCT03517566|Experimental|ZPL389 Dose 3|Dose 3 of ZPL389
2861614|NCT03517566|Experimental|ZPL389 Dose 4|Dose 4 of ZPL389
2861615|NCT03517553|Experimental|EMS users in ESRD|Subjects then initiate passive electrical muscle stimulation (EMS) delivered by a commercially available FDA approved neuromuscular stimulator (EMPI 300PV or its replacement, EMPI Continuum device obtained from EMPI, Inc., St Paul MN) 3 times a week to the quadriceps muscle groups (15 minutes on each side, 30 minutes total) while on hemodialysis. The duration of training will last for 4 months. Subjects will be monitored at regular intervals during the training to make sure they are doing the training correctly and they are not experiencing any problems.
2861616|NCT03517540|Experimental|Arm A: Tropifexor (LJN452) - Dose 1|
2861617|NCT03517540|Experimental|Arm B: Cenicriviroc (CVC)|
2861618|NCT03517540|Experimental|Arm C: Tropifexor (LJN452) Dose 1 + CVC|
2861619|NCT03517540|Experimental|Arm D: Tropifexor Dose 2 + CVC|
2861620|NCT03517527|No Intervention|Control|
2861621|NCT03517527|Experimental|Intervention|
2861622|NCT03517501|Active Comparator|ART-123|
2861623|NCT03517501|Placebo Comparator|Placebo|
2861624|NCT03517488|Experimental|XmAb20717|XmAb20717 administered by intravenous dosing on Days 1 and 15 of each 28-day cycle for a total of two cycles
2861625|NCT03517475|Experimental|Supervising for Home Safety modified|We will train caregivers to provide adequate levels of supervision to the 3-4 year-old children.
2861626|NCT03517475|Placebo Comparator|Services as Usual|Clients will receive home visiting services from Head Start
2861627|NCT03517462|Experimental|Ivermectin|Single dose directly observed treatment with Ivermectin 3Mg Tab (150 ug/kg) delivered orally.
2861628|NCT03517449|Experimental|Lenvatinib 20 mg + Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 milligram (mg) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus lenvatinib 20 mg administered orally (PO) once daily (QD) during each 21-day cycle for up to 35 cycles.
2861629|NCT03517449|Active Comparator|Treatment of Physician's Choice|Participants will receive either of the following treatments: doxorubicin 60 milligram per square meter (mg/m^2) administered by IV on Day 1 of each 21-day cycle for up to a maximum cumulative dose of 500 mg/m^2 OR paclitaxel 80 mg/m^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.
2861630|NCT03517436|Experimental|Edwards CENTERA THV|
2861631|NCT03517410||Smart phone Use Experimental group|Patients with CLBP
2861632|NCT03517397|Experimental|Mobile Contingency Management|
2861633|NCT03517384|Experimental|I-CBT for Body Dysmorphic Disorder|All participants will receive our Internet-Cognitive Behavioral Therapy treatment for Body Dysmorphic Disorder.
2861634|NCT03517371|Experimental|mHealth delivered exercise program|"Participants in the mHealth delivered exercise program have up to 10 in-person visits with a physical therapist over 12 months. The mHealth exercise program, consisting of walking, strengthening and stretching exercises, is prescribed and remotely adapted by a physical therapist over 1 year. Approximately 5-7 exercises are implemented 5 days per week. The exercise program is video-recorded and accessed on a smartphone or computer tablet via an application (app). Cognitive-behavioral elements are integrated emphasizing participant engagement in managing their health condition. Components of the mHealth program include goal setting, action planning, automated rewards, self-monitoring of progress and a remote connection to a physical therapist through a messaging feature."
2861667|NCT03517176|Experimental|Part B (Expansion)|Safety and early efficacy of CEND-1 in combination with nab-paclitaxel (125mg/m^2) and gemcitabine (1000mg/m^2) will be evaluated (dosing on Days 1, 8, 15 of the 28-day treatment cycle). Treatment cycles will be repeated every 4 weeks based on toxicity and response. Treatment may continue as long as there is perceived benefit or until disease progression.
2861708|NCT03516929|Sham Comparator|low risk group|No history or stroke,TIA. NO left main stem disease
2861635|NCT03517371|Active Comparator|Exercise only|Participants in the control group have up to 10 in-person visits with a physical therapist over 12-months - equivalent to the dose provided to the mHealth condition. Participants are instructed by the physical therapist to engage in walking and perform the same progressive resistance and stretching exercises (tailored to their needs and provided in written format) at the same frequency (5x/week) as participants in the mHealth condition. Participants in the control condition are instructed to gradually progress their exercise program and to increase the amount of walking over a 1-year period. No cognitive-behavioral approaches or mHealth technology will be provided.
2861636|NCT03517358|Active Comparator|Pharmacy|service of care: pharmacy
2861637|NCT03517358|Active Comparator|Case management|service of care: case management
2861638|NCT03517345|Experimental|Prebiotic group|Given a prebiotic product (inulin + oligofructose; 5 g) mixed with conventional yogurt (100 g) which given as snack, twice a day.
2861639|NCT03517345|Experimental|Control group|Given conventional yogurt (100 g) which given as snack, twice a day.
2861640|NCT03517332||Cohort 1|"Have a diagnosis of a malignancy in clinical stage 0 to IV including but not limited to: colon or rectal cancer, pancreatic and gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, bladder cancer, melanoma~Subjects of cohort 1 must not:~• Have been treated for above diagnosed malignancy"
2861641|NCT03517332||Cohort 2|"Negative cohort with subjects that have not been diagnosed with a malignancy (cohort 2).~Subjects of cohort 2 must:~• Meet the listed matching criteria~Subjects of cohort 2 must not:~• Have been diagnosed/treated for a malignancy previously"
2861642|NCT03517319|Placebo Comparator|Placebo|Normal Saline 0.9% 1.2 ml will be injected to finger flexor muscles
2861643|NCT03517319|Experimental|Treatment dose 15|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U will be injected to finger flexor muscles
2861644|NCT03517319|Experimental|Treatment dose 30|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U will be injected to finger flexor muscles
2861645|NCT03517319|Experimental|Treatment dose 50|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U will be injected to finger flexor muscles
2861646|NCT03517319|Experimental|Treatment dose 70|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U will be injected to finger flexor muscles
2861647|NCT03517306||Beijing|No interventions
2861648|NCT03517306||Ningxia|No interventions
2861649|NCT03517306||Wenzhou|No interventions
2861650|NCT03517306||Changzhou|No interventions
2861651|NCT03517293|Experimental|Aerobic Exercise Intervention|Aerobic Exercise training 50 minutes of moderate intensity exercise, 3 times per week from ~16-40 weeks of pregnancy
2861652|NCT03517293|No Intervention|Control|usual daily activities - not exercise, not elevating heart rate
2861653|NCT03517280||Children with Neuroblastoma|Children undergoing treatment for Neuroblastoma at ITACI in Sao Paolo in Brazil who are under the age of 18 years.
2861654|NCT03517254|Experimental|Glutamine and strength training program|Three times per week, standardized and supervised resistance training by physicians will be conducted at the National Institute of Rehabilitation for 6 weeks of follow up. At the beginning and at the end of the training session, the experimental group will receive by mouth 10 grams of glutamine dissolved in 120 milliliters of water, all participants and team of researchers will not be aware of the supplement.
2861655|NCT03517254|Placebo Comparator|Placebo and strength training program|Three times per week a standardized and supervised resistance training by physicians will be conducted at the National Institute of Rehabilitation for 6 weeks after discharge. At the beginning and at the end of the training session, the placebo group will receive by mouth10 grams of maltodextrin dissolved in 120 milliliters of water. All participants and team of researchers will not be aware of the supplement content.
2861656|NCT03517241||Geographic atrophy secondary to AMD|20 patients clinically diagnosed with geographic atrophy (GA) secondary to AMD.
2861657|NCT03517241||Stargards disease|20 patients clinically and genetically diagnosed with Stargards disease (STGD)
2861658|NCT03517241||Branch retinal artery occlusion|20 patients clinically diagnosed with branch retinal artery occlusion (BRAO)
2861659|NCT03517241||Full thickness macular hole|20 patients clinically diagnosed with acute full thickness macular hole (FTMH) before and after macular surgery
2861660|NCT03517241||Healthy controls|20 healthy control subjects. Visual acuity of 20/16- 20/32
2861661|NCT03517228|Experimental|total laparoscopic or robotic-assisted hysterectomy|All patients who are consented for a total laparoscopic or robotic-assisted hysterectomy will be eligible for the trial, unless the surgeon does not plan to use a uterine manipulator.
2861662|NCT03517215|Experimental|Enhanced CB-ASP|If a site is randomized to the enhanced CB-ASP, prescribers at that site will be required to attend an education session. In the four months following the initial session, prescribers will be asked to complete one on-line eModule for each target condition (acute sinusitis, sore throat, acute bronchitis and acute uncomplicated cystitis) each month. Each module will take approximately 15 minutes to complete. Two audit and feedback reports (every 3 months) of their clinic's prescriptions for these conditions will be provided where they will be asked to review and discuss with their colleagues and study staff.
2861663|NCT03517215|Active Comparator|Standard CB-ASP|If a site is randomized to the standard CB-ASP strategy arm, prescribers will be offered the opportunity to attend the 1 hour introductory seminar by a web-link, provided with access to the short e-learning modules each month by email, and sent their clinic's audit and feedback reports by email for review two times during the study.
2861664|NCT03517215|No Intervention|Control|If a site is randomized to the control arm, the site will not receive any active interventions. Prescribers at the site will be offered access to the eModules at the completion of the study and provided with one audit and feedback report of their clinic's antibiotic prescribing patterns for local quality improvement needs as desired.
2861665|NCT03517189|Experimental|Aorta no-touch|Aorta no-touch off-pump coronary artery bypass surgery.
2861666|NCT03517176|Experimental|Part A (Dose Escalation)|Safety of ascending dose levels of CEND-1 in combination with gemcitabine and nab-paclitaxel will be evaluated. Patients will receive an IV bolus of CEND-1 on Day 1 of the 1-week run-in period. This is followed by one treatment cycle (28 days) with the CEND-1 / nab-paclitaxel (125mg/m^2) / gemcitabine (1000mg/m^2) combination given on Days 1, 8, 15.
2861668|NCT03517163||Prospective Group|Individuals enrolled or just finished kindergarten who were diagnosed with Autism Spectrum Disorder through the DSM-5 diagnostic criteria
2861669|NCT03517150|Experimental|Experimental group|This group will use an oral appliance for treatment of obstructive sleep apnea. The oral appliance is custom-made and its titration is attained by means of progressive mandibular advancement that incrementally moves the mandible forward. This group of patients will use the oral appliance for 45 days.
2861670|NCT03517150|Active Comparator|Control group|This group will use a single adjustable silicone appliance in maxillar for 45 days, in order to compare to the experimental group.
2861671|NCT03517137|Experimental|Treatment|
2861672|NCT03517124|Experimental|Zirconia restorations|Dental restorations in surface modified zirconia bonded to tooth substance by dual cure resin cement
2861673|NCT03517124|Active Comparator|e.max|Restorations in e.max bonded to tooth substance by dual cure resin cement
2861674|NCT03517111|Experimental|Nutrition/substance use prevention|Parenting and nutrition curriculum targeting substance use prevention and diet improvement.
2861675|NCT03517111|Active Comparator|Substance use prevention only|Parenting curriculum targeting substance use prevention only.
2861676|NCT03517111|Sham Comparator|Academic success program|Control program focused only on academic success.
2861677|NCT03517098|Experimental|The D-ERAS group|Patients will be treated with the D-ERAS pathway
2861678|NCT03517098|Other|The non-ERAS group|Patients undergoing THA or TKA will receive conventional care.
2861679|NCT03517085|Experimental|DTX401 Dose 1|DTX401 solution for intravenous (IV) infusion
2861680|NCT03517085|Experimental|DTX401 Dose 2|DTX401 solution for intravenous (IV) infusion
2861681|NCT03517085|Experimental|DTX401 Dose 3|DTX401 solution for intravenous (IV) infusion
2861682|NCT03517059||PD patients|30 PD patients in ON and OFF levodopa conditions
2861683|NCT03517059||Healthy control subjects|30 age matched healthy control subjects
2861684|NCT03517059||Neurological control subjects|10 patients with defined supra nuclear palsy
2861685|NCT03517046|Experimental|CartiLife (low-dose group)|Total defect volume in low-dose group is less than 2 ㎤. Low- and high-dose group are sequentially processed.
2861686|NCT03517046|Experimental|CartiLife (high-dose group)|Total defect volume in High-dose group is 2 ~ 4 ㎤.
2861687|NCT03517033|Experimental|Test|Torrent's Nebivolol Tablets 20 mg
2861688|NCT03517033|Active Comparator|Reference|Forest Pharmaceuticals Inc's Bystolic Tablets 20 mg
2861689|NCT03517020|Experimental|Test|Torrent's Nebivolol Tablets 20 mg
2861690|NCT03517020|Active Comparator|Reference|Forest Pharmaceuticals Inc.'s Bystolic® Tablets 20 mg
2861691|NCT03517007|Experimental|Opt-Out Protocol|Should an eligible patient pass the safety screen and be randomized to the intervention arm of the trial, the designated pharmacist will approach the patient's primary provider in charge of antibiotic decision-making The pharmacist will inform the provider the patient's antibiotics can be de-escalated unless the provider opts out.
2861692|NCT03517007|No Intervention|Standard of Care|Provider continues routine, standard of care on the patient.
2861693|NCT03516994|Experimental|Structured Advance Care Planning|In the structured advance care planning approach, patients will participate in a 60 to 90 minute facilitated advance care planning conversation with a trained person using Respecting Choices (First Steps) guide and will receive a state advance directive form. The advance care planning facilitator will follow-up as needed after the session to answer additional questions.
2861694|NCT03516994|Active Comparator|Patient Driven Advance Care Planning|In the patient-driven advance care planning approach, patients receive a Five Wishes Form (easy to understand advance directive written in plain language), a state advance directive form, and at least two follow-up phone calls with an advance care planning contact who will answer questions.
2861695|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + MK-4280|Participants receive pembrolizumab 200 mg Q3W plus MK-4280 200 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
2861696|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
2861697|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + MK-4280|Participants receive pembrolizumab 200 mg Q3W plus MK-4280 200 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
2861698|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
2861699|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + MK-4280|Participants receive pembrolizumab 200 mg Q3W plus MK-4280 200 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
2861700|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
2861701|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + MK-4280|Participants receive pembrolizumab 200 mg Q3W plus MK-4280 200 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
2861702|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
2861703|NCT03516968|Experimental|Monthly bolus arm|
2861704|NCT03516968|Active Comparator|Daily arm|
2861705|NCT03516968|Other|Control group|Group of obese patients without vitamin D deficiency
2861706|NCT03516942||Observational (questionnaire)|Patients complete questionnaires over 20-60 minutes at baseline and at 3, 6, 12, and 24 months after cancer diagnosis.
2861714|NCT03516916||Israel|Patients with a permanent colostomy after curative surgery for rectal cancer
2861715|NCT03516916||Lithuania|Patients with a permanent colostomy after curative surgery for rectal cancer
2861716|NCT03516916||the Netherlands|Patients with a permanent colostomy after curative surgery for rectal cancer
2861717|NCT03516916||Portugal|Patients with a permanent colostomy after curative surgery for rectal cancer
2861718|NCT03516916||Russia|Patients with a permanent colostomy after curative surgery for rectal cancer
2861719|NCT03516916||South Africa|Patients with a permanent colostomy after curative surgery for rectal cancer
2861720|NCT03516916||Spain|Patients with a permanent colostomy after curative surgery for rectal cancer
2861721|NCT03516916||Sweden|Patients with a permanent colostomy after curative surgery for rectal cancer
2861722|NCT03516916||Turkey|Patients with a permanent colostomy after curative surgery for rectal cancer
2861723|NCT03516916||the United Kingdom|Patients with a permanent colostomy after curative surgery for rectal cancer
2861724|NCT03516903|Active Comparator|Methotrexate & Folic acid|ddMTX-LDE 40mg/m2 (100mL total volume) IV and Folic acid 5mg by mouth (the day after ddMTX-LDE) weekly for 6 weeks
2861725|NCT03516903|Placebo Comparator|Placebo & folic acid|Placebo-LDE IV 100mL and Folic acid 5mg by mouth (the day after Placedo-LDE) weekly for 6 weeks
2861726|NCT03516877|Experimental|ESRT|"Volunteer surgery and anesthesia faculty from UCSF working at Parnassus Hospital site and interested in training.~Volunteer surgery and anesthesia faculty from UCSF working at Zuckerberg San Francisco General Hospital site and interested in training.~Volunteer surgery and anesthesia faculty from UCSF working at Mission Bay Hospital site and interested in training."
2861727|NCT03516851|Active Comparator|Precision bypass group|Using ICG with Flow800 software and multimodal neuronavigation to choose the recipient vessel
2861728|NCT03516851|No Intervention|Empirical group|choosing the recipient vessel by the surgeon's own experience
2861729|NCT03516838|Experimental|ACTIVA™ BioACTIVE|Restoring cavity using ACTIVA filling material
2861730|NCT03516838|Active Comparator|Compomer|Restoring cavity using compomer filling material
2861731|NCT03516825|Experimental|Musical Neglect Training (MNT)|A single-subject design was used. All participants took Musical Neglect Training.
2861732|NCT03516812|Experimental|Treatment (olaparib, testosterone enanthate)|Participants receive olaparib PO BID on days 1-28 and testosterone enanthate IM on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2861733|NCT03516799|Experimental|Acupuncture (ACU) Group|The group of participants who opt in to acupuncture
2861734|NCT03516799|No Intervention|Treatment-as-Usual (TAU) Group|The group of participants who enroll in the study but opt out of acupuncture (treatment-as-usual)
2861735|NCT03516773|Experimental|EB612 (EBP05) Regimen 1|Intervention: EB612 (EBP05) - Option 1 for daily regimen and dose for Oral PTH (1-34)
2861736|NCT03516773|Experimental|EB612 (EBP05) Regimen 2|Intervention: EB612 (EBP05) - Option 2 for daily regimen and dose for Oral PTH (1-34)
2861737|NCT03516773|Active Comparator|Comparator Injection|Intervention: NATPARA/NATPAR PTH(1-84) subcutaneous injection
2861738|NCT03516760|Experimental|GEM333|application of GEM333, a CD33 targeted bispecific antibody engaging T-cells
2861739|NCT03516747|Experimental|investigation group|participants that suffer hypercalcemia due to primary hyperparathyroidism. include all participants in the trial
2861740|NCT03516734|Experimental|Iron fortified lentils|Lentils will be fortified with iron in the lab setting at the Crop Development Center (CDC) of The University of Saskatchewan, Canada. The study will fortify lentil by spraying iron fortificant NaFeEDTA solution. A small sprayer will be placed at the beginning of the lentil polishing machine at a commercial lentil mill located near Saskatoon, Canada. The iron solution will be applied as a fine mist which will be absorbed into the lentil as it travels through the polishing drum. As the fortified lentil leaves the drum it will be bagged in 20 kg food grade bags. The expected concentration of Fe in the final product will be approximately 21 mg/100 g of lentil (fortified with NaFeEDTA solution with 1600 ppm of Fe).
2861741|NCT03516734|Active Comparator|Non iron-fortified lentils|It will be the same Saskatchewan (province of Canada) grown small cotyledon color lentil (Iron content 75-90ppm) without the iron fortification.
2861742|NCT03516734|Placebo Comparator|Usual Intake (no intervention)|It will be the usual intake of lentil- no additional lentil will be provided. However, participants will be free to consume lentils from anywhere (homemade or restaurants) if they want to, except our fortified lentils.
2861743|NCT03516721|Other|Obese adolescents|
2861744|NCT03516721|Other|Lean adolescents|
2861745|NCT03516708|Experimental|Arm A: Pharmacodynamic Cohort|"Patients will receive epacadostat at 100mg PO BID during the 21 weeks of standard of care preoperative therapy.~Standard of care preoperative therapy will consist of a total of approximately 20 weeks' preoperative therapy followed by surgery. Breakdown of the 20 weeks of preoperative therapy are as follows:~Short-course pelvic radiation therapy, 5 fractions over 1 week~2 to 3 weeks of break; tumor biopsy will be obtained on or after the last radiation day (D5-8) and before the start of chemotherapy (D21-28)~6 cycles of CAPOX for a total of 18 weeks~surgery will follow approximately 4 to 6 weeks after completion of chemotherapy~CAPOX is typically capecitabine at 1000 mg/m2 PO BID and oxaliplatin 130 mg/m2 IV Q3W. The second cycle of epacadostat will begin when CAPOX starts (so may be more than 21 days long depending on when exactly CAPOX starts)."
2861746|NCT03516708|Experimental|Arm B: Phase 1b Safety Lead-In|"-Receive epacadostat at 100mg PO BID. Pembrolizumab administered as a 200 mg IV infusion over 30 minutes on Day 1 of each 21-day cycle during the 21 weeks of standard of care preoperative therapy. Pembrolizumab will be administered after epacadostat and before IV chemotherapy if given on the same day.~Standard of care preoperative therapy will consist of a total of approximately 20 weeks' preoperative therapy followed by surgery. Breakdown of the 20 weeks of preoperative therapy are as follows:~Short-course pelvic radiation therapy, 5 fractions over 1 week~2 to 3 weeks of break; tumor biopsy will be obtained on or after the last radiation day (D5-8) and before the start of chemotherapy (D21-28)~6 cycles of CAPOX for a total of 18 weeks~surgery will follow approximately 4 to 6 weeks after completion of chemotherapy -The second cycle of epacadostat and pembrolizumab will begin when CAPOX starts (so may be more than 21 days long depending on when exactly CAPOX starts)"
2861836|NCT03516110||Prostate cancer subjects ≥ 75 years|
2861837|NCT03516097|Experimental|Experimental Group A|Structured school based intervention + mobile app usage
2861747|NCT03516708|Experimental|Arm B: Phase II|"-Receive epacadostat at 100mg PO BID. Pembrolizumab administered as a 200 mg IV infusion over 30 minutes on Day 1 of each 21-day cycle during the 21 weeks of standard of care preoperative therapy. Pembrolizumab will be administered after epacadostat and before IV chemotherapy if given on the same day.~Standard of care preoperative therapy will consist of a total of approximately 20 weeks' preoperative therapy followed by surgery. Breakdown of the 20 weeks of preoperative therapy are as follows:~Short-course pelvic radiation therapy, 5 fractions over 1 week~2 to 3 weeks of break; tumor biopsy will be obtained on or after the last radiation day (D5-8) and before the start of chemotherapy (D21-28)~6 cycles of CAPOX for a total of 18 weeks~surgery will follow approximately 4 to 6 weeks after completion of chemotherapy -The second cycle of epacadostat and pembrolizumab will begin when CAPOX starts (so may be more than 21 days long depending on when exactly CAPOX starts)"
2861748|NCT03516682|No Intervention|Usual Care|Parents will receive usual care for their child at Kaiser Permanente Colorado. This includes recommendations for well child visits at 2, 4, 6 and 12 months of age as well as automated reminders for age eligible children to receive the flu shot during flu season.
2861749|NCT03516682|Experimental|Reminders|Parents randomized to the reminder arm will receive automated reminders to complete a 6 month and 12 month vaccine visit for their child. They will receive 2 reminders before the child is 6 and 12 months of age and 2 reminders after their child is 6 and 12 months of age. Reminders will not occur if they have received vaccines within the eligible time frame to receive a vaccine or have a visit scheduled. After randomization, participants in the intervention arm will have an opportunity to provide their preference on how they receive reminders (text, phone and/or email). Participants not providing a preference will receive text reminders. If a child is randomized into the study after the child is 7 months of age, the parent will only be eligible for reminders for the 12 month vaccine visit.
2861750|NCT03516669|Other|Intraluminal Clarithromycin eradication|20 Patients receive intraluminal Clarithromycin eradication of H. pylori.
2861751|NCT03516669|Other|Oral standard triple therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor and two antibiotics ( amoxicillin, and clarithromycin) for 14 days.
2861752|NCT03516656|Active Comparator|Standard heparin dose|The investigators will identify surgical patients placed on fixed dose heparin infusions at their attending surgeon's discretion-the proposed research will not dictate the initiation of the heparin drip intraoperatively. However, the investigators will identify patients already on heparin, evaluate steady state heparin anti-Xa levels and adjust patient's dose if necessary based on steady state anti-Xa levels. Eligible patients will be started on heparin fixed-dose intraoperatively and transitioned to a weight-based dose by their surgeons. Steady state anti-Xa levels will be drawn at least 6 hours after initiation of heparin infusion. Goal anti-Xa levels will be 0.1-0.35 IU/mL.
2861753|NCT03516656|Active Comparator|Real time heparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time heparin dose adjustment and will receive follow-up steady state anti-Xa levels. Anti-Xa level monitoring will be discontinued when in range peak levels are obtained, when heparin infusions are discontinued at surgeon discretion, or when the patient is discharged
2861754|NCT03516643|Experimental|Shockwave|Extracorporeal Shockwave treatment on Ischemic Myocardium
2861755|NCT03516630|Experimental|TRZ 20|Product is administered as single dose in the morning, under fasting conditions. 10 drops for the dose of 20 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
2861756|NCT03516630|Experimental|TRZ 60|Product is administered as single dose in the morning, under fasting conditions. 30 drops for the dose of 60 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
2861757|NCT03516630|Experimental|TRZ 140|Product is administered as single dose in the morning, under fasting conditions. 70 drops for the dose of 140 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
2861758|NCT03516630|Placebo Comparator|Placebo|Product is administered as single dose in the morning, under fasting conditions. Trazodone-matching placebo corresponding to 70 drops is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
2861759|NCT03516630|Active Comparator|Moxifloxacin|Product is administered as single dose in the morning, under fasting conditions. One 400 mg tablet is swallowed (without chewing) with 240 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
2861760|NCT03516617|Experimental|Arm A (acalabrutinib)|Participants receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 courses.
2861761|NCT03516617|Experimental|Arm B (acalabrutinib, obinutuzumab)|Participants receive acalabrutinib PO BID on days 1-28 and obinutuzumab IV on days 1, 2, 8, and 15 of course 1 and days 1 of subsequent courses. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 courses.
2861762|NCT03516617|Active Comparator|Arm C (observation)|Participants will be observed every 6 months for up to 2 years.
2861763|NCT03516604|Experimental|PF-04995274|"PF-04995274, three x 5mg tablet (15mg total), once daily for 7-9 days~+ 1 placebo capsule, once daily for 7-9 days"
2861764|NCT03516604|Active Comparator|Citalopram|"Citalopram, one x 20mg capsule, once daily for 7-9 days~+ 3 placebo tablets, once daily for 7-9 days"
2861765|NCT03516604|Placebo Comparator|Placebo|3 placebo tablets and 1 placebo capsule, once daily for 7-9 days
2861766|NCT03516591|Experimental|Dose Escalation (3+3 design)|A 3 + 3 design, with dose-escalation of AMV564, up to a Maximum Tolerated Dose (MTD) level
2861838|NCT03516097|Experimental|Experimental Group B|mobile app usage
2861839|NCT03516097|Active Comparator|Control Group|Structured school based intervention
2861767|NCT03516591|Experimental|Dose Expansion|Following determination of the MTD of AMV564, the study will expand at the MTD or a dose level lower than the MTD to obtain initial estimates of response rates and additional information on safety.
2861768|NCT03516565||Pregnancy group|Pregnant group included women, who were in their second trimester (weeks 16-24) and third trimester (weeks 25-34)
2861769|NCT03516565||Postpartum group|Postpartum group included women, who were evaluated 6 months after giving birth
2861770|NCT03516565||Non-pregnant group|Women who were systemically healthy and non-pregnant.
2861771|NCT03516552||Hemoglobin content on blood loss|Hemoglobin content on blood loss, to assess ratio hemoglobin/volume.
2861772|NCT03516539|Experimental|Group ML|Mcgrath videolaryngoscopy
2861773|NCT03516539|Active Comparator|Group DL|direct Macintosh laryngoscope
2861774|NCT03516526|Other|All patients in this study|Patients treated with natalizumab with a minimum of 1 year, without signs of disease activity (relapses, new T2 lesions on MRI) for a minimum of 1 year.
2861775|NCT03516513|Active Comparator|Problem Solving Therapy as Usual|"Clinicians in this arm of care will have access to the Case Management Tracking System which is already in use.~Intervention: unguided PST"
2861776|NCT03516513|Experimental|Assisted Problem Solving Therapy|"This arm will be designed and finalized in Phase 1 and 2 of the project. We anticipate that the intervention will leverage clinical notes required to be completed by clinicians and will provide information to clinicians to help patients improve over time, as well as help clinicians implement PST to high quality.~Intervention: guided PST"
2861777|NCT03516500|Experimental|Iron Sucrose injection group|The investigators inject Iron Sucrose (100 mg dissolved in 50 mL saline) through a butterfly needle into the bronchus of the targeting segment.
2861778|NCT03516487|Experimental|SYNB1618|A single or multiple oral dose of SYNB1618 in a chilled buffered solution
2861779|NCT03516487|Placebo Comparator|Placebo|A single or multiple oral dose of placebo (100mL of a chilled buffer solution)
2861780|NCT03516474||St. Michael's Hospital|"St. Michael's Hospital is an Acute care centre for the diabetic lower extremity.~n=100"
2861781|NCT03516474||South Riverdale Community Health Centre|South Riverdale is a Community Health Centre focused on prevention. n=100
2861782|NCT03516474||Westpark|Westpark is a rehabilitation site focused on post-operative/amputation care and preservation of the opposite limb. n=100
2861783|NCT03516474||Women's College Hospital|Women's College Hospital is an outpatient wound clinic focused on the management of DFUs. n=100
2861784|NCT03516461|Experimental|Selective Microbiota Transplantation|Three frequencies
2861785|NCT03516448|Active Comparator|the Tyroserleutide for injection|the Tyroserleutide for injection at the dosage of 6mg/d Gan Fu Le Tablets，6 tablets,po,tid
2861786|NCT03516448|Placebo Comparator|the placebo group|the placebo Gan Fu Le Tablets，6 tablets,po,tid
2861787|NCT03516435|Experimental|Parasacral transcutaneous ES|20min./session, 2 sessions/week ,12 sessions of Parasacral transcutaneous electrical stimulation.
2861788|NCT03516435|Active Comparator|Intravaginal electrical stimulation|20min./session, 2 sessions/week ,12 sessions of Intravaginal electrical stimulation.
2861789|NCT03516422|Placebo Comparator|STANDARD CARE GROUP|The subject positioned so absorbent pads are in position to catch irrigation solution. The saline bottle will be held 10-15 cm from wound bed, and squeezed to spray all surfaces of wound in a sweeping motion, from clean to dirty area of wound. Irrigation will be repeated as necessary to remove exudate, slough, and debris from the wound until the solution draining from the wound is clear. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into the wound cavity, undermining, or tunnel to fill the dead space without causing the wound to stretch or bulge or be packed tightly. Packing should be in contact with entire wound base and edges. Dressings changed once every 3 days by the patient's care provider.
2861790|NCT03516422|Experimental|ULTRASOUND DEBRIDEMENT GROUP:|Low-frequency ultrasound SonicOne O.R. (Misonix, New York, US) generates ultrasound waves with 22.5 kHz frequency. Each probe is attached to a set of irrigation solution (saline 0.9%), they transform electric energy into mechanical vibrations to induce tiny particles of water from irrigation fluid. Absorbent pads are positioned to catch excess saline. With SonicOne set at continuous mode with minimum pump flow, the debridement will begin at most distal aspect of ulcer with the hand piece in constant motion until entire ulcer surface has been debrided until as much necrotic tissue has been removed. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into wound cavity.
2861791|NCT03516409|Active Comparator|Bio-Kult Infantis|1 sachet once a day mixed with milk, water or food.
2861792|NCT03516409|Placebo Comparator|Placebo|1 sachet once a day mixed with milk, water or food.
2861793|NCT03516396|Experimental|Training Plus|"Intervention: Community Development~Training plus enhanced community development activities"
2861794|NCT03516396|Active Comparator|Control|No inputs
2861795|NCT03516396|Experimental|Training Only|"Intervention: Training~Training Only (livestock management and child nutrition)"
2861796|NCT03516383||Experimental|"ABI < 0.6, confirmed PAD~50 - 90 years of age~In-patients or out-patients~Participants who understand the study and are able to give consent~Participants who can be followed by the same investigating team for the whole period of their participation in the study"
2861797|NCT03516383||Control|"ABI of 0.9 < ABI < 1.2~50 - 90 years of age~Participants who understand the study and are able to give consent~Participants who can be followed by the same investigating team for the whole period of their participation in the study"
2861798|NCT03516370|Experimental|study group|Scaling and root planning was followed by placement of Lyophilized Saccharomyces Boulardii 250 MG in the pocket. S. boulardii was delivered subgingivally by by mixing 1gm of sachet containing 250mg of lyophilized yeast with 0.5ml of distilled water this prepared paste was injected in the perio pocket with luer lock syring and cannula.
2861799|NCT03516370|Placebo Comparator|control group|Control site received placebo i.e distilled water as a mixture after scaling and root planning.
2861800|NCT03516357||low myopia|−3.00D < spherical equivalent refractive error < −0.50D
2861801|NCT03516357||moderate myopia|−6.00D < spherical equivalent refractive error ≤ −3.0D
2861802|NCT03516357||high myopia|spherical equivalent refractive error ≤ −6.0D
2861803|NCT03516344|No Intervention|Control|Subjects will remain at rest in supine position for one minute.
2861804|NCT03516344|Experimental|Iliac psoas muscle|In supine position with a high-density foam cushion under the subject's feet, they will be asked to make a push in the caudal direction, against the cushion, alternating between both feet with their knees stretched out, for one minute
2861805|NCT03516344|Experimental|Diaphragmatic Breathing|Subjects perform five cycles of diaphragmatic breathing in the supine position.
2861806|NCT03516344|Experimental|Liver pumping|A technique of hepatic supine pumping is performed by simultaneous compression in the right hypochondrium and epigastrium, in the opposite direction, during the inspiratory phase, stopping during the expiratory phase and repeating the maneuver for five respiratory cycles.
2861807|NCT03516344|Experimental|Spinal manipulation|A semi-direct vertebral manipulation, type Dog Technique in extension, will be performed on level D8
2861808|NCT03516331|Experimental|Part 1:FDL176 & FDL169 coadministration|To receive a single dose of FDL176 on Day 1, followed up FDL169 TID starting Day 8; and another single dose of FDL176 on Day 22.
2861809|NCT03516331|Experimental|Part 2:FDL176 & FDL169 coadministration|To receive FDL176 QD starting Day 1, and FDL169 TID starting Day 8
2861810|NCT03516318|Experimental|SMART Connections|"The intervention components include:~Informational messages that reflect the content of the structured group counseling curriculum and are posted to the Facebook group wall on a regular basis for approximately 4 to 5 months~Moderated, closed group chats in a secret Facebook group where YLHIV can interact with their peers and with a trained support group facilitator~Access to a trained facilitator via Facebook Messenger for the duration of the intervention who will be able to provide information or basic counseling on ART/HIV care related issues, with referral to health care services as needed"
2861811|NCT03516318|No Intervention|Control|All study participants, in both study arms, will receive standard services currently available to YLHIV in these facilities and communities. The services currently include: routine clinical care for HIV treatment including laboratory testing (CD4, viral load tests); active case management by community volunteers with intensive adherence support during the first 4 weeks of ART; adherence support through phone calls and SMS (short messaging service) reminders; and enhanced adherence counseling for patients with unsuppressed viral loads.
2861812|NCT03516305|Experimental|Staccato Alprazolam 1 mg|a single inhaled dose
2861813|NCT03516292||OAB-POP group|As an Observational Case-Control Study, the participants will divided in two groups depending whether they suffer from overactive bladder symptoms or not. All participants will have POP.
2861814|NCT03516292||POP only group|As an Observational Case-Control Study, the participants will divided in two groups depending whether they suffer from overactive bladder symptoms or not. All participants will have POP.
2861815|NCT03516279|Experimental|Treatment (pembrolizumab, dasatinib, imatinib, nilotinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and dasatinib, imatinib mesylate, or nilotinib PO as clinically indicated per the treating physician. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients with detectable MRD after course 18 continue pembrolizumab and dasatinib, imatinib mesylate, or nilotinib every 21 days for up to an additional 18 courses in the absence of disease progression or unacceptable toxicity. Patients with UMRD at any time before course 18 discontinue pembrolizumab after course 18 and continue dasatinib, imatinib mesylate, or nilotinib every 21 days for up to an additional 18 courses in the absence of disease progression or unacceptable toxicity.
2861816|NCT03516253|Experimental|Intervention group|Dietary Supplement: Fish oil + EPO. Fish oil (2 gel capsules, each 1g fish oil with 500 mg EPA+DHA) and EPO (Evening primrose oil 3 gel capsules with 117 mg GLA), 3 months with lunch.
2861817|NCT03516253|No Intervention|Control group|Dietary Supplement: Olive oil (5 gel capsules, each 1g olive oil), 3 months with lunch.
2861818|NCT03516240|Experimental|Experimental|Participants receive the topical analgesic, Biofreeze.
2861819|NCT03516240|Placebo Comparator|Placebo|Participants receive a placebo cream.
2861820|NCT03516227|Experimental|HRVBF|Heart rate variability biofeedback
2861821|NCT03516227|No Intervention|Control|Usual Care
2861822|NCT03516214|Experimental|EGF816 and trametinib|Patients will receive oral EGF816 and trametinib at escalating dose levels. Intra-patient dose-escalation will not be allowed.
2861823|NCT03516201||obese patients after bariatric surgery|obese adults (≥ 18 years) who underwent bariatric surgery
2861824|NCT03516201||obese adultes without bariatric surgery|obese adults (≥ 18 years) who did not underwent bariatric surgery at the time of the examination
2861825|NCT03516188|Experimental|Alginate-antacid group|Participants will take normal meals with late night supper (i.e.two chicken burgers and one cup or 250 ml of teh-tarik) plus alginate-antacid.
2861826|NCT03516188|Experimental|Non antacid alginate group|Participants will take normal meals with late night supper (i.e.two chicken burgers and one cup or 250 ml of teh-tarik) plus antacid alone.
2861827|NCT03516175|Active Comparator|Tight fitting mask|Pre oxygenation with tight facemask with 100% oxygen
2861828|NCT03516175|Experimental|High flow nasal oxygen|High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange is used for pre oxygenation
2861829|NCT03516162||Patients With Brain Tumors|"Patients with a brain tumour scheduled for maximum safe resection via craniotomy.~Participants fulfilling all of the following inclusion criteria are eligible for the study:~Consent of the patient~Age: ≥18~Fluent language skills in German~Patient is capable to use a smartphone (based on the Google Android system) and uses a smartphone since at least 3 months~Preoperative smartphone-assessed day-to-day behaviour can be recorded for at least 1 week (7 days)"
2861830|NCT03516162||Patients With Hydrocephalus|"Patients with hydrocephalus scheduled for VP-shunting~Participants fulfilling all of the following inclusion criteria are eligible for the study:~Consent of the patient~Age: ≥18~Fluent language skills in German~Patient is capable to use a smartphone (based on the Google Android system) and uses a smartphone since at least 3 months~Preoperative smartphone-assessed day-to-day behaviour can be recorded for at least 1 week (7 days)"
2861831|NCT03516149|Experimental|Foam Rolling Group|The participants in this group will receive foam rolling exercise.
2861832|NCT03516149|No Intervention|Control Group|The participants in this group will receive no foam rolling. They will only be evaluated.
2861833|NCT03516123|Experimental|CS3006|Participants will receive CS3006 orally at specified dose on specified days
2861834|NCT03516110||Prostate cancer subjects 60-<70 years|
2861835|NCT03516110||Prostate cancer subjects 70-<75 years|
2861844|NCT03516045|Experimental|18F-AlF-NOTA-neurotensin PET/CT|One injection of the radioligand 18F-AlF-NOTA-neurotensin Device: PET/CT Following injection of 18F-AlF-NOTA-neurotensin the participants will be subjected to whole body PET/CT
2861845|NCT03516032|Experimental|walking exercises|walking in the hospital corridor
2861846|NCT03516032|Experimental|balance exercises|heel rise exercises
2861847|NCT03516019|Experimental|Weekday am personalized notices|Participants in this arm receive personalized weekday am notices on Wednesday at 7am.
2861848|NCT03516019|Experimental|Weekday pm personalized notices|Participants in this arm receive a personalized weekday pm notices on Wednesday at 7pm.
2861849|NCT03516019|Experimental|Weekend am personalized notices|Participants in this arm receive a personalized weekend am notices on Saturday at 7am.
2861850|NCT03516019|Experimental|Weekend pm personalized notices|Participants in this arm receive personalized pm notices on Saturday at 7pm.
2861851|NCT03516019|Experimental|Weekday am standard notices|Participants in this arm receive standard weekday notices on Wednesday at 7am.
2861852|NCT03516019|Experimental|Weekday pm standard notices|Participants in this arm receive standard weekday notices on Wednesday at 7pm
2861853|NCT03516019|Experimental|Weekend am standard notices|Participants in this arm receive standard weekend notices on Saturday at 7am
2861854|NCT03516019|Experimental|Weekend pm standard notices|Participants in this arm receive standard weekend notices on Saturday at 7pm
2861855|NCT03516006|Experimental|UCMSC|infusion of aUCMSC and Ursodeoxycholic acid therapy
2861856|NCT03516006|Active Comparator|UDCA|Ursodeoxycholic acid therapy 15mg/kg/d
2861857|NCT03515980|Experimental|Mild hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh A score 5 to 6 points
2861858|NCT03515980|Experimental|Moderate hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh B score 7 to 9 points
2861859|NCT03515980|Experimental|Severe hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh C score 10 to 15 points
2861860|NCT03515980|Experimental|Normal hepatic function|Based on Hepatic Function Impairment as defined by the investigator
2861861|NCT03515967|Experimental|Injured Athletes|Athletes tested for mild traumatic brain injury (mTBI) after injury using the I-PAS goggles
2861862|NCT03515967|Active Comparator|Non-Injured Athletes|Athletes tested for mild traumatic brain injury (mTBI) with no injury using the I-PAS goggles
2861863|NCT03515941|Experimental|Arm 1: Adjuvant Chemotherapy|Three cycles of chemo with CAPEOX (Oxaliplatin:130 mg/m2 by IV and Capecitabine: 625 mg/m2 by PO) on 21 day-cycle, or FOLFOX (Oxaliplatin:85 mg/m2 by IV, Leucovorin:400 mg/m2 by IV,5-fluorouracil: 400 mg/m2 and 2400 mg/m2 by IV) on 14 day-cycle
2861864|NCT03515941|Experimental|Arm 2: Adjuvant Chemoradiation|"Three cycles of chemo with Capecitabine: 750 mg/m2 by PO on 28 day-cycle or 5-fluorouracil (Leucovorin:400 mg/m2 by IV,5-fluorouracil: 400 mg/m2 and 1200 mg/m2 by IV) on 14 day-cycle.~After 1st chemo cycle above, chemoradiation for 5 weeks with 45 Gy in 1.8 Gy/fraction, 5 days a week, to the entire gastric bed (including anastomosis) and draining lymph nodes, and a single agent fluoropyrimidine, either capecitabine or 5-fluorouracil After 5 weeks chemoradiation, 2 cycles of chemo as described above."
2861865|NCT03515928|Active Comparator|Noise Exposed Group|
2861866|NCT03515928|Placebo Comparator|Control Group|
2861867|NCT03515902|Experimental|mouthguard|Mouthguard arm is application of mouthguard while swimming
2861868|NCT03515902|Experimental|mouthguard with desensitizing toothpaste|Mouthguard with desensitizing toothpaste arm is application of mouthguard with desensitizing toothpaste containing 8% arginine and calcium carbonate while swimming
2861869|NCT03515889|Experimental|Ideal Protein Weight Loss Protocol|This arm will follow the Ideal Protein method as documented in the Ideal Protein Clinic Manual and in the Ideal Protein Coaches Manual.
2861870|NCT03515889|Active Comparator|Standard Weight Loss|This arm utilizes evidence-based, low fat, low calorie strategies that have been shown to be effective for long-term weight loss and weight loss maintenance.
2861871|NCT03515876||Control|Patients will receive intravenous propofol infusion.
2861872|NCT03515876||Dexmedetomidine 0.5 microgram/kg group|Patients will receive dexmedetomidine 0.5 microgram/kg and then intravenous propofol infusion.
2861873|NCT03515876||Dexmedetomidine 1 microgram/kg group|Patients will receive dexmedetomidine 1 microgram/kg and then intravenous propofol infusion.
2861874|NCT03515863||Grave's disease with TAO|Patients with Grave's disease and TAO
2861875|NCT03515863||Grave's disease without TAO|Patients with Grave's disease but without TAO
2861876|NCT03515837|Experimental|Pembro+Pemetrexed+Chemo|Participants receive pembrolizumab (pembro) 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W with no restrictions on the number of cycles PLUS platinum chemotherapy (chemo) (either carboplatin Area Under the Curve [AUC] 5 via IV infusion Q3W for 4 cycles [Cycles 1-4] or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles [Cycles 1-4]).
2861877|NCT03515837|Active Comparator|Placebo+Pemetrexed+Chemo|Participants receive normal saline solution via IV infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W with no restrictions on the number of cycles PLUS platinum chemotherapy (chemo)(either carboplatin AUC 5 via IV infusion Q3W for 4 cycles [Cycles 1-4] or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles [Cycles 1-4]).
2861878|NCT03515824|Experimental|MK-1696 Dose Level A|Participants receive MK-1697 Dose Level A by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
2861879|NCT03515824|Experimental|MK-1697 Dose Level B|Participants receive MK-1697 Dose Level B by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
2861880|NCT03515824|Experimental|MK-1697 Dose Level C|Participants receive MK-1697 Dose Level C by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
2861881|NCT03515824|Experimental|Expansion Cohort|Participants with select tumor types receive MK-1697 at the RP2D by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
2861882|NCT03515811||Abdominal|"Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri-Staple™ 2.0 Intelligent Reloads.~Abdominal (approximately 53 subjects)."
2861883|NCT03515811||Thoracic|"Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri-Staple™ 2.0 Intelligent Reloads.~Thoracic (approximately 74 subjects)."
2861884|NCT03515798|Experimental|Pembrolizumab|(F)EC Paclitaxel + Pembrolizumab Injection
2861885|NCT03515798|Active Comparator|Standard neoadjuvant chemotherapy|(F)EC Paclitaxel alone
2861886|NCT03515785||Ph+ ALL Patients|Patients with Ph+ ALL being treated with Iclusig®.
2861887|NCT03515772||Amlodipine with Dolutegravir|"This is the control group regarding HIV drug interaction potential on amlodipine"
2861888|NCT03515772||Amlodipine with Darunavir|"This is the case group regarding HIV drug interaction potential on amlodipine"
2861889|NCT03515772||Atorvastatin with Dolutegravir|"This is the control group regarding HIV drug interaction potential on atorvastatin"
2861890|NCT03515772||Atorvastatin with Darunavir|"This is the case group regarding HIV drug interaction potential on atorvastatin"
2861891|NCT03515772||Rosuvastatin with Dolutegravir|"This is the control group regarding HIV drug interaction potential on rosuvastatin"
2861892|NCT03515772||Rosuvastatin with Darunavir|"This is the case group regarding HIV drug interaction potential on rosuvastatin"
2861893|NCT03515759||hypertensive patients|60 pregnant women with singleton living fetus between 34 -38 wks gestation known to have severe hypertension in the current pregnancy were included
2861894|NCT03515746|Active Comparator|Exergaming2D|The participants will practise grab and grasp through exergaming in virtual environment (VE) on a laptop computer. During the task, they will sit in a comfortable chair in front of the screen.
2861895|NCT03515746|Active Comparator|Exergaming3D|The participants will practise grab and grasp through exergaming in virtual environment (VE) in 3D VE using Oculus Rift CV1 3D goggles. During the task, they will sit in a comfortable chair with head-mounted 3D display.
2861896|NCT03515733|Experimental|PF-04995274|PF-04995274, three x 5mg tablet (15mg total), once daily for 7-9 days
2861897|NCT03515733|Placebo Comparator|Placebo|3 placebo tablets, once daily for 7-9 days
2861898|NCT03515720|Experimental|Study group|Painful points will be located in the path of the sensory nerves of the knee in which asepsis and antisepsis will be performed, and then 0.5-1 ml of 5% dextrose solution will be applied subcutaneously at a 45º angle along the way. of the nerve with a 27 gauge needle of ½ inch. The number of injections will vary according to the symptoms to be treated. The application will be made once a week for 6 weeks. After the first application of neuroprolotherapy, the patient will be trained to perform a rehabilitation therapy program based on thermotherapy, kinesitherapy and knee strengthening exercises. At the end of the 6 sessions, a new assessment will be made with the WOMAC, EVA and measurement of movement arcs to assess the evolution after treatment.
2861899|NCT03515720|No Intervention|Control group|Physical therapy consisting of 10 sessions based on thermotherapy, kinesitherapy and muscle strengthening exercises to the knee. Subsequently, the patient will perform this therapy home until completing 6 weeks. At the end a new assessment will be made with measurement of movement arcs, WOMAC scale and EVA to assess the evolution after treatment.
2861900|NCT03515707|Experimental|Treatment (busulfan, etoposide, ASCT)|Patients receive busulfan IV or oral every 6 hours on days -7 to -4 and etoposide IV on day -3. Patients then undergo autologous stem cell transplant on day 0.
2861901|NCT03515694|Placebo Comparator|Dose of 0mg/kg TOF1|
2861902|NCT03515694|Placebo Comparator|Dose of 0mg/kg TOF2|
2861903|NCT03515694|Experimental|Dose of 0 ,5mg/kg TOF1|
2861904|NCT03515694|Active Comparator|Dose of 0,5mg/kg TOF2|
2861905|NCT03515694|Experimental|Dose of 1mg/kg TOF1|
2861906|NCT03515694|Active Comparator|Dose of 1mg/kg TOF2|
2861907|NCT03515694|Experimental|Dose of 2mg/kg TOF1|
2861908|NCT03515694|Active Comparator|Dose of 2mg/kg TOF2|
2861909|NCT03515681|Experimental|Intervention|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
2861910|NCT03515681|No Intervention|Control|Subjects randomized to the control arm will receive the messages regarding their kiosk blood pressure levels currently provided by higi to kiosk users. These messages are provided at the kiosk at the time of the blood pressure measurement (no text messages).
2861911|NCT03515668|Experimental|Ritalin|20 mg Ritalin, 90 min before testing
2861912|NCT03515668|Placebo Comparator|Control|Identical size/taste placebo pill, 90 min before testing
2861913|NCT03515642|Experimental|HIIT group|The HIIT modality consisted of 30-40 minutes (min) of steady-state, high-intensity training 3 d/wk on a stationary bicycle at the target heart rate (HR) range equivalent to 85% to 95% of the individual's maximum oxygen consumption rate (VO2max). Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6-weeks.
2861914|NCT03515642|Active Comparator|SIT group|The SIT modality consisted of 6 to 10 repetitions of a 30 s segment of all-out exercise interspersed with 2 min of recovery, 3 d/wk on a stationary bicycle at the target heart rate (HR) range equivalent to 90% to 95% of the individual's maximum oxygen consumption rate (VO2max).
2861915|NCT03515629|Active Comparator|Pembrolizumab|Pembrolizumab
2861916|NCT03515629|Experimental|REGN2810/ipi|REGN2810/ipi
2861917|NCT03515629|Experimental|REGN2810/chemo/ipi|REGN2810/chemo/ipi
2861918|NCT03515603|Active Comparator|microsurgical technique|
2861919|NCT03515603|Active Comparator|endoscopic technique|
2861920|NCT03515590|Experimental|Emulsion with solid droplets|Emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
2861921|NCT03515590|Experimental|Emulsion with liquid droplets|Emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
2861922|NCT03515577|Experimental|Diagnostic ([68]Ga-PSMA-11 PET/CT, Axumin PET/CT)|Participants receive (68)Ga-PSMA-11 IV and 60-90 minutes later, undergo PET/CT imaging over 3 hours. Participants also undergo best standard of care Axumin PET/CT within 2 weeks before or after (68)Ga-PSMA-11 PET/CT.
2861923|NCT03515564|Experimental|Alternative therapy|"Dance/Movement Therapy, Art Therapy, Mindful Yoga, or HIIT~90 minutes once weekly for 12 weeks"
2861924|NCT03515564|Active Comparator|Current standard care|12 weeks of therapy or clinical care as currently standard
2861925|NCT03515551|Experimental|IMCnyeso dose Escalation Phase (Arm 1)|Phase (Arm 1) n=up to 33 Melanoma, NSCLC, urothelial carcinoma and synovial sarcoma patients to establish the MTD/RP2D
2861992|NCT03515122||Persons with Spinal cord injury (SCI)|The total population of a specified group of persons with traumatic SCI will be invited to participate.
2861926|NCT03515551|Experimental|IMCnyeso expansion phase (Arm 2)|Patients will be enrolled into 1 of 3 cohorts depending on disease type (NSCLC, urothelial carcinoma or synovial sarcoma) n=30 and treated at the RP2D of IMCnyso to determine the efficacy in these indications
2861927|NCT03515538|Experimental|RRx-001 Pre-Treatment plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC (four doses total). No additional RRx-001 will be given during the course of RT/cisplatin
2861928|NCT03515538|Experimental|RRx-001 Pre-Treatment, 2 Concurrent Doses plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC. In addition, one dose of RRx-001 will be given on the last radiation day in each of weeks 2 and 5 during RT/cisplatin administration
2861929|NCT03515538|Experimental|RRx-001 Pre-Treatment, 6 Concurrent Doses plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC. In addition, one dose of RRx-001 will be given on the last radiation day of each of the first 6 weeks during RT/cisplatin administration
2861930|NCT03515538|Active Comparator|Standard of Care|No doses of RRx-001 will be administered. Patients assigned to this arm will receive only standard of care in the form of a 7-week course of fractionated radiation therapy concurrent with a high-dose cisplatin regimen (100 mg/m2 dose in each of RT weeks 1, 4, and 7).
2861931|NCT03515525||Hematoma side|Drain secretion volume prior to revision surgery on the breast side affected by hematoma.
2861932|NCT03515525||Non-hematoma side|Drain secretion volume prior to revision surgery on the breast side not affected by hematoma.
2861933|NCT03515512|Experimental|Enasidenib|Enasidenib will be administered orally once daily in 28-day cycles
2861934|NCT03515499|Active Comparator|Control|The control arm will have medication monitoring sensors placed on their asthma medications. They will have reminders to take their medicines and access to a mobile app that will show them trends in their medication use.
2861935|NCT03515499|Experimental|Treatment arm|The treatment arm will have medication monitoring sensors placed on their asthma medications. They will have reminders to take their medicines and access to a mobile app that will show them trends in their medication use. Additionally, they will be paid up to $1 per day for perfect medication adherence.
2861936|NCT03515486|Experimental|Post-stroke mood disorders evaluation|Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations.
2861937|NCT03515473||CI532|Patients with CI532 cochlear implant
2861938|NCT03515473||CI522|Patients with CI522 cochlear implant
2861939|NCT03515473||CI512|Patients with CI512 cochlear implant
2861940|NCT03515460|Experimental|sugar oral load|oral ingestion of a high carbohydrate meal
2861941|NCT03515460|Experimental|fat oral load|oral ingestion of a high fat meal
2861942|NCT03515460|Experimental|sugar and fat oral loads|oral ingestion of a high carbohydrate and fat meal
2861943|NCT03515447||Before period|During this period no patient received Romiplostim.
2861944|NCT03515447||After period|"Application of the transfusion saving strategy protocol through Romiplostim treatment.~The first subcutaneous injection of 1.5 to 2 µg/kg of romiplostim was administered in the post-operative periods. An algorithm based on patient weight and platelet count was established to determine romiplostim doses. One injection per week was performed. Romiplostim posology was adjusted between 2 and 5µg/kg every week according to platelet count with a maximum of 4 administrations in the ICU."
2861945|NCT03515434|Active Comparator|ESP Block|Ultrasound-guided Erector spinae plane (ESP) block will be performed at the finishing of the surgery with 30 ml of a bupivacaine/lidocaine mixture. The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
2861946|NCT03515434|Active Comparator|TAP Block|Ultrasound-guided Transversus abdominis plane (TAP) block will be performed at the finishing of the surgery with 30 ml of a bupivacaine/lidocaine mixture. The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
2861947|NCT03515434|Sham Comparator|Control|The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
2861948|NCT03515421|Experimental|Blood Glucose monitoring System (BGMS)|"Intervention: Blood Glucose monitoring Systems (BGMSs): Frazier 3 Verio and Frazier 3 UltraPLus.~Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)"
2861949|NCT03515408|Experimental|Real rTMS (motor area)|Real rTMS targeting motor area for 30 min
2861950|NCT03515408|Experimental|Real rTMS (parietal gyrus)|Real rTMS targeting parietal gyrus for 30 min
2861951|NCT03515408|Experimental|Real rTMS (both brain area)|Real rTMS targeting motor area and parietal gyrus for 15 min, separately
2861952|NCT03515408|Sham Comparator|Sham rTMS|Sham rTMS targeting motor area and parietal gyrus for 15 min, separately
2861953|NCT03515382|Experimental|Treatment A|single dose GLPG1690.
2861954|NCT03515382|Experimental|Treatment B|Single dose itraconazole + single dose GLPG1690.
2861955|NCT03515382|Experimental|Treatment C|Single dose voriconazole + single dose GLPG1690.
2861956|NCT03515369|Experimental|Hepatectomy plus Babaodan|Surgical removal of all lesions and take Babaodan oral capsule after operation
2861957|NCT03515369|Placebo Comparator|Hepatectomy plus Placebo|Surgical removal of all lesions and take Placebo oral capsule after operation
2861958|NCT03515356|Experimental|MI-Walk Intervention|"Subjects who are already receiving FOLFOX prescribed by their oncologist (as standard of care) will receive a physical education pamphlet.~In addition, subjects will receive 8-weeks of motivational enhancement therapy- and a home-based aerobic walking intervention. Motivational interviewing will be delivered with concurrent feedback and motivational techniques in 30-45-minute sessions at intervention orientation (T2), 2 weeks (T4), and 4 weeks (T5)."
2861959|NCT03515356|Active Comparator|PA Education Alone|Subjects who are already receiving FOLFOX prescribed by their oncologist (as standard of care) will receive a physical education pamphlet.
2862136|NCT03514277|Active Comparator|Local infiltration of EXPAREL and Bupivacaine|
2861960|NCT03515343||Optical diagnosis with Optivista|Participants for which the optical diagnosis of detected colorectal polyps will be done with the new technique Pentax Optivista.
2861961|NCT03515343||Optical diagnosis with iScan|Participants for which the optical diagnosis of detected colorectal polyps will be done with the oldest technique Pentax iScan.
2861962|NCT03515330|No Intervention|Standard of Care|Participants in the control arm will be instructed to take their immunosuppressant medications as prescribed and attend required follow-up as is standard of care, and will not receive the mHealth application.
2861963|NCT03515330|Experimental|mHealth Intervention|Participants in the intervention arm will receive the mHealth app either while they are an inpatient post-transplant, or at their first post-transplant clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the application and explain its functioning. Participants will then use the application to aid in immunosuppressant medication adherence post-transplant.
2861964|NCT03515317|Experimental|LoRETA Z-score NF group|BrainMaster Discovery 24E (BrainMaster Technologies, Inc.) combined with Neuroguide software (Applied Neuroscience, Inc.) to conduct both LoRETA Z-score NF. A total treatment dosage of 600 minutes is needed.
2861965|NCT03515317|Experimental|theta/beta NF group|BrainMaster Discovery 24E (BrainMaster Technologies, Inc.) combined with Neuroguide software (Applied Neuroscience, Inc.) to conduct both theta/beta NF. A total treatment dosage of 600 minutes is needed.
2861966|NCT03515317|No Intervention|control group|The control group involves no NF training. The control group will be designed to parallel the cognitive tasks to control for practice effects due to repeated testing (pre- and post- assessments) and the time effect on cognitive function recovery (spontaneous recovery of cognition).
2861967|NCT03515304|Experimental|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
2861968|NCT03515304|Placebo Comparator|Placebo|Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
2861969|NCT03515291|Experimental|iMP cell injection|iMP cells injected in to the epicardial surface of the heart during coronary artery bypass graft surgery.
2861970|NCT03515291|Placebo Comparator|Control injection|Control (cell suspension solution) injected in to the epicardial surface of the heart during coronary artery bypass graft surgery.
2861971|NCT03515278|Experimental|suprascapular nerve block (SCNB) group|"SCNB with physiotherapy. Suprascapular nerve block: Ultrasound-guided SCNB by 3 c.c. 1% lidocaine with 20mg triamcinolone.~Physiotherapy: The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise. (stretching, mobilization and ROM exercise, and strengthening)"
2861972|NCT03515278|Active Comparator|intra-articular corticosteroid injection (IACI) group|"IACI with physiotherapy. Intra-articular steroid Injections: Receive intra-articular corticosteroid injection.Ultrasound-guided IACI with 3c.c. 1% lidocaine and 20mg triamcinolone.~Physiotherapy: The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise. (stretching, mobilization and ROM exercise, and strengthening)"
2861973|NCT03515265|Experimental|Fiber resin composite|Fiber reinforced resin composite restoration used as dentin substitute covered by conventional resin composite
2861974|NCT03515265|Active Comparator|Microhybrid resin composite|Microhybrid resin composite restoration with lower strength compared to Fiber reinforced resin composite restoration
2861975|NCT03515252|Experimental|Late stage lung cancer and liver cancer|Immune Killer Cells (IKC)
2861976|NCT03515226|Active Comparator|Traditional Training|24 hours of didactic and simulated case role play training in CBT principles, depression assessment and cultural competency.
2861977|NCT03515226|Experimental|ITS based training|Traditional training plus the addition of an algorithmic based training computer program that trains clinicians in clinical micro-competencies.
2861978|NCT03515213|Active Comparator|Active|
2861979|NCT03515213|Placebo Comparator|Placebo|
2861980|NCT03515200|Experimental|Treatment|"This study will be done in two parts: Part 1: Dose escalation and Part 2: Dose expansion.~In Part 1 - Dose escalation: Patients that lack Ph+ or Ph-like ALL, Palbociclib, initially at 50mg/m2/day, 40% of the adult MTD, will be administered on Days 1-5 and 11-15, and escalated based on tolerability.~In Part 2 - Dose expansion: After determination of dose in Part 1, an additional 10 patients will be enrolled to confirm tolerability."
2861981|NCT03515187|Experimental|A1 Medicine treatment group|0.3%sodium hyaluronate ophthalmic solution + 0.1 sodium bromide solution, 28 days
2861982|NCT03515187|Experimental|A2 Combined treatment group|0.3%sodium hyaluronate ophthalmic solution + 0.1 sodium bromide solution，with meibomian gland massage , 28 days
2861983|NCT03515187|Placebo Comparator|B1 Control group|Placebo
2861984|NCT03515187|Experimental|B2 Experiment group|0.3%sodium hyaluronate ophthalmic solution, 12 months
2861985|NCT03515174|Experimental|Interventional Program|Patients will participate in a structured supportive care program.
2861986|NCT03515174|Active Comparator|Control Group|Patients in the control group will receive usual care.
2861987|NCT03515161|Experimental|Closed-loop|Study patients will receive a baseline crystalloid infusion of 3 cc/kg/hr and all additional fluid management will be performed manually using the assisted fluid management sofware from the EV1000 monitor. A closed-loop system will automatically administer vasopressor based on the predefined target MAP chosen by the anesthesiologist in charge of the patient
2861988|NCT03515148|Experimental|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion. Previously subjects should cold their leg in ice water during sexteen minutes at a temperature of 8ºC (+/-2ºC)
2861989|NCT03515148|Experimental|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
2861990|NCT03515135|Experimental|Intervention group|"Subjects in this group will receive the Metacognitive Executive Function Training (MEFP) program in aiming to reduce ADHD symptoms and improve the executive function."
2861991|NCT03515135|No Intervention|Waiting group|Subjects in this group will not receive the MEFP program during the study period.
2861993|NCT03515122||Matched control group|A matched control group of the general population at a ratio of 3-4 to each person with SCI will be recruited from the Swedish Cardiopulmonary and Bioimage Study.
2861994|NCT03515109|Active Comparator|group A|Altis tape surgical placement
2861995|NCT03515109|Placebo Comparator|group B|TVT transobturator tape placement
2861996|NCT03515096|Experimental|Eltrombopag|Thrombopoietin- receptor (TPO-R) agonist
2861997|NCT03515096|Placebo Comparator|rhTPO|Recombinant human thrombopoietin (rhTPO)
2861998|NCT03515083|Experimental|Experimental|"In the experimental group, each patient will be issued an AliveCor Kardia electrocardiogram monitor that is compatible with their smartphone. Patients will be instructed on the use of the monitor at the initial visit with the study nurse. The patient will submit daily electrocardiogram transmission via on online portal. The study nurse may contact them via text message to remind them to submit their recordings, if they forget.~The remainder of the treatment of the experimental group will be identical to the control group. At the conclusion of the study, the patient will complete their final atrial fibrillation symptom assessment scale. Their smartphone electrocardiogram monitor will be reviewed to ensure that all of the recordings were retrieved successfully."
2861999|NCT03515083|No Intervention|Control|"Patients in the control group would receive the standard of care treatment for atrial fibrillation, including cardioversion and ablation as indicated. At monthly visits with the study nurse, a smartphone electrocardiogram monitor will be used to record patient's heart rhythm. No other intervention would be performed during the monthly visit. It is necessary to meet the subject at least once per month to receive the previous month's supply of pills and provide them with the next month's supply of pills. If these subjects were met less frequently, it is possible that the previous month's supply of pills might be lost by the end of the study.~During the study, if the patient is taken off anticoagulation due to medical contraindication or after an ablation, they will continue to be followed monthly but will not receive apixaban medication."
2862000|NCT03515057|Experimental|Atrial Fibrillation Spot-Check|For eligible patients from primary care clinics randomly selected for the Atrial Fibrillation Spot-Check arm, practice medical assistants will screen assenting patients for undiagnosed AF during regularly scheduled office visits using a single-lead handheld electrocardiogram (ECG). Single-lead handheld electrocardiogram readings detecting AF will be confirmed during the same office visit with a standard 12-lead ECG at the discretion of the primary care physician. If AF is detected, the patient's PCP will be able to address the condition with them during the clinic visit and initiate appropriate follow-up to manage the AF.
2862001|NCT03515057|No Intervention|Usual Care|For eligible patients from primary care clinics randomly selected for the Usual Care arm, they will receive standard care during outpatient visits without change.
2862002|NCT03515044|Experimental|Cohort 1 40 mg Rifaximin SSD once daily|40 mg Rifaximin immediate release (IR) rifaximin SSD once daily (QD) and lactulose
2862003|NCT03515044|Experimental|Cohort 2 40 mg Rifaximin SSD twice daily|40 mg Rifaximin immediate release (IR) rifaximin SSD twice daily (BID) and lactulose
2862004|NCT03515044|Experimental|Cohort 3 80 mg Rifaximin SSD once daily|80 mg Rifaximin sustained extended release (SER) rifaximin SSD once daily (QD) and lactulose
2862005|NCT03515044|Experimental|Cohort 4 80 mg Rifaximin SSD twice daiy|Cohort 4 80 mg Rifaximin SSD twice daily (BID) and lactulose
2862006|NCT03515044|Experimental|Cohort 5 Placebo twice daily|SSD placebo twice daily (BID) and lactulose
2862007|NCT03515031|Experimental|High Flow Nasal Cannula Oxygenation|High Flow Nasal Cannula Oxygenation with a minimum flow ≥ 60L / min, and an FiO2 such as to maintain a SpO2 ≥ 92% for at least 48 hours until clinical stability
2862008|NCT03515031|Active Comparator|Venturi Mask Oxygenation|Venturi Mask Oxygenation, with an FiO2 such as to maintain an SpO2 ≥ 92% for at least 48 hours until clinical stability
2862009|NCT03515018|Experimental|Hydroxyurea|Drug: hydroxyurea, pulse therapy
2862010|NCT03515018|Active Comparator|imatinib|Drug: imatinib, 400mg PO per day
2862011|NCT03515005|Experimental|Lay Health Advisors|Intervention patients will meet monthly in small groups with a trained Lay Health Advisor.
2862012|NCT03515005|No Intervention|Usual Care|Control patients will receive usual care from their doctors.
2862013|NCT03514992|Experimental|Sensory Motor Lateralization (SML)|This was a group of 8 junior high school students who received SML in school for handwriting difficulty during the 2012-13 School Year. The participants received left eye-and-ear occlusion, fitness exercises, fine motor speed training, and handwriting practice on their right hand only.
2862014|NCT03514992|Active Comparator|Conventional School-Based OT (CON)|This was a group of 8 junior high school students who received conventional school-based Occupational Therapy service for handwriting difficulty during the 2012-13 School Year. The participants received a like fitness exercises, fine motor speed training, and handwriting practice on their dominant hand instead.
2862015|NCT03514979|Experimental|AAV patients treated with rituximab|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
2862016|NCT03514979|Experimental|AAV patients - never received rituximab|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
2862017|NCT03514979|Experimental|Healthy controls|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
2862018|NCT03514966|No Intervention|Conventional group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the conventional group will receive no intervention. Thirty and 40 min after dimethicone administration, subjects will additionally take 200 ml and 800 ml water, respectively, and undergo MCE examination.
2862019|NCT03514966|Experimental|Position change group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
2862020|NCT03514953|Experimental|Reduced Physical Activity|Participants will reduce their physical activity level by >5000 steps per day for two weeks.
2862134|NCT03514290|Placebo Comparator|GPLACEBO|the laser tip was positioned without the emission of light (placebo effect) + tooth bleaching with 35% hydrogen peroxide (HP).
2862021|NCT03514927|Experimental|Treatment (HIFU, radical prostatectomy)|"HIFU PHASE: Participants undergo mpMRI and CEUS pre-HIFU treatment and then CEUS post-HIFU treatment. Participants then undergo HIFU treatment over 2-2.5 hours.~PROSTATECTOMY PHASE: Within 2-4 weeks post-HIFU treatment, participants undergo mpMRI 1-2 days prior to radical prostatectomy. On the day of surgery, participants undergo CEUS prior to radical prostatectomy."
2862022|NCT03514914|Experimental|CHARM2 Intervention|CHARM2 intervention will involve gender, culture & contextually-tailored family planning and gender equity counseling for married couples. Two sessions for men delivered by male health providers and two sessions for women delivered by ANMs.
2862023|NCT03514914|No Intervention|Control|Control clusters will receive standard of care.
2862024|NCT03514901|Experimental|Experimental combination beyond Focal Progression|Local treatment (i.e. surgery, radiotherapy) + Vemurafenib 240mg tablets (4 tabs/twice daily for 28 consecutive days) + Cobimetinib 20mg tablets (3 tabs/day for 21 consecutive days) beyond focal progression.
2862025|NCT03514901|Active Comparator|Pembrolizumab or Nivolumab|Pembrolizumab daily dose 2 mg/kg milligram(s)/kilogram or Nivolumab daily dose 3 mg/kg milligram(s)/kilogram.
2862026|NCT03514888|Experimental|HIPEC after Radical Cystectomy|After completion of radical cystectomy, HIPEC will be administered using closed abdomen technique for a duration of 60 minutes.
2862027|NCT03514875|Experimental|MitoQ-Placebo|Subjects will be tested on two different days, first day will be baseline and MitoQ intake, and second day will be placebo intake. Testing will take place 40-minutes after MitoQ and placebo intake. There will be a 2-week washout between testing days.
2862028|NCT03514875|Experimental|Placebo-MitoQ|Subjects will be tested on two different days, first day will be baseline and placebo intake, and second day will be MitoQ intake. Testing will take place 40-minutes after placebo and MitoQ intake. There will be a 2-week washout between testing days.
2862029|NCT03514862|Experimental|Intervention|Participants will participate in 4 weeks of the Mindfulness-Based Intervention (MBI) and then will be invited to continue to participate in 4 additional Mindfulness Booster Training.
2862030|NCT03514862|Active Comparator|Control|Participants will participate in 4 weeks of the Mindfulness-Based Intervention (MBI) and then continue to Self-Practice for 4 weeks.
2862031|NCT03514849|Experimental|PCI group|
2862032|NCT03514849|Placebo Comparator|Control group|
2862033|NCT03514836|Experimental|DCVac and ONCOS-102|ONCOS-102 is given intra-tumor up to 4 times, cyclophosphamide is given prior to the first dose of ONCOS-102 and at the fifth week of treatment DCVac is given sc every 21-28 days for up to 10 doses
2862034|NCT03514823|Experimental|IMT Group|
2862035|NCT03514823|Sham Comparator|No IMT Group|
2862036|NCT03514810|Placebo Comparator|Sertralin & Ketoprofen in MDD|To compare the median of Beck Depression Inventory-II (BDI-II) score of MDD patients after treatment with sertralin (50mg) daily+placebo and after treatment with combination of (sertralin & ketoprofen) for two months.
2862037|NCT03514810|Experimental|Interleukins in MDD after treatment|Some Interleukines level were estimated before and after treatment with sertralin 50 mg in combination with either placebo or ketoprofen 100mg daily.
2862038|NCT03514797|Experimental|Combined technique|A single session of in-office tooth bleaching will be performed with 35% hydrogen peroxide for 45 minutes. Following, the teeth will be further bleached with customized trays filled with 10% carbamide peroxide and used for 1h per day.
2862039|NCT03514797|Active Comparator|At-home bleaching|The teeth will be bleached only with customized trays filled with 10% carbamide peroxide and used for 1h per day.
2862040|NCT03514784|Active Comparator|BB-12 with LGG (Lower Dose)|BB-12 with LGG (Multistrain probiotic; lower dose): 2 billion CFUs
2862041|NCT03514784|Placebo Comparator|Placebo|Maltodextrin
2862042|NCT03514784|Active Comparator|BB-12 with LGG (Higher Dose)|BB-12 with LGG (Multistrain probiotic: higher dose): 10 billion CFUs
2862043|NCT03514771|Other|All Subjects|All subjects will have one side of their face treated with the laser and one side not treated to serve as the control.
2862044|NCT03514758|Experimental|normal hearing participants|normal hearing participants with and without hearing aids
2862045|NCT03514745|Active Comparator|GlideScope group|After the induction of anesthesia, endobronchial intubation is performed using the GlideScope.
2862046|NCT03514745|Experimental|Lighted stylet group|After the induction of anesthesia, endobronchial intubation is performed using a lighted stylet.
2862047|NCT03514732|Experimental|Novanuit® Triple Action|2 capsules of Novanuit® Triple Action once daily for 2 weeks, 30 minutes to 1 hour before bedtime.
2862048|NCT03514719|Experimental|89Zr-avelumab PET|89Zr-avelumab injection followed by 89Zr-avelumab PET
2862049|NCT03514706|Experimental|Volume controlled ventilation|Group V: Patients will receive volume controlled mechanical ventilation. (Vt 7ml/kg ideal body weight).
2862050|NCT03514706|Experimental|Pressure controlled ventilation|Group P: Patients will receive pressure controlled mechanical ventilation. (to achieve Vt 7 ml/kg ideal body weight, Pmax 30 cmH2O)
2862051|NCT03514693|Active Comparator|PVI alone|PVI, and ablation for AF triggers from non-PV foci, the cavotricuspid isthmus, clinical coexisting tachyarrhythmia such as atrial flutter (AFL), atrial tachycardia (AT), and supraventricular tachycardia, if necessary
2862052|NCT03514693|Placebo Comparator|PVI plus additional ablation|PVI, additional CFAE or linear ablation after PVI, and ablation for AF triggers from non-PV foci, the cavotricuspid isthmus, clinical coexisting tachyarrhythmia such as atrial flutter (AFL), atrial tachycardia (AT), and supraventricular tachycardia, if necessary
2862053|NCT03514680|No Intervention|Period I|-Consented patients will complete electronic versions of the PRO-CTCAE CIPN severity and interference items, 0 - 10 worst CIPN pain numerical rating scale, and QLQ-CIPN20 via tablet prior to their clinician visit at the outpatient oncology center at the baseline, six week, and 12 week time points.
2862054|NCT03514680|Experimental|Period II|"Consented patients will complete the same battery of assessments from the usual care period at the baseline, six week, and 12 week time points.~Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm"
2862055|NCT03514667|Active Comparator|intervention group|80 mg nanomicielle curcumin capsules once a day for 12 weeks
2862056|NCT03514667|Placebo Comparator|control group|placebo capsules once a day for 12 weeks
2862057|NCT03514654|Active Comparator|Mastectomy +/- reconstruction|Either a simple mastectomy or skin sparing mastectomy technique will be used. Women in this arm will be offered either immediate or delayed breast reconstruction according to standard practice. Reconstructions will be followed by chemotherapy and/or endocrine therapy as determined by local clinicians . Chest wall and/or regional nodal radiotherapy will be prescribed according to local centre policy.
2862058|NCT03514654|Active Comparator|Therapeutic Mammoplasty|"Therapeutic Mammoplasty (TM) comprises well-established surgical techniques involving volume displacement using breast reduction techniques, or volume replacement to maximize the volume of tissue that can be excised resulting in effective local control whilst maximizing cosmetic outcomes. This group will either have one disease site lumpectomy in the case of multifocal tumours or distant disease site lumpectomies in multicentric cancers."
2862059|NCT03514641|Other|Sequence 1|Period 1: Placebo Period 2: Bexagliflozin Period 3: Bexagliflozin
2862060|NCT03514641|Other|Sequence 2|Period 1: Placebo Period 2: Bexagliflozin Period 3: Placebo
2862061|NCT03514641|Other|Sequence 3|Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Bexagliflozin
2862062|NCT03514641|Other|Sequence 4|Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Placebo
2862063|NCT03514628|Experimental|Valsalva Assist Device (VAD)|Intervention is the use of Valsalva Assist Device (VAD) to deliver the Valsalva strain
2862064|NCT03514628|Active Comparator|Standard Care|Intervention is the use of Standard technique to deliver Valsalva strain eg blowing on empty syringe
2862065|NCT03514615|Placebo Comparator|Placebo Gel|Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active gel and the other placebo.
2862066|NCT03514615|Experimental|Active Gel|Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active gel and the other placebo.
2862067|NCT03514602|Experimental|Multicomponent behavioral intervention|The multicomponent intervention group will receive education and counseling, monitoring and feedback, contingent financial incentives, and family support.
2862068|NCT03514602|Active Comparator|Control|The control group will receive smoking cessation education only.
2862069|NCT03514589|Active Comparator|Arm 1|250 mcg IV synacthen
2862070|NCT03514589|Experimental|Arm 2|Nasal Synacthen
2862071|NCT03514576|Experimental|Pasireotide75|75 micrograms Pasireotide 0.3 MG/ML s.c. before a meal tolerance test (MTT)
2862072|NCT03514576|Experimental|Pasireotide150|150 micrograms Pasireotide 0.3 MG/ML s.c. before a meal tolerance test (MTT)
2862073|NCT03514563||Group A|MRI imaging, Optical scan and 3D photography for patients with Class I (non-skeletal) malocclusion with no facial asymmetry or other pathology.
2862074|NCT03514563||Group B|MRI imaging, Optical scan and 3D photography for patients with Class III (skeletal-based) malocclusion with maxillary deficiency and normal vertical facial relationships, with no facial asymmetry or other pathology
2862075|NCT03514563||Group C|MRI imaging, Optical scan and 3D photography for patients with Cleft lip and/or palate and a Class III malocclusion and no other pathology
2862076|NCT03514550|Experimental|total intravenous anesthesia|Patients, scheduled for nephrectomy for kidney cancer will receive neuraxial epidural block and propofol for perioperative anesthesia
2862077|NCT03514550|Active Comparator|Volatile anesthesia|Patients, scheduled for nephrectomy for kidney cancer will receive neuraxial epidural block and sevoflurane for perioperative anesthesia
2862078|NCT03514537|Experimental|Lipoaspiration|Closed microcannula harvesting of small volume of subdermal adipose tissue, including the stromal cellular and stromal tissue using sterile, disposable, microcannula system
2862079|NCT03514537|Experimental|Isolation & Concentration of cSVF|Isolation and Concentration of cellular stromal vascular fraction (cSVF) using a Healeon Medical CentriCyte 1000 centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocols
2862080|NCT03514537|Experimental|Delivery cSVF via Intravenous|cSVF from Arm 2 is suspended in a 500cc of sterile Normal Saline and deployed through 150 micron in-line filtration and intravenous route over 30-60 minute time frame.
2862081|NCT03514524|Experimental|healthy ageing|
2862082|NCT03514524|Experimental|TBI|
2862083|NCT03514524|Experimental|CTE|
2862084|NCT03514524|Experimental|Ischemic stroke|
2862085|NCT03514524|Experimental|aMCI and MBI|
2862086|NCT03514511|Experimental|Cohort 1 in healthy subjects|LEO 138559 (dose regiment 1) or LEO 138559 placebo
2862087|NCT03514511|Experimental|Cohort 2 in healthy subjects|LEO 138559 (dose regiment 2) or LEO 138559 placebo
2862088|NCT03514511|Experimental|Cohort 3 in healthy subjects|LEO 138559 (dose regiment 3) or LEO 138559 placebo
2862089|NCT03514511|Experimental|Cohort 4 in healthy subjects|LEO 138559 (dose regiment 4) or LEO 138559 placebo
2862090|NCT03514511|Experimental|Cohort 5 in healthy subjects|LEO 138559 (dose regiment 5) or LEO 138559 placebo
2862091|NCT03514511|Experimental|Cohort 6 in healthy subjects|LEO 138559 (dose regiment 6) or LEO 138559 placebo
2862092|NCT03514511|Experimental|Cohort 7 in healthy subjects|LEO 138559 (dose regiment 7) or LEO 138559 placebo
2862093|NCT03514511|Experimental|Cohort 8 in subjects with atopic dermatitis|LEO 138559 (dose regiment 8) or LEO 138559 placebo
2862094|NCT03514511|Experimental|Cohort 9 in subjects with atopic dermatitis|LEO 138559 (dose regiment 9) or LEO 138559 placebo
2862095|NCT03514498||Autism Spectrum Disorder|Children aged 4-12 years with a clinical diagnosis of mild-to-moderate Autism Spectrum Disorder undergoing dental surgery
2862096|NCT03514498||Typically Developed Controls|Children with no neurodevelopmental delays matched to Autism Spectrum Disorder participants according to age (within 6 months), gender, and ASA physical status level, scheduled to undergo dental surgery
2862097|NCT03514485|Active Comparator|P+S- (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the primary care intervention Yes We Can Children's Asthma Program.
2862098|NCT03514485|Active Comparator|P-S+ (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the school intervention Open Airways for Schools Plus.
2862135|NCT03514290|Experimental|GLASER|treated with Low-lever laser + tooth bleaching with 35% hydrogen peroxide (HP).
2862099|NCT03514485|Active Comparator|P+S+ (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the enhanced school intervention Open Airways for Schools Plus, School-Based Asthma Therapy and the primary care intervention Yes We Can Children's Asthma Program.
2862100|NCT03514485|No Intervention|P-S- (Partner School)|This arm includes children who attend one of the partnering schools, and are randomized to the control group (no primary care or school intervention).
2862101|NCT03514485|Active Comparator|P+ (Non-Partner School)|This arm includes children who do not attend one of the partnering schools and who are randomized to receive the primary care intervention Yes We Can Children's Asthma Program.
2862102|NCT03514485|No Intervention|P- (Non-Partner School)|This arm includes children who do not attend one of the partnering schools and who are randomized to the control group (no primary care intervention and ineligible for the school intervention).
2862103|NCT03514472|Active Comparator|Group A (Below 18 years)|Dried Moringa oleifera leaves (15g/recipe)
2862104|NCT03514472|Active Comparator|Group B (Above 18)|Dried Moringa oleifera leaves (15g/recipe)
2862105|NCT03514459|No Intervention|Control|Control clinics: Clinics randomized to the control arm will continue usual procedures. Periodic evaluation of cervical cancer screening rates will be examined every 3 months using FP register data.
2862106|NCT03514459|Experimental|Intervention with SAIA|Clinics randomized to the intervention arm will be introduced to the five steps of SAIA by study staff. The cascade analysis will be performed within the FP clinic to identify drop-offs in cervical cancer screening and referrals, using an Excel-based tool adapted from previous SAIA trials. Flow mapping performed by clinic and study staff will describe the cervical cancer screening process including who the client interacts with, timing of these interactions, any cervical cancer screening performed, and any referrals made. Initial drafts will be reviewed together with clinic and study stuff to ensure adequate and complete representations of processes. Study staff will work with clinic staff to identify bottlenecks in the process and potential solutions to improve flow. Proposed solutions will be implemented, and the process will be examined again to determine the effect of the implemented changes. The cycle will be repeated approximately every 6-8 weeks during the RCT.
2862107|NCT03514446|Experimental|Antibiotic therapy duration for 7 days|
2862108|NCT03514446|No Intervention|Antibiotic therapy duration for 14 days|
2862109|NCT03514433|No Intervention|Historical Control|This study will be utilizing electronic health record data to identify patients that match the TRIP eligibility criteria and received patient navigation prior to study rollout in June 2018. These patients will receive standard patient navigation at their care site and will act as historical controls in comparison to the TRIP experimental group.
2862110|NCT03514433|Experimental|TRIP Patient Navigation Intervention|This study will be enhancing current patient navigation at the participating 6 hospitals with the 3 components of the TRIP intervention (a shared patient registry, a social determinants of health platform, and additional training and support for Patient Navigators). All patients that are identified as TRIP eligible will receive these intervention benefits and will be categorized into the experimental arm of the study.
2862111|NCT03514420|Experimental|AKCEA-ANGPTL3-LRX Dose 1|
2862112|NCT03514407|Experimental|INCB059872|INCB059872
2862113|NCT03514394|Active Comparator|Problem Solving Therapy (PST)|6 weekly sessions to teach patients seven steps of problem solving (problem orientation, problem definition, goal setting, brain storming, decision making, action planning, solution evaluation).
2862114|NCT03514394|Experimental|Modified PST|This intervention will be a modification of PST, based on clinician feedback. It will be developed in phase 1 and 2 of this study. It will include elements of cognitive processing therapy, behavioral activation and distress tolerance. Anticipated number of sessions is 6.
2862115|NCT03514381|Other|Patients starting a treatment with Doxorubicin and Ifosfamide|
2862116|NCT03514368|Other|Patients treated with immune checkpoint blockade|
2862117|NCT03514355|Experimental|Intervention|Mindfulness-Based Stress Reduction (MBSR) is a program intended to draw upon the group's shared experiences to facilitate the development of mindfulness. MBSR is offered in 2.5-h classes on a weekly basis for 8 consecutive weeks, with a retreat day in between classes 6 and 7. This day involves guided meditations, allowing for continuity in practice. Classes include specific exercises (e.g. identifying thoughts, emotions and body sensations associated with illness); these are then extended as homework and discussed in the subsequent class. The curriculum themes and content are arranged week by week to reflect these principles.
2862118|NCT03514355|No Intervention|Control|The control group will receive usual care, with no treatment restrictions. Treating physicians will be informed of CES-D results. Patients will be asked to fulfill the same clinical assessment and questionnaires, and to provide the same biosamples than those patients in the intervention.
2862119|NCT03514342||Interscalene brachial plexus block|Ultrasound-guided interscalene brachial plexus block with 25 ml to 30 ml of 0.75% ropivacaine
2862120|NCT03514329|Experimental|Vapor Ablation|Patients treated with Bronchoscopic Thermal Vapor Ablation for lung cancer
2862121|NCT03514316|Active Comparator|Scalpel Gingivectomy|Patients treated with Scalpel Gingivectomy on the labial side of the anterior maxillary teeth
2862122|NCT03514316|Active Comparator|Laser Gingivectomy|Patients treated with Laser Gingivectomy on the labial side of the anterior maxillary teeth
2862123|NCT03514316|Active Comparator|Nonsurgical periodontal treatment|Patients treated with a full-mouth periodontal debridement
2862124|NCT03514303||Ragweed|Subjects will test positive or negative to the allergen Ragweed.
2862125|NCT03514303||Timothy Grass|Subjects will test positive or negative to the allergen Timothy Grass.
2862126|NCT03514303||Johnson Grass|Subjects will test positive or negative to the allergen Johnson Grass.
2862127|NCT03514303||Bermuda Grass|Subjects will test positive or negative to the allergen Bermuda Grass.
2862128|NCT03514303||Cladosporium|Subjects will test positive or negative to the allergen Cladosporium.
2862129|NCT03514303||Cat Dander|Subjects will test positive or negative to the allergen Cat Dander.
2862130|NCT03514303||Cockroach|Subjects will test positive or negative to the allergen Cockroach.
2862131|NCT03514303||Dust Mite|Subjects will test positive or negative to the allergen Dust Mite.
2862132|NCT03514303||Oak|Subjects will test positive or negative to the allergen Oak.
2862133|NCT03514303||Dog Dander|Subjects will test positive or negative to the allergen Dog Dander.
2862139|NCT03514264|Experimental|GUTTA PERCHA and AHPLUS cement (group A)|43 patients will undergo endodontic treatment with obturation with AHPlus cement and Gutta-Percha cones. This treatment will be performed in 2 sessions. First intervention: endodontic instrumentation and introduction of intra-canal medication that will remain in the tooth for 4 weeks. Second intervention: removal of intracanal medication and filling with cement and gutta percha AHPlus.
2862140|NCT03514264|Experimental|PBS CIMMO cement (group B)|43 patients will undergo endodontic treatment with PBS CIMMO® cement (single material).This treatment will be performed in 1 session.Single intervention: endodontic instrumentation and cement filling PBS CIMMO.
2862141|NCT03514251|No Intervention|Control group|Routine thyroidectomy and central lymph node dissection
2862142|NCT03514251|Experimental|Parathyroid marker group|When the lower parathyroid gland is first seen, the parathyroid gland is sutured with a suture during the operation, and then during this subsequent cleaning, rapid parathyroid localization and parathyroid glands are performed through this marker.
2862143|NCT03514238|Experimental|Adults (BMI: ≥30 kg/m2)|"Obese individuals will participate to three conditions:~Control Sitting Condition (C), Sitting for 35 minutes Acute Bout of Continuous Moderate Aerobic Exercise (MOD) 50-55% of heart rate reserve Acute Bout of High Intensity Interval Aerobic Exercise (HIIT) 85-90% heart rate reserve"
2862144|NCT03514238|Experimental|Adults (BMI: 18.5-24.9 kg/m2)|"Normal weight individuals will participate to three conditions:~Control Sitting Condition (C), Sitting for 35 minutes Acute Bout of Continuous Moderate Aerobic Exercise (MOD) 50-55% of heart rate reserve Acute Bout of High Intensity Interval Aerobic Exercise (HIIT) 85-90% heart rate reserve"
2862145|NCT03514225|Other|Metacognitive Therapy for Social Anxiety|Exact sessional content of the MCT intervention is likely to involve attention training and situational attentional refocussing techniques, verbal reattribution strategies aimed to facilitate a reduction of self-processing strategies and to challenge metacognitive beliefs, and between-session tasks for participants to practice at home.
2862146|NCT03514212|Experimental|ProActiveS|As this was a feasibility study, all participants received the intervention.
2862147|NCT03514199|Experimental|Mediterranean-type diet|Recommends high consumption of whole grains, vegetables, nuts, fruits, vegetables and olive oil as the main source of fat used for salads. Moderate to high fish consumption and low consumption of red and processed meats. Poultry and dairy products (such as yogurt or cheese) will be consumed in small quantities and moderate consumption of alcohol, usually in the form of red wine, will be recommended with meals for usual drinkers.
2862148|NCT03514199|Active Comparator|Low fat diet|It recommends reducing the intake of foods rich in fats, especially those saturated and hydrogenated.
2862149|NCT03514186|Experimental|Intensive Comprehensive Aphasia Program|60 hours of comprehensive speech and language therapy applied intensively, 4 hours per day, 5 days a week for three weeks.
2862150|NCT03514186|Active Comparator|Distributed Comprehensive Aphasia Tx|60 hours of comprehensive speech and language therapy distributed over 15 weeks (i.e. two 2-hour visits per week).
2862151|NCT03514160|Active Comparator|Group exercise|Group exercise training at a community site. Exercises included supervised upper and lower-body strength and balance exercises twice per week. Hand-made, weighted bars were used for resistance props and balance. The exercises included: chair squats; standing single leg hip abduction; hip extension; balance heal-to-toe walking; seated hip adduction and knee extension; wall push-ups; bent-over rows; shoulder press; elbow flexion and extension).
2862152|NCT03514160|No Intervention|Attention-Control group|Attendance to community site usual activities offered to older adults. Participants in this group were offered the exercise routine after completing the 12-week study.
2862153|NCT03514147|Experimental|Experimental|Pelvic Floor Muscle Training in group. Exercise Protocol: The exercise group was supervised and met for 1 hour, one time per week, for 12 weeks. Participants were instructed to perform their respective daily exercises.
2862154|NCT03514147|Active Comparator|Control|Pelvic Floor Muscle Training in home Exercise Protocol:The same exercise were performed at home for 12 weeks, without supervision. Participants were instructed to perform their respective daily exercises.
2862155|NCT03514134|Experimental|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual comparator, participants will participate in Virtual Reality Job Interview Training.
2862156|NCT03514134|Active Comparator|Services as Usual|Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
2862157|NCT03514121|Experimental|Phase 1a dose escalation|The study consists of Phase 1a dose escalation, Phase 1a dose exploration and Phase 1b dose expansion
2862158|NCT03514108|Active Comparator|Hydralazine Isosorbide Dinitrate|"Tablet BiDil (Hydralazine 37.5 mg/ isosorbide dinitrate (ISDN) 20 mg) 2 tablets x 3 daily.~Average treatment period 4 years."
2862159|NCT03514108|Placebo Comparator|Placebo (Hydralazine Isosorbide Dinitrate)|Tablet Placebo 2 tablets x 3 daily. Average treatment period 4 years.
2862160|NCT03514108|Active Comparator|Metformin|Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily). Average treatment period 4 years.
2862161|NCT03514108|Placebo Comparator|Placebo (Metformin)|Tablet Placebo 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily). Average treatment period 4 years.
2862162|NCT03514095|No Intervention|Control Group|The control group shall participate in the usual home-based care provided by their carer.
2862163|NCT03514095|Experimental|Individual Cognitive Stimulation Therapy|The experimental group shall participate in the Making a Difference 3 program (Yates et al., 2015) is aimed at elderly people with mild or major neurocognitive disorder, where informal caregiver (family, friend or neighbour) assume a partnering role in an one-to-one approach. The program is composed by a range of stimulating activities (sessions), each with two levels of difficulty. The carers are introduced to a set of key principles that guides them during individual cognitive stimulation sessions, tailoring the interventions to the needs and reality of the elderly participants.
2862164|NCT03514082||Adolescent Idiopathic Scoliosis|Subjects with AIS who are beginning to the conservative treatment.
2862165|NCT03514069|Experimental|ruxolitinib + radiation x 60 Gy for 6 weeks|Unmethylated O6-methylguanine DNA methyltransferase (MGMT) Glioblastoma and grade III glioma Every patient gets ruxolitinib + radiation x 60 Gy for 6 weeks over 6 weeks. The dose of radiation therapy is fixed at 60 Gy over 6 weeks
2862520|NCT03511651|Experimental|FRC at clinical PEEP + 5cmH2O|Increasing PEEP to clinical PEEP + 5cmH2O
2862166|NCT03514069|Experimental|ruxolitinib + radiation x 60 Gy + temozolomide 75 mg/m|"Methylated MGMT Glioblastoma and grade III glioma. Arm 2 will start once the safe dose has been established for Arm 1 for every dose level.~Every patient gets ruxolitinib + radiation x 60 Gy + daily temozolomide at 75 mg/m2 for 6 weeks over 6 weeks.~The dose of radiation therapy is fixed at 60 Gy over 6 weeks (2 Gy x 30). The dose of temozolomide is 75 mg/m2 daily for 6 weeks"
2862167|NCT03514056||1|group Behcet
2862168|NCT03514056||2|group fibromyalgia
2862169|NCT03514043||Ambulatory care surgical patients|Patients who have attended the surgical assessment unit with an emergency general surgical condition and have their care completed without an inpatient stay.
2862170|NCT03514030||positive|serum AQP4-antibody is positive
2862171|NCT03514030||negtive|serum AQP4-antibody is negtive
2862172|NCT03514017|Experimental|Pembrolizumab and Ibrutinib|"Treatment with pembrolizumab and ibrutinib and follow-up period of up to 24 months.~Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.~Ibrutinib is an inhibitor of Bruton's tyrosine kinase (BTK). Ibrutinib is a small-molecule inhibitor of BTK."
2862173|NCT03514004|Experimental|Intervention|"The ICT-based intervention is known as Project Clan. Each participant randomized to the intervention group will have access to the web platform and mobile applications of Project Clan - a virtual community that seeks to promote adolescent mental health and wellbeing as students interact, express themselves, and resolve concerns, with the support of peers and mental health professionals. During the three-month intervention, participants will have complete anonymity, unless trained psychologists supervising the platform as community counselors identify behaviors associated with suicide risk and proceed to follow an established emergency protocol. The counselors will be available to answer community questions and provide support on an individual basis."
2862174|NCT03514004|No Intervention|Control|Participants in the control group will also be assigned a username and password to access the website, but they will be met with a user interface that only displays a space to answer the corresponding assessments. In addition to the introductory presentation, they will be given a brochure with information regarding adolescent suicide and wellbeing and tips with regard to seeking help and assisting others. This will include the contact information for a telephone hotline, to ensure they can receive professional help if needed.
2862175|NCT03513991|Experimental|IF-VLP (very low protein)|Participants were exclusively fed with an infant formula containing 1g of protein/dL, 26% alpha lactoalbumin, and 100% A2 casein for 4 months.
2862176|NCT03513991|Other|IF-LP (low protein)|Participants were exclusively fed with an infant formula containing 1.3 g of protein/dL, 26% alpha lactoalbumin, 100% A2 casein for 4 months.
2862177|NCT03513991|Other|IF-CSP (control standard protein)|Participants were exclusively fed with an infant formula containing 1.5 g of protein/dL, 50% A1 casein and 50% A2 casein for 4 months.
2862178|NCT03513991|No Intervention|HM (human milk)|Participants were exclusively breastfed
2862179|NCT03513978|Experimental|IAI Protocol|A progressive exercises with transference to sport protocol, oriented to improve the proprioception.
2862180|NCT03513978|Active Comparator|FIFA 11+ Protocol|A typical exercises protocol to soccer
2862181|NCT03513965|Experimental|Symptoms as Side Effects Mindset|Both arms are given identical treatment instructions at their first clinic visit, including practical strategies for taking doses and managing symptoms. Families are given comprehensive instructions for recognizing life-threatening symptoms and administering epinephrine when appropriate. However, information about the implications of non-life-threatening symptoms differs between arms. At the first clinic visit, families are given verbal (e.g., provider explanations) and written information (e.g., brochures on symptom management) informing them about symptoms in different ways. In this arm, families are informed that these non-life-threatening symptoms are an unfortunate part of treatment that must be endured, similar to side effects from common medications.
2862182|NCT03513965|Experimental|Symptoms as Positive Signals Mindset|Both arms are given identical treatment instructions at their first clinic visit, including practical strategies for taking doses and managing symptoms. Families are given comprehensive instructions for recognizing life-threatening symptoms and administering epinephrine when appropriate. However, information about the implications of non-life-threatening symptoms differs between arms. At the first clinic visit, families are given verbal (e.g., provider explanations) and written information (e.g., brochures on symptom management) informing them about symptoms in different ways. In this arm, families are informed that symptoms are a sign that that their bodies are gradually increasing desensitization, similar to having sore muscles after a difficult workout.
2862183|NCT03513952|Experimental|Group 1 (CYT107, atezolizumab)|Participants receive CYT107 IM on days 1, 8, 15, and 22, and atezolizumab IV over 60 minutes on day 8 of cycle 1. Following cycle 1, participants receive atezolizumab IV over 30-60 minutes on day 1. Courses with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2862184|NCT03513952|Experimental|Group 2 (atezolizumab)|Participants receive atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2862185|NCT03513939|Experimental|T1DM Cell Pouch™ Recipients|Eligible Type 1 Diabetes Mellitus (T1DM) subjects with hypoglycemia unawareness and a history of severe hypoglycemic episodes undergoing Sernova Cell Pouch™ intervention
2862186|NCT03513926||Non-OSA group|Patients with out sleep apnea.
2862187|NCT03513926||OSA group|Patients with OSA, without cardiovascular comorbidities who could be treated with Continuous Positive Airway Pressure
2862188|NCT03513926||OSA with hypertension group|Patients with OSA, with hypertension who could be treated with Continuous Positive Airway Pressure
2862189|NCT03513926||OSA with CVE group|Patients with OSA, with a previous ictus or stroke who could be treated with Continuous Positive Airway Pressure
2862190|NCT03513913|Experimental|IVF|Oocytes fertilized by conventional in vitro fertilization (IVF) method
2862191|NCT03513913|Experimental|ICSI|Oocytes fertilized by intracytoplasmic sperm injection (ICSI) method
2862192|NCT03513900||cirrhosis|In this cross-sectional study , we will collect all patients with cirrhosis who meet the inclusion and exclusion criteria criteria coming to The Second Affiliated Hospital, Xi'an Jiaotong University since March 2018 to December 2018.
2862193|NCT03513887||Group/Cohorts|we will prospectively collect patients with liver cirrhosis who fulfill all inclusion criterias and will be treated in the Department of Gastroenterology of the Second Affiliated Hospital of Xi'an Jiaotong University.
2862196|NCT03513861|Experimental|Aim 1: Parental FASTER tool training|The goal is to see whether the child's parent/ guardian can be trained in overall severity of illness assessment using the FASTER Tool, to match the performance of a professional.
2862197|NCT03513861|Active Comparator|Aim 2: Intervention group|The intervention group parents will be taught the FASTER assessment tool. Intervention group parents will each be asked to monitor their own hospitalized child hourly using the FASTER assessment tool, and put up color-coded flags indicating severity of illness to the healthcare team. Parents will record the frequency of healthcare provider assessments of their child over the 24 hour intervention period.
2862198|NCT03513861|No Intervention|Aim 2: Control Group|The control group parents will not be taught the FASTER assessment tool. Hence they will not be involved in monitoring their child, nor signaling severity of their child's illness per color-coded flag system. Control group parents will record the frequency of healthcare provider assessments of their child over the 24 hrs enrollment period.
2862199|NCT03513848|Experimental|Bright Light|
2862200|NCT03513848|Placebo Comparator|Dim Light|
2862201|NCT03513822|Active Comparator|Chronic neuropathic pain and bedsore Ketamine group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).~Patients medullary wounded with chronic pain and ulcer pressure (inflammation factor).~Midazolam 1mg before infusion. KETAMINE INFUSION IVSE 1mg/kg during 2 hours (0,5mg/kg/h). Preparation of 100mg in fifty cc, syringe with 2mg/ml. Rate of administration: Speed = Patient weight divided by four.~Maximum 100mg. One and only perfusion."
2862202|NCT03513822|Placebo Comparator|Chronic neuropathic pain and bedsore Placebo group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).~Patients medullary wounded with chronic pain and ulcer pressure (inflammation factor).~Midazolam 1mg before infusion. Sodium chloride infusion IVSE during 2 hours. Rate of administration : Speed = patient weight divided by four.~One and only perfusion."
2862203|NCT03513822|Active Comparator|Chronic neuropathic pain without bedsore Ketamine group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).~Patients medullary wounded with chronic pain and no ulcer pressure (no inflammation factor).~Midazolam 1mg before infusion. KETAMINE INFUSION IVSE 1mg/kg during 2 hours (0,5mg/kg/h). Preparation of 100mg in fifty cc, syringe with 2mg/ml. Rate of administration: Speed = Patient weight divided by four.~Maximum 100mg. One and only perfusion."
2862204|NCT03513822|Placebo Comparator|Chronic neuropathic pain without bedsore Placebo group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).~Patients medullary wounded with chronic pain and no ulcer pressure (no inflammation factor).~Midazolam 1mg before infusion. Sodium chloride infusion IVSE during 2 hours. Rate of administration : Speed = patient weight divided by four.~One and only perfusion."
2862205|NCT03513809||Acute hypoxemic respiratory failure|Patients with acute hypoxemic respiratory failure breathing spontaneously with no requirements of immediate intubation connected to thoracic electrical impedance tomography.
2862206|NCT03513770|Experimental|Ketorolac|The Wrist-to-Elbow occlusion procedure will be performed followed by 2 ketorolac tromethamine + saline infusions into the occluded arm.
2862207|NCT03513770|Placebo Comparator|Control|The Wrist-to-Elbow occlusion procedure will be performed followed by 2 saline only infusions into the occluded arm.
2862208|NCT03513757|Active Comparator|propofol|Each patient will receive 1 mg/kg lidocaine followed by 2 mg/kg propofol IV once prior to continuous propofol infusion for MRI sedation at 200 mic/kg/min. Dose will be increased by 50 mic/kg/min up to 300 mic/kg/min for movement and decreased to 150 mic/kg/min if no movement after 30 minutes. Additional 1 mg/kg propofol bolus administered at time of each movement. Study to be terminated if movement persists despite above interventions.
2862209|NCT03513757|Experimental|propofol dexmedetomidine|Each patient will receive: 1 mg/kg lidocaine, 2 mg/kg propofol, 4 mic/kg glycopyrrolate and single dose dexmedetomidine administered prior to scan. Dexmedetomidine dose is dependent on expected duration of scan and will be equal to 1 mic/kg/hour x duration of scan in hours. 1 mg/kg propofol will be administered for movement up to 2 times. For continued movement after that, begin propofol infusion at 150 mic/kg/min. Study to be terminated if movement persists despite above interventions.
2862210|NCT03513744|Experimental|infant formula containing five HMOs|
2862211|NCT03513744|No Intervention|infant formula|
2862212|NCT03513744|No Intervention|breast milk group|
2862213|NCT03513731|Experimental|Adipose-derived stem cell injection|ADRC treatment group will receive ADRCs yielded from processing of lipoaspirate by a fluoroscopic-guided injection into the affected segment. The segment will consist of 2 joints per level and up to two levels (no more than 4 joints) injected during the procedure.
2862214|NCT03513731|Active Comparator|Corticosteroid injection|The control group will undergo standard fluoroscopy guided injection of glucocorticoids and local anesthetics.
2862215|NCT03513705|Experimental|Best practice|Enhanced implementation of best practices in pancreatic cancer care
2862216|NCT03513705|No Intervention|Current practice|Pancreatic cancer care according to current practice
2862217|NCT03513692|Active Comparator|Fill-Up composite resin|"In this arm of the study, participants will have the dental restoration completed with FillUp from Coltene, a composite resin a CE marked and licensed restorative material."
2862218|NCT03513692|Active Comparator|Conventional; composite|In this arm of the study, participants will have the dental restoration completed with a conventional composite resin using a CE marked and licensed restorative material.
2862219|NCT03513679|Experimental|Surgical Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
2862220|NCT03513679|No Intervention|Control Group|Gait and balance testing to be administered once in healthy subjects
2862221|NCT03513666|Experimental|treatment arm|
2862222|NCT03513653||Acute heart failure|Patients hospitalized for acute heart failure and underwent echocardiography with speckle-tracking imaging
2862223|NCT03513627||Implant|Post-occlusive reactive hyperaemia test (PORH test) in the gingiva at a dental implant born crown in the front region of the jaw
2862224|NCT03513627||Tooth|Post-occlusive reactive hyperaemia test (PORH test) in the gingiva at the contralateral natural tooth
2862225|NCT03513614|Active Comparator|ALND|Tailored axillary surgery followed by axillary lymph node dissection (ALND) and regional nodal irradiation excluding the dissected axilla.
2862226|NCT03513614|Active Comparator|No ALND|Tailored axillary surgery followed by regional nodal irradiation including the full axilla.
2862227|NCT03513601|Experimental|(R)-CHOP regimen|(R)-CHOP regimen((rituximab)，cyclophosphamide，epirubicin，vincristine and prednisone)，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
2862228|NCT03513601|Experimental|(R)-CVP regimen|(R)-CVP regimen((rituximab)，cyclophosphamide，vincristine and prednisone) The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .
2862229|NCT03513588|Placebo Comparator|Placebo|
2862230|NCT03513588|Experimental|PF-06865571 100 mg|
2862231|NCT03513588|Experimental|PF-06865571 600 mg|
2862232|NCT03513575|Active Comparator|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink."
2862233|NCT03513575|Experimental|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
2862234|NCT03513575|Experimental|Group 3: 0.2% chlorhexidine|"The subject collects unstimulated saliva in a sterile glass dish for measurement of baseline pH of saliva. The subject is then given 100ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will use 10 ml of 0.2% Chlorhexidine mouthrinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected thereafter to measure and record the pH of saliva at 15, 30 and 45 minutes after subject completes the gargle as an intervention."
2862235|NCT03513575|Experimental|Group 4: fluoridated tooth paste|"The subject collects unstimulated saliva in a sterile glass dish for measurement of baseline pH of saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will brush with fluoridated toothpaste (Colgate Total®, Colgate-Palmolive Co., Mumbai, India) for 2 minutes using soft brush. Unstimulated saliva samples are collected thereafter to measure and record the pH of saliva at 15, 30 and 45 minutes after subject completes the brushing as an intervention."
2862236|NCT03513575|Experimental|Group 5: Polyol containing gum|"The subject collects unstimulated saliva in a sterile glass dish for the measurement of baseline pH of saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will chew polyol containing gum (Orbit®, Wrigley Company) for 5 minutes and spit. Unstimulated saliva samples are thereafter collected from to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
2862237|NCT03513575|Experimental|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
2862238|NCT03513562|Experimental|Treatment (venetoclax, ibrutinib)|Participants receive venetoclax PO daily on days 1-28 and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 or 24 courses in the absence of disease progression or unacceptable toxicity. Participants with MRD negativity after 12 or 24 courses discontinue treatment, while participants with MRD positivity continue treatment with venetoclax in the absence of disease progression or unacceptable toxicity.
2862239|NCT03513549||Loxapine 10 MG|ADASUVE (loxapine) inhalation powder in a 10-milligram (mg) single-use oral inhaler. One dose in a 24-hour period.
2862240|NCT03513536|Experimental|Intervention 1|The women in this arm will receive the Citrus-Based Aromatherapy product to apply regularly for 6 days.
2862241|NCT03513536|Experimental|Intervention 2|The women in this arm will receive the Mint-Based Aromatherapy product to apply regularly for 6 days.
2862242|NCT03513536|Experimental|Intervention 3|The women in this arm will receive the Spice-Scented Aromatherapy product to apply regularly for 6 days.
2862243|NCT03513536|Placebo Comparator|Control|The women in this arm will receive a vegetable oil roll-on product to apply regularly for 6 days.
2862244|NCT03513523|Experimental|Group 1: 250 mg NRPT|
2862245|NCT03513523|Experimental|Group 2: 500 mg NRPT|
2862246|NCT03513523|Placebo Comparator|Group 3: Placebo|
2862521|NCT03511638|Experimental|Bausch & Lomb DVisc40|Ophthalmic viscosurgical device
2862247|NCT03513510|Experimental|iChoose|6 biweekly family sessions, 6 biweekly telephone support calls to parents, 6 biweekly newsletters for children, and 3 supervised exercise sessions per week/3 months; delivers intervention to parents and children only
2862248|NCT03513497|Experimental|Periodontal Profile Class (PPC-A)|Periodontally healthy participants (PPC-A) will wear customized acrylic mouthguard only during tooth brushing for 21 days.
2862249|NCT03513497|Experimental|Periodontal Profile Class (PPC-G)|Participants with severe periodontal disease (PPC-G) will wear customized acrylic mouthguard only during tooth brushing for 21 days.
2862250|NCT03513484|Experimental|Treatment (nintedanib, azacitidine)|Participants receive nintedanib PO BID on days 1-28 and azacitidine IV or SC on days 1-7. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, participants may discontinue treatment, receive nintedanib every 4-8 weeks, or receive nintedanib and azacitidine every 4-8 weeks.
2862251|NCT03513471|Experimental|Anakinra then Placebo Treatment|Subjects randomized to this arm will receive the experimental treatment of Anakinra on their first exposure to the Dermatophagoides Farinae (dust mite) allergen challenge, followed by the Anakinra matching placebo on their second exposure.
2862252|NCT03513471|Experimental|Placebo then Anakinra Treatment|Subjects randomized to this arm will receive the inactive placebo on their first exposure to the Dust Mite Allergen challenge, followed by the experimental treatment of Anakinra on their second exposure.
2862253|NCT03513458|Experimental|Anakinra then Placebo|Subjects randomized to this arm will receive the experimental treatment of Anakinra on their first exposure to Dermatophagoides Farinae (dust mite) allergen challenge, followed by the Anakinra matching placebo on their second exposure.
2862254|NCT03513458|Experimental|Placebo then Anakinra|Subjects randomized to this arm will receive the inactive placebo on their first exposure to the Dust Mite Allergen challenge, followed by the experimental treatment of Anakinra on their second exposure.
2862255|NCT03513445|Experimental|Lumbar Spine Surgery with Injection|Patients undergoing lumbar spine surgery will receive a peri-incisional injection of pain medications (morphine, epinephrine, and ropivacaine) during their surgery.
2862256|NCT03513445|No Intervention|Lumbar Spine Surgery without Injection|Patients undergoing lumbar spine surgery will NOT receive a peri-incisional injection of pain medications during their surgery.
2862257|NCT03513432|Experimental|Beer with 5.20 % alcohol|330 ml beer (5.20 % alcohol)/day
2862258|NCT03513432|Experimental|Non-alcoholic beer with 0.45 % alcohol|330 ml non-alcoholic beer (0.45 % alcohol)/day
2862259|NCT03513432|Experimental|Non-alcoholic beer with 0.00 % alcohol|330 ml non-alcoholic beer (0.00 % alcohol)/day
2862260|NCT03513419|Experimental|AMOR Method|The AMOR Method: The parent resilience training involves a series of eight weekly 90-minute group sessions, as well as three individual sessions. Group session content includes training in mindfulness, grief and loss processing, acceptance and committed actions, optimistic thinking, and resilience through the use of didactic training, group discussions, and homework assignments. Individual session content will center on additional and individualized training in grief and loss processing, optimistic thinking, and maintaining resilience over time.
2862261|NCT03513419|No Intervention|Wait List|Participants assigned to the waitlist will continue stable treatments and will be offered the opportunity to participate in the treatment after completion of the 8-week trial.
2862262|NCT03513406|Active Comparator|Sugammadex|Muscle relaxant reversal will be attained with sugammadex 2 mg/kgm IV.
2862263|NCT03513406|Active Comparator|Neostigmine|Muscle relaxant reversal will be attained with neostigmine 50 mcg/kgm plus glycopyrrolate10 mcg/kgm IV.
2862264|NCT03513393|Experimental|A: Epclusa + omeprazole + Coca Cola (test 1)|Day 1 - 6 40mg omeprazole QD; on Day 5 a single-dose of SOF/VEL with 250 mL of Coca Cola Classic is administered (test 1).
2862265|NCT03513393|Experimental|B: Epclusa + omeprazole + water (test 2)|Day 8 - 13: 40mg omeprazole QD; on Day 12 a single-dose of SOF/VEL is administered (test 2).
2862266|NCT03513393|Active Comparator|C: Epclusa + water (Reference)|Day 15 - 21: no treatment with omeprazole; on Day 19 a single-dose of SOF/VEL is administered (reference).
2862267|NCT03513380|Experimental|Exergaming|free access to the exergame PedalTanks
2862268|NCT03513380|No Intervention|Control|recommended to continue with their normal daily routine
2862269|NCT03513367||Boys with Muscular Duchenne Dystrophy|"105 boys with Muscular Duchenne Dystrophy (DMD) distributed as follows: 35 patients with Duchenne muscular dystrophy by age category, 8-12 years old and 13-18 years old.~Children will complete the questionnaire of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale regardless of his parents"
2862270|NCT03513367||Parents of boys with Muscular Duchenne Dystrophy|105 parents of boys with Muscular Duchenne Dystrophy For the 5-7 age group, only parents answer the questionnaire but medical data are collected : 35 by age category (5-7; 8-12; 13-18) Parents will complete the questionnaire of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale regardless of their children
2862271|NCT03513354|No Intervention|Control group|The control group did not perform any of the interventions.
2862272|NCT03513354|Experimental|Soil group|(2) Stretching from the lateral flexors of the cervical spine, elbow flexors and extensors, trunk lateral flexors, flexors and extensors of hip with support of 30 seconds (1x30), (3) aerobic workout through front and lateral gait walking for 20 minutes, (4) resisted exercise for upper limbs (anterior, middle and posterior deltoid, biceps, triceps) and to the lower limbs (abductors, flexors and extensors of hip and flexors and extensors knee, calf), using dumbbells and shin guards for the resistance (20 minutes), (5) balance and proprioception training through front and backward walking on mattresses, march in a straight line with one foot in front of the other, one-feet support orthostatism, touching some points marked on the ground with the toe (15 minutes)
2862273|NCT03513354|Experimental|Pool group|(2) Stretching from the lateral flexors of the cervical spine, elbow flexors and extensors, trunk lateral flexors, flexors and extensors of hip with support of 30 seconds (1x30), (3) aerobic workout through front and lateral gait walking for 20 minutes, (4) resisted exercise for upper limbs (anterior, middle and posterior deltoid, biceps, triceps) and to the lower limbs (abductors, flexors and extensors of hip and flexors and extensors knee, calf), using dumbbells and shin guards for the resistance (20 minutes), (5) balance and proprioception training through front and backward walking on mattresses, march in a straight line with one foot in front of the other, one-feet support orthostatism, touching some points marked on the ground with the toe (15 minutes)
2862274|NCT03513341||Maastricht University First Year Students|Maastricht University 2017-2018 undergraduate first year students are invited to participate in the study. The participants are invited to complete a demographics questionnaire, wear an ActivPAL accelerometer for 7 days, and to complete daily diaries (modified International Physical Activity Questionnaire) for 7 days.
2862275|NCT03513328|Experimental|Group A--Thiotepa single dose|Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
2862276|NCT03513328|Experimental|Group A--Thiotepa escalated dose|Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
2862277|NCT03513328|Active Comparator|Group B--Thiotepa single dose|Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
2862278|NCT03513328|Active Comparator|Group B--Thiotepa escalated dose|Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg)added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
2862279|NCT03513315|Experimental|Intervention Community Clusters|For the community-based arm of the study, 16 clusters will be randomized into intervention and control groups. Those in the intervention group will receive education from community health workers on the signs and symptoms of heat-related illness, how to prevent the illness, and when to seek treatment. In addition, the intervention group will receive SMS messaging with information about heatwaves. The education and Short Message Service (SMS) messaging will occur in March and April via meetings in households and in public spaces. There will be a total of 40 activities, each lasting approximately two hours.
2862280|NCT03513315|Experimental|Control Community Clusters|8 community clusters of 1000 population each where regular community-based healthcare services will be provided without focused interventions on identification and management of heat-related illnesses
2862281|NCT03513302|Placebo Comparator|placebo|
2862282|NCT03513302|Active Comparator|nitrate|
2862283|NCT03513289||Patient, Carer, and Clinician Interviews|This group/cohort consists of patients who experienced critical illness and were hospitalized in an ICU setting.
2862284|NCT03513276|Experimental|Multimodal analgesia + Local Infiltration Anesthesia|100cc of 2% ropivacaine + Adrenaline 10mcg/ml + 20cc saline solution
2862285|NCT03513276|Active Comparator|Multimodal analgesia + saline solution|120cc of saline solution
2862286|NCT03513263|Active Comparator|Scaling and polishing plus oral hygiene instruction|This arm will contain RA participants with PD who will continue with their treatment for RA and also receive the intervention of scaling and polishing plus oral hygiene instructions
2862287|NCT03513263|Sham Comparator|only oral hygiene instructions|This arm will contain rheumatoid arthritis (RA) participants with periodontitis who will continue with their treatment for (RA) and also receive only oral hygiene instructions
2862288|NCT03513250|Experimental|hyoscine-n-butylbromide group|one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
2862289|NCT03513250|Placebo Comparator|control group|the same volume (1 ml) of normal saline intravenously immediately before the end of the cesarean section.
2862290|NCT03513237|Experimental|Cervical dilation group|the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal after extraction of placenta and membranes and will remove the outer gloves after digital dilatation of the cervix.
2862291|NCT03513237|No Intervention|no cervical dilation group|No cervical dilation will be done.
2862292|NCT03513224|Experimental|eDosette|
2862293|NCT03513211|Experimental|Dose escalation arm|Suba-itraconazole in combination dose escalating hydroxychloroquine H
2862294|NCT03513211|Experimental|Phase II: Dose expansion arm|Suba-itraconazole with recommended phase II dose of hydroxychloroquine as determined by phase I arm.
2862295|NCT03513198||Non-resectable pancreatic cancer|"All patients with a suspicion of pancreatic masses will undergo EUS (including EUS-FNA for confirmation of diagnosis). A positive cytological diagnosis will be taken as a final proof of malignancy of the pancreas mass. The diagnoses obtained by EUS-FNA will be further verified during a clinical follow-up of at least 6 months.~Both pancreatic adenocarcinomas and pancreatic neuroendocrine tumors will be included.~Endoscopic ultrasound (including fine needle aspiration for confirmation of diagnosis) with sequential contrast-enhanced endoscopic ultrasound and elastography endoscopic ultrasound and contrast-enhanced computed tomography will be performed before and 2 months after the first course of treatment"
2862296|NCT03513185||Patients with SSD|Patients are diagnosed with SSD by physician according to DSM-5,and will be treated with Deanxit, SSRI or SRNI on the basis of severity assessment by physician.
2862297|NCT03513185||Patients with non-SSD|No SSD is diagnosed by physician according to DSM-5
2862298|NCT03513172|Active Comparator|Brimonidine Pre-Administration During First Visit|
2862299|NCT03513172|Active Comparator|Brimonidine Pre-Administration During Second Visit|
2862300|NCT03513159|Experimental|Pathfinder support|Pathfinder Support with development of an individual care plan for the Intervention patients and their informal caregivers, with the hospital physicians already inside the hospital Setting. This will then be develop and improved further during twelve months after hospital release with the Primary physician. The pathfinders will coordinate the ambulatory care team services and involve closely the primary physicians. The patients and their informal caregivers will be empowered and educated to achieve a stabilization or improvement in functionality, independence, quality of life, coping with disease, nutritional status and wound healing process. In the regular assessments they will be tested for functionality and nutritional parameters, quality of life and stress scores.
2862522|NCT03511638|Active Comparator|Alcon VISCOAT®|Ophthalmic viscosurgical device
2862301|NCT03513159|No Intervention|Control without pathfinder support|Control patients will not be supported by pathfinders. In regular assessments they will be tested for functionality and nutritional parameters, quality of life and stress scores.
2862302|NCT03513146|Experimental|OPAMM group|"During the pre-feeding period, infants will receive mother's colostrum (to the maximum of 0.2 ml) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 2 to 4 hours.~When an infant fits the criteria to start enteral feeding, 0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol.~This practice will be continued till the infants reach full oral feeding."
2862303|NCT03513146|No Intervention|Control Group|"During the pre-feeding period, preterm infants will remain NPO. When an infant fits the criteria to start enteral feeding, own mother's colostrum or milk will be given by the regular gavage feeding on intervals regulated by the feeding protocol.~This practice will be continued till the infants reach full oral feeding."
2862304|NCT03513133|Experimental|working memory training|Patients with severe TBI will receive a hierarchical training of working memory according to a previously described methodology. They will receive 3 sessions per week during three months (each session=1 h approximately)
2862305|NCT03513094|Experimental|Without and With Transversus Abdominis|"Without:~Participants performed three trials of self-selected, comfortable paced walking in the motion lab to collect kinetic data, without transversus abdominis contraction.~With:~Participants performed three trials of self-selected, comfortable paced walking in the motion lab to collect kinetic data, with 50% MVIC transversus abdominis contraction."
2862306|NCT03513081|Experimental|Educative Session|The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child tasted it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
2862307|NCT03513081|No Intervention|Control|Children in the control group don´t receive an educative session. Before the study starts children are asked to eat a salad. After 9 weeks, all children in the control group will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
2862308|NCT03513068|No Intervention|Standard Of Care (SOC)|Standard of care long-term oxygen therapy
2862309|NCT03513068|Experimental|SOC + POC (Portable Oxygen Concentrator)|Standard of care long-term oxygen therapy + POC
2862310|NCT03513055|Experimental|inject premixed insulin|patients inject premixed insulin themselves then nurse inject premixed insulin
2862311|NCT03513042||Cohort|"Intervention:~- Standard of care Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy.~Baseline measurements:~- All patients undergo baseline FDG PET-CT and FAZA PET-CT of the head-neck area.~Interim measurements conventional):~FDG PET-CT will be repeated at the end of the second week of IMPT.~FAZA PET will only be repeated at the end of the second week of IMPT if a hypoxic tumour volume was found at baseline scanning.~A subcohort will also undergo activation PET imaging three times during IMPT."
2862312|NCT03513029|Experimental|Study Device|VytronUS Ablation System
2862313|NCT03513016|Experimental|UBX0101|UBX0101, single intra-articular injection, ascending dose
2862314|NCT03513016|Placebo Comparator|Placebo|Placebo, single intra-articular injection, ascending dose
2862315|NCT03513003|Experimental|Functional pacifier|Swap from the habitual pacifier to a functional pacifier
2862316|NCT03513003|Active Comparator|Stop habit|Stop the use of the habitual pacifier and or baby bottle
2862317|NCT03512990|Experimental|Bupivacaine - Superior Trunk Block|"Patients scheduled for rotator cuff surgery received 6 mL of 0,5% bupivacaine in the superior Trunk.~6 mL of methylene blue will be injected into cadavers with the same technique."
2862318|NCT03512977|Experimental|Sphenopalatine Ganglion Block Group|patients will be performed transnasal sphenopalatine block and conservative treatment ( iv hydration, analgesic agents, caffeine or theophylline)
2862319|NCT03512977|Active Comparator|Standard Treatment Group|patients will receive standard supportive treatment ( Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline)
2862320|NCT03512964|Other|Rapid HIV Treatment Initiation|Initiation and reinitiation of antiretroviral therapy with dolutegravir 50 mg by mouth once daily and descovy 1 tablet by mouth once daily the same-day as HIV diagnosis and/or first clinic visit for people newly diagnosed with HIV and patients previously diagnosed with HIV but not on medications and not in care for over six months.
2862321|NCT03512951|Experimental|Normal hearing|A control group including ten normal-hearing participants. These participants are recruited because they can be considered as a reference when compared to hearing-impaired patients. They usually provide homogeneous results that are expected to be significantly different than those obtained with hearing-impaired patients. In this study, normal-hearing participants are expected to provide better and more consistent performance of auditory distance estimation.
2862322|NCT03512951|Experimental|10 experienced hearing impaired|A group of ten (expected sample size) severe-to-profound hearing-impaired patients who have a past and/or present experience of more than 6 months with remote microphone systems. These patients are expected to be aware of the drawbacks of the current remote microphone technology with respect to sound localization, auditory distance estimation, and audio-visual fusion.
2862323|NCT03512951|Experimental|10 naive hearing impaired|A group of ten severe-to-profound hearing-impaired patients with no past or current experience with remote microphone systems. They are referred to as naïve patients. These patients must have similar profiles to the patients in the experienced group as regards the degree of hearing loss, origin of hearing loss (congenital, pre- or post-lingual disability), age, gender, and hearing aid technology. They will be selected and recruited on the basis of the patients included in experienced group
2862324|NCT03512938|Active Comparator|Non-smoker Group|This group included non-smoker generalized aggressive periodontitis patients.
2862325|NCT03512938|Experimental|Smoker Group|This group included smoker generalized aggressive periodontitis patients.
2877537|NCT03406793|Active Comparator|4. Dispersible zinc supplement|
2862326|NCT03512925|Experimental|Standardized debriefing|Intervention: Standardized debriefing session of coercive measures. Patients allocated to this arm receive a standardized debriefing session of the coercive measure they experienced using the developed guidelines.
2862327|NCT03512925|No Intervention|Control group|Patients allocated to this arm are treated following usual standards and routine. The offered debriefing sessions of coercive measures do not follow the developed standardized guidelines.
2862328|NCT03512899|Active Comparator|Internal jugular vein access|Internal jugular vein access preferably right, assisted by ultrasound and radioscopy. Catheter: districath®, 8.5 French.
2862329|NCT03512899|Active Comparator|Axilar vein access|Axilar vein access with single incision, assisted by ultrasound and radioscopy. Catheter: districath®, 8.5 French.
2862330|NCT03512886|Active Comparator|Single task training|The exercise program consisting of 10 different motor tasks will be implemented in a single task training group.
2862331|NCT03512886|Experimental|Multi-task training|In the multitasking training group, a second motor task in the first two weeks, a cognitive task in the third and fourth week, both motor and cognitive tasks in the last two weeks will be added to these 10 different motor tasks.
2862332|NCT03512886|No Intervention|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
2862333|NCT03512873|Experimental|Tranilast|
2862334|NCT03512860|Experimental|E4/DRSP (Treatment A) - E4/DRSP + VAL (Treatment B)|Sequence A-B: A single oral dose of E4 combined with DRSP (Treatment A) will be administered during the Period 1. After a washout, subjects will enter into the Period 2. They will receive the Treatment B which consists in multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration.
2862335|NCT03512860|Experimental|E4/DRSP + VAL (Treatment B) - E4/DRSP (Treatment A)|Sequence B-A: During Period 1, subjects will receive the Treatment B (multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration) . After a washout, subjects will enter into the Period 2 and receive the Treatment A (a single oral dose of E4 combined with DRSP).
2862336|NCT03512834|Experimental|Paclitaxel+Avelumab|Paclitaxel combination with Avelumab for inoperable angiosarcoma
2862337|NCT03512821|Experimental|Ursodiol 500mg tablets|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
2862338|NCT03512821|Active Comparator|Urso Forte 500mg tablets|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
2862339|NCT03512808|Experimental|Ursodiol 500mg tablets|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
2862340|NCT03512808|Active Comparator|Urso Forte 500mg tablets|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
2862341|NCT03512782|No Intervention|CONTROL|
2862342|NCT03512782|Experimental|INTERVENTION|
2862343|NCT03512756|Experimental|Lower dose metyrosine-derivative|Combination of lower dose metyrosine-derivative, low-dose sirolimus, phenytoin and methoxsalen
2862344|NCT03512756|Experimental|Higher dose metyrosine-derivative|Combination of higher dose metyrosine-derivative, low-dose sirolimus, phenytoin and methoxsalen
2862345|NCT03512730|Experimental|Titanium brush, H2O2 3%, plastic curettes|
2862346|NCT03512730|Active Comparator|H2O2 3%, plastic curettes|
2862347|NCT03512717|Experimental|Potenfill|
2862348|NCT03512717|Active Comparator|Powerfill|
2862349|NCT03512691|Experimental|Information on CVD risk|Respondents will receive information on the predicted probability of having a heart attack or stroke within 10 years. The predictions will be obtained from the Globorisk tool (www.globorisk.org). All information will be provided within a risk perceptions module of the baseline survey. Only this module will differ across the two treatment groups (information and lottery) and the control group. Information obtained from earlier modules will be retrieved automatically and used to make predictions of CVD risk consistent with the risk factor profile of the respondent.
2862350|NCT03512691|Experimental|Lottery Incentive|Respondents will be offered a ticket for a lottery with a money prize on condition that they visit a specific public health clinic for a checkup. There will be one prize per barangay giving each respondent a one in ten chance of winning P5000 (US$100). The prize is equivalent to approximately 14 days earnings at the regional minimum wage.
2862351|NCT03512691|No Intervention|Control|No intervention will be introduced to the participants in this arm.
2862352|NCT03512665|Experimental|Full dose supplement group|Patients assigned to this group will receive a daily dose of 7 mL of the study supplement (a mixture of pine, macadamia and pomegranate oils). The appearance and organoleptic properties will be similar to those of the interventions in the other two groups
2862353|NCT03512665|Experimental|Low dose Supplement group|Patients assigned to this group will receive a daily dose of 7 mL of a mixture containing 50% study supplement and 50% sunflower oil. The appearance and organoleptic properties will be similar to those of the interventions in the other two group
2862354|NCT03512665|Other|Control Oil Group|Patients assigned to this group will receive a daily 7 mL dose of an oil (sunflower oil) with appearance and organoleptic properties similar to those of the supplement provided in the intervention groups
2862355|NCT03512652|Other|Patello|
2862356|NCT03512639|Active Comparator|Study|Patients in the study group were given homeopathic medication (Arnica montana C30 and Bellis perennis C30) .
2862357|NCT03512639|Placebo Comparator|control|Patients in the control group were given placebo medication. The placebos and the active medication were indistinguishable in appearance, taste and smell
2862358|NCT03512626|Experimental|Multifocal IOL (OptiVis)|"Ambulatory surgery was performed by the same, experienced surgeon, under topical anesthesia, using as a technique phacoemulsification with small incision (2.75) in clear cornea in the most curved meridian.~The randomly assigned IOL (in this arm: a hybrid (refractive-diffractive) multifocal IOL (OptiVis, Aaren Scientific) was implanted in the capsular bag. The second eye with the same type of lens of the first eye was operated within 2-4 weeks."
2862359|NCT03512626|Active Comparator|Monofocal IOL|"Ambulatory surgery was performed by the same, experienced surgeon, under topical anesthesia, using as a technique phacoemulsification with small incision (2.75) in clear cornea in the most curved meridian.~The randomly assigned IOL (in this arm: a monofocal IOL (AR40e, AMO) was implanted in the capsular bag. The second eye with the same type of lens of the first eye was operated within 2-4 weeks."
2862523|NCT03511625|Experimental|Acthar|80 units of Acthar Injectable Product will be injected subcutaneously daily for three days, followed by twice weekly for four weeks.
2862360|NCT03512600|Experimental|Study group|"All patients will follow four different dietary interventions (with or without cacao) for 1 day prior to the taking of a urine sample.~After the sample is taken the patient will follow a washout period of 6 days before following a different diet and this process will be repeated for each patient until they have followed the four diets."
2862361|NCT03512587|Experimental|Personal quantum sonotherapy group|Patients who will listen through MP3 devices the personalized quantum sonotherapy previously created through a especialized software, before the application of regional anesthesia.
2862362|NCT03512587|Placebo Comparator|Control group|Patients will wear headphones but without playing the personalized quantum sonotherapy
2862363|NCT03512574|Experimental|Group PD|combination of pregabalin and dexmedetomidine
2862364|NCT03512574|Active Comparator|Group P|pregabalin +placebo
2862365|NCT03512574|Active Comparator|Group D|placebo + dexmedetomidine
2862366|NCT03512574|Placebo Comparator|Group C|placebo + placebo
2862367|NCT03512548|Experimental|Part 1 Period 1|Part 1 Period 1: Relacorilant 350mg will be given once on Day 1
2862368|NCT03512548|Experimental|Part 1 Period 2|Part 1 Period 2: Itraconazole 200mg will be given for three days
2862369|NCT03512548|Experimental|Part 1 Period 3|Part 1 Period 3: Relacorilant 350mg will be given once with concomitant itraconazole and itraconazole will continue for three additional days
2862370|NCT03512548|Experimental|Part 2 Period A|"Part 2 Period A: Relacorilant higher dose will be given once daily for 14 days"
2862371|NCT03512548|Experimental|Part 2 Period B|"Part 2 Period B: Relacorilant lower dose will be given once daily for 14 days"
2862372|NCT03512548|Experimental|Part 2 Period C|"Part 2 Period C: Relacorilant lower dose will be given once daily for 14 days in combination with itraconazole"
2862373|NCT03512535||Stage 1|Samples from up to 20 participants will be used to finalise the analytical methods
2862374|NCT03512535||Stage 2|Samples from up to 200 participants will be used to then validate the normal ranges of these markers across different age ranges in both genders
2862375|NCT03512522|Experimental|Online Group|An 8-week remotely-delivered pain self-management program tailored to older adults that have been experiencing pain for at least three months. Participants randomized to the Online Group will receive access to the course on the computer (online). A researcher will act as a guide who provides general support and encouragement, as opposed to a clinician who would offer comprehensive therapy. The guide will aim to contact participants weekly via telephone for approximately 5 to 10 minutes.
2862376|NCT03512522|Experimental|Workbook Group|An 8-week remotely-delivered pain self-management program tailored to older adults that have been experiencing pain for at least three months. Participants randomized to the Workbook Group will receive access to the course in a printed (workbook) format. A researcher will act as a guide who provides general support and encouragement, as opposed to a clinician who would offer comprehensive therapy. The guide will aim to contact participants weekly via telephone for approximately 5 to 10 minutes.
2862377|NCT03512522|No Intervention|Wait List Control Group|Participants who are randomly allocated to the wait list control group will be provided access to the course after the twelve-week period has passed.
2862378|NCT03512509|Experimental|A|Low glycaemic potato
2862379|NCT03512509|Experimental|B|High glycaemic potato
2862380|NCT03512496|Placebo Comparator|Acute energy drink - Control|Coloured Water was given 40 min prior to the OGTT test.
2862381|NCT03512496|Active Comparator|Acute energy drink - Caffeine|Sugar Free energy drink at 5mg/kg caffeine was given 40 min prior to OGTT test.
2862382|NCT03512496|Sham Comparator|Acute energy drink- Decaf|Sugar free decaf energy drink (vitamins only) was given 40 min prior to OGTT test. Amount of drink was same as that of Caffeine
2862383|NCT03512483|No Intervention|Usual Care|Participants in the control arm will receive usual GP care in their rural communities. Usual care will include some combination of treatment, education, and support as per each GPs individual practice. Participants will also have contact with the research team during the four data collection time points (baseline, 3 months, 6 months, and 12 months).
2862384|NCT03512483|Experimental|Virtual Atrial Fibrillation Clinic|Participants in the intervention group will receive usual GP care plus the vAFC which consists of telehealth appointments with Nurse Practitioner/Cardiologist and access to an AF specific educational website. It is anticipated the vAFC, as with the onsite clinic, will include a maximum of four scheduled telehealth appointments: an initial appointment following randomization, at 4-6 weeks, 3 months, and 6 months. Participants will attend appointments at their local hospital. Appointments will follow the usual protocol of the onsite AF clinic in Kelowna including, but not limited to, reviewing with patients their vials, tests (e.g., Echo, Holter, stress test), symptom management, concerns, and medications.
2862385|NCT03512470|Experimental|Sistema Prevena ™ (TVAC)|Negative topical pressure system (Sistema Prevena ™).
2862386|NCT03512470|Active Comparator|Standard medication|Standard medication with sterile gauzes and a TNT patch or medicated patch
2862387|NCT03512457|Experimental|Intensive Intervention|Participants receive brochure, card advising how to make an appointment with dermatology, and reminder in one week to perform SSE.
2862388|NCT03512457|Active Comparator|Minimal Intervention|Participants receive brochure, card advising how to make an appointment with dermatology, and reminder in one week to perform SSE.
2862389|NCT03512444|Experimental|Negative pressure|"Negative pressure system is applied with negative pressure (Active)~at a participant's unilateral arm"
2862390|NCT03512444|No Intervention|No negative pressure|"Negative pressure system is applied without negative pressure (Inactive)~at a participant's contralateral arm"
2862391|NCT03512431||Study group|Only one arm in the present study
2862392|NCT03512418|Experimental|PrEPsteps|Participants receive the PrEPsteps intervention that is programmed at the randomization study visit. They will use PrEPsteps and the digital pill to measure Truvada adherence for month 1, then they will revert to digital pill alone with Truvada for month 2 and 3.
2862393|NCT03512418|Active Comparator|Control|Participants receive digital pills with Truvada to measure PrEP adherence at the randomization study visit and continue with digital pills with Truvada for month 2 and 3.
2862394|NCT03512405|Experimental|Treatment (pembrolizumab, blinatumomab)|Participants receive pembrolizumab IV over 30 minutes on day 15 of course 1 and days 1 and 22 of courses 2 -4, and blinatumomab IV on days 1-28. Treatment repeats every 35-42 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2862395|NCT03512392|Experimental|Conservative fluid and deresuscitation|"Fluid restriction (avoidance of maintenance intravenous fluid and minimisation of drug diluent volumes)~Daily assessment of eligibility for deresuscitation for 4 days (eligible if oedema in more than 1 site and cumulative fluid balance > 2 litres)~Deresuscitation to target negative daily fluid balance of 1 to 3 litres:~5mg Indapamide daily (enteral) 100mg Spironolactone daily (enteral) 0.5mg/kg furosemide once (intravenous, max 40mg) 2.5-20mg/hr furosemide infusion titrated to effect OR continuous renal replacement therapy with fluid removal"
2862396|NCT03512392|Active Comparator|Usual care|Usual care at the discretion of the treating team
2862397|NCT03512379|Experimental|Robot assisted surgery group|Spinal surgery using TIANJI Robot system.
2862398|NCT03512379|Active Comparator|Free hand surgery group|Spinal surgery using fluoroscopy-based free hand technique
2862399|NCT03512366|Experimental|Desarsda's technique|"These patients wil be operated by the Desarda's technique without using any prosthetic mesh. A strip of external oblique aponeurosis will be used to strengthen the defect.~Both field block and local infiltration with tumescent anaesthesia techniques will be used for anaesthesia~Intervention:~A strip will be separated from the upper leaf of the external oblique aponeurosis keeping its insertion and continuity with the muscle intact. This strip will be sutured with the inguinal ligament below and the newly formed upper leaf above behind the spermatic cord to form the new inguinal floor. Continuous non absorbable prolene 2-0 suture will be used to secure it to the inguinal ligament inferiorly , and will be secured superiorly to the internal oblique muscle using interrupted absorbable vicryl sutures."
2862400|NCT03512366|Active Comparator|Lichtenstein's technique|"These patients will be operated using prosthetic mesh described as Lichtenstein's tension free mesh hernioplasty.~Both field block and local infiltration with tumescent anaesthesia techniques will be used for anaesthesia.~Intervention :~A 6 × 11 cm polypropylene mesh will be fashioned to fit the posterior wall of the inguinal canal and sutured to the fibro-periosteum of the pubic bone and continued laterally, suturing the inferior edge of the mesh to the shelving edge of the inguinal ligament to a point 2 cm lateral to the internal ring. Laterally, 2 cm silt will be made through the mesh to accommodate the cord. while the two tails will be sutured to create a new deep ring made of mesh."
2862401|NCT03512353|Experimental|Carfilzomib Plus Dexamethasone|Describe the safety profile of carfilzomib plus dexamethasone regimen (Kd 56 mg/m2 twice weekly for cycles 1-6 followed by Kd 70 mg/m2 once weekly for cycles 7-12) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1-3 prior lines of therapy at study entry. Describe subjects' adherence and satisfaction by evaluating a carfilzomib plus dexamethasone twice-weekly dosing regimen followed by a once-weekly dosing regimen.
2862402|NCT03512340|Experimental|Part A|Part A will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of SRF231 as a monotherapy in patients with advanced solid tumors and lymphoma/Chronic lymphocytic leukemia.
2862403|NCT03512340|Experimental|Part B Cohort 1|Depending upon the results from Part A of the study and the decision from the Safety Review Committee, 1 or 2 doses or dosing frequencies of SRF231 in select advanced solid and hematologic malignancies.
2862404|NCT03512327|Experimental|Autoimmune protocol (AIP) diet|Adult patients with active Crohn's disease or ulcerative colitis, undergoing 11 week autoimmune protocol diet, to examine therapeutic efficacy
2862405|NCT03512314|Experimental|Tadekinig alfa|Active drug treatment during 26 weeks
2862406|NCT03512301|Experimental|CAMCI Baseline Only|Computerized and paper-pencil neuropsychological tests, baseline
2862407|NCT03512301|Experimental|CAMCI Baseline + Follow-Up|Computerized and paper-pencil neuropsychological tests, Baseline + Follow-Up
2862408|NCT03512288|Experimental|Multivalent|Pneumococcal conjugate vaccines
2862409|NCT03512288|Active Comparator|Control|13vPnC
2862410|NCT03512275|Experimental|400mg cohort, no prior treatment with anti-TNF agent(s)|N=10 patients that have had no prior treatment with biological agents that block TNF will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.
2862411|NCT03512275|Experimental|400 mg cohort, prior treatment with anti-TNF agent(s)|N=10 patients that have failed anti-TNF therapy will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.
2862412|NCT03512262|Experimental|Abaloparatide (BA058)|Abaloparatide is an active synthetic peptide of parathyroid hormone
2862413|NCT03512262|Placebo Comparator|Placebo|Placebo with no peptide of parathyroid hormone
2862414|NCT03512249|Experimental|H56:IC31|"The H56 fusion protein is formulated with IC31 in a GMP-compliant environment in a ready to use final formulated vaccine.~H56:IC31 is administered twice with a 56 days (+/-10) interval, as 5 μg H56 adjuvanted with IC31 consisting of 500 nmol KLK and 20 nmol ODN1a, in a total volume of 0.5mL by the intramuscular route in the deltoid area using standard aseptic technique."
2862415|NCT03512249|Placebo Comparator|Placebo|Sterile saline for injection
2862416|NCT03512236|Experimental|BC Pram Ins|Single subcutaneous injection of BC Pram Ins + injection of placebo (0.9% NaCl) to ensure the double dummy
2862417|NCT03512236|Active Comparator|Symlin® and Humulin®|Simultaneous subcutaneous injections avec pramlintide and human insulin
2862418|NCT03512236|Active Comparator|Humalog®|Single subcutaneous injection of lispro + injection of placebo (0.9% NaCl) to ensure the double dummy
2862419|NCT03512223|Experimental|Group A (IV dexamethasone)|Perineural (30ml of 0.75% ropivacaine + 0.5 ml normal saline) and IV (9.0 ml normal saline + 1 ml of 10 mg/ml Dexamethasone)
2862420|NCT03512223|Experimental|Group B (IV + perineural dexamethasone)|(IV + perineural dexamethasone): Perineural (30ml of 0.75% ropivacaine + 0.5 ml of 10 mg/ml Dexamethasone) and IV (9.5 ml normal saline + 0.5 ml of 10 mg/ml Dexamethasone)
2862421|NCT03512223|No Intervention|Group C (control with no adjuvant dexamethasone)|Perineural (30ml of 0.75 ropivacaine + 0.5 ml normal saline) and IV (10 ml normal saline)
2862422|NCT03512210|Experimental|Oral fixed dose combination sofosbuvir/velpatasvir|Participants will receive fixed dose combination (FDC) sofosbuvir/velpatasvir (SOF/VEL) [Tradename: Epclusa] (400mg/100mg) orally once daily with or without food.
2862524|NCT03511625|Active Comparator|Depo Medrol|40 milligrams of Depo Medrol will be injected intramuscularly one time
2862525|NCT03511612|Other|Pattern A|Intervention : Each subject has 3 measurements of ABI starting with oscillometric device and then using the Doppler method.
2863158|NCT03507270|Other|FABP group|Coronary angiography and PCI (according to indications).
2862423|NCT03512197|Experimental|Midostaurin + chemotherapy|Participants will receive Midostaurin 50mg twice a day until not achieving CR nor CRi without adequate hematologic recovery for continuation of treatment, intolerable toxicity, relapse or consent withdrawal plus chemotherapy whichever occurs first during induction and consolidation followed by midostaurin monotherapy for 12 cycles of 28 days cycle duration.Chemotherapy consists of daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation.
2862424|NCT03512197|Placebo Comparator|Midostaurin Placebo + chemotherapy|Participants will receive matching placebo to midostaurin with same dose, plus chemotherapy. Chemotherapy consists of daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation
2862425|NCT03512184|Other|YMCA Class|This Arm's objective is to determine the effect of the YMCA's Diabetes Prevention Program on NAFLD as determined by comparison of liver enzymes pre- and post- program.
2862426|NCT03512171|Experimental|Amphetamine|One oral dose of dextroamphetamine (0.43 mg/kg) up to a maximum dose of 45mg. The dose is administered in 10mg and 2.5mg capsules prepared by the Vanderbilt Investigational Drug Services (IDS). Note: We are not testing the effect of dextro-amphetamine on a symptom. Rather it is part of the diagnostic intervention that is used to measure dopamine release assessed as the decline in [18F]fallypride binding relative to baseline.
2862427|NCT03512171|Placebo Comparator|Placebo|One oral placebo dose, with capsules prepared by the Vanderbilt Investigational Drug Services (IDS). This provides the baseline against which dopamine release is measured.
2862428|NCT03512171|Experimental|[18F]-FE-PE2I|[18F]-FE-PE2I is a radioligand for measuring dopamine transporters with positron emission tomography (PET). All participants complete this arm. The arm does not include administration of amphetamine or placebo.
2862429|NCT03512158|Experimental|High NCPAP|Administration of high nasal continuous positive airway pressure (NCPAP) (> 8 cmH2O) following failure of traditional NCPAP pressures (≤ 8 cmH2O)
2862430|NCT03512158|Active Comparator|NIPPV|Administration of non-invasive positive pressure ventilation (NIPPV) following failure of traditional NCPAP pressures (≤ 8 cmH2O)
2862431|NCT03512145|Experimental|VIPUN Balloon Catheter|Recording of gastric motility with the investigational medical device. Gastric emptying rate of a liquid meal is assessed with the 13C-octanoate breath test.
2862432|NCT03512132||control|
2862433|NCT03512132||T1D with normal albumin levels|
2862434|NCT03512132||T1D with microalbuminuria|
2862435|NCT03512132||T1D with macroalbuminuria|
2862436|NCT03512119||Patient|Patient with cystic fibrosis homozygous for Phe 508 del CFTR having a glucose intolerance or newly diagnosis diabetes
2862437|NCT03512106|Experimental|Acupuncture group|Chinese traditional acupuncture
2862438|NCT03512106|Placebo Comparator|Sham group|Sham
2862439|NCT03512093||Retrospective chart review|
2862440|NCT03512093||Focus Group Discussion (FGD) of the medical staff|
2862441|NCT03512093||Interviews of mothers|
2862442|NCT03512080||Stable International Normalised Ratio|Consenting adult patients with either venous thromboembolism (VTE), atrial fibrillation (AF) on warfarin with a target International Normalised Ratio (INR) (INR range 2-3) or valvular heart disease with a target INR (INR range 3-4).
2862443|NCT03512067|Experimental|Patients given EMV Ventilation|Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
2862444|NCT03512054|Experimental|Experimental procedure|
2862445|NCT03512041|Experimental|RLIC - 5 Cycles|Remote Limb Ischemic Conditioning (RLIC) is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 5 Cycles of RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
2862446|NCT03512041|Experimental|RLIC - 4 Cycles|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 4 Cycles of RLIC requires 35 minutes and involves 4 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
2862447|NCT03512041|Experimental|RLIC - 3 Cycles|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 3 Cycles of RLIC requires 25 minutes and involves 3 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
2862448|NCT03512041|Sham Comparator|Sham Conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the non-dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-7.
2862449|NCT03512028|Experimental|Remote Limb Ischemic Conditioning (RLIC)|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the dominant arm. RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-8.
2862450|NCT03512028|Sham Comparator|Sham Conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-8.
2862451|NCT03512015|Experimental|LuCApp + Standard Care|"LuCApp (Lung Cancer App) is an application developed by researchers and lung cancer clinicians to gather symptom data in real time and to share it with healthcare professionals.~LuCApp allows daily monitoring and grading of a list of symptoms which trigger alerts to the physicians in case predefined severity thresholds are met."
2862526|NCT03511612|Other|Pattern B|Intervention : Each subject has 3 measurements of ABI starting with Doppler method and then using oscillometric device.
2862555|NCT03511352|Experimental|Frequent Sit-to-Stands (Protocol B)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period and a mid-point bathroom break.
2877538|NCT03406793|Experimental|5. Intermittent zinc supplement|
2862452|NCT03512015|Active Comparator|Standard Care|Usual care will consist of standard procedures currently available at participating centers for monitoring and documenting symptoms. These therapeutical procedures are based on the guidelines developed by the National Comprehensive Cancer Network (NCCN) and the Associazione Italiana di Oncologia Medica (AIOM). Symptoms for control arm patients will be discussed and registered during scheduled clinical visits with the oncologists. Standard-of-care patients will fill out their PROMs following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.
2862453|NCT03512002|Active Comparator|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
2862454|NCT03512002|Other|Continued Current Care|Participants will continue their current care.
2862455|NCT03511989|Active Comparator|Bone Borne distractor|The device being investigated, Boneborne distraction appliance
2862456|NCT03511989|Other|Tooth borne distractor|The control device Toothborne distraction appliance
2862457|NCT03511989|No Intervention|Segmental LF1 osteotomy group 1|Control Group, no stabilization of palatal vault
2862458|NCT03511989|Active Comparator|Segmental LF1 osteotomy group 2|Testgroup, biodegradable plate at osteotomy site in palate
2862459|NCT03511989|Active Comparator|Segmental LF1 osteotomy group 3|Testgroup, autologous bonegraft at palatal osteotomy site
2862460|NCT03511976|No Intervention|Business as Usual (BAU)|One-third of participants will be assigned to this condition and will receive academic accommodations and interventions as deemed appropriate by their teachers, school personnel, and parents. This condition is intended to mirror current standard procedures for youth with ADHD. Thus, the specific accommodations and interventions are expected to vary across students. Some students' parents and physicians may choose to start stimulant medication with a goal of improving classroom performance.
2862461|NCT03511976|Experimental|Response to Intervention (RTI): Tier 1|Two-thirds of participants will be assigned to the RTI Tier 1 Arm. Teachers of students in this arm will receive consultation in RTI Tier 1 Classroom Management strategies.
2862462|NCT03511976|Experimental|RTI: Daily Report Card (DRC)|Students assigned to the RTI Tier 1 Arm, who do not respond to the initial RTI Tier 1 Classroom Management strategies, will move to the RTI DRC Arm of the study. Teachers of students in this arm of the study will receive consultation to implement a daily report card.
2862463|NCT03511976|Experimental|RTI: Enhanced|Half of students in the RTI DRC Arm who do not respond to the DRC intervention will be randomly assigned to the RTI: Enhanced Arm. Students in this arm will receive a more intensive classroom behavioral intervention directed at individual target behaviors through an enhanced DRC.
2862464|NCT03511976|Experimental|Medication|Half of students in the RTI DRC Arm who do not respond to the DRC intervention will be randomly assigned to the Medication arm and will receive stimulant medication as an additional intervention.
2862465|NCT03511963|Experimental|HLX04|
2862466|NCT03511963|Active Comparator|Bevacizumab|
2862467|NCT03511937|Experimental|Sugar-Sweetened Beverage Health Warning Label|
2862468|NCT03511937|Other|Neutral Label|
2862469|NCT03511924|Experimental|Intradialytic resistance training|During the 12-week intradialysis training plan subjects will performed 3 to 5 sets of 5 different lower extremities exercises, each set will consist of 12 up to 18 repetition of single exercise. The resistance training will be realized 3 times per week and will be performed during haemodialysis. External loading for exercises will variating from 60 % up to 70 % of 12MR and will be provided by elastic bands and therapeutic balls. Subjects will took 1 to 2 minutes rests between sets. After completion of the first 12 weeks of experiment, the experimental subjects will be switched onto control condition.
2862470|NCT03511924|No Intervention|Control programme|Patients randomized to the control will received no intervention during the first 12-weeks of experiment. Through the 12-week control period all participants will be instructed to maintain standard treatment regimen and to maintain their customary dietary and physical activity patterns. After completion of 12-week control period, the control subjects will be switched onto experimental condition.
2862471|NCT03511911|Experimental|GROUP A1|In GROUP A1, participants are all healthy women.A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the participant her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,participants in group A1 will be tested by inspector B twice in the same way as what they have done the first day.
2862472|NCT03511911|Experimental|GROUP A2|In GROUP A2,participants are all healthy women.A gynecological physician evaluates participant's pelvic floor muscle strength by vaginal palpation without telling the participant her result, and records it on a unique paper other than in the Case Report Form as what GROUP A1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,participants in group A2 will be tested by inspector A twice in the same way as what they have done the first day.
2862473|NCT03511911|Experimental|GROUP B1|In GROUP B1,patients are all with pelvic floor disorders.A gynecological physician evaluates the patient's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the patient her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,patients in group B1 will be tested by inspector B twice in the same way as what they have done the first day.
2862474|NCT03511911|Experimental|GROUP B2|In GROUP B2,patients are all with pelvic floor disorders.A gynecological physician evaluates the patient's pelvic floor muscle strength by vaginal palpation without telling patient her result, and records it on a unique paper other than in the Case Report Form as what GROUP B1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,patients in group B2 will be tested by inspector A twice in the same way as what they have done the first day.
2862554|NCT03511352|No Intervention|Control Condition (Protocol A)|Following a one-hour sitting run-in period, participants will sit for a 5-hour period including a mid-point bathroom break.
2862475|NCT03511911|Experimental|GROUP C1|In GROUP C1,participants are all female who give birth to a child within a year(compliance and twice assessment are guaranteed,but PFMT are not allowed during the interval).A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the participant her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,participants in group C1 will be tested by inspector B twice in the same way as what they have done the first day.
2862476|NCT03511911|Experimental|GROUP C2|In GROUP C2,participants are all female who give birth to a child within a year(compliance and twice assessment are guaranteed,but PFMT are not allowed during the interval).A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation without telling patient her result, and records it on a unique paper other than in the Case Report Form as what GROUP C1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,participants in group C2 will be tested by inspector A twice in the same way as what they have done the first day.
2862477|NCT03511898|Experimental|THR-149 dose level 1|
2862478|NCT03511898|Experimental|THR-149 dose level 2|
2862479|NCT03511898|Experimental|THR-149 dose level 3|
2862480|NCT03511885||high cardiovascular risk patients|"Coronary patients~Elective coronary artery bypass surgery (CABG).~Elective percutaneous coronary intervention (PCI) .~Acute coronary syndromes (acute myocardial infarction with ST elevation (STEMI) and Non ST elevation MI (Non- STEMI) including those treated with primary PCI and/or CABG, and unstable angina).~People at high risk of cardiovascular disease (CVD) who have been prescribed one or more of the following medications: (i) blood pressure and/or (ii) lipid and/or (iii) glucose lowering (diet and/or oral hypoglycaemic agents and/or insulin) treatments prescribed by a physician."
2862481|NCT03511872|Experimental|Peers' group|"36 Medical students are allocated randomly to Peers' group where they are trained on BLS skills by senior students.~Four students from the latest three years of study in medical schools in Syria (4th, 5th, and 6th) are randomly selected and enrolled to be instructors for basic life support training course to transfer the resuscitation skills to medical students from pre-clinical years."
2862482|NCT03511872|Experimental|Professionals' group|36 students are allocated randomly to professionals' group where they are trained on BLS skills by professional trainers in emergency. Four professionals (2 emergency doctors, cardiologist and anesthesiologist) are leading training to the control group to deliver the basic life support training course with the same duration and content as the intervention group.
2862483|NCT03511859||Control Group|Mammography/ultrasonography confirmed no findings.
2862484|NCT03511859||Cancer Group|The biopsy result is breast cancer.
2862485|NCT03511846|Experimental|Oral capsaicin|
2862486|NCT03511846|Sham Comparator|Oral capsaicin and Medical Air|
2862487|NCT03511846|Experimental|Oral Capsaicin and Low Flow Oxygen|
2862488|NCT03511846|Experimental|Oral capsaicin and High Flow Oxygen|
2862489|NCT03511846|Experimental|Topical capsaicin|
2862490|NCT03511846|Sham Comparator|Topical capsaicin and Medical Air|
2862491|NCT03511846|Experimental|Topical capsaicin and Low Flow Oxygen|
2862492|NCT03511846|Experimental|Topical capsaicin and High Flow Oxygen|
2862493|NCT03511846|Experimental|Intranasal capsaicin|
2862494|NCT03511846|Sham Comparator|Intranasal capsaicin and Medical Air|
2862495|NCT03511846|Experimental|Intranasal capsaicin and Low Flow Oxygen|
2862496|NCT03511846|Experimental|Intranasal capsaicin and High Flow Oxygen|
2862497|NCT03511846|Experimental|Cold water irrigation|
2862498|NCT03511846|Sham Comparator|Cold water irrigation and Medical Air|
2862499|NCT03511846|Experimental|Cold water irrigation and Low Flow Oxygen|
2862500|NCT03511846|Experimental|Cold water irrigation and High Flow Oxygen|
2862501|NCT03511833|Active Comparator|Morphine group|Morphine group will receive IV medication and IN saline.
2862502|NCT03511833|Experimental|Ketamine group|Ketamine group will receive IV saline and IN medication.
2862503|NCT03511807|Experimental|Electrical/ Acoustic stimulation|
2862504|NCT03511794||1|Chart review of participants who received at least one dose of the hepatitis B vaccine.
2862505|NCT03511781|Experimental|Single Arm study|Hypofractionated Radiotherapy Schedule of 35 GY in 10 fractions is being administered in advanced Incurable Breast Cancer for female patients
2862506|NCT03511768|Experimental|18F-AlF-NOTA-octreotide PET/CT|One injection of the radioligand 18F-AlF-NOTA-octreotide
2862507|NCT03511755|Experimental|TEN 1-11 kHz|Transdermal Electrical Neuromodulator (TEN) waveform pulsed biphasic current (1-11 kHz)
2862508|NCT03511755|Active Comparator|TEN 1-3 kHz|Transdermal Electrical Neuromodulator (TEN) waveform pulsed biphasic current (1-3 kHz)
2862509|NCT03511729||A single exposure to general anesthesia|Participants who have surgery under general anesthesia (without anesthesia/surgery before)
2862510|NCT03511729||Multiple exposures to general anesthesia|Participants who have surgery under general anesthesia (had anesthesia/surgery before)
2862511|NCT03511703|Experimental|Apatinib|
2862512|NCT03511703|Other|TACE|
2862513|NCT03511690|Experimental|BRCA-Gist Intervention|Participants randomized to BRCA-gist will complete the adapted intervention. BRCA-gist is a web-based tutoring system that emulates one-to-one human tutoring via avatars to communicate risk of BRCA1/2. We estimate a completion time of 90 minutes.
2862514|NCT03511690|Active Comparator|NCI Arm|Participants randomized to the NCI arm will have up to 90 minutes to read the NCI webpage content that overlaps with BRCA-gist.
2862515|NCT03511677|Experimental|Intervention Group|Customized insole with metatarsal support
2862516|NCT03511677|Placebo Comparator|Control Group|Placebo flat insole
2862517|NCT03511664|Experimental|177Lu-PSMA-617 plus BS/BSC|Patients randomized to receive the investigational product will receive 7.4 GBq (±10%) 177Lu-PSMA-617 intravenously every 6 weeks (±1 week) for a maximum of 6 cycles. + Best supportive/best standard of care (BS/BSOC)
2862518|NCT03511664|Other|BS/BSC alone|Patients randomized to this arm will receive best supportive/best standard of care (BS/BSOC) as determined by the investigator
2862519|NCT03511651|Other|FRC at clinical PEEP level|Measuring FRC at clinical PEEP level
2862527|NCT03511599|Experimental|D-Cycloserine|Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
2862528|NCT03511599|Active Comparator|Placebo|Participants will ingest a capsule identical to the study medication, however this capsule will contain a placebo.Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
2862529|NCT03511560|Active Comparator|Tacrolimus, Immediate release|Tacrolimus (immediate-release) will be administered twice daily per clinical judgment of supervising physician (dosing and monitoring in accordance with center protocol) to a minimum whole blood tacrolimus concentration of at least 8 ng/mL.
2862530|NCT03511560|Experimental|Envarsus XR|Envarsus XR (Tacrolimus Extended Release Oral Tablet) will be administered once daily at initial weight-based dose of 0.12 mg/kg. Dosing and monitoring thereafter predicated on clinical judgment to a minimum whole blood tacrolimus concentration of at least 8 ng/mL. When possible, patients will receive their daily dose of Envarsus using the fewest number of pills possible.
2862531|NCT03511547|Active Comparator|Intervention group 1: Pitch-Patch|Reconstruction with patch augmentation using a synthetic patch
2862532|NCT03511547|Active Comparator|Intervention group 2: ArthroFlex|Reconstruction with patch augmentation using a biological human dermis patch
2862533|NCT03511547|No Intervention|Control|
2862534|NCT03511534|Active Comparator|Psychotherapy|Participants will receive evidenced based psychotherapy by a trained psychologist
2862535|NCT03511534|Active Comparator|Pharmacotherapy|Participants will receive pharmacotherapy by a psychiatrist
2862536|NCT03511521|Experimental|NPH Insulin|"NPH will be given at the time of steroid administration to the patient in addition to standard basal/bolus insulin the patient may be receiving in the following doses:~Prednisone Dose (mg/day) - NPH dose (Units): 10-20 mg/day - 1.2U (units)/mg; 21-40 mg/day - 0.6U/mg; 41-60 mg/day - 0.45U/mg; 61-80 mg/day - 0.3U/mg; >80 mg/day - no additional NPH. Note that the amounts of NPH are added to each other for the various prednisone doses. For example, a dose of 75 mg/day of prednisone would come out to be (1.2U x 20mg = 24U) + (0.6U x 20mg = 12U) + (0.45U x 20mg = 9U) + 0.3U x 15 mg = 4.5U) for a total of 24 + 12 + 9 + 4.5 = 49.5U of NPH for 75 mg of prednisone."
2862537|NCT03511521|Active Comparator|Basal/Bolus Insulin|"Basal insulin (glargine) and Bolus insulin (insulin aspart) will be increased (doses given in U [units]/kg) according to the Prednisone dose (mg/day) as follows:~Prednisone Dose (mg/day) - doses of insulin (U/kg): Prednisone 0 mg - Glargine 0.25U/kg, Bkfst Aspart 0.08U/kg, Lunch Aspart 0.08U/kg, Dinner Aspart - 0.08U/kg; Prednisone 10-20 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.15U/kg, Dinner Aspart - 0.2U/kg; Prednisone 21-40 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.2U/kg, Dinner Aspart - 0.25U/kg; Prednisone 41-60 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.25U/kg, Dinner Aspart - 0.30U/kg; Prednisone 61-80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.30U/kg, Dinner Aspart - 0.35U/kg; Prednisone >80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.35U/kg, Dinner Aspart - 0.40U/kg."
2862538|NCT03511508|Active Comparator|CHROPREG|The participants in the intervention Group receive the interdisciplinary multimodal intervention
2862539|NCT03511508|No Intervention|Control group|"Participants in the control group receive the standard maternity care for pregnant women with chronic disease.~The standard care is given to the participants in the control group. The standard care for pregnant women with chronic disease include five routine visits at a non-specialized midwife and an individually scheduled number of visits with an obstetrician, depending on the type and severity of the chronic Medical disease and possible pregnancy complications.~The women in the control Group have the same amount of ultrasound examinations as do the women in the intervention Group.~Women in the control Group can attend auditorium antenatal classes at the hospital."
2862540|NCT03511495||Keratoconic Patients|
2862541|NCT03511482|Experimental|MyAsthma Application and Lloyds Pharmacy Online Doctor|Web based applications to support people with Asthma management
2862542|NCT03511469|Experimental|Control Group|Patients in this group will only received standardized rehabilitation protochol after Bankart surgery
2862543|NCT03511469|Experimental|Concentric Group|Patients in this group will receive concentric training for rotator cuff muscles with isokinetic device in addition the the standart rehabilitation protocol.
2862544|NCT03511469|Experimental|Eccentric Group|Patients in this group will receive eccentric training for rotator cuff muscles with isokinetic device in addition the the standart rehabilitation protocol.
2862545|NCT03511456||FLLDH-PELD|Extraforaminal LDH patients received PELD operation
2862546|NCT03511443|Other|Diagnostic performance of hsRDT|Comparing diagnostic power of two diagnostics
2862547|NCT03511417|Experimental|Middle-aged adults|Participants will use an over-the-counter hearing device in one ear until asymptotic speech perception performance is noted (maximum 12 weeks). The same individuals will use over-the-counter hearing devices in each ear until asymptotic performance is noted (the order of these two phases will be randomized across participants). They will be asked to use these devices at least 4 hours/day.
2862548|NCT03511404|Experimental|Chronical LBP|Patients with chronic low back pain to be measured with Numeric Pain Rating Scale (NPRS).
2862549|NCT03511391|Experimental|Experimental arm|"Stereotactic body radiotherapy concurrent with checkpoint inhibitor treatment:~Pembrolizumab or Nivolumab + SBRT"
2862550|NCT03511391|Active Comparator|Control arm|"Checkpoint inhibitor treatment only:~Pembrolizumab or Nivolumab"
2862551|NCT03511378|Experimental|Lupin's Pegfilgrastim|6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
2862552|NCT03511378|Experimental|Neulasta®|6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
2862553|NCT03511365|Experimental|Probiotic administration|After baseline collection of serum and fecal microbiota, each subject will be administered the probiotic formulation VSL#3 450 Billion CFU Twice daily for 8 weeks. Serum and fecal microbiota will again be collected at the end of the intervention and compared with baseline with each subject serving as his or her own control.
2863330|NCT03506035||Rheumatoid arthritis|Patients who meet the criteria of the 1987 ACR
2862556|NCT03511352|Experimental|Stand More (Protocol C)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 8-minute standing breaks, 1 per hour, and a mid-point bathroom break.
2862557|NCT03511326|Experimental|Luxerm®|
2862558|NCT03511313|Experimental|Renal denervation|Renal angiography and renal denervation (with sterile irrigated deflectable ablation catheter in renal artery), and maintaining anti-hypertensive medications
2862559|NCT03511313|Sham Comparator|Renal angiography|Renal angiography and maintaining anti-hypertensive medications
2862560|NCT03511300|Placebo Comparator|Standard Instructions|Participants will receive standard instructions for cognitive tasks.
2862561|NCT03511300|Experimental|Goal Setting Instructions|Participants will receive goal-setting instructions for cognitive tasks.
2862562|NCT03511287|Experimental|IMT group|"Group intervention: home-based interval inspiratory muscle training:~during 8 weeks (two sessions per day, daily)~two times 30 breaths with one-minute rest between them in each session~training resistance set to the highest tolerable load according to scores pointed by the patient on the Borg score (between 4 and 6) aiming 50% of actual pimax or higher adjusted in the supervised weekly session"
2862563|NCT03511274|Experimental|Hygiene based educational film|Women randomised to receive the CMV educational intervention will fill in a questionnaire and view the film. The website will also contain interactive information about CMV and how to prevent it. After watching the film and reading the information, women will be asked to fill in a post-intervention questionnaire. The website will be accessible via the participants' own mobile device or computer or dedicated study tablets or computers on-site. Using a web-based intervention, we will be able to monitor use of the educational intervention and also collect data in real time.
2862564|NCT03511274|No Intervention|Treatment as usual (TAU)|Women who are randomised to the TAU group will also be asked to log-on the website. Instead of receiving specific information about prevention of CMV in pregnancy, they will receive information about routine antenatal immunisation. In the UK, the Department of Health recommends that all pregnant women should be offer immunisation against pertussis (whooping cough) and influenza (if pregnant during the influenza session). This will ensure that participants in the TAU arm of the study also derive benefit from the study.
2862565|NCT03511261|Active Comparator|10%Curcumin mucoadhesive gel|"Drug: Curcumin arm Curcumin10% mucoadhesive gel~Group 1 patients:~Drug : 10% curcumin mucoadhesive gel usage : Topical application Frequency : Twice daily Duration : 6 months"
2862566|NCT03511261|Active Comparator|Curcumin capsules 500mg|"Group 2 patients:~Drug : curcumin 500 mg capsules usage : oral intake Frequency : Twice daily Duration : 6 months"
2862567|NCT03511261|Active Comparator|5% Curcumin gel+Curcumin capsules 250mg|"Group 3 patients:~Drug: 5% Curcumin mucoadhesive gel & Curcumin capsules 250mg usage : Topical application and oral intake Frequency : Twice daily Duration : 6 months"
2862568|NCT03511261|Placebo Comparator|Placebo capsules|Group 4 patients Drug: Placebo capsules usage : oral intake Frequency : Twice daily Duration : 6 months
2862569|NCT03511248|Experimental|Nitrate-rich Beetroot Juice|Individuals will receive a once daily dose of dietary nitrate in the form of a beetroot juice concentrate (70mL) containing ~5-6mmol inorganic nitrate (James White Drinks, UK) for 12 +/- 2 weeks. This dose has been chosen due to several reports demonstrating efficacy in patients with cardiovascular disease.
2862570|NCT03511248|Placebo Comparator|Nitrate-deplete Beetroot Juice|The placebo control is an identical juice from which the nitrate anion has been removed using a standard anion exchange resin. Visually there is no detectable difference between the juices and previous spectral, ion concentration, sugar levels, ascorbate analysis and taste testing has confirmed no differences in colour and constituents. The process to extract nitrate from the juice is the same technique used to remove inorganic nitrate from general drinking water supplies, and has been approved for use by Ethics Committees. The nitrate-free juice is not considered a drug or medicine, and is classified as a foodstuff.
2862571|NCT03511222|Experimental|Dose Escalation: Vorolanib + Nivolumab|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at the assigned dose level.~Patients receiving nivolumab will get it on an outpatient basis as a 30-minute intravenous infusion at a dose of 480 mg on Day 1 of each 28-day cycle~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
2862572|NCT03511222|Experimental|Dose Escalation: Vorolanib + Pembrolizumab|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at the assigned dose level~Patients receiving pembrolizumab will get it on an outpatient basis as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 200 mg on Day 1 of each 21-day cycle~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
2862573|NCT03511222|Experimental|Dose Expansion: Vorolanib + Pembrolizumab (HCC)|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at recommended phase II dose~Patients receiving pembrolizumab will get it on an outpatient basis as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 200 mg on Day 1 of each 21-day cycle~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
2862574|NCT03511222|Experimental|Dose Expansion: Vorolanib + Nivolumab (Gastric or GE Junction)|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at recommended phase II dose~Patients receiving nivolumab will get it on an outpatient basis as a 30-minute intravenous infusion at a dose of 480 mg on Day 1 of each 28-day cycle~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
2862575|NCT03511209|Experimental|CBTI plus Taper method A|Participants in this arm will receive CBTI plus the novel hypnotic tapering method.
2862576|NCT03511209|Active Comparator|CBTI plus Taper method B|Participants in this arm will receive CBTI plus the usual tapering method used by the VA.
2862598|NCT03511118||clindamycin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
2862577|NCT03511196|Experimental|Adaptive ADT+ Standard of Care|Participants will undergo 4 weeks of ADT with GnRH analog, followed by 8 weeks of combinational therapy with ADT and abiraterone plus prednisone. 14 participants who achieve >75% PSA decline after the 12 weeks of run-in period will be enrolled. ADT and abiraterone will be stopped after study enrollment. PSA and testosterone level will be measured every 2 weeks during the run-in period, then every 4 weeks after study enrollment. Imaging studies with CT and bone scan will be performed at the time of study enrollment and these will be considered baseline scans. Study treatment will be restarted if participant's PSA reaches 2 fold or higher of his baseline PSA. Selection of treatment will be based on participant's testosterone level.
2862578|NCT03511183|Experimental|alternative regiment|"The first stage:XELOX + bevacizumab chemotherapy and XELIRI + bevacizumab chemotherapy (alternation of every two cycles) until one of the schemes appears imaging progress or intolerance.And then enter the second stage.~The second stage: continue to apply another plan until there is progress or intolerance."
2862579|NCT03511183|Placebo Comparator|classical regiment|Use the XELOX + bevacizumab chemotherapy until appears imaging progress or intolerance.And then change to the XELIRI + bevacizumab chemotherapy until there is progress or intolerance.
2862580|NCT03511170|Experimental|alternative regiment|The first stage:XELOX chemotherapy and XELIRI chemotherapy (alternation of every two cycles) until one of the schemes appears imaging progress or intolerance.And then enter the second stage. The second stage: continue to apply another plan until there is progress or intolerance.
2862581|NCT03511170|Placebo Comparator|classical regiment|Use the XELOX chemotherapy until appears imaging progress or intolerance.And then change to the XELIRI chemotherapy until there is progress or intolerance.
2862582|NCT03511157|Experimental|Ischemic Preconditioning|A standard blood pressure cuff will be placed on the right or left thigh, depending on the affected side, to occlude blood flow. The cuff will be inflated to 225 mmHg to prevent blood flow. Each session will consist of 4 cycles of 5 minute IPC applications, followed by 5 minutes of reperfusion for a total of 35 minutes.
2862583|NCT03511157|Sham Comparator|Control|The sham intervention protocol will be identical to the IPC protocol except blood flow to the affected leg is unchanged as cuff pressure will be raised to between the venous and diastolic pressures
2862584|NCT03511144|Active Comparator|Measured resection|Total knee replacement using the Unity Knee™ implanted with the measured resection surgical technique
2862585|NCT03511144|Active Comparator|Ligament balancing|Total knee replacement using the Unity Knee™ implanted with the ligament balancing surgical technique
2862586|NCT03511131|Other|QSE Resp (Only follow)|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who responded to QSE, were randomized at month-6 to no additional treatment, and then followed for the rest of the study.
2862587|NCT03511131|Other|QSE Resp (KIU at 6-month)|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who responded to QSE, were randomized at month-6 to receive Keep It Up (KIU), and then followed for the rest of the study.
2862588|NCT03511131|Other|QSE Non-Resp, KIU-Control Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), responded to KIU-Control at month-6, and then were followed for the rest of the study.
2862589|NCT03511131|Other|QSE Non-Resp, KIU-Control Non-Resp, KIU|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), did not respond to KIU-Control at month-6, and so were randomized into Keep It Up (KIU). After KIU, they were followed for the rest of the study.
2862590|NCT03511131|Other|QSE Non-Resp, KIU Control Non-Resp, YMHP|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), did not respond to KIU-Control at month-6, and so were randomized into Young Men's Health Project (YMHP). After YMHP, they were followed for the rest of the study.
2862591|NCT03511131|Other|QSE Non-Resp, KIU Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), responded to KIU at month-6, and then were followed for the rest of the study.
2862592|NCT03511131|Other|QSE Non-Resp, KIU Non-Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), did not respond to KIU at month-6, and then were randomized into no treatment/just follow for the rest of the study.
2862593|NCT03511131|Other|QSE Non-Resp, KIU Non-Resp, YMHP|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), did not respond to KIU at month-6, and then were randomized into Young Men's Health Project. After YMHP, they were followed for the rest of the study.
2862594|NCT03511118||Tranexamic acid (TXA)|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
2862595|NCT03511118||labetalol|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
2862596|NCT03511118||metformin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
2862597|NCT03511118||nifedipine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
2863221|NCT03506854|Experimental|Moderate Renal Impairment|Presence of moderate renal impairment (eGFR 30-59 mL/min/1.73m2). Subjects will receive 1 dose of ISIS 681257.
2862599|NCT03511118||oxycodone|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
2862600|NCT03511118||azithromycin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
2862601|NCT03511118||escitalopram|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
2862602|NCT03511118||sertraline|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
2862603|NCT03511118||ondansetron|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
2862604|NCT03511105|Experimental|Subjects receiving GSK2798745|Eligible subjects will receive two tablets of 2.4 milligrams GSK2798745 on the morning of Day 1. Subjects will then undergo segmental challenge at 2 hours after first dose wherein LPS will be instilled into the right middle segment and saline control into the lingula segment of the contralateral side. The second dose of a single tablet of 2.4 milligrams of GSK2798745 will be administered 10 hours after LPS and saline challenge.
2862605|NCT03511105|Placebo Comparator|Subjects receiving matching Placebo|Eligible subjects will receive two tablets of placebo on the morning of Day 1. Subjects will then undergo segmental challenge at 2 hours after first dose wherein LPS will be instilled into the right middle segment and saline control into the lingula segment of the contralateral side. The second dose placebo will be administered 10 hours after LPS and saline challenge.
2862606|NCT03511092|Experimental|HMB-FA|
2862607|NCT03511092|Experimental|HMB-Ca|
2862608|NCT03511092|Experimental|alfa-HICA|
2862609|NCT03511092|Placebo Comparator|Placebo|
2862610|NCT03511079|Experimental|Music|This group will be given a subscription to Pandora Plus for the duration of the study. Beginning two nights before surgery, they will listen to a music playlist they created for 30 minutes prior to going to sleep. This will continue each night with the final time being 6 nights after surgery.
2862611|NCT03511079|No Intervention|Control|This group will not listen to music each night for the duration of the study.
2862612|NCT03511066|Experimental|CT-P27 Dose1|CT-P27 will be administrated once in IV infusion.
2862613|NCT03511066|Experimental|CT-P27 Dose2|CT-P27 will be administrated once in IV infusion.
2862614|NCT03511066|Placebo Comparator|Placebo|Placebo will be administrated once in IV infusion.
2862615|NCT03511053|Experimental|All participants|Epidural Lavage followed by Lumbar Epidural Steroid Injection
2862616|NCT03511040|Experimental|Lumenate Intraluminal Device|Dilation of vasospastic intracranial vessels
2862617|NCT03511027|Experimental|Intervention (SME + Karie Device)|Patients randomly assigned to receive SME+Karie will 1) undergo Screening for Self Medication Readiness to determine self-management capacity, 2) will receive self-medication education (SME) by a study Occupational Therapist, and 3) receive a 5-day self-medication performance assessment by an Registered Nurse prior to discharge. In addition, this group will receive orientation to the Karie Automated Medication Delivery by the study Occupational Therapist. The participants in the intervention arm will use the Karie device for all applicable medications for the study duration.
2862618|NCT03511027|Active Comparator|Control (SME only)|"West Park has a Self-Medication Education Program policy in place which seeks to establish independent medication self-medication capacity during the inpatient stay. Eligibility criteria for SME include a need to manage medications independently at home; stabilized on medication (as per pharmacist/physician discretion); and mild-moderate cognitive/physical impairments (as per an OT assessment). During SME participants receive training by an Occupational Therapist, followed by a 5-day self-medication performance assessment by an Registered Nurse prior to discharge. Participants in the SME group will fill prescriptions as usual for the duration of study."
2862619|NCT03511014|Experimental|microcurrent|
2862620|NCT03511014|Sham Comparator|control|
2862621|NCT03511001|Experimental|E-Cigarette|6 weeks of JUUL electronic cigarettes
2862622|NCT03511001|Active Comparator|Assessment Only|6 weeks of smoking as usual
2862623|NCT03510988|Experimental|Women with newly diagnosed breast cancer|
2862624|NCT03510975|Sham Comparator|Verbal Behavioral Therapy|All children and their parents were instructed only a verbal behavioral therapy
2862625|NCT03510975|Experimental|Check-list|All participants were instructed a behavioral therapy with a written formed check-list for parents to complete
2862626|NCT03510975|Active Comparator|Desmopressin plus verbal therapy|All children in Group III received desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) plus verbal behavioral therapy.
2862627|NCT03510962|Active Comparator|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test mixed fruit juice,Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test mixed fruit juice."
2862654|NCT03510793||Total intravenous anesthesia|Patients receiving total intravenous anesthesia (TIVA) using propofol + remifentanil with target-controlled infusion according to the attending physician's decision.
2862725|NCT03510325|Experimental|Paliperidone long-acting injection|dosage form:im dosage:75-150mg frequency:once a month duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
2864298|NCT03499262|Experimental|Group Social ABcs|Participants receiving Group Social ABCs intervention
2862628|NCT03510962|Experimental|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test mixed fruit juice,Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
2862629|NCT03510962|Experimental|Group 3: 0.2% chlorhexidine|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
2862630|NCT03510962|Experimental|Group 4: fluoridated tooth paste|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will Brush with fluoridated toothpaste (Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the brushing as an intervention."
2862631|NCT03510962|Experimental|Group 5: Polyol containing gum|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will chew polyol containing gum (Orbit®, Wrigley Company) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
2862632|NCT03510962|Experimental|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
2862633|NCT03510949|Other|Group N|Patients' nasal mucosa will be anaesthetized and vasoconstricted. K-Y gel will be applied to the tip of nasopharyngeal airway (NPA) of appropriate size. The NPA will then be advanced into the dominant nostril along the septum horizontally.
2862634|NCT03510949|Other|Group L|K-Y gel will be applied to the tip of the laryngeal mask (LMA) of appropriate size. The LMA will be introduced along the hard palate towards the hypopharynx until resistance is felt.
2862635|NCT03510936|No Intervention|blue light phototherapy|the patients in this arm will not receive probiotics.
2862636|NCT03510936|Experimental|probiotics concurrent with phototherapy|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks
2862637|NCT03510923||Patients who underwent an appendectomy|Patients of all ages who underwent an appendectomy in the elective or non-elective setting.
2862638|NCT03510923||Patients who underwent a cholecystectomy|Patients of all ages who underwent a cholecystectomy in the elective or non-elective setting.
2862639|NCT03510910|Experimental|Acetaminophen along with a reduced quantity of Percocet|
2862640|NCT03510910|Experimental|Percocet only|
2862641|NCT03510897|Active Comparator|QPI-1002|QPI-1002 Injection, Single dose
2862642|NCT03510897|Placebo Comparator|Placebo|isotonic saline
2862643|NCT03510884|Experimental|Alirocumab|Alirocumab (one of 2 doses, depending on body weight) will be administered subcutaneously (SC). Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.
2862644|NCT03510884|Placebo Comparator|Placebo|Alirocumab Placebo will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose
2862645|NCT03510871|Experimental|nivolumab plus ipilimumab|
2862646|NCT03510858|Experimental|Intervention group|
2862647|NCT03510858|Other|Control group with crossover|Participants in the control group will receive the intervention after 12 months, cross-over design
2862648|NCT03510845|Experimental|Repairable ACL tear|Patients whose ACL found to be avulsed from its femoral insertion or has a proximal tear, and intra-operatively, found to have a good tissue quality, will undergo arthroscopic ACL primary repair using fiberwires and SwiveLock screw to anchor the ligament into its origin, in the femoral condyle.
2862649|NCT03510845|Other|Irreparable ACL tear|Patients whose ACL cannot be repaired, will undergo arthroscopic ACL reconstruction using hamstring tendons.
2862650|NCT03510832||STEMI patients undergoing Emergent PCI|
2862651|NCT03510806|Placebo Comparator|Placebo|taste, color, and calorie-matched to supplement
2862652|NCT03510806|Experimental|Supplement|Proprietary protein and fruit extract blend
2862653|NCT03510793||Balanced anesthesia|Patients receiving balanced anesthesia (desflurane + remifentanil) according to the attending physician's decision
2864338|NCT03499002|Experimental|Simulation Lab|
2864339|NCT03499002|Experimental|ER in situ Simulation|
2862655|NCT03510780|Active Comparator|EMD treated patients|"Periodontal surgery with Enamel Matrix Derivative is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers EMD will be applied to the entire root surfaces ; then, ABG will be applied alternatively with EMD into the IBD according to the sandwich technique until the IBD will be completely filled. Finally the flap will be repositionated and sutures completed by interrupted sutures."
2862656|NCT03510780|Experimental|PRF treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers , the PRF membrane cut into small pieces and mixed with the ABG will be placed within the IBDs until they will be completely filled. Then the other two PRF membranes in each patient will be adapted over the grafted defect Finally horizontal mattress and interrupted sutures will be carried out.
2862657|NCT03510767|Experimental|TQ-B3525|
2862658|NCT03510741|Active Comparator|Sodium Benzoate|Sodium Benzoate added to TAU will be administered at 1000mg daily
2862659|NCT03510741|Active Comparator|N-Acetylcysteine|N-Acetylcysteine added to TAU 1000 mgs twice daily dose
2862660|NCT03510741|Active Comparator|Placebo|Placebo added to TAU
2862661|NCT03510741|Active Comparator|Sodium Benzoate Plus N-Acetylcysteine|Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
2862662|NCT03510728|No Intervention|No single-session intervention-EMA|Participants will be assessed both using a computer and using their phone. However, they will not receive an intervention at the start of the study and will only be using their phone for ecological assessment only data collection.
2862663|NCT03510728|Active Comparator|Standard single-session intervention-EMA|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will be followed up. Participants in this condition will interact with their phone only for assessment purposes.
2862664|NCT03510728|Experimental|Augment single-session intervention-EMA|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will also take a computerized intervention developed to increase the use of protective behavioral strategies during drinking (Protective Behavioral Strategies Intervention). Participants in this condition will interact with their phone only for assessment purposes.
2862665|NCT03510728|Experimental|No single-session intervention-EMI|Participants in this group will not take a single-session intervention at baseline, but will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
2862666|NCT03510728|Experimental|Standard single-session intervention-EMI|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will be followed up. Participants in this condition will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
2862667|NCT03510728|Experimental|Augment single-session intervention-EMI|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will also take a computerized intervention developed to increase the use of protective behavioral strategies during drinking (Protective Behavioral Strategies Intervention). Participants in this condition will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
2862668|NCT03510715|Experimental|Alirocumab|All patients will receive subcutaneously (SC) (one of 2 doses, depending on body weight) alirocumab Q2W at entry on top of background treatments.
2862669|NCT03510702||Periodontal patients.|Taking gingival Crevicular fluid.
2862670|NCT03510702||Periodontally healthy patients.|Taking gingival Crevicular fluid.
2862671|NCT03510676|Experimental|NiTiDES|Single arm
2862672|NCT03510663|Experimental|OPC-61815 16mg|OPC-61815 16mg will be intravenously administered once a week.
2862673|NCT03510663|Experimental|OPC-61815 32mg|OPC-61815 32mg will be intravenously administered once a week.
2862674|NCT03510663|Active Comparator|Moxifloxacin|400mg tablet will be administrated once a week.
2862675|NCT03510663|Placebo Comparator|Placebo|Placebo will be intravenously administered once a week.
2862676|NCT03510650||Patients|50 patients with sepsis versus 50 patients with HLH [anticipated]
2862677|NCT03510624|Experimental|Rebaudioside A 3g|
2862678|NCT03510611|Experimental|Period 1: fed control → Period 2: fasted control|Period 1: administration of Ensartinib 225mg at 7:30am, 30 minutes after the breakfast；Period 2: administration of Ensartinib 225mg at 7:30am, without the breakfast
2862679|NCT03510611|Experimental|Period 1: fasted control → Period 2: fed control|Period 1: administration of Ensartinib 225mg at 7:30am, without the breakfast；Period 2: administration of Ensartinib 225mg at 7:30am, 30 minutes after the breakfast
2862680|NCT03510598|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the submental area with a new applicator design.
2862681|NCT03510598|Experimental|Drug Treatment for Fat Reduction|Kybella will be used after two treatments with the ZELTIQ applicator.
2862682|NCT03510585|Experimental|saline and sniffing|This RRC is the combination of positioning (laying down), sniffing (only one side), throat vibration and saline instillation. And then the other side.
2862683|NCT03510585|Placebo Comparator|sniffing|Pacient will be in a lay down condition and will perform sniffing with throat vibration several times each side (but with no saline instillation)
2862684|NCT03510572|Experimental|Healthy volunteer|Cognitively healthy subjects will receive a single IV injection of [18F]PI-2620.
2862685|NCT03510572|Experimental|Alzheimer's Disease|Alzheimer's Disease Subjects will receive a single IV injection of [18F]PI-2620.
2862686|NCT03510572|Experimental|Frontotemporal dementia|frontotemporal dementia Subjects will receive a single IV injection of [18F]PI-2620.
2862687|NCT03510572|Experimental|Parkinson's disease|Parkinson's disease Subjects will receive a single IV injection of [18F]PI-2620.
2862723|NCT03510325|Experimental|Amisulpride|dosage form:po dosage:0.4-1.2g frequency:2 doses duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
2862724|NCT03510325|Experimental|Aripiprazole|dosage form:po dosage:15-30mg frequency:qd duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
2862688|NCT03510559|Active Comparator|Brachial Plexus Block|It will be at the discretion of the anesthesiologist performing the block to choose a supraclavicular, infraclavicular or axillary block to achieve adequate surgical anesthesia of the operative arm. After sterile skin preparation with chlorhexidine, a linear array transducer probe is placed on the skin and the appropriate nerve structures are identified. Local anesthetics (30 mL of 50:50 mix of 0.5% bupivacaine and 2% lidocaine) will then be injected in 5 mL aliquots after negative aspiration for blood to achieve circumferential spread around the brachial plexus. Patients who have a failed brachial plexus block may undergo a rescue forearm block, and will be recorded as requiring supplemental local anesthetic.
2862689|NCT03510559|Experimental|Forearm Nerve Block|Patients allocated to the forearm block will have it performed in the semi-setting position. After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a linear array transducer probe is placed at the distal forearm to visualize each peripheral nerve (radial, ulnar, median, and lateral antebrachial cutaneous). A 5 cm 22 G insulated needle is then used to target each nerve individually and infiltrate 7.5mL of the 50:50 mixture (similar to the brachial plexus block group) at each nerve to a total of 30mL.
2862690|NCT03510546|Experimental|Active|"De-novo: Each capsule contains 60 mg. pyridostigmine. 1 capsule is administered twice within 4 hours.~Chronic: Each capsule contains 60 mg. pyridostigmine. Number of administered capsules per dosage depend on the patient's usual dosage. Study drug is administered twice within 4 hours.~Patients are examined/rated before 1st dose, 1 hour after 1st dose, 1 hour after 2nd dose (Visit 1). After cross-over (Visit 2), patients will be rated open-label at 1 month (Visit 3) and 3 months (Visit 4)."
2862691|NCT03510546|Placebo Comparator|Placebo|"Same as Active, however capsules contain placebo."
2862692|NCT03510533|Experimental|Eating disorders patients|first clinical visit in nutrition department of CHU de Rouen for eating disorders (anorexia nervosa, hyperphagia or bulimia) according to the classification DSM-V
2862693|NCT03510533|Other|healthy volunteers|Volunteers with negative SCOFF test (No active or history of eating disorders)
2862694|NCT03510520|Experimental|Medium Cut-Off Haemodialysis (Theranova)|Participants will receive medium cut-off haemodialysis treatment for 6 months in total (3 times per week treatment).
2862695|NCT03510520|Active Comparator|On-Line Haemodiafiltration|Participant will remain on their usual on-line haemodiafiltration (HDF) treatment for the 6 month study duration (3 times per week treatment).
2862696|NCT03510494|Experimental|Intervention|Trebling of weekly curricular physical education (270 minutes per week)
2862697|NCT03510494|No Intervention|Control|Standard curriculum physical education (90 minutes per week)
2862698|NCT03510481|Experimental|1|Arm 1: (n=70) will receive 3 doses of PfSPZ Vaccine (9 x10^5) via DVI at 0, 8, and 16 weeks.
2862699|NCT03510481|Experimental|2|Arm 2: (n=70) will receive 3 doses of PfSPZ Vaccine (9 x10^5) via DVI at 0, 1 and 4 weeks.
2862700|NCT03510481|Placebo Comparator|3a|Arm 3a: (n=35): Will be the control Arm 1. Volunteers will receive 3 doses of placebo saline injection via DVI at 0, 8 and 16 weeks.
2862701|NCT03510481|Placebo Comparator|3b|Arm 3b: (n=35): Will be the control Arm 2. Volunteers will receive 3 doses of placebo saline injection via DVI at 0, 1 and 4 weeks.
2862702|NCT03510468|Experimental|1|(1) TAF once daily alone (days 1-14) and (2) TAFonce daily + weight-based RPT + INH (withpyridoxine) once weekly (days 15-31)
2862703|NCT03510455|Experimental|Single Arm (TIO Subjects)|Phase 2, open-label, non-randomized, single-arm, drug treatment trial. 10 subjects will be studied. Treatment duration of 6 months with 3 months off drug follow-up and optional extension phase.
2862704|NCT03510442||Patients - sJIA|Patients with signs and symptoms of sJIA
2862705|NCT03510442||Patients - AOSD|Patients with signs and symptoms of AOSD
2862706|NCT03510442||Patients - Inflammatory condition|Patients with an inflammatory condition
2862707|NCT03510429|Active Comparator|Routine post-op care|Routine post-op care (N=20)
2862708|NCT03510429|Experimental|Routine post-op care with Nutritional supplement|Routine post-op care + Nutritional supplement by specific product (N=20)
2862709|NCT03510416|Experimental|apatinib combined with TACE|Apatinib is administered after TACE 4-7 days, and TACE treatment is performed after discontinuation of apatinib for 4 days.Every 28 days is a cycle.
2862710|NCT03510403|Experimental|Device : nasal airway stent|Patients with OSA or snoring use the nasal airway stent nastent™ each night for sleeping. The device is a tube-shaped medical device that is inserted from the nose and the tip of the tube reaches the soft palate. The inserted tube aids breathing by preventing the obstruction of the airway which causes poor sleep, frequent awakening during sleep and snoring.
2862711|NCT03510390|Experimental|Metformin|Participants will be orally administered 850 mg of metformin twice daily between the therapeutic decision of the tumor board and the surgical resection of the tumor. The duration of the treatment is 9-14 days
2862712|NCT03510377|Experimental|Aquatic physical intervention|Aquatic physical intervention: Ai-Chi
2862713|NCT03510377|Experimental|On-land physical intervention|On-land physical intervention: Tai-Chi
2862714|NCT03510377|Experimental|Non physical intervention|Non physical intervention: Guided imagery
2862715|NCT03510364|Experimental|Dietary intervention|All participants consumed a meal that contains 60% of their energy daily energy requirement as a lunch time meal for 14 consecutive days.
2862716|NCT03510351||Treated subjects|All patients with Pseudomonas infections treated with ceftolozane-taezobactam who meet the inclusion criteria
2862717|NCT03510338|Experimental|Sublingual sildenafil (fasted)|Subjects receive a single dose of 100 mg sildenafil
2862718|NCT03510338|Active Comparator|Oral sildenafil (fed)|Subjects receive a single dose of 50 mg sildenafil (Viagra)
2862719|NCT03510338|Experimental|Sublingual sildenafil (fed)|Subjects receive a single dose of 100 mg sildenafil
2862720|NCT03510338|Active Comparator|Oral comparator (fasted)|Subjects receive a single dose of 50 mg sildenafil (Viagra)
2862721|NCT03510325|Experimental|Olanzapine|dosage form:po dosage:5-20mg frequency:qn duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
2862722|NCT03510325|Experimental|Risperidone|dosage form:po dosage:4-6mg frequency:2 doses duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
2862726|NCT03510312||Long-term follow up, observational|This cohort does not involve interventions, just follow up of prognosis of ischemic stroke/transient ischemic attack patients.
2862727|NCT03510299|Placebo Comparator|Control group|
2862728|NCT03510299|Experimental|McGrath group|
2862729|NCT03510286||Pregnant women|Pregnant women attending ANC clinics in Techiman Holy Family Hospital and Kintampo North and South districts (all hospitals and clinics inclusive where ANC services are provided) are the primary participant group- primarily women of reproductive age. Pregnant women attending routine ANC will be enrolled. In addition to routine ANC, pregnant women will be tested with the Test-it™ PrCr Urinalysis Strips. Pregnant women are a potentially vulnerable population whose participation in this research is necessary given the target use case for this diagnostic tool: providing reliable and accurate point of care screening of proteinuria in ANC settings. The legal age of consent in Ghana is 18 years and women under the age of 18 will not be recruited for this study.
2862730|NCT03510273|Other|Thermocoagulation treatment|Acceptability of Liger Medical Thermocoagulator treatment
2862731|NCT03510260|Placebo Comparator|Control Group|Subject will undergo regular consenting only. At our unit consent for an elective cesarean delivery occurs in the same day of surgery, few hours before the procedure in a private room in labor and delivery while awaiting surgery. The COMRADE questionnaire (our primary outcome) will be obtained after the completion of the paper consent form.
2862732|NCT03510260|Experimental|Study Group I|Subject will receive an electronic invitation to complete the consent process electronically and will proceed through the Confirmed Consent system prior to arrival to labor and delivery on day of surgery, which is the routine patient flow at this time. The COMRADE questionnaire (our primary outcome) will be obtained prior to the initiation of the traditional consent (as in control group) before the completion of the paper consent form, in order to assess satisfaction and understanding of the e-confirmed consenting process completed before the procedure. After completion of the survey, the subject will sign the regular paper consent for the procedure as standard in our institution.
2862733|NCT03510260|Experimental|Study Group II|Subject will undergo the same intervention as group II but the COMRADE survey questionnaire will be obtained after the paper consent is obtained in order to assess whether both methods combined together improve the subjects' satisfaction of the consenting methods and better understanding of the surgical procedure.
2862734|NCT03510221|Active Comparator|Antioxidants|Subjects received 3 antioxidant capsules (1 capsule of blueberry + 1 capsule of cranberry + 1 capsule pomegranate - a day) during 4 weeks.
2862735|NCT03510221|Placebo Comparator|Placebo|Subjects received 3 placebo capsules during 4 weeks.
2862736|NCT03510208|Experimental|Group A (panitumumab, panitumumab-IRDye800, NIR)|Participants receive panitumumab IV over 60 minutes on day 0, and following a 15-minute observation period, receive panitumumab-IRDye800 IV over 60 minutes. Participants then undergo NIR imaging during standard of care surgery 1-5 days after receiving panitumumab-IRDye800.
2862737|NCT03510208|Experimental|Group B (panitumumab-IRDye800, NIR)|Participants receive panitumumab-IRDye800 IV over 60 minutes on day 0. Participants then undergo NIR imaging as in Group A.
2862738|NCT03510195|Experimental|MEDICORP HO PREPARATORY MODULE|The participants that will have intervention which is the module
2862739|NCT03510182|Experimental|transcranial Direct Current Stimulation|tDCS will be given to all qualified patients with aphasia.
2862740|NCT03510169|Experimental|NeoVest|Negative pressure ventilation using NeoVest
2862741|NCT03510156|Experimental|Treatment|
2862742|NCT03510156|No Intervention|Observation|
2862743|NCT03510143|No Intervention|Control|No use of Neoveil in the neck node dissection area
2862744|NCT03510143|Experimental|Neoveil|Use of Neoveil in the neck node dissection area
2862745|NCT03510130|Experimental|Routine leg movement|Intervention group- In the second stage of labor, attending physician or nurse will help the participant in routine leg movements every 20-30 minutes.
2862746|NCT03510130|No Intervention|Control group|Control group which includes women during the second stage of labor with no intervention (routine leg movement).
2862747|NCT03510117|Other|Mindfulness|Mindfulness
2862748|NCT03510104|Experimental|MRX-2843|MRX-2843: Dose Escalation Successive dose escalation cohorts to determine MTD
2862749|NCT03510091|Experimental|Video-Assisted Counseling|Patients receiving video-assisted counseling
2862750|NCT03510078|Experimental|Intensive glycemic control|With a target of blood glucose range of 130 mg/dL or less
2862751|NCT03510078|Experimental|Conventional glycemic control|With a target of blood glucose range of 130-180 mg/dL
2862752|NCT03510052|Other|Diet Modification Pilot Program|Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit.
2862753|NCT03510039|Active Comparator|"Before Group"|35 Thirds benefiting from the usual care
2862754|NCT03510039|Experimental|"After Group"|"Recruit 35 Thirds for the phase phase After : Early device / Follow up by nurses"
2862755|NCT03510026|Other|Low thermal device preparation|One participant acts simultaneously as a control and active comparator. One internal thoracic artery is prepared with the normal electrocautery device. The other internal thoracic artery is prepared with the new low thermal device. The participant does not know, which internal thoracic artery is defined to be prepared with the low thermal device.
2862756|NCT03510013|Experimental|1-1-8 wash-in|Wash-in using O2:N2O or O2:air 1:1 L/min with sevoflurane 8%
2862757|NCT03510000|Experimental|Main arm|Single arm open-label cross-over study with random order of SGLT-2 inhibitor intervention (Empagliflozin 25mg po qd), in which each cross-over phase includes different meal strategies (carbohydrate counting, meal announcement, no meal announcement) on separate days in the setting of single hormone artificial pancreas
2862758|NCT03509987|Other|hb analysis with Hemacue|Hb analysis with Hemacue and with arterial blood gas analyser in geriatric ill patients requiring intensive care
2862759|NCT03509974|Experimental|Bone Anchored Hearing Device (OSIA)|All subjects will receive the Bone Anchored Hearing Device (OSIA)
2862827|NCT03509519|Experimental|NMES-Millicurrent Group|NMES-millicurrent group will receive the NMES experimental treatment. Stimulating electrodes will be applied to the quadriceps muscle of each leg 3 times a week for 4 weeks (12 sessions) for 40min on each leg.
2864340|NCT03498989|Experimental|preterm formula milk neoborn|will be given preterm formula milk
2862760|NCT03509961|Other|Observational Arm|"Patients are enrolled to the observational arm to proceed with NGS-MRD testing pre-HCT. If NGS-MRD negative, eligible patients may be considered for the Treatment Arm to receive a myeloablative non-TBI conditioning regimen prior to HCT.~If NGS-MRD positive, patients may continue in the observational arm and receive HCT under the direction of their transplant physician and followed on the study for outcome."
2862761|NCT03509961|Other|Treatment Arm|Patients enrolled to the observational arm that are NGS-MRD pre-HCT are considered for the Treatment Arm. Patients will receive a myeloablative non-TBI conditioning regimen prior to the transplant consisting on busulfan, fludarabine and thiotepa. Patients will be followed for outcome for up to 5 years.
2862762|NCT03509948|Experimental|Schedule A|"Schedule A (6 participants):~Period 1: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)~Period 2: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)"
2862763|NCT03509948|Experimental|Schedule B|"Schedule B (6 participants):~Period 1: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)~Period 2: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)"
2862764|NCT03509935|Experimental|Intervention Ultrasound Group|"Patients will be submitted to Ultrasound protocol, namely:~In the first 6 to 12 hours of admission to ICU~Second US after 12-24 hours of inclusion.~Third US after 24-48 hours of inclusion.~Protocol:~US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions.~US inferior vena cava, collapsability or distensibility index according to the patient's conditions, in spontaneous or controlled ventilation, respectively.~Cardiac US: subjective evaluation of contractility between normal, reduced or severely reduced.~The US findings will be communicated to the attending physicians who will conduct the patient, according to the protocol, recommending the administration of volume or not, and the use of vasopressors and/or inotropic drugs."
2862765|NCT03509935|No Intervention|Control Group|Patients randomized to this group will receive care according to the indication of the attending physicians, composed mainly of intensive care physicians, without bedside US. Patients may be submitted to echocardiographic, abdominal and vascular examinations, among others, requested to ultrasound service, according to the indication.
2862766|NCT03509922|Experimental|Anplag Tab. 100mg bid|sarpogrelate hydrochloride 100mg bid for 24 weeks
2862767|NCT03509922|Experimental|Anplag Tab. 100mg tid|sarpogrelate hydrochloride 100mg tid for 24 weeks
2862768|NCT03509909|Experimental|Hatha yoga|12- week group-based yoga class
2862769|NCT03509909|Active Comparator|Supportive physical activity|12-week group-based stretching and strengthening class
2862770|NCT03509896||Participants newly diagnosed with CML-CP|
2862771|NCT03509883|Experimental|Apixaban sprinkle capsules followed by apixaban tablets|Apixaban (BMS-562247) sprinkle capsules (treatment period 1) followed by apixaban tablets (treatment period 2)
2862772|NCT03509883|Experimental|Apixaban tablets followed by apixaban sprinkle capsules|Apixaban (BMS-562247) tablets (treatment period 1) followed by apixaban sprinkle capsules (treatment period 2)
2862773|NCT03509870|Other|mesenchymal stromal cells|mesenchymal stromal cells in collagen scaffold
2862774|NCT03509857|Placebo Comparator|normal standard of care infusion of propofol without analgesia|normal standard of care infusion of propofol without analgesia
2862775|NCT03509857|Experimental|infusion of propofol with application of vibration analgesia|infusion of propofol with application of vibration analgesia
2862776|NCT03509844|Experimental|Prolonged Exposure|Psychotherapy: 10 weeks, Prolonged Exposure (individual sessions) according to the manual developed by Foa et al., adapted for a residential care setting
2862777|NCT03509844|Experimental|STAIR|Psychotherapy: 10 weeks, Skills Training in Affect and Interpersonal Regulation (STAIR) (group sessions), according to the manual developed by Cloitre et al., adapted for a residential care setting
2862778|NCT03509844|Experimental|STAIR/NT|Psychotherapy: 16 weeks, 10 weeks Skills Training in Affect and Interpersonal Regulation (STAIR) (group sessions), followed by 6 weeks of Narrative Therapy (NT) (individual sessions), according to the manual developed by Cloitre et al., adapted for a residential care setting.
2862779|NCT03509831|Other|INT2150-A|
2862780|NCT03509831|Other|INT2150-B|
2862781|NCT03509818|Experimental|Strength|Effects of strength exercise (12 weeks)
2862782|NCT03509818|Experimental|Aerobic|Effects of aerobic exercise (12 weeks)
2862783|NCT03509805|Experimental|OSA in obese patient during pregnancy|OSA in polysomnography
2862784|NCT03509805|Experimental|no OSA in obese patient during pregnancy|no OSA in polysomnography
2862785|NCT03509792|Experimental|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
2862786|NCT03509792|Placebo Comparator|Attention placebo|Smartphone activity for same amount of time.
2862787|NCT03509779||NSCLC|NSCLC localized disease treated by surgery
2862788|NCT03509766|Experimental|Skin testing|All subject both allergic and non-allergic will be tested. There is only one (1) arm.
2862789|NCT03509753|Experimental|High Fiber|Per 10 ounces of feed: 4 g oat-soy fiber with 45% short-chain fructooligosaccharides, 296 kCal, 19 g protein, 8 g fat, and 39 g carbohydrates. Feed rate/duration individualized for each patient.
2862790|NCT03509753|Active Comparator|Low Fiber|Per 10 ounces of feed: 0 g fiber, 296 kCal, 19 g protein, 8 g fat, and 39 g carbohydrates. Feed rate/duration individualized for each patient.
2862791|NCT03509740|Experimental|tramadol|Intravenous 100 mg tramadol in 100 ml saline with slow infusion.
2862792|NCT03509740|Active Comparator|paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with slow infusion.
2862793|NCT03509714|Active Comparator|Experimental: Part 1 Oxaloacetate Random|Participants take 2 capsules Jubilance 100 mg Oxaloacetate/150 mg Ascorbic Acid blend per day during their entire menstrual cycle (approximately 28 days) or 2 capsules of 250 mg rice flour (Placebo). After one menstrual cycle, they cross-over to the other option.
2862794|NCT03509714|Active Comparator|Experimental: Part 2 Oxaloacetate Second|Participants take 2 capsules of 250 mg rice flour (Placebo) per day during their entire menstrual cycle (approximately 28 days). After one menstrual cycle, they cross-over to 2 capsules of Jubilance 100 mg Oxaloacetate/150 mg Ascorbic Acid blend.
2862888|NCT03509168|Active Comparator|Misoprostol Pfizer Brand arm|participants receive a single dose of 400mcg vaginal misoprostol preoperatively (60minutes before) during open myomectomy
2862795|NCT03509701||Subject (RCVS)|Patients who meet the definition of RCVS. (1) acute and severe headache with or without focal deficits or seizures, (2) uniphasic course without new symptoms more than 1 month after clinical onset, (3) segmental vasoconstriction of cerebral arteries shown by computed tomography angiography (CTA), magnetic resonance angiography (MRA) or transfemoral cerebral angiography (TFCA),(4) normal or near normal cerebrospinal fluid analysis and (5) complete or substantial normalisation of arteries shown by follow-up angiography within 12 weeks.
2862796|NCT03509701||Control|Patients with thunderclap headache and intracranial stenosis, but not diagnosed as RCVS.
2862797|NCT03509688|Experimental|entecavir|drug:entecavir 0.5mg/day, one time/day,144weeks
2862798|NCT03509688|Experimental|entecavir+resveratrol|entecavir 0.5mg/day, 144weeks intervention:resveratrol 1000mg/day, 48weeks
2862799|NCT03509688|Experimental|entecavir+thymosin α1|entecavir 0.5mg/day, 144weeks thymosin α1 2 times/week, 24weeks
2862800|NCT03509675|Placebo Comparator|Placebo|
2862801|NCT03509675|Active Comparator|Active ingredient|
2862802|NCT03509662|Placebo Comparator|Placebo group|Group 1 will be treated with placebos for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
2862803|NCT03509662|Active Comparator|Vitamin C - 3 gr/day|Group 2 will be treated with 1.5 gr Vitamin C b.i.d. (3 gr/day) for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
2862804|NCT03509662|Active Comparator|Vitamin C - 10 gr/day|Group 3 will be treated with 5 gr Vitamin C b.i.d. (10 gr/day) for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
2862805|NCT03509649|Experimental|Experienced - Positive|Participants will receive cervical spine manipulation after being given a positive description of the technique from an experienced clinician
2862806|NCT03509649|Experimental|Experienced - Negative|Participants will receive cervical spine manipulation after being given a negative description of the technique from an experienced clinician
2862807|NCT03509649|Active Comparator|Novice - Positive|Participants will receive cervical spine manipulation after being given a positive description of the technique from a novice clinician
2862808|NCT03509649|Active Comparator|Novice - Negative|Participants will receive cervical spine manipulation after being given a negative description of the technique from a novice clinician
2862809|NCT03509636|Experimental|Treatment|Fluzoparib capsule
2862810|NCT03509623|Experimental|Blood coagulation and aflibercept|Blood sampling through direct peripheral venous puncture will be collected from treatment naive patients commencing treatment with intravitreal injections of aflibercept for neovascular AMD before the first intravitreal injection of aflibercept and at 7 and 30 days post-injection. Blood coagulation parameters will be evaluated at each timepoint.
2862811|NCT03509610|Active Comparator|CONTROL|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
2862812|NCT03509610|Experimental|LOW SUG|Diet consisting of 50% carbohydrate (<5% sugar), 15% protein, 35% fat
2862813|NCT03509610|Experimental|LOW CHO|Diet consisting of <8% carbohydrate (<5% sugar), 15% protein, >77% fat
2862814|NCT03509597|Experimental|Aerobic Exercise|This program consists of an exercise dosage of 180 min/week administered in 3 sessions of 60 minutes. Each session includes 10 minutes of warm-up exercise before the main exercise and 10 minutes of cool-down afterwards.the principal exercise section includes 20 minutes of aerobic exercise and 20 minutes of resistance and strength exercises. The exercise intensity will be regulated according to the heart rate measured by a pulsimeter throughout the exercise. The target intensity level will be individualized according to the heart rate to set the moderate intensity level (HR values between ventilatory thresholds) and high intensity level (HR values from 2nd. ventilatory threshold to the peak threshold).
2862815|NCT03509597|Experimental|Cognitive Training|The CT group participates in a cognitive remediation program. This program consists of 3 sessions of 90 minutes per week. CT will be administered in groups of 5-8 subjects. The cognitive domains involved in the CT are attention/concentration, memory/learning, language, executive functions, social cognition and social skills. Cognitive Remediation will be provided by using REHACOP, a cognitive remediation training tool designed and validated for Spanish patients with schizophrenia.
2862816|NCT03509597|Sham Comparator|Treatment as usual|The TaU Group receives the usual treatment that patients with schizophrenia in Spain enriched with occupational activities administered 3 times a week with a duration of 90 minutes each session.
2862817|NCT03509584|Experimental|part #1a|non-small cell lung cancer (NSCLC) patients with bone metatase(s) eligible for localized hypo-fractionated radiotherapy
2862818|NCT03509584|Experimental|part #1b|non-small cell lung cancer (NSCLC) patients with bone metatase(s) eligible for localized hypo-fractionated radiotherapy
2862819|NCT03509584|Experimental|part #2a|NSCLC patients eligible for a localized radiotherapy of one target lesion (outside the brain)
2862820|NCT03509584|Experimental|part #2b|NSCLC patients eligible for a localized radiotherapy of one target lesion (outside the brain)
2862821|NCT03509571|Experimental|Ketogenic Diet Group|Ketogenic diet is a high-fat, low-carbohydrate diet (lipid to carbohydrate + protein ratio of 3:1) that included ≈72% total energy as fat, ≈25% as protein, and ≈3% as carbohydrate during enteral feeding and ≈65% total energy as fat, ≈27% as protein, and ≈8% as carbohydrate and fiber during solid feeding. Patients will start receiving ketogenic diet within the 72 hours injury, after completing their baseline measurements.
2862822|NCT03509571|Other|Standard Diet Group|Patients will start to receive standard hospital diet within 72 hours of injury after completing their baseline measurements. Standard diet includes ≈35% total energy as fat, ≈27% as protein, and ≈44% as carbohydrate and fiber.
2862823|NCT03509558|Active Comparator|Transcutaneous spinal stimulation & Physical therapy|Transcutaneous electrical stimulation combined with physical therapy that targets rehabilitation of walking and standing functions
2862824|NCT03509558|Active Comparator|Physical therapy only|Physical therapy that targets rehabilitation of walking and standing functions
2862825|NCT03509545|Experimental|CHF Patients: ER Torsemide 40 mg|CHF patients will be given 40 mg ER Torsemide
2862826|NCT03509545|Active Comparator|CHF Patients: Furosemide 40 mg|CHF patients are on 40 mg of Furosemide
2862889|NCT03509168|Other|No misoprostol arm|standard of care
2863331|NCT03506035||Arthritis not Rheumatoid arthritis|Patients with psoriatic arthritis, peripheric spondyloarthropathies and connective tissue diseases.
2862828|NCT03509519|Sham Comparator|NMES-Microcurrent Group|The NMES-microcurrent group will receive the Sham Treatment. The Sham Treatment will consist of electrode pad application for 40 mins on each leg, but electrical current will not be delivered. Otherwise all procedures will be the same as the NMES-millicurrent experimental group. Participants will be informed they are receiving microcurrent stimulation which is typically not felt by patients. Microcurrent stimulation is an actual type of electrical stimulation that is used therapeutically and is typically not felt by patients, however, participants will not receive this treatment. Participants will be informed of the actual treatment received at the study conclusion. Those in the Sham Group will be given the opportunity to receive the treatment at the conclusion of the study.
2862829|NCT03509506|No Intervention|Non-App Group|"The participants will be instructed to continue their daily routine, track their daily steps with a pedometer, and record their daily steps on the Activity Log paper form."
2862830|NCT03509506|Experimental|App Group|The participants will be trained how to use the mobile application (Heart Failure Health Storyline (HFHS)) to track their health status, physical activity, manage their medications schedule, and explore the other features that the application has. Additionally, they will receive a pedometer to track their daily steps and record their data on the mobile application.
2862831|NCT03509493||Patients without structural heart disease|
2862832|NCT03509493||Patients with structural heart disease|
2862833|NCT03509493||Patients with high risk parameters for AF development|
2862834|NCT03509493||Patients post-cryptogenic stroke|
2862835|NCT03509493||Patients post-cardioversion therapy|
2862836|NCT03509493||Patients post-ablation therapy|
2862837|NCT03509480|Active Comparator|Curettage with Vitoss|ultraporous beta-tricalcium phosphate mixed with autologous bone marrow aspirate for patients undergoing surgical curettage for benign bone lesions
2862838|NCT03509480|Active Comparator|Curettage with Prodense|ultraporous beta-tricalcium phosphate mixed with calcium sulfate for patients undergoing surgical curettage for benign bone lesions
2862839|NCT03509467|Experimental|Intervention Group A - Now Open|"Intervention Group A: Non-Hispanic White Population~Post determination of MC1R Genotypes, participants randomized to the intervention group, will receive personalized information about ways that they can protect themselves and their child from developing melanoma.~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk."
2862840|NCT03509467|Experimental|Intervention Group B - Will Open Soon|"Intervention Group B: Hispanic Population~Post determination of MC1R Genotypes, participants randomized to the intervention group, will receive personalized information about ways that they can protect themselves and their child from developing melanoma.~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk."
2862841|NCT03509467|Placebo Comparator|Control Group A - Now Open|"Control Group A: Non-Hispanic White Population~Post determination of MC1R Genotypes, participants randomized to the control group, you will receive standard information about ways that they can protect themselves and their child from developing melanoma.~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk. Participants randomized into the control group, by the end of the study will also have had the opportunity to receive personalized information about ways they can protect themselves and their child from developing melanoma."
2862842|NCT03509467|Placebo Comparator|Control Group B - Will Open Soon|"Control Group B: Hispanic Population~Post determination of MC1R Genotypes, participants randomized to the control group, you will receive standard information about ways that they can protect themselves and their child from developing melanoma.~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk. Participants randomized into the control group, by the end of the study will also have had the opportunity to receive personalized information about ways they can protect themselves and their child from developing melanoma."
2862843|NCT03509454||Type 1 DM, Normo albuminuric|Type 1 diabetics with no history of albumnuria (UACR < 30 mg/g in 2 out of 3 consecutive samples)
2862844|NCT03509454||Type 1 DM, Micro albuminuric|Type 1 diabetics with history of micro albumnuria (UACR 30-299 mg/g in 2 out of 3 consecutive samples)
2862845|NCT03509454||Type 1 DM, Macro albuminuric|Type 1 diabetics with history of macro albumnuria (UACR 30-299 mg/g in 2 out of 3 consecutive samples)
2862846|NCT03509454||Healthy subjects|Subjects with no history of diabetes, other diseases or intake of medicine which in the judgement of the investigator could affect the results, specifically renal, cardiovascular or inflammatory/infectious diseases should be considered for exclusion.
2862847|NCT03509441||South Asians with Insulin Resistance|125 patients (anticipated)
2862848|NCT03509441||South Asians without Insulin Resistance|125 patients (anticipated)
2862849|NCT03509428|No Intervention|Control|Usual care plus additional monitoring
2862850|NCT03509428|Experimental|SRETP|Structured Responsive Exercise Training Programme (SRETP) prior to surgery
2862851|NCT03509428|Experimental|Psychological support|Psychological support prior to surgery
2862852|NCT03509428|Experimental|SRETP and psychological support|Structured Responsive Exercise Training Programme (SRETP) and psychological support prior to surgery
2862853|NCT03509402|Experimental|Short implants|A full-arch screw-retained mandibular prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6mm)
2862854|NCT03509402|Active Comparator|Long implants|A full-arch srew-retained mandibular prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm)
2862855|NCT03509376|Experimental|Suture repair|Diastasis recti is repaired using nylon suture for the plication
2862856|NCT03509376|Experimental|Rolled mesh repair|Diastasis recti is repaired with self gripping mesh to reinforce the suture line
2862890|NCT03509155|No Intervention|Control group|The first arm as a control group obtaining only routine IYCF consultation by the posyandu (integrated health service post) cadres and without the provision of biscuits.
2862916|NCT03508999|Other|SMS Text Reminder|Subjects will be provided biweekly reminder via SMS in the form of text message reinforcing oral hygiene. Additionally, patients will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
2862857|NCT03509363|Experimental|Intervention|Participants allocated to the intervention group will be prescribed a set of exercise video with QR code provided in home exercise pamphlets and they have to perform the prescribed exercises under the guidance of video.The content of home exercise program in both groups is the same and is based on the recommendations from the National Stroke Foundation Clinical Guidelines, including mobilization exercise, strengthening exercise and balance training which is tailor-made for different mobility level of stroke patients. Suitability of participating home exercise program will be assessed by physiotherapists based on environmental risk, fall risk and competence of patients or carers in performing exercise with patients. The number of exercises prescribed, frequency and intensity of exercise varies from participants and will be determinated by physiotherapists
2862858|NCT03509363|No Intervention|Control|Participants in control group will be given instructions for their home exercise program in a traditional pamphlet includes photographs and instructions of exercise demonstration.
2862859|NCT03509350|Experimental|Treatment Protocol|Participants randomized to the treatment protocol will receive the VICTAS Intervention, consisting of intravenous vitamin C, thiamine, and hydrocortisone for four days or until ICU discharge.
2862860|NCT03509350|Placebo Comparator|Control Protocol|A placebo to match the VICTAS intervention will be administered for four days or until ICU discharge. During the treatment period, if an indication for steroids exist, the treating physicians are permitted to initiate open-label corticosteroid therapy based on local practice and international guidelines. If this occurs, the hydrocortisone/placebo will be withheld and subjects will be started on open-label corticosteroids.
2862861|NCT03509324|Other|duration of disease|different duration of disease receive insulin LISPRO
2862862|NCT03509311||Asthma Group|"That group consists from patients who had diagnosed as asthma by doctors from Chest Diseases Department of Gazi University Hospital.~Physical activity level assesment, maximal and submaximal exercise capacity assesment, respiratory function assesment, respiratory muscle strength assesment, respiratory muscle endurance assesment, peripheral muscle strength assesment, quality of life assesment about disease specific, respiratory, sleep and cough associated, fatigue severity assesment, depression and anxiety level assesment and asthma management knowledge assesment apply to this group."
2862863|NCT03509311||Healthy Group|That group consists from participants who do not have any diagnosed disease. Physical activity level assesment, maximal and submaximal exercise capacity assesment, respiratory function assesment, respiratory muscle strength assesment, respiratory muscle endurance assesment, peripheral muscle strength assesment, quality of life assesment about disease specific, respiratory, sleep and cough associated, fatigue severity assesment and depression and anxiety level assesment apply to this group.
2862864|NCT03509298|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
2862865|NCT03509298|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
2862866|NCT03509298|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2862867|NCT03509285|Placebo Comparator|Qualification Y|Placebo; administered orally as a single dose of 2 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
2862868|NCT03509285|Active Comparator|Qualification Z|Alprazolam 2.0 mg; administered orally as a single dose of 2 x 1.0 mg alprazolam tablets, over-encapsulated
2862869|NCT03509285|Placebo Comparator|Treatment A|Placebo; administered orally as a single dose of 4 x cenobamate-matched placebo tablets and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
2862870|NCT03509285|Active Comparator|Treatment B|Alprazolam 1.5 mg; administered orally as a single dose of 3 x 0.5 mg alprazolam tablets, over-encapsulated and 4 x cenobamate-matched placebo tablets
2862871|NCT03509285|Active Comparator|Treatment C|Alprazolam 3.0 mg; administered orally as a single dose of 3 x 1.0 mg alprazolam tablets, over-encapsulated and 4 x cenobamate-matched placebo tablets
2862872|NCT03509285|Experimental|Treatment D|Cenobamate, 200 mg; administered orally as a single dose of 2 x 100 mg cenobamate tablets, 2 x cenobamate-matched placebo tablets, and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
2862873|NCT03509285|Experimental|Treatment E|Cenobamate, 400 mg; administered orally as a single dose of 4 x 100 mg cenobamate tablets and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
2862874|NCT03509272|No Intervention|Control Group|
2862875|NCT03509272|Experimental|remote monitoring group|
2862876|NCT03509259||Asthma|"If the doctor has been diagnosed with asthma and one or more of the following criteria is met;~FEV1 (Forced expiratory volume in 1 second) increased more than 12% & 200 mL after 10-20 minutes of inhalation of short-acting bronchodilator (200-400 mg salbutamol)~Positive bronchial provocation tests (methacholine, mannitol, exercise, aspirin, etc.)~FEV1 Increased more than 12% & 200 mL from baseline FEV1 after anti-inflammatory treatment for 4 weeks or longer."
2862877|NCT03509259||Asthma-COPD overlap (ACO)|Satisfy the diagnostic criteria of asthma described above + post-bronchodilator FEV1/FVC (forced vital capacity) ratio < 70%
2862878|NCT03509259||Healthy control|Subjects who performed coronary artery calcium scoring CT for health checkup purpose.(retrospective group = historical control group)
2862879|NCT03509246|Experimental|Pegylated liposomal doxorubicin plus Bortezomib combination|At BRCA wild-type platinum-resistant recurrent ovarian cancer patients, Pegylated liposomal doxorubicin and Bortezomib combination theraphy for 6 cycles
2862880|NCT03509233|Active Comparator|Q-SRP|Quadrant scaling and root planing
2862881|NCT03509233|Experimental|FMS|Full mouth scaling and root planing
2862882|NCT03509233|Experimental|FMD|Full mouth disinfection
2862883|NCT03509233|Experimental|FMDP|Full mouth disinfection with periopolishing
2862884|NCT03509220|Experimental|PBK-1701TC|2-Day Split-Dosing Regimen
2862885|NCT03509220|Active Comparator|Standard oral preparation|2-Day Split-Dosing Regimen
2862886|NCT03509207|Experimental|Vorinostat, Zolinza Oral Capsules|Vorinostat Oral Capsules 400mg daily
2862887|NCT03509194||Pediatric liver disease patients|Comparison of outcome of pediatric liver disease and prognostic functional liver test results and gene expression in liver biopsies.
2862891|NCT03509155|Active Comparator|National portion & IYCF counseling|The second arm as the national portion & IYCF counseling group to get biscuit with standardized portion as recommended by Ministry of Health and also given the IYCF counseling by the cadres and nutritionist.In the second and third arm, treatment was administered for 3 months according to the recommended duration of biscuit delivery by the Ministry of Health, but all respondents from three arms will continue to be followed in third, sixth, and ninth months from the beginning of treatment.
2862892|NCT03509155|Experimental|Adjusted portion & local food counseling|the third arm as the adjusted portion & local food counseling group receiving biscuit with adjustment in portion and IYCF Counseling that emphasize the optimization of local food. In the second and third arm, treatment was administered for 3 months according to the recommended duration of biscuit delivery by the Ministry of Health, but all respondents from three arms will continue to be followed in third, sixth, and ninth months from the beginning of treatment.
2862893|NCT03509142|Experimental|IBS implantation|Implantation of IBS in patients with coronary artery lesions. All the subjects will be randomly assigned to queue 1 (n=30) and queue 2 (n=15)
2862894|NCT03509129|Active Comparator|TECH (Technology)|Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.
2862895|NCT03509129|Experimental|TECH+COMP (Technology + Competition)|Participants will receive the same intervention components as the TECH goup, as well as a study designed team competition.
2862896|NCT03509116||Patient group 1|Observations only
2862897|NCT03509116||Patient group 2|Qualitative interview, key stakeholders, documentary analysis
2862898|NCT03509103|Experimental|Electronic partograph|"The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely."
2862899|NCT03509103|Active Comparator|Paper Partograph|An standard training on how to use and fill out partograph was conducted
2862900|NCT03509090|Experimental|ESP block group|Unilateral ESP block will be apllied as postoperative regional analgesia technique in addition to the multimodal therapy. Before patient is awakened, she is positioned in a right lateral position to perform ESP blocks. The skin will be disinfected with 2% chlorhexidine and 70% alcohol. ESP block at one side will be performed in the lateral decubitis position and at T4 transverse process level by using 10-MHz lineer ultrasound probe (Logic E book XP General Electrics, USA). The probe will be located 3 cm lateral to T4 spinous process in longitudinal parasagittal orientation. An 8 cm 21 gauge needle (BRAUN Stimuplex A®, Germany) will be inserted by using out of plane technique. The ESP blocks proceed with 15 ml of 0,25% bupivacaine, 7,5 ml 1 % lidocaine, ,7,5 ml 0,9 % NaCl as total 30 ml . The injections will be applied after the confirmation of location by hidrodisection developed anterior to erector spinae muscle with 1-2 ml of local anesthetic solution.
2862901|NCT03509090|Active Comparator|Control group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia prepared with tramadol.Patient controlled analgesia (PCA) with tramadol at 3mg/cc concentration is programmed with no basal infusion, demand dose 10 mg and 20 minute lock-out interval.Also, patients received 1 gr paracetamol in every 6 hours.
2862902|NCT03509064||1: Patients with small fiber neuropathy|patients with Sjogren syndrome have a definite small fiber neuropathy
2862903|NCT03509064||2: Patients without peripheral neuropathy|patients with Sjogren syndrome without signs of peripheral neuropathy (small or large fiber)
2862904|NCT03509051|Experimental|B vaccination|One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.
2862905|NCT03509038|Experimental|Urinary incontinence before bariatric surgery|All patients with urinary incontinence before bariatric surgery will be addressed for a urodynamic exam
2862906|NCT03509025|Experimental|Long Term Follow-up after Jointstem Transplantation|
2862907|NCT03509012|Experimental|HNSCC Arm 1|Durvalumab + cisplatin with radiation in patients with locally advanced squamous cell carcinoma of the head and neck (HNSCC)
2862908|NCT03509012|Experimental|NSCLC Arm 1|Durvalumab + cisplatin and etoposide with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
2862909|NCT03509012|Experimental|NSCLC Arm 2|Durvalumab + carboplatin and paclitaxel with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
2862910|NCT03509012|Experimental|NSCLC Arm 3|Investigator's choice of carboplatin and pemetrexed OR cisplatin and pemetrexed
2862911|NCT03509012|Experimental|SCLC Arm 1|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
2862912|NCT03509012|Experimental|SCLC Arm 2|Patients with limited-stage small-cell lung cancer (SCLC) should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
2862913|NCT03509012|Experimental|SCLC Arm 3|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin. Note: Arm 3 will only be opened if the regimen in SCLC Arm 1 is safe and tolerable.
2862914|NCT03509012|Experimental|SCLC Arm 4|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin Note: Arm 4 will only be opened if the regimen in SCLC Arm 2 is safe and tolerable.
2862915|NCT03508999|Experimental|Metronidazole Gel|Group A subjects will be given standard oral hygiene instructions on the visit with a standard 0.8 % metronidazole gel instructed to apply topically on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
2863332|NCT03506035||Healthy controls|From health blood donors
2862917|NCT03508999|Placebo Comparator|Placebo|Group C will be subjects will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
2862918|NCT03508973|Experimental|Sculptra|Sculptra, an injectable implant containing microparticles of ply-L-lactic acid, carboxymethylcellulose, non-pyrogenic mannitol and sterile water, will be injected into the decolletage.
2862919|NCT03508947|Experimental|WVE-210201 (Dose A) or placebo|
2862920|NCT03508947|Experimental|WVE-210201 (Dose B) or placebo|
2862921|NCT03508947|Experimental|WVE-210201 (Dose C) or placebo|
2862922|NCT03508947|Experimental|WVE-210201 (Dose D) or placebo|
2862923|NCT03508947|Experimental|WVE-210201 (Dose E) or placebo|
2862924|NCT03508934|Active Comparator|Intervention group (Continuous Glucose Monitroring and POC)|Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS) and Point of Care (POC) finger-stick blood glucose levels with application of hypoglycemia prevention protocol (activated based the GTS lower glucose alarms)
2862925|NCT03508934|Placebo Comparator|Control group (Point of Care-POC)|Hospitalized patients with DM2 will be monitored with POC blood glucose levels and application of hypoglycemia prevention protocol (activated based the POC values)
2862926|NCT03508921|Experimental|Periprocedural Antibiotics Only|Patients receive a one-time dose of antibiotics at the time of injection, prior to injection.
2862927|NCT03508921|Experimental|Extended Antibiotics|Patients receive a peri-procedural dose of antibiotics and an extended (3-day) course of antibiotics to be taken post-procedurally.
2862928|NCT03508908|No Intervention|Observation Period|HIV testing will only be done if ordered by the primary care clinician. Individuals diagnosed with HIV who have not yet notified partners will be offered assisted partner notification at a 6-week visit.
2862929|NCT03508908|Active Comparator|Intervention Period|Combination intervention with HIV-1 RNA testing followed by rapid tests if positive for HIV diagnosis, immediate ART if diagnosed, assisted partner notification with HIV-1 RNA testing of partners, and PrEP for uninfected partners in discordant relationships.
2862930|NCT03508895|Experimental|Whole hemp seed protein|25 grams of hemp seed protein powder, twice a day
2862931|NCT03508895|Experimental|Whole hemp seed protein plus bioactive peptides|22.5 grams of hemp seed protein and 2.5 grams of hemp seed protein hydrolysate derived bioactive peptides, twice a day
2862932|NCT03508895|Active Comparator|Casein protein|25 grams of protein powder, twice a day
2862933|NCT03508882|Active Comparator|Preseptal-pretarsal|The Preseptal-pretarsal group will receive injections of Botulinum Toxin Type A 100Unit/Vial (Product) in the preseptal site (Injection pattern A) and Saline Solution for Injection (placebo control) in the pretarsal site for 2 cycles at 3 months apart. Both groups will crossover and receive the alternative intervention. Hence in the second half of the trial, the Preseptal-pretarsal group will be injected with BtA in Pattern B and Pretarsal-preseptal group will receive Pattern A.
2862934|NCT03508882|Active Comparator|Pretarsal-preseptal|The Pretarsal-preseptal group will initially receive injections Botulinum Toxin Type A 100Unit/Vial (Product) in the reverse with the intervention at the pretarsal site (Injection pattern B) for 2 cycles at 3 months apart. Groups 1 and 2 will crossover and receive the alternative intervention. Both groups will crossover and receive the alternative intervention. Hence in the second half of the trial, the Preseptal-pretarsal group will be injected with BtA in Pattern B and Pretarsal-preseptal group will receive Pattern A.
2862935|NCT03508869|Active Comparator|Mirvaso® (brimonidine) topical gel, 0.33%|Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
2862936|NCT03508869|Active Comparator|Dysport®|Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
2862937|NCT03508869|Active Comparator|Dysport® in conjunction with Mirvaso|Dysport® in conjunction with Mirvaso
2862938|NCT03508856|Experimental|Picato 0.015% gel|Picato 0.015% gel, is a topical treatment for actinic ketatoses.
2862939|NCT03508843|Experimental|interactive virtual presence|install a car seat using advice from a remotely-located certified car seat technician communicating via interactive virtual presence
2862940|NCT03508830|Experimental|Liposomal Bupivacaine|
2862941|NCT03508830|Active Comparator|Standard Bupivacaine|
2862942|NCT03508817|Experimental|Atropine Sulfate 0.01% Eye Drops Group|Intervention group will receive atropine sulphate eye drops 0.01% once nightly for 2 years.
2862943|NCT03508817|No Intervention|Control group|Control group will not receive any medication.
2862944|NCT03508804|Experimental|Lidocaine-prilocaine cream|5-10 minutes prior to the start of the procedure, the participant will self-administer 10ml of the lidocaine-prilocaine cream vaginally using a syringe
2862945|NCT03508804|Placebo Comparator|Placebo cream (pain lucubrating gel)|5-10 minutes prior to the start of the procedure, the participant will self-administer 10ml of the placebo cream vaginally using a syringe
2862946|NCT03508791|Active Comparator|Trendelenburg group|Arterial, end-tidal, and transcutaneous carbon dioxide partial pressure are monitored in the Trendelenberg position
2862947|NCT03508791|Active Comparator|reverse Trendelenburg group|Arterial, end-tidal, and transcutaneous carbon dioxide partial pressure are monitored in the reverse Trendelenberg position
2862948|NCT03508765|Experimental|rsfMRI + Neurocognitive Tests|Participants diagnosed with multiple myeloma in complete, partial or very good partial remission per standard International Myeloma Working Group Criteria will complete neurocognitive tests and structural and functional rsfMRI (brain MRIs).
2862949|NCT03508752|Experimental|Radiation|Stereotactic Radiosurgery
2862950|NCT03508739|Experimental|ARM 1: randomization order AB|Subjects will present for a baseline mixed meal study day 1 (no medication). Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order AB). At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3. After an IV is placed, neprilysin activity will be measured at baseline. Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides. Following this, subjects will ingest a mixed meal. Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total. Blood pressure and heart rate will be monitored.
2862951|NCT03508739|Experimental|ARM 2: randomization order BA|Subjects will present for a baseline mixed meal study day 1 (no medication). Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order BA). At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3. After an IV is placed, neprilysin activity will be measured at baseline. Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides. Following this, subjects will ingest a mixed meal. Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total. Blood pressure and heart rate will be monitored.
2862952|NCT03508726|Experimental|Phase I dose escalation/Phase II portion|"Phase 1 dose escalation:~Patients will receive radiation therapy over 5 weeks, during which time they will be receiving ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation.~Phase II portion:~Patients will receive radiation therapy over 5 weeks, during which time they will be receiving intravenous (IV) ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation."
2862953|NCT03508713||early RA patients|patients must fulfill the 1987 ACR classification criteria for rheumatoid arthritis or 2010 Rheumatoid arthritis classification criteria of ACR/EULAR, and meet the condition that the course of disease was no more than 6 months. If enrolled, patients will be treated with disease modified antirheumatic drugs or biological agents.
2862954|NCT03508700|Experimental|TNX-102 SL 5.6 mg|2 tablets of TNX-102 SL 2.8 mg taken simultaneously and sublingually (under the tongue) each day at bedtime starting on Day 0 for 40 weeks
2862955|NCT03508687|Experimental|300mg Gemcabene daily week 1-12|Patients will receive 300mg gemcabene daily for weeks 1-12, starting on Day 1/ Visit T1.
2862956|NCT03508687|Experimental|Group 1: 300 mg Gemcabene daily week 12-24|After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.
2862957|NCT03508687|Experimental|Group 2: 600mg Gemcabene daily week 12-24|After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.
2862958|NCT03508674|Experimental|Intervention|Levita Magnetic Surgical System
2862959|NCT03508661|Experimental|SPIN-SSLED Program|
2862960|NCT03508648|Placebo Comparator|Matching Placebo|Subjects previously enrolled in the placebo arm of study G201002.
2862961|NCT03508648|Active Comparator|1 mg GTx-024|Subjects previously enrolled in the 1 mg GTx-024 arm of study G201002.
2862962|NCT03508648|Active Comparator|3 mg GTx-024|Subjects previously enrolled in the 3 mg GTx-024 arm of study G201002.
2862963|NCT03508635|Experimental|SAD Cohorts 1 through 6|Subjects will receive single doses of 5 mg up to 400 mg of CORT125134 (capsule) in a dose escalation format. The doses selected will be subject to amendment based on emerging data.
2862964|NCT03508635|Placebo Comparator|SAD Cohorts 1 through 6 Placebo|Subjects will receive single doses of Matching Placebo of CORT125134 (capsule).
2862965|NCT03508635|Experimental|Food Effect Cohort 7|Subjects will receive a single dose of CORT125134 (capsule) with a standard high fat breakfast. The dose will be chosen such that it has been previously administered in a prior SAD cohort.
2862966|NCT03508635|Experimental|Pharmacological Effect Cohort 8|Subjects will receive a single dose of 25 mg of prednisone on Day -19; a single dose of 25 mg prednisone and 600 mg of Mifegyne® on Day -12; and a single dose of 25 mg prednisone and a single dose of CORT125134 on Day 1. The dose of CORT125134 will be chosen such that it has been previously administered in a prior SAD cohort.
2862967|NCT03508635|Experimental|Proof of Concept (POC) Cohort 9|Subjects will receive a single dose of 25 mg of prednisone on Day -19; a single dose of 25 mg of prednisone and 600 mg of Mifegyne® on Day -12; and a single dose of 25 mg prednisone and a single dose of CORT125134 on Day 1. An oral glucose tolerance test will be administered on each study day. The dose of CORT125134 will be chosen such that it has been previously administered in a prior SAD cohort.
2862968|NCT03508635|Experimental|MAD Cohorts 10 and 11|Subjects will receive the selected dose of CORT125134 (capsule) following receipt of data from Cohorts 1-9 up to a maximum frequency of twice a day for a total of 14 days.
2862969|NCT03508635|Placebo Comparator|MAD Cohorts 10 and 11 Placebo|Subjects will receive Matching Placebo of CORT125134 (capsule) up to a maximum frequency of twice a day for a total of 14 days.
2862970|NCT03508635|Experimental|MAD of PoPE Cohorts 12 and 13|Proof of Pharmacological Effect (PoPE+POC). Subjects will receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day -5. Subjects will then receive the selected dose of CORT125134 (capsule) for a total of 13 days. Subjects may either receive a higher dose level than previously administered or a repeat of a dose level given in 1 of the previous 2 MAD Cohorts. Subjects will then receive 25 mg of prednisone (both cohorts) ad an oral glucose tolerance test (Cohort 13 only) on Day 14.
2862971|NCT03508635|Placebo Comparator|MAD of PoPE Cohort 12 and 13 Placebo|Subjects will receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day -5. Subjects will then receive the Matching Placebo of CORT125134 (capsule) for a total of 13 days. Subjects will then receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day 14.
2862972|NCT03508622|Experimental|Telehealth|This group will receive weight management treatment via 12 online group sessions, over 6 months. They will have Bluetooth-enabled scales that will allow them to transmit their weight data to the PI in between research visits. They will answer questionnaires and have research visits at baseline, 3 months, and 6 months.
2862973|NCT03508622|Active Comparator|Empower|This group will receive standard in-clinic individualized weight management with a multi-disciplinary group of providers, via 6 monthly clinic visits, over 6 months. They will answer questionnaires at baseline, 3 months, and 6 months.
2862974|NCT03508596|Experimental|Intervention|An educational intervention for the supervisors
2862975|NCT03508596|No Intervention|Control|
2862976|NCT03508596|No Intervention|Non-Intervention|
2863418|NCT03505385|No Intervention|Usual care|
2862977|NCT03508583||Participation|"Parents will complete the The Measure of Processes of Care 56- 20 (MPOC 56-20) questionary~Service providers will complete The Measure of Processes of Care for Service Providers (MPOC-SP)"
2862978|NCT03508570|Experimental|Group I (nivolumab)|Participants receive nivolumab i.p. over 90 minutes on days 1, 15, and 29. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
2862979|NCT03508570|Experimental|Group II (nivolumab and ipilimumab)|Participants receive nivolumab as in group I and ipilimumab i.p. on day 1. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
2862980|NCT03508570|Experimental|Group III (nivolumab and ipilimumab)|Participants receive both nivolumab and ipilimumab at the doses determined to be safest based on the results of Groups 1 and 2. Up to 12 participants will take part in this group.
2862981|NCT03508557|Experimental|Advance care planning tools|Advance care planning education and structured conversation using tools
2862982|NCT03508544|Active Comparator|Lumbar ESP block|Ultrasound-guided lumbar Erector spinae plane (ESP) block performed at the begining of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
2862983|NCT03508544|Active Comparator|QLB Block|Ultrasound-guided transmuscular quadratus lumborum block (QLB) performed at the begining of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
2862984|NCT03508544|Sham Comparator|Control|Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
2862985|NCT03508531|Active Comparator|ESP Block|Ultrasound-guided bilateral Erector spinae plane block performed at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
2862986|NCT03508531|Active Comparator|OSTAP Block|Ultrasound-guided bilateral OSTAP block performed at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
2862987|NCT03508531|Sham Comparator|Control|Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed. No block will be performed in this group.
2862988|NCT03508518|Experimental|Shared care device in psychiatry (DSPP)|System focused on collaboration between general medicine (GP) and psychiatry, offering psychiatric assessment consultations and guidance for patient addressed by his/her GP. Referrals are made to the GP with support for care or the patient can be oriented to routine psychiatric care.
2862989|NCT03508518|Active Comparator|Care as usual|"Patient will have usual care :~Psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center"
2862990|NCT03508492|Active Comparator|Knee surgeons|Four knee surgeons
2862991|NCT03508492|Active Comparator|Hip surgeons|Six hip surgeons
2862992|NCT03508492|Active Comparator|Cardiac surgeons|6 cardiac surgeons
2862993|NCT03508492|Active Comparator|Colon surgeons|6 colon surgeons
2862994|NCT03508479|Experimental|RG-HRV16 Inoculation|While wearing a dental bib, subjects will be asked to blow the nose prior to inoculation. With the head tilted back, a total of 0.5 mL (0.25 mL/nostril) will be administered using the MAD Nasal™ Intranasal Mucosal Atomization Device. Subjects instructed not to blow nose for 30 minutes afterwards.
2862995|NCT03508466||Group 1|adult participants from 18-65 years of age previous hypersensitivity reaction grades I-IV to intravenous ferric carboxymaltose (Ferinject)
2862996|NCT03508466||Group 2|adult participants from 18-65 years of age previous intravenous ferric carboxymaltose (Ferinject) and no hypersensitivity reaction
2862997|NCT03508466||Group 3|adult participants from 18-65 years of age previous hypersensitivity reaction grades I-IV to iron sucrose (Venofer)
2862998|NCT03508466||Group 4|adult participants from 18-65 years of age previous intravenous iron sucrose (Venofer) and no hypersensitivity reaction
2862999|NCT03508453|Active Comparator|IC14 (monoclonal anti-CD14 antibody)|IC14 4 mg/kg intravenously twice weekly for 12 weeks
2863000|NCT03508453|Placebo Comparator|Placebo|Placebo intravenously twice weekly for 12 weeks
2863001|NCT03508440|Active Comparator|Standard of Care|Oral steroids (prednisone or prednisolone) 60mg per day for 10 days or 60mg/day for 5 days followed by a 5 day taper
2863002|NCT03508440|Experimental|SOC + injection|Oral steroids as described above + intratympanic injection of dexamethasone (up to 1cc of 24mg/ml) - 3 injections over three weeks.
2863003|NCT03508440|Other|Injection only|Only Intratympanic injection of dexamethasone (up to 1cc of 24mg/ml) - 3 injections over three weeks
2863004|NCT03508427|Experimental|Toi Même plus treatment as usual|"One-Arm study Intervention: Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.~Tool: Toi Même mobile app"
2863005|NCT03508414|Experimental|Ketogenic diet|
2863006|NCT03508414|Experimental|Intermittent therapeutical fasting|
2863007|NCT03508414|Active Comparator|Control group|The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.
2863051|NCT03508063||Healthy population|Healthy subjects receiving stimuli (thermal stimuli and stressogenic physical stimuli) at rest, and being monitored MCPM.
2863052|NCT03508050|Experimental|Clamping double lumen tube|Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
2863053|NCT03508050|No Intervention|Not Clamping double lumen tube|Not Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
2863008|NCT03508401|Experimental|ICU intubated patients|"After inclusion, Echo-Doppler measurements are performed with Vivid S6 model (GE Healthcare France, Lyon, France). The left ventricular outflow tract velocity time index (LVOT TVI) will be measured with this device. Then, a passive leg raising (PLR) will be performed and finally LVOT VTI will be measured again after PLR~Patients will be classified in two groups according to the hemodynamic response to PLR :~Patients are responders if LVOT VTI increases of at least 10% after PLR~patients are non-responders if LVOT VTI does not increase or increase of less than 10% after PLR."
2863009|NCT03508375|Experimental|SSc without ILD|
2863010|NCT03508375|Experimental|SSc with ILD|
2863011|NCT03508375|Active Comparator|patients with idiopathic pulmonary fibrosis|
2863012|NCT03508362|Experimental|Drug user|Regular use of cocaine
2863013|NCT03508362|Active Comparator|Healthy volunteers|non-drug user
2863014|NCT03508349|Experimental|IST using RDT|Women presenting for their first ANC visit to facilities will be consecutively enrolled after providing informed consent. Women in the intervention group (IST+ routine care) will be tested for malaria at the health center during their ANC visits with an RDT. If positive, they will be treated with artemisinin-based combination therapy (ACT) in second or third trimester or quinine in the first trimester.
2863015|NCT03508349|No Intervention|Routine Antenatal Care|Women presenting for their first ANC visit to facilities will be consecutively enrolled after providing informed consent. Women in the comparison group (routine care) will receive routine antenatal care services per the national guidelines. They will not be tested for malaria at each antenatal care visit unless they are symptomatic for malaria.
2863016|NCT03508336||patients with disorders of consciousness|Patients with disorders of consciousness from several brain injury, assessed by Coma Recovery Scale-Revised (CRS-R), have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state.
2863017|NCT03508323|Experimental|Teneligliptin|
2863018|NCT03508323|Placebo Comparator|Placebo|
2863019|NCT03508310|Experimental|Intervention|29-minute clinic waiting room video intervention that includes three vignettes and a 2-part animation sequence about main characters who model overcoming challenges to optimal HIV care. The video was played on continuous loop in recognition of typically short patient wait times. Waiting room posters used images from the video to direct patients' attention to the video and reinforce prevention messages.
2863020|NCT03508310|No Intervention|Comparison|Historical comparison condition. Patients were exposed to standard waiting room environment (absent of intervention video and posters).
2863021|NCT03508284||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
2863022|NCT03508284||Healthy group|Healthy individuals without chronic disease
2863023|NCT03508271||Elderly individuals with NVAF and HF who are taking OAC's|
2863024|NCT03508258||Participants with NVAF starting Apixaban|
2863025|NCT03508258||Participants with NVAF starting Warfarin|
2863026|NCT03508245|Other|Wearable short wavelength light therapy|Wearable short wavelength light therapy
2863027|NCT03508232|Placebo Comparator|Placebo control|Two placebo capsules upon enrollment, followed by one placebo capsule p.o. every 12 hours for 7 days
2863028|NCT03508232|Experimental|Doxycycline hyclate|Two 100mg doxycycline capsules (200 mg) p.o. upon enrollment, followed by one 100 mg capsule p.o. every 12 hours for 7 days
2863029|NCT03508219|Experimental|BiOSS LIM C|The treatment strategy consists of contemporary PCI of the left-main bifurcation, using the BiOSS LIM C stent system, following diagnostic angiography demonstrating significant distal unprotected left main disease and local Heart Team discussion applying the anatomic SYNTAX Score.
2863030|NCT03508206|Experimental|SBRP arm|Food supplement in hard gelatin capsule form containing a Standardized botanical blend rich in polyphenols (SBRP)
2863031|NCT03508206|Placebo Comparator|Placebo arm|Hard gelatin capsule form containing maltodextrin, with the same appearance as SBRP capsules
2863032|NCT03508193|Experimental|Intervention|Whole-foods based smoothie as nutritional therapy
2863033|NCT03508180|Experimental|foot reflexology|patients WITH foot reflexology session during chemotherapy treatments
2863034|NCT03508180|Placebo Comparator|platinum-based treatment|Patients WITHOUT ANY foot reflexology session during chemotherapy treatments
2863035|NCT03508167|Experimental|Thermal Band plus Dorilax®|
2863036|NCT03508167|Other|Thermal Band plus Placebo|
2863037|NCT03508154|Active Comparator|Control Meal 1|Control carbohydrate solution
2863038|NCT03508154|Active Comparator|Control Meal 2|Control carbohydrate solution
2863039|NCT03508154|Experimental|Experimental Nutritional Product|Study nutritional formulation
2863040|NCT03508141|Experimental|Fibrinogen Concentrate|Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 60mg/kg FC FIBTEM A5 1-4mm = 50mg/kg FC FIBTEM A5 5-6mm = 40mg/kg FC FIBTEM A5 7-8mm = 30mg/kg FC FIBTEM A5 9-10mm = 20mg/kg FC
2863041|NCT03508141|Active Comparator|Cryoprecipitate|Fibrinogen Replacement using Cryoprecipitate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 6ml/kg Cryoprecipitate FIBTEM A5 1-4mm = 5ml/kg Cryoprecipitate FIBTEM A5 5-6mm = 4ml/kg Cryoprecipitate FIBTEM A5 7-8mm = 3ml/kg Cryoprecipitate FIBTEM A5 9-10mm = 2ml/kg Cryoprecipitate
2863042|NCT03508128||Micra subjects|Surgical procedure
2863043|NCT03508102|Experimental|Remifentanil 1 μg kg-1 (R1)|Received remifentanil 1μg/kg when induction of general anesthesia
2863044|NCT03508102|Experimental|Remifentanil 0.5 μg kg-1 (R0.5),|Received remifentanil 0.5μg/kg when induction of general anesthesia
2863045|NCT03508102|No Intervention|saline (control)|Injected the equal volume normal saline when induction of general anesthesia
2863046|NCT03508089|Other|Control Arm|
2863047|NCT03508089|Active Comparator|Multiple Sclerosis Arm|
2863048|NCT03508076|Sham Comparator|Sham Capsule|Patients swallowed 1 sham Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
2863049|NCT03508076|Experimental|Vibration Capsule of low level|Patients swallowed 1 low level vibration Capsule Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
2863050|NCT03508076|Experimental|Vibration Capsule of high level|Patients swallowed 1 high level vibration Capsule Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
2863054|NCT03508037|Experimental|Experimental group|The subject receives the Functional Electrical Stimulation (FES) when he or she has the intention to move. It is obtained through electroencephalography.
2863055|NCT03508037|Active Comparator|Control group|The subject receives the Functional Electrical Stimulation (FES) after o before (0.5 seconds) when he or she has the intention to move. It is obtained through electroencephalography.
2863056|NCT03508011|Experimental|IMP4297|
2863057|NCT03507998|Experimental|CGX1321 Dosing|"Dose Escalation Phase: Ascending doses of CGX1321 will be administered by cohort to determine the maximum tolerated dose. Patients will receive CGX1321, once daily, orally, for 3 weeks (21 days) followed by a one week (7 day) washout period in each 28 day cycle, according to the cohort they are assigned.~Dose Expansion Phase: Patients will receive the recommended dose (identified in the Dose Expansion Phase) of CGX1321"
2863058|NCT03507985||The exposed group|The exposed group where patients receive morphine analgesia The patient will realise two tests evaluating memory and attention, for the first at the inclusion visit after giving his consent, and in a second time during the follow up visit 15 days or 1 month later.
2863059|NCT03507985||The unexposed group|"The unexposed group where patients receive 1 +/- 2-stage analgesia is non-opioid analgesics.~The patient will realise two tests evaluating memory and attention, for the first at the inclusion visit after giving his consent, and in a second time during the follow up visit 15 days or 1 month later."
2863060|NCT03507972|Other|Ankle ultrasound & ankle MRI|Ankle ultrasound performed on the day of emergency consultation member MRI (without injection of contrast products) performed within 7 days following the trauma
2863061|NCT03507959|Experimental|OLP scientifically-objective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
2863062|NCT03507959|Experimental|OLP personally-affective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.
2863063|NCT03507959|Experimental|DP scientifically-objective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.
2863064|NCT03507959|Experimental|DP personally-affective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
2863065|NCT03507959|No Intervention|Control group|This group does not take the nasal spray.
2863066|NCT03507946|Experimental|Test|"Subject self control; Plaque 1: Dermawrap - combined 460nm, 633nm, and 830nm LED therapyDaily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.~Plaque 2: No Intervention"
2863067|NCT03507920|Experimental|Neck passive mobilizations|
2863068|NCT03507920|Placebo Comparator|Manual contact|
2863069|NCT03507907|Experimental|Study Group|Mulligan mobilization techniques were applied to the older adults.
2863070|NCT03507907|Other|Control Group|Conventional physiotherapy programs were applied to the older adults who included in control group.
2863071|NCT03507894||m-health stroke rehabilitation|8-week multimodal exercise rehabilitation program (MERP) based on aerobic exercise, task oriented activities, balance and stretching exercises complemented with a mobile app technology
2863072|NCT03507881||Ennovate|Implantation of an Ennovate® internal fixation
2863073|NCT03507868||Group 1|Periodontally healthy individuals
2863074|NCT03507868||Group 2|Chronic periodontitis patients
2863075|NCT03507855|Experimental|Noise reduction|Reduced operating room personnel, low ambient light and soft background music during induction and emergence from anesthesia.
2863076|NCT03507855|Active Comparator|Control|Normal operating room environment.
2863077|NCT03507842|Experimental|High-dose cytarabine|High-dose cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).
2863078|NCT03507842|Experimental|high-dose daunorubicin|cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7) plus high-dose daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).
2863079|NCT03507829|Active Comparator|Basal insulin|NPH Insulin Titration Regimen : Pre-dinner Capillary blood glucose NPH dose initiation (IU/day) NPH dose adjustment(IU/day) > 240 mg/dl 14 Increase by 4 > 180 mg/dl 12 Increase by 4 > 140 mg/dl 10 Increase by 4 > 120 mg/dl 0 Increase by 2 100 to 119 mg/dl 0 Maintain the dose 80 - <100 mg/dl 0 Decrease by 4 60 - <80 mg/dl 0 Decrease by 8 < 60 mg/dl 0 Give ½ of previous dose
2863080|NCT03507829|Active Comparator|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation
2863081|NCT03507829|Active Comparator|Sensor-augmented Insulin Pump|Continuous subcutaneous sensor-augmented insulin-pump therapy (SAPT) with an insulin pump from Medtronic (Paradigm® Velo) for a period of approximately 3 months post-transplantation.
2863082|NCT03507803|Experimental|Gait Biofeedback|This group will receive audiovisual feedback about the position of their foot during walking. Feedback will be provided over 8 total sessions.
2863083|NCT03507803|No Intervention|Control|This arm will not receive any audiovisual feedback about the position of their foot during walking.
2863084|NCT03507790|Active Comparator|Active Treatment- CT1812 100 mg|CT1812 at a dose of 100 n=8 group
2863085|NCT03507790|Active Comparator|Active Treatment- CT1812 300 mg|CT1812 at a dose of 300mg, n=8 group
2863086|NCT03507790|Placebo Comparator|Placebo Comparator - Placebo|Placebo, n=8 group
2863087|NCT03507777|Active Comparator|Coronary PCI guided by OCT|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with OCT guidance according to the algorithm described in the protocol. OCT imaging is required pre and post stent implantation.~At the end of the procedure, a final OCT imaging run must be performed."
2863088|NCT03507777|Active Comparator|Coronary PCI guided by Angiography|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with angiography guidance according to local standard practice.~At the end of the procedure, a blinded OCT shall be performed to document final stent dimensions and results."
2863089|NCT03507764|No Intervention|Control Group|"During the randomized study phase (6 months),subjects will perform their usual activity without access to the treadmill workstation in the dispatch center.~After six months, all subjects will continue to be assessed with free access to the treadmill workstation at the workplace."
2863090|NCT03507764|Experimental|Experimental Group|"During the randomized study phase, subjects will have an open access to the treadmill workstation with the indication to use it for at least one hour (continuous or split) on working days.~After six months, all subjects will continue to be assessed with free access to the treadmill workstation."
2863091|NCT03507751||Meropenem|Patients who require meropenem and CRRT during ICU (intensive care unit) stay
2863092|NCT03507738|Experimental|Adult MT-5625 middle dose|Adult receiving intramuscular injection with either middle dose of MT-5625 or placebo
2863093|NCT03507738|Experimental|Adult MT-5625 high dose|Adult receiving intramuscular injection with either high dose of MT-5625 or placebo
2863094|NCT03507738|Experimental|Toddler MT-5625 middle dose|Toddler receiving intramuscular injection with either middle dose of MT-5625 or placebo
2863095|NCT03507738|Experimental|Toddler MT-5625 high dose|Toddler receiving intramuscular injection with either high dose of MT-5625 or placebo
2863096|NCT03507738|Experimental|Infant MT-5625 low dose|Infant receiving intramuscular injection with either low dose of MT-5625 or placebo
2863097|NCT03507738|Experimental|Infant MT-5625 middle dose|Infant receiving intramuscular injection with either middle dose of MT-5625 or placebo
2863098|NCT03507738|Experimental|Infant MT-5625 high dose|Infant receiving intramuscular injection with either high dose of MT-5625 or placebo
2863099|NCT03507738|Active Comparator|Rotarix|Infant receiving oral administration with Rotarix
2863100|NCT03507725|Experimental|Usual Care + Meditation|Usual care (local anaesthesia) + audio-recorded brief mind-dody intervention for 10 minutes before and for 10 minutes during the prostate biopsy procedure
2863101|NCT03507725|Active Comparator|Usual Care Group|Time-and-attention control group receiving usual care (local anesthesia) including optional background music in the biopsy procedure room
2863102|NCT03507712|Active Comparator|Symmetrical IO weakening.|Same surgery in both eyes
2863103|NCT03507712|Active Comparator|Asymmetrical IO weakening.|Different amounts or different surgery in each eye
2863104|NCT03507699|Experimental|Immunotherapy alone|Nivolumab will be administered at a dose of 3mg/kg every 2 weeks. Ipilimumab will be administered at a dose of 1mg/kg every 6 weeks. CMP-001 will be administered both into the liver metastasis (once), and also injected subcutaneously (four times, over six weeks) at a dose of 5-10 mg.
2863105|NCT03507699|Experimental|Combined radiotherapy and immunotherapy|"Liver radiation therapy: three treatments to one liver metastasis, administered on alternate days.~Nivolumab will be administered at a dose of 3mg/kg every 2 weeks. Ipilimumab will be administered at a dose of 1mg/kg every 6 weeks. CMP-001 will be administered both into the liver metastasis (once), and also injected subcutaneously (four times, over six weeks) at a dose of 5-10 mg."
2863106|NCT03507686|Experimental|AAV2-REP1|Bilateral sub-retinal administration of AAV2-REP1 at a range of intervals.
2863107|NCT03507673||Progynova/Dydrogesterone|
2863108|NCT03507673||Spontaneous cycle|
2863109|NCT03507673||Progynova/Crinone|
2863110|NCT03507673||Others Medication|
2863111|NCT03507660|Experimental|verbal instruction|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:~squeeze the pelvic floor muscles.~squeeze and lift the pelvic floor muscles as if stopping the flow of urine~Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.~squeeze the anus~shorten the penis~elevate the scrotum"
2863112|NCT03507647|Experimental|Mindfulness Based Cognitive Therapy added to usual care|Patients in the MBCT arm will be invited to participate in MBCT added to their usual care.
2863113|NCT03507647|Active Comparator|Usual Care|Usual care will typically consist of pharmacotherapy, psycho-education and self-management interventions (usually with a psychiatric nurse).
2863114|NCT03507634|Active Comparator|Opioid Based Anesthesia|General anesthesia will be induced using Propofol , fentanyl , and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with Remi-fentanyl and Sevoflurane.
2863115|NCT03507634|Active Comparator|Opioid Free Anesthesia|General anesthesia will be induced using dexmedetomidine and lidocaine started 10 minutes before induction, Propofol and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with IV infusion of dexmedetomidine , lidocaine and Sevoflurane.
2863116|NCT03507621||Propofol Group|1- Propofol Group: Propofol group will use 1 mg / kg propofol for the patient.Preoperative blood will be taken from the patients and cortisol, acth, glucagon, aldosterone, adrenalin, noradrenalin, PGE2, CRH will be studied. During the operation, the patient's systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, oxygen saturation will be followed. Analgesia will be provided according to the body movements of the patient and VAS measurement will be performed. Remifentanyl will be used as a anelgesic 0.5 mcg/ kg during operation. The patient's pain will be assessed by the VAS (Visuel Analogue Scale) scoring system and during the first hour postoperatively after the patient's consciousness is complete .
2863117|NCT03507621||Sevoflurane Group|1- Sevofluran Group: sevoflurane was administered at one minimum alveolar concentration (MAC) to end-tidal concentrations of 3% to 5%.Preoperative blood will be taken from the patients and cortisol, acth, glucagon, aldosterone, adrenalin, noradrenalin, PGE2, CRH will be studied. During the operation, the patient's systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, oxygen saturation will be followed. Analgesia will be provided according to the body movements of the patient and VAS measurement will be performed. Remifentanyl will be used as a anelgesic 0.5 mcg/ kg during operation. The patient's pain will be assessed by the VAS (Visuel Analogue Scale) scoring system and during the first hour postoperatively after the patient's consciousness is complete.
2863118|NCT03507608|Experimental|flutamide|50mg flutamide prior to brachytherapy and prostatic biopsy
2863119|NCT03507608|Placebo Comparator|placebo|placebo prior to brachytherapy and prostatic biopsy
2863120|NCT03507595||Patients with initial diagnosis of PCa|"T2 stage: PSA>20ng/ml, Gleason Score >= 8;~T3 or T4 stage;~The imaging examination was negative or localized metastasis of the pelvic lymph node, but there was no distant metastasis of lymph nodes or bone and internal organs other than the pelvic cavity."
2863121|NCT03507595||Patients with biochemical recurrent PCa|"After the RRP surgery,the serum PSA was over 0.2 ng/ml in two consecutive sera;~After the radiotherapy: the lowest PSA is up to 2 ng/ml."
2863155|NCT03507309||To be specified by Steering Committee.|
2863122|NCT03507595||Patients with CRPC|"The serum testosterone is in the castration level (< 50 ng/dL or < 1.7 nmol/L);~The PSA is elevated 3 times in a row, the base value is increased by more than 50%, and the PSA > 2ng/mL(the interval is one week);~The continuation of the anti-androgen drugs, flunamine was stopped for at least 4 weeks, and biglumide was suspended for at least 6 weeks;~Despite the continued standard androgen deprivation therapy, the PSA is still progressing."
2863123|NCT03507582|Active Comparator|Virtual Reality Distraction|This intervention consists of a disposable virtual reality headset which will enable the use of virtual reality in clinic through the commodity hardware iPod Touch. An additional piece of software on an iPad will allow clinical staff to act as an orchestrator and trigger events that occur for the patient's benefit in the virtual reality environment. The mechanism for the dashboard will be dashboard software running on an iPad tablet that will wirelessly communicate to the iPod Touch the patient is wearing. A study timer will be incorporated into the orchestration dashboard. The VAS/FACES scale will be incorporated into the iPad used for orchestration.
2863124|NCT03507582|Active Comparator|Standard of Care Distraction|This intervention consists of a two dimensional distraction (ie TV/tablet) as well as verbal distraction (ie singing/talking/music) will be allowed by caregivers, nurses and phlebotomy staff but will not qualified or quantified. IV procedures will proceed in Groups A and B. At the completion of the IV procedure the nurse orchestrator will stop the procedure timer. The Subject, Guardian and Nurse orchestrator will complete the Final VAS/FACES assessment on the iPad.
2863125|NCT03507569|Experimental|RO7017773|The first two participants of the first cohort are anticipated to receive a single dose of RO7017773 orally. The doses to be tested in the subsequent cohorts of participants will be determined by review of PET scan, PK, and safety results from the previous dose level.
2863126|NCT03507556|Experimental|Triple paste and induced bleeding|The triple paste is a mixture of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol will be used and next visit intracanal bleeding will be induced
2863127|NCT03507543|Experimental|IMP4297|
2863128|NCT03507504||care pathway with SCU-B|250 patients with dementia and behavioural and psychological symptoms of dementia (BPSD) followed up by six clinical centres with a Special Care Unit for BPSD (SCU-B)
2863129|NCT03507504||care pathway without SCU-B|250 patients with dementia and BPSD followed up by six clinical centres without SCU-B
2863130|NCT03507491|Experimental|Gemcitabine + Nab-paclitaxel|Participants receiving gemcitabine and nab-paclitaxel for refractory and/or relapsed solid tumors of childhood.
2863131|NCT03507478|Experimental|BPI1000013|Subjects suffering from pain associated with plantar fasciitis or general heel pain
2863132|NCT03507465|Experimental|Letrozole Plus Low-Dose Metronomic Capecitabine|
2863133|NCT03507465|Active Comparator|EC-T|
2863134|NCT03507452|Experimental|BAY2287411 Injection|Dose Escalation Cohorts in Subjects with Mesothelioma or Ovarian Neoplasm
2863135|NCT03507439||Heart failure patients|Patients hospitalized due acute heart failure, either with preserved (EF ≥ 45%) or reduced ejection fraction (EF ≤ 35%)
2863136|NCT03507426|Active Comparator|Retrobulbar group|Retrobulbar block
2863137|NCT03507426|Active Comparator|Ketamine group|Intravenous analgesia
2863138|NCT03507426|No Intervention|Control group|General anesthesia alone
2863139|NCT03507413|Active Comparator|INVESTIGATIONAL DRUG|oral metformin treatment with 2000Mg daily: 2x Metformin Hydrochloride 1000Mg Tablet (1-0-1) daily for 1 year
2863140|NCT03507413|Placebo Comparator|COMPARATIVE DRUG|Placebo Oral Tablet treatment twice daily (1-0-1) for 1 year
2863141|NCT03507400|Experimental|non-waiting list group|Intervention: Introvision: mental and emotional self-regulation
2863142|NCT03507400|Experimental|waiting list group|"Intervention: Introvision: mental and emotional self-regulation~Introvision is teached to participants of the waiting-list group at least 6 weaks or more after first group"
2863143|NCT03507387|Experimental|Intramuscular phenylephrine group|Patients in intramuscular phenylephrine group will receive spinal anesthesia with bupivacaine. 5 mg (1ml) phenylephrine intramuscular injection will be given into the gluteus maximus muscle before anesthesia.1ml of 0.9% normal saline intravenous injection will be given after the subarachnoid injection is completed.
2863144|NCT03507387|Active Comparator|Intravenous phenylephrine group|Patients in intravenous phenylephrine group will receive spinal anesthesia with bupivacaine. 1ml of 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia.100ug (1ml) phenylephrine intravenous injection will be given after the subarachnoid injection is completed.
2863145|NCT03507387|Placebo Comparator|Placebo group|Patients in intravenous phenylephrine group will receive spinal anesthesia with bupivacaine. 1ml of 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia. 1ml of 0.9% normal saline intravenous injection will be given after the subarachnoid injection is completed.
2863146|NCT03507374|Placebo Comparator|Placebo Comparator|After review of eligibility criteria, 20 patients will be randomized to the placebo arm of the study where patient will administer one subcutaneous injection of placebo every two weeks for a total of 52 weeks. Additionally, per standard-of-care, patient will also be treated with atorvastatin 40-80 mg.
2863147|NCT03507374|Active Comparator|Active Comparator|After review of eligibility criteria, 20 patients will be randomized to receive the investigational treatment of alirocumab 150mg which will be administered subcutaneously with a single-dose pre-filled pen syringe every 2 weeks for a total of 52 weeks. Additionally, per standard-of-care, patient will also be treated with atorvastatin 40-80 mg
2863148|NCT03507361|Experimental|MUSIC|Music will be administered through a normal computer equipped with a technology (Sound-of-Soul) that translates the patient's heart rate variability (HRV) into sounds according to a digital computer music-library. Music will start 10 minutes before and will end at the completion of the interventional procedure
2863149|NCT03507361|No Intervention|DUMB EARPHONES|Dumb earphones will be placed over patient's ears starting 10 minutes before and ending at the completion of the interventional procedure.
2863150|NCT03507348|Other|Desensitization with Tocilizumab and rituximab (MFI >15000)|
2863151|NCT03507348|Other|Desensitization with Rituximab only (MFI<15000)|
2863152|NCT03507335||Atrial fibrillation|Patients with atrial fibrillation during measurements
2863153|NCT03507335||Sinus|Patients with sinus rhythm during measurements
2863154|NCT03507322||Ultrasound texturization|Application of ultrasound texturization (2D/3D ultrasound scanning)
2863159|NCT03507257||Early Onset Alzheimer's Disease (EOAD)|"Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia~Amyloid positive status (florbetaben PET scan with evidence of elevated amyloid as determined by a central read)~CDR score ≤ 1.0~flortaucipir (18F-AV-1451) PET scanning"
2863160|NCT03507257||Cognitively Normal (CN) Controls|"Meets criteria for cognitively normal, based on an absence of significant impairment in cognitive functions and activities of daily living~Mini-Mental State Exam score between 26-30~CDR score = 0~flortaucipir (18F-AV-1451) PET scanning"
2863161|NCT03507244|Experimental|Group 1,Intra-pemetrexed, radiotherapy|The treatment regimen consisted of intrathecal chemotherapy (via lumbar puncture, pemetrexed 10 mg, plus dexamethasone 5 mg, once per week, 5-8 times, 4-7 weeks in total) and radiotherapy. Radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on magnetic resonance imaging, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40-50 Gy.
2863162|NCT03507231|Active Comparator|Control|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination.
2863163|NCT03507231|Experimental|Direct Incentive|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination. They are offered an Incentive for Vaccination ($5 Amazon Gift Card).
2863164|NCT03507231|Experimental|Indirect Incentive|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination. They are offered an Incentive for completing a short survey ($5 Amazon Gift Card).
2863165|NCT03507218||1|Children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
2863166|NCT03507205||HOST-BIOLIMUS-Korea-3000|Active prospective registration of patients receiving biodegradable polymer-coated biolimus-eluting stents (BP-BES; Biomatrix, Biomatrix Flex, Nobori)
2863167|NCT03507205||EXCELLENT-PRIME|Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents (DP-EES; Xience Prime)
2863168|NCT03507205||EXCELLENT Prospective cohort|Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents and sirolimus-eluting stents (Xience V/Promus; Cypher)
2863169|NCT03507205||HOST-RESOLINTE|Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES-RI; Resolute Integrity)
2863170|NCT03507205||RESOLUTE-Korea|Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES; Endeavor; Resolute)
2863171|NCT03507192|No Intervention|Arm 1|30 subjects In arm 1, no intervention is performed.
2863172|NCT03507192|Active Comparator|Arm 2|30 patients In arm 2 , active comparators, Muscle relaxation using full body massage machine is performed every morning and evening for 30 minutes.
2863173|NCT03507179|Placebo Comparator|conventional dentures|a complete denture made through conventional processing technique
2863174|NCT03507179|Active Comparator|3d printed dentures|a complete denture made through 3D printing
2863175|NCT03507166|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
2863176|NCT03507153|Active Comparator|Bre-fllex group|Maxillary class III modification I edentulous patients that will recieve Bre-flex partial denture
2863177|NCT03507153|Experimental|PEEK group|Maxillary class III modification I edentulous patients that will recieve PEEK partial denture
2863178|NCT03507127|Active Comparator|Varenicline|
2863179|NCT03507127|Placebo Comparator|Placebo|
2863180|NCT03507114|Experimental|Rumination-Focused CBT (RFCBT)|RFCBT seeks to change the process of thinking as opposed to the content of thoughts as in standard CBT. The underlying idea is that shifting individuals repetitive negative thinking into the concrete mode will reduce unconstructive ruminations and worries.
2863181|NCT03507114|No Intervention|Wait List Control Group|This arm represents the wait-list comparison group.
2863182|NCT03507101||Invasive GAS infection study patients|
2863183|NCT03507088|Experimental|fulvestrant|500mg fulvestrant on days 0, 14, 28 and every 28 days thereafter Fluoroestradiol-PET is performed at baseline and after 28 days
2863184|NCT03507075|Active Comparator|Contingent|The Contingent group will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner.
2863185|NCT03507075|Sham Comparator|Noncontingent|The Noncontingent group will receive payments each day they successfully provide samples independent of the alcohol content of those samples.
2863186|NCT03507062|Experimental|Chloride-rich solution|Patients will receive two boluses of 10 and 20 ml/kg of the 0.9% saline in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
2863187|NCT03507062|Experimental|Low-chloride solution A|Patients will receive two boluses of 10 and 20 ml/kg of Ringer's lactate in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
2863188|NCT03507062|Experimental|Low-chloride solution B|Patients will receive two boluses of 10 and 20 ml/kg of Ringer's acetate in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
2877539|NCT03406793|Placebo Comparator|6. Placebo powder|
2863189|NCT03507062|Experimental|Very low-chloride solution|Patients will receive two boluses of 10 and 20 ml/kg of a plasmalyte-like solution (namely soluzione elettrolitica reintegrante [SER]) in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
2863190|NCT03507049|Active Comparator|Intervention group|The intervention Group receives operation with SI-joint arthrodesis with the iFuse implant. The patient undergoes full anesthesia. The procedure starts with an approximately 5cm long skin incision over the posterolateral aspect of the pelvis. A guide-pin is inserted over the sacroiliac joint at the desired entry-point, verified by fluoroscopy. The surgeons drills and boraches over the pin and the ifuse implant is inserted. This is repeated for a total of three implants. The wound is closed with non-resorbable suture. An injection of the SIJ with Marcaine is performed under guidance of fluoroscopy after closure.
2863191|NCT03507049|Sham Comparator|Sham group|"The sham operation will consist of the surgeon making the same skin incision as for an iFuse procedure, although nothing more, and then closing the wound.~The patients undergoing a sham operation will be under general anesthesia for a random time of 20-40minutes in order to keep the two procedures as similar as possible.~An injection of the SIJ with Marcain is performed under guidance of fluorscopy after closure."
2863192|NCT03507036|Experimental|Treatment|"All patients will undergo treatment with Profound system device. Using the radiofrequency and temperature setting within the FDA approved limits (460 +/- 5kHz and 65-75°C +/- 1°C), patients will be treated one time over the entire suprapatellar region bilaterally and followed for a 6 month period. The acute effect of the radiofrequency application will be determined by subjective and objective analysis using standard, close-up, 3D, cross-polarized, high resolution ultrasound, optical coherence tomography, transepidermal water loss measurements, and/or BTC 2000 measurements.~Biopsies will be taken using 0.33mm WellTech Rapid Core 0.33mm Biopsy Punch. Biopsies will allow investigators to correlate changes seen in skin measurements with histology and gene expression."
2863193|NCT03507023|Placebo Comparator|Placebo Control|2 capsules per day, each with 400 mg Cellulose microcrystalline, for 6 weeks.
2863194|NCT03507023|Experimental|Dietetic Supplement Group|2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 6 weeks.
2863195|NCT03507010|Experimental|Radiotherapy|Patients assigned to the Radiotherapy group are treated with electrons and will receive a total dose of 30 Gy.
2863196|NCT03507010|Placebo Comparator|Sham Radiotherapy|Patients assigned to the sham-radiotherapy group will not actually receive radiation. For these patients the radiation is simulated.
2863197|NCT03506997|Experimental|Pembrolizumab|Pembrolizumab will be given at a dose of 200mg IV every 3 weeks for a maximum of two years
2863198|NCT03506984|Experimental|Group A|the participant will do a program of inspiratory muscle training for 10-15 minutes once daily using Threshold Inspiration Muscle Training Device
2863199|NCT03506984|Experimental|Group B|the participant will start cycling slowly for five minutes without resistance at the beginning of the exercise as warming up, then the active phase will last 20-30 minutes, then decrease the speed with no resistance at the end of the exercise as cooling down using Electronic Bicycle Ergometer
2863200|NCT03506971|Experimental|Participants|"As part of this research, families will benefit from~pediatric nurse's interventions : home visits by a pediatric nurse who will center around three times: a time of observation of the development and progress of the baby, a time for play with the baby and a time to listening the parents.~psychologist's evaluation and joint home visits : home visits by the coordinating psychologist to evaluate three areas: child development, parenthood and parent-child interaction."
2863201|NCT03506971|Other|Control|"psychologist's evaluation : home visits by the coordinating psychologist to evaluate three areas: child development, parenthood and parent-child interaction."
2863202|NCT03506958||General Practice|Hundred patients with an X-ray confirmed diagnosis of a non-complex fracture or dislocation and planned to be treated in the general practice Zorgplein Lemmer.
2863203|NCT03506958||Hospital|Hundred patients with an X-ray confirmed diagnosis of a non-complex fracture or dislocation and planned to be treated in the Antonius Hospital Sneek.
2863204|NCT03506945|Experimental|mPEP|Behavioral Activation Therapy - Increase engagement in pleasant activities
2863205|NCT03506945|Active Comparator|Bibliotherapy|Bibliotherapy - Develop improved coping and problem-solving skills
2863206|NCT03506932|Experimental|Untreated|Bread containing 20% yellow pea flour.
2863207|NCT03506932|Experimental|Heat treated with 0% moisture|Bread containing 20% yellow pea flour.
2863208|NCT03506932|Experimental|Heat treated with 10% moisture|Bread containing 20% yellow pea flour.
2863209|NCT03506932|Active Comparator|Wheat|Bread made with 100% wheat flour
2863210|NCT03506919|Experimental|Arthitec 1|
2863211|NCT03506919|Experimental|Arthitec 2|
2863212|NCT03506906||Patients on established home mechanical ventilation|
2863213|NCT03506893|Experimental|Alphapump|Alfapump® device implantation under general anesthesia (30-45 minutes)
2863214|NCT03506893|Active Comparator|Ascites puncture|Iterative paracentesis compensated for by albumin infusions in ambulatory care.
2863215|NCT03506880|Experimental|MADD Materials|Handbook developed by MADD and the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
2863216|NCT03506880|Active Comparator|Surgeon General Materials|Information published by the Surgeon General about teens and drinking
2863217|NCT03506880|No Intervention|Control|
2863218|NCT03506867|Active Comparator|Usual care arm|We will provide the participants in this arm with pamphlets and knowledge about available services in the city through partner agencies. The life skills, training, and work arm will be offered to the usual care arm participants after the first six months of study enrollment.
2863219|NCT03506867|Active Comparator|Life skills, training, and work arm|Participants will receive life-skills workshops, training, education resources and access to small-paid or volunteering positions.
2863220|NCT03506854|Experimental|Normal Renal Function|Subjects with normal renal function will be matched by age (±10 years), weight (± 20%), and gender to the pooled mean values of subjects with the moderate renal impairment. Subjects will receive 1 dose of ISIS 681257.
2863222|NCT03506841|Active Comparator|Cerbrolysin|Preterm infants with gestational age less than 32 weeks at birth will receive once weekly Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections) starting at the corrected postnatal age of 5 months.
2863223|NCT03506841|No Intervention|Control|Preterm infants with gestational age less than 32 weeks at birth will receive routine care.
2863224|NCT03506828|Active Comparator|Surgical sympathectomy|All patients in this group will have standard surgical procedure
2863225|NCT03506828|Active Comparator|Radiofrequency ablation with phenol injection|patient will receive radiofrequency ablation of T2 and T3 sympathetic ganglia + phenol 6% (0.5ml) injection
2863226|NCT03506815|Experimental|Rivaroxaban Thromboprophylaxis|Rivaroxaban 10 mg po daily for 90 days(+/- 3 days). After the Day - 90 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.
2863227|NCT03506815|No Intervention|Standard of care|No rivaroxaban prophylaxis. Management will be at the discretion of the attending physician.
2863228|NCT03506802|Experimental|Treatment (Genetically engineered PBMC and PBSC)|Refer to outline
2863229|NCT03506789|Active Comparator|Treatment A:|24 mg dexamethasone i.v. perioperatively and 24 mg dexamethasone i.v. on the first postoperative day
2863230|NCT03506789|Active Comparator|Treatment B:|24 mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
2863231|NCT03506789|Placebo Comparator|Placebo|Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
2863232|NCT03506776|Active Comparator|Education Only Group|The education only group will receive foot self-management education.
2863233|NCT03506776|Experimental|Education and Thermometer Group|The intervention group will receive foot self-management education. Additionally, the intervention group will receive a Commercially Available Infrared Thermometer (CAIT). Education on use of the CAIT will be provided through demonstration using a foot model and CAIT.
2863234|NCT03506763|Placebo Comparator|Placebo Oral + Placebo Oral|Placebo Oral + Placebo Oral
2863235|NCT03506763|Active Comparator|Diclofenac oral + Placebo Oral|Diclofenac oral + Placebo Oral
2863236|NCT03506763|Active Comparator|Diclofenac oral + scopolamina oral|Diclofenac oral + scopolamina oral
2863237|NCT03506750|Experimental|IVC-1day|patients with proliferative diabetic retinopathy receiving IVC 1 days before surgery
2863238|NCT03506750|Experimental|IVC-2day|patients with proliferative diabetic retinopathy receiving IVC 2 days before surgery
2863239|NCT03506750|Experimental|IVC-3day|patients with proliferative diabetic retinopathy receiving IVC 3 days before surgery
2863240|NCT03506750|Experimental|IVC-4day|patients with proliferative diabetic retinopathy receiving IVC 4 days before surgery
2863241|NCT03506750|Experimental|IVC-5day|patients with proliferative diabetic retinopathy receiving IVC 5 days before surgery
2863242|NCT03506750|Experimental|IVC-6day|patients with proliferative diabetic retinopathy receiving IVC 6 days before surgery
2863243|NCT03506750|Experimental|IVC-7day|patients with proliferative diabetic retinopathy receiving IVC 7 days before surgery
2863244|NCT03506750|Sham Comparator|IVC-sham|patients with proliferative diabetic retinopathy receiving sham IVC
2863245|NCT03506750|Placebo Comparator|non-DR|patients with other retinopathy (idiopathic macular hole or epiretinal membrane)
2863246|NCT03506737|Experimental|Conventional exercise protocol|Conventional global exercise
2863247|NCT03506737|Experimental|Cycle ergometer exercise protocol|Stationary cycle ergometer exercise
2863248|NCT03506724|Other|Oral nifedipine|Oral medication 10mg and 20mg
2863249|NCT03506724|Other|Intravenous labetalol|intravenous medication 20mg, 40mg, 80 mg
2863250|NCT03506711|Active Comparator|T1DM Children and adolescents|Children and adolescents with Type 1 Diabetes Mellitus
2863251|NCT03506711|Active Comparator|Healthy Children and adolescents|Healthy community-dwelling children on no medication
2863252|NCT03506685|No Intervention|control group Standard ACL protocol|This group will receive the standard ACL protocol rehab
2863253|NCT03506685|Experimental|Dry needling and STM group|This group will also receive the standard ACL protocol in addition to STM and DN
2863254|NCT03506672|Experimental|Experimental group|Approach based on the meanings of vocal behaviours
2863255|NCT03506672|Active Comparator|Control group|Usual practices of formal caregivers regarding vocal behaviours
2863256|NCT03506659|Active Comparator|Test|2000 patients healthy in anesthesiology consultation
2863257|NCT03506659|Experimental|Patients|2000 patients in pain clinic consultation
2863258|NCT03506646|Experimental|Beetroot juice-Placebo|Subjects will be tested on two different days. The first day will be beetroot juice and the second day will be a placebo. Testing will take place approximately one hour after intake. There will be a 14 day washout period between testing days.
2863259|NCT03506646|Experimental|Placebo-Beetroot juice|Subjects will be tested on two different days. The first day will be a placebo and the second day will be beetroot juice. Testing will take place approximately one hour after intake. There will be a 14 day washout period between testing days.
2863260|NCT03506633|Experimental|MitoQ-Placebo|Subjects will be tested on two different days, first day will be baseline and MitoQ and second day will be Placebo. Testing will take place forty-minutes after MitoQ/placebo intake. There will be a 2-week washout between testing days.
2863261|NCT03506633|Experimental|Placebo-MitoQ|Subjects will be tested on two different days, first day will be baseline and Placebo and second day will be MitoQ. Testing will take place forty-minutes after placebo/MitoQ intake. There will be a 2-week washout between testing days.
2863262|NCT03506620|Placebo Comparator|Control|Subjects will be randomized to receive a single-injection QL block with normal saline (Saline Solution for Injection).
2863263|NCT03506620|Experimental|QL Block|Subjects will be randomized to receive a single-injection QL block with either local anesthetic (0.25% Ropivacaine injection).
2863264|NCT03506607|Experimental|Exercise in hypoxia 1500m|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 16%.
2863609|NCT03503968|Active Comparator|Phase II - HLA*other - disease entity 1|Investigator Choice therapy
2863265|NCT03506607|Experimental|Exercise in hypoxia 2500m|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 14%.
2863266|NCT03506607|Placebo Comparator|Exercise in normoxia|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). For the exercise performed in normoxia conditions, subjects will breathe room air.
2863267|NCT03506594|Active Comparator|Radiofrequency ON and Kinesiotherapy|The radiofrequency application protocol with CAPENERGY device, which has two electrodes: an active one, which will be introduced into the vagina, using a condom and gel to the emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The temperature used in the treatment will be 41° C, which this parameter will be placed in the equipment, maintained for 2 minutes at the anterior wall and 2 others minutes at the posterior wall. Five RF sessions will be performed, with a seven-day interval between them. For the application, participants will be placed in supine position. The session will be quick, with an average duration of 20 minutes. Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given.
2863268|NCT03506594|Placebo Comparator|Radiofrequency OFF and Kinesiotherapy|"The patient will be in supine decubitus, the vaginal probe of the radiofrequency apparatus will be introduced, with the gel previously heated. The radiofrequency will be off.~Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given."
2863269|NCT03506568|No Intervention|Control - no reminder|For Group 1, there will be no changes to their instructions or smart phone, which is the most common clinical situation.
2863270|NCT03506568|Active Comparator|Smart phone calendar app|For Group 2, their smart phone calendar app will be updated to give a scheduled medication alert, which patients uncommonly use but requires only a smart phone.
2863271|NCT03506568|Experimental|Integrated daily reminder using the D3 app|For Group 3, they will have their D3 app turned on to deliver both a push notification reminder to their smart phone and audio and visual reminders to their D3 device.
2863272|NCT03506555|Active Comparator|the arm A (Veress needle)|a standard reusable Veress needle technique was performed for laparoscopic entry
2863273|NCT03506555|Active Comparator|the arm B (Hasson)|the standard open Hasson technique was performed for laparoscopic entry
2863274|NCT03506542|Experimental|Ologen (OLO)|Ologen implant (model 830601) placed over scleral flap during phacotrabeculectomy
2863275|NCT03506542|Active Comparator|Mitomycin C (MMC)|Mitomycin C (MMC) 0.3 mg/ml for 3 minutes under the scleral flap during phacotrabeculectomy (standard procedure)
2863276|NCT03506516|Experimental|single type|Restricted to drinking only one type of alcohol
2863277|NCT03506516|Active Comparator|mixed type|Drinking and mixing different types of alcohols freely
2863278|NCT03506503|Experimental|processed Nanofat grafting|processed autologous Nanofat will be injected into the area of the scalp with androgenic alopecia.
2863279|NCT03506490|Experimental|Experimental|The participants of this study were 33 subjects of both genders (M = 68 years old; SD = 4.2 years old) and were divided in two groups: a control group (N = 15; M = 67, 6 years old; SD = 4.1 years old) and an experimental group (N = 18; M = 67, 4 years old; SD = 4.4 years old). The participants performed a Soda Pop test before the aerobic training session (Baseline). The training session lasted 45 minutes and was composed of running exercises. After the training session, the motor memory consolidation was held in three different stages: Training; 1 hour after training; 24 hours after training.
2863280|NCT03506477|Experimental|Enstilar® foam|Enstilar® foam - a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%.
2863281|NCT03506477|Placebo Comparator|Vehicle foam|does not contain the active ingredient
2863282|NCT03506464|Experimental|plantar fasciitis group|Myofascial release technique
2863283|NCT03506464|No Intervention|control group|None of the control group received the treatment
2863284|NCT03506451|Other|Single arm non-therapeutic interventional study|All subjects who enroll on study will be asked to complete questionnaires at baseline before treatment starts; the questionnaires are repeated at one month, three and six months after radiation therapy has been completed. the demographics questionnaire is completed at baseline only; the FACT-HN is completed at all four time points.
2863285|NCT03506438|Experimental|Mobile app group|Clinicians and family members will receive access to versions of the needs-focused mobile app that differ in content.
2863286|NCT03506438|Placebo Comparator|Usual care|Usual ICU care
2863287|NCT03506425|Experimental|Group 1|Standard care for 1 month, then standard care and Triheptanoin for 5 months.
2863288|NCT03506425|Experimental|Group 2|Standard care and Triheptanoin for 6 months.
2863289|NCT03506425|No Intervention|Group 3|Healthy controls for biomarkers
2863290|NCT03506412|Experimental|Entresto™|HFpEF patients will be given Entresto™
2863291|NCT03506399|Experimental|Oral Contraceptive (OC)|Ethinyl estradiol and levonorgestrel administered as a single dose, orally
2863292|NCT03506399|Experimental|Lanabecestat|Single oral dose of lanabecestat
2863293|NCT03506399|Experimental|Lanabecestat and OC|A single oral dose of oral contraceptive and single daily doses of lanabecestat
2863294|NCT03506386||MM participants|Participants diagnosed with MM and have initiated treatment will be observed since the diagnosis of MM (within the eligibility window of time, between January 1, 2008 and December 31, 2016) and the cut-off date for data collection (December 31, 2016), unless a participant has died or been lost to follow-up before that. The study is planned to last for approximately 24 months since its initiation. Initiation defined as the initiation visit for the first site.
2863295|NCT03506373|Experimental|Treatment (ixazomib citrate, ibrutinib)|Participants receive ixazomib citrate PO on days 1, 8, and 15 and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
2863329|NCT03506048|Experimental|Treatment (lenvatinib)|Patients receive lenvatinib PO QD for 8 weeks and up to 12 weeks in the absence of disease progression or unaccepted toxicity. Patients also receive radioactive iodine (RAI) I-131 orally as standard of care.
2863296|NCT03506360|Experimental|Treatment (ixazomib citrate, pembrolizumab, dexamethasone)|Participants receive ixazomib citrate PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71 and pembrolizumab IV over 30 minutes on days 1, 22, 43, 64. Participants also receive dexamethasone PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71. Courses with dexamethasone repeat every 84 days for up to 1 year and courses with ixazomib citrate and pembrolizumab repeat every 84 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2863297|NCT03506347|Active Comparator|Vancomycin 15mg/kg IV|Will receive 15mg/kg based on actual body weight (maximum of 2g) of vancomycin via the systemic route at a rate of 15mg/kg as per hospital guidelines. Systemic IV vancomycin is given via a forearm vein, given over an infusion timed to finish immediately prior to surgery.
2863298|NCT03506347|Experimental|Vancomycin 500mg Intraosseous|Will have the limb exsanguinated and an above knee tourniquet inflated to 300mmHg. Immediately following tourniquet inflation, Group B will receive 500mg of vancomycin, via an EZ-IO intraosseous cannula. The vancomycin would be administered in 150ml of saline solution. The intraosseous cannula would be placed into the epiphysis of the proximal tibia. The tourniquet will be left inflated for 10 minutes following completion of the IORA injection then deflated.
2863299|NCT03506334|Experimental|Pediatric Scoliosis Patients|
2863300|NCT03506321|Other|LANS|Lesions are assessed with chromoendoscopy, HD-WL & NBI
2863301|NCT03506308|Other|LUTONIX 035 Drug Coated Balloon PTA Catheter|This is a single-arm study. All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
2863302|NCT03506295|Other|Control|Standard of Care - Transbronchial cryobiopsies are obtained as a standard of care under fluoroscopy guidance
2863303|NCT03506295|Experimental|Intervention|In the intervention arm , radial ultrasound probe will be used in addition to standard of care described above to confirm adequate position of the cryoprobe before transbronchial cryobiopsy is obtained.
2863304|NCT03506282|No Intervention|No music|The participants will be required to run on a treadmill at 3 different speeds (6-8-10 km/h) with no music.
2863305|NCT03506282|Active Comparator|Traffic audio track|In addition to running on the treadmill, participants will be listening to an audio track resembling normal outdoor noise (70 dB) through earphones connected to a mobile phone.
2863306|NCT03506282|Experimental|Music at moderate volume|In addition to running on the treadmill, participants will be listening to music at a moderate volume (80 dB) through earphones connected to a mobile phone.
2863307|NCT03506282|Experimental|Music at moderate-to-high volume|In addition to running on the treadmill, participants will be listening to music at a moderate-to-high volume (85 dB) through earphones connected to a mobile phone.
2863308|NCT03506256|Experimental|Norofloxacin|The recommended dosage of norfloxacin for urinary-tract infections in adults is 400 mg orally every 12 hours; the drug should be given for 7 to 10 days in uncomplicated infections and for 10 to 21 days in complicated ones. Adverse drug effects were mild and included disturbances of the gastrointestinal tract and the central nervous system. The study shall be completed in accordance with the ICH topic E6 (R1)(CPMP/ICH/one hundred thirty five/95) guiding principle for top medical practice and the ideas enunciated within the announcement of Helsinki and the approval by way of an Institutional Ethics Committee.
2863309|NCT03506243|Experimental|Test group|Follitrope PFS
2863310|NCT03506243|Active Comparator|Control group|Gonal-F pen
2863311|NCT03506230|Experimental|Incentives group|a bonus to buy their medications if they improve their HbA1c
2863312|NCT03506230|No Intervention|Standard group|Will buy their medications as usual
2863313|NCT03506217||mitral valve prolaps|Hemodynamic recovery and anesthesia revealed by invasive arterial cardiac output (CO) measurement (Vigileo Flo-trac device) in 13 cases who underwent mitral valve (MV) repair with the transapical off-pump minimally invasive method in our clinic.
2863314|NCT03506178|Experimental|Obstructive sleep apnea patients|
2863315|NCT03506178|Other|Healthy controls|
2863316|NCT03506165|Experimental|Rheumatoid Arthritis with Periodontitis|Rheumatoid Arthritis patients with Periodontitis diagnosed after oral examination then treated with Periodontal treatment
2863317|NCT03506165|No Intervention|Rheumatoid without Periodontitis|Rheumatoid Arthritis patients without Periodontitis diagnosed after oral examination with. No interventions
2863318|NCT03506152||Culture positive|
2863319|NCT03506152||Culture negative|
2863320|NCT03506139|Experimental|Radiation Therapy|External beam radiation therapy delivered to target volume.
2863321|NCT03506126|Experimental|Leucine Adults > 65|In this arm, all subjects will receive all 8 of the leucine test levels, assigned in random order.
2863322|NCT03506113|Active Comparator|Gram stain-guided therapy group|The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics. The results of the Gram stains are categorised as Gram-positive cocci (GPC) chains, GPC clusters, Gram-positive bacilli (GPB), Gram-negative rods (GNR), or a combination of these. A non-pseudomonal beta-lactam antibiotic is selected when the Gram stain of the endotracheal aspirate shows only GPC chains and/or GPB. An anti-MRSA agent is selected when the Gram stain results show GPC clusters without GNR. An anti-pseudomonal agent is selected when the Gram stain results show GNR without GPC clusters. The combination of an anti-pseudomonal agent and an anti-MRSA agent is selected when the Gram stain results show both GPC clusters and GNR.
2863323|NCT03506113|Active Comparator|Guidelines-based therapy group|Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to the Infectious Disease Society of America and the American Thoracic Society (IDSA/ATS) guidelines because 47.7% of S. aureus isolates are MRSA in Japanese ICUs
2863324|NCT03506100|Other|water walking in spirometric values|Experimental: practice swimming complemented with water walking
2863325|NCT03506087|Experimental|Coaching|Receives printed advance care planning (ACP) materials. Receives advance care planning coaching session. May receive followup coaching session, typically by telephone.
2863326|NCT03506087|Active Comparator|Enhanced Control|Receives printed advance care planning materials only.
2863327|NCT03506074||General population|"Adult volunteers (≥18 years of age) selected as part of a project to investigate the role of lifestyle in preventing chronic diseases supported by the Campus Salute association (www.campussalute.it).~All volunteers performed the flavor test as described in Maione et al, Endocrine, 2016 (doi:10.1007/s12020-015-0690-y)."
2863328|NCT03506061|Experimental|Orkambi|Participants will receive Orkambi for 28 days
2877646|NCT03406013|Experimental|Group II|Written Information Prescription
2863333|NCT03506022|Other|patients with type 1 mellitus diabetes|All participants were admitted in sleep laboratory and screened for one night of 8 hours employing standard polysomnography (Brainnet System - Medatec) parameters
2863334|NCT03506009|Experimental|Argatroban combined with rt-PA|
2863335|NCT03506009|Active Comparator|rt-PA|
2863336|NCT03505996|Experimental|CS1001|Participants will receive CS1001 1200 mg by intravenous infusion every three weeks
2863337|NCT03505983|Active Comparator|ESR Prosthetic Foot First|Subject will start with an energy storing and returning (ESR) prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR prosthetic foot, and a powered prosthetic foot for 1 week. During the final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
2863338|NCT03505983|Active Comparator|Articulating ESR Prosthetic Foot First|Subjects will start with an Articulating ESR prosthetic foot first for 1 week, then will complete an additional week with the ESR prosthetic foot, and a powered prosthetic foot for 1 week.The final 4 weeks, all prosthetic feet will be available for use and subjects will self-select which foot to use for daily activities.
2863339|NCT03505983|Active Comparator|Powered Prosthetic Foot First|Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR prosthetic foot and an ESR prosthetic foot for 1 week. The final 4 weeks, all prosthetic feet will be available for use and subjects will self-select which foot to use for daily activities.
2863340|NCT03505970|Experimental|Sodium bicarbonate|0.3 g∙kg-1body mass of sodium bicarbonate
2863341|NCT03505970|Placebo Comparator|Placebo|Individuals will ingest 0.3 g/kg maltodextrin before undergoing exercise
2863342|NCT03505957|Experimental|SafeBreak Vascular Intervention|Every study participant will have SafeBreak Vasculars installed in each of their IV lines.
2863343|NCT03505944|Experimental|Treatment|Venetoclax+lenalidomide+rituximab
2863344|NCT03505931||Eluvia|Patients treated with Eluvia stent
2863345|NCT03505918|No Intervention|Standard municipal rehabilitation|Standard care with postoperative rehabilitation at the municipal facility.
2863346|NCT03505918|Experimental|No referral for rehabilitation|No referral for supervised postoperative rehabilitation. Only standard information booklet and advice during hospitalization.
2863347|NCT03505905|Experimental|Pregnenlone (phase 1 and 2)|Participants will receive pregnenolone at phase 1 (baseline-WK 7) and 2 (WK 8-16). The titration schedule is as follows: at baseline a 50 mg (BID, 7 days). WK 1=150 mg (BID, 7 days); WK 2=250 mg (BID, 14 days) and WK 4=250 mg (BID, 14 days) (BID, 14 days). At phase 2 (WK 8) to maintain the double blind of rerandomization, treatment in all conditions recommence at a dosage frequency similar to phase 1. At WK 8=250 mg (BID, 7 days); at WK 9=250 mg (BID, 7 days); WK 10=250 mg (BID, 14 days) and WK 12=250 mg (BID, 14 days) . During the participants' final WK (16), they will be instructed to titrate down the treatment according to the following schedule: 150 mg (BID, 4 days) and 50 mg (BID, 4 days), discontinue.
2863348|NCT03505905|Placebo Comparator|Placebo rerandom to placebo|Participants will receive placebo at phase 1 (baseline-WK 7) & treatment response assessed (MADRS score reduced <50% at WK8). Nonresponders are rerandomized to receive either treatment at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1= placebo (7 days); at WK 2=placebo (14 days) and WK 4=placebo (14 days). Placebo nonresponders rerandomized to placebo: At WK 8=placebo (7 days);WK 9=placebo (7 days);WK 10=placebo (14 days) and WK 12=placebo (14 days). During the participants' final WK (16), they will be instructed to titrate down (done in order to maintain the double blind) the treatment according to the following schedule: placebo (4 days) and placebo (4 days), discontinue.
2863349|NCT03505905|Experimental|Placebo rerandom to pregnenolone|Participants will receive placebo at phase 1 (baseline-WK 7) & treatment response assessed (MADRS score reduced <50% at WK8). Nonresponders are rerandomized to receive either treatment at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1=placebo (7 days); WK 2=placebo (14 days) & WK 4=placebo (14 days). Placebo nonresponders who are rerandomized to pregnenolone: At WK 8=250 mg (7 days);WK 9=250 mg (7 days);WK 10=250 mg (14 days) & WK 12=250 mg (14 days). During the participants' final WK (16), they will be instructed to titrate down the treatment according to the following schedule: 150 mg (4 days) and 50 mg (4 days), discontinue.
2863350|NCT03505905|Placebo Comparator|Placebo responsive cont placebo|Participants will placebo throughout phase 1 (baseline- WK 7) & treatment response assessed (MADRS score reduced <50% at WK8). Responders continue to receive placebo at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1=placebo (7 days); WK 2=placebo (14 days) & WK 4=placebo (14 days). Placebo responders remain on placebo: At WK 8, placebo (7 days); WK 9=placebo (7 days); WK 10=placebo (14 days) & WK 12=placebo (14 days). During the participants' final WK (16), they will be instructed to titrate down (done in order to maintain the double blind) the treatment according to the following schedule: placebo= 4 days) and placebo=4 days, discontinue.
2863351|NCT03505892||Participants receiving adalimumab|Participants with AS receiving adalimumab
2863352|NCT03505866|Other|Mutual support groups of HIV|HIV-positive people who did not enroll in a community home-based care intervention and receiving regular HIV services and support from mutual support groups of HIV
2863353|NCT03505853|Experimental|Givosiran with 5-probe cocktail|
2863354|NCT03505840||antiphospholipid group|pregnant ladies in the third trimester who have antiphospholipid syndrome
2863355|NCT03505840||control group|pregnant ladies in the third trimester who have no medical disorders with pregnancy
2863356|NCT03505827||TECNIS Monofocal|This group of patients has chosen to undergo implantation of a TECNIS monofocal ZCB00 lens during cataract surgery. This decision was made prior to enrolment in the study. This group of patients will receive standard of care cataract surgery, as any other patient would. The sole intervention we will be undertaking is a 24-2 Humphrey visual field test prior to surgery, and a 24-2 SITA standard Humphrey visual field test after surgery at 1 month post-operatively.
2863357|NCT03505827||TECNIS Symfony|This group of patients has chosen to undergo implantation of a TECNIS Symfony extended depth of focus lens during cataract surgery. This decision was made prior to enrolment in the study. This group of patients will receive standard of care cataract surgery, as any other patient would. The sole intervention we will be undertaking is a 24-2 SITA standard Humphrey visual field test prior to surgery, and a 24-2 Humphrey visual field test after surgery at 1 month post-operatively.
2880112|NCT03388580||BAL|patients undergoing elective bronchoalveolar lavage
2863358|NCT03505814|Experimental|Optiflow Group|high flow (6l/min), humidified oxygen administred into nasal cannula for post-extubation new born ventilated patients.
2863359|NCT03505814|Active Comparator|Control Group|Conventional oxygen therapy for post extubation care
2863360|NCT03505788|Placebo Comparator|high-dose loop diuretics+placebo|"At the moment of randomization (day 1), oral loop diuretics are stopped and the patient receives IV loop diuretics at a dose equal to the double of his oral daily maintenance dose + 500 mg IV bolus of placebo.~If the patient still have signs of volume overload the next mornings (day 2 and day 3), the patient will receive IV loop diuretics at a dose equal to the oral daily maintenance dose + 500 mg IV bolus of placebo. It the patient has no sign of volume overload at these time points, the study treatment will be stopped."
2863361|NCT03505788|Experimental|high-dose loop diuretics+acetazolamide|"At the moment of randomization (day 1), oral loop diuretics are stopped and the patient receives IV loop diuretics at a dose equal to the double of his oral daily maintenance dose + 500 mg IV bolus of acetazolamide.~If the patient still have signs of volume overload the next mornings (day 2 and day 3), the patient will receive IV loop diuretics at a dose equal to the oral daily maintenance dose + 500 mg IV bolus of acetazolamide. It the patient has no sign of volume overload at these time points, the study treatment will be stopped."
2863362|NCT03505775|Other|23Na-MRI|A 23Na magnetic resonance imaging of the calf (muscle and skin) was performed in every participating patient after clinical and laboratory examinations.
2863363|NCT03505762|Experimental|Arm I (tailored prednisone dose)|Participants receive rituximab IV, vincristine sulfate IV, doxorubicin hydrochloride IV, and cyclophosphamide IV on day 1. Participants also receive tailored prednisone dose PO QD on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2863364|NCT03505762|Active Comparator|Arm II (usual care prednisone dose)|Participants receive rituximab, vincristine sulfate doxorubicin hydrochloride, and cyclophosphamide as in Arm I. Participants also receive usual care prednisone dose PO QD on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2863365|NCT03505749|Experimental|TI-MBRP|Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be an 8-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
2863366|NCT03505749|Active Comparator|Standard MBRP|The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is an 8-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
2863367|NCT03505736||Diagnostic (stress test)|Within 2 years of initiating anti-estrogen therapy or 2 years after completing chemotherapy, participants undergo a stress test which consists of receiving adenosine IV over 1-5 minutes or regadenoson IV over 2 minutes and then undergoing CMR imaging over 45-60 minutes at baseline, and again 3-6 months later.
2863368|NCT03505723|Active Comparator|Tranexamic Acid (TXA)|Patients will receive a 1g loading dose of intravenous TXA before surgery and a 1g loading dose of intravenous TXA at the end of surgery (wound closure).
2863369|NCT03505723|Placebo Comparator|Placebo (0.9% normal saline)|Patients will receive a 1g loading dose of placebo (0.9% normal saline) before surgery and a 1g loading dose of placebo (0.9% normal saline) at the end of surgery (wound closure).
2863370|NCT03505723|Active Comparator|Hypotension-avoidance strategy|Aims to avoid hypotension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).
2863371|NCT03505723|Placebo Comparator|Perioperative hypertension-avoidance strategy|Aims to avoid hypertension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).
2863372|NCT03505710|Experimental|Cohort 1: HER2 OE|Cohort 1 will enroll approximately 40 subjects with HER2-over-expressing (OE)(immunohistochemistry [IHC] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma to receive trastuzumab deruxtecan (DS-8201a).
2863373|NCT03505710|Experimental|Cohort 2: HER2 Mutated|Cohort 2 will enroll approximately 40 subjects with HER2-mutated, unresectable and/or metastatic NSCLC to receive trastuzumab deruxtecan (DS-8201a).
2863374|NCT03505697|Experimental|IMT+PR Group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training. In addition standard pulmonary rehabilitation, patients received inspiratory muscle training.
2863375|NCT03505697|Experimental|PR group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training.
2863376|NCT03505684|Experimental|CTP group|1,000 mg of collagen tripeptide (CTP) was orally administered per day for 12 weeks.
2863377|NCT03505684|Placebo Comparator|Control group|1,000 mg of placebo (starch) was orally administered per day for 12 weeks
2863378|NCT03505671|Experimental|Group 1 (acupuncture)|Participants undergo 8 45-minute acupuncture treatments over 10 weeks.
2863379|NCT03505671|Active Comparator|Group 2 (usual care)|Participants receive usual care.
2863380|NCT03505658|Experimental|Intervention|The Intervention is educational with 6 workshops for 2 hrs a week. Data/ assessments are collected, pre and post the 6 weeks intervention and 6 months post follow-up.
2863381|NCT03505658|No Intervention|Control|One or two non-intervention related workshop talks are given; 1 hr each during the same 6 weeks as the intervention arm. Pre and post assessment/ data collection and 6 months follow-up are completed.
2863382|NCT03505645|Active Comparator|Treatment group 1: Periarticular infiltration|Patients undergoing total knee replacement who are randomised to Treatment Group 1.
2863383|NCT03505645|Active Comparator|Treatment Group 2: Intra-articular infiltration|Patients undergoing total knee replacement who are randomised to Treatment Group 2.
2863384|NCT03505632|Experimental|Recruitment with low PEEP|Recruitment maneuver ( RM) will carried out during 2 minutes with increasing PEEP in stepwise manner.PEEP increase from 5 to 10 cmH2O (3 breaths),then to 15 cm H2O (3 breaths), PEEP to 20 cmH2O (10 breaths).Then decrease by 5 cmH2O every 3 breaths till back to preset PEEP 5 cmH2O .Recruitment carried out at the following times: post intubation(T1) , after insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40cmH2O .
2863385|NCT03505632|Active Comparator|High PEEP without RM|"Patients will receive from the start during anesthesia high PEEP (15 cmH2O) with maintaining the peak airway pressure below 40 cm H2O.~Monitoring times: after intubation(T1), post-insufflation(T2), after desuflation (T3) and before extubation(T4)."
2863386|NCT03505619|Experimental|ASSIST 1.0|A ten-week intervention program using a person-centred approach to support the older person to set up goals to perform daily activities that he/she wants or needs to do. The activity goals will target improvements in quality of life, physical health, mental well-being, and conditions for social community. The focus will be on supporting the older person's activities in everyday life that are considered meaningful for the individual. During the intervention, a specially designed application will send reminders and feedback related to the older adults' activity goals of doing their prioritized everyday activities both to the older adults and to the home care providers via mobile phones, tablet etc. The home care providers will participate in coaching sessions supporting the intervention held by the team of researchers.
2863387|NCT03505619|No Intervention|Ordinary home care services|The home care providers in the control group (CG) will provide services as usual to older adults participating in the control group. They will however, identify potential older persons to participate in the control group according to the same procedure and criteria as the intervention group.
2863388|NCT03505606|Active Comparator|Control|Visual acuity tests on control participants
2863389|NCT03505606|Experimental|Amblyopic|Visual acuity tests on amblyopic participants.
2863390|NCT03505567|Other|Random Sequenced Interventions|Participants from three condition groups (normal, glaucoma, retinal disease) assigned two interventions (Kowa OCT Bi-μ and the Optovue iVue 100) under random sequence assignments.
2863391|NCT03505554|Experimental|Lorlatinib|100 mg QD
2863392|NCT03505541||Control group|Healthy, term, non-obese (BMI < 30) pregnant women with a singleton gestation scheduled for CS delivery at 37-41 weeks of gestation.
2863393|NCT03505541||Study group 1|Term pregnant, non-obese (BMI <30), diagnosed with gestational diabetes, scheduled for CS delivery between 37-41 weeks of gestation.
2863394|NCT03505541||Study group 2|Term pregnant, obese (BMI >30), non-diabetic and scheduled for CS delivery between 37-41 weeks of gestation
2863395|NCT03505528|Experimental|Cohort Group|There are five patient cohort groups. Each will receive a progressively higher starting dose of phenelzine sulfate, consecutively. Cohort A will start at 15mg/day and will be increased to 30mg/d by week 2 and further increased to 45mg/d for week 3, which will be maintained throughout the study. Cohort B will start at 45mg/d and will be held constant throughout the Study. Similarly, Cohort C, D & E will start at 60, 75 and 90mg/d, respectively, and will also be held on this dose throughout the study. The decision to escalate the dose for the next cohort will be made on the basis of the number of dose limiting toxicity (DLT) events observed during the first 8 weeks in the preceding cohort group. In addition, all cohort groups will receive a constant dose of Abraxane at 100mg/m2.
2863396|NCT03505515||Lung Cancer Patricipants in China|Participants with advanced/metastatic lung cancer (advanced NSCLC (IIIB/IV) and extensive disease SCLC) in China
2863397|NCT03505502|Placebo Comparator|placebo arm|group receive i/v saline plus irrigation of the myoma bed with normal saline
2863398|NCT03505502|Experimental|IV tranexamic acid group|group received IV tranexamic 1gm in normal saline
2863399|NCT03505502|Active Comparator|topical tranexamic acid group|group received topical tranexamic 2gm in normal saline
2863400|NCT03505489|Experimental|Mannitol challenge|Mannitol challenge performed per standard mannitol challenge procedure with deep inhalation technique
2863401|NCT03505489|Experimental|Mannitol challenge w/ TBI|Mannitol challenge performed per standard mannitol challenge procedure except with tidal breathing technique
2863402|NCT03505489|Experimental|Methacholine challenge w/ DI|Methacholine challenge performed per standard 2-minute tidal breathing challenge procedure except with deep inhalation technique
2863403|NCT03505489|Experimental|Methacholine challenge|Methacholine challenge performed per standard 2-minute tidal breathing challenge procedure (tidal breathing technique)
2863404|NCT03505476|Experimental|Study Participants|Device: Entac Medical device application Other: Patient Daily Assessment Other: Patient Discharge Assessment
2863405|NCT03505463||Injured participants|
2863406|NCT03505463||Healthy participants|
2863407|NCT03505450||Population sample|
2863408|NCT03505450||Purposive Sample|
2863409|NCT03505437|Experimental|Stress + Exposure|Stress Condition: Cold water condition of the socially evaluated cold pressor test (SECPT; Schwabe et al, 2008).
2863410|NCT03505437|Active Comparator|Control + Exposure|Control condition: Warm water condition of the SECPT.
2863411|NCT03505424|Active Comparator|Group 1: Standard of Care|Parents of infants born from April -August 2018 (Group 1)
2863412|NCT03505424|Active Comparator|Group 2: SMART NICU2HOME app|Parents of infants born from September 2018- January 2019 (Group 2)
2863413|NCT03505411|Experimental|melatonin, submaximal effort|1 arm 5 mg melatonin 1 hr before bedtime for 30 days
2863414|NCT03505398|Experimental|central vision disorder|
2863415|NCT03505398|Experimental|peripheral vision disorder|
2863416|NCT03505398|Other|control|
2863417|NCT03505385|Experimental|Co-created intervention|Stage 1. Workshops and co-creation protocol. A purposive sampling strategy will be used to identify a total of 5 to 6 residents living in one care home in Glasgow and in one care home in Barcelona. The service-learning methodology will be integrated within a current module in the Physical Therapy degree in a University located in Glasgow and in the Sport Sciences degree in a University located in Barcelona. A group of students will be involved in the design of two workshops for care home residents. After the two workshops, we will conduct two discussion groups. The first discussion group will be conducted by the same three to four students with researcher supervision. The second discussion group will be conducted by the same students, two researchers, three health professionals working in the care home (e.g. physical therapist, nurse, occupational therapist, geriatrician), one caregiver, one family member, and one policy maker will be invited.
2863419|NCT03505372|Experimental|Contrast enhanced mammography|"The CESM images will be performed according to clinical protocol~Images will be acquired within approximately 2-12 minutes of contrast injection~A total of four images per breast will be acquired with low and high energy~Two radiologists will prospectively review the CESM, and will use a third as tie-breaker~The CESM will be evaluated for the biopsy site and up to two additional findings in either breast~The biopsy site will be evaluated for abnormal findings that would suggest malignant involvement"
2863420|NCT03505359|Experimental|Experimental group|Group treated by the new protocol with partial knee immobilization
2863421|NCT03505359|Active Comparator|Control group|Group treated by a standard protocol for ACL reconstruction.
2863422|NCT03505346|Experimental|percutanous coronary intervention(PCI)|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. two times. 14-21 days before intervention and 30-35 days after intervention
2863423|NCT03505346|Experimental|Coronary artery bypass-graft(CABG)|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. two times. 14-21 days before intervention and 30-35 days after interventionintervention
2863424|NCT03505333|Experimental|conventional suture ligature|use of conventional sutures for hysterectomy
2863425|NCT03505333|Active Comparator|Liga Sure|use of conventional sutures plus use of Liga-sure for hysterectomy
2863426|NCT03505320|Experimental|zolbetuximab (Cohort 1A and Cohort 1B)|Participants will be treated with zolbetuximab on a 21-day cycle in which zolbetuximab will be administered as a single agent every 3 weeks until disease progression, toxicity requiring cessation, start of another anti-cancer treatment or other treatment discontinuation criteria are met. Cohort 1B will be opened if at least 1 participant achieves a confirmed response (complete response [CR] or partial response [PR]) as assessed by an independent central reader.
2863427|NCT03505320|Experimental|mFOLFOX6 plus zolbetuximab (Cohort 2)|Participants will be treated with zolbetuximab and mFOLFOX6 on a 42-day cycle in which zolbetuximab is administered on days 1 and 22, and mFOLFOX6 is administered on days 1, 15 and 29; however, for the first cycle, zolbetuximab will be administered on day 3 (instead of day 1) to allow for pharmacokinetic collection. Participants will receive 12 mFOLFOX6 treatments (4 cycles). Beginning at cycle 5, participants may continue on 5-FU and leucovorin along with zolbetuximab for the remainder of the study per investigator's discretion. mFOLFOX6 treatment includes oxaliplatin: intravenous [IV] infusion, leucovorin: IV infusion, fluorouracil bolus: IV bolus, fluorouracil infusion: continuous IV infusion.
2863428|NCT03505294|Experimental|Task-oriented training|"Task-oriented training consisting of 10 different motor tasks will be applied."
2863429|NCT03505294|No Intervention|Control group|The control group will be taught relaxation exercises and will be asked to perform.
2863430|NCT03505268|Experimental|telemedicine intervention|The intervention group, in addition to usual care, will get 10 telemedicine interventions by a certified nurse and dietitian who both specialize in treatment of type 1 diabetes.
2863431|NCT03505268|No Intervention|usual care|Usual care consisted of visits to the diabetes center every three months and communication with their doctor by phone when needed.
2863432|NCT03505255|Active Comparator|Group A|Group A: 40 patients will receive intraperitoneal neostigmine 0.25 mg in 30 ml normal saline and 1 ml normal saline intramuscular.
2863433|NCT03505255|Active Comparator|Group B|Group B: 40 patients will receive intraperitoneal neostigmine 0.5 mg in 30 ml normal saline and 1 ml normal saline intramuscular.
2863434|NCT03505255|Active Comparator|Group C|Group C: 40 patients will receive intramuscular neostigmine 0.5 mg in 1 ml volume plus 30 ml normal saline intraperitoneal.
2863435|NCT03505255|Placebo Comparator|Group D|Group D (control group): 40 patients will receive intraperitoneal 30 ml normal saline and 1 ml normal saline intramuscular.
2863436|NCT03505242|Experimental|BB|
2863437|NCT03505242|Experimental|DLT|
2863438|NCT03505229|Experimental|Stereotactic Body Radiotherapy (SBRT)|"Prior to SBRT, fiducial markers will be placed to aid with image guidance during radiation delivery. Fiducials will be inserted endoscopically (preferable) or intraoperatively. After this procedure, patients will have radiotherapy planning. During treatment, the fiducials will be used for registration with the images acquired during treatment (including kV fluoroscopy, MV or optical). The acquired images may be processed to determine fiducial location using KIM or MATT software from University of Sydney. SBRT 30-45Gray in 5 fractions will be given over 2 weeks.~Four weeks after completion of SBRT participants will repeat a re-staging PET and CT scans. Those considered to be resectable will proceed to have surgery 6-10 weeks post SBRT."
2863439|NCT03505216||Patient population|Children referred to paediatric pulmonary outpatient clinics for respiratory symptoms such as wheeze, cough, dyspnea, exercise- and sleep-related breathing problems.
2863440|NCT03505203|Experimental|Sleep Soothe|An intervention in which parents are given information on how to respond to their baby's cues related to sleeping and fussiness.
2863441|NCT03505203|Active Comparator|Sleep Safe|An intervention in which parents are given information on a safe sleep environment, as well as other strategies to keep baby safe
2863442|NCT03505190|Experimental|Cohort 1|Eight participants will be administered subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931 and two participants will receive matching placebo.
2863443|NCT03505190|Experimental|Cohort 2|Eight participants will be administered subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931 and two participants will receive matching placebo.
2863444|NCT03505190|Experimental|Cohort 3|Eight participants will be administered subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931 and two participants will receive matching placebo.
2863445|NCT03505190|Experimental|Cohort 4|Eight participants will be administered subcutaneously (SC) 3.0 milligram per kilogram (mg/kg) of RO7062931 and two participants will receive matching placebo.
2863446|NCT03505190|Experimental|Cohort 5 (Optional)|Eight participants will be administered subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931 and two participants will receive matching placebo.
2863447|NCT03505177|Experimental|Chitin-glucan|Supplementation during 3 weeks with 4.5g per day of chitin-glucan fiber
2863448|NCT03505151|Experimental|All subjects|
2863449|NCT03505138|Experimental|Group intervention|Conventional management for COPD will take place in our health care system more telematics intervention.
2863450|NCT03505138|Active Comparator|Group control|Is performed only conventional management of COPD in our health care system.
2863451|NCT03505125||PKU Patients|Adults with PKU will be interviewed about the symptoms and impacts of PKU.
2863452|NCT03505125||Observers|Close friends and family members of adults with PKU will be interviewed about the behaviors they have observed in adults with PKU
2863453|NCT03505125||Clinical Experts|Experienced, practicing clinicians currently treating adults with PKU will be interviewed about the symptoms and impacts of PKU on their patients.
2863454|NCT03505112|Experimental|Goal-directed therapy group|The patients in goal-directed therapy (GDT) group will be managed according to the goal-directed therapy protocol during the surgery.
2863455|NCT03505112|No Intervention|Control group|The patients in control group will be managed according to standard perioperative care.
2863456|NCT03505099|Experimental|AVXS-101|One-time intravenous infusion of AVXS-101 at 1.1 X 1014 vg/kg
2863457|NCT03505086||cohort|All patients fulfilling the elligibility criteria who can be asked for consent. Basic register of only patient diagnosis, treatment and bleeding yes or no (without identifiable information).
2863458|NCT03505086||cases|Patient with clinically relevant bleeding, defined as major and clinically relevant non-major bleeding that leads to substantial additional medical care: WHO score 3-4 and part of the WHO score 2 bleedings (depending on the need for additional care).
2863459|NCT03505086||controls|Patient without clinically relevant bleeding matched to a case patient based on diagnosis and therapy.
2863460|NCT03505060|Experimental|Group 1: DNA CON-S env + IHV01|Participants will receive 4 mg of DNA CON-S env at Months 0 and 1. They will receive 4 mg of DNA CON-S env and 150 mcg of IHV01 at Months 3 and 6.
2863461|NCT03505060|Placebo Comparator|Group 2: Placebo|Participants will receive placebo at Months 0, 1, 3, and 6.
2863462|NCT03505047|Experimental|Immediate group:|The copper IUD will be inserted within 24 hours of the expulsion of the fetus and placenta or after surgical evacuation for placental remains, and prior to discharge from the facility.
2863463|NCT03505047|No Intervention|Delayed Group|The copper IUD will be inserted at a local community health centre 14-28 days after discharge.
2863464|NCT03505034|Experimental|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
2863465|NCT03505021|Experimental|Levosimendan|Levosimendan 1 mg capsules for oral administration, once to twice a day. The total duration of treatment 48 weeks
2863466|NCT03505021|Placebo Comparator|Placebo for levosimendan|Placebo capsule for oral administration, once to twice a day. The total duration of treatment 48 weeks.
2863467|NCT03505008|Experimental|MTX-Monotherapy Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the maximum tolerated dose (MTD) of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and simple disease activity index (SDAI) remission is achieved at Week 24, the MTX therapy will continue until Week 48.
2863468|NCT03505008|Experimental|ADA/MTX-Maximum Tolerated Dose Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the MTD of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and SDAI remission is not achieved at Week 24, Adalimumab (ADA) 40 mg will be administered subcutaneously every other week in addition to the MTX therapy until Week 48.
2863469|NCT03505008|Experimental|ADA/MTX-Reduced Dose Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the MTD of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and SDAI remission is not achieved at Week 24, Adalimumab (ADA) 40 mg will be administered subcutaneously every other week in addition to low-dose MTX (6 to 8 mg/week) treatment until Week 48.
2863470|NCT03504995|Experimental|IRE patients|patients who will underwent 'Focal irreversible electroporation of the prostate cancer'
2863471|NCT03504982|Experimental|Treatment 1|Treatment sequences: A*-B-C-D
2863472|NCT03504982|Experimental|Treatment 2|Treatment sequences: D-A-B-C*
2863473|NCT03504956|Other|Healthy Volunteers|"Approximately 100 healthy male/female adult normals or controls will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant."
2863474|NCT03504956|Other|Coronary Artery Disease (CAD) Patients|40 male/female adult outpatients who are suspected of having or have been diagnosed with coronary artery disease (CAD) will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant.
2863475|NCT03504943|Active Comparator|Early Intradialytic Exercise|Intradialytic cycling will occur in the first half of hemodialysis treatment
2863476|NCT03504943|Experimental|Late Intradialytic Exercise|Intradialytic cycling will occur in the second half of hemodialysis treatment
2863477|NCT03504930||Impact of biotherapy on postoperative morbidity|Impact of biotherapy on postoperative morbidity in ulcerative colitis
2863478|NCT03504917|Experimental|Balovaptan|
2863479|NCT03504917|Placebo Comparator|Placebo|
2863480|NCT03504904|Experimental|Internet-delivered ACT and CFT|8 week, guided internet- delivered acceptance and commitment therapy (ACT) and compassion focused therapy (CFT)
2863481|NCT03504904|No Intervention|Wait list control group|Wait list control group, received treatment at later point.
2863482|NCT03504891|Experimental|MRI Prior to CRT for Upgrades|MRI will be performed prior to CRT upgrade.
2863483|NCT03504891|Active Comparator|MRI Prior to de novo CRT Implants|MRI will be performed prior to de novo CRT implants.
2863484|NCT03504878||Patients undergoing laparoscopic appendectomy|Appendix removal via scope.
2863485|NCT03504878||Patients undergoing open appendectomy|Open operation for removal of appendix
2863486|NCT03504865|Experimental|Liposomal bupivacaine|"If a patient is randomized to the LB arm, at the appropriate time, under a surgeon's direction, 266 mg of (liposomal bupivacaine) LB in 20 cc of solution was expanded with various amounts of normal saline to cover the appropriate surgical field. Our routine expansion for a bilateral mastectomy is to add 80 mL of saline to 20 mL (266 mg) of LB. In our practice,we use an 18-gauge needle to inject the medication in a field-effect encompassing all 4 quadrants of the chest muscles (pectoralis and serratus) followed by injecting around the edges of the skin incision and drain site. This occurs prior to dissection of the pectoralis muscle and implant or tissue expander placement."
2864341|NCT03498989|Experimental|exclusive breast milk|will be given exclusive breast milk
2863487|NCT03504865|Active Comparator|Standard bupivacaine|Patients randomized to the SB arm will receive weight-based dosing of bupivacaine, administered in the same manner as the LB arm.
2863488|NCT03504865|Placebo Comparator|Placebo|Patients who are in the placebo arm will have a similar volume of saline injected into the operative site.
2863489|NCT03504852|Experimental|Secukinumab 300 mg every 2 weeks|2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter every 2 weeks. Subjects will remain on secukinumab 300 mg every 2 weeks until the end of treatment
2863490|NCT03504852|Active Comparator|Secukinumab 300 mg every 4 weeks|2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter every 4 weeks. Starting at Week 6, 2 secukinumab placebo (dummy drug) injections will be alternated every 4 weeks to maintain the blind. Subjects in this arm who do not achieve PASI 90 response at Week 16 will be randomized at Baseline to either remain on secukinumab 300 mg every 4 weeks or to receive secukinumab 300 mg every 2 weeks starting at Week 16 until the end of the treatment period
2863491|NCT03504839|Other|Intervention|S-ICD implantation.
2863492|NCT03504826|Experimental|Locomotor training using adaptive robot|The intervention will consist of 60 sessions of locomotor training using the HAL adaptive robot. The training sessions will be scheduled 5 days per week for 12 weeks. A physical therapist with expertise in SCI walking rehabilitation and use of the HAL will oversee all intervention sessions. The intervention sessions will include a total of 45 minutes of stepping time, which may take up to 2 hours to complete due to set up time and rest breaks.
2863493|NCT03504813|Experimental|Urinary Incontinence|"The involuntary loss of urine through the urethra, objectively demonstrable and constituting for the person who suffers it a social and hygienic problem.~In this arm, participants will receive the following interventions: physical activities program, training of the pelvic floor and counseling about occupational performance"
2863494|NCT03504813|Experimental|Insomnia|"A condition characterized by an unsatisfactory amount or quality of sleep which persists for a considerable period. This disorder includes difficulties for the falling and/or staying asleep and early awakening in the final phase of sleep.~In this arm, participants will receive the following interventions: physical activities program, relaxation training and counseling about occupational performance."
2863495|NCT03504813|Experimental|Risk of falls|"Involuntary events that cause people to lose balance and find themselves on the ground or other firm surfaces. The factor of falls can be intrinsic (related to the person) or extrinsic (derived from the activity or environment of the individual).~In this arm, participants will receive the following interventions: physical activities program, and counseling about occupational performance"
2863496|NCT03504800||Group A: Classification of Corneal Irregularities|This group will consist of participants >14 years old with various types of corneal irregularities. Their data will be compared against participants with healthy corneas. Data for this group will be gathered only once.
2863497|NCT03504800||Group B: Detection of Keratoconus Progression|Participants from Group A who are diagnosed with keratoconus will be selected for this longitudinal study to monitor keratoconus progression. They will be followed up to 4 years.
2863498|NCT03504800||Group C: OCT-and-Topography Guided PTK|Participants from Group A will be selected for this group if they have vision primarily limited by scars, dystrophy, or high astigmatism that could be treated by PTK. They will be followed up to 1 year.
2863499|NCT03504774|Experimental|Cashew Oral Immunotherapy|Participants, ages 12 to 55 years, inclusive, with an allergy to Cashew.
2863500|NCT03504774|Experimental|Milk Oral Immunotherapy|Participants, ages 12 to 55 years, inclusive, with an allergy to Milk.
2863501|NCT03504774|Experimental|Shrimp Oral Immunotherapy|Participants, ages 12 to 55 years, inclusive, with an allergy to Shrimp.
2863502|NCT03504761|Experimental|ClariCore System|ClariCore System study designed to obtain prostate biopsies utilizing real-time tissue classification with the ClariCore Optical Biopsy System.
2863503|NCT03504748|Active Comparator|deep rTMS-active doble coil|patients undergoing of deep rTMS real with doble coil
2863504|NCT03504748|Sham Comparator|deep rTMS-sham|patients undergoing to placebo deep rTMS
2863505|NCT03504735|Placebo Comparator|Therapeutic Lifestyle Change+Placebo|Therapeutic Life-style change intervention with Placebo pills.
2863506|NCT03504735|Active Comparator|Therapeutic Lifestyle Change+Caduet|Therapeutic Lifestyle Change intervention with Caduet pills.
2863507|NCT03504722|Experimental|RESCUE+PE|RESCUE is designed to adapt to individualized needs based on each veteran's performance. The volunteer training consists of weekly sessions lasting 90 minutes each and occurring at area Society for the Prevention of Cruelty to Animals (SPCA) facilities.All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD.
2863508|NCT03504722|Active Comparator|PE+delayed RESCUE|All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD.
2863509|NCT03504709||Patient (n=50)|Adults with acute severe traumatic brain injury who undergo advanced neuroimaging and electrophysiological studies while in the intensive care unit and are followed for 6 months post injury.
2863510|NCT03504709||Healthy (n=25)|Healthy adults with no neurological, psychiatric, or medical disease.
2863511|NCT03504696||Patients with Advanced Melanoma|RIC-Mel patients with advanced (unresectable or metastatic) melanoma treated with nivolumab in the context of nivolumab ATU program (occurred from 12-Sep-2014 to 31-Aug-2015)
2863512|NCT03504683|Experimental|Early Time-Restricted Feeding|
2863513|NCT03504683|Experimental|Mid-day Time-Restricted Feeding|
2863514|NCT03504683|Placebo Comparator|Control Schedule|
2863515|NCT03504670|Experimental|Early amniotomy|Women randomized to early amniotomy will have their membranes ruptured in usual fashion using an amniotomy hook when the cervix is less than 4cm dilated. This will occur after cervical ripening has taken place, with 1) a cervical Foley balloon catheter with or without oxytocin or 2) misoprostol. Prior to amniotomy, the obstetric provider will assess whether or not the fetal head is engaged. If the fetal head is not engaged (applied to the cervix), amniotomy will be deferred. The patient will be examined every 2 hours until amniotomy can be safely performed (in keeping with our institutional standard of care to examine women every 2-4 hours in labor).
2863610|NCT03503968|Experimental|Phase II - HLA*02:01 - disease entity 2|MDG1011 administration of Phase II recommended dose
2863516|NCT03504670|Experimental|Late amniotomy|Women randomized to late amniotomy will have their membranes ruptured once the cervix reaches at least 4cm dilation. This will occur after cervical ripening has taken place, with 1) a cervical Foley balloon catheter with or without oxytocin or 2) misoprostol. If the cervix fails to reach 4cm dilation 12 hours following cervical ripening, amniotomy will be performed.
2863517|NCT03504657|Experimental|Drug-coated balloon angioplasty|
2863518|NCT03504657|Active Comparator|stenting angioplasty|
2863519|NCT03504644|Experimental|Treatment (venetoclax, vincristine liposomal)|Patients receive venetoclax PO QD on days 1-42 of course 1 and days 43-70 of course 2. Patients also receive vincristine liposomal IV weekly for 4 weeks starting on day 14 of course 1.
2863520|NCT03504631||Breast cancer patients on tamoxifen|Patients currently on treatment with tamoxifen for at least 4 months.
2863521|NCT03504618||Metastatic colon cancer patients|Colon cancer patients with metastase at the diagnostic time, impossibility of radical resection, adenocarcinoma, treated by at least 3 cycles of FOLFOXIRI in the first-line in the Oncology and Palliative Care Department
2863522|NCT03504605|Experimental|Self-compassion intervention|Participants will be asked to recall and write (in an online text-box) about a parenting event during which they felt shame. They will then receive the online self-compassion intervention as detailed in Sirois, Bögels and Emerson (in revision). This involves parents in the experimental condition being given a validated set of instructions asking them to reflect on the event and write self-compassionate responses (see intervention).
2863523|NCT03504605|No Intervention|Control|Participants will be asked to recall and write (in an online text-box) about a parenting event during which they felt shame. Those in the control condition will be asked to re-read the account of the event and make notes about factual information (e.g. time of day, who was there, etc.). It should be noted that if the SCI is found to reduce state shame and increase state self-compassion, it will be offered to participants in the control group.
2863524|NCT03504592|Experimental|Glooko App|Glooko application and meter compatibility device (if required)
2863525|NCT03504592|Active Comparator|Traditional Care|Traditional clinic reporting system: paper/MyChart/emailed glucose logs
2863526|NCT03504579|Experimental|rt-fMRI neurofeedback aimed at STG|One session of rt-fMRI neurofeedback from the patient's STG.
2863527|NCT03504579|Sham Comparator|sham rt-fMRI|One session of rt-fMRI neurofeedback from the patient's motor cortex.
2863528|NCT03504566|Other|Intervention|All patients recieve, in randomomized order a four way treatment schedule. Due to the nature of the study, the individual patient will serve as his/hers own comparator.
2863529|NCT03504553|Experimental|Noise reduction|Reduced operating room personnel, low ambient light and soft background music during induction and emergence from anesthesia.
2863530|NCT03504553|No Intervention|Control|Normal operating room environment.
2863531|NCT03504540||Case (with pseudo-drusen-like deposits)|"Patients with lupus, treated or not with antimalarial drugs, with pseudo-drusen-like deposits"
2863532|NCT03504540||Control (without pseudo-drusen-like deposits)|"Patients with lupus, treated or not with antimalarial drugs, without pseudo-drusen-like deposits"
2863533|NCT03504527|Experimental|triple combinations|Budesonide/Fermotil inhalant 160ug/4.5ug bid; Tiotropium bromide inhalants 18ug qd
2863534|NCT03504527|Active Comparator|double combinations|Fermotil inhalants 4.5ug bid; Tiotropium bromide inhalants 18ug qd
2863535|NCT03504514|No Intervention|Conventional mechanical ventilation|Conventional mechanical ventilation, with patient ventilator usual parameters
2863536|NCT03504514|Experimental|Adapted mechanical ventilation|Mechanical ventilation with parameters specifically modified to improve speech the effect is evaluated with speech trials during different ventilation conditions
2863537|NCT03504501|Experimental|Exp. I: Noonan Syndrome - Lovastatin|200 mg Lovastatin daily for four days / Lovastatin-placebo (cross-over) prior to transcranial magnetic stimulation and test of attentional performance
2863538|NCT03504501|Experimental|Exp. II: Noonan Syndrome - Lamotrigine|300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance
2863539|NCT03504501|Experimental|Exp. III: Neurofibromatosis Type 1 - Lamotrigine|300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance
2863540|NCT03504488|Experimental|BA3021|All patients will receive BA3021, CAB-ROR2-ADC.
2863541|NCT03504475|Experimental|Paroxetine Hydrochloride Tablet|During the study session, healthy subjects will be administered a single dose of Paroxetine Hydrochloride Tablet 20mg under Fasting and Fed conditions.
2863542|NCT03504475|Active Comparator|Paxil®|During the study session, healthy subjects will be administered a single dose of Paxil® 20mg under Fasting and Fed conditions.
2863543|NCT03504462|Experimental|Distal tibial nerve block|Patient receiving a specific block of medial and lateral plantar nerves in order to preserve the calcaneal nerve
2863544|NCT03504449|Experimental|surgery without neoadjuvant chemoradiotherapy|For T3N1-2M0 rectal cancer with negative circumferential resection margin based on MRI assessment, recieve surgery without neoadjuvant chemoradiotherapy.
2863545|NCT03504449|Experimental|surgery with neoadjuvant chemoradiotherapy|For T3N1-2M0 rectal cancer with negative circumferential resection margin based on MRI assessment, recieve surgery following neoadjuvant chemoradiotherapy.
2863546|NCT03504423|Experimental|CPI-613, mFolfirinox|"CPI-613, mFolfirinox~CPI-613 at 500 mg/m2 IV infusion at a rate of 4mL/min via a central venous port on day 1 and 3 of a 14-day cycle.~mFolfirinox (given immediately after CPI-613 administration): Oxaliplatin (Eloxatin) at 65 mg/m2 given as a 2 hr IV infusion, Folinic acid at 400 mg/m2 given as a 90 min (1.5hr) infusion immediately after Oxaliplatin, and concurrently with Irinotecan (irinotecan at 140mg/m2 given as a 90 min IV infusion) via a Y-connector, Flurouracil at 400 mg/m2 as bolus followed by a 46 hr infusion at 2400mg/m2 starting immediately after completion of colonic acid and Irinotecan."
2863547|NCT03504423|Active Comparator|Folfirinox|"Folfirinox~Folfirinox (given immediately after CPI-613 administration): Oxaliplatin (Eloxatin) at 85 mg/m2 given as a 2 hr IV infusion, Folinic acid at 400 mg/m2 given as a 90 min (1.5hr) infusion immediately after Oxaliplatin, and concurrently with Irinotecan (irinotecan at 180mg/m2 given as a 90 min IV infusion) via a Y-connector, Flurouracil at 400 mg/m2 as bolus followed by a 46 hr infusion at 2400mg/m2 starting immediately after completion of colonic acid and Irinotecan."
2863611|NCT03503968|Active Comparator|Phase II - HLA*other - disease entity 2|Investigator Choice therapy
2863548|NCT03504410|Experimental|CPI-613 + HD Cytarabine and Mitoxantrone|"CPI-613 + HD Cytarabine and Mitoxantrone~CPI-613 at 2,000 mg/m2/day from day 1 to 5.~Cytarabine at 1gm/m2 (5 doses), every 12 hours starting on day 3.Mitoxantrone at 6gm/m2 (3 doses), everyday following the first, third and final doses of Cytarabine."
2863549|NCT03504410|Active Comparator|HD Cytarabine and Mitoxantrone|"HD Cytarabine and Mitoxantrone~Cytarabine at 1gm/m2 (5 doses), every 12 hours starting on day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the first, third and final doses of Cytarabine."
2863550|NCT03504397|Experimental|Arm A (zolbetuximab plus mFOLFOX6)|Participants will receive a loading dose of zolbetuximab at Cycle 1 Day 1 followed by a lower dose in subsequent cycles every 3 weeks. Additionally, participants will receive 12 treatments of mFOLFOX6 (or components of mFOLFOX6 if some components are discontinued due to toxicity) over 4 cycles (each cycle has 42 days) in which mFOLFOX6 is administered on Days 1, 15 and 29. Participants may continue to receive fluorouracil (5-FU) and leucovorin at the investigator's discretion until the subject meets study treatment discontinuation criteria.
2863551|NCT03504397|Placebo Comparator|Arm B (Placebo plus mFOLFOX6)|Participants will receive placebo starting at Cycle 1 Day 1 and every 3 weeks thereafter. Additionally, participants will receive 12 treatments of mFOLFOX6 (or components of mFOLFOX6 if some components are discontinued due to toxicity) over 4 cycles (each cycle has 42 days) in which mFOLFOX6 is administered on Days 1, 15 and 29. Participants may continue to receive fluorouracil (5-FU) and leucovorin at the investigator's discretion until the subject meets study treatment discontinuation criteria.
2863552|NCT03504371|Active Comparator|bilateral erector spinae block|The patient placed in a lateral position and ultrasound transducer placed 3 cm lateral to the T7 spinous process. Three muscles will be identified: trapezius, rhomboid major, and erector spinae. 8-cm 22-gauge block needle will be inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between rhomboid major and erector spinae muscles, as evidenced by visualization of local anesthetic spreading in a linear pattern between erector spinae and the bony shadows of the transverse processes. 20 mL of 0.25% bupivacaine will be injected then it will be repeated on the other side in the same way without changing the position of the patient to achieve sensory block T5-T10 .
2863553|NCT03504371|Sham Comparator|Thoracic epidural anesthesia|an epidural catheter placed at the T7-8 interspace after proper sterilization and positioning of the patient in the sitting position then standard technique of application will be applied, then a test dose consists of 3 ml of 1.5% preservative free lidocaine will be injected followed by 5-6 ml of bupivacaine 0.25%
2863554|NCT03504358||Analysis before liver resection|Multivariate analysis of predictive factors associated with survival
2863555|NCT03504358||Different risk group|Low-risk group, moderate-risk group, high-risk group
2863556|NCT03504358||Model comparison|Comparison of models in predicting survival
2863557|NCT03504345|Active Comparator|Control Group|This arm of the study will have their frozen-thawed embryo transfer take place on the sixth day of progesterone supplementation (Prometrium), which is the standard protocol in our clinic.
2863558|NCT03504345|Experimental|Experimental Group|This arm of the study will have their frozen-thawed embryo transfer take place on the seventh day of progesterone supplementation (Prometrium).
2863559|NCT03504332|Experimental|Calcium Hydroxide in revascularization|Revascularization of necrotic anterior teeth: canals disinfection step. Pure Calcium Hydroxide powder mixed with saline will be placed as intra-canal medication in the 1st visit of dental pulp revascularization.
2863560|NCT03504332|Active Comparator|Di-antibiotic paste in revascularization|Revascularization of necrotic anterior teeth: canals disinfection step. Mix 1:1 ciprofloxacin: metronidazole to a final concentration of 0.1 mg/ml, placed as intra-canal medication in the 1st visit of dental pulp revascularization.
2863561|NCT03504319||Lean Group|Pre-pregnancy BMI between 18.5 and 24.9 kg/m2
2863562|NCT03504319||Obese Group|Pre-pregnancy BMI ≥30 kg/m2
2863563|NCT03504280|Active Comparator|high dose IM|cholecalciferol 600,000 IU given intramuscularly
2863564|NCT03504280|Active Comparator|high dose oral|cholecalciferol 600,000 IU given orally
2863565|NCT03504280|Active Comparator|low dose oral|cholecalciferol 400,000 IU given orally in 2 divided doses given monthly for 2 consecutive months followed by daily maintenance dose of 1000 IU
2863566|NCT03504267|Experimental|Physical Activity Group|The PAG (physical activity) group will receive evidence-based educational information as well as a list of local resources for pursuing physical activity.
2863567|NCT03504267|No Intervention|Standard of Care Group|The SOC (standard of care) group will receive no additional information beyond standard-of-care brochures and information
2863568|NCT03504254||CSM|A total of 50 CM patients requiring surgical decompression will be recruited. The inclusion criteria are a clinical diagnosis of CM including the signs of corticospinal lesions together with the appropriate radiographic findings. Patients with acute spinal cord injuries, prior spinal intervention or claustrophobia will be excluded.
2863569|NCT03504241|Experimental|MSCs 10^4 cells/kg+anti-rejection drugs|The first dosing cohort of 2 participants will receive 12 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg every 4-weeks.
2863570|NCT03504241|Experimental|MSCs 10^5 cells/kg+anti-rejection drugs|If the first 3 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10^5 cells/kg every 4-weeks.
2863571|NCT03504241|Experimental|MSCs 10^6 cells/kg+anti-rejection drugs|If the first 3 infusions of 10^5 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10^6 cells/kg every 4-weeks.
2863572|NCT03504215|Experimental|young adults|Both young adults born preterm (n=60) and term (n=30) will undergo the exercise intervention.
2863573|NCT03504202|Other|Trimetazidine improves coronary microvascular dysfunction|
2863574|NCT03504189|Experimental|PregSense™|PregSense™ wearable device and the standard of care CTG (cardiotocography) will be applied for maternal-fetal monitoring
2863575|NCT03504176||Intervention|Patients will be ventilated according to the bundle; including ventilation targets, tidal volume, end expiratory pressure-fraction of inspired oxygen titration.
2863576|NCT03504176||Control|Standard of care prior to implementation of the ventilation bundle
2863612|NCT03503955|Experimental|study group|fine motor skills activities and Leap-Motion virtual reality games
2863613|NCT03503955|Experimental|control group|fine motor skills activities
2863577|NCT03504163|Experimental|Pembrolizumab (MK-3475)|Patients will receive Pembrolizumab (MK-3475) administered after TUR as single agent initial therapy. Pembrolizumab (MK-3475) will be administered as a 200 mg IV infusion at 3-week intervals for 9 doses over a 24 week period, unless there is unacceptable toxicity or other reasons to discontinue treatment occur.
2863578|NCT03504150|Experimental|SPHERE|It is an online self-guided comprehensive cognitive-behavioural therapy program that offers a headache diary, learning modules that teach a variety of cognitive and behavioural skills to cope better with their headaches, and a discussion forum where users may interact.
2863579|NCT03504150|Experimental|PRISM|It is an online self-guided brief cognitive-behavioural therapy program that offers a headache diary and helps users discover their headache triggers and non-triggers. Then the program provides the users with a few personalized recommendations to help them to cope with their triggers.
2863580|NCT03504150|No Intervention|Usual care|
2863581|NCT03504137|Experimental|mHealth Intervention|Participants will receive the mHealth application either while they are an inpatient post-transplant, or at one of their post-transplant clinic visits. Study personnel will assist participants with downloading the mHealth application and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
2863582|NCT03504124|Experimental|Intervention group|Patients will receive a multicomponent intervention.
2863583|NCT03504124|No Intervention|Control group|Patients will receive the usual care.
2863584|NCT03504111|Active Comparator|Needle Tenotomy|1 group will be assigned to get the standard treatment for chronic tendinopathy, percutaneous needle tenotomy (PNT). It is currently considered a standard treatment option. Ultrasound guided PNT with approximately 25 passes through the tendon and enthesis with approximately an 18 gauge needle with adequate amount of anesthetic (lidocaine) for effective anesthesia. Investigators will keep track of the number of passes through the tendon. Investigators will keep track of the amount and type of anesthetic used
2863585|NCT03504111|Active Comparator|Platelet Rich Plasma|1 group will be assigned to the PRP arm. Investigators will have a trained provider draw the blood, and prepare the PRP according to manufacturer and departmental (KP) protocol. Ultrasound guided injection of this PRP using approximately an 18 gauge needle with a single pass through the tendon into affected area as demonstrated on ultrasound. Adequate amount of anesthetic will be given in a separate syringe with adequate amount of anesthetic (lidocaine) for effective anesthesia. Investigators will keep track of amount and type of anesthetic used. The amount of anesthesia will be the same in both arms of the study
2863586|NCT03504098||Lung cancer patients tumor|Using to analysis metabolomic markers, one carbon folate nutrition levels in lung cancer patients.
2863587|NCT03504098||Lung cancer patients blood|Using to analysis folate, B12, homocysteine levels in plasma and RBC. Using to analysis cDNA gene test in buffy coat.
2863588|NCT03504098||Lung cancer patients|Supply nutrition counseling
2863589|NCT03504085|Experimental|Hatha Yoga|This arm will receive the active Hatha yoga intervention. Instructors lead participants through various yoga poses for 60-minutes, 1-2x weekly for 12 weeks, and daily home practice is recommended.
2863590|NCT03504085|Active Comparator|Restorative Yoga|This arm will receive a restorative yoga intervention. Instructors guide participants through relaxation exercises, typically with eyes closed, laying down, and minimal movement 60-minutes, 1-2x weekly for 12 weeks.
2863591|NCT03504072|Active Comparator|Tofacitinib 5mg|tofacitinib 5 mg 12 hourly daily for 9 months. Evaluation schedule will be baseline, 1st month, 3rd months and 3 monthly for 9 months. relevant investigations will be done at each visit. occurrence of tuberculosis and infections will be recorded at follow up visits.
2863592|NCT03504072|Active Comparator|Etanercept 50 mg|Etanercept 50 mg subcutaneously every 7 days interval for 1st month then, Etanercept 50 mg in 15 days interval for 2nd month then 50 mg every 21 days interval for 9 months. Occurrence of tuberculosis and infections will be recorded at follow up visits.
2863593|NCT03504059|No Intervention|Control|The usual educational program is applied
2863594|NCT03504059|Active Comparator|Short Intervention|A two-year specially designed educational program is applied. This program aims to encourage a healthy lifestyle through gamification, including diet education, physical activity and self esteem.
2863595|NCT03504059|Active Comparator|Long Intervention|A four-year specially designed educational program is applied. This program aims to encourage a healthy lifestyle through gamification, including diet education, physical activity and self esteem.
2863596|NCT03504046|Experimental|Artificial Pancreas App|After completing a 1 week open-loop run in period, subjects will use the APS APP for a 48-hour period in an observed transitional environment.
2863597|NCT03504033|Experimental|Xenon|Xenon concentration of 50-60 % will be used for maintenance of general anesthesia and will be adjusted to maintain Bispectral index (BIS) value between 40 and 60.
2863598|NCT03504033|Active Comparator|Desflurane|Desflurane concentrations of 4-5%/0.8 minimum alveolar concentration (MAC) respectively will be used for maintenance of general anesthesia and will be adjusted to maintain BIS index value between 40 and 60.
2863599|NCT03504020|Experimental|ECG Belt|The ECG Belt arm will utilize the ECG Belt Research System at implant and all follow up visits.
2863600|NCT03504020|No Intervention|Control Arm|Standard CRT through 6 months follow-up.
2863601|NCT03503994|Other|Drug|"Patients receiving inhaled beclomethasone diproprionate in four escalating doses:~200 mcg bid~400 mcg bid~600 mcg bid~800 mcg bid"
2863602|NCT03503981||Anxiety unit|Patients have anxiety as a primary diagnose. Receive treatment for anxiety (CBT and MCT).
2863603|NCT03503981||Eating disorder unit|Patients have eating disorder as primary diagnose. Receive treatment for their eating disorder (CBT and compassion-focused therapy).
2863604|NCT03503981||Depression unit|Patients have depression as primary disorder. Receive treatment for their depression (Short-term dynamic therapy, existential therapy and relational psychodynamic therapy).
2863605|NCT03503981||Family unit|One of the members of the family has a psychological disorder. The treatment is focused towards the family and family dynamics.
2863606|NCT03503981||Trauma unit|Patients have PTSD and relational trauma as primary diagnosis. Receive stabilizing treatment and exposure therapy.
2863607|NCT03503968|Experimental|Phase I - 3 disease entities|MDG1011 administration of escalating doses
2863608|NCT03503968|Experimental|Phase II - HLA*02:01 - disease entity 1|MDG1011 administration of Phase II recommended dose
2863614|NCT03503942|Experimental|Treatment arm|Participants in the treatment arm will receive structured group-based lifestyle interventions with stepwise addition of metformin for selected high-risk participants.
2863615|NCT03503942|No Intervention|Control|Participants in the control arm will receive the current standard of care for pre-diabetes which includes counseling on lifestyle modifications and follow up by primary care physicians.
2863616|NCT03503929|Other|LaparoGuard System|All patients receiving laparoscopic surgery, candidates for prolonged time under anesthesia, and are admitted for gynecological, urological or general surgery procedures who consent to use of the LaparoGuard System.
2863617|NCT03503903|Experimental|Wet Cupping|One armed self-controlled study. Individuals in this arm will receive three concecutive WCT application
2863618|NCT03503877|Other|SAGE Media|SAGE single-step MEDIA
2863619|NCT03503877|Other|GLOBAL Media|LIFE GLOBAL single-step MEDIA
2863620|NCT03503864|Experimental|Arsenic Trioxide(+)|Patients receive arsenic trioxide combined with conventional induction chemotherapy.
2863621|NCT03503864|Other|arsenic trioxide(-)|Patients receive conventional induction chemotherapy without arsenic trioxide.
2863622|NCT03503851|Active Comparator|One CLIP|Implantation of single MitraClip
2863623|NCT03503851|Active Comparator|Two CLIPs|Implantation of second MitraClip (after successful Implantation of single MitraClip)
2863624|NCT03503838|Experimental|Online Yoga|The intervention will be 12 weeks in duration and will consist of a series of pre-approved online yoga classes. MPN patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). Qualified Udaya yoga instructors who collectively have over 200 years of training and experience will expertly instruct the online yoga classes.
2863625|NCT03503838|No Intervention|Wait-List Control|The control group will be asked to maintain their usual level of activity for 16 weeks before being given access to the yoga intervention. Once study participants in the yoga group have completed all outcome measures up through the 4-week follow-up (week 16), participants in the control group will be allowed to participate in the same online yoga prescription that was provided to the yoga group.
2863626|NCT03503825|Experimental|Healthy Volunteers|Healthy volunteers will be administered [Tc-99m]-RPI-T-087 Injection, single IV dose of 925 MBq and will be monitored for safety, knee image evaluation, and radioactivity biodistribution and dosimetry.
2863627|NCT03503825|Experimental|Osteo Arthritis of the knee|Subjects with knee osteoarthritis will be administered [Tc-99m]-RPI-T-087 Injection, single IV dose of 925 MBq and will be monitored for safety and knee image evaluation.
2863628|NCT03503812|No Intervention|No intervention to DDS exposure - Asthma in Children|
2863629|NCT03503812|Experimental|Intervention 1 - Asthma in Children|
2863630|NCT03503812|Experimental|Intervention 2 - Asthma in Children|
2863631|NCT03503812|No Intervention|No intervention to DDS exposure - Atrial Fibrillation|
2863632|NCT03503812|Experimental|Intervention 1 - Atrial Fibrillation|
2863633|NCT03503812|Experimental|Intervention 2 - Atrial Fibrillation|
2863634|NCT03503799||Observational Group|Patients with primary invasive breast cancer, Stage I/II; ER positive, HER2 (human epidermal growth factor receptor 2) negative, N0-N1, T1-T3, tested with EndoPredict®, age over 18 years, informed consent
2863635|NCT03503786|Active Comparator|Arm A|Carboplatin AUC 5+Paclitaxel 175 mg/m2 q 21days for 6-8 cycles and Avelumab
2863636|NCT03503786|Experimental|Arm B|Carboplatin AUC 5+ Paclitaxel 175 mg/ m2+Avelumab 10 mg/kg q 21days for 6 -8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity
2863637|NCT03503773|Experimental|Treatment Arm:|Renal denervation (using the Peregrine Kit) performed with alcohol infused through the Peregrine Catheter
2863638|NCT03503773|Sham Comparator|Sham Control Arm|Only renal angiography performed
2863639|NCT03503760|Experimental|true-sham|"Patients first received the true LIMFA Therapy® treatment for 3 weeks followed by 3 weeks of washout and then six sham sessions for 3 weeks more."
2863640|NCT03503760|Experimental|sham-true|"Patients first received the sham treatment for 3 weeks followed by 3 weeks of washout and then six true LIMFA Therapy® sessions for 3 weeks more."
2863641|NCT03503734||Integrated headache care|"The treatment can be realized on an inpatient, outpatient and/or day care basis, according to the severity level of illness and comorbidities.~The inpatient treatment takes place at the Department of Internal and Integrative Medicine. The stay is slated for 14 days.~Day care can follow the inpatient stay or can be applied as sole therapy. As part of the standard care provided at the Department for Internal and Integrative Medicine, it occurs at a semi-residential clinic for 6 hours once a week over a total of 10 weeks.~The outpatient treatment is delivered in the Department's outpatient ward. It consists of acupuncture, cupping, hydrotherapy and massages as well as nutritional counseling. The patients can additionally be offered one-to-one mind-body-medicine interventions."
2863642|NCT03503721|Experimental|BipolEP|includes all patients undergoing BipolEP surgery
2863643|NCT03503721|Active Comparator|TURP|includes all patients undergoing TURP surgery
2863644|NCT03503708|Experimental|Intervention Group|All the eligible participants will receive Livitol-17 capsules. It consist of 390 mg of whole herbs and extract of Phyllanthus niruri (Bhumyamalaki), Boerhaavia diffusa (Punarnava) and Picroorrhiza kurroa (Katuki).
2863645|NCT03503695|Active Comparator|Auricular Acupuncture|Sterile acupuncture semi-permanent (ASP) gold needles will be administered in the following acupuncture points: Cingulate Gyrus, Thalamus point, Omega 2, Point Zero, and Shen Men starting in either ear and alternating left and right until 10 ASP needles are placed. The needles may remain in the AA points for 3-4 days.
2863646|NCT03503695|No Intervention|Comparison Group|There will be no intervention. The participants will be instructed to return on Day 8.
2863647|NCT03503682|Active Comparator|standard treatment|Patients in this group are treated with 3000 cGy in 10 daily fractions
2863648|NCT03503682|Experimental|short course treatment|Patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
2863649|NCT03503669|Active Comparator|Memory Training|Group memory training will be administered for amnestic mild cognitive impairment (MCI)
2863650|NCT03503669|Experimental|Kundalini yoga and meditation|Participants will engage in weekly yoga classes and daily 12 minute meditation
2863651|NCT03503656||CompuFlo|All the consecutive patients undergoing to an epidural catheter placement in Gynecological and Obstetric setting
2863652|NCT03503630|Experimental|Locally advanced rectal cancer patients|"Week 1: D1-5: radiotherapy 25 Gy in 5 fractions~mFOLFOX-6: Oxaliplatin 85 mg/m2 in a 2-hour infusion Leucovorin 400 mg/m² over 2 hours Bolus fluorouracil 400 mg/m² followed by a 48-hour infusion of fluorouracil 2,400 mg/m² + COMPOUND 2055269 10 mg/kg every 2 weeks (first administration at D15, for a total of 6 cycles)~Week 16 or 17 (2 to 3 weeks after last cycle of chemotherapy + COMPOUND 2055269): Total Mesorectal Excision"
2863653|NCT03503617|Experimental|RehabTouch Exercise Program|Participants will perform targetted movement exercises by interacting with the RehabTouch pucks, as described and monitored on a computer. Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks.
2863654|NCT03503617|Active Comparator|Conventional tabletop exercise program|Conventional tabletop exercise program is a traditional exercise program described in a booklet similar to what is typical provided to stroke patients upon their discharge from the hospital. Participants will be asked to perform these exercises at least 3 hours per week for 3 consecutive weeks.
2863655|NCT03503604|Experimental|group 1|hPV19 mAb plus FOLFOX(5-Fluorouracil,Oxaliplatin,Leucovorin)
2863656|NCT03503604|Experimental|group 2|hPV19 mAb plus paclitaxel/carboplatin
2863657|NCT03503604|Experimental|group 3|hPV19 mAb plus gemcitabine/carboplatin
2863658|NCT03503604|Experimental|group 4|hPV19 mAb plus FOLFIRI(5-Fluorouracil,Irinotecan, Leucovorin)
2863659|NCT03503578|Experimental|EEG Dynamics|EEG data will be collected on patients receiving sevoflurane, and sevoflurane and ketamine together.
2863660|NCT03503565||Moderate block group|maintaining moderate intraoperative neuromuscular blockade (TOF count 1 or 2) during surgery and reversal using sugammadex 2 mg/kg after surgery
2863661|NCT03503565||Deep block group|maintaining deep intraoperative neuromuscular blockade (PTC 1 or 2) during surgery and reversal using sugammadex 4 mg/kg after surgery
2863662|NCT03503539|Experimental|Mini percutaneous nephrolithotomy|All operations were performed or supervised by the same surgeon. Right after the patients in mini-PNL group were placed a 5F ureteral catheter with general anesthesia, they were had a prone position and the access was performed by choosing the optimal calyx to reach the stone following the contrast agent was given. The guide wire was then placed and the stones were broken with a laser lithotripter using a 12F nephroscope (Modular minimally invasive PCNL system, Karl Storz, Tuttlingen, Germany) following the dilatation using an one step dilator with a 16.5F access sheath. When necessary, stones were removed using the stone removal forceps. Right after a 14-Fr nephrostomy tube was inserted and an antegrade pyelography was taken, the operation was terminated.
2863663|NCT03503539|Active Comparator|Retrograde intrarenal surgery|Following the general anesthesia performed, a safety guide wire was placed and semirigid ureteroscopy (9.5 / 11.5F) was performed. Stones were fragmented using a 270 micron meter laser fiber with the help of 7.5-F fiber optic flexible ureterorenoscope after the placement of ureteral access sheat (9.5 / 11.5 F). Stone fragmentation was accomplished using a laser energy of 0.5-1.5 J and a rate of 5-15 Hz and adjusting this range according to stone hardness. 4.7F JJ stent was routinely placed at the end of the operation because of worries about possible edema etc. due to access sheath. In this group, access sheath could not be placed in 2 patients due to the small diameter of the ureter, and JJ stent was placed, and 2 weeks later, the procedure was performed as it was in the others.
2863664|NCT03503526|Experimental|Music therapy treatment|"An intervention consisting of 12 weekly sessions of trauma-focused treatment in form of group music and imagery therapy.~Receptive music therapy."
2863665|NCT03503526|No Intervention|Wait List Control|No treatment for approximately 12 weeks.
2863666|NCT03503513|Experimental|Gentamicin sulfate followed by saline|
2863667|NCT03503513|Experimental|Saline followed gentamicin sulfate|
2863668|NCT03503500|Experimental|Laid-back breastfeeding|Women will breastfed in relaxed, laid-back position, with her baby laying prone on her, so that the baby's body is in the largest possible contact with mother's curves, without following particular procedure to breastfed.
2863669|NCT03503500|Active Comparator|Standard care|Staff will show to mothers how to breastfeed and will help them to attach the baby correctly to the breast,
2863670|NCT03503487|No Intervention|Control|Patients receiving standard informed consent procedure before intervention
2863671|NCT03503487|Experimental|Planner 1|Patients receiving 3D informed consent procedure before intervention with Surgical Theater
2863672|NCT03503487|Experimental|Planner 2|Patients receiving 3D informed consent procedure before intervention with Vesalius
2863673|NCT03503474||CDI cases|
2863674|NCT03503474||CDI negative controls|
2863675|NCT03503461||Control group|Control group is a population of subjects admitted to day hospitalization for renal function tests or in conventional hospitalization, but without kidney transplant. Exosome analysis will be perform in urine sample.
2863676|NCT03503461||Kidney transplants group|Kidney transplants group is a kidney transplant subjects population 3 months ago. Exosome analysis will be perform in urine sample collected at 3 months.
2863677|NCT03503448|Other|space between 11/21|Osteotomy between the maxillary central incisors
2863678|NCT03503448|Other|space between 12/13 and 22/23|Osteotomy between the maxillary lateral incisors and canines
2863679|NCT03503435|Other|Art therapy intervention|Participants will then take part in six-weeks of group art therapy with a goal of increasing self-awareness and expression. During the intervention sessions, participants will have access to a wide range of materials conventionally used in art therapy excluding materials that may be abrasive or powdery and unsuitable around people wearing a stoma.
2863680|NCT03503422|Experimental|tDCS (anodal) + therapeutic exercises|"Real transcranial direct current stimulation associated with therapeutic exercises~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
2863681|NCT03503422|Sham Comparator|tDCS (sham) + therapeutic exercises|"Sham transcranial direct current stimulation associated with therapeutic exercises~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
2863682|NCT03503409|Experimental|AG-120|Subjects enrolled will receive continuous 28-day cycles of AG-120 - 500 mg. AG-120 will be dispensed on Day 1 of each treatment cycle
2863761|NCT03502824|Active Comparator|PuraPly® AM plus Standard of Care|
2863683|NCT03503396|Experimental|BAC feedback|Participants will receive a warning when their BAC is above a set limit (cutpoint is not disclosed by well below legal limit). Warning will notify them that their results indicate it is not safe for them to drive.
2863684|NCT03503396|Active Comparator|No Feedback|Participants will not receive any information on their BAC from their device.
2863685|NCT03503383||Controlled group|pregnant women without any medical disorders during pregnancy
2863686|NCT03503383||Diseased group|Patients complaining of hypertension with pregnancy
2863687|NCT03503370|Experimental|chlorhexidine|Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
2863688|NCT03503370|Placebo Comparator|placebo|Participants randomized to the placebo will wash their feet using bath CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
2863689|NCT03503357|Experimental|IFT Testing 1|Participants will be fitted with and IFT cuff and randomized to command list A intra-operatively to assess awareness.
2863690|NCT03503357|Experimental|IFT Testing 2|Participants will be fitted with and IFT cuff and randomized to command list B intra-operatively to assess awareness.
2863691|NCT03503357|Experimental|IFT Testing 3|Participants will be fitted with and IFT cuff and randomized to command list C intra-operatively to assess awareness.
2863692|NCT03503357|Experimental|IFT Testing 4|Participants will be fitted with and IFT cuff and randomized to command list D intra-operatively to assess awareness.
2863693|NCT03503344|Experimental|Arm I (apalutamide, SBRT)|Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Beginning 60 days after first dose of apalutamide, participants also undergo stereotactic body radiation therapy for 1-5 fractions.
2863694|NCT03503344|Active Comparator|Arm II (SBRT)|Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
2863695|NCT03503331|Experimental|[C-11]PiB-PET/MRI|All participants in this study will undergo an amyloid-PET imaging using the tracer [C-11]PiB with a simultaneous PET/MRI system. The [C-11]PiB dosage is 300-670 MBq (8 - 18 mCi) given intravenously, and the PET/MRI imaging time is approximately 60 min.
2863696|NCT03503318|Experimental|TV-46000 - A|Dose regimen A
2863697|NCT03503318|Experimental|TV-46000 - B|Dose regimen B
2863698|NCT03503318|Placebo Comparator|Placebo|Matching Placebo
2863699|NCT03503305|Experimental|Adipose Derived Regenerative Cell group|Subjects in the treated group will receive an Adipose derived regenerative cells (ADRCs) injection into the wrist using a fluoroscopic-guided injection .
2863700|NCT03503305|Active Comparator|Corticosteroid group|Subjects in the active control group will receive a corticosteroid injection into the wrist using a fluoroscopic-guided injection.
2863701|NCT03503292|Experimental|CYP2D6 rapid metabolizer|Participants with CYP2D6 rapid metabolizer status will received granisetron for for post operative nausea and vomiting prophylaxis and treatment
2863702|NCT03503292|Experimental|CYP2D6 normal metabolizer|Participants with CYP2D6 poor or normal metabolizer status will received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment
2863703|NCT03503279|No Intervention|Macintosh Laryngoscope|
2863704|NCT03503279|Active Comparator|Totaltrack Video Laryngeal Mask|
2863705|NCT03503266|Experimental|[14C] MT-7117|14-C MT-7117
2863706|NCT03503253|Other|Single-arm|LAA leak closure using detachable coils; Interlock-35 Fibered IDC Occlusion System, Concerto Helix Detachable Coil System
2863707|NCT03503227|Active Comparator|Aspirin|Patients will receive daily oral low dose Acetylsalicylic acid (75 mg) starting day 20 of the previous cycle withGonadotrophin releasing hormone agonist (GnRH agonist)
2863708|NCT03503227|Active Comparator|Aspirin and prednisolone|Patients will receive daily oral low dose Acetylsalicylic acid (75 mg) and Low dose prednisolone (10 mg/day) starting day 20 of the previous cycle withGonadotrophin releasing hormone agonist (GnRH agonist).
2863709|NCT03503214||Septic patients|Patients with sepsis or septic shock according to the SEPSIS-III (Singer M Jama 2016) admitted to the general Intensive Care Unit
2863710|NCT03503214||Healthy volunteers|Subjects without known respiratory, cardiovascular, hepatic, renal or hematologic diseases.
2863711|NCT03503201|Active Comparator|treatment|patients receive chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) for 2 months before Intracytoplasmic sperm injection cycle
2863712|NCT03503201|No Intervention|No treatment|patients will not receive chromium supplementation before Intracytoplasmic sperm injection cycle
2863713|NCT03503188|Experimental|All participants|
2863714|NCT03503175|Experimental|Novel urinary access system|Participants randomized to this arm will receive the novel urinary access system (CystoSureTM).
2863715|NCT03503175|Active Comparator|Standard Foley catheter|Participants randomized to this arm will receive a standard Foley catheter and rigid cystoscopy.
2863716|NCT03503162|Experimental|Colonoscopy with Pure-Vu System|Standard colonoscopy procedure with Pure-Vu System
2863717|NCT03503136|Experimental|A (TPF+P-RT)|Induction docetaxel, cisplatin, and fluorouracil plus concurrent chemoradiotherapy with cisplatin
2863718|NCT03503136|Experimental|B (TNF+N-RT)|Induction docetaxel, nedaplatin, and fluorouracil plus concurrent chemoradiotherapy with nedaplatin
2863719|NCT03503136|Experimental|C (TPX+P-RT)|Induction docetaxel, cisplatin, and capecitabine plus concurrent chemoradiotherapy with cisplatin
2863720|NCT03503136|Experimental|D (TNX+N-RT)|Induction docetaxel, nedaplatin, and capecitabine plus concurrent chemoradiotherapy with nedaplatin
2863721|NCT03503123||COPD patients with deventilation dyspnoea|Ten severe COPD patients (age>18yr) using chronic NIV with severe symptoms of deventilation dyspnoea (Borg Dyspnoea Scale ≥ 5)
2863722|NCT03503123||COPD patients without deventilation dyspnoea|Ten severe COPD patients (age>18yr) using chronic NIV without symptoms of deventilation dyspnoea, matched with the first cohort/group with regard to the degree of static lung hyperinflation and NIV settings.
2863762|NCT03502824|Active Comparator|Standard of Care (SOC) for Pressure Ulcers|
2863763|NCT03502811||MitraClip NTR/XTR System|Percutaneous mitral valve repair using the MitraClip NTR and XTR system
2863723|NCT03503110|Experimental|dMRI and electrocorticography|Direct measurements of cortical electrical properties of patients operated on awake surgery for a brain tumor, using electrocorticography (ECoG), based on the dMRI tractography data previously acquired for each patient.
2863724|NCT03503097||Ancillary-Correlative (questionnaires, Color kit, counseling)|Participants receive web-based or hard-copy questionnaires and saliva collection kits via mail or in person. Participants also provide saliva samples to be mailed back to Color Genomics for genetic testing once complete. Participants then receive phone-based genetic counseling if they are identified to have an inherited mutation in a DNA repair gene. All participants have access to phone-based genetic counseling whether or not they are not found to have a mutation.
2863725|NCT03503084|Experimental|TCC group|Classical Yang's TCC exercise
2863726|NCT03503058|Experimental|Group 1|N=140 will receive PfSPZ Vaccine; three doses of 9x10^5 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals.
2863727|NCT03503058|Placebo Comparator|Group 2|N=70 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals.
2863728|NCT03503058|Experimental|Group 3|"N=140 will receive PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis; three doses of 2x10^5 PfSPZ of PfSPZ Challenge administered by DVI at 0, 28 and 56 day intervals (or 0, 4 and 8 week intervals), with weekly CQ.~CQ will first be given as a loading dose of 600 mg base two days before the first administration of PfSPZ Challenge, followed by weekly 300 mg doses of CQ with the last dose 5 days after the last dose of PfSPZ Challenge."
2863729|NCT03503058|Placebo Comparator|Group 4|"N=70 will receive normal; three doses of NS administered by DVI given at 0, 28 and 56 day intervals (or 0, 4 and 8 week intervals), with weekly CQ.~CQ will first be given as a loading dose of 600 mg base two days before the first administration of NS, followed by weekly 300 mg doses of CQ with the last dose 5 days after the last dose of NS."
2863730|NCT03503032||Fenestrated|Standard extracardiac fontan undergoing Fontan fenestration creation
2863731|NCT03503032||Non fenestrated|Standard extracardiac fontan without fenestration
2863732|NCT03503019||Diabetic|
2863733|NCT03503019||Non-diabetic|
2863734|NCT03502993||MOFICHE|This is an observational study assessing the management and outcome of children presenting to Emergency Departments (ED) with fever across Europe. This study will use large departmental datasets to collect information on at least 50,000 febrile episodes . This study will use large-scale, pseudo-anonymized departmental data, and will not involve consented patient recruitment; nor will it use patient samples. Data included in MOFICHE will be based on that collected as part of routine clinical care. Antibiotic prescription, hospitalisation and number/type of investigations, re-attendance at ED within 5 days of the first hospital presentation will be recorded.
2863735|NCT03502993||BIVA studies|A minimum of 3,000 children will be recruited to the BIVA-ED study, in order to capture sufficient children with confirmed bacterial infection. Additional children with less common febrile illnesses will also be recruited: 500 critically ill (BIVA-PIC); 200 at high-risk of bacterial illness through primary or secondary immunodeficiency (BIVA-HR); 150 with an inflammatory diagnosis, whose initial presentation is difficult to discriminate from bacterial infection (BIVA-INF). Samples collected from recruits in the BIVA studies will be used for the validation of biomarkers (clinical, proteomic and transcriptomic biomarkers) for diagnosis of febrile illness, including markers of bacterial and viral infection (confirmed by culture and/or molecular microbiology) and inflammatory conditions.
2863736|NCT03502980|Active Comparator|Peripherally inserted central venous catheters|Bard PowerPICC
2863737|NCT03502980|Active Comparator|Midline|Bard PowerMidline catheter
2863738|NCT03502967|Experimental|Hyperpolarized [1-13C] Pyruvate|Injection with hyperpolarized [1-13C] Pyruvate during MRI.
2863739|NCT03502967|Experimental|Hyperpolarized [2-13C] Pyruvate|Injection with hyperpolarized [2-13C] Pyruvate during MRI.
2863740|NCT03502954|Experimental|ABY-039 IV|
2863741|NCT03502954|Experimental|ABY-039 SC|
2863742|NCT03502954|Placebo Comparator|Placebo IV|
2863743|NCT03502954|Placebo Comparator|Placebo SC|
2863744|NCT03502941|Experimental|A single dose of EAAs/whey|Subjects will consume 6.3 g of EAAs/whey in ~12 oz water.
2863745|NCT03502941|Experimental|A double dose of EAAs/whey|Subjects will consume 12.6 g of EAAs/whey in ~12 oz water
2863746|NCT03502941|Experimental|Whey protein alone|Subjects will consume 12.6 g of whey protein isolate which is an equal amount to the double dose of EAAs/whey.
2863747|NCT03502928|Active Comparator|Conventional Treatment|Motor Control + Manual Therapy
2863748|NCT03502928|Experimental|Experimental Treatment|Motor Control + Manual Therapy + Dry Needling
2863749|NCT03502915|Experimental|Nitrous Oxide|Patients will receive nitrous oxide during the version procedure.
2863750|NCT03502915|Placebo Comparator|Oxygen|Patients will receive placebo (100% oxygen) during the version procedure.
2863751|NCT03502902|Experimental|HEC68498|administered once on first day in each Treatment Period， HEC68498 VS placebo 3:1 ratio
2863752|NCT03502902|Placebo Comparator|placebo|administered once on first day in each Treatment Period
2863753|NCT03502889|Active Comparator|Adductor Canal Block Alone|Control arm to receive Adductor Canal Block without additional interventions Intervention: ropivacaine 0.5% 15cc injected under ultrasound guidance
2863754|NCT03502889|Experimental|SPANK Block Plus Adductor Canal Block|Experimental arm to receive Adductor Canal Block plus SPANK Block (Sensory Posterior Articular Nerves of the Knee) without additional interventions Intervention: ropivacaine 0.5% 15cc injected under ultrasound guidance into the adductor canal plus 20cc ropivacaine 0.5% injected into the posterior tissues of the knee
2863755|NCT03502863|Experimental|Digital refraction|Web-based application for obtaining the refractive error and visual acuity of each eye, using a computer and a smart phone
2863756|NCT03502863|Active Comparator|Manual Refraction|Manual manifest refraction is performed by an eyesore specialist using a phoropter.
2863757|NCT03502850|Experimental|ASK120067|patients take ASK120067 orally once per day at different dose
2863758|NCT03502837||Healthy controls|age-matched right-handed healthy volunteers
2863759|NCT03502837||the mininally conscious state|Patients present reproducible signs of awareness such as purposeful eye movements or response to verbal order
2863760|NCT03502837||the vegetative state|Patients preserved autonomous functioning (e.g., preserved sleep-wake cycles),but without awareness of oneself or of the environment
2863765|NCT03502785|Experimental|Cohort A|Participants with locally advanced unresectable or metastatic/recurrent UCa, who have confirmed disease progression during or following treatment with an anti-PD-1/PD-L1 therapy. Cohort A participants will be treated with INO-5401 and INO-9012 in combination with atezolizumab.
2863766|NCT03502785|Experimental|Cohort B|Participants with locally advanced unresectable or metastatic/recurrent UCa who are treatment naïve and ineligible for cisplatin-based chemotherapy. Cohort B participants will be treated with INO-5401 and INO-9012 in combination with atezolizumab.
2863767|NCT03502772|Experimental|Pilates exercises group|
2863768|NCT03502772|Active Comparator|Home exercise program group|
2863769|NCT03502759|No Intervention|Pre-intervention|Seizure patients receive usual care.
2863770|NCT03502759|Experimental|Post-intervention|Physicians provide care enhanced by computer based clinical decision support about SUDEP.
2863771|NCT03502746|Experimental|Nivolumab + Ramucirumab|Nivolumab 240mg IV + Ramucirumab 8mg/kg IV
2863772|NCT03502733|Experimental|Treatment (copanlisib, nivolumab)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 and nivolumab IV over 30 minutes on day 1 or on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2863773|NCT03502720||Control Patients|"Data obtained retrospectively from Scaphoid fixation surgeries performed at our center using the standard procedure (no device for guide wire positioning).~This control group should have registered al parameters and variables to be studied."
2863774|NCT03502720||Case Patients|Prospective series of ten patients on which the external 3D guide system will be used.
2863775|NCT03502707|Placebo Comparator|Cohort (C)1 Group (G)1: Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
2863776|NCT03502707|Experimental|C1 G2: RSV preF Protein|Participants will receive intramuscular injection of 50 microgram (mcg) RSV preF protein on Day 1, Day 57 and at Month 12.
2863777|NCT03502707|Placebo Comparator|C1 G3: Placebo for Ad26.RSV.preF/RSV preF or RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
2863778|NCT03502707|Experimental|C1 G4: Mixture of Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of a mixture of 5*10^10 viral particles (vp) of Ad26.RSV.preF/RSV preF 50 mcg protein on Day 1, Day 57 and at Month 12.
2863779|NCT03502707|Experimental|C1 G5: RSV preF Protein|Participants will receive intramuscular injection of 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.
2863780|NCT03502707|Placebo Comparator|C1 G6: Mixture of Placebo for Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
2863781|NCT03502707|Experimental|C1 G7: Mixture of Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of a mixture of 5*10^10 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.
2863782|NCT03502707|Placebo Comparator|C1 G8: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1 and at Month 12 and in only 1 arm on Day 57.
2863783|NCT03502707|Experimental|C1 G9: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1*10^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and at Month 12 and placebo in another arm on Day 1 and at Month 12.
2863784|NCT03502707|Experimental|C1 G10: Ad26.RSV.preF, RSV preF Protein and Placebo|Participants will receive intramuscular injection of 1*10^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.
2863785|NCT03502707|Experimental|C2 G11: Ad26.RSV.preF and Placebo|Participants will receive intramuscular injection of 1*10^11 vp of Ad26.RSV.preF in 1 arm and placebo in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.
2863786|NCT03502707|Experimental|C2 G12: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 5*10^10 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.
2863787|NCT03502707|Experimental|C2 G13: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1*10^11 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.
2863788|NCT03502707|Experimental|C2 G14: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1*10^11 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.
2863789|NCT03502707|Experimental|C2 G15: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 5*10^10 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.
2863790|NCT03502707|Experimental|C2 G16: Ad26.RSV.preF, RSV preF Protein and Placebo|Data from C1 G10 will be pooled with those of C2 G16. Participants will receive intramuscular injection of 1*10^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.
2863791|NCT03502707|Experimental|C2 G17: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Data from C1 G9 will be pooled with those of C2 G17. Participants will receive intramuscular injection of a mixture of 1*10^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and at Month 12 and placebo in another arm on Day 1 and at Month 12.
2863792|NCT03502707|Placebo Comparator|C2 G18: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo in separate arms on Day 1 and at Month 12 and in only 1 arm on Day 57.
2863793|NCT03502707|Experimental|C3 G19: Fluarix Placebo, Selected Regimen (SR) + Fluarix, SR|Participants assigned to one-dose regimen in this group will receive intramuscular injection of placebo for seasonal influenza vaccine (Fluarix) at least 14 days prior to Day 1 followed by selected regimen in 1 arm and Fluarix in another arm on Day 1 followed by selected regimen at Month 12, for one-dose regimen. The participants who are randomized to two-dose regimen will receive an additional intramuscular injection of selected regimen on Day 57.
2863821|NCT03502538|Experimental|Curaprox 5460 Ultra Soft|Brushing with a Curaprox Ultra Soft 5460 toothbrush for one minute timed without orientations about brushing techniques and without supervision
2864342|NCT03498976|Other|Pulsed radiofrequency on SE nerve|Single technic
2863794|NCT03502707|Experimental|C3 G20: Fluarix, SR + Fluarix Placebo, SR|Participants assigned to one-dose regimen in this group will receive intramuscular injection of Fluarix at least 14 days prior to Day 1 followed by selected regimen in 1 arm and placebo for Fluarix in another arm on Day 1 followed by selected regimen at Month 12, for one-dose regimen. The participants who are randomized to two-dose regimen will receive an additional intramuscular injection of selected regimen on Day 57.
2863795|NCT03502707|Experimental|C3 G21: Fluarix Placebo, SR + Fluarix, SR Placebo|Participants assigned to one-dose regimen in this group will receive intramuscular injection of placebo for Fluarix at least 14 days prior to Day 1 followed by selected regimen in 1 arm and Fluarix in another arm on Day 1 followed by placebo for selected regimen at Month 12, for one-dose regimen. The participants who are randomized to two-dose regimen will receive an additional intramuscular injection of selected regimen on Day 57.
2863796|NCT03502707|Experimental|C3 G22: Fluarix, SR + Fluarix Placebo, SR Placebo|Participants assigned to one-dose regimen in this group will receive intramuscular injection of Fluarix at least 14 days prior to Day 1 followed by selected regimen in 1 arm and placebo for Fluarix in another arm on Day 1 followed by placebo for selected regimen at Month 12, for one-dose regimen. The participants who are randomized to two-dose regimen will receive an additional intramuscular injection of selected regimen on Day 57.
2863797|NCT03502707|Experimental|C3 G23: Fluarix, SR Placebo + Fluarix Placebo, SR Placebo|Participants assigned to one-dose regimen in this group will receive intramuscular injection of Fluarix at least 14 days prior to Day 1 followed by placebo for selected regimen in 1 arm and placebo for Fluarix in another arm on Day 1 followed by placebo for selected regimen at Month 12, for one-dose regimen. The participants who are randomized to two-dose regimen will receive an additional intramuscular injection of placebo for selected regimen on Day 57.
2863798|NCT03502694|Experimental|Regimen A (Low-Dose Lumicitabine)|Participants will receive a single 750 milligram (mg) loading dose (LD) (Dose 1) of lumicitabine and matching placebo followed by nine 250 mg tablets as maintenance doses (MDs) (Doses 2 to 10) of lumicitabine and matching placebo administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
2863799|NCT03502694|Experimental|Regimen B (High-Dose Lumicitabine)|Participants will receive a single 1000 mg LD (Dose 1) of lumicitabine followed by nine 500 mg tablets as MDs (Doses 2 to 10) of lumicitabine and matching placebo tablet, administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
2863800|NCT03502694|Placebo Comparator|Regimen C (Placebo)|Participants will receive a placebo LD (Dose 1) followed by nine MDs (Doses 2 to 10) of matching placebo, administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
2863801|NCT03502681|Experimental|Maximum tolerated dose (MTD) cohort|"The initial 9-12 patients (MTD cohort) will be enrolled to determine safety of avelumab in combination with eribulin mesylate.~Upon determination of maximum tolerated dose (MTD), 12 additional patients will be enrolled in an expansion cohort (efficacy cohort) to determine objective response rate (ORR) at 6 months."
2863802|NCT03502668|Experimental|Phase 1 Stage A|3 cohorts of 6 subjects each in a 10-day schedule in 28-day cycles of ASTX727 LD
2863803|NCT03502668|Experimental|Phase 1 Stage B|4 cohorts of 6 subjects each in a 14-day schedule in 28-day cycles of ASTX727 LD
2863804|NCT03502668|Experimental|Phase 2|40 additional subjects randomized in a 1:1 ratio into 1 of 2 doses/schedules of ASTX727 LD selected from Phase 1
2863805|NCT03502655|Other|Intervention message (first phase)|Standardized message The intervention will consist in the delivery of a message with a positive content regarding the insertion of the peripheral venous catheter. The message will be delivered through an audio record
2863806|NCT03502655|Active Comparator|Control message (first phase)|Standardized message The intervention will consist in the delivery of a control message, whose content is based upon the usual caregiver-patient communication prior to the insertion of a peripheral venous catheter. The message will be delivered through an audio record.
2863807|NCT03502655|Other|Intervention message (second phase)|Standardized message The intervention will consist in the delivery of message with a positive content regarding the insertion of the peripheral venous catheter. The message will be delivered by the health providers themselves before inserting the catheter.
2863808|NCT03502655|Active Comparator|Control message (second phase)|Standardized message In this arm, the patient will be delivered a control message, which content is based upon the usual caregiver-patient communication prior to the insertion of a peripheral venous catheter. The message will be delivered by the caregivers themselves before inserting the catheter.
2863809|NCT03502642|Placebo Comparator|Placebo (P)|Placebo group parturients will receive spinal anesthesia with intrathecal morphine and will have continuous normal saline wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain).
2863810|NCT03502642|Active Comparator|Ropivacaine (R)|Ropivacaine group parturients will receive spinal anesthesia without intrathecal morphine and will have continuous ropivacaine (Ropivacaina Molteni®) wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain).
2863811|NCT03502629|Experimental|GB226 3mg/kg every 2 weeks|GB226 3mg/kg every 2 weeks
2863812|NCT03502616|Experimental|Tofacitinib|
2863813|NCT03502616|Placebo Comparator|Placebo|
2863814|NCT03502603|Active Comparator|Cerebral neurological illness (CNI) participants|Identified from the department of Rehabilitation, Psychiatry, and Medicine and referred to the research staff via in-person communication, email or staff message
2863815|NCT03502603|Active Comparator|Non-CNI participants|Identified from the department of Rehabilitation, Psychiatry, and Medicine and referred to the research staff via in-person communication, email or staff message
2863816|NCT03502590|Experimental|IGEL arm|
2863817|NCT03502577|Experimental|Treatment (Chemotherapy, BCMA-specific CAR T-cells, LY3039478)|Participants receive fludarabine and cyclophosphamide on days -4 to -2. Participants then receive BCMA-specific CAR T-cells IV over 20-30 minutes on day 0 and LY3039478 PO on days 2, 4, 7, 9, 11, 14, 16, and 18.
2863818|NCT03502564|Active Comparator|CBT for ED only|In this arm, participants will receive CBT for ED following intensive ED treatment (see intervention section for description).
2863819|NCT03502564|Experimental|Concurrent CBT for ED and PTSD|In this arm, participants will receive concurrent CBT for ED and PTSD following intensive treatment. (see intervention section for description).
2863820|NCT03502551|Experimental|Treatment with Ketamine|In this arm an IV infusion of 0.5 mg/kg of ketamine will be administered over 40 minutes.
2864343|NCT03498976|Other|Pulsed radiofrequency on SE + CF nerves|Combinated technic
2863822|NCT03502538|Active Comparator|Oral-B Indicator Plus|Brushing with a Oral-B Indicator Plus toothbrush for one minute timed without orientations about brushing techniques and without supervision
2863823|NCT03502525|Experimental|Break the Cycle Intervention|All study participants are assigned to this experimental arm.
2863824|NCT03502512|Experimental|Group 1: REVOLVE Tissue Process|
2863825|NCT03502512|Experimental|Group 2: PureGraft Tissue Process|
2863826|NCT03502499|Experimental|Half-normal saline|
2863827|NCT03502499|Active Comparator|Normal saline|
2863828|NCT03502486|Experimental|Moderate exercise|20 minutes of cycle ergometry at 50 - 60% of heart rate max.
2863829|NCT03502486|Experimental|Intense Exercise|20 minutes of cycle ergometry at 70 - 80% of heart rate max.
2863830|NCT03502486|Active Comparator|Rest|20 minutes of seated reading.
2863831|NCT03502473|Experimental|One pass/no treatment arm|One random flank will be treated with UltraShape Power device with one pass or remained as a control (no treatment)
2863832|NCT03502473|Experimental|Multiple passes treatment arm|Second flank will be treated with UltraShape Power device with multiple passes.
2863833|NCT03502460|Other|ORFALU|"Lung ultrasound consists of the application of a high-frequency ultrasound probe type Trans Thoracic Echography (ETT) on the anterior and lateral chest of the patient. Since air and bone do not pass through the US, it is the artefacts due to these structures that constitute ultrasound lung semiology.~Esophageal Doppler is a means of monitoring cardiac output measuring stroke volume (SV)."
2863834|NCT03502447|Experimental|TearCare|TearCare subjects will receive TearCare thermal treatment followed by manual clearing of the meibomian glands.
2863835|NCT03502447|Active Comparator|Warm Compress & Lid Massage|Subjects will perform warm compress and lid massage at home daily.
2863836|NCT03502434|Experimental|90 mg/mL SM04755 in water|90 mg/mL SM04755 in water applied via patches
2863837|NCT03502434|Experimental|90 mg/mL SM04755 in aqueous Vehicle|90 mg/mL SM04755 in aqueous Vehicle applied via patches
2863838|NCT03502434|Experimental|90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol)|90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol) applied via patches
2863839|NCT03502434|Other|Vehicle|Aqueous Vehicle applied via patches
2863840|NCT03502434|Other|White petrolatum|White petrolatum (Negative control) applied via patches
2863841|NCT03502434|Other|Sodium lauryl sulfate|Sodium lauryl sulfate (SLS 0.5%) (Positive control) applied via patches
2863842|NCT03502421|Experimental|Ketamine|Continuous infusion of Ketamine 0.3 to 0.5 mg/kg per hour PCA Dilaudid 2.0-2.5 mg
2863843|NCT03502421|No Intervention|Opioid Only|Patient-controlled analgesia Dilaudid 2.0-2.5 mg
2863844|NCT03502408|Experimental|Endovascular Thrombectomy|Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
2863845|NCT03502395|Active Comparator|Group I|Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure).
2863846|NCT03502395|Placebo Comparator|Group II|A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
2863847|NCT03502382|Other|radilogical|Radiological: standing antero-posterior full-length digital images of the lower extremities
2863848|NCT03502369|Experimental|QL group|Anterior Quadratus lumborum block will be done for all patients of these group. Local anaesthetic (30ml of bupivacaine) will be injected in fascial plane between the quadratus lumborum muscle and Psoas major muscle by using the ultrasound.
2863849|NCT03502369|No Intervention|C group|Patients of these group will be the control group. The will receive acetaminophen 1g every 8h, ketorolac 30mg ever 12h and as required morphine 2mg for post operative analgesia after hip arthroplasty.
2863850|NCT03502356|Active Comparator|Control Group|This group will include 200women undergoing elective cs. In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
2863851|NCT03502356|No Intervention|Study Group|This group will include 200women undergoing elective cs. In this group, patients will receive only standard prophylaxis antibiotic(CEFAZOLIN)
2863852|NCT03502343|Experimental|Modified Gemcitabine plus nab-Paclitaxel|The intervention group
2863853|NCT03502330|Experimental|Cohort 1 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.
2863854|NCT03502330|Experimental|Cohort 2 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.
2863855|NCT03502330|Experimental|Cohort 3 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.
2863856|NCT03502330|Experimental|Cohort 4 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.
2863857|NCT03502330|Experimental|Cohort 5 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.
2863858|NCT03502330|Experimental|Cohort 6 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.
2863859|NCT03502330|Experimental|Cohort 7 Advanced Melanoma|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
2863860|NCT03502330|Experimental|Cohort 8 NSCLC|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
2863861|NCT03502330|Experimental|Cohort 9 RCC|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
2863862|NCT03502317|Experimental|Prehabilitation Study Arm|Patients will participate in a two-pronged prehabilitation strategy - physical prehabilitation and psychological prehabilitation. Prehabilitation will last from a minimum of 21 days to a maximum of 42 days before a patient's clinically indicated surgery.
2863884|NCT03502135|Experimental|Intranasal Anesthesia|Two intranasal sprays of tetracaine HCl and oxymetazoline HCl nasal spray anesthetic administered 4 minutes apart into the nostril corresponding to the side of the treated tooth. If inadequate anesthetic response obtained within 10 minutes, a third spray will be administered and assessed for effective anesthesia after 4 minutes.
2863863|NCT03502317|No Intervention|Usual Care Study Arm|No specific exercises or stress reduction techniques are prescribed and the patient will be counseled to continue their current level of activity, and will be given the information on exercise as outlined in the Cancer Care Ontario guidelines. Patients in the Usual Care arm will also be given the same Fitbit activity tracker as patients in the Prehabilitation arm in order to eliminate the activity tracker as an intervention itself and to be able to track the activity (steps) for comparison. Patients in the Usual Care arm will be required to wear their Fitbit activity tracker from the day of randomization to 90 days post-surgery. Patients will record their steps in the diary provided.
2863864|NCT03502304|Active Comparator|Control group|No-exercise
2863865|NCT03502304|Experimental|Endurance training plus resistant training|To concurrent training (endurance training plus resistant training, RT) program will be use cycle ergometers adapted for obese adults (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) were used. Prior to the CT intervention, all subjects were familiarized (during 3 sessions) with the training protocols. The CT intervention included 3 weekly sessions of both ET and RT. The core part of each session included RT followed by ET exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
2863866|NCT03502291|Active Comparator|Study One: LAIV + Inoculation|LAIV Nasal Spray: Inoculation (FLUMIST or FLUENZ) plus intramuscular placebo then inoculation with pneumococci bacteria
2863867|NCT03502291|Placebo Comparator|Study One: Placebo + inoculation|Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo then inoculation with pneumococci bacterial
2863868|NCT03502291|Active Comparator|Study Two: Inoculation + LAIV|Inoculation with pneumococci bacteria then Live attenuated Influenza Vaccine Nasal Spray (FLUMIST or FLUENZ) plus intramuscular placebo
2863869|NCT03502291|Placebo Comparator|Study Two: Inoculation + placebo|Inoculation with pneumococci bacteria then Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo
2863870|NCT03502278|Active Comparator|PTSD lay-led group treatment program|This group will go through the Islamic Trauma Healing Program
2863871|NCT03502278|No Intervention|Waitlist|Waitlist
2863872|NCT03502265|Experimental|Otteroo adjunct|A single-subject research design will be used: measures of infant development will be collected across a 4-week baseline period (standard care), 4 weeks of intervention (standard care and Otteroo use), and a 4 weeks of reversal/retention period (standard care). There is only one arm due to the study design. It is a within-subjects comparison, not a between-subjects comparison of different study arms.
2863873|NCT03502252|Experimental|Treatment Group|Semillas de Apego is a group-based psychosocial program for victimized caregivers with children 2 to 5 in Colombia, a country devastated by violence. The program's builds upon scientific evidence on (i) the way in which violence hinders early childhood development and erodes mothers' mental health and their capacity to form nurturing relationships with their children, and (ii) the effectiveness of promoting healthy child-parent attachments to mitigate the effects of toxic stress on toddlers (Lieberman and Van Horn, 2011).
2863874|NCT03502252|No Intervention|Control Group|Centers and participants assigned to the this group continue to have access to the regular early childhood programs offered through the centers to which children are affiliated.
2863875|NCT03502239|Experimental|Treatment group|Subjects randomly assigned to this arm will train on the Mega Team video game.
2863876|NCT03502239|No Intervention|Control- wait list group|Subjects randomly assigned to this arm will be the wait-list group. They are allowed to play the video games that they usually play.
2863877|NCT03502226|Experimental|Intervention group|Received tailored feedback regarding sexual health risks
2863878|NCT03502226|No Intervention|Control group|Did not receive tailored feedback.
2863879|NCT03502187|Active Comparator|Primary Care Management (PCM)|Non-specific LBP, where the cause for the pain cannot be determined, accounts for ninety percent of LBP cases.(Koes, et al, 2006) Reducing pain and continuing daily activity to prevent deconditioning are the primary therapy goals of PCM. Traditional PCM treatment of LBP will include advice/information on self-care options, over-the-counter analgesics, heat application, and remaining active.(Chou, et al., 2007; Koes, et al, 2010) Despite evidence that physical activity is effective, limiting activity remains common; individuals cite pain or re-injury fear as a limiting factor.( Lethem, et al., 1983; Poirandeau, et al., 2006; Steenstra, et al., 2016)
2863880|NCT03502187|Experimental|NeuromuscularElectricalStimulation(NMES)|Rehabilitation requires activation of deep stabilizing muscle groups in the lumbopelvic region. Traditional exercises specific for these muscles are hard to teach with poor compliance. NMES is effective in stimulating these muscles, (Porcari, et al., 2005; Glaser, et al., 2001) resulting in enhanced activation, and improved performance. (Coghlan, et al., 2011) NMES devices are programmed to exercise core muscles through a series of stimulated muscle contractions. Concurrent muscle stimulation of the abdominal wall and lumbar paraspinal area has been shown to be most effective to maximally activate deep lumbar stabilizers in LBP patients. (Baek, et al., 2016) NMES provides as much pain relief as transcutaneous electric nerve stimulation (TENS) in LBP subjects. (Moore SR, Shurman J, 1997)
2863881|NCT03502187|Experimental|Progressive Exercise Plan (PEP)|The literature suggests that this intervention may be of benefit in military personnel with subacute LBP. (Chou, et al., 2007;Marshall PW, Murphy BA, 2006) Meta-analysis showed evidence that graded-activity exercise improved patient outcomes in subacute LBP; however, evidence for other exercise programs were inconsistent. (Hayden, et al., 2005) A strengthening program involving the trunk and abdomen muscles showed clinical reductions in low back pain and disability with high adherence. (Kendall, et al., 2015) Systematic reviews were unable to support any one type of exercise over another. The use of pain-relieving modalities combined with muscle strengthening, such as home-based electrotherapy or progressive exercise, could reduce pain and improve function more rapidly.
2863882|NCT03502161||All subjects|Those receiving a SOT and coming off either 3 months or 6 months of antiviral prophylaxis.
2863883|NCT03502148|Experimental|Open-Label, Single Arm Study of PRV111|In Stage 1, subjects will receive 3 treatment applications of PRV111 (Cisplatin Transmucosal System) at each of the 4 planned visits within 3 weeks prior to their tumor surgery. Following review of Stage 1 subject data, additional subjects will be enrolled in Stage 2 and will receive 2, 3 or 5 treatment applications dependent on the results of Stage 1 at each of the 4 visits prior to their tumor surgery.
2864009|NCT03501251|Experimental|Moxidectin 24 mg|Three tablets of 8 mg of moxidectin ( = 24 mg)
2864344|NCT03498963|Other|bronchoalveolar lavage|
2863885|NCT03502122|Experimental|VR rehabilitation|Virtual Reality based rehabilitation therapy for motor function, 1 hour a time at an intensity of three times per week over 8 weeks (total, 24 sessions).
2863886|NCT03502122|Active Comparator|control- conventional rehabilitation|conventional rehabilitation therapy for motor function, 1 hour a time at an intensity of three times per week over 8 weeks (total, 24 sessions).
2863887|NCT03502109|Experimental|Intervention group|Medication review with follow-up every 2 months, conducted by a trained pharmacist.
2863888|NCT03502109|No Intervention|Control group|Usual care by physicians, nurses and dieticians.
2863889|NCT03502096|Experimental|100% portion size|100% portion sizes of all foods served (baseline). To-go container and controls received this meal.
2863890|NCT03502096|Experimental|125% portion size|125% of baseline portions served. To-go container and controls received this meal.
2863891|NCT03502096|Experimental|150% portion size|150% of baseline portions served. To-go container and controls received this meal.
2863892|NCT03502096|Experimental|175% portion size|175% of baseline portions served. To-go container and controls received this meal.
2863893|NCT03502070|Other|Open-Label Placebo|One dose (4 capsules) of placebo
2863894|NCT03502057|Experimental|Investigational group|"Treated by instrumented transforaminal lumbar interbody fusion (TLIF).~Fusion will include placement of any static PEEK cage, FDA cleared for TLIF with the central cavity filled in with P-15L; in addition, the interdiscal space around the cage is to be filled to the greatest extent possible.~Bilateral posterior pedicle screw fixation is required.~The procedure will not include decortication and/or grafting in the posterolateral gutters."
2863895|NCT03502057|Placebo Comparator|Control group|"Treated via TLIF.~Fusion will include placement of a static FDA cleared Transforaminal lumbar interbody fusion (TLIF) Polyetheretherketone (PEEK) cage with the central cavity filled with local autologous bone harvested from millings and osteophytes.~The remainder of the interdiscal space should be filled around the cage to the greatest extent possible."
2863896|NCT03502044|Active Comparator|Arm 1, active KOS treatment|Patients in arm 1 receive active KOS treatment throughout study, which means 16 active KOS treatments. Patients receive KOS treatments twice a week during 8 consecutive weeks.
2863897|NCT03502044|Placebo Comparator|Arm 2, 8 inactive KOS treatments then 8 active KOS treatments|Patients in arm 2 receive inactive KOS treatment during the first 8 KOS treatments of the study. Thereafter patients in arm 2 receive 8 active KOS treatments. Patients receive KOS treatments twice a week during 8 consecutive weeks.
2863898|NCT03502031|Active Comparator|ACE or (ARB) Inhibitor alone|ACE inhibitor or an angiotensin receptor blocker (ARB) inhibitor
2863899|NCT03502031|Active Comparator|ACE or ARB with Spironolactone|Spironolactone+ACE or angiotensin receptor blocker (ARB)
2863900|NCT03502018|Placebo Comparator|Saline|This arm will receive Saline along with Bupivacaine
2863901|NCT03502018|Experimental|Bupivacaine liposome|This arm will receive Exparel along with Bupivacaine
2863902|NCT03502005|Experimental|BIKTARVY®|initiation of single pill once daily bictegravir/emtricitabine/tenofovir alafenamide from prior efavirenz/emtricitabine/tenofovir DF
2863903|NCT03501992|Other|Practice A|Practice A will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice A will be assigned to receive the current care intervention. in the second step, Practice A will be assigned to receive the current care intervention. In the third step, Practice A will receive the reminder-recall intervention. In the fourth step, Practice A will receive the combined reminder-recall and audit-and-feedback intervention.
2863904|NCT03501992|Other|Practice B|Practice B will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice B will be assigned to receive the current care intervention. In the second step, Practice B will be assigned to receive the reminder-recall intervention. In the third step, Practice B will receive the combined reminder-recall and audit-and-feedback intervention. In the fourth step, Practice A will receive the combined reminder-recall and audit-and-feedback intervention.
2863905|NCT03501992|Other|Practice C|Practice C will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice C will be assigned to receive the current care intervention. In the second step, Practice C will be assigned to receive the audit-and-feedback intervention. In the third step, Practice C will receive the audit-and-feedback intervention. In the fourth step, Practice C will receive the combined reminder-recall and audit-and-feedback intervention.
2863906|NCT03501992|Other|Practice D|Practice D will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice D will be assigned to receive the current care intervention. In the second step, Practice D will be assigned to receive the current care intervention. In the third step, Practice D will receive the audit-and-feedback intervention. In the fourth step, Practice D will receive the combined reminder-recall and audit-and-feedback intervention.
2863907|NCT03501992|Other|Practice E|Practice E will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice E will be assigned to receive the current care intervention. In the second step, Practice E will be assigned to receive the reminder-recall intervention. In the third step, Practice E will receive the reminder-recall intervention. In the fourth step, Practice E will receive the combined reminder-recall and audit-and-feedback intervention.
2863908|NCT03501992|Other|Practice F|Practice F will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice F will be assigned to receive the current care intervention. In the second step, Practice F will be assigned to receive the audit-and-feedback intervention. In the third step, Practice F will receive the combined reminder-recall and audit-and-feedback intervention. In the fourth step, Practice F will receive the combined reminder-recall and audit-and-feedback intervention.
2863909|NCT03501979|Experimental|Tucatinib + Trastuzumab + Capecitabine|Tucatinib will be taken orally at 300 mg twice a day starting with Cycle 1, Day 1. A cycle consists of 21 days. Capecitabine will be taken orally at 1000 mg/m2 twice a day on Days 1-14 starting with cycle 1. Trastuzumab is given intravenously as a loading dose of 8 mg/kg on Cycle 1, Day 1 and then at 6 mg/kg for all subsequent cycles.
2863910|NCT03501966|Active Comparator|Acetazolamide including Diet|"Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet."
2863911|NCT03501966|Active Comparator|Optic Nerve Sheath Fenestration|"Acetazolamide including Diet plus Optic Nerve Sheath Fenestration (ONSF) Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.~ONSF performed by qualified, certified orbital surgeon using either a medial or supero-medial lid crease approach. ONSF will be performed in one or both eyes, depending on criteria."
2863912|NCT03501966|Active Comparator|Ventriculoperitoneal CSF Shunting|"Acetazolamide including Diet plus Ventriculoperitoneal CSF Shunting (VPS) Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.~VPS performed by qualified, certified neurosurgeon using a frameless image-guided stereotactic system and positioning a shunt catheter in the lateral ventricle of the cerebral hemisphere not associated with speech. The catheter will be connected to an adjustable valve, and a distal shunt system will be placed in the peritoneal cavity."
2863913|NCT03501953|Experimental|Nature Exposure|6-week physical activity course in a natural environment
2863914|NCT03501953|Active Comparator|Urban Exposure|6-week physical activity course in an urban environment
2863915|NCT03501927|Active Comparator|FOCUS (focused cardiac ultrasound)|Patients allocated to FOCUS will receive a preoperative FOCUS examination in conjunction with a standard anesthetic preoperative evaluation.
2863916|NCT03501927|No Intervention|Control|Patients allocated til control arm will receive a standard anesthetic preoperative evaluation according to hospitals' standards.
2863917|NCT03501914|Experimental|Mindfulness Based Intervention|Mindfulness principles based manualized intervention will be provided to the participants which is developed by colleagues in Manchester. This intervention will be adapted to be accessible for people having intellectual disability (ID) in Pakistan.Sessions will take place once-weekly for 12 weeks including an initial orientation session. It will include breathing, soles of the feet, body scan, guided meditation, mindful stretching and walking
2863918|NCT03501888|Active Comparator|Cognitive Behavior Therapy (CBT)|CBT: individually, ca 18 weeks.
2863919|NCT03501888|Active Comparator|Acceptance and Commitment Therapy (ACT)|ACT: given in a group setting: ca 18 weeks.
2863920|NCT03501875|Experimental|CAC Score|CAC Score evaluated by the Agatston method
2863921|NCT03501862|Experimental|Mindfulness-based intervention|Intervention: a twelve 1.5 weekly program on mindfulness-based cognitive therapy (psychosis)
2863922|NCT03501862|Active Comparator|Psychoeducation|Intervention: a twelve 1.5 hours weekly program on psychoeducation (psychosis)
2863923|NCT03501849|Experimental|Polypectomy using a cold snare|Polypectomy by cold-snare technique and Optivista imaging
2863924|NCT03501836|Experimental|Rapid Rhythm Handheld 8-lead ECG Device|Participants will have measurements taken with the 8 lead ECG system, which will be compared to the conventional standard care 12 lead ECG.
2863925|NCT03501823||Peripheral vascular disease|"All adult patients (aged 18 years and above) proven or highly suspected to have peripheral arterial or venous disease.~Ultrasound to be performed first in order to correct Photoacoustic tomography positioning.~Photoacoustic tomography to be performed after ultrasound"
2863926|NCT03501823||Oncology|"All adult patients (ages 18 years and above) proven or highly suspected to have solid organ malignancy Ultrasound to be performed first in order to correct Photoacoustic tomography positioning.~Photoacoustic tomography to be performed after ultrasound"
2863927|NCT03501797|Experimental|Early singing intervention (AB)|Participants receive a 16 weeks of singing-based rehabilitation and standard care (SC) followed by 16 weeks of SC only.
2863928|NCT03501797|Experimental|Late singing intervention (BA)|Participants receive a 16 weeks of SC only followed by 16 weeks of singing intervention and SC.
2863929|NCT03501784|Experimental|Novidia Dental bonding and flow|Nobio particles incorporated within Novidia Dental Bonding and Flow.
2863930|NCT03501784|Active Comparator|Filtek bond and flow composite|standard of care class V composite restoration performed with Filtek and 3M
2863931|NCT03501771|Experimental|Acupuncture|Acupuncture needle will be administered.
2863932|NCT03501758||Remission with treatment|Patients randomized to continue medical treatment with biologics
2863933|NCT03501758||Remission without treatment|Patients randomized to stop medical treatment with biologics
2863934|NCT03501745|Other|Management Group|
2863935|NCT03501745|Other|control group|
2863936|NCT03501732|Experimental|Values Affirmation plus Risk Feedback|Values Affirmation with Risk Feedback in substance use and HIV domains of risk
2863937|NCT03501732|Active Comparator|Risk Feedback|Sham Values Affirmation with Risk Feedback in substance use and HIV domains of risk
2863938|NCT03501732|No Intervention|Sleep Control|Description of sleep habits in lieu of values affirmation/sham values affirmation. No risk feedback
2863939|NCT03501719||Triple ART|Patients who remain in triple ART during the follow-up.
2863940|NCT03501719||Dual ART|Patients switched to dual ART during the follow-up.
2863941|NCT03501719||Monotherapy|Patients switched to monotherapy during the follow-up.
2863942|NCT03501706|Experimental|Active Training (AT) Group|Participants will complete eight computerized training programs to improve executive function (EF), including Sequenced Recall of Digits—Auditory; Sequenced Reverse Recall of Digits—Auditory; Sequenced Recall of Digits—Visual; Sequenced Reverse Recall of Digits—Visual; Sequenced Recall of Words—Auditory; Sequenced Reverse Recall of Words—Auditory; Sequenced Recall of Words—Visual; Sequenced Reversed Recall of Words--Visual
2863943|NCT03501706|No Intervention|Control Training (CT) Group|Participants will complete the eight computerized programs relating to executive function (EF), but without memory requirements for control.
2863944|NCT03501693|Experimental|DBT plus S-View|Breast images utilizing DBT plus S-View
2863945|NCT03501693|Active Comparator|FFDM alone|FFDM alone images
2863946|NCT03501680|Experimental|Group A: intensive insulin|Group A: intensive insulin (glycemic control 4.4-6.1mmol/L)
2863947|NCT03501680|Active Comparator|Group B: standard insulin|Group B: standard insulin (glycemic control 7.8-10.0 mmol/L),
2863948|NCT03501680|Active Comparator|Group C: plasmapheresis|Group C: plasmapheresis
2880955|NCT03383042|Experimental|Cohort 6|Multiple-ascending cohort 1
2863949|NCT03501667|Active Comparator|Use of decision support tool|Trainee using decision support tool while assessing a clinical case. This intervention will affect the study participant fund of knowledge on the case.
2863950|NCT03501667|Active Comparator|Use of UpToDate|Control group, participants using current literature prior to assessing a clinical case. Allowing 10 minutes to read on a topic during clinical care is an active intervention in the study participant fund of knowledge.
2863951|NCT03501654|Experimental|TecnisSymfony intraocular lens insertion group|
2863952|NCT03501641|Experimental|image-based virtual reality learning|The participants will undergo 10-minute image-based virtual reality learning for history taking and physical examination of otolaryngology.
2863953|NCT03501641|Active Comparator|video-based learning|The participants will undergo 10-minute video-based learning for history taking and physical examination of otolaryngology.
2863954|NCT03501628|Placebo Comparator|Placebo|"2 servings daily~Serving information:~204 kcal~2.8 g fat~44.4 g carbohydrate~0.4 g protein (0 g L-leucine)"
2863955|NCT03501628|Experimental|L-leucine + maltodextrin|"2 servings daily~Serving information:~200 kcal~2.0 g fat~43.1 g carbohydrate~2.8 g protein (2.8 g L-leucine)"
2863956|NCT03501628|Experimental|Whey protein concentrate|"2 servings daily~Serving information:~184 kcal~3.5 g fat~12 g carbohydrate~26.3 g protein (2.8 g L-leucine)"
2863957|NCT03501628|Experimental|Hydrolyzed whey protein concentrate|"2 servings daily~Serving information:~192 kcal~4.6 g fat~12.2 g carbohydrate~25.4 g protein (2.9 g L-leucine)"
2863958|NCT03501628|Experimental|Soy protein concentrate|"2 servings daily~Serving information:~266 kcal~4.5 g fat~17.2 g carbohydrate~39.2 g protein (2.9 g L-leucine)"
2863959|NCT03501602|Active Comparator|LMA protector group|The LMA Protector is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts
2863960|NCT03501602|Active Comparator|I-gel LMA group|The I-gel is an alternative supraglottic device which provides the seal over the airway versus an inflatable cuff.
2863961|NCT03501576|Experimental|Inactivated Influenza Vaccine|Patients receive seasonal inactivated influenza vaccine IM at day 0.
2863962|NCT03501563||Case Group|"Participants with ASA 1-2, aged 18-60 years, undergoing hypotensive anesthesia in the operation of the septoplasty in Recep Tayyip Erdoğan University Medical Faculty Training and Research Hospital. Participants with uncontrolled hypertension, diabetes mellitus, cerebrovascular disease, cogulopathy, morbid obesity (BMI ≥35) and renal disease will not be taken.~Participants were first pre-medicated with an infusion of midazolam 0.05 mg/kg, fentanyl 1 µg/kg, lidocaine 1 mg/kg. Induction of anesthesia was achieved with an infusion of propofol 1-2 mg/kg and vecuronium bromide 0.6 mg/kg and after 2 to 3 minutes participants were intubated with the appropriate tube size. Anesthesia was maintained with an infusion of remi fentanyl (0.05 - 1 µg/Kg/min), with oxygen (O2) in air with desflurane."
2863963|NCT03501550|Experimental|CDI-31244 + SOF/VEL|CDI-31244 in combination with SOF/VEL
2863964|NCT03501537|Experimental|Surgical treatment with free gingival graft|Free gingival graft harvested from the palate will be placed around the diseased implant
2863965|NCT03501524|Experimental|VATS evacuation|patients selected for VATS after failure of first thoracostomy tube drainage
2863966|NCT03501524|Experimental|thoracostomy tube|patients selected for thoracostomy tube reinsertion after failure of drainage with first thoracostomy tube
2863967|NCT03501511|Active Comparator|IDF modules|Diabetes educations using IDF Arabic translated modules
2863968|NCT03501511|Experimental|Conversational Maps|Diabetes Educations using Ramadan fasting conversational maps (Arabic maps)
2863969|NCT03501498|Experimental|loperamide|Slows intestinal transit time
2863970|NCT03501498|Experimental|senna|Speeds up intestinal transit time
2863971|NCT03501472|Experimental|Text-only PWL, immediate post|"Exposure to 4 FDA-mandated warning labels and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
2863972|NCT03501472|Experimental|Text-only PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
2863973|NCT03501472|Experimental|Low-emot PWL, immed post|"Exposure to 4 FDA-mandated warning labels paired with images that elicit little emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
2863974|NCT03501472|Experimental|Low-emot PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit little emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
2863975|NCT03501472|Experimental|High-emot PWL, immed posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit high emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
2863976|NCT03501472|Experimental|High-emot PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit high emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
2863977|NCT03501459|Experimental|Rituximab|
2863978|NCT03501433|Experimental|Nicotinamide Riboside Chloride (Niagen)|7 days of nicotinamide riboside supplementation (250 mg/d x 2/day).
2863979|NCT03501433|Placebo Comparator|Placebo|7 days of placebo supplementation (2/day)
2863980|NCT03501420||Physicians|A sample of 230 to 325 rheumatologists actively involved in management and treatment decisions of pSS subjects in France, Italy, Spain, Germany and the United States will be included in the survey.
2863981|NCT03501420||Subjects with pSS|Subjects with a confirmed diagnosis of pSS under consultation of the rheumatologists enrolled in the study will be included.
2863982|NCT03501407||Erythema migrans|Patients for whom a diagnosis of acute phase of Lyme disease is done on the basis of the existence of an erythema migrans and a tick bite history in the days preceding the occurrence of erythema (before and after antibiotics treatment) will be recruited
2863983|NCT03501407||No-erythema migrans|"Patients with unspecific symptoms (the most common symptoms being:~headache, arthralgia, myalgia, febrile episode) appearing within 3 months after a tick bite will be recruited"
2863984|NCT03501394|Experimental|Single Arm|25 patients with pathologically confirmed invasive breast cancer who will undergo neoadjuvant chemotherapy treatment (NACT) and surgery will be recruited. During the study, patients will receive the standard care and the current study will not alter the care plan offered to them. All patients in the single arm will undergo 4 magnetic resonance imaging scan sessions. Histopathological analysis will be performed on the core biopsy and tumour tissue removed in surgery. Health questionnaire will be completed by each patient.
2863985|NCT03501381|Active Comparator|High Dose Interleukin 2|HD IL-2 600,000 IU/kg Every 8 hours on Days 1-5 and Days 15-19
2863986|NCT03501381|Experimental|High Dose Interleukin 2 plus Entinostat|HD IL-2 600,000 IU/kg Every 8 hours on Days 1-5 and Days 15-19 plus Entinostat 5 mg orally every 2 weeks starting Day -14
2863987|NCT03501368|Experimental|Ceritinib Treatment|Study treatment will be given in cycles. Each cycle will be 4 weeks (28 days). Post-Treatment (follow-up) Period: Participants will return to the study site between 30-40 days after the last dose of ceritinib for an end-of-treatment assessment. Additional follow-up will occur for related Adverse Events (AEs) that are not resolved by this time and related Serious Adverse Events (SAEs) that occur after the time of this visit. Participants will be followed for survival every 3 months for the first year following end of treatment, and then every 6 months for up to 5 years after end of treatment.
2863988|NCT03501355|Active Comparator|Strength training group|Intervention:Inspiratory muscle strength training group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
2863989|NCT03501355|Active Comparator|Endurance training group|Intervention: Inspiratory muscle endurance training group received inspiratory muscle endurance training (IMT) using POWERbreathe Classic threshold loading device
2863990|NCT03501342|Experimental|Virtual reality group|In virtual reality group, 30 minutes of Pilates training, 10 minutes of rest and then 20 minutes of virtual reality will be applied.
2863991|NCT03501342|Active Comparator|Dynamic Balance Training|"In the Dynamic Balance Training group, 20 minutes of dynamic balance exercises will be applied after Pilates training."
2863992|NCT03501342|No Intervention|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
2863993|NCT03501329||Outpatients in Community Psychiatry|"Treatment with consultations, social support, psychological and psychopharmacological treatment. This is routine psychiatric care.~Treatment was not changed as a result of the investigation in itself."
2863994|NCT03501316|Active Comparator|Hand Instrumentation|Root surface debridement using hand instruments.
2863995|NCT03501316|Active Comparator|Ultrasonic Instrumentation|Root surface debridement using ultrasonic scaler.
2863996|NCT03501303|Experimental|No touch|No touch technique. Patients are randomized to no touch vein harvesting. The technique is used as routine in Medical care by some hospitals.
2863997|NCT03501303|Other|Control|Control technique. Patients are randomized to Control vein harvesting. The technique is used as routine in Medical care.
2863998|NCT03501290|Other|Oral Nutritional Supplement Group|All patients will be in one group, receiving the active product, Oral Nutritional Supplement with 'Fortimel® Protein supplementation'
2863999|NCT03501277|Experimental|Sequence I: ABCD|SYR-322-4833 BL (alogliptin 25 [milligram] mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 1 (Treatment A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 2 (Treatment B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 3 (Treatment C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 4 (Treatment D).
2864000|NCT03501277|Experimental|Sequence II: BCDA|Alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 1 (Treatment B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 2 (Treatment C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 3 (Treatment D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 4 (Treatment A).
2864001|NCT03501277|Experimental|Sequence III: CDAB|SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 1 (Treatment C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 2 (Treatment D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 3 (Treatment A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 4 (Treatment B).
2864002|NCT03501277|Experimental|Sequence IV: DABC|Alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 1 (Treatment D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 2 (Treatment A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 3 (Treatment B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 4 (Treatment C).
2864003|NCT03501264|Experimental|Intervention group|This group receives the game
2864004|NCT03501264|Active Comparator|Control Group|This group receives LGBTQ resources only
2864005|NCT03501251|Experimental|Moxidectin 8 mg|A single tablet of 8 mg of moxidectin
2864006|NCT03501251|Experimental|Moxidectin 8 mg + Albendazole|A single tablet of 8 mg of moxidectin plus a single tablet of albendazole (400 mg)
2864007|NCT03501251|Experimental|Moxidectin 16 mg|Two tablets of 8 mg of moxidectin ( = 16 mg)
2864008|NCT03501251|Experimental|Moxidectin 16 mg + Albendazole|Two tablets of 8 mg of moxidectin ( = 16 mg) plus a single tablet of albendazole (400 mg)
2880956|NCT03383042|Experimental|Cohort 7|Multiple-ascending cohort 2
2864010|NCT03501251|Experimental|Moxidectin 24 mg + Albendazole|Three tablets of 8 mg of moxidectin ( = 24 mg) plus a single tablet of albendazole (400 mg)
2864011|NCT03501251|Placebo Comparator|Placebo|A single tablet of placebo
2864012|NCT03501238|Experimental|BSG|Participant receives bovine milk, then milk substitute, then milk substitute treated with gelatin
2864013|NCT03501238|Experimental|BGS|Participant receives bovine milk, then milk substitute with gelatin, then milk substitute
2864014|NCT03501238|Experimental|SBG|Participant receives milk substitute, then bovine milk, then milk substitute with gelatin.
2864015|NCT03501238|Experimental|SGB|Participant receives milk substitute, then bovine milk, then milk substitute with gelatin
2864016|NCT03501238|Experimental|GSB|Participant receives milk substitute with gelatin, then milk substitute, then bovine milk.
2864017|NCT03501238|Experimental|GBS|Participant receives milk substitute with gelatin, then bovine milk, then milk substitute.
2864018|NCT03501225|Experimental|ozone|tooth extraction under irrigation with ozonated water
2864019|NCT03501225|Experimental|water|tooth extraction under irrigation with ozonated water or doubly distilled water
2864020|NCT03501212|Active Comparator|Interventional|EMLA group layer of 2.5 gr EMLA cream (standard adult dose) was applied to both wrists
2864021|NCT03501212|Placebo Comparator|Placebo|Placebo cream was applied to both wrists
2864022|NCT03501199|Experimental|PRF Group|PRF is will be used in immediate dental implant placement.
2864023|NCT03501199|Experimental|Graft Group|The xenogenic graft is will be used in immediate dental implant placement.
2864024|NCT03501199|Experimental|Control Group|No extra material is will be used in immediate dental implant placement.
2864025|NCT03501186|Experimental|Group 1|forward walking on leveled surface
2864026|NCT03501186|Active Comparator|Group 2|forward walking on sand.
2864027|NCT03501186|Experimental|Group 3|Backward walking on leveled surface
2864028|NCT03501186|Active Comparator|Group 4|Backward walking on sand.
2864029|NCT03501173||Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)|Participants will be defined as having mCSPC if there is a new mCSPC diagnosis in the past 3 months, documented metastatic prostate cancer, and no more than 90 days of androgen deprivation therapy (ADT).
2864030|NCT03501173||Metastatic Castrate-Resistant Prostate Cancer (mCRPC)|Participants will be defined as having mCRPC if there is mCRPC diagnosis at any time, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated prostate specific antigen [PSA] despite testosterone less than [<]50 nanogram per deciliter [ng/dL] [<1.7 nano moles per liter{nmol/L}]), and the first treatment for mCRPC was started in the past 3 months or is scheduled to begin.
2864031|NCT03501147|Experimental|Intervention|15 minutes of resistance training at the work place every day
2864032|NCT03501147|No Intervention|Control|Usual work
2864033|NCT03501134||Tumor treating fields|Patients diagnosed with WHO Grade IV malignant glioma who are approved and planned to use the NovoTTF device
2864034|NCT03501108|No Intervention|Control|Patients in the control arm receive usual pharmaceutical care in hospital i.e. daily medication review by the attending physicians and ward-assigned pharmacist.
2864035|NCT03501108|Experimental|Intervention|Patients in the intervention arm receive usual pharmaceutical care as per the control group plus application of STOPPFrail deprescribing criteria advice points on their medication list at a single time point i.e. within 24 hours of randomization. The bespoke STOPPFrail advice report is presented to the patient's attending physician who then adjusts the patient's prescriptions according to the STOPPFrail advice points. The attending physician can implement as few or as many STOPPFrail advice points as he/she sees appropriate.
2864036|NCT03501095||patients|patients who must undergo general and/or urology surgery of an elective type
2864037|NCT03501082|Experimental|L. Reuteri PNG Strain|10 participants will be assigned to this group and provided with a one time dose of L. Reuteri PNG strain provided on day 4 of each diet period. 5 of the participants will be assigned to consume their usual diet for the first diet period, and 5 participants will be assigned to consume a non-western diet that will be prepared by the research team. After a 2 week washout period, participants will cross over into the arm they were not previously assigned to. The L. Reuteri PNG strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
2864038|NCT03501082|Experimental|L. Reuteri MM4 Strain|10 participants will be assigned to this group and provided with a one time dose of L. Reuteri MM4 strain provided on day 4 of each diet period. 5 of the participants will be assigned to consume their usual diet for the first diet period, and 5 participants will be assigned to consume a non-western diet that will be prepared by the research team. After a 2 week washout period, participants will cross over into the arm they were not previously assigned to. The L. Reuteri MM4 strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
2864039|NCT03501082|Placebo Comparator|Placebo|10 participants will be assigned to this group and provided with a one time dose of a placebo provided on day 4 of each diet period. 5 of the participants will be assigned to consume their usual diet for the first diet period, and 5 participants will be assigned to consume a non-western diet that will be prepared by the research team. After a 2 week washout period, participants will cross over into the arm they were not previously assigned to. The placebo will be provided as a drinkable solution (approximately 2 g maltodextrain dissolved in 50 ml of water).
2864040|NCT03501069|Experimental|Non-Japanese Cohort 1: TAK-418 120 mg and TAK-418 160 mg|TAK-418 120 milligram (mg) or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period A followed by a minimum of 14 days of washout period, followed by TAK-418 160 mg or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period B. The actual TAK-418 dose for Period B will be determined based on safety, tolerability, and PK data available from the previous dose in Period A.
2864041|NCT03501069|Experimental|Non-Japanese Cohort 2: TAK-418 20 mg|TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for up to 10 days.
2864042|NCT03501069|Experimental|Non-Japanese Cohort 3: TAK-418 40 mg|TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for up to 10 days. The actual TAK-418 dose for Cohort 3 will be determined based on safety, tolerability, and PK data available from the previous doses.
2864130|NCT03500458|No Intervention|Typical Sleep|All participants will sleep for 6 nights (Sunday - Thursday) in the home environment per their usual school schedule.
2864043|NCT03501069|Experimental|Non-Japanese Cohort 4: TAK-418 60 mg|TAK-418 60 mg or TAK-418 matching placebo, capsule, orally, once daily for up to 10 days. The actual TAK-418 dose for Cohort 4 will be determined based on safety, tolerability, and PK data available from the previous doses.
2864044|NCT03501069|Experimental|Japanese Cohort 5: TAK-418 20 mg|TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for up to 10 days. The actual TAK-418 dose for Cohort 5 will be determined based on safety, tolerability, and PK data available from the previous doses.
2864045|NCT03501069|Experimental|Japanese Cohort 6: TAK-418 40 mg|TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for up to 10 days. The actual TAK-418 dose for Cohort 6 will be determined based on safety, tolerability, and PK data available from the previous doses.
2864046|NCT03501056|Experimental|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
2864047|NCT03501056|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
2864048|NCT03501056|No Intervention|conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2864049|NCT03501043|Experimental|Dysport|Subjects will receive 1000 to 1500 units of Dysport to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors for one injection.
2864050|NCT03501030|Experimental|Activity restriction|Women in the intervention group will be recommended activity restriction. Activity restriction is defined as the following forms of activity restriction: pelvic rest and prohibition of sexual activity, reduction of work and/or non work activity. Bed rest will not recommended.
2864051|NCT03501030|No Intervention|No activity restriction|Women in the control group will not receive any reccomandation regarding activity restriction. Bed rest and abstain from sexual intercourse will also not recommended.
2864052|NCT03501017|Experimental|Intervention group|The 12-week physical activity program was implemented under the guidance of nurse, in outdoors with the group, 5 days a week with warm up and cooling down for 10 minutes and normal walking tempo at a moderate pace for 30-45 minutes (3-6 km/hour).
2864053|NCT03501017|Active Comparator|Control Group|As routine practice, a brochure provided from the Public Health Directorate on protection from CVD was delivered to the individuals in the control group.
2864054|NCT03501004|Experimental|The Acupuncture Group|Sterile acupuncture needles for single use will be used.The intervention is going to be executed using the acupuncture points GV14（Dazhui）and GB20 (Fengchi) for 20 minutes.The acupuncture needles will be inserted to a depth of 0.8 to 1 cm using GV14（Dazhui）and GB20 (Fengchi).
2864055|NCT03501004|Sham Comparator|The Sham Acupuncture Group|Sterile acupuncture needles for single use will be used.The sham acupuncture group's acupuncture needles will be inserted to a depth of 0.1 to 0.2 cm with nonacupuncture points located 0.5 cm in lateral to the real acupoint or to the right for midline points for 20 minutes.
2864056|NCT03500991|Experimental|ARM A (Tumor Cavity Infusion)|"patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity~Intervention: HER2-specific chimeric antigen receptor (CAR) T cell"
2864057|NCT03500991|Experimental|ARM B (Ventricular System Infusion)|"patients with either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the fourth ventricle or lateral ventricle, respectively~Intervention: HER2-specific chimeric antigen receptor (CAR) T cell"
2864058|NCT03500978|Experimental|Peer CBT Intervention|Women allocated to the peer-specialist delivered CBT intervention group will be mailed an intervention workbook (CBT exercises) and have their first telephone-based intervention session scheduled. The CBT intervention group will receive 8 telephone-based CBT intervention sessions (over 9 weeks) delivered by peer specialists. Each session will last up to 30 minutes.
2864059|NCT03500978|No Intervention|Control|Women allocated to the observation-only control group will not receive any intervention.
2864060|NCT03500965|Experimental|Text-only PWL, absol risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
2864061|NCT03500965|Experimental|text-only PWL, relative risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
2864062|NCT03500965|Experimental|graphic PWL, absol risk|Exposure to FDA-mandated warning labels, paired with a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
2864063|NCT03500965|Experimental|graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
2864064|NCT03500952|Experimental|Patient Decision Aid|Birth Control After Pregnancy patient decision aid and supporting document
2864065|NCT03500952|Active Comparator|Patient Information Leaflet|Postpartum Birth Control patient information leaflet
2864066|NCT03500939|Experimental|Normobaric hyperoxygenation + standard of care|Normobaric hyperoxygenation (NBHO), i.e. inhalation of 100% oxygen at high flow (≥ 40 L/min) via a sealed non-rebreather face-mask with reservoir, or in case of intubation/ventilation for (study-independent) TBY, ventilation with an inspiratory oxygen fraction (FiO2) of 1.0. NBHO is started within 3 hours of stroke symptom onset (witnessed or last seen well) and within 20 minutes after end of baseline brain imaging and applied until the end of TBY procedure (defined by removal of guide catheter from sheath) or, in case TBY is not attempted, 4 hours after start of study treatment.
2864067|NCT03500939|Active Comparator|standard of care alone|standard of care alone; oxygen supplementation if SpO2 ≤ 94% at 2 to 4 L/min via nasal cannula according to guidelines of the European Stroke Organisation (ESO), or in case of TBY-related intubation/ventilation, ventilation with an initial FiO2 of 0.3 to be gradually increased if SpO2 ≤ 94%.
2864068|NCT03500926|Active Comparator|hype standard|total hip replacement with standard femoral stem
2864069|NCT03500926|Experimental|hype mini|total hip replacement with short uncemented femoral stem
2864131|NCT03500458|Experimental|Sleep Extension|Participants will be prescribed a sleep schedule that allows them to obtain 1 hour more time in bed compared to Typical Sleep.
2864070|NCT03500913||Adults with growth hormone deficiency|Subjects who present to the CUMC neuroendocrine unit for therapy of GH deficiency or who are followed in the unit and have active GH deficiency and are planning to initiate a therapy.
2864071|NCT03500913||Control group|Healthy subjects matched to the GH deficiency subjects for age (+/- 5 years), gender and total fat mass (+/- 4%).
2864072|NCT03500900|Experimental|Vildagliptin|DPP-4 inhibitor, acute administration (50 mg.)
2864073|NCT03500900|Placebo Comparator|Placebo|Placebo treatment, acute administration
2864074|NCT03500887|Other|1. Bag inflated so that intrabagpressure increases with 2 mmHg|
2864075|NCT03500887|Other|2. Bag inflated to ¾ volume of 1|
2864076|NCT03500874|Experimental|Systematic Chemotherapy + HAI(FUDR)|"Patients will receive Systemic FOLFOX + HAI (FUDR) every 28 days:~Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1,15; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1,15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1,15.~floxuridine (FUDR) 0.12mg/Kg/d,d1-14 and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
2864077|NCT03500874|Active Comparator|Systematic Chemotherapy|"Patients will receive FOLFOX every every 28 days:~Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1,15; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1,15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1,15."
2864078|NCT03500861|Experimental|Dry Needling|While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.
2864079|NCT03500861|Sham Comparator|Sham Dry Needling|In the Sham Dry Needling (SDN) group, three times a week for 2 weeks, the SDN procedure was applied into the adipose tissue located at any area where an active TrPs was absent.
2864080|NCT03500848|Active Comparator|Tacrolimus-based group|Tacrolimus-based immunosuppression regimen: Tacrolimus+MMF and/or steroids
2864081|NCT03500848|Experimental|Sirolimus-based group|Sirolimus-based immunosuppression regimen: Tacrolimus (Tacrolimus elimination 30 (± 5) days post LT)+Sirolimus+MMF and/or steroids
2864082|NCT03500835|Experimental|App Plus Coaching (AC)|6 month addiction model based weight loss intervention in the form of an iPhone app coupled with personalized coaching.
2864083|NCT03500835|Experimental|App Alone (AA)|6 month addiction model based weight loss intervention in the form of an iPhone app.
2864084|NCT03500835|Experimental|Clinic|In-Clinic Multi-disciplinary monthly weight management program. Curriculum adapted from the KidsNFitness Program and administered by an MD, RD, Psychologist and Health Educator over 90 minute sessions
2864085|NCT03500822|Experimental|Metronome-paced tachypnea|Dynamic hyperinflation by the method of metronome-paced tachypnea.
2864086|NCT03500822|Experimental|Exspiratory-stenosis breathing|Dynamic hyperinflation by the method of expiratory-stenosis breathing.
2864087|NCT03500809|Experimental|Aqueous release (Burping) of the wound|"Following uneventful cataract surgery, wound burping will be performed in all eligible patients who gave their informed consent. The procedure will be offered whenever the intraocular pressure (IOP) is either higher than 30 mmHg or deemed inappropriate in view of the ocular condition (e.g. glaucoma).~After 'burping' the wound, patients will have their IOP measured using Goldmann application tonometry (GAT) immediately and at 2 hours. The 'burping' procedure will be repeated until satisfactory pressure is achieved and care will be taken to avoid shallowing of the anterior chamber while fluid is released. We will assess for the presence of leaks from the wound with a Seidel test with fluorescein 5% once the IOP is satisfactory. To prevent any infection after each procedure, we will prescribe post-op drops including chloramphenicol 0.5% four times a day for 2 weeks or minimum of 3 days and these will continue as per routine. All other complications will be recorded at follow-up."
2864088|NCT03500796|Other|Corneal perforation patients|"Patients who had/impeding corneal perforation due to melting of the cornea after infection with a corneal pathogen (bacterial or viral), with no previous surgical intervention.~Patients will undergo:~Platelet rich plasma clot implantation Wound closure with amniotic membrane"
2864089|NCT03500783|Experimental|Nitric Oxide|Patients of this group receive treatment with exogenous gaseous nitric oxide supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting for coronary artery disease.
2864090|NCT03500783|Placebo Comparator|Standard CPB|Patients of this group receive sham-treatment without supplying nitric oxide to the cardiopulmonary bypass circuit during coronary artery bypass grafting for coronary artery disease. Considering dilution of nitric oxide at a high ratio of 1 to 25,000 in the gas mixture of the cardiopulmonary bypass circuit (CPB), no addition of any inert gas to the CPB circuit is required in sham-treatment group.
2864091|NCT03500770|Experimental|Transcranial Direct Current Stimulator|The Transcranial Direct Current Stimulator device (tDCS) is a safe technique which poses a non-significant risk to study subjects. This technique uses weak current which is applied by using two electrodes. In the literature, no undesirable or long-lasting side effects due to device have been reported, nor have any participants reportedly abandoned a study due to discomfort.
2864092|NCT03500757|Experimental|360-degree Display of solid tumors|Evaluate the feed back of using the HoloLens headset to have a 360 degree visualization of patient tumors during percutaneous liver tumor ablation
2864093|NCT03500744|Experimental|Erector spinae plane block|"The ESPB will be performed with ultrasound guidance. After identifying a suitable location between 8th and 10th thoracic spine transverse process, the overlying skin will be infiltrated with local anesthetic. A 22 gauge 90-mm needle will be inserted to make contact with the transverse process and withdraw slightly. Ropivacaine 0.5% 20 mL will be injected at this location. The same procedure will be performed on the other side.~Additionally, patients will receive acetaminophen, gabapentin and intravenous patient-controlled analgesia opioids."
2864094|NCT03500744|Sham Comparator|Shame block|"A sham block will be performed by performing ultrasound examination of the back looking for intended location for ESPB placement. Skin will be infiltrated with local anesthetics but ESPB will not be performed.~Additionally, patients will receive acetaminophen, gabapentin and intravenous patient-controlled analgesia opioids."
2864095|NCT03500731|Experimental|Lung and Bone Marrow Transplantation|"All patients will undergo a cadaveric, partially HLA-matched lung transplantation followed by a CD3+/CD19+ depleted BMT from the same donor. In this study, the investigators will use a ≥1/6 HLA-matched T cell depleted bone marrow transplantation from a cadaveric organ donor with an identical ABO blood type as the recipient. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.~Subjects will undergo lung transplantation utilizing standard induction regimens selected by the CO-PIs based on the subject's underlying comorbidities and allosensitization. Rituximab may be initiated prior to the lung transplantation with tacrolimus as the ongoing maintenance immunosuppression.~Subjects will undergo BMT utilizing CD3+/CD19+-depleted bone marrow with bone marrow conditioning beginning no less than 8 weeks after lung transplantation. Bone marrow will be recovered alongside solid organs and will be processed and cryopreserved."
2864096|NCT03500718|Experimental|Pediatric patients with bilateral sensorineural hearing loss|One group will be studied: Patients undergoing cochlear implantation surgery between age 1 and 6 years who meet the above inclusion and exclusion criteria seen in JIPMER during the study period.
2864097|NCT03500705|Experimental|Mirror Therapy + Cross-Education.|Patients performed 4 sets of 5 maximal isometric elbow extensions with their less-affected upper limb (Cross-Education of Strengthening) while observing the reflection of the exercising limb in the mirror (Mirror Therapy) which was placed in the patient's mid-sagittal plane. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
2864098|NCT03500705|Active Comparator|Cross-Education of Strengthening.|Patients trained without a mirror entirely. They performed 4 sets of 5 maximal isometric elbow extensions with their less-affected upper limb (Cross-Education of Strengthening). Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
2864099|NCT03500692||MitraClip NT System|Percutaneous mitral valve repair using MitraClip NT System
2864100|NCT03500679|Experimental|Group 1: ExPEC4V (JNJ-63871860)|Participants will receive vaccination of ExPEC4V dose as an intramuscular (IM) injection into deltoid muscle on Days 1 and 181. The ExPEC4V doses contain polysaccharide antigen (4:4:4:8 microgram [mcg]) from the ExPEC4V serotypes O1A, O2, O6A, and O25B.
2864101|NCT03500679|Placebo Comparator|Group 2: Placebo|Participants will receive placebo matching to ExPEC4V as an IM injection on Days 1 and 181.
2864102|NCT03500666|Experimental|Robot lateral neck lymph node dissection|Robot neck lateral lymph node dissection was performed in patients with thyroid cancer and lateral cervical lymph node metastasis.
2864103|NCT03500666|Experimental|Total endoscopic lateral cervical lymph node dissection|Patients with thyroid cancer and lateral cervical lymph node metastases underwent total endoscopic neck dissection.
2864104|NCT03500653|Active Comparator|Active|4 gr Curcumin daily for 1 year in addition to vedolizumab 300 mg per infusion (standard of care)
2864105|NCT03500653|Placebo Comparator|Sham|4 gr placebo daily for 1 year in addition to vedolizumab300 mg per infusion (standard of care)
2864106|NCT03500640|Active Comparator|DPP Plus: 30-minute calls|Following the 6-month DPP core program, 30-minute group-interactive telephone calls will be implemented once-per-month between months 7 and 12, and every-two-months between months 13 and 24.
2864107|NCT03500640|Placebo Comparator|DPP Minimal: 15-minute calls|Following the 6-month DPP core program, 15-minute group-interactive telephone calls will be implemented once-per-month between months 7 and 12, and every-two-months between months 13 and 24.
2864108|NCT03500627|Experimental|Cohort 1|20 mg/kg OP-101 administered intravenously for over 1 hour.
2864109|NCT03500627|Experimental|Cohort 2|40 mg/kg OP-101 administered intravenously for over 1 hour.
2864110|NCT03500627|Experimental|Cohort 3 (optional)|80 mg/kg OP-101 administered intravenously for over 1 hour.
2864111|NCT03500614|Experimental|Cohort 1|Participants (n=70) will receive either true or sham air cleaner treatment for 1 week and then alternate the treatment after a wash out interval (Air cleaner use method 1). Exposure monitoring for PM2.5 will continue throughout the treatment period and air and fine particle phase phthalates samples will be collected during the last day (24 hours) of the treatment period; and health variables will be measured and biological samples will be collected immediately after the completion of each intervention period.
2864112|NCT03500614|Experimental|Cohort 2|Participants (n=30) will undergo extended treatment period covering the start, peak and end phases of smog episodes in Beijing, with either true or sham air cleaner treatment and then alternate the treatment after a wash out interval (Air cleaner use method 2). Exposure monitoring for PM2.5 will continue throughout the treatment period and repeated health examinations will be conducted at time points corresponding to the start, peak and end phases of the smog episodes.
2864113|NCT03500601|Experimental|Active treatment|Nut components
2864114|NCT03500601|Placebo Comparator|Placebo|Placebo
2864115|NCT03500588||normotensive pregnant women more than 20 weeks gestation.|Twenty pregnant women after 20 weeks with normal blood pressure were evaluated for VEGF gene mutation by using PCR.
2864116|NCT03500588||Pregnant women after 20 weeks with preeclampsia.|Thirty pregnant women after 20 weeks with preeclampsia were evaluated for VEGF gene mutation by using PCR.
2864117|NCT03500575|Experimental|photopheresis|
2864118|NCT03500575|No Intervention|control|
2864119|NCT03500562||HCV participant population in China|
2864120|NCT03500549|Experimental|Group 1 - Monotherapy APL-2 (n=35)|Complement (C3) Inhibitor
2864121|NCT03500549|Active Comparator|Group 2 - Monotherapy Eculizumab (n=35)|Complement (C5) Inhibitor
2864122|NCT03500536|No Intervention|Waitlist Control|8 weeks of treatment as usual followed by 8 weeks of IntelliCare treatment.
2864123|NCT03500536|Experimental|Experimental|8 weeks of IntelliCare treatment followed by 8 weeks of treatment as usual.
2864124|NCT03500523|Experimental|1-study group|study group: pregnant women
2864125|NCT03500523|Experimental|2-control group|control group: healthy non pregnant women
2864126|NCT03500484|Experimental|obese subjects|Subjects will self-administer Liraglutide once daily for 12 weeks.
2864127|NCT03500484|No Intervention|lean subjects|no intervention
2864128|NCT03500471||Experimental: Robotic surgery|Robotic-assisted Total Gastrectomy with D2 Lymphadenectomy
2864129|NCT03500471||Compared: Laparoscopic surgery|Laparoscopic-assisted Total Gastrectomy with D2 Lymphadenectomy
2864132|NCT03500445|Experimental|Treatment Arm (D-KRd)|
2864133|NCT03500432|Active Comparator|periprostatic group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+periprostatic block
2864134|NCT03500432|Active Comparator|PAT group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+periapical triangle (PAT) block
2864135|NCT03500432|Experimental|TPA switch group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+TPA switch (transperineal prostate biopsy local anesthesia switch) block
2864136|NCT03500419|Sham Comparator|Group 1 - Control|No treatment will be administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes. After the 6 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired
2864137|NCT03500419|Experimental|Group 2 - PTT 1x daily x 5 days/week x 5 months|Men will utilize penile traction therapy for 30 minutes once daily, 5 times a week, beginning 4 weeks post-prostatectomy. Men will remain in this phase for a period of 5 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
2864138|NCT03500419|Experimental|Group 3 - PTT 2x daily x 7 days/week x 5 months|Men will utilize penile traction therapy for 30 minutes twice daily, 7 times a week, beginning 4 weeks post-prostatectomy. Men will remain in this phase for a period of 5 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
2864139|NCT03500406|Sham Comparator|Group 1 - Control|No treatment will be administered and men will procedure right to their IPP procedure
2864140|NCT03500406|Experimental|Group 2 - PTT 3x daily x 3 months|Men will utilize penile traction therapy for 30 minutes three times daily for the 3 months prior to placement of their IPP
2864141|NCT03500393|Active Comparator|Unsupervised Exercise (UNSUP)|The control condition represents a minimalist intervention that could occur in any setting: (1) enthusiastic provision on an exercise prescription and (2) provision of a fitness device (i.e., the Garmin VivioActive) that can help participants track their exercise engagement. Participants are instructed in how to use the device to track their adherence to the exercise prescription.
2864142|NCT03500393|Experimental|Remotely Supervised Exercise (REM)|The REM program is designed to function as an Acceptance-based health coaching intervention and will utilize theory-based behavior change techniques (i.e., goal setting/action planning, self-monitoring, receiving feedback, and reviewing relevant goals in the light of feedback) to promote adoption and adherence to the exercise prescription.
2864143|NCT03500380|Experimental|RC48-ADC|Participants will receive RC48-ADC 2.0 mg/kg intravenous (IV) infusion each 14-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
2864144|NCT03500380|Active Comparator|Lapatinib + Capecitabine|Participants will receive lapatinib 1250 mg orally once daily during each 21-day cycle + capecitabine 2000 mg/m^2 orally daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.
2864145|NCT03500367|Experimental|rapamycin|rapamycin, 2 mg a day, orally ,for 3months
2864146|NCT03500354|Experimental|Nutrient|Nutrient drink
2864147|NCT03500328|Active Comparator|Early Aggressive Therapy|"Higher efficacy disease-modifying therapy (Early Aggressive Therapy) for treatment of multiple sclerosis~Early Aggressive Therapy choices and maximum allowable doses:~Natalizumab (Tysabri), 300 mg intravenously (IV) every 4 weeks~Alemtuzumab (Lemtrada), 12 mg IV daily for 5 days; 1 year later: 12 mg IV daily for 3 days~Ocrelizumab (Ocrevus), 300 mg IV every 2 weeks (for 2 doses) at initiation; subsequently, 600 mg IV every 6 months~Rituximab (Rituxan), 1000 mg IV every 2 weeks (for 2 doses); may repeat every 16-24 weeks"
2864148|NCT03500328|Active Comparator|Traditional Therapy|"First-line disease-modifying therapy (Traditional Therapy) for treatment of multiple sclerosis~Traditional Therapy choices and maximum allowable doses:~Glatiramer acetate (Copaxone, Glatopa, and other generics), 20 mg subcutaneously (SC) daily, or 40 mg SC three times a week~Intramuscular interferon (Avonex), 30 mcg intramuscularly (IM) weekly~Subcutaneous interferon (Betaseron, Extavia, Rebif), 0.25 mg SC every other day (Betaseron, Extavia); 44 mcg SC three times a week (Rebif)~Pegylated interferon (Plegridy), 125 mcg SC every 14 days~Teriflunomide (Aubagio), 14 mg orally (PO) daily~Dimethyl fumarate (Tecfidera), 240 mg PO twice a day~Fingolimod (Gilenya), 0.5 mg PO daily"
2864149|NCT03500315|Experimental|HIV D+/R+|HIV-infected individuals that accept an organ from an HIV-infected deceased donor - enrollment 80
2864150|NCT03500315|No Intervention|HIV D-/R+|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor -enrollment 80
2864151|NCT03500315|No Intervention|HIV D-/R+ (observational)|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and randomized to observational group - enrollment 200
2864152|NCT03500302|Experimental|Evolocumab|All enrolled patients will receive evolocumab sq once a month for a total of two doses
2864153|NCT03500289|Experimental|Ketamine|
2864154|NCT03500289|Placebo Comparator|Midazolam|
2864155|NCT03500276|Experimental|Yoga program|"12 weeks of Yoga in daily life practice, 2x weekly for 90 minutes including physical exercises (asanas), breathing exercises (pranayama), relaxation and meditation exercises."
2864156|NCT03500276|Active Comparator|Arthritis-education control|12 weeks of arthritis - education classes, consisting of 1x weekly sessions for 120 minutes including lectures on arthritis and related issues followed by group discussion.
2864157|NCT03500263|Active Comparator|Cohorts 1 and 2: PTI-808 Active Co-admin with PTI-801 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
2864158|NCT03500263|Placebo Comparator|Cohorts 1 and 2: PTI-808 Placebo Co-admin with PTI-801 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
2864159|NCT03500263|Active Comparator|Cohort 3 PTI-808 Active + PTI-801 Active + PTI-428 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
2864160|NCT03500263|Placebo Comparator|Cohort 3 PTI-808 placebo + PTI-801 Placebo + PTI-428 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
2880957|NCT03383042|Experimental|Cohort 8|Multiple-ascending cohort 3
2864161|NCT03500263|Active Comparator|Cohort 4 PTI-808 Active + PTI-801 Active + PTI-428 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for 7 days immediately followed by PTI-808 co-administered with PTI-801 or placebos once-a-day for 7 days. A follow-up visit will occur on Day 21.
2864162|NCT03500263|Placebo Comparator|Cohort 4 PTI-808 Placebo + PTI-801 Placebo + PTI-428 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for 7 days immediately followed by PTI-808 co-administered with PTI-801 or placebos once-a-day for 7 days. A follow-up visit will occur on Day 21.
2864163|NCT03500250||Nurses|Nurses working on the neurological wards of three hospitals (one university hospital and two general hospitals)
2864164|NCT03500237|Experimental|Team-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will provide support within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.
2864165|NCT03500237|Active Comparator|Self-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no psychological intervention will be provided. A team member from the Unit will contact the participant only if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms).
2864166|NCT03500224|Experimental|[14C]-TAK-954 0.5 mg|[14C]-TAK-954 0.5 milligram (mg), (containing approximately 1.5 microcurie [mCi] of radioactive tracer), administered as 60-minute infusion, intravenously, once on Day 1.
2864167|NCT03500211|Experimental|Lidoderm 5% Topical Patch|5% lidocaine patch applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second 5% lidocaine patch applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
2864168|NCT03500211|Sham Comparator|Sham Topical Patch|Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
2864169|NCT03500185|Experimental|PFMT in group|Participants randomized to this group will perform the PFMT protocol in a group, with physiotherapeutic supervision, lasting 1 hour, in the Outpatient Clinic of Gynecology of Hospital of Clinics of Porto Alegre (HCPA), for a period of 3 months. You will also be instructed to perform exercises at home. After this period, they will be reassessed and will follow the same protocol for another 3 months now at home. After this period, they will be evaluated again.
2864170|NCT03500185|Active Comparator|PFMT at home|Randomized participants for this group will receive guidance on the home PFMT protocol on the day of the initial evaluation. They will be instructed to perform the exercises daily for a period of 3 months. After 3 months they will be re-evaluated and will follow the same protocol for another 3 months at home. After this period they will be evaluated again.
2864171|NCT03500172|Active Comparator|DTP, Continue DTP if Responsive|
2864172|NCT03500172|Active Comparator|DTP, Standard of Care (SoC) if Responsive|
2864173|NCT03500172|Active Comparator|DTP, Continue DTP if Non-Responsive|
2864174|NCT03500172|Active Comparator|DTP, DTP+ICM if Non-Responsive|
2864175|NCT03500172|Active Comparator|ICM, Continue ICM if Responsive|
2864176|NCT03500172|Active Comparator|ICM, SoC if Responsive|
2864177|NCT03500172|Active Comparator|ICM, Continue ICM if Non-Responsive|
2864178|NCT03500172|Active Comparator|ICM, ICM+DTP if Non-Responsive|
2864179|NCT03500159|Experimental|AQX-1125|AQX-1125 200 mg
2864180|NCT03500159|Placebo Comparator|Placebo|Matching placebo
2864181|NCT03500146||Normal sexual function|Patients with an overall FSFI score equal to or above 26.5 will be in the normal sexual function group. Patients in both groups will be treated with an overactive bladder treatment, either anticholinergics, beta-agonists or PTNS.
2864182|NCT03500146||Low sexual function|Female sexual dysfunction is defined as an overall FSFI score below 26.5, patients meeting this criteria will be in the low sexual function group. Patients in both groups will be treated with an overactive bladder treatment, either anticholinergics, beta-agonists or PTNS.
2864183|NCT03500133|Experimental|Group A|"Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.~No radiotherapy if CR at the end of chemotherapy."
2864184|NCT03500133|Experimental|Group B|"Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.~No radiotherapy if CR at the end of chemotherapy"
2864185|NCT03500133|Experimental|Group B2|"Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
2864186|NCT03500133|Experimental|Group C|"Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.~No radiotherapy if CR at the end of chemotherapy."
2864187|NCT03500133|Experimental|Group D|"Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
2864188|NCT03500133|Experimental|Group E|"High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.~No radiotherapy if CR at the end of chemotherapy"
2864189|NCT03500133|Experimental|Group F|"High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
2864190|NCT03500120||Primary Aldosteronism|"1. ARR≥2.0 (ng/dl)/(mIU/l) or ARR<2.0 (ng/dl)/(mIU/l) but PA was strongly suspected.~and 2. PAC post-FST≥8 ng/dl"
2864191|NCT03500120||non Primary Aldosteronism|1. ARR<2.0 (ng/dl)/(mIU/l) and 2. PAC post-FST<8 ng/dl
2864225|NCT03499847|Active Comparator|Passive Intervention|subjects will be given a pamphlet about the advanced medical directive
2864192|NCT03500107|Experimental|Blue LED 401 +/- 5 nm|The Blue LED 401 +/- 5 nm will be applied in the participant, in a closed room by a physiotherapist for 1 hour. The apparatus will be supported on a tripod, statically, externally, 5 cm away from the vulva abd vaginal region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol consists of only one session. This part of the study will see if there is bactericidal effect of the blue LED.
2864193|NCT03500094|Experimental|migalastat HCl 150 mg|"One migalastat 123 mg capsule equivalent to 150 mg migalastat HCl (herein referred to as migalastat) will be administered with water every other day for 12 months."
2864194|NCT03500081||Cancer Patients|Cancer patients with any solid tumor type planning to undergo a course of radiation therapy.
2864195|NCT03500081||Healthy Volunteers|Faculty members in the Department of Radiation Oncology have volunteered to participate in this research project. They are investigators and are interested in the abilities of this new machine(MR-Linac) and the potential benefits to patients who will be treated in their department. These scans will be used to optimize scanning parameters for various body sites and to identify appropriate positioning methods for future patient treatments.
2864196|NCT03500055|Experimental|Abdominal Closure Bundle|Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin.
2864197|NCT03500055|No Intervention|Control|Normal operative procedure. The abdominal closure bundle will not be used.
2864198|NCT03500042|Experimental|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, expiratory pressure threshold device and concurrent inspiratory and expiratory muscle device for one minute randomly.
2864199|NCT03500042|Experimental|normal respiratory muscle|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, expiratory pressure threshold device and concurrent inspiratory and expiratory muscle device for one minute randomly.
2864200|NCT03500029|Experimental|TMS treatment group|In the Transcranial magnetic stimulation (TMS) treatment group patients with severe depression receive rTMS treatment without drug treatment.
2864201|NCT03500029|Active Comparator|medication group|In the medication group patients with severe depression are treated with anti-depressants.
2864202|NCT03500029|No Intervention|healthy control group|The control group don't accept intervention and treatment.
2864203|NCT03500016|Experimental|Acute exercise and exercise training|"Euglycemic-hyperinsulinemic clamp before and after 8 weeks supervised exercise training. Before exercise training the participants will also do an acute exercise on 1 hour with muscle biopsies taken before and after exercise and then again 4 hours into recovery."
2864204|NCT03500003|Experimental|Milk acute intake|14 adult and 14 elderly volunteers will consume 600mL of milk. Blood (11 sampling points) and urine samples (3 collection points) will be collected before the ingestion and during the postprandial period (6h).
2864205|NCT03500003|Experimental|Yogurt acute intake|14 adult and 14 elderly volunteers will consume 600mL of yogurt. Blood (11 sampling points) and urine samples (3 collection points) will be collected before the ingestion and during the postprandial period (6h).
2864206|NCT03499977|Experimental|Sitting|The participant will be asked to sit for 10 min (not increasing their heart rate) then do the anti-saccade task
2864207|NCT03499977|Experimental|Low-Intensity Cycling|Participant will be asked to cycle for 10 min (<40% VO2R) and then perform the anti-saccade task
2864208|NCT03499977|Experimental|Moderate-Intensity Cycling|The participant will be asked to do 10 min of cycling (40-59% VO2R) followed but the anti-saccade task
2864209|NCT03499977|Experimental|High-Intensity Cycling|The participant will be asked to do 10 min of cycling (60%-84% VO2R) followed but the anti-saccade task
2864210|NCT03499964|Experimental|Optilume Treatment|The treatment arm will be the Urotronic Optilume Drug Coated Balloon (DCB).
2864211|NCT03499964|Active Comparator|Control Treatment|The control arm will be treated by a urethral dilation method considered to be best standard of care for the study site and subject. A control treatment may be either a rod, uncoated balloon or DVIU.
2864212|NCT03499951|Other|Wheelchair Skills Trainers|Individuals will receive remotely delivered wheelchair skills training, after which they will be assessed on their ability to teach the Wheelchair Skills Trainees a series of wheelchair skills in a one-on-one environment. The intervention for this group is Wheelchair Skills Training - Remote.
2864213|NCT03499951|Other|Wheelchair Skills Trainees|Individuals will receive one-on-one wheelchair skills training from the Wheelchair Skills Trainers. The intervention for this group is Wheelchair Skills Training - In Person.
2864214|NCT03499925|Experimental|Test Group|Telephone consultation effectiveness and cognitive behaviors
2864215|NCT03499925|No Intervention|Comparison Group|Routine product inspection
2864216|NCT03499899|Experimental|LAG525 + spartalizumab|approximately 32 patients will be randomized in this arm
2864217|NCT03499899|Experimental|LAG525+spartalizumab+carboplatin|approximately 32 patients will be randomized in this arm
2864218|NCT03499899|Experimental|LAG525 + carboplatin|approximately 32 patients will be randomized in this arm
2864219|NCT03499886|Experimental|Ketamine Hydrochloride 50Mg/1mL|"In the intervention group, Ketamine Hydrochloride 50Mg/1mL was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds). Patient assessment was performed before and two minutes after ketamine injection, and then every 5 minutes after the reduction of the fracture, by an anesthetist blind to the type of intervention."
2864220|NCT03499886|Experimental|Ketamine Hydrochloride 50Mg/mL|in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds. Patient assessment was performed before and two minutes after ketamine injection, and then every 5 minutes after the reduction of the fracture, by an anesthetist blind to the type of intervention.
2864221|NCT03499873|Experimental|Nepafenac 0.3% Opthalmic Suspension|Test product manufactured by Indoco Remedies, Ltd for Actavis LLC.
2864222|NCT03499873|Active Comparator|Ilevro 0.3% Opthalmic Suspension|Reference product manufactured by Alcon Laboratories Inc.
2864223|NCT03499873|Placebo Comparator|Placebo (vehicle) Opthalmic Suspension|Placebo (vehicle) manufactured by Indoco Remedies, Ltd for Actavis LLC.
2864224|NCT03499847|Active Comparator|Active Intervention|subjects will be given a pamphlet about the advanced medical directive, and a standardized face-to-face counselling session will be conducted with their healthcare provider
2864226|NCT03499847|No Intervention|Control|
2864227|NCT03499834|Experimental|Study Group|26 patients who has successfully undergone the screening criteria will be enrolled for treatment. Immune Killer Cells (IKC) will be administered through Intravenous Injection (I.V.) Frequency: One injection per week, twenty-four injections on-treatment
2864228|NCT03499821|Experimental|Study population|EDOF ICL implanted into both eyes of eligible subjects.
2864229|NCT03499808|Experimental|Treatment (isatuximab)|Patients receive isatuximab IV on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
2864230|NCT03499795|Experimental|VGX-3100|Adult participants, who are HIV negative with histologically confirmed anal or anal/peri-anal HSIL associated with HPV-16 and/or 18, will receive VGX-3100 administered by IM injection followed immediately by EP using the CELLECTRA™ 5PSP device. Participants will receive at least 3 doses of VGX-3100 at Day 0, Week 4 and Week 12. For partial responders at Week 36, a fourth dose may be administered at Week 40. All participants are scheduled to be followed to Week 88.
2864231|NCT03499769|Experimental|natural orifice|Patients who underwent laparoscopic surgery and removed the specimen from the natural orifice will be gathered. demographic data and perioperative results will be compiled
2864232|NCT03499769|No Intervention|conventional|patients who underwent laparoscopic surgery and removed specimen with conventional will be gathered. demographic data and perioperative results will be compiled. (conventional extraction is suprapubic or median incision)
2864233|NCT03499756|Experimental|Couple-based interpersonal psychotherapy|The intervention consists of three weekly 2-hour antenatal sessions and two 30-minute telephone follow-up sessions delivered within four weeks postpartum.
2864234|NCT03499756|No Intervention|Control|The control group will receive the standard prenatal and postnatal care.
2864235|NCT03499743|Experimental|group A (hyoscine Butyl-bromide group)|oral hyoscine butyl bromide 20 mg (BUSCOPAN two tablets, produced by Chemical Industries Development (CID), Giza - A.R.E. under licence of Boehringer Ingelheim International GmbH - Germany) will be taken 30 minutes before IUD insertion.
2864236|NCT03499743|Placebo Comparator|group B(PLACEBO GROUP)|two tablets of placebo equal in size and shape will be taken 30 minutes before IUD insertion.
2864237|NCT03499704|Experimental|Pioglitazone + Alogliptin + Metformin (PAM)|SYR-322-4833 (pioglitazone 15 milligram ([mg] and alogliptin 25 mg) fixed dose combination (FDC) tablet, orally once daily and metformin greater than or equal to (>=) 500 mg, tablet, orally, twice a day for up to 52 weeks. At Week 12, if participants has HbA1c >=7.5 percent (%), pioglitazone dose will be titrated up to 30 mg based on investigator's opinion and up-titrated dose will be maintained up to Week 52.
2864238|NCT03499704|Active Comparator|Glimepiride + Alogliptin + Metformin (GAM)|Glimepiride 2 mg, tablet, orally, once daily with alogliptin, tablet, orally, once daily, and metformin tablet, orally, twice a day, for up to Week 52. At Week 12, if participants has HbA1c >=7.5%, glimepiride dose will be titrated up to 4 mg based on investigator's opinion and up-titrated dose will be maintained up to Week 52.
2864239|NCT03499691|Experimental|Expanded Hemodialysis (HDx) Therapy|Patients will undergo 3 dialysis sessions per week with Theranova 500 for up to 24 weeks.
2864240|NCT03499691|Active Comparator|Hemodiafiltration (HDF) Therapy|Patients will undergo 3 dialysis sessions per week with on-line HDF for up to 24 weeks.
2864241|NCT03499678||Lung Cancer|Small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC)
2864242|NCT03499678||Control|Age and sex matched control individuals
2864243|NCT03499665|Experimental|PNF, Myofascial Releasing Maneuvers, Home Exercise Group|This group of patients received patients with bruxism. It was applied proprioceptive neuromuscular facilitation (PNF), myofascial releasing maneuvers and home exercises.
2864244|NCT03499665|Active Comparator|Myofascial Releasing Maneuvers and Home Exercises Group|This group of patients received patient with bruxism. It was applied myofascial releasing maneuvers and home exercises.
2864245|NCT03499665|Active Comparator|Control Group|This group of patients received patient with bruxism. It was applied conventional treatment and no myofascial releasing or Proprioceptive Neuromuscular Facilitation exercises were applied.
2864246|NCT03499652||derivation cohort|The data of derivation cohort are used to derive the neonatal bacterial meningitis risk score
2864247|NCT03499652||validation cohort|The data of validation cohort are used to validate the neonatal bacterial meningitis risk score
2864248|NCT03499639|Other|patients with HCV and ESKD|Ombitasvir / Paritaprevir / Ritonavir/Ribavirin Oral Tablet
2864249|NCT03499626|Experimental|ASLAN001|A 3+3 study de-escalating dose design will be employed for dose determination. Subjects will receive treatment in 21-day cycles until disease progression, intolerable toxicities or withdrawal of consent.
2864250|NCT03499613||Chronic low back pain|Patients with chronic low back pain participating to a 3 weeks Multidisciplinary rehabilitation program
2864251|NCT03499600|Experimental|Clinical Assessment+Cultural Formulation Interview|CA+CFI families will receive the Cultural Formulation Interview prior to their standard Clinical Assessment during their intake.
2864252|NCT03499600|Active Comparator|Diagnostic & Clinical Assessment|CA families will receive a standard Clinical Assessment during intake.
2864253|NCT03499587||Obese pregnant women|BMI >30 with early OB visit medical records accessible
2864254|NCT03499587||Normal weight pregnant women|BMI 18.5-25 with early OB visit medical records accessible.
2864255|NCT03499574|Experimental|Biofeedback group|Dysphagia therapy using surface EMG as biofeedback - 10 x 45 minute sessions of swallow strength and skill training using surface electromyography as biofeedback tool. This group will also receive usual care provided by Speech and Language Therapists, which may involve assessment, review, therapy, patient/family education.
2864256|NCT03499574|Other|Control group|This group will receive usual care provided by Speech and Language Therapists, which may involve assessment, review, therapy, patient/family education
2864257|NCT03499561||pregnant women in first Trimester|A urine sample will be taken from pregnant women before 14 weeks of pregnancy
2864258|NCT03499561||pregnant women in second Trimester|A urine sample will be taken from pregnant women from 14 weeks +1 day till 28 weeks
2864259|NCT03499561||pregnant women in third Trimester|A urine sample will be taken from pregnant women from 28 weeks +1 day till 40 weeks
2864260|NCT03499548|Experimental|Intervention|10 hours of intensive CBT for suicide will be delivered to male prisoners who are having thoughts of ending their lives. This will be delivered in 2 hours sessions, 5 times across 2 weeks.
2864261|NCT03499535|Active Comparator|Study 1: Radon&Smoking Synergistic/EPA|Participants viewed radon and smoking risk information taken from the EPA's pamphlet on the dangers of radon gas exposure.
2864262|NCT03499535|Active Comparator|Study 1: Radon&Smoking Synergistic/Idaho|Participants viewed radon and smoking risk information taken from Idaho's Department of Health and Human Welfare's pamphlet on the dangers of radon gas exposure.
2864263|NCT03499535|Experimental|Study 1: Radon Only / EPA|Participants viewed only radon risk information taken from the EPA's pamphlet on the dangers of radon gas exposure.
2864264|NCT03499535|Experimental|Study 1: Radon Only / Idaho|Participants viewed only radon risk information taken from Idaho's Department of Health and Human Welfare's pamphlet on the dangers of radon gas exposure.
2864265|NCT03499535|Experimental|Study 2: Radon Only|Participants viewed a radon-only message that focused only on the effect of radon on lung-cancer risk.
2864266|NCT03499535|Other|Study 2: Radon and Smoking Isolated|Participants viewed a radon-and-smoking-isolated message that covered the individual effects of radon and of smoking on lung cancer, but without mentioning their synergistic effect.
2864267|NCT03499535|Active Comparator|Study 2: Radon & Smoking Synergistic|Participants viewed a radon-and-smoking-synergistic message that covered the individual effects of radon and of smoking but that also included information about their synergistic effect.
2864268|NCT03499522||Observational group|"80 patients with congenital coagulopathies (hemophilia A and B, and von Willebrand's disease), of legal age, will be included in the study. Patients will be recruited in six centers, from different regions of Spain.~The inclusion criteria to participate in the present study are patients: with a medical diagnosis of congenital coagulopathies (hemophilia A and B, or von Willebrand's disease); adults; in a prophylactic or on demand regimen with FVIII / FIX concentrates; and that they have signed the informed consent document.~On the other hand, those patients with: neurological or cognitive alterations that impede the comprehension of the questionnaires will be excluded from the study; inability to walk autonomously or with an orthosis; and without access to digital media to complement the measuring instruments."
2864269|NCT03499509|Experimental|Low Glycemic Diet|
2864270|NCT03499509|Placebo Comparator|High Glycemic Diet|
2864271|NCT03499483|Experimental|Open Label Biktarvy|Single arm all participants receive open label study product intervention.
2864272|NCT03499470|Active Comparator|Intervention|"The intervention mainly consists of a developed protocol for education about the disease and medications AND an education of the equipment and how to use it to have the best benefit.~Actions in structured discharge and follow up protocol:~Patient education for disease severity and medications~Education of family/relatives about medications and types of equipment~Detailed education for LTOT and/or NIV (how to use, duration of use, solutions for possible common problems)~Preparation of home environment for patients needs~Regular telephone visits on day 7 and day 14 after discharge and telephone visits in emergency situations and early referral to the hospital when needed~Outpatient control for the first month"
2864273|NCT03499470|No Intervention|Control|Control patients will receive usual care
2864274|NCT03499457|Experimental|treatment|penicillin chalange test, as descibed.
2864275|NCT03499444|Experimental|Oral Rucaparib monotherapy|Part I: Dose Escalation, Part II: Dose Expansion (Additional patients will be enrolled at the recommended dose as defined in Part I of the study.)
2864276|NCT03499418||newborns with TTN|Group of late preterm and full-term newborns with TTN evaluated by modified Silverman scale
2864277|NCT03499418||newborns with PPHN|Group of late preterm and full-term newborns with respiratory failure with PPHN evaluated by echocardiography
2864278|NCT03499405|Experimental|Intervention group|Intervention group will receive a family navigator intervention from a culturally matched family navigator.
2864279|NCT03499405|No Intervention|Control group|Control group will not receive a family navigator intervention from a culturally matched family navigator.
2864280|NCT03499392|Other|psychological investigation|
2864281|NCT03499353|Experimental|TALAZOPARIB|SINGLE ARM, NON-RANDOMIZED
2864282|NCT03499340|Experimental|Text-only PWL, absolute risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
2864283|NCT03499340|Experimental|Text-only PWL, relative risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
2864284|NCT03499340|Experimental|Low arousal graphic PWL, absolute risk|Exposure to FDA-mandated warning labels, paired with a low arousal graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
2864285|NCT03499340|Experimental|Low arousal graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a low arousal graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
2864286|NCT03499340|Experimental|High arousal graphic PWL, absolute risk|Exposure to FDA-mandated warning labels, paired with a high arousal graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
2864287|NCT03499340|Experimental|High arousal graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a high arousal graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
2864288|NCT03499327|Active Comparator|Wheat germ oil (UV treated)|Wheat germ oil (UV treated)
2864289|NCT03499327|Placebo Comparator|Wheat germ oil (untreated)|Wheat germ oil (untreated)
2864290|NCT03499327|No Intervention|Control|no study products
2864291|NCT03499314|Experimental|RS-tDCS Stimulation|20 times 20 minute stimulation session supervised by a study technician through a videoconferencing platform, VSee
2864292|NCT03499314|Placebo Comparator|Sham Stimulation|20 ×20-minute sessions sham tDCS
2864293|NCT03499301||Chronic pain|Patients with chronic pain when arrived to emergency room.
2864294|NCT03499301||No chronic pain|Patients without chronic pain when arrived to emergency room.
2864295|NCT03499288||Children and youth with cerebral palsy|Subjects between 1 month and 18 years of age with Cerebral Palsy who visited the coordinating HCP within the past 12 months.
2864296|NCT03499275|Sham Comparator|Sham NMES|Sham neuromuscular electrical stimulation plus home exercise programme and advice on breathlessness management
2864297|NCT03499275|Experimental|Active NMES|Neuromuscular electrical stimulation plus home exercise programme and advice on breathlessness management
2864299|NCT03499249|Experimental|N-Acetylcysteine Treatment|Will receive continuous intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
2864300|NCT03499236|Experimental|Treatment|Treatment arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation
2864301|NCT03499236|Other|Control|Control arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility, but will not have transseptal catheterization or shunt implantation.
2864302|NCT03499236|Experimental|Roll in|Roll in arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation
2864303|NCT03499223|Experimental|Ranibizumab + THR-317|Subjects will receive intravitreal ranibizumab in combination with THR-317
2864304|NCT03499223|Active Comparator|Sham + ranibizumab|Subjects will receive a sham injection in combination with intravitreal ranibizumab
2864305|NCT03499210|Experimental|Investigational group|All subjects will participate in study procedures involving use of the ReWalk ReStore device.
2864306|NCT03499184|Experimental|Local Probiotics|P Flor (Lactobacillus reuteri 1.2 billion CFU) will be delivered locally every 12 hours for 12 weeks
2864307|NCT03499184|Experimental|Systemic Probiotics|P Flor (Lactobacillus reuteri 1.2 billion CFU) will be administered every 12 hours for 12 weeks
2864308|NCT03499184|Active Comparator|Systemic Antibiotics|Amoxil 500 mg capsule and Flagyl 400 mg tablet by mouth, will be given every 8 hours for 5 days
2864309|NCT03499171|Experimental|Citalopram|20mg, once a day
2864310|NCT03499171|Placebo Comparator|Placebo|Once a day
2864311|NCT03499158||1|affected arms of patients who had gone to electrodiagnostic study and diagnosed as carpal tunnel syndrome
2864312|NCT03499158||2|healthy arms of patients who had gone to electrodiagnostic study and diagnosed as carpal tunnel syndrome in the other arms
2864313|NCT03499145|Experimental|Eligible patients for AI test.|Device: ophthalmology diagnostic system. An artificial intelligence to make comprehensive evaluation and treatment decision of ocular diseases.
2864314|NCT03499132||General anesthesia (with opioids)|orthopedic surgery plus general anesthesia
2864315|NCT03499132||Epidural anesthesia (without opioids)|orthopedic surgery plus epidural anesthesia (without opioids use)
2864316|NCT03499132||Subarachnoid anesthesia (with opioids)|orthopedic surgery plus subarachnoid anesthesia (plus intrathecal opioid)
2864317|NCT03499132||Regional anesthesia (without opioids)|orthopedic surgery plus regional anesthesia (peripheral nerve block, continous or single shot, without opioid use)
2864318|NCT03499119|Other|Cohort 1|Subjects with a body weight at Day 1 of less than weight threshold.
2864319|NCT03499119|Other|Cohort 2|Subjects with a body weight at Day 1 of weight threshold or more.
2864320|NCT03499106|Experimental|Healthy Volunteers|Period 1: Single dose of IW-1973. Period 2: ITZ is dosed once daily (QD) for 17 days; a single dose of IW-1973 is administered 1 hour after the fourth ITZ QD dose.
2864321|NCT03499093||Prosthetic patient with esthetic expectations|Prosthetic patients with esthetic expectations (PP-E, n=35), Patients seeking for restoration or replacement of anterior teeth, or expressing any esthetic expectation
2864322|NCT03499093||Prosthetic patients without esthetic expectations|Prosthetic patients without esthetic expectations (PP-NE, n=35) Patients pending restoration or replacement of posterior teeth (premolars and molars), expressing only functional expectation
2864323|NCT03499093||Dental patient with esthetic concern|Dental patient with esthetic concern(C-E, n=35) Patient consulting for follow up, having crowns or removable denture replacing anterior teeth
2864324|NCT03499093||Dental patient without any esthetic concern|Dental patient without any esthetic concern (C-NE, n=35) Patient consulting for follow up, having no crown or removable denture replacing anterior teeth.
2864325|NCT03499080||Patients in medication free treatment|Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).
2864326|NCT03499080||Patients in treatment as Usual Åråsen|Inpatient unit colocated with the medication free unit. Same level of care. Similar treatment program, shorter treatment duration (on average 3 weeks).
2864327|NCT03499080||Patients in treatment as Usual Myrvegen|Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).
2864328|NCT03499054|No Intervention|control group|Hemodialysis patients in the control group who receive only routine nursing care during hemodialysis
2864329|NCT03499054|Experimental|exercise group|The exercise group are asked to perform breathing exercises during hemodialysis for the study period of 3 months.
2864330|NCT03499041|Experimental|LY3314814 Control|LY3314814 administered orally to participants with normal hepatic function
2864331|NCT03499041|Experimental|LY3314814 Mild|LY3314814 administered orally to participants with mild hepatic impairment
2864332|NCT03499041|Experimental|LY3314814 Moderate|LY3314814 administered orally to participants with moderate hepatic impairment
2864333|NCT03499041|Experimental|LY3314814 Severe|LY3314814 administered orally to participants with severe hepatic impairment
2864334|NCT03499028|No Intervention|Standard of Care Group|The Standard of Care Group will receive standard, routine medical care and will communicate with their surgeon and clinical care team through conventional methods such as phone.
2864335|NCT03499028|Experimental|Experimental (JointCOACH) Group|The Experimental Group will receive standard, routine medical care and utilize a web-based communication platform called JointCOACH to communicate with their care team via computer or smartphone throughout their episode of care. They will also receive information personalized to their treatment plan and will be asked to complete online questionnaires.
2864336|NCT03499015|No Intervention|Ear without BET|ear without BET treatment works as control
2864337|NCT03499015|Experimental|BET ear|ear with BET treatment works as intervention arm
2864345|NCT03498950|No Intervention|Placebo Group|submitted to the routine laser therapy protocol in addition to simulated laser irradiation on the taste papillae
2864346|NCT03498950|Experimental|Test Group|submitted to the same laser therapy protocol as that of the Placebo Group, however, laser irradiation on the taste papillae will be effective.
2864347|NCT03498937|Experimental|Group 1|Subjects suffering from Borderline Personality Disorder randomly assigned to start the trial by 10 active tDCS sessions, followed by 10 sham tDCS sessions
2864348|NCT03498937|Experimental|Group 2|Subjects suffering from Borderline Personality Disorder randomly assigned to start the trial by 10 sham tDCS sessions, followed by 10 active tDCS sessions
2864349|NCT03498924||CASES|Patients with endometrial cancer
2864350|NCT03498924||CONTROLS|Matched controls without neoplasm disease
2864351|NCT03498911|Active Comparator|envelope Coronally Advanced Flap (eCAF)|A mucogingival surgery where an envelope flap is coronally advanced and sutured to cover the mucosal recession
2864352|NCT03498911|Experimental|Modified Tunnel Technique (MTT)|A mucogingival surgery where the gingiva is released without reflecting a flap (as described for tunnel techniques) and then coronally advanced and sutured to cover the mucosal recession
2864353|NCT03498898|Active Comparator|Group A|American Society of Anesthesiologists (ASA) Score 2-3 with chronic use of Beta adrenergic receptor blockers planned to undergo total hip replacement
2864354|NCT03498898|No Intervention|Group B|American Society of Anesthesiologists (ASA) Score 2-3 with no chronic use of Beta adrenergic receptor blockers planned to undergo total hip replacement
2864355|NCT03498898|Active Comparator|Group C|American Society of Anesthesiologists (ASA) Score 2-3 with chronic use of Beta adrenergic receptor blockers planned to undergo total knee replacement.
2864356|NCT03498898|No Intervention|Group D|American Society of Anesthesiologists (ASA) Score 2-3 with no chronic use of Beta adrenergic receptor blockers planned to undergo total knee replacement
2864357|NCT03498885|Experimental|Low ligation|Left colic artery (LCA) is identified, tie the sigmoid artery and superior rectal artery,Apical lymph node dissection with the left colic artery preservation is performed.
2864358|NCT03498885|Active Comparator|High ligation|The IMA is ligated and divided at 2 cm from its origin. Apical lymph nodes dissection is performed.
2864359|NCT03498872|Active Comparator|Able-bodied individuals|
2864360|NCT03498872|Experimental|Transtibial amputee|
2864361|NCT03498872|Experimental|Transfemoral amputee|
2864362|NCT03498859|Other|Home-based training|10 weeks of home-based training with no supervision of a physiotherapist
2864363|NCT03498859|Other|Physiotherapist-supervised training|Physiotherapist-supervised training once per week during 10 weeks in addition to home-based training
2864364|NCT03498846|Experimental|Modified EA and AMLK|Modified corneal epithelial autograft (EA) combined with allogeneic middle lamellar keratoplasty (AMLK) is used for the treatment of patients with severe corneal burn.
2864365|NCT03498846|Active Comparator|LA and AMLK|Limbal autograft (LA) combined with AMLK is used for the treatment of patients with severe corneal burn.
2864366|NCT03498833|Other|Test-retest reliability testing|Minimum 60 IKOA will be evaluated with the scale on two occasions within two weeks to establish test retest reliability.
2864367|NCT03498820|Experimental|Analgesia Nociception Index|Intraoperative remifentanil administration guided by the Analgesia Nociception Index
2864368|NCT03498820|Active Comparator|Usual practice|Intraoperative remifentanil administration managed in standard practice
2864369|NCT03498807|Experimental|Control group_Use Ventilator P/V tool|Use the Pressure/Volume Loop
2864370|NCT03498807|Active Comparator|Study group_Use EIT|Use the Electrical Impedance Tomography
2864371|NCT03498794|Active Comparator|Ureteral stent|"Technique of ureteral stent insertion:~All patients will be in lithotomy position, and an endoscopy operating table with fluoroscopic imaging capability will be used. Before the procedures, all patients will have retrograde ureteropyelography. Then, a 0.035-inch hydrophilic guide wire will be placed into the renal pelvis under the guidance of flexible cystoscope.~The ureteral stent will be inserted retrograde by using flexible cystoscope, under mild sedation or local anesthesia by instilling 2% xylocain gel per urethra. Patients will be covered by specific antimicrobial therapy according to urine and/or blood culture. This treatment will be continued until there was no fever and any evidence of infection disappeared. A Foley's catheter will be left in the bladder for 2 hours in all patients. In each case the type of stent will be that of 5 or 6 F, with side-holes and remain in place until definitive treatment of stone."
2864372|NCT03498794|Active Comparator|Percutaneous nephrostomy tube|"Technique of PCN insertion:~Percutaneous nephrostomy will be performed in the angiography suite by a urologist with the patient under local anesthesia. All the patients will be given non-nephrotoxic antibiotics pre-operatively. The patients will be placed on the ultrasound table with fluoroscopic imaging capability in prone position and a pillow placed under the abdomen on the affected side to support the kidney. Then the initial puncture site will be chosen, cleaned and draped. Local anesthesia was injected and a stab incision was given at the puncture site. The 18-gauge Chiba needle will be inserted at the renal angle or at the posterior axillary line under ultrasound guidance into dilated pelvicalyceal system. Urine or pus drained out spontaneously or will be sucked with a disposable syringe and sample was sent to the laboratory for culture and sensitively."
2864373|NCT03498781|Experimental|Exercise-only intervention|Participants will receive information regarding the health benefits of regular aerobic and resistance training exercise and current physical activity guidelines for adults.
2864374|NCT03498781|Experimental|Sedentary Screen-only intervention|Participants will receive information regarding the health risks of sedentary behavior and suggestions for reducing or breaking up screen time.
2864375|NCT03498781|Experimental|Exercise+Sedentary Screen intervention|Participants will receive information on the health benefits of increasing physical activity and reducing sedentary screen behavior.
2864376|NCT03498781|Sham Comparator|Control intervention|Participants will receive information regarding the health risks of chronic stress as well as suggested methods to reduce stress.
2864377|NCT03498768||Inpatients with lung nodules|All inpatients in our department are invited to finish the questionnaire at inpatient education on the first day of hospitalization as the baseline date, then they are followed up by phone call to reevaluate their psychosocial status at 6 months and 1 year after the surgery.
2865065|NCT03493828|Active Comparator|TAP using Bupivacaine 0.25%|TAP using Bupivacaine 0.25%
2864378|NCT03498755|Experimental|Multi-sectoral anemia behavior change|Address multiple behavioral determinants of anemia by promoting the identification, knowledge, valuation and practice of four behavioral domains: 1) consumption of micronutrient-rich animal-source foods; 2) malaria and soil-transmitted helminth infection control practices; 3) water, sanitation and hygiene (WASH) best practices; and 4) women's autonomy in decision-making and control of the use of earned income.
2864379|NCT03498755|Experimental|Strengthening market engagement of fish processors|Assist women in overcoming limited access to credit, inadequate storage facilities, and insufficient information about market prices, which constrain the timeliness and amount of market-ready product available for sale, through a three-pronged approach that includes: 1) a conditional cash transfer; 2) entrepreneurship training; and 3) enhanced access to market price information.
2864380|NCT03498755|Experimental|Improving fish smoking technology and practices|Introduce and promote a recently developed fish smoking oven known as the Ahotor, which was explicitly designed to reduce emission from biomass fuel combustion, decrease polycyclic aromatic hydrocarbon (PAH) levels of smoked fish, and increase fuel efficiency. Use of this oven will reduce workload, increase earnings, and reduce harmful occupational exposures. Introduction of this improved fish smoking oven will be combined with behavior change education focused on promoting optimal fish smoking and handling practices.
2864381|NCT03498742||No SABA users|Asthmatic subjects that did not use short acting beta2 agonists in the last 3 months and being using none agent or ICS, systemic corticosteroids of combined ICS/LABA as relief symptoms agent.
2864382|NCT03498742||SABA users|Most of the asthmatic subjects usually inhale SABA as rescue medication and many times SABA is the only one prescribed treatment for asthma.
2864383|NCT03498729||Persistent AF|
2864384|NCT03498729||Paroxysmal AF|
2864385|NCT03498729||Psoriasis|
2864386|NCT03498729||Healthy Controls|
2864387|NCT03498716|Experimental|Atezolizumab + Chemotherapy|"Participants will receive atezolizumab (in combination with chemotherapy as described below) every 2 weeks for 10 doses, followed by atezolizumab maintenance therapy every 3 weeks to complete 1 year of treatment from the first dose~Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)"
2864388|NCT03498716|Active Comparator|Chemotherapy|Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
2864389|NCT03498703|Experimental|Azathioprine|
2864390|NCT03498703|Placebo Comparator|Control|
2864391|NCT03498690|Active Comparator|Integrative|
2864392|NCT03498690|Active Comparator|Role Specific|
2864393|NCT03498690|Active Comparator|Consecutive|
2864394|NCT03498677|Active Comparator|Method of presentation one|
2864395|NCT03498677|Active Comparator|Method of presentation two|
2864396|NCT03498664|Experimental|EMR-C group|"A plastic cap for mucosectomy (MH-597, Olympus Optical Co., Ltd, Tokyo, Japan) with an outer diameter of 17 mm and a length of 15 mm will be preloaded on the tip of the colonoscope. Inside the distal end of the cap there is a gutter which positions the opened polypectomy snare.~After submucosal injection, the cap will be applied against the lesion which will be aspirated by controlled suction, avoiding excessive protrusion of tissue in order not to trap the muscular layer.~The tissue will then be gripped with the snare and resection will be performed. A specific polypectomy snare which can be adapted into the gutter of the cap will be used (SD-221U-25, Olympus Optical Co., Ltd, Tokyo, Japan)."
2864397|NCT03498664|Active Comparator|EMR-S group|The resection will be performed using a standard polypectomy snare, which diameter will be chosen according to the size of the lesion, after lifting the lesion from the underlying layers with a submucosal injection of liquid.
2864398|NCT03498651|Experimental|Computer CBM-I, low attrition|Computer-based Cognitive Bias Modification - Interpretation training
2864399|NCT03498651|Experimental|Phone CBM-I, low attrition|Phone-based Cognitive Bias Modification - Interpretation training
2864400|NCT03498651|Experimental|Computer CBM-I, high attrition, coach|Computer-based Cognitive Bias Modification - Interpretation training + Coaching
2864401|NCT03498651|Experimental|Computer CBM-I, high attrition, no coach|Computer-based Cognitive Bias Modification - Interpretation training
2864402|NCT03498651|Experimental|Phone CBM-I, high attrition, coach|Phone-based Cognitive Bias Modification - Interpretation training + Coaching
2864403|NCT03498651|Experimental|Phone CBM-I, high attrition, no coach|Phone-based Cognitive Bias Modification - Interpretation training
2864404|NCT03498651|Active Comparator|Psychoeducation control|Online psychoeducation about anxiety
2864405|NCT03498638|Experimental|Couples Therapy|Couples Therapy
2864406|NCT03498638|Placebo Comparator|Control|Couples Therapy after an 8 week waiting period
2864407|NCT03498625|Other|Clinical remission CD|
2864408|NCT03498612|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 18 courses in the absence of disease progression or unacceptable toxicity.
2864409|NCT03498599|Experimental|Novelty facilitated extinction|Behavioral intervention. After Pavlovian fear conditioning, the shock is omitted and replaced by a novel, surprising, and neutral auditory tone.
2864410|NCT03498599|Other|Standard extinction|The shock is omitted during standard extinction
2864411|NCT03498586|Experimental|Half-normal saline|
2864412|NCT03498586|Active Comparator|Normal saline|
2864413|NCT03498573|Experimental|tunneling surgical technique|
2864414|NCT03498560||MGH Surgery Patients|PSG data will be collected, and delirium assessments conducted, on patients undergoing surgery at MGH.
2864415|NCT03498547|Active Comparator|Caudal Block|For the caudal block, sacral horns are palpated and sacral hiatus and epidural area will be determined at S4-S5 level through ultrasonography. The 20 G adult caudal needle will then be placed to the caudal epidural space and 25 mL bupivacaine at a concentration of 0.5% will be applied in the prone Jack-Knife position with resistance loss.
2864581|NCT03497325|Experimental|PRP|55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision
2864416|NCT03498547|Active Comparator|Saddle Block|In the saddle block group hyperbaric bupivacaine at a dose of 7 mg will be given to the intrathecal space after a 25 G quincke spinal needle is inserted with ultrasonography guidance between L4-L5 vertebral disc and clear cerebrospinal fluid is seen. The patient will be placed in sitting position for 5 minutes.
2864417|NCT03498534|Active Comparator|Patients with a -TST|In all patients with a negative TST test, Isoniazid 300 mg per day will be administered for 6 months
2864418|NCT03498534|Active Comparator|Patients with a +TST|In patients with a +TST test researchers will test for HIV, hepatic function and we will take a chest x-ray. Isoniazid 300 mg per day will be administered for 6 months
2864419|NCT03498534|Active Comparator|HIV positive patients|The researchers will test hepatic function and take a chest x-ray. Isoniazid 300 mg per day will be administered for 6 months
2864420|NCT03498521|Experimental|Molecularly-Guided Therapy|Participants will be assigned molecularly-guided therapy based on genetic profile.
2864421|NCT03498521|Active Comparator|Platinum-Based Chemotherapy|Participants will receive platinum-doublet) chemotherapy (Carboplatin/Paclitaxel, Cisplatin/Gemcitabine, or Carboplatin/Gemcitabine)
2864422|NCT03498508||Healthcare professionals in Dalarna County Council|Healthcare professionals working in-hospital at the hospitals in Mora, Avesta and Falun, Sweden, n=1473.
2864423|NCT03498508||Healthcare professionals in Region Västmanland|Healthcare professionals working in-hospital at the hospital in Västerås, Region Västmanland, Sweden, n=1571.
2864424|NCT03498495|Experimental|SMART Intervention|
2864425|NCT03498495|No Intervention|Usual Care|
2864426|NCT03498482|Experimental|FORNET|During FORNET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress and committed violence. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for the client's emotions, cognitions, physiological reactions, and sensory informations during traumatic and aggressive events to link them to an autobiographical context, namely time and place. In total the individuals receive 8 sessions of FORNET, every session lasting between 1.5 and 2 hours depending on the needs of the participant.
2864427|NCT03498469|Active Comparator|No Parenting program|Participants assigned to this comparison arm will receive a standardized reintegration package that includes individualized case management support and a reunification cash grant. Individualized case management will consist of a caseworker-developed individualized care plan with routine caseworker visits at the household level. At a minimum, each family will be visited on a monthly basis during the first 6 months post-placement and then every other month for the next 9 months. For the cash grant, the family of each enrolled child will receive a reunification cash grant in the Ugandan Shilling equivalent of $125, administered in two equal disbursements. It is designed to offset the cost of child care.
2864428|NCT03498469|Experimental|Parenting program|Those in the intervention arm will receive an enhanced reintegration package of services that consist of the standard package (case management and cash grant) plus a parenting program called 'Esanyu Mu Maka' or Happiness in the Home. The parenting curriculum used will be an adaptation of the evidence-based Sinovuyo Kids curriculum, tailored for caregivers of children age 1 to 13 years. It will have specifically designed components to address parenting challenges under reunification/reintegration conditions and to support the child and caregiver in building their relationship. It will be delivered at the household level by project trained parenting facilitators. The program will consist of approximately 13 bi-weekly sessions, which will be delivered over the course of 7 months.
2864429|NCT03498456|Experimental|Tegoprazan/Amoxicillin/Clarithromycin|Tegoprazan 50 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg
2864430|NCT03498456|Active Comparator|Lansoprazole/Amoxicillin/Clarithromycin|Lansoprazole 30 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg
2864431|NCT03498430|Experimental|Copanlisib (Aliqopa, BAY80-6946)|Planned at least 12 patients who meet the entry criteria will receive 60 mg copanlisib as single agent, with dosing on Days 1, 8 and 15 of each 28-day treatment cycle
2864432|NCT03498417||Graves' diseases|Patients with Graves' disease. No interventions foreseen
2864433|NCT03498417||Autoimmune thyroiditis|Patients with autoimmune thyroiditis. No interventions foreseen
2864434|NCT03498417||Healthy Subjects|Normal healthy subjects. No interventions foreseen
2864435|NCT03498404|Experimental|Photodynamic Therapy and SRP|"Procedure/Surgery: Photodynamic Therapy After a surgical access, the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). Teeth with furcation lesion will increase over 60 seconds into the lesion. Before the application, the supragingival plaque will be removed.~Treatment with TFDa in the Test Group maintained the protocol of applications in the periods of 2, 7 and 14 days post-surgical intervention."
2864436|NCT03498404|Sham Comparator|SRP and Sham Photodynamic Therapy|Procedure/Surgery: Sham Photodynamic Therapy After a surgical access, the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. Before the application, the supragingival plaque will be removed.
2864437|NCT03498391|Experimental|Propofol|Propofol sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.
2864438|NCT03498391|Experimental|Ketamine|Ketamine sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.
2864439|NCT03498378|Experimental|Avelumab, Palbociclib, and Cetuximab|Identify the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) for the combination of palbociclib, avelumab, and cetuximab
2864440|NCT03498365|Experimental|Online MCDA|
2864441|NCT03498365|Active Comparator|Online Delphi|
2864442|NCT03498326|Experimental|gemcitabine|one group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection.
2864443|NCT03498326|Experimental|gemcitabine plus celecoxib|the other group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection, and receive additional celecoxib every days during chemotherapy period.
2864613|NCT03497000|Active Comparator|ICGA group|Patients in this group underwent normal ICGA-guided half dose photodynamic therapy.
2864444|NCT03498313|Experimental|Transdermal Estradiol + Placebo|.1mg per 24 hours transdermal estradiol applied to the skin weekly, and sugar pill manufactured to mimic the progesterone pills taken twice daily by mouth, for 14 days.
2864445|NCT03498313|Experimental|Oral Micronized Progesterone + Placebo|100 mg oral micronized progesterone pill taken twice daily by mouth, and clear patch manufactured to mimic the E2 patch applied to the skin weekly, for 14 days.
2864446|NCT03498313|Placebo Comparator|Placebos|Sugar pill designed to mimic the P4 pills taken twice daily by mouth, and clear patch manufactured to mimic the E2 patch applied to the skin weekly, for 14 days.
2864447|NCT03498300|Experimental|Experimental|A single dose of Tdap vaccine at GA 27 - 36 weeks
2864448|NCT03498300|No Intervention|Active comparator|dT vaccine as standard protocol
2864449|NCT03498287|Experimental|Study Device|Small, non-invasive, stiff patch for the wrist
2864450|NCT03498287|Sham Comparator|Sham Device|Device that looks like the Study Device but modified to prevent or remove the main mechanism of action.
2864451|NCT03498274|Experimental|Fitting System|a self-directed hearing screening based on a known algorithm from Audiology Inc. sold in an automated audiogram by Grason Stadler, GSI and a simplified version of the software. The flow of the new software is driven by the end user, but a trained professional should always assist with the fitting. The new software will first perform a hearing screening on the end user and then recommend a hearing aid and prescribe amplification to the hearing aid based on the hearing screening results.
2864452|NCT03498274|Active Comparator|Traditional Fitting System|A traditional fitting method will be used as a control. This system is controlled by a trained professional, who performs the entire fitting without much interaction from the end user. The hearing instruments will be fit with the same settings as the experimental arm.
2864453|NCT03498261|Active Comparator|Gabapentin|The primary outcome of interest will be used to evaluate the efficacy of a single preoperative dose of gabapentin when compared to placebo on opioid consumption in patients undergoing rhinoplasty.
2864454|NCT03498261|Placebo Comparator|Placebo|The primary outcome of interest will be used to evaluate the efficacy of a single preoperative dose of gabapentin when compared to placebo on opioid consumption in patients undergoing rhinoplasty.
2864455|NCT03498248|Experimental|Neutropenia in chemotherapy|Neutropenia after cytotoxic chemotherapy
2864456|NCT03498235|Experimental|Team Sevoflurane|
2864457|NCT03498235|Experimental|Team Propofol|
2864458|NCT03498222|Experimental|Dose Level -1|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 9mg/m2
2864459|NCT03498222|Experimental|Dose Level 1|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 18mg/m2
2864460|NCT03498222|Experimental|Dose Level 2|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 36mg/m2
2864461|NCT03498196|Experimental|Avelumab|Avelumab 10 mg/kg intravenously, over 60 minutes every 2 weeks for 3 cycles or 42 days.
2864462|NCT03498183|Experimental|ARM experimental|All the patients will have MIBI-Tc99m/Iodine-123 . Following the injections they will have a scintigraphy.
2864463|NCT03498170|Other|Period 1 and Period 2|"Period 1 - BCT197 14mg on Day 1~Period 2 - itraconazole 200mg on Day 1 to 14 and BCT197 14mg on Day 7"
2864464|NCT03498157|Experimental|Partly Supervised Prehabilitation|Will be offered an initial one week (5 days for 3 hours each) supervised exercise prehabilitation program including a two hour group-based prehabilitation class at Penn State Rehabilitation Hospital, Hummelstown. The following weeks till surgery the learned exercise program should be done home-based for 5 times a week. A weekly phone call during this period will help to support and adapt the exercise program.
2864465|NCT03498157|Active Comparator|Home-based Prehabilitation|Will be offered an individual one-on-one appointment for an exercise introduction session with an exercise and cancer specialist and weekly phone calls to support and adapt the exercise program. The exercises should be done home-based for 5 times a week until the time of surgery. Furthermore, a two hour group-based prehabilitation class at the Penn State Hershey Cancer Institute will be offered.
2864466|NCT03498157|Active Comparator|Control Group|Will be offered a two hour group-based prehabilitation class at the Penn State Hershey Cancer Institute.
2864467|NCT03498144||Patients with acquired punctal stenosis|Patients with acquired punctal stenosis with epiphora
2864468|NCT03498144||Control subjects|normal subjects, without evidence of any punctal abnormalities.
2864469|NCT03498131|Experimental|3 mg Melatonin|Subjects will receive 3 mg melatonin once a day.
2864470|NCT03498131|Experimental|5 mg Melatonin|Subjects will receive 5 mg melatonin once a day.
2864471|NCT03498118|Experimental|Transversus Abdominis Plane Block group|after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
2864472|NCT03498118|Active Comparator|Wound Infiltration group|at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure
2864473|NCT03498105||Emergency Department (ED)|"450-500 participants who will;~self present to the Emergency Department (ED) will chest pain~be brought in by ambulance to ED with acute chest pain~be referred from Primary care or Urgent care centre with cardiac sounding chest pain"
2864474|NCT03498105||Community Cardiology Service (CCS)|This study group will consist of between 80-100 participants who self present to the Community Cardiology Service (CCS) in Milton Keynes primary care surgery
2864475|NCT03498105||Participants with stable angina|This study group will consist of 450-500 participants with stable angina who have been referred for Stress Echocardiography.
2864476|NCT03498105||Elective Coronary Angioplasty|This study group will consist of between 50-100 participants who will have been referred for elective coronary angioplasty
2864477|NCT03498105||Cardio-toxic Chemotherapy|Consecutive patients being initiated on any of the following medication deemed as cardio toxic and requiring cardiac function will be approached to be recruited into the study.
2864478|NCT03498092|Experimental|Bupivacaine-Dexmedetomidine group|After general anesthesia, patients will receive a cocktail of isobaric bupivacaine 2.5 mg/ml plus 5 micrograms (mcg)/ml adrenaline and 1mcg/kg dexmedetomidine in a volume of 0.5 ml/kg injected superficial to serratus muscle between and below latissimus dorsi muscle.
2864614|NCT03496987|No Intervention|Manual Drainage|Patients undergo drainage of pleural fluid via manual (syringe) system
2864479|NCT03498092|Active Comparator|Bupivacaine group|After general anesthesia, patients will receive a cocktail of isobaric bupivacaine 2.5 mg/ml plus 5 micrograms (mcg)/ml adrenaline in a volume of 0.5 ml/kg injected superficial to serratus muscle between and below latissimus dorsi muscle.
2864480|NCT03498092|Placebo Comparator|Saline group|This group will serve as a control and blinding group and will receive saline infiltration in the same manner.
2864481|NCT03498066|Experimental|Discontinuation of the Betablockers (βB)|1850 post-MI patients treated with chronic βB treatment will undergo withdrawal of their βB treatment..
2864482|NCT03498066|Active Comparator|Continuation of the Betablockers (βB)|1850 post-MI patients treated with chronic βB treatment will be continued under their usual βB treatment without modification.
2864483|NCT03498053|Other|Cigarette brands smoked by participant|"The 3 experimental days per participant are exactly the same, except the cigarette brand they smoke.~The content of an experimental day is described in the study design."
2864484|NCT03498040||Patients with or at risk of carcinoid heart disease|"Adult patients with well-differentiated metastatic ileum or bronchial neuroendocrine tumor~Adult patients with carcinoid syndrome or elevated urinary 5HIAA regardless of primary site"
2864485|NCT03498027||Data Collection|
2864486|NCT03498014|Active Comparator|Prescription as standard|
2864487|NCT03498014|Experimental|Pharmacogenetic-guided prescription|
2864488|NCT03498001|Experimental|Patients|
2864489|NCT03497988|Experimental|Syntocinon (=Oxytocin), then Placebo|"Single-Dose Intranasal Oxytocin~Single-Dose Placebo"
2864490|NCT03497988|Experimental|Placebo, then Syntocinon (=Oxytocin)|"Single-Dose Placebo~Single-Dose Intranasal Oxytocin"
2864491|NCT03497975|Active Comparator|Active|162 mg nalbuphine ER tablets, BID
2864492|NCT03497975|Placebo Comparator|Placebo|Matching placebo tablets
2864493|NCT03497962||ITU patients|25 patients will be recruited from the Intensive Care Unit/ High dependency unit Inclusion- Adults (>18years) with community acquired pneumonia (CAP).
2864494|NCT03497962||Healthy volunteer|24 healthy adult volunteers will be recruited to establish a comparison data set and to extend the laboratory observations to include other bacterial pathogens.
2864495|NCT03497936|Experimental|Women's Stories|Participants in this group will be randomly assigned to use the Women's Stories intervention.
2864496|NCT03497936|No Intervention|Programming as usual|Participants in this group will be randomly assigned participate in their usual programming.
2864497|NCT03497923|Active Comparator|Neostigmine|Patients are anesthesized with Propofol and receive 0.6mg-1 of rocuronium for tracheal intubation. Neuromuscular monitoring will be done on the ulnar nerve by train-of-four (TOF) using a TOF-Watch-SX® acceleromyograph (Organon [Ireland] Ltd). After spontaneous recovery of 2 twitches at the train-of-four monitor (TOF), patients receive neostigmine 50 μg kg-1.
2864498|NCT03497923|Experimental|Sugammadex|Patients are anesthesized with Propofol and receive 0.6mg-1 of rocuronium for tracheal intubation. Neuromuscular monitoring will be done on the ulnar nerve by train-of-four (TOF) using a TOF-Watch-SX® acceleromyograph (Organon [Ireland] Ltd). After spontaneous recovery of 2 twitches at the train-of-four monitor (TOF), patients receive sugammadex (Bridion®) 2 mg kg-1.
2864499|NCT03497897|Experimental|LYS006 high dose|
2864500|NCT03497897|Experimental|LYS006 low dose|
2864501|NCT03497897|Placebo Comparator|Placebo|
2864502|NCT03497884|Experimental|Real rTMS (low frequency)|Real rTMS (low frequency) is 1Hz.
2864503|NCT03497884|Sham Comparator|Sham rTMS|Sham rTMS session includes low frequency and high frequency stimulations.
2864504|NCT03497884|Experimental|Real rTMS (high frequency)|Real rTMS (high frequency) is 10Hz.
2864505|NCT03497871|Experimental|HeartMan intervention group|"80 patients are in the intervention group (40 in Belgium and 40 in Italy).~They use the HeartMan system in addition to receiving standard care."
2864506|NCT03497871|No Intervention|Standard care (control) group|"40 patients are in the no-intervention group (20 in Belgium and 20 in Italy).~They receive standard care, which consists of optimal medical treatment according to the international guidelines. In addition, written and oral education on heart failure disease and its management is provided by the heart failure nurse at the moment a patient has been diagnosed with heart failure or whenever he is rehospitalized for heart failure if necessary. Further support after discharge is possible by giving the patient the opportunity to call with the heart failure nurse in case he has questions about his treatment or health condition. Regular visits with the treating physician are scheduled several times per year."
2864507|NCT03497858|Experimental|coconut water|participants will complete the simulated basketball game with coconut water supplementation
2864508|NCT03497858|Placebo Comparator|Placebo - water|participants will complete the simulated basketball game with water supplementation
2864509|NCT03497858|Experimental|Sports drink|participants will complete the simulated basketball game with sports drink supplementation
2864510|NCT03497845|Experimental|a VN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of Vietnam (VN) (H5N1) vaccine with AS03 Adjuvant (Dose 1, Day 1), followed by single dose of gf/Washington (WA) (H5N8) vaccine with AS03 Adjuvant (Dose 2, Day 42).
2864511|NCT03497845|Experimental|b IN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 1, Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2, Day 42).
2864512|NCT03497845|Experimental|c dk/BANG with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of dk/Bangladesh (BANG) (H5N1) vaccine with AS03 Adjuvant (Dose 1, Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2, Day 42).
2864513|NCT03497845|Experimental|d gf/WA with AS03 Adjuvant, then IN with AS03 Adjuvant|Single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 1, Day 1), followed by single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 2, Day 42).
2864514|NCT03497845|Experimental|e dk/BANG with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant|Two doses of dk/BANG (H5N1) vaccine with AS03 Adjuvant (Dose1 , Day 1; Dose 2, Day 42), followed by single dose of bhg/Qinghai Lake(QL) (H5N1) vaccine with AS03 Adjuvant (Day 142).
2864515|NCT03497845|Experimental|f gf/WA with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant|Two doses of gf/WA (H5N3) vaccine with AS03 Adjuvant (Dose 1, Day 1; Dose 2, Day 42), followed by single dose of bhg/QL (H5N1) vaccine with AS03 Adjuvant (Day 142)
2864582|NCT03497325|Placebo Comparator|placebo|55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
2864516|NCT03497845|Experimental|g VN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of VN (H5N1) vaccine with MF59 Adjuvant (Dose 1, Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2, Day 42).
2864517|NCT03497845|Experimental|h IN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 1, Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2, Day 42).
2864518|NCT03497845|Experimental|i dk/BANG with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1, Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2, Day 42).
2864519|NCT03497845|Experimental|j gf/WA with MF59 Adjuvant, then IN with MF59 Adjuvant|Single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1, Day 1), followed by single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 2, Day 42).
2864520|NCT03497845|Experimental|k dk/BANG with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant|Two doses of dk/BANG (H5N1) vaccine with MF59 Adjuvant, followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant.
2864521|NCT03497845|Experimental|l gf/WA with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant|Two doses of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1, Day 1; Dose 2, Day 42), followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
2864522|NCT03497819|Experimental|CARTmeso/19 treatment arm|Patients with pancreatic cancer receiving CARTmeso and CART19 autologous cells via artery infusion or i.v. with cyclophosphamide precondition
2864523|NCT03497806|Experimental|High Dose CP101|The active ingredient of CP101, Full-Spectrum Microbiota™, is derived from the stools of normal healthy donors who are highly screened, tested, and monitored in a clinically structured donation program.
2864524|NCT03497793|Experimental|Skin-to-skin care with SNUBY|Mothers providing skin-to-skin care with the use of SNUBY
2864525|NCT03497780||ACL Tear|Patients with ACL tears
2864526|NCT03497780||Healthy Subjects|Healthy subjects
2864527|NCT03497767|Experimental|Osimertinib|80mg Osimerinib taken once daily
2864528|NCT03497767|Experimental|Stereotactic Radiosurgery + Osimertinib|Upfront Stereotactic Radiosurgery (SRS) followed by 80mg Osimerinib taken once daily
2864529|NCT03497754|Experimental|Cardiac output measurements|Cardiac output will be measured using TTE with and without the use of Probefix so not 2 arms but 2 consecutive measurements in the same patient
2864530|NCT03497715|Experimental|Experimental 1|Treatment order: Ibuprofen liquid capsules, Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen (Wockhardt)
2864531|NCT03497715|Experimental|Experimental 2|Treatment order: Ibuprofen lysine, Ibuprofen (Wockhardt), Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen liquid capsules
2864532|NCT03497715|Experimental|Experimental 3|Treatment order: Ibuprofen liquid capsules, Ibuprofen (Nurofen)1, Ibuprofen sodium, Ibuprofen (Wockhardt), Ibuprofen lysine
2864533|NCT03497715|Experimental|Experimental 4|Treatment order: Ibuprofen (Wockhardt), Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen liquid capsules, Ibuprofen sodium
2864534|NCT03497702|Experimental|Experimental|Patients receive neoadjuvant chemotherapy (doxorubicin 60mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 every 3 weeks for 4 cycles followed by docetaxel 75mg/m2 IV on day 1 every 3 weeks for 4 cycles) plus letrozole with or without leuproelin depending on menopausal status
2864535|NCT03497689|Experimental|Intravenous/Subcutaneous Treprostinil; Oral Treprostinil|Intravenous (IV) or subcutaneous (SC) treprostinil induction followed by transition to oral treprostinil
2864536|NCT03497676|Experimental|Cohort 1C: CAB|"Step 1: CAB administered orally as one 30 mg tablet once daily, beginning at the Entry visit, for 4-6 weeks.~Step 2: CAB LA administered as one IM injection at Week 4b (Step 2 Entry) study visit (600 mg/3 mL), at Week 8 (400 mg/2 mL), and at Week 12 (400 mg/2 mL)."
2864537|NCT03497676|Experimental|Cohort 1R: RPV|"Step 1: RPV administered orally as one 25 mg tablet once daily, beginning at the Entry visit, for 4-6 weeks.~Step 2: RPV LA administered as one IM injection at Week 4b (Step 2 Entry) study visit (900 mg/3 mL), at Week 8 (600 mg/2 mL), and at Week 12 (600 mg/2 mL)."
2864538|NCT03497676|Experimental|Cohort 2: CAB + RPV|"Step 3: CAB administered orally as one 30 mg tablet once daily AND RPV administered orally as one 25 mg tablet once daily, beginning at the Entry visit for 4-6 weeks.~Step 4: First injection: CAB LA administered as one 600 mg (3 mL) IM injection AND RPV LA administered as one 900 mg (3 mL) IM injection, at Week 4b (Step 4 Entry). Subsequent injections: CAB LA administered as a 400 mg (2 mL) IM injection AND RPV LA administered as a 600 mg (2 mL) IM injection, every four weeks through Week 96."
2864539|NCT03497663|Experimental|VIA Family intervention|VIA Family is a family based intervention. A multidisciplinary team of specialists from adult mental health services, child and adolescent mental health services and social services will be responsible for providing the basic treatment elements that are: case management and regular contact with the case manager, psychoeducation for the whole family, parental training (Triple P) and early intervention for mental problems of the child.
2864540|NCT03497663|Active Comparator|Treatment as Usual (TAU)|TAU is defined as any kind of help and support focusing on high risk children and parental mental illness. At present, the municipalities and the mental health services do not offer any kind of family focused intervention addressing parental mental illness that can be compared to the VIA Family program.
2864541|NCT03497650|Experimental|Mirror Therapy + Cross-Education.|Patients performed 4 sets of 5 maximal isometric ankle dorsiflexions with their less-affected lower limb while observing the reflection of the exercising limb in the mirror which was placed in the patient's mid-sagittal plane. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
2864542|NCT03497650|Active Comparator|Cross-Education of Strengthening.|Patients trained without a mirror entirely. They performed 4 sets of 5 maximal isometric ankle dorsiflexions with their less-affected lower limb. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
2864543|NCT03497637|Active Comparator|Pd/Pa guided Therapy|use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
2864544|NCT03497637|Active Comparator|FFR guided therapy|use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
2864545|NCT03497611||Patients with aortic stenosis|Patients receiving Edwards SAPIEN 3 Transcatheter aortic valve implantation
2864612|NCT03497000|Experimental|OCTA group|Patients in this group underwent OCTA-guided half-dose photodynamic therapy.
2864546|NCT03497598|Experimental|mannose|"2g d-mannose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months.The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.~rUTI diary"
2864547|NCT03497598|Placebo Comparator|placebo|"2g Hänseler lactose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months. The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.~rUTI diary"
2864548|NCT03497585||Activity Pacing Framework|Adult patients attending rehabilitation programmes underpinned by the activity pacing framework.
2864549|NCT03497559|Experimental|Music|Patients will received 30 minutes of classical music 3 times per day . Music will be delivered with noise cancellation headphones.
2864550|NCT03497559|Sham Comparator|Noise cancellation|Patients will received 30 minutes of silent recording 3 times per day . Music will be delivered with noise cancellation headphones.
2864551|NCT03497559|No Intervention|Control|Patients will receive standard of care.
2864552|NCT03497546|Experimental|Exercise|Usual care PLUS concurrent (aerobic and strength) supervised exercise program of 16 weeks (3 sessions/week, 60 min/session, progressively increasing in volume and intensity). The program will be conducted by certified Exercise Science professionals.
2864553|NCT03497546|No Intervention|Control|Usual care routinely delivered after bariatric surgery, based on national (Spanish) and international recommendations, focused on nutritional status monitoring and diet/physical activity counseling.
2864554|NCT03497533|Experimental|TriCAR-T-CD19|Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously
2864555|NCT03497520|Experimental|scoliosis patients|scoliosis patients who have cobb angle over 10 degree perform asymmetric spinal stabilization exercise
2864556|NCT03497507|Placebo Comparator|Sham bracelet|Patients randomized to sham group will wear bracelets on both hands which will not apply acupressure
2864557|NCT03497507|Experimental|Acupressure bracelet|Patients randomized to the experimental group will wear bracelets on both hands which will apply acupressure to the P6 acupoint.
2864558|NCT03497494|Active Comparator|Without hiatal suture|the different distance of pylorus without hiatal suture
2864559|NCT03497494|Active Comparator|With hiatal suture|the different distance of pylorus without hiatal suture
2864560|NCT03497481||Neopterin Dosage|Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis
2864561|NCT03497468|Active Comparator|Control group|Patients in this group will receive combined exercise training included aerobic and strengthening exercises, 3 times a week for 6 weeks. All exercise sessions will be performed under the supervision of a physiotherapist.
2864562|NCT03497468|Experimental|Training group|Patients in this group will receive task-oriented training additional to combined exercise training 3 times a week for 6 weeks. Task-oriented training included more functional daily life mobility activities like reaching, obstacle walking, stairs climbing. All exercise sessions will be performed under the supervision of a physiotherapist.
2864563|NCT03497442|Experimental|Treatment Arm|This is a randomized vehicle controlled, double blinded, interventional study. Patients of East Asian descent with a history of Asian Flushing Syndrome will be asked to apply a thin layer of brimonidine 0.33% gel to one half of their face thirty minutes before consuming alcohol (1.5 oz vodka for women, 3.0 oz vodka for men). The Photos will be taken 30 minutes, one hour, and 1.5 hours after consumption of alcohol. Erythema will be assessed at each time point by both the patient and study investigator using a 5- point erythema assesment score. Patient blood alcohol content (BAC) will be measured noninvasively at each time point.
2864564|NCT03497442|Placebo Comparator|Placebo Arm|This is a randomized vehicle controlled, double blinded, interventional study. Patients of East Asian descent with a history of Asian Flushing Syndrome will be asked to apply a thin layer of vehicle gel to one half of their face thirty minutes before consuming alcohol (1.5 oz vodka for women, 3.0 oz vodka for men). The Photos will be taken 30 minutes, one hour, and 1.5 hours after consumption of alcohol. Erythema will be assessed at each time point by both the patient and study investigator using a 5- point erythema assesment score. Patient blood alcohol content (BAC) will be measured noninvasively at each time point.
2864565|NCT03497429|Experimental|Cohort 1: Niraparib 200 mg|Niraparib 200 milligrams (mg), capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.
2864566|NCT03497429|Experimental|Cohort 2: Niraparib 300 mg|Niraparib 300 mg, capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.
2864567|NCT03497416||Anemic|
2864568|NCT03497416||Non-anemic|
2864569|NCT03497403|Active Comparator|Control|Socket preservation control. After tooth extraction, bone graft is applied to socket and a non-cross-linked membrane is used in primary intentional healing.
2864570|NCT03497403|Experimental|Experimental|Socket preservation experimental. After tooth extraction, bone graft is applied to socket and a cross-linked membrane is used in secondary intention healing.
2864571|NCT03497390|Active Comparator|EMERALD|Patients will have 1-year multicomponent program (EMERALD) intervention including a total of 3 interactive workshops focusing on empowerment skills, healthy eating and exercise. Please refer to the protocol for further details.
2864572|NCT03497390|Placebo Comparator|Usual care|Usual management without any workshop or program
2864573|NCT03497377|Experimental|18F-DCFPyL Injection & 18F-NaF|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL injected by slow IV push. A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose
2864574|NCT03497364|Experimental|Bupivacaine group|Pregnant women received combined spinal-epidural anesthesia by injecting bupivacaine. The dose of bupivacaine depended on height of subjects.
2864575|NCT03497364|Experimental|Ropivacaine group|Pregnant women received combined spinal-epidural anesthesia by injecting ropivacaine. The dose of ropivacaine depended on height of subjects).
2864576|NCT03497364|No Intervention|Control group|Pregnant women received combined spinal-epidural anesthesia by injecting bupivacaine. 2ml bupivacaine (0.75% bupivacaine (2 ml) + cerebrospinal fluid (1 ml)) was injection for all subjects.
2864577|NCT03497351|Experimental|Group N|the group treated with nicardipine
2864578|NCT03497351|Experimental|Group U|the group treated with Urapidil
2864579|NCT03497338|Experimental|new anticoagulation strategy group|
2864580|NCT03497338|No Intervention|tradition strategy group|
2865066|NCT03493828|Placebo Comparator|Placebo|TAP using normal saline
2864583|NCT03497299|Experimental|Active rTMS (20Hz)|Active rTMS administered with the MagProX100/R30 stimulator equipped with the B65 active coil for dorsolateral prefrontal cortex (DLPFC) stimulator (MagVenture, Farum, Denmark).The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with tobacco dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) tobacco abstinence.
2864584|NCT03497299|Sham Comparator|Sham rTMS|Sham rTMS administered with the MagProX100/R30 stimulator equipped with the B65 placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark). The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with tobacco dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) tobacco abstinence.
2864585|NCT03497286|Experimental|Treatment|Participants in the treatment condition will be enrolled in the text-based mentorship program and will be able to engage with their assigned mentor as much or as little as they choose.
2864586|NCT03497286|Active Comparator|Control|Participants in the control condition will receive periodic informational texts related to the growth and development of their new baby.
2864587|NCT03497273|Experimental|Itacitinib + corticosteroids|Itacitinib administered in combination with corticosteroids.
2864588|NCT03497260|Experimental|Fructose in water first, water only second|Intake of 20 g of fructose dissolved in 200 ml of tap water at first visit; intake of 200 ml of tap water at second visit
2864589|NCT03497260|Experimental|Water only first, Fructose in water second|Intake of 200 ml of tap water at first visit; intake of 200 ml of 20 g of fructose dissolved in 200 ml of tap water at second visit
2864590|NCT03497247|Experimental|Mindfulness-Based Cognitive-Behavioral Therapy|
2864591|NCT03497247|Active Comparator|Cognitive-Behavioral Therapy|
2864592|NCT03497234|Experimental|All women eligible to participate|All women presenting who sign the consent and found eligible will have a VF and AF sample taken and analyzed on the Perilynx Analyzer to measure AF and VF fluid. This does not affect their regular standard of care and diagnosis
2864593|NCT03497221|Other|Education intervention|The educational intervention is based on a hospital institutional protocol for patient using enteral tubes. A clinical simulation will be performed using a low fidelity manikin, where nursing technicians will identify and correct erros, such as: inconsistency between the patient's identification and the diet label, the administration of the diet with a low headboard, fixation of tube not detached and dirty, delay of the diet and others. The simulation will be described through a guide.
2864594|NCT03497221|Other|Visual identity campaign|"The visual identity will be given by a set of actions, called campaign. The campaign consists in the creation and implantation of different materials to be used at the bedside of the patients in use of diet by SNE, such as: (a) poster summarizing care, (b) colored adhesive label to identify devices (c) badge with safety care reminders."
2864595|NCT03497208|Experimental|Microneedling+cell susp+phototherapy|Experiment is about the use of abrasion technic with dermaroller, equipped with a 0,25mm needle, applied on a vitiligo lesion. After that, a transplant with non cultured cell suspension (melanocytes and keratinocytes) will be applied to pacient 's skin scalp.
2864596|NCT03497208|Active Comparator|Microneedling and phototherapy|Technique involves only the abrasion with dermaroller equipped with 0,25mm on the lesion of vitiligo.
2864597|NCT03497195|Active Comparator|Community level screening; Arm 1|use of chest X-ray plus Xpert Ultra for community level TB screening
2864598|NCT03497195|Active Comparator|Community level screening: Arm 2|use of C-reactive Protein and Xpert Ultra for community level TB screening
2864599|NCT03497182|Experimental|Breath sample collection|
2864600|NCT03497130|Experimental|regimen group|After 1 week washout period using provided Dove® Soap without any moisturizer, participants in the skin care regimen group will receive Vaseline® Moisturizer, Dove® Soap, and application log. These participants will be asked to apply the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks. All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use.
2864601|NCT03497130|No Intervention|control group|"After 1 week washout period using provided Dove® Soap without any moisturizer, Individuals in the control group will continue with the provided Dove® Soap for 2 weeks.~All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use."
2864602|NCT03497117|Other|CF pulmonary exacerbation group|"Patients with cystic fibrosis being treated for a pulmonary exacerbation will undergo Lung Clearance Index (LCI) and an MRI with PFP.~LCI testing will take place before the MRI. Each test will take 5-20 minutes and up to three tests will be performed with at least 5-minute rest periods between each test.~PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. Before and after the MRI is complete, participants will perform spirometry maneuvers in a room outside of the magnet."
2864603|NCT03497091||Enteral Tube fed children|Enteral Formula
2864604|NCT03497078|Other|Refered patients for scintigraphy|
2864605|NCT03497052||Group 1|Oocytes and embryos will be cultured in GEMS single step medium (in vitro culture in medium 1)
2864606|NCT03497052||Group 2|Oocytes and embryos will be cultured in IRVINE single step medium (in vitro culture in medium 2)
2864607|NCT03497039|Experimental|Active Treatment|In the active treatment arm, DDEA gel will be applied topically at a dose of 4 gram (g) on 400 square centimeter (cm^2) twice a day for 7 days to the target knee (the knee planned for arthroplasty surgery).
2864608|NCT03497039|Placebo Comparator|Placebo Control|In the placebo control arm, placebo gel will be applied topically at a dose of 4 gram (g) on 400 square centimeter (cm^2) twice a day for 7 days to the target knee (the knee planned for arthroplasty surgery).
2864609|NCT03497026|Experimental|Robotic Bronchoscopy|Robotic bronchoscopy with Robotic Bronchoscopy Platform
2864610|NCT03497013|Experimental|Active tDCS|All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
2864611|NCT03497013|Sham Comparator|Sham tDCS|For sham stimulation, the device was set to turn off after 30 seconds(study model).
2881066|NCT03382236|Placebo Comparator|Sham osteopathy|
2864615|NCT03496987|Experimental|Vacuum Bottle Drainage|Patients undergo drainage of pleural fluid via a vacuum bottle system (evacuated cylinder)
2864616|NCT03496974|Experimental|200 mg cohort|
2864617|NCT03496974|Experimental|400 mg cohort|
2864618|NCT03496961|Experimental|Yan Nian Jiu Zhuan Fa|The kneading process will be done under the therapist guidance for 30 minutes with an average pressure of 5 Newton each time for 3 times every day.
2864619|NCT03496961|Placebo Comparator|cognitive psychology education|Psychological counseling and behavioral cognition education are conducted once a week and the rest 6 times online or by phone.
2864620|NCT03496961|No Intervention|blank control|this group will have no therapeutic exercises or cognitive education when other two groups receive therapy.
2864621|NCT03496948|Experimental|TeGeCoach|Home-based exercise program consisting of telephone health coaching, remote walking exercise monitoring based on wearable monitors and intensified primary care.
2864622|NCT03496948|No Intervention|Usual care group (TAU)|Patients randomized to TAU receive written information about courses offered by their statutory health insurance. Health insurance companies offer a variety of courses to encourage regular exercise and to promote lifestyle changes, including SEPs (vascular and cardio exercise), physical therapy, nutritional assistance programs, smoking cessation programs, weight loss programs, and patient education programs for obesity and diabetes.
2864623|NCT03496935|Active Comparator|Tunneled dialysis catheter|In this arm, patients will be randomized to undergo tunneled dialysis catheter insertion.
2864624|NCT03496935|Active Comparator|Non-tunneled dialysis catheter|In this arm, patients will be randomized to undergo non-tunneled dialysis catheter insertion.
2864625|NCT03496922|Experimental|Tobacco Products|Participants will be asked to sample ventilated and unventilated cigarettes (and possibly alternative nicotine products such as cigarillos). During the experimental sessions, they will be given the opportunity to purchase ventilated and unventilated cigarettes (and possibly alternative nicotine products) using an account balance in the Experimental Tobacco Marketplace. However, besides the required sampling session, participants will not be required to purchase any nicotine products.
2864626|NCT03496909|Active Comparator|Standard OT|
2864627|NCT03496909|Experimental|PhysioTouch|
2864628|NCT03496896|Experimental|"TARGET intervention"|The intervention group will receive a standardized transition care intervention by a trained nurse composed of a pre-discharge component and 2 post-discharge follow-up phone calls 3 days and 14 days after discharge.
2864629|NCT03496896|No Intervention|Control|The group control will receive usual care without additional intervention.
2864630|NCT03496883|Active Comparator|Recombinant Activated Factor VII (rFVIIa)|FVIIa given as IV injection over 2 minutes within 2 hours of symptom onset
2864631|NCT03496883|Placebo Comparator|Placebo|Matching placebo given as IV injection over 2 minutes within 2 hours of symptom onset
2864632|NCT03496870|Experimental|Opicapone once daily with Carbidopa/Levodopa|Opicapone administered once daily for 14 days; carbidopa/levodopa administered at set frequency on Study Days 1, 2 & 15
2864633|NCT03496857|Experimental|Photobiomodulation analgesia|"LED therapy sessions will be held in the pre-labor room. The patient who will undergo analgesia and the professional responsible for placing the LED plate on the patient's back, between T10 and L2, will be present at the time of the intervention. The LED plate will be covered with clear disposable plastic (PVC) to avoid cross-contamination and ensure hygiene. During the interventions, the patient will be allowed to choose the position that is the most comfortable for her.~Three 10-min LED applications will be performed when the patient has a cervical dilatation of 4-5, 6-7, and 8-9 cm. Data on the level of pain, characteristics of the membrane (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after each intervention."
2864634|NCT03496857|Active Comparator|bath therapy|The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
2864635|NCT03496844|No Intervention|Routine F-18 fluciclovine-PET/CT scan|This arm will consist of prostate cancer patients who have had an F-18 fluciclovine-PET/CT scan for routine standard of care for biochemical recurrence. These patients would be asked to participate in the study only if there is a need for a standard of care bone biopsy.
2864636|NCT03496844|Active Comparator|Research F-18 fluciclovine-PET/CT scan|This arm will consist of prostate cancer patients who would not ordinarily obtain an Axumin-PET scan for routine standard of care but have a need for bone biopsy. This will include patients with metastatic castrate resistant prostate cancer. For example, a patient with known lymph node recurrence of prostate cancer and suspicious finding on a bone scan would be asked to participate in the study and get a F-18 fluciclovine-PET/CT scan prior to the standard of care bone biopsy.
2864637|NCT03496831||Rheumatoid Arthritis|Registered in DANBIO with a diagnosis of M05.9, M06.0 or M06.9.
2864638|NCT03496831||Spondyloarthritis|Registered in DANBIO with a diagnosis of M45.9, M46.1, M46.8+M02.9, M46.8+M07.4, M46.8+M07.5 or M46.9.
2864639|NCT03496831||Psoriatic Arthritis|Registered in DANBIO with a diagnosis of M07.3 or M46.8+M07.2.
2864640|NCT03496818||Crohn's Disease|Participants age 18-80 years old, diagnosed with Crohn's disease with active disease based on MR enterography or CT enterography confirmed within the prior 30 days.
2864641|NCT03496818||Healthy controls|Participants age 18-80 years old, with no diagnosis of inflammatory bowel disease.
2864642|NCT03496805|Experimental|MGE group|Patients will be randomized to muscadine grape extract (MGE). The patients will take 4 capsules by mouth BID (twice daily). Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
2864643|NCT03496805|Placebo Comparator|Placebo group|Patients will be randomized to placebo. The patients will take 4 capsules by mouth BID (twice daily). Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of placebo.
2864644|NCT03496792|Experimental|Tilt + external pressure|"Tilt + external pressure on legs performed in both BP elevated with standing and BP maintained with standing groups."
2882564|NCT03371771|Active Comparator|MSW-delivered Behavioral Activation|
2864645|NCT03496792|Placebo Comparator|Tilt + no external pressure|"Tilt + no external pressure performed in both BP elevated with standing and BP maintained with standing groups."
2864646|NCT03496792|Experimental|Limb occlusion + negative pressure|"Limb occlusion + negative pressure performed in both BP elevated with standing and BP maintained with standing groups."
2864647|NCT03496792|Placebo Comparator|Limb occlusion + no negative pressure|"Limb occlusion + no negative pressure performed in both BP elevated with standing and BP maintained with standing groups."
2864648|NCT03496779|Experimental|Experimental|"Patients treated with gemcitabine will receive Brentuximab Vedotin-induction for 4 cycles of induction.~Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation.~Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with Brentuximab Vedotin-maintenance every 3 weeks for 12 infusions."
2864649|NCT03496766|Experimental|Experimental Arm|Tipifarnib 900 mg, po, bid daily on days 1-7 and 15-21 of 28-day treatment cycles for up to 24 months
2864650|NCT03496753|Experimental|Led Therapy|The following will be the phototherapeutic parameters: total spot area: 1.44 cm²; continuous emission mode; output power: 10 mW; infrared wavelength (880 to 904 nm); fluence: 4 J/cm²; and application time: 10 minutes/session. Sessions will be held three times a week on alternating days for six consecutive weeks, totaling 18 sessions.
2864651|NCT03496753|No Intervention|Control|The control group will receive orientation regarding breast care and adequate breastfeeding techniques. The experimental group will receive the same orientation plus phototherapy sessions using a device developed especially for the treatment of nipple trauma. Both groups will be followed up for six consecutive weeks.
2864652|NCT03496740|Active Comparator|Penile Block|"Ultrasound guided dorsal penile nerve block will be administered after general anesthesia.~0,25% Bupivacaine 0,5ml/kg (max. 20ml) will be used for the blocks"
2864653|NCT03496740|Active Comparator|Pudendal Block|Nerve stimulator-guided pudendal block. 0,25% Bupivacaine 0,5ml/kg (max. 20ml) will be used for the blocks
2864654|NCT03496727||Serratus anterior plane block|Anesthesia induction was performed to all patients. At the end of the operation, patients were performed SAPB under Ultrasound guidance by the same anesthetist.For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
2864655|NCT03496727||Patient controlled analgesia|Anesthesia induction was performed on all patients.At the end of the operation, all patients were performed with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
2864656|NCT03496714|Active Comparator|PSYED-T|In PSYED-T (psychoeducation on trauma symptoms), participants will receive a psychoeducation handout and watch a related video on common reactions to trauma. Participants in this condition will also receive a rationale stating that both learning about the nature of trauma reactions and monitoring symptoms are important for preventing development of PTSD.
2864657|NCT03496714|Experimental|PSYED-T+SB|Participants in PSYED-T+SB (Combined psychoeducation on trauma reactions and safety behaviors) will receive psychoeducation handouts and videos on the nature of trauma symptoms and the nature of safety behaviors and how to fade them. Participants in this condition will also receive a rationale stating that learning about the nature of trauma reactions and safety behaviors, learning to fade safety behaviors, and monitoring symptoms are important in the prevention of PTSD.
2864658|NCT03496714|No Intervention|Monitoring-only control|The third condition will be a monitoring-only control and thus will receive no psychoeducation information. Participants in the control condition will receive a rationale that monitoring symptoms is important in the prevention of PTSD development.
2864659|NCT03496688|Active Comparator|bone substitute material MCBA|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using mineralized sol-vent-dehydrated bone allograft material.
2864660|NCT03496688|Active Comparator|bone substitute material FDBA|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using freeze-dried mineralized bone allograft material.
2864661|NCT03496688|Active Comparator|bone substitute material ABB|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using anorganic bovine bone material.
2864662|NCT03496688|Active Comparator|bone substitute material EB|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using equine-derived bone material.
2864663|NCT03496688|Active Comparator|bone substitute material HA-β-TCP 30/70|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using synthetic micromacroporous bi-phasic calcium-phosphate block consisting of 70% beta-tricalcium phosphate and 30% hy-droxyapatite material.
2864664|NCT03496688|Active Comparator|bone substitute material BC|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using bioapatite-collagen material.
2864665|NCT03496675|Other|Standard care|Participants receive standard care as locally available. The components of standard care are recorded.
2864666|NCT03496675|Experimental|Group Music Therapy (GMT)|"GMT is provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.~In line with usual practice, and as appropriate in local contexts, residents of a unit allocated to GMT may be divided into smaller groups (e.g. around 5 participants)."
2864667|NCT03496675|Experimental|Recreational Choir Singing (RCS)|"RCS is provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.~RCS may be conducted in larger groups (e.g. with all residents of the unit in one group)."
2864668|NCT03496675|Experimental|GMT + RCS|Group Music Therapy and Recreational Choir Singing are both provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.
2865725|NCT03489330||Henry Ford Hospital data|Inpatient intravenous vancomycin use
2864669|NCT03496662|Experimental|Part A - Experimental|"BMS-813160 daily oral pill~Nivolumab will be given as a 30-minute intravenous infusion at a flat dose of 480 mg on Day 1 (+/- 2 days) of each 28-day cycle~Gemcitabine will be given as a 30-minute intravenous infusion at the assigned dose on Days 1, 8, and 15 of each 28-day cycle~Nab-paclitaxel will be given as a 30-40-minute intravenous infusion at the assigned dose on Days 1, 8, and 15 of each 28-day cycle~Post-treatment biopsy at the end of cycle 2~Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles"
2864670|NCT03496662|Active Comparator|Part A - Control|"Gemcitabine will be given as a 30-minute intravenous infusion at the assigned dose on Days 1, 8, and 15 of each 28-day cycle Nab-paclitaxel will be given as a 30-40-minute intravenous infusion at the assigned dose on Days 1, 8, and 15 of each 28-day cycle~Post treatment biopsy at the end of cycle 2~Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles"
2864671|NCT03496662|Experimental|Part B - Dose expansion|"BMS-813160 daily oral pill~Nivolumab will be given as a 30-minute intravenous infusion at a flat dose of 480 mg on Day 1 (+/- 2 days) of each 28-day cycle~Gemcitabine will be given as a 30-minute intravenous infusion at the maximum tolerated dose on Days 1, 8, and 15 of each 28-day cycle~Nab-paclitaxel will be given as a 30-40-minute intravenous infusion at the maximum tolerated dose on Days 1, 8, and 15 of each 28-day cycle~Post-treatment biopsy at the end of cycle 2~Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles"
2864672|NCT03496649|Experimental|Dysport|"Dysport administration by intramuscular injection Each patient will receive one dose of Dysport at Visit 1.~At least 2 of the 3 muscles below will be injected, depending on which muscles are affected:~250 IU for the gracilis muscle 200 IU for the pectineus muscle 300 IU for the adductor longus muscle These injections will be uni or bilateral, it will depend on clinical diagnosis.~If necessary, the 3 muscles will be injected with a maximum of 1500U Dysport. The total dose cannot exceed 1500 units."
2864673|NCT03496636|Experimental|Ovarian tissue transplant|Transplantation of ovarian tissue into the abdomen. Only for patients who have previously frozen ovarian tissue
2864674|NCT03496623|Experimental|Inhaled Treprostinil|Inhaled treprostinil delivered via an ultrasonic nebulizer with a target dosing regimen of 12 breaths (72 mcg) 4 times daily (QID)
2864675|NCT03496623|Placebo Comparator|Placebo|Placebo delivered via an ultrasonic nebulizer for QID administration
2864676|NCT03496610|Active Comparator|Quadratus Lumborum (QL) Block|Patients will receive a bilateral ultrasound guided QL block by the anesthesia team.
2864677|NCT03496610|Active Comparator|Surgical wound infiltration|Patients will receive 166 mg of liposomal bupivacaine mixed with 50 mg non-liposomal bupivacaine infiltrated into the wound by the surgeon.
2864678|NCT03496597||Patients|type 1 diabetes patients
2864679|NCT03496597||Control|non diabetic control subjects of the same age
2864680|NCT03496584|Active Comparator|Pomegranate Juice|Postprandial high fat meal will be administered with pomegranate juice with the first dose of the intervention, Pomegranate Juice , followed by 12 weeks of pomegranate juice consumption.
2864681|NCT03496584|Placebo Comparator|Placebo Juice|Postprandial high fat meal will be administered with pomegranate juice with the first dose of the intervention, Placebo Juice , followed by 12 weeks of pomegranate juice consumption.
2864682|NCT03496571|Placebo Comparator|Placebo|Subjects in this arm will receive 4 monthly doses of placebo.
2864683|NCT03496571|Experimental|1 mg/kg of AK002|Subjects in this arm will receive 4 monthly doses of AK002: a first dose of 0.3 mg/kg, a second dose of 1 mg/kg, a third dose of 1 mg/kg, and a fourth dose of 1 mg/kg
2864684|NCT03496571|Experimental|3 mg/kg of AK002|Subjects in this arm will receive 4 monthly doses of AK002: a first dose of 0.3 mg/kg, a second dose of 1 mg/kg, a third dose of 3 mg/kg, and a fourth dose of 3 mg/kg
2864685|NCT03496558|Experimental|150 pregnant women with a history of risk|
2864686|NCT03496558|No Intervention|150 healthy pregnant women|
2864687|NCT03496545|Other|Acetaminophen|standard of care - acetaminophen 650mg every 4 hours PO/NG/FT (per oral, nasogastric tube, feeding tube) for 48 hours, initiated within 1 hour after temperature reading ≥ 38.3ºC.
2864688|NCT03496545|Experimental|Bromocriptine|bromocriptine 2.5mg every 6 hours PO/NG/FT for 48 hours, initiated within 1 hour after temperature reading ≥ 38.3ºC.
2864689|NCT03496532|Experimental|Pulse generator change under sedation|"The efficacy of every set will be measured on induced changes in LFP recorded from the STN electrodes.LFP will be compared between before, during and right after each stimulation conditions. The stimulation order will be randomized. All other stimulation parameters will be the same (macrocontact with most beta-oscillations, 1 minute, 1.5mA) .~Hence 4 sets of 1 minutes of STN stimulation will be performed, for:~Symmetrical biphasic pulses versus standard pseudo monophasic pulses (study I; 2 sets).~Pseudorandom uniform distribution stimulation paradigms versus pseudorandom Poisson distribution stimulation paradigms (study II: 2 sets)."
2864690|NCT03496532|Experimental|First pulse generator implantation under general an|The depth of anesthesia will be documented, recording the BIS spectral analysis index. The difference in spectral amplitude density of LFP, in particular in beta band oscillations will be correlated with the depth of anesthesia as measured with the BIS index.
2864691|NCT03496519|Experimental|Dose Escalation|"Dose escalation will occur following a 3+3 design in all advanced tumor types meeting the inclusion and exclusion criteria.~Cohort -1 (if necessary): Durvalumab 1125mg with Trabectedin 0.5mg/m2~Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2~Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2~Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2~Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2"
2864692|NCT03496519|Experimental|Dose Expansion|Patients at this level will receive the safest dose of Durvalumab and Trabectedin that was determined during the Dose Escalation Phase. There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be fixed dosage of Trabectedin for each cohort, given through intravenous infusion as an outpatient, over a 24 hour period on Day 1 every 21 days.
2882565|NCT03371758|Experimental|vitiligo patients|
2864693|NCT03496506|Experimental|Sequential treatment arm|Subjects receive 1 tablet of selexipag twice daily from Day 1 to Day 9 and 1 tablet in the morning of Day 10. In the morning of Day 4 and 1 hour before the administration of selexipag, they receive 4 tablets of clopidogrel. Then from Day 5 to Day 10, 1 hour before the morning administration of selexipag, they receive 1 tablet of clopidogrel .
2864694|NCT03496493||All patients|All patients enrolled in trial will have peripheral oxygen saturation simultaneously recorded with both study devices on non-adjacent (second and fourth) fingers of the same hand.
2864695|NCT03496467|Active Comparator|Nepafenac PPDS|N-PPDS (Nepafenac Punctal Plug Deliver System) is an L-shaped, silicone punctal plug with a drug eluting core that contains nepafenac (active)
2864696|NCT03496467|Placebo Comparator|Placebo PPDS|p-PPDS (placebo Punctal Plug Delivery System) is an L-shaped, silicone punctal plug with a drug insert that contains no active ingredient (placebo).
2864697|NCT03496454|Other|PfSPZ Challenge|this is a basic sciences protocol designed to study the effect of pre-exposure to Plasmodium falciparum (Pf) on malaria parasite kinetics, clinical symptoms and immunity after Controlled Human Malaria Infection by administration of an injection PfSPZ Challenge in Gambian adults. Based on a well-defined serological profile representing the extremes of current malaria exposure in The Gambia, two cohorts will be identified to study the impact of naturally acquired immunity on susceptibility for a Controlled Human Malaria Infection. The classification as a clinical trial results from the administration of the PfSPZ Challenge to the healthy volunteers
2864698|NCT03496441||Group 1|Colorectal cancer patients who will undergo a surgical resection with digestive anastomosis. Fecal sample collection for analysis before and after surgery (2 samples).
2864699|NCT03496441||Group 2|Patients having undergone surgical resection with digestive anastomosis for colorectal cancer or inflammatory bowel disease, complicated by anastomotic leakage. Fecal sample collection for analysis after surgery, once the leak is confirmed.
2864700|NCT03496441||Group 3|Patients with uncomplicated hernia pathology, without gastrointestinal comorbidity to undergo a surgery to heal this hernia without involving a gastrointestinal resection. Fecal sample collection for analysis before surgery (1 sample).
2864701|NCT03496441||Group 4|Inflammatory bowel disease patients waiting for elective surgery involving gastrointestinal resection. Fecal sample collection for analysis during surgery, directly from the bowel content (1 sample).
2864702|NCT03496428|Other|Dental implant Impression Techniques|"Dental implant impressions- Different Techniques An customized impression coping will be created based on the provisional crown emergence profile which will be used to perform a silicone implant impression. A conventional cast will be created based on the silicone impression and an extra-oral scanner reading will be performed with a 3shape D2000.~An intra-oral scanner (Trios, 3Shape) will be used to scan the entire arch. The STL file created will be compared and tooth positions and soft tissues discrepancies will be determined"
2864703|NCT03496415|Experimental|Remote ischemic conditioning|
2864704|NCT03496415|Sham Comparator|Sham remote ischemic conditioning|
2864705|NCT03496402|Experimental|High risk Cohorts|Cohort 1 : High risk Neuroblastoma, High risk Rhabdomyosarcoma, High risk Ewing Sarcoma Family Tumor, High risk Osteosarcoma, High risk Leukaemia (secondary acute myeloid leukaemia or biphenotypic acute leukaemia) Cohort 2 : Extracerebral and cerebral high risk tumor, High risk Leukaemia (leukaemia with high MRD) Sampling on blood, bone marrow and cerebrospinal fluid
2864706|NCT03496402|Experimental|Low risk Cohort|Cohort 3 : Intermediate or low risk tumors : Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family Tumor, Osteosarcoma Sampling on blood, bone marrow and cerebrospinal fluid
2864707|NCT03496389|Experimental|Gabapentin + panadol|
2864708|NCT03496389|Active Comparator|Tramadol + panadol|
2864709|NCT03496376|Experimental|Kinesio Taping Group|Kinesio Taping Group received three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set plus thoracic kinesio taping application.
2864710|NCT03496376|Active Comparator|Control Group|Control Group received three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set.
2864711|NCT03496363||CHD with Hypothyroidism|
2864712|NCT03496350|Experimental|Internet CBT|Internet-based cognitive behavioural therapy in Arabic with therapeutic guidance through email.
2864713|NCT03496350|No Intervention|Wait-list|Wait-list control
2864714|NCT03496324|Active Comparator|Test (fed): Nurofen for Children|"Nurofen for Children® 400 mg/10 ml by mouth under fed condition~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
2864715|NCT03496324|Active Comparator|Test (fasted): Nurofen for Children|"Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
2864716|NCT03496324|Experimental|Reference (fed): Algifor Junior|"Algifor® Junior 400 mg/20 ml by mouth under fed condition.~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
2864717|NCT03496324|Experimental|Reference (fasted): Algifor Junior|"Algifor® Junior 400 mg/20 ml by mouth under fasted condition.~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
2864718|NCT03496311||Pregnant Women|Pregnant women with gestational age > 35 weeks undergoing spinal anesthesia for elective cesarean section.
2864719|NCT03496311||Control Group|Fertile, non-pregnant women undergoing spinal anesthesia for elective surgery.
2864720|NCT03496298|Experimental|Efpeglenatide Dose 1|Efpeglenatide dose 1 once weekly
2864721|NCT03496298|Experimental|Efpeglenatide Dose 2|Efpeglenatide dose 2 once weekly
2864722|NCT03496298|Placebo Comparator|Placebo|Placebo once weekly
2864723|NCT03496259|Experimental|On-Q Group|Patients in this group will have an On-Q pump placed at the end of the operation
2864724|NCT03496259|Active Comparator|Epidural Group|Patients in this group will have an epidural catheter placed at the end of the operation
2864725|NCT03496246|Active Comparator|Group A|patients with vitamin D deficiency are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
2864918|NCT03494881|Experimental|Treatment Arm|This is an open-label pilot investigation and all study participants are assigned to active treatment. There is no placebo arm in this study.
2864726|NCT03496246|Active Comparator|Group B|patients with vitamin D insufficiency are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
2864727|NCT03496246|Active Comparator|Group C|patients with normal vitamin D level normal are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
2864728|NCT03496233|Experimental|All patients included|All patients included will be treated with Elbasvir/grazoprevir for 8 weeks
2864729|NCT03496220|Experimental|Feedback|The ICU with feedback will be equipped with display device corresponding to each Angulus device with an interactive software interface which displays the patient's elevation.
2864730|NCT03496220|Other|No Feedback|The Angulus device will be on the patient but will NOT have the corresponding display data on patient elevation available to nurses.
2864731|NCT03496207|Placebo Comparator|Placebo|Placebo SC every 21 days plus SOC for 24 weeks
2864732|NCT03496207|Experimental|Sotatercept 0.3 mg/kg|Sotatercept, 0.3 mg/kg SC every 21 days plus SOC for 24 weeks
2864733|NCT03496207|Experimental|Sotatercept 0.7 mg/kg|Sotatercept, 0.7 mg/kg SC every 21 days plus SOC for 24 weeks
2864734|NCT03496194||Head of Post Anaesthesia Care Unit|The chief physician of PACUs at all Danish Anaesthesia departments will receive electronic survey on postoperative pain treatment
2864735|NCT03496181||Bilingual Participants with Glioma|"Bilingual (English and Spanish speaking) patients will be recruited from the clinical service of the Department of Neurosurgery of MSK. All patients on the Neurosurgery service scheduled to undergo a resection of a tumor in or adjacent to the primary language areas will be screened to participate in this study.~The study will be performed in concert with patient's regularly scheduled clinical care for his/her brain tumor. Clinical care (which will be performed whether or not the patient participates in the current study) will include: 1) pre-operative routine (anatomical) MRI and fMRI, 2) the surgery to remove the tumor, 3) intra-operative cortical stimulation to identify the essential motor and/or language areas. It should be stressed that neither the brain tumor surgery, nor the intra-operative cortical mapping will be changed in any way from routine practice."
2864736|NCT03496181||Healthy Volunteers|Normal, healthy volunteers who express interest in participation and who meet the eligibility criteria will be recruited for this study. It is anticipated that healthy volunteers will mostly consist of medical professionals. They will consist of 10 monolinguals (defined as native English speakers), 10 early bilinguals (defined as acquiring proficiency in the second language before 10 years of age), and 10 late bilinguals (defined as acquiring proficiency in the second language after 10 years of age).
2864737|NCT03496168|Experimental|mavacamten (MYK-461)|
2864738|NCT03496155|Experimental|Intervention Group (main)|"Will receive the Build Your Teen's Strengths educational pamphlet, health coaching sessions, and provider endorsement."
2864739|NCT03496155|No Intervention|Control Group (main)|Will receive usual care at well-child visit.
2864740|NCT03496155|Experimental|Intervention Group (asthma subgroup)|"Will receive the Build Your Teen's Strengths educational pamphlet, health coaching sessions, and provider endorsement."
2864741|NCT03496155|No Intervention|Control Group (asthma subgroup)|Will receive usual care at well-child visit.
2864742|NCT03496142|Active Comparator|Transperineal prostate biopsy|Patient will have a transperineal prostate biopsy.
2864743|NCT03496142|Active Comparator|Transrectal prostate biopsy|Patient will have a transrectal prostate biopsy.
2864744|NCT03496129|Experimental|Personalized Feedback|
2864745|NCT03496129|Experimental|Personalized feedback and text messages|
2864746|NCT03496129|Active Comparator|Information Only|
2864747|NCT03496116|Experimental|ECIG Session: 0.5 Ohms, 3 mg|Heating coil resistance 0.5 Ohms Liquid nicotine concentration 3 mg
2864748|NCT03496116|Experimental|ECIG Session 0.5 Ohms, 8 mg|Heating coil resistance 0.5 Ohms Liquid nicotine concentration 8 mg
2864749|NCT03496116|Experimental|ECIG Session 1.5 Ohms, 3 mg|Heating coil resistance 1.5 Ohms Liquid nicotine concentration 3 mg
2864750|NCT03496116|Experimental|ECIG Session 1.5 Ohms, 8 mg|Heating coil resistance 1.5 Ohms Liquid nicotine concentration 8 mg
2864751|NCT03496103|Other|Allergic Subjects|After recording baseline symptoms, subjects were exposed to ragweed pollen for three hours and symptoms were recorded
2864752|NCT03496103|Other|Healthy|After recording baseline symptoms, subjects were exposed to ragweed pollen for three hours and symptoms were recorded
2864753|NCT03496090|Experimental|Free diet|Free diet or free demand, being comparable to the normal or zero hospital diet
2864754|NCT03496090|Active Comparator|Progressive diet|Progressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day.
2864755|NCT03496077|Experimental|Flavored LCCs|Half of the group will start with a flavored little cigar/cigarillo (LCC) and cross over to unflavored LCC. The LCCs will be a popular brand already available for sale on the market.
2864756|NCT03496077|Experimental|Unflavored LCCs|Half of the group will start with an unflavored little cigar/cigarillo (LCC) and cross over to flavored LCC. The LCCs will be a popular brand already available for sale on the market.
2864757|NCT03496064||Anterior circulation LVO patients with ASPECTS <6|
2864758|NCT03496064||Anterior circulation LVO patients with NIHSS<8|
2864759|NCT03496064||Posterior versus anterior circulation LVO patients|
2864760|NCT03496064||LVO patients with isolated PCA or ACA occlusions|
2864761|NCT03496064||Tandem lesions versus non-tandem lesion|
2864762|NCT03496064||Bridging vs Direct MT|
2864763|NCT03496038|Experimental|Leukocyte and Platelet Rich Fibrin (L-PRF)|"For the test group the sub-sinus cavity will be filled with Leukocyte en Platelet Rich Fibrin (L-PRF).~Before starting the surgery, 8 tubes (9 ml) of venous blood will be collected from the patients. A centrifugation standard L-PRF protocol will be followed followed (12 minutes centrifugation, 2700 rpm/408g RCF).~After full centrifugation of the tubes, the L-PRF clots will be removed from the tubes using surgical tweezers. The clots will be thereafter gently compressed into membranes using a sterile metal box (Xpression, Intra-Lock, Florida, USA)."
2865023|NCT03494062|Experimental|Exercise|Home-based exercise intervention
2864764|NCT03496038|Active Comparator|Deproteinized Bovine Bone Mineral (DBBM)|For the test group the sub-sinus cavity will be filled with deproteinized bovine bone mineral (DBBM). The product used will be a xenograft (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland).
2864765|NCT03496025|Experimental|Electrical stimulation|
2864766|NCT03496012|Experimental|AAV2-REP1 High Dose|Subjects will receive a single administration of high-dose AAV2-REP1 in one eye.
2864767|NCT03496012|Experimental|AAV2-REP1 Low Dose|Subjects will receive a single administration of low-dose AAV2-REP1 in one eye.
2864768|NCT03496012|No Intervention|Untreated control group|Untreated control subjects will be observed for 12 months.
2864769|NCT03495999||Normouricemia|Serum uric of 7mg/dl or less in men or 6mg/dl or less in women
2864770|NCT03495999||Hyperuricemia|Serum uric of 7mg/dl or more in men or 6mg/dl or more in women
2864771|NCT03495986|Experimental|Home-Based Exercise & Diet Group|16-week home based functional electrical stimulation leg cycle ergometry exercise program and diet intervention
2864772|NCT03495986|Placebo Comparator|Home-Based Diet Alone Group|Diet intervention
2864773|NCT03495973||Participants with Crohn's Disease (CD)|Participants with CD will be assessed for the effectiveness of ustekinumab in accordance with national guidelines and routine standard of care. Data will be prospectively collected with the aid of the Swedish inflammatory bowel disease (IBD) registry, SWIBREG and medical records of each participant. Data will also be collected retrospectively from SWIBREG and other databases including national databases such as the participant registry in which cases the national databases will be considered source data.
2864774|NCT03495960|Experimental|Lenalidomide (experimental arm of part A)|"Patients in part A will receive 2 courses of induction chemo-immunotherapy:~Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11.~The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy.~Lenalidomide is given 25 mg/d per os, days 1 to 21 every 4 weeks for 24 courses"
2864775|NCT03495960|Active Comparator|Procarbazine (comparator arm of part A)|"Patients in part A will receive 2 courses of induction chemo-immunotherapy:~Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11.~The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy.~Procarbazine is given 100 mg/d per os, days 1 to 5 every 4 weeks for 6 courses"
2864776|NCT03495960|Other|Radiotherapy, temozolomide and rituximab (single arm part B)|"Patients ineligible for high-dose-methotrexate will be treated in the single-arm phase II part B of the trial and will receive~whole-brain radiotherapy (2340 cGy in 5 weekly fractions)~temozolomide 75 mg/m2/d during radiotherapy~4 weekly doses of rituximab 375 mg/m2, starting on day 2 of the whole-brain radiotherapy.~Patients will then receive maintenance therapy with 12 courses of temozolomide administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses."
2864777|NCT03495934|Experimental|single oral administration of 14C-pracinostat in the fas|
2864778|NCT03495921|Experimental|Vigil + Irinotecan and Temozolomide|"Group A Schedule:~Temozolomide 100 mg/m2 daily, oral, Days 1 - 5, every 21 days Irinotecan 50 mg/m2 daily, oral, Days 1 - 5, every 21 days Vigil 1.0 x 10e6 cells/injection, intradermal, Day 15, every 21 days for a minimum of 4 administrations to a maximum of 12 administrations depending on quantity of Vigil manufactured from surgical specimens and so long as the patient is clinically stable and without disease progression.~Subjects may receive repeat cycles of treatment until disease progression, unacceptable toxicity, withdrawal of consent or other criterion is met for discontinuation from study."
2864779|NCT03495921|Active Comparator|Irinotecan and Temozolomide|"Group B Schedule:~Temozolomide 100 mg/m2 daily, oral, Days 1 - 5, every 21 days Irinotecan 50 mg/m2 daily, oral, Days 1 - 5, every 21 days~Subjects may receive repeat cycles of treatment until disease progression, unacceptable toxicity, withdrawal of consent or other criterion is met for discontinuation from study.~Within 6 weeks of second relapse or progression, subjects randomized to Group B, will be allowed to cross-over to receive single agent Vigil every 21 days following End of Treatment assessments. Subjects who cross-over may receive up to 12 doses of Vigil depending upon the quantity of Vigil manufactured. Cross-over must occur within 2 years of End of Treatment assessments of Group B enrollment."
2864780|NCT03495908|Experimental|VGo with Regular Human Insulin|
2864781|NCT03495908|Active Comparator|VGo with Rapid Acting Insulin|
2864782|NCT03495895|Experimental|Minding the Baby|Families are visited weekly beginning in the mother's third trimester of pregnancy up through the child's first birthday, at which point visits take place biweekly up through the child's second birthday.
2864783|NCT03495895|Other|Control|Usual care control condition. Families in the control Group receive the usual care that is offered to families in the target group
2864784|NCT03495882|Experimental|AGEN1884 + AGEN2034|AGEN1884 in combination with AGEN2034 in subjects with Subjects with Metastatic or Locally Advanced Solid Tumors, and Expansion into Select Solid Tumors (cervical)
2864785|NCT03495869||Individuals with Cocaine Use Disorder|"This group will consist of individuals who are determined to have DSM5 diagnosis of Cocaine Use Disorder. The enrollment number is 2:1 over the targeted sample size (N=90, n=10 in this cohort), in order to account for screen fails and individuals who fail to continue the study due to lack of interest, loss to follow-up, etc.~Individuals will be recruited from an existing registry (VCU IRB HMHM20000294, Keyser-Marcus, PI)"
2864786|NCT03495869||Individuals with Opioid Use Disorder|This group will consist of individuals who are determined to have DSM5 diagnosis of Opioid Use Disorder. The enrollment number is 2:1 over the targeted sample size (N=90, n=10 in this cohort), in order to account for screen fails and individuals who fail to continue the study due to lack of interest, loss to follow-up, etc.
2864787|NCT03495869||Individuals with Cocaine and Opioid Use Disorder|This group will consist of individuals who are determined to have DSM5 diagnosis of Cocaine and Opioid Use Disorder. The enrollment number is 2:1 over the targeted sample size (N=90, n=10 in this cohort), in order to account for screen fails and individuals who fail to continue the study due to lack of interest, loss to follow-up, etc.
2864823|NCT03495570||B|HIV-infected on cART with HIV viral load <50 copies/mL within the 6 months prior to study entry, at least one measure of HCV (chronic or acute infection) showing a detectable HCV viral load and not in receipt of HCV treatment at study entry.
2864788|NCT03495869||Healthy Controls|This group will consist of individuals who are determined to be non-drug using healthy controls. The enrollment number is 2:1 over the targeted sample size (N=90, n=60 in this cohort), in order to account for screen fails and individuals who fail to continue the study due to lack of interest, loss to follow-up, etc.
2864789|NCT03495856|Experimental|Mindfulness Training For Chronic Pain|The intervention is adapted from the mindfulness-based stress reduction program. The adapted mindfulness training program consists of four, weekly 90 minute group sessions that focus on education on chronic pain and mindfulness, instruction and in-class mindfulness skills practice, and group discussion.
2864790|NCT03495830||Carotid endarterectomy|Patients that underwent intervention (CEA or CAS) are followed by clinical examination and carotid duplex on 12, 24 and 36 month If there is coexisting contralateral carotid stenosis with grade greater than 50% and not requiring interventional treatment (CEA or CAS), patient should cross in optimal medical therapy group.
2864791|NCT03495830||Optimal medical therapy group|Patients not subjected to intervention (or in whom one carotid has been treated with CAS or CEA and contralateral has stenosis is greater than 50%) will be followed with carotid duplex (at 12, 24 and 36 months) and MRI imaging of carotid tree from aortic arch up to the circle of Willis after 12 and 36 months.
2864792|NCT03495817|Experimental|Open Label ATI-50002 Topical Solution|
2864793|NCT03495804|Active Comparator|mannitol|Participants are given a minimum of 1500 mL of a preparation of mannitol as oral contrast agent over an hour prior to the examination.
2864794|NCT03495804|Experimental|polyethylene glycol|Participants are given a minimum of 1500 mL of a preparation of polyethylene glycol as oral contrast agent over an hour prior to the examination.
2864795|NCT03495791|Experimental|EI development phase.|
2864796|NCT03495791|No Intervention|Pilot-testing phase.|
2864797|NCT03495778|Experimental|Test Granola|50.5 g Test Granola
2864798|NCT03495778|Placebo Comparator|Control Granola|54.3 Control Granola
2864799|NCT03495765|Active Comparator|Well controlled|Eligibile people with diabetic macular oedema and HBA1C < 7.5
2864800|NCT03495765|Active Comparator|Poorly controlled|eligible people with Diabetic macular oedema and HBAIC >10.0
2864801|NCT03495752|Experimental|Pre/Post Repeated Measures|Performance on the forward-step-down test (FSDT) before and at one, five, and ten minutes following the Bruce Fatigue Protocol
2864802|NCT03495739|Experimental|RDG-17012® capsule|RDG-17012 ® capsule(dabigatran etexilate tosylate)
2864803|NCT03495739|Active Comparator|Pradaxa® capsule|Pradaxa® capsule(dabigatran etexilate mesylate)
2864804|NCT03495726|Experimental|Headspace app|Participants randomized to use the mindfulness app for 6 weeks.
2864805|NCT03495726|No Intervention|Waitlist control group|This group will receive treatment as usual for 6 weeks. After the completing the 6-week surveys, the waitlist group will receive a subscription to the Headspace app.
2864806|NCT03495713|Experimental|Single Arm|
2864807|NCT03495700|Experimental|L-PRF block|"For the test group the sub-sinus cavity will be filled with L-PRF block and the window will be closed with L-PRF membranes.~Eight tubes (9 ml) of venous blood will be collected from the patients. For 6 tubes (red cap) a 12 min centrifugation at 2700 rpm/408g RCF will be followed. Two tubes (white cap) will be centrifuged (IntraSpin, Intra-Lock, Florida, USA) for 3 minutes only to form the Liquid Fibrinogen.~The L-PRF clots will be removed from the tubes using surgical tweezers. The clots will be thereafter gently compressed into membranes using a sterile metal box (Xpression, Intra-Lock, Florida, USA).~To prepare the L-PRF Block, L-PRF membranes will be cut into small pieces and mixed with DBBM (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland). The Liquid Fibrinogen will be added to the homogeneous mix, and stirred gently for ± 10 seconds while shaping it to the L-PRF block"
2864808|NCT03495700|Active Comparator|DBBM|For the control group the sub-sinus cavity will be filled with deproteinized bovine bone mineral (DBBM). The product used will be a xenograft (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland). The window will be closed with a collagen membrane (Bio-Gide, Geistlich AG, Wolhusen, Switzerland).
2864809|NCT03495674|Experimental|Cycling Exercise - Lynch Syndrome|"Lower GI endoscopy performed on Day 0. Cardiopulmonary exercise test (CPET) and EKG, and questionnaire performed on Day 15. CPET performed again 30 days after visit 3.~On Day 15 participants enroll in 3 cycling classes every week (for a total of 12 cycling classes each month) while wearing a FITBIT.~Another endoscopy performed between Day 300-360. Thirty days after that, questionnaires completed."
2864810|NCT03495661|Active Comparator|Surgical (Decompression)|Central decompression of the stenotic segment(s) with undercutting of the lateral recesses.
2864811|NCT03495661|No Intervention|Non-surgical|"Physical therapy according to the Östersund model: training on stationary bicycle 30 min, 3 times/week under 4 months."
2864812|NCT03495648|Experimental|Walking Group|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market.
2864813|NCT03495648|Active Comparator|Non-walking Group|Subjects will drive themselves to the farmer's market.
2864814|NCT03495635|Experimental|BBBS Community-Based Mentoring|Big Brothers Big Sisters Community-Based Mentoring Program
2864815|NCT03495635|No Intervention|Control|Not eligible to participate in a Big Brothers Big Sisters mentoring program, but may participate in other mentoring programs.
2864816|NCT03495622|Experimental|Intervention/Treatment|Home visits by community health worker to deliver motivational interviewing and set up a structured text messaging strategy designed around a pre-determined quit date for smoking cessation.
2864817|NCT03495622|No Intervention|Control|All participants will receive brief verbal advice about the hazards of smoking and the benefits of smoking cessation.
2864818|NCT03495609|Experimental|Ovitrelle|
2864819|NCT03495596||Videolaryngoscopy patients|The patients who were attempted to be intubated with videolaryngoscopy
2864820|NCT03495583|Experimental|Early introduction|Six commonly allergenic foods introduced (in a randomly assigned order) into the diets of exclusively breastfed infants from about 3 months of age.
2864821|NCT03495583|No Intervention|Standard introduction|Infants followed UK DoH standard advice for weaning
2864822|NCT03495570||A|HIV-infected (chronic or acute infection) with a HIV viral load of >1000 copies/mL in the 6 months prior to study entry and not (yet) in receipt of combination antiretroviral therapy (cART) at study entry.
2864886|NCT03495102|Experimental|Dulaglutide 4.5 mg|Dulaglutide 4.5 mg administered SC once a week.
2864824|NCT03495570||C|HCV mono-infected (chronic or acute infection) with detectable HCV viral load (>lower limit of quantification) in the prior 6 months and not in receipt of HCV treatment at study entry.
2864825|NCT03495570||D|HBV mono-infected (chronic or acute infection) patients with detectable HBV viral load in the prior 6 months and not in receipt of HBV treatment at study entry.
2864826|NCT03495557|Sham Comparator|Control|Simple closure
2864827|NCT03495557|Experimental|Experimental|Simple closure + mesh
2864828|NCT03495544||Hereditary BC|Pathogenic germline mutations in DNA-repair genes (TP53 MLH1 MSH2 MSH6 PMS2 EPCAM APC MUTYH CDKN2A CDK4 ATM KIT PDGFRA CDH1 CTNNA1 PRSS1 SPINK1 BRCA1 BRCA2 FANCI FANCL PALB2 RAD51B RAD51C RAD54L RAD51D CHEK1 CHEK2 CDK12 BRIP1 PPP2R2A BARD1 PARP1 STK11 XRCC3)
2864829|NCT03495544||Sporadic BC|Without germline mutations in DNA-repair genes (TP53 MLH1 MSH2 MSH6 PMS2 EPCAM APC MUTYH CDKN2A CDK4 ATM KIT PDGFRA CDH1 CTNNA1 PRSS1 SPINK1 BRCA1 BRCA2 FANCI FANCL PALB2 RAD51B RAD51C RAD54L RAD51D CHEK1 CHEK2 CDK12 BRIP1 PPP2R2A BARD1 PARP1 STK11 XRCC3)
2864830|NCT03495531|No Intervention|Standard of Care|Standard of Care
2864831|NCT03495531|Experimental|VR Use|Obstetrics patients who use virtual reality
2864832|NCT03495518|Active Comparator|Symptom feedback to Health Care Provider|"For those randomized to the intervention arm, symptom screening using SPARK will be completed once daily for 5 days on an iPad using the approach refined in aim 2. Daily SSPedi reports will be printed and provided in the patient chart. On days 1 and 3±1, a report describing symptoms that are a lot or extremely bothersome will be emailed to the physician providing direct medical care"
2864833|NCT03495518|Active Comparator|Standard of care|For those randomized to the control arm, a clinical research associate will visit the participant on days 1 and 5±1 and will obtain SSPedi scores on an iPad. Reports will not be printed or emailed to the physician.
2864834|NCT03495505|Experimental|WiSE-CRT eligible|Patients need to meet all the inclusion and none of the exclusion criteria in order to be eligible for the study. All these patients will receive the WiSE-CRT implant.
2864835|NCT03495492|Experimental|Participants|Group receiving dermal chelation and nutritional therapy
2864836|NCT03495479||OMN54 -Treated|Six-month, daily oral dosing in softgel capsules throughout the first 6 months of treat.
2864837|NCT03495466|Active Comparator|Local only Anesthesia|The patient will receive local only anesthesia during the first surgery and local with sedation anesthesia for their second surgery.
2864838|NCT03495466|Active Comparator|Local with sedation anesthesia|The patient will receive local with sedation anesthesia during the first surgery and local only anesthesia for their second surgery.
2864839|NCT03495453|Active Comparator|CSI's DIAMONDBACK 360® Peripheral Orbital Atherectomy (OAS)|OAS (using CSI device) followed by Inpact Admiral drug coated balloon (DCB)
2864840|NCT03495453|Active Comparator|Medtronic's Hawkone Directional Atherectomy system (DAS)|DAS (using the Hawkone device) followed by DCB
2864841|NCT03495440|Experimental|Center Sessions|Treatment condition in which participants receive psychoeducation and communication coaching.
2864842|NCT03495440|Active Comparator|At-home|Active, self-study control condition in which participants receive regular communication with study personnel and self-study materials to review on their own.
2864843|NCT03495427|Experimental|Radioactive Diagnostic Imaging|Participants will receive F-DCFPyL PSMA PET imaging annually for 4 years. An administered dose of 9 ± 1 mCi (333 ±37 MBq) F-DCFPyL Injection will be administered via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access.
2864844|NCT03495414||Healthy Controls (HC)|Controls will be physically and psychologically healthy and will show no indication of clinical hypersexuality.
2864845|NCT03495414||Patients with hypersexual disorder (HD)|Patients will meet diagnostic criteria for HD as defined in the DSM-5 proposed criteria for hypersexual disorder (Kafka, 2010)
2864846|NCT03495401|Experimental|fortified synbiotic milk|100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
2864847|NCT03495401|Placebo Comparator|non-fortified synbiotic milk|100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
2864848|NCT03495388||Major Inpatient Surgeries|Children ages 8-17.9 undergoing pectus excavatum or idiopathic scoliosis spinal fusion at Riley Hospital for Children, who have consented to participate in an observational clinical study as approved by the IU IRB, protocol #1707525204.
2864849|NCT03495375|Experimental|Treatment with a probiotic|Synbiotic2000Forte (SF) it is composed of 3 LAB species known to have anti-inflammatory effects and restoring the intestinal barrier, and 4 fermentable fibers: Pediococcus pentosaceus 5-33:3, Lactobacillus paracasei subsp paracasei 19, and Lactobacillus plantarum 2362 in combination with the following four fermentable fibres: betaglucan, inulin, pectin and resistant starch, a formula that is currently produced by Synbiotic AB, Sweden.
2864850|NCT03495375|Placebo Comparator|Treatment with placebo powder|Placebo will be a non-digestable carbohydrate with similar texture and flavor to the SF also provided by Synbiotic AB, Sweden.
2864851|NCT03495362|Experimental|Intervention group|"Ingredients: yeast beta-glucan, and capsule shell Capsule, per capsule with 500mg insoluble beta-glucan, twice a day, 1 capsule each time.~The intervention period is about 3 months."
2864852|NCT03495362|Placebo Comparator|Placebo group|Ingredients: starch, and capsule shell Capsule, per capsule with 500mg starch, twice a day, 1 capsule each time. The intervention period is about 3 months.
2864853|NCT03495349||Diabetic foot infection|All of the patients followed for a diabetic foot infection in Hospices Civils of Lyon
2864854|NCT03495336|Experimental|Washout period|Coffee abstention phase for 2 weeks.
2864855|NCT03495336|Experimental|Light roast coffee (LR)|Participants will follow LR Coffee consumption procedure and consume at least 3 cups of Light (LR) roast Turkish coffee brews per day for 4 weeks after a washout period (WO) of 2 weeks.
2864856|NCT03495336|Experimental|Second washout period|coffee abstention phase for 2 weeks
2864857|NCT03495336|Experimental|Dark roast coffee (DR)|Participants will follow DR Coffee consumption procedure and consume at least 3 cups of Dark (DR) roast Turkish coffee brews per day for 4 weeks after a washout period (WO) of 2 weeks.
2864858|NCT03495323|Experimental|Prexasertib + LY3300054|"Prexasertib is administered intravenously twice per cycle~LY3300054 is administered intravenously twice per cycle"
2865024|NCT03494062|No Intervention|Control|Usual care
2864859|NCT03495310|Experimental|Mindfulness|"In this group, children and their parents will receive a mindfulness session once a week, with a duration of 90 minutes, during 8 weeks (sessions will be separated for children and parents). Mindfulness sessions will be coordinated by experts in mindfulness techniques in children and adults respectively from the collaborator Institution Spanish School of Transpersonal Development Previous to the session, a 24-hour food recall questionnaire will be applied to offer a meal plan restricted in 500 kcal. The 24-R will be repeated at each session in order to make adjustments to the meal plan if necessary. Also a 60-minute walk 3 times a week will be recommended"
2864860|NCT03495310|No Intervention|Control|In this group, children and their parents will receive information regarding what is a healthy diet and physical activity attached to the World Health Organization recommendations. The session will be coordinated by a pediatric endocrinologist. Previous to the session, a 24-hour food recall questionnaire will be applied to offer a meal plan restricted in 500 kcal. The 24-R will be repeated at each session in order to make adjustments to the meal plan when necessary. Also a 60-minute walk 3 times a week will be recommended
2864861|NCT03495297|No Intervention|S-ICD Implant with defibrillation test|Patients undergoing de novo S-ICD implantation including induction of VF and defibrillation testing post-implant
2864862|NCT03495297|Experimental|S-ICD Implant without defibrillation test|Patients undergoing de novo S-ICD implantation without induction of VF and defibrillation testing post-implant
2864863|NCT03495284|Experimental|Potato treatment|Participants will be provided with one potato-based side dish, equivalent to one medium sized potato, every day for 4 weeks for incorporation into their self-selected diet. The potato-based side dish will be prepared at the Penn State Metabolic Kitchen. The potato side dish will consist of commonly consumed potato-based sides in the U.S. and there will be limited inclusion of ingredients high in saturated fat, refined sugars or sodium. French fries will not be provided. The variety of potatoes will represent consumption patterns in the U.S. including white, russet, yellow and red potatoes.
2864864|NCT03495284|Active Comparator|Refined grain treatment|Participants will be provided with a calorie-matched refined grain-based side dish every day for 4 weeks for incorporation into their self-selected diet. The refined grain-based side dishes will be prepared at the Penn State Metabolic Kitchen and ingredients high in saturated fat, refined sugar or sodium will not be used. These will be sides commonly eaten in the U.S. (e.g. pasta made with white flour and white rice, white bread rolls). During this treatment, participants will be told not to consume potatoes.
2864865|NCT03495271||Hemodialysis Patients|"Inclusion Criteria:~Patient's undergoing hemodialysis.~Male and female of any race~18 years/ older.~Those with dysphagia were excluded.~In both participant groups, before each tasting protocol commences, sterile cotton dental rolls will be placed in the participant's mouth. This will be used to collect a saliva sample and determine salivary flow.~Tasting Protocol: The hemodialysis patients will taste each solutions twice, both before and after their dialysis session. An sensory questionnaire and an open ended comment box will be given for participants to type in other words to describe the sensations.~In dialysis patients only, blood will be drawn pre and post dialysis for serum ion concentrations."
2864866|NCT03495271||Healthy Controls|"Inclusion Criteria~No tongue, lip, or cheek piercings~Over 18 years of age~Normal taste and smell function~No known issues with salivation or dry mouth~Willing to comply with study protocol (taste samples and provide saliva)~The above protocol will be mimicked in the healthy control group. The only difference is that instead of a pre/post dialysis tastings, the control population will have a 2-4 hour gap in between tastings in order to follow the approximate time-frame of the dialysis patients. Finally they will not be required to provide blood samples."
2864867|NCT03495258|Experimental|Clarion Evolve Laser Vaporization System|Clarion Evolve Laser Vaporization System
2864868|NCT03495258|Experimental|Olympus TURis Plasma Vaporization|Olympus TURis Plasma Vaporization
2864869|NCT03495245||Opioid Usage|Patients that are currently diagnosed with fibromyalgia and taking opioids.
2864870|NCT03495245||No Opioid Usage|Patients that are currently diagnosed with fibromyalgia and are not taking opioids.
2864871|NCT03495219||Esophageal Manometry|Esophageal manometry is a test to assess motor function of the upper esophageal sphincter, esophageal body and lower esophageal sphincter
2864872|NCT03495206|Experimental|Y-2 sublingual tablet|
2864873|NCT03495193|Active Comparator|Exercise Group|Subjects randomized to the exercise training group will complete 16 weeks of exercise training. Exercise training will be performed 3x/week.
2864874|NCT03495193|Active Comparator|No Exercise Group|Subjects randomized to the no-Ex group will receive a handout with tips for improving sleep hygiene. Additionally, study staff will provide the title page for a book on sleep relaxation techniques that is recommended for persons with sleeping difficulty.
2864875|NCT03495180|Experimental|Standard EEG or SSEP|the intensity of an experimental pain stimulus and perceived (self-rating, subjective) pain intensity.
2864876|NCT03495167|Experimental|SyB C-1101|
2864877|NCT03495154|Experimental|Parietene DS Composite Mesh|Patients treated with Parietene DS Composite Mesh
2864878|NCT03495141|Active Comparator|Supervised|Participants first take part in supervised/coached colonoscopy module session twice (case one and case two) and then transition to performing an unassisted colonoscopy module twice (case three and case four).
2864879|NCT03495141|Active Comparator|Unsupervised|Participants will either first partake in an unsupervised colonoscopy module twice (case one and case two) and then transition to a supervised/coached colonoscopy module session twice (case three and case four).
2864880|NCT03495128|Experimental|Bed rest|Three days of bed rest at -6 degrees of head-down tilt
2864881|NCT03495128|Experimental|Reconditioning|Three days of one-legged knee extension contractions to recondition one leg
2864882|NCT03495115|Active Comparator|SCREENING MRI|Standard MRI procedure will be used.
2864883|NCT03495115|Experimental|SCREENING MG BI-RADS 4/5|"RSI is a DWI sequence with a built in distortion-correction technique that can be applied to any diffusion technique using echo planar imaging acquisition.~RSI will be performed using pulsed-field gradient, spin-echo, echo planar imaging with multi-shell diffusion data .~The b0 images will be collected in both the forward and reverse phase encoding directions to allow for post-processing correction of spatial distortion from magnetic field."
2864884|NCT03495102|Experimental|Dulaglutide 1.5 mg|Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.
2864885|NCT03495102|Experimental|Dulaglutide 3 mg|Dulaglutide 3 mg administered SC once a week.
2864887|NCT03495089|Experimental|patients with type 2 DM|"Patients with type 2 DM over 40 years of age, with or without symptoms of neuropathy, attended in Primary Care.~Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance- DEC quantification using the Sudoscan® device."
2864888|NCT03495089|Experimental|prediabetes|"Patients with intermediate alterations of glucose metabolism defined as impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) determined by OGTT after 2-hour 75 g oral glucose administration.~Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance-DEC quantification using the Sudoscan® device."
2864889|NCT03495089|Experimental|control group|Patients without glucose alterations (normal glucose tolerance). Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance-DEC quantification using the Sudoscan® device.
2864890|NCT03495076|Experimental|Saline injection|In the saline condition, acute neck pain will be induced via 0.5 ml hypertonic (5% NaCl) saline solution.
2864891|NCT03495076|Sham Comparator|Sham injection|In the sham injection condition, a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience.
2864892|NCT03495076|No Intervention|Control|Participants in the control condition will not receive any kind of pain or pinprick sensation.
2864893|NCT03495063|Experimental|Natural Caffeine|Subjects will be their own control and will have repeated measures after the consumption of a drink with 400mg of natural caffeine. Blood pressure measurements will be taken at baseline, then hourly for four hours.
2864894|NCT03495063|Experimental|Synthetic Caffeine|Subjects will be their own control and will have repeated measures after the consumption of a drink with 400mg of synthetic caffeine. Blood pressure measurements will be taken at baseline, then hourly for four hours.
2864895|NCT03495037|Experimental|Real World Strategy Training|Group intervention including education and strategy training to manage everyday functional difficulties.
2864896|NCT03495037|Active Comparator|Psychosocial Education|Group sessions including education on brain health.
2864897|NCT03495024|Other|Smoking cessation with varenicline|FDA-approved indication of varenicline for smoking cessation
2864898|NCT03495011||Group 1|Patient with suspicious calcifications identified on mammogram would complete a research quantitative, multiparametric breast MRI prior to core needle biopsy. Patients diagnosed with pure DCIS on breast biopsy and subsequent surgical resection will receive Oncotype DX DCIS score testing.
2864899|NCT03494998||Children and young people|Aged 0-16 years
2864900|NCT03494985|Experimental|OralBalance moisturizing gel|All the participants in this arm used an experimental Oralbalance gel as instructed under the supervision of trained site staff on their visits.
2864901|NCT03494985|Experimental|Oral rinse|All the participants in this arm used an Oral rinse as instructed under the supervision of trained site staff on their visits.
2864902|NCT03494985|Experimental|Moisturizing mouth spray|All the participants in this arm used a moisturising mouth spray as instructed under the supervision of trained site staff on their visits.
2864903|NCT03494985|Sham Comparator|Water only use|All the participants in this arm used water as instructed under the supervision of trained site staff on their visits.
2864904|NCT03494972|Active Comparator|drain|Tetracyclin drain
2864905|NCT03494972|Sham Comparator|No-drain|No drain
2864906|NCT03494959|Experimental|Treatment with Pentaglobin|Patients should receive the best available first-line therapy, usually a combination therapy, based on the in vitro susceptibility results of the pre-treatment screening swab in combination to Pentaglobin 5ml/kg over a 12h i.v. infusion for 3 consecutive days.
2864907|NCT03494946|Experimental|Arm A|Patients that suffer from Colorectal cancer and metastasis to liver that are randomized to Group A, will undergo Liver transplantation
2864908|NCT03494946|Active Comparator|Arm B|Patients that suffer from Colorectal cancer and metastasis to liver that are randomized to Group B, will be given chemotherapy, TACE, SIRT or other available treatment options.
2864909|NCT03494933|Experimental|CRT-P group|Intervention: CRT-P implantation
2864910|NCT03494933|Active Comparator|CRT-D group|Intervention: CRT-D implantation
2864911|NCT03494920|Other|Direct endovascular clot retrieval|Endovascular clot retrieval (ECR) within 4.5 hours stroke
2864912|NCT03494920|Other|Bridging thrombolysis followed by ECR|Intravenous tPA (at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour) followed by ECR
2864913|NCT03494907|Experimental|Seltorexant (Low and high dose)|Participants will receive seltorexant tablets orally in 2 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
2864914|NCT03494907|Experimental|Moxifloxacin|Participants will receive moxifloxacin tablets orally in 1 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
2864915|NCT03494907|Experimental|Placebo Matched to Seltorexant|Participants will receive seltorexant placebo tablets orally in 3 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
2864916|NCT03494907|Experimental|Placebo Matched to Moxifloxacin|Participants will receive moxifloxacin placebo tablets orally in 3 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
2864917|NCT03494894||patients with Cystic Fibrosis and Primary Ciliary Dyskinesia|
2882566|NCT03371758|Experimental|healthy controls|
2864919|NCT03494868|No Intervention|Fasting|Fasting prior to elective cesarean section delivery (standard of care)
2864920|NCT03494868|Experimental|Carbohydrate Drink|Subjects will drink 2 carbohydrate drinks prior to elective cesarean section delivery
2864921|NCT03494855||Neonates|<1 month of age SyMRI software used for brain imaging and radiological interpretation
2864922|NCT03494855||Infants|1mth - 2 years of age SyMRI software used for brain imaging and radiological interpretation
2864923|NCT03494855||Adolescents|2 - 12 years of age SyMRI software used for brain imaging and radiological interpretation
2864924|NCT03494855||Teenagers|13-18 years of age SyMRI software used for brain imaging and radiological interpretation
2864925|NCT03494855||Healthy Adults|Preliminary Evaluation SyMRI software used for brain imaging and radiological interpretation
2864926|NCT03494842|Active Comparator|the active TENS group|Transcutaneous nerve stimulation (TENS)
2864927|NCT03494842|Placebo Comparator|the placebo TENS group|Placebo Transcutaneous nerve stimulation (TENS)
2864928|NCT03494816|Experimental|Axitinib|Axitinib - oral tablet twice daily for 8 weeks prior to surgery. Starting dose 5mg.
2864929|NCT03494803||Control|
2864930|NCT03494803||Prostate Cancer|
2864931|NCT03494777|Experimental|Adherence-based incentivization|"Participants will be eligible for prize drawings at every regular clinic visit based on high adherence as measured by MEMS-caps. In addition there will be an annual prize drawing that is conditional on showing high adherence over the course of the year.~This arm will receive the intervention 'Incentivization based on high adherence' and the intervention 'Annual adherence prize drawing' and (if eligible) the intervention 'Year 2 booster'.~Note: the 70 treatment initiating clients will all be assigned to this arm to receive preliminary data as to whether incentives may work for this group."
2864932|NCT03494777|Experimental|Viral suppression-based incentivization|"Participants will be able to participate in prize drawings at every clinic visit where eligibility will be based on timely drug refills (that coincide with the clinic visits). Participants will also have a chance to enter a prize drawing at the end of every year if they show viral suppression.~This arm will receive the intervention 'Incentivization based on timely clinic visit' and the intervention 'Annual viral suppression-based prize drawing', and (if eligible) the intervention 'Year 2 booster'."
2864933|NCT03494777|No Intervention|Control|This arm will receive care as usual, including the adherence support mechanisms that are part of usual care practices.
2864934|NCT03494764|Active Comparator|5 Days Hyperbaric Therapy|Patients will be enrolled and follow an identical medical treatment algorithm. At day 3 responders (based on partial Mayo score) will be re-randomized in a 1:1 fashion to complete 5 total days of HBOT (1 session per day) or to stop after 3 days of HBOT. Non-responders will be entered into an open label arm to complete 5 total days of HBOT.
2864935|NCT03494764|Active Comparator|3 Days Hyperbaric Therapy|Patients will be enrolled and follow an identical medical treatment algorithm. At day 3 responders (based on partial Mayo score) will be re-randomized in a 1:1 fashion to complete 5 total days of HBOT (1 session per day) or to stop after 3 days of HBOT. Non-responders will be entered into an open label arm to complete 5 total days of HBOT.
2864936|NCT03494751|Experimental|Heart Monitor|We used the device (heart monitor) in the patients with myocardial infarction.
2864937|NCT03494751|Active Comparator|No Heart Monitor|No heart monitor device in the patients with myocardial infarction (control).
2864938|NCT03494738||Newborn infants|Neonates born from consented women at the study hospital
2864939|NCT03494725|Active Comparator|Lpc-37|"Lactobacillus paracasei Lpc-37~1x 1 capsule in the morning for 5 weeks"
2864940|NCT03494725|Placebo Comparator|Placebo|"Placebo capsule manufactured to mimic Lpc-37 capsule~1x 1 capsule in the morning for 5 weeks"
2864941|NCT03494712|Experimental|S 95010|Increasing single doses of S 95010 to 5 subjects.
2864942|NCT03494712|Placebo Comparator|Placebo|Increasing single doses of Placebo to 2 subjects.
2864943|NCT03494699|Experimental|Intervention group|
2864944|NCT03494699|No Intervention|Control group|
2864945|NCT03494686|Experimental|LLETZ under local anaesthesia|The LLETZ procedure will be performed under local anaesthesia
2864946|NCT03494686|Active Comparator|LLETZ under general anaesthesia|The LLETZ procedure will be performed under general anaesthesia
2864947|NCT03494673||Control|Normal controls without headaches will undergo BOLD MRI with prospective CO2 targeting
2864948|NCT03494673||Migraineurs|Patients diagnosed with migraine based on the ICHD-3 beta will undergo BOLD MRI with prospective CO2 targeting
2864949|NCT03494647|Active Comparator|Cheetah Heel Cup|Subjects randomly assigned to this group will receive the Cheetah Heel Cup at their initial visit.
2864950|NCT03494647|Active Comparator|The X Brace|Subjects randomly assigned to this group will receive the X Brace at their initial visit.
2864951|NCT03494634|Experimental|Chidamide|
2864952|NCT03494621|No Intervention|Control group|Participants randomly assigned to the control group will have three prenatal contacts at the same gestational ages as the intervention participants. These contacts will include collection of covariate data, review of locally available educational materials on pregnancy/infant care led by trained study staff, and assessment of the overall session quality and acceptability. The educational materials provided during these sessions are drawn from materials currently available at local health care facilities
2864953|NCT03494621|Experimental|Protecting Babies While They Sleep|The intervention curriculum derives from information gathered at previously conducted focus groups and interviews, which aimed to ascertain the role of caregiver knowledge, beliefs, and access to resources in implementation of infant safe sleep practices. The protocol for the focus groups and interviews has been reviewed by the Tribal Institutional Review Board. The focus groups were conducted in Rapid City and a western Tribal reservation with pregnant adult women and pregnant, parenting, or other interested adolescent women; fathers (adult men); and elder women. Two focus groups were held for each category of individuals. Additional qualitative data was collected via key informant interviews with individuals vested and experienced in maternal and child health.
2864954|NCT03494595||Thrombosis|Patients who will develop thrombosis perioperatively
2864955|NCT03494595||No thrombosis|Patients who will not develop thrombosis perioperatively
2864956|NCT03494582|Experimental|Sacral Hysteropexy|Abdominal approach for uterine suspension
2864957|NCT03494582|Experimental|sacrospinous Hysteropexy|Transvaginal approach for uterine suspension
2882827|NCT03369938|No Intervention|usual care|
2864958|NCT03494569|Experimental|Treatment (TMLI, fludarabine, melphalan)|Participants undergo TMLI BID on days -8 to -5, and receive fludarabine IV on days -4 to -2 and melphalan on day -2. Participants then undergo alloHCT on day 0.
2864959|NCT03494556||No Intervention|Paramedic will use data collected during routine care to complete four risk stratification tools.
2864960|NCT03494530||Early initiation of edoxaban|Participants will be initiated on edoxaban within ≤ 5 days following ischemic stroke
2864961|NCT03494530||Delayed initiation of edoxaban|Participants will be initiated on edoxaban within 6-14 days following ischemic stroke
2864962|NCT03494517||Preeclampsia|"Women aged 18-45 years~Confirmed pregnancy > 30 weeks of gestation~Singleton or multiple pregnancies~Admission in maternity of the Women's hospital with clinically suspected signs of severe preeclampsia:~Systolic blood pressure >140 mmHg or diastolic pressure > 90 mmHg and~Proteinuria > 0.3 grams in a 24-hour urine or protein:creatinine ratio >0.3 or~Signs of end-organ dysfunction (platelet count < 100'000G/l, serum creatinine >110 mg/l, or doubling of the serum creatinine, elevated serum transaminases to twice normal concentration)"
2864963|NCT03494504|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
2864964|NCT03494504|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
2864965|NCT03494504|Placebo Comparator|Vehicle Ophthalmic Solution|
2864966|NCT03494478|Experimental|Cohort group|All participants will have evaluations at inclusion and 12 months. Neuropsychological testing Actimetry Selfquestionnaires on emotional topics
2864967|NCT03494465|Active Comparator|MEDICAL TREATMENT GROUP|"Medical treatment will be used in a staggered manner and may also associate laser trabeculoplasty. If necessary, then surgical treatment would be indicated: trabeculectomy. or another filtering surgery.~Inadequate IOP control will be determined by the local ophthalmologist, and additional treatment will be indicated to achieve an target IOP."
2864968|NCT03494465|Experimental|INTERVENTION GROUP|"In lens extraction arm, patients will undergo lens phacoemulsification with intraocular lens implant (IOL) within 60 days after randomization.~If additional treatment is required, the same stepped sequence of therapy described for medical treatment group will be used and will be considered a therapeutic failure."
2864969|NCT03494452||Low back pain - no intervention|Patients who perform sitting occupational activities for at least 4 hours/day and have had low back pain for at least the previous 6 months
2864970|NCT03494452||Healthy - no intervention|Healthy persons who perform sitting occupational activities for at least 4 hours/day
2864971|NCT03494426|Experimental|interventional group|patients will receive Radiofrequency thoracic sympathectomy then will receive pregabalin ,tramadol,and tricyclic antidepressants
2864972|NCT03494426|Active Comparator|control group|patients will receive pregabalin ,tramadol,and tricyclic antidepressants
2864973|NCT03494413|Experimental|20 patients (1-20) validation arm|Accuracy of cerebral flow measurement between TPS and CDS in 20 patients undergoing cardiovascular surgery with cardiopulmonary bypass
2864974|NCT03494413|Experimental|20 patients (21-40) HCA arm|Assessment and comparison of TPS and CDS in hypothermic circulatory arrest (HCA) during cardiovascular surgery
2864975|NCT03494400|Experimental|Tamoxifen Aerobic Training Presential|A group of women with breast cancer who use Tamoxifen and will perform aerobic training presential.
2864976|NCT03494400|Experimental|Aromatase Inhibitor Training Presential|A group of women with breast cancer who use Aromatase Inhibitor and will perform aerobic training presential.
2864977|NCT03494400|Active Comparator|Training Presential without Cancer|A group of women without breast cancer who use Aromatase Inhibitor and will perform aerobic training presential.
2864978|NCT03494400|No Intervention|Training with Breast Cancer|A group of women with breast cancer who use hormone therapy and will not perform any physical training
2864979|NCT03494400|Experimental|Tamoxifen Training Home-based|A group of women with breast cancer who use Tamoxifen and will perform aerobic training home-based.
2864980|NCT03494400|Experimental|Aromatase Inhibitor Home-based|A group of women with breast cancer who use Aromatase Inhibitor and will perform aerobic training presential.
2864981|NCT03494387|Experimental|1|
2864982|NCT03494387|Experimental|2|
2864983|NCT03494374|Experimental|treatment group|Treatment with UCBL and exercise therapy
2864984|NCT03494361||Young normal group|normal participants below 60 years
2864985|NCT03494361||Old normal group|normal participants above 60 years
2864986|NCT03494348|No Intervention|Cruciate Retaining Polyethylene (CR)|This is the standard Polyethylene articular surface
2864987|NCT03494348|Active Comparator|Medial Congruent Polyethylene (MC)|The intervention here will be the MC articular surface. This is the new Polyethylene articular surface with a more congruent medial side and a more flat lateral side which should better resemble natural anatomy.
2864988|NCT03494335|Experimental|Volunteer participants|Volunteer participants will participate in surveys assessing their perception of various imaging aspects.
2864989|NCT03494322|Experimental|Avelumab + cetuximab|"Patients will receive treatment in 4-week cycles and treatment may continue for up to 1 year.~Avelumab + cetuximab combination therapy:~Cycle 1~Day 1: Cetuximab 500* mg/m2 given IV over approx 3 hrs~Day 15: Cetuximab 500* mg/m2 given IV over approx 2 hrs + avelumab 10 mg/kg given IV over approx 1 hr~All other cycles:~- Days 1 and 15: Cetuximab 500* mg/m2 given IV over approx 2 hrs + avelumab 10 mg/kg given IV over approx 1 hr~*Cetuximab dose will be dependent on outcome of safety run-in.~There must be a 60 minute break between the administration of cetuximab and avelumab."
2864990|NCT03494322|Other|Avelumab monotherapy|"Patients will receive treatment in 4-week cycles and treatment may continue for up to 1 year.~Avelumab monotherapy will be given as follows:~All cycles Avelumab 10 mg/kg on days 1 and 15 given IV over approximately 1 hour"
2864991|NCT03494309|Experimental|ORIF|Open Reduction & Internal Fixation
2864992|NCT03494309|Active Comparator|CREF|Closed Reduction & External Fixation
2864993|NCT03494296||Open, multi-center, prospective|All enrolled and relapsed patients received D-COP regimen chemotherapy
2864994|NCT03494283||CrossFit injuries|
2864995|NCT03494270|Experimental|Rosuvamibe Tab|Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks
2864996|NCT03494270|Active Comparator|Monorova Tab|Rosuvastatin 20mg qd for 24 weeks
2864997|NCT03494257|Active Comparator|Brinzolamide-Brimonidine fixed combination|1 drop of the brinzolamide-brimonidine fixed combination instilled in the patients cul de sac immediately after surgery
2882828|NCT03369925|Placebo Comparator|Placebo|
2864998|NCT03494257|No Intervention|No topical IOP reducing medication|No IOP reducing drops instilled after surgery
2864999|NCT03494244||ADM|Patients having undergone direct-to-implant breast reconstruction using acellular dermal matrix.
2865000|NCT03494244||Non-ADM (Vicryl)|Patients having undergone direct-to-implant breast reconstruction using non-acellular dermal matrix mesh (Vicryl mesh).
2865001|NCT03494231|Experimental|HLX06, in patients with solid cancers|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX06 once per week. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 500, 750, 900, 1200, 1500 mg, starting from 500 mg/kg.
2865002|NCT03494218|Experimental|vegetative state|patients with vegetative state lack awareness of self and environment even in the presence for eye-opening and sleep-wake cycles using CRS-R. The nailbed pressure was applied for 5 seconds and ended as soon as the behavioral response were captured. The raters recorded patients' behavioral responses using Nociception Coma Scale (NCS) during 10 seconds after each noxious stimulus.
2865003|NCT03494218|Experimental|minimally conscious state|Patients with minimally conscious state display inconsistent, but reproducible and discernible signs of awareness using CRS-R. The nailbed pressure was applied for 5 seconds and ended as soon as the behavioral response were captured. The raters recorded patients' behavioral responses using Nociception Coma Scale (NCS) during 10 seconds after each noxious stimulus.
2865004|NCT03494205|Experimental|Test group|"For the patients of the test-group Urtica comp gel is applied three times per day locally on the skin as soon as the patient senses itching, tingling and/or reddening. Otherwise the skincare is exactly as the control group in line with the departments general guidelines.~In case of marked worsening, e.g. epitheliolysis, the patient may receive Flammazine and Ialugen plus as rescue-care.~Rescue care: according to the departments therapeutic guidelines patients will receive Flammazine and/or Ialugen plus as clinically indicated at the discretion of the treating physician (usually in cases of marked worsening of the skin condition like e.g. epitheliolysis)."
2865005|NCT03494205|Active Comparator|Control group|"Control group receiving the institutional standard skin care Excipial-Hydrolotion - all other therapeutic interventions, assessments and rescue-care will be the same in both groups."
2865006|NCT03494192|Experimental|scapula based|"Cold pack~Stretching Exercises~Exercise training focus on scapulothoracic muscles will be applied two times per week total 12 week"
2865007|NCT03494192|Experimental|scapula&rotator cuff based|"Cold pack~Stretching Exercises~Exercise training focus on scapulothoracic muscles~Exercise training focus on rotator cuff muscles will be applied two times per week total 12 week"
2865008|NCT03494179|Experimental|High Dose of ICP-022|Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
2865009|NCT03494179|Experimental|Low Dose of ICP-022|Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
2865010|NCT03494166|No Intervention|Low Need Benchmark or Follow-up|In the low need benchmark or follow-up group, they will receive baseline and 13-week assessments (about 30-40 minutes) over the telephone. A brief assessment (about 5 minutes) at week 4 over the telephone will assess symptoms. Approximately 35% of all participants will be in this group.
2865011|NCT03494166|Experimental|High Need A-SMH or TIP-C|Participants will be mailed the printed Symptom Management and Survivorship Handbook (SMH). The Group A participant will be called every week for 4 weeks to ask about symptoms and suggest strategies from the SMH to relieve symptoms. Calls will last approximately 10 minutes. After 4 weeks, participants will be re-randomized to continue in SMH for 8 more weeks or to add Telephone Interpersonal Counseling (TIP-C) Intervention for the subsequent 8 weeks. If the TIP-C is added, the counselor will call the participant once per week for about 35-40 minutes to assess and discuss strategies for managing symptoms, provide survivorship education, and discuss interpersonal relationships, communication, and social support. At week 13, the participant will complete the second assessment.
2865012|NCT03494166|Experimental|High Need B-TIP-C+SMH|Participant will be called every week for the first 8 weeks using a combination of TIP-C and SMH. The counselor will assess and discuss interpersonal relationships, communication, social support, managing symptoms and survivorship. At the end of 8 weeks, the final 4 calls will focus be the SMH protocol. At week 13, the second assessment will be conducted.
2865013|NCT03494127|Experimental|Group A|DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks followed by DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
2865014|NCT03494127|Experimental|Group B|DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks followed by DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks
2865015|NCT03494114|Experimental|COPD Patients|Folate imaging will be performed with 68Ga-EC2115 prior to scheduled bronchoscopy, which will be performed for clinical purposes to evaluate a suspicious lung nodule. The unused portion of the bronchoalveolar lavage (not necessary for clinical purposes), will be interrogated to compare PET imaging with parameters of inflammation in BAL, including the number/percentage of macrophages expressing FRβ. In addition, PET imaging data will be compared with disease severity, based on pulmonary function testing.
2865016|NCT03494114|Experimental|Individuals without COPD|Folate imaging will be performed with 68Ga-EC2115 prior to scheduled bronchoscopy, which will be performed for clinical purposes to evaluate a suspicious lung nodule. The unused portion of the bronchoalveolar lavage (not necessary for clinical purposes), will be interrogated to compare PET imaging with parameters of inflammation in BAL, including the number/percentage of macrophages expressing FRβ.
2865017|NCT03494101||Non-typhoid Salmonella infection|Patients with a non-typhoid Salmonella infection. Blood samples, stool samples and clinical information will be collected.
2865018|NCT03494101||Acute, infectious diarrhea|Patients with acute, infectious diarrhea without non-typhoid Salmonella infection. Blood samples, stool samples and clinical information will be collected.
2865019|NCT03494101||Healthy individuals|Healthy individuals with no symptoms of acute or chronic diarrhea. Blood samples, stool samples and clinical information will be collected.
2865020|NCT03494088||Children with Autism with gastrointestinal (GI) symtpoms|
2865021|NCT03494088||Children with Autism without gastrointestinal (GI) symtpoms|
2865022|NCT03494088||Healthy Children|
2882829|NCT03369925|Experimental|Cognizin|
2865025|NCT03494049|Active Comparator|Veil sparring HoLEP|"Early mucosal incision lateral to the Veru followed by early separation of the adenoma from the sphincter ring after identification of the plane of enucleation, this minimizes sphincter stretch.~Furthermore, more proximal incision of the 12 O`clock mucosal strip sparring a veil of mucosa covering the sphincter ring."
2865026|NCT03494049|Active Comparator|Standard HoLEP|Standard HoLEP TECHNIQUE as described by Elhilali et al 2010
2865027|NCT03494036|Experimental|Synbiotic|Synbiotic capsule containing 3x1.000.000.000 Colony Forming Units probiotics (Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, dan Bifidobacterium bifidum R0071 20%) and fructooligosaccharide 80 mg. The dosage is once daily and it is given for 60 days
2865028|NCT03494036|Placebo Comparator|Placebo|Placebo capsule containing saccharum lactis. The dosage is once daily and it is given for 60 days
2865029|NCT03494010||prospective cohort|Patients will be followed to determine the impact of the hybrid closed-loop (HCL) system that was prescribed at part of clinical care.
2865030|NCT03494010||historical controls|Medical record data of these patients, who did not use the HCL system, will be compared with patients in the HCL cohort.
2865031|NCT03493997|Experimental|Radiotherapy+Ialuril®+Ialuril Soft Gels®|Radiotherapy+Ialuril®+Ialuril Soft Gels®
2865032|NCT03493997|Active Comparator|Radiotherapy only|Radiotherapy only
2865033|NCT03493984|Experimental|Ginger exosomes|
2865034|NCT03493984|Experimental|Aloe exosomes|
2865035|NCT03493984|Experimental|Ginger and aloe exosomes|
2865036|NCT03493984|Placebo Comparator|Placebo|
2865037|NCT03493971|Active Comparator|Carotid artery stenting (CAS)|Carotid revascularization performed using CAS
2865038|NCT03493971|Active Comparator|Carotid endarterectomy (CEA)|Carotid revascularization performed using CEA
2865039|NCT03493958|Active Comparator|Education/control|Education/monitor only (insomnia education web-based program that participants access and read at their own pace contains no customization of program based on sleep diary responses). Participants in the control group are given educational information (like they might see on WebMD or National Sleep Foundation websites), but are left to apply it themselves.
2865040|NCT03493958|Experimental|Intervention Group|6 sessions modules of SHUTi intervention (at least one module completed while inpatient, the rest while outpatient): In SHUTi, customization is based on multiple variables, including sleep diary responses. The SHUTi program tailors specific recommendations based on sleep diary responses or other input within the program (e.g., responses on the Dysfunctional Beliefsand Attitude Scale trigger recommendations for specific cognitive restructuring strategies).
2865041|NCT03493945|Experimental|Arm 1.1|M7824 + ALT-803
2865042|NCT03493945|Experimental|Arm 2.1A|M7824 + BN-Brachyury
2865043|NCT03493945|Experimental|Arm 2.2A|M7824 + BN-Brachyury + ALT-803
2865044|NCT03493945|Experimental|Arm 2.3A|M7824 + BN-Brachyury + ALT-803 + Epacadostat
2865045|NCT03493945|Experimental|Arm 2.1B|M7824 + BN-Brachyury
2865046|NCT03493945|Experimental|Arm 2.2B|M7824 + BN-Brachyury + ALT-803
2865047|NCT03493945|Experimental|Arm 2.3B|M7824 + BN-Brachyury + ALT-803 + Epacadostat
2865048|NCT03493932|Experimental|1|Recurrent Glioblastoma patients
2865049|NCT03493919|Experimental|rMenB+OMV NZ Group|Approximately 510 healthy subjects vaccinated intramuscularly with Bexsero vaccine at Day 1 and Day 61 and have blood collected at Day -83, Day 8 and Day 98.
2865050|NCT03493919|Experimental|MenACWY 1 Group|Approximately 170 healthy subjects vaccinated intramuscularly with Menveo vaccine at Day 1 and have blood collected at Day -83, Day 8 and Day 151.
2865051|NCT03493919|Experimental|MenACWY 2 Group|Approximately 170 healthy subjects vaccinated intramuscularly with Menveo vaccine at Day 1 and have blood collected at Day -60, Day 31 and Day 151.
2865052|NCT03493919|Experimental|MenACWY 3 Group|Approximately 170 healthy subjects vaccinated intramuscularly with Menveo vaccine at Day 1 and have blood collected at Day -30, Day 61 and Day 151.
2865053|NCT03493906|Experimental|Intervention|Patient Ambassador Support
2865054|NCT03493893|Active Comparator|Affixus|To compare Affixus to PFNA and TFNA
2865055|NCT03493893|Active Comparator|PFNA|To compare PFNA to Affixus and TFNA
2865056|NCT03493893|Active Comparator|TFNA|To compare TFNA toPFNA and Affixus
2865057|NCT03493880||naCT|Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemotherapy.
2865058|NCT03493880||naCRT|Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemoradiotherapy.
2865059|NCT03493867|Other|Vitaliti|The subject's blood pressure will be simultaneously determined and recorded using the invasive arterial line blood pressure reading and the test Vitaliti device readings.
2865060|NCT03493854|Active Comparator|Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy|Participants will receive 8 cycles of investigator's choice of neoadjuvant chemotherapy. This will include either: 1) 4 cycles of dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks (Q2W) (given with granulocyte colony-stimulating factor [G-CSF] support as needed according to local guidelines) followed by paclitaxel Q1W for 12 weeks; or 2) 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab will be given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.
2865061|NCT03493854|Experimental|Arm B: FDC of Pertuzumab and Trastuzumab SC + Chemotherapy|Participants will receive 8 cycles of investigator's choice of neoadjuvant chemotherapy. This will include either: 1) 4 cycles of ddAC Q2W (given with G-CSF support as needed according to local guidelines) followed by paclitaxel once every week (QW) for 12 weeks; or 2) 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The fixed-dose combination (FDC) of pertuzumab and trastuzumab will be given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of the FDC of pertuzumab and trastuzumab SC for a total of 18 cycles.
2865062|NCT03493841|Experimental|Group A|Group A will receive racemic lipoic acid first and R-lipoic acid second
2865063|NCT03493841|Experimental|Group B|Group B will receive R- lipoic acid first and racemic lipoic acid second
2865064|NCT03493828|Active Comparator|TAP using Bupivacaine 0.5%|TAP using Bupivacaine 0.5%
2865067|NCT03493815|Experimental|Transabdominal Ultrasound Guided IUD Insertion|Comparing IUD insertion to traditional blind insertion
2865068|NCT03493815|Active Comparator|Traditional Blind IUD Insertion|Comparing IUD insertion to traditional blind insertion
2865069|NCT03493802||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
2865070|NCT03493802||Healthy individuals as controls|Age and gender-matched healthy controls
2865071|NCT03493789|Experimental|Diagnostic (FDG-PET, SBRT)|Participants receive fludeoxyglucose F-18 IV and after 60 minutes undergo positron emission tomography (PET) within 4 weeks of the first planned stereotactic body radiation therapy (SBRT) fraction, prior to the second planned fraction, and prior to the fifth planned fraction.
2865072|NCT03493776|Active Comparator|Pre-Transplant Group|VZV Subunit vaccine will be administered
2865073|NCT03493776|Experimental|Post-Transplant Group|VZV Subunit vaccine will be administered
2865074|NCT03493763||serum AFP negative HCC patients|"Patients who received liver resection within 3 months;~Hepatocellular carcinoma confirmed pathologically;~Serum alpha-fetoprotein level lower than 20ng/ml before hepatectomy."
2865075|NCT03493750|No Intervention|Healthplan guide alone|"Nurse applies the daily-practice questionnaire called Healthplan guide to screen and identify people with dental diseases, among those in vulnerable situation, and to sensitize them about the importance of oral hygiene and how to improve it.~After that, the nurse has to state if, from her/his point of view the patient needs dental care or not. Whatever the answer, the nurse makes an appointment to a dental practice, in the 30 following days, and gives it to the patient with a free bus ticket. Randomization is done at that time.~The dentist, blinded of the patient's group, makes a dental exam and says if the patient needs dental care or not.~If care are indicated, they will be organized but outside this trial."
2865076|NCT03493750|Experimental|Oral and dental evaluation|"After application of the Healthplan guide, nurse statement of the need of dental care or not, making of an appointment to the dental practice and gift of a free bus ticket, if the patient is randomized in the experimental group, the nurse completes the evaluation with a mouth inspection in order to count missing, coloured, injured teeth, and evaluate dental plaque, halitosis, inflammatory gums, mucosal injuries, low masticatory surface. At the end of this exam, the nurse has to state again if, from her/his point of view the patient needs dental care or not.~The dentist, blinded of the patient's group, makes a dental exam and says if the patient needs dental care or not.~If care are indicated, they will be organised but outside this trial."
2865077|NCT03493737||HaH (Hospital-at-Home)|Bortezomib is injected at Outpatient hospital at day 1 and at Home at further day of cycles
2865078|NCT03493737||OH (Outpatient Hospital)|Bortezomib is always injected at Outpatient hospital
2865079|NCT03493711||Breast Fed|Exclusively breastfed for first 3 months of life
2865080|NCT03493711||Milk-based fomula fed|Exclusively on Similac Advance Formula for at least 1 month prior to visit
2865081|NCT03493698|Experimental|Treatment A: Midazolam|All subjects will receive a single oral dose of 2 mg Midazolam on Day 1
2865082|NCT03493698|Experimental|Treatment B and C: Inarigivir|All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3, Day 6-18
2865083|NCT03493698|Experimental|Treatment D: Inarigivir with Midazolam|All subjects will receive a single oral dose of 400 mg Inarigivir coa administered with a single oral dose of 2 mg Midazolam on Day 19
2865084|NCT03493685|Experimental|sparsentan|Sparsentan will be administered as a single oral morning dose; an initial dose of 400 mg daily titrating up to a target dose of 800 mg, daily
2865085|NCT03493685|Active Comparator|irbesartan|Irbesartan will be administered as a single oral morning dose; an initial dose of 150 mg daily titrating up to a target dose of 300 mg, daily
2865086|NCT03493659|No Intervention|Sit-Sit|The participants will sit during the tutorials, and sit during the concept tests given to measure their learning.
2865087|NCT03493659|Active Comparator|Sit-Stand|The participants will sit during the tutorials. Intervention: Behavioral: Standing during Concept Test will be administered
2865088|NCT03493659|Active Comparator|Stand-Stand|The participants will stand during the tutorials, and stand during the concept tests given to measure their learning. Intervention: Behavioral: Standing during Concept Test and regular tutorial session will be administered.
2865089|NCT03493659|Active Comparator|Stand-Sit|"The participants will stand during the tutorials. Intervention: Behavioral: Standing during regular tutorial session will be administered.~However, participants will sit during the concept tests given to measure their learning."
2865090|NCT03493646|Active Comparator|Azacitidine|6 cycles of azacitidine (28 day cycle)
2865091|NCT03493646|Experimental|CC 486|6 cycles CC 486 (28 day cycle)
2865092|NCT03493633||EzyGain at Home|Setting up a walking device at home for people aged 60 years with partial walking disability regardless of etiology and pathology leading to walking disability.
2865093|NCT03493620|Experimental|Device arm|Gastric endosuturing will be performed until the entire gastric body is sutured in the form of a tube.
2865094|NCT03493620|Sham Comparator|Sham arm|Group II is a control group (only the endoscopist will know which group each patient belongs to)
2865095|NCT03493607|Experimental|AMO-01|Intravenous Infusion
2865096|NCT03493594|No Intervention|Control|"Control group will receive standard health care.~To improve the compliance of the subjects, both intervention group and control group can attend one vision development workshop at 2-month postpartum and two parenting workshops at 6- and 12-month postpartum."
2865097|NCT03493594|Experimental|Nutrition education program|"The intervention group will receive an early nutrition program for 12 months. Workshops format will be mainly in form of talks and experience sharing groups which run by lactation consultants, nutritionists / dietitians. All classes and workshops will be run for 4-6 times to cater for subjects recruited in different phases.~To improve the compliance of the subjects, both intervention group and control group can attend one vision development workshop at 2-month postpartum and two parenting workshops at 6- and 12-month postpartum."
2865098|NCT03493581|Experimental|NSCLC patients|
2865099|NCT03493568|Experimental|Genvoya 150Mg-150Mg-200Mg-10Mg Table|switch to the treatment Genvoya 150Mg-150Mg-200Mg-10Mg Table (1 pill every 24 hour)
2865100|NCT03493568|Active Comparator|Dolutegravir 50 mg plus one RTI (at label dose)|Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)
2865101|NCT03493555|Experimental|Intervention Development|Peer Health Navigator for PrEP
2865102|NCT03493542|Experimental|Chinese Girls Aged 9 to 19 Years|Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
2865103|NCT03493542|Active Comparator|Chinese Young Women Aged 20 to 26 Years|Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
2865104|NCT03493529||Normal Weight|BMI: Between 18.50 and 29.99 kg/m2
2865105|NCT03493529||Obesity Clas I|BMI between 30 and 34.99 Kg/m2
2865106|NCT03493529||Obesity Clas II|BMI between 35 and 39.99 Kg/m2
2865107|NCT03493529||Obesity Clas III|BMI> 40 Kg/m2
2865108|NCT03493503|Experimental|Salbutamol loading dose|Salbutamol loading dose of 15 mcg/kg in 10 minutes, with a maximum of 750 mcg.
2865109|NCT03493503|Placebo Comparator|Sodium Chloride 0.9%|10 ml of Sodium Chloride 0.9% in 10 minutes.
2865110|NCT03493490|Experimental|Neodolpasse|"In the Neodolpasse® arm patients receive two infusions over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.~Neodolpasse® Infusion Solution combines 75 mg (250 mL) of the NSAID diclofenac with 30 mg of the muscle-relaxant orphenadrine."
2865111|NCT03493490|Active Comparator|Diclofenac|"In the Diclofenac arm patients receive two infusions over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.~The Infusion solution contains 75 mg (250 mL) of the NSAID diclofenac."
2865112|NCT03493490|Placebo Comparator|Placebo|In the Placebo arm patients receive two physiologic saline infusion (250 mL) over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.
2865113|NCT03493477||Skeletal Class II Group|From the lateral cephalometric radiograph , Steiner analysis (ANB angle should be higher than mean value, mean value 3 ±2), Witt's appraisal should be higher than mean value (mean value zero), and McNamara analysis (A-B diff NV should be higher than mean value, mean value 4±2).At least two of the three mentioned analyses should verify skeletal class II relation
2865114|NCT03493477||Skeletal Class III Group|From the lateral cephalometric radiograph , Steiner analysis (ANB angle should be lower than mean value, mean value 3 ±2), Witt's appraisal should be lower than mean value (mean value zero), and McNamara analysis (A-B diff NV should be lower than mean value, mean value 4±2).At least two of the three mentioned analyses should verify skeletal class III relation
2865115|NCT03493464|Experimental|Treatment|Subjects will receive a single dose of BR55 at 0.03 mL/kg or 0.05 mL/kg.
2865116|NCT03493451|Experimental|NK/T cell lymphoma and with other mature T-cell neoplasms|"In this cohort, subjects will be treated with BGB A317 200 mg IV on Day 1 of each cycle.BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.~Cohort 1: Patients with relapsed or refractory extranodal NK/T cell lymphoma (nasal or non-nasal type)~Cohort 2: Patients with other mature T-cell neoplasms, limited to the following histologies: peripheral T-cell lymphoma-not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma, and anaplastic large cell lymphoma"
2865117|NCT03493438|Experimental|Relaxation Group|Patients performed Jacobson relaxation technique in supine position. Respiration control and various visual imaging techniques were used during the technique. Relaxation exercises were made within the supervision of a physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
2865118|NCT03493438|Experimental|Proprioceptive Neuromuscular Facilitation Group|Patients exercised with proprioceptive neuromuscular facilitation technique for trunk muscles using chopping and lifting patterns with ritmic initiation PNF exercises were made by the physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
2865119|NCT03493438|Experimental|Core stabilization group|Patients had core stabilization exercises that involved spinal mobility. The patients performed the drawing-in maneuver within various visual imaging techniques during all exercises, especially with respiratory control. Exercises were made within the supervision of a physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
2865120|NCT03493438|Other|control group|Patients in the control group were told the importance of a single session exercise
2865121|NCT03493425|Active Comparator|Arm A (surgery, IMRT, cisplatin, carboplatin)|Patients undergo standard of care surgery. Beginning 4-6 weeks after surgery, patients undergo image guided IMRT QD for 5 fractions per week for 30 fractions. Patients with positive margins/positive ECS in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin IV over 1-2 hours or carboplatin IV over 30 minutes (for patients who are ineligible to receive cisplatin) weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
2865122|NCT03493425|Experimental|Arm B (docetaxel, cisplatin, carboplatin, surgery, IMRT)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Patients who are ineligible to receive cisplatin receive carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery no later than 6 weeks following the last dose of chemotherapy. Beginning 4-6 weeks after surgery, patients undergo image guided IMRT QD for 5 fractions per week for 30 fractions. Patients with positive margins/positive ECS in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin IV or carboplatin IV weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
2865123|NCT03493412|Experimental|BH4-Placebo|Subjects will be tested on two different days, first day will be baseline and Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin) and second day will be Placebo. Testing will take place one-hour after BH4/placebo intake. There will be a 2-week washout between testing days.
2865124|NCT03493412|Experimental|Placebo-BH4|Subjects will be tested on two different days, first day will be baseline and placebo and second day will be Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin). Testing will take place one-hour after BH4/placebo intake. There will be a 2-week washout between testing days.
2865125|NCT03493399|Experimental|Problem Gamblers|Interference
2865126|NCT03493386|Experimental|Treatment Group A: Part 1|Subjects will be randomized to receive single dose of two tablets of 2 mg daprodustat in Period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat. There will be a wash-out period of 5 days between the Periods.
2865127|NCT03493386|Experimental|Treatment Group B: Part 1|Subjects will be randomized to receive single dose of 4 mg daprodustat in Period 1 and in Period 2 subjects will receive single dose of two tablets of 2 mg daprodustat. There will be a wash-out period of 5 days between the Periods.
2865128|NCT03493386|Experimental|Treatment Group C: Part 2|Subjects will be randomized to receive single dose of 4 mg daprodustat in fed state during Period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat in fasted state. There will be a wash-out period of 5 days between the Periods.
2865129|NCT03493386|Experimental|Treatment Group D: Part 2|Subjects will be randomized to receive single dose of 4 mg daprodustat in fasted state during period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat in fed state. There will be a wash-out period of 5 days between the Periods.
2865130|NCT03493373|Experimental|Exercise and nervous system mobilization|This group will receive neural mobilization and therapeutic exercise: two sessions of 60 minutes during 8 weeks.
2865131|NCT03493373|Experimental|Exercise|This group will receive therapeutic exercise: two sessions of 60 minutes during 8 weeks.
2865132|NCT03493360|Experimental|Visual feedback|Participants will be asked to perform movements of the low back while looking at a mirror for visual feedback.
2865133|NCT03493360|Active Comparator|No visual feedback|Participants will be asked to perform movements of the low back while the mirrors are covered and no visual feedback is provided.
2865134|NCT03493347|Experimental|Equine-assisted Occupational Therapy|All children will receive the Equine-assisted Occupational Therapy (EAOT) intervention, which includes occupational therapy administered in an equine environment. Common intervention activities include grooming, tacking, mounting, and riding the horse.
2865135|NCT03493334|Experimental|Visual feedback|Participants in this group will receive visual feedback of their neck when performing 10 repetitions of each of neck movements (flexion, extension, side-flexion and rotation).
2865136|NCT03493334|Active Comparator|No visual feedback|Participants in this group will perform 10 repetitions of each of neck movements (flexion, extension, side-flexion and rotation) without feedback.
2865137|NCT03493321|Experimental|PRF with MTA|PRF with MTA with PRF with Theracal as intervention
2865138|NCT03493308|Experimental|Pain neuroscience and exercise|Participants will received an 8 week intervention consisting of pain neuroscience education and exercise. Pain neuroscience education will be conducted in line with international guidelines, covering the neurophysiology of pain, transition from from acute to chronic pain and the nervous system ability to modulate the pain experience. exercise will include general exercise and dance.
2865139|NCT03493295||Levonogestrel IntraUterine System (LNG-IUS)|Women in childbearing age between 18 to 30 years old and who have freely chosen a LNG-IUS for contraception after being adequately counselled and informed of all contraceptive options by their physician at the routine clinical practice setting in Spain
2865140|NCT03493282|Active Comparator|Active Treatment- CT1812 100 mg|7 subjects randomized to 100 mg CT1812
2865141|NCT03493282|Active Comparator|Active Treatment- CT1812 300 mg|7 subjects randomized to 300 mg CT1812
2865142|NCT03493282|Placebo Comparator|Placebo|7 subjects randomized to matching placebo
2865143|NCT03493269|Experimental|BAY1834845|Part 1: 4 dose groups with ascending dose levels in healthy male subjects.
2865144|NCT03493269|Placebo Comparator|Matching Placebo|Part 1: Matching placebo in healthy male subjects.
2865145|NCT03493269|Experimental|High dose A of BAY1834845|Part 2: This dose level will be adminstered in female and male patients with RA or psoriasis
2865146|NCT03493269|Experimental|Low dose B of BAY1834845|Part 2: This dose level will be adminstered in female and male patients with RA or psoriasis
2865147|NCT03493269|Experimental|Placebo|Part 2: The placebo will be adminstered in female and male patients with RA or psoriasis
2865148|NCT03493256||type 2 neurological complications present|The group of patients diagnosed with postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.
2865149|NCT03493256||type 2 neurological complications absent|The group of patients without neurological complications.
2865150|NCT03493243||Adolescents exposed|Only clinical questionnaires
2865151|NCT03493230|Experimental|Patient with malignant melanoma|Patient with advanced or metastatic malignant melanoma (stage IIIB inoperable or IIIC or stage IV) will have a first blood test before any treatment, then at day 15 or 30 after initiation of therapy, and every two months until recurrence or progression for a maximum of 22 months.
2865152|NCT03493217|Experimental|ICP-022|Two regimens of ICP-022 (High and low dose QD) are designed for study Part I to determine RP2D. The RP2D determined will be used in Part II to further evaluate the preliminary efficacy of ICP-022 in Chinese subjects with R/R CLL/SLL.
2865153|NCT03493204|Experimental|Home-delivered, salt restricted|Meal description: salt-restricted (1500 mg to 2000 mg daily), > 2100 kilocalorie, high protein (>80 g daily) in addition to receiving standard pamphlet receipt
2865154|NCT03493204|Active Comparator|Dietary Advice|Standard of care, advice on salt-restriction using standard pamphlet receipt
2865155|NCT03493191|Experimental|0.5 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 0.5μg/kg SHR0410 (n=6) or placebo (n=2)
2865156|NCT03493191|Experimental|1 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 1μg/kg SHR0410 (n=6) or placebo (n=2)
2865157|NCT03493191|Experimental|2 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 2μg/kg SHR0410 (n=6) or placebo (n=2)
2865158|NCT03493191|Experimental|5 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 5μg/kg SHR0410 (n=6) or placebo (n=2)
2865159|NCT03493191|Experimental|10 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 10μg/kg SHR0410 (n=6) or placebo (n=2)
2865160|NCT03493191|Experimental|20 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 10μg/kg SHR0410 (n=6) or placebo (n=2)
2865161|NCT03493178||MCI|30 Subjects with MCI will receive N-acetylcysteine and glycine for 12-weeks. 30 subjects will received alanine for 12-weeks. All subjects will be studied at baseline prior to supplementation, after completing 12-weeks of supplementation, and 12-weeks after stopping supplementation (i.e. at 24-weeks). Supplements are only provided for first 12-weeks.
2865162|NCT03493139|Experimental|PAAC-R|Physical Activity Across the Curriculum-Remote (PAAC-R) will include protocol specific activity breaks delivered remotely via a television in the classroom.
2865163|NCT03493139|Experimental|PAAC-T|Physical Activity Across the Curriculum-Teacher (PAAC-T) will include protocol specific activity breaks delivered by the classroom teacher.
2882830|NCT03369912|Experimental|Active|CSJ148
2865164|NCT03493126|Experimental|Estradiol|Estrace: pea sized amount 2 times per week from week 1 postpartum to 3 months postpartum.
2865165|NCT03493126|Placebo Comparator|Placebo|Placebo: pea sized amount 2 times per week from week 1 postpartum to 3 months postpartum.
2865166|NCT03493100|Experimental|oral nutritional supplementation|This group receives optimized nutritional support, by ONS for a period of four weeks.
2865167|NCT03493100|Other|Control|The control group will receive treatment according to usual care.
2865168|NCT03493087|Active Comparator|Menakinon-7|Menakinon-7 360 µg tablet by mouth, every day for 6 weeks
2865169|NCT03493087|Active Comparator|Diet with vitamin K|Diet rich in vitamin K for 6 weeks
2865170|NCT03493061|Experimental|Systemic CPT-11 + HAI (FUDR+L-OHP)|"Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days:~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
2865171|NCT03493048|Experimental|Cetuximab Plus FOLFOXIRI|Cetuximab Plus FOLFOXIRI Patients will receive Cetuximab Plus FOLFOXIRI every 14 days: Cetuximab 500mg/m2 ivd over 90 minutes on Day 1; Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1; Irinotecan 130 mg/m2 ivd over 90 minutes on Day 1; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
2865172|NCT03493048|Active Comparator|Cetuximab Plus FOLFOX|Patients will receive Cetuximab Plus FOLFOX every 14 days: Cetuximab 500mg/m2 ivd over 90 minutes on Day 1; Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
2865173|NCT03493035||MCA group|Patients , who had midle cerebral artery aneurysm in screening CTA.
2865174|NCT03493035||non MCA group|Patients , who had no midle cerebral artery aneurysm in screening CTA.
2865175|NCT03493022|Experimental|Test Granola|50.5 g Test Granola
2865176|NCT03493022|Placebo Comparator|Control Granola|54.3 Control Granola
2865177|NCT03493009|Experimental|10mg Magnesium citrate|subjects will be required to follow a specific bowel preparation instruction consisting of dietary restrictions (no dried fruit, seeds or nuts) starting 5 days prior to the colonoscopy, an low residue diet at the day before the procedure, followed by a split dose of 10 mg of Magnesium citrate, followed by colonoscopy procedure with Pure-Vu System
2865178|NCT03493009|Experimental|15mg Magnesium citrate|subjects will be required to follow a specific bowel preparation instruction consisting of dietary restrictions (no dried fruit, seeds or nuts) starting 5 days prior to the colonoscopy, an low residue diet at the day before the procedure, followed by a split dose of 15 mg of Magnesium citrate, followed by colonoscopy procedure with Pure-Vu System
2865179|NCT03492996|Experimental|LCB01-0371 dose with a [14C]-LCB01-0371-tracer|A mass balance study to investigate the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose in healthy male subjects
2865180|NCT03492983|No Intervention|Control group|No intervention
2865181|NCT03492983|Experimental|Intervention group|Addition of 10 g/day of high cocoa content chocolate to the usual diet for six months
2865182|NCT03492970|Other|10 adult patients with SMS|Specify the evolution of the nycthemeral cycle of melatonin secretion in adult subjects carrying an SMS Behavioral characterization of adult subjects with SMS Make recommendations on the management of sleep / sleep rhythm disorders and behavior in adult subjects with SMS
2865183|NCT03492957|Experimental|Physical activity|A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change. There is no control group ion this feasibility study.
2865184|NCT03492944||Ultrasound Microbubble Contrast Agent|All subjects will receive intravenous Lumason microbubble contrast agent; there is no comparative ultrasound contrast agent. Contrast Enhanced Ultrasound findings/results will be correlated with comparable, clinically performed, CTE/MRE findings/results
2865185|NCT03492931|Experimental|Treatment arm|Single dose of ticagrelor based on age
2865186|NCT03492918|Experimental|pembrolizumab group|Drug:Pembrolizumab Dose/Potency:200 mg Dose Frequency:Q3W Route of Administration:IV infusion Regimen/Treatment Period:Day 1 of each 3 week cycle Use:Experimental
2865187|NCT03492905|Experimental|Internet-based CBT|Internet-based Cognitive Behaviour Therapy (iCBT)
2865188|NCT03492892|Experimental|Acupuncture|Use real acupuncture treatment for blood pressure management in patients with hypertension
2865189|NCT03492892|Sham Comparator|Sham Acupuncture|Use non-acupoint as the stimulating site in acupuncture for the treatment of hypertension
2865190|NCT03492879|Experimental|Biopsy: Routine tests & EIT Technology|The patients will undergo a routine liver biopsy and also routine liver Ultrasonography, Shear wave elastography and Electrical Impedance Technology (EIT).
2865191|NCT03492879|Experimental|Routine tests & EIT Technology|The patients will undergo a routine liver Ultrasonography, Shear wave elastography and Electrical Impedance Technology (EIT).
2865192|NCT03492879|Experimental|NASH : Routine tests & EIT Technology|The patients will undergo a routine liver Ultrasonography, Shear wave elastography and quantification of liver steatosis using the Electrical Impedance Technology (EIT).
2865193|NCT03492866|Active Comparator|Gentamicin Sulfate|All subjects will be treated with topical gentamycin applied twice daily (1 fingertip unit (FTU)) to the right half of the scalp. Total study period: 6 months.
2865194|NCT03492866|No Intervention|No treatment|The medication won't be applied to the left half of the scalp.
2865195|NCT03492853||patients with AMD|150 patients with age related macular degeneration more than 50 years old who will have retina photodocumented and genotyped for AMD SNP's
2865196|NCT03492853||control group|150 patients in control group without the clinical signs of the disease more than 50 years old who will have retina photodocumented and genotyped for AMD SNP's
2865290|NCT03492242||Adverse drug reaction induced by immune checkpoint inhibitors|Case reported in the World Health Organization (WHO) and the Base Nationale de PharmacoVigilance of patient treated by ICI, with a chronology compatible with the drug toxicity
2865197|NCT03492840|Experimental|RZL-012|"A single-time injection, multiple subcutaneous injections of RZL-012 administered into the subcutaneous fat.~Dercum's disease - dosing according to nodule size:~Nodule of 2-2.9cm - 2 injections (0.1 mL each); total of 10 mg RZL-012.~Nodules of 3-3.9cm - 3 injections (0.1 mL each); total of 15 mg RZL-012.~Nodules of 4-8cm - 4 injections (0.1 mL each); total of 20 mg RZL-012.~Lipedema -~2 subjects will receive 20mg RZL-012 in 4 injections in each leg adding up to 8 injections of 40mg RZL-012.~2 subjects will receive 30mg RZL-012 in 6 injections in each leg adding up to 12 injections of 60mg RZL-012.~2 subjects will receive 40mg RZL-012 in 8 injections in each leg adding up to 16 injections of 80mg RZL-012."
2865198|NCT03492827|Experimental|gargle group|drugs，chlorhexidine acetate gargle dosage，15ml，twice daily， duration，3days before ESD
2865199|NCT03492827|No Intervention|Control group|Control group will not be interventioned with gargle
2865200|NCT03492814|Experimental|Partial wound closure|3 sutures distal to second molar and leaving the vertical releasing incision open without any sutures.
2865201|NCT03492814|Active Comparator|Total wound closure|5 interrupted sutures with 2 sutures closing the vertical releasing incision and 3 sutures distal to second molar leading to a complete hermetic closure of the wound.
2865202|NCT03492801||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood samples at baseline and every 12 weeks for up to 6 times.
2865203|NCT03492788|Active Comparator|ECGI-optimized VV-offset|
2865204|NCT03492788|Placebo Comparator|Zero VV-offset|
2865205|NCT03492775|Active Comparator|Arm A:Obinutuzumab single agent|"Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1~If at least 'stable disease':~Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45"
2865206|NCT03492775|Active Comparator|Arm B:Obinutuzumab plus Bendamustine|"Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1 plus Bendamustine 70 mg/m2 iv d1+2 of each of four 28 -day cycles~If at least 'stable disease':~Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45"
2865207|NCT03492749||Group Busulfan|Patients submitted a Bone marrow transplantation with the busulfan chemotherapy in the conditioning. Saliva monitoring
2865208|NCT03492749||Group no busulfan|Patients submitted a Bone marrow transplantation without busulfan chemotherapy in the conditioning.Saliva monitoring
2865209|NCT03492736|Experimental|Melatonin|30 days 10mg Melatonin taken nightly 1 hour before bed
2865210|NCT03492736|Placebo Comparator|Placebo|30 days placebo taken nightly 1 hour before bed
2865211|NCT03492723|Experimental|garlic groupe|Concentrated Aged Garlic Extract Microcrystalline Cellulose 133 mg Carboxymethylcellulose Calcium 6 mg Agar Powder 35 mg Silicon Dioxide 3.5 mg Calcium Stearate 3.5 mg Total Weight 307 mg
2865212|NCT03492723|Placebo Comparator|placebo groupe|Microcrystalline Cellulose 258.55 mg Carboxymethylcellulose Calcium 6 mg Agar Powder 35 mg Coloring Agent 0.45 mg Details: Gardenia Extractive 44.5%, Corn Syrup 55% Potassium pyrophosphate 0.5% Silicon Dioxide 3.5 mg Calcium Stearate 3.5 mg Total Weight 307 mg
2865213|NCT03492710|Experimental|IGIV-SN|Immunoglobulin, Supplied in 5g (100mL) and/or 10g (200mL)
2865214|NCT03492697|Experimental|PF-06882961|
2865215|NCT03492671|Experimental|Chemotherapy and SBRT|"Pre-Operative Chemotherapy: Within 28 days of study enrollment, subjects will receive a combination of Gemcitabine and Nab-paclitaxel for a maximum of four 28-day cycles. Gemcitabine 1000 mg/m2 IV on Days 1,8,15. Nab-paclitaxel 125 mg/m2 on Days 1,8,15.~Post-Operative Chemotherapy: Within 5-10 weeks after surgery, subjects will receive a combination of Gemcitabine and Nab-paclitaxel for a maximum of two 28-day cycles. Gemcitabine 1000 mg/m2 IV on Days 1,8,15. Nab-paclitaxel 125 mg/m2 on Days 1,8,15.~Standard Stereotactic Body Radiation Therapy (SBRT) fractionation of 6 Gy per day will be used for all patients to a total dose of 30 Gy."
2865216|NCT03492658|Experimental|Combination therapy (MTX/abatacept)|Treatment with a combination of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) for another 6 months.
2865217|NCT03492658|Active Comparator|Methotrexate (MTX) monotherapy|Treatment with methotrexate monotherapy (10 - 25 mg once weekly) for 12 months.
2865218|NCT03492645|Active Comparator|Office Group|
2865219|NCT03492645|Experimental|Telephone Group|
2865220|NCT03492632||Women with Psoriasis|Reproductive age women newly diagnosed with psoriasis
2865221|NCT03492632||Women without Psoriasis|Reproductive age women without psoriasis to serve as control
2865222|NCT03492619|Active Comparator|Non-Intensive Intervention|Three short group sessions that promote healthy lifestyles
2865223|NCT03492619|Experimental|Intensive Intervention|a) Individual level: a six-month intervention comprised of 12 two-hour sessions, three follow-up monthly sessions, two workshops with the participants' household members and community members and one final session that will be graduation day; b) Household level: 2 workshops about co-responsibility in the household, and self-care and nutrition, including a theater performance. Six assignments with household members' participation; c) Community level: Distribution of 2 different educational materials (one about co-responsibility and another about self-care, including healthy nutrition) and carry out the 2 workshops mentioned above, both with household and community members.
2865224|NCT03492606||multiple sclerosis patients|
2865225|NCT03492593|Experimental|lycopene|A dose of lycopene (20 mg) is provided as part of an emulsified liquid meal (with or without 160 mg powdered ferrous sulfate). Samples from the upper digestive tract (gastric or duodenal) are aspirated over 4 hours, and blood collected over 7 hours. Blood plasma and chylomicron fractions isolated. The subject returns for 3 additional visits with 2 weeks between each visit. The same protocol is followed, with the subject receiving all combinations of meal (w/ and w/o iron) and upper digestive tract sampling (gastric or duodenal)
2865226|NCT03492593|Experimental|13C beta-carotene|A dose of 13C beta-carotene (20 mg) is provided as part of an emulsified liquid meal. Samples from the upper digestive tract (gastric or duodenal) are aspirated over 5 hours, blood collected over 7 hours, and urine collected over 7 hours. Blood plasma and chylomicron fractions isolated. The subject returns for 1 additional visit with a minimum of 4 weeks between each visit. The same protocol is followed, with sampling taken from the remaining upper digestive tract compartment (gastric or duodenal)
2865227|NCT03492593|Placebo Comparator|control|The same procedure is followed (as detailed in the experimental arms) but the subject receives an emulsified liquid meal without carotenoids or vitamin E.
2865291|NCT03492229|Experimental|tDCS+AMT|
2865228|NCT03492580||Cohort 1: Canagliflozin|A target cohort which includes new users of canagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. Truven Health MarketScan Commercial Claims and Encounters Database (CCAE) 2. Truven Health MarketScan Medicare Supplemental and Coordination of Benefits Database (MDCR) 3. Truven Health MarketScan Multi-state Medicaid Database (MDCD) 4. OptumInsight's de-identified Clinformatics Datamart, Extended-Date of Death (Optum).
2865229|NCT03492580||Cohort 2: Canagliflozin with Cardiovascular Disease (CVD)|A target cohort which includes new users of canagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2865230|NCT03492580||Cohort 3: Empagliflozin|A comparator cohort which includes new users of empagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2865231|NCT03492580||Cohort 4: Empagliflozin with CVD|A comparator cohort which includes new users of empagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2865232|NCT03492580||Cohort 5: Dapagliflozin|A comparator cohort which includes new users of dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2865233|NCT03492580||Cohort 6: Dapagliflozin with CVD|A comparator cohort which includes new users of dapagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2865234|NCT03492580||Cohort 7: Empagliflozin or Dapagliflozin|A target cohort which includes new users of empagliflozin or dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2865235|NCT03492580||Cohort 8: Empagliflozin or Dapagliflozin with CVD|A target cohort which includes new users of empagliflozin or dapagliflozin with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2865236|NCT03492580||Cohort 9: DPP-4 inhibitor (i)/ GLP-1 agonist (a)/ other AHA|A comparator cohort which includes new users of any dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonist, or other select antihyperglycemic agents (AHA) for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2865237|NCT03492580||Cohort 10: DPP-4 (i)/ GLP-1 (a)/ other AHA with CVD|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2865238|NCT03492580||Cohort 11: DPP-4 (i),GLP-1 (a),TZD, SU, insulin, other AHA|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, thiazolidinediones (TZD), sulfonylureas (SU), insulin, or other select AHA for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2865239|NCT03492580||Cohort 12: DPP-4(i), GLP-1(a), TZD, SU, insulin, AHA with CVD|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2865240|NCT03492567|Experimental|Blood monocyte precursors/osteoclasts|Blood test
2865241|NCT03492541|Experimental|SYSTANE Complete|Propylene glycol-based eye drops, 1 drop in each eye twice a day (BID) (morning and evening) for 28 days. Patients can administer additional doses in between the scheduled daily doses as needed
2865242|NCT03492528|Experimental|Cardiovascular patients treated for a cancer|
2865243|NCT03492515|Experimental|experimental group|Accepting the treatment of rhTPO according platelet and bleeding condition
2865244|NCT03492515|Active Comparator|non-administered group|No rhTPO will be used. If necessary, the patients will be given transfusion of platelets according to the their conditions.
2865245|NCT03492515|No Intervention|healthy control group|Healthy pregnant women and no use of any medicine。
2865246|NCT03492502|Experimental|Allo-SCT patients with GI related GVHD|"Allo-SCT patients above 18 years of age with acute steroid-resistant GI-related GVHD grade III-IV.~The diagnosis of GVHD will be made on clinical grounds (in line with the major associations' recommendations) - the appearance of characteristic mucoid diarrhea within 100 days after Allo-SCT, with or without associated skin/liver involvement. In cases of atypical presentation - we will recommend biopsy or endoscopy for diagnosis. Patients suspected to have Clostridium difficille associated diarrhea will be tested for toxin (CDT).~Steroid-resistant GI-related GVHD will be defined as lack of improvement (same stage) or worsening of GI symptoms after 7 days of steroid therapy (≥ 2 ml/kg of IV methylprednisolone)."
2865247|NCT03492476|Experimental|Circaid|Compression sleeve on the day associated with the night wearing of the system of contention circaid®
2865248|NCT03492476|Active Comparator|Reference treatment|Compression sleeve during the day associated with a possible treatment with it during the night, according to the recommendations of the HAS
2865249|NCT03492463|Active Comparator|Nicotine e-cigs + Nicotine patches|Participants will receive e-cigarettes containing nicotine and nicotine patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
2865250|NCT03492463|Active Comparator|Non-nicotine e-cigs + Nicotine patches|Participants will receive e-cigarettes not containing nicotine and nicotine patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
2865251|NCT03492463|Active Comparator|Nicotine e-cigs + Placebo patches|Participants will receive e-cigarettes containing nicotine and placebo patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
2865252|NCT03492463|Placebo Comparator|Non-nicotine e-cigs + Placebo patches|Participants will receive e-cigarettes not containing nicotine and placebo patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
2865253|NCT03492450|No Intervention|Control Group|All subjects continue participating in their normal daily and physical activities.
2865254|NCT03492450|Experimental|Treadmill training Group|16 sessions (2 sessions/week for 8 weeks) of treadmill training as recommended in a review on this subject (Langeskov-Christensen, 2015) aimed at the reduction/stabilization of gait and balance disturbances.
2865292|NCT03492229|Active Comparator|tDCS|
2865255|NCT03492437|Experimental|Dabigatran, Then Tepotinib followed by Dabigatran+Tepotinib|Dabigatran etexilate in treatment period 1 followed by tepotinib alone for 7 days and then tepotinib co-administered with Dabigatran in treatment period 2. Two treatment periods will be separated by a 3-day wash-out period.
2865256|NCT03492424||Focal therapy for prostate cancer|"All men >18 years of age undergoing focal therapy for primary or salvage treatment of prostate cancer will be included. Men who had received prior focal therapy are also eligible for inclusion.~The purpose of this study is collect observational data regarding patterns of care and outcomes of focal therapies for prostate cancer, including but not limited to: high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation, irreversible electroporation, photodynamic therapy, and brachytherapy."
2865257|NCT03492411|Experimental|eHealth Intervention|This group will receive information about an eHealth breastfeeding co-parenting resource. They will have a short demonstration of the site and will receive weekly emails for 6 weeks reminding them about the resource and their participation in the study.
2865258|NCT03492411|No Intervention|Usual Care|This group will not receive any intervention. They will receive emails for 6 weeks reminding them that they are in the study.
2865259|NCT03492398|Experimental|Cohort A HY209 0.05% gel|single dose of HY209 0.05% gel or single dose of placebo
2865260|NCT03492398|Experimental|Cohort A HY209 0.1% gel|single dose of HY209 0.1% gel or single dose of placebo
2865261|NCT03492398|Experimental|Cohort A HY209 0.3% gel|single dose of HY209 0.3% gel or single dose of placebo
2865262|NCT03492398|Experimental|Cohort A HY209 0.5% gel|single dose of HY209 0.5% gel or single dose of placebo
2865263|NCT03492398|Experimental|Cohort B HY209 0.05% gel|multiple dose of HY209 0.05% gel or multiple dose of placebo
2865264|NCT03492398|Experimental|Cohort B HY209 0.1% gel|multiple dose of HY209 0.1% gel or multiple dose of placebo
2865265|NCT03492398|Experimental|Cohort B HY209 0.3% gel|multiple dose of HY209 0.3% gel or multiple dose of placebo
2865266|NCT03492385|Experimental|1: 100 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
2865267|NCT03492385|Experimental|2: 300 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
2865268|NCT03492385|Experimental|3: 1000 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
2865269|NCT03492385|Experimental|4: 1000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride With Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
2865270|NCT03492385|Experimental|5: 3000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
2865271|NCT03492385|Experimental|6: 9000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
2865272|NCT03492385|Experimental|7: 18000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
2865273|NCT03492385|Experimental|8: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses
2865274|NCT03492385|Experimental|9: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre and Post-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses and 180 mg 24 hours post-dose
2865275|NCT03492385|Experimental|10: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre-Txt)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses
2865276|NCT03492372||Spine patients|Patients undergoing spine surgery where spinal tissue is discarded/removed will be recruited. Tissue samples will be used to look at normal and pathologic molecular signatures.
2865277|NCT03492359|Active Comparator|Normal Control|Participants with no diagnosis of respiratory disease between the ages of 0 and 80 whose breathing will be measured using Thora-3Di structured light plethysmography, body plethysmography and spirometry.
2865278|NCT03492359|Active Comparator|COPD Patients|Participants with chronic obstructive pulmonary disease between the ages of 0 and 80 whose breathing will be measured using Thora-3Di structured light plethysmography, body plethysmography and spirometry.
2865279|NCT03492346||LGMD2E Subject Population|"Individuals:~Confirmed LGMD2E diagnosis by genetic testing or~Suspected of having LGMD type 2E due to symptoms and a diagnosed family member or a member of a community with a large population of one of these two types"
2865280|NCT03492333|Experimental|Gluten free diet|Single arm
2865281|NCT03492307|Active Comparator|Standard Flow Protocol|Patients randomized to this arm will receive HFNC according to our current protocol with a maximum of 8L/min.
2865282|NCT03492307|Experimental|Weight-Based Flow Protocol|Patients randomized to this arm will receive HFNC according to a weight-based algorithm at 2L/kg/min.
2865283|NCT03492294||patients with disorders of consciousness|patients with disorders of consciousness from several brain injury have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state. These patients were scaned by functional magnetic resonance imaging.
2865284|NCT03492281|Experimental|Vibegron + Placebo to match Tolterodine|
2865285|NCT03492281|Placebo Comparator|Placebo to match vibegron + Placebo to match Tolterodine|
2865286|NCT03492281|Active Comparator|Tolterodine + Placebo to match vibegron|
2865287|NCT03492268|Experimental|BCMA-CART|autologous T cells transduced to express a human BCMA-targeting chimeric antigen receptor (CAR)
2865288|NCT03492255|Active Comparator|Eurolupus: Cyclophosphamide + Methylprednisolone + oral GC|The EUROLUPUS group will receive Cyclophosphamide (6 doses of 500 mg / fortnightly) + 3 doses of Methylprednisolone (750 mg) initial + oral glucocorticoid (GC) (prednisone) ≤ 30 mg/day with a gradual reduction of 5 mg/month (EUROLUPUS). From the 3rd month, the group will receive oral mycophenolate mofetil (MMF) (2-3 g) until 6 months with gradual reduction of GC from 5 mg/month until the minimum dose of 5 mg/month.
2865289|NCT03492255|Experimental|Cyclones Group: Cyclophosphamide+Methylprednisolone no oral GC|CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg / fortnightly) + Methylprednisolone [500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)] without oral glucocorticoid (GC). From the third month, the group will receive only oral MMF (2-3 g) until the 6th month. Patients using GC ≤ 20 mg/day may enter the protocol with immediate reduction to 15 mg/day with a reduction of 5mg/month until complete withdrawal.
2865295|NCT03492216|No Intervention|Control|All participants will receive brief alcohol and adherence counseling according to Uganda Ministry of Health guidelines.
2865296|NCT03492216|Experimental|Escalating incentives (EtG tests)|Escalating incentives for EtG negative urine test (Intervention: Incentives for negative EtG test).
2865297|NCT03492216|Experimental|Escalating incentives (IsoScreen tests)|Escalating incentives for IsoScreen positive urine tests (Intervention: Incentives for positive IsoScreen test).
2865298|NCT03492216|Experimental|Escalating incentives (EtG + IsoScreen)|Escalating incentives for EtG negative tests and for IsoScreen positive urine tests with the incentives rewarded separately (Interventions: Incentives for negative EtG test and Incentives for positive IsoScreen test).
2865299|NCT03492203|Experimental|Active Cognitive Remediation -Long-term|Participants in the long-term treatment will receive 24 weeks of active cognitive remediation. Participants will complete 24 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
2865300|NCT03492203|Active Comparator|Active Cognitive Remediation -Short-term|Participants in the short-term treatment will receive 12 weeks of active cognitive remediation (the standard length of time in the literature). Participants will complete 12 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
2865301|NCT03492203|Placebo Comparator|Cognitive Remediation Control|Participants in the comparison training group will login to the same training environment but the cognitive load will not adjust as it does in the experimental conditions. Participants in this group will complete 12 weeks of on-line computer exercises.
2865302|NCT03492190||adults|"Select the individual:~Healthy, non-pregnant adults 18-65 years of age, not taking any medication, including NSAIDs, not taking antibiotics within 4 weeks of study, BMI within 18-35 range and stable weight.~Exclusion criteria: children and elderly (over 65), pregnancy, diagnosed with non-communicable or communicable disease, being under restrictive diet, antibiotics within 4 weeks of study, medications within 4 weeks of study. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, adults will be eat the bean enrichment of deuterium for availability protein, collected urine, saliva and blood."
2865303|NCT03492190||Children|"Fifty children will be recruited from ages varying from 1 to 3 years and of both sexes. Children who use medications, who do not habitually consume beans, will be excluded and when there is no explicit written authorization from the parents or guardians.~All the children with different status of nutrition will be eaten the beans. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, children will be eat the bean enrichment of deuterium for availability protein, collected urine or saliva depend on the best biological samples of pilot study (adult)."
2865304|NCT03492190||Elderly|Fifty individuals of both sexes will be recruited, previously evaluated by complete clinical / laboratory examination and medical history. The elderly will be excluded from antiinflammatory, chemotherapeutic, corticoid, allergy and bean aversion or antibiotic therapy. These drugs could interfere with protein bioavailability. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, elderly will be eat the bean enrichment of deuterium for availability protein, collected urine or saliva depend on the best biological samples of pilot study (adult).
2865305|NCT03492177|Experimental|open label selexipag|The first dose of selexipag (Uptravi) will be administered in the evening of Day 1 and will be based on the body weight. Thereafter selexipag will be administered twice daily (morning and evening). Selexipag will be up-titrated during the first 12 weeks, with weekly increments equal to the starting dose until the subjects reach their individual maximum tolerated dose (iMTD) or until a maximum dose corresponding to their baseline weight category is achieved (which will be 8-fold of the corresponding starting dose). Up-titration is followed by a stable maintenance treatment period from Week 12 to Week 16, at the maximum tolerated dose. Thereafter, subjects will be treated with selexipag as long as the treatment is beneficial to the subject, as per investigator's decision
2865306|NCT03492138|Experimental|Participants with relapsed/refractory multiple myeloma|ONC201, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Run-in phase of ONC201 and dexamethasone weekly until progression at 4 weeks, lack of response at 8 weeks, or progression followed by the addition of weekly ixazomib.
2865307|NCT03492125|Experimental|low dose|MS-533
2865308|NCT03492125|Experimental|mid low dose|MS-533
2865309|NCT03492125|Experimental|mid high dose|MS-533
2865310|NCT03492125|Experimental|high dose|MS-533
2865311|NCT03492099|Experimental|Buprenorphine Arm|This is the main and only arm of the study. All patients in this arm will undergo the steps outlined in the protocol to convert to buprenorphine treatment.
2865312|NCT03492086|Experimental|Rosemary and alkylglycerol capsules|
2865313|NCT03492086|Placebo Comparator|Control capsules|
2865314|NCT03492073|Experimental|Emotional Supportive Mindfulness-based Program|"The program is based on 15/20 minutes sessions of meditative practices in which can participate only the patients, only his/her caregiver, or both.~Number of sessions is an independent outcome, because it depends on the number of days of hospitalization."
2865315|NCT03492073|Active Comparator|Emotional Supportive Program|"The program is based on 15/20 minutes sessions based on narrative therapy, in which the patient or his/her caregiver or both can talk about their emotions.~Number of sessions is an independent outcome, because it depends on the number of days of hospitalization."
2865316|NCT03492060||Individuals with a variant in the HNRNPH2 gene|
2865317|NCT03492047|Active Comparator|control|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks only
2865318|NCT03492047|Experimental|high dose N-acetyl cysteine|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and high dose N-acetylcysteine (1200 mg twice daily) for the paclitaxel treatment period
2865319|NCT03492047|Experimental|low dose N-acetyl cysteine|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and low dose N-acetylcysteine (600mg twice daily) for the paclitaxel treatment period.
2865320|NCT03492034|Active Comparator|IUD during CS|
2865321|NCT03492034|Active Comparator|IUD after puerperium|
2865322|NCT03492021|Experimental|Adequate Protein_Carbohydrate Post Therapy|Diet Intervention - Adequate Protein (1.0 g/kg/d) - Carbohydrate Post Therapy [AP-CPT]
2865726|NCT03489330||University of Michigan Hospital data|Inpatient intravenous vancomycin use
2865323|NCT03492021|Experimental|Optimal Protein_Protein Post Therapy|Diet Intervention - Optimal Protein (2.0 g/kg/d) - Protein Post Therapy [OP-PPT]
2865324|NCT03492008|Active Comparator|Conventional technique|Nasogastric tube
2865325|NCT03492008|Experimental|Contralateral cricothyroid pressure|Nasogastric tube
2865326|NCT03492008|Experimental|Ipsilateral head turning|Nasogastric tube
2865327|NCT03491995|Experimental|Quadruple therapy|Moxifloxacin, Nitazoxanide, Omeprazole sodium bicarbonate, Doxycyclin
2865328|NCT03491995|Active Comparator|Classic treatment|Omeprazole, clarithromycin, amoxicillin
2865329|NCT03491969|Experimental|Alpha-Lipoic Acid(α-LA)|Double blind treatment period consisted of treatment with CHF standard treatments, followed by α-LA 200 mg tid over a total duration of 24 months.
2865330|NCT03491969|Placebo Comparator|Placebo|Double blind treatment period consisted of treatment with CHF standard treatments, followed by Placebo 200 mg tid over a total duration of 24 months.
2865331|NCT03491956|Other|DFPP group|self contrast (before and after DFPP)
2865332|NCT03491943|Experimental|Midline group|Preprocedural ultrasound-assisted midline approach of spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
2865333|NCT03491943|Active Comparator|Paramedian group|Preprocedural ultrasound-assisted paramedian approach of spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
2865334|NCT03491930|Experimental|Interventional Cohort|"VA MOVE! Coach app: Weight loss using the VA MOVE! Coach weight loss app which presents positive feedback, education in nutrition and portion sizes, coping mechanisms, charts and graphs. App will be used for three months.~Telephone Coaching: Weekly phone coaching will provide further support and assist with problem solving and goal setting for a three month period.~Standard of care for weight loss (the 2013 AHA/ACC/TOS guidelines). Followed for three months.~Pre and post weight loss metabolic measurements will be obtained."
2865335|NCT03491930|Active Comparator|Control Cohort|"Standard of care for weight loss (2013 AHA/ACC/TOS guidelines). Followed for three months.~Pre and post weight loss metabolic measurements will be obtained."
2865336|NCT03491917|Experimental|DBT plus S-View|Breast images utilizing DBT plus S-View
2865337|NCT03491917|Active Comparator|FFDM alone|Breast images using FFDM alone only
2865338|NCT03491904|Experimental|Auto-injector (AI)|
2865339|NCT03491904|Experimental|Prefilled syringe (PFS)|
2865340|NCT03491878|Experimental|3D approach|Three dimensional laparoscopic cholecystectomy including segments IVB and V
2865341|NCT03491878|Active Comparator|open approach|Open cholecystectomy including segments IVB and V
2865342|NCT03491865|Experimental|REAL media Plus|Participants in this group will be assigned to use the REAL media Plus curriculum.
2865343|NCT03491865|No Intervention|programming as usual|Participants in this group will participate in their usual school curriculum. They will have the opportunity to use the REAL media Plus curriculum at the conclusion of the study.
2865344|NCT03491852|Experimental|BOOST Intervention|"The BOOST intervention consists of 8 group-based, weekly one-hour sessions. While every BOOST session is different, in general they will focus on helping participants fight back against stigmatizing thoughts and develop a sense of self-worth and empowerment. BOOST sessions are group-based and facilitated by trained clinicians, with the aid of a peer support worker to provide unique insights on living with and overcoming self-stigma. Content of sessions involve group discussions, exercises conducted in session, and between-session missions (i.e., home practice activities)."
2865345|NCT03491852|Active Comparator|Waitlist Controls|Participants on the waitlist will still receive treatment as usual, which includes medical, psychosocial, and occupational interventions to help maximize patients' integration within the community and support recovery from a first episode of psychosis. Frequency of contact largely depends on the individual needs of patients. Waitlist controls will be offered the BOOST intervention 3 months post-enrollment.
2865346|NCT03491826||ROM before 34 weeks (A)|premature rupture of membrane before 34 weeks
2865347|NCT03491826||ROM after 34 weeks (B)|premature rupture of membrane after 34 weeks
2865348|NCT03491800|Other|Question/Topic Prompt List|The Question/Topic Prompt List is provided to HF Patients and their family member (if applicable) for completion prior to being seen by the doctor.
2865349|NCT03491787||Ultrasound guidance|The ultrasound guidance was used to establish intraosseous access
2865350|NCT03491787||Not ultrasound guidance|The ultrasound guidance was not used to obtain intraosseous access
2865351|NCT03491774|Experimental|Montessori Intervention|Participants will receive Montessori intervention for three months,twice weekly sessions over the period of three months.
2865352|NCT03491761|Experimental|PRP Treatment|PRP is injected using 22 gauge needles through the classic approach (lateral midpatellar) in a sterile setting. The PRP is obtained from a maximum 16 cc sample of the patients' blood drawn at the time of treatment. Using sterile technique, the venous blood is transferred to a centrifuge and prepared by the centrifugation process for 5 minutes. 4-7 mL of PRP is transferred from the large outer syringe into the small inner syringe and injected within 30 minutes of being spun to negate the need of anticoagulants. The procedure will take approximately 20-30 minutes.
2865353|NCT03491761|Active Comparator|HA Treatment|HA is injected using 22 gauge needles through the classic approach (lateral midpatellar) in a sterile setting. Supartz® will be prepared according to the package insert.
2865354|NCT03491748|Experimental|Part A (SAD): Cohort 1, 100 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and pharmacokinetics (PK) of a single ascending dose (SAD) of oral ETX0282. Participants will be treated with a single oral dose of 100 milligrams (mg) ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
2865355|NCT03491748|Experimental|Part A (SAD): Cohort 2, 200 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
2865372|NCT03491683|Experimental|Cohort A: Unmethylated MGMT Promoter|Cohort A will include participants with a glioblastoma tumor with an unmethylated MGMT promoter. Participants will receive INO-5401 and INO-9012 and cemiplimab as well as radiation and temozolomide (TMZ; only during radiation therapy), if clinically indicated.
2865356|NCT03491748|Experimental|Part A (SAD): Cohort 3, 400 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 400 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
2865357|NCT03491748|Experimental|Part A (SAD): Cohort 4, 800 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 800 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
2865358|NCT03491748|Experimental|Part A (SAD): Cohort 5, 600 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 600 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
2865359|NCT03491748|Experimental|Part A (SAD): Cohort 6 (Elderly), 300 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Elderly participants (aged 65 years or older) will be treated with a single oral dose of 300 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
2865360|NCT03491748|Experimental|Part B (Food Effect): Cohort 7, 300 mg ETX0282/Placebo|Part B of the study will explore the effect of food on oral ETX0282. Participants will be treated with a single oral dose of 300 mg ETX0282 or placebo (Day 1) while fasted and with a single oral dose of 300 mg ETX0282 or placebo (Day 4) with a high-fat meal. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post fed state dose assessments (Day 7).
2865361|NCT03491748|Experimental|Part C (MAD): Cohort 8, 100 mg ETX0282/Placebo|Part C of the study will explore the safety, tolerability, and PK of multiple ascending doses (MAD) of oral ETX0282. Participants will be treated with a single oral dose of 100 mg ETX0282 or placebo on the morning of Day 1, and will then be dosed twice daily (BID) beginning on the morning of Day 2 (i.e., 24 hours after the Day 1 dose) through Day 7. Participants will be treated with a single oral dose of 100 mg ETX0282 or placebo on the morning of Day 8. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 8 dose assessments (Day 11).
2865362|NCT03491748|Experimental|Part C (MAD): Cohort 9, 200 mg ETX0282/Placebo|Part C of the study will explore the safety, tolerability, and PK of MAD of oral ETX0282. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 1, and will then be dosed BID beginning on the morning of Day 2 (i.e., 24 hours after the Day 1 dose) through Day 7. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 8. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 8 dose assessments (Day 11).
2865363|NCT03491748|Experimental|Part C (MAD): Cohort 10, 400 mg ETX0282/Placebo|Part C of the study will explore the safety, tolerability, and PK of MAD of oral ETX0282. Participants will be treated with a single oral dose of 400 mg ETX0282 or placebo on the morning of Day 1, and will then be dosed BID beginning on the morning of Day 2 (i.e., 24 hours after the Day 1 dose) through Day 7. Participants will be treated with a single oral dose of 400 mg ETX0282 or placebo on the morning of Day 8. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 8 dose assessments (Day 11).
2865364|NCT03491748|Experimental|Part C (MAD): Cohort 11, 600 mg ETX0282/Placebo|Part C of the study will explore the safety, tolerability, and PK of MAD of oral ETX0282. Participants will be treated with a single oral dose of 600 mg ETX0282 or placebo on the morning of Day 1, and will then be dosed BID beginning on the morning of Day 2 (i.e., 24 hours after the Day 1 dose) through Day 7. Participants will be treated with a single oral dose of 600 mg ETX0282 or placebo on the morning of Day 8. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 8 dose assessments (Day 11).
2865365|NCT03491748|Experimental|Part D: Cohort 12, ETX0282/Placebo plus Cefpodoxime Proxetil|Part D of the study will explore the safety, tolerability, and PK of oral ETX0282 when administered as a single oral dose in combination with cefpodoxime proxetil tablets to healthy participants in a fasted state. Participants will be treated with a single oral dose of 600 mg ETX0282 or placebo in a fasted state on Day 1, with a single oral dose of 400 mg cefpodoxime proxetil in a fasted state on Day 4, and with a single oral dose of 600 mg ETX0282 or placebo plus a single oral dose of 400 mg cefpodoxime proxetil dosed at the same time in a fasted state on Day 7. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 7 dose assessments (Day 10).
2865366|NCT03491748|Experimental|Part E: Cohort 13, ETX0282/Placebo plus Cefpodoxime Proxetil|This part of the study is to gain greater experience for a safety de-risking of regimen for Phase 2. A multiple-dose combination of ETX0282 and cefpodoxime proxetil tablets will be administered to healthy participants. Participants will be treated with an oral dose of 600 mg ETX0282 or placebo plus an oral dose of 400 mg cefpodoxime proxetil BID through Day 10, and once a day on Day 11. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 11 dose assessments (Day 14).
2865367|NCT03491735||Group A|Patients referred to glaucoma sub-specialty clinics in Kasr Al-Aini Hospital, Cairo University, Egypt in the year 2018
2865368|NCT03491735||Group B|Patients referred to glaucoma sub-specialty clinics in Sadguru Netra Chikitsalaya Postgraduate Institute of Ophthalmology, Mumbai, India in the year 2018
2865369|NCT03491709|Experimental|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection 250mg/m2 single administration
2865370|NCT03491709|Active Comparator|Cetuximab injection|Cetuximab,Erbitux 250mg/m2 single administration
2865371|NCT03491696|Experimental|Patients|It is an open label study, designed with 14 patients, men and women, from 18 to 60 years old, hospitalized for a characterized depressive episode (as defined by International Classification of Diseases version 10 criteria). They have to be refractory to an antidepressant treatment prescribed in primary care medicine and have a Dexamethasone Suppression Test (DTS) non-suppression status. All patients included will take the association of SSRI/SNRI and METYRAPONE for 28 days.
2865394|NCT03491553|Experimental|HBeAg-negative CHB, GS-9688 3 mg|Participants will remain on their current OAV and receive GS-9688 3 mg (2 x 1.5 mg tablet) for 24 doses. After the 24th dose, participants will continue on their current OAV therapy until the end of study (Week 48/ED).
2865373|NCT03491683|Experimental|Cohort B: Methylated MGMT Promoter|Cohort B will include participants with a glioblastoma tumor with a methylated MGMT promoter or with indeterminate MGMT status. Participants will receive INO-5401 and INO-9012 and cemiplimab as well as radiation and temozolomide (TMZ), if clinically indicated. Participants will continue to receive TMZ following radiation therapy, for up to six additional cycles, if clinically indicated.
2865374|NCT03491657|Experimental|virtual reality distraction (Yes VR)|In addition to their standard pain medications, patients will play a virtual realty game named SnowWorld during some portions of their burn wound cleaning procedure, on each study day.
2865375|NCT03491657|Active Comparator|music distraction (No VR condition)|In addition to their standard pain medications, patients will listen to music during comparable portions of their burn wound cleaning procedure, on each study day.
2865376|NCT03491644|Active Comparator|Liberal oxygen|"Liberal oxygen administration (to mimic current practice) for the first 24 hours without interruption.~In the trauma bay and during intrahospital transportation this implies administration of a FiO2 of 1.0 for intubated patients and an oxygen flow on a non-rebreather with reservoir of 15 l/min for non-intubated patients. In the operating room, patients will receive a FiO2 of ≥ 0.8 to obtain a saturation of ≥ 98%. Patients admitted to the ICU/PACU/floor will receive and FiO2 of ≥ 0.8 or more to obtain a saturation of ≥ 98% when intubated and for non-intubated patients a non-rebreather with reservoir will be set to 15 l/min."
2865377|NCT03491644|Experimental|Titrated oxygen|"Titrated oxygen administration for the first 24 hours without interruption. Lowest dosage of oxygen possible in order to achieve a saturation of at least 94%, either using mechanical ventilation (intubated patients), a nasal cannula, a non-rebreather or nothing.~A saturation above 94% shall not be aimed for using supplemental oxygen, and thus only patients without oxygen requirement shall have saturations above 94%.~The intervention will only be interrupted in case the saturation becomes unmeasurable - if this happens, the treating physician shall treat the patient as he/she judges best fit. As soon as the saturation is measurable again, the intervention will resume. The treating physician must document and explain the situation."
2865378|NCT03491631|Experimental|2 drugs combination group|
2865379|NCT03491631|Experimental|3 drugs combination group|
2865380|NCT03491618|Active Comparator|PARALLEL|Thick canulae (18 gauge) placed parallel to Medial Branch under fluoroscopy.
2865381|NCT03491618|Active Comparator|PERPENDICULAR|Thin canulae (22 gauge) placed perpendicular to Medial Branch under fluoroscopy.
2865382|NCT03491605||peripheral EBV-DNA load|subjects with high load (>1×103 copies/ml）of EBV-DNA copies in peripheral blood.
2865383|NCT03491592|Experimental|Enhanced Physical Activity Intervention|A data driven enhanced Pasos Hacia La Salud intervention based on results and participant feedback from the motivationally-tailored, Spanish Language, Internet-based Physical Activity intervention in the parent study.
2865384|NCT03491592|Active Comparator|Original Physical Activity Intervention|The original Internet-based program is a computer expert system-driven, individually tailored Spanish language intervention, guided by Social Cognitive Theory (SCT) and the Transtheoretical Model (TTM).
2865385|NCT03491579|Experimental|Dosis finding|Epacadostat is given for 2 cycles of 28 days at a dose according to the titration design together with standard chemotherapy (Cladribine and Cytarabine)
2865386|NCT03491566|Experimental|Clinic Pilates Group|Initial assessments of participants were made and they were taught key components of the Clinical Pilates exercises. Exercises were administered for 4 weeks, 3 days/week, 40-50 minutes/session under the supervision of a physiotherapist. Groups of 9-10 people with similar physical characteristics and fitness level for session times were created. The sessions were started with level 1 exercises requiring more support and less control. Each exercise was repeated 8-10 times; as the physical level of the participants increased, exercises progressed towards level 3 exercises requiring more attention, concentration and control. Each session consisted of an average of 10 minutes warm-up, 20 to 30 minutes of matt and 10 minutes cooling of of Clinical Pilates exercises.
2865387|NCT03491566|Experimental|Aerobic Exercise Group|"Initial assessments of participants were made before the first session. Using an elliptical bicycle or bicycle, or treadmill under the supervision of a physiotherapist, a total of 150 minutes moderate intensity (50-70% of maximal heart rate (HRmax)) aerobic exercise in accordance with the World Health Organization's guideline was applied, 3 days/week (50 mins/session) or 5 days/week (30 mins /session) for 8 weeks. The instruments to be used for the exercises were chosen according to the preference of the individual. HRmax was calculated using the Karvonen Formula (220-years). For example; at the age of 20 years, the target heart rate was determined as 100-140 beats/min for moderate physical activity in a person with HRmax 200 beats/min."
2865388|NCT03491566|Other|Control Group|"Initial assessments of participants were made before the study. Participants were recruited groups of 10 people and for once 30-minutes training session was organized covering topics such as What is physical activity, what are the effects of physical activity on health, factors that blocking physical activities and ways of overcoming obstacles, and recommending physical activity appropriate to their ages. Participants were requested to save activity log to track of their physical activity levels. However, no intervention was made to change their daily routines. The purpose of the given training was to motivate participants to increase their level of physical activity."
2865389|NCT03491553|Experimental|Hepatitis B e antigen (HBeAg)-positive CHB, Placebo|Participants will remain on their current OAV and receive placebo for 24 doses. After the 24th dose, participants will continue on their current OAV therapy until the end of study (Week 48/Early Discontinuation [ED]).
2865390|NCT03491553|Experimental|HBeAg-positive CHB, GS-9688 1.5 mg|Participants will remain on their current OAV and receive GS-9688 1.5 mg (1 x 1.5 mg tablet) plus placebo for 24 doses. After the 24th dose, participants will continue on their current OAV therapy until the end of study (Week 48/ED).
2865391|NCT03491553|Experimental|HBeAg-positive CHB, GS-9688 3 mg|Participants will remain on their current OAV and receive GS-9688 3 mg (2 x 1.5 mg tablet) for 24 doses. After the 24th dose, participants will continue on their current OAV therapy until the end of study (Week 48/ED).
2865392|NCT03491553|Experimental|HBeAg-negative CHB, Placebo|Participants will remain on their current OAV and receive placebo for 24 doses. After the 24th dose, participants will continue on their current OAV therapy until the end of study (Week 48/ED).
2865393|NCT03491553|Experimental|HBeAg-negative CHB, GS-9688 1.5 mg|Participants will remain on their current OAV and receive GS-9688 1.5 mg (1 x 1.5 mg tablet) plus placebo for 24 doses. After the 24th dose, participants will continue on their current OAV therapy until the end of study (Week 48/ED).
2865395|NCT03491540|Experimental|"1)  MBP and oral antibiotics  group"|Sennosides colonic preparation Oral Gentamycin Oral Ornidazole
2865396|NCT03491540|Placebo Comparator|"2)  MBP alone  group"|Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole
2865397|NCT03491527|Active Comparator|Conventional Resin Cement|Resin cement without MTA
2865398|NCT03491527|Active Comparator|MTA Resin Cement|Resin cement with MTA
2865399|NCT03491514|Experimental|Test Granola|51 g of Test Granola
2865400|NCT03491514|Placebo Comparator|Control Granola|54.1 Control Granola
2865401|NCT03491501||Industrial employees|Ergonomic evaluation using questionnaires in different Industrial settings will be conducted and thus Industrial employees form the included subject group.
2865402|NCT03491488|Experimental|Intervention Group|"300 children in the randomly selected crèche classrooms receiving the Brain Games intervention.~The Brain Games intervention we propose in this project is designed to complement and improve current government efforts. Given the importance of executive functioning skills and the high plasticity around age three, early programs like the ones proposed here may be the most effective tool to reduce socioeconomic and intergenerational disparities, and thus nicely complement current social protection policies."
2865403|NCT03491488|No Intervention|Control Group|300 children in the randomly selected creches classrooms receiving the regular Brazilian curriculum.
2865404|NCT03491475||Negative Ajmaline test|No appearance of a type 1 ECG during Ajmaline test
2865405|NCT03491475||Positive Ajmaline test|Appearance of a type 1 ECG during Ajmaline test
2865406|NCT03491462|Experimental|Arimoclomol|Arimoclomol, capsule
2865407|NCT03491462|Placebo Comparator|Placebo|Placebo oral capsule (matching to experimental Arm)
2865408|NCT03491449|Experimental|Group A: pressure ≥140 and ≤160mmHg|Intensive management of blood pressure, maintaining a systolic blood pressure ≥ 140 and ≤ 160 mm Hg for 72 hours.
2865409|NCT03491449|Active Comparator|Group B: Keep systolic pressure <185mmHg|Intensive management of blood pressure, maintaining systolic blood pressure <185 mm Hg for 72 hours.
2865410|NCT03491436|Experimental|Remote monitoring group|Women (at risk of) GDM will be included in this study. They receive a iHealth Align (a glucose monitor) and associated glycemiestrips. The app of iHealth will be downloaded on the pregnant women's Smartphone to collect the data and to send them to the researcher in the hospital.
2865411|NCT03491423|Experimental|Patients|
2865412|NCT03491410|Placebo Comparator|1|Arm 1: standard Unit´s protocol + placebo
2865413|NCT03491410|Experimental|B|Arm 2: standard Unit´s protocol + aspirin
2865414|NCT03491397|Experimental|GAE OA|Subjects will be treated with a genicular artery embolization (GAE) procedure performed with Embozene Microspheres. The microspheres will be delivered in a saline-contrast medium solution and will be delivered to the arteries supplying the areas of the subject's pain.
2865415|NCT03491371|Experimental|osteosarcoma|all patients had been given apatinib alone
2865416|NCT03491371|Experimental|Ewing sarcoma|Some of patients had been given apatinib alone while some of them had been given apatinib+everolimus
2865417|NCT03491371|Experimental|soft tissue sarcoma|Some of the patients had been given apatinib alone while some of the patients had been given apatinib together with GT chemotherapy, which was gemcitabine 1000 mg/m2 d1,8 and docetaxel 75 mg/m2 d8 once every 21 day.
2865418|NCT03491371|Experimental|Chondrosarcoma|Patients were given apatinib alone
2865419|NCT03491358|Active Comparator|Wright jet nebulizer|Will employ the Wright jet nebulizer for use in an allergen challenge triad
2865420|NCT03491358|Experimental|Solo vibrating mesh nebulizer|Will employ the Aerogen Solo vibrating mesh device for use in an allergen challenge triad
2865421|NCT03491345|Experimental|avelumab|
2865422|NCT03491332|Placebo Comparator|group C|general circuit group
2865423|NCT03491332|Active Comparator|group H|warm circuit group
2865424|NCT03491332|Experimental|group SH|new warm circuit group
2865425|NCT03491319|Placebo Comparator|Group C Control|spinal anaesthesia was given with table in neutral positon. Same position was maintained after spinal anaesthesia
2865426|NCT03491319|Active Comparator|Group X|spinal anaesthesia was given with table in neutral positon. 10 degree head low position was maintained for 10 minutes following spinal
2865427|NCT03491319|Active Comparator|Group Y|the table was put in 10 degree head low position before proceeding to give spinal anaesthesia. Head low position was maintained for 10 minutes following spinal
2865428|NCT03491306|Active Comparator|Group 1|patients will receive partial denture constructed from breflex material
2865429|NCT03491306|Experimental|Group 2|patients will receive partial denture constructed from PEEK material
2865430|NCT03491293|Active Comparator|Behavioral Weight Loss + Text chat|Internet delivery of a behavioral weight control program via text in a group format facilitated by an experienced registered dietitian. Participants will have access to study materials including behavioral weight loss lessons on the study's website. Participants will weigh themselves daily and report their weight privately (data will only be accessible by research personnel) on the study website.
2865431|NCT03491293|Experimental|Behavioral Weight Loss + Video chat|Internet delivery of a behavioral weight control program via video in a group format facilitated by an experienced registered dietitian. Participants will have access to study materials including behavioral weight loss lessons on the study's website. Participants will be given smart scales to weigh daily, and weight will be transmitted to a secure website accessible only by research personnel.
2865432|NCT03491280||Group 1|Subjects with unclear rare diseases, clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating location, genetic diagnostic (NGS diagnostic) must be performed.
2865433|NCT03491280||Group 2|Subjects with unclear rare diseases, genetic diagnostic (NGS diagnostic) is already performed.
2865434|NCT03491267|Experimental|Subjects with alopecia-- area treated|One area will be treated
2865435|NCT03491267|Experimental|Subjects with alopecia-- area un-treated|One area will be un-treated
2865436|NCT03491254||Group A/exposure group|Huaier Granule & biliary drainage
2865437|NCT03491254||Group B/non-exposure group|biliary drainage.
2865438|NCT03491241|Experimental|pre-diabetics obese patients|These pre-diabetic obese patients will be treated by hypocaloric diet therapy plus metformine.
2882831|NCT03369912|Placebo Comparator|Placebo|5% dextrose
2865439|NCT03491241|Placebo Comparator|pre-diabetics patients|These pre-diabetic patients will be treated by hypocaloric diet therapy alone.
2865440|NCT03491241|Active Comparator|obese patients|These obese patients will be treated by hypocaloric diet therapy.
2865441|NCT03491215|Experimental|Ruxolitinib|All patients will receive ruxolitinib in addition to corticosteroids +/-calcineurin inhibitor (CNI)
2865442|NCT03491202||atrial fibrillation|Patients with a diagnosis of atrial fibrillation will be eligible for enrollment
2865443|NCT03491189|Active Comparator|Lag screw fixation|Lag screw fixation
2865444|NCT03491189|Active Comparator|Helical Blade fixation|Helical Blade fixation
2865445|NCT03491176|Experimental|MRI and Biomarker Testing|
2865446|NCT03491163||Patients|Syndecan-1 concentration evaluation
2865447|NCT03491150|Experimental|Crenezumab|Participants will receive intravenous (IV) Crenezumab.
2865448|NCT03491124|Sham Comparator|Sham Treatment|Participants will continue to receive usual care from their primary care provider, which can include medications, physical therapy, biofeedback, and education according to DoD/VA guidelines for LBP management. Participants randomized to this arm will also receive a sham intervention, pointing a laser pointer to the ear without turning the laser on.
2865449|NCT03491124|Experimental|Auricular Acupuncture|Participants will continue to receive usual care from their primary care provider, which can include medications, physical therapy, biofeedback, and education according to DoD/VA guidelines for LBP management. Participants randomized to this arm will receive up to five ASP needles per ear placed in the predetermined BFA pattern. Needles are placed until the participant states pain is reduced 1/10.
2865450|NCT03491111|Experimental|IMT & EMT|Interventions: Respiratory muscle training for EMT+IMT. Respiratory muscle training for IMT (Inspiratory muscle training)+EMT (Expiratory muscle training). Respiratory muscle breathing training for patients with inspiratory muscle weakness and swallowing disturbance (MIP less than 70% of normal range).
2865451|NCT03491111|Active Comparator|Control group|Intervention: Non-training group, receive regular rehabilitation. All participants will receive usual rehabilitation care including body positioning instruction, postural correction, breathing control, cough maneuver, respiratory muscle stretch, chest wall mobility exercise and ventilation, fatigue management.
2865452|NCT03491111|Experimental|EMT group|Intervention: Respiratory muscle training for EMT. Respiratory muscle breathing training for swallowing disturbance. EMT for patients with swallowing disturbance will commence from 15% to 75% of threshold load of an individual's MEP.
2865453|NCT03491098|Placebo Comparator|momestone furoate spray first group: will be given|Nasonex spray one puff in each nostril daily for 8 weeks
2865454|NCT03491098|Placebo Comparator|prednisolone sodium phosphate 15mg second group: will be given|Predsol fort tablet three times per day for 1 week then gradual withdrawal over 2 weeks
2865455|NCT03491098|Placebo Comparator|hypertonic sea water solution spray third group: will be given|Nasal spray one puff in each nostril daily for 8 weeks
2865456|NCT03491085|Active Comparator|tonsillictomy with antibiotics|
2865457|NCT03491085|No Intervention|tonsillictomy Without Antibiotics|
2865458|NCT03491072|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Patients will receive IV fentanyl 1µg /Kg with the application of conventional TENS in which constant mode will be chosen. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
2865459|NCT03491072|Active Comparator|Fentanyl|Patients will receive IV fentanyl 1µg /Kg. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
2865460|NCT03491059|Experimental|Full Study - Radiation|
2865461|NCT03491059|No Intervention|Dress Rehearsal Only - No Radiation|
2865462|NCT03491046|Experimental|Patient population with ACL injury or reconstruction|
2865463|NCT03491046|Experimental|Patient population without ACL injury or reconstruction|
2865464|NCT03491033||advanced-stage ovarian cancer group|250 patients with pathologically confirmed epithelial ovarian cancer who received at least 1 cycle of NAC at Yonsei Cancer Hospital from 2006 to 2017.
2865465|NCT03491020||Respiratory syncytial virus (RSV)|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify RSV.
2865466|NCT03491020||Enteroviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify enterovirus.
2865467|NCT03491020||Adenoviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify adenovirus.
2865468|NCT03491020||Coronaviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify coronavirus.
2865469|NCT03491020||Metapneumoviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify metapneumovirus.
2865470|NCT03491020||Chlamydia pneumoniae|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify chlamydia pneumoniae.
2865471|NCT03491020||Mycoplasma|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify mycoplasma.
2865472|NCT03491020||Parainfluenza|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify parainfluenza.
2865473|NCT03491020||Neisseria meningitides|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify neisseria meningitides.
2865474|NCT03491020||Bordetella pertussis|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify bordetella pertussis.
2865871|NCT03488212|Experimental|Online Treatment; Monthly Lessons & Feedback for Maintenance|
2865475|NCT03491020||Rhinovirus|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify rhinovirus.
2865476|NCT03491007|No Intervention|Placebo|Subjects will receive a one-time oral dose of PBO prior to initial brain imaging followed by sustained administration of PBO for 6 weeks.
2865477|NCT03491007|Placebo Comparator|DHEA|Subjects will receive a one-time oral dose of DHEA prior to initial brain imaging followed by sustained administration of DHEA for 6 weeks.
2865478|NCT03490994|Experimental|Rivaroxaban|Rivaroxaban
2865479|NCT03490994|Active Comparator|Warfarin|warfarin + enoxaparin
2865480|NCT03490981|Other|TAU only|Primary care treatment as usual
2865481|NCT03490981|Experimental|TAU plus Brief CBT-CP|Primary care treatment as usual and Brief CBT-CP
2865482|NCT03490968|Other|Healthy Subjects|
2865483|NCT03490968|Experimental|Peripheral Artery Disease (PAD) with Supervised Exercise|Subjects will be referred for supervised exercise therapy. Subjects will have 3 visits per week for 12 weeks. Each visit will include a minimum of 30 to 40 minutes of exercise to improve ambulation with a certified trainer.
2865484|NCT03490968|Active Comparator|PAD with Leg Bypass Surgery|This group of patients are receiving leg bypass surgery as part of standard of care.
2865485|NCT03490955|Sham Comparator|Salad|Subjects will consume a vegetable salad without dressing one time in the morning.
2865486|NCT03490955|Active Comparator|Salad dressing|Subjects will consume a vegetable salad with dressing one time in the morning
2865487|NCT03490955|Active Comparator|black pepper|Subjects will consume a vegetable salad without dressing but with black pepper one time in the morning
2865488|NCT03490955|Active Comparator|Salad dressing and black pepper|Subjects will consume a vegetable salad with dressing and with black pepper one time in the morning
2865489|NCT03490942|Experimental|CSGI high infusion rate|Glucagon given as a continuous subcutaneous infusion for 28 days
2865490|NCT03490942|Experimental|CSGI low infusion rate|Glucagon given as a continuous subcutaneous infusion for 28 days
2865491|NCT03490942|Placebo Comparator|Placebo high infusion rate|Placebo given as a continuous subcutaneous infusion for 28 days
2865492|NCT03490942|Placebo Comparator|Placebo low infusion rate|Placebo given as a continuous subcutaneous infusion for 28 days
2865493|NCT03490929|Experimental|Contrast-enhanced ultrasound arm|contrast-enhanced ultrasound
2865494|NCT03490916|Experimental|Acetazolamide normal dose|One (1) dose of 250mg of Acetazolamide
2865495|NCT03490916|Placebo Comparator|Placebo|One (1) dose of placebo
2865496|NCT03490903|Experimental|VR with or without Moderate Sedation|"Patients randomized to receive a Virtual Reality Intervention will be fitted with a VR headset and headphones and undergo a continuous immersive meditation experience. This will begin immediately prior to the start of the procedure, and continue until the procedure is completed.~Patient pain and anxiety levels will be frequently assessed by procedure operator and circulating nurse, and pain medication or anxiolytic medications will be administered in the absence of contraindications. Baseline amounts of sedation pre-procedurally will not be used in either arm. Pain and Anxiety Scores will be assessed pre, intra, and post-procedurally. If no contraindications, the operator will decide upon how much sedation medication to administer if indicated or requested. This is the usual manner in which pain and anxiety is treated in the cath lab."
2865497|NCT03490903|Active Comparator|Moderate Sedation without VR|Subjects randomized to the comparison arm will not undergo the Virtual Reality Intervention. Baseline amounts of sedation pre-procedurally will not be used in either arm. Subjects will be assessed periodically by physicians and/or circulating nurses for their pain and anxiety levels. The patient may also prompt the staff that they are anxious or in pain, and if no contraindications, the operator will decide upon how much medication to administer. This is the usual manner in which pain and anxiety is treated in the cath lab.
2865498|NCT03490890|Experimental|Microwave ablation in the GGO|Patients with GGO were treated with microwave ablation.
2865499|NCT03490864|Experimental|Meal timing + Melatonin|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 14 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a 3mg melatonin supplementation given daily during the intervention.
2865500|NCT03490864|Experimental|Meal timing + Placebo|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 14 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also inc
2865501|NCT03490864|Experimental|Melatonin|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No extended overnight fasting will be imposed. This arm will include a 3mg melatonin supplementation given daily during the intervention.
2865502|NCT03490864|Placebo Comparator|Placebo|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No extended overnight fasting will be imposed. This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention
2865503|NCT03490851|Experimental|Oatmeal + OatWell28XF Intervention 1|2g β-glucan
2865504|NCT03490851|Experimental|Oatmeal + OatWell28XF Intervention 2|4g β-glucan
2865505|NCT03490851|Experimental|Oatmeal + OatWell28XF Intervention 3|4g β-glucan plus β-glucanase
2865506|NCT03490851|Placebo Comparator|Cream of Rice|27 grams of cream of rice
2865507|NCT03490838|Experimental|Phase I: Dose Escalation Cohort 1|3.70 GBq (100 mCi) x 3 times = 11.10 GBq
2865508|NCT03490838|Experimental|Phase I: Dose Escalation Cohort 2|7.40 GBq (200 mCi) x 3 times = 22.2 GBq
2865509|NCT03490838|Experimental|Phase I: Dose Escalation Cohort 3|9.25 GBq (250 mCi) x 3 times = 27.75 GBq
2865510|NCT03490838|Experimental|Phase II: Dose Expansion Cohort|Dose to be chosen from Phase I
2865511|NCT03490825|Experimental|Meal timing + Melatonin|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 14 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a 3mg melatonin supplementation given daily during the intervention.
2865541|NCT03490617|Active Comparator|Vaginal Misoprostol Group|Vaginal misoprostol (400 μg) 4 hours prior to IUD insertion
2865542|NCT03490617|Placebo Comparator|Placebo group|Vaginal placebo tablets 4 hours prior to IUD insertion
2865512|NCT03490825|Experimental|Meal timing + Placebo|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 14 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention.
2865513|NCT03490825|Experimental|Melatonin|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No overnight fasting period will be imposed. This arm will include a 3mg melatonin supplementation given daily during the intervention.
2865514|NCT03490825|Placebo Comparator|Placebo|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No overnight fasting period will be imposed. This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention.
2865515|NCT03490812|Experimental|Prospective population|
2865516|NCT03490812|Experimental|Retrospective population|
2865517|NCT03490786|Experimental|Dose escalation|Single arm dose escalation.
2865518|NCT03490760|Experimental|Durvalumab plus Radiation Therapy|Durvalumab 1500 mg (or 20 mg/m2 if <30 kg) IV every 4 weeks plus 24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
2865519|NCT03490747|Experimental|Co-developed referral scheme|A physical activity referral scheme co-developed by multidisciplinary stakeholders to incorporate behaviour change support and ensure pragmatic relevance and feasibility.
2865520|NCT03490747|Active Comparator|Usual care referral scheme|Comparative, usual care exercise referral scheme.
2865521|NCT03490747|No Intervention|No treatment control|Lifestyle advice leaflet only (provided to participants in all arms during baseline assessments).
2865522|NCT03490734|Active Comparator|Beverage A (Sweetened)|"One quarter of the group to receive black cherry and orange flavored beverage with added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
2865523|NCT03490734|Active Comparator|Beverage B (Sweetened)|"One quarter of the group to receive strawberry kiwi & lemonade flavored beverage with added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
2865524|NCT03490734|Active Comparator|Beverage A (Unsweetened)|"One quarter of the group to receive black cherry and orange flavored beverage no added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
2865525|NCT03490734|Active Comparator|Beverage B (Unsweetened)|"One quarter of the group to receive strawberry kiwi & lemonade flavored beverage no added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
2865526|NCT03490721|Experimental|Intervention|Clustering care for 20 minutes.
2865527|NCT03490721|No Intervention|Control|Standard care non clustered.
2865528|NCT03490708|Experimental|Tranilast|Subjects who were treated with tranilast
2865529|NCT03490695|Experimental|Practice Facilitation Group A|After the first 12 months of usual care (No Practice Facilitation), group A will begin to receive the Practice Facilitation (PF) Strategy at the CHPS compounds in addition to Ghana's National Health insurance and the World Health Organization (WHO) CVD Risk Assessment package.
2865530|NCT03490695|Experimental|Practice Facilitation Group B|"Group B will receive Usual Care (no PF) between 12-24 months which includes Ghana's National Health Insurance, behavioral counseling and referral to care through the usual care system.~After 24 months into the trial, Group B will then receive Practice Facilitation strategy in addition to Ghana's National Health insurance and the World Health Organization (WHO) CVD Risk Assessment package for a duration of another 12 months, as this is a stepped wedge design.~During this 12 months period, practice facilitation will end in the Group A arm."
2865531|NCT03490682|Active Comparator|Non-pregnant control|adult females aged less than 40 years, not currently pregnant, without significant medical history (American Society of Anesthesiologists ASA 1), fasting for at least 6 hours for solids and 1 hour for clear fluids.
2865532|NCT03490682|Active Comparator|Pregnant control|adult females aged less than 40 years, pregnant in the third trimester (gestation greater than 32 weeks on the day of the study) according to dates and the calculation of term established at the start of the pregnancy by an obstetrician, without significant medical history (American Society of Anesthesiologists ASA 1), fasting for at least 6 hours for solids and I hour for clear fluids.
2865533|NCT03490682|Experimental|Parturient|adult females aged less than 40 years, without significant medical history (American Society of Anesthesiologists ASA 1), in labour in the delivery suite, with a working epidural, having consumed solid food more than 6 hours before inclusion in the study and clear fluids more than 1 hour before inclusion in the study, and allowed to ingest solids during labour (cervical dilatation strictly less than 8cm) conforming to local protocols.
2865534|NCT03490669|Experimental|Dose Escalation|Multiple dose levels of MSC-1 treatment once every 3 weeks
2865535|NCT03490669|Experimental|Dose Expansion|MSC-1 treatment at the recommended Phase 2 dose once every 3 weeks
2865536|NCT03490656|Experimental|Healthy volunteer population|
2865537|NCT03490656|Experimental|Patient population|
2865538|NCT03490643|Other|TMD Group|people who has TMD
2865539|NCT03490643|Other|Control Group|individuals who dont have healthy temporomandibular joint
2865540|NCT03490630||All patients|Patients undergoing elective surgery with anesthesia
2883248|NCT03366818|Experimental|thrombectomy|thrombectomy by Versi system
2865543|NCT03490591|Experimental|Robotic-assisted intervention|In the Robotic-assisted intervention :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week)
2865544|NCT03490578|Experimental|Robot-assisted gait training|Robot-assisted gait training using an exoskeletal robot (Walkbot_S; P&S Mechanics Co. Ltd., Seoul, Korea)
2865545|NCT03490578|Active Comparator|Intensive treadmill training|Intensive treadmill training using an usual treadmill
2865546|NCT03490565|Active Comparator|EX group|Exercise training
2865547|NCT03490565|No Intervention|CON-group|Usual Care
2865548|NCT03490552|Sham Comparator|group A|include clots which have been extracted by mechanical thrombectomy and with definite stroke etiology and submitted to the RNA analysis in blinded coded label .
2865549|NCT03490552|Experimental|group B|include all clots which have been extracted by mechanical thrombectomy and with unknown stroke etiology and submitted to RNA analysis in cryptogenic label.
2865550|NCT03490539||azathioprine (AZT)|Patients with MG who are receiving azathioprine as part of routine clinical care
2865551|NCT03490539||mycophenolate mofetil (MMF)|Patients with MG who are receiving mycophenolate mofetil as part of routine clinical care
2865552|NCT03490526|Experimental|Root canal disinfection with XP-endo Finisher|
2865553|NCT03490526|Active Comparator|Root canal disinfection with passive ultrasonic irrigation|
2865554|NCT03490513|Placebo Comparator|Weight loss plus placebo|Participants will take a placebo every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and undergo supervised exercise training program.
2865555|NCT03490513|Experimental|Weight loss plus anastrozole|Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and undergo supervised exercise training program.
2865556|NCT03490500||S100B protein dosage|Biological
2865557|NCT03490487|Active Comparator|A antiepileptic|will receive conventional antiepileptic drugs only
2865558|NCT03490487|Experimental|B steroid|will receive oral steroid for 3 months beside conventional antiepileptic drugs
2865559|NCT03490487|Experimental|C diazepam|will receive oral diazepam for 3 months beside conventional antiepileptic drugs
2865560|NCT03490487|Experimental|D diazepam and oral steroid|will receive both oral diazepam and oral steroid for 3 months beside conventional antiepileptic drugs.
2865561|NCT03490474|Experimental|Pain Inducing Massage|Participants will receive manual pressure applied to one myofascial trigger point.
2865562|NCT03490474|Active Comparator|Pain Free Massage|Participants will receive light touch applied to one myofascial trigger point.
2865563|NCT03490474|Placebo Comparator|Coldpressor|Participants will place hand into water cooled to 6 degrees Celsius (males) or 8 degrees Celsius (females).
2865564|NCT03490461||Statin group|Statin therapy was defined as the administration of statins for more than 30 days after liver transplantation
2865565|NCT03490461||Non-statin group|the administration of statins for less than 30 days after liver transplantation
2865566|NCT03490448|Other|intervention group|aerobic exercise and appropriate caloric control
2865567|NCT03490435||Study participants|Both healthy and ailing individuals, both sex, including adults and children.
2865568|NCT03490422|Experimental|Pulpotomy|Pulpotomy is performed in carious-exposed pulp in mature permanent teeth
2865569|NCT03490409|Experimental|compression stocking|The intervention group will receive a thigh compression stocking, which is to be used for 24 hours a day for 14 days after surgery.
2865570|NCT03490409|No Intervention|Conventional treatment|The control group will receive conventional treatment, a compression bandage placed at the end of surgery and removed on the night of the surgery.
2865571|NCT03490396|Experimental|Arm 1 (Gelclair at time of conditioning)|All subjects in study Arm 1 will receive GEL starting on the first day of conditioning.
2865572|NCT03490396|Active Comparator|Arm 2 (Gelclair when OM diagnosed)|Subjects in Arm 2 will be observed from initiation of conditioning to Day +14. If subjects develop G1 or G2 OM via WHO OM scale during this period, they will at that time be randomized to immediately receive GEL.
2865573|NCT03490396|Active Comparator|Arm 3 (MMW when OM diagnosed)|Subjects in Arm 2 will be observed from initiation of conditioning to Day +14. If subjects develop G1 or G2 OM via WHO OM scale during this period, they will at that time be randomized to immediately receive MMW.
2865574|NCT03490383||patients without CBD calculi|patients without CBD calculi
2865575|NCT03490383||CBD calculi without ERCP history|patients with CBD calculi without ERCP history
2865576|NCT03490383||CBD calculi with ERCP history|patients with CBD calculi and ERCP history
2865577|NCT03490370|Experimental|Electronic Muscle Stimulation Activity|Electro-muscular stimulation using NeuroTrac MyoPlus 2/4. All participants taking part will be allocated to the Electronic Muscle Stimulation Activity (EMS) intervention from baseline for the duration of 12 weeks. There will be 6 EMS sessions of 35mins/per session each week.
2865578|NCT03490357|Active Comparator|Control - Transversus Abdominus Plane Block|Standardized ERAS regional nerve block
2865579|NCT03490357|Experimental|Quadratus Lumborum Block|Quadratus lumborum nerve block
2865580|NCT03490344|Experimental|Participants with Multiple Myeloma|Participants with MM with very good partial response (VGPR) or better after induction therapy with/without consolidative HDT/ASCT and MRD positive by bone marrow flow cytometry and MM participants who were previously MRD negative after induction and consolidation and recently (within last 3 months) turned MRD positive by bone marrow flow cytometry will be enrolled.
2865581|NCT03490331|Experimental|Genetically corrected cultured epidermal autograft|"The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate epidermal cells including stem cells. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where they will be corrected, expanded and prepared as final sheets to be implanted.~In the second surgery, genetically corrected cultured epidermal autograft (Hologene17) will be implanted into the selected area. The specialist surgeon will either use a local or general anaesthetic for the implant operation. The treated area will be immobilized for some days after this operation. Antibiotics and anti-inflammatory drugs will be administered (if necessary) to prevent infections and to minimise swelling."
2865582|NCT03490318||Patients with DMO and/or PDR|
2865583|NCT03490305||Combatants|Men 16-50 years old or combatants by own admission.
2865584|NCT03490305||Civilians|Children <16 years, all women and men ≥50 years.
2865585|NCT03490292|Experimental|Run-In Phase|"6 patients enrolled will receive weekly carboplatin (AUC2) and paclitaxel (50 mg/m2) [intravenous infusion on days 1, 8, 15, 22, & 29] while undergoing radiation therapy [23 fractions, M-F, estimated completion day 35].~Avelumab combined with Chemoradiation - Avelumab (10 mg/kg IV) every 2 weeks starting on the day of the last chemotherapy infusion (day 29). A total of 3 doses administered during the pre-operative period and an additional 6 doses of avelumab post-operatively.~Trial enrollment will be stopped after the first 6 patients are enrolled to fully assess the safety and tolerability of the treatment (up to the first post-operative clinic visit ~ 2-4 weeks after resection). If 2 or more patients experience dose limiting toxicities associated with the proposed treatments, further accrual of the subjects will be halted and trial will be suspended. Trial may be reopened in the future with appropriate schedule and dose modifications of the proposed treatment."
2865586|NCT03490292|Experimental|Expansion Cohort|Following a determination of safe and tolerable treatment outcome of the Run-In Phase, Part 2 of the trial will enroll 18 additional patients to evaluate activity of the proposed treatment and to obtain further safety information (carboplatin, paclitaxel, radiation & Avelumab combined with Chemoradiation).
2865587|NCT03490279|Experimental|A|Lactoferrin CRX 100 mg, capsule formulation, 2 tablets taken together once daily, on an empty stomach (before breakfast)
2865588|NCT03490279|Placebo Comparator|B|Placebo 100 mg, capsule formulation, 2 tablets taken together once daily, on an empty stomach (before breakfast)
2865589|NCT03490266|Active Comparator|Laparoscopic Repair|The abdomen will be entered and insufflated utilizing a 5 mm optical port. Only 5 mm ports will be utilized laterally to take down all anterior abdominal wall adhesions. A mid-density polypropylene mesh with a one-sided adhesion barrier that provides at least 5 cm of overlap in all directions will be inserted through a 11 or 12 mm port placed through the defect. Excision of hernia sac and preperitoneal fat and defect closure will be performed per current practice. The mesh will be secured in four points with 0-PDS sutures and/or tacked with a double crown of tacks per our current practice.
2865590|NCT03490266|Experimental|Robotic Repair|Three lateral ports will be placed including a 12 port for the camera. Adhesions will be taken down from the anterior abdominal wall. Hernia sac and preperitoneal fat will be excised per current practice and defect will be closed using a running locking barbed suture. A mid-density polypropylene mesh with a one-sided adhesion barrier that provides at least 5 cm of overlap in all directions will be inserted through the 12 mm port. The mesh will be secured circumferentially with a running barbed suture.
2865591|NCT03490253|Active Comparator|Static Messaging|Participants in this arm will receive educational and motivational messages about physical activity, depression, and diabetes, according to a prespecified content order.
2865592|NCT03490253|Experimental|Adaptive Messaging|Participants in this arm will receive the DIAMANTE intervention in which a machine learning algorithm will be adapting the motivational content they receive to try to optimize physical activity based on the message type.
2865593|NCT03490240|Experimental|BIPAMS|The behavioral intervention consists of two primary components, a dedicated Internet website and one-on-one video chats with a behavioral coach via Skype. The behavioral intervention focuses on the skills, techniques, resources, and strategies for becoming and staying physically active with MS, but it does not provide a prescription for exercise or physical activity itself.
2865594|NCT03490240|Active Comparator|WELLMS|The control condition provides an Internet website and one-on-one video chats that discuss materials about self-managing MS consequences and health indicators through methods other than physical activity.
2865595|NCT03490214|Experimental|Muscular Dystrophia|Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: Musculus brachioradialis
2865596|NCT03490214|Active Comparator|Healthy Volunteer|Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: Musculus brachioradialis
2865597|NCT03490201|Active Comparator|Randomized - Control|
2865598|NCT03490201|Active Comparator|Randomized - Treatment|
2865599|NCT03490201|Experimental|Non-randomized - Treatment|
2865600|NCT03490188|Experimental|Treatment Arm|Patients assigned to treatment arm will receive standard post-transplantation discharge care that includes weekly follow-up visits and 24-hour access to transplant triage call center. In addition, they will be matched with a mentor who will conduct 5 meetings with the patients (which includes one video chat meeting, 4 30-minute phone calls) and discuss the following topics related to post-discharge: Medications, Lab Work, Fluid Intake and Adherence to doctor's appointment
2865601|NCT03490188|No Intervention|Control Arm|Control arm recipient will receive standard post-transplantation discharge care that includes weekly follow-up visits and 24-hour access to transplant triage call center
2865602|NCT03490175||All patients|Patients undergoing general anesthesia for elective surgery
2865603|NCT03490162|Experimental|Food Effect|300 mg of DM1157 (2 capsules of 150 mg) orally with high fat diet, n=6, and matching placebo (2 capsules) orally with high fat diet, n=2
2865604|NCT03490162|Experimental|MAD 1|150 mg of DM1157 (1 capsule) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (1 capsule) orally daily for three days with 240 ml of water after an overnight fast, n=2
2865605|NCT03490162|Experimental|MAD 2|300 mg of DM1157 (2 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (2 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
2865606|NCT03490162|Experimental|MAD 3|600 mg of DM1157 (4 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (4 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
2865607|NCT03490162|Experimental|MAD 4|900 mg of DM1157 (6 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (6 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
2865608|NCT03490162|Experimental|SAD 1|9 mg of DM1157 (1 capsule) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (1 capsule) orally with 240 ml of water after an overnight fast, n=2
2865609|NCT03490162|Experimental|SAD 2|27 mg of DM1157 (3 capsules of 9 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (3 capsules) orally with 240 ml of water after an overnight fast, n=2
2865610|NCT03490162|Experimental|SAD 3|81 mg of DM1157 (9 capsules of 9 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (9 capsule) orally with 240 ml of water after an overnight fast, n=2
2865611|NCT03490162|Experimental|SAD 4|150 mg of DM1157 (1capsule) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (1 capsule) orally with 240 ml of water after an overnight fast, n=2
2865612|NCT03490162|Experimental|SAD 5|300 mg of DM1157 (2 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (2 capsules) orally with 240 ml of water after an overnight fast, n=2
2865613|NCT03490162|Experimental|SAD 6|600 mg of DM1157 (4 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (4 capsules) orally with 240 ml of water after an overnight fast, n=2
2865614|NCT03490162|Experimental|SAD 7|900 mg of DM1157 (6 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (6 capsules) orally with 240 ml of water after an overnight fast (n=2)
2865615|NCT03490149||ECT|
2865616|NCT03490149||Medication - Treatment as usual|
2865617|NCT03490149||Healthy controls|
2865618|NCT03490123|Experimental|Intervention|"Repeated total community treatment, TCT with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single dose every 6 months, for 12 months (3 doses).~Study interventions are:~R1-Total community treatment with azithromycin, R2-Total community treatment with azithromycin, R3-Total community treatment with azithromycin."
2865619|NCT03490123|Active Comparator|Control|"Single total community treatment, TCT, with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single, at month 0 (1 dose); followed by two total targeted treatment, TTT, with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single, at months 6 and 12.~Study interventions are:~R1-Total community treatment with azithromycin, R2-Total targeted treatment with azithromycin, R3-Total targeted treatment with azithromycin."
2865620|NCT03490110|Experimental|State regulation skill training|This arm utilizes a training system designed to strengthen cognitive-emotional state regulation skills. Trainees practice skills across a range of challenge contexts, and coaches guide learning for success in applying skills to challenges in personal life. Digital scenarios provide experiential learning opportunities, allowing Veterans to apply skills to tackle challenges that are calibrated to maximize learning. Coaches focus efforts on generalizing the skills to help trainees apply the skills in other life settings.
2865621|NCT03490110|Active Comparator|Treatment-as-usual|In this arm, participants receive clinical care as usual in VA clinics.
2865622|NCT03490097|Experimental|Group I|low dose of simvastatin10 mg plus sofosbuvir 400mg / daclatasvir 60 mg / ribavirin 1000 mg for patients<75kg and 1200mg for patients >75kg daily for 12 weeks.
2865623|NCT03490097|Active Comparator|Group II|sofosbuvir plus daclatasvir plus ribavirin
2865624|NCT03490084||Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
2865625|NCT03490084||Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
2865626|NCT03490058||Young women|Sexually active HIV-uninfected women between 16-25 years of age will be given Truvada.
2865627|NCT03490045|Experimental|Intervention Condition|Postpartum women and their infants will be randomly assigned to the treatment condition and receive a diaper incentive for their participation.
2865628|NCT03490045|Active Comparator|Comparison Condition|Postpartum women and their infants will be randomly assigned to the control condition and will be offered a gift card incentive for their participation but will not receive diapers.
2865629|NCT03490032|Experimental|Phase I|PK and dosimetry following single dose 3 MBq/kg
2865630|NCT03490032|Experimental|Phase II: Biochemically Recurrent Prostate Cancer|determine diagnostic effectiveness in this population
2865631|NCT03490032|Experimental|Phase II: Metastatic Prostate Cancer|determine diagnostic effectiveness in this population
2865632|NCT03490019|Experimental|Metformin Therapy|Metformin therapy once daily for 24 weeks with a dose of 500, 850 or 1000 mg depending on body weight
2865633|NCT03490006|Active Comparator|Paravertebral Block|For this arm, the initial level will be at T3-4 and an out-of-plane technique to guide the needle tip to a point between the costotransverse ligament and the parietal pleura between the visualized transverse processes. Then, a few milliliters of 0.5% ropivacaine will be injected slowly to displace the pleura ventrally as the paravertebral space fills with local anesthetic. After negative aspiration, the rest of 0.5% ropivacaine (total 10 ml) will be injected in 5 ml increments to further fill the paravertebral space. The procedure will then be repeated in the same exact fashion at the T5-6 level. We will observe local anesthetic spread under real-time ultrasound imaging.
2865634|NCT03490006|Experimental|Erector Spinae Plane Block|For this arm, the needle tip will be directed under ultrasound guidance using an in-plane technique towards the T5 transverse process until the needle tip contacts os. Then, a few milliliters of ropivacaine will be injected slowly to separate the plane between the erector spinae muscle and the transverse process. After negative aspiration, the rest of the 0.5% ropivacaine will be injected (total 20ml)
2865635|NCT03489993||FGF23-Related Hypophosphatemic Diseases|The diagnostic tests Ang II, Ang-(1-7), FGF23, and klotho will be measured in the cohort. Patients in the cohort will have the diseases X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets type 1 (ARHR1), autosomal recessive hypophosphatemic rickets type 2 (ARHR2), osteoglophonic dysplasia, Jansen-type metaphyseal chondrodysplasia, Raine syndrome, McCune-Alright syndrome, and epidermal nevus syndrome (ENS).
2865636|NCT03489980||Ambulatory consultation waiting room|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form before a medial consultation with hospital practitioner.
2865637|NCT03489980||Hemodialysis service|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form during hemodialysis.
2865638|NCT03489980||Day hospitalization service : psychiatry|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form during day hospitalization.
2865639|NCT03489967|Active Comparator|16g of carbohydrates - Glucose levels < 3.0 mmol/L|Hypoglycemia treatment with 16g of carbohydrates will be given when glucose levels are below 3.0 mmol/L.
2865724|NCT03489330||Northwestern Memorial Hospital data|Inpatient intravenous vancomycin use
2865640|NCT03489967|Active Comparator|16g of carbohydrates - Glucose levels 3.0-3.5 mmol/L|Hypoglycemia treatment with 16g of carbohydrates will be given when glucose levels are between 3.0 and 3.5 mmol/L.
2865641|NCT03489967|Active Comparator|32g of carbohydrates - Glucose levels < 3.0 mmol/L|Hypoglycemia treatment with 32g of carbohydrates will be given when glucose levels are below 3.0 mmol/L
2865642|NCT03489967|Active Comparator|32g of carbohydrates - Glucose levels 3.0-3.5 mmol/L|Hypoglycemia treatment with 32g of carbohydrates will be given when glucose levels are between 3.0 and 3.5 mmol/L.
2865643|NCT03489954||Non-specific chronic neck pain group|In evaluation of participants, endurance of deep cervical flexor muscles will be measured using stabilizer pressure biofeedback unit with cranio-cervical flexion test. Neck position sense of 6-direction (flexion, extension, right-left lateral flexion and right-left rotation) will be measured by CROM device (cervical range of motion device). Body balace will be measured by Balance Master System.
2865644|NCT03489954||Healthy group|In evaluation of participants, endurance of deep cervical flexor muscles will be measured using stabilizer pressure biofeedback unit with cranio-cervical flexion test. Neck position sense of 6-direction (flexion, extension, right-left lateral flexion and right-left rotation) will be measured by CROM device (cervical range of motion device). Body balace will be measured by Balance Master System.
2865645|NCT03489941|Experimental|EM-100|One drop of EM-100 in either the right or left eye once on Day 1.
2865646|NCT03489941|Experimental|Zaditor®|One drop of Zaditor® in either the right or left eye once on Day 1.
2865647|NCT03489941|Experimental|Vehicle|One drop of Vehicle in either the right or left eye once on Day 1.
2865648|NCT03489928|Experimental|Oral Misoprostol|50ug po q4h orally, as needed
2865649|NCT03489928|Experimental|Low dose vaginal misoprostol|25-50ug q6h, vaginally, as needed
2865650|NCT03489928|Experimental|Usual vaginal dinoprostone|1-2mg q6h, vaginally as needed
2865651|NCT03489915||Patients with macular edema due to RVO|assessment of visual acuity using Landolt chart and follow up of macular edema using OCT
2865652|NCT03489902|Experimental|Transobturator arm|Transobturator Paravaginal Repair
2865653|NCT03489902|Experimental|Transvaginal arm|traditional transvaginal Paravaginal Repair
2865654|NCT03489889|Experimental|capsule|pharmaceutical form: capsule ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months
2865655|NCT03489889|Experimental|tablet|pharmaceutical form: tablet ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months
2865656|NCT03489876|Experimental|Synthetic Cartilage Implant|Participants receive the synthetic cartilage implant. The synthetic cartilage implant that will be used is the Cartiva implant.
2865657|NCT03489876|Active Comparator|Osteochondral Autograft Transfer|Participants receive the current standard osteochondral autograft transfer procedure.
2865658|NCT03489863|Active Comparator|Prasugrel|Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).
2865659|NCT03489863|Active Comparator|Ticagrelor|Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).
2865660|NCT03489850|Active Comparator|Ibudilast|20mg BID Days 1-2 50mg BID Days 3-14
2865661|NCT03489850|Placebo Comparator|Placebo|Matched to active
2865662|NCT03489837|Experimental|Levotuss CR tab|oral taken
2865663|NCT03489837|Active Comparator|Levotuss syrup|oral taken
2865664|NCT03489824|Experimental|modified-WIM colonoscopy in RLP|Modified-water immersion method colonoscopy is performed to patients with right-lateral starting position (RLP). Patients will lie in the right lateral position with both hips and knees flexed at the beginning and change the position into supine and at last left-lateral position when it is needed.
2865665|NCT03489824|Active Comparator|modified-WIM colonoscopy in LLP|Modified-water immersion method (WIM) colonoscopy is performed to patients with left-lateral starting position (LLP). Patients will lie in the left lateral position with right hip and knee flexed and left leg straight at the beginning and change the position into supine and at last right lateral position when it is needed.
2865666|NCT03489811|Experimental|Test Essential Oil Blend|Participants in this arm receive the test essential oil inhaler to administer during the 4-week intervention.
2865667|NCT03489811|Active Comparator|Active Essential Oil Blend|Participants in this arm receive an active essential oil inhaler to administer during the 4-week intervention.
2865668|NCT03489811|Placebo Comparator|Control|Participants in this arm receive a control inhaler to administer during the 4-week intervention.
2865669|NCT03489798|Experimental|6 Misoprostol|Up to six doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
2865670|NCT03489798|Active Comparator|3 misoprostol|Up to 3 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
2865671|NCT03489785||Movement|If there is unexpected movement
2865672|NCT03489785||No movement|If there is no unexpected movement
2865673|NCT03489772|Experimental|1 mg ITI-214|Single dose
2865674|NCT03489772|Experimental|10 mg ITI-214|Single dose
2865675|NCT03489772|Placebo Comparator|Placebo|Single dose
2865676|NCT03489759|Experimental|ViE15-A|The patients were randomly allocated to two groups by using computer-generated numbers. The renal replacement therapy will be started using ViE15-A hemofilter
2865677|NCT03489759|Active Comparator|REXEED-15A|TThe patients were randomly allocated to two groups by using computer-generated numbers. The renal replacement therapy will be started using REXEED-15A
2865678|NCT03489746|Experimental|Inhaled corticosteroid withdrawal|Patients meeting the study criteria for withdrawal will have their ICS containing regime changed to a LABA/LAMA regime without ICS.
2865679|NCT03489746|Active Comparator|Standard care|Patients will continue on their current recommended regimen including ICS.
2865680|NCT03489733|Experimental|Intervention Group|
2865681|NCT03489733|Experimental|Control Group|
2865682|NCT03489733|No Intervention|Breast Fed Group|
2865683|NCT03489720|No Intervention|No Exercise Program|Anesthesia Residency Class 3 (CA-3)
2865684|NCT03489720|Experimental|Usual Exercise Program and Prescribed Exercise Program|Interns and Anesthesia Residency Classes 1 and 2
2883806|NCT03362853|Active Comparator|Moxifloxacin 400Mg Tablet|
2865685|NCT03489707|Experimental|Home-based human papillomavirus (HPV) DNA screening|Men randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.
2865686|NCT03489707|Active Comparator|Clinic-based human papillomavirus (HPV) DNA screening|Men randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.
2865687|NCT03489694||Subjects|Each subject will undergo skin test endpoint titrations with three different testers.
2865688|NCT03489681|Experimental|Acupuncture, low dosage|treat as six acupoints
2865689|NCT03489681|Experimental|Acupuncture, high dosage|treat as 18 acupoints
2865690|NCT03489681|No Intervention|Control group|no acupuncture treatment, healthy control
2865691|NCT03489668|Active Comparator|PCOS|Metformin administration 1500mg/day
2865692|NCT03489668|No Intervention|Control|
2865693|NCT03489655|Experimental|Maintenance Phase Intervention|Participants receive a phone-based Community Health Worker (CHW) intervention in addition to bi-monthly data collection calls with a research assistant.
2865694|NCT03489655|No Intervention|Maintenance Phase Control|Participants receive no further interventions, but have bi-monthly data collection calls with a research assistant.
2865695|NCT03489642|Experimental|COPD Telehealth Program|Participants will take part in a structured telehealth program for 12 weeks. Web-based educational tools will be made available to participants. Study participants will meet with a registered respiratory therapist two times per week.
2865696|NCT03489629|Experimental|Treatment|"Subjects are treated with one oral antibiotic, one topical antibiotic, an oral rinse, and instructed to use environmental decontamination techniques.~Trimethoprim Sulfamethoxazole (TMP/SMX) is the primary oral antibiotic to be used. Subjects with allergy or intolerance to TMP_SMX will use minocycline as an alternative antibiotic. Topical antibiotics are nasal Mupirocin, and the oral rinse/gurgle with 0.12% chlorhexidine gluconate."
2865697|NCT03489616|Experimental|Radiotherapy+chemotherapy+ rhGM-CSF|Patients with PR or SD after first-line chemotherapy will be treated with pemetrexed on d1 (500mg/m2) or other single agent on d1, d8. Local radiotherapy dose will be＞ 4Gy per time（or BED ＞45Gy） from day 2 to day 15 in a cycle of 21 days. Subcutaneous injection of rhGM-CSF (200ug/m² per day) will be executed 24 hours after chemotherapy. Repeat in the second metastatic lesions.
2865698|NCT03489616|Experimental|Single agent maintenance therapy|Maintenance treatment by single agent in a cycle of 21 days.
2865699|NCT03489590|Experimental|19F MRI with PFP|PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. Before and after the MRI is complete, participants will perform spirometry maneuvers in a room outside of the magnet.
2865700|NCT03489564||Active|Physically active will be defined by self-report and confirmed by step counts >8,000 per day from activity monitoring.
2865701|NCT03489564||Sedentary|Sedentary lifestyle will be defined by self-report and confirmed by step counts <5,000 per day from activity monitoring.
2865702|NCT03489551|Experimental|Oral Haldol in patients undergoing HSCT|Prior to stem cell transplant participants will receive 5mg of liquid or pill form, oral Haldol. Every other day visits will take place following the first administration of the study drug until 14 days after the transplant.
2865703|NCT03489538||RYGB Patients|Laparoscopic long limb roux-en-Y gastric bypass group. All consecutive patients eligible for bariatric surgery.
2865704|NCT03489525|Experimental|Dose Escalation, MEDI2228, ADC|Single agent MEDI2228, ADC (antibody drug conjugate) will be administered to adult subjects with relapsed/refractory (R/R) multiple myeloma (MM).
2865705|NCT03489525|Experimental|Dose Expansion, MEDI2228, ADC|Single agent MEDI2228, ADC (antibody drug conjugate) will be administered to adult subjects with R/R MM in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
2865706|NCT03489512|Experimental|A (Chloraprep)|2% chlorhexidine gluconate with 70% isopropyl alcohol with a sterile 3ml single dose applicator. Use for the preparation of the skin before insertion of the central venous catheters and at each dressing change.
2865707|NCT03489512|Active Comparator|B (Clorhexidine 2%)|2% aqueous base chlorhexidine (10 ml single dose containers). Use for the preparation of the skin before insertion of the central venous catheters and at each dressing change.
2865708|NCT03489499||All patients|Patients undergoing elective surgery with anesthesia
2865709|NCT03489460|Active Comparator|Receive sleep health messages + GAD|Procedures will be delivered to users of the GAD, individuals who have opted in via their smartphone application, to receive messages about various areas of health.
2865710|NCT03489460|Active Comparator|Sleep message No GAD|For two weeks participants agree to receive sleep health messages and wear the GAD
2865711|NCT03489447||Sepsis group|All adult (>= 18 years) patients with a diagnosis of sepsis included in the Swedish ICU Registry between 2008-01-01 and 2016-10-18
2865712|NCT03489447||Non-sepsis group|All adult (>=18 years) patients without a diagnosis of sepsis included in the Swedish ICU Registry between 2008-01-01 and 2016-10-18
2865713|NCT03489434|Experimental|Intervention Group|Preliminary prevention program component content is based on evidence-based prevention programs and will integrate prevention content for substance use, sexual assault, and sexual risk behaviors.
2865714|NCT03489434|No Intervention|Control|Assessment only control.
2865715|NCT03489421||HIV Infected|
2865716|NCT03489421||Un-infected controls|Controls without HIV from a historical pre-approved-IRB-protocol database
2865717|NCT03489395|Experimental|Edoxaban|Used for Treatment. All patients will receive edoxaban 60 mg once a day, with open-label design, for 4 weeks. Edoxaban daily dose will be reduced to 30 mg/day in case of: body weight ≤60 kg, or concomitant therapy with verapamil/quinidine/dronedarone.
2865718|NCT03489382|No Intervention|Control|Emergency Departments providing usual care, which includes assessment in hospital followed by placement on a wait list for psychiatric services and access to regional community resources for suicide prevention.
2865719|NCT03489382|Experimental|Smartphone Assisted PST|Emergency Departments providing the option to refer men who self-harm to a service that will deliver smartphone-assisted problem solving therapy.
2865720|NCT03489369|Experimental|Sym022|Sym022 will be administered at up to 4 planned dose levels.
2865721|NCT03489356|Experimental|Intervention|Addressing Behavior Change (ABC) intervention delivery method
2865722|NCT03489356|No Intervention|Control|Control
2865723|NCT03489343|Experimental|Sym023|Sym023 will be administered at up to 7 planned dose levels.
2865727|NCT03489317||No metabolic syndrome|Participants who do not fulfill any of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
2865728|NCT03489317||Metabolic syndrome- partial|Participants who fulfill one or two of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
2865729|NCT03489317||Metabolic syndrome- full|Participants who fulfill three or more of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
2865730|NCT03489304|Other|Zaleplon|Open-label zaleplon 5-10mg daily
2865731|NCT03489291|Experimental|Single infusion of AMT-061|Subjects will receive a single infusion of AAV5-hFIXco-Padua (AMT- 061) at baseline. After IMP administration (post IMP), subjects will be monitored for tolerance to the IMP and detection of potential immediate AEs at the clinical trial site for 24 hours (overnight stay).
2865732|NCT03489278||Affected|Affected with ALS or a related disorder.
2865733|NCT03489265|Other|Eluxadoline followed by Placebo|Following a 2-week run-in period, patients will receive Eluxadoline 100 mg twice daily for 4 weeks then placebo tablets taken twice daily for 4 weeks followed by a 2-week follow-up period during which placebo will be administered twice daily.
2865734|NCT03489265|Other|Placebo followed by Eluxadoline|Following a 2-week run-in period, patients will receive placebo twice daily for 4 weeks then Eluxadoline 100 mg twice daily for 4 weeks followed by a 2-week follow-up period during which placebo will be administered twice daily.
2865735|NCT03489252|Experimental|Device Feasibility (Fitbit Charge 2)|Participants wear the Fitbit Charge 2 device from the time of CT simulation for RT planning throughout the entire RT course.
2865736|NCT03489239|Experimental|Single Arm|SingleArm: TAF 25 mg
2865737|NCT03489226|Active Comparator|Capsimax 2 mg|single dose with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
2865738|NCT03489226|Placebo Comparator|Placebo|single dose with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
2865739|NCT03489226|Active Comparator|Capsimax 4 mg plus 250 kcal meal|single dose with 250 kcal meal with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
2865740|NCT03489226|Placebo Comparator|Placebo plus 250 kcal meal|single dose with 250 kcal meal with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
2865741|NCT03489213|Active Comparator|Arm I (DGA/AICR)|Patients receive DGA/AICR-based dietary intervention for 6 months consisting of 12 education sessions (60 minutes each) every other week. Lectures will take place in an urban garden where fruit, vegetable, and herb harvesting 1-2 times per week is encouraged. All participants will be given a FitBit and regular physical activity will be encouraged. Finally, remote health coaching is offered to all study subjects for the duration of the intervention (12 weeks).
2865742|NCT03489213|Experimental|Arm II (DGA/AICR plus Beef)|Patients receive the same intervention as in Arm I with the addition of 18 ounces of lean beef provided by the study to each subject. Subjects will be encouraged to consume the lean beef and lectures will incorporate healthy beef consumption into each lesson and cooking demonstration.
2865743|NCT03489200|Experimental|EH301|
2865744|NCT03489200|Placebo Comparator|Placebo|
2865745|NCT03489187||VTTS as standard of care|VTTS as standard of care.
2865746|NCT03489174|Experimental|Monthly Pregnancy Screening|Patients at the Hamilton Clinic present to the clinic most often on a weekly basis to provide a urine sample for urine drug screening and to meet with their MRP. This same urine sample will be tested for pregnancy in the intervention group once per month. Resulting positive test results will be reported to the patient through their attending physician on the day of testing.
2865747|NCT03489174|Active Comparator|Usual Care|Participants in the control group will not receive study-initiated urine pregnancy testing but will receive usual care, which may include pregnancy testing based on patient request or clinical judgement.
2865748|NCT03489161|Experimental|Buprenorphine|Buprenorphine administered in the emergency room after patients presenting to the emergency department (ED) due to opioid OD who have been treated with opioid antagonist (naloxone) and are stable and alert.
2865749|NCT03489148|Experimental|Tamarkoz®|A Sufi method to focus, called Tamarkoz®. Participants had met in class twice a week for two and a half hours total for three months. One day of the week, they met for theoretical teachings of Sufism, and for the second day in the week they met with a Tamarkoz® instructor to learn meditation techniques.
2865750|NCT03489148|Active Comparator|Stress Management Resources|The self-care stress management group used the campus resources such as counseling, health-coaching, health and wellness groups, use of an automated massage chair, and online reading materials for stress management as needed for themselves.
2865751|NCT03489148|No Intervention|Waitlist|The waitlist control group did not receive Tamarkoz® and did not use the stress management resources on campus for the duration of the study.
2865752|NCT03489122|Experimental|Iyengar yoga and coherent breathing|The yoga intervention consists of Iyengar yoga method and coherent breathing sessions for 90 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
2865753|NCT03489122|Active Comparator|Walking|The walking intervention consists of walking sessions at 2.5 miles an hour on a flat surface for 60 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
2865754|NCT03489109|Experimental|1|Intermittent Caloric Restriction
2865755|NCT03489109|Active Comparator|2|Standard of care dietary and healthy lifestyle counseling
2865756|NCT03489096|Experimental|Cryoballoon Ablation|Cryoballoon Ablation: PVI + substrate modification. Left atrial fibrosis ablation in addition to standard pulmonary vein isolation in patients with paroxysmal and persistent atrial fibrillation. Ablation will be performed utilizing the Medtronic Arctic Front Advance Cryoballoon catheter.
2865757|NCT03489083|Experimental|Trained Group|Subjects performing strength training three times per week for twelve weeks.
2865758|NCT03489083|Placebo Comparator|No Training Group|"Subjects performing placebo stretching/relaxing session once a week (for adherence purposes) for twelve weeks."
2865759|NCT03489070|Active Comparator|Traumastem®|Oxidized nonregenerated cellulose hemostatic agents.Traumastem® absorbable patches, applied topically, once, intraoperatively to stop bleeding.The patches are used on the wound surface of the liver.
2865832|NCT03488524|Experimental|AMX0035|AMX0035 twice daily--a combination therapeutic including 3 gram of Phenylbutyrate and 1g TUDCA
2865760|NCT03489070|Active Comparator|Surgicel®|Oxidized regenerated cellulose hemostatic agents.Surgicle® absorbable patches, applied topically, once, intraoperatively to stop bleeding.The patches are used on the wound surface of the liver.
2865761|NCT03489057|Experimental|PERC Program|Prostate Cancer Education and Resources for Couples (PERC) program. Participants assigned to experimental condition will receive access to the PERC website.
2865762|NCT03489057|Active Comparator|usual care plus NCI website|Participants in this usual care plus NCI website group will be automatically directed to the NCI prostate cancer website after logging in to the study website homepage.
2865763|NCT03489044|Experimental|Active treatment arm (Levetiracetam)|When in the active arm, after a baseline visit, participants will up-titrate Levetiracetam in 250mg steps at intervals of one week to Levetiracetam 500mg twice daily (two tablets twice daily). Participants will be maintained on Levetiracetam 500mg bd for four weeks and have a further full assessment at 8 weeks after being on Levetiracetam. Participants will then down-titrate Levetiracetam by 250mg every week until weaned to nil.
2865764|NCT03489044|Placebo Comparator|Control arm (placebo oral tablets)|When in the control arm, after a baseline visit, participants will up-titrate placebo (manufactured to look identical to Levetiracetam 250mg) in one tablet steps at intervals of one week to two tablets twice daily. Participants will be maintained on placebo for four weeks and have a further full assessment at 8 weeks after being on placebo. Participants will then down-titrate placebo by one tablet every week until weaned to nil.
2865765|NCT03489031||Diabetes Mellitus, Type 1|patients with type 1 diabetes
2865766|NCT03489031||Diabetes Mellitus, Type 2|patients with type 2 diabetes
2865767|NCT03489005|Other|Treatment Period 1|"Interventions to be administered:~Schema 1:~400 mg BIA 5-1058~1200 mg BIA 5-1058~Placebo~Moxifloxacin~Schema 2:~1200 mg BIA 5-1058~Placebo~400 mg BIA 5-1058~Moxifloxacin"
2865768|NCT03489005|Other|Treatment Period 2|"Interventions to be administered:~Schema 1~1200 mg BIA 5-1058~Placebo~400 mg BIA 5-1058~Moxifloxacin~Schema 2:~1200 mg BIA 5-1058~Moxifloxacin~400 mg BIA 5-1058~Placebo"
2865769|NCT03489005|Other|Treatment Period 3|"Interventions to be administered:~Schema 1~Placebo~400 mg BIA 5-1058~Moxifloxacin~1200 mg BIA 5-1058 Schema 2~1. 400 mg BIA 5-1058 2. 1200 mg BIA 5-1058 3. Moxifloxacin 4. Placebo"
2865770|NCT03489005|Other|Treatment Period 4|"Interventions to be administered:~Schema 1~Moxifloxacin~Placebo~1200 mg BIA 5-1058~400 mg BIA 5-1058 Schema 2~1. Moxifloxacin 2. 400 mg BIA 5-1058 3. Placebo 4. 1200 mg BIA 5-1058"
2865771|NCT03488992|Experimental|MVM/phytochemical supplement|a multi-vitamin, multi-mineral, phytochemical supplement
2865772|NCT03488992|Placebo Comparator|Placebo|a placebo tablet (microcrystalline cellulose) identical in size, shape and color to the treatment
2865773|NCT03488979||Educational Interventional Group|Primary outcome measure: Difference in MOSSAS-3HF score between intervention group and control group, administered 4 weeks after discharge.
2865774|NCT03488979||Attention Control Group|Primary outcome measure: Difference in MOSSAS-3HF score between intervention group and control group, administered 4 weeks after discharge.
2865775|NCT03488966|Experimental|MB-EAT|Behavioral: group psychotherapy. Eight weekly sessions, each session is 2 hours in duration.
2865776|NCT03488966|No Intervention|Waitlist Control|Wait list control.
2865777|NCT03488953|Other|Transplantation Arm|
2865778|NCT03488940|Active Comparator|24-hours group|"The septic patients randomized to 24-hours group will be received enteral nutrition preparation by 24 hours of continuously pumping through stomach tube every day.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
2865779|NCT03488940|Experimental|16-hours group|"The septic patients randomized to 16-hours group will be received enteral nutrition preparation by 16 hours of continuously pumping through stomach tube every day.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
2865780|NCT03488940|Experimental|intermittent group|"The septic patients randomized to intermittent group will be received enteral nutrition preparations by four meals every day(08:00,12:00 18:00,22:00), each meal are pumped within 60mins through stomach tube.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
2865781|NCT03488927|Experimental|Intervention|This arm will receive the intervention, followed by a six-month follow-up evaluation.
2865782|NCT03488927|No Intervention|Wait-list Control|This arm will receive the intervention after a six-month follow-up evaluation.
2865783|NCT03488914|Other|Intervention|
2865784|NCT03488914|Other|Enhanced Treatment as Usual|
2865785|NCT03488901||methotrexate sensitive|patients with gestational choriocarcinoma cured with methotrexate alone
2865786|NCT03488901||methotrexate resistant|patients with gestational choriocarcinoma not cured with methotrexate alone
2865787|NCT03488901||polychemotherapy sensitive|patients with gestational choriocarcinoma cured with polychemotherapy
2865788|NCT03488901||polychemotherapy resistant|patients with gestational choriocarcinoma not cured with polychemotherapy
2865789|NCT03488901||hydatidiform moles without malignant transformation|patients treated for hydatidiform moles but who did not turn into trophoblastic tumors (=controls)
2865790|NCT03488901||placental site trophoblastic tumors|patients with placental site trophoblastic tumors not cured with polychemotherapy
2865791|NCT03488888|Sham Comparator|Normal Saline|"General Anesthesia + Bilateral Pectoral injection of Normal Saline 0,9%~Ultrasound-guided visualization of Pectoralis major and pectoralis minor muscles~Injection of 10 mL normal saline 0,9% between muscles lateral to the thoracoacromial artery.~Visualization of Pectoralis menor and Serratil Muscles~3- Injection of 20 mL of normal saline 0,9% between Pectoralis minor and serratil muscles 4-Visualize the hydrodissection performed by the solution"
2865792|NCT03488888|Experimental|Bupivacaine|"General Anesthesia + Bilateral Pectoral injection of 30 mL of 0.25% Bupivacaine~Ultrasound-guided visualization of Pectoralis major and pectoralis minor muscles~Injection of 10 mL of local anesthetic between muscles lateral to the thoracoacromial artery.~Visualization of Pectoralis minor and Serratil Muscles~3- Injection of 20 mL of local anesthestic between Pectoralis minor and Serratil muscles 4-Visualize the hydrodissection performed by the solution"
2865793|NCT03488875|Experimental|mMBRT|Individuals in the mMBRT group will receive an 8-week mindfulness-based intervention in groups of approximately 15 individuals in 8 weekly 2-hour classes (one of these classes, toward the end of the course, is approximately 4 hours and integrates many of the practices and teachings covered throughout the training program).
2865794|NCT03488875|No Intervention|Waitlist control group|Individuals in the waitlist control group will complete the same assessments as those in the active treatment group, but will not be offered any intervention until the conclusion of the trial. At this time, control group participants will be offered the intervention.
2865795|NCT03488836|Active Comparator|race|race rotation protocol
2865796|NCT03488836|Active Comparator|reciproc|reciprocal endodontic treatment group
2865797|NCT03488823|Experimental|Young with Flavanol|Young patients (< 45 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink with flavanols ( 2x400 mg Flavanols).
2865798|NCT03488823|Placebo Comparator|Young without Flavanol|Young patients (< 45 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink without flavanols .
2865799|NCT03488823|Experimental|Old with Flavanol|Old patients (>60 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink with flavanols ( 2x400 mg Flavanols).
2865800|NCT03488823|Placebo Comparator|Old without Flavanol|Young patients (>60 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink without flavanols.
2865801|NCT03488810|Active Comparator|Arm A: ADT + radiation therapy|"Patient will receive 2 injections of a three-monthly LHRH agonist depot plus non-steroidal anti-androgen (rescue treatment) (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection.~All patients will receive standard fractionation radiation therapy (RT) between 0 and 12 weeks after first injection of LHRH agonist."
2865802|NCT03488810|Experimental|Arm B: ADT + radiation therapy + Apalutamide|"Patients will receive 2 injections of a three-monthly LHRH agonist depot. Apalutamide treatment: 240 mg PO daily, started the same day as the first LHRHa injection, for 6 months.~All patients will receive standard fractionation radiation therapy (RT) between 0 and 12 weeks after first injection of LHRH agonist."
2865803|NCT03488797|Experimental|Experimental|Supervised web- and home-based exercise intervention
2865804|NCT03488797|No Intervention|No Intervention|"Control group - Standard of Care~Re-assessment 24 weeks (6 month) after enrolment.~Afterwards crossover into experimental group"
2865805|NCT03488771||Control|Kidney transplant recipients without clinical/laboratory/biopsy signs of infection or graft rejection
2865806|NCT03488771||Infection|Kidney transplant recipients presenting with clinical or laboratory signs of infection (bacterial or viral)
2865807|NCT03488771||Rejection|Kidney transplant recipients presenting with clinical, laboratory or biopsy signs of graft rejection.
2865808|NCT03488758|Active Comparator|CMF|infant formula based on cow milk protein fractions
2865809|NCT03488758|Experimental|GMF|infant formula based on whole goat milk
2865810|NCT03488745|Experimental|IntelliCare + Phone Coaching|Participants will receive IntelliCare apps with phone coaching for 7 weeks. In this arm, participants will pick two IntelliCare apps to use every week. Participants will receive a phone coaching call before they use the apps, for approximately 30 minutes, as well as 3 weeks after initiating app use (10 minute call).
2865811|NCT03488732||Patients undergonig transcatheter valvular interventions|
2865812|NCT03488719|Experimental|Cohort 1|Tesofensine 0.25mg
2865813|NCT03488719|Experimental|Cohort 2|Tesofensine 0.50mg
2865814|NCT03488719|Experimental|Cohort 3|Tesofensine 0.75mg
2865815|NCT03488706||Gray Zone Group|The gray zone group PSA between 4.00 to 10.99 ng/ml.
2865816|NCT03488693|Active Comparator|No Regional Radiotherapy|A. Whole Breast Irradiation (WBI) following BCS or; B. No Radiotherapy (RT) following mastectomy
2865817|NCT03488693|Active Comparator|Regional Radiotherapy|A. WBI plus RT to the regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following BCS or; B. RT to the chestwall and regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following mastectomy
2865818|NCT03488680|Experimental|Intervention group|Behavior change communication
2865819|NCT03488680|No Intervention|Control group|No Behavior change communication
2865820|NCT03488667|Experimental|mFOLFOX6 (Leucovorin-Fluorouracil-Oxaliplatin) + Pembrolizumab|"Drug: Pembrolizumab Dose: 200 mg Dose Frequency: Every three weeks (Q3W) Route: Intravenous (IV) infusion~Drug: Oxaliplatin Dose: 85 milligrams per meter squared (mg/m2) Dose Frequency: Every 2 weeks (Q2W) Route: IV infusion~Drug: Leucovorin Dose: 400 mg/m2 Dose Frequency: Q2W Route: IV infusion~Drug: Fluorouracil Dose: 400 mg/m2 Dose Frequency: Q2W Route: IV bolus~Drug: Fluorouracil Dose: 2,400 mg/m2 Dose Frequency: Q2W Route: IV continuous 46-hour infusion~Pembrolizumab will be administered at a fixed dose of 200 mg IV over 30 minutes every 3 weeks. Participants will receive 3 doses of the drug on Days 1, 22, 43 during the neoadjuvant phase of the study, and 12 doses of the drug on Days 1, 22, 43 during the adjuvant phase of the study (total 15 doses). Participants will receive 4 doses of mFOLFOX6 regimen on Days 1, 15, 29, 43 during the neoadjuvant phase of the study, and 4 doses during the adjuvant phase of the study (total 8 doses)."
2865821|NCT03488628|Active Comparator|Noninvasive ventilation|Noninvasive ventilation delivered through a face mask, in alternance with standard nasal oxygen therapy
2865822|NCT03488628|Experimental|High-Flow Nasal Oxygen therapy|High-Flow Nasal Oxygen therapy delivered continuously over the first 24 hours by the AIRVO2® device (Fisher & Paykel Healthcare,New Zealand) through nasal canula.
2865823|NCT03488602|Experimental|F-SPS Intervention|This group will receive the F-SPS intervention.
2865824|NCT03488602|Active Comparator|Enhanced Usual Care (EUC)|This group will receive Enhanced Usual Care (EUC)
2865825|NCT03488576|Active Comparator|Complete Peeling|Patient underwent scheduled vitrectomy for epiretinal membrane or macular hole with complete macular peeling of the internal limiting membrane.
2865826|NCT03488576|Experimental|Foveal Sparing|Patient underwent scheduled vitrectomy for epiretinal membrane or macular hole with partial peeling the internal limiting membrane (foveal sparing).
2865827|NCT03488563|Experimental|B244 Dose 1|B244 1X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
2865828|NCT03488563|Experimental|B244 Dose 2|B244 4X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
2865829|NCT03488563|Placebo Comparator|Vehicle|Vehicle, 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
2865830|NCT03488550|Experimental|ANX007-GLA-01|
2865831|NCT03488537|Other|patients referred for colonoscopy|All patients referred for colonoscopy where invited to participate in our study.
2886602|NCT03342807|Experimental|Group Insulin|
2865833|NCT03488511|Experimental|Intervention group|The intervention group will receive meals from FoodforCare at Home. The FoodforCare at Home concept consists of five small protein and energy enriched meals and snacks that will be delivered twice a week. After an individual intake, the composition of the dishes will be tailored to the needs of the patient in terms of composition, diet, taste, flavor and portion size. Besides the meals, patients in the intervention group will also receive an information leaflet about the importance of protein during treatment and how to reach their protein requirements.
2865834|NCT03488511|No Intervention|Control group|The control group will continue their usual diet for 3 weeks and have no restrictions to their diet.
2865835|NCT03488498||Receiving NSAID medication|Receiving NSAID medication
2865836|NCT03488498||Receiving NSAID medication and weight bath therapy,|
2865837|NCT03488498||Receiving weight bath therapy,|
2865838|NCT03488485|Other|DAA arm|"Direct Acting Antivirals therapy An algorithm was developed using DAA (Sofosbuvir-based regimens to treat all patients (RKD).~Non Cirrhotics: Sofosbuvir (SOF)+ Daclatasvir (DCV) for 12-weeks~Cirrhotics:~Genotype 3 were treated with SOF+DCV+ ribavirin (RBV) for 24 weeks, Non-Genotype 3 patients were treated with SOF+LDV+RBV for 12-weeks or with SOF+LDV for 24-weeks (in RBV intolerant patients)."
2865839|NCT03488472|Experimental|NovoTTF-200A device + Stereotactic Radiosurgery (SRS)|Patients will undergo SRS treatment followed by continuous TTFields by wearing the NovoTTF-200A device over 18 hours QD. Treatment continues for up to 1 year or until progression.
2865840|NCT03488459|Other|Routine preoperative information from a nurse|
2865841|NCT03488459|Experimental|Additional information support from a psychologist|
2865842|NCT03488433|Active Comparator|Antirotation sling|Patients who undergo reverse shoulder arthroplasty or rotator cuff repair will be randomly assigned to this group.
2865843|NCT03488433|Active Comparator|abduction brace|Patients who undergo reverse shoulder arthroplasty or rotator cuff repair will be randomly assigned to this group.
2865844|NCT03488420||Atrial Fibrillation with confirmed valvular heart disease|Subjects taking edoxaban 30mg or 60 mg will be followed for 2 years. Subjects will perform the Montreal Cognitive Assessment (MoCA) Test at baseline and 1-year follow up. They will also answer the Anti-Clot Treatment questionnaire (ACTS-Q) at 1-year.
2865845|NCT03488381|Experimental|Soccer Heading|
2865846|NCT03488381|Sham Comparator|Kicking-Control|
2865847|NCT03488368||Supportive-care group|Observation of IgAN patients who received supportive care measures (without additional immunosuppression) during the first three years after randomization, i.e. trial phase of the original STOP-IgAN trial.
2865848|NCT03488368||Immunosuppression group|Observation of IgAN patients who received supportive care measures and additional immunosuppression during the first three years after randomization, i.e. trial phase of the original STOP-IgAN trial.
2865849|NCT03488355|Experimental|Modified Reporting|Modified laboratory report
2865850|NCT03488355|No Intervention|Standard Reporting|Standard laboratory report
2865851|NCT03488342|Other|Rives technique|Rives technique for primary inguinal hernia
2865852|NCT03488342|Other|Lichtenstein repair|Lichtenstein repair for primary inguinal hernia
2865853|NCT03488329|Experimental|Intervention|"Intervention group~Individual nutritional therapy"
2865854|NCT03488329|No Intervention|Control|"Control group~Standard treatment"
2865855|NCT03488316|Active Comparator|Calcium Hydroxide temporary filling material|Temporary filling with Ca(OH)2
2865856|NCT03488316|Active Comparator|MTA temporary filling material|Temporary filling with MTA
2865857|NCT03488303||Main group|Study has only one group
2865858|NCT03488290|Experimental|LTP Plus TF CBT|LTP Plus TF CBT group participants will receive group intervention by masters' level trained facilitators weekly during the first two months and then fortnightly. It comprises of two components i.e. LTP and TF CBT. LTP aims at enabling parents to improve their child's psychosocial development by educating about child development and the importance of mother-child play. TF CBT aim is to modify excessively negative appraisals of the trauma and its sequelae by careful questioning
2865859|NCT03488290|Other|Treatment as Usual|TAU group will receive routine care consisting of routine follow ups
2865860|NCT03488277|Experimental|LE: leg elevation group|the patients of this group will be positionned in supine with 15° left tilt and will have a leg elevation with a 30 cm pillow positionned under the heels. this position will be hold immediately after spinal anesthesia until fetal extraction
2865861|NCT03488277|No Intervention|CG: Control group|The patients of this group will be positiooned in supine with 15° left tlit after spinal anesthesia. no leg elevation
2865862|NCT03488264||United States|50 participants will be recruited from the United States.
2865863|NCT03488264||Jamaica|50 participants will be recruited from Jamaica.
2865864|NCT03488251|Experimental|MT-3724 10mcg/kg-GEMOX|MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with GEMOX. If the treatment with MT-3724 is continued to Cycle 3 and Cycle 4, then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle.
2865865|NCT03488251|Experimental|MT-3724 25mcg/kg-GEMOX|MT-3724 25 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with GEMOX. If the treatment with MT-3724 is continued to Cycle 3 and Cycle 4, then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle.
2865866|NCT03488251|Experimental|MT-3724 50mcg/kg- GEMOX|MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with GEMOX. If the treatment with MT-3724 is continued to Cycle 3 and Cycle 4, then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle.
2865867|NCT03488225|Experimental|Hyper-CVAD + Inotuzumab Ozogamicin|"Each cycle is 21 days.~Participants receive Hyper-CVAD during Cycles 1 and 3.~Participants receive Methotrexate and Cytarabine during Cycles 2 and 4. On Days 1 and 8, Participants Ofatumumab or Rituximab.~Participants receive Inotuzumab Ozogamicin during Cycles 5-8, on Days 1 and Day 8 of each cycle.~Cycles 9-20 is maintenance therapy. Each cycle is 28 days.~Three (3) times a day, participant takes Mercaptopurine tablets. One (1) time a week, participant takes methotrexate tablets. On Day 1 of each cycle, participant receives vincristine. On Days 1-5 of each cycle, participant takes prednisone tablets."
2865868|NCT03488212|Active Comparator|Basic Implementation Intervention|
2865869|NCT03488212|Experimental|Enhanced Implementation Intervention|
2865870|NCT03488212|Active Comparator|Online Treatment; Control Maintenance Intervention|
2865872|NCT03488212|Experimental|Online Treatment; Refresher Courses for Maintenance|
2865873|NCT03488199|Active Comparator|Stent Acculink™ (RX ACCULINK CAROTID STENT SYSTEM)|50 Carotid stenting (RX ACCULINK CAROTID STENT SYSTEM)
2865874|NCT03488199|Experimental|Stent CGuard™ (The CGuardTM Embolic Prevention System (EPS))|50 Carotid stenting (The CGuardTM Embolic Prevention System (EPS))
2865875|NCT03488186|Experimental|Lansoprazole Capsules|Lansoprazole Capsules of Beijing Sihuan Pharm, 30 mg
2865876|NCT03488186|Active Comparator|Lansoprazole enteric-coated Capsules|Lansoprazole enteric-coated Capsules of Takeda Pharmaceutical Company Limited, 30 mg
2865877|NCT03488173|Experimental|Lansoprazole Capsules|Lansoprazole Capsules 30 mg of Beijing Sihuan Pharm
2865878|NCT03488173|Active Comparator|Lansoprazole enteric-coated Capsules|Lansoprazole enteric-coated Capsules 30 mg of Takeda Pharmaceutical Company Limited
2865879|NCT03488160|Experimental|Single arm|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:the first day,the second day Duration:total two times
2865880|NCT03488147|Experimental|Esomeprazole Only|Subjects assigned to the treatment group 'A' will receive one 20 mg esomeprazole tablet daily starting 1 week prior to the cervical operation and will continue to receive the esomeprazole until the end of the study
2865881|NCT03488147|Active Comparator|Esomeprazole and Placebo Oral Tablet|Subjects belonging to the treatment group 'B' will receive one placebo tablet (physically resembling an esomeprazole tablet 20 mg ) daily starting one week prior to the cervical operation. Subjects will then receive one 20 mg esomeprazole daily starting immediately after the operation and will continue to receive the esomeprazole until the end of the study.
2865882|NCT03488147|Placebo Comparator|Placebo Oral Tablet Only|Subjects belonging to the treatment group 'C' will receive one placebo tablet (physically resembling a 20 mg esomeprazole tablet) daily starting one week prior to the cervical operation and will continue to receive the placebo tablet until the end of the study
2865883|NCT03488121|Experimental|Poster Only|This arm will only receive motivational posters.
2865884|NCT03488121|Experimental|Thank-you Letter Only|This arm will only receive thank-you letters.
2865885|NCT03488121|Experimental|Double Incentive|This arm will receive both motivational posters and thank-you letters.
2865886|NCT03488121|No Intervention|Control|This arm will not receive any intervention.
2865887|NCT03488108|Experimental|Platelet Rich Plasma first, then Minoxidil Foam|Subjects will be randomized into the Platelet Rich Plasma group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Minoxidil Foam for 12 weeks.
2865888|NCT03488108|Experimental|Minoxidil Foam first, then Platelet Rich Plasma|Subjects will be randomized into the Minoxidil Foam group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Platelet Rich Plasma.
2865889|NCT03488095|Other|Behavior changing intervention|Thirty minutes behavior counselling (PPT.) to experimental group. BCI for SLT and BQ Use in Adolescents: A CRT
2865890|NCT03488095|No Intervention|Control Cluster|No thirty minutes behavior counselling (PPT.) to control group
2865891|NCT03488082|Experimental|Measurement of the bold signal|
2865892|NCT03488056|Experimental|Test - ICCMS|"The dentists will perform clinical examination on children following the ICCMS sequence:~The patient's caries risk assessment, Diagnosis of caries lesion and activity assessment Intraoral risk assessment, Decide on a personalized care plan for patient and clinical interventions.After asses all the factors and defining the patient's individual risk, the system presents a personalized treatment plan, indicating the appropriate home care instructions, clinical interventions and specific treatment for each caries lesion categories.~The return intervals will be scheduled according to the risk: low risk (return of 1 year), moderate risk (6 months) and high risk (3 months)"
2865893|NCT03488056|Active Comparator|Control - Standard care SESC|"The clinical sequence in this group will be:~Caries Diagnosis Operative and non-operative treatments Indication of recall interval according to the dentist However, dentists will do that without a schematic guide to follow. They will do as they usually do in their practices."
2865894|NCT03488043||Retrospective cohort|All patients having a CT-guided transthoracic biopsy from September 2012 and September 2017.
2865895|NCT03488043||Prospective cohort|All patients having a CT-guided transthoracic biopsy from April 2018.
2865896|NCT03488030||All Participants|Participants diagnosed with moderate to severe UC or CD from the 7 participating sites will be observed on Day 1 for cross-sectional evaluation of disease activity, treatment patterns, burden of disease and quality of life along with retrospective data collection for previous 3 years from the date of UC or CD diagnosis until Day 1 to assess the IBD treatments, medical history and comorbidities, treatment patterns and use of health resources.
2865897|NCT03488017|Experimental|Placebo Ocular Coil (left eye)|Left eye
2865898|NCT03488017|Experimental|Placebo Ocular Coil (right eye)|Right eye
2865899|NCT03487991|Experimental|personalized behavioral recommendations|Will receive recommendations for altering sleep related behavior based on data from in-home monitoring.
2865900|NCT03487991|No Intervention|educational control|Will receive the data without recommendations. Will receive personalized recommendations after the follow up assessment.
2865901|NCT03487978||Migraineurs|Patients diagnosed with migraine based on the ICHD-3 beta will undergo 3-tesla resting-state functional MRI.
2865902|NCT03487978||Control|Normal controls without headaches will undergo 3-tesla resting-state functional MRI.
2865903|NCT03487965|Experimental|Low dose Polyphenol|130 mg of Aronia Extract with 120 mg of licorice root combination blend provided to subjects once per day for 16 weeks.
2865904|NCT03487965|Experimental|High dose Polyphenol|200 mg of Aronia extract provided to subjects once per day for 16 weeks
2865905|NCT03487965|Placebo Comparator|Placebo control|Inert tablet provided to subjects once per day for 16 weeks
2865906|NCT03487952||LDCT screening group|People receive questionnaire administration at baseline, then subsequent yearly chest LDCT scan and follow up.
2865907|NCT03487939|Experimental|FOLFOXIRI|Patients received 4 cycles of neoadjuvant FOLFOXIRI chemotherapy before surgical resection.
2865908|NCT03487926||Group 1 (IBD primary diagnosis)|Participants have active IBD
2865909|NCT03487926||Group 2( IBD + comorbid MDE)|1 [18F]FEPPA PET scan in those with IBD symptoms in the past 2 years as well present with MDE
2866020|NCT03487198|Placebo Comparator|Placebo|2-3 mg/day, once daily for 6 weeks, oral administration
2865910|NCT03487926||Group 3-Controls|"Matched for Level of Depressive Symptoms and Otherwise Healthy~-Subjects in an otherwise healthy state with major depressive episodes, obsessive compulsive disorder, or generalized anxiety disorder will provide psychiatric diagnosis matched controls to those with IBD. Data for group three will be largely obtained from previous recent studies (it is anticipated that 95% of this data is already available)."
2865911|NCT03487913|Experimental|High dose|Oral lixivaptan
2865912|NCT03487913|Experimental|Low dose|Oral lixivaptan
2865913|NCT03487900|Other|Clinical remission CD|
2865914|NCT03487874|Experimental|Interscalene block with C8 root block|The 5th to 8th cervical nerve root block under ultrasound guidance using 25 to 30 ml of 0.75% ropivacaine
2865915|NCT03487874|Active Comparator|Conventional interscalene block|The 5th to 7th cervical nerve root block under ultrasound guidance using 25 to 30 ml of 0.75% ropivacaine
2865916|NCT03487848|Experimental|Daclatasvir with Sofosbuvir|
2865917|NCT03487835|Experimental|Kinesiotape group|
2865918|NCT03487835|Experimental|Control group|
2865919|NCT03487822|Experimental|Path Pain|Path Pain participants will be receiving 8 weekly therapy session by license clinicians trained in the Path Pain intervention. They will also receive 4, 15-minute phone booster sessions, on a monthly basis after their final therapy session. They will also be invited to monthly group educational sessions. Both intervention and usual care participants will be receiving a pain educational booklet.
2865920|NCT03487822|No Intervention|Usual Care with Education|Usual Care with Education (UCE) will receive a pain educational booklet. Following completion of their 24 weeks in the study, they will also be invited to attend the monthly group educational sessions.
2865921|NCT03487809||NTUH|National Taiwan University Hospital, all participants receive Duasma (budesonide, 200mcg/puff)
2865922|NCT03487809||SHH|Shuang Ho Hospital, all participants receive Duasma (budesonide, 200mcg/puff)
2865923|NCT03487809||CGH|Cathay General Hospital, all participants receive Alvesco (Ciclesonide, 160mcg/puff)
2865924|NCT03487796|Experimental|MySTYLE|MySTYLE is online, brief and encourages parent-adolescent communication about sex and HIV prevention. Participants (non-heterosexual Black adolescent males and parents/caregivers) will receive two texts per week (for eight weeks) with links to intervention content that includes video, games and graphics to improve knowledge, motivation and skills for HIV prevention. Topics include assertive communication, sexual safety, goal setting, and resilience.
2865925|NCT03487796|Active Comparator|MyHealth|MyHEALTH is an attention-equivalent comparison condition with the same format as MySTYLE. Participants (non-heterosexual Black adolescent males and parents/caregivers) will receive two texts per week (for eight weeks) with links to intervention content that includes video, games and graphics to improve knowledge, motivation and skills for general health behavior.
2865926|NCT03487783|Experimental|Aripiprazole Oral Solution|1 mg/mL, 2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal
2865927|NCT03487783|Placebo Comparator|Placebo Oral Solution|2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal
2865928|NCT03487770|Experimental|Aripiprazole Oral Solution|1 mg/mL, 2 ~ 15 mg/day (2 ~ 15 mL/day), taken once daily for 8 weeks. Administrate about at the same time each day, either before or after meals;
2865929|NCT03487770|Placebo Comparator|Placebo Oral Solution|2 ~ 15 mg/day (2 ~ 15 mL/day), taken once daily for 8 weeks. Administrate about at the same time each day, either before or after meals.
2865930|NCT03487757|Active Comparator|Control Group|After recording the demographic and clinical information at the beginning of the study and after 8 weeks, respiratory muscle strength, respiratory functions and postural control evaluations will be performed to the children. They won't receive any intervention by this time. At the end of 8 weeks, they may be included in the 8-week physiotherapy program, which will be once a week and 45-60 minutes by supervision of physiotherapist and 4 days a week home exercise program. The program will include core stabilization exercise training.
2865931|NCT03487757|Experimental|Training Group|After recording the demographic and clinical information at the beginning of the study, respiratory muscle strength, respiratory functions and postural control evaluations will be performed to the children. They will be included in the 8-week physiotherapy program, which will be once a week and 45-60 minutes by supervision of physiotherapist and 4 days a week home exercise program. The program will include core stabilization exercise training. After the eight week training program the evaluations will be repeated.
2865932|NCT03487744|Active Comparator|Promote without fiber|Lower osmolality enteral tube feed formulation
2865933|NCT03487744|Active Comparator|Osmolite 1.5|Higher osmolality enteral tube feed formulation
2865934|NCT03487731|Placebo Comparator|Group 1 - Placebo|Group 1 - Five (5) subjects will be treated with a single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection. These subjects will be part of the control (Standard care) group.
2865935|NCT03487731|Experimental|Group 2 - Allogeneic Human Mesenchymal Stem Cells (hMSCs)|Group 2 - Five (5) subjects will be treated with a single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml. These subjects will be part of the experimental group.
2865936|NCT03487731|Experimental|Group A - Allogeneic Human Mesenchymal Stem Cells (hMSCs)|Group A will consist of 15 subjects that will receive 20 million Allogeneic hMSCs delivered via lumbar level injection based on pain originator.
2865937|NCT03487731|Placebo Comparator|Group B - Placebo|Group B will consist of 15 subjects who will receive 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution via lumbar level injection based on pain originator.
2865938|NCT03487718|Active Comparator|Control group|Under the effect of local anesthetic tooth will be extracted then a d-PTFE membrane will be used to cover the socket without any bone graft material to preserve the ridge.
2865939|NCT03487718|Experimental|Test group|Under the effect of local anesthetic tooth extraction will be followed by the collection of about 50 ml of the patient's venous blood, then without adding any anticougulant the blood will be spun to make a plug. The Leukocyte platelet rich fibrin plug + d-PTFE membrane will be used to preserve the ridge.
2865940|NCT03487705|Other|child essential tremor|electromyogram with accelerometer
2866021|NCT03487185|Experimental|Continuous Positive Airway Pressure|Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep hygiene counseling
2865941|NCT03487692|Experimental|2018 Training Cohort|10 health centers will be randomized to the 2018 Training Cohort. Teams from these health centers will be trained and will implement a 6 month diabetes group visit and text messaging intervention (Diabetes MESSAGES Program).
2865942|NCT03487692|Other|2020 Training Cohort|10 health centers will be randomized to the 2020 Training Cohort. Prior to beginning training, these health centers will collect data on randomly selected patients receiving usual care to serve as the control group. After this first parallel group trial period, teams from these health centers will be trained and will implement the 6 month diabetes group visit and text messaging intervention during a second single group trial period (Diabetes MESSAGES Program (second trial)).
2865943|NCT03487679|Experimental|Fasting|Participants will undergo one day of habitual eating followed by 36 hours of water only fasting and final day of habitual eating of the exact same diet consumed on the first eating day. Blood draws will be performed on Day 1 in a 10-12 hr fasted state and 2 hour postprandial state and again on Day 3 in a 36hr fasted state and a 2 hour post prandial state. Microbiome samples and blood glucose data will be collected throughout the course of the study.
2865944|NCT03487666|Experimental|Arm A|Nivolumab 360 mg iv q3weeks for x 6 cycles
2865945|NCT03487666|Active Comparator|Arm B|Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles
2865946|NCT03487666|Experimental|Arm C|Nivolumab 360mg iv q3weeks + Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles
2865947|NCT03487640||Transanal rectal mucosa resection|TARMR: Transanal resection of rectal mucosa for at least 5cm in length.
2865948|NCT03487640||Laparoscopic rectal suspension and colectomy|LARSC: We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically
2865949|NCT03487627|Experimental|mHealth and Care Support Manager Service|Participants receive mHealth electronic content and contact with a Care Support Manager
2865950|NCT03487627|Active Comparator|Enhanced treatment-as-usual (TAU)|Participants receive enhanced treatment-as-usual
2865951|NCT03487614|Experimental|Behavior-based parental intervention|The study intervention included two primary components: 1) physician-family health behavior conversations during well-child visits, and 2) four monthly visits with a RDN to evaluate, educate, and implement improved feeding habits and nutritional choices. A third optional component of the intervention included counseling sessions with a social worker to help families overcome barriers to change, such as food security, family relationships, and general parenting strategies.
2865952|NCT03487614|No Intervention|Control|Control parents signed the informed consent document and then completed all baseline assessments during their child's medical visit. Control participants then received their usual medical care. Follow-up evaluations, including child anthropometry and completion of study surveys were assessed approximately 6 months later during a second office visit. For children <3 years of age at baseline, follow up visits coincided with their subsequent well-child visit (i.e. 30-month or 3-year appointment) as per AAP visit frequency recommendations. For patients ≥3 years of age, families attended a separate office visit 6 months after their baseline visit in order to complete follow-up study assessments.
2865953|NCT03487601|Active Comparator|Active tDCS|Active transcranial direct current stimulation: Participants will undergo five consecutive days (Monday-Friday) of active stimulation beginning the Monday after their on-study chemotherapy administration. Questionnaires and cognitive assessment will be completed on the first and last days of stimulation (i.e., Monday and Friday). On all 5 days, participants will engage in cognitive tasks while receiving stimulation (either active or sham) in order to maximize stimulation effects 43. In order to assess for duration of subjective effects, participants will complete self-report measures of subjective fatigue, cognitive function and QOL immediately prior to their next chemotherapy (approximately 10-14 days after completion of stimulation).
2865954|NCT03487601|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation: Participants will undergo five consecutive days (Monday-Friday) of sham stimulation beginning the Monday after their on-study chemotherapy administration. Questionnaires and cognitive assessment will be completed on the first and last days of stimulation (i.e., Monday and Friday). On all 5 days, participants will engage in cognitive tasks while receiving stimulation (either active or sham) in order to maximize stimulation effects 43. In order to assess for duration of subjective effects, participants will complete self-report measures of subjective fatigue, cognitive function and QOL immediately prior to their next chemotherapy (approximately 10-14 days after completion of stimulation).
2865955|NCT03487588|Experimental|A-101 Topical Solution|Open Label Arm
2865956|NCT03487575|Experimental|Open trial|
2865957|NCT03487562|Experimental|Sequence 1|Part I: A-B-D-C A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
2865958|NCT03487562|Experimental|Sequence 2|Part I: B-C-A-D A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
2865959|NCT03487562|Experimental|Sequence 3|Part I: C-D-B-A A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
2865960|NCT03487562|Experimental|Sequence 4|Part I: D-A-C-B A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
2865961|NCT03487562|Experimental|A|Part II: (DWP14012 B mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
2865962|NCT03487562|Experimental|B|Part II: (DWP14012 A mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
2865963|NCT03487562|Experimental|C|Part II: (Lansoprazole 30 mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
2865964|NCT03487549|Other|Open label|This is an open label study. All subjects will receive treatment to their common warts per protocol with VP-102, cantharidin topical film forming solution, using the VP-102 applicator.
2865965|NCT03487523|Active Comparator|Intervention 1|Text message (SMS Message)
2865966|NCT03487523|Active Comparator|Intervention 2|Text message (SMS Message)
2865967|NCT03487523|No Intervention|Intervention 3|no intervention
2865968|NCT03487510||NO groups|no groups apply.
2865969|NCT03487497||Patients|Patients who underwent lateral column lengthening osteotomy
2865970|NCT03487497||Healthy subjects|Healthy subjects without intervention
2866022|NCT03487185|Other|Sleep Hygiene Control|Initial sleep hygiene counseling alone
2865971|NCT03487484||With protective stoma|Patients in which intraoperatively the decision was made to add a protective stoma (following a risk algorithm) to total mesorectal excision. In patients quality of life, the Gastrointestinal Quality of Life Index (GIQLI) questionnaire, Quality of Life Questionnaire for gastrointestinal tract and Faecal Incontinence Score will be applied.
2865972|NCT03487484||No stoma|"Patients in which intraoperatively the decision was made to refrain from adding a protective stoma (following a risk algorithm) to total mesorectal excision.~In patients quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index), Quality of Life Questionnaire for gastrointestinal tract and Faecal Incontinence Score will be applied."
2865973|NCT03487471|Active Comparator|Real-time elastography|98 patients with breast lesion will a receive breast ultrasound (real time elastography)
2865974|NCT03487471|Active Comparator|Shear Wave|98 patients with breast lesion will a receive breast ultrasound (shear wave elastography)
2865975|NCT03487458|No Intervention|Control|participants receive no surgical treatment
2865976|NCT03487458|Experimental|Rib Fixation Surgery|participants receive surgical treatment
2865977|NCT03487445|Experimental|ACT-246475 - 8 mg|Single s.c. administration
2865978|NCT03487445|Experimental|ACT-246475 - 16 mg|Single s.c. administration
2865979|NCT03487432|Experimental|OPN NC|Patients receiving a Super High-Pressure NC PTCA Balloon (OPN NC)
2865980|NCT03487432|Experimental|NSE Alpha|Patients receiving a Scoring PTCA Balloon (NSE Alpha)
2865981|NCT03487419||patients develop atrial fibrillation|patients post coronary artery bypass grafting who develop atrial fibrillation post operative
2865982|NCT03487419||patients who not develop atrial fibrillation|patients post coronary artery bypass grafting who don't develop atrial fibrillation post operative
2865983|NCT03487406|Placebo Comparator|Placebo Ticagrelor & placebo Aspirin|Placebo Ticagrelor 90 mg- one tablet, twice daily. Placebo Aspirin 75 mg- one tablet, once a day.
2865984|NCT03487406|Active Comparator|Aspirin & Placebo Ticagrelor|Aspirin 75mg - one tablet, once a day. Placebo Ticagrelor 90 mg- one tablet, twice daily.
2865985|NCT03487406|Active Comparator|Placebo Aspirin & Ticagrelor|Placebo Aspirin 75 mg - one tablet, once a day. Ticagrelor 90 mg- one tablet, twice daily.
2865986|NCT03487406|Experimental|Aspirin & Ticagrelor|Aspirin 75 mg - one tablet, once a day. Ticagrelor 90 mg- one tablet, twice daily.
2865987|NCT03487393|Experimental|Vitalflow treatment|The subject's exposure will be through a ramp model of increments in magnetic stimulation power delivered to the facial nerves bilaterally. Increases in magnetic stimulation will be 10% for 10 seconds from 10% to 60%. Subsequent to this will be evaluated for 5 minutes in the power of tolerability of the subject (60% 70%, 80% or 90%).
2865988|NCT03487380|Experimental|Alzheimer with rapid DCR|
2865989|NCT03487380|Experimental|Alzheimer without rapid DCR|
2865990|NCT03487380|Sham Comparator|Control|
2865991|NCT03487367||Early stage subjects|This cohort is defined by individuals with a total SARA score of less than or equal to 9.5
2865992|NCT03487367||Premanifest mutation carriers|This cohort is defined by the presence of positive genetic diagnosis but no signs of ataxia and total SARA score of less than or equal to 2.5
2865993|NCT03487367||50%-at-risk subjects|This cohort is defined by individuals who are at risk for SCA1 or SCA3 because they have a family member who tested positive for SCA1 or SCA3. Total SARA score is less than or equal to 2.5
2865994|NCT03487367||Previously diagnosed early stage|This cohort is defined by individuals who were included in prior CRC-SCA, EUROSCA, ESMI or SPATAX studies who had a total SARA score of less than or equal to 10 in 2009-2012
2865995|NCT03487354|Active Comparator|Single daily dose|
2865996|NCT03487354|Active Comparator|Multiple daily doses|
2865997|NCT03487341|Active Comparator|Cord drainage|
2865998|NCT03487341|Active Comparator|Cord clamping|
2865999|NCT03487328|Active Comparator|Modified technique for Sacrospinous-Sacrotuberous Fixation|Modified technique for Sacrospinous-Sacrotuberous Fixation
2866000|NCT03487328|Active Comparator|Conventional technique for Sacrospinous-Sacrotuberous Fixation|Modified technique for Sacrospinous-Sacrotuberous Fixation
2866001|NCT03487315|Experimental|specific IgE|Different level of specific IgE and immunoblot
2866002|NCT03487302||cCHD|
2866003|NCT03487302||CONTROLS|
2866004|NCT03487289|Experimental|natural orifice|Patients who underwent laparoscopic surgery and removed the specimen from the natural orifice will be gathered. demographic data and perioperative results will be compiled
2866005|NCT03487289|No Intervention|conventional|patients who underwent laparoscopic surgery and removed specimen with conventional will be gathered. demographic data and perioperative results will be compiled. (conventional extraction is suprapubic or median incision)
2866006|NCT03487276|Placebo Comparator|Cohort 1|Placebo
2866007|NCT03487276|Experimental|Cohort 2|Minimum Dose IFX-1
2866008|NCT03487276|Experimental|Cohort 3|Low dose IFX-1
2866009|NCT03487276|Experimental|Cohort 4|Medium Dose IFX-1
2866010|NCT03487276|Experimental|Cohort 5|High Dose IFX-1
2866011|NCT03487263|Experimental|IC14 dose level 1|For the initial 3 patients: intravenous IC14 at a dosage of 2 mg/kg on Study Day 1, then 1 mg/kg once daily on Study Days 3-5 for 4 total doses
2866012|NCT03487263|Experimental|IC14 dose level 2|For the subsequent 7 patients: intravenous IC14 at a dosage of 4 mg/kg/day on Day 1, followed by IC14 2 mg/kg/day on Days 2-4
2866013|NCT03487250||TenJet System|Percutaneous ultrasound guided medial and lateral tenotomy using the TenJet HydroSurgery System
2866014|NCT03487237|Experimental|All patient|Included patients will undergo a formal work up for pulmonary embolism: Ddimer testing, followed if positive by a computed tomography pulmonary angiogram or V/Q scan.
2866015|NCT03487224||Hoarding Disorder|Adults diagnosed with Hoarding Disorder
2866016|NCT03487224||Healthy Controls|Adults without mental illness
2866017|NCT03487211|Active Comparator|Duloxetine Group|Duloxetine 30mg once daily to be started for 1 week. Dose will then be titrated to 60mg once daily and the patients followed for a total of 12 weeks.
2866018|NCT03487211|Experimental|Escitalopram Group|Escitalopram 10mg once daily to be started for 1 week. Dose will then be titrated to 20mg once daily and the patients followed for a total of 12 weeks.
2866019|NCT03487198|Experimental|Brexpiprazole|2-3 mg/day, once daily for 6 weeks, oral administration
2866023|NCT03487172|Other|Right Side Treated|Subjects will be randomized to have their right side treated with PLLA and their left side treated with normal saline.
2866024|NCT03487172|Other|Left Side Treated|Subjects will be randomized to have their left side treated with PLLA and their right side treated with normal saline.
2866025|NCT03487159|Other|Liver biopsy ,Elastography and MRE|Performance of routine Liver biopsy,Shear Wave Elastography and investigational MRE (Magnetic Resonance Elastography) in order to evaluate liver fibrosis stage.
2866026|NCT03487159|Other|Elastography and MRE|Performance of routine Shear Wave Elastography and investigational MRE (Magnetic Resonance Elastography) in order to evaluate liver fibrosis stage.
2866027|NCT03487146|No Intervention|HD(hemodialysis) group|HD group as conventional control arm
2866028|NCT03487146|Active Comparator|HD+HP(hemodialysis+hemoperfusion) group|HD+HP as active interventional group.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.
2866029|NCT03487133|Experimental|bortezomib/dexamethasone|Subjects who have been diagnosed with stable lesions more than 4 cycles of induction therapy (Induction Therapy Part I) will receive additional induction therapy 4 cycles (Induction Therapy Part II) Patients who have been diagnosed with a stable disease response after a total of eight cycles of induction therapy receive up to one year of maintenance therapy.
2866030|NCT03487120|No Intervention|lumbar laminectomy|
2866031|NCT03487120|Active Comparator|lumbar laminectomy with denervation of the facet joint|
2866032|NCT03487107|Experimental|SOF 400 mg+DAG181 100 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF 400 mg+DAG181 100 mg for 12 weeks.
2866033|NCT03487094|Active Comparator|Growth, Tolerance of Infants-Exp|Infant Formula
2866034|NCT03487094|Active Comparator|Growth,Tolerance of Infants-Com|Infant Formula
2866035|NCT03487081|Experimental|Social regulation|Following the fMRI session, participants in the social regulation group will be asked to rate their mood twice a day for 3 weeks. Furthermore, every other day, they will receive one event written by another participant. They will be asked to help the other person use emotion regulation strategies to feel less negative. The participant will answer brief questions related to his/her feelings after receiving the event and after providing social emotion regulation.
2866036|NCT03487081|Active Comparator|Self regulation|Following the fMRI session, participants in the self regulation group will be asked to rate their mood twice a day for 3 weeks. Furthermore, every other day, they will write an event that caused them negative emotions. They will be asked to use emotion regulation strategies to decrease their negative emotions. The participant will answer brief questions related to his/her feelings after writing the event and after implementing the emotion regulation strategy.
2866037|NCT03487068|Other|Patients with NAFLD|
2866038|NCT03487055|Experimental|treatment group|The subjects would receive 120 mg TK006 every 4-week over a period of 84 days.
2866039|NCT03487042|Experimental|Generalized vitiligo patients|"Each patient with generalized vitiligo will be subjected to the following:~One side will be treated by narrow band ultraviolet rays sessions twice weekly for 3 months + topical bimatoprost 0.03% ophthalmic solution solution twice daily ( 1 drop for each 2 cm2 ) and the other side will be treated by topical bimatoprost 0.03% ophthalmic solution twice daily ( 1 drop for each 2 cm2 ) + narrow band ultraviolet rays sessions twice weekly for 3 months + 10.600-nm fractional carbon dioxide laser sessions twice monthly for 3 months."
2866040|NCT03487029|Experimental|short duration group|30sn %100 Wmax 120sn %25 Wmax 3 sessions/week total 8 weeks
2866041|NCT03487029|Experimental|long duration group|4dk %85 Wmax 120sn %25 Wmax 3 sessions/week total 8 weeks
2866042|NCT03487016|Active Comparator|A: Gemcitabine/nab-Paclitaxel (Standard)|"Nab-paclitaxel 125 mg/m2, i.v. infusion over about 30 minutes followed by Gemcitabine 1000 mg/m2 as a 30-minute i.v. infusion on D1, D8, D15 of a 28-day cycle.~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
2866043|NCT03487016|Experimental|B: NAPOLI regimen|"On Day 1 of a 14-day cycle:~Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
2866044|NCT03487016|Experimental|C: seq-NAPOLI-FOLFOX|"The NAPOLI regimen and the mFOLFOX6 regimen are applied in an alternating fashion, starting with the NAPOLI regimen.~NAPOLI:~On Day 1 of a 14-day cycle:~Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)~mFOLFOX6:~On Day 1 of a 14-day cycle:~Oxaliplatin 85 mg/m2 as i.v. infusion over 2 to 6 hours according to local practice at trial site Folinic acid 400 mg/m2 as i.v. infusion; infusion duration according to local practice at trial site followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
2866045|NCT03487003|Active Comparator|MR group|When the patients asleep, 0.3 mg/kg rocuronium is administered.
2866046|NCT03487003|Experimental|NMR group|When the patients asleep, 0.3 mg/kg saline is administered.
2866047|NCT03486990|Experimental|Cohort 1|0.1 mg/kg, single IV infusion TIMP-GLIA
2866048|NCT03486990|Experimental|Cohort 2|0.5 mg/kg, single IV infusion TIMP-GLIA
2866049|NCT03486990|Experimental|Cohort 3|1 mg/kg, single IV infusion TIMP-GLIA
2866050|NCT03486990|Experimental|Cohort 4|2 mg/kg, single IV infusion TIMP-GLIA
2866051|NCT03486990|Experimental|Cohort 5|4 mg/kg, single IV infusion TIMP-GLIA
2866052|NCT03486990|Experimental|Cohort 6|8 mg/kg, single IV infusion TIMP-GLIA
2866053|NCT03486990|Experimental|Cohort 7|10 mg/kg, single IV infusion TIMP-GLIA
2866054|NCT03486990|Experimental|Cohort 8|Repeat dose, two IV infusions TIMP-GLIA, dose level to be determined
2866055|NCT03486977||Establishments with telemedicine system|Establishments equipped for telemedicine (teleconsultation, casualty) as part of the regional project of the Aquitaine regional program telemedicine device deployment.
2866056|NCT03486977||Establishments without telemedicine system|"Defined and equipped for telemedicine EHPAD after mating on the number of residents, the GMP (average weighted GIR), the PMP (weighted average PATHOS), the distance to a hospital with an emergency shelter service.~The rate of unscheduled hospitalizations will be collected during follow-up visits in clinical departments of the healthcare of the Gironde by a research staff"
2866057|NCT03486964||DPP-4 plus other therapies|Patients in therapy with DPP-4 inhibitors in addition to sulfonylureas and/or biguanides and/or thiazolidinediones and/or insulin
2866058|NCT03486964||Other therapies|Patients in therapy with other hypoglycemic classes, such as sulphonylureas and/or biguanides and/or thiazolidinediones and/or insulin.
2866059|NCT03486938|Placebo Comparator|Placebo Oral Tablet|Matching placebo to AGB101 tablet once daily, taken orally, for 78 weeks.
2866060|NCT03486938|Experimental|AGB101 220 mg tablet|Single 220 mg AGB101 tablet once daily, taken orally, for 78 weeks.
2866061|NCT03486925|Experimental|oxytocin group|
2866062|NCT03486925|Placebo Comparator|placebo group|
2866063|NCT03486912|Experimental|BMS-986036 Dose Level 1|Administered by subcutaneous injection
2866064|NCT03486912|Experimental|BMS-986036 Dose Level 2|Administered by subcutaneous injection
2866065|NCT03486912|Experimental|BMS-986036 Dose Level 3|Administered by subcutaneous injection
2866066|NCT03486912|Placebo Comparator|Placebo|Administered by subcutaneous injection
2866067|NCT03486899|Experimental|BMS-986036 Dose Level 1|Administered by subcutaneous injection
2866068|NCT03486899|Experimental|BMS-986036 Dose Level 2|Administered by subcutaneous injection
2866069|NCT03486899|Experimental|BMS-986036 Dose Level 3|Administered by subcutaneous injection
2866070|NCT03486899|Placebo Comparator|Placebo|Administered by subcutaneous injection
2866071|NCT03486886|Experimental|PSMA -PET/CT scanning|
2866072|NCT03486873|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations or more for First Course participants and up to 17 administrations for Second Course participants.
2866073|NCT03486873|Experimental|Pembrolizumab+SOC (Per Parent Study)|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle PLUS standard of care (SOC) treatment (or per parent study if there is no SOC) for up to 35 administrations or more for First Course participants and up to 17 administrations for Second Course participants. Participants receiving a pembrolizumab-based combination treatment will receive the dose regimen of the combination drug(s) which is recommended per SOC, or was used in the parent study protocol if there is no SOC recommendation.
2866074|NCT03486873|Active Comparator|SOC (Per Parent Study)|Participants receive the same non-pembrolizumab SOC treatment (e.g. chemotherapy) they were receiving in the parent study for up to 35 administrations or more for First Course participants and up to 17 administrations for Second Course participants.
2866075|NCT03486860|Experimental|Turtle Program|The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
2866076|NCT03486860|Other|Waitlist Control|Untreated comparison group during the study, received parent psychoeducation intervention after the active treatment group.
2866077|NCT03486847|Experimental|Repetitive alveolar recruitment with PEEP|One alveolar recruitment at before surgery and repetitive alveolar recruitment (once an hour) during surgery
2866078|NCT03486847|Active Comparator|One alveolar recruitment with PEEP|One alveolar recruitment at before surgery
2866079|NCT03486834|Experimental|V160 3-Dose Regimen|Participants will receive V160 vaccination by intramuscular (IM) injection on Day 1, Month 2, and Month 6.
2866080|NCT03486834|Experimental|V160 2-Dose Regimen|Participants will receive V160 vaccination by IM injection on Day 1 and Month 6 and placebo at Month 2.
2866081|NCT03486834|Placebo Comparator|Placebo|Participants will receive placebo by IM injection on Day 1, Month 3, and Month 6.
2866082|NCT03486821|Experimental|Hypofrac Radiation Therapy|"All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.~Radiation treatment will start approximately 1-2 weeks after the simulation scan. Prior to each treatment, you will be asked to have a full bladder and empty rectum. You will be asked to take a liquid diet starting the afternoon prior to each treatment, and a laxative (such as Miralax) in the evening prior to each treatment. You will also be asked to take a Fleet's enema about 1 hours prior to the treatment time to ensure that the rectum is empty. To ensure full bladder, you will be asked to drink about 32 oz of water after the enema. This is the same procedure as above for the prep before the simulation scan.~Each treatment should take about 10-20 minutes."
2866083|NCT03486808|Experimental|Dual stimulation|i) anodal stimulation of left inferior frontal cortex ii) anodal stimulation on left dorsolateral prefrontal cortex
2866084|NCT03486808|Active Comparator|IFG stimulation|anodal stimulation of left inferior frontal cortex
2866085|NCT03486808|Active Comparator|DLPFC stimulation|anodal stimulation on left dorsolateral prefrontal cortex
2866086|NCT03486808|Sham Comparator|Sham stimulation|sham stimulation
2866087|NCT03486795|Experimental|Dual stimulation|"anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex~anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area"
2866088|NCT03486795|Experimental|M1 stimulation|anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
2866089|NCT03486795|Experimental|PMC stimulation|anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area
2866090|NCT03486795|Sham Comparator|Sham stimulation|Sham stimulation
2866091|NCT03486782|Active Comparator|Dual stimulation|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional supraorbital area ii) anodal stimulation on ipsilesional dorsolateral prefrontal cortex and cathodal stimulation of contralesional supraorbital area
2866092|NCT03486782|Active Comparator|Single stimulation 1|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional inferior frontal cortex
2866093|NCT03486782|Active Comparator|Single stimulation 2|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional supraorbital area
2866094|NCT03486769|Experimental|Dual Stimulation 1|i) anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex, ii) anodal stimulation on ipsilesional premotor cortex and cathodal stimulation on contralesional supraorbital area.
2866159|NCT03486275|Active Comparator|Source articles|9 articles from independent journals based on evidence (reviews by Prescrire and Minerva)
2866095|NCT03486769|Experimental|Dual Stimulation 2|i) anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex, ii) anodal stimulation on ipsilesional anterior intraparietal sulcus and cathodal stimulation on contralesional supraorbital area.
2866096|NCT03486769|Experimental|Single stimulation|anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex
2866097|NCT03486756|Experimental|Internet-CBT|Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform.
2866098|NCT03486743|Experimental|Intervention arm|Participants in the intervention arm will be asked to watch a short educational video on LARC (Long acting reversible contraceptive) and to complete a survey before and after watching the video.
2866099|NCT03486743|No Intervention|Control arm|Participants in the intervention arm will only be asked to complete a survey.
2866100|NCT03486730|Experimental|Dose escalation phase|Groups of patients will receive increasing doses of BT1718 to find a safe dose that best targets the cancer cells. In this phase it is expected that approximately 40-50 patients with advanced solid tumours will be entered in the study.
2866101|NCT03486730|Experimental|Dose expansion phase|Larger groups of patients will receive the selected dose of BT1718 to allow us to find out more about how the drug is working. In this phase it is proposed that approximately 60-70 patients with either Triple Negative Breast Cancer (TNBC), Non-Small Cell Lung Cancer (NSCLC) or Sarcoma will be entered in the study, as these tumour types are commonly known to overexpress MT1-MMP.
2866102|NCT03486704|Experimental|Face to Face VRRS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
2866103|NCT03486704|Active Comparator|Usual rehabilitation program|The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
2866104|NCT03486704|Active Comparator|FTF VRRS plus unstructured CS|Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week.
2866105|NCT03486691|Experimental|preoperative left lobe measurement|routine preoperative left lobe measurement
2866106|NCT03486691|Active Comparator|Control group|Control group without routine measurement of left lobe
2866107|NCT03486678|Experimental|SHR1210+GEMOX|This is a single arm trial. Participants will receive SHR1210 + GEMOX treatment.
2866108|NCT03486665||Diagnosed with Multiple Sclerosis|Patients previously diagnosed with Multiple Sclerosis
2866109|NCT03486665||Newly Diagnosed with Multiple Sclerosis|Patients diagnosed for the first time with Multiple Sclerosis and hospitalized
2866110|NCT03486665||Healthy Volunteers|Health volunteers who do not have an autoimmune diseases, including Multiple Sclerosis
2866111|NCT03486639||Patients undergoing urodynamic|All patients older than 18 who are refered for Urodynamics examination
2866112|NCT03486626|Experimental|Patients|
2866113|NCT03486613|Other|Group AT|PROM registration via the DANBIO App on a smartphone and thereafter the touch screen solution
2866114|NCT03486613|Other|Group TA|PROM registration via the touch screen solution and thereafter the DANBIO App
2866115|NCT03486600|Other|fluid resuscitation|Patients will be evaluated and the bleeding site to be investigated and hemorrhagic shock confirmed and there is an expected delay in blood and blood products transfusion for more than 40 minutes. 6% HES 130/0.4 (Voluven®) will be administered intravenously to maintain or restore hemodynamic stability up to a maximum dose of 50 mL/kg body weight.
2866116|NCT03486587|Experimental|Changfukang® group|Patients in Changfukang group will receive Changfukang® (Bacillus Cereus tablets).
2866117|NCT03486574||Gastric cancer|Pathologically proven diseases after upper gastroendoscopy and biopsy. Previous pathological reports and endoscopic image can be used.
2866118|NCT03486574||non-gastric cnacer|Rull out gastric cancer by upper gastroendoscopy. The results 3 moths before enrollment is available.
2866119|NCT03486561|Other|Ranolazine|Ranolazine was approved by the U.S. Food and Drug Administration in 2006 in 500 mg and 1000 mg extended‐release doses, advising 500 mg BID as a starting dose and 1000 mg BID as maximum dose
2866120|NCT03486548|Sham Comparator|control group|adductor canal block with sham block
2866121|NCT03486548|Experimental|sciatic group|adductor canal block with popliteal sciatic nerve block
2866122|NCT03486535||Diabetic patients|Diabetic patients will receive ultrasound-guided infraclavicular brachial plexus blocks (ICBs) with the mixture of 15 mL lidocaine 2% and 15 mL bupivacaine 0.5%.
2866123|NCT03486535||Non-diabetic patients|Nondiabetic patients will receive ultrasound-guided infraclavicular brachial plexus blocks (ICBs) with the mixture of 15 mL lidocaine 2% and 15 mL bupivacaine 0.5%.
2866124|NCT03486509|Experimental|afatinib 40mg bid plus chemotherapy|afatinib 40mg bid po plus chemotherapy
2866125|NCT03486496|Experimental|Gefitinib and Berberine|Experimental: Gefitinib and Berberine Patients will be treated with Gefitinib and Berberine. Gefitinib: 250 mg p.o., daily. Berberine: 50 mg p.o., tid.
2866126|NCT03486483|Experimental|Supervised Slackline Training|Supervised Slackline training in children and teenagers with spastic cerebral palsy (grade I and II of the Gross Motor Function Classification System). Intervention included 18 slackline rehabilitation sessions for 6 weeks: 3 sessions per week on non-consecutive days, 30 min each one.
2866127|NCT03486483|No Intervention|Physical Activity|The control group followed its usual weekly physical activity routine.
2866128|NCT03486457|Experimental|Treatment Sequence A|Tofacitinib 5 mg BID for 6 months
2866129|NCT03486457|Placebo Comparator|Treatment Sequence B|Placebo for 3 months then tofacitinib 5 mg BID for 3 months
2866155|NCT03486301|Experimental|BDB001 in Combination with Pembrolizumab|"In the combination arm of the study, a standard 3+3 dose escalation design will be utilized for all dose levels.~When the MTD or RP2D of single agent BDB001 is reached, the first dose level cohort of the combination arm will begin. Once the MTD or RP2D in combination has been determined, twenty additional subjects will be enrolled in the expansion phase of the study."
2866156|NCT03486288||Delirium|
2866157|NCT03486288||No Delirium|
2866130|NCT03486444|Experimental|Patient population|When a patient receives an ultrasound examination as part of standard of care or within another clinical research trial, such an examination may serve for an intra-individual comparator examination between conventional and new, ultra-portable ultrasound imaging. Patients will be identified in the clinical setting when appropriate and will be appropriately approached for consent for a combination of ultrasound with the physical exam, for medical student education, IV access, and novel application. Patients will be enrolled and accounted for in the appropriate sub-population.
2866131|NCT03486444|Experimental|Healthy volunteer population|The volunteer population will allow us to practice the use of this equipment and understand the limitations and applicability. The results will be the images acquired as well as surveys from the volunteers and those performing the scans, who will be enrolled in the staff population of this study.
2866132|NCT03486444|Experimental|Student and staff population|To understand the impact of ultraportable ultrasound, survey tools will be used to understand the workflow and clinical care applications and integration of these devices. All staff and student members will be appropriately consented; however, we anticipate that this portion of the study will be minimal risk.
2866133|NCT03486431|Experimental|Level I|5 x 7 Gy SABR
2866134|NCT03486431|Experimental|Level II|3 x 10 Gy SABR
2866135|NCT03486431|Experimental|Level III|1 x 20 Gy SABR
2866136|NCT03486405|Experimental|Intervention group|The experimental group will have no in person education by researchers. All education and running modification will be performed via video. Education on running form, a home exercise program, and a 4 week return to run program will be provided to the subjects through e-mail. They will also receive the same in person video analysis performed at weeks 0 (initial), 10 and 6 months to assess running kinematics.
2866137|NCT03486405|Active Comparator|Control group|This group will have the same 4 week return to run program, home exercise program, and video analysis performed at weeks 0 (initial), 10 and 6 months to assess running kinematics.
2866138|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 1|Participants will receive a JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 26-week treatment phase.
2866139|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 2|Participants will receive a JNJ-64565111 Dose Level 2 SC once-weekly for 26-week treatment phase.
2866140|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 3|Participants will receive a JNJ-64565111 Dose Level 3 SC once-weekly for 26-week treatment phase.
2866141|NCT03486392|Placebo Comparator|Double-Blind: Placebo|Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 26-week treatment phase.
2866142|NCT03486392|Active Comparator|Open-Label: 3.0 milligram (mg) Liraglutide|Participant will receive once-daily doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg. The participants will receive liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1. Participants will be instructed to increase the dose of liraglutide by 0.6 mg dose increment every 7 days, up to the full dosage of 3.0 mg by Week 5. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
2866143|NCT03486366|Other|Workpackage1 WP1|Non interventional trial: male or female children with a definite diagnosis of TSC (Roach 1998), aged up to 4 years, diagnosis of epilepsy established on the basis of clinical seizures or epileptiform changes on EEG within 1-7 days prior to baseline. We plan to enroll 60 TSC patients into WP1 to Epimarker in 12 months.
2866144|NCT03486366|Other|Workpackage2 WP2|Non interventional trial: male or female children with a definite diagnosis of TSC (Roach criteria: Roach 1998) and epilepsy, aged up to 16 years, seizure free, in whom a decision to withdraw antiepileptic drugs was made. We plan to enroll 60 TSC patients into WP2 to Epimarker in 12 months. The data obtained in children seizure free at the end of follow-up and patients with recurrent seizures will be compare.
2866145|NCT03486353|Experimental|Run-In Phase, Regimen 1|Patients will be treated with FF-10501-01 at a dose of 400 mg/m2 twice daily (BID) for 14 days plus azacitidine at a dose of 75 mg/m2 either subcutaneously (SC) or intravenously (IV) x 7 days every 28 days. One treatment cycle will be 28 days in duration.
2866146|NCT03486353|Experimental|Run-In Phase, Regimen 2|Patients will be treated with FF-10501-01 at a dose of 400 mg/m2 BID for 21 days plus azacitidine at a dose of 75 mg/m2 either SC or IV x 7 days every 28 days.
2866147|NCT03486340|Experimental|Cardiological assessment|a sub-acute cardiologic assessment and aggressive management of risk factors before oncologic treatment
2866148|NCT03486340|No Intervention|Standard treatment|Standard chemotherapeutic treatment
2866149|NCT03486327|Experimental|0.03mL/kg Dose Group|A group of up to 8 subjects to receive a single dose of BR55 at 0.03mL/kg.
2866150|NCT03486327|Experimental|0.05mL/kg Dose Group|A group of up to 8 subjects to receive a single dose of BR55 at 0.05mL/kg.
2866151|NCT03486327|Experimental|0.08mL/kg Dose Group|A group of 8 subjects to receive a single dose of BR55 at 0.08mL/kg.
2866152|NCT03486314|Experimental|Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg|Pevonedistat 50 milligram per square meter (mg/m^2), infusion, intravenously, once on Day 1 and 10 along with rifampin 600 milligram (mg), capsule, orally, once daily from Day 3 up to Day 11 in Part A. After completion of Part A, participants will have opportunity to continue into optional Part B.
2866153|NCT03486314|Experimental|Part B: Pevonedistat|Pevonedistat is given intravenously at 25 mg/m^2 in combination with docetaxel 75 mg/m^2 or at 20 mg/m^2 in combination with carboplatin AUC5+paclitaxel 175 mg/m^2; pevonedistat is given in combination on Day 1 and as a single agent on Days 3 and 5 of each 21-day cycle. Participants will be treated for up to 12 cycles or symptomatic deterioration or PD, treatment is discontinued for another reason, or until the study is stopped in Part B. The choice of combination partner (docetaxel or carboplatin + paclitaxel) will be based on investigator discretion. If the sponsor and investigator determine that a participant would derive clinical benefit from continued treatment, the participant may remain on the current combination therapy or receive pevonedistat as a single agent beyond 12 cycles.
2866154|NCT03486301|Experimental|Single Agent BDB001|A single subject will be enrolled at each dose level in the single agent arm until any ≥ Grade 2 treatment-emergent adverse event (TEAE) is observed in the first cycle. Then dose escalation will follow a traditional 3+3 dose escalation design. Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of single agent BDB001 is reached.
2866158|NCT03486275|Active Comparator|Hygie game|Prototype video game called Hygie on the 5 most common reasons of consultation in general practice using 9 articles from independent journals based on evidence (reviews by Prescrire and Minerva).
2866161|NCT03486249|Experimental|Patient difficult to wean|Repetition of medical examinations performed as part of the care. All patients will have a cardiac echo examination and diaphragm function assessment before the spontaneous breathing trial.
2866162|NCT03486236|Experimental|Cohort C1|
2866163|NCT03486236|Placebo Comparator|Cohort C1: Triple Placebo|
2866164|NCT03486236|Experimental|Cohort C2|
2866165|NCT03486236|Placebo Comparator|Cohort C2: Triple Placebo|
2866166|NCT03486223|Experimental|Placebo, GSK2256294|Subjects will receive placebo oral capsule daily by mouth for 7 days, then seven week washout and then GSK2256294 daily by mouth for 7 days.
2866167|NCT03486223|Experimental|GSK2256294, Placebo|Subjects will receive GSK2256294 daily by mouth for 7 days, then seven week washout and then placebo oral capsule daily by mouth for 7 days.
2866168|NCT03486210||Phase 1 Group 1|Healthy volunteers
2866169|NCT03486210||Phase 1 Group 2|Health professionals
2866170|NCT03486210||Phase 2 Group 1|Control group : patients obese without surgery
2866171|NCT03486210||Phase 2 Group 2|Patients who have underwent a sleeve gastrectomy
2866172|NCT03486210||Phase 2 Group 3|Patients who have underwent a gastric bypass
2866173|NCT03486197|Experimental|Treatment (Pembrolizumab, neutron radiation therapy)|Participants receive pembrolizumab IV on days 1 and 22. On day 23, participants may undergo an optional tumor biopsy and receive 3-5 treatments of neutron radiation therapy over 2 weeks on days 23-42. Participants receive pembrolizumab IV on day 43 and continue per standard of care in the absence of disease progression or unacceptable toxicity.
2866174|NCT03486158|Experimental|CalproSmart application|In addition to regular outpatient clinic visits and a routine CalproSmart test every 3 months, patients are instructed to obtain fecal samples if they experience symptoms suspect of recurrent IBD and to perform home analysis with CalproSmart™ system test kit
2866175|NCT03486158|No Intervention|Standard follow-up|in addition to regular outpatient clinic visits and a routine calprotectin test in the same week as the visit date, patients bring home an F-calpro tube and envelope and are instructed to obtain fecal samples and send these to local lab if they experience symptoms suspect of recurrent IBD
2866176|NCT03486145|Experimental|FVS (fruit and vegetable juice supplement)|The supplement contained ≈ 260-280 mg or 4 mmoles nitrate per two-ounce serving along with ≈ 51 mg total polyphenols. The FVS contains 7880 mg of a proprietary blend of beet root extract (Beta vulgaris), celery stem and leaf extract (Apium graveolens), red spinach leaf extract (Amaranthus dubius), stevia leaf extract (Stevia rebaudiana), and a fruit and vegetable extract blend (green tea leaf, red grape, white grape, bilberry, carrot, grapefruit, papaya, pineapple, strawberry, apple, apricot, cherry, orange, broccoli, green cabbage leaf, onion, garlic, black current, asparagus, tomato, olive and cucumber). Virtually all of the nitrates in FVS derive from the beet, celery, and red spinach extracts.
2866177|NCT03486145|Placebo Comparator|PRU (prune juice)|The placebo supplement was prune juice (Sunsweet brand 100% prune juice) (PRU). Prune juice was selected based on its very similar caloric and sugar content, its high antioxidant and phenolic profile, but low nitrate content. The prune juice contained <0.6 mg nitrates and 133 mg total polyphenols per two-ounce serving.
2866178|NCT03486132|Other|interrupted repair of mediolateral episiotomy|"using the interrupted suture (IT) which involves placing three layers of sutures: a continuous non-locking stitch to close the vaginal epithelium. commencing above the apex of the wound and finishing at the level of the fourchette; three or four interrupted sutures to reapproximate the deep and superficial perineal muscles; and interrupted transcutaneous technique to close the skin.~The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0 Mediolateral episiotomy:it is defined as an incision beginning in the midline and directed laterally and downwards away from the rectum .The incision is usually about four centimeters long. In addition to the skin and subcutaneous tissues the bulbocavernosus, transverse perineal, and puborectalis muscles will be cut"
2866179|NCT03486132|Other|continous repair of mediolateral episiotomy|continuous knotless suturing technique (CKT) which involves placing the first stitch above the apex of vaginal trauma to secure any bleeding points that might not be visible. Vaginal wound, perineal muscles (deep and superficial), and skin are reapproximated with a loose, continuous, non-locking technique. The skin sutures will be placed closely fairly deeply in the subcutaneous tissue, reversing back and finishing with a terminal knot placed in the vagina beyond the hymeneal remnants Mediolateral episiotomy:it is defined as an incision beginning in the midline and directed laterally and downwards away from the rectum .The incision is usually about four centimeters long. In addition to the skin and subcutaneous tissues the bulbocavernosus, transverse perineal, and puborectalis muscles will be cut The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0
2866180|NCT03486132|Other|interrupted repair of lateral episiotomy|"using the interrupted suture (IT) which involves placing three layers of sutures: a continuous non-locking stitch to close the vaginal epithelium. commencing above the apex of the wound and finishing at the level of the fourchette; three or four interrupted sutures to reapproximate the deep and superficial perineal muscles; and interrupted transcutaneous technique to close the skin.~The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0 And Lateral episiotomy; It begins in the vaginal introitus 1 or 2 cm lateral to the midline and is directe downwards towards the ischial tuberosity"
2866181|NCT03486132|Other|continuous repair of lateral episiotomy|continuous knotless suturing technique (CKT) which involves placing the first stitch above the apex of vaginal trauma to secure any bleeding points that might not be visible. Vaginal wound, perineal muscles (deep and superficial), and skin are reapproximated with a loose, continuous, non-locking technique. The skin sutures will be placed closely fairly deeply in the subcutaneous tissue, reversing back and finishing with a terminal knot placed in the vagina beyond the hymeneal remnants And Lateral episiotomy; It begins in the vaginal introitus 1 or 2 cm lateral to the midline and is directe downwards towards the ischial tuberosity The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0
2866182|NCT03486106|Placebo Comparator|Headphones without music|Participants in the control group will receive noise-cancelling wireless headphones that will not play any noise throughout the procedure. They will also receive propofol for sedation as needed.
2866283|NCT03485365|Placebo Comparator|Part A: Cohort 5: Placebo|Eligible subjects will receive placebo matching to GSK3858279 via IV route.
2866183|NCT03486106|Experimental|Headphones with music|Participants in the experimental group will receive the same noise-cancelling wireless headphones but will be permitted to listen to the music of their choice while in the operating room. They will also receive propofol for sedation as needed.
2866184|NCT03486093|Experimental|CVC managed by healthcare workers|Patients with CVC managed by healthcare workers trained/retrained to GAVECELT recommendations.
2866185|NCT03486093|Experimental|CVC managed by healthcare workers plus port protector|Patients with CVC managed by healthcare workers trained/retrained to GAVECELT recommendations with the aid of port protector devices.
2866186|NCT03486080|Active Comparator|Dutogliptin/filgrastim combination|Twice daily SC injections of 60 mg dutogliptin tartrate for 14 days in combination with 10 µg/kg filgrastim injectable product for 5 days
2866187|NCT03486080|Placebo Comparator|Placebo control|Twice daily dutogliptin SC placebos for 14 days in combination with matching filgrastim SC placebos for 5 days
2866188|NCT03486067|Experimental|Administration of CC-93269|CC-93269 by intravenous (IV) infusion on a 28 day cycle.
2866189|NCT03486054|Experimental|INTERCEPT|Transfusion with one bag of Whole blood treated with amustaline and glutathione, a pathogen inactivation (PI) system, ordered and administered to study patients by their treating physicians
2866190|NCT03486054|Active Comparator|Conventional Whole Blood|Transfusion intervention with one conventional whole blood ordered and administered to study patients by their treating physicians.
2866191|NCT03486054|Experimental|INTERCEPT (dose escalation)|Transfusion intervention with two Whole blood treated with amustaline and glutathione, a pathogen inactivation system, ordered and administered to study patients by their treating physicians.
2866192|NCT03486041|Experimental|immediate ComB|12 weekly sessions of ComB treatment in individual therapy, following a detailed manual.
2866193|NCT03486041|Placebo Comparator|Minimal Attention Control|Weekly brief phone call from therapist to check on participant safety, medication changes if any, and recent stressors. After week 12, participants in this arm received delayed ComB [as in the Experimental condition -- 12 weekly sessions of individual therapy for TTM based on ComB model].
2866194|NCT03486028||ASAM Counties/non-computerized|Pre- and 1115-waived counties that are implementing the ASAM. Intervention is adherence to ASAM protocols.
2866195|NCT03486028||ASAM Counties/computerized|Counties using a computerized system to assist in intervention determination according to ASAM protocols. Intervention is adherence to ASAM protocols.
2866196|NCT03486028||Non-ASAM Counties|"Pre- and non-waived control counties that are not implementing the ASAM. Intervention is non-adherence to ASAM protocols."
2866197|NCT03486015|Experimental|30% glucose|This group will be given 2 ml of 30% glucose in the mouth before the physical examination of the infant.
2866198|NCT03486015|Placebo Comparator|Sterile water|This group will be given 2 ml of sterile water in the mouth before the physical examination of the infant.
2866199|NCT03486002|Other|Cleansweep closed suction system|
2866200|NCT03486002|Other|Halyard closed suction system|
2866201|NCT03485989|Experimental|Hazelnuts|Participants given 2 ounces (~57 grams) of dry roasted hazelnuts to consume each day.
2866202|NCT03485976|Experimental|Ixekizumab treatment arm|Ixekizumab 160 mg subcutaneous injection at week 0, followed by 80 mg subcutaneous injections at week 2, 4, 6, 8, 10, 12, 16, and 20
2866203|NCT03485963|Experimental|Fixed dose HIV-1 specific T-cells (HST-NEETs)|Patients will be screened for eligibility in Step 1 and undergo a blood draw of 100-120mL to allow production of autologous HST-NEETS. patients will receive a fixed dose of 2x10e7/m2. For the first 3 recipients, the infusions will occur 4 weeks apart. If no adverse reactions occur that are attributable to the HST-NEETs, the recipients thereafter will receive the two infusions separated by 2 weeks.
2866204|NCT03485950|Experimental|Ceftolozane-Tazobactam Group|Participants receive Ceftolozane-Tazobactam by vein over 1 hour every 8 hours.
2866205|NCT03485950|Experimental|Standard Treatment Antibiotic Group|"Participants receive a standard treatment antibiotic. This may include one of the following 3 options:~Cefepime by vein over about 30 minutes every 8 hours.~Meropenem by vein over about 30 minutes every 8 hours.~Piperacillin/tazobactam by vein over about 1 hour every 6 hours."
2866206|NCT03485937|Experimental|Pre-Operative Videos + verbal/written instructions|This video contains the same instructions that the patient receives when they arrive at the clinic, as well as a video walk through of the clinic/patient room. Videos will be created by the study team to ensure that the content coincides with what is delivered in the standard-of-care verbal and written instructions.
2866207|NCT03485937|Active Comparator|verbal/written instructions|This arm will receive the standard-of-care verbal/written instructions and the pre-operative video explanation. These instructions contain the same content as in the pre-operative videos
2866208|NCT03485924|Active Comparator|EUS-FNA with ROSE|EUS/FNA with ROSE will be performed using standard techniques via 22-g FNA needle (Cook Medical EchoTip Ultra or Boston Scientific Expect or Medtronic Beacon). Lesions will be identified using EUS and punctured with the FNA needle (10-15 back and forth movements per needle pass, fanning as appropriate). After the lesion is punctured, the stylet will be removed and 10cc suction will be applied. FNA specimens will be processed for ROSE using standard techniques with bedside smear slide evaluation and liquid-based cytology and cell-block preparation.
2866209|NCT03485924|Active Comparator|EUS-FNB without ROSE|EUS/FNB without ROSE will be performed using similar techniques for tissue acquisition as FNA using 22-g FNB needle (Medtronic SharkCore or Boston Scientific Acquire). Lesions will be identified using EUS and punctured with the 22-g FNB needle (10-15 back and forth movements per needle pass, fanning as appropriate). After the lesion is punctured, the stylet will be removed and 10cc suction will be applied. FNB samples will be placed directly into formalin containers and sent to be processed by surgical pathology.
2866210|NCT03485911|Experimental|BCX7353 110 mg once daily|BCX7353 administered as oral capsules once daily
2866211|NCT03485911|Experimental|BCX7353 150 mg once daily|BCX7353 administered as oral capsules once daily
2866212|NCT03485911|Placebo Comparator|Placebo|Matching placebo administered as oral capsules once daily
2866243|NCT03485612||change of the optic nerve sheath diameter|The test group will be male and female patients, aged over 18 and below 90 years of age. Each patient will be operated for urological reasons in the position for lithotomy.
2866244|NCT03485599||HIV infected people|Blood samples will be taken and rapid HIV test by ELIZA will be done ,for positive cases Westron blot done
2866213|NCT03485872|Experimental|Self-Screening and Referral Information|The intervention will include a combination of self-screening and UI specific information and resources. Older adults in the intervention group will complete a gender specific UI Self-Screening tool. Men will complete the International Consultation on Incontinence Modular Questionnaire (ICIQ) for Males and women will complete the ICIQ for Females. In addition, the intervention group will receive a fact sheet with UI specific information, contact information to the local incontinence clinic and a link to a website with patient incontinence resources and education.
2866214|NCT03485872|Active Comparator|Control Group|Older adults assigned to the control group will receive standard care from their physicians. Standard care may differ from general practitioner to general practitioner. Usual care for urinary incontinence (UI) from general practitioners is generally minimal. Most patients do not tell their physicians about UI, and most physicians do not ask about UI. If this topic does come up during a GP appointment, a patient may be offered no treatment, lifestyle advice (e.g., do not drink before bed), told to do Kegels (but likely not instructed how to do these properly) or in some cases, offered pharmacological therapies (which will be captured in our questionnaire with the participants). But standard of care is unfortunately very often no care.
2866215|NCT03485859|Experimental|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. The binder was placed on the abdomen across the laparoscopic incision, with the upper border not higher than the lower margin of the rib cage, ensuring minimal restriction of lateral costal expansion and diaphragmatic excursion. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
2866216|NCT03485859|Placebo Comparator|Control group|In subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
2866217|NCT03485846|Experimental|Narlaprevir + Ritonavir + Daclatasvir|All of enrolled patients receive equal study therapy with Narlaprevir/Ritonavir/Daclatasvir daily for 12 weeks
2866218|NCT03485833|Experimental|EEO and EIO test|velocity time integral of the aorta measured by transesophageal echocardiography during end expiratory and end inspiratory occlusion test to predict volume responsiveness.Responders are defined by an increase in velocity time integral over 15% after infusion of 5ml/kg of crystalloid solution.
2866219|NCT03485820|Experimental|COMPASS|COMPASS is a complex intervention that combines 2 evidence-based treatment strategies at a new point of care (transition from inpatient rehabilitation). The objective of home visits by an OT provider is to remediate barriers in the home and community that influence daily activities and community participation. The treatment will include a set of 1 predischarge and four 75-minute postdischarge visits. The intervention is followed by 2 booster sessions.
2866220|NCT03485820|Sham Comparator|Education program|"An OT practitioner will deliver the program in accordance with Evidence-Based Educational Guidelines for Stroke Survivors after Discharge Home. Topic order is determined by participants. Four 75-minute sessions will be provided. Topics may include stroke symptoms, risk factors and preventing stroke recurrence, nutrition, managing emotions, sleep, pain. Written materials from the National Stroke Association and the American Stroke Association are provided."
2866221|NCT03485807|Experimental|Mindfulness Training (MT)|
2866222|NCT03485807|Experimental|Active Coping Training (CT)|
2866223|NCT03485794||Diagnostic (biospecimen collection)|Patients undergo collection of blood for metabolic profiling via LC/Q-TOF/MS.
2866224|NCT03485768|Experimental|percutaneous disc decompression with coblation nucleoplasty|PDCN will be performed in patients who are allocated to this group by using the COBLATION Perc-DC SpineWand surgical device (ArthroCare System 2000, ArthroCare corporation, Heredia, Costa Rica, USA)
2866225|NCT03485768|Active Comparator|Manual Therapy|Participants who are allocated to this group will undergo manual therapy treatments containing two kinds: sustained natural apophyseal glides (SNAGs) plus passive joint mobilisations (PJMs)
2866226|NCT03485755||Children|Children 8-10 years of age
2866227|NCT03485755||Biological Mothers|Biological mothers of children now ages 8-10 years of age
2866228|NCT03485729|Experimental|Biopsy-mandated|
2866229|NCT03485729|Experimental|Biopsy-optional|
2866230|NCT03485716|Experimental|running under hypoxia - first|running under hypoxia (first day) and normoxia (second day)
2866231|NCT03485716|Active Comparator|running under normoxia - first|running under normoxia (first day) and hypoxia (second day)
2866232|NCT03485703|Experimental|azithromycin group|A control group composed of 40 newborns receiving azithromycin
2866233|NCT03485703|Placebo Comparator|placebo group|comparative group composed of 40 newborns who would receive saline 0.9%
2866234|NCT03485690||COPD|COPD patients with no restrictions. The study protocol does not consider ad-hoc different patient groups. Prospective follow-up will be equally done in all recruited patients
2866235|NCT03485677|Experimental|Cohort 1: Eliglustat monotherapy|"Eliglustat for two years. Cohort 1 patients that experience significant clinical decline will receive rescue treatment.~Rescue Treatment Step 1: Switch from eliglustat to imiglucerase monotherapy.~Rescue Treatment Step 2: Patients who after 6 months of rescue therapy with imiglucerase monotherapy do not show improvement in the parameter(s) that led to the switch from eliglustat to imiglucerase, will then receive combination therapy with eliglustat + imiglucerase."
2866236|NCT03485677|Experimental|Cohort 2: Eliglustat plus imiglucerase|Eliglustat plus imiglucerase for two years, at the dose of enzyme replacement therapy received before enrollment. After Week 52, Cohort 2 patients will switch to eliglustat monotherapy for the remainder of the study if the desired clinical response has been achieved.
2866237|NCT03485664||Study Group|Severe pain on percussion of the relevant tooth was considered as basic criteria when deciding on acute infection phase. The acutely infected teeth were labelled as the study group
2866238|NCT03485664||Control Group|The asymptomatic teeth were labelled as the control group
2866239|NCT03485638||Cetuximab administration|
2866240|NCT03485625|Experimental|Lidocaine|Patients in group C will receive 3 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
2866241|NCT03485625|Experimental|Lidocaine+ Ketorolac|Patients in group K receive 3 mg/kg of lidocaine 2% + 20 mg ketorolac diluted with saline to a total volume of 40 ml.
2866242|NCT03485625|Experimental|Lidocaine+Paracetamol|Patients in group P will receive 3 mg/kg of lidocaine 2% + 300 mg paracetamol diluted with saline to a total volume of 40 ml.
2866245|NCT03485586||Group:Traditional ultrasonic biological|The measurement of axial length was performed in 60 eyes (30 eyes for each group) with senile cataract of vitrectomised eye of diabetic retinopathy using lenstar and traditional ultrasonic biological combined with cornea curvimeter.In this group,we use traditional ultrasonic biological combined with cornea curvimeter to measure the ocular parameter.
2866246|NCT03485586||Group:Lenstar|The measurement of axial length was performed in 60 eyes (30 eyes for each group) with senile cataract of vitrectomised eye of diabetic retinopathy using lenstar and traditional ultrasonic biological combined with cornea curvimeter.In this group,we use lenstar to measure the ocular parameter.
2866247|NCT03485560|Experimental|internvention of Chrinic skin conditions|All cases of chronic skin conditions will be included to measure the effect on the 3 of them and whihc one will respond to the treatment better
2866248|NCT03485547|Experimental|Venetoclax|"Venetoclax is administered on a daily basis orally.~The investigators will use a modified 3+3 with a de-escalation dose level design to establish the appropriate and tolerable dose of venetoclax."
2866249|NCT03485534|Experimental|Tenofovir Disoproxil|Tenofovir Disoproxil 245mg, a daily dose for 48 weeks
2866250|NCT03485534|Placebo Comparator|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate 300mg, a daily dose for 48 weeks
2866251|NCT03485521|Active Comparator|Practical Work|15 students who participate in a practical work lasting two hours about the procedures of the tracheobronchial aspiration
2866252|NCT03485521|Experimental|Stimulation Group|Group with competences and reasoning clinic 15 students Simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence after reading the procedures of the tracheobronchial aspiration
2866253|NCT03485495|Experimental|Divaza|
2866254|NCT03485495|Placebo Comparator|Placebo|
2866255|NCT03485482|Experimental|Group Ivabradine|six healthy volunteers will administer Ivabradin tablet only once single 10 mg oral dose
2866256|NCT03485482|Experimental|Group Bisoprolol|six healthy volunteers will administer bisoprolol tablet only once single oral dose of 5mg
2866257|NCT03485482|Experimental|Group combination|six healthy volunteers will administer only once a combination of a single dose of ivabradine 10 mg and bisoprolol 5 mg
2866258|NCT03485469|Other|Usual Care|The control group will benefit from a standard care dietary consultation in the service and 9 dietary consultations by phone every 15 days.
2866259|NCT03485469|Other|Hypnosis|The experimental group will benefit from a dietary consultation in the service, 9 dietary consultations by telephone every 15 days to which will be associated 7 individual sessions of hypnosis and 3 individual sessions of learning to autohypnosis. A recording containing the induction of a self-hypnosis session will be given to the subject at the end of the 10 sessions, in order to promote the continuation of home-made autohypnosis.
2866260|NCT03485456|Experimental|Tobramycin|Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
2866261|NCT03485443|Active Comparator|Group I (%0.9 NaCl 10ml/kg)|"The group (Group 1) received 10 ml kg-1 throughout the entire surgical procedure.~Four point scale using scored vomiting. m CHEOPS Scale using scored between 0-10."
2866262|NCT03485443|Active Comparator|Group II (%0.9 NaCl 20ml/kg)|"The group (Group 2) received 30 ml kg-1 throughout the entire surgical procedure.~Four point scale using scored vomiting. m CHEOPS Scale using scored between 0-10."
2866263|NCT03485430|Active Comparator|Intervention|Receives tapering of opioid dose at baseline
2866264|NCT03485430|No Intervention|Control|Waiting-list. Receives tapering after 4 months.
2866265|NCT03485417|Active Comparator|Aripiprazole Arm|Aripiprazole (oral or depot) Oral: 10-30mg daily Depot: 300-400mg every four week; Intramuscularly
2866266|NCT03485417|Active Comparator|Paliperidone Arm|Paliperidone (oral or depot) Oral: 3-12mg Depot: Intramuscularly; a) sustenna 50-150mg every four weekly, or b) trinza 273-819mg every 12 weekly
2866267|NCT03485417|Other|Treatment as Usual Arm|Treatment as Usual arm
2866268|NCT03485404|Experimental|VB12+FA|Patients will receive oral supplementation of 0.5mg methylcobalamin, 3/day and 5 mg folic acid, 1/day for 7 days before non-cardiac surgery.
2866269|NCT03485404|Placebo Comparator|Placebo|Patients with receive oral tablets of placebo for folic acid 1/d and placebo for methylcobalamin 3/d, which look exactly like the interventional drugs as oral supplementation for 7 days before non-cardiac surgery.
2866270|NCT03485404|Other|Non-surgical controls|Age and sex-matched community elderly people are included for two sessions of NPB test evaluation for calculation of POCD incidence as normal control to in Z value calculation of POCd incidence to rule out learning effect.
2866271|NCT03485391|Experimental|PE+Exposure Workout Buddy|Prolonged Exposure with assistance of Veteran who has successfully completed treatment to meet patients at exposure sites in the community to offer support during exposure.
2866272|NCT03485391|Active Comparator|PE+Peer General Support|Prolonged Exposure with assistance of Veteran who has successfully completed treatment to call and talk to patients once per week, informally meet at patient appointments, encourage session attendance and check in about progress.
2866273|NCT03485378|Experimental|Treatment Arm: Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease
2866274|NCT03485365|Experimental|Part A: Cohort 1: GSK3858279|Eligible subjects will receive GSK3858279 up to a dose of 0.1 milligram/kilogram (mg/kg) via IV route.
2866275|NCT03485365|Placebo Comparator|Part A: Cohort 1: Placebo|Eligible subjects will receive placebo matching to GSK3858279 via IV route.
2866276|NCT03485365|Experimental|Part A: Cohort 2: GSK3858279|Eligible subjects will receive GSK3858279 up to a dose of 0.3 mg/kg via IV route.
2866277|NCT03485365|Placebo Comparator|Part A: Cohort 2: Placebo|Eligible subjects will receive placebo matching to GSK3858279 via IV route.
2866278|NCT03485365|Experimental|Part A: Cohort 3: GSK3858279|Eligible subjects will receive GSK3858279 up to a dose of 1 mg/kg via IV route.
2866279|NCT03485365|Placebo Comparator|Part A: Cohort 3: Placebo|Eligible subjects will receive placebo matching to GSK3858279 via IV route.
2866280|NCT03485365|Experimental|Part A: Cohort 4: GSK3858279|Eligible subjects will receive GSK3858279 up to a dose of 3 mg/kg via IV route.
2866281|NCT03485365|Placebo Comparator|Part A: Cohort 4: Placebo|Eligible subjects will receive placebo matching to GSK3858279 via IV route.
2866282|NCT03485365|Experimental|Part A: Cohort 5: GSK3858279|Eligible subjects will receive GSK3858279 up to a dose of 10 mg/kg via IV route.
2866284|NCT03485365|Experimental|Part A: Cohort 6: GSK3858279|Eligible subjects will receive GSK3858279 between 1 mg/kg and 3 mg/kg via SC route.
2866285|NCT03485365|Placebo Comparator|Part A: Cohort 6: Placebo|Eligible subjects will receive placebo matching to GSK3858279 via SC route.
2866286|NCT03485365|Experimental|Part B: GSK3858279|Eligible subjects will receive GSK3858279 one or two dose levels, up to 10 mg/kg, to be determined based on data from Part A) via IV route.
2866287|NCT03485365|Placebo Comparator|Part B: Placebo|Eligible subjects will receive placebo matching to GSK3858279 via IV route.
2866288|NCT03485352||Bariatric Surgery patients|Patients attending a private clinic specialized in the treatment of obesity and bariatric surgery. Patients to be analyzed should have a medical indication for bariatric surgery.
2866289|NCT03485339||Case|Ketamine user with psychotic disorders
2866290|NCT03485339||Control Group 1|Ketamine user without psychotic disorders
2866291|NCT03485339||Control Group 2|Non-ketamine-using drug user with psychotic disorders
2866292|NCT03485339||Control Group 3|Non-ketamine-using drug user without psychotic disorders ( identified from register-based medical record system)
2866293|NCT03485326||Safety|Safety
2866294|NCT03485300||Patients with chronic liver or kidney diseases|"Patients with chronic liver diseases may affect warfarin therapeutic outcome as liver is the site of metabolism of the drug by cytochrome p 450 enzymes so it decrease warfarin absorption~Kidney diseases also affect the clearance of the drug these patients will undergo liver function tests and kidney function tests"
2866295|NCT03485300||Non compliance of the patient|Missed dose of the warfarin or intermittent drug intake may affect drug therapeutic outcome as well as changing time of drug administration during the day
2866296|NCT03485300||Drugs or food interactions|Administration of other drugs beside warfarin may affect its therapeutic outcome either by inhibition or synergism certain food may also interfere with warfarin especially vitamin k and c rich food so patients will be followed up for drug or food interactions
2866297|NCT03485287|Experimental|MDMA and Psychotherapy|Three sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
2866298|NCT03485274|Active Comparator|Vortioxetine Arm|Oral: 5-20mg daily
2866299|NCT03485274|Active Comparator|Treatment as Usual|Any medication or Rx other than vortixoetine
2866300|NCT03485261||Group A|patient group include 50 female patients with chronic renal failure (eGFR <15ml/min/1.7m2 )
2866301|NCT03485261||Group B|the control group including 50 healthy females age matched with the patient group
2866302|NCT03485248|Active Comparator|Beetroot juice|Beetroot Juice cotaining on average 9mmol of nitrate per dose
2866303|NCT03485248|Placebo Comparator|Placebo beet juice (Nitrate depleted)|Beetroot juice nitrate depleted
2866304|NCT03485235|Experimental|D&C|
2866305|NCT03485235|Other|No D&C|
2866306|NCT03485222|Experimental|Empagliflozin|10mg once a day
2866307|NCT03485222|Placebo Comparator|Placebos|placebo once a day
2866308|NCT03485209|Experimental|Tisotumab Vedotin|Tisotumab Vedotin [2.0 mg/kg] every 3 weeks
2866309|NCT03485196||MSI-H group|We use the immunohistochemical expression of mismatch repair proteins (MutS protein homolog 2( MSH2),MutS protein homolog 6( MSH6) and PMS2（postmeiotic segregation increased 2 ）) to Determine the MSI status . When two antibodies or more show negative nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite instability high (MSI-H).
2866310|NCT03485196||MSI-L group|We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status. When one antibodies show negative nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite unstable low (MSI-L).
2866311|NCT03485196||MSS group|We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status . when all the four antibodies show positive nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite stable (MSS).
2866312|NCT03485183|Experimental|Intervention Group|The PI will set up the PicTek white/pink noise machine on the bedside table, and it will automatically turn on at 2200 and off at 0800 to the patient's preferred sound. The staff nurses will chart Nu-DESC scores every shift and as needed for change in mental status as is the current policy. The PI will collect Nu-DESC scores for the duration of the participants' hospital stays, age, race, gender, presence of a dementia diagnosis, and use of a pharmacological sleep aid.
2866313|NCT03485183|Other|Control Group|The PI will perform a chart review of patients who were admitted the month prior to the intervention being implemented. The PI will collect Nu-DESC scores for the duration of the participants' hospital stays, age, race, gender, presence of a dementia diagnosis, and use of a pharmacological sleep aid. These patients will receive the standard of care for delirium prevention.
2866314|NCT03485170|Other|PET|Hemophilia patients receive PET evaluation
2866315|NCT03485157|Experimental|Micronized dHACM|Injection of micronized dHACM
2866316|NCT03485157|Placebo Comparator|Saline|Injection of 0.9% Sodium Chloride Injection, USP
2866317|NCT03485144|Experimental|TV003|Live Attenuated Virus Vaccine-TetraVax-DV
2866318|NCT03485144|Placebo Comparator|Placebo for TV003|Placebo
2866319|NCT03485131|Experimental|Transcranial direct-current stimulation|Intervention of 2 mAmp Transcranial direct-current stimulation treatments given twice daily for 20 min each per day for 4 weeks on consecutive weekdays. Twice-daily sessions were separated by at least 3 hours (one in the AM and the other one in the PM)
2866320|NCT03485131|Sham Comparator|Sham tDCS|Intervention of placebo stimulation with ranscranial direct-current stimulation(sham tDCS), the stimulation parameters were displayed, but after 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse was delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period
2866321|NCT03485118|Experimental|HS006+Chemotherapy|"Participants received six 21-day cycles of HS006(375 mg per square meter) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone/prednisolone(CHOP) chemotherapy(21-day cycles).~Participants received six 21-day cycles of HS006(500 mg per square meter) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles)."
2866365|NCT03484832|Placebo Comparator|Placebo group|Using placebo cream and placebo spray
2886603|NCT03342807|Experimental|Group Aphesis|
2866322|NCT03485118|Active Comparator|Rituxan+Chemotherapy|Participants received six 21-day cycles of Rituxan combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles).
2866323|NCT03485105||CTX-benefit group|CTX-benefit group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, this group will be beneficial from adjuvant chemotherapy
2866324|NCT03485105||no-benefit group|no-benefit group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, this group will not be beneficial from adjuvant chemotherapy
2866325|NCT03485105||high-risk group|high-risk group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, the prognosis of this group will be worse compared to others regardless of the response to adjuvant chemotherapy
2866326|NCT03485092|Active Comparator|Empagliflozin|Empagliflozin 10mg tablets for oral self-administration once daily
2866327|NCT03485092|Placebo Comparator|Placebo Oral Tablet|placebo tablets for oral self-administration once daily
2866328|NCT03485066|Experimental|Training|20 healthy participants, 4 week training of a challenging cognitive task (Tetris) between PET/MR measurements
2866329|NCT03485066|No Intervention|Control|20 healthy participants, no training between PET/MR measurements
2866330|NCT03485053|Experimental|IOP Injection|Administered IV infusion
2866331|NCT03485027|Experimental|XELOX regimen|oxaliplatin 130mg/m2，intravenous，on Day1 capecitabine 1000mg/m2，oral，bid，on Day1-14 every three weeks
2866332|NCT03485027|Experimental|FOLFOX regimen|oxaliplatin 85mg/m2，intravenous，on Day1 leucovorin 400mg/m2，intravenous，on Day1 5-FU 400mg/m2，intravenous，on Day1 5-FU 2.4g/m2，CIV 46h every two weeks
2866333|NCT03485027|Experimental|FOLFIRI regimen|irinotecan 85mg/m2，intravenous，on Day1 leucovorin 400mg/m2，intravenous，on Day1 5-FU 400mg/m2，intravenous，on Day1 5-FU 2.4g/m2，CIV 46h every two weeks
2866334|NCT03485027|Experimental|IRI regimen|irinotecan single agent 180mg/m2，intravenous，on Day1 every two weeks
2866335|NCT03485014|Experimental|Experimental: EXPAREL 4 mg/kg|Single dose of EXPAREL 4 mg/kg
2866336|NCT03485001|Sham Comparator|Sham of Argon Laser Treatment|Slit lamp light exposure
2866337|NCT03485001|Experimental|Argon Laser Treatment|Argon Laser Treatment
2866338|NCT03484988|Placebo Comparator|Placebo oil|Ingredients: Corn oil, 500mg per capsule
2866339|NCT03484988|Experimental|Echium oil|Ingredients: Echium oil,500mg per capsule
2866340|NCT03484988|Experimental|Mixed oil|Ingredients:Mixed oil(Echium oil,camelina oil,safflower oil) 500mg per capsule
2866341|NCT03484975|Other|Observation group|Patients undergoing coronary angiography and intravascular imaging for either diagnostic purposes or for PCI following a presentation with either stable angina or an acute coronary syndrome.
2866342|NCT03484962|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
2866343|NCT03484962|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
2866344|NCT03484962|No Intervention|No intervention|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2866345|NCT03484949|Experimental|pre-endoscopic screening risk assessment|
2866346|NCT03484949|No Intervention|routine screening|
2866347|NCT03484936|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to 2014 chinese guideline for the diagnosis and treatment of intracerebral hemorrhage.
2866348|NCT03484936|Placebo Comparator|Sham RIC+Standard medical treatment|Sham remote ischemic conditioning (Sham RIC) is simulated by the measurement of blood pressure twice daily for 7 days.Additionally,the patients will be treated with standard medical treatment according to 2014 chinese guideline for the diagnosis and treatment of intracerebral hemorrhage.
2866349|NCT03484923|Experimental|LAG525 + Spartalizumab (PDR001)|Spartalizumab and LAG525 will be administered intravenously
2866350|NCT03484923|Experimental|Capmatinib (INC280) and Spartalizumab (PDR001)|Spartalizumab will be administered intravenously. Capmatinib will be administered orally.
2866351|NCT03484923|Experimental|Canakinumab and Spartalizumab (PDR001)|Spartalizumab will be administered intravenously. Canakinumab will be administered subcutaneously.
2866352|NCT03484910|Experimental|BFB group|Exercise therapy - Six-week training program of stationary cycling with a real-time visual EMG biofeedback
2866353|NCT03484910|Active Comparator|CON group|Exercise therapy - Six-week training program of stationary cycling without EMG biofeedback
2866354|NCT03484897|Experimental|P927 - LICHTENA DermAD CREMA CORPO|Application of the product under study mono-laterally at level of the forearm, including the antecubital fold, on the right or left side according to a randomization list defined by the investigator.
2866355|NCT03484884||Thyroid cancer/nodal metastasis|Participants will have thyroid cancer and nodal metastasis in the neck, supraclavicular, axillary and/or inguinal area.
2866356|NCT03484858|Other|High glycaemic index meal and exercise|
2866357|NCT03484858|Other|High glycaemic index meal and rest|
2866358|NCT03484858|Other|Low glycaemic index meal and exercise|
2866359|NCT03484858|Other|Low glycaemic index meal and rest|
2866360|NCT03484845|Active Comparator|Oral lactoferrin|women who take oral lactoferrin sachets 100 mg twice daily for one month.
2866361|NCT03484845|Active Comparator|Oral ferrous fumarate|women who take oral ferrous fumarate tablet 30 mg elemental iron twice daily for one month.
2866362|NCT03484845|Active Comparator|Combined lactoferrin & ferrous fumarate|women who take lactoferrin sachets 100 mg and ferrous fumarate tablet 30 mg elemental iron once daily for one month.
2866363|NCT03484832|Experimental|Spray group|Using Walter Ritter Ethyl Chloride Spray and placebo cream
2866364|NCT03484832|Experimental|EMLA group|Using EMLA cream and placebo spray
2866516|NCT03483714||Chronic low back pain participants|Spinal Manipulation
2866366|NCT03484819|Experimental|Treatment (copanlisib, nivolumab)|Participants receive copanlisib IV over 1 hour on days 1, 8 and 15. Participants also receive nivolumab IV over 60 minutes on days 1 and 15 of courses 1 to 8 and on day 1 of subsequent courses. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2866367|NCT03484793|Experimental|AESOP integrated to CPOE for reducing medication errors|18 were assigned to the experimental group
2866368|NCT03484793|No Intervention|Non AESOP|19 were assigned to the traditional CPOE system
2866369|NCT03484780|Experimental|VisONE ADS|Patients implanted with a VisONE stimulator and leads for receiving continual Asymptomatic Diaphragmatic Stimulation
2866370|NCT03484767||Methylmalonic Acidemia Participants|Individuals with isolated MMA (mut0 and mut-)
2866371|NCT03484767||Propionic Acidemia Participants|Individuals with isolated PA
2866372|NCT03484754|Experimental|corrugator|single injection of 10 Units of botulinum toxina in the corrugator and procerus
2866373|NCT03484754|Active Comparator|orbicularis oculi|single injection of 10 Units of botulinum toxina in the lateral muscle orbicularis oculi (involved in crow's feet wrinkles)
2866374|NCT03484741|Experimental|MSC and PRP|15 patients will be given autologous bone marrow-derived mesenchymal stem cells (BM-MSC) and mesenchymal stem cell from allogeneic umbilical cord tissue (UC-MSC) combined with platelet-rich plasma (PRP) by intravenous infusion.
2866375|NCT03484715|Experimental|Physical Activity Intervention|Each participant in this arm will outline a small number of activity-related goals and will receive a 4 month personalised physical programme where additional physical activity will be incorporated into their daily routines. Nursing home staff will receive two educational sessions, which will provide them with the necessary skills to monitor participants physical activity programmes within the nursing home.
2866376|NCT03484715|No Intervention|Usual Care Control|The participants in the control arm will receive usual care, which will be guided by current nursing and medical care plans.
2866377|NCT03484702|Experimental|Administration of JCAR017|JCAR017 will be infused at a dose of 1 x 10^8 JCAR017-positive transfected viable T cells (5×10^7 CD8+ CAR+ T cells and 5×10^7 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of lymphodepleting chemotherapy [LD]).
2866378|NCT03484689|Other|MBCT arm|8-week MBCT program
2866379|NCT03484676|Other|Unilateral Non comminuted zygomatic complex fracture|Patient undergo treatment no control group
2866380|NCT03484663|Experimental|Small catheter with chest tube after uniport vats|Insertion of small catheter drainage in the same opening with chest tube after uniport vats
2866381|NCT03484663|No Intervention|Chest tube only after uniport vats|After uniport vats we put chest tube only
2866382|NCT03484650|Placebo Comparator|Control|Patients will receive standard care plus infusion of placebo
2866383|NCT03484650|Experimental|Lidocaine|Patients will receive lidocaine infusions peri-operatively
2866384|NCT03484637||Lifestyle-medicine intervention|Photographic follow-up every 4 weeks
2866385|NCT03484624|Experimental|Treadmill walking|All subjects underwent measurements of muscle fatigue, foot pressure, and respiratory metabolism energy during treadmill walking at a comfortable speed for 6 minutes and measured by three conditions (①NoGEMS-free gait, ②Torque off with GEMS, and ③Torque on with GEMS)
2866386|NCT03484611|Active Comparator|AMH < 0.3 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH < 0,3 ng/ml
2866387|NCT03484611|Active Comparator|AMH 0.3 to 0.7 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH 0.3 to 0.7 ng/ml
2866388|NCT03484611|Active Comparator|AMH > 0.7 to 1 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH 0.7 to 1 ng/ml
2866389|NCT03484598|Experimental|SPEAC Treatment Arm|All study participants will be provided with a SPEAC System to use in their home environment.
2866390|NCT03484585|Experimental|Rogaratinib (BAY1163877)|Healthy male subjects
2866391|NCT03484559||1|
2866392|NCT03484546||folicular|Women who will undergo endometrioma cystectomy in her follicular phase of menstrual period.
2866393|NCT03484546||ovulatory|Women who will undergo endometrioma cystectomy in her ovulatory phase (12-14th day of mestrual period cycle for women regular period) of menstrual cycle.
2866394|NCT03484546||luteal|Women who will undergo endometrioma cystectomy in her luteal phase of menstrual period.
2866395|NCT03484533|Active Comparator|HIV Self-test kit|
2866396|NCT03484533|Active Comparator|Invitation letter-standard of care|
2866397|NCT03484520|Experimental|Venetoclax + Dinaciclib|Venetoclax and dinaciclib will be administered in combination. Different combinations of dose levels for venetoclax and dinaciclib will be explored.
2866398|NCT03484507|Active Comparator|Chlorhexidine monotherapy|Topical chlorhexidine 0.04%
2866399|NCT03484507|Experimental|Chlorhexidine plus povidone iodine|Topical chlorhexidine 0.04% plus povidone iodine 2.5%
2866400|NCT03484507|Experimental|Early corticosteroids|Topical prednisolone sodium phosophate 1% for weeks 4-11
2866401|NCT03484507|Experimental|Late corticosteroids|Artificial tears for weeks 4-5, then topical prednisolone sodium phosophate 1% for weeks 6-11
2866402|NCT03484507|Placebo Comparator|Placebo|Artificial tears for weeks 4-11
2866403|NCT03484494|Other|Active first|Subjects receive active Low Field Magnetic Stimulation in the first imaging visit and sham in the second.
2866404|NCT03484494|Other|Sham first|Subjects receive sham Low Field Magnetic Stimulation in the first imaging visit and active in the second.
2866405|NCT03484481||1;Oral nutritional support (ONS)|patients ongoing hemodialysis who received only oral nutritional support (Nutrena) and refused intradialytic parenteral nutrition; n: 14
2866406|NCT03484481||2; Intradialytic Parenteral Nutrition|patients ongoing hemodialysis who received only Intradialytic Parenteral Nutrition (Kabiven central) and refused parenteral nutrition; n: 14
2866407|NCT03484481||group 3; combination group|patients ongoing hemodialysis received both ONS and Intradialytic Parenteral Nutrition NS; n: 10
2866408|NCT03484481||group 4; dietetic support group;|patients ongoing hemodialysis who refused all types of nutritional support and only followed by counselling, n: 18
2866409|NCT03484468||femtosecond_laser|participants had there lasik corneal flap creation using femtosecond laser
2866410|NCT03484468||moria_microkeratome|participants had there lasik corneal flap creation using moria microkeratome
2866835|NCT03481439||Secondary cohort|Secondary cohort : Cohort of patient between February and March 2018
2866411|NCT03484429|Experimental|Group 1|Standard medical therapy and 30 to 60 days of peripheral nerve stimulation starting within 7 days after surgery
2866412|NCT03484429|Active Comparator|Group 2|Standard medical therapy only
2866413|NCT03484416|Active Comparator|Routine calcium|Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium (by calcium carbonate) and 1,000 IU/day cholecalciferol for 2 weeks, beginning on the first postoperative day
2866414|NCT03484416|No Intervention|control|Patients in the control group did not receive calcium or cholecalciferol for 2 weeks
2866415|NCT03484403|Active Comparator|Control Group|Study participants will not receive a back brace but will receive back school education and the same physical therapy exercise instruction as the treatment group.
2866416|NCT03484403|Experimental|Treatment Group|Study participants in this group will receive a lumbar support back brace and will receive back school education and the same physical therapy exercise instruction as the control group.
2866417|NCT03484390|Experimental|Mindfulness-based stress reduction|The MBSR program is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 120 minute sessions, once per week for eight weeks.
2866418|NCT03484390|Active Comparator|Wellness Group|The Wellness control group uses a health education manual that provides information on various aspects of health, including diet, physical activity, sleep, stress management, and communication. The manual is used during weekly check-in phone calls for an 8-week period.
2866419|NCT03484377|Experimental|Anodal tDCS|The anodal tDCS electrode will be placed over the area corresponding to the right DLPFC (F4 of the EEG10-20 international system). The anodal tDCS condition will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.
2866420|NCT03484377|Sham Comparator|Sham tDCS|The sham (cathodal) electrode will be placed over the left supraorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session.
2866421|NCT03484364|Experimental|Intervention Group|The ENACTS intervention is eight weeks of peer-facilitated educational classes about hypertension self-management and autonomous support from family or friend enrolled as support person.
2866422|NCT03484364|No Intervention|Waitlist Group|Usual care and $30 in groceries each week for 8 weeks.
2866423|NCT03484351|Experimental|Fall Monty Activity Programme (FallMAP)|A multifactorial falls prevention activity programme
2866424|NCT03484338|Experimental|Intervention|
2866425|NCT03484338|Active Comparator|Wait list controlled|
2866426|NCT03484299|Other|Treatment|Irreversible electroporation and treatment with either FOLFIRINOX or Gemcitabine (based upon which chemotherapy regimen received prior to IRE)
2866427|NCT03484286|Other|Control group|Subject to standard care. No interventions above and beyond what is deemed standard care for heart failure patients in the region where the study takes place.
2866428|NCT03484286|Experimental|Intervention group|Device: OPTILOGG
2866429|NCT03484273|Experimental|Full Compression|The LifeWrap compression garment will be fully secured with all straps.
2866430|NCT03484273|Experimental|Abdominal and Pelvic Compression|The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.
2866431|NCT03484273|Experimental|Lower Limb Compression|The Lifewrap compression garment calf and ankle straps only will be secured.
2866432|NCT03484273|No Intervention|No Compression|None of the LifeWrap compression garment straps will be secured.
2866433|NCT03484260||Case group: Testosterone Product|Male subjects prescribed testosterone in UK
2866434|NCT03484260||Control group|Matched male subjects not prescribed testosterone in the UK
2866435|NCT03484247|Active Comparator|Group Infraclavicular|Infraclavicular Brachial Plexus Block: The inferolateral of the subclavian artery will be targeted with a 85 mm peripheral nerve stimulator needle with ultrasound guidance. When the needle tip was seen near the posterior cord of brachial plexus local anesthetic will be administered with single injection after aspiration.
2866436|NCT03484247|Active Comparator|Group Axillary|Axillary Brachial Plexus Block: The procedure will be performed with a 50 mm peripheral nerve stimulator needle with ultrasound guidance. Local anesthetic will be administered with multiple injection (radial, ulnar, median and musculocutaneous nerves) after aspiration.
2866437|NCT03484234|Experimental|Ultimaster stent|
2866438|NCT03484234|Active Comparator|Xience alpine stent|
2866439|NCT03484221|Experimental|FOLFOXIRI+short-course radiation+XELOX|Firstly, 4 cycles of neoadjuvant FOLFOXIRI chemotherapy were administered. Subsequently, a short-course radiation therapy (5Gy*5) will be performed. After that, 4 cycles of XELOX chemotherapy will be administered followed by surgery.
2866440|NCT03484195|Experimental|FOLFOXIRI|Patients received 4 cycles of neoadjuvant FOLFOXIRI chemotherapy before surgical resection.
2866441|NCT03484182|Active Comparator|Standard Home Exercise Program|
2866442|NCT03484182|Experimental|Web-based Home Exercise Program|
2866443|NCT03484169|No Intervention|Control group|No intervention
2866444|NCT03484169|Experimental|intervention group|"The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:~Combination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;"
2866445|NCT03484156|Experimental|Volunteers|"The Installation of 3PEGASE Sensor in elders volunteers to monitor clinical indicators at home.The instrument is for monitoring functional and cognitive autonomy in frail or disable elderly persons living alone at home.~The volunteers will have 70 years old or more, living alone at home, frail of disable (ADL> or =3) and able to walk by themselves."
2866446|NCT03484143|Active Comparator|Active Neuro RX Gamma device|Neuro RX Gamma device delivers low-energy near-infrared light, through 5 diodes, to the brain transcranially and intranasally
2866447|NCT03484143|Sham Comparator|Sham Neuro RX Gamma device|Sham Neuro RX Gamma device is identical in appearance and sound as the active Neuro RX Gamma device but does not emit low-energy near infrared light
2866448|NCT03484130||High-Risk Normotensives|These high-risk normotensives are considered to be enriched for subclinical autonomous aldosterone secretion and have a high risk for developing incident hypertension
2866449|NCT03484117|No Intervention|Treatment as Usual|Participants in this arm will receive bilingual written materials on healthy living with HIV at the baseline visit. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers to care for Hispanic immigrants.
2866450|NCT03484117|Experimental|Community Health Worker|Participants in the intervention arm will receive 5 one-on-one sessions over 24 weeks with a Spanish-speaking CHW. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers to care for Hispanic immigrants
2866451|NCT03484104||Hypothermic circulatory arrest|Patients undergoing cardiac surgery with hypothermic circulatory arrest and selective antegrade cerebral perfusion
2866452|NCT03484091|Experimental|H group|Single dose of Hyruan-One 3 mL intra-articular knee injection.
2866453|NCT03484091|Active Comparator|S group|Single dose of Hylan G-F 20 (Synvisc) 6 mL intra-articular knee injection.
2866454|NCT03484091|Placebo Comparator|N group|Single dose of normal saline 6 mL intra-articular knee injection.
2866455|NCT03484078|Experimental|Vibration Platform|The vibration group will stand on a platform that emits a mild vibration 10 minutes per day for 6 months. There will also be a 6 month no-treatment period.
2866456|NCT03484078|Placebo Comparator|Placebo Platform|The placebo group will stand on a placebo platform 10 minutes per day for 6 months. There will also be a 6 month no-treatment period.
2866457|NCT03484065||Afibrinogenemia|
2866458|NCT03484052|Other|Jugular ultrasound|
2866459|NCT03484039|Experimental|Immediate Intervention Group|The immediate intervention group will receive the module (a 1-2 hour course on either medication adherence, seizure documentation, memory improvement or stress management) right after a baseline assessment. A post assessment and delayed post assessment will be conducted after the module is administered.
2866460|NCT03484039|Experimental|Delayed Intervention Group|The delayed intervention group will receive a baseline assessment. 6 weeks to 3 months later (average 2 months) a pre-intervention assessment will be conducted just prior to administering the modules (a 1-2 hour course on either medication adherence, seizure documentation, memory improvement or stress management). A post-intervention assessment will then be administered.
2866461|NCT03484026|Experimental|BioFe Medical Food|Consumption of BioFe Medical Food in a single cohort of up to 8 female subjects with iron deficiency.
2866462|NCT03484000|Experimental|Immediate MBCR group|The Online Mindfulness Based Cancer Recovery (MBCR) program intervention is delivered in 12 weekly real-time interactive 55-minute sessions offered over consecutive weeks.
2866463|NCT03484000|Other|Waitlist control group|Treatment as usual, followed by a delayed (wait-list) intervention of the same Online Mindfulness Based Cancer Recovery (MBCR) program after the post-CT assessment.
2866464|NCT03483987|Experimental|Sof+Ledi+R arm|"Participants with HCV genotype 1,4, 5 or 6 and relapsed with following regimens will be treated with sofosbuvir, ledipasvir and ribavirin combination~Sofosbuvir plus velpatasvir with or without ribavirin for 12 weeks~Sofosbuvir plus ribavirin with or without pegylated interferon for 12 or 24 weeks~Sofosbuvir plus velpatasvir with or without ribavirin for 24 weeks and are not eligible for pegylated interferon"
2866465|NCT03483987|Experimental|Sof+Ledi+R+Peg-IFN arm|Participants with HCV genotype 1,4, 5 or 6, who have relapsed after a 24 weeks treatment regimen of sofosbuvir plus velpatasvir with or without ribavirin combination and are eligible for pegylated interferon, will be treated with a combination of sofosbuvir, ledipasvir, ribavirin plus pegylated interferon
2866466|NCT03483987|Experimental|Sof+Dacla+R arm|"Participants with HCV genotype 2 or 3 and relapsed with following regimens will be treated with a combination of sofosbuvir, daclatasvir and ribavirin~Sofosbuvir plus velpatasvir with or without ribavirin for 12 weeks~Sofosbuvir plus ribavirin with or without pegylated interferon for 12 or 24 weeks~Sofosbuvir plus velpatasvir with or without ribavirin for 24 weeks and are not eligible for pegylated interferon"
2866467|NCT03483987|Experimental|Sof+Dacla+R+Peg-IFN arm|Participants with HCV genotype 2 or 3, who have relapsed after a 24 weeks treatment regimen of sofosbuvir plus velpatasvir with or without ribavirin combination and are eligible for pegylated interferon, will be treated with a combination of sofosbuvir, ledipasvir, ribavirin plus pegylated interferon
2866468|NCT03483987|Experimental|Sof+Velpa+R arm|"Following group of participants will be treated with sofosbuvir, velpatasvir and ribavirin combination~who were treated earlier with 12 week treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin or~who were earlier treated with a 24 treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin and are not eligible for pegylated interferon"
2866469|NCT03483987|Experimental|Sof+Velpa+R+Peg-IFN arm|Participants, who have relapsed after a 24 week treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin and are eligible for pegylated interferon will be treated with sofosbuvir, velpatasvir, ribavirin and pegylated interferon combination
2866470|NCT03483974||neoplasm|neoplasm found in follow up
2866471|NCT03483974||non-neoplasm|non-neoplasm patients in follow up
2866472|NCT03483961|Experimental|Arm 1|20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)
2866473|NCT03483961|Experimental|Arm 2|6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
2866474|NCT03483961|Experimental|Arm 3|10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
2866475|NCT03483961|Experimental|Arm 4|20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)
2866476|NCT03483961|Experimental|Arm 5|Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
2866477|NCT03483961|Experimental|Arm 6|Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
2866478|NCT03483961|Experimental|Arm 7|Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)
2866479|NCT03483961|Experimental|Arm 8|Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)
2866584|NCT03483259|Experimental|Arm A-Sulfatinib T capsule|The subjects in this arm will receive sulfatinib T capsules from Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd.
2866480|NCT03483948|Experimental|HMPL-523 & Azacitidine|HMPL-523 will be taken orally once daily continuously through a 28-days Cycle of study treatment. Azacitidine will be administered subcutaneously, beginning on Day 1 through Day 7 of each Cycle.
2866481|NCT03483935|Experimental|Microwave energy treatment|The microwave treatment will be delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for this indication, will be used to deliver the microwave treatment. A measured dose, determined from data acquired from Stage 1 of this study, will be used per AK.
2866482|NCT03483935|No Intervention|Control|No treatment will be given.
2866483|NCT03483922||chronic hepatitis B|This group will include 50 with hepatitis B subjects and the diagnoses will be based on AASLD practice guideline.
2866484|NCT03483922||HCC Cases|"This group will include 350 in stage 0, stage A, stage B, Stage C+D of hepatocellular carcinoma.~HCC staging will be diagnosed according to EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma"
2866485|NCT03483922||Healthy|This group will include 50 healthy sex and age matched controls.
2866486|NCT03483909|Experimental|left IFG iTBS|intermittent theta burst stimulation over the left inferior frontal gyrus
2866487|NCT03483909|Active Comparator|right IPL cTBS|continuous theta burst stimulation over the right inferior parietal cortex
2866488|NCT03483909|Placebo Comparator|placebo|Placebo TMS stimulation over the left inferior parietal cortex
2866489|NCT03483896|No Intervention|Control|At the 4 facilities in the control arm, participants received the usual care. During the period from 8:00 - 10:00 AM each day, the control group was taken to a similar sized area indoors (without daylight) for socialization under typical electrical lighting conditions.
2866490|NCT03483896|Active Comparator|Daylight Intervention|At the 4 facilities in the active light intervention arm, staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
2866491|NCT03483883|Experimental|Single Arm|
2866492|NCT03483870|Placebo Comparator|Morphine sulphate & Placebo|20 parturients under intrathecal anesthesia will receive 200 ug morphine sulphate intrathecally and 2 mL of normal saline 0.9% (placebo) IV injection preoperative.
2866493|NCT03483870|Active Comparator|Morphine sulphate & Granisetron|20 parturients under intrathecal anesthesia will receive 200 ug morphine sulphate intrathecally and 2 mL of 2 mg granisetron IV injection preoperative.
2866494|NCT03483857|Experimental|Peer Navigation|Individuals assigned to the PN condition will be assigned to one of 10 PN case managers who will follow an SOP described for initial intake and follow up visits with each participant. Participants will be asked to provide contact information for themselves and up to 3 individuals whom study staff can contact in case they cannot make direct contact with the study participant assigned to PN. PN will meet with their clients at least once monthly to discuss treatment related issues including medication access, side effects, adherence, stigma or discrimination related to HIV or their taking ART medication, etc. Participants will have contact information for their assigned PN and may contact them for reasons related to their treatment between scheduled monthly visits if they choose. All visits with PN will be recorded by the PN. and participants who fail to attend up to 3 scheduled PN appointments will be considered LTFU for the intervention.
2866495|NCT03483857|No Intervention|Standard of Care|Individuals assigned to SOC will be referred directly to the NCHC/RLS staff for treatment initiation or continuation. At intake they will receive standard treatment information per MPDOH guidelines, as well as information about Anova's RLS and Health4Men clinical and psychosocial services available at the NCHC. They will receive monthly text message reminders from study staff to refill ART prescriptions, and a separate reminder in month 6 to schedule complete their 6-month clinical visit. Study staff will verify that participants have picked up medications and attended all scheduled clinical visits by means of chart review and data extraction. Per MPDOH guidelines, individuals who fail to collect medications 3 months in a row, or who fail to attend their 6-month HIV clinical follow-up appointment, will be considered non-engaged and lost to follow up (LTFU).
2866496|NCT03483831|Experimental|Intervention group|Students of 5 secondary school classes aged 12-14
2866497|NCT03483831|No Intervention|Control group|Students of 5 secondary school classes aged 12-14
2866498|NCT03483818|Active Comparator|Pharmacist-Led Pathway|Assessment & Treatment of HCV infection with oral antivirals in a community pharmacy pathway
2866499|NCT03483818|Active Comparator|Conventional Care Pathway|Assessment & Treatment of HCV infection with oral antivirals in a conventional care pathway
2866500|NCT03483805|Experimental|Treatment|Protalsafe product, daily, 12 weeks
2866501|NCT03483805|Placebo Comparator|Placebo|Placebo product, daily, 12 weeks
2866502|NCT03483792||PCOS group|
2866503|NCT03483792||Control group|
2866504|NCT03483779|Experimental|Experimental group:Ginkgo biloba pills|Five Ginkgo biloba pills a time and three times a day. One treatment period including 8 weeks.
2866505|NCT03483779|Placebo Comparator|Control group:placebo pills|Five placebo pills a time and three times a day. One treatment period including 8 weeks.
2866506|NCT03483766|No Intervention|Baseline before robotic functional rehabilitation|Baseline spinal cord MRI scan
2866507|NCT03483766|Experimental|post rehabilitation|Those patients will receive 3 months muscle strength enhancement as pre-rehabilitation. Then, we will design robotic hand rehabilitation programme for each individuals. All participants will receive robotic rehabilitation for 1 year. After then, a follow-up spinal cord MRI scan and clinical assessment will evaluate the results of this project.
2866508|NCT03483753|Experimental|Vasopressin group|Blinded vasopressin
2866509|NCT03483753|Active Comparator|Norepinephrine group|Blinded norepinephrine
2866510|NCT03483740|Experimental|Cognitive remediation group therapy|8 weekly 3-hour sessions of CRGT
2866511|NCT03483740|Active Comparator|Mutual aid support group|8 weekly 3-hour sessions of HIV group therapy
2866512|NCT03483727|Experimental|Digital cognitive aid|The digital cognitive aid is designed as a smartphone app.
2866513|NCT03483727|Experimental|no digital cognitive aid|No cognitive aid in the hand of the leader during crises management.
2866514|NCT03483714||Healthy Participants|Spinal manipulation
2866515|NCT03483714||Acute Low back pain participants|Spinal Manipulation
2866517|NCT03483701|Experimental|Cognitive Remediation Therapy|Participants in the experimental group will continue to receive IPS services, which is part of their standard care. In addition, they will be required to complete up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer, on their own schedule. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.
2866518|NCT03483701|No Intervention|Treatment as Usual|Participants in the control condition will continue to receive IPS services as usual.
2866519|NCT03483688|Experimental|CD19-directed CAR-T cells|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
2866520|NCT03483675|Active Comparator|Arm I (discontinued IST)|Participants have their IST tapered and discontinued per the plan.
2866521|NCT03483675|Experimental|Arm II (continued IST)|Participants continue to receive a fixed dose IST for an additional 9 months with no taper.
2866522|NCT03483662|Experimental|Multicomponent Intervention|Protocol-based treatment using the SPRINT stepped-care intensive BP management algorithm, dissemination of SPRINT study findings among provider-teams, patients, and administrators, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification
2866523|NCT03483662|Active Comparator|Enhanced Usual Care|Webinar education session for providers on the new ACC/AHA hypertensive clinical guideline and the SPRINT study findings
2866524|NCT03483649|Experimental|HLX04|
2866525|NCT03483649|Active Comparator|United States (US) Avastin®|
2866526|NCT03483649|Active Comparator|European Union (EU) Avastin®|
2866527|NCT03483649|Active Comparator|China (CN) Avastin®|
2866528|NCT03483636|Experimental|Lemborexant|Participants will be randomized to receive a 10 milligram (mg) lemborexant tablet administered with 50 milliliter (mL) water followed by a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
2866529|NCT03483636|Experimental|Lemborexant Plus Alcohol|Participants will be randomized to receive a 10 mg lemborexant tablet administered with 50 mL water followed by alcohol (0.6 grams per kilogram [g/kg] of alcohol for females or 0.7 g/kg of alcohol for males) for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
2866530|NCT03483636|Experimental|Alcohol|Participants will be randomized to receive a 10 mg lemborexant-matched placebo tablet administered with 50 mL water followed by alcohol (0.6 g/kg of alcohol for females or 0.7 g/kg of alcohol for males) for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
2866531|NCT03483636|Placebo Comparator|Placebo|Participants will be randomized to receive a 10 mg lemborexant-matched placebo tablet administered with 50 mL water followed by alcohol for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
2866532|NCT03483623|Experimental|NATO WELP combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels, laser Doppler pressure units, and interface pressures on NATO litter and WELP mattress combination
2866533|NCT03483623|Experimental|NATO FIS combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels, laser Doppler pressure units, and interface pressures on NATO litter and Fluid Immersion System (FIS) mattress combination
2866534|NCT03483623|Experimental|RAVEN WELP combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels, laser Doppler pressure units, and interface pressures on Raven 90C litter and WELP mattress combination
2866535|NCT03483623|Experimental|RAVEN FIS combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels, laser Doppler pressure units, and interface pressures on Raven 90C litter and Fluid Immersion System (FIS) mattress combination
2866536|NCT03483610|Active Comparator|screening and referral|
2866537|NCT03483610|Active Comparator|behavioral intervention|
2866538|NCT03483597||rheumatologists|Inclusion criteria: Registered rheumatoid specialist physicians subordinated to the 12 designated hospitals The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in rheumatologists.
2866539|NCT03483597||patients|Inclusion criteria: Aged over 18, confirming RA for more than 6 months Exclusion criteria. Patients with Chinese reading comprehension barriers (unable to complete the questionnaire independently), without any RA treatment The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in patients.
2866540|NCT03483558|Experimental|Control|Participants were fed a standardized diet (without any vegetables) in this experiment.
2866541|NCT03483558|Experimental|Spinach|Participants were fed a standardized diet with 200g spinach in this experiment.
2866542|NCT03483558|Experimental|Celery|Participants were fed a standardized diet with 200g celery in this experiment.
2866543|NCT03483558|Experimental|Onion|Participants were fed a standardized diet with 200g onion in this experiment.
2866544|NCT03483558|Experimental|Mixed Vegetables|Participants were fed a standardized diet with 200g of mixed vegetables (spinach, celery, and onion) in this experiment.
2866545|NCT03483545|Experimental|Follitropin delta and HP-hMG|Follitropin delta combined with highly purified human menopausal gonadotrophin
2866546|NCT03483532||Lit Control pH Up without cocoa extract|The nutritional exposure will consist in the intake of 1 capsule of the food supplement based on citrate and plant extract without cocoa extract dosed at the rate of one during breakfast and another during dinner, during a period of 14 days to a group of 30 patients.
2866547|NCT03483532||Lit Control pH Up with dry cocoa extract|The nutritional exposure will consist in the intake of 1 capsule of the food supplement based on citrate and plant extract with cocoa extract dosed at the rate of one during breakfast and another during dinner, during a period of 14 days to a group of 30 patients.
2866548|NCT03483519|Experimental|Prehabilitation|Patients in the Prehabilitation Group and are randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care
2866549|NCT03483519|Active Comparator|Standard of Care|Patients in the Standard of Care will not receive an additional an exercise program, patients will receive the usual care received by all orthopaedic patients.
2866550|NCT03483506|Experimental|All subjects|
2866551|NCT03483493|Experimental|Exposure Response Prevention for tics|10-weeks, online delivered, therapist supported exposure response prevention (ERP) therapy for tics
2866552|NCT03483493|Active Comparator|Active Control (Psychoeducation)|10-weeks, online delivered, therapist supported psychoeducation for tics
2866553|NCT03483480|Experimental|Non powered-NPWT|
2866554|NCT03483480|Active Comparator|Open Technique|
2866555|NCT03483467|Experimental|1|Application of Omnigen
2866556|NCT03483467|Placebo Comparator|2|Dummy Omnigen Packaging
2866557|NCT03483454|Experimental|Exercise classes|This group of children and their parents will participate in an exercise class for 8 weeks.
2866558|NCT03483454|Experimental|Home exercise|"This group of children and their parents will participate in exercise at home for 8 weeks. This is currently the standard of care in the weight management clinic (advise to continue increasing activity at home). This group is considered the control group."
2866559|NCT03483441|Placebo Comparator|Placebo pill prior to PDT|BCC tumors will be treated with ALA-PDT, without any active pretreatment
2866560|NCT03483441|Active Comparator|Vitamin D pill prior to PDT|Patients will take oral Vit D supplements (10,000 IU/day) immediately prior to PDT of their BCC tumors.
2866561|NCT03483428|Experimental|Parent Coaches|"Parent coaches will complete interventionist training and supervision in the Family Check-Up, an evidence-based behavioral parent training (BPT) program, including in the adaptations for families with DHH children. Each parent coach will deliver the intervention to 5 parent-child dyads."
2866562|NCT03483428|Experimental|Parent-Child Dyads|"Parents and children will receive the adapted Family Check-Up behavioral parent training (BPT) intervention delivered by parent coaches."
2866563|NCT03483415|Experimental|Grup L|"IV patient-controlled analgesia (PCA) morphine~+ Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine"
2866564|NCT03483415|Active Comparator|Group P|IV patient-controlled analgesia (PCA) morphine
2866565|NCT03483402|Experimental|PEXG treated with MLT|Patients with pseudoexfoliation glaucoma (PEXG) under prostaglandine analogue monotherapy with inadequate IOP control treated with 360-degrees 532nm micropulse laser trabeculoplasty (MLT)
2866566|NCT03483389|Experimental|Alcohol, placebo|Alcohol, ethyl - Placebo
2866567|NCT03483389|Experimental|Alcohol, low dose|Alcohol, ethyl - Low dose
2866568|NCT03483389|Experimental|Alcohol, moderate dose|Alcohol, ethyl - Moderate dose
2866569|NCT03483376|Active Comparator|Dental prophylaxis|Study volunteers with black plaque stained teeth will receive standard dental prophylactic cleaning to remove the stain. The prophylaxis will be carried out using an ultrasonic scaler, prophylaxis brush and abrasive paste.
2866570|NCT03483376|Experimental|Dental prophylaxis + aPDT|"Study volunteers with black plaque stained teeth will receive standard dental prophylactic cleaning, followed by antimicrobial photodynamic therapy (aPDT) to remove the stain. The prophylaxis will be carried out using an ultrasonic scaler, prophylaxis brush and abrasive paste. The aPDT protocol is as follows:~Patient will rinse the oral cavity with 20 ml of an aqueous solution of curcumin (photosensitizer; 1.5 g/L) for 30 seconds.~Blue light from a Bluephase 20i curing lamp will be applied perpendicularly for 1 min per tooth (30 seconds on the vestibular side and 30 seconds on the palatal side).~Remaining photosensitizer will be removed using the prophylaxis brush. The aPDT protocol is repeated following a rest period of 10 days."
2866571|NCT03483363|Experimental|topical irrigation with the antibiotic bacitracin|Fractures will be irrigated with Bacitracin topical antibiotic (50,000 units) prior to closure. All groups with receive standard parenteral intravenous (IV) prophylactic antibiotic.
2866572|NCT03483363|Active Comparator|topical irrigation with sterile normal saline (NS)|Fractures will be irrigated with sterile normal saline prior to closure. All groups with receive standard parenteral (IV) prophylactic antibiotic.
2866573|NCT03483350|Experimental|1- 1st group|1- 1st group will include 30 patients will receive intravenous granisetron 10 μg/kg after induction of anesthesia and before start of surgery
2866574|NCT03483350|Experimental|2- 2nd|2- 2nd group will include 30 patients will receive intravenous midazolam 50 μg/kg after induction of anesthesia and before start of surgery
2866575|NCT03483350|Experimental|3- 3rd group|3- 3rd group will include 30 patients will receive combination intravenous granisetron 5 μg/kg with midazolam 25 μg/kg after induction of anesthesia and before start of surgery
2866576|NCT03483337||30 recurrent or metastatic head and neck cancer patients|Patients will be imaged on a 1.5 T or 3 T MR scanner. Patients will receive a test-retest scan in on session prior to start of treatment.
2866577|NCT03483337||50 recurrent or metastatic SCC head and neck cancer patients|Patients will be imaged on a 1.5 T or 3T MR scanner within one week prior to treatment initiation and at two months and four months after treatment completion (+/- 1 week).
2866578|NCT03483324|Experimental|Experimental|Unmanipulated umbilical cord blood plus AB-110
2866579|NCT03483311|Experimental|psoriasis patients|Tissue levels of resolvin D1 in psoriatic patients before and after NB-UVB.
2866580|NCT03483311|Experimental|controls|Tissue levels of resolvin D1 in controls
2866581|NCT03483298||elevated sperm DNA fragmentation|Couples with male partners who will be undergoing a TESA procedure secondary to elevated DNA fragmentation (>25% DFI) as part of their routine IVF treatment will have half of the women's eggs inseminated with ejaculated sperm and the other half with surgically obtained sperm via the ICSI procedure
2866582|NCT03483285|Active Comparator|heart rate|Effects of İntubation with Airtraq or Storz to heart rate
2866583|NCT03483285|Active Comparator|mean arterial pressure|Effect of intubation with Airtraq or Storz to mean arterial pressure
2866977|NCT03480386|Placebo Comparator|Control|Patients randomized in this arm will start the exercises in 12 weeks.
2866585|NCT03483259|Experimental|Arm B-Sulfatinib R capsule|The subjects in this arm will receive sulfatinib R capsules from Beijing Yiling Bioengineering Technology Co., Ltd.
2866586|NCT03483246|Experimental|Group A - fecal microbiota transplantation|Patients receiving the fecal microbiota transplantation (FMT) in 3 times after inclusion and randomisation
2866587|NCT03483246|Placebo Comparator|Group B- Sham-transplantation|Patients receiving the sham-transplantation in 3 times after inclusion and randomisation
2866588|NCT03483233|Experimental|fMRI and EEG study|
2866589|NCT03483220||cases|patients with substance use disorder
2866590|NCT03483207|Experimental|MVT with anticoagulation therapy(heparin &warfarin)|patients with confirmed diagnosis of acute MVT on CT scan but having no signs of peritonitis or established CT signs of gangrene will be treated conservatively with anticoagulation(heparin &warfarin) while other cases will be for surgical management and not included in the study.
2866591|NCT03483207|Experimental|MVT with failure of anticoagulation therapy(heparin &warfarin)|patients who underwent conservative therapy with anticoagulation (heparin &warfarin) but showed no improvement .
2866592|NCT03483194|Active Comparator|Kalinox®|The included patients in this group will have, during the intervention, a local anesthesia by xylocaine® 10 mg / mL (1 bottle of 20 mL) in complement of a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen (Kalinox®)
2866593|NCT03483194|Experimental|Virtual Reality|The included patients in this group will have, during the intervention, a local anesthesia by xylocaine® 10 mg / mL (1 bottle of 20 mL) in complement of a virtual reality (VR) session.
2866594|NCT03483181||Orthopedic surgery patient records|Medical records from patients aged 18 years or older with orthopedic surgeries during the hospitalization
2866595|NCT03483168|Experimental|Culturally sensitive pain education|
2866596|NCT03483168|Active Comparator|Standard pain education|
2866597|NCT03483142|Experimental|misoprostol group|misoprostol group ( study group ) ( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation
2866598|NCT03483142|Placebo Comparator|placebo group|( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol.
2866599|NCT03483129|Experimental|Consultation|The consultation will provide the participant with one to one information regarding the benefits of physical activity and healthy eating. Emphasis will placed on the importance of achieving at least 150 minutes of moderate physical activity each week as well as adhering to healthy dietary habits, based on the NHS Eatwell Guide (Eatwell Guide, 2016). Furthermore, participants will have the opportunity to discuss pre-diabetes with a trained practice nurse and ask any questions they may have.
2866600|NCT03483129|No Intervention|Control|All participants will receive an information leaflet detailing pre-diabetes, the associated risks and steps that can be taken to avoid developing diabetes.
2866601|NCT03483116|Experimental|High dose RV3-BB neonatal schedule|High dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
2866602|NCT03483116|Experimental|Mid dose RV3-BB neonatal schedule|Mid dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
2866603|NCT03483116|Experimental|Low dose RV3-BB neonatal schedule|Low dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
2866604|NCT03483116|Experimental|High dose RV3-BB infant schedule|High dose infant RV3-BB vaccine schedule. Placebo for Investigational product dose 1 (0-5 days) and RV3-BB Vaccine for Investigational product doses 2 (week 6) 3 (week 10) and dose 4 (week 14)
2866605|NCT03483103|Experimental|Treatment|Lisocabtagene maraleucel at a dose of 1×10^8 CAR+ T cells (5×10^7 CD8+ CAR+ T cells and 5×10^7 CD4+ CAR+ T cells), will be given IV in a single-dose schedule on Day 1 (between 2 and 7 days following the completion of lymphodepleting chemotherapy).
2866606|NCT03483090|Experimental|Treatment A|4000mg Swisse High Strength Deep Sea Krill Oil (Superba BOOST) (4 capsules containing 1000mg each)
2866607|NCT03483090|Placebo Comparator|Treatment B|4 capsules of matching Placebo orally daily (1000mg each of mixed vegetable Oil)
2866608|NCT03483077|Experimental|BI 730460|
2866609|NCT03483077|Placebo Comparator|Placebo|
2866610|NCT03483064|No Intervention|Control group|Subjects without low back pain to whom the electric current is put but it is not activated.
2866611|NCT03483064|Experimental|Healthy group|Subjects without low back pain to whom the electric current is put but it is activated.
2866612|NCT03483064|No Intervention|LBP-control group|Subjects with low back pain to whom the electric current is put but it is not activated.
2866613|NCT03483064|Experimental|LBP group|Subjects with low back pain to whom the electric current is put but it is activated.
2866614|NCT03483051|Experimental|Potassium Nitrate (KNO3)|Capsules containing 18 mmoles of KNO3 per day, given as one capsule (6 mmoles) three times a day for 4 weeks.
2866615|NCT03483051|Sham Comparator|Potassium Chloride|Capsules containing 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day for 4 weeks.
2866616|NCT03483038|Experimental|Liposomal irinotecan with FOLFOX|Subjects will receive 8 cycles and each cycle is 14 days.
2866617|NCT03483025|Other|Hair Cleansing product 1|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
2866618|NCT03483025|Other|Hair cleansing product 2|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
2866619|NCT03483025|Other|Hair cleansing product 3|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
2866620|NCT03483025|Other|Hair cleansing product 4|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
2866621|NCT03483025|Other|Hair cleansing product 5|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
2866622|NCT03483025|Other|Hair cleansing product 6|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
2867043|NCT03479879|Experimental|Estradiol + Misoprostol|
2866623|NCT03483012|Experimental|Atezolizumab + Stereotactic radiosurgery (SRS)|"Atezolizumab administered intravenously once every 3 weeks~Stereotactic radiosurgery (SRS) begin within 14 days after brain MRI obtained"
2866624|NCT03482999||Control|Standard Wound Closure with drains
2866625|NCT03482999||TissuGlu Surgical Adhesive|TissuGlu was used for approximation and adhesion of the flaps in conjunction with drains
2866626|NCT03482986|Experimental|Group A|Subject will be advised to follow dietary habits plan A. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage, but will be made public once enrollment closes.
2866627|NCT03482986|Experimental|Group B|Subject will be advised to follow dietary habits plan B. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage, but will be made public once enrollment closes.
2866628|NCT03482973|Experimental|Interventional Bupivacaine|20 cc of 0.25% bupivacaine on each side of the sternum at two time points after surgery and POD1
2866629|NCT03482973|Placebo Comparator|Interventional Placebo|20 cc of saline on each side of the sternum at two time points after surgery and POD1
2866630|NCT03482960|Experimental|129Xe MRI followed by 19F MRI with PFP|Participants will self-administer hyperpolarized xenon gas via inhalation prior to the investigators acquiring MRI images. MRI imaging will be taken during approximately 15-second breath-holds. After the MRI is complete, participant performs spirometry maneuvers in a room outside the magnet. Once a minimum of 15 minutes has elapsed since leaving the MRI scanner, the participant will return to the MRI scanner, where the second phase of the study will occur. PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath.
2866631|NCT03482960|Experimental|19F MRI with PFP followed by 129Xe MRI|PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. After the MRI is complete, participant performs spirometry maneuvers in a room outside the magnet. Once a minimum of 15 minutes has elapsed since leaving the MRI scanner, the participant returns to the MRI scanner, where he/she will self-administer hyperpolarized xenon gas prior to acquiring MRI images. MRI imaging will be taken during approximately 15-second breath-holds.
2866632|NCT03482947|Experimental|TAP|ultrasonography-guided transversus abdominis plane block administration of (0.3 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).
2866633|NCT03482947|Experimental|Caudal|Caudal epidural block administration of (1 mL/kg of bupivacaine 0.25% &1 μ/kg dexmedetomidine
2866634|NCT03482934||hypertensive patients|
2866635|NCT03482908|Experimental|Responsive parenting treatment|Early Healthy Lifestyles (EHL) screening tool reported by participants to identify potentially obesogenic parenting practices and child behaviors; data sharing/coordination into electronic health records to inform counseling by trained providers; responsive parenting curriculum delivered by trained WIC nutritionists.
2866636|NCT03482908|No Intervention|Standard Care Control|Standard of pediatric and WIC care
2866637|NCT03482895||Patient: Blood sampling & Feces sampling|"Blood samplings at different times after a meal test: 0, 15, 30, 60, 90 and 120 minutes.~Feces sampling: collection during 24 hours"
2866638|NCT03482882|Experimental|Drug - pimavanserin|
2866639|NCT03482869|Experimental|Diabetic patients|Patients referred for the equilibrium or diagnosis of diabetes mellitus will be proposed to participate and estimate their walking ability with the WELSH (Walking estimated limitation stated by History) based solely on images
2866640|NCT03482856|Experimental|Modern Neuroscience Approach (MNA) plus CBT-I|MNA (i.e. modern pain neuroscience approach) combined with CBT-I (i.e. cognitive-behavioural therapy for insomnia)
2866641|NCT03482856|Active Comparator|MNA alone|The MNA (i.e. modern pain neuroscience approach) alone
2866642|NCT03482843||Vitamin D Deficiency|25-Vitamin D level <25 ng/ml
2866643|NCT03482843||Sufficient Vitamin D Level|25-Vitamin D Level >=25-70 ng/ml
2866644|NCT03482817|Experimental|Probe drug cocktail / Ze 117|One-sequence, Probe drug cocktail alone and in combination with Ze 117.
2866645|NCT03482791|Experimental|Arm 1: Resectable (proton beam therapy)|"Proton beam therapy: total dose of 60 Gy~Standard of care chemotherapy - the clinical trial doesn't dictate anything about the chemotherapy given, it is the treating physician's decision~Surgery should ideally be performed no later than 8 to 10 weeks after completing chemoradiation~Patient-reported outcome measures (PROs) performed at several time points"
2866646|NCT03482791|Experimental|Arm 2: Unresectable (proton beam therapy)|"Proton beam therapy: total dose of 50 Gy~Standard of care chemotherapy - the clinical trial doesn't dictate anything about the chemotherapy given, it is the treating physician's decision~Patient-reported outcome measures (PROs) performed at several time points"
2866647|NCT03482778||AYA Patients|Qualitative data collection will occur through one-on-one semi-structured interviews with AYA patients (n=36). AYA patients are eligible if they: (1) are 15 to 39 years of age, (2) were diagnosed with cancer at 15 to 39 years of age; (3) are able to read and understand English; (4) have a new cancer diagnosis and are receiving curative treatment OR are currently 0 to 5 years post-treatment. AYA patients will be excluded if they: (1) were diagnosed with basal cell skin cancer; (2) experienced a cancer recurrence; (3) are currently receiving palliative or hospice care; (4) had an infertility diagnosis prior to their cancer diagnosis, or (5) report a significant psychiatric history.
2866648|NCT03482778||AYA Providers|Qualitative data collection will occur through one-on-one semi-structured interviews with AYA providers (n=36). Providers will be health professionals who provide supportive care for AYAs to help address financial, body image, and fertility/future parenthood concerns or needs. Psychosocial providers (e.g., social workers, patient navigators, psychologists) will all be eligible to participate. We will also include reproductive endocrinologists, nurse practitioners, and other medical professionals who have expertise in the appropriate area of health-related quality of life (HRQOL). Additional inclusion criteria will be: (1) provision of care to AYAs; (2) ≥2 years practicing; (3) English-speaking.
2866649|NCT03482778||Content Experts|Qualitative data collection will occur through one-on-one semi-structured interviews with content experts (n=36). Content experts are a purposive sample of scientists and clinicians who have recognized expertise in each of the three domains of interest to this project - financial burden, body image, and fertility/future parenthood.
2866650|NCT03482765|Experimental|Probiotic 1|Probiotic 1: A dietary probiotic supplement which contains Bifidobacterium Lactise. Dose: > 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.
2866651|NCT03482765|Experimental|Probiotic 2|Probiotic 2: A dietary probiotic supplement which contains Lactobacillus acidophilus. Dose: > 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.
2866652|NCT03482765|Placebo Comparator|Placebo|The Placebo contains MCC.
2866653|NCT03482739|Experimental|Immunocompromised patients|All patients will receive the nine-valent HPV vaccine
2866654|NCT03482726|Other|Cycling Cadence Modulation|3 initial visits to collect baseline information; 6-week HIIT indoor cycling program at the individual prescribed cadence; final study visit for post-intervention measures.
2866655|NCT03482713|Experimental|Gefapixant 45 mg|Participants will receive a gefapixant 45 mg film-coated tablet BID for 28 days.
2866656|NCT03482713|Placebo Comparator|Placebo|Participants will receive a film-coated placebo tablet matching gefapixant BID for 28 days.
2866657|NCT03482700|Other|Intervention|The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
2866658|NCT03482700|Other|Control|Usual standard of care
2866659|NCT03482687|Experimental|Me & You: Building Healthy Relationships|Me & You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid.
2866660|NCT03482687|No Intervention|Comparison Group|No intervention was provided, only usual care.
2866661|NCT03482674|No Intervention|Control Group|The control group will receive standard care as provided by the German statutory health insurance.
2866662|NCT03482674|Experimental|Intervention group|The intervention group receives the DIMINI lifestyle intervention for a period of three months.
2866663|NCT03482661|No Intervention|Control|The patients swallowed the capsule with water in the supine position. When the capsule reached the stomach, the capsule was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After completing the stomach examination, the capsule moved automatically without magnetic control and entered the duodenum under physiological conditions. The position of the capsule was verified through real-time viewer.
2866664|NCT03482661|Experimental|Magnetic steering|After finishing the stomach examination as the control protocol, the capsule was lifted with the magnetic control, then rotating the capsule until the camera end oriented toward the pylorus . Next, the endoscopist could drag the capsule close to the pylorus with the guidance magnet robot, waiting for the open of pylorus. Once the pylorus opened, the capsule could enter the duodenum with gastric peristalsis.
2866665|NCT03482648|Experimental|Single Ascending Doses|
2866666|NCT03482648|Experimental|Multiple Ascending Doses|
2866667|NCT03482635|Experimental|Group 1- Placebo Group|
2866668|NCT03482635|Experimental|Group 2- Small Dose Group|
2866669|NCT03482635|Experimental|Group 3- Medium Dose Group|
2866670|NCT03482635|Experimental|Group 4 - High Dose Group|
2866671|NCT03482622||Patients undergoing Mohs surgery|Skin samples excised during Mohs surgery will be measured by the Fast Raman device. The Fast Raman measurements will be compared to gold standard histopathology to determine measurement accuracy.
2866672|NCT03482596|Experimental|Intervention|All participants will follow the personalised multifaceted intervention to reducing/breaking prolonged sitting.
2866673|NCT03482583|Other|Cognitive Behavior Therapy with NRT|Cognitive Behavior Therapy (CBT) will be provided by a certified tobacco treatment specialist (CTTS) using vidyo, a HIPAA-compliant video based platform. Participants in this arm, if interested will be provided a 2 week supply of nicotine replacement therapy (NRT). The intervention in this arm would be NRT along with the CBT counseling.
2866674|NCT03482583|Other|Referral to Area Health Education Center|The Area Health Education Center (AHEC) is a locally available tobacco cessation program aimed at strengthening the capacity of Florida's healthcare system to deliver effective evidence based tobacco use treatment, and prevention services throughout the state. The intervention is education on the health effects related to tobacco use, and benefits of quitting and what to expect when quitting. A tobacco cessation specialist of trained facilitator guides participants as they identify triggers and withdrawal symptoms, and discuss ways to cope with them. The program offers free nicotine replacement therapy, educational materials, goodies for their quit day and follow up support.
2866675|NCT03482583|Other|Referral to Qutiline|"Quitline is a local program in the state where smokers can call a toll free number to talk to coach who can help them quit. There is also an option of online program if they prefer to engage in online help to quit tobacco use.~The intervention in this arm is counseling support by phone or online with an option of Nicotine replacement therapy. If participants prefer this option, our nurse will refer them to locally available quitline service using EPIC."
2866676|NCT03482557|Experimental|CESM VS MRI|"Each enrolled participant will receive both a CESM and MRI exam prior to the breast biopsy, if they had not been performed already as part of clinical care.~MRI: Breast MRI will be performed, if not already performed as part of clinical care.~CESM: After the MRI is complete, patients will be brought to the mammography department for the contrast enhanced mammogram. The CESM will only occur if not already performed as part of the patient's clinical care.~Biopsy: Patients will then have their biopsy. Any additional findings seen on the CESM or MRI will be worked up also.~Reader Study: The CESM and the MRI images will be included in a case set that is ready by 10 study radiologists at a later date, after the biopsy is performed. These radiologists will look at the images to see if CESM and MRI find the same number of breast cancers."
2866677|NCT03482544|Active Comparator|Pregabalin Group|We will give 150 mg pregabalin capsule orally 1 day before surgery and 1 hour before surgery (totally two times) to the pregabalin group patients.
2866678|NCT03482544|Active Comparator|Control Group|In control group, we will empty the drug material from capsules and give only empty capsules to the control group patients at the same times.
2866679|NCT03482531||before group|"In the before group, the investigators retrospectively included 405 patients who had a dinoprostone vaginal insert for cervical ripening before induction of labor, between January 2015 and September 2016.~Multivariate and regression analysis showed that the factors significantly increasing the time to delivery were: Nulliparity, obesity, a closed cervix on initial examination, and intact membranes at the time of insertion. The investigators also described a regression equation that allows to calculate the mean time from insert placement to delivery for each patient."
2866680|NCT03482531||after group|"The investigators will prospectively include all eligible patients with a vaginal dinoprostone insert for cervical ripening during the next two years, starting on April 1st, 2018. At Angers hospital, there are around 600 cases of dinoprostone vaginal inserts per year, so the investigators will be able to include 400 to 500 patients during the study's duration.~The equation will be incorporated when scheduling patients for cervical ripening with vaginal dinoprostone insert. The main objective of this study is to analyze to evaluate our mathematical model. One of the secondary objectives is to analyze whether the use of the personalized scheduling based on the mathematical model would decrease the rate of nocturnal deliveries (between midnight and 6 a.m.)."
2866681|NCT03482518|Experimental|Intervention Group|The intervention group volunteers will receive a pair of custom slippers with perforated synthetic leather cover with elements in insoles. They will be advised to wear the slipper for 4 hours in the first week and up to 8 hours after that period. Should any part of you feel uncomfortable, the participant should return immediately so that the appropriate adjustments are made in the slipper
2866682|NCT03482518|Sham Comparator|Control group|"The control (sham) group volunteers will receive a pair of custom slippers with perforated synthetic leather cover as those used by GI.~The difference will be that these slippers will not have the elements in the insoles."
2866683|NCT03482492|Active Comparator|Tramadol|Group Tramadol patients received tramadol 1 mg kg-1 iv
2866684|NCT03482492|Active Comparator|Tramadol-Paracetamol|Group Tramadol-Paracetamol patients received paracetamol 1 gr iv in addition to tramadol 1 mg kg-1 iv 30 minutes before the end of the operation and after the operation at 6 hour intervals for 24 hours
2866685|NCT03482479|Experimental|Naltrexone Hydrochloride|Naltrexone hydrochloride for oral use, 4.5 mg per capsule, taken once a day for 6 weeks.
2866686|NCT03482479|Placebo Comparator|Placebo Comparator|Placebo to match naltrexone for oral use to be taken once a day for 6 weeks.
2866687|NCT03482466|Experimental|PTSD patients|12 PTSD patients will be recruited to undergo neurofeedback training .
2866688|NCT03482453|Experimental|Part 1 Cohort 1: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1.
2866689|NCT03482453|Experimental|Part 1 Cohort 2: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 1.
2866690|NCT03482453|Experimental|Part 1 Cohort 3: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 2.
2866691|NCT03482453|Experimental|Part 1 Cohort 4: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 3.
2866692|NCT03482453|Experimental|Part 1 Cohort 5: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 4.
2866693|NCT03482453|Experimental|Part 2: TAK-788 Fed + TAK-788 Fasted|TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fed conditions (Treatment A), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fasted conditions (Treatment B). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.
2866694|NCT03482453|Experimental|Part 2: TAK-788 Fasted + TAK-788 Fed|TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fed conditions (Treatment A). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.
2866695|NCT03482440|Placebo Comparator|Placebo|
2866696|NCT03482440|Experimental|Salsalate|
2866697|NCT03482427|Experimental|Intervention|After completion of the Healthy Hear Score assessment, participants will receive a lifestyle intervention based on the Healthy Heart Score results for 12-weeks by trained dietetic interns on-site. Participants will receive a check-in email or phone 6 weeks after the initial visit. A Registered Dietitian is also available to speak with patients. The intervention will consist on educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors
2866698|NCT03482427|No Intervention|Control|Participants in the control group will follow their usual care protocol after taking the Healthy Heart Score assessment. Researchers will provide the Healthy Heart Score survey results, but will not discuss or interpret the results with them. Participants can discuss any concern they have with their usual physician if they choose. After the follow-up visit and upon completion of the study, all participants in the control group may also receive the educational handouts and will be granted access to the Healthy Heart Score application if they wish.
2866699|NCT03482414|Active Comparator|traditional wooden checkerboard|upper limb training with traditional wooden checkerboard
2866700|NCT03482414|Experimental|gaming board with single-player games|upper limb training with a LED-based interactive gaming board equipped with single-player games
2866701|NCT03482414|Experimental|gaming board with two-player games|upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games
2866702|NCT03482401|Experimental|Polyphenol group|Patients consumed a polyphenol-rich dietary supplement (commercial lemon, orange, pomegranate, olive, grape, cocoa, curcuma and broccoli extracts), mainly rich in simple phenolics such as hydroxytyrosol and the polyphenols procyanidins, hesperidin, eriocitrin, curcumin, resveratrol, punicalagin and ellagic acid. Cocoa extract also contains the methylxanthines theobromine and caffeine.
2866703|NCT03482401|No Intervention|Control group|Participating patients did not consume the supplement but provided biological samples to the trial
2866704|NCT03482388|Experimental|Crowdsourced intervention|A multimedia component will deliver two videos and two images promoting HBV and HCV testing developed through a crowdsourcing contest in China. A participatory component will invite men to submit suggestions for how to improve crowdsourced videos and images.
2866705|NCT03482388|Other|Control|No images or videos will be viewed, and suggestions for improving hepatitis testing materials will not be collected.
2866706|NCT03482375||No Stones on POC after ERCP|This is a cohort in which there are no stones seen on Cholangioscopy after ERCP and cholangiogram to treat gall stones.
2866707|NCT03482375||Stones seen on POC after ERCP|This is a cohort in which there are no stones seen on Cholangioscopy after ERCP and cholangiogram to treat gall stones.
2866708|NCT03482362|Experimental|Cohort A; KRASmt, BRAFwt, BRAF-like CC|Patients with KRAS mutant and BRAF wildtype colon cancer that met the BRAF-like signature according to the validated test of Agendia will be treated with vinorelbine tartrate.
2866709|NCT03482362|Experimental|Cohort B; KRASwt, BRAFmt, BRAF-like CC|Patients with KRAS wildtype and BRAF mutant colon cancer that met the BRAF-like signature according to the validated test of Agendia will be treated with vinorelbine tartrate.
2866710|NCT03482349|Experimental|Total Knee Robotically-Assisted|The intervention is then performed with a new device and surgical procedure. At first the femur and the tibia are fixed to the operating table with a special clamp and the knee bones are exposed with the standard technique; then the surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.
2866711|NCT03482349|No Intervention|Total Knee Manual-Executed by Surgeon|Your orthopaedic surgeon will remove the damaged cartilage and bone, and then position the new metal and plastic implants to restore the alignment and function of your knee.
2866712|NCT03482336|Other|Uninstructed Group|"For the first block of participants recruited (39, one of which withdrew from boredom), no overt reference was made regarding the FOP labels that were present on the images that participants viewed during the course of the video game. Participants comprising this block were referred to as uninstructed."
2866713|NCT03482336|Other|Minimally trained|"Realizing that subjects might not use the FOP during decision making when not informed that it contained nutrition information, we conducted a second experiment (N= 41) which provided minimal information about the FOP. These subjects (the minimally instructed group) were provided with further instruction. At the beginning of the experiment, in addition to being shown the basic premise of the game and told that Munchy preferred to eat healthy options, the researcher pointed to one of the FOPs and told children this information might be helpful when you decide what's healthy."
2866714|NCT03482323|Experimental|Exercise intervention|Exercise class will run twice a week for 12 weeks. Participants will be encouraged to maintain their exercise beyond the intervention. An exercise trainer will lead the classes. The main activity of the classes includes aerobic exercises of walking on treadmill, or out-doors depending on group preference and weather, at a set pace individually tailored for moderate intensity of exercise, determined by baseline physical functioning assessment and modified based on Rated Perceived Exertion (RPE), or cycling on a stationary bike, using a set resistance to the physical functioning assessment and RPE. A set of four strengthening exercises are included in one of the exercise classes each week. These exercises are chosen to increase strength in the leg, arm, abdomen and improve trunk stability. Weights for the strengthening exercise will be set to give participants a moderate level of intensity of exercise.
2866715|NCT03482323|Experimental|Tai-chi intervention|The classes will run twice a week for 12 weeks with each session lasting approximately 60 minutes. Classes will be taught by an experienced tai-chi master, who will explain the theory behind tai-chi and the principles of the techniques. The supervised session includes a warm up, self-massage and a guided run through of the movements, breathing techniques, and relaxation in tai-chi. The tai-chi master will guide participants to practice the tai-chi they learn in the classes at home each day. Upon completion of the 12 weeks course, participants will be encouraged to continue their tai-chi practice, given guidance on local services and programmes they may join if they wish to.
2866716|NCT03482323|No Intervention|Control group|Participants randomised to the control group shall receive written information on health levels of physical activity, which they can participate in at home (self-management) and continue to receive their usual care, participants will be followed up with an assessment at 12 weeks, 6 months and one year. At the end of the evaluation stage of the study, survivors in the control group will be invited to take part in an intervention of their choice.
2866717|NCT03482310|Experimental|Cortical Control of Grasp Patterns|Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
2866718|NCT03482284|Experimental|Monosaccharide 1|Participants receive standardized meals with a defined amount of monosaccharide 1.
2866719|NCT03482284|Experimental|Monosaccharide 2|Participants receive standardized meals with a defined amount of monosaccharide 2.
2866720|NCT03482258|Experimental|Treatment Prebiotic|3 week daily dose of Vivinal-GOS (galacto-oligosaccharide)
2866721|NCT03482258|Placebo Comparator|Placebo|3 week daily dose of Maltodextrin
2866722|NCT03482245|Experimental|Pneumonia: Blue Light|High illuminance (1000lux), blue spectrum (peak 441 nm) light for an initial 24 hour photoperiod and then a 12 hour photoperiod for days 2 and 3 after randomization.
2866723|NCT03482245|Experimental|Diverticulitis: Blue Light|High illuminance (1000lux), blue spectrum (peak 441 nm) light for an initial 24 hour photoperiod after surgery for diverticulitis
2866724|NCT03482245|Experimental|Appendicitis: Blue Light|High illuminance (1000lux), blue spectrum (peak 441 nm) light for an initial 24 hour photoperiod after surgery for diverticulitis
2866725|NCT03482245|No Intervention|Pneumonia: Ambient Light|Standard ambient hospital lighting (~300 lux) for an initial 24 hour photoperiod and then a 12 hour photoperiod for days 2 and 3 after randomization.
2866726|NCT03482245|No Intervention|Diverticulitis: Ambient Light|Standard ambient hospital lighting (~300 lux)for an initial 24 hour photoperiod after surgery for diverticulitis.
2866727|NCT03482245|No Intervention|Appendicitis: Ambient Light|Standard ambient hospital lighting (~300 lux) for an initial 24 hour photoperiod after surgery for diverticulitis.
2866728|NCT03482232||Patients visiting GP|All patients visiting GP. The frequency of some drugs and diagnosis tests include in the Do-Not-Do recommendations will be analyzed.
2866729|NCT03482232||Patient visiting pediatricians|All patients visiting pediatricians (0 to 14 years old). The frequency of some drugs and diagnosis tests include in the Do-Not-Do recommendations will be analyzed.
2866730|NCT03482219|Experimental|Intensive treatment|"Participants will undergo 8 sessions with an occupational therapist. Participants will meet with the occupational therapist to establish the home exercise program and set up the home exercise app. The app has videos depicting each exercise and ability to track adherence to exercises. The occupational therapy consists of the following which will be provided as appropriate:~Thermal Modalities Hot packs, focused on areas with limitations Paraffin, focused on digital limitations~Application of the Physiotouch (a low-intensity negative pressure device)~Passive Range of Motion~Active Range of Motion~Functional Activities"
2867044|NCT03479879|Placebo Comparator|Placebo + Misoprostol|
2866731|NCT03482219|Active Comparator|Home app intervention|Participants will meet with the occupational therapist to establish the home exercise program and set up the home exercise app. The app has videos depicting each exercise and ability to track adherence to exercises.
2866732|NCT03482206|Experimental|Healthy subjects|Healthy adult volunteers (age 18 or greater) that are not claustrophobic, do not have hyperventilation or panic disorders, not pregnant, have no metal implants and can pass the MRI screening questions.
2866733|NCT03482193||Adolescents|Adolescents in 2nd or 4th year in secondary school, from 9 different schools in Liège, Belgium.
2866734|NCT03482180|Experimental|Treatment|KI1106
2866735|NCT03482180|Active Comparator|Control|Atorvastatin Calcium
2866736|NCT03482167|Placebo Comparator|Placebo|placebo
2866737|NCT03482167|Experimental|Nicotinamide Riboside|Niagen® (ChromaDex, Inc.) 500 mg, twice daily
2866738|NCT03482154||With Malglycemia|
2866739|NCT03482154||Without Malglycemia|
2866740|NCT03482141|Other|WES|Whole exome sequencing (WES) will take place.
2866741|NCT03482128||preAlgorithm|Standard coagulation management of patients undergoing cardiac surgery
2866742|NCT03482128||postAlgorithm|Coagulation management guided by SONOCLOT of patients undergoing cardiac surgery
2866743|NCT03482115|Experimental|Comatose patient|Subject with coma of traumatic or anoxic aetiology : PET examination with radiopharmaceutical drug [18F] DPA-714, MRI examination and Blood samples.
2866744|NCT03482115|Other|control volunteers|subject control : PET examination with radiopharmaceutical drug [18F] DPA-714, MRI examination and Blood samples.
2866745|NCT03482102|Experimental|Tremelimumab + Durvalumab + Radiation|"Durvalumab via IV infusion every 28 days for up to 4 doses/cycles~Tremelimumab via IV infusion every 28 days for up to 4 doses/cycles, and then continue durvalumab monotherapy every 4 weeks starting on Week 16 for up to 8 months.~Radiation therapy will only be given during cycle 2"
2866746|NCT03482089|Experimental|Cystoprostatectomy|(Open, laparoscopic or robot-assisted ) cystoprostatectomy with urinary diversion surgery and extended pelvic lymph node dissection; without adjuvant androgen deprivation therapy;
2866747|NCT03482089|Active Comparator|Radiotherapy|Radiotherapy by external beam radiotherapy (81 Gy，2.4-4 Gy per fraction over 4-6 weeks); with adjuvant androgen deprivation therapy for the least 3 years
2866748|NCT03482076|Other|transferrin receptor concentration|Prevelance of iron deficiency in this patients
2866749|NCT03482063|Experimental|Swisse Ultiboost Memory + Focus|two tablets daily, one tablet during or immediately after breakfast, and one tablet during or immediately after lunch, for the duration of the trial period
2866750|NCT03482063|Placebo Comparator|Placebo|two tablets daily, one tablet during or immediately after breakfast, and one tablet during or immediately after lunch, for the duration of the trial period
2866751|NCT03482050|Experimental|AstroRx|
2866752|NCT03482037|Experimental|Rec 0/0438|Rec 0/0438 1 mg (first cohort), 2 mg (second cohort) to be administered by intravesical instillation once daily for four weeks
2866753|NCT03482037|Placebo Comparator|Placebo|Placebo, to be administered by intravesical instillation once daily for four weeks
2866754|NCT03482024|Experimental|LY3298176 - Healthy|Group 1 - LY3298176 administered subcutaneously (SC) to healthy participants with normal renal function.
2866755|NCT03482024|Experimental|LY3298176 - Mild Renal Impairment|Group 2 - LY3298176 administered SC to participants with mild renal impairment.
2866756|NCT03482024|Experimental|LY3298176 - Moderate Renal Impairment|Group 3 - LY3298176 administered SC to participants with moderate renal impairment.
2866757|NCT03482024|Experimental|LY3298176 - Severe Renal Impairment|Group 4 - LY3298176 administered SC to participants with severe renal impairment.
2866758|NCT03482024|Experimental|LY3298176 - End Stage Renal Disease (ESRD)|Group 5 - LY3298176 administered SC to participants with ESRD.
2866759|NCT03482011|Experimental|Mirikizumab|Mirikizumab administered subcutaneously (SC)
2866760|NCT03482011|Placebo Comparator|Placebo|Placebo administered SC
2866761|NCT03481998|Experimental|Cohort 1 (Part 1)|Participants receive SHR6390 (at protocol defined dose levels) in combination with letrozole 2.5 mg, orally once daily (continuously).
2866762|NCT03481998|Experimental|Cohort 2 (Part 1)|SHR6390 (TBD), in combination with letrozole 2.5 mg, orally once daily (continuously).
2866763|NCT03481998|Experimental|SHR6390 + Letrozole (Part 2)|SHR6390 (RP2D, recommended Phase 2 dose), in combination with letrozole 2.5 mg, orally once daily (continuously).
2866764|NCT03481972|Experimental|Doxy/TUDCA|"doxycicline (100 mg / BID)~tauroursodeoxycholic acid (250 mg / TID)"
2866765|NCT03481972|Active Comparator|Standard of care|Standard of care therapies.
2866766|NCT03481959|Experimental|Methylphenidate|Methylphenidate delay shape, 10 and 30 mg capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).
2866767|NCT03481959|Placebo Comparator|Matching Placebo|
2866768|NCT03481946|Experimental|BAY1093884 in subjects with Hemophilia|Single dose of BAY1093884 over 30 minutes administered in subjects with severe congenital Hemophilia A or B, with inhibitors or without inhibitors
2866769|NCT03481933|Experimental|1:left-excitatory tDCS|20 SD patients who receive left-excitatory trans cranial stimulation
2866770|NCT03481933|Active Comparator|2:right-inhibitory tDCS|20 SD patients who receive right-inhibotory trans cranial stimulation
2866771|NCT03481933|Sham Comparator|3:sham tDCS|20 SD patients who receive sham stimulation
2866772|NCT03481920|Experimental|PEGPH20 + Avelumab|PEGPH20, a multi-site PEGylated enzyme generated by conjugating N-hydroxysuccinimidyl ester of methoxypoly(ethylene glycol)-butanoic acid (MSBA30K/B or PEG) and recombinant human hyaluronidase (rHuPH20). PEGPH20 has a half-life of approximately 2 days, thereby enabling systemic activity and sustained duration of action to degrade HA. In many different tumor types tested in murine xenograft models, response to PEGPH20 has been shown to be more robust for tumors characterized by higher HA expression.
2866798|NCT03481699|Other|Educational intervention|1 hour educational intervention (about the human brain) consisting on several tasks to be completed on paper individually.
2866799|NCT03481686|Experimental|Patients with injections of ESA|Patients with injections of ESA
2867178|NCT03478982|Experimental|Staccato Alprazolam 1.0 mg|single dose for inhalation
2866773|NCT03481907|Other|Internalized Control|Subjects will receive 2 punch biopsy created wounds, one on each thigh, which will be addressed with primary closure with sutures or will be treated with Nuvagen collagen powder at time of wounding and daily thereafter. Suture(s) will be removed in 2 weeks. At week four, the wounded site will be biopsied again for tissue collection/evaluation, and treated with primary closure again. Suture(s) will be removed within to weeks. For those using collagen powder, the biopsy site will be biopsied again at week 4, and wound care will again be with NuvagenTM collagen powder until closure.
2866774|NCT03481894|Experimental|Kabiven®|Kabiven is a sterile, hypertonic emulsion in a three chamber container. The separate chambers contain either amino acids with electrolytes, dextrose, or lipid injectable emulsion.
2866775|NCT03481894|Active Comparator|Compounded standard parenteral nutrition|"The control drug will be compounded for each individual patient as prescribed by the physician. Compounding will be performed according to normal hospital procedure which meets the requirements of the United States Pharmacopeial Convention (USP) <797> Pharmaceutical Compounding—Sterile Preparations."
2866776|NCT03481868||Chronic Myeloid Leukemia|Patients newly diagnosed for Chronic Myeloid Leukemia, according to inclusion and exclusion criteria
2866777|NCT03481855||Progressive bleeding simulation|The study intervention by a lower-body-low-pressure chamber is performed in this group of healthy volunteers with progressive increase of negative pressure by a step-wise approach (-15mmHg, -30mmHg, -45mmHg).
2866778|NCT03481855||Prolonged bleeding simulation|The study intervention by a lower-body-low-pressure chamber is performed in this group of healthy volunteers with prolonged exposure to a negative pressure of -15mmHg.
2866779|NCT03481842|Experimental|Vaginal Suppositories|"Daily single administration of vaginal suppository in diagnosed endometriosis. Duration of admission-five days, two days-off. The total duration of treatment is 6 weeks. General course -30 vaginal suppositories ELTA~The composition of the suppository:~Axitinib (inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit) in a minimally sufficient therapeutic dose~Afatinib (BIBW2992) EGFR / HER2 including EGFR (wt), EGFR (L858R), EGFR (L858R / T790M) and HER2 inhibitor - minimally sufficient therapeutic dose~Linifanib (ABT-869) ATP-competitive VEGFR / PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ - minimally sufficient therapeutic dose"
2866780|NCT03481829||1|Women 18 and older who are getting prenatal care at Phoenix Indian Medical CenterMothers and children who were in the LIFE-Moms Phoenix study
2866781|NCT03481816|Active Comparator|1/Dose De-Escalation|Subjects enrolled to dose de-escalation cohorts
2866782|NCT03481816|Active Comparator|2/Dose expansion|Subjects enrolled at the MTD after the MTD is established
2866783|NCT03481790|Experimental|Lactoferrin|100mg of bovine lactoferrin (Pravotin sachets, Hygint, Egypt) twice a day.
2866784|NCT03481790|Experimental|ferrous sulphate + folic acid (vitamin B9)|150mg of dried ferrous sulphate + folic acid (vitamin B9) 0.50mg (Ferrofol, E.I.P.I.C.O, Egypt) three capsules per day.
2866785|NCT03481777|Active Comparator|Remote Ischemic Conditioning|"Remote ischemic conditioning (RIC) is applied in the hyperacute prehospital phase using an automated RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg; but if initial systolic blood pressure is above 175 mmHg, the cuff is automatically inflated to 35 mmHg above the systolic blood pressure.~Initial remote ischemic conditioning: prehospital phase, all included patients~Remote ischemic conditioning at +6 hours: In-hospital, only patients with AIS and ICH, all centres~Remote Ischemic Postconditioning (twice daily for 7 days): In-hospital/rehabilitation, Only patients with AIS and ICH and only at Aarhus University Hospital~Usual care with or without acute reperfusion therapy"
2866786|NCT03481777|Sham Comparator|Sham - Remote Ischemic Conditioning|"Sham remote ischemic conditioning (Sham-RIC) is applied in the hyperacute prehospital phase using an automated Sham-RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be always be 20 mmHg.~Initial Sham remote ischemic conditioning: prehospital phase, all included patients~Sham Remote ischemic conditioning at +6 hours: In-hospital, only patients with AIS and ICH, all centres~Sham Remote Ischemic Postconditioning (twice daily for 7 days): In-hospital/rehabilitation, Only patients with AIS and ICH and only at Aarhus University Hospital~Usual care with or without acute reperfusion therapy."
2866787|NCT03481764||FS: Febrile Seizures|Involved patient with diagnosed Febrile Seizures which were hospitalized or recieved ambulatory treatment in University Children´s Hospital in Belgrade. Ages 5-14 years
2866788|NCT03481764||CN: Control group|The control group was made of healthy children older than 5 years of age, which have never had any neurological disorders in their anamnesis and who were patients in preschool or school dispensaries in the city of Belgrade
2866789|NCT03481764||SFS : group of individuals with simple FS|Simplex febrile seizures (SFS) last shorter than 15 minutes and their type is tonic-clonic. Also, they did not show signs of recidivism during the first 24 hours and were diagnosed at the patients aged from 6th months to 5th year
2866790|NCT03481764||CFS : group of individuals with complex FS|Complex febrile seizures (CFS) were diagnosed at those patients that had focal seizure or epileptic status or seizure having the body temperature lower than 38 degree, which occurred outside of the typical age group and finally which repeated in the first 24 hours again
2866791|NCT03481764||WFS: group of individuals with FS and without epilepsia|group of children with Febrile Seizure and not developed epilepsia
2866792|NCT03481764||EFS: group of individuals with epilepsia and Febrile Seizures|Group of children with Febrile Seizures, who have developed Epilepsy
2866793|NCT03481751||Patients with Crohn Disease|Patients with Crohn's disease scheduled for ileocolonoscopy
2866794|NCT03481738||PKD Diagnosed|Patients diagnoses with PK Deficiency by PKLR genetic mutation analysis (either compound heterozygote or homozygous recessive) as well as clinical features
2866795|NCT03481725|Experimental|Peripheral Nerve Stimulation|ACTIVE percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electrical current
2866796|NCT03481725|Sham Comparator|Sham|SHAM percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does NOT generate electrical current
2866797|NCT03481699|Experimental|Incremental theory of personality|1 hour behavioral intervention (based on ITP) consisting on several tasks to be completed on paper individually.
2866800|NCT03481673|Experimental|Intervention|This pre-experimental pilot project is a single group, pretest-posttest design with a 6-week post-intervention follow-up. A single group design was chosen for this feasibility pilot study because the COPE for Asthma intervention is newly adapted for 8 to 12-year-old children with asthma in an urban setting. The intervention will consist of 7 weekly sessions (30 minutes each). COPE for Asthma is a manualized, cognitive behavior skills-building intervention to improve the physical and mental health outcomes of children with asthma and elevated symptoms of anxiety or depression. Surveys with children and their parents/caregivers (CGs) will occur at baseline, immediately post-intervention and 6 weeks' post-intervention.
2866801|NCT03481660|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule
2866802|NCT03481660|Active Comparator|Aflibercept 2 mg|Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks
2866803|NCT03481647|Active Comparator|Intervention|The intervention consists of professional oral care and swabbing of the mucosal membranes with a saline and bicarbonate solution, five daily rinses with a saline and bicarbonate solution, a diary to register oral care measures and rinses
2866804|NCT03481647|No Intervention|Control|Professional oral care once a week according to existing routine
2866805|NCT03481634|Experimental|Brolucizumab 3 mg|Brolucizumab 3 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule
2866806|NCT03481634|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule
2866807|NCT03481634|Active Comparator|Aflibercept 2 mg|Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks
2866808|NCT03481621|Active Comparator|Group1a, Acupuncture on Vulvodynia|Focus on using the local points in pudendal nerve distribution area
2866809|NCT03481621|Active Comparator|Group1b, Acupuncture on Vulvodynia|Focus on traditional acupuncture using common meridian or distal points
2866810|NCT03481621|Active Comparator|Group2, Standard care or waiting lists|Standard care without acupuncture
2866811|NCT03481608|Active Comparator|Olive Oil Shake|"Intervention: No Lauric Acid~A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil."
2866812|NCT03481608|Experimental|Coconut Oil Shake|"Intervention: Lauric Acid~A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil."
2866813|NCT03481595|No Intervention|Group A|Group A will receive standard, routine medical care. If you are randomized to standard, routine medical care you will need to communicate with your Doctor and clinical care team through conventional methods such as over the phone or through MyChart.
2866814|NCT03481595|Experimental|Group B|Group B will be asked to use the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care. Patients randomized to use the Health Loop app will be able to communicate with their Doctor and clinical care team directly through the app. Patients will also participate in mobile and web-based surveys, receive reminders related to their healthcare, and receive information personalized to their treatment plan.
2866815|NCT03481582|Active Comparator|Group without nitroglycerin|They will be subjected to TV ultrasound for folliculometry till maturation of the follicle ≥18mm then Three dimensional power Doppler will be used to assess the uterine and sub-endometrial blood flow.
2866816|NCT03481582|Experimental|Group with nitroglycerin|They will receive (nitrodermal®) 5 mg (patch) from 2nd day of cycle till maturation of the follicles ≥ 18 mm then Three dimensional power Doppler will be used to assess the uterine and sub-endometrial blood flow.
2866817|NCT03481569|Experimental|Pharmacokinetic sample|Plasma and cerebrospinal fluid samples performed at different timepoint during administration of antibiotic prescribed in routine use
2866818|NCT03481556|Experimental|A (melflufen+bortezomib+dex)|Melflufen 30 mg and 40 mg or 20 mg i.v. Day 1 of each 28-day cycle in combination with bortezomib at 1.3mg/m² S.Q. on Days 1, 4, 8, 11 and dexamethasone 20 mg (12 mg ≥ 75 years) Days 1, 4, 8, 11 and 40 mg (20 mg ≥ 75 years) on Day 15 and 22 of each 28-day cycle.
2866819|NCT03481556|Experimental|B (melflufen+daratumumab+dex)|Melflufen 30 mg and 40 mg or 20 mg i.v. Day 1 of each 28-day cycle in combination with daratumumab 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks until PD. Dexamethasone will be given day of and after daratumumab infusions, 20 mg i.v. pre daratumumab and 20 mg p.o. day after daratumumab (20 mg total for ≥ 75 years).
2866820|NCT03481543|Experimental|In-line nebulization through NIV mask|Bronchodilator nebulization is given through NIV circuit.
2866821|NCT03481543|Active Comparator|Off-NIV nebulization|Bronchodilator nebulization is given during which NIV mask is taken off for a short time and reapplied when nebulization is finished.
2866822|NCT03481530|Other|Blinded|Continuing Glucose Monitoring System will be blinded
2866823|NCT03481530|Other|Unblinded|Continuing Glucose Monitoring System will be open. Participant can review results if they choose.
2866824|NCT03481517|Experimental|Wound with local anesthesia|5 mL Bupivacaine is injected into subcutaneous area near surgical wound
2866825|NCT03481517|No Intervention|Wound without local anesthesia|Nothing is injected into subcutaneous area near surgical wound
2866826|NCT03481504|Experimental|ACT-ETP|Cognitive behavioral treatment
2866827|NCT03481504|No Intervention|Usual care|no intervention
2866828|NCT03481491|Sham Comparator|Sham cerebellar stimulation|Participants will receive a Sham stimulation (inefficient probe) applied over the cerebellum.
2866829|NCT03481491|Active Comparator|Real cerebellar stimulation|Participants will receive a real continuous theta burst stimulation (cTBS) applied over the cerebellum.
2866830|NCT03481478||Patients with greater tuberosity fractures|If humeral surgical neck fractures can be detected through CT or MRI in such groups.
2866831|NCT03481478||Dislocation patients with greater tuberosity fractures|If humeral surgical neck fractures can be detected through CT or MRI in such groups.
2866832|NCT03481452|Experimental|psychotherapy intervention group|NBO behavioral intervention would be used to improve mother-infant dyad interaction and infants' disorders of regulation of states.
2866833|NCT03481452|No Intervention|control group|No behavioral intervention would be used.
2866834|NCT03481439||Primary cohort|Primary cohort : Cohort of patient between January and February 2017
2867179|NCT03478982|Placebo Comparator|Placebo|single dose for inhalation
2866836|NCT03481426|Experimental|Workplace intervention group|Workers with back problems receive both information/advice and participatory workplace intervention organized by Occupational Health Physioterapist.
2866837|NCT03481426|No Intervention|Information and advice group|Workers with back problems receive only information / advice by Occupational Health Physiotherapist, not the workplace intervention.
2866838|NCT03481400|Experimental|Calcitonin gene-related peptide|Calcitonin gene-related peptide infusion (1.5 micrograms/min for 20 mins)
2866839|NCT03481400|Experimental|Placebo|Infusion with placebo (isotonic saline)
2866840|NCT03481387|Other|PERCEVAL S valve|patients to be treated with PERCEVAL S valve
2866841|NCT03481374|Active Comparator|subjects with Type 1 Diabetes mellitus|Type 1 diabetes patients without cardiovascular disease undergo autonomic function testing
2866842|NCT03481374|Placebo Comparator|Healthy controls|healthy people without known disease undergo autonomic function testing
2866843|NCT03481348|Experimental|Pharyngeal Electrical Stimulation|PES for 10 minutes per day on 3 consecutive days in addition to standard therapy (logopedic counselling, advice for nutrition, learning of swallowing techniques)
2866844|NCT03481348|No Intervention|Control|Standard therapy (logopedic counselling, advice for nutrition, learning of swallowing techniques)
2866845|NCT03481335|Experimental|Intervention Community|Intervention communities (barangays) will receive the intervention (CHAP-P sessions).
2866846|NCT03481335|No Intervention|Control Community|Control communities (barangays) will receive care as usual.
2866847|NCT03481322|Active Comparator|Cooked diet with controlled amount of salt|Patients will receive intervention diet (cooked with controlled amount of salt)
2866848|NCT03481322|Placebo Comparator|Cooked without salt|Patients will receive the standard diet (cooked without salt and 2 grams of salt separated will be added by the patient)
2866849|NCT03481309|Active Comparator|anodal tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This anodal tDCS on the left motor cortex will be stimulated with 2mA for 10 minutes.
2866850|NCT03481309|Active Comparator|cathodal tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This cathodal tDCS on the left motor cortex will be stimulated with -2mA for 10 minutes.
2866851|NCT03481309|Sham Comparator|sham tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). Sham stimulation with 2mA for 40 seconds will be applied.
2866852|NCT03481296|Active Comparator|Advanced Control|The advanced control group receives a set of standard materials regarding colorectal cancer screening.
2866853|NCT03481296|Experimental|Culturally Adapted Decision Support Navigation Intervention|The culturally adapted decision support navigation intervention group receives everything advanced group receives as well as decision support and navigation contacts.
2866854|NCT03481270|Placebo Comparator|Discordant|Does not receive the concordant provider.
2866855|NCT03481270|Experimental|Concordant|The intervention is that the subject receives the concordant provider.
2866856|NCT03481257||Ticagrelor|ACS patients treated with aspirin (100mg/d) and ticagrelor (90mg bid)
2866857|NCT03481257||Clopidogrel + very low dose rivaroxaban|ACS patients treated with aspirin (100mg/d), clopidogrel(75mg/d) and very low dose rivaroxaban (2.5mg bid)
2866858|NCT03481218||Patients with type 1 diabetes|Young adults (male and female) between the ages of 18 and 35, who have type 1 diabetes for at least one year.
2866859|NCT03481218||Individuals without chronic diseases|Young adults (male and female) between the ages of 18 and 35, without chronic diseases.
2866860|NCT03481205|Experimental|Ischemic Conditioning|Doctormate device used en route to the comprehensive stroke center
2866861|NCT03481192|Experimental|A group using amnesic substances|"A group of patients admitted for IMV exclusively using amnesic substances. Benzodiazepines, benzodiazepines, tricyclic antidepressants, neuroleptics, antihistamines, other atropine substances, anti-epileptics and opiates.~Two visits for evaluation, the first one for the first evaluation of cognitive functions directly following the psychiatric interview, and the second one at 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place."
2866862|NCT03481192|Active Comparator|A control group|"A control group that ingested exclusively non-amnesic substances among them most frequently ingested in this context, ie the following classes: level 1 analgesics, antibiotics, serotonergic and noradrenergic antidepressants, oral antidiabetic, thyroid hormones, anti oral coagulant.~Two visits for evaluation, the first one for the first evaluation of cognitive functions directly following the psychiatric interview, and the second one at 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place."
2866863|NCT03481179|Experimental|Experimental: hf rTMS and Physical therapy|High frequency TMS will be applied with an eight shaped coil angled at 45 degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1) injured. Forty stimulus trains will be provide at 10Hz over the injured hemisphere, at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 2000 pulses for approximately 20 minutes, with 120% of resting motor threshold (RMT). After TMS, patients will be submitted to 50 minutes of physical therapy protocol.
2866864|NCT03481179|Sham Comparator|Control: Sham hf rTMS and Physical theraphy|In this group, the volunteer will start with sham TMS, will be the same parameters was used in experimental group, however, it will be performed using two coils, one connected to the magnetic stimulator, away from the patient's scalp and another uncoupled from the stimulator and positioned in the same way as in real stimulation. After, the volunteer will be submitted to 50 minutes of physical therapy protocol.
2866865|NCT03481166|Experimental|Education on breastfeeding pain|Both the experimental and control groups will receive usual prenatal education offered through our regional public health program. In addition to usual prenatal education, the experimental group will also receive a one-hour, nurse led (a Registered Nurse specially trained in perinatal care), small group-based education session with specific focus on breastfeeding pain. The goals of this educational intervention are to provide pregnant women with anticipatory guidance around pain which is commonly experienced while breastfeeding in the first two weeks postpartum. Education will include the prevalence, etiology and management of various types of breastfeeding-related pain experienced postpartum.
2867151|NCT03479190|Active Comparator|Platelet rich plasma|ultrasound guided injection of Platelet rich plasma
2866866|NCT03481166|No Intervention|Usual prenatal education|Women allocated to the usual prenatal education group will receive prenatal classes through their local public health unit. Women enrolled in classes will receive approximately 12 hours of combined in-class and online prenatal content. Topics include: discomforts of pregnancy, labor and birth, medical interventions, adjustment to parenting, breastfeeding, and caring for the newborn. Breastfeeding-related material includes basic mechanisms of milk production, benefits of breastfeeding, benefits of skin-to-skin, correct breastfeeding latch, breastfeeding positions, timing of feeds, responding to infant cues, and caring for nipples. Women in the usual prenatal education group will not receive education on the prevalence and etiology of nipple pain, nor specific pain management strategies.
2866867|NCT03481153|Placebo Comparator|Sham tDCS|Participants will be participate in a 20-minute sham tDCS session. tDCS electrodes will be placed on the left (anodal positive polarity) and right (cathodal;negative polarity) dorsolateral prefrontal cortex. Sham stimulation will be applied.
2866868|NCT03481153|Active Comparator|tDCS|Participants will participate in a 20-minute tDCS session. tDCS electrodes will be placed on the left (anodal positive polarity) and right (cathodal;negative polarity) dorsolateral prefrontal cortex.
2866869|NCT03481140||Control|donor site DIEP flap breast reconstruction procedure with standard wound closure with drains
2866870|NCT03481140||TissuGlu Surgical Adhesive|donor site DIEP flap breast reconstruction procedure with standard wound closure with TissuGlu Surgical Adhesive and no drains
2866871|NCT03481127|Active Comparator|Arm 1: Usual Care|-No psychosocial care in clinic
2866872|NCT03481127|Experimental|Arm 2: Integrated Care|-Those who receive integrated care will receive a one-page care plan completed by Dr. Vanderlan including their scores from screening questionnaires , recommendations for coping strategies and available supportive resources.
2866873|NCT03481114|No Intervention|Standard chemoradiotherapy|Patients receiving standard radiotherapy will receive a total dose of 60 Gy in 30 fractions over 6 weeks, delivered to all involved lesions (tumors and lymph nodes)
2866874|NCT03481114|Experimental|PET-based, dose-painted, accelerated chemoradiotherapy,|For patients receiving PET-based, dose-painted, accelerated chemoradiotherapy, lesions with MTV exceeding 20 cc will be treated with 55 Gy in 20 fractions over 4 weeks, while lesions with MTV below 20 cc will receive 48 Gy in 20 fractions over the same 4 weeks
2866875|NCT03481101|Other|All patients|Both patients receiving chemotherapy and immunotherapy are observed during the same intervention with PET/CT and liquid biopsy. No primary comparison are made between the groups.
2866876|NCT03481088|Other|Functional appliance therapy|"All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.~Stage- I (pre-treatment),~Stage- II (after pre-functional therapy)~Stage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)"
2866877|NCT03481075|Experimental|Rigid and Elastic registration softwares|
2866878|NCT03481062||Neutral|
2866879|NCT03481062||abduction|
2866880|NCT03481062||pad|
2866881|NCT03481062||combination|
2866882|NCT03481049|Experimental|Usual CM|Participants will earn at least 3 prize draws each time they submit an alcohol negative urine samples during weeks 5-20, plus treatment as usual
2866883|NCT03481049|Experimental|High-Magnitude CM|Participants will earn twice as many prize draws than those in the Usual CM for alcohol abstinence during weeks 5-20, plus treatment as usual.
2866884|NCT03481049|Experimental|Shaping CM|Participants will earn prize draws for light drinking during weeks 5-8 instead of alcohol abstinence and will then earn prize draws for abstinence during weeks 9-20, plus treatment as usual.
2866885|NCT03481036|Experimental|Direct Acting Antiviral Agents (DAA) arm|Patients with liver cirrhosis and genotype (GT-3) are being treated with Direct Acting Antivirals i.e. Sofosbuvir (SOF)+Daclatasvir (DCV) for 12 weeks, while non-GT-3 patients were treated with SOF+ Ledipasvir (LDV) for 12-weeks; SVR-12 is mandatory in all patients. Patients < 35 kg will be given half doses of medications and patients ≥35 kg will be given adult dosages of SOF (400 mg), LDV (90 mg) and DCV (60 mg) per day
2866886|NCT03481023|Experimental|Esophageal thermal regulation device|
2866887|NCT03481023|Active Comparator|LET monitoring|
2866888|NCT03481010|Experimental|PAO with hip arthroscopy|"Patient's in the Scope PAO group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the Scope-PAO group have been randomized to receive a periacetabular osteotomy with a hip arthroscopy."
2866889|NCT03481010|Active Comparator|PAO without hip arthroscopy|"Patient's in the PAO-only group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the PAO-only group have been randomized to receive a periacetabular osteotomy only."
2866890|NCT03480997|Experimental|albuterol sulfate 100 mcg|albuterol sulfate 100 mcg Test MDI
2866891|NCT03480997|Active Comparator|albuterol sulfate 200 mcg|albuterol sulfate 200 mcg Reference MDI
2866892|NCT03480997|Experimental|albuterol sulfate and ipratropium bromide|albuterol sulfate 100 mcg and ipratropium bromide 20 mcg Test MDI
2866893|NCT03480984|Active Comparator|Programmed Intermittent Bolus|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus
2866894|NCT03480984|Active Comparator|Continuous Infusion|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion
2866895|NCT03480971|Active Comparator|Active 600 mg Tempol Solution|Patients will take 600 mg of Tempol a day for the duration of radiation treatment (6-8 weeks)
2866896|NCT03480971|Placebo Comparator|Placebo Solution|Patients will take placebo solution everyday for the duration of radiation treatment (6-8 weeks)
2866897|NCT03480958|Active Comparator|ESP group|Erector Spinae Plane Block administered group
2866898|NCT03480958|Active Comparator|TPVB group|Thoracic Paravertebral Block administered group
2866899|NCT03480958|Other|Control Group|No regional anesthesia technique will be applied to control group; but will be provided with iv PCA
2866900|NCT03480932|Active Comparator|SOF+DAC+PEG|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) for 4 weeks with a field-based DOT approach
2866901|NCT03480932|Active Comparator|SOF+DAC, DOT|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with a field-based DOT approach
2866902|NCT03480932|Active Comparator|SOF+DAC, standard|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with standard of care dispensation (4 monthly doses)
2866903|NCT03480919|Experimental|Shen Men acupuncture|Single acupuncture needles will be placed bilaterally onto the patient's Shen Men acupuncture point in the ear for a duration of 20 minutes.
2866904|NCT03480919|Sham Comparator|Sham acupuncture|Single acupuncture needles will be placed bilaterally onto a sham location in the ear for a duration of 20 minutes.
2866905|NCT03480919|Placebo Comparator|Simulated acupuncture|Acupuncture will be simulated with a paper clip.
2866906|NCT03480906|Experimental|Microdose administration|Latanoprost ophthalmic solution administered as a microdose using the Eyenovia MiDD
2866907|NCT03480906|Active Comparator|Eyedrop administration|Latanoprost ophthalmic solution administered as an eyedrop
2866908|NCT03480893|Experimental|Small size interarcuair decompression|Patients will undergo small size interarcuair decompression
2866909|NCT03480893|Active Comparator|Laminectomy|Patients will undergo laminectomy
2866910|NCT03480880|Experimental|Group BIS|Thiopentone dosing during induction of anaesthesia based on guidance of Bispectral Index values.
2866911|NCT03480880|No Intervention|Group Clinical|Thiopentone dosing during induction of anaesthesia based on clinical guidance targeted to loss of eyelash reflex or loss of response to noxious stimulus.
2866912|NCT03480867|Experimental|Pre-operative RT and TMZ|Single Arm: Pre-operative Radiation +Temozolomide followed by Surgery plus six cycles of Temozolomide
2866913|NCT03480854|No Intervention|Baseline Analysis|To conduct studies of variation in performance across microsystems and to utilize benchmarking analyses to identify top performers.
2866914|NCT03480854|Experimental|The effect of continuous quality improvements (CQI)|To study the comparative improvement of selected primary process performance indicators (DMT and MRI process measures) over a 3 year period (Years 2-3) in microsystems receiving CQI interventions versus those not receiving CQI intervention, and between two different CQI intervention types (IHI Breakthrough Series and Patient Centered Medical Home).
2866915|NCT03480841|Experimental|LENA with Feedback|Mothers who will run the Language ENhancement Assessment/intervention system with their young children, and will receive initial feedback from researchers on LENA output and how to enhance the language the home language environment.
2866916|NCT03480815|Active Comparator|TLA device|These patients will be withdrawal of omalizumab treatment and receive nocturnal temperature controlled laminar flow device at nighttime for 12 months.
2866917|NCT03480815|Placebo Comparator|None device|These patients will be withdrawal of omalizumab treatment and do not receive TLA device for 12 months.
2866918|NCT03480802|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
2866919|NCT03480802|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
2866920|NCT03480789|Experimental|eye patch|wearing the eye patch from 22:00 to 6:00 of the next day
2866921|NCT03480789|Experimental|Dexmedetomidine|given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
2866922|NCT03480789|Experimental|eye patch + DEX|given dexmedetomidine to meet RASS -1 and wearing the eye patch from 22:00 to 6:00 of the next day
2866923|NCT03480789|No Intervention|usual treatment|treatment as usual
2866924|NCT03480776|Active Comparator|Acetylsalicylic Acid (ASA)|
2866925|NCT03480776|Sham Comparator|Placebo|
2866926|NCT03480763|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
2866927|NCT03480763|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
2866928|NCT03480750|Experimental|trientine with chemotherapy|trientine dihydrochloride PO daily (in different dose levels) plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1
2866929|NCT03480737|Experimental|Active rTMS|
2866930|NCT03480737|Sham Comparator|Sham rTMS|
2866931|NCT03480724|Active Comparator|Google Cardboard VRA|This group of subjects will receive VRA intervention using Google Cardboard Virtual reality head- mounted display powered by a iPod touch.
2866932|NCT03480724|Active Comparator|Oculus Rift VRA|This group of subjects will receive VRA with Oculus Rift
2866933|NCT03480724|No Intervention|Control|This group of subjects will receive no intervention beyond standard sedation, anesthetic, and/or restraint—this group will serve as the control group
2866934|NCT03480711|Experimental|Group (A)|20 eyes of 20 patients of uncontrolled POAG administrated intervention will be subscleral trabeculectomy (SST) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml
2866935|NCT03480711|Experimental|group (B)|20 eyes of 20 patients of uncontrolled POAG d Administrated intervention will be ESST another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)
2866936|NCT03480698||Cerebrolysin and standard stroke care|
2866937|NCT03480698||Standard stroke care|
2866938|NCT03480685|Active Comparator|IVUS catheter|A vessel segment will be imaged with an IVUS catheter.
2866939|NCT03480685|Active Comparator|OCT catheter|The same vessel segment will be imaged with an OCT catheter
2866940|NCT03480672|Experimental|Pembrolizumab + aRCH|Application of pembrolizumab, i.v., in 3-week cycle (q3w) 200 mg, in combination with standard treatment (adjuvant radio-chemotherapy aRCH)
2866941|NCT03480672|Active Comparator|aRCH|adjuvant radio-chemotherapy (aRCH)
2867152|NCT03479190|Placebo Comparator|Normal saline|ultrasound guided injection of Normal saline
2866942|NCT03480659||Breast Cancer|Early stage luminal A and triple negative breast cancer [TNBC] (estrogen receptor-negative (ER-), progesterone receptor-negative (PR-) and HER2-negative (HER2-)
2866943|NCT03480659||Control|Age matched control females
2866944|NCT03480646|Experimental|CPI-1205 Combination with Enzalutamide|
2866945|NCT03480646|Experimental|CPI-1205 Combination with Abiraterone/Prednisone|
2866946|NCT03480633||Control|Defined as no history of heart failure, with age and sex matched to the overall heart failure subjects.
2866947|NCT03480633||Heart Failure w/NormalEjectionFraction|Heart Failure with Normal Ejection Fraction is defined as having a Left Ventricle Ejection Fraction of greater than or equal to 45%.
2866948|NCT03480633||HeartFailure w/ReducedEjectionFraction|Heart Failure with Reduced Ejection Fraction is defined as having a Left Ventricle Ejection Fraction of less than 45%.
2866949|NCT03480620|Experimental|Telerehabilitation|Participant randomized into the telerehabilitation group will receive verbal and written discharge recommendations from each member of the team as usual. They will also be given a login to the online telerehabilitation platform where they will find the designated flexibility routines which can be accessed from a computer, tablet/slate, or smart phone at any time. Participant will receive electronic reminders via email and/or text message to perform their home program and complete the follow up questionnaires. Other physical therapy exercises may be recommended based on individual patient's need. These exercises will be provided in verbal and written form.
2866950|NCT03480620|Active Comparator|Usual care|Participants randomized into the usual care group will receive verbal and written discharge recommendations from each member of the team as usual. They will be provided with a copy of the DVD and instructed to practice one of the two routines at least 5 days per week. They will also be given a login to the online platform but will only have access to complete the follow up questionnaires. Participant will receive electronic reminders via email and/or text message to complete the follow up questionnaires. Other physical therapy exercises may be recommended based on individual patient's need. These exercises will be provided in verbal and written form.
2866951|NCT03480607|Active Comparator|Dexmedetomidine group|Dexmedetomidine in conjunction with bupivacaine for infra-orbital nerve block
2866952|NCT03480607|Active Comparator|Dexamethasone group|Dexamethasone in conjunction with bupivacaine f
2866953|NCT03480594|Experimental|Fatty Liver Patients|Hyperpolarized [13C] Pyruvate Injection in Fatty Liver patients
2866954|NCT03480594|Experimental|Healthy Control Subjects|Hyperpolarized [13C] Pyruvate Injection in Healthy Control Subjects
2866955|NCT03480581|Experimental|Reverse First ICARE Training|Participants will engage in 12-sessions in the reverse direction followed by 12-sessions in the forward direction.
2866956|NCT03480581|Experimental|Forward First ICARE Training|Participants will engage in 12-sessions in the forward direction followed by 12-sessions in the reverse direction.
2866957|NCT03480568|Experimental|alirocumab|Alirocumab 150 mg q 2 weeks for 12 weeks
2866958|NCT03480555|Active Comparator|Replenish Protein group|Subjects randomized to this group will receive 2 g of protein/kg/day of added protein supplement, which is the Beneprotein targeting acceptable range for this group as 1.8 - 2.2 g of protein/kg/day for day 6-14.
2866959|NCT03480555|Other|Standard Protein group|The subjects randomized to this group will receive protein at 0.8 - 1.0 g of protein/kg/day for day 6-14
2866960|NCT03480529||Arthritis or lupus or CLS induced by a drug|Case reported in the World Health Organization (WHO) of arthritis or lupus or capillary leak syndrome of patient treated by a drug, with a chronology compatible with the drug toxicity
2866961|NCT03480516|Experimental|SDF arm|SDF arm is application of 38% silver diamine fluoride solution (SDF) on cavitated caries in primary molar, , cavities in anterior teeth will be applied only on additional consent obtained.
2866962|NCT03480516|Experimental|Fluoride varnish arm|Fluoride varnish arm is application of 5% sodium fluoride varnish on all surface of every tooth.
2866963|NCT03480516|Experimental|Combination arm|Combination arm is application of 38% silver diamine fluoride solution(SDF) on cavitated caries in primary molar, , cavities in anterior teeth will be applied only on additional consent obtained and then apply of 5% sodium fluoride varnish on all surface of every tooth.
2866964|NCT03480503||study group|Patients with acne vulgaris , measurement of serum apelin12 by using ELISA technique ,complete lipid profile and fasting blood glucose.
2866965|NCT03480503||Control group|Healthy control volunteers, measurement of serum apelin12 by using ELISA technique ,complete lipid profile and fasting blood glucose.
2866966|NCT03480477||Pelvic Floor Disorders Group|Will collect patient information from new patients who present to the Urogynecology Clinic
2866967|NCT03480477||Control Group|Will collect patient information from patients who present to Gynecologic Clinic for their annual examination
2866968|NCT03480477||Chronic Pelvic Pain Group|Will collect patient information from patients who present to their Chronic Pelvic Pain Clinic appointment
2866969|NCT03480464|Experimental|App-technology group|"App-technology to increase physical activity Participants in the intervention group (App-technology) will use a newly developed smartphone application (app) in which the participants are able to register their daily physical activity in bouts of 10 min and their intake if supplementary vitamins. They will also be able to set personal goals every week for the level (minutes) of physical activity and get feedback every week in whether they fulfilled the goal or not. They will also get feedback on the intake of supplementary vitamin intake."
2866970|NCT03480464|No Intervention|Control group|The control group will receive standard information about the benefit of physical activity after surgery.
2866971|NCT03480451|Other|Single Arm|Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being
2866972|NCT03480438|Experimental|Blinatumomab|"Patients will receive blinatumomab at a dose of 28 μg/day as continuous intravenous infusion at constant flow rate for four weeks defined as one treatment cycle. Up to four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9 μg/day."
2866973|NCT03480425|Experimental|Intubated patient|
2866974|NCT03480412||Follicular Phase|
2866975|NCT03480412||Luteal Phase|
2866976|NCT03480386|Active Comparator|Intervention|Patients randomized in this arm will start with the home based pulmonary rehabilitation exercises.
2866978|NCT03480360|Other|Johns Hopkins' conditioning regimen|Cyclophosphamide, fludarabine, total body irradiation, immune suppression including tacrolimus and cellcept, Granulocyte colony-stimulating factor (G-CSF), and peripheral blood transplant
2866979|NCT03480334|Experimental|Arm A|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
2866980|NCT03480321|Active Comparator|Cilostazol 100 mg|
2866981|NCT03480321|Experimental|PMR 150 mg|
2866982|NCT03480321|Experimental|PMR 200 mg|
2866983|NCT03480308|Active Comparator|Bupivacaine fentanyl group|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
2866984|NCT03480308|Active Comparator|Bupivacaine dexamethasone group|Patients will receive bupivacaine (0.5%) 20 ml , dexamethasone 4 mg in paravertebral block
2866985|NCT03480308|Active Comparator|Bupivacaine fentanyl dexamethasone group|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg in paravertebral block
2866986|NCT03480295|Experimental|HA0.4%+TAU0.5%|Patients had to administer 4 drops/day of an ophthalmic solution containing hyaluronic acid 0.4% and taurine 0.5% in addition to the ongoing glaucoma treatment
2866987|NCT03480295|Active Comparator|HA0.2%|Patients took 4 drops/day of an ophthalmic solution containing hyaluronic acid 0.2%
2866988|NCT03480282|Experimental|Prognosis Information and Provider Scripts|Investigators will send the PCP via secure email the patient's prognosis calculated by the Lee-Schonberg index three days before the patient visit. Investigators will also send PCPs information on patient life expectancy from Cho et al.'s US life tables and scripts developed to sensitively include information on patient prognosis when recommending patients stop being screened for cancer. After five of their patients have participated or recruitment goals are met, investigators will ask PCPs to complete a 10 minute web-based questionnaire about their experience.
2866989|NCT03480256|Experimental|SHR6390 combined with pyrotinib|Group A:pyrotinib 400mg qd combined with SHR 6390 100mg qd Group B: pyrotinib 400mg qd combined with SHR 6390 125mg qd Group C: pyrotinib 400mg qd combined with SHR 6390 150mg qd Group D: pyrotinib 400mg qd combined with SHR 6390 175mg qd Group E: pyrotinib 320mg qd combined with SHR 6390 100mg qd
2866990|NCT03480243|Experimental|Padsevonil and Erythromycin|"Treatment Period 1 (Day 1 to Day 11):~Padsevonil 100 mg twice daily (bid) on Day 1 to Day 4~Padsevonil 100 mg single dose on Day 5~1 week of wash-out (from evening of Day 5 to Day 11)~Treatment Period 2 (Day 12 to 22):~Padsevonil 100 mg twice daily (bid) on Day 12 to Day 15~Padsevonil 100 mg single dose on Day 16~1 week of wash-out (from evening of Day 16 to Day 22)~Treatment Period 3 (Day 23 to Day 38):~Erythromycin 500 mg twice daily (bid) on Day 23 to Day 25~Padsevonil 100 mg bid and erythromycin 500 mg bid on Day 26 to Day 32~Padsevonil 100 mg single dose on Day 33~Erythromycin 500 mg twice daily (bid) on Day 33 to Day 36~Erythromycin 500 mg single dose on Day 37"
2866991|NCT03480230|Experimental|Treatment arm|"Non-squamous histology:~Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses.~Compound 565994 500 mg/m2 administered over 10 minutes, and~Compound 232673 AUC=5 mg/mL/min administered over 15-60 minutes or Compound 454893 at 75 mg/m2 over 1 hour.~Compound 565994 and platinum are to be given on day 1 of every 3-week cycle for 3 cycles.~Squamous histology:~Compound 121564 10 mg/Kg administered over 60 minutes every 2 weeks for 4 doses.~Compound 232673 AUC=5 mg/mL/min administered over 15-60 minutes or Compound 454893 at 75 mg/m2 over 1 hour on day 1 of every cycle.~Compound 343782 1,000 mg/m2 administered over 30 minutes on days 1 and 8 of each cycle.~Platinum and Compound 343782 will be given for 3 cycles."
2866992|NCT03480217|Experimental|Multifaceted Implementation Strategy|Patients will be screened for hypertension by primary care providers, registered nurses, medical assistants, and front desk staff from clinics randomized to receive the intervention, Multifaceted Implementation Strategy.
2866993|NCT03480217|No Intervention|Usual Care|Patients will be screened for hypertension by primary care providers, nurses, medical assistants, and front desk staff of clinics randomized to the usual care group that do not intentionally receive any parts of the multifaceted implementation strategy.
2866994|NCT03480165|Experimental|20 mg Parecoxib + 0.75% Ropivacaine|1 ml of 20 mg Parecoxib is given concurrently with 19 mls of 0.75% ropivacaine
2866995|NCT03480165|Active Comparator|0.75% Ropivacaine only|19 ml of Ropivacaine at a concentration of 0.75% is given concurrently with 1 ml of 0.9% saline
2866996|NCT03480152|Experimental|1/Phase I Arm|Escalating doses of mRNA vaccine
2866997|NCT03480152|Experimental|2/Phase II Arm|MTD of mRNA vaccine established in Phase I
2866998|NCT03480139||1|A cohort of pregnant women seeking care at the prenatal clinic of the Perinatology Research Branch in Detroit, Michigan.
2866999|NCT03480126|Placebo Comparator|Herbal Tea 1|Placebo Tea should will be ingested 3 times per day for 3 months
2867000|NCT03480126|Experimental|Herbal Tea 2|Experimental Herbal Tea A will be ingested 3 times per day for 3 months
2867001|NCT03480126|Experimental|Herbal Tea 3|Experimental Herbal Tea B will be ingested 3 times per day for 3 months
2867002|NCT03480126|Experimental|Herbal Tea 4|Experimental Herbal Tea C will be ingested 3 times per day for 3 months
2867003|NCT03480113|Experimental|Mindfulness-based Intervention|1 session of health education regrading the harms from smoking and 6 sessions of Mindfulness-based intervention, 1 hour each session.
2867004|NCT03480113|Active Comparator|Physical Fitness intervention|1 session of health education regrading the harms from smoking and 6 sessions of physical fitness and stretch exercise, 1 hour each session.
2867005|NCT03480100||Xylometazoline Nasal spray|1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day
2867006|NCT03480100||Xylometazoline + Ectoin Nasal Douche|Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Douche (END01): 1 spray per nostril 2-6 times per day or as often as required
2867007|NCT03480087||Chemotherapy alone|Patient treated with anthracycline containing chemotherapy
2867008|NCT03480087||Chemotherapy plus radiotherapy|Patient treated with anthracycline containing chemotherapy followed by mediastinal radiotherapy
2867009|NCT03480074|Active Comparator|Staple Ligation|Arm 1: Staple Ligation
2867010|NCT03480074|Active Comparator|Selective Suture Ligation|Arm 2: Selective Suture Ligation
2867011|NCT03480074|Active Comparator|Single Suture Ligation|Arm 3: Single Suture Ligation
2889225|NCT03325660|No Intervention|control group|No intervention
2867012|NCT03480061|Active Comparator|Dexmedetomidine Hydrochloride Group|Patients will receive a loading dose of 1 μg/kg dexmedetomidine prior to transfer to CVICU over 20 min immediately postoperative, followed by continuous infusion of 0.1- 1.0 μg/kg/h for up to 24 hours or until patient is ready for discharge from CVICU (whichever is earlier).
2867013|NCT03480061|No Intervention|Standard of Care Group|Standard sedation protocols will be followed at the discretion of the attending physician.
2867014|NCT03480048|Experimental|Breastfeeding and weight loss support|Participants receive a combination of in-person, phone, and online support for breastfeeding and postpartum weight management.
2867015|NCT03480048|No Intervention|Usual care|Participants receive usual care from their prenatal care provider.
2867016|NCT03480022|Experimental|Liraglutide Pen Injector (Saxenda)|Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily
2867017|NCT03480022|Placebo Comparator|Placebo liraglutide pen injector|Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily
2867018|NCT03480009|Experimental|Dextromethorphan and narcotic|Dextromethorphan hydrobromide and patient opts for narcotics (oxycodone or other standard narcotics)
2867019|NCT03480009|Placebo Comparator|Placebo and narcotic|Dextromethorphan hydrobromide and patient opts for narcotics (oxycodone or other standard narcotics)
2867020|NCT03480009|Experimental|Dextromethorphan without narcotic|Avicel PH101 (Microcrystalline Cellulose NF) for Compounding and receives active drug
2867021|NCT03480009|Placebo Comparator|Placebo without narcotic|Avicel PH101 (Microcrystalline Cellulose NF) for Compounding and patient declines narcotic
2867022|NCT03479996|Experimental|Anesthetic|
2867023|NCT03479996|No Intervention|Control|
2867024|NCT03479983|Experimental|AMX160|500 mg (one capsule) x 2 times daily for 90 days
2867025|NCT03479983|Placebo Comparator|Placebo|500mg (one capsule) x 2 times daily for 90 days.
2867026|NCT03479970|Experimental|GNPT + Social Cognition|"Experimental Group: will undertake a rehabilitation treatment integrated by a set of tasks aimed at working attention, memory and executive functions together with a computerized treatment for the rehabilitation of the Social Cognition. The treatment will be carried out through the cognitive telerehabilitation platform Guttmann, NeuroPersonalTrainer® (GNPT).~The treatment will consist of the carrying out of 24 treatment sessions"
2867027|NCT03479970|Active Comparator|GNPT|Control Group: will only conduct a cognitive rehabilitation treatment through the cognitive telerehabilitation platform Guttmann, NeuroPersonalTrainer® (GNPT) focused on attention, memory and executive functions.
2867028|NCT03479957|Experimental|REMOTE-CR|Remotely monitored and coached exercise training in real time using the REMOTE-CR system. The patients randomized to remotely monitored exercise can either work out with self-selected activities e.g. Nordic-walking, cycling, skiing or participate in supervised exercise session via video link.
2867029|NCT03479957|Other|Usual care|The patients randomized to be controls will receive individualized information and instructions regarding current exercise recommendations but will not be monitored or coached during their exercise sessions (usual care).
2867030|NCT03479944|Experimental|FLACS|FLACS in 1 eye, with manual conventional surgery in the fellow eye, as randomized
2867031|NCT03479944|Active Comparator|Conventional|Manual conventional surgery in 1 eye, with FLACS in the fellow eye, as randomized
2867032|NCT03479931|Experimental|Without placement of a catheter|Without preoperatively placement of an indwelling catheter during Caesarean section
2867033|NCT03479931|Active Comparator|With placement of a catheter|Normal pre-operative routines with placement of an indwelling catheter during Caesarean section
2867034|NCT03479918|Active Comparator|R-DA-EPOCH-21|The protocol involves 4-6 cycles. Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid.
2867035|NCT03479918|Active Comparator|R-BL-M-04|"Course A:~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1500 mg/m2 12 h IV 1 day, Ifosfamide 800 mg/m2/day 1 h IV 1 - 5 days, Etoposide 100 mg/m2/day IV 4, 5 days, Doxorubicin 50 mg/m2/day IV day 3, Vincristine 2 mg IV 1 day, Cytarabine 150 mg/m2/day IV 1 h 4, 5 days.~Course C:~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1500 mg/m2 12 h IV 1 day, Vinblastine 5 mg/m2 IV day 1, Cytarabine 2000 mg/m2/day IV 3 h 2, 3 days, Etoposide 150 mg/m2/day IV 3-5 days.~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
2867036|NCT03479918|Active Comparator|R-DA-EPOCH-21 + auto-SCT|"The protocol involves 4-6 cycles. Patients with complete remission after 4 cycles undergo auto-SCT.~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
2867037|NCT03479918|Active Comparator|R-BL-M-04 + auto-SCT|"The protocol involves 4 cycles. Patients with complete remission after 4 cycles undergo auto-SCT.~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
2867038|NCT03479905|Sham Comparator|Salter nasal cannula|A Salter nasal cannula will be used at 4L/ minute during the colonoscopy. The FiO2 delivered to the patient at this rate has been shown to be equal to 36%
2867039|NCT03479905|Sham Comparator|Face mask group|A standard face mask will be used at 8L/minute during the colonoscopy. The FiO2 delivered to the patient at this rate has been shown to be equal to 60%.
2867040|NCT03479905|Experimental|High Floow Oxygen delivery|Oxygen will be delivered by using high flow nasal cannula
2867041|NCT03479892|Experimental|NNC0194-0499|Participants will receive increasing doses of NNC0194-0499. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.
2867042|NCT03479892|Placebo Comparator|Placebo|Participants will receive NNC0194-0499 matched placebo. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.
2867045|NCT03479853||Cases : suffering from ocular or oculo-cutaneous rosacea|Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.
2867046|NCT03479853||Witnesses|"Without any present or past palpebral meibomian Gland Dysfunction~Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device."
2867047|NCT03479840||Patients undergoing PCI|all-comer population undergoing PCI
2867048|NCT03479827|Experimental|Experimental|Subjects will undergo three Wavefront measurements, once with no contact lens, once with a monofocal contact lens and once with a bifocal contact lens.
2867049|NCT03479814|Experimental|IMRT-SIB plus sequential IG-RT boost|45 Gy plus 5 Gy concomitant boost are delivered to rectum and locoregional lymphnodes (25 fractions); sequential IG-RT (imaging guided-radiotherapy) boost of 5 Gy in 2 fractions is planned with 18-FDG-PET
2867050|NCT03479801||Conventional Open|Conventional open thyroidectomy group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
2867051|NCT03479801||Transoral Endoscopic Surgery|Transoral endoscopic thyroidectomy via vestibular approach group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
2867052|NCT03479801||Endoscopic Thyroidectomy via Breast|Endoscopic thyroidectomy via breast approach or bilateral areola approach group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
2867053|NCT03479788||DM|Observational study. NO intervention
2867054|NCT03479788||non-DM|Observational study. NO intervention
2867055|NCT03479775||Youth female athletes with poor muscle function|
2867056|NCT03479775||Youth female athletes with good muscle function|
2867057|NCT03479762||Liraglutide|
2867058|NCT03479749|Placebo Comparator|RegenoGel-OSP - RegenoGel-OSP|First injection- the patients will receive RegenoGel-OSP; Second injection (after 3 months interval)- the patients will receive RegenoGel-OSP also
2867059|NCT03479749|Placebo Comparator|RegenoGel - RegenoGel|First injection- the patients will receive RegenoGel; Second injection (after 3 months interval)- the patients will receive RegenoGel also
2867060|NCT03479749|Placebo Comparator|Placebo - RegenoGel-OSP|First injection- the patients will receive Placebo; Second injection (after 3 months interval)- the patients will receive RegenoGel-OSP
2867061|NCT03479749|Placebo Comparator|Placebo - RegenoGel|First injection- the patients will receive Placebo; Second injection (after 3 months interval)- the patients will receive RegenoGel
2867062|NCT03479736||Cohort 1: Participants with Achilles Tendon Rupture (ATR)|Participants will be defined as having ATR if they receive a diagnosis for ATR as well as one of the following procedures: tenotomy or primary ruptured Achilles Tendon (AT) repair (with or without graft) within 7 days of diagnosis. Index will be based on the earlier date of diagnosis or procedure. Participants with ATR, and exposures to Fluoroquinolone (FQ) or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
2867063|NCT03479736||Cohort 2: Participants with Retinal Detachment (RD)|Participants will be defined as having a RD if they received a diagnosis of RD and a procedure for RD, e.g.: sclera buckle, vitrectomy, retinopexy, retinal cryotherapy, silicone oil fill, air gas fluid exchange or pneumatic retinopexy, within 14 days of index. Index will be defined as the earlier date of diagnosis or procedure. Participants with RD, and exposures to FQ or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
2867064|NCT03479736||Cohort 3: Participants with Aortic Aneurysm & Dissection (AAD)|Participants will be defined as having AAD if they received a primary diagnosis for aortic aneurysm, aortic rupture or dissection and have also received an aortic repair surgical procedure concurrently to the AAD diagnosis, in an inpatient or emergency department (ED) setting. Index will be defined as the earlier date of diagnosis or procedure. Participants with AAD, and exposures to FQ or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
2867065|NCT03479710|Experimental|FMT infusion|FMT will be performed using frozen donor stool samples obtained from the stool bank of CUHK. 100-200ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via OGD.
2867066|NCT03479710|No Intervention|Control|No FMT infusion.
2867067|NCT03479697|Active Comparator|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
2867068|NCT03479697|Other|Continued Current Care|Participants will continue their current care.
2867069|NCT03479684|Experimental|Gene-directed group|the first day given model prediction dose * 1.5 times（＜6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
2867070|NCT03479684|Active Comparator|Standard care group|the first day given 4.5mg; adjusted dose based on INR from the second day
2867071|NCT03479671|No Intervention|Saline|Insulin sensitivity (rate of glucose disposal)
2867072|NCT03479671|Experimental|Low Dose Fatty Acids|Insulin sensitivity (rate of glucose disposal) in response to 30 ml/hr fatty acid infusion
2867073|NCT03479671|Experimental|Medium Dose Fatty Acids|Insulin sensitivity (rate of glucose disposal) in response to 60 ml/hr fatty acid infusion
2867074|NCT03479658|Experimental|HIIT two sessions|Two sessions per week of HIIT + nutritional education (1 session/week)
2867075|NCT03479658|Experimental|HIIT one session|One session per week of HIIT + nutritional education (1 session/week)
2867076|NCT03479658|Active Comparator|Nutritional education|Nutritional education (1 session/week)
2867077|NCT03479645|No Intervention|Control|Control arm - usual practice. Simple SMS reminder that informs patients they are overdue for CRC screening and requests they contact the clinic.
2867078|NCT03479645|Experimental|Intervention|Serial text messages and mailed FIT kit
2867079|NCT03479632|Experimental|Intervention Group|The intervention group will undergo an aerobic walking program using a treadmill, a body-weight support system, and an assistive device.
2867080|NCT03479632|Active Comparator|Control Group|The control group will receive standard physical therapy (PT).
2867081|NCT03479619|Experimental|A/28/1|Lancing device A with personal lancet of size 28 G and minimum puncture depth.
2867082|NCT03479619|Experimental|A/28/5|Lancing device A with personal lancet of size 28 G and maximum puncture depth.
2867083|NCT03479619|Experimental|A/30/1|Lancing device A with personal lancet of size 30 G and minimum puncture depth.
2867084|NCT03479619|Experimental|A/30/5|Lancing device A with personal lancet of size 30 G and maximum puncture depth.
2867085|NCT03479619|Experimental|A/33/1|Lancing device A with personal lancet of size 33 G and minimum puncture depth.
2867086|NCT03479619|Experimental|A/33/5|Lancing device A with personal lancet of size 33 G and maximum puncture depth.
2867087|NCT03479619|Experimental|B/28/1|Lancing device B with personal lancet of size 28 G and minimum puncture depth.
2867088|NCT03479619|Experimental|B/28/5|Lancing device B with personal lancet of size 28 G and maximum puncture depth.
2867089|NCT03479619|Experimental|B/30/1|Lancing device B with personal lancet of size 30 G and minimum puncture depth.
2867090|NCT03479619|Experimental|B/30/5|Lancing device B with personal lancet of size 30 G and maximum puncture depth.
2867091|NCT03479619|Experimental|B/33/1|Lancing device B with personal lancet of size 33 G and minimum puncture depth.
2867092|NCT03479619|Experimental|B/33/5|Lancing device B with personal lancet of size 33 G and maximum puncture depth.
2867093|NCT03479619|Experimental|C/28/1|Lancing device C with personal lancet of size 28 G and minimum puncture depth.
2867094|NCT03479619|Experimental|C/28/5|Lancing device C with personal lancet of size 28 G and maximum puncture depth.
2867095|NCT03479619|Experimental|C/30/1|Lancing device C with personal lancet of size 30 G and minimum puncture depth.
2867096|NCT03479619|Experimental|C/30/5|Lancing device C with personal lancet of size 30 G and maximum puncture depth.
2867097|NCT03479619|Experimental|C/33/1|Lancing device C with personal lancet of size 33 G and minimum puncture depth.
2867098|NCT03479619|Experimental|C/33/5|Lancing device C with personal lancet of size 33 G and maximum puncture depth.
2867099|NCT03479606|Experimental|Immediate Intervention|Participants will receive 24 online emotional regulation skills-training sessions twice weekly and will complete online questionnaires sent every four weeks throughout baseline, the 12-week intervention, and 12-week follow-up.
2867100|NCT03479606|Active Comparator|Waitlist Intervention|After a 12-week wait-period without any intervention, participants will receive 24 online emotion regulation skills-training sessions. Every four weeks, participants will complete online questionnaires every throughout baseline, 12-week wait-period, 12-week intervention, and 12-week follow-up.
2867101|NCT03479593||CMR and OCT in NSTEMI patients with MVD|NSTEMI patients with multi vessel disease
2867102|NCT03479567|Other|HC|Healthy controls, i.e. older adults without cognitive impairment
2867103|NCT03479567|Other|MiD|older adults with mild dementia
2867104|NCT03479567|Other|MoD|older adults with moderate dementia
2867105|NCT03479554|Experimental|Early antihypertensive treatment group|BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group.
2867106|NCT03479554|Active Comparator|Delayed antihypertensive treatment group|All home antihypertensive medications will be discontinued in the first seven days after randomization. Study participants will receive antihypertensive treatment on day eight after randomization.
2867107|NCT03479541|Experimental|Physical Therapy (Early)|"Two sub-arms include Vestibular Rehabilitation  n=40, and Vestibular Rehabilitation with Home Monitoring n=40"
2867108|NCT03479541|Experimental|Physical Therapy (Standard of Care)|"Two sub-arms include Vestibular Rehabilitation  n=40, and Vestibular Rehabilitation with Home Monitoring n=40"
2867109|NCT03479528||Dyspepsia|All patients who were satisfied with the inclusion criteria and exclusion criteria in the department of the second affiliated hospital of Xi'an jiaotong university received investigation.
2867110|NCT03479515||Formerly-Premature Toddlers|Data will be used to create and evaluate predictive equation
2867111|NCT03479502|Active Comparator|Methylprednisolone|Patients meeting the inclusion criteria will be randomized into either the control group of intra-articular injection of 40mg Methylprednisolone once every 2 two weeks for 4 weeks (day 1, week 2, week 4) with 20 patients in each group. Injections will be administered by the treating physician.
2867112|NCT03479502|Active Comparator|Doxycycline|Patients meeting the inclusion criteria will be randomized or the experimental group of intraarticular injection of 50 mg doxycycline once every 2 two weeks for 4 weeks (day 1, week 2, week 4), with 20 patients in each group. Injections will be administered by the treating physician.
2867113|NCT03479489|Experimental|Human dehydrated amnion/chorion allofraft|Closed hemorrhoidectomy patched with human dehydrated amnion chorion allograft
2867114|NCT03479476|Placebo Comparator|Placebo Medication|The placebo will be dosed in a weight-dependent manner. Liquid placebo will be provided to any participants unable to swallow the placebo capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
2867175|NCT03478995|Experimental|Dose-escalation|GX-I7 60,120, 240, 480 or 600 µg/kg on Day1 of each cycle.
2867176|NCT03478995|Experimental|Dose-expansion|GX-I7 optimal fixed dose from Dose-escalation stage on Day1 of each cycle (MTD or MED or MAD level or consecutive lower or upper dose level which does not exceed MTD based on SMC decision)
2867177|NCT03478982|Experimental|Staccato Alprazolam 0.5 mg|single dose for inhalation
2867115|NCT03479476|Active Comparator|Active Metformin Medication|The active metformin medication will be dosed in a weight-dependent manner. Liquid metformin (100mg/cc) will be provided to any participants unable to swallow the metformin capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
2867116|NCT03479463||Treatment with Dehydrated Human Amnion Chorion Allograft|
2867117|NCT03479463||Standard of Care|
2867118|NCT03479424||Training Set|n = 333
2867119|NCT03479424||Validation Set|n = 167
2867120|NCT03479411|Experimental|Part 1 single ascending dose|Intervention: drug Itraconzaole powder: single dose of 5mg, 10mg or 25 mg Other name: PUR1900
2867121|NCT03479411|Experimental|Part 2 multiple ascending dose|Intervention: drug Itraconzaole powder: 10 mg or 20 mg daily for 14 days Other name: PUR1900
2867122|NCT03479411|Active Comparator|Part 3 2-period crossover single dose|Intervention: drug Itraconzaole powder: 20 mg single dose and Itraconzaole oral solution 200 mg single dose Other names: PUR1900, Sporanox
2867123|NCT03479398||App Condition|Although we will be mostly observing routine practice, we will randomize patients into either an App condition or paper condition. The App condition refers to patients completing routine Cognitive Behavioral Therapy (CBT) worksheets on a mobile application during session. Everything else that occurs in treatment sessions will be consistent with routine care practices.
2867124|NCT03479398||Paper Condition|Although we will be mostly observing routine practice, we do randomize patients into either an App condition or paper condition. The paper condition refers to patients completing routine CBT worksheets on paper (the current standard) during session.
2867125|NCT03479385|Experimental|Integrative Medicine Intervention|Study participants randomized to the Integrative Medicine intervention will attend 14 sessions with an Integrative Medicine clinician over the course of 6 months potentially followed by a 6 month maintenance phase. The treatment modalities employed in the study will include nutrition and lifestyle recommendations.
2867126|NCT03479385|Experimental|Health Education Intervention|Study participants randomized to the Health Education intervention will attend 14 sessions with a Health Educator over the course of 6 months. The emphasis in the sessions will be to provide engaging educational information on common survivorship issues.
2867127|NCT03479372|Experimental|PAN-90806 Eye Drops, dose 1|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
2867128|NCT03479372|Experimental|PAN-90806 Eye Drops, dose 2|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
2867129|NCT03479372|Experimental|PAN-90806 Eye Drops, dose 3|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
2867130|NCT03479359||Group 1|In this group, internship are given the pathology outcome of each prostate biopsy regularly twice a month.
2867131|NCT03479359||Group 2|In this group, internship are not given the pathology outcome of each prostate biopsy.
2867132|NCT03479346|Experimental|GGT group|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
2867133|NCT03479346|Placebo Comparator|Placebo group|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
2867134|NCT03479333|Experimental|Short implant|
2867135|NCT03479333|Active Comparator|standard implant with sinus lift|
2867136|NCT03479320|Experimental|Lidocaine group|Lidocaine group will receive intravenous bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the completion of surgery
2867137|NCT03479320|Placebo Comparator|Placebo|They will receive the same volume of 0.9% of normal saline as calculated for the experimental group
2867138|NCT03479307|Experimental|Bilastine Ophthalmic Solution 0.6%|
2867139|NCT03479307|Placebo Comparator|Ketotifen Ophthalmic Solution 0.025% (Zaditen)|
2867140|NCT03479307|Placebo Comparator|Vehicle of Bilastine Ophthalmic Solution|
2867141|NCT03479294||Exposure group|Exposure group patients are those who voluntarily choose to use Shenlingcao Oral Liquid recommended by the doctor in NSCLC patients receiving adjuvant chemotherapy. Jiangzhong Group will donate the first 30 bottles of medicine, and afterwards, patients may purchase if they still need to take it. The length of time and dose of Shenlingcao Oral Liquid are unlimited and other adjunctive treatments may be used at the same time.
2867142|NCT03479294||Control group|Control group patients are those who voluntarily choose not to use Shenlingcao Oral Liquid recommended by the doctor in NSCLC patients receiving adjuvant chemotherapy.
2867143|NCT03479268|Experimental|Treatment (pevonedistat, ibrutinib)|Participants receive pevonedistat IV over 1 hour on days 1, 3, and 5, and ibrutinib PO daily on days 2-21 of course 1 and days 1-21 of subsequent courses. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Participants then receive only ibrutinib PO daily on days 1-21. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
2867144|NCT03479255|Experimental|Smartphone-enabled structured exercise therapy (SE-SET)|"This arm involves a smartphone app Movn - rehabilitation platform based on MULTIFIT, a case-management system for secondary prevention and patient surveillance after acute MI.~The key features of the smartphone app include daily reminders to exercise, virtual diary for patients to enter data on exercise sessions, two-way secure messaging with the health coach, and educational videos on heart and vascular health."
2867145|NCT03479255|Active Comparator|Standard exercise therapy|Self-directed, unsupervised exercise as prescribed by the patient's physician.
2867146|NCT03479229|Experimental|Geneveve Treatment|Active Treatment
2867147|NCT03479229|Placebo Comparator|Sham Treatment|Sham Treatment
2867148|NCT03479216|Experimental|Precedex|5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
2867149|NCT03479216|Experimental|Magnesium Sulfate|5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
2867150|NCT03479203|Experimental|Healthy, Non-Smokers|Non-nicotinized electronic cigarette aerosol (16 2-second long puffs)
2867153|NCT03479177|Experimental|High Intensity Interval Training|The exercise group will participate in a home and telephone-based program consisting of a 12-week high intensity interval training workout (HIIT). The home-based exercise sessions will be prescribed by the program exercise counselor, with a goal to exercise three times per week. The program will be tailored to meet specific fitness and strength needs of the participant. The participant will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. At 12 weeks, participants in both the exercise and wait-list control group will complete online questionnaires. The ActiGraph will be returned to the University of Minnesota research staff via a pre-paid postage envelope.
2867154|NCT03479177|No Intervention|Wait-List Control Group|Participants in the wait-list control condition will have the option of receiving the exercise intervention program after completion of the final assessment.
2867155|NCT03479164|Experimental|Ultra Low-Dose CT|One non-contrast gated aortic (NCGA) computer tomography scan, a low radiation, non-contrast, low cost CT based study
2867156|NCT03479151|Experimental|MR-HIFU of painful bone metastases|Magnetic Resonance guided High Intensity Focused Ultrasound (MRgHIFU) for Pain Palliation of Bone Metastases
2867157|NCT03479138||Neutrophilic asthma|Patients 18 to 80 years old diagnosed of severe asthma, requiring treatment at least with LABA+ high doses ICS, with eosinophil count in blood<300/mm3. They must be ex-smokers with less than 10 packs-year and no other relevant pulmonary disease.
2867158|NCT03479138||Non neutrophilic asthma|Patients 18 to 80 years old diagnosed of severe asthma, requiring treatment at least with LABA+ high doses ICS, with eosinophil count in blood<300/mm3. They must be ex-smokers with less than 10 packs-year and no other relevant pulmonary disease.
2867159|NCT03479125||Historical emricasan or placebo subjects|Subjects with liver fibrosis or cirrhosis who have received at least one dose of emricasan or placebo in a prior IDN-6556 study including IDN-6556-07, IDN-6556-12, IDN-6556-14 or IDN-6556-17.
2867160|NCT03479112|Experimental|Flashcards|Study participants in this arm of the trial received bleeding control flashcards that contain diagrams and figures to correctly identify the severity of the injury and visual instructions on the appropriate application of pressure dressing, hemostatic packing, and tourniquet.
2867161|NCT03479112|Experimental|Audio-kit|Study subjects in this arm received a commercially available audio bleeding control kit. The kit included a diagram and visual aids to identify the correct severity of the injury and determine the appropriate method of bleeding control. The kit also had buttons on it to play stepwise audio instructions on the application of compression dressing, hemostatic packing and tourniquet application in two languages (English and Spanish). The audio kits were bought at the market price and the name of the manufacturer was not mentioned in the manuscript to avoid conflict of interest.
2867162|NCT03479112|Experimental|Bleeding Control (B-Con) training|Study subjects in this arm were given the American College of Surgeons Bleeding Control Basic (B-Con) in-person training course by qualified instructors. This curriculum was developed by a collaboration between American College of Surgeons and the Hartford Consensus. The session included a multimedia presentation in a class format that included some background information about extremity hemorrhage and potential benefits of immediate first-response and hemorrhage control, steps to take in a mass casualty scenario and instructional videos on hemorrhage control modalities and their appropriate use. This was followed by hands-on training in hemorrhage control, with 1:4, instructor to trainee ratio.
2867163|NCT03479112|No Intervention|Control|Study subjects in this arm of the trial received no intervention (no training or access to point-of-care prompts) to assess baseline competence in hemorrhage control.
2867164|NCT03479112|Experimental|Retention of B-Con course|Control, Audio-kit, and flashcard arms undergo B-Con training at the completion of the initial evaluation, and the B-Con arm completed training prior to testing in order that all participants obtain training and then can be evaluated at retention testing. a. 3-9 months after the trial, investigators planned to test all study subjects with a simulated mass causality scenario for retention of knowledge and skills. This test will be the same as the initial test for competence at tourniquet placement in the trial and the same evaluation form will be used to evaluate the study subjects.
2867165|NCT03479086|Experimental|Topiramate|Topiramate 200mg/day
2867166|NCT03479086|Experimental|Naltrexone|Naltrexone 50mg/day
2867167|NCT03479073||Stroke group|Patients who experienced stroke or systemic embolic event following catheter ablation for AF.
2867168|NCT03479073||Control group|Patients who did not experienced stroke or systemic embolic event following catheter ablation for AF.
2867169|NCT03479060|Active Comparator|Continue WCT Application|From the 3rd month to the 12th month Wet cupping applied as an intervention MIDAS was applied at the end of the 6th and 12th months.
2867170|NCT03479060|No Intervention|Discontinue WCT Application|No intervention in this arm.Only MIDAS applied
2867171|NCT03479047|Experimental|Ventilated patients|During a spontaneous breathing trial (SBT) we will simultaneously, for all included patient, assess diaphragmatic displacement (DD) using ultrasonography, respiratory rate (RR) and tidal volume (VT) on ventilator screen.
2867172|NCT03479034||Group 1|"Ages 18-85~Cognitively able to understand instructions and care for themselves~Lives in the community (not institutionalised)~Owner of a smartphone and able to use Apps~On 3 or more chronic prescription medications~Has had experience with prescriptions in Australia for at least 1 year~Current patient attending Holdsworth House Medical Practice~Willing to use the ScalaMed ePrescription application"
2867173|NCT03479008||Phase I|This phase will recruit healthy volunteers who will be vibrated with the prototype device using various vibration frequencies to determine which frequency produces the optimal physiologic response. Physiologic responses will be determined with a number of devices capable of measuring such things as tissue oxygenation, oxygen consumption, and muscle activity. Blood samples will also be taken to measure certain chemical markers associated with activity and increase blood flow. Volunteers will be randomized to receive alternating 5 minute episode of various vibration frequencies.
2867174|NCT03479008||Phase 2|Based on data collected from Phase I used to determine optimal vibration strategies, the investigators will recruit critically ill patients from the Intensive Care unit who are expected to be immobilized for a prolonged period of time due to the nature of their illness. these patient subjects will undergo up to three 5-10 minute vibration sessions a day for 5 days. Similar physiologic responses will be measured in these patients. Baseline blood values will be taken at prior to the first day of vibration and then additional samples taken at the end of each day of vibration. No randomization will take place in this phase.
2867180|NCT03478969|Experimental|Group A|Continuous subcutaneous insulin infusion (CSII) with Accu-Chek® Solo Micropump system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
2867181|NCT03478969|Experimental|Group B|Multiple daily injections (MDI) for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
2867182|NCT03478969|Experimental|Group C|Continuous subcutaneous insulin infusion (CSII) with the mylife™ OmniPod® Insulin Management system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
2867183|NCT03478956|Experimental|Low Frequency Etrolizumab|Etrolizumab will be administered by subcutaneous (SC) injection every 8 weeks.
2867184|NCT03478956|Experimental|High Frequency Etrolizumab|Etrolizumab will be administered by SC injection every 4 weeks.
2867185|NCT03478930|Experimental|Cohort A: Study GA39688 Omalizumab|Participants who received omalizumab once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in Study GA39688 will continue to receive omalizumab at Week 24 at the same dosing schedule.
2867186|NCT03478930|Experimental|Cohort A: Study GA39688 Placebo|Participants who received placebo Q2W or Q4W in Study GA39688 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
2867187|NCT03478930|Experimental|Cohort B: Study GA39855 Omalizumab|Participants who received omalizumab Q2W or Q4W in Study GA39855 will continue to receive omalizumab at Week 24 at the same dosing schedule.
2867188|NCT03478930|Experimental|Cohort B: Study GA39855 Placebo|Participants who received placebo Q2W or Q4W in Study GA39855 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
2867189|NCT03478917||Arm 1|Subjects previously enrolled onto protocol 05-H-0019 who were hospitalized with vasoocclusivecrisis.
2867190|NCT03478904|Experimental|B/Sequence BA|Enzalutamide liquid (Treatment B) followed byenzalutamide capsule (Treatment A)
2867191|NCT03478904|Experimental|A/ Sequence AB|Enzalutamide capsule (Treatment A) followed byenzalutamide liquid (Treatment B)
2867192|NCT03478891|Experimental|Group 1|5 mg/kg IV
2867193|NCT03478891|Experimental|Group 2|25 mg/kg IV
2867194|NCT03478891|Experimental|Group 3|50 mg/kg IV
2867195|NCT03478878|Experimental|Supplementation|Experimental
2867196|NCT03478865|Experimental|Supplementation|
2867197|NCT03478852||1|Adults and children age 8 years and older referred with a known or suspected diagnosis of epilepsy.
2867198|NCT03478839||1|People with GACI or ARHR2, both living and deceased, and their parents and siblings.
2867199|NCT03478813|Experimental|Intervention group|Voiding school (VS) is based on urotherapy guidelines for educating children with incontinence highlighting regular voiding habits and life-style advice. Learning by doing, understanding the body function by concrete example videos and pictures, and discussing are the main teaching methods.The intervention is delivered face-to-face in groups of 4-6 children. The VS includes three sessions one months apart. Duration of each VS session is three hours. The intervention is delivered with detailed manual. The intervention is provided by an urotherapist and a public-health nurse.
2867200|NCT03478813|No Intervention|Usual care group|The control group receives treatment according to the new 2016 guidelines of incontinence care in child welfare clinics in the city concerning. Treatment is carried out by public health nurse individually in consulting hours or by telephone.
2867201|NCT03478800|Experimental|High school football players and acupuncture|50 healthy high school football players without active musculoskeletal injury
2867202|NCT03478787|Experimental|Risankizumab|Risankizumab administered by subcutaneous (SC) injection.
2867203|NCT03478787|Active Comparator|Secukinumab|Secukinumab administered by subcutaneous (SC) injection.
2867204|NCT03478774|Active Comparator|Control|These patients will receive HFNCT with oxygen 70l/min after induction of general anesthesia. Throughout the entire measurement period of 15 minutes, continuous videolaryngoscopy will be performed.
2867205|NCT03478774|Experimental|High flow|These patients will receive HFNCT with oxygen 70l/min after induction of general anesthesia. Throughout the entire measurement period of 15 minutes, jaw thrust will be performed.
2867206|NCT03478774|Experimental|medium flow|These patients will receive oxygen 10l/min after induction of general anesthesia. Throughout the entire measurement period of 15 minutes, jaw thrust will be performed.
2867207|NCT03478774|Experimental|low flow|These patients will receive oxygen 2l/min after induction of general anesthesia. Throughout the entire measurement period of 15 minutes, jaw thrust will be performed.
2867208|NCT03478748|Active Comparator|one-to-one dental health education|Conventional oral health education programme that mainly focuses at child level, which has been the normal practice at the Ministry of Health, were provided to the control participants.
2867209|NCT03478748|Experimental|anticipatory guidance technique|Anticipatory guidance technique were applied where appropriate dental health education (according to the children's milestones) were provided to mothers and their children.
2867210|NCT03478735|Experimental|Ultrasound Guided GON Block at C2|Ultrasound Guided Greater Occipital Nerve Block at C2
2867211|NCT03478735|Active Comparator|Landmark based GON Block|Landmark-Based Greater Occipital Nerve Block
2867212|NCT03478722||Maintenance Hemodialysis Patients|Protein meal, stable isotope amino acid infusion
2867213|NCT03478722||Control Subjects|Protein meal, stable isotope amino acid infusion
2867214|NCT03478709||Volume expansion|
2867215|NCT03478709||norepinephrine|
2867216|NCT03478696|Experimental|FF/UMEC/VI 100/62.5/25 mcg|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning plus placebo to match budesonide/formoterol via MDI, two inhalations twice daily plus placebo to match tiotropium via HandiHaler once daily in the morning for 84 days in the treatment period.
2867217|NCT03478696|Active Comparator|Budesonide/formoterol plus tiotropium|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered budesonide/formoterol 160/4.5 mcg via MDI, two inhalations twice daily plus tiotropium 18 mcg via HandiHaler once daily in the morning plus placebo via ELLIPTA once daily in the morning for 84 days in the treatment period.
2868583|NCT03469193|Active Comparator|internal PUC implanted with mechanical ancillary|
2867218|NCT03478683|Experimental|FF/UMEC/VI 100/62.5/25 mcg|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning plus placebo to match budesonide/formoterol via MDI, two inhalations twice daily plus placebo to match tiotropium via HandiHaler once daily in the morning for 84 days in the treatment period.
2867219|NCT03478683|Active Comparator|Budesonide/formoterol plus tiotropium|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered budesonide/formoterol 160/4.5 mcg via MDI, two inhalations twice daily plus tiotropium 18 mcg via HandiHaler once daily in the morning plus placebo via ELLIPTA once daily in the morning for 84 days in the treatment period.
2867220|NCT03478670||ADA-SCID subjects treated with Strimvelis or GSK2696273|Subjects with ADA-SCID who have received Strimvelis (or GSK2696273) gene therapy
2867221|NCT03478657|Experimental|Subjects using placebo ELLIPTA DPI|Subjects in stratum 1 and stratum 2 will be of age group from 5 to 7 years and 8 to 11 years respectively. Subjects will take placebo ELLIPTA DPI once daily. During Visit 2 (Day 28) subjects will be randomized to receive questionnaire on ELLIPTA DPI usage either version A or B.
2867222|NCT03478644|Experimental|Experimental Denture Wipe|Participants of this arm were instructed to use the experimental wipe to clean their dentures up to 4 times daily.
2867223|NCT03478644|Placebo Comparator|Tap Water|Participants of this arm were instructed to use running tap water to clean their dentures up to 4 times daily.
2867224|NCT03478631|Experimental|High Nitrate Dehydrated Vegetables|Participants are given high-nitrate dehydrated vegetable powders contained in opaque sachets. Participants are advised to consume three sachets per day, over the course of three meals, for 16 weeks.
2867225|NCT03478631|Active Comparator|Low-Nitrate Dehydrated Vegetables|Participants are given low-nitrate dehydrated vegetable powders contained in three opaque sachets. Participants are advised to consume three sachets per day, over the course of three meals, for 16 weeks.
2867226|NCT03478618|Active Comparator|Group R|30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative.
2867227|NCT03478618|Active Comparator|Group L|30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative.
2867228|NCT03478605|Experimental|Olanzapine|Olanzapine 5 mg/day p.o. d 0-4 + ondansetron 16 mg IV d 1 + dexamethasone 12 mg IV d 1, 8 mg b.i.d.; IM or P.O. d 2-4;
2867229|NCT03478605|Active Comparator|Aprepitant|Aprepitant 125 mg p.o d 1 + 80 mg p.o d 2,3 + ondansetron 16 mg IV d 1 + dexamethasone 12 mg IV d 1, 8 mg b.i.d. IM or P.O. d 2-4;
2867230|NCT03478592|Experimental|reference technique slow freezing|In reference technique slow freezing arm, embryon will be frozen with the conventional slow freezing procedure with the Freezal device apply a slow decreasing in temperature with moderate cryoprotector concentration
2867231|NCT03478592|Experimental|vitrification technique|In vitrification technique arm, embryon will be frozen with automated vitrification system
2867232|NCT03478579||Emergency physicians|The observational group will be composed of emergency physicians working in the French Midi-Pyrenees region. Physicians must work since 2 years in emergency service
2867233|NCT03478566|Experimental|Transcutaneous CO2 monitoring|
2867234|NCT03478553||People with IPF|
2867235|NCT03478553||Family members without IPF|
2867236|NCT03478527|Experimental|verum condition probiotics|The verum condition probiotics in the present study is a freely available product, Vivomixx® powder (dietary supplement). Each dose (4.4g) contains 450 billion bacteria, composed of eight bacterial strains: Lactobacilli (L. paracasei, L. plantarum, L. acidophilus, L.delbrueckii subsp. bulgaricus), Bifidobacteria (B. longum, B. infantis, B. breve), and Streptococcus thermophiles. 30 Participants will be randomly assigned to this condition. The intake period is 28 days, daily dose = 4.4g.
2867237|NCT03478527|Placebo Comparator|placebo condition|In the placebo condition participants will receive a placebo powder (comparable in taste and consistency to Vivomixx® = verum condition probiotics) that contains no probiotic bacteria. 30 Participants will be randomly assigned to that condition. The intake period is 28 days, daily dose = 4.4g.
2867238|NCT03478514|Experimental|Single Arm|"All patients will receive palbociclib at 100 mg oral once a day for 21 days, followed by 7 days off.~Ibrutinib will be administered at 560 mg oral continuously."
2867239|NCT03478501|Experimental|Decision Aid Group|Participants randomized to this arm will view the decision aid on a tablet in the emergency department.
2867240|NCT03478501|No Intervention|Control Group|Participants randomized to this arm will be asked to review general suicide prevention information on a tablet in the emergency department.
2867241|NCT03478488|Experimental|KN035|"KN035 plus Gemcitabine & oxaliplatin KN035 2.5 mg/Kg, administered as subcutaneous injection, weekly of each 21-day cycle.~Gemcitabine 1000 mg/m^2, IV infusion on Day 1 and Day 8, and oxaliplatin 85 mg/m^2, IV infusion on Day 1 of each 21-day cycle for no more than 6 cycles."
2867242|NCT03478488|Active Comparator|Gemcitabine & oxaliplatin|Gemcitabine 1000 mg/m^2, IV infusion on Day 1 and Day 8, and oxaliplatin 85 mg/m^2, IV infusion on Day 1 of each 21-day cycle for no more than 6 cycles.
2867243|NCT03478475|Experimental|Vitamin D group|The vitamin D group received three times per week a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada)
2867244|NCT03478475|Placebo Comparator|Placebo group|The placebo group received three times per week a tablet containing microcrystalline cellulose (66.3%), starch (33.2%), and magnesium stearate (0.5%), per serving.
2867245|NCT03478462|Experimental|CLR 131|Single CLR 131 intravenous administration
2867246|NCT03478449|Experimental|Fine sorting lymph node group|
2867247|NCT03478449|No Intervention|Regional sorting lymph node group|
2867248|NCT03478436|Other|fed group|14 once daily oral doses of doxycycline 40 mg, preceded by a standardized high-fat, high-calorie breakfast
2867249|NCT03478436|Other|fasting group|14 once daily oral doses of doxycycline 40 mg in fasting conditions (no food allowed 8 hours prior to dosing)
2867287|NCT03478241|Active Comparator|Group 3: single file reciprocal motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using WaveOne Ni-Ti system.
2867312|NCT03478046|Experimental|Obese individuals|Apparently healthy, weight-stable, obese and physically inactive male volunteers will be recruited. Intervention is an 8 to 10% weight loss induced by chronic exercise training and dietary modification
2867250|NCT03478423|Experimental|Codeine|"Patients will be provided with 30mg tablets of codeine, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
2867251|NCT03478423|Experimental|Oxycodone|"Patients will be provided with 5mg tablets of oxycodone, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
2867252|NCT03478423|Experimental|Hydromorphone|"Patients will be provided with 1mg tablets of hydromorphone, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
2867253|NCT03478410|Other|Atrial fibrillation|An epicardial fat biopsy will be taken from patients with chronic atrial fibrillation or paroxysmal atrial fibrillation who undergo any cardiac surgery
2867254|NCT03478410|Other|Control|An epicardial fat biopsy will be taken from patients without any history of atrial fibrillation who undergo any cardiac surgery
2867255|NCT03478397|Active Comparator|Multicomponent mHealth Intervention|Women with HPV self-collected tests will receive a multicomponent intervention which includes SMS text messages to remind them to attend triage. In addition, CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
2867256|NCT03478397|No Intervention|Usual Care|Women with HPV self-collected tests receive usual care. Upon opting for the HPV self-collected test, women will be instructed to go to the health care center in 30 days to pick up the results.
2867257|NCT03478384|Experimental|Coaching group|Patient coaching
2867258|NCT03478384|No Intervention|Control group|Control group - no additional coaching provided
2867259|NCT03478371|Sham Comparator|Marketed Tampon D|Regular absorbency tampon
2867260|NCT03478371|Sham Comparator|Marketed Tampon M|Regular absorbency tampon
2867261|NCT03478371|Sham Comparator|Marketed Tampon T|Regular absorbency tampon
2867262|NCT03478371|Sham Comparator|Marketed Tampon V|Regular absorbency tampon
2867263|NCT03478358|Experimental|177Lu-DOTA-EB-TATE 1|The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-20 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
2867264|NCT03478358|Experimental|177Lu-DOTA-EB-TATE 2|The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
2867265|NCT03478358|Experimental|177Lu-DOTA-TATE|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177LuDOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
2867266|NCT03478345|Experimental|THRIVE Study|
2867267|NCT03478332|Active Comparator|Treatment group|The aim of the arm is to test if the addition of Yangxinshi pills to the conventional coronary heart disease medicine will improve the exercise tolerance of the coronary heart disease
2867268|NCT03478332|Placebo Comparator|Control group|The patients of the control group are treated with conventional coronary heart disease medicine plus the placebos-Yangxinshi simulant
2867269|NCT03478319|Experimental|Part 1 - Cohort 1|ACE-2494 or placebo 0.06 mg/kg SC Day 1
2867270|NCT03478319|Experimental|Part 1 - Cohort 2|ACE-2494 or placebo 0.2 mg/kg SC Day 1
2867271|NCT03478319|Experimental|Part 1 - Cohort 3|ACE-2494 or placebo 0.6 mg/kg SC Day 1
2867272|NCT03478319|Experimental|Part 2 - Cohort 4|ACE-2494 or placebo 0.2 mg/kg SC Days 1, 29, 57
2867273|NCT03478319|Experimental|Part 2 - Cohort 5|ACE-2494 or placebo 0.6 mg/kg SC Days 1, 29, 57
2867274|NCT03478319|Experimental|Part 2 - Cohort 6|ACE-2494 or placebo ≤ 2.0 mg/kg SC Days 1, 29, 57
2867275|NCT03478306|Active Comparator|Arm 1|Melatonin, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.
2867276|NCT03478306|Placebo Comparator|Arm 2|Place, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.
2867277|NCT03478293|Experimental|iStent inject surgery|Single-arm study. Intervention is micro-invasive glaucoma surgery (MIGS) to implant iStent inject
2867278|NCT03478280|Active Comparator|Brodalumab|Subjects will receive 210 mg of Kyntheum administered by subcutaneous injection at Weeks 0, 1 and 2 followed by 210 mg every other week (EOW) thereafter.
2867279|NCT03478280|Placebo Comparator|Placebo|Subjects will receive placebo doses administered by subcutaneous injection at Weeks 0, 1 and 2 followed by placebo EOW thereafter.
2867280|NCT03478267||Fetal heart rate 110-130 bpm|Pregnancies in which the fetal baseline heart rate is between 110 beats per minute and 130 beats per minute.
2867281|NCT03478267||Fetal heart rate 140-160 bpm|Pregnancies in which the fetal baseline heart rate is between 140 beats per minute and 160 beats per minute.
2867282|NCT03478254||Influenza Vaccination|All type 1 diabetes adults patients attended in Ciudad Real General University Hospital willl be checked for Influenza Vaccination status.
2867283|NCT03478254||Pneumococcal Vaccination|All type 1 diabetes adults patients attended in Ciudad Real General University Hospital willl be checked for Pneumococcal Vaccination status.
2867284|NCT03478254||Hepatitis B Virus (HBV) Vaccination|All type 1 diabetes adults patients attended in Ciudad Real General University Hospital willl be checked for Hepatitis B Virus (HBV) status.
2867285|NCT03478241|Active Comparator|Group 1: single file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using OneShape Ni-Ti system.
2867286|NCT03478241|Active Comparator|Group 2: multiple file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using Revo S Ni-Ti system.
2867288|NCT03478228|Experimental|Multi-Sensory Training (MST)|Multi-Sensory Training. 6 treatment sessions, supervised by a physiotherapist, during a 3 months training period, and a written exercise program that is to be performed daily at home. The participants keep a home exercise diary during the training period.
2867289|NCT03478228|Active Comparator|Wrist Stabilisation Training (WT)|Wrist Stabilisation Training. 6 treatment sessions, supervised by a physiotherapist, during a 3 months training period, and a written exercise program that is to be performed daily at home. The participants keep a home exercise diary during the training period.
2867290|NCT03478215|Experimental|MSC infusion|"Mesenchymal stem cells (MSCs) are the intervention. MSCs will be administered intravenously at surgery and day 4 posttransplant in a dose-escalation fashion beginning as 1x10^6 cells for the first dose group, 2x10^6 cells for the second dose group, or 3x10^6 cells for the last dose group. The infusion set-up will be covered to mask the group assignment.~Participants will also receive basiliximab, tacrolimus, mycophenolate mofetil, and corticosteroids as routine care."
2867291|NCT03478215|Placebo Comparator|Placebo Infusion|"A normal saline infusion is the intervention. A placebo (normal saline) infusion will occur at surgery and day 4 posttransplant. The infusion set-up will be covered to mask the group assignment.~Participants will also receive basiliximab, tacrolimus, mycophenolate mofetil, and corticosteroids as routine care."
2867292|NCT03478202|Experimental|Open Label RELEASE Supplement|
2867293|NCT03478176||Patients|
2867294|NCT03478163|No Intervention|Control|The patient will not receive antibiotics as part of the study, though if at any time her provider chooses to administer antibiotics either prophylactically or for treatment she will not prohibited in any way from this or any other treatment as appropriate.
2867295|NCT03478163|Experimental|Antibiotics|The patient will receive a 24-hour course of antibiotics. The primary antibiotic of choice will be cefazolin 1 gm iv q8 hours. If the patient has contraindications to the use of cefazolin including cefazolin allergy, hypersensitivity, or severe beta lactam allergy, then clindamycin 900 mg iv q8 hours will be used instead.
2867296|NCT03478150|Experimental|zinc oxide nano-particles|The zinc oxide nano-powder will be mixed with ethanol and applied in the cavity, where the ethanol evaporates, while the zinc oxide nano-particles infiltrate into the carious floor of the cavity.
2867297|NCT03478150|Experimental|laser diode|Each cavity will be irradiated in contact mode with continuous wave of radiation. The laser light is transferred through a 600µm flexible fiber optic tip by a special hand piece. The fiber optic will be disinfected for each use by 70% ethyl alcohol and inserted inside the cavity to 1mm with a spiral continuous movement clockwise from the top to the floor and anti-clockwise in the reverse direction. This procedure improves the distribution of the laser light inside the cavity and to avoid excessive heat generation in the internal cavity surface. Irradiation time will be 15 seconds and repeated 5 times with 15 second intervals with contact, according to manufacture instructions. During this study the output power will be adjusted at 1.5W.
2867298|NCT03478137|Experimental|CPAP intervention|Over the course of 4-7 months, participants will have to wear the CPAP every night, at least 4 hours per night.
2867299|NCT03478137|No Intervention|Control 1|Eligible participants who declined to participate in the study. Their main study visit data will be used to compare with the intervention group.
2867300|NCT03478137|No Intervention|Control 2|Eligible participants who were not approached, hence not given the opportunity to accept or decline. Their main study visit data will be used to compare with the intervention group.
2867301|NCT03478124||PSP patients|Patients suffering from Progressive Supranuclear Palsy (PSP)
2867302|NCT03478124||PD Patients|Patients suffering from Parkinson's disease (PD)
2867303|NCT03478111|Experimental|CMAB008+MTX|"Drug: CMAB008 (recombinant chimeric anti-TNF-α monoclonal antibody injection) infusion of 3mg/kg in Week 0, 2, 6, 14, 22, 30.~Drug: MIX (methotrexate) will be oral administered at a dose of 7.5mg~15mg weekly from Week 0 to 38."
2867304|NCT03478111|Active Comparator|Remicade+MTX|"Drug: Remicade (recombinant chimeric anti-TNF-α monoclonal antibody injection) infusion of 3mg/kg in Week 0, 2, 6, 14, 22, 30.~Drug: MIX (methotrexate) will be oral administered at a dose of 7.5mg~15mg weekly from Week 0 to 38."
2867305|NCT03478098|Experimental|10 Roux-en-Y Gastric Bypass patients|4 study days in randomized order are conducted with interventions: Low GI mealtest, High GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest and subsequent exercise
2867306|NCT03478098|Experimental|10 control subjects|4 study days in randomized order are conducted with interventions: Low GI mealtest, High GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest and subsequent exercise
2867307|NCT03478085|Active Comparator|Traditional exercise therapy|Training will be performed three times a week for 12 weeks. Each session will take place on a GaitKeeper treadmill (Sammons Preston, IL) treadmill and will last 45 minutes with a 5 minute warm up and cool down of either cycling or walking.
2867308|NCT03478085|Experimental|Oxygen guided exercise therapy|Training will be performed three times a week for 12 weeks. Each session will take place on a GaitKeeper treadmill (Sammons Preston, IL) treadmill and will last 45 minutes with a 5 minute warm up and cool down of either cycling or walking. All patients will be outfitted during exercise with the PortaMon NIRS device on the most affected calf (including subjects in the symptom-driven exercise cohort). The intensity of training will be adjusted to either pain (claudication) rating or oxygen tension. In preliminary studies, a 50% reduction in the tissue saturation index is typically not associated with severe claudication and will be used as the lower level threshold to gauge physical effort (i.e., if subjects do not desaturate by >50% then the intensity of training - the walking pace - will be increased). The training duration, intensity, pain rating, and oxygen tension will be recorded.
2867309|NCT03478085|Placebo Comparator|Control|Patients will be advised to walk independently.
2867310|NCT03478059|Experimental|Mild Traumatic Brain Injury|"60 minute, 3 times per week, 6 week long Cognitive and Motor Dual-task Intervention program. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI.~Subjects with mTBI residuals will be gently progressed through exercise stations in an individually tailored fashion."
2867311|NCT03478059|Other|Healthy Control|"60 minute, 3 times per week, 6 week long Cognitive and Motor Dual-task Intervention program. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI.~In addition to providing comparison data, the healthy control, athletic 18-34 year old subjects will be used to identify levels and intensity of progressions of dual-task training stations appropriate for highly trained athletes and military personnel recovering from concussion."
2867313|NCT03478033|Active Comparator|Rifampicin group|"Rifampicin group: Intensive treatment（4 types of anti-TB medicines）for 2 months, then isoniazid and rifampicin for 4 months of consolidation therapy.~isoniazid: 10-15mg/kg rifampicin: 10-20mg/kg pyrazinamide: 30-40mg/kg thambutol: 0.75(W＜50kg)；1.0 g/d（W≥50kg）"
2867314|NCT03478033|Experimental|Rifabutin group|"Rifabutin group: Intensive treatment（4 types anti-TB medicines）for 2 months,then isoniazid and rifabutin for 4 months of consolidation therapy.~isoniazid: 10-15mg/kg rifabutin: 0.45g/d(W＜50kg); 0.6g/d( W≥50kg） pyrazinamide: 30-40mg/kg thambutol: 0.75(W＜50kg)；1.0 g/d（W≥50kg）"
2867315|NCT03478020|Experimental|Pre-Treatment, Treatment Cycles A & B|"Pre-Treatment: Two cycles of a combined oral contraceptive (COC) taken orally once daily for 21 days followed by 7 COC-free days.~Treatment Period A: COC containing taken orally once daily for 21 days followed by 7 COC-free days.~Treatment Period B: COC taken orally once daily for 21 days, with once daily oral 200 mg AQX-1125 (2 x 100 mg tablets) co-administered from Day 13 to 21, followed by 7 COC-free days"
2867316|NCT03478007|No Intervention|Usual Treatment|Usual standard of care (exercises)
2867317|NCT03478007|Experimental|Intervention Technology Only|Exercises with technology alone
2867318|NCT03478007|Experimental|Intervention Technology Plus Coaching|Exercises with technology plus coaching
2867319|NCT03477994|Active Comparator|dexmedetomidine group|"Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4~+4 Combative ,+3 Very agitated ,+2 Agitated,+1 Restless, 0 Alert and calm, -1 Drowsy , -2 Light sedation, -3 Moderate sedation, -4 Deep sedation, -5 Unarrousable Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h. Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur."
2867320|NCT03477994|Sham Comparator|clonidine group|In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4 Five ampoules of clonidine(750 μg) will be drawn up and diluted in 45ml of normal saline.
2867321|NCT03477981|Other|Study cohort|Participants will receive standard white bread for two weeks and then alginate bread for two weeks. All participants will receive the bread in the same order.
2867322|NCT03477968||PE|Patients presenting with PE suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.
2867323|NCT03477968||DVT|Patients presenting with DVT suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.
2867324|NCT03477955|Active Comparator|Peek Group|Patients that received PEEK interspinous spacer
2867325|NCT03477955|Active Comparator|Silicon Group|Patients that received Silicon interspinous spacer and did not receive PEEK interspinous spacer
2867326|NCT03477955|Active Comparator|Control Group|Patients that did not receive PEEK interspinous spacer nor Silicon interspinous spacer
2867327|NCT03477942|Experimental|Osteoarthritis|The OA subgroup will be patients aged 18-60 years who have chronic knee pain due to early OA that have not responded to conservative, non-invasive measures such as physical therapy, medications, and activity modification.
2867328|NCT03477942|Experimental|Cartilage|The focal chondral defect subgroup will be patients aged 18-60 years who participate in recreational or professional sports and are symptomatic from a focal chondral defect shown on MRI.
2867329|NCT03477929|Experimental|ganirelix|multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
2867330|NCT03477929|Experimental|cetrorelix|multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
2867331|NCT03477916|Other|Control (Placebo FMT and cellulose)|
2867332|NCT03477916|Experimental|FMT only (FMT followed by cellulose)|
2867333|NCT03477916|Other|Prebiotic only (Placebo FMT and prebiotic fiber)|
2867334|NCT03477916|Experimental|FMT + prebiotic fiber|
2867335|NCT03477903|Experimental|Group A: TAK-954 0.1 mg|TAK-954 0.1 milligram (mg), intravenously, administered as 60 minute-infusion, once daily along with 2 milliliter (mL) normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
2867336|NCT03477903|Experimental|Group B: TAK-954 0.3 mg|TAK-954 0.3 mg, intravenously, administered as 60 minute-infusion, once daily along with 2 mL normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
2867337|NCT03477903|Experimental|Group C: TAK-954 1.0 mg|TAK-954 1.0 mg, intravenously, administered as 60 minute-infusion, once daily along with 2 mL normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
2867338|NCT03477903|Active Comparator|Group D: Metoclopramide 10 mg|Metoclopramide 10 mg, injection, intravenously, three times a day along with 100 mL normal saline 60-minute infusion, intravenously, once daily for a minimum of 5 days up to a maximum of 14 days.
2867339|NCT03477890|Active Comparator|Intervention group (coronary function test results disclosed)|Coronary function tests are measured and disclosed to the clinician for re-evaluation of the initial diagnosis and treatment as compared with initial angiography. The intervention involves measurement of FFR, CFR, IMR and RRR in a major coronary artery followed by reactivity testing using incremental doses of acetylcholine (10-4 Molar (M), 10-5 M, 10-6 M) to assess endothelial function, bolus of ACh (10-4 M; 100 micrograms) for vasospasm, followed by glyceryl trinitrate (300 micrograms). FFR will be measured in all arteries with a diameter >=2.5 mm and a stenosis 40% to 90% in severity. Endotypes are based on criteria for abnormal coronary vasodilator function, vasospasm and microvascular resistance. The endotypes (diagnostic strata) are: obstructive CAD, vasospastic angina, microvascular angina, mixed (ie both vasospastic and microvascular disorders), endothelial dysfunction (no angina), normal (non-cardiac). A diagnosis may be ruled-in or ruled-out based on the test results.
2867340|NCT03477890|Sham Comparator|Usual care group (coronary function results not disclosed)|Coronary function tests are measured but not disclosed to the attending clinician or the participant. The same coronary function tests are undertaken as in the intervention group. Masking is achieved by obscuring the catheter laboratory monitors from the attending clinician and participant. The effectiveness of masking and protocol adherence is prospectively monitored.
2867341|NCT03477877|Experimental|Indashyikirwa|Sectors which receive the full Indashyikirwa programme, including (1) couples training and activist training and support by RWAMREC, and (2) opinion leader training and establishment of women's spaces by the Rwanda Women's Network.
2867342|NCT03477877|Active Comparator|VSLA Only|Sectors that continue to receive only the village savings and loan association (VSLA) programmes offered by CARE Rwanda
2867343|NCT03477864|Experimental|Arm A (REGN2810, SBRT, surgery)|Participants receive anti-PD-1 monoclonal antibody REGN2810 IV over 30 minutes on day 1 of week 1 and in week 4, and undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
2867344|NCT03477864|Experimental|Arm B (ipilimumab, SBRT, surgery)|Participants receive ipilimumab via intraprostatic injection on day 1 of week 1, and undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
2867345|NCT03477864|Experimental|Arm C (REGN2810, ipilimumab, SBRT, surgery)|Participants receive anti-PD-1 monoclonal antibody REGN2810 as in Arm A and ipilimumab as in Arm B. Participants also undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
2867346|NCT03477851|Placebo Comparator|Placebo|Patients randomized to receive 0,9% sodium hydrochloride solution 5ml i.m. (gluteus muscle) after spinal anesthesia, simultaneously with the sciatic nerve block.
2867347|NCT03477851|Experimental|Tramadol|Patients randomized to receive 100mg of Tramadol hydrochloride in 5ml 0,9% sodium hydrochloride i.m. (gluteus muscle) after spinal anesthesia, simultaneously with the sciatic nerve block.
2867348|NCT03477838|Experimental|CGM Intervention arm|Patients eligible for care at the free clinic with diabetes and A1c greater than 8% on insulin therapy will be identified for CGM use.
2867349|NCT03477825|Placebo Comparator|Placebo|"Group A: Placebo group (n = 10)~Supplement appearing similar to Herbal formulations~Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~Dose: subjects in this group will take 4 placebo tablets per day"
2867350|NCT03477825|Experimental|Rubia Cordifolia|"Group B: R. cordifolia group (n = 10)~2,000 mg R. cordifolia per day - supplied by Banyan Botanicals and following standard supplementation doses on commercially available supplement (https://www.banyanbotanicals.com/manjistha-tablets/)~Each tablet contains 500 mg of R. cordifolia per tablet."
2867351|NCT03477825|Experimental|Triphala|"Group C: Triphala group (n= 10)~Tablets of Triphala will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/triphala-tablets-11/)~Each tablet contains mix Emblica officinalis, Terminalia bellerica, and Terminalia chebula~Dose: subjects will take 4 tablets per day, with a total dose of 2,000 mg of total herb."
2867352|NCT03477812||Healthy children|Healthy children 7-14 years of age.
2867353|NCT03477812||Nocturnal enuresis with polyuria|Children with nocturnal enuresis and polyuria aged 7-14 years.
2867354|NCT03477812||Nocturnal enuresis without polyuria|Children without nocturnal enuresis and polyuria aged 7-14 years.
2867355|NCT03477799|Active Comparator|Active|anodal stimulation over the right dlPFC
2867356|NCT03477799|Placebo Comparator|Sham|sham stimulation over the right dlPFC
2867357|NCT03477786|Active Comparator|tight BP|"Interventions: anti-hypertension drug prescription by physician and case management by health educator.~Blood pressure is targeted at 120/80 mmHg in the tight BP control group."
2867358|NCT03477786|Placebo Comparator|usual BP|"Interventions: The physicians follow their usual care patterns to prescribe anti-HT drugs.~Blood pressure is targeted at < 140/90 mmHg in the usual BP control group."
2867359|NCT03477773|Experimental|Intervention|Perform three session of high-intensity, interval training sessions per week over the 6-week intervention
2867360|NCT03477773|No Intervention|Control|Continue with their normal habitual lifestyle over the 6-week intervention
2867361|NCT03477747|Experimental|Resistance Training Microcurrent|"Participants will combine a 10-week periodized and controlled resistance programme with 3 h of microcurrent after training.~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
2867362|NCT03477747|Sham Comparator|Resistance Training Shadow|"Participants will combine a 10-week periodized and controlled resistance programme with 3 h of sham comparator after training.~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
2867363|NCT03477747|Experimental|Endurance Training Microcurrent|"Participants will combine a 10-week periodized and controlled endurance programme with 3 h of microcurrent after training.~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
2867364|NCT03477747|Sham Comparator|Endurance Training Shadow|"Participants will combine a 10-week periodized and controlled endurance programme with 3 h of microcurrent after training.~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
2867365|NCT03477734|Experimental|CS1 & heart monitor - AF patients|Males and females diagnosed with atrial fibrillation will be fitted with the CardiacSense1 and Holter heart monitor for 24-48 hours while going about daily activities, results shall be compared and analysed
2867366|NCT03477734|Active Comparator|CS1 & heart monitor -Healthy volunteers|Males and females not diagnosed with atrial fibrillation will be fitted with the CardiacSense1 and Holter heart monitor for 24-48 hours while going about daily activities, results shall be compared and analysed
2868584|NCT03469193|Experimental|Internal PUC implanted with robotic assistance|
2867367|NCT03477721||Group with cancer cachexia (CTB)|For diagnosis of cachexia it will be used the following criteria (Evans et al., 2008)
2867368|NCT03477721||Group without cancer cachexia (TB)|
2867369|NCT03477708||Study group|TCCO2 monitoring
2867370|NCT03477708||Control group|Routine monitoring
2867371|NCT03477695|Experimental|Upright device|Ambulatory use of the Upright device
2867372|NCT03477682|Experimental|Early Ambulation Group|The patient will remain on bed rest for one day following surgery and will be encouraged to be out of bed and ambulating on the second day following surgery.
2867373|NCT03477682|No Intervention|Standard Group|The patient will remain on bed rest for five days following surgery and will be encouraged to be out of bed and ambulating on the sixth day following surgery.
2867374|NCT03477669|Experimental|chamomile/probiotic arm|Infant will receive 5 drops of the study product once per day with a feeding at midday.
2867375|NCT03477669|Placebo Comparator|Placebo of chamomile/probiotic arm|Infant will receive 5 drops of a placebo product once a day at midday.
2867376|NCT03477656|Experimental|Large volume specific immunoadsorption|1 to 2 sessions of large volume specific immunoadsorption according to the initial isoagglutinin titer.
2867377|NCT03477656|Experimental|Double Filtration Plasmapheresis|1 to 5 sessions of double filtration plasmapheresis according to the initial isoagglutinin titer.
2867378|NCT03477643||Refractory Multiple Myeloma|Patients with relapsed and refractory multiple myeloma who have received treatment with pomalidomide, cyclophosphamide, and dexamethasone following the GEM-PETHEMA clinical practice guidelines between January 1, 2015 and January 1, 2017.
2867379|NCT03477630|Experimental|Platelet Rich Plasma|Infiltration injected 8 cc per session, 4 sessions, 1 session every 15 days.
2867380|NCT03477630|Active Comparator|Hyaluronic Acid|Infiltration, injected 6 cc per session, 1 sessions.
2867381|NCT03477617|Experimental|Intraoperative Hemodynamic Algorithm|In the experimental group, the anesthesiologist will have complete access to data from the minimal invasive cardiac output monitor. During the intraoperative period, the anesthesiologist will be instructed to use a hemodynamic management algorithm to manage episodes of significant hypotension
2867382|NCT03477617|Active Comparator|Usual Hemodynamic Management|In the control arm, the participant will be monitored by the cardiac output monitor, but the anesthesiologists in the operating room will be blinded to hemodynamic data from the monitor. Data from the monitor will be stored electronically and used to compare hemodynamic parameters between study arms.
2867383|NCT03477604|Experimental|MicroStent|Implant of the MicroStent peripheral vascular stent system for treatment of arterial lesions below the knee.
2867384|NCT03477591|Experimental|Evidence + PDA|Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources), plus a blog post on PDAs and the relevant decision aid from the Portal database
2867385|NCT03477591|Experimental|Evidence only|The same evidence-based information as group 1 (Evidence + PDA), but without the PDA to quantify the effect of accessing evidence through the Portal alone
2867386|NCT03477591|Sham Comparator|Attention control|Information on how to distinguish high from low-quality health information, not specific to cancer screening or PDAs
2867387|NCT03477578||FoG+|Parkinsonian patients with Freezing of Gait
2867388|NCT03477578||FoG-|Parkinsonian patients withou Freezing of Gait
2867389|NCT03477565|Experimental|Sperimental group|"Patients who belong to the sperimental group (SPER) will receive the standard treatment and Kinesio tape lymphatic drainage technique application.~The experimental group also receives the expected standard treatment, consisting in physiotherapeutic evaluation and physiotherapy counseling."
2867390|NCT03477565|No Intervention|Control group|"Patients who belong to the control group (CONTR) will receive only the standard treatment. Standard treatment consists in physiotherapy evaluation and counseling. The educational part, the demonstration of the exercises and the prosthesis mobilization are included in this treatment."
2867391|NCT03477552|Experimental|Accuvein V400 device|In the Accuvein group, the nurse uses the Accuvein device to identify the veins before any puncture to infuse the patient and then proceeds as usual, under illumination of the device.
2867392|NCT03477552|Active Comparator|Routine procedure|In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
2867393|NCT03477539|Experimental|Treatment (daratumumab, ASCT, lenalidomide)|"CONSOLIDATION I: Participants receive IV on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION II: Beginning 8 weeks after completion of daratumumab course 2, participants undergo ASCT.~MAINTENANCE: Within 14 days after completion of day 100 visit post-SCT, participants receive daratumumab IV on day 1 and lenalidomide PO daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Participants who are still maintaining response continue to receive daratumumab IV every 3 months in the absence of disease progression or unacceptable toxicity."
2867394|NCT03477526|Experimental|COPD patients (GOLD stage III-IV)|
2867395|NCT03477526|Active Comparator|IPF patients|
2867396|NCT03477500|Experimental|HSCT (Cyclophosphamide and ATG)|"Day 1: Cyclophosphamide 2.0 g/m2 body surface area Days 5-10: Granulocyte colony stimulating factor (filgrastim) 5 mcg/kg body weight/day sc.~Day 11 and until apheresis is discontinued: Granulocyte colony stimulating factor (filgrastim) 5 mcg/kg body weight x 2 sc/day.~HSCT days -5 to -2: Cyclophosphamide 50 mg/kg/day. HSCT days -5 to -1: Anti-thymocyte globulin (ATG-rabbit, Thymoglobuline®) 0.5 mg/kg body weight iv on day -5, 1.0 mg ATG-rabbit/kg will be given iv on day -4, and 1.5 mg ATG-rabbit /kg will be given iv on days -3,-2 and -1 over 10 hours.~HSCT day 0: Reinfusion of a minimum of 3,0 x 106 CD 34+ cells/kg body weight."
2867397|NCT03477500|Active Comparator|Alemtuzumab|Alemtuzumab 12 mg iv daily on 5 consecutive days at first alemtuzumab treatment cycle, followed by 3 consecutive days at the second alemtuzumab treatment cycle 12 months later.
2867398|NCT03477487|Experimental|Lowest dose|The lowest dose of XT-150 in the escalation schedule
2867399|NCT03477487|Experimental|Second dose|The 2nd dose of XT-150 in the escalation sequence
2867400|NCT03477487|Experimental|Third dose|The 3rd dose of XT-150 in the escalation sequence
2867401|NCT03477487|Experimental|Highest dose|The highest dose of XT-150 in the escalation sequence
2867402|NCT03477461||terlipressin group|patients presented with oliguria or high levels creatinine
2867403|NCT03477448|Active Comparator|PPD group|"This group will include 20 patients who will be treated with IL injection of PPD at a dose of 10 IU (0.1 ml) supplied an insulin syringe in the largest wart.~Injections will be repeated for all patients into the same lesion (largest wart) every 2 weeks for three treatment sessions"
2867404|NCT03477448|Active Comparator|Bleomycin group|"This group will include 20 patients who will be treated with IL injection of bleomycin.~Injections will be repeated for all patients into the same lesion (largest wart) every 2 weeks for three treatment sessions, if needed."
2867405|NCT03477435|Experimental|Opt-in clinical reminder|As the investigators have done previously, the reminder will be self-explanatory, and will walk staff through each step of referral. The reminder will include the following domains: normative advice, referral to treatment, handout
2867406|NCT03477435|Experimental|Opt-out tobacco treatment|The investigators will directly change the treatment status quo by implementing a clinical reminder that automatically initiates tobacco treatment referral at the time the reminder is activated.
2867407|NCT03477422|Experimental|CSE-1034 (Ceftriaxone + Sulbactam + EDTA)|"CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was an Experimental drug in this study and is a combination of Ceftriaxone 1000mg, Sulbactam 500mg and EDTA 37mg available as dry powder for reconstitution. It was administered twelve hourly through intravenous route as infusion over 30 minutes. The duration of the active treatment was for 5-14 days depending upon the severity of the disease, which was determined by the Principal Investigator (PI).~Interventions:~Drug: CSE-1034 (Ceftriaxone + Sulbactam + EDTA)~Drug: Matching Placebo"
2867408|NCT03477422|Active Comparator|Meropenem|"Meropenem was the active comparator in the study. It was also available as dry powder for reconstitution and contained active ingredient Meropenem 1000mg. It was administered eight hourly through intravenous route as infusion over 30 minutes.The duration of the active treatment was for 5-14 days depending upon the severity of the disease, which was determined by the PI.~Interventions:~Drug: Meropenem~Drug: Matching Placebo"
2867409|NCT03477409||Neonatal intensive care patients|The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
2867410|NCT03477396|Experimental|Treatment (ribociclib, aromatase inhibitor)|Participants receive ribociclib orally PO QD on days 1-21 and aromatase inhibitor per treating investigator's discretion. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2867411|NCT03477383||Adult patients|Adult patients (18 years or older) undergoing heart transplantation
2867412|NCT03477383||Pediatric patients|Pediatric patients (0-17 years) undergoing heart transplantation
2867413|NCT03477344|Active Comparator|Dexmédétomidine|Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
2867414|NCT03477344|Placebo Comparator|Sodium Chloride 0,9%|Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
2867415|NCT03477318||Patients undergoing screening colonoscopy|Patients undergoing first-time colonoscopy using white light with at least 1 polyp resected.
2867416|NCT03477305|Experimental|BerryCare Participants|Subjects will be recruited to participate in a community gardening program where they will learn the benefits of both physical active gardening and consuming homegrown foods through blackberry consumption.
2867417|NCT03477292|Experimental|Long duration of antibiotics|14 days of Colistin
2867418|NCT03477292|Active Comparator|Short duration of antibiotics|7 days of Colistin
2867419|NCT03477279|No Intervention|Individual (SOC)|Women enrolled in the individual arm of the study will receive Standard of Care Option B+ procedures.
2867420|NCT03477279|Experimental|Couple (Intervention)|In addition to receiving standard of care procedures, women in the couple arm will be provided with an intervention aimed at recruiting their male partners, providing enhanced couple counseling and testing, engaging their male partners in their care, and supporting male partners to receive care and treatment services.
2867421|NCT03477266|Experimental|Mouth dissolving mosapride|Fluxopride 5mg of Macryrl egypt 2 tablets one day before and immediately after elective cesarean section every 8hour for maximum of 5 days
2867422|NCT03477266|Placebo Comparator|Placebo mouth dissolving tablets|Dummy identical tablets taken in the same way
2867423|NCT03477253|Active Comparator|LC within the first 3 days of disease|
2867424|NCT03477253|Active Comparator|LC after the first 3 days of disease|
2867425|NCT03477227|Experimental|Short stocking|After radiofrequency ablation of the GSF and phlebectomy varicose tributaries, patients will wear compression socks without foot for four weeks
2867426|NCT03477227|Active Comparator|Usual stocking|After radiofrequency ablation of the GSF and phlebectomy varicose tributaries, patients will wear usual compression socks for four weeks (usual care)
2867427|NCT03477214||Normal|No UI, no OAB conditions. Transvaginal biomechanical and electromyography mapping will be completed.
2867428|NCT03477214||Urinary incontinence|Urinary incontinence conditions. Transvaginal biomechanical and electromyography mapping will be completed.
2867429|NCT03477214||Overactive bladder|Overactive bladder conditions
2867430|NCT03477201|Experimental|Laparoscopic robotic DaVinci assisted inguinal hernia repair|Intervention: 30 patients will undergo a robotic assisted laparoscopic inguinal hernia repair. This will be done using the DaVinci Robotic Platform by Intuitive Surgical. This an accepted safe method of repairing inguinal hernia. This platform uses special robotic ports produced and supplied by Intuitive Surgical required to dock the machine to the patient. Monopolar energy will be provided by a ForceTriad system (Covidien, Boulder, CO), standard an common system used in most ORs. This will be used for dissection. The investigators will obtain small biopsies from port site to assess stray energy transfer injury, a model described by earlier studies.
2867455|NCT03477097|Experimental|Nutrition 1 + physical activity group w/o social network|Subjects received the nutrition I (e.g., food plate and multiple vitamin/ minerals powder) and exercise (e.g., personalized homed-based exercise plan) intervention.
2867456|NCT03477097|Experimental|Nutrition 1 + physical activity group w/ social network|Subjects received the nutrition I (e.g., food plate and multiple vitamin/ minerals powder), exercise (e.g., personalized homed-based exercise plan), and social network intervention.
2867431|NCT03477201|Active Comparator|Standard Laparoscopic inguinal hernia repair|Intervention: 30 patients will undergo a laparoscopic inguinal hernia repair, an accepted safe method of repairing inguinal hernia. This platform uses standard laparoscopic ports. In our institution we use plastic ports made by Covidien, Boulder, CO. The operation will require two 5mm VersaPort (Covidien) and a Hassan Port. As in the robotic arm, monopolar energy will be provided by a ForceTriad system (Covidien, Boulder, CO), standard an common system used in most ORs. This will be used for dissection. The investigators will obtain small biopsies from port site to assess stray energy transfer injury, a model described by earlier studies.
2867432|NCT03477188|Experimental|Somatosensorial and Vestibular Exercises Group|This group of patients received patients with acute stroke. It will be applied somatosensorial and vestibular rehabilitation additional conventional therapy
2867433|NCT03477188|Active Comparator|Conventional Group|This Group patients received patient with acute stroke. It will be applied classical physiotherapy and conventional exercises.
2867434|NCT03477175|Experimental|Cohort A : Lenvatinib|The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib monotherapy or who crossed over from a comparator arm to receive lenvatinib monotherapy in their parent study will continue to receive lenvatinib monotherapy.
2867435|NCT03477175|Experimental|Cohort B: Lenvatinib plus Comparator drug|The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib combination therapy or who crossed over from a comparator arm to receive lenvatinib combination therapy in their parent study will continue to receive lenvatinib combination therapy.
2867436|NCT03477175|Experimental|Cohort C: Comparator drug|The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive comparator treatment, with exception of participants receiving placebo.
2867437|NCT03477162|Experimental|Metformin|Patients enrolled will be treated with metformin (administered orally; 750 mg QD for 4 days, then 750 mg BID for 3-6 days; or clinically indicated metformin) for a total of 7-10 days prior to surgery, up until the night before surgery.
2867438|NCT03477149|Experimental|Embolization with Easyx|Patients requiring embolization of varicocele, portal vein before ablation, type 2 endoleak, angiomyolipoma or active bleeding will be treated with the liquid embolic agent Easyx during index procedure.
2867439|NCT03477136||First group: semen parameter showing normospermic|"group will include 30 male~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
2867440|NCT03477136||second group: semen parameter asthenozoospermic|"group will include 30 male~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
2867441|NCT03477136||Third group: semen parameter oligozoospermic|"group will include 30 male~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
2867442|NCT03477136||Forth groupsemen parameter: astheno-teratozoospermic,|"group will include 30 male~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
2867443|NCT03477136||Fifth group semen parameter: oligo asthenoteratozoospermia|"group will include 30 male~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
2867444|NCT03477123|Experimental|Intervention|Walking therapy with Exo-H2 exoskeleton
2867445|NCT03477123|No Intervention|Control|Group receiving conventional walking therapy without robotic exoskeleton
2867446|NCT03477110|Experimental|Treatment (temozolomide, radiation, NovoTTF-200A device)|Participants receive temozolomide PO QD starting day 1 to the end of radiation therapy and undergo 30 fractions of radiation therapy over 15-20 minutes each, 5 days a week (Monday-Friday) for 6 weeks. Beginning day 1 of radiation therapy, participants undergo tumor treatment fields therapy using NovoTTF-200A device over 18 hours or more daily in the absence of disease progression or unacceptable toxicity. Beginning 28 days after the last dose of radiation therapy, participants receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2867447|NCT03477097|No Intervention|Control group w/o social network intervention|Subjects did not receive any intervention of nutrition, physical activity and social network.
2867448|NCT03477097|Experimental|Control group w/ social network intervention|Subjects only received the intervention of social network.
2867449|NCT03477097|Experimental|Nutrition group 1 w/o social network intervention|Subjects only received the nutrition I intervention (e.g., food plate and multiple vitamin/ minerals powder).
2867450|NCT03477097|Experimental|Nutrition group 1 w/ social network intervention|Subjects received the nutrition I intervention (e.g., food plate and multiple vitamin/ minerals powder) and social network intervention as well.
2867451|NCT03477097|Experimental|Nutrition group 2 w/o social network intervention|Subjects only received the nutrition II intervention (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil).
2867452|NCT03477097|Experimental|Nutrition group 2 w/ social network intervention|Subjects received the nutrition II intervention (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil) and social network intervention as well.
2867453|NCT03477097|Experimental|Physical activity group w/o social network intervention|Subjects only received the personalized homed-based exercise prescription, which consisted of a combination of strength, flexibility, balance and endurance training.
2867454|NCT03477097|Experimental|Physical activity group w/ social network intervention|Subjects received the personalized homed-based exercise prescription, which consisted of a combination of strength, flexibility, balance and endurance training, and social network intervention as well.
2867562|NCT03476213|Active Comparator|Group TIVA|induction and anesthesia will be held by manual dosing of propofol and sufentanil
2867457|NCT03477097|Experimental|Nutrition 2 + physical activity group w/o social network|Subjects only received the nutrition II (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil) and exercise (e.g., personalized homed-based exercise plan) intervention.
2867458|NCT03477097|Experimental|Nutrition 2 + physical activity group w/ social network|Subjects only received the nutrition II (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil), exercise (e.g., personalized homed-based exercise plan), and social network intervention.
2867459|NCT03477084||Long Term Care Facilities|Spread of ESBL-producing E. coli and K. pneumoniae among the residents of Long Term Care Facilities.
2867460|NCT03477084||Households|Household transmission of ESBL-producing bacteria after hospital discharge of a patient carrying ESBL-producing E. coli or K. pneumoniae.
2867461|NCT03477058|Experimental|WO 3308 cosmetic product for topical use|WO 3308 is used to treat acute or chronic pruritus
2867462|NCT03477045|Active Comparator|Fish oil|Fish oil providing 450 mg of eicosapentaenoic acid plus docosahexaenoic acid per dose
2867463|NCT03477045|Experimental|Camelina seed oil|Camelina seed oil providing 450 mg of eicosapentaenoic acid plus docosahexaenoic acid per dose
2867464|NCT03477019|Experimental|Breast cancer target lesion|This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for breast cancer.
2867465|NCT03477019|No Intervention|Breast cancer control lesion|This arm will only receive treatment with conventional chemotherapy for breastcancer and microbubbles intravenously.
2867466|NCT03477019|Experimental|Colorectal cancer target lesion|This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for colorectal cancer.
2867467|NCT03477019|No Intervention|Colorectal cancer control lesion|This arm will only receive treatment with conventional chemotherapy for colorectal cancer and microbubbles intravenously.
2867468|NCT03477006|Experimental|LTLR-WB|Receiving 2 units of low titer, leucocyte reduced, platelet replete whole blood initiated in the prehospital setting during air medical transport and continued (up to 6 units of whole blood followed by standard component resuscitation) thru the early in-hospital phase of care
2867469|NCT03477006|No Intervention|Standard Care|Redeiving standard prehospital air medical care and standard of care component (1:1:1) trauma resuscitation thru the early in-hospital phase of care
2867470|NCT03476993|Experimental|BCD-085|All patients will receive BCD-085 (subcutaneous injection) in combination with ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day
2867471|NCT03476980|Active Comparator|Randomized to Umbilical Cord Milking at birth|Milking the umbilical cord towards the infant at a speed of 20cm/2seconds at birth.
2867472|NCT03476980|Active Comparator|Randomized to Delayed Cord Clamping at birth|Delayed clamping of the umbilical cord at birth.
2867473|NCT03476967||Pretreatment x Posttreatment|The group was evaluated through non-invasive complementary examinations before laser therapy and at the 1-year follow-up visit to analyze possible optical disc alterations that may occur after retinal panretinal photocoagulation in patients with proliferative diabetic retinopathy.
2867474|NCT03476941|Experimental|Antibiotic Irrigation|The drain will be irrigated twice/day with the above antibiotic solution for 7 days maximum
2867475|NCT03476941|Placebo Comparator|Normal Saline Irrigation|The drain will be irrigated twice/day with normal saline
2867476|NCT03476928|Experimental|Treatment Group A1|4 treatment periods of 12 weeks, each separated by 1 bleeding episode
2867477|NCT03476928|Experimental|Treatment Group A2|2 treatment periods of 24 weeks, separated by 2 bleeding episodes
2867478|NCT03476915||screened infants|Asymptomatic infants under age of 6 months, presenting to the pediatric orthopaedic outpatient clinic at Assiut university hospital for other problems will be subjected to ultrasound examination of the hip joint.
2867479|NCT03476902|Experimental|Integrated Mobile Treatment|Individuals will receive 4 introductory sessions with a therapist followed by weekly phone calls. Participants will utilize nOCD application to assist with treatment protocol adherence.
2867480|NCT03476889|Experimental|Intervention|Cows milk based infant formula containing fermented infant formula and prebiotic oligosaccharides
2867481|NCT03476889|Active Comparator|Control|Cows milk based infant formula containing prebiotic oligosaccharides (commercially available Aptamil ProNutra)
2867482|NCT03476889|No Intervention|Breastfed reference|Exclusively breastfed from birth to study completion
2867483|NCT03476876|Experimental|Dermacell|Subject will receive treatment for deep diabetic foot ulcer using Dermacell acellular matrix. Subject will be followed for 16 weeks post treatment.
2867484|NCT03476876|Active Comparator|Integra|Subject will receive treatment for deep diabetic foot ulcer using Integra acellular matrix. Subject will be followed for 16 weeks post treatment.
2867485|NCT03476863|Experimental|Alveolar Recruitment Maneuver|
2867486|NCT03476863|Active Comparator|Conventional mechanical ventilation|
2867487|NCT03476850|Active Comparator|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
2867488|NCT03476850|Active Comparator|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
2867489|NCT03476837|Experimental|Behavioral Treatment|Following baseline, the CHWs will deliver three doses of the intervention to the treatment (intervention) group over a 6-month period with follow-up at 12 months for all WCGs. At 1, 3, and 6 months, WCGs will receive motivational interviewing, educational materials and biofeedback based on the child's saliva sample.
2867490|NCT03476837|Active Comparator|Control|WCGs will receive educational materials in the mail at 1, 3, and 6 months.
2867491|NCT03476811|No Intervention|Control Group|Normal treatment paradigm (no anesthetic pump) with pain medications, only.
2867492|NCT03476811|Active Comparator|Marciano Group|Subcutaneous pain control with OnQ pump (0.25% Marcaine at 2ml/hr) and pain medications.
2867493|NCT03476811|Placebo Comparator|Placebo Group|OnQ pump with placebo (normal saline at 2ml/hr) and pain medications.
2867494|NCT03476798|Experimental|Bevacizumab + Rucaparib|
2867495|NCT03476785|Experimental|High Intensity Exercise|Subjects randomized to receive high intensity aerobic exercise will undergo exercise training for 1 year. A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded.
2867496|NCT03476785|Placebo Comparator|Yoga|Subjects randomized to yoga will receive instructions on strength and flexibility exercises.
2867497|NCT03476772||A|children undergoing hypospadius repair given 1 ml/kg of bupivicaine 0.25 % via caudal route to achieve post operative analgesia
2867498|NCT03476772||B|children undergoing hypospadius repair given 1 ml/kg of bupivicaine 0.25 % plus 0.1 mg nalbuphine via caudal route to achieve post operative analgesia
2867499|NCT03476759|Active Comparator|Tubal adhesiolysis|laparoscopic tubal adhesiolysis and\or tuboplasty
2867500|NCT03476759|Active Comparator|IVF/ICSI|These patients will undergo IVF/ICSI
2867501|NCT03476746|Experimental|LEO 90100 foam|"LEO 90100 foam (containing calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g).~Pilot part: 6 single applications of LEO 90100 foam on Day 1 (for 12 sites in total).~Pivotal part: To be decided based on the result of the pilot part"
2867502|NCT03476746|Active Comparator|Dovobet® ointment|"Pilot part: 6 single applications of Dovobet® ointment on Day 1 (for 12 sites in total).~Pivotal part: To be decided based on the result of the pilot part"
2867503|NCT03476733||patient with drug related problem|patient with drug related problem
2867504|NCT03476733||patient without drug related problem|patient without drug related problem
2867505|NCT03476707||Anemic|People with a preoperative hematocrit less than 0.39
2867506|NCT03476707||Non-anemic|People with a preoperative hematocrit greater than or equal to 0.39
2867507|NCT03476694|Experimental|20ml of 0.75% Ropivacine|
2867508|NCT03476694|Experimental|25ml of 0.75% Ropivacine|
2867509|NCT03476681|Experimental|NEO-201|Subjects will receive the assigned dose of NEO-201 intravenously, once every 2 weeks for a total of 4 doses (57 days). This course will be repeated in the absence of disease progression or unacceptable toxicity.
2867510|NCT03476668|Active Comparator|RPD PD patients|Right-side affected PD patients. Intervention: MIRT
2867511|NCT03476668|Active Comparator|LPD PD patients|Left-side affected (LPD) PD patients. Intervention: MIRT
2867512|NCT03476655||Participants with Chronic Lymphocytic Leukemia (CLL)|This study will collect retrospective data on effectiveness and outcome parameters for participants of CLL being managed with ibrutinib in the clinical practice. The primary data source for this observational study will be the medical records of each enrolled participant.
2867513|NCT03476655||Participants with Mantle Cell Lymphoma (MCL)|This study will collect retrospective data on effectiveness and outcome parameters for participants of MCL being managed with ibrutinib in the clinical practice. The primary data source for this observational study will be the medical records of each enrolled participant.
2867514|NCT03476642|Active Comparator|Ropivacaine with Epinephrine|Group RE will have 20mL of 0.5% Ropivacaine with epinephrine injected at the left or right T5 transverse process.
2867515|NCT03476642|Active Comparator|Ropivacaine without Epinephrine|Group R will have 20mL of 0.5% Ropivacaine without epinephrine injected at the left or right T5 transverse process.
2867516|NCT03476629|Experimental|Combined Training|Combined Training with 2 types of physical activity
2867517|NCT03476629|Experimental|Standard Training|Physical activity with aerobic exercise
2867518|NCT03476629|Experimental|Respiratory Muscle Training|Respiratory muscle performance
2867519|NCT03476616|Active Comparator|Eplerenone (-based therapy) arm|"Obese pts with hypertension, starting treatment with eplerenone 25mg twice daily (BD). ABPM wil be scheduled at wks 8, 16 and 24.~At wk 8 if mean ABPM < 130/80mm Hg will continue to monotherapy with eplerenone. If not controlled (mean ABPM > 130/80mm Hg) at wk8, amlodipine 5mg OD will be added.~At wk 16 if mean ABPM < 130/80mm Hg will continue to monotherapy with eplerenone, or dual therapy with eplerenone and amlodipine. If not controlled (mean ABPM > 130/80mm Hg) at wk16, indapamide 1,5mg OD will be added. All patients will be followed up for 24 weeks."
2867520|NCT03476616|Active Comparator|Valsartan (-based therapy) arm|"Obese pts with hypertension, starting treatment with valsartan 160mg once daily (OD). ABPM wil be scheduled at wks 8, 16 and 24.~At wk 8 if mean ABPM < 130/80mm Hg will continue to monotherapy with valsartan. If not controlled (mean ABPM > 130/80mm Hg) at wk8, amlodipine 5mg OD will be added.~At wk 16 if mean ABPM < 130/80mm Hg will continue to monotherapy with valsartan, or dual therapy with valsartan and amlodipine. If not controlled (mean ABPM > 130/80mm Hg) at wk16, indapamide 1,5mg OD will be added. All patients will be followed up for 24 weeks."
2867521|NCT03476590|No Intervention|standard care|In standard care group the patients will be recommended to visit physician/cardiologists in standard healthcare system. Two non-interventional visits will be performed: recruitment visit (day of enrolment) and summary visit (12th month after the enrolment)
2867522|NCT03476590|Experimental|intervention group|"In intervention group patients will be referred to ambulatory care point (ACP) and the physicians will perform remote teleconsultations. The visits will be realized by nurses supported with vital sign assessment based on bioimpedance diagnostic methods (impedance cardiography, bioimpedance scale). The ambulatory visits will be performed according to the schedule: (1') recruitment visit (1st day of enrolment) performed by physician -> 7 ambulatory visits: (1) 1st day of enrolment (performed by nurse and physician), (2) 7th-10th day (performed by nurse and physician), (3) 1st month, (4) 3th month, (5) 6th month, (6) 9th month, (7) 12th month after the enrolment (visits no 3-7 performed by nurse with tele-supervision by physician) and -> (7') summary visit (12th month after the enrolment) performed by physician.~The plan of visits may be modified if required by the clinical status change, i.e. deterioration of clinical parameters and interim hospitalizations for worsening heart failure."
2867523|NCT03476564|Experimental|intervention group|intervention group will receive pentoxifylline (Trental S.R.) 400 mg/BD plus vit E (PHARCO) 400 mg/BD 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled.
2867524|NCT03476564|No Intervention|comparison group|. The comparison group will not receive the above drugs. The main outcome measure will be clinical pregnancy rate.
2867675|NCT03475433||Beast cancer patients|All participants that suffer from breast cancer.
2867525|NCT03476499|Experimental|Planned skin flap procedure|"Inclusion Criteria: i. Planned skin flap procedure, ii. SpO2 above 96% and iii: Written informed consent.~Exclusion criteria: Use of epinephrine, patent blue V or methelyne blue during procedure.~The near infrared imaging NIR device is experimental. Experimental means that the NIR imaging is not used routinely in patients' care.~The research will require no extra study visits. Images will be taken at 3 - 4 time points and a separate photo consent will be obtained prior to imaging.~One set of pre-procedure images, NIR images will be taken prior to the start of the breast surgery.~One set of intra-operative Images that will be taken intra-operatively following the mastectomy.~One to two follow-up sets of NIR images will be taken at the standard post-op follow-up visits at 1 to 2 weeks post-op for up to 30 days post-op. Follow-up visits will be scheduled as per the standard of care."
2867526|NCT03476486|Experimental|Treatment|The hand that was subject to thread carpal tunnel release surgery
2867527|NCT03476486|No Intervention|Control|The hand that was not treated
2867528|NCT03476460|Experimental|Oral sodium chloride|Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, patients will take 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.
2867529|NCT03476460|Active Comparator|Intravenous sodium chloride|Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.
2867530|NCT03476447|Active Comparator|High dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a high dose per daily oral feeding
2867531|NCT03476447|Active Comparator|Medium dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a medium dose per daily oral feeding
2867532|NCT03476447|Active Comparator|Low dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a low dose per daily oral feeding
2867533|NCT03476447|Placebo Comparator|Lactose Placebo|10 participants will receive powdered lactose per daily oral feeding
2867534|NCT03476434|No Intervention|group A (HR-WLE)|Two tandem colonoscopies: first inspection was on high-resolution white-light endoscopy from the cecum/ileo-colonic anastomosis to the rectum, followed by a second inspection also on HR-WLE.
2867535|NCT03476434|Experimental|group B (HR_CE)|two tandem colonoscopies: first inspection was on HR-WLE from the cecum/ileo-colonic anastomosis to the rectum, followed by a second inspection with panchromoendoscopy on indigo carmine.
2867536|NCT03476421||R0 hepatectomy|Those HCC patients operated with standard R0 hepatectomy
2867537|NCT03476421||R1par hepatectomy|Those HCC patients operated with R1par hepatectomy
2867538|NCT03476421||R1vasc hepatectomy|Those HCC patients operated with R1vasc hepatectomy
2867539|NCT03476421||R1par+R1vasc hepatectomy|Those HCC patients operated with both R1par and R1vasc hepatectomy
2867540|NCT03476408|Experimental|Single Group Correlation|Correlation between these topics.
2867541|NCT03476382|Experimental|Experimental Group|Participants use active Ultrasound Bone Growth Stimulator device according to Investigational Protocol.
2867542|NCT03476369|Experimental|Fentanyl and Crushed Ticagrelor|Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered crushed (180 mg dose)
2867543|NCT03476369|Active Comparator|Fentanyl and Non-crushed Ticagrelor|Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered as a whole tablet (180 mg dose)
2867544|NCT03476356|Experimental|Group L|This group will receive oral clomiphene citrate (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle plus oral carnitine supplementation (Carnivita Forte, Eva Pharma, Egypt) (1g tablet, three times per day) from the third day of the cycle until the day of the pregnancy test.
2867545|NCT03476356|Active Comparator|Group C|This group will receive oral clomiphene citrate only (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle.
2867546|NCT03476343|Experimental|MRI for Neonates|MRI
2867547|NCT03476330|Experimental|Quercetin|All patients will be treated with oral quercetin for a total of 24 months.
2867548|NCT03476317|Experimental|Fluconazole|Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus fluconazole orally once daily (Day 1-14).
2867549|NCT03476317|Placebo Comparator|Placebo|Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus placebo.
2867550|NCT03476304|Experimental|Semi-direct composite endocrown restorations|
2867551|NCT03476304|Active Comparator|Post retained direct composite restoration|
2867552|NCT03476304|Active Comparator|Post retained ceramic restoration|
2867553|NCT03476291||Normal|normal macular structure of horizontal OCT B-scans
2867554|NCT03476291||Abnormal|abnormal macular structure of horizontal OCT B-scans, including many sub-categories of pathological features, like epiretinal membrane, pigment epithelium detachment, ect.
2867555|NCT03476278||regional|patients who underwent surgery under regional anesthesia.
2867556|NCT03476265|Experimental|Ineffective Esophageal Motility and GERD|Patients with gastroesophageal reflux disease (GERD) refractory to proton pump inhibitors (PPI) and ineffective esophageal motility (IEM) according to the Chicago classification v3.0.
2867557|NCT03476252|Experimental|patients|ST elevation myocardial infarction
2867558|NCT03476239|Experimental|blinatumomab|Approximately 120 Chinese adult subjects
2867559|NCT03476226|Experimental|Group 1|"The research team will provide the intervention to subjects. Intervention: The nursing-driven Cognitive Dysfunction Coping Strategy Teaching Sheet and provide education as to its use.~QOL survey administered"
2867560|NCT03476226|No Intervention|Group 2|Provide current standard of education for cognitive dysfunction. QOL survey administered
2867561|NCT03476213|Experimental|Group TCI|induction and anesthesia will be held by using target-controll infusion
2867563|NCT03476200|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy consisting of fourteen weekly group sessions, one hour and a half each, directed by two clinical psychologist.
2867564|NCT03476200|No Intervention|Control Group|Control Group with no intervention.
2867565|NCT03476187|Experimental|µCor wearers|Wear the µCor device
2867566|NCT03476174|Experimental|Pembrolizumab and HD Interleukin 2|Pembrolizumab 200 mg IV over 30 minutes; Day 1 of each cycle 3 weeks (21 days) for 2 cycles. IL-2 600,000 IU/kg2 IV over 15 minutes every 8 hours for up to 14 doses over 5 days; Days 1-5 = Cycle 1; 9 days of rest in between; Days 15-19 = Cycle 2
2867567|NCT03476161|Other|Group 1|"upper left and lower right 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive~upper right and lower left 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive"
2867568|NCT03476161|Other|Group 2|"upper right and lower left 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive~upper left and lower right 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive"
2867569|NCT03476148|Experimental|Interactive Device Rehabilitation|
2867570|NCT03476148|Active Comparator|Inpatient Rehabilitation|
2867571|NCT03476135|Experimental|MenACYW conjugate vaccine|Booster dose of meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine
2867572|NCT03476122||Disease Group|The disease group is diagnosed with colorectal cancer 0-4 and has not been treated.
2867573|NCT03476122||Control Group|The control group will receive Colonoscopy
2867574|NCT03476109|Active Comparator|Omalizumab|"Patients randomized to omalizumab and then prolonged or not (based on their response at 4 months) until the end of the study (22mo).~Non responders will be switched to mepolizumab arm."
2867575|NCT03476109|Active Comparator|Mepolizumab|"Patients randomized to mepolizumab and then prolonged or not (based on their response at 6 months) until the end of the study (22mo).~Non responders will be switched to omalizumab arm."
2867576|NCT03476096||Control|healthy pregnant women
2867577|NCT03476096||Pre-eclampsia|high-risk pregnant women
2867578|NCT03476083|Experimental|Group A|This is the experimental group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 14-16 and continue until delivery. The mothers will be followed together with their infants until postpartum week 28. Infants will receive hepatitis B vaccine at birth and additional hepatitis B (HBV) vaccine at the age of week 4 and week 24. HBIg will be omitted for the infants in this group.
2867579|NCT03476083|Active Comparator|Group B|This is the comparative group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 28 and continue until delivery. Patients in group B will have similar follow-up schedules as those in the experimental group. Infants will receive hepatitis B vaccine plus HBIg at birth and additional hepatitis B vaccine at the age of week 4 and week 24.
2867580|NCT03476070||AYA cancer patients|Patients (aged between 15-39) diagnosed with breast cancer, lymphoma or germ cell tumor
2867581|NCT03476070||Healthy controls|Healthy controls
2867582|NCT03476057||Advanced gastrointestinal tumor|200 patients with pathologically confirmed Advanced gastrointestinal tumor who never treated with chemotherapy at Fujian Cancer Hospital
2867583|NCT03476044|Active Comparator|Group Placebo|40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
2867584|NCT03476044|Active Comparator|Group Selenium|40 patients will receive Selenium (selenium NATURE'S BOUNTY, INC. Bohemia) 200 mcg orally with sips of water 2 hours before induction of general anesthesia
2867585|NCT03476031||study group|patients with hepatitis c nephropathy detected by lab and renal biopsy
2867586|NCT03476018|Placebo Comparator|Placebo|
2867587|NCT03476018|Experimental|0.2 microgram Z-100|
2867588|NCT03476018|Experimental|2 microgram Z-100|
2867589|NCT03476018|Experimental|20 microgram Z-100|
2867590|NCT03476005|Active Comparator|Proficiently Trained interns -|Provided with proficiency based progression training supported by technology enhanced learning
2867591|NCT03476005|No Intervention|Historical controls|no extra training provided
2867592|NCT03475992|Experimental|Pre-diagnosed breast cancer|"Low-power microwave breast imaging system.~Core needle biopsy performed at least 2 weeks before the microwave breast investigation"
2867593|NCT03475992|Experimental|Pre-diagnosed breast cyst|"Low-power microwave breast imaging system.~No prior biopsy"
2867594|NCT03475992|Experimental|Pre-diagnosed benign lesion|"Low-power microwave breast imaging system.~Core needle biopsy performed at least 2 weeks before the microwave breast investigation"
2867595|NCT03475966|Experimental|Prehabilitation|Exercise, nutrition and relaxation techniques all beginning four weeks prior to surgery date.
2867596|NCT03475966|Active Comparator|Rehabilitation|Exercise, nutrition and relaxation techniques all beginning immediately after surgery.
2867597|NCT03475953|Experimental|Phase 1 : Regorafenib + Avelumab|Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
2867598|NCT03475953|Experimental|Phase 2 : Regorafenib + Avelumab|Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
2867599|NCT03475914||Psoriasis vulgaris|Pathological conditions stable for at least 1 month before collection. One punch biopsy from each patient, was taken from a big reddish and scaly plaque and another punch biopsy from the perilesional healthy skin.
2867600|NCT03475914||Psoriasis guttate|One punch biopsy from each patient, was taken from a small reddish and scaly plaque and another punch biopsy from the perilesional healthy skin.
2867601|NCT03475914||Healthy skin of psoriasis vulgaris|Healthy skin area of 2mm2 belonging to the left gluteus from patients affected by psoriasis vulgaris
2867602|NCT03475914||Healthy skin of psoriasis guttate|Healthy skin area of 2mm2 belonging to the left gluteus rom patients affected by psoriasis guttate
2867603|NCT03475888|Active Comparator|Group A|Patients who have undergone a successful percutaneous CTO recanalization
2867604|NCT03475888|Active Comparator|Group B|Patients who have undergone a failed percutaneous CTO recanalization
2867605|NCT03475888|Active Comparator|Group C|Patients with an untreated CTO
2867606|NCT03475875|Experimental|TEST/CONTROL/CONTROL|Subjects that are of 18 years or older and current spherical soft contact lens wearers will wear the Test and Control lenses for two weeks each in random order with one of the study lenses being worn twice for a total of 6 weeks per subject.
2867607|NCT03475875|Experimental|CONTROL/TEST/TEST|Subjects that are of 18 years or older and current spherical soft contact lens wearers will wear the Test and Control lenses for two weeks each in random order with one of the study lenses being worn twice for a total of 6 weeks per subject.
2867608|NCT03475862|Experimental|PTI-821 Manipulated|oxycodone 40 mg capsule
2867609|NCT03475862|Active Comparator|Oxycodone|Oxycodone 40 mg IR tablet crushed
2867610|NCT03475862|Active Comparator|OxyContin|Oxycodone ER 40 mg tablet crushed
2867611|NCT03475862|Placebo Comparator|Placebo|Matching placebos for experimental and active comparator arms
2867612|NCT03475862|Experimental|PTI-821 Non-manipulated|Oxycodone 40 mg non-manipulated
2867613|NCT03475849||RYGB subjects|Morbidly obese patients who has undergone an uncomplicated gastric bypass surgery more than 12 months before study start.
2867614|NCT03475849||Control subjects|Age, sex and BMI-matched healthy controls
2867615|NCT03475849||SG subjects|Morbidly obese patients who has undergone an uncomplicated sleeve gastrectomy surgery more than 12 months before study start.
2867616|NCT03475836|Placebo Comparator|Placebo|Vegetable oil
2867617|NCT03475836|Active Comparator|High-dose mint essential oil|100 μL Mentha piperita essential oil (in vegetable oil)
2867618|NCT03475836|Active Comparator|Low-dose mint essential oil|50 μL Mentha piperita essential oil (in vegetable oil)
2867619|NCT03475823|Placebo Comparator|Placebo control|Inert comparator indistinguishable from active interventions
2867620|NCT03475823|Active Comparator|Active control|240 mg ginkgo biloba
2867621|NCT03475823|Experimental|Low dose sideritis scardica|475 mg sideritis scardica
2867622|NCT03475823|Experimental|High dose sideritis scardica|950 mg sideritis scardica
2867623|NCT03475810|Experimental|VR GROUP|Patients watches 3D documentary videos on virtual reality glasses
2867624|NCT03475810|Active Comparator|midazolam|Patients do not watch virtual reality videos but will be administered iv sedative drugs before spinal attempt.
2867625|NCT03475797|Experimental|Occipital Nerve Stimulation (ONS)|Occipital nerve stimulation with percutaneous or surgical lead plus optimal medical management
2867626|NCT03475797|Active Comparator|Optimal Medical Management (OMM)|Optimal Medical Management according to what is done in routine clinical practice
2867627|NCT03475784|Experimental|Restricted fluid therapy group|Restrictive fluid therapy: this group will not receive fluid pre-load, and will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 2mL/Kg/hour.
2867628|NCT03475784|Active Comparator|Liberal fluid therapy group|Liberal fluid therapy: this group will receive fluid pre-load (5 mL/Kg), and will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 6 mL/Kg/hour.
2867629|NCT03475758|No Intervention|chemotherapy without goserelin|these patients will receive their chemotherapy without addition of Goserelin
2867630|NCT03475758|Experimental|chemotherapy with goserelin|these patients will receive their chemotherapy with addition of Goserelin
2867631|NCT03475745||Aphasia|Post stroke aphasia patients without any additional interventions for research purposes.
2867632|NCT03475745||Control|Healthy controls
2867633|NCT03475732|Experimental|XueBiJing injection|100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days
2867634|NCT03475719|Active Comparator|HUG186-B and HUG186-D|Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)
2867635|NCT03475719|Experimental|HUG186|Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)
2867636|NCT03475706|Experimental|Solabegron immediate release tablets low dose|
2867637|NCT03475706|Experimental|Solabegron immediate release tablets high dose|
2867638|NCT03475706|Placebo Comparator|Placebo Comparator|
2867639|NCT03475693|Experimental|Treatment arm|Patients will receive PO magnesium 400 mg, Zofran 4 mgODT, and Tylenol 500 mg in the emergency department. They will then continue with 500 mg Tylenol BID and 400 mg MagOx tablets BID for the next 5 days. Symptom severity scores will be obtained and compared throughout this time as mentioned in the study design.
2867640|NCT03475693|Placebo Comparator|Placebo arm|Patients will receive PO Zofran 4 mgODT, and Tylenol 500 mg in the emergency department. They will then continue with 500 mg Tylenol BID for the next 5 days. Symptom severity scores will be obtained and compared throughout this time as mentioned in the study design.
2867641|NCT03475680|Experimental|"1)  MBP and oral antibiotics  group"|"Sennosides colonic preparation Oral Gentamycin Oral Ornidazole~Sennosides colonic preparation (X-PREP) :~1 per day, on day -2 and day -1.~Gentamycin :~80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials.~Ornidazole :~g per day (2 tablet per day), on day -2 and day -1; In tablets."
2867642|NCT03475680|Placebo Comparator|"2)  MBP alone  group"|"Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole~Sennosides colonic preparation (X-PREP) :~1 per day, on day -2 and day -1.~Placebo for oral gentamycin:~Same presentation as oral gentamycin x4 per day on day -2 and day -1. - Placebo for oral ornidazole : Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1."
2867643|NCT03475680|Experimental|"3)  Oral antibiotics alone  group"|"Oral Gentamycin Oral Ornidazole~Gentamycin :~80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials.~Ornidazole :~g per day (2 tablet per day), on day -2 and day -1; In tablets."
2867644|NCT03475680|Placebo Comparator|"4)  No preparation  group"|"Oral placebo Gentamycin Oral placebo Ornidazole~- Placebo for oral gentamycin : Same presentation as oral gentamycin x4 per day on day -2 and day -1~- Placebo for oral ornidazole : Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1"
2867645|NCT03475654|Experimental|technology-assisted rehabilitation|The experimental group will receive treatment as usual, in addition to training with the Jintronix platform. Participants will undergo their prescribed therapy regimen for 3 months, with outcomes follow-up to 12 months post-discharge.
2867676|NCT03475433||Prostate cancer patients|All participants that suffer from prostate cancer.
2867848|NCT03474237||Pheochromocytoma|patients who were diagnosed with pheochromocytoma biochemically or histologically
2867646|NCT03475654|Active Comparator|Usual care|The control group will receive treatment as usual, which includes a personalized home exercise program prescribed by a burn therapist, prior to hospital discharge. Participants will undergo their prescribed therapy regimen for 3 months, with outcomes follow-up to 12 months post-discharge.
2867647|NCT03475641|Active Comparator|The current standard anesthesia|Standard treatment during procedure
2867648|NCT03475641|Experimental|Femoral nerve blockade|Femoral nerve blockade added to the standard treatment.
2867649|NCT03475628|Experimental|Daratumumab|Daratumumab at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter.
2867650|NCT03475615|Experimental|SOXP|
2867651|NCT03475615|Active Comparator|SOX|
2867652|NCT03475602||Cyclophosphamide|Drug: Cyclophosphamide，CTX Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody
2867653|NCT03475602||Cyclosporin|Drug: Cyclosporin Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody
2867654|NCT03475589|Other|single group|
2867655|NCT03475576|Other|all participants|The intervention, offered to the older civilians and their informal care groups will consist of a updated version of the 'Keuzewijzer'. This is a self-management tool which stimulates the communication within the informal care groups to make behaved choices concerning the care for the older civilian, taking into account the standards, values, concerns and needs of every informal caregiver and older civilian.
2867656|NCT03475563||Patients with coronary artery disease|(coronary artery disease)
2867657|NCT03475550|Active Comparator|Standard of care 1|"Patients will receive one of 2 different descriptions of the medication's risks and benefits. Both descriptions meet ethical standards of transparency and respect for person and are commonly used but have never been compared. Standard of Care 1 includes more details than Standard of Care 2."
2867658|NCT03475550|Active Comparator|Standard of care 2|"Patients will receive one of 2 different descriptions of the medication's risks and benefits. Both descriptions meet ethical standards of transparency and respect for person and are commonly used but have never been compared. Standard of Care 2 includes fewer details than Standard of Care 1."
2867659|NCT03475537|Experimental|the treatment of vagus nerve stimulation|the treatment of vagus nerve stimulation by the neck without invasive. Based on the anatomy of the vagus nerve, single nerve stimulation can be used to affect many different organs and diseases. The end of the vagus nerve in the brain stem structure is called the nucleus tractus solitarius (NTS). 3 times a day, 2 minutes each time
2867660|NCT03475524|Experimental|study Metformin 1000 mg|
2867661|NCT03475524|Experimental|study Metformin 500 mg|
2867662|NCT03475524|Placebo Comparator|control group|
2867663|NCT03475485|Experimental|ID-Capsules- Active|"Randomly-assigned ingestions of ID-Capsules containing ingestible sensors (ID-Capsule- Active) while wearing the ID-Cap Reader (Wearable Sensor) under direct observation~• Subjects will ingest ID-Capsules containing the ingestible sensor which emits a signal from within the subject's stomach. This signal is detected by the wearable Reader, and the ingestion event is recorded."
2867664|NCT03475485|Placebo Comparator|ID-Capsules- Inactive|"Randomly-assigned ingestions of ID-Capsules containing no ingestible sensors while wearing the ID-Cap Reader under direct observation~• Subjects will also ingest empty placebo capsules that do not contain ingestible sensors. In the absence of an ingested sensor, no signal is received by the Reader after the capsule is ingested, and the ingestion event is not recorded."
2867665|NCT03475459|Experimental|study drug|Study drug (NPC-15 and/or Placebo ) will be orally administered once with 200 ml of water at 20:00 on the first days of Period I, Period II and Period III.
2867666|NCT03475446|Placebo Comparator|sham tES healthy elderly|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
2867667|NCT03475446|Placebo Comparator|sham tES MCI|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
2867668|NCT03475446|Placebo Comparator|sham tES AD|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
2867669|NCT03475446|Experimental|real anodal tDCS healthy elderly|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
2867670|NCT03475446|Experimental|real anodal tDCS MCI|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
2867671|NCT03475446|Experimental|real anodal tDCS AD|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
2867672|NCT03475446|Experimental|real tACS healthy elderly|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
2867673|NCT03475446|Experimental|real tACS MCI|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
2867674|NCT03475446|Experimental|real tACS AD|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
2867677|NCT03475420||National Cancer Database|Use existing data to define surveillance strategy in use for patients in this cohort. We will use 10 randomly selected lung cancer resection patients from each accredited institution with stage I-III NSCLC (potentially curative resection) diagnosed in 2006-2007 and with 5 years of complete follow up or reported as deceased before 2012.
2867678|NCT03475407|Experimental|Treatment Group|Ozurdex intravitreal injection
2867679|NCT03475394|Active Comparator|Group 1 (Chlorhexidine gel)|Non surgical periodontal treatment at baseline and 0.1 ml of 1% chlorhexidine gel administered in subsequent visits.
2867680|NCT03475394|Experimental|Group 2 (Morus alba gel)|Non surgical periodontal treatment at baseline and 0.1 ml of 16% Morus alba gel administered in subsequent visits.
2867681|NCT03475381||Orkambi treated patients|All patients with CF who started ivacaftor+lumacaftor outside of a clinical trial between January 22nd 2016 and January 22nd 2017.
2867682|NCT03475368|Experimental|Vegetarian diet|People randomized to interventional groups will take a vegetarian diet (i.e. without animal products, except milk and eggs)
2867683|NCT03475368|Experimental|Low carbs|People randomized to interventional groups will take a low carbs diet (i.e. with a limited amount of carbohydrates).
2867684|NCT03475368|Active Comparator|Mediterranean diet|People randomized to interventional groups will take a mediterranean diet (i.e. with low glycemic index carbohydrates and vegetables).
2867685|NCT03475355|Experimental|EG1|Each patient will be instructed to carefully observe the finalized movement of the upper limb of an experimenter seated in front (the experimenter's left hand is right in front of the patient's right hand), without moving or imagining the movement.
2867686|NCT03475355|Experimental|EG2|Each patient will be instructed to look at a computer screen that is in front of him that will show a daily routine task (actions).
2867687|NCT03475355|Experimental|EG3|Each patient will be instructed to carefully observe the finalized movement performed by an experimenter standing in front of him (the examiner's left leg will be in front of the patient's right leg).
2867688|NCT03475355|Experimental|EG4|Each patient will be instructed to look at a computer screen that is in front of him that will show a daily routine task (actions).
2867689|NCT03475355|Active Comparator|CG1|"Participants will be shown for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. For each CGail patient condition a sequence of images will be presented for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, will be displayed together with an intrusive image (intruder) that the patient will be asked to identify so that his attention span can be controlled in real time. Participants will then be invited to perform movements of the limbs as far as possible for 2 minutes according to a standard sequence that involves articular mobilizations of upper limbs and simulates that performed by the experimental groups."
2867690|NCT03475355|Active Comparator|CG2|"Participants will be shown for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. For each CGail patient condition a sequence of images will be presented for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, will be displayed together with an intrusive image (intruder) that the patient will be asked to identify so that his attention span can be controlled in real time. Participants will then be invited to perform movements of the limbs as far as possible for 2 minutes according to a standard sequence that involves articular mobilizations of lower limbs and simulates that performed by the experimental groups."
2867691|NCT03475342|Active Comparator|Tranexamic acid|One intravenous injection of tranexamic acid. Total dose 1 gram (10mL)
2867692|NCT03475342|Placebo Comparator|Placebo|One Injection of the placebo which is 10 mL Sodium Chloride (0.9%)
2867693|NCT03475329||adenoidectomy with bilateral partial tonsillectomy|
2867694|NCT03475329||adenoidectomy with complete unilateral tonsillectomy|
2867695|NCT03475316|Experimental|Social Dancing|The program includes Fox-trot, Waltz, and Latin dances.
2867696|NCT03475316|Active Comparator|Treadmill Walking|The treadmill walking training protocol is based on the recommendations of the American College of Sports Medicine (ACSM) and American Heart Association (AHA) for older adults.
2867697|NCT03475303|Experimental|early hospital discharge|women will be discharged early from hospital 12 hours postoperatively after elective cesarean sections.
2867698|NCT03475290|Experimental|Self-Efficacy and Perceived Social Support|
2867699|NCT03475290|Experimental|Perceived Social Support and Self-Efficacy|
2867700|NCT03475290|Active Comparator|Self-Efficacy|
2867701|NCT03475290|Active Comparator|Perceived Social Support|
2867702|NCT03475277||Volunteers|"Participants will receive an IV infusion of ketamine (~.05mg/kg and 0.5mg/kg) or placebo.~Ketamine is an FDA-approved dissociative anesthetic. The study doses are in the subanesthetic range. During the infusion, an ACLS-certified psychiatrist or anesthesiologist will provide continuous monitoring.~Afterwards, patients will be monitored on-site by an ACLS-certified MD or highly skilled research nursing staff, and an on-call emergency response team for 4 hours (ketamine's half-life is 15 min; 4 hrs= 16 half-lives)."
2867703|NCT03475264||Healthy|Healthy Participants
2867704|NCT03475264||BPD cohort|Participants born prematurely with a diagnosis of BPD
2867705|NCT03475264||Non-BPD cohort|Participants born prematurely without a diagnosis of BPD
2867706|NCT03475251|Experimental|CS1003|
2867707|NCT03475238||Cohort for nursing care|Patients in ICU under oxygen and/or mechanical ventilation and/or vasoactive drugs and/or non-invasive ventilation
2867708|NCT03475225|Experimental|Experimental Arm|Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level <30ng/ml) Cholecalciferol. 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 6 months
2867709|NCT03475225|Placebo Comparator|Control Arm|Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level<30ng/ml) Placebo than cholecalciferol. 5 doses of placebo in 3 months than 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 3 months.
2867738|NCT03475043|No Intervention|Passive control group|Listeners will be evaluated on pre-training and post-training tests, but will receive no training at all.
2867739|NCT03475030|No Intervention|Usual Care|Patients receive usual care and can continue using their existing pharmacy.
2867710|NCT03475212|Experimental|Virus specific T cell lines (VSTs) against three viruses|The study will evaluate whether partially-HLA matched allogeneic multivirus-specific VSTs, activated using overlapping peptide libraries spanning immunogenic antigens from CMV, adenovirus and EBV, will be safe and produce anti-viral effects in immunodeficient recipients infected with one of more of the targeted viruses that are persistent despite conventional anti-viral therapy.
2867711|NCT03475199|Experimental|FabLife group|Fablife personnalised support and telephone follow-up with a dietician.
2867712|NCT03475199|No Intervention|Control group|General dietary recommendations.
2867713|NCT03475186|Experimental|Ramipril|Ramipril will be taken once daily by mouth. It will be titrated during the first 3 weeks of chemoradiation to the highest tolerable dose (2.5-5 mg). This dose will be taken each day until 4 months post-chemoradiation treatment (22 weeks).
2867714|NCT03475160|Active Comparator|Sildenafil Citrate|Sildenafil Citrate vaginal suppositories: 25 mg every 6 hours. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
2867715|NCT03475160|Placebo Comparator|Placebo|Placebo vaginal suppositories: every 6 hours. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
2867716|NCT03475147|Active Comparator|eyeFusion Control Subjects|Healthy normal controls with no known eye disorders age 18-80.
2867717|NCT03475147|Experimental|eyeFusion Patients|Scotoma subjects aged 18-80.
2867718|NCT03475134|Experimental|TIL-ACT +/- Nivolumab rescue|Non-myeloablative lymphodepleting chemotherapy (cyclophosphamide and fludarabine), Tumor Infiltrating Lymphocyte (TIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2), Nivolumab rescue
2867719|NCT03475121|Experimental|Low Risk Patients|Patients with IRSS stage I, pT1, pT2 and pT3 stage will not receive adjuvant therapy
2867720|NCT03475121|Experimental|Higher Risk Patients|Patients with IRSS stage I, pT3b, pT3c, pT3d will receive 6 cycles of adjuvant chemotherapy plus 6 doses of intrathecal topotecan
2867721|NCT03475121|Experimental|Stage II Patients|Patients with Stage II (pT4) will receive 6 cycles of adjuvant chemotherapy plus 6 doses of intrathecal topotecan and orbital radiotherapy
2867722|NCT03475121|Experimental|Patients with buphthalmus|Patients with buphthalmus (cT3c, cT3e) will receive 2 cycles of neo-adjuvant chemotherapy plus 6 doses of intrathecal topotecan followed by secondary enucleation and 6 cycles of adjuvant chemotherapy.
2867723|NCT03475108|Experimental|Community Health Worker Group|Patients are assigned a community health worker for one year, in addition to standard diabetes care.
2867724|NCT03475108|No Intervention|Standard Diabetes Care Group|Patients receive standard diabetes care.
2867725|NCT03475095|Experimental|LDH patients|"ribs and bones Tuina therapy According to the diagnostic criteria ofvertebral dislocation,determine the position,degree and direction of the dislocation,assess the activity of the affected vertebrae.Treated with combining Tuina of muscle-loosing and bone-setting such as reinforcing ribs，kneading and plucking method,20 min every treatment,twice a week for a total time of 4 weeks."
2867726|NCT03475082|Placebo Comparator|Placebo TENS|30 minute TENS treatment where the stimulation ramps slowly to zero after 45 seconds. The lights/display on the unit are identical to the Active unit.
2867727|NCT03475082|Active Comparator|High Frequency TENS|30 minute TENS treatment at 100 HZ. Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
2867728|NCT03475082|Active Comparator|Alternating frequency TENS|30 minute TENS treatment with a pre programed mode alternating from 4 Hz and 100 HZ. Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
2867729|NCT03475082|Active Comparator|Modulated frequency TENS|30 minute TENS treatment at a pre programmed mode that ramps between 4 and 125 HZ over 12 seconds. Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
2867730|NCT03475082|Active Comparator|High frequency TENS - increasing intensity|30 minute TENS treatment at 100 HZ. Intensity set at initial strong but comfortable setting on day one as above, then subjects asked for possible increases in intensity every 5 minutes on all five days.
2867731|NCT03475069|Experimental|Individual intervention|This exercise program was prepared specific to each patient in this group according to his/her physiotherapy assessment, functional performance tests and body analysis results. This exercise type focuses on patients' physical demands. Exercises were applied by a researcher physiotherapist.
2867732|NCT03475069|Experimental|Plates intervention|Plates exercises were applied as a group treatment. This exercise type contains non-impact exercises to develop strength, flexibility, balance, and inner awareness.Plates exercises were applied as a group treatment. Exercises were applied by a researcher physiotherapist.
2867733|NCT03475069|Experimental|Chalistenics intervention|These exercises included range of motion exercises of neck (flexion, extension, lateral flexion and rotation), shoulder (flexion, extension, abduction, adduction, internal and external rotation), elbow (flexion and extension), forearm (pronation and supination), wrist (flexion and extension), hip (flexion, extension, abduction and adduction, internal and external rotation), knee (flexion and extension), foot (dorsi and plantar flexion, pronation and supination) and trunk (flexion, extension, lateral flexion and rotation). Exercises were applied by a researcher physiotherapist.
2867734|NCT03475056|Experimental|cAd3-Marburg vaccine at 1x10(10) PU dose|Twenty (20) subjects enrolled in Group 1 will receive a 1x10(10) PU dose of cAd3-Marburg vaccine administered intramuscular (IM) with needle and syringe in a volume of 1 mL.
2867735|NCT03475056|Experimental|Ad3-Marburg vaccine at 1x10(11) PU dose|Twenty (20) subjects enrolled in Group 2 will receive a 1x10(11) PU dose of cAd3-Marburg vaccine administered intramuscular (IM) with needle and syringe in a volume of 1 mL.
2867736|NCT03475043|Experimental|Auditory training: temporal contrasts|Listeners will hear target acoustic stimuli that vary in a temporal (timing/duration) cue for 9, 1-hour training sessions and will receive correct-answer feedback.
2867737|NCT03475043|Active Comparator|Auditory training: non-temporal contrasts|Listeners will hear target acoustic stimuli that vary in either stimulus intensity or stimulus frequency during 9, 1-hour training sessions and will receive correct-answer feedback.
2868719|NCT03468348|Placebo Comparator|placebo group|
2867740|NCT03475030|Active Comparator|Conventional Pillbox|Patients receive usual care, continue using their existing pharmacy, and are provided with a conventional pillbox to manage their medications.
2867741|NCT03475030|Experimental|Smart Pillbox|Patients receive pre-filled medication trays from Curant Health Pharmacy or the Brigham and Women's Hospital Outpatient Pharmacy. The smart pillbox in which pre-filled medication trays are housed provide automated medication reminders.
2867742|NCT03475017|Active Comparator|Supplement A|Administration of 3 capsules with 500mg of curcumin and piperine per day, for 12 weeks
2867743|NCT03475017|Placebo Comparator|Supplement B|Administration of 3 capsules with 500mg of placebo (maize starch) per day, for 12 weeks
2867744|NCT03475004|Experimental|Combination Therapy|"Cohort A: Patients will start with 7-day run-in of binimetinib on day -7 of cycle 1 only. Pembrolizumab and bevacizumab will then be added to binimetinib on cycle 1 day +1. Cycle 1 will end on day 21. Patients will start treatment with pembrolizumab, binimetinib, and bevacizumab on day 1 of all subsequent cycles.~Cohort B: Patients will be treated with pembrolizumab, bevacizumab, and binimetinib together on day 1 of all cycles including cycle 1. Patients will start treatment with pembrolizumab, binimetinib, and bevacizumab on day 1 of all subsequent cycles."
2867745|NCT03474991|Active Comparator|Celestamine® N 0.5|oral betamethasone solution, once daily for two consecutive days at 0.1-0.2 mg/kg
2867746|NCT03474991|Placebo Comparator|Placebo|oral placebo matched to the product described above
2867747|NCT03474978|Experimental|Upper Extremity Insertion|Peripherally Inserted Central Venous Cather (PICC) inserted in upper extremity
2867748|NCT03474978|Experimental|Lower Extremity Insertion|Peripherally Inserted Central Venous Cather (PICC) inserted in lower extremity
2867749|NCT03474965|Experimental|Crizanlizumab|SEG101 (crizanlizumab) drug administered at a dose of 5.0 mg/kg on Week 1 Day 1, Week 3 Day 1 and Day 1 of every 4-week cycle.
2867750|NCT03474952|Experimental|Remote ischemic preconditioning (RIPC)|Intervention is remote ischemic preconditioning (RIPC) consists of 4 cycles of 5-min ischemia (using pneumatic cuff pressure of 200 mmHg) and subsequent 5-min reperfusion applied to upper arm.
2867751|NCT03474952|Sham Comparator|Control (Sham-RIPC)|Intervention is Sham-RIPC (ischemia pressure < 10 mmHg) applied to upper arm.
2867752|NCT03474939|Active Comparator|MIDAZOLAM|Patients receive midazolam 7,5mg night before and 60 minutes prior to surgery as part of preanesthetic medication
2867753|NCT03474939|Placebo Comparator|PLACEBO|Patients receive 1000mg Glucose tablets night before and 60 minutes prior to surgery during premedication
2867754|NCT03474926|Experimental|Routine lymph node dissection (LND) during nephroureterectomy|"Template-based LND was carried out in all patients in this group. The anatomical extent of LND is described in previous study. Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
2867755|NCT03474926|Active Comparator|LND for lymph nodes enlargement found before or during surgery|LND was carried out only in patients who have lymph nodes enlargement in preoperative imaging (CTU or enhanced MRI) or who were found lymph nodes enlargement during surgery.
2867756|NCT03474913|Active Comparator|Upright MRI first, Standard MRI second|People randomized to have the upright MRI first and the standard MRI second
2867757|NCT03474913|Active Comparator|Standard MRI first, Upright MRI second|People randomized to have the standard MRI first and the Upright MRI second
2867758|NCT03474900|Experimental|PLGA implant, Bioretec ltd. Finland|Treatment with biodegradable elastic stable intramedullary nail in unstable forearm shaft fracture in paediatric population
2867759|NCT03474900|Active Comparator|Titanium elastic stable nail|Treatment with titanium elastic stable intramedullary nail in unstable forearm shaft fracture in paediatric population
2867760|NCT03474887||DIGI-Throat|Patients choosing to seek primary care through an online consultation with chief complaint sore throat.
2867761|NCT03474887||DIGI-Resp|Patients choosing to seek primary care through an online consultation with chief complaint cough/common cold/influenza.
2867762|NCT03474887||DIGI-Dysuria|Patients choosing to seek primary care through an online consultation with chief complaint dysuria.
2867763|NCT03474887||PHYSI-Throat|Patients choosing to seek primary care through physical consultation with chief complaint sore throat.
2867764|NCT03474887||PHYSI-Resp|Patients choosing to seek primary care through physical consultation with chief complaint cough/common cold/influenza.
2867765|NCT03474887||PHYSI-Dysuria|Patients choosing to seek primary care through physical consultation with chief complaint dysuria
2867766|NCT03474887||CONTROL-Throat|Patients seeking primary care prior to implementation of online consultations, with a chief complaint of sore throat.
2867767|NCT03474887||CONTROL-Resp|Patients seeking primary care prior to implementation of online consultations, with a chief complaint of cough/common cold/influenza.
2867768|NCT03474887||CONTROL-Dysuria|Patients seeking primary care prior to implementation of online consultations, with a chief complaint of dysuria.
2867769|NCT03474861|Experimental|Combination therapy|The subjects will be given combination therapy which consists of an anticancer medication (A01) and immune cells (IC01).
2867770|NCT03474848|Experimental|HABIT|Protocol of 90-hour of Hand-Arm Bimanual Intensive Training - 6 hours/day; 5 days/week, for 3 weeks
2867771|NCT03474848|Active Comparator|Conventional Occupational Therapy (OT)|Provision of 2 sessions/week (45 minutes), for 3 weeks
2867772|NCT03474835|Other|ISCHEMIC HEART DISEASE and PROSTATE ADENOCARCINOMA|
2867773|NCT03474835|No Intervention|ISCHEMIC HEART DISEASE and PROSTATE hyperplasia|
2867774|NCT03474822|Experimental|Blood-stage infection of P.vivax|This is a single arm study that plans to enroll 30 patients in each type cancer and each patient will be vaccinated with P.vivax-infected red blood cells containing approximately 0.3-1.0 × 10^7 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.
2867775|NCT03474796|Experimental|Novice|
2867776|NCT03474796|Experimental|Expert|
2867777|NCT03474783|Experimental|multidisciplinary intervention|
2867846|NCT03474263|Experimental|IC14 (monoclonal anti-CD14 antibody)|Biologic: IC14 (monoclonal anti-CD14 antibody) 4 mg/kg intravenously followed by IC14 2 mg/kg intravenously on Days 2-4. This four-day cycle will be repeated on Days 8-11.
2868720|NCT03468348|Active Comparator|duloxetine 30|
2867778|NCT03474770|Experimental|BIS-001ER|Dose administration for each participant will begin at 0.25mg b.i.d. escalating sequentially every 4 days to a maximum tolerated dose or target dose of 1.75mg b.i.d. Upon reaching the target dose or maximum tolerated dose, participants will maintain that dose for the balance of the 1 month out-patient titration period, after which they will begin a 96-hour in-patient video EEG monitoring treatment period.
2867779|NCT03474757||SPAF patients in Colombia_Rivaroxaban|First time users of rivaroxaban in the Audifarma database
2867780|NCT03474757||SPAF patients in Colombia_Dabigatran|First time users of dabigatran in the Audifarma database
2867781|NCT03474757||SPAF patients in Colombia_Apixaban|First time users of apixaban in the Audifarma database
2867782|NCT03474744|Experimental|Experimental Arm|Copanlisib 60 mg i.v. fixed dose days 1,8,15 Rituximab 375 mg/m2 day 1 i.v.
2867783|NCT03474731|Experimental|Diabetes Self Management Program only|group education classes of the Diabetes Self-Management Program, (DSMP)
2867784|NCT03474731|Experimental|Tailored Patient Navigation (PN) only|assisting patients in navigation to physician offices, allowing for standard of care to follow.
2867785|NCT03474731|Experimental|DSMP AND Tailored Patient Navigation|Both group education classes and patient navigation
2867786|NCT03474718|Experimental|Group A|At the baseline visit subjects will be randomized to either group A or group B. Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
2867787|NCT03474718|Experimental|Group B|At the baseline visit subjects will be randomized to either group A or group B. Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
2867788|NCT03474705|Experimental|Eccentric Training Group|Eccentric training of the upper trapezius muscles. The intervention will consist of ten sessions of 25-30 minutes (twice a week over 5 consecutive weeks) of eccentric exercises of the shoulder muscles, as neural activation increases after 4 weeks of eccentric training. The total duration of the intervention will be 2 hours and a half.
2867789|NCT03474679|Experimental|Ibrutinib|Participants will receive 420 milligram (mg) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
2867790|NCT03474666|Active Comparator|Strict Glycemic Control Group|Intravenous insulin as described by Keegan and Cols. 2010.
2867791|NCT03474666|Active Comparator|Standard Glycemic Control Group|Subcutaneous insulin as instititional protocol.
2867792|NCT03474653||Latitude 1 (Bulking)|Women with first line stress incontinence who choose to have Bulkamid as a treatment
2867793|NCT03474653||Latitude 2 (Choice)|Women with first line stress incontinence who choose to have any treatment including Bulking.
2867794|NCT03474640|Experimental|TAB001 80 mg repeat dose every 14 days|3-6 subjects
2867795|NCT03474640|Experimental|TAB001 240 mg repeat dose every 14 days|3-6 subjects
2867796|NCT03474640|Experimental|TAB001 480 mg repeat dose every 14 days|3-6 subjects
2867797|NCT03474627|Active Comparator|Non-coated HA/TCP particles|Biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
2867798|NCT03474627|Experimental|PLGA-coated HA/TCP particles|Biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
2867799|NCT03474614|Experimental|treatment group|A Treatment group of ten (n=10) patients that will receive oral propranolol at a dose of 60mg per day (one 60mg ER capsule per day) for 7- to 10-days prior to surgery plus their usual medications.
2867800|NCT03474614|Other|Control Group|A control group of 10 (n=10) patients will receive only their routine medications (no propranolol) during the (-7 to -10 days) preoperative period. A control group (n=10) is required to allow for a semi-quantitative comparison with mRNA and miRNA levels in the treatment group.
2867801|NCT03474601||Acromegaly|Patients diagnosed with acromegaly
2867802|NCT03474601||Cushing's disease|Patients diagnosed with Cushing's disease
2867803|NCT03474601||Hyperprolactinemia/prolactinomas|Patients diagnosed with hyperprolactinemia/prolactinoma
2867804|NCT03474601||Pituitary stalk lesions|Patients diagnosed with pituitary stalk lesions
2867805|NCT03474601||Nonfunctioning pituitary adenomas|Patients diagnosed with nonfunctioning pituitary adenomas
2867806|NCT03474601||Central diabetes insipidus|Patients diagnosed with central diabetes insipidus
2867807|NCT03474601||Craniopharyngioma|Patients diagnosed with craniopharyngiomas
2867808|NCT03474601||Others|Patients diagnosed with other suprasellar/parasellar lesions
2867809|NCT03474588|Active Comparator|Standard Treatment (ST)|"This is the same as the treatment normally received at this clinic. This will be tailored to participants' needs, but generally includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as:~Teaching about the treatment program~Teaching important ideas about recovery~Increasing knowledge about specific problems about addiction~Demonstrating new ways of coping with skills designed to fit each participant"
2867810|NCT03474588|Experimental|2. Standard treatment (ST) PLUS web-based CBT4CBT|"This is the same as the treatment normally received at this clinic. This will be tailored to participants' needs, but generally includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as:~Teaching about the treatment program~Teaching important ideas about recovery~Increasing knowledge about specific problems about addiction~Demonstrating new ways of coping with skills designed to fit each participant PLUS~Participants will have access the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on."
2867811|NCT03474575|Other|COPD patient|Prevention of re-hospitalization rate for Early supported discharge and enhanced homecare to patient admited for COPD exacerbation
2867812|NCT03474562|Experimental|Duowell Tab|Telmisartan 40mg/Rosuvastatin 20mg qd for 24 weeks
2867813|NCT03474562|Active Comparator|Monorova Tab + Amlopin Tab|Rosuvastatin 20mg + Amlodipine 5mg qd for 24 weeks
2867814|NCT03474549|Experimental|Tigertriever revascularization device|Mechanical thrombectomy with Tigertriever
2867847|NCT03474237||Non-functioning adrenal incidentaloma|patients who were diagnosed with non-functioning adrenal incidentaloma on computed tomography or magnetic resonance imaging
2867815|NCT03474523|Experimental|Experimental or Diathermy-Radiofrecuency|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Diathermy-Radiofrecuency (manual 70% intensity of about 40-43º resistive modality for about 30 minutes and authomatic capacitive modality for about 10 minutes) and application of Presotherapy (intensity 35%, compression 35seg, pause 15 seg, speed 9, for about 30 minutes). Non-invasive treatment
2867816|NCT03474523|Active Comparator|Control or Cavitation|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Cavitation (plane electrode for about 30 minutes and focal electrode for about 10 minutes) at 70% intensity and application of Presotherapy (intensity 35%, compression 35seg, pause 15 seg, speed 9, for about 30 minutes). Non-invasive treatment
2867817|NCT03474510|Experimental|EXPAREL|Those patients randomized to receive LIA of EXPAREL will have 266mg EXPAREL diluted to 100mL, and drawn into (5) 20mL syringes affixed with (5) 22-gauge needles. Investigators will administer the syringes to the tissue in small increments with the plunger held steady while withdrawn from the tissue to avoid saturating the area around the needle sticks since EXPAREL doesn't readily travel through the tissue.
2867818|NCT03474510|Active Comparator|interscalene nerve block|Patients will then receive 0.2% preservative-free ropivacaine at 8mL/hr beginning at the conclusion of surgery and delivered for approximately 50 hours (or finish of 400mL) via elastomeric infusion system (OnQ Pain Relief System: Select A Flow, Kimberly-Clark Corporation, Roswell, Georgia). Patients are instructed prior to discharge how to pull the catheters at home. Patients may also return to surgeon's office for catheter removal once the pain ball is empty if they prefer.
2867819|NCT03474497|Experimental|Pembrolizumab/IL-2/Radiotherapy|All patients will receive pembrolizumab and intralesional IL-2 in combination with hypofractionated radiotherapy.
2867820|NCT03474484||np-AECOPD|Patients with evidence of acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) and pulmonary infiltrate on chest X -ray at admission
2867821|NCT03474484||p-AECOPD|Patients with evidence of acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) without pulmonary infiltrate on chest X -ray at admission
2867822|NCT03474471|Experimental|Group 1:PR-EBV treatment|Follow a Pulmonary rehabilitation program PRIOR to the EBV treatment
2867823|NCT03474471|Experimental|Group 2: EBV treatment-PR|Follow a Pulmonary rehabilitation program AFTER the EBV treatment
2867824|NCT03474471|Active Comparator|Group 3: EBV treatment|Only EBV treatment
2867825|NCT03474458|Experimental|Experimental intervention|doxycycline (100 mg bid)
2867826|NCT03474458|Active Comparator|Control intervention|Standard of care therapy
2867827|NCT03474445|Active Comparator|Control group|Volar Plate Osteosynthesis Aptus 2.5
2867828|NCT03474445|Active Comparator|Study Group|Volar Plate Osteosynthesis Inteos 2.5
2867829|NCT03474432|Other|Optical Coherence Tomography|Patients who have undergone clinically-indicated PCI of LM where OCT was performed as part of the routine index procedure will be approached for the study and enrolled if eligible.
2867830|NCT03474393|No Intervention|Normal diabetes care|Continue with their normal diabetes care. Come in for control visits
2867831|NCT03474393|Experimental|Systematic intensive therapy|Intensive Internet and telephone contact for 4 months and Control visits
2867832|NCT03474380|Experimental|Intervention|"Implementation of iHI-FIVES program~Intervention: Behavioral: iHI-FIVES"
2867833|NCT03474380|No Intervention|Usual Care|Pre-implementation before iHI-FIVES program
2867834|NCT03474367||Unplanned Peritoneal Dialysis|CKD patients stage 5 (eGFR < 15 ml/min/1,73m²) or stages 4 with abrupt worsening requiring dialysis treatment immediately followed or not by nephrologists prior to renal replacement therapy (RRT) indication that agree to initiate PD in less than 48 hours after implantation of the peritoneal catheter, without family training or adequacy of the home and don't have any absolute contraindications. Absolute contraindication to the PD method are: presence of recent abdominal surgery (less than 30 days); multiple previous abdominal surgery (more than two); presence of fibrosis or peritoneal adhesions; fungal peritonitis; severe respiratory insufficiency (FiO2> 70%); abdominal infections; severe hyperkalemia with changes characteristic in ECG; and acute pulmonary edema. These patients will be treated with HD.
2867835|NCT03474367||Unplanned Hemodialysis|CKD patients stage 5 (eGFR < 15 ml/min/1,73m²) or stages 4 with abrupt worsening requiring dialysis treatment immediately followed or not by nephrologists prior to RRT indication that agree to initiate HD without a functional arteriovenous fistula, ie, with a central venous catheter (nontunneled or tunneled).
2867836|NCT03474341||Resectable esophageal squamous cell- or adenocarcinoma|"Patients (>18 years) with potentially resectable locally advanced squamous cell- or adenocarcinoma of the esophagus or gastroesophageal junction, receiving nCRT according to the CROSS regimen prior to surgery.~CROSS regimen: weekly carboplatin (doses titrated to achieve an area under the curve of 2 mg per milliliter per minute) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions, delivered 5 days per week on workdays with intensity modulated radiotherapy, including photon and proton therapy)"
2867837|NCT03474328|Experimental|Treatment arm|
2867838|NCT03474315||CHF and CIED patients|600 CHF patients with ICD or CRT admitted to regulatory ambulatory visit.
2867839|NCT03474302|Experimental|Physical Activity|The intervention will be a 12-week community-based physical activity promotion program
2867840|NCT03474302|Active Comparator|Successful Aging|Those randomized to the successful aging group will receive health information pertinent to African Americans over the 12 weeks
2867841|NCT03474289|Experimental|Escalation|SHR-1316 administrated intravenously(IV) at protocol defined dose levels
2867842|NCT03474289|Experimental|Expansion|SHR-1316 administrated IV in advanced solid tumors and selected tumor type
2867843|NCT03474276|Active Comparator|Control group|"Fortified Blended Flour (in association with a single dose of Albendazole at inclusion for children older than 12 months).~200 grams / day for children between 6 and 11 months. 300 grams / day for children aged from 12 to 24 months old."
2867844|NCT03474276|Active Comparator|Azythromycin|Fortified Blended Flour (in association with a single dose of Albendazole at inclusion for children older than 12 months) associated to Azythromycin, 20mg/kgs/days during the three first days of the study.
2867845|NCT03474276|Active Comparator|Prebiotic|Fortified Blended Flour mixed with Inuline and fructo-oligosaccharides (Synergy1) 2g/day, given to the child through the whole intervention (in association with a single dose of Albendazole at inclusion for children older than 12 months)
2867849|NCT03474237||Primary aldosteronism|patients who were diagnosed with primary aldosteronism by saline loading test
2867850|NCT03474237||Adrenal cushing syndrome|patients who were diagnosed with adrenal cushing syndrome by dexamethasone suppression test and 24 urine free cortisol test.
2867851|NCT03474237||Adrenocortical carcinoma|patients who were diagnosed with adrenocortical carcinoma by imaging study or histologic exam
2867852|NCT03474224||FloTrac patients|patients belong to this group will be managed with a stroke volume target hemodynamic protocol
2867853|NCT03474211||vaccinated|
2867854|NCT03474211||non vaccinated|
2867855|NCT03474198|Active Comparator|Standard TB Management Strategy|Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol, then 16 weeks rifampicin, isoniazid only
2867856|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen B|"TRUNCATE-TB Management Strategy: 8 weeks* of initial treatment using Regimen B; close monitoring after treatment completion; treatment of relapse with 24 weeks of standard treatment.~*If persistent symptoms and positive smear at week 8, extend to 12 weeks of treatment using Regimen B; if persistent symptoms and positive smear at week 12, switch to standard treatment regimen and extend to 24 weeks of treatment.~Regimen B: Rifampicin (35mg/kg), isoniazid, pyrazinamide, ethambutol, linezolid"
2867857|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen C|"TRUNCATE-TB Management Strategy as described above, using Regimen C in place of B.~Regimen C: Rifampicin (35mg/kg), isoniazid, pyrazinamide, ethambutol, clofazimine"
2867858|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen D|"TRUNCATE-TB Management Strategy as described above, using Regimen D in place of B.~Regimen D: Rifapentine, isoniazid, pyrazinamide, linezolid, levofloxacin"
2867859|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen E|"TRUNCATE-TB Management Strategy as described above, using Regimen E in place of B.~Regimen E: Isoniazid, pyrazinamide, ethambutol, linezolid, bedaquiline"
2867860|NCT03474185||Single Cohort|"The intervention for the entire cohort will be Taking Charge of your Heart Health Cardiac Education Classes, delivered via four 2.5-hour group-based classes at TotalCardiology Rehabilitation in Calgary, Canada. Classes review physiology, risk factors, medications, nutrition, exercise, and stress management. Patients are required to complete these classes prior to starting CR exercise sessions."
2867861|NCT03474172|Experimental|Real Tuina|Participants will receive real tuina manipulated on their skin in addition to the conventional therapy given by the doctors. The whole process of the Tuina, which may last for 15 minutes, should be completed under the Cloak Shape device. After that the parents and the observers may be required to fill out corresponding questionnaires. The outcomes assessors will ask the child the sense perception of the manipulation via a questionnaire if he is equal or older than 3 years old.
2867862|NCT03474172|Sham Comparator|Sham Tuina|Except for the conventional therapy given by doctors, participants in this group will receive sham Tuina. A cloak shape device will be adopted, while inside the cover the therapist will use one hand to hold the childrens' hand or just put one hand on childrens' body and the other hand will do the manipulations on the therapist's own hand instead of childrens' hand or childrens' body. The acupoints and the manipulation time are the same as real Tuina group. Same questionnaires as those adopted in real Tuina group are also required to be completed.
2867863|NCT03474159|Other|patients|patients with Bicuspid aortic valve (defined using the Sievers classification) and confirmed with either Transthoracic Ecocardiogrphy, computed tomography, or Magnetic Resonance Imaging Carotid pulse rate measured on carotid arteries by UF
2867864|NCT03474146|Experimental|Ocimum sanctum extract as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
2867865|NCT03474146|Active Comparator|Chlorhexidine Gluconate as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
2867866|NCT03474146|Placebo Comparator|Propylene Glycol as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
2867867|NCT03474133|Experimental|Brentuximab|Brentuximab vedotin 1,8 mg/kg, every 21 days, up to 16 cycles
2867868|NCT03474120||IVF treatment group|Patients treated with IVF. IVF promotion process, ovulation, fertilization, embryo quality, transplantation and final outcome were collected after the treatment cycle was completed.
2867869|NCT03474120||No IVF treatment group|the patients who did not have received IVF treatment .Patients were followed up to collect hormone levels, ultrasound results.
2867870|NCT03474107|Experimental|Arm A: enfortumab vedotin|Participants will receive enfortumab vedotin (EV) on days 1, 8 and 15 of each 28 day cycle.
2867871|NCT03474107|Active Comparator|Arm B: chemotherapy|Participants will receive either docetaxel, vinflunine or paclitaxel as determined prior to participant's randomization. Participants will receive the assigned drug on day 1 of every 21 day cycle.
2867872|NCT03474094|Experimental|pre-operative radiotherapy and atezolizumab|Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery
2867873|NCT03474094|Experimental|pre-operative atezolizumab and post-operative radiotherapy|2 cycles of atezolizumab followed by surgery then post-operative radiotherapy
2867874|NCT03474094|Active Comparator|pre-operative radiotherapy and post-operative atezolizumab|Pre-operative radiotherapy then surgery followed by 2 cycles of atezolizumab
2867875|NCT03474081|Experimental|Subjects receiving FF/UMEC/VI + Placebo to match tiotropium|Eligible subjects will receive FF/UMEC/VI with a dose of 100/62.5/25 microgram (mcg) administered once daily in the morning via ELLIPTA along with placebo to match tiotropium administered once daily in the morning via HANDIHALER. Subjects will self-administer 4 puffs of rescue medication (Albuterol/salbutamol) via metered dose inhaler (MDI).
2867876|NCT03474081|Experimental|Subjects receiving Tiotropium + Placebo to match FF/UMEC/VI|Eligible subjects will receive Tiotropium with a dose of 18 mcg administered once daily in the morning via HANDIHALER along with placebo to match FF/UMEC/VI administered once daily in the morning via ELLIPTA. Subjects will self-administer 4 puffs of rescue medication (Albuterol/salbutamol) via MDI.
2867877|NCT03474055|Experimental|LBRV-PV Lot A|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot A).
2867878|NCT03474055|Experimental|LBRV-PV Lot B|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot B).
2867879|NCT03474055|Experimental|LBRV-PV Lot C|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot C).
2868112|NCT03472508|Active Comparator|0.4mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.4mg)
2867880|NCT03474055|Active Comparator|ROTASIIL|The study participants in this arm will receive ROTASIIL, the licensed lyophilized rotavirus vaccine in India.
2867881|NCT03474042|Experimental|GLPG2737|GLPG2737 will be provided as capsules for oral use.
2867882|NCT03474042|Placebo Comparator|Placebo|Placebo will be provided as capsules for oral use.
2867883|NCT03474029|Experimental|6 weeks of daily rifapentine (6wP)|Rifapentine daily for 6 weeks: 600 mg of Rifapentine (RPT) given once daily for 6 weeks
2867884|NCT03474029|Active Comparator|12-16 week rifamycin-based regimen|"A 12-16 week rifamycin-based regimen available at the participant's site:~Rifapentine and Isoniazid weekly for 12 weeks (3HP) or Rifampin and Isoniazid daily for 12 weeks (3HR) or Rifampin daily for 16 weeks (4R)"
2867885|NCT03474016||Patients with early breast cancer(30)|
2867886|NCT03474016||Patients with advanced breast cancer(30)|
2867887|NCT03474016||Patients with benign breast diseases(20)|
2867888|NCT03474016||Apparently healthy females as a control group(36)|
2867889|NCT03473990|Active Comparator|Laboratory HIT|Supervised (Laboratory HIT) exercise in the lab up to 4 times per week for 4 weeks
2867890|NCT03473990|Active Comparator|Home HIT|Unsupervised (Home HIT) exercise at home up to 4 times per week for 4 weeks
2867891|NCT03473990|No Intervention|Control Group|No intervention
2867892|NCT03473977|Experimental|Benralizumab|This Arm is a subcutaneous dose of 30 mg of Benralizumab
2867893|NCT03473977|Placebo Comparator|Placebo|This Arm is a subcutaneous dose of 30 mg of Placebo
2867894|NCT03473964||Treatment|The study intervention is the observation of study subjects who have received H.P. Acthar® Gel (adrenocorticotrophic hormone), 40 units twice weekly injections in patients who have sarcoid uveitis and to assess it's effectiveness by measuring changes the degree of aqueous and vitreous inflammatory cells present, the degree of aqueous flare, and changes in visual acuity, macular thickness, intraocular pressure and quality of life measures assessed by using the National Eye Institute Visual Function Questionnaires (VFQ-25)
2867895|NCT03473951||Hyperuricemia|Hyperuricemia is defined as a serum uric acid level of 7 mg/dl or more in men or 6 mg/dl or more in women
2867896|NCT03473938||Spatz3 AIGB|Patients with implanted Spatz3 AIGB balloon.
2867897|NCT03473925|Experimental|Navarixin Dose A + Pembrolizumab|Participants receive navarixin Dose A via oral capsules once daily PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
2867898|NCT03473925|Experimental|Navarixin Dose B + Pembrolizumab|Participants receive navarixin Dose B via oral capsules once daily PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
2867899|NCT03473912||RA patients|before or after medication
2867900|NCT03473912||Systemic sclerosis patients|before or after medication
2867901|NCT03473912||IgG4 RD patients|before or after medication
2867902|NCT03473912||Lupus patients|before or after medication
2867903|NCT03473899|Active Comparator|rESWT + RP|Device: rESWT
2867904|NCT03473899|Placebo Comparator|sham-rESWT + RP|Device: sham-rESWT
2867905|NCT03473886|Experimental|Intervention Arm: PP-MI|Participants will complete an 8-week group physical activity and positive psychology program, in which they will complete exercises related to increasing positive emotions and physical activity during and between the group sessions. They will track their activity (steps) and set personalized physical activity goals each week, as complete a group walk or indoor exercise during the group sessions. We will ask questions about participants' health and health behaviors, and ask them to wear a physical activity monitor at the beginning and end of the program.
2867906|NCT03473873||SHIELD|Patients with anterior cruciate ligament injury
2867907|NCT03473847|Experimental|Repeatability and Reproducibility - Normal eyes|"This arm will include 20 eyes of 20 patients with no previous ocular surgery.~The research participant will be scanned a number of times using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). The scan sequence will be undertaken on a single day as follows:~5 consecutive repeated scans of the cornea will be performed by the first operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set).~There will be a break of about 30 minutes.~5 consecutive repeated scans of the cornea will be performed by the second operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set)."
2867908|NCT03473847|Experimental|Repeatability and Reproducibility - Post-op eyes|"This arm will include 20 eyes of 20 patients between 3 and 9 months after corneal laser refractive surgery.~The research participant will be scanned a number of times using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). The scan sequence will be undertaken on a single day as follows:~5 consecutive repeated scans of the cornea will be performed by the first operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set).~There will be a break of about 30 minutes.~5 consecutive repeated scans of the cornea will be performed by the second operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set)."
2867909|NCT03473847|Experimental|Comparison between devices - Normal eyes|"This arm will include 101 eyes of 101 patients with no previous ocular surgery.~The research participant will be scanned once using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). Expected total time approximately 20 minutes to complete all four scans."
2867910|NCT03473847|Experimental|Comparison between devices - Post-op eyes|"This arm will include 101 eyes of 101 patients between 3 and 9 months after corneal laser refractive surgery.~The research participant will be scanned once using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). Expected total time approximately 20 minutes to complete all four scans."
2867911|NCT03473834|Experimental|Modified exercise programme|Modified exercise program is the intervention for the exercise group that they will be received this programm over 1 month.
2867912|NCT03473834|Active Comparator|Parkinson's disease Medication|Medication is the standard treatment for individuals with Parkinson's disease. Therefore, the control group will be received the medication only.
2867913|NCT03473821|No Intervention|Neuromuscular Training|Participants in this group will undergo rehabilitation for ACL injury consisting of neuromuscular training according to care-as-usual treatment common to physical therapy professionals.
2867914|NCT03473821|Experimental|Neuromuscular Training Plus Dynamic Motor Imagery|Participants in this group will receive an intervention that has been developed according to our new training model, known as MOTIFS. In this intervention, patients will receive a neuromuscular training rehabilitation program with integrated dynamic motor imagery.
2867915|NCT03473808|Experimental|therapy + vibratoin|Imperceptible vibration applied to the wrist during a standardized hand task practice therapy program.
2867916|NCT03473795||healthy participants and participants diagnosed with NCDs|This protocol will entail prospective collection of data on healthy participants and participants diagnosed with NCDs managed at collaborating institutions in SSA. Information to be obtained includes socio-demographic data, risk factors, disease-specific data, investigation and treatment details, as well as findings during follow-up. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality. Follow-up data will be updated during clinic visits and also via phone calls.
2867917|NCT03473782||Voiding Diary|
2867918|NCT03473782||Urodynamics Correlation Study|
2867919|NCT03473769|Experimental|Vital Signs at 2 Hours + CAM-ICU|enhanced vital sign and delirium monitoring in patients for who the per-sepsis algorithm reaches alert threshold.
2867920|NCT03473769|No Intervention|No Intervention|No intervention. Patient treated per standard of care.
2867921|NCT03473756|Experimental|Rogaratinib + Atezolizumab in Part A|"Part A: Part A is conducted in patients who are cisplatin-ineligible and have had no prior systemic treatment for locally advanced or metastatic disease.~Patients will receive rogaratinib plus atezolizumab combination treatment."
2867922|NCT03473756|Placebo Comparator|Placebo + Atezolizumab|Part B:Patients will receive placebo in combination with atezolizumab until disease progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
2867923|NCT03473756|Experimental|Rogaratinib + Atezolizumab in Part B|Part B:Patients will receive rogaratinib in combination with atezolizumab until disease progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
2867924|NCT03473743|Experimental|Phase 1b: Dose Escalation|Two dosing cohorts (standard and alternative) are explored in Phase 1b of the study. The participants will receive erdafitinib orally, the dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified. Whereas, the participants will receive a fixed dose of JNJ-63723283 intravenously (IV).
2867925|NCT03473743|Experimental|Phase 2: Dose Expansion|The participants will be randomized in a 1:2 manner to receive either erdafitinib alone (orally) or the identified RP2D of Phase 1b for erdafitinib (orally) in combination with JNJ-63723283 (IV).
2867926|NCT03473730|Experimental|Bladder Cancer Cohort|Participants receive Daratumumab by vein 1 time each week for 4 weeks before cystectomy.
2867927|NCT03473730|Experimental|Renal Cancer Cohort|"Participants receive Daratumumab by vein 1 time each week for 4 weeks before nephrectomy, metastasectomy, or biopsy.~Participants may receive additional doses of Daratumumab after the surgery/biopsy for up to one year after first dose."
2867928|NCT03473717|Active Comparator|classic method group|IUD/IUS insertion will be done using the conventional method
2867929|NCT03473717|Active Comparator|direct method group|IUD/IUS insertion will be done using the direct method
2867930|NCT03473704|Experimental|Treatment group (TG)|The treatment group (TG) will receive the web treatment, which consists of 9 weekly sessions.
2867931|NCT03473704|Placebo Comparator|Control group (CG)|The control group (CG) will be evaluated in the same phases as the TG.
2867932|NCT03473691|Experimental|Glembatumumab vedotin (GV)|
2867933|NCT03473678|Active Comparator|Nitrate-rich beetroot juice|2 x 70mL concentrated juice per day for 10 days
2867934|NCT03473678|Placebo Comparator|Nitrate-depleted beetroot juice|2 x 70mL concentrated juice per day for 10 days
2867935|NCT03473665|Active Comparator|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
2867936|NCT03473665|Active Comparator|Diclofenac|Diclofenac Delayed Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
2867937|NCT03473665|Active Comparator|Meloxicam|Meloxicam tablet 7.5mg by mouth, every 12 hours for 6 weeks
2867938|NCT03473665|Active Comparator|Celecoxib|Celecoxib 200mg capsule by mouth, every 12 hours for 6 weeks
2867939|NCT03473652|Other|Adapted walking platform|
2867940|NCT03473639|Experimental|Entinostat and Capecitabine|"Dose escalation of the combination of entinostat and capecitabine in MBC patients. This dose will be given to MBC patients and to BC patients with residual invasive disease after neoadjuvant chemotherapy and surgery.~The dose combinations include:~Combination 1: 3 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 2: 5 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 3: 3 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine Combination 4: 5 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine~If a participant experiences unacceptable side effects, he or she will receive the next lowest dose combination. If he or she is on Combination 1, he or she will stop study treatment."
2867941|NCT03473626|Experimental|Alicaforsen tablets|Regimen A - Alicaforsen tablets with food
2867942|NCT03473626|Experimental|alicaforsen tablets|Regimen B - Alicaforsen tablets without food
2867943|NCT03473613|Active Comparator|Calcium infusion|10ml 10%calcium gluconate in 200ml normal saline solution given intravenously over thirty minutes, on ovum pick up day and continued for 4days
2867944|NCT03473613|Active Comparator|Oral Cabergoline|Receiving oral Cabergoline (cabergamon 0.5 milligram tablet ) from ovum pick up day and continued for 7days,once daily
2867945|NCT03473600|Experimental|study group|•The first group (20 patients) will be treated with cryotherapy using liquid nitrogen spray, two cycles each one 3-5 seconds, one session every two weeks, for three months.
2867946|NCT03473600|Active Comparator|control group|•The second group (20 patients) will be treated with intralesional injection of 4mg/ml/ session of triamcinolone-acetonide, it will be injected into deep dermis or upper subcutaneous tissue using a 0.5-inch long 30-gauge needle at multiple sites, 1 cm apart and 0.1 ml into each site, once every three weeks, for three months, using insulin syringes.
2868113|NCT03472508|Active Comparator|0.6mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.4mg) with 0.2 mg folic acid
2867947|NCT03473587|Experimental|Motivational Interview|Subjects will engage in a brief motivational interview to establish an action plan and discuss follow-up interviews a 3 and 6 months post ED visit
2867948|NCT03473587|Active Comparator|Standard of Care|Subjects will be provided a standard of care colorectal cancer screening brochure at the time of ED visit
2867949|NCT03473574|Experimental|Durvalumab, Tremelimumab and Gemcitabine|Durvalumab 1.5g q3w Tremelimumab 75mg q3w cycles ≥4 Gemcitabine 1000mg/m2 q3w cycles 8
2867950|NCT03473574|Experimental|Durvalumab, Tremelimumab, Gemcitabine and Cisplatin|Durvalumab 1.5g q3w, Tremelimumab 75mg q3w cycl ≥4, Gemcitabine 1000mg/m2 q3w cycl 8, Cisplatin 25mg/m2 q3w cyl 8
2867951|NCT03473574|Other|Gemcitabine and Cisplatin|Gemcitabine: 1000mg/m2 q3w Cisplatin: 25mg/m2 q3w
2867952|NCT03473561|Experimental|Racecadotril plus standard treatment oral rehydration solution|
2867953|NCT03473561|Active Comparator|ORS (standard treatment)|
2867954|NCT03473548|Experimental|Portable Sleep Monitor|Type III portable monitor obtaining greater than or equal to 6 hours of data adequate for polysomnography analysis and determination of an apnea hypopnea index (AHI), average SPO2, and SPO2 nadir.
2867955|NCT03473535|Experimental|Smartphone Assisted PST|Emergency departments providing the option to refer men who self-harm to a service that will deliver smartphone-assisted PST.
2867956|NCT03473522|Experimental|anodal tDCS +Exercise Therapy|Anodal tDCS (2mA of intensity, for twenty minutes) over the motor cortex representation of trunk and lower limbs. Immediately after tDCS application all the patients will participate in an exercise therapy protocol involving balance control, strength,
2867957|NCT03473522|Sham Comparator|Sham tDCS+ Exercise Therapy|Anodal tDCS (2mA of intensity, for twenty minutes but thirdy seconds ON) over the motor cortex representation of trunk and lower limbs.
2867958|NCT03473509|Experimental|Chronic Kidney Disease (CKD) Registry|The CKD registry provided primary care practice teams with point-of-care data about patient-specific CKD status, recent ambulatory clinic blood pressure (BP) readings, status of Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) prescription, and quantification of albuminuria (UACR). It also provided data about diabetes care, immunization status, and data pertinent to age appropriate cancer screening, to align with usual care. Point-of-care decision support reminded primary care providers (PCPs) about guideline concordant care for individuals with CKD. Quarterly feedback to practice teams and individual PCPs identified patients with CKD and BP >140/90 mmHg, those not prescribed an ACEi/ARB, and those with albuminuria.
2867959|NCT03473509|No Intervention|Usual Care Registry|Usual care consisted of an electronic registry that was in use before trial implementation. It provided practice teams with point-of-care data about diabetes care, age-appropriate cancer screening and immunizations, but no CKD-related data. Medical assistants were encouraged to use the usual care registry to identify patients who were due for cancer screening or immunizations. Quarterly feedback was not provided for practice teams randomized to receive usual care.
2867960|NCT03473496|Experimental|CART therapy in multiple myeloma|In order to assess the safety and validity of using CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD56-CART or CD38-CART,subjects will receive 10^6—10^7/Kg transduced CAR T cells at one time.
2867961|NCT03473483|Experimental|SREC only or cigarette only use|Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 for 3 day in-patient stay that includes a standardized session of product use; 4-hr abstinence; PK blood draws; ad libitum use of product; CV monitoring, 24-hr urine collections, and circadian blood draws.
2867962|NCT03473483|Experimental|Alternate product from Arm 1|Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 for 3 day in-patient stay that includes a standardized session of product use; 4-hr abstinence; PK blood draws; ad libitum use of product; CV monitoring, 24-hr urine collections, and circadian blood draws.
2867963|NCT03473483|Experimental|Standardized Dual Use|Four days of SREC and/or usual product use as regular with daily diary. Admitted to hospital research ward on Day 5 for 3 day in-patient stay that includes 8 standardized sessions of SREC use each day; ad libitum SREC and cigarette use; CV monitoring, 24-hr urine collections, and circadian blood draws.
2867964|NCT03473470|No Intervention|not warmed|Not warming system
2867965|NCT03473470|Active Comparator|warmed group 1|forced air warming and warmed intravenous fluids
2867966|NCT03473470|Active Comparator|warmed group 2|warmed intravenous fluids
2867967|NCT03473457|Experimental|CART therapy in Acute myeloid leukemia|In order to assess the safety and validity of using CAR-T therapy refractory/relapsed acute myeloid leukemia（AML）patients with one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART,subjects will receive 10^6—10^7/Kg transduced CAR T cells at one time.
2867968|NCT03473431|Experimental|ketamine|single infusion of 0.5 mg / kg ketamine
2867969|NCT03473431|Sham Comparator|control|physiological solution at 0.9 % with the same physical characteristics of ketamine solution,
2867970|NCT03473418|Experimental|Ketoconazole gel|use of Ketoconazole in situ gel for treatment of vaginal candidiasis
2867971|NCT03473418|Active Comparator|terconazole cream|use of terconazole 0.8 cream for treatment of vaginal candidiasis
2867972|NCT03473405|Sham Comparator|Control|In the control arm, the ABS device will be placed as usual on the patient, but the airflow will NOT be activated. Only the technician in the room will be aware whether the device is turned on or not.
2867973|NCT03473405|Experimental|Air Barrier System|In the experimental (intervention) arm, the ABS device will be placed as usual on the patient, and the airflow will be activated. Only the technician in the room will be aware whether the device is turned on or not.
2867974|NCT03473379||Phase 1: concept elicitation and coding|The aim of this phase is to elicit concepts from patients, caregivers, and oncology clinicians through focus groups of patients and caregivers, qualitative interviews and surveys. Approximately 55 patients or caregivers will participate in this phase.
2867975|NCT03473379||Phase 2: Item generation and analysis|The aim of this phase is produce a draft version of the questionnaire. Approximately 90 patients or caregivers will be recruited in this phase for item ranking and analysis through questionnaire evaluation and cognitive interviews.
2867976|NCT03473379||Phase 3: Instrument refinement and internal validation|The aim of this phase is generate the final version of the instrument. Approximately 101 patients or caregivers will participate in this phase by completing the questionnaire
2867977|NCT03473379||Phase 4: External validation|In this phase the questionnaire will undergo further psychometric testing for validation and approximately 220 patients or caregivers will be asked to complete the PROFTC-I questionnaire along with quality of life instruments
2867978|NCT03473366|Experimental|Tao Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Tao Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
2867979|NCT03473366|Active Comparator|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
2867980|NCT03473353|Other|Pediatric Clinicians|Survey data will be gathered from pediatric clinicians and also parents of pediatric patients at two time periods. At baseline, no Medical Scribes will be working with the clinicians, and then several months later, data will be gathered when Medical scribes ARE working with clinicians.
2867981|NCT03473340|Experimental|Pirfenidone Capsule|"Method of Administration: Oral (capsule)~Dosing:~Days 1 through 7, 267 mg three times daily;~Days 8 through 14, 534 mg three times daily;~Days 15 through end of treatment (24 weeks), 801 mg three times daily"
2867982|NCT03473340|Placebo Comparator|Placebo Capsule|"Method of Administration: Oral (capsule)~Dosing:~Days 1 through 7, 267 mg three times daily;~Days 8 through 14, 534 mg three times daily;~Days 15 through end of treatment (24 weeks), 801 mg three times daily"
2867983|NCT03473314|Experimental|Nitric Oxide gas at 160ppm|Nitric Oxide 160ppm for 50 minutes three-times a day (TID) for 60 days
2867984|NCT03473301|Experimental|Allogeneic Umbilical Cord Blood|Subjects will receive a single intravenous infusion of a maximum of 10x107/kg allogeneic umbilical cord blood (CB) cells
2867985|NCT03473301|Experimental|Cord Tissue Mesenchymal Stromal Cells|Subjects will receive three intravenous infusions of 2x106/kg human umbilical cord tissue cells (hCT-MSC), manufactured from allogeneic umbilical cord donors
2867986|NCT03473301|Active Comparator|Natural History|Subjects will not receive any study product infusion until after the 12 month assessment. At the 12 month visit, they will receive an infusion of allogeneic umbilical cord blood cells so that all study participants will receive some type of cellular therapy.
2867987|NCT03473288|Active Comparator|Moderate Intensity Treadmill Exercise|Moderate intensity treadmill exercise three times per week for 10-12 weeks
2867988|NCT03473288|Placebo Comparator|Sedentary Controls|Serve as a sedentary (little exercise) control for 10-12 weeks
2867989|NCT03473275||1: control|Healthy normotensive participants. Cold pressor test on feet 6 times for 1 minute during BOLD fMRI
2867990|NCT03473275||2: untreated hypertensive|"Untreated (or off antihypertensive drugs) hypertensive patients (ABPM proven essential hypertension).~Cold pressor test on feet 6 times for 1 minute during BOLD fMRI"
2867991|NCT03473275||3. resistant hypertensive|Patients with proven resistant hypertension and not renal denervated. Cold pressor test on feet 6 times for 1 minute during BOLD fMRI
2867992|NCT03473275||4. renal denervation|"Patients with a renal denervation or for whom a renal denervation is planned according to the criteria of the CHUV.~Cold pressor test on feet 6 times for 1 minute during BOLD fMRI"
2867993|NCT03473262||EMPA|Empagliflozin 25 mg/day
2867994|NCT03473262||INS|Insulin Glargine dose-titrated
2867995|NCT03473249|No Intervention|Retrospective Review|Comparison of CT and CEUS results from retrospective chart review of children who have had a CEUS for trauma at the Children's Hospital of Philadelphia (CHOP).
2867996|NCT03473249|No Intervention|Prospective Observation|Prospective observation of comparison of CT and CEUS results among children who are undergoing a CEUS and abdominal CT as part of clinical care.
2867997|NCT03473249|Other|Contrast-Enhanced Ultrasound using Lumason|Prospective intervention using contrast enhanced ultrasound with IV contrast Lumason.
2867998|NCT03473236|Experimental|Cohort 1A|Dose 1 Single Ascending Dose Protocol
2867999|NCT03473236|Experimental|Cohort 2A|Dose 2 Single Ascending Dose Protocol
2868000|NCT03473236|Experimental|Cohort 3A|Dose 3 Single Ascending Dose Protocol
2868001|NCT03473236|Experimental|Cohort 4A|Dose 4 Single Ascending Dose Protocol
2868002|NCT03473236|Experimental|Cohort 5A|Dose 5 Single Ascending Dose Protocol
2868003|NCT03473236|Experimental|Cohort 1B|Dose 1 Multiple Ascending dose protocol
2868004|NCT03473236|Experimental|Cohort 2B|Dose 2 Multiple Ascending Dose Protocol
2868005|NCT03473236|Experimental|Cohort 3B|Dose 3 Multiple Ascending dose protocol
2868006|NCT03473223|Experimental|CSL112|Apolipoprotein A-I [human]
2868007|NCT03473223|Placebo Comparator|Placebo|25% albumin solution diluted to 4.4%
2868008|NCT03473210|Active Comparator|Amniopatch group|in which women were subjected to active treatment included prophylactic antibiotics and antenatal corticosteroids with an effort to seal the ruptured membranes using the amniopatch technique.
2868009|NCT03473210|Active Comparator|control group|in which women were subjected to conservative management with prophylactic antibiotics and antenatal corticosteroids
2868010|NCT03473197|Experimental|Cohort 1 (Healthy Volunteers)|
2868011|NCT03473184|Experimental|Cohort 1 (Healthy Volunteers)|Cohort 1 will receive CCP-020 (diacerein 1% ointment) and vehicle as described below.
2868012|NCT03473171|Experimental|Nasal non-invasive ventilation with RAM cannula|
2868013|NCT03473158|Active Comparator|Mechanical|fetal reduction will be achieved by mechanical disruption of the fetal heart till asystole is achieved, and may be aided by partial or total suction of the fetus, using suction device attached to the embryo reduction needle
2868014|NCT03473158|Active Comparator|Chemical|fetal reduction will be achieved by injecting 0.5 mL of potassium chloride (Potassium Chloride® 15% , EIPICO, Egypt) into the cardiac region through the embryo reduction needle
2868015|NCT03473145|Active Comparator|Group A - Health Living Attention Control|Participants in the attention control condition will receive a healthy aging educational intervention. This group will receive two in-person health coaching sessions and 8 phone counseling sessions.
2868016|NCT03473145|Experimental|Group B - Stand More|Participants in the Stand More condition will receive an intervention aimed at increasing daily standing time. This group will receive seven in-person health coaching sessions and three phone counseling sessions.
2868017|NCT03473145|Experimental|Group C - Sit-to-Stand Transition|Participants in the Sit-to-Stand Transition condition will receive an intervention aimed at increasing the daily number of brief sit-to-stand transitions. This group will receive seven in-person health coaching sessions and three phone counseling sessions.
2868018|NCT03473132|Experimental|Treatment|Based on starting international normalized ratio (INR) and target INR, the dose of four factor prothrombin complex concentrate will be calculated and infused. Coagulation factor levels will be assessed over 48-72 hours.
2868019|NCT03473119||Control|Healthy individuals
2868020|NCT03473119||Asthma|Asthma acute exacerbations
2868021|NCT03473119||Asthma with CAP|Asthma acute exacerbations with community-acquired pneumonia
2868022|NCT03473119||COPD|Acute exacerbations of chronic obstructive pulmonary disease
2868023|NCT03473119||COPD with CAP|Acute exacerbations of chronic obstructive pulmonary disease with community-acquired pneumonia
2868024|NCT03473119||CAP|Community-acquired pneumonia
2868025|NCT03473106|Experimental|Surgical Side|Surgical side requiring the use of a pneumatic tourniquet.
2868026|NCT03473106|No Intervention|Non Surgical Side|Contralateral side (Control Thigh).
2868027|NCT03473093|Active Comparator|morphine|This group will receive only morphine infusion (20microgram/kg/h)
2868028|NCT03473093|Active Comparator|pregabalin|This group will receive only morphine infusion (20microgram/kg/h) and oral pregabalin (150 mg)
2868029|NCT03473080|Other|Internet CBT|Participants and their parents receive 16 weeks of internet-delivered cognitive behavior therapy (CBT) with psychologist support.
2868030|NCT03473067|Experimental|Social Norms Marketing|This arm includes a social norms marketing campaign tailored to the school.
2868031|NCT03473067|Active Comparator|Capacity Building|This arm includes a series of teacher training, and parent engagement meetings, with the goal of building capacity to address violence in the school.
2868032|NCT03473054||Web-based Mindfulness Course|Participants will complete a 2 week baseline phase, followed by the four week web-based mindfulness course intervention phase, and a four week follow-up period.
2868033|NCT03473041|Active Comparator|Hybrid sling|70 patients with stress urinary incontinence treated with surgeon tailored hybrid sling
2868034|NCT03473041|Active Comparator|TVT-O|70 patients with stress urinary incontinence treated with conventional TVT-O
2868035|NCT03473028|Active Comparator|transabdominal ultrasound|400 obese female undergo transabdominal ultrasound guided embryo transfer
2868036|NCT03473028|Active Comparator|transvaginal group|400 obese female undergo transvaginal ultrasound guided embryo transfer
2868037|NCT03473015|Experimental|PICSO arm|STEMI patients with elevated pre-stenting index of microcirculatory resistance (IMR) greater than 40 units treated with pressure-controlled intermittent coronary sinus occlusion (PICSO)
2868038|NCT03473015|No Intervention|Control|Matched historical cohort of STEMI patients with elevated IMR greater than 40, not treated with PICSO
2868039|NCT03473002|Placebo Comparator|Placebo|One dose of placebo (0.9% Sodium Chloride) intranasally, n=4
2868040|NCT03473002|Experimental|SeVRSV|1 x 10^7 EID50 (one dose) of SeVRSV vaccine intranasally, n=16
2868041|NCT03472989|Active Comparator|Radial extracorporeal shock wave|Active shock wave treatment. All patients will get standardized information and custom made foot orthosis.
2868042|NCT03472989|Sham Comparator|Sham-radial extracorporeal shock wave|Sham- shock wave treatment. All patients will get standardized information and custom made foot orthosis.
2868043|NCT03472989|Active Comparator|Standardized high-load exercise program|High-load exercise treatment. All patients will get standardized information and custom made foot orthosis.
2868044|NCT03472989|Active Comparator|Usual care|Only standardized information and custom made foot orthosis
2868045|NCT03472976|Experimental|Group 1|0.1 ml of influenza A/H5N1 IIV vaccine (9 mcg HA) intradermally 15 minutes after the application of approximately 250 mg of Imiquimod (Aldara) cream topically (deltoid) on Day 1 and Day 22. N=25
2868046|NCT03472976|Experimental|Group 2|0.1 ml of influenza A/H5N1 IIV vaccine (9 mcg HA) intradermally 15 minutes after the application of approximately 250 mg of Aqueous Cream B.P. (Control Cream) topically (deltoid) on Day 1 and Day 22. N=25
2868047|NCT03472963|No Intervention|Pre- drug|Participants will not receive any drug. They will be asked to return 1-6 weeks after the screening visit for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, rectal swabs, urine sample, and rectal biopsy via rigid sigmoidoscopy.
2868048|NCT03472963|Experimental|Group A.1|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 2 hours after dosing.
2868049|NCT03472963|Experimental|Group A.2|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 24 hours after dosing.
2868050|NCT03472963|Experimental|Group A.3|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 72 hours after dosing.
2868051|NCT03472963|Experimental|Group B.1|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 4 hours after dosing.
2868052|NCT03472963|Experimental|Group B.2|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 48 hours after dosing.
2868721|NCT03468348|Active Comparator|duloxetine 60|
2868053|NCT03472963|Experimental|Group B.3|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 96 hours after dosing.
2868054|NCT03472963|Experimental|Group C|Participants will be given a one- day supply of with Genvoya and Darunavir®. Participants return 8 hours (+/- 30min window), 24 hours (+/- 1 hr), and 48 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 8 hours after taking the medication.
2868055|NCT03472950|Experimental|Ranolazine 500mg|Participants will take Ranolazine 500mg twice daily for up to 4 weeks.
2868056|NCT03472950|Experimental|Ranolazine 1000mg|Participants will take Ranolazine 1000mg twice daily for up to 4 weeks.
2868057|NCT03472937|Active Comparator|Inpatient cervical ripening group|Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.
2868058|NCT03472937|Active Comparator|Outpatient cervical ripening group|Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (intervention arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next day to be admitted to labor and delivery for induction of labor with oxytocin.
2868059|NCT03472924|Experimental|Kinesio Tape|Kinesiotaping of the peroneus longus according to the guidelines provided by the Kinesio Taping Association (Kase, K. 2016) followed by standardized set of therapeutic exercises that are commonly implemented in ankle rehabilitation programs.
2868060|NCT03472924|No Intervention|Control|Baseline measures followed by standardized set of therapeutic exercises that are commonly implemented in ankle rehabilitation programs, but no use of kinesiotape.
2868061|NCT03472885|Experimental|Group 1: 100 mg ACH-0144471 TID + Eculizumab|100 mg ACH-0144471 TID to start in combination with eculizumab.
2868062|NCT03472885|Experimental|Group 2: 150 mg ACH-0144471 TID + Eculizumab|150 mg ACH-0144471 TID to start in combination with eculizumab.
2868063|NCT03472885|Experimental|Group 3: 200 mg ACH-0144471 TID + Eculizumab|200 mg ACH-0144471 TID to start in combination with eculizumab.
2868064|NCT03472885|Experimental|Group 4: Optimal Dose of ACH-0144471 TID + Eculizumab|Optimal dose (100 mg, 150 mg or 200 mg, as determined from Groups 1-3) of ACH-0144471 TID to start, in combination with eculizumab.
2868065|NCT03472872|Experimental|Ketorolac Arm|The patient will receive a 0.9% normal saline bolus of 1,000ml at 500ml/hr, 25mg diphenhydramine IV, 10mg prochlorperazine IV, 15mg ketorolac in 100mL 0.9% normal saline IVPB
2868066|NCT03472872|Experimental|Acetaminophen Arm|The patient will receive a 0.9% normal saline bolus of 1,000ml at 500ml/hr, 25mg diphenhydramine IV, 10mg prochlorperazine IV, 1,000mg acetaminophen in a 100ml IVPB
2868067|NCT03472859|Experimental|Split-face group 1|In group 1 the left side of the face will be treated with KTP and right side with PHOTOLASE.
2868068|NCT03472859|Experimental|Split-face group 2|In group 2 the right side of the face will be treated with KTP and left side with PHOTOLASE.
2868069|NCT03472846|Active Comparator|Group 1 - DMAB|postmenopausal women without type 2 diabetes mellitus treated with denosumab
2868070|NCT03472846|Active Comparator|Group 2 - TPTD|postmenopausal women with type 2 Diabetes mellitus treated with teriparatide
2868071|NCT03472846|Active Comparator|Group 3 - DMAB|postmenopausal women with type 2 diabetes mellitus treated with denosumab
2868072|NCT03472846|Active Comparator|Group 4 - TPTD|postmenopausal women without type 2 diabetes mellitus treated with teriparatid
2868073|NCT03472833|Experimental|High-dose|"Intervention with high dose oral vitamin D3 supplementation.~1 drop equals 400 I.U. This group will get 180.000 I.U. on day 1, and then 4000 I.U. per day for 60 days."
2868074|NCT03472833|Active Comparator|Standard-dose|"Intervention with standard dose oral vitamin D3 supplementation.~1 drop equals 400 I.U. This group will get 800 I.U. per day for 60 days."
2868075|NCT03472820|Experimental|Intervention Group|The intervention will be diet, lifestyle, exercise and stress management recommendations combined with taking two different supplements twice daily, in divided doses.
2868076|NCT03472820|No Intervention|Control Group|The control group will undergo the same testing measures as the intervention group, but will not have access to the education information or be instructed to change diet or lifestyle factors. They will have access to the information after the study is complete.
2868077|NCT03472807|Other|Cancer patient|"Collection of blood sample or saliva~Collection of a tumor sample taken before the participation of the patient in study~Collection of blood sample if tumor sample is not available"
2868078|NCT03472807|Other|Parent of cancer patient|-Collection of blood sample or saliva
2868079|NCT03472781||Children with intraocular inflammation|All children diagnosed with intraocular inflammation at Singapore National Eye center from from January 1989 to January 2017.
2868080|NCT03472768||ECMO-supported group|Thirty critically-ill children (age newborn to 18 years) who are intubated and supported by ECMO. Normal adult-level haptoglobin concentrations are achieved by 6-12 months of age. We will target enrollment of 15 subjects less than 12 months of age and 15 subjects over 12 months of age
2868081|NCT03472768||Age-matched group with respiratory failure|Sixty critically-ill children (age newborn to 18 years) who are intubated with acute respiratory failure due to any cause and not supported by ECMO. Two control subjects will be enrolled for every 1 experimental ECMO subject.
2868082|NCT03472755|Other|The posterolateral approach|The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone
2868083|NCT03472755|Other|Direct anterior techniques.|. In the direct anterior technique, patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached.
2868114|NCT03472508|Active Comparator|0.8mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg)
2868084|NCT03472729|Experimental|AGE-ON Workshop|Intervention participants will take part in a 6-week workshop to learn 1) basic features of the iPad; 2) how to use the internet; 3) how to take and view photos; 4) how to send and receive emails; and 5) other 'fun' functions.
2868085|NCT03472729|No Intervention|Wait-list control|Wait-list control group to be offered workshops after the study is complete
2868086|NCT03472716||Samples|Included patients will undergo 2 biological samples : a 5-ml blood sample included in the standard care and a tumoral sample (from the surgical exeresis or from the initial diagnosis biopsy). Patients with a confirmed pancreatic carcinoma will be followed during 18 months in this cohort. In case of relapse, patients will have 2 new biological samples (blood and tumoral).
2868087|NCT03472703|Other|Hungry|Her subjects will first have a break, then undergo all measurement and at the end of the study-day they will receive their lunch
2868088|NCT03472703|Other|Satiated|Her subjects will first receive their lunch, then perform all the tasks and last will have a break
2868089|NCT03472690|Experimental|Active|0.1 mL, self-administered subcutaneous injection, every second day
2868090|NCT03472690|Placebo Comparator|Placebo|0.1 mL, self-administered subcutaneous injection, every second day
2868091|NCT03472677|Experimental|Cohort 1|A comparison of two cooling methodologies in healthy volunteers after single intra-articular (IA) injection (15 mL) of 2% lidocaine (without epinephrine).
2868092|NCT03472677|Experimental|Cohort 2|Controlled cooling wrap versus ice pack cooling.
2868093|NCT03472677|Experimental|Cohort 3|Controlled cooling parameters will be determined after evaluation of data from prior cohorts.
2868094|NCT03472677|Experimental|Cohort 4|Controlled cooling with knee device versus no cooling (determined after evaluation of data from previous cohorts).
2868095|NCT03472664|Experimental|Modified Mediterranean Ketogenic Diet|"The MMKD is a low carbohydrate/high fat diet aimed at inducing ketosis, as the experimental diet in the proposed study. Participants on the MMKD will keep their daily carbohydrate consumption below 20 grams per day throughout the 4 month intervention.The MMKD group will be supplied with extra virgin olive oil during their in person visits to use as a source of fat in their diet, and will be encouraged to eat plentiful fish, lean meats, and nutrient rich foods that meet the requirement of <20 grams total carbohydrates per day.~Participants will receive a daily multivitamin (Centrum Silver) over the course of the study and instructed to take 1 tablet each day while on the diet."
2868096|NCT03472664|Experimental|American Heart Association Diet|The American Heart Association Diet (AHAD), is a low fat/high carbohydrate diet (<40 grams/day) will be used as the control diet. Participants on the AHAD will be encouraged to limit their amount of fat intake to <40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber. Participants will receive the same daily multivitamin supplement (Centrum Silver) over the course of the study and instructed to take 1 tablet each day while on the diet.
2868097|NCT03472651|Experimental|Cohort A1 Fasted condition|Subjects in cohort A1 will be administered the Investigational Medicinal Product in a fasted state, 30 subjects per cohort
2868098|NCT03472651|Experimental|Cohort A2 Fed condition|Subjects in cohort A2 will be administered the Investigational Medicinal Product in a fed state, 30 subjects per cohort
2868099|NCT03472638|Experimental|Active -> Sham|15 days of active, followed by 15 days of sham rTMS, targeting dorsomedial prefrontal cortex bilaterally, two sessions per day (1 hour apart), 20 Hz stimulation, at 120% resting motor threshold
2868100|NCT03472638|Experimental|Sham -> Active|15 days of sham, followed by 15 days of active rTMS, targeting dorsomedial prefrontal cortex bilaterally, two sessions per day (1 hour apart), 20 Hz stimulation, at 120% resting motor threshold
2868101|NCT03472625||Acute stroke patients|All acute stroke patients will be screened for aphasia, dysarthria or dysphagia. When one of the symptoms is present, standardized assessments will follow to evaluate the severity. Recovery in time will be measured +/- 1 week following stroke.
2868102|NCT03472612|Experimental|CPAP withdrawal|Short-term withdrawal of CPAP therapy in moderate to severe OSA (intervention)
2868103|NCT03472599|Experimental|Genital Nerve Stimulation|Study participants in this arm will use take-home genital nerve stimulation for 24+ months in order to assess its effectiveness at decreasing urinary incontinence. In order to set effective genital nerve stimulation parameters, study participants will undergo clinical urodynamics every 6 months in which sensitivity to and tolerance of electrical stimulation are assessed.
2868104|NCT03472586|Experimental|Treatment (ipilimumab, nivolumab, immunoembolization)|Participants receive ipilimumab IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Participants also undergo immunoembolization on day 2. Courses repeat every 3 weeks for 12 weeks in the absence of disease progression or unacceptable toxicity. Participants with complete response, partial response, or stable disease may receive nivolumab IV over 30 minutes on day 1 and undergo immunoembolization on day 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2868105|NCT03472573|Experimental|Treatment (palbociclib, dexamethasone)|"INDUCTION: Participants receive palbociclib PO daily and dexamethasone PO daily for 28 days in the absence of disease progression or unacceptable toxicity. Participants with disease response (M0, M1, or M2) continue to Maintenance. Patients without a disease response discontinue treatment.~MAINTENANCE: Participants receive dexamethasone with a taper PO daily on days 1-7. Participants also receive palbociclib daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2868106|NCT03472560|Experimental|Avelumab in combination with axitinib|Avelumab administered at 800 mg IV every two weeks in combination with axitinib, 5 mg PO BID.
2868107|NCT03472547|Experimental|Cohort 1 (Healthy Volunteers)|CCP-020 (Diacerein 1%) Topical Ointment and Vehicle, approximately 0.2 mL, applied topically under occlusive patch conditions to the infrascapular area of the back, 3 times weekly for 3 weeks (9 applications) during the Induction Phase, and one time at Challenge (10 times in total).
2868108|NCT03472534|Experimental|Cohort 1 (Healthy Volunteers)|
2868109|NCT03472521|Experimental|Gabapentin|Gabapentin 300 mg capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
2868110|NCT03472521|Placebo Comparator|Control|Matched placebo capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
2868111|NCT03472508|Sham Comparator|0 mg folic acid|Enalapril Maleate (10mg) with 0 mg folic acid
2868722|NCT03468348|Active Comparator|duloxetine 90|
2868115|NCT03472508|Active Comparator|1.2mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 0.4 mg folic acid
2868116|NCT03472508|Active Comparator|1.6mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 0.8 mg folic acid
2868117|NCT03472508|Active Comparator|2.0mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 1.2 mg folic acid
2868118|NCT03472508|Active Comparator|2.4mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 1.6 mg folic acid
2868119|NCT03472495|Active Comparator|Oral Immediate Release Diltiazem|Diltiazem immediate release 60mg orally once (Diltiazem oral product)
2868120|NCT03472495|Active Comparator|Continuous Infusion IV Diltiazem|Diltiazem 2.5-5 mg/hour intravenous Titrate by 1.25 mg every 15-60 minutes. Maximum titration dose 15 mg/hour. Titration Goal of HR <110 (Diltiazem Injectable Product)
2868121|NCT03472482||Ab+ cognitively intact volunteers|"amyloid-positive cognitively intact controls (55-80 years)~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
2868122|NCT03472482||Ab- cognitively intact volunteers|"amyloid-negative cognitively intact controls (55-80 years)~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
2868123|NCT03472482||amyloid-positive MCI patients|"amyloid-positive patients with Mild Cognitive Impairment~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
2868124|NCT03472482||amyloid-negative MCI patients|"amyloid-negative patients with Mild Cognitive Impairment~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
2868125|NCT03472482||AD patients|"patients in the dementia stage of Alzheimer's Disease~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
2868126|NCT03472482||LBD patients|"patients with Lewy Body Dementia~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
2868127|NCT03472469|Active Comparator|Treatment Strategy #1 - descending dose arm|Treatment Strategy #1 is the descending dose arm. Inclusion in this arm will involve one of the following 6 drug combinations, and the treating physician will choose strategy. The 6 strategies are: 1. Acetaminophen 1g intravenous (IV)/ per oral (PO) q6 hours in the first 48 hours, and Acetaminophen 1g PO q6 hours thereafter; 2. Ketorolac 30mg IV once and Celebrex 200mg PO q12 hours in the first 48 hours, and Naproxen 500mg PO q12 hours thereafter; 3. Tramadol 100mg PO q6 hours in the first 48 hours, and Tramadol 100mg PO q6 hours thereafter; 4. Pregabalin 100mg PO q8 hours in the first 48 hours, and Gabapentin 300mg PO q8 hours thereafter; 5. Lidocaine patch q12 hours in the first 48 hours, and Lidocaine patch q12 hours thereafter; and 6. Opioids (Regional anesthesia) in the first 48 hours, and Opioids and Regional anesthesia thereafter.
2868128|NCT03472469|Active Comparator|Treatment Strategy #2 - escalating dose arm|Treatment Strategy #2 is the escalating dose arm. Inclusion in this arm will involve one of the following 6 drug combinations, and the treating physician will choose strategy. The 6 strategies are: 1. Acetaminophen 1g PO q6 hours at admission and thereafter; 2. Ketorolac 30mg IV once and Naproxen 500mg PO q12 hours at admission and thereafter; 3. No drug; 4; Gabapentin 300mg PO q8 hours at admission and thereafter; 4. Gabapentin 300mg PO q8 hours at admission and thereafter; 5. Lidocaine patch q12 hours at admission and thereafter; and 6. Tramadol and Opioids and Regional anesthesia at admission and thereafter.
2868129|NCT03472456||Articaïne|
2868130|NCT03472456||Eugénol|
2868131|NCT03472443|Experimental|Sinew Acupuncture|
2868132|NCT03472443|No Intervention|Waitlist|
2868133|NCT03472430|Active Comparator|Treatment group|Transcutaneous electrical nerve stimulation machine, start 5 minutes before start of oocyte retrieval and stop 5 minutes after removal of oocyte retrieval needle
2868134|NCT03472430|Sham Comparator|Placebo group|TENS machine with electrodes not emitting any impulses, start 5 minutes before start of oocyte retrieval and stop 5 minutes after removal of oocyte retrieval needle
2868135|NCT03472417|Active Comparator|Active partial rebreathing device|
2868136|NCT03472417|Sham Comparator|Dummy partial rebreathing device|
2868137|NCT03472404|Experimental|Intervention Group|Internal Brace augmented ankle Ligament reconstruction
2868138|NCT03472404|Active Comparator|Control Group|Brostrom-Gould ankle Ligament reconstruction
2868139|NCT03472391|Active Comparator|Intervention|Supervised exercise therapy by physical therapist: patients allocated to physical therapy will participate in a 4-week (2 sessions a week of 40 minutes) supervised and tailored exercise program mainly consisting of light strength training. The exercise program is an add-on treatment to the primary treatment of re-nutrition and somatic stabilization.
2868140|NCT03472391|No Intervention|Control|The control group follows ordinary treatment in consisting of re-nutrition and somatic stabilization
2868141|NCT03472378|Experimental|Active Treatment Group|DFN-15
2868142|NCT03472378|Placebo Comparator|Placebo Group|
2868143|NCT03472365|Experimental|Cohort 1|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w . Study treatment will be started on Day 1 of each 3-week cycle.
2868144|NCT03472365|Experimental|Cohort 2|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus apatinib 500 mg daily (QD) continous oral. Study treatment will be started on Day 1 of each 3-week cycle.
2868145|NCT03472352|Experimental|Single Arm|The subjects will be given an anticancer medication (A01) and immune cells (IC01).
2868146|NCT03472339|Experimental|Group A|diclofenac sodium75 mg, intravenously, once
2868147|NCT03472339|Active Comparator|Group B|diclofenac sodium 100 mg, orally, once
2868148|NCT03472326|Experimental|Part 1: Sentinel Cohort|Treatment experienced participants will receive open-label GS-9131 60 mg (2 x 30 mg tablets) once daily + current failing ART regimen for 10 days
2868149|NCT03472326|Experimental|Part 1: Randomized Cohort (Treatment Arm A: GS-9131 30 mg)|Participants will receive GS-9131 30 mg (1 x 30 mg tablet) once daily + current failing ART regimen for 10 days
2868150|NCT03472326|Experimental|Part 1: Randomized Cohort (Treatment Arm B: GS-9131 60 mg)|Participants will receive GS-9131 60 mg (2 x 30 mg tablets) once daily + current failing ART regimen for 10 days
2868151|NCT03472326|Experimental|Part 1: Randomized Cohort (Treatment Arm C: GS-9131 90 mg)|Participants will receive GS-9131 90 mg (3 x 30 mg tablets) once daily + current failing ART regimen for 10 days
2868152|NCT03472326|Experimental|Part 1: Randomized Cohort (Treatment Arm D: GS-9131 Placebo)|Participants will receive GS-9131 placebo + current failing ART regimen for 10 days
2868153|NCT03472326|Experimental|Part 2: GS-9131 30 mg + BIC + DRV+RTV Regimen|Participants from Treatment Arms A and D in Part 1 will receive GS-9131 30 mg (1 x 30 mg tablet) + bictegravir (BIC) + darunavir (DRV)+ritonavir (RTV) for 24 weeks
2868154|NCT03472326|Experimental|Part 2: GS-9131 60 mg + BIC + DRV+RTV Regimen|Participants from Sentinel Cohort, and, Treatment Arms B and C in Part 1 will receive GS-9131 60 mg (2 x 30 mg tablets) + BIC + DRV+RTV for 24 weeks
2868155|NCT03472326|Experimental|Open-label Extension Phase|Participants in Part 2 may have the option to receive open-label GS-9131 + BIC + DRV+RTV for an additional 24 weeks or until the product becomes accessible to participants through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.
2868156|NCT03472313|Experimental|Experimental: [18F]MNI-958|To assess the safety and tolerability and to determine the radiation dosimetry of [18F]MNI-958.
2868157|NCT03472300||Frederiksberg Citizens|All citizen in the Frederiksberg Community aged 60-69
2868158|NCT03472287|Experimental|Cohort 1 (Adolescents, Adults)|8-10 adolescent and adult patients with EB (aged 12 and older) to receive CCP-020 daily for 10 days
2868159|NCT03472287|Experimental|Cohort 2 (Children, Infants)|8-10 infants/children with EB (aged 6 months to 11 years, inclusive) to receive CCP-020 daily for 10 days
2868160|NCT03472274|Active Comparator|Cisplatin-based neoadjuvant chemotherapy|"Patients allocated to the control arm will receive any of the following cisplatin based neoadjuvant treatment:~Regimen 1: Gemcitabine + Cisplatin Regimen 2: Methotrexate + Vinblastine + Doxorubicin + Cisplatin Regimen 3: Gemcitabine + Paclitaxel + Cisplatin"
2868161|NCT03472274|Experimental|Durvalumab plus Tremelimumab|Patients randomized to experimental arma will receive 28-day treatment cycle x 3 cycles of Durvalumab + Tremelimumab 75 mg every 4 weeks
2868162|NCT03472261|Experimental|Experimental Group|Patients treated by Botulinum toxin A and twister and specific home exercise program
2868163|NCT03472261|Active Comparator|Conventional Therapy Group|Patients treated by Botulinum toxin A and specific home exercise program
2868164|NCT03472248|Experimental|Acceptance and Commitment Therapy|Eight weeks of smartphone delivered Acceptance and Commitment Therapy for the adolescent and eight weeks of internet delivered parental support to one or two parents of the adolescent.
2868165|NCT03472235|Active Comparator|A|include 20 patients will be treated with TCA25% +microneedle 8 sessions for TCA 25 peel and 4 sessions for microneedle (derma pen).
2868166|NCT03472235|Active Comparator|B|include 20 patient will be treated with TCA 25% only ( 8 sessions)
2868167|NCT03472222|Experimental|Family Intervention Program|
2868168|NCT03472209||Group A|ETCO2=26-35 mmHg
2868169|NCT03472209||Group B|ETCO2=36-45 mmHg
2868170|NCT03472196|Experimental|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
2868171|NCT03472183|Other|Patients with Alzheimer's disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
2868172|NCT03472183|Other|Patients with Parkinson's disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
2868173|NCT03472183|Other|Patients without neurodegenerative disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
2868174|NCT03472170|Experimental|Experimental Arm|
2868175|NCT03472170|Placebo Comparator|Control Arm|
2868176|NCT03472157|Experimental|Bariatric surgery|"Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy.~Decision of the surgery type will be made according to surgical expertise, habits of investigation centers and the patient's desire. All patients receive nutritional support and therapeutic education adapted to recommendations bariatric surgery care."
2868177|NCT03472157|Active Comparator|Lifestyle therapy|The group will received the medical standard treatment defined as lifestyle therapy combining diet with increased physical activity (standard treatment, control) (figure 1, design of study).
2868178|NCT03472144|Experimental|CRSwNP - Subgrp 1(Momentasone - Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only on right side and placebo on left side
2868179|NCT03472144|Experimental|CRSwNP-Subgrp 2(Levofloxacin - Right)|Patients undergoing balloon sinuplasty with receive a gel loaded with antibiotic (Levofloxacin) only on right side and placebo on left side
2868180|NCT03472144|Experimental|CRSwNP-Subgrp 3(Steroid/Antibotic Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on right side and placebo on left side
2868181|NCT03472144|Experimental|CRSsNP - Subgrp 1 (Momentasone Right)|Patients undergoing ballon sinuplasty will receive a gel loaded with steroids (Momentasone) only on right side and placebo on left side
2868182|NCT03472144|Experimental|CRSsNP - Subgrp 2 (Levofloxacin Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only on right side and placebo on left side
2868183|NCT03472144|Experimental|CRSsNP-Subgrp 3(Steroid/Antibiotic Right|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on right side and placebo on left side
2868184|NCT03472144|Active Comparator|CRSwNP - Subgrp 1 (Momentasone Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only on left side and placebo on right side
2889973|NCT03320005|No Intervention|Non training group|sedentary elderly
2868185|NCT03472144|Active Comparator|CRSwNP - Subgrp 2 (Levofloxacin Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only left side and placebo on right side
2868186|NCT03472144|Active Comparator|CRSwNP-Subgrp 3(Steroid/Antibiotic Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on left side and placebo on right side
2868187|NCT03472144|Active Comparator|CRSsNP - Subgrp 1 (Momentasone Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only left side and placebo on right side
2868188|NCT03472144|Active Comparator|CRSsNP - Subgrp 2 (Levofloxacin Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only left side and placebo on right side
2868189|NCT03472144|Active Comparator|CRSsNP-Subgrp 3(Steroid/Antibiotic Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on left side and placebo on right side
2868190|NCT03472131|Experimental|Septic spondylodiscitis|A unilateral posterolateral approach and debridement with titanium cage insertion supplemented by screw fixation for severe sick patients suffering from septic spondylodiscitis
2868191|NCT03472118|Experimental|High Flow Apneic Oxygenation|Apneic oxygenation using Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE)
2868192|NCT03472105|Other|Habitual diet|
2868193|NCT03472105|Active Comparator|New Nordic Renal Diet|
2868194|NCT03472092|Experimental|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a psychological coping skills training using education on gate control theory of pain, behavioral strategies such as muscle relaxation and activity pacing, and cognitive strategies including distraction, problem solving, and using calming self-statements.
2868195|NCT03472092|Placebo Comparator|Placebo|The placebo pill will be administered once a day at home, to be taken by mouth.
2868196|NCT03472092|Active Comparator|Amitriptyline|Amitriptyline will be administered once a day at home, to be taken by mouth. Dosage will be weight-based.
2868197|NCT03472066||a group of women who have been conized|Previous conization
2868198|NCT03472066||control group with asymptomatic patients|on routine second trim no previous conization
2868199|NCT03472053|Experimental|BIO-11006 plus standard of care|Aerosolized BIO-11006 (125mg BID) plus standard of care (Pemetrexed plus Carboplatin) is administered for three months.
2868200|NCT03472053|Experimental|Standard of Care|Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's Formula) is administered every three weeks for three months.
2868201|NCT03472040|Experimental|BCX7353 110 mg once daily|
2868202|NCT03472040|Experimental|BCX7353 150 mg once daily|
2868203|NCT03472027|Experimental|BCD-145|anti-CTLA-4 monoclonal antibody Q3W
2868204|NCT03472014|Experimental|IMVAMUNE®|Two subcutaneous vaccinations with 0.5 mL IMVAMUNE® vaccine administered at a 4 week intervals
2868205|NCT03472001|Experimental|Training group|2-hour training based on reflection and feedback
2868206|NCT03472001|Active Comparator|Lecture group|1-hour lecture
2868207|NCT03472001|No Intervention|Control group|The remaining students only attending dermatology electives
2868208|NCT03471988|Experimental|AK1820|Participants will receive a loading dose of isavuconazole, 200 mg three times a day by intravenous infusion (IV) or orally for the first 2 days followed by a maintenance dose from Day 3 of 200 mg once daily either IV or orally until they will reach a treatment endpoint or for a maximum of 84 days.
2868209|NCT03471988|Active Comparator|Voriconazole|Participants will receive a loading dose of voriconazole, 6 mg/kg every 12 hours IV or 300 mg every 12 hours orally for the first 24 hours, followed by a maintenance dose from Day 2 of 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they will reach a treatment endpoint or for a maximum of 84 days.
2868210|NCT03471975|Active Comparator|direct laryngoscope|teaching tracheal intubation using McGrath video laryngoscope as direct laryngoscope. Only trainer can see the monitor.
2868211|NCT03471975|Active Comparator|video laryngoscope|"teaching tracheal intubation using McGrath video laryngoscope using video function.~Trainer and Trainee both see the monitor."
2868212|NCT03471949|Experimental|CGM in a population with normal OGTT|A non-randomized, days 1-7 blinded, and days 8-14 non-blinded Dexcom G4 (CGM) trial. Each subject will sample capillary blood with the HemoCue meter and measure the concentration of glucose, minimum 3 times per day for 14 days.
2868213|NCT03471936|Other|Acquisition of pressure-volume loops|
2868214|NCT03471923||CD Patients|Subjects must have a prior diagnosis of cervical dystonia and be capable of participating in all study procedures. Subjects will undergo assessment of non-motor features.
2868215|NCT03471923||Family Members|Subjects must be a first order relation of a Vanderbilt patient diagnosed with cervical dystonia. The subject must pass a short neurological examination to ensure the subject does not have cervical dystonia or any sensory deficits. Subjects will undergo assessment of non-motor features.
2868216|NCT03471923||Healthy volunteers|Subjects must be healthy volunteers who are neurologically normal. The subject must pass a short neurological examination to ensure the subject does not have cervical dystonia or any sensory deficits. Subjects will undergo assessment of non-motor features.
2868217|NCT03471910|Experimental|Diosmin|Diosmin 600mg, one tablet once daily
2868218|NCT03471910|Active Comparator|Diosmin + Hesperidin|Diosmin 900mg + Hesperidin 100mg, one tablet once daily
2868219|NCT03471897||RCC|Patients with pathologically confirmed diagnosis of RCC
2868220|NCT03471897||Controls|Subjects self-reported as healthy
2868221|NCT03471884|Experimental|Nonintubated thoracoscopic lobectomy|Lung cancer patients undergoing thoracoscopic lobectomy without tracheal intubation
2868222|NCT03471884|Active Comparator|Intubated thoracoscopic lobectomy|Lung cancer patients undergoing thoracoscopic lobectomy with tracheal intubation and one-lung ventilation
2868223|NCT03471871|Experimental|HV Cohort,Sequence A:Placebo,Lemborexant 10mg,Lemborexant 25mg|Eligible healthy adult and elderly participants will receive lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 1, followed by lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 2, and then lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
2869068|NCT03466021|Placebo Comparator|Placebo|Placebo, matching injection pen
2868224|NCT03471871|Experimental|HV Cohort,Sequence B:Lemborexant 10mg,Lemborexant 25mg,Placebo|Eligible healthy adult and elderly participants will receive lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 1, followed by lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 2, and then lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period
2868225|NCT03471871|Experimental|HV Cohort,Sequence C:Lemborexant 25mg,Placebo,Lemborexant 10mg|Eligible healthy adult and elderly participants will receive lemborexant 25 mg (2 lemborexant 10 mg tablet and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 1, followed by lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 2, and then lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
2868226|NCT03471871|Experimental|OSA Cohort, Sequence D: Placebo, Lemborexant 10mg|Eligible adult and elderly participants with mild OSA will receive lemborexant-matched placebo (3 matched tablets) on the night of Day 1 through Day 8 of Treatment Period 1, followed by lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each Treatment Period.
2868227|NCT03471871|Experimental|OSA Cohort, Sequence E: Lemborexant 10mg, Placebo|Eligible adult and elderly participants with mild OSA will receive lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 through Day 8 of Treatment Period 1, followed by lemborexant-matched placebo (3 matched tablets) on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each Treatment Period.
2868228|NCT03471858|Active Comparator|Cervical Balloon|Transcervical 2-way 18 French (18F) single balloon Foley catheter, applied using a sponge-holding forceps into the cervical canal with the balloon inflated to a minimum of 30ml and maximum of 60ml with sterile water or saline [1]. This will be administered once during the study and will be retained for a maximum of 12 hours within the 24 hour study period.
2868229|NCT03471858|Active Comparator|Prostaglandin|Prostaglandin E2 (Prostin®) 3mg tablet, placed high in the vaginal fornix. This will be administered per vaginum once in the first 6 hours; a second dose is administered at the discretion of the clinician / clinical team 6 hours after the first pessary, for a cumulative total of 6mg within the 24 hour study period.
2868230|NCT03471845|Experimental|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
2868231|NCT03471819||Patients withf Atopic Dermatitis|Diagnosis is based upon American Academy of Dermatology recommendations for Diagnostic Criteria 2014.
2868232|NCT03471819||healthy volunteers|Normal individuals not complaining of any dermatological diseases
2868233|NCT03471806|Experimental|Bulimia Nervosa patients|Bulimia Nervosa patient group: Assessment of dopamine release to food reward at baseline (before treatment) and to food reward after treatment.
2868234|NCT03471806|Experimental|Healthy controls|Healthy control group: Assessment of dopamine release to food reward at baseline, for comparison with Bulimia Nervosa patients.
2868235|NCT03471793||Colonic polyp|Patients referred for EMR of a colonic polyp >20mm
2868236|NCT03471767|Experimental|AXS-05|Participants will receive AXS-05 (Dextromethorphan Immediate Release + Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
2868237|NCT03471767|Active Comparator|Bupropion SR|Participants will receive Bupropion SR (Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
2868238|NCT03471754|Experimental|Treatment Arm A|TESA-HB Device, Mode 3 (15mA). Treatment arm involves two 5-day treatment cycles over a 2-week period, with 2 days off between each of the 5-day cycles. The treatment period will as for two full weeks.
2868239|NCT03471741||MARA-2: IMRT with concomitant boost|A forward planned IMRT technique was used and the prescribed dose to the whole breast was 50 Gy plus a concomitant boost of 10 Gy to the tumor bed
2868240|NCT03471741||CG: 3D-RT with sequential boost|The whole breast received 50.4 Gy in 28 fractions delivered with 3D-RT, followed by a sequential boost on the tumor bed of 10 Gy in 4 fractions delivered with electrons
2868241|NCT03471728||Irritable Bowel Syndrome|Irritable Bowel Syndrome with Constipation (IBS-C) patients who have used linaclotide for the first time
2868242|NCT03471702|Experimental|Single Arm Study|All subjects enrolled on study will utilize Aqueduct's Smart External Drain (SED) from the time of external drain implementation until end of study upon discharge of SED or switch to standard of care external drain.
2868243|NCT03471689|Experimental|Mindfulness|
2868244|NCT03471689|Active Comparator|Positive reappraisal|
2868245|NCT03471676||Muscular oximetry|6 minutes walking test performed in the routine medical care with muscle oximetry recording in children suffering from neuromuscular diseases
2868246|NCT03471663|Experimental|D-0502|D-0502
2868247|NCT03471663|Experimental|D-0502 in combination with palbociclib|D-0502 in combination with palbociclib
2868248|NCT03471650|Experimental|18F-DCFPyL Injection|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
2868249|NCT03471637|Experimental|Compassion-Focused Therapy|"Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy [based on Compassion-Focused Therapy for Dummies (Welford, 2016)]"
2868250|NCT03471624|Experimental|Tenofovir Alafenamide for 24 months|Subjects on any antiviral treatment for chronic HBV who plan to be switched by their physician to be treated with TAF 25 mg for 24 months.
2868251|NCT03471611|Experimental|Subjects with Endothelial Dysfunction|Subjects will be treated with Granulocyte Colony-Stimulating Factor (G-CSF) for 5 days at a dose of 5 mg/kg twice daily. When count of CD34+ cells is sufficient, the CD34+ cells will be collected by apheresis. Autologous CD34+ cells will be injected into the subjects at a rate of 10 ml/min.
2868295|NCT03471260|Experimental|Ivosidenib + Venetoclax|"Participants take Venetoclax by mouth 1 time each day on Days 1-14 of each 28 day cycle.~Participants take Ivosidenib by mouth once each day starting with Day 15 of Cycle 1."
2868447|NCT03470194|Active Comparator|Interpretation Modality: Telephonic|Participants assigned to this group will use a phone interpreter for the duration of the UROGYN office visit
2868252|NCT03471585|Placebo Comparator|Placebo oral capsule|Participants came in for an encoding session, followed 48 hours later by a retrieval session. Participants received a placebo capsule (dextrose) during the retrieval session, 2 hours prior to their memories being tested. Participants were monitored for the next 2 hours including physiological and subjective measures every 30 minutes. After 2 hours, participants' memory for the emotional stimuli and Deese-Roediger-McDermott (DRM; a false memory task) stimuli was tested. After the memory tests and 3.5 hours post-capsule, if participants' physiological and subjective measures had returned to baseline, they were allowed to leave. Other than the capsule, this arm was identical to the THC arm.
2868253|NCT03471585|Experimental|THC|Participants came in for an encoding session, followed 48 hours later by a retrieval session. Participants received a capsule containing THC (dronabinol) during the retrieval session, 2 hours prior to their memories being tested. Participants were monitored for the next 2 hours including physiological and subjective measures every 30 minutes. After 2 hours, participants' memory for the emotional stimuli and Deese-Roediger-McDermott stimuli was tested. After the memory tests and 3.5 hours post-capsule, if participants' physiological and subjective measures had returned to baseline, they were allowed to leave. Participants were monitored for the next 2 hours including physiological and subjective measures every 30 minutes. Other than the capsule, this arm was identical to the Placebo arm.
2868254|NCT03471572||1|Ovarian Cancer
2868255|NCT03471559|Active Comparator|Reference formulation|Cannabidiol capsule, 200 mg
2868256|NCT03471559|Experimental|New formulation|Cannabidiol, intranasal gel (XX mg, dose need to be determined during the study)
2868257|NCT03471546|Experimental|Palliative care|Newly diagnosed patients will be referred to a palliative care provider in the clinic for initial consultation and follow-up during their initial treatment for WHO Grade IV malignant glioma. Patients will be asked to complete a number of questionnaires and assessment forms at different time intervals during the course of their initial treatment. In addition, we will ask patients' neuro-oncology providers for feedback regarding their satisfaction with the Palliative Care services provided to the patient.
2868258|NCT03471533|Experimental|Ëxperimental|Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg
2868259|NCT03471533|Placebo Comparator|Placebo|
2868260|NCT03471520|Experimental|Earplugs and eye masks|
2868261|NCT03471507|Experimental|Bonipar|
2868262|NCT03471507|Active Comparator|Diclofenac gel 1%|
2868263|NCT03471494||Breast cancer|
2868264|NCT03471494||Gastric cancer|
2868265|NCT03471494||Colon cancer|
2868266|NCT03471468|Experimental|kinetics of microparticles under chemotherapy|kinetics of microparticles under chemotherapy in patients with pancreatic or gastric cancer by serial measurements of microparticles procoagulant activity.
2868267|NCT03471455|Active Comparator|Terbinafine alone|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks.
2868268|NCT03471455|Active Comparator|Terbinafine plus isotretinoin|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.
2868269|NCT03471455|Active Comparator|Itraconazole only|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks.
2868270|NCT03471455|Active Comparator|Itraconazole plus isotretinoin|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.
2868271|NCT03471442|Active Comparator|Paravertebral|Ultrasound-guided paravertebral block performed pre-operatively with 20ml of a ropivacaine / bupivacaine mixture.
2868272|NCT03471442|Experimental|Erector spinae plane|Ultrasound-guided erector spinae plane block performed pre-operatively with 20ml of a ropivacaine / bupivacaine mixture.
2868273|NCT03471429||Dog|Patient sees therapy dog for 15 minutes, which is standard of care at this hospital.
2868274|NCT03471429||No Dog|Patient receives standard of care
2868275|NCT03471416||Children with ALL|Children undergoing ALL treatment at UNOP Guatemala who are under the age of 18 years.
2868276|NCT03471403||FAP|FAP patients with duodenal adenomas
2868277|NCT03471390|Experimental|ProQuaS 2- Intervention|
2868278|NCT03471377|Active Comparator|standard scheduling process|Scheduling office assigns start time and room for case and places case on schedule. At this point a default case duration is evaluated by the scheduling office, to see if the value is considered excessively short or excessively long.
2868279|NCT03471377|Experimental|assigned a planned case duration value from predictive model|Predictive model calculates new duration for case at 3AM the day before surgery, and the predictions are made available on a SecureShare-site.
2868280|NCT03471364|Experimental|Arm I (ketoconazole)|Participants apply ketoconazole topically BID on days 1-28.
2868281|NCT03471364|Placebo Comparator|Arm II (placebo)|Participants apply placebo topically BID on days 1-28.
2868282|NCT03471351|Experimental|Tenalisib+Pembrolizumab|Participants receive Tenalisib in escalating doses Orally BID and pembrolizumab as a fixed dose intravenously (IV) in Escalation and Expansion.
2868283|NCT03471338|Experimental|Experimental Group|Patients benefit cognitive rehabilitation
2868284|NCT03471338|Sham Comparator|Standard Psychological care|Patients do not benefit cognitive rehabilitation
2868285|NCT03471325|Experimental|Plaque Disclosed with Air Flow (PDAF)|Plaque will be disclosed prior to polishing with the air flow system.
2868286|NCT03471325|Experimental|Plaque Disclosed with Rubber Cup (PD-RC)|Plaque will be disclosed prior to polishing with the rubber cup and fine grit prophylaxis paste.
2868287|NCT03471325|Experimental|Non Plaque Disclosed Air Flow (NPD-AF)|Air polishing system will be used to remove the plaque
2868288|NCT03471325|Placebo Comparator|Non Plaque Disclosed Rubber Cup (NPD-RC)|Rubber Cup polishing to remove plaque.
2868289|NCT03471312||treated with magnesium therapy|will receive magnesium sulphate 10 mg \kg \day as a single oral dose for one month duration
2868290|NCT03471312||treated with placebo drug|will receive placebo drug
2868291|NCT03471286|Experimental|Sub-Protocol A|Epacadostat
2868292|NCT03471273|Other|endoscopic management|
2868293|NCT03471273|Other|follow up|
2868294|NCT03471273|Other|surgery|
2891155|NCT03311334|Experimental|DSP-7888 in combination with Nivolumab|
2868296|NCT03471247|Experimental|In-Bed Cycle Ergometer + Routine PT|Patients will receive 30 minutes of in-bed cycling once per day, 5 days per week, while they remain in the ICU, for up to a maximum of 28 days. They will also receive routine physiotherapy.
2868297|NCT03471247|Active Comparator|Routine PT|Patients will receive routine physiotherapy interventions per current institutional practice
2868298|NCT03471221|Experimental|Therapy Dog Visits|"Participants randomized to Therapy Dog Visits will receive a visit from a therapy dog and handler team up to one time per week for up to four weeks, depending on length of hospitalization and therapy dog team capacity.~Therapy dog visits will last up to about 20 minutes and activities may include: petting the dog, watching the dog perform a trick, and talking with the dog handler.~All activities will follow the current procedures and regulations in place at Seattle Children's Hospital."
2868299|NCT03471221|No Intervention|Control Group|Participants randomized to the Control Group will receive usual medical care.
2868300|NCT03471208|Experimental|Dynamic Navigation|Dental implant surgery via dynamic navigation assistance
2868301|NCT03471208|Active Comparator|Freehand|Dental implant surgery via conventional freehand
2868302|NCT03471195||CP|A total of 20 children with cerebral palsy and dental decay will undergothe following Collection of Saliva Total Salivary Cytokine Profile
2868303|NCT03471195||Control|A total of 20 verbal children without cerebral palsy matched for age and extent of dental decay will undergo the following Collection of Saliva Total Salivary Cytokine Profile
2868304|NCT03471182|Active Comparator|Psychiatric and Cognitive Testing|All participants will complete psychiatric assessment and cognitive testing.
2868305|NCT03471182|Active Comparator|Cocaine Self-adminstration|This arm plans to assess the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug in a human laboratory study of self-regulated cocaine administration.
2868306|NCT03471182|Active Comparator|Positron Emission Tomography|All participants will complete a PET scan to assess mGluR5 receptors using [18-F]FPEB
2868307|NCT03471182|Active Comparator|Magnetic Resonance Imaging|All participants will complete one MRI scan to assess brain structure and function.
2868308|NCT03471169|Experimental|Desirable TEG|Patients receiving antiplatelet medication and desirable thrombelastogram(TEG) test results.
2868309|NCT03471169|Sham Comparator|Undesirable TEG|Patients receiving antiplatelet medication and undesirable thrombelastogram(TEG) test results.
2868310|NCT03471156||Post EMR|Patients are observed post EMR procedure for pain. Standard of care data is collected
2868311|NCT03471143|Experimental|IV VTS-270 for NPC1 infants|"Phase 1: Dosing frequency will be twice a week administered via a peripherally inserted central catheter (PICC) for six weeks for a total of 12 administrations. Doses 3-12 will occur as an outpatient.~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6 will receive 500 mg/kg Cohort 2: Subjects 7-12 will receive 1000 mg/kg Subjects who demonstrate statistically significant reduction either in the glycine-conjugated trihydroxycholanic acid biomarker or serum bilirubin (direct bilirubin or direct bilirubin:total bilirubin ratio) will be allowed to crossover into the second phase of the study, an open-label phase of six months duration. In the this phase of the study, dosing frequency will be monthly with IV VTS-270 administered via peripheral IV access for six months for a total of six administrations."
2868312|NCT03471130|Experimental|Low dose MT-8554 or placebo to match|Low dose MT-8554
2868313|NCT03471130|Experimental|High dose MT-8554 or placebo to match|High dose MT-8554
2868314|NCT03471117|Active Comparator|Pioglitazone|The subjects will be given 1 month supply of Pioglitazone pills. Pioglitazone is a class of anti-diabetic drugs called thiazolidinediones that are primarily used in the treatment of type 2 diabetes. The aim of the study is to determine if Pioglitazone also reduces ADMA and sympathetic nerve activity in CKD patients. This drug will be taken orally as a pill or capsule for one month. The dosage is 15 mg/day. This is on the lower dosage side for pioglitazone with the maximum dosage being 45mg/day. The research subjects are not responsible for the cost of the drug or for drug administration costs. The subjects will be verbally instructed to take 1 pill everyday by mouth, for 1 month. In addition, the pill bottle will be labeled with the same instructions.
2868315|NCT03471117|Placebo Comparator|Placebo|Placebo will consist of sugar capsules of similar color and appearance as Pioglitazone pills.
2868316|NCT03471104|Experimental|PAID in clinical diabetes consultations|Participants randomised to the intervention arm. Participants complete the Problem Area in Diabetes scale (PAID) and evaluation PROMs. Participants with specified PAID scores will be offered an empowerment-based follow-up by diabetes specialist nurses.
2868317|NCT03471104|No Intervention|Control group|Participants randomised to the control group. Participants complete PROMs but the results/answers will not be available in the electronic patient records until the trial is finished. The participants will receive standard care.
2868318|NCT03471091|Experimental|Intervention group|"Intervention group subjects will use NIV with the integrated tele-monitoring management program as home therapy and accomplish the following tasks via mobile COPD Butler APP: 1) upload daily NIV usage data， blood pressure, oxygen saturation, and heart rate measurement; 2) daily medication taken recording; 3) regular self-reported health questionnaire and symptom recording; 4) read health education materials.~Information collected from the intervention group by the APP will be monitored by physician team from the leading hospital through physician web portal. The physician team will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly."
2868319|NCT03471091|No Intervention|Control group|Control group subjects will only use NIV according to their treatment plan at home. NIV usage data will be read from the NIV secure digital memory card for the control group.
2868320|NCT03471078|Experimental|Avatrombopag|Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
2868321|NCT03471078|Placebo Comparator|Placebo|Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
2868322|NCT03471065|Experimental|SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV|Patients will be implanted with the SAPIEN 3 Ultra THV using the SAPIEN 3 Ultra Delivery System
2868323|NCT03471052|Experimental|Radiofrequency ablation (RFA)|Radiofrequency ablation (RFA)
2868324|NCT03471052|No Intervention|Sham procedure|Endoscopy will be performed under conscious sedation and all BarrX RFA equipment will be set up in room. A sound recording of the BarrxTM RFA device will be played (a distinct bell sound that is emitted from the generator) during the procedure.
2868325|NCT03471039|Active Comparator|Active|PACAP-27
2868326|NCT03471039|Placebo Comparator|Placebo|Saline
2868327|NCT03471026||pCMS+|Children undergoing infratentorial craniotomy for brain tumour resection whom develop pCMS will undergo pre-, post-operative and delayed follow-up advanced MRI sequences
2868328|NCT03471026||pCMS-|Children undergoing infratentorial craniotomy for brain tumour resection whom do not develop pCMS will undergo pre-, post-operative and delayed follow-up advanced MRI sequences
2868329|NCT03471026||Controls|Healthy control children whom have never undergone intracranial surgery have had advanced MRI sequences acquired
2868330|NCT03471013||Patients and caregivers|Patients suffering from schizophrenia accompanied by their caregiver
2868331|NCT03471000|Experimental|Short implants Treatment|Group 2 (G2; n=15 patients) had short implants (OsseoSpeed ™ L6mm Ø4 mm) [DENTSPLY Implants, Waltham, MA, USA] placed without sinus lift and augmentation procedure.
2868332|NCT03471000|Active Comparator|Regular Implants Treatment|Group 1 (G1; n=15 patients) had conventional dental implants (OsseoSpeed ™ L11 Ø4 mm and L13 Ø4 mm) [DENTSPLY Implants, Waltham, MA, USA] placed, preceded by the sinus lift procedure from a lateral window approach with the application of the xenogeneic bone graft Geistlich Bio-Oss® [Geistlich AG, Wolhusen, Switzerland]. The lateral window approach sinus lift surgery was performed 6 weeks prior to the implant placement by the same surgeon.
2868333|NCT03470987||Group 1:nO-Ctrl|Non-obese patients without generalized chronic periodontitis who were undergone Phase I periodontal therapy
2868334|NCT03470987||Group 2:nO-CP|Non-obese patients with generalized chronic periodontitis who were undergone Phase I periodontal therapy
2868335|NCT03470987||Group 3: O-Ctrl|Obese patients without generalized chronic periodontitis who were undergone metabolic control and Phase I periodontal therapy
2868336|NCT03470987||Group 4: O-CP|Obese patients with generalized chronic periodontitis who were undergone metbolic control and Phase I periodontal therapy
2868337|NCT03470974|Experimental|Intervention Group|The intervention group receives self-titration strategy training and lifestyle education.
2868338|NCT03470974|No Intervention|Control Group|The control group receives usual care and lifestyle education.
2868339|NCT03470961|Experimental|Anti-Tlymphocyte Globulins|intravenous，2mg/kg/d，for 5 days
2868340|NCT03470961|Active Comparator|Anti-thymocyte Globulins|intravenous，1.5mg/kg/d，for 4 days
2868341|NCT03470922|Experimental|Arm A: Relatlimab + Nivolumab|Combination
2868342|NCT03470922|Experimental|Arm B: Nivolumab|Monotherapy
2868343|NCT03470909|Other|Skin-Sparing Mastectomy (SSM)|
2868344|NCT03470909|Other|Nipple-Sparing Mastectomy (NSM)|
2868345|NCT03470896|Active Comparator|Preanesthesia teleconsultation|Preanesthesia teleconsultation through video-conference, between an anesthesiologist of the surgical center Emile Galle, in a medical consulting room in the surgical center Emile Galle, and a patient at home or at work. The patient must be in a quiet area, which allows the confidential medical contact.
2868346|NCT03470896|Active Comparator|Preanesthesia traditional consultation|Preanesthesia traditional consultation between an anesthesiologist of the surgical center Emile Galle, and a patient, in a medical consulting room in the surgical center Emile Galle.
2868347|NCT03470896|Other|Bis traditional consultation|"If a patient, in the group  preanesthesia teleconsultation  cannot realized his teleconsultation because of technical problem, he will be assigned on the sub group  bis traditional preanesthesia consultation ."
2868348|NCT03470883||endoscopic resection of a colorectal lesion|Patient having undergone endoscopic resection of a colorectal lesion stage 4 or 5 of the modified Vienna classification during the last 5 years at the institute.
2868349|NCT03470870||Patients discharged before 2 days after surgery|patients discharged before 2 days of hospitalization following surgery
2868350|NCT03470870||Patients discharged after 2 days after surgery|patients discharging after 2 days of hospitalization following surgery
2868351|NCT03470857||Patients|Oncological patients: lymphomas (Hodgkin's, DLBCL), breast and ovarian cancers, brain gliomas.
2868352|NCT03470857||Control|The number at most half as large as the patients' group, composed of healthy people at similar age and the same sex as patients.
2868353|NCT03470844||5-10 years post severe burn injury|"Interventions:~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~Quality of Life Self-Assessment data."
2868354|NCT03470844||2-5 years post severe burn injury|"Interventions:~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~Quality of Life Self-Assessment data."
2868355|NCT03470844||1-2 years post severe burn injury|"Interventions:~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~Quality of Life Self-Assessment data."
2868428|NCT03470311|Placebo Comparator|Placebo|Matched placebo (1mL) to active Benralizumab subcutaneously
2869574|NCT03462589|Experimental|SY-008 dose 6|A single dose of SY-008 (2~30mg) taken orally.
2868356|NCT03470844||Control|"Healthy age, gender, socioeconomic and educational level matched control.~Interventions:~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~Quality of Life Self-Assessment data."
2868357|NCT03470818|Experimental|Intervention group|"Preparatory instructional videos (flipped classroom model)~32 participants~Application of a flipped classroom model~Prior to the simulation session, the intervention group will have received the study intervention. This consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session"
2868358|NCT03470818|Sham Comparator|Control group|"Sham videos~Participants in the control group will also be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility.~This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to."
2868359|NCT03470805|Experimental|Olaparib|Olaparib orally twice daily at 150 mgs bid continually
2868360|NCT03470792|Experimental|Microcirculation-assisted|ECMO blood flow will be adjusted by conventional clinical conditions, hemodynamic parameters and microcirculation parameters
2868361|NCT03470792|Active Comparator|Control|ECMO blood flow will be adjusted by clinical conditions and conventional hemodynamic parameters
2868362|NCT03470779|Experimental|Treatment group|Participants randomly assigned to the treatment group will participate in an interdisciplinary treatment program in which local Kurdish psychotherapists and physiotherapists provide a 10-week intervention program. Treatment will consist of group physiotherapy and group psychotherapy
2868363|NCT03470779|No Intervention|Wait-list group|Participants randomly assigned to the wait-list group will not receive treatment but will participate in outcome data collection for comparison purposes.
2868364|NCT03470766|Active Comparator|Active Lead (AL)|One octad lead placed where contacts 4 and 5 span the T9-T10 disc space.
2868365|NCT03470766|Sham Comparator|Sham Lead (SL)|One octad lead implanted subcutaneously behind the IPG and will serve to dissipate the current from the battery
2868366|NCT03470753|Active Comparator|Exercise Amount|Phase 1: 2 or 4 exercises.
2868367|NCT03470753|Active Comparator|Type of instruction|Phase 1: Handout on paper versus handout and visual demonstration/performance.
2868368|NCT03470753|Active Comparator|Delivery Type|Phase 2: Handout vs electronic delivery
2868369|NCT03470753|Experimental|Reminder Type|Phase 2: Mobile reminders vs no mobile reminders
2868370|NCT03470740|Other|intervention group|An individualized home-based rheumatoid arthritis self-management program for managing RA patients' physical behavioral problems was applied for the intervention group. The program was based on the self-efficacy theory and the four resources were incorporated to emphasize patients' knowledge, skill, and responsibility in managing their RA situations.
2868371|NCT03470740|No Intervention|control group|The control group received general information on rheumatoid arthritis care and follow-up.
2868372|NCT03470727|Experimental|Citrate arm|Citrate dialysate Phase 1 : Reduce heparin to 50% Phase 2: Reduce heparin to 25% Phase 3: Heparin free
2868373|NCT03470714|Experimental|Kinesiotaping Group|The group in which kinesiotaping is applied to non-dominant biceps brachii muscle of participants before 24 hours the force irradiation experiment.
2868374|NCT03470714|Active Comparator|Control group|The group in which the participants only perform the the force irradiation experiment.
2868375|NCT03470701|No Intervention|Control - usual care|This arm will receive usual care.
2868376|NCT03470701|Experimental|Mailed Urinalysis Smartphone Kit|This arm will receive a mailed urinalysis smartphone kit if they do not complete albuminuria screening after the initial reminder to do so.
2868377|NCT03470688||Originator|Originator anti-TNF agents. Dosage as per physician's decision based on approved indication.
2868378|NCT03470688||Biosimilar|Biosimilar anti-TNF agents. Dosage as per physician's decision based on approved indication.
2868379|NCT03470675|Placebo Comparator|Epidural saline + IV saline|Sterile saline via the epidural catheter. Sterile saline via intravenous catheter.
2868380|NCT03470675|Active Comparator|Epidural morphine 3 mg + IV saline|3 milligrams morphine via the epidural catheter. Sterile saline via intravenous catheter.
2868381|NCT03470675|Active Comparator|Epidural morphine 3 mg + IV ketamine 0.3 mg/kg|3 milligrams morphine via the epidural catheter. Ketamine 0.3 milligrams per kilogram via intravenous catheter.
2868382|NCT03470662|Experimental|experimental group|Care bundle
2868383|NCT03470662|No Intervention|control group|routine care
2868384|NCT03470649|Experimental|Treatment|Patients in this group would receive Iron Isomaltoside 1000 (Monofer®) after main procedure of total knee arthroplasty. The dose of iron isomaltoside would be determined based on the patient's body weight.
2868385|NCT03470649|No Intervention|Control|Patients in this group would receive 100ml of normal saline after main procedure of total knee arthroplasty.
2868386|NCT03470636|Experimental|HeartLight X3|Pulmonary vein isolation using HeartLight X3
2868387|NCT03470623|Experimental|bioabsorbable screws|hallux valgus treated with chevron osteotomy using bioabsorbable screws
2868388|NCT03470623|Experimental|steel screws|hallux valgus treated with chevron osteotomy using steel screws
2868389|NCT03470597||Pregnant women with pre-gestational HSG history|All enrolled pregnant women with pre-gestational ethiodized-oil HSG will be followed up without grouping and be kept track for maternal and offspring's health outcomes in this case registry study.
2869945|NCT03460054||Mesangioproliferative Glomerulonephritis (MPGN)|Biopsy-Proven MPGN
2868390|NCT03470584||Tzu Chi Vegetarian Study|12062 Tzu Chi volunteers of the Buddhist Tzu Chi Foundation recruited throughout communities in Taiwan in the year 2005. All participants filled out a self-administered questionnaire on basic information, medical history, lifestyle, and diet. Diet exposure: 1/3 vegetarians, 2/3 nonvegetarians.
2868391|NCT03470584||Tzu Chi Health Study|6002 participants who came for health examination at the Dalin Tzu Chi Hospital between the years 2007 to 2009. 77% were Tzu Chi volunteers. All participants were interviewed on a structured questionnaire including basic information, medical history, lifestyle, and diet, and received a comprehensive health examination. Diet exposure: 1/3 vegetarians, 2/3 nonvegetarians.
2868392|NCT03470558||Sleeve gastrectomy patients|Patients electing to undergo sleeve gastrectomy will monitor their dietary habits.
2868393|NCT03470545|Experimental|mavacamten (MYK-461)|
2868394|NCT03470545|Placebo Comparator|Placebo|
2868395|NCT03470532|Experimental|Group A|buccal infiltration of 4% Articaine with epinephrine
2868396|NCT03470532|Active Comparator|Group B|buccal infiltration of 2% Mepivacaine with epinephrine
2868397|NCT03470506||Ischemic stroke|Diagnosed with an ischemic stroke by a Vascular Neurologist
2868398|NCT03470506||Transient Ischemic Attack|Diagnosed with a Transient Ischemic Attack by a Vascular Neurologist
2868399|NCT03470493|Experimental|Participants|ApneaLink Air
2868400|NCT03470480|Experimental|Treatment rTMS + meth pictures|Participants in this group will receive real repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of methamphetamine-related pictures to evaluate response to methamphetamine visual cues while receiving real rTMS treatments. This group will be referred to as real METH (RM).
2868401|NCT03470480|Active Comparator|Treatment rTMS + neutral pictures|Participants in this group will receive real repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of neutral pictures to evaluate response to neutral visual cues while receiving real rTMS treatments. This group will be referred to as real neutral (RN).
2868402|NCT03470480|Sham Comparator|Sham rTMS + meth pictures|Participants in this group will receive sham repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of methamphetamine-related pictures to evaluate response to methamphetamine visual cues while receiving sham rTMS treatments. This group will be referred to as sham METH (SM).
2868403|NCT03470480|Sham Comparator|Sham rTMS + neutral pictures|Participants in this group will receive sham repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of neutral pictures to evaluate response to neutral visual cues while receiving sham rTMS treatments. This group will be referred to as sham neutral (SN).
2868404|NCT03470454||diabetics on linagelptin|Diabetic patients were given linagelptin for blood glucose control
2868405|NCT03470454||diabetics on other DPP4 inhibitors|Diabetic pateints were given other DPP4 inhibitors eg: vlidagliptin for blood glucose control
2868406|NCT03470441|Experimental|FDY-5301 Low Dose|Anticipated n=20
2868407|NCT03470441|Experimental|FDY-5301 Intermediate Dose|Anticipated n=20
2868408|NCT03470441|Experimental|FDY-5301 High Dose|Anticipated n=20
2868409|NCT03470441|Placebo Comparator|Placebo|Anticipated n=20
2868410|NCT03470428||Pediatric Fontan Patients|Participants ages 10 to 18 who have had Lateral Tunnel or Extracardiac Fontan procedures.
2868411|NCT03470428||Adult Fontan Patients|Participants ages 18 to 60 who have had Lateral Tunnel or Extracardiac Fontan procedures.
2868412|NCT03470415||Group A|Patients with type 2 diabetes milletus with normoalbuminuria.
2868413|NCT03470415||Group B|Patients with type 2 diabetes milletus with microalbuminuria.
2868414|NCT03470415||Group C|Patients with type 2 diabetes milletus with macroalbuminuria.
2868415|NCT03470402|Experimental|Intervention group|"Women who screen as eligible for BRCA genetic counseling will receive the education and decision support tool, RealRisks, along with standard educational material and a high-risk message. The high-risk status of the women will also be flagged in the online tool used by the hospital to visualize electronic health record data (iNYP).~The enrolled health care providers of these women will be given access to BNAV, which summarizes their enrolled patients' breast cancer risk profiles and provides educational resources on genetic testing and prevention options. Before their clinical encounter with an enrolled patient, these providers will also be sent the personalized breast cancer risk summary that is created by data the patient entered into RealRisks."
2868416|NCT03470402|Active Comparator|Control group|Women who screen as eligible for BRCA genetic counseling will receive standard educational material and a high-risk message. The high-risk status of the women will also be flagged in the online tool used by the hospital to visualize electronic health record data (iNYP).
2868417|NCT03470389|Experimental|HVPG|Blood test, Doppler ultrasound, computed tomography and HVPG measurements will be performed within 5 days and treatments that may affect HVPG will be avoided during this possess.
2868418|NCT03470376|Experimental|Nutraceutical combination (NC)|Patients on standardized diet regimen taking a NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day for 3 months
2868419|NCT03470376|Active Comparator|No nutraceutical combination (noNC)|Patients on standardized diet regimen without taking any NC
2868420|NCT03470363|Active Comparator|Group Spinal anesthesia|"Knee surgery under spinal anesthesia~Intervention involves spinal administration of 12,5 mg bupivacaine and 2,5 microgram sufentanil."
2868421|NCT03470363|Active Comparator|Group Sevoflurane anesthesia|"Knee surgery under sevoflurane anesthesia~Intervention involves administration of inhaled sevoflurane for maintenance of general anesthesia"
2868422|NCT03470350|Experimental|TGF-beta activated colorectal cancer|TGF-beta activated advanced colorectal cancer treated with galunisertib and capecitabine
2868423|NCT03470337|Experimental|Phlogenzym|Treatment with German licensed drug Phlogenzym (6 tablets/day)
2868424|NCT03470337|Placebo Comparator|Placebo|Placebo equates Phlogenzym but without active ingredients
2868425|NCT03470324|Active Comparator|[standard STN] + swallowing therapy|standard stimulation on subthalamic (STN) contacts plus swallowing therapy
2868426|NCT03470324|Experimental|[STN+SNr] + swallowing therapy|Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) plus swallowing therapy
2868427|NCT03470311|Active Comparator|Benralizumab|Benralizumab 30mg in 1mL subcutaneously
2868429|NCT03470298|Active Comparator|Mid luteal Endometrial Scratching (MLES)|Making injury to endometrium by using Manual Vacuum Aspiration cannula size 5 . At this arm scratching done at mid luteal phase (day21) of the cycle before induction for ICSI
2868430|NCT03470298|Active Comparator|Retrieval Endometrial Scratching (RES)|Making injury to endometrium by using Manual Vacuum Aspiration cannula size 5 .Here scratching done at same day of ovum pick up of ICSI cycle the difference only between arm of MLES and RES only in the timing of scratching .
2868431|NCT03470285|Other|Patients with small solid renal tumor|In addition to the actual workflow for a patient presenting a renal tumor, patients will undergo an additional Multiparametric MR imaging (mpMRI).
2868432|NCT03470272|Experimental|Active Device|"Active Device: The FB Professional LED red light therapy system~FB Professional is a treatment regime using the FB Professional device for fat removal using red light therapy.~Intervention device: FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs."
2868433|NCT03470259|Experimental|EMI-137 0.09mg/kg administration|"Three patients will be once administered with EMI-137 0.09 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
2868434|NCT03470259|Experimental|EMI-137 0.13mg/kg administration|"Three patients will be once administered with EMI-137 0.13 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
2868435|NCT03470259|Experimental|EMI-137 0.18mg/kg administration|"Three patients will be once administered with EMI-137 0.18 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
2868436|NCT03470259|Experimental|EMI-137 0.045mg/kg administration|"If we have a excellent tumor to background ratio ((tumor fluorescence)/(surrounding tissue fluorescence)) in the 0.09 mg/kg group, we will de-escalate back to a 0.045 mg/kg group to evaluate TBR and reduce possible tracer toxicity in a thyroid cancer population with 90% 20 year survival.~Three patients will be once administered with EMI-137 0.045 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
2868437|NCT03470246|No Intervention|CABG control group|The group of coronary artery disease patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after coronary artery bypass grafting. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
2868438|NCT03470246|Experimental|PACO intervention for CABG patients|The group of coronary artery disease patients receiving the PACO intervention for CABG patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after coronary artery bypass grafting. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
2868439|NCT03470246|No Intervention|AVR control group|The group of aortic valve stenosis patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after aortic valve replacement. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
2868440|NCT03470246|Experimental|PACO intervention for AVR patients|The group of aortic valve stenosis patients receiving the PACO intervention for AVR patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after aortic valve replacement. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
2868441|NCT03470246|No Intervention|MVR control group|The group of mitral valve insufficiency patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after mitral valve repair. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
2868442|NCT03470246|Experimental|PACO intervention for MVR patients|The group of mitral valve insufficiency patients receiving the PACO intervention for MVR patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after mitral valve repair. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
2868443|NCT03470220||Ultrasound|All included patients will be examined with ultrasound
2868444|NCT03470207|No Intervention|Post-Intervention Cohort (Aim 1)|This arm will not have the intervention of the implementation of the structured post-pulmonary embolism follow up protocol that is outlined in Aim 1.
2868445|NCT03470207|Experimental|Pre-Intervention Cohort (Aim 3)|This arm will have the intervention of the implementation of the structured post-pulmonary embolism follow up protocol that is outlined in Aim 1.
2868446|NCT03470194|Active Comparator|Interpretation Modality: In person|Participants assigned to this group will use an in person interpreter for the duration of the UROGYN office visit
2869946|NCT03460054||Minimal Change Disease (MCD)|Biopsy-Proven MCD
2868448|NCT03470181||Participants with Diagnosed CVS|This cohort will consist of 15 current patients previously diagnosed with Cyclic Vomiting Syndrome.
2868449|NCT03470181||Healthy Volunteers|This cohort will consist of 15 healthy volunteers, with no history of Cyclic Vomiting.
2868450|NCT03470168|Experimental|Hyperbaric Oxygen Therapy|Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.
2868451|NCT03470168|Placebo Comparator|Placebo group|were also taken inside the Hyperbaric Chamber, but received only normobaric oxygen therapy for the same period of time at 1 ATA
2868452|NCT03470155||functional mitral insufficiency op|Patients with functional mitral insufficiency with restricted leaflet movement during systole (type IIIb Carpentier) undergoing operative reconstruction (mitral valve repair)
2868453|NCT03470142|Active Comparator|traditional laparoscopy-assisted surgery|The traditional laparoscopic operation undergo and then a small incision(5cm) is made in the middle of the lower abdominal wall to trim the mesangial membrane and remove the specimen. At last the anastomosis operation undergo by the laparoscopic operation.
2868454|NCT03470142|Experimental|total laparoscopic surgery with no incision (NOSES)|The whole procedures undergo by total laparoscopic surgery with no incision in the abdominal wall. The specimen then will be removed through natural orifice such as anal.
2868455|NCT03470129|Active Comparator|Helioseal F|fissure sealing with the conventional product
2868456|NCT03470129|Experimental|Helioseal F Plus|fissure sealing with the new product
2868457|NCT03470116|Experimental|MacGrath MAC video laryngoscopy|Patients will benefit MacGrath MAC video laryngoscopy for intubation after curarization
2868458|NCT03470116|Active Comparator|direct laryngoscopy|Patients will benefit direct laryngoscopy for intubation after curarization
2868459|NCT03470103||Treatment naïve wAMD|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
2868460|NCT03470103||Treatment naïve DME|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
2868461|NCT03470103||Previously treated wAMD|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
2868462|NCT03470103||Previously treated DME|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
2868463|NCT03470090|Experimental|Neuromuscular Exercises Group|This group of patients received patient with knee osteoarthritis. It will be applied classical physiotherapy and neuromuscular exercises training
2868464|NCT03470090|Active Comparator|Conventional Group|This group of patients received patient with knee osteoarthritis. It will be applied classical physiotherapy and conventional exercises.
2868465|NCT03470077|Experimental|Group A|40 randomly allocated Patients undergoing strabismus surgery will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.
2868466|NCT03470077|Experimental|Group B|40 randomly allocated Patients undergoing strabismus surgery.will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.
2868467|NCT03470064||RV Dysfunction|All pediatric patients who present to pediatric cardiothoracic unit, Assiut University Hospital and who meet the listed inclusion and exclusion criteria will be eligible for the study. Patients' charts will be retrieved based on their surgical procedures. The charts will be reviewed and eligible patients will be filtered. The needed variables will be entered into our data base for later data analysis
2868468|NCT03470051||(2) QT Ultrasound scans prior to breast biopsy|Subjects will undergo a baseline QT scan, and a follow-up QT scan performed between 90 days and 180 days from their baseline QT Scan accompanied by a HHUS and ultrasound-guided breast biopsy following the first follow-up QT scan. BI-RADS will be confirmed by the radiologist at the time of the first HHUS. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for an additional follow-up QT Scan 12 months from the time of their baseline QT Scan.
2868469|NCT03470051||(0-1) QT Ultrasound scans prior to breast biopsy|"Subjects that have not had (2) two QT Scans before their breast biopsy and who haven't yet had a breast biopsy will undergo an optional baseline QT scan accompanied by a HHUS and ultrasound-guided breast biopsy. BI-RADS will be confirmed by the radiologist. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for a follow-up QT Scan between 90 and 180 days from the time of their study biopsy.~Subjects that have had a breast biopsy on their identified breast mass(es) prior to study enrollment and have not already had two (2) QT Scans will undergo an optional baseline QT scan if between 0 and 30 days from their breast biopsy.~Subjects will be asked to come back for a follow-up QT Scan 12 months from the time of their study biopsy."
2868470|NCT03470038|Experimental|NGF phase|All participants will receive five injections with NGF (1ug/0.5ml) into the tibialis anterior muscle in their non-dominant leg
2868471|NCT03470038|Placebo Comparator|Control phase|All participants will receive five injections with isotonic saline (9%/0.5ml) into the tibialis anterior muscle in their non-dominant leg
2868472|NCT03470025|Experimental|Psychological Intervention|A weekly combined face to face & telephone-based PI (F-TPI); Psychological Intervention and medical therapy
2868473|NCT03470025|Experimental|A telephone-based PI (TPI)|Psychological Intervention - A telephone-based PI (TPI); Psychological Intervention and medical therapy
2868474|NCT03470025|No Intervention|Optimal medical therapy|Patients will receive optimal medical therapy
2868475|NCT03470012|Experimental|Treatment Arm|Investigational tape
2868476|NCT03469999|Experimental|Dysport Injectable Product|All participants will participate in baseline data collection of energy expenditure, gait analysis, and lower limb spasticity assessment. All participants will receive single event multi level chemoneurolysis with Dysport and will have repeat data collection at 4 weeks and 12 weeks post injection.
2868477|NCT03469986||Autism Spectrum Disorder|Children who meet criteria based on expert clinical diagnosis for autism spectrum disorder will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.
2868478|NCT03469986||Non-autism Spectrum Disorder|Children who do not meet criteria for autism spectrum disorder based on expert clinical diagnosis will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.
2869947|NCT03460041|Placebo Comparator|Control|
2868479|NCT03469960|Active Comparator|Arm A : standard treatment|6 months of treatment by nivolumab + ipilimumab then nivolumab + ipilimumab then in case of progression platinum-based doublet recommended
2868480|NCT03469960|Experimental|Arm B : experimental arm|6 months of treatment by nivolumab + ipilimumab then observation the in case of progression nivolumab + ipilimumab then in case of progression platinum-based doublet recommended
2868481|NCT03469947|Experimental|Prehospital Tranexamic Acid|1 gram of Tranexamic Acid will be given during medical transport
2868482|NCT03469947|No Intervention|Matched Controls|Retrospective matched controls
2868483|NCT03469934|Experimental|ANB020|ANB020, administration of ANB020
2868484|NCT03469934|Placebo Comparator|Placebo|Placebo, administration of Placebo
2868485|NCT03469921||15-17 years old|15-17 years old
2868486|NCT03469921||18-25 years old|18-25 years old
2868487|NCT03469921||26-30 years old|26-30 years old
2868488|NCT03469921||acute leukemia|acute leukemia
2868489|NCT03469921||non-Hodgkin's lymphoma|non-Hodgkin's lymphoma
2868490|NCT03469921||Hodgkin lymphoma|Hodgkin lymphoma
2868491|NCT03469921||pediatric therapeutic regimen administered|pediatric therapeutic regimen administered
2868492|NCT03469921||adult therapeutic regimen administered|adult therapeutic regimen administered
2868493|NCT03469921||patients included in clinical trials|patients included in clinical trials
2868494|NCT03469921||patients not included in clinical trials|patients not included in clinical trials
2868495|NCT03469895||active CLL treated with ibrutinib or idelalisib for CAI|"Patient with CLL Active autoimmune cytopenia Initiation of a treatment with ibrutinib or idelalisib for autoimmune cytopenia.~The progressive nature of contemporary CAI LLC is not a criterion of exclusion."
2868496|NCT03469882|Experimental|High protein and exercise (HPE) group|Begining within 48 hours of ICU admission participants will receive nutrition support with energy expenditure measured by indirect calorimetry, 2.0 to 2.5 g/kg/day of protein and in-bed cycle ergometry exercise.
2868497|NCT03469882|Other|Usual care group|Participants randomized to the usual care group will receive usual care protein and exercise
2868498|NCT03469869|Experimental|balanced and sustainable diet|The intervention group will receive menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the control group will receive menu recommendation of balanced diet for 8 weeks. these menus are given in the apps
2868499|NCT03469869|Active Comparator|balanced diet|the intervention group receive get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will receive menu recommendation of balanced diet for 8 weeks. these menus are given in the apps
2868500|NCT03469856|Other|single arm|The ASET Pilot study is a multicenter, single arm, open-label trial of single antiplatelet therapy with prasugrel for patients undergoing successful and optimal PCI for chronic stable angina with normal cardiac biomarkers values. angiographic and/or findings from intracoronary imaging, only then patients will be enrolled in the study and loaded with prasugrel 60 mg and continued with prasugrel only (10 mg once a day) for three months. Aspirin and clopidogrel will be discontinued. At the 3-months follow-up visit, prasugrel (only) will be replaced by aspirin (only) or dual-antiplatelet therapy according to local standard of care.
2868501|NCT03469843||Patients|patients with transposition of the great arteries long after repair with the arterial switch operation
2868502|NCT03469830|Experimental|SSCP & SPMS|"The smart scar care pad (SCCP):~The SCCP is a newly invented insert material that can maximise treatment outcomes via enhanced compression and occlusion. The wearing regime for SCCP is 4 hours a day for the first day, with 2-hour increments added every other day until the total wearing time reached 23 hours. SSCP was cleaned twice a day for hygienic reasons.~The smart pressure monitored suit(SPMS):~The SPMS is a type of custom-made pressure garment. SPMS was used 23 hours a day and only removed when showering."
2868503|NCT03469830|Active Comparator|SPMS|"The smart pressure monitored suit(SPMS):~The SPMS is a type of custom-made pressure garment. SPMS was used 23 hours a day and only removed when showering."
2868504|NCT03469817|No Intervention|Patients who have undergone THR with Trident Cup|Patients who have had THR with Trident Cups and have previously had an MRI taken at the Hospital for Special Surgery at 1 year post-op.
2868505|NCT03469817|Other|Patients who have undergone THR with Trident II Cup|Patients who have had THR with Trident II Cups and will have an MRI taken at their one year post-operative visit.
2868506|NCT03469804|Experimental|Pembrolizumab|Pembrolizumab Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)
2868507|NCT03469791|Active Comparator|Micro-decompression alone|In Surgical treatment of Degenerative Spondylolisthesis patients are operated on with a midline-precerving decompression without fusion
2868508|NCT03469791|Active Comparator|Decompression and instrumented fusion|In Surgical treatment of Degenerative Spondylolisthesis patients are operated on with a decompression followed by an instrumental fusion with or without an additional Cage
2868509|NCT03469778|Experimental|Robotic Therapy|After consent, 10 participants will be included in a training program, as described below: 1º session will be robotic calibration and assessment; the following 18 sessions will be conducted the robotic therapy for upper limbs, three times a week. Each session will have a total duration of 55 minutes, including initial patient positioning and adjusting and after a sequence of game tasks.
2868510|NCT03469765||Group of patients after aortic surgery|with subanalysis of patients with/without supra-/infrarenal surgery
2868511|NCT03469752|Experimental|Intervention group|8 weekly education sessions 2.5 hours
2868512|NCT03469752|No Intervention|Wait-list control group|No education sessions
2868513|NCT03469726|Other|Patients with (suspected) PDAC|"Patients with (suspected) pancreatic cancer will undergo additional Contrast-enhanced Diffusion-weighted MRI (CE-DW-MRI) within two weeks from the CECT.~Suspected liver lesions on CECT and/or CE-DW-MRI will be biopsied to obtain histopathology as reference standard. For liver lesions without histopathologic proof of metastases a paired follow-up CECT and CE-DW-MRI serve as a composite reference standard. Follow up CECT and CE-DW-MRI will be performed in all patients at 3, 6, and 12 months."
2868580|NCT03469219||Control group|Healthy volunteers. measuring serum granulysin level for all healthy volunteers and tissue granulysin level for a number of them using Enzyme Linked Immunosorbent Assay.
2868581|NCT03469206|Sham Comparator|Direct IAT|Direct intra-arterial thrombectomy (IAT) with no intravenous thrombolysis
2868514|NCT03469713|Experimental|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
2868515|NCT03469700|Experimental|GA+PVB|Patients will receive general anesthesia with paravertebral block
2868516|NCT03469700|Active Comparator|GA+placebo PVB|Patients will receive general anesthesia with placebo block
2868517|NCT03469687|Other|Symax uncemented hip stem|The Symax hip stem is an uncemented design forged from Ti6Al4V alloy (Stryker EMEA). Primary mechanical stability is provided by anatomical metaphyseal geometry. The hip stem features a size dependent anteversion, neck length and offset, with a CCD angle of 128°. Secondary biological stability is accomplished by fast osseous integration due to the BONIT-HA coating on the metaphyseal part of the stem.
2868518|NCT03469674|Experimental|Molecular profile based treatment|Determination of the integrated clinicopathological and molecular profile to determine adjuvant treatment: observation for favourable profile; vaginal brachytherapy for intermediate profile; external beam radiotherapy for unfavourable profile
2868519|NCT03469674|Active Comparator|Vaginal brachytherapy|Adjuvant vaginal brachytherapy (standard treatment)
2868520|NCT03469661||Immune Thrombocytopenia Diagnosis|
2868521|NCT03469661||Myelodysplastic Syndrome Diagnosis|
2868522|NCT03469622|Active Comparator|EndoRings|Colonoscopy is performed with the EndoRings attached
2868523|NCT03469622|Active Comparator|Standard Colonoscopy|Standard colonoscopy without any additional devices
2868524|NCT03469609|Experimental|Perioperative mucous fistula refeeding|Perioperative mucous fistula refeeding between enterostomy creation and enterostomy closure
2868525|NCT03469609|No Intervention|No mucous fistula refeeding (standard of care)|No perioperative mucous fistula refeeding
2868526|NCT03469583|Experimental|EYP001 dose1|EYP001 capsules by mouth
2868527|NCT03469583|Active Comparator|Entecavir 1mg|2 tablets of 0.5mg, by mouth
2868528|NCT03469583|Experimental|EYP001 dose 1 + Entecavir 1mg|EYP001 capsules and 2 tablets of Entecavir 0.5mg by mouth
2868529|NCT03469570|Experimental|Assisted Fluid Management|
2868530|NCT03469557|Experimental|ESCC|
2868531|NCT03469557|Experimental|GC and GEJ carcinoma|
2868532|NCT03469544||Group 1 (30)|"Patient with cancer thyroid proved by cytological analysis Interventions;complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood ,Enzyme linked Immunosorbent Assay for serum midkine level"
2868533|NCT03469544||Group 2 (30)|"Patient with benign thyroid nodule Interventions;complete blood picture ,serum urea and creatinine,liver function test ,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
2868534|NCT03469544||Group 3 (30)|"Normal healthy subjects as control group Interventions;complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
2868535|NCT03469531|Experimental|experimental group|Patients receive nimotuzumab combined with cisplatin and undergo external-beam radiation and brachytherapy as the patients in experimental group.
2868536|NCT03469531|Active Comparator|control group|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as the patients in control group.
2868537|NCT03469518|Sham Comparator|β-Cx plus PS|Fruit and milk based beverage enriched with beta-cryptoxanthin and plant sterols
2868538|NCT03469518|Active Comparator|β-Cx plus PS plus GOS|Fruit and milk bases beverage enriched with beta-criptoxanthin, plant sterols and galactooligosaccharides
2868539|NCT03469505|Active Comparator|data from veterans using COPES|Data from veterans using COPES for chronic pain
2868540|NCT03469505|Active Comparator|data from veterans using CBT-CP|Data from veterans using CBT-CP for chronic pain
2868541|NCT03469492|Active Comparator|type 2 diabetes mellitus|Subjects with type 2 diabetes on insulin.
2868542|NCT03469492|Active Comparator|type 1 diabetes mellitus|Subjects with type 1 diabetes on insulin.
2868543|NCT03469479|Experimental|Resection plus HAIC with FOLFOX|Patients receive 4 times of neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX and hepatic resection
2868544|NCT03469479|Active Comparator|Resection|Patients receive hepatic resection without neoadjuvant hepatic arterial infusion chemotherapy
2868545|NCT03469466||untrained|Volunteers untrained in bedside ultrasound technique
2868546|NCT03469466||trained|Volunteers previously trained and experienced in bedside ultrasound technique
2868547|NCT03469466||healthy volunteer|Standardized patient who will undergo ultrasound study
2868548|NCT03469453|Experimental|Internet-delivered CBT|Internet-delivered Cognitive Behavioral Therapy (ICBT) for GAD, 10 weeks. Patients and their parents work with separate programs via the Internet. Both have contact with a therapist. Participants practice awareness of worry through daily worry monitoring. They identify their own behaviors that reinforce worry, i.e. control and avoidance behaviors. The program gives a rationale for behavior change, which is then implemented. Participants practice problem solving and exposure to uncertainty inducing situations and thoughts. Parents receive support and psycho education about worry. They practice alternative parental behaviors, which decrease focus on worry while validating the child's feelings. Treatment contains planning for maintenance of treatment gains for both patients and parents.
2868549|NCT03469440|Active Comparator|Goal-directed therapy|Patients randomized to this group will be monitoring by continuous central venous oxygen saturation. Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.
2868550|NCT03469440|Other|Standard protocol|The control group will keep the standard therapy.
2868582|NCT03469206|Sham Comparator|IVT combine with IAT|Intravenous thrombolysis before intra-arterial thrombectomy
2868551|NCT03469414||Wheelchair Mobility and Speed|This group will participate in activity-based measures employed in routine occupational and physical therapy practice to assess participants' wheelchair speed, maneuverability, and endurance. These measures include: the Life Space Assessment Scale, 6-Minute Push Test, Forward Push Test, Wheelchair Slalom Test, Craig Handicap Assessment and Reporting Technique, and PART-O.
2868552|NCT03469414||GPS Tracking|A GPS tracker will be placed on the wheelchairs of 25 individuals who consent to participate in this arm of the project. Using a GPS tracker will provide a direct measure of the community locations these participants go. The GPS location is collected every minute, and mapped to Google Maps, which would allow calculation of speed of movement.
2868553|NCT03469401||intervention|Adult patient (over 18 yr-old) admitted to the ICU for acute peritonitis with a peritoneal fl:uid sample obtained via surgery or radiological drainage
2868554|NCT03469388|Experimental|elective EVAR patients|Elective EVAR patients will be included in one arm only
2868555|NCT03469375||LAPC patients with mFOFLRINOX-based neoadjuvant therapy|LAPC patients were enrolled prospectively and diagnosed by MDT group in our hospital. These patients further received the neoadjuvant therapy with mFOLFIRINOX, the Overall survival, Progression survival, response to mFOLFIRINOX, chemo-related Toxicities, Postoperative complications and Histopathologic staging were measured.
2868556|NCT03469362|Experimental|Extracorporal Urinary Diversion (ECD)|"Study participants receiving standard-of-care Extracorporal Urinary Diversion after robot assisted radical cystectomy (RARC):~Post-operative care involving use of a standardized enhanced-recovery after surgery (ERAS) protocol.~Activities of Daily Living questionnaire~Instrumental Activities of Daily Living questionnaire~Hand Grip Strength Test~Timed Up and Go Walking Test~SF-8 Questionnaire~FACT-VCI Questionnaire"
2868557|NCT03469362|Experimental|Intracorporal Urinary Diversion (ICD)|"Study participants receiving standard-of-care Intracorporal Urinary Diversion after robot assisted radical cystectomy (RARC):~Post-operative care involving use of a standardized enhanced-recovery after surgery (ERAS) protocol.~Activities of Daily Living questionnaire~Instrumental Activities of Daily Living questionnaire~Hand Grip Strength Test~Timed Up and Go Walking Test~SF-8 Questionnaire~FACT-VCI Questionnaire"
2868558|NCT03469349|Experimental|Actovegin 1200 mg|Actovegin 1200 mg, intravenously (IV), once daily for up to 2 weeks followed by actovegin 200 mg, tablets, orally, thrice daily (TID) (1200 mg/day) for up to 10 weeks.
2868559|NCT03469349|Placebo Comparator|Placebo|Actovegin placebo-matching, IV, once daily for up to 2 weeks and actovegin placebo-matching tablets, orally, TID for up to 10 weeks.
2868560|NCT03469336|Other|All subjects|All subjects will receive all six interventions/treatments applied to six different treatment fields.
2868561|NCT03469323|Experimental|Nonintubated VATS succinylcholine|Nonintubated VATS using mini-dose succinylcholine in the beginning of open pneumothorax
2868562|NCT03469323|Placebo Comparator|Nonintubated VATS placebo|Nonintubated VATS not using succinylcholine in the beginning of open pneumothorax
2868563|NCT03469310|Experimental|Acetaminophen|Tylenol (also known as acetaminophen) 1000mg every 6 hours for 3 days and tramadol 50 mg every 6 hours as needed for moderate to severe pain
2868564|NCT03469310|Active Comparator|Codeine Acetaminophen|Tylenol #3 (codeine-acetaminophen) 1 tab every 4 hours or 2 tabs every 6 hours as needed for pain
2868565|NCT03469297|Experimental|Brown Glaucoma Implant|
2868566|NCT03469284|Experimental|Conventional Therapy + MB 0.025%|"Methylene blue oral rinse used for about 5 minutes every 6 hours until side effects go away or until methylene blue runs out, whichever comes first.~Participants called by a member of the study staff the day after treatment completion and at Days 2, and 7 after that."
2868567|NCT03469284|Experimental|Conventional Therapy + MB 0.05%|"Methylene blue oral rinse used for about 5 minutes every 6 hours until side effects go away or until methylene blue runs out, whichever comes first.~Participants called by a member of the study staff the day after treatment completion and at Days 2, and 7 after that."
2868568|NCT03469284|Experimental|Conventional Therapy + MB 0.1%|"Methylene blue oral rinse used for about 5 minutes every 6 hours until side effects go away or until methylene blue runs out, whichever comes first.~Participants called by a member of the study staff the day after treatment completion and at Days 2, and 7 after that."
2868569|NCT03469284|Other|Standard Therapy|Participants called by a member of the study staff the day after treatment completion and at Days 2, and 7 after that.
2868570|NCT03469271|Other|Training and Placebo|Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo for eight weeks
2868571|NCT03469271|Other|Sham Training and Vitamin D3 Metabolite|Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25 (OH)2 D3 orally for eight weeks
2868572|NCT03469271|Other|Training and Vitamin D3 Metabolite|Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25(OH)2 D3 orally for eight weeks
2868573|NCT03469271|Other|Sham Training and Placebo|Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo orally for eight weeks
2868574|NCT03469258|Experimental|Zenpep|"Pancrelipase (Zenpep) will be administered with every meal (breakfast, lunch, dinner) and snack(s), continuously.~Participants will begin pancrelipase on the day of enrollment and continue therapy until 1 year after surgery per calendar date"
2868575|NCT03469245||abdominal aortic aneurysms treated by fenestrated endovascular|Patients have an abdominal aortic aneurysms treated by fenestrated endovascular anacondaTM of society Vascutek will be included. Predisurge society will perform numerical simulation.
2868576|NCT03469232|Experimental|Huanglian-Jiedu Decoction in acute pericoronitis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
2868577|NCT03469232|Experimental|Huanglian-Jiedu Decoction in recurrent aphthous stomatitis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
2868578|NCT03469232|Experimental|Huanglian-Jiedu Decoction in recurrent herpes simplex labialis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
2868579|NCT03469219||Study group|patients with psoriasis vulgaris. measuring serum granulysin level for all patients and tissue granulysin level in lesional and perilesional skin for a number of patients using Enzyme Linked Immunosorbent Assay.
2869948|NCT03460041|Active Comparator|Magnesium|
2868585|NCT03469180|Active Comparator|Control Group|Childrens in this group will receive treadmill training, three times a week for 8 weeks. Each season will be supervised and last 45 minutes.
2868586|NCT03469180|Experimental|Training Group|İn addition to treadmill training, childrens in this group (after a rest for 5 minutes) will also receive whole body vibration training for 15 minutes.
2868587|NCT03469167|Experimental|CEGP003|
2868588|NCT03469167|Active Comparator|Injection Tx|
2868589|NCT03469154|Experimental|Dyad training|The participants in this arm will train in teams of two. Participants will be instructed in paediatric basic life support by instructional videos in a computer programme and train on children resuscitation manikins. Training involves recognition of cardiac arrest, cardio-pulmonary resuscitation and foreign body airway obstruction management. The training involves series of short video clips and following exercises. Each participant performs the exercise and the other gives feedback. Afterwards roles are changed. The procedure is done for all exercises after a video clip. The duration of the training is maximum 50 minutes
2868590|NCT03469154|Active Comparator|Instructor led training|"Participants train in courses of up to 6 participants with an instructor. Training content is identical to dyad training content involving: recognition of cardiac arrest, cardio-pulmonary resuscitation and foreign body airway obstruction management.~Skills are instructed by an instructor using af 4 step approach (1. show skills, 2. show with explanation, 3. participants instruct instructor, 4. participants performs the skills on resuscitation manikins). Training is maximum two hours but course duration is adjusted to number of participants two allow for similar hands-on time per participant as in the experimental arm."
2868591|NCT03469141|No Intervention|Control Group|The control group will continue to have the WC sensor system for measurement only and will not receive biofeedback after receiving instructions on the importance of pressure relief (PR) maneuvers for skin care, as well as training regarding the three pressure relief maneuvers. Materials (including fact sheets, etc.) will be incorporated in the educational content of the project.
2868592|NCT03469141|Experimental|Intervention Group|The intervention group will receive biofeedback via the smartphone app.
2868593|NCT03469128|Active Comparator|Cognitive processing therapy|Cognitive Processing Therapy (CPT) in which participants completed 12 sessions of CPT
2868594|NCT03469128|Active Comparator|Medication|Medication group in which patients with co-occurrence PTSD & SUD disorders were treated by medicine (Disulfiram).
2868595|NCT03469128|Placebo Comparator|Control group|Control group that consists of patients with co-occurrence PTSD & SUD disorders who were not treated yet (waiting lists in the hospital).
2868596|NCT03469115|Active Comparator|BMI above 95%|Serum blood will be taken from obese youths with suspected metabolic syndrome
2868597|NCT03469115|Active Comparator|BMI below 3%|Serum blood will be taken from slim youths
2868598|NCT03469089|Placebo Comparator|Placebo/placebo|Placebo for ketamine (0.9% NaCl) + Placebo for modafinil (microcrystalline cellulose capsule)
2868599|NCT03469089|Experimental|Ketamine 0.58/placebo|Ketamine (0.23 mg/kg + 0.58 mg/kg/h) + Placebo for modafinil
2868600|NCT03469089|Experimental|Ketamine 0.58/modafinil|Ketamine (0.23 mg/kg + 0.58 mg/kg/h) + Modafinil (200 mg)
2868601|NCT03469089|Experimental|Ketamine 0.31/placebo|Ketamine (0.12 mg/kg + 0.31 mg/kg/h) + Placebo for modafinil
2868602|NCT03469076|Experimental|ACN Cream|Patients with mild to moderate acne using ACN Cream
2868603|NCT03469063|Experimental|AferBio|Daily oral AferBio (20 g/day, in sachets)
2868604|NCT03469063|Placebo Comparator|Placebo|Daily oral placebo (20 g/day, in sachets)
2868605|NCT03469050|Experimental|Rifaximin delayed released 800 mg b.i.d.|(i.e. 2 x 400 mg tablet twice a day; total daily dose: 1600 mg) for 10 consecutive days a month, for 12 months
2868606|NCT03469050|Experimental|Rifaximin delayed released 400mg b.i.d|(i.e. 1x400 mg tablet plus 1 placebo tablet twice a day; total daily dose: 800 mg) for 10 consecutive days a month, for 12 months
2868607|NCT03469050|Placebo Comparator|Placebo b.i.d.|(i.e. 2 x placebo tablets twice a day) for 10 consecutive days a month, for 12 months.
2868608|NCT03469037|Experimental|Oxygen first|Optiflow with an inspired fraction of oxygen of 100% in the first seance Optiflow with an inspired fraction of oxygen of 21 % in the second seance
2868609|NCT03469037|Experimental|Air first|Optiflow with an inspired fraction of oxygen of 21 % in the first seance Optiflow with an inspired fraction of oxygen of 100 % in the second seance
2868610|NCT03469024|Experimental|Home rehabilitation program|It consists in a home rehabilitation program. Patients will recieve electroanalgesia with TENS and an exercise program following the McKenzie method. At first and second sessions, patients will be instructed on how to use electroanalgesia and how to perform the exercises. Then, patients will perform the therapy at home. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
2868611|NCT03469024|Active Comparator|e-Health program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
2868612|NCT03469011|Experimental|Imatinib oral100mg tablets|"A standard 3+3 trial design will be utilized for the imatinib dosing. In general, patients will be treated in cohorts of 3-6 with escalating doses of imatinib using oral 100mg tablets.~Dose Level -1=100mg, +1=200mg (starting dose for cohort 1), +2=300mg, +3=400mg, +4=600mg (if needed)."
2868613|NCT03468998|Active Comparator|Ridge Preservation with Small Particle Allograft|
2868614|NCT03468998|Active Comparator|Ridge Preservation with Large Particle Allograft|
2868615|NCT03468998|Active Comparator|Ridge Augmentation with Small Particle Allograft|
2868616|NCT03468998|Active Comparator|Ridge Augmentation with Large Particle Allograft|
2868617|NCT03468985|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2868785|NCT03467906||Good weight loss group|Sleeve gastrectomy surgery patients with good weight loss outcomes will take part in in-laboratory assessment.
2868786|NCT03467880||Healthy subjects|Healthy subjects.
2868618|NCT03468985|Experimental|Arm B (nivolumab, cabozantinib s-malate)|Patients receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2868619|NCT03468985|Experimental|Arm C (nivolumab, cabozantinib s-malate, ipilimumab)|Patients receive nivolumab IV over 60 minutes on day 1, cabozantinib s-malate PO daily on days 1-28, and ipilimumab IV over 90 minutes every 8 weeks. Courses for nivolumab and cabozantinib s-malate repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2868620|NCT03468985|Experimental|Arm T (nivolumab, cabozantinib s-malate, ipilimumab)|Patients with ROS1 gene rearrangement, MET exon 14 splice mutations, MET high amplification, or RET gene rearrangement receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2868621|NCT03468972|Experimental|Immunosuppression|corticosteroids or cyclophosphamide added on corticosteroids
2868622|NCT03468972|Active Comparator|Intensive supportive care|intensive supportive care with RAS blockers, blood pressure control, and protein restriction diet
2868623|NCT03468959||Mother-child pairs|Families were recruited from lists of children receiving autism services obtained via the California Department of Developmental Services (DDS), from other studies at the Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, or by self-referrals. The inclusion criteria were: a) mother or father had a biological child with ASD, and the mother was b) at least 18 years old; c) pregnant or planning a pregnancy, and biologically able to become pregnant; d) living within 2 hours of the MIND Institute; e) sufficiently fluent in English.
2868624|NCT03468946|Other|high caries risk|children with high caries -identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
2868625|NCT03468946|Other|medium caries risk|children with medium caries- identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
2868626|NCT03468946|Other|low risk|no caries or low risk- identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
2868627|NCT03468933|Active Comparator|Fibrinolytic therapy group|Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.
2868628|NCT03468933|Active Comparator|Medical Thoracoscopy group|Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.
2868629|NCT03468920|Experimental|Arm 1: IV Acetaminophen group|Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively
2868630|NCT03468920|Active Comparator|Arm 2: PO Acetaminophen group|Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively
2868631|NCT03468907|Experimental|Early cessation|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. Antiviral therapy was discontinued in intrapartum.
2868632|NCT03468907|Experimental|Late cessation|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. After delivery, mothers ceased antiviral treatment at postpartum 6 weeks.
2868633|NCT03468907|No Intervention|Control|Eligible patients who refused antiviral therapy but consented to the study were assigned to the control arm.
2868634|NCT03468894|No Intervention|Control|The control group will continue to work as usual at their regular workstations.
2868635|NCT03468894|Experimental|Intervention|A shared treadmill workstation will be installed in participating offices, or in a nearby location in case there is no space to fit the workstation in the office, enrolled to this group. Within the intervention group there will be a maximum allocation of two participants per treadmill desk. The participants in the intervention group will be asked to interrupt their sitting with 20 minutes of self-selected light-intensity walking at a speed of 1-4 km/h each hour for a minimum of 6 hours per shift to accumulate a total of 2 hours of light-intensity activity per work day.
2868636|NCT03468881||Breast cancer radiation therapy|Observation over a period of all treatment sessions for radiotherapy.
2868637|NCT03468868|Active Comparator|Facility-based rehabilitation|Participants will conduct the exercise program for people with MS in a facility, for example a gym, or rehabilitation center. They will receive coaching on site at the facility.
2868638|NCT03468868|Active Comparator|Telerehabilitation|Participants will conduct the exercise program for people with MS at home and receive coaching via phone or Skype sessions.
2868639|NCT03468855|Experimental|ATI-50002 Topical Solution|ATI-50002 topical solution, high dose active, twice-daily, 24 weeks
2868640|NCT03468842|Placebo Comparator|Placebo|Composition: excipients without probiotic: 2%w/v Guam guar and 6% w/v hydroxyethilcellulose Application in mouth of a bucoadhesive gel. Applied by the profesional at days 0, 15 and 30 and by the participants the rest of the days Frequency: each 48 h by the participants Duration: during 30 days
2868641|NCT03468842|Active Comparator|Probiotic|Composition: Streptococcus dentisani: 2,5E+09CFUs, 2% (p/v) Guam Guar and 6% (p/v) Hidroxietilcelulosa. Dose of 2.5E+09 cfu/vial considering one administration every 48 hours, it will be equivalent to a dose of 1.0E+10 cfu/week Application in mouth of a bucoadhesive gel. Applied by the profesional at days 0, 15 and 30 and by the participants the rest of the days Frequency: each 48 h by the participants Duration: during 30 days
2868642|NCT03468829|Experimental|ALX-0171 Dose 1|
2868643|NCT03468829|Experimental|ALX-0171 Dose 2|
2868644|NCT03468829|Placebo Comparator|Placebo|
2868645|NCT03468816|Experimental|Type A|Absorbest moisture sensor on a DryMax Extra Softs hydrophilic back side.
2868646|NCT03468816|Experimental|Type B|Absorbest moisture sensor with a layer of hydrophobic non-woven, on a DryMax Extra Softs hydrophilic non-woven.
2868647|NCT03468803|Experimental|Beta D Glucan (BDG) in surgery|Serial Beta D Glucan measurements in each patients before, during, and after surgery
2869949|NCT03460041|Active Comparator|Dexmetedomedine|
2868648|NCT03468790|Experimental|CMAB007 + Seretide/Symbicort + Ventolin|CMAB007(recombinant humanized anti-IgE monoclonal antibody for injection ) will be at a fixed dose determined by the subjects' total IgE and weight at V0. All the subjects will be treated subcutaneously for 24 weeks. The 4-week total dose is 0.016mg/kg/IgE(IU/ml), administered every 2 or 4 weeks, for the subjects with total IgE level 60-700IU/ml. If the total IgE level is 700-1500IU/ml, they will be administered 375mg every 2 weeks. Symbicort(Budesonide and formoterol fumarate powder for inhalation) or Seretide (salmeterol xinafoate and fluticasone propionate powder for inhalation) will be used 1/2 inhalations bid as asthma-controlled drug during the whole study. Ventolin (Salbutamol sulphate aerosol) will be used as asthma rescue drug.
2868649|NCT03468790|Placebo Comparator|Placebo + Seretide/Symbicort + Ventolin|Placebo is without active components of the study drug and used as same as the study drug.
2868650|NCT03468777|Experimental|Part 1: Treatment Sequence (ABC)|Participants will receive Treatment A as a single oral dose of 1000 milligram (mg) lumicitabine (4*250 mg tablets) under fasted condition on Day 1 of period 1 then Treatment B as a single oral dose of 30 mg lansoprazole under fasted condition on Days 1 to 4 and on Day 5 (administered 2 hours before a single oral dose of 1,000 mg lumicitabine) in period 2 followed by Treatment C (optional Part 2) as a single dose of 150 mg ranitidine administered after 2 hours of single dose of 1000 mg lumicitabine (4*250 mg tablets) under fasted condition on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
2868651|NCT03468777|Experimental|Part 1: Treatment Sequence (BAC)|Participants will receive Treatment B on Days 1 to 5 of period 1 then Treatment A on Day 1 of period 2 followed by Treatment C (optional Part 2) on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
2868652|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (DEF)|Participants will receive Treatment D as a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) after standardized breakfast on Day 1 of period 1 then Treatment E as a single oral dose of 30 mg lansoprazole under fasted condition on Days 1 to 4 and on Day 5 (administered 2 hours before a single oral dose of 1,000 mg lumicitabine) in period 2 followed by Treatment F as a single oral dose of 150 mg ranitidine administered after 2 hours after a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) after standardized breakfast on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
2868653|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (EFD)|Participants will receive Treatment E on Days 1 to 5 of period 1 then Treatment F on Day 1 of period 2 followed by Treatment D on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
2868654|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (FDE)|Participants will receive Treatment F on Days 1 of period 1 then Treatment D on Day 1 of period 2 followed by Treatment E on Days 1 to 5 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
2868655|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (FED)|Participants will receive Treatment F on Day 1 of period 1 then Treatment E on Days 1 to 5 of period 2 followed by Treatment D on Days 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
2868656|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (EDF)|Participants will receive Treatment E on Days 1 to 5 of period 1 then Treatment D on Day 1 of period 2 followed by Treatment F on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
2868657|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (DFE)|Participants will receive Treatment D on Day 1 period 1 then Treatment F on Day 1 of period 2 followed by Treatment E on Days 1 to 5 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
2868658|NCT03468751|Experimental|HLX10, in patients with solid tumors|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX10 once every two weeks. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 0.1, 0.2, 0.5, 1.0, 3.0, 6.0, and 10 mg/kg, starting from 0.1 mg/kg.
2868659|NCT03468725|Experimental|XPF-008|Single oral dose
2868660|NCT03468725|Active Comparator|Placebo|Single oral dose
2868661|NCT03468712|Experimental|Experimental group|Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy
2868662|NCT03468699|Experimental|Autologous BMMC transplantation|Stem cell transplantations include 2 administrations of autologous bone marrow mononuclear cells via the hepatic artery at baseline and 6 months afterward
2868663|NCT03468686|Active Comparator|bilateral rTMS|sequential bilateral repetitive Transcranial Magnetic Stimulation (rTMS)
2868664|NCT03468686|Sham Comparator|Sham rTMS|Sham Transcranial Magnetic Stimulation (rTMS)
2868665|NCT03468660|Experimental|Experimental group|Auditory training with feedback
2868666|NCT03468660|Active Comparator|Active control group|Listening paradigm with no feedback.
2868667|NCT03468647|Experimental|FRAGIL-IT testing group|FRAGIL-IT tools : connected soles, connected weighting machine and measure of gripping force
2868668|NCT03468634||Adenocarcinoma|patients diagnosed with adenocarcinoma
2868669|NCT03468634||Squamous cell cancer|patients diagnosed with squamous cell cancer
2868670|NCT03468634||Other|patients diagnosed with another condition
2868671|NCT03468634||Barrett's oesophagus|patients diagnosed with Barrett's oesophagus
2868672|NCT03468634||Low-grade dysplasia|patients diagnosed with low-grade dysplasia
2868673|NCT03468634||High-grade dysplasia|patients diagnosed with high-grade dysplasia
2868674|NCT03468634||Indefinite for dysplasia|patients where the diagnosis is unclear
2868675|NCT03468634||no dysplasia|patients not diagnosed with any cancer
2868676|NCT03468621|Other|Intradermal wound closure|Intradermal wound closure of the groin wound
2868677|NCT03468621|Other|Transdermal wound closure|Wound closure of the groin wound with metal staples
2868678|NCT03468608||Phase 1: Instrument Development|An initial set of questionnaire items will be created based on the questionnaires noted in the literature review as well as the semi-structured interviews conducted with parents and healthcare team members in our facility.
2868679|NCT03468608||Phase 2: Pre-Test Evaluation|Parents and healthcare team members will be asked to comment on the quality of the draft questionnaire created in phase 1 of this study.
2868787|NCT03467880||Chronic obstructive pulmonary disease|Patience with chronic obstructive pulmonary disease.
2868788|NCT03467880||Asthma|Patience with asthma.
2868680|NCT03468608||Phase 3: Pilot|"Parents will be asked to complete the questionnaire developed during phase 2 of this study. Upon completing the questionnaire, parents will be asked to rate the overall face validity of the tool using a 5-point Likert scale.~Healthcare team members will be asked to rate the content validity of each item on the questionnaire."
2868681|NCT03468608||Phase 4: Validation|Parents will be asked to complete the questionnaire developed during phase 3 of this study.
2868682|NCT03468595|Experimental|test 1|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with CHX (Drogsan, Istanbul, Turkey, 0.2%) was performed at one session for once.
2868683|NCT03468595|Experimental|test 2|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with Listerine (Johnson & Johnson, Istanbul, Turkey, containing, 21.6% ethanol, 0.092% eucalyptol, 0.064% thymol, 0.042% menthol and 0.06% methyl salicylate) was performed at one session for once.
2868684|NCT03468595|Active Comparator|control|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with distilled water was performed at one session for once.
2868685|NCT03468582|Experimental|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
2868686|NCT03468569|Experimental|Functional Movement Screen|Movement Analysis for injury risk
2868687|NCT03468569|Experimental|Vertical Jump Test|Jump test Height Measurement, Functional Movement Screen
2868688|NCT03468569|Experimental|Y Balance Test|Functional lower extremity reach with balance, Functional Movement Screen
2868689|NCT03468569|Experimental|Illinois Agility Test|Agility measurement, Functional Movement Screen
2868690|NCT03468569|No Intervention|Injury History|Athletes injury history for last year was recorded as injury count.
2868691|NCT03468556|Experimental|test drug|2 tabs of SNP-610
2868692|NCT03468556|Placebo Comparator|placebo|2 tabs of placebo
2868693|NCT03468543|Experimental|Cohort 1|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation A; then formulation B; following each administration MRI will be performed for up to 14 days
2868694|NCT03468543|Experimental|Cohort 2|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation C; then formulation D; following each administration MRI will be performed for up to 14 days
2868695|NCT03468543|Experimental|Cohort 3|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation E; followed by MRI for up to 14 days
2868696|NCT03468517|No Intervention|Control group|Standard preoperative evaluation process will continue without any intervention.
2868697|NCT03468517|Active Comparator|Bathe Group|In the comparator group of patients, Bathe method will be applied at preoperative evaluation process.
2868698|NCT03468504|Experimental|Mirror Therapy & Treadmill Training|"Mirror Therapy: Participants view a mirror reflection of their non-affected limb which is placed in their mid-sagittal plane for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
2868699|NCT03468504|Placebo Comparator|Placebo Mirror & Treadmill Training|"Placebo Mirror Therapy: Participants view a mirror which is placed forward/ahead of them in their mid-sagittal plane, and cannot see a reflection of any lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
2868700|NCT03468491|Experimental|Combined training group|Biomechanical taping will first being applied to the participants of the combined training group. They will be asked to perform following exercises in this session afterwards. As the treatment session goes on, a set of foot intrinsic muscle strengthening exercise and lower extremity neuromuscular exercise will be provided.
2868701|NCT03468491|Active Comparator|Proximal training group|For participants of the proximal training group, only a set of lower extremity neuromuscular exercise will be provided. This set of exercises is designed to be the same as for participants of combined training group.
2868702|NCT03468478|Experimental|sirolimus +tacrolimus|Patients will receive initial dose of 0,05 mg/kg BID oftacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of sirolimus of 3mg once a day to reach blood trough concentration between 4-8 ng/mL.
2868703|NCT03468478|Experimental|everolimus +tacrolimus|Patients will receive initial dose of 0,05 mg/kg BID de tacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of 1.5 mg BID of everolimus to reach blood trough concentration between 4-8 ng/mL.
2868704|NCT03468478|Active Comparator|mycophenolate +tacrolimus|Patients will receive initial dose of 0,1 mg/kg BID de tacrolimusto reach blood trough concentration between Fixed dose of mycophenolate (mycophenolate mofetil, 1 g BID or sodium mycophenolate, 720 mg BID).
2868705|NCT03468465|Experimental|Medical device: Transcutaneous electrical neurostimulation|Medical device 4 weeks with daily sessions of 30 minutes
2868706|NCT03468465|Active Comparator|Solifenacin|10 mg tablet daily during 75 days maximum
2868707|NCT03468452||Early extubation|The endotracheal tube is removed in the operation room, and no suction support is required after surgery.
2868708|NCT03468452||late extubation|"Take the tracheal tube back to the ward for respiratory support or removal of air.~The catheter is inserted again within 48h."
2868709|NCT03468439|Other|femoral nerve block|
2868710|NCT03468426|Experimental|BI 836880 + BI 754091|
2868711|NCT03468413|Experimental|Single ascending dose, CP1050 or Placebo|
2868712|NCT03468413|Experimental|Multiple ascending dose, CP1050 or Placebo|
2868713|NCT03468387|Active Comparator|Primary realignment|
2868714|NCT03468387|Active Comparator|Suprapubic cystostomy|
2868715|NCT03468374|Active Comparator|Lymphoscintigraphy|Nuclear Medicine diagnostic device using radioactive material
2868716|NCT03468374|Active Comparator|Single Photon Emission Tomography|Nuclear Medicine diagnostic device using fusion technique between SPECT and CT
2868717|NCT03468361|Placebo Comparator|Control Group|Patients in control group will be allowed to continue their conventional medications and with a placebo.
2868718|NCT03468361|Experimental|Intervention Group|Patients in intervention group who would be taking their usual medications along with parsley in a convenient dosage form.
2868723|NCT03468335|Other|Single Arm|"Cancer treatment for PDAC:~Nal-IRI 80 mg/m2 as 1.5 hour infusion~5-FU 2400 mg/m2 as 46 hour infusion~Folinic acid 400 mg/m2 as 0.5 hour infusion~all on D1 of each cycle; Cycle q2w ± 5 days~Treatment until progressive disease or intolerable toxicity or withdrawal of consent."
2868724|NCT03468322|Experimental|AC-203 1% ointment|AC-203 1% ointment, QD
2868725|NCT03468322|Placebo Comparator|Vehicle ointment|Vehicle ointment, QD
2868726|NCT03468309||Genecept Assay and G-DIG decision tool|Veterans who have been prescribed 5 or more medications, with at least two being for a mental health diagnosis. Also allowable would be one medication for a mental health diagnosis and another medication for side effects related to a medication prescribed for the mental health diagnosis.
2868727|NCT03468296|Experimental|Continued Q2 Week Treatment|Will receive intravitreal aflibercept (2.0mg) injections for an additional four consecutive 2 week intervals at weeks 18, 20, 22, and 24
2868728|NCT03468296|Active Comparator|Treat-And-Extend Treatment|Will receive intravitreal aflibercept (2.0mg) injections on a treat-and-extend basis through week 24 with a minimum inter-treatment interval of q4 weeks.
2868729|NCT03468283|Experimental|Intervention|"Intervention was the addition of mobile healthcare-based diabetes self-management education, which consisted of mobile application for diabetes and individualized regular message feedback sent by healthcare professionals, to current diabetes management."
2868730|NCT03468283|No Intervention|control|Participants of control group maintained previous diabetes management in Kangbuk Samsung Hospital throughout this study. Providers were not involved with patient prescriptions.
2868731|NCT03468257|Active Comparator|Control|
2868732|NCT03468257|Experimental|Fruit pairings|
2868733|NCT03468244|Experimental|Personalized mRNA Tumor Vaccine|Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma
2868734|NCT03468231|Active Comparator|Sorafenib plus HAIC of FOLFOX|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin, Fluorouracil and Leucovorin
2868735|NCT03468231|Experimental|Sorafenbi plus HAIC of OXA|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin
2868736|NCT03468218|Experimental|Treatment (pembrolizumab, cabozantinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and cabozantinib PO QD on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
2868737|NCT03468205||Main Cohort|Main cohort of patients meeting all of the eligibility criteria enrolled through newspaper adds, flyers and via non personal recruitment.
2868738|NCT03468205||Subgroup|Smaller group of patients, meeting eligibility criteria for the main study, enrolled through clinical visits. These patients will be followed more closely and also be recorded in a logbook in order for later review. Some of the participants in this group will be interviewed in a semi-qualitative interview about their experiences of breathlessness.
2868739|NCT03468192|Experimental|non-precaution group|Study Group: Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed.
2868740|NCT03468192|No Intervention|precaution group|Control Group: the precaution group (PG) had standard postoperative hip precautions included limited flexion of the hip to 90° (avoid reaching down to toes or bringing knee up beyond 90°) and limited adduction of the hip (avoid sleeping on side and avoid crossing legs at knees or ankles). The mandatory assistive equipment to use for at least 3 months were reacher and stocking application aid. The patients were instructed only to use elevated chair, bed and toilet in order not to flex more than 90° in the hip. For the same reason a brace over the knee was prescribed for 6 weeks, particularly in patients with cognitive limitations.
2868741|NCT03468179|Experimental|Oatmeal|Subjects will arrive for study fasting. IV access will be obtained, and baseline blood drawn. They will be fed 80gm/100kg oatmeal, and blood levels will be drawn at 30, 60, 90, and 120 minutes.
2868742|NCT03468166||Chronic stroke|The data for motor function and gait pattern analysis was obtained.
2868743|NCT03468153|Experimental|CAR-T cell therapy|Patient-derived dual specificity CD19 and CD22 CAR-T
2868744|NCT03468140|Experimental|Current end stage liver disease patients|Eculizumab
2868745|NCT03468140|Other|Historical controls|The Ochsner database will be used to obtain 5 historical matches for each study participant. Matching criteria for each patient will include: 1) gender; 2) (MELD) Score ± 5; 3) age ± 5 years; 4) body mass index (BMI) ± 5 kg/m2; 5) donor macrosteatosis ± 5%; and 6) CIT± 3 hours.
2868746|NCT03468114|Experimental|Intervention|Participant households will receive 4 visits by health extension workers delivering intervention
2868747|NCT03468114|Active Comparator|Control|Participant households will receive 4 visits by health extension workers delivering standard care
2868748|NCT03468101||Dairy farmers COPD|
2868749|NCT03468101||Non farmers COPD|
2868750|NCT03468088|Experimental|Hand grip strengthening|This group will receive handgrip strengthening exercises.
2868751|NCT03468088|Active Comparator|Conventional treatment|This group will receive conventional exercises.
2868752|NCT03468075|Experimental|Gemcitabine + High-Dose Ascorbate|Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.
2868753|NCT03468062|Experimental|Dexmedetomidine|0.5 mg/kg of dexmedetomidine (Precedex; Hospira, Lake Forest, IL) is mixed in normal saline 100mL and administered for 5 minutes after anesthetic induction.
2868754|NCT03468062|Placebo Comparator|Placebo|Only normal saline 100mL is administered for 5 minutes after anesthetic induction.
2868755|NCT03468049|Experimental|Topical App. of Allium Cepa Extract|Intervention: 5mg of Allium Cepa Extract (Allium Cepa oil) will be applied on the shoulder joint of the participant, followed by kneading massage until the Allium Cepa oil deeply penetrate into the shoulder joint in addition to standard physiotherapy management of shoulder pain post stroke. Three times in a week for four weeks
2868789|NCT03467880||Interstitial lung disease|Patience with interstitial lung disease.
2868790|NCT03467880||Upper airway obstruction|Patience with upper airway obstruction.
2868756|NCT03468049|Experimental|Phonophoresis of Allium Cepa extract|Intervention: 5mg of Allium Cepa extract (Allium Cepa oil) would be applied on the shoulder joint of the participant, followed by phonophoresis using ultrasound set at at treatment parameter of pulse mode (50%), 1mHz transducer frequency and stroking technique of 1.5w/cm square for 5mins to allow deeper penetration of the Allium Cepa oilinto the joint in addition to standard physiotherapy management of shoulder pain post stroke.Three times in a week for four weeks
2868757|NCT03468049|Experimental|Raw mashed Allium Cepa Application|Intervention: 5g or a small size Raw Allium Cepa (onion)bulb will be cut into pieces and then mashed inside pestle and mortar, thereafter the Raw mashed Allium Cepa will then be applied on the surface of the shoulder joint of the participant and then secured with a gauze bandage for 2 hours to allow deeper penetrationin addition to standard physiotherapy management of shoulder pain post stroke. Three times in a week for four weeks
2868758|NCT03468049|Active Comparator|Standard physiotherapy group (SPG)|Participant in this group will be receiving standard physiotherapy management of shoulder pain post stroke. The standard physiotherapy management will divided into two forms of activities, the first approach is soft tissue manipulation using common massage medium in particular powder would be used in this study. The second approach is the use of therapeutic exercises and this therapeutic exercises will be categorized into three (basic level, intermediate level and advance level of shoulder joint exercises) depending on the stage of recovery of the participants. Three times in a week for four weeks
2868759|NCT03468036||Extubation with 100% O2|for further information please refer to study protocol
2868760|NCT03468036||Extubation with 35% O2|for further information please refer to study protocol
2868761|NCT03468023|Experimental|Short arm cast|Patient treated with below-elbow cast
2868762|NCT03468023|Active Comparator|Long arm cast|Patients treated with above-elbow cast
2868763|NCT03468010|Active Comparator|The control group (Group A)|In Group A, observation is given after chemoradiation
2868764|NCT03468010|Experimental|The experiment group (Group B)|in Group B, three cycles of Paclitaxel, Cisplatin are administered after radiation with concurrent cisplatin. The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel 135mg/m2 plus Cisplatin 60mg/m2 once 3 weeks.
2868765|NCT03467997|No Intervention|Filtered Air|Subjects sit in a room for two hours breathing in filtered air which resembles levels of air pollution found in the ambient environment
2868766|NCT03467997|Active Comparator|Diesel Exhaust|Subjects sit in a room for two hours breathing in diesel exhaust at 200 micrograms of meter cubed.
2868767|NCT03467997|Active Comparator|TSST/Stress only|Subjects undergo a mental stress test, known as the Trier Social Stress Test (TSST), which involves a public speaking and math task.
2868768|NCT03467997|Active Comparator|Diesel Exhaust and stress|Subjects sit in a room for two hours breathing in diesel exhaust at 200 micrograms of meter cubed and are subject to a mental stress test (TSST) which involves a public speaking and math task.
2868769|NCT03467984|Experimental|LBVE|Infants will receive a 0.5mL intramuscular injection of LBVE at 6,10 and 14 weeks of age
2868770|NCT03467984|Active Comparator|Prevnar13|Infants will receive a 0.5mL intramuscular injection of Prevnar13 at 6,10 and 14 weeks of age
2868771|NCT03467971|Experimental|Sequence 1|Metformin and Gliclazide fixed combination tablet in fasting state (Treatment period 1) followed by Metformin and Gliclazide fixed combination tablet in fed state (Treatment period 2). Each treatment period will be separated by a 14-day wash-out period.
2868772|NCT03467971|Experimental|Sequence 2|Metformin and Gliclazide fixed combination tablet in fed state (Treatment period 1) followed by Metformin and Gliclazide fixed combination tablet in fasting state (Treatment period 2). Each treatment period will be separated by a 14-day wash-out period.
2868773|NCT03467958|Experimental|Administration of oral Ozanimod|Subjects will receive a single 0.92 mg capsule [equivalent to ozanimod HCl 1 mg] once daily x 48 weeks
2868774|NCT03467945|Experimental|Sequence 1|Metformin and Gliclazide fixed combination tablet in treatment period 1 followed by individual tablets of Metformin and Gliclazide in treatment period 2 followed by Metformin tablet in treatment period 3 and then Gliclazide tablet in treatment period 4. Each treatment period will be separated by a 14 day wash-out period.
2868775|NCT03467945|Experimental|Sequence 2|Individual tablets of Metformin and Gliclazide in treatment period 1 followed by Gliclazide tablet in treatment period 2 followed by Metformin and Gliclazide fixed combination tablet in treatment period 3 and then Metformin tablet in treatment period 4. Each treatment period will be separated by a 14 day wash-out period.
2868776|NCT03467945|Experimental|Sequence 3|Metformin tablet in treatment period 1 followed by Metformin and Gliclazide fixed combination tablet in treatment period 2 followed by Gliclazide tablet in treatment period 3 and then individual tablets of Metformin and Gliclazide in treatment period 4. Each treatment period will be separated by a 14 day wash-out period.
2868777|NCT03467945|Experimental|Sequence 4|Gliclazide tablet in treatment period 1 followed by Metformin tablet in treatment period 2 followed by individual tablets of Metformin and Gliclazide in treatment period 3 and then Metformin and Gliclazide fixed combination tablet in treatment period 4. Each treatment period will be separated by a 14 day wash-out period.
2868778|NCT03467932|Active Comparator|ORMD-0801 once daily - QHS|Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
2868779|NCT03467932|Active Comparator|ORMD-0801 twice daily - BID|Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
2868780|NCT03467932|Active Comparator|ORMD-0801 three times daily - TID|ORMD-0801 three times daily - TID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.
2868781|NCT03467932|Placebo Comparator|Matched Placebo Oral Capsule|Placebo matched to one of the three active comparator arms. (either QHS, BID, or TID)
2868782|NCT03467919|Experimental|Stem Cells (with PRP)|Intra-articular knee injection of autologous Adipose-Derived Mesenchymal Stem Cells (ADSC) harvested from the thigh using tumescent liposuction and processing with syringe emulsification and cell concentration using Harvest Adiprep System. This harvested tissue will then be combined with leukocyte poor-platelet-rich plasma (PRP) processed using the Harvest PRP system and then injected into the patient's knee.
2868783|NCT03467919|Active Comparator|Conventional therapy|Intra-articular injection of corticosteroid (Triamcinolone 40mg)
2868784|NCT03467906||Poor weight loss group|Sleeve gastrectomy surgery patients with poor weight loss outcomes will take part in in-laboratory assessment.
2891156|NCT03311334|Experimental|DSP-7888 in combination with Atezolizumab|
2868791|NCT03467867|Experimental|Venetoclax + Rituximab|Participants will be initially placed in a venetoclax 5 weeks ramp-up period, and will be administered an initial 20 mg oral tablet dose once daily (QD), incrementing weekly up to a maximum dose of 400 mg. Participants will then continue taking venetoclax 400 mg QD from Week 5 onwards, as directed by the investigator in combination with rituximab 375 mg/m^2 IV on Day 1 of Cycle 1 followed by 13.4 mL of rituximab SC 1,600 mg/26,800 Units vial (1,600 mg rituximab and 26,800 Units hyaluronidase human) on Day 1 of Cycle 2-6.
2868792|NCT03467854||VV ECMO|Patients 18 years of age or older, initiated on veno-venous (VV) ECMO for acute respiratory distress syndrome, and receiving piperacillin/tazobactam.Four blood samples will be obtained after the first dose of piperacillin/tazobactam: one sample before the second dose, 30-minutes, 2-hours, and 6-hours into the infusion. An additional four blood samples will be drawn on day 2 at the same time points.
2868793|NCT03467828|Experimental|Study Group|Infants diagnosed with BPD.
2868794|NCT03467828|No Intervention|Control Group|Infants born in similar gestational week and birth weight but not diagnosed with BPD.
2868795|NCT03467789|Experimental|Group A: D3 prior to first PDT|Group A will take D3 pills prior to the first PDT treatment, and placebo pills prior to the second PDT treatment. Both Group A and Group B will take no study drug prior to their third PDT visit.
2868796|NCT03467789|Experimental|Group B: D3 prior to second PDT visit|GROUP B will receive placebo prior to their first PDT visit, and Vitamin D3 prior to their second PDT visit. Both Group A and Group B will take no study drug prior to their third PDT visit.
2868797|NCT03467776||healthy|healthy control, 5 months to 3 years
2868798|NCT03467776||wheezing with atopy|suspected asthma with wheezing (＞3 episodes per year) and atopy
2868799|NCT03467776||wheezing without atopy|wheezing without atopy
2868800|NCT03467763|Active Comparator|Metformin Hydrochloride Extended Release|Patients will be assigned to take their baseline medication regimen plus 2 weeks of 250 mg per day of metformin extended release, followed by 500 mg metformin XR, 750 mg, and 1,000 mg metformin XR with each treatment period separated by a 2-week course of placebo.
2868801|NCT03467763|Placebo Comparator|Placebo|Patients will be assigned to take their baseline medication regimen plus 2 weeks of 250 mg per day of placebo, followed by 500 mg placebo, 750 mg, and 1,000 mg placebo with each treatment period separated by a 2-week course of metformin XR in the same increments of dosage.
2868802|NCT03467750|Experimental|Ketorolac|Participants randomized to the ketorolac group will receive 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis has been achieved
2868803|NCT03467750|Active Comparator|Standard of Care|Participants randomized to this group will receive the pain management standard of care for the adenotonsillectomy procedure.
2868804|NCT03467737|Experimental|Normal sorghum porridge, algal starch|Sorghum porridge with 13C-algal starch
2868805|NCT03467737|Experimental|Normal sorghum porridge, algal dextrins|Sorghum porridge with 13C-algal starch limit dextrins
2868806|NCT03467737|Experimental|Normal sorghum porridge, labeled flour|Sorghum porridge with 13C-labeled sorghum flour
2868807|NCT03467737|Experimental|Modified sorghum porridge, labeled flour|Modified sorghum porridge with 13C-labeled sorghum flour
2868808|NCT03467737|Experimental|Thinned sorghum porridge, labeled flour|Modified thinned sorghum porridge with 13C-labeled sorghum flour
2868809|NCT03467737|Experimental|Modified sorghum porridge, octanoic acid|Modified sorghum porridge with 13C-labeled octanoic acid
2868810|NCT03467724|Active Comparator|Fractional radiofrequency|Each surgical scar will be divided equally into two sections. One section of the scar will receive the study treatment while the other section will receive no study treatment for the duration of the study.
2868811|NCT03467724|No Intervention|No fractional radiofrequency|Each surgical scar will be divided equally into two sections. One section of the scar will receive the study treatment while the other section will receive no study treatment for the duration of the study.
2868812|NCT03467698|Experimental|Active tDCS|active HD-tDCS will be administered
2868813|NCT03467698|Sham Comparator|Sham tDCS|sham HD-tDCS will be administered
2868814|NCT03467685|Placebo Comparator|VAD Off arm|This will be the group that has the VAD placed on their skin in the off mode, i.e. no vibration
2868815|NCT03467685|Experimental|VAD On arm|This will be the group that has the VAD placed on their skin in the on mode, i.e. vibration
2868816|NCT03467672||Infected patients|
2868817|NCT03467672||Control group|
2868818|NCT03467659|Experimental|Cracked whole wheat porridge|Large particle whole wheat porridge
2868819|NCT03467659|Experimental|Semolina wheat porridge|Large particle refined wheat porridge
2868820|NCT03467659|Experimental|Whole wheat flour porridge|Small particle whole wheat porridge
2868821|NCT03467659|Experimental|Refined wheat flour porridge|Small particle refined wheat porridge
2868822|NCT03467659|Experimental|Refined wheat flour porridge,fine bran|Small particle refined wheat porridge with small particle bran
2868823|NCT03467659|Experimental|Refined wheat flour porridge,coarse bran|Small particle refined wheat porridge with large particle bran
2868824|NCT03467646|Active Comparator|Sleeve Gastrectomy|Patients undergo a laparoscopic sleeve gastrectomy as bariatric procedure
2868825|NCT03467646|Active Comparator|Roux-en-Y gastric bypass|Patients undergo a laparoscopic Roux-en-Y gastric bypass as bariatric procedure
2868826|NCT03467646|Experimental|One-Anastomosis gastric bypass|Patients undergo a laparoscopic One-Anastomosis gastric bypass as bariatric procedure
2868827|NCT03467633|Experimental|High-intensity interval training (HIIT)|Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the University of Ottawa Heart Institute prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
2868828|NCT03467633|No Intervention|Usual Care Control|Participants assigned to the control group will have usual care, which involves no behavioural interventions leading up to their electro-cardioversion.
2868829|NCT03467620|Experimental|Cannabidiol oral capsule|25-mg capsule of Cannabidiol (CBD) per day taken daily for a duration of 12 weeks.
2868830|NCT03467620|Placebo Comparator|Placebo oral capsule|One placebo capsule per day for a duration of 12 weeks
2868831|NCT03467607|Active Comparator|3ml/kg|15 patients ventilated with 3ml/kg ideal body weight while on one lung ventilation
2868832|NCT03467607|Active Comparator|4ml/kg|15 patients ventilated with 4ml/kg ideal body weight while on one lung ventilation
2868833|NCT03467607|Active Comparator|control|15 patients ventilated using the anaesthetists usual ventilation strategy
2868834|NCT03467594|Experimental|Intervention arm|"8 week workplace based exercise programme, 3 exercise sessions each week. Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be supervised and conducted in groups, with the option to request individual one-to-one sessions if preferred.~Outcome measures assessed at baseline and follow-up (8 weeks)"
2868835|NCT03467594|No Intervention|Control|Outcome measures only at baseline at follow-up (8 weeks)
2868836|NCT03467568|Active Comparator|Sodium chloride / Water|The sodium chloride / water arm involves 300mg sodium chloride being consumed in a capsule and on two occasions 150ml of water being drunk
2868837|NCT03467568|Active Comparator|Sodium chloride / no water|A capsule containing 300mg of sodium chloride will be consumed but no water will be drunk over the morning
2868838|NCT03467568|Active Comparator|Placebo / water|A capsule containing a placebo will be consumed and on two occasions 150ml of water will be drunk
2868839|NCT03467568|Placebo Comparator|Placebo / no water|A capsule containing a placebo will be consumed but no water will be drunk over the morning
2868840|NCT03467555|Experimental|distalization group|Class II correction using zygomatic miniplates
2868841|NCT03467542|Experimental|dAVF treatment|PHIL® Liquid Embolic System
2868842|NCT03467516|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with uveal melanoma will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide followed by infusion of up to 2x10^11 TIL infused intravenously through a central vein catheter and Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
2868843|NCT03467503|No Intervention|Nutrition Education|Participants will be given nutrition educational counseling on healthy dietary habits and gestational weight gain.
2868844|NCT03467503|Experimental|Dietary Intervention|Participants will be given dietary blueberries and soluble fiber.
2868845|NCT03467490|Experimental|Treatment|65 participants will be invited to receive a one-day educational intervention (first study visit) at the Ivey Eye Institute. The educational intervention includes watching a short video series and receiving educational handouts which summarize the content of the videos. Participants will have access to the educational handbook for reference. At two months post-intervention, participants will be invited back to St. Joseph's Hospital to complete the second administration of the heiQ and OSDI. Participants will have an opportunity to ask the ophthalmologist any question during the question and answer period. Participants will then be asked to provide feedback on the video series using a participation satisfaction survey and will be given an educational handbook which may be used to as a reference/guide on how to self-manage
2868846|NCT03467490|No Intervention|Control|Patients will continue with treatment as usual without any educational intervention. They will complete the heiQ and OSDI at baseline and 2 months later during a routine office visit. At the 2-month visit, participants will be asked to complete the second administration of the heiQ and OSDI before being offered the opportunity to view the videos series, receive the educational handbook, and provide feedback on the educational material.
2868847|NCT03467477|Experimental|Subjects with Early Symptomatic AD|Patients who receive 18F-AV-1451 dose after being successfully screened and are interested in participating in AD therapeutic clinical trials (and are not known to meet any exclusion criteria for those AD therapeutic clinical trials).
2868848|NCT03467464|Experimental|Intervention|EMDR treatment
2868849|NCT03467438|Experimental|A|Zinc-l-carnosine, liquid oral formulation, 75mg twice daily (20mL, using the measuring cup, twice daily), to be swallowed on an empty stomach (waiting at least one hour from the last meal).
2868850|NCT03467438|Placebo Comparator|B|Placebo, liquid oral formulation, 75mg twice daily (20mL, using the measuring cup, twice daily), to be swallowed on an empty stomach (waiting at least one hour from the last meal).
2868851|NCT03467425|Experimental|TRELEGY ELLIPTA (FF/UMEC/VI: 100 mcg/62.5 mcg/25 mcg)|Eligible subjects will receive a blended combination of FF in the first strip (100 mcg per blister) and UMEC/VI in second strip (62.5 mcg UMEC per blister and 25 mcg VI per blister), a single inhalation once daily in the morning in the same TRELEGY ELLIPTA Dry Powder Inhaler (DPI) via inhalation route for a period of 24 weeks. Study treatment may be augmented with other prescribed COPD medications such as including rescue medications, which will be prescribed and obtained according to usual practice.
2868852|NCT03467425|Active Comparator|Non-ELLIPTA MITT|Eligible subjects will receive the ICS/LAMA/LABA products twice daily and dosing regimens as prescribed by their physician for a period of 24 weeks. Study treatment may be augmented with other prescribed COPD medications such as including rescue medications, which will be prescribed and obtained according to usual practice.
2868853|NCT03467412|Experimental|0.00625 μg FOL-005|0.00625 μg FOL-005, solution. 50 μl injected sub-cutaneous three times per week for 12 weeks.
2868854|NCT03467412|Experimental|0.025 μg FOL-005|0.025 μg FOL-005, solution. 50 μl injected sub-cutaneous three times per week for 12 weeks.
2868855|NCT03467412|Experimental|0.050 μg FOL-005|0.050 μg FOL-005, solution. 50 μl injected sub-cutaneous three times per week for 12 weeks.
2868856|NCT03467412|Experimental|0.100 μg FOL-005|0.100 μg FOL-005, solution. 50 μl injected sub-cutaneous three times per week for 12 weeks.
2868857|NCT03467412|Placebo Comparator|Placebo|Placebo. 50 μl injected sub-cutaneous three times per week for 12 weeks.
2868858|NCT03467399|Experimental|Cochlear implant users|This is a within-subject, repeated measures study. There was one arm in this study, each subject served as their own control. All subjects received all interventions.
2868859|NCT03467386|Experimental|Treatment (TMLI, cyclophosphamide)|Patients undergo TMLI BID on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus given by CIV on days 5-90, and filgrastim beginning on day 5 until ANC is at least 1,500/mm^3 for 3 consecutive days.
2868860|NCT03467373|Experimental|Part 1: Dose Escalation r/r FL|Dose finding in participants with r/r FL: the study will explore different doses of RO7082859 in the induction period, starting at a dose of 70 mcg administered in combination with standard of care doses of G/R CHOP and R-CHOP on an every 3 weeks (Q3W) schedule. Participants with r/r FL will receive 6 cycles (Cycles 1-6) of induction treatment (G/R-CHOP). RO7082859 will be administered in Cycles 2-6 on Day 8. Participants who achieve a complete response (CR), partial response (PR), or stable disease (SD) at the end of induction (EOInd) will receive post-induction treatment (referred to as maintenance) with RO7082859 alone.
2868861|NCT03467373|Experimental|Part 2: Dose Expansion r/r FL|Participants with r/r FL will be assigned to an expansion cohort to further explore RO7082859 at the MTD/OBD determined in Part I.
2868862|NCT03467373|Experimental|Part 2: DLBCL G-CHOP|Participants with untreated DLBCL will receive G-CHOP in Cycle 1, followed by R-CHOP + RO7082859 in cycles 2-8. The starting dose of RO7082859 for each arm may be one or more levels below the MTD/OBD determined in Part I.
2868863|NCT03467373|Experimental|Part 2: DLBCL R-CHOP|Participants with untreated DLBCL will receive R-CHOP in Cycle 1, followed by R-CHOP + RO7082859 in cycles 2-8. The starting dose of RO7082859 for each arm may be one or more levels below the MTD/OBD determined in Part I.
2868864|NCT03467360|Experimental|One experimental arm|non randomized, open-label extension cohort, evaluating the safety of acetazolamide in combination with platinum and etoposide-based radiochemotherapy in patients with Localized small lung cancer
2868865|NCT03467347|Experimental|VR used continuously for approximately 90 days|One silicone elastomer vaginal ring (VR) containing the active 200 mg dapivirine (DPV) and 320 mg levonorgestrel (LNG), used continuously for approximately 90 days.
2868866|NCT03467347|Experimental|VR used cyclically for approximately 90 days|One silicone elastomer vaginal ring (VR) containing the active 200 mg dapivirine (DPV) and 320 mg levonorgestrel (LNG), used cyclically for approximately 90 days. Use the VR for 28 days, remove for 2 days.
2868867|NCT03467334|Experimental|B. breve|Group that will receive B. breve CECT7263 one dose per day in a capsule to open and suspend the powder in infant milk or water.
2868868|NCT03467334|Experimental|B. breve plus L. fermentum|Group that will receive B. breve CECT7263 and L. fermentum CECT5716 in one dose per day in a capsule to open and suspend the powder in infant milk or water.
2868869|NCT03467334|Active Comparator|Simethicone 20 mg|Control group that will receive simethicone 4 times (10 drops) a day.
2868870|NCT03467321||Pregnant group|Balance with the one leg balance test with the eyes open and closed, pulmonary functions with a spirometer, and LBP with the Visual Analogue Scale (VAS) were assessed.
2868871|NCT03467321||Non-pregnant group|Balance with the one leg balance test with the eyes open and closed, pulmonary functions with a spirometer, and LBP with the Visual Analogue Scale (VAS) were assessed.
2868872|NCT03467308||Colorectal cancer patients|50 Patients confirmed histopathologically to have early stages of colorectal cancer.
2868873|NCT03467308||Risky group|20 risky patients (those with ulcerative colitis, chron's disease, familial adenomatous polyposis).
2868874|NCT03467295||Surgically treated group|Surgical removal of intracerebral CMs by craniotomy with or without following stereotactic radiosurgery.
2868875|NCT03467295||Conservatively treated group|Observation with the best medicine administration and supportive treatment are performed.
2868876|NCT03467282|Experimental|Probiotic|1g probiotic mix (twice day): Lactobacillus acidophilus 1x109 CFU + Bifidobacterium lactis 1x109 CFU + Lactobacillus rhamnosus 1x109 CFU + Lactobacillus paracasei 1x109 CFU
2868877|NCT03467282|Placebo Comparator|Placebo|1g polydextrose- twice day
2868878|NCT03467256|Experimental|experimental|Patients will receive fludarabine 120 mg/m2 (totally) intravenously (IV) over 30 minutes on days -5 to -2 and cyclophosphamide 750 mg/m2 IV over 60 minutes on day -2. One hour prior to infusion of CAR T-cells patients will receive tocilizumab IV 8 mg/kg (max 800 mg) over 1 hour. Patients then receive CD19-CAR T cells IV over 20-30 minutes on day 0.
2868879|NCT03467243|Experimental|CBSST|Veterans participate in 20 weekly group sessions using Cognitive Behavioral Social Skills Training model
2868880|NCT03467243|Experimental|SST|Veterans participate in 20 weekly group sessions using Social Skills Training model
2868881|NCT03467243|Active Comparator|GFSC|Veterans participate in 20 weekly group sessions using Goal Focused Supportive Contact model
2868882|NCT03467230||NoL Index|All patients will be monitored by PMD-200 device
2868883|NCT03467217|Active Comparator|Losartan potassium capsule|Dose will be one 50 mg capsule of losartan per day for one week and then increased to two capsules of 50 mg of losartan per day (100 mg total) for 23 weeks patients with baseline weight ≥ 70 kg to <150 kg.
2868884|NCT03467217|Placebo Comparator|Placebo losartan capsule|Dose will be one 50 mg capsule of placebo losartan per day for one week and then increased to two capsules of 50 mg of placebo losartan per day (100 mg total) for 23 weeks for patients with baseline weight ≥ 70 kg to <150 kg.
2868885|NCT03467191|Experimental|Alcohol Beverage|Moderate dose of alcohol (target BAC .08%)
2868886|NCT03467191|Placebo Comparator|Placebo Beverage|
2868887|NCT03467178|Experimental|Decitabine plus Carboplatin|Carboplatin AUC 5 d 8 q 28 plus Decitabine 10 mg/mq iv d1-5 q 28
2868888|NCT03467178|Other|Standard Treatment|Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 or Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28
2868889|NCT03467165|Experimental|Hand ExAblate|MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)
2868890|NCT03467165|Experimental|Hip ExAblate|MRgFUS treatment of pain caused by hip OA
2868891|NCT03467152|Experimental|E2027|Participants will be randomized to receive a 50 milligram (mg) once daily oral dose of E2027 for 12 weeks.
2868892|NCT03467152|Placebo Comparator|Placebo|Participants will be randomized to receive a 50 mg once daily oral dose of E2027-matched placebo for 12 weeks.
2868893|NCT03467139|Experimental|Study Group|Hotpack was applied for 15 min and TENS was applied for 15 min and ultrasonics for 5 min. Then scapular mobilization and passive stretching exercises were applied in 10 sets of 3 sets (flexion, abduction, internal and external rotation) to increase joint range of motion by physiotherapist. Then, abdominal breathing exercise training was given 3 times a week as 30 sets of 3 sets a week and the patients were treated for 8 weeks
2868961|NCT03466593|Active Comparator|Retrospective cohort|Routine care before the prehabilitation program was introduced
2868962|NCT03466593|Experimental|Extra early mobilization|Mobilization the day of surgery
2868894|NCT03467139|No Intervention|Control Group|Hotpack was applied for 15 min and TENS was applied for 15 min and ultrasonics for 5 min. Then scapular mobilization and passive stretching exercises were applied for 8 weeks in 10 sets of 3 sets (flexion, abduction, internal and external rotation) to increase joint range of motion.
2868895|NCT03467126|Experimental|AcQMap Imaging and Mapping|Use of the AcQMap Imaging and Mapping System as a diagnostic modality in an ablation retreatment procedure for recurrent atrial fibrillation following a failed AF ablation.
2868896|NCT03467113|Experimental|ZX008 0.2 and 0.8 mg/kg/day|FZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive open-label ZX008 (0.2 mg/kg/day titrated to 0.8 mg/kg/day)
2868897|NCT03467100|Experimental|XEN901|Single ascending dose: Single oral dose for each cohort; Multiple ascending dose: 7 days of single oral dose twice daily for each cohort
2868898|NCT03467100|Placebo Comparator|Placebo|Single Ascending Dose: Single oral dose for each cohort; Multiple Ascending Dose: 7 days of single oral dose twice daily for each cohort
2868899|NCT03467087|Experimental|Electrical muscle stimulation|Electrical muscle stimulation is administered on both thighs and upper arms using a Myopuls 2000D device. Pre-set training time is 30 minutes per day (15 minutes for thighs and 15 minutes for upper arms) for at least 5 days a week.
2868900|NCT03467061|Active Comparator|Nitrate-rich beetroot juice|2 x 70mL concentrated juice per day for 14 days
2868901|NCT03467061|Placebo Comparator|Nitrate-depleted beetroot juice|2 x 70mL concentrated juice per day for 14 days
2868902|NCT03467061|Other|Antibacterial mouthwash|2 x 10mL antibacterial mouthwash per day for 14 days
2868903|NCT03467048|Experimental|McGrath videolaryngoscopy|Endotracheal intubation using McGrath videolaryngoscopy in an appropriate size (usually blade size 3 or 4)
2868904|NCT03467048|Active Comparator|Direct laryngoscopy|Endotracheal intubation using direct laryngoscopy with an appropriately sized Macintosh blade (usually size 3 or 4)
2868905|NCT03467035||desaturation|"ΔSpO2 >10% or lowest SpO2<90 during baseline six minute walk test~Check serum level of inflammasone, such as IL-1beta, TGF-beta TRT-PCR for PBMC"
2868906|NCT03467035||non-desaturation|"ΔSpO2 <10% and lowest SpO2>90 during baseline six minute walk test~Check serum level of inflammasone, such as IL-1beta, TGF-beta TRT-PCR for PBMC"
2868907|NCT03467009|Experimental|iPACT Intervention|"In-clinic brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention.~Eight-week longitudinal tailored CBT-based text-message program."
2868908|NCT03467009|Active Comparator|Control: Enhanced Usual Care (EUC)|The investigators will provide participants with a standard resource sheet with information on bullying and mental health resources.
2868909|NCT03466996|Experimental|Intervention group|The intervention group will participate in face-to-face video telemedicine visits, in addition to routine annual visits to the Spina Bifida Clinic. These 30-minute visits will occur at 2 weeks, 3 months, 6 months and 9 months from last in-person clinic appointment. The visits will consist of structured counseling using a plan-do-study-act cycle approach to incrementally adopt elements of a well-planned transition. Using qualitative notes from each session, we will identify common themes or challenges across patients and develop adjunctive education, support, and monitoring tools for patients and families in transition.
2868910|NCT03466996|Active Comparator|Standard of care group|The control group will receive the current standard of care transition program. In addition to this, they will receive encouraging text messages and e-mails relating to their transition goals. These messages will be sent 2 weeks, 3 months, 6 months and 9 months from the last in-person clinic appointment.
2868911|NCT03466983|Experimental|Iron Isomaltoside|Iron Isomaltoside (Monofer) administered IV
2868912|NCT03466983|Active Comparator|Ferric Carboxymaltose|Ferric Carboxymaltose (Injectafer) administered IV
2868913|NCT03466970||IgG4 patient|20 samples of IgG4 patients
2868914|NCT03466970||healthy donors|20 healthy donors
2868915|NCT03466957|Experimental|3D printed applicator|individually designed applicator for BT
2868916|NCT03466944||5-24 year old paediatric patients with childhood Leukaemia|Cooperative paediatric individuals and young adults (5-24-years-old) with proven Acute Lymphoblastic Leukaemia (ALL) or Acute Myeloblastic Leukaemia (AML) planned for bone marrow transplantation.
2868917|NCT03466931|Experimental|Dietary intervention|Meals containing Milk and Milk
2868918|NCT03466931|No Intervention|Historical cohort|Standard care
2868919|NCT03466918|Experimental|Patients with SAPIEN 3 THV|Patients will be treated with Edwards SAPIEN 3 Transcatheter Heart Valve and Commander delivery system
2868920|NCT03466905|Active Comparator|Intervention|Assessment of Ambulance Medical Service
2868921|NCT03466905|No Intervention|Control|Local treatment guidelines
2868922|NCT03466879||Active device users|Users will use an active SYNUS Pain Relief device
2868923|NCT03466879||Sham device users|Users will use a sham SYNUS Pain Relief device that is not providing treatment
2868924|NCT03466866|Experimental|COPDE|Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
2868925|NCT03466866|Active Comparator|Intensive Diabetes Education|In-home diabetes education
2868926|NCT03466840|Experimental|The Coronally Advanced Lingual Flap|"On the lingual side of mandible, a full-thickness muco-periosteal flap is elevated until reaching mylohyoid line. Using a blunt instrument, a connective tissue band is localized continuing with the epimysium of the mylohyoid muscle and is inserted into the inner part of the lingual flap . The blunt instrument is inserted below the connective band, and with gentle traction in the coronal direction, this muscular insertion was detached from the lingual flap. Using a periodontal probe the amount of advancement is measured."
2868963|NCT03466593|Active Comparator|Traditional mobilization|Routine care with mobilization the day after surgery
2868964|NCT03466580|Experimental|Intervention|('Standard' specialized palliative care +) The Carer Support Needs Assessment Tool (CSNAT) intervention.
2868965|NCT03466580|No Intervention|Control|('Standard' specialized palliative care). No intervention offered.
2868966|NCT03466567|Experimental|Oral semaglutide, ciclosporin, probenecid|Participants will receive oral semaglutide in treatment period 1, ciclosporin in treatment period 2, and probenecid in treatment period 3.
2868927|NCT03466840|Active Comparator|Modified periosteal releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side. Near the base of muco-periosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade, or a blunt instrument, with sweeping motion. This motion helps stretching the flap over the submucosa, thereby permitting the flap to be mobile.Using a periodontal probe the amount of advancement is measured"
2868928|NCT03466814||JIA participants|
2868929|NCT03466801|Experimental|Group prednisone|Prednisone was taken 1mg/kg/d(maximum 60mg/d)for 8 weeks to start.Then decreased 5mg every 2 weeks; When reduced to 40mg,reduced 5mg every 4 weeks. When reduced to 20mg, reduced 2.5mg every 8 weeks until the end.
2868930|NCT03466801|Active Comparator|Group MP and CTX|The first month,Methylprednisolone(MP) was injected for 3 days(weight >60kg,500mg/d;<60 kg,300mg/d),and 0.4mg/kg/d for 27 day.The second month,Cyclophosphamide(CTX) orally was 100mg/d for 1 month.And this regimen is repeated for six months.
2868931|NCT03466788|Other|Patients treated with chemotherapy|
2868932|NCT03466788|Other|Patients not treated with chemotherapy|
2868933|NCT03466749|Experimental|Intervention group|Paclitaxel Eluting Balloon Catheter treatment
2868934|NCT03466736||cognitively intact older adults|Each subject will receive an amyloid PET scan with [18F]flutemetamol
2868935|NCT03466736||Mild Cognitive Impairment|Each subject will receive an amyloid PET scan with [18F]flutemetamol
2868936|NCT03466736||Alzheimer's disease|Each subject will receive an amyloid PET scan with [18F]flutemetamol
2868937|NCT03466710|Active Comparator|Colposcopy arm|Patients received colposcopy as per standard of care
2868938|NCT03466710|Experimental|Pap arm|Patients received a Pap test only
2868939|NCT03466710|Experimental|HPV arm|Patients received an HPV test only
2868940|NCT03466697|Other|Healthy subjects|All subjects will be injected twice for each visit (normal saline or glucose)
2868941|NCT03466684|Experimental|BIA-directed fluid resuscitation|After the achievement of CVP, MAP and ScvO2 goals, if hyperhydration (HL > 74.3%) was found, then the following fluid management was applied with each passing 6h. If HL was above 87% (severe level), fluid infusion was restricted, a furosemide drip was used, and CRRT was initiated with an ultrafiltration rate when patients were failure or inadequate response to above diuretic therapy that gave a net negative fluid balance of at least 1500 ml during the next 6h. If HL was 81%-87% (moderate level), above methods were used to trigger a net negative fluid balance (about 1000 ml) for the next 6h. Similarly, If HL was 74.3%-81% (mild level), a net negative fluid balance of about 500 ml would be achieved during the next 6h of ICU hospitalization. If HL was blow 71%, a state of dehydration, CVP, MAP, and ScvO2 was maintained as above during ICU resuscitation.
2868942|NCT03466684|Active Comparator|Traditional fluid resuscitation|A timely restricted intravenous fluid regimen or dehydration therapy was implemented by two senior clinicians according to cumulative fluid balance recording and hemodynamic condition such as heart rate, blood pressure, central venous pressure, mean arterial pressure, urine output and body weight change.
2868943|NCT03466671|Other|Low dose once per day and placebo|"Four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.~After four weeks washout, four weeks administrations of placebo twice per day in morning and evening."
2868944|NCT03466671|Other|Low dose twice per day and placebo|Four weeks administrations of TTA-121 3U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.
2868945|NCT03466671|Other|High dose once per day and placebo|"Four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.~After four weeks washout, four weeks administrations of placebo twice per day in morning and evening."
2868946|NCT03466671|Other|High dose twice per day and placebo|Four weeks administrations of TTA-121 10U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.
2868947|NCT03466671|Other|Placebo and low dose once per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.
2868948|NCT03466671|Other|Placebo and low dose twice per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U twice per day in morning and evening.
2868949|NCT03466671|Other|Placebo and high dose once per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.
2868950|NCT03466671|Other|Placebo and high dose twice per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U twice per day in morning and evening.
2868951|NCT03466658|Experimental|JumpStart group|This group will have the JumpStart dressing pre-operatively. Intervention: JumpStart dressing
2868952|NCT03466658|No Intervention|Control group|This group will have no intervention pre-operatively. Intervention: none
2868953|NCT03466645|Active Comparator|1st group, receiving vancomycin|The 1st group receives vancomycin an hour before craniotomy
2868954|NCT03466645|Active Comparator|2nd group, receiving cefazolin|The 2nd group receives cefazolin an hour before craniotomy
2868955|NCT03466632|Active Comparator|• Propofol Group|propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure..
2868956|NCT03466632|Active Comparator|• Dexmedetomidine Group|dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
2868957|NCT03466619|Experimental|inflatable penile prosthesis (IPP)|inflatable penile prosthesis (IPP)
2868958|NCT03466606|Experimental|Prehabilitation|Personalized supervised resistance training and program to promote physical activity and healthy lifestyles
2868959|NCT03466606|No Intervention|Control|Conventional treatment
2868960|NCT03466593|Experimental|Prospective cohort-prehabilitation|A prehabilitation program including advice about diet, increased physical activity and cessation of smoking and drinking alcohol.
2869031|NCT03466203|Experimental|LLF580|LLF580 every 28 days * 3
2868967|NCT03466567|Experimental|Probenecid, oral semaglutide, ciclosporin|Participants will receive probenecid in treatment period 1, oral semaglutide in treatment period 2, and ciclosporin in treatment period 3.
2868968|NCT03466567|Experimental|Ciclosporin, probenecid, oral semaglutide|Participants will receive ciclosporin in treatment period 1, probenecid in treatment period 2, and oral semaglutide in treatment period 3.
2868969|NCT03466554|Experimental|HBOT|60 daily HBOT sessions will be administrated 5 days per week. Comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
2868970|NCT03466554|No Intervention|Control|"The standard of care of psychological and mediational support .~After 3 months of follow up, participants will be re-evaluated. The individuals in the control group will then be offered to receive the treatment and to be re-reevaluated after the treatment is over (3 months)."
2868971|NCT03466541|Experimental|Riskbruk|The employees randomised to the Riskbruk group will be offered two consultations a ∼15 min with the OHS. The subjects will receive individual feedback on the screening results. During these sessions, Motivational Interviewing will be used.
2868972|NCT03466541|Experimental|Balance|The group allocated to the Balance intervention will follow a comprehensive multi-session eHealth intervention with personalised feedback on the screening results.
2868973|NCT03466541|No Intervention|Control group/usual care|The control group will receive the usual follow-up provided by the OHS for persons with risky alcohol behaviour. In order to provide something that appears as a plausible follow-up to the control participants, they will be given a booklet that covers general information about alcohol and potential risks and harms of drinking. The booklet contains no advise on how to achieve a change in drinking behaviour.
2868974|NCT03466528|Active Comparator|Standard treatment - Pabrinex alone|Pabrinex alone
2868975|NCT03466528|Active Comparator|Pabrinex + magnesium sulphate|standard treatment and magnesium sulphate
2868976|NCT03466528|Experimental|Magnesium sulphate alone|This group receives the study intervention and delayed Pabrinex
2868977|NCT03466515|Experimental|intervention|Patients enrolled in the study will be treated for their anal fistula by surgical closure of the internal opening, debridement of the fistula and injection of patients own stem cells enriched fatty tissue around the fistula. Stem cells preparation will be performed prior to fistula treatment by liposuction and then isolation.
2868978|NCT03466502|No Intervention|No oral vancomycin|
2868979|NCT03466502|Experimental|Oral vancomycin 125 mg twice daily|
2868980|NCT03466502|Experimental|Oral vancomycin 125 mg daily|
2868981|NCT03466489|Experimental|Floraseal|The surgical site will first be cleaned with isopropyl alcohol. Once the site is dry, alcohol based chlorhexidine gluconate preparatory solution will be applied to the surgical site. Once dry, the FloraSeal surgical preparatory solution will be applied per the manufacturers recommendations. The extremity will be draped in sterile fashion however adhesive drapes over the surgical site itself will not be applied.
2868982|NCT03466489|No Intervention|Control|The operative site is first cleaned with isopropyl alcohol. Once the site is dry, alcohol based chlorhexidine gluconate preparatory solution will be applied to the surgical site. The operative site will then be draped in sterile fashion. An iodine impregnated adhesive drape will then be applied to the surgical site.
2868983|NCT03466476|Experimental|Wearable Technology|Patients in this arm will be provided with their own Consensus TracPatch wearable device as well as instructions on its use.
2868984|NCT03466476|No Intervention|Current Standard|Patients in this arm will not be provided with any wearable device.
2868985|NCT03466463|Experimental|GNT0003|2 doses of the IMP assessed in a dose escalation, open-label, phase 1/2 study
2868986|NCT03466450|Experimental|Glasdegib and Temozolomide Oral Capsule|"During Phase Ib, Four to six weeks after surgical diagnosis, concurrent with radiotherapy (STUPP) + temozolomide (75mg/m2/day for 42 days) + PF-04449913 (Glasdegib) (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered.~During Phase II, Radiation therapy, temozolomide and glasdegib will be administered. This last, as the dose that have been selected previously, based on the Phase Ib results. Glasdegib ( PF-04449913) recommended dose until progresion of disease, unacceptable toxicity, non-compliance, consent withdrawal up to 2 years."
2868987|NCT03466437|Experimental|Glass-fiber post + composite resin restoration|
2868988|NCT03466437|Experimental|Glass-fiber post + metalceramic crown|
2868989|NCT03466437|Active Comparator|Cast-metal post + metalceramic crown|
2868990|NCT03466424||Group 1|preoperative short-course radiotherapy(5×6Gy) followed by 4×mFOLFOX6 chemotherapy
2868991|NCT03466424||Group 2|preoperative short-course radiotherapy(5×7Gy) followed by 4×mFOLFOX6 chemotherapy
2868992|NCT03466424||Group 3|preoperative short-course radiotherapy(5×8Gy) followed by 4×mFOLFOX6 chemotherapy
2868993|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 1 (Guselkumab)|Participants will receive guselkumab (Dose 1) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) phase and continue to receive guselkumab.
2868994|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 2 (Guselkumab)|Participants will receive guselkumab (Dose 3) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
2868995|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 3 (Guselkumab)|Participants will receive guselkumab (Dose 4) by intravenous (IV) infusion, followed by guselkumab (Dose 5) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
2868996|NCT03466411|Active Comparator|Phase 2 (GALAXI 1): Group 4 (Ustekinumab)|Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE and continue to receive ustekinumab.
2868997|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 5 (Placebo/Ustekinumab)|Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (Ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
2869032|NCT03466203|Placebo Comparator|Placebo|Placebo to LLF580 every 28 days * 3
2868998|NCT03466411|Experimental|Phase 3 (GALAXI 2 and 3): Group 1 and Group 2 (Guselkumab)|Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
2868999|NCT03466411|Active Comparator|Phase 3 (GALAXI 2 and 3): Group 3 (Ustekinumab)|Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE phase and continue to receive ustekinumab.
2869000|NCT03466411|Experimental|Phase 3 (GALAXI 2 and 3): Group 4 (Placebo/Ustekinumab)|Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
2869001|NCT03466398|Experimental|Intervention Arm|Patients will use the Vivify Health RPM protocol as part of their diabetes management. They required to complete the Care Plan questions on a daily basis, and will upload blood glucose readings directly to the tablet twice a day. They will also have scheduled video conferences with study team physicians or advanced practice nurses on a weekly basis, to discuss ongoing diabetes management and educational objectives.
2869002|NCT03466398|No Intervention|Control Arm|Patients in this arm will manage their diabetes at home per normal standard of care, without any extra intervention from the study investigators.
2869003|NCT03466385|Experimental|Nasal High Flow|Patients randomized to NHF device with initial settings of flow=50-60 L·min−1, temperature=37ο Celsius and FiO2 adjusted to maintain SpO2 between 88%-92%.
2869004|NCT03466385|Active Comparator|Non-Invasive Ventilation|Patients randomized to NIV with initial settings EPAP=3cmH2O, IPAP=15cmH2O, I:E=1:2 to 1:3, inspiratory time=0.8-1.2sec and FiO2 adjusted to maintain SpO2 between 88%-92%.
2869005|NCT03466372|Experimental|biofeedback 1|biofeedback training with progression of targets
2869006|NCT03466372|Active Comparator|biofeedback 2|biofeedback training with progression of targets and speeds
2869007|NCT03466359|Experimental|DEF-EI|these adolescents will follow a dietary restriction of 10% of their daily energy intake.
2869008|NCT03466359|Experimental|DEF-EX|these adolescents will increase their physical activity-induced energy expenditure by 10% per day.
2869009|NCT03466346|Active Comparator|Interpersonal psychotherapy|IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.
2869010|NCT03466346|Active Comparator|fluoxetine|Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
2869011|NCT03466333|Experimental|Investigational medicinal product|Oral enalapril maleate once daily: 5mg for 1 week, then 10mg for 2 weeks, then 20mg maintenance (for total of 6 months postpartum)
2869012|NCT03466333|Placebo Comparator|Placebo|Oral placebo once daily for 6 months postpartum
2869013|NCT03466333|No Intervention|Observational arm|For participants who decline to be take part in the interventional part of the study (decline randomisation to IMP/placebo) however they consent to the observational components of the study (serial echocardiography and biomarkers postpartum).
2869014|NCT03466320|Experimental|Segment 1 - T7-DL1|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -9, -8 and -7.~Dose 1: 1x108 NKR-2 (adjusted at 1.5x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 7 days (T7) after the end of the preconditioning regimen"
2869015|NCT03466320|Experimental|Segment 1 - T3-DL1|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.~Dose 1: 1x108 NKR-2 (adjusted at 1.5x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
2869016|NCT03466320|Experimental|Segment 1 - T3-DL2|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.~Dose 2: 3x108 NKR-2 (adjusted at 4.6x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
2869017|NCT03466320|Experimental|Segment 2 - extension|This extension segment will enroll more patients (to reach 9 evaluable patients in total) to further evaluate the selected treatment regimen, i.e., the recommended NKR-2 dose (1x108 or 3x108 NKR-2/injection) with the CYFLU preconditioning treatment administered at the recommended interval (T3 or T7) prior to NKR-2 administration.
2869018|NCT03466307||Group A|Thirty patients with nocturnal shoulder pain
2869019|NCT03466307||Group B|Thirty patients without nocturnal shoulder pain
2869020|NCT03466307||Group C|Healthy controls
2869021|NCT03466294|Experimental|Azacitidine and Venetoclax|On day 1 of cycle 1, Azacitidine 75 mg/m2 will be given by injection or infusion, and will continue for 7 days. Azacitidine doses will be given in subsequent cycles for patients who do not achieve response. Venetoclax will be administered orally once daily on days 2 through 28 in cycle 1. Beginning with cycle 2, and each subsequent cycle, venetoclax will be administered Days 1 through 28.
2869022|NCT03466281|Active Comparator|IBS School|Patient education provided in a group setting
2869023|NCT03466281|Active Comparator|Internet patient education|Patient education provided via the internet
2869024|NCT03466268|Experimental|Dose escalation study of Glumetinib|To determine the maximum tolerated dose (MTD) of Glumetinib
2869025|NCT03466255||Cardiac outpatients|Subjects referred for outpatient coronary angiography.
2869026|NCT03466242|Experimental|Intranasal Dexmedetomidine|Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine (1-2ug/kg)
2869027|NCT03466242|Active Comparator|IV Ketamine|Evaluate sedative and analgesic effects of Intravenous Ketamine (1mg/kg)
2869028|NCT03466229|Active Comparator|Antioxidant|Androferti - 1 twice per day
2869029|NCT03466229|Placebo Comparator|Placebo|Placebo - 1 twice per day
2869030|NCT03466216|Experimental|AlphaMedix|There is only a single treatment arm.
2869033|NCT03466190|Experimental|Custom made PEEK plate fixation|Open Reduction Internal Fixation using Custom made PEEK plates.
2869034|NCT03466190|Active Comparator|Titanium plate fixation|Open Reduction Internal Fixation using conventional titanium plating system.
2869035|NCT03466177||Ab+ AD patients|"amyloid positive Alzheimer's Disease patients~Venous blood sampling Hematology and chemistry~Genotyping: apolipoprotein E (apoE) polymorphism Cerebral imaging~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence~18F-Flutemetamol PET CT~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
2869036|NCT03466177||Ab+ Mild Cognitive Impairment (MCI) patients|"amyloid positive Mild Cognitive Impairment patients~Venous blood sampling Hematology and chemistry~Genotyping: apoE polymorphism Cerebral imaging~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence~18F-Flutemetamol PET CT~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
2869037|NCT03466177||Ab+ cognitively intact volunteers|"amyloid positive cognitively intact volunteers~Venous blood sampling Hematology and chemistry~Genotyping: apoE polymorphism Cerebral imaging~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence~18F-Flutemetamol PET CT~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
2869038|NCT03466177||Ab- cognitively intact volunteers|"amyloid negative cognitively intact volunteers~Venous blood sampling Hematology and chemistry~Genotyping: apoE polymorphism Cerebral imaging~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence~18F-Flutemetamol PET CT~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
2869039|NCT03466164|Experimental|Behavioral: Mindfulness Based Stress Reduction Program|Mindfulness-Based Stress Reduction MZ: identical (monozygotic; MZ) twins are tested in a pre-post manner, with only one twin randomly assigned to MT in between the two testing sessions
2869040|NCT03466164|No Intervention|Control MZ|Control MZ twin will complete 2 testing sessions without intervention.
2869041|NCT03466151|Experimental|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
2869042|NCT03466151|Active Comparator|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
2869043|NCT03466138||General Anesthesia|subjects requiring a surgical procedure under general anesthesia. monitored by PMD-200
2869044|NCT03466125||Adult patients who underwent cardiac surgery in Massachusetts|No interventions. A retrospective cohort study of patients who underwent cardiac surgery in Massachusetts in calendar years 2012 - 2016.
2869045|NCT03466112|Experimental|endurance training|endurance training with stationary bicycles
2869046|NCT03466112|Active Comparator|balance and tone program|flexibility, core strength, balance, relaxation
2869047|NCT03466099|Experimental|KVD001 Injection (high dose)|
2869048|NCT03466099|Experimental|KVD001 Injection (low dose)|
2869049|NCT03466099|Sham Comparator|Sham Procedure|
2869050|NCT03466086|Experimental|TEST Eye Drops|
2869051|NCT03466086|Active Comparator|CONTROL Eye Drops|
2869052|NCT03466073|Experimental|Single Dose 6 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg v. placebo (NSS) in addition to standard of care
2869053|NCT03466073|Experimental|Multiple Dose 6 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
2869054|NCT03466073|Experimental|Multiple Dose 12 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 12 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
2869055|NCT03466073|Experimental|Multiple Dose 24 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 24 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
2869056|NCT03466060|Active Comparator|etafilcon A|etafilcon A will be used to evaluate 3 lens solutions; Opti-Free, RevitaLens, and Clear Care
2869057|NCT03466060|Active Comparator|senofilcon A|senofilcon A will be used to evaluate 3 lens solutions; Opti-Free, RevitaLens, and Clear Care
2869058|NCT03466060|Active Comparator|senofilcon C|senofilcon C will be used to evaluate 3 lens solutions; Opti-Free, RevitaLens, and Clear Care
2869059|NCT03466047|Experimental|Protein distal bowel|Protein microcapsule released in distal bowel Encapsulated macronutrients in a drink
2869060|NCT03466047|Experimental|Protein stomach|Protein microcapsule released in stomach Encapsulated macronutrients in a drink
2869061|NCT03466047|Experimental|CHO distal bowel|CHO microcapsule released in distal bowel CHO microcapsule released in distal bowel
2869062|NCT03466047|Experimental|CHO stomach|CHO released in stomach CHO released in stomach
2869063|NCT03466047|Experimental|Fat distal bowel|Fat Microcapsule released in distal bowel Fat Microcapsule released in distal bowel
2869064|NCT03466047|Experimental|Fat stomach|Fat microcapsule released in stomach Encapsulated macronutrients in a drink
2869065|NCT03466034||Endometriod|Type I (endometrioid and mucinous carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.
2869066|NCT03466034||Serous|Type II (serous and clear cell carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.
2869067|NCT03466021|Active Comparator|Liraglutide|Liraglutide injection 3.0 mg daily
2869069|NCT03466008|Experimental|Whole body cryotherapy arm|intervention consisted of 10 sessions of WBC (three minutes for each session) which were performed in addition to usual care in a standard cryotherapy room over a duration of 8 days.
2869070|NCT03466008|No Intervention|Usual treatment arm|usual care
2869071|NCT03465995||NKI iPAS Diagnostic Protocol|Research participants who qualify for this study will put on EKG leads, and then a non-invasive device called iPAS, which will record heart rate and eye tracking data while participants perform a task on the screen of the device. The testing session will not exceed 30 minutes. Participants will take a total of 3 recordings over a period of roughly 5 weeks.
2869072|NCT03465982|Active Comparator|Standard Interval Time Arm|Minimally invasive surgery after 8 weeks from chemoradiation treatment
2869073|NCT03465982|Active Comparator|Delayed Interval Time Arm|Minimally invasive surgery after 12 weeks from chemoradiation treatment
2869074|NCT03465969|Other|Liver or kidney transplant participants of Advagraf|Transplant participants will provide 1 whole blood venepuncture sample and 1 whole blood finger prick MITRA sample at pre-dose of participant's usual oral dose of commercial Advagraf and at approximately 1 and 3 hours post-dose.
2869075|NCT03465956|Other|Laparoscopic Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy for patients with morbid obesity using the gastro-intestinal anastomosis stapler.
2869076|NCT03465943|Active Comparator|Ringer|This group will receive 1 L of Ringer's solution as a preload
2869077|NCT03465943|Active Comparator|Voluven|This group will receive 500 ml of 6% hydroxyethyl starch ( Voluven ) and 500 ml Ringer's solution as a preload
2869078|NCT03465930||Patients with lymphedema|Patients affected by primary or secondary lymphedema. The intervention will consist in supermicrosurgical lymphatico-venous anastomoses (sLVA) to allow drainage of the lymph in the venous stream distal to the obstruction. sLVA is a minimally invasive procedure performed under local anesthesia. It requires an accurate visualization of the lymphatic vessels that are still functional.
2869079|NCT03465917|Experimental|Renal Denervation|Renal denervation using the Peregrine Catheter for extravascular administration of ethanol
2869080|NCT03465904|Experimental|Verum|2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
2869081|NCT03465904|Sham Comparator|Sham|2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
2869082|NCT03465891|Experimental|atezolizumab|All patients will receive open-label atezolizumab 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).
2869083|NCT03465891|Experimental|atezolizumab plus low-dose, local radiotherapy|All patients will receive open-label atezolizumab 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year). 4Gy will be administered in 2 fractions to a single nodal site amenable to radiation as identified by the radiation oncologist on day 2 and day 3 of Cycle 1 (over the two days following to the first dose of atezolizumab ).
2869084|NCT03465878|Experimental|LY900014 Subcutaneous|Single, subcutaneous (SC) dose of LY900014 administered via injection, in one of two study periods
2869085|NCT03465878|Active Comparator|Insulin Lispro (Humalog) SC|Single, SC dose of insulin lispro (Humalog) administered via injection, in one of two study periods
2869086|NCT03465878|Experimental|LY900014|Single, SC bolus dose of LY900014 via continuous subcutaneous insulin infusion (CSII) in one of two study periods
2869087|NCT03465878|Active Comparator|Insulin Lispro (Humalog)|Single, SC bolus dose of insulin lispro (Humalog) via CSII in one of two study periods
2869088|NCT03465865||ILM-flap|Patients after surgical repair of macular holes with ILM-flap transposition are invitied to a follow-up for optical coherence tomography and visual acuity testing one year after surgery
2869089|NCT03465852|Experimental|Intervention arm|Persons randomized to this arm will have completed the study consent process (including being tested with the INSTI rapid HIV test to verify their self-reported HIV negative status and their eligibility to participate in the study) and the baseline survey, and will receive the Spanish language ChiCAS intervention shortly after being randomized and will complete a follow-up assessment 6 months after completing the intervention.
2869090|NCT03465852|Other|Wait list comparison (control) arm|Persons randomized to this arm will have completed the study consent process (including being tested with the INSTI rapid HIV test to verify their self-reported HIV negative status and their eligibility to participate in the study) and the baseline survey, but will not receive the Spanish language ChiCAS intervention until they complete a follow-up assessment 6 months after completing the baseline assessment.
2869091|NCT03465839|Experimental|Bedside handover|Education for improving handovers quality + Education for improving bedside handovers
2869092|NCT03465839|Active Comparator|Control|Education for improving handovers quality
2869093|NCT03465826|Experimental|PainCOACH Pain Coping Skills Training|Migraineurs will participate in 4 weeks of daily headache monitoring, baseline questionnaires, followed by 8 weeks of the PainCOACH migraine mHealth Pain Coping Skills Training program (developed by Drs. Keefe and Rini based on social cognitive theory and in-person pain coping therapy sessions). Following the 8 week mHealth intervention, participants will immediately complete post-treatment assessments and later will complete follow-up assessments at 3 and 6 months.
2869094|NCT03465826|Active Comparator|Treatment as Usual|Participants will keep headache diaries for 4 weeks, followed by baseline assessments + 8 weeks of daily headache monitoring (as a parallel to the PainCOACH intervention). Post-assessments will immediately follow, and participants later will complete follow-up assessments at 3 and 6 months.
2869095|NCT03465813|Experimental|CaringGuidance Intervention|Three months of web-based CaringGuidance psychoeducational program use, independently on home computer in addition to usual care.
2869096|NCT03465813|No Intervention|Usual Care|Three months of care as usual from subjects' clinics and community as the subject chooses.
2869097|NCT03465800|Active Comparator|Self-Monitoring|Participants self-monitor their physical activity
2869098|NCT03465800|Experimental|Daily Incentives|daily payments for physical activity
2869099|NCT03465800|Experimental|Delayed Lump Sum Incentives|lump sum payments for physical activity
2869100|NCT03465787|Experimental|Lurasidone HCL 160 mg|Lurasidone HCL 160 mg/day
2869101|NCT03465787|Active Comparator|Quetiapine XR 600 mg|Quetiapine XR 600 mg/day
2869612|NCT03462329|Active Comparator|patients with erythema migrans|Patients will be treated with antibiotics for Lyme disease.
2869102|NCT03465774|Experimental|Indwelling Pleural Catheter (IPC)|Participants complete 2 questionnaires before the IPC is inserted, 10 and 14 days after the catheter is placed, and 1 time each month for up to 1 year after the IPC is removed.
2869103|NCT03465774|Experimental|Indwelling Pleural Catheter (IPC) + Doxycycline|"Participants complete 2 questionnaires before the IPC is inserted, 10 and 14 days after the catheter is placed, and 1 time each month for up to 1 year after the IPC is removed.~Participants given a prescription for a fentanyl patch to help control pain after the IPC is placed.~At Day 5 check up after IPC placed, participants receive Fentanyl by vein over a few minutes, if needed to help control pain. Doxycycline placed in the IPC as catheter is drained."
2869104|NCT03465761|Experimental|ExAblate 4000 System|ExAbalte treatment of Bilateral Essential Tremor
2869105|NCT03465748|Experimental|Experimental-OrthoK|The study will be a randomized control study using a single-masked design to investigate axial elongation and myopic progression in children wearing ortho-k lenses (study group) versus single-vision spectacles or soft contact lenses (control group) for a period of 24 months. A minimum of 40 and a maximum of 60 subjects will be recruited from patients at Illinois Eye Institute. Once eligibility has been determined by an unmasked observer, patients will be randomly assigned to either the orthokeratology group or the single-vision contact lens /spectacle group
2869106|NCT03465748|No Intervention|Control|The study will be a randomized control study using a single-masked design to investigate axial elongation and myopic progression in children wearing ortho-k lenses (study group) versus single-vision spectacles (control group) for a period of 24 months. A minimum of 40 and a maximum of 60 subjects will be recruited from patients at Illinois Eye Institute. Once eligibility has been determined by an unmasked observer, patients will be randomly assigned to either the orthokeratology group or the single-vision contact lens /spectacle group
2869107|NCT03465735|Other|Standard of Care|Ultrasound of the leg with DVT and leg circumference measurement at 3 days, 10 days, and 3 months. Ultrasound data will include data on thrombus resolution, such as size and recanalization present.
2869108|NCT03465735|Other|Vascular Boot Group|"For each vascular boot session, the following data will be recorded:~Wearing the vascular boot during first 10 days of study for minimum of 30 minutes per day"
2869109|NCT03465722|Experimental|avapritinib|300 mg PO QD
2869110|NCT03465722|Active Comparator|regorafinib|160 mg PO QD
2869111|NCT03465709|Experimental|APL-2 Study Drug|
2869112|NCT03465696|No Intervention|Group #1 (Control)|"Group #1 (Control)~Oral survey 1 will be administered and patients will be asked:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
2869113|NCT03465696|Experimental|Group #2 (Intervention)|"Group #2 (Intervention)~Survey 2 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
2869114|NCT03465696|Experimental|Group #3 (Intervention)|"Group #3 (Intervention)~Survey 3 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~What do you think would be the best way to describe this to a patient?~Stelara® acts in an almost all-natural way to help control psoriasis.~Stelara® blocks one of the genetic causes of psoriasis.~Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance~Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
2869115|NCT03465670|Active Comparator|CHX|Post-surgery use of a 0.2% chlorhexidine (CHX) mouthrinse (10 ml for 1 minute, t.i.d. for 21 days)
2869116|NCT03465670|Experimental|CHX+HA+ADS|Post-surgery use of a 0.2% chlorhexidine (CHX) mouthrinse containing 0.2% hyaluronic acid (HA) and Anti-Discoloration System (ADS) (10 ml for 1 minute, t.i.d. for 21 days)
2869117|NCT03465644|Experimental|Tailored arm|early (<6-month post-PCI) intensified (low-dose ticagrelor [120 mg loading, then 60 mg bid maintenance] and aspirin) and late (>6-month post-PCI) deescalated (clopidogrel alone) strategy
2869118|NCT03465644|Active Comparator|Conventional arm|clopidogrel + aspirin for 12months
2869119|NCT03465631|Experimental|SMART Glove system with dual-tDCS|VR-based SMART Glove system with dual-tDCS
2869120|NCT03465631|Sham Comparator|SMART Glove system with sham-tDCS|VR-based SMART Glove system with sham-tDCS
2869121|NCT03465618|Experimental|surgical patients|Patients will be i.v. injected with approximately 5 mCi (~3.4-6.7 nanomoles) of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (specific activity range 750.0 - 1450 mCi/ µmol) and undergo the microdosing study for purposes of collecting particle tracer kinetic and dosimetry data. The patient's PET/CT Brain scans will be acquired prior to surgery.
2869122|NCT03465618|Experimental|non-surgical patients|Before the patient's PET Brain scans patients will be i.v. injected with approximately 5 mCi (~3.4-6.7 nanomoles) of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (specific activity range 750.0 - 1450 mCi/ µmol) and undergo the microdosing study for purposes of collecting particle tracer kinetic and dosimetry data.
2869123|NCT03465592|Experimental|Nivolumab|Nivolumab of 3 mg/kg IV will be infused over 60 minutes every 14 days, for a maximum of 24 cycles. A cycle will be considered 28 days. Participants may continue to receive Nivolumab unless they develop serious side effects or the tumor worsens.
2869124|NCT03465579|Other|Cohort 1|Men with suspected clinically-significant PCa (CS-PCa) who are candidates for prostate biopsy or after first-round negative transrectal ultrasonography (TRUS) biopsy
2869125|NCT03465579|Other|Cohort 2|Men framed in Active Surveillance (PRIAS study), scheduled for PRIAS repeat biopsy.
2869126|NCT03465579|Other|Cohort 3a|Men with high-risk PCa (HR-PCa) prior to radical surgery.
2869127|NCT03465579|Other|Cohort 3b|Men diagnosed with CS-PCa prior to nerve-sparing prostate surgery (NSS).
2869613|NCT03462329|No Intervention|controls|Control subjects will not be given antibiotics.
2869128|NCT03465566||Children with BECTS|"Children with active BECTS according to state-of-the-art diagnostic criteria of ILAE (International League Against Epilepsy). Eligible subjects will be recruited at their first clinical observation in the epilepsy centers involved in the study.~All subjects will perform five diagnostic evaluations named:~IDS (Intelligence and Development Scale) MMSPE (Mini Mental State Pediatric Examination) CDI 2 (Children Depression Inventory 2) CBCL (Child Behavior Check List) Tests of facial expression evaluation"
2869129|NCT03465566||Healthy children|"Healthy controls matched for sex, age range, and education with no family history for epilepsy or other neuropsychiatric disorders.~All subjects will perform the following tests:~MMSPE (Mini Mental State Pediatric Examination) CDI 2 (Children Depression Inventory 2) CBCL (Child Behavior Check List) Tests of facial expression evaluation"
2869130|NCT03465553|Experimental|Short course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation.
2869131|NCT03465540|Experimental|AMG 397 Treatment|AMG 397 administered orally once daily for 2 consecutive days followed by 5 days break at a weekly interval, as part of a 28-day treatment cycle in adult subjects with selected RR hematological malignancies
2869132|NCT03465527|Experimental|Prednisolone|"Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days~Hydration, antibiotics, allopurinol, nutritional supplements, and so on."
2869133|NCT03465501||Low Dose Rate|Patients treated with brachytherapy at low dose rate of the anal canal with aim of boost
2869134|NCT03465501||High Dose Rate|Patients treated by brachytherapy with a high dose rate of the anal canal aiming for boost
2869135|NCT03465488|Experimental|Subjects|All participants that meet all inclusion criteria and none of the exclusion criteria will be enrolled in the study and receive a subject identifier (SubjectID). At baseline, all participants will receive a single treatment of albendazole 400mg and their stool will be examined for helminth eggs. Two to three weeks after treatment a follow-up examination of their stool is performed.
2869136|NCT03465475||Group 1|The patient who receive 5 mL/kg (ideal body weight) fresh gas flow during the general anesthesia
2869137|NCT03465475||Group 2|The patient who receive 10 mL/kg (ideal body weight) fresh gas flow during the general anesthesia
2869138|NCT03465462|Active Comparator|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
2869139|NCT03465462|Active Comparator|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
2869140|NCT03465462|Active Comparator|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
2869141|NCT03465449|Active Comparator|usual care|
2869142|NCT03465449|Experimental|CKD-PC arm|
2869143|NCT03465436|Experimental|Lasmiditan Dose 1 + Placebo|Lasmiditan Dose 1 and placebo for moxifloxacin administered orally in one of four study periods.
2869144|NCT03465436|Experimental|Lasmiditan Dose 2 + Placebo|Lasmiditan Dose 2 and placebo for moxifloxacin administered orally in one of four study periods.
2869145|NCT03465436|Placebo Comparator|Placebo + Placebo|Placebo for lasmiditan and placebo for moxifloxacin administered orally in one of four study periods.
2869146|NCT03465436|Active Comparator|Moxifloxacin + Placebo|Moxifloxacin and placebo for lasmiditan administered orally in one of four study periods.
2869147|NCT03465423||patients with nonfunctioning pituitary tumor|patients with nonfunctioning pituitary tumor undergoing transsphenoidal pituitary surgery under total intravenous anesthesia
2869148|NCT03465423||patients with pituitary somatotroph tumor|patients with pituitary somatotroph tumor undergoing transsphenoidal pituitary surgery under total intravenous anesthesia
2869149|NCT03465410|Active Comparator|GROUP I Standard adjustment|Standard dosage of Tacrolimus
2869150|NCT03465410|Experimental|GROUP II Bayesian prediction adjustment|Bayesian prediction Tacrolimus dosage
2869151|NCT03465397|Experimental|experimental|Biomarkers driven immunosuppressive therapy: the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
2869152|NCT03465397|No Intervention|control|All patients receive the usual triple immunosuppressive treatment, without depending on the results of any biomarker.
2869153|NCT03465384|Active Comparator|Comet in group format|The standard format of the intervention that is well established in primary and specialized care in Sweden. Parents receive the education/training in small groups led by two group leaders.
2869154|NCT03465384|Experimental|Internet-based Comet|The same content as the group format of Comet, but delivered mainly as online self-help.
2869155|NCT03465371|Experimental|OnDemand Training Intervention|Participants receiving the OnDemand Training Intervention
2869156|NCT03465371|Active Comparator|InPerson Intervention|Participants receiving the InPerson Intervention
2869157|NCT03465345|Experimental|Metformin + OPC dose escalation|
2869158|NCT03465332||Lung specialist|Approximately 30 lung specialists in Germany with a sufficient number of COPD subjects under supervision will be enrolled in the study to document physician's attitudes on COPD diagnosis and therapy, and to document data on about 250 subjects with COPD.
2869159|NCT03465332||Subjects with COPD|Data from approximately 250 subjects with COPD under supervision of lung specialists enrolled in the study will be analyzed.
2869160|NCT03465319||Sevoflurane|10 patients receiving an anesthesia with sevoflurane
2869161|NCT03465319||Desflurane|10 patients receiving an anesthesia with desflurane
2869162|NCT03465306|Experimental|Intensive digital CBT|
2869163|NCT03465306|Active Comparator|Standard digital CBT|
2869164|NCT03465293||SUDD post-menopausal female|Post-menopausal women with non-specific left side pain and altered bowel habit who are having mechanical bowel preparation for a colonoscopy
2869165|NCT03465267|Experimental|Armeo power|Armeo power robot for upper extremity
2869166|NCT03465267|Experimental|Armeo spring|Armeo spring robot for upper extremity
2869167|NCT03465254||Cohort|Recruited members of the cohort are children aged 9-14 years old and eligible to receive the dengue vaccine at the time of the initiation of community-based dengue immunization program of the Department of Health.
2869781|NCT03461315|No Intervention|Traditional Mode|Traditional Model: Team That Cares for the Rest of the Community
2869168|NCT03465241||Monitoring by NGS group|This group will accept the ctDNA dynamic monitoring on the following phase:the day before surgery,the 3rd to 7th day after surgery,3 to 4 weeks after adjuvant chemotherapy finished, then every 6 months in the following 2 years.
2869169|NCT03465228|Experimental|Training group|This group will do the Deep Water Running, with intervals and continuous training twice a week, and before each session, will be applied the LED equipment. The training will be thirty minutes and will be controlled by heart rate, 70% to 80% maximum heart rate in continuous training, and maximum heart rate in intervals training.
2869170|NCT03465228|Experimental|Training and LED group|This group will receive the photobiomodulation treatment and the same training model of training group.
2869171|NCT03465228|Experimental|LED group|This group will receive only the photobiomodulation treatment with 30 seconds of light emitting in four points of lumbar region.
2869172|NCT03465215|Experimental|Assessment of inflammation grade|Tissue obtained by CD patients will be analyzed using digital holographic microscopy and comparing histological analysis.
2869173|NCT03465202|Experimental|Capecitabine|
2869174|NCT03465176|Experimental|Intervention|The women in this arm will receive an essential oil blend to inhale each afternoon for two weeks.
2869175|NCT03465176|Placebo Comparator|Control|The women in this arm will receive an odorless vegetable based oil to inhale each afternoon for two weeks as a control/placebo.
2869176|NCT03465163|No Intervention|Recovery|Two months recovery (no stimulation) following bilateral implantation of Medtronic PC+S devices into the anterior nucleus of the thalamus and the hippocampus. Thirty second EEG snapshots will be recorded every 15 minutes
2869177|NCT03465163|No Intervention|Baseline|No stimulation, 30 second EEG snapshots recorded every 15 minutes We require a minimum of 5 seizures to occur during this phase.
2869178|NCT03465163|Experimental|Probing|"Deep Brain Stimulation Electrically stimulate the thalamus continuously at a low frequency (2Hz). Thirty second EEG snapshots recorded every 15 minutes.~We require a minimum of 5 seizures to occur during this phase."
2869179|NCT03465163|Experimental|Probe Calibrated Deep Brain Stimulation|Deep Brain Stimulation In this phase we explore 18 deep brain stimulation parameter configurations (three stimulus intensities; 3,4,5 Volts, six different frequencies; 125 130, 135, 140,145, 150 Hz) during two of the clinic visits. Each deep brain stimulation parameter configuration will be tested for 1 minute with 4 minutes between each configuration test. The probing responses will be used to optimise the deep brain stimulation parameters for each participant. This phase of the study continues for 2 months.
2869180|NCT03465163|Experimental|Open Deep Brain Stimulation|Deep Brain Stimulation During this phase the deep brain stimulation parameters may be altered from the probing optimised parameters according to patient needs.
2869181|NCT03465137|Experimental|Immediate therapy|Participants randomized to the immediate therapy arm will receive a weekly individual psychotherapy intervention called Coordinated Anxiety Learning and Management (CALM). The CALM program is an evidence based, exposure-focused therapy (http://calmtoolsforliving.org). Its computer-assisted format guides the therapist through psychoeducation, an introduction to cognitive restructuring, in-session and at-home exposures, and relapse prevention. Therapy will be delivered in 10 weekly 50-minute sessions within a 12 week period.
2869182|NCT03465137|No Intervention|Waitlist|Participants randomized to the waitlist arm will receive no intervention for 12 weeks. After this 12 week period they will receive a the same weekly individual psychotherapy intervention as the immediate therapy group: Coordinated Anxiety Learning and Management (CALM). The CALM program is an evidence based, exposure-focused therapy (http://calmtoolsforliving.org). Its computer-assisted format guides the therapist through psychoeducation, an introduction to cognitive restructuring, in-session and at-home exposures, and relapse prevention. Therapy will be delivered in 10 weekly 50-minute sessions within a 12 week period.
2869183|NCT03465124|Active Comparator|Femtosecond Laser assisted Cataract Surgery|Femtosecond Laser assisted Cataract Surgery will be performed unilateral in randomized order.
2869184|NCT03465124|Active Comparator|Manual Cataract Surgery|Manual Cataract Surgery will be performed in contralateral (to LCS) eye of patient with bilateral age-related cataract.
2869185|NCT03465111|Experimental|Twice Weekly Treatment Arm|Patients in this treatment arm will receive mandatory 80 U twice weekly treatment with SC ACTH (adrenocorticotropic hormone) gel, starting at the Baseline visit (Day 0) until end of week 16. Starting at week 17, the treatment will be administered on as needed basis, based on the retreatment criteria.
2869186|NCT03465111|Experimental|Thrice Weekly Treatment Arm|Patients in this treatment arm will receive mandatory 80 U thrice weekly treatment with SC ACTH (adrenocorticotropic hormone) gel, starting at the Baseline visit (Day 0) until end of week 16. Starting at week 16, the treatment will be administered on as needed basis, based on the retreatment criteria.
2869187|NCT03465098|Experimental|enrolled patients|All enrolled patients will be received a strict low carbohydrate (< 3gr/day of carbohydrate) and 12h fasting before 18F-FDG PET/CT exam and 24h after a 18F-FDG PET/CT preceded by a low carbohydrate diet with 12h fasting
2869188|NCT03465085|Experimental|Group I: Heparin nebulized group|Group (I): 20 patients received inhaled Unfractionated Heparin at a dose of 10000 IU/4h by nebulizer, with the total daily dose of nebulized Unfractionated Heparin 60,000 IU
2869189|NCT03465085|Experimental|Group II: Streptokinase group|Group (II): 20 patients received inhaled Streptokinase at a dose of 250,000 IU/4h by nebulizer, with the total daily dose of nebulized Streptokinase 1,500,000 IU.
2869190|NCT03465085|No Intervention|Group III: Control group|Twenty patients whom guardian declined to participate actively in the study but accepted to participate passively by consenting for using their data were assigned as Group III or the control group and received conservative management
2869191|NCT03465072|Experimental|Exercise training|8 Weeks exercise training 3x per week 30-40 minutes per session
2869192|NCT03465059|Experimental|Normal Hepatic Function|Participants with normal hepatic function will be administered a single oral dose of Zanubrutinib (80 mg).
2869193|NCT03465059|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
2869194|NCT03465059|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
2869665|NCT03462069|Experimental|Treatment A (Test)|Sotagliflozin 2 tablets administered once daily with 1 empagliflozin placebo capsule prior to the first meal of the day
2869195|NCT03465059|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
2869196|NCT03465046|Experimental|low performance group 1|Protocol 1 will be the intervention administered with 80 h modified constraint induced movement therapy and 20 h bimanual intensive therapy
2869197|NCT03465046|Experimental|low performance group 2|Protocol 2 will be the intervention administered with 80h bimanual intensive therapy and 20h modified constraint induced movement therapy
2869198|NCT03465046|Experimental|moderate-high performance group1|Protocol 1 will be the intervention administered with 80 h modified constraint induced movement therapy and 20 h bimanual intensive therapy
2869199|NCT03465046|Experimental|moderate-high performance group 2|Protocol 2 will be the intervention administered with 80h bimanual intensive therapy and 20h modified constraint induced movement therapy
2869200|NCT03465033|No Intervention|Usual Care|Patients will receive basic indications of rehabilitation consisting of daily mobilization of the jaw (perform several movements a day opening movements, laterotrusion and mouth protrusion).
2869201|NCT03465033|Experimental|Early Physiotherapy|
2869202|NCT03465020||ITP patients|On active treatment
2869203|NCT03465007|Active Comparator|Hydrocortisone|100mg Hydrocortisone will be administered prior to hemodialysis
2869204|NCT03465007|Placebo Comparator|Placebo|100mg normal saline will be administered prior to hemodialysis
2869205|NCT03464994|Other|ichthyosis patients|patients presenting an Hereditary ichthyosis, whatever form or ongoing therapy will have an ophthalmological examination.
2869206|NCT03464994|Other|control population|patient without ichthyosis disease and consulting an ophthalmologist for refractive surgery screening or systematic eye examination will have an ophthalmological examination
2869207|NCT03464981||Advanced HF patients scheduled to undergo LVAD implantation|
2869208|NCT03464968|Experimental|mFOLFOX|D1 oxaliplatin 100mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr 5FU 2400mg/m2 over 46hr Every 2 weeks
2869209|NCT03464968|Experimental|mFOLFIRI|D1 Irinotecan 150mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr 5FU 2400mg/m2 over 46hr Every 2 weeks
2869210|NCT03464955|No Intervention|Control|The control group will be provided standard of care, which is no use of technologies.
2869211|NCT03464955|Experimental|Intervention Group with Passive Content|Interventional arm will use technology based distractions (VR headsets, AR headset, tablets, or BERT projector) to prevent high anxiety before non-invasive surgical subspecialty procedures.
2869212|NCT03464955|Experimental|Intervention Group with Active Content|Interventional arm will use technology based distractions (VR headsets, AR headset, tablets, or BERT projector) to prevent high anxiety before non-invasive surgical subspecialty procedures.
2869213|NCT03464942|Active Comparator|Single Dose|SABR 20Gy given as a single dose (to 1 -4 metastases with at least 1 untreated metastasis) followed by atezolizumab (1200 mg) every 3 weeks for 24 months.
2869214|NCT03464942|Active Comparator|Fractionated Dose|SABR 24Gy given as 3 fractions (to 1 -4 metastases with at least 1 untreated metastasis) followed by atezolizumab (1200 mg) every 3 weeks for 24 months.
2869215|NCT03464929||Airtraq indirect laryngoscopy|Intubation attempts using Airtraq device.
2869216|NCT03464929||King Vision indirect laryngoscopy|Intubation attempts using King Vision device
2869217|NCT03464916|Experimental|CAR2 Anti-CD38 A2 CAR-T Cells|Relapsed or Refractory Multiple Myeloma
2869218|NCT03464890|Experimental|LICHTENA DermAD|"Comparison within subjects of P926 - LICHTENA DermAD CREMA VISO and P927 - LICHTENA DermAD CREMA CORPO versus placebo and versus untreated control area. Study products were applied once, on experimentally induced erythema by repeated tape stripping on 4 different adjacent skin areas of the forearms (volar surface - 2 areas on each side)"
2869219|NCT03464877|Experimental|Intervention group|Standardized six-week duration multi-station full-body supervised exercise program. The frequency was 2-3 sessions per week. The duration of each session was 60 minutes.
2869220|NCT03464864|Experimental|Treprostinil Inhalation Powder 30 mcg|
2869221|NCT03464864|Experimental|Treprostinil Inhalation Powder 60 mcg|
2869222|NCT03464864|Experimental|Treprostinil Inhalation Powder 90 mcg|
2869223|NCT03464864|Experimental|Treprostinil Inhalation Powder 120 mcg|
2869224|NCT03464864|Experimental|Treprostinil Inhalation Powder 150 mcg|
2869225|NCT03464864|Experimental|Treprostinil Inhalation Powder 180 mcg|
2869226|NCT03464864|Experimental|Treprostinil Inhalation Powder 240 mcg|
2869227|NCT03464864|Experimental|Treprostinil Inhalation Powder 300 mcg|
2869228|NCT03464851|Active Comparator|Unknown/Normal/Mild Disease|No prior carotid duplex study or known normal or mild disease in the ICAs (PSV <= 125 cm/sec)
2869229|NCT03464851|Active Comparator|Known moderate or severe ICA Stenosis (PSV>125 cm/sec)|
2869230|NCT03464851|Active Comparator|Known ICA Fibromuscular Dysplasia|
2869231|NCT03464838|Experimental|Real Stimulation tDCS with CBT|24 participants will attend to one weekly tDCS stimulation session with intensity 2 milliamps for 8 consecutive weeks. Following the tDCS session, participants will attend to a cognitive behavioural therapy (CBT) session. One tDCS + CBT session per week (Total: 8 sessions).
2869232|NCT03464838|Sham Comparator|Sham tDCS with CBT|24 participants will attend to one weekly Sham tDCS session with intensity 0 milliamps for 8 consecutive weeks. Following the Sham tDCS session, participants will attend to a CBT session. One Sham tDCS + CBT session per week (Total: 8 sessions).
2869233|NCT03464825|Other|Intervention|Participants in the intervention group receive balance training during 3 months 3 times per week
2869234|NCT03464825|No Intervention|Control|Care as usual
2869235|NCT03464812|Other|DSMES Group|Patients with type 2 diabetes will undergo a diabetes education program (DSMES) and evaluated for outcomes before and after completing the program.
2869236|NCT03464786|Experimental|absorbable collagen membrane|Subjects randomized in this arm will receive Lando® absorbable collagen membrane after tooth extraction.
2869237|NCT03464786|Active Comparator|Bio-Gide resorbable bilayer membrane|Subjects randomized in this arm will receive Bio-Gide resorbable bilayer membrane after tooth extraction.
2869370|NCT03463902|Active Comparator|left IFG cathodal|2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
2869238|NCT03464773|Other|Pathway|The PIUO Pathway is implemented by clinicians (MD and RN) with expertise in treating pain in children. Each participant proceeds through the PIUO Pathway as long as their pain persists, but will exit the PIUO Pathway at any stage in case their pain is resolved. The Pathway has two steps: Step 1 is a thorough history and patient evaluation, including directed testing. Step 2 is a series of screening tests to further explore any potential underlying disease or injury not apparent based on history and physical examination.
2869239|NCT03464773|No Intervention|Waitlist|Participants randomized to the Waitlist will cross over to the Pathway after 8 weeks.
2869240|NCT03464760|Placebo Comparator|Placebo|
2869241|NCT03464760|Experimental|Spirulina-Silicon supplementation|
2869242|NCT03464734|Experimental|Pembrolizumab + nab-paclitaxel|pembrolizumab 200 mg + nab-paclitaxel 125 mg/m2, intravenously
2869243|NCT03464721||Surgery Outpatients|
2869244|NCT03464708|Experimental|HMB|HMB 3 g/day until hospital discharge or 28-days (whichever comes first). HMB to be provided in powder form and administered via enteral feeding tube whilst in the ICU and orally once able to eat and drink.
2869245|NCT03464708|Placebo Comparator|Placebo|Placebo (lactose) 3 g/day until hospital discharge or 28-days (whichever comes first). Placebo to be provided in powder form and administered via enteral feeding tube whilst in the ICU and orally once able to eat and drink.
2869246|NCT03464695|Active Comparator|O2matic|Oxygen administered by O2matic. Automatic adjustment based on continuous measurement of SpO2.
2869247|NCT03464695|No Intervention|Manual|Oxygen administered by manual control based on nurse's intermittent measurement of SpO2.
2869248|NCT03464682|Experimental|HS-25 10mg|HS-25 10mg, Placebo of HS-25 1 tablet, Placebo of Aorvastatin 1 tablet, oral once daily
2869249|NCT03464682|Experimental|HS-25 20mg|HS-25 20mg, Placebo of Aorvastatin 1 tablet, oral once daily
2869250|NCT03464682|Experimental|HS-25 10mg combination with Atorvastatin|HS-25 10mg, Aorvastatin 10mg, Placebo of HS-25 1 tablet, oral once daily
2869251|NCT03464682|Experimental|HS-25 20mg combination with Atorvastatin|HS-25 20mg, Aorvastatin 10mg, oral once daily
2869252|NCT03464682|Experimental|Aorvastatin|Aorvastatin 10mg, Placebo of HS-25 2 tablets, oral once daily
2869253|NCT03464682|Placebo Comparator|Placebo of HS-25 and Aorvastatin|Placebo of HS-25 2 tablets, Placebo of Aorvastatin 1 tablet, oral once daily
2869254|NCT03464669||Group prenatal education|Prenatal education delivered in-person by health and social services centers
2869255|NCT03464669||Online prenatal education|Online prenatal education provided or recommended by health and social services centers
2869256|NCT03464669||Control group|Absence of prenatal education
2869257|NCT03464656|Experimental|Patients|"Patients presenting with male infertility, who are found to have abnormal semen analysis shall be recruited to this study.~Interventions:~Patients will be given Fairhaven Pro for Men as antioxidant in a dose of 3 tablets twice daily for 3 months.~Full assessment of fertility will be done."
2869258|NCT03464643|Other|Single embryo culture|Embryo is cultured individually in 25 ul media
2869259|NCT03464643|Other|Group embryo culture|2-3 Embryos are group cultured in 50 ul media
2869260|NCT03464630|Experimental|Mom & Baby Net|Skills based maternal depression treatment and targeted infant social-communication promotion
2869261|NCT03464630|Active Comparator|Developmental Awareness System|Depression and infant develop awareness
2869262|NCT03464604||Group 1 Control group|Patients randomized into this group will follow normal standard of care in Nova Scotia
2869263|NCT03464604||Group 2 Active group|"Patients randomized into this group will be part of the active arm of the study. They will be pre-screened and asked the following questions:~Sign an Information and Authorization form~Demographic data: gender, date of birth, ethnicity~Health history (duration of lesion, changes in lesion, specific changes, who identified the lesion, measurement in two greatest dimensions radially and color."
2869264|NCT03464565||Patients with acute ischemic stroke|
2869265|NCT03464552|Active Comparator|Celecoxib group|will receive oral Celecoxib 200 mg capsule (Celebrex®200, Pfizer, USA) once 3 hours before the colposcopic guided biopsy
2869266|NCT03464552|Placebo Comparator|Placebo group|will receive oral placebo capsule once 3 hours before the colposcopic guided biopsy
2869267|NCT03464539|Other|CD patients|PG low molecular weight chitosan 3 times per day
2869268|NCT03464526|Active Comparator|Orvepitant 10mg|Orvepitant 10mg tablet, once daily for 12 weeks
2869269|NCT03464526|Active Comparator|Orvepitant 20mg|Orvepitant 20mg tablet, once daily for 12 weeks
2869270|NCT03464526|Active Comparator|Orvepitant 30mg|Orvepitant 30mg tablet, once daily for 12 weeks
2869271|NCT03464526|Placebo Comparator|Placebo|Placebo tablet, once daily for 12 weeks
2869272|NCT03464513|Other|Patients with GIT bleeding|Patients with active lower Gastrointestinal bleeding
2869273|NCT03464500|Active Comparator|AMAZ-02 Low dose|
2869274|NCT03464500|Active Comparator|AMAZ-02 High Dose|
2869275|NCT03464500|Active Comparator|Placebo|
2869276|NCT03464487|Active Comparator|Daily LGIT|The children with drug resistant epilepsy in this arm will receive Low Glycemic Index Therapy diet everyday along with the antiepileptic drugs.
2869277|NCT03464487|Active Comparator|Intermittent LGIT|The children with drug resistant epilepsy in this arm will receive Low Glycemic Index Therapy Diet on five days of each week along with antiepileptic drugs. Rest of the two days, they will receive a liberal diet.
2869278|NCT03464474|Experimental|Assessment of inflammation grade|Colonic biopsies will be acquired. Biopsies from all patients will be examined using digital holographic microscopy as well as performing a histopathological analysis using the Nancy-score (Goldstandard).
2869279|NCT03464461|Placebo Comparator|0 mg|0 mg ketorolac - placebo
2869280|NCT03464461|Active Comparator|10 mg|10 mg ketorolac - low dose ketorolac
2869281|NCT03464461|Active Comparator|30 mg|30 mg ketorolac - usual dose ketorolac
2869282|NCT03464448||1|Patients with RRMS who have been newly prescribed Teriflunomide.
2869283|NCT03464448||2|Healthy Controls
2869284|NCT03464435|Experimental|tacrolimus and loteprednol etabonate/tobramycin|topical eye drops
2869285|NCT03464422|Active Comparator|HIV Positive MSM|15 HIV+ MSM will take part in 12 group sessions.
2869286|NCT03464422|Active Comparator|HIV Negative MSM|15 HIV- MSM will take part in 12 group sessions.
2869287|NCT03464409|Active Comparator|SCI Patient - Nerve Transfer Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury seeking nerve transfer surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline (pre-operatively), Early Followup (1 month post-operatively) and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
2869288|NCT03464409|Active Comparator|SCI Patient - Tendon Transfer Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury seeking tendon transfer surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline (pre-operatively), Early Followup (1 month post-operatively) and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
2869289|NCT03464409|Active Comparator|SCI Patient - No Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury who did not chose to have surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline, Early Followup (1 month later), and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
2869290|NCT03464396||Preterm infant study visits|"Preterm infants Study Visits~Bedside Physiology Study at 28, 32, 36, 40, and 52 weeks GA.~Respiratory tests:~Carotid Body Function Test will be completed at 32, 36, 40 and 52 weeks GA~Room Air Challenge (RAC) or Hypoxia Challenge Test (HCT) will be completed at 36 weeks GA~Effects of nasal cannula flow be completed at 28, 32, 36, 40 and 52 weeks GA~Magnetic Resonance Imaging (MRI): Completed on a subset of infants between 37-40 weeks GA or before discharge, whichever comes first.~Echocardiogram (Echo): Completed at 32, 36 and 52 weeks GA~Blood sample: Obtained at 32, 36 and 52 weeks GA"
2869291|NCT03464383|Experimental|Epileptologist-Driven Treatment|The intervention will consist of initiating a chronic care management plan in the epilepsy clinic and an initial prescription from the epileptologist for escitalopram 10mg daily. Escitalopram dose adjustment will be made based on biweekly repeated screening of anxiety and depression symptoms, as well as side effects identified on biweekly telephone calls or the 6-week advanced practice provider (APP) follow up visit. Escitalopram dose may be titrated up to a maximum of 20mg daily in 5-10mg increments every 2 weeks for treatment effect, or titrated down to 5mg if needed for adverse effects. If a participant is unable to tolerate escitalopram, then venlafaxine XR 37.5mg will be substituted, to be titrated in a similar manner biweekly based on side effects and anxiety and depression symptoms (with 37.5-75mg increment dose changes and maximum dose of 225mg daily).
2869292|NCT03464383|Active Comparator|Standard of Care|A psychiatry referral order placed by epileptologist under typical care circumstances (internal or external referral based on the participant's geographic preferences). Internal referrals will be processed by current clinic/institutional protocols. External referral orders will be printed and provided to the patient along with brief instructions on how to find a provider covered by the patient's insurance.
2869293|NCT03464370|Experimental|TLE-AE Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
2869294|NCT03464370|Active Comparator|Non AE epileptic Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
2869295|NCT03464370|Active Comparator|Extra-temporal epilepsy Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors and then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
2869296|NCT03464370|Active Comparator|Healthy volunteers Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors
2869297|NCT03464357|Active Comparator|Symptomatic patients with dry eye|8 symptomatic patients with dry eye (mild to severe) assessed using a validated questionnaire (OSDI score, Appendix 1) associated with a disabling photophobia (need to wear sunglasses permanently outside, restriction of the outputs in case of significant brightness, restriction of the use of the screens because of the visual embarrassment ...). The fMRI will be carried out following the inclusion visit after all the necessary checks
2869298|NCT03464357|Active Comparator|Asymptomatic patient|"8 asymptomatic patients presenting neither photophobia (even minimal) or dry eye.~The fMRI will be carried out following the inclusion visit after all the necessary checks"
2869299|NCT03464344|Other|Patients with cortical superficial siderosis.|During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
2869300|NCT03464344|Other|Patients without cortical superficial siderosis|During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
2869301|NCT03464331|Experimental|EXP group|Participants in EXP group (EXP) will be asked to practise Zero-time exercises (ZTE) at least 20-30 minutes per day, and on most and preferably all days of the week.
2869302|NCT03464331|Placebo Comparator|CON group|Participants in CON group (CON) will be asked to practise relaxation exercises (RE) and deep-breathing exercises (DBE) at least 30 mins every day.
2869303|NCT03464305|Experimental|Aspirin|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
2869304|NCT03464305|Placebo Comparator|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
2869371|NCT03463902|Active Comparator|left IPL anodal|2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
2869305|NCT03464292|Placebo Comparator|Vehicle Patch|Control patch will be the same topical solution but will not contain capsaicin. The patch will applied to the hand for 30 - 60 min. Patients will be instructed to not touch or wash their hands during the course of the study to minimize spreading of the patch to other areas of the body. Subsequently, the patch will be immediately removed.
2869306|NCT03464292|Active Comparator|Capsaicin Patch 8%|8% Capsaicin topical patch. The patch will applied to the hand for 30 - 60 min. Patients will be instructed to not touch or wash their hands during the course of the study to minimize spreading of the patch to other areas of the body. Subsequently, the patch will be immediately removed.
2869307|NCT03464279|Experimental|Intervention Site|"The intervention Site (Urgent Care Center at LAC+USC Medical Center) will receive a three part intervention consisting of (1) Email Choosing Wisely® guidelines and presented journal club to all 16 urgent care clinicians, (2) leveraging EHR performance data to provide individual clinicians with case-specific audit-feedback (both via emails and in-person while precepting nurse practitioners) on low-value antibiotic prescribing, and (3) using a behavioral nudge, urgent care clinicians will sign a large poster committing to avoid prescribing low-value antibiotics for uncomplicated URIs displayed in the clinic."
2869308|NCT03464279|Active Comparator|Control Site|The control site (Urgent Care Center at Olive View-Medical Center) will receive broader health system efforts to reduce antibiotic prescribing consisting of Center for Disease Control prescription pads for non-antibiotic treatments (e.g., decongestants) that offer patients alternatives to antibiotics.
2869309|NCT03464266|Active Comparator|DMPA and PrEP|
2869310|NCT03464266|Active Comparator|DMPA and no PrEP|
2869311|NCT03464266|Active Comparator|Condoms only and PrEP|
2869312|NCT03464266|Active Comparator|Condoms only and no PrEP|
2869313|NCT03464240|Active Comparator|Glucose|50 grams glucose in 50 ml water
2869314|NCT03464240|Placebo Comparator|Water|50 ml water
2869315|NCT03464227|Experimental|UCB0107|Subjects randomized to this arm will receive UCB0107. This arm will consist of a maximum of 7 cohorts. The dose for cohort 1 will be fixed, proposed doses for cohorts 2,3,4,5,6 and 7 may be adapted based upon recommendation by the Safety Review Group.
2869316|NCT03464227|Placebo Comparator|Placebo|Subjects randomized to this arm will receive matching Placebo to UCB0107. This arm will consist of a maximum of 7 cohorts.
2869317|NCT03464214|Active Comparator|Vibration Group|Local vibration on neck muscles
2869318|NCT03464214|Active Comparator|Stabilization Group|Cervical stabilization exercises on cervical region
2869319|NCT03464214|No Intervention|Control Group|Individuals performed only daily living activities
2869320|NCT03464201|Experimental|Enzalutamide|Enzalutamide 160 mg daily p.o. (4 capsules 40mg per day)
2869321|NCT03464188|No Intervention|Usual Care|Usual care family caregiver participants will be informed of the UAB Comprehensive Cancer Center Patient and Family Resources webpage.
2869322|NCT03464188|Experimental|Project Cornerstone|
2869323|NCT03464175|Active Comparator|Heated-humidifier left on during nebulization|
2869324|NCT03464175|Active Comparator|Heated-humidifier turned off 30 minutes before nebulization|
2869325|NCT03464175|Experimental|Use of a heat and moisture exchanger (HME) filter|
2869326|NCT03464162|Experimental|Social Network Meetings Group|This arm will receive Social Network Meetings for a 6 month period. Meetings may occur as often as 3 times a week when there is a crisis or more commonly would occur once every other week. These meetings will last between 60 and 90 minutes and will take place for however long the clients and their social networks would like within the project period. Ideally, each client and his/her Social Network would participate in 4 meetings during the 6 month period. This group would continue to receive care as usual with the addition of these meetings.
2869327|NCT03464162|No Intervention|No Social Network Meetings Group|This arm will not receive the Social Network Meetings intervention. Clients in this arm will participate in the study for 6 months and receive care as usual during this time.
2869328|NCT03464149|Experimental|Study Arm|"One armed study, blood from each patient is analysed by the following assays:~Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)"
2869329|NCT03464136|Experimental|Group 1 (Ustekinumab)|Participants will receive intravenous (IV) infusion of ustekinumab (approximately 6 milligram/kilogram [mg/kg]) and 4 subcutaneous (SC) injections of placebo for adalimumab at Week 0, followed by 2 SC injections of placebo at Week 2. From Week 4 to Week 56, participants will self-administer one SC injection of ustekinumab 90 milligram (mg) every 8 weeks (q8w) starting at Week 8 and placebo adalimumab at the other designated every 2 weeks (q2w) dosing intervals.
2869330|NCT03464136|Active Comparator|Group 2 (Adalimumab)|Participants will receive IV infusion of placebo for ustekinumab and 4 SC injections of adalimumab (each 40 mg, total dose 160 mg) at Week 0, followed by 2 SC injections of adalimumab (each 40 mg, total dose 80 mg) at Week 2. From Week 4 to Week 56, participants will self-administer 1 SC injection of adalimumab 40 mg q2w.
2869331|NCT03464110|No Intervention|Standard of Care|Investigator will compare patients randomized into the intervention group to those who receive standard of care.
2869332|NCT03464110|Experimental|Communication Intervention|The intervention will contain elements of Motivational Interviewing coaching but also will teach providers how to address patient emotion and increase the efficiency of their visits. Clinicians randomized to the intervention will receive a tailored communication coaching intervention that includes didactic elements, audio recording encounters and providing feedback, and role-playing.
2869333|NCT03464097|Experimental|Administration of oral Ozanimod|Subjects will receive a single 0.92 mg capsule [equivalent to ozanimod HCl 1 mg] once daily x 40 weeks
2869334|NCT03464097|Placebo Comparator|Administration of Placebo|Subjects will receive placebo capsule orally once daily x 40 weeks
2869335|NCT03464084|Other|bright light placebo|
2869336|NCT03464084|Other|bright light melatonin|
2869337|NCT03464084|Other|dim light|
2869338|NCT03464071|Experimental|Group HVM|When randomized to the Hyperinflation with mechanical ventilator (HVM) group, there will be an increase in initial positive inspiratory pressure until reaching a peak pressure of 40 cmH2O and PEEP equal to 7 cmH2O
2869372|NCT03463902|Active Comparator|left IPL cathodal|2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
2869777|NCT03461354|Active Comparator|B|Sodium Bicarb Control Arm
2869339|NCT03464071|Experimental|Group HM|When randomized to the Manual hyperinflation (HM) group, the manual resuscitation bag will be connected to the oxygen system at five liters per minute. The participant will be disconnected from the ventilator and then initiate a slow inspiration with inspiratory pause followed by abrupt expiration, totaling twelve (12) cycles / minute.
2869340|NCT03464058|Experimental|Part 1: Regimen A|Participants will be treated with a BOS172767 200 milligram (mg) spray dried dispersion tablet (2 × 100 mg tablets) in the fasted state on Day 1.
2869341|NCT03464058|Experimental|Part 1: Regimen B|Participants will be treated with a BOS172767 200 mg lipid capsule (2 × 100 mg capsules) in the fasted state on Day 1.
2869342|NCT03464058|Experimental|Part 1: Regimen C|Participants will be treated with a BOS172767 200 mg micronized capsule (2 × 100 mg capsules) in the fasted state on Day 1.
2869343|NCT03464058|Experimental|Part 1: Regimen D|Participants will be treated with a BOS172767 200 mg immediate release reference capsule formulation (2 × 100 mg capsules) in the fasted state on Day 1.
2869344|NCT03464058|Experimental|Part 1: Regimen E|Participants will be treated with a selected dose of a prototype formulation of BOS172767 in the fasted state on Day 1.
2869345|NCT03464058|Experimental|Part 1: Regimen F|Participants will be treated with a selected dose of a prototype formulation of BOS172767 in the fed state on Day 1.
2869346|NCT03464058|Experimental|Part 2: Regimen G|Participants will be treated with 400 mg of the selected BOS172767 prototype in the fasted state on Day 1.
2869347|NCT03464058|Experimental|Part 2: Regimen H|Participants will be treated with 600 mg of the selected BOS172767 prototype in the fasted state on Day 1.
2869348|NCT03464058|Experimental|Part 2: Regimen I|Participants will be treated with 800 mg of the selected BOS172767 prototype in the fasted state on Day 1.
2869349|NCT03464058|Experimental|Part 2: Regimen J|Participants will be treated with rabeprazole on Days -3 to -1, and a selected dose of the BOS172767 prototype in the fasted state on Day 1.
2869350|NCT03464058|Experimental|Part 3: Regimen K|Participants will be treated with 400 mg of a BOS172767 prototype or matching placebo once daily (QD) or twice daily (BID) for 14 days (Days 1 to 14).
2869351|NCT03464058|Experimental|Part 3: Regimen L|Participants will be treated with 600 mg of a BOS172767 prototype or matching placebo QD or BID for 14 days (Days 1 to 14).
2869352|NCT03464058|Experimental|Part 3: Regimen M|Participants will be treated with 800 mg of a BOS172767 prototype or matching placebo QD or BID for 14 days (Days 1 to 14).
2869353|NCT03464045||type 2 diabetes patients|
2869354|NCT03464032|Experimental|BCD-135|Dose-escalation Arm (0.4, 1, 3, 10, 20 mg/kg)
2869355|NCT03464019|Experimental|Etripamil|"The dose of etripamil to be evaluated in NODE-301 is 70 mg. Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System; instructions for its use will be given in writing to the patient.~The same formulation will be used for the Test Dose Randomization Visit and for the Treatment Period."
2869356|NCT03464019|Placebo Comparator|Placebo|Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System; instructions for its use will be given in writing to the patient.
2869357|NCT03464006|Experimental|Online Support Module|Patients in the online support module group will receive a tablet which has the developed peripheral arterial disease platform installed on it. The platform helps the patient to monitor factors related to their peripheral arterial disease such as exercise, smoking, and diet and helps them to track and modify these behaviours.
2869358|NCT03464006|Active Comparator|Standard of Care|Patients in this arm will receive the standard of care as provided by the institution.
2869359|NCT03463993|Experimental|Group A|Participants receive a low dose of Tranexamic acid (10mg/kg) administered slowly over 5 minutes intravenously (iv) 10 minutes prior to skin incision in elective caesarean section with prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby.
2869360|NCT03463993|Active Comparator|Group B|Participants receive prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby
2869361|NCT03463980|Experimental|Compassion meditation (CM)|The CM participants will attend six weekly sessions (each 120 minute), and will be video and/or audiotaped. Each weekly CM session will entail a 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants will be encouraged to meditate at least 30 minutes a day and will be asked to track their daily meditation time and bring in their tracking sheet to each session.
2869362|NCT03463980|Active Comparator|Support group (SG)|SG participants will attend six weekly sessions, 90 minutes in length. It will be unstructured. Participants will use this time to talk about current concerns and to receive support and guidance from other group members and the leaders.
2869363|NCT03463967|Active Comparator|Lycopene supplemented|Energy-restricted diet supplemented with lycopene-enriched tomato juice
2869364|NCT03463967|Sham Comparator|Calories Restricted|Energy-restricted diet
2869365|NCT03463954|Experimental|Novilase Laser Ablation and excision|Eligible subject will receive image-guided laser ablation of a targeted malignant breast tumor. At 4-6 weeks following the ablation, she will receive a MRI and excision. Pathology and MRI will determine rate of complete ablation. Subject is expected to proceed with radiation and/or adjuvant therapy per standard of care.
2869366|NCT03463941|Experimental|African American church members|
2869367|NCT03463915|Experimental|Oral gabapentin capsules|Oral gabapentin 300 mg capsules with gradual scheduled titration to the full study dose of 1,200 mg daily (300 mg in morning and afternoon and 600 mg at night for a total of 4 capsules/day) over the course of 14 days. Participants will continue the full dose of study medication during the 6 weekly bladder instillations until the morning after their last bladder instillation (week 8 of study).
2869368|NCT03463915|Placebo Comparator|Oral placebo capsules|Oral placebo capsules (matching gabapentin) with gradual scheduled titration to the full study dose of 4 capsules daily (1 capsule in morning and afternoon and 2 capsules at night) over the course of 14 days. Participants will continue the full dose of study medication during the 6 weekly bladder instillations until the morning after their last bladder instillation (week 8 of study).
2869369|NCT03463902|Experimental|left IFG anodal|2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
2869439|NCT03463395|No Intervention|Standard of Care|Group A will receive standard of care
2869373|NCT03463902|Placebo Comparator|Placebo|anodal electrode over left IFG, cathodal electrode over right IFG, stimulation only during 30 sec ramp at beginning and end of 10 min
2869374|NCT03463889|Experimental|Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)|Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.
2869375|NCT03463876|Experimental|SHR-1210+Apatinib|Patients will received apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks.
2869376|NCT03463850|Experimental|Non-fracture|subjects without a lumbar fracture will have a Dexa scan and Dual Energy CT (DECT) scan for observation/evaluation
2869377|NCT03463850|Experimental|Fracture|subjects with one or more lumbar fractures will have a Dexa scan andDual Energy CT (DECT) scan for observation/evaluation
2869378|NCT03463837|Experimental|Treatment with JUUL 5%, Virginia Tobacco|JUUL 5%,Virginia Tobacco [5 days] in confinement.
2869379|NCT03463837|Experimental|Treatment with JUUL 5%, Cool Mint, ENDS|JUUL 5%, Cool Mint [5 days] in confinement.
2869380|NCT03463837|Experimental|Treatment with JUUL 5%, Mango, ENDS|JUUL 5%, Mango [5 days] in confinement.
2869381|NCT03463837|Experimental|JUUL 5%, Creme Bruele, ENDS|JUUL 5%, Creme Bruele [5 days] in confinement.
2869382|NCT03463837|Active Comparator|Combustible cigarette|Exclusive use of combustible cigarette [5 days] in confinement.
2869383|NCT03463837|Sham Comparator|Smoking cessation (no smoking)|Smoking cessation (no smoking).
2869384|NCT03463824|Experimental|Experimental Group 1|Participants will produce progressively larger lumbar flexion excursions at each game level and across treatment sessions.
2869385|NCT03463824|Experimental|Experimental Group 2|Participants will produce progressively larger lumbar flexion excursions at each game level and across treatment sessions.
2869386|NCT03463798||Patients|Patients with a suspicion of diaphragmatic dysfunction
2869387|NCT03463798||Healthy volunteers|Subjects without any medical condition
2869388|NCT03463785||Chinese|Chinese mild or moderate OSA patients
2869389|NCT03463785||Dutch|Dutch mild or moderate OSA patients
2869390|NCT03463772|Active Comparator|standard IVF|On the Day2/3 of the menstrual cycle, qualified participants will be randomized into either of two groups. Participants in group A will receive standard IVF procedure. Other standard assisted reproductive treatments are similar and parallel between two groups.
2869391|NCT03463772|Active Comparator|In vitro maturation|On the Day2/3 of the menstrual cycle, qualified participants will be randomized into either of two groups. Participants in group B will receive IVM procedure.Other standard assisted reproductive treatments are similar and parallel between two groups.
2869392|NCT03463759||Recurrent Low Back Pain Patients|Participants experiencing a current episode of their recurrent non-specific low back pain at the time of recruitment.
2869393|NCT03463759||Healthy Volunteers|Participants matched in age and gender to one of the recurrent low back pain patients, with no significant past low back pain, chronic pain or other relevant medical disorders.
2869394|NCT03463746|Experimental|Experimental group (EG)|Subacute stroke patients will get standard individual physical therapy 2x/week, 45min and electromechanical-assisted gait training on LYRA® gait trainer 3x/week, 45min.
2869395|NCT03463746|Active Comparator|Comparator group (CG)|The CG will get standard individual physical therapy 5x/week, 45min without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
2869396|NCT03463733|Experimental|Daily hydroxyurea and temozolomide|"Hydroxyurea and temozolomide will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. Oral hydroxyurea (dose specified by the Dose Cohort below) and oral temozolomide (50 mg/m2/day) will be administered daily in 28-day cycles for 12 cycles or until unacceptable toxicity, intolerance, progressive disease, or withdrawal of consent. Patients will be treated in dose cohorts of 3 with each cohort receiving a specific daily dose assignment of hydroxyurea.~All patients in the study will receive temozolomide at 50 mg/m2/day (dose-intense schedule). The starting dose level for hydroxyurea will be 200 mg daily (QD) up to a maximum of 2000mg hydroxyurea a day."
2869397|NCT03463720||Extremity wound|Patients with extremity wounds. Infected and not infected patients will be compared.
2869398|NCT03463707|Experimental|Treatment with BP101|
2869399|NCT03463707|Placebo Comparator|Treatment with placebo|
2869400|NCT03463694|Experimental|Hypertonic Saline ~2.6% NaCl|3 drops each nostril of Hypertonic Saline (HS) at least 4 times a day until asymptomatic or maximum of 28 days
2869401|NCT03463694|No Intervention|Standard Care|Control arm of standard symptomatic care only
2869402|NCT03463681|Experimental|Cabozantinib|all subjects will recieve open label Cabozantinib 60 mg orally once daily
2869403|NCT03463668||symptomatic non-covered duodenal prosthesis|Any symptomatic duodenal stenosis with symptomatic duodenal duodenal prosthesis between 2010 and 2017.
2869404|NCT03463655||solid cancer in a palliative situation with ascites|Patient over the age of 18, followed for a solid cancer in a palliative metastatic situation, having had a puncture of ascites.
2869405|NCT03463642|Experimental|Vitamin D3 pill|100 pills = 100,000IU + Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
2869406|NCT03463642|Placebo Comparator|Pill placebo|100 pills = Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
2869407|NCT03463642|Experimental|Vitamin D3 oral liquid|100 drops = 100,000IU in orange syrup
2869408|NCT03463642|Placebo Comparator|Oral liquid placebo|100 drops orange syrup
2869409|NCT03463642|Experimental|Skin oil + Vitamin D3 + penetrator|100,000IU + mineral oil+ Tangerine essential oil (10ml)
2869410|NCT03463642|Experimental|Skin oil + Vitamin D3|100,000IU + mineral oil
2869411|NCT03463642|Placebo Comparator|Skin oil placebo|Skin application: 100ml of mineral oil coloured with food colourant to match active oil sample
2869440|NCT03463395|Experimental|Reza band use|Group B will receive standard care plus the Reza band (worn as recommended by the manufacturer)
2869441|NCT03463382|Active Comparator|ESP Group|"Erector Spinae Plane Block Group~Block Drug: 0,25% bupivacaine 0,5ml/kg (max.20ml) were used for blocks"
2869442|NCT03463382|Active Comparator|QLB Group|"Quadratus Lumborum Block Group~Block Drug: 0,25% bupivacaine 0,5ml/kg (max.20ml) were used for blocks"
2869782|NCT03461315|Experimental|Study Model|Study Model:Team Dedicated Exclusively to the Home Patient
2869412|NCT03463629|Experimental|Specialized multidisciplinary diabetes team (SMDT) approach|"The implementation of the pilot study will consist of a specialized multidisciplinary diabetes team care (SMDT) that includes endocrinologists, a nurse practitioner, dieticians, pharmacists and a licensed professional counselors (LPCs) to collaborate and coordinate care. Subjects in the pilot study will follow a multidisciplinary team approach process with the following team members: pharmacist, LPC, and dietician.~There will be 3 individualized visits: 1 visit with the counselor (LPC), 1 visit with the Pharmacist, and 1 visit with the Dietician.~In addition, a follow up phone call post visit, that can range from 5 to 30 minutes, will be scheduled from each of the team members during the study. Also, throughout the pilot study participant's blood glucose readings will be monitored weekly via a transmittable wireless patient transmission monitor."
2869413|NCT03463629|Active Comparator|Traditional model of care|Receive the traditional model of care, but will not receive diabetes education by pharmacists or counseling services. Data for this arm will be collected through retrospective chart review.
2869414|NCT03463616||CT abdomen|Patients who had a CT abdomen as primary work-up before treatment planning for rectal cancer.
2869415|NCT03463616||MRI Abdomen|Patients who had a MRI abdomen as primary work-up before treatment planning for rectal cancer.
2869416|NCT03463603||Asian racial identity|"Those who self-report Asian or related terms as their racial identity."
2869417|NCT03463603||South Asian racial identity|"Those who self-report South Asian or related terms as their racial identity."
2869418|NCT03463603||Other racial identity|"All others, who self-report neither Asian, South Asian or their related terms as their racial identity."
2869419|NCT03463590|Experimental|DBS|All subjects will undergo bilateral surgical implantation of DBS system to habenula. The DBS system will be active at one week after surgery.
2869420|NCT03463577||Exposed Group|Pregnant women vaccinated with Boostrix on or after the 1st day of the 27th week of pregnancy; who were not vaccinated with any other Tdap vaccine at any other time during the pregnancy are in scope of this study.
2869421|NCT03463577||Unexposed Group|Women matched to the exposed cohort and pregnant sometime during the approximate estimated period between 1/1/2012-12/31/2013 who did not receive any Tdap vaccine during the pregnancy are in scope of this study.
2869422|NCT03463564|Active Comparator|Insulin pump|Insulin Pump with rapid acting insulin analog lispro
2869423|NCT03463564|Active Comparator|Insulin injections|Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection at bed-time of basal insulin glargine or degludec
2869424|NCT03463551|Experimental|ABL-101 IV as per dosing cohort + Supplementary O2 for 24h|"Patients will receive either ABL-101 or placebo (equivalent volume of 0.9% Sodium Chloride) within ascending dose groups of 6 patients each (4 to ABL-101, 2 to placebo).The starting cohort will be Cohort 1: 0.5mL/kg.~In the event that the start dose of Cohort 1 is considered intolerable in the opinion of the iDMC based on incidence of patients experiencing dose-limiting toxicities (DLTs), the iDMC will have the option of recommending a lower dose cohort (Cohort -1) of 0.25ml/kg (to a maximum of 25ml) be undertaken.~Cohort 1: 0.5 mL/kg to a maximum of 50ml; Cohort 2: 1.5mL/kg to a maximum of 150ml; Cohort 3: 3.0mL/kg to a maximum of 300ml.~All patients will receive Oxygen 60% by face mask (8l/min) for approximately 24h after ABL-101 or placebo administration."
2869425|NCT03463551|Placebo Comparator|IV 0.9% NaCl as per dosing cohort + supplementary O2 for 24h|"Cohort 1: Volume matched to the calculation used for ABL-101 using patient weight; Cohort 2: Volume matched to the calculation used for ABL-101 using patient weight; Cohort 3: Volume matched to the calculation used for ABL-101 using patient weight.~All patients will receive Oxygen 60% by face mask (8l/min) for approximately 24h after ABL-101 or placebo administration."
2869426|NCT03463538|Active Comparator|Arthroscopic capsular release|Surgical release performed under general anesthetic
2869427|NCT03463538|Active Comparator|Hydro-dilatation|injection of water under local anesthetic in to shoulder joint
2869428|NCT03463525|Experimental|[11C]osimertinib + oral osimertinib|IV microdose administrations of [11C]osimertinib co-administered with 80 mg daily oral osimertinib.
2869429|NCT03463512|Experimental|Racecadotril plus standard treatment oral rehydration solution|
2869430|NCT03463512|Active Comparator|ORS (standard treatment)|
2869431|NCT03463499|Experimental|Hyaluronic Acid and Chondroitin Sulfate|Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.
2869432|NCT03463473|Experimental|MSB2311 Injection|MSB2311 will be administered as an IV infusion once every 3 weeks (Q3W). The planned doses starts at 0.3 mg/kg and may be escalted to 20 mg/kg, but dose levels or the dosing interval may be adjusted during the study based on emerging data.
2869433|NCT03463460|Experimental|Treatment (pembrolizumab, sunitinib malate)|Participants receive pembrolizumab IV over 30 minutes on day 1 and sunitinib malate PO daily on days 1-14. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
2869434|NCT03463447|Experimental|Hand strength|We selected volunteers without motor abnormalities with aged 6 to 17 years divided in groups (n = 30) according to an age group. The tests were performed in a single session lasting 20 minutes, when volunteers used a hydraulic dynamometer and an electronic dynamometer, in order to quantify the hand strength.
2869435|NCT03463434|Experimental|Air Fluidized Therapy|Patients will be placed on the Envella AFT bed
2869436|NCT03463434|Active Comparator|Continuous Low Pressure-LAL|Patients will receive a Continuous low pressure mattress with low air loss
2869437|NCT03463408|Experimental|Immunotherapy arm|"Cohort A will comprise adult soft tissue sarcoma patents who consent to and receive ipilimumab + nivolumab concurrently with standard of care radiation. Ipilimumab will be given at a dose of 1 mg/kg every 6 weeks (total two doses) and nivolumab given as a flat dose of 240 mg every 2 weeks (total four doses).~Standard surgical resection will be done 2 to 4 weeks after completion of radiotherapy. Accrual is expected to occur over 2 years. Follow up data will be collected for up to 3 years post-treatment."
2869438|NCT03463408|No Intervention|no immunotherapy arm|"Cohort B will comprise patients eligible for the trial who do not wish to receive immunotherapy but consent to the same blood draws, surveys, and specimen analysis as Cohort A. Cohort B will serve as a non-randomized but pragmatic and clinically relevant control group.~Standard surgical resection will be done 2 to 4 weeks after completion of radiotherapy. Accrual is expected to occur over 2 years. Follow up data will be collected for up to 3 years post-treatment."
2869443|NCT03463369|Experimental|Placebo + Nucleos(t)ide Analogs (NA)|Participants will receive placebo intramuscular (IM) injection on Day 1, Week 4, and Week 12, along with standard of care NA treatment.
2869444|NCT03463369|Experimental|JNJ-64300535 + NA|Participants will receive JNJ-64300535 IM injection on Day 1, Week 4, and Week 12, along with standard of care NA treatment.
2869445|NCT03463356|Experimental|Shame Intervention|Participants will complete a two shame intervention sessions approximately one week apart.
2869446|NCT03463343|Experimental|Manual manipulation|In the Manual manipulation group, the thrust was applied in the right side of C3/C4 with neutral flexion/extension, ipsilateral side bending and contralateral rotation. Then, a low amplitude, high velocity thrust in rotation was delivered.
2869447|NCT03463343|Active Comparator|Mechanical manipulation|In the Mechanical manipulation group, the Activator instrument was applied on the right transverse apophyses of C3.
2869448|NCT03463343|Placebo Comparator|Placebo|The subjects were positioned in the same pre-manipulative position as the manual manipulation group, but the thrust didn't occur. Instead, the position was hold for 3 seconds and then the subject's head returned passively to neutral position.
2869449|NCT03463343|No Intervention|Control|The subjects stayed in supine position and no intervention occurred.
2869450|NCT03463330|Experimental|Intervention Group|Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice the Qigong exercise during the study.
2869451|NCT03463330|Sham Comparator|Control Group|Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice a mild body exercise during the study.
2869452|NCT03463317|Experimental|LAA closure group|Left atrial appendage closure by use of CE-mark approved LAA closure devices followed by post procedure treatment (antiplatelet therapy e.g. acetylsalicylic acid, clopidogrel)
2869453|NCT03463317|Active Comparator|Best medical care group|No left atrial appendage closure. Treatment with best medical care (NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) or VKA (phenprocoumon, warfarin)
2869454|NCT03463291||Study group|All patients with bony lesions
2869455|NCT03463278||0-4 blastocysts|group A: cumulative pregnancy rate of 0-4 blastocysts vitrified
2869456|NCT03463278||5-7 blastocysts|group B: cumulative pregnancy rate of 5-7 blastocysts vitrified
2869457|NCT03463278||>7 blastocysts|group C: cumulative pregnancy rate of >7 blastocysts vitrified
2869458|NCT03463265|Experimental|ABI-009|
2869459|NCT03463265|Experimental|ABI-009 + bevacizumab|
2869460|NCT03463265|Experimental|ABI-009 + temozolamide|
2869461|NCT03463265|Experimental|ABI-009 + lomustine|
2869462|NCT03463265|Experimental|ABI-009 + temozolamide + radiotherapy|
2869463|NCT03463252|Active Comparator|MPA for EC without progesterone contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
2869464|NCT03463252|Experimental|MPA+Mirena® for EC without contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
2869465|NCT03463252|Experimental|Mirena® for EC without contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
2869466|NCT03463252|Active Comparator|GnRH agonist+Mirena® for EC with contraindication|The enrolled patient (endometrial cancer with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
2869467|NCT03463252|Experimental|Mirena® for EC with contraindication|The enrolled patient (endometrial cancer with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
2869494|NCT03463122|Other|Waiting first|This group completed four weeks of conventional therapy followed by 20 sessions of a field of regard-focused visual exploration therapy program using an head mount display (five daily sessions per week over a period of four weeks) in addition to conventional therapy.
2869783|NCT03461302|Experimental|Topical Coal Tar treatment|
2869468|NCT03463252|Active Comparator|Mirena® for EAH without progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia without contraindication of oral high dose progesterone) is allocated to either MPA or LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
2869469|NCT03463252|Experimental|MPA for EAH without progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia without contraindication of oral high dose progesterone) is allocated to either MPA or LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
2869470|NCT03463252|Active Comparator|Mirena® for EAH with progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
2869471|NCT03463252|Experimental|GnRH-a+Mirena® for EAH with progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
2869472|NCT03463239|Experimental|Autologous tissue engineered corpora|All subjects enrolled will undergo a corpora cavernosum biopsy. Endothelial and smooth muscle cells will be isolated and expanded, then seeded onto a scaffold that will later be implanted into the subject.
2869473|NCT03463226||Low testosterone|"Patients with HF and testosterone deficiency.~Cardiopulmonary exercise test~Muscle Sympathetic Nerve Activity~Dual-energy X-ray absorptiometry~Venous occlusion plethysmography~Blood sample collection~Dynamometers for Handgrip Strength"
2869474|NCT03463226||Normal testosterone|"Patients with HF and normal plasma levels of testosterone.~Cardiopulmonary exercise test~Muscle Sympathetic Nerve Activity~Dual-energy X-ray absorptiometry~Venous occlusion plethysmography~Blood sample collection~Dynamometers for Handgrip Strength"
2869475|NCT03463213|Experimental|SHE Tribe|SHE Tribe is a social network-based peer-facilitated intervention to promote adoption of health behaviors
2869476|NCT03463200|No Intervention|Control group|It will not apply any tape.
2869477|NCT03463200|Experimental|Experimental group 1|Apply the KT with tension in the erector spine muscles.
2869478|NCT03463200|Experimental|Experimental group 2|Apply the KT without tension in the erector spine muscles.
2869479|NCT03463200|Experimental|Experimental group 3|Apply Micropore tape in the erector spine muscles.
2869480|NCT03463187|Experimental|80mg SHR-1314|SHR-1314 80mg, subcutaneously
2869481|NCT03463187|Experimental|160mg SHR-1314|SHR-1314 160mg, subcutaneously
2869482|NCT03463187|Experimental|240mg SHR-1314|SHR-1314 240mg, subcutaneously
2869483|NCT03463187|Experimental|20mg SHR-1314|SHR-1314 20mg, subcutaneously
2869484|NCT03463187|Experimental|40mg SHR-1314|SHR-1314 40mg, subcutaneously
2869485|NCT03463174|Experimental|Single-implant mandibular overdenture|Participants allocated to this group will have a dental implant placed in the mandibular midline followed by the immediately insertion of a ball attachment and the incorporation of a retention matrix to the mandibular denture.
2869486|NCT03463174|Active Comparator|Mandibular complete denture|Participants allocated to this group will not receive any additional treatment besides the new set of conventional complete dentures. When needed, retreatment or any adjustment/repair in the dentures will be performed accordingly. Participants will receive regular maintenance for their dentures, including adjustments for the elimination of sore areas, denture relining and repair of fractures, when needed, until the end of the follow-up period.
2869487|NCT03463161|Experimental|Acquired Resistance Group|"Participants that have benefited from prior treatment with immunotherapy. Defined as response to prior treatment and/or stable disease lasting at least 5 months and disease worsening seen on most recent imaging.~Participants will receive Pembrolizumab and Epacadostat."
2869488|NCT03463161|Experimental|Suboptimal Benefit Group|"Participants that have not benefited from prior treatment with immunotherapy. Defined as stable disease lasting at least 5 months or suboptimal response (11-49% shrinkage of tumors). Disease continues to be stable on most recent imaging.~Participants will receive Pembrolizumab and Epacadostat."
2869489|NCT03463148||1|Men/Women who meet the inclusion/exclusion criteria of this protocol.
2869490|NCT03463135|Experimental|SAR439794 [PE SLIT + GLA)]|GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks
2869491|NCT03463135|Experimental|Placebo for GLA + SLIT PE|Placebo for GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks
2869492|NCT03463135|Placebo Comparator|Placebo for GLA + Placebo for SLIT PE|Placebo for GLA repeated doses then Placebo for SLIT PE escalating doses once daily for 12 weeks
2869493|NCT03463122|Other|Training first|This group completed 20 sessions of a field of regard-focused visual exploration therapy program using an head mount display (five daily sessions per week over a period of four weeks) in addition to conventional therapy followed by four weeks of conventional therapy
2869572|NCT03462589|Experimental|SY-008 dose 4|A single dose of SY-008 (2~30mg) taken orally.
2869495|NCT03463109|Other|Healthy Volunteers|Electrocutaneous stimulation. A standardized grid will be drawn over the participants' lumbar region. Circular electrodes, connected to a constant current stimulator, will be applied at points on the grid selected at random. Participants will be blinded to the electrode locations. Sets of painful electrocutaneous stimuli will be randomly delivered for each electrode. Participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet the location on which they will perceive each painful stimulation.
2869496|NCT03463109|Other|Chronic Low Back Pain|"Assessment + Electrocutaneous stimulation. Patients with chronic low back pain will be asked to provide information about their lifestyle, level of disability, current pain, general pain and to undergo an assessment of kinesiophobia and health status.~After the assessment, a standardized grid will be drawn over the patients' lumbar region. Circular electrodes, connected to a constant current stimulator, will be applied at points on the grid. Patients will be blinded to the electrode locations. Sets of painful electrocutaneous stimuli will be randomly delivered for each electrode. Patients will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation."
2869497|NCT03463096|Experimental|Centrifuge study|High G acceleration on a long-arm human centrifuge
2869498|NCT03463083|Active Comparator|Bupivacaine dexmedetomidine group|Group 1 (bupivacaine + dexmedetomidine (BD) group); will Receive an epidural study solution of 18 ml of 0.25% of bupivacaine hydrochloride plus 1 ml of dexmedetomidine (1 mcg/kg) plus 1 ml normal saline keeping the total volume of 20 ml in a syringe pump .
2869499|NCT03463083|Active Comparator|Bupivacaine fentanyl group|Group 2 (bupivacaine + fentanyl (BF) group) ; will Receive an epidural study solution of 18 ml of 0.25% bupivacaine plus 2 ml fentanyl (1 mcg/kg) keeping the total volume of 20 ml in a syringe pump .
2869500|NCT03463070|Active Comparator|preoperative misoprostol group|70 women who received 600 mg misoprostol rectally preoperatively before cesarean section
2869501|NCT03463070|Active Comparator|postoperative misoprostol group|70 women who received 600 mg misoprostol postoperatively at operating theatre after cesarean section
2869502|NCT03463057|Other|Atezolizumab|18 cycles atezolizumab followed by 12 months of observation
2869503|NCT03463044|Placebo Comparator|Placebo|
2869504|NCT03463044|Experimental|MOTREM 1|
2869505|NCT03463044|Experimental|MOTREM 2|
2869506|NCT03463044|Experimental|MOTREM 3|
2869507|NCT03463044|Experimental|MOTREM 4|
2869508|NCT03463044|Experimental|MOTREM 5|
2869509|NCT03463044|Experimental|MOTREM 6|
2869510|NCT03463044|Experimental|MOTREM 7|
2869511|NCT03463044|Experimental|MOTREM 8|
2869512|NCT03463031|Experimental|GSP 301 NS|Fixed dose combination of olopatadine hydrochloride 665 μg and mometasone furoate 25 μg NS
2869513|NCT03463031|Placebo Comparator|GSP 301 Placebo NS|GSP 301 Placebo nasal spray
2869514|NCT03463018|Experimental|Echinacea angustifolia|20 mg tablet of Echinacea angustifolia root extract standardized for a specific alkamide profile, two tablets twice daily (total daily dose of 80 mg) for two weeks
2869515|NCT03463018|Placebo Comparator|Placebo|Identical excipients as in the experimental arm, without the active ingredient
2869516|NCT03463005|Experimental|Royal jelly|The study subjects included healthy women who had husbands with male-factor infertility problems.
2869517|NCT03463005|Active Comparator|IUI group|The study subjects included in IUI group were healthy women who had husbands with male-factor infertility problems.
2869518|NCT03462992||FIT-positive individuals|Patients being positive to an FIT test performed in the context of the Flemish (Northern Belgium) colorectal cancer screening campaign. These patients are male and female between 56 and 74 years old.
2869519|NCT03462979|Experimental|Open Results with home testing|Participants in the open results arm will be provided with Gluten Detective home testing kits (immunochromatographic lateral flow tests) at week 5 of the study for immediate qualitative (yes/no) feedback about the presence of biomarkers of gluten in their stool and/or urine. During the period from week 5 to week 30, participants will be contacted a total of 6 times at random intervals to collect and test urine and stool samples and complete a questionnaire. During this time participants will also keep a diary of suspected gluten exposures. All samples collected will be returned during the week 30 study visit.
2869520|NCT03462979|No Intervention|Blinded (sample collection only)|Participants in the blinded arms will not be given a test kit but will be given sample collection materials. During the period from week 5 to week 30 of the study, participants will be contacted a total of 6 times at random intervals, instructed to collect stool and urine samples, and complete a questionnaire. Participants will also keep a diary of suspected gluten exposures. All samples collected will be returned during the week 30 study visit. After completion of sample collection, all participants will be unblinded and notified of the results once the samples have been processed.
2869521|NCT03462966|Experimental|Therapeutic|40 subjects with diarrhea-predominant IBS (IBS-D) or mixed IBS (IBS-M) will be enrolled in the study. At the first clinic visit, subjects will undergo rectal sensitivity testing, as well as lactulose breath testing. Subjects will be asked to record their symptoms and bowel habits in a diary over the next 7 days. During the second clinic visit, subjects will receive a 14-day course of rifaximin (550 mg PO TID). During these 14 days, subjects will record their symptoms and bowel habits. Subjects will return to the clinic after completion of the medication and will undergo repeat evaluation via rectal sensitivity testing to assess for change in rectal sensitivity.
2869522|NCT03462953|Placebo Comparator|individuals with healthy gingiva|Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls.
2869523|NCT03462953|Placebo Comparator|periodontally diseased individuals|Gingival tissue samples will be harvested during periodontal surgery and extraction of the periodontally hopeless tooth for the periodontitis patients.
2869524|NCT03462940|Experimental|TUDCA Group|All subjects will receive 500 mg/day in a one week run-in period and then 1750 mg/day in one week treatment period of of the nutritional supplement Tauroursodeoxycholic acid (TUDCA).
2869525|NCT03462927|Experimental|MC2-01 Cream|MC2-01 cream (CAL and BDP, w/w 0.005%/ 0.064%).
2869526|NCT03462927|Active Comparator|CAL/BDP combination|CAL/BDP ointment (w/w 0.005%/0.064%).
2869527|NCT03462901|Experimental|Elastic rod fixation|Percutaneous intramedullary fixation of displaced midshaft clavicular fractures
2869573|NCT03462589|Experimental|SY-008 dose 5|A single dose of SY-008 (2~30mg) taken orally.
2869528|NCT03462875||Crohn's Disease Patients|Subjects having confirmed diagnosis of Crohn's disease which is defined by endoscopy, radiology and histology; and having documented ileocaecal or right-sided colonic disease
2869529|NCT03462875||Non-household Controls|Non-affected subjects who will under colonoscopy for polyp or colorectal cancer screening, or investigations of gastrointestinal symptoms other than Inflammatory Bowel Disease
2869530|NCT03462875||First Degree Relatives|Non-affected first degree relatives of cases
2869531|NCT03462875||Household/co-habitant Controls|Non-affected subjects living in the same household with the cases in the recent 6 months
2869532|NCT03462862|Experimental|Group 1|patients will receive partial denture constructed from PEEK material
2869533|NCT03462862|Active Comparator|Group 2|patients will receive partial denture constructed from breflex material
2869534|NCT03462849|Other|Patients with EFL at PEP 5|Patients with EFL at PEP 5 at the time of inclusion either in supine or semi-recumbent position
2869535|NCT03462849|Other|Patients with no EFL at PEP 5|Patients with no EFL at PEP 5 at the time of inclusion in both supine and semi-recumbent positions
2869536|NCT03462836|Experimental|IV ketamine/lidocaine/IV PCA (MA) group|In addition to basic anesthetic methods, multimodal analgesia with IV ketamine, lidocaine and IV PCA apply
2869537|NCT03462836|Active Comparator|IV PCA only (CA) group|In addition to basic anesthetic methods, only IC PCA apply for pain control
2869538|NCT03462823|Active Comparator|Control treatment|ACL-reconstruction using hamstring autograft with hybrid fixation in accordance with in-house standard of care.
2869539|NCT03462823|Experimental|Experimental treatment|ACL-reconstruction using hamstring autograft with hybrid fixation combined with the osteoconductive device under study.
2869540|NCT03462784||Cases|
2869541|NCT03462771|Experimental|Group exercise fish oil|Using the Randomizer Research program, 15 elderly women will participate in a resistance exercise protocol and receive omega-3 fatty acid supplements to be ingested 2g in the main meals, totaling 4g daily.
2869542|NCT03462771|Placebo Comparator|Group exercise placebo|Using the Randomizer Research program, 15 elderly women will participate in a resistance exercise protocol and receive sunflower oil to be ingested 2g in the main meals, totaling 4g daily.
2869543|NCT03462758|Other|Control Group|IUD placed 6-8 weeks postpartum (standard of care, interval placement)
2869544|NCT03462758|Experimental|Intervention Group|IUD placed 2-4 weeks postpartum (early postpartum placement, EPP)
2869545|NCT03462745|Experimental|Cannulation with AccuVein AV 300|The AccuVein AV300 device helps in venepuncture and intravenous (IV) cannulation. It uses infrared light that can be absorbed by the blood hemoglobin so that veins location is clearly viewed on the skin's surface.
2869546|NCT03462745|No Intervention|Standard insertion|Intravenous cannulation is an invasive procedure of inserting an intravenous catheter blindly through the skin, into the lumen of a peripheral vein.
2869547|NCT03462732|Active Comparator|Group I|Endotracheal tube plus Nelaton catheter
2869548|NCT03462732|Active Comparator|Group II|Endotracheal tube
2869549|NCT03462719|Experimental|Treatment Arm A: Ibrutinib and Venetoclax (I+VEN)|Participants will initially receive ibrutinib (420 mg [milligrams]/day) for 3 cycles. Venetoclax dose ramp up (from 20 mg to 400 mg over 5 weeks) will begin at Cycle 4 and the combination of ibrutinib and venetoclax will be given for 12 cycles. Following the completion of I+VEN treatment, ibrutinib will be given for another 3 cycles for a total of up to 18 cycles of treatment (each cycle is equivalent to 28 days).
2869550|NCT03462719|Active Comparator|Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb)|Participants will receive chlorambucil and obinutuzumab (G-Clb) for 6 cycles. Participants will receive obinutuzumab, 1000 mg intravenously (IV) on Days 1, 8 and 15 of Cycle 1, and on Day 1 of Cycles 2 to 6 and chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight, on Days 1 and 15 of Cycles 1 to 6.
2869551|NCT03462706|Experimental|Cold Snare|Polyps sized 6mm to 15mm found during colonoscopy will be removed using cold snare techniques.
2869552|NCT03462706|Experimental|Hot Snare|Polyps sized 6mm to 15mm found during colonoscopy will be removed using hot snare techniques.
2869553|NCT03462706|Experimental|Cold EMR|Polyps sized 6mm to 15mm found during colonoscopy will be removed using cold EMR techniques.
2869554|NCT03462706|Experimental|Hot EMR|Polyps sized 6mm to 15mm found during colonoscopy will be removed using hot EMR techniques.
2869555|NCT03462693||Group 1|Dry needling plus standard physiotherapy treatment
2869556|NCT03462693||Group 2|Standard physiotherapy treatment
2869557|NCT03462680|Active Comparator|niacin|Niacin 250 mg is compared to placebo tablet.
2869558|NCT03462680|Placebo Comparator|placebo|placebo
2869559|NCT03462667|Experimental|Stoma Boot Camp|Participants will attend the Stoma Boot Camp session prior to surgery.
2869560|NCT03462667|Active Comparator|Regular Care|Participants will receive normal standard of care prior to surgery.
2869561|NCT03462654|Active Comparator|individual LiFE (iLiFE)|In iLiFE, LiFE activities to increase strength, improve balance, and promote physical activity as well as habitualization strategies are introduced and taught in 7 highly individualized, one-to-one home visits.
2869562|NCT03462654|Experimental|group LiFE (gLiFE)|In gLiFE, the same LiFE activities as performed in iLiFE are introduced and taught in 7 group sessions with 8 to 12 participants. Implementation and habitualization strategies will be addressed within the group setting, making use of group dynamics and processes.
2869563|NCT03462641|Active Comparator|Flumazenil|Flumazenil 1mg in 10cc normal saline will be given intravenously (iv) over 5-10 minutes and a detailed clinical assessment will follow for the next 90 minutes.
2869564|NCT03462641|Placebo Comparator|Placebo|10 cc of normal saline placebo will be given intravenously (iv) over 5-10 minutes and a detailed clinical assessment will follow for the next 90 minutes.
2869565|NCT03462628|Experimental|Study Group|PVI with additional low-voltage substrate modification
2869566|NCT03462628|Active Comparator|Control Group|PVI
2869567|NCT03462602|Experimental|NGT group|NGT group
2869568|NCT03462602|Experimental|non-NGT group|non-NGT group
2869569|NCT03462589|Experimental|SY-008 dose 1|A single dose of SY-008 (2~30mg) taken orally.
2869570|NCT03462589|Experimental|SY-008 dose 2|A single dose of SY-008 (2~30mg) taken orally.
2869571|NCT03462589|Experimental|SY-008 dose 3|A single dose of SY-008 (2~30mg) taken orally.
2869575|NCT03462563|Experimental|INTERCEED™|patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen).
2869576|NCT03462563|Placebo Comparator|standard of care treatment|During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
2869577|NCT03462550|Active Comparator|LMA Supreme|
2869578|NCT03462550|Experimental|LMA Protector|
2869579|NCT03462537|Experimental|Experimental group 1|This group performed aerobic exercise just after low level laser therapy in the abdominal region with eight electrodes distributed in line.
2869580|NCT03462537|Experimental|Experimental group 2|This group performed aerobic exercise just after low level laser therapy in the abdominal region with eight electrodes distributed in line, but low level laser therapy device was switched off.
2869581|NCT03462537|Placebo Comparator|Placebo group|Low level laser therapy without power. This group performed the low level laser therapy protocol, but low level laser therapy device was switched off.
2869582|NCT03462524||Neoadjuvant chemotherapy|
2869583|NCT03462524||Neoadjuvant chemoradiation|
2869584|NCT03462511|No Intervention|Control Group|Dyads randomized to the control group will receive standard care and education handouts.
2869585|NCT03462511|Experimental|Intervention Group|In addition to standard care and education handouts, dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
2869586|NCT03462498|Active Comparator|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists and clopidogrel monotherapy for 59 months
2869587|NCT03462498|Active Comparator|12-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists; 11-month DAPT composed of aspirin and clopidogrel and aspirin monotherapy for 48 months
2869588|NCT03462485|Experimental|Golf intervention|The golf intervention will be an eight-week golf programme in which participants will be taught to play golf in two 150-min sessions each week. Each session will begin with 30 minutes of socialising, then 90 minutes playing golf, followed by another 30 minutes socialising. The golf sessions will progress from putting, to chipping, and then a full swing, with sessions taking place on a nine-hole golf course.
2869589|NCT03462485|No Intervention|Control|Control participants will continue their normal activities.
2869590|NCT03462472|Experimental|15 minute lower leg heating|
2869591|NCT03462472|Experimental|45 minute lower leg heating|
2869592|NCT03462472|No Intervention|Control|
2869593|NCT03462472|Experimental|15 minute lower leg TENS|
2869594|NCT03462472|Experimental|45 minute lower leg TENS|
2869595|NCT03462459|Experimental|Vancomycin|125 mg, oral capsule by mouth, once daily, for the duration of standard-of-care antibiotic therapy plus 5 days
2869596|NCT03462459|Placebo Comparator|Placebo|125 mg placebo capsule by mouth, once daily, for the duration of standard-of-care antibiotic therapy plus 5 days
2869597|NCT03462446||Treatment group with Rivaroxaban|Patients treated with Rivaroxaban
2869598|NCT03462446||Control group with VKAs|Patients treated with VKAs. This control group will be subsequently divided based on the TTR value in the last 6 months (below 65% and above 65%).
2869599|NCT03462420|Experimental|PT+ walking|Participants in this group will be referred to a physical therapy facility according to their preferences and the intervention will be chosen by the treating physical therapist. In addition, participants will be asked to perform free walking at their own pace for 30-45 min, 5 days per week for 6 consecutive weeks and to record their walking date/time on a diary form provided by the research team before commencing the study. Participants in PT+ group will also be provided with accelerometer to accurately estimate their physical activity level.
2869600|NCT03462420|Active Comparator|Regular PT|Participants in this group will be referred to a physical therapy facility according to their preferences and the intervention will be chosen by the treating physical therapist. Participants in this group will not be notified about the walking program.
2869601|NCT03462407|Experimental|DAID|Trained assistants will help participants train their dog to engage in imitation based dog training, using positive reinforcement training (operant conditioning) focused on physical activities.
2869602|NCT03462407|Active Comparator|Dog walking|Trained assistants will help children train their dog to walk on a loose leash (eliminate pulling behavior) during this period using positive training techniques. The focus of this group will be on appropriate walking behavior to facilitate enjoyable independent dog-walking at home.
2869603|NCT03462407|No Intervention|Control|This group will all own family dogs but will not participate in either intervention during year 1. All participants assigned to the waitlist will be offered the DAID intervention the subsequent summer.
2869604|NCT03462394|Active Comparator|Current Script Version|This arm will receive the version of the call script currently used as part of regular care at NYU Langone Health.
2869605|NCT03462394|Active Comparator|Script Iterations|This arm will receive an iterated version of the script that might contain changes in wording or structure that are different from the current version of the script.
2869606|NCT03462381|Experimental|Protein|Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
2869607|NCT03462381|Placebo Comparator|Carbohydrate|Three endurance training sessions weekly with carbohydrate supplementation post-exercise and before sleep.
2869608|NCT03462368|Active Comparator|Control|Root surface treatment by scaling and root planing
2869609|NCT03462368|Experimental|antimicrobial photodynamic therapy|Root surface treatment by antimicrobial photodynamic therapy
2869610|NCT03462368|Active Comparator|Photobiomodulation|Treatment of the whole surgical site with laser
2869611|NCT03462342|Experimental|1- Olaparib Pill + AZD6738.|"All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
2869784|NCT03461302|Active Comparator|Topical Corticosteroids treatment|
2869614|NCT03462316|Experimental|NY-ESO-1 TCR Specific T cell Therapy|"NY-ESO-1 TCR specific T cells are prepared by lentiviral infection. The dose-limiting toxicity was administered in a dose escalation test according to the 3 + 3 design. Four days prior to infusion of TCR-T cell, patients receive fludarabine at dose 15 mg/m2/d for 3 day and six day prior to infusion , patients receive cyclophosphamide treatment at dose 15mg/kg/d for 2 days and take a rest for one day before infusion.~A single dose of Anti-NY-ESO-1 TCR transduced T cells will be intravenously administered. Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, interleukin(IL)-2 subcutaneous injections (250,000 IU/day) will be administered for 14 days concomitantly to each subject."
2869615|NCT03462303|Placebo Comparator|tDCS sham + balanced drink|
2869616|NCT03462303|Experimental|tDCS sham + tyrosine depleted drink|
2869617|NCT03462303|Experimental|tDCS anodal + balanced drink|
2869618|NCT03462303|Experimental|tDCS anodal +tyrosine depleted drink|
2869619|NCT03462290|Experimental|Botulinum toxin|
2869620|NCT03462290|Placebo Comparator|placebo|
2869621|NCT03462277||Control group|Control group was defined as people with negative findings in coronary angiograms.
2869622|NCT03462277||Coronary Heart Disease group|CHD patients was defined as at least one lesion in a coronary artery or branches in coronary angiograms.
2869623|NCT03462264|No Intervention|Control Group / Group 1|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic.
2869624|NCT03462264|Experimental|Group 2|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic as well as a pre-formatted diary for them to fill out.
2869625|NCT03462264|Experimental|Group 3|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic as well as a link to download the free ScolioGold App on to their mobile from the clinic.
2869626|NCT03462251|Experimental|Arm A|Combination of ribociclib and aromatase inhibitor
2869627|NCT03462251|Active Comparator|Arm B|Paclitaxel +/- bevacizumab
2869628|NCT03462238|Other|Kidney transplant patients|Group of renal transplant patients for 24 months
2869629|NCT03462238|Other|Dialysis patients|Group of dialysis patients for 24 months
2869630|NCT03462212|Other|Standard treatment|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d 1 q 21 for 6 cycles + Bevacizumab 15 mg/kg d 1 q 21 days for 22 cycles (in combination and maintenance)
2869631|NCT03462212|Experimental|Carboplatin + Paclitaxel + Bevacizumab + Rucaparib|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d1 q 21 days for 6 cycles + Bevacizumab 15 mg/kg d1 q 21 for 22 cycles (in combination and maintenance) + Rucaparib at the dose defined by the Phase I study continuously for 2 years (Rucaparib only in maintenance)
2869632|NCT03462212|Experimental|Carboplatin + Paclitaxel + Rucaparib|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d1 q 21 days for 6 cycles + Rucaparib 600 mg BID continuously for 2 years (Rucaparib only as maintenance).
2869633|NCT03462199|Placebo Comparator|Placebo|
2869634|NCT03462199|Experimental|Actazin High Dose|
2869635|NCT03462199|Experimental|Actazin Low Dose|
2869636|NCT03462199|Active Comparator|Control Formula|
2869637|NCT03462199|Experimental|Livaux High Dose|
2869638|NCT03462199|Experimental|Livaux Low Dose|
2869639|NCT03462186|Experimental|Intervention|Invitation to use healthfinder website
2869640|NCT03462186|No Intervention|Control|No intervention
2869641|NCT03462173|Experimental|30 mg single dose|Healthy subjects, receiving a single dose of 30 mg yimitasvir(N=6) or placebo(N=2)
2869642|NCT03462173|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg yimitasvir (N=6) or placebo(N=2)
2869643|NCT03462173|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg yimitasvir (N=6) or placebo(N=2)
2869644|NCT03462173|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg yimitasvir (N=6) or placebo(N=2)
2869645|NCT03462173|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg yimitasvir (N=6) or placebo(N=2)
2869646|NCT03462173|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg yimitasvir (N=6) or placebo(N=2)
2869647|NCT03462173|Experimental|1000 mg single dose|Healthy subjects, receiving a single dose of 1000 mg yimitasvir (N=6) or placebo(N=2)
2869648|NCT03462160|Placebo Comparator|Placebo supply for 90 days|Patients will receive placebo (in blinded sachets)
2869649|NCT03462160|Experimental|Probiotic supply for 90 days|Patients will receive probiotics containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 (in blinded sachets).
2869650|NCT03462147|Sham Comparator|SHAM|No stimulation will be given
2869651|NCT03462147|Experimental|High Density Stimulation|New way of spinal cord stimulation
2869652|NCT03462147|Active Comparator|Conventional stimulation|the most used stimulation of the spinal cord
2869653|NCT03462134||Survey amongst orthopaedic surgeons|Selected of 20 patients from the Escape trial (NCT01850719)
2869654|NCT03462121|Experimental|RPh201|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the IMP (20 mg RPh201).
2869655|NCT03462121|Placebo Comparator|Placebo|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the vehicle control.
2869656|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Adult|3 doses of 1 ml of Rotavirus vaccine per oral
2869657|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Children|3 doses of 1 ml of Rotavirus vaccine per oral
2869658|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Neonates|3 doses of 1 ml of Rotavirus vaccine per oral
2869659|NCT03462108|Placebo Comparator|Placebo-Neonates|3 doses of 1 ml of Placebo (contains 30% sucrose in DMEM) per oral
2869660|NCT03462095|No Intervention|no Auto-HSCT|After completing prolonged consolidation T-cell ALL patients will continue with 2 years maintenance
2869661|NCT03462095|Experimental|Auto-HSCT|After completing prolonged consolidation T-cell ALL patients will get autologous HSCT followed by 2 years maintenance
2869662|NCT03462082|No Intervention|Baseline STN-DBS|Maintenance of baseline bilateral STN-DBS settings.
2869663|NCT03462082|Experimental|Asymmetric STN-DBS 1|Unilateral 50% reduction of voltage (e.g. right side)
2869664|NCT03462082|Experimental|Asymmetric STN-DBS 2|Unilateral 50% reduction of voltage (e.g. left side)
2869666|NCT03462069|Active Comparator|Treatment B (Reference)|Empagliflozin 1 capsule administered once daily with 2 sotagliflozin placebo tablets prior to the first meal of the day
2869667|NCT03462056|Experimental|CF Ready to Use Supplemental Food.|Participants will receive Cystic Fibrosis Ready to Use Supplemental Food sufficient to provide approximately 20% of estimated daily caloric needs up to 500kcal of total calories, 18.5 grams of protein and 28g of fat. The supplement is also optimized to provide excellent protein quality and optimal polyunsaturated fatty acid composition
2869668|NCT03462043|Active Comparator|Sequence A|
2869669|NCT03462043|Active Comparator|Sequence B|
2869670|NCT03462043|Active Comparator|Sequence C|
2869671|NCT03462043|Active Comparator|Sequence D|
2869672|NCT03462030|Experimental|Baked Milk Immunotherapy|Subjects will receive baked milk oral immunotherapy with baked non-fat cow's milk powder as the intervention. Subjects will undergo an initial dose escalation, build-up, and then a maintenance period.
2869673|NCT03462030|Placebo Comparator|Placebo|Subjects will receive oral immunotherapy with the placebo control (tapioca powder). Subjects will undergo an initial dose escalation, build-up, and then a maintenance period.
2869674|NCT03462017|Experimental|SAR247799|SAR247799 repeated doses once daily in the morning under fasted condition for 28 days according to a sequential dose design
2869675|NCT03462017|Placebo Comparator|Placebo|Identical matching placebo for SAR247799 and for sildenafil once daily in the morning under fasted condition for 28 days
2869676|NCT03462017|Active Comparator|Sildenafil|Sildenafil once daily in the morning under fasted condition for 28 days
2869677|NCT03462004|Experimental|Cohort 1: HPIV3/ΔHNF/EbovZ GP vaccine|Participants will receive two doses of 10^6.0 PFU/mL of HPIV3/ΔHNF/EbovZ GP vaccine on Days 0 and 28 (+28).
2869678|NCT03462004|Placebo Comparator|Cohort 1: Placebo|Participants will receive two doses of placebo on Days 0 and 28 (+28).
2869679|NCT03462004|Experimental|Cohort 2: HPIV3/ΔHNF/EbovZ GP vaccine|Participants will receive two doses of 10^7.0 PFU/mL of HPIV3/ΔHNF/EbovZ GP vaccine on Days 0 and 28 (+28).
2869680|NCT03462004|Placebo Comparator|Cohort 2: Placebo|Participants will receive two doses of placebo on Days 0 and 28 (+28).
2869681|NCT03461991|Other|Patients scheduled for corneal transplantation|
2869682|NCT03461978|Other|10 patients with meibomian gland dysfunction|
2869683|NCT03461978|Other|10 patients with cataract|
2869684|NCT03461978|Other|10 patients after minimally invasive glaucoma surgery (MIGS)|
2869685|NCT03461978|Other|10 patients after partial corneal transplantation|
2869686|NCT03461978|Other|5 patients with demodicosis|
2869687|NCT03461978|Other|5 patients with conjunctival pathologies|
2869688|NCT03461978|Other|5 patients with Acanthamoeba keratitis|
2869689|NCT03461978|Other|5 patients with aniridia|
2869690|NCT03461965|Experimental|Education with 3D printed model|The experimental group will be educated on MMS with a standardized script in addition to a 3D MMS model
2869691|NCT03461965|Active Comparator|Verbal Counselling|Patients in the control group will be educated on MMS according to the current standard of care, verbal counselling, with a standardized script
2869692|NCT03461952|Experimental|Nivolumab|240mg Q2W
2869693|NCT03461952|Experimental|Nivolumab + Ipilimumab|Nivolumab 240mg Q2Wk + Ipilimumab 1mg/kg Q6W
2869694|NCT03461939||ePRIME|"Participants in the study will receive training in using the ePRIME system to report their symptoms and side effects on a weekly basis from home via the internet for 12 weeks while receiving early phase trial treatment. Patients will be sent email/text reminders to enter their symptoms on the system once a week. Patients will be reminded that the data they enter via the online system will not be reviewed promptly by their hospital team and therefore they should continue to contact their treatment team via the contact numbers they have been given.~As part of the research project, we will monitor the number of notifications for severe AE generated by the system to address concerns from the interviews conducted in the first phase of this research project that ePROs will lead to increased workload for clinicians."
2869695|NCT03461926|Experimental|HAPA-treatment|(SB-related planning + daily text messages)
2869696|NCT03461926|No Intervention|Control|(No Treatment) Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaires.
2869697|NCT03461913|Active Comparator|normal pregnancy|women at full term healthy pregnancy who underwent elective Cesarean section
2869698|NCT03461913|Active Comparator|pregnancy hypertension|women at full term pregnancy associated with hypertension who underwent elective Cesarean section
2869699|NCT03461900|Experimental|Minifluid challenge|100 ml of 4% Albumin will be deliver to assess fluid responsiveness
2869700|NCT03461900|Experimental|Control|Patient will be treated as defined by most recent surviving sepsis campaign guidelines
2869701|NCT03461887|Experimental|Exercise intervention|Home-based, minimal equipment exercise training program.
2869702|NCT03461887|No Intervention|Control|Usual care (study participation does not have any impact on regular treatment or treatment decisions, including participation in other exercise training programs or rehabilitation programs)
2869703|NCT03461874|Active Comparator|Treatment as usual|Education of patients followed by Pharmacological Prophylaxis, prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Calcium channel blockers
2869704|NCT03461874|Experimental|Treatment as usual + ACT|"Education of patients, Pharmacological Prophylaxis prescribed based on patients' profile, and eight group sessions of 90 minutes of ACT.~The ACT consists in 6 weekly sessions, 90 minutes each, and 2 supplementary booster sessions, at two and four weeks after the conclusion of the weekly session. The main focus of the six ACT session will be the following: 1) Creative helplessness: the problem of control; 2) Indentifying values: introduction to Mindfulness; 3) Actions guided by values: working with thought; 4) Working with Acceptance and Willingness; 5) Committed Actions: self-as-context; 6) Integration: working with obstacles - wrap-up. The booster session starts with a mindfulness exercise, followed by a review of the contents covered across the ACT program."
2869705|NCT03461861|Active Comparator|Levetiracetam 250 mg/day|Levetiracetam (LEV), 250 mg/day capsule, given as twice-daily dosing (125 mg twice daily) for two weeks.
2869706|NCT03461861|Placebo Comparator|Placebo|Placebo given as a capsule, twice-daily for two weeks.
2869826|NCT03460977|Experimental|DL 2|PF-06821497 150 mg BID
2869707|NCT03461848|Experimental|CYPHP Evelina London Model|Practice clusters across Lambeth and Southwark have been randomised to introduce either the CYPHP Evelina London model of care, or Enhanced Usual Care.
2869708|NCT03461848|Active Comparator|Enhanced Usual Care Model|Practice clusters across Lambeth and Southwark have been randomised to introduce either the CYPHP Evelina London model of care, or Enhanced Usual Care.
2869709|NCT03461835|Active Comparator|M4|High risk classification if the chance of the PUL being an EP ≥5 %; a calculation based on the average value of the two hCG and the ratio of these two hCG (0 h/48 h). Otherwise a low risk classification is made and a predicted outcome of either an IUP or failed PUL is presented.
2869710|NCT03461835|Active Comparator|NICE|High risk classification if the change in rising hCG levels ≤ 63 % or the change in declining hCG ≤ 50 %. If these cut-offs are exceeded the PUL is classified as low risk and predicted to be either an IUP or failed PUL depending on rising or declining hCG levels.
2869711|NCT03461822||SRT in primary-inoperable solid tumors|stereotactic radiotherapy in hypofractionated regimes in 1-5 fractions in primary-inoperable solid tumors
2869712|NCT03461822||Classic radiotherapy in primary-inoperable solid tumors|Classic radiotherapy in 1.8-2.0 Gy per fraction in primary-inoperable solid tumors
2869713|NCT03461822||SRT in oligometastatic cancer|stereotactic radiotherapy in hypofractionated regimes in 1-5 fractions in oligometastatic cancer
2869714|NCT03461822||Classic radiotherapy in oligometastatic cancer|Classic radiotherapy in 1.8-2.0 Gy per fraction in oligometastatic cancer
2869715|NCT03461809||Ocular motor nerve palsy treated by ocular acupuncture|Ocular motor nerve palsy patients who received ocular acupuncture treatment
2869716|NCT03461783|Experimental|Zorflex Activated Carbon Dressing|Patients randomized into the experimental group will only be treated using an activated carbon dressing (Zorflex® Activated Carbon Cloth Dressing; Chemviron Carbon Cloth Carbon, West Midlands, United Kingdom; a division of Calgon Carbon Corporation, Pittsburgh, PA) for wet wounds or with saline and Zorflex® Activated Carbon Cloth Dressing for dry wounds.
2869717|NCT03461783|Active Comparator|Standard of Care for Wound Care|Patients with wet wounds randomized into the control group will be treated using foam, calcium alginate or compressive dressings, whereas those with dry wounds will be treated with hydrogel and compressive dressings.
2869718|NCT03461770|No Intervention|Control group|Patients will receive anesthesia induction with Sevoflurane using a circular circuit without CPAP. Protective ventilation with 5 cmH20 of positive end-expiratory pressure (PEEP) will be initiated after induction. At the end of surgery, mechanical ventilation will stop allowing spontaneous ventilation. Patients will be extubated without CPAP. Lung ultrasound examinations will be performed at different times-points: before anesthesia induction, during surgery, at the end of surgery and before extubation, and after extubation.
2869719|NCT03461770|Experimental|CPAP group|Patients will receive anesthesia induction using 5 cmH20 of CPAP until the moment of intubation. After induction patients will receive the same protective ventilation than the control group. A lung recruitment maneuver will be applied if these patients present atelectasis during surgery. At the end of surgery, patients will be extubated under the modality of CPAP with 5 cmH20. Lung ultrasound examinations will be performed at different times-points: before anesthesia induction, during surgery, at the end of surgery and before extubation, and after extubation.
2869720|NCT03461757|Experimental|Arm 1: BHV-3000 (Active)|
2869721|NCT03461757|Placebo Comparator|Arm 2: Placebo Comparator Drug|
2869722|NCT03461731|Sham Comparator|Control|Participant will receive a sham treatment that consists of just the 660-nm aiming beam
2869723|NCT03461731|Experimental|800 nm laser|800 nm laser will be applied at 4.4 Joules per square cm on the forearm during 40 repetitive hand grips
2869724|NCT03461731|Experimental|combination laser|905 nm and 800 nm will be applied at 4.4 joules per square cm with a total of 8.8 Joules per square cm during 40 repetitive handgrips.
2869725|NCT03461731|Experimental|905 nm laser|905 nm laser will be applied at 4.4 Joules per square cm on the forearm during 40 repetitive hand grips
2869726|NCT03461718|Experimental|Ketamine|Group will receive ketamine 0.5-1mg/kg for a loading dose then subsequent IV pushes of 10-20mg for maintenance. 1mg IV of midazolam will be administered prior to ketamine for anxiolysis and to help minimize emergence reaction.
2869727|NCT03461718|Active Comparator|Control|This group will receive midazolam and fentanyl alternated as currently preformed for endoscopy.
2869728|NCT03461705|Experimental|Primary|All patients who are referred for coronary angiography and require physiological assessment of intermediate lesions will have both RFR and iFR measured during their standard of care procedure. Both the RFR wire (St. Jude Medical (SJM) Aeris Pressure Wire System) and iFR (Volcano Verrata Pressure Wire) wire will be advanced across the lesion with the sensor located at least 3 cm distal from the lesion.
2869729|NCT03461679|Experimental|Intervention|Adductor canal block Femoral triangle block
2869730|NCT03461679|Active Comparator|Standard|Femoral triangle block
2869731|NCT03461666|Active Comparator|Cognitive Behavior Therapy-Insomnia|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
2869732|NCT03461666|Active Comparator|Focus Of Attention|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
2869733|NCT03461666|Active Comparator|Combined-CBT-I and FOA Group|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
2869734|NCT03461666|Active Comparator|Sleep Hygiene|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
2869735|NCT03461653|Other|Telemedicine counselling|intervention group Women who will receive telemedicine counselling
2869736|NCT03461653|No Intervention|Standard care|Women who will receive standard face-to-face counselling
2869778|NCT03461341||Patients post curative intent surgery for esophageal cancer|Patients post potentially curative surgery for cTxNxM0 esophageal or esophagogastric junction (Siewert type I, II and III) cancer.
2869779|NCT03461328|Experimental|Mg-group|10% MgSO4 solution will be used, a loading dose of 30mg/kg over 20 min (equivalent to infusion rate of 0.9 ml/kg/hr for 20 min) will be given followed by continuous infusion of 10mg/kg/hr (equivalent to infusion rate of 0.1ml/kg/hr).
2869780|NCT03461328|No Intervention|Control group|In control group, same rates of infusion for loading and maintenance will be applied using 0.9 normal saline.
2869827|NCT03460977|Experimental|DL 3|PF-06821497 250 mg BID
2869737|NCT03461640|Experimental|Community-based doula support for labour|"Women will receive support from a Community-based doula (CBD) plus standard labour support. Women will meet twice with the CBD prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. The CBD will then stay with her throughout her labour and birth and support her with interpretation/Communication with the staff and emotional and instrumental support. The CBD-support will be in addition to any other support people she may have, such as her partner.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation.~CBDs will be recruited, trained and employed by non-profit organization MIRA, using well-tested processes."
2869738|NCT03461640|Active Comparator|Standard labour support|"Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation."
2869739|NCT03461627|Experimental|Salmeterol Xinafoate and Fluticasone Propinate Powder|Salmeterol Xinafoate and Fluticasone Propinate Powder for inhalation (50ug/250ug) 50ug/250ug 1 puff twice a day for 4 weeks
2869740|NCT03461627|Active Comparator|Seretide|50ug/250ug 1 puff twice a day for 4 weeks
2869741|NCT03461614|Experimental|Exercise Group|In addition to the service routine rehabilitation program, in this group all participant receive as group training with instructor supervising 5-6 participants. The specific days of the week and time of day in which the participants trained remained constant throughout each training protocol. Training programs lasted 6 weeks and comprised 2 training sessions per week with a total of 12 training sessions. A 45-60 min training sessions per week with a 2 day gap between each session.
2869742|NCT03461614|Other|Control Group|In addition to the service routine rehabilitation program, participants in the Control group participated in leisure activities such as table tennis/basketball under service staff supervision for 45-60 minutes, 2 times a week, 6 weeks similar time period of Exercise group.
2869743|NCT03461601|Active Comparator|HCG uterine flushing group|Uterine flushing was done one day before Intrauterine insemination (IUI) with HCG (500 IU) in 10 ml of saline followed by Intrauterine insemination (IUI).
2869744|NCT03461601|Placebo Comparator|IUI alone group|Intrauterine insemination alone plus vaginal flushing with 10 ml normal saline
2869745|NCT03461588|Active Comparator|Free-breathing|standard treatment
2869746|NCT03461588|Experimental|Deep inspiratory breath-holding|new technique
2869747|NCT03461575|Experimental|HU007|"Cyclosporine 0.02%, trehalose 3%~1 drop b.i.d at 12hr interval for 12 weeks"
2869748|NCT03461575|Active Comparator|Restasis|"Cyclosporine 0.05%~1 drop b.i.d at 12hr interval for 12 weeks"
2869749|NCT03461575|Active Comparator|Moisview|"trehalose 3%~1 drop b.i.d at 12hr interval for 12 weeks"
2869750|NCT03461562|Experimental|Experimental|
2869751|NCT03461562|Active Comparator|Control|
2869752|NCT03461549||Healthy adults|Evaluate sensor performance on both lower limbs of healthy adult subjects for pressure sensing and skin temperature sensing.
2869753|NCT03461549||Venous Leg Ulcer Adults|Evaluate sensor performance on both lower limbs of adult subjects with an active venous leg ulcer or history of a venous leg ulcer for pressure sensing and skin temperature sensing.
2869754|NCT03461536|Active Comparator|Clinical Decision Support|Participants in this arm will receive the study intervention, the clinical decision support.
2869755|NCT03461536|No Intervention|Usual care|Participants in this arm will not receive the the clinical decision support tool.
2869756|NCT03461510|Experimental|Type 2 Diabetes|Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
2869757|NCT03461510|No Intervention|Lean Control|Controls do not undergo Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
2869758|NCT03461510|No Intervention|Obese Control|Controls do not undergo Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
2869759|NCT03461497||Patients Cohort|Patients undergoing abdominal surgery
2869760|NCT03461471|Experimental|Intervention Group|Exercise intervention
2869761|NCT03461458|Experimental|5×10^6 AD-MSCs|Subjects will receive one injection of 5 million Autologous Adipose-Derived Mesenchymal Stromal Cells
2869762|NCT03461458|Experimental|20×10^6 AD-MSCs|Subjects will receive one injection of 20 million Autologous Adipose-Derived Mesenchymal Stromal Cells
2869763|NCT03461445|Active Comparator|Immediate Release Tacrolimus|Patients will receive immediate release tacrolimus
2869764|NCT03461445|Experimental|Envarsus|Patients will be converted to Envarsus formulation of tacrolimus
2869765|NCT03461432|Experimental|Personalised Cognitive Remediation Therapy (pCRT)|A case-control study design with pre- and post-therapy assessment, comparing a group of participants with schizophrenia who received standard CRT, with a similar group of participants receiving pCRT.
2869766|NCT03461419|Experimental|Microcannula Harvest Adipose Stroma|Acquisition of AD-tSVF via closed syringe microcannula
2869767|NCT03461419|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via enzymatic isolation/concentration closed system to create cellular stromal vascular fraction (cSVF)
2869768|NCT03461419|Experimental|Sterile Normal Saline IV|Re-suspension of cSVF pellet in Sterile Normal Saline Intravenous Delivery
2869769|NCT03461406|Experimental|Fibrin Sealant Grifols|human fibrinogen (component 1: 80 mg/mL solution) and human thrombin (component 2: 500 IU/mL solution)
2869770|NCT03461406|Active Comparator|EVICEL|human fibrinogen (55-85 mg/mL) and human thrombin (800-1200 IU/mL)
2869771|NCT03461393||Intervention Group|Repetitive Training with Medical-Eye-Trainer (MET)
2869772|NCT03461380|Experimental|Menopause Relief EP-40|Fixed combination of black cohosh EP-40 and Rhodiola rosea EPR-7 206.5 mg orally twice daily; daily dose 413 mg of active ingredients
2869773|NCT03461380|Active Comparator|High Dose Black Cohosh|Black cohosh 500 mg orally twice daily; daily dose 1000 mg of active ingredient
2869774|NCT03461380|Placebo Comparator|Placebo|Placebo capsule 600 mg excipients orally twice daily
2869775|NCT03461380|Active Comparator|Low Dose Black Cohosh|Black cohosh 6.5 mg orally twice daily; daily dose 13 mg of active ingredient
2869776|NCT03461354|Experimental|A|Mucolox Arm
2869785|NCT03461289|Experimental|AVXS-101|AVXS-101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).
2869786|NCT03461276|Experimental|ABvac40|Six administrations of ABvac40; the first five administered once every 4 weeks and the sixth at week 42. Each administration consists of 1mL subcutaneous injection of ABvac40.
2869787|NCT03461276|Placebo Comparator|Placebo|Six administrations of Placebo; the first five administered once every 4 weeks and the sixth at week 42. Each administration consists of 1mL subcutaneous injection of the vaccine's vehicle buffer without the active component.
2869788|NCT03461263|Active Comparator|Group A|phonophoresis treatment using pumpkin seeds oil
2869789|NCT03461263|No Intervention|Group B|Low intensity Ultrasound
2869790|NCT03461263|No Intervention|Group C|Placebo Low intensity Ultrasound
2869791|NCT03461250||HCV serology negative in HD|Risk factors
2869792|NCT03461250||HCV serology positive in HD|Risk factors HCV viral load HCV genotype Liver elastography by Fibroscan
2869793|NCT03461224||MARA-1: accelerated hypofractionated RT|A forward planned IMRT technique was used and the prescribed dose to the breast was 40 Gy in 16 fx with a concomitant boost of 4 Gy.
2869794|NCT03461224||CG: conventional fractionated RT|In the CG, the whole breast received 50.4 Gy in 28 fractions (fx) delivered with 3D-RT, followed by a sequential boost on the tumour bed of 10 Gy in 4 fx delivered with electrons
2869795|NCT03461211|Experimental|Teprotumumab 20 mg/kg|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
2869796|NCT03461198|Experimental|Treatment|Restylane® Silk to a defined area of mid to low cheeks.
2869797|NCT03461185|Experimental|EGFR-TKI plus anti-angiogenesis|EGFR-TKI(erlotinib or gefitinib) plus anti-angiogenesis(endostatin or apatinib or anlotinib)
2869798|NCT03461185|Active Comparator|EGFR-TKI|EGFR-TKI(erlotinib or gefitinib)
2869799|NCT03461172||patients operated for breast cancer|patients operated for histologically proven breast cancer
2869800|NCT03461159|Experimental|H-reflex conditioning - Healthy|Operant conditioning of H-reflexes in healthy volunteers
2869801|NCT03461159|Experimental|H-reflex conditioning - Stroke|Operant conditioning of H-reflexes in people post-stroke
2869802|NCT03461159|Experimental|MEP conditioning - Healthy|Operant conditioning of motor evoked potentials in healthy volunteers
2869803|NCT03461159|Experimental|MEP conditioning - Stroke|Operant conditioning of motor evoked potentials in people post-stroke
2869804|NCT03461146|Experimental|MT-6548|
2869805|NCT03461133||Reference|All patients admitted to the participating surgical wards from 2015-01-01 to 2015-12-31
2869806|NCT03461133||Intervention|All patients admitted to the participating surgical wards from 2016-07-01 to 2017-06-30
2869807|NCT03461120|Experimental|Treatment|Bupivacaine 0.3% infusion for 7 days via femoral and sciatic perineural catheters
2869808|NCT03461120|Other|Control|Bupivacaine 0.1% infusion for 1 day followed by normal saline for a total of 7 days via femoral and sciatic perineural catheters
2869809|NCT03461107||patients with heart failure|
2869810|NCT03461081|Experimental|Group I|Period I: administration of telmisartan/Amlodipine for 10 days then administration of telmisartan/amlodipine and atorvastatin for 4 days Period II: atorvastatin for 4 days
2869811|NCT03461081|Experimental|Group II|Period I: administration of atorvastatin for 4 days Period II: administration of telmisartan/amlodipine for 10 days then administration of telmisartan/amlodipine and atorvastatin for 4 days
2869812|NCT03461068|Experimental|Ketone monoester|Acute morning dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.45 ml/kg body weight)
2869813|NCT03461068|Placebo Comparator|Placebo|Acute morning dose of flavour-matched placebo.
2869814|NCT03461055|Experimental|Lavender|Lavandula angustifolia aromatherapy. 1 drop on a cotton ball placed in a porous pouch. Given to patients at the time of their intrauterine insemination.
2869815|NCT03461055|Placebo Comparator|Water|1 drop of water on a cotton ball placed in a porous pouch. Given to patients at the time of their intrauterine insemination.
2869816|NCT03461042|Experimental|Arm R|Co-administer following medication for 12 weeks since informed consent; R group: taking capsule of Ramelteon 8mg once daily before sleeping.
2869817|NCT03461042|Placebo Comparator|Arm PL|Co-administer following medication for 12 weeks since informed consent; Placebo group: taking capsule of Placebo once daily before bedtime.
2869818|NCT03461029||BIS|Group of 196 patients in whom sedation monitoring is performed using the Bispectral Index Monitoring (BIS) system.
2869819|NCT03461016|Experimental|Smartphone-Based Exposure Therapy|Participants assigned to the Smartphone-Based Exposure Therapy group will receive two weeks of exposure therapy via their smartphone. Participants will have the opportunity to receive up to 50 minutes of exposure video intervention daily for the two weeks.
2869820|NCT03461016|No Intervention|Waitlist Control|Participants who have been randomly assigned to participate in the Waitlist Control group will not receive treatment; however, after the two weeks of no intervention, participants in this condition will be offered the same treatment as the treatment condition.
2869821|NCT03461003|Experimental|NICHE method|In the NICHE method, antihypertensive therapy will be chosen using an n-of-trial to identify the preferred therapy. Preferred therapy is defined a priori as that which produces the greatest reduction in ambulatory BP without intolerable side effects. Tested drugs will include amlodipine or losartan, lisinopril, and hydrochlorothiazide.
2869822|NCT03461003|Active Comparator|Usual Care|No protocol will be introduced to standardize BP management in the control arm.
2869823|NCT03460990|Experimental|Triple Combination|Subjects will receive 240 mg VX-659 / 100 mg TEZ / 150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening
2869824|NCT03460990|Active Comparator|TEZ/IVA|Subjects will receive 100 mg TEZ/150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening
2869825|NCT03460977|Experimental|DL 1|PF-06821497 75 mg BID
2869831|NCT03460964|Experimental|Patients with Diabetes|All participants will receive a minimum of 2 doses of pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat. Glucose will be measured with both an adhesive (needle-free) glucose sensor and a glucometer, at fasting, and time points ranging from 15 to 200 minutes after consuming a standardized meal. There are no other interventions.
2869832|NCT03460951||CIDP patients|15 patients with CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy ) who satisfy the definite CIDP criteria of the Joint Task Force of the EFNS and PNS 1 (situations A and B according to the French CIDP work group2), and who agree to undergo cervical MRI.
2869833|NCT03460951||Normal volunteers|15 healthy subjects matched for age and gender to CIDP patients
2869834|NCT03460951||Charcot-Marie-Tooth disease type 1A patients (CMT-1A)|15 CMT-1A patients (proven by genetic testing), will be included as Charcot-Marie-Tooth disease type 1A patients (CMT-1A) is one of the main differential diagnoses of CIDP characterized by the diffuse demyelination of peripheral nerves.
2869835|NCT03460938|Experimental|RIPC|
2869836|NCT03460938|No Intervention|Control|
2869837|NCT03460925|Experimental|SBRT plus chemotherapy|"Patients with unresectable or borderline resectable locally advanced pancreatic carcinoma at time of diagnosis"
2869838|NCT03460912||All participants|
2869839|NCT03460899|Experimental|Clamp Arm|All 14 subjects will undergo an Euglycaemic Clamp at Visit 2 as well as a Hyperinsulinaemic/Hypoglycaemic Clamp at Visit 3 with the Intervention of reaching certain plasma glucose levels for blood sampling regarding platelet activity parameters. Infusion of Dextrose and human soluble insuline (Actrapid) will be used to reach certain plasma glucose levels.
2869840|NCT03460886|Experimental|Bihemispheric stimulation|"Anodal stimulation on ipsilesional leg motor primary cortex and supplementary motor area~Anodal stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
2869841|NCT03460886|Experimental|Ipsilesional stimulation|"Anodal stimulation on ipsilesional leg motor primary cortex and supplementary motor area~Sham on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
2869842|NCT03460886|Experimental|Contralesional stimulation|"Sham stimulation on ipsilesional leg motor primary cortex and supplementary motor area~Anodal stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
2869843|NCT03460886|Active Comparator|Sham|"Sham stimulation on ipsilesional leg motor primary cortex and supplementary motor area~Sham stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
2869844|NCT03460860|Experimental|Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)|
2869845|NCT03460860|Placebo Comparator|Placebo|
2869846|NCT03460834||Obese asthmatic patients|Observational Cohort
2869847|NCT03460821||Employees|Male and female employees (≥ 18 years of age) of the Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité Universitätsmedizin Berlin experienced in the field of neurocognitive testing: residents, specialist physician for anesthesiology, senior physicians, medical students engaged in research projects
2869848|NCT03460808|Experimental|atorvastatin, acetylcysteine & danazol|atorvastatin 20mg qd po plus acetylcysteine 400mg tid po plus danazol 200mg bid po for 12 weeks
2869849|NCT03460795|Experimental|Conventional plus MSC treatment|
2869850|NCT03460769||Pancreatic Cancer|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
2869851|NCT03460769||Chronic Pancreatitis|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
2869852|NCT03460769||Type 3c Diabetes Mellitus|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
2869853|NCT03460756|Experimental|Ganaxolone|Oral
2869854|NCT03460756|Placebo Comparator|Placebo|Oral
2869855|NCT03460743|Experimental|Study group|single or two doses of quadrivalent recombinant 180 ugm hemagglutinin influenza vaccine
2869856|NCT03460743|Active Comparator|Control group|single or two doses of quadrivalent inactivated influenza vaccine.
2869857|NCT03460730|Experimental|Immunised children|Single 0.5 ml sub-cutaneous dose of 23-valent pneumococcal polysaccharide vaccine (Pneumovax)
2869858|NCT03460717|Experimental|Intervention group: PNFS-TMC|Procedure- The patients in the intervention group were examined and the most painful points over the knee with the avoidance of the proposed site for skin incision for a future knee replacement operation were marked. The marked points received an intervention in the form of application of Peripheral Nerve Field Stimulation by Thermal Micro-Cautery (PNFS-TMC), an intense heat by metal rod was applied to the painful points for 0.3 to 0.5 seconds. The patients to receive 4 sessions over a period of 8 weeks with 2 weeks rest after every session.
2869859|NCT03460717|No Intervention|Control group: Stepladder analgesics|Patients with painful knee osteoarthritis and on the waiting list for a total knee replacement surgery and declined to have PNFS-TMC were included in the control group. The control group received the stepladder analgesic protocol for pain management. The analgesic protocol was managed by the orthopaedic team without any interference by the investigators.
2869860|NCT03460704|Experimental|Drug: Colistimethate Sodium|1 M units equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45% Other Name: Promixin
2869861|NCT03460704|Placebo Comparator|Drug: Saline Solution|1 ml saline solution 0.45%
2869862|NCT03460691||Group 1|Group 1:patients who will undergo the bariatric surgery
2869863|NCT03460678|Other|Pemetrexed Arm|Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium)
2869864|NCT03460678|Other|Erlotinib Arm|Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride)
2869865|NCT03460665|Experimental|Microparticles|arteriography and an injection of inert microparticles of 75 µm in neovessels
2869866|NCT03460665|Placebo Comparator|Placebo|knee arteriography and injection of saline solution in neovessels
2869867|NCT03460652|Experimental|Active Treatment|KP415 oral capsule 20, 30 or 40 mg (total d-MPH from IR d-MPH and KP415 prodrug)
2869868|NCT03460639|Active Comparator|Active laser|Three points on the masseter muscle (upper, middle and lower portions) and one point on the anterior temporal on each side of the face will be irradiated with a wavelength of 780 nm, radiant exposure of 134 J/cm2, power of 50 mW and irradiance of 1.675 W/cm2 for 80 seconds per point, resulting in an energy of 4 J per point and total energy of 32 J per volunteer.20,21 Point application will be performed with a conventional tip in contact with the skin (beam spot: 0.04 cm2).
2869869|NCT03460639|Sham Comparator|Sham laser|The same procedures will be performed in the sham group, but the device will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.
2869870|NCT03460639|Other|Control group|In this group, no treatment will be done, we will only induce fatigue, for evaluation.
2869871|NCT03460626|Placebo Comparator|Group-I (Control group)|This group will be administered a placebo that is an odorless oil without any therapeutic effect)
2869872|NCT03460626|Experimental|Group-II (Treated group)|This group will be administered lavender oil.
2869873|NCT03460626|No Intervention|Group-III (Untreated group)|No intervention will be provided in this group.
2869874|NCT03460613|Other|FGID Patients|
2869875|NCT03460613|No Intervention|Hepatology Control Group|
2869876|NCT03460613|No Intervention|Healthy Volunteers|
2869877|NCT03460587|Experimental|Home-based Telerehabilitation|Home-based Telerehabilitation
2869878|NCT03460574|Experimental|INFORMATION|"Participants in this condition receive a manipulation suggesting that the performance test TEMINT, they previously worked on, has been shown to be highly relevant for daily life and professional success. We anticipated that after receiving this fake information about the TEMINT, it would be difficult for participants to engage in cognitive immunization processes because the validity and utility of the expectation-disconfirming experience is explicitly highlighted."
2869879|NCT03460574|Experimental|SALIENCE|Participants in this condition are asked to think about how well they performed on this really difficult performance test. We anticipated that this manipulation would enhance expectation change, as the salience of the expectation-disconfirming experience was explicitly increased.
2869880|NCT03460574|Experimental|ATTENTION|Before working on the performance test, participants in this conditions receive the instruction to attentionally focus on their personal result in the performance test. Further, they are asked to specify what would be personally good result for them. We anticipated that after receiving this instruction, the expectation-disconfirming performance feedback should be salient for the participants, hence making it difficult for them to engage in cognitive immunization strategies.
2869881|NCT03460574|Experimental|CONTROL|Participants in this condition receive no further information. Therefore, they are passing through the standard procedure of the previously developed experimental paradigm.
2869882|NCT03460561|Active Comparator|TEA group|peri operative thoracic epidural block (TEA) via fentanyl-levo bupivacaine infusion.
2869883|NCT03460561|Active Comparator|RSB group|peri operative rectus sheath block (RSB) via fentanyl-levo bupivacaine infusion.
2869884|NCT03460548|Experimental|Remogen|
2869885|NCT03460548|Active Comparator|Cationorm|
2869886|NCT03460522|Experimental|Induction Therapy with Inotuzumab Ozogamicin|Patients will receive up to 3 cycles Inotuzumab with applications on day 1, 8 and 15 in each cycle. First dose will be 0.8 mg/m² on Day 1. All subsequent doses will be 0,5 mg/m².
2869887|NCT03460509|Placebo Comparator|Sugammadex 0 mg/kg|Placebo NaCl 0,9%
2869888|NCT03460509|Active Comparator|Sugammadex 0,25 mg/kg|Sugammadex 0.25 mg/kg IBW
2869889|NCT03460509|Active Comparator|Sugammadex 0,5 mg/kg|Sugammadex 0.50 mg/kg IBW
2869890|NCT03460509|Active Comparator|Sugammadex 1mg/kg|Sugammadex 1.0 mg/kg IBW
2869891|NCT03460509|Active Comparator|Sugammadex 2mg/kg|Sugammadex 2 mg/kg IBW
2869892|NCT03460496|Experimental|APN-led Intervention|"Intervention group being provided with the interventions described below.~Advanced practice nurses' interventions~Neonatologists: neonatal outpatient consultation~psychological support~lactation consultant~physiotherapeutic interventions~collaboration with social workers~music therapy~close collaboration with other health care professionals~interprofessional roundtable meetings"
2869893|NCT03460496|No Intervention|Control, Standard Care|Control group receiving standard care
2869894|NCT03460483|Experimental|Comprehensive LS genetic testing|Testing for inherited forms of cancer and tumor sequencing
2869895|NCT03460470|Active Comparator|Sildenafil 40mgx3 daily|Sildenafil 40mgx3 daily for 6 months
2869896|NCT03460470|Placebo Comparator|Placebo tablet x3 daily|Placebo for Sildenafil 40mgx3 daily for 6 months
2869897|NCT03460457|Experimental|TQB2450|
2869898|NCT03460444|Experimental|MCT Oil Supplementation|Participants consume MCT oil (97-99% octanoic acid) twice per day for 14 days while consuming a diet similar to the recommended health guidelines (40-50% carbohydrate; 30-40% fat; 20-25% protein).
2869899|NCT03460431|Experimental|fractional CO2 laser 10,600nm|fractional CO2 laser 10,600nm one session every month for 4 months
2869900|NCT03460431|Experimental|Nd YAG laser 1064nm|Nd YAG laser 1064nm
2869901|NCT03460431|Experimental|combined two laser types|combined fractional CO2 laser 10,600nm and Nd YAG laser 1064nm lasers treatment to keloid
2869902|NCT03460418||Multiloc nail|Fracture treated with a Multiloc nail (patients treated between 2012 and 2017)
2869903|NCT03460418||Philos plate|Fracture treated with a Philos plate (patients treated between 2012 and 2017)
2869904|NCT03460418||arthroplasty|Fracture treated by arthroplasty (patients treated between 2012 and 2017)
2869905|NCT03460405|Experimental|VI-DT vaccine (adults,adolescent)|1 dose of 0.5 ml Vi-DT vaccine
2869906|NCT03460405|Active Comparator|Vi polysaccharide (adults,adolescent)|1 dose of 0.5 ml Vi polysaccharide vaccine
2869907|NCT03460405|Experimental|VI-DT vaccine (children)|1 dose of 0.5 ml Vi-DT vaccine
2869908|NCT03460405|Active Comparator|Vi polysaccharide vaccine (children)|1 dose of 0.5 ml Vi polysaccharide vaccine
2869909|NCT03460405|Experimental|VI-DT vaccine (infants)|1 dose of 0.5 ml Vi-DT vaccine
2869910|NCT03460405|Active Comparator|IPV Vaccine (infants)|1 dose of 0.5 ml IPV vaccine
2869911|NCT03460392||Neurological and behavioral disorders|Subjects with neurological or behavioral disorders such as Tourette syndrome are enrolled.
2869912|NCT03460392||Subjects affected by bone diseases|Subjects affected by bone diseases such as infective osteomyelitis or osteoporosis are enrolled.
2869913|NCT03460392||Dysmetabolic and/or endocrine disorders|Patients with endocrine disorders, such as thyroid disfunctions, or with metabolic disorders, including diabetes mellitus,are enrolled.
2869914|NCT03460392||Subjects performing agonistic activity|Subjects performing physical activity at agonistic level are enrolled.
2869915|NCT03460392||Gastroenteric disorders|Subjects affected by gastric and/or enteric disorders are enrolled.
2869916|NCT03460392||Prolonged antibiotic therapy|Patients subjected to prolonged antibiotic therapies and undergone a variety of surgical procedures are enrolled.
2869917|NCT03460392||Healthy subjects|Subjects without any known ongoing disease are enrolled.
2869918|NCT03460340|Experimental|FM group|patients diagnosed with Fibromyalgia receiving dTMS treatment.
2869919|NCT03460340|Sham Comparator|placebo group|patients diagnosed with Fibromyalgia receiving sham- treatment.
2869920|NCT03460288|Experimental|Intervention Group|The training-program includes ten pictures related to slot-machine gambling and 10 neutral pictures that need to be either pushed (i.e., avoidance) or pulled (i.e., approach) with the computer mouse or finger (when a tablet is used) according to a non-affective dimension (color of the frame). Pictures are presented in random order.
2869921|NCT03460288|No Intervention|Wait-list control group|The participants of the wait-list control condition do not receive the retraining intervention during the intervention period of 8 weeks, but may continue any treatment that has already been started before, including pharmacological treatment. Participants in the wait-list control condition receive full access to the training program after completion of the post-assessment.
2869922|NCT03460275|Other|single group|Osimertinib Mesylate Tablets 80 mg, one time a day until disease progression
2869923|NCT03460262|Active Comparator|Standard dressing-Cutiplast®|
2869924|NCT03460262|Experimental|Negative pressure wound therapy-PICO®|
2869925|NCT03460249|Active Comparator|BP table or chair, systolic or diastolic|record the BP obtained in each patient position
2869926|NCT03460249|Active Comparator|as above|as above
2869927|NCT03460236||PRP|Symptomatic early knee osteoarthritis subjects who have elected to receive PRP treatment.
2869928|NCT03460223|Experimental|Conventional plus MSC treatment|
2869929|NCT03460184||G.A Group A|Group A: n= 30 Parturiant patients will receive general anesthesia. General anesthesia will be conducted After pre-oxygenation for 3-5 minutes. 5% thiopental (5 mg/kg) will be administered intravenously over 30s, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium as needed. After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by intravenous infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake, the anesthesia is adequately reversed, and the patient is following commands
2869930|NCT03460184||Spinal A Group B|"Group B: n= 30 Parturiant patients will receive spinal anesthesia. In the sitting position and after complete aseptic precaution are taken, 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, either via midline or paramedian approaches using 22 guage Quinke needle with the bevel directed laterally. 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl (0.5 ml) will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage.~The patient will be put flat in the supine position with left uterine displacement using wedge under the right loin and the surgeon will be allowed to sterilize and wrap the field after confirmation of the solidity of the block its level.~All patiens will be observed for cardiac complications in the form of non-fatal MI, arrhythmias and sudden cardiac death until discharged after at least 72h."
2869931|NCT03460158|Experimental|Restylane-L®, Restylane-L® Lyft, and Restylane Silk®|Hyaluronic acid
2869932|NCT03460145|Experimental|Strip with Lavender Oil (Lx)|"Application of Nasal Strip with essential oil (Lavender), 20minutes before induction.~VAS- Anxiety scores pre and post inhalation."
2869933|NCT03460145|Placebo Comparator|Strip without Lavender Oil (Px)|Application of Nasal strip without essential oil, acting as placebo. VAS- Anxiety scores pre and post placebo.
2869934|NCT03460132|Experimental|Extraction cases|patients receive Tomas orthodontic miniscrew implant as a mean of anchorage augmentation
2869935|NCT03460093||case (SHPB+)|Superior hypogastric plexus block present
2869936|NCT03460093||control (SHPB-)|Superior hypogastric plexus block not present
2869937|NCT03460080||Hepatocellular carcinoma patients|Serum samples are collected before liver resection.
2869938|NCT03460080||Hepatic hemangioma patients|
2869939|NCT03460067|Experimental|Arm A|Patient is required to have lumpectomy with sentinel lymph node biopsy shows pCR and will complete 1 year of trastuzumab +/- pertuzumab treatment. No radiation, or an omission of radiation, will be given on this arm, including external beam, brachytherapy or intraoperative radiation. Patients will be required to follow up with a medical, surgical, or radiation oncologist every 3 months for 5 years. At these follow up visits, a physical exam will be performed to assess for any disease recurrence. Screening mammogram or MRI is recommended every 6 months for patients on this arm.
2869940|NCT03460067|No Intervention|Arm B|Patient is required to have her-2 positive breast cancer, clinically node negative from exam. Patient will complete neoadjuvant chemotherapy per Medical Oncologist. This arm will undergo lumpectomy with sentinel lymph node biopsy shows pCR. The patient will proceed with radiation as standard of care. This arm includes a review of outcomes in the patient's medical chart as well as a collection of biospecimens such as blood and urine, for correlative studies.
2869941|NCT03460067|No Intervention|Arm C|Patient is required to have her-2 positive breast cancer, clinically node negative from exam. patient will complete neoadjuvant chemotherapy per Medical Oncologist. This arm will not undergo lumpectomy with sentinel lymph node biopsy shows pCR. The patient will proceed with radiation as standard of care. This arm includes a review of outcomes in the patient's medical chart as well as a collection of biospecimens, such as blood and urine, for correlative studies.
2869942|NCT03460054||IgA Nephropathy (IgAN)|Biopsy-Proven IgAN
2869943|NCT03460054||Focal Segmental Glomerulosclerosis (FSGS)|Biopsy-Proven FSGS
2869950|NCT03460028|Experimental|Yoga Condition|Participants randomized to the Yoga Condition will participate in a specialized yoga intervention.
2869951|NCT03460028|No Intervention|Wait-List Control Condition|Participants randomized to the Wait-List Control Condition will participate in a specialized yoga intervention once the Yoga Condition has completed their assigned intervention.
2869952|NCT03460015|Experimental|Sevoflurane group|
2869953|NCT03460015|Active Comparator|Propofol group|
2869954|NCT03460002|Experimental|Measles vaccine|In intervention villages children will be weighed and receive standard measles vaccine in one dose if they are between 9-59 months old.
2869955|NCT03460002|Experimental|Oral polio vaccine|In intervention villages children will be weighed and receive standard oral polio vaccine in one or two doses if they are between 0-8 months old.
2869956|NCT03460002|No Intervention|Weighing-MV|In control villages children aged 9-59 months acting as controls to the MV-intervention arm will be weighed only.
2869957|NCT03460002|No Intervention|Weighing-OPV|In control villages children aged 0-8 months acting as controls to the OPV-intervention arm will be weighed only.
2869958|NCT03459989||pregnant women|we will measure expected fetal weight by ultrasound by hadlock's formula and thigh soft tissue for each pregnant woman
2869959|NCT03459976||2 groups|
2869960|NCT03459963|Experimental|group C|indwelling urinary catheter
2869961|NCT03459963|No Intervention|group N|Non cathetrized patients
2869962|NCT03459950||Chronic Insomnia group|60 patients with chronic insomnia are included in the Chronic Insomnia group. Men and women half, the age of 18-60 years old, signature to the Information for Patient.
2869963|NCT03459950||Normal control group|60 normal people are included in the normal control group. Men and women half, the age of 18-60 years old, signature to the Information for Patient.
2869964|NCT03459937|Experimental|Hatha Yoga Intervention|This intervention will be a behavioral weight loss intervention that includes group intervention session, prescribed dietary recommendations, and inclusion of Hatha Yoga.
2869965|NCT03459937|Experimental|Vinyasa Yoga Intervention|This intervention will be a behavioral weight loss intervention that includes group intervention session, prescribed dietary recommendations, and inclusion of Vinyasa Yoga.
2869966|NCT03459911|Experimental|Losartan potassium 100 mg Tablets|Losartan potassium is the test product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Losartan potassium.
2869967|NCT03459911|Active Comparator|Cozaar® (Losartan potassium)100 mg Tablets|Cozaar® (Losartan potassium) is the reference product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Cozaar®.
2869968|NCT03459898|Other|Active Breathing Control|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
2869969|NCT03459898|Other|Deep Inspiration Breath Hold|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
2869970|NCT03459885|Experimental|PAS|The intervention is given to peripheral nerve - motor cortex pairs selected by the investigator.
2869971|NCT03459872||Acupuncture Intervention group|RU-Fit gathers measurements of fine motor control were gathered from this group before and after acupuncture treatments.
2869972|NCT03459872||Control/ Non-Intervention|This group received no intervention but still had measurements of fine motor control gathered from RU-Fit medical device.
2869973|NCT03459859|Experimental|Pevonedistat 10 LDAC 20|Dose Level -1: Pevonedistat 10 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
2869974|NCT03459859|Experimental|Pevonedistat 15 LDAC 20|Dose Level 1 (Starting Dose): Pevonedistat 15 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
2869975|NCT03459859|Experimental|Pevonedistat 20 LDAC 20|Dose Level 2: Pevonedistat 20 mg/m2, low dose Cytarabine 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
2869976|NCT03459859|Experimental|Pevonedistat 25 LDAC 20|Dose Level 3: Pevonedistat 25 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
2869977|NCT03459859|Experimental|Pevonedistat 30 LDAC 20|Dose Level 4: Pevonedistat 30 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
2869978|NCT03459846|Experimental|Arm 1: Durvalumab/Placebo|Durvalumab 1500 mg intravenous (IV) every 4 weeks (q4w) starting on week 1 day 1/Placebo orally (PO) twice a day (BID) starting on week 1 day 1.
2869979|NCT03459846|Experimental|Arm 2: Durvalumab/Olaparib|Durvalumab 1500 mg IV q4w starting on week 1 day 1/Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.
2869980|NCT03459833|Experimental|group 1|15 patients They will receive a topical anesthetic agent for 30 minutes (Emla cream; lidocaine 25 mg, prilocaine 25 mg, Astra Xeneca, Mississauga, Canada) followed by injection of two prefilled 1 ml syringes with 30 G needle of hyaluronic acid (HA; Teosyal® PureSense Global Action, Teoxane Laboratories, Geneva, Switzerland). After 18 months from the HA injection, cross-over to placebo arm will be done.
2869981|NCT03459833|Placebo Comparator|group 2|They receive by the same method 2 ml saline as a placebo. After one month of the injection, cross-over to HA arm will be done.
2869982|NCT03459820|Experimental|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT Scan
2869983|NCT03459807|Experimental|Home systolic blood pressure (SBP) <140 mmHg|"Participants will be asked to take morning and evening blood pressures every two weeks on a non-dialysis day.~Participants will be asked to transmit these measures to the study team at minimum every 2 weeks either via Bluetooth technology, a manual log, telephone call, text message, e-mail, or verbal communication.~Assigned intervention will be dry weight adjustment and/or adjustment of standard anti-hypertensive medications."
2869984|NCT03459807|Active Comparator|Pre-dialysis SBP <140 mmHg|"Blood pressures taken in the clinical setting at prior to start of dialysis treatment will be recorded.~Assigned intervention will be dry weight adjustment and/or adjustment of standard anti-hypertensive medications."
2869985|NCT03459794|Active Comparator|Ivermectin|Ivemectin will be administered once at 150mcg/kg, orally.
2869986|NCT03459794|Placebo Comparator|Control|An oral placebo will be administered once
2870083|NCT03459092|Experimental|Botox-based treatment regimen|First intervention is a Botulinum toxin type A injection. If further treatment is necessary, strabismus surgery can be performed.
2869987|NCT03459781|Experimental|Cognitively-Based Compassion Training|Cancer survivors and their informal caregivers (family and close friends), one of whom has at least mild depression and/or anxiety features (determined by PROMIS Depression 4a and PROMIS Anxiety 4a, respectively) who are randomized to CBCT®.
2869988|NCT03459781|Active Comparator|CHE (Cancer Health Education)|Cancer survivors and their informal caregivers (family and close friends), one of whom has at least mild depression and/or anxiety features (determined by PROMIS Depression 4a and PROMIS Anxiety 4a, respectively) who are randomized to CHE.
2869989|NCT03459755|Experimental|Lifestyle Intervention|Patients assigned to the Physical Activity arm will undergo exercise testing protocol and have supervised physical activity interventions while on study. Patients will also complete questionnaires and have research blood drawn.
2869990|NCT03459755|No Intervention|Usual care|Patients will complete questionnaires and have research blood drawn.
2869991|NCT03459742|Experimental|Intervention|Gamification strategy. In 2018, the intervention group are 15 schools from Municipality of Santiago. In 2019, the intervention will cover all eligible schools in the Municipality of Santiago.
2869992|NCT03459742|No Intervention|Control|In 2018, the control group will be 5 randomly selected schools from Municipality of Santiago and 4 schools from Municipality of Estación Central. In 2019, the control group will be 4000 participants chosen from neighboring municipalities
2869993|NCT03459729|Experimental|Antitumor B KAC-α|
2869994|NCT03459716||Systemic sclerosis patients w/ PH|Pulmonary hypertension will be defined as a mean pulmonary artery pressure≥25mmHg on right heart catheterization
2869995|NCT03459716||Systemic sclerosis patients w/o PH|Pulmonary hypertension will be excluded based on all of the following echocardiogram features: estimated systolic pulmonary artery pressure<35mmHg and absence of right atrial or right ventricular (RV) enlargement and lack of qualitative RV dysfunction. If a subject has any of these echo features, they will be referred for right heart catheterization (RHC) and included in the appropriate group based on their RHC results.
2869996|NCT03459703|Experimental|Early Time-Restricted Feeding|
2869997|NCT03459703|Active Comparator|Control Schedule|
2869998|NCT03459690|Experimental|Experienced meditators|Meditation ≥ 30 min per day for at least 5 days per week over the past 1 year
2869999|NCT03459690|Experimental|Novice meditators|No meditation practice in the previous year and < 20 entire lifetime hours
2870000|NCT03459677|Experimental|Back2School Condition|"The Back2School condition is a Modular Trans-Diagnostic Cognitive Behavioral Therapy (MTCBT) treating school absenteeism in youths.~The MTCBT intervention consist of 10 sessions and 4 school meetings, conducted over a period of 4 months."
2870001|NCT03459677|Active Comparator|Treatment As Usual Condition|"The Treatment As Usual condition (TAU) consist of an array of interventions that the municipality is required to give youths presenting school absenteeism.~The TAU condition will last for 4 months."
2870002|NCT03459664|Experimental|RECOVER|The intervention in the RECOVER stepped-care model includes specific evidence-based treatment options for severity grade 1 to 4.
2870003|NCT03459664|Active Comparator|Treatment As Usual|The active comparator is treatment as usual (TAU) and provides all common care options within the German health care system, depending on the severity grade 1 to 4.
2870004|NCT03459651|Experimental|ANS training|
2870005|NCT03459638||Periodontitis|Screening for DM, ASCVD, MetS and OSAS in patients with periodontitis
2870006|NCT03459638||No periodontitis|'Screening for DM, ASCVD, MetS and OSAS in patients without periodontitis
2870007|NCT03459625|Experimental|Mindfulness-Based Stress Reduction (MSBR)|MSBR (Kabat-Zinn, 1990), 8-week group-based intervention where participants learn mindfulness skills to help alleviate parenting stress among parents of young children with Autism Spectrum Disorder.
2870008|NCT03459625|Active Comparator|Psychoeducational Support Group (PE)|PE is a 8-week group-based intervention to provide psychosocial support and resources for parents of young children with Autism Spectrum Disorder.
2870009|NCT03459612|Placebo Comparator|Placebo|Placebo administered orally in one of four study periods.
2870010|NCT03459612|Experimental|Lasmiditan Dose 1|Lasmiditan Dose 1 administered orally in one of four study periods.
2870011|NCT03459612|Experimental|Lasmiditan Dose 2|Lasmiditan Dose 2 administered orally in one of four study periods.
2870012|NCT03459612|Active Comparator|Diphenhydramine|Diphenhydramine administered orally in one of four study periods.
2870013|NCT03459599|Active Comparator|Prophylaxis|Current protocol of administering antibiotics maintained
2870014|NCT03459599|Active Comparator|No prophylaxis|Antibiotics withheld, with appropriate observation and follow up
2870015|NCT03459586|Experimental|9zest app facilitated exercise|App to facilitate exercises for 3 times a week for 12 weeks. The app includes physical therapist-designed exercises that are modified using an algorithm to the participants physical capabilities and PD status. Exercises include strengthening, balance, range of motion, and endurance type exercise.
2870016|NCT03459573|Active Comparator|T2D: One Drop with Fitbit Ionic|
2870017|NCT03459573|Active Comparator|T2D: One Drop without Fitbit Ionic|
2870018|NCT03459573|No Intervention|T2D: Waitlist Control|
2870019|NCT03459573|Active Comparator|T1D: One Drop with Fitbit Ionic|
2870020|NCT03459573|Active Comparator|T1D: One Drop without Fitbit Ionic|
2870021|NCT03459573|Active Comparator|PD: One Drop with Fitbit Charge 2|
2870022|NCT03459573|Active Comparator|PD: One Drop without Fitbit Charge 2|
2870023|NCT03459560|Experimental|PolyPill|Single daily dose of PolyPill and 6-monthly visits
2870024|NCT03459560|No Intervention|Control|Only 6-monthly visits
2870025|NCT03459547|Experimental|dental implant + PEEK (test)|Dental implant insertion, material polyetheretherketone
2870026|NCT03459547|Active Comparator|dental implant + Ti-5 (control)|Dental implant insertion, material titanium group 5
2870027|NCT03459547|Active Comparator|dental implant + zirconia (control)|dental implant insertion, material zirconia
2870028|NCT03459547|Active Comparator|dental implant + Ti-4 (control)|dental implant insertion, material titanium group 4
2870084|NCT03459092|Active Comparator|Surgery-based treatment regimen|First intervention is strabismus surgery. If further treatment is necessary, strabismus surgery can be repeated.
2870085|NCT03459079|Active Comparator|lanifibranor arm|Two arm, randomized (1:1), double-blind, placebo-controlled, 24-week treatment study receiving lanifibranor 800 mg/day.
2870029|NCT03459534|Experimental|Radotinib|"Enrolled subjects will continue to administer radotinib 400mg twice daily (800mg/day) orally every 12 hours at regular dosing hours for 12 months.~Dose modification is allowed if the subject cannot comply with the protocol-defined dosing schedule due to hematologic or non-hematologic toxicities and toxicities resolve within 28 days (within 42 days for hematologic toxicities). For radotinib, maximum 2 dose reductions will be allowed by stage to 600mg and to 400mg."
2870030|NCT03459521|Experimental|Fendrix HBV vaccine|Drug: Fendrix Fendrix suspension for injection GlaxoSmithKline Route of administration, dose regimen: Intra-muscular Dose: 0.5 ml (20mcg of Hepatitis B Surface Antigen) per vaccination at baseline, 1, 2 and 6 months.
2870031|NCT03459508||Primary antiphospholipid syndrome women|"Informed consent~Detailed history emphasizing on~a. obstetric complications related to antiphospholipid syndrome: i. Recurrent miscarriage ii. Fetal demise iii. Fetal growth restriction iv. Severe pre-eclampsia or eclampsia v. Placental insufficiency vi. Placental abruption b. Systemic vascular complications related to antiphospholipid syndrome: i. Arterial thrombosis ii. Venous thrombosis iii. Small-vessel thrombosis~Revision of diagnosis of primary antiphospholipid syndrome:~Exclusion of antiphospholipid syndrome secondary to SLE and other autoimmune diseases by: antinuclear (ANA), anti-Smith (Sm) and anti-double stranded DNA (dsDNA) antibodies.~Ophthalmological examination:"
2870032|NCT03459495|Active Comparator|Group A|Group A: ultrasound group
2870033|NCT03459495|Placebo Comparator|Group P|Group P: placebo ultrasound group
2870034|NCT03459482|Experimental|Group 1 - True Food Elimination Diet|Group 1 (experimental group): Subjects will be given an elimination diet based upon foods with a positive antibody profile in the Biomerica InFoods® IBS test. The elimination diet will also exclude any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates.
2870035|NCT03459482|Sham Comparator|Group 2 - Sham Food Elimination Diet|"Group 2 (control group): Subjects will be given a Sham elimination diet. The sham diet will eliminate the same number of foods but none of the actual foods to which the patient had a positive antibody profile in the Biomerica InFoods® IBS test. The sham diet will also eliminate any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates."
2870036|NCT03459469|Experimental|Investigational drug|An open-label, non-randomized study to evaluate safety of Tegavivint administered intravenously to subjects with proven primary or recurrent desmoid tumor that is unresectable and symptomatic or progressive.
2870037|NCT03459456||OCD subjects|"Subjects meeting inclusion/exclusion criteria with OCD will be exposed to the following:~Provocation OC task (Provoc)~Trier Social Stress Test (TSST)~Exposure provocation task"
2870038|NCT03459456||Control subjects|"Subjects meeting inclusion/exclusion criteria without OCD (age and gender matched with OCD subjects) will be exposed to the following:~Provocation OC task (Provoc)~Trier Social Stress Test (TSST)~Exposure provocation task"
2870039|NCT03459430|Experimental|Low Intensity training group|Low Intensity training group will complete a 6 week core stability training program with low intensity/oscillation exercises
2870040|NCT03459430|Experimental|High Intensity training group|High Intensity training group will complete a 6 week core stability training program with high intensity/oscillation exercises
2870041|NCT03459430|No Intervention|Control group|Control group will have 6 weeks with no intervention before post-test
2870042|NCT03459417|Active Comparator|intrathecal morphine+LA|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine.
2870043|NCT03459417|Active Comparator|intrathecal morphine+LA+Mg sulp. 50|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 50 mg.
2870044|NCT03459417|Active Comparator|intrathecal morphine+LA+ Mg sulp.100|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
2870045|NCT03459404||Sufentanil NanoTab PCA System/15 mcg|"Drug: Sufentanil 15 mcg~Unless contraindicated patients also received around the clock regimen of NSAIDS (ketoprofen 200 mg/day) and acetaminophen (1000 mg every 8 hours)."
2870046|NCT03459391|Experimental|XC221 60 mg|Cohort 1:16 subjects were randomized in a 3:1 ratio to be treated either with 60 mg XC221 (12 subjects) or placebo (4 subjects, see placebo arm).
2870047|NCT03459391|Experimental|XC221 200 mg|Cohort 2: 16 subjects were randomized in a 3:1 ratio to be treated either with 200 mg XC221 (12 subjects) or placebo (4 subjects, see placebo arm).
2870048|NCT03459391|Placebo Comparator|Placebo|Placebo comparator arm consists of 8 subjects (4 subjects from each cohort).
2870049|NCT03459365|Experimental|Euflexxa|Two sets of Euflexxa injection at 0 and 6 months. Each set consists of 3 injections 1 week apart.
2870050|NCT03459339|Experimental|Experimental OFDI capsule imaging|"Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.~Intervention: 'Tethered Capsule Endomicroscopy (TCE) Imaging of Barrett's esophagus using OFDI capsule"
2870051|NCT03459326||control group|men in relation
2870052|NCT03459326||FIV group|men whose couple taken care of fecundation in vitro
2870053|NCT03459326||ICSI group|men whose couple taken care of intracytoplasmic injection
2870054|NCT03459326||IUI group|men whose couple taken care of intrauterine insemination
2870055|NCT03459313|Experimental|Active group|The active group will be provided the intervention program, i.e. access to a website.
2870056|NCT03459313|No Intervention|Control group|The control group will continue to train according to their routines and will get access to the website after 4 months.
2870057|NCT03459287|Experimental|INTERCEPT (test)|The INTERCEPT treatment process uses amustaline and glutathione together with a processing solution in a single-use disposable set and results in pathogen and leukocyte inactivated RBCs suspended in SAG-M additive solution (INTERCEPT RBCs). The INTERCEPT treatment will be performed on leukocyte reduced RBC components prepared from whole blood collections and suspended in AS-5 additive solution within 24 hours of collection. The test component is allogeneic INTERCEPT RBCs suspended in SAG-M and stored at 1°C to 6 for up to 35 days post-donation and administered intravenously. Dose and schedule of RBC transfusions will be determined by the treating physician.
2870086|NCT03459079|Placebo Comparator|Placebo|Two arm, randomized (1:1), double-blind, placebo-controlled, 24-week treatment study receiving placebo.
2870185|NCT03458403|Experimental|Motions during gastroscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for.
2870058|NCT03459287|Active Comparator|Conventional (Control)|The control transfusion component is a conventional leukocyte-reduced RBC component in an FDA approved additive solution (AS-1, AS-3 or AS-5) stored at 1°C to 6°C for up to 35 days post-donation and administered intravenously. The Control RBC components will be handled and labeled in a manner so as to maintain blinding. Dose and schedule of RBC transfusions will be determined by the treating physician.
2870059|NCT03459274||VR-Biofeedback Feedback Sharers|These participants would express either interest or a lack of interest in trying biofeedback/virtual reality therapy. They will be instructed on how to use the virtual reality equipment and program. Then, they will have the option to participate in the biofeedback/virtual reality experience, if they choose to do so, before sharing their feedback.
2870060|NCT03459261||POM|post-traumatic osteomyelitis group (POM), the participants who developed post-traumatic osteomyelitis after primary surgical treatment and were taken blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4). Patients were included in POM group after additional assessment of meeting the CDC/NHSN surveillance definition criteria for osteomyelitis: positive intraoperative withdrawal bone and soft tissue sample, types of cultured bacteria, histopathologic proof of osteomyelitis and clinical signs of surgical site infection.
2870061|NCT03459261||NO POM|No POM group, the participants who did not develop postraumatic osteomyelitis to tibia after primary surgical treatment and were taken blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4) in follow up interval of 6 months /control group/. Patients were included in No POM group after assessment of not meeting the CDC/NHSN surveillance definition criteria for osteomyelitis.
2870062|NCT03459248|Experimental|Dual therapy|Patients will receive 10 mg metoclopramide with 4mg ondansetron before induction of general anesthesia
2870063|NCT03459248|Active Comparator|Monotherapy|Patients will receive 10 mg metoclopramide before induction of general anesthesia.
2870064|NCT03459235|Experimental|population from registry data|the intervention involves completing several quality of life questionnaires validated in the medical literature (LARS score, FSFI, USP, IIEF, IPPS, QLQ C-30, QLQ-CR29)
2870065|NCT03459222|Experimental|Arm A|Relatlimab + Nivolumab + BMS-986205
2870066|NCT03459222|Experimental|Arm B|Relatlimab + Nivolumab + Ipilimumab
2870067|NCT03459196|Experimental|Treatment Group|A novel radiofrequency ablation catheter combining microelectrodes, thermocouples, porous tip irrigation and contact force sensing nMARQ Multi-Channel RF Generator with Software including TGA mode (Temperature Guided Ablation).
2870068|NCT03459183|Experimental|Infrasound - verum|In this condition, participants are exposed with non-audible infrasound from the Infrasound (85dB; 6Hz) source, for 8 constant hours during their night sleep. The source is placed close to the participant's bed (approximately 1-2 meters).
2870069|NCT03459183|Placebo Comparator|Infrasound - placebo|In this condition, participants are not exposed to any sound. The infrasound dummy source is placed close to the participant's bed, exactly like in the Infrasound - verum condition (1-2 meters). The Infrasound dummy source looks exactly like the active infrasound source but produces no sound at all. Participants are told that this source emits sound for 8 constant hours during their night sleep.
2870070|NCT03459183|Experimental|Ultrasound - verum|In this condition, participants are exposed to non-audible ultrasound, emitted by the Ultrasound (10dB below hearing threshold; 22.4 kHz) source for 8 constant hours during their night sleep. The source is placed close to the participant's bed (1-2 meters), at the level of the participant's head (for instance on a nightstand).
2870071|NCT03459183|Placebo Comparator|Ultrasound - placebo|In this condition, participants are not exposed to any sound. The Ultrasound dummy source is placed close to the participant's bed, exactly like in the Infrasound - verum condition (1-2 meters). The Ultrasound dummy source looks exactly like the active ultrasound source, but produces no sound at all. Participants are told that this source emits sound for 8 constant hours during their night sleep.
2870072|NCT03459170|Experimental|BPX-501 T cells and rimiducid|"All subjects will receive 3 ccourses of BPX-501 T cell infusions at escalating dose levels (DL). DL1 on Day 0, DL2 on Days 30 and 60. The first dose of BPX-501 T cells will occur ≥30 days after hematopoietic stem cell transplant (HSCT).~Two doses of AP1903 ( 0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion."
2870073|NCT03459157|Other|HIV prevention package including PrEP|
2870074|NCT03459144|Experimental|photodynamic therapy|Participants will be given the standard verteporfin photodynamic therapy at baseline followed by additional standard verteporfin PDT as needed (every three months)(namely 1+PRN regimen).
2870075|NCT03459144|Experimental|intravitreal ranibizumab|Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab will be given to the participants when necessary (every month) (namely 1+PRN regimen).
2870076|NCT03459144|Experimental|combination therapy of PDT and IVR|Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the standard verteporfin PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary (every month)(namely 1+PRN regimen).
2870077|NCT03459131|Other|BIOFINITY ENERGYS then BIOFINITY|Comfilcon A with Digital Zone Optics™ contact lenses worn first, followed by comfilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for 7 days in a daily wear modality.
2870078|NCT03459131|Other|BIOFINITY then BIOFINITY ENERGYS|Comfilcon A contact lenses worn first, followed by comfilcon A with Digital Zone Optics™ contact lenses. Each product will be worn bilaterally (in both eyes) for 7 days in a daily wear modality.
2870079|NCT03459118|Experimental|Function Focused Care|FFC-AL-EIT is implemented by a Research Nurse Facilitator working with the champion and stakeholders using our four step approach: (I) Environment and Policy Assessments; (II) Education; (III) Establishing Resident Function Focused Care Service Plans; and (IV) Mentoring and Motivating.
2870080|NCT03459118|Placebo Comparator|Education Only|Education only sites are exposed to Step II of the Four step approach described under the treatment arm. They receive baseline education of staff.
2870081|NCT03459105|Experimental|Ultrasound-assisted|Preprocedural ultrasound-assisted paramedian spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
2870082|NCT03459105|Active Comparator|Landmark-guided|Landmark-guided spinal anesthesia will be performed, via either midline or paramedian approach. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
2870087|NCT03459066||Institution-Group 8 district|Group of patients belonging to institutions of district 8. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
2870088|NCT03459066||Institution-Group 9 district|Group of patients belonging to institutions of district 9. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
2870089|NCT03459066||Institution-Group 10 district|Group of patients belonging to institutions of district 10. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
2870090|NCT03459053|Experimental|CBART|6 weeks participation in CBART protocol before beginning IVF treatment
2870091|NCT03459053|No Intervention|Wait control|Participants will receive treatment as usual and will be able to receive the intervention after the study is complete.
2870092|NCT03459040|Experimental|alpha-1-antitrypsin (AAT)|16 doses of AAT through a catheter placed into a blood vessel over eight weeks.
2870093|NCT03459027|Active Comparator|Nitrate Rich Beetroot Powder (nitrate)|Dietary nitrate in the form of beetroot powder (10g) mixed in water will be administered acutely
2870094|NCT03459027|Placebo Comparator|Placebo Beetroot Powder|Beetroot powder devoid of nitrate (10g) will be mixed in water and administered acutely
2870095|NCT03459014|Experimental|Stimulus rich VE|Participants will be tested during 1 RAG session in the Lokomat. Participants in the experimental group will walk in a stimulus rich VE such as walking in a park.
2870096|NCT03459014|Active Comparator|Stimulus poor VE|Participants will be tested during 1 RAG session in the Lokomat. Participants in the control group will walk in a stimulus poor VE, such as walking through an endless hallway.
2870097|NCT03459001||Tube Fed Malnourished Outpatients|Outpatients that are malnourished or at risk of malnutrition and have been placed on a nutritional care plan, which includes a complete tube feeding formula as sole source nutrition
2870098|NCT03458988|Other|All patients|Nellcor™ Adult SpO2 Sensor
2870099|NCT03458975|Active Comparator|Selected liver metastases of the patient|Liver metastases randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive theusual systemic chemotherapy (FOLFIRI + Bevacizumab)
2870100|NCT03458975|Placebo Comparator|Not-selected liver metastases of the patient|Liver metatstases not randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy like the active comparator arm (FOLFIRI + Bevacizumab)
2870101|NCT03458962||Genetic Enrollees|Enrollment of patients for whom WGS may be beneficial. Patients who are ill and for whom a genetic diagnosis is suspected but not yet established.
2870102|NCT03458923|Active Comparator|Group A|15 eyes will receive 0.1 ml containing 500µg of diclofenac intravitreally, repeated monthly for 3 months.
2870103|NCT03458923|Active Comparator|Group B|15 eyes will receive 0.5 mg Ranibizumab intravitreally, repeated monthly for 3 months.
2870104|NCT03458910|Experimental|HRV-increase group|Half of the participants will be randomly assigned to this group who will undergo daily practice to increase their heart rate variability (HRV).
2870105|NCT03458910|Experimental|HRV-decrease group|Half of the participants will be randomly assigned to this group who will undergo daily practice to decrease their HRV and heart rate.
2870106|NCT03458897|Experimental|MRI arm|Subjects with sickle cell disease undergoing bone marrow transplantation will undergo serial functional MRI (up to 4 scans).
2870107|NCT03458884|Experimental|Cardiorespiratory interval training|Cardiorespiratory interval training program on ergometer cycle, 30-40 minutes, 3 days a week for 8 weeks.
2870108|NCT03458884|No Intervention|Usual care|Usual ESD care including information about post-stroke fatigue, support and practical advice about how to identify and manage fatigue symptoms in daily tasks, such as the adaptation and prioritization of activities, physical activity and rest.
2870109|NCT03458871|Experimental|4-week TTNS home based protocol|Transcutaneous Tibial Nerve Stimulation (TTNS) applied to subjects for 4-week protocol.
2870110|NCT03458858|Other|Mixed Berry Diet|Participants will receive between 400 to 800 grams of mixed berries daily, as a proportion of their daily caloric intake added to their base diet. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
2870111|NCT03458858|Other|Carbohydrate Control Jello|Participants will receive between 400 to 800 grams of strawberry jello daily, as a proportion of their daily caloric intake added to their base diet. The jello will be matched to the mixed berries in both total carbohydrate level and gram quantity. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
2870112|NCT03458858|Other|Fiber Enriched Jello|Participants will receive between 400 to 800 grams of fiber enriched strawberry jello daily, as a proportion of their daily caloric intake added to their base diet. The jello will be matched to the mixed berries in both total carbohydrate level and fiber content, and in the same gram quantity. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
2870113|NCT03458858|Other|Low Fiber Mixed Berry Juice|Participants will receive 1 liter per day of low fiber mixed berry juice added to their base diet. The juice will be squeezed from the mixed berries, then filtered. The sugar level of the juice will match that of the mixed berries. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
2870114|NCT03458845||Group 1|This group consists of cirrhotic patients with any abdominal hernia
2870115|NCT03458845||Group 2|This group consists of cirrhotic patients without any hernias
2870116|NCT03458832||FSHD-COM|All participants will be asked to undergo FSHD-specific functional rating scale tests and procedures and Electrical Impedance Myography.
2870117|NCT03458819||Control|Patients on neither active Vitamin D or a statin
2870118|NCT03458819||Vit D|Patients on active Vitamin D but not a statin
2870119|NCT03458819||Statin|Patients on a statin but not active Vitamin D
2870120|NCT03458819||D + Statin|Patients on both active Vitamin D and a statin
2870184|NCT03458416|Experimental|Cannabidiol Oral Solution: 20-40 mg/kg/day|Participants will receive total daily doses between 20 milligrams per kilograms per day (mg/kg/day), 30 mg/kg/day, and 40 mg/kg/day. The two equivalent doses will be administered twice a day with a standard meal approximately every 12 hours.
2870121|NCT03458806||Control|Subjects with echocardiographically confirmed valvular disease of less than moderate-to-severe grading with regards to aortic stenosis (AS) and mitral regurgitation (MR). Note that within this cohort will be a sub cohort consisting of subjects with structurally normal hearts, with no greater than mild valvular disease of any valve, no prior valvular intervention, and no evidence of congenital heart disease.
2870122|NCT03458806||AS Case|Subjects with echocardiographically confirmed aortic stenosis (AS) of moderate-to-severe or greater grading.
2870123|NCT03458806||MR Case|Subjects with echocardiographically confirmed mitral regurgitation (MR) of moderate-to-severe or greater grading.
2870124|NCT03458806||Control Subgroup|Subjects with structurally normal hearts, with no greater than mild valvular disease of any valve, no prior valvular intervention, and no evidence of congenital heart disease.
2870125|NCT03458793|Experimental|The experimental group|The experimental group will take part in the 12 week intervention after randomisation consisting of group walking and educational workshops performed once weekly for up to 90 minutes in total for each session.
2870126|NCT03458793|No Intervention|The control group|The control group will be a wait-listed arm that will be offered an intervention at 12 weeks after the randomisation (the delayed intervention).
2870127|NCT03458780||Yellow Fever Vaccine Participant|Healthy participants who receive the Yellow fever vaccine for travel and/or occupational risk will have peripheral blood samples collected longitudinally at time points selected for different immune events post-vaccination according to published studies (Day 0 baseline; Days: 3, 7, 14, and 42).
2870128|NCT03458767|Experimental|Intervention group|Eight weekly 90-minute group educational sessions attended via a computer, tablet, or smart phone using a web-based video conference platform.
2870129|NCT03458767|No Intervention|Control group|Enhanced usual care control group will receive an illustrated instructional booklet on Physical Activity for persons with MS developed by the National Center on Health, Physical Activity and Disability (NCHPAD).
2870130|NCT03458754||Patients|Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)
2870131|NCT03458754||Healthy controls|Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)
2870132|NCT03458728|Experimental|Dose escalation of BAY806946 in Phase 1|It is estimated that 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Safety and MTD/RP2D dose will be evaluated in 2 age groups (< 1 year old and ≥ 1 year old).
2870133|NCT03458728|Experimental|Patients with Neuroblastoma in Phase 2|Recommended Phase 2 dose (RP2D) for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
2870134|NCT03458728|Experimental|Patients with Osteosarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
2870135|NCT03458728|Experimental|Patients with Rhabdomyosarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
2870136|NCT03458728|Experimental|Patients with Ewing sarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
2870137|NCT03458715|Experimental|SGLT2 inhibitor (Empagliflozin 25 MG)|We add SGLT2 inhibitor (Empagliflozin 25 MG, oral, once daily) to type 2 diabetes patient poorly controlled with premix insulin therapy for 6 months.
2870138|NCT03458715|Active Comparator|DPP4 inhibitor (Linagliptin 5 MG)|We add DPP4 inhibitor (Linagliptin 5 MG, oral, once daily) to type 2 diabetes patient poorly controlled with premix insulin therapy.for 6 months.
2870139|NCT03458702|Experimental|YogaFit|Participants participated in a 30 min YogaFit Session
2870140|NCT03458702|No Intervention|Quiet Rest|Participants participated in 30 min of Quiet Rest
2870141|NCT03458689|Other|Left hemicolectomy without nerve blocks|Left hemicolectomy, laparoscopic technique Enteral and parenteral analgesics such as paracetamol and oksykodon
2870142|NCT03458689|Active Comparator|Left hemicolectomy with TAP block|Left hemicolectomy, laparoscopic technique TAP block bilateral with Naropin 3,75 mg/ml, 2 x 20 ml
2870143|NCT03458689|Active Comparator|Left hemicolectomy with QL block|Left hemicolectomy, laparoscopic technique QL block bilateral with Naropin 3,75 mg/ml, 2 x 20 ml
2870144|NCT03458676|Experimental|Advanced MR Imaging (AMRI) Scan|"AMRI scan performed within 2 weeks before standard of care brain surgery.~During the surgery, neurosurgeon(s) use the information collected from the AMRI to decide what area of the brain tumor will be biopsied."
2870145|NCT03458663|Experimental|Prevena|Patients randomized to application of Prevena ™ and ACTIV.A.C ™ Therapy System 4-7 days post-operatively. Patients will return to the surgical day clinic to have the system removed either at day 7 or when/ if function ceases. Patients receive 3 days oral antibiotics postoperatively (Ciproxin 250 mg x 2 and Metronidazole 500 mg x 3). Sutures are removed at clinical control after 14 days and patients are seen again by BCL surgeon after 3 months and are discharged when completely healeddrainage and conventional wound dressing
2870146|NCT03458663|No Intervention|Conentional postoperative care|patients randomized to convetional postoperative regime with a penrose drain (passive) and a dry draping for 24 hours and after usage of sanitary pads. Patients receive 3 days oral antibiotics postoperatively (Ciproxin 250 mg x 2 and Metronidazole 500 mg x 3). Drain is removed after 24 hours and Sutures are removed at clinical control after 14 days and patients are seen again by BCL surgeon after 3 months and are discharged when completely healeddrainage and conventional wound dressing.
2870147|NCT03458650|Experimental|LXI-15028 50 mg|For 50 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo
2870148|NCT03458650|Experimental|LXI-15028 100 mg|100 mg dose group plans to enroll 14 healthy subjects (investigational drug:placebo=10:4), half males and half females. Five subjects of each gender will receive LXI-15028, while 2 subjects of each gender will receive placebo. Intra-group randomization will be implemented in each dose group; each subject will receive either LXI-15028 or placebo.
2870149|NCT03458650|Experimental|LXI-15028 200 mg|200 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo
2870150|NCT03458637|Experimental|LITE Program with usual care.|LITE Program with usual care. LITE program involves four x 180 min weekly sessions, followed by three x 90 min monthly sessions, for adolescents and parents. The key aspects covered in the LITE program are in keeping with Health Promotion Board guidelines for the management of overweight and obesity and include healthy food choices and eating patterns, increasing physical activity and reducing sedentary behavior. The parenting aspects aim to support and increase parental capacity to implement and maintain the lifestyle changes.
2870151|NCT03458637|Active Comparator|Usual Care|Usual care consisting of Weight management clinic consultation at baseline randomization, 3 and 6 months post randomization in a tertiary setting in KK Hospital. Duration of treatment is 6 months. Qualified pediatrician, trained in screening for causes and medical complications of obesity in children, runs the weight management clinic and review the participant at each visit. Optional physical activity, dietary consultation at each weight management clinic visit.
2870152|NCT03458624||Not applicable-observational study|Not applicable-observational study
2870153|NCT03458611|Experimental|Group A|In period 1 group A will receive the active intervention and in period 2 they will receive the placebo intervention.
2870154|NCT03458611|Experimental|Group B|In period 1 group B will receive the placebo intervention and in period 2 they will receive the active intervention.
2870155|NCT03458598|Experimental|Single shot rectus sheath block|The treatment group will have pre-operative ultrasound-guided single shot bilateral rectus sheath blocks with 20 ml of a ropivacaine / bupivacaine mixture per side.
2870156|NCT03458598|Sham Comparator|Placebo Control|The control group will have a pre-operative sham ultrasound-guided subcutaneous injection of 1ml saline per side.
2870157|NCT03458585||Group 1: patients attending for a 99mTc-MDP bone scan.|Group 1: Patients will be approached after they had their injection for the bone scan procedure. Completion of questionnaire will take place during the three hour uptake period, before they have the scan.
2870158|NCT03458585||Group 2: patients attending for a 18F- FDG PET/CT scan.|Group 2: Patients will be approached and consented after they had their injection and scan for 18F- FDG PET/CT. Completion of questionnaire will take place immediately after patients have changed and wait to leave the department, while they wait for their scan to be checked .
2870159|NCT03458572|Experimental|Intervention|1.5mm Seirin Pyonex needle at LI11 point
2870160|NCT03458572|Sham Comparator|Control|0.3mm Seirin Pyonex needle at TB10 point
2870161|NCT03458559|Active Comparator|Radium-223-chloride|Radium-223-chloride 50kBg/kg, every 4 weeks intravenously, for a total of 6 administrations.
2870162|NCT03458559|Experimental|Rhenium-188-HEDP|Rhenium-188-HEDP 40MBq/kg, every 8 weeks intravenously, for a total of 3 administrations.
2870163|NCT03458546|Experimental|Roflumilast and R-CHOP|
2870164|NCT03458533||Group 1|Obese patients with indication to bariatric surgery
2870165|NCT03458533||Group 2|Overweight or obese patients without indication to bariatric surgery, able to obtain weight loss trough diet and lifestyle changes
2870166|NCT03458533||Group 3|Overweight or obese patients without indication to bariatric surgery, not able to obtain weight loss trough diet and lifestyle changes
2870167|NCT03458520||Image Registry|patients with proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor will receive MR imaging, PET/MR imaging (and if available, PET/CT imaging)
2870168|NCT03458507|Active Comparator|Usual interface|"Patients which begin with their usual interface for one week, home polygraphy and side effect assessment at the end of the first week.~Switch for alternative interface, seven days familiarisation, second polygraphy and side effect assessment at the end of the second week."
2870169|NCT03458507|Active Comparator|Alternative interface|"Patients which begin with the alternative interface for one week, home polygraphy and side effect assessment at the end of the first week.~Switch for usual interface, seven days with usual device, second polygraphy and side effect assessment at the end of the second week."
2870170|NCT03458494|Experimental|Mediterranean Diet|during one week participants will receive food products common in the diet of Mediterranean populations
2870171|NCT03458494|Experimental|Low-fat diet|during one week participants will receive food products low in fat content
2870172|NCT03458481|Experimental|SOF+DAG181 100 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 100 mg for 12 weeks.
2870173|NCT03458481|Experimental|SOF+DAG181 200 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 200 mg for 12 weeks.
2870174|NCT03458468|Experimental|Group A|Tranexamic Acid 1g IV
2870175|NCT03458468|Placebo Comparator|Group B|Saline injection
2870176|NCT03458455||A|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions
2870177|NCT03458455||B|Patients with brain metastases from malignant melanoma receiving stereotactic radiosurgery to selected lesions
2870178|NCT03458455||C|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions + nivolumab or pembrolizumab
2870179|NCT03458455||D|Patients with brain metastases from malignant melanoma receiving stereotactic radiosurgery to selected lesions + ipilimumab, nivolumab or pembrolizumab
2870180|NCT03458455||E|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions + epidermal growth factor receptor (EGFR) inhibitors
2870181|NCT03458442|Experimental|Intervention Arm|Standard surgical training + simulation-based surgical training
2870182|NCT03458442|Active Comparator|Control Arm|Standard surgical training
2870183|NCT03458429|Experimental|Frail, older subjects|Treated subjects are the frail, older subjects who will be treated with Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma (GMFFP) in this protocol.
2870213|NCT03458182|No Intervention|No intervention|No added exercise period (normal exercise test).
2870186|NCT03458390|Experimental|HyGIeaCare and PillCam COLON|Patient will receive the HyGIeaCare colon irrigation prior to their PillCam COLON procedure
2870187|NCT03458377|Experimental|Telephone call group|The patient receives the colonoscopy information from the primary care center on the day of the request for the test and a 20 minute educational telephone call 7 days before de procedure.
2870188|NCT03458377|No Intervention|Non-telephone call group|The patient only receives the colonoscopy information from the primary care center on the day of the request for the test.
2870189|NCT03458364|Experimental|High flow nasal cannula|High flow nasal cannula (HFNC) is a type of oxygen device, which provides high concentration oxygen in a high flow, which exceeds patient's inspiratory flow demand, to improve oxygenation.
2870190|NCT03458364|Active Comparator|Noninvasive ventilation|Non-invasive ventilation (NIV) refers to the provision of ventilatory support through the patient's upper airway using a mask. This technique is distinguished from those which bypass the upper airway with a tracheal tube, laryngeal mask, or tracheostomy and are therefore considered invasive.
2870191|NCT03458351|Active Comparator|Remote ischemic preconditioning|"Remote ischemic conditioning after anesthesia induction~- four cycles of 5 min of ischemia followed by 5 min of reperfusion by inflation to 200 mm Hg and deflation of a blood pressure cuff on the upper arm"
2870192|NCT03458351|Sham Comparator|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10mm Hg.
2870193|NCT03458325|Experimental|Furoscix Infusor Prospective Treatment|Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor outside the hospital.
2870194|NCT03458325|No Intervention|Propensity-Matched Historical Control|The control arm will be populated with claims data for patients with HF and fluid overload who presented to the emergency department and were admitted to the hospital for ≤ 72 hours for the treatment of HF with intravenous diuretics. Patients admitted for diuresis-only will be identified by using diagnostic codes for admittance from a claims database.
2870195|NCT03458312|No Intervention|Family and Network support measurements|"The perceived 'Family support' and 'Caregiver burden' (FNC) will be measured among 30 families.~Test time points:~Post 1. FNC (week 1-2), post FNC 2 (week 8-10) and post FNC 3 (week 28-30) and post the 4. FNC (week 50-52)"
2870196|NCT03458312|Experimental|Family and network consultations|Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns.
2870197|NCT03458299|Experimental|Motivational Interviewing|The MI intervention will incorporate open-ended questions, personalized feedback, and discussion about participants' alcohol use and drug, associated risk behaviors (e.g., drinking and driving), and the consequences of these behaviors. Individual MI procedures will incorporate the core principles of MI described by Miller and Rollnick, including expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. Therapist interventions will be tailored to the participants' readiness to change/current stage of change (pre-contemplation, contemplation, preparation, action, maintenance, and relapse).
2870198|NCT03458299|Experimental|Psychoeducation|Four weekly one hour sessions of therapist assisted educational DVD about adolescent alcohol use, drug use, and driving under the influence provided by Human Relations Media, Mount Kisco, NY (hrmvideo.com).
2870199|NCT03458286|No Intervention|Control group|The control group will be required to attend the diabetic foot clinic for their usual care for their diabetic foot ulcer with weekly review for a maximum of eight weeks. They will also have a follow up appointment 4 weeks after completion of treatment.
2870200|NCT03458286|Experimental|Experimental Arm|A device- BRH-A2 wound healing device will provide Combined ultrasound and electric current stimulation (CUSECS) treatment which is the intervention for this arm. Participants in this group will receive an adjunctive combined ultrasound and electric current stimulation (CUSECS) treatment along their usual treatment for their diabetic ulcer twice weekly for 8 weeks using the BRH-A2 wound healing device. They will also have a follow up appointment 4 weeks after completion of treatment.
2870201|NCT03458273||Zero fluoro|Patients in whom Zero fluoroscopy ablation was performed under the guidance of Ensite for mapping and ablation and fluoroscopy will not be used during the procedure.
2870202|NCT03458273||Conventional ablation without 3D|"Patients in whom Conventional fluoroscopy ablation was performed under fluoroscopic guidance only.~Additional use of Ensite/Carto/Localisa for mapping was not allowed."
2870203|NCT03458273||Conventional ablation with 3D|"Patients in whom Conventional fluoroscopy ablation was performed under fluoroscopic and Ensite/Carto guidance and ablation during the procedure.~Use of fluoroscopy and additional Ensite/Carto for mapping and ablation was mandatory."
2870204|NCT03458260|Experimental|Experimental|Pixantrone plus rituximab, ifosfamide and etoposide.
2870205|NCT03458247|Active Comparator|Abiraterone acetate standard dose|1000 mg/day
2870206|NCT03458247|Experimental|Abiraterone acetate escalated dose|2000 mg/day
2870207|NCT03458234|Experimental|Focal SBRT with intra-urethral radiotransponder|This study will enroll patients that have a confirmed histology of prostate cancer. They will undergo a 3T MRI scan as well as a CT simulation with 16 French Foley Catheter containing dummy beacons for treatment planning purposes. The patient will then receive focal stereotactic body radiotherapy (SBRT) at a dose of 40 gy in 5 total fractions. Patients will be followed for 24 total months with specific follow-ups at 3, 6, 9, 12, 18, and 24 months.
2870208|NCT03458221|Experimental|itraconazole / tamoxifen|In case of HedgeHog pathway positivity itraconazole will be administered in case of ER pathway positivity tamoxifen will be adminisered
2870209|NCT03458208|Experimental|Metformin|"First aIntervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition~Third Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
2870210|NCT03458208|Active Comparator|Glucophage®|"Second Intervention Period:~Single administered dose of Glucophage® ( 1 000 mg tablet immediate release) in a fasting condition~Fourth Intervention Period:~Single administered dose of Glucophage® ( 1 000 mg tablet immediate release) in a fed condition"
2870211|NCT03458195|Experimental|Crohn's disease patients|Patients aged 18 or more, for whom Crohn's disease diagnosis is confirmed and ileum or ileocecal Crohn's disease require surgical resection. in addition to usual practice, a bio-banking (blood samples, biopsies and surgical specimens) is collected.
2870212|NCT03458182|Experimental|Added exercise|After completion of the standard exercise test, an intervention period of 2 minutes of low intensity exercise is added.
2870214|NCT03458169|Experimental|LEAP usability|"Therapist LEAP session feedback~Participant LEAP session feedback~LEAP risk control validation"
2870215|NCT03458156|Experimental|SLE group|The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.
2870216|NCT03458156|Experimental|LN group|The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.
2870217|NCT03458156|Experimental|the control group|The patients will be assigned to the control group.
2870218|NCT03458143||ketamine 150 ng/ml|The first group will receive the classical premedication with 2 mg of Midazolam. A bolus dose of Ketamine will be given, then to be titrated in TCI mode with a target concentration of 150 ng/ml. Right after, the Remifentanil TCI will be started at a concentration of 1 ng/ml and the procedure can begin.
2870219|NCT03458143||ketamine 200 ng/ml|The second group will be treated in the exact way as the first, with the exception that the target effect site concentration is aimed at 200 ng/ml.
2870220|NCT03458130|Active Comparator|AG10 Low Dose|Low dose group
2870221|NCT03458130|Active Comparator|AG10 High Dose|High dose group
2870222|NCT03458130|Placebo Comparator|Placebo|
2870223|NCT03458117|Experimental|Talimogene Laherparepvec (T-VEC)|Intralesional injections of T-VEC up to 4.0 mL of 10 to the 6 plaque-forming Units/mL (PFU/mL)
2870224|NCT03458104|Experimental|Vocal Cord Atrophy|Quantify changes in aerodynamic and aeroacoustics patterns in patients with vocal cord atrophy (VCA) before and after voice therapy. To evaluate changes, subjects will have Laryngovideostroboscopy, Acoustic/Auerodynamic testing, and Cone Beam CT scans of the larynx before and after voice therapy.
2870225|NCT03458104|Active Comparator|Healthy Volunteer|Develop a validated computational model for assessing normative laryngeal aerodynamic and aeroacoustic patterns in healthy elderly individuals. To assess normal laryngeal aerodynamic and aeroacoustic patterns in this cohort, subjects will subjects will have Laryngovideostroboscopy, Acoustic/Auerodynamic testing, and Cone Beam CT scans of the larynx.
2870226|NCT03458091|Active Comparator|Intubation|The patients will be intubated and ventilated
2870227|NCT03458091|Experimental|THRIVE|The patients will be oxygenated during apnea using THRIVE
2870228|NCT03458078|Placebo Comparator|Group C|Control group
2870229|NCT03458078|Active Comparator|Group Mg|Magnesium sulfate group
2870230|NCT03458078|Active Comparator|Group MDZ|Midazolam group
2870231|NCT03458065||S-ICD|
2870232|NCT03458065||T-ICD|
2870233|NCT03458039|Active Comparator|Live TTT|This is the standard of care train-the-trainer approach for experienced counselors
2870234|NCT03458039|Experimental|Technology TTT|This is an experimental technology-based train-the-trainer approach for experienced counselors
2870235|NCT03458026|Experimental|connected object + SMS of physical activity reminders|"The patients will be included during their visit of follow-up and will receive a watch connected. They will have an information meeting for their to explain how step shows it. They will also receive advice to practise an adapted physical activity. During 12 weeks of SMS (text messages) every week to motivate them to realize these exercises.~At the end of 12 weeks the connected watch will be deprived of them as well as SMS (text messages). They will have to realize an activity in autonomy during 12 weeks.~At the end of the twenty-fourth week, they will get back their watch. They will have in more 1 session with a coach and 2 sessions to be made in autonomy during 12 weeks.~In 36 week, they return the watch and finish the study."
2870236|NCT03458026|Other|Without connected object|"The patients will be included during their visit of follow-up.They will have an information to practice suitable activity during 12 weeks At the end of 12 weeks, they realised follow-up. They will have to realize an activity in autonomy during 12 weeks.~At the end of the twenty-fourth week, they will have 1 session with a coach and 2 sessions to be made in autonomy during 12 weeks.~In 36 week, the study will be finished."
2870237|NCT03458013|Experimental|Mindfulness Meditation plus Hand Therapy|Participants will be recruited from patients suffering from a traumatic injury who are entering hand therapy at a community based clinic in the Los Angeles area.
2870238|NCT03458013|No Intervention|Standard Care in Hand Therapy|Participants will be recruited from patients suffering from a traumatic injury who are entering hand therapy at a community based clinic in the Los Angeles area.
2870239|NCT03458000|Active Comparator|Active Control|Video Capsule Endoscopy will be administered during ED, but video will not be read until after inpatient EGD. Subject will have hospital admission with an EGD conducted during hospital stay.
2870240|NCT03458000|Experimental|Experimental|Subject will have Video Capsule Endoscopy read during ED length of stay, disposition will be determined using Capsule Endoscopy Risk Assessment.
2870241|NCT03457974|Experimental|congenital heart disease|42 patients
2870242|NCT03457974|Other|helathy children|42 children
2870243|NCT03457961||Adjunctive Perampanel|A group of patients who aged 12 years or above and have a diagnosis of epilepsy with simple partial seizure and/or complex partial seizures
2870244|NCT03457948|Experimental|Group I [pembrolizumab, CT-guided RFA]|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. Patients with up to 6 liver lesions, largest being no larger than 4 cm who have < 25% liver parenchyma replacement by tumors, undergo CT-guided Radiofrequency Ablation (RFA) over 2-3 hours, 3-7 days following the first dose of pembrolizumab.
2870245|NCT03457948|Experimental|Group II [pembrolizumab, TAE]|Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest being no larger than 5 cm, who have < 75% liver parenchyma replacement by tumors, undergo Arterial Embolization (TAE) over 2-3 hours, 3-7 days following the first dose of pembrolizumab.
2870246|NCT03457948|Experimental|Group III [pembrolizumab, yttrium-90 microsphere RE]|Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest measuring more than 5 cm, who have < 75% liver parenchyma replacement by tumors, undergo yttrium-90 microsphere Radio Embolization (RE) 3-15 days following the first dose of pembrolizumab.
2870247|NCT03457948|Experimental|Group IV [pembrolizumab, CT-guided cryoablation]|Patients receive pembrolizumab as in Group I. Patients with up to 6 liver lesions, largest being no larger than 4 cm who have < 25% liver parenchyma replacement by tumors, undergo CT-guided cryoablation over 2-3 hours, 3-7 days following the first dose of pembrolizumab.
2870248|NCT03457935||Control|No lung diseases
2870251|NCT03457922||Group Therapy|Patients in the Stanford Department of Psychiatry and Behavioral Sciences who are enrolling in a trans-diagnostic anxiety therapy group will be invited to participate in research on group processes and outcomes.
2870252|NCT03457909|Experimental|DS-MCE|outpatients who have esophagus symptoms will take conventional endoscopy examination and DS-MCE examination successively.
2870253|NCT03457896|Experimental|Arm 1|"Guardant360 test on blood from select patients with known HER2 status.~Prior to assignment to Arm 1, HER2 test on blood obtained from Quadruple Wild-Type patients who received anti-EGFR therapy. Patients with HER2 amplified, HER2 Wild-Type or HER2 mutated will recieve:~• Neratinib daily + Trastuzumab weekly until disease progression"
2870254|NCT03457896|Experimental|Arm 2|"Patients with HER2 Wild Type or HER2 amplified with no prior anti-EGFR therapy will receive:~• Neratinib daily + Cetuximab weekly until disease progression"
2870255|NCT03457883|Experimental|group A|accepted herniamesh mesh
2870256|NCT03457883|Experimental|group B|accepted biological graft of cook
2870257|NCT03457870|Experimental|Intermittent Energy Restriction|Dietary intervention: Intermittent energy restriction
2870258|NCT03457870|Experimental|Chewing|Mastication intervention: chewing
2870259|NCT03457870|Experimental|Chewing + Intermittent Energy Restriction|Dietary and mastication intervention: Intermittent energy restriction and chewing
2870260|NCT03457870|No Intervention|Control|No intervention: Control
2870261|NCT03457857|Other|Group 1 - Cleanser|Regimen with Baby Cleanser Only
2870262|NCT03457857|Other|Group 2 - Cleanser and Lotion|Regimen containing Baby Cleanser/Shampoo and Baby Lotion
2870263|NCT03457844|Experimental|Anlotinib|
2870264|NCT03457831||Status Epilepticus|Convulsive and Non-Convulsive Status Epilepticus ; and Pseudo Status Epilepticus
2870265|NCT03457818|Experimental|Treatment Group|Denosumab 60 mg/ml [Prolia] SC at baseline and 6 months.
2870266|NCT03457818|Placebo Comparator|Control Group|Placebo SC at Baseline and 6 months.
2870267|NCT03457805|Other|Prostatic Artery Embolization (PAE)|PAE performed under local anesthesia using officially approved microspheres.
2870268|NCT03457792||Abatacept for Rheumatoid Arthritis (RA)|Participants diagnosed with moderate to severe active RA within the last 24 months and initiated treatment with Abatacept
2870269|NCT03457779|Experimental|Non Glucose Arm|4 patients without glucose infusion
2870270|NCT03457779|Experimental|Glucose Arm|12 Patients with glucose infusion
2870271|NCT03457766|Experimental|Patients with skin lesions|Using HIFU in identification of safety margins of lesions clinically apparent locally malignant, or malignant
2870272|NCT03457753|Experimental|Subjects with ALS|Riluzole Oral Soluble Film (ROSF) 50 mg will be administered in subjects with ALS twice daily. It is intended that at least five (5) of the twenty-five (25) subjects enrolled will be subjects scoring greater than 20 on the Eating Assessment Tool (EAT-10) (representative of ALS patients reporting moderate swallowing impairments in a patient report validated scale).
2870273|NCT03457740|Experimental|Formula 1|Formula 1 with nutrients and herbs, 4 capsules daily, 6 weeks
2870274|NCT03457740|Experimental|Formula 2|Formula 2 with nutrients and herbs, 4 capsules daily, 6 weeks
2870275|NCT03457740|Placebo Comparator|Placebo|Placebo, 4 capsules daily, 6 weeks
2870276|NCT03457727|Experimental|Subjects receiving danirixin: Part A|Subjects will receive a single oral dose of 50 mg danirixin reference and test formulations with food and 240 mL of water in a cross-over manner.
2870277|NCT03457727|Experimental|Subjects receiving danirixin without omeprazole: Part B|Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) in fasted or fed state in a cross-over manner.
2870278|NCT03457727|Experimental|Subjects receiving danirixin with omeprazole: Part B|Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) along with once daily 40 mg OMP capsule in fasted or fed state in a cross-over manner.
2870279|NCT03457714||Guided I-CBT for persons with SCI|Persons with spinal cord injury
2870280|NCT03457714||Caregiver Burden|Caregivers of persons with spinal cord injury
2870281|NCT03457701|Experimental|rhEPO+57Fe followed by Daprodustat+58Fe|Subjects will be randomly assigned to remain on their current therapy (either epoetin alfa or darbepoetin alfa) in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, subjects will be administered ferrous sulfate containing a stable isotope of iron (57Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 28 subjects will be crossed over to receive Daprodustat in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, subjects will again be administered ferrous sulfate containing the stable iron isotope (58Fe) orally. Subjects will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: Histamine [H2] receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
2870282|NCT03457701|Experimental|rhEPO+58Fe followed by Daprodustat+57Fe|Subjects will be randomly assigned to remain on their current therapy (either epoetin alfa or darbepoetin alfa) in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, subjects will be administered ferrous sulfate containing a stable isotope of iron (58Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 28 subjects will be crossed over to receive Daprodustat in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, subjects will again be administered ferrous sulfate containing the stable iron isotope (57Fe) orally. Subjects will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
2870283|NCT03457701|Experimental|Daprodustat+57Fe followed by rhEPO+58Fe|Subjects will be randomly assigned to receive Daprodustat in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, subjects will be administered ferrous sulfate containing a stable isotope of iron (57Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 28 subjects will be crossed over to receive rhEPO (either epoetin alfa or darbepoetin alfa) in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, subjects will again be administered ferrous sulfate containing the stable iron isotope (58Fe) orally. Subjects will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
2870284|NCT03457701|Experimental|Daprodustat+58Fe followed by rhEPO+57Fe|Subjects will be randomly assigned to receive Daprodustat in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, subjects will be administered ferrous sulfate containing a stable isotope of iron (58Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 28 subjects will be crossed over to receive rhEPO (either epoetin alfa or darbepoetin alfa) in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, subjects will again be administered ferrous sulfate containing the stable iron isotope (57Fe) orally. Subjects will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
2870285|NCT03457688|Active Comparator|prebiotic inulin-type fructans|
2870286|NCT03457688|Placebo Comparator|placebo maltodextrin|
2870287|NCT03457675|Experimental|Activa PC+S DBS implant for OCD|all subjects will receive surgical implantation of DBS system
2870288|NCT03457675|Experimental|One Month Blinded Discontinuation Period|all subjects will enter a one-month blinded discontinuation period to confirm clinical benefit at the end of Month 8.
2870289|NCT03457662|Active Comparator|OMC and pseudo-SDT|Optimal medical care (OMC) and pseudo-SDT are administrated in this arm. OMC is established according to the standards established by the 2016 ACC-AHA Guidelines for the Management of Patients with Peripheral Artery Disease in order to promote best practices for risk factor management.
2870290|NCT03457662|Experimental|OMC and SDT|OMC and SDT are administrated in this arm.
2870291|NCT03457649|Active Comparator|ARGX-113|SAD and MAD with test product at different increasing doses
2870292|NCT03457649|Placebo Comparator|Placebo|SAD and MAD with placebo at different increasing doses
2870293|NCT03457636|Experimental|doxycycline anhydrous 40 mg once daily and adapalene/benzoyl p|All subjects will receive at Baseline doxycycline anhydrous 40 mg and Adapalene-Benzoyl Peroxide Gel .3-2.5% (Epiduo) to be applied once daily
2870294|NCT03457623|Experimental|Innovative supported|In addition to usual care, patients benefit from connected tools (overpoise, sphygmomanometer...), physical activity, a strong accompaniment with a referent person
2870295|NCT03457623|No Intervention|conventional supported|Patients benefit from usual care
2870296|NCT03457610|Experimental|Speech and language intervention|
2870297|NCT03457597|Experimental|Period 1|Period 1 (Study Days 1 to 4): Midazolam hydrochloride and metoprolol tartrate will be given once on Day 1. Pioglitazone hydrochloride, tolbutamide and omeprazole will be given once on Day 2
2870298|NCT03457597|Experimental|Period 2|Period 2 (Study Days 5 to 13): Relacorilant will be given daily from Day 5 to Day 13.
2870299|NCT03457597|Experimental|Period 3|Period 3 (Study Days 14 to 17): Midazolam hydrochloride and metoprolol tartrate will be given once on Day 14. Pioglitazone hydrochloride, tolbutamide and omeprazole will be given once on Day 15. Relacorilant will be given daily from Day 14 to Day 17.
2870300|NCT03457584|Active Comparator|BSS arm|BSS is given at the end of surgery
2870301|NCT03457584|Experimental|air arm|air-tamponade is given at the end of surgery
2870302|NCT03457545|Experimental|Intervention|Eligible participants will take part in the home-based pulmonary rehabilitation using the Aidcube platform in-person assessment and training with a research coordinator (i.e. physical exercise capacity assessment, SPPB, disability survey, exercise prescription determination, exercise training, dyspnea control techniques) and complete an follow-up assessment at the 8th week.
2870303|NCT03457545|No Intervention|No Intervention|Ineligible participants will receive standard of care
2870304|NCT03457532|Experimental|Dose escalation study of Glumetinib|To determine the maximum tolerated dose (MTD) of Glumetinib
2870305|NCT03457519|Active Comparator|Intervention Group A|"CHWs trained in ChARM and using ChARM as a self-monitoring tool for 8 months while counting respiratory rate of children under 5 visually using a timer.~Intervention: The Children's Respiration Monitor (also known as ChARM) device is routinely used to diagnose Pneumonia cases but in this study it will be used as a self-monitoring and teaching aide for strengthening CHWs skills."
2870306|NCT03457519|Active Comparator|Intervention Group B|"CHWs trained in ChARM and using ChARM as a self-monitoring tool for 4 months while counting respiratory rate of children under 5 visually using a time; then discontinue using ChARM and continue to monitor the respiratory rate visually using a timer only for the remaining 4 months.~Intervention: The Children's Respiration Monitor (also known as ChARM) device is routinely used to diagnose Pneumonia cases but in this study it will be used as a self-monitoring and teaching aide for strengthening CHWs skills."
2870307|NCT03457519|No Intervention|Control Group C|CHWs who did not receive the ChARM training and will be monitoring the respiratory rate of children under 5 visually using a timer only, as per the MoH traditional training.
2870308|NCT03457506|Other|Patients undergo a digital PET/CT|Single arm prospective study of paired PET scans. Patients who are referred to the nuclear medicine department to undergo a PET scan, will undergo a PET/CT scan on the conventional scanner as well as the digital PET/CT scanner.
2870309|NCT03457493|Experimental|Healthy Controls, DPA-714-PET/MRI|
2870310|NCT03457493|Experimental|Early Parkinson's Disease, DPA-714-PET/MRI|
2870311|NCT03457480|Experimental|Focus Group|Participants take part in a focus group about opinions about different tobacco products. Brief questionnaires answered related to these products, demographic background, health literacy, and questions about the text messages themselves.
2870312|NCT03457480|Experimental|Health Communication Student Review|"Participants review of a series of text messages about tobacco products. Questionnaires completed about demographics (age, race, sex, and so on), health literacy, and questions about the text messages themselves.~Participants review a series of text messages. The text messages contain information about both conventional and new and emerging tobacco products. Participants asked 3 questions about each text message."
2870337|NCT03457298|Experimental|Ossix Volumax|lateral bone augmentation using volume maintaining collagen scaffold (Ossix Volumax)
2870338|NCT03457298|Active Comparator|FDBA with collagen membrane|lateral bone augmentation using the current gold standard FDBA plus resorbable collagen membrane
2870339|NCT03457285|Experimental|Physiotherapy via the Salaso Apllication Intervention|"All participants' physiotherapy- prescribed exercise programmes will be monitored via the Salaso application. Telehealth appointments will occur monthly and modifications to exercises will be made as required.~This will continue for the 6-month duration of the intervention."
2870313|NCT03457480|Experimental|Youth Perceptions of Tobacco|"Participants answer questions on smartphone using a link the study team sends.~Participants receive 2 text messages a day for 30 days. The text messages are related to tobacco products and tobacco use. There are 8 different type of messages. While receiving the text messages, participants receive a link to a short survey at the end of each week.~7 days and 3 months after the 30-day text messaging period, participant asked to answer more questions on smartphone using a link the study team sends.~After the 3-month post-test, participants again receive 2 text messages a day for 30 days. Text messages related to tobacco products and tobacco use. There are 8 different type of messages.~7 days and 3 months after the second 30-day text messaging period, participants asked to answer more questions on smartphone using a link the study team sends."
2870314|NCT03457480|Experimental|Text Messages with Pictures|"Survey completed at visit 1 and 3.~Participants will read a series of 64 messages for up to 30 minutes. These images will have pictures."
2870315|NCT03457480|Experimental|Text Messages without Pictures|"Survey completed at visit 1 and 3.~Participants will read a series of 64 messages for up to 30 minutes. These images will NOT have pictures."
2870316|NCT03457467|Experimental|SBRT+apatinib group|Apatinib mesylate tablets: 500mg / day, 28 days / cycle, follow-up to the progress of the disease, toxicity intolerable or patients require withdrawal; SBRT: according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment.
2870317|NCT03457454|Experimental|Participant Level Education|-Participants receive low-literacy educational and instructional brochures at the time of fecal occult blood test (FOBT) referral. Participants with a positive FOBT receive a second low-literacy brochure on bowel preparation for colonoscopy and the importance of follow-up, and assist with scheduling and completing colonoscopy
2870318|NCT03457441|Other|Near visual acuity +1.0 and +0.7 logMAR|Subjects with near visual acuity between +1.0 and +0.7 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
2870319|NCT03457441|Other|Near visual acuity +0.6 and +0.3 logMAR|Subjects with near visual acuity between +0.6 and +0.3 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
2870320|NCT03457441|Other|Near visual acuity +0.2 and +0.0 logMAR|Subjects with near visual acuity between +0.2 and +0.0 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
2870321|NCT03457415||Healthy Cohort|Healthy Cohort: current non-smoker who has smoked less than 5 pack-years in his or her lifetime, and if smoked, quit more than 15 years ago, and has no known lung disease.
2870322|NCT03457415||High-risk Cohort|High-risk Cohort: individual aged ≥55-74 who is a current smoker with a smoking history of at least 30 pack-years or current non-smoker who has a smoking history of at least 30 pack-years and quit smoking within the past 15 years.
2870323|NCT03457415||Cancer Cohort|Cancer Cohort: individual who has been diagnosed by a physician as highly suspect for having lung cancer, but has not yet undergone a biopsy nor received therapy, and after providing a sputum sample is confirmed to have lung cancer by biopsy.
2870324|NCT03457402|Experimental|Treatment|Participants in the Experimental arm will begin the Shaping Delay Tolerance behavioral intervention immediately after baseline, and this training will last for about 6 weeks.
2870325|NCT03457402|Active Comparator|Wait-list Control|After baseline, participants in the Wait-list Control arm will wait for about 6-weeks before entering the pre-treatment phase, which is a repeat of effortful control assessments and behavior questionnaires, and then they will begin training for with the Shaping Delay Tolerance behavioral intervention.
2870326|NCT03457389|Experimental|Experimental group|Serum prolactin level is adjusted to less than 5 ng/mL during cabergoline administration.
2870327|NCT03457389|Active Comparator|Control group|Serum prolactin level is adjusted to normal range during cabergoline administration.
2870328|NCT03457363|Experimental|Double Trunk Mask|DTM will be add above nasal cannula
2870329|NCT03457363|Active Comparator|Nasal Cannula Alone|Patients receive oxygen only thought nasal Cannula
2870330|NCT03457350|Experimental|office hysteroscopy|Office hysteroscopy 30 degrees 2.6 mm telescope with an outer sheath of 3.2 mm (Storz Co., Tutlingen, Germany). Hysteroscopy is performed as usual by proper examination of the vagina and the ectocervix for any abnormality followed by introduction of the hysteroscope into the cervical canal. At this step, the hysteroscopist waits for a while until the distending fluid forms a micro-cavity. At this point, the telescope is advanced with necessary rotatory movements of the 30 degrees telescope guided by the vision of the dark spot which is the internal os. If it is reached, again waiting for some time to allow fluid distension of the internal os area.
2870331|NCT03457350|Experimental|blind cervical probing|Cervical probing is started with a 2 mm probe after grasping the cervix with a multi-tooth tenaculum put anteriorly or posteriorly according to prior transabdominal or transvaginal sonographic examination of the cervical canal. If the probe succeedes to bypass the internal os, a higher caliber probe is used. Thereafter, a uterine sound (4mm = 1.33 Fr) is introduced into the endometrial cavity. Lastly, gentle cervical dilatation up to Hegar's 8 is performed as usual with classic leaving each dilator for 30 seconds inside the internal os. If probes couldn't bypass the internal os, the procedure is considered failed. If the probe enters a cavity other than endometrial cavity, a false passage is considered.
2870332|NCT03457337|Experimental|S-1 plus Gefitinib|"S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally, continuous administration of 14 days, rest for 7 days. BSA <1.25 m2, 80 mg / day; BSA 1.25 m2 to <1.5 m2, 100 mg / day; BSA 1.5 m2 or more, 120 mg / day. Until disease progression, intolerance of toxicity or withdrawal of informed consent from the subject.~Gefitinib: 250mg, 1 day, orally, fasting or with the same service. Until disease progression, intolerance of toxicity or withdrawal of informed consent from the subject."
2870333|NCT03457337|Active Comparator|Gefitinib|Gefitinib 250 mg/day oral daily
2870334|NCT03457324|Experimental|JCM-16021 Group|JCM-16021 granules 8g/sachet, three times daily for 8 weeks.
2870335|NCT03457324|Placebo Comparator|Placebo Group|Placebo granules 8g/sachet, three times daily for 8 weeks
2870336|NCT03457311|Other|OGSP measurement|For the OGSP measurement, subjects will be orally administered with 1.25 ml/kg G.S.P. oral solution (400 mg/ml of galactose). At least 20 ml water will be given to subjects after drinking G.S.P. oral solution within 3 to 5 minutes. Sixty minutes after oral G.S.P. solution, a sample of 0.5 ml of whole blood will be taken from subject's finger for the determination of OGSP value.
2870342|NCT03457259|Active Comparator|Midline|Pt. will receive midline catheters. The outcomes will be registered and some patients will be examined once weekly for thrombosis with ultrasound.
2870343|NCT03457259|Active Comparator|Conventional|Pt. will receive the conventional treatment (PVC and/or PICCline/CVC). The outcomes will be registered.
2870344|NCT03457246|Experimental|D-Pigment rich texture|Hand with 5 to 10 lentigos (graded 6 or more on the severity grading scale) treated by test product ( D-pigment rich texture).
2870345|NCT03457246|Placebo Comparator|Hydrance optimale riche|Hand with 5 to 10 lentigos (graded 6 or more on the severity grading scale) treated by reference product (Hydrance optimale riche)
2870346|NCT03457233|Active Comparator|Normal weight|18.5- 24.9 kg/m2
2870347|NCT03457233|Active Comparator|Overweight|BMI 25-29.9 kg/m2
2870348|NCT03457233|Active Comparator|Obese|BMI ≥ 30 kg/m2
2870349|NCT03457207|Experimental|combined minilaparotomy- laparoscopy approach|women undergo the new technique of surgical treatment of endometriomas of the ovary
2870350|NCT03457194||Pregnant women|"150 participants (pregnant women at least 18 years of age and meeting eligibility criteria) will be enrolled and administered the FluQuadri, the quadrivalent influenza vaccine which will be administered by single-dose intramuscular injection.~Single-dose intramuscular injection of Adacel - DTP vaccine (multiple actives) will also be administered to all enrolled pregnant women who are at gestation 28 weeks or greater at the time of enrolment.~Where the vaccines are to be co-administered, FluQuadri will be administered into the dominant arm and Adacel into the non-dominant arm.~Pregnant women will be at a gestation of 20 weeks or greater at the time of enrolment. The vaccines administered are currently licensed and recommended in Australia to be given during pregnancy."
2870351|NCT03457181|Active Comparator|music group|in music group, patient was asked to choose one music genres from 5 different music genres according to his/her preference. Patient selected music was delivered by an iPhone 6 and Music app (Apple Inc., USA) through the iPhone's headphones.
2870352|NCT03457181|Active Comparator|operating room noise group|in operating room noise group, operating room noise was delivered by an iPhone and Microphone App (Free version, Von Bruno). This application allows the iPhone to be used as a live microphone.
2870353|NCT03457168|Active Comparator|Intensive asleep SBP control|To reduce the asleep SBP mean up to a target <110 mmHg. Treatment of elevated asleep SBP mean
2870354|NCT03457168|Active Comparator|Conventional asleep SBP control|To reduce the asleep SBP mean up to a target <120 mmHg. Treatment of elevated asleep SBP mean
2870355|NCT03457142|Experimental|Treatment (abatacept, ixazomib citrate, dexamethasone)|Patients receive abatacept IV over 30 minutes on day 1 of course 1, then SC on days 2, 8, 15, and 22 of course 1, and then on days 1, 8, 15, and 22 of subsequent courses. Patients also receive ixazomib citrate PO QD on days 1, 8, and 15 and dexamethasone on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2870356|NCT03457129|Active Comparator|Fycompa 2 week titration intervals|Perampanel oral tablet: 2mg by mouth every 24 hours for two weeks, then up-titrated by 2 mg every two weeks to a target dose of 6 mg/day. Minimum total daily dose = 2 mg/day. Maximum daily dose is 12 mg/day. Total daily dose will be determined by the Investigator based on tolerability and seizure control.
2870357|NCT03457129|Experimental|Fycompa 3 week titration intervals|Perampanel oral tablet: 2mg by mouth every 24 hours for three weeks, then up-titrated by 2 mg every three weeks to a target dose of 6 mg/day. Minimum total daily dose = 2 mg/day. Maximum daily dose is 12 mg/day. Total daily dose will be determined by the Investigator based on tolerability and seizure control.
2870358|NCT03457116|Active Comparator|Test Arm|400mg of Ibuprofen or
2870359|NCT03457116|Active Comparator|Control Arm|Norco( hydrocodone 5mg- acetaminophen 325mg)
2870360|NCT03457103|Experimental|CATCH Group|A portable capnometer (CapnoTrainer, Better Physiology, Cheyenne, WY) will be used in-session to provide continuous visual feedback of RR, ETCO2, rhythm, and depth of breathing, and ratio of inspirations to expiration. CATCH will be once weekly for 6 weeks, for a total of 6 sessions; each session will be approximately 60 minutes duration. The principal investigator will implement the CATCH intervention
2870361|NCT03457103|Active Comparator|Control Group|Pulmonary Rehabilitation (PR). Patients in both treatment groups will participate in a 10-week (16 - 20 sessions) comprehensive PR program.
2870362|NCT03457090|Experimental|Patient treated with ECMO|Patient treated with ECMO will have Examination : a TCD and Trans-Thoracic Echocardiography (TTE)
2870363|NCT03457077|Experimental|Brief Intervention|Participants will receive a brief intervention at week 0
2870364|NCT03457077|Other|Delayed Intervention|Participants will receive a brief intervention at 6 months
2870365|NCT03457064|No Intervention|Physical Activity (PA)|Physical activity (PA) involved a program of physical exercise alone.
2870366|NCT03457064|Active Comparator|PA+Social Adherence Intervention(PASAI)|PA+Social Adherence Intervention(PASAI) involved a program of physical exercise combined with a social adherence intervention.
2870367|NCT03457051|Active Comparator|Total Knee Arthroplasty (TKA)|In total (complete) knee arthroplasty (TKA), the orthopaedic surgeon removes the damaged areas of the knee and replaces the components with an artificial joint that is made of plastic or metal.
2870368|NCT03457051|Experimental|Unicompartmental Knee Arthroplasty (UKA)|Unicompartment (partial) knee arthroplasty (UKA) has been available for over 40 years and differs from TKA in that only the most affected and symptomatic compartment (most commonly medial, but occasionally lateral and patella femoral) are replaced
2870369|NCT03457038|Experimental|Patient with Septic Shock|Patient Hospitalized in Intensive Care Unit for sepsis of any etiology. The number of follow-up visits will not be changed compared to usual patient follow-up hospitalized in the intensive care unit but there will be blood testing more frequently
2870370|NCT03457025|Active Comparator|Standard of Care Therapy|Reference Therapy
2870371|NCT03457025|Experimental|Standard of Care + HOTB|Reference therapy in addition to Hyperbaric Oxygen Therapy
2870372|NCT03457012||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
2870373|NCT03456999|Active Comparator|MAU868|BKV-specific, pan-serotype neutralizing antibody
2870374|NCT03456999|Placebo Comparator|Placebo|Matching placebo
2891291|NCT03310476|Experimental|Boiled, consumed hot potatoes|
2870375|NCT03456986|Experimental|PATH neurotraining|Subject looks at computer screen to determine whether bars in fish-shaped window move left or right relative to background bars. The subject reports which way center pattern moves by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes contrast of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern more similar to that in fish, by increasing pattern's complexity level, and by increasing number of directions of movement from one to two directions of motion. Intervention will be trained for one training cycle, between 10-20 minutes, 3 times each week for 12 weeks.
2870376|NCT03456986|Active Comparator|Brain HQ Target Tracker|To do Target Tracker, the subject starts by seeing a few target and distractor objects on the screen. Subject's job: to keep track of the targets as all the objects move around the screen. When the objects stop moving, subject clicks on each target to identify it. As subject moves through the cognitive training exercise, it gets harder by: 1) objects travel more quickly, for longer amounts of time, and over larger areas, 2) contrast between the objects and background decreases, making it harder to track targets, 3) adds to number of objects being tracked if subject's successful and subtracts from the number if subject's struggling. Target Tracker limited to 20 minutes each time.
2870377|NCT03456973|Experimental|Nurse AMIE|
2870378|NCT03456960|Experimental|Pilot phase of Study 1,TAK-438ASA + TAK-438 and Aspirin|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a wash-out period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).
2870379|NCT03456960|Experimental|Pilot phase of Study 1,TAK-438 and Aspirin + TAK-438ASA|One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a wash-out period (Days 2 to 15), followed by, one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).
2870380|NCT03456960|Experimental|Pivotal phase of Study 1, TAK-438ASA + TAK-438 and Aspirin|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a wash-out period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).
2870381|NCT03456960|Experimental|Pivotal phase of Study 1, TAK-438 and Aspirin + TAK-438ASA|One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a wash-out period (Days 2 to 15), followed by, one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).
2870382|NCT03456960|Experimental|Study 2,TAK-438ASA (Fasted + Fed condition)|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 15), followed by one TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 2 in Study 2 (Day 16).
2870383|NCT03456960|Experimental|Study 2,TAK-438ASA (Fed + Fasted condition)|One TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in Study 2 (Day 16).
2870384|NCT03456947|No Intervention|control group|the patients receive routine preoperative preparation without having Pregabalin
2870385|NCT03456947|Experimental|Pregabalin150mg group|the patients receive 150mg pregabalin 60 minutes prior to the surgery
2870386|NCT03456947|Experimental|Pregabalin300mg group|the patients receive 300mg pregabalin 60 minutes prior to the surgery
2870387|NCT03456934|Experimental|Experimental Group|Modified infant formula given from 3 to 12 months of age, as per standard requirement.
2870388|NCT03456934|Active Comparator|Control Group|Standard infant formula given from 3 to 12 months of age, as per standard requirement.
2870389|NCT03456934|No Intervention|Breast-fed Reference Group|Non-randomized infants who are predominantly breast-fed at time of enrollment.
2870390|NCT03456921|Experimental|Game participants|"All participants will engage in playing the end-of-life conversation game called Hello, which involves answering open-ended questions about medical decision making and end-of-life issues."
2870391|NCT03456908|Experimental|myeloma before MV-NIS treatment|"Perform [18F]BF4-PET and [99mTc]pertechnetate-SPECT imaging in 10 patients with myeloma before MV-NIS treatment, and at Day 8-9 to monitor NIS activity in the tumors. To show the correlation of positive regional uptake with tissue histopathology for NIS, biopsies will be taken, when accessible, after the day 8 scan. Patients will be selected from subjects electing to participate in IRB 06-005263 at Mayo Clinic: Phase I/II Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma,"
2870392|NCT03456908|Experimental|endometrial cancer before VSV-hINF-NIS treatment|"Perform [18F]BF4-PET and [99mTc]pertechnetate-SPECT imaging in 10 patients with endometrial cancer before VSV-hINF-NIS treatment, and at Day 3-5 to monitor NIS activity in the tumors. To show the correlation of positive regional uptake with tissue histopathology for NIS, biopsies will be taken, when accessible, after the day 3-5 scan. Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Metastatic and/or Incurable Endometrial and Epithelial Ovarian Cancer, IRB 15-007000"
2870393|NCT03456895|Experimental|Healthy volunteer population|"Healthy volunteer participants will have one of two options for participation:~completion of an electronic survey tool to assess the perception and preference of environmental factors (virtual participation)~completion of the above survey and participation in environmental experiences and providing feedback about their experience (physical participation)"
2870394|NCT03456895|Experimental|Patient population|Patient participants will complete a survey tool and either participate in specific environmental experience testing or may be exposed to an environmental experience during the imaging examination. The imaging exam will be assessed in regard to quality factors such as motion artifacts as an indicator of being relaxed during the examination.
2870395|NCT03456895|Experimental|Staff population|Staff participants who work in imaging-related healthcare environments will complete survey tools regarding their perception and preference of environmental factors and/or will participate in environmental experiences and provide feedback.
2870468|NCT03456297|Experimental|Experimental cluster|The Web-based clinical pedagogy program (WCP) will be provided to the participants in the experimental cluster.
2870396|NCT03456882|Active Comparator|RNS60|RNS60 for injection, i.e. in the IV bags, is produced using 0.9% Sodium Chloride for injection. RNS60 for inhalation, i.e. in the syringes, is produced using 0.9% Sodium Chloride for irrigation. Syringes and IV bags are to remain refrigerated at 2 to 8°C (36 to 46°F) when not in use. RNS60 meets its stability specification for 12 months.
2870397|NCT03456882|Placebo Comparator|NORMAL SALINE|"Normal saline (NS) for injection, i.e. in the IV bags, is packaged 0.9% Sodium Chloride for injection. NS for inhalation, i.e. in the syringes, is packaged 0.9% Sodium Chloride for irrigation. NS does not require refrigerated storage for use. However, for blinding purposes refrigeration is required before distributing to subjects. NS meets stability specifications for 24 months.~RNS60 has been tested in three Phase I safety studies, NCT01264783, NCT01057498, and NCT01511302 in the USA, and a Phase IIa (NCT02422121) study in UK without any safety concern. Two other Investigator initiated Phase IIa trials are currently ongoing, one in Mass General Hospital (NCT02525471), and one in the University of Zurich (with University of Innsbruck as a second site)."
2870398|NCT03456869|Experimental|PSI group|The patient specific implant (PSI) is used to completed the genioplasty.
2870399|NCT03456856|Experimental|Initial Dose: 5 mg BID|"5mg Ivabradine: On day 1, eligible subjects with confirmed sinus rhythm and HR ≥ 70 bpm will be enrolled into a 57-day open-label treatment period. The starting dose of ivabradine is 5 mg twice daily (BID).~2.5mg Ivabradine: In subjects with a history of conduction defects, or in subjects in whom bradycardia could lead to hemodynamic compromise, therapy is to be initiated at 2.5 mg BID.~Changes in HR from baseline will be correlated with the genetic background of the studied population, as well as with the changes from baseline in activity level of the subjects, as measured by both a standard 6-minute walk distance and an accelerometer device."
2870400|NCT03456843|Experimental|Arm I (ADT, docetaxel)|Participants receive antiandrogen therapy with or without docetaxel at the discretion of the treating physician.
2870401|NCT03456843|Experimental|Arm II (ADT, radical prostatectomy, docetaxel)|Participants receive antiandrogen therapy for at least 1 month, then undergo cytoreductive radical prostatectomy. Participants continue antiandrogen therapy and may receive docetaxel within 3 months after surgery at the discretion of the treating physician.
2870402|NCT03456830|Experimental|ALLN-177|ALLN-177 3,750 units per capsule
2870403|NCT03456830|Placebo Comparator|Placebo|Placebo capsule
2870404|NCT03456817|Experimental|Treatment Arm - high dose ATG|High dose ATG at 10 mg/kg will be infused on days -4, -3, -2, -1 and 0. Before each infusion of ATG (thymoglobulin), patient will receive medications preventing side effects from the ATG, including diphenhydramine (Benadryl), acetaminophen (Tylenol) and methylprednisolone (Solumedrol). The high dose ATG will be given into patient's vein via central venous catheter. Each infusion of ATG will take 4-8 hours. No CSA (cyclosporine A) will be given. Standard dose methotrexate will be given.
2870405|NCT03456817|Other|Control Arm - standard of care|Low dose ATG (thymoglobulin) at 4.5 mg/kg will be infused on days -2, -1 and 0, and CSA (cyclosporine A) will be given from day -1 through day 84. Standard dose methotrexate will also be given.
2870406|NCT03456804|Experimental|Treatment ESK981|Patients receive pan-VEGFR/TIE2 (Vascular Endothelial Growth Factor Receptor/angopoeitin receptor2) tyrosine kinase inhibitor CEP-11981 PO QD for 5 days (Monday-Friday). Treatment repeats for up to 8 weeks in the absence of disease progression or unacceptable toxicity. If treatment is successful after 8 weeks, patients may receive up to 6 months of pan-VEGFR/TIE2 tyrosine kinase inhibitor CEP-11981.
2870407|NCT03456791||endometrial carcinoma( cases)|42 patients with abnormal uterine bleeding and diagnosed endometrial cancer at prior endometrial biopsy, underwent staging laparotomy will be subjected to withdrawal of blood sample for measurement of human epididymis protein 4
2870408|NCT03456791||benign diseases(control)|42 patients with abnormal uterine bleeding and diagnosed benign endometrial pathology by endometrial biopsy will be subjected to withdrawal of blood sample for measurement of human epididymis protein 4
2870409|NCT03456778|Experimental|Platelet-Rich Plasma Injection|Participants will receive a Platelet-Rich Plasma (PRP) injection to treat chronic tendinopathy
2870410|NCT03456752|Experimental|Dexamethasone|Dexamethasone 8mg intravenously prior to anesthesia induction
2870411|NCT03456752|Placebo Comparator|Control|Normal Saline 8mg intravenously prior to anesthesia induction
2870412|NCT03456739||suppurative otitis media with effusion|
2870413|NCT03456739||non suppurative otitis media with effusion|
2870414|NCT03456726|Experimental|FL with EZH2 gene mutation|Participants with follicular lymphoma (FL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 milligrams (mg) twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.
2870415|NCT03456726|Experimental|DLBCL with EZH2 gene mutation|Participants with diffuse large B-cell lymphoma (DLBCL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 mg twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.
2870416|NCT03456713|Experimental|LY3074828 Formulation A|LY3074828 solution formulation in two prefilled syringes, administered as subcutaneous (SC) injection
2870417|NCT03456713|Experimental|LY3074828 Formulation B|LY3074828 solution formulation in a prefilled syringe, administered as a SC injection
2870418|NCT03456713|Experimental|LY3074828 Formulation C|LY3074828 solution formulation in an auto-injector
2870419|NCT03456713|Experimental|LY3074828 Formulation D|LY3074828 solution formulation in an auto-injector
2870420|NCT03456700|Experimental|Treatment (auranofin, sirolimus)|Participants receive auranofin PO QD and sirolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
2870421|NCT03456687|Experimental|Exenatide|This group will receive a weekly Exenatide 2mg injection for one year.
2870422|NCT03456674|Experimental|LaseMD System|Subjects will receive LaseMD System treatment(s) for treatment of melasma.
2870423|NCT03456661|Active Comparator|Levobupivacaine|Study Group 1 (Group L): patients undergoing an ultrasound guided modified pectoral nerve block (technique described by Blanco et al[1]) with levobupivacaine 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml) (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).
2870467|NCT03456310|Experimental|Trans-perineal ultrasound|Transperineal ultrasonography is done by 2D ultrasound machine, curved probe is placed in the perineum, mid sagittal and axial views are obtained Then it's accuracy is assessed according to findings on dynamic pelvic MRI .
2870424|NCT03456661|Active Comparator|Levobupivacaine + Dexmedetomidine|Study Group 2 (Group LD): patients undergoing an ultrasound guided modified pectoral nerve block (a technique described by Blanco et al[1]) with levobupivacaine 0.25% 29,5ml + Dexmedetomidine 50µg (0,5ml)with a total volume of 30ml. (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).
2870425|NCT03456648|Experimental|Part A : postdialysis low dose|Interdialytic kinetics of low dose (2.5 mg apixaban) post-dialysis
2870426|NCT03456648|Experimental|Part A: ipostdialysis high dose|Interdialytic kinetics of high dose (5 mg apixaban) post-dialysis
2870427|NCT03456648|Experimental|Part B : predialysis low dose|Intra- and interrdialytic kinetics of low (2.5 mg) apixaban pre-dialysis
2870428|NCT03456648|Experimental|Part B : predialysis high dose|Intra- and interrdialytic kinetics of high (5 mg) apixaban pre-dialysis
2870429|NCT03456635|No Intervention|usual antimicrobial prophylaxys|standard of care: perioperative antimicrobial prophylaxis without computerized decision support system
2870430|NCT03456635|Experimental|guided antimicrobial prophylaxis|perioperative antimicrobial prophylaxis guided by a computerized decision support system
2870431|NCT03456609|Experimental|shenqifuzheng|
2870432|NCT03456609|Placebo Comparator|0.9%sodium chloride|
2870433|NCT03456596||Institution|Community cancer centers implementing ENABLE
2870434|NCT03456583||Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
2870435|NCT03456570|Active Comparator|progesterone|these patients will be offered Dydrogesterone 10 mg twice daily will be offered for 10 days , then they will be seen Post-menstrual or delayed menses for 1 week after treatment
2870436|NCT03456570|Placebo Comparator|placebo|those patients will be offered placebo tablets twice daily will be offered for 10 days , then they will be seen Post-menstrual or delayed menses for 1 week after treatment
2870437|NCT03456544||VAN-AKI|Patients who had vancomycin associated acute kidney injury.
2870438|NCT03456544||None VAN-AKI|Patients who didn't have vancomycin associated acute kidney injury.
2870439|NCT03456531|Active Comparator|group 1|20 patients will receive pulsed radiofrequency for 6 minutes to suprascapular nerve
2870440|NCT03456531|Placebo Comparator|group 2|"20 patients will receive their medical treatment in the form of NSAIDs ibubrofen,Aspirin"
2870441|NCT03456505|Experimental|Mindfulness|Participants randomly assigned to the mindfulness meditation condition will meet for five, 15-minute sessions, in which they will receive training in basic mindfulness skills (Wallace, 2006).
2870442|NCT03456505|Active Comparator|Active Listening|Participants randomly assigned to the active listening condition will meet for five, 15-minute sessions, in which they will listen to Gilbert White's The Natural History of Selborne.
2870443|NCT03456492||case|elderly patients (>70 years) with hip fractures
2870444|NCT03456492||control|elderly patients(>70 years) undergoing joint replacement or cataract surgery
2870445|NCT03456466|Experimental|TQB2303|
2870446|NCT03456466|Active Comparator|Rituximab|
2870447|NCT03456453|Experimental|NIDA Standard via Facebook|
2870448|NCT03456453|No Intervention|Re-entry services as usual|
2870449|NCT03456440||hepatitis C child pugh's class A|patients are examined with MRI
2870450|NCT03456440||normal individuals|controls cases are examined with MRI
2870451|NCT03456427|Other|All Study Participants|All subjects will undergo standard of care imaging on one breast. The other breast will be imaged using Patient-Assisted Compression (PAC), followed by Technologist-controlled (TC) Compression.
2870452|NCT03456414|Experimental|Virtual reality during hemodialysis|During 12 weeks subjects will exercise during hemodialysis. The intervention will be virtual reality exercise during hemodialysis.
2870453|NCT03456414|No Intervention|Control period - no exercise|During 12 weeks subjects will not exercise during hemodialysis
2870454|NCT03456401|Other|Sorafenib or Sunitinib|Sorafenib will be administered at 400 mg bid daily Sunitinib will be administered at 50 mg die orally (4 week on/2 weeks off)
2870455|NCT03456388|Experimental|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 7 ascending cohorts . Each cohort will be administered in different dose once for 7 days.
2870456|NCT03456388|Active Comparator|Placebo Enteric-coated Tablets|There will be 7 ascending cohorts. placebo enteric-coate tablets to mimic Ammoxetine Hydrochloride Enteric-coated tablets.
2870457|NCT03456362|Active Comparator|Cerebellar iTBS|Intermittent theta burst stimulation applied immediately before the daily physical therapy session for a period of three weeks.
2870458|NCT03456362|Sham Comparator|Sham iTBS|Sham intermittent theta burst stimulation applied immediately before the daily physical therapy session for a period of three weeks.
2870459|NCT03456349|Experimental|Low dose|HTL0018318
2870460|NCT03456349|Experimental|Medium dose|HTL0018318
2870461|NCT03456349|Experimental|High dose|HTL0018318
2870462|NCT03456349|Placebo Comparator|Placebo|Placebo
2870463|NCT03456336|Active Comparator|Active Treatment Group|Infants assigned to the active treatment group will receive indomethacin or ibuprofen per their local site usual care dosing and schedule if the infant has a sPDA. The choice of indomethacin or ibuprofen will be left to the center, however, infants may only receive one or the other.
2870464|NCT03456336|Active Comparator|Expectant Management Group|Infants assigned to the expectant management group will receive indomethacin or ibuprofen if cardiopulmonary compromise occurs.
2870465|NCT03456323|Experimental|Palliative Care Consultation|After enrollment the palliative care consultation team will meet with the patient-surrogate pair one or more times to (1) assess symptoms, (2) provide supportive counseling, (3) make symptom treatment recommendations to the primary team of physicians, and (4) will address goals of care.
2870466|NCT03456323|Placebo Comparator|Usual Care|Patient-surrogate pairs randomized to usual care will continue to receive care by their primary physicians without having a palliative care consultation intervention offered.
2893667|NCT03293563||Patients|Adult patients with kidney cancer
2870469|NCT03456297|No Intervention|Control cluster|The participants in the control cluster will receive the current face-to-face preceptorship course.
2870470|NCT03456284|Experimental|Normothermic Liver perfusion|This group has the liver grafts preserved using the Normothermic Liver perfusion Device
2870471|NCT03456271||fracture group|
2870472|NCT03456271||non-fracture group|
2870473|NCT03456258|Experimental|Lactoferrin|To measure hemoglobin difference and serum ferritin
2870474|NCT03456258|Experimental|Ferrous sulphate|To measure hemoglobin difference and serum ferritin
2870475|NCT03456245|Other|Vision device validation|In the single arm of this study, all members of this group were examined using a number of mobile eyesight assessment devices.
2870476|NCT03456232|Experimental|High-flux hemodialysis|High-flux hemodialysis lasting for 4 hours
2870477|NCT03456232|Active Comparator|Hemodiafiltration|Hemodiafiltration lasting for 4 hours
2870478|NCT03456219|Experimental|Shift workers|Night workers of the Hospital of Clinics of Uberlândia, Federal University of Uberlândia, received the isocaloric diet.
2870479|NCT03456219|Experimental|Night workers|Night workers of the Hospital of Clinics of Uberlândia, Federal University of Uberlândia, received the higher-protein diet.
2870480|NCT03456206||DHC|"Participants from the Diet, Health and Cancer cohort with no CID diagnosis at entry to the DHC study. The number of persons developing a CID (defined as at least one of the mentioned CIDs) during follow up (1993/1997 - 2018) and the number of persons not developing a CID will be investigated.~Based on the participants reporting of dietary habits in the Food Frequency Questionnaire (FFQ) from the DHC study, the exposure intake of red and processed meat and fibres will be investigated in both CID cases and non-cases.~Other exposure variables are Lifestyle factors independently or combined and are also obtained from the data in the DHC cohort."
2870481|NCT03456193|Experimental|LA transplantation|The left atrium and pulmonary veins will be transplanted into the recipient
2870482|NCT03456180||Haemoadsorption with Cytosorb cartridge|patients with septic shock and acute renal failure requiring renal replacement therapy with the haemoadsorption cartridge Cytosorb
2870483|NCT03456167|Experimental|Mobile app for follow-up care|Participants will use an app to submit photos of their surgical site, QoR15 scores, and EORTC selected adverse events scores daily for 2 weeks post-op & weekly for another 4 weeks. Surgeons will use a wireless interface to access that data and monitor the patient's condition. Participants will complete questionnaires and keep diaries related to satisfaction, medical system encounters, surgical complications, followup-related financial costs, and telemedicine satisfaction at 2 & 6 weeks post-op. They will attend prescribed follow-up appointments with their surgeon with the option to skip 1 or more follow-up appointments dependent on their recovery trajectory & surgeon.
2870484|NCT03456167|No Intervention|Conventional inperson followup care|The conventional follow-up care group will keep to conventional follow-up schedules of all surgeons involved. They will complete questionnaires and keep diaries related to satisfaction, medical system encounters, surgical complications, and followup-related financial costs at 2 & 6 weeks post-op and attend all scheduled follow up appointments.
2870485|NCT03456154|Experimental|Botox|In this group patients will receive 3 injections of botox on each masseter (left and right), after randomization. This injection will be performed once, and the patient will be evaluated after 3 and 6 months after this day.
2870486|NCT03456154|Active Comparator|Occlusal splint|In this group patients will receive an occlusal splint, which will be manufactured after taking their full mouth impression. This appliance has to be worn everyday, for 6 months, at night.
2870487|NCT03456128|Experimental|Intervention|The experimental group will receive CAPABLE services. These include ≤10 sessions: ≤ 6 with an Occupational Therapist (OT) and ≤ 4 sessions with a Registered Nurse (RN) and up to ≤ $1,500 of home safety and home modifications from a licensed handyman who is guided by the OT. The OT and RN sessions will target participants' self-identified functional goals (e.g., getting safely into the tub, getting upstairs to sleep in own bed).
2870488|NCT03456128|No Intervention|Usual Care|Participants in the usual care group will not receive visit from study clinicians and will continue to receive their usual VNSNY CHOICE benefits and healthcare.
2870489|NCT03456115|Experimental|Mechanical Nasal Dilator|All participants will be trialing the 5 devices and reporting their thoughts on comfort, and perception of symptoms of mechanical nasal obstruction by way of survey completion. The devices include 4 commercially available nasal dilators: Breathe Right, Max Air, Sleep Right, Nozovent, and the study team's investigational device dubbed the Schnozzle.
2870490|NCT03456102|Other|Pravastatin 80 mg|Pravastatin 80 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 2 will only be recruited if pravastatin 80 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
2870491|NCT03456102|Other|Pravastatin 120 mg|Pravastatin 120 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 3 will only be recruited if pravastatin 120 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
2870492|NCT03456102|Other|Pravastatin 160 mg|Pravastatin 160 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days
2870493|NCT03456102|Other|Pravastatin 40 mg|Pravastatin 40 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 4 will only be recruited if pravastatin 80 mg is not tolerated as specified in protocol.
2870494|NCT03456089||Neurogenic Bladder Patients|Patients with neurogenic bladder undergoing urodynamics testing
2870495|NCT03456076|Experimental|Alectinib|
2870496|NCT03456076|Active Comparator|Platinum-Based Chemotherapy|
2870497|NCT03456063|Experimental|Arm A: Atezolizumab + platinum-based chemotherapy|"Neoadjuvant treatment will consist of 4 cycles; atezolizumab + platinum-based chemotherapy~Platinum-based chemotherapy may include:~carboplatin + pemetrexed~carboplatin + nab-paclitaxel~cisplatin + pemetrexed~Post-operative adjuvant treatment will consist of 16-cycles of atezolizumab"
2870498|NCT03456063|Placebo Comparator|Arm B: Placebo + platinum-based chemotherapy|"Neoadjuvant treatment will consist of 4 cycles; placebo + platinum-based chemotherapy~Platinum-based chemotherapy may include:~carboplatin + pemetrexed~carboplatin + nab-paclitaxel~cisplatin + pemetrexed~Participants will receive best supportive care and monitoring after surgery"
2870499|NCT03456050|Experimental|FRC group|This group will receive FRC exercise.
2870500|NCT03456050|Experimental|Conventional treatment|This group will receive conventional exercise.
2870501|NCT03456011|Other|BFA with Eufflexa injections|"BFA treatment before Sodium Hyaluronate injections.~Intervention: BFA"
2870502|NCT03456011|No Intervention|Anesthetic with Eufflexa injections|"Receiving Standard of care determined by their provider~No interventions"
2870503|NCT03455998||post surgery|Patienst consultation Questionnaires
2870504|NCT03455998||pre and post surgery|Patient consultation Questionnaires
2870505|NCT03455985|Experimental|Discharge Order Set (DOS)|Patients in the DOS group will receive instructions for self-titration of basal insulin as part of the discharge order. The DOS contains a comprehensive checklist for basic diet, hospital follow-up, glucose targets and instructions for monitoring, insulin pens and pen needles, glucose testing supplies, and ancillary orders. Phone calls will assess adherence with instructions for self-titration. Glucose lowering medication management following discharge will otherwise be conducted by the patient's usual or designated standard of care provider.
2870506|NCT03455985|Other|Enhanced Standard Care (ESC)|Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.
2870507|NCT03455972|Experimental|CART-19/BCMA|
2870508|NCT03455959|Experimental|Allergic Asthmatic or Healthy Control Adults|Allergic Asthmatic or Healthy Control Adults will undergo Bronchoscopy/BAL, airway brushing, and endobronchial biopsy
2870509|NCT03455946|Experimental|Interventional|DASH Cloud with Alexa
2870510|NCT03455933|Experimental|Shockwave Light Pain Group|Sham Comparator. It will received a light intensity shockwave in the lateral epicondyle regulated until reach a 3/10 in the Visual Analog Scale (VAS) scale.
2870511|NCT03455933|Experimental|Shockwave Moderate Pain Group|Experimental Intervention. It will received a moderate intensity shockwave in the lateral epicondyle regulated until reach a 6/10 in the Visual Analog Scale (VAS) scale.
2870512|NCT03455933|Other|Cold Pressure Group|Control Group. The cold pressure test will be apply to this group. The investigators will use a container with an outer part filled with ice and an inner part filled with water, both separated by a screen that prevents direct contact between the ice and the hand. The water will be regularly stirred to maintain the temperature near to 0.7ºC.
2870513|NCT03455920|Experimental|Multidisciplinary arm|Patients randomized in this group will have their first sleep clinic evaluation with the clinical nurse. She will then discuss each case with the pulmonologist and validate the diagnostic and therapeutic avenue.
2870514|NCT03455920|Active Comparator|Pulmonologist arm|Patients randomized in this group will have their first sleep clinic evaluation with the pulmonologist.
2870515|NCT03455907||Patients|patients with ovarian, colorectal or bronchopulmonary cancer receiving Bevacizumab
2870516|NCT03455894|Experimental|Smart carpet|
2870517|NCT03455881||NICU TED Genetic Cohort|This study involves one inpatient biofluid collection encounter from the subject, one biofluid collection encounter from each biological parent, and an optional biofluid collection encounter from other biological family members.
2870518|NCT03455881||NICU TED MRI Cohort|This study involves up to three inpatient NICU MRI encounters. The first MRI may be done before surgical repair if the clinical team feels the infant is clinically stable. The second MRI may be completed post-surgical repair of TED. An additional 3rd MRI may be done prior to the time of discharge from the NICU. The pre repair, post-surgical, and pre discharge MRIs will provide valuable data for the understanding of tracheal esophageal malformation disorders and may provide clinical guidance for the participant's care.
2870519|NCT03455881||TED Genetic Cohort|This study involves one biofluid collection encounter from the subject, one biofluid collection encounter from each biological parent, and an optional biofluid collection encounter from other biological family members.
2870520|NCT03455881||NICU Control MRI Cohort|This study involves two inpatient NICU MRI encounters. The first MRI will occur within the first month of life, and the second MRI will occur prior to discharge.
2870521|NCT03455868||Sleeve gastrectomy|35 Men and women with type 2 diabetes and obesity undergoing bariatric surgery : Sleeve gastrectomy
2870522|NCT03455868||Roux-in-Y gastric bypass|35 Men and women with type 2 diabetes and obesity undergoing bariatric surgery : Roux-in-Y gastric bypass
2870523|NCT03455868||Biliopancreatic diversion with duodenal switch|35 Men and women with type 2 diabetes and obesity undergoing bariatric surgery : Biliopancreatic diversion with duodenal switch
2870524|NCT03455868||Control|20 Men and women with a normal BMI and normoglycemia matched for age and sex with bariatric groups
2870525|NCT03455855|Experimental|treated with the Jetstream System|It is intended that all patients with qualifying lesions would be considered for enrollment and treated with the Jetstream System.
2870526|NCT03455842|Experimental|BCD-089 weekly|
2870527|NCT03455842|Experimental|BCD-089 biweekly|
2870528|NCT03455842|Placebo Comparator|Placebo|
2870529|NCT03455829|Experimental|Part 1: G1T38 + Osimertinib|Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
2870530|NCT03455829|Experimental|Part 2: G1T38 + Osimertinib|Patients will be randomized to receive G1T38 at the dose determined in Part 1 in combination with osimertinib 80 mg, each administered once-daily.
2870531|NCT03455829|Active Comparator|Part 2: Osimertinib|"Patients will be randomized to receive osimertinib 80 mg once-daily.~At the time of disease progression per RECIST v1.1, patients who were initially randomized to receive osimertinib alone may crossover to receive G1T38 + osimertinib."
2870532|NCT03455816|Experimental|Group that uses the Social Diabetes App (research group)|This group use the App Social diabetes with the glucometer Glucomen Areo to monitoring the glucemia during 6 month
2870533|NCT03455816|Active Comparator|Usual clinical monitoring group (control group)|This group does not use the App. This group have an intermediate visit at 3 months with de doctor to see blood glucose self-monitoring and propose adjustments
2870672|NCT03454906||LAL Hemoglobin|LAL Hemoglobin: low amplitude fluctuation with low hemoglobin; all 6 months with low or target range hemoglobin levels
2870534|NCT03455790|Experimental|Wheelchair Basketball|"Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests."
2870535|NCT03455790|Experimental|20 Meters Sprint Test|It will be done to evaluate the speed of sportsmen's wheelchair use. The sportsman will be prompted to take the chair as fast as possible after the wheelchair has been positioned so that the front bar is on the field edge. The 2 meter slow-down distance will also be counted in seconds and the completion time of the 20 meter track will be measured.
2870536|NCT03455790|Other|Slalom test|It will be done to measure the ability of sportsmen to use wheelchairs. Five cones will be placed starting 1.5 meters from the starting line of the Sahara, with a distance of 1.5 meters between them. Sportsmen will be required to complete the course by making a slalom between these topics and making a slalom in the same way by turning back and passing through the starting line. Track completion times will be recorded in seconds.
2870537|NCT03455790|Other|Zone Shot Test|Zone Shot test will be applied to evaluate the shooting skills of the athletes. In the starting position the athlete will be asked to shoot the pot from the athlete with the warning given while on the foul shooting line and then to take their own rebounds. They will have to shoot again from the point where they have taken the rebound and rebound and go back to the foul line. The test will continue for 2 minutes in this manner. At the end of the 2-minute training period, the athletes will score the correct shot 2, the missed shot 1 point and the total score will be recorded.
2870538|NCT03455790|Other|Aerobic Capacity|To measure aerobic capacity values, it shall be measured with Cosmed K5® device and Cosmos-Saturn branded treadmill using TS which is used in routine workout with customized ramp protocol. Before starting the test, the athlete's TS walking belt at a speed of 1 mph (1.7 km / h) at 0% incline for 3 min. and it will be checked whether or not the gas measuring equipment is disturbing the participant. If the athlete is unable to continue, the time at which the test will end will be determined. Time min. . The air that the individual exposes during the test will be collected using a breath by breath method.
2870539|NCT03455790|Other|Anaerobic Capacity|Using the Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement, TS basketball athletes will be subjected to a Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions.
2870540|NCT03455790|Other|Isokinetic shoulder muscle strength|Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer.
2870541|NCT03455777|Experimental|AKCEA-ANGPTL3-LRX Dose 1|
2870542|NCT03455764|Experimental|MCS110+ Trametinib + Dabrafenib|"For Phase 1 MCS110 will be administered intravenously every 3 weeks.~Dabrafenib is given orally every 12 hours.~Trametinib is given orally daily"
2870543|NCT03455764|Experimental|MCS110 + Trametinib + Dabrafenib Phase 2|"MCS110 will be administered intravenously every 3 weeks.~The Dosage will be determine by the DLT of Phase 1~Dabrafenib is given orally every 12 hours.~Trametinib is given orally daily"
2870544|NCT03455751|No Intervention|Control|The control arm will receive no intervention and will follow standard of care for post-operative pain management.
2870545|NCT03455751|Experimental|PGx-guided|The PGx-guided arm will received altered post-operative pain management based on the results of pharmacogenomic testing.
2870546|NCT03455725|Active Comparator|CardiAMP cell therapy system|"Roll-in phase:~Up to 10 subjects with refractory chronic myocardial ischemia CCS class III-IV will be treated in an unblinded, uncontrolled roll-in phase.~In the subsequent randomized phase:~Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 222 Subjects will be randomized to treatment with the CardiAMP cell therapy system."
2870547|NCT03455725|Sham Comparator|Sham procedure control|"Randomized phase:~Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 111 subjects will be treated with a Sham Treatment (no introduction of trans endocardial delivery catheter and no administration of autologous cells)"
2870548|NCT03455712|Experimental|Intervention|Subjects to receive the Gestational Weight Gain Card at enrollment in addition to standard prenatal care.
2870549|NCT03455712|No Intervention|Standard-of-Care|No intervention to be delivered. Subjects to receive standard prenatal care.
2870550|NCT03455699||Experimental: VenaSeal SCS|Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).
2870551|NCT03455699||Active Comparator: RFA|Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV). Heat is applied to the target vein using radiofrequency energy to ablate the target vein. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).
2870552|NCT03455699||Experimental: Roll-in (VenaSeal SCS)|Prior to initiation of the randomized cohort at each site for the VeClose study (NCT01807585), a non-randomized cohort of 2 subjects per site (roll-in phase) were enrolled and treated with VenaSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.
2870553|NCT03455686|Experimental|Patients with and without lung disease|All enrolled patients will undergo pulmonary function testing, questionnaires, 1H MRI, static ventilation and/or diffusion-weighted hyperpolarized 129Xe MRI and sputum induction at one or more timepoints over five years.
2870554|NCT03455673||Atrial fibrillation|ATE score will be determined for patients hospitalized for ablation of atrial fibrillation or symptomatic left atrial tachycardia
2870555|NCT03455660||Pre-January 2015|Patients who underwent cesarean delivery between February 2013 and December 2014.
2870556|NCT03455660||Post-January 2016|Patients who underwent cesarean delivery between February 2016 and December 2017.
2870673|NCT03454906||LAH Hemoglobin|LAH Hemoglobin: low-amplitude fluctuation with high hemoglobin levels 6 months with target-range or high hemoglobin levels)
2870557|NCT03455647|Experimental|ASF Promotion plus Girinka|Participants have received a cow from the government of Rwanda through the Girinka program and will receive an animal source food promotion intervention from the study.
2870558|NCT03455647|No Intervention|Girinka only|Participants have received a cow from the government of Rwanda through the Girinka program and will not receive any intervention from the study.
2870559|NCT03455647|No Intervention|Girinka eligible|Participants are eligible to receive a cow through the government of Rwanda Girinka program, but have not yet received a cow. They will not receive any intervention from the study.
2870560|NCT03455634|Active Comparator|Twin Block|Twin Block functional appliance
2870561|NCT03455634|Active Comparator|Sander|Sander bite jumping appliance
2870562|NCT03455634|No Intervention|Control|no intervention
2870563|NCT03455621|Placebo Comparator|Pea-size amount of non-F dentifrice|Non-fluoride dentifrice (0 ppm F); to be used twice/day. Amount to be used: 0.3 g (pea-size amount)
2870564|NCT03455621|Experimental|0.025 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.025 g
2870565|NCT03455621|Experimental|0.05 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.05 g
2870566|NCT03455621|Experimental|0.1 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.1 g
2870567|NCT03455621|Active Comparator|Pea-size amount of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.3 g (pea-size amount)
2870568|NCT03455608|Active Comparator|RE-ACTIVE|Reactive intervention started promptly if/when dysphagia is identified (RE-ACTIVE)
2870569|NCT03455608|Active Comparator|PRO-ACTIVE EAT|Early low intensity proactive intervention started before RT commences
2870570|NCT03455608|Active Comparator|PRO-ACTIVE EAT + EXERCISE|Early high intensity proactive intervention started before RT commences
2870571|NCT03455582|Experimental|patient|PPMS diagnosis according to McDonald 2010 criteria (Polman et al, 2011)
2870572|NCT03455582|Active Comparator|Control|30 Healthy controls
2870573|NCT03455582|Active Comparator|Control - 2|30 Healthy controls
2870574|NCT03455569|Experimental|Behavioral sleep education|manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
2870575|NCT03455569|Experimental|Education only|education on sleep, aging, and dementia but without specific or individualized recommendations
2870576|NCT03455556|Experimental|Treatment (anetumab ravtansine, atezolizumab)|Participants receive anetumab ravtansine IV over 60 minutes and atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2870577|NCT03455543|Experimental|Active Group|Treatment with active Provant Therapy System
2870578|NCT03455543|Sham Comparator|Sham Group|Treatment with in-active (sham) Provant Therapy System
2870579|NCT03455530|Experimental|Intervention Group|The intervention group will receive the IH-enhanced CHW intervention before (~3 months) the other arm (Delayed Intervention Group).
2870580|NCT03455530|Other|Delayed Intervention Group|The delayed intervention group will receive the IH-enhanced CHW intervention after (~3 months) the other arm (Intervention Group).
2870581|NCT03455517|Experimental|Veritas|"Step 1. All patients: venetoclax 5-weeks dose-titration phase with weekly increases in the dose of venetoclax.~Step 2. All patients will receive 6 courses of the VR combination.~Step 3. After 6 courses of VR combination:~3a. Patients with no response will be off treatment; 3b. Patients with clinical response (CR or PR) after 6 courses of VR combination will receive venetoclax as a single agent for 6 months. Then, patients will be observed clinically until disease progression or until month 36."
2870582|NCT03455504|Experimental|Cohort 1|FLAI + V400 mg
2870583|NCT03455504|Experimental|Cohort 2|FLAI + V600 mg
2870584|NCT03455491|Experimental|Group A|"XC221 100 mg orally.~1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period"
2870585|NCT03455491|Experimental|Group B|XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
2870586|NCT03455491|Placebo Comparator|Group C|Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period
2870587|NCT03455478|Experimental|corrected refractive error|
2870588|NCT03455478|No Intervention|uncorrected refractive error|
2870589|NCT03455465|No Intervention|No intervention|Patients in this arm will not be approached by community health workers during their visit to the Emergency Department.
2870590|NCT03455465|Active Comparator|Community Health Worker Program|Participants in this group will be approached by a community health worker during their visit to the Emergency Department with the goal of enrolling them in a comprehensive post-discharge program.
2870591|NCT03455452||Renal Cell Carcinoma (RCC) Participants|Participants diagnosed with advanced RCC and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of RCC
2870592|NCT03455439||Rivaroxaban|Adult patients diagnosed with Atrial Fibrilation and Heart Failure who started treatment with rivaroxaban at least 4 months prior to inclusion
2870593|NCT03455426|Experimental|letrozole group|letrozole 5mg/day starting from day 3 of menstrual cycle for 5 days
2870594|NCT03455426|No Intervention|natural cycle group|
2870595|NCT03455387||sampling of serum marker Flt1 and PIGF|sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
2870596|NCT03455374|Experimental|Treatment with CSI atherectomy device|removal of the plaque from vessel wall by optical coherence tomography
2870597|NCT03455361||Stark Implant with low primary stability|Patient who had received bone level V-Blast implants with low primary stability.
2870598|NCT03455361||Stark Implant with primary stability|Patient who had received bone level V-Blast implants and achieved primary stability.
2870599|NCT03455348|No Intervention|cathete to less than 4 four centimeters to the wrist joint|
2870600|NCT03455348|Active Comparator|catheter to more than four centimeters to the wrist joint|
2870601|NCT03455335|Experimental|low dose cohort|20 million hMSCs .
2870602|NCT03455335|Experimental|mid dose cohort|40 million hMSCs
2870603|NCT03455335|Experimental|high dose cohort|80 million hMSCs .
2870881|NCT03453463|No Intervention|control|Calcium and Vitamin-D-supplementation (i.e. 800 mg/800 IE/d)
2870604|NCT03455322|Active Comparator|norepinephrine|norepinephrine continuous intravenous infusion in a dose of 0.05-0.3ug/Kg/min. average7-10 days to keep mean arterial pressure ≥ 80-100mmHg & continued either until HRS reversal or for maximum 10 days.
2870605|NCT03455322|Active Comparator|midodrine & octreotide|midodrine 5mg three times/day orally & can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous & if needed increased to 200ug/6hS.C. for 7-10 days
2870606|NCT03455309|Active Comparator|NDV-3A|0.5 mL dose containing 300 micrograms of recombinant Als3 protein in phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide
2870607|NCT03455309|Placebo Comparator|Placebo|0.5 mL dose containing phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide
2870608|NCT03455296|Active Comparator|central venous oxygen saturation ScVO2 normalization|Fluid therapy is initiated with maintenance fluid (Ringer or Ringer acetate) plus replacement with crystalloids (Ringer, Ringer acetate or saline 0.9%) 500ml / 30 min. guided by ScVO2with target value ≥ 70%
2870609|NCT03455296|Active Comparator|Lactate clearance|Fluid therapy is initiated with maintenance fluid (Ringer or Ringer acetate) plus replacement with crystalloids 500ml / 30 min. guided by lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study
2870610|NCT03455283||Clariscan 0.5 mmol/ml|Participants will receive Clariscan 0.5 mmol/ml injection as apart of clinical practice at the medical discretion of the prescribing physician.
2870611|NCT03455283||All Gadolinium-Based Contrast Agents (GBCAs)|Participants will receive GBCA as part of clinical practice at the medical discretion of the prescribing physician.
2870612|NCT03455270|Experimental|Part 1: Dose Escalation|"Patients in Part 1 will receive a single oral dose of G1T48 on Cycle 1 Day -3 and will begin once-daily dosing on Cycle 1 Day 1.~The initial dose cohort shall receive an identified starting dose and subsequent cohorts shall receive higher doses based on the safety and PK data obtained from the previous dose levels."
2870613|NCT03455270|Experimental|Part 1: Food Effect Cohort|"In Part 1, an additional G1T48 cohort of 8 patients may be enrolled to assess the effect of a high-fat meal on the rate and extent of the absorption of G1T48.~Patients will receive a single oral dose of G1T48 on Cycle 1 Day -10 and on Cycle 1 Day -3. Patients will begin G1T48 once-daily dosing on Cycle 1 Day 1."
2870614|NCT03455270|Experimental|Part 2: Dose Expansion|Patients in Part 2 will receive G1T48 once-daily at the dose determined in Part 1.
2870615|NCT03455257|No Intervention|Control|Families assigned to this arm will be assessment only controls that do not receive the cash transfer.
2870616|NCT03455257|Experimental|Intervention|Families assigned to this arm will recieve a cash transfer following an in-depth conversation with the head of household and the signing of a contract stating they understand the purpose of the study.
2870617|NCT03455231|Experimental|Short course radiotherapy|The radiotherapy is delivered over two days with accelerated hypo-fractionation
2870618|NCT03455218|Experimental|Nitric Oxide|20 ppm of Nitric Oxide delivered to the oxygenator via the INOmax device for the duration of the cardiopulmonary bypass time
2870619|NCT03455218|Placebo Comparator|Placebo|INOmax device attached to the oxygenator, but no gas is delivered through the device
2870620|NCT03455205|Experimental|shenqifuzheng injection|"Shenqifuzheng injection of 500 ml,intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment,The programme provides for chemotherapy regimens:~Colorectal cancer: CapeOX scheme - oxaliplatin + capecitabine Esophageal cancer: DP/TP programme - docetaxel/paclitaxel + cisplatin/carboplatin Gastric cancer: SOX scheme - oxaliplatin + tigio All test drugs should be covered with dark bags before infusion, and use a dark infusion to guarantee the implementation of the blind method."
2870621|NCT03455205|Placebo Comparator|0.9% sodium chloride injection|0.9% sodium chloride injection of 500 ml,intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment,The programme provides for chemotherapy regimens: Colorectal cancer: CapeOX scheme - oxaliplatin + capecitabine Esophageal cancer: DP/TP programme - docetaxel/paclitaxel + cisplatin/carboplatin Gastric cancer: SOX scheme - oxaliplatin + tigio No interventions have been included in Arm Description for '0.9% sodium chloride injection'
2870622|NCT03455192|Experimental|Synbiotic supplements|One synbiotic tablet, per day, during 30 days
2870623|NCT03455192|Placebo Comparator|Placebo Oral Tablet|One placebo tablet , per day, during 30 days
2870624|NCT03455179|Experimental|Slow-speed traditional resistance training|Resistance training with variable resistances (elastic band) at high intensity and slow-speed (2s of concentric contraction and 2s of eccentric contraction) twice a week over 20 weeks.
2870625|NCT03455179|Experimental|High-speed resistance training|Resistance training with variable resistances (elastic band) at low intensity and high-speed (``as fast as possible´´ for the concentric contraction, pause for 1 second and 2-3 seconds for the eccentric contraction) twice a week over 20 weeks.
2870626|NCT03455179|Experimental|Multicomponent training|Training sessions with balance, resistance, aerobic, flexibility and coordination components twice a week over 20 weeks.
2870627|NCT03455179|No Intervention|Control|Participants randomized into the CONTROL group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet.
2870628|NCT03455166|Other|Psoriasis|
2870629|NCT03455166|Other|Psoriatic arthropathy|
2870630|NCT03455153||Most active|COPD patients with higher physical activity levels as defined by daily step counts.
2870631|NCT03455153||Least active|COPD patients with lower physical activity levels as defined by daily step counts.
2870632|NCT03455140|Experimental|Group 1 - Leukaemia|PEG- BCT-100 in patients with Leukaemia Starting dose 1600U/Kg IV infusion weekly
2870633|NCT03455140|Experimental|Group 2 - Neuroblastoma|PEG- BCT-100 in patients with Neuroblastoma Starting dose 1600U/Kg IV infusion weekly
2870634|NCT03455140|Experimental|Group 3 - Sarcomas|PEG- BCT-100 in patients with Sarcomas Starting dose 1600U/Kg IV infusion weekly
2870635|NCT03455140|Experimental|Group 4 - High Grade Glioma|PEG- BCT-100 in patients with High Grade Gliomas Starting dose 1600U/Kg IV infusion weekly
2870674|NCT03454906||HA Hemoglobin|HA Hemoglobin ; high-amplitude fluctuation low, target-range, and high hemoglobin levels within the 6 month period
2870636|NCT03455127|No Intervention|Classic Public Works as Usual|Half of the sample will be eligible to receive or be receiving the Government of Rwanda's (GOR) flagship social protection programming, Vision 2020 Program (VUP). One component of this program is to provide cash for work opportunities for labor endowed vulnerable households, i.e. one able bodied adult. Vulnerable households are those in Poverty Level 1 category, the GOR's poverty classification system. Furthermore, this study will require households in the control group receiving classic public works as usual to have at least one child between the ages of 6 months to 36 months.
2870637|NCT03455127|Experimental|Classic Public Works + FSI ECD|Half of the sample will receive the FSI ECD home visiting parenting program alongside the GOR's classic public works programming. These households will be in Poverty Level 1 with an able-bodied adult, thus eligible to receive or be received the GORs public works programming. They will have a child between 6 and 36 months at enrollment. Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
2870638|NCT03455114|Experimental|capsular fixation surgery|patients required capsule centration safely undergo capsular fixation surgery with AssiAnchor under local anesthesia .
2870639|NCT03455101||Patients with diabetes mellitus|Patients with type 1 or type 2 diabetes who were under follow-up in the same center for at least a year.
2870640|NCT03455088|Experimental|DBT group|DBT group has 55 patients, maybe we divided them into 7 groups. Every group has 8-10 patients. Every group receive 12 times DBT group therapy and 1 times a week for 120 minutes each time.
2870641|NCT03455088|Active Comparator|Drug therapy group|Drug therapy group has 55 patients, and we may use fluoxetine as treatment drug.
2870642|NCT03455088|Experimental|DBT and drug therapy group|DBT and drug therapy group has 55 patients, maybe we can divide them into 7 groups. Every group has 8-10 patients. Every group receive 12 times DBT group therapy and 1 times a week for 120 minutes each time. At the same time, we use fluoxetine as treatment drug.
2870643|NCT03455075|Experimental|Lower DMAU + LNG|DMAU 100 mg + LNG 30 mcg administered orally in capsules.
2870644|NCT03455075|Experimental|Middle DMAU + LNG|DMAU 200 mg + LNG 30 mcg administered orally in capsules.
2870645|NCT03455075|Experimental|Middle DMAU + Placebo|DMAU 200 mg + placebo administered orally in capsules.
2870646|NCT03455075|Experimental|Higher DMAU + Placebo|DMAU 400 mg + placebo administered orally in capsules.
2870647|NCT03455075|Placebo Comparator|Placebo|Placebo administered orally capsules.
2870648|NCT03455049|Experimental|Normal subject experimental|Participants get Andrographis Paniculata Extract 550 mg, two capsules, twice a day, for 14 days.
2870649|NCT03455049|Placebo Comparator|Normal subject placebo|Participants get placebo consist of Lactose 98%, Mg 2%, two capsules, twice a day, for 14 days.
2870650|NCT03455049|Experimental|Prediabetes subject experimental|Participants get Andrographis Paniculata Extract 550 mg, two capsules, twice a day, for 14 days.
2870651|NCT03455049|Placebo Comparator|Prediabetes subject placebo|Participants get placebo consist of Lactose 98%, Mg 2%, two capsules, twice a day, for 14 days.
2870652|NCT03455036|Experimental|Whole body vibration training|Healthy female subjects complete whole body vibration training (10 x 1 min exposure)
2870653|NCT03455023|Experimental|pharmaceutical care intervention group|Patients will receive individualized pharmaceutical care in addition to usual medical care.
2870654|NCT03455023|No Intervention|control group|Patients will receive usual medical care.
2870655|NCT03455010|No Intervention|Normal load|Healthy subjects walking for 30 minutes on a treadmill with normal body weight
2870656|NCT03455010|Experimental|Increased load|Healthy subjects walking for 30 minutes on a treadmill with 20% additional body weight
2870657|NCT03455010|Experimental|Reduced load|Healthy subjects walking for 30 minutes on a treadmill with 20% lower body weight
2870658|NCT03454997|Active Comparator|Standard Implementation Intervention|The standard version will train community mental health program staff to become ACHIEVE-D coaches and peers to become ACHIEVE-D peer-leaders, will include in-person and online training and avatar-assisted motivational interviewing practice as well as organizational strategy meetings.
2870659|NCT03454997|Active Comparator|Enhanced Implementation Intervention|The enhanced version will train community mental health program staff to become ACHIEVE-D coaches and peers to become ACHIEVE-D peer-leaders, will include in-person and online training and avatar-assisted motivational interviewing practice as well as organizational strategy meetings. The enhanced version will also include performance coaching.
2870660|NCT03454984|Experimental|SGI-110|"SGI 110 (Guadecitabine) will start on day 40, In case the patient is not eligible yet, he should be assessed again each 30 days until day 130, after what, he is not considered eligible for a preventive treatment by SGI.~Initial dose will be 30/m2/day SQ for 5 days~total 10 cycles of SGI-110"
2870661|NCT03454971|Experimental|MinOS arm|Patients are followed according to MinOS protocol:
2870662|NCT03454958|Other|Data collection|Data will be collected at four time points over the course of approximately one year and nine months. Participating couples (women and men) will be recruited during the first trimester of their first pregnancy. First measurement will take place in the week of the first routine ultrasound scan (week 12 of pregnancy) (=T0). First follow-up measures will take place six weeks postpartum (=T1). The second and third follow-up measurements will take place at six months postpartum (=T2) and twelve months postpartum (=T3).
2870663|NCT03454945|Experimental|Doxycyline|Oral Vibramycin antibiotic100 mg capsule every 12 hours for 3 months
2870664|NCT03454945|Active Comparator|Phototherapy|UVA+ psoralen 3 sessions per week for 3 months
2870665|NCT03454932||Rheumatoid Arthritis|Patients with Rheumatoid Arthritis
2870666|NCT03454932||Psoriatic Arthritis|Patients with Psoriatic Arthritis
2870667|NCT03454932||Spondylarthritis|Patients with Spondylarthritis
2870668|NCT03454919|Other|Palbociclib|single arm
2870669|NCT03454906||L Hemoglobin|L Hemoglobin: consistently low all 6 months with low hemoglobin levels
2870670|NCT03454906||T Hemoglobin|T Hemoglobin; consistently within the target range all 6 months with target-range hemoglobin levels
2870671|NCT03454906||H Hemoglobin|H Hemoglobin: consistently high all 6 months with high hemoglobin levels
2870675|NCT03454893|Experimental|Single Assignment AVR-RD-01|AVR-RD-01 Drug Product (autologous CD34+ cell-enriched fraction that contains cells transduced with Lentiviral Vector/alpha-galactosidase A (AGA) encoding for the human AGA complementary deoxyribonucleic acid (cDNA) sequence
2870676|NCT03454867|Experimental|Hemofiltration (treatment)|Standard acute ischemic stroke treatment + hemofiltration Standard treatment included thrombolytic therapy for eligible candidates (tPA 0,9 mg/kg, max dose 90 mg)
2870677|NCT03454867|Active Comparator|Control|Standard acute ischemic stroke treatment Standard treatment included thrombolytic therapy for eligible candidates (tPA 0,9 mg/kg, max dose 90 mg)
2870678|NCT03454854|Experimental|APP-assisted anti-thrombotic therapy|Intelligent response system:real-time receiving data or events that doctor or patient terminal upload,then spontaneously evaluate the thrombosis and bleeding risk based on code of point built-in,respectively send messages to doctor and patient after this, then doctors direct the patients to adjust treatment schedule.Develop an exemplary anti-thrombotic therapy network data platform and a intelligent terminal APP, establish an new pattern used in long-time anti-thrombotic management based on dynamic risk evaluation, and promoted and verified by 10 thousands large sample's cohort study.
2870679|NCT03454841|Active Comparator|Prasugrel|Patients with myocardial infarction will receive prasugrel as a part of dual antiplatelet therapy with aspirin.
2870680|NCT03454841|Active Comparator|Ticagrelor|Patients with myocardial infarction will receive ticagrelor as a part of dual antiplatelet therapy with aspirin.
2870681|NCT03454828|Experimental|obese carbohydrate diet|Obese adolescents with a body mass index (BMI) >95th percentile.
2870682|NCT03454828|Active Comparator|lean carbohydrate diet|Lean adolescents with a body mass index (BMI) <85th percentile.
2870683|NCT03454815|Experimental|Patency Group|apical patency was maintained during chemomechanical preparation
2870684|NCT03454815|No Intervention|Non Patency Group|Apical patency was not maintained during chemomechanical preparation
2870685|NCT03454802|Active Comparator|Normal subjects|Normal subjects 'Passive Leg Raising'
2870686|NCT03454802|Active Comparator|ICU patients|ICU patients 'Passive Leg Raising'
2870687|NCT03454802|Active Comparator|Cardiac Outpatients|Cardiac Outpatients 'Passive Leg Raising'
2870688|NCT03454789|Active Comparator|LB Group|Ultrasound-guided brachial plexus block for LB Group (15 ml lidocaine 1% + 15 ml bupivacaine 0.5%)
2870689|NCT03454789|Active Comparator|BS Group|Ultrasound-guided brachial plexus block for BS Group (20 ml bupivacaine 0.5% + 10 ml normal saline)
2870690|NCT03454789|Active Comparator|LS Group|Ultrasound-guided brachial plexus block for LS Group (20 ml lidocaine 1% + 10 ml normal saline)
2870691|NCT03454789|Active Comparator|BL Group|and Ultrasound-guided brachial plexus block for BL Group (20 ml bupivacaine 0.5% + 10 ml lidocaine 1%)
2870692|NCT03454776|Active Comparator|Unloader One brace|Patients receiving an active brace, Unloader One with active straps facilitating unloading of affected knee compartment
2870693|NCT03454776|Placebo Comparator|Placebo brace|Patients receiving a dummy, lookalike or placebo brace without active straps that facilitate unloading of the affected knee compartment
2870694|NCT03454763|Experimental|Arm A, Intensive|Arm A, Intensive every 5 weeks
2870695|NCT03454763|Experimental|Arm B, Non Intensive|Arm B, Non Intensive every 8-10 weeks
2870696|NCT03454750|Experimental|177Lu-PSMA|177Lu PSMA
2870697|NCT03454737|Experimental|mesenchymal stem cells|
2870698|NCT03454737|Active Comparator|Pure platelet-rich plasma|
2870699|NCT03454724|Experimental|MeRes100 BRS|MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
2870700|NCT03454724|Active Comparator|Xience EES|Xience EES is a Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
2870701|NCT03454711|Experimental|Patient with food addcitions|"Patients (20) will be selected from the Yale Food Addiction Scale (YFAS): a validated screening of FA questionnaire.~Three clinical visits will be realized in less than two months"
2870702|NCT03454711|Experimental|Patients without food addictions|"Patients (20) will be selected from the Yale Food Addiction Scale (YFAS): a validated screening of FA questionnaire.~Three clinical visits will be realized in less than two months"
2870703|NCT03454698|Other|Contol|"Usual care for patients in the CG is defined as follows: Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the wound expert according to the hospital's own standards. This standard corresponds to the one from the EWMA."
2870704|NCT03454685||NCSLC I and NSCLC II|Early lung cancer patients, including NCSLC I and NSCLC II.
2870705|NCT03454685||NCSLC III and NCSLC IV|Advanced lung cancer patients，including NCSLC III and NCSLC IV
2870706|NCT03454659||high (0.8 )|The purpose of this study is to compare the effect of high 0.8 and low 0.4 FiO2 ventilation primarily on surgical field infection and secondarily on postoperative pulmonary complications in patients are undergoing supratentorial craniotomy surgeons.
2870707|NCT03454659||low (0,4) fiO2|The purpose of this study is to compare the effect of high 0.8 and low 0.4 FiO2 ventilation primarily on surgical field infection and secondarily on postoperative pulmonary complications in patients undergoing supratentorial craniotomy surgeons.
2870708|NCT03454646|Experimental|Group randomized for continuing treatment|"Group who continues the cholinesterase inhibitors (CI). The treatment is one of the CI (donepezil, galantamine or rivastigmine) with market authorization and commercialized for more than 15 years in France. The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual.~All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months."
2870709|NCT03454646|No Intervention|Group randomized for stopping treatment|Group who stops the CI. No placebo will be given, over 2 years All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months.
2870710|NCT03454633|Experimental|Mild hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass at temperature 28.1 - 34 degrees Celsius
2870711|NCT03454633|Active Comparator|Moderate hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass at temperature 20.1 - 28 degrees Celsius
2870712|NCT03454620|Experimental|GC1118 combination with irinotecan|GC1118 weekly(3mg or 4mg) + irinotecan 180mg/m2 biweekly dosing
2870713|NCT03454620|Experimental|GC1118 combination with FOLFIRI|GC1118 weekly(3mg or 4mg) + FOLFIRI biweekly dosing
2870714|NCT03454607|Experimental|FREE robot|Patients undergoing sinus surgery with the FREE robot
2870715|NCT03454594|Experimental|low level laser hemotherapy|nasal and wrist low level laser irradiation applied for 30 min with the highest power twice per week for 3 months
2870716|NCT03454581|Experimental|Photobiomodulation group (PBM)|"Gallium-aluminium-arsenide (GaAlAs) diode laser (MM Optics Recover, São Carlos, São Paulo, Brazil) with a wavelength of 808 nm, punctual contact mode,spot size of 0.03 cm2, power output of 100 mW, output density of 333 mW∕cm2, energy density of 13.3 J ∕cm2, 40 s exposure time per point, and 4 Joules (J) of total energy per point.~18 individuals"
2870717|NCT03454581|Experimental|Manual Therapy group (MT)|"At masticatory muscles were performed circular movements, slip and compression with fingers movements. At the temporomandibular joint (TMJ) was performed a caudal distraction with anterior projection, placing the thumb on the second or third molar.~16 individuals."
2870718|NCT03454581|Experimental|Combined therapy group (CT)|Applied the protocols of PBM group and immediately after, to MT group. 17 individuals.
2870719|NCT03454555|Active Comparator|Arm 1|Arm 1 patients will receive guideline-concordant pharmacotherapy based on clinical guidelines for opioid therapy for chronic noncancer pain plus the Shared Decision-Making (SDM) intervention.
2870720|NCT03454555|Active Comparator|Arm 2|Arm 2 patients will receive the guideline-concordant pharmacotherapy based on clinical guidelines for opioid therapy for chronic noncancer pain plus the Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT+CP) Intervention.
2870721|NCT03454542|Experimental|Menicon DSRB Redesign|Menicon DSRB Modified Lens Design is a single use contact lens with revised thickness specifications worn for 6 hours or more.
2870722|NCT03454542|Active Comparator|Menicon DSRB Original Design|Menicon DSRB Initial Lens Design is a single use contact lens with the original thickness specifications worn for 6 hours or more.
2870723|NCT03454529|Experimental|Treatment (simvastatin)|Patients receive simvastatin PO daily for 2-4 weeks in the absence of disease progression or unacceptable toxicity.
2870724|NCT03454516|No Intervention|Standard Care|This group is the usual standard treatment group
2870725|NCT03454516|Other|Telemonitoring group|This group will followed up with telemonitoring
2870726|NCT03454503||First cohort|Newly diagnosed patients
2870727|NCT03454503||Second cohort|Patients switched from reference product (Glivec® )
2870728|NCT03454477|Experimental|conventional open surgery|Patients who met the inclusion criteria were selected for a conventional open surgery procedure for a conventional neck incision for thyroid surgery.
2870729|NCT03454477|Experimental|endoscopic thyroidectomy|Patients who met the inclusion criteria were selected to undergo thyroid surgery via endoscopic thyroidectomy
2870730|NCT03454477|Experimental|robotic thyroidectomy|Patients who met the inclusion criteria chose the Da Vinci robot for thyroid surgery.
2870731|NCT03454464|Sham Comparator|Conventional operation group|Conventional operation group,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure.
2870732|NCT03454464|Experimental|central neck dissection first group|central neck dissection first group,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
2870733|NCT03454451|Experimental|Cohort 1a|CPI-006
2870734|NCT03454451|Experimental|Cohort1b|CPI-006 + CPI-444
2870735|NCT03454451|Experimental|Cohort 1c|CPI-006 + pembrolizumab
2870736|NCT03454451|Experimental|Cohort 2a|CPI-006
2870737|NCT03454451|Experimental|Cohort 2b|CPI-006 + CPI-444
2870738|NCT03454451|Experimental|Cohort 2c|CPI-006 + pembrolizumab
2870739|NCT03454438|Experimental|Algorithm|Use of electronic structured referral sheets using the algorithms for rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.
2870740|NCT03454438|Experimental|Triage|Triage by rheumatologist in a primary care setting.
2870741|NCT03454438|No Intervention|Usual care|Control group consisting of usual care.
2870742|NCT03454425|Experimental|Exablate Subthalamotomy|Exablate treatment for Parkinson's Disease Motor Features
2870743|NCT03454425|Sham Comparator|Sham ExAblate Subthalamotomy|
2870744|NCT03454399|No Intervention|TEE image before suction|Suction orogastric tube which is attached to TEE probe
2870745|NCT03454399|Experimental|TEE image after suction|Suction orogastric tube which is attached to TEE probe
2870746|NCT03454386|Active Comparator|Active Treatment|"Stress Management and Resilience Training Program~This group will be initially enrolled in the program."
2870747|NCT03454386|Other|Control|"Self-Management Stress Reduction Program~This group will be placed in a self-management stress reduction program. During this time these participants will be given a popular stress reduction book to read over 12 weeks. They will complete questionnaires at weeks 4 and 12. After the 12 weeks, this group will be enrolled in the online SMART program and complete assessments at week 24 (upon completion of the program."
2870748|NCT03454373|Experimental|Incentive for return to care|"Standard of care HIV primary care services, including counseling to return to care, plus a one-time re-start incentive of 22,500 TZS to return to care."
2870749|NCT03454373|No Intervention|Comparator|Standard of care HIV primary care services, including counseling to return to care.
2870750|NCT03454347|Experimental|Protein Supplementation Group|Participants in this group will complete two weeks of lower limb suspension and receive 75g/day of supplemental protein in addition to education aimed at increasing protein intake through their diet.
2870751|NCT03454347|Active Comparator|Non-Supplemental Group|Participants in this group will complete two weeks of lower limb suspension and will receive no supplementation or nutritional education.
2870752|NCT03454334|Active Comparator|AMO Tecnis Symfony|"Multifocal with extended range of vision, Diffractive, No Preloaded, Aspheric, +3.25 D near add and +2.17 D intermediate 6.0mm Hydrophilic~-0.20~Has nine diffractive steps, The proprietary achromatic technology corrects chromatic aberration. This creates improved contrast sensitivity."
2870823|NCT03453892||anti PD-1/PD-L1|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti PD-1/PD-L1) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
2870975|NCT03452722||Study group|Applied rtPA
2870753|NCT03454334|Active Comparator|AcrySof ReSTOR (Alcon Laboratories)|"Multifocal ,Diffractive, +3.00D and for Near, Aspheric, Has 9 steps (rings), Light: 41% for far; 41% for near: 18% reflected (lost).~6.0mm Silicone~-0.10 Bifocal ,One piece,Blue filter ,Central diffractive region of 3.6_mm for near and distance vision ,Apodised ,peripheral refractive region is dedicated to distance vision"
2870754|NCT03454334|Active Comparator|AT Lisa tri (CarlZeiss Meditec AG)|Trifocal, diffractive, +3.33 D near add and +1.66 D intermediate add at the IOL plane, aspheric (aberration correcting) Optic Diameter 6.0 mm Total Diameter 11.0 mm Haptic Angulation 0° Lens Design Single-piece, MICS Incision Size 1.8 mm Company Labeled A-Constant1 118.6 Diopter Range 0.0 to +32.0 D, 0.5 D increments ACD 5.32
2870755|NCT03454334|Active Comparator|PanOptix(Alcon Laboratories)|"Trifocal,Difractive,+3.25D Near,+2.17 D intermediate 6.0mm hydrophobic~-0.27 One piece ,aspheric , Focal 4.5 mm (15 diffractive zones)"
2870756|NCT03454308|Experimental|SMASH|Automated reminder functions activated on pill monitoring device, motivational text messages, at home BP monitoring
2870757|NCT03454308|Other|Enhanced SC|No reminder functions on the pill monitoring device, attention control text messages
2870758|NCT03454295|Experimental|Part I|Focus group (Part 1) of four to ten GBM ICs bereaved at least one year to help determine our recruitment strategy. Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received. Should consensus among participants be reached (e.g., if the majority report that being approached at time of their loved one's cancer recurrence would have been the optimal time for enrollment), we will target our enrollment timeline to this point (and this timeline will be reflected in amended inclusion criteria). If no consensus is reached, the study staff will enroll ICs at all points in the caregiving trajectory and revisit the appropriateness of various points of contact during the Part 2 individual interviews.
2870759|NCT03454295|Experimental|Part II|In Part 2, we will recruit 60 ICs of patients with GBM who will be randomized to receive either MCP-C or EUC. MCP-C will be delivered individually over 7 1-hour-long sessions within 7 - 14 weeks.
2870760|NCT03454282|Experimental|FMD Arm|The intervention consists in 5-day FMD (Fasting Mimicking Diet) to be followed for one cycle (Cohorts A and B) or for 4 consecutive every-four week cycles postoperatively.
2870761|NCT03454269|Active Comparator|PD patients with visual hallucinations (PD-VH)|PD patients without hallucinations or illusions
2870762|NCT03454269|Active Comparator|Patients with illusions (PD-I)|PD patients with Illusions and without hallucinations
2870763|NCT03454269|Active Comparator|Patients without visual hallucinations or illusions (PD-nVHI))|PD patients without Illusions and with hallucinations
2870764|NCT03454256|Experimental|Virtual Reality Group (VRG)|The Virtual Reality Group (VRG) will perform the rehabilitation trough the Virtual Reality Rehabilitation system (VRRS, Khymeia,Italy). The patient standing upright on a balance board will practice exercises of vertical position control with a visual biofeedback received from the VRRS and interacting with the serious video-games. The difficulty level of the exercises will increase gradually session by session. Every session will last 45 minutes with a frequency of at least 5 times a week.
2870765|NCT03454256|No Intervention|Control Group (CG)|The Control Group (CG) will perform the traditional treatment consisting of the exercises of rehabilitation of gait and postural passages, exercises for postural control, and proprioceptive exercises in a vertical position according to the method chosen by the physiotherapist. Every session will last 45 minutes with a frequency of at least 5 times a week.
2870766|NCT03454243|Experimental|RXDX-106|
2870767|NCT03454230|Experimental|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
2870768|NCT03454230|No Intervention|Common repositioning practice|pressure ulcer prevention cares are provided according to usual practice. Frequency and modality of positioning applied to the patients are collected.
2870769|NCT03454217|Active Comparator|Oxycodone|Postoperative pain treatment with oxycodone
2870770|NCT03454217|Active Comparator|Tramadol|Postoperative pain treatment with tramadol
2870771|NCT03454204||Pharmacokinetic|Establish a pharmacokinetic relationship between plasma concentration and the effect of norepinephrine in patients under concentration-target intravenous anesthesia by identifying significant covariates during general anesthesia.
2870772|NCT03454191|Experimental|Erector spinae plane block|
2870773|NCT03454191|Placebo Comparator|Placebo|
2870774|NCT03454178||Hypertensive patients|150 Chinese patients with a diagnosis of essential hypertension from a primary care clinic
2870775|NCT03454165|Experimental|Single Arm|Evaluate the MTD of BNC105P in combination with ibrutinib in patients with relapsed/refractory CLL. Treatment will be administered on an outpatient basis but will also be permitted inpatient. BNC105P will be administered as a single agent prior to initiation of ibrutinib. Beginning with cycle 2, ibrutinib will be administered concomitantly with BNC105P at a starting dose of 420 mg PO daily. Each cycle will last for 21 days. Provided no toxicities occur, each patient will be treated for 6 cycles.
2870776|NCT03454152||patients|pediatric patients with diabetic ketoacidosis come to Assuit University Children Hospital within one year. Electrocardiogram and echocardiography will be done to all patient with diabetic ketoacidosis
2870799|NCT03454048|Experimental|Group 1 (Cohort A) LD-PIP/LD-PIP2/PIP|Cohort A will be subjected to a standard controlled human malaria infection (CHMI) delivered by five Pf-infected mosquitoes. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 1 (LD-PIP/LD-PIP2/PIP) will be curatively treated with piperaquine (960mg).
2870879|NCT03453476|No Intervention|Control|Scaling and root planing only
2870777|NCT03454139|Active Comparator|Subcostal TAP group|Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,25 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia. After that, the patient is positioned to lithotomy position and the open-end catheter is inserted. After that the patient is turned to prone position and the percutaneous nephrolithotomy is performed. Tramadol 100 mg iv is administrated 20 minutes before the end of the surgery. Morphine patient controlled analgesia is planned for postoperative pain management.
2870778|NCT03454139|No Intervention|Non- TAP group|Percutaneous nephrolithotomy is performed under general anesthesia. No regional analgesia is administered to this patients. Paracetamol 1000 mg/100ml; iv and Tramadol 100mg iv is administered 20 minutes before the end of the surgery for postoperative analgesia. Morphine patient controlled analgesia is planned for postoperative pain management.
2870779|NCT03454126|Experimental|Cohort 1: BIIB095 5 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 5 mg or placebo orally, followed by a fast of at least 4 hours post dose.
2870780|NCT03454126|Experimental|Cohort 2: BIIB095 25 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 25 mg or placebo orally, followed by a fast of at least 4 hours post dose.
2870781|NCT03454126|Experimental|Cohort 3: BIIB095 100 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 100 mg or placebo orally, followed by a fast of at least 4 hours post dose.
2870782|NCT03454126|Experimental|Cohort 4 (Fasted): BIIB095 200 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 200 mg or placebo orally, followed by a fast of at least 4 hours post dose.
2870783|NCT03454126|Experimental|Cohort 4 (Fed): BIIB095 200 mg|After a minimum 2 week washout period, followed by an overnight fast of at least 8 hours, participants will consume a high fat breakfast. Participants will then receive a single dose of either BIIB095 200 mg or placebo orally within 30 minutes after starting the breakfast, followed by a fast from food for at least 4 hours post dose.
2870784|NCT03454126|Experimental|Cohort 5: BIIB095 400 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 400 mg or placebo orally, followed by a fast of at least 4 hours post dose.
2870785|NCT03454126|Experimental|Cohort 6: BIIB095 600 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 600 mg or placebo orally, followed by a fast of at least 4 hours post dose.
2870786|NCT03454126|Experimental|Cohort 7: BIIB095 50 mg BID|Participants will receive a single dose of either BIIB095 50 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
2870787|NCT03454126|Experimental|Cohort 8: BIIB095 100 mg BID|Participants will receive a single dose of either BIIB095 100 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
2870788|NCT03454126|Experimental|Cohort 9: BIIB095 200 mg BID|Participants will receive a single dose of either BIIB095 200 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
2870789|NCT03454126|Experimental|Cohort 10: BIIB095 300 mg BID|Participants will receive a single dose of either BIIB095 300 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
2870790|NCT03454100|Experimental|multi-sectoral package of activities|Villages in the experimental arm received the full multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
2870791|NCT03454100|No Intervention|Control|Villages in the control arm did not receive teh multi-sectoral package of village level activities.
2870792|NCT03454087|Experimental|Enteral Dextrose Infusion|Critically-ill participants with sepsis enrolled in the interventional arm will receive a 24-hour infusion of dextrose solution by the enteral route to be initiated via an existing nasogastric or orogastric tube within the first 48 hours of meeting sepsis criteria.
2870793|NCT03454087|Placebo Comparator|Placebo|Critically-ill participants with sepsis in the placebo arm will receive a 24-hour enteral free water infusion via an existing orogastric or nasogastric tube within 48 hours of meeting sepsis criteria.
2870794|NCT03454074|Experimental|B-Fit intervention|Combines group education about brain health with individualized goal-setting and group problem-solving to help participants effectively integrate healthy behavioral changes into their everyday lives.
2870795|NCT03454074|Active Comparator|Education Only|Provide group education about healthy behavior changes without problem-solving component.
2870796|NCT03454074|No Intervention|Wait-list|No intervention administered. Will be offered intervention following a delay.
2870797|NCT03454061|Experimental|Intervention|Physical activity intervention
2870798|NCT03454061|No Intervention|Control|Keep usual activities in kindergarten
2870821|NCT03453905|Other|Mirels|Decision on preventive surgery vs follow-up will be based on expert judgement and Mirels' score
2870822|NCT03453892||anti CTLA-4|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti CTLA-4) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
2870800|NCT03454048|Experimental|Group 2 (Cohort A) LD-PIP/LD-PIP2/SP|Cohort A will be subjected to a standard controlled human malaria infection (CHMI) delivered by five Pf-infected mosquitoes. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 2(LD-PIP/LD-PIP2/SP) will be curatively treated with sulfadoxine-pyrimethamine (1000mg/50mg).
2870801|NCT03454048|Experimental|Group 3 (Cohort B) LD-PIP/LD-PIP2/PIP|Cohort B will be subjected to a standard blood stage challenge with ~2,800 Pf-infected erythrocytes by intravenous injection. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 3 (LD-PIP/LD-PIP2/PIP) will be curatively treated with piperaquine (960mg)
2870802|NCT03454048|Experimental|Group 4 (Cohort B) LD-PIP/LD-PIP2/SP|Cohort B will be subjected to a standard blood stage challenge with ~2,800 Pf-infected erythrocytes by intravenous injection. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 4 (LD-PIP/LD-PIP2/SP) will be curatively treated with sulfadoxine-pyrimethamine (1000mg/50mg).
2870803|NCT03454035|Experimental|Open-label, single arm Phase I|Ulixertinib added to palbociclib
2870804|NCT03454022|Active Comparator|Usual care|"Participants receive an educational pamphlet from the National Kidney Foundation, Choosing a Treatment for Kidney Failure."
2870805|NCT03454022|Experimental|DART|"Participants receive an educational pamphlet from the National Kidney Foundation, Choosing a Treatment for Kidney Failure. They also receive a link to access the web-based decision-aid program, Decision-Aid for Renal Therapy (DART). Participants may access this program using a computer at home throughout the duration of the trial. Those who do not have a computer with web access at home are assisted in watching the program in the clinic."
2870806|NCT03454009|Experimental|Multimodal hygiene intervention|"Employees will receive hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer. Training materials discuss the importance of performing hygiene behaviors to prevent the spread of pathogens, such as, cleaning hands, using tissues to cover one's mouth and nose when coughing or sneezing, and keeping office surfaces clean.~In addition, hygiene materials will be placed in common areas frequented by employees in the intervention group that include, educational hygiene posters, free standing hand sanitizer delivery stands, and bottles of hand sanitizer ."
2870807|NCT03454009|No Intervention|Control|Employees will complete all surveys but will not have access to additional hygiene products. Will follow usual hygiene behaviors.
2870808|NCT03453996|Experimental|Intervention|Cardiologists will receive computerized clinical decision support information for CI-AKI prevention for patients identified above the median (> 5%) risk of AKI based on the NCDR risk prediction model for CI-AKI.
2870809|NCT03453996|Other|Control|Usual care.
2870810|NCT03453983|Experimental|Anodal tDCS Intervention Group|Transcrainial Direct Current Stimulation (tDCS): The right primary motor cortex will be localized and a saline soaked sponge electrode will be placed onto M1 with a second saline soaked sponge electrode placed on the contralateral supraorbital region.
2870811|NCT03453983|Sham Comparator|Sham tDCS Intervention Group|Transcrainial Direct Current Stimulation (tDCS): The right primary motor cortex will be localized and a saline soaked sponge electrode will be placed onto M1 with a second saline soaked sponge electrode placed on the contralateral supraorbital region.
2870812|NCT03453970|Experimental|Therapeutic Education Program|"The program is based on adapted interventions and will consist of the following phases:~Phase I: Identification of self-care needs in Diabetes Mellitus through the EBADE questionnaire. This instrument will identify the needs grouped by constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention).~Phase II: Application of interventions adapted according to the behavioral mediator who encounters barriers. The interventions will be applied both in the face-to-face and telephone modality, using the Nursing Intervention Classification and their respective activities.~Phase III: measurement of the clinical variables and reported by the patients described in the objectives."
2870813|NCT03453970|No Intervention|Usual Care|The conventional intervention consists of the usual care that is followed in the nursing consultations in primary care to patients with type 2 DM, based on the recommendations of the Clinical Practice Guide of the National Health System
2870814|NCT03453957|Experimental|Professional Development Program|Therapists who participate in workshops and consultation sessions with study trainers during study-related therapy sessions and their participating patients/clients.
2870815|NCT03453957|No Intervention|Control|Therapists who did not participate in workshops and consultations sessions while engaging in study-related therapy sessions and their participating patients/clients.
2870816|NCT03453944|Experimental|VF03-K active stimulation|NMES applied to the abdominal wall muscles using the VentFree prototype (VF03-K). Stimulation is applied twice daily for 30 minutes, 5 days per week, for 6 weeks or until the patient is weaned from mechanical ventilation, whichever occurs sooner.
2870817|NCT03453944|Sham Comparator|VF03-K sham stimulation|Sham stimulation applied to the abdominal wall muscles using the VentFree prototype (VF03-K). Sham stimulation is applied twice daily for 30 minutes, 5 days per week, for 6 weeks or until the patient is weaned from mechanical ventilation, whichever occurs sooner.
2870818|NCT03453918|Experimental|Polyphenols|patients will receive during the meal, 2 capsules of Oligopin® containing 50 mg of polyphenols each. They will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of Oligopin® contains two excipients: 150 mg of maltodextrin and 30 mg of magnesium stearate.
2870819|NCT03453918|Experimental|Placebo|patients will receive during the meal, 2 capsules of placebo, visually identical to Oligopin®. The patient will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of placebo contains two excipients: 218.9 mg of maltodextrin and 1.1 mg of magnesium stearate.
2870820|NCT03453905|Experimental|CTFEA|Decision on preventive surgery vs follow-up will be based on expert judgement, Mirels' score and CTFEA
2870976|NCT03452722||Control study|rtPA not applied
2870824|NCT03453879||1: Study population|Participants in this study are working staff (junior and senior doctors, midwifes and other health personal) in the maternity wards of two hospitals in Central Region Denmark: Horsens Regional Hospital and Aarhus University Hospital, Skejby.
2870825|NCT03453866|Experimental|Warmed Arthroscopic Fluids|Arthroscopic Fluids will be warmed to 38 degrees Celsius during procedure with active warming device. Temperature will be measured in real time.
2870826|NCT03453866|Active Comparator|Room Temperature Arthroscopic Fluids|Arthroscopic fluids will be kept at room temperature and will not be warmed per current standard of care. Temperature will be measured in real time.
2870827|NCT03453853|Experimental|Mitral Loop Cerclage|Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device
2870828|NCT03453840|Active Comparator|HIV-infected 3-day AL|Standard 3-day twice daily (BID) regimen of artemether-lumefantrine for uncomplicated malaria, given over 4 days (Study Days 0, 1, 2 and 3) so that sampling will begin in the morning of day 3. These participants are HIV-infected and stabilized on EFV-based ART.
2870829|NCT03453840|Experimental|HIV-infected 5-day AL|Extended 5-day BID regimen of artemether-lumefantrine, given over 6 days (Study Days 0, 1, 2, 3, 4, and 5) so that sampling will begin in the morning of day 5. These participants are HIV-infected and stabilized on EFV-based ART.
2870830|NCT03453840|Active Comparator|HIV-uninfected 3-day AL|Standard 3-day BID regimen of artemether-lumefantrine for uncomplicated malaria, given over 4 days (Study Days 0, 1, 2 and 3) so that sampling will begin in the morning of day 3. These participants are HIV-uninfected.
2870831|NCT03453840|Experimental|HIV-uninfected 5-day AL|Extended 5-day BID regimen of artemether-lumefantrine, given over 6 days (Study Days 0, 1, 2, 3, 4, and 5) so that sampling will begin in the morning of day 5. These participants are HIV-uninfected.
2870832|NCT03453827||PEX|Patients after Cataract surgery with PES
2870833|NCT03453827||Control|Patients after Cataract surgery without PES
2870834|NCT03453814|Experimental|Interventional|Music therapy.
2870835|NCT03453814|No Intervention|Comparison|No music therapy.
2870836|NCT03453801|Experimental|Group A: MZ twins 2-5 years (LAIV4)|Group A Monozygotic twins, 2-5 yo (annual return): Individual twin participants will be given FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0, 7 and 60 post-immunization. Vaccine naive children will receive two immunizations in the first year, 28 days apart then return annually for flu immunization. Blood samples will be obtained on Days 0, 7 and 60 post second-immunization. Beginning in 2015-2016, participants in Group A will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) following ACIP recommendation not to give LAIV4.
2870837|NCT03453801|Experimental|Group B: 6 mo-10 yr (IIV4 or LAIV4)|Group B non-twins 6 mo-10 years (annual return): Participants between 6-23 mo, and 9-10 yr will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) IM. Participants 2-8 yr will be given FluMist® live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0 and 60 post immunization. Vaccine naive children will get two doses of vaccine the first yr then return annually for flu immunization and blood samples on Day 0 and 60 post second immunization. Beginning in 2015-2016 all participants in Group B 6 mo through10 yr will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) following ACIP recommendation not to give LAIV4.
2870838|NCT03453801|Experimental|Group C: 6-12 mo Flu/MMRV Naïve (IIV4)|Group C non-twins 6-12 mo (annual return): Participants 6-12 mo who are flu and MMRV naïve will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) annually. In Year 1, participants will return for a second flu immunization at least 28 days later and for blood samples on Days 0 and 60 post-second immunization and on Day 60 post MMRV (to be given by primary care physician). In Years 2-5, participants will return annually for Fluzone® IIV4 flu immunization and for blood samples on Days 0 and 60 post-immunization.
2870839|NCT03453788|Experimental|Intervention group|Alternating follow-up visits by nurse and doctor. In the nurse-led consultations, the patients will be introduced to the smartphone LETSGOapp with access to information on cancer treatment and side effects, physical activity advice. Two-monthly assessment of 12 symptoms that may represent relapse through the app.The patients will fill in an electronic questionnaire package at baseline, 3, and 6 months after treatment.
2870840|NCT03453788|No Intervention|Reference group|Regular hospital follow-up.The patients will fill in an electronic questionnaire package at baseline, 3, and 6 months after treatment.
2870841|NCT03453775|Active Comparator|Ultrasound guided infiltration|"Ultrasound guided periradicular lumbar infiltration. Prone position. Lumbar spine level located in a median sagittal plane (spinous processes). High resolution curved 5MHz ultrasound probe. Probe is then rotated 90° for a median transverse image. Transverse plane translation towards desired side to have in the same plane: spinous process, vertebral blade, zygapophysial articulation, lateral facet, transverse process. Needle passes skin at 45° angle, directed in plane to the foramen. Fluoroscopy then performed to check needle's correct position. Poorly positioned needles will be replaced to obtain an intra-foraminal/epidural periradicular diffusion of the contrast medium. Once position is confirmed, Depomedrol 40mg + lidocaine 2% (1ml) is injected."
2870842|NCT03453775|Active Comparator|Fluoroscopy guided infiltration|"Fluoroscopy guided periradicular lumbar infiltration. Prone position. Anatomical identification by radioscopy: antero-posterior and sagittal planes. Needle placement in an anteroposterior view, needle is then advanced in an inclined plane of 20° with respect to the initial axis, tunnel vision type image. Foramen is then reached in a sagittal view (not to progress too far in the intra-foraminal level). Needle progression is secured by neurostimulation (territory concerned by the root, intensity 0.2 milliampere to be at a distance of 1mm from the nerve root). Once needle is in place, fluoroscopy is performed to verify correct positioning (Omnipaque 300mg/ml of Iohexol, 0.2 to 0.5ml). Once position confirmed, mixture Depomedrol 40mg + lidocaine 2% (1ml) is injected."
2870843|NCT03453762|Active Comparator|Recruitment maneuver group|After anesthetic induction, recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
2870844|NCT03453762|Experimental|Lung ultrasonography group|After anesthetic induction, recruitment maneuver is performed, being guided by ultrasonography.
2870845|NCT03453749|Other|Salovum|Patients will be given Salovum 1g/kg body weight/24 hours, divided into 6 dosages and given during 5 consecutive days.
2870880|NCT03453463|Experimental|exercise|Predominately resistance exercise training 3x week for 18 months Calcium and Vitamin-D-supplementation (i.e. 800 mg/800 IE/d)
2870846|NCT03453736||Robotic procedures|Experiences and practices in Robotic theatres will be studied via semi-structured interviews with staff as well as team observations during real time robotic surgery. As the study is a qualitative one, data collection will continue till we reach saturation of theoretical categories. We expect 20 interviews and 10 observations to suffice.
2870847|NCT03453736||Non-Robotic procedures|"Staff involved in robotic surgery will have almost definitely worked in non-robotic theatres ie major abdominal and laparoscopic. Staff interviews will explore differences in experiences and practices between these different theatre setups.~In addition, we aim to observe further 5 non-robotic procedures to evaluate staff teamwork and communication within the more regular theatre setup."
2870848|NCT03453723|Experimental|magic glove hypnosis|Magic glove hypnosis technique use before propofol infusion
2870849|NCT03453723|Active Comparator|lidocaine|extemporaneous mixture with lidocaine for propofol infusion
2870850|NCT03453710|Active Comparator|Bankart Repair and Remplissage|Patients randomized to the all-arthroscopic group (Bankart repair and remplissage) will undergo a standard arthroscopic anterior labral repair with a minimum of 3 suture anchors, followed by remplissage with 1 or 2 anchors, at the discretion of the treating surgeon.
2870851|NCT03453710|Active Comparator|Latarjet Coracoid Transfer|Patients randomized to the open Latarjet coracoid transfer will undergo a Latarjet coracoid transfer through a deltopectoral approach and horizontal split in the subscapularis at the superior 2/3, inferior 1/3 junction. The coracoid process will be oriented in the conventional manner, with the inferior surface against the glenoid vault, secured with two cannulated screws
2870852|NCT03453697|Experimental|acute intermittent hypoxia|Adjust the proportion of nitrogen and oxygen, through increasing the suction nitrogen concentration, the subject's blood oxygen saturation could decrease to 80%~90% within 30 seconds and also lasts 30 seconds; then quickly reduce the concentration of nitrogen gas suction to make the subject's blood oxygen saturation gradually return to normal level (consistent with the air inhalation), and then continue breathing air about 60 seconds to enter the next round of hypoxic state.Through adjusting the inhaled nitrogen concentration in patients, the patients could be simulated as the OSA patients who had intermittent hypoxic state due to upper airway collapse at night. This process is equivalent to acute intermittent hypoxia 25-30 times/h, which is clinically intermediate to severe OSA.
2870853|NCT03453684|Experimental|Administration of Vancomycin|Administration of Vancomycin 15 mg/kg over 1 hour prior to surgical incision
2870854|NCT03453671|Experimental|Mindfulness|Participants will use the strategy of mindfulness, i.e., present moment awareness with nonjudgment and acceptance, while exercising.
2870855|NCT03453671|Experimental|Distraction|Participants will use the strategy of distraction, i.e., directing their attention to something other than exercise (specifically a podcast) while exercising.
2870856|NCT03453671|Active Comparator|Self-Monitoring|Participants will monitor their internal experience while exercising, without distraction and without being taught mindfulness skills of nonjudgment and acceptance.
2870857|NCT03453658|Active Comparator|Manual instrumentation|Manual instrumentation: Endodontic treatment will be performed with the use of conventional endodontic manual files.
2870858|NCT03453658|Experimental|Reciprocating instrumentation|Mechanized instrumentation: Endodontic treatment will be performed with the use of reciprocating mechanized files. The files are activated by an engine that produces reciprocating movements.
2870859|NCT03453632|Experimental|Botulinic toxin|Injections of botulinic toxin (Dysport®, Allergan) 200 UI
2870860|NCT03453632|Placebo Comparator|Placebo|Injections of physiological serum
2870861|NCT03453619|Experimental|APL-2|Open Label, Study Drug, APL-2
2870862|NCT03453606|Active Comparator|home group|
2870863|NCT03453606|Active Comparator|center group|
2870864|NCT03453567||TAVR|Transcatheter Aortic Valve Replacement
2870865|NCT03453567||Sutureless AVR|Sutureless Aortic Valve Replacement
2870866|NCT03453567||Conventional AVR|Conventional Aortic Valve Replacement
2870867|NCT03453554|Experimental|DMN/Smart Home Partnership|Participants will learn how to use a digital memory notebook partnered with smart environment prompting technology to support everyday activities of daily living and reduce problems associated with memory deficits.
2870868|NCT03453554|Active Comparator|Digital Memory Notebook app|Participants will learn how to use a Digital Memory Notebook app to support everyday activities of daily living and reduce problems associated with memory deficits.
2870869|NCT03453541|Experimental|Ketorolac|This group receives Ketorolac 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use, 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
2870870|NCT03453541|Placebo Comparator|Saline|This group will receive an equivalent weight-based volume of 0.9% NaCl solution at the completion of the tonsillectomy in the operating room.
2870871|NCT03453528|Experimental|68Ga-PSMA|68Ga-PSMA
2870872|NCT03453515|Experimental|HEART|Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
2870873|NCT03453515|Other|Growing Minds|Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.
2870874|NCT03453502|No Intervention|Before-intervention phase|All the very low birth weight (VLBW) and extremely low birth weight (ELBW) infants who were admitted from January 2017 to December 2017 to the NICUs of different hospitals.
2870875|NCT03453502|Experimental|Intervention phase|All the VLBW and ELBW infants who were admitted from January 2018 to December 2018 to the NICUs.During this phase,multiple intervention bundles of quality improvement will be implemented.
2870876|NCT03453502|Experimental|Sustainability intervention phase|All the VLBW and ELBW infants who were admitted from January 2019 to December 2019to the NICUs.In the Sustainability intervention phase,multiple intervention bundles of quality improvement will be continuous implemented.
2870877|NCT03453489|Experimental|Treatment (AMT-PET, telotristat etiprate)|Participants undergo AMT-PET within 7 days prior to, and 9-14 days after start of telotristat etiprate treatment. Participants receive telotristat etiprate PO TID for 9-14 days.
2870878|NCT03453476|Experimental|SRP and Fotosan 630|Scaling and root planing, photodynamic therapy using Fotosan 630
2870882|NCT03453450||Health TAPESTRY volunteers|Volunteers in a primary care setting connecting with Health TAPESTRY clients
2870883|NCT03453450||Health TAPESTRY Volunteer Coordinators|The coordinators of volunteers
2870884|NCT03453437|No Intervention|Control group|Receiving no intervention (control groups will be offered the intervention after the experimental group has completed the course)
2870885|NCT03453437|Experimental|Active group|Receiving Mindful Self-Compassion intervention
2870886|NCT03453424|Active Comparator|TEA+DEX group|"Intra operative thoracic epidural injection of (bupivacaine 0.125% +fentanyl 2 mic/ ml) , initial bolus dose of 8 ml before skin incision followed by fixed rate infusion of 6 ml/h till end of abdominal layer closure.~Postoperative, thoracic epidural injection of (bupivacaine 0.0625%+fentanyl 2 mic /ml + dexmedetomidine 0.5 mic/ ml) at infusion rate 6 ml /h and bolus dose of 3 ml with lockout time 10 min"
2870887|NCT03453424|Active Comparator|TEA group|"Intraoperative,thoracic epidural injection of bupivacaine (0.125%+fentanyl 5 mic/ml ) ,initial bolus dose of 8 ml before skin incision followed by fixed rate infusion of 6 ml/h till start of abdominal layer closure.~Postoperative, thoracic epidural injection of (bupivacaine 0.0625%+fentanyl 2 mic /ml) at infusion rate 6 ml /h and bolus dose of 3 ml with lockout time 10 min"
2870888|NCT03453411||Non interventional study|
2870889|NCT03453398|Experimental|Group 1|Shifts over 24-hours, shift cycle of 5 days (morning, afternoon, night, night off, rest).
2870890|NCT03453398|Experimental|Group 2|Shifts over 24-hours, shift cycle of 10 days (morning, morning, afternoon, afternoon, rest, night, night, night off, rest, rest).
2870891|NCT03453398|Active Comparator|Group 3|Only diurnal shifts, shift cycle of 5 days (morning, afternoon, morning, afternoon, morning, rest, rest).
2870892|NCT03453385|No Intervention|Control|Participants will not receive an NJOY electronic cigarette to sample and will continue smoking their usual cigarettes as much or as little as they would like.
2870893|NCT03453385|Experimental|Sampling|Participants will receive an NJOY electronic cigarette to sample and will continue smoking their usual cigarettes as much or as little as they would like.
2870894|NCT03453372|Experimental|Active|MRgFUS treatment of pain caused by knee osteoarthritis
2870895|NCT03453372|Placebo Comparator|Placebo|Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.
2870896|NCT03453359|Experimental|BIS|Group of patients (90) in whom sedation is adjusted using as main parameters the information obtained by the BIS sedation monitor (BIS VISTA, Aspect Medical Systems, USA).
2870897|NCT03453359|Active Comparator|Ramsay|Group of patients (90) in whom sedation is based on subjective monitoring of the level of sedation, using the Ramsay scale as a reference.
2870898|NCT03453346|Experimental|Noncirrhotic and cirrhotic GT-2|Generic sofosbuvir tablet 400 mg once daily plus weight-adjusted ribavirin tablet (1000 mg for <75 kg, and 1200 mg for >=75 kg) twice daily with meal, orally given, for 12 successive weeks
2870899|NCT03453333|Experimental|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
2870900|NCT03453333|Experimental|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
2870901|NCT03453320|Experimental|Rapid - Slow|"Two infusions of 3 ml/kg bodyweight of hyperoncotic albumin 20%, with an interval of 3 to 20 weeks between.~First time rapid (30 minutes), second time slow (120 minutes). Albumin solution"
2870902|NCT03453320|Experimental|Slow - Rapid|"Two infusions of 3 ml/kg bodyweight of hyperoncotic albumin 20%, with an interval of 3 to 20 weeks between.~First time rapid (120 minutes), second time slow (30 minutes). Albumin solution"
2870903|NCT03453307||Group-1|NSCLC patients receiving chemotherapy or target therapy treatment.
2870904|NCT03453294|Experimental|Apnoeic oxygenation using THRIVE|Oxygenation by apnoea oxygenation using THRIVE
2870905|NCT03453294|Active Comparator|Endotracheal intubation and mechanical ventilation|Ventilation and oxygenation by an endotracheal tub and mechanical ventilation
2870906|NCT03453281|Experimental|Aflibercept Injection [Eylea]|Intravitreal injection of 2 mg in 0.05 ml Aflibercept. Frequency: once Duration: 10-15 minutes
2870907|NCT03453268|Other|1: Interventional (drug reduction)|"STEP DOWN strategy.~Proposition of reduction of the number of antihypertensive medication according to:~the systolic blood pressure levels,~co-morbidities"
2870908|NCT03453268|Other|2: Control|Usual treatment
2870909|NCT03453255|Experimental|t(8;21)AML|chemotherapy 5-Aza-2'-deoxycytidine IV 20mg/m2 d8-12 homoharringtonine IV 2mg d1-5 chidamide P.O. 30mg twice/W cytarabine IV 1000mg/m2(<60 year old) 500mg/m2(>60 year old) IV q12h d1,3,5
2870910|NCT03453216|Experimental|Behavioral test and fMRI|Neuropsychological tests and training in behavioral tasks and a Functional Magnetic Resonance Imaging (fMRI) exam
2870911|NCT03453203|Placebo Comparator|Control|"Both arms with be diagnosed using tenderpoints In the control arm the tenderpoint will Be palpated for 90 secs with no counterstrain treatment applied.~Both treatment and control groups will remain on their current migraine medication regiment."
2870912|NCT03453203|Other|Treatment (conterstrain)|Both arms with be diagnosed using tenderpoints. Treatment arm will be treated with counterstrain technique. Counterstrain is a passive manipulative technique which the tissue being treated is positioned at a point of balance, or ease, AWAY from the restrictive barrier (The most thought of form of manipulative technique is high velocity low amplitude which is typically performed by chiropractors in spinal manipulation which goes TOWARD the restrictive barrier and actually pass through the restrictive barrier). Once a tenderpoint is found in the muscles the area of treatment is placed in a (three dimensional) position that will eliminate the sensation (tenderness).The treatment position is held for 90 seconds or until a release is felt (a decrease in muscle tension). Both treatment and control groups will remain on their current migraine medication regiment.
2870913|NCT03453190|Other|Psoriasis Patients on Comb. Treatment|Patients will be given Apremilast 30 mg bid and Clobetasol Spray 0.05 % bid on a tapering schedule over 16 weeks.
2870914|NCT03453177|No Intervention|Standard of Care|ampicillin 50mg/kg twice daily and gentamicin [3mg/kg for babies <2kg or 5mg/kg for babies >2kg] once daily for 7 days, as per Kenyan guidelines).
2870977|NCT03452709|No Intervention|Control group: no intervention|Only the normal practise
2871094|NCT03451890|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
2870915|NCT03453177|Experimental|Standard of Care plus Fosfomycin|Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).
2870916|NCT03453164|Experimental|Radiotherapy + Nivolumab|Localized short-term radiotherapy (22.5 Gy/5 fractions/5 days, Day 1-5) + nivolumab (starting on Day 15-22, a dose of 3 mg/kg (body weight), every 2 weeks to a total of 6 courses)
2870917|NCT03453151|Experimental|Regional nerve anesthesia|
2870918|NCT03453138|Experimental|LMA Protector Group|LMA Protector will be inserted by a blind researcher after standart anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale
2870919|NCT03453138|Experimental|Tracheal Intubation Group|Patients will be intubated after standart anesthesia induction and we will record heamodynamic variables. including mean blood pressure and heart rate
2870920|NCT03453125|Experimental|Spanish mSMT Experimental Treatment|Administered by computer and paper and pencil.
2870921|NCT03453125|Active Comparator|Spanish mSMT Control Treatment|Administered by computer and paper and pencil.
2870922|NCT03453112|Experimental|Foster 100/6mg NEXThaler|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler (NEXThaler)
2870923|NCT03453112|Active Comparator|Foster 100/6mg pMDI|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with Hydrofluoroalkane ( HFA) -134a propellant.
2870924|NCT03453099||Study Cohort|Any ASA I or II patients scheduled for elective day case general anaesthesia at Chelsea & Westminster Hospital, involving Larygneal Mask Airway (LMA) airway insertion and a standard propofol-fentanyl induction regimen, aged between 18-65 years . See specific exclusion criteria below.
2870925|NCT03453086|Active Comparator|Group I:|These patients will receive single ipsilateral Ultrasound TPVB which performed with the patient in the sitting position at the level of the T4 with the probe in a vertical position 2.5-3 cm lateral to the midline. The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes which visualized with the superior costo-transverse ligament and the pleura visible in between . After this, 15-20 cc of bupivacaine 0.25% will be injected
2870926|NCT03453086|Active Comparator|Group II :|These patients will receive serratus anterior plane block. The block will be performed while the patient is in the supine position by using a linear Ultrasound probe of high frequency (6-13 MHz) after sheathing. The probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted inferiorly and laterally, until the 5th rib is identified in the midaxillary line. The latissimus dorsi (superficial and posterior) , teres major (superior) and serratus muscles (deep and inferior) will be then easily identifiable by U/S overlying the fifth rib.
2870927|NCT03453073||chocolate consumption level referent|women who ate 1 oz. (28.35 g) of chocolate <1 time/month
2870928|NCT03453073||chocolate consumption level 2|women who ate 1 oz. (28.35 g) of chocolate between 1 and <1.5 times/month
2870929|NCT03453073||chocolate consumption level 3|women who ate 1 oz. (28.35 g) of chocolate between 1.5 and <3.5 times/month,
2870930|NCT03453073||chocolate consumption level 4|women who ate 1 oz. (28.35 g) of chocolate between 3.5 times/month and <3 times/week
2870931|NCT03453073||chocolate consumption level 5|women who ate 1 oz. (28.35 g) of chocolate >3 times/week
2870932|NCT03453073||No physician diagnosis|No incidence of serious chronic disease prior to visit 3
2870933|NCT03453073||Physician diagnosis|Incidence of serious chronic disease prior to visit 3
2870934|NCT03453073||Younger|Age<65 years at follow-up baseline
2870935|NCT03453073||Older|Age>=65 years at follow-up baseline
2870936|NCT03453060|Experimental|E-WE Thrombin|
2870937|NCT03453060|Placebo Comparator|Placebo|
2870938|NCT03453047||1|Healthy volunteers. Liver donor groups; Course of the research: Blood samples from all groups shall be taken for S100β and NSE in preoperative period, in the operating room and after 1 and 6 months in postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients who were transplanted liver with S100β and NSE. Demographic data of the patients, accompanying diseases, American Society of Anesthesia classification, etiology, Model For End-Stage Liver Disease score, Child classification, sodium, potassium, total bilirubin, alanine aminotransferase, aspartate aminotransferase, Alkaline phosphatase, International Normalized Ratio, creatinine and urea shall be recorded. Intraoperative medicine administration and fluid balance, duration of operation, graft hot ischemia and graft cold ischemia durations, initial pulmonary artery pressure, blood component transplantations shall be recorded.
2870939|NCT03453047||2|Liver transplant groups;Course of the research Blood samples from all groups shall be taken for S100β and NSE in preoperative period, in the operating room and after 1 and 6 months in postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients who were transplanted liver with S100β and NSE. Demographic data of the patients, accompanying diseases, American Society of Anesthesia classification, etiology, Model For End-Stage Liver Disease score, Child classification, sodium, potassium, total bilirubin, alanine aminotransferase, aspartate aminotransferase, Alkaline phosphatase, International Normalized Ratio, creatinine and urea shall be recorded. Intraoperative medicine administration and fluid balance, duration of operation, graft hot ischemia and graft cold ischemia durations, initial pulmonary artery pressure, blood component transplantations shall be recorded.
2870940|NCT03453034|Experimental|TQ-B3233 capsule|QD or BID; patients are given the doses according to the protocal, and a cycle is 28 days.
2870941|NCT03453021||mepolizumab|Patients will receive a subcutaneous injection of mepolizumab 100 mg every 4 weeks for one year, for a total of 12 injections
2870942|NCT03452995|Active Comparator|Physiotherapy: LYMPHO DRAINAGE|Patients will be treated on the second postoperative day, on the 4th postoperative day and on the 6th post-operative day by means of Manual lymphodrainage consisting in special massage technique that allows lymphatic drainage, or removal of interstitial fluid stagnation according to Vodder, in association to the standard rehabilitation protocol for TKA (Kinetec, functional rehabilitation and walking training
2871018|NCT03452436||Prostate cancer patients|Forty prostate cancer patients included prior to medical castration and radiotherapy.
2870943|NCT03452995|Active Comparator|Physiotherapy: KINESIOTAPING|Patients will be treated on the second postoperative day, on the 4th postoperative day and on the 6th post-operative day through the use of patches acting through the sensory system giving stimuli to receptors on the skin, in association to the standard rehabilitation protocol for TKA (kinetec, functional rehabilitation and walking training .
2870944|NCT03452995|Experimental|Physiotherapy:LYMPHO+KINESIO|Patients will ne treated with both kinesiotaping and lymphodreinage on the second post-operative day, on 4 days post-operative and on the 6th post-operative day, in association to the standard rehabilitation protocol for TKA (kinetec, functional rehabilitation and walking training
2870945|NCT03452982|Experimental|Patients with ovarian cancer|Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection
2870946|NCT03452956||FTD Cohort|No intervention-observation only
2870947|NCT03452943|Experimental|TEV-50717|TEV-50717 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
2870948|NCT03452943|Placebo Comparator|Placebo|Matching Placebo
2870949|NCT03452930|Experimental|Stage 1A - Group 1: EDO-S101|Dose Escalation: Participants receive EDO-S101 on Day 1 of each 21 day Cycle.
2870950|NCT03452930|Experimental|Stage 1B - Group 2: EDO-S101|Dose Escalation: Participants receive EDO-S101 on Day 1 and 15 of a 28 day Cycle.
2870951|NCT03452930|Experimental|Stage 2: EDO-S101 + Radiation Therapy|"Participants receive radiation consisting of fractionated focal irradiation administered using 1.8-2 Gy/fraction daily x 5 days/week for ~6 weeks for a total dose of up to 60 Gy.~EDO-S101 administered weekly with radiation and the dosing schedule during stage 2 determined based on the results of the 2 dosing schemas evaluated during Stage 1."
2870952|NCT03452930|Experimental|Maximum Tolerated Dose (MTD): EDO-S101 + Radiation Therapy|Once the MTDs of EDO-S101 in Stage 1 and Stage 2 have been separately determined, the safety and preliminary efficacy of EDO-S101 given in combination with radiation followed by administration of EDO-S101 in the adjuvant phase investigated in an MTD expansion cohort.
2870953|NCT03452917|Placebo Comparator|Placebo|2 ml of normal saline (n=500)
2870954|NCT03452917|Experimental|sodium nitrite|45 mg IV of sodium nitrite (n=500) or 60 mg IV sodium nitrite (n=500) given during active resuscitation from out of hospital cardiac arrest.
2870955|NCT03452904|Experimental|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
2870956|NCT03452904|Active Comparator|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting stent
2870957|NCT03452891|Experimental|SIM-MCL|
2870958|NCT03452891|Placebo Comparator|MCL|
2870959|NCT03452878||Aggressive refractory patient|A pre defined group of individuals will be included in the study. This group is considered aggressive refractory patient and will be submitted to the bilateral amygdalotomy surgery.
2870960|NCT03452865|Experimental|Esomeprazole|Patients randomized to Esomeprazole Group will receive a bolus of 160 mg of esomeprazole (diluted in 100 ml of 0.9% sodium chloride for intravenous use and administered over 60 minutes) and an intravenous infusion of 12 mg/hr (diluted in 0.9% sodium chloride at a concentration of 8 mg/ml will be injected at a rate of 1.5 ml/hr) for 72 hours .
2870961|NCT03452865|Placebo Comparator|Placebo|Patients randomized to Placebo Group will receive a bolus of 100 ml of 0.9% sodium chloride for intravenous use administered over 60 minutes with no active principle and an intravenous infusion of 0.9% sodium chloride at a rate of 1.5 ml/hr with no active principle for 72 hours .
2870962|NCT03452852|Other|NPWT (PICO device)|In this arm, investigators will use the PICO system (Smith and Nephew) for compression therapy after split thickness skin graft of leg ulcers.
2870963|NCT03452852|Other|Compression bandaging (Coban 2 lite)|In this arm, investigators will use the Coban 2 lite compression bandaging for compression therapy after split thickness skin graft of leg ulcers.
2870964|NCT03452839|Experimental|Continuous infusion|"Patient randomized to continuous infusion group, will receive a continuous infusion of meropenem according to their renal function (creatinine clearance -ClCr- estimated by Cockcroft-Gault formula and study day~for ClCr > 50 ml/min: 3 g / day, prepared as follows: 10 mg/ml of meropenem in NaCl 0.9% at 12,5 ml/h.~for ClCr < 50 ml/min: 2 g / day, prepared as follows: 10 mg/ml of meropenem in NaCl 0.9% at 8,3 ml/h.~This solution will be replaced every time its duration exceeds the stability in use stated by the producer"
2870965|NCT03452839|Active Comparator|Bolus|"Patient randomized to bolus group, will receive a bolus infusion of meropenem according to their renal function (creatinine clearance -ClCr- estimated by Cockcroft-Gault formula):~for Cl-Cr > 50 ml/min 1 g every 6 hours on first 24 hours, every 8 hours after~for Cl-Cr < 50 ml/min 1 g every 8 hours on first 24 hours, every 12 hours after"
2870966|NCT03452826|Experimental|Antibiotic therapy according to the result of mPCR|Combined use of a respiratory broad panel Multiplex polymerase chain reaction (mPCR) (performed on a lower respiratory tract sample : bronchoalveolar lavage fluid or tracheal aspirate, otherwise sputum) and procalcitonin.
2870967|NCT03452826|No Intervention|Antibiotic therapy at discretion of ICU physicians|Antibiotic therapy at discretion of ICU physicians
2870968|NCT03452787||Boston Puerto Rican Health Study (NCT01231958)|40 with CC and 40 with TT genotypes at APOA2 rs5082. Participants of each genotype will be further divided into two subgroups based on SFA intake: low, <22 grams/day, high, ≥22 grams/day.
2870969|NCT03452787||GOLDN (NCT00083369)|107 participants with CC genotype and 272 with TT genotype for APOA2 rs5082.
2870970|NCT03452787||Framingham Heart Study (NCT00005121)|73 with CC and 170 with TT genotypes at APOA2 rs5082. Participants of each genotype will be further divided into two subgroups based on SFA intake: low, <22 grams/day, high, ≥22 grams/day.
2870971|NCT03452774||Study Group|Eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP).
2870972|NCT03452748|Experimental|FTIR arm|all excised membranes are examined with FTIR spectroscopy
2870973|NCT03452735||patients diagnosed before age 40|Patient between 18 and 50 years-old with Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Chronic juvenile arthritis, Chronic Inflammatory Rheumatism who will answer to a questionnaire about fertility
2870974|NCT03452735||Control Group|Patient between the ages of 18 and 50 years, not diagnosed with Chronic inflammatory rheumatism, having consulted in Rheumatology for a mechanical pathology, presenting no chronic pathology, having no chemo or radiotherapy or immunosuppressive therapy, or pelvic surgery before age 40 years who will answer to a questionnaire about fertility
2870978|NCT03452709|Experimental|therapeutic exercise|In this group the intervention is the prescription of physical activity. The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week.
2870979|NCT03452709|Experimental|ABPM|In this group the arterial pressure is evaluated with ABPM.
2870980|NCT03452709|Experimental|therapeutic exercise + ABPM|
2870981|NCT03452696|Experimental|Calcium supplement 10/90|Microencapsulated calcium, 1389 mg orally (10% protein and 90% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 doses of 1389 mg each orally, to make a total contribution of 1,000 mg. of calcium element.
2870982|NCT03452696|Experimental|Calcium supplement 5/95|Microencapsulated calcium1316 mg orally (5% protein and 95% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 shots of 1,316 mg each orally, to make a total contribution of 1,000 mg. calcium element
2870983|NCT03452696|Active Comparator|Calcium carbonate supplement|1,250 mg orally (500 mg of calcium element). There will be 2 doses of 1,250 mg. each orally, to make a total contribution of 1,000 mg. of calcium element.
2870984|NCT03452696|Active Comparator|Calcium citrate supplement|1,500 mg orally (315 mg of calcium element). There will be 2 taken orally, to make a total contribution of 945 mg. calcium element
2870985|NCT03452683|No Intervention|Usual Care|Participants randomized to the Usual Care arm will receive educational handouts.
2870986|NCT03452683|Experimental|Movn Mobile App|Participants randomized to the Movn Mobile App arm will have the Movn app downloaded to their cell phone. Participants will enter in their weight and symptoms into the app every day.
2870987|NCT03452670|Experimental|Active Group|Participants in this group will use a contemplative wellness application for 8 weeks.
2870988|NCT03452670|Other|Waitlist Group|The waitlist group will receive no intervention during the study but will be able to use the wellness application after completion of the study.
2870989|NCT03452657|Experimental|Ranibizumab|Participants received 0.5mg intravitreal ranibizumab injection
2870990|NCT03452657|Sham Comparator|Sham-injection|No drug involved in the sham procedure; patient's eye is anesthetized and a syringe without needle gently pressed on the conjunctival surface to simulate the force of an actual injection
2870991|NCT03452618|Experimental|patients with a NIV equipment|Determination of diagnosis variables in a group of patient who benefit of the Non Invasive ventilation equipment one year after the diagnostic
2870992|NCT03452618|Active Comparator|patients without a NIV equipment|Determination of diagnosis variables in a group of patient who not benefit of the Non Invasive ventilation equipment one year after the diagnostic
2870993|NCT03452605|Experimental|high cocoa flavanol drink|high cocoa flavanol drink (900 mg cocoa flavanol dissolved in 300 ml skimmed milk) 2h pre-fMRI
2870994|NCT03452605|Placebo Comparator|low cocoa flavanol drink|low cocoa flavanol drink (30 mg cocoa flavanol dissolved in 300 ml skimmed milk), matched for theobromine, caffeine and macronutrients with the high cocoa flavanol drink 2h-pre fMRI
2870995|NCT03452592|Experimental|The way patients take Alflutinib|patients take Alflutinib orally once per day at dose of 80mg or160mg
2870996|NCT03452579|Active Comparator|Nivolumab + Standard Dose Bevacizumab|nivolumab 240 mg and standard dose bevacizumab 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity
2870997|NCT03452579|Experimental|Nivolumab + Reduced Dose Bevacizumab|nivolumab 240 mg and reduced dose bevacizumab 3mg/kg every 2 weeks until disease progression or unacceptable toxicity
2870998|NCT03452566|Experimental|ingenol mebutate gel|Phase 1/2, always 3 consecutive days, with 24 hours interval, dosage from 5 mg/cm2 to 18 mg/cm2 in a 3+3 design.
2870999|NCT03452553|Experimental|Open Label Treatment|Chemoembolization using LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin
2871000|NCT03452540|Experimental|DS102|Participants in this group will receive 2000mg DS102 capsules daily.
2871001|NCT03452540|Placebo Comparator|Placebo|Participants in this group will receive placebo capsules daily.
2871002|NCT03452527|Experimental|ICON-1 maintenance therapy|ICON-1 maintenance therapy after initial aflibercept treatment
2871003|NCT03452527|Experimental|ICON-1 combination therapy|ICON-1 combination therapy with aflibercept treatment
2871004|NCT03452514||Cohort 1 - Low Dose CT (LDCT) Scan|Individuals undergoing their first or subsequent annual LDCT screening study
2871005|NCT03452514||Cohort 2 - Diagnostic CT Scan|Individuals referred for a follow-up diagnostic chest CT scan due to a lung-RADS category 3 or 4 result on a previous LDCT scan
2871006|NCT03452501||Naïve group|Newly diagnosed patients
2871007|NCT03452501||Switched group|Patients who received at least one dose of Infliximab reference medicinal product (RMP) before the first infusion of Remsima®
2871008|NCT03452488|Placebo Comparator|Arm 1 - Placebo oral capsule|"4 capsules taken twice a day: in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.~Component : Microcrystalline cellulose, Colloidal anhydrous silica"
2871009|NCT03452488|Experimental|Arm 2 - BIO101 - Half daily dose 350 mg|"4 capsules taken twice a day (2 placebo and 2 experimental study drug) in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.~Study Drug Component : 251 mg per capsule including 175 mg of active principle 20-hydroxyecdysone (20E) containing also the following compendial excipients: colloidal silica, microcrystalline cellulose and magnesium stearate."
2871010|NCT03452488|Experimental|Arm 3 - BIO101 - Full daily dose 700 mg|"4 capsules taken twice a day (4 experimental study drug) in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.~Study Drug Component : 251 mg per capsule including 175 mg of active principle 20E containing also the following compendial excipients: colloidal silica, microcrystalline cellulose and magnesium stearate."
2871011|NCT03452475|Active Comparator|Arterolane-piperaquine|Arterolane-piperaquine for 3 days
2871012|NCT03452475|Active Comparator|Arterolane-piperaquine+mefloquine|Arterolane-piperaquine + mefloquine for 3 days
2871013|NCT03452475|Active Comparator|Artemether-lumefantrine|Artemether-lumefantrine for 3 days
2871014|NCT03452462|Experimental|Direct His Bundle Pacing|Pacing from the His bundle lead
2871015|NCT03452462|Active Comparator|Biventricular Pacing|Pacing from the right ventricular and coronary sinus leads
2871016|NCT03452449||Lumbar spine surgery|Patients undergoing planned lumbar spine surgery
2871017|NCT03452436||Testicular cancer patients|Forty testicular cancer patients included after orchiectomy but prior to any further treatment.
2871019|NCT03452436||Healthy controls|Forty age- and education-matched healthy controls (20 matched to testicular cancer patients, 20 matched to prostate cancer patients).
2871020|NCT03452423|Experimental|ACRFP|Patient suffering from osteoarthritis of knee joints, and planning to receive ACRFP, are enrolled into this study. Gait pattern is obtained preoperatively, 3 months, and 6 months postoperatively.
2871021|NCT03452397|Active Comparator|OC-02 Low Dose|
2871022|NCT03452397|Active Comparator|OC-02 Mid Dose|
2871023|NCT03452397|Active Comparator|OC-02 High Dose|
2871024|NCT03452397|Placebo Comparator|Placebo|
2871025|NCT03452384|Experimental|acupucture|For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface.
2871026|NCT03452384|Sham Comparator|control|For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998). The needles will be affixed with plastic O-rings and adhesive tapes. The needles with blunt tips will be quickly put onto the same acupoints used in real acupuncture without inserting into the skin.
2871027|NCT03452371|Active Comparator|Enhanced Traditional Care|Participants in this arm will receive usual care to help with smoking cessation offered to all patients who are smokers and some additional resources they can access for support.
2871028|NCT03452371|Experimental|Patient Navigation Intervention|Participants in this arm will meet with the trained patient navigator either in-person if she is available, or by telephone. They will receive up to two hours of patient navigation over a one-month period.
2871029|NCT03452345|Experimental|MEDITOXIN|
2871030|NCT03452345|Placebo Comparator|Placebo|
2871031|NCT03452332|Experimental|Durvalumab + Tremelimumab + SABR|"Participants receive Tremelimumab by vein over about 1 hour on Day 1 of Cycles 1-4. Participants receive Durvalumab by vein over about 1 hour on Day 1 of every cycle (about 1 hour after the end of the Tremelimumab dose during Cycles 1-4).~On Days 8, 10, and 12 of Cycle 1, participants also receive SABR over about 30-45 minutes each time.~Participants only receive SABR during cycle 1 and Tremelimumab over 4 cycles. Participants may continue to receive Durvalumab for up to 8 cycles.~Study conducted in 4 week cycles."
2871032|NCT03452319|Experimental|Pretraining|Increased physical activity daily Daily strength training Daily inspiratory and expiratory muscle training Standard care during hospital stay and continued training after discharge.
2871033|NCT03452319|Active Comparator|Usual care treatment|Standard care including preoperative information and postoperative breathing exercises and mobilization during hospital stay.
2871034|NCT03452306|Experimental|Metformin|"First aIntervention Period:~Single administered dose of Metformin (750 mg tablet extended-release in a fasting condition~Third Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
2871035|NCT03452306|Active Comparator|Glucophage® Long|"Second Intervention Period:~Single administered dose of Glucophage® ( 750 mg tablet extended-release) in a fasting condition~Fourth Intervention Period:~Single administered dose of Glucophage® ( 750 mg tablet extended-release) in a fed condition"
2871036|NCT03452267|Experimental|Metformin|
2871037|NCT03452267|Experimental|Pioglitazone|
2871038|NCT03452267|Placebo Comparator|Placebo|
2871039|NCT03452254|Active Comparator|Experimental Group|Active bi-hemispheric transcranial Direct Current Stimulation combined with modified Constraint Induced Movement Therapy.
2871040|NCT03452254|Sham Comparator|Control Group|Sham bi-hemispheric transcranial Direct Current Stimulation combined with modified Constraint Induced Movement Therapy.
2871041|NCT03452241|Experimental|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver it and other materials about the harm of substance use.
2871042|NCT03452241|Other|Control Group|The participants only receive the materials about the harm of substance use
2871043|NCT03452228|Experimental|evinacumab|
2871044|NCT03452228|Experimental|Placebo|
2871045|NCT03452215|Experimental|Study|
2871046|NCT03452215|Sham Comparator|Control|
2871047|NCT03452202|Experimental|Active Stimulation|crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
2871048|NCT03452202|Sham Comparator|Sham Stimulation|crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
2871049|NCT03452189|Active Comparator|250mg of oral vancomycin First|After 3 months, initial experimental group will be switched to placebo for 3 months.
2871050|NCT03452189|Placebo Comparator|Placebo First|After three months, the control group will be crossed over to weekly oral vancomycin (250mg)
2871051|NCT03452176|Experimental|Scrambler|This arm will receive the Scrambler intervention for 1 hour daily x10 days.
2871052|NCT03452176|Sham Comparator|Sham-Control|This arm will receive the Sham-Control intervention for 1 hour daily x10 days.
2871053|NCT03452163|Experimental|Anesthesia, General|Subjects under anesthesia that are expected to stay for at least 24 hours in the ICU/NICU will be monitored by the PMD-200 device. An EEG monitor device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.
2871054|NCT03452150|Experimental|Daily oral dose of D-0316|
2871055|NCT03452137|Active Comparator|Atezolizumab|Participants will receive Atezolizumab for 16 cycles, or up to 1 year (whichever occurs first)
2871056|NCT03452137|Experimental|Placebo|Participants will receive Placebo for 16 cycles, or up to 1 year (whichever occurs first).
2871057|NCT03452124|Active Comparator|IQOS|I quit ordinary smoking (IQOS) assistes cessation program
2871058|NCT03452124|Active Comparator|Smoker control|Conventional cigarette smoking continuation
2871059|NCT03452111|Experimental|Nestorone (NES) + testosterone (T) combined gel|A combination Gel with Nestorone® (NES) and Testosterone (T) applied transdermally. The amount of gel to be applied daily will be approximately 5 mL in volume (2.5 mL to each shoulder and upper arm per day). This daily gel volume will contain approximately 62 mg of T that will deliver 6 mg T to the body per day and will also contain 8 mg of NES that will deliver about 0.8 mg NES to the body per day (NES 8 mg/day + T 62 mg/day (NES-8/T-62) gel).
2871060|NCT03452085|Active Comparator|artificial saliva spray (AS)|"The randomized part of the participants who started first with the artificial saliva spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days.~After wash out phase they take for three days the marine water throat spray taking it three times a day for a three days treatment."
2871061|NCT03452085|Placebo Comparator|maritime throat spray (TT)|"The randomized part of the participants who started first with the marine water throat spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days.~After wash out phase they take for three days the artificial saliva spray taking it three times a day for a three days treatment."
2871062|NCT03452072|Experimental|0.25% Timolol gel under the paraffin gauzes|"Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied~Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing~This daily routine continues for 12 weeks' post-surgery (even if the surgical defect has completely healed in the interim)"
2871063|NCT03452072|Active Comparator|Standard of Care dressings|"Vaseline will be applied to wound bed immediately after surgery before dressing is applied~Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing~This daily routine continues for 12 weeks' post-surgery (even if the surgical defect has completely healed in the interim)"
2871064|NCT03452059|Experimental|AiLegs/AiWalker|use of lower extremity rehabilitation training robot assisted walking (including AiLegs, AiWalker)
2871065|NCT03452059|Active Comparator|HKAFO/RGO|use hip and knee ankle foot orthosis (HKAFO) assisted walking
2871066|NCT03452046||PS 10 mmHg, PEEP 5 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
2871067|NCT03452046||PS 10 mmHg PEEP 0 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
2871068|NCT03452046||PS 0 mmHg PEEP 5 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
2871069|NCT03452046||t tube (PS 0 mmHg PEEP 0mmHg)|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
2871070|NCT03452033|Placebo Comparator|H-1337 Placebo|H-1337 Placebo
2871071|NCT03452033|Experimental|H-1337 [1]|H-1337 [1]
2871072|NCT03452033|Experimental|H-1337 [2]|H-1337 [2]
2871073|NCT03452033|Experimental|H-1337 [3]|H-1337 [3]
2871074|NCT03452020|Other|Tyto Thermometer, SoC Thermometer, Predicate IR Th|"All the study participants undergo temperature measurements with:~Tyto Thermometer~Standard of Care thermometer~Predicate IR thermometer"
2871075|NCT03452007|Experimental|Bladder Mapping and Training|Individuals already implanted with a spinal cord epidural stimulator will receive epidural stimulation targeted at enhancing both the storage and voiding phase of micturition cycle.
2871076|NCT03451994||Body odor|individuals self-reporting idiopathic body odor with or without bad breath
2871077|NCT03451994||Breath odor|individuals self-reporting idiopathic bad breath but no body odor
2871078|NCT03451981|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
2871079|NCT03451981|Experimental|Er:YAG laser|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine. Furthermore, Er:YAG laser treatment will be provided on the implant surface.
2871080|NCT03451981|Experimental|Air Powder|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Clorhexidine. Furthermore, an Air-Powder treatment will be provided on the implant surface.
2871081|NCT03451968|Experimental|critically ill|"amino acid tracer injection for metabolism analysis The dose needed to be injected from the tracer element in the beginning of the study is a bolus of 16ml Amino acid tracer (non-radioactive).~it is a single bolus, no other elements or drug will be administered."
2871082|NCT03451968|Active Comparator|control|amino acid tracer injection for metabolism analysis The dose needed to be injected from the tracer element in the beginning of the study is a bolus of 16ml Amino acid tracer (non-radioactive) it is a single bolus, no other elements or drug will be administered.
2871083|NCT03451955|Experimental|Intervention group|Patients in the intervention group follow a gluten-free diet for six months.
2871084|NCT03451955|No Intervention|Control group|Patients in the control group follow their usual diet for six months
2871085|NCT03451942|Experimental|surgery group after FLOT regimen chemotherapy|After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
2871086|NCT03451942|Placebo Comparator|FLOT regimen chemotherapy|Continue 4 cycles of the FLOT regimen chemotherapy and evaluate the efficacy every 8 weeks.
2871087|NCT03451916|Placebo Comparator|PLX-PAD|• Arm 1 - PLX-PAD (120 subjects): 150×106 PLX-PAD cells (10×106 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte.
2871088|NCT03451916|Placebo Comparator|Placebo|Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO [v/v], 5% HSA [w/v], and PlasmaLyte, without cells).
2871089|NCT03451903||Mechanical thrombectomy group|Patients with acute stroke treated by mechanical thrombectomy.
2871090|NCT03451903||Combined procedure group|Patients with acute stroke treated by intravenous thrombolysis (with actilyse) and mechanical thrombectomy.
2871091|NCT03451890|Experimental|Cohort 1: E2730 40 mg|Participants will receive a single oral dose of E2730 40 milligrams (mg) under fasted conditions.
2871092|NCT03451890|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
2871093|NCT03451890|Experimental|Cohort 2: E2730 80 mg|Participants will receive a single oral dose of E2730 80 mg under fasted conditions.
2871095|NCT03451890|Experimental|Cohort 3: E2730 120 mg|Participants will receive a single oral dose of E2730 120 mg under fasted conditions.
2871096|NCT03451890|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
2871097|NCT03451890|Experimental|Cohort 4: E2730 160 mg|Participants will receive a single oral dose of E2730 160 mg under fasted conditions.
2871098|NCT03451890|Placebo Comparator|Cohort 4: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
2871099|NCT03451877|Active Comparator|Study group|Children with cycloplegia refractive error more than -6 D TGFB1 AND LAMA1 GENE POLYMORPHISMS were examined
2871100|NCT03451877|Other|Control group|Emmetropic children TGFB1 AND LAMA1 GENE POLYMORPHISMS were examined
2871101|NCT03451864||Deficient Vit D|Mothers with serum 25(OH) D levels less than 20 ng/dl
2871102|NCT03451864||Normal vit D|Mothers with serum 25(OH) D levels more than 20 ng/dl
2871103|NCT03451851|Experimental|Part 1 Group 1: Guselkumab|Participants in Part 1a (age greater than or equal to (>=) 12 - less than (<) 18 years) will receive a weight-based dose of guselkumab subcutaneously (SC) at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of guselkumab until they lose >=50% of their Week 16 PASI response, then they receive 1 dose guselkumab, followed by a dose 4 weeks later, and every 8 weeks (q8w) thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a placebo injection at Week 16 and continue to receive guselkumab q8w from Week 20 through Week 52. Participants who are eligible and willing to continue guselkumab may enter the Long Term Extension (LTE) and continue to receive guselkumab until drug approval for pediatric psoriasis or discontinuation of drug development. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
2871104|NCT03451851|Placebo Comparator|Part 1 Group 2: Placebo for Guselkumab|Participants in Part 1a (age >= 12 - <18 years) will receive placebo for guselkumab administered SC at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of study intervention until they lose >=50% of their Week 16 PASI response, at which time they will receive a weight-based guselkumab SC dose, followed by a dose 4 weeks later, and q8w thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a weight-based guselkumab dose at Weeks 16 and 20, followed by q8w dosing thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE of the study and continue to receive guselkumab until drug approval for pediatric psoriasis or discontinuation of drug development. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
2871105|NCT03451851|Active Comparator|Part 1 Group 3: Etanercept|Participants in Part 1a (age >= 12 - <18 years) will receive weight-based etanercept dose up to 50 milligram SC weekly through Week 15. Participants who elect to continue in the study will receive a weight-based guselkumab dose at Weeks 20 and 24, followed by q8w dosing thereafter through Week 48. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE of the study and continue to receive guselkumab until drug approval for pediatric psoriasis or discontinuation of drug development. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
2871106|NCT03451851|Experimental|Part 2: Guselkumab|Participants will receive a weight-based dose of open-label guselkumab SC at Weeks 0, 4 and q8w thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE of the study and continue to receive guselkumab at Week 52 and q8w thereafter until drug approval for pediatric psoriasis or discontinuation of drug development.
2871107|NCT03451838||Diabetes mellitus|Pregnant women with diabetes mellitus will be examined by us to measures placental volume and thickness ,IV thickness and HbA1c
2871108|NCT03451838||control group|Pregnant women with no medical disorders will be examined by us to measures placental volume and thickness ,IV thickness and HbA1c
2871109|NCT03451825|Experimental|Phase 1: Avelumab|
2871110|NCT03451825|Experimental|Phase 2, Cohort 1: Avelumab|
2871111|NCT03451825|Experimental|Phase 2, Cohort 2: Avelumab|
2871112|NCT03451812||prostate cancer|The newly diagnostic number for the high-risk PCa patients in our hospital annually is ~70, it is clinically feasible to recruit 40 patients a year since the study begins. The study could be completed in 3 years with 120 cases.
2871113|NCT03451799|Experimental|Ketogenic diet+radiation+temozolomide|Ketogenic diet in combination with standard-of-care radiation and standard-of-care temozolomide
2871114|NCT03451773|Experimental|1.1/M7824 De-Escalation /Gemcitabine 1,000 mg/m2|1,000 mg/m2 Gemcitabine
2871115|NCT03451773|Experimental|1.2/M7824 De-Escalation /Gemcitabine 600 mg/m2|600 mg/m2 Gemcitabine
2871116|NCT03451773|Experimental|2.1/M7824 Expansion /Gemcitabine 1,000 mg/m2|1,000 mg/m2 Gemcitabine
2871117|NCT03451773|Experimental|2.2/M7824 Expansion /Gemcitabine 600 mg/m2|600 mg/m2 Gemcitabine
2871118|NCT03451760|Experimental|Feru-guard|Over a 12 week period participants will take two 280 mg hard gel capsules of Feru-guard 100M per day (1 capsule am, 1 capsule pm). One capsule will be taken in the morning with a meal and one capsule will be taken in the afternoon with a meal. Each capsule contains 180.32 mg ferulic acid and 20.02 mg of Angelica archangelica. Total daily dose will be 560mg of Feru-guard 100M, with 360.64 mg of ferulic acid and 40.04 mg of Angelica archangelica.
2871119|NCT03451760|Placebo Comparator|Placebo|Over a 12 week period participants will take two 280 mg hard gel capsules of a placebo per day (1 capsule am, 1 capsule pm). One capsule will be taken in the morning with a meal and one capsule will be taken in the afternoon with a meal.Total daily dosage will be 560mg of a maltodextrin, calcium stearate, and vanilla food flavor mixture.
2871120|NCT03451747||postmenopausal hypertensive women|
2871121|NCT03451747||mached hypertensive men|
2871122|NCT03451734||Olanzapine|
2871123|NCT03451734||Risperidone|
2871124|NCT03451734||Aripiprazole|
2871125|NCT03451734||Ziprasidone|
2871126|NCT03451734||Amisulpride|
2871127|NCT03451734||Haloperidol|
2871128|NCT03451721||ImageReady™ MR Conditional Defibrillation System|"Subject is indicated to Class I/II indications per guidelines/consensus released by Chinese Society of Cardiac Pacing and Electrophysiology~Subject must have the ImageReady System as their initial (de novo) defibrillation system implant"
2871129|NCT03451708|Experimental|Optimization of OKS|Crossover study examining various OKS protocols on improving symptoms of hemispatial neglect
2871130|NCT03451708|Experimental|Safety and efficacy study|Randomized study assessing the safety and efficacy of OKS in treating hemispatial neglect
2871131|NCT03451708|Experimental|Effect of repetitive stimulation|Benefits of daily, repetitive OKS in treating hemispatial neglect
2871132|NCT03451708|Experimental|OKS and gait|Effect of OKS on gait and balance
2871133|NCT03451695|Experimental|Morphine group|Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).
2871134|NCT03451695|Placebo Comparator|Placebo group|Placebo group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1 ml).
2871135|NCT03451682|Experimental|procyanidine group|
2871136|NCT03451682|No Intervention|Control group|
2871137|NCT03451669||Shunt suspected to be functioning|
2871138|NCT03451669||Shunt suspected to not be functioning|
2871139|NCT03451643|Experimental|Endoscopic Expandable Stent|Procedure/Surgery. Endeosocpically a self-expandable metal stent will be placed in the colon rectum. Chemotherapy will be added
2871140|NCT03451643|Active Comparator|Colorectal Resection|Procedure/Surgery. A standard open or laparoscopic surgery will be performed to remove the colorectal cancer. Chemotherapy will be added
2871141|NCT03451630|Active Comparator|High-Touch|High-Touch leverages a personalized service design that includes payer-employed registered nurses and social workers to provide intensive, in-person support and resources for eligible patient participants in their homes and/or communities for approximately three to four months following hospitalization.
2871142|NCT03451630|Active Comparator|High-Tech|The High-Tech intervention uses less in-person resources by leveraging telehealth and remote monitoring technology to support self-directed care management in real time for approximately three to four months following hospitalization.
2871143|NCT03451630|Active Comparator|Usual Care/Optimal Discharge Planning|The Optimal Discharge Planning protocol utilizes a health plan-employed transition coordinator provides comprehensive, evidence-based support at the time of discharge and for two days post discharge, including: development and distribution of an easy-to-read, written discharge plan; detailed disease management and medication education; confirmation of and connection to family/caregiver support and resources; scheduling an ambulatory follow-up appointment within five days of discharge; post-discharge assessment completed via telephone or, for high-risk members for whom it is indicated, a single home visit; and hand-off to a health plan-based telephonic nurse care manager as needed. The individualized support usually lasts for approximately one month following hospitalization.
2871144|NCT03451617|Other|Xpedition stent delivery system|
2871145|NCT03451617|Other|Alpine stent delivery system|
2871146|NCT03451591|Active Comparator|Isosorbide Mononitrate XL (ISMN)|Oral Isotard® 25mg XL (Isosorbide Mononitrate) tablets. Oral Isotard® 25mg XL: Day 1-5 / 25mg daily morning dose. Day 6 to week 52 / 50mg daily morning dose. Week 53 / 25mg daily morning dose. Week 54 / NIL dose. Or Oral Isosorbide mononitrate (ISMN) non-XL 20mg tablets: Day 1-5 / 20mg daily evening dose. Day 6 to week 52 / 20mg twice daily morning & evening. Week 53 / 20mg daily morning dose. Week 54 / NIL dose.
2871147|NCT03451591|Active Comparator|Cilostazol|Oral Cilostazol 100mg tablets. Day 1-5 / 50mg daily evening dose. Day 6-10 / 50mg twice daily morning & evening. Day 11-15 / 50mg daily morning dose & 100mg daily evening dose. Day 16 to week 52 / 100mg twice daily morning & evening. Week 53 / 50mg twice daily morning & evening. Week 54 / NIL dose.
2871148|NCT03451591|Active Comparator|ISMN XL and Cilostazol|Oral Isotard® 25 mg XL (ISMN) and oral Cilostazol 100mg tablets. Day 1-5 / ISMN - 25mg daily evening dose / Cilostazol - NIL. Day 6-10 / ISMN - 50mg daily morning dose and Cilostazol - NIL. Day 11-15 / ISMN - 50mg daily morning dose / Cilostazol - 50mg daily evening dose. Day 16-20 / ISMN - 50mg daily morning dose and Cilostazol - 50mg twice daily morning & evening. Day 21-25 / ISMN - 50mg daily morning dose and Cilostazol - twice daily, 50mg morning & 100mg evening dose. Day 26-30 ISMN - 50mg daily morning dose and Cilostazol 100mg - twice daily morning & evening. Day 30 to week 52 / ISMN 50mg morning dose and Cilostazol 100mg - twice daily morning & evening. Week 53 / ISMN 25mg daily morning dose and Cilostazol 50mg twice daily morning & evening. Week 54 / NIL dose
2871149|NCT03451591|Placebo Comparator|Neither ISMN nor cilostazol|Neither isosorbide mononitrate nor Cilostazol is administered for the entire duration of the study.
2871150|NCT03451578|Other|Advanced Dry macular degeneration|
2871151|NCT03451552|No Intervention|Control (211 services)|Patients allocated to the control arm will be directed to the Ontario 211 navigation service, which is already available to the general public free of charge. After consenting to participate in the study and completing the telephone survey, the research assistant will inform these patients that they can use existing navigation services provided by Ontario 211 to help them access the CR referred to them by their PHCP. The research assistant will instruct patients to dial 2-1-1 to obtain additional information on the nature of this service.
2871152|NCT03451552|Experimental|Intervention (Patient Navigator)|Patients allocated to the intervention arm will be offered the services of the ARC Patient Navigator. After consenting to participate in the study and completing the telephone survey, the research assistant will inform these patients that they can use the services offered by the ARC patient navigator to help them access the CR referred to them by their PHCP. Following a brief description of the services provided by the navigator (e.g., arrange transportation, make appointments, fill out forms, etc.), patients will be offered to be contacted by the navigator by telephone or to meet with the navigator in person on a day and time that is most convenient for them.
2871153|NCT03451526||Surgeries+adjuvant chemotherapies|Patients who received radical resection of lung cancer + adjuvant chemotherapies
2871154|NCT03451526||Perioperative chemotherapies|Patients who received perioperative chemotherapies
2871155|NCT03451513|Experimental|Pride Body Project (PBP)|Participants assigned to this condition take part in a two-session intervention based on dissonance theory which encourages them to challenge the body ideal.
2871156|NCT03451513|Active Comparator|Media Advocacy (MA)|Participants assigned to this condition take place in a time and attention-matched active control where they discuss the role of media in promoting the body ideal.
2871157|NCT03451500|Experimental|Carbidopa-levodopa 2 tablets daily|carbidopa-levodopa 25-100 mg 2 tablets daily hs
2871158|NCT03451500|Experimental|carbidopa-levodopa 6 tablets daily|carbidopa-levodopa 25-100 mg, 2 tablets, 3 times daily, with breakfast, with supper and hs
2871190|NCT03451292|Experimental|SMT + Albutein 20%|
2871159|NCT03451500|Placebo Comparator|Placebo|Placebo, 2 tablets, 3 times daily, with breakfast, with supper and hs
2871160|NCT03451487|Placebo Comparator|Reference drug (1000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period I and II. The study was completed when there were at least 12 evaluable subjects.~Panadol® oral dosage form (500 mg*2 tablets = 1000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
2871161|NCT03451487|Experimental|Test drug (1000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period I and II. The study was completed when there were at least 12 evaluable subjects.~SafeTynadol® oral dosage form (500 mg*2 tablets = 1000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
2871162|NCT03451487|Placebo Comparator|Reference drug (4000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period III and IV. The study was completed when there were at least 12 evaluable subjects.~Panadol® oral dosage form (500 mg*8 tablets = 4000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
2871163|NCT03451487|Experimental|Test drug (4000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period III and IV. The study was completed when there were at least 12 evaluable subjects.~SafeTynadol® oral dosage form (500 mg*8 tablets = 4000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study"
2871164|NCT03451474|Experimental|Upper extremity nerve transfer surgery|Upper extremity nerve transfer surgery is a surgical procedure where axons from an intact, functioning upper extremity peripheral nerve are moved to a target muscle that demonstrates significant weakness or paralysis as a result of spinal cord injury. After allowing time for recovery from surgery and for nerve growth to occur, the patient undergoes hand/occupational therapy in order to retrain motor skills.
2871165|NCT03451448||Healthy volunteers|Healthy volunteers to undergo MRI using USPIO contrast
2871166|NCT03451448||Stable coronary artery disease|Patients with coronary artery disease without recent (3 months) acute coronary syndrome or revascularisation
2871167|NCT03451448||Recent acute coronary syndrome|Patients with recent (3 months) type 1 myocardial infarction
2871168|NCT03451435|No Intervention|Control|No intervention will be administered in this group as it serves as a control group.
2871169|NCT03451435|Experimental|NAC Treatment|N-Acetyl Cysteine treatment during root canal revascularization
2871170|NCT03451422|Active Comparator|AMG 592|For phase 1b, subjects within a dosing cohort will be randomized in a 5:2 ratio to AMG 592 or placebo in addition to standard of care therapy. AMG 592 or placebo will be administered either weekly (QW) or biweekly (Q2W) by subcutaneous (SC) injection in abdomen. The phase 2a part of the study will commence after a RP2D is identified. Approximately 111 subjects will receive AMG 592 or matching placebo by subcutaneous injection. Subjects will be randomly assigned in a 2:1 ratio to either AMG 592 or placebo.
2871171|NCT03451422|Placebo Comparator|Placebo|For phase 1b, subjects within a dosing cohort will be randomized in a 5:2 ratio to AMG 592 or placebo in addition to standard of care therapy. AMG 592 or placebo will be administered either weekly (QW) or biweekly (Q2W) by subcutaneous (SC) injection in abdomen. The phase 2a part of the study will commence after a RP2D is identified. Approximately 111 subjects will receive AMG 592 or matching placebo by subcutaneous injection. Subjects will be randomly assigned in a 2:1 ratio to either AMG 592 or placebo.
2871172|NCT03451409|Active Comparator|OCD Proband|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
2871173|NCT03451409|Active Comparator|OCD Siblings|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
2871174|NCT03451409|Active Comparator|Healthy Controls|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
2871175|NCT03451396|Active Comparator|Mild Dry Eye Cohort|Prospective 3 month study of subjects with Tear Osmolarity >308 and VAS eye dryness ≥ 40 using 5% Lifitegrast ophthalmic solution BID.
2871176|NCT03451396|Active Comparator|Moderate to Severe Dry Eye Cohort|Prospective 3 month study of subjects with Tear Osmolarity >320 and VAS eye dryness ≥ 40 using 5% Lifitegrast ophthalmic solution BID.
2871177|NCT03451383||Breast Cancer Case|Women age 60+ with a newly diagnosed breast adenocarcinoma staged 0-3.
2871178|NCT03451383||Non-Cancer Controls|Women age 60+ with no diagnosis of breast cancer.
2871179|NCT03451357||patients with Dependence degree|Dependence degree already certificated by Dependence Law: It is calculated by accepting an expected proportion of 40% patients with dependence, with a precision 6.5% and confidence level of 95%, obtaining a N= 200 patients. Assuming a 15% of loses, we estimate we will need N=230 to be followed. This sample size would enable us to construct logistic regression models including simultaneously up to 5 predictive factors to assess the relationship between each of the independent variables and the occurrence of dependency.
2871180|NCT03451344|Experimental|Integrated rehabilitation group|Participants will receive the standardized community-based rehabilitation and simultaneously receive a 6-month integrated rehabilitation based on the Community-based Addiction Rehabilitation Electronic System.
2871181|NCT03451344|Active Comparator|Community-based rehabilitation group|Participants will receive the standardized community-based rehabilitation.
2871182|NCT03451331|Experimental|Arm A|Gemcitabine plus carboplatin plus nivolumab
2871183|NCT03451331|Experimental|Arm B|Gemcitabine plus oxaliplatin plus nivolumab
2871184|NCT03451318|Active Comparator|drug therapy|Nasonex(mometasone furoate),1 spray,QD (Quaque Die in Latin),for 3 months.
2871185|NCT03451318|Active Comparator|tonsillar adenoidectomy|tonsillar adenoidectomy
2871186|NCT03451318|Active Comparator|orthodontic treatment|Apply Twin-block appliance combined with maxillary expander
2871187|NCT03451318|Active Comparator|tonsillar adenoidectomy plus orthodontic treatment|Apply Twin-block appliance combined with maxillary expander one month after tonsillar adenoidectomy .
2871188|NCT03451305|Experimental|Pillow group|Before surgery, with the patient lying in the supine position, a soft pillow was placed under the segment of the collapsed vertebrae, which resulted in a hyperextension position. 12 hours duration suggested from 11:00 pm 1 night before the surgery till next day.
2871189|NCT03451305|No Intervention|No pillow group|No intervention was given in this group before surgery.
2871192|NCT03451266|Experimental|Vitamin C|1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum (vitamin C arm).
2871193|NCT03451266|Placebo Comparator|placebo|100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum (placebo arm).
2871194|NCT03451253|Experimental|amino acid mixture beverage|amino acid based hydration beverage. It will be given 8 oz, twice daily for the first 4 weeks of randomized blinded intervention. It will be given in same dose during 4 week open label intervention.
2871195|NCT03451253|Active Comparator|glucose based sports drink|glucose based hydration beverage. It will be given 8oz, twice daily for the first 4 weeks of randomized blinded intervention.
2871196|NCT03451240|Experimental|Intervention|
2871197|NCT03451227|Experimental|Dexmedetomidine Group|The study drug dexmedetomidine (PrecedexTM) is supplied as dexmedetomidine HCL 200mcg/vial (100mcg/ml). This will be added to 98 ml 0.9% NaCl to achieve a concentration of 2mcg/ml and infused at 0.2-1mcg/kg/hour from the start of the case. The infusion rate will be commenced at 1mcg/kg/hour in those less than or equal to 65 years of age, and at 0.7mcg/kg/hr in those greater than 65 years of age, and then titrated based on the intraoperative sedation scores (to achieve a Sedation and Agitation scale (SAS) score of less than or equal to 4) and cardiovascular parameters (within 30% of baseline).
2871198|NCT03451227|Active Comparator|Remifentanil Group|Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline)
2871199|NCT03451214|Experimental|diet zinc|3 dietary zinc levels: 6 mg/d, 11 mg/d and 25 mg supplemental zinc/d
2871200|NCT03451201|Experimental|High Intensity Interval Training|High Intensity Interval Exercise Training in cycle ergometer 3 times a week for 8 weeks
2871201|NCT03451201|Active Comparator|Moderate Continuous Exercise Training|Moderate Continuous Interval Training
2871202|NCT03451201|Other|Non-exercise|Sedentary Type 1 Diabetes Controls.
2871203|NCT03451162|Experimental|Dose Escalation Cohort: DHES0815A|Participants will receive DHES0815A in escalating doses in the dose-escalation cohort of the study. Participants will receive additional infusions of DHES0815A on Day 1 of subsequent cycles provided that they meet the protocol specified criteria for acceptable toxicity and ongoing clinical benefit.
2871204|NCT03451162|Experimental|Dose Expansion Cohort: DHES0815A|Participants will be treated at or below the Maximum Tolerated Dose (MTD) of DHES0815A (based on the review of the totality of the data) to obtain additional safety, tolerability, PK, and anti-tumor activity data.
2871205|NCT03451149|Experimental|Intervention|Undergo transjugular intrahepatic portosystemic shunt creation using a radiofrequency wire (Powerwire) in lieu of a trocar needle to cut through liver parenchyma
2871206|NCT03451123|Experimental|FET-PET/MRI|O-(2-[F-18]FET)-L-tyrosine (FET) for brain PET/MRI
2871207|NCT03451110|Experimental|Part 1: Lemborexant plus Loestrin|Healthy female participants will receive a single oral dose of Loestrin 1.5/30 (containing ethinyl estradiol [EE] 0.030 milligrams [mg] and norethindrone [NE] 1.5 mg) in the evening of Day 1 after a fast of at least 3 hours. After a washout period of at least 4 days, participants will receive 10 mg lemborexant orally for 10 days. Lemborexant will continue to be administered in the evening on Days 15 through 18, followed by a single oral dose of Loestrin on Day 15 when administered with lemborexant after fasting in the evening for at least 3 hours.
2871208|NCT03451110|Experimental|Part 2: Lemborexant plus Famotidine|Healthy participants will receive a single oral dose of 10 mg lemborexant in the morning of Day 1 after an overnight fast of at least 10 hours. On Day 15, participants will receive a single oral dose of 40 mg famotidine, followed at least 2 hours later by a single dose of 10 mg lemborexant. After a washout period of up to 14 days participants will receive 10 mg lemborexant orally for 10 days.
2871209|NCT03451110|Experimental|Part 3: Lemborexant plus Fluconazole|Healthy participants will receive a single oral dose of 10 mg lemborexant in the morning of Day 1 after an overnight fast of at least 10 hours. After a washout interval of approximately 10 days, on Day 11, participants will be administered 400 mg fluconazole followed by 200 mg fluconazole once daily from Days 12 to 26. During this time a single dose of 10 mg lemborexant will be administered following an overnight fast of at least 10 hours along with fluconazole on Day 15 only.
2871210|NCT03451084|Experimental|ASLAN003 100mg|
2871211|NCT03451084|Experimental|ASLAN003 200mg|
2871212|NCT03451084|Experimental|ASLAN003 300mg|
2871213|NCT03451058||Mild TBI Group|History of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
2871214|NCT03451058||Moderate to Severe TBI Group|History of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
2871215|NCT03451058||Healthy Controls|No history of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
2871216|NCT03451045|Experimental|Lenabasum 20 mg BID|
2871217|NCT03451045|Experimental|Lenabasum 5 mg BID|
2871218|NCT03451045|Placebo Comparator|Placebo BID|
2871219|NCT03451019|Active Comparator|sevelamer hydrochloride|the subject receive a single dose of 2,4 g
2871220|NCT03451019|Active Comparator|lanthanum carbonate|the subject receive a single dose of 1.0 g
2871221|NCT03451006|Experimental|Metformin|Metformin 500mg tablet by mouth, every 6 to 8 hours for one year
2871222|NCT03451006|Active Comparator|Placebo|Placebo by mouth every 6 to 8 hours for one year
2871223|NCT03450993|Experimental|Immediate SMART Program Intervention|Subjects will receive the SMART-3RP intervention following study enrollment.
2871224|NCT03450993|Other|Delayed SMART Program Intervention|Subjects will record symptoms following enrollment and receive the SMART-3RP intervention approximately 3 months following study enrollment.
2871225|NCT03450980|Other|EyeTurn App|All participants will have their eye alignment measured with both the experimental device (EyeTurn app) and the clinical gold standard tests or ground truth (simulated strabismus gaze angles).
2871226|NCT03450967|Experimental|Durvalumab Plus Tremelimumab|Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.).
2871227|NCT03450954||Case(AMT patients)|patients who have undergone amniotic membrane transplant in our unit up till 2016.
2871228|NCT03450954||Control(Patients without AMT)|bullous keratopathy patients awaiting endothelial keratoplasty
2871229|NCT03450928|Active Comparator|Short POEM|Patients in the Short POEM-group will undergo a Peroral Endoscopic Myotomy (POEM) extended for a total of 7 cm (including 4 cm above the esophago-gastric junction and 3cm on the stomach).
2871230|NCT03450928|Active Comparator|Long POEM|Patients in the Long POEM-group will receive a 12cm-long Peroral Endoscopic Myotomy (POEM), including 9 cm on the esophagus and 3cm on the gastric wall
2871231|NCT03450915|Experimental|M-001|Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.
2871232|NCT03450915|Placebo Comparator|Saline|Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.
2871233|NCT03450902|Experimental|Chinese herb & acupuncture|Participants will take Yiqi Suoquan granule and receive acupuncture.
2871234|NCT03450902|Active Comparator|Chinese herb & sham acupuncture|Participants will take Yiqi Suoquan granule and receive sham acupuncture.
2871235|NCT03450902|Active Comparator|Placebo & acupuncture|Participants will take placebo granule and receive acupuncture.
2871236|NCT03450902|Placebo Comparator|Placebo & sham acupuncture|Participants will take placebo granule and receive sham acupuncture.
2871237|NCT03450889||Intervention arm|This study uses only one arm. All patients in this intervention arm will be surveyed using the aforementioned study protocol, which means patients will undergo a colonoscopy (or sigmoidoscopy in patients with previous subtotal colectomy) with surveillance intervals of either 1 or 2 years, depending on the amount and type of polyps resected during previous surveillance.
2871238|NCT03450876||Healthy Control|Individuals without melanoma (stage III or IV) diagnosis that have been included in the PROFILES cohort
2871239|NCT03450876||24 to < 36 months post-ipilimumab treatment|24 to 36 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2014 in one of the 14 melanoma centers in the Netherlands
2871240|NCT03450876||≥ 36 to < 48 months post-ipilimumab treatment|36 to 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2013 in one of the 14 melanoma centers in the Netherlands
2871241|NCT03450876||≥ 48 months post-ipilimumab treatment|Greater than 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab between 2011 and 2012 in one of the 14 melanoma centers in the Netherlands
2871242|NCT03450863||Fast-acting insulin aspart|Participants will receive fast-acting insulin aspart at the treating physician's discretion as part of the usual clinical practice. The prescription and use of fast-acting insulin aspart is completely independent of this study. Total study duration for the individual patient will be approximately 24 weeks.
2871243|NCT03450850|Other|NOVOTTF-200A|NOVOTTF-200A treatment in Bevacizumab-Naïve Subjects with Recurrent WHO Grade III Malignant Astrocytoma
2871244|NCT03450837||Anabolic androgenic steroids users|"This group had been involved in strength training for at least 2 years, self-administering anabolic androgenic steroids in periodic cycles lasting from 8 to 12 weeks for at least 2 years with 2-4 cycles per year. All participants were on a cycle over the course of the study.~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
2871245|NCT03450837||Anabolic androgenic steroids nonusers|"This group had been involved in strength training for at least 2 years and they have never took anabolic androgenic steroids.~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
2871246|NCT03450837||Sedentary control|"This group were sedentary men without cardiovascular disease.~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
2871247|NCT03450824||The study group|The participants with patellofemoral pain.
2871248|NCT03450824||The control group|The participants without patellofemoral pain.
2871249|NCT03450811|Active Comparator|Study group|The patients underwent elective open or laparoscopic inguinal hernia repair at a general surgery clinic.
2871250|NCT03450811|No Intervention|Control group|patients who were admitted to the outpatient clinics with various diseases or healthy persons
2871251|NCT03450798|Active Comparator|SOFT block group|needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected
2871252|NCT03450798|Sham Comparator|spinal anesthesia group|patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.
2871253|NCT03450772|Experimental|Creon® 25000 then Creon® 10000|Pancreatic enzyme
2871254|NCT03450772|Active Comparator|Creon® 10000 then Creon® 25000|Pancreatic enzyme
2871255|NCT03450759|Experimental|Treatment sequence 1|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:~AZD9977 oral suspension (reference) AZD9977 capsule AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate)"
2871256|NCT03450759|Experimental|Treatment sequence 2|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:~AZD9977 capsule AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate) AZD9977 oral suspension (reference)"
2871257|NCT03450759|Experimental|Treatment sequence 3|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:~AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate) AZD9977 Oral suspension (reference) AZD9977 capsule"
2871258|NCT03450759|Experimental|Treatment sequence 4|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:~AZD9977 ER capsule (Int. rate) AZD9977 Oral suspension (reference) AZD9977 capsule AZD9977 ER capsule (fast rate)"
2871259|NCT03450746||Healthy patients for orthopaedic surgery|Standard general anaesthesia and ventilation with FiO2 0.50 for at least 45 minutes following the standard settings in our department.
2871260|NCT03450733||Previously Implanted (Group 1)|Subjects previously implanted with components of the Wright Medical Technology (WMT) Metal-on-Metal (MoM) Total Hip Arthroplasty (THA) System
2871262|NCT03450720|Experimental|GLPG2737 single dose.|Single dose of GLPG2737 oral suspension.
2871263|NCT03450707|Experimental|Thiamine|Patients randomized to the thiamine arm will receive thiamine 500mg in 100mL of normal saline intravenously every 12 hours for 5 doses. Patients will be connected to a noninvasive monitor for measurement of global oxygen consumption (VO2) for at least 48 hours or until extubated, whichever comes first. Blood will be drawn at 0,6,12,24,72 and 168 hours for measurement of lactate, thiamine level, pyruvate dehydrogenase, NSE, S100 and other markers of organ injury. CPC-E score will be assessed prior to hospital discharge and at 30 and 90 days to evaluate differences in neurologic and functional impairment.
2871264|NCT03450707|Placebo Comparator|Placebo|Patients randomized to placebo will receive 100mL normal saline intravenously every 12 hours for 5 doses. All other aspects of the protocol will be the same as in the experimental arm. Patients will be connected to a noninvasive monitor for measurement of global oxygen consumption (VO2) for at least 48 hours or until extubated, whichever comes first. Blood will be drawn at 0,6,12,24,72 and 168 hours for measurement of lactate, thiamine level, pyruvate dehydrogenase, NSE, S100 and other markers of organ injury. CPC-E score will be assessed prior to hospital discharge and at 30 and 90 days to evaluate differences in neurologic and functional impairment.
2871265|NCT03450681|Placebo Comparator|No pulsed radiofrequency|Procedure consists of a mock incision at the pulsed radiofrequency needle insertion site and standard perioperative pain management by the pain clinic (femoral catheter and PCA)
2871266|NCT03450681|Experimental|Pulsed Radiofrequency|Procedure consists in pre-operative pulsed radiofrequency under ultrasound guidance of the saphenous nerve and standard postoperative pain management by the pain clinic (femoral catheter and PCA)
2871267|NCT03450668|Active Comparator|standard incubator|routinely used standard incubator already used in the neonatal unit
2871268|NCT03450668|Experimental|mOm incubator|new test incubator
2871269|NCT03450655|Experimental|Intervention Group|Weeks 1-10: exercise program in group. Weeks 11-20: no intervention. Weeks 21-31: no intervention.
2871270|NCT03450655|Experimental|Control group|Weeks 1-10: no intervention. Weeks 11-20: no intervention. Weeks 21-31: exercise program at home.
2871271|NCT03450642||Observation|Patients presenting with right Iliac Fosse pain
2871272|NCT03450629|Experimental|Brimonidine Tartrate Ophthalmic Suspension|
2871273|NCT03450629|Active Comparator|Brimonidine Tartrate Ophthalmic Solution|
2871274|NCT03450616|Experimental|Negative Pressure Wound Therapy|Subjects will have one venous stasis ulcer treated with the PICO Negative Pressure Wound Therapy Device
2871275|NCT03450616|Active Comparator|Compression Dressing- Standard of Care|Subjects will have one venous stasis ulcer treated with the standard of care compression dressing.
2871276|NCT03450603||stable COPD|Chronic obstructive pulmonary disease (COPD) was confirmed if the patient had a baseline post-bronchodilator FEV1 less than 80% of the reference value and forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) quotient of less than 70%.Select patients with COPD without acute attack within three months．
2871277|NCT03450603||exacerbation of COPD|Exacerbation was defined as an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough, and/or sputum that was beyond normal day to day variations and may have warranted a change in regular medication in a patient with underlying COPD.
2871278|NCT03450577||PCI of bifurcation lesions|Patients who have undergone bifurcation coronary artery stenting.
2871279|NCT03450564|Experimental|Women Education|In the married women arm there will be an intervention with health education provision based on the baseline finding so as to fill the gap. Family planning experts, Health extension workers and model women who use family planning will be responsible in providing the health education message. Every month there will be a provision of health education message about family planning for a total of 9 months. The message will be designed by the investigator. Data will be collected at baseline, mid line and end line to see the effect of the intervention on family planning use and intention to use.
2871280|NCT03450564|Experimental|Male Involvement|The description for this arm will be an intervention with health education about family planning by family planning experts, Health extension workers and clan and religious leader to enhance family use. Every month there will be a provision of health education message about family planning for a total of 9 months. Data will be collected at baseline, mid line and end line to see the effect of the intervention on family planning use and intention to use.
2871281|NCT03450564|Other|Control group|The third arm in this community-based intervention will be following the community without provision of male and married women education. In this arm, there will be no intervention by the researchers. However, the activities performed by the government about family planning provision will be maintained.
2871282|NCT03450551|Experimental|Twin Block|61 patients will receive the Twin Block appliance (one of the three appliances being studied)
2871283|NCT03450551|Active Comparator|Herbst|61 patients will receive the Herbst appliance (one of the three appliances being studied)
2871284|NCT03450551|Active Comparator|Frog distalising appliance|61 patients will receive the Frog distalising appliance (one of the three appliances being studied)
2871285|NCT03450499|Experimental|analgesic effects of ketamine|the experimental group will receive ketamine intravenously at 0.25 mg per kg before skin incision.
2871286|NCT03450499|Placebo Comparator|placebo|they will receive same volume of 0.9% normal saline as calculated for experimental group before skin incision.
2871287|NCT03450486|Experimental|affected limb|measurements of balance from the affected side of individuals with unilateral knee osteoarthritis following an exercise session
2871288|NCT03450486|Active Comparator|unaffected limb|measurements of balance from the unaffected side of individuals with unilateral knee osteoarthritis following an exercise session
2871289|NCT03450473|Other|SurgiMend® MP|Patients will not be randomized as this is a case series study involving the evaluation of only 1 type of mesh (SurgiMend MP®).
2871290|NCT03450460|Experimental|2/week peer support|These individuals with acquired brain injury will receive the Ontario Brain Injury Association Peer Support program twice per week.
2871291|NCT03450460|Experimental|1/week peer support|These individuals with acquired brain injury will receive the Ontario Brain Injury Association Peer Support program once per week.
2871292|NCT03450460|No Intervention|wait list control group|These individuals with acquired brain injury will receive the Ontario Brain Injury Association Peer Support once the trial period is complete.
2871296|NCT03450434|Placebo Comparator|Placebo|Placebo 2 mg, 10 mg or 100 mg orally
2871297|NCT03450421|Experimental|Actamax™Adhesion Barrier|Following Myomectomy, subjects randomized to the Actamax™Adhesion Barrier Arm will have up to 30mL of product applied to all sites of surgery (area of treatment/trauma).
2871298|NCT03450421|No Intervention|Surgical Control|Myomectomy will be performed with no adhesion barrier application.
2871299|NCT03450408|Active Comparator|Placement with gloved hand|The Foley bulb transcervical dilator will be placed blindly with a gloved hand.
2871300|NCT03450408|Active Comparator|Placement with sterile speculum|The cervix will be directly visualized using a sterile speculum, and an instrument will be used to advance the Foley bulb transcervical dilator into the cervical os.
2871301|NCT03450395|Placebo Comparator|Cereal - Cream of Rice|40 g cream of rice
2871302|NCT03450395|Experimental|Cereal - Oats containing beta-glucan|40 g oats
2871303|NCT03450382|Experimental|Hans Kai Participant|Participants receiving Hans Kai intervention
2871304|NCT03450382|No Intervention|Control|Participants not enrolled in Hans Kai
2871305|NCT03450369|Experimental|NB01|Open label and dose escalation of a single application of NB01 to subjects with moderate acne, with approximately 5 subjects assigned to lower bound dose before escalation to upper bound dose.
2871306|NCT03450343|Experimental|Oral azacitidine + R-ICE|Patients will receive 7 days of oral azacitidine (CC-486) leading into cycle 1 day 1 of R-ICE chemotherapy. R-ICE chemotherapy may be administered as an inpatient or as an outpatient . Oral azacitidine will be administered on days 8-21 of cycles 1 and cycle 2. R-ICE will be administered per standard of care.
2871307|NCT03450330|Experimental|daily dose of AZD4205|daily dose of AZD4205
2871308|NCT03450317|Experimental|Aspirin|Aspirin 80mg once daily
2871309|NCT03450317|No Intervention|Non-treatment group|No intervention
2871310|NCT03450291|Experimental|Recovered from anorexia nervosa|Those who have a past diagnosis of AN (defined by the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria) but are currently recovered, as shown by BMI over 18.5 throughout the last 12 months (self-report and current weight measured). Defined as either 'fully recovered'and: score must be within the 'normal range' of the Eating Disorders Examination Questionnaire (EDE-Q) global mean scores for young women, below 20 on the EAT-26 and below 16 on the Clinical Impairment Assessment for Eating Disorders (CIA); or partially recovered where one or more of these scores may be above the above-mentioned cutoffs.
2871311|NCT03450291|Experimental|High scoring on the EAT-26|Those who score above 20 on the EAT-26, but who do not declare a former diagnosis of an eating disorder (though they may meet criteria for a current diagnosis during the Structured Clinical Interview for the DSM-5).
2871312|NCT03450291|Experimental|Healthy controls|No history of or current diagnosis of any psychiatric disorder (especially eating disorders) which could impact study results.
2871313|NCT03450278|No Intervention|control|canine retraction without any means of acceleration.
2871314|NCT03450278|Experimental|micro-osteoperforation|canine retraction accelerated with micro-osteoperforation
2871315|NCT03450265|Experimental|Hemopatch|Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.
2871316|NCT03450265|Active Comparator|TachoSil|Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.
2871317|NCT03450252|Experimental|Active pacing|Active ventricular pacing. The pacemaker is set-up with a short atrio-ventricular delay to allow for appropriate pacing capture of the ventricle.
2871318|NCT03450252|Sham Comparator|Back-up pacing|Back-up pacing. The pacemaker is set-up to sense and pace only in the right atrium (AAI) without any pacing capacity in the ventricle.
2871319|NCT03450239|Experimental|Recovered from anorexia nervosa|Women who have recovered from Anorexia Nervosa for over a year. BMI over 18.5, aged 18-40, scores on Eating Disorder Examination (EDE) within 1 standard deviation of the global mean. All these participants undergo an MRI scan.
2871320|NCT03450239|Experimental|Healthy controls|Healthy control women. BMI over 18.5, aged 18-40, scores on EDE within 1 standard deviation of the global mean. All these participants undergo an MRI scan.
2871321|NCT03450226|Experimental|treatment|patients will receive a stellate ganglion block with 10 ml of 0.25 % bupivacaine
2871322|NCT03450226|No Intervention|control|patients will be controlled
2871323|NCT03450213|Active Comparator|Patients with keratoconus|Pentacam will be used for comparison between astigmatism in patients with keratoconus and normal people at the same age and sex.
2871324|NCT03450213|Placebo Comparator|Normal people at the same age and sex|Pentacam will be used for comparison between astigmatism in patients with keratoconus and normal people at the same age and sex.
2871325|NCT03450200|Experimental|Exercises Group|three times daily exercises of hands and fingers exercises and foot exercises which last for 10 minutes in eight weeks, and health education about diabetic foot care
2871326|NCT03450200|Other|Control Group|health education about diabetic foot care
2871327|NCT03450187|Active Comparator|Cohort A|50 mg TP-271 q24 (n=6), a novel, broad-spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
2871328|NCT03450187|Active Comparator|Cohort B|100 mg TLP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
2871329|NCT03450187|Active Comparator|Cohort C|200 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
2871330|NCT03450187|Active Comparator|Cohort D|300 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
2871331|NCT03450187|Active Comparator|Cohort E|400 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
2871332|NCT03450174|Placebo Comparator|Control|this group, only placebo product will be given
2871333|NCT03450174|Experimental|Formative messages|this group will be received only daily formative messages on diet diversity, healthy and best nutrition practices
2871334|NCT03450174|Experimental|Fortified product|this group will be received only fortified product on alternate day up to 6 months
2871335|NCT03450174|Experimental|Fortified product plus|this group will receive fortified product along with daily messages on diet diversity and healthy nutrition practices
2871336|NCT03450161|Experimental|High-Dose Bolus of Fentanyl|"5 minutes prior to sternotomy, patients will receive a fentanyl bolus of 20 mcg/kg BW (verum) and a perfusion pump with sodium chloride (NaCl 0.9%; placebo) will be begun according to the Shibutani dosing scheme.~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
2871337|NCT03450161|Experimental|Low-Dose Bolus of Fentanyl|"5 minutes prior to sternotomy, patients will receive a fentanyl bolus of 3 mcg/kg BW (verum) and a perfusion pump with sodium chloride (NaCl 0.9%; placebo) will be begun according to the Shibutani dosing scheme.~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
2871338|NCT03450161|Experimental|Continuous Dose of Fentanyl|"5 minutes prior to sternotomy, patients will receive a NaCl 0.9% bolus (placebo) and a perfusion pump with fentanyl (verum) will be begun according to the Shibutani dosing scheme.~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
2871339|NCT03450148|Experimental|Pavlok wristband with electric stimulus|Participants in intervention group will wear wristband and will get a slight electric stimulus when they press the device
2871340|NCT03450148|Placebo Comparator|Pavlok wristband without electric stimulus|Participants in control group will wear wristband and will not get a slight electric stimulus when they press the device
2871341|NCT03450135|Experimental|Mid-pubertal girls|Adolescent girls (ages 12-14) who are undergoing a healthy pubertal transition (Tanner developmental stage 3 or 4) will perform Trier Social Stress Test and Emotional go/no-go task.
2871342|NCT03450122|Experimental|Cohort 0: Modified T Cells|"Run In Cohort:~Participants receive Cyclophosphamide by vein on Day -2.~Participants receive a single infusion of NY-ESO-1-specific CTL alone and observed for any signs of toxicity.~Low-dose IL-2 given subcutaneously within 6 hours of T cell infusion, then 2 times each day after that for 14 days."
2871343|NCT03450122|Experimental|Cohort 1: Modified T Cells + LV305|"Participants receive Cyclophosphamide by vein on Day -2.~Participants receive modified T cells by vein on Day 0. Low-dose IL-2 given subcutaneously within 6 hours of T cell infusion, then 2 times each day after that for 14 days.~Participants receive injections of LV305 on Days 1, 22, 43, and 64."
2871344|NCT03450122|Experimental|Cohort 2: Modified T Cells + LV305 + CMB305|"Participants receive Cyclophosphamide by vein on Day -2.~Participants receive modified T cells by vein on Day 0. Low-dose IL-2 given subcutaneously within 6 hours of T cell infusion, then 2 times each day after that for 14 days.~Participants receive injections of LV305 on Days 1, 14, 43, and 70. Participants also receive injections of CMB305 on Days 29, 57, and 85."
2871345|NCT03450109|Experimental|LY01005|One LY01005 3.6 mg gluteal IM injection.
2871346|NCT03450109|Active Comparator|Zoladex|One Zoladex 3.6 mg subcutaneous injection into the anterior abdominal wall
2871347|NCT03450096|Active Comparator|Treatment group|A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
2871348|NCT03450096|No Intervention|Control group|Patients in the control group (and in the active treatment group) will receive an opioid-based analgesia with a hydromorphone-patient controlled analgesia (PCA) depending on their analgesic demand
2871349|NCT03450083|Active Comparator|Benralizumab treatment group|Benralizumab Active treatment group delivered subcutaneously
2871350|NCT03450083|Placebo Comparator|Placebo group|Placebo treatment group delivered subcutaneously
2871351|NCT03450057|Experimental|Daratumumab + Dexamethasone|"Daratumumab at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter.~Dexamethasone 40 mg (20 mg for patients>75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle"
2871352|NCT03450044|Experimental|Vaccinated|Transfer of autologous dendritic cells interspersed with chemotherapy doses
2871353|NCT03450044|No Intervention|Control|Control patients who follow their basic treatment with chemotherapy with the A/C scheme
2871354|NCT03450031|Experimental|NAC (no drug/no device) and NFP|NAC with mixed grass pollen will be conducted. Nasal mucosal inflammatory mediators will be collected via nasal filter paper (NFP)
2871355|NCT03450031|Experimental|NAC (no drug/no device) and NFP AND NLF|NAC with mixed grass pollen will be conducted. Nasal filter paper (NFP)sampling will be conducted from one nostril per time point. Subjects in Cohort B will also undergo nasal lavage (NLF) pre-NAC and at serial time points thereafter up to 8 hours
2871356|NCT03450018|Experimental|SLC-0111 + Gemcitabine|"Dose Level 1 - SLC-0111 (500 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m^2 IV on day 1, 8, and 15)~Dose Level 2 - SLC-0111 (750 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m^2 IV on day 1, 8, and 15)~Dose Level 3 - SLC-0111 (1000 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m^2 IV on day 1, 8, and 15)"
2871357|NCT03450005||emerging Candida isolates|Web-based registry of invasive infections by Candida species
2871358|NCT03449992|Experimental|Intervention group|Participants in this group ingested nitrate-rich beetroot juice for 15 days
2871359|NCT03449992|Placebo Comparator|Placebo group|Participants in this group ingested a placebo drink for 15 days
2871360|NCT03449979|Experimental|alpha stimulation|Participants will receive 2mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
2871361|NCT03449979|Placebo Comparator|sham stimulation|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.
2871362|NCT03449966|Experimental|Target biopsy under pCLE|(Cellvisio® with confocal minoprobe™, Mauna Kea Technologies, France)
2871363|NCT03449966|Active Comparator|Random biopsy at cancer lesion under WLE|WLE (GIF-HQ290, Olympus, Japan) group
2871388|NCT03449758|Experimental|Sarilumab|Sarilumab is to be administered every 2 weeks over the treatment period alone or in combination with csDMARD
2871389|NCT03449732|Experimental|PDR measurement group A|Two measurements of PDR perioperatively before and after opioid administration in toddlers (28 days until 23 months)
2871364|NCT03449940|Active Comparator|Immediate repair (group 1)|"Penile explorations were done within 24 hours of presentation, under general or spinal anaesthesia.~1g Ceftriaxone IV was given.~Incision-‐ Subcoronal, circumferential & degloving.~Repair-- Continuous technique with inverted knots using 3-0 polyglactin suture.~All patients were discharged from hospital within 24 hours."
2871365|NCT03449940|Active Comparator|Delayed repair (group 2)|"Patients were not admitted; instead they were discharged from hospital and given an elective surgery date. Oral Diclofenac Sodium 50mg was prescribed to be taken as needed and instructions to abstain from any sexual activity.~In an ambulatory setting, surgery was done 7 - 10 days later.~1g Ceftriaxone IV was given.~Local anaesthesia (dorsal penile nerve block): 1% Lidocaine 10cc was given.~Incision--‐ 2 - 3cm localized incision over the site of the rolling sign.~Repair--‐ Continuous technique with inverted knots using 3-0 polyglactin suture."
2871366|NCT03449927|Active Comparator|Control Arm: Regular menu|"Calorie count initiated on day +1 of transplant and ending upon count recovery~Symptom worksheet initiated on day +1 of transplant and ending upon count recovery (absolute neutrophil count of 1000)~Goals to monitor: calorie and protein intake, self-reported diarrhea and nausea~Interventions provided for control group: standard of care, verbal or printed handouts, standard educations created by Barnes Jewish Hospital (BJH) oncology dietitians"
2871367|NCT03449927|Experimental|Intervention Arm: Specialized Menu|"Calorie count and tool provided on day +1 and ending upon count recovery~Symptom worksheet initiated on day +1 of transplant and ending upon count recovery (absolute neutrophil count of 1000)~Goals to monitor: calorie and protein intake, self-reported diarrhea and nausea~Interventions provided for intervention group: standard of care provided by BJH oncology dietitians, tools including nausea and diarrhea menus and follow up by registered dietitian (RD) to provide additional counseling on menus as symptoms arise"
2871368|NCT03449901|Experimental|ADI-PEG 20 + Gemcitabine + Docetaxel|"ADI-PEG 20 will be given on Day -7 of Cycle 1 and then on Days 1, 8, and 15 of each subsequent cycle. Cycles are 21 days. ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m2 via intramuscular injection into either the deltoid or gluteal muscle.~Gemcitabine will be given intravenously at a dose of 900 mg/m2 over 90 minutes on Days 1 and 8 of each cycle. Docetaxel will be given intravenously at a dose of 75 mg/m2 over 60 minutes on Day 8 of each cycle.~Treatment may continue for up to 34 cycles (103 weeks)"
2871369|NCT03449888||St. Louis VA Healthcare System stress testing referrals|St. Louis VA Healthcare System cardiac stress testing laboratory referrals who are eligible and willing to complete an arm exercise ECG stress test, a treadmill ECG stress test if able, a regadenoson myocardial perfusion imaging stress test, and a coronary artery calcium score and cardiac computed tomographic angiography evaluation within 60 days if not referred for invasive coronary arteriography.
2871370|NCT03449862|Experimental|LEGAL-COST|Clinicians were first presented malpractice case law summary information (which suggests clinician not likely to be sued for not ordering CT scan) then patient out-of-pocket cost information for brain CT image (which provides them insight into what the patient is likely to pay for the test)
2871371|NCT03449862|Active Comparator|COST-LEGAL|Clinicians were first presented with patient out-of-pocket cost information for brain CT image (which provides them insight into what the patient is likely to pay for the test) then malpractice case law summary information (which suggests clinician not likely to be sued for not ordering CT scan)
2871372|NCT03449849|Other|Base diet|Subjects will consume a base diet prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
2871373|NCT03449849|Other|Kale Treatment|Subjects will consume 500 g of kale per 2000 kcal of food, split between breakfast and dinner, as a supplement to the base diet.
2871374|NCT03449836|Experimental|Streptococcus salivarius 24SMBc + Strept.oralis 89a|spray with Streptococcus salivarius 24SMBc + Strept. oralis 89a
2871375|NCT03449836|Active Comparator|fluticasone + mometasone|spray with fluticasone and mometasone
2871376|NCT03449836|Placebo Comparator|placebo|spray with isotonic solution
2871377|NCT03449823||TTTS Cases|Cases of monochorionic / diamniotic twin pregnancies diagnosed with twin-twin transfusion syndrome.
2871378|NCT03449823||MCDA Controls|Controls of monochorionic / diamniotic twin pregnancies without a diagnosis of twin-twin transfusion syndrome.
2871379|NCT03449810|Experimental|Muscles Energy Technique (Group A)|Muscles Energy Technique: the participant will be asked to lie supine on a couch with the hip at the edge and both lower limbs freely off the couch. The participant would place one of his legs over the therapist's shoulder and push up with the opposite leg into therapist's hand. A total of 4 contractions will be resisted by force equal to the participant's, held for 5sec with 5sec rest b/w each contraction. Also, restriction barrier (i.e. where movement is not possible due to impairment resulting from LBP) will be identified and the patient will be instructed to make a contraction of about 20-30% 0f maximal voluntary isometric contraction, held for 8-10secs, relaxed for 2-3secs and the limb will be moved to a new barrier. The procedure is repeated for about 4-6 times.
2871380|NCT03449810|Experimental|Core Stability Exercises (Group B)|Core Stability Exercises involves 4 different exercises; 1) Upper-body roll-out. 2) Inclined press-up. 3) Contralateral single-leg hold. 4) Quadruped exercise
2871381|NCT03449810|Experimental|MET plus CSE (Group C)|This group would receive a combination of Both Muscles Energy Technique plus Core Stability Exercise procedure.
2871382|NCT03449810|Active Comparator|Education and Counselling|Patient Education and Counselling involves Educating participant in-home care treatment program and Recommendation of strategies to prevent recurrent problems e.g. Functional movement training/re-education, this commonly involves identifying movements that are associated with low back pain, such as excessive flexion of the lumbar spine when rising from a chair instead of utilizing flexion of the hip for executing the movement, then providing cuing and education on movement options that enable the activity to be performed with fewer, or no, symptoms.
2871383|NCT03449797|Sham Comparator|Group A|AAVS performed with no intraprocedural rapid cortisol assay
2871384|NCT03449797|Experimental|Group B|AVS performed plus intraprocedural rapid cortisol assay
2871385|NCT03449784||patients with dyslipidemia non achieving LDL-C target|patients with dyslipidemia non achieving LDL-C target
2871386|NCT03449784||patients with dyslipidemia achieving LDL-C target|patients with dyslipidemia achieving LDL-C target
2871387|NCT03449771|Experimental|Single Arm|To estimate the acceptability and the impact on the management of a systematic identification of the use of psychoactive substances and / or anxio-depressive disorders by self-questionnaire.
2871390|NCT03449732|Experimental|PDR measurement group B|Two measurements of PDR perioperatively before and after opioid administration in children (2 until 11 years)
2871391|NCT03449732|Experimental|PDR measurement group C|Two measurements of PDR perioperatively before and after opioid administration in adolescents (12 until 18 years)
2871392|NCT03449719|Active Comparator|Abiraterone|The treatment phase consists of systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist (control arm).
2871393|NCT03449719|Experimental|Abiraterone associated withAblative Radiation|"the patients in the experimental arm will receive SBRT to all metastatic lesions, concomitantly with abiraterone acetate.~SBRT will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations.~Considering an Alfa/beta of 3, a BED3 > 100 Gy is recommended"
2871394|NCT03449693|Experimental|Magnesium Oxide Supplement|Magnesium Oxide 250 mg tablet, daily for 30 days.
2871395|NCT03449693|No Intervention|No Supplement|No Intervention
2871396|NCT03449680|Experimental|Femoral Articular Branch Block|Patients will receive an ultrasound-guided femoral articular branch block with an injection of 20ml of ropivicaine 0.5%
2871397|NCT03449680|Placebo Comparator|Placebo Block|Patients will receive an ultrasound simulation of the location of a femoral articular branch block , this is to maintain blinding. A subcutaneous injection of 1ml of normal sterile saline will be administered
2871398|NCT03449667|Active Comparator|Cryoneurolysis|Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
2871399|NCT03449667|Sham Comparator|Sham Comparator|Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
2871400|NCT03449654|Other|Liraglutide|
2871401|NCT03449654|Other|placebo|
2871402|NCT03449641|Other|Positive airway pressure (PAP) treatment|Positive airway pressure (PAP),which reverses upper airway obstruction, is effective in the majority of patients with stable obesity hypoventilation syndrome (OHS).
2871403|NCT03449628|Experimental|L. casei DG®|"Interventions: Lactobacillus paracasei CNCMI1572 (At least 24 billion live cells per capsule)~1 capsule, b.i.d. for 12 weeks"
2871404|NCT03449628|Placebo Comparator|Placebo|"Interventions : capsules for oral use, indistinguishable from active product.~1 capsule, b.i.d. for 12 weeks"
2871405|NCT03449602|Experimental|Mini-thoraoscopy|The mini-thoracoscope manufactured by Richard Wolf GmbH, Knettligen, Germany will be used for performing thoracoscopic pleural biopsies. It has an outer diameter of 5.5 mm and a working channel diameter of 3.5 mm.
2871406|NCT03449602|Active Comparator|Conventional rigid thoracoscopy|The rigid thoracoscope manufactured by Richard Wolf GmbH, Knettligen, Germany will be used for performing thoracoscopic pleural biopsies. It has an outer diameter of 10 mm and channel internal diameter of 5 mm.
2871407|NCT03449589||Smokers|RA patients currently smoking
2871408|NCT03449589||Former smokers|RA patients who previously smoked
2871409|NCT03449589||Non smokers|Non smoking RA patients
2871410|NCT03449576|Experimental|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 15 sessions of individualized exposure therapy and 14 sessions of group-based social and emotion rehabilitation.
2871411|NCT03449576|Placebo Comparator|Exposure Therapy with Psychoeducation|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 15 sessions of individualized exposure therapy and 14 session of group-based psychoeducation.
2871412|NCT03449563|Placebo Comparator|Placebo group (group G)|
2871413|NCT03449563|Active Comparator|Ultrasound-guided TPVB group (group U)|
2871414|NCT03449563|Experimental|open TPVB group(group E)|
2871415|NCT03449550|Active Comparator|Diagnostic Randomizing|Randomizing to start with home respiratory polygraphy (HRP) or Standard Polysomnography (PSG)
2871416|NCT03449550|Active Comparator|Therapeutic Randomizing|Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP) or Standard Polysomnography (PSG)
2871417|NCT03449537|Experimental|EHCF+LGG|extensively hydrolyzed casein formula supplemented with the probiotic Lactobacillus rhamnosus GG
2871418|NCT03449537|Active Comparator|AAF|hypoallergenic formula based on amino acid-based formula
2871419|NCT03449524|Active Comparator|75mg CXA-10|Once daily dosing of 75mg CXA-10 in the morning
2871420|NCT03449524|Active Comparator|150mg CXA-10|Once daily dosing of 150mg CXA-10 in the morning
2871421|NCT03449524|Placebo Comparator|Placebo|Once daily dosing in the morning
2871422|NCT03449511|Active Comparator|Ginger aromatherapy|Ginger essential oil (GIN-106) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
2871423|NCT03449511|Active Comparator|Orange aromatherpy|Orange essential oil (ORG-114) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
2871424|NCT03449511|Active Comparator|Lavender aromatherapy|Lavender essential oil (LAV-110) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
2871425|NCT03449511|Placebo Comparator|Jojoba aromatherapy|"Jojoba oil in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles. One drop of jojoba oil is on the other three aromatherapy inhalers. Jojoba oil is a carreir oil for essential oils which will be used as a comparator and placebo in this study."
2871426|NCT03449498|Experimental|study group|Intensive qualitative functional therapy
2871427|NCT03449498|Experimental|control group|Intensive functional therapy
2871428|NCT03449459|Experimental|oral probiotics|
2871429|NCT03449459|Experimental|aerosol inhaled amikacin|
2871430|NCT03449459|Experimental|combined vaccination|
2871431|NCT03449459|No Intervention|conventional therapy (blank control)|According to the subjects' personal characteristics and guidance of The Global Initiative for Chronic Obstructive Lung Disease(GOLD) 2017, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled glucocorticoids and long term oxygen therapy.
2871432|NCT03449446|Experimental|SEL+ GS-0976 + GS-9674 Placebo|SEL + GS-0976 + GS-9674 Placebo for 48 weeks
2871433|NCT03449446|Experimental|SEL+ GS-0976 Placebo + GS-9674|SEL + GS-0976 Placebo + GS-9674 for 48 weeks
2871434|NCT03449446|Experimental|SEL+ GS-0976 Placebo + GS-9674 Placebo|SEL + GS-0976 Placebo + GS-9674 Placebo for 48 weeks
2871435|NCT03449446|Experimental|SEL Placebo + GS-0976 + GS-9674 Placebo|SEL Placebo + GS-0976 + GS-9674 Placebo for 48 weeks
2871436|NCT03449446|Experimental|SEL Placebo + GS-0976 Placebo + GS-9674|SEL Placebo + GS-0976 Placebo + GS-9674 for 48 weeks
2871437|NCT03449446|Experimental|SEL Placebo + GS-0976 Placebo + GS-9674 Placebo|SEL Placebo + GS-0976 Placebo + GS-9674 Placebo for 48 weeks
2871438|NCT03449446|Experimental|SEL Placebo + GS-0976 + GS-9674|SEL Placebo + GS-0976 + GS-9674 for 48 weeks
2871439|NCT03449433|Experimental|LY900014|Single, subcutaneous (SC) dose of LY900014
2871440|NCT03449433|Active Comparator|Insulin Lispro (Humalog®)|Single, SC dose of insulin lispro
2871441|NCT03449433|Active Comparator|Insulin Aspart (NovoRapid®)|Single, SC dose of insulin aspart
2871442|NCT03449433|Active Comparator|Insulin Aspart (Fiasp®)|Single, SC dose of insulin aspart
2871443|NCT03449420||Post Partum Hemorrhage|Patients presenting with a post partum hemorrhage. A thromboelastography analysis is realized at discretion of the anesthesiologist in charge
2871444|NCT03449394|Active Comparator|Delusions (Tx)|
2871445|NCT03449394|No Intervention|Delusions (TAU)|
2871446|NCT03449394|Active Comparator|Depression (Tx)|
2871447|NCT03449394|No Intervention|Depression (TAU)|
2871448|NCT03449381|Experimental|Dose Escalation|
2871449|NCT03449381|Experimental|Dose Expansion|
2871450|NCT03449368||Cohort 1|Includes age group 5-10 with a cap at 50 subjects. This is a retrospective, observational study.
2871451|NCT03449368||Cohort 2|Includes age group 11-15 with a cap of 50 subjects. This is a retrospective, observational study.
2871452|NCT03449368||Cohort 3|Includes age group 16-20 with a cap of 40 subjects. This is a retrospective, observational study.
2871453|NCT03449368||Cohort 4|Includes age group 21-30 with a cap of 40 subjects. This is a retrospective, observational study.
2871454|NCT03449368||Cohort 5|Includes age group 31-40 with a cap at 40 subjects. This is a retrospective, observational study.
2871455|NCT03449368||Cohort 6|Includes age group 41-50 with a cap at 40 subjects. This is a retrospective, observational study.
2871456|NCT03449368||Cohort 7|Includes age group 51-60 with a cap at 20 subjects. This is a retrospective, observational study.
2871457|NCT03449368||Cohort 8|Includes age group 61-70 with a cap at 20 subjects. This is a retrospective, observational study.
2871458|NCT03449355||vaginal group|
2871459|NCT03449355||cesarean section group|
2871460|NCT03449342|Experimental|Turoctocog alfa|Previously treated moderate or severe haemophilia A patients will receive routine prophylaxis treatment and treatment of bleeding episodes.
2871461|NCT03449329|Placebo Comparator|placebo SIP block|This group will receive a placebo SIP block injection with 60mL NaCl 0.9%
2871462|NCT03449329|Active Comparator|Locoregional SIP block|"This group will receive a SIP block using:~3mg/kg Ropivacain 1%~1mcg/kg dexmedetomidine (Dexdor®) 100mcg/ml Addition of NaCl 0.9% up to 60ml"
2871463|NCT03449316|Experimental|Inhaler technique education|This group will receive a structured and regular follow-up plan, with education on inhaler technique. Patients will be trained by a Family Doctor (the primary investigator) in terms of the inhaler technique using placebo devices similar to their own devices. A teach-to-goal approach will be used, repeating all correct steps as many times as needed in order for patients to perform them correctly at each evaluation. There will be visits at baseline and after 3, 6 and 12 months to assess outcomes. In each visit, and prior to the main intervention with the primary investigator, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adhesion and quality of life) will be performed by a secondary blinded investigator.
2871464|NCT03449316|No Intervention|Usual Care|"This group will receive usual care from their own Family doctors, with no specific intervention. Each doctor will perform the necessary consultations according to his real life judgment. Besides this, this group will perform visits at baseline and after 3, 6 and 12 months to assess secondary outcomes. At each visit, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adhesion and quality of life) will be performed by a secondary blinded investigator. At any appointment, if the patient asks for or if the clinician decides to teach inhaler technique, that will be recorded.~If any adjustments are made in drug classes or device types in every participants, this information will be recorded."
2871465|NCT03449303|Active Comparator|EOI|10% dilution of Curcuma longa, Piper nigrum, Pelargonium asperum, Zingiber officinale, Mentha x piperita, and Rosmarinus officinalis ct. cineole in Simmondsia chinensis
2871466|NCT03449303|Placebo Comparator|Placebo|Simmondsia chinensis
2871467|NCT03449290|Experimental|Kinesio taping group|Kinesio taping was applied on trunk muscles
2871468|NCT03449290|Sham Comparator|Control group|Sham Kinesio taping was applied on trunk muscles
2871469|NCT03449277|Active Comparator|take oral nifedipine tablets|Women who take the oral tablets of nifedipine till discharge of hospital
2871470|NCT03449277|Active Comparator|take oral labetalol tablets|Women who take the oral tablets of labetalol till discharge of hospital
2871471|NCT03449264|Experimental|Biological collection|"samples of different natures:~Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery.~Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out.~In parallel to this biological collection, standardized clinical data will be entered into a database"
2871472|NCT03449251|Experimental|Substudy 1A - Apelin|In sub-study 1A Healthy participants will receive systemic infusions of Apelin to establish a dose range
2871587|NCT03448328|Active Comparator|Apple juice|Apple juice
2871588|NCT03448315|Active Comparator|real tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions)
2871473|NCT03449251|Experimental|Substudy 1B - Apelin/Normal Saline|In sub-study 1B , individuals with Type 2 Diabetes and individuals with increase weight will receive systemic infusions of Apelin or Normal Saline
2871474|NCT03449251|Experimental|Substudy 2A - Relaxin/Normal Saline|In sub-study 2A Healthy participants will receive intra-arterial infusions of Relaxin
2871475|NCT03449251|Experimental|Substudy 2B - Relaxin|In sub-study 2B Healthy participants will receive intra-arterial infusions of Relaxin followed by verapamil (on a background infusion of either LN Monomethyl Arginine or Normal Saline, to test effects on nitric oxide)
2871476|NCT03449251|Experimental|Substudy 3A - Relaxin with Apelin/Saline|In sub-study 3A Healthy participants will receive intra-arterial infusions of Relaxin (background infusion apelin/Normal Saline)
2871477|NCT03449251|Experimental|Substudy 3B - Apelin with Relaxin/Saline|In sub-study 3B Healthy participants will receive intra-arterial infusions of Apelin (background infusion Relaxin/Normal Saline)
2871478|NCT03449251|Experimental|Substudy 4 - Apelin and Relaxin|In sub-study 4 Healthy participants, Individuals with Type 2 Diabetes and Individuals with increase weight will receive systemic infusions of Normal saline, Relaxin, Apelin and relaxin
2871479|NCT03449238|Other|pembrolizumab and SRS|Pembrolizumab will be infused the day before SRS, at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
2871480|NCT03449225|No Intervention|Control Arm|The participant will be given a digital device (IPad or Kindle Fire) to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once the survey is complete, the participant will proceed with standard education, provided by a resident/physician in the clinic, about prenatal screening and testing for chromosome conditions and for carrier status. Once the standard education has been completed, the participant will be approached to complete a post-education survey which includes questions about knowledge, intent to have or decline screening or testing, and demographic variables.
2871481|NCT03449225|Experimental|Test Arm|• The participant she will be given a digital device on which to access the computer aided genetics educational module. Prior to accessing the module, the patient will be asked to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once she has completed the survey, she will interact with the Computer-Aided Genetic Education Module which is tailored for her clinical situation. Once the participant has completed reviewing the module, she will be asked to complete the web-based post-module survey which includes questions about knowledge, intent to have or decline screening or testing, acceptability of the module, and demographic variables.
2871482|NCT03449212||SOD1 ALS|
2871483|NCT03449212||Sporadic ALS|
2871484|NCT03449212||Asymptomatic SOD1 gene carriers|
2871485|NCT03449199|Experimental|TMX-049 dose 1|
2871486|NCT03449199|Experimental|TMX-049 dose 2|
2871487|NCT03449199|Placebo Comparator|TMX-049 Placebo|
2871488|NCT03449186||Pregnancy group|Women, who were in their second trimester (weeks 16-24) or third trimester (weeks 25-34)selected for the study. Saliva and GCF samples were collected and clinical periodontal measurements were made gently
2871489|NCT03449186||Postpartum group|Postpartum women 6 months after giving birth recalled. Saliva and GCF samples were collected and clinical periodontal measurements were made.
2871490|NCT03449173|Experimental|Sunitinib|Sunitinib orally administered at 50 mg once daily for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks
2871491|NCT03449160|Active Comparator|Physical Therapy|Receive standard physical therapy
2871492|NCT03449160|Experimental|posture training device|Receive a posture training device in addition to standard physical therapy
2871493|NCT03449147|Experimental|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg film-coated tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).
2871494|NCT03449147|Experimental|Gefapixant 15 mg BID|Participants will receive a gefapixant 15 mg film-coated tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).
2871495|NCT03449147|Placebo Comparator|Placebo|Participants will receive a matching placebo tablet BID during the 24-week main study period and during the 28-week extension period.
2871496|NCT03449134|Experimental|Gefapixant 45 mg BID|Participants received a gefapixant 45 mg film-coated tablet BID during the main study period (12 weeks) and also during the extension period (40 weeks).
2871497|NCT03449134|Experimental|Gefapixant 15 mg BID|Participants received a gefapixant 15 mg film-coated tablet BID during the during the 12-week main study period and during the 40-week extension period.
2871498|NCT03449134|Placebo Comparator|Placebo|Participants received a matched placebo tablet BID during the 12-week main study period and during the 40-week extension period.
2871499|NCT03449121|Experimental|Slow breathing|Slow breathing techniques with exhale greater than inhale
2871500|NCT03449108|Experimental|Ovarian Cancer|
2871501|NCT03449108|Experimental|Osteosarcoma|
2871502|NCT03449108|Experimental|Other Bone and Soft Tissue Sarcomas|
2871503|NCT03449095|Experimental|Alcohol Administration|A moderate dose of alcohol (Target BAC .08%)
2871504|NCT03449095|No Intervention|Control Beverage Administration|Participants consume a non-alcoholic beverage
2871505|NCT03449082|Experimental|High concentration of Allo-ASC group|High concentration of Allo-ASC 0.5cc (Total: 10 million cells) & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
2871506|NCT03449082|Experimental|Low concentration of Allo-ASC group|Low concentration of Allo-ASC 0.5cc (Total: 1 million cells) & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
2871507|NCT03449082|Placebo Comparator|Placebo Comparator (Fibrin) group|Normal saline 0.5cc & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
2871508|NCT03449069|Experimental|MSC-AFP|This is a single treatment group study. All patients will receive treatment of a stem cell coated fistula plug.
2871509|NCT03449056|Experimental|TREATMENT|salbutamol nebulization
2871510|NCT03449030|Experimental|Part A Escalation Stage: TAK-164 Q3W|TAK-164 0.004 milligram per kilogram (mg/kg) starting dose, intravenous infusion, on Day 1 every 3 Week (Q3W) in a 21-day treatment cycle, followed by a rest period of 20 days until disease progression, unacceptable toxicity or discontinuation by participant. Dose escalation will be performed to determine the MTD and RP2D.
2894213|NCT03289598|No Intervention|Controlgroup|
2871511|NCT03449030|Experimental|Part A Escalation Stage: TAK-164 Q2W|TAK-164 to be determined (TBD) mg/kg starting dose, intravenous infusion, on Days 1 and 15 every 2 Week (Q2W). Dose escalation will be performed to determine the MTD and RP2D.
2871512|NCT03449030|Experimental|Part B Expansion Stage: TAK-164|TAK-164 dose and dosage regimen to be decided based on safety data and MTD/RP2D obtained from Part A escalation stage.
2871513|NCT03449017|Experimental|E-cig use condition|Participants self-administer their own electronic cigarette device
2871514|NCT03448978|Experimental|Descartes-08 (cells)|Autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
2871515|NCT03448939|Experimental|S5G4T-1|topical cream
2871516|NCT03448939|Placebo Comparator|S5G4T-2|topical cream
2871517|NCT03448926||DCIS|Patients must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast without evidence of invasive cancer (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable)
2871518|NCT03448913||PECS block+ General anesthesia|Patients undergoing mastectomy, partial mastectomy and/or axillary clearance who received PECS block AND general anesthesia for the surgery.
2871519|NCT03448913||General anesthesia|Patients undergoing mastectomy, partial mastectomy and/or axillary clearance who received general anesthesia only for the surgery.
2871520|NCT03448900|Experimental|Multicomponent intervention|The intervention group consisted in face-to-face 50-minute meeting [motivational interviewing (MI)]; online self-help material focused on: (1) decisions; (2) moods; (3) social life; (4) smoking health effects; and (5) quitting; e-mail 15 days before the MI, group therapy 2 months after the MI (60 minutes), a second follow-up visit 4 months after the MI (20 minutes).
2871521|NCT03448900|Active Comparator|Brief advice|The control group received a brief advice (5-10minutes) and a self-help pamphlet called 'Stop smoking'. Before giving brief advice, the nurse assessed smokers' habits and their willingness to quit. As is usually in this type of studies there were no follow-up sessions for this group.
2871522|NCT03448887|Experimental|Study group|Extended HD with MCO dialyzer
2871523|NCT03448887|Active Comparator|Control group|Online hemodiafiltration
2871524|NCT03448874|Experimental|Seal-G MIST System|Seal-G MIST System is a surgical sealant that will be applied adjunctively to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.
2871525|NCT03448874|No Intervention|Standard of care|Patients in the control arm will receive the standard of care [SOC] for colorectal resection surgery with primary anastomosis (no additional intervention)
2871526|NCT03448861|Experimental|Polso Wearable watch|Polso Wearable watch for the purpose of NEWS measurement
2871527|NCT03448848|Experimental|study|
2871528|NCT03448848|Placebo Comparator|control|
2871529|NCT03448835|Experimental|atezolizumab and chemotherapy|1 cycle of atezolizumab followed by 4 cycles atezolizumab, capecitabine, oxaliplatin and docetaxel
2871530|NCT03448822||sentinel node procedure|a robot-assisted laparoscopic sentinel node procedure.
2871531|NCT03448809|Experimental|MMM (Mind My Mind training)|Mind My Mind training
2871532|NCT03448809|Active Comparator|TAU (Treatment as Usual)|Treatment as Usual
2871533|NCT03448796|Active Comparator|HTO-group|Group receives opening wedge high tibial osteotomy with Tomofix -plate. Operative intervention is followed by supervised physiotherapeutic rehabilitation.
2871534|NCT03448796|Active Comparator|FT -group|Group receives only supervised physiotherapeutic rehabilitation.
2871535|NCT03448770|Active Comparator|Lactulsoe|Lactulose : 20-30gm 2-3 doses per day
2871536|NCT03448770|Experimental|Polyethlene Glycol|PEG (Polyethlene Glycol)- 17 gm sachet 3-4 times per day
2871537|NCT03448757|Experimental|Autonomic response|"Group for determination of biofeedback response - 40 individuals. For the formation of this study group of subjects, 20 healthy volunteers and 20 patients with advanced hepatocellular carcinoma will be selected and studied.~Group for determination of ideal frequency - 20 patients. For the formation of this study group of subjects, 20 patients with advanced hepatocellular carcinoma participants in the group will be selected and studied to determine biofeedback response.~Group for determination of new specific frequencies - 20 individuals. For the formation of this study group of subjects, 20 patients with advanced hepatocellular carcinoma not exposed to any specific frequency will be selected."
2871538|NCT03448744|Experimental|combiantion therapy group|thymosin alpha 1 (1.6 mg subcutaneously injection twice a week) plus ETV (0.5 mg orally, daily) for 24 weeks, and followed by continuous ETV for at least 48 weeks
2871539|NCT03448744|Placebo Comparator|entecavir group|ETV (0.5 mg orally, daily) at least for 72 weeks
2871540|NCT03448731|Experimental|Doxycycline|Doxycycline 50 mg p.o. daily during 6 weeks
2871541|NCT03448718|Experimental|Olaparib Monotherapy|The starting dose of olaparib tablets will be dependent on the subject's calculated creatinine clearance (CrCl). Subjects with a CrCl of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of > 30 to < 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
2871542|NCT03448705|Experimental|Group 1 - Study drug 1 (i.e. 4Fluart ID 1 µg/0.1 ml QIV)|Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 1 µg haemagglutinin per virus strain in 0.1 ml as a single dose.
2871543|NCT03448705|Experimental|Group 2 - Study drug 2 (i.e. 4Fluart ID 2 µg/0.1 ml QIV)|Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 2 µg haemagglutinin per virus strain in 0.1 ml as a single dose.
2871544|NCT03448705|Active Comparator|Group 3 - Comparator drug (i.e. 3Fluart IM 6 µg/0.5 ml TIV)|Vaccination of 12 subjects will be performed with the intramuscular trivalent influenza vaccine containing 6 µg haemagglutinin per virus strain in 0.5 ml as a single dose.
2871545|NCT03448692|Experimental|PF-06730512 Cohort 1|Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV.
2871546|NCT03448692|Experimental|PF-06730512 Cohort 2|Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV.
2871547|NCT03448666|Experimental|pembrolizumab and elettrochemiotherapy|drug: Pembrolizumab 200 mg flat dose every three weeks procedure: elettrochemiotherapy once after first pembrolizumab dose
2871548|NCT03448653|Experimental|Colonoscopy with NBI|
2871589|NCT03448315|Sham Comparator|sham tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions) but stimulation device is turned off without the participant knowledge
2871549|NCT03448627||Group 1: HSCT recipients|Pulmonary functions [spirometry], maximal exercise capacity [Modified-Incremental Shuttle Walk Test (ISWT)], inspiratory and expiratory muscle strength (MIP and MEP, respectively) [mouth pressure device] and peripheral muscle strength [hand-held dynamometer] were evaluated in allogeneic HSCT recipients (n=66).Vital signs, dyspnea and fatigue perception [Modified Borg Scale] were recorded as pre-post measurements of Modified-ISWT.
2871550|NCT03448627||Group 2: healthy individuals|Healthy individuals (n=50) were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
2871551|NCT03448601|Active Comparator|Non-tailored intervention group|
2871552|NCT03448601|Experimental|Culturally tailored intervention group|
2871553|NCT03448588||group with normal T4 level or T4/T3|participants with T4 within 4.3-12.5ug/dl and ratio of T4/T3(T4(ug/dl)/T3 (ng/ml)) ≤7.52, which are considered to be normal T4 level and T4/T3.
2871554|NCT03448588||group with elevated T4 level or T4/T3|participants with T4 more than 12.5ug/dl and ratio of T4/T3(T4(ug/dl)/T3 (ng/ml)) ＞ 7.52, which are considered to be elevated T4 level and T4/T3.
2871555|NCT03448575|Sham Comparator|Control - Medication Alert Only|The control arm medication alert is a simple text pop-up in the EMR that will inform the prescriber of Choosing Wisely® recommendations developed the American Psychiatric Association regarding antipsychotic medication use in children and adolescents.
2871556|NCT03448575|Experimental|Intervention - Alert + CAP Review AND Enhanced BH Access|"The intervention alert prompts the prescriber to keep/remove the antipsychotic order, and/or order any study services: behavioral health navigation, expedited psychotherapy access, virtual consult with a child and adolescent psychiatrist (CAP). Passive case review by the study CAP will occur for all intervention arm cases. A virtual consult will be scheduled if the prescriber ordered it or the CAP needs to discuss the case. The CAP will provide the prescriber with a written summary of his/her review.~Following review by the CAP, a navigator reaches out to the eligible intervention arm patient/family to offer extra support. The navigator's role is to (a) provide extra support to facilitate access and engagement in appropriate psychosocial therapies; (b) coordinate short-duration bridging therapy sessions for teens/families not engaged in psychotherapy, when appropriate; and (c) keep the prescriber informed of any clinically relevant updates."
2871557|NCT03448562|Experimental|Study Group|CPVI plus electrophysiologic substrate ablation in the left atrium during sinus rhythm (STABLE-SR)
2871558|NCT03448562|Active Comparator|Control Group|CPVI alone
2871559|NCT03448549|Experimental|Group A (TGOP-OX)|Colorectal cancer patients p-staged III are randomized and assigned with TGOP-OX (Tegafur，gimeracil and oteracil potassium+Oxaliplatin) as adjuvant chemotherapy.
2871560|NCT03448549|Active Comparator|Group B (XELOX)|Colorectal cancer patients p-staged III are randomized and assigned with XELOX (Xeloda+Oxaliplatin) as adjuvant chemotherapy.
2871561|NCT03448536|Experimental|Naproxen Sodium : Acetaminophen|1/2 adolescent and adult female patients with primary dysmenorrhea will be randomized in this arm, in a crossover fashion to a single dose of naproxen sodium 440 mg (Treatment A) and a single dose of acetaminophen 1000 mg (Treatment B)
2871562|NCT03448536|Experimental|Acetaminophen : Naproxen Sodium|1/2 adolescent and adult female patients with primary dysmenorrhea will be randomized in this arm, in a crossover fashion to Treatment B and Treatment A
2871563|NCT03448523|Experimental|Right To Play's Positive Child and Youth Development program|Behavioural intervention
2871564|NCT03448523|No Intervention|Control|No intervention; intervention to be offered after end line assessment
2871565|NCT03448510|Experimental|Irreversible electroporation treatment|Subjects will receive irreversible electroporation of the prostate
2871566|NCT03448510|Active Comparator|standard medication group|Subjects will receive either α-blocker or 5α reductase monotherapy or combination therapy.
2871567|NCT03448497||Advanced Melanoma patients who intiated first-line therapy|patients who initiated any first-line therapy for advanced melanoma and had not previously received treatment for their advanced disease
2871568|NCT03448484|Experimental|Intervention|Intervention (agriculture-focused package + nutrition-sensitive and nutrition-specific interventions=integrated package)
2871569|NCT03448484|Other|Control|Control (agriculture-focused package)
2871570|NCT03448471||Group 1: severe-fatigued recipients|These recipients had Fatigue Severity Scale score ≥36. All recipients evaluated with similar methods. Meaurements were Pulmonary function tests, Respiratory muscle strength, Peripheral muscle strength, Functional exercise capacity, Dyspnea, Fatigue, Depression and Quality of life.
2871571|NCT03448471||Group 2: non-severe-fatigued recipients|These recipients had Fatigue Severity Scale score <36. All recipients evaluated with similar methods. Meaurements were Pulmonary function tests, Respiratory muscle strength, Peripheral muscle strength, Functional exercise capacity, Dyspnea, Fatigue, Depression and Quality of life.
2871572|NCT03448458|Experimental|Gallium Ga 68-DOTATATE PET/CT|Patients receive gallium Ga 68-DOTATATE IV. Within 55-70 minutes, patients undergo PET (positron emission tomography)/CT (computed tomography).
2871573|NCT03448445||High-risk MCI|This cohort will include participants with high-risk mild cognitive impairment (MCI).
2871574|NCT03448445||Low-risk MCI|This cohort will include participants with low-risk MCI.
2871575|NCT03448419|Experimental|Empagliflozin|
2871576|NCT03448419|Placebo Comparator|Placebo|
2871577|NCT03448406|Experimental|Empagliflozin|
2871578|NCT03448406|Active Comparator|Placebo|
2871579|NCT03448393|Experimental|Dose escalation|CD19/CD22-CARtransduced T cells at escalating doses
2871580|NCT03448393|Experimental|Dose expansion|CD19/CD22-CARtransduced T cells at MTD or highest dose administered
2871581|NCT03448380||SMBG and FreeStyle Libre|During the intervention phase, subjects will use FreeStyle Libre Flash Glucose Monitoring System for 6 months to managed their diabetes.
2871582|NCT03448367||SMBG/FreeStyle Libre|During the intervention phase, subjects will use FreeStyle Libre Flash Glucose Monitoring System for 6 months to managed their diabetes.
2871583|NCT03448354|Experimental|NAC-IDS-HIPEC|Under the clinicians' decision, HIPEC procedures will be performed at the time of IDS.
2871584|NCT03448354|No Intervention|NAC-IDS|Under the clinicians' decision, HIPEC procedures will not be performed at the time of IDS.
2871585|NCT03448328|Experimental|Pea Protein|NUTRALYS pea protein supplement
2871586|NCT03448328|Experimental|Whey Protein|Whey protein supplement
2871590|NCT03448302||Patients with colorectal adenocarcinoma|The patients will undergo computed tomography perfusion
2871591|NCT03448289|No Intervention|Control|This group will not receive the RLPT.
2871592|NCT03448289|Experimental|Intervention|This group will receive the RLPT.
2871593|NCT03448276|Experimental|Training in the vibrating platform|20-minute workout will be held, which will include: heating (5 minutes and stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
2871594|NCT03448276|Active Comparator|Walk|Will be held 30 minutes of training, which will include the heating (5 minutes of stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
2871595|NCT03448263|Experimental|Group BF|The root canals were cleaned and shaped using a #40 instrument for thin or curved canals and a #55 file for widespread canals.
2871596|NCT03448263|Experimental|Group WON|WaveOne files was used to prepare narrow, straight and curved canals, and a file (40.08) was used for large and wide canals.
2871597|NCT03448263|Experimental|Reciproc instruments|Reciproc instrument was used in thin and curved RC, and R40 files (40.06) were used in wide canals.
2871598|NCT03448250|Experimental|Optimune|Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
2871599|NCT03448250|Active Comparator|Care-as-Usual|As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).
2871600|NCT03448237|Active Comparator|Speech therapy|Speech therapy adapted to the child,
2871601|NCT03448237|Active Comparator|Proprioceptive treatment|This treatment aims to stabilize a central reference instability revealed to Maddox Postural by the use of neurosensory decoys
2871602|NCT03448237|Experimental|Combined Treatment|Association of speech therapy and proprioceptive treatment, adapted to the child.
2871603|NCT03448224|Experimental|Group I (web-based Indoor Tanning intervention)|Participants receive intervention, weekly text messages about IT reduction, and personalized booster intervention. Participants then receive text messages twice weekly for 4 weeks.
2871604|NCT03448224|Active Comparator|Group II (wait-list)|Participants are placed on wait-list and may receive full intervention after follow-up.
2871605|NCT03448211|Experimental|Para-toluenesulfonamide Injection (PTS)|Investigational product
2871606|NCT03448198|Other|Knee arthritis|Total knee replacement
2871607|NCT03448185|Placebo Comparator|Control|Subjects randomized to control group will receive olive oil placebo capsules and yoga intervention for 1 year.
2871608|NCT03448185|Experimental|Exercise and omega-3 fatty acids|Subjects will receive high dose omega-3 fatty acids as well as aerobic exercise intervention for 1 year.
2871609|NCT03448185|Active Comparator|Yoga and omega-3 fatty acids|Subjects will receive high dose omega-3 fatty acids as well as yoga intervention for 1 year.
2871610|NCT03448185|Active Comparator|Exercise control|Subjects will receive olive oil placebo as well as aerobic exercise intervention for 1 year.
2871611|NCT03448172|Experimental|Investigational Product|[14C]PF-05221304
2871612|NCT03448159|Experimental|Fluoxetine Hydrochloride|Fluoxetine (Prozac) will be administered to this group. A ramp up period of 3-5 weeks will take place where the patient takes 10mg of Prozac per day. After that, the participant will take the regular dose of 20mg for the duration of the exercise intervention (12 weeks).
2871613|NCT03448159|Placebo Comparator|Placebo|"An over-encapsulated placebo, or sugar pill (so it appears identical to the trial drug) will be administered to this group. During the 3-5 week ramp up period for the experimental group, these participants will take a placebo identical to the 10mg Prozac capsule. After that, the participant will take a placebo identical to the 20mg Prozac capsule for the duration of the exercise intervention (12 weeks)."
2871614|NCT03448146|Experimental|Para-Toluenesulfonamide|".The dose of PTS injected into multiple points in a single tumor was about 0.1-1.0 mL, and the appropriate specific doses were kept within the tumor without leakage. An appropriate low dose could be given firstly, and the following doses could be adjusted based on the response of patient and the tumor.~. In general, the daily dose of PTS injected into a single tumor was no more than 5mL, and the daily dose of PTS was no more than 10mL for each patient.~The injection was provided 2-3 times a week, with 2 weeks as a cycle of treatment. No less than 4 times of PTS treatment were recomended for the first cycle of treatment, and for other cycles of treatment, the number of PTS injections could be adjusted appropriately based on the condition of the patient."
2871615|NCT03448133|Experimental|rTMS treatment group|The participants will be devided into rTMS treatment and sham treatment by means of randomized methods.The protocol of treatment is to use rTMS with high frequency 10/20Hz 120%RMT 20 times for one month. The device is Magtism rTMS made in London, UK
2871616|NCT03448133|Sham Comparator|sham treatment group|The control group is to receive sham treatment. The device is the same as the one used in the real treatment group.
2871617|NCT03448120|No Intervention|Control Group|The volunteers who will remain in prolonged rest (10 minutes for homeostasis plus 30 minutes of no intervention).
2871618|NCT03448120|Experimental|Acupuncture Group|The volunteers will receive six needles in six acupoints in the non-dominant upper limb for 30 minutes.
2871619|NCT03448120|Experimental|Dry needling Group|The volunteers will receive application of six needles arranged in the non-dominant biceps brachialis for 30 minutes.
2871620|NCT03448107|Experimental|Simple Prevention|"One drop (0.05 ml) of silver diamine fluoride (Advantage ArrestTM) solution at 38% concentration (2.24 F-ion mg/dose) will be dispensed per child. Posterior tooth surfaces to be treated will be dried, after which the SDF will be applied with a micro-brush to all asymptomatic carious lesions and to all pits and fissures on bicuspids and molar teeth for thirty seconds. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
2871656|NCT03447873|Experimental|Switch to dual therapy B|Switch to dual therapy with Dolutegravir (50 mg) + lamivudine (300 mg) once daily
2871621|NCT03448107|Active Comparator|Complex Prevention|"Pits and fissures on all bicuspids and molar teeth will be sealed with glass ionomer sealants (GC Fuji IX). Glass ionomer sealants (interim therapeutic restorations) will also be placed on all frank asymptomatic carious lesions. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
2871622|NCT03448094|Experimental|Resveratrol|500mg of Veri-te Resveratrol (consumed as two 250mg tablets, at two timepoints each day).
2871623|NCT03448094|Placebo Comparator|Placebo|Matched placebo capsules (1 capsule consumed at two timepoints each day).
2871624|NCT03448081|Active Comparator|SNA-120 + Calcipotriene|
2871625|NCT03448081|Placebo Comparator|Placebo + Calcipotriene|
2871626|NCT03448068|Experimental|Ketamine Therapy|"Ketamine 0.3 mg/kg (IBW) bolus with induction.~Ketamine infusion 0.2 mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion will not be titrated.~Remaining care will be identical to standard therapy group."
2871627|NCT03448068|Active Comparator|Standard Therapy|"Calculation ideal body weight (IBW)~Pre-op dexamethasone~Pre-op midazolam at discretion of anesthesiologist~Anesthesia Induction - Propofol and fentanyl, anesthesiologist discretion. Neuromuscular block with succinylcholine and/or rocuronium at discretion of anesthesiologist. Orotracheal intubation.~Anesthesia Maintenance - Sevoflurane/rocuronium. Addl. doses of fentanyl, discretion of anesthesiologist.~Emergence from anesthesia - Acetaminophen, Ketorolac and Ondansetron unless contraindicated. Sugammadex depending on twitch response per drug manufacturer recommended protocol.~Post-Op Analgesia - Hydromorphone, acetaminophen and ketorolac~Other post-op care as per usual surgical routine"
2871628|NCT03448055|Other|Interventional|Immunocal 20gm daily
2871629|NCT03448042|Experimental|Dose Escalation|Participants will be assigned sequentially to escalating doses of BTRC4017A, up to the maximum tolerated dose (MTD).
2871630|NCT03448042|Experimental|Dose Expansion|Participants will receive BTRC4017A based on the MTD or maximum allowed dose (MAD) identified during dose escalation.
2871631|NCT03448029||Endovascular Patients|Patients undergoing endovascular interventions for symptomatic PAD
2871632|NCT03448016|Experimental|Alcohol use disorders|[C-11]NOP-1A PET Scan
2871633|NCT03448016|Experimental|Controls|[C-11]NOP-1A PET Scan
2871634|NCT03448003|Experimental|Integrative Oncology (IO) Group|"Participants take part in the cancer prevention program.~Questionnaires completed at baseline, after completing 12 weeks of the cancer prevention program, and then again about 26 and 52 weeks after that.~Participants complete 12 weeks of online counseling sessions.~Participants also have 1 behavioral counseling session each week for up to 26 weeks.~Participants take part in an interview about experience in the study and in making lifestyle changes at week 52."
2871635|NCT03448003|Other|Delayed Intervention (DI) Control Group|"Participants have a follow-up visit at about 12 and 26 weeks.~Questionnaires completed at baseline, 12, and 26 weeks.~Participants take part in an interview about experience in the study and in making lifestyle changes at week 52."
2871636|NCT03447990|Other|Cohort1|Crossover, Single ascending dose of MYK-491/placebo
2871637|NCT03447990|Other|Cohort 2|Crossover, Single ascending dose of MYK-491/placebo
2871638|NCT03447977|Experimental|cervical group|cervical spinal mobilizations, exercises, 2 session for 6 weeks
2871639|NCT03447977|Experimental|thoracic group|cervical and thoracic spinal mobilizations, exercises, 2 session for 6 weeks
2871640|NCT03447977|Experimental|exercise group|exercises, 2 session for 6 weeks
2871641|NCT03447964||Type 1 diabetes|dosing of sphingolipids
2871642|NCT03447964||Type 2 diabetes|Dosing of sphingolipids
2871643|NCT03447951|Experimental|PTS100 (Para-Toluenesulfonamide): 20%TTV|Group 1: total dose = 20% total tumor volume
2871644|NCT03447951|Experimental|PTS100 (Para-Toluenesulfonamide): 30%TTV|Group 2: total dose = 30% total tumor volume
2871645|NCT03447938|Active Comparator|CABG with sternotomy|Patients in this group will undergo coronary artery bypass grafting (CABG) in the usual way, through an incision in the middle of the chest, through the breastbone or sternum (conventional CABG).
2871646|NCT03447938|Experimental|Minimally-invasive CABG|Patients in this group will undergo coronary artery bypass grafting (CABG) using a minimally-invasive approach (MICS CABG), through smaller incisions between the ribs.
2871647|NCT03447925|Experimental|Medicinal Plant X Salicylate|Treatment Group (TG) will receive topical treatment with medicinal plant and Salicylate Group (SG) will receive topical treatment with salicylate 10%, both once a day, for 30 consecutive days.
2871648|NCT03447925|Experimental|Medicinal Plant X Vaseline|Treatment Group (TG) will receive topical treatment with medicinal plant and Control Group (CG) will receive topical treatment with vaseline cream, both once a day, for 30 consecutive days.
2871649|NCT03447912|Experimental|Intervention Condition|Fourteen communities will be assigned to the intervention.
2871650|NCT03447912|No Intervention|Control Condition|The 14 communities assigned as controls will participate in the population-level survey and will be provided with a site-specific summary of findings but will not participate in any aspects of the intervention. To examine potential contamination in the control communities, a follow-up interview will be conducted with public health center leaders to assess any local coalition or grassroots actions regarding tobacco control that may have naturally occurred or be influenced by coalition activity in other communities.
2871651|NCT03447899|Experimental|ABC Intervention|"The investigators will deliver the Attachment and Biobehavioral Catch-up (ABC) in the home weekly using live, in-room coaching, to give caregivers feedback as they use targeted skills during interactions with the child. The intervention will last 10 sessions. Study participants in both groups will complete study measures at baseline, 1 month, 3 months, post-intervention, 6 months, and 12 months."
2871652|NCT03447899|No Intervention|Standard of Care|"Subjects will receive normal standard of care without the Attachment and Biobehavioral Catch-up (ABC)."
2871653|NCT03447886||Quality Of Life|"This study uses qualitative research methods, specifically semi-structured interviews.~This will include moderator guide development,~Phone interviews with breast cancer survivors will be conducted~Qualitative data analysis of the phone interviews will be conducted"
2871654|NCT03447873|Active Comparator|Triple therapy|To Continue with triple therapy with Elvitegravir/cobicistat + tenofovir alafenamide + emtricitabine or Dolutegravir + abacavir + lamivudine once daily.
2871655|NCT03447873|Experimental|Switch to dual therapy A|Switch to dual therapy with Darunavir/cobicistat (800150 mg) + lamivudine (300 mg) once daily once daily.
2871657|NCT03447860|Active Comparator|REACH-VA|A cognitive-behavior based multi-component caregiver intervention to reduce caregiver stress.
2871658|NCT03447860|Experimental|PAACC|A mindfulness-based multi-component caregiver intervention to reduce caregiver stress.
2871659|NCT03447847|Experimental|Phase 1|A=oligomineral water, B=oligomineral water
2871660|NCT03447847|Experimental|Phase 2|A=oligomineral water, B=bicarbonate-rich water
2871661|NCT03447847|Experimental|Phase 3|A=bicarbonate-rich water, B=oligomineral water
2871662|NCT03447847|Experimental|Phase 4|A=bicarbonate-rich water, B=bicarbonate-rich water
2871663|NCT03447834|Experimental|intervention group - Intracoronary cooling|Patients will be eligible for this study if they are admitted for acute anterior wall ST-elevation anterior wall infarction with a total ST-segment deviation of at least 5 mm. If the patient has TIMI 0 or 1 flow the intervention group will be treated with intracoronary cooling before the normale PPCI.
2871664|NCT03447834|Other|Control group - PPCI|The control group will receive the standard PPCI treatment
2871665|NCT03447821|Active Comparator|400 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
2871666|NCT03447821|Active Comparator|800 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
2871667|NCT03447821|Active Comparator|1200 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
2871668|NCT03447808|Experimental|Treatment (daratumumab, ibrutinib)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Beginning course 2, patients also receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2871669|NCT03447795|Experimental|autogenous tooth grafted sites|
2871670|NCT03447795|Active Comparator|autogenous demineralised dentin grafted sites|
2871671|NCT03447782|Experimental|NDPH Persistent|"Patients will be evaluated in clinic 1 month after the phone call evaluation. At this time, patients will begin a 3 month trial of low-dose naltrexone (Naltrexone HCL powder compounded to provide 4.5mg once per day orally).~Patients will be evaluated in clinic 3 months after beginning treatment with naltrexone."
2871672|NCT03447769|Experimental|canakinumab|Participants will be administered receive canakinumab for 18 cycles (approximately 54 weeks).
2871673|NCT03447769|Placebo Comparator|Placebo|Participants will be administered receive canakinumab placebo for 18 cycles (approximately 54 weeks).
2871674|NCT03447756|Experimental|ABX-1431|One or more oral capsules containing 2 mg or 10 mg or 50 mg of ABX-1431 HCl or matching placebo are administered daily to enrolled patients. Patients will undergo a blinded dose escalation. All patients will receive placebo on some days to assess safety and neuropathic pain. Patients will undergo an optimized titration of ABX-1431 HCl with the daily dose between 8 mg and 24 mg of ABX-1431. Each patients dose will be determined by the Investigator based on assessment of adverse events.
2871675|NCT03447756|Placebo Comparator|Placebo oral capsule|One or more oral capsules containing placebo are administered daily to enrolled patients. Patients will undergo a blinded dose escalation. All patients will receive placebo on some days to assess safety and neuropathic pain. Patients will undergo an optimized titration of placebo. Each patients dose will be determined by the Investigator based on assessment of adverse events.
2871676|NCT03447743|Experimental|XR-NTX P&P office|30 participants will receive on-going XR-NTX injections in the local rural P&P office
2871677|NCT03447743|Active Comparator|XR-NTX services as usual|30 participants will receive on-going XR-NTX injections in a local community clinic
2871678|NCT03447730|Experimental|SYNB1020|SYNB1020 (5 × 10 to the 11th CFU, TID for 6 days)
2871679|NCT03447730|Placebo Comparator|Placebo|Placebo (100 mL masking solution, TID for 6 days)
2871680|NCT03447717|Experimental|ActiGait|Patients who get the ActiGait implant
2871681|NCT03447704|Experimental|BCD-085|
2871682|NCT03447704|Placebo Comparator|Placebo|
2871683|NCT03447691|Experimental|DES Group|"Desflurane will be administered via tracheal intubation tube at the level of 0.7-1.1 MAC. Remifentanil will be maintained intravenously by continuous infusion rate of 0.01-0.1 mcg / kg / min~DES Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate)."
2871684|NCT03447691|Active Comparator|TIVA Group|"Propofol and remifentanil will be administered via intravenous, using an infusion pump capable of effect site target controlled infusion.~TIVA Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate)."
2871685|NCT03447678|Experimental|Pembrolizumab|subjects with PD-L1 low (PD-L1Lo), EGFR wt, EML4/ALK fusion negative NSCLC
2871686|NCT03447665|No Intervention|Control|Infant sleep monitoring and parental surveys only
2871687|NCT03447665|Experimental|Intervention (Bedtime only)|Infant behavioral sleep intervention implemented at bedtime only. Parents are instructed to soothe/help their infant back to sleep after night wakings. Includes a tailored sleep schedule and bedtime routine, as well as support from a sleep interventionist.
2871688|NCT03447665|Experimental|Intervention (All night)|Infant behavioral sleep intervention implemented at bedtime and after each subsequent infant night waking. Includes a tailored sleep schedule and bedtime routine, as well as support from a sleep interventionist.
2871689|NCT03447652|No Intervention|Control Group|Each patient in the control group did not perform any rehabilitation exercises. Over the intervention time frame, the patient was required to check in with a member of the research team each week to discuss any changes in their ankle or report any injury incidence.
2871690|NCT03447652|Experimental|Resistance Band Group|Each session, patients completed resistance training using a resistance band in 4 directions of ankle motion (plantarflexion, dorsiflexion, inversion and eversion). Patients would complete 3 sets of 10 repetitions during each session. Every 3 sessions, the band resistance would increase.
2871755|NCT03447158|Experimental|15% Dextrose group|
2871756|NCT03447158|Placebo Comparator|control group|
2871691|NCT03447652|Experimental|Biomechanical Ankle Platform System|The Biomechanical Ankle Platform System board is an oval shaped board that utilizes a half-sphere on the bottom of the board to allow the patient to train on an unstable surface. A one legged stance on their involved limb was performed on the Biomechanical Ankle Platform System board while clockwise and counterclockwise circles were completed. The initial rotation of direction was selected by the patient and changed every 10 seconds of the 40-second trial. Five 40-second trials were completed with 1-minute rest intervals in between the trials. Progression was determined by the supervising clinician and was based on the patient's ability to make smooth transitions between direction changes and completion of smooth circular rotations in both directions.
2871692|NCT03447652|Experimental|Combination Group|Patients completing the combination protocol completed both the resistance band and Biomechanical Ankle Platform System board protocols during each session. The order of exercise completion was counterbalanced for each session.
2871693|NCT03447639|Experimental|Povidone-Iodine Irrigation|Bladder irrigation with 2% povidine-iodine irrigation immediately prior to catheter removal
2871694|NCT03447639|No Intervention|Standard of Care|Catheter removal with no bladder irrigation
2871695|NCT03447626||Prospective Group- Robotic UKA Arm|Robotic UKA with the MAKO machine.
2871696|NCT03447626||Control- Fixed and Mobile UKA Arm|Patients who have received fixed or mobile bearing UKA
2871697|NCT03447626||Control-Total Knee Arthroplasty|Patients who have had cemented or cementless total knee arthroplasty
2871698|NCT03447613||elderly participants with surgery|The studied cohort were participants 50 years old or older, without a diagnosis of dementia, and scheduled to have orthopedic or urological surgery under spinal anesthesia at Shanghai 10th People's Hospital.
2871699|NCT03447600|Experimental|Alternate day fasting|Participants randomised to Alternate Day Fasting weight loss intervention. One day fasting of 25% total energy requirements alternated with one day ad libitum intake until study completion at >/=5% weight loss which is an average of 12 weeks.
2871700|NCT03447600|Active Comparator|Continuous caloric restriction|Participants randomised to continuous caloric restriction weight loss intervention. Every day intake of 75% total energy requirements until study completion at >/=5% weight loss which is an average of 12 weeks.
2871701|NCT03447587|Experimental|Electroacupuncture|Subjects will receive 4 weeks of acupuncture following with a semi-standardized protocol.
2871702|NCT03447587|Placebo Comparator|Sham acupuncture group|Subjects will receive sham acupuncture with the same sterilization procedure as traditional acupuncture group.
2871703|NCT03447574|Experimental|Aim 1|The ethanol dilution is, in essence, a non-invasive dilution method. It is of interest because of how ethanol readily dissolves itself exclusively into the water space of the body[4], is non-toxic in reasonable concentrations, is metabolized in a 0th order reaction above concentrations of 0.015 g/dL[4], and there are non-invasive methods for determining blood alcohol concentration[5, 6]. Thus, by drinking a known amount of ethanol, total body water can be calculated after a few hours of periodic breathalyzer analyses. Ethanol has been validated against deuterium oxide, the invasive gold standard for determining total body water[4]. The ethanol dose will be 0.5g/kg body weight.
2871704|NCT03447574|Active Comparator|Aim 2|30mL/kg body weight of saline will be rapidly infused after the baseline measurements completed in Aim 1. Non-invasive methods for fluid volume determination (CO-pulse-oximetry, ethanol breathalyzer, BIS) will be conducted and change from baseline calculated. To determine if non-invasive fluid volume techniques can accurately determine fluid changes in healthy participants.Non-invasive methods for fluid volume determination (CO-pulse-oximetry, ethanol breathalyzer, BIS) will be conducted and change from baseline calculated.
2871705|NCT03447561|Experimental|Anticipatory + consummatory food reward|PET-MR scan session with a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake). This scan session will consist of four blocks with a duration of 45 minutes each and 15 minute breaks in between. The first three blocks represent the 'control condition' (viewing neutral images and drinking sips of water) and the fourth block the 'food reward condition' (viewing high-calorie food images and drinking sips of chocolate milkshake).
2871706|NCT03447561|Experimental|Consummatory food reward|PET-MR scan session with purely consummatory food reward (drinking sips of chocolate milkshake). This scan session will consist of four blocks with a duration of 45 minutes each and 15 minute breaks in between. The first three blocks represent the 'control condition' (drinking sips of water) and the fourth block the 'food reward condition' (drinking sips of chocolate milkshake).
2871707|NCT03447548|Experimental|Processing speed training|Neurofeedback processing speed training
2871708|NCT03447548|Active Comparator|Active control|Computer games
2871709|NCT03447535||classic oppositional defiant disorder|"CODD Group:  classic  oppositional defiant disorder~SDQ total difficulties score and the parents report SDQ total difficulties score:~Group CODD ( classic  oppositional defiant disorder): teacher report SDQ total difficulties score (≥ 12), parents report SDQ total difficulties score (≥14)"
2871710|NCT03447535||intrafamilial oppositional defiant disorder|"IODD group: intrafamilial oppositional defiant disorder~SDQ total difficulties score and the parents report SDQ total difficulties score:~Group IODD (Intrafamilial Oppositional Defiant Disorder): teacher report SDQ total difficulties score normal (<12), parents report SDQ total difficulties score abnormal (>16)"
2871711|NCT03447509|Active Comparator|Arm 1|Examine physiological mechanisms contributing to the control of precision and power grip behaviors. To accomplish this aim the investigators propose to complete one main experiment. The investigators will test the hypotheses that there are two fundamentally distinct modes of hand operation after SCI. One involves brainstem pathways, and permits whole-hand 'power grip', while the other involves corticospinal and motor cortical connections, and allows a wide range of fractionated finger movements (precision grip) after SCI. Measurements of corticospinal, reticulospinal, and motoneuron excitability will be tested during index finger abduction, precision and power grip.
2871712|NCT03447509|Active Comparator|Arm 2|To accomplish this aim the investigators propose to complete one main experiment. The investigators will use iTMS and an acoustic startle stimuli to test the hypothesis that induced-plasticity protocols (iTMS and startle stimuli) will enhance EMG and force output in hand muscles during grasping. In a randomized sham crossover design, SCI and controls will be assigned to two groups: (1) iTMS applied during precision and power grip (two randomized sessions), and (2) startle applied during precision and power grip (two randomized sessions).
2871757|NCT03447145|Experimental|TQ-B3203|
2871713|NCT03447509|Active Comparator|Arm 3|To accomplish this aim the investigators propose to complete one main experiment. The investigators will combine iTMS and acoustic startle with precision and power grip training to test the hypothesis that 'precision and power grip training outcomes will be enhanced by iTMS and startle induced plasticity'. In a randomized sham controlled design, SCI and control subjects will be assigned to: training+iTMS and training+sham iTMS and training+startle and training+sham startle.
2871714|NCT03447496||Closed reduction|The children were treated with closed reduction.
2871715|NCT03447496||Open reduction|The children were treated with open reduction.
2871716|NCT03447483|Other|Cohort of patients starting a treatment by ICI|
2871717|NCT03447470|Other|Module 1, Part A|Patients will be allocated to a dose and reviewed for Dose Limiting Toxicities Once the DLT period is complete the next arm will be at a higher dose until MTD
2871718|NCT03447457|Other|standard oxygen group|Patients are treated with standard oxygen delivered through nasal cannula, face mask or non-rebreathing reservoir
2871719|NCT03447457|Other|High-flow oxygen group|Patients are treated with high-flow nasal cannula oxygen continuously applied via large-bore nasal prongs with a gas flow rate of 50 L/min
2871720|NCT03447444|Other|music and physical activity|An intervention consisting of physical activity, music and walking, was systematically implemented for eight weeks
2871721|NCT03447431||MSI colon tumours|MSI colon tumours (as compared to MSS CRCs and matching normal colonic mucosa) Identification of exon/intron sites affected by aberrant splicing events due to MSI in CRC
2871722|NCT03447418|Other|no treatment, open label|
2871723|NCT03447405|Experimental|Dino Egg Safety and useability|Test the usability of the device (safety for the NICU was confirmed), not the effectiveness of the parents' voice delivery for the infant. Parent and nursing questionnaires about the importance of the device availability and its usability will be collected from parents and RN staff that choose to provide the feedback.
2871724|NCT03447405|No Intervention|Standard of Care|
2871725|NCT03447392|Experimental|patient education and Chinese medicine|1-hour, one-on-one teaching session with a educator to the standard discharge education of Integrated Traditional and Western Medicine
2871726|NCT03447392|No Intervention|patient education|no discharge education
2871727|NCT03447379|Active Comparator|P2Y12 monotherapy after 3 months of DAPT|P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day)
2871728|NCT03447379|Active Comparator|Dual-antiplatelet therapy for a year|DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day) for a year
2871729|NCT03447366|Experimental|Mitral doppler|Mitral doppler before and after vascular filling
2871730|NCT03447353|Experimental|"Sober or Double Placebo"|Subject receives two tablets, both containing placebo
2871731|NCT03447353|Experimental|Active Xanax, Active Norco|Subject receives two tablets, one containing Xanax and one containing Norco
2871732|NCT03447353|Experimental|Active Xanax, Placebo Norco|Subject receives two tablets, one containing Xanax and one containing placebo
2871733|NCT03447353|Experimental|Placebo Xanax, Active Norco|Subject receives two tablets, one containing Norco and one containing placebo
2871734|NCT03447340|Experimental|Cafeteria and behavior|Receives cafeteria intervention and behavior intervention
2871735|NCT03447340|Active Comparator|Cafeteria only|Receives only cafeteria intervention
2871736|NCT03447327|Other|operated group|patients undergoing surgery for chronic subdural hematoma by single burr hole under local anaesthesia
2871737|NCT03447314|Experimental|Part 1: Dose Escalation Cohort|In Part 1, subjects with advanced solid tumors will be enrolled.
2871738|NCT03447314|Experimental|Part 1: PK/Pharmacodynamic cohort|Subjects will be enrolled into PK/PD cohort to collect additional data on safety, PK, and pharmacodynamic endpoints. Subjects will be enrolled at previously completed dose levels following dose escalation.
2871739|NCT03447314|Experimental|Part 2: Expansion Cohort|In Part 2, subjects with SCCHN will be included.
2871740|NCT03447301|Experimental|Extra virgin olive oil|Extra virgin olive oil (30mL) daily
2871741|NCT03447301|No Intervention|Control|No consumption of extra virgin olive oil
2871742|NCT03447275||Controls|Apparently healthy subjects without type 2 diabetes
2871743|NCT03447275||Patients with type 2 diabetes|type 2 Diabetes since 5 years or longer
2871744|NCT03447262|Experimental|Open-label triple combination|"Subjects will receive 240 mg VX-659 / 100 mg TEZ / 150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening.~Parent studies are Phase 3 Vertex studies investigating VX-659 in combination with TEZ and IVA. This includes, but is not limited to, NCT03447249."
2871745|NCT03447249|Experimental|Triple Combination|Subjects will receive 240 mg VX-659 / 100 mg TEZ / 150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening
2871746|NCT03447249|Placebo Comparator|Placebo|
2871747|NCT03447236|Experimental|Feuerstein Program|All subjects participating in the Feuerstein Program will be evaluated by anatomical and functional MRI as well as computerized cognitive assessment prior to and following intervention as outlined in the protocol.
2871748|NCT03447223||ADHD-patients|The children 3-15 years old with ADHD. Diagnoses of the children with ADHD were made in Xijing Hospital according to criteria described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Children with ADHD had an IQ score above 70.
2871749|NCT03447223||Controls-healthy children|Age- and gender- matched healthy 3-15 years old children.
2871750|NCT03447210|Experimental|Assisted Partner Services|All participants in this arm will be offered assisted partner services (APS) which involves outreach to sexual partners and to individuals with whom they use injection drugs. When partners are contacted they are offered HIV and HCV testing. There is no comparison arm.
2871751|NCT03447197|Active Comparator|On-Pump|Use of extracorporeal circulation
2871752|NCT03447197|No Intervention|Off-Pump|
2871753|NCT03447184||Androgen priming|Eight weeks prior to stimulation for IVF - at the onset of menses, patients will start treatment with a low dose of rhCG (Ovitrelle). At the same time daily treatment with the aromatase inhibitor will commence, concomitantly with GnRHa down-regulation with a depot GnRHa (28days). After 8 weeks, a standard rFSH stimulation with either 300 IU rFSH or 300 IU rFSH+rLH will start. The androgen priming (hCG and aromatase inhibitor) will stop on the first day of stimulation.
2871754|NCT03447171||Refractive Error|
2871758|NCT03447132|Active Comparator|Fulvestrant 500mg + Palbociclib 125mg|+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months
2871759|NCT03447132|Placebo Comparator|Fulvestrant 500mg + Placebos|+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months
2871760|NCT03447119|Experimental|Living Well with a Disability|The parents will work together with the project directors to deliver the adapted curriculum to participating families. With bi-weekly meetings for 10 weeks between parent facilitators and family participants in the home or another desired location. The project directors have already participated in the facilitator training and will serve as mentors to newly trained facilitators. At the end of the online training session, the parent facilitators will be equipped to successfully implement the Living Well curriculum.
2871761|NCT03447106|Experimental|Open|
2871762|NCT03447106|Experimental|Laparoscopic|
2871763|NCT03447106|Experimental|Robotic|
2871764|NCT03447093||Control group|30 healthy volunteers were included in the healthy control group
2871765|NCT03447093||Drug treatment group|30 GD patients who received treatment with Methimazole Pill or propylthiouracil pill
2871766|NCT03447093||Incipient group|30 untreated GD patients
2871767|NCT03447093||Hashimoto's thyroiditis group|30 HT patients
2871768|NCT03447080|Other|Control 1|White bread
2871769|NCT03447080|Other|Control 2|White bread
2871770|NCT03447080|Experimental|Rice bran soybean milk|White Bread with 195ml of rice bran soybean mil
2871771|NCT03447080|Experimental|Soybean milk|White Bread with 195ml of soybean milk
2871772|NCT03447067|Experimental|Conventional surgery|"comprised 9 patient undergoing surgical removal of deeply impacted mandibular third molar by regular manor.~(Based on :Panorama and CBCT ) technique : 1- flap design 2- bone removal 3- tooth division 4- closure flap (suture)"
2871773|NCT03447067|Experimental|computer guided surgery|"comprised 9 patient undergoing surgical removal of deeply impacted mandibular third molar using computer guided surgical cutting stent.~Based on (panorama , CBCT and fabricating computer guided stent technique: 1- flap design 2- accurate setting stent in a predesign site 3- bony window removing according to the stent design 4- surgical separation of the teeth with extraction the remaning part . 5- identify the nerve 6- replace the bony window in to original place with stability 7- closure and depridment"
2871774|NCT03447054|Experimental|Combined TDCS active and ICT active|Five consecutive days: Twenty minutes of TDCS on the right dorsolateral prefrontal cortex while performing an alcohol-cue inhibitory control training consisting to systematically paired go responses with non-alcohol pictures and no-go responses with alcohol-related pictures.
2871775|NCT03447054|Active Comparator|Combined TDCS sham and ICT active|Five consecutive days: Twenty minutes of sham TDCS on the right dorsolateral prefrontal cortex, while performing a no-cue go/no-go training consisting to carry out a go/no-go paradigm with no alcohol-related content.
2871776|NCT03447054|Active Comparator|Combined TDCS active and ICT inactive|Five consecutive days: Twenty minutes of active TDCS in association with no-cue go/no-go training consisting to carry out a go/no-go paradigm with no alcohol-related content.
2871777|NCT03447054|Sham Comparator|Combined Sham TDCS and inactive ICT|Five consecutive days: Twenty minutes of Inactive TDCS combined with an non alcohol-cue inhibitory control training consisting to carry out a go/no-go paradigm with no alcohol-related content.
2871778|NCT03447041||the keratoplasty group|Patients who accepted cornea transplantation surgery after 1 year were performed quick CSF from Adaptive Sensory Technology company
2871779|NCT03447015|Experimental|intervention|"women will be encouraged to ambulate Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking)."
2871780|NCT03447015|No Intervention|control|women will receive usual maternity care.
2871781|NCT03446989|Experimental|Case management|
2871782|NCT03446976|Experimental|CT-P13 SC Auto-injector|CT-P13 SC Auto-injector
2871783|NCT03446976|Experimental|CT-P13 SC Pre-filled Syringe|CT-P13 SC Pre-filled Syringe
2871784|NCT03446963|Experimental|Single arm: Groups 4 Health|Social group intervention. The aim is to practice participating in a social group within a safe environment; to identify groups and social networks which are meaningful for the person; and to understand any barriers people may have to engaging with these groups/networks.
2871785|NCT03446950|Active Comparator|Candy Cane|Participants in this arm will be positioned with their legs in candy cane stirrups. Patients will then undergo scheduled vaginal surgery and be asked to complete PROMIS questionnaires before and after surgery.
2871786|NCT03446950|Active Comparator|Boot Stirrups|Participants in this arm will have their feet placed in boot stirrups. Patients will then undergo scheduled vaginal surgery and be asked to complete PROMIS questionnaires before and after surgery.
2871787|NCT03446937|Experimental|Dexamethasone sodium phosphate injection|Intervention: Drug: Dexamethasone sodium phosphate injection Two doses Intramuscular Dexamethasone sodium phosphate 12mg given12 hours apart. (produced by Taizhou Overseas International Ltd. 126-128 Qingnian Road Jiaojiang, Taizhou, Zhejiang, China)
2871788|NCT03446937|Experimental|Betamethasone sodium phosphate injection|Intervention: Drug: Betamethasone sodium phosphate injection Two doses of intramuscular betamethasone sodium phosphate 12mg given 12 hours apart. (obtained from Twinbrook pkwy, Rockville, MD Singapore. CAT No 1068004, Lot: R004e0)
2871789|NCT03446937|Placebo Comparator|Water for injection|Intervention. Drug: Water for injection. Two doses of intramuscular water for injection given 12 hours apart.
2871790|NCT03446924|Placebo Comparator|Control|The control group will be given a single dose of 1.5 g rice flour in capsule form (250 mg / capsule). The gelatine capsules (MyProtein, Northwich, UK) used are identical to those used in the treatment group. Capsules are prepared by the investigatory team using good hygiene practice in the research kitchen of the School of Sport, Exercise and Rehabilitation (University of Birmingham).
2871817|NCT03446703|Active Comparator|TAR Training in affect recognition|Training in Affect Recognition it is a 12-session training on facial affect recognition over a period of 6 weeks.
2871818|NCT03446690|Experimental|MI Varnish Group|33 subjects were prospectively recruited for the project in the MI Varnish group. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, UAB. MI Varnish were applied on their teeth initially for 4 weeks (twice) and then 3 monthly intervals.
2894940|NCT03284463|Placebo Comparator|Placebo|Placebo for Glibenclamide
2871791|NCT03446924|Active Comparator|Treatment|"The treatment group will be given a single dose of 1.5g phosphatidic acid in capsule form (250 mg / capsule). Capsules are prepared by the investigatory team using good hygiene practice in the research kitchen of the School of Sport, Exercise and Rehabilitation (University of Birmingham).~PA is considered a dietary supplement ingredient according to the US FDA. The source of PA will be a commercial available soy-derived PA (Mediator®, Chemi Nutra, White Bear Lake, MN). The safety of Mediator® Soy-PA has been thoroughly demonstrated in humans. Mediator® Soy-PA does not contain any compounds with narcotic, psychotropic or pharmaceutical effects and is in compliance with banned substances requirements as espoused by the World Anti-Doping Agency. Mediator® Soy-PA is not a medicinal product."
2871792|NCT03446911|Active Comparator|SABR|Patients receive prior to surgery (lobectomy) SABR.
2871793|NCT03446911|Active Comparator|SABR + pembrolizumab|Patients receive prior to surgery (lobectomy) SABR + 2 rounds of pembrolizumab
2871794|NCT03446898||Adults Living at Qinghai-Tibet Plateau for Work Purpose|Qinghai-Tibet Plateau is a high altitude area in which human would be exposed in chronic hypoxia environment.
2871795|NCT03446872||All Study Participants|Patients in South Korea with a diagnosis of metastatic pancreatic cancer who have been prescribed ONIVYDE
2871796|NCT03446859|Experimental|TENS|It consists of 25 subjects with primary dysmenorrhea which were put on TENS for 30 minutes, three for 3 days. The subject were placed in supine lying in a comfortable position as possible. The abdomen to the inguinal region were decently exposed and cleaned, after inspection of the area for cuts, skin infections or any abnormalities. A pair of electrodes ( inactive electrodes) will be placed a little below the umbilicus ( Right and Left) and the other pair(active electrode) along the inguinal region at the level of pubic symphysis ( Right and Left) according to (Akinbo et al 2000). A quadripolar method will be used for electrode placement.
2871797|NCT03446859|No Intervention|Control|These are 25 subjects which were not in any intervention. These were subjects that were not placed on TENS and were not used to drug taken for the amelioration of the dysmenorrhea. They were educated on the purpose of research and their inform consent was obtained. Their pain intensity was measured firs, third and 5th days
2871798|NCT03446846|Experimental|5.0 mg MIN-117|
2871799|NCT03446846|Experimental|2.5 mg MIN-117|
2871800|NCT03446846|Placebo Comparator|Placebo|
2871801|NCT03446833|Experimental|All Subjects|Subjects who meet the intraoperative criteria will receive The LFP Beta aDBS System.
2871802|NCT03446820|Other|Sleep participants|Crossover from standard sheets to hygro cotton sheets
2871803|NCT03446807|Experimental|Droxidopa|The Droxidopa starting dose for all eligible patients in the Titration Periods are 100mg three times daily (TID). Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved or the subject doesn't notice an improvement in their subjective fatigue on a higher dose compared to the most recent dose. Half of the subjects will be on Droxidopa for 3 months during the double-blind phase. All subjects will be on Droxidopa for 3 months during the open-label phase.
2871804|NCT03446807|Placebo Comparator|Placebo Oral Tablet|The placebo starting dose for all eligible patients in the Titration Period is 100mg TID. Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved. Half of the subjects will be on placebo for 3 months during the double-blind phase.
2871805|NCT03446794||patients with NVAF and ESCKD on HD|
2871806|NCT03446781|Active Comparator|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
2871807|NCT03446781|Placebo Comparator|Placebo|Placebo
2871808|NCT03446768|Active Comparator|Reactive Care (RC)|Participants in the RC arm of the study will be provided access to the COPD Information Line if they feel they would benefit from the support of a peer health coach. Peer health coaches working the information line are patients also living with COPD who can offer peer level support.
2871809|NCT03446768|Active Comparator|Proactive Care (PC)|Participants in the PC arm of the study will be provided access to the COPD Information Line if they feel they would benefit from the support of a peer health coach. Peer health coaches working the information line are patients also living with COPD who can offer peer level support. Additionally, the PC group will also receive access to an online study portal which houses an educational health curriculum covering topics related to COPD and OSA. The portal allows participants to send online messages to peer coaches and respiratory therapist coaches. PC group will also receive weekly updates.
2871810|NCT03446755|Experimental|Intra uterine Cook balloon|
2871811|NCT03446742||Cardiovascular rehabilitation group|Initially all patients will have their charts analyzed, from which data will be extracted for characterization of the population, and anthropometric data will be measured for calculation of body mass index. Afterwards, patients will have their clinical, physical and biochemical parameters. They will be followed up for a period of 2 months during the routines of the cardiovascular rehabilitation sessions for assessment of signs and symptoms. In the second stage the patients will perform the normal routines of their cardiovascular rehabilitation program for a period of 6 months. In the third stage, patients will have their clinical, physical and biochemical parameters and then followed up for another 2 months during the routines of the sessions of the cardiovascular rehabilitation program to evaluate signs and symptoms, which will allow to evaluate if gains/losses in the physical parameters can exert influences in the appearance of signs and symptoms during the sessions.
2871812|NCT03446729|Experimental|Memory Self Monitoring (MSM)|"Intervention: Guided self-help Behavioral Weight Loss. The MSM group is assigned to self-monitor in habit books what they consume in their previous meal immediately prior to each meal, similar to other studies exploring the effect of episodic meal memory on food intake."
2871813|NCT03446729|Active Comparator|Caloric Self Monitoring (CSM)|"Intervention: Guided self-help Behavioral Weight Loss. The CSM group is assigned to self-monitor what food they consume, and the associated caloric content after each meal in their habit books in line with traditional BWL self-monitoring."
2871814|NCT03446716|Experimental|EXTENSION|During the extension condition, caregivers were instructed to put their child to bed 90 minutes earlier than their habitual bedtime for five consecutive nights. Caregivers were provided a list of tips to aid in implementing the earlier bedtime.
2871815|NCT03446716|No Intervention|CONTROL|Children followed their normal bedtime routine for five consecutive nights.
2871816|NCT03446703|Experimental|SCIT Social cognition interactive|Psychosocial intervention based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs & Penn; Lahera & Benito, in press).
2871819|NCT03446690|Other|Control group|A control group was comprised of 29 orthodontically treated subjects who received routine treatment and oral hygiene regimes. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, School of Dentistry, University of Alabama at Birmingham. No intervention for this group.
2871820|NCT03446677|Experimental|Asymptomatic persons with HIV|
2871821|NCT03446664|Experimental|Microburst Stimulation|Microburst stimulation to tolerability and effectiveness
2871822|NCT03446651|Experimental|Lysine Chloride|Participants will be randomized to 7 days of therapy with either 115 mmol/day of lysine chloride or placebo. People in the Lysine Chloride group will receive the active intervention.
2871823|NCT03446651|Placebo Comparator|Placebo|Participants will be randomized to 7 days of therapy with either 115 mmol/day of lysine chloride or placebo. People in the Placebo group will receive placebo.
2871824|NCT03446638|Experimental|Computational Biology-Informed Treatment|Patients randomized to this arm will receive an FDA-approved drug or combination of drugs predicted to have a therapeutic effect based on their individual MDS disease genetic profile by a computational biology simulation software program. The specific drug or combination of drugs that a patient on this arm will receive will be decided jointly by a molecular oncology board comprised of physicians, pharmacists, and nurse coordinators and the treating physician. Patients will receive a minimum of 2 months and a maximum of 4 months of treatment with the selected drug or combination of drugs.
2871825|NCT03446638|Active Comparator|Standard of Care Treatment|Patients randomized to this arm will receive either one of three standard of care treatment regimens of the treating physician's choice (low-dose cytarabine, 7 + 3 induction, or FLAG induction) or supportive care alone. Patients will receive a minimum of 2 months and a maximum of 4 months of the selected treatment regimen or of supportive care alone.
2871826|NCT03446625|Experimental|Resveratrol|Resveratrol will be administered orally at the dose of 2 g/day for 9 days, starting on the day of ovulation triggering.
2871827|NCT03446625|Placebo Comparator|Control|Placebo treatment will be administered for 9 days, starting on the day of ovulation triggering.
2871828|NCT03446612|Experimental|Subjects receiving Daprodustat|Subjects will receive 2 milligram (mg) daprodustat tablets once daily via oral route for a period of 41 days.
2871829|NCT03446612|Active Comparator|Subjects receiving Darbepoetin alfa (Aranesp)|Subjects will receive Darbepoetin alfa solution for injection, administered as a single subcutaneous injection, once every two weeks (Days 1, 14 and 28).
2871830|NCT03446599|Experimental|Hydroxocobalamin|Participants in this arm will receive one intravenous 5-gram dose of hydroxocobalamin reconstituted in 200ml of normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
2871831|NCT03446599|Experimental|Methyelene blue|Participants in this arm will receive one intravenous 2mg/kg dose of methylene blue diluted in 200ml of normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
2871832|NCT03446599|Placebo Comparator|Normal saline|Participants in this arm will receive an intravenous administration of 200ml normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
2871833|NCT03446573|Experimental|DTG + 3TC 50 mg/300 mg|Participants will receive a single tablet of a two-drug regimen of DTG 50 mg + 3TC 300 mg once daily from Day 1 through Week 100 (Early and Late Switch Phase).
2871834|NCT03446573|Active Comparator|TAF based regimen (TBR)|Participants will continue their TBR from Day 1 to Week 52 (Early Switch Phase), and eligible participants will switch to DTG + 3TC once daily from Week 52 to 100 (Late Switch Phase).
2871835|NCT03446560|Active Comparator|CPAP, conventional follow up|Follow up of patients after initiation of treatment according to clinical routine at the study site.
2871836|NCT03446560|Active Comparator|CPAP, telemedicine based follow up|Follow up of patients after initiation of treatment according to a telemedicine based routine.
2871837|NCT03446547|No Intervention|Arm A|SBRT and follow-up
2871838|NCT03446547|Experimental|Arm B|SBRT followed by Durvalumab
2871839|NCT03446534|Experimental|Amoxicillin|Amoxicillin 100mg/ml mixture (Imacillin), 0.25ml/kg every 8 hours for 7 days.
2871840|NCT03446534|Placebo Comparator|Placebo|Placebo mixture 0.25ml/kg every 8 hours for 7 days
2871841|NCT03446521||Test group|Patients undergoing liver transplantation, no intervention (study-specific) is planed
2871842|NCT03446521||Control Group|Respective organ donors of the included liver recipients, no intervention (study-specific) is planed
2871843|NCT03446508|Experimental|Active frontal|Active HD-tDCS
2871844|NCT03446508|Experimental|Active parietal|Active HD-tDCS
2871845|NCT03446508|Sham Comparator|Sham control|Sham HD-tDCS
2871846|NCT03446495||Trabectedin + PLD|Trabectedin + PLD according to SmPC
2871847|NCT03446469|Experimental|Individuals with Chronic Ankle instability|Individuals with history of ankle sprains will be screened using the inclusion criteria before being included in the study
2871848|NCT03446456|Placebo Comparator|Saline|"Under direction of a research team member, participants will self-administer intranasal normal saline shortly before beginning the fMRI experiment.~Investigators, staff, and participants were blinded to the treatment options. Each of the agents will be administrated by means of a nasal spray. Participants will be instructed by a nurse/PI to self-administer the nasal spray as follows: one spray in each nostril alternating sides, 30 seconds apart for a total of two sprays per nostril."
2871849|NCT03446456|Experimental|Arginine vasopressin|"Under direction of a research team member, participants will self-administer intranasal vasopressin shortly before beginning the fMRI experiment. The of AVP will be 40IU. The quantity per unit (1 mL) of Arg8-vasopressin synthetic, manufactured by Polypeptide Group Inc. (http://www.polypeptide.com) was 0.323 mg. This amount was diluted in 0.9% sodium chloride (B. Broun Medical Inc.).~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment. Participants will be first stratified for sex and then randomized to saline (0.4 mL) or vasopressin (40 IU) group, respectively."
2871850|NCT03446443|Experimental|Honghe Fujie lotion group|
2871851|NCT03446443|Active Comparator|Metronidazole Suppositories group|
2871852|NCT03446430|Experimental|Hypertensives|PWV measurement by LDV
2871853|NCT03446417|Experimental|Dose escalation|Up to 6 sequential dose escalation cohorts until maximum tolerated dose or recommended phase 2 dose is identified
2871854|NCT03446417|Experimental|Dose expansion|ZN-e4 in subjects with T790M mutation in epidermal growth factor receptor (EGFR) gene.
2871855|NCT03446404||Existing Cohort|"The existing cohort will be age 62-92 years, average age approximately 71 years, at the start of this study. This cohort will consist of participants who already have symptomatic knee OA, in many cases advanced disease, or who had risk factors at the start of the Multicenter Osteoarthritis Study but have not developed symptomatic knee OA. All of the existing cohort who have 1 or 2 native knees will be approached providing native knees are not considered to be Kellgren-Lawrence grade 4 (bone on bone)."
2871856|NCT03446404||New Cohort|The new cohort will consist of subjects with knee pain, aching or stiffness at baseline and participants without any knee symptoms in the previous 30 days. Both knees with Kellgren-Lawrence grades of radiographic OA of 0, 1, or 2 in the tibiofemoral (TF) and patellofemoral (PF) compartments.
2871857|NCT03446391||Kinematic alignment with GMK Sphere®|Patients enrolled prospectively with surgeries planned to get kinematic alignment
2871858|NCT03446391||Mechanical alignment with GMK Sphere®|Historical group who had mechanical alignment, match-paired with the prospective group
2871859|NCT03446378|Experimental|Anodal tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the contralateral supraorbital region. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
2871860|NCT03446378|Experimental|Cathodal tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where cathodal electrode will be on the affected hemisphere and the anodal electrode, on the contralateral supraorbital region. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
2871861|NCT03446378|Sham Comparator|Sham tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the contralateral supraorbital region. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off after 30 seconds After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
2871862|NCT03446365|Experimental|ASMAS|ASMAS is an asthma self-management program based on NHLBI clinical guidelines for optimal school-based asthma management. It involves 4, 1½ hour sessions delivered in group format in the urban, middle school setting by a Latino High School Peer who has asthma. ASMAS focuses on asthma pathophysiology, symptom management, asthma medications, and trigger control.
2871863|NCT03446365|Active Comparator|Asthma education plus child health|"Asthma Education plus Child Health control condition will be delivered by an adult Health Educator , and includes 4 sessions (1 1/2 hrs long) of our existing asthma education (Asthma's Magic Number) with added general health topics (nutrition, physical activity, safety)."
2871864|NCT03446365|No Intervention|No Treatment Control|Students randomly assigned to this arm , will receive standard of care, which is no treatment, and will not participate in any group intervention sessions.
2871865|NCT03446352|Experimental|Psychomotor exercise program|The experimental group 1 (EG1) intervention comprises a psychomotor program. The program integrates 3 sessions / week of 75 minutes on alternated days. The psychomotor intervention includes exercises promoting simultaneous motor and cognitive stimulation (interval training).
2871866|NCT03446352|Experimental|Combined exercise program|The experimental group 2 (EG2) intervention combines the psychomotor program with a WBV program. The program integrates 3 sessions / week of 75 minutes (including the 6 minutes of WBV) on alternated days.
2871867|NCT03446352|No Intervention|Control Group|Usual care. After the study, control group (CG) participants will be offered the opportunity to integrate a similar fall prevention program.
2871868|NCT03446326|Experimental|Stroke volume and cardiac output|"Pacing runs will occur at the following rates:~50 beats per minute (bpm)~60 bpm~70 bpm~80 bpm~90 bpm~100 bpm~110 bpm~120 bpm~130 bpm~The finger blood pressure cuff will be calibrated between pacing runs.~Following the final pacing run while supine, the patient will be given 10 minutes to rest prior to the upright portion of the study. They will then be strapped into the table (so they will not fall) and then they will be tilted up to >70 degrees (almost standing up). They will stand for ~10 minutes prior to commencing the next pacing trains."
2871869|NCT03446313|Experimental|MVN Group|Participants assigned to the MVN Group will be using the Movn Rehab mobile app after they are discharged from cardiac rehab.
2871870|NCT03446313|No Intervention|Usual Care|Participants assigned to the Usual Care group will receive standard instructions and educational handouts after they are discharged from cardiac rehab.
2871871|NCT03446300||college student population|
2871872|NCT03446300||working population|
2871873|NCT03446300||aged more than 50 years old population|
2871874|NCT03446261|Experimental|Rosuvamibe® Tab|Rosuvamibe® Tab (rosuvastatin 5mg/ezetimibe 10mg) qd for 8 weeks
2871875|NCT03446261|Active Comparator|Monorova® Tab|Monorova® Tab (rosuvastatin 10mg) qd for 8 weeks
2871876|NCT03446248|Active Comparator|Fetal Acoustic Stimulator|Participants in this group will receive fetal vibroacoustic stimulation with the Corometrics-146 device first, followed by the mobile phone application second.
2871877|NCT03446248|Experimental|Mobile Phone Application|Participants in this group will receive fetal vibroacoustic stimulation with the mobile phone application first, followed by the Corometrics-146 device second.
2871878|NCT03446235|Experimental|Connected Health|This group will get 2 interviews about physical exercise (exercise instruction with motivational interview) and 6 communications with individualized instruction and counseling of their physical exercise (investigators can access activity data and exercise log) including the usage of the monitoring device.
2871879|NCT03446235|Active Comparator|Self-Monitoring|This group will do physical exercise following the initial instruction and self-monitor them. Investigators can access activity data and exercise log but will not discuss with the subjects about the data.
2871880|NCT03446222|Active Comparator|Catheter Ablation|Catheter based radiofrequency ablation with wide antral circumferential PVI and isolation of posterior wall will be performed. Mitral and cavo-tricuspid isthmus ablation will be done only if such isthumus dependent flutters are documented prior to / during the procedure.
2871881|NCT03446222|Active Comparator|Mini-maze surgical procedure|Wolf Mini-maze surgical ablation along with left atrial appendage ligation will be performed.
2871882|NCT03446209|Experimental|Tocilizumab|Tocilizumab Infusion RoAcemtra (EU) or Actemra (Rest of the world)
2871884|NCT03446196|Experimental|MOSTCARE UP|Clinician will be able to read MOSTCARE parameters and to choose the best treatment to adequate hemodynamics considering that current literature suggests a fluid IV expansion only if PPV > 15%
2871885|NCT03446196|No Intervention|CLINICIAN EXPERIENCE|Fluid replacement will be made based on clinician experience
2871886|NCT03446183||Smoking cessation prospective|Smoking cessation workshops
2871887|NCT03446183||Smoking cessation retrospective|File review of former workshop participants
2871888|NCT03446170|Experimental|Loss-framed, branded|Participants assigned to this arm use cigarette packs with loss-framed graphic warnings communicating the risks of smoking on branded packages.
2871889|NCT03446170|Experimental|Loss-framed, plain|Participants assigned to this arm use cigarette packs with loss-framed graphic warnings communicating the risks of smoking on plain or standardized packages.
2871890|NCT03446170|Experimental|Gain-framed, branded|Participants assigned to this arm use cigarette packs with gain-framed graphic warnings communicating the benefits of quitting smoking on branded packages.
2871891|NCT03446170|Experimental|Gain-framed, plain|Participants assigned to this arm use cigarette packs with gain-framed graphic warnings communicating the benefits of quitting smoking on plain or standardized packages.
2871892|NCT03446170|No Intervention|Control|Participants assigned to this arm use their regular cigarette packs and complete study measures only.
2871893|NCT03446157|Experimental|Open-label, single arm, Phase II|Cetuximab and palbociclib
2871894|NCT03446144|Experimental|IONIS-FB-Lrx|
2871895|NCT03446144|Placebo Comparator|Placebo (sterile saline 0.9%)|
2871896|NCT03446118|Experimental|MRI to detect inflammation and fibrosis in EoE patients|To assess through MRI the existence of an inflammatory and fibrotic component in strictures of eosinophilic esophagitis patients and to determine if this component is responsive to a therapeutic course of budesonide.
2871897|NCT03446105|Experimental|App-based behavioral intervention|Participants randomized to this study arm will take part in the Achieving Wellness After Kancer in Early life (AWAKE) behavioral intervention for 8 weeks.
2871898|NCT03446105|Active Comparator|Attention control group|Participants randomized to this study arm will take part in a behavioral intervention and coaching for 8 weeks.
2871899|NCT03446092|Experimental|Mindfulness group|Group will receive mindfulness intervention
2871900|NCT03446079|Experimental|Primary Subjects|Male or female subjects 21 or older that meet the specified inclusion/exclusion criteria taking genetic test and applying topical anti aging cream per the protocol.
2871901|NCT03446066||case group|20 cases suffering from excessive daytime sleepiness (4 females and 16 males) with their age range 32-58yrs and BMI range is 24.97-39.06 kg/m2
2871902|NCT03446066||control group|20 healthy subjects (5 females and 15 males) with their age range 31-55yrs and BMI range is 23.40-43.0 kg/m2
2871903|NCT03446053|Experimental|N-Rephasin® SAL200|Forty subjects will be randomly assigned to receive either N-Rephasin® SAL200 injection or a placebo administered by a 60-min intravenous infusion. Within each group, 8 subjects (6 active and 2 placebo) will receive a single dose of 6 mg/kg, followed by multiple ascending dose of 3, 6, 9, and 12 mg/kg/day.
2871904|NCT03446053|Placebo Comparator|INT200-Placebo|Saline
2871905|NCT03446040|Experimental|Arm A|BMS-986258
2871906|NCT03446040|Experimental|Arm A1|BMS-986258 + rHuPH20
2871907|NCT03446040|Experimental|Arm B|Dose Escalation: BMS-986258 + Nivo
2871908|NCT03446040|Experimental|Arm C|Dose Expansion: BMS-986258 + Nivo
2871909|NCT03446027|No Intervention|Control|There will be no change to the local site standard of care for patients with IC attributed to participation in this trial. Those sites with Supervised Exercise Therapy (SET) will continue to provide this intervention as per their normal standard of care and locally agreed protocol.
2871910|NCT03446027|Experimental|Device|Local therapy + Neuromuscular Electrical Stimulation (NMES)
2871911|NCT03446014||Control Group for Fitbit Sub-Study|Patient will be given Fitbit device, but will have no access to Fitbit website or interface. The coordinator will set up the patient's Fitbit on the office computer and will have access to the fitbit's associated username and password (this will be generated by the coordinator). The patient will be instructed to walk as much as they can each day, and to check the Fitbit wrist band periodically throughout the day to view their walking progress. At the end of the three month intervention, the patient will complete questionnaires and undergo a repeat 6 minute walk test.
2871912|NCT03446014||Intervention Group for Fitbit Sub-Study|Patient will be given the Fitbit device and instructed on how to use it. They will be given their username and password to the Fitbit device, and instructed on how to interact with other patients in the study as well as the coordinator on the Fitbit website. The coordinator will also show the patient how to install the application on a smart phone device and use the device via smartphone. The patient will then be instructed to walk as far as they can each day for a period of 12 weeks. Patients will check their steps daily and interact with other patients who participate in the study. Patients will return for a 3 month follow-up appointment where they will undergo a redo 6 minute walk test and questionnaires.
2871913|NCT03446001|Experimental|TRx0237 8 mg/day|
2871914|NCT03446001|Placebo Comparator|Placebo|
2871915|NCT03445988|Active Comparator|Cognitive Behavioral Therapy|A trained psychologist delivers pain-CBT to individual patients or groups of patients with chronic pain. Group treatment is delivered across 8 weekly sessions that last for 2 hours each. Pain-CBT incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session. Pain-CBT is effective for reducing pain intensity, pain catastrophizing, depression and social impacts.
2871916|NCT03445988|Active Comparator|Chronic Pain Self Management Program|The CPSMP is similar to pain-CBT in format and content but is peer-led, and is effective across pain conditions (e.g., back pain, arthritis) for improving pain and pain self-efficacy. The CPSMP consists of six weekly 2-hour group sessions in which two peer co-leaders provide patient education about pain, effective self-management, pain impacts, and other symptoms from a highly structured manual. Peers are people with chronic pain who live in the communities in which they teach. For this project, at least one peer facilitator per workshop will have had experience with prescription opioid use. Intervention fidelity is determined by having a trained observer with a checklist attend random workshop sessions. Similar to pain-CBT, CPSMP incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session.
2871917|NCT03445988|Placebo Comparator|Taper Only (Usual Care)|Participants allocated to 'Taper Only' will engage in a physician-guided, patient-centered opioid tapering program without additional behavioral intervention.
2871918|NCT03445988|No Intervention|Observational Arm|Participants that do not wish to reduce their opioid medications but are otherwise eligible and interested in the research study will be offered participation in the observational arm. The observational arm of the study will not include interventions of any kind and will only collect survey data for the year following consent.
2871919|NCT03445975|Experimental|Experimental|The 3-in-1 perineal care washcloth procedure has been adopted to deliver hygiene care (total or perineal) or baths
2871920|NCT03445975|No Intervention|standard|The deliver of hygiene care (total or perineal) or baths has been performed using water and pH neutral soap
2871921|NCT03445962||Down Syndrome (DS)|Assessment of OSAS predictive factors in Down Syndrome without or without OSAS
2871922|NCT03445949|Other|30 days DAPT|short postimplantation dual antiplatelet therapy
2871923|NCT03445949|Other|6 months DAPT|extended postimplantation dual antiplatelet therapy
2871924|NCT03445936|Active Comparator|Parietene Macro|Parietene Macro is a macroporous synthetic mesh used in retro muscular sublay position to prevent incisional hernia after loop-ileostomy closure.
2871925|NCT03445936|Active Comparator|Permacol|Permacol is a acellular porcine dermal implant used in retro muscular sublay position to prevent incisional hernia after loop-ileostomy closure.
2871926|NCT03445923|No Intervention|Morphology|Embryos for transfer will be selected based on standard morphological evaluation.
2871927|NCT03445923|Active Comparator|TLM|Embryos for transfer will be selected base on standard morphological evaluation and information from time-lapse monitoring.
2871928|NCT03445910|Experimental|Human chorionic gonadotrophin|The hCG Group included 50 patients who had an intrauterine injected of 500 IU of hCG on the day of ovum pick-up
2871929|NCT03445910|No Intervention|control|The Control Group included 50 patients who went through the ICSI conventional protocol without intrauterine injection.
2871930|NCT03445897|Experimental|Intervention|miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
2871931|NCT03445884|Experimental|Acute myocardial infarctions group|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. three times. 1-3 days after intervention, 7-10 days after intervention and 30-35 days after intervention.
2871932|NCT03445884|Active Comparator|Control group|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. one time.
2871933|NCT03445871|Active Comparator|Patients with active rheumatoid arthritis|Patients with active rheumatoid arthritis will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
2871934|NCT03445871|Sham Comparator|Patients with rheumatoid arthritis into remission|Patients with rheumatoid arthritis into remission will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
2871935|NCT03445858|Experimental|Pembrolizumab, Decitabine, Radiation|Patients will receive pembrolizumab and decitabine every 28 days, and a single 3 day course of fixed-dose hypofractionated index site radiation.
2871936|NCT03445845|Experimental|targeting IL-23/17 axis|"The experimental group (targeting IL-23/17 axis) receiving secukinumab in compliance with the marketing authorization regimen: 150 mg per week for 5 weeks, and then every month by subcutaneous injection.~Blood specimen at each visits"
2871937|NCT03445845|Active Comparator|TNF blocker|"• The control group receiving a second TNF blocker in compliance with the marketing authorization regimen:~The TNF blocker (originator or biosimilar) will be different to the TNF used before the inclusion and will be chose by the investigator:~infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~etanercept: 50mg per week in subcutaneous injection,~adalimumab: 40mg every other week in subcutaneous injection,~certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~golimumab: 50mg every month in subcutaneous injection, in case of overweight (>100kg) an inadequate response, 100mg every month is allow.~Blood specimen at each visits"
2871938|NCT03445819|Other|Group A: Surgical Treatment|Open reduction and internal fixation (ORIF) of the patellar fracture will be performed using screws, wires, pins, or plate fixation at the discretion of the treating surgeon. The trial is designed in a pragmatic fashion to allow participating surgeons from the multiple participating sites to perform fixation as per the standard of care at their institution. Post-operative care will include standard-of-care antibiotics and deep vein thrombosis (DVT) prophylaxis, both prescribed at the discretion of the attending surgeon.
2871939|NCT03445819|Other|Group B: Conservative Treatment|Patients randomized to non-operative treatment will receive identical treatment to the operative group, minus the surgery. Patients will be weight bearing as tolerated immediately in a removable knee immobilizer, with progressive range-of-motion exercises begun at two weeks following randomization
2871940|NCT03445780|Experimental|First Group|Skin cooling with ethyl chloride spray will be used for 5 seconds prior to injection
2871941|NCT03445780|Experimental|Second Group|The skin between the distal palmar crease and the palmo-digital crease and the palmo-digital crease will be pinched for 5 seconds prior to injection
2871942|NCT03445780|Experimental|Third Group|Skin cooling with ethyl chloride spray will be used for 5 seconds prior to injection as well as a second pinch to the skin between the distal palmar crease and the palmo digital crease
2871943|NCT03445780|Experimental|Fourth Group|Subjects will sit behind a screen with a small opening large enough to introduce the injection hand. They will not see any of the procedure.
2871944|NCT03445767|No Intervention|Standard Care|All patients will receive perioperative care per the standards of TOH. Standard care relevant to our study consists of a history by a nurse or physician; a best possible medication history performed by a pharmacy technician; and standardized perioperative-specific medication recommendations (e.g., anticoagulant, diabetes agent, and ACE-inhibitor management) based on medical directives. Medication recommendations beyond these medical directives do not occur as standard care in our clinics. Participants will be informed that their medical care will proceed as usual and that they are being recruited for a study to evaluate medication recommendations before surgery
2871983|NCT03445546||intravenous P2Y12 inhibition|Patients with cardiac arrest and myocardial infarction treated with intravenous P2Y12 Inhibitor (cangrelor)
2871984|NCT03445533|Experimental|Arm A: ipilimumab|ipilimumab 3 mg/kg intravenous
2872455|NCT03442218|Experimental|Clorhexidine|Vaginal wash with clorhexidine solution
2871945|NCT03445767|Experimental|Intervention|In addition to standard care, the intervention will include a structured preoperative polypharmacy management strategy that consists of: a) input of best possible medication history and comorbidities into our polypharmacy management tool (MedSafer); b) communication of the prioritized deprescribing plan (if indicated) to the patient's active treating physicians (automatically via fax), to the perioperative team (surgeon, anesthesiologist), and to the electronic medical record. During the pre-operative visit, the patient will receive a generalized information flyer about deprescribing. As in the usual care phase, patients will continue to receive usual recommendations from the perioperative team based on medical directives relevant to the perioperative period.
2871946|NCT03445754|Experimental|Interventional Arm|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour.
2871947|NCT03445754|Sham Comparator|Control|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour.
2871948|NCT03445741|Active Comparator|Supervised treadmill group (%70 VO2 max)|Supervised treadmill group (%70 VO2 max) (group 1): The participants were instructed walking exercise at their target heart rate, (% 70 of maximum oxygen consumption) on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
2871949|NCT03445741|Experimental|Supervised treadmill group (%50 VO2 max)|Supervised treadmill group (%50 VO2 max) (group 2): The participants were instructed walking exercise at their target heart rate, (% 50 of maximum oxygen consumption) on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
2871950|NCT03445741|Experimental|ECE PEDO pedometer group (%50 VO2 max)|ECE PEDO pedometer group (%50 VO2 max) (group 3): The participants were instructed walking with ECE PEDO which the number of steps taken in a minute corresponding to target HR at % 50 of maximum oxygen consumption were provided.
2871951|NCT03445728|Experimental|Treatment arm|Patients were randomly assigned to two groups before emergent coronary angiography: those who received intravenous (iv.) nicorandil before and after (ivgtt.) reperfusion with PCI (nicorandil group);
2871952|NCT03445728|Placebo Comparator|Placebo arm|Patients were randomly assigned to two groups before emergent coronary angiography, those who received placebo before and after reperfusion with PCI.
2871953|NCT03445715|Experimental|Cohort I|Single intra-articular injection ART-I02: 2.4x10E12 vg / wrist joint
2871954|NCT03445715|Experimental|Cohort II|Single intra-articular injection of ART-I02: 2.4x10E13 vg / wrist joint
2871955|NCT03445715|Experimental|Cohort III|Single intra-articular injection in the wrist joint of ART-I02 Maximum Tolerated Dose (MTD) as assessed in cohorts I and II:
2871956|NCT03445702|Experimental|Metformin intolerant & metformin|Metformin 1000mg once
2871957|NCT03445702|Placebo Comparator|Metformin intolerant & placebo|Placebo 1000mg once
2871958|NCT03445702|Active Comparator|Metformin tolerant & metformin|Metformin 1000mg once
2871959|NCT03445702|Placebo Comparator|Metformin tolerant and placebo|Placebo 1000mg once
2871960|NCT03445676|No Intervention|Usual Care|Study personnel silently observe and record what the healthcare worker does at each hand hygiene opportunity without direction to the healthcare worker
2871961|NCT03445676|Experimental|ABHR directly on gloves|Healthcare worker will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity
2871962|NCT03445676|Placebo Comparator|Ideal Standard|Healthcare worker will be directed by study personnel to remove gloves, perform hand hygiene and replace gloves at each hand hygiene opportunity
2871963|NCT03445663|Experimental|AMG 424|Comparison of different dosages of AMG 424
2871964|NCT03445650|Experimental|ADX-102 1% Topical Dermal Cream (reproxalap)|
2871965|NCT03445650|Placebo Comparator|Vehicle of ADX-102 Topical Dermal Cream|
2871966|NCT03445624||patient on traditional therapy|Drug: steroid,5ASA , immuran for assesment the outcome of therapy in inflammatory bowel disease steroid(40- 60mg tablet),5ASA(pentasa 3-4gm tablet),azathioprin (immuran 100 mg tablet)
2871967|NCT03445624||patient on infliximab|drug : infliximab (5mglkg intravenous)for the first dose,the second dose after 2 weeks the third dose after 6 weeks then every 2 months
2871968|NCT03445611|Experimental|Group 1|These patients will receive a corticosteroid solution with lidocaine containing parabens.
2871969|NCT03445611|Active Comparator|Group 2|These patients will receive corticosteroid solution with paraben free lidocaine.
2871970|NCT03445598|Experimental|Interactive CCBT group|This group receives Interactive and Personalized CCBT
2871971|NCT03445598|Active Comparator|Limited CCBT control group|This group receives Feature-limited CCBT
2871972|NCT03445598|Other|Waitlist control group|This group receives waitlist control
2871973|NCT03445585||Primary Sclerosing Cholangitis|Patients with a diagnosis of primary sclerosing cholangitis (PSC).
2871974|NCT03445585||Primary Biliary Cirrhosis/Cholangitis|Patients with a diagnosis of primary biliary cirrhosis (PBC).
2871975|NCT03445585||Control group 1|Patients who do not have PBC or PSC but do have another form of chronic liver disease.
2871976|NCT03445585||Control group 2|Patients without liver disease.
2871977|NCT03445572|Experimental|Meditative Slow Breathing (MSB) Group|"Participant performs MSB 2 times each day (1 time in the morning, 1 time in the evening) for 28 days.~Participant completes 1 questionnaire every week about symptoms and quality of life. Participant completes an additional symptom questionnaire during Weeks 1 and 4."
2871978|NCT03445572|Experimental|Isha Kriya (IK) Meditation Group|"Participant performs IK meditation 2 times each day (1 time in the morning, 1 time in the evening) for 28 days.~Participant completes 1 questionnaire every week about symptoms and quality of life. Participant completes an additional symptom questionnaire during Weeks 1 and 4."
2871979|NCT03445572|Experimental|Wait List Group|"Participant receives standard supportive care during the first 28 days of the study.~After 28 days, participant may be able to switch over to Group 2 and take part in IK meditation."
2871980|NCT03445559|No Intervention|Control|No intervention
2871981|NCT03445559|Experimental|Intervention|The intervention is comprised of three components: 1) Clinical Order Check, 2) Academic Detailing, and 3) Audit and Feedback.
2871982|NCT03445546||oral P2Y12 inhibition|Patients with cardiac arrest and myocardial infarction treated with oral P2Y12 Inhibitor (from the historic cohort of NCT02914795)
2894941|NCT03284450|Experimental|Dance performance fitness test (DPFT)|
2871985|NCT03445533|Experimental|Arm B: IMO-2125 plus ipilimumab|IMO-2125 by intratumoral injection plus ipilimumab 3 mg/kg intravenous
2871986|NCT03445520|No Intervention|Transition Passport Comparison Group|This group will only receive the Transition Passport, which includes the Transition Checklist, Student Snapshot, Parent/Caregiver Guide, and Student Guide.
2871987|NCT03445520|Experimental|Intervention Coaching Group|This group will also receive the Transition Passport, which includes the Transition Checklist, Student Snapshot, Parent/Caregiver Guide, and Student Guide. This group will also receive coaching support to implement these resources. The coach will be a member of the research team who will introduce the resources to the family, briefly teach them fundamental information about the transition process, provide brief coaching phone calls, and help parents identify an appropriate person at the school or district who can work with them to complete the Student Snapshot. This group will also use ParentSquare to enhance and encourage communication between parent and members of the child's school team.
2871988|NCT03445507|Experimental|Intervention|Use of an evidence-based chat bot for smoking cessation
2871989|NCT03445507|Active Comparator|Control|Usual care (Madrid Health System Portfolio).
2871990|NCT03445494|Experimental|Brace|After surgery the patient must wear the brace for 6 weeks, for the first 3 weeks during day and night and for the following 3 weeks only at night
2871991|NCT03445494|Experimental|Normal sling|After surgery the patient must wear the normal sling for two weeks
2871992|NCT03445481|Experimental|Femoral prosthesis|newly developed prosthesis for trans-femoral amputation
2871993|NCT03445468|Experimental|IL-YANG Quadrivalent Influenza Vaccine|The vaccine contains both B strain (Yamagata, Victoria)
2871994|NCT03445468|Active Comparator|IL-YANG Flu Vaccine Pre-filled Syringe|The vaccine contains the B/Yamagata strain and it was approved for commercial sale by Ministry of Food and Drug Safety.
2871995|NCT03445455||De novo AHRF|"Acute hypoxemic non hypercapnic respiratory failure with a PaO2/FiO2 ratio < 200.~The following oxygenation devices are used and assessed during routine care:~High concentration mask, High flow nasal canula, NIV using buco-nasal mask or Helmet.~Electro impedence tomography signal will be recorded throughout this assessement for tidal volume measurement"
2871996|NCT03445442||Group 1|Sacrocolpopexy (SCP)
2871997|NCT03445442||Group 2|Native tissue repair surgery (NTR)
2871998|NCT03445442||Group 3|Vaginal mesh repair surgery (VMR)
2871999|NCT03445429|Experimental|3D-display system|Subjects in this arm will perform the tasks on the minimal-invasive training set-up first with the 3D-display system. Then they will do the NASA task load index questionnaire. After that they will perform the tasks with the 4 K-display system. After that again a NASA Task load index questionnaire is performed.
2872000|NCT03445429|Experimental|4K-display system|Subjects in this arm will perform the tasks on the minimal-invasive training set-up first with the 4K-display system. Then they will do the NASA task load index questionnaire. After that they will perform the tasks with the 3D-display system. After that again a NASA Task load index questionnaire is performed.
2872001|NCT03445416|Experimental|Intervention: POL arm|POL intervention. Enrolled POLs will be randomized at their intake visit; those randomized to the intervention arm will attend the popular opinion leader training (developed in Aim 1) and will be asked to diffuse the intervention messages to their network recruits.
2872002|NCT03445416|Active Comparator|Comparison group|POLs who are randomized to the comparison arm will receive an abbreviated version of the POL training that includes general health messaging, but does not incorporate medical mistrust, stigma or specific vaccination messaging.
2872003|NCT03445403|Experimental|Chronic pain disorders|Administration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm.
2872004|NCT03445403|Active Comparator|Healthy controls|Administration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm.
2872005|NCT03445390|Experimental|Acetaminophen Group|Patients in this group are presenting for surgery and will be administered 1 gram of intravenous acetaminophen twice during the operation. Patients are randomly assigned to this group.
2872006|NCT03445390|Placebo Comparator|Placebo|Placebo
2872007|NCT03445377|Active Comparator|Real-time continuous glucose monitoring|Subjects will be reviewed and a blood sample will be taken for the measurement of HbA1c. Training on the use of DEXCOM G5 or similar will be provided by the research team. Competency on the use of the system will be evaluated. Participants will be advised to use real-time CGM continuously for the next 8 weeks. At the end of the first intervention, a blood sample for the measurement of HbA1c will be taken. Validated questionnaires evaluating diabetes-related distress, management and user acceptance will be completed.
2872008|NCT03445377|Placebo Comparator|Self-monitoring of blood glucose|Subjects will be reviewed and a blood sample will be taken for the measurement of HbA1c. During the Control Period, masked CGM will be applied for one week, during Week 1, 4 and 8. At the end of this, a blood sample for the measurement of HbA1c will be taken. Validated questionnaires evaluating diabetes-related distress, management and user acceptance will be completed.
2872009|NCT03445364|Active Comparator|Low coronary injection-pressure, 200 psi|"Patients with STEMI who undergo Primary PCI with the use of low intracoronary dye injection pressure (of 200 psi), by using ACIST automated injector. Patients will recieve bare-metal stents at the courtasy of the interventional cardiologist, only in infarct-related artery.~Use of different injection pressure during primary PCI"
2872010|NCT03445364|Active Comparator|High coronary injection-pressure,550 psi|"Patients with STEMI who undergo Primary PCI with the use of higher intracoronary dye injection pressure (of 500 psi), by using ACIST automated injector. Patients will recieve bare-metal stents at the courtasy of the interventional cardiologist, only in infarct-related artery.~Use of different injection pressure during primary PCI"
2872011|NCT03445351|Experimental|Aerobic, resistance and concorrent|The group underwent exercise program with protocols of resistance training, aerobic training and concurrent training, with frequency of three times per week.
2872012|NCT03445338|Experimental|Cohort 1|
2872013|NCT03445325|Experimental|LiGHT v2.1|Participants will be assigned the intervention (use of the parent or teen app for 4.5 months) and asked to use throughout the intervention period (all participants are assigned to the intervention arm and results will be analyzed pre- and post-intervention).
2895376|NCT03281330||persons with Multiple Sclerosis|
2872014|NCT03445312||study cohort|All non-ICU medicine and surgery patients at Sinai Health System who have a mid-stream urine culture ordered
2872015|NCT03445299|Experimental|Music|Daily music listening for 30 minutes at bedtime
2872016|NCT03445286|Experimental|Silver Diamine Fluordie Application|This group will receive Silver Diamine Fluoride (SDF) application once every week within three weeks period
2872017|NCT03445286|Active Comparator|Chlorhexidine Application|This control group will receive chlorhexidine (CHX) application once a week within three-week period
2872018|NCT03445260|Placebo Comparator|Placebo|Each placebo is composed of a collagen-based filler with exactly the same taste and texture as the intervention.
2872019|NCT03445260|Experimental|Nutritional Supplements|carbohydrate loading, immunonutrition (formulated liquid diet), protein supplement
2872020|NCT03445247|Sham Comparator|Control|No intervention, no placebo, but do the same blood tests and examinations as experiment group at the same time points
2872021|NCT03445247|Experimental|Extracorporeal low-intensity shockwave group|with 12 times extracorporeal low intensity shockwave therapy and do the blood test and assessments at baseline, 3, 6, 12 m after initiation of therapy.
2872022|NCT03445234|Experimental|Blueberry|Freeze-dried blueberry powder
2872023|NCT03445234|Placebo Comparator|Placebo|Placebo powder
2872024|NCT03445234|Experimental|Banana|Acute banana ingestion
2872025|NCT03445234|Experimental|No banana|No banana ingestion
2872026|NCT03445221|Active Comparator|Group I|patients will take preoperative oral immunonutrition in form of glutamine, Omega-3 fatty acid, multivitamins and trace elements (2KCAL FIBRE DRINK product) once daily for 5 days before surgery in addition to a conventional diet.
2872027|NCT03445221|Active Comparator|Group C|patients will continue preoperative oral conventional diet.
2872028|NCT03445208|Experimental|Cohort 1|BMI 18.0 to ≤ 25.0
2872029|NCT03445208|Experimental|Cohort 2|BMI >25.0 to ≤ 30.0
2872030|NCT03445208|Experimental|Cohort 3|BMI >30.0 ≤ 40.0
2872031|NCT03445195|Experimental|Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin|
2872032|NCT03445195|Placebo Comparator|Placebo + Imipenem/Cilastatin|
2872033|NCT03445182|Active Comparator|Control group|Local anaesthesia with conventional syringe
2872034|NCT03445182|Active Comparator|DentalVibe group|Local anaesthesia with conventional syringe + DentalVibe
2872035|NCT03445169|Experimental|Fasting|PT2977 tablets taken after fasting
2872036|NCT03445169|Experimental|Non-Fasting|PT2977 taken after eating a high calorie meal
2872037|NCT03445156|Experimental|Pilot Study|After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game or a nonviolent shooting video game for 20 minutes. Video game play was recorded. A debriefing followed.
2872038|NCT03445156|Experimental|Experiment Proper|"After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game, a nonviolent shooting video game, or a nonviolent non-shooting video game for 20 minutes. Next, they shot a training pistol at a mannequin 20 feet (6.1 meters) away using 16 Velcro bullets. A debriefing followed."
2872039|NCT03445130|Active Comparator|Lavandula Angustifolia oil (LO)|2 Drops in Oxygen Mask
2872040|NCT03445130|Active Comparator|Michelia Alba Leaf oil (MA)|2 Drops in Oxygen Mask
2872041|NCT03445130|Active Comparator|Almond oil (AO)|2 Drops in Oxygen Mask
2872042|NCT03445130|Active Comparator|Water|2 Drops in Oxygen Mask
2872043|NCT03445117|Experimental|Intervention|Clinics assigned to the intervention arm will receive an educational intervention. This comprises posters on vaccination to be put up in the clinic, as well as a flyer which will be handed out by the clinic assistants to all patients 65 years and above, at the point of registration. The poster and flyer content will provide simple messaging to encourage patients to receive influenza and pneumococcal vaccinations and inform them of available healthcare subsidies.
2872044|NCT03445117|No Intervention|Control|Clinics assigned to control arm will run as per their normal operations and not have the interventions implemented.
2872045|NCT03445104|Experimental|Huperzine A|Huperzine A will be provided in the form of a single capsule for oral ingestion.
2872046|NCT03445104|Placebo Comparator|Rice Flour|Placebo will be provided in the form of a single capsule for oral ingestion.
2872047|NCT03445091|Experimental|Patients using investigational product|Open-label use of SANKOM Patent Socks
2872048|NCT03445078|Active Comparator|A|Participants will be administered firstly selenium-rich corn powder 20g/d for 1 month and ordinary corn powder 20g/d for another month subsequently with a month washout period.
2872049|NCT03445078|Placebo Comparator|B|Participants will be administered firstly ordinary corn powder 20g/d for 1 month and selenium-rich corn powder 20g/d for another month subsequently with a month washout period.
2872050|NCT03445065|Experimental|Cohort 1|Patients with HbA1c > 8% will be randomized into two groups: enabled group using subcutaneously implanted sensor (CGM) and a control group with usual SMBG or FGM with CGM in autolog mode.
2872051|NCT03445065|Experimental|Cohort 2|Patients with T1D (time in hypoglycemia) spending >1.5 hour with sensor glucose <70 mg/dl per day will be randomized into two groups: enabled group using subcutaneously implanted sensor (CGM) and a control group with usual SMBG or FGM with CGM in autolog mode.
2872052|NCT03445052|Experimental|2018 XPAND Intervention Arm|This group will receive the personalised adherence intervention in 2018 in addition to routine clinical care.
2872053|NCT03445052|No Intervention|2018 XPAND Control Arm|This group will receive routine clinical care and act as the control group for the primary objective: To compare the mean daily dose of UVR (SEDs) reaching the face between the intervention group and control group over a 3 week period in June to July (follow-up 1). This group will receive the intervention in 2019, to allow within group change to be assessed.
2872054|NCT03445039|Experimental|TSFE using osteotomes with bone grafting|The patients in this group will receive transalveolar sinus floor elevation with osteotomes and mallet. The bone substitute is placed in this group.The interventions in the arm are bone grafting and the TSFE will be performed by osteotomes.
2872055|NCT03445039|Experimental|TSFE using osteotomes without bone grafting|The patients in this group will receive transalveolar sinus floor elevation with osteotomes and mallet. The bone substitute will not be placed in this group.The intervention in the arm is the TSFE will be performed by osteotomes.
2872056|NCT03445039|Experimental|modified TSFE with bone grafting|The patients in this group will receive modified transalveolar sinus floor elevation with the Dask drills. The cortical plate of the sinus floor is grinded or removed by the dome like drills. And the membrane is elevated by the surgical instruments. The bone substitute is placed before the implant placement.Interventions in the arm are bone grafting and the TSFE will be performed by dask drills.
2872057|NCT03445039|Experimental|modified TSFE without bone grafting|The patients in this group will receive modified transalveolar sinus floor elevation with the Dask drills. The cortical plate of the sinus floor is grinded or removed by the dome like drills. And the membrane is elevated by the surgical instruments. The bone substitute will not be placed in this group.The intervention in the arm is the TSFE will be performed by dask drills.
2872058|NCT03445013|Experimental|SB414 6%|SB414 6% topically twice daily
2872059|NCT03445013|Placebo Comparator|Vehicle Cream|Vehicle Cream topically twice daily
2872060|NCT03445000|Experimental|Trial treatment|"Alectinib is administered orally, 600 mg, twice per day (1200 mg per day) until progression, refusal or unacceptable toxicity.~Trial treatment may also continue beyond progression, with physician and patient agreement, for as long as the patient may still derive clinical benefit as per investigator decision."
2872061|NCT03444987||patients group|"include 40 premenopausal women (age ˂ 45 year) with uterine fibroids who are diagnosed through clinical gynecological, ultrasound and other auxiliary examinations.~The protein expression of the followings markers will be estimated in tumor tissue samples:~Fibroblast activation protein (FAP) will be measured by quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~Autophagy markers level (LC3 and p62) will be measured by qRTPCR (mRNA level) and by immunohistochemical analysis.~Phosphorylated protein kinase B (pAKT) level will be measured by western blot analysis.~Circulating (cFAP) will be measured using ELISA in blood of UF patients."
2872062|NCT03444987||Control group|"include 40 (age, BMI) matched healthy females~The protein expression followings markers will be estimated in normal myometrial tissue samples( 1cm from UF lesions):~Fibroblast activation protein (FAP) will be measured by quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~Autophagy markers level (LC3 and p62) will be measured by qRTPCR (mRNA level) and by immunohistochemical analysis.~Phosphorylated protein kinase B (pAKT) level will be measured by western blot analysis.~Circulating (cFAP) will be measured using ELISA in blood of healthy controls"
2872063|NCT03444974|Active Comparator|Patient therapy group|"Adolescents with drug abuse and dependency problems~Receiving an adapted treatment according to the Matrix therapy"
2872064|NCT03444974|Active Comparator|Parental therapy group|"Parents of adolescents with drug abuse problems~Receiving an adapted treatment according to the Matrix therapy"
2872065|NCT03444974|No Intervention|Patient waiting list group|"Adolescents with drug abuse and dependency problems~On the waiting list for receiving a Matrix therapy treatment"
2872066|NCT03444974|No Intervention|Parental waiting list group|"Parents of adolescents with drug abuse problems~On the waiting list for receiving a Matrix therapy treatment"
2872067|NCT03444974|No Intervention|control group|"Adolescents with no history of or current drug abuse or dependency~no other intake of psychotropic substances such as psychotropic medication"
2872068|NCT03444961|Experimental|CAREN system training|CAREN training
2872069|NCT03444948|Experimental|3 radiofrequency ablation procedures + standard medical care|
2872070|NCT03444948|Active Comparator|standard medical care|
2872071|NCT03444935|Experimental|Intervention|Participants randomized to the intervention group will receive a predetermined amount of follow-up phone calls after discharge from the Crisis Centre. They can expect a minimum of one call and a maximum of five calls over the five week period immediately following discharge to the community. The number and nature of phone calls they receive will be different from participants in the control group. Participants will be informed upon discharge of the dates they should anticipate phone calls, but it will not be revealed to them which group they were randomized to.
2872072|NCT03444935|Other|Control|Participants randomized to the control group will receive a predetermined amount of follow-up phone calls after discharge from the Crisis Centre. They can expect a minimum of one call and a maximum of five calls over the five week period immediately following discharge to the community. The number and nature of phone calls they receive will be different from participants in the intervention group. Participants will be informed upon discharge of the dates they should anticipate phone calls, but it will not be revealed to them which group they were randomized to.
2872073|NCT03444922|Placebo Comparator|Placebo|Participants consume Vanilla Wafer cookie
2872074|NCT03444922|Experimental|BPA 4 ug/kg BW|Participants consume 4 ug/kg BW of BPA on a Vanilla Wafer Cookie
2872075|NCT03444922|Experimental|BPA 50 ug/kg BW|Participants consume 50 ug/kg BW of BPA on a Vanilla Wafer Cookie
2872076|NCT03444909|Experimental|cardiotocograph and Toconaute|monitoring with cardiotocograph and next with the Toconaute of Bioserenity
2872077|NCT03444909|Experimental|Cardiotocograph and Toconaute and Electrophysiological device|monitoring withardiotocograph and next with Toconaute and next with the electrophysiological device
2872078|NCT03444909|Experimental|Cardiotocograph and electrophysiological device|monitoring with the cardiotocograph and next with the electrophysiological device (Micromed)
2872079|NCT03444896|Experimental|Acupuncture group|
2872080|NCT03444896|Placebo Comparator|Sham acupuncture group|
2872081|NCT03444883|Active Comparator|Treatment Group|10mg Ilaprazole x 2 tablets
2872082|NCT03444883|Placebo Comparator|Control Group|10mg placebo of Ilaprazole x 2 tablets
2872083|NCT03444870|Experimental|Gantenerumab|Gantenerumab will be administered as SC injections with gradual uptitration.
2872084|NCT03444870|Placebo Comparator|Placebo|Placebo will be administered as SC injections with gradual uptitration.
2872085|NCT03444857|Experimental|CPAP treatment|Continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) plus standard care (according to current STEMI guidelines) for 3 months after pPCI
2872086|NCT03444857|No Intervention|Control|Standard care (according to current STEMI guidelines) for 3 months after PPCI with no intervention for OSA
2872087|NCT03444844|Experimental|Ga-68 P16-093 PET/CT scan|IV injection of 2 - 6 mCi of Ga-68 P16-093 followed by PET/CT scanning for approximately 150 minutes
2872088|NCT03444831|Experimental|Buspirone plus Omeprazole|
2872089|NCT03444831|Placebo Comparator|Placebo plus Omeprazole|
2895377|NCT03281330||Healthy controls|
2872090|NCT03444818|Experimental|[14C]-E6007|Participants will receive a single oral dose of 60 milligrams (mg) of [14C]-E6007.
2872091|NCT03444805||NISSC-2|SSC patients treated with AHSCT
2872092|NCT03444792|Experimental|Group I (dilation group)|the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal of the patients after the extraction of placenta and membranes. The outer glove will be removed after this procedure. - If failed we will use artery forceps to dilate cervix
2872093|NCT03444792|No Intervention|Group II (non dilatation group)|the surgeon will perform cesarian section without attempting cervical dilatation
2872094|NCT03444779|Active Comparator|Control group|The patients will be treated with an open technique: cutaneous incision with submeniscal arthrotomy under guidance of a fluoroscope. The reduction will be performed using a spatula, a bone tamp or open reduction internal fixation. The osteosynthesis and filling of the cavity will be performed by the same surgical access.
2872095|NCT03444779|Experimental|Experimental group|"The patients will be treated with the Tibial Tuberoplasty technique under fluoroscopic guidance with or without arthroscopy. The reduction will be performed by an anterior approach using a kyphoplasty balloon. The combined osteosynthesis including cannulated screws and cementoplasty will both be performed by a percutaneous technique."
2872096|NCT03444766|Experimental|Monotherapy|administering nivolumab only
2872097|NCT03444753|Experimental|Arm A|BMS-986299
2872098|NCT03444753|Experimental|Arm B|BMS-986299 in combination with nivolumab and ipilimumab
2872099|NCT03444727|Experimental|Ice Pre-treatment|Participants will hold an exam glove filled with ice to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
2872100|NCT03444727|Placebo Comparator|Room Temperature Water Pre-Treatment|Participants will hold an exam glove filled with room temperature water to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
2872101|NCT03444714|Experimental|RiMO-301+Radiotherapy|3 dose levels (5%, 10%, and 15% of the total baseline tumor volume, respectively) will be tested in a 3 + 3 dose escalation study
2872102|NCT03444701|Experimental|E7130 (2-Week Regimen)|Part 1 (Cycle 1; 28 days): The first cohort of 3 participants will receive 25 micrograms per meters squared (μg/m^2) of E7130, on Day 1 and Day 15 as an intravenous infusion. If a drug-related Grade 2 or higher toxicity is not observed in the initial cohort, dose-limiting toxicities (DLTs) will be evaluated in successive dose levels with single participants until such a toxicity is observed. Once the maximum tolerated dose (MTD) is observed, participants will be administered E7130 at the determined dose level on Days 1 and 15 of every 28-day cycle until they meet any of the criteria for discontinuation. Part 2: Participants with Her2-negative breast cancer and other solid tumors will be evaluated at the dose level determined in Part 1 in a 2-week regimen based on the evaluations in Part 1.
2872103|NCT03444701|Experimental|E7130 (3-Week Regimen)|Part 1 (Cycle 1; 21 days): On Day 1, participants will receive E7130 at (-1) a lower dose than the dose at which the first DLT was observed in the 2-week regimen. If a drug-related Grade 2 or higher toxicity is not observed in the initial cohort, DLTs will be evaluated in successive dose levels with single participants until such a toxicity is observed. Once the MTD is observed, participants will be administered E7130 at the determined dose level on Day 1 of every 3-week cycle until they meet any of the criteria for discontinuation. Part 2: Participants with Her2-negative breast cancer and other solid tumors will be evaluated at the dose level determined in Part 1 in a 3-week or regimen based on the evaluations in Part 1.
2872104|NCT03444688|Active Comparator|CT, Control Group|Conventional Gait Training
2872105|NCT03444688|Experimental|WT, Experimental Group|Gait rehabilitation with walker
2872106|NCT03444662|Placebo Comparator|Placebo|Intervention: Dietary Supplement: Placebo supplement
2872107|NCT03444662|Experimental|Cognizin and Omega-3|Intervention: Dietary Supplement: Citicoline and Omega-3 supplement
2872108|NCT03444662|Experimental|Omega-3|Intervention: Dietary Supplement: Omega-3 supplement
2872109|NCT03444649|Experimental|Dosis finding|Epacadostat is given for 2 cycles of 28 days at a dose according to the titration design together with Standard chemotherapy (Idarubicin and Cytarabine)
2872110|NCT03444636|Experimental|Ropivacaine/Fentanyl|
2872111|NCT03444636|Active Comparator|Bupivacaine/Fentanyl|
2872112|NCT03444610|Other|Arm (blood transfusion escalation rate)|The intervention for the arm (blood transfusion escalation rate) will be about giving blood transfusion with escalating rate as described in intervention part to Any condition that expected to receive more than one blood transfusion, like thalassemia major or intermedia, sickle cell anemia, aplastic anemia, malignant diseases.
2872113|NCT03444584|Experimental|MEDI0382/Dapaglifozin|MEDI0382 Solution for injection in combination with Dapaglifozin
2872114|NCT03444584|Placebo Comparator|Placebo/Dapaglifozin|Placebo Solution for injection in combination with Dapaglifozin
2872115|NCT03444571|No Intervention|Control|
2872116|NCT03444571|Experimental|DNA based diagnosis|
2872117|NCT03444558|Experimental|Dietary Supplement|50 subjects with the metabolic syndrome receiving natural supplement containing chlorogenic acid and luteolin (450 mg/die)
2872118|NCT03444558|Placebo Comparator|Placebo|50 subjects with the metabolic syndrome receiving placebo (without any active ingredients)
2872119|NCT03444532|Experimental|12-week aerobic exercise and cognitive-behavioral therapy|12-week aerobic exercise, two times per week, and cognitive-behavioral therapy for insomnia in total four sessions
2872120|NCT03444532|No Intervention|Control group|Patients assigned to the control group will receive usual care
2872121|NCT03444519|Experimental|Mannitol A|in this group, Mannitol (1.0mg/kg) is given just after the induction of general anesthesia
2872122|NCT03444519|Active Comparator|Mannitol B|in this group, Mannitol (1.0mg/kg) is given at the time of skin incision
2872123|NCT03444506|Placebo Comparator|Placebo nasal spray|Placebo nasal spray - 2 sprays per nostril, BID
2872124|NCT03444506|Experimental|Molo 1 (also referred as GSP 301-2 NS)|Fixed Dose Combination of Molo nasal spray (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg nasal spray) - 2 sprays per nostril, BID
2872125|NCT03444506|Experimental|Molo 2 (also referred as GSP 301-1 NS)|Fixed Dose Combination of Molo nasal spray (olopatadine hydrochloride 665 mcg and mometasone furoate 50 mcg nasal spray) - 2 sprays per nostril, QD
2872126|NCT03444506|Active Comparator|DYMISTA nasal spray|Fixed Dose Combination of azelastine hydrochloride 137 mcg and fluticasone propionate 50 mcg nasal spray - 1 spray per nostril, BID
2872127|NCT03444506|Active Comparator|PATANASE nasal spray|Olopatadine hydrochloride 665 mcg nasal spray - 2 sprays per nostril, BID
2872128|NCT03444493|Experimental|Exercise|The exercise group performed specific localized exercises aimed at restoring the stabilizing protective function of the transversus abdominis (TrA). The exercises were designed specifically to activate and train the isometric holding function of the TrA muscle at the affected vertebral segment. Additionally, the exercise group was informed about protecting for biomechanics of lumbar spine.
2872129|NCT03444493|No Intervention|Control|Control group was informed about protecting for biomechanics of lumbar spine.
2872130|NCT03444480|Experimental|Remimazolam Tosylate 1|IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start， 0.5 mg Flumazenil is administered
2872131|NCT03444480|Experimental|Remimazolam Tosylate 2|IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start time,0.5ml placebo is administered
2872132|NCT03444467|Experimental|NNC9204-1513|Participants will receive increasing doses of NNC9204-1513.
2872133|NCT03444467|Active Comparator|Glucagon|Participants will receive a single fixed dose of glucagon.
2872134|NCT03444454|Experimental|VRRS Khymeia|"The group will receive a kit home-based (a tablet home, an exercise equipment, access to a daily individualized training program).~The exercise program will be remotely charged by therapist on the patient's computer.~Each patient's performed session will be reviewed remotely by the therapist."
2872135|NCT03444454|Active Comparator|Usual care program|The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
2872136|NCT03444428||Non Invasive Ventilation|"Age, height, weight~History and Physical Examination~Evaluation of dyspnoea: mMRC, Borg scale (Seated-Supine)~Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)~Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5)~24h Blood Pressure monitor~Spirometry - FEV1 and FVC~Respiratory muscle strength - MIP, MEP, and SNIP~Arterial Blood Gases~Carotid-femoral pulse wave velocity~Breath CO exhale"
2872137|NCT03444428||Without Non Invasive Ventilation|"Age, height, weight~History and Physical Examination~Evaluation of dyspnoea: mMRC, Borg scale (Seated-Supine)~Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)~Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5)~24h Blood Pressure monitor~Spirometry - FEV1 and FVC~Respiratory muscle strength - MIP, MEP, and SNIP~Arterial Blood Gases~Carotid-femoral pulse wave velocity~Breath CO exhale"
2872138|NCT03444415|Experimental|Motivational interviewing in groups|The Intervention is performed at Primary Care Centers by health professionals (General Practitioners, Nurses, Pediatricians and Midwives), during pregnancy and the first 2 years of the child. Researchers will be trained in motivational interviewing and group dynamics. Intervention consists of six 90 minutes workshops, two of those during pregnancy and the other four within the following two years after the birth of the children. They intend to encourage the shift towards healthy lifestyles to parents on issues related to diet, physical activity and smoking habit, encourage breastfeeding and increase their knowledge and self-efficacy to promote healthy habits regarding diet, physical activity and sleep habits of their children.
2872139|NCT03444415|Other|Control Group|"Control Group: Usual Care as established in the Programa Integral de Atención a la Mujer (Comprehensive Program of Woman Assistance) and the Programa de Atención al Niño Sano (Well Child Program) in the Servicio Murciano de Salud.~Parents will receive information about height, weight, and BMI percentile provided by a health professional during usual well child visits."
2872140|NCT03444402|Experimental|Group A|Period 1: Test drug(CKD-381 formulation I), Period 2: Test drug(CKD-381 formulation II), Period 3: Reference drug(D026)
2872141|NCT03444402|Experimental|Group B|Period 1: Test drug(CKD-381 formulation II), Period 2: Reference drug(D026), Period 3: Test drug(CKD-381 formulation I)
2872142|NCT03444402|Experimental|Group C|Period 1: Reference drug(D026), Period 2: Test drug(CKD-381 formulation I), Period 3: Test drug(CKD-381 formulation II)
2872143|NCT03444389||Study group|Patients with hemorrhoids
2872144|NCT03444389||Control group|Healthy participants without hemorrhoids
2872145|NCT03444376|Experimental|GX-188E, Keytruda|GX-188E: 1st day of week 1,2,4,7,13,19, 46/ 2mg Keytruda:Day 1 q3 weeks/ 200mg
2872146|NCT03444363|Experimental|Study group|SRP plus diode laser (810 nm wavelength, 1 W power)
2872147|NCT03444363|Active Comparator|Control group|SRP plus placebo
2872148|NCT03444350|Active Comparator|Control group|SRP plus placebo
2872149|NCT03444350|Experimental|Gaseous ozone group|SRP plus gaseous ozone [1 W (100 mJ, 10 Hz)]
2872150|NCT03444337||Catheter Ablation Group|Patients undergoing FIRM guided ablation of paroxysmal or persistent atrial fibrillation with pre-procedure high resolution cardiac MRI
2872151|NCT03444324|Experimental|BT524|Investigational Human Fibrinogen Concentrate
2872152|NCT03444324|Active Comparator|Fresh Frozen Plasma (FFP)|Standard of Care
2872153|NCT03444311|Active Comparator|A: 1 dosis|1 dosis (3E+09 cfu/day + 6 g of fiber/day)
2872154|NCT03444311|Active Comparator|B: 2 dosis|2 dosis (3E+09 cfu/day + 12 g of fiber/day)
2872155|NCT03444298|Placebo Comparator|Placebo first, then Gamma Tocopherol|Participants that are randomized to placebo treatment will take a short treatment course of Safflower Oil followed by chamber exposure with wood smoke particulate. After a 4-week washout period, participants will cross over to the gamma Tocopherol (active) treatment group.
2872156|NCT03444298|Active Comparator|GammaTocopherol first, then Placebo|Participants that are randomized γT treatment will take a short treatment course of gamma Tocopherol followed by chamber exposure with WSP. After a 4-week washout period, participants will cross over to the placebo treatment group.
2872157|NCT03444285|Active Comparator|Warm Up|
2872158|NCT03444285|Active Comparator|Hot Pack|
2872159|NCT03444272|Experimental|Hepatitis C patients|HCV Treatment (Sofosbuvir and Daklatasuvir)
2872160|NCT03444259||Atrial fibrillation|Patients with atrial fibrillation
2872161|NCT03444259||Coronary bypass|Patients undergoing coronary bypass
2872162|NCT03444259||Aortic valve replacement|Patients undergoing aortic valve replacement
2872163|NCT03444259||Mitral valve repair|Patients undergoing mitral valve repair
2872164|NCT03444259||Other|Patients undergoing cardiac surgery for indication other than above
2872165|NCT03444246|Experimental|Iodine free diet group|The arm with non iodized salt，the subject in the non iodized salt group used the iodized salt for the first three months, and the iodized salt was changed after three months.
2872166|NCT03444246|Active Comparator|Normal iodine diet group|The arm with iodized salt，the subject in the control group were consumed with iodized salt within six months.
2872167|NCT03444233|Experimental|low f1 diet|low fructose diet week 1
2872168|NCT03444233|Experimental|fruit rich diet|fruit rich diet week 2
2872169|NCT03444233|Experimental|low f2 diet|low fructose diet week 3
2872170|NCT03444233|Experimental|HFCS rich diet|HFCS rich diet week 4
2872171|NCT03444220|Active Comparator|ACHIM|Anaerobically Cultivated Human Intestinal Microbiota
2872172|NCT03444220|Placebo Comparator|Placebo|Anaerobically Cultivated medium
2872173|NCT03444207|Experimental|Group A|Endurance training
2872174|NCT03444207|Experimental|Group B|Endurance-strength training
2872175|NCT03444194|Experimental|Biopsi arm|
2872176|NCT03444181|Experimental|Music lessons|
2872177|NCT03444181|Active Comparator|Training intervention|
2872178|NCT03444181|No Intervention|No intervention|
2872179|NCT03444168||Candidate for Lumbar Spine Surgery|Participants have been designated to be a candidate for lumbar spine surgery to treat chronic low back and/or leg pain and you have agreed to proceed with the surgery.
2872180|NCT03444168||Lumbar Failed Back Surgery Syndrome|Participants have been diagnosed with having lumbar failed back surgery syndrome and have persistent and moderate-to-severe low back and/or leg pain for more than 6 months after a lumbar spine surgery.
2872181|NCT03444168||Healthy Volunteer|Participants are a healthy volunteer wishing to participate in a research study.
2872182|NCT03444155|Active Comparator|Panmol-B-Complex|B1 (2,77mg), B2 (3,53mg), B3 (40,32mg), B5 (15,12mg), B6 (3,53mg), B7 (0,13mg), B9 (0,50mg), B12 (6,3µg) daily for 6 weeks.
2872183|NCT03444155|Active Comparator|Synthetic Vitamin B-complex|B1 (2,77mg), B2 (3,53mg), B3 (40,32mg), B5 (15,12mg), B6 (3,53mg), B7 (0,13mg), B9 (0,50mg), B12 (6,3µg) daily for 6 weeks.
2872184|NCT03444142|Active Comparator|Drug: Exenatide LAR|Exenatide LAR 2 mg, once weekly subcutaneously before breakfast during 4 weeks.
2872185|NCT03444142|Active Comparator|Drug: Dulaglutide|Dulaglutide .75 mg, once weekly subcutaneously Before breakfast during 4 weeks.
2872186|NCT03444129|Active Comparator|Control|This group will participate in a health education workshop with weekly sessions (control group)
2872187|NCT03444129|Experimental|Game|This group will participate in the health education workshop plus the interactive health game (intervention group).
2872188|NCT03444116||Cases (+FDO)|Patients who underwent an FDO
2872189|NCT03444116||Controls (-FDO)|Same as cases but did not undergo an FDO
2872190|NCT03444103|Active Comparator|Clazakizumab / Clazakizumab|Monthly subcutaneous injections of 25mg clazakizumab for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).
2872191|NCT03444103|Placebo Comparator|Placebo / Clazakizumab|Monthly subcutaneous injections of placebo (saline) for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).
2872192|NCT03444090|Experimental|Insertion/withdrawal colon polypectomy|For participants assigned in the experimental group, the colon is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both insertion and withdrawal phases.Colon polypectomy for polyp size <10 mm will be performed when they are identified during insertion and withdrawal of the colonoscope. Colon polypectomy for polyp size >10 mm will be performed only during withdrawal of the scope.
2872193|NCT03444090|Active Comparator|Withdrawal colon polypectomy|For participants assigned in the control group, deliberate mucosa inspection and colon polypectomy will be performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum.
2872194|NCT03444077|Active Comparator|Control group|The patients allocated in the control group will be managed as recommended in the local guidelines and protocols. As the trial involves participating centers with different prehospital and hospital realities and local practices, the control group will reflect a wide panel of levels of care and will not be limited to a unique approach.
2872195|NCT03444077|Experimental|Intervention group|"Patients will be classified in two categories regarding their TICCS value. Patients with TICCS ≥ 10 will be classified as in need for DCR; while patients with TICCS < 10 will be classified as not in need for DCR.~TICCS < 10 This subgroup will be considered without a need for DCR and without coagulopathy. There will not be any activation of the DCR components (no phone contact to the blood bank, to the surgical team, no prehospital transfusion). There will be any prehospital treatment/prevention of the hyperfibrinolysis using Tranexamic acid (TXA). Crystalloids infusion will be allowed.~TICCS ≥ 10 This subgroup will be considered with a need for DCR and with coagulopathy. They will be treated using the STTTOPPP the bleeding protocol."
2872196|NCT03444064|No Intervention|Control|Participants in this arm receive islet transplant only, and no PolyTregs.
2872197|NCT03444064|Experimental|Treatment|Participants in this arm receive PolyTregs infusion at week 6 post islet transplant.
2872198|NCT03444051||20-gauge Procore®|"Between March and December 2017, 68 EUS-FNB were consecutively performed in our unit for a pancreatic or peripancreatic mass. The choice of the needle depended upon the availability at the time of admission:~34 punctures were performed with a 20-gauge Procore® during the period study"
2872199|NCT03444051||22-gauge Acquire®|"Between March and December 2017, 68 EUS-FNB were consecutively performed in our unit for a pancreatic or peripancreatic mass. The choice of the needle depended upon the availability at the time of admission:~34 punctures were performed with a 22-gauge Acquire® during the period study"
2872200|NCT03444038|Experimental|NBI-98854|NBI-98854 administered once daily for up to 24 weeks
2872201|NCT03444025|Experimental|Group A|Goserelin 3.6 mg depot injection will be administered subcutaneously every month along with standard chemotherapy regimen: AC-P: Doxorubicin 60 mg/m2 IV plus cyclophosphamide 600 mg/m2 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 by 1 hour infusion every week for 12 weeks. Each cycle is 21 days.
2872202|NCT03444025|No Intervention|Group B|Standard chemotherapy regimen: AC-P: Doxorubicin 60 mg/m2 IV plus cyclophosphamide 600 mg/m2 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 by 1 hour infusion every week for 12 weeks. Each cycle is 21 days.
2872203|NCT03443986|Experimental|Resistance training associated with vibration|The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes.
2872204|NCT03443986|Sham Comparator|Resistance training associated with sham|"The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration sham and 5 minutes of slowdown. The vibration sham; will be held with the disconnected platform. A device will be connected producing a noise similar to the sound of the connected platform for a time equivalent to the treatment protocol, since it will not be possible to distinguishing noticeably stimulate vibrator. Participants that will undergo false vibration will not have contact with those who carry out the real treatment."
2872205|NCT03443986|No Intervention|Control group|Will not be submitted to any physical intervention. It continues in your daily life with only monitoring via phone callings. Guidelines about foot care.
2872206|NCT03443973|Experimental|Gantenerumab|Gantenerumab will be administered as SC injections with gradual uptitration.
2872207|NCT03443973|Placebo Comparator|Placebo|Placebo will be administered as SC injections with gradual uptitration.
2872208|NCT03443960|Experimental|Treatment A (TNX-102 SL)|2 x TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 2.8 mg once daily for 20 consecutive days
2872209|NCT03443960|Active Comparator|Treatment B (AMRIX)|1 x AMRIX ER capsule 30 mg once daily for 20 consecutive days
2872210|NCT03443947|Experimental|D group|
2872211|NCT03443921|Experimental|Surgery Group|In Surgery Group, an artery divestment combined pancreatectomy will be performed if no pre-operative contra-indication or intra-operative metastasis were revealed. Post-operative adjuvant chemotherapies were prescribed according to performance status.
2872212|NCT03443921|Active Comparator|NeoChemo Group|In NeoChemo (Neoadjuvant Chemotherapy) Group, neoadjuvant chemotherapy will be utilized. After 2 circles of neoadjuvant chemotherapies, patients will be reevaluated and curative operation would be attempted if without disease progression.
2872213|NCT03443908||CPAP therapy|CPAP therapy (minimum of 3-4 weeks)
2872214|NCT03443895|Active Comparator|Experimental: AEF0117|Subjects in cohorts 1 through 3 receive active treatments. Subjects in Cohorts 1 through 3 will receive a single dose of 0.6, 2 and 6mg respectively of AEF0117 on Day 1 to Day 7.
2872215|NCT03443895|Placebo Comparator|Placebo|Subjects in Cohorts1 through 3 will be randomly assigned in an 6:2 allocation to receive active or placebo treatments.
2872216|NCT03443882|Active Comparator|Astaxanthin formulation #1|capsules
2872217|NCT03443882|Active Comparator|Astaxanthin formulation #2|tablets
2872218|NCT03443882|Active Comparator|Astaxanthin formulation #3|powder
2872219|NCT03443882|Experimental|Astaxanthin formulations|fast condition
2872220|NCT03443869|Experimental|Letermovir|Letermovir (LET) 480mg (or 240 mg when co-administered with cyclosporin A) tablet orally; placebo to VGCV tablet orally once daily; and 400 mg capsule of acyclovir (ACV) orally every 12 hours for 28 weeks
2872221|NCT03443869|Active Comparator|Valganciclovir|900 mg Valganciclovir (VGCV) tablet orally, once daily; placebo to LET tablet orally once daily; and placebo to ACV orally every 12 hours for 28 weeks
2872222|NCT03443856|Other|chemotherapy arm|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
2872223|NCT03443856|Experimental|immunotherapy arm|Treatment: Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year. No chemotherapy.
2872224|NCT03443843|Experimental|Sequence 1|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
2872225|NCT03443843|Experimental|Sequence 2|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
2872226|NCT03443843|Experimental|Sequence 3|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
2872227|NCT03443843|Experimental|Sequence 4|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
2872228|NCT03443830|Experimental|0.2 mg/kg|Subject will be administered with 0.2 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
2872229|NCT03443830|Experimental|0.5 mg/kg|Subject will be administered with 0.5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
2872230|NCT03443830|Experimental|1 mg/kg|Subject will be administered with 1 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
2872231|NCT03443830|Experimental|5 mg/kg|Subject will be administered with 5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
2872232|NCT03443830|Experimental|10 mg/kg|Subject will be administered with 10 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
2872233|NCT03443830|Experimental|20 mg/kg|Subject will be administered with 20 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
2872234|NCT03443817|No Intervention|Control group|There is no conventional rehabilitation follow up program, but all patients are encouraged to continue training
2872235|NCT03443817|Experimental|Intervention group|The intervention group will obtain telerehabilitation
2872236|NCT03443804|Experimental|Test(DW1401)|tid PO, DW1401+Placebo of Stillen tab.
2872237|NCT03443804|Active Comparator|Reference(Stillen tab.)|tid PO, Stillen tab.+Placebo of DW1401
2872238|NCT03443791|Experimental|women enrolled|pregnant women enrolled in trial
2872239|NCT03443791|Other|newborns of female study participants|newborns will be tested to determine if virus is present.
2872240|NCT03443778|Active Comparator|Nacl 0,9% (Control) group|Nacl 0,9% 3-5 ml separately two part for each tonsil before surgery
2872241|NCT03443778|Active Comparator|Bupivacaine 0,5%|Bupivacaine 0.5% 1 mg/kg with in Nacl 0,9% 3-5 ml separately two part for each tonsil before surgery
2872242|NCT03443778|Active Comparator|Bupivacaine 0,5% , Dexamethasone|Bupivacaine 0,5% 1 mg/kg,dexamethasone 0.5 mg/kg (max dosage 8mg) 3-5 ml separately two part for each tonsil before surgery
2872243|NCT03443765||Patients with Pityriasis alba|
2872244|NCT03443765||Healthy participants (control group)|
2872245|NCT03443752|Experimental|Shotokan-Karate|The protocol for Shotokan-karate training will involve a one hour training session which will be broken down into 3 major components. The training program will consist of warm-up exercises, katas (choreographed karate movements), and cool-down exercise.
2872246|NCT03443752|Experimental|Tai-Chi|The protocol for Tai Chi will involve a one-hour training session which will be conducted by an instructor at the Sun Life Financial Movement Disorders and Rehabilitation Centre.The following program will be held three times per week.
2872247|NCT03443726|Experimental|Infiltrative technique|Patients in this arm will have buccal and lingual infiltrative anesthesia with 4% articaine 1:100.000 epinephrine for third molar extraction.
2872248|NCT03443726|Active Comparator|Nerve block technique|Patients in this arm will have inferior alveolar nerve and buccal nerve block with 4% articaine 1:100.000 epinephrine for third molar extraction.
2872249|NCT03443713|Experimental|Aerobic exercise|Subjects in this arm will complete aerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G5 CGM and a Dexcom G6 CGM.
2872250|NCT03443713|Experimental|Anaerobic exercise|Subjects in this arm will complete anaerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G5 CGM and a Dexcom G6 CGM.
2872251|NCT03443713|Experimental|High intensity interval exercise|Subjects in this arm will complete high intensity interval exercise at home and at OHSU for the study. Subjects will use a Dexcom G5 CGM and a Dexcom G6 CGM.
2872252|NCT03443700|Active Comparator|sLT|Standard neurorehabilitation locomotor training during the whole study period (8 weeks).
2872253|NCT03443700|Experimental|sLT + EX-T|Standard neurorehabilitation locomotor training (sLT) during the whole study period (8 weeks), plus a training with a new-generation robotic anthropomorphic exoskeleton (EKSO-GT locomotor training) during the first 4 study weeks.
2872254|NCT03443687|Active Comparator|Pelvic Floor Physical Therapy|If randomized to this arm, women will complete demographic forms and questionnaires. They will then undergo 4 pelvic floor physical therapy visits over 3 months. At that time they will return for a follow up visit and complete questionnaires.
2872255|NCT03443687|Experimental|Home Biofeedback|If randomized to this arm, women will complete demographic forms and questionnaires. They will then be given a pelvic floor exercise device that is bluetooth linked to a smartphone application. They will be instructed on how to use the device daily for 3 months. At that time they will return for a follow up visit and complete questionnaires.
2872256|NCT03443674|Experimental|SCB-313|Dose Escalation - 5 Sequential Dose Cohorts.
2872257|NCT03443661|Experimental|FOLFOXIRI|oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
2872258|NCT03443635|Experimental|Treatment|Subjects receiving hands-on cooking and nutrition education classes
2872259|NCT03443635|No Intervention|Control|Subjects not receiving any additional nutrition education aside from that contained in their curricula (for trainees) or medical care (for patients)
2872260|NCT03443622|Experimental|SC-43 100 mg/day|SC-43 Oral Solution (100 mg/ml), 1 ml by mouth, q.d. for 28 days
2872261|NCT03443622|Experimental|SC-43 200 mg/day|SC-43 Oral Solution (100 mg/ml), 2 ml by mouth, q.d. for 28 days
2872262|NCT03443622|Experimental|SC-43 400 mg/day|SC-43 Oral Solution (100 mg/ml), 4 ml by mouth, q.d. for 28 days
2872263|NCT03443622|Experimental|SC-43 600 mg/day|SC-43 Oral Solution (100 mg/ml), 6 ml by mouth, q.d. for 28 days
2872264|NCT03443622|Experimental|SC-43 900 mg/day|SC-43 Oral Solution (100 mg/ml), 9 ml by mouth, q.d. for 28 days
2872265|NCT03443622|Experimental|SC-43 1200 mg/day|SC-43 Oral Solution (100 mg/ml), 12 ml by mouth, q.d. for 28 days
2872266|NCT03443609|Other|68Ga-HBED-CC-PSMA PET / CT|"Patients will receive 68Ga-HBED-CC-PSMA PET / CT imaging for the detection of prostate cancer recurrence sites. This determination will be made at the patient and lesion level by reference to the gold standard (or truth standard) that will be obtained from the histology data and / or from an imaging and evolution follow-up. PSA over a period of at least 6 months (RECIST 1.1 criteria)."
2872267|NCT03443596|Active Comparator|Early intensive BP control|BP in participants in this arm is treated aggressively, lowered and maintained at systolic blood pressure between 140-160mmHg, within 6 hours of stroke onset and maintained in this range for first 72 hours.
2872268|NCT03443596|No Intervention|Guidelined based BP control|Participants are treated according to the current international guidelines in thrombolysed acute ischemic stroke patients, i.e., less than 180/105mmHg
2872269|NCT03443570|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take rituximab in combination with bortezomib at the indicated dose
2872270|NCT03443570|Active Comparator|control group|100 enrolled patients are randomly picked up to take rituximabalone at the indicated dose
2872271|NCT03443557||oral nutrition supplement group|hospitalized malnourished patients who were received oral nutrition supplement during hospital course
2872272|NCT03443557||control group|hospitalized malnourished patients who were received only hospital food during hospital course
2872273|NCT03443544||Intestinal origin|Either perianal abcess or rectal carcinoma
2872274|NCT03443544||Testicular Origin|Complicated epididymitis with fascitis,
2872275|NCT03443544||Urinary Origin|From urinary tract infection or fistulae from urethral trauma
2872276|NCT03443544||Cutaneous Origin|mostly folliculitis, and skin infections
2872277|NCT03443531|Experimental|TCM|Patients in this group will receive two types of TCM treatment, which are Bufei Huatan granule, Yifei Qinghua granule. The herbal extract twice daily for 24 weeks for lower dosage. The two granules are corresponding to the two traditional Chinese syndromes in sequence, which are syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung, Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung.
2872278|NCT03443531|Placebo Comparator|placebo TCM|Patients in this group will be given two placebo TCM treatment, which are which are placebo Bufei Huatan granule, placebo Yifei Qinghua granule, corresponding to the two traditional Chinese syndromes in sequence, which are syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung, Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung.
2872279|NCT03443518|Experimental|Psoas Compartment Block (PCB)|30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical land mark for psoas plexus, also normal saline 0.9% IV infusion will be in the same rate of the Remifentanil infusion for the other group.
2872456|NCT03442218|Placebo Comparator|Saline solution|Vaginal wash with saline solution
2872280|NCT03443518|Experimental|L.A infiltration /Remifentanil infusion|L.A infiltration (lidocaine) 5 ml of 2% will be injected subcutaneous as L.A infiltration then Remifentanil infusion with rate 0.03-0.1 μg / kg / min to achieve Visual Analog Scale 3 or less.
2872281|NCT03443492|Experimental|SLOG|800 mg/m2 gemcitabine at a fixed rate of 10 mg/m2/min followed by a 2-hour intravenous infusion of oxaliplatin on day 1 plus twice daily oral S-1 80-120 mg/day (based on BSA) and oral leucovorin 30 mg twice a day on day 1 to day 7, every 14 days as a cycle
2872282|NCT03443492|Experimental|mFOLFIRINOX|oxaliplatin at a dose of 85 mg/m2, given as a 2-hour infusion, with the addition, after 30 minutes, of irinotecan at a dose of 150 mg/m2, given as a 90-minute infusion. The treatment was immediately followed by a continuous intravenous infusion via central venous catheter of leucovorin 400 mg/m2 given as a 2-hour infusion and 5-FU 2400 mg/m2 over a 46-hour period on day 1 every 14 days/cycle.
2872283|NCT03443479||Patients with type II ARF|All patients with type II respiratory failure that were deemed by the treating physician to require ventilatory support either with non-invasive ventilation (NIV) or High-Flow Nasal Cannula (HFNC).
2872284|NCT03443466|Experimental|Epidural electrical stimulation (EES)|n=20
2872285|NCT03443466|Active Comparator|Loss of resistance (LOR)|n=20
2872286|NCT03443453|Experimental|MIV-711 ABCD|Subjects will first receive the tablet formulation under fasted conditions (A) followed by the tablet formulation administered under fed conditions (B). Thereafter they will receive the capsule formulation under fasted conditions (C) followed by the capsule formulation administered under fed conditions (D).
2872287|NCT03443453|Experimental|MIV-711 CDAB|Subjects will first receive the capsule formulation under fasted conditions (C)followed by the capsule formulation administered under fed conditions (D). Thereafter they will receive the tablet formulation under fasted conditions (A) followed by the tablet formulation administered under fed conditions (B).
2872288|NCT03443427|Experimental|Schedule 1|100 planned subjects receiving three doses of the GSK3277511A investigational vaccine at Visit 1 (Day 1), Visit 3 (Day 61) and Visit 5 (Day 181) and one dose of placebo at Visit 7 (Day 361).
2872289|NCT03443427|Experimental|Schedule 2|100 planned subjects receiving three doses of the GSK3277511A investigational vaccine at Visit 1 (Day 1), Visit 3 (Day 61) and Visit 7 (Day 361) and one dose of placebo at Visit 5 (Day 181).
2872290|NCT03443414|Experimental|0.75 mg RPL554|
2872291|NCT03443414|Experimental|1.5 mg RPL554|
2872292|NCT03443414|Experimental|3 mg RPL554|
2872293|NCT03443414|Experimental|6 mg RPL554|
2872294|NCT03443414|Placebo Comparator|Placebo|
2872295|NCT03443401||patient participants|patients with chronic low back pain receiving standard physical therapy care
2872296|NCT03443401||Physical Therapy clinician participants|Licensed physical therapist that is providing standard physical therapy care for a patient participant
2872297|NCT03443388|Active Comparator|Part 2: Helmet|After a screening period, 20 subjects with drug resistant epilepsy will be assigned to wear one Hövding inflatable helmet in their daily lives. Subjects will fill out questionnaires about their seizures, injuries, and the circumstances of inflation when it occurs. Participation may last for up to 6 months.
2872298|NCT03443388|No Intervention|Part 2: No Helmet|After a screening period, 20 subjects with drug resistant epilepsy will be assigned to not wear an inflatable helmet. Subjects will fill out questionnaires about their seizures and injuries. Participation may last for up to 6 months.
2872299|NCT03443375|Experimental|Nonperiodized resistance training|The Nonperiodized group performed was an intervention based on resistance exercise program with a constant intensity.
2872300|NCT03443375|Experimental|Daily undulating periodized|The Daily undulating periodized program was an intervention based on daily alterations on exercise load. .
2872301|NCT03443375|No Intervention|Control group|The control group remained their regular habits of life during all study period, without engaging in physical exercise programs.
2872302|NCT03443362||Chronic urticaria|50 consecutive chronic urticaria patients receiving medical care within the CHU Brugmann Hospital. Diagnose according to the European Academy of Allergy and Clinical Immunology (EAACI) guidelines.
2872303|NCT03443362||Control|20 healthy control patients, without chronic urticaria. Patients coming to the CHU Brugmann hospital for the excision of atypical naevi.
2872304|NCT03443349|Other|Use of the medical Device: Vibwife One|"The medical device will be used according to its market authorization.~Because it will be used for the first time in pregnant women, the following three step application procedure has been determined:~First five pregnant women use the device for 10 minutes. Each of them in a position and module proposed by the midwife with the agreement of the woman.~Next 10 pregnant women use the device for 20 minutes. Again, position and module according to the decision of the midwife with the agreement of the woman.~All the remaining pregnant women (35) use the device for 30 minutes. Position and module according to the decision of the midwife with the agreement of the woman.~During the intervention period, position and module might be changed once if required."
2872305|NCT03443323|Experimental|OST-S Intervention group|
2872306|NCT03443323|No Intervention|Treatment as usual control group|
2872307|NCT03443310|Other|Ultrasound assessment of DVT|DVT ultrasound vs Clinical assessment in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
2872308|NCT03443297|Experimental|Early Feeding group|Active ingredient: maternal expressed breast milk Time of initiation of first feeding: 24 to 48 hours of age. Doses: Initially 4 hourly feeding will be started with 0.5 ml and 1 ml expressed breast milk in babies with birth weight <1200 grams and >1200 grams respectively. On the following day 3 hourly, thereafter 2 hourly feeding will be provided in both groups. Gradually amount of feeding will be increased after reaching 2 hourly feeding at the rate of 10 ml/kg/day for initial 10 days then 20ml/kg/day in 2 aliquots till full feeding(150ml/kg/day).For babies with birth weight <1200 gram, rate of feeding advancement 10 ml/kg/day till full feeds. Time of starting first feeding and time to reach full feeding, both will be documented in a questionnaire for each patient.
2872309|NCT03443297|No Intervention|Late Feeding group|Feeding with maternal breast milk will be given in conventional way
2872310|NCT03443284|Experimental|Intervention (Health Partner)|The mobile health (mHealth) product, Health Partner for Knees and Hips (Health Partner), is a combination of an iPhone or iPod Touch Operating System (iOS) mobile application (app) and a health care provider (HCP) portal.
2872454|NCT03442231||Journey™ UNI Unicompartmental Knee System|Subjects previously received knee replacement
2872311|NCT03443284|Other|Control|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Providence Health & Services.
2872312|NCT03443271|Experimental|Group T (TAP Block with Bupivicaine)|Ultrasound guided TAP block will be performed in this group. Bupivicaine 0.25 % 20 ml will be administered in the block on either side.
2872313|NCT03443271|Placebo Comparator|Group C (TAP Block with Placebo drug)|Ultrasound guided TAP block will be performed in this group. 0.9 % Saline 20 ml will be administered in the block on either side.
2872314|NCT03443258|Experimental|Intervention Group (IG)|Patients receive needs assessment tool integrated in nursing consultation in accordance with requirements by Danish Health and Medicine Board follow-up program for HNC patients. The consultation consists of 6 steps 1. Welcoming patient; 2. Introducing patient to assessment tool; 3. Discuss symptoms and concerns patient wishes to discuss; 4. Follow up on patients symptoms, concerns and emotional reactions/problems; 5. Accompany/support patient during appointment with surgeon and in cooperation with patient and surgeon ensure that problems arising from the tool needing medical attention are focused on; 6. Continue the consultation after appointment with surgeon; refer patient to multi-disciplinary team members when needed
2872315|NCT03443258|No Intervention|Control Group (CG)|CG will receive standard care according to the Danish Health and Medicine Board's follow-up program for HNC patients. At present this is done by a staff nurse interviewing the patient, who is a member of the rehabilitation team who perform nursing consultations. The interview takes place after the appointment with the surgeon. The nurse refers the patient to physical rehabilitation if needed
2872316|NCT03443245||Stroke patients|Patient will have thrombolysis treatment as part of their standard care.
2872317|NCT03443245||Healthy Volunteers|Healthy volunteers to act as control group for stroke patients.
2872318|NCT03443232|Experimental|Cryoballoon ablation group|Persistens atrial fibrillation in Cryoballoon ablation group will apply cryoablation
2872319|NCT03443232|Other|Radiofrequency ablation group|Persistens atrial fibrillation in Radiofrequency ablation group will apply Radiofrequency ablation
2872320|NCT03443219|Experimental|Spritztube®|The patients were randomly allocated to two groups by using computer-generated numbers.In Spritztube® group, Spritztube® was inserted into each patient after anesthesia induction.
2872321|NCT03443219|Active Comparator|LMA Supreme™|The patients were randomly allocated to two groups by using computer-generated numbers.In vgroup, LMA Supreme™was inserted into each patient after anesthesia induction.
2872322|NCT03443206|Experimental|Intervention|This condition will include access to a website that includes a social component, in addition to psychoeducation and access to resources.
2872323|NCT03443206|Active Comparator|Control|This condition will include access to a website that includes psychoeducation and access to resources.
2872324|NCT03443193|Experimental|Linear training|Linear training consists to a progressive improvement of the training load during the 3 month-program.
2872325|NCT03443193|Experimental|Non-linear training|Non-linear training consists to an undulating progressive improvement of the training load during the 3 month-program.
2872326|NCT03443180|Other|Dietary intervention|Participants will be asked to remove food containing gluten and ATI from their diets for 4 weeks.
2872327|NCT03443167|Active Comparator|Intervention group|Training on emergency telephone numbers and mnemonics
2872328|NCT03443167|Sham Comparator|Control group|Sham generic formation on the cardiopulmonary arrest.
2872329|NCT03443141|Experimental|Vitamin E dressing|Patients will receive a Vitamin E-containing dressing over the wound
2872330|NCT03443141|Sham Comparator|Standard dressing|Patients will receive a standard dressing over the wound
2872331|NCT03443128|Experimental|Vinorelbine monotherapy treatment|Patients will be treated with Vinorelbine. Four weeks as a course. There are 20 courses in total.
2872332|NCT03443102||SARS survivors|First-line HCWs infected during the SRAS-CoV pandemic in Peking University People's Hospital, China. Diagnose was further confirmed by SARS-CoV seropositive results.
2872333|NCT03443102||Controls|"Coworkers of the infected HCWs, who also exposed to SARS patients or specimens. Infection was further excluded by SARS-CoV seronegative results.~Healthy controls matched for age, sex and disease condition, but without exposures to SARS virus."
2872334|NCT03443089|Experimental|Test formulation|Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/mL+ estradiol cypionate 5 mg/mL (Depomês®, Biolab Sanus Farmacêutica Ltda.)
2872335|NCT03443089|Active Comparator|Reference formulation|Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole (Cyclofemina®, Millet Roux Ltda.)
2872336|NCT03443076|Experimental|EPA + DHA in SMEDS Formulation|Subject will receive a single 500 mg oral dose of EPA + DHA in a SMEDS formulation
2872337|NCT03443076|Active Comparator|EPA + DHA (Lovaza)|Subject will receive a single 840 mg oral dose of EPA + DHA as Lovaza
2872338|NCT03443063|Experimental|Group 1: Severe Renal Impairment|Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] 15 to 29 milliliters per minute (mL/min/1.73 square meter [m^2]) and not on dialysis) will receive a single dose of 10 milligrams (mg) lemborexant (oral tablet) in the morning after an overnight fast.
2872339|NCT03443063|Experimental|Group 2: Normal Renal Function|Participants with normal renal function (eGFR ≥90 mL/min/1.73 m^2) demographically matched to participants in Group 1 will receive a single dose of 10 mg lemborexant (oral tablet) in the morning after an overnight fast.
2872340|NCT03443050|Experimental|Experimental|Balance training on unstable surfaces
2872341|NCT03443050|Active Comparator|Control|Balance training on stable surface
2872342|NCT03443037||Amantadine group|Patients admitted to the critical care with diagnosis of coma state who have received amantadin 200 mg / day for fourteen days according to İCU protocols decided by primary physician
2872343|NCT03443037||Control group|Patients admitted to the critical care with diagnosis of coma state who haven't received amantadin
2872344|NCT03443024|Experimental|Group 1|Lebrikizumab, 125 mg every 4 weeks
2872345|NCT03443024|Experimental|Group 2|Lebrikizumab, 250 mg every 4 weeks
2872346|NCT03443024|Experimental|Group 3|Lebrikizumab, 250 mg every 2 weeks
2872347|NCT03443024|Placebo Comparator|Group 4|Placebos, every 2 weeks
2872457|NCT03442205|Experimental|Group A|
2872348|NCT03443011|Experimental|participants|All participants will be examined with both CT techniques. First a low dose CT without intravenous contrast followed by the standard method, a full dose CT with intravenous contrast
2872349|NCT03442998|Other|Suburban|Study participants will wall on a suburban sidewalk setting for 50 minutes.
2872350|NCT03442998|Other|Nature|Study participants will wall on a nature path setting for 50 minutes.
2872351|NCT03442985|Experimental|Palovarotene 2.5 mg daily regimen|
2872352|NCT03442985|Experimental|Palovarotene 5.0 mg daily regimen|
2872353|NCT03442985|Placebo Comparator|Placebo regimen|
2872354|NCT03442972|Experimental|Teduglutide|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose
2872355|NCT03442972|Placebo Comparator|Placebo|Placebo, subcutaneous, single dose
2872356|NCT03442959||patient with primary resection of the Small Intestinal TNE|
2872357|NCT03442959||patient without primary resection of the Small Intestinal TNE|
2872358|NCT03442946||INS|Patients in need of a cardiovascular surgery will be included in this observational study. The focus is on the nutrition therapies provided to these critically ill patients according to institutional or international nutrition guidelines, what ever applies for the participating sites.
2872359|NCT03442933|Active Comparator|Road cycling|They will be examined before and after 3 hour road cycling task.
2872360|NCT03442933|Active Comparator|Mountain Biking|They will be examined before and after 3 hour mountain-biking task.
2872361|NCT03442920|Experimental|Obese women|Obese women who participated exercise programme.
2872362|NCT03442920|No Intervention|Normal weighted|Normal weighted women with non-periodontitis
2872363|NCT03442907|Experimental|Study group|"The intraoperative blood pressure target for all patients in the study group is the mean arterial pressure (+ 10mmHg maximum) derived from the prior 24-hour blood pressure measurement.~To achieve the blood pressure target, fluid or vasoactive substances will be used."
2872364|NCT03442907|Active Comparator|Control group|Study patients of the control group are treated according to the standard operating procedures (SOP) of the Department of Anaesthesiology, University Medical Centre Hamburg Eppendorf.
2872365|NCT03442894|Active Comparator|Standard PT Treatment|"This group will receive manual therapy and exercise interventions provided by their physical therapist. The treatment will occur for 10 sessions over 6 weeks.~Interventions: Manual therapy interventions including mobilization and manipulation of the shoulder girdle spine and ribcage. Exercise interventions will include strengthening and flexibility exercises for rotator cuff and shoulder girdle musculature."
2872366|NCT03442894|Experimental|Standard PT Treatment plus DN|In addition to the standard PT interventions, the Dry Needling (DN) group will receive 6 DN sessions as part of their rehabilitation visits.
2872367|NCT03442894|Sham Comparator|Standard PT Treatment plus Sham DN|In addition to the standard PT treatment, patients in the sham DN group will receive 6 sessions of sham DN intervention.
2872368|NCT03442881||benign adnexal mass|pathological examination of the specimen after excision reveals benign criteria
2872369|NCT03442881||Malignant adnexal mass|pathological examination of the specimen after excision reveals malignant criteria
2872370|NCT03442868|Experimental|High frequency rTMS|High frequency rTMS will be applied to different neural loci based on the randomized sessions.
2872371|NCT03442829|Experimental|Sweet food consumption|Sweet breakfasts. Participants are asked to consume a sweet breakfast every day. All foods will be provided.
2872372|NCT03442829|Active Comparator|Non-sweet food consumption|Non-sweet breakfasts. Participants are asked to consume a non-sweet breakfast every day. All foods will be provided.
2872373|NCT03442816|Experimental|MHRC camera|Subjects will undergo a retina imaging session with the MHRC camera.
2872374|NCT03442803|Experimental|Propofol TCI|Delivery of Propofol via a Target-controlled infusion pump for procedural sedation.
2872375|NCT03442790|Experimental|Agitated Saline Method|The proper placement of the central venous line will be confirmed using agitated saline under ultrasound vision
2872376|NCT03442790|Active Comparator|Chest X-Ray Confirmation|The proper placement of the central venous line will be compared with chest x-ray obtained in supine position after central line placement
2872377|NCT03442777|Experimental|Study Arm 1 (on top of standard of care)|"Allevyn® brand silicone adhesive multilayer foam dressings~Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith & Nephew (Allevyn® brand)."
2872378|NCT03442777|Experimental|Study Arm 2 (on top of standard of care)|"Mepilex® brand silicone adhesive multilayer foam dressings~Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand)."
2872379|NCT03442777|No Intervention|Study Arm 3 (standard of care)|"Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~No silicone adhesive multilayer foam dressings will be applied on the skin sites of interest for this trial (sacrum, heel right/left, greater trochanter right/left)."
2872380|NCT03442764|Experimental|Group 1|Active Treatment for participants with base target trough concentration
2872381|NCT03442764|Experimental|Group 2|Active Treatment for participants with higher target trough concentration
2872382|NCT03442764|Placebo Comparator|Placebo|Placebo Group
2872383|NCT03442751|Active Comparator|CXL Treatment Group|Study eye receives Paracel 1, Paracel 2 R0185 and irradiated using KXL High Power System (10 J)
2872384|NCT03442751|Sham Comparator|Sham Treatment/Control Group|Sham eye receives Paracel Placebo and irradiated using KXL High Power System (2 J)
2872385|NCT03442738||Group I Endocuff group|Group I Endocuff cap use
2872386|NCT03442738||Group II standard colonoscope|Group II standard colonoscope, no further device used
2872387|NCT03442725|Other|Severely decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
2872388|NCT03442725|Other|Normal renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
2872389|NCT03442725|Other|Mildly decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
2872390|NCT03442725|Other|Moderately decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
2872391|NCT03442712|Active Comparator|Treatment arm 1|"Auricular acupressure (AA) plus smartphone App:~Semen Vaccaria laccaria will be applied on one ear only, and seed plasters will be changed every 3 days to 4 days to the opposite ear. Subjects will be requested to apply pressure on the acupoints thrice per day. The subjects will install the smartphone App specifically designed for this study. The App will send out regular AA reminders to the subjects. The total treatment period will be 8 weeks."
2872392|NCT03442712|Active Comparator|Treatment arm 2|The participants will only receive AA treatment and are required to perform daily self-administered seeds pressing.
2872393|NCT03442712|No Intervention|Treatment arm 3|The participants in the waitlist control group will maintain their usual dietary and exercising patterns.
2872394|NCT03442699|Experimental|Cognitive Behavioral Therapy|Participants will receive up to 10 daily sessions of cognitive behavioral therapy (depending on length of stay), for about an hour each day. During this time the therapist will work to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.
2872395|NCT03442686|Experimental|Spring 2018 Compass Course Group|Two groups of up to 15 participants (30 total) will receive the study intervention during Spring 2018. All participants will complete study questionnaires before and after the Spring sessions.
2872396|NCT03442686|No Intervention|Spring 2018 Comparison Group|Two groups of up to 15 participants will receive the study intervention in Fall 2018. All participants will complete study questionnaires before and after the Spring sessions. Those who enroll in the study and agree to participate in the Fall sessions will serve as a no-treatment comparison group.
2872397|NCT03442673|Active Comparator|CG (Chemotherapy/G-CSF) - Regime|Vinorelbine 35 mg/m2 at day 1 as an i.v. infusion over 10 minutes or gemcitabine 1250 mg/m2 as a 30 minutes infusion at day 1. G-CSF will be started at day 4 at 10mcg/kg b.w. split in two daily doses, until the end of the stem cell collection procedure, with the first collection attempt on day 8.
2872398|NCT03442673|Experimental|G (G-CSF) - Regime|G-CSF at 10mcg/kg b.w. split in two daily doses starting from day 1 until the end of the stem cell collection procedure, with the first collection attempt on day 5.
2872399|NCT03442660|Other|Data collection|An electronic data capture (EDC) system will be used to collect data in electronic format. Data will be collected at the enrolment visit, at the follow-up visit (8 weeks +/-2 weeks) and 1 to 4 days after the follow-up visit.
2872400|NCT03442647|Active Comparator|Living donors|sinistrin clearance dynamic measurement
2872401|NCT03442647|Active Comparator|ADPKD patients|sinistrin clearance dynamic measurement
2872402|NCT03442647|Active Comparator|Patients with primary renal tumor|sinistrin clearance dynamic measurement
2872403|NCT03442634|Experimental|Early Hydration Group|this study group will get 200 ml of sugar free water within 1 hour after cesarean section followed by oral hydration as per patients' desire then starting semisolid and solid foods when patients are open bowel Intervention: Early Oral Hydration
2872404|NCT03442634|Active Comparator|Traditional Hydration Group|this study group will get 200 ml of sugar free water after 6 hours after cesarean section followed by oral hydration as per patients' desire then starting semisolid and solid foods when patients are open bowel Intervention: Traditional Oral Hydration
2872405|NCT03442621|Experimental|Relacorilant Fasted|Relacorilant Fasted
2872406|NCT03442621|Experimental|Relacorilant with a high fat breakfast|Relacorilant with a high fat breakfast
2872407|NCT03442621|Experimental|Relacorilant with a moderate breakfast|Relacorilant with a moderate breakfast
2872408|NCT03442608|Experimental|mild hypothermia|Device: Zoll 2000 and/or CureWrap 3500 cooling system,lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
2872409|NCT03442608|Placebo Comparator|northermia|normal physical cooling methods,like ice bag, conditionally required.
2872410|NCT03442595||Cases|patients with uncontrolled type 2 diabetes mellitus that participate in the MedStar Diabetes Pathway
2872411|NCT03442595||Matched controls|patients with uncontrolled type 2 diabetes that match the cases on 5 criteria and received standard of care diabetes management with a MedStar provider
2872412|NCT03442582||Afluria|Afluria exposure in pregnancy
2872413|NCT03442569|Experimental|Open-label, single arm, Phase II|Nivolumab and ipilimumab with panitumumab
2872414|NCT03442556|Experimental|Treatment (docetaxel, carboplatin, rucaparib camsylate)|"INDUCTION: Patients receive docetaxel IV and carboplatin IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive rucaparib camsylate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2872415|NCT03442543|Experimental|charcoal|
2872416|NCT03442543|Experimental|silver wire|
2872417|NCT03442530|Active Comparator|Tobacco Treatment As Usual (TTAU)|Eligible women assigned to the control group will be informed of the risks of tobacco use and benefits of quitting using the ACOG 5A's approach by their healthcare provider.5 This standard takes approximately 5-15 minutes, and is offered at each prenatal and postpartum appointment. The study coordinator will invite participants to complete the tobacco use questionnaires (TUQ),urine cotinine validation, and Expired Air Carbon Monoxide (EACO) analysis to assess ongoing tobacco use at the designated time points.
2872453|NCT03442244|Placebo Comparator|Vehicle foam|"Each subject has each of the 2 investigational products applied at the same time on 2 sites on the back. The location on which the treatments are applied is randomised in a double-blinded manner.~Foam vehicle does not contain active ingredients"
2872458|NCT03442205|Experimental|Group B|
2872418|NCT03442530|Experimental|ToPIC|Eligible women assigned to the intervention will receive TTAU plus ToPIC administered by the CTTS. At least once monthly, at routinely scheduled prenatal visits or through telephone, the CTTS will provide cessation counseling. The CTTS will invite participants to complete TUQs,urine cotinine validation and EACO analysis to assess ongoing tobacco use at the designated time points.
2872419|NCT03442517|Experimental|Group-based phone counseling (GBPC)|Participants will take part in weekly group-based phone counseling sessions for 6 weeks starting between 16-30 weeks of pregnancy.
2872420|NCT03442517|Active Comparator|Usual prenatal care|Participants will continue their usual prenatal care.
2872421|NCT03442504|Other|FES PET/CT|"The images will be made immediately after the injection of the FES in a dynamic acquisition, of 30 minutes, centered on a positive FDG lesion. The imaging will then be completed 1 hour after the injection, after obtaining a urination, by an acquisition whole body (from the top of the skull to the root of the thighs or more if element on FDG or conventional imaging) which will be performed in the supine position with arms around the body. During the PET / CT scan, patients will breathe spontaneously. The acquisition will last 30 minutes."
2872422|NCT03442491||Hayman's Haemostatic Suture|Women that had major Post-partum Haemorrhage, defined as postpartum blood loss in excess of 2000 ml, resistant to pharmacologic treatment and that underwent Hayman's Haemostatic Suture.
2872423|NCT03442478|Experimental|2D/3D Tomosynthesis|2D/3D Tomosynthesis images will be obtained in addition to standard mammographic images.
2872424|NCT03442465||Regenerative Osseous Surgery|Participants undergoing osseous reconstructive surgery (RegOS) for bone sarcoma
2872425|NCT03442465||Other Reconstructive Surgery|Participants undergoing other reconstructive surgery for bone sarcoma
2872426|NCT03442452|Other|Electronic Decision Aid|For this study, we will be testing a novel electronic decision aid to improve Acute Myeloid Leukemia patients' understanding of their illness, prognosis, and treatment options.
2872427|NCT03442439|Active Comparator|Nutrition and Play Intervention (NPI)|Half of the mother-child dyads who are enrolled into the study will be randomly assigned to the Nutrition and Play Intervention group.
2872428|NCT03442439|Experimental|Family Nurture Intervention (FNI)|Half of the mother-child dyads who are enrolled into the study will be randomly assigned to the Family Nurture Intervention group.
2872429|NCT03442426|Experimental|Intervention Cohort|Integrated model of primary care
2872430|NCT03442413|Experimental|2-[18F]-FA PET/CT|Subjects will participate in two separate 10-hour PET/CT Scan Sessions (each with 2 hours of actual PET/CT scanning): one following an overnight abstinence and one following two overnights of abstinence. To achieve and confirm two overnights of abstinence, participants will present to the inpatient CHPS the day prior to the scheduled scan and stay overnight
2872431|NCT03442400|Experimental|FFR/iFR arm|Volcano iFR/FFR Verrata Plus coronary pressure/flow wire
2872432|NCT03442387|Experimental|Positive frame|The numerical expressions were presented in a positive way: e.g. treatment was successful for 4 out of 10 persons.
2872433|NCT03442387|Experimental|Negative frame|The numerical expressions were presented in a negative way: e.g. treatment was unsuccessful for 6 out of 10 persons.
2872434|NCT03442374|Experimental|Exercise|A single bout of moderate intensity lumbar extensor muscle exercise.
2872435|NCT03442374|No Intervention|Non-exercise|No exercise intervention.
2872436|NCT03442361||Intralipid|Standard soybean oil-based therapy
2872437|NCT03442361||Clinoleic|Olive oil based therapy
2872438|NCT03442348|Experimental|Omega 3 fatty acid supplements|Participants in this arm (N>32) will be required to take one 500mg capsule of Omega 3 along with a meal daily for 6 weeks.
2872439|NCT03442348|Active Comparator|Inulin fibre|The participants in the control arm (N>32) will be asked to take 20 g of fibre (inulin fibre) per day for a period of 6 weeks.
2872440|NCT03442335||Recurrent miscarriage: 2+ miscarriages|Women who suffered 2 or more unexplained recurrent miscarriages.
2872441|NCT03442335||Extreme recurrent miscarriage: 5+ miscarriages|Women who suffered 5 or more unexplained recurrent miscarriages.
2872442|NCT03442322|Active Comparator|transdisciplinary approach|The transdisciplinary approach that is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability
2872443|NCT03442322|Active Comparator|multidisciplinary approach|The multidisciplinary approach that is problem-based and draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
2872444|NCT03442309|Experimental|Simple Prevention|"One drop (0.05 ml) of silver diamine fluoride (Advantage ArrestTM) solution at 38% concentration (2.24 F-ion mg/dose) will be dispensed per child. Posterior tooth surfaces to be treated will be dried, after which the SDF will be applied with a micro-brush to all asymptomatic carious lesions and to all pits and fissures on bicuspids and molar teeth for thirty seconds. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
2872445|NCT03442309|Active Comparator|Complex prevention|"Pits and fissures on all bicuspids and molar teeth will be sealed with glass ionomer sealants (GC Fuji IX). Glass ionomer sealants (interim therapeutic restorations) will also be placed on all frank asymptomatic carious lesions. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
2872446|NCT03442296|Experimental|Immediate Treatment Group|Immediate treatment with Baltimore HEARS intervention
2872447|NCT03442296|Placebo Comparator|Delayed Treatment Group|3-month delayed treatment with Baltimore HEARS intervention
2872448|NCT03442283||Supplementation|
2872449|NCT03442283||No Supplementation|
2872450|NCT03442257|Experimental|SMS group|Participants in the intervention group will receive four semi-personalized messages per week in addition to their usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
2872451|NCT03442257|No Intervention|Control|The control group will receive usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
2872452|NCT03442244|Experimental|LEO 90100 foam|Each subject has each of the 2 investigational products applied at the same time on 2 sites on the back. The location on which the treatments are applied is randomised in a double-blinded manner LEO 90100 foam contains Calcipotriol hydrate 52.2 μg/g (equivalent to 50.0 μg/g calcipotriol) plus Betamethasone dipropionate 0.643 mg/g
2872459|NCT03442205|Experimental|Group C|
2872460|NCT03442192|No Intervention|PrEP Standard of Care|The standard of care (SOC) arm will receive traditional face-to-face clinical PrEP services. The practice offers CDC-guided PrEP activities including peer PrEP case management for linkage and retention services and has numerous providers with extensive training in HIV prevention and treatment services. Patients randomized to the SOC arm will receive all services offered by the clinic without study intervention. Medical information will be obtained by the research team through patient interview and/or medical record abstraction
2872461|NCT03442192|Active Comparator|PrEP Care Anywhere Services|The PrEP Care Anywhere intervention adapts peer PrEP case management for virtual delivery and provides clinical services through a tele-health program, delivered by the same clinic providers. After an initial face-to-face intake clinical evaluation within the clinic, patients randomized to the PrEP Care Anywhere Virtual TeleHealth Visit arm will then receive the remaining PrEP clinical evaluations via telemedicine using the HIPPA compliant polycom platform. Case management interventions will be conducted virtually via the PrEPme application, telephone consultation, text, or email.
2872462|NCT03442179|Active Comparator|Treatment Group|Anesthesiologists in the treatment group use the unprocessed EEG waveforms and EEG spectrogram to maintain appropriate levels of unconsciousness for general anesthesia while avoiding burst suppression.
2872463|NCT03442179|No Intervention|Control Group|Anesthesiologists managing patients assigned to the control group will manage each anesthetic based on their clinical judgment, using standard monitoring required by American Society of Anesthesiologists (ASA), which include cardiac and respiratory monitoring, but not EEG monitoring.
2872464|NCT03442166|Active Comparator|LED group|The patients (n=17) will receive daily intra and extra oral LED applications from the immediate postoperative period up to 7 days after the surgical procedure. The LED irradiation will be performed in two areas, one intra and one extra oral. The LED to be used in the intraoral site will be red, 660+/-20nm wavelength, 5 mW power, 2.7J/cm2 energy density for 7 min, 2J energy per point, knowing that the 6 irradiated spots will have 12J in total. In the extra oral site the infra-red LED will be used, 850+/-20nm wavelength, power of 5mW, 3.8J/cm2 of energy density for 10 min, 3J of energy per point, knowing that 36 will be irradiated, so we will have 108J in total.
2872465|NCT03442166|Sham Comparator|Sham group|Patients (n=17) will be treated in the same way as the LED group. The person in charge of the application will simulate the intraoral and extraoral irradiation by positioning the LED in the same locations described for the LED group, but the equipment will be kept off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of application.
2872466|NCT03442153|Experimental|Solgar No7|Aflapin 100 mg and Collagen UC2 40 mg by mouth every 24 hours for 90 days
2872467|NCT03442153|Placebo Comparator|Placebo for Solgar No7|Placebo 1 Capsule by mouth, every 24 hours for 90 days
2872468|NCT03442140|Experimental|Experimental|Patients who completed the Baylor Martha Foster Lung Center Pulmonary Rehabilitation Program at least six months ago will participate in the 12-week harmonica program
2872469|NCT03442127|Other|Patient Group|Program users
2872470|NCT03442114|Experimental|Hydroxyurea SDM Toolkit (H-SDM)|During the H-SDM toolkit condition, sites will develop methods for identifying Eligible Patients & Monitoring Progress, have the opportunity to use Implementation Tools, and will use the Visit Decision Aids. The H-SDM toolkit has four visit decision aids to support parents in their decision about hydroxyurea: pre-visit brochure, in-visit issue card, after-visit booklet and video narratives {videos of parents telling their story about how they made a decision about hydroxyurea).
2872471|NCT03442114|Active Comparator|Clinician Pocket Guide|In this condition, sites will provide current guidelines for offering hydroxyurea and use the American Society of Hematology (ASH) pocket guide as a reference. ASH developed 'The Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease' clinician pocket guide based on the National Heart, Lung, and Blood Institute's Evidence Based Management of Sickle Cell Disease: Expert Panel Report, 2014.'
2872472|NCT03442088|Experimental|Apremilast for Treatment of Psoriasis with the AM-endotype|Psoriasis patients with the AM-endotype will be followed during treatment over 16 weeks with 5 monthly individual blood draws will be enrolled.
2872473|NCT03442088|No Intervention|Untreated healthy control|Untreated healthy controls will also be enrolled and will provide two blood draws. These are needed to maintain quality control of the normal levels of the biomarkers being tested.
2872474|NCT03442075||Group 1|Group 1 an analgesic suppository was applied
2872475|NCT03442075||Group 2|Group 2 was administered analgesic orally
2872476|NCT03442075||Group 3|Group 3 was given trans rectal gel
2872477|NCT03442075||Group 4|Group was performed peri prostatic infiltration.
2872478|NCT03442075||Group 5|Group was performed by placebo oral
2872479|NCT03442062|Experimental|AFIX|Clinics randomly assigned to this arm will receive an Assessment Feedback Incentives and eXchange (AFIX) consultation delivered in-person by a state health department immunization specialist.This arm includes ~ 90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
2872480|NCT03442062|Experimental|Physician-to-physician engagement|Clinics randomly assigned to this arm will receive physician-to-physician (P2P) consultations delivered remotely to providers by physician educators. This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
2872481|NCT03442062|Experimental|AFIX + P2P|Clinics randomly assigned to this arm will receive both an Assessment Feedback Incentives and eXchange (AFIX) consultation and a physician-to-physician (P2P) consultation.This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
2872482|NCT03442062|Other|Active Intervention Control|Clinics randomly assigned to this arm will receive a brief non-HPV vaccine related quality improvement consultation. This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
2872483|NCT03442049|Experimental|Study group|Spinal stabilization exercises in addition to home exercise program
2872484|NCT03442049|Active Comparator|Control Group|Home exercise program
2872485|NCT03442036|Active Comparator|Through-the-Needle Technique|"Perineural catheters are inserted through a straight hollow-bore needle.~The perineural catheter will then be used to infuse local anesthetic directly onto the nerve to provide postoperative pain control."
2872550|NCT03441711||Group 2|normal sFlt-1/PlGF ratio
2872551|NCT03441698|Experimental|Genuine acupuncture (A)|Genuine acupuncture (A) with neutral communication (A1) or positive communication (A2)
2872486|NCT03442036|Experimental|Suture-Method Technique|"Perineural catheters are attached to the back of a hollow suture-shaped needle that pulls the catheter adjacent to the target nerve.~The perineural catheter will then be used to infuse local anesthetic directly onto the nerve to provide postoperative pain control."
2872487|NCT03442023|Experimental|Chlorhexidine 2%|Subjects in this arm will receive standard care plus mouth rinse every 12 hours via spray with 2% chlorhexidine concentration, one week intervention, Drug: Chlorhexidine gluconate at 2%
2872488|NCT03442023|Active Comparator|Chlorhexidine 0.12%|Subjects in this arm will receive standard care plus mouth rinse every 12 hours via spray with 0.12% chlorhexidine concentration, one week intervention, Drug: Chlorhexidine gluconate at 0.12%
2872489|NCT03442010||People with adverse drug event|People with adverse drug event
2872490|NCT03442010||People without adverse drug event|People without adverse drug event
2872491|NCT03441997|Experimental|Full mind-body exercises|Participants will be trained to perform a type of mind-body exercise that involves low intensity exercise and body movements similar to Tai Chi. Participants will be asked to exercise 2 times per day for 8 weeks.
2872492|NCT03441997|Active Comparator|Light mobility exercises: Control Group|The Light mobility exercises group will perform a similar exercise as the experimental group. However without a few components. Participants will be asked to exercise two times per day for 8 weeks.
2872493|NCT03441997|No Intervention|Healthy Controls|Healthy females will be asked to make one visit to complete aerobic exercise test, questionnaires, and provide blood samples.
2872494|NCT03441984|Experimental|Subjects with treatment sequence ABC|The subjects in Part 1 of the study, will receive a single dose of treatment A= adult TRIUMEQ (DTG 50 mg/ABC 600 mg/3TC 300 mg, 1 conventional tablet) administered as direct-to-mouth, in TP1; treatment B=Pediatric TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg, 10 dispersible tablets) administered as a dispersion and taken immediately in TP2; and treatment C=Pediatric TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg, 10 dispersible tablets) administered as direct-to-mouth in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
2872495|NCT03441984|Experimental|Subjects with treatment sequence BCA|The subjects in Part 1 of the study, will receive treatment B in TP1, treatment C in TP2 and treatment A in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
2872496|NCT03441984|Experimental|Subjects with treatment sequence CAB|The subjects in Part 1 of the study will receive a single dose each of, treatment C in TP1, treatment A in TP2 and treatment B in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
2872497|NCT03441984|Experimental|Subjects with treatment sequence ACB|The subjects in Part 1 of the study will receive, treatment A in TP1, treatment C in TP2 and treatment B in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
2872498|NCT03441984|Experimental|Subjects with treatment sequence BAC|The subjects in Part 1 of the study will receive a single dose each of, treatment B in TP1, treatment A in TP2 and treatment C in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
2872499|NCT03441984|Experimental|Subjects with treatment sequence CBA|The subjects in Part 1 of the study will receive a single dose each of, treatment C in TP1, treatment B in TP2 and treatment A in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
2872500|NCT03441984|Experimental|Subjects with treatment sequence DEF|The subjects in Part 2 of the study, will receive a single dose of treatment D= Adult DTG (50 mg, 1 conventional tablet) and adult 3TC (300 mg, 1 conventional tablet) administered as direct-to-mouth, in TP1; treatment E= Pediatric DTG/3TC (DTG 5 mg/3TC 30 mg, 10 dispersible tablets) administered as a dispersion and taken immediately in TP2; and treatment F= Pediatric DTG/3TC (DTG 5 mg/3TC 30 mg, 10 dispersible tablets) administered as direct-to-mouth in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
2872501|NCT03441984|Experimental|Subjects with treatment sequence EFD|The subjects in Part 2 of the study, will receive a single dose respectively of treatment E in TP1, treatment F in TP2 and treatment D in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
2872502|NCT03441984|Experimental|Subjects with treatment sequence FDE|The subjects in Part 2 of the study, will receive a single dose of treatment F in TP1, treatment D in TP2 and treatment E in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
2872503|NCT03441984|Experimental|Subjects with treatment sequence DFE|The subjects in Part 2 of the study, will receive a single dose of treatment D in TP1, treatment F in TP2 and treatment E in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
2872504|NCT03441984|Experimental|Subjects with treatment sequence EDF|The subjects in Part 2 of the study, will receive a single dose of treatment E in TP1, treatment D in TP2 and treatment F in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
2872505|NCT03441984|Experimental|Subjects with treatment sequence FED|The subjects in Part 2 of the study, will receive a single dose of treatment F in TP1, treatment E in TP2 and treatment D in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
2872506|NCT03441958|Experimental|ECT-001 (UM171) expanded cord blood|"Patients will receive a nonmyeloablative conditioning regimen containing Fludarabine 30 mg/m2 x 3 days and total body irradiation 200 cGy.~The cord to be expanded is thawed 7 days prior to transplant and undergoes CD34+ selection. The CD34+ product will be placed in the fed-batch culture with UM171 for a 7-day expansion and is infused fresh on Day 0. The CD34- product is cryopreserved and will be thawed and infused on Day +1.~Patients will receive standard supportive care and GVHD prophylaxis with Mycophenolate mofetil and Tacrolimus."
2872507|NCT03441945|No Intervention|control|"The patients swallowed the capsule with water in the lying position.After finishing the stomach examination, the operation of the capsule is adjusted to small bowel mode without magnetic control. Capsule entered the duodenum under physiological peristalsis. The position of the capsule was established using a real-time viewer. If the capsule failed to enter the duodenum after one hour, domperidone (10 mg) was orally administered."
2872508|NCT03441945|Experimental|magnetic steering|"After finishing the stomach examination as the control protocol, the capsule was lifted with the magnetic control, then rotating the capsule until the camera end oriented toward the pylorus . Next, the endoscopist could drag the capsule close to the pylorus with the guidance magnet robot, waiting for the open of pylorus. Once the pylorus opened, the capsule could enter the duodenum with gastric peristalsis. After reaching the duodenal bulb, capsule was held to the maximum position of Z, then the capsule would scan the duodenal bulb automatically with the mode 360° automatic scanning."
2872509|NCT03441932|Active Comparator|Dysphagia screening failed arm|"Subjets within the this arm will have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree. An ENT resident blinded to the result of the screening test will do this intervention"
2872510|NCT03441932|Active Comparator|Dysphagia screening passed arm|"Subjets within the this arm will have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree. An ENT resident blinded to the result of the screening test will do this intervention"
2872511|NCT03441919||Patients with type 1 diabetes, poor glycemic control|"Diagnosis based on clinical criteria~Duration of diabetes ≥10 years~Age ≥20 years, ≤ 60 years~HbA1c >64 mmol/mol"
2872512|NCT03441919||Patients with type 1 diabetes, good glycemic control|"Diagnosis based on clinical criteria~Duration of diabetes ≥10 years~Age ≥20 years, ≤ 60 years~HbA1c <64 mmol/mol"
2872513|NCT03441919||Healthy subjects|"Absence of disease, no use of medication~Matched for age, gender and BMI~HbA1c <42 mmol/mol"
2872514|NCT03441893|Experimental|Patients with ulcerative colitis|
2872515|NCT03441893|Experimental|Participants (control group)|
2872516|NCT03441893|Active Comparator|UC patients (cohort 1)|
2872517|NCT03441893|Active Comparator|UC patients (cohort 2)|
2872518|NCT03441893|Active Comparator|UC patients (cohort 3)|
2872519|NCT03441867|Experimental|(CBT-Sz) - PNES|Participants with history of a head injury and confirmed PNES will complete 2 brain fMRI scans along with 12 weeks of one hour CBT-Sz sessions by a trained therapist.
2872520|NCT03441867|Experimental|(CBT-Sz) - PTE|Participants with history of a head injury and confirmed post-traumatic epilepsy (PTE) will complete 2 brain fMRI scans along with 12 weeks of one hour CBT-Sz sessions by a trained therapist.
2872521|NCT03441867|Active Comparator|TBI Control|Participants with TBI will complete 2 brain fMRI scans.
2872522|NCT03441854||HFNC group|The investigators will prospectively include 30 patients admitted to 13- bed PICU after liver transplantation and treated with HFNC oxygen delivery after extubation.
2872523|NCT03441854||Control Group|For each study group patient, a match control subject (matching criteria: age ± 10%, PaO2/FiO2 ± 30, diagnosis, Model for End-Stage Liver Disease (MELD) ± 10%) will be chosen from a group of 70 patients treated with conventional oxygen delivery (Venturi Mask) during the previous 2 years.
2872524|NCT03441841|Experimental|Lidocaine + prilocaine|Single topical dose of a combination of nanoencapsulated lidocaine (2.5%) and prilocaine (2.5%) formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
2872525|NCT03441841|Active Comparator|Lidocaine|Single topical dose of lidocaine nanoencapsulated gel (2.5 %) formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
2872526|NCT03441841|Active Comparator|Prilocaine|Single topical dose of prilocaine (2.5 %) nanoencapsulated gel formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
2872527|NCT03441828|Experimental|Group DNMB|"Deep Neuromuscular Block group Intervention: maintenance of a deep neuromuscular block by infusion of rocuronium at the starting dose of 0.3-0.6 mg / kg / h, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point)"
2872528|NCT03441828|Active Comparator|Group MNMB|"Moderate Neuromuscular Block group Intervention: maintenance of a moderate neuromuscular block. neuromuscular blockade will be maintained with intravenous bolus of rocuronium (0.15-0.25 mg/kg) titrated to obtain a TOF count of 1-3.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point)"
2872529|NCT03441815|Experimental|XC8 2 mg|Cohort 1: 6 subjects were randomized in a 2:1 ratio to be treated either with 2 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
2872530|NCT03441815|Experimental|XC8 10 mg|Cohort 2: 6 subjects were randomized in a 2:1 ratio to be treated either with 10 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
2872531|NCT03441815|Experimental|XC8 50 mg|Cohort 3: 6 subjects were randomized in a 2:1 ratio to be treated either with 50 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
2872532|NCT03441815|Experimental|XC8 200 mg|Cohort 4: 10 subjects were randomized in a 4:1 ratio to be treated either with 200 mg XC8 (8 subjects) or placebo (2 subjects, see placebo arm).
2872533|NCT03441815|Placebo Comparator|Placebo|Placebo comparator arm consists of 8 subjects (2 subjects in each cohort).
2872534|NCT03441802|Active Comparator|Cases|
2872535|NCT03441802|Other|Controls|
2872536|NCT03441789|Experimental|Otezla plus Enstilar foam|Subjects randomized to this group will receive Otezla 30mg by mouth twice daily and Enstilar applied to affected areas once daily
2872537|NCT03441789|Placebo Comparator|Otezla plus vehicle foam|Subjects in this group will take Otezla 30mg by mouth twice daily and vehicle foam applied to affected areas once daily
2872538|NCT03441776|Other|Randomized GVRT|Randomized Generalized Vestibular Rehabilitation Treatment (8 treatments) as part of standard of care (not research visits)
2872539|NCT03441776|Other|Randomized IVRT|Randomized Individualized Vestibular Rehabilitation Treatment (3 treatments) as part of standard of care (not research visits)
2872540|NCT03441763|Experimental|Normal participants|Emed foot device 3 times/measure to determine foot pressure in normal participants. .
2872541|NCT03441763|Experimental|Over weight participants|Emed foot device 3 times/measure to determine foot pressure in over weight participants.
2872542|NCT03441763|Experimental|Obese participants|Emed foot device 3 times/measure foot pressure in obese participants.
2872543|NCT03441750|Experimental|metformin plus standard lifestyle intervention|Metformin starting dose is 850mg/d, it will be titrated to 850mg twice daily after 2 weeks and maintained until the last subject completes 2 years' intervention.
2872544|NCT03441750|Other|Standard lifestyle intervention|Standard lifestyle advice will be united for all subjects by providing special booklet.
2872545|NCT03441737|Experimental|Exercise|Aerobic exercise intervention
2872546|NCT03441737|Active Comparator|Non-Exercise|Non-aerobic exercise intervention
2872547|NCT03441724||STEMI before PCI|ST-segment elevation, recording acquired before coronary intervention
2872548|NCT03441724||STEMI after PCI|ST-segment elevation, recording acquired from the same patients after coronary intervention
2872549|NCT03441711||Group 1|elevated sFlt-1/PlGF ratio
2872552|NCT03441698|Placebo Comparator|Sham Acupuncture (B)|Sham acupuncture (B) with neutral communication (B1) or positive communication (B2)
2872553|NCT03441698|Active Comparator|Rest (C)|Rest (C) with neutral communication (C1) or positive communication (C2)
2872554|NCT03441685|Experimental|Verb strategies|"The examiner labels each target word and performs the corresponding action six times in each condition. She elicits the target word from the participant two times per word per condition and provides feedback on accuracy each time. In the semantic cues condition, the examiner prompts the child to perform the target action twice. In the syntactic cues condition, instead of only saying the target word with the present progressive verb marker, the examiner uses two forms of complete sentences while performing the action (i.e., I am X-ing, and See. I X.). In the combined condition, the examiner prompts the child to perform the target action and consistently uses complete sentences."
2872555|NCT03441672|Experimental|Intervention|Participants in the intervention group interact with the game technology to learn about prenatal screening, in addition to usual care provided in the clinic.
2872556|NCT03441672|No Intervention|Control|Participants in the control group learn about prenatal screening through usual care in the clinic.
2872557|NCT03441633||Group 1. Apixaban|"Patients who are on treatment with apixaban.~1a. patients who have initiated with apixaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~1b. patients who previously have been treated with VKA in the 12 months before index date."
2872558|NCT03441633||Group 2. VKA|"Patients who are on treatment with VKA.~2a. patients who have initiated with VKA as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~2b. patients who previously have been treated with VKA in the 12 months before index date."
2872559|NCT03441633||Group 3. Dabigatran|"Patients who are on treatment with dabigatran.~3a. patients who have initiated with dabigatran as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~3b. patients who previously have been treated with VKA in the 12 months before index date."
2872560|NCT03441633||Group 4. Rivaroxaban|"Patients who are on treatment with rivaroxaban.~4a. patients who have initiated with rivaroxaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~4b. patients who previously have been treated with VKA in the 12 months before index date."
2872561|NCT03441620|Placebo Comparator|Control|Calorie and fiber-matched control powder
2872562|NCT03441620|Experimental|Strawberry one serving|Freeze-dried powder equivalent to one serving fresh strawberries per day.
2872563|NCT03441620|Experimental|Strawberry two-half servings|Freeze-dried powder equivalent to 2.5 serving fresh strawberries per day.
2872564|NCT03441607|Active Comparator|Drug|Intervention: 40 mg of micronized human amnion chorion membrane biologic (mHACMb); administered 1(x) on first visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
2872565|NCT03441607|Placebo Comparator|Placebo|Intervention: 1cc of saline will be administered as a one time injection on 1 visit, administered 1(x) on first visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
2872566|NCT03441607|Active Comparator|Drug (2)|Intervention: 100 mg of micronized human amnion chorion membrane biologic (mHACMb); administered 1(x) on first visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
2872567|NCT03441607|Placebo Comparator|Placebo (2)|Intervention: 2ccs of saline will be administered as a one time injection on 1 visit; administered: 1(x) on first visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
2872568|NCT03441581|Experimental|Cohort 1|IBS-D participants with evidence of BAM treated with Eluxadoline 100 mg oral tablets twice daily (BID) with food.
2872569|NCT03441581|Experimental|Cohort 2|IBS-D participants without evidence of BAM treated with Eluxadoline 100 mg oral tablets BID with food.
2872570|NCT03441568|Experimental|BAY987534|Infants and children with quiescent Atopic Dermatitis
2872571|NCT03441555|Experimental|Venetoclax + Alvocidib|Venetoclax administered orally once daily (QD) and Alvocidib administered as an intravenous infusion on Days 1, 2, and 3 for all 28-day treatment cycles. Different combinations of dose levels for venetoclax and alvocidib may be explored.
2872572|NCT03441542|Experimental|Data-assisted Case Navigation|Patients are recruited and consented into the study by the patient navigator after which the navigator provides assistance with scheduling, reminders, and transportation. The navigator is also charged with responding to patient questions, and monitoring and documenting if and when patients achieve HCV care milestones. Each month, the project will update the Grady Liver Clinic HCV patient registry, to generate information about the patient's HCV care progress and use this information to develop instructions sheets regarding the expected care milestones to be achieved that month for each patient. During the month, the navigator will participate in project meetings and report on milestone achievement and barriers for patients assigned to the experimental arm of the study.
2872573|NCT03441542|Active Comparator|Standard of Care|Patients are recruited and consented into the study by the patient navigator at which time they will be reminded of their infection, consequences of untreated disease, and the availability of study sponsored antiviral treatment should they seek it. Patients will not be subsequently contacted by the study. Patients who seek treatment without patient navigation services will receive the same study provided HCV pre-treatment care and study provided treatment drugs when indicated. Self-referral to care and antiviral therapy when indicated are known to be effective in curing HCV among some patients, this arm is classified as an active comparator.
2872574|NCT03441529|Experimental|Treatment Sequence 1 (AB)|Participants will receive Treatment A as a single oral dose of 1000 milligram (mg) lumicitabine (4*250 mg tablets) on Day 1 of period 1 followed by Treatment B as a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) together with piperacillin/tazobactam administered as three 30-minute Intravenous (IV) infusions of 4.5 gram (g) piperacillin/tazobactam (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1 of period 2. A washout period of at least 21 days will be maintained between each treatment period.
2872575|NCT03441529|Experimental|Treatment Sequence 2 (BA)|Participants will receive Treatment B on Day 1 of period 1 followed by Treatment A on Day 1 of period 2. A washout period of at least 21 days will be maintained between each treatment period.
2872576|NCT03441516|Experimental|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400mg bid + Donepezil 10mg qd for 24 weeks
2872577|NCT03441516|Active Comparator|Aripezil® Tab.|Donepezil 10mg qd for 24 weeks
2873657|NCT03434080||Patients|Children with cerebral palsy, ages 3 months up to 5 years of age.
2872578|NCT03441503|Experimental|Child HCAHPS: Automated Administration|"Child HCAHPS: Automated day-of-discharge survey~On the day of discharge at the hospital, parents will be contacted to solicit survey responses using patient televisions (GetWell) as follows:~Day 0 (Day of likely discharge): Respondent will be promoted to complete Child HCAHPS on their television as part of the routine discharge process. Respondent will also be asked for their email address to complete post-discharge items and their appropriate contact information will be collected.~Days 2-42: Standard hospital protocol (i.e., mail, email, or IVR) with the post-discharge questions."
2872579|NCT03441503|No Intervention|Standard Administration of Child HCAHPS|Parents will be contacted to complete Child HCAHPS using the standard protocol for mail, email, or IVR survey administration. The surveys will be administered by the survey vendor contracted by the participating site to administer Child HCAHPS.
2872580|NCT03441490|Active Comparator|ICBT standard|Internet-based cognitive behavioural therapy with therapeutic guidance through mail
2872581|NCT03441490|Experimental|ICBT chat|Internet-based cognitive behavioural therapy with therapeutic guidance through chat
2872582|NCT03441490|Experimental|ICBT learning support|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through mail
2872583|NCT03441490|Experimental|ICBT with learning support and chat|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through chat
2872584|NCT03441464|Experimental|1st Tier Dose Level|3 patients administered single dose of LUM015 at 0.5 mg/kg. Imaging with the LUM imaging device will be performed ex vivo on resected tissue.
2872585|NCT03441464|Experimental|2nd Tier Dose Leel|3 patients administered single dose of LUM015 at 1.0 mg/kg. Imaging with the LUM imaging device will be performed ex vivo on resected tissue.
2872586|NCT03441464|Experimental|3rd Tier Dose Level|After evaluation of the fluorescence signal observed with the LUM imaging device in the three other cohorts,the subsequent 3 patients will receive a dose of 0.5-1.5 mg/kg.
2872587|NCT03441464|No Intervention|Auto-fluorescence|No LUM015 injection will be given to three (3) patients to measure baseline tissue fluorescence. The tissue will still be imaged ex-vivo using the LUM Imaging Device
2872588|NCT03441438|Active Comparator|Control|Patients without asthma or aspirin intolerance who may or may not react to alcoholic beverages
2872589|NCT03441438|Active Comparator|Aspirin Tolerant Asthma|Patients with asthma who are tolerant to aspirin and/or other NSAIDs and note sensitivity to alcoholic beverages
2872590|NCT03441438|Active Comparator|Aspirin Intolerant Asthma / AERD|Patients with AERD who note sensitivity to alcoholic beverages
2872591|NCT03441425|No Intervention|Control|The control group participants will complete a cardiac arrest simulation scenario on the first day in which the mannequin returns to spontaneous circulation at the end of the scenario. They will then complete a retention simulation session three months later.
2872592|NCT03441425|Experimental|Unexpected death|The experimental group participants will complete a cardiac arrest simulation scenario on the first day in which the mannequin unexpectedly dies at the end of the scenario. They will then complete a retention simulation session three months later.
2872593|NCT03441412|Experimental|Ticagrelor/Epinephrine/Metoprolol|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg−1 min−1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
2872594|NCT03441399|Experimental|Escalating Incentives|Participants assigned to the escalating financial incentives will receive an increasing financial incentive for taking their antidepressant medication for the initial 6 weeks of treatment.
2872595|NCT03441399|Experimental|De-escalating Incentives|Participants assigned to the de-escalating financial incentives will receive a decreasing financial incentive for taking their antidepressant medication for the initial 6 weeks of treatment.
2872596|NCT03441399|No Intervention|Control|Participants in this condition will receive usual care.
2872597|NCT03441386|Experimental|Cognitive Study|Cognitive Responses was analyzed after different intensities physical exercise sessions.
2872598|NCT03441373|Experimental|XC8 20 mg and Placebo (Group A)|XC8 20 mg orally. 2 tablets of XC8 10 mg +2 tablets of Placebo 100 mg (in total 4 tablets) once daily during 5 days of treatment period
2872599|NCT03441373|Experimental|XC8 100 mg and Placebo (Group B)|"XC8 100 mg orally.~1 tablet of XC8 100 mg +2 tablets of Placebo 10 mg + 1 tablet of Placebo 100 mg (in total 4 tablets) once daily during 5 days of treatment period"
2872600|NCT03441373|Experimental|XC8 200 mg and Placebo (Group C)|XC8 200 mg orally. 2 tablets of XC8 100 mg +2 tablets of Placebo 10 mg (in total 4 tablets) once daily during 5 days of treatment period.
2872601|NCT03441373|Placebo Comparator|Placebo (Group D)|Placebo orally.
2872602|NCT03441360|Experimental|Eribulin mesylate 1.4 mg/m^2: RMS|Pediatric participants with relapsed/refractory rhabdomyosarcoma (RMS) will receive eribulin mesylate administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 milligrams per meters squared (mg/m^2). Participants will continue study therapy until progression of disease (per Response Evaluation Criteria In Solid Tumors [RECIST] 1.1), intolerable toxicity, or withdrawal of consent.
2872603|NCT03441360|Experimental|Eribulin mesylate 1.4 mg/m^2: NRSTS|Pediatric participants with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) will receive eribulin mesylate administered as an IV infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 mg/m^2. Participants will continue study therapy until progression of disease (per RECIST 1.1), intolerable toxicity, or withdrawal of consent.
2872604|NCT03441360|Experimental|Eribulin mesylate 1.4 mg/m^2: EWS|Pediatric participants with Ewing sarcoma (EWS) will receive eribulin mesylate administered as an IV infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 mg/m^2. Participants will continue study therapy until progression of disease (per RECIST 1.1), intolerable toxicity, or withdrawal of consent.
2872605|NCT03441347|Experimental|Specific rehabilitation program|Specific, personalized, multidisciplinary rehabilitation program consisting of physical- and occupational therapy.
2872606|NCT03441347|Other|Usual Care|Usual care for people with neuralgic amyotrophy, may vary per individual
2872980|NCT03438773|Other|Tacrolimus|Control group - Tacrolimus twice daily in addition to standard of care.
2872607|NCT03441334|Experimental|High Frequency rTMS|The High Frequency rTMS group will receive real repetitive transcranial magnetic stimulation (rTMS) in 5Hz at 90% of resting motor threshold delivered to the bilateral motor areas via a figure of 8 air-filmed coil. The stimulation is structured as 24 10-second trains with a inter-train interval of 30 second.
2872608|NCT03441334|Sham Comparator|Sham rTMS|The Sham rTMS group will receive the same protocol but delivered via a sham coil which generates the same auditory and cutaneous feedback as the real stimulation. However, there will be no active stimulation.
2872609|NCT03441321|Experimental|Group I (focusing on indoor tanning and healthy body image)|Participants periodically read the content on the study-specific secret Facebook group related to living a healthy lifestyle including avoiding indoor tanning and excessive ultraviolet exposure, managing stress, healthy eating, promoting physically active lifestyles, and promoting a healthy body image, and participate in the group by providing reactions, commenting on the posts, or by sharing study relevant information within the group for 8 weeks.
2872610|NCT03441321|Active Comparator|Group II (focusing on other health topics)|Participants participate in secret Facebook groups that utilize content from the intervention content library related to other health topics of interest (e.g., physical activity, healthy eating, alcohol misuse prevention, stress reduction, sleep) for 8 weeks.
2872611|NCT03441308|Active Comparator|Educational method of group treatment|Educational method of group treatment based on regular meals and food based on Nordic nutrition recommendations. The method has been developed by a district nurse at Ljungby. Ten meetings in groups of 6-8 participants over 6 months. Group meeting number 5 includes short individual consultations. In addition, individual consultation after group meeting 1 and 10.
2872612|NCT03441308|Placebo Comparator|Dietary advice|The control group is offered dietary advice according to the Swedish National Food Agency's guidelines for overweight and obesity (including brochures) at one occasion.
2872613|NCT03441295|Experimental|Study 1 Ligamys|Repair Surgery.
2872614|NCT03441295|Experimental|Study 1 Internal Bracing|Repair Surgery.
2872615|NCT03441295|Experimental|Study 2 Internal Bracing|Repair Surgery.
2872616|NCT03441295|Active Comparator|Study 2 Reconstruction|Reconstructive Surgery.
2872617|NCT03441282||ASA Patients I|"Age 18-80 years old, English-speaking, not on current Fentanyl/opioid therapy, no use of opioid medications in the 3 months prior to surgery, scheduled for elective surgery at UAB main.~A normal healthy patient Healthy, non-smoking, no or minimal alcohol use"
2872618|NCT03441282||ASA Patients III|"Age 18-80 years old, English-speaking, not on current Fentanyl/opioid therapy, no use of opioid medications in the 3 months prior to surgery, scheduled for elective surgery at UAB main.~A patient with severe systemic disease Substantive functional limitations; One or more moderate to severe diseases. Examples include (but not limited to): poorly controlled DM or HTN, COPD, morbid obesity (BMI ≥40), active hepatitis, alcohol dependence or abuse, implanted pacemaker, moderate reduction of ejection fraction, ESRD undergoing regularly scheduled dialysis, premature infant PCA < 60 weeks, history (>3 months) of MI, CVA, TIA, or CAD/stents."
2872619|NCT03441269|Active Comparator|400mg/dose|Oral Ibuprofen dose of 400mg/dose for mild to moderate acute pain in ED patients.
2872620|NCT03441269|Active Comparator|600mg/dose|Oral Ibuprofen dose of 600mg/dose for mild to moderate acute pain in ED patients.
2872621|NCT03441269|Active Comparator|800mg/dose|Oral Ibuprofen dose of 800mg/dose for mild to moderate acute pain in ED patients.
2872622|NCT03441256|Experimental|Intervention|All participant in the intervention group will undergo the LION procedure and subsequent neurostimulation.
2872623|NCT03441256|Active Comparator|Control|All participants in the control group will be issued with a device for neuromuscular electrical stimulation.
2872624|NCT03441243||Case group:Cesarean section urgently|- 43 patients had an emergency caesarean section between 01/01/2015 and 31/12/2016.
2872625|NCT03441243||Case group:Hemorrhage of deliverance|- 85 patients had haemorrhage of the delivery with need for a transfusion between 01/01/2015 and 31/12/2017.
2872626|NCT03441243||Control group: delivery physiological low path|- A control group will consist of 128 patients who had a physiological low birth delivery over the same period.
2872627|NCT03441230|Active Comparator|Circumference of 13 cm, sphere form (diameter of 4 cm)|
2872628|NCT03441230|Active Comparator|Circumference of 13 cm, cylinder form, length 11 cm|
2872629|NCT03441230|Active Comparator|Circumference of 16 cm, sphere form (diameter of 5 cm)|
2872630|NCT03441230|Active Comparator|Circumference of 16 cm, cylinder form, length 11 cm|
2872631|NCT03441230|Active Comparator|Circumference of 16 cm, cylinder form, length 18 cm|
2872632|NCT03441230|Active Comparator|Circumference of 19 cm, sphere form (diameter of 6 cm)|
2872633|NCT03441230|Active Comparator|Circumference of 19 cm, cylinder form, length 11 cm|
2872634|NCT03441230|Active Comparator|Circumference of 22 cm, sphere form (diameter of 7 cm)|
2872635|NCT03441230|Active Comparator|Circumference of 25 cm, sphere form (diameter of 8 cm)|
2872636|NCT03441230|Active Comparator|Circumference of 28 cm, sphere form (diameter of 9 cm)|
2872637|NCT03441217|Experimental|Hyoscine Butylbromide 20Mg/1mL Injection|Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide IV upon arrival in the Labor and Delivery Unit (4-5 cms).
2872638|NCT03441217|Placebo Comparator|Saline solution|Nulliparous women with gestations at term receive Saline Solution IV upon arrival in the Labor and Delivery Unit (4-5 cms).
2872639|NCT03441204|Active Comparator|LTOT 24 h/day (intervention)|Long-term oxygen therapy (LTOT) prescribed 24 h/day. The LTOT is provided according to standard clinical practice using oxygen concentrator, cylinders or liquid oxygen and administered mainly through nasal prongs. The oxygen dose (l/min) is titrated aiming at a PaO2 on oxygen > 8 kPa in accordance with current routine practice and management guidelines.
2872640|NCT03441204|Active Comparator|LTOT 15 h/day (control)|Long-term oxygen therapy (LTOT) prescribed 15 h/day. The LTOT is provided according to standard clinical practice using oxygen concentrator, cylinders or liquid oxygen and administered mainly through nasal prongs. The oxygen dose (l/min) is titrated aiming at a PaO2 on oxygen > 8 kPa in accordance with current routine practice and management guidelines.
2872641|NCT03441191|Experimental|Active AVS|Active AVS consists of a 30-minute pulsing lights (red, green, blue) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
2873273|NCT03436732|Experimental|2/Dose Expansion|Dose expansion - patients with mesothelioma treated with LMB-100+SEL-110 at RP2D
2872642|NCT03441191|Placebo Comparator|Placebo Control AVS|The placebo control AVS program consists of 30 minutes of constant dim light that slowly changes in color, and a steady monotone at ultra-low (<1 Hz) frequency (outside of the entrainment range).
2872643|NCT03441178|Experimental|Colectomy/Gynecological/Thoracic|Any colectomy/gynecological/thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.
2872644|NCT03441152|Experimental|tDCS+CT|application of tDCS in combination with CT
2872645|NCT03441152|Sham Comparator|Sham tDCS|application of sham tDCS in combination with CT
2872646|NCT03441152|Active Comparator|CT|application of CT
2872647|NCT03441139|Experimental|Cryotherapy + medical analgesics|Percutaneous Cryotherapy and medical analgesics according to the investigator's discretion
2872648|NCT03441139|Active Comparator|Medical analgesics|Medical analgesics alone according to the investigator's discretion
2872649|NCT03441126||Multicenter Quality Improvement program|Locally developed and reliably implemented ICU Quality Improvement program to reduce blood culture use.
2872650|NCT03441113|Other|Cohort 1: Study GS-US-352-0101|Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-0101 for a maximum duration of 96 weeks.
2872651|NCT03441113|Other|Cohort 2: Study GS-US-352-1214|Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1214 for a maximum duration of 96 weeks.
2872652|NCT03441113|Other|Cohort 3: Study GS-US-352-1154|Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1154 for a maximum duration of 96 weeks.
2872653|NCT03441100|Experimental|Experimental: IMA202 Product|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~One dose of IMA202 product will be infused intravenously. Four dose levels will be evaluated. At least two patients per cohort will be treated.~Post-infusion of IMA202 product, administration of low dose recombinant human interleukin-2"
2872654|NCT03441087|Other|Transvaginal ultrasound|Transvaginal ultrasound was applied 216 women with abnormal uterine bleeding.The transvaginal ultrasound diagnoses were compared with the received endometrial samples.
2872655|NCT03441087|Other|Hysteroscopy|Hysteroscopy was also performed under general anesthesia.Hysteroscopy was performed by a single operator (NNY).The operator and two supervising endoscopists were blinded to the ultrasound results.After the hysteroscopy, endometrial sampling was also done. The diagnoses were compared with the received endometrial samples.
2872656|NCT03441074|Experimental|Intervention Group|Patients randomly assigned to intervention group will get enhanced olfactory stimuli during the perioperative period
2872657|NCT03441074|No Intervention|Non-intervention Group|Patients randomly assigned to non-intervention group will not get any olfactory stimuli during the perioperative period
2872658|NCT03441061|Experimental|Inotuzumab Ozogamicin|"Participants receive Inotuzumab Ozogamicin by vein over about 1 hour on Days 1, 8, and 15 of Cycle 1 and Days 1 and 8 of Cycles 2-6.~Each cycle is 28 (+/- 7) days."
2872659|NCT03441048|Experimental|IV infusion of Lintuzumab AC225 following CLAG-M chemotherapy|CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m2/day IV over two hours on days 2-6; cytarabine 2 gm/m2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy. Dose-escalation will be conducted according to a 3+3 design. The initial dose of Lintuzumab-Ac225 will be 0.25 uCi/kg (Dose level 1), and the highest dose administered will be 0.75uCi/kg.
2872660|NCT03441035||Adults, uncomplicated|Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.
2872661|NCT03441035||Adults, complicated|Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until hospital discharge or postoperative day 21. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points. A infusion of deuterium labeled phenylalanine will be given in the ICU at 1-3 occasions to determine the synthesis rate of albumin.
2872662|NCT03441035||Children|Children undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. P-albumin and B-Hb is only taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.
2872663|NCT03441022|Experimental|Cardioversion|Amiigo watch during atrial fibrillation cardioversion. Optional sub-study: additional 30 days wearing Amiigo watch as well as BodyGuardian device.
2872664|NCT03440996|Experimental|Clinpro™ 5000|Participants will use Clinpro™ 5000 to brush their teeth for two minutes twice daily for 4 months.
2872665|NCT03440996|Experimental|Clinpro™ Tooth Crème|Participants will use Clinpro™ Tooth Crème to brush their teeth for two minutes twice daily for 4 months.
2872666|NCT03440996|Active Comparator|MI-Paste Plus|Participants will use MI-Paste Plus to brush their teeth for two minutes twice daily for 4 months.
2872667|NCT03440983|Experimental|MRI data acquiring in healthy volunteers|MRI data acquiring in healthy volonteers
2872668|NCT03440970|Experimental|Lysine Chloride|Patients will be randomized to receive either lysine chloride or placebo. Patients will receive the study drug twice a day for 5 days of randomized therapy, starting after the completion of a blood volume assessment.
2872669|NCT03440970|Placebo Comparator|Placebo|Patients will be randomized to receive either lysine chloride or placebo. Patients will receive the study drug twice a day for 5 days of randomized therapy, starting after the completion of a blood volume assessment.
2872670|NCT03440957|Other|Osteopathy treatment|
2872671|NCT03440944|Active Comparator|Ultrasound Guided Peripheral IV Catheter|Patients if randomized to this group will receive a standard ultrasound guided peripheral IV. The IV is 4.88cm in length.
2872672|NCT03440944|Active Comparator|Midline Catheter|Patients if randomized to this group will receive a midline catheter. The catheter is 10cm in length.
2872673|NCT03440918|Active Comparator|Baseline Antimicrobial Stewardship|Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
2872674|NCT03440918|Experimental|Procalcitonin-Guided Antimicrobial Stewardship|In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
2872675|NCT03440892||1|
2872676|NCT03440879|Experimental|ADT group|Prostate cancer patients currently receiving androgen deprivation therapy (Zoladex)
2872677|NCT03440879|No Intervention|No-ADT group|Prostate cancer patients without any history of receiving any form of androgen deprivation therapy
2872678|NCT03440866|Experimental|Intervention|Administration of drugs concomitantly.
2872679|NCT03440866|No Intervention|Control|Administration of oral Mifepristone 600 mg and after interval of 48 hours administration of oral Misoprostol 400 mcg.
2872680|NCT03440853|Experimental|TASCCI|Patients randomized to TASCCI will receive a stepped-care approach of pharmaco and/or behavioral therapy for 12 weeks. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference.
2872681|NCT03440853|Other|Technology Delivered Health Education|Patients randomized to the Technology Delivered Health Education Intervention health education group will receive technology delivered health education material on topics relevant to dialysis.
2872682|NCT03440840|Experimental|Computer Training with active tDCS|Participants randomized to this arm will receive computer-based cognitive training using a car racing game with active transcranial direct current stimulation (tDCS).
2872683|NCT03440840|Active Comparator|Computer Training with sham tDCS|Participants randomized to this arm will receive computer-based cognitive training using a car racing game with sham transcranial direct current stimulation (tDCS).
2872684|NCT03440840|Placebo Comparator|Computer Training with or without tDCS|Participants in this arm will watch educational videos as a comparator to computer training with the car racing game (watching educational videos).
2872685|NCT03440827|Other|Child with slow-flow malformation|"Phase 1: Collect of experiences, perceptions, difficulties, needs and expectations of patients with slow-flow vascular malformation (for the age group of 11 to 15 years-old) using the focus group method.~Phase 2 : Administration of the scale of life's quality for validation."
2872686|NCT03440814|Experimental|DCCR|75 - 450 mg DCCR
2872687|NCT03440814|Placebo Comparator|Placebo|75 - 450 mg placebo for DCCR
2872688|NCT03440801|Experimental|Synergy|Biodegradable-polymer everolimus-eluting stent Synergy
2872689|NCT03440801|Active Comparator|Xience|Durable-polymer everolimus-eluting stent Xience
2872690|NCT03440775|Experimental|Experimental|
2872691|NCT03440775|Sham Comparator|Comparator|
2872692|NCT03440762|Other|AF awareness education|AF awareness education face to face
2872693|NCT03440749|Experimental|Children with Cerebral Palsy (PC)|Serial reaction time task: repeating a sequence of movements according to the luminous stimuli
2872694|NCT03440749|Active Comparator|Control Group|Serial reaction time task: of movements according to the luminous stimuli
2872695|NCT03440736|Active Comparator|Secukinumab 300 mg s.c.|Patients in arm A receive therapy with Secukinumab 300 mg s.c., which consists of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection is performed at week 24)
2872696|NCT03440736|Experimental|Secukinumab 300 mg s.c. and lifestyle intervention|Arm B: Patients in arm B receive therapy with Secukinumab 300 mg s.c., which consists of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection is performed at week 24). In addition they participate in a lifestyle intervention program.
2872697|NCT03440723|Active Comparator|Standard Dilation Exam|Participants receive two standard digital cervical dilation examinations conducted by two different physicians.
2872698|NCT03440723|Experimental|Dilation Exam with DilaCheck|Participants receive two cervical dilation examinations using DilaCheck devices conducted by two different physicians.
2872699|NCT03440710|Experimental|with BET|with BET and Tympanoplast
2872700|NCT03440710|Other|without BET|with Tympanoplast only
2872701|NCT03440697||Aortopathy- Closed to external enrollment|Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography)
2872702|NCT03440697||Syndromic- Open to external enrollment|"Subjects with a genetic diagnosis of Marfan Syndrome (MFS), Loeys-Dietz Syndrome (LDS), Vascular Ehlers-Danlos Syndrome (EDS)~•positive genetic testing and/or a previous cardiac study required to be eligible"
2872703|NCT03440697||Aortopathy with Positive Genetic Results- Open to Enrollment|Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography) who also have positive genetic testing results related to aortopathy.
2872704|NCT03440697||Aortic Valve Disease- Closed to enrollment|Subjects with aortic valve disease (bicuspid, unicuspid, or tricuspid disease)
2872705|NCT03440697||Family Members- Open to external enrollment|"Family members of eligible subjects~•Only family members of subjects with syndromic diagnoses are eligible for external enrollment at this time"
2872706|NCT03440697||Controls- Closed to external enrollment|Control subjects having tissue removed during a surgical procedure (e.g. coronary artery bypass graft surgery (CABG), cardiac transplant, etc.)
2872707|NCT03440684|Experimental|Healthy individuals|Forty-one healthy individuals were volunteer to participate in the study and 39 of them had no neurological disease, were from 18 to 65 years old, and had no upper extremity injuries. And they have joined to exercise training during 6 weeks.
2872708|NCT03440671|Experimental|Hutox Inj|Hutox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
2872709|NCT03440671|Active Comparator|Botox Inj|Botox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
2872710|NCT03440645|Experimental|Family or Household Members|
2872735|NCT03440437|Experimental|FS118 weekly|The initial cohorts will enroll sequentially as single-patient cohorts. If no DLT or ≥Grade 2 study drug related adverse event is observed, then dosing will proceed in a 3+3 design.
2873005|NCT03438591|Experimental|Cerclage-CRT (medtronic 4196 lead)|trans-coronary sinus intraseptal pacing (cerclage pacing) which technology to position the pacemaker lead into the septum for 'parahisian pacing'
2872711|NCT03440632|Other|FES start|"Start: 4 weeks 'adaptation phase' and 8 weeks 'FES phase'. Adaption phase: the stimulus (in Volt) will gradually be increased up to an effective level and the wear time has to be increased from 30 minutes to 6 hours a day. FES phase: the participants have to wear the FES device for minimal 6 hours a day during walking. Usual physiotherapy can be continued during the FES phase.~Second: after the FES phase, this group will enter the 'wash-out' period of 6 weeks for fading of the therapeutic effects, in which they return to their conventional therapy. Afterwards, 12 weeks of conventional therapy (orthoses/shoes and usual physiotherapy) with measurements at start and end will follow."
2872712|NCT03440632|Other|Conventional start|"Start: wearing usual orthoses/shoes on a daily basis for the first 12 weeks of the study. Usual physiotherapy can be continued.~Second: after 12 weeks this group will enter a 6 week watch out phase, and next be switched to FES treatment for 12 weeks, consisting of: 4 weeks 'adaptation phase' with gradual increase of the treatment and 8 weeks 'FES phase'."
2872713|NCT03440606|Experimental|MCAT Supervision Group|The 6-week 3-hour Mindful-Compassion Art Therapy (MCAT) supervision will include intervention elements of brief psycho-education, weekly mindfulness mediation that serve as a foundation to foster creative art making, reflective writing, group sharing and discussion.
2872714|NCT03440606|Experimental|Waitlist Control Group|Those assigned to the waitlist control group will not receive Mindful-Compassion Art Therapy (MCAT) supervision until approximately 1.5 month later; equivalent intervention and assessment procedures will be administered.
2872715|NCT03440593|Experimental|Measured Arm|Patients allocated to the measured energy expenditure (group M) will receive the intervention. Caloric delivery will target results of IC measurement.
2872716|NCT03440593|No Intervention|Estimated Arm|Patients allocated to the estimated energy expenditure (group E) will receive nutrition with caloric intake calculated based on the Penn State equation.
2872717|NCT03440580|Active Comparator|Intervention|The intervention school will receive the BOOSTH intervention: Boosth activity tracker, Boosth sync app, Boosht game app
2872718|NCT03440580|No Intervention|control group|The control school will receive the standard curriculum. After the study is finished the children of the control school will receive the Boosth product
2872719|NCT03440567|Experimental|Cohort I (avelumab, utomilumab, RICE)|Patients receive rituximab IV on day 1, etoposide phosphate IV on days 1-3, avelumab IV over 60 minutes on day 2, ifosfamide IV over 24 hours on day 2, and carboplatin IV on day 2 or rituximab IV on day 1, etoposide phosphate IV on days 1-3, avelumab IV over 60 minutes on days 2, utomilumab IV over 60 minutes on day 2, ifosfamide IV over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients may then undergo autologous hematopoietic stem cell transplantation.
2872720|NCT03440567|Experimental|Cohort II (avelumab, utomilumab, rituximab, ibrutinib)|Patients receive rituximab IV on day 1, avelumab IV over 60 minutes on days 2 and 16, and ibrutinib PO QD or rituximab IV on day 1, avelumab IV over 60 minutes on days 2 and 16, utomilumab IV on day 2, and ibrutinib PO QD. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
2872721|NCT03440554|Experimental|Whole Body Non-Contrast MRI|
2872722|NCT03440541|Experimental|treated|Patients who received patches of REGE pro on psoriasis lesion weekly for 8 weeks
2872723|NCT03440515|Experimental|prednisone|prednisone 30mg/day 3weeks oral, if on rash or pruritus prednisolone 20mg/day 3weeks -> 10mg/day->7.5mg/day->5mg/day->stop
2872724|NCT03440502||control group.|Parturients aged 18 or older (American Society of Anesthesiologist physical status II-III parturients ASA II-III) undergoing cesarean delivery under spinal anaesthesia, singleton pregnancy, full term, elective
2872725|NCT03440502||study group|The same as control group but with DM or gestational diabetes Parturients aged 18 or older (American Society of Anesthesiologist physical status II-III parturients ASA II-III) undergoing cesarean delivery under spinal anaesthesia, singleton pregnancy, full term, elective
2872726|NCT03440489|Other|six-minute walking test|physical performance of the muscle: measured by Gait speed test, Timed up and go test, six-minute walking test , 30 seconds chair stand test
2872727|NCT03440476|Placebo Comparator|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains only a reminder to participate in follow-up surveys.
2872728|NCT03440476|Active Comparator|Intervention plus feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receives the Feedback-only booster. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies. The content is clearly automatically generated.
2872729|NCT03440476|Active Comparator|Intervention plus feedback and personal contact booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receives the Feedback-plus-personal-contact booster. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies. The email is sent from a member of the research staff.
2872730|NCT03440463|Placebo Comparator|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains only a reminder to participate in follow-up surveys.
2872731|NCT03440463|Experimental|Intervention plus Norms-only booster|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and their own use.
2872732|NCT03440463|Experimental|Intervention plus Norms-plus-Strategies booster|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and their own use. It also includes reported harm reduction strategies, and other strategies they might consider.
2872733|NCT03440450|Experimental|Cohort 1: Treatment at 1.2 mg/m2|FF-10832 Gemcitabine Liposome Injection, 1.2 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
2872734|NCT03440450|Experimental|Cohort 2: Treatment at 2.4 mg/m2|FF-10832 Gemcitabine Liposome Injection, 2.4 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
2872736|NCT03440424|Experimental|Cohort A: Mild Hepatic Impairment (Child Pugh Class A)|Participants with mild hepatic impairment will receive a single 10 milligram (mg) dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 milliliters (mL) of water following an overnight fast of at least 10 hours.
2872737|NCT03440424|Experimental|Cohort B: Moderate Hepatic Impairment (Child Pugh Class B)|Participants with moderate hepatic impairment will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
2872738|NCT03440424|Experimental|Cohort C: Healthy Participants (Control)|Healthy participants matched to participants in Cohorts A and B will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
2872739|NCT03440411|Active Comparator|ARM A|Treatment with pom-dex Pomalidomide: 4 mg/day on days 1-21 Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
2872740|NCT03440411|Experimental|ARM B|Treatment with pom-cyclo-dex Pomalidomide: 4 mg/day on days 1-21 Cyclophosphamide: 50 mg every other day Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
2872741|NCT03440411|Experimental|ARM I|Early treatment patients will receive treatment at biochemical relapse with pomalidomide-dexamethasone (Arm A) or pomalidomide-cyclophosphamide-dexamethasone (Arm B) according to randomization. The randomization between Arm A and B will be disclosed at biochemical relapse.
2872742|NCT03440411|Active Comparator|ARM II|Late treatment patients will be randomized at biochemical relapse and they will start treatment with pomalidomide-dexamethasone (Arm A) or pomalidomide-cyclophosphamide-dexamethasone (Arm B) at the onset of CRAB symptoms/significant paraprotein increase. The randomization between Arm A and B will be disclosed at the onset of CRAB symptoms/significant paraprotein increase.
2872743|NCT03440398|Active Comparator|Open NSM|Conventional Nipple Sparing Mastectomy
2872744|NCT03440398|Experimental|Robotic NSM|Robotic Nipple-Sparing Mastectomy
2872745|NCT03440385|Experimental|Administration of oral Ozanimod|Subjects will receive ozanimod 0.92 mg capsule orally starting with a 7-day dose escalation
2872746|NCT03440385|Placebo Comparator|Administration of Placebo|Subjects will receive placebo capsule orally starting with a 7-day dose escalation
2872747|NCT03440372|Experimental|Administration of oral Ozanimod|Subjects will receive ozanimod 0.92 mg capsule orally starting with a 7-day dose escalation
2872748|NCT03440372|Placebo Comparator|Administration of Placebo|Subjects will receive placebo capsule orally starting with a 7-day dose escalation
2872749|NCT03440359|Other|# 1- no progesterone therapy|Letrrozole 2.5 to 5 mg oral tablet cycle day 3-7.Pelvic ultrasound at cycle day 11 or 12 and repeat if needed until leading follicle is >17 mm. Ovidrel 250 mcg injected sq. Timed intercourse or intrauterine insemination. No supplemental progesterone therapy in luteal phase
2872750|NCT03440359|Active Comparator|# 2 - Progesterone Vaginal Gel 8%|Letrrozole 2.5 to 5 mg oral tablet cycle day 3-7. Pelvic ultrasound at cycle day 11 or 12 and repeat if needed until leading follicle is >17 mm. Ovidrel 250 mcg injected sq. Timed intercourse or intrauterine insemination.Crinone 8% (progesterone) vaginal therapy was provided in luteal phase for 14 days .Administration was started the second day after intrauterine insemination or timed intercourse.
2872751|NCT03440346|Experimental|Few-foods diet intervention|
2872752|NCT03440320|Experimental|MY-Skills Intervention|Participants will complete an 8-week, 16 session class. Each class will consist of approxmiately an hour of yoga and self-management designed to meet the needs of a caregiving dyad with chronic pain.
2872753|NCT03440320|Active Comparator|MY-SKILLS control|Participants will complete an 8-week, 16 session class. Each class will consist of approxmiately an hour of exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain.
2872754|NCT03440307|Placebo Comparator|Email Only|Participants received weekly email about health and fitness education. No face-to-face intervention, and not provided any other information about bisphenol exposure.
2872755|NCT03440307|Experimental|Face-to-Face Meetings|Participants met with a counselor once per week for 3-weeks to reduce bisphenol exposure. Intervention included same weekly email about health and fitness education as Email only group, and a weekly face-to-face meetings to reduce bisphenol exposures from food, cosmetics, and packaged products. Women provided with bisphenol-free cosmetics, hygiene, and glass food/water containers.
2872756|NCT03440294|Other|with neoprene suit and life jacket|"Realization of the following examinations WITH neoprene suit and life jacket :~resting standard spirometry~maximum exercise testing. No drug and no placebo will be used in this arm."
2872757|NCT03440294|Other|without neoprene suit and life jacket|"Realization of the following examinations WITHOUT neoprene suit and life jacket :~resting standard spirometry~maximum exercise testing. No drug and no placebo will be used in this arm."
2872758|NCT03440281||Preterm group|included pregnant females delivered prior to completed 37 weeks of gestation. All participants underwent assessment of uterine artery Doppler indices and maternal serum homocysteine estimation
2872759|NCT03440281||Term group|Included pregnant females delivered after completed 37 weeks of gestation. All participants underwent assessment of uterine artery Doppler indices and maternal serum homocysteine estimation
2872760|NCT03440268|Experimental|N Acetyl Cysteine|NAC in pre operatory 150mg/kg infusion in 2 hours. NAC during the surgery 50mg/kg in 6 hours. The influence of NAC will be assess in post operatory moment with routine exams
2872761|NCT03440268|Placebo Comparator|Placebos|Saline solution in pre operatory. Saline Solution duing the surgery. The post operatory datas of both groups will be compare
2872762|NCT03440255|Experimental|Transcutaneous Vagus Nerve Stimulation|TaVNS 8 sessions, 30 min, 4 weeks GAD: 20 Hertz (Hz) - 80 microseconds (µs) CP: 5Hz-200µs IBS: 3Hz-250µs
2872763|NCT03440242||JJVC Contact Lens (Asymptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the JJVC Contact Lens arm based on their habitual lenses and then stratified to an Asymptomatic group based on wear time responses during the baseline assessment.
2872764|NCT03440242||JJVC Contact Lens (Symptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the JJVC Contact Lens arm based on their habitual lenses and then stratified to a Symptomatic group based on wear time responses during the baseline assessment.
2872812|NCT03440008||Control|Able-bodied, age matched subjects with no foot and ankle pathology
2872813|NCT03440008||OA|Subjects with ankle OA, with all classifications of ankle misalignment (varus, neutral, valgus)
2872765|NCT03440242||Marketed Contact Lens (Asymptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the Marketed Contact Lens arm based on their habitual lenses and then stratified to an Asymptomatic group based on wear time responses during the baseline assessment.
2872766|NCT03440242||Marketed Contact Lens (Symptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the Marketed Contact Lens arm based on their habitual lenses and then stratified to a Symptomatic group based on wear time responses during the baseline assessment.
2872767|NCT03440229|No Intervention|Emuslfier-free diet|This is western style diet prepared without any emulsifiers. Emulsifier free brownies and sorbet are provided daily.
2872768|NCT03440229|Experimental|Emulsifier-containing diet|This is a western style diet prepared without any emulsifiers with the exception of the CMC that is included in brownies and sorbet that are provided daily.
2872769|NCT03440216|Experimental|Sampling if GFR = or > 30 mL/min|"Note: GFR = Glomerular Filtration Rate~Patients with a normal of moderately decreased renal function~Temocillin: 6 g in continuous infusion over 24 h;~Ceftriaxone: bolus 2 g (in 30 min) every 12h~Meropenem: prolonged infusion (3 h) of 2 g every 8h~Blood sampling for antibiotic (temocillin, ceftriaxone or meropenem) pharmacokinetic analysis / Tissue sampling (lung) for determination of antibiotic content when possible / Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic concentration when possible"
2872770|NCT03440216|Experimental|Sampling if GFR < 30 mL/min|"Patients with severe renal insufficiency or hemodialysis:~Temocillin: 6 g in continuous infusion over 24 h;~Ceftriaxone: bolus 2 g (in 30 min) every 12h~Meropenem: prolonged infusion (3 h) of 2 g every 8h~Blood sampling for antibiotic (temocillin, ceftriaxone or meropenem) pharmacokinetic analysis / Tissue sampling (lung) for determination of antibiotic content if possible / Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic concentration if possible"
2872771|NCT03440203||no Diabetic neuropathy|
2872772|NCT03440203||Diabetic peripheral neuropathy|
2872773|NCT03440203||Diabetic peripheral neuropathic pain|
2872774|NCT03440151|Experimental|contralateral submental flap for tongue cancer defect|
2872775|NCT03440151|Active Comparator|primary closure for tongue cancer defect|
2872776|NCT03440138||University Hospital Zurich|
2872777|NCT03440138||St Pierre University Hospital, Brussels, Belgium|
2872778|NCT03440138||Sana Klinikum, Offenbach, Germany|
2872779|NCT03440138||Complutense University of Madrid, Spain|
2872780|NCT03440138||Musgrove Park Hospital, Taunton, UK|
2872781|NCT03440138||University of Gothenburg, Sweden|
2872782|NCT03440138||AZ Sint-Jan Hospital in Bruges, Belgium|
2872783|NCT03440138||Bristol|
2872784|NCT03440138||Cleveland Clinic, Weston, Florida, USA|
2872785|NCT03440138||Oswaldo Cruz German Hospital, Sao Paolo, Brazil|
2872786|NCT03440138||Clínica Las Condes, Santiago, Chile|
2872787|NCT03440138||Brown University, Providence Rhode Island|
2872788|NCT03440138||Fresno Bariatric, CA, USA|
2872789|NCT03440138||Rijnstate Hospital, Arnhem, The Netherlands|
2872790|NCT03440138||CHU Nice, France|
2872791|NCT03440138||Claraspital Basel, Switzerland|
2872792|NCT03440138||Gastro-Obeso-Center Advanced Med Inst, Brazil|
2872793|NCT03440138||Hospital Dipreca Santiago Región Metropolitana , Chile|
2872794|NCT03440138||Medical University Wien, Austria|
2872795|NCT03440125|Experimental|Healthy|Healthy participants with no low back pain. 20 min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical) on the back will be administered.
2872796|NCT03440125|Experimental|LBP patients - CPC Group|Participants suffering from low back pain (LBP) receiving 10 times (within 3 weeks) 20min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical).
2872797|NCT03440125|Experimental|LBP patients - CPC and ES/M Group|Participants suffering from low back pain (LBP) receiving 10 times (within 3 weeks) 20min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical), and half of the subject also receiving 10 min electrical Stimulation and 10 min massage Treatment on the back.
2872798|NCT03440112|Active Comparator|Clarithromycin|Clarithromycin 250mg (1 capsule) will be taken orally twice a day for 3 days and if tolerated will be increased to 500mg (2 capsules) orally twice a day for 4-6 days.
2872799|NCT03440112|Placebo Comparator|Placebo|Placebo will be taken exactly as the clarithromycin arm: 1 capsule orally twice a day for 3 days and if tolerated will be increased to 2 capsules orally twice a day for 4-6 days.
2872800|NCT03440099|Other|Training|All participants will participate in the 16-week resistance exercise training program.
2872801|NCT03440086|Experimental|Abdominal Jackson-Pratt drain|Patients in this arm will undergo one-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
2872802|NCT03440086|No Intervention|Controls|Patients in this arm will not undergo one-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
2872803|NCT03440073|Experimental|Mulligan Concept Intervention|Mulligan Concept Intervention, including Mobilizations with Movement intervention is administered. Up to 30 minutes total treatment time.
2872804|NCT03440073|Sham Comparator|Sham Mulligan Concept Treatment|Assessment procedures of the Mulligan Concept are followed, but no manual pressure is applied to the participant during treatment to provide a sham Mulligan Concept Treatment.
2872805|NCT03440060|No Intervention|standard group|participants receive systematically empiric antibiotic therapy on admission with amoxicillin- acid clavulanic or levofloxacin in case of allergy
2872806|NCT03440060|Active Comparator|Procalcitonin group|participants receive antibiotics only if the procalcitonin value is at or greater than 0.25 ng/ml
2872807|NCT03440047|Experimental|Fuji Flim Processor VP-7000|Screening or surveillance colonoscopy using Fuji Flim Processor VP-7000, Light Source BL-7000
2872808|NCT03440034|Experimental|Pioglitazone|All subjects will be provided Pioglitazone 15mg tablets, total dose of 45mg (3 tablets) for oral administration once daily. 32-week treatment period.
2872809|NCT03440021|Experimental|High-dosage (60mg) ORM-12741|6 x 10 mg ORM-12741 immediate release capsules in a single dose
2872810|NCT03440021|Experimental|Low-dosage (10mg) ORM-12741|1 x 10 mg ORM-12741 immediate release capsules and 5 x placebo capsules in a single dose
2872811|NCT03440021|Placebo Comparator|Placebo|6 x placebo capsules in a single dose
2872814|NCT03439995|Experimental|Open Lung Protective Ventilation|Volume cycled assist control ventilation with tidal volume 8 cc/kg predicted body weight, PEEP 10 cm water (H2O), recruitment maneuvers every 8 hours and after any ventilator disconnect
2872815|NCT03439995|Active Comparator|Conventional Ventilation|Volume cycled assist control ventilation with tidal volume 10 cc/kg predicted body weight, PEEP 5 cm H2O, recruitment maneuvers after any ventilator disconnect
2872816|NCT03439982|Experimental|FMT|Open label FMT administered at week 0 by colonoscopy and weeks 1-4 by enema
2872817|NCT03439969|No Intervention|Control|Dental appointment, one hour and included activities that are normally part of a SPT (Suportive Periodontal Treatment) consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback considered crucial to the accomplishment of long term behavior change. Moreover, special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation) in order to focus patients´ attention on the varied facets of oral health care and increase their perception of the treatment needs. In this group, the device SOPROCARE® by Acteon and Text Messages were not used.
2872818|NCT03439969|Experimental|Intra Oral Camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback. Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.
2872819|NCT03439969|Experimental|Mobile Text Messages|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback.. Participants in the SMS group further received a total of 16 messages (SMS). One per week.
2872820|NCT03439969|Experimental|Intra Oral Camera and Text Messages|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback. Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.Participants also received SMS a total of 16 messages (SMS). One per week.
2872821|NCT03439956||Transvaginal specimen extraction (cases)|Pregnant women that underwent previous laparoscopic myomectomy or ovarian cystectomy with transvaginal specimen extraction.
2872822|NCT03439956||Controls|Pregnant women that did not undergo previous laparoscopic myomectomy or ovarian cystectomy with transvaginal specimen extraction.
2872823|NCT03439943|Experimental|Lixisenatide|Lixisenatide (10μg/d for 14 days and then 20μg/d): once daily subcutaneous
2872824|NCT03439943|Placebo Comparator|Placebo|Placebo: once daily subcutaneous injection
2872825|NCT03439930|Active Comparator|Uni-axial|Subjects in this group perform exercises on an uni-axial balance board
2872826|NCT03439930|Active Comparator|Multidirectional|Subjects in this group perform exercises on a multidirectional balance board
2872827|NCT03439917|Experimental|Carnitine and Meal Replacement Drink|2g L-carnitine tartrate consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.
2872828|NCT03439917|Placebo Comparator|Placebo and Meal Replacement Drink|2g Maltodextrin consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.
2872829|NCT03439904|Experimental|pharmaceutical care intervention group|Patients will receive individualized pharmaceutical care in addition to usual medical care
2872830|NCT03439904|No Intervention|control group|Patients will receive usual medical care
2872831|NCT03439891|Experimental|Lead-in Arm I (Part 2: nivolumab, sorafenib)|After determination of MTD [Part 1] participants receive nivolumab IV over 30 minutes on days 1 and 15, and sorafenib PO beginning on day 15 of course 1, then on days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2872832|NCT03439891|Experimental|Lead-in Arm II (Part 2: sorafenib, nivolumab)|After determination of MTD [Part 1] participants receive sorafenib PO on days 1-28, and nivolumab IV over 30 minutes beginning on day 15 of course 1, then on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2872833|NCT03439878|Experimental|Galactose|Ingestion of 0.75 g/kg body mass of d-galactose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.
2872834|NCT03439878|Active Comparator|Glucose|Ingestion of 0.75 g/kg body mass of dextrose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.
2872835|NCT03439865|Experimental|standard of care treatment + ivacaftor|topical nasal steroid spray and culture-directed antibiotics + ivacaftor 150 mg tablet
2872836|NCT03439865|Placebo Comparator|standard of care treatment|topical nasal steroid spray and culture-directed antibiotics
2872837|NCT03439852|Experimental|Light to Moderate Physical Activity/Sedentary Time|The telephone counseling plus group cohesion intervention is designed to increase Light-to-Moderate intensity physical activity (LMPA) and reduce Sedentary time (ST). The 12-wk intervention includes group discussions during 3 regular monthly club meetings when clubs' accumulated milestones for LMPA/ST min/wk will be identified and future cumulative club goals for PA/ST set. In addition, each member will receive 12 weekly personalized phone calls from health coaches who will use motivational interviewing to set individualized LMPA/ST goals setting, reduce barriers, and facilitate social support for LMPA/ST change.
2872838|NCT03439852|No Intervention|Delayed Treatment/Healthy Aging|Delayed Treatment (DT) / Healthy Aging materials Condition is for 12 weeks and participants receive 12 phone calls using a previously developed contact-matched protocol that uses mailed healthy aging information and telephone calls to assess symptom ratings. After the initial 12 weeks they then receive the LMPA/ST intervention
2872839|NCT03439839|Experimental|LNP023|10 patients receiving LNP023 daily over up to 48 weeks
2872840|NCT03439813|Experimental|TASK-CBT|Web and telephone-delivered cognitive behavioural therapy designed for anxiety after stroke and TIA. Six personalized telephone CBT sessions, one week apart by a trained and supervised medical professional using the TASK Therapist's Manual. Treatment website contains multimedia content to cover key CBT skills with weekly online tasks.
2872841|NCT03439813|Active Comparator|TASK-Relax|Web and telephone-supported relaxation therapy. Treatment website contains five relaxation exercises: i) audio- and visually-guided breathing exercise, ii) relaxing imagery and sounds, iii) music for relaxation, iv) audio-guided progressive muscle relaxation, and v) a selection of sounds of nature. Telephone instruction given and treatment website contains multimedia content to explain to participant how to practice relaxation regularly during the trial period.
2872842|NCT03439800|Experimental|Mental and Physical Practice|"Action observation: is defined as the observation of the motor action, in this study, through a video.~Mental Practice: is defined as motor imagery training with the aim of improving the engine performance. Is the imagination of a motor action without its physical implementation.~Physical Practice: is the execution of the motor action."
2872843|NCT03439800|Active Comparator|Physical Practice|Physical Practice: is the execution of the motor action.
2872844|NCT03439787|Active Comparator|Active Popliteal Plexus Block|10 ml Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution
2872845|NCT03439787|Placebo Comparator|Placebo Popliteal Plexus Block|10 ml Sodium Chloride 0.9 %
2872846|NCT03439774|Other|Adults 18 years old or older|
2872847|NCT03439761|Experimental|PT-112 Injection|PT-112 Injection alone
2872848|NCT03439748|Experimental|Positive Affect Treatment|Sessions 1-7: Planning for engagement in pleasurable activities and reinforcement of positive mood effects of those activities Sessions 8-10: Exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention
2872849|NCT03439748|Active Comparator|Negative Affect Treatment|Sessions 1-7: Exposures to avoided scenarios Sessions 8-10: Cognitive restructuring Sessions 11-14: Normalization of arousal response to exposure Session 15: Relapse prevention
2872850|NCT03439735|Experimental|Palbociclib and Aromatase Inhibitor|Participants will undergo blood collection (intervention) at time of initiating treatment with an aromatase inhibitor and palbociclib, at 4 weeks after initiating this treatment, and every 3-4 months while on treatment. If a participant progresses on this treatment, they will have a blood collection at that time.
2872851|NCT03439722||Patients|Episodic cluster headache patients will be admitted for 1 night where a polysomnography will be performed by the Danish Center of Sleep Medicine.
2872852|NCT03439722||Controls|Controls will be admitted for 1 night where a polysomnography will be performed by the Danish Center of Sleep Medicine.
2872853|NCT03439709|Experimental|intervention|Gamma knife radiosurgery (Leksell Gamma Knife, Elekta AB, Stockholm, Sweden) is used for intervention. Administration of standard medical therapy using Lanreotide 60 mg concurrently starts with radiosurgery
2872854|NCT03439709|Active Comparator|control|Without radiosurgery, standard medical therapy (Lanreotide 60Mg Solution for Injection) same with interventional group is applied
2872855|NCT03439696|Experimental|Needlescopic-assisted|Thoracoscopic surgery performed with the fashion of single 2.5-3.5 cm intercostal incision and 1-2 additional 2-3 mmm needlescopic ports.
2872856|NCT03439696|Active Comparator|Uniportal|Conventional uniportal VATS with single 2.5-3.5 cm intercostal incision
2872857|NCT03439683||Physicians|"Definition: Physicians working in the ICU for at least 50% of their time in the hospital~Intervention: Survey about patient-ventilator asynchrony"
2872858|NCT03439683||Nurses|"Definition: Nurses working in the ICU for at least 20 hours/week~Intervention: Survey about patient-ventilator asynchrony"
2872859|NCT03439683||Respiratory Therapists|"Definition: Respiratory Therapists working in the ICU for at least 20 hours/week~Intervention: Survey about patient-ventilator asynchrony"
2872860|NCT03439670|Experimental|Treatment Group 1|Patients enrolled in Treatment Group 1 (experimental group) will receive vamorolone 2.0 mg/kg/day for the duration of the study.
2872861|NCT03439670|Experimental|Treatment Group 2|Patients enrolled in Treatment Group 2 (experimental group) will receive vamorolone at 6.0 mg/kg/day for the duration of the study.
2872862|NCT03439670|Active Comparator|Treatment Group 3|Patients enrolled in Treatment Group 3 (active comparator group) will receive prednisone 0.75 mg/kg/day for 24 weeks followed by 20 weeks of treatment with 2.0 mg/kg/day vamorolone.
2872863|NCT03439670|Active Comparator|Treatment Group 4|Patients enrolled in Treatment Group 4 (active comparator group) will receive prednisone 0.75 mg/kg/day for 24 weeks followed by 20 weeks treatment with 6.0 mg/kg/day vamorolone.
2872864|NCT03439670|Placebo Comparator|Treatment Group 5|Patients enrolled in Treatment Group 5 (placebo comparator group) will receive placebo daily for 24 weeks followed by 20 weeks treatment with 2.0 mg/kg/day vamorolone.
2872865|NCT03439670|Placebo Comparator|Treatment Group 6|Patients enrolled in Treatment Group 6 (placebo comparator group) will receive placebo daily for 24 weeks followed by 20 weeks treatment with 6.0 mg/kg/day vamorolone.
2872866|NCT03439657|Experimental|Co-Ad Group|Subjects at least 50 years of age at the time of the first vaccination, who will receive the first dose of GSK1437173A and one dose of Prevenar13 at Day 1 and the second dose of GSK1437173A at Month 2. Both vaccines will be administered intramuscularly, GSK1437173A will be administered in the deltoid muscle of the non-dominant arm, while Prevenar13 will be administered in the deltoid muscle of the dominant arm.
2872867|NCT03439657|Active Comparator|Control Group|Subjects at least 50 years of age at the time of the first vaccination, who will receive one dose of Prevenar13 at Day 1, the first dose of GSK1437173A at Month 2 and the second dose of GSK1437173A at Month 4. Both vaccines will be administered intramuscularly, GSK1437173A will be administered in the deltoid muscle of the non-dominant arm, while Prevenar13 will be administered in the deltoid muscle of the dominant arm.
2872868|NCT03439631|Active Comparator|Tiered OR Satisfaction|Patient satisfaction questionnaire with surgical experience in Tiered OR
2872869|NCT03439631|Other|Status Qou OR satisfaction|Patient satisfaction questionnaire with surgical experience in Tiered OR
2872870|NCT03439618|Other|continuous feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h
2872871|NCT03439618|Other|time-restricted feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 6h (7:00-9:00,11:00-13:00,17:00-19:00).
2872872|NCT03439592||hyperglycemic patients|diabetic patients admitted for STEMI and with hyperglycemia at hospital admission.
2872873|NCT03439592||normoglycemic patients|diabetic patients admitted for STEMI and with normoglycemia at hospital admission.
2872874|NCT03439579|Experimental|Home weight loss program|Participants will be instructed to daily monitor their body weight, minutes of activity, number of steps, and calories consumed for the duration of the pilot study, and they will receive recorded individualized feedback on this self-monitored data from Weight Management Center clinicians (registered dietitians, exercise psychologists, and behavioral specialists).
2872875|NCT03439566||Total hip arthroplasty|No intervention will take place. Only registration and data collection of patient´s care and treatment will take place. There will be no changes in patient´s treatment.
2872876|NCT03439553|Experimental|Intervention|People shown ads with referral to target websites.
2872877|NCT03439553|Active Comparator|Intervention with control websites|People shown ads with referral to control websites.
2872878|NCT03439553|No Intervention|Control|People who make target queries, but are not shown the ads.
2872879|NCT03439540|Placebo Comparator|Placebo|Individuals receive a placebo daily, for 2 months.
2872880|NCT03439540|Experimental|Plantago major|Individuals receive Plantago major daily, for 2 months.
2872881|NCT03439527|Experimental|MPC-group|All patients are treated by the same product: Autologous MPCs
2872882|NCT03439527|Other|NMES+MPC-group|After treatment, the patients will be randomized 1:1 in the MPC-group or NMES+MPC-group to investigate the benefits of an additional physiotherapy (Neuromuscular Electromagnetic Stimulation, NMES)
2872883|NCT03439514|Experimental|Part 1 Double-blind Treatment|ARRY-371797 tablet orally OR matching placebo tablet orally
2872884|NCT03439514|Experimental|Part 2 Open-label Treatment|ARRY-371797 tablet orally
2872885|NCT03439501|Other|avelumab|"1 Cycle: 10mg/kg Avelumab administered via IV every 2 weeks (1st, 15th)~Interval of 1 cycle: 28 days ③ Administration schedule: Repeated until disease progression or unacceptable toxicity and dose adjustments may be permitted based on the toxicity that occurs every cycle."
2872886|NCT03439488|Experimental|Part 1 (Healthy Participants): Single Ascending Dose (SAD)|Participants in Cohorts 1 to 5 and 3 optional cohorts (Cohorts 6, 7 and 10) will receive a single dose of JNJ‑440/placebo on Day 1. Two cohorts will receive a second dose of JNJ-440/placebo in a fed state (participants from Cohort 3 will also participate in Cohort 8) or as an alternative JNJ-440 formulation (participants from Cohort 2 will also participate in optional Cohort 9) after a washout window of at least 10 days. In Cohorts 1 to 4, study drug will be administered under fasted conditions; in the remaining cohorts, study drug will be administered under fasted/fed conditions depending on the results of the food effect evaluation.
2872887|NCT03439488|Experimental|Part 2 (Healthy Participants): Multiple Ascending Dose (MAD)|Participants in Cohorts 1 and 2 will receive a once daily dose of JNJ-440/placebo for the duration of 7 days under fasted or fed conditions. Participants in an optional cohort (Cohort 3) may receive a once daily dose of JNJ-440/placebo for the duration of 7 or 14 days under fasted or fed conditions. The starting dose for Cohort 1 in Part 2 will be determined by the Sponsor in consultation with the Principal Investigator based on the data from Part 1. Dose escalation will be performed only after review of safety and pharmacokinetic (PK) data after a minimum of 7 days of study drug administration.
2872888|NCT03439488|Experimental|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD|Participants in Cohorts 1 and 2 and 3 optional cohorts (Cohorts 3, 4, and 5) will receive multiple ascending doses of JNJ‑440/placebo once daily for 28 days under fed or fasted conditions. The starting dose and formulation for Cohort 1 will be determined based on the review of available data in healthy participants from Part 1 (SAD) and Part 2 (MAD). Dose escalation will be performed only after review of safety, tolerability, and PK data after a minimum of 14 days of study drug administration from at least 8 CHB participants.
2872889|NCT03439436|Experimental|xylo+dex nasal spray (0.1 mg+5 mg/dose)|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
2872890|NCT03439436|Active Comparator|Nasic|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
2872891|NCT03439423||Patients who underwent EVAR|
2872892|NCT03439410||Internal Medicine ward|The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.
2872893|NCT03439410||Subacute ward|The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.
2872894|NCT03439397|Experimental|Ballon Technique group|Intervention：Ballon Technique
2872895|NCT03439397|Active Comparator|SOAI group|Intervention：Selective Ophthalmic Artery Infusion
2872896|NCT03439384|Experimental|Experimental: Home Telemonitoring|Patients will receive home telemonitoring devices and monitor their health for 60 days post-enrollment. A monitoring nurse will receive and review the patients health on a daily basis for the 60 day duration and provide remote care, counseling and education.
2872897|NCT03439384|No Intervention|Control: No Home Telemonitoring|The patient will not receive any home telemonitoring once enrolled and will continue to receive the usual care he/she can expect as part of his/her care plan.
2872898|NCT03439371|Experimental|HLA-mismatched micro-transplantation|HLA-mismatched micro-transplantation
2872899|NCT03439358|Experimental|Magnesium sulfate|Magnesium sulfate (MgSO4) infusion will be commenced prior to epidural top-up.
2872900|NCT03439358|Placebo Comparator|Normal saline|Normal saline infusion will be commenced prior to epidural top-up.
2872901|NCT03439345|Experimental|Fenofibrate 145 mg|Name: fenofibrate; Form: tablet; Dosage: 145 mg; Frequency: one tablet daily with normal renal function, one tablet every 2nd day with chronic kidney disease
2872902|NCT03439345|Placebo Comparator|Placebo Oral Tablet|Name: placebo; Form: tablet; Dosage: not applicable; Frequency: one tablet daily with normal renal function, one tablet every 2nd day with chronic kidney disease
2872903|NCT03439319|Active Comparator|MyndMove® therapy|Non-invasive Functional Electrical Stimulation (FES) technique with surface electrodes to stimulate from 3 to 8 muscles to create purposeful movements in one or both hands/arms
2872904|NCT03439319|Active Comparator|Intensive Conventional therapy|Using Conventional therapy which focuses exclusively on the purposeful movements in one or both hands/arms
2872905|NCT03439306||healthy adult volunteer|"Subject is 18 to 50 years of age.~Subject is a non-smoker or who has not smoked within 2 days prior to the study."
2872942|NCT03439033|Experimental|PET/MRI|PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC.
2872906|NCT03439293|Experimental|Ixazomib 4 mg + Daratumumab 16 mg/kg + Dexamethasone 20 mg|Ixazomib, 4 mg, capsules, orally, on Days 1, 8 and 15 of each 28-day cycle along with daratumumab, 16 mg/kg, intravenously (IV), on Days 1, 8, 15 and 22 of Cycles 1 and 2, on Days 1 and 15 (every 2 weeks) for Cycles 3 to 6 and on Day 1 (every 4 weeks) for Cycle 7 and beyond along with dexamethasone, 20 mg, tablets, orally on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle until progressive disease (PD), have an unacceptable toxicity, or withdraw consent, or when the study has completed or until the sponsor terminates the study.
2872907|NCT03439280|Experimental|Phase 1 Cohort 1: TAK-079|TAK-079, injection, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons. Dose escalation of TAK-079 will range from 45 milligram (mg) to 1800 mg and may be done using a 3 + 3 dose escalation design to determine a MTD and/or RP2D.
2872908|NCT03439280|Experimental|Phase 2a: TAK-079 TBD|TAK-079, injection, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons. TAK-079 dose for this phase will be determined based on review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data obtained from the Phase 1 portion of the study.
2872909|NCT03439267|Active Comparator|Proactive Pooled Cohort|Standard Interventional Control Group. Will receive treatment according to the current AHA/ACC guidelines for statin initiation and follow-up.
2872910|NCT03439267|Experimental|Proactive CAC Group|Investigational Interventional Group. Will undergo coronary artery calcium screening and will receive statin treatment based on the cardiovascular risk algorithm.
2872911|NCT03439254|Experimental|Obeticholic Acid (OCA) 10 mg|10 mg OCA for up to 12 months
2872912|NCT03439254|Experimental|Obeticholic Acid (OCA) 10 mg to 25 mg|10 mg OCA for the first 3 months and then may titrate up to 25 mg OCA for the remaining 9 months of the study
2872913|NCT03439254|Placebo Comparator|Placebo|Placebo for up to 12 months
2872914|NCT03439241|Experimental|Silent arm|The participants test the new Coloplast ostomy device use the product as they usually would.
2872915|NCT03439241|Experimental|Active arm|The participants test the tnew Coloplast ostomy device and are guided by the measuring device
2872916|NCT03439228|Experimental|Brace|Lumbar brace wear prescribed for 3 months post-operation
2872917|NCT03439228|No Intervention|No brace|No lumbar brace prescribed
2872918|NCT03439215|Experimental|PF-06463922 (Lorlatinb) Arm|Eligible patients will be treated with PF-06463922 at the dose of 100 mg QD p.o.
2872919|NCT03439202|Other|No arm used|No drug use for this study. No arm used in this study. Subjects are exposed to hypoxic conditions (clinical study).
2872920|NCT03439176|Experimental|Test of new adhesive strips|"The subjects will test adhesives strips made of 4 different adhesives:~Standard adhesive 1 Standard adhesive 2 PL4 PL16-L"
2872921|NCT03439163||PD patients|the entire group underwent MRI scan
2872922|NCT03439150|Other|Study arm|The study arm will undergo absolute flow and resistance measurements immediately after PPCI of the culprit artery
2872923|NCT03439137|Experimental|MT-6548|
2872924|NCT03439137|Active Comparator|Darbepoetin alfa|
2872925|NCT03439124|Experimental|Ceftobiprole [HAP]|Ceftobiprole medocaril in Hospital-Acquired Pneumonia
2872926|NCT03439124|Active Comparator|Ceftazidime [HAP]|Ceftazidime in Hospital-Acquired Pneumonia
2872927|NCT03439124|Experimental|Ceftobiprole [CAP]|Ceftobiprole medocaril in Community-Acquired Pneumonia
2872928|NCT03439124|Active Comparator|Ceftriaxone [CAP]|Ceftriaxone in Community-Acquired Pneumonia
2872929|NCT03439111|Placebo Comparator|Placebo|Intervention : Placebo + Standardized Lycium chinense Fruit Extract (LCF) capsules Placebo Comparator : Oral administration, 600 mg two capsules (600 mg of Starch/capsule) three times a day for 4 week treatment 3 week wash-out Experimental : Oral administration, 600 mg two capsules (146 mg of the Standardized Lycium chinense Fruit Extract (LCF)/capsule) three times a day for 4 week treatment
2872930|NCT03439111|Experimental|Experimental|Intervention : Standardized Lycium chinense Fruit Extract (LCF) capsules + Placebo Experimental : Oral administration, 600 mg two capsules (146 mg of the Standardized Lycium chinense Fruit Extract (LCF)/capsule) three times a day for 4 week treatment 3 week wash-out Placebo Comparator : Oral administration, 600 mg two capsules (600 mg of Starch/capsule) three times a day for 4 week treatment
2872931|NCT03439098|Experimental|Fermented Codonopsis lanceolata 525mg|Fermented Codonopsis lanceolata 525mg/day
2872932|NCT03439098|Experimental|Fermented Codonopsis lanceolata 1050mg|Fermented Codonopsis lanceolata 1050mg/day
2872933|NCT03439098|Placebo Comparator|Placebo|Placebo
2872934|NCT03439085|Experimental|HPV-16/18 Cervical Cancer|"Participants receive MEDI0457 at Weeks 1, 3, 7, 12, and then every 8 weeks after that. After the injection, participant receives electroporation (EP) around the site of the injection.~Participants receive Durvalumab by vein over about 1 hour every 4 weeks, beginning with Week 4."
2872935|NCT03439085|Experimental|HPV-16/18 Rare Tumors (Anal, Penile, Vulvar, Vaginal)|"Participants receive MEDI0457 at Weeks 1, 3, 7, 12, and then every 8 weeks after that. After the injection, participant receives electroporation (EP) around the site of the injection.~Participants receive Durvalumab by vein over about 1 hour every 4 weeks, beginning with Week 4."
2872936|NCT03439085|Experimental|HIV (+) HPV-16/18 Malignancies (Any Site)|"Participants receive MEDI0457 at Weeks 1, 3, 7, 12, and then every 8 weeks after that. After the injection, participant receives electroporation (EP) around the site of the injection.~Participants receive Durvalumab by vein over about 1 hour every 4 weeks, beginning with Week 4."
2872937|NCT03439072|Other|G-Pen followed by Lilly Glucagon|1 mg G-Pen at the first treatment visit followed by 1 mg Lilly Glucagon at the second treatment visit
2872938|NCT03439072|Other|Lilly Glucagon followed by G-Pen|1 mg Lilly Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit
2872939|NCT03439059|Experimental|Reducing Sedentary Behaviour Group (intervention group)|prompted to do 10min of light physical activity 3x/day
2872940|NCT03439059|No Intervention|Control group|go about their normal daily living
2872941|NCT03439046|Experimental|ribociclib+letrozole|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
2872979|NCT03438773|Other|Envarsus|Study group - Envarsus once daily in addition to standard of care.
2872943|NCT03439033|Experimental|Multiple PET/MRI|Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will be invited to participate in two visits within two years, the second being an optional visit. During each visit, subjects will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC. This arm will be restricted to subjects who plan to undergo focal therapy.
2872944|NCT03439033|Experimental|PET/CT|PET/CT with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/CT after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC.
2872945|NCT03439020|Experimental|FCSEMS + Plastic|"Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture and insert an additional plastic stent to anchor the metal stent.~(Plastic stent anchoring)"
2872946|NCT03439020|Active Comparator|FCSEMS|Insert only a fully covered self expandable metal stent (FCSEMS) without a plastic stent for malignant biliary stricture.
2872947|NCT03439007||Hypotensive|A group of pediatric patients who showed hypotension during induction of anesthesia
2872948|NCT03439007||Normotensive|A group of pediatric patients who did not show hypotension during induction of anesthesia
2872949|NCT03438994|Active Comparator|Participants diagnosed with ASD|
2872950|NCT03438994|Experimental|Participants diagnosed with OND|
2872951|NCT03438994|Active Comparator|Typically developing participants|
2872952|NCT03438968|Experimental|High-Intensity aerobic training|Individuals will exercise using a high-intensity interval exercise training protocol
2872953|NCT03438968|Active Comparator|Standard Moderate continuous training|Individuals will exercise using a standard moderate intensity continuous exercise training protocol
2872954|NCT03438955|Experimental|Cohort A|Administration of omacor soft capsule 4000mg for 16 days, and followed by omacor soft capsule 4000mg and Pritor tablet 40mg in combination for 7 days.
2872955|NCT03438955|Experimental|Cohort B|Administration of Pritor tablet 40mg for 7 days, and followed by Pritor tablet 40mg and Omacor soft capsule 4000mg in combination for 16 days.
2872956|NCT03438942|Experimental|Folic acid and iron supplementation|Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months
2872957|NCT03438942|Active Comparator|Control group|Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months
2872958|NCT03438903||Normal group|Healthy subjects without any ocular problems Repeat exams of OCT device (SD and SS-OCT)
2872959|NCT03438903||Retinal diseases group|Patients with various macular diseases Repeat exams of OCT device (SD and SS-OCT)
2872960|NCT03438890|Experimental|Warm saline group|In subjects allocated to the warm saline group, a thermos flask, which was filled with heated sterile water, was used. A 1000 ml bottle of sterile water was heated to 60 ˚C in a stove for an hour at minimum. Just before introducing into the abdominal cavity, the laparoscope was placed into the thermos flask for 30 seconds at minimum . After each incidence of laparoscopic lens fogging (LLF), the scope was briefly inserted into the thermos flask about 10 seconds, and was then wrapped gauze around the lens before abdominal reinsertion.
2872961|NCT03438890|Experimental|anti-fog agent group|In the anti-fog agent group, Ultra-Stop TM (Sigmaphrarm, Vienna, Austria), which is a commercial anti-fogging solution containing alcohol, surfactant, and water for medical optical devices, was used. Wiping the lens with gauze soaked in Ultra-Stop TM and allowing the surfactant to act for 5 seconds, the laparoscope was introduced into the abdominal cavity. After each laparoscopic lens fogging (LLF), the scope was removed from the abdomen and cleaned using the same corresponding method.
2872962|NCT03438890|Experimental|chlorhexidine group|In the chlorhexidine group, the lens was wiped with gauze soaked in 4% chlorhexidine detergent solution (Firson, Cheonan, Korea) for 5 seconds before introducing into the abdominal cavity, and chlorhexidine was reapplied on the lens at the occurrence of laparoscopic lens fogging (LLF).
2872963|NCT03438890|No Intervention|control group|In the control group, the lens was not wiped gauze or applied any solution before use of the laparoscope. When occurred the event of each laparoscopic lens fogging (LLF) that splatter of irrigation fluid, blood, and body fluids affected visual clearance, the laparoscopic lens was manually rubbed with clean gauze by a scrub nurse.
2872964|NCT03438877|Experimental|Intervention group|Intervention group is intensive dosage of PD.
2872965|NCT03438877|Active Comparator|Control group|Control group is regular dosage of PD.
2872966|NCT03438864|Experimental|10 Hz|Interferential current, entry frequency 4000 Hz and 4010 Hz, beat frequency 10 Hz, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
2872967|NCT03438864|Experimental|100 Hz|Interferential current, entry frequency 4000 Hz and 4100 Hz, beat frequency 100 Hz, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
2872968|NCT03438864|Sham Comparator|Placebo-Sham Control|No current except for first 5 seconds, device open but does not appy electrotherapy.
2872969|NCT03438851|Experimental|Full-time Cognitive Rehabilitation Program|Participants in full-time program will be asked to complete 4 experimental sessions with the NeuroCatch Platform™ over the course of 3 months (i.e. one session/ month).
2872970|NCT03438851|Experimental|Part-time Cognitive Rehabilitation Program|Participants in the part-time program will be asked to complete 3 experimental sessions with the NeuroCatch Platform™ over 3 months (i.e. one session/1.5 months).
2872971|NCT03438838|Active Comparator|Laparoscopic Heller's Myotomy (LHM)alone|A minimum 10 patients undergo Laparoscopic Heller's myotomy alone
2872972|NCT03438838|Active Comparator|LHM with Anterior Fundoplication|A Minimum 10 patients undergo Laparoscopic Heller's myotomy along with fundoplication
2872973|NCT03438812|Experimental|Poor ovarian responders with DHEA|Women who meet the Bologna criteria receive dehydroepiandrosterone (DHEA, 90 mg daily for two months at least) supplementation prior to the IVF cycle.
2872974|NCT03438812|No Intervention|Poor ovarian responders|Women who meet the Bologna criteria undergo the IVF cycle without pretreatment with DHEA
2872975|NCT03438812|No Intervention|Normal ovarian responders|Women who do not meet the Bologna criteria and have normal ovarian response to ovarian stimulation.
2872976|NCT03438799||Cordio|Cordio R&D database to develop the Cordio System
2872977|NCT03438786|Experimental|group A|Patients undergoing trans-inguinal pre-peritoneal (TIPP) hernioplasty
2872978|NCT03438786|Experimental|group B|Patients undergoing lichtnestein's hernioplasty
2872981|NCT03438760|Placebo Comparator|Science + Phonological Awareness|In all conditions, science is taught via the Full Option Science System Next Generation Edition (FOSS, 2015, https://www.fossweb.com/) curriculum that involves 1) Prediction, 2) Experiment, 3) Journal/Reflection, and 4) dialogic reading centered around a given theme such as plant life. In the control condition, a minimum of six phoneme identifications and five rhymes will be incorporated into each lesson of this curriculum. While these activities are likely to improve the children's awareness of the sounds of the language (a foundational skill for learning to read), they are not likely to improve their access to the science being taught. Therefore, this intervention constitutes a placebo.
2872982|NCT03438760|Experimental|Science + Grammar Intervention|In the science + grammar condition, focused stimulation, an intervention commonly used to target expressive language, will be used to treat complement clauses during the FOSS activities. The approach is incidental, rather than explicit. The active ingredients are models and recasts of the target structure. Recasts occur when an examiner responds to a child's naturally occurring utterance by expanding or extending the child's utterance to include a target grammatical structure. Recasts and/or models will be provided at an average rate of one per minute, an accepted therapeutic dose.
2872983|NCT03438760|Experimental|Science + Vocabulary Intervention|This arm involves Robust Vocabulary Instruction, an explicit approach that emphasizes multiple and rich encounters in authentic contexts to promote depth of semantic knowledge of 20 words that pertain to scientific practices applicable to the FOSS lessons. The children receive a cumulative exposure of at least 20 times per word (a minimum of 5 times per each of four lessons) and at least 4 chances to produce the word (a minimum of 1 chance per each of four lessons).
2872984|NCT03438747|Experimental|P-15L Bone Graft|The investigational group will be treated with P-15L Bone Graft in an instrumented TLIF
2872985|NCT03438747|Active Comparator|Local autologous bone|The active control group will be treated with local autologous bone in an instrumented TLIF
2872986|NCT03438734|Active Comparator|Low flow|"Anesthesia was maintained with desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen-air mixture in both groups. While target minimum alveolar concentration (MAC) was 1-1.5 and the flow rate was adjusted to 0.75 L/min. Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.~The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of Bispectral Index (BIS, Bispectral Index, Monitoring System) decreases with the deepening of anesthesia."
2872987|NCT03438734|Sham Comparator|Normal flow|"Anesthesia was maintained with desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen-air mixture in both groups. While target minimum alveolar concentration (MAC) was 1-1.5 and the flow rate was adjusted to 1.5 L/min.Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.~The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of Bispectral Index (BIS, Bispectral Index, Monitoring System) decreases with the deepening of anesthesia."
2872988|NCT03438721|Experimental|Infant Obesity Prevention|The infant obesity prevention arm will provide parents with education on optimal infant feeding, sleep, and screen time practices.
2872989|NCT03438721|Experimental|Financial Coaching|The financial coaching arm will provide parents with education on basic financial literacy topics and coaching to help parents achieve financial goals.
2872990|NCT03438708|Experimental|Axitinib Oral Tablet [Inlyta]|Axitinib 5 mg PO BID for 8-10 weeks
2872991|NCT03438695|Experimental|Motorized Spiral Enteroscopy|Patients with indication for total enteroscopy. day1: anterograde motorized spiral enteroscopy, day 2: retrograde motorized spiral enteroscopy
2872992|NCT03438682||Essure Hysteroscopic Sterilization|Women who have undergone Essure hysteroscopic sterilization
2872993|NCT03438682||Laparoscopic Sterilization|Women who have undergone laparoscopic sterilization
2872994|NCT03438682||Intrauterine device (IUD) placement|Women who have undergone IUD placement
2872995|NCT03438656|Experimental|Behavioral Activation Arm|See treatment description for information on Behavioral Activation. Participants will receive 12 weekly sessions of Behavioral Activation.
2872996|NCT03438643||Patient|Patients treated with ECP and corticosteroid as first-line treatment for cGVHD
2872997|NCT03438630||Study cohort|All patients with a first registration (baseline) in the BOA Register between 2008 and 2016 (approximately n=75 000). These patients have sought treatment for knee and/or hip pain in primary health care in Sweden and been referred to the standardized core treatment of education and supervised exercises after confirmed clinical and/or radiographic OA diagnose.
2872998|NCT03438630||Control cohort|Covering the general Swedish population, who never have been included in the BOA register, will be recruited from the Swedish population register at Statistics Sweden and matched (1:3) to each patient in the study cohort by the same year of birth, gender and residence (as for the study cohort at baseline) (approximately n=225 000).
2872999|NCT03438617|Experimental|First Cohort|The first cohort of 3 CHCs will receive the peer support intervention for the full duration of the study period (12 months).
2873000|NCT03438617|Other|Second Cohort|The second cohort of 3 CHCs will serve as a control group for the first 3 months of the study. After 3 months, the second cohort will implement the peer support intervention according to the protocols established in the first cohort. The participants in this cohort will receive the intervention for 9 months.
2873001|NCT03438617|Other|Third Cohort|The third cohort of 4 CHCs will serve as a control group for the first 6 months of the study. After 6 months, the third cohort will implement the peer support intervention according to the protocols established in the first cohort. The participants in this cohort will receive the intervention for 6 months.
2873002|NCT03438604|Other|Donepezil TDS with Heat Applied|Corplex Donepezil TDS 5 mg/day with heat applied
2873003|NCT03438604|Other|Donepezil TDS without Heat|Corplex Donepezil TDS 5 mg/day with no heat applied
2873004|NCT03438604|Other|Donepezil TDS Extension Study with Heat|Corplex Donepezil TDS 5 mg/day with heat. Two skin sensors will be placed underneath the TDS and adjacent to the TDS.
2873030|NCT03438435|Experimental|QRH-882260 Heptapeptide|Five mL of reconstituted (with sterile 0.9% NaCl) QRH-882260 Cy-5-labeled heptapeptide
2873006|NCT03438578|Experimental|Efficacy Safety Score monitoring|Patients monitored with wireless vital signs and Efficacy Safety Score after discharge from the post-anesthesia care unit to an ordinary ward
2873007|NCT03438578|No Intervention|Regular|Patients receiving standard postoperative care after discharge from the post-anesthesia care unit to an ordinary ward
2873008|NCT03438565||Participants with intracranial large vessel occlusive stroke|50 patients who have been treated with the Asahi Chikai Black 18 neurovascular guidewire.
2873009|NCT03438565||Historical Control Group|The historical control will include 50 retrospective consecutive patients (who fulfill inclusion and exclusion criteria) treated for acute anterior circulation large vessel occlusive stroke prior to the initiation of the Sure -18 registry.
2873010|NCT03438552|Experimental|SBRT at a total dose of 30Gy|Placement of fiducials marker seeds in the prostate followed by the administration of SBRT at 30 Gy (5 sessions at a level of 6 Gy each- 1 session per day) 30Gy is the first dose-level. During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
2873011|NCT03438552|Experimental|SBRT at a total dose of 25Gy|Placement of fiducials marker seeds in the prostate followed by the administration of SBRT at 25 Gy (5 sessions at a level of 5 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
2873012|NCT03438552|Experimental|SBRT at a total dose of 36Gy|Placement of fiducials marker seeds in the prostate followed by the administration of SBRT at 36 Gy (6 sessions at a level of 6 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
2873013|NCT03438539|Sham Comparator|Attentional Control with Normative Feedback|Control training tasks will include completion of basic arithmetic problems for approximately 5 minutes. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
2873014|NCT03438539|Experimental|Inhibitory Control Training with Normative Feedback|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
2873015|NCT03438539|Experimental|Working Memory Training with Normative Feedback|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
2873016|NCT03438539|No Intervention|Attentional Control without Normative Feedback|Control training tasks will include completion of basic arithmetic problems for approximately 5 minutes. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
2873017|NCT03438539|Experimental|Inhibitory Control Training without Normative Feedback|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
2873018|NCT03438539|Experimental|Working Memory Training without Normative Feedback|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
2873019|NCT03438526|Experimental|Melatonin (Circadin ®)|
2873020|NCT03438526|Placebo Comparator|Placebo|
2873021|NCT03438513||Problem Solving Therapy|This program is intended for caregivers to acquire techniques to manage stressful situations encountered in everyday life.
2873022|NCT03438513||Speaking group|The group will be led by a psychologist.
2873023|NCT03438513||Standard medical care|Occupational Therapy Assessment Psychological assessment
2873024|NCT03438500|Experimental|Active Shockwave Therapy|Patients in this group receive shockwave therapy.
2873025|NCT03438487||Flucelvax Trivalent or Quadrivalent Influenza Vaccine|Flucelvax Trivalent or Quadrivalent exposure in pregnancy
2873026|NCT03438474|Active Comparator|Arm A standard surgical procedure|"Standard surgical procedure for endometrial cancer:~total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)"
2873027|NCT03438474|Experimental|Arm B systematic lymphadenectomy (LNE)|"In addition to standard procedures as defined for Arm A:~systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels"
2873028|NCT03438461|Experimental|Part 1|In Part 1, all participants will receive a single oral dose of seltorexant (40 milligram [mg]) in all the 6 treatments as Treatment A (Formulation 1 in fasted state), B (Formulation 1 in semi-fasted state), C (Formulation 2 in fasted state), D (Formulation 2 in semi-fasted state), E (Formulation 3 in fasted state) and F (Formulation 3 in semi-fasted state) and the participants will be assigned to one of the 8 sequences (that is, ADBCEF, ADBCFE, BACDEF, BACDFE, CBDAEF, CBDAFE, DCABEF, DCABFE). A washout period of at least 7 days between subsequent study drug administrations on Day 1 of each treatment period will be maintained.
2873029|NCT03438461|Experimental|Part 2 (Optional)|Optional Part 2 will only be performed if considered to be warranted by the sponsor based on the preliminary pharmacokinetic (PK) analysis of the results from Part 1. Participants will receive a single oral dose of seltorexant (20 mg) as 3 different formulations assigned to one of the either 6 or 4 treatment sequences under fasted or semi-fasted conditions. The treatment will be assigned in 1 of the 6 or 4 assigned sequences per treatment period that is either Period 1 to 6 or Period 1 to 4).
2873658|NCT03434080||Healthy Volunteers|Children without cerebral palsy, ages 3 months up to 5 years of age.
2873031|NCT03438422|Experimental|GROUP A|1 tablet a day of pollen A extract containing (140 mg aqueous extract and 8mg lipid purified pollen, aqueous extract pumpkin seed 300mg, 10mg Vitamin E)
2873032|NCT03438422|Active Comparator|GROUP B|1 tablet a day of pollen B extract containing (140 mg aqueous extract and lipid 8 mg of purified pollen)
2873033|NCT03438422|Active Comparator|GROUP C|1 tablet a day of pollen extract C containing (Pollen extract 160 mg, pumpkin seed extract, 300 mg and Vitamin E 10 mg)
2873034|NCT03438422|Placebo Comparator|PLACEBO|1 tablet a day of placebo
2873035|NCT03438409|Experimental|Single Arm Study|This study has a single arm with repeated baseline measures. This arm will complete the robotic gait training.
2873036|NCT03438396|Experimental|Single arm|tisotumab vedotin (IV), 2.0 mg/kg, every 3 weeks (1Q3W)
2873037|NCT03438383|Sham Comparator|Sham Bi-PAP|"Sham Bi-PAP was applied through nasal mask for 3 days postoperatively. Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of Bi-PAP. With this modality, also used on previous studies, the applied pressure by sham Bi-PAP was constant and equal to 2 cm H2O."
2873038|NCT03438383|Active Comparator|Bi-PAP|Bi-PAP through nasal mask, at individualized IPAP/EPAP pressures, was applied for 3 days postoperatively. IPAP and EPAP in the Bi-PAP system were individualized for each patient in accordance with accepted values of SpO2, PaCO2, and patient synchronization and tolerability with the device.Individualized setting of pressures in patient group was applied gradually starting with 12/4 cm H2O (IPAP/EPAP) and up to 18/10 (IPAP/EPAP) with consecutive increases of 2 cm H2O.
2873039|NCT03438370|No Intervention|Three monthly ART supply at facilities|Sites at which patients will be provided three monthly ART supply at health facilities.
2873040|NCT03438370|Experimental|Three monthly ART supply at CAGs|Sites at which patients will be provided three monthly ART supply at Community ART Groups (CAGs).
2873041|NCT03438370|Experimental|Six monthly ART supply at outreaches|Sites at which patients will be provided six monthly ART supply at Community distribution points or outreaches.
2873042|NCT03438357||Patients with multiple sclerosis|
2873043|NCT03438344|Experimental|Arm I (CMV-MVA triplex vaccine)|Patients receive multi-antigen CMV-modified vaccinia Ankara vaccine via injection on days 28 and 56 post-HCT.
2873044|NCT03438344|Placebo Comparator|Arm II (placebo)|Patients receive placebo via injection on days 28 and 56 post-HCT.
2873045|NCT03438331|Experimental|CBT-I|
2873046|NCT03438331|Active Comparator|CBT-D|
2873047|NCT03438331|No Intervention|Waiting-list control|
2873048|NCT03438318|Experimental|Part A (CMP-001 + atezolizumab)|Part A of the study will evaluate the safety and preliminary signs of efficacy for the combination of CMP-001 and atezolizumab. The combination of CMP-001 and atezolizumab has not been previously evaluated so Part A of the study will commence with a safety run in of 5 subjects treated with the combination treatment. After the first 5 subjects have passed a safety DLT observation period of 30 days and upon approval from the Safety Review Committee (SRC), Part A of the study will continue with enrollment of an additional 7 subjects to complete Part A Stage 1. If an acceptable safety profile is established and at least 2 responders out of 12 evaluable subjects are seen in Part A Stage 1, the study will enroll an additional 23 evaluable subjects in Part A Stage 2. A maximum of 35 evaluable subjects will be enrolled in Part A.
2873049|NCT03438318|Experimental|Part B (low level radiation + CMP-001 + atezolizumab)|"Part B will evaluate the addition of low-level radiation therapy to the combination of CMP-001 and atezolizumab. Radiation therapy will consist of a dose of 20Gy delivered in 5 fractions (using either photons or protons). The radiation will be delivered to target lesion(s) (either a metastatic lymph node or a metastatic lesion), which will later be injected by CMP-001. Radiation will be delivered over the course of 5 consecutive days, prior to the first IT CMP-001 injection.~Part B will follow the same Simon-2 stage optimal design approach as Part A by enrolling 12 subjects in Part B Stage 1 and continuing with enrollment of 23 additional subjects in Part B Stage 2 only if an acceptable safety profile is established and there are at least 2 out of 12 responders in Part B Stage 1. There will be no safety run in for Part B of the study. A maximum of 35 evaluable subjects will be enrolled in Part B."
2873050|NCT03438305||Group D|
2873051|NCT03438305||Group N|
2873052|NCT03438292|Experimental|Group A|After an 8-10 hour overnight fast, Group A will receive two soft capsules of TPGS emulsified berberine. Following a 7 day wash out period, Group A participants will then receive two hard shell capsules of the berberine reference powder. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
2873053|NCT03438292|Experimental|Group B|After an 8-10 hour overnight fast, Group B will receive a single dose of the berberine reference powder in hard shell capsules. Following a 7 day wash out period, Group B participants will then receive two soft gel capsules of TPGS emulsified berberine.Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
2873054|NCT03438279||First-Line Ipilimumab|patients who received ipilimumab as their first-line treatment
2873055|NCT03438266|Experimental|JUVÉDERM VOLUMA® XC injectable gel with cannula|Subjects will have 1 cheek injected with JUVÉDERM VOLUMA® XC injectable gel with a cannula
2873056|NCT03438266|Other|JUVÉDERM VOLUMA® XC injectable gel with needle|Subjects will have 1 cheek injected with JUVÉDERM VOLUMA®XC injectable gel with a needle
2873057|NCT03438240|Active Comparator|Group BF|Bupivacaine plus Fentanyl
2873058|NCT03438240|Active Comparator|Group BD|Bupivacaine plus Dexmedetomidine
2873059|NCT03438227|Experimental|Intravenous iron dextran infusion|Women randomized to receive intravenous iron infusion will receive a single infusion of dextran 1000mg IV as an inpatient on the antepartum or Labor & Delivery Unit. They will receive continuous fetal monitoring for 30 minutes before and after the infusion as well for the duration of the infusion
2873060|NCT03438227|Active Comparator|Oral ferrous sulfate supplementation|Women randomized to continue oral iron will continue to take ferrous sulfate 325mg one to three tablets daily, with the final dose at the discretion of the patient's obstetric provider.
2873061|NCT03438214|Active Comparator|Vancomycin continuous infusion|Continuous infusion of vancomycin
2873062|NCT03438214|Active Comparator|Vancomycin intermittent infusion|Intermittent infusion of vancomycin
2873063|NCT03438201|Active Comparator|High-protein diet|High Protein Diet (2,0 - 2,5g/Kg body weight/day) Physical Activity protocol
2873064|NCT03438201|Active Comparator|Normoproteic diet|Standard Protein Diet (1,0 - 1,2g/Kg body weight/day) Physical Activity protocol
2873065|NCT03438188|Experimental|Smoker Group|The smokers group will be scanned on 2 occasions: (1) after a 4 day monitored practice quit attempt (biochemically verified), and (2) after 4 days of smoking as usual (order counterbalanced).
2873066|NCT03438188|No Intervention|Non-Smoking Comparison Group|Healthy non-smokers will complete one period (comparable to abstinence arm) of the study to serve as a baseline comparison group.
2873067|NCT03438175|No Intervention|Control|Families of Critically Ill will be informed about patients'clinical status only by oral communication during daily family meeting
2873068|NCT03438175|Experimental|Intervention|Families of critically ill patients will receive during the first ICU day of their loved one a brochure presenting the ICU and inviting them to visit a website specifically created for this project: www.intensiva.it Moreover, in the waiting room of the ICU will be placed 8 posters to improve comprehension and to legitimize emotions.
2873069|NCT03438162|No Intervention|Control group|Patients in both groups received diabetes education during the hospital stay. Standardized diabetes education includes education regarding the disease, diet, physical activity, alcohol intake, smoking, education regarding diabetes medication, self monitoring of glucose, and education regarding acute and chronic complications.
2873070|NCT03438162|Experimental|Intervention group|Patients in both groups received diabetes education during the hospital stay. Standardized diabetes education includes education regarding the disease, diet, physical activity, alcohol intake, smoking, education regarding diabetes medication, self monitoring of glucose, and education regarding acute and chronic complications. Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
2873071|NCT03438136|Experimental|Intervention arm|This arm will be enrolled in the intervention.
2873072|NCT03438136|No Intervention|No intervention arm|This arm will be enrolled in a no contact control group.
2873073|NCT03438084|Experimental|Interesterified|Commercially available interesterifed fat spread. 50g fat.
2873074|NCT03438084|Active Comparator|Non- interesterified|Commercially available non-interesterified fat. 50g fat.
2873075|NCT03438084|Active Comparator|Control|Rapeseed oil. 50 g fat.
2873076|NCT03438071||Control group|
2873077|NCT03438071||Videoconference group|
2873078|NCT03438058||With complement-activating anti-HLA DSAs|Patients with complement-activating anti-HLA DSAs either C1q, C3d, C4d and IgG subclass
2873079|NCT03438058||Without complement-activating anti-HLA DSAs|Patients with anti-HLA DSAs but without the ability to activate the complement (either C1q, C3d, C4d and IgG subclass)
2873080|NCT03438058||Without DSAs and without complement-activating DSAs|Matching group of patients without DSAs and without complement-activating DSAs
2873081|NCT03438045|Experimental|Partnered Intervention|The aspects of the partnering package of evidence-based intervention strategies are: (1) written agreements of collaboration for dental screening, health promotion, and incentives; (2) culturally-tailored and language-specific adaptation of materials; (3) demonstrations with role-playing of proper brushing with fluoride toothpaste and flossing techniques; and (4) CHW follow-up with patients of oral health care receipt and dental hygiene behaviors. Additionally, bilingual (English and Mandarin Chinese) CHWs will receive additional training in oral health promotion demonstration, oral health services and programs available at local clinics and hospitals, information about dental and health insurance, and evidence-based oral health behaviors.
2873082|NCT03438032||SSc-ILD|SSc-ILD subjects will be defined by those who fulfill 2013 American College of Rheumatology SSc criteria and have forearm modified Rodnan skin scores/mRSS ≥1 (a validated, semi-quantitative scoring system for dermal fibrosis) and clinically relevant SSc-interstitial lung disease (ILD). A subject will be defined as having ILD if they have radiographic evidence for ILD and a forced vital capacity <70% on PFT.
2873083|NCT03438032||Control|Healthy control subjects recruited from the Northwestern community will complete demographic and basic medical forms to ensure health
2873084|NCT03438019|Experimental|TIRE IMT|The TIRE IMT group will receive a tablet with the TIRE software installed and a PrO2® device through which they will train. Training consists of six levels (A-F) with six inspirations at each level for a total of 36 breaths. Recovery times between breaths range from 40 to 5 seconds as the subject advances each level. TIRE data will be stored in the tablet for subsequent interrogation and data retrieval.
2873085|NCT03438019|Experimental|Standard IMT group|The Standard IMT group will receive a Threshold® Inspiratory Muscle Trainer. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject. Subjects will be instructed to perform up to 36 breaths daily. To compare with TIRE training, we will ask participants to perform this within a 30-minute session.
2873086|NCT03438019|Sham Comparator|Sham IMT group|The Sham IMT group will also receive a Threshold® device and undergo the exact protocol of group 2 but with minimal resistance applied (7 cm H2O, the lowest in the device).
2873087|NCT03438006||Cervarix group|Healthy female Chinese subjects aged between 9 and 25 years, vaccinated according to the Prescribing Information (PI) as per routine practice.
2873088|NCT03437993|Experimental|Recollect|Recollect is a video game which incorporates scientifically supported renditions of N-Back, Item Span, and Multiple-Identity tracking tasks. These tasks are independently shown to improve working memory in a manner that transfers to untrained tasks.
2873089|NCT03437993|Sham Comparator|Tetris|Tetris is a video game which has not been shown to have any benefits in the improvement of executive functioning.
2873090|NCT03437980|Experimental|propofol spinal acceptance|"The surgeon and the anesthetist will discuss the exclusion criteria. Then they will discuss the information's about spinal and general anesthesia with the illegible patients, also reply the patient's questions in a preoperative visit. The primary decision for the patient; either spinal or general anesthesia will be recorded.~The patients refusing spinal anesthesia will be discussed again to detect the rate of acceptance of spinal anesthesia if propofol sedation is ensured during the procedure to provide a painless spinal injection. The final decision will be applied; either spinal with procedural sedation, or general anesthesia."
2873161|NCT03437499|Active Comparator|Positive Pressure Ventilation|Positive Pressure Ventilation ( peak pressure set at 25 cmH20 and PEEP set at 5 cmH2O, with 40 inflations per minute)
2873162|NCT03437499|Experimental|Sustained Inflation|Prolonged inflation ( 25 cmH20 for 15 seconds) followed by PEEP set at 5 cmH2O
2873693|NCT03433833|Experimental|Intervention|Patients will be given digoxin orally daily for 12 weeks
2873091|NCT03437967|Other|ABAB|"Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA).~ABAB initial period is active treatment - LASER.~Active Treatment:~LASER light is delivered to the skin and deeper tissues affected by pain using either a wand or glass roller ball. Ten to 25 Watts of LASER energy is delivered to the painful regions for 8 to 16 minutes depending on the size of the area treated and other factors such as skin pigmentation."
2873092|NCT03437967|Other|BABA|"Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA).~BABA initial period is sham treatment - LOW LEVEL LASER.~LOW LEVEL LASER treatment:~Low level LASER is provided in a similar fashion using LASER power levels (1 Watt) that produce warmth only at superficial skin levels."
2873093|NCT03437954|Other|Standard soft diet|
2873094|NCT03437954|Other|Non-restricted diet|
2873095|NCT03437941|Experimental|Dose Escalation|Patients will be treated with enzalutamide monotherapy once daily for 28 days followed by combination treatment with CORT125281 at escalating dose levels and enzalutamide once daily in 28-day dosing cycles.
2873096|NCT03437941|Experimental|Dose Expansion - Cohort A|Patients who have progressed during treatment with abiraterone and no other AR-blocking therapies will be treated with CORT125281 and enzalutamide.
2873097|NCT03437941|Experimental|Dose Expansion - Cohort A Food Effect|Sub-Cohort (first 10 patients enrolled into Cohort A). Patients enrolled into this subcohort will receive a single dose of CORT125281 at Cycle 1 Day -7 and a single dose of CORT125281 at Cycle 1 Day 1 30 minutes after a standard breakfast to assess the effect of food on PK parameters. Patients will then begin CORT125281 in combination with enzalutamide on Cycle 1 Day 2 and continue in 28-day dosing cycles.
2873098|NCT03437941|Experimental|Dose Expansion - Cohort B|Patients who progressed during treatment with enzalutamide or second-generation AR-blocking therapies will be treated with a daily dose of CORT125281 and enzalutamide.
2873099|NCT03437928|Experimental|Directional Deep Brain Stimulation|
2873100|NCT03437915|Experimental|Treatment Arm|28.5 Gy delivered in 5 daily fractions then 4-12 weeks post NIBB, surgery via partial mastectomy
2873101|NCT03437902|Experimental|Rutin C group|patients will receive Rutin 60 mg in combination with vitamin C 160 mg three times daily in addition to usual antidiabetic treatment for 8 weeks..
2873102|NCT03437902|Experimental|Vitamin C group|patients will receive vitamin C 500 mg once daily in addition to usual antidiabetic treatment for 8 weeks.
2873103|NCT03437902|No Intervention|Control group|patients will receive their usual antidiabetic treatment only for 8 weeks.
2873104|NCT03437889|Experimental|Epidural analgesia/anesthesia for childbirth|
2873105|NCT03437876|Experimental|patients with HBV induced cirrhosis|patients with HBV induced cirrhosis will be recruited for study, which involved a 4 times intestinal microbiota transplant and the time interval is generally 2 weeks.
2873106|NCT03437863|Experimental|Mobile application|Participants recruited from a self-management course are asked to use (single time) a mobile application to support reflection of personal strengths. The participant borrows an Ipad and uses the application to 1) reflect and identify their strengths by reviewing a list of examples, 2) define personal goals, and 3) link strengths to goals.
2873107|NCT03437850||South African cohort|
2873108|NCT03437850||Swedish Cohort|
2873109|NCT03437824|Experimental|Cyanocobalamin|Vitamin B12, 1,000 mg, Once
2873110|NCT03437824|Placebo Comparator|Placebo|Normal Saline Solution (0.9% Sodium Chloride), Once
2873111|NCT03437811|Other|Active Treatment|Active arm, Electro Flo Percussor, Model 5000 airway clearance system for daily basis as needed (pro re nata).
2873112|NCT03437785|Experimental|Experimental Group 1|Patients assigned to this group are treated with CKD-495 75mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 150mg, ,Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
2873113|NCT03437785|Experimental|Experimental Group 2|Patients assigned to this group are treated with CKD-495 150mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
2873114|NCT03437785|Placebo Comparator|Placebo Group|Patients assigned to this group are treated with 4 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
2873115|NCT03437785|Active Comparator|Active comparator Group 1|Patients assigned to this group are treated with Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of the Rebamipide 100mg Tab.)
2873116|NCT03437785|Active Comparator|Active comparator Group 2|Patients assigned to this group are treated with Rebamipide 100mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.)
2873117|NCT03437772||CBT with mindfulness|
2873118|NCT03437772||Treatment as Usual: Barkley therapy|
2873119|NCT03437759|Experimental|Experimental group|Our intervention is to add treatment of exosomes derived from mesenchymal stem cells (MSC-Exo) after pars plana vitrectomy(PPV) and ILM peeling.
2873120|NCT03437759|No Intervention|Control group|Control group that receives treatment of only pars plana vitrectomy(PPV) and ILM peeling.
2873121|NCT03437733|Experimental|Intervention|Ablation with Multi-electrode Radiofrequency (RF) Balloon Catheter
2873122|NCT03437720|Experimental|SAR425899 (Low Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
2873123|NCT03437720|Experimental|SAR425899 (High Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
2873124|NCT03437720|Placebo Comparator|Placebo (Low Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
2873125|NCT03437720|Placebo Comparator|Placebo (High Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
2873914|NCT03432286|Experimental|Galcanezumab|Galcanezumab administered by subcutaneous (SQ) injection.
2873126|NCT03437707|Placebo Comparator|placebo|250 ml saline will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
2873127|NCT03437707|Active Comparator|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
2873128|NCT03437707|Active Comparator|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
2873129|NCT03437694|Experimental|Medication Optimization Intervention|This group will represent those participants whose medical records have been provided to the pharmacist.
2873130|NCT03437694|Active Comparator|Medication Optimization Control|This group will represent those participants whose medical records have not been provided to the pharmacist.
2873131|NCT03437681|Experimental|Insufficient sleep|Each participant will receive 4 nights of insufficient sleep.
2873132|NCT03437668|Experimental|Withania Somnifera Extract (WSE)|WSE 500 mg bid for 12 weeks
2873133|NCT03437668|Placebo Comparator|Placebo tablets|Placebo oral tablet bid for 12 weeks
2873134|NCT03437655|Active Comparator|Zinc oxide and eugenol|Temporary direct restoration with zinc oxide and eugenol.
2873135|NCT03437655|Active Comparator|Mineral trioxide aggregate|Temporary direct restoration with Mineral trioxide aggregate.
2873136|NCT03437642||Tako-Tsubo - STP|Short term psychotherapy + Classic cardiological therapy
2873137|NCT03437642||Tako-Tsubo - Control|Classic cardiological therapy only
2873138|NCT03437642||Oncologic - STP|Short term psychotherapy + Classic oncological therapy
2873139|NCT03437642||Oncologic - Control|Classic oncological therapy only
2873140|NCT03437642||AMI - STP|Short term psychotherapy + Classic cardiological therapy
2873141|NCT03437642||AMI - Control|Classic cardiological therapy only
2873142|NCT03437642||Healthy Subjects|No therapy
2873143|NCT03437629|Active Comparator|Calcium Hydroxide temporary cement|Cementation of a temporary crown with cement based on calcium hydroxide.
2873144|NCT03437629|Active Comparator|MTA temporary cement|Cementation of a temporary crown with cement based on Mineral trioxide aggregate .
2873145|NCT03437616|Experimental|Tulppa rehabilitation|8-10 weekly 3-hour group sessions and two follow-up sessions (6 and 12 months).
2873146|NCT03437616|No Intervention|Control group|Control group does not receive Tulppa rehabilitation during the study.
2873147|NCT03437603|Experimental|Eltrombopag group|Starting dose is 25mg daily for the first 3 days, then increasing to 50mg for another week. Maintenance dosage is 50mg or 75 mg per day dependent on patients' status and doctors' opinion.Planned duration of treatment with eltrombopag is 8 weeks.When patients achieve persistent complete response for 2 weeks,they may stop medicine.
2873148|NCT03437590|Experimental|Part 1: JNJ-55308942 and [18F]-JNJ-64413739|Participants will first undergo a baseline positron emission tomography (PET)/ magnetic resonance (MR) scan with [18F]-JNJ-64413739 on Day 1. In Period 1 (on Day 2) and Period 2 (on Day 1), participants will receive oral dose of JNJ-55308942 (maximum dose 120 milligram [mg]). After approximately 4 hours of JNJ-55308942 dosing, participants will receive an intravenous (IV) injection of [18F]-JNJ-64413739, followed by a PET/MR scan. Doses will be selected based on the principal investigator's discretion. A wash-out period of at least 7 days will be maintained between the 2 doses of JNJ-55308942.
2873149|NCT03437590|Experimental|Part 2: JNJ-55308942 and [18F]-JNJ-64413739|Participants will first undergo a baseline PET/MR scan with [18F]-JNJ-64413739 on Day 1. Participants will receive oral dose of JNJ-55308942 (maximum dose 120 mg) on Day 2, followed by two post-treatment scans, one obtained at Tmax (4 hours postdose) and one at 24 hours postdose. Doses will be selected based on the principal investigator's discretion.
2873150|NCT03437577|Active Comparator|immediate-release tacrolimus|This is standard of care
2873151|NCT03437577|Experimental|extended release tacrolimus|replace standard of care
2873152|NCT03437564|Experimental|Lu AA21004 one 20 mg tablet + two 10 mg tablets|Lu AA21004 20 mg (one 20 mg tablet) on Day 1 in Period 1 in a fasted state + Lu AA21004 20 mg (two 10 mg tablets) on Day 1 in Period 2 in a fasted state.
2873153|NCT03437564|Experimental|Lu AA21004 two 10 mg tablets + one 20 mg tablet|Lu AA21004 20 mg (two 10 mg tablets) on Day 1 in Period 1 in a fasted state + Lu AA21004 20 mg (one 20 mg tablet) on Day 1 in Period 2 in a fasted state.
2873154|NCT03437551||no intervention|Cross-sectional Observation study
2873155|NCT03437538|Active Comparator|First MCO-HD, then High-flux-HDF|Participants with ongoing HDF-treatments (>3months) will have measurements during an intervention with a 4h dialysis with MCO-HD, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during a 4h dialysis with High-flux-HDF
2873156|NCT03437538|Active Comparator|First High-flux-HDF, then MCO-HD|Participants with ongoing HDF-treatments (>3months) will have measurements during a 4h dialysis with High-flux-HDF, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during an intervention with a 4h dialysis with MCO-HD
2873157|NCT03437525|Experimental|Peer Support Intervention|The experimental group will receive the peer support intervention for 12 months.
2873158|NCT03437525|No Intervention|Control|Usual care
2873159|NCT03437512|Experimental|Active tDCS and fluency training|Participants will receive anodal tDCS at 2milliampere (mA) intensity for 20 minutes during speech fluency training (5 consecutive days).
2873160|NCT03437512|Sham Comparator|Sham tDCS and fluency training|Participants will receive sham tDCS. Sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
2895379|NCT03281304|Experimental|CP-690,550 10 mg|CP-690,550 10 mg BID
2873163|NCT03437486||Familial Pulmonary Fibrosis|Subjects asked to participate in this study will be unaffected family members of patients previously diagnosed with familial interstitial pneumonia (FIP) which is the familial form of idiopathic pulmonary fibrosis (IPF).
2873164|NCT03437473|Active Comparator|Active stimulation QD|
2873165|NCT03437473|Active Comparator|Active stimulation QID|
2873166|NCT03437473|Sham Comparator|No stimulation|
2873167|NCT03437460|Active Comparator|Ibuprofen 600mg|Treatment group participants receive a single 600 mg of over-the-counter ibuprofen.
2873168|NCT03437460|Placebo Comparator|Prenatal vitamins|The placebo group participants receive a single dose of a pre-natal multivitamin.
2873169|NCT03437460|No Intervention|Control group|Control-group participants are not provided with any treatment and they are fully informed regarding their treatment status.
2873170|NCT03437447|Experimental|First Cisticid, Then Biltricide, Then Biltricide|Cisticid (Test) in Treatment Period 1 followed by Biltricide (Reference) in Treatment Period 2 and Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
2873171|NCT03437447|Experimental|First Biltricide, Then Cisticid, Then Biltricide|Biltricide (Reference) in Treatment Period 1 followed by Cisticid (Test) in Treatment Period 2 and then Biltricide (Reference) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
2873172|NCT03437447|Experimental|First Biltricide, Then Biltricide, Then Cisticid|Biltricide (Reference) in Treatment Period 1 and Treatment Period 2 followed by Cisticid (Test) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
2873173|NCT03437434||BunnyLens and Gore-Tex suture|All patients Underwent 4 point PC-IOL scleral fixation with Gore-Tex sutures
2873174|NCT03437421|Experimental|Type II diabetic patients|3 month Vitamin D3 (cholecalciferol) supplementation in patients with vitamin D deficiency, based on 25-OH-D3 dosage.
2873175|NCT03437421|Experimental|Type I diabetic patients|3 month Vitamin D3 (cholecalciferol) supplementation in patients with vitamin D deficiency, based on 25-OH-D3 dosage.
2873176|NCT03437408|Experimental|Mapping and ablation|Automated Substrate maps with different pacing modes. Validation of collected substrate. Data collection during ablation
2873177|NCT03437395|Other|Partial Breast Irradiation|All participants will be treated with partial breast irradiation by utilizing 3D conformal external beam irradiation or balloon brachytherapy. This is not a randomized study.
2873178|NCT03437382|Other|RFA + radioembolization|Quirem Medical Holmium-166 radioembolization microspheres
2873179|NCT03437369|Experimental|Ivabradine|Drug: Ivabradine Oral tablets 2.5 mg Dose: 10-15 mg/day Duration: 30 days
2873180|NCT03437369|Other|Standard of Care|The study drug will be compared with standard of Care treatment
2873181|NCT03437356|Active Comparator|ADT ON Group|'CLOSE'-guided PVI with continuation of antiarrhythmic drug therapy (ADT) at the end of the 3-months blanking period after ablation.
2873182|NCT03437356|Active Comparator|ADT OFF Group|'CLOSE' guided PVI with discontinuation of antiarrhythmic drug therapy (ADT) at the end of the 3-months blanking period after ablation
2873183|NCT03437330|Experimental|Empagliflozin (Jardiance®)|Dose/frequency: 25 mg once daily for 12 weeks Route of administration: oral
2873184|NCT03437330|Active Comparator|Insulin Glargine (Lantus®)|"Thus, insulin glargine doses should be adapted as follows:~FBG 6-7 mmol/L: +2 IU FBG 7-8 mmol/L: +4 IU FBG > 8 mmol/L: +6 IU"
2873185|NCT03437317|Experimental|Active - MEG|Participants completed 1 session of 8 Perceptual Retraining blocks following an instructional presentation.
2873186|NCT03437317|Sham Comparator|Control - MEG|Participants completed 1 session of 8 blocks of Gender Discrimination Task.
2873187|NCT03437317|Experimental|Active - 3 Behavior/EEG|Participants completed 3 sessions of Perceptual Retraining following an instructional presentation. The first session included 6 blocks of perceptual training, and the second session included 12 blocks of perceptual training. No perceptual training was performed in session 3. Sessions were spaced approximately 7 days apart, with a minimum of 3 days and a maximum of 14 days apart.
2873188|NCT03437317|Experimental|Active - 1 Behavior/MEG|Participants completed 1 session of 6 Perceptual Retraining blocks following an instructional presentation.
2873189|NCT03437317|Sham Comparator|Control - 3 Behavior/MEG|Participants completed 3 sessions of a Gender Discrimination Task. The first session included 6 blocks of gender discrimination task, and the second session included 12 blocks of the gender discrimination task. No gender discrimination task was performed in session 3. Sessions were spaced approximately 7 days apart, with a minimum of 3 days and a maximum of 14 days apart.
2873190|NCT03437304|Experimental|Immunose™ FLU 1%|Immunose™ FLU 1%. QIV, 30 μg HA/strain and 1% Endocine™ 200 μl for intranasal administration, 2 dosing occasions.
2873191|NCT03437304|Experimental|Immunose™ FLU 2%, 200 μl|Immunose™ FLU 2%. QIV, 30 μg HA/strain and 2% Endocine™, 200 μl for intranasal administration, 2 dosing occasions.
2873192|NCT03437304|Experimental|Immunose™ FLU 2%, 300 μl|Immunose™ FLU 2%, 300 μl. QIV, 30 μg HA/strain and 2% Endocine™, 300 μl for intranasal administration, 2 dosing occasions.
2873193|NCT03437304|Experimental|Influenza antigen|Influenza antigen. QIV, 30 μg HA/strain, 200 μl for intranasal administrations, 2 dosing occasions.
2873194|NCT03437304|Placebo Comparator|Placebo|Placebo. Saline (NaCl), 200 μl for intranasal administration, 2 dosing occasions.
2873195|NCT03437304|Experimental|i.m comparator and Immunose™ FLU 2%|i.m comparator: QIV 15 μg HA/strain, 500 µl for a single intramuscular administration, and Immunose FLU 2%: QIV 30 μg HA/strain and 2% Endocine™, 200 μl for intranasal administration. A second dose of Immunose FLU 2% will be administered 3 weeks later.
2873196|NCT03437304|Active Comparator|i.m comparator|i.m comparator. QIV 15 μg HA/strain, 500 µl for a single intramuscular administration.
2873197|NCT03437291||Abnormal placental invasion|patients had placenta previa with histopathologically confirmed abnormal invasion with all three grades i.e. accreta, increta and percreta,
2873198|NCT03437291||Normal placenta|patients had placenta previa with no abnormal invasion
2873199|NCT03437278|Experimental|A. Ligelizumab high dose|1 injection of ligelizumab (high dose) every 4 weeks from Day 1 to Week 20 (inclusive)
2873200|NCT03437278|Experimental|B.Ligelizumab low dose|1 injection of ligelizumab (low dose)every 4 weeks from Day 1 to Week 20 (inclusive)
2873272|NCT03436732|Experimental|1/Dose Escalation|Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses
2873201|NCT03437278|Placebo Comparator|C. Placebo|1 injection of placebo at Day 1, Week 4, Week 8; followed by the same treatment as in Arm A from week 12 onwards to week 20 (inclusive)
2873202|NCT03437265|Experimental|NER1006 powder for oral solution|"Oral administration of 1 sachet (115.96 g) NER1006 Dose 1 (containing PEG 3350, sodium sulfate and electrolytes), to be reconstituted with water and made up to 500 mL, consumed over approximately 30 min, followed by 500 mL water, consumed over approximately 30 min. Additional water may be drunk ad libitum after the dose.~Following 1 hour rest period, oral administration of 2 sachets (101.91 g) NER1006 Dose 2 (containing sodium ascorbate, PEG 3350, ascorbic acid and electrolytes), to be reconstituted with water and made up to 500 mL, consumed over approximately 30 min, followed by 500 mL water, consumed over approximately 30 min. Additional water may be drunk ad libitum after the dose."
2873203|NCT03437239|Experimental|Occlusion Training|Patients undergoing a biceps tenodesis that are expected to begin a rehabilitation protocol with strength training by 6 weeks postoperatively for a continued 12 weeks course of 2-3 times per week of occupational therapy to include occlusion training.
2873204|NCT03437239|No Intervention|Non-occlusion Training|Patients undergoing a biceps tenodesis that are expected to begin a rehabilitation protocol with strength training by 6 weeks postoperatively for a continued 12 weeks course of 2-3 times per week of occupational therapy without occlusion training (standard of care).
2873205|NCT03437226|Experimental|Levosimendan Arm|Patients receive 6 or 24 hours infusion depending on the site. Levosimendan 2.5 MG/M 6h infusion group: 0,2 μg/kg/min 7 times (day 0, 14, 28, 42, 56, 70, 84) Levosimendan 24h infusion group: 0,1 μg/kg/min 5 times (day 0, 21,42,63,84) Levosimendan
2873206|NCT03437226|Placebo Comparator|Placebo Arm|Patients receive 6 or 24 hours infusion depending on the site. 6h infusion group: 0,2 μg/kg/min 7 times (day 0, 14, 28, 42, 56, 70, 84) Placebo 24h infusion group: 0,1 μg/kg/min 5 times (day 0, 21,42,63,84) Placebo
2873207|NCT03437213|Experimental|Total intravenous anesthesia group|propofol, and fentanyl-based regimen.
2873208|NCT03437213|Active Comparator|Total intravenous plus block group|ultrasound guided paravertebral block before induction then propofol and fentanyl maintenance.
2873209|NCT03437200|Experimental|Arm A: Chemoradiation + Nivolumab|"All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX followed by 3 cycles of 2 weeks of FOLFOX without RT.~Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year."
2873210|NCT03437200|Experimental|Arm B: Chemoradiation + Nivolumab + Ipilimumab|Same as arm A + induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year
2873211|NCT03437187|Other|Cholecystectomy without nerve blocks|Cholecystectomy, enteral and parenteral analgesics
2873212|NCT03437187|Placebo Comparator|Cholecystectomy with placebo nerve block|Cholecystectomy, NaCl as a placebo Quadratus lumborum block
2873213|NCT03437187|Active Comparator|Cholecystectomy with naropin nerve block|Cholecystectomy, Quadratus lumborum block with naropin
2873214|NCT03437161|Experimental|Radiation Therapy (RT)|Patients attend a simulation visit and undergo two CT scans, one in the prone position and one in the supine position with DIBH. Within 1 week after the simulation visit, patients undergo radiation therapy either in the supine position with DIBH or in the prone position daily for 15-30 consecutive days as per physician's prescription.
2873215|NCT03437148|Experimental|patients with Atrial septal defect type Ostium Secundum|patients with Atrial septal defect type Ostium Secundum, eligible for an interventional closure
2873216|NCT03437135||Witness patients|Healthy Volunteers
2873217|NCT03437135||Type 1 diabetic patients|patients with type 1 diabetes
2873218|NCT03437135||Type 2 diabetic patients|patients with type 2 diabetes
2873219|NCT03437122|Experimental|All|
2873220|NCT03437096|Other|venipuncture pain|pain during venipuncture
2873221|NCT03437083||Eribulin|Eribulin was administered at a dose of 1.4 milligrams per meters squared (mg/m^2) (as eribulin 1.23 mg/m^2) by a 2- to 5-minute intravenous infusion or as a diluted solution on Day 1 and Day 8 every 21 days.
2873222|NCT03437070|Experimental|TDO Dose Level 1|Trabectedin [T], Doxorubicin [D], and Olaratumab [O] Dose Level 1
2873223|NCT03437070|Experimental|TDO Dose Level 2|Trabectedin [T], Doxorubicin [D], and Olaratumab [O] Dose Level 2
2873224|NCT03437070|Experimental|TDO Dose Level 3|Trabectedin [T], Doxorubicin [D], and Olaratumab [O] Dose Level 3
2873225|NCT03437070|Experimental|TDO Dose Level 4|Trabectedin [T], Doxorubicin [D], and Olaratumab [O] Dose Level 4
2873226|NCT03437057|Experimental|Patients treated with KARDEGIC 75mg|Prospective single-arm study to estimate the risk of renal hematoma when performing a session of lithotripsy for renal lithiasis, on a 15-day scanner, in patients treated with KARDEGIC 75mg No suspended.
2873227|NCT03437044|Experimental|Ticagrelor|180 mg loading dose (LD) followed by a 60 mg bid maintenance (MD) starting 12 h (± 1 h) after the LD
2873228|NCT03437044|Active Comparator|Clopidogrel|600 mg LD followed by a 75 mg od MD starting 24 hours (± 1 h) after the LD
2873229|NCT03437031|No Intervention|Latent-Control|Patients in the latent phase of labor who will receive no intervention.
2873230|NCT03437031|Experimental|Latent-VR|Patients in the latent phase of labor who will receive the VR intervention.
2873231|NCT03437031|No Intervention|Active-Control|Patients in the active phase of labor who will receive no intervention.
2873232|NCT03437031|Experimental|Active-VR|Patients in the active phase of labor who will receive the VR intervention.
2873233|NCT03437005|Experimental|Desonide 0.05%|Low potency steroid topical medication applied to specific locations on the face and extremities, twice daily for two weeks
2873234|NCT03437005|Experimental|Ketoconazole 2%|Antifungal topical medication applied to specific locations on the face and extremities, twice daily for two weeks
2873235|NCT03436992|Experimental|Women with type 1 diabetes|Women with type 1 diabetes will be randomly assigned to 1 of the 3 interventions (Antioxidant cocktail, Resveratrol, or placebo)
2873236|NCT03436992|No Intervention|Healthy control women|Healthy women who participate will receive no intervention and serve as controls.
2873237|NCT03436992|Experimental|Men with type 1 diabetes|Men with type 1 diabetes will be randomly assigned to 1 of the 3 interventions (AOX cocktail, Resveratrol, or placebo)
2873915|NCT03432286|Placebo Comparator|Placebo|Placebo administered by SQ injection.
2873238|NCT03436979||Subjects|Subjects who are undergoing surgical treatment for uterine prolapse will be included in the study and will be treated using the NeuGuide™ System.
2873239|NCT03436953|Experimental|CX-8998 T-type calcium channel blocker|
2873240|NCT03436953|Placebo Comparator|Comparator|
2873241|NCT03436940|Active Comparator|On Demand Discharge Planning (DDP)|Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team only in case of a specific request by the unit of hospitalization.
2873242|NCT03436940|Experimental|Routine Discharge Planning (RDP)|All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
2873243|NCT03436927|Experimental|Nintendo Wii Fit|Participants in the Nintendo Wii group were included to exercise program that consisted of 16 individual PT-supervised sessions (two 60-minute sessions/week), which were prepared to improve balance. Each session started with 10 minutes of non-resistance cycling work for warm-up.
2873244|NCT03436927|Experimental|Balance Trainer|Participants in the Balance Trainer group were included to exercise program that consisted of 16 individual PT-supervised sessions (two 60-minute sessions/week), which were prepared to improve balance. Each session started with 10 minutes of non-resistance cycling work for warm-up.
2873245|NCT03436927|No Intervention|Control|Patients in the 'Group III-control group' were included in the waiting list until the end of the study.
2873246|NCT03436914|Experimental|PPI|Esomezol®
2873247|NCT03436901|Other|Testicular cancer st. II-III|MRI with DWI vs CT
2873248|NCT03436875||FH+|FH+ = having at least 1 parent with type 2 diabetes
2873249|NCT03436875||FH-|FH- = having no history of type 2 diabetes for two generations (parents and grandparents)
2873250|NCT03436862|Experimental|Nivolumab|Patients will receive Nivolumab 240 mg by intravenous infusion (IV) starting Day 45-120 post-transplant (±10 days) every 2 weeks for up to a maximum of 6 months of treatment.
2873251|NCT03436849|Experimental|ESN364 dose-1 group in Part 1|Healthy male subjects will receive a single dose of ESN364.
2873252|NCT03436849|Experimental|ESN364 dose-2 group in Part 1|Healthy male subjects will receive a single dose of ESN364.
2873253|NCT03436849|Placebo Comparator|Placebo group in Part 1|Healthy male subjects will receive a single dose of Placebo.
2873254|NCT03436849|Experimental|Male ESN364 group in Part 2|Healthy male subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
2873255|NCT03436849|Experimental|Pre-menopausal female ESN364 group in Part 2|Healthy pre-menopausal female subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
2873256|NCT03436849|Experimental|Post-menopausal female ESN364 group in Part 2|Healthy post-menopausal female subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
2873257|NCT03436849|Placebo Comparator|Male placebo group in Part 2|Healthy male subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
2873258|NCT03436849|Placebo Comparator|Pre-menopausal female placebo group in Part 2|Healthy pre-menopausal female subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
2873259|NCT03436849|Placebo Comparator|Post-menopausal female placebo group in Part 2|Healthy post-menopausal female subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
2873260|NCT03436836|Experimental|Group N|"group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU) and 4mg of nalbuphine in 1 ml normal saline.~Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe. If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study"
2873261|NCT03436836|Active Comparator|Group C|Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline
2873262|NCT03436823|Experimental|R.TMS + nurse semi-structured interview|Repeated Transcranial Magnetic Stimulation sessions associated with nurse semi-structured interview
2873263|NCT03436823|Sham Comparator|R.TMS + Music & Relaxation|Repeated Transcranial Magnetic Stimulation sessions associated with music listening & relaxation with eyes closed
2873264|NCT03436810|Experimental|Experimental group|The experimental group will receive training programs of Motor imagery (MI) for 25 minutes and Task-Oriented Circuit Class Training (TOCCT) for 65 minutes. Overall duration of program session will be 90 minutes. Training for 3 times a week over duration of 4 weeks.
2873265|NCT03436810|Active Comparator|Control group|The control group receives programs of Health education (HE) for 25 minutes and Task-Oriented Circuit Class Training (TOCCT) for 65 minutes. Overall duration will be 90 minutes. They will be trained for 3 times a week over duration of 4 weeks.
2873266|NCT03436784|No Intervention|Control Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group. The control group participants received no lessons. Control group participants received the same study assessments at the same timepoints as the intervention group. The control group participants may have had limited contact with the nutrition educators only to update contact information, to set or remind of appointments to complete study assessments, or to receive non-nutrition or non-resource management resources.
2873267|NCT03436784|Experimental|Intervention Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group.The Intervention group participants received lessons from the nutrition educators, completed the same study assessments at the same timepoints as the control group, and may have had additional interaction with the nutrition educators in accordance with normal Indiana SNAP-Ed protocol.
2873268|NCT03436771||JCAR017-treated|Patients who received previous treatment with JCAR017
2873269|NCT03436771||JCARH125-treated|Patients who received previous treatment with JCARH125
2873270|NCT03436745|Experimental|Zolpidem pre and post castration|5 mg oral dose of zolpidem prior to undergoing ADT followed by 5 mg oral dose of zolpidem after ADT and testosterone reaches castrate levels
2873271|NCT03436745|Active Comparator|Female|Single 5 mg oral dose of zolpidem
2873274|NCT03436719|Experimental|Oral with Intravenous|Oral metronidazole and erythromycine administration on the day before surgery with intravenous cefoperazone before surgery (30-90 min) and additional doses every third hour during surgery
2873275|NCT03436719|Active Comparator|Intravenous|Intravenous dose cefoperazone before surgery (30-90 min) and additional doses every third hour during surgery
2873276|NCT03436706||Participants|The cohort will consist of male and female children ages 11-12 accompanied by a participating parent over the age of 18 years. The family income of participants in this cohort cannot exceed 200% of the federal poverty level established in 2018.
2873277|NCT03436693|Experimental|Canagliflozin 100mg|
2873278|NCT03436693|Placebo Comparator|Placebo|
2873279|NCT03436680|Experimental|Group 1: Home-Based Neurofeedback (HBNF) Group|"Participants have an electroencephalogram (EEG) at baseline and during each HBNF session.~Participants complete at least 2 neurofeedback training sessions each week for up to 5 weeks (20 training sessions total).~At each neurofeedback training session, participants rate symptoms on the computer on a scale of 0-10 before beginning the neurofeedback training and again after the session is complete.~Questionnaires completed at baseline and within 1 week after the last neurofeedback training session."
2873280|NCT03436680|Other|Group 2: Waitlist Control Group|"Participants have an electroencephalogram (EEG) at baseline.~Questionnaires completed at baseline and again in 6 weeks."
2873281|NCT03436667||Orthopedic surgery|Pediatric patients presenting for ambulatory orthopedic procedures
2873282|NCT03436654|Experimental|ADT + Apalutamide|
2873283|NCT03436654|Experimental|ADT + Apalutamide + Abiraterone Acetate + Prednisone|
2873284|NCT03436628|Experimental|App Use|Kids (10-15 years old) with type 1 diabetes and one of their parents will receive the MyT1DHero app to use for a 3-month period. Participants are urged to use the app four times each day.
2873285|NCT03436615|Experimental|SB206 4%|SB206 4% topically twice daily
2873286|NCT03436615|Experimental|SB206 8%|SB206 8% topically twice daily
2873287|NCT03436615|Experimental|SB206 12%|SB206 12% topically once or twice daily
2873288|NCT03436615|Placebo Comparator|Placebo (vehicle gel)|Vehicle Gel topically once or twice daily
2873289|NCT03436602||Training cohort|Cohort of follicular lymphoma patients for the development of the multilayer risk stratification model
2873290|NCT03436602||Validation cohort|Cohort of follicular lymphoma patients for the validation of the developed multilayer risk stratification model
2873291|NCT03436589|No Intervention|Control Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group. The control group participants received no lessons. Control group participants received the same study assessments at the same timepoints as the intervention group. The control group participants may have had limited contact with the nutrition educators only to update contact information, to set or remind of appointments to complete study assessments, or to receive non-nutrition or non-resource management resources.
2873292|NCT03436589|Experimental|Intervention Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group.The Intervention group participants received lessons from the nutrition educators, completed the same study assessments at the same timepoints as the control group, and may have had additional interaction with the nutrition educators in accordance with normal Indiana SNAP-Ed protocol.
2873293|NCT03436576|Active Comparator|Autologous Serum 20%|Treatment with Autologous Serum 20% for 2 months
2873294|NCT03436576|Active Comparator|Autologous Serum 50%|Treatment with Autologous Serum 50% for 2 months
2873295|NCT03436563|Experimental|Cohort A: MSI-H mCRC|M7824 administered intravenously at a dose of 1200 mg every 14 days. M7824 administered until documented PD, unacceptable toxicity, or withdrawal of informed consent.
2873296|NCT03436563|Experimental|Cohort B: CMS4 mCRC|M7824 administered intravenously at a dose of 1200 mg every 14 days. M7824 administered until documented PD or unacceptable toxicity, or withdrawal of informed consent.
2873297|NCT03436563|Experimental|Cohort C: Non-CRC MSI-H Solid Tumors|M7824 administered intravenously at a dose of 1200 mg every 14 days. M7824 administered until documented PD, unacceptable toxicity, or withdrawal of informed consent.
2873298|NCT03436550||Patients with Chronic Liver Disease|
2873299|NCT03436550||Control Group|
2873300|NCT03436537||Gingival recession (GR) group|GR group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale
2873301|NCT03436537||Gingival enlargement (GE) group|GE group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale.
2873302|NCT03436537||periodontal healthy (H) group|H group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale.
2873303|NCT03436524||Training cohort|Cohort of chronic lymphocytic leukemia patients at Binet A stage for the development of the risk stratification model
2873304|NCT03436524||Validation cohort|Cohort of chronic lymphocytic leukemia patients at Binet A stage for the validation of the risk stratification model
2873305|NCT03436511||Subjects with COPD|Subjects with a COPD diagnosis confirmed with a post-bronchodilator Forced Expiratory Volume in 1 second/Forced Vital capacity <70% recorded at any time in the medical record who have a qualifying peripheral blood eosinophil test recorded in the 3 months prior to the inclusion visit attend to a routine follow-up visit during the inclusion period, fulfill the inclusion/exclusion criteria and provide informed consent to participate, will be included in this study.
2873306|NCT03436498|Experimental|SAR341402/NovoLog|SAR341402 will be self-administered via continuous subcutaneous insulin infusion via an insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion. After 4 weeks of SAR341402 as treatment, patient will switch with NovoLog® as treatment.
2873307|NCT03436498|Experimental|NovoLog/SAR341402|Novolog will be self-administered via continuous subcutaneous insulin infusion via an insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion. After 4 weeks of NovoLog® as treatment, patient will switch with SAR341402 as treatment.
2873308|NCT03436485|Experimental|ODM-208 Part 1 Dose escalation|
2873309|NCT03436485|Experimental|ODM-208 Part 2 Dose expansion|
2873351|NCT03436251|Experimental|Local Hyperthermia at 44℃ for CIN2/HPV+|Local hyperthermia at 44℃ for 30 mins at days of 1,2,3 and 17, 18. HPV+ and CIN2.
2873398|NCT03435939|Experimental|losartan|a daily dose of 50 mg losartan for 7 days (for tolerability). Then, the losartan dose will be increased to 100 mg daily for 12 weeks.
2873310|NCT03436472|Experimental|dexmedetomidine group|For patients who were not intubated, dexmedetomidine was infused at a rate of 0.1 microgram/kg per hour from study recruitment on the day of surgery until 8:00 am on the first day after surgery. For patients who were intubated and mechanically ventilated, dexmedetomidine infusion was started after the Richmond Agitation Sedation Scale was -2 or higher after intensive care unit admission until 8:00 am on the first day after surgery.
2873311|NCT03436472|Placebo Comparator|placebo group|Normal saline was infused in the same rate for the same duration as that in the placebo group.
2873312|NCT03436459|Active Comparator|Extracorporeal shock wave therapy group|Patients in the shock wave therapy group received total of 1000 shock waves for each treatment at the frequency of 10Hz, with 2 Bar pressure and energy flux density (EFD) of 0.25 mJ/mm2 per minute by using BTL-6000 SWT Topline Power® 3 times with a week's interval between the treatments.
2873313|NCT03436459|Active Comparator|Low Level Laser Therapy group|Patients in the laser therapy group received LLLT once a day for three weeks (altogether 15 working days) to the trigger points and around them in the upper trapezius. The type of laser used: PR999 4 Watt (W) scanning laser; Medical Italia®, around trigger points with 3 Joule /centimeter² (J/cm²), power 800 milliwatt (mW), frequency 2000 Hertz (Hz), on trigger points with 9 J/cm², power 2000mW, frequency 5000Hz for total of 2 minutes on each spot.
2873314|NCT03436446||Orthopedic Patients|Orthopedic patients will undergo an interview with the research team regarding the framing of various social incentives to promote increased response rates for patient reported outcome measures post-operatively.
2873315|NCT03436433|Active Comparator|Lacosamide|Enrolled subjects will be randomized to receive Lacosamide.
2873316|NCT03436433|Active Comparator|Levetiracetam|Enrolled subjects will be randomized to receive Levetiracetam.
2873317|NCT03436433|No Intervention|No anti-epileptic|Enrolled subjects will be randomized to not receive anti-epileptic drugs.
2873318|NCT03436420|Experimental|Gemcabene|Children receiving 12 weeks of treatment with gemcabene
2873319|NCT03436407||PrEP Group|Subject offered to start PrEP treatment in routine clinical practice
2873320|NCT03436407||Control Group|"Enrolled patients will be regarded as their own control when it comes to their sexual health and quality of life reported for period prior to inclusion in the study.~Subjects diagnosed with HIV within last 12 months in general clinical practice and referred to the outpatient clinic at the Dept. of Infectious Diseases, OUS. (details in protocol 3.3.2)~Frequency of STI reported to the National Institute of Public Health (MSIS) will be compared with the frequency of STIs in the study cohort."
2873321|NCT03436394|Experimental|Evobrutinib: Normal Renal Function|Subjects with estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 90 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2) will receive a single oral dose of evobrutinib under fasting conditions.
2873322|NCT03436394|Experimental|Evobrutinib: Severe Renal Impairment|Subjects with eGFR less than (<) 30 mL/min/1.73 m^2 will receive a single oral dose of evobrutinib under fasting conditions.
2873323|NCT03436394|Experimental|Evobrutinib: Moderate Renal Impairment|Subjects with eGFR >= to 30 mL/min/1.73 m^2 and < 60 mL/min/1.73 m^2 will receive a single oral dose of evobrutinib under fasting conditions.
2873324|NCT03436394|Experimental|Evobrutinib: Mild Renal Impairment|Subjects with eGFR >= to 60 mL/min/1.73 m^2 and < 90 mL/min/1.73 m^2 will receive a single oral dose of evobrutinib under fasting conditions.
2873325|NCT03436381||Overweight and obese patients|Patient undergoing elective upper endoscopy or colonoscopy, body mass index equal or greater than 25 kg/m2.
2873326|NCT03436368|Active Comparator|CSA group|Continuous Spinal Anesthesia
2873327|NCT03436368|Active Comparator|GA group|General Anesthesia
2873328|NCT03436355|Experimental|Physical activity|60 minutes of daily physical activity (see intervention)
2873329|NCT03436342|Experimental|68Ga-Pentixafor, PET/CT|Inject 68Ga-Pentixafor and then perform PET/CT scan.
2873330|NCT03436329|Experimental|Vein ligation first|During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.
2873331|NCT03436329|Active Comparator|Artery ligation first|During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.
2873332|NCT03436316|Experimental|Cohort 1|6 Participants will receive AZD8154 (single inhaled dose 1) and 2 participants will receive placebo.
2873333|NCT03436316|Experimental|Cohort 2|6 Participants will receive AZD8154 (single inhaled additional dose 2) and 2 participants will receive placebo.
2873334|NCT03436316|Experimental|Cohort 3|6 Participants will receive AZD8154 (single inhaled additional dose 3) and 2 participants will receive placebo.
2873335|NCT03436316|Experimental|Cohort 4|6 Participants will receive AZD8154 (single inhaled additional dose 4) and 2 participants will receive placebo.
2873336|NCT03436316|Experimental|Cohort 5|6 Participants will receive AZD8154 (single inhaled additional dose 5) and 2 participants will receive placebo.
2873337|NCT03436316|Experimental|Cohort 6|6 Participants will receive AZD8154 (single inhaled additional dose 6) and 2 participants will receive placebo.
2873338|NCT03436316|Experimental|Cohort 7|Participants will receive single IV dose 7 of AZD8154.
2873339|NCT03436303|Experimental|CEE 0.625 mg/MP 100mg|CEE 0.625 mg/micronized progesterone (MP) 100 mg daily for the last 12 days of every 28 days for two years
2873340|NCT03436303|Experimental|CEE 0.3 mg/MP 100mg|CEE 0.3mg/micronized progesterone (MP) 100 mg daily for the last 12 days of every 28 days for two years
2873341|NCT03436303|Experimental|CEE 0.625 mg/dydrogesterone 10mg|CEE 0.625 mg/dydrogesterone 10 mg daily for the last 12 days of every 28 days for two years
2873342|NCT03436290|Experimental|Palliative Care Intervention|
2873343|NCT03436290|No Intervention|Standard of Care|
2873344|NCT03436277|Placebo Comparator|Placebo|Sucralose 1,5 g
2873345|NCT03436277|Experimental|L-Carnitine|L- Carnitine 1,5 g
2873346|NCT03436264||high sensitivity to pain|
2873347|NCT03436264||low sensitivity to pain|
2873348|NCT03436251|Experimental|Local Hyperthermia at 44℃ for HPV+/CIN-1|Local hyperthermia at 44℃ for 30 mins on cervical region, at days of 1,2,3 and 17, 18. HPV+ and normal cytology or HPV+/CIN-1
2873349|NCT03436251|Sham Comparator|local hyperthermia at 37℃ for 30 mins|HPV+/CIN-1
2873350|NCT03436251|Active Comparator|coniztion of the cervix treatment|coniztion of cervix for HPV+/CIN2, including LEEP or cold knife coniztion
2873916|NCT03432273|Experimental|Nicotine 2 mg mint lozenges|
2873352|NCT03436238||MINSS cohort|"Adult patients >= 50 years old undergoing elective, major, abdominal surgery requiring at least one overnight stay in hospital.~Major abdominal surgery is defined as those classified as major OR major/complex by the Surgical Outcome Risk Tool (SORT) (www.sortsurgery.com)."
2873353|NCT03436225|Other|Group one|Group one will receive dexamethasone orally (0.15mg /kg / dose) twice daily for 3 to 5 days.
2873354|NCT03436225|Other|Group two|Group two will receive dexamethasone parenteral (0.15mg /kg /dose) twice daily for 3 to 5 days.
2873355|NCT03436225|Other|Group three|Group three will receive inhaled nebulized budesonide (1 mg/2ml) twice daily for 3 to 5 days.
2873356|NCT03436225|Other|Group four|Group four will receive symptomatic treatment in form of inhaled nebulized salbutamol(0.15mg/kg/ dose) daily every 6-8 hours.
2873357|NCT03436212|Other|Continuous Glucose Monitoring (CGM)|DEXCOMG4 device for 14 days
2873358|NCT03436199|Experimental|ADS-5102 137 mg|
2873359|NCT03436199|Experimental|ADS-5102 274 mg|
2873360|NCT03436199|Other|Placebo|placebo capsules
2873361|NCT03436186||no arm|no arm
2873362|NCT03436173|Experimental|Fluoxetine|Fluoxetine 10 mg/2.5 ml
2873363|NCT03436173|Placebo Comparator|Placebo|Peppermint syrup measured to equivalent volume
2873364|NCT03436160|Experimental|WR826647|100 mcg Carbon-14 radio labeled WR826647 administered via IV
2873365|NCT03436160|Experimental|WR909388|100 mcg Carbon-14 radio labeled WR909388 administered via IV
2873366|NCT03436160|Experimental|WR909390|100 mcg Carbon-14 radio labeled WR909390 administered via IV
2873367|NCT03436147||Vaginal Assisted Laparoscopic Sacrohysteropexy(VALS)|Patients who were performed vaginal assisted laparoscopic sacrohysteropexy (VALH)
2873368|NCT03436147||Vaginal Hysterectomy and Mc Call Culdoplasty (VAH+Mc Call)|Patients who were performed vaginal hysterectomy and Mc Call culdoplasty
2873369|NCT03436134|Active Comparator|Plasma Exchange Group|Patients receiving Exchange plasma as a treatment of chronic antibody mediated rejection.
2873370|NCT03436134|Experimental|Double filtration PlasmaPheresis Group|Patients receiving double filtration plasmapheresis as a treatment of chronic antibody mediated rejection.
2873371|NCT03436121|Experimental|Experimental Arm|Participants will be assigned to receive a single dose of IV ketamine (0.3 mg.kg) + midazolam
2873372|NCT03436121|Active Comparator|Active Placebo Arm|Participants will be assigned to receive a single dose of IV placebo + midazolam
2873373|NCT03436108||PCOS group|patients who have PCOS
2873374|NCT03436108||control group|patients who donnot have PCOS
2873375|NCT03436095||research group|bundle measures to help patient to weaning ventilator
2873376|NCT03436095||historical control group|retrospect the patients who were difficult to wean from ventilator and collect some materials to compare.
2873377|NCT03436095||External control group|contrast other same level hospitals measures to patients who are difficult to wean ventilator.
2873378|NCT03436082||Data from a mHealth platform after bariatric surgery|Patients that have undergone sleeve gastrectomy or gastric bypass will pilot test the use of the patient-led, smartphone based, mhHealth platform HUGO.
2873379|NCT03436082||Data from a mobile health platform after atrial fibrillation|Patients that have undergone a catheter-based atrial fibrillation ablation will pilot test the use of the patient-led, smartphone based, mobile health platform HUGO.
2873380|NCT03436056|Other|Dose escalation cohort - DOSE LEVEL 1|Intervention: One dose pembrolizumab 200 mg (week 1) followed by lung Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#) in week 3. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
2873381|NCT03436056|Other|Dose escalation cohort - DOSE LEVEL 2|Intervention: One dose of pembrolizumab 200 mg (week 1) followed by lung Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#) in week 3. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
2873382|NCT03436056|Other|Part B - Expansion cohort|Intervention: One dose of pembrolizumab 200 mg (week 1) followed in by lung Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose determined in Part A in week 3, dosed at the maximum tolerated dose determined in Part A. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
2873383|NCT03436043|Experimental|Transmural stenting|In patients of walled off necrosis with disconnected pancreatic duct syndrome, metal stent will be removed at 3-4 weeks followed by transmural plastic stenting in the residual cavity.
2873384|NCT03436043|No Intervention|No stenting|In patients of walled off necrosis with disconnected pancreatic duct syndrome, metal stent will be removed at 3-4 weeks without any further intervention.
2873385|NCT03436030|Experimental|Single arm, breathing manuevers|All subjects perform/undergo Valsalva, Muller, CPAP, hand grip, and passive leg raise, with ultrasound examination of heart recorded before and during the manoeuvre.
2873386|NCT03436017||ADHD|Patient with ADHD diagnosis criterion. The aim is the identification of Biomarkers of ADHD by a Metabolomic Approach
2873387|NCT03436017||non ADHD|"Patient with symptom of hyperactivity and/or attention deficiency but without ADHD diagnosis criterion.~The aim is the identification of Biomarkers of ADHD by a Metabolomic Approach."
2873388|NCT03436004|Experimental|Experimental|Colonoscopy with specific device with CE marking (Endocuff Vision)
2873389|NCT03436004|Active Comparator|Active Comparator|Colonoscopy with standard device of the center
2873390|NCT03435991||OAB patients|
2873391|NCT03435991||Healthy volunteers|
2873392|NCT03435978||MetS+|Obese group with metabolic syndrome/Data processing from Patient Medical Files
2873393|NCT03435978||MetS-|Obese group without metabolic syndrome/Data processing from Patient Medical Files
2873394|NCT03435965||PPROM from 20- less than 28 weeks|pregnant ladies with PROM from 20 - 28 weeks
2873395|NCT03435965||PROM from more than 28 weeks - less than 37 weeks|pregnant ladies with PROM from more than 28- less than37 weeks
2873396|NCT03435965||control group pregnant ladies in labour after 37 weeks|control group pregnant ladies in labour after 37 weeks with rupture of membrane in labour or in cs
2873397|NCT03435952|Experimental|Pembrolizumab + Clostridium novyi-NT|"Participants receive Pembrolizumab by vein over about 30 minutes on Day 0 and then every 3 weeks for up to 12 months.~Clostridium novyi-NT injected into the tumor on Day 8.~Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT"
2873399|NCT03435913|Experimental|Standard PEEP ventilation|During pneumoeperitoneum insufflation the patient is ventilated with 7 ml/kg per ideal body weight, inspiration:expiration (I:E) ratio 1:2, and respiration rate (RR) to maintain EtCO2 at 35-38 mmHg and 5 cmH20 of PEEP at every intra-abdominal pressure (IAP) step (8, 12 and 15 mmHg).
2873400|NCT03435913|Experimental|Matched PEEP Ventilation|"During pneumoeperitoneum insufflation the patient is ventilated with 7 ml/kg per ideal body weight, inspiration:expiration (I:E) ratio 1:2, and respiration rate (RR) to maintain EtCO2 at 35-38 mmHg and a level of PEEP matched to every IAP step (8, 12 and 15 mmHg).~1 mmHg = 1,36 cmH20.~Between the standard and matched PEEP intervention there is a washout period that with a recruitment maneuver to re-establish baseline lung condition."
2873401|NCT03435900|Experimental|Intervention group|
2873402|NCT03435900|Active Comparator|Control group|
2873403|NCT03435887|Active Comparator|Alere q HIV-1/2 Detect for point of care infant testing|POC testing with Alere q HIV-1/2 Detect at birth and 6-weeks postnatal in parallel with standard of care HIV DNA PCR testing
2873404|NCT03435887|Active Comparator|GeneXpert HIV-1 Qual for point of care infant testing|POC testing with GeneXpert HIV-1 Qual at-birth and at 6-weeks postnatal in parallel with standard of care HIV DNA PCR testing
2873405|NCT03435874|Experimental|Group 1 Active|n=6. Age 18-35 years. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 at D56.
2873406|NCT03435874|Placebo Comparator|Group 1 Comparator|n=3. Age 18-35 years. Rabies vaccine at D0 and D56.
2873407|NCT03435874|Experimental|Group 2a Active|n=6. Age 1-6 years. 1x10 10 vp ChAd63 RH5 at D0 and 1x10 8 pfu MVA RH5 D56.
2873408|NCT03435874|Placebo Comparator|Group 2a Comparator|n=3. Age 1-6 years. Rabies vaccine at D0 and D56.
2873409|NCT03435874|Experimental|Group 2b Active|n=12. Age 1-6 years. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 D56.
2873410|NCT03435874|Placebo Comparator|Group 2b Comparator|n=6. Age 1-6 years. Rabies vaccine at D0 and D56.
2873411|NCT03435874|Experimental|Group 3a Active|n=6. Age 6-11 months. 1x10 10 vp ChAd63 RH5 at D0 and 1x10 8 pfu MVA RH5 D56.
2873412|NCT03435874|Placebo Comparator|Group 3a Comparator|n=3. Age 6-11 months. Rabies vaccine at D0 and D56.
2873413|NCT03435874|Experimental|Group 3b Active|n=12. Age 6-11 months. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 D56.
2873414|NCT03435874|Placebo Comparator|Group 3b Comparator|n=6. Age 6-11 months. Rabies vaccine at D0 and D56.
2873415|NCT03435861|Experimental|VX-745|In the present study, VX-745 will be given at the dosage of 40 mg twice a day (1 tab. of 40 mg, twice), orally for 12 weeks
2873416|NCT03435861|Placebo Comparator|placebo|In the present study, placebo will be given twice a day (1 tab. , twice), orally for 12 weeks
2873417|NCT03435848|Experimental|BST-236|BST-236 Intravenous, 4.5 g/m2/d or 2.5 g/m2/d, for 6 days
2873418|NCT03435835|Sham Comparator|Thermoneutral|Participants will be dressed in water-circulating trousers that are connected to a pump. Water at 33ºC will be circulated through the pants for 80 minutes.
2873419|NCT03435835|Active Comparator|Heat Therapy|Participants will be dressed in water circulating trousers that are connected to. Warm water (42-43ºC) will be circulated through the pants for 80 minutes.
2873420|NCT03435822|Other|asthma action plan management group|Patients in this group will be provided both written asthma action plan and mobile-based APP to remind them take medicine regularly and direct them what to do when asthma get worse.
2873421|NCT03435822|Other|conventional management group|Patients in this group will be provided conventional management method with prescriptions and asthma diaries.
2873422|NCT03435809|Active Comparator|Pozzi for intrauterine insemination|Treatment done with a pozzi tenaculum forceps
2873423|NCT03435809|Active Comparator|No Pozzi for intrauterine insemination|Treatment done without a tenaculum forceps
2873424|NCT03435796|Other|Subjects exposed to Gene-modified (GM) T cell therapy|Subjects will be followed for 15 years from the last GM T cells infusion until withdrawal of consent, lost to follow-up, or death, whichever occurs first. Annual safety assessments will be conducted every 6 months during the first 5 years from the date of last GM T cell infusion. Laboratory evaluations and safety assessments will be conducted during this period. After 5 years, subjects will continue to be followed yearly. During the trial, pediatric subjects will be monitored for growth, development and sexual maturity. Stage 5 per Tanner Staging Criteria must be reached prior to study discontinuation.
2873425|NCT03435783|Experimental|Intervention|
2873426|NCT03435783|Active Comparator|Attention-matched control|
2873427|NCT03435770|Experimental|EUSRA RFA needle|This procedure is very similar to the standard technique of EUS-guided fine needle aspiration. All patients would undergo EUS with a linear array or therapeutic echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the EUSRA RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue.
2873428|NCT03435757|Experimental|Test Group OFD+IMP+CPS|OFD+IMP+CPS; open flap debridement (OFD) and intramarrow penetration (IMP) plus calcium phosphosilicate putty (CPS)
2873429|NCT03435757|Active Comparator|Control group (OFD+IMP)|OFD+IMP;open flap debridement (OFD) and intramarrow penetration (IMP)
2873430|NCT03435744|Experimental|Simvastatin with TAU|Participants will receive Simvastatin 20 mg added to TAU for 3 months
2873431|NCT03435744|Placebo Comparator|Placebo Oral Tablet with TAU|Participants will receive placebo added to TAU for 3 months
2873432|NCT03435731|Experimental|Treatment Group|This group will undergo 1 month Dual Therapy.
2873433|NCT03435718|Experimental|OXF6|Patients receive a single 6 mg/kg dose of oxfendazole administered orally.
2873434|NCT03435718|Experimental|OXF15|Patients receive a single 15 mg/kg dose of oxfendazole administered orally.
2873435|NCT03435718|Experimental|OXF30|Patients receive a single 30 mg/kg dose of oxfendazole administered orally.
2873436|NCT03435718|Experimental|OXF15x3|Patients receive a 15 mg/kg dose of oxfendazole administered orally once a day for each of three consecutive days.
2873437|NCT03435718|Active Comparator|ALB400|Patients receive a single 400 mg/kg dose of albendazole administered orally.
2873438|NCT03435705|Experimental|intervention arm|maintaining of occupational therapy for a 4 months period
2873439|NCT03435705|No Intervention|control arm|usual care after the end of the recommended initial program
2873466|NCT03435536|Experimental|Circulating tumor DNA|circulating tumor DNA rate at various times of pancreatic cancer resection
2873440|NCT03435692|Experimental|Lumbar Plexus Catheter|"Children undergoing pediatric hip surgery will have a lumbar plexus catheter placed (with bolus and continuous infusion of ropivacaine) intraoperatively for perioperative pain control.~An intraoperative pain protocol will dictate if the patient will receive IV fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with PRN morphine and oxycodone as well as scheduled acetaminophen."
2873441|NCT03435692|Active Comparator|Lumbar Epidural Catheter|"Children undergoing pediatric hip surgery will have an epidural catheter placed (with bolus and continuous infusion of ropivacaine) intraoperatively for perioperative pain control.~An intraoperative pain protocol will dictate if the patient will receive IV fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with PRN morphine and oxycodone as well as scheduled acetaminophen."
2873442|NCT03435692|Active Comparator|Patient Controlled Analgesia|"Children undergoing pediatric hip surgery will have patient controlled analgesia (with morphine) started in the post anesthesia care unit for post operative pain control.~An intraoperative pain protocol will dictate if the patient will receive IV fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with PRN morphine and oxycodone as well as scheduled acetaminophen."
2873443|NCT03435679|Experimental|one-stage|one-stage surgical treatment of the infected knee arthroplasty
2873444|NCT03435679|Active Comparator|two-stage|two-stage surgical treatment of the infected knee arthroplasty with a interim period of 8-10 weeks between stages
2873445|NCT03435666|Experimental|Capecitabine|Capecitabine is the test product.In period 1, period 2 and period 3, 13 of 39 Subjects were given Single oral dose (1250 mg/m2) Capecitabine.
2873446|NCT03435666|Active Comparator|XELODA|XELODA is the reference product.In period 1, period 2 and period 3, 13 of 39 Subjects were given Single oral dose (1250 mg/m2) XELODA.
2873447|NCT03435653|Active Comparator|Control group|Control group OFD with DFDBA
2873448|NCT03435653|Experimental|Test group|Test group OFD with decortication and DFDBA
2873449|NCT03435640|Experimental|Doublet: NKTR-262 + NKTR-214|"Phase 1 Doublet: NKTR-262 in escalating doses, will be combined with NKTR-214. The goal of this dose escalation part of the study is to establish a safe and tolerable recommended phase 2 dose (RP2D) for NKTR-262 in combination with NKTR-214 in an Every Three Week (Q3W) fixed dose.~Phase 2 Doublet: NKTR-262 RP2D will be combined with a Q3W dose of NKTR-214 in select tumor indications to evaluate anti-tumor activity and to obtain additional safety data.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
2873450|NCT03435640|Experimental|Triplet: NKTR-262 + NKTR-214 + Nivolumab|"Phase 1 Triplet: The RP2D of NKTR-262 RP2D will be combined with a Q3W dose regimen of NKTR-214 plus nivolumab. The goal of this arm is to establish the safety and tolerability of the triplet.~Phase 2 Triplet: The RP2D of NKTR-262 will be combined with a Q3W dose regimen of NKTR-214 plus nivolumab in select tumor indications to evaluate anti-tumor activity and to obtain additional safety data.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
2873451|NCT03435627||Norditropin® (naïve participants)|The treatment period of Norditropin® for naïve participants will be up to 208 weeks.
2873452|NCT03435627||Norditropin® (non-naïve participants)|The treatment period of Norditropin® for non-naïve participants will be up to 442 weeks.
2873453|NCT03435614||Critically ill patients|Mechanically ventilated critically ill adults receiving regular opioids for more than 72 hours will be prospectively followed for the emergence of withdrawal symptoms upon weaning of opioids.
2873454|NCT03435601|Experimental|Anifrolumab|Anifrolumab 300 mg IV administration Q4W, a total of 6 doses
2873455|NCT03435601|Placebo Comparator|Placebo|Placebo IV administration Q4W, a total of 6 doses
2873456|NCT03435588|Active Comparator|EUS-FNA with ROSE|EUS-FNA with ROSE is performed with a 22 gauge FNA needle. The sampled specimen is expressed into a glass slide with a stylet; then using another glass slide the sample is spread out to make smears on two slides. Each pair of slides is then numbered according to their respective needle passes. One slide is air dried and stained with modified Giemsa stain for ROSE, while the other slide is fixed in 95% ethanol and later coated with with Papanicolaou stain.
2873457|NCT03435588|Experimental|EUS-FNB alone|EUS-FNB is performed with a 22 gauge Core-needle. Tissue sampling technique is standardized between the endoscopists. Two passes are performed using the core needle. The biopsied samples are then expressed using a stylet into a jar filled with 10% formalin. A third pass is allowed if, on macroscopic inspection of the acquired sample, the specimen is deemed insufficient by the endoscopist.
2873458|NCT03435575|Active Comparator|Intervention group|Children in the intervention group will receive Boosth: Boosth activity tracker, Boosth syncc app and Boosth game app
2873459|NCT03435575|No Intervention|Control group|Standard care
2873460|NCT03435562|Experimental|JUUL electronic cigarette use|During each session, participants will first complete a 10-puff product use bout with JUUL, and then a 90-minute ad lib product use bout with JUUL (each session will be approximately 3 hours).
2873461|NCT03435562|Experimental|IQOS electronic cigarette use|During each session, participants will first complete a 10-puff product use bout with IQOS, and then a 90-minute ad lib product use bout with IQOS (each session will be approximately 3 hours).
2873462|NCT03435562|Active Comparator|Own brand cigarette use|During each session, participants will first complete a 10-puff product use bout with their own brand cigarettes, and then a 90-minute ad lib product use bout with their own brand cigarette (each session will be approximately 3 hours).
2873463|NCT03435549|No Intervention|Arm 1: Control Arm (Usual care)|If Patient is randomized to Arm 1, no contact will occur, patient will receive standard and routine clinical care
2873464|NCT03435549|Experimental|Arm 2a: Remote monitoring|If Patient is randomized to Arm 2a they will remote monitoring for 6 weeks post-surgery
2873465|NCT03435549|Experimental|Arm 2b: Remote monitoring plus goal setting and social support|If Patient is randomized to Arm 2b, they will receive a remote monitoring plus social support and nudge messaging for 6 weeks post-surgery
2873467|NCT03435523|Experimental|Open lung approach|Recruitment maneuver during OLV in thoracic surgery
2873468|NCT03435510|Other|Live Donor Champion|The Live Donor Champion program is the sole educational intervention for this trial. LDC consists of 6 monthly sessions of approx. 1 hour each. Each LDC session is led by a transplant physician or clinical coordinator. LDC sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LDC sessions are as follows: 1) education about ESRD, KT, and LDKT 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) encouraging candidate self-efficacy 6) Program Recap.
2873469|NCT03435497|Experimental|Game Changers Intervention|Game Changers is an intervention that aims to empower and mobilize people living with HIV to be agents for HIV prevention and behavioral change in their social networks.
2873470|NCT03435497|No Intervention|Control|The control group will receive standard of care during the intervention assessment period. All control participants will be offered the Game Changers program once all assessments for the primary study outcomes have been completed.
2873471|NCT03435484|Active Comparator|Usual Care|Participants in this group will receive the current version of instructions (a verbal reminder) for completing the Health Assessment Questionnaire.
2873472|NCT03435484|Active Comparator|Additional Instructions|Participants in this group will be exposed to additional instructions that remind them to complete the Health Assessment Questionnaire.
2873473|NCT03435471|Experimental|G1 - Clinician-Directed Therapy|"Clinician-Directed Weekly Swallowing Therapy: Once weekly face-to-face meetings with a study speech pathologist for a total of six sessions, to participate in active swallowing exercises and review the home swallowing exercise program. Each session will last 30 minutes +/- ten minutes. Other assessments include:~Clinician-Directed Prophylactic Swallowing Exercises~Prophylactic Swallowing Home Exercise Program~Penetration/Aspiration Scale (PAS)~Functional Oral Intake Scale (FOIS)~Eating Assessment Tool-10 (EAT-10)~University of Washington Quality of Life (UW-QOL)~Performance Status Scale for Head and Neck Cancer Patients (PSS-HN)"
2873474|NCT03435471|Active Comparator|G2 - Patient-Directed Home Therapy|"Patient-Directed Home Swallowing Therapy: One face-to-face meeting with a study speech pathologist prior to initiation of treatment. During that session, they will be encouraged to practice the given exercises independently on a specific daily schedule regime throughout their treatment. Other assessments include:~Prophylactic Swallowing Home Exercise Program~Penetration/Aspiration Scale (PAS)~Functional Oral Intake Scale (FOIS)~Eating Assessment Tool-10 (EAT-10)~University of Washington Quality of Life (UW-QOL)~Performance Status Scale for Head and Neck Cancer Patients (PSS-HN)"
2873475|NCT03435458|Experimental|Balloon catheter + oral misoprostol|
2873476|NCT03435458|Active Comparator|Oral misoprostol alone|
2873477|NCT03435445|Experimental|Online platform group|Online platform with diet, physical activity and behavior change recommendations for 24 weeks
2873478|NCT03435445|Experimental|Online dietitian coaching|Diet, physical activity and behavior change recommendations for 24 weeks and online sessions with a dietitian specialist for 12 weeks
2873479|NCT03435445|Active Comparator|Control group|Videos with diet, physical activity and behavior change recommendations for 24 weeks
2873480|NCT03435432|Active Comparator|Glucose|50 grams of glucose in 50 ml water
2873481|NCT03435432|Placebo Comparator|Water|50 ml water
2873482|NCT03435419||CL suspects|"Individuals with suggestive signs of cutaneous leishmaniasis presenting themselves at the National Malaria & Leishmaniasis Control Program (NMLCP) Leishmaniasis clinic in Kabul, Afghanistan.~These will be tested by diagnostic tests under evaluation:~i) LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection ii) CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection And their performance compared against a reference combining microscopy and PCR."
2873483|NCT03435406||cirrhosis with HPS|Diagnosed as HPS
2873484|NCT03435406||cirrhosis without HPS|Not Diagnosed as HPS
2873485|NCT03435380|Experimental|Control (C)|Targeted mailed educational materials (C).
2873486|NCT03435380|Experimental|Patient activation (PA)|C + patient activation (PA) consisting of (1) smartphone app with HIPAA compliant survivorship care plan that can be viewed, printed, or emailed to their primary care provider; and (2) two-way (interactive) tailored text messages with links to video vignettes discussing the primary barriers to breast MRI and mammography.
2873487|NCT03435380|Active Comparator|Patient activation + primary care provider activation (PA+PCP)|C + PA + PCP activation (PA+PCP) with physician materials about breast cancer risk in this population along with national and international guidelines for breast cancer surveillance.
2873488|NCT03435367|Experimental|Intervention Group (VR)|The patient will be allowed to 'try-out' the VR system (including all auditory and visual features) for ~5 minutes prior to the start of the procedure. In addition to usual care, consisting of child-life presence and topical analgesics if ordered by the treating medical team, children in the experimental condition will wear the VR HMD plus headphones and hold the VR controller.
2873489|NCT03435367|Active Comparator|Control Group (Standard Care - Video)|The patient will be allowed to watch an age-appropriate video on a tablet device. The patient will be offered to wear the same headphones as in the experimental condition. The patient will have the tablet and headphones for ~5 minutes prior to the start of the procedure. In addition, the patient will receive standard care consisting of a child life specialist and topical analgesics (if ordered by the treating medical team).
2873490|NCT03435354|Experimental|Intervention|Physical activity counselling during cardiac clinic visit with additional supports for community physical activity and access to a kinesiologist.
2873491|NCT03435354|No Intervention|Usual Care|Cardiac clinic visit with usual care but no physical activity counselling
2873492|NCT03435341||Patients diagnosed with AML|The study population will consist of approximately 150 patients over 60 with AML diagnosis according to WHO 2016 criteria.
2873493|NCT03435328|Experimental|TENS intervention|"one group receiving TENS:~- The electrode of TENS unit will be placed vertically, externally on skin overlying the parotid gland, in the preauricular area bilaterally, 1 cm in front of the tragus area."
2873494|NCT03435315|Active Comparator|Treadmill exercise|
2873495|NCT03435315|Experimental|Treadmill exercise with behavioral techniques|
2873496|NCT03435302|Experimental|Temozolomide Plus Cisplatin|per os 200 mg/m^2/d temozolomide on days 1 to 5 plus i.v. 75 mg/m^2 cisplatin divided into 3 days,which was repeated every 3 weeks for six cycles
2873758|NCT03433378|Active Comparator|RETIN-A® (tretinoin) cream, 0.05%|Apply once a day application, under at-home use conditions.
2873497|NCT03435302|Active Comparator|High-Dose IFN-a2b|Participants will be treated with i.v. 15×10^6U/m^2/d IFN-a2b on days 1 to 5 each week for 4 weeks, followed by s.c. 9×10^6U IFN- a2b three times per week for 48 weeks.
2873498|NCT03435289|Other|CPI-613, Gemcitabine and Nab-paclitaxel|CPI-613 in Combination With Gemcitabine 1000mg/m2 iv and Nab-paclitaxel 125mg/m2 iv
2873499|NCT03435276|Experimental|Cohort 1|Randomized subjects will receive AZD9977 50 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose Day 2 to Day 7
2873500|NCT03435276|Experimental|Cohort 2|Randomized subjects will receive AZD9977 150 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7
2873501|NCT03435276|Experimental|Cohort 3|Randomized subjects will receive AZD9977 300 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7
2873502|NCT03435263||hospital admission group B|Women presented with premature rupture of membranes will be admitted at hospital.
2873503|NCT03435263||home management group A|home management
2873504|NCT03435250|Experimental|AG-270|AG-270 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle.
2873505|NCT03435185||Blockade Group|Grater occipital nerve and supraorbital nerve blockade injections with %2 lidocaine
2873506|NCT03435185||Placebo Group|Grater occipital nerve and supraorbital nerve injections with saline
2873507|NCT03435172|Experimental|Treatment Group|Device-ADRCs intravenously infusion 20 million ADRCs generated by Celution device will be intraveously infused through peripheral vein. Standard care of split thickness skin graft (STSG) meshed at either (2:1 or 3:1) will be used.
2873508|NCT03435172|No Intervention|Usual Care|Standard care of split thickness skin graft (STSG) meshed at either (2:1 or 3:1) will be used.
2873509|NCT03435159|Experimental|Manual Chiropractic Spinal Manipulation|Demographic informations, pain, previous trauma, diseases, current medicine, past surgical operations, pregnancy, smoking use and cervical artery dissection history in family are questioned. Cervical flexion, extension, right and left rotations, right and left lateral flexions are measured by physiotherapist, in sitting position and with goniometer.Upper extremity muscle strength was measured with manual muscle testing in sitting position by physical therapist. The muscles innervated by C4, C5, C6, C7, C8 and T1 cervical nerves were examined bilaterally. Cervical foraminal compression test was used to eliminate cervical root compression.Vertebrobasilar artery was assessed by premanipulative vertebrobasilar insufficiency test.Neck Disability Index was used to evaluate the functional neck status of the participants. After all assessments, participants who were eligible for this study were undertaken Doppler Ultrasonography before and after manual manipulative intervention.
2873510|NCT03435159|Experimental|Instrumental Chiropractic Spinal Manipulation|The same assessments were applied to determine the eligibility of participants for this study. After all assessments, participants who were eligible for this study were undertaken Doppler Ultrasonography before and after instrumental manipulative intervention.
2873511|NCT03435146|Experimental|Group 1 and 2|"Group 1: The first 12 participants (Group 1A) will undergo semi-intensive PK sampling and will be key to determining whether an increased dosing of dolutegravir is required in groups 1B. Group 1B will receive dolutegravir at the new dose (if applicable) and will also undergo semi-intensive PK sampling. All will undergo safety and HIV VL assessments.~3HP plus DTG +2NRTIs~Group 2: The subsequent 30 (Group 2) will receive dolutegravir at the new dose and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.~3HP plus DTG +2NRTIs"
2873512|NCT03435133|Active Comparator|Prasugrel|
2873513|NCT03435133|Active Comparator|Ticagrelor|
2873514|NCT03435120||Breakthrough Cancer Pain|No intervention (Non Interventional Study)
2873515|NCT03435107|Experimental|Durvalumab|"The mismatch repair deficient or microsatellite instable, or POLE mutated metastatic colorectal cancer patients who were refractory to fluoropyrimidines, irinotecan and oxaliplatin with or without targeted agents will be accrued.~After checking the eligibility for the study entry, patients will be entered into the study treatment with durvalumab monotherapy."
2873516|NCT03435094||Fosamax®|1 group will be treated with alendronate 70 mg tablets (Fosamax®)
2873517|NCT03435094||Binosto®|1 group will be treated with alendronate 70 mg effervescent tablets for buffered solution (Binosto®)
2873518|NCT03435081|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2873519|NCT03435081|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2873520|NCT03435081|Placebo Comparator|Placebo|Placebo administered orally.
2873521|NCT03435068|Experimental|Ceramic rotary bur|For the ceramic bur group(Meisenger gingivectomies, ceramic rotary burs were used with 400-rpm rotary systems and with no serum irrigation, per the manufacturer's recommendation.
2873522|NCT03435068|Experimental|Diode laser|In the laser group (LG), a diode laser was applied to the operation sites in accordance with the manufacturer's guidelines (2.8 W continuous wave mode, wavelength 980 nm). The fiber optic laser tip had a 320-μm diameter with a 2.8 W output power. The laser never made contact with the gingival tissue. The practice distance did not affect the laser spot size, which was 0.5 cm-1 cm. Smoke associated with the laser application was aspirated from the surgical site.
2873523|NCT03435068|Active Comparator|Scalpel|In the scalpel group following the local anesthetic administration, the gingivectomy was performed with a #15 scalpel. Subsequent to the operation, the borderline of gingiva was determined via the use of a pointer dental tweezers, and excessive gingival tissue was then removed with Gracey curettes
2873524|NCT03435055|Experimental|Nitrous Oxide - inhaled|Each volunteer will participate in one scanning visit in which simultaneous fMRI/EEG data will be collected wherein they receive placebo (20 minutes) followed by inhaled nitrous oxide at subanalgesic levels (35% inhaled concentration) over 40 minutes.
2873525|NCT03435042|Experimental|Children with cancer + their siblings|
2873526|NCT03435042|Experimental|Parents of children with cancer|
2873527|NCT03435029|Experimental|Cognitive Remediation Program (REHACOP)|The cognitive rehabilitation program (REHACOP) is a 5 month intervention that allows both individual and group intervention. For the purpose of this study, we included intervention in several domains: attention, language, memory, processing speed, and executive functioning for 3 months, 3 times per week, in 60 minute per session.
2873559|NCT03434743|Experimental|Rehabilitative Intervention|Experimental rehabilitative intervention consists of non-nutritive sucking on emptied breast, one time per day for 10 minutes.
2873528|NCT03435029|Active Comparator|Occupational Therapy|The control group performed of occupational group activities (memory tasks, reading the newspaper, drawing, singing or doing crafts). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
2873529|NCT03435016|Other|Diagnosis|
2873530|NCT03435003|Experimental|Intervention Arm|"A) Pre-operatively: aprepitant 80 mg oral capsule and scopolamine transdermal patch.~B) Intra-operatively: total intravenous anesthesia (TIVA) will be maintained with IV infusions of propofol, and dexmedetomidine infusion or intermittent bolus dosing of fentanyl after induction. Sugammadex (2-4 mg/Kg IV) will be used for reversal of neuromuscular blockade in both groups. A single dose of dexamethasone 8 mg IV will be administered after induction, and a single dose of ondansetron 4 mg IV will be administered approximately 20 minutes prior to the end of operation.~C) Post-operatively: Scheduled ondansetron and Raglan every 6 hours, using Compazine as a rescue medication."
2873531|NCT03435003|Active Comparator|Control Arm|"A) Pre-operatively: No intervention~B) Intra-operatively: inhalation anesthetics (sevoflurane or desflurane) and intermittent opioid boluses will be used for maintenance of anesthesia, as standard practice in the institution of the investigators and across the country. PONV prevention measures in the control group will be limited to dexamethasone 8 mg and ondansetron 4 mg.~C) Post-operatively: Scheduled ondansetron and Raglan every 6 hours, using Compazine as a rescue medication."
2873532|NCT03434990|Experimental|Spinal manipulation/myofascial release|2x/week, for 3 weeks, performed by a chiropractor. Sessions will last 20 minutes, with 1 individual per session. Myofascial release will be done on paravertebral muscle (Erector spinae, quadratus lumborum) and on gluteus maximus and piriform muscles, the pressure will depend of pain tolerance of each subject. After this procedure, the spinal manipulation will be performed on the sacroiliac join and on the lumbar vertebrae with less mobility.
2873533|NCT03434990|Active Comparator|Spinal manipulation|2x/week, for 3 weeks, performed by a chiropractor. Sessions will last 20 minutes, with 1 individual per session. The spinal manipulation will be performed on the sacroiliac join and on the lumbar vertebrae with less mobility.
2873534|NCT03434977|Experimental|TAK-536 10 mg (fasted) + TAK-536 10 mg (fed)|TAK-536 10 milligrams (mg) granule formulation (pediatric formulation), once daily on Day 1 of Period 1 (6 days) in the morning under fasted condition, followed by wash-out (6 days), followed by TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 2 (6 days) after starting breakfast.
2873535|NCT03434977|Experimental|TAK-536 10 mg (fed) + TAK-536 10 mg (fasted)|TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 1 (6 days) after starting breakfast, followed by wash-out (6 days), followed by TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 2 (6 days) in the morning under fasted condition.
2873536|NCT03434951|Experimental|Intrathecal morphine and bupivacaine|0,2mg intrathecal morphine and 12,5mg bupivacaine administered
2873537|NCT03434951|Active Comparator|Placebo|12,5mg bupivacaine and NaCl 0,9% to match the same volume administered
2873538|NCT03434938|Experimental|MI Intervention|Standard geriatric rehabilitation combined with 4 MI sessions (within 72 hours from admission, within 6 days, at 1 week from the second session and pre-discharge, respectively). MI will be delivered by nurses trained through a certified MI course and additional group coaching sessions will be offered them throughout the study. Quality control of the MI sessions will be carried out using Motivational Interviewing Treatment Integrity (MITI) Code 3.1.1 through random video recording.
2873539|NCT03434938|No Intervention|Standard rehabilitation|Routine geriatric rehabilitation will include a multidisciplinary and individualized treatment plan based on comprehensive geriatric and specific rehabilitation assessments. As a specific control intervention, within 72 hours from admission a nurse without training in MI will handle the patient written information about generic benefits of exercising.
2873540|NCT03434899|Experimental|Intervention group|Health care plan including physical exercise and online support during the entire study
2873541|NCT03434899|Active Comparator|Control Group|Health care plan including physical exercise
2873542|NCT03434886|Experimental|CF View|
2873543|NCT03434886|Active Comparator|CF Educational videos|
2873544|NCT03434886|Active Comparator|CF View and videos|
2873545|NCT03434886|No Intervention|Usual standard of care|
2873546|NCT03434873|Active Comparator|Sacral magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks, over sacral roots
2873547|NCT03434873|Active Comparator|Cortical magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks, over motor cortex
2873548|NCT03434860|Active Comparator|probiotic|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day.
2873549|NCT03434860|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day.
2873550|NCT03434847|No Intervention|Control|Standard preoperative assessment
2873551|NCT03434847|Active Comparator|Education|Pre-operative education regarding post-operative pain expectations
2873552|NCT03434834|Experimental|OCT of esophagus|optical coherence tomography of esophagus
2873553|NCT03434782|Experimental|G1- Negative Control|Group with no desensitizing treatment. Prior to bleaching therapy, a water-soluble placebo gel, with non-active agent will be applied to dental vestibular surfaces. After bleaching therapy, the LASER tip will be positioned in two points (apical and cervical), without light emission (placebo).
2873554|NCT03434782|Experimental|G2- LASER (Positive Control)|Group treated with placebo gel before bleaching and with LLLT after in-office bleaching.
2873555|NCT03434782|Experimental|G3- KNO3 (Positive Control)|Group treated with desensitizing gel before bleaching and after in-office bleaching, the LASER tip will be positioned in two points (apical and cervical), without light emission (placebo).
2873556|NCT03434782|Experimental|G4- KNO3 + LASER|Group treated with desensitizing gel before bleaching and with LLLT after in-office bleaching.
2873557|NCT03434769|Experimental|Cyclophosphamide + Fludarabine + Infusion of CAR-T Cells|Lymphodepletive regimen, consisting of Cyclophosphamide 60mg/kg IV on day -6 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of Chimeric antigen receptor T-cells (CAR-T) on day 0
2873558|NCT03434756|Experimental|Propioceptive Training|
2873560|NCT03434743|Active Comparator|Control Intervention|Control active comparator intervention consists of non-nutritive sucking on a pacifier, one time per day for 10 minutes.
2873561|NCT03434730|Experimental|Adult Participants With High Risk Hematologic Malignancies|
2873562|NCT03434717|Experimental|Control (high distress)|Control group receiving care as usual
2873563|NCT03434717|Experimental|Individualised rehabilitation|"Patients with high distress receive the intervention individualized rehabilitation including evaluation of individual needs and based on that physical, psychological or social interventions to promote rehabilitation."
2873564|NCT03434717|Experimental|Control group (low distress)|Control group receiving care as usual
2873565|NCT03434704|Experimental|Single Arm Treatment|"Conditioning treatment Thiotepa-Treosulfan-Fludarabine; PBSC graft; GvHD prophylaxis; Primary antifungal prophylaxis."
2873566|NCT03434691|Experimental|DEX group|continuous infusion of Dexmedetomidine at 0.4 μg/kg per hour and remifentanyl A microdialysis probe was placed into the femoral quadriceps. An initial set of measurements will be obtained during the sedation with Midazolam and remifentanyl (before randomization). This set of measurements will be considered as baseline. Then samples were collected every 6 hours for 3 days. The changes in the energy-related metabolites lactate, the lactate/pyruvate ratio, glucose and glycerol were analyzed. Concomitantly with dialysate sampling, the effects on global haemodynamics, were assessed. Lactate and L/P clearances were also calculated.
2873567|NCT03434691|Active Comparator|MDZ group|continuous infusion of a Midazolam at 0,1 mg/kg/h and remifentanyl A microdialysis probe was placed into the femoral quadriceps. An initial set of measurements will be obtained during the sedation with Midazolam and remifentanyl (before randomization). This set of measurements will be considered as baseline. Then samples were collected every 6 hours for 3 days. The changes in the energy-related metabolites lactate, the lactate/pyruvate ratio, glucose and glycerol were analyzed. Concomitantly with dialysate sampling, the effects on global haemodynamics, were assessed. Lactate and L/P clearances were also calculated.
2873568|NCT03434678|Experimental|Epidural-General Anesthesia|
2873569|NCT03434678|Active Comparator|General Anesthesia|
2873570|NCT03434665|Other|Recruited patients|Transradial celiac artery angiography
2873571|NCT03434652|Active Comparator|Active percutaneous neurostimulation|Subject randomized to 5 days of active vs sham neurostimulation therapy during an illness cycle. With next illness cycle, each subject will cross over to the other one (active vs sham).
2873572|NCT03434652|Sham Comparator|Sham percutaneous neurostimulation|Each subject randomized to 5 days of active vs sham neurostimulation therapy during an illness cycle. With next illness cycle, each subject will cross over to the other one (active vs sham).
2873573|NCT03434639||1 - Ophthalmology patients|Ophthalmology patients who are receiving an intravenous dose of either fluorescein or indocyanine green (ICG) as part of their routine ophthalmic care (e.g. as part of a fluorescence angiography examination) will be recruited to the first stage of this study. These patients will take part in preliminary studies aimed at determining whether it is possible to detect fluorescein and ICG in the blood using transcutaneous fluorescence measurements.
2873574|NCT03434639||2 - Healthy subjects|Healthy subjects with no known issues of increased gut permeability. These subjects will act as negative controls in all gut permeability studies.
2873575|NCT03434639||3 - Increased permeability|Gastro-intestinal (GI) and non-GI patients who are expected to exhibit increased gut permeability (e.g. patients with celiac disease, inflammatory bowel disease (IBD), liver disease, HIV or another condition in which increased intestinal permeability is common). The more extreme cases in this group will act as positive controls.
2873576|NCT03434626|Experimental|ACP Education|Eligible patients in the experimental group will receive an educational intervention from an advance care planning navigator consisting of Alberta Goals of Care Documentation form, a 4-item values tool and, if applicable, watch a cardiopulmonary resuscitation video.
2873577|NCT03434626|Active Comparator|Usual care|Patients in the usual care group will meet with their family physician to discuss Alberta Goals of Care Documentation form.
2873578|NCT03434613|Active Comparator|Rosuvastatin monotherapy|Rosuvastatin 5mg 1T daily for 6 months
2873579|NCT03434613|Experimental|Rosuvastatin + ezetimibe combination therapy|Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
2873580|NCT03434600|Active Comparator|Oxford|Patients receiving an Oxford UKA, which is the standard treatment for patients with medial osteoarthritis of the knee at our department.
2873581|NCT03434600|Experimental|Sigma|Patients receiving a Sigma UKA, which is the experimental treatment.
2873582|NCT03434587|Experimental|Syndactyly|Syndactyly
2873583|NCT03434587|Active Comparator|Reduction and inmobilization|Closed reduction and splint inmobilization
2873584|NCT03434574|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 1-hard capsule regimen (500 mg)
2873585|NCT03434574|Active Comparator|Aronia extract|Formulation of an aronia extract ingredient in a 1-hard capsule regimen (500 mg)
2873586|NCT03434548||Cohort 1|Healthy Controls
2873587|NCT03434548||Cohort 2|Huntington's Disease Gene Expansion Carriers (HDGECs premanifest near-onset, peri-manifest, and manifest) and Healthy Controls
2873588|NCT03434535|Experimental|Intervention|The participants will complete a digital health-related quality of life survey on a programmed tablet at baseline and each month for the following 3 months. They will also receive an activity sensor and weight scale. Health state data from this group will be generated over a 3 month period and remotely monitored. These data will be used to provide personalized feedback regarding the participant's progress towards established goals.
2873589|NCT03434535|No Intervention|Control|The participants will complete a digital health-related quality of life survey on a programmed tablet at baseline and each month for the following 3 months.
2873590|NCT03434509|Experimental|Tai Chi|Ongoing, continuous Tai Chi and mindful movement instruction, 1 hour, twice per week
2873591|NCT03434496|Experimental|Experimental group|The investigators will enroll 30 patients with PD, randomly divided into two groups: (A) gait training with Music; (B) conventional treadmill gait training. The 15 patients in the experimental group will perform training by means of the device Gait Trainer 3 (Biodex), where they will train on a tredmill equipped with music. They will walk following specific musical beets and rhythms so to entrain their own internal rhythm. Subjects will attend 3 sessions a week for at least 4 weeks. Each session will last 45-min.
2873917|NCT03432273|Active Comparator|NiQuitin 2 mg mint lozenges|
2873592|NCT03434496|Active Comparator|Control Group|The control group will perform only conventional gait treadmill training, besides physical exercises to improve muscle force and tone. Subjects will attend 3 sessions a week for at least 4 weeks. Each session will last 45-min.
2873593|NCT03434483||Acute Coronary Syndrome|Patients with an episode of acute coronary syndrome. Clinical evaluation 1 year. Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis.
2873594|NCT03434483||ACS-Angiographic substudy|"Patients included in the Acute Coronary Syndrome group with clinical indication for revascularization.~Clinical evaluation. Assessment of the atherosclerotic plaque in a moderate lession at baseline and 1-year .~Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis"
2873595|NCT03434483||Chronic coronary atherosclerosis|Patients with chronic atherosclerosis. Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis.
2873596|NCT03434457||Prenatal and 3 to 72 months|
2873597|NCT03434444|Active Comparator|Low Dose Oxytocin|The myometrial samples are bathed in an oxytocin solution at increasing concentrations (from 10 -15M to 10 -10M)
2873598|NCT03434444|Active Comparator|Propranolol|The myometrial samples are bathed in a propranol solution at 10 -7M
2873599|NCT03434444|Active Comparator|Propranolol + low dose oxytocin|The myometrial samples are bathed in an oxytocin solution at increasing concentrations (from 10 -15M to 10 -10M) plus propranol (10 -7M)
2873600|NCT03434444|Active Comparator|High Dose Oxytocin|The myometrial samples are bathed in an oxytocin solution (10 -5M), followed by increasing concentrations of oxytocin (from 10 -10M to 10 -5M)
2873601|NCT03434444|Active Comparator|High Dose Oxytocin, Propranolol-pretreated|The myometrial samples are bathed in an oxytocin solution (10 -5M) plus propranolol (10 -7M), followed by increasing concentrations of oxytocin (from 10 -10M to 10 -5M)
2873602|NCT03434444|Active Comparator|High dose oxytocin + propranolol|The myometrial samples are bathed in an oxytocin solution (10 -5M), followed by increasing concentrations of oxytocin (from 10 -10M to 10 -5M) plus propranolol (10 -7M)
2873603|NCT03434418|Experimental|osimertinib|
2873604|NCT03434405|Experimental|SocialMind|The experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
2873605|NCT03434405|Other|TAU|The control arm will receive treatment as usual (TAU), consisting on both psychotropic and psychosocial treatment delivered by patients' practitioner(s)
2873606|NCT03434392|Active Comparator|Healthy Controls|"Subjects with no pancreatic disease and no abdominal pain.~Subjects will undergo the following Interventions: QST tests 1, 2, and 3.~They will also fill out validated questionnaires."
2873607|NCT03434392|Active Comparator|Suspected CP|"Suspected Chronic Pancreatitis patients.~Subjects will undergo the following Interventions: QST tests 1, 2, and 3.~They will also fill out validated questionnaires."
2873608|NCT03434392|Active Comparator|Definite CP|"Definite Chronic Pancreatitis patients.~Subjects will undergo the following Interventions: QST tests 1, 2, and 3.~They will also fill out validated questionnaires.~A subset of these patients who undergo endotherapy as per clinical recommendation from clinical provider independent of this study will be followed for 6 months after their clinical intervention for repeat QST tests 1, 2, and 3 and questionnaires."
2873609|NCT03434392|Active Comparator|Sphincter of Oddi Dysfunction or Functional Dyspepsia|"Patients with Sphincter of Oddi Dysfunction Type 1 or Type 2, or who have a prior diagnosis of Functional Dyspepsia.~Subjects will undergo the following Interventions: QST tests 1, 2, and 3.~They will also fill out validated questionnaires."
2873610|NCT03434379|Experimental|Atezolizumab + Bevacizumab|Participants will receive Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator
2873611|NCT03434379|Active Comparator|Sorafenib|Participants will receive Sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator
2873612|NCT03434366|Experimental|ketamine and dexmedetomidine group|intranasal ketamine and dexmedetomidine was treated in the children
2873613|NCT03434366|Experimental|ketamine group|intranasal ketamine was treated in the children
2873614|NCT03434366|Placebo Comparator|control group|intranasal insaline was used in the children
2873615|NCT03434353|Experimental|Group 1 (Inarigivir 50 mg + TAF)|Inarigivir 50 mg (2 x 25 mg capsule) plus TAF for 12 weeks, followed by TAF for 36 weeks
2873616|NCT03434353|Experimental|Group 2 (TAF)|TAF for 48 weeks
2873617|NCT03434353|Experimental|Group 3 (Inarigivir 200 mg + TAF)|Inarigivir 200 mg (2 x 100 mg tablet) plus TAF for 12 weeks, followed by TAF for 36 weeks
2873618|NCT03434353|Experimental|Group 4 (Inarigivir 100 mg)|Inarigivir 100 mg tablet for 12 weeks in virally suppressed participants currently being treated with a commercially available NUC
2873619|NCT03434340|Experimental|Granisetron & Dexamethasone & Peppermint essential oil|Granisetron 1mg and Dexamethasone 4mg administer as intravenous injection once right after delivery of newborn followed by Peppermint essential oil 2 drops on nasal strip applied for 6 hours
2873620|NCT03434340|Active Comparator|Granisetron & Dexamethasone|Granisetron 1mg and Dexamethasone 4mg administer as intravenous injection once right after delivery of newborn
2873621|NCT03434327|Experimental|Strength Training|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2s concentric and 3s eccentric. All training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for12 consecutive weeks, for a total of 24 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
2873622|NCT03434327|Experimental|Power Training|For power training the subjects will perform the concentric phase at high speed, while eccentric portion will last approximately 2 sec. Loads will vary from 30-80% of the subject's maximum depending on the biomechanical nature of the joints involved in the exercise. All training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 24 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
2895809|NCT03278470|Experimental|HL237 1200mg|take oral tablet once
2873623|NCT03434314|Experimental|MISACE arm|"Minimally-Invasive Segmental Artery Coil-Embolization~MISACE procedure prior to aneurysm repair~segmental arteries are occluded with coils or plugs in one to three MISACE sessions (staged procedure)"
2873624|NCT03434314|No Intervention|control arm|receives treatment of aneurysm as usual: open surgical repair or endovascular repair without MISACE
2873625|NCT03434301|Active Comparator|Mesh with absorbable tack fixation|Mesh with absorbable tack (ReliaTack™) fixation
2873626|NCT03434301|Active Comparator|Mesh with non-absorbable fixation|Mesh with non-absorbable (Protack™) fixation
2873627|NCT03434288||Diabetic patients with foot osteomyelitis|Biological and MRI signs of foot osteomyelitis
2873628|NCT03434275|Experimental|N1539 30 mg|N1539 (meloxicam injection for IV use) 30 mg every 24 hours
2873629|NCT03434275|Placebo Comparator|IV Placebo|IV Placebo every 24 hours
2873630|NCT03434262|Experimental|A: ribociclib + gemcitabine|Stratum A participants with a diagnosis of refractory or recurrent medulloblastoma (Group 3/4) or refractory or recurrent ependymoma. (including: ependymoma, not otherwise specified (NOS), WHO Grade III; ependymoma, RELA fusion positive; anaplastic ependymoma; ependymoma, NOS, WHO grade II). They receive combination treatment with ribociclib and gemcitabine. They may also receive growth therapy support with filgrastim or pegfilgrastim.
2873631|NCT03434262|Experimental|B: ribociclib + trametinib|Stratum B participants with a diagnosis of one of the following refractory or recurrent CNS diseases: medulloblastoma, [sonic hedgehog (SHH)- or WNT-activated];; high grade glioma (including: high grade glioma, (NOS), WHO Grade III or IV; anaplastic astrocytoma, IDH mutant; glioblastoma, IDH-wildtype; glioblastoma, IDH-mutant; diffuse midline glioma, H3K27-mutant; anaplastic oligodendroglioma, IDH mutant and 1p/19q-codeleted; anaplastic pleomorphic xanthoastrocytoma); select CNS embryonal tumors (including: embryonal tumors with multilayered rosettes, C19MC-altered; embryonal tumors with multilayered rosettes, NOS; medulloepithelioma; CNS neuroblastoma; CNS ganglioneuroblastoma; CNS embryonal tumor, NOS; atypical teratoid/rhabdoid tumor; CNS embryonal tumor with rhabdoid features). They receive combination treatment with ribociclib and trametinib.
2873632|NCT03434262|Experimental|C: ribociclib + sonidegib|Stratum C participants with refractory or recurrent medulloblastoma (SHH-activated) >6 months off smoothened inhibitor, presence of 9q loss or PTCH1 mutant, skeletally mature. They received combination treatment with ribociclib and sonidegib.
2873633|NCT03434249|Experimental|Group I|patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
2873634|NCT03434249|Placebo Comparator|Group II|patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
2873635|NCT03434236|Placebo Comparator|Placebo|Patients will be taking placebo twice daily for 5 days prior to surgery. The placebo has a similar taste and smell as the active supplement.
2873636|NCT03434236|Experimental|low dose Lipinova (30mL)|Patients will take 15 mL Lipinova (a dietary supplement containing omega-3 PUFA's) twice daily for 5 days prior to surgery.
2873637|NCT03434236|Experimental|high dose Lipinova (60mL)|Patients will take 30mL of Lipinova (a dietary supplement containing omega-3 PUFA's) twice daily for 5 days prior to surgery.
2873638|NCT03434223||Single Cohort|
2873639|NCT03434210|Experimental|LAT-treated Community Model|The subjects in experimental group are on 'LAT-treated Community Model'. which means,beside care as usual, subjects will be treated by paliperidone palmitate, Psychiatrists will guide community mental health professinals about the treatment and management. Psychiatrists will give community mental health professinals and patients/ caregiver long acting injection related education information.
2873640|NCT03434210|Other|Care as usual|"The subjects in control group are on  cared as usual Which means Patients will be managed follow the request of National Continuing Management and Intervention Program for Psychoses. Patients will managed by community mental health professionals, get education information and rehablitation guidence from them."
2873641|NCT03434197|Experimental|SFPP (Esflurbiprofen plaster)|A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)
2873642|NCT03434197|Active Comparator|Diclofenac gel|A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
2873643|NCT03434171|Active Comparator|Aerobic excercise|women who practiced treadmill exercise program for 30 minutes at 60% to 70% of maximum heart rate. The treatment sessions will be repeated 3 times per week for 12 weeks
2873644|NCT03434171|Active Comparator|Dietary modfications|women who received diet modification contains soy products (phytoestrogen) such as soy milk and soy beans every day for 12 weeks only
2873645|NCT03434158|Experimental|Olaparib|600 mg/day
2873646|NCT03434145||patients with chronic kidney diseases|patients with end stage retinal disease undergoing hemodialysis underwent various ophthalmologic exams before and after hemodialysis.
2873647|NCT03434132|Active Comparator|Open Radical Cystectomy|Open Radical Cystectomy, pelvic lymph node dissection, urinary diversion (neobladder or ileal conduit)
2873648|NCT03434132|Experimental|Robot assisted radical cystectomy|Robot assisted radical cystectomy, pelvic lymph node dissection, intracorporeal urinary diversion (neobladder or ileal conduit)
2873649|NCT03434119|Experimental|Soliqua 100/33|Soliqua 100/33 once daily in the morning an hour before breakfast on top of background 1 or 2 antidiabetic agents (OADs)
2873650|NCT03434119|Active Comparator|Lantus|Lantus once daily at any time of the day but at about the same time every day on top of background 1 or 2 OADs
2873651|NCT03434106|Experimental|primary Sjögren's syndrome|The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.
2873652|NCT03434106|Experimental|secondary Sjögren's syndrome|The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.
2873653|NCT03434106|Experimental|meibomian gland dysfunction|The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.
2873654|NCT03434106|Experimental|control|the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.
2873655|NCT03434093|Active Comparator|PPC-DLPFC|In this arm, the TMS paired-pulses will be first delivered over the posterior parietal cortex (PPC) and then over the dorsolateral prefrontal cortex (DLPFC)
2873656|NCT03434093|Active Comparator|DLPFC-PPC|Arm Description: In this arm, the TMS paired-pulses will be first delivered over the over the dorsolateral prefrontal cortex (DLPFC) and then posterior parietal cortex (PPC)
2873659|NCT03434067||Primary hyperthyroidism|Patients diagnosed with primary hyperparathyroidism are prepared for parathyroid surgery. PTH test paper is used addtional at the time point according to Miami principle
2873660|NCT03434067||Secondary hyperthyroidism|Patients diagnosed with Secondary hyperthyroidism are prepared for parathyroid surgery. PTH test paper is used addtional at the time point according to Miami principle
2873661|NCT03434067||Unilateral thyroidectomy|Patients diagnosed with unilateral thyroid benign tumor were prepared for unilateral thyroidectomy. PTH test paper is used addtional at postoperation
2873662|NCT03434067||thyroidectomy and bilateral CCD|Patients diagnosed with bilateral thyroid carcinoma were prepared to undergo total thyroidectomy and bilateral central clearing.PTH test paper is used addtional at postoperation
2873663|NCT03434054|Experimental|Losartan|single dose of 50mg losartan, tablet, over-encapsulated, to be taken orally
2873664|NCT03434054|Placebo Comparator|Placebo|single dose of placebo (main ingredient microcrystalline cellulose), tablet, over-encapsulated, to be taken orally
2873665|NCT03434041|Experimental|Intranasal Esketamine plus Oral Antidepressant|Eligible participants will self-administer esketamine (56 mg or 84 mg) intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Treatment Phase. All participants will start at a dose of 56 milligram (mg) on Day 1. The dose may be increased to 84 mg or maintained at 56 mg per investigator's discretion. In addition, participants will simultaneously initiate a new, open-label 1 of 4 oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of the 4-week Double-Blind Treatment Phase.
2873666|NCT03434041|Active Comparator|Oral Antidepressant plus Intranasal Placebo|Eligible Participants will self-administer matching placebo intranasally twice per week for 4 weeks in Double-Blind Treatment Phase. In addition, participants will simultaneously initiate a new, open-label oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Treatment Phase.
2873667|NCT03434028|Other|Restrictive Fluids|The general approach will be to use vasopressors to treat hypotension as opposed to intravenous fluids. Maintenance fluids should not be used.
2873668|NCT03434028|Other|Liberal Fluids|The general approach is to use fluid boluses to treat hypotension.
2873669|NCT03434015||Left atrial appendage closure|"All patient referred to a department of interventional cardiology for percutaneous left atrial appendage closure may be included.~All centers practicing this procedure in France will participate to the present study, whatever the technique used. The patients included in the protocol will be followed as part of the care by centers that will have carried out the procedure."
2873670|NCT03434002|Experimental|Arm-A|Randomized 15 residents out of 30 Post Graduate Year 1 or 2 anesthesia residents (not involved in initial Virtual Reality testing) will be receive Local Anesthetic Systemic Toxicity simulation training by Virtual Reality simulation
2873671|NCT03434002|Experimental|Arm-B|Randomized other 15 residents out of 30 Post Graduate Year 1 or 2 anesthesia residents (not involved in initial Virtual Reality testing) will be receive Local Anesthetic Systemic Toxicity simulation training by mannequin based simulation
2873672|NCT03433989|Experimental|Diagnosis and follow up arm|
2873673|NCT03433976|Other|Hyperbaric Bupivacaine|spinal anesthesia for planned cesarean sections control group
2873674|NCT03433976|Active Comparator|Hyperbaric Prilocaïne|spinal anesthesia for planned cesarean sections
2873675|NCT03433963|Experimental|L-Arg supplement group|Study participants in the group will take L-Arg supplement during the trial.
2873676|NCT03433963|Placebo Comparator|Control group|Study participants in the group will take placebo during the trial.
2873677|NCT03433950||Fluctuator|Parkinson's subjects with rises in systolic blood pressure exceeding 50% of baseline during motor off periods to select for subjects with severe blood pressure fluctuations.
2873678|NCT03433937|Experimental|Negative pressure wound therapy|
2873679|NCT03433937|Active Comparator|Control|Micropore tape
2873680|NCT03433911|Experimental|FemBloc|Investigational device and procedure
2873681|NCT03433911|Active Comparator|Control|Laparoscopic bilateral tubal sterilization
2873682|NCT03433898|Experimental|Part 1|
2873683|NCT03433898|Experimental|Part 2|
2873684|NCT03433898|Experimental|Part 3|
2873685|NCT03433885||Progressors|Progressors are those individuals with early or intermediate AMD at baseline who progress to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who progress to advanced AMD in both eyes.
2873686|NCT03433885||Nonprogressor|Nonprogressors are those individuals with early or intermediate AMD at baseline who do not progressed to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who do not progress to advanced AMD in fellow eye.
2873687|NCT03433872|Other|Caregivers|"Caregiver refers to teachers and child care providers in infant and toddler classrooms in center-based or FCC settings. All caregivers in the study will be assigned to the intervention. The PD providers supporting these caregivers will be trained in the We Grow Together: The Q-CCIIT Professional Development System."
2873688|NCT03433859|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA in intradermal Injections on residual lower limb
2873689|NCT03433859|Active Comparator|Topical Aluminium Chloride|Topical Aluminium Chloride (cosmetic product) on the lower limb
2873690|NCT03433846||Preterm Infants|Blood and stool samples will be obtained from preterm and former preterm infants at birth and then monthly until hospital discharge. The sample would consist of either up to 0.5ml of blood obtained during a requested clinical blood draw, discarded blood, or a dried blood spot specimen. If no discard samples are available and study blood samples need to be obtained instead, this will occur for a maximum period of 6 months and no more than 3ml of blood will be collected over the entire study period. .
2873691|NCT03433846||Term Infants|Blood and stool samples will be obtained from term control infants admitted to the NICU with non-immune or infectious problems monthly until hospital discharge. The sample would consist of either up to 0.5ml of blood obtained during a requested clinical blood draw, discarded blood, or a dried blood spot specimen. If no discard samples are available and study blood samples need to be obtained instead, this will occur for a maximum period of 6 months and no more than 3ml of blood will be collected over the entire study period.
2873692|NCT03433846||Healthy Adults|A 3-5ml blood sample and a small volume 0.5ml sample will be obtained.
2895810|NCT03278470|Experimental|HL237 1600mg|take oral tablet once
2873694|NCT03433820|Experimental|randomized repeated biopsy|"The study will entail 1 cohort with a randomized repeated biopsy collection time. Three skin punch biopsies (3 mm) of the lower back will be taken from each volunteer on day 0. One biopsy sample taken on day 0 will serve as a baseline measurement for the repeated samples regarding the histology, immunohistochemistry, and RNA sequencing (RNA-seq) or real-time reverse transcription polymerase chain reaction (qRT-PCR) assessments.~Repeated biopsies of the same location as on day 0 will be taken on day 7, 14 or 21 (biopsy lesion and day randomized), and day 28, 42 or 56 (biopsy lesion and day randomized) for all subjects. The observation biopsy (biopsy lesion randomized) will serve as primary biopsy and followed for all measurements."
2873695|NCT03433794|Placebo Comparator|Control|The control group spent 60 minutes on an online education session (Lilly for Better Health) directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
2873696|NCT03433794|Active Comparator|Intervention Only|Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
2873697|NCT03433794|Experimental|Intervention-plus-Booster|Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Importantly, their email 2 weeks later contained a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and reported harm reduction strategies.
2873698|NCT03433781|Experimental|Absorbic Acid|All patients will receive at least 1 cycle of treatment (4 weeks). Patients with clinical benefit (CR,PR, or SD) then will undergo a second 4-week cycle of treatment.
2873699|NCT03433768||poor responders|
2873700|NCT03433768||normal responders|
2873701|NCT03433755|Active Comparator|Evolocumab 140 mg SC Q2W|Approximately 150 Subjects
2873702|NCT03433755|Active Comparator|Evolocumab 420 mg SC QM|Approximately 150 Subjects
2873703|NCT03433755|Placebo Comparator|Placebo SC Q2W|Approximately 75 Subjects
2873704|NCT03433755|Placebo Comparator|Placebo SC QM|Approximately 75 Subjects
2873705|NCT03433742|Other|Preoperative Group|This is a group of 30 patients who will be undergoing a total hip replacement with a Trident II shell. This group of patients will have their bloods drawn and tested for metal ion levels at a preoperative visit.
2873706|NCT03433742|Other|1 year Postoperative Group|This is the same group of 30 patients who are now one year post op after having a total hip replacement with a Trident II shell. This group of patients will have their bloods drawn and tested for metal ion levels at their one year visit.
2873707|NCT03433729|Experimental|Patient Agenda Form|Patient Agenda form: Patients receive an agenda form to use before their consultation.
2873708|NCT03433729|No Intervention|Usual care|Patients' appointment continues as usual.
2873709|NCT03433716|Experimental|PNM group|Subjects were treated for 3 weeks, once a week. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol by Valera and Minaya. The subjects were seated while their arms were supported by an arm rest, forearms pronated and elbows moderately flexed. The radial nerve was located at 4cm proximal to the tip of the lateral epicondyle of humerus using an ultrasound machine (cross-section), subsequently, an acupuncture needle (0.30mm x 30mm) was inserted in a short axis approach, perpendicular to the surface of the skin, until the perineurium of the radial nerve (in close proximity).
2873710|NCT03433716|No Intervention|Control group|the subects of the control group received no any treatment
2873711|NCT03433703|Experimental|Lenvatinib|Participants will receive lenvatinib 12 or 8 milligrams (mg) once daily in continuous 28-day cycles until disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor. Upon completion of lenvatinib treatment, participants may continue to receive commercially available treatment for hepatocellular carcinoma in the subsequent treatment period.
2873712|NCT03433690|Experimental|High Intensity Interval Training|Twelve weeks of High Intensity Interval Training, twice a week, in combination with multidisciplinary treatment at outpatient obesity clinic.
2873713|NCT03433690|Active Comparator|Moderate training|Twelve weeks of Moderate Training, twice a week, in combination with multidisciplinary treatment at outpatient obesity clinic.
2873714|NCT03433677|Experimental|LY900014|LY900014 administered by continuous subcutaneous insulin infusion (CSII)
2873715|NCT03433677|Experimental|Insulin Lispro|Insulin lispro administered by CSII
2873716|NCT03433664|Experimental|Treatment|Each treatment half of the scar received three standardised CO2 laser treatments using the DeepFX setting hand piece (Ultrapulse, Lumenis), performed under general anaesthetic at 4-6 week intervals. All treatments consisted of a single pass of 300Hz, 5% density and 50mJ energy with minimal overlapping. Post-operatively all laser treatment and control zones had emollient applied and silicone dressings which were removed at 48 hours. Further emollient was applied twice daily for 2 weeks to all areas of the scar. Standard care scar management (including silicone, massage and pressure garments) was directed by burn occupational therapists and was continued for all areas of scar.
2873717|NCT03433664|No Intervention|Control|Each control half of the scar received emollient applied twice daily for 2 weeks to all areas of the scar after each treatment. Standard care scar management (including silicone, massage and pressure garments) was directed by burn occupational therapists and was continued for all areas of scar.
2896713|NCT03272048|Experimental|High-Fear/Not-Temporary|
2873718|NCT03433651|Experimental|creatine monohydrate|Experimental will take by mouth 5 grams a day of creatine monohydrate powder. Subjects will be given a 30 day supply of the study powder. They will be reminded to take the powder as instructed.
2873719|NCT03433651|Placebo Comparator|Placebo|Placebo will take by mouth 5 grams a day of placebo powder. Subjects will be given a 30 day supply of the study powder. They will be reminded to take the powder as instructed.
2873720|NCT03433625|Experimental|Behavioural experiments (CBT)|"Behavioural experiments involve selecting a specific thought to be tested (e.g., uncertainty makes me unable to act) and designing a detailed experiment to test out the thought."
2873721|NCT03433625|No Intervention|Waiting list|6 week wait (with assessments) before being transferred to the experimental condition.
2873722|NCT03433612|Other|All Patients|"Estimates of the location of the L4-L5 intervertebral space will be done by the classic intercristal line technique and novel SAIL technique. Each technique will be performed by different randomly assigned investigators.~* Both techiques will be assessed on all patients"
2873723|NCT03433599|Experimental|dAIH + Rapael Glove|Participants will receive daily acute Intermittent Hypoxia (dAIH) and training with an Exoskeleton Rapael glove.
2873724|NCT03433599|Active Comparator|dAIH + training by research staff|Participants will receive daily acute Intermittent Hypoxia (dAIH) and training by research staff.
2873725|NCT03433599|Active Comparator|dAIH|Participants will receive daily acute Intermittent Hypoxia (dAIH) and no training.
2873726|NCT03433599|Sham Comparator|Room Air + Rapael Glove|Participants will receive normal room air and training with an Exoskeleton Rapael glove.
2873727|NCT03433599|Sham Comparator|Room Air + training by staff|Participants will receive normal room air and training by research staff.
2873728|NCT03433599|Sham Comparator|Room air|Participants will receive normal room air and no training.
2873729|NCT03433586|Active Comparator|Placebo|Placebo pills that are visually identical to the Aspirin pills will be administered orally, daily for 10+/-3 days followed by a washout period of the same length.
2873730|NCT03433586|Active Comparator|Aspirin|Aspirin (81mg) will be taken orally, daily for 10+/-3 days followed by a washout period of the same length.
2873731|NCT03433586|Other|No treatment control|No treatment will be administered for 10+/-3 days followed by a washout period of the same length.
2873732|NCT03433573|Experimental|Intervention|Abbott Sensor Based Glucose Monitoring System
2873733|NCT03433560||Korean female breast cancer patients|
2873734|NCT03433547|Experimental|Buckle|Macular buckling, Limbal paracentesis, and intraocular gas injection.
2873735|NCT03433547|Active Comparator|Vitrectomy|Vitrectomy, peeling internal limiting membrane, and gas tamponade.
2873736|NCT03433534||Pharmacokinetic of Nivolumab|Patients under nivolumab (Opdivo 10 MG/ML) for the treatment of non small cell lung carcinoma or renal cell carcinoma. Measure of nivolumab residual concentration 14 days after administration of nivolumab and just before the new perfusion.
2873737|NCT03433508|Experimental|Liberal|2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
2873738|NCT03433508|Active Comparator|Restrictive|To maintain the target Hemoglobin of 7 to 8 gm/dL.
2873739|NCT03433495|Active Comparator|Melodic Intonation Therapy|The duration of therapy was 12 sessions performed over a 6-week period. Each session lasted 30 minutes. They were performed individually by a speech-experienced therapist previously trained in Melodic Intonation Therapy.
2873740|NCT03433495|No Intervention|Waiting list|No intervention
2873741|NCT03433482|Experimental|GSK3536820A ACWY_Liq24 Group|Approximately 417 healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1.
2873742|NCT03433482|Active Comparator|ACWY_1 Group|Approximately 417 healthy subjects receiving a single dose of the licensed GSK' MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.
2873743|NCT03433482|Experimental|GSK3536820A ACWY_Liq30 Group|Approximately 417 healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.
2873744|NCT03433482|Active Comparator|ACWY_2 Group|Approximately 417 healthy subjects receiving a single dose of the licensed GSK' MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.
2873745|NCT03433469|Experimental|Treatment (osimertinib)|Participants receive osimertinib orally, once a day (PO QD) on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgical resection of their cancer.
2873746|NCT03433456|Experimental|Home visitation + HABITS Program|The HABITS module will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children. Participants will receive the HABITS module in addition to their standard home visitation services.
2873747|NCT03433456|Active Comparator|Standard home visitation program|Participants will receive the standard of care home visitation regularly delivered through the existing home visitation program without the HABITS module.
2873748|NCT03433443|Active Comparator|Control group|Usual physical rehabilitation group
2873749|NCT03433443|Experimental|Intervention group|Case manager assisted rehabilitation
2873750|NCT03433430|Other|truSculpt|truSculpt treatment
2873751|NCT03433417|Other|Cutera truSculpt|One truSculpt treatment
2873752|NCT03433404|Experimental|Soft Tissue Mobilization|The arm will utilize a Physical Therapy technique call soft tissue mobilization.
2873753|NCT03433404|Active Comparator|Soft Tissue Massage|This arm will utilize standard soft tissue massage applied to the low back in pregnant patients complaining of third trimester low back pain.
2873754|NCT03433404|No Intervention|No manual treatment|Group will still receive acetaminophen, heating pad application, and/or rest which is standard of care.
2873755|NCT03433391|Other|Surgery Plus Oxiplex|Oxiplex will be applied after hemostasis is achieved and prior to closure, in adult patients undergoing single level partial discectomy.
2873756|NCT03433391|Other|Surgery Only|Standard of care procedures for adult patients undergoing single level partial discectomy will be followed.
2873757|NCT03433378|Active Comparator|Tretinoin cream, 0.05%|Apply once a day application, under at-home use conditions.
2873759|NCT03433378|Placebo Comparator|Vehicle of the test product|Apply once a day application, under at-home use conditions.
2873760|NCT03433365||1|Potential study subjects will sign an informed consent prior undergoing any study related procedure. Patients enrolled in this study will receive Lenalidomide-based regimen as maintenance therapy according to their previous decided therapeutic schedule. All consecutive patients treated with Lenalidomide-based regimen as maintenance therapy and with inclusion criteria will be asked to participate to this study.
2873761|NCT03433352||Control group|30 healthy volunteers were included in the healthy control group
2873762|NCT03433352||Recrudescence group|30 GD patients who received recurrence within 2 years after treatment with Methimazole Pill or propylthiouracil pill
2873763|NCT03433352||No recrudescence group|30 GD patients who did not receive recurrence within 2 years after treatment with Methimazole Pill or propylthiouracil pill
2873764|NCT03433339|Experimental|Active Treatment|Thoracic anodal transcutaneous spinal direct current stimulation 2.5mA for 20 min/ three times per week for 8 weeks.
2873765|NCT03433339|Sham Comparator|Sham Treatment|Thoracic anodal transcutaneous spinal direct current stimulation during a few seconds at the beginning and end of stimulation session of 20min/ three times per week for 8 weeks.
2873766|NCT03433313|Experimental|EG12014|Epirubicin and cyclophosphamide followed by EG12014 plus paclitaxel. All patients will be scheduled for surgery (breast and axillary lymph nodes) at 3 to 6 weeks after completion of neoadjuvant chemotherapy.
2873767|NCT03433313|Active Comparator|Herceptin|Epirubicin and cyclophosphamide followed by Herceptin plus paclitaxel. All patients will be scheduled for surgery (breast and axillary lymph nodes) at 3 to 6 weeks after completion of neoadjuvant chemotherapy.
2873768|NCT03433300|Experimental|Microprocessor Knee|Ottobock Kenevo
2873769|NCT03433300|Active Comparator|Nonmicroprocessor knee|Ottobock 3R60 for K3 participants, Ottobock 3R62 for K2 participants.
2873770|NCT03433287|Experimental|18F-NaF-PET/MRI|Eligible patients who give informed consent will be offered a NaF -PET/MRI scan
2873771|NCT03433274|Experimental|Surgical Candidate Arm - Treatment Group|Treatment of mitral regurgitation with the Tendyne Mitral Valve System
2873772|NCT03433274|Active Comparator|Surgical Candidate Arm - Control Group|Treatment of mitral regurgitation with standard of care repair or total chordal-sparing replacement
2873773|NCT03433274|Experimental|Non-Surgical Candidate|Treatment of mitral regurgitation with the Tendyne Mitral Valve System
2873774|NCT03433261|No Intervention|Normal Diet|The participant will eat their usual diet for at least 72 hrs prior to the experiment, document their diet during that time and be tested for ketone level immediately prior to the experiment.
2873775|NCT03433261|Experimental|Ketogenic Diet|The participant will follow a ketogenic diet for 72 hrs prior to the experiment and consume a ketone supplement 60 minutes prior to the experiment. They will document their diet and be tested for ketone level immediately prior to the experiment.
2873776|NCT03433248|Experimental|EMPA/LINA 10/5 mg QD (n=22)|8w EMPA followed by 8w EMPA/LINA 10/5 mg QD (n=22)
2873777|NCT03433248|Experimental|LINA/EMPA 5/10 mg QD (N=22)|8w LINA followed by LINA/EMPA 5/10 mg QD (N=22)
2873778|NCT03433248|Active Comparator|Gliclazide 30 mg QD/BID (N=22)|8w Gliclazide 30 mg QD, followed by 8w Gliclazide BID (N=22)
2873779|NCT03433235|Experimental|Early edoxaban initiation group|Low dose of edoxaban (15 or 30 mg) once daily from Day 2, then standard dose of edoxaban (30 or 60 mg) according to '3-6' rule.
2873780|NCT03433235|Active Comparator|Conventional edoxaban initiation group|No antithrombotic treatment† -- then standard dose of edoxaban (30 or 60 mg) according to '3-6' rule.
2873781|NCT03433222|Experimental|HF-LED-RL Phototherapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to HF-LED-RL phototherapy and two subjects randomized to mock therapy).~After either a maximally tolerated dose (MTD) has been established or the study endpoint of 640 J/cm2 has been achieved, an additional 24 or 27 HF-LED-RL phototherapy subjects (for a total of 30) and 16 or 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
2873782|NCT03433222|Sham Comparator|Mock Therapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to HF-LED-RL phototherapy and two subjects randomized to mock therapy).~After either a maximally tolerated dose (MTD) has been established or the study endpoint of 640 J/cm2 has been achieved, an additional 24 or 27 HF-LED-RL phototherapy subjects (for a total of 30) and 16 or 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
2873783|NCT03433209|Active Comparator|Ligasure device|This group of women undergoing hysterectomy were randomized to the Ligasure energy device
2873784|NCT03433209|Active Comparator|Articulating Enseal|This group of women undergoing hysterectomy were randomized to the articulating Enseal energy device
2873785|NCT03433196|Experimental|HS-25 and Atorvastatin|HS-25 20mg, Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet
2873786|NCT03433196|Active Comparator|Atorvastatin|Atorvastatin 20mg, Placebo of HS-25 2 tablets
2873787|NCT03433183|Experimental|Selumetinib and Sirolimus|A Simon's two-stage phase 2 trial of MEK inhibitor selumetinib in combination with the mTOR inhibitor sirolimus to determine the safety and clinical benefit in patients with unresectable or metastatic MPNSTs. Both agents will be given orally on an empty stomach. Selumetinib will be given orally at a dose of 50mg twice daily continuously. Sirolimus will be given orally at a dose of 4mg once daily with a cycle 1 day 1 loading dose of 12mg. Each cycle will be considered 28 days.
2873788|NCT03433170|Experimental|Quadrupled semitendinosus graft|Autologous quadrupled semitendinosus graft is used to reconstruct the ACL injury
2873789|NCT03433170|Active Comparator|ST-Gracilis graft|Both gracilis and semitendinosus autologous graft are used to reconstruct the ACL injury
2873790|NCT03433157|Experimental|Hall technique|SSCs placed on primary teeth using Hall technique
2873791|NCT03433157|Active Comparator|Traditional technique|SSCs placed on primary teeth using Traditional technique
2873792|NCT03433144|Experimental|Intervention TXA|patients receiving TXA10mg/kg IV pre-operatively
2873793|NCT03433144|Placebo Comparator|Placebo|patients will receive an equivalent amount of normal saline 0.9% IV pre-operatively
2873794|NCT03433118|Experimental|Acupuncture|Acupuncture administered by specially-trained therapeutic radiographers to patients attending the UCH radiotherapy department for radiotherapy intended to be curative of their cancer
2873795|NCT03433118|No Intervention|Standard care|Standard care for patients attending the UCH radiotherapy department for radiotherapy intended to be curative of their cancer
2873796|NCT03433105||1/patients with tracheostomy tubes and prolonged MV use|Patients who have tracheostomy tubes and with prolonged mechanical ventilation
2873797|NCT03433092||Jing Huang et. al, 2017|
2873798|NCT03433092||Max Leenders et. al,2014|
2873799|NCT03433092||Yusuke Okuyama et. al,2014|
2873800|NCT03433092||GC Kabat et. al,2012|
2873801|NCT03433092||Christina Persson et. al,2008|
2873802|NCT03433092||M Jenab et. al,2006|
2873803|NCT03433092||Kenji Wakai et. al,2005|
2873804|NCT03433092||Christian C. Abnet et. al,2003|
2873805|NCT03433092||N Malila et. al,2002|
2873806|NCT03433092||G Pappalardo et. al,1997|
2873807|NCT03433079||Acute Kidney Injury|Patients > 18 years of age with acute kidney injury were enroled into the study. Arterial levels of neutrophil gelatinase-associated lipocalin (NGAL), arterial lactate, interleukin-6 (IL-6), procalcitonin (PCT) and myoglobin were investigated in all patients.
2873808|NCT03433066|Experimental|group I (Test)|Advanced platelet-rich fibrin mixed with biphasic alloplast
2873809|NCT03433066|Active Comparator|Group II (control)|Biphasic alloplast mixed with saline
2873810|NCT03433053|Placebo Comparator|Control|Participants will be exposed to a generic HIV testing message.
2873811|NCT03433053|Experimental|Experiment|Participants will be exposed to a targeted HIV testing message, developed specifically for African American women.
2873812|NCT03433040|Other|non obese|250mg 17 OHP-C
2873813|NCT03433040|Other|obese - control|250mg 17 OHP-C
2873814|NCT03433040|Experimental|obese|500mg 17 OHP-C
2873815|NCT03433027|Experimental|BB-401|BB-401 Intratumoral injection
2873816|NCT03433014|Active Comparator|0.5% Levobupivacaine|The trocar insertion sites are infiltrated before the skin incision is made. Using the Lap-Assist Transversus Abdominis Plane Block Technique, the total volume of infiltrated 0.5% Levobupivacaine is 20 ml, divided proportionally according to the length of the skin incision.
2873817|NCT03433014|Other|Control|The control group will not receive any local infiltrative agent.
2873818|NCT03433001||Ixazomib + Lenalidomide + Dexamethasone|Participants will take ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone will not be defined by the protocol but according to the package insert of each drug.
2873819|NCT03432988|Experimental|nurses in the hemodialysis service|Nursing Solution-Focused: Two two-hour training modules were designed by two recognized solution-focused therapy experts. In each module, participants watched videos that illustrated solution-focused communication on fluid adherence, and practiced the skills in role-plays.
2873820|NCT03432975|Experimental|Povidone Iodine 10%|The side of the mouth receiving the subgingival irrigations of povidone iodine.
2873821|NCT03432975|Placebo Comparator|Sterile saline solution|The other side of the mouth will be irrigated with a sterile saline solution.
2873822|NCT03432962||Food code group|The participants freely selected foods from the online dietary assessment tool to record what they had eaten over the last 24h. They then provided information on brand details. The recalls were recoded to take into account all branded items and then recoded again to take represent all generic (ie. no brands) foods.
2873823|NCT03432949|Experimental|Dexamethasone plus Radium-223|Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.
2873824|NCT03432936|Experimental|MRI guided procedure software evaluation|Evaluate the workflow and effectiveness of the Philips Interventional iSuite software during biopsies and/or ablations versus standard MR imaging in aiding needle placement.
2873825|NCT03432923|Experimental|Benzocaine 8 mg|Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
2873826|NCT03432923|Placebo Comparator|Placebo|Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
2873827|NCT03432910|Other|treatment group|Participants of the study undergo the standard stages of the clinical routine within a PAP therapy setting: a diagnostic night followed by one or two treatment nights.
2873828|NCT03432897|Experimental|Treatment|"Olaparib 300 mg BID q 4 weeks for up to 3 cycles. The 3rd cycle will not be given if patient is found to progress post cycle 2.~Between 22-42 days post Olaparib, patients will undergo a prostatectomy."
2873829|NCT03432884|Experimental|Part A: BGB-3111|
2873830|NCT03432884|Placebo Comparator|Part A: Placebo|
2873831|NCT03432884|Experimental|Part B: BGB-3111, Placebo, and Moxifloxicin|
2873832|NCT03432871|Experimental|Nicotinamide Riboside|"This is an open-label experimental medicine study.~All subjects will receive the same dosage of the supplement Nicotinamide Riboside."
2873833|NCT03432858|Active Comparator|Vancomycin|
2873834|NCT03432858|Active Comparator|Cefazolin|
2873835|NCT03432858|Placebo Comparator|Saline|
2873836|NCT03432845||Sugammadex reversal group|Surgical patients will have their muscle relaxant reversed with sugammadex
2873837|NCT03432845||Glycopyrrolate / Neostigmine reversal group|Surgical patients will have their muscle relaxant reversed with glycopyrrolate and neostigmine
2873838|NCT03432832|Experimental|Emotion Awareness/Skills Enhancement|"EASE Therapy includes 16 weekly sessions. Sessions include mindfulness exercise, review of prior content, practicing prior skills, outline of current session, discussion of the new skill, handouts, practice and plan for out of session practice. The investigators will apply a multimodal teaching approach, where individual therapy is buttressed by parent involvement, practice sessions in the youth's community, and technology-based supports/teaching aids. A secure website developed for this project (emotion-Coach or e-Coach) will augment the intervention by providing online supports to increase treatment intensity or dosage. There will be specific information on how to reinforce the skills at home and in the community. eCoach usage will be monitored so that the investigators can evaluate its influence on outcome."
2896714|NCT03272048|Experimental|High-Fear/Temporary|
2873839|NCT03432832|Active Comparator|Supportive Therapy|Supportive Therapy will include 16 weekly sessions. Each session will include the same discussion about emotions and stressful situations and problem-solving with counselor. Supportive Therapy will involve attending 16 weekly therapy sessions held in Webster Hall in Pittsburgh or at the Child Study Center in Blacksburg. The intervention will not involve mindfulness, but other forms of stress management or problem-solving may be utilized. This program does not have an online component.
2873840|NCT03432819|Experimental|Siempre Seguiré|We will conduct a small RCT, testing study protocols and materials, the acceptability of randomization, and overall program feasibility. The pilot will help to identify logistical considerations; assess whether the program is acceptable and understandable LMSM; and collect initial data on how successfully the program motivates change in coping and adherence. It will allow us to estimate expected attrition and response rates, and to perform preliminary power analyses in preparation for a fully powered RCT.
2873841|NCT03432819|No Intervention|Control|Control participants will not be randomized to receive the intervention and will receive standard of care during the intervention period. We will offer the program to any interested control participants shortly after the 6-month follow-up surveys are completed.
2873842|NCT03432806||presumptive Stage II or III colon cancer|
2873843|NCT03432806||Stage IV colon cancer with resectable hepatic metastases|
2873844|NCT03432806||Stage IV colon cancer with unresectable hepatic metastases|
2873845|NCT03432806||Stage I colon cancer, pre-neoplastic or benign colon lesions|
2873846|NCT03432793|Experimental|TD-9855 + Fluvoxamine + Caffeine|Male smokers will receive TD-9855, fluvoxamine, and caffeine
2873847|NCT03432793|Experimental|TD-9855 + Itraconazole + Caffeine|Male non-smokers will receive TD-9855, itraconazole, and caffeine
2873848|NCT03432780|Experimental|Docetaxel, hormone and radiation therapy|Radiation therapy combined with weekly docetaxel (20 mg/m2) and hormone therapy.
2873849|NCT03432780|Active Comparator|Hormone and radiation therapy|Radiation therapy and hormone therapy
2873850|NCT03432767||Women having a vaginal delivery|A non-invasive hemoglobin monitor will be attached to the patient's finger and kept on for 2 hours after she delivers. Heart rate and blood pressure will be measured every 10 minutes.
2873851|NCT03432754|Experimental|Mindfulness-Based Attention Training|Four weekly group mindfulness attention training sessions of a 1.5-hour duration. Participants provided with audio recordings, readings, and homework assignments consisting of various mindfulness practices.
2873852|NCT03432754|Active Comparator|Lifestyle Education Group|Four weekly group lifestyle education sessions of a 1.5-hour duration. Homework consisting of reading, diet monitoring, stretching/toning exercises, and brainstorming new healthy living techniques/ideas.
2873853|NCT03432741|Experimental|Treatment (FDG-PET, direct tumor microinjection)|Patients undergo FDG-PET and receive saline intralesionally on day 1. Patients also receive up to five additional injections of gemcitabine hydrochloride, romidepsin, belinostat, carfilzomib, nivolumab, trastuzumab, daratumumab, obinutuzumab, pembrolizumab, or rituximab intralesionally per investigator on day 1. Beginning 5 days later, patients with nodal disease undergo restaging FDG-PET and biopsy (if clinically feasible). Within 3-7 days, patients with cutaneous disease undergo restaging FDG-PET, photography, and biopsy.
2873854|NCT03432728||S-ECC|Children in their fifth year of life with severe early childhood caries Children selected will require complete dental rehabilitation under general anesthesia All enrolled children will receive treatment of all dental carious lesions under general anesthesia
2873855|NCT03432728||Control|Children age and sex matched with the S-ECC group who are free of dental caries
2873856|NCT03432715|Experimental|Wellness Champions for Change + Students|Schools randomized to the WCC+S arm will receive both the Teacher Intervention and the Student Wellness Champion Intervention.
2873857|NCT03432715|Experimental|Wellness Champions for Change|Schools randomized to the WCC+S arm will receive only the Teacher Intervention.
2873858|NCT03432715|No Intervention|Control|The control group will not receive either intervention. Schools will be given a modified SWC curriculum as well as the teacher training at the end of the data collection period.
2873859|NCT03432702|Active Comparator|Alveolar ridge augmentation without ABG|Horizontal ridge augmentation using guided bone regeneration without autogenous block graft (ABG)
2873860|NCT03432702|Experimental|Alveolar ridge augmentation with ABG|Horizontal ridge augmentation using guided bone regeneration with autogenous block graft (ABG).
2873861|NCT03432689|Experimental|D-Cycloserine|Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
2873862|NCT03432689|Placebo Comparator|Placebo|Participants will ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
2873863|NCT03432676|Experimental|Pembrolizumab + Epacadostat|"Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of each 21 day cycle.~Participants take 2 Epacadostat pills by mouth every day while on study. Tablets should be taken about 12 hours apart (1 morning dose, 1 evening dose) at the same time each day."
2873864|NCT03432663|Experimental|24h infusion|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached Intravenous amiodarone (1)
2873865|NCT03432663|Experimental|72h infusion|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached Intravenous amiodarone (2)
2873866|NCT03432650|Experimental|QLB Block + Standard of Care|"Patients will receive either a spinal (4cc Mepivacaine) or combined spinal epidural anesthetic (dose up 50 5 cc 2% lidocaine) with IV sedation. Intraoperative anti-emetics will consist of IV ondansetron and IV dexamethasone. Intra-operative analgesics will be IV fentanyl, IV acetaminophen, IV ketorolac, and IV ketamine. No Block will be given.~Patients will receive a single shot anterior QLB (30cc 0.5% Bupivacaine with 2mg preservative free dexamethasone)."
2873913|NCT03432299|Experimental|RFA for PTMC|Group who will undergo RFA after diagnosis of PTC
2873867|NCT03432650|No Intervention|Standard of Care|Patients will receive either a spinal (4cc Mepivacaine) or combined spinal epidural anesthetic (dose up 50 5 cc 2% lidocaine) with IV sedation. Intraoperative anti-emetics will consist of IV ondansetron and IV dexamethasone. Intra-operative analgesics will be IV fentanyl, IV acetaminophen, IV ketorolac, and IV ketamine. No Block will be given.
2873868|NCT03432637|Experimental|SV|undergoing thoracoscopic lobectomy under spontaneous ventilation (SV)
2873869|NCT03432637|Active Comparator|SLV|undergoing thoracoscopic lobectomy under intubated anesthesia with single-lung mechanical ventilation(SLV)
2873870|NCT03432624||Experiment Subgroup, Group One|Experiment Subgroup, Group One consists of pancreatic cancer patients, in which 120 are operable, and 120 are not operable.
2873871|NCT03432624||Control Subgroup, Group One|Control Subgroup, Group One consists of 150 patients, in which 30 are of gallbladder carcinoma, 60 are of biliary tract lower segment carcinoma, 60 are of gastrointestinal carcinoma.
2873872|NCT03432624||Interference Subgroup, Group One|Interference Subgroup, Group One consists of 150 patients, in which 60 are of chronic pancreatitis, 90 are of other types of pancreatic tumor, in which 30 are of IPMN (intraductal papillary mucinous neoplasm), 30 are of SPT (solid pseudopapillary tumor of pancreas), and 30 pancreatic cystic adenoma.
2873873|NCT03432624||Experiment Subgroup, Group Two|Group Two consists of 210 patients selected from Group One, of which the Experiment Subgroup, Group Two consists of the 120 operable pancreatic cancer patients who have had successful surgery.
2873874|NCT03432624||Control Subgroup, Group Two|Control Subgroup, Group Two consists of 90 patients of other cancers who have had successful surgery, in which 30 are of gallbladder carcinoma, and 60 are of biliary tract lower segment carcinoma.
2873875|NCT03432611|Experimental|Complete app|198 women with primary dysmenorrhea who receive an app which includes a self-care information feature and a self-acupressure feature.
2873876|NCT03432611|Active Comparator|Control intervention I|198 women with primary dysmenorrhea who receive an app for menstrual pain which includes the self-care information feature, but not the self-acupressure feature.
2873877|NCT03432611|Active Comparator|Control intervention II|198 women with primary dysmenorrhea who receive an app for menstrual pain which includes the self-acupressure feature, but not the self-care information feature.
2873878|NCT03432598|Experimental|Non-squamous NSCLC|
2873879|NCT03432598|Experimental|Squamous NSCLC Cohort A|
2873880|NCT03432598|Experimental|Squamous NSCLC Cohort B|
2873881|NCT03432598|Experimental|SCLC|
2873882|NCT03432585||Family Support Grant applicants|Participants include applicants for the Family Support Grants that will be provided for the American Society for Nutrition annual meeting who are willing to complete the applicant survey.
2873883|NCT03432572|Experimental|pyridium|Group A will take 200 mg of oral Pyridium 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
2873884|NCT03432572|Active Comparator|riboflavin|Group B will take 400 mg of riboflavin 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
2873885|NCT03432572|Placebo Comparator|thiamine|Group C will take the placebo (50 mg of thiamine) 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
2873886|NCT03432559|Other|endoscopy|endoscopy of the upper GI tract
2873887|NCT03432546||ICU patients|Over 18-year old intensive care patients, non-interventional prospective observational study
2873888|NCT03432533|Active Comparator|HCP administration with PFS|During the open-label treatment period, subjects will receive 210 mg romosozumab SC QM either by HCP administration with 2 PFS
2873889|NCT03432533|Active Comparator|Subject self-administration with AI/Pen|During the open-label treatment period, subjects will receive 210 mg romosozumab SC QM either by self-administration with 2 AI/Pens.
2873890|NCT03432507||disc herniation|patients suffering from disc herniation
2873891|NCT03432507||spinal stenosis|patients suffering from spinal stenosis
2873892|NCT03432494|Experimental|Study Arm 1|Subjects undergoing transcaval access for TAVR
2873893|NCT03432481|Experimental|Knee Arthroplasty using BUKS|Unicompartmental Knee Arthroplasty Surgery
2873894|NCT03432468|Active Comparator|postmenopausal hypertensive women|
2873895|NCT03432468|Placebo Comparator|age-matched hypertensive male patients|
2873896|NCT03432442|Experimental|Group 1 (6 dengue patients)|Volunteers weighed > 30 kg receiving 400 µg of ivermectin per 1 kg of body weight
2873897|NCT03432442|Experimental|Group 2 (6 dengue patients)|Volunteers weighed > 30 kg receiving 600 µg of ivermectin per 1 kg of body weight
2873898|NCT03432442|Experimental|Group 3 (6 dengue patients)|Volunteers weighed 15 to 30 kg receiving 400 µg of ivermectin per 1 kg of body weight
2873899|NCT03432442|Experimental|Group 4 (6 dengue patients)|Volunteers weighed 15 to 30 kg receiving 600 µg of ivermectin per 1 kg of body weight
2873900|NCT03432416|Experimental|Regimen 1: Continuous Usage|Contraceptive vaginal ring delivering a daily dose of Nestorone® and estradiol (NES-E2 CVR) worn continuously for 91 days.
2873901|NCT03432416|Experimental|Regimen 2: Cyclical Usage|Contraceptive vaginal ring delivering a daily dose of Nestorone® and estradiol (NES-E2 CVR) worn for 91 days, but is removed for 2 days each month (days 29-30, 59-60, and 90-91).
2873902|NCT03432403||New LMA or Old LMA|newly designed LMA or older designed LMA
2873903|NCT03432390|Experimental|CPAP|
2873904|NCT03432390|Active Comparator|Aberto|
2873905|NCT03432364|Experimental|ST-400 Investigational product|ST-400 Investigational product is composed of autologous CD34+ hematopoietic stem/progenitor cells that are genetically modified ex vivo at the erythroid-specific enhancer of the BCL11A gene
2873906|NCT03432351||Children: 0-36mo|EEG sensor will be placed on the subject's forehead to observe and record EEG activity. No other applicable intervention.
2873907|NCT03432338||idiopathic parkinson|Classical Parkinson´s disease, idiopathic
2873908|NCT03432338||secondary parkinsonism|parkinsonism due to other reasons than idiopathic
2873909|NCT03432338||controls|persona matched by age and gender, non parkinsonism
2873910|NCT03432325|Experimental|Neural Enabled Prosthesis|Neural Enabled Prosthesis Treatment Group
2873911|NCT03432312|Experimental|Nicotine 4 mg mint lozenges|
2873912|NCT03432312|Active Comparator|NiQuitin 4 mg mint lozenges|
2873918|NCT03432260|Experimental|DUR-928|Dose escalation including 3 doses: 30mg, 90 mg and 150 mg
2873919|NCT03432247|Experimental|Interactive Music Therapy|Six 45-minute individual interactive music therapy sessions.
2873920|NCT03432247|Active Comparator|Verbal-based support|Six 45-minute individual verbal support sessions
2873921|NCT03432234||COPD and frequent exacerbation|Patient with COPD diagnosis and at least two exacerbations by year (FE)
2873922|NCT03432234||COPD no frequent exacerbation|Patient with COPD diagnosis with no frequent exacerbation, less than 2 by year (NE).
2873923|NCT03432234||Healthy (control)|Healthy volunteers patients (H)
2873924|NCT03432221||MDD|Patients who met DSM-5 criteria for MDD attending the outpatient psychiatric service of the Hospital Universitari Parc Taulí. Patients must have a lack of response to SSRI (Maximize dose for adequate time), being the next therapeutic option the introduction of desvenlafaxine.
2873925|NCT03432221||Healthy Controls|Healthy participants matched by age, gender and educational level without history of psychiatric disorders and no familial history of mood disorders will be recruited
2873926|NCT03432208|Active Comparator|ESOPHAGO-GASTRO-DUODENOSCOPY (EGD)|Investigation using EGD
2873927|NCT03432208|Experimental|ENDOSCOPIC ULTRASOUND (EUS)|Investigation using EUS
2873928|NCT03432195|Experimental|Donepezil TDS Back|Corplex Donepezil TDS 10 mg/day applied to the Back for 1 week (7 days)
2873929|NCT03432195|Experimental|Donepezil TDS Buttock|Corplex Donepezil TDS 10 mg/day applied to the Buttock for 1 week (7 days)
2873930|NCT03432195|Experimental|Donepezil TDS Leg|Corplex Donepezil TDS 10 mg/day applied to the Leg for 1 week (7 days)
2873931|NCT03432182|Other|very premature infants|Electroencephalography allowing sleep observation
2873932|NCT03432169|Active Comparator|Yoga|Stretching with mindfulness
2873933|NCT03432169|Active Comparator|Stretching|Stretching exercises without mindfulness
2873934|NCT03432156|Experimental|Experimental group|subjects who are treated with autologous Tcm cells immunotherapy
2873935|NCT03432156|No Intervention|No intervention group|subjects who are treated without autologous Tcm cells immunotherapy
2873936|NCT03432143|Experimental|Community Reviewers|24 community members will receive training and mentoring in reviewing manuscripts. Approximately 284 manuscripts will be randomized into the intervention group over the duration of the study. Manuscripts will be reviewed by both a community member and scientific reviewers.
2873937|NCT03432143|No Intervention|Scientific Reviewers Only|Approximately 284 manuscripts will be randomized into the control group over the duration of the study. Manuscripts will be reviewed by multiple scientific reviewers. Community reviewers will not be involved in reviewing these manuscripts.
2873938|NCT03432130|Experimental|Experimental group|Performing a structural training program twice a week, 30 minutes each.
2873939|NCT03432130|No Intervention|Control group|
2873940|NCT03432117|Experimental|Fixed respiratory rehabilitation program(A)|respiratory rehabilitation program for 12 weeks
2873941|NCT03432117|Experimental|Mixed respiratory rehabilitation program(B)|Fixed respiratory rehabilitation for 6 weeks, and then responsive respiratory rehabilitation for 6 weeks
2873942|NCT03432117|No Intervention|Control(C)|Ordinary rehabilitation service of the site for 12 weeks
2873943|NCT03432104|Experimental|Verum|This arm receives 1 x 450 mg-capsule of Oxxynea®, a blend of polyphenol-rich fruit and vegetable extracts
2873944|NCT03432104|Placebo Comparator|Placebo|This arms receives 1 x 450 mg-capsule of Placebo, containing maltodextrin only
2873945|NCT03432078|Active Comparator|Individual hypnotherapy|Treatment given on a individual basis, face to face.
2873946|NCT03432078|Active Comparator|Group hypnotherapy|Treatment given in a group setting, face to face.
2873947|NCT03432065|Experimental|Buspirone|Buspirone tablets will be administered twice daily, and will be titrated to a maximum daily dose of 60mg for 8 weeks.
2873948|NCT03432039|Placebo Comparator|Psychoeducation arm|This arm will provide information about admission procedures, story telling and a follow-up phone call
2873949|NCT03432039|Experimental|Behavioral intervention|This arm will provide information about what invasive procedures maybe given to the child, the emotional and behavioral reactions of the child while on the ward, games and stories that the child can engage with the mother and a follow-up phone call
2873950|NCT03432026||Non-smoker COPD patients|stable non-smoker COPD patients diagnosed by a previous spiromtery to have FEV1/FVC less than 70
2873951|NCT03432013|Active Comparator|SUD-CBT|Standard cognitive behavioral therapy for substance use disorder
2873952|NCT03432013|Experimental|CUD-AMT|Experimental affective management training for cannabis use disorder specifically
2873953|NCT03432000|Experimental|subjects with schizophrenia|Performances on temporal task Subjective alterations of time perception in patients with an adapted scale (EAWE) Global symptomatology with PANSS (positive and negative symptom scale)
2873954|NCT03432000|Sham Comparator|healthy subjects|Evaluate the links (correlation) between perception of temporal sequencing and perception of causality using an adapted experimental paradigm (Michotte paradigm) and to compare performance between healthy subjects and controls Investigate the existence of a correlation between these alterations and the peculiarities of the subjective experience of time (EAWE scale) in the group of subjects with schizophrenia
2873955|NCT03431987||Marijuana Users|
2873956|NCT03431974|Experimental|Aminopterin oral capsule|LD-Aminopterin tablets (0.5 mg tablet) over-encapsulated, 3.0 mg (6 tablets) once orally each week for 14 weeks (14 doses).
2873957|NCT03431974|Placebo Comparator|Placebo oral capsule|Placebo capsules containing microcrystalline once orally each week for 14 weeks (14 doses).
2873958|NCT03431961|Placebo Comparator|Placebo|0.9% normal saline administered twice daily for 14 days
2873959|NCT03431961|Experimental|Intranasal Corticosteroid|Triamcinolone acetonide aqueous nasal spray at a dose of 220 mcg administered twice daily (for a total daily dose of 440 mcg) for 14 days
2873960|NCT03431948|Experimental|SBRT with Nivolumab and Urelumab|Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and urelumab.
2873961|NCT03431948|Experimental|SBRT with Nivolumab and Cabiralizumab|Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and cabiralizumab .
2873962|NCT03431922|Experimental|endovascular denervation|endovascular denervation
2874309|NCT03429582|Experimental|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
2873963|NCT03431909|Experimental|Kallikrein group|Subjects receive kailikang treatment according to real clinical practice (suggest above 14 days treatment),0.15 peptide nucleic acids(PNA), once a day.
2873964|NCT03431909|Sham Comparator|Control group|Patients in control group will receive foundation treatment, including aspirin® (100 mg/d), clopidogrel® (75 mg/d), and atorvastatin® (20 mg/d) for 14 days
2873965|NCT03431896||Primary|"1.) To evaluate the relative amount of misfolded ATTR oligomers in asymptomatic ATTR amyloid genetic carriers and correlate their levels with clinical symptoms and outcomes.~Determine if misfolded ATTR oligomers are elevated compared to healthy control data obtained by Scripps during probe development~Describe the levels longitudinally~Determine if treatment with ATTR-specific medications (examples: diflunisal, doxycycline, ursodiol, tauroursodeoxycholic acid (TUDCA), green tea extract, curcumin, tafamidis, inotersen, patisiran) lead to reduction in the probe levels in those with elevated levels at baseline"
2873966|NCT03431870|Other|Aorta dilated|Patients with aorta of 40mm or more who undergo a cardiac surgery. The intervention include: Trans-Esophageal Echocardiography
2873967|NCT03431857||Anatomic TESS V2 shoulder|Subjects who meet the inclusion/exclusion criteria and who received the Anatomic TESS V2 shoulder prosthesis .
2873968|NCT03431857||Reverse TESS V2 shoulder|Subjects who meet the inclusion/exclusion criteria and who received the ReverseTESS V2 shoulder prosthesis .
2873969|NCT03431831|Active Comparator|Intervention Control|All participants will receive diet/physical intervention. One arm will receive diet/physical activity intervention alone as a Intervention/usual care condition.
2873970|NCT03431831|Experimental|Counselling|These participants will receive usual care and counseling in the form of motivational interviewing weekly with goal setting for the first 5 weeks and monthly intervention for the final 5 months.
2873971|NCT03431831|Experimental|Contrave|These participants will receive usual care and prescription of Contrave for weight loss. They will be seen weekly for the first 5 weeks and monthly for the final 5 months.
2873972|NCT03431831|Experimental|Contrave and counseling|These participants will receive usual care of diet and physical activity recommendations and Contrave prescription and counseling (motivational interviewing interventions weekly for the first 5 weeks and then monthly for 5 months.
2873973|NCT03431805|Experimental|Tranexamic acid|intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)
2873974|NCT03431805|Placebo Comparator|Chloride solution|sodium intravenous administration of 10-mL of chloride solution (0.9% -10mL).
2873975|NCT03431792|Experimental|Long-Tail-FETO|"Fetus with severe CDH and o/e TFLV Ratio of < 25% or < 35% with liver herniation. The Long tail FETO will performed between 26 and 30 weeks of gestation.~The MRI control will be perfirmed ar 32-34 weeks of gestation. Long Tail FETO: fetal i.m. application of 0.1 mg/kg Pancuronium, 1 µg/kg Fentanyl® and 0.01 mg/kg atropine. (Long-Tail Goldbal 5, 2,5 ml, BALT Extrusion, Montmorency, France). The fetoscope (Karl Storz, Tuttlingen, Germany) with a diameter of 1.3 mm, will be percutaneously inserted through a sheath into the uterus and then into the fetal trachea. The fetoscope will be removed and the balloon will be inserted under 4-D ultrasound guidance into the fetal trachea. The position of the balloon and suture will be visualized using the fetoscopy.~The Long tail ballon will be removed by a second FETO after 34 weeks' gestation or bei the fetus itself with or without of the long tail balloon puncture with 22 gauge needle. The EXIT procedure is also possible."
2873976|NCT03431779|Experimental|Adipose derived stem cell transplantation via lipofilling|Liposuction of 60cc abdominal fat with its adipose derived stem cells which will be reinjected (10-20 cc) in the vestibular area after centrifugation for 3 minutes at 1000 rpm and decantation of oil and red blood cells.
2873977|NCT03431779|Active Comparator|Surgical excision|Excision of painful areas
2873978|NCT03431766|Placebo Comparator|control group A|on this group a placebo gel will be applied on the internal surface of the implant during all the surgical and prosthetic phases of the treatment.
2873979|NCT03431766|Experimental|test group B|on this group a 0.20% chlorhexidine gel will be applied on the internal surface of the implant during all the surgical and prosthetic phases of the treatment described on the study protocol.
2873980|NCT03431753|Experimental|PSA, STHLM3 and mpMRI for PC detection|mpMRI, and if suspect MR-targeted prostate biopsy, in men with increased PC risk as judged from the STHLM3 test and/or an elevated prostate specific antigen test.
2873981|NCT03431714|Experimental|single arm|Artesunate amodiaquine tablets containing 25/67.5 mg, 50/135mg and 100/270 mg base of artesunate-amodiaquine were administered according to body weight Dihrdroartemisinin piperaquine tablets containing 160/20mg and 320/40mg base of piperaquine dihydroartemisinin were administered according to body weight
2873982|NCT03431701|Experimental|Group chlorhexidine|Patients will receive chlorhexidine abdominal and vaginal scrubbing
2873983|NCT03431701|Active Comparator|Group iodine|Patients will receive iodine abdominal and vaginal scrubbing
2873984|NCT03431688|Active Comparator|PAM|treatment with PPI, metonidazole, amoxicillin
2873985|NCT03431688|Active Comparator|PBMT|treatment with PPI, metonidazole, bismuth, tetracyclin
2873986|NCT03431675|No Intervention|Standard care|No chemoprevention for contacts of cases of meningitis (current standard of care) with a health promotion visit by a study nurse after the first notification of cases during the epidemic
2873987|NCT03431675|Active Comparator|Household prophylaxis arm|Chemoprophylaxis with a single dose of oral ciprofloxacin for household members of reported cases of meningitis. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension)
2873988|NCT03431675|Active Comparator|Community prophylaxis arm|Chemoprophylaxis with ciprofloxacin in the setting of a village-wide distribution after the notification of the first case of meningitis in a village. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension)
2873989|NCT03431662|Experimental|Ellipse IM HTO Nail|In this arm, the subjects varus malalignment is corrected with Ellipse Intramedullary High Tibial Osteotomy Intramedullary Nail, which is a CE device. The device achieves the correction via progressive distraction osteogenesis.
2873990|NCT03431662|Active Comparator|TomoFix|In this arm, the subjects varus malalignment is corrected with Synthes TomoFix system, which is a CE device. The device achieves the correction via fixating an accute intraoperative correction of the varus malalignment.
2873991|NCT03431649|Experimental|Beraprost Sodium|"Beraprost 1mcg/kg/day, divided in 3 doses orally patient was followed up for 12 weeks, then echocardiography evaluation was performed in patient completed the study.~22 patients"
2873992|NCT03431649|Active Comparator|Sildenafil citrate|"Sildenafil 0.4 mg/kg/time, 4 times daily per oral patient was followed up for 12 weeks, then echocardiography evaluation was performed in patient completed the study.~20 patients"
2873993|NCT03431636|Experimental|Immersion in cold water|"The athlete will remain submerged in a Cryo Control - Ice Bath Systems® bathtub, which allows filtration and maintenance of constant water temperature, and shoulder blade water (Getto and Golden, 2013) for 15 minutes in the 15 degrees Celsius (Machado et al, 2016)."
2873994|NCT03431636|Active Comparator|Ice pack|The athlete will remain for 20 minutes with plastic packets of 500 grams of ice each, in the region of the evaluated muscles.
2873995|NCT03431636|Sham Comparator|Control|Group in which the athlete will be instructed to remain seated in a comfortable position, at rest, for 20 minutes.
2873996|NCT03431623|Experimental|CKD-11101(Darbepoetin alfa)|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
2873997|NCT03431623|Active Comparator|NESP(Darbepoetin alfa)|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
2873998|NCT03431610|Experimental|SB414 2%|SB414 2% topically twice daily
2873999|NCT03431610|Experimental|SB414 6%|SB414 6% topically twice daily
2874000|NCT03431610|Placebo Comparator|Vehicle Cream|Vehicle Cream topically twice daily
2874001|NCT03431597|Experimental|oral nutritional supplementation|Daily novel micronutrient supplement: 800 μg folic acid, 5.2 μg cyanocobalamin (B12), 2.8 mg Riboflavin-5'- phosphate (B2), 4g trimethylglycine (betaine) in drink powder form. The drink will be dissolved in 200ml of water and taken daily for 12 weeks
2874002|NCT03431597|Active Comparator|oral nutritional supplementation, UNIMMAP|The United Nations Multiple Micronutrient Preparation (UNIMMAP) supplement is a capsule containing 15 micronutrients (vitamins A, D, E, B1, B2, B6, B12, C, Niacin, Folic Acid, Fe, Zn, Cu, I, Se) at the Recommended Daily Allowance level. UNIMMAP will be provided in capsule form and taken daily with water for 12 weeks.
2874003|NCT03431597|No Intervention|control|no treatment will be given to this group observation only (no placebo)
2874004|NCT03431584|Active Comparator|Infiltration of corticosteroids|
2874005|NCT03431584|Experimental|Infiltration of corticosteroids and hyaluronic acid|
2874006|NCT03431571|Other|Single arm|ReLEx SMILE treatment can be done binocular or monocular, no masking and randomization used, no control group
2874007|NCT03431558|Experimental|Group 1|"bLF (Bovine Lactoferrin plus Glucan D 99.4%) Dose: 150 mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).~Duration: 1 month"
2874008|NCT03431558|Experimental|Group 2|"bLF (Bovine Lactoferrin plus Glucan D 99.4%) Dose: 300mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).~Duration: 1 month"
2874009|NCT03431558|Placebo Comparator|Group 3|"Placebo: Only Glucan-D (99.4% glucoseDose: 150 mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).~Duration: 1 month"
2874010|NCT03431545|Experimental|PALS and BEECH|Play and Learning Strategies (PALS) and Beginning Education: Early Childcare at Home (BEECH) include web-based parent and teacher training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.
2874011|NCT03431545|Active Comparator|Control condition|Parents and teachers conduct business as usual in regards to care-giving in the school and at home.
2874012|NCT03431532||neuraxial anesthesia|Patients with total knee replacement surgery having neuraxial anesthesia along with the procedure.
2874013|NCT03431532||general anesthesia|Patients with total knee replacement surgery having General anesthesia along with the procedure.
2874014|NCT03431519||Group A|The subjects received VP with PEEK and Sr-HA
2874015|NCT03431519||Group B|The subjects received VP with PEEK and PMMA
2874016|NCT03431506|Active Comparator|non-training group|
2874017|NCT03431506|Experimental|training group|
2874018|NCT03431493|Experimental|Behavioral Activation - Rehabilitation|Behavioral Activation - Rehabilitation
2874019|NCT03431493|No Intervention|Usual Care Control|Usual Care Control
2874020|NCT03431480|Experimental|hCBMNC|Autologous human placental cord blood mononuclear cells (buffy coat fraction)
2874021|NCT03431467|No Intervention|Control|VA-ECMO alone per standard clinical protocol.
2874022|NCT03431467|Experimental|Experimental|VA-ECMO with early institution of Impella CP LV venting
2874023|NCT03431454|Active Comparator|home-based vision orthoptic therapy (HBVOT) group|In the home-based vision orthoptic therapy (HBVOT) group, patients were trained to do the pencil push-ups procedure 15 minutes per day, five days a week
2874024|NCT03431454|Active Comparator|office-based vision orthoptic therapy (OBVOT) group|In the office-based vision orthoptic therapy (OBVOT) group, 60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed
2874025|NCT03431454|Active Comparator|augmented office-based vision orthoptic therapy (AOBVOT) group|For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
2874026|NCT03431441|Experimental|JJVC Marketed Contact Lens|ACUVUE 2 Vivid Style
2874027|NCT03431428|Experimental|transanal surgery|"To ensure the complete cutting edge with no residual tumor, the tumor with corresponding mesorectal excision was removed by the distance edge of 1cm.~The intestinal wall was sutured to ensure the integrity of the bowel."
2874028|NCT03431428|Placebo Comparator|Miles surgery|According to the total mesorectal excision(TME) principle, complete mesorectum, lymph node and the anus was excised. A sigmoid colostomy was finally performed.
2875311|NCT03422666|Placebo Comparator|Placebo|Placebo, subcutaneous, single dose
2874029|NCT03431415|Active Comparator|Surgery|Patients that will undergo surgery (anatomical segmentectomy, lobectomy or bilobectomy) as primary lung cancer treatment
2874030|NCT03431415|Active Comparator|SBRT (Stereotactic Body Radiation Therapy)|Patients that will undergo SBRT as primary lung cancer treatment
2874031|NCT03431402|Other|Acute stroke receive hyperbaric oxygen|
2874032|NCT03431402|No Intervention|Acute stroke receive only conventional treatment|
2874033|NCT03431389|Active Comparator|Decannulated group|Decannulation was considered when the patients were no longer in need for tracheostomy tube and fulfilled the criteria of decannulation: No need for mechanical ventilation, no chocking with oral intake, no chest infection, effective cough reflex, laryngeal examination show bilateral mobile vocal cords with sufficient gap. Trial of decannulation was considered successful, if there was no need to reapply tracheostomy within 6 months of decannulation.
2874034|NCT03431389|Active Comparator|Failure of decannulation group|Decannulation was considered when the patients were no longer in need for tracheostomy tube and fulfilled the criteria of decannulation: No need for mechanical ventilation, no chocking with oral intake, no chest infection, effective cough reflex, laryngeal examination show bilateral mobile vocal cords with sufficient gap. Decannulation trail was considered failed if there was a need to reapplication of tracheostomy at the time of decannulation or within six months of decannulation the duration of follow up.
2874035|NCT03431363||Observational group|Patient dosing options will be stratified into three groups defined as standard, frail/elderly (age > 65 or ECOG 2), and cannabis-experienced (> weekly use of cannabis in the past year outside of NYC Medical Marijuana program). NYC specified cannabis formulation options are defined by THC:CBD ratio as 1:1, low THC:high CBD, high THC:low CBD, and high THC:high CBD.
2874036|NCT03431350|Experimental|Dose Selection: Niraparib and JNJ-63723283 (Part 1)|Dose regimen 1: The participants will receive niraparib 200 milligram (mg) orally once daily in combination with JNJ-63723283 240 mg intravenously (IV) once every 2 weeks. Dose regimen 2: The participants will receive niraparib 200 mg orally once daily in combination with JNJ-63723283 480 mg IV once every 4 weeks in 28-day treatment cycles until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. The safety evaluation team (SET) will determine if an additional cohort is necessary, based on the data from dose regimens 1 and 2.
2874037|NCT03431350|Experimental|Dose Expansion: Niraparib and JNJ-63723283 (Part 2)|Participants will be assigned to either Cohort 1A (Biomarker [BM] positive [+]) or Cohort 1B (BM negative [-]), and will receive RP2D of JNJ-63723283 determined in Part 1 and niraparib 200 mg once daily as RP2D, in Part 2. A futility analysis will be performed for the Cohort 1B after 10 BM- participants are enrolled in Part 2. This cohort will be closed if the response rate is 13 percent (%) or less for the participants.
2874038|NCT03431337|Experimental|High dose|Amoxicillin/clavulanate 875mg/125mg & amoxicillin 875 mg twice a day x 7 days
2874039|NCT03431337|Active Comparator|Standard dose|Amoxicillin/clavulanate 875 mg/125mg & placebo (lactase) twice a day x 7 days.
2874040|NCT03431324|Experimental|Mating-EFT Intervention Effectiveness|"Study 1: 90 participants will attend an initial session, at which point they will provide demographic information as well as their relationship status. They will then be randomly assigned to complete either the Episodic Future Thinking about Mating Opportunities intervention, a general-EFT intervention, or an unrelated questionnaire (yoked control condition).~All participants will submit daily reports of the number of cigarettes smoked for a period of one week. Participants will then complete a series of questionnaires measuring individual differences in fundamental social motives (including mate-seeking motives), self-efficacy, and nicotine dependence."
2874041|NCT03431324|Experimental|Message Tailoring for Smoking Cessation|Study 2: A quasi-experimental design will be employed in order to determine whether targeting individuals who are single and highly motivated to seek a mate with a Targeted Mating-EFT Intervention is a more effective means of reducing cigarette consumption than presenting all individuals with a general-EFT intervention. A total of 180 smokers who intend to quit or reduce smoking will be recruited as participants. These individuals will be selected from a larger pool of participants based upon responses to screening questions. The screening questions will measure relationship status and mate seeking motivation.
2874042|NCT03431311|Experimental|Adoptive Cell Therapy (ACT)|"The ACT will be administered as two intravenous (i.v.) injections of GMP TCR T cells per week for 6 weeks.~Escalating dose per week, from 1 x108 cells (week 1) to 2x109 cells (week 4 onwards) using a central venous catheter. The doses listed indicate the maximum number of T cells per injection at any given time point."
2874043|NCT03431298|Experimental|Aerobic exercise & movement control|"The duration of intervention is 8 weeks.~Individualized functional movement control training is 60 min/week~Aerobic exercise is 60 min/week"
2874044|NCT03431298|Active Comparator|Aerobic exercise|"The duration of intervention is 8 weeks.~Frequency: 2 times/ week~Duration: 60min/ time"
2874045|NCT03431285|Active Comparator|Morphine Group|Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline (NS) infused over 30 minutes in addition to standard IV hydration.
2874046|NCT03431285|Active Comparator|Ketamine Group|Patients will receive low dose ketamine 0.3 mg/kg in 100ml normal saline (NS) infused over 30 minutes in addition to standard IV hydration
2874047|NCT03431272|Experimental|Treatment|lifitegrast ophthalmic solution 5.0%, to be instilled 1 drop in each eye, twice a day
2874048|NCT03431259|Experimental|Enrollment group|
2874049|NCT03431259|No Intervention|Information group|
2874050|NCT03431246|Experimental|Gardasil and Gardasil-9|
2874051|NCT03431233|Experimental|Group 1|protein enriched bar->commercial cereal bar->water
2874052|NCT03431233|Experimental|Group 2|protein enriched bar->water->commercial cereal bar
2874053|NCT03431233|Experimental|Group 3|commercial cereal bar->protein enriched bar->water
2874054|NCT03431233|Experimental|Group 4|commercial cereal bar->water->protein enriched bar
2874055|NCT03431233|Experimental|Group 5|water->protein enriched bar->commercial cereal bar
2874056|NCT03431233|Experimental|Group 6|water->commercial cereal bar->protein enriched bar
2874057|NCT03431220|Experimental|RENASYS TOUCH NPWT System|Negative Pressure Wound Therapy (NPWT)
2874058|NCT03431207||healthy group|"For the healthy group, the visual acuity of both eyes was in the 95% referenced range with no structural abnormalities.~The referenced range could be found in the following publication:~Mayer, DL., et al. Monocular acuity norms for the Teller Acuity Cards between ages one month and four years. Investigative Ophthalmology & Visual Science. 36(3):671 (1995)"
2874059|NCT03431207||mildly impaired group|"The mildly impaired group was defined as a VA out of the 95% reference range in at least 1 eye, but the VA of both eyes was in the 99% referenced range with structural abnormalities."
2874060|NCT03431207||severely impaired group|"For the severely impaired group, the VA of both eyes was out of the 99% referenced range or worse than light perception with structural abnormalities."
2874061|NCT03431194|Active Comparator|midodrine group|Patients will receive midodrine tablets
2874062|NCT03431194|Placebo Comparator|placebo group|Patients receive sugary oral tablets therapy
2874063|NCT03431181|Experimental|MAP target 60-65 mmHg|Treating teams will adjust vasopressors to a target MAP range of 60 to 65 mmHg, avoiding vasopressor-induced MAP above this range.
2874064|NCT03431181|Active Comparator|Usual Care|Patients in the control arm will receive usual care (as per local practices).
2874065|NCT03431168|Active Comparator|Azithromycin/TMPS|"Azithromycin 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit.~TMPS double strength 1 tablet po daily."
2874066|NCT03431168|Placebo Comparator|Placebo/TMPS|"Azithromycin placebo 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit.~TMPS double strength 1 tablet po daily."
2874067|NCT03431155|Experimental|Experimental group|Nursing intervention
2874068|NCT03431155|No Intervention|Control Group|- Receive routine nursing care
2874069|NCT03431142|Experimental|Clopidogrel monotherapy|On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue clopidogrel monotherapy in the following 9 months.
2874070|NCT03431142|Active Comparator|Clopidogrel plus aspirin|On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue DAPT (aspirin+clopidogrel) in the following 9 months.
2874071|NCT03431116||Low implanted placenta group|
2874072|NCT03431103|Other|After home exercise program|"Patients will be instructed to use the Wii Fit for 20 minutes at least twice a week for 12 weeks using specific Wii Fit exercises while on the Wii pressure sensor floor mat. The Wii Fit exercises will be as follows: 1. Basic Run (warm-up exercise by walking in place); 2.Bird's Eye, Bull's-Eye (mostly arms, requires arm flipping); 3.Free Step (lower extremity exercise); 4.Hula Hoop (gyration exercise)"
2874073|NCT03431090|Experimental|CliniMACS Isolation|The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
2874074|NCT03431077|Experimental|LJPC-501|Angiotensin II administered via continuous infusion (1.25 - 40 ng/kg/min) for 24 hours up to 168 hours.
2874075|NCT03431064||Surgical patients less than 18 years old|Patients less than 18 years old having surgery with general anesthesia at Boston Children's Hospital
2874076|NCT03431051|Active Comparator|Healthy Beverage Initiative|A Healthy Beverage Initiative and health education will be implemented at two hospital campuses.
2874077|NCT03431051|No Intervention|Control Arm|No change in beverages or education at two hospital campuses.
2874078|NCT03431025|No Intervention|Control|Participants in the Control Arm will wear sensors to monitor their upper limb movement but will not receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
2874079|NCT03431025|Experimental|Intervention|Participants in the Experimental Arm will wear sensors to monitor their upper limb movement and will receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
2874080|NCT03431012|Experimental|Virus Agency/Negative Attribute Framing|Participants in this condition, after reading a hypothetical scenario, received health messages describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to the pandemic flu virus itself (Virus Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of experiencing side effects after using them (Negative Framing).
2874081|NCT03431012|Experimental|Human Agency/Negative Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to humans (Human Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of experiencing side effects after using them (Negative Framing health messages).
2874082|NCT03431012|Experimental|Human Agency /Positive Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to humans (Human Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of not experiencing side effects after using them (Positive Framing).
2874083|NCT03431012|Experimental|Virus Agency /Positive Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to the pandemic flu virus itself (Virus Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of not experiencing side effects after using them (Positive Framing).
2874084|NCT03430999|Experimental|Group 1 (Japanese) Calmangafodipir|
2874085|NCT03430999|Placebo Comparator|Group 1 (Japanese) Placebo|
2874086|NCT03430999|Experimental|Group 2 (Caucasian) Calmangafodipir|
2874087|NCT03430999|Placebo Comparator|Group 2 (Caucasian) Placebo|
2874088|NCT03430986|Experimental|VOLUMA with Lidocaine|Participants will be treated with Voluma with Lidocaine injectable gel during the control period. Participants are eligible for touch-up treatment at day 29.
2874089|NCT03430986|Experimental|No-treatment control|No treatment during the control period. Optional treatment with VOLUMA with Lidocaine during the Post-Control period.
2874090|NCT03430973|Experimental|Experiment 1|The purpose of Experiment 1 is to develop a standardized measure of aggressive driving for driver simulation experiments. After giving their consent, participants (N=200) will complete several personal variables (i.e., gender, age, driving experience, driving frequency, trait anger, self-reported aggressive and prosocial driving). Next, participants will watch several short videos of aggressive driving (e.g., speeding, tailgating, driving on shoulder), and road rage (e.g., hitting another vehicle or pedestrian). Participants will indicate whether the driver's behavior was aggressive (yes, no), and will rate how aggressive it was on an 11-point scale (0=not at all aggressive to 10=extremely aggressive). A debriefing will follow.
2874091|NCT03430973|Experimental|Experiment 2|Experiment 2 tests whether participants actually drive more aggressively after a playing a violent or nonviolent racing video game. After giving their consent, participants (N=60, n=30 each group) will complete the same personal variables as in Experiment 1, and will report the video games they play. Next, participants will be randomly assigned to play one of two types of video games for 20 minutes: (1) violent racing video game, (2) nonviolent racing game, or (3) a neutral game. After participants complete the driving scenario, participants will complete measures of state and hostile appraisals. A debriefing will follow.
2874092|NCT03430973|Experimental|Experiment 3|"Experiment 3 tests the effects of racial bumper stickers on black and white participants. After giving their consent, participants (N=120; n=60 black, n=60 white) will complete the personal variables (see Experiment 1), the race IAT, and report their political party. Some cars in the driving scenario will contain bumper stickers. Experiment 3 contains four conditions: (1) white participants / All Lives Matter stickers, (2) black participants / All Lives Matter stickers, (3) white participants / Black Lives Matter stickers, (4) black participants / Black Lives Matter stickers. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will report their attitudes toward the #BLM and #ALM movements. A debriefing will follow."
2874093|NCT03430973|Experimental|Experiment 4|"Experiment 4 tests the effects of political bumper stickers on aggressive driving in Republicans versus Democrats. After giving their consent, participants (N=120; n=60 Republicans, n=60 Democrats) will complete the personal variables (see Experiment 1). Some cars in the driving scenario will contain bumper stickers. Experiment 4 has four conditions: (1) Republicans / Donald Trump for President 2016 stickers, (2) Republicans / Hillary Clinton for President 2016 stickers, (3) Democrats / Donald Trump for President 2016 stickers, (4) Democrats / Hillary Clinton for President 2016 stickers. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will report their attitudes toward Trump and Clinton. A debriefing will follow."
2874094|NCT03430973|Experimental|Experiment 5|Experiment 5 tests whether alcohol-related cues can increase aggressive driving. After giving their consent, participants (N=60) will complete the personal variables (see Experiment 1). Next, participants will be randomly assigned to one of two conditions: (1) case of beer on passenger seat, or (2) case of water on passenger seat. Participants will be told that the object on the seat is part of a different experiment that the other experimenter forgot to clean up, which they should ignore it. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
2874095|NCT03430973|Experimental|Experiment 6|Experiment 6 will test the effects of music with aggressive versus prosocial lyrics on aggressive driving. The tempo of the music will also be manipulated because it might influence arousal levels. After giving their consent, participants (N=150, n=30 per group) will complete the personal variables (see Experiment 1). Music will be played over the car's sound system. Participants will be randomly assigned to one of five conditions: (1) violent lyrics / upbeat tempo, (2) violent lyrics / calm tempo, (3) prosocial lyrics / upbeat tempo, (4) prosocial lyrics / calm tempo, or (5) no music control. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
2874096|NCT03430973|Experimental|Experiment 7|"Experiment 7 tests whether roadside vegetation can reduce aggression in frustrated drivers. After giving their consent, participants (N=90, n=30 per group) will complete the personality variables (see Experiment 1). Next, they will complete the Enjoyment of Nature Scale (Cheng & Moore, 2012), which contains 7 items (e.g., I like to see wild flowers in nature and Being in the natural environment makes me feel peaceful; 1=strongly disagree to 5= strongly disagree; Cronbach =.87). Next, participants will be randomly assigned to one of three driving scenarios: (1) roadside vegetation, (2) trash, or (3) control (no roadside vegetation / no trash). After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed."
2874097|NCT03430960|Other|Group A - Standard of Care|
2874098|NCT03430960|Experimental|Group B - mCare group|
2874099|NCT03430947|Experimental|Treatment|all patients will be treated with Vemurafenib + Cobimetinib
2874100|NCT03430934|Experimental|Mohs Tumor patients|Patients who meet selection criteria (18 years or older, all races and ethnicity, smokers and non-smokers) will be recruited from the scheduled Mohs clinic patients by the Mohs surgeon and Dermatology residents that routinely perform the Mohs procedure. Dr. Gold routinely performs Mohs surgery and is part of research team and therefore will recruit his patients for the study. The clinicians will discuss the NAVI research project with the patients, check with them regarding voluntary participation, and consent them on their day of surgery
2874101|NCT03430921|Other|Enlighten™ Laser and a MLA Attachment|Enlighten™ Laser and a Micro-Lens Array Handpiece Attachment
2874102|NCT03430908||Participants with an endotracheal tube|Participants undergoing general anesthesia with an endotracheal tube will have a gastric tube blindly inserted by an anesthesia provider.
2874103|NCT03430895|Experimental|combination of durvalumab and tremelimumab|Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting at Week 16 for 9 doses (total treatment duration of 12 months).
2874104|NCT03430882|Experimental|TAK-228 + Paclitaxel + Carboplatin|"Participants take TAK-228 by mouth at about the same time each day on Days 2-4, 9-11, and 16-18 of Cycles 1-6. Participants then take TAK-228 on Day 1 of Cycles 7 and beyond.~Participants receive Carboplatin by vein over about 60 minutes on Day 1 of Cycles 1-6.~Participants receive Paclitaxel by vein over about 3 hours on Days 1, 8, and 15 of Cycles 1-6.~Each cycle is 21 days."
2874105|NCT03430869|Experimental|F-18 AV-45|F-18 AV-45 imaging
2874106|NCT03430869|Experimental|F-18-THK-5351|F-18-THK-5351 imaging
2874107|NCT03430856|Experimental|Insulin Tregopil (IN-105) - 45mg|Strength of each tablet is 15mg
2874108|NCT03430856|Experimental|Insulin Tregopil (IN-105) - 30mg|Strength of each tablet is 15mg
2874109|NCT03430856|Active Comparator|Insulin Aspart|Pre-filled pen: 100 U/L
2874110|NCT03430843|Experimental|BGB-A317|BGB-A317 will be administered with 200 mg intravenous dosing (IV) on Day1, given every 21 days.
2874111|NCT03430843|Active Comparator|Investigator chosen chemotherapy|"Paclitaxel will be administered at a dose of 135-175 mg /m² IV, Day 1, given every 21 days or 80-100mg/m2 IV given on a weekly schedule.~OR docetaxel will be administered at a dose of 75 mg/m2 IV, Day 1, given 21 days.~OR irinotecan will be administered at a dose of 125mg/m2 IV, Day 1, 8, given 21 days."
2896715|NCT03272022||women|never-pregnant women
2874112|NCT03430830|Experimental|GROUP 1|1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 19th to 25th day： Ravidasvir 200mg administered orally once daily.
2874113|NCT03430830|Experimental|GROUP 2|1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
2874114|NCT03430830|Experimental|GROUP 3|1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
2874115|NCT03430830|Experimental|GROUP 4|1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: Ravidasvir 200mg administered orally once daily; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
2874116|NCT03430830|Experimental|GROUP 5|1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
2874117|NCT03430830|Experimental|GROUP 6|1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
2874118|NCT03430817|Experimental|Group C|Citicholine Drug
2874119|NCT03430817|Experimental|Group A|Amantadine Drug
2874120|NCT03430817|Experimental|Group D|Both Citocholine and Amantadine
2874121|NCT03430804||Single gruop320 parturients|Measurement of cervical length and digital examination of Bishop score in 320 women undergoing induction of labour will be carried out in ain shams university maternity hospital.
2874122|NCT03430791|Experimental|Nivolumab Monotherapy|Nivolumab 240 mg IV every 2 weeks for maximum of 24 months. TTF (Optune) for max of 24 months
2874123|NCT03430791|Experimental|Nivolumab+Ipilimumab|"Nivolumab IV 3 mg/kg with ipilimumab then 240 mg every 2 weeks for maximum of 24 months.~Ipilimumab 1 mg/kg IV every 6 weeks maximum of 4 times. TTF (Optune) for maximum 24 months"
2874124|NCT03430778|Experimental|High CO2 group|end tidal CO2 : 40-45 mmHg
2874125|NCT03430778|Placebo Comparator|Low CO2 group|end tidal CO2 : 30-35 mmHg
2874126|NCT03430765|Experimental|Acceptance and Commitment Therapy|Standard breast cancer treatment plus a single 2 hour individual Acceptance and Commitment Therapy coping skills session.
2874127|NCT03430765|No Intervention|Treatment as Usual|Standard breast cancer treatment.
2874128|NCT03430752||Survivors of Childhood Solid Tumors|Survivors of Childhood Solid Tumors were invited to fill in a set of questionnaires.
2874129|NCT03430752||Survivors of Childhood Leukemia|Survivors of Childhood Leukemia were invited to fill in a set of questionnaires.
2874130|NCT03430739||Babies; Usage time of Helmet between 15-18 hours a day|Babies who worn the helmet for 15-18 hours a day
2874131|NCT03430739||Babies; Usage time of Helmet between 19-23 hours a day|Babies who worn the helmet for 19-23 hours a day
2874132|NCT03430726|Experimental|Healthy Kids Probiotic Yogurt Drink Group|Healthy children will be given a commercially available yogurt drink containing a multi-strain probiotic, Bio-Kidz® (12.5 billion CFU/98g; Lactobacillus acidophilus CL1285®, Lactobacillus casei LBC80R® and Lactobacillus rhamnosus CLR2®), daily for 14 days.
2874133|NCT03430713|Experimental|Dental colour measurement|Comparison of dental colour measurement between two shade guides VITA Classical and VITA Toothguide 3D-Master and two spectrophotometers VITA Easyshade and Spectroshade Micro
2874134|NCT03430700|Experimental|Treatment|All patient will receive Pembrolizumab (100 mg/ 4mL) every 3 weeks for a maximum of 2 years. Pembrolizumab 200mg will be administered as a 30 minute IV infusion every 3 weeks.
2874135|NCT03430687|Experimental|Treatment (talimogene laherparepvec)|Patients receive talimogene laherparepvec intravesically (10ml of 10^6 PFU/mL) on days 1, 8, 15, 22, 29, and 36 or days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity.
2874136|NCT03430674|Experimental|Exercise Intervention|Clinic and at home exercise sessions.
2874137|NCT03430661|Experimental|Part A: Group 1|Clopidogrel will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax
2874138|NCT03430661|Experimental|Part A: Group 2|Clopidogrel will be administered 12 h after ACT-246475 or placebo
2874139|NCT03430661|Experimental|Part A: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and clopidogrel may be studied
2874140|NCT03430661|Experimental|Part B: Group 1|Prasugrel will be administered 12 h after ACT-246475 or placebo
2874141|NCT03430661|Experimental|Part B: Group 2|Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied
2874142|NCT03430661|Experimental|Part B: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied
2874143|NCT03430661|Experimental|Part C: Group 1|Ticagrelor will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax
2874144|NCT03430661|Experimental|Part C: Group 2|Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied
2874145|NCT03430661|Experimental|Part C: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied
2874146|NCT03430648||Cognitively and metabolically normal|This group has been defined as being cognitively and metabolically normal.
2874147|NCT03430648||Cognitively normal with prediabetes|This group has been defined as being cognitively normal but showing signs of prediabetes.
2874148|NCT03430648||Persons with Mild Cognitive Impairment|This group has been defined as being mildly cognitively impaired.
2874149|NCT03430648||Persons with early Alzheimer's disase|This group has been defined as having early Alzheimer's disease.
2874300|NCT03429608||patients with low thrombus burden|patients with the lower volume of aspirated thrombi, as measured using micro-CT
2896716|NCT03272022||pregnant women|pregnant
2874150|NCT03430622|Experimental|LTP Plus|LTP Plus group participants will receive intervention over the telephone for 3 months one session per week for 2 months and rest of the sessions fortnightly by trained graduates, expert in delivering LTP plus intervention.
2874151|NCT03430622|Active Comparator|Treatment as Usual (TAU)|TAU group will receive routine care and their follow up will be done after completion of the intervention and then at 6-month post randomization.
2874152|NCT03430609|Active Comparator|Bipolar tweezers Astus Medical©|Laparoscopic treatment for endometrioma Astus© will use Bipolar coagulation (bipolar tweezers, Astus Medical ©, Copyright 2015, Tampa FL, USA) with 30 W power and a Valleylab generator (Medronic ©, Copyright 2017, Medtronic Parkway, Minneapolis, USA); the number of coagulated points will be counted, and the time for coagulation will be measured in seconds. Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
2874153|NCT03430609|Active Comparator|2-0 Vicryl® Suture|Laparoscopic treatment for endometrioma Vicryl® will use suturing with simple suture (2-0/Vicryl polyglactin absorbable synthetic suture; Ethicon Inc., New Jersey, USA); the number of sutures will be recorded. Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
2874154|NCT03430609|Active Comparator|Surgicel®|Laparoscopic treatment for endometrioma Surgicel® will use Hemostatic matrix (Surgicel® Original Absorbable Hemostat, Ethicon, USA). Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
2874155|NCT03430596|Experimental|pramipexole|pramipexole ,flexible dose (0.375mg/d-0.75mg/d)
2874156|NCT03430596|Active Comparator|Antan|Antan,flexible dose (2-4mg/d)
2874157|NCT03430583||MZ101|Dosing per treatment regimen
2874158|NCT03430570|Experimental|Tablet TRAC Emotion Regulation Intervention|
2874159|NCT03430570|No Intervention|Waitlist Control|Control participants are assessed on the same schedule as the treatment condition and offered the intervention after the 3-month follow-up
2874160|NCT03430557|Experimental|Periapical surgery with PRP|MTA Retrograde filling will be performed after apicectomy for involved teeth and PRP will be filled in the lesion before closure of flap
2874161|NCT03430557|Active Comparator|Periapical surgery without PRP|MTA Retrograde filling will be performed after apicectomy for involved teeth and flap will be closed without placement of PRP
2874162|NCT03430544|Placebo Comparator|Placebo|
2874163|NCT03430544|Experimental|1.5 mg/d cariprazine|
2874164|NCT03430544|Experimental|3.0 mg/d cariprazine|
2874165|NCT03430531|Experimental|Sphenopalatine ganglion block|Sphenopalatine ganglion block: this block will be performed by inserting swabs, with lidocaine squirted on them, into each nostril and reaching the nasopharyngeal wall.
2874166|NCT03430518|Experimental|Her2-negative Metastatic Breast Ca and Recurrent Ovarian Ca|Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian cancer
2874167|NCT03430505|Active Comparator|Bilevel|Bilevel 10 minutes after bronchoprovocation with saline solution 4.5%. IPAP 12 and EPAP 8
2874168|NCT03430505|Active Comparator|Albuterol|400micrograms after bronchoprovocation with saline solution 4.5%.
2874169|NCT03430479|Experimental|Cohort A|
2874170|NCT03430479|Experimental|Cohort B|
2874171|NCT03430466|Experimental|Durvalmab&Tremelimumab&Fulvestrant|
2874172|NCT03430453|Experimental|Patient with ultrasound guided peripheral nerve blockade|A needle is placed at the target under ultrasound guidance, the nerve stimulator is turned on and the intensity increased until motor response is observed.
2874173|NCT03430440|Experimental|CIPKA mode|The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button.
2874174|NCT03430440|Active Comparator|Conventional mode|The conventional mode in which only the basal infusion rate is set to be fixed.
2874175|NCT03430427||Community-Dwelling Older Adults|The group will consist of 240 community-dwelling older adults with a range of mobility function based on the short physical performance battery (SPPB).
2874176|NCT03430414||Therapy Responders|
2874177|NCT03430414||Non-Responders|
2874178|NCT03430401|Experimental|Perceptual-based memory encoding|It will involve the use of visual imagery and the method of loci. To achieve this, each of the 15 daily tasks will be filmed and a short video created. In addition, each task will be broken down into 5-6 photographed steps based on activity analysis and task breakdown. The program will prompt the user to indicate in which room of the house the task would usually be completed. Once correct location is identified, the program will prompt the user to watch a chosen daily task video and then visualise themselves completing the task in their home environment.
2874179|NCT03430401|Experimental|Semantic-based memory encoding|It will incorporate association-based strategies to assist with recalling the steps of daily tasks. The steps of a given daily task will be provided and the user will be prompted to link the steps using a honeycomb concept, which makes use of the chunking method to encode the sequenced steps. Following this, the program will prompt the user to categorise the steps according to their association with given words cues. The word cues will represent time, places, objects, and people. The program will then take the user response and form a verbal and visual story according to the responses given. The program will help identify any problems in the sequencing and prompt the user to re-categorise if required.
2874180|NCT03430401|Active Comparator|Cognitive stimulation|Participants will complete an online cognitive exercise program, Lumosity (Sarkar, Scanlon, & Drescher, 2007). A study conducted by Hardy, Drescher, Sarkar, Kellett, and Scanlon (2011) indicated that participants who engaged in Lumosity showed greater improvements in memory in comparison to a non-intervention control group.
2874181|NCT03430388|Active Comparator|Rheumatic diseases patients|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
2874182|NCT03430388|Active Comparator|Healthy controls|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
2874301|NCT03429608||patients with high thrombus burden|patients with the higher volume of aspirated thrombi, as measured using micro-CT
2874302|NCT03429595|Experimental|Group 1: ATx201 GEL 2%|
2874183|NCT03430375|Active Comparator|Alternating air then static air cushion|The participants in all three populations or groups (healthy adults, adults with stroke, and adults with spinal cord injury) will first sit on the alternating air wheelchair cushion for 32 minutes and then the static air cushion for 32 minutes under two conditions (static: sitting without intentional moving) and (active: reaching with their upper extremity) while pressure mapping and skin responses are recorded. The Ease alternating air wheelchair cushion inflates/deflates which shifts the points of pressure [every 3 minutes] and allows fresh blood to flow where the pressure has been lifted. The Roho static air cushion is a common wheelchair cushion currently used for pressure relief purposes.
2874184|NCT03430375|Active Comparator|Static air then alternating air cushion|The participants in all three populations or groups (healthy adults, adults with stroke, and adults with spinal cord injury) will first sit on the static air wheelchair cushion for 32 minutes and then the alternating air cushion for 32 minutes under two conditions (static: sitting without intentional moving) and (active: reaching with their upper extremity) while pressure mapping and skin responses are recorded. The Roho static air cushion is a common wheelchair cushion currently used for pressure relief purposes. The Ease alternating air wheelchair cushion inflates/deflates which shifts the points of pressure [every 3 minutes] and allows fresh blood to flow where the pressure has been lifted.
2874185|NCT03430362|Active Comparator|Hyoscine group|7. Group A will receive injection Hyoscine butyl bromide 20 mg first dose at the time of amniotomy, and second dose 2 hours after.
2874186|NCT03430362|Placebo Comparator|Control group|Group B, will receive normal saline same volume first dose at the time of amniotomy, and second dose 2 hours after
2874187|NCT03430349|Experimental|group 1|vaccination with novel OPV2 candidate vaccine 2 - 15 subjects
2874188|NCT03430349|Experimental|group 2|vaccination with novel OPV2 candidate vaccine 1 - 15 subjects
2874189|NCT03430336|Experimental|Computer-assisted medication management|"Family physician adds, modifies and optimizes medication in patient's with polypharmacy assisted by an user-initiated computerized decision support system (CDSS) which provides drug-therapy relevant information about patients (e.g. diagnoses and treatments) and alerts in case of drug-drug, drug-disease, drug-age interactions to systematically assess the appropriateness of medication:~CDSS provides drug-therapy relevant information~modification of medication~assessment of medication appropriateness~medication plan~Guidance in medication process"
2874190|NCT03430336|No Intervention|Control arm|Patients will receive the usual clinical care based on current clinical practice guidelines during intervention period. After completion of trial, the patients in the control group will be invited to participate after written informed consent to receive the intervention.
2874191|NCT03430310|Experimental|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. Participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
2874192|NCT03430310|Placebo Comparator|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide <2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
2874193|NCT03430297|Experimental|JS001 240mg Q2W|
2874194|NCT03430297|Active Comparator|Dacarbazine 1000mg/m2 Q3W|
2874195|NCT03430284|Experimental|Integrated Treatment|
2874196|NCT03430284|Other|General Treatment|
2874197|NCT03430271|Active Comparator|Physical Activity (PA) Intervention|
2874198|NCT03430271|Placebo Comparator|Health Education (HE) Intervention|
2874199|NCT03430258|Placebo Comparator|conventional oxygen therapy|oxygen was delivered by a nasal cannula or nonrebreather mask
2874200|NCT03430258|Active Comparator|High-flow Nasal Cannula Oxygen Therapy|High-flow Nasal Cannula Oxygen Therapy
2874201|NCT03430245|Experimental|VelaShape III & UltraShape Power|VelaShape III treatment with radiofrequency, infrared and massage combined with UltraShape Power treatment, using pulsed, focused ultrasound treatment.
2874202|NCT03430232|Experimental|Part I (Panel 1): STR-324 or placebo|Subjects will receive STR-324 dose level 1, 3, 5, 7 or placebo as a short infusion according to randomization.
2874203|NCT03430232|Experimental|Part I (Panel 2): STR-324 or placebo|Subjects will receive STR-324 dose level 2, 4, 6, 8 or placebo as a short infusion according to randomization.
2874204|NCT03430232|Experimental|Part II (Panel 1): STR-324 or placebo|Subjects will receive STR-324 dose level A or placebo as a long infusion according to randomization.
2874205|NCT03430232|Experimental|Part II (Panel 2): STR-324 or placebo|Subjects will receive STR-324 dose level B or placebo as a long infusion according to randomization.
2874206|NCT03430232|Experimental|Part II (Panel 3): STR-324 or placebo|Subjects will receive STR-324 dose level C or placebo as a long infusion according to randomization.
2874207|NCT03430219||Subchondroplasty Procedure|The SCP Procedure targets and fills bone defects with AccuFill bone substitute material utilizing an arthroscopic / percutaneous approach
2874208|NCT03430206|No Intervention|Control|Control subjects will undergo their scheduled procedure and recovery with the usual care. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
2874303|NCT03429595|Experimental|Group 2: ATx201 GEL 4%|
2874304|NCT03429595|Experimental|Group 3: ATx201 GEL 4% plus vehicle|
2874305|NCT03429595|Experimental|Group 4: ATx201 GEL 4% plus vehicle|
2874306|NCT03429595|Placebo Comparator|Group 5: Vehicle|
2874209|NCT03430206|Experimental|Intervention|Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-2L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
2874210|NCT03430193|Experimental|FIRM group|FIRM program consisted of total 10 days session including PT, in two times twenty-minute sessions per day and 4 times OT during admission initiated before transfer to rehabilitation ward. PT (Weight bearing exercise, strengthening exercise, gait training, aerobic exercise and functional training) progressed gradually based on individual functional level and OT of activities of daily life (ADL) training (transfer, sit to stand, bed mobility, dressing, self-care retraining and using adaptive equipment) was provided.
2874211|NCT03430193|Active Comparator|Conventional group|Conventional rehabilitation program consisted of total 10 days session of PT focused on simple standing and gait training, in one time twenty-minute sessions per day.
2874212|NCT03430193|No Intervention|No-rehabilitation group|Discharged patients not transferred to rehabilitation unit after surgery for hip fracture.
2874213|NCT03430180|Placebo Comparator|placebo nasal spray|Drug: placebo nasal spray One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
2874214|NCT03430180|Active Comparator|Naloxone hydrochloride 40mg/ml nasal spray|Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
2874215|NCT03430167|Other|Group I - Formal Therapy|Supervised physical therapy will be ordered 2 times/week initially for 6 weeks and then tailored to a minimum of 1 visit/week based upon the individual progress of each patient. Home exercises will be provided to the patient by the therapist to be performed daily. Supervised physical therapy will be discontinued once the patient demonstrates independence with the final phase of rehabilitation, which represents the graduated strengthening program.
2874216|NCT03430167|Other|Group II - Home Therapy|In the study group all patients will be instructed in a standardized fashion regarding a home exercise program. This program will involve a standardized a set of five exercises. These exercises will be reviewed with patients in clinic in a standardized fashion and patients will be provided with an instructive hand-out.
2874217|NCT03430154||Adults with hemophilia and obesity/overweight|Adults (any gender) aged ≥18 years with hemophilia (any severity, with or without inhibitors) self-identified with obesity or overweight
2874218|NCT03430154||Caregivers identified with obesity/overweight|Caregivers of children (any gender) currently aged <18 years with hemophilia (any severity, with or without inhibitors) caregiver-identified with obesity or overweight
2874219|NCT03430154||Spouses or partners self-identified with obesity/overweight|Spouses or partners of adults (any gender) aged ≥18 years with hemophilia (any severity, with or without inhibitors) self-identified with obesity or overweight
2874220|NCT03430154||Healthcare profs. managing hemophilia and obesity/overweight|Healthcare professional (pediatric or adult hematologist, nurse, nurse practitioner, physician assistant, physical therapist, social worker) actively working in a federally designated hemophilia-treatment center for at least 3 years and with experience managing patients with hemophilia and obesity or overweight.
2874221|NCT03430141|Experimental|Intervention for all participants|Nutritarian Diet-style: Intervention for all participants: All participants are exposed to the same nutrition treatment/intervention protocol.
2874222|NCT03430128|Experimental|Oral IMPACT|"Perioperative immunonutrition will commence 5-7 days prior to surgery, and will continue for 5-7 days post-surgery, as soon as the patient is able to consume full feeds as instructed by his/her primary physician.~The recommended dose for IMPACT immunotherapy is one packet, to be taken three times a day."
2874223|NCT03430128|Active Comparator|Standard Nutrition (ENSURE)|Standard nutritional supplementation will commence 5-7 days prior to surgery, and will continue for 5-7 days post-surgery, as soon as the patient is able to consume full feeds as instructed by his/her primary physician.
2874224|NCT03430115||Weight loss plus exercise (WL+EX)|This group was randomized and previously assigned to weight loss plus exercise.
2874225|NCT03430115||Exercise alone (EX)|This group was randomized and previously assigned to exercise alone.
2874226|NCT03430115||Weight loss alone (WL)|This group was randomized and previously assigned to weight loss alone.
2874227|NCT03430115||Control|This group was randomized and previously assigned to control.
2874228|NCT03430102||LeftHeartCath|Patients scheduled for LV catheterization for direct measurement of LVEDP
2874229|NCT03430089|Experimental|Group 1: 6 to 35 months|Shz QIV 0.25 mL, 2 doses
2874230|NCT03430089|Experimental|Group 2: 3 to 8 years|Shz QIV 0.5 mL, 2 doses
2874231|NCT03430089|Experimental|Group 3: 9 to 17 years|Shz QIV 0.5 mL, single dose
2874232|NCT03430089|Experimental|Group 4: 18 to 60 years|Shz QIV 0.5 mL, single dose
2874233|NCT03430089|Experimental|Group 5: 61 years and older|Shz QIV 0.5 mL, single dose
2874234|NCT03430076|Experimental|Revascularization by (Propaten)®|Revascularization by PTFE with heparin bonded luminal surface (Propaten)®
2874235|NCT03430076|Active Comparator|Revascularization by Crude PTFE|
2874236|NCT03430063|Experimental|SDREGN2810|
2874237|NCT03430063|Experimental|SDREGN2810/ipi|
2874238|NCT03430063|Experimental|HDREGN2810|
2874239|NCT03430050|Active Comparator|Progesterone|Prometrium 200mg. Take one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
2874240|NCT03430050|Placebo Comparator|Placebo|Placebo. ake one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
2874241|NCT03430037|Experimental|Treatment|Fisetin 20/mg/kg/day, orally for 2 consecutive days, for 2 consecutive months.
2874242|NCT03430037|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days, for 2 consecutive months.
2896717|NCT03272009|Experimental|Treatment A|oral EYP001a
2874243|NCT03430024||Cases|"We will enrol 100 women who have been newly diagnosed with T2 (>2cm) palpable invasive breast cancer having primary surgical treatment at Maidstone Hospital. We will exclude all patients with a metabolic disorder, significant co-morbidities and locally advanced or metastatic disease as well as those with a previous history of cancer treatment. We will collect data on tumour size, grade and phenotype as well as ER, progesterone receptor (PR) and Her-2 expression status and patient demographic information.~We will investigate the Association of Myosin VI with oestrogen receptor."
2874244|NCT03430024||Controls|A cohort of control breast tissue will be obtained from 20 patients undergoing benign surgical breast procedures. For those control patients having reduction mammoplasties the excised tissue will be core biopsied but patients having other types of benign surgery will have an extra core biopsy taken from breast tissue surrounding the lesion being excised.
2874245|NCT03430011|Experimental|JCARH125|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by a single dose of JCARH125
2874246|NCT03429998|Placebo Comparator|LDL apheresis|LDL apheresis during at least one year
2874247|NCT03429998|Active Comparator|Evolocumab|140 mg evolocumab biweekly
2874248|NCT03429998|Active Comparator|LDL apheresis and evolocumab|LDL-apheresis monthly evolocumab 140 mg biweekly
2874249|NCT03429985|Experimental|FRRM Intervention|The experimental arm will receive the FRRM intervention.
2874250|NCT03429985|No Intervention|Control|The control arm will not receive the FRRM intervention.
2874251|NCT03429972|Experimental|Paclitaxel and Elasto-Gel™ Cryotherapy|Cryotherapy will be applied using Elasto-Gel™ hypothermia mitts and slippers for 15 minutes before, during and 15 minutes after each paclitaxel infusion.
2874252|NCT03429972|Other|Paclitaxel alone|Paclitaxel will be administered without cryotherapy.
2874253|NCT03429959|Experimental|SOCKNLEG|Donning and doffing success of the study stocking compared with both stockings, wearing of the study stocking for a day, standardized non invasive measurement to calculate leg volume of the study leg
2874254|NCT03429959|Active Comparator|SIGVARIS Cotton|Donning and doffing success of the study stocking compared with both stockings, wearing of the study stocking for a day, standardized non invasive measurement to calculate leg volume of the study leg
2874255|NCT03429946|Active Comparator|Hypoglycemia and Spironolactone|Participants undergo two 120-minute hypoglycemic hyperinsulinemic clamp procedures (50 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of 100 mg of spironolactone - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
2874256|NCT03429946|Active Comparator|Hypoglycemia and Placebo|Participants undergo two 120-minute hypoglycemic hyperinsulinemic clamp procedures (50 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of placebo - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
2874257|NCT03429946|Placebo Comparator|Euglycemia and Placebo|Participants undergo two 120-minute euglycemic hyperinsulinemic clamp procedures (90 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of placebo - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
2874258|NCT03429933|Experimental|Single Ascending Dose|BMS-986278 or placebo
2874259|NCT03429933|Experimental|Multiple Ascending Dose|BMS-986278 or placebo
2874260|NCT03429920|Experimental|Q CAN PLUS POWDER|QCAN PLUS POWDER:2 pouches per day, each pouch contains(12-15gms of fermented soy powder)
2874261|NCT03429920|Placebo Comparator|placebo|Sprouted brown rice protein with flavor (provided by BESO Biological Research Inc.)
2874262|NCT03429907|Experimental|Mind-Body Exercises|"Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are presented on an online application (app) that runs on participant's personal electronic device (such as a mobile phone or tablet).~Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy."
2874263|NCT03429907|Other|Standard of Care|Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
2874264|NCT03429894|Other|Subset 1|Consecutively enrolIed patients will undergo baseline and 6 month angiography, percutaneous coronary intervention with stent implantation and Intravascular Ultrasound (IVUS).
2874265|NCT03429894|Other|Subset 2|Consecutively enrolIed patients will undergo baseline and 9 month angiography, percutaneous coronary intervention with stent implantation and IVUS.
2874266|NCT03429881|Active Comparator|Laparoscopic stripping ovarian endometriomas|
2874267|NCT03429881|Active Comparator|Laser CO2 treatment ovarian endometriomas|
2874268|NCT03429868|Experimental|integrated PET/MRI|The enrolled subjects receive an integrated 18F-FDG PET/MRI during tumor staging.
2874269|NCT03429855|Experimental|study group|Bobath based trunk exercises
2874270|NCT03429855|Other|control group|conventional physiotherapy approaches
2874271|NCT03429829|Experimental|Flairesse varnish|"All children in this group will recieve a dental examination (DMFS/dmfs) index at baseline as well as after 12, 24 and 36 months. Directly after the baseline examination Flairesse varnish (40ml) will be applied on all teeth using a soft brush according to manufacturares instructions, including flossing to spread the vanish to proximal areas.~In addition to the intervention, all children will receive supervised toothbrushing throughout the study (treatment as usual) using fluoridated toothpaste (Colgate, fluoride ions 1100 ppm)."
2874307|NCT03429582|Active Comparator|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
2896718|NCT03272009|Experimental|Treatment B|oral EYP001a
2874272|NCT03429829|No Intervention|Control|"All children in this group will recieve a dental examination (DMFS/dmfs) index at baseline as well as after 12, 24 and 36 months, but they will not receive a sham or placebo treatment.~However, all children will receive supervised toothbrushing throughout the study (treatment as usual) using fluoridated toothpaste (Colgate, fluoride ions 1100 ppm)."
2874273|NCT03429816|Experimental|Interventional Arm|"Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen.~Organoid cultures of pre-treatment tumor biopsies will be established and exposed to the same chemotherapy as the corresponding patient; in vitro response to treatment will be correlated with the in vivo response of patients.~Whole genome, methylome and RNA sequencing of tumors biopsies and organoids will be performed prior to as well as after systemic treatment."
2874274|NCT03429803|Experimental|TAK-580 (MLN2480)|"Phase I~Patients (< 18 years) with radiographically recurrent or radiographically progressive non-hematologic malignancies (Central Nervous System (CNS) or solid tumors) associated with activation of the RAS/RAF/MEK/ERK pathway will be eligible~Study treatment cycle lasts 28 days,oral, once a week"
2874275|NCT03429803|Experimental|TAK-580 (MLN2480) Stratum I|"Phase II~Patients with radiographically recurrent or radiographically progressive low grade glioma (LGG) containing a BRAF truncated fusion lesion (KIAA1549 or similar translocations) not previously treated with a BRAF or MEK inhibitor~Study treatment cycle lasts 28 days,oral, once a week"
2874276|NCT03429803|Experimental|TAK-580 (MLN2480) Stratum II|"Phase II~Patients with Neurofibromatosis 1(NF1) defined clinically OR genetically, and radiographically recurrent or radiographically progressive LGG not previously treated with a BRAF or MEK inhibitor~Study treatment cycle lasts 28 days,oral, once a week"
2874277|NCT03429790|Experimental|group intra-operative cell salvage|"The theoretical amount of blood transfusion should be based on the following formula:~The amount of blood transfusion needed (ML) * Hb= (Hb2-Hb1) * blood volume of blood transfusion Hb1: actual measured hemoglobin; Hb2: target hemoglobin (100 g / L) Blood volume = 100ml/kg * body weight The difference between the actual blood transfusion and the theoretical blood transfusion should be controlled within ± 15% of the theoretical blood transfusion (in terms of hemoglobin), whether the experimental group or the no intervention group."
2874278|NCT03429790|Active Comparator|group allogeneic blood transfusion|"The theoretical amount of blood transfusion should be based on the following formula:~The amount of blood transfusion needed (ML) * Hb= (Hb2-Hb1) * blood volume of blood transfusion Hb1: actual measured hemoglobin; Hb2: target hemoglobin (100 g / L) Blood volume = 100ml/kg * body weight The difference between the actual blood transfusion and the theoretical blood transfusion should be controlled within ± 15% of the theoretical blood transfusion (in terms of hemoglobin), whether group intra-operative cell salvage or group allogeneic blood transfusion."
2874279|NCT03429777|Experimental|Hearing Loss Group|The investigators will characterize hearing-in-noise thresholds (also referred to as a speech-reception threshold) as measured by the HearMe app in patients with hearing loss.
2874280|NCT03429777|Active Comparator|Control Group|The investigators will characterize hearing-in-noise thresholds (also referred to as a speech-reception threshold) as measured by the HearMe app in control subjects without any prior or current hearing loss.
2874281|NCT03429764|Active Comparator|Control group (CG),CISS|continuous independent sling sutures (CISS) will be placed with minimum two intact contact points at the surgical site,
2874282|NCT03429764|Experimental|Test group (TG),VIMS|internal mattress suture (VIMS) will be placed with minimum two intact contact points at the surgical site,
2874283|NCT03429751|Experimental|Liberal fluid group|received 30 ml/Kg/h crystalloid for maximum 3 hours.
2874284|NCT03429751|Active Comparator|Restrictive fluid group|received 10 ml /Kg/h crystalloids for maximum 3 hours.
2874285|NCT03429738|Experimental|Experimental Drug|Drug: Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets Temmler Werke GmbH/ Part of Aenova Group, Germany, Intervention: one tablet administered after an overnight fast of at least 10 hours
2874286|NCT03429738|Active Comparator|Active Comparator|Active Comparator: RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets Wyeth Santé Familiale, France, Intervention: one tablet administered after an overnight fast of at least 10 hours
2874287|NCT03429725|Experimental|Individualism|Participant will be randomly allocated to either the individualism condition or the collectivism condition. For individualism condition, participant is tasked to write statements relating to his/her differences from the his/her immediate community, circle pronouns that relate to the self, and read passages related to individualism.
2874288|NCT03429725|Experimental|Collectivism|Participant will be randomly allocated to either the individualism condition or the collectivism condition. For collectivism condition, participant is tasked to write statements relating to his/her similarities to the his/her immediate community, circle collective pronouns, and read passages related to collectivism.
2874289|NCT03429712|Experimental|Dose Split CT|
2874290|NCT03429699|Experimental|Intervention group|
2874291|NCT03429699|Other|Control group|
2874292|NCT03429686|Experimental|DRT Intervention|Intervention: Individual digital reminiscence therapy programme.
2874293|NCT03429673||Patients with surgeries|Pathologically diagnosed elderly early Chinese patients with non-small cell lung cancer who received lobectomy or segment/wedge dissection
2874294|NCT03429660||Cohort|"Data to be collected are :~- Medical information on Immune Thrombocytopenia treatment"
2874295|NCT03429647|Other|Sigmoid perfusion|Measured by visible light spectroscopy
2874296|NCT03429634|Experimental|Balloon-Stent Kissing technique|randomly, patients with bifurcation lesion treated by Balloon-Stent Kissing intervention technique in this group.For procedure,stent in main vessel and balloon protect of side branch,final kiss-balloon was performed.
2874297|NCT03429634|Sham Comparator|Jailed Wire technique|randomly,patients with bifurcation lesion treated by Jailed Wire intervention technique in this group.For procedure,stent in main vessel and only wire protect of side branch.If need,post-stent rewire of branch,and balloon dilation of side branch was performed.
2874298|NCT03429621|Experimental|Simethicone|Each woman in the intervention group will be given Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery.
2874299|NCT03429621|No Intervention|No simethicone|The women will not be given Simethicone.
2874308|NCT03429582|Experimental|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
2874310|NCT03429569|Sham Comparator|accelerated conventional technique|"Pachymetry greater than 400μm~Topographic criteria for keratoconus evolution:~Variation over a 6-month period of the following changes:~An increase equal to or greater than 1D of maximum keratometry (Kmax) And / or an increase in mean keratometry (Kmean) greater than or equal to 0.75D And / or an increase in the difference between the meridian and the most arched and the least arched (Kmax-Kmin) greater than or equal to 0.75D And / or a decrease in the central thickness greater than or equal to 2% Criteria of non-inclusion Age under 18 Ectasies post LASIK Pregnant women breastfeeding Major corneal opacities Absence of consent to participation in the study No affiliation to Social Security or State Medical Aid (AME) or Universal Medical Coverage (CMU)"
2874311|NCT03429569|Sham Comparator|iontophoresis|"Pachymetry greater than 400μm~Topographic criteria for keratoconus evolution:~Variation over a 6-month period of the following changes:~An increase equal to or greater than 1D of maximum keratometry (Kmax) And / or an increase in mean keratometry (Kmean) greater than or equal to 0.75D And / or an increase in the difference between the meridian and the most arched and the least arched (Kmax-Kmin) greater than or equal to 0.75D And / or a decrease in the central thickness greater than or equal to 2% Criteria of non-inclusion Age under 18 Ectasies post LASIK Pregnant women breastfeeding Major corneal opacities Absence of consent to participation in the study No affiliation to Social Security or State Medical Aid (AME) or Universal Medical Coverage (CMU)"
2874312|NCT03429556|Experimental|EB-001 Injections|
2874313|NCT03429556|Placebo Comparator|Placebo Injections|
2874314|NCT03429543|Experimental|Linagliptin|Linagliptin arm. Oral route. Linagliptin tablets administered once daily for 52 weeks
2874315|NCT03429543|Experimental|Empagliflozin|Empagliflozin arm. Oral route. Start with a low dose of empagliflozin administered once daily and randomly up titrate to the high dose of empagliflozin administered once daily if HbA1c ≥ 7% at week 12
2874316|NCT03429543|Placebo Comparator|Placebo|Placebo arm. Oral route. Placebo tablets administered once daily up to 26 weeks and then linagliptin or low dose of empagliflozin or high dose of empagliflozin administered once daily up to 52 weeks
2874317|NCT03429530||Group1|20 patients with chronic HCV
2874318|NCT03429530||GroupII|20 patient with chronic HCV related liver cirrhosis
2874319|NCT03429530||GroupIII|40 patients with chronic HCV related liver cirrhosis complicated by hepatocellular cacinoma
2874320|NCT03429530||group IV|20 healthy blood donors will also be included as a control group
2874321|NCT03429517||Patients|ACS Lipogram
2874322|NCT03429517||Controls|Normal LDL-C level Lipogram
2874323|NCT03429504||Obese breast cancer patients|Response to treatment and progression free survival in obese breast cancer patients
2874324|NCT03429504||non obese breast cancer patients|Response to treatment and progression free survival in non obese breast cancer patients
2874325|NCT03429491|Placebo Comparator|Placebo|Protein-free, LC n-3 PUFA-free juice based supplement
2874326|NCT03429491|Experimental|Leucine-enriched protein|Juice based supplement containing leucine-enriched protein
2874327|NCT03429491|Experimental|Leucine-enriched protein + LC n-3 PUFA|Juice based supplement containing leucine-enriched protein and LC n-3 PUFA
2874328|NCT03429478|Experimental|Music|Preoperative application of a Bluetooth enabled headphones with standard music played for atleast 2 hours preoperatively.
2874329|NCT03429478|Active Comparator|No Music|Preoperative application of a Bluetooth enabled headphones with no music played and headphones will just mask the surrounding noise.
2874330|NCT03429465|Experimental|EVO|All children receive 4 weeks of EVO 5 days/week for 20 minutes per day in a stepped wedge design.
2874331|NCT03429439|Experimental|IMT Combined with Antiviral Therapy|"60 chronic hepatitis B patients ongoing antiviral therapy will be recruited for the study, which involved a 6 times intestinal microbiota transplant and the time interval is generally 2 weeks.~Interventions:~Procedure: Intestinal Microbiota Transplantation Procedure: antiviral therapy"
2874332|NCT03429439|Other|Antiviral Agents|"60 chronic hepatitis B patients ongoing antiviral therapy will be recruited for the study, which involved 12 months antiviral therapy.~Interventions:~Procedure: antiviral therapy"
2874333|NCT03429426||Rheumatoid arthritis|"Patients with Rheumatoid arthritis ≥5 years according to the ACR/EULAR 2010 classification criteria or the American Rheumatism Association 1987 revised criteria.~ICD-10: M059 Seropositive rheumatoid arthritis UNS, M060 Seronegative rheumatoid arthritis, M069 Rheumatoid arthritis UNS."
2874334|NCT03429426||Pre-Rheumatoid arthritis|Patients with joint pain, but no swelling and Anti-CCP 3 times above the upper limit.
2874335|NCT03429426||Healthy Subjects|Healthy age- and sex-matched Individuals are recruited, as a control group.
2874336|NCT03429413|Active Comparator|Parents|Parents of 11-12 year old children who visit participating interventional clinics during study period.
2874337|NCT03429413|Active Comparator|Health Care Provider|Health care providers and clinic staff for 11-12 year old patients at 4 participating pediatric clinics.
2874338|NCT03429413|No Intervention|Adolescents at Intervention clinics|Adolescents between 11-12 years of age. Adolescent vaccination data is used in the study, adolescents will assent to participate. The parents, however, use the HIT system.
2874339|NCT03429413|No Intervention|Adolescents at Control Clinic|Parents of 11-12 year old children who visit participating control clinics during study period.
2874340|NCT03429413|No Intervention|Health Care Provider at Control Clinic|Health care providers and clinic staff for 11-12 year old patients at 3 participating pediatric control clinics.
2874341|NCT03429400|Other|Morphine Sulfate|oral morphine sulfate tablets oral morphine sulfate oral solution
2874342|NCT03429387|Experimental|FDG-PET/CT arm|Participants with persistent febrile neutropenia after 72 hours of onset who are randomized to this arm will have an FDG-PET/CT performed to look for source of fever.
2874343|NCT03429387|Active Comparator|Conventional CT arm|Participants with persistent febrile neutropenia after 72 hours of onset who are randomized to this arm will have a conventional CT (HRCT chest and sinuses +/- other regions as per clinician's discretion) performed to look for source of fever.
2874344|NCT03429374|Active Comparator|Liquiband Fix8 glue mesh fixation|
2874345|NCT03429374|Active Comparator|Mesh fixation with absorbable tacks|
2874346|NCT03429348|No Intervention|No additional rehabilitation|No additional rehabilitation will be done
2874347|NCT03429348|Other|Sauna rehabilitation|An additional rehabilitation in a sauna will be done
2874348|NCT03429335|Experimental|Teaching session & Just TRAC It|"Youth will attend a single one-on-one teaching session with a cardiology nurse (RN) the same day as their pediatric cardiology clinic visit. The RN will also explain Just TRAC It! and help the youth to enter their health information into their phone."
2874349|NCT03429335|Active Comparator|Teaching session & MyHealth Passport|"Youth will attend a single one-on-one teaching session with a cardiology nurse (RN) the same day as their pediatric cardiology clinic visit. The RN will help youth complete and print out a MyHealth Passport to track their medical information."
2874350|NCT03429322|Experimental|Medical Care and Resource Facilitation|All intervention components will be delivered remotely: there will be no face-to-face interaction with the participants. The intervention is comprised of the clinical, educational, and supportive services of Mayo's Brain Rehabilitation Clinic integrated with the MN BIA RF program.
2874351|NCT03429322|Active Comparator|Usual care|Individuals with TBI, their family members and PCPs assigned to the usual care group will receive care and provide services as usual in their communities. Individuals with TBI assigned to the usual care group will receive RF as routinely provided by MN BIA.
2874352|NCT03429309|Other|Anesthesia-induction with propofol|
2874353|NCT03429296|Experimental|Autohypnosis learning|In this arm, patients are taught autohypnosis during sessions in groups of 3 to 6 with a qualified hypnotherapist. Sessions are set every two weeks, for a total of 6 sessions. Individual sessions are possible for patients who missed a session.
2874354|NCT03429296|No Intervention|Standard of care|In this arm, patients are not taught autohypnosis and are treated according to standard of care.
2874355|NCT03429270|Experimental|Urodynamics Arm|
2874356|NCT03429257||Pregnant Women in Mukono Uganda|Single-group study
2874357|NCT03429244|Experimental|Low and intermediate risk prostate cancer|
2874358|NCT03429231||Active Group|Women who are taking coenzyme Q and who will continue taking it for 3 months
2874359|NCT03429231||Control Group|Women who are not taking coenzyme Q and who will not take it in the next 3 months
2874360|NCT03429218|Experimental|Single Arm TP 0184|Daily dose of TP 0184 by oral administration
2874361|NCT03429205|Experimental|No heating - Study group|Patient will undergo bariatric surgery without utilization of external heating device.
2874362|NCT03429205|Other|Heating - Control group|Patient will undergo bariatric surgery with utilization of external heating device.
2874363|NCT03429192||N2 non-small cell lung cancer|Chinese patients with N2 non-small cell lung cancer
2874364|NCT03429179|Experimental|Group A|all the patients received an load dose infusion butorphanol 15μg/kg was infused and 7.5 μg/kg/h to maintain.
2874365|NCT03429179|No Intervention|Group B|all the patients received a normal saline infusion
2874366|NCT03429179|Experimental|Group C|all the patients received an load dose infusion butorphanol 15μg/kg was infused and 7.5 μg/kg/h to maintain.
2874367|NCT03429179|No Intervention|Group D|all the patients received a normal saline infusion
2874368|NCT03429166|Experimental|STAIR|STAIR stands for Skills Training in Affective and Interpersonal Regulation a non-trauma-focused treatment
2874369|NCT03429166|Active Comparator|PCT|PCT stands for Present Centered Therapy, a non-trauma-focused treatment
2874370|NCT03429140|Experimental|Group 1 - Gel-One|Gel-One (3ml/30 mg Hyaluronan) one time injection at visit 3
2874371|NCT03429140|Placebo Comparator|Group 1 - Saline Placebo|3 ml saline placebo one time injection at visit 3
2874372|NCT03429127||Normal saline fluid group|The patients in this group will receive up to 2000 ml of normal saline during neurosurgical operation.
2874373|NCT03429127||Balanced fluid group|The patients in this group will receive up to 2000 ml of balanced fluids during neurosurgical operation.
2874374|NCT03429114||Binge eating/purging|Adolescents engaging in recurrent binge eating and/or purging behavior.
2874375|NCT03429114||Healthy comparison|Adolescents who do not have a history of eating disorders
2874376|NCT03429101|Experimental|Poziotinib|"Part 1: Dose Finding The MTD/MAD of poziotinib in combination with the standard dose of T-DM1 will be determined by using a 3+3 design. At least 3 patients may be enrolled in each cohort before a decision is made to proceed to the next cohort.~Part 2: MTD/MAD Expansion An additional 10 patients will be treated at the dose identified during Part 1 to further evaluate the combination at the MTD or the MAD."
2874377|NCT03429088|Experimental|Telephone counseling|Participants were provided with approximately 7 telephone-based motivational interviewing over a 24-week period to increase their physical activity.
2874378|NCT03429088|No Intervention|Usual care|Participants in the usual care arm received a packet of places near their home in which they could engage in physical activity if they chose.
2874379|NCT03429075|Experimental|Psilocybin|
2874380|NCT03429075|Active Comparator|Escitalopram|
2874381|NCT03429062||personal training|Individuals with a diagnosis of MS and any level of function will be recruited to participate in exercise two times per week with trained personal trainers. Exercise consists of strengthening, stretching, balance, endurance and gait when able. Equipment to be used include treadmill, stationary bike, weight equipment.
2874382|NCT03429062||Whole Body Platform|Individuals with a diagnosis of MS and able to walk with or without an assistive device will be recruited to participate in whole body platform training two times per week with a physical therapist. The exercise on the whole body platform includes strengthening, balance, stretching, and endurance for 30 second bouts. The whole body platform is on for 30 seconds then off. Each exercise will use the 30 seconds to complete.
2874383|NCT03429049|Placebo Comparator|Placebo|Single intra-articular 1.0 mg Placebo Injection
2874384|NCT03429049|Experimental|CNTX-4975-05|Single intra-articular 1.0 mg CNTX-4975-05 (trans-capsaicin) injection
2874385|NCT03429036||1|Subjects must be diagnosed with a disorder of the head and neck region
2874386|NCT03429010|Experimental|"New guideline"|"New guideline anesthesia strategy team (Group A)"
2874387|NCT03429010|No Intervention|Current strategy|Current anesthesia strategy team (Group B)
2874388|NCT03428984|Experimental|EXPAREL 20 + 20|20 mL EXPAREL with 20 mL normal saline
2874389|NCT03428984|Experimental|EXPAREL 20 + 10|20 mL EXPAREL with 10 mL normal saline
2874390|NCT03428958|Experimental|NUC-3373+ leucovorin|Cohort 1a: NUC-3373 administered intravenously (IV) followed by a 2-week washout period. Then, LV 400 mg/m2 IV over 2 hours prior to each NUC-3373 infusion and NUC-3373 administered IV every 2 weeks.
2874391|NCT03428958|Experimental|NUC-3373|Cohort 1b: LV 400 mg/m2 administered IV over 2 hours prior to NUC-3373 infusion followed by a 2-week washout period. Then, NUC-3373 administered IV every 2 weeks.
2874392|NCT03428958|Experimental|NUC-3373 + oxaliplatin|Cohort 2a: NUC-3373 administered every 2 weeks in combination with oxaliplatin (85 mg/m2). Leucovorin may also be administered with this combination, depending on data from Part 1.
2874393|NCT03428958|Experimental|NUC-3373 + oxaliplatin + bevacizumab|Cohort 2b: NUC-3373 administered every 2 weeks in combination with oxaliplatin (85 mg/m2) and bevacizumab (5 mg/kg). Leucovorin may also be administered with this combination, depending on data from Part 1.
2874394|NCT03428958|Experimental|NUC-3373 + oxaliplatin + panitumumab|Cohort 2c: NUC-3373 administered every 2 weeks in combination with oxaliplatin (85 mg/m2) and panitumumab (6 mg/kg). Leucovorin may also be administered with this combination, depending on data from Part 1.
2874395|NCT03428958|Experimental|NUC-3373 + irinotecan|Cohort 3a: NUC-3373 administered every 2 weeks in combination with irinotecan (180 mg/m2). Leucovorin may also be administered with this combination, depending on data from Part 1.
2874396|NCT03428958|Experimental|NUC-3373 + irinotecan + cetuximab|Cohort 3b: NUC-3373 administered every 2 weeks in combination with irinotecan (180 mg/m2) and cetuximab 400 mg/m2 (first dose) and 250 mg/m2 (subsequent doses). Cetuximab is administered weekly. Leucovorin may also be administered with this combination, depending on data from Part 1.
2874397|NCT03428945|Experimental|Hydroxychloroquine|Hydroxychloroquine compound for oral use
2874398|NCT03428945|Placebo Comparator|Placebo|Placebo tablet matching active drug
2874399|NCT03428932|No Intervention|Standard Care|Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months. Neurocognitive testing and brain MRI/fMRI will be done at enrollment and 6 months.
2874400|NCT03428932|Active Comparator|Closed-Loop|Subjects will transition from their current treatment (insulin pump or injections) onto the Medtronic 670G insulin pump (intervention arm as a comparator) and will have close contact with the study team. Neurocognitive testing and brain MRI/fMRI will be done at enrollment and 6 months.
2874401|NCT03428919|Active Comparator|Intracytoplasmic Sperm Injection (ICSI)|"All patients undergoing IVF/ICSI will be treated with a GnRH antagonist protocol. Criteria for hCG (6,500 IU) using will be the presence of at least three leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering.~Insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.~Fertilization check will be performed under inverted microscope at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3 under ultrasound guidance. A maximum of 2 embryos will be transferred into the uterus. The remaining grade 1 and 2 embryos will be frozen."
2874402|NCT03428919|Active Comparator|In Vitro Fertilization (IVF)|"All patients undergoing IVF/ICSI will be treated with a GnRH antagonist protocol. Criteria for hCG (6,500 IU) using will be the presence of at least three leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering.~Insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.~Fertilization check will be performed under inverted microscope at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3 under ultrasound guidance. A maximum of 2 embryos will be transferred into the uterus. The remaining grade 1 and 2 embryos will be frozen."
2874403|NCT03428906|Experimental|Oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (8 IU or 13.44 mg; Syntocinon-spray; Novartis, Switzerland) .
2874404|NCT03428906|Placebo Comparator|Placebo|Placebo contains all ingredients except for the peptide in three puffs of 1.33 IU per 2.24mg nostril.
2874405|NCT03428893|Experimental|Mobile Application Group|The mobile app group will receive physical therapy as determined by the physical therapist and agree to receive the home exercise prescription using a mobile app on their phone or personal tablet
2874406|NCT03428893|No Intervention|Control|The control group will receive physical therapy as determined by the physical therapist based on clinical practice guidelines and will receive the home exercise program in the traditional way through paper exercise handouts
2874407|NCT03428880|Active Comparator|spinal morphine|intrathecal morphine with 10 mg bupivacaine, 5 gamma sufenta and 100 gamma morphine. Intervention: In the end of surgery a QLB block is done with 20 ml of normal saline per side.
2874408|NCT03428880|Active Comparator|quadratus lumborum block|"intrathecal anesthesia with10 mg bupivacaine, 5 gamma sufena and 1 ml normal saline.~Procedure : a quadratus lumborum block is done with 20 ml of bupivacaine 0,125% per side."
2874409|NCT03428841||Patients with dural puncture at epidural|Patients who sustained an accidental dural puncture during the epidural procedure.
2874410|NCT03428841||Patients with no dural puncture|Patients with no dural puncture during epidural procedure, to serve as a control group.
2874411|NCT03428828|Experimental|Amygdala Neurofeedback|attempt to up regulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Five sessions will be performed within a 2 month period.
2874412|NCT03428828|Active Comparator|Parietal Neurofeedback|attempt to upregulate the left horizontal segment of the intraparietal sulcus, a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback. Five sessions will be performed within a 2 month period.
2874413|NCT03428815|Experimental|PCM liner|Willowwood Smart Temp Liner
2874414|NCT03428815|Active Comparator|regular liner|User's regular prescribed liner
2874415|NCT03428802|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants with disease progression may continue pembrolizumab for up to 1 year.
2874416|NCT03428789||Innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral deep inferior epigastric artery perforator (DIEP) flap breast reconstruction with additional sensory nerve coaptation.
2874417|NCT03428789||Non-innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral deep inferior epigastric artery perforator (DIEP) flap breast reconstruction without sensory nerve coaptation.
2874418|NCT03428776|Sham Comparator|Controls|Self returns
2874419|NCT03428776|Active Comparator|Standard Compliance-linked incentives|Standard mobile-phone reminders and compliance-linked incentives
2874420|NCT03428776|Active Comparator|Intelligent Compliance-linked incentives|Intelligent mobile-phone reminders and compliance-linked incentives
2874421|NCT03428763|Experimental|Homebased disease monitoring (eHealth)|Participants allocated to the intervention group will be trained in self-monitoring of their RA
2874422|NCT03428763|Active Comparator|Standard clinical disease monitoring|Those allocated to the control arm of the study will continue usual clinical care (i.e. they will not self-monitor or have access to the eHealth solution). No other medication changes will be mandated and participating investigators will be asked to manage all other care according usual clinical practice. Individuals in the control group will not be given the option to self-monitor.
2874423|NCT03428750|Active Comparator|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
2874424|NCT03428750|Placebo Comparator|Placebo|
2874425|NCT03428737|Other|First arm : nocturnal controlled pressure control ventilation.|use of an inspiratory pressure of 20 cm of H2O and an respiratory frequency chosen to stop all spontaneous breathing activity during the night
2874426|NCT03428737|Other|Second arm : nocturnal pressure support ventilation.|use of a pressure support level identical during the night to the pressure support level at the end of the day.
2874427|NCT03428724|Active Comparator|standard group|standard polyethylene glycol preparation for colonoscopy
2874428|NCT03428724|Experimental|individualized group|either a low or a high volume bowel preparation according to patient characteristics
2874429|NCT03428711|Placebo Comparator|Placebo Oral Tablet|Placebo comparator twice-a-day, for 12 months
2874430|NCT03428711|Experimental|Mesoglycan Oral Tablet|"a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~50 mg, twice-a-day, for 12 months"
2874431|NCT03428698|Experimental|experimental device|The extraction was completed, the socket was filled with a topical amino acid + sodium hyaluronate gel (Aminogam®, sterile syringe 2 ml).
2874432|NCT03428698|Placebo Comparator|control no device|The extraction was completed, socket was flushed, using a 2ml sterile syringe similar to one utilized to apply the gel, with sterile physiological solution.
2874433|NCT03428685|Active Comparator|Intervention group|
2874434|NCT03428685|Placebo Comparator|Placebo group|
2874435|NCT03428672|Experimental|osteoporotic fractures|patients with osteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
2874436|NCT03428672|Sham Comparator|nonosteoporotic fractures|patients with nonosteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
2874437|NCT03428659||Sub-acute stroke|More than 1 week post-stroke Ischemic or hemorrhagic stroke
2874438|NCT03428633|Active Comparator|Group A|Thoracic paravertebral block using ropivacaine
2874439|NCT03428633|Active Comparator|Group B|Morphine IV
2874440|NCT03428620|Experimental|Mobilization|High Velocity Low Amplitude mobilization group. The three joints that will be manipulated include proximal tibiofibular, the distal tibiofibular, and talocrural joints and will be mobilized the first three sessions prior to the participants performing the exercise protocol.
2874441|NCT03428620|Active Comparator|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
2874442|NCT03428607|Experimental|AZD6738+Olaparib|AZD6738 160mg QD per os administered for 7 days and olaparib 300mg BID per os administered daily. One cycle is considered of 28 days.
2874443|NCT03428594|Experimental|CKD-11101|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
2874444|NCT03428594|Active Comparator|NESP|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
2874445|NCT03428581|Experimental|ALND with ARM +/- LVB|Axillary Lymph Node Dissection (ALND) using Axillary Reverse Mapping (ARM) with Lympho-venous bypass (LVB) will be performed.
2874446|NCT03428581|Active Comparator|ALND without ARM +/- LVB|Axillary Lymph Node Dissection (ALND)
2874447|NCT03428568|Experimental|Herbal Melanin|Herbal melanin 1800 milligram(mg) orally thrice a day with meals (300mgx2 capsules)
2874448|NCT03428568|Active Comparator|Nexium|omeprazole 40 mg once per day for one month.
2874449|NCT03428568|Experimental|H-Pylori infected : Herbal Melanin|Herbal melanin 1800 mg orally thrice a day(TID) with meals (300 mg x2 capsules)
2874450|NCT03428568|Active Comparator|nexium+ amoxil+clarithromycin|"omeprazole40 mg P.O. Twice per Day(BID) for one month + Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks.~Omeprazole+Amoxil+clarithromycin is the standard triple therapy given"
2874451|NCT03428568|Experimental|nexium +Herbal melanin|omeprazole 40 mg P.O. BID for one month +1800 mg Herbal melanin PO TID (300mg x2 capsules) Omeprazole + Herbal melanin will be tested
2874452|NCT03428568|Experimental|Herbal melanin+amoxil+ clarithromycin|Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks +1800 mg Herbal melanin PO TID(300 mg X 2 capsules) Herbal melanin+Amoxil+Clarithromycin will be tested
2874453|NCT03428555|Experimental|Integrate Care Pathway|"The intervention is an Integrated Care Pathway with 3 key components.~Clinical Practice Guidelines (CPG) recommendations: The initial template of the treatment protocol was based on the NICE CPGs for Depression in Children and Young People.~Provider engagement: The clinicians at CAMH reviewed the template and collaboratively developed a flow chart defining the treatment protocol.~Measurement-based care: Feedback measures are taken every four weeks and the results are provided to the clinician, patient and family to inform treatment decisions. The feedback measures are the Mood and Feelings Questionnaire, the Columbia Impairment Scale (CIS) and the General Functioning Domain of the McMaster Family Assessment Device (MFAD)."
2874488|NCT03428282|Experimental|VR Box|Inferior alveolar nerve block will be performed with the aid of VR box as a means of distracting patients' attention.
2896719|NCT03272009|Experimental|Treatment C|oral EYP001a
2874454|NCT03428555|Active Comparator|Treatment As Usual|Treatment As Usual : Participants at SHSC will receive treatment at could include a psychiatric evaluation, possible medication management and various types of psychotherapy, including cognitive-behavioural therapy, interpersonal psychotherapy, psychodynamic psychotherapy and family therapy. There is no structured protocol and no systematic Measurement Based Care. A research assistant will record the interventions received in either group via chart review.
2874455|NCT03428542|No Intervention|Control arm|Instructed not to practice any yoga or mindfulness during the five-week study period.
2874456|NCT03428542|Active Comparator|Yin yoga intervention arm|"The Yin yoga intervention arm will receive Yin yoga, a calm-paced practice that uses seated and lying down positions.~Participants were also provided a CD which contained a 10-minute voice recording called conscious breathing. The guided instructions encouraged participants to keep awareness on their breath and to use calm, slow, nostril breathing."
2874457|NCT03428542|Active Comparator|YOMI program intervention arm|"The YOMI intervention arm will receive stress education + yoga, and bring together education about stress, mindfulness and yoga practice. It will involve weekly group meetings, homework, and yoga postures. Stress education and mindfulness will make up one portion of the intervention. This will take place in a group lecture format and shall be conducted by a mental health professional(s). Yoga practice in a group format will make up the second portion of the intervention.~Participants were also provided a CD which contained a 10-minute voice recording called conscious breathing. The guided instructions encouraged participants to keep awareness on their breath and to use calm, slow, nostril breathing."
2874458|NCT03428529|Experimental|Capecitabine|Neoadjuvant capecitabine plus RT
2874459|NCT03428529|Active Comparator|5-Flourouracil|Neoadjuvant 5-Fluorouracil plus RT
2874460|NCT03428516|Experimental|Fixed CPAP|CPAP always deliver air with the same pressure
2874461|NCT03428516|Active Comparator|Auto-adjusting CPAP|Auto-CPAP changes the pressure delivered depending on events detected at any time (apnea, hypopnea …) and applies the lowest pressure required to eliminate events.
2874462|NCT03428503|Experimental|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solution Bristol-Myers Squibb_UK) intravenous (IV) was given 100 patients
2874463|NCT03428503|Experimental|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
2874464|NCT03428490|Experimental|Fully Integrated Treatment|Evidence-based substance use treatment combined with Cognitive Behavioral Therapy (CBT) for Social Anxiety Disorder Intervention name: Fully integrated treatment
2874465|NCT03428490|Active Comparator|Usual Intensive Outpatient Care|Evidence-based substance use disorder treatment Intervention name: Stand-alone Intensive Outpatient Program
2874466|NCT03428477|Experimental|Icosapent Ethyl (EPA-EE)|Soft gelatin capsules containing 1g pure EPA-EE equivalent to 914mg EPA-FFA. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.
2874467|NCT03428477|Placebo Comparator|Placebo|Soft gelatin capsules containing light mineral oil. 4 capsules to be taken per day (2 in the morning and 2 in the evening).
2874468|NCT03428464|Experimental|Sodium bicarbonate|During the treatment period, participants will receive 0.5 mEq/kg-lean body weight (LBW)/day of oral sodium bicarbonate for 8 weeks.
2874469|NCT03428464|Placebo Comparator|Placebo|During the control period, participants will take the same number of placebo capsules as if they were assigned 0.5 mEq/kg-LBW/day of sodium bicarbonate.
2874470|NCT03428451|Experimental|NaCl 3% hypertonic saline|patients will receive NaCl 3% hypertonic saline at a dose of 4 ml/kg/hr (Group A) and 2ml/kg/hr (Group B) ; 30 min before the subarachnoid block, and continued all through the procedure at the same rate.
2874471|NCT03428451|Experimental|NaCl 0.9% normal saline|patients will receive NaCl 0.9% normal saline at a dose of 6ml/kg/hr (Group c); 30 min before the subarachnoid block, and continued all through the procedure at the same rate.
2874472|NCT03428438|Other|Study group SMS to home phone|A physical reminder by a physiotherapist, and a daily reminder of physical exercise by SMS on weekdays A through E.
2874473|NCT03428438|Other|Controlled group hospital based|Physical rehabilitation in the ward physiotherapist
2874474|NCT03428425|Experimental|apatinib paclitaxel S-1|
2874475|NCT03428412|Experimental|TCM plus conventional drug|The experimental group will receive three type of TCM in addition conventional drug according to 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.
2874476|NCT03428412|Placebo Comparator|TCM placebo plus conventional drug|The control group will receive three type of placebo TCM in addition conventional drug according to 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.
2874477|NCT03428399||Breast reconstruction patients|Self-reported psychosocial variables and a clinical interview assessing mental health history will be administered prior to participants' scheduled mastectomy and breast reconstruction surgery (which is part of their routine medical care for cancer treatment or prevention). Follow up self-report measures will be collected after the surgery as well.
2874478|NCT03428386|Experimental|Gastric plication ileal bypass|single-anastomosis plication ileal bypass
2874479|NCT03428373|Experimental|Len-Dex+Rivaroxaban|Patients with MM will receive Len-Dex combination and Rivaroxaban (10 mg) daily
2874480|NCT03428373|Active Comparator|Len-Dex+ASA|Patients MM will receive Len-Dex combination and ASA 81 mg daily
2874481|NCT03428360|Experimental|Subjects with Epilepsy|male or female pediatric, adolescent and adult subjects with a clinical diagnosis of epilepsy and with bouts of increased seizure activity, Acute Repetitive Seizures (ARS), frequent breakthrough seizures, seizure clusters or cluster seizures.Subjects with epilepsy self-administer Diazepam Buccal Soluble Film 5, 7.5,10, 12.5, and 15 mg or with the caregiver's assistance if applicable to treat seizures, in response to the occurrence of the same characteristic events as they previously would with their usual rescue medication, e.g. Diastat® AcuDial™ or usual rescue therapy.
2874482|NCT03428347|Experimental|Group 1|1.4 mg/kg body weight
2874483|NCT03428347|Experimental|Group 2|7 mg/kg body weight
2874484|NCT03428347|Experimental|Group 3|14 mg/kg body weight
2874485|NCT03428334|Experimental|Oral roflumilast|oral roflumilast 500 microgram daily for 4 weeks
2874486|NCT03428308|Experimental|Individualized treatment of detected somatic disease(s)|
2874487|NCT03428295|Experimental|Experimental: Single Cohort in CRC|This study is a single-arm, single-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting.
2874489|NCT03428282|Experimental|Tablet device|Inferior alveolar nerve block will be performed with the aid of a tablet device as a means of distracting patients' attention.
2874490|NCT03428282|Active Comparator|Anesthesia|Inferior alveolar nerve block will be performed in the normal manner without any specific intervention to distract patients' attention. Classic anesthesia will be applied.
2874491|NCT03428269|Experimental|simulation by gaming group|In the simulation by gaming group, the students will individually play with two cases of the LabforGames Warning game (postoperative hemorrhage case and brain trauma in elderly case). After each case, a debriefing to which with all players will participate will be conducted by an instructor.
2874492|NCT03428269|Active Comparator|traditional education group|In traditional education group, the students will individually work on the two same cases but the two vignettes and adjoining questions will be presented and answered by the student on a paper sheet. Then a global review of the two cases and the major messages to be retained will be presented by a teacher.
2874493|NCT03428256|Active Comparator|Pre-oxygenation with a standard anaesthetic face mask|Pre-oxygenation delivered in the standard way; 3 minutes, Fraction of inspired oxygen (FiO2) 1.0, 8 vital capacity breaths in the last minute
2874494|NCT03428256|Experimental|Pre-oxygenation using Optiflow and THRIVE technique|Pre-oxygenation delivered via nasal high flow humidified oxygen (Optiflow) and THRIVE technique. Gradually increased to 70 litres/minute, mouth closed, 8 vital capacity breaths in the last minute
2874495|NCT03428243||truSculpt|truSculpt effectiveness after 18 months
2874496|NCT03428230|Experimental|D1|30 mg Paracetamol 3% (1 mL), solution for injection, single dose by intrathecal injection (IT)
2874497|NCT03428230|Experimental|D2|60 mg Paracetamol 3% (2 mL), solution for injection, single dose by intrathecal injection (IT)
2874498|NCT03428230|Experimental|D3|90 mg Paracetamol 3% (3 mL), solution for injection, single dose by intrathecal injection (IT)
2874499|NCT03428230|Placebo Comparator|P|Placebo, 0.9% saline solution (1 mL, 2 mL or 3 mL), solution for injection, single dose by intrathecal injection (IT)
2874500|NCT03428217|Experimental|CB-Cabo|CB-839 orally twice daily + cabozantinib orally once daily
2874501|NCT03428217|Placebo Comparator|Pbo-Cabo|Placebo orally twice daily + cabozantinib orally once daily
2874502|NCT03428204|Other|180 seconds balloon dilation|Percutaneous angioplasty with balloon dilation during 180 seconds for percutaneous treatment of femoropopliteal artery stenosis
2874503|NCT03428204|Other|300 seconds balloon dilation|Percutaneous angioplasty with balloon dilation during 300 seconds for percutaneous treatment of femoropopliteal artery stenosis
2874504|NCT03428178|Experimental|rAAV2-ND4|A Single IVT of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4)（0.05ml).The dose is 1 × 10^10 vg/0.05 mL for test groups.
2874505|NCT03428165|Other|human chorionic gonadotropin (HCG)|Ovulation triggered using HCG: choriogonadotropin alpha (Ovitrelle, Merck Serono), 250 μg/0.5ml
2874506|NCT03428165|No Intervention|spontaneous|
2874507|NCT03428152||Hypo|The participants with a superior hypogastric block
2874508|NCT03428152||NoHypo|The participants without a superior hypogastric block; the patients with an epidural catheter, who receive a different block technique (ie: TAP block), or who are unsuitable for SHP block (ie: if retro-peritoneum is opened intraoperatively by the surgeon)
2874509|NCT03428139|Active Comparator|Group I|Each patient in this group was treated with pulsed radiofrequency on the affected dorsal root ganglion at 42°C for 120 seconds
2874510|NCT03428139|Active Comparator|Group II|Each patient in this group was treated with pulsed radiofrequency as in group I plus oral alpha lipoic acid (ALA) 600 mg.
2874511|NCT03428126|Experimental|Durvalumab + Trametinib|"Participants take Trametinib tablets by mouth every day. Trametinib taken alone for the first 7 days of the study then participants begin receiving it in combination with Durvalumab.~Participants receive Durvalumab by vein every 4 weeks.~Each cycle is 28 days."
2874512|NCT03428113||ICU patient unable to void for 6 hours|ICU patients unable to void after 6 hours after a indwelling urinary catheter is removed or since time of admission
2874513|NCT03428113||renal failure with low urine volume|ICU patients with renal failure, acute kidney injury or acute on chronic with minimal urine output without an indwelling urinary catheter
2874514|NCT03428100|Experimental|Baricitinib High Dose|Baricitinib administered orally in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
2874515|NCT03428100|Experimental|Baricitinib Mid Dose|Baricitinib administered orally in combination with topical corticosteroids. Placebo administered orally in combination with topical corticosteroids to maintain the blind.
2874516|NCT03428100|Experimental|Baricitinib Low Dose|Baricitinib administered orally in combination with topical corticosteroids. Placebo administered orally in combination with topical corticosteroids to maintain the blind.
2874517|NCT03428100|Placebo Comparator|Placebo|Placebo administered orally in combination with topical corticosteroids.
2874518|NCT03428087||patients undergoing prostatic biopsy|Patients who are candidates for prostate biopsy as suffering from urinary symptoms accompanied by clinical suspicions such as high total PSA value and / or presence of prostate nodule and / or evidence of obvious lesion to available imaging methods.
2874519|NCT03428074||Patients with the surgery of Ivor-Lewis|Pathologically diagnosed IA-IIIB patients with esophageal cancer who received minimally invasive surgery of Ivor-Lewis
2874520|NCT03428074||Patients with the surgery of Mckeown|Pathologically diagnosed IA-IIIB patients with esophageal cancer who received minimally invasive surgery of Mckeown
2874521|NCT03428061||Intervention group|The intervention under study will be the integrated care for cardiovascular risk management (CVRM), based on the Dutch CVRM guideline. Patients with a history of cardiovascular disease (CVD), a high cardiovascular risk (CVR) (>10%) or use of antihypertensives or lipid lowering drugs are included in the program. Patients will be invited for an intake consultation, including a blood test, an interview, physical examination and estimation of the 10-years cardiovascular risk. If indicated, treatment with medication will be started and general lifestyle advises will be given. Patients can be referred to smoking cessation therapy, dietician and exercise programs or a physiotherapist. Patients will be controlled on a regular base to evaluate and adjust their personal goals.
2874556|NCT03427814|Placebo Comparator|Arm B|Approximately 270 subjects to receive placebo orally.
2874557|NCT03427801||Treatment Group|Chronic kidney disease patient receiving palliative care and erythropoiesis-stimulating agent
2874522|NCT03428061||Control group|Usual care will be based on the Dutch CVRM guideline, describing how to calculate the CVR and advices to lower this risk by lifestyle intervention and/or medication. However systematic identification of patients eligible for CVRM, actively inviting patients for a visit, regular follow-up and standardized collaboration with other disciplines in the health care chain are not necessarily part of usual care.
2874523|NCT03428035|Experimental|Modified Package Insert|Simplified and focused on neutral risk perception. The representations and formulations are based on the findings from research on evidence-based patient information and risk communication. The package insert contains the same information as the statutory package insert to ensure that it complies with the legal requirements.
2874524|NCT03428035|No Intervention|Verbal Information|The patient is informed verbally about side effects and does not receive any package insert.
2874525|NCT03428035|Active Comparator|Control|Package insert according to EU Directive 2001/83 / EC (usual package insert)
2874526|NCT03428022|Experimental|Apatinib combined with EGFR-TKI|Apatinib（Tablet（Tab. ）500millgram（mg）/day（d）） combined with EGFR-TKI（as previously）
2874527|NCT03428009||Dystonia group|Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.
2874528|NCT03428009||Control Group|Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.
2874529|NCT03427996||Coronary disease|
2874530|NCT03427983|Other|US-guided regular injection|US in-plane injection with corticosteroid and 1cc of lidocaine. Total of 2cc.
2874531|NCT03427983|Other|US-guided hydrodissection|US in-plane injection with corticosteroid and 1cc of lidocaine, and 3cc of saline. Total of 5cc.
2874532|NCT03427970|Active Comparator|control group|Control subjects will receive observation for 6 months.
2874533|NCT03427970|Experimental|experimental group|Experimental group will perform three-dimensionally integrated exercise for scoliosis for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 20-min period per day under the supervision of the parents at home.The treatment regimens lasted for 6 months.
2874534|NCT03427957|Experimental|New hysteroscopic grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the new grasper with knurled terminal end and cutting jaws.
2874535|NCT03427957|Active Comparator|Classic spoon grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the classic spoon grasper.
2874536|NCT03427944|Active Comparator|Calcium Dobesilate group|Calcium dobesilate group was treated with calcium dobesilate (500mg, tid , po), its conservative treatment was the same as that of the conventional treatment group
2874537|NCT03427944|Placebo Comparator|Conventional Treatment group|conventional treatment group was treated with conventional conservative treatment of renal failure (low protein, low salt, low fat, low phosphorus diet, balance the internal environment; control blood pressure ; remove intestinal toxins etc.)
2874538|NCT03427931|Experimental|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data by wearing the device at home a minimum of 28 days but may continue for up to 3 months.
2874539|NCT03427918|Experimental|patient-partner|patients and their partners will receive a weekly Mindfulness-Based Sex Therapy program. The treatments will deliver by a group of facilitators to groups of women consisting of 4-7 women.
2874540|NCT03427918|Experimental|patient-partner and health care providers|patients and their partners as well as health care providers will receive a weekly Mindfulness-Based Sex Therapy program. Th treatments will deliver by a group of facilitators to groups of women consisting of 4-7 women.
2874541|NCT03427918|No Intervention|Control group|The control group will receive a routine counseling
2874542|NCT03427905|Active Comparator|GROUP I|lipoaspiration and transplantation of ADSVCs (for adipose-derived stromal vascular cells/primary fresh cells without culture) Interventions: - Procedure: Lipoaspiration; - Procedure: Transplantation
2874543|NCT03427905|Active Comparator|GROUP II|lipoaspiration and transplantation of ADSCs (for adipose-derived mesynchymal stem cells/after culture) Interventions: - Procedure: Lipoaspiration; - Procedure: Transplantation
2874544|NCT03427892|Experimental|Brexpiprazole|Brexipiprazole will be taken orally beginning at 0.5 mg/day with an increase to 1 mg/day at week 1 and 2 mg/day at week 2. If reduction in mood symptoms does not occur, the dose will increase to 3 mg/day and 4 mg/day.
2874545|NCT03427879|Placebo Comparator|Low flavonoid beverage|Subjects will consume 310 milliliters per day of a dairy-based, low flavonoid, sports nutrition recovery beverage 14 days.
2874546|NCT03427879|Active Comparator|High flavonoid beverage|Subjects will consume 310 milliliters per day of a dairy-based, high flavonoid, sports nutrition recovery beverage 14 days.
2874547|NCT03427866|Experimental|Ruxolitinib Eligible pre-HSCT|"Ruxolitinib will be taken orally at a fixed dose twice every day~Dosing will be continuous, with a new cycle scheduled to start every 28 days.~There will be no break in dosing between cycles~Ruxolitinib can be administered with or without food."
2874548|NCT03427866|Experimental|Ruxolitinib Not Eligible pre-HSCT|"Ruxolitinib will be taken orally at a fixed dose twice every day after transplant~Dosing will be continuous, with a new cycle scheduled to start every 28 days.~There will be no break in dosing between cycles~Ruxolitinib can be administered with or without food."
2874549|NCT03427853|Experimental|LY06006|LY06006 18mg, 60mg 120mg subcutaneous injection
2874550|NCT03427853|Placebo Comparator|Placebo|Placebo subcutaneous injection
2874551|NCT03427840||Hypo|The participants with a superior hypogastric block
2874552|NCT03427840||NoHypo|The participants without a superior hypogastric block; the patients with an epidural catheter, who receive a different block technique (ie: TAP block), or who are unsuitable for SHP block (ie: if retroperitone is opened intraoperatively by the surgeon)
2874553|NCT03427827|Experimental|Adjuvant PD-1 antibody arm|Patients randomized to this arm will receive PD-1 antibody (SHR-1210), 3mg/kg (≤200mg), ivdrip (>30 minutes), d1, q4w × 12 cycles, begining at 4-6 weeks after chemoradiation
2874554|NCT03427827|No Intervention|Observation arm|Patients randomized to this arm will receive no aditional treatment after chemoradiation
2874555|NCT03427814|Experimental|Arm A|Approximately 270 subjects to receive BGB-290 orally.
2896720|NCT03272009|Experimental|Treatment D|oral EYP001a
2874558|NCT03427801||Control Group|Chronic kidney disease patient receiving palliative care without erythropoiesis-stimulating agent
2874559|NCT03427788|Experimental|Verum|Study group 1-11 of BAY2328065 (increasing dose levels for study group 2-11)
2874560|NCT03427788|Placebo Comparator|Placebo|Study group 1-11 of Placebo
2874561|NCT03427775||pre-MP3|before implementation of the multimodal analgesia protocol
2874562|NCT03427775||post-MP3|after implementation of the multimodal analgesia protocol
2874563|NCT03427762|Experimental|Healthy cycling group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Then there is a bicycle every 1 hour.
2874564|NCT03427762|Experimental|Healthy xbox group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Then they will train 1 hour every day on an xbox program.
2874565|NCT03427762|No Intervention|Healthy controll group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Thereafter, the group does not move only in everyday life.
2874566|NCT03427762|Experimental|PD groupe|"Patients with PD have already been evaluated and compared to the results of a healthy group within a separate experiment.~The study and the results have been completed. Clinical trial number:NCT03193268"
2874567|NCT03427736||Drug of Interest|Individuals receiving ketamine (IV) or hydromorphone (IV) per standard of care
2874568|NCT03427723|Active Comparator|Standard care|visualization and palpation
2874569|NCT03427723|Experimental|Accuvein|system uses an infrared laser beam to project the image of superficial veins to the skin
2874570|NCT03427710|Experimental|Cohort A1|CiVi007 dose 1
2874571|NCT03427710|Experimental|Cohort A2|CiVi007 dose 2
2874572|NCT03427710|Experimental|Cohort A3|CiVi007 dose 3
2874573|NCT03427710|Experimental|Cohort A4|CiVi007 dose 4
2874574|NCT03427710|Experimental|Cohort A5|CiVi007 dose 5
2874575|NCT03427710|Placebo Comparator|Combined placebo group|group response from placebo subsets of dosing cohorts
2874576|NCT03427697|Experimental|Intervention group|Head-mounted video display which shows video with virtual reality and accommodation relax technique in combination,40 minutes per day
2874577|NCT03427697|No Intervention|Control group|No intervention will be performed in the control group
2874578|NCT03427684|Experimental|Hypo-fractionated radiotherapy|Hypo-fractionated neoadjuvant radiotherapy concurrent with S1 chemotherapy for local advanced gastric cancer
2874579|NCT03427671|Experimental|Occlusin 500 microspheres|Uterine fibroid embolization
2874580|NCT03427658|Experimental|Increase sweet food consumption|Participants are asked to increase their consumption of sweet foods throughout their diet. Participants will be supported through an individual dietary interview where sweet foods will be highlighted and additional sweet food consumption recommended.
2874581|NCT03427658|Active Comparator|Decrease sweet food consumption|Participants are asked to decrease their consumption of sweet foods throughout their diet. Participants will be supported through an individual dietary interview where sweet foods will be highlighted and substitutions for sweet food consumption will be recommended.
2874582|NCT03427645|No Intervention|Control Surrogate Arm|Usual care control group will complete baseline and follow-up questionnaires with standard decision making techniques. This group will not be asked to use the decision making tool.
2874583|NCT03427645|Experimental|Surrogate Decision Tool Arm|This group will complete a baseline questionnaire, then use the tool and complete follow up questionnaires.
2874584|NCT03427632||percutaneous Vertebroplasty|patients meet the inclusion and exclusion criteria will be subjected to percutaneous vertebroplasty receiving bone cement (Polymethyl methacrylate)
2874585|NCT03427619|Experimental|OK432 (Picibanil)|There is no control in this study. All participants will receive the actual drug -OK432. With each injection they may receive .1mg-.2mg 6-12 weeks apart up to 4 injections total.
2874586|NCT03427606|Experimental|Continuous Suture|
2874587|NCT03427606|Active Comparator|Single 5-points Suture|
2874588|NCT03427593|Experimental|Patients|Patients with the phenotype (PID and Neutropenia and lymphoproliferation)
2874589|NCT03427593|Other|relatives (parents)|
2874590|NCT03427593|Sham Comparator|Controls|
2874591|NCT03427580|Experimental|treatment group|
2874592|NCT03427580|Experimental|delayed treatment control group|
2874593|NCT03427567||Sublobar dissection|Chinese NSCLC patients who received sublobar dissection
2874594|NCT03427554|Experimental|Tretinoin cream 0.1%|Once daily at home, to apply the entire affected areas of the face.
2874595|NCT03427554|Active Comparator|RETIN-A® Cream|Once daily at home, to apply the entire affected areas of the face.
2874596|NCT03427554|Placebo Comparator|Vehicle of the test product|Once daily at home, to apply the entire affected areas of the face.
2874597|NCT03427541||Patients with surgeries|NSCLC patients with surgeries
2874598|NCT03427528|Experimental|FAB Pilot Study (Male Participants)|"Dyads including a female client and her male partner will receive separate interventions. The inventions are complimentary and will be implemented in parallel.~Male partners will receive Fathers and Babies (FAB Intervention) while his female partner will receive MB 1-on-1 plus MB-TXT."
2874599|NCT03427528|Experimental|MB 1-on-1 Plus TEXT (Female Participants)|"Dyads including a female client and her male partner will receive separate interventions. The inventions are complimentary and will be implemented in parallel.~Female clients will receive the Mothers and Babies with -Text Messages intervention (i.e., MB 1-on-1 plus MB-TXT) while her male partner will receive FAB."
2874600|NCT03427515|Experimental|Lactobacillus|Lactobacillus rhamnosus GG (ATCC 53103) - encapsulated
2874601|NCT03427515|Placebo Comparator|Placebo|Placebo - encapsulated mixture of maltodextrins
2874602|NCT03427515|Experimental|Saccharomyces|Saccharomyces boulardii (CNCM I-1079) - encapsulated
2874636|NCT03427229|Experimental|Multiple-infusion FMT|Repeated fecal infusions by colonoscopy. Before FMT, vancomycin is administered in all patients for 3 days
2874637|NCT03427229|Active Comparator|Single-infusion FMT|Single fecal infusion by colonoscopy.Before FMT, vancomycin is administered in all patients for 3 days
2874638|NCT03427216|Active Comparator|Vaginal Baclofen/diazepam supp|Insert vaginal suppository once daily
2874639|NCT03427216|Placebo Comparator|Vaginal Placebo supp|Insert vaginal suppository once daily
2874603|NCT03427502|Experimental|Study Group|"Experimental: Study Group At the end of surgery before nasal packing, scrub nurse will prepare 10 ml solution 0.5% bupivacaine with 1:2,00,000 adrenaline in a syringe and pass it over to the operating surgeon. The surgeon will block anterior ethmoidal nerve.~Injection technique: External nasal nerve will be blocked through an inter-cartilaginous injection into the dorsum of the nose.~Internal nasal nerve will be blocked in septum and lateral wall of nose. Septal block is done in upper anterior part of nasal septum. Three injections will be given on lateral nasal wall. First injection will be given just antero-superior to the attachment of middle turbinate (axilla). Second injection will be given at the anterior end of middle turbinate and third injection at the medial surface of middle turbinate. Withdrawal of injection will be done prior to deposition of solution every time to ensure that the solution is not deposited directly into a blood vessel."
2874604|NCT03427502|Placebo Comparator|Control Group|"At the end of surgery before nasal packing, scrub nurse will pass 10 ml of normal saline in a syringe to the surgeron.~Injection technique remains the same as in Study group."
2874605|NCT03427489||Coronary heart disease|Qatari individuals presenting with or have a history of an acute coronary syndrome (myocardial infarction or unstable angina) are being recruited as study subjects.
2874606|NCT03427489||Controls|Ethnicity-matched individuals without history of CHD such as myocardial infarction or prior PCI are being recruited as controls.
2874607|NCT03427476|Experimental|Metastatic RCC (> 3 lesions)|Patients with metastatic renal cell carcinoma and planned biopsy of a metastatic lesion (N = 5)
2874608|NCT03427476|Experimental|RCC patients with primary lesions > 7 mm in diameter|Cohort B: Patients with evidence of primary renal cell carcinoma and lesions > 7 cm (may also have metastatic disease) (N = 5)
2874609|NCT03427463|Active Comparator|receiving 0.1 mg IT morphine|Patients will receive the standard of care dose 0.1 mg of intrathecal morphine
2874610|NCT03427463|Experimental|recieving 0.05 mg IT morphine|Patients will receive 0.05 mg of intrathecal morphine
2874611|NCT03427450||Healthy Volunteers (Controls)|A control population of healthy volunteers (HVs) consisting of women with no prior/current history of cancer and no known history of breast disease (the information obtained from the HVs may be 'self-reports', as complete medical records may not be available at the enrolling site for these control subjects), and with a broadly similar age range to the cancer patient study population. All eligible and consenting subjects will have blood draw.
2874612|NCT03427450||MBC Patients (Cancers)|Women with either newly diagnosed metastatic breast cancer who are about to start a new line of therapy of any type for the treatment and/or management of their disease or those with currently progressive or recurrent disease (as determined by any means) will be eligible for enrollment into the cancer population. All eligible and consenting subjects will have blood draw.
2874613|NCT03427437|Active Comparator|Conventional Group|Caudal block was performed by conventional method with %0,25 bupivacaine plus 1/200.000 adrenalin
2874614|NCT03427437|Active Comparator|Ultrasound Group|Caudal block was performed by ultrasound method with %0,25 bupivacaine plus 1/200.000 adrenalin
2874615|NCT03427424||1-Healthy Participants|(1) healthy, non-drug using control participants (CON)
2874616|NCT03427424||6-Early-in-treatment with opioid and alcohol use disorder|(6) Early-in-treatment, healthy dual prescription opioid and alcohol use disorder participants currently enrolled in PHPs within 2 month of starting treatment (POAUD-E),
2874617|NCT03427424||4-Early-in-treatment with alcohol use disorder|(4) Early-in-treatment, healthy alcohol use disorder participants currently enrolled in PHPs within about 2 month of starting treatment (AUD-E),
2874618|NCT03427424||5-Long-term-in-treatment with alcohol use disorder|(5) Long-term-in-treatment, healthy alcohol use disorder participants currently enrolled in PHPs more than 2 months and less than 5 years (AUD-L),
2874619|NCT03427424||3-Long-term-in-treatment with opioid use disorder|(3) Long-term-in-treatment, healthy prescription opioid use disorder participants currently enrolled in PHPs more than 2 months and less than 5 years (POUD-L),
2874620|NCT03427424||7-Long-term-in-treatment with opioid and alcohol use disorder|(7) Long-term-in-treatment, healthy dual prescription opioid and alcohol use disorder participants currently enrolled in PHPs more than 2 months and less than 5 years (POAUD-L).
2874621|NCT03427424||2-Early-in-treatment with opioid use disorder|(2) Early-in-treatment, healthy prescription opioid use disorder participants currently enrolled in physician health programs (PHP) within about 2 month of starting treatment (POUD-E),
2874622|NCT03427411|Experimental|Arm 1|HPV associated cancer
2874623|NCT03427398|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2874624|NCT03427385|Experimental|Minimum Effective dose|Local anesthetic Ropivacaine 0.5% injection for adductor canal block
2874625|NCT03427359|Experimental|experimental arm|Induction chemotherapy: capecitabine tablet 1000mg/m2 po bid from day1 to 14,cisplatin injection 80mg/m2 iv day1,every 3 weeks for a total of 3 cycles. Then followed by concurrent chemoradiotherapy with cisplatin injection 100mg/m2 iv every 3 weeks for a total of 2 cycles.
2874626|NCT03427346|Active Comparator|EMR|Endoscopic mucosal resection
2874627|NCT03427346|Active Comparator|ESD|Endoscopic submucosal dissection
2874628|NCT03427333|Experimental|The Rook® Epicardial Access Kit|The Rook® Epicardial Access Kit will be used to gain access the epicardial surface of the heart via a subxiphoid approach in adult patients with a normal, non-distended pericardial space.
2874629|NCT03427320|Experimental|[131]I-IAZA whole body and SPECT imaging|Injection of a single dose of 185MBq ( range 150-220MBq) of [131]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
2874630|NCT03427294||Care providers involved in lumbar arthrodesis|surgeons, physiotherapists, behavioral therapists, researchers, occupational therapists
2874631|NCT03427281|Experimental|Cohort: Belgian orthopaedic surgeons & neurosurgeon|
2874632|NCT03427268|Experimental|PM060184|PM060184
2874633|NCT03427255|Active Comparator|CBT group treatment|CBT group treatment-plus involving partners: 10 group sessions and 3 couple sessions
2874634|NCT03427255|Other|Waiting list|Six months waiting-list control condition.
2874635|NCT03427242|Experimental|treatment arm|oral apatinib
2874934|NCT03425149|Experimental|Treatment Group I|0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.5 ml Placebo on Day 7
2874640|NCT03427203|Experimental|Arm 1|"The subjects test the products in the following order~SenSura Mio (comparator) Coloplast Ostomy device 1 Coloplast Ostomy device 2 Coloplast Ostomy device 3"
2874641|NCT03427203|Experimental|Arm 2|"The subjects test the products in the following order~SenSura Mio (comparator) Coloplast Ostomy device 1 Coloplast Ostomy device 3 Coloplast Ostomy device2"
2874642|NCT03427190|Active Comparator|Control|Phone contact with patient will be made by a professional psychologist within 21 days of hospital discharge. If contact cannot be made after 9 attempts, post-cards will be sent monthly at M2, M3, M4 and M5, asking the participant to establish contact with the designated psychologist. The phone call will determine whether or not the participant is in a state of suicidal crisis. If yes, steps will be taken to attend the crisis within 24 hours.
2874643|NCT03427190|Other|APSOM|In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.
2874644|NCT03427177|Experimental|Treatment|Participants randomized to the treatment arm of the study will be given the mychoice tool to use prior to meeting with their clinician.
2874645|NCT03427177|No Intervention|Control|Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).
2874646|NCT03427164|Experimental|TIPS|Participants will have measurements taken of spleen stiffness before and after TIPS. Participation will last about 12 months, with visits at 1-2 weeks post-TIPS, 3 months, 6 months, and 12 months.
2874647|NCT03427151|Experimental|IPP-201101|every 4 weeks
2874648|NCT03427138|Experimental|Jasper|JASPER (Joint Attention Symbolic Play Engagement Regulation) is a targeted intervention that focusses on early communication skills.
2874649|NCT03427138|Experimental|Parent Education|Parent education intervention focusses on parenting a child with autism.
2874650|NCT03427125|Experimental|Tenapanor 10 mg, 20 mg, 30 mg BID|During the 26-week open label part, all enrolled subjects will receive 30 mg BID doses of tenapanor. Investigators may decrease or increase the dose in 10 mg increments to a minimum of 10 g BIDor a maximum of 30 mg BID
2874651|NCT03427125|Placebo Comparator|Placebo|Placebo
2874652|NCT03427125|Active Comparator|Sevelamer Carbonate|Subjects randomized into the active control group, for safety analysis, will receive sevelamer carbonate, open label, for the entire 52-week study period. Sevelamer carbonate will be dosed based on package insert instructions (standard of care)
2874653|NCT03427099|Active Comparator|Control group|usual care
2874654|NCT03427099|Experimental|Intervention group|Rehabilitation with a biopsychosocial focus
2874655|NCT03427086|Active Comparator|Interventional|Patient will received high dose of biotin (300 mg/day)
2874656|NCT03427086|Placebo Comparator|Placebo|Patients will receive placebo
2874657|NCT03427073|Experimental|Solid tumours|"Part 1 - Dose escalation of ALM201 in patients with advanced solid tumours.~Daily dosing of ALM201 on Days 1-5, 8-12 and 15-19 of 21 day cycle. Escalating dose cohorts"
2874658|NCT03427073|Experimental|Ovarian cancer|"Part 2 - Dose expansion of ALM201 Maximum Tolerated Dose (MTD) in patients with advanced ovarian cancer~Daily dosing of ALM201 on Days 1-5, 8-12 and 15-19 of 21 day cycle at the Maximum Tolerated Dose (MTD) determined in Part 1."
2874659|NCT03427060|Experimental|Coversin treatment|Coversin - 22.5mg followed by 45mg for 6 months.
2874660|NCT03427047|Active Comparator|MyKnee with single use Efficiency Instrument|Patients randomized in this group will undergo Total Knee Arthroplasty utilizing patient matched cutting blocks and single use instruments. Customization will be by a CT scan of patients knee.
2874661|NCT03427047|Active Comparator|Stryker Navigational with conventional metal instruments|Patients randomized in this group will undergo Total Knee Arthroplasty with conventional metal instruments. CT scan are not utilized with this arm.
2874662|NCT03427034|Experimental|Cystoscopic surveillance|Patients with previous history of bladder cancer undergoing flexible cystoscopy will privide a urine sample to see if BladderLight system can exclude presence of bladder cancer
2874663|NCT03427034|Experimental|Haematuria group|Patients referred with haematuria to exclude bladder cancer will privide a urine sample to see if BladderLight system can exclude presence of bladder cancer
2874664|NCT03427034|No Intervention|Longitudinal group|Patient with Negative cystoscopy with a positive BladderLight® test will be followed for 12 months to see if they subsequently develop bladder cancer.
2874665|NCT03427021|Experimental|Arm A|will be treated with consistent exposure to oral ice
2874666|NCT03427021|Active Comparator|Arm B|Will not be treated with consistent exposure to oral ice.
2874667|NCT03427008|No Intervention|Standard of Care|Participants in the control arm will be instructed to take their immunosuppressive medications as prescribed and attend required follow-up as is standard of care, and will not receive the mHealth app.
2874668|NCT03427008|Experimental|mHealth Intervention|Participants in the intervention arm will receive the mHealth app either while they are an inpatient post-transplant, or at their first post-transplant clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the mHealth app and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
2874669|NCT03426995|Experimental|GSK3358699, Part A, Cohort 1|Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose, during TP (1 to 3) with planned escalated doses as 1 mg, 10 mg and 35 mg. Dose of 1 mg will be given as solution and doses of 10 mg and 35 mg, will be given as a capsule. Each TP will be of 1 day and separated by a washout period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654.
2874935|NCT03425149|Experimental|Treatment Group II|0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.5 ml Placebo on Day 28
2874670|NCT03426995|Experimental|GSK3358699, Part A, Cohort 2|Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose during TP (1 to 3) with planned escalated doses as 3 mg, 20 mg and 45 mg. Dose of 3 mg will be given as solution and that of 20 and 45 mg, as capsule. Each TP will be of 1 day and separated by a washout period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive 60 microgram per meter^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654.
2874671|NCT03426995|Placebo Comparator|Placebo, Part A, Cohort 1|Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 1 mg and a matching placebo capsule to the study drug GSK3358699, 10 mg and 35 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive Placebo at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654.
2874672|NCT03426995|Placebo Comparator|Placebo, Part A, Cohort 2|Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 3 mg and a matching placebo capsule to the study drug GSK3358699, for 20 and 45 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive Placebo at a dose level already given in TP 1-3, and will then receive 60 microgram per meter^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654.
2874673|NCT03426995|Experimental|GSK3358699, Part B|The subjects in this arm will receive single oral dose of GSK3358699, at a dose level evaluated in Part A, following either fed or fasted condition. This cohort intended to evaluate the effect of food.
2874674|NCT03426995|Experimental|GSK3358699, Part C|The dose level for the first cohort in Part C will be decided following completion of Part A of the study for GSK3358699. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive GSK3358699, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
2874675|NCT03426995|Placebo Comparator|Placebo, Part C|The subjects in this cohort will receive a matching placebo to GSK3358699, Part C, as a single oral dose once daily for 14 consecutive days. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive placebo, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
2874676|NCT03426982|Experimental|Anti-Xa group|- Heparin was monitored by Anti-Xa activity, and clinicians adjusted dose of heparin to maintain it within the therapeutic range between 0.30 and 0.70 IU/mL
2874677|NCT03426982|Experimental|APTT group|- Heparin was monitored by APTT, and clinicians adjusted dose of heparin to maintain it within the therapeutic range between 1.5 and 2.5 time the basiline.
2874678|NCT03426969|Experimental|Haplo-HCT + Cyclophosphamide|Participants receive stem cell transplant from a tissue-mismatched (haploidentical) donor, followed by cyclophosphamide. Melphalan, fludarabine, and total body irradiation (TBI) also given before the transplant as standard care.
2874679|NCT03426956|Experimental|Glucose|
2874680|NCT03426956|Experimental|Glucose + Canagliflozin|
2874681|NCT03426943|Experimental|CVVH using oXiris™ filter|"Patients included in this arm will have renal replacement therapy by performing Continuous Veno-Venous Hemofiltration (CVVH) using oXiris™ membrane.~They will also have arterial blood sampling and ultrafiltrate sampling during the CVVH."
2874682|NCT03426943|Active Comparator|CVVH using PrismafleX HF1400 filter|"Patients included in this arm will have renal replacement therapy by performing CVVH using a standard polysulfone filter (PrismafleX HF1400).~They will also have arterial blood sampling and ultrafiltrate sampling during the CVVH."
2874683|NCT03426930|Active Comparator|The reference treatment of dysmorphophobia used|
2874684|NCT03426930|Experimental|The reference treatment with the virtual reality|
2874685|NCT03426904|Experimental|Neoadjuvant FOLFOX|4 cycles of FOLFOX (Folinic acid, fluorouracil and oxaliplatin) neoadjuvant followed by surgery and 8 cycles of FOLFOX
2874686|NCT03426904|Active Comparator|Conventional adjuvant FOLFOX|surgery followed by 12 cycles of FOLFOX
2874687|NCT03426891|Experimental|Combination Therapy|Pembrolizumab and Vorinostat Combined with Temozolomide and Radiotherapy. There are two parts to this study: Part 1 (dose escalation) and Part 2 (dose expansion). Dose Expansion: Twenty participants will be treated with vorinostat at the maximum tolerated dose (MTD) from dose escalation phase, pembrolizumab, temozolomide and radiation. During the maintenance phase, participants will receive Temozolomide (for the first 6 months), vorinostat (for 12 months), and pembrolizumab (for 12 months).
2874688|NCT03426878|Active Comparator|Traditional genetic counseling|This will be typical genetic counseling that a patient would receive in a traditional genetic counseling setting.
2874932|NCT03425162|Active Comparator|Group A|Group A:Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+PCA (morphine)
2874689|NCT03426878|Experimental|Modified genetic counseling|This will be genetic counseling that is modified for a lower literacy patient and will include fewer technical terms and less complicated genetic information.
2874690|NCT03426865|Experimental|Axumin PET scan|Only one arm is being evaluated--the arm receiving PET scan
2874691|NCT03426852||Study group|Individuals with lumbar back pain plus sacroiliac disc herniation
2874692|NCT03426852||Control Group|Individuals with lumbar back pain
2874693|NCT03426839|Active Comparator|Conventional group|In the conventional group (group 1) haemostasis strategy guided by conventional coagulation tests will be carried out.
2874694|NCT03426839|Active Comparator|Point of care group|In the point of care group (group 2) transfusion algorithms guided by point-of-care (POC) tests will be applied. We will use viscoelastic thromboelastometry and impedance aggregometry.
2874695|NCT03426826|Placebo Comparator|Arm 1|Placebo Comparator placebo into the jejunum through upper endoscopy.
2874696|NCT03426826|Active Comparator|Arm 2|Active Comparator: Donor Stool Transplant Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool into the jejunum through upper endoscopy.
2874697|NCT03426813|Other|Early mobilization|Historical control group for early mobilization
2874698|NCT03426800|Experimental|Migraine_acupuncture and training|Migraine acupuncture and training
2874699|NCT03426800|Experimental|Migraine training|Migraine training
2874700|NCT03426800|Experimental|Tension_acupuncture and training|Tension headache acupuncture and training
2874701|NCT03426800|Experimental|Tension headache training|Tension headache training
2874702|NCT03426787|Experimental|Decision Aid|A decision supports tool that guides patients with Hepatitis C and Chronic Kidney Disease through choices about whether, when, and how to treat each illness.
2874703|NCT03426774|Experimental|YG ( 25-59yrs) -GJogger|Gentle Jogger applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
2874704|NCT03426774|Experimental|OG (Greater than 60 yrs)-GJogger|Gentle Jogger applied to each individual in (1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
2874705|NCT03426774|Experimental|YG ( 25-59yrs) -GJumper|Gentle Jumper applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
2874706|NCT03426774|Experimental|OG (Greater than 60 yrs)-Gjumper|Gentle Jumper applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
2874707|NCT03426774|Sham Comparator|YG ( 25-59yrs) -GJogger Sham|A Sham Gentle Jogger is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
2874708|NCT03426774|Sham Comparator|OG (Greater than 60 yrs)- GJogger-Sham|A Sham Gentle Jogger is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
2874709|NCT03426774|Sham Comparator|YG ( 25-59yrs) -GJumper- Sham|A Sham Gentle Jumper is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
2874710|NCT03426774|Sham Comparator|OG (Greater than 60 yrs)-GJumper Sham|A Sham Gentle Jumper is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
2874711|NCT03426761|Experimental|Dalbavancin|Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions
2874712|NCT03426761|Active Comparator|Standard of Care|Standard of care intravenous antibiotic based on microbiology susceptibility testing. Infusions may be one to three times daily for three to eight weeks. Examples of standard of care include vancomycin, daptomycin, nafcillin, cefazolin.
2874713|NCT03426748|Active Comparator|Low dose rate brachytherapy|Device: Radiation. Low dose rate prostate brachytherapy is delivered under anesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.
2874714|NCT03426748|Experimental|High dose rate brachytherapy|"Device: Radiation. High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anesthesia, but no follow-up imaging visit is required.~HDR brachytherapy is also accomplished as an out-patient."
2874715|NCT03426735|Experimental|Dry heat|Dry heat application with a termal bag
2874716|NCT03426735|Active Comparator|Dry cold|Dry cold application with a termal bag
2874717|NCT03426722|Active Comparator|L-carnitine|L-carnitine 500mg three times daily (per oral)
2874718|NCT03426722|Placebo Comparator|Placebo|Placebo 500mg three times daily (per oral)
2874719|NCT03426709|Experimental|Low intensity Internet-delivered psychotherapy|improved Treatment-as-usual (TAU) + face to face (2 sessions of 90 minutes/session) + low intensity psychological intervention (6 sessions of 60 minutes/session) applied by ICTs (Information and communication technologies) in groups of 8-12 people.
2874720|NCT03426709|No Intervention|Improved Treatment-as-usual (TAU)|In this group, the general practitioner (GP) will apply the usual but improved treatment. The GP will have a training meeting and will be provided with the recommendations of one of the Guidelines for the Treatment of Adult Depression in AP most used in our country.
2874721|NCT03426696||Thyroid Related Eye Disease|Survey about the psychological condition would done with the patients of Thyroid Related Eye Disease
2874722|NCT03426683|Experimental|Standardized IMT|The patients will receive Standardized Intestinal Microbiota Transplantation(Standardized IMT). The IMT was given to mid-gut by nose-jejunum nutrition tube or capsules. It was given three times a week.
2874723|NCT03426683|No Intervention|traditional drugs|The patients will receive traditional medicine treatment as usual.
2874724|NCT03426670|Active Comparator|OraQuick HIV Self-Test|Sex workers in the intervention arm will be instructed to self-test before starting each monthly course of PrEP. HIV Self-testing will be performed during the months between scheduled quarterly visits.
2874725|NCT03426670|No Intervention|In-clinic testing|All study participants will receive quarterly in-clinic HIV testing as standard-of-care.
2874933|NCT03425162|Sham Comparator|Group P|Group P:PCA (morphine)
2875084|NCT03424057|Active Comparator|Group 2|Group 2 were treated with the standard Karydakis technique.
2874726|NCT03426657|Experimental|Durvalumab + Tremelimumab + RT|Durvalumab (1500 mg,q4W) + Tremelimumab (75 mg, q4W) for up to a maximum of 4 doses/cycles combined with radiotherapy (35 x 2.0/1.8/1.6 Gy) followed by durvalumab monotherapy 1500mg via IV infusion q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 8 additional durvalumab doses.
2874727|NCT03426644|Active Comparator|Group A|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target.
2874728|NCT03426644|Experimental|Group B|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group B.
2874729|NCT03426644|Experimental|Group C|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target.In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group C.
2874730|NCT03426644|Experimental|Group D|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group D.
2874731|NCT03426631|Placebo Comparator|Placebo|Placebo before sleep
2874732|NCT03426631|Experimental|DAW1033B2 oral capsule|DAW1033B2 before sleep
2874733|NCT03426618||Pediatric participants with Hepatitis B Virus (HBV)|All participants who received at least 1 dose of Baraclude.
2874734|NCT03426605|Experimental|LAM-003|Open label LAM-003 at three increasing dose levels of 200, 300 and 450 mg.
2874735|NCT03426592|Active Comparator|Vitamin D3, 10000 Intl Units Oral Capsule|Vitamin D3, 10000 Intl Units Oral Capsule, daily for 6 months
2874736|NCT03426592|Placebo Comparator|Placebo oral capsule|Oleic acid capsule by mouth, daily for 6 months
2874737|NCT03426579||Reliability of NeuroSENSE ®in children|Children scheduled for direct laryngoscopy with surgical intervention the reliability of NeuroSENSE ®monitoring will be evaluated
2874738|NCT03426566||patients with diabetes|Data from medical records from : non-ulcer patients with DM (diabetes mellitus) from the Diabetic Foot Centre (DFC) in Wroclaw. As it is a retrospective analysis no intervention is planned.
2874739|NCT03426553|Experimental|Riboflavin+UV RBC|35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology
2874740|NCT03426553|Active Comparator|irradiated RBC|35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension
2874741|NCT03426540|Experimental|Conbercept|intravitreal conbercept (10 mg/mL, 0.5 mg) immediately after surgery
2874742|NCT03426540|No Intervention|control group|Pars plana vitrectomy alone
2874743|NCT03426527|Placebo Comparator|Levobupivacaine|Patients will receive bilateral superficial cervical plexus block using levobupivacaine General anesthesia
2874744|NCT03426527|Active Comparator|Levobupivacaine-Dexmedetomidine|Patients will receive bilateral superficial cervical plexus block using levobupivacaine-dexmedetomidine General anesthesia
2874745|NCT03426514|Experimental|Three-port Laparoscopic Surgery|Patients with colorectal cancer undergo three-port laparoscopic surgery.
2874746|NCT03426514|Experimental|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（4 or more ports）.
2874747|NCT03426488||Västerbotten Intervention Programme|"The cohort is population-based and consists of blood and data from primarily 40, 50 and 60 year olds, taken every year in this age group in connection with the Västerbotten health surveys from 1985 - present.~The blood samples consist primarily of EDTA and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat and for a certain percentage, the DNA is extracted.~The database NSDD (Northern Sweden Diet Database) consists of survey data from VIP concerning nutritional factors.~A large part is fasting samples.~Individuals: 105,700 Individuals with repeated samples: 40,700 Sampling occasions: 156,300"
2874748|NCT03426488||Mammography Screening Project|"Samples and data are collected in connection with mammography screenings 1995-2006. The blood samples consist primarily of EDTA and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat, and for a certain percentage, the DNA is also extracted. The cohort consists of women, 18-82 years old (95% between 48 and 70 years old).~Survey data can be linked to the blood samples.~Individuals: 28,800 Individuals with repeated samples: 14,600 Sampling occasions: 54,000"
2874749|NCT03426488||The Northern Swedish MONICA Project|"The MONICA study is a longitudinal population-based database for research in cardiovascular disease and diabetes. Since 1985, seven screenings has been performed (1986, 1990, 1994, 1999, 2004, 2009 and 2014) of a randomized selection of the population in the counties of Västerbotten and Norrbotten in Northern Sweden.~Individuals: 11,800 Individuals with repeated samples: 3,500 Sampling occasions: 15,300 (March 2015)"
2874750|NCT03426475|No Intervention|Control Group|Care of nursing home residents as usual.
2874751|NCT03426475|Experimental|Interventional Group|Implementation of interprof ACT measures to improve collaboration and communication between general practitioners and nursing staff. Measures are selected and adapted by nursing home management / nurses, GPs and residents' relatives or representatives.
2874752|NCT03426462|Experimental|Age 1-6 years|"Induction of anesthesia with propofol using infusion pumps that are programmed with a pharmacokinetic model to achieve a calculated plasma concentration of the drug; this is followed by two anesthetic deepening episodes.~The target plasma concentrations achieved, as calculated by the programmed pump, is exactly the same in both age groups."
2874753|NCT03426462|Experimental|Age 8-13 years|"Induction of anesthesia with propofol using infusion pumps that are programmed with a pharmacokinetic model to achieve a calculated plasma concentration of the drug; this is followed by two anesthetic deepening episodes.~The target plasma concentrations achieved, as calculated by the programmed pump, is exactly the same in both age groups."
2874754|NCT03426449|Active Comparator|Posterolateral sphincterotomy|Division of internal anal sphincter at 5 o'clock position
2874755|NCT03426449|Active Comparator|Lateral sphincterotomy|Division of internal anal sphincter at 3 o'clock position
2874799|NCT03426098|Experimental|Treatment|After baseline evaluation, all subjects will undergo a series of 3 facial treatments with the Secret Micro-Needle Fractional RF System® at 4 week intervals.
2874756|NCT03426436|Other|Test|Obtain two consecutive 15-lead ECGs; The first 15-lead ECG will have an additional three electrodes/stickers on the right side of the chest and the second 15-lead ECG will have an additional three electrodes/stickers on the posterior side.
2874757|NCT03426423|Experimental|Intervention|12 weeks smoking cessation intervention tailored to diabetic and gender specificities, delivered by a study nurse.
2874758|NCT03426423|Active Comparator|Control|Usual care comprising a unique intervention of 5-10 minutes, non tailored smoking cessation intervention, delivered by a study nurse.
2874759|NCT03426397||Study population|
2874760|NCT03426384|Active Comparator|Intervention Group|"The Intervention Group will enter daily tasks into the Mymee app. After the first intake session, the subject will participate in weekly 20-30-minute coaching sessions with the Health Coach. At the second session, the Health Coach will review the symptoms and the free text entered by the subject to determine which dietary and environmental factors will be monitored in the Mymee app.~Each subsequent week, the Health Coach will review and discuss with the subject the food diary and the data entered into the Mymee app during the previous week. Based on this discussion and the subject's medical records, the Health Coach will determine or revise which symptoms will continue to be monitored using the Mymee App."
2874761|NCT03426384|No Intervention|Control Group|The Control Group subjects will receive no training, coaching, or other intervention services from Mymee. The Control Group subjects will complete the same battery of assessments at the same intervals as the Intervention Group subjects.
2874762|NCT03426371|Experimental|Experimental|All eligible subjects will receive KL-140 in combination with mFOLFOX-6 chemotherapy regimen.
2874763|NCT03426371|Placebo Comparator|Placebo Comparator|All eligible subjects will receive Placebo in combination with mFOLFOX-6 chemotherapy regimen.
2874764|NCT03426358|Experimental|Patients undergoing HSCT|LSM assessed by Elastographic Techniques
2874765|NCT03426345|Experimental|Relamorelin 10μg|Relamorelin 10μg injected subcutaneously twice daily for 12 weeks.
2874766|NCT03426345|Placebo Comparator|Placebo|Placebo injected twice daily for 12 weeks.
2874767|NCT03426319||Primary adrenal insufficiency|Patients with primary adrenal insufficiency on hormone replacement therapy with hydrocortisone.
2874768|NCT03426306|Experimental|4DCT-ventilation|The patient will undergo 4DCT imaging. The 4DCT imaging data along with image processing techniques will be used to generate a 4DCT-ventilation map. All surgical decisions will be based on the current standard of care imaging (VQ scans) and not on the 4DCT imaging results.
2874769|NCT03426293||Arterial procedure and ACT measurement|All patients undergoing an open or endovascular arterial procedure in which heparin is used peri-procedurally and the ACT is measured to determine effect of heparin
2874770|NCT03426280|Experimental|Apple Watch|Clinic pharmacists will issue Apple Watches to study arm patients and teach them the usage of the Activity app. In addition to usual care, these patients will each receive an in-person 3-minute coaching session during clinic visit at 2, 4, 6 and 12 months.
2874771|NCT03426280|No Intervention|Usual Care|Usual care.
2874772|NCT03426267|Experimental|SDN-037|
2874773|NCT03426267|Placebo Comparator|vehicle|
2874774|NCT03426254|Experimental|Injections Subcutaneously Talazoparib|"Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Auto-Injector delivers a single dose of 1 mg Talazoparib injection (subcutaneous)"
2874775|NCT03426254|Active Comparator|Oral capsules Talazoparib|Patients receive 1 mg of Talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2874776|NCT03426241||smoking chronic periodontitis|
2874777|NCT03426241||non-smoking periodontitis|
2874778|NCT03426241||smoking healthy|
2874779|NCT03426241||non-smoking healthy|
2874780|NCT03426215||Ten year follow-up group|No interventions will be administered (Magnetic Resonance Imaging (MRI) will be administered as an outcome measurement).
2874781|NCT03426202|Experimental|modafinil group|a single dose of p.o. modafinil (200mg)
2874782|NCT03426202|Experimental|placebo group|a single dose of p.o. placebo (200mg)
2874783|NCT03426189||HIV infected individuals on long term ART|"Leukapheresis~Lymph node biopsy"
2874784|NCT03426176|Experimental|male oxytocin and ATD group|male subjects receiving oxytocin and ATD treatment
2874785|NCT03426176|Experimental|male oxytocin and placebo group|male subjects receiving oxytocin and ATD-placebo treatment
2874786|NCT03426176|Experimental|male placebo and ATD group|male subjects receiving oxytocin placebo and ATD treatment
2874787|NCT03426176|Placebo Comparator|male placebo group|male subjects receiving oxytocin placebo and ATD placebo treatment
2874788|NCT03426163|Experimental|VR group|Application of virtual reality 12 hours before arthroscopic surgery
2874789|NCT03426163|No Intervention|Non-VR group|Application of knee MRI 12 hours before arthroscopic surgery
2874790|NCT03426150|Experimental|CPP-ACP|Tooth mousse (GC, Japan) application on the specimen surface for 3 min.
2874791|NCT03426150|Placebo Comparator|Deionized water|Deionized water application on the specimen surface for 3 min
2874792|NCT03426137|Active Comparator|Full Dose (FD)|Participants in the FD arm will receive NSAIDs and Oxycodone (10mg).dosed in accordance with the Guidelines for Use from University of Maryland Shock Trauma Center.
2874793|NCT03426137|Placebo Comparator|PR (Partial Reinforcement)|Participants in this group will receive NSAIDs, Oxycodone (10mg), and placebo pills to reach a 50% reduction of the total intake of opioids.
2874794|NCT03426137|Placebo Comparator|C (Control)|Participants in this group will receive NSAIDs and placebo pills
2874795|NCT03426124||Retrospective|Individuals with submassive or massive pulmonary embolism who were consecutively treated with the Ekosonic Endovascular System (EKOS) and thrombolytic drug between January 2014 and one year prior to site activation.
2874796|NCT03426124||Prospective|Individuals who are experiencing submassive or massive pulmonary embolism where the treating physician has selected the EKOS device and thrombolytic drug. The procedure and volume of thrombolytic drug is selected per standard of care.
2874797|NCT03426111|Placebo Comparator|Placebo|Diagnostic upper endoscopy plus lifestyle modification.
2874798|NCT03426111|Active Comparator|Treatment|Endoscopic gastric tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) plus lifestyle modification.
2874800|NCT03426085|Placebo Comparator|Placebo|Same formulation as active medication minus the active ingredient. Patients will start with 0.1 mL of liraglutide placebo and will escalate the dose every week in 0.1 ml increments until the 0.3 ml dose is reached. Escalation will be done according to patients' tolerance and glucose control
2874801|NCT03426085|Experimental|Liraglutide 6 mg Solution for Injection|After randomization, patients will undergo a treatment dose escalation phase. Liraglutide will be started at 0.6 mg SQ QD for 1 week, increased to 1.2 mg subcutaneous, per day (SQ, QD) for 1 week, and then increased and maintained on 1.8 mg SQ QD or maximally tolerated dose if self monitored blood glucose (SMBG) is at goal. Escalation will be done according to patients' tolerance and glucose control
2874802|NCT03426072|Experimental|modified IHI breakthrough series|"The SCOPE intervention is a complex, high facilitation, multi-component intervention operating at the microsystem (resident care unit) level of the organization and is designed to engage, develop, and equip Health Care Aides to implement improvement initiatives."
2874803|NCT03426072|No Intervention|Control|The control units (propensity matched) have no intervention and form a naturalistic control
2874804|NCT03426059||Phelan-McDermid Syndrome|
2874805|NCT03426046|Experimental|Biodentine|Partial pulpotomy treatment with Biodentine
2874806|NCT03426046|Active Comparator|Calcium Hydroxide|Partial pulpotomy treatment with Calcium Hydroxide
2874807|NCT03426046|Experimental|Mineral Trioxide Aggregate|Partial pulpotomy treatment with Mineral Trioxide Aggregate
2874808|NCT03426033|Experimental|Single dose of warfarin|Single dose of warfarin administered to obtain pharmacokinetic information.
2874809|NCT03426033|Experimental|Warfarin in combination with ISIS 681257|ISIS 681257 administered and pharmacokinetic assessments are taken. Then ISIS 681257 is administered with warfarin and additional pharmacokinetic information is obtained.
2874810|NCT03426020|Active Comparator|Oral midazolam (Demizolam®)|To prevent emergence agitation patient premedicated by 0.5 mg oral midazolam At the end of sugery patients postoperatif emergence agitation evaluated by PAED(pediatric anesthesia emergence delirium scale).
2874811|NCT03426020|Active Comparator|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor|To prevent emergence agitation patient premedicated by watching a short movie (at URL: http://www.animaturk.com/animasyon/suko-ameliyat-oluyor ) At the end of sugery patients postoperatif emergence agitation evaluated by PAED(pediatric anesthesia emergence delirium scale).
2874812|NCT03426020|Active Comparator|Play game (PC fishing game)|To prevent emergence agitation patient premedicated by playing a simple PC game (fishing game) At the end of sugery patients postoperatif emergence agitation evaluated PAED(pediatric anesthesia emergence delirium scale).
2874813|NCT03426007|Experimental|Uterine Lavage|Embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).
2874814|NCT03425994||Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide|Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) tablet by mouth, once daily for 48 weeks
2874815|NCT03425981|Experimental|WB-EMS-SRT|Training with basic global electrostimulation
2874816|NCT03425981|Experimental|WB-EMS-WT|Training with specific global electrostimulation for runners
2874817|NCT03425981|Placebo Comparator|CG|The participants in the control group will maintain the volume and intensity of the training prior to the intervention study and the subjects of the WB-EMS and WB-EMS-AC groups will substitute one conventional training day for one with global electrostimulation for six weeks; the training of the first group will be non-specific and that of the second specific for runners and the duration of both will be 20 minutes.
2874818|NCT03425968||Knee hyperextension group|athletes who has knee hyperextension
2874819|NCT03425968||Control group|athletes who doesn't have knee hyperextension
2874820|NCT03425955|Experimental|GROUP 1|Normotypic or overweight subjects with rounded, oval or squared face (aged 35-50 years)
2874821|NCT03425955|Experimental|GROUP 2|"Thin subjects with oval or triangular face and sagging skin (aged 45-60 years)"
2874822|NCT03425942|Experimental|Internet CBT for insomnia|The intervention consists of Internet-based Cognitive Behavioral Therapy for insomnia (ICBT-i) (the main components are sleep restriction and stimulus control) for five consecutive weeks.
2874823|NCT03425942|Active Comparator|Internet ART for insomnia|The intervention consists of internet-based applied relaxation exercises/techniques (ART) (different and commonly used) for five consecutive weeks.The acronyme for this intervention is (IART-i).
2874824|NCT03425929|Active Comparator|Oxytocin (6 days)|Intranasal administration, 24 international units (IU) oxytocin for three days after the first trauma movie exposure and three days after the second trauma movie exposure (24 IU per day)
2874825|NCT03425929|Active Comparator|Oxytocin (3 days)|Intranasal administration, 24 international units (IU) oxytocin for three days after the first trauma movie exposure (24 IU per day) and placebo nasal spray for three days after the second trauma movie exposure
2874826|NCT03425929|Placebo Comparator|Placebo|Placebo nasal spray for six days
2874827|NCT03425916||Primiparous women|Women after normal, not operative, vaginal one-child delivery
2874828|NCT03425916||Nulliparous women|Women without any child or pregnancy, age-matched
2874829|NCT03425903|Active Comparator|Whole Body Cryotherapy sessions|10 Whole Body Cryotherapy sessions administered on alternate days. Patient fills the questionaires and then comes into the cabin wearing only underwear. The door is closed and the session begins, with the release of nitrogen gas to the cabin indoors, which will be in contact with the patient's body surface for 3 minutes. The intervention is performed on alternate days, so 3 sessions per week are administered. Afterwards will be compared when intervening as an control group without sessions, and with 3 visits per week and fills in the questionnaires
2874830|NCT03425903|No Intervention|Control group|Without sessions. Patient attends a control visit weekly, for 3 consecutive weeks and fills in the questionnaires to control the variables while treatment is not applied. Afterwards will be compared when intervening as an intervention group receiving 3 sessions per week and fills in the questionnaires.
2874890|NCT03425513||Hepatitis B group|
2874891|NCT03425500|Experimental|Bridging Rotator Cuff Group|Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using GRAFTJACKET™ allograft.
2874892|NCT03425500|Active Comparator|Superior Capsular Group|Superior Capsular Reconstruction of massive rotator cuff tear
2875544|NCT03421158|Experimental|Breastfeeding|Newborns were breastfed during the procedure
2874831|NCT03425890|Experimental|SURE Program Group|The intervention group will receive a SURE program booklet and will perform individualized daily self-exercise and functional use of the arm and hand on their own outside of therapy for 60 minutes/day, 6 days/week for 4 weeks. These self-exercises and upper limb functional use will be performed in addition to usual care. Three SURE program booklets have been developed which relate to the affected upper limb motor capability using individual Fugl Meyer (ULFM) score. Each SURE program booklet consists of warm-up exercises, strengthening exercises and motor tasks. The SURE program booklet also includes selected functional motor tasks to be performed by the participants using their affected upper limb. The performance of the exercises and functional motor tasks will be reviewed three times per week for the first 2 weeks, two times for the third week and one time for the fourth week of intervention period.
2874832|NCT03425890|Experimental|Education Group|The control group will receive an education booklet with 10 modules. The education booklet will contain information on stroke, recovery and management strategies after stroke. Participants are to complete 2-3 modules per week and answer 1-2 simple questions after each module. Each module including answering questions takes approximately 5-10 minutes to complete. CPI will review the information with the participants 3 times per week for the first 2 weeks, two times for the third week and one time for the fourth week of intervention period.The participants in the control group will continue with their usual care in the hospital.
2874833|NCT03425877|Experimental|Parkinson's disease Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
2874834|NCT03425877|Experimental|Stroke Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
2874835|NCT03425877|Experimental|Healthy Subjects Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
2874836|NCT03425864|Other|immediate implant|patient will receive immediate implant alone.
2874837|NCT03425864|Active Comparator|immediate implant with connective tissue graft|patient will receive immediate implant and connective tissue gaft
2874838|NCT03425851|Experimental|Intervention Group|Receive 600 diapers.
2874839|NCT03425851|Active Comparator|Control Group|Receive resources of diaper banks as requested.
2874840|NCT03425838|Active Comparator|Strategy A CDK4/6 inhibitor in 1st line|Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician) plus CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib, depending on availability and physician's preference) in first line followed by fulvestrant in second line.
2874841|NCT03425838|Active Comparator|Strategy B CDK4/6 inhibitor in 2nd line|Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician) in first line followed by fulvestrant plus CDK4/6 inhibitor in second line (palbociclib, ribociclib or abemaciclib, depending on availability and physician's preference).
2874842|NCT03425825||LD-SCLC receiving 1st line treatment|patients with LD-SCLC receiving first-line treatment, including potential maintenance treatment
2874843|NCT03425825||ED-SCLC receiving 1st line treatment|patients with ED-SCLC receiving first-line treatment, including potential maintenance treatment
2874844|NCT03425825||relapsed/refractory receiving 2nd or later-line treatment|relapsed/refractory patients receiving second- or later-line treatment
2874845|NCT03425812|Experimental|Non- NSAIDS group|To withdraw NSAIDS therapy
2874846|NCT03425812|Active Comparator|NSAIDS group|To continue NSAIDS therapy
2874847|NCT03425799|Placebo Comparator|Sodium Chloride 0.9%|Sodium Chloride 0.9% infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
2874848|NCT03425799|Experimental|Tranexamic Acid 10 mg/mL|Tranexamic Acid 10 mg/mL infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
2874849|NCT03425786|Experimental|Early BPPV Management|Diagnostic and treatment training for BPPV.
2874850|NCT03425786|Active Comparator|Late BPPV Management|Diagnostic training for BPPV. Sports Medicine providers will refer patients positive for BPPV to an Otolaryngologist at our institution for treatment.
2874851|NCT03425773|Experimental|BVAC-B|BVAC-B IV injection at 0, 4, 8, 12nd weeks.
2874852|NCT03425747|Active Comparator|Calcium Carbonate|Calcium Carbonate
2874853|NCT03425747|Active Comparator|calcium Citrate|Calcium Citrate
2874854|NCT03425734|Experimental|D group|The drug will be prepared in 50 ml saline 0.5 ml DEX (100mc/ml +49.5 cc saline 1ml=1mg), and the dose will be calculated according to body weight.
2874855|NCT03425734|Experimental|S group|50 ml saline
2874856|NCT03425721||All Participants|Subjects who present with late occurring nodules, occurring more than 4 weeks but less than 2 years after the latest injection of any HA soft tissue filler. This population will only include subjects who, before receiving the HA soft tissue filer were naïve to soft tissue fillers or had previously received only HA-based soft tissue fillers.
2874857|NCT03425708|Active Comparator|Treatment group1|Febuxostat pill 20mg was used to treat CKD patients with hyperuricaemia.
2874858|NCT03425708|Active Comparator|Treatment group2|Febuxostat pill 40mg was used to treat CKD patients with hyperuricaemia.
2874859|NCT03425708|No Intervention|Control group|Treatment of CKD patients with hyperuricaemia with conventional methods.
2874930|NCT03425175|No Intervention|Control group|Standard care with recording of video but no audio-recording
2874931|NCT03425175|Experimental|Intervention group|Standard care with the addition of simultaneous audio-recording during the operation.
2874860|NCT03425695|Experimental|Test group|"Free Gingival Graft (FGG) + Low Level Laser Therapy (LLLT) + Clinical Examination~The test group received LLLT with a diode laser (CheseeTM Diode Laser, Wuhan, China ) at the FGG sites with a wavelength of 810 nm and output power of 0.1 W, for 60 s, with an energy density of 6 J/cm2 in the continuous wave mode (spot size:0.5 cm). The laser beam was directed perpendicularly toward the tissue in the noncontact mode. The laser was irradiated at the recipient sites immediately after surgery and 1, 3, 7, and 14 days later."
2874861|NCT03425695|Placebo Comparator|Control group|"Free Gingival Graft (FGG)+Placebo Low Level Laser Therapy (PLLLT) + Clinical Examination~The control group received PLLLT with a diode laser (CheseeTM Diode Laser, Wuhan, China ) same as test group without pushing the start button"
2874862|NCT03425682||Cervical Fusion - ACDF|A minimum of 25 patients undergoing anterior cervical discectomy and fusion (ACDF) using ViBone will be enrolled.
2874863|NCT03425682||Lumbar Fusion - TLIF or PLIF|A minimum of 100 patients undergoing transforaminal lumbar interbody fusion (TLIF) or posterior lumbar interbody fusion (PLIF) using ViBone will also be enrolled.
2874864|NCT03425669|Active Comparator|Placebo medication and sham stimulation|Patients will be randomly chosen to the group who will get a combination of placebo and sham stimulation.
2874865|NCT03425669|Active Comparator|Active medication|Patients are randomly chosen to the group who will get active medication without stimulation.
2874866|NCT03425669|Sham Comparator|Active stimulation|Patients are randomly chosen to the group who will get acitive stimulation without taking medicine.
2874867|NCT03425669|Active Comparator|Controls with sham stimulation|Controls without ADHD are randomly chosen to the group who will get sham stimulation.
2874868|NCT03425669|Sham Comparator|Controls with active stimulation|Controls without ADHD are randomly chosen to the group who will get active stimulation.
2874869|NCT03425656|Experimental|Trastuzumab (AryoTrust)|Trastuzumab (AryoTrust) is given concomitantly with docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
2874870|NCT03425656|Active Comparator|Trastuzumab (Herceptin)|Trastuzumab (Herceptin) is given concomitantly with docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
2874871|NCT03425643|Experimental|NAC + Neoadjuvant/Adjuvant Pembrolizumab|"Neoadjuvant: Prior to surgery, participants receive 4 cycles (cycle length: 3 weeks) of pembrolizumab [200 mg, intravenous (IV); given on cycle day 1] in combination with platinum doublet neoadjuvant chemotherapy (NAC), consisting of cisplatin [75 mg/m^2, IV; given on cycle day 1] and either Gemcitabine [1000 mg/m^2, IV; given on cycle days 1 and 8] or Pemetrexed [500 mg/m^2, IV; given on cycle day 1].~Adjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of pembrolizumab [200 mg, IV; given on cycle day 1]."
2874872|NCT03425643|Placebo Comparator|NAC + Neoadjuvant/Adjuvant Placebo|"Neoadjuvant: Prior to surgery, participants receive 4 cycles (cycle length: 3 weeks) of placebo [normal saline, IV; given on cycle day 1] in combination with platinum doublet NAC, consisting of cisplatin [75 mg/m^2, IV; given on cycle day 1] and either Gemcitabine [1000 mg/m^2, IV; given on cycle days 1 and 8] or Pemetrexed [500 mg/m^2, IV; given on cycle day 1].~Adjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of placebo [normal saline, IV; given on cycle day 1]."
2874873|NCT03425630|Experimental|Argicolina (cross-over vs Normolip)|Argicolina is a dietary supplement containing monacolin (sachets)
2874874|NCT03425630|Active Comparator|Normolip (cross-over vs Argicolina)|Normolip is a dietary supplement containing monacolin (tablets)
2874875|NCT03425617|Experimental|Tiotropium + Olodaterol first|tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose in Visit 3 followed by PLACEBO via Respimat® single dose in Visit 4
2874876|NCT03425617|Experimental|PLACEBO FIRST|Placebo via Respimat® single dose in Visit 3 followed bytiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose in Visit 4
2874877|NCT03425604||Endometriosis I y II, according to ASRM classification|Cycles were chosen for analysis only when all the following selection criteria were satisfied: < 38 years old women, antral follicle count > 6, basal FSH < 10mUI/ml, BMI<30, Infertility time <4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, < 3 previous IUI cycles, no male severe factor associated
2874878|NCT03425604||patients without endometriosis|Cycles were chosen for analysis only when all the following selection criteria were satisfied: < 38 years old women, antral follicle count > 6, basal FSH < 10mUI/ml, BMI<30, Infertility time <4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, < 3 previous IUI cycles, no male severe factor associated
2874879|NCT03425591||Cohort 1: Chronic Lymphocytic Leukemia (CLL) Participants|Participants with confirmed diagnosis of CLL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 1. The primary data source for this observational study will be the medical records of each enrolled participant.
2874880|NCT03425591||Cohort 2: Mantle-Cell Lymphoma (MCL) Participants|Participants with confirmed diagnosis of MCL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 2. The primary data source for this observational study will be the medical records of each enrolled participant.
2874881|NCT03425578|Experimental|MSG + CHO|Participants will ingest 150 mg/kg body mass monosodium glutamate followed by 75 g dextrose.
2874882|NCT03425578|Active Comparator|MSG + placebo B|Participants will ingest 150 mg/kg body mass monosodium glutamate followed by a non-caloric, flavoured placebo.
2874883|NCT03425578|Active Comparator|Placebo A + CHO|Participants will ingest placebo capsules followed by 75 g dextrose.
2874884|NCT03425565|Experimental|Pembrolizumab|
2874885|NCT03425552|Experimental|Test treatment|Paliperidone palmitate extended-release injectable suspension for intramuscular use 156 mg (100 mg of Paliperiodne)
2874886|NCT03425552|Active Comparator|Reference treatment|Paliperidone palmitate 156 mg (equivalent to Paliperidone 100 mg) extended release injectable suspension
2874887|NCT03425539|Experimental|Lucerastat|
2874888|NCT03425539|Placebo Comparator|Placebo|
2874889|NCT03425526|Experimental|Cytotoxic T Lymphocytes|"Participants receive single infusion of cryopreserved third-party donor cells within 5 days of enrollment.~The total adenovirus specific CTL dose ≤ 2 x 10^5/kg total viable CD3+ T cells/kg.~Patients who fail to respond may receive additional infusions."
2874893|NCT03425487|Experimental|MBSR+TAU|Mindfulness based Intervention (MBSR) + Usual specialized treatment in mental health. MBSR consists of 8 weekly groupal sessions of 150 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
2874894|NCT03425487|Experimental|ABCT+TAU|Compassion based Intervention (ABCT) + Usual specialized treatment in mental health. ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
2874895|NCT03425487|Active Comparator|TAU|Usual specialized treatment in mental health (psychological or/and psychiatric)
2874896|NCT03425474|Experimental|Remimazolam Tosilate|Remimazolam Tosilate at 5mg for initial dose
2874897|NCT03425474|Active Comparator|Propofol|Propofol at 1.5mg/kg for initial dose
2874898|NCT03425461|Experimental|Arm A (anti-SEMA4D VX15/2503, nivolumab)|ARM A: Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and nivolumab IV over 30 minutes every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
2874899|NCT03425461|Experimental|Arm B (anti-SEMA4D VX15/2503, ipilimumab)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and ipilimumab IV over 30 minutes every 21 days for courses 1-4, then receive anti-SEMA4D monoclonal antibody VX15/2503 every 28 days for subsequent courses for up to 12 months in the absence of disease progression or unacceptable toxicity.
2874900|NCT03425448|Active Comparator|Heparin group|
2874901|NCT03425448|Experimental|Neotrolin Group|
2874902|NCT03425422|Experimental|Therapy|VITARIA system implantation on the right cervical vagus nerve in addition to stable guideline-directed medical therapy
2874903|NCT03425422|No Intervention|Control|Stable guideline-directed medical therapy
2874904|NCT03425409|Other|Continuous Flow|Oxygen delivery at 4 liters per minute is the standard method
2874905|NCT03425409|Other|Pneumatic Pulsed Flow|Oxygen delivery using test method
2874906|NCT03425396|Experimental|Omadacycline; Omadacycline tablets|
2874907|NCT03425396|Active Comparator|Nitrofurantoin; Nitrofurantoin capsules|
2874908|NCT03425383||Test group|Subjects having periapical disease diagnosed clinically and radiographically and free from any other systemic illness. FMD and c-IMT will be determined by ultrasound
2874909|NCT03425383||Control group|Healthy subject. FMD and c-IMT will be determined by ultrasound
2874910|NCT03425370|Experimental|Wound Side A: buried sutures, Wound Side B: tissue adhesive|Wounds halves will be labeled as A (left/superior) or B (right/inferior), the halves will be randomized to receive either tissue glue or deep sutures.
2874911|NCT03425370|Experimental|Wound Side A: tissue adhesive, Wound Side B: buried sutures|Wounds halves will be labeled as A (left/superior) or B (right/inferior), the halves will be randomized to receive either tissue glue or deep sutures.
2874912|NCT03425357|Experimental|Low Load Exercises|An exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction.
2874913|NCT03425344|Other|Diagnostic|All participants will be exposed to shoulder- MRI, ultrasound and sonoelastography.
2874914|NCT03425331|Experimental|Nivolumab+Ipilimumab|Nivolumab will be administered once every 2 weeks intravenously Ipilimumab will be administered once every 6 weeks intravenously
2874915|NCT03425318|Experimental|Single arm|
2874916|NCT03425292|Active Comparator|Standard radiation plus temozolomide|Standard conformal brain radiation therapy with concurrent and adjuvant temozolomide
2874917|NCT03425292|Experimental|Nivolumab|Nivolumab
2874918|NCT03425292|Experimental|Nivolumab plus ipilimumab|Nivolumab plus Ipilimumab
2874919|NCT03425279|Experimental|BA3011|All patients will receive BA3011, CAB-AXL-ADC.
2874920|NCT03425266|Experimental|Interactive decision support tool|Online interactive multimedia decision support tool that the patient interacts with before seeing their provider that helps them learn more about chronic pain, identify treatment goals and preferences, and communicate more effectively with their provider. The tool takes between 20-45 minutes to use. It generates and transmits a preference summary for the patient and a summary of relevant shared decision making elements and medical history elements intended for sharing with providers if the patient chooses.
2874921|NCT03425266|No Intervention|Control|Our control arm is a leading consumer-facing website designed for people with chronic pain (the ACPA). Subjects randomly assigned to this arm will be directed to the page focusing on communication tools, which also includes links to other parts of the website. The specific page is: https://theacpa.org/Communication-Tools
2874922|NCT03425253|Experimental|BELKYRA® and Juvéderm® VOLUMA™ with Lidocaine|BELKYRA® is injected into preplaytsmal fat tissue in the submental area. When the Investigator and subject agree that no further intervention is required to achieve the desired result, subjects will be eligible to receive VOLUMA™ treatment. VOLUMA™ is injected along the mandibular border.
2874923|NCT03425240|Experimental|Nerve Stimulation|Acute placement of electrodes and electrostimulation of the pelvic plexus nerves during open radical prostatectomy.
2874924|NCT03425227|Experimental|study group / control group|"The subjects belonging to the study group carried out three sessions per week over a 6-week period. Each session involved 20 minutes of activity divided into three parts.~The subjects belonging to the control group continued to lead their daily lives in the course of which they had no physical activity scheduled."
2874925|NCT03425214|Experimental|NC with RBD|fMRI and video polysmnography
2874926|NCT03425214|Experimental|NC without RBD|fMRI and video polysomnography
2874927|NCT03425214|Experimental|control group (healthy subjects)|fMRI
2874928|NCT03425201|Experimental|Niraparib plus Cabozantinib|"Patients will receive niraparib and cabozantinib p.o. once daily in 28-day cycles.~In phase I, patients will be accrued to each dose level in cohorts of 6 patients. Escalation will continue until a dose-limiting toxicity (DLT) is observed or the highest dose-level is reached.~In phase II study patients will receive niraparib p.o. once daily and cabozantinib p.o. once daily in 28-day cycles at doses recommended in the phase I study."
2874929|NCT03425188||remedē System Subjects|Subjects who were implanted with the remedē System and actively followed as part of the remedē System Pivotal Trial at the time of study closure.
2874936|NCT03425149|Experimental|Treatment Group III|0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.25 ml Placebo on Day 7
2874937|NCT03425149|Experimental|Treatment Group IV|0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.25 ml Placebo on Day 28
2874938|NCT03425149|Placebo Comparator|Treatment Group V|0.5 ml Placebo on Day 0, 7 and 28
2874939|NCT03425136|Experimental|SAIA (Systems Analysis & Improvement)|Intervention is a five-step package of industrial engineering methods known as SAIA (the systems analysis and improvement approach) delivered by district maternal and child health managers to subordinate health facilities that provide prevention of mother-to-child HIV services.
2874940|NCT03425136|No Intervention|Control|Routine provision of prevention of mother-to-child HIV transmission services and routine support from district maternal and child health managers to subordinate facilities.
2874941|NCT03425123|Experimental|REP Group|All participants in this single arm study will receive Regenerative Endodontic Procedure (REP). It regenerates the root tip on recently erupted permanent teeth that did not complete root development due to pulp infection and necrosis by allowing cells to migrate from the surrounding periapical tissue and enter the pulp space. Cells contained within the intentional bleeding create at the root tip help in root completion as well as increasing the thickness of the canal walls over up to two years following the procedure.
2874942|NCT03425097|Experimental|Fexofenadine then Placebo|Patients in this group will get 2 weeks of fexofenadine, then 1 week of nothing, then 2 weeks of placebo.
2874943|NCT03425097|Experimental|Placebo then Fexofenadine|Patients in this group will get 2 weeks of placebo, then 1 week of nothing, then 2 weeks of fexofenadine.
2874944|NCT03425084|Experimental|Morphine|Intravenous morphine (0,15 mg/kg) will be given as a single dosis at the end of the surgery followed by morphine administrated by patient-controlled analgesia (PCA) as single boluses (0,04mg/kg)
2874945|NCT03425071||Healthy volunteers|"Healthy volunteers - subjects without exposure to tacrolimus. Blood samples from these subjects will be used in in vitro experiments."
2874946|NCT03425071||kidney transplant (KTx) months 1-2|"Kidney transplant recipients recruited during the months 1 to 2 of follow up after kidney transplantation surgery. These are subjects expected to be exposed to high blood levels of tacrolimus. Blood samples from these subjects will be used in ex vivo experiments."
2874947|NCT03425071||KTx months 4-5|"Kidney transplant recipients recruited during the months 4 to 5 of follow up after kidney transplantation surgery. These are subjects expected to be exposed to standard blood levels of tacrolimus. Blood samples from these subjects will be used in ex vivo experiments."
2874948|NCT03425045|Experimental|Repetitive Transcranial Magnetic Stimulation|Patients in this study arm will undergo the rTMS stimulation as described above.
2874949|NCT03425045|Sham Comparator|Sham stimulation|Patients in this study arm will undergo the sham stimulation as described above.
2874950|NCT03425045|Active Comparator|Ginkgo Biloba Extract|Patients in this study arm will receive medication therapy as described above, without any rTMS or sham procedure.
2874951|NCT03425019|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
2874952|NCT03425006|Experimental|Itacitinib and Pembrolizumab|
2874953|NCT03424993|Experimental|Dietary Sodium Restriction|Daily habitual dietary sodium intake < 2000mg
2874954|NCT03424993|Sham Comparator|Control|Routine habitual dietary sodium intake >3400mg
2874955|NCT03424980||Tyrosine kinase inhibitors|Diagnosed patients with advanced non-small cell lung cancer (NSCLC) with brain metastases who were administered with tyrosine kinase inhibitors only or combination therapies of tyrosine kinase inhibitors
2874956|NCT03424967|Experimental|ABM therapy|The attention bias modification treatment comprises of six computerized sessions, twice a week, in purpose of modulate biases in attention for threat stimuli.
2874957|NCT03424954|Experimental|EpxOstomy|Post-operative ileostomy patients will receive the study intervention for 30 days following discharge from the hospital.
2874958|NCT03424941|Experimental|FFR-guided PCI and TAVI|FFR-guided PCI and subsequently TAVI treatment with the Medtronic CoreValve Evolut R or Medtronic CoreValve Evolut R PRO
2874959|NCT03424941|Active Comparator|CABG and SAVR|CABG and SAVR
2874960|NCT03424928|Experimental|Pomalidomide 4 MG Oral Capsule|per os,capsule,4mg,1 capsule per period
2874961|NCT03424928|Experimental|Pomalidomide 4 MG Oral Capsule-Pomalyst|per os,capsule,4mg,1 capsule per period
2874962|NCT03424915||Regular exercisers group|There is no treatment on this study, it is a onetime assessment.
2874963|NCT03424915||Non-exercising group|There is no treatment on this study, it is a onetime assessment.
2874964|NCT03424902||group1|patients with no or mild paravalular leakage
2874965|NCT03424902||group 2|patients with moderate or or severe paravalvular leakage
2874966|NCT03424889|Experimental|Xylometazoline|Patients receiving topical xylometazoline nasally during bronchoscopy
2874967|NCT03424889|Placebo Comparator|Saline placebo|Patients receiving topical saline nasally during bronchoscopy
2874968|NCT03424876||Arm A|Imatinib 400 mg/day or 600mg/day, and within 6 weeks after surgery, continuous treatment was not tolerated until tumor progression, recurrence or adverse reactions were not tolerated.
2874969|NCT03424876||Arm B|Sunitinib 37.5 mg/day, continuous taking, or 50 mg/day (4/2), began within 6 weeks after surgery, and was continuously administered until tumor progression, recurrence or adverse reactions were not tolerated
2874970|NCT03424863|Experimental|Aortic stent graft patients|Patients who have received an aortic stent graft who will perform one session of moderate intensity muscle strengthening during which blood pressure will be measured.
2874971|NCT03424863|Experimental|Healthy volunteers|Healthy volunteers in general good health with no history of heart disease who will perform one session of moderate intensity muscle strengthening during which blood pressure will be measured.
2874972|NCT03424850|Experimental|HDR brachytherapy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 21 Gy.
2874973|NCT03424837|Experimental|Intervention Arm: SoC and ASCENT|Health care per institutional standard plus ASCENT via the TrueNTH website.
2874974|NCT03424837|No Intervention|Control Arm: SoC and TrueNRH|Health care per institutional standard, plus access to the public information on the TrueNTH website; such as the symptom tracker, exercise & diet, and lived experiences modules.
2874975|NCT03424824|Experimental|BP1.3656 low dose|
2874976|NCT03424824|Experimental|BP1.3656 intermediate dose|
2874977|NCT03424824|Placebo Comparator|Placebo|
2874978|NCT03424811|Experimental|Intervention Group|Includes core behavior change strategies and behavioral skills training designed to promote healthy eating behaviors.
2874979|NCT03424811|No Intervention|Control Group|Information provided will mimic what families may receive during a routine well-child visit.
2874980|NCT03424772||Patients with unexplained DD/ID|Whole genome sequencing will be performed on pediatric patients with unexplained developmental delay(DD)/intellectual disability(ID), multiple congenital abnormalities and other rare and undiagnosed diseases.
2874981|NCT03424759|Experimental|AZD9291|Patients will be treated 80 mg/day of AZD9291 orally (1 cycle for 21 days).
2874982|NCT03424746|Experimental|Open label EDTA chelation|EDTA-based chelation therapy plus vitamins in diabetic patients with severe peripheral artery disease presenting with impending amputation and determine if there is an improvement in outcomes and a delay or reduction of amputations.
2874983|NCT03424733|Active Comparator|Current Plegridy Users|Members in this group have been previously titrated and are currently taking the pegylated interferon beta-1 (Plegridy) injection once every two weeks. These patients will complete a total of six study injections of Plegridy (125 micrograms) totaling a 12 week study duration. Subjects must take two 325mg tablets of Tylenol 1 hour prior to each study injection, and one 20mg Prednisone tablet 4-5 hours prior to injections two through six only.
2874984|NCT03424733|Experimental|New Plegridy Users|Members in this group have never taken the pegylated interferon beta-1a (Plegridy) injection, and so they must first by titrated by injecting with a 63 and 94 microgram Plegridy dose. Titrations, along with full dose injections (125 micrograms) occur every two weeks. Patients must take two 325mg tablets of Tylenol prior to each titration injection. The third study dosage involves subjects taking the full 125 microgram Plegridy dosage with two 325mg Tylenol tablets prior to injection. The final five study injections (four through eight) require patients to take two 325mg Tylenol tablets 1 hour prior to injection, and one 20mg Prednisone tablet 4-5 hours prior to injection.
2874985|NCT03424720|Experimental|Comparison of PLE and BIS|Investigators assess PLE and BIS values as indicators of the depth of anesthesia during induction and emergence of anesthesia and facial nerve integrity monitoring
2874986|NCT03424707|Experimental|combination|
2874987|NCT03424707|Active Comparator|single|
2874988|NCT03424707|Placebo Comparator|placebo|
2874989|NCT03424694|Experimental|2 fractions of 14.5 Gy HDR Brachytherapy|"High Dose Rate (HDR) Brachytherapy as monotherapy at a dose of 29 Gy is delivered in 2 fractions of 14.5 Gy, minimum 6 hours a part, delivered on a single implant procedure with 2 MRI assisted plannings and dosimetries.~HDR brachytherapy implant is done under anesthesia with ultrasound guidance as an out-patient procedure."
2874990|NCT03424694|Experimental|1 fraction of 19.5 Gy HDR brachytherapy|"HDR Brachytherapy as monotherapy at a dose 19.5 Gy is delivered in 1 fraction. Treatment is done on a single ultrasound guided implant, post implant MRI assisted planning and dosimetry.~HDR brachytherapy implant is done under anesthesia with ultrasound guidance as an out-patient procedure."
2874991|NCT03424681|Experimental|Modafinil|Modafinil 300 mg by mouth each day
2874992|NCT03424681|Placebo Comparator|Placebo|Identical looking capsule/number of capsules by mouth each day without active medication
2874993|NCT03424655|Experimental|Group TFA|Twisted files were used serially with a single controlled motion according to the manufacturer's instructions.
2874994|NCT03424655|Experimental|Group BF|The root canals were cleaned and shaped using a #40 instrument for thin or curved canals and a #55 file for widespread canals.
2874995|NCT03424655|Experimental|Group WON|WaveOne files was used to prepare narrow, straight and curved canals, and a file (40.08) was used for large and wide canals.
2874996|NCT03424655|Experimental|Group REC|Reciproc instrument was used in thin and curved RC, and R40 files (40.06) were used in wide canals.
2874997|NCT03424642|Experimental|Interactive 4D-ultrasound examination|Pregnant women who are randomized to 4D-ultrasound intervention group will receive additional 4D-ultrasound examinations 2-3 times between gestational weeks 25-32. Patients in this group will also receive psychologist's interview twice and fill out questionaries.
2874998|NCT03424642|No Intervention|Control group|Pregnant women who are randomized to control group will receive psychologist's interview twice twice and fill out questionaires.
2874999|NCT03424629|Experimental|Low-Dose UC-MSCs|Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 1 x 10^6 cells/kg in normal saline injection
2875000|NCT03424629|Experimental|High-Dose UC-MSCs|Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 3 x 10^6 cells/kg in normal saline injection
2875001|NCT03424629|Active Comparator|Methotrexate|5-25mg Methotrexate orally
2875002|NCT03424616|Experimental|Postoperative immediate Deep brain stimulation|The addicts undergone the deep brain stimulation while the stimulation (Suzhou Sceneray® DBS System) was turned on 1-2 weeks postoperatively.
2875003|NCT03424616|Sham Comparator|Postoperative delayed Deep brain stimulation|The addicts undergone the deep brain stimulation while the stimulation (Suzhou Sceneray® DBS System) was off until 25 months postoperatively, during which the following up was kept, then the the stimulation was turned on 25 months postoperatively.
2875004|NCT03424603|Experimental|STRO-001|intravenous
2875005|NCT03424590|Active Comparator|COTS|Volunteers will be provided with Clearblue connected Ovulation test system to use during the study period, accortding to the instructions for use.
2875006|NCT03424590|No Intervention|Control|Volunteers will not be provided with Clearblue Connected Ovulation Test System and will be instructed not to use any other ovulation predictions tests during the study period.
2875007|NCT03424577|Experimental|H3B-6527|Healthy male participants will be randomly assigned to 1 of 2 possible treatment sequences: either H3B-6527 capsule with food on Day 1 and H3B-6527 capsule without food on Day 5 (treatment sequence fed/fasted), or H3B-6527 capsule without food on Day 1 and H3B-6527 capsule with food on Day 5 (treatment sequence fasted/fed).
2896721|NCT03272009|Placebo Comparator|Treatment E|oral placebo
2875008|NCT03424564|Experimental|Perampanel single-dose Part: 2 mg group|Participants will receive a single 2 milligrams (mg) dose of perampanel orally under fasted conditions.
2875009|NCT03424564|Experimental|Perampanel single-dose Part: 4 mg group|Participants will receive a single 4 mg dose of perampanel orally under fasted conditions.
2875010|NCT03424564|Experimental|Perampanel single-dose Part: 8 mg group|Participants will receive a single 8 mg dose of perampanel orally under fasted conditions.
2875011|NCT03424564|Experimental|Perampanel multiple-dose Part|Participants will receive multiple oral dose of perampanel (2 milligrams per day [mg/day] from Day 1 to Day 7 and 4 mg/day from Day 8 to Day 21). Fasted condition is required for Days 1 and 21.
2875012|NCT03424551|Experimental|Vibrator|Local or Whole body vibration will be applied at four different frequencies to Healthy control and spastic spinal cord injury.For local vibration, vibration frequencies are 50,100,120 and 150 Hz . For whole body vibration, vibration frequencies are 28, 31, 34 and 37 Hz
2875013|NCT03424538|Experimental|MSt|The MSt group that received 5 weeks of intensive therapy.
2875014|NCT03424538|No Intervention|MSc|The MS controll group that did not receive treatment.
2875015|NCT03424538|Experimental|MStp|The MStp Group performs a traditional physiotherapy for 5 weeks.
2875016|NCT03424525|Experimental|Biodistribution|The Biodistribution cohort referred from orthopedics who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution [11C]trimethoprim PET/CT scans over a period of approximately 2 ½ hours.
2875017|NCT03424525|Experimental|Dynamic|The Dynamic cohort will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans imaging post injection of [11C]trimethoprim. Some subjects who may be selected clinically to undergo surgical or antibiotic treatment may undergo a second therapy may also undergo an optional second [11C]trimethoprim PET/CT after the initiation of therapy to collect pilot data on the changes in [11C]trimethoprim biodistribution and uptake with therapy, the timing of this scan may vary depending on the type of treatment the patient is receiving.
2875018|NCT03424512|Experimental|Group Metacognitive Therapy|Group metacognitive therapy (MCT) is a brief psychological intervention designed to be delivered in small groups of 4-8 patients over a course of six, 90 minute sessions conducted on a weekly basis
2875019|NCT03424499|Active Comparator|Single-use catheter|"Participants will use a sterile single-use catheter of polyvinyl chloride (PVC) for intermittent urethral catheterization.~Intermittent Bladder Catheterization will be done using clean technique, each PVC catheter will be sterile and used only once for each catheterization.~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
2875020|NCT03424499|Experimental|Reused catheter|"Participants will use a clean reused catheter of polyvinyl chloride for intermittent urethral catheterization.~Intermittent Bladder Catheterization will be done using clean technique. The PVC catheter will be used for 1 week, cleaning the catheter with water and soup after each catheterization and stored in a container with 0.5% benzalkonium chloride.~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
2875021|NCT03424486||Adolescents (14 to 17 years old)|Patients with CF
2875022|NCT03424486||Parents|Parents of adolescents (14 to 17 years old with CF (father, mother and other)
2875023|NCT03424460|Experimental|population 1-A1 : DM1 with VTE|Myotonic dystrophy type 1 patients with a history of venous thromboembolism (pulmonary embolism and/or deep vein thrombosis)
2875024|NCT03424460|Active Comparator|population 1-B1 : DM1 without VTE|Myotonic dystrophy type 1 patients without a history of venous thromboembolism
2875025|NCT03424460|Active Comparator|population 1-C1 : Healthy volunteers|Healthy volunteers without any medical history or treatment
2875026|NCT03424460|Experimental|population 2-A2 : DM1 liver samples|Liver samples of patients with myotonic dystrophy type 1
2875027|NCT03424460|Active Comparator|population 2-B2 : Healthy liver samples|Liver samples from patients without any medical history
2875028|NCT03424447|No Intervention|Non stimulated|Prospective data obtained from non stimulated patients
2875029|NCT03424447|Experimental|Stimulated|Prospective data obtaied from stimulated patients
2875030|NCT03424434||Medical staff of an UHC, practitioners and residents|The target population is practitioners and residents who works at hospital in an UHC, they are also specialists, surgeons, dental surgeons.
2875031|NCT03424421|Experimental|subscapular sling|semitendinosus subscapular sling procedure
2875032|NCT03424408|Other|Aspirin 81 mg|Healthy volunteers will receive 5 days of aspirin. Following cessation of aspirin, daily blood samples will be collected for serum thromboxane B2 measurement
2875033|NCT03424395|Other|Personalized dietary and wellness program|An integrated personalized nutrition program which includes a combination of dietary and wellness advice/counseling on wellness and meals, or dietary and wellness advice/counseling alone, each for 10 weeks.
2875034|NCT03424382||Phase I|Participants will complete an intake form and assessment tool survey on an electronic device provided by research staff in their hospital room. If an individual is unable to complete the instrument, he or she may have another individual enter his or her answers on the electronic device.
2875035|NCT03424382||Phase II|Participants will complete an intake form and assessment tool survey on an electronic device provided by research staff in their hospital room. If an individual is unable to complete the instrument, he or she may have another individual enter his or her answers on the electronic device.
2875036|NCT03424369||Eustachian tube unobstructed|
2875037|NCT03424369||Eustachian tube dysfunction|
2875038|NCT03424356|Experimental|lma with rocuronium bromide|In study group, 2-3 mg/kg propofol, 1mcg/kg fentanyl and 0.15 mg/kg rocuronium bromide will be administered during lma insertion in cystoscopy procedure.
2875039|NCT03424356|Active Comparator|lma with saline solution|In control group, 2-3 mg/kg propofol, 1 mcg/kg fentanyl and saline(no rocuronium) will be administered during lma insertion in cystoscopy procedure.
2875040|NCT03424343||cancer survivor, parents, sibling|
2875041|NCT03424330|Experimental|Arm1 - ReX first|Subjects begin with the ReX-C Intervention stage followed by Standard of Care stage.
2875042|NCT03424330|Experimental|Arm 2- Standard of Care first|Subjects start with Standard of Care stage followed by ReX-C Intervention.
2875043|NCT03424317|Active Comparator|Sodium intake reduction and exercise|education of sodium intake reduction and regular exercise
2875044|NCT03424317|Placebo Comparator|Exercise|education of regular exercise only
2875045|NCT03424304|Other|Excel V™ Laser With Green Genesis|Treatment with Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment for skin quality in desired area
2875046|NCT03424291|Experimental|Apatinib plus chemoradiation|Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
2875047|NCT03424278|Active Comparator|Motor Control|
2875048|NCT03424278|Experimental|Resistance Training|
2875049|NCT03424265|Experimental|9g of EAA mixture supplement|Twice a day for 12 consecutive weeks.
2875050|NCT03424265|Experimental|9g of placebo (whey protein)|Twice a day for 12 consecutive weeks.
2875051|NCT03424252|Experimental|FDL169 Dose Level 1,sublingual to oral|Dose level 1 sublingual first and oral second.
2875052|NCT03424252|Experimental|FDL169 Dose Level 1 dosing,oral to sublingual|Dose level 1 oral first and sublingual second.
2875053|NCT03424252|Experimental|FDL169 Dose Level 2 sublingual to oral,Optional|Dose level 2 sublingual first and oral second.
2875054|NCT03424252|Experimental|FDL169 Dose Level 2 oral to sublingual,Optional|Dose level 2 oral first and sublingual second.
2875055|NCT03424239|Experimental|Drug: Zoledronic Acid|Subjects will receive zoledronic acid (5mg), administered as an intravenous infusion.
2875056|NCT03424239|Placebo Comparator|Drug: Placebos|Subjects will receive sterile free water for injection, administered as an intravenous infusion.
2875057|NCT03424226|Experimental|day of acetazolamide|acetazolamide 125mg twice a day, started morning of ascent
2875058|NCT03424226|Active Comparator|night before acetazolamide|acetazolamide 125mg twice a day, started evening before ascent
2875059|NCT03424213||white low aggressive|low aggressive = Gleason score < 7 and stage cT1-cT2 and PSA < 10 ng/ml
2875060|NCT03424213||white high aggressive|high aggressive = Gleason score ≥ 8 or PSA > 20 ng/ml or Gleason score = 7 and stage cT3-cT4
2875061|NCT03424213||white intermediate aggressive|intermediate aggressive = all other cases
2875062|NCT03424213||AA low aggressive|low aggressive = Gleason score < 7 and stage cT1-cT2 and PSA < 10 ng/ml
2875063|NCT03424213||AA high aggressive|high aggressive = Gleason score ≥ 8 or PSA > 20 ng/ml or Gleason score = 7 and stage cT3-cT4
2875064|NCT03424213||AA intermediate aggressive|intermediate aggressive = all other cases
2875065|NCT03424200|Other|Coaching plus Routine Care|Participants will receive coaching plus routine care
2875066|NCT03424200|Other|Routine Care|Participants will receive the routine care
2875067|NCT03424187|Experimental|whole chickpea|a test meal containing 26g available carbohydrates from chickpea (full structure)
2875068|NCT03424187|Experimental|flour chickpea|a test meal containing 26g available carbohydrates from flour chickpea (destroyed structure)
2875069|NCT03424187|Experimental|intact cell chickpea|a test meal containing 26g available carbohydrates from intact cell chickpea flour (full structure)
2875070|NCT03424174|Experimental|Coated Total Knee Arthroplasty|Implantation coated Total Knee Arthroplasty
2875071|NCT03424174|Active Comparator|Standard Total Knee Arthroplasty|Implantation Standard Total Knee Arthroplasty
2875072|NCT03424161|Other|Secret RF|Treatment with Secret RF for skin quality
2875073|NCT03424148|Other|Excel V™ Laser & Micro-Lens Array Attach|Treatment with Excel V™ Laser and a Micro-Lens Array Attachment for skin quality
2875074|NCT03424135|Experimental|Test product + Reference product|Each treatment sequence consists of two treatment periods (Dosing Periods 1 and 2) with each period consisting of 4 days starting with an overnight fast of at least 10 hours. Subjects will consume a standardized high calorie, high fat breakfast approximately 30 minutes prior to dosing followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two study drug administrations are separated by a 7 calendar days washout phase.
2875075|NCT03424135|Experimental|Reference product + Test product|Each treatment sequence consists of two treatment periods (Dosing Periods 1 and 2) with each period consisting of 4 days starting with an overnight fast of at least 10 hours. Subjects will consume a standardized high calorie, high fat breakfast approximately 30 minutes prior to dosing followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two study drug administrations are separated by a 7 calendar days washout phase.
2875076|NCT03424122|Experimental|Treatment A|INCB050465 + Rituximab
2875077|NCT03424122|Experimental|Treatment B|INCB050465 + Bendamustine + Rituximab
2875078|NCT03424122|Experimental|Treatment C|INCB050465 + Ibrutinib
2875079|NCT03424109||Beneficiaries with a one-year mortality of at least 30%|The patient cohort will be extracted via the Centers for Medicare and Medicaid Services (CMS) Research Data Assistance Center (ResDAC) using a two-step process to maximize diversity, and minimize intentional or unintentional exclusions based on risk, age, health literacy, demographics, or expected adherence.
2875080|NCT03424083||1 cohort|adult patients of both sexes (>18 and <80 years) with no previous diagnosis or follow up by a pulmonologist, send by a general practitioner to the lung function lab
2875081|NCT03424070|Active Comparator|Laryngoscopy view with a shoulder roll|The primary outcome is the difference in the height of the lateral canthus of the eyelid of the laryngoscopist above the OR table during laryngoscopy with and then without the shoulder roll. These two positions will be compared using photos of the best glottic view taken during laryngoscopy with a shoulder roll in place. Then a photo of the best glottic view will be taken during laryngoscopy without the shoulder roll in place. These two views will be compared by a blinded anesthesiologist using the POGO scale.
2875082|NCT03424070|Placebo Comparator|Laryngoscopy without a shoulder roll|The primary outcome is the difference in the height of the lateral canthus of the eyelid of the laryngoscopist above the OR table during laryngoscopy without and then with the shoulder roll. These two positions will be compared using photos of the best glottic view taken during laryngoscopy with a shoulder roll in place. Then a photo of the best glottic view will be taken during laryngoscopy without the shoulder roll in place. These two views will be compared by a blinded anesthesiologist using the POGO scale.
2875083|NCT03424057|Experimental|Group 1|"Group 1 were treated with the new technique (Asymmetric Primary Closure and Additional Skin Excision).~In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method, but an advancement tissue flap was performed using additional skin excision, in order to reduce the dead-space volume."
2875085|NCT03424044|Experimental|Dual Hormone Closed-loop Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in dual hormone mode and XeriSol glucagon to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery and an increase in glucagon delivery upon detection.
2875086|NCT03424044|Experimental|Single Hormone Closed-loop Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in single hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery upon detection.
2875087|NCT03424044|Experimental|Predictive Low Glucose Suspend Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in predictive low glucose suspend mode. The system will run through the closed-loop system but will utilize the patient's optimized basal rates, correction factors and carb ratios as they would normally run on their own insulin pump. But the mode will have the additional safety net of the pump suspending insulin when it predicts a hypoglycemic event.
2875088|NCT03424031|Experimental|Verticalization|the patient will be placed in the most vertical position possible.
2875089|NCT03424031|No Intervention|Passive mobilization|Passive mobilization of the lower limb deficit
2875090|NCT03424018|Experimental|BMN 111|
2875091|NCT03424005|Active Comparator|Capecitabine|"Participants will receive Capecitabine until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1).~Participants who progressed on treatment may have the option of receiving Atezolizumab + Chemo, provided they meet the eligibility criteria"
2875092|NCT03424005|Experimental|Atezolizumab + Ipatasertib|"Participants will receive doublet combination treatment with atezolizumab + Capecitabine until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Participants who progressed on treatment may have the option of receiving Atezolizumab + Chemo, provided they meet the eligibility criteria"
2875093|NCT03424005|Experimental|Atezolizumab + SGN-LIV1A|"Participants will receive doublet combination treatment with atezolizumab plus SGNLIV1A until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Participants who progressed on treatment may have the option of receiving Atezolizumab + Chemo, provided they meet the eligibility criteria"
2875094|NCT03424005|Experimental|Atezolizumab + Bevacizumab|Participants will receive doublet combination treatment with atezolizumab plus Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Participants who progressed on treatment may have the option of receiving Atezolizumab + Chemo, provided they meet the eligibility criteria
2875095|NCT03424005|Experimental|Atezolizumab + Bevacizumab + Cobimetinib|"Participants will receive doublet combination treatment with atezolizumab + Bevacizumab + Cobimetinib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Participants who progressed on treatment may have the option of receiving Atezolizumab + Chemo, provided they meet the eligibility criteria"
2875096|NCT03424005|Experimental|Atezolizumab + Capecitabine|"Participants will receive doublet combination treatment with atezolizumab + Capecitabine until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Participants who progressed on treatment may have the option of receiving Atezolizumab + Chemo, provided they meet the eligibility criteria"
2875097|NCT03424005|Experimental|Atezolizumab + Chemo (Gemcitabine + Carboplatin or Eribulin)|Participants will receive doublet combination treatment with atezolizumab plus Chemotherapy (Gemcitabine + Carboplatin or Eribulin) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
2875098|NCT03423992|Experimental|Biological: Chimeric antigen receptor T cells|
2875099|NCT03423979|Experimental|Optilume™ BPH Prostatic DCB Dilation Catheter|Optilume™ BPH Prostatic DCB treatment procedure
2875100|NCT03423966|Experimental|Self Objective Mobility Evaluation|Usual Care Plus a Smartphone pedometer App
2875101|NCT03423966|No Intervention|Usual Care (UC)|Usual Care of obesity
2875102|NCT03423953||Anatomic|Patients receiving the Anatomic or Hemi verison of the Comprehensive Nano.
2875103|NCT03423953||Reverse|Patients who have received the Reverse version of the Comprehensive Nano.
2875104|NCT03423940|Experimental|Evaluation of Treatment Dosage|The goal of intervention for arm 1 is to examine the optimal duration of treatment with functional communication training (FCT). Investigators will treat each subject's behavior using FCT in three distinct contexts which will be associated with either short, moderate, or extended treatment durations. The investigators will counterbalance the order of treatment durations (short, moderate, and extended) across subjects, but each subject will receive treatment at each duration. Resurgence will be tested following each treatment duration.
2875105|NCT03423940|Active Comparator|Empirically Derived Schedule Thinning|The goal of the intervention for arm 2 is to develop the optimal progression for reinforcement schedule thinning during functional communication training. The investigators will use measurements of destructive behavior, appropriate behavior, and reinforcer deliveries during each treatment session to inform the frequency of reinforcers that will be available during upcoming treatment sessions. The investigators will develop the schedule thinning progression by plugging these measurements into the quantitative model to describe the proper steps to schedule thinning to decrease the probability of a relapse of destructive behavior. The investigators will compare these results to those in the extant literature.
2875106|NCT03423927|Experimental|Intervention group : hypnosis + self-care|Groupal intervention combining self-care techniques and self-hypnosis exercises
2875107|NCT03423927|No Intervention|Control group : no intervention|Control group receiving usual care but not the intervention
2875108|NCT03423914|Experimental|Writing Intervention Group|Expressive writing The participant will write four days about her deepest thoughts and feelings in relation to the experience of hospitalization of the premature newborn and how this experience is related to your current life and to your future.
2875109|NCT03423914|Active Comparator|Control Group|Only Writing The participants will write about situations not related to the subjective human experience of their preterm birth, but about general aspects.
2875110|NCT03423901|Experimental|ABO/HLA incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 12 ABO and HLA incompatible kidney transplantation (KT)
2875111|NCT03423901|Experimental|ABO incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 28 ABO incompatible kidney transplantation
2875112|NCT03423901|Experimental|HLA incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 20 HLA incompatible kidney transplantation
2875113|NCT03423888|Experimental|High-flow nasal oxygen|
2875114|NCT03423875|No Intervention|Control|Patients assigned to the control condition will be treated using the current standard of care, clinical assessments, to identify delirium.
2875115|NCT03423875|Experimental|Intervention|PrEDICTgame score (subject's relative risk of delirium) will be shared with ED physicians in the intervention arm. After viewing the tests results, ED physicians will be asked to reassess delirium risk, and indicate if they would change their management based on the PrEDICT app scores.
2875116|NCT03423849|Experimental|The original program (NG/NP)|Vinorelbine injection 25mg/m2 on day 1 and day 8, Gemcitabine injection 1250mg/m2 on day1 and day 8,every 3 weeks for 3 cycles（for the patients who used the NG salvage therapy） or Vinorelbine injection 25mg/m2 on day 1 and day 8,Cisplatin injection 25mg/m2 on day1,every 3 weeks for 3 cycles（for the patients who used the NP salvage therapy ）
2875117|NCT03423849|Experimental|One of the original program (N)|Vinorelbine injection,25mg/m2 on day 1 and day 8,every 3 weeks for 6 cycles. or, Vinorelbine oral 60mg/m2 on day 1,every week for 6 cycles.
2875118|NCT03423849|Experimental|Capecitabine monotherapy|Capecitabine oral 1250mg/m2,bid,for 6 cycles
2875119|NCT03423836||High Risk Infants|Motor infants born prior to 35 weeks gestational age, or, infants small (<10th percentile) for gestational age.
2875120|NCT03423836||Low Risk Infants|Motor infants born after the completion of the 37th week of gestation and appropriate for gestational age.
2875121|NCT03423823|Experimental|Study Drug Arm|Receiving 1.25mg of 0.05mL of Ziv-aflibercept intravitreal injection every month
2875122|NCT03423823|Other|Control Arm|Receiving bevacizumab, ranibizumab, or aflibercept intravitreal injection every 5 to 12 weeks (varied intervals based on individual need for treatment)
2875123|NCT03423810|Experimental|Group 1: Hydralazine|Participants will take hydralazine twice daily for total of 6 weeks. The dose of hydralazine will be increased every 2 weeks.
2875124|NCT03423797|Active Comparator|NaF without fTCP|25% AgNO3 solution followed by 5% NaF.
2875125|NCT03423797|Experimental|NaF with fTCP|25% AgNO3 solution followed by 5% NaF with fTCP.
2875126|NCT03423784|Experimental|HA BPX V3.3|A HMWHA gel available in a formulation specificaly designed for use in infants
2875127|NCT03423784|Active Comparator|Dentinox-Gel N|Gold standard for teething symptoms
2875128|NCT03423771|Experimental|NPF-08 Low dose （1-day treatment）|
2875129|NCT03423771|Experimental|NPF-08 Medium dose （2-day split dose）|
2875130|NCT03423771|Experimental|NPF-08 High dose （2-day split dose）|
2875131|NCT03423771|Experimental|NPF-08 Medium dose （1-day treatment）|
2875132|NCT03423771|Experimental|NPF-08 High dose （1-day treatment）|
2875133|NCT03423771|Experimental|NPF-08 Low～High dose （1-day treatment）|
2875134|NCT03423771|Experimental|NPF-08 Medium～High dose （2-day split dose）|
2875135|NCT03423758||Healthy controls|Healthy subjects with age more than 60 years
2875136|NCT03423758||Pseudoexfoliation Glaucoma|Already diagnosed Pseudoexfoliation glaucoma patients with age more than 50 years
2875137|NCT03423758||Angle closure Glaucoma|Already diagnosed Angle closure Glaucoma patients with age more than 21 years
2875138|NCT03423732|Active Comparator|Active Group|Patients randomized to the active treatment group will receive CardioCell consist 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin); 15 000 000 via common femoral artery injection and 15 000 000 via intramuscular injections above the knee (ATK, 6 injection sites) and below the knee (BTK, 6 injection sites).
2875139|NCT03423732|Placebo Comparator|Control Group|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) injections in the same manner.
2875140|NCT03423719|Experimental|Verum|This arm receives 2 x 450 mg capsules of Fiit-ns®, a blend of polyphenol-rich fruit and vegetables extracts, daily for 16 weeks.
2875141|NCT03423719|Placebo Comparator|Placebo|This arm receives 2 x 450 mg capsules of Placebo, containing maltodextrin only, daily for 16 weeks.
2875142|NCT03423706|Experimental|new model of haplo-HSCT|use the new model of haplo-HSCT to treat the r/r B-ALL patients matching the inclusion criterion
2875143|NCT03423693||Asthma with SAO+|Asthmatic patients with RV/TLC > or = 40
2875144|NCT03423693||Asthma with SAO-|Asthmatic patients with RV/TLC < 40
2875145|NCT03423693||ACO|Asthmatic patients with smoking > or = 10 pack years who have persistent airway obstruction (post-BD FEV1/FVC < 0.7) or COPD patients who have bronchodilator (BD) reversibility (absolute increase in FEV1 > or = 200 ml and FEV1% > or =12% after BD)
2875146|NCT03423693||COPD|Patients with history of smoking > or = 10 pack year with post-BD FEV1/FVC < 0.7 and negative BD reversibility (absolute increase in FEV1 < 200 ml and FEV1% <12% after BD)
2875147|NCT03423680|Experimental|Abilify (Tablet)|
2875148|NCT03423680|Placebo Comparator|Placebo of Abilify (Tablet)|
2875149|NCT03423667|Experimental|N-acetylcysteine|
2875150|NCT03423667|Placebo Comparator|Lactose powder|
2875151|NCT03423654|Experimental|Training Group|Spatial training
2875152|NCT03423654|Other|Control Group|Letter number matching
2875153|NCT03423641||Direct Acting Antivirals|Patients who receive a direct acting antiviral enter the DAA cohort at the time of initiation of the drug.
2875154|NCT03423641||Comparison|The exposure time of patients who have not received a direct acting antiviral (patients can change from the comparison to the DAA group once they receive the medication)
2875155|NCT03423628|Experimental|AZD1390 + Radiation Therapy|AZD1390 + Radiation Therapy
2875180|NCT03423446|Experimental|Healthy Control|Up to 8 healthy control subjects with normal hepatic function
2875199|NCT03423329|Experimental|Group A|"Intervention:Drug: Brufen & Placebo~Brufen syrup 10 ml, once, 1 hour before local anesthesia"
2875200|NCT03423329|Experimental|Group B|"Intervention: Drug: Cital and Placebo~Cital Syrup 10 ml, once 1 hour before Local anesthesia"
2875201|NCT03423329|Placebo Comparator|Group C|"Intervention: Drug: Placebo~Other names:~(Placebo for Brufen) (Placebo for Cital)~Sansovit Iron Multivitamin syrup, an orange-coloured, orange-flavoured"
2875202|NCT03423316|No Intervention|Healthy Controls|
2875545|NCT03421158|Experimental|Oral Sucrose|Newborns were given oral sucrose during the procedure
2875156|NCT03423615|Experimental|CHHIP Arm|"All enrolled students in schools in the CHHIP Arm were eligible to receive the CHHIP intervention. The CHHIP intervention was delivered by lay fieldworkers (SHAs). Intervention activities included:~Health Education: activity-based curriculum with lessons delivered once per week. Units include hygiene, nutrition, safety, disease prevention& management, and social, emotional, and behavior development.~Basic Primary Health Services: school-based treatment including deworming and iron supplementation; screening and referral programs including growth monitoring, well-child exam, vision screening, epilepsy screening, and oral health; psychosocial and counseling support for students with atypical behaviors.~Health School Environment: improvements to physical infrastructure including latrines and water systems; modeling of positive behavior reinforcement, inclusive learning environment, and avoidance of corporal punishment."
2875157|NCT03423615|No Intervention|Comparison Arm|All enrolled students in schools in the Comparison Arm received school health activities as were routinely available in their school, through their curriculum, or through special events.
2875158|NCT03423602|Experimental|Investigational device|PerQseal® closure system
2875159|NCT03423589|Experimental|VSL#3|Participants will be given the probiotic supplement VSL#3, a commercially available product. VSL#3 is taken by mouth, either once or twice daily, and is dispensed in sachets, each containing 450 billion colony forming units of bacterial strains. Participants will undergo a screening visit. They will be asked to provide a stool sample by the next visit. Within 3 weeks they will return with a stool sample and receive the VSL#3 sachets as well as another stool collection kit. After 6 weeks of taking VSL#3, they will return for their final visit, with their stool sample. Blood will be drawn at the second and third visits.
2875160|NCT03423576|Experimental|Intervention|comprehensive patient-centered outpatient health service with multiple components. These components included the addition of a case-manager, structured interventions to improve patient education and adherence to therapy, psychological counselling, social services, and exercise advice. For each Patient, relevant components were identified and a written Intervention plan was negotiated and signed.
2875161|NCT03423576|No Intervention|Control|Standard care
2875162|NCT03423563|Experimental|Flexible fiberoptic bronchoscopy|Fiberoptic intubation has been considered for a long time the gold standard technique for intubation when there is anticipated or known difficult airway or as a rescue device in can't intubate but can ventilate scenarios
2875163|NCT03423563|Experimental|Fexible intubation video endoscopy|Video-assisted techniques allow to indirectly visualize the laryngeal structures with fiber optical or camera chip technique and to show the video picture on an external or built-in monitor
2875164|NCT03423550|Active Comparator|New technique group|
2875165|NCT03423550|No Intervention|Conventional group|
2875166|NCT03423537|Experimental|Group 1 [HCG (+) group]|"Group 1 will indicate the application of the protocol by adding hCG with the initiation of standard GnRH agonist protocol for IVF / ICSI with rFSH"
2875167|NCT03423537|Placebo Comparator|Group 2 [placebo]|"Group 2 will indicate the application of the standard GnRH agonist protocol without the addition of hCG, but placebo, instead"
2875168|NCT03423524|Experimental|Arm: Investigational Device|"Implantation of monofocal intraocular lens (IOL) Micropure 1.2.3. consisting of hydrophobic material"
2875169|NCT03423511|Experimental|MiStent II Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
2875170|NCT03423511|Active Comparator|Xience or Promus Coronary Artery Stents|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
2875171|NCT03423498|Experimental|groups with toe-spread-out exercise|This arm included individuals with hallux valgus (research group A) and without deformation (research group B), who were patients of Department of Rehabilitation, Poznan University of Medical Sciences. They performed the toe-spread-out exercises for 14 days and were examined twice: before and after exercises. The examination of participants included a surface electromyography, electroneurography and goniometer tests to measure the range of motion in the hallux joints.
2875172|NCT03423498|No Intervention|control group|This arm included individuals with hallux valgus deformity from the control group which did not undergo any therapy of hallux. They were patients of Department of Rehabilitation as well. These participants were examined twice at an interval of 14 days in the same way as the patients from experimental arm.
2875173|NCT03423485|Experimental|Study arm|Anastomosis is performed according to Standard of Care with the addition of the CG-100 Intraluminal Bypass Device
2875174|NCT03423472|Experimental|Full intervention|Healthy Baby Toolkit (HBT) in addition to Orange Fleshed Sweet Potato (OFSP) agriculture promotion and education on family nutrition, with special emphasis on women and children < 2y; especially diet diversity and vitamin A intake
2875175|NCT03423472|Active Comparator|Partial intervention|Orange Fleshed Sweet Potato (OFSP) agriculture promotion and education on family nutrition, with special emphasis on women and children < 2y; especially diet diversity and vitamin A intake
2875176|NCT03423472|Other|Control|Government standard of care for nutrition education through the Health Development Army
2875177|NCT03423459||CT Cohort|"Compare the rate of ≥mild PVL in patients with none/mild versus moderate/severe LVOT calcification.~Comparison of the rate of PPM implantation in patients with none/mild versus moderate/severe LVOT calcification.~Determine how the Evolut PRO conforms to LVOT calcification.~Compare the impact of LVOT calcification on the implantation depth of the Evolut PRO.~Analyze the interaction and geometry of the Evolut PRO in patients with moderate/severe LVOT calcification.~Assess for leaflet thickening, subclinical leaflet thrombosis and/or restricted leaflet motion 30-60 days after TAVR."
2875178|NCT03423459||Non-CT Cohort|"Compare the rate of ≥mild PVL with the Evolut PRO with a propensity score matched cohort of historical control subjects who underwent TAVR with the Evolut R and/or CoreValve within the MedStar Health System.~Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict ≥mild PVL.~Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict PPM implantation."
2875179|NCT03423446|Experimental|Severe Hepatic Impairment|Up to 8 subjects with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15 points)
2875181|NCT03423433|No Intervention|Control condition|"This condition will recruit fifteen chronic stroke sufferers. In the first visit, participants will undertake five Stroop familiarisation tests alongside baseline pulse wave analysis (PWA) and pulse wave velocity (PWV). Participants will practice this movement before maximum voluntary contractions (MVC) will be measured using electromyography.~During the second two visits, participants will have either undergo a 180 minute seated protocol or a 180 minute heel raising protocol (10 heel raises per 10 minutes) After 10, 30, 90, 120, 150 and 180 minutes in both protocols, PWA, PWV and Stroop task results will be recorded. NIRS will measure peripheral and cerebral oxygen perfusion throughout the 180 minutes. EMG will record muscle activation during heel raises after each 30 minutes.~Ten weeks after these sessions have been completed, participants will return to the laboratory for follow-up a session assessing resting measures in an identical protocol to the first visit."
2875182|NCT03423433|Experimental|Experimental (heel raise) condition|"This condition will recruit fifteen chronic stroke sufferers. In the first visit, participants will undertake five Stroop familiarisation tests alongside baseline pulse wave analysis (PWA) and pulse wave velocity (PWV). Participants will practice this movement before maximum voluntary contractions (MVC) will be measured using electromyography. During the second two visits, participants will have undergo a 180 minute seated or a 180 minute heel raise protocol (10 heel raises per 10 minutes) After 10, 30, 90, 120, 150 and 180 minutes, PWA, PWV and Stroop task results will be recorded. NIRS will measure peripheral and cerebral oxygen perfusion throughout. EMG will record muscle activation during heel raises after each 30 minutes.~Participants in this arm will be prescribed a ten-week heel-raise programme involving hourly heel raises. Ten weeks later, participants will return to the laboratory for follow-up sessions assessing resting measures in an identical protocol to the first visit."
2875183|NCT03423407|Experimental|PET/MR|"Participants will be scanned on a PET-MRI scanner which is FDA-approved and will operate within FDA-approved guidelines.~Participants will be asked to lie still within the scanner for up to 90 minutes"
2875184|NCT03423394|Experimental|Motivational Enhancement Therapy|The MET intervention will consist of three 45-90 minute telephone delivered sessions that will be staggered to occur 1 week, 1 month, and 2 months after the baseline assessment.
2875185|NCT03423394|Active Comparator|Treatment as Usual|The treatment as usual (TAU) condition was selected to mirror the existing process in the Army and Air Force for identifying and encouraging treatment for personnel who screen positive for PTSD.
2875186|NCT03423381|Experimental|Cereal product 1|Cereal based müsli no. 1, made from typical Swedish cereals. All experimental products have different types and amounts of dietary fibre (df). The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
2875187|NCT03423381|Experimental|Cereal product 2|Cereal based muesli no. 2 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
2875188|NCT03423381|Experimental|Cereal product 3|Cereal based muesli no.3 made from typical Swedish cereals. All experimental products have different types and amounts of df.The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
2875189|NCT03423381|Experimental|Cereal product 4|Cereal based muesli no. 4 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
2875190|NCT03423381|Experimental|Cereal product 5|Cereal based muesli no. 5 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
2875191|NCT03423381|Placebo Comparator|Control product|A cereal based product with low concentrations of df. The control portion is consumed as a single evening meal prior to determinations of test variables in the morning.
2875192|NCT03423368|Experimental|Libramed|Each patient will be admistered 6 tablets/day (3 tablets before lunch, 3 tablets before dinner) of Libramed for 30 days
2875193|NCT03423368|Placebo Comparator|Placebo|Each patient will be admistered 6 tablets/day (3 tablets before lunch, 3 tablets before dinner) of placebo for 30 days
2875194|NCT03423355|Active Comparator|Dapagliflozin|"Treatment with the SGLT2 inhibitor dapagliflozin will be compared to matching placebo and the reference HCT in a parallel design. The study will be performed under double-blinded conditions with respect to treatment with dapagliflozin or matching placebo.~In this study, the effect of dapagliflozin on EPO levels, physical fitness and biomarkers for erythropoiesis and hemodynamic regulation are evaluated and compared to that of matching placebo and the diuretic and anti-hypertensive drug HCT."
2875195|NCT03423355|Placebo Comparator|Placebo dapagliflozin|"Treatment with the SGLT2 inhibitor dapagliflozin will be compared to matching placebo and the reference HCT in a parallel design. The study will be performed under double-blinded conditions with respect to treatment with dapagliflozin or matching placebo.~In this study, the effect of dapagliflozin on EPO levels, physical fitness and biomarkers for erythropoiesis and hemodynamic regulation are evaluated and compared to that of matching placebo and the diuretic and anti-hypertensive drug HCT."
2875196|NCT03423355|Other|Hydrochlorothiazide|"Treatment with the SGLT2 inhibitor dapagliflozin will be compared to matching placebo and the reference HCT in a parallel design. However, treatment in the reference group will not be blinded.~In this study, the effect of dapagliflozin on EPO levels, physical fitness and biomarkers for erythropoiesis and hemodynamic regulation are evaluated and compared to that of matching placebo and the diuretic and anti-hypertensive drug HCT."
2875197|NCT03423342|Experimental|Nicotinamide Riboside|Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.
2875198|NCT03423342|Placebo Comparator|Placebo|Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.
2896722|NCT03272009|Active Comparator|Treatment F|oral Entecavir
2875203|NCT03423316|No Intervention|Age-Matched Controls|Subjects without PAD who have the same average age as the PAD patients
2875204|NCT03423316|Experimental|PAD Patients|Patients with PAD. Approximately 75% of PAD patients will be enrolled in the 12-week exercise therapy program.
2875205|NCT03423303|Experimental|Screening arm|Invitation to prostate cancer screening and questionnaires.
2875206|NCT03423303|No Intervention|Control arm|Registry-based follow-up and a questionnaire.
2875207|NCT03423277|Experimental|Easy Stretch Toolkit|All participants will be using one or more of devices for 60 minutes 2 times per day for the duration of the 12 week trial. Prescriptive instructions for specific intraoral placements will be given based on the participant's deficit areas.
2875208|NCT03423264|Experimental|Gabapentin|Participants randomized to this arm will receive gabapentin beginning on evening of the first day of radiation treatment at a dose of 600 mg. Gabapentin will continue to be taken twice a day (morning and evening) for the next 4 days of radiation treatment at increasing doses (up to 900 mg). Participants will continue to receive standard best supportive care medications as per their treating physician's recommendation.
2875209|NCT03423264|No Intervention|Supportive Care Only|Participants will receive standard best supportive care medications as per their treating physician's recommendation.
2875210|NCT03423238|Active Comparator|Rehab Only|Patients will be randomized to Rehab only using a randomization scheme with blocking stratified by sex and obesity severity (BMI<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation, which includes meeting with dietitian, exercise, health education, and exercise compliance.
2875211|NCT03423238|Experimental|Rehab+Weight Loss (WL)|Patients will be randomized to Rehab+WL using a randomization scheme with blocking stratified by sex and obesity severity (BMI<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation in addition to a weight-loss intervention, which includes meeting with dietitian, exercise, health education, and exercise compliance, calorie-restricted diet, behavioral modification, and weight-loss compliance.
2875212|NCT03423225|Experimental|ADVAGRAF®|One arm: Treatment conversion will take placefrom twice daily tacrolimus to once daily tacrolimus (ADVAGRAF) 3 months after transplant in new liver transplant recipients.
2875213|NCT03423212|Experimental|Experimental Condition|Participants assigned to the experimental arm will be enrolled in the 2-session Just Do You intervention described elsewhere.
2875214|NCT03423212|No Intervention|Treatment as Usual Condition|Participants assigned to treatment as usual will receive the PROS program that is standard in the agencies without any additional intervention.
2875215|NCT03423212|Active Comparator|Active Control Condition|Participants assigned to the active control condition will receive the PROS program that is standard in the agencies, and a two-session curriculum on maintaining healthy relationships, which is an identified issue for the population.
2875216|NCT03423199|Experimental|Palbociclib + Tamoxifen ± Goserelin|Palbociclib 125 mg/day, orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
2875217|NCT03423199|Active Comparator|Placebo + Tamoxifen ± Goserelin|Placebo orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
2875218|NCT03423186|Experimental|Dose group 1|SOBI003 dose 3 mg/kg once weekly for 24 weeks
2875219|NCT03423186|Experimental|Dose group 2|SOBI003 dose to be decided once weekly for 24 weeks
2875220|NCT03423186|Experimental|Dose group 3|SOBI003 dose to be decided once weekly for 24 weeks
2875221|NCT03423173|Experimental|TDV Lot 1|TDV, Lot 1, 0.5 mL, injection, subcutaneously (first dose), once on Day 1, followed by TDV, Lot 1, 0.5 mL, injection, subcutaneously, once on Day 90 (second dose).
2875222|NCT03423173|Experimental|TDV Lot 2|TDV, Lot 2, 0.5 mL, injection, subcutaneously (first dose), once on Day 1, followed by TDV, Lot 2, 0.5 mL, injection, subcutaneously, once on Day 90 (second dose).
2875223|NCT03423173|Experimental|TDV Lot 3|TDV, Lot 3, 0.5 mL, injection, subcutaneously (first dose), once on Day 1, followed by TDV, Lot 3, 0.5 mL, injection, subcutaneously, once on Day 90 (second dose).
2875224|NCT03423173|Placebo Comparator|Placebo|Normal Saline (0.9% NaCl) 0.5 mL injection, subcutaneously (first dose), once on Day 1, followed by TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 90 (second dose).
2875225|NCT03423160||Autism|Right-handed children, ages 8.0-12.9, diagnosed with high-functioning ASD (and no co-morbid conditions, excluding anxiety disorders)
2875226|NCT03423160||Control|Right-handed children, ages 8.0-12.9, with no neurological or psychiatric diagnoses, currently or by history
2875227|NCT03423147|Experimental|Chlorhexidine gluconate vaginal scrub and cloth|Patients will have a 2% chlorhexidine gluconate cloth applied to their abdomen as well as 4% chlorhexidine gluconate vaginal scrub applied as a vaginal cleanse in the operating room prior to cesarean section
2875228|NCT03423147|Active Comparator|Standard Treatment|Patients who are not in the intervention arm will receive the standard of care prior to a cesarean section. In the operating room the patient will receive an abdominal cleanse with 2% Chloraprep solution (2% chlorhexidine gluconate) in addition to routine IV antibiotics.
2875229|NCT03423134|Experimental|Test of new adhesive strip|A new adhesive strip will be tested in this investigation
2875230|NCT03423121|Experimental|TUDCA Treatment|Tauroursodeoxycholic acid (Taurolite) 250 mg four capsules by mouth, twice daily for 16 weeks.
2875231|NCT03423121|Placebo Comparator|Placebo oral capsule|Placebo oral capsule four capsules by mouth, twice daily for 16 weeks.
2875232|NCT03423108|No Intervention|Usual care|Participants randomized to this group will continue their usual care practices, without being intervened by the study.
2875233|NCT03423108|Experimental|G150|Participants randomized to this group will be enrolled to a 150 min/week structured and supervised exercise training. The program consists of 3 sessions in a week, each of these lasting 50 minutes. The session will be composed of aerobic training (25 minutes at 60-75% of HRmax) and strength training (25 minutes, 8 whole-body exercises at up to 8-12 maximal repetitions).
2875234|NCT03423108|Experimental|G300|Participants randomized to this group will be enrolled to the same structural settings of G150 group (type of exercise, exercise intensity and weekly frequency). They will receive twice the G150 group dose's. To do so, each session will last 100 minutes (50 minutes of aerobic exercise training and 50 minutes of strength training).
2875310|NCT03422666|Experimental|Teduglutide|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose
2875235|NCT03423095|Placebo Comparator|Active Jaw Exercise with Relaxation|Participants randomized to this arm will complete active jaw exercises and visualization relaxation exercise (control group).
2875236|NCT03423095|Active Comparator|Active Tongue Exercise|Participants randomized to this arm will complete active tongue exercises only.
2875237|NCT03423095|Experimental|Active Tongue Exercise + Mental Practice|Participants randomized to this arm will complete active tongue exercises and mental practice of tongue exercise via motor imagery.
2875238|NCT03423095|Experimental|Mental Practice Tongue Exercise|Participants randomized to this arm will complete mental practice of tongue exercise via motor imagery only.
2875239|NCT03423082|Experimental|18F fluciclovine PET scan|Subjects with recently biopsy-proven malignancy of the cervix or uterus undergo an 18F fluciclovine PET scan on a hybrid PET/MRI scanner after they have completed a standard-of-care F-18 FDG PET/CT study.
2875240|NCT03423069|Experimental|Diet low in FODMAPs|Diet low in FODMAPs (diet A) during 12 weeks (with intermediate nutritional checks every 4 weeks) before returning to the final study visit.
2875241|NCT03423069|Active Comparator|Specific dietary advice for IBS|Dietary advice for IBS (diet B) during 12 weeks (with intermediate nutritional checks every 4 weeks) before returning to the final study visit.
2875242|NCT03423056|Experimental|Preoperative exercise program|"The individualized aerobic training program will be developed according to Karvonem's equation . It will programmed in 3 sessions/week (not in row) during 4 weeks.~Each 50-minutes session will be organized in three phases: warm up, central and back to calm. The heart rate target will be prescribed as follows:~Week 1: heart rate target: 50% of maximum heart rate Week 2: heart rate target: 60% of maximum heart rate Week 3: heart rate target: 70% of maximum heart rate Week 4: heart rate target: 60% of maximum heart rate The aerobic exercise will be carried on a treadmill or in a stationary bicycle, according to the patient's preferences and will be supervised by a physical therapist."
2875243|NCT03423043||Distal Radius Fracture Patients|Adult patients who have sustained a Distal Radius Fracture.
2875244|NCT03423030|Experimental|Panel A - Active|N = 6, 10 mg then 40 mg of PBTZ169 Formulation
2875245|NCT03423030|Placebo Comparator|Panel A - Placebo|N = 2, 10 mg then 40 mg of matching placebo
2875246|NCT03423030|Experimental|Panel B - Active|N = 6, 20 mg then 80 mg of PBTZ169 Formulation
2875247|NCT03423030|Placebo Comparator|Panel B - Placebo|N = 2, 20 mg then 80 mg of matching placebo
2875248|NCT03423030|Experimental|Panel C - Active|N = 6, First dosing of Panel C with 160 mg PBTZ169 Formulation then Second dosing of Panel C with 160 mg PBTZ169 Native Crystalline Powder (NCP)
2875249|NCT03423030|Active Comparator|Panel C - Placebo|N = 2, 160 mg of matching placebo for the two interventions
2875250|NCT03423030|Experimental|Panel D - Active|N = 6, First dosing of Panel D with 320 mg PBTZ169 Formulation then Second dosing of Panel D with 320 mg PBTZ169 Native Crystalline Powder (NCP)
2875251|NCT03423030|Active Comparator|Panel D - Placebo|N = 2, 320 mg of matching placebo for the two interventions
2875252|NCT03423017|Other|Pierre Robin sequence|"Infants with PRS : retrognathism, glossoptosis, cleft palate~Group 1a : isolated PRS Group 1b : PRS with bone disease or collagen disease (Stickler) Group 1c : syndromic PRS or associated PRS without bone disease or collagen disease"
2875253|NCT03423017|Other|Superior airway obstruction, AWO|Infants with AWO : laryngomalacia, tracheal stenosis, laryngeal stenosis, others etiology
2875254|NCT03423017|Other|Healthy infants|Healthy infants : siblings of sudden unexpected death of the infant
2875255|NCT03423004|Experimental|Patient with lesional skin|the sample will be taken by superficial cutaneous biopsy in psoriasic patients
2875256|NCT03423004|No Intervention|Patients with healthy skin|the skin will be recovered during a surgical procedure (surgical waste) for patients who will not be opposed
2875257|NCT03422991|Other|Congestive Heart Failure patients Cohort|Cluster of patients with congestive heart failure NYHA ≥2, with at least one cardiac decompensation, NT-proBNP (N-terminal pro-brain natriuretic peptide) > 500 ng/l. Will be followed during 18 months.
2875258|NCT03422978|Sham Comparator|Saline bolus|10mL normal saline solution administered intravenously over 60 seconds starting after intubation.
2875259|NCT03422978|Experimental|Dexmedetomidine 0.25 mcg/kg|0.25 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
2875260|NCT03422978|Experimental|Dexmedetomidine 0.50 mcg/kg|0.50 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
2875261|NCT03422978|Experimental|Dexmedetomidine 1.00 mcg/kg|1.00 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
2875262|NCT03422965|Active Comparator|Type 1 Diabetes Mellitus|Cohort of Type 1 DM patients
2875263|NCT03422965|Sham Comparator|Healthy controls|Cohort of Healthy controls
2875264|NCT03422939||Less experienced dietitians|There was no intervention, but we conducted separate analyses to identify differences according to the level of experience of the dietician. We used the median number of years of professional experience (median=8) to split the sample and create two subgroups: 1) less experienced dieticians (less than 9 years of experience; n= 225)
2875265|NCT03422939||More experienced dietitians|and 2) more experienced dieticians (9 years of experience or more; n=215).
2875266|NCT03422926|Experimental|Intervention|Social marketing messaging campaign
2875267|NCT03422926|No Intervention|Control|No messaging campaign
2875268|NCT03422913|Experimental|CLCVP Group|Controlled low central venous pressure(CLCVP) will be performed combined with intraoperative combined hilar intermittent (Pringle method)
2875269|NCT03422913|No Intervention|Control Group|Only intraoperative combined hilar intermittent (Pringle method) will be performed
2875270|NCT03422900|Experimental|Specific Diabetes Formula|"Diabetes-Specific Enteral Formula:~Caloric density: 1,0 kcal/ml~Energy: 100 kcal~Carbohydrates: 10,1 g/100 ml;~Fat: 4,5 g/100 ml~Prot: 3,8 g/100 ml~Osmolarity: 345 mOsm/l~Fiber: 1,78 g/100 ml (80% soluble; 20% insoluble)."
2875271|NCT03422900|Active Comparator|Standard Formula|"Standard Enteral Formula:~Caloric density: 1,0 kcal/ml~Energy: 100 kcal~Carbohydrates: 13,8 g/100 ml;~Fat: 3,4 g/100 ml~Prot: 3,8 g/100 ml~Osmolarity: 220 mOsm/l~Fiber: 0 g/100 ml"
2875272|NCT03422887|Active Comparator|flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg
2875273|NCT03422887|Experimental|nalbuphine|nalbuphine intraoperative administration 0.1mg/kg
2875274|NCT03422887|Experimental|nalbuphine and flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg and nalbuphine intraoperative administration 0.1mg/kg
2875275|NCT03422874|Experimental|Nelfinavir plus MLN9708|"Both Nelfinavir and MLN9708 will be given orally (by mouth). MLN9708 will be given as 3 mg orally twice weekly. Study drugs will be administered on 21-day treatment cycles. All cycles are 21 days.~During the first cycle of MLN9708 only will initially be administered orally at a fixed dose of 3mg twice weekly for 2 weeks, on Mondays and Thursdays during this treatment cycle. During the third week there will be no study combination drug therapy(for Cycle 1 only). During Cycles 2 and 3, MLN9708 administered twice weekly on Mondays and Thursdays for the first 2 weeks of Cycles 2 and 3. Nelfinavir (escalating cohorts [1250mg, 1875mg, 2500mg, 3125mg]) will be administered orally twice daily in the dose cohorts listed."
2875276|NCT03422861|Active Comparator|Nabilone Treatment|Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and nabilone as per protocol
2875277|NCT03422861|Placebo Comparator|Placebo Treatment|Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and placebo
2875278|NCT03422848|Active Comparator|Water intervention arm|The water intervention group will increase their habitual daily water intake with 1.5 L of tap water. Furthermore they will receive general life style advice (general oral and written advice on diet and physical activity).
2875279|NCT03422848|Other|Control arm|Control group that will receive general life style advice (general oral and written advice on diet and physical activity).
2875280|NCT03422835|Active Comparator|R-TME|Robotic total mesentery excision surgery for rectal cancer.
2875281|NCT03422835|Experimental|R-TaTME|Robotic transanal total mesentery excision surgery for rectal cancer.
2875282|NCT03422822|Experimental|PF-04965842 100 mg|
2875283|NCT03422822|Experimental|PF-04965842 200 mg|
2875284|NCT03422796|Active Comparator|Sumatriptan|headache is induced with Cilostazol. This headache is treated double-blinded with 6mg/ml sumatriptan
2875285|NCT03422796|Placebo Comparator|Placebo|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placeb
2875286|NCT03422783|Experimental|Included patients|There is only one arm in this study. Intervention will be electrical forearm stimulus under general anesthesia and the response of NOL index following this stimulus and its correlation with postoperative parameters such as pain and opioid consumption in post anesthesia care unit.
2875287|NCT03422770|Other|Mild aortic stenosis|25 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.
2875288|NCT03422770|Other|Moderate aortic stenosis|25 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.
2875289|NCT03422770|Other|Severe aortic stenosis|50 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.
2875290|NCT03422770|Other|Controls|100 subjects, all undergoing echocardiography and blood test, 30 undergoing MRI.
2875291|NCT03422757|Experimental|adaptive DBS|adaptive Deep Brain Stimulation, by AlphaDBSvext.
2875292|NCT03422757|Active Comparator|conventional DBS|conventional Deep Brain Stimulation, by AlphaDBSvext.
2875293|NCT03422744|Experimental|patient with peripheral lung lesion|"Patient presenting a peripheral lung lesion seen at Ct-scan but invisible at simple endoscopy.~Intervention : trans bronchial biopsy guided by echo-endoscopic miniprobes.~Intervention: If first intervention doesn't give a diagnosis we get cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control"
2875294|NCT03422731||Cohort I TMLI+FLT/TMLI|Patients may undergo optional fluorothymidine F-18 PET scan over 2 hours at baseline, and on days -1, 30, and 60. Patients undergo DECT and water-fat MRI scan over 30 minutes at baseline, on days -1, 30, 60, and 180, and at years 1 and 2. Patients also undergo collection of bone marrow and blood samples at baseline, on days -4, -1, 30, 60,100, and 180, and at years 1 and 2; Patients undergo fluorothymidine F-18 PET, DECT, water-fat MRI, and collection of bone marrow and blood samples as in TMLI+FLT
2875295|NCT03422731||Cohort TBI|Patients undergo DECT and water-fat MRI scan over 30 minutes at baseline and 1 year. Patients undergo collection of bone marrow and blood samples at baseline, on days 30 and 100, and at 1 year.
2875296|NCT03422718|Experimental|Arm 1|No healthy behavior texts BP Monitoring Weekly Via Text Messaging No physician appointment and transportation scheduling
2875297|NCT03422718|Experimental|Arm 2|Healthy Behavior Texts BP Monitoring Weekly Via Text Messaging No physician appointment and transportation scheduling
2875298|NCT03422718|Experimental|Arm 3|No healthy behavior texts BP Monitoring Daily Via Text Messaging No physician appointment and transportation scheduling
2875299|NCT03422718|Experimental|Arm 4|Healthy Behavior Texts BP Monitoring Daily Via Text Messaging No physician appointment and transportation scheduling
2875300|NCT03422718|Experimental|Arm 5|No healthy behavior texts BP Monitoring Weekly Via Text Messaging Physician appointment and transportation scheduling
2875301|NCT03422718|Experimental|Arm 6|Healthy Behavior Texts BP Monitoring Weekly Via Text Messaging Physician appointment and transportation scheduling
2875302|NCT03422718|Experimental|Arm 7|No healthy behavior texts BP Monitoring Daily Via Text Messaging Physician appointment and transportation scheduling
2875303|NCT03422718|Experimental|Arm 8|Healthy Behavior Texts BP Monitoring Daily Via Text Messaging Physician appointment and transportation scheduling
2875304|NCT03422705|Sham Comparator|Standard of care|No intervention - no programming, no medical intervention.
2875305|NCT03422705|Experimental|Optimised programming|Optimised pacemaker programming to avoid right ventricular pacing.
2875306|NCT03422705|Experimental|Medical therapy|Lisinopril uptitrated to optimally tolerated dose.
2875307|NCT03422692|Experimental|BioXlude memebrane|Subjects in this arm will receive demineralized freeze dried bone allograft covered with BioXclude amnion-chorion membrane following tooth extraction
2875308|NCT03422692|Active Comparator|Mem-Lok|subjects in this arm will receive demineralized freeze dried bone allograft covered with Mem-Lok collagenous membrane following tooth extraction
2875309|NCT03422679|Experimental|CB-103|CB-103 capsules will be administered orally as a continuous once daily (QD) dosing during the treatment period of Part A (escalation) and Part B (expansion). The administration schedule may be adapted during dose escalation (e.g. twice-daily, intermittent dosing schedule) depending on the PK and safety signals that occur.
2875312|NCT03422653|Active Comparator|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
2875313|NCT03422653|Placebo Comparator|Placebo|IV Placebo administered after each dialysis session (3 times/week)
2875314|NCT03422640|Experimental|Treatment arm with apremilast|Open label arm treating frontal fibrosing alopecia with apremilast
2875315|NCT03422627|Experimental|Phase 1b|The phase 1b portion of this study will be conducted as a multiple ascending dose study. Each dosing cohort will consist of 3 subjects who will receive either weekly or biweekly AMG 592 plus protocol permitted background therapy for up to 52 weeks.
2875316|NCT03422627|Experimental|Phase 2|The phase 2 portion of this study will be conducted as a single arm, multi-center, open‑label trial in subjects with steroid refractory cGVHD. All subjects will receive the recommended phase 2 dose of AMG 592 for up to 52 plus protocol permitted background therapy for cGVHD.
2875317|NCT03422614||Patient|Patients with Primary Immunodeficiency
2875318|NCT03422614||Control|Healthy Controls
2875319|NCT03422601||3 months treatment|FOLFOX or CAPOX
2875320|NCT03422601||6 months treatment|FOLFOX or CAPOX
2875321|NCT03422588|Experimental|Intracorporeal|Totally laparoscopic right colectomy with intracorporeal anastomosis
2875322|NCT03422588|Active Comparator|Extracorporeal|Laparoscopic assisted right colectomy with extracorporeal anastomosis
2875323|NCT03422575|Experimental|Test|Etoricoxib 120Mg film-coated Tablet at single dose was given to subjects in this arm.
2875324|NCT03422575|Active Comparator|Reference|Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk) was given to subjects in this arm.
2875325|NCT03422562|Active Comparator|Probiotic|Florababy probiotic (0.5g per day) will be started at or after 72 hours of life and will be administered in 1ml sterile water prior to feed.
2875326|NCT03422562|No Intervention|Control|Standard of care arm
2875327|NCT03422549|Active Comparator|CPAP|"Nasal continuous positive airway pressure is a frequently used modality for non-invasive respiratory support in preterm infants.~Intervention: Device: Drager VN500 Ventilator"
2875328|NCT03422549|Active Comparator|NHFOV|"Non-invasive high-frequency ventilation is a relatively new modality that is being utilized to support preterm infants and prevent the need for invasive ventilation, but this particular modality has not been well studied to date.~Intervention: Device: Drager VN500 Ventilator"
2875329|NCT03422536|Experimental|Arm I (ficlatuzumab)|Patients receive ficlatuzumab IV over 30-60 minutes every 2 weeks in the absence of disease progression or unaccepted toxicity. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2875330|NCT03422536|Experimental|Arm II (ficlatuzumab, cetuximab)|Patients receive cetuximab IV over 60 -120 minutes and ficlatuzumab IV over 30-60 minutes every 2 weeks in the absence of disease progression or unaccepted toxicity. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2875331|NCT03422523|Active Comparator|Arm A Control|6 Cycles of R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) every 14 days.
2875332|NCT03422523|Experimental|Arm B Experimental|"1 Cycle of R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) followed by 5 cycles of R-GemOx with Atezolizumab every 14 days.~Followed by 8 maintenance cycles of Atezolizumab every 21 days."
2875333|NCT03422510|Experimental|Regimen 1 - CXA-10 75 mg|Subjects in regimen 1 will start at 75 mg and may stay at 75 mg or increase to 150 mg. This treatment arm stays at 75 mg.
2875334|NCT03422510|Experimental|Regimen 1 - CXA-10 150 mg|Subjects in regimen 1 will start at 75 mg and may stay at 75 mg or increase to 150 mg. This treatment arm increases to 150 mg.
2875335|NCT03422510|Experimental|Regimen 2 - CXA-10 150 mg|Subjects in regimen 2 will start at 150 mg and may stay at 150 mg or increase to 300 mg. This treatment arm stays at 150 mg.
2875336|NCT03422510|Experimental|Regimen 2 - CXA-10 300 mg|Subjects in regimen 2 will start at 150 mg and may stay at 150 mg or increase to 300 mg. This treatment arm increases to 300 mg.
2875337|NCT03422497||Male hip fracture surgery patients|Individuals 65 years or older admitted non-electively to hospital with a diagnosis of hip fracture who have surgery for their hip fracture and have male sex listed in their discharge abstract
2875338|NCT03422497||Female hip fracture surgery patients|Individuals 65 years or older admitted non-electively to hospital with a diagnosis of hip fracture who have surgery for their hip fracture and have female sex listed in their discharge abstract
2875339|NCT03422484||People with at least one medication error|People with at least one medication error at hospital admission
2875340|NCT03422484||People without medication error at hospital admission|People without medication error at hospital admission
2875341|NCT03422471|Experimental|Hypoglycemia|Participants are exposed to two 90 minute episodes of hypoglycemia (50 mg/dl) through a hyperinsulinemic hypoglycemic clamp. Baroreflex sensitivity will be assessed before, during, and 16 hours after the hypoglycemia.
2875342|NCT03422458|No Intervention|natural healing|no treatment and the coagulum within the socket is left open for spontaneous healing
2875343|NCT03422458|Experimental|Alveolar Ridge Preservation|A bone substitute material (BioOss Collagen) is placed within the bony envelope at least to the level of the palatal/ lingual bone plate. Subsequently, the soft tissue borders of the alveole is de-epithelialized using a diamond drill under copious irrigation with water. A collagen matrix (Mucograft Seal) is adapted to the soft tissue borders again using single interrupted sutures.
2875344|NCT03422458|Experimental|Immediate Implant + Alveolar Ridge Preservation|An immediate implant (Winsix) placement is performed. After implant insertion, a bone substitute material (BioOss Collagen) is placed in the gap occurred between the implant surface and the hard tissue walls of the extraction socket at least to the level of the palatal/ lingual bone plate. Subsequently, the soft tissue borders of the alveole is de-epithelialized using a diamond drill under copious irrigation with water. A collagen matrix (Mugograft Seal) is adapted to the soft tissue borders again using single interrupted sutures.
2875345|NCT03422445|Experimental|Apatinib plus Temozolomide|this trial is designed single arm. all the subjects enrolled will receive the experimental intervention,apatinib+temozolomide.
2875346|NCT03422432|Experimental|Group 1|Patients are identified pre-operatively on radiological imaging. Prophylactic HIPEC will be delivered intra-operatively, immediately after the resection of the primary tumour, and only if the patient is deemed well enough to receive the HIPEC.
2876274|NCT03416192|Active Comparator|High-flux HDF|Hemodiafiltration with standard high-flux filter
2875347|NCT03422432|Experimental|Group 2|Patients are identified post-operative based on histological findings. They will be counselled to receive prophylactic HIPEC only. If peritoneal nodules are found during surgery, these patients will be excluded from the study.
2875348|NCT03422419|Experimental|TIPS+Anticoagulation|
2875349|NCT03422419|Active Comparator|Anticoagulation|
2875350|NCT03422406||HH group|Group (participants) with pre-gestational history of undergoing hysterosalpingography (HSG) using an oil-soluble iodinated contrast medium
2875351|NCT03422406||Non-HH group|Group (participants) without pre-gestational history of undergoing hysterosalpingography (HSG)
2875352|NCT03422393|Experimental|venetoclax with high-dose ibrutinib|venetoclax with high-dose ibrutinib for the treatment of patients with chronic lymphocytic leukemia with progressive disease on single agent ibrutinib.
2875353|NCT03422380||Weight Loss Maintainers (WLM)|Individuals maintaining ≥13.6 kg (30 lb) weight loss for ≥1 year
2875354|NCT03422380||Normal Weight Controls (NC)|Individuals with normal weight whose BMI was matched to the current BMI of the WLM. NC had to be weight stable and not maintaining a weight loss of ≥13.6kg
2875355|NCT03422380||Controls with Overweight/Obesity (OC)|Individuals with overweight/obesity whose BMI was matched to the pre-weight loss maximum BMI of WLM. OC had to be weight stable and not maintaining a weight loss of ≥13.6kg
2875356|NCT03422367|Experimental|Treatment Group|The Treatment Group begins the JASPER intervention immediately upon enrollment in the study.
2875357|NCT03422367|Active Comparator|Delayed Treatment Group|The Delayed treatment group receives the same JASPER intervention as the Treatment Group, but after 6 months of receiving services in the community as usual.
2875358|NCT03422367|No Intervention|Control|Participants who are unable to complete JASPER due to age or time/distance commitment can enroll for single-time point participation
2875359|NCT03422354|Active Comparator|Paravertebral block Group|Patients will receive single shot L1-L2 PVB before undergoing GA Full monitoring with ECG , NIBP , puls oximetry will be applied. The level between L1 and L2 will be identified using U/S as well as transverse processes depth. Insertion points will be marked 2.5 cm lateral to the superior aspect of corresponding spinous processes, A 22-gauge Tuohy needle will be advanced until it made contact with the transverse process. The needle will be withdrawn slightly and walked off caudally to an additional depth of 1 cm. Once this is reached, 20cc of bupivacaine 0.25% will be injected slowly To control intraoperative blood pressure, fentanyl will be used as well as hypotensive drugs ( propranolol and nitroglycerine and the total dose will be recorded.
2875360|NCT03422354|Active Comparator|General anesthesia Group|"Patients will receive only GA All patients in the study will receive GA in the form of propofol 2mg/kg , atracurium 0.5ml/kg ,fentanyl 100 microgram in induction with ETT and mechanical ventilation , full monitoring with ECG , NIBP and puls oximetry will be applied.~To control intraoperative BP,fentanyl will be used as well as,hypotensive drugs ( propranolol and nitroglycerine and the total dose will be recorded.~To achieve post operative analgesia, intravenous paracetamol( 1gram ) and pethidine IV (50 mg ) will be added when needed"
2875361|NCT03422341|Experimental|GenePOC testing|"The swab will be used for the testing on the revogene using the GenePOC Strep A, C/G assay.~Intervention will be the Comparison between GenePOC CR and Reference Method."
2875362|NCT03422341|Active Comparator|Reference Method|"The swab will be used to detect the presence or absence of Strep A, C/G using standard microbiology method.~Intervention will be the Comparison between GenePOC CR and Reference Method."
2875363|NCT03422328|Experimental|Open-label macitentan 10 mg|10 mg macitentan film coated tablet, administered orally once daily
2875364|NCT03422315|Experimental|External control|propofol;injection;2mg/kg;single-dose
2875365|NCT03422302|Experimental|CPAP + DIBH|"During simulation visit before SBRT, participant has CT scans while breathing normally, then, participant has CT scans while using the breath-holding technique.~Following simulation visit, participant fitted with a CPAP device. Participant scheduled for final CT simulation while using CPAP 2-3 days later.~Based on the CT scan results, the doctor will decide if participant will use the breath-holding method or the CPAP device during SBRT therapy."
2875366|NCT03422289|Experimental|Myo-inositol + folic acid|2 g myo-inositol and 0.2 mg folic acid orally twice a day for three months, in order to induce ovulation.
2875367|NCT03422289|Experimental|Myo-inositol + folic a. + α-lactalbumin|2 g myo-inositol and 0.2 mg folic acid plus 50 mg α-lactalbumin, twice a day for three months in order to test if α-lactalbumin addition allows to induce ovulation
2875368|NCT03422276|Active Comparator|Rehabilitation Discharge Plan|Commission on Accreditation of Rehabilitation Facilities (CARF) standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury, including patient and family education, written discharge care instructions, and telephone follow up from a clinical provider.
2875369|NCT03422276|Active Comparator|Rehabilitation Transition Plan|Approximately 12 scheduled contacts from a TBI care manager 6 months following discharge in addition to the CARF standards for discharge.
2875370|NCT03422263||Patients with T2DM under new therapy with SGLT-2-Inhibitors|Patients with T2DM under new therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.
2875371|NCT03422263||Patients with T2DM without SGLT-2-Inhibitors.|Patients with T2DM without therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.
2875372|NCT03422263||Patients without T2DM manifesting similar comorbidities|Patients without T2DM manifesting similar comorbidities (Haemoglobin value, renal function, similar body mass index, cardiovascular disease profile)
2875373|NCT03422250|Experimental|Arm 1|Anodal tDCS of disconnected networks
2875374|NCT03422250|Experimental|Arm 2|Cathodal tDCS of hyper-connected networks
2875375|NCT03422237|Experimental|RSV ΔNS2/Δ1313/I1314L vaccine|Participants will receive a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
2875376|NCT03422237|Experimental|RSV 276 vaccine|Participants will receive a single dose of the RSV 276 vaccine at study entry (Day 0).
2875377|NCT03422237|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
2875378|NCT03422224||Good transplant function|
2875379|NCT03422224||Transplant Rejection|
2875380|NCT03422211||Sports orthopaedic surgery|Patients that recently underwent orthopaedic sports surgery performed by two separate surgeons
2875381|NCT03422198|Experimental|Short course vaginal cuff brachytherapy|Patients undergo short course vaginal cuff brachytherapy for 2 fractions with 1 week apart.
2875382|NCT03422198|Active Comparator|Vaginal cuff brachytherapy|Patients undergo standard of care vaginal cuff brachytherapy for 3-5 fractions over no more than 3 weeks.
2875383|NCT03422172|Experimental|Subjects receiving CAB|Eligible subjects will receive oral doses of CAB 30 milligrams (mg) tablets once daily for 4 weeks followed by IM injectable suspension of CAB LA 600 mg at Week 5, Week 9, Week 17, Week 25 and Week 33. There will be an approximately 1-week washout period between the last oral dose and the first injection of CAB at Week 5.
2875384|NCT03422159|Experimental|Treatment Arm|Based on published clinical data, vitamin C pharmacokinetic modeling, the package insert as well as the preliminary study by Marik et al, Vitamin C will be administered as an intravenous dose of 6gm per day divided in 4 equal doses. This dosage is reported to be devoid of any complications or side effects. Hydrocortisone will be dosed according to the consensus guidelines of the American College of Critical Care Medicine. Thiamine will be administered according to current recommendations in a dose of 200mg q 12 hourly. This will be continued for 4 days, or less if discharged from the ICU prior.
2875385|NCT03422159|Placebo Comparator|Placebo Arm|"Vitamin C placebo will consist of an identical bag of 100mL normal saline (but with no vitamin C) and will be labeled Vitamin C or Placebo. Placebo will be infused over 30 minutes as per the infusion instructions of the active vitamin and protected from light with a brown bag. Hydrocortisone placebo will be provided as an identical 3mL syringe as 1mL of normal saline.The thiamine placebo will be placed in a 50mL bag of Normal Saline labeled Thiamine 200mg or Placebo and run over 30 minutes (100mL/hr) Placebo patients will receive a matching 50mL bag of Normal Saline. All of these will be given for up to 4 days, or less if discharged from the ICU prior."
2875386|NCT03422146|Experimental|Cliradex® eyelid hygiene|Cliradex® is a novel over-the-counter eyelid wipe which contains the most active ingredient of TTO. Previous studies have shown the clinical and antimicrobial efficacy of eyelid hygiene with tea tree oil (TTO) in resolving chronic blepharitis.
2875387|NCT03422146|Other|I-Lid 'n Lash® Hygiene|Lid 'n Lash® Hygiene, is an over-the-counter eyelid wipe, without any medicinal ingredients,
2875388|NCT03422133||Pre-Implementation Phase|"Participants in this group (before the eHealth app is implemented in the PAU) will be English or French speaking patients, aged 18 and older, scheduled for major non-cardiac elective surgery.~Patients will be recruited using standardized procedures, and process and outcome measures will be recorded using the same tools and methods in both study phases to decrease the risk of measurement and selection bias."
2875389|NCT03422133||Post-Implementation Phase|Participants in this group (after the eHealth app is implemented in the PAU) will be English or French speaking patients, aged 18 and older, scheduled for major non-cardiac elective surgery.
2875390|NCT03422120||Healthy Donors|Healthy patients, without a diagnosis of cancer and age>40. The Natural Killer Cell Activity Assay (NKA) will be measured with a blood test.
2875391|NCT03422120||Colorectal Cancer Surgery Patients|Patients >40 years of age with a histologically confirmed diagnosis of primary colorectal cancer and a planned surgical resection of the primary tumour. The Natural Killer Cell Activity Assay (NKA) will be measured at various perioperative time points with a blood test.
2875392|NCT03422107||TAVI|Transcatheter Aortic Valve Implantation
2875393|NCT03422107||cAVR|Conventional Valve Replacement
2875394|NCT03422107||rCABG|minimally invasive coronary artery bypass graft
2875395|NCT03422107||cCABG|Conventional Coronary Artery Bypass Graft
2875396|NCT03422094|Experimental|Cohort A: NeoVax+Nivolumab (start at time of progression)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~Nivolumab 480 mg i.v. given on Day 1 of each cycle beginning at time of progression"
2875397|NCT03422094|Experimental|Cohort B: NeoVax+Nivolumab (start with Cycle 2)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~Nivolumab 480 mg i.v. given on Day 1 of each cycle beginning with Cycle 2 (start of boosting phase)"
2875398|NCT03422094|Experimental|Cohort C: NeoVax + Nivolumab (start with Cycle 1)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~Nivolumab 480 mg i.v. given on Day 1 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)"
2875399|NCT03422094|Experimental|Cohort D: NeoVax+Ipilimumab+Nivolumab (start with Cycle 3)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~Ipilimumab 1 mg/kg i.v. given on Days 1 and 22 of Cycle 1 (priming phase)~Nivolumab 480 mg i.v. given on Day 1 of Cycle 3 and then on Day 1 of each subsequent cycle"
2875400|NCT03422094|Experimental|Cohort E: NeoVax+Ipilimumab+Nivolumab (day 1&15 each cycle)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~Ipilimumab 1 mg/kg i.v. given every 6 weeks beginning on Day 1 of Cycle 1 (C1D1, C2D15, C4D1, C5D15, C7D1, C8D15 …)~Nivolumab 3 mg/kg i.v. given on Days 1 and 15 of each cycle (q2w) beginning on Day 1 of Cycle 1"
2875401|NCT03422081||growth hormone deficiency|
2875402|NCT03422081||small for gestational age|
2875403|NCT03422081||matched controls|
2875404|NCT03422068|Experimental|BI 1015550|
2875405|NCT03422068|Placebo Comparator|Placebo|
2875406|NCT03422055|Experimental|99mTc-Fucoidan SPECT|
2875407|NCT03422042|Active Comparator|Short duration of antibiotic|group A: will received intravenous antibiotic until the temperature is less than 37.8 c for 72 hours, then antibiotic is discontinued
2875408|NCT03422042|Active Comparator|Standard treatment of antibiotic|group B: will received intravenous antibiotic for 7 days, and followed by oral antibiotic for 7 days, regardless of body temperature
2875409|NCT03422029|Experimental|177Lu-Dotatate PRRT|177Lu-Dotatate A maximum of 8 cycles of 1000mCi 177Lu-Dotatate, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 8 cycles, every 8 weeks
2875410|NCT03422016||autistic spectrum disorder|intelligence quotient IQ>85 age 4-25yrs
2875411|NCT03422016||control|age 4-25yrs no eye disorder
2875412|NCT03422003|Experimental|Arm 1: Hypofractionation|16 fractions of radiation therapy (daily, Monday through Friday) to the chest wall with or without internal mammary nodes, and 15 fractions to the supraclavicular (with or without axillary) lymph nodes.
2876275|NCT03416179|Experimental|Arm A (Intensive Study)|Glasdegib + '7+3' Induction(s)
2875413|NCT03422003|Active Comparator|Arm 2: Conventional Radiation Therapy|25 fractions of radiation therapy (daily, Monday through Friday) to the chest wall with or without internal mammary nodes, and 23‐25 fractions to the supraclavicular (with or without axillary) lymph nodes.
2875414|NCT03421990||Group A|General anesthesia technique
2875415|NCT03421990||Group B|Regional anesthesia technique
2875416|NCT03421964|Active Comparator|Resilience/Adjustment Counseling|Intervention to promote resilience and adjustment (RAI) - The RAI was developed based upon considerable clinical experience and research review. The RAI is a structured approach to helping individuals after traumatic brain injury address issues related to resilience and adjustment to injury. The RAI is implemented in seven, 60-minute, in-person sessions.
2875417|NCT03421964|Experimental|Resilience/Adjustment Counseling with Booster Sessions|Intervention to promote resilience and adjustment (RAI) is implemented in seven, 60-minute, in-person sessions; however individuals within this study arm will receive three additional 60-minute, in-person sessions three months after completing the seven initial sessions. The three booster sessions provide an opportunity for individuals to review course content, consolidate gains, and discuss challenges.
2875418|NCT03421938|Experimental|Group 1 (Downhill Exercise Group)|This group will have downhill walking exercises with %10 slope.
2875419|NCT03421938|Experimental|Group 2 ( Uphill Exercise Group)|This group will have uphill walking exercises on the treadmill with %10 slope.
2875420|NCT03421925|Other|Divided mesh group|In this group, surgeon will use a mesh divided in to two legs in laparoscopic totally extraperitoneal repair
2875421|NCT03421925|Other|Non divided mesh group|In this group, surgeon will use a non divided mesh in laparoscopic totally extraperitoneal repair
2875422|NCT03421912|Experimental|Arm A : Cicaplast balm B5|Use of Cicaplast balm B5, 2 to 3 applications per day, since the first day of iEGFR treatment initiation for 30 days to avoid or limit appearance of cutaneous toxicities related to iEGFR treatment.
2875423|NCT03421912|Active Comparator|Arm B : Dexeryl|Use of Dexeryl, 2 to 3 applications per day, since de first day of iEGFR treatment initiation for 30 days to avoid or limit appearence of cutaneous toxicities related to iEGFR treatment.
2875424|NCT03421899||Genetic Parkinson's group|Those participants with Parkinson's disease and a genetic mutation known to cause or increase risk of Parkinson's disease (e.g. Parkin, PINK1, GBA or LRRK2)
2875425|NCT03421899||Idiopathic Parkinson's group|Those participants with Parkinson's disease but without a known genetic mutation known to cause or increase risk of Parkinson's disease
2875426|NCT03421899||Healthy control group|Those participants unaffected by Parkinson's disease
2875427|NCT03421886|Experimental|Aerodentis system|30 patients will be systematically assigned to the treatment group (wearing Aerodentis Device).
2875428|NCT03421886|Active Comparator|Invisalign clear aligner system|15 patients will be systematically assigned to the control group (wearing clear aligners).
2875429|NCT03421873||Intervention (Implementation) group|Chest pain patients enrolled during a 10 month period after a change in routine care, i.e. the implementation of a 0h/1h hs-cTnT protocol
2875430|NCT03421873||Control group|Chest pain patients managed at the 3 intervention EDs during the corresponding 10 months of the previous year (intervention hospitals acting as their own controls) as well as chest pain patients managed during the corresponding before-and-after period at EDs not implementing the protocol (concurrent controls).
2875431|NCT03421860|Active Comparator|ephedrine|will receive ephedrine :a bolus of 9 mg after SA once intervention: will receive complementary doses of ephedrine 6 mgto maintain systolic blood pressure above 80 % of baseline
2875432|NCT03421860|Active Comparator|phenylephrine|will receive Phenylephrine : a bolus of 100 mcg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
2875433|NCT03421860|Active Comparator|ondansetron|will receive ondansetron: a bolus of 8 mg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
2875434|NCT03421860|Active Comparator|norepinephrine|will receive noradrenaline (norepinephrine) a bolus of 0,25 mcg/kg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
2875435|NCT03421847||Major Depression Group|We will measure the vestibular activity of Major depression patients with Rotatory Test and electronystagmography
2875436|NCT03421847||Healthy Control Group|We will measure the vestibular activity of Healthy subjects with Rotatory Test and electronystagmography.
2875437|NCT03421834|Experimental|Prophylactic VT ablation prior to ICD implantation|
2875438|NCT03421834|Active Comparator|ICD implantation and optimal medical treatment|ICD implantation and optimal medical care until at least 2 appropriate ICD shock occurs or an arrhythmic storm and catheter ablation thereafter.
2875439|NCT03421821|Experimental|Subfascial Injection Group|30 ml of 0.33% ropivacaine was injected to subfascial.
2875440|NCT03421821|Active Comparator|Extrafascial Injection Group|30 ml of 0.33% ropivacaine was injected to extrafascial.
2875441|NCT03421808|Experimental|SYNC TMS|Patients will receive daily left prefrontal transcranial magnetic stimulation (TMS), 120% MT, 3000 pulses/session, for 30 sessions. They will have EEG and the TMS will be delivered at their individual alpha frequency (IAF) (8-12 Hz) and the first TMS pulse in each train of 40 pulses will be synchronized with the EEG so that the TMS pulse fires during the rising phase of the alpha rhythm.
2875442|NCT03421808|Active Comparator|Non-Sync TMS|Patients will receive daily left prefrontal transcranial Magnetic stimulation (TMS), 120% MT, 3000 pulses/session, for 30 sessions. They will have EEG and the TMS will be delivered at their individual alpha frequency (IAF) (8-12 Hz) and the first TMS pulse in each train of 40 pulses will NOT be synchronized with the EEG so that the TMS pulse fires during the rising phase of the alpha rhythm. This is the way conventional TMS is delivered now and is FDA approved.
2875443|NCT03421795|Experimental|Let's Talk About Pain Training|Participants complete pre-, post- and follow-up measures, and receive a pain training program. The pain assessment and management training will be based on a training previously developed and piloted by Genik et al. (2017). The training will be facilitated by the same researcher (L.G.) throughout the study.
2875546|NCT03421158|Experimental|Skin to skin contact|Newborns were placed in direct contact with their mothers during the procedure
2875547|NCT03421158|Experimental|Non-nutritive sucking|Newborns were given a pacifier to suck on during the procedure
2898232|NCT03260920|Experimental|Medium Dose|
2875444|NCT03421795|Sham Comparator|Family Centered Care Training|Participants complete all of the same measures as those in the intervention, but receive a training about family centered care. This training will be facilitated by Andrea Cross (PhD Candidate) from CanChild and will be related to the F-words of childhood disability (function, family, fitness, fun, friends, future; Rosenbaum & Gorter, 2012) .
2875445|NCT03421782|Experimental|Exercise - Arm I|Patients undergo POWER exercise intervention consisting of supervised exercise training sessions over 50 minutes every 7 days for a total of 12 sessions and 150 minutes of moderate-intensity exercise weekly for 12 weeks.
2875446|NCT03421782|Experimental|Exercise plus PROSPECT Cognitive Behavior Therapy (CBT)|Patients undergo POWER exercise intervention consisting of supervised exercise training sessions over 50 minutes every 7 days for a total of 12 sessions and 150 minutes of moderate-intensity exercise weekly for 12 weeks. Patients also undergo PROSPECT internet-based CBT intervention over 12 weeks.
2875447|NCT03421769|Experimental|EA and AMLK|Corneal epithelial autograft (EA) combined with allogeneic middle lamellar keratoplasty (AMLK) is used for the treatment of patients with severe ocular burns.
2875448|NCT03421769|Active Comparator|LA and AMLK|Limbal autograft (LA) combined with AMLK is used for the treatment of patients with severe ocular burns.
2875449|NCT03421756|Experimental|Non Myeloablative regimen (Alemtuzumab)|Sickle cell patient receives sibling donor peripheral blood stem cell transplant with non-myeloablative pre-transplant conditioning.
2875450|NCT03421743|Experimental|Inhaled molgramostim/antimycobacterials|Inhaled molgramostim administered in subjects who remain sputum culture positive while currently on a multidrug Nontuberculous Mycobacterial (NTM) guideline based antimycobacterial regimen, which has been ongoing for at least 6 months prior to the Baseline Visit
2875451|NCT03421743|Experimental|Inhaled molgramostim|Inhaled molgramostim administered in subjects who remain sputum culture positive but have stopped a multidrug Nontuberculous Mycobacterial (NTM) guideline based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance, or who never started such treatment
2875452|NCT03421730|Experimental|(A)|5 four-second inhalations of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
2875453|NCT03421730|Experimental|(B)|10 four-second inhalations of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
2875454|NCT03421730|Experimental|(C)|20 four-second inhalations of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
2875455|NCT03421730|Experimental|(D)|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
2875456|NCT03421717|Experimental|Test|Treatment/maintenance of implants postsurgically performed by the use of chitosan brushes
2875457|NCT03421717|Active Comparator|Control|Treatment/maintenance of implants postsurgically performed by the use of titanium curettes
2875458|NCT03421691|Other|Excel V laser|excel V Laser Genesis procedure utilizing 1064 nm Nd:YAG laser
2875459|NCT03421678||Japanese American|Two parents of Japanese descent
2875460|NCT03421678||Non-Hispanic Whites|Two parents of non-Hispanic white descent
2875461|NCT03421678||Native Hawaiians|At least one parent of Hawaiian descent
2875462|NCT03421665||Titan 3-D Wedge System|Subjects who receive one or more Titan 3D wedge(s).
2875463|NCT03421652|Experimental|Treatment (nivolumab, radiation therapy)|Given IV
2875464|NCT03421639|Active Comparator|Ulipristal acetate|control group treated with Ulipristal acetate as control
2875465|NCT03421639|Experimental|Aromatase inhibitor plus GnRH analog|experimental group treated with aromatase inhibitor plus GnRH analog
2875466|NCT03421626||Primary Enrollment|Initial enrollment of patients with history of CML
2875467|NCT03421613|Experimental|3VM1001 cream|Patients will be randomized to self treat with 2 g of VM1001 cream times daily for ten days, have a five day wash out period and then 10 days of self treatment with the comparator.
2875468|NCT03421613|Placebo Comparator|Placebo|Patients will be randomized to self treat with either active product or placebo comparator thrice daily for 10 days followed by a 5 day wash out period then 10 days of experimental treatment thrice daily for 20 days.
2875469|NCT03421600|Active Comparator|Blue laser imaging|Blue laser imaging
2875470|NCT03421600|Experimental|White light imaging|White light imaging
2875471|NCT03421587||Individuals exposed to an intentional trauma|
2875472|NCT03421587||Individuals exposed to a non-intentional trauma|
2875473|NCT03421587||Healthy controls without trauma-exposure|
2875474|NCT03421574|Experimental|MR-Guided Focused Ultrasound|
2875475|NCT03421561|Experimental|DCB Subjects|"The Stellarex DCB is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.~Basic Catheter Specifications~Guidewire: 0.035~Balloon Length: 40/80/120 mm~Sheath Compatibility: greater than or equal to 6 French~Balloon Diameter: 4/5/6 mm~Shaft length: 135 cm The nominal dose density of paclitaxel on the Stellarex DCB is 2.0 μg/mm2. Indications The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm."
2875476|NCT03421561|Placebo Comparator|PTA Subjects|"The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).~Basic Catheter Specifications~Guidewire: 0.035~Balloon Length: 40/80/120 mm~Sheath Compatibility: greater to or equal to 6 French~Balloon Diameter: 4/5/6 mm~Shaft length: 135 cm Indications The EverCross Balloon Catheter is intended to dilate stenosis in the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries, and to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for stent post-dilation in the peripheral vasculature. For additional information refer to the EverCross Instructions for Use."
2875477|NCT03421548|Experimental|BKpro I with EyeMate|Keratoprosthesis surgery indicated, defined as having a severely opaque and vascularised cornea AND either a verifiable history of two or more prior failed corneal transplant procedures, limbal stem cells deficiency or a medical condition such as alkali burns or autoimmune disease that makes the success of a traditional corneal transplant procedure unlikely. Potential study subjects will be solicited for participation in the clinical trial only after they have consented to the keratoprosthesis operation.
2898233|NCT03260920|Experimental|High Dose|
2875478|NCT03421548|No Intervention|BKpro I|Keratoprosthesis surgery indicated, defined as having a severely opaque and vascularised cornea AND either a verifiable history of two or more prior failed corneal transplant procedures, limbal stem cells deficiency or a medical condition such as alkali burns or autoimmune disease that makes the success of a traditional corneal transplant procedure unlikely. Potential study subjects will be solicited for participation in the clinical trial only after they have consented to the keratoprosthesis operation.
2875479|NCT03421535|Active Comparator|Sleeper stretch group|A certified athletic trainer supervised and observed the athlete as he performed the sleeper stretch on his dominant shoulder.
2875480|NCT03421535|Experimental|Opposite SI joint Stretch|A certified athletic trainer supervised and observed the athlete as he performed the SI joint stretch opposite his dominant shoulder.
2875481|NCT03421522|Experimental|Intervention - ICBN preservation|For participants randomized to the ICBN preserving technique, surgeons will perform axillary dissection in which the second ICBN, just inferior to the axillary vein, will be preserved.
2875482|NCT03421522|No Intervention|Control - Usual Care|For participants allocated to the usual surgical care arm, attending surgeons will perform a standard Level 1 and 2 axillary node dissection (sacrifice of the ICBN), either alone or with mastectomy or breast conserving surgery.
2875483|NCT03421496|Experimental|Cannabidiol Oral Solution (CBD)|"Cannabidiol Oral Solution, up to 40 milligrams per kilogram per day (mg/kg/day), participants will be dosed approximately every 12 hours with food.~Participants will also be taking vigabatrin, up to 150 mg/kg/day, divided twice daily with food."
2875484|NCT03421496|Placebo Comparator|Placebo|"Matching CBD placebo, up to 40 mg/kg/day, participants will be dosed approximately every 12 hours with food.~Participants will also be taking vigabatrin, up to 150 mg/kg/day, divided twice daily with food."
2875485|NCT03421483|Active Comparator|Folic Acid supplementation|Participants receive an adult multivitamin supplement along with a folic acid supplement
2875486|NCT03421483|Placebo Comparator|No supplementation|Participants only receive an adult multivitamin supplement
2875487|NCT03421457|Experimental|Lateral suspension|"Uterus-preserving Laparoscopic lateral suspension with mesh technique will be performed in this arm."
2875488|NCT03421457|Experimental|Sacrocervicopexy|"Uterus-preserving Laparoscopic sacrocervicopexy with mesh technique will be performed in this arm."
2875489|NCT03421431|Experimental|EDP-305 Dose 1|Subjects will take 2 tablets once a day orally for 12 weeks
2875490|NCT03421431|Experimental|EDP-305 Dose 2|Subjects will take 2 tablets once a day orally for 12 weeks
2875491|NCT03421431|Placebo Comparator|Placebo|Subjects will take 2 tablets once a day orally for 12 weeks
2875492|NCT03421418|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
2875493|NCT03421418|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
2875494|NCT03421405|Experimental|Intervention Arm|All participants will be asked to attend 4 separate experimental sessions over the course of approximately 4 weeks (i.e. one session/week). During each session, participants will listen to three different auditory stimulus sequences including sounds and words while EEG activity is recorded using the NeuroCatch Platform™ device.
2875495|NCT03421392||Idiopathic thrombocytopenic purpura|
2875496|NCT03421392||non immunological thrombocytopenia|patient with constitutive thrombocytopenia, myelodysplastic syndrome, or chemotherapy-induced thrombocytopenia
2875497|NCT03421392||without thrombocytopenia|
2875498|NCT03421379|Experimental|Glucagon Nasal Powder|Single dose of glucagon nasal powder.
2875499|NCT03421379|Active Comparator|Glucagon Hydrochloride Solution|Single IM dose of glucagon hydrochloride solution.
2875500|NCT03421366||Cystic Fibrosis on Posaconazole|"Able to provide written informed consent~Greater than 18 years of age or older~Have a diagnosis of cystic fibrosis~No known azole hypersensitivity~To commence as part of their standard of care the newer modified release oral formulation of posaconazole to treat Aspergillus~Able to provide a pre-treatment sputum collected for fungal culture as part of standard of care~Have been prescribed a loading dose of 300mg bd for 1 day of the modified release posaconazole tablet followed by 300mg daily."
2875501|NCT03421353|Experimental|A1: AZD9150+Durvalumab|AZD9150 will be given every two weeks (Q2W) plus durvalumab given every four weeks (Q4W).
2875502|NCT03421353|Experimental|A2(a): AZD9150+Durvalumab+Cisplatin+5-FU|AZD9150 will be given once weekly (QW) plus durvalumab every three weeks (Q3W) plus Cisplatin on Day 1 plus 5-flourouracil (5-FU) on Days 1 to 4. This regimen will be repeated every 3 weeks for up to 18 weeks. In Arm A2(a) there will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
2875503|NCT03421353|Experimental|A3:AZD9150+Durvalumab+Cisplatin|Depending on the results of Arm A2(a), Arm A3 may not be enrolled. AZD9150 will be given every two weeks (Q2W) plus durvalumab given every three weeks (Q3W) plus cisplatin on Day 1 plus 5-flourouracil (5-FU) over Days 1 to 4. This regimen will be repeated every 3 weeks for up to 18 weeks.
2875504|NCT03421353|Experimental|A4:AZD9150+Durvalumab+Cisplatin/Carboplatin+Gemcitabine|"AZD9150 will be given every two weeks (Q2W) plus durvalumab given every three weeks (Q3W) plus gemcitabine on Days 1 and 8. This regimen will be repeated every 3 weeks. In addition, the following will be added to the regimen:~For cisplatin-eligible patients: cisplatin on Day 1 (every 3 weeks for up to 12-18 weeks); or~For cisplatin ineligible patients: carboplatin on Day 1 and Day 8 (every 3 weeks for up to 12-18 weeks)."
2875505|NCT03421353|Experimental|A5:AZD9150+Durvalumab+Carboplatin+Nab-Paclitaxel|AZD9150 will be given every two weeks (Q2W) plus durvalumab every three weeks (Q3W) plus carboplatin on Day 1 plus nab-paclitaxel on Days 1, 8, and 15 (every 3 weeks for up to 12-18 weeks).
2875506|NCT03421353|Experimental|B1: AZD9150 + Durvalumab|"AZD9150 will be given once weekly (QW) plus durvalumab every four weeks (Q4W).~1:1 Randomization"
2875507|NCT03421353|Experimental|B2: AZD9150 + Durvalumab|"AZD9150 will be given every two weeks (Q2W) plus durvalumab every four weeks (Q4W).~1:1 Randomization"
2875508|NCT03421353|Experimental|C1:AZD9150+Durvalumab+Carboplatin+Nab-Paclitaxel|AZD9150 will be given every two weeks (Q2W) plus durvalumab every three weeks (Q3W) plus standard of care (SOC) chemotherapy (nab-paclitaxel plus carboplatin Q3W) for 12-18 weeks followed by AZD9150 Q2W plus durvalumab Q4W.
2875575|NCT03420898||1|General Medicine in Hospital Unit 70 Bed. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
2875509|NCT03421353|Experimental|A2(b): AZD9150+Durvalumab+Cisplatin+5-FU|AZD9150 will be given once weekly (QW) plus durvalumab every three weeks (Q3W) plus Cisplatin on Day 1 plus 5-flourouracil (5-FU) on Days 1 to 4. This regimen will be repeated every 3 weeks for up to 18 weeks. In Arm A2(b) doing will start on Day 1 of Week 0 for all agents. The last chemotherapy dose will be given in Week 15. Post discontinuation of chemotherapy the regimen will include AZD9150 IV QW + durvalumab IV Q4W. Administration of durvalumab will continue Q3W through Week 19, at which time the schedule will switch to Q4W.
2875510|NCT03421340|Other|ERC Arm|After screening examination and confirmed presence of non-complex bile duct stone by image, patients will be randomly assigned by stratified randomization to Electroscopic Retrograde Cholangioscopy (ERC) treatment.
2875511|NCT03421340|Other|DSC Arm|After screening examination and confirmed presence of non-complex bile duct stone by imagine, patients will be randomly assigned by stratified randomization to fluoroscopy/radiation-free direct solitary cholangioscopy (DSC).
2875512|NCT03421327||Families at-risk for HD|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
2875513|NCT03421327||Families at-risk for hereditary cancer|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
2875514|NCT03421327||Genetic Counselors|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
2875515|NCT03421314|Experimental|Zinc|Participants in this arm will take a daily 30 mg dose of zinc gluconate during 6 months
2875516|NCT03421314|Experimental|Selenium|Participants in this arm will take a daily 200 mcg of selenium yeast during 6 months
2875517|NCT03421314|Experimental|Zinc + Selenium|Participants in this arm will take a daily 30 mg dose of zinc gluconate + 200 mcg of selenium yeast during 6 months
2875518|NCT03421314|No Intervention|Control|Participants in this arm will not take supplementation as a control.
2875519|NCT03421301|Experimental|1. Dietary portfolio (DP)|the dietary portfolio was given daily in the breakfast and dinner for 2.5 months
2875520|NCT03421301|Placebo Comparator|2. placebo (P)|the placebo (P) was based was given daily in the breakfast and dinner for 2.5 months
2875521|NCT03421288|Experimental|Arm A: FLOT with Atezolizumab|Patients randomized to treatment Arm A will receive atezolizumab (840 mg IV over 1 hour) + FLOT in four 2-week treatment cycles prior to undergoing surgery. Following surgery, patients will receive four further 2-week cycles of atezolizumab + FLOT followed by 8 additional 3-week treatment cycles with atezolizumab alone (maintenance setting: 1,200 mg q3w). FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.
2875522|NCT03421288|Active Comparator|Arm B: FLOT alone|Patients randomized to Arm B will receive FLOT alone for four 2-week treatment cycles prior to surgery. Following surgery, patients will receive four further 2-week cycles of chemotherapy alone. FLOT can be deescalated to FLO, FLT or FL in case of chemo-related toxicity at any time and at the discretion of investigator. Docetaxel 50 mg/m², d1 Oxaliplatin 85 mg/m², d1 Calciumfolinat 200 mg/m², d1 5-Fluorouracil 2600 mg/m², d1
2875523|NCT03421275|Experimental|Esketamine|intravenous anaesthetic and analgetic
2875524|NCT03421275|Active Comparator|Fentanyl Citrate|intravenous opioid analgetic
2875525|NCT03421275|Placebo Comparator|Saline Nasal|"intravenous Natriumklorid b. Braun 9 mg/ml"
2875526|NCT03421262|Experimental|One-step:IADPSG Criteria|Gestational diabetes screening with fasting 2 hour 75g. Receive a fasting 2 hour 75 gr oral glucose tolerance test and diagnosed based on the IADPSG which is if one or more values exceed the following diagnostic threshold: Fasting 92, 1-hour 180, or 2-hour 153 mg/dL.
2875527|NCT03421262|Active Comparator|Two-step:NDDG Criteria|"Step 1: Perform a 1h 50-g glucose load test (nonfasting. If the plasma glucose level measured 1 h after the load is 140 mg/dL, proceed to a 100-g OGTT.~Step 2: 100-g OGTT. The diagnosis of GDM is made if at least two of the following four plasma glucose levels(measured fasting and 1 h, 2 h, 3 h after the OGTT) are met or exceeded: 105mg/dl, 190mg/dl, 165mg/dl and 145mg/dl respectively"
2875528|NCT03421249|Active Comparator|Group A - Intervention|Submitted to knee and hip muscle strengthening exercises and electromagnetic field therapy with Magnetron ® (Meditea - ARG) using the coplanar technique
2875529|NCT03421249|Active Comparator|Group B - exercises|Performed exercises to strengthen the hip and knee muscles
2875530|NCT03421249|Placebo Comparator|Group C - Placebo|Performed hip and knee strengthening exercises and electromagnetic field therapy with the coplanar Magnetron® technique, but with the device switched off
2875531|NCT03421249|Active Comparator|Group D - Apparatus|Only use electromagnetic field therapy with the coplanar Magnetron® technique
2875532|NCT03421236|Experimental|non muscle invasive bladder cancer patient|intravesical instillation of Ty21a in patients not requiring BCG
2875533|NCT03421223||Case|Individuals diagnosed with chronic pain
2875534|NCT03421223||Control|Individuals without chronic pain
2875535|NCT03421210|Other|Nicotine Replacement Therapy|Participants will receive nicotine replacement therapy for 10 weeks after quitting smoking.
2875536|NCT03421197|Experimental|PPC-06 400 mg QD|Tepilamide Fumarate 400 mg once per day
2875537|NCT03421197|Experimental|PPC-06 400 mg BID|Tepilamide Fumarate 400 mg twice per day
2875538|NCT03421197|Experimental|PPC-06 600 mg BID|Tepilamide Fumarate 600 mg twice per day
2875539|NCT03421197|Placebo Comparator|Placebo BID|White placebo tablet to mimic Tepilamide Fumarate
2875540|NCT03421184|Experimental|Patient with Systemic Lupus Erythematosus|30 women with SLE
2875541|NCT03421184|Active Comparator|Patients with other autoimmune diseases|20 patients with rheumatoid arthritis, 20 patients with autoimmune thrombocytopenia
2875542|NCT03421184|Active Comparator|Healthy control|30 healthy control women
2875543|NCT03421158|No Intervention|Control|Newborns received no pain interventions during the procedure
2898375|NCT03259789|Active Comparator|Bexagliflozin tablets, 20 mg|
2875548|NCT03421119|Experimental|CinnaGen-liraglutide|CinnaGen-liraglutide (Liraglutide 6 MG/ML Pen Injector by CinnaGen Company) will be administered 1.8 mg/day subcutaneously. Doses of CinnaGen-liraglutide will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up to 1.8 mg/day from the start of the fifth week to the end of 26th week. Patients in this group will continue to receive metformin along with a Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose.
2875549|NCT03421119|Active Comparator|Victoza®|Victoza® (Liraglutide 6 MG/ML Pen Injector by Novo Nordisk Company) will be administered 1.8 mg/day subcutaneously. Doses of Victoza® will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up to 1.8 mg/day from the start of the fifth week to the end of 26th week. Patients in this group will continue to receive metformin along with a Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose.
2875550|NCT03421106|Experimental|Intervention Food Pantries|Food pantries will transform to offer healthier and more appealing food ; the effect on clients will be measured.
2875551|NCT03421106|Active Comparator|Control Food Pantries|Food pantries will make no changes during the evaluation period; the effect on clients will be measured.
2875552|NCT03421093||Surgeries and adjuvant therapies|Surgeries or surgeries plus adjuvant therapies
2875553|NCT03421080|Active Comparator|MoodGYM Only|The MoodGYM only Internet intervention will consist of a popular, automated, self-help cognitive behavioral therapy program for depression comprising five modules to be completed over five weeks and an online workbook incorporating 29 exercises. A series of published research trials has shown MoodGYM to be effective in reducing depressive symptoms in users in a range of settings (e.g., schools, universities, Lifeline suicide prevention, U.K. NHS Choices online), for different aspects of the mental health service spectrum (e.g., prevention vs treatment), and different age groups (adults, adolescents).
2875554|NCT03421080|Experimental|MoodGYM + CYD|The MoodGYM + CYD intervention condition will consist of the MoodGYM only intervention and an online intervention providing feedback on quantity and frequency of drinking, severity of hazardous drinking, and provides recommendations for safe levels of alcohol consumption (Check Your Drinking - CYD). The CYD Final Report will be provided as part of the participant's MoodDYM dashboard.
2875555|NCT03421054|Other|nutraceutical containing HA|pain reduction of the affected knee in the patients assuming nutraceutical containing HA
2875556|NCT03421041|Experimental|Dexamethasone group|
2875557|NCT03421041|No Intervention|control group|
2875558|NCT03421028|No Intervention|Control group|Patients with no masticatory muscle pain and no sleep bruxism
2875559|NCT03421028|Experimental|Experimental group (FES and EMG-biofeedback)|Patients diagnosed with masticatory muscle pain and sleep bruxism
2875560|NCT03421015||case group|patients with biochemical recurrence and positive imaging (case group)
2875561|NCT03421015||Control Group|patients without biochemical recurrence (control group)
2875562|NCT03421002|Experimental|Micafungin|Micafungin will be administered a minimum of 14 days
2875563|NCT03420989|Active Comparator|Active snack food|snack food with carob and seaweeds 50 gr per day
2875564|NCT03420989|Placebo Comparator|Control snack food|snack food without carob and seaweeds 50 gr per day
2875565|NCT03420976|Experimental|Novel Supplement-based Therapy|"Low FODMAP diet + supplements outlined below:~Product Name: Liver-G.I. Detox Active Ingredients: Alpha lipoic acid, n-acetyl-l-cystine, turmeric root extract, milk thistle seed extract, broccoli sprout concentrate, artichoke leaf extract, taurine, glycine, l-glutamine, l-methionine, and chlorella.~Product Name: l-Glutamine Active Ingredients: l-glutamine~Product Name: MicroDefense Active Ingredients: berberine sulfate, olive leaf extract, sweet wormwood, clove bud powder, and grapefruit seed and fruit extract.~Product Name: A.C. Formulla II Active Ingredients: calcium and magnesium undecylenate, calcium and magnesium caprylate, bromelain, grapefruit seed and fruit extract, and berberine sulfate~Product Name: Probiotic-5 (Pure Encapsulations) Active Ingredients: Probiotic blend~Product Name: Digestive Enzymes Ultra with Betaine HCl Active Ingredients: Digestive enzyme blend and betaine HCl"
2875566|NCT03420963|Experimental|NK Cells + Chemotherapy|"Participants assigned to a dose level of NK cells based on when study is joined. Up to 2 dose levels of NK cells will be tested. Once the maximum tolerated dose is reached, expansion phase begins.~Participants receive cyclophosphamide and etoposide by vein over about 30 minutes on Days 1-5. Participants then receive NK cells by vein on Day 8.~Mesna will start with dose prior to cyclophosphamide and then 3 and 6 hours after each dose for total of at least 80% of cyclophosphamide dose."
2875567|NCT03420950|Other|Sedative first|Rapid sequence intubation: sedative first
2875568|NCT03420950|Other|Paralytic agent first|Rapid sequence intubation: paralytic first
2875569|NCT03420937|Experimental|Deep Neuromuscular Block|"Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Post-tetanic Count (PTC) = 1-2; PTC measurement every 4 min.~Intervention: Neuromuscular blockade reversal at the end of anesthesia: sugammadex 2 mg/kg iv (when PTC is 18-20 and TOF-count 0) or sugammadex 4 mg/kg iv (when PTC under 18).~Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1,5-2,5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv.~Extubation when patient is conscious and attained recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
2875570|NCT03420937|Experimental|Moderate Neuromuscular Block|Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Train-of-Four (TOF) count = 1-2, TOF-count measurement every 1 min. Intervention: Neuromuscular blockade reversal at the end of anesthesia: neostigmine 0.03 mg/kg iv + atropine 0.5-1.0 mg iv Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1.5-2.5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv Extubation when patient is conscious and attained the recovery from neuromuscular blockade to a TOF-ratio of at least 0,9.
2875571|NCT03420924|Experimental|Thermal suit|
2875572|NCT03420924|Active Comparator|Conventional hospital clothes|
2875573|NCT03420911|Active Comparator|dexketoprofen trometamol group|Received the study drugs in 100 mL of normal saline within 5 minutes. The dexketoprofen trometamol dose was 50 mg
2875574|NCT03420911|Active Comparator|dexketoprofen trometamol plus midazolam group|Received the study drugs in 100 mL of normal saline within 5 minutes. The dexketoprofen trometamol dose was 50 mg and the midazolam dose was 1 mg.
2875856|NCT03419052|Active Comparator|Control|Consumption of low polyphenol foods and online (inert) games
2875576|NCT03420898||2|General Medicine in Hospital 38 Bed Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
2875577|NCT03420898||3|Cardiovascular Surgery in Hospital Unit 36 bed. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
2875578|NCT03420898||4|General Surgery in Hospital 24 bed Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
2875579|NCT03420898||5|Cardiac 36-bed in Hospital Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
2875580|NCT03420898||6|General Medicine 26 Bed in Hospital Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
2875581|NCT03420885|Experimental|Ba Duan Jin Group|Ba Duan Jin plus health education. Participants take part in 16-week program. The health education is conducted as the Health Education Group. Besides, the participants attended two 90-minute sessions of group-based Ba Duan Jin training per week and practiced at least three 30-minute Ba Duan Jin sessions at home per day.
2875582|NCT03420885|Active Comparator|Health Education Group|Health education. Participants take part in 16-week program. The health education includes work, rest, diet and other basic programs according to the different conditions of participants.
2875583|NCT03420872||Subset from PROGRESS cohort|Participants included children 4-6 years of age from mother-child pairs in the Programming Research in Obesity, Growth Environment and Social Stress (PROGRESS) prospective birth cohort in Mexico City
2875584|NCT03420846|Experimental|OCT Mapped arm|OCT is used to map the tumour margins as the first stage MMS estimate
2875585|NCT03420846|No Intervention|Control arm|Standard MMS is performed
2875586|NCT03420833|Experimental|CRT-On first, then CRT-Off|Subjects will be randomized to have the cardiac resynchronization therapy pacemaker (CRT-P) programmed on in the first intervention period, and after six months the CRT function will be turned off in the second intervention period.
2875587|NCT03420833|Experimental|CRT-Off first, then CRT-On|Subjects will be randomized to have the cardiac resynchronization therapy pacemaker (CRT-P) programmed off in the first intervention period, and after six months the CRT function will be turned on in the second intervention period.
2875588|NCT03420820|Experimental|5% Betadine, Ocular Surface only|Use of 5% P-I from bottle dropper to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.
2875589|NCT03420820|Experimental|10% Betadine, Ocular Surface only|Use of 10% P-I swabstick to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.
2875590|NCT03420820|Experimental|10% Betadine, Ocular Surface and Adnexa|Use of 10% P-I swabstick to sterilize the ocular surface and surrounding lids and eyelashes only, prior to injection. Intervention: bacterial culture swab.
2875591|NCT03420807|Experimental|MHRC camera|Subjects will undergo a retina imaging session with the MHRC camera.
2875592|NCT03420794|Active Comparator|Control Group|Patients undergoing total laparoscopic hysterectomy for benign disease who will receive celecoxib 200mg, acetaminophen 1000mg, and gabapentin 600mg by mouth once just prior to surgery.
2875593|NCT03420794|Experimental|Study Group|Patients undergoing total laparoscopic hysterectomy for benign disease who will receive celecoxib 200mg, acetaminophen 1000mg, and gabapentin 600mg by mouth once 3-4 hours prior to surgery.
2875594|NCT03420781|Experimental|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily for 46 weeks.
2875595|NCT03420781|Experimental|Relamorelin 10 μg, followed by Placebo|Relamorelin 10 μg injected subcutaneously twice daily for 40 weeks, followed by placebo injected twice daily for 6 weeks.
2875596|NCT03420781|Experimental|Placebo, followed by Relamorelin 10 μg|Placebo injected subcutaneously twice daily for 40 weeks, followed by Relamorelin 10 μg injected twice daily for 6 weeks.
2875597|NCT03420768|Experimental|Part 1 BMS-986263 45mg weekly|
2875598|NCT03420768|Experimental|Part 1 BMS-986263 90mg weekly|
2875599|NCT03420768|Placebo Comparator|Part 1 Placebo weekly|
2875600|NCT03420768|Experimental|Part 2 BMS-986263 45mg every 2 weeks|
2875601|NCT03420768|Experimental|Part 2 BMS-986263 90mg every 2 weeks|
2875602|NCT03420768|Experimental|Part 2 BMS-986263 90mg every 4 weeks|
2875603|NCT03420768|Placebo Comparator|Part 2 Placebo every 2 weeks|
2875604|NCT03420755|Experimental|MB 1-on-1 Only|Mothers and Babies 1-on-1. MB 1-on-1 -12-session intervention Each MB session lasts 15-20 minutes and is delivered as part of a regularly scheduled home visit (English or Spanish).
2875605|NCT03420755|Experimental|MB 1-on-1 Plus TEXT|Mothers and Babies Plus Text. MB 1-on-1 along with text enhancements both in English and Spanish.
2875606|NCT03420742|Experimental|Midazolam 3 mg + Brigatinib 90 mg|Midazolam 3 mg, orally, once on Day 1, followed by brigatinib 90 mg, orally, once daily on Days 2 to 8, further followed by brigatinib 180 mg, orally, once daily on Days 9 to 28 in Part A Cycle 1 (28 days treatment cycle). Participants escalating to brigatinib 180 mg once daily will also receive midazolam 3 mg, orally, once on Day 21 of Part A Cycle 1. After completion of Part A, participants will continue into Part B. Participants in Part B will receive brigatinib up to 180 mg (or at the highest tolerated dose in Part A), orally, once daily in a 28 day treatment cycle, up to a maximum of 23 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
2875607|NCT03420729|Experimental|magnetic assisted capsule endoscopy|All participants will undergo magnetic assisted capsule endoscopy at the sloan medical centre
2875608|NCT03420729|Active Comparator|gastroscopy|All participants will undergo gastroscopy as standard of care at sheffield teaching hospitals
2875609|NCT03420716|Experimental|functional yogurt|Participants are given the symbiotic yogurt daily (180 ml)
2875610|NCT03420716|Experimental|control yogurt|Participants are given the control yogurt daily (180 ml)
2875611|NCT03420703|Active Comparator|Block group|Erector espine plane block will be administrated to this group. An intravenous patient controlled analgesia device will be given to the patients postoperatively
2898376|NCT03259789|Placebo Comparator|Bexagliflozin tablets, Placebo|
2875612|NCT03420703|Sham Comparator|control group|An intravenous patient controlled analgesia device will be given to the patients postoperatively
2875613|NCT03420690||Family of patient|
2875614|NCT03420677|Active Comparator|Application of tones|During non-rapid eye movement (NREM) sleep short tones will be played
2875615|NCT03420677|Sham Comparator|No application of tones|During NREM sleep no short tones will be played
2875616|NCT03420664|Experimental|Cast immobilisation|A below knee cast is applied in order to achieve ankle immobilisation for one hour
2875617|NCT03420664|Experimental|Orthosis (VACOped) immobilisation|A below knee orthosis which allows for ankle movement is applied for one hour.
2875618|NCT03420651|Experimental|PEFR Guided Management|Peak Expiratory Flow Rate (PEFR) Patients in this group will perform PEFR testing every 30 minutes and this data along with the National Asthma Prevention and Education Program guidelines will be considered by primary ED medical providers in the management of this group.
2875619|NCT03420651|Experimental|Non-PEFR Guided Management|Standard Clinical Judgement Patients in this group will receive management based on primary medical provider's clinical judgement.
2875620|NCT03420638|Experimental|Adjunct Exparel|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication—bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.—into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side. Following the standard medication, the principal investigator will infiltrate 0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% [13.3 mg/mL], i.m.) into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine liposome injectable suspension on each side.
2875621|NCT03420638|Other|Standard Care|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication—bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.—into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.
2875622|NCT03420625|Active Comparator|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
2875623|NCT03420625|Active Comparator|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
2875624|NCT03420625|Active Comparator|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
2875625|NCT03420625|Active Comparator|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJO,TM, CefarCompex Mi-Theta 500 stimulator
2875626|NCT03420612||training|The training cohort was used to determine the influencing factors of the pain during the colonoscopy and establish the intubation discomfort score (IDS)
2875627|NCT03420612||validation|The validation cohort was used to verify the IDS
2875628|NCT03420599||health control|healthy controls are all from normal volunteers
2875629|NCT03420599||splenectomy|Traumatic patients after total splenectomy
2875630|NCT03420586|Active Comparator|Nitrous oxide Group|The nitrous oxide group (GN2O) will receive air in 30% O2 during general anesthesia until the last 30 min of surgery, when 70% N2O in 30% O2 will be administered.
2875631|NCT03420586|No Intervention|Oxygen Group|The Oxygen group will receive gas carrier mixture consisting of air in 30% O2 during general anesthesia.
2875632|NCT03420560|Experimental|warmer temperature|To compare the incidence and intensity of pain on injection that is caused by propofol in warm temperature（27℃） versus normal temperature(23℃).
2875633|NCT03420560|Placebo Comparator|normal temperature|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol in different room temperature(27 VS 23).
2875634|NCT03420547|Experimental|Intervention group|Group of participants receiving the RISE intervention
2875635|NCT03420547|No Intervention|Standard Care (waitlist)|Group receiving no intervention in first 6 weeks.They will have the option of participating in the RISE program after their second assessment at week 6.
2875636|NCT03420534|Experimental|iloperidone in fasting|iloperidone 1mg by mouth once for 6 days in the first cycle or the second cycle
2875637|NCT03420534|Active Comparator|placebo tablets in fasting|placebo mimic iloperidone 1mg by mouth once for 6 days in the second cycle or the first cycle
2875638|NCT03420534|Active Comparator|placebo tablets in postprandial|placebo mimic iloperidone 1mg by mouth once for 6 days
2875639|NCT03420534|Experimental|iloperidone in postprandial|iloperidone 1mg by mouth once for 6 days
2875640|NCT03420521|Other|Nivolumab plus Ipilimumab|Nivolumab-240 mg IV over 60 minutes Q2W Ipilimumab 1mg/kg IV over 30 minutes Q6W
2875641|NCT03420508|Experimental|ensartinib|The screening portion of the trial will test archival tumor material for the presence of ALKATI using a Nanostring-based RNA assay for any patients deemed to be current or future candidates for this trial. This will require approximately 5 formalin-fixed paraffin- embedded (FFPE) slides of 5-8 micron thickness. For the treatment portion of the study, all patients will receive ensartinib orally at a dose of 225mg daily.
2875642|NCT03420495|Experimental|OCD Group|Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for principal OCD. These participants will complete clinician interviews, self-report questionnaires, and receive the Decision-Making Tasks Intervention.
2875643|NCT03420495|Experimental|Non-psychiatric Control Group|No current DSM-5 diagnosis. These participants will also complete clinician interviews, self-report questionnaires, and receive the Decision-Making Tasks Intervention.
2875644|NCT03420482|Experimental|Fecal Microbiota Transplant (FMT) oral capsules|Subjects will receive 15 oral capsules of FMT on days 1, 2, 7, 14, and 21.
2875645|NCT03420482|Placebo Comparator|Placebo capsules|Subjects will receive placebo capsules on the same schedule as the experimental arm (days 1, 2, 7, 14, and 21).
2875646|NCT03420469|Experimental|Single Group|CYP2D6 activity will be determined on three occasions using a single oral dose of dextromethorphan (30 mg PO) as a probe drug: 1) at baseline (control); 2) with a single dose of bupropion (150 mg PO) (single dose inhibition); and 3) after 14 days pretreatment with bupropion (150 mg twice daily PO) (multiple dose inhibition). Single dose and steady state pharmacokinetics of bupropion will also be determined.
2898642|NCT03257865|Placebo Comparator|Placebo|Daily, oral, tablet
2875647|NCT03420456|Experimental|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy and the light energy may activate under-stimulated brain regions.
2875648|NCT03420456|Sham Comparator|Sham Transcranial Light Therapy|For the sham group, the transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy.
2875649|NCT03420443|Experimental|Oat bran|45 g oat bran
2875650|NCT03420443|Experimental|Oat bran and blueberry husks|13 g freeze dried blueberry husks and 22 g oat bran + probiotic bacteria.
2875651|NCT03420443|Other|No oral supplementation|No oral supplementation.
2875652|NCT03420417|Experimental|Assessement of respiratory mechanics|Measurement of respiratory mechanics characteristics
2875653|NCT03420404|Experimental|Collaborative care with TCM physicians|TCM physician involved collaborative care model (TCMCMC): The intervention arm will involve the TCM physician in the management of patients with AxSpA in addition to the usual rheumatological care.
2875654|NCT03420404|No Intervention|Usual care only|The attending rheumatologist will prescribe a variety of treatment inclusive of medications such as non-steroidal anti-inflammatory drugs and physiotherapy.
2875655|NCT03420391|Placebo Comparator|Placebo PBMT|Participants received Photobiomodulation Therapy (PBMT) placebo
2875656|NCT03420391|Active Comparator|5 Minutes|Participants performed the eccentric exercise protocol 5 minutes after PBMT. Assessments were performed before any procedure, and 1 minute, 1, 24 and 48 hours after the end of exercise protocol.
2875657|NCT03420391|Active Comparator|3 Hours|"3 hours: Participants performed the eccentric exercise protocol 3 hours after PBMT.~Assessments were performed before any procedure, and 1 minute, 1, 24, 48 hours after the end of exercise protocol."
2875658|NCT03420391|Active Comparator|6 Hours|"6 hours: Participants performed the eccentric exercise protocol 6 hours after PBMT.~Assessments were performed before any procedure, and 1 minute, 1, 24, 48 hours after the end of exercise protocol."
2875659|NCT03420391|Active Comparator|24 hours|"24 hours: Participants performed the eccentric exercise protocol 24 hours after PBMT.~Assessments were performed before any procedure, and 1 minute, 1, 24, 48 hours after the end of exercise protocol."
2875660|NCT03420378|No Intervention|Healthy Arm|The cutaneous silent period will be compared to the healthy population.
2875661|NCT03420378|Active Comparator|Interventional Arm|Patients with vitamin D deficiency will receive vitamin D replacement therapy. Before and after therapy, cutaneous silent period will be measured from each upper extremity and latencies will be recorded. Their LANSS scores and Notthingham Health Profile will be recorded before and after treatment.
2875662|NCT03420365|Experimental|Type of intervention|A single bout of aerobic exercise, or a single bout of balance and coordination exercise, or reading a magazine
2875663|NCT03420352|Other|butterfly needle with valve|thromboelastography
2875664|NCT03420352|Other|Standard hypodermic needle|thromboelastography
2875665|NCT03420339||Subjects on stimulant medication|All participants: Children and adolescents diagnosed with AD/HD, displaying disruptive behavior, and taking stimulant medication.
2875666|NCT03420326||Atria fibrillation (AF) group|"Detection of AF during 30 seconds ECG assessment~Once diagnosed with atrial fibrillation before~Undergo the frailty status assessment"
2875667|NCT03420326||Non-AF group|"No detection of AF during 30 seconds ECG assessment~Undergo the frailty status assessment"
2875668|NCT03420313|Experimental|Interim Buprenorphine Treatment|"Interim Buprenorphine Treatment includes (a) Maintenance treatment with Buprenorphine/ naloxone sublingual tablets with bi-monthly clinic visits for observed dosing and the remaining doses dispensed at home via a secure computerized portable device (Med-O-Wheel, Addoz, Finland).~(b) nightly calls from an automated Interactive Voice Response (IVR) phone system to assess any drug use, withdrawal and craving, (c) IVR-generated random call-backs for urinalysis and pill counts, and (d) HIV+Hepatitis education delivered via iPad."
2875669|NCT03420313|No Intervention|Waitlist Control|Waitlist Control participants will remain on the waitlist for their treatment of choice but complete the same 4-, 8- and 12-week assessments.
2875670|NCT03420300|Experimental|EBR/GZR|Elbasvir/grazoiprevir (EBR/GZR 50mg/100mg fixed dose combination [FDC]): 1 table per os per day for 12 weeks
2875671|NCT03420287|Experimental|MPM prepared from allogenic bone graft|All patients in this group will receive MPM prepared from allogenic bone graft
2875672|NCT03420287|Active Comparator|Autogenous bone graft group|All patients in this group will receive autogenous bone graft only
2875673|NCT03420274|Experimental|Intervention|This arm will utilize a point-of-care shared decision-making tool (NEST).
2875674|NCT03420274|Placebo Comparator|Control|This group will utilize usual care with respect to healthcare provider practice for education and counseling.
2875675|NCT03420261|Active Comparator|Crystalloid group|individualized goal-directed fluid optimization (cardiac preload) by 250 ml boluses of 0.9% saline (up to a maximum of 30 ml/kg)
2875676|NCT03420261|Experimental|Colloid group|individualized goal-directed fluid optimization (cardiac preload) by 250 ml boluses of HES 130/0.4 (up to a maximum of 30 ml/kg, VOLUVEN ®, Fresenius Kabi)
2875677|NCT03420248|Experimental|Non-spherical polyvinyl alcohol particle|For embolic material, non-spherical polyvinyl alcohol particle is used.
2875678|NCT03420248|Experimental|Tris-acryl gelatin microsphere|For embolic material, Tris-acryl gelatin microsphere is used.
2875679|NCT03420235|No Intervention|Control group|Control group will receive standard care alone.
2875680|NCT03420235|Experimental|Home monitoring group|Intervention will consist of a home monitoring program added to standard care.
2875681|NCT03420222|Experimental|AVP-786|Dose 1 capsules administered twice a day over a 12-week period
2875682|NCT03420222|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
2875683|NCT03420209|Experimental|Group applying PNF technique|The experimental goup who are applying PNF technique with elastic bands for the upper extremities. Before the group will perform stretching and resisted exercises at the warming up period, after they will do PNF exercises with elastic bands on two PNF pattern for the upper extremities and finally they will do some stretching exercises for the cool down period. The programme will continue for 30-45 minutes, three times a week, for 12 weeks. They will work one by one with a physical therapist.
2899382|NCT03252951|Experimental|Concentric Training|
2875684|NCT03420209|No Intervention|Home Programme|This group will perform only breathing exercises daily at home during 12 weeks.
2875685|NCT03420196|Experimental|Supervised Rehabilitation program|It will be consist in a supervised exercise program by physical therapist, including the following structures: diaphragm, tranverse abdominis muscle, pelvic, gluteus, CORE and spinal mobility
2875686|NCT03420196|Active Comparator|Nonsupervised rehabilitation program|It will consist in an exercise program for home, nonsupervised, including the following structures: diaphragm, tranverse abdominis muscle, pelvic, gluteus, CORE and spinal mobility. The patients will perform an exercise program at home.
2875687|NCT03420183|Experimental|Phase 1b-Dose Finding|Cirmtuzumab followed by Cirmtuzumab plus ibrutinib
2875688|NCT03420183|Experimental|Phase 1b-Dose Expansion|Cirmtuzumab plus ibrutinib
2875689|NCT03420183|Experimental|Phase 2-Cirmtuzumab plus ibrutinib|Phase 2 safety and efficacy evaluation
2875690|NCT03420183|Active Comparator|Phase 2-Ibrutinib|Phase 2 safety and efficacy evaluation
2875691|NCT03420170|Experimental|Graded Exercise Integrated Education|"The graded exercise (8 weeks)~Strengthening exercise~Aerobic Exercise~Educational session to increase exercise self-efficacy and physical activity level (16 weeks)"
2875692|NCT03420170|Active Comparator|Conventional physical therapy|Normal routine of physical therapy (8 weeks)
2875693|NCT03420157||Focus Group 1 & 2|Each Focus Group of 10 women will be led by a psychologist according to a semi-directive interview pattern. This interview guideline specifies in details the ideal proceedings of Focus Group, as well as the various predetermined topics to be addressed in the form of questions and / or relaunches. The interview guideline is divided into 2 parts: the accompanying letter and the leaflet explaining how to perform the vaginal self-sampling.
2875694|NCT03420144|Active Comparator|Standard Medical Therapy|Standard medical therapy: diuretics, lactulose, rifaximin, diuretics, albumin infusion, nutritional support (as required)
2875695|NCT03420144|Active Comparator|Growth hormone|Growth Hormone: GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (based on IGF-1 levels) subcutaneously for 1 year.
2875696|NCT03420131||FFR-iFR-QFR group|
2875697|NCT03420118|Experimental|Tumor tissue and blood samples collection|
2875698|NCT03420105|Other|Group A|Patients perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
2875699|NCT03420105|Other|Group B|Patients perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
2875700|NCT03420105|Other|Healthy volunteers|Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
2875701|NCT03420092|Experimental|Treatment A|The participant will be administered with Form 1 of AZD5718 tablets with an overnight fast of at least 10 hours.
2875702|NCT03420092|Experimental|Treatment B|The participant will be administered with Form 2 of AZD5718 tablets with an overnight fast of at least 10 hours.
2875703|NCT03420092|Experimental|Treatment C|The participant will be administered with Form 3 of AZD5718 tablets with an overnight fast of at least 10 hours.
2875704|NCT03420092|Experimental|Treatment D|The participant will be administered with Form 4 of AZD5718 tablets with an overnight fast of at least 10 hours.
2875705|NCT03420092|Experimental|Treatment E|The participant will be administered with Form 5 of AZD5718 tablets with an overnight fast of at least 10 hours.
2875706|NCT03420092|Experimental|Treatment F|The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
2875707|NCT03420079|Experimental|fcn-411 4mg|Cohort 1: 4 mg once daily
2875708|NCT03420079|Experimental|fcn-411 8mg|Cohort 2: 8 mg once daily
2875709|NCT03420079|Experimental|fcn-411 16mg|Cohort 3: 16 mg once daily
2875710|NCT03420079|Experimental|fcn-411 24mg|Cohort 4: 24 mg once daily
2875711|NCT03420079|Experimental|fcn-411 32mg|Cohort 5: 32mg once daily
2875712|NCT03420066||Retrospective data collection|Group includes subjects that were implanted with the Nexus device as part of compassionate use procedure before joining the CIP008 study. Only intervention foreseen by CIP008 study is retrospective collection of data previously recorded as standard of care in medical charts (refer to Intervention/treatment section)
2875713|NCT03420053|Experimental|Group 1 HIV- vaccine recipients|"Group 1: n=6, HIV negative vaccine recipients will receive 9.0x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 1, n=9, where volunteers will be randomized in a 1:2 ratio to receive either normal saline placebo (NS) or PfSPZ Vaccine.~Efficacy will be assessed by controlled human malaria infection (CHMI) at +3 weeks (+2 to +10 weeks) after the last dose of PfSPZ Vaccine. CHMI will be by DVI of 3,200 PfSPZ Challenge."
2875714|NCT03420053|Placebo Comparator|Group 1 HIV- NS controls|"Group 1: n=3, HIV negative NS placebo recipients will receive NS at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 1, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of NS. CHMI will be by DVI of 3,200 PfSPZ Challenge."
2875715|NCT03420053|Experimental|Group 2a HIV+ vaccine sentinels|Group 2a: n=3, HIV positive vaccine recipients will receive 4.5x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days.
2875716|NCT03420053|Experimental|Group 2b HIV+ vaccine recipients|"Group 2b: n=6, HIV positive vaccine recipients will receive 9.0x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 2b, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of PfSPZ Vaccine. CHMI will be by DVI of 3,200 PfSPZ Challenge."
2875717|NCT03420053|Placebo Comparator|Group 2b HIV+ placebo controls|"Group 2b: n=3, HIV positive NS placebo recipients will receive NS at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 2b, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of NS. CHMI will be by DVI of 3,200 PfSPZ Challenge."
2875718|NCT03420040|Experimental|QS-M Needle Free Injector group|To observe the use of insulin in glycemia under good blood glucose control in the QS-M Needle Free Injector group.
2875719|NCT03420040|Active Comparator|Glargine pen group|To observe the amount of insulin used by the Glargine pen group under good blood glucose control.
2875720|NCT03420014|Active Comparator|Arm 1: Doxorubicin|Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
2875721|NCT03420014|Experimental|Arm 2: L19TNF plus doxorubicin|"Patients will receive a fixed dose of L19TNF in combination with a fixed dose doxorubicin.~Doxorubicin will be administered as a 15 ± 5 minutes i.v. infusion on day 1 of each 21-day cycle followed by at least 30 minutes pause before starting infusion of L19TNF."
2875722|NCT03420001||VBAC|secundiparous women after one vaginal birth after caesarean section
2875723|NCT03420001||controls|women after one vaginal delivery
2875724|NCT03419988|Experimental|Exercise Intervention|8-weeks exercise intervention: 3-days per week for 45-55 minutes per session
2875725|NCT03419988|No Intervention|Control|8-weeks control: asked not to change anything or start exercising.
2875726|NCT03419975|Experimental|TJO-002|
2875727|NCT03419975|Active Comparator|latanoprost|
2875728|NCT03419962||COPD patients|Chronic obstructive pulmonary disease
2875729|NCT03419936||Helicobacter pylori(HP) positive|Participants who are diagnosed with gastric cancer and Helicobacter Pylori infection will be treated with subtotal gastrectomy.
2875730|NCT03419923|Placebo Comparator|saline flushes|saline flushes with 250 mL were carried out every 30 min.
2875731|NCT03419923|Active Comparator|one stage regional citrate|one stage regional citrate:4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
2875732|NCT03419923|Experimental|two stage regional citrate|two stage regional citrate:4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
2875733|NCT03419910|Experimental|BMS-986165 and cyclosporine|BMS-986165 and cyclosporine administered orally
2875734|NCT03419897|Experimental|BGB-A317|BGB-A317: 200 mg once every 3 weeks (Q3W), intravenous dosing (IV)
2875735|NCT03419871||monitoring sleep effects on toddlers|Monitoring the sleep characteristics of toddlers living in economically stressed communities.
2875736|NCT03419858|Experimental|Mindfulness Meditation Group|"Subjects participated in four sessions (20 min/session) of mindfulness training. Participants were taught that perceived sensory events are momentary and fleeting and require no further evaluation. They were asked to close their eyes, relax and to focus on the flow of their breathing and simply let go of discursive thoughts."
2875737|NCT03419858|Active Comparator|Placebo Meditation Group|The purpose of this intervention was to lead subjects to attend to one's breathing in a non-evaluative manner. Subjects were instructed to sit with a straight posture, closed eyes, and to take a deep, slow breaths every 2-3 minutes.
2875738|NCT03419858|Active Comparator|Slow-Breathing Group|A validated (Chalaye et al., 2009) slow breathing training regimen was employed, using fluctuating light, to teach individuals to independently lower their respective respiration rate. Subjects practiced lowering their respiration rates across four, 20 minute sessions.
2875739|NCT03419845|Experimental|Step Right Buddy arm|To use modified walking frame using the Step Right Buddy
2875740|NCT03419832|Experimental|NEAT Form|Study participants will be randomized to the NEAT form and the materials that accompany it (also detailing the ARIC study).
2875741|NCT03419832|Active Comparator|Standard Form|Study participants will be randomized to the traditional standard consent form (detailing the ARIC study).
2875742|NCT03419819|Experimental|PKU Sphere|"Phase 1: 1 week To evaluate the acceptability of PKU Sphere during a short-term (1 week) period. Individuals with PKU will aim to consume a minimum of 30% of the medical food component of the diet as PKU Sphere. The amount will be assessed and advised on an individual basis.~Phase 2: 4 weeks To evaluate longer-term acceptability and metabolic control in individuals with PKU consuming an agreed target of 50 - 100% of their medical food component of the diet as PKU Sphere for 4 weeks. Some individuals, particularly young children between the ages of 3 - 6 years, may require a 1 - 3 week build up period to reach target volume which will be assessed on an individual basis."
2875743|NCT03419806|Experimental|Infudopa i.v.|Infudopa i.v. in 75% of the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid i.v. constant rate administration followed by continuous i.v. infusion.
2875744|NCT03419806|Experimental|Infudopa s.c.|Infudopa s.c. in the same dosage as the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion.
2875745|NCT03419806|Active Comparator|LCIG (Duodopa)|Individually optimized dosing of LCIG (Duodopa) (delivered directly to the proximal small intestine via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube connected to a portable infusion pump) will be delivered over a 16-h period, administered as a morning rapid constant rate administration followed by continuous infusion.
2875746|NCT03419793|Experimental|physical therapy intervention and segmental muscle vibration|physiotherapy intervention and segmental muscle vibration device
2875747|NCT03419793|Sham Comparator|physical therapy intervention|physical therapy intervention alone
2875748|NCT03419780|Active Comparator|Single-Unit Blood Transfusion Protocol|In this arm, patients receive a 1 unit pRBC transfusion with the plan for post-transfusion blood count at 4-6 hours post-transfusion and clinical reassessment.
2875749|NCT03419780|Active Comparator|Multiple-Unit Blood Transfusion Protocol|In this arm, patients receive 2 units of pRBCs, followed by 4-6 hour post-transfusion blood count and clinical reassessment.
2875750|NCT03419767|Active Comparator|surgery with melatonin|Patients under carotid revascularization surgery with melatonin taken during perioperative period.
2875751|NCT03419767|Sham Comparator|surgery with blank control|Patients under carotid revascularization surgery with nothing unnecessary taken during perioperative period
2875752|NCT03419754|Experimental|Glucose and Fidgetting|75 g of glucose will be given at the beginning of the study day (days one with glucose+fidgeting )
2875753|NCT03419754|Placebo Comparator|Fidgetting|Subjects will fidget their legs in an up and down motion for 2.5 min on and then 2.5 min off for the duration of the study.
2875754|NCT03419741|Active Comparator|Active rTMS treatment|Transcranial Magnetic Stimulation Clinical Research System will be used for the active rTMS treatment. Stimulation frequency for all active subjects: 10 Hertz - Pulse train duration (on time) 5 seconds, Inter-train interval (off time) 10 seconds (15 second cycle time), Power (intensity) level 100% resting motor threshold, Total 60 trains, 15 minutes, Total pulses 3000 per day, 3000 x 5 = 15000 pulses for 5 sessions.
2875857|NCT03419039|Experimental|Anthocyanins|Medox. 2 capsules x 2 daily, 320 mg daily.
2875755|NCT03419741|Sham Comparator|Sham rTMS treatment|Transcranial Magnetic Stimulation Clinical Research System -sham TMS will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
2875756|NCT03419728|Experimental|Healthy Families, Healthy Futures|Family coaches meet with participating pregnant and parenting females, the woman's partner, and the child. Visit frequency varies from once per week to once per month, depending on the length of time in the program, the client's needs, and the accomplishment of program milestones. In the short term, the program seeks to increase the use of Long-Acting Reversible Contraception (LARC), enhance family functioning including improving father involvement, and to meet the baby's child development needs. In the long term, the program aims to delay subsequent pregnancies, ensure positive child development, and increase parents' self-sufficiency.
2875757|NCT03419728|No Intervention|Control group|"No active treatment for control group. Control group has access to business as usual services in community."
2875758|NCT03419715|Experimental|Bimatoprost Topical Solution|0.03% bimatoprost topical solution applied daily to the nail bed of fingers on one hand for 12 weeks
2875759|NCT03419715|Placebo Comparator|Control|Saline placebo topically applied daily to the nail be of fingers on one hand for 12 weeks
2875760|NCT03419702|No Intervention|Control|No almonds
2875761|NCT03419702|Experimental|Experimental|Almonds
2875762|NCT03419689|Experimental|Sample Collection|"The following samples may be collected during the study:~Tumour tissue samples~Blood samples~Ascites samples~Other fluids requiring drainage"
2875763|NCT03419676|No Intervention|Control|No reinforcement.
2875764|NCT03419676|Experimental|Hemopatch|Reinforcement with Hemopatch.
2875765|NCT03419663||gastric cancer|
2875766|NCT03419650|Other|Treatment arm|treatment arm for 12 weeks followed by observation period of 12 weeks, and a bone density at week 52.
2875767|NCT03419637|No Intervention|Control - Standard of Care|The standard of care consists of in-clinic counseling, informational handouts, and access to patient medical records
2875768|NCT03419637|Experimental|Intervention - Mobile app|The mobile app, or app, is used to document before and after photos of the excised skin areas and to document related diagnoses. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
2875769|NCT03419624|Experimental|Dapagliflozin plus Exenatide|Dapagliflozin (10mg orally once daily) plus Exenatide (2mg subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy
2875770|NCT03419624|Placebo Comparator|Placebo plus Placebo|Placebo (film-coated tablet once daily) plus Placebo (subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy
2875771|NCT03419624|Active Comparator|Placebo plus Exenatide|Placebo (film-coated tablet once daily) plus Exenatide (2mg subcutaneous once- weekly injection) as add-on to high dose intensive insulin therapy
2875772|NCT03419611|Experimental|Multi-Modal|3 Times Per Week for 4 weeks - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component followed by more treatment for 12 weeks
2875773|NCT03419611|Experimental|Multi-Modal + High Intensity Multi-Modal|3 Times Per Week - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 4 weeks, increasing to 5 times per week for 12 weeks
2875774|NCT03419611|Placebo Comparator|Treatment as Usual|Teacher provided with word list for 4 weeks followed by more treatment as usual for 12 weeks
2875775|NCT03419611|Experimental|Treatment as Usual + Multi-Modal|Teacher provided with word list for 4 weeks followed by 3 Times Per Week - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 12 weeks
2875776|NCT03419611|Experimental|Treatment as Usual + High Intensity Multi-Modal|Teacher provided with word list for 4 weeks followed by Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 5 times per week for 12 weeks
2875777|NCT03419598|Experimental|ToKa HTO|"Opening wedge high tibial osteotomy~ToKa subject specific custom HTO plate"
2875778|NCT03419598|Active Comparator|Generic HTO|"Opening wedge high tibial osteotomy~Generic HTO plate"
2875779|NCT03419585|Experimental|Intervention light|30 minutes of intervention systematic light exposure daily for the course of radiation therapy (approximately 8 weeks).
2875780|NCT03419585|Active Comparator|Comparison light|30 minutes of comparison systematic light exposure daily for the course of radiation therapy (approximately 8 weeks).
2875781|NCT03419572||Second line therapy|Data collection
2875782|NCT03419572||Third and later line therapy|Data collection
2875783|NCT03419559|Experimental|Cohort 1 LN-145 alone|After nonmyeloablative (NMA) lymphodepletion, patients are infused with their autologous (LN-145) followed by IL-2 administration
2875784|NCT03419559|Active Comparator|Cohort 2 LN-145 in combination with durvalumab|After nonmyeloablative (NMA) lymphodepletion, patients are infused with their autologous (LN-145) followed by IL-2 administration. Patients in cohort 2 will also receive durvalumab Q4Weeks
2875785|NCT03419546||Bronchoscopic procedures|Bronchoscopies performed in different sites to evaluate the level of satisfaction of the operators with the device Ambu® aScope™ 4
2875786|NCT03419533||4CMenB vaccinated|4CMenB vaccinated school leavers
2875787|NCT03419533||Unvaccinated|School leavers not vaccinated with 4CMenB vaccine
2875788|NCT03419520|Experimental|Intervention group|Schools receive healthy actions aimed to reduce the risk of developing obesity, along the study
2875789|NCT03419520|No Intervention|Control group|Schools monitored along the study but won't receive any healthy action.
2875790|NCT03419507|Active Comparator|Macintosh group|After separating participants into two groups, doctors that drawed envelop number 1 will be asked to intubate with laryngoscope by using No. 3 Macintosh laryngoscope
2875791|NCT03419507|Active Comparator|Endotracheal tube introducer group|After separating participants into two groups, doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by using the adult size endotracheal tube introducer with using No. 3 Macintosh laryngoscope.
2875792|NCT03419494||VDCLD regimen containing PLD|PLD 36mg/㎡.d d1、d15，ivdrip，1h，VCR 1.4mg/㎡.d d1，d8，d15，d22 iv，CTX 800mg/㎡.d d1 ivdrip，L-asp 6000u/㎡.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
2875793|NCT03419494||VDCLD regimen containing DNR|DNR 45mg/㎡.d d1～3，ivdrip，1h，VCR 1.4mg/㎡.d d1，d8，d15，d22 iv，CTX 800mg/㎡.d d1 ivdrip，L-asp 6000u/㎡.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
2875794|NCT03419481|Experimental|pembrolizumab|
2875795|NCT03419468|Experimental|1|iPad administration of Self Geriatric Assessment Measure (SGAM)
2875796|NCT03419468|Active Comparator|2|Paper survey administration of Self Geriatric Assessment Measure (SGAM)
2875797|NCT03419455||Men|Health Professionals Follow-up Study: a prospective cohort of male health professionals
2875798|NCT03419455||Women|Nurses' Health Study: a prospective cohort of female registered nurses
2875799|NCT03419442||Ra-223 therapy before chemotherapy|Treatment sequence 1 will include all mCRPC patients who received Ra-223 alone or in combination with abiraterone or enzalutamide and subsequently received chemotherapy
2875800|NCT03419442||Ra-223 after chemotherapy|Treatment sequence 2 includes all mCRPC patients who received chemotherapy before Radium 223 therapy
2875801|NCT03419429|Experimental|Simvastatin/Occlusive membrane|open flap procedure, 1.2%simvastatin gel applied and covering the defect with resorbable collagen occlusive membrane .
2875802|NCT03419429|Experimental|Simvastatin/perforated membrane|open flap procedure, 1.2% simvastatin gel and covering the defect with resorbable collagen modified perforated membrane.
2875803|NCT03419429|Experimental|EDTA/Simvastatin/Occlusive membrane|open flap procedure, 24% EDTA root surface etching,1.2% simvastatin gel and then coverage of the defect with occlusive membrane.
2875804|NCT03419429|Experimental|EDTA/Simvastatin/perforated membrane|open flap procedure, 24% EDTA root surface etching, 1.2% simvastatin gel and then coverage of the defect with modified perforated membrane.
2875805|NCT03419403|Experimental|Arm B: Standard Steroids + Vasoconstrictor + Cold Compress|Arm B: Steroid eye drop plus vasoconstrictor eye drop and cold compress plus depatuxizumab mafodotin during both the chemoradiation therapy (RT and TMZ) and the adjuvant therapy [TMZ] periods of this study.
2875806|NCT03419403|Experimental|Arm A: Standard Steroid (SS)|Arm A: Steroid Eye Drops plus depatuxizumab mafodotin during both the chemoradiation therapy (radiation [RT] and temozolomide [TMZ]) and the adjuvant therapy [TMZ] periods of this study.
2875807|NCT03419403|Experimental|Arm C: Enhanced Steroids+Vasoconstrictor+Cold Compress (ES/VC)|Arm C: Steroid Eye Drop plus ophthalmic steroid ointment plus vasoconstrictor eye drop and cold compresses plus depatuxizumab mafodotin during both the chemoradiation therapy (RT and TMZ) and the adjuvant therapy [TMZ] periods of this study.
2875808|NCT03419390|Other|Healthy subjects|One eye of each participant will be scanned with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
2875809|NCT03419390|Other|Diseased groups|lf one eye is affected, this will be chosen. lf both eyes are be affected, the eye with the severest symptoms will be chosen. Scanning with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
2875810|NCT03419390|Other|Diseased subgroups|"Every second subject will be allocated to the subgroup.~Scanning with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)~Thickness measurement with reference medical device."
2875811|NCT03419377|Experimental|Standard care and sexological counseling|Standard care including gynecological examination and 6-8 sexological consultations.
2875812|NCT03419377|No Intervention|Standard care|Standard care including gynecological examination.
2875813|NCT03419364|Experimental|Nicotinamide|All participants will receive study agent
2875814|NCT03419351|Other|Main group|Main study group including all individuals that underwent the study procedures
2875815|NCT03419338|Experimental|Test group|Surgical alveolus + maxillary sinus lift with inorganic bovine bone + newly forming bone + collagen membrane
2875816|NCT03419338|Active Comparator|Control group|Maxillary sinus lift with inorganic bovine bone + collagen membrane
2875817|NCT03419325|Experimental|HTPR/LOF|"Presence of both high on-treatment platelet reactivity (HTPR) and CYP2C19 loss-of-function (LOF) alleles:~An alternative therapy with either prasugrel or ticagrelor (in line with specific contraindications and precautions for each agent) will be strongly recommended for HPR/LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
2875818|NCT03419325|Experimental|HTPR/no-LOF|"Presence of HTPR, but no CYP2C19 LOF allele found:~An alternative therapy should be considered for HTPR/no-LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
2875819|NCT03419325|Experimental|no-HTPR/LOF|"Presence of a CYP2C19 LOF allele, but no HTPR:~An alternative therapy should be considered for no-HTPR/LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
2875820|NCT03419325|Experimental|No-HTPR/No-LOF|"Absence of both HTPR and CYP2C19 LOF alleles:~Maintaining clopidogrel for no-HPR/no-LOF patients. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
2875821|NCT03419312|Experimental|Study sequence A|"Proclaim™ Elite 5: Burst - Washout - Sham~14 days of burst stimulation.~7 days washout.~14 days of sham stimulation."
2875822|NCT03419312|Experimental|Study sequence B|"Proclaim™ Elite 5: Sham - Washout - Burst~14 days of sham stimulation.~7 days washout.~14 days of burst stimulation."
2875823|NCT03419299||Pre- Application|Patients admitted prior to use of tube feeding application
2875824|NCT03419299||Post- Application|Patients admitted when tube feeding application was being used.
2875825|NCT03419286||EGFR MUTATED|patient with lung cancer with EGFR mutation before transformation into small cell lung cancer
2875826|NCT03419286||EGFR NON MUTATED|patient with lung cancer without driver oncogenic before transformation into small cell lung cancer
2875827|NCT03419260||Cohort|Critically ill child undergoing clinically indicated EEG monitoring and electrographic seizure management.
2875828|NCT03419247|Experimental|Tumor tissue and blood sample collection|
2875858|NCT03419039|Placebo Comparator|Placebo|2 identically appearing placebo capsules daily
2875859|NCT03419026||breast cancer|
2875860|NCT03419026||control|
2875861|NCT03419013|Experimental|Test of new adhesive strip|A new adhesive strip has been developed and will be tested in this investigation
2875829|NCT03419234|Experimental|Arm A (abiraterone acetate, prednisone, cabazitaxel)|Patients receive abiraterone acetate PO QD on days 1-21, prednisone PO BID on days 1-21. Courses of abiraterone acetate and prednisone repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients receive cabazitaxel IV over 1 hour on day 1, and treatment with cabazitaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
2875830|NCT03419234|Active Comparator|Arm B (abiraterone acetate, prednisone)|Patients receive abiraterone acetate and prednisone as in Arm A. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
2875831|NCT03419221|Active Comparator|A: Patients with PET/CT performs at day 14 after the drawing|Arm A: Patients with PET/CT performs at day 14 after the drawing of the first blood culture
2875832|NCT03419221|Placebo Comparator|B : Patients' routine care with performance of explorations|Arm B : Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
2875833|NCT03419208|Experimental|SPIN-HAND Program|Offered the SPIN-HAND program
2875834|NCT03419208|No Intervention|Treatment as usual|Not offered SPIN-HAND program, treatment as usual
2875835|NCT03419195|Experimental|Cardiovascular Exercise|Cardiovascular exercise training is conducted 3 times a week for 3 months under the supervision of experienced exercise specialists. Each session will last a total of one hour - a 5 minute warm up, 50 minutes of cardiovascular exercise using a treadmill, stationary bike, elliptical, rowing machine, or a combination of machines, and a 5 minute cool-down. Exercise intensity will be based on heart rate. There will also be a 3 week ramp-up period to get accustomed to exercising. This is in addition to the 3 month intervention.
2875836|NCT03419182|Active Comparator|RCT - ORIF|A patient in this study arm consents to randomization and receives RCT - ORIF as his/her treatment assignment. He/she will have his/her acetabular fracture treated by open reduction internal fixation.
2875837|NCT03419182|Active Comparator|RCT - (THA) + ORIF|A patient in this study arm consents to randomization and receives RCT - (THA) + ORIF as his/her treatment assignment. He/she will have his/her acetabular fracture treated by open reduction internal fixation with primary total hip arthroplasty.
2875838|NCT03419182|No Intervention|OBS - ORIF|A patient in this study arm does not consent to randomization, but does agree to be involved in the observational study. He/she decides, with input from his/her surgeon, to have his/her acetabular fracture treated by open reduction internal fixation.
2875839|NCT03419182|No Intervention|OBS (THA) + ORIF|A patient in this study arm does not consent to randomization, but does agree to be involved in the observational study. He/she decides, with input from his/her surgeon, to have his/her acetabular fracture treated by open reduction internal fixation with primary total hip arthroplasty.
2875840|NCT03419169|Experimental|Light load BFR resistance training|This arm of the clinical trial will involve eight weeks of twice weekly light load resistance training with BFR. Patients in this arm will complete four sets (30, 15, 15 and 15 repetitions, respectively) of unilateral leg press exercise at 30% of predicted one repetition maximum. BFR will be applied at 80% of total limb arterial occlusive pressure. Both legs will be trained, with the affected limb trained first and the unaffected limb matched for volume at a relative percentage of one repetition maximum. Both legs will be trained with BFR.
2875841|NCT03419169|Active Comparator|Heavy load resistance training|This arm of the clinical trial will involve eight weeks of twice weekly heavy load resistance training. Patients in this arm will complete three sets of ten repetitions of unilateral leg press exercise at 70% of predicted one repetition maximum. Both legs will be trained, with the affected limb trained first and the unaffected limb matched for volume at a relative percentage of one repetition maximum.
2875842|NCT03419156|Experimental|Text Message Arm|Patients in the Text Message Arm will receive a weekly set of text messages inquiring about the patients' symptoms instead of a weekly phone call from the nurse team (standard of care). Potentially harmful symptoms identified by the automated system will generate an alert that will be sent to the medical team. The alert will be immediately sent via email to the nursing team. The nurse will be able to contact the patient to decide the best further treatment. The nurses will check patient response rates daily. If a patient does not respond to their weekly message, then the patient will be called.
2875843|NCT03419143||Biologic-naive adults initiating abatacept for PsA|Adult patients, naïve of abatacept and any other biologic agent, initiating abatacept for PsA, under usual practice conditions
2875844|NCT03419143||Adults initiating abatacept for PsA after one failed TNFi|Adult patients, naïve of abatacept, who previously failed one tumor necrosis factor inhibitor (TNFi), initiating abatacept for PsA, under usual practice conditions
2875845|NCT03419130|Experimental|Cohort I (pembrolizumab, hypofractionated RT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients also receive hypofractionated RT over 5 fractions for 14 days.
2875846|NCT03419130|Experimental|Cohort II (pembrolizumab, conventionally fractionated RT)|Patients receive pembrolizumab as in Cohort I. Patients also receive conventionally fractionated RT over 30 fractions for 52 weeks.
2875847|NCT03419117|Experimental|Treatment|Patients in the experimental arm will receive an ESP block prior to induction of general anesthetic for their thoracoscopic wedge resection
2875848|NCT03419117|Placebo Comparator|Placebo|Patients allocated to the placebo-control arm will receive a placebo injection of normal saline in a fashion almost identical to that of the ESP block.
2875849|NCT03419104|Experimental|Preoperative walk test|Patients undergoing bariatric surgery who will complete a preoperative 60 meters 60 seconds walk test.
2875850|NCT03419091|Active Comparator|Reusable Ureteroscope|Standard ureteroscope.
2875851|NCT03419091|Experimental|single-use flexible digital ureteroscope (LithoVue)|Disposable ureteroscope being tested.
2875852|NCT03419065|Other|Relaxation Intervention|Women hospitalized on bed-rest for high risk pregnancy participated in Relaxation Interventions.
2875853|NCT03419052|Experimental|MINDSpeed Intervention|Consumption of foods high in polyphenols (i.e., MIND foods) AND speed of processing training
2875854|NCT03419052|Experimental|MIND food and training control|Consumption of foods high in polyphenols and online (inert) games
2875855|NCT03419052|Experimental|Control foods and speed of processing traini|Consumption of low polyphenol foods and speed of processing training
2875862|NCT03419000|Experimental|Patient|Patients suffering from drug-resistant focal epilepsy or from drug-resistant generalized epilepsy according to ILAE classification and undergoing long-term video-EEG monitoring in Epilepsy unit of Lyon to record and characterize her/his seizure
2875863|NCT03419000|Active Comparator|healthy volunteers|Adult (≥ 18 years) Without history of neurological disorders and/or psychiatric disorders, and/or general medical disorders
2875864|NCT03418987||Deformities of the spinal column|Patients with adolescent idiopathic scoliosis or adult degenerative scoliosis, treated or untreated.
2875865|NCT03418974|Experimental|Pitavastatin treatment|The drug pitavastatin is given to the patient according to the doctor's order and restricted to BangZhi produced by Jiangsu Wanbang Medicine Marketing Co., Ltd..
2875866|NCT03418974|Experimental|Atorvastatin treatment|The drug atorvastatin is given to the patient according to the doctor's order and the drug band is unspecified.
2875867|NCT03418974|Experimental|Rosuvastatin treatment|The drug atorvastatin is given to the patient according to the doctor's order and the drug band is unspecified.
2875868|NCT03418961|Experimental|Arm I (carvedilol)|Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive carvedilol PO BID. Courses repeat every 12 weeks for 108 weeks in the absence of disease progression or unacceptable toxicity.
2875869|NCT03418961|Active Comparator|Arm II (no intervention)|Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive no study intervention for up to 108 weeks.
2875870|NCT03418961|Active Comparator|Arm III (observation)|Patients undergo observation for up to 108 weeks.
2875871|NCT03418948|Active Comparator|2 x CC|2 x conventional colonoscopy (CC), back-to-back design
2875872|NCT03418948|Active Comparator|CC followed by EC|Conventional colonoscopy followed by Endocuff Vision- assisted colonoscopy, back-to-back design
2875873|NCT03418948|Active Comparator|EC followed by CC|Endocuff Vision-assisted colonoscopy followed by conventional colonoscopy, back-to-back design
2875874|NCT03418948|Active Comparator|2 x EC|2 x Endocuff Vision-assisted colonoscopy
2875875|NCT03418935|Experimental|Remaxol 400 ml|Group I: treatment with Remaxol 400 ml IV + Ringer solution 400 ml IV for 7 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
2875876|NCT03418935|Experimental|Remaxol 800 ml|Group II: treatment with Remaxol 800 ml IV for 7 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
2875877|NCT03418935|Placebo Comparator|Control|Group III: Ringer's solution 800 ml IV for 7 days. Drug: Ringer's solution
2875878|NCT03418922|Experimental|Part 1: Lenvatinib Plus Nivolumab|Participants will receive specified doses of lenvatinib (oral) and nivolumab (intravenous) on specified days.
2875879|NCT03418922|Experimental|Part 2: Lenvatinib Plus Nivolumab|If tolerable in Part 1, participants will receive specified doses of lenvatinib and nivolumab on specified days until criteria for discontinuation are met.
2875880|NCT03418909||Primary TORS group|Eligible patients with histologically verified early stage (T1-2, N1, M0) squamous cell carcinoma of the oropharynx undergoing transoral robotic surgery
2875881|NCT03418909||Primary oncological group|Eligible patients with histologically verified any stage squamous cell carcinoma of the oropharynx undergoing primary oncological treatment.
2875882|NCT03418896|Experimental|human chorion gonadotropin|Pregnyl, hCG, 5000 IU times one im.
2875883|NCT03418883|Experimental|Mirror therapy|Patient is sitting on a conventional chair and placed her/his forearms on a table. A mirror (45 cm × 40 cm) is positioned between the two arms, at right angle with the patient's trunk. The reflective surface is oriented so that the participant could easily see the mirror image of his/her sound arm. Patient practises his/her sound arm with exercises, ranging from the simple elbow flexion-extension to complex tasks.
2875884|NCT03418883|Sham Comparator|Sham therapy|Patient is sitting on a conventional chair and placed her/his forearms on a table. A box (45 cm × 40 cm) is positioned between the two arms, at right angle with the patient's trunk. The opaque surface replaces the mirror reflecting surface. Patient practises his/her sound arm with exercises,ranging from the simple elbow flexion-extension to complex tasks.
2875885|NCT03418870|Experimental|Family Integrated Care (mFI-Care)|Parents of infants assigned to the Family Integrated Care (mFI-Care) intervention will be treated as primary caregivers for their infants and participate in daily medical rounds, with mFI-Care-trained nurses serving as teachers and coaches. Parent training on the Canadian FI-Care Parent Curriculum will be provided during small group sessions facilitated by the study team. Parents will receive peer support from mFI-Care-trained alumni parents and can interact with other mFI-Care parents through the We3Health App secure online parent forum. mFI-Care parents will be expected to track time spent with their infant; record infant activity, feeds and output; track learning and skills acquisition; and keep a journal of the NICU experience using the We3Health app.
2875886|NCT03418870|No Intervention|Family-Centered Care (FCC)|Infants assigned to usual FCC will have NICU nurses as primary caregivers per standard NICU protocol. FCC provides parents with orientation to the NICU; individualized teaching and support; and encouragement to participate in infant care under nursing supervision. Individualized support from social workers, lactation consultants and other specialists will be offered. As part of the study, parents will be asked to use the We3Health mobile app track their time in the NICU, time learning and time spent in infant caregiving activities and to keep of a journal of their NICU experience.
2875887|NCT03418857|Experimental|Experimental|Participants will consume one yogurt smoothie daily for the duration of the intervention that contains 3.16 × 109 colony forming units (CFU) bifidobacterium animalis subsp. lactis BB-12. Participants will be asked to refrain from consumption of other yogurt or probiotic-containing foods.
2875888|NCT03418857|Placebo Comparator|Control|Participants will consume one yogurt smoothie daily for the duration of the intervention that contains no BB-12. Participants will be asked to refrain from consumption of other yogurt or probiotic-containing foods.
2875889|NCT03418844|Other|Interest group (patients treated with chemotherapy)|Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment
2875890|NCT03418844|Other|Patient control group (patients not treated with chemotherapy)|Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment
2875891|NCT03418844|Other|Healthy volunteers|Healthy volunteers will complete several self-questionnaires on living conditions and quality of life.
2875894|NCT03418805|Experimental|Ibuprofen CR Tablet 600 mg-fasting|One tablet of IBUCR 600 mg under fasting condition
2875895|NCT03418805|Experimental|Ibuprofen CR Tablet 600 mg-fed|One tablet of IBUCR 600 mg under fed condition
2875896|NCT03418805|Active Comparator|Advil Ibuprofen table 200 mg-fasting|IBUAdv with a 4-hour dosing interval for 3 tablets (3×200 mg, q4h) under fasting condition
2875897|NCT03418805|Active Comparator|Motrin IB Ibuprofen Tablets 200 mg-fasting|IBUMot with a 4-hour doing interval for 3 tablets (3×200 mg, q4h) under fasting condition
2875898|NCT03418792||60Gy HNC Patients|Head and Neck Cancer patients on 60Gy radiotherapy dose regimen
2875899|NCT03418792||70Gy HNC Patients|Head and Neck Cancer patients on 70Gy radiotherapy dose regimen
2875900|NCT03418779|Experimental|Combination Therapy|Optimized supportive care, oral granular infusion of Yi-Qi-Qing-Jie herbal compound, prednisolone plus intravenous cyclophosphamide.
2875901|NCT03418779|Experimental|Immunosuppressive Monotherapy|Optimized supportive care, oral granular infusion of Yi-Qi-Qing-Jie herbal compound placebo, prednisolone plus intravenous cyclophosphamide.
2875902|NCT03418766||Normal|Normal healthy individual without migraine.
2875903|NCT03418766||Magraine|Clinical history of migraine diagnosed by a neurologist according to the International Classification of Headache Disorders.
2875904|NCT03418753||single|subjects with abnormal intracranial pressure
2875905|NCT03418740||FA Children|Children between the ages of 2 and 18 with genetically confirmed Friedreich's Ataxia
2875906|NCT03418727|Experimental|Study Drug Arm #1|Combination Therapy: brimonidine (0.2%) administered as eye drops, followed by corticosteroid eye drops, two times a day (BID) for 12 weeks
2875907|NCT03418727|Experimental|Study Drug Arm #2|Monotherapy: brimonidine (0.2%) administered as eye drops followed by placebo, two times a day (BID) for 12 weeks
2875908|NCT03418727|Placebo Comparator|Control Arm|Placebo: sodium carboxymethylcellulose (0.25%) administered as eye drops followed by a second application, two time a day (BID) for 12 weeks
2875909|NCT03418714|Experimental|Salvinorin A administration|All volunteers will be assigned to the salvinorin A administration arm.
2875910|NCT03418701|Active Comparator|Patient Centered Culturally Sensitive WLM|This program is designed to enable physicians to: (a) talk with their patients about their weight, weight loss goals, goal barriers, strategies for overcoming these barriers, and deliver this talk in patient-centered, culturally sensitive ways, (b) assist their patients with engaging in self-identified strategies for achieving and sustaining their self selected goals for weight loss and overall health, (c) be knowledgeable about health-smart behaviors, (d) use behaviors and display attitudes in physician-patient interactions with patients that are provider cultural sensitivity indicators in published literature, and (e) say and display behaviors and attitudes that patients identified as important when discussing obesity and losing weight.
2875911|NCT03418701|Active Comparator|Standard Behavioral WLM|This program is designed to enable physicians to: (a) implement motivational interviewing approaches when talking with their patients about their weight loss goals and behavioral strategies to achieve these goals, (b) become knowledgeable about empirically supported behavioral change principles that have been used to help patients maintain weight loss in previous interventions, (c) communicate how to use these empirically supported behavioral change principles to have patients initiate or maintain their self-selected health-smart goals related to weight loss and/or weight loss maintenance, and (d) use motivational interviewing approaches to communicate empathy and understanding with patients who are struggling to maintain their weight loss and/or accomplish a behavioral goal.
2875912|NCT03418688|Active Comparator|COR388|Increasing doses of COR388 will be administered for 10 days in cohorts 1-3 and for 28 days in cohort 4.
2875913|NCT03418688|Placebo Comparator|Placebo|Matching placebo capsules will be administered for 10 days in cohorts 1-3 and for 28 days in cohort 4.
2875914|NCT03418675|Placebo Comparator|Placebo|1 milligram per day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.
2875915|NCT03418675|Experimental|Rexulti|1 milligram per day day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.
2875916|NCT03418662|No Intervention|Control Arm (Standard Colonoscopy)|Standard colonoscopy with no device attachment.
2875917|NCT03418662|Experimental|EndoRings Colonoscopy|Colonoscopy with EndoRings device attached to the distal end of the scope.
2875918|NCT03418649|Experimental|Experimental|Eplerenone 50 Mg Tab
2875919|NCT03418649|Placebo Comparator|Control|Placebo Oral Tablet
2875920|NCT03418636|Experimental|Staying Safe (Ssafe)|"Ssafe is delivered in a small group format (consisting of approximately 10-12 participants) by a trained facilitator over 4 2.5-hour sessions (10 hours total). To help promote the maintenance of risk reduction over the trial's 12-month follow-up period, Ssafe participants will be provided with a novel interactive, smartphone-delivered booster application based on core Ssafe principles and risk reduction strategies."
2875921|NCT03418636|Active Comparator|Healthy Living|Healthy Living is a time- and attention-matched control intervention of equivalent session structure and duration as Ssafe (4 2.5-hour sessions; 10 hours total), also delivered in a small group format (10-12 participants). Healthy Living participants will be provided with a publicly available, sleep hygiene-focused smartphone app to promote healthy sleep habits over the trial's follow-up period.
2875922|NCT03418623|Experimental|GET73|
2875923|NCT03418623|Placebo Comparator|Placebo|
2875924|NCT03418610|Other|Open Label Single Arm|Azelaic Acid Foam 15% applied twice daily
2875925|NCT03418597|Experimental|Deep local anesthesia + Virtual reality|Pre-medication procedures and lidocaïne injection are the same as in the current practice. During the intervention delay, the patient will also experience hypnosis through a virtual reality procedure .
2875926|NCT03418597|Active Comparator|Deep local anesthesia alone|The musculoskeletal biopsy is performed according to the standard practice using a deep local anesthesia with premedication and lidocaïne.
2875927|NCT03418584|Experimental|HybridAPC|The patient with Barrett's esophagus is treatment by HybridAPC.
2875928|NCT03418571|Experimental|ALX-0171 Dose 1|
2875929|NCT03418571|Experimental|ALX-0171 Dose 2|
2875930|NCT03418571|Experimental|ALX-0171 Dose 3|
2875931|NCT03418571|Experimental|ALX-0171 Dose 4|
2875932|NCT03418571|Placebo Comparator|Placebo|
2899383|NCT03252951|Experimental|Isometric Training|
2875933|NCT03418558|Experimental|HERACLES RESCUE|Patients will receive trastuzumab-emtansine, iv 3,6 mg/kg every 21 days. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first
2875934|NCT03418532|Experimental|single arm|MP0250 DARPin® drug candidate (6 mg/kg or 8 mg/kg or 12 mg/kg, infusion) on day 1 of each 21 day cycle. Osimertinib according to label
2875935|NCT03418519|Experimental|CIMT group|4 hours a day for 15days(dosage = 60hours)
2875936|NCT03418519|No Intervention|Control group|no CIMT
2875937|NCT03418506|Experimental|Intervention|A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
2875938|NCT03418506|No Intervention|Control|No specific education will be given to the control group.
2875939|NCT03418493|Experimental|LY3316531 (Part A)|LY3316531 administered IV and/or SC.
2875940|NCT03418493|Placebo Comparator|Placebo (Part A)|Placebo matching LY3316531 administered IV.
2875941|NCT03418493|Experimental|LY3316531 (Part B)|LY3316531 administered IV and/or SC.
2875942|NCT03418493|Placebo Comparator|Placebo (Part B)|Placebo matching LY3316531 administered IV and/or SC.
2875943|NCT03418493|Experimental|LY3316531 (Part C)|LY3316531 administered IV and/or SC.
2875944|NCT03418480|Experimental|RNA Vaccine A|Arm 1A: 15 (6+9) patients with previously treated HPV16+ head and neck squamous cell carcinoma receiving increasing doses of HPV vaccine.
2875945|NCT03418480|Experimental|RAN Vaccine B|Arm 1B: 29 (15+14) patients with HPV16+ advanced disease receiving increasing doses of HPV vaccine.
2875946|NCT03418467||tachycardiomyopathy|Sustained heart rate of over 100 bpm, exclusion of other causes of congestive heart failure including significant valvular disease and coronary artery stenosis over 50%, and partial or complete recovery of left ventricular function after restoration of sinus rhythm or rate control and characteristic histological findings.
2875947|NCT03418467||dilated cardiomyopathy|Patients with dilated cardiomyopathy according to the 2016 ESC (European Heart Association) Guidelines for the diagnosis and treatment of acute and chronic heart failure.
2875948|NCT03418454||Oral Squamous Cell Carcinoma|Buccal mucosa samples for Extraction of BACTERIAL DNA
2875949|NCT03418454||Oral Epithelial Dysplasia|Buccal mucosa samples for Extraction of BACTERIAL DNA
2875950|NCT03418454||Control: Healthy age matched patients|Buccal mucosa samples for Extraction of BACTERIAL DNA
2875951|NCT03418454||Osteonecrosis of the Jaw|Buccal mucosa samples for Extraction of BACTERIAL DNA
2875952|NCT03418454||Underlying disease, no necrosis of the jaw|Buccal mucosa samples for Extraction of BACTERIAL DNA
2875953|NCT03418428||Test group|Patients who underwent total or subtotal gastrectomy for the treatment of gastric cancer
2875954|NCT03418428||Control group 1|Patients who underwent endoscopic mucosal resection/submucosal dissection for the treatment of gastric cancer
2875955|NCT03418428||Control group 2|In-house relatives of Test group and Control group 1 participants
2875956|NCT03418428||Control group 3|Patients with long-term history of proton pump inhibitor usage
2875957|NCT03418415|Experimental|Renal denervation|Procedure: Renal denervation
2875958|NCT03418402|Experimental|Airseal®|Low pression laparoscopy with a 8 to 10 mmHg pneumoperitoneum.
2875959|NCT03418402|Active Comparator|Standard insufflator|laparoscopy realised with our usual insufflation system and a 12 to 15 mmHg pneumoperitoneum.
2875960|NCT03418389||Pediatric-onset Hypophosphatasia|
2875961|NCT03418376|Experimental|MS beta-alanine supplementation|Subjects will perform a 6-month exercise intervention and receive beta-alanine supplements.
2875962|NCT03418376|Placebo Comparator|MS placebo group|Subjects will perform a 6-month exercise intervention and receive placebo tablets.
2875963|NCT03418376|Experimental|HC beta-alanine supplementation|Subjects will perform a 6-month exercise intervention and receive beta-alanine supplements.
2875964|NCT03418376|Placebo Comparator|HC placebo group|Subjects will perform a 6-month exercise intervention and receive placebo tablets.
2875965|NCT03418363|Active Comparator|DHEA Oral Capsule|Subjects will take 100mg DHEA (dehydroepiandrosterone) daily
2875966|NCT03418363|Placebo Comparator|Placebo Oral Capsule|
2875967|NCT03418337|Experimental|dexilansoprazole group (Dexilant 60 mg)|After randomization, 60 subjects will receive oral dexlansoprazole (Dexilant 60 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks. Subjects will record their symptoms (cough, globus, NCCP, heart burn, and acid regurgitation) at daytime and nighttime everyday for 8 weeks. Symptoms suspecting drug adverse effect including nausea, diarrhea, constipation, headache, dizziness, fatigue, flatulence, etc will be recorded for 8 weeks.
2875968|NCT03418337|Active Comparator|lansoprazole group (Takepron OD 30 mg)|After randomization, 60 subjects will receive oral lansoprazole (Takepron OD 30 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks. Subjects will record their symptoms (cough, globus, NCCP, heart burn, and acid regurgitation) at daytime and nighttime everyday for 8 weeks. Symptoms suspecting drug adverse effect including nausea, diarrhea, constipation, headache, dizziness, fatigue, flatulence, etc will be recorded for 8 weeks.
2875969|NCT03418324|Experimental|Arm A: TRC105 + Abiraterone|Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone
2875970|NCT03418324|Experimental|Arm E: TRC105 + Enzalutamide|Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide
2875971|NCT03418311|No Intervention|Control-Group|Control-group-women receive management as usual; i.e. expectant management with interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications.
2875972|NCT03418311|Experimental|Cervical Pessary-Group|placement of the cervical pessary (non-invasive) at enrollment; removal of the cervical pessary (non-invasive) in a regular preventive examination at WoG 37.
2875973|NCT03418298|Experimental|Prehabilitation group|Subjects will carry out a preoperative internet-based program including aerobic and resistance training three sessions per week
2875974|NCT03418272||PICU|This will be a prospective descriptive case series where tracheal cultures and PCR results will be analyzed at initial intubation and again several days into the ICU stay.
2875975|NCT03418272||OR (Control)|For the healthy operating room children, also a case series where a single set of studies will be obtained. tracheal cultures and PCR results will be analyzed after intubation These two groups will be compared, non-randomized.
2875976|NCT03418259|Experimental|Active KCS Medical Device|
2875977|NCT03418259|Placebo Comparator|Inactive KCS Medical Device|
2875978|NCT03418246|Sham Comparator|GIC filling|"Intervention/treatment One group will be treated with a tooth colored filling that will be placed near the gum line (Glass Ionomer).~Placebo Comparator: GIC~Participants will have a restoration placed with GIC in the lesion near the gum line. Device: GIC Application of a tooth colored filling in the cavitated dental lesion. Other Name: Resin modified glass ionomer"
2875979|NCT03418246|Experimental|Biodentine filling|"Intervention/treatment The second group will be treated with Biodentine that will be placed near the gum line.Experimental: Biodentine~Participants will have a restoration placed with Biodentine in the lesion near the gum line. Device: Biodentine Application of a white colored filling in dental lesion."
2875980|NCT03418233|Active Comparator|Active Group|"Patients randomized to the active treatment group: Transcoronary or trans-bypass graft administration of CardioCell consist 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin) will be performed using a dedicated cell delivery catheter.~The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system, Balton, Poland) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties."
2875981|NCT03418233|Placebo Comparator|Control Group|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.
2875982|NCT03418220|Other|AMD early / intermediate|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD early / intermediate
2875983|NCT03418220|Other|AMD exudative|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD exudative
2875984|NCT03418220|Other|AMD atrophic|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD atrophic
2875985|NCT03418220|Other|control group|A blood and aqueous humor sample will be taken during cataract surgery in patients with cataract (control group)
2875986|NCT03418207|Other|TTMB for patients|give trans-perineal template-guided mapping biopsy for participants suspected prostate cancer
2875987|NCT03418194|Experimental|TAES group|Patients in group TAES group received transcutaneous acupoint electrical stimulation (disperse-dense waves, frequency 4/20Hz) at the points of PC6 (Neiguan) and PC4 (Ximen) from 30 min before anesthesia induction to the end of surgery,
2875988|NCT03418194|Placebo Comparator|control group|Patients in group C received electrode plate atthe points of PC6 (Neiguan) and PC4 (Ximen) without any electrical stimulation.
2875989|NCT03418181|Other|Standard Haemodialysis|Thrice weekly dialysis (control arm) - dialysis dose will not be adjusted according to Residual Kidney Function and subjects will be dialysed initially for 3.5-4 hours thrice weekly to ensure a target minimum eKt/V of 1.2.
2875990|NCT03418181|Experimental|Incremental dialysis|"Twice weekly dialysis - dialysis dose will be adjusted according to Residual Kidney Function.~Patients will commence dialysis for 3.5-4 hours twice weekly and have residual renal urea clearance formally measured by interdialytic urine collection at the end of the week following dialysis initiation. Subsequent to this, dialysis dose will be adjusted."
2875991|NCT03418168|Experimental|Molidustat (BAY85-3934)|Molidustat group
2875992|NCT03418155|Experimental|Treatment of TongBi Capsule|
2875993|NCT03418155|Placebo Comparator|Treatment of TongBi Placebo|
2875994|NCT03418142|Experimental|Priovi|Priovi is an Internet-administered intervention for people with BPD.
2875995|NCT03418142|Active Comparator|Care-as-Usual (CAU) / wait list|Additionaly, they will be informed about helpful and free available online self-help-proposals for BPD patients immediately after randomization.
2875996|NCT03418129|Experimental|Mobile App Mindfulness|Participants engage in the use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
2875997|NCT03418129|Experimental|Mobile App Neurofeedback|Participants engage in use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
2875998|NCT03418129|Experimental|Mobile App Relaxation|Participants engage in use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
2875999|NCT03418116|Experimental|Argus II|"Implantation of the Argus II Retinal Prosthesis in patients with advanced Retinitis Pigmentosa who have a measurable central residual visual field smaller than or equal to 5 degrees radius. The array will be placed parafoveally, adjacent to the preserved central visual field (i.e., tunnel vision) in these subjects."
2876000|NCT03418090|Active Comparator|Arm 1|Subjects will first undergo hyperpolarized 129Xe MRI followed by 133Xe scintigraphy
2876001|NCT03418090|Active Comparator|Arm 2|Subjects will first undergo 133Xe scintigraphy followed by hyperpolarized 129Xe MRI
2876002|NCT03418077|Experimental|Energy drink|
2876003|NCT03418077|Placebo Comparator|Placebo|
2876004|NCT03418064|Experimental|fanfilcon A toric|Subjects who wore fanfilcon A toric contact lens, either as the first or second lens in this cross-over study.
2876005|NCT03418064|Active Comparator|lotrafilcon B|Subjects who wore lotrafilcon B toric contact lens, either as the first or second lens in this cross-over study.
2876006|NCT03418051|No Intervention|Control|Control group that will receive no intervention throughout the duration of the study (2-weeks).
2876007|NCT03418051|Experimental|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade III anterior-to-posterior talocrural joint mobilization with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
2899384|NCT03252951|Active Comparator|Biofeedback|
2876008|NCT03418051|Experimental|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage bouts with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
2876009|NCT03418038|Experimental|Arm A (ascorbic acid, combination chemotherapy)|Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 courses may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2876010|NCT03418038|Active Comparator|Arm B (placebo, combination chemotherapy)|Patients receive placebo (normal saline) IV on days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 courses may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2876011|NCT03418038|Experimental|Arm C (ascorbic acid and combination chemotherapy)|Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17 and 19. Patients also receive ifosfamide, carboplatin, and etoposide IV or PO, or cisplatin, cytarabine, and dexamethasone IV or PO, or gemcitabine hydrochloride, dexamethasone, and cisplatin IV or PO, or gemcitabine hydrochloride and oxaliplatin IV or PO, or oxaliplatin, cytarabine, and dexamethasone IV or PO according standard regimen schedule. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve MR or SD after 2 courses may switch to an alternative chemotherapy regimen.
2876012|NCT03418025|Experimental|Group I (Exercising Together program)|"Exercise Intervention. All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment. The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment.~EXERCISING TOGETHER PROGRAM: Participants complete three exercise sessions (approximately 1 hour per session) per week over 5-8 weeks during radiation treatment. Participants also receive a DVD of a partnered strength training exercise program to continue on their own after radiation is completed."
2876013|NCT03418025|Active Comparator|Group II (pre and post testing)|Questionnaire Administration & Survey Administration. All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment. The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment.
2876014|NCT03418012|Experimental|Cervical Pessary-Group|Cervical Pessary Group: placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at WoG 37
2876015|NCT03418012|Other|Control-Group|Control-Group women receive management as usual; i.e. expectant management with interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications
2876016|NCT03417999|Experimental|Cohort 1|"Cohort 1A:~Dexmedetomidine 2 μg/kg~Under general oral endotracheal anesthesia~7 subjects age >2 yo and ≤ 6 yo~7 subjects age ≥1 mo and ≤2 yo~Cohort 1B:~Dexmedetomidine 2 μg/kg~Under sedation with a natural airway~7 subjects age >2 yo and ≤ 6 yo~7 subjects age ≥1 mo and ≤2 yo"
2876017|NCT03417999|Experimental|Cohort 2|"Dexmedetomidine 4 μg/kg~Under general oral endotracheal anesthesia~7 subjects age >2 yo and ≤ 6 yo~7 subjects age ≥1 mo and ≤2 yo"
2876018|NCT03417999|Experimental|Cohort 3|"Dexmedetomidine 6 μg/kg~Under general oral endotracheal anesthesia~7 subjects age >2 yo and ≤ 6 yo~7 subjects age ≥1 mo and ≤2 yo"
2876019|NCT03417986|Experimental|Group 1a: TEP 26 mg daily for 4d|
2876020|NCT03417986|Experimental|Group 1b: TEP 52 mg daily for 4d|
2876021|NCT03417986|Experimental|Group 2: TEP 26 mg daily for 54d|
2876022|NCT03417973||complex regional pain syndrome|Chronic regional pain of lower limb(s) patients medically indicated to have dorsal root ganglion (DRG) stimulation for control of pain. DRG stimulator will be implanted for trial of 3-4 days and then permanently, if patient find acceptable levels of pain control with trial.
2876023|NCT03417973||Chronic pelvic pain|Chronic pelvic or urological pain patients medically indicated to have dorsal root ganglion (DRG) stimulation for control of pain. DRG stimulator will be implanted for trial of 3-4 days and then permanently, if patient find acceptable levels of pain control with trial.
2876024|NCT03417960|Experimental|iTBS|accelerated iTBS to Left DLPFC
2876025|NCT03417947|Placebo Comparator|Placebo|Placebo identical to the vitamin D bolus in taste and appearance. The placebo will be administered once, at the beginning of the study. The oral liquid placebo will be prepared at the Pharmacy in coded syringes and will be administered to the participants by a nurse at the sickle cell disease Clinic.
2876026|NCT03417947|Experimental|Vitamin D bolus|The vitamin D bolus is an oral liquid supplement that will be administered once, at the beginning of the study. The oral liquid vitamin D bolus will be prepared at the Pharmacy in coded syringes and will be administered to the participants by a nurse at the sickle cell disease Clinic.The dose of vitamin D3 contained in the bolus is 300 000 IU.
2876027|NCT03417921|Experimental|Pancreatic cancer|Sodium 2-hydroxylinoleic (starting 1,300 mg tid orally) in combination with gemcitabine and nab-paclitaxel will be given to patients with pancreatic cancer, up to 12 months from initiation
2876028|NCT03417908|Active Comparator|COPD - PNF|COPD - PNF
2876029|NCT03417908|Sham Comparator|COPD - sham|COPD - sham
2876030|NCT03417908|Active Comparator|Individuals Without COPD - PNF|Individuals Without COPD - PNF
2876031|NCT03417908|Sham Comparator|Individuals Without COPD - sham|Individuals Without COPD - sham
2876032|NCT03417895|Experimental|A(SHR-1210+Apatinib)|• SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
2876033|NCT03417895|Experimental|B(SHR-1210+Apatinib)|• SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD（5 Days on, 2 Days off）
2876034|NCT03417895|Experimental|C(SHR-1210+Apatinib)|• SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD（7 Days on, 7 Days off）
2876159|NCT03417037|Experimental|Arm B|BMS-986205 and Nivolumab administered in combination with chemotherapy
2876035|NCT03417882|Experimental|Cohort 1|Cohort 1: Subjects with newly diagnosed, metastatic PD-L1+ (TPS ≥ 50%) NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations,
2876036|NCT03417882|Experimental|Cohort 2|Cohort 1: Subjects with newly diagnosed, metastatic PD-L1+ (TPS ≥ 50%) NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations,
2876037|NCT03417856||Control|Healthy subjects with no history of ichthyosis from 1 year to 60 years of age.
2876038|NCT03417856||Ichthyosis|Subjects with a diagnosis of Netherton syndrome or ichthyosis from 1 year to 60 years of age.
2876039|NCT03417843|Experimental|EUSRA RF electrode|new ablation catheter RFA (RADIOFREQUENCY under EUS), developed by TAEWOONG company for the treatment of pancreatic premalignant and early malignant cystic lesion.
2876040|NCT03417830|Experimental|Subjects with ATTR-CM in Part A|Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part A will participate in two anti-SAP dosing sessions approximately 26 days in duration. The first two subjects in Part A will have up to three 89Zr PET scans, while the remaining subject will undergo up to two 89Zr PET scans.
2876041|NCT03417830|Experimental|Subjects with ATTR-CM in Part B|Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part B will participate in one anti-SAP dosing session. Subjects will undergo up to two 89Zr PET scans.
2876042|NCT03417817|Other|Healthy subjects|Bravo wireless pH monitoring over 96 hours
2876043|NCT03417791||kidney function recovery|the registry and follow up of consecutive patients with increased serum creatinine during hospital in 2007
2876044|NCT03417778|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
2876045|NCT03417778|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
2876046|NCT03417778|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
2876047|NCT03417765|Experimental|Cohort A: 5 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
2876048|NCT03417765|Experimental|Cohort B: 10 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
2876049|NCT03417765|Experimental|Cohort C: 25 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
2876050|NCT03417752|Experimental|Exposure to firearm safety PSA|Exposure to the firearm safety PSA (approx. 2.5 minutes long) once per week for 3 weeks.
2876051|NCT03417752|Experimental|Exposure to a mix of PSAs|Exposure to a general health promotion video (approx. 2 minutes long) 1 week post-randomization followed by exposure to firearm safety PSA at 2- and 3-weeks post-randomization.
2876052|NCT03417752|Active Comparator|Active control|Exposure to the general health promotion video once per week for 3 weeks.
2876053|NCT03417739|Experimental|BVD-523|BVD-523 is to be taken twice daily orally for 28 consecutive days
2876054|NCT03417713||All Subjects|This group/cohort is expected to be representative of the general population that would require mobile fluoroscopic imaging with C-arm devices, such as OEC Elite.
2876055|NCT03417700|Experimental|Training NW|exercise and supplementation
2876056|NCT03417700|Experimental|Training HICT and vitamin D|Training HICT plus vitamin D
2876057|NCT03417700|Experimental|Placebo|placebo Vitamin D
2876058|NCT03417687|Active Comparator|Arm 1|Subjects will undergo hyperpolarized 129Xe MRI first, followed by 133Xe scintigraphy
2876059|NCT03417687|Active Comparator|Arm 2|Subjects will undergo 133Xe scintigraphy first, followed by hyperpolarized 129Xe MRI
2876060|NCT03417674|Experimental|Intervention group|Lifestyle intervention with meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
2876061|NCT03417674|No Intervention|Control group|Routine care.
2876062|NCT03417661|Experimental|HEXI-PREP By Clinell Wipes vs Placebo|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
2876063|NCT03417661|Experimental|HEXI-PREP By Clinell Wipes vs Chloraprep|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
2876064|NCT03417661|Experimental|Chloraprep vs Placebo|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
2876065|NCT03417648|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
2876066|NCT03417648|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
2876067|NCT03417635|Experimental|Guided focused attention|"Participants will take part in a guided focused attention practice led by the researcher. This will include strategies used in meditations where participants focus on their breathing. More specifically, they will be instructed to close their eyes and focus on the sensation of breathing in one area of the body for the entire session. They will be given reminders throughout the session to remain on task (focusing on the breath) and not to let their thoughts wander.~Participants will be asked to either sit on a chair or cushion on floor to ensure they are comfortable to sit still for the session, but not so much that they might fall asleep."
2876094|NCT03417440|Other|PA App+ On Your Feet+ CoachMe+ Proof Pos|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 3 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); (2) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers); and (3) Proof Positive (explicit and implicit messaging to promote positive aging views)."
2876068|NCT03417635|Active Comparator|Acoustic music|"Participants will be instructed to listen to a prepared soothing acoustic music track. The sessions will be led by a researcher. Participants will be asked to close their eyes and relax while listening to the music.~Participants will be asked to sit on a chair or cushion on floor to ensure they are comfortable to sit still for the session, but not so much they might fall asleep This group is used as active control group to control for socialization in group settings and any effects of consciously relaxing for the meetings."
2876069|NCT03417622|Experimental|Post-treatment volume-resection margin|Lumpectomy is performed with resection margin of the clinically / radiologically identifiable post-treatment tumor.
2876070|NCT03417622|Active Comparator|Pre-treatment volume-resection margin|Lumpectomy is performed with resection margin of the bracketed tissue.
2876071|NCT03417609||Sarcopenia|Elderly patients with sarcopenia
2876072|NCT03417609||Control|Elderly patients without sarcopenia
2876073|NCT03417596|Experimental|Vestibular Rehabilitation|"Adaptation Exercises The exercises were performed in horizontal and vertical planes, for a period of one minute each, three times a day.~Substitution Exercises Standing dynamic balance exercises: The patient stands and moves without walking. The patient might march in place, step forward or backward, step to the side, step up or down, or turn around.~Habituation exercises: These exercises that cause mild to moderate difficulty in daily life was given as an exercise to the patient. These exercises involved movements and positions sufficient to cause mild-to-moderate symptoms during the patient's daily activities Ambulation exercises: Exercises that include walking with head moving towards different sides.~The exercise program consisted of one session per week for a period of eight weeks. Each session lasted approximately 30-45 minutes and was conducted in the rehabilitation unit."
2876074|NCT03417596|Experimental|Vestibular Rehabilitation+Pharmacological Therapy|"Same exercises that were applied in first group were also applied to this group.~For pharmacological therapy, patients were assessed by a neurologist and appropriate drug options were applied based on patients' needs and features. Propranolol was selected primarily and other prophylactic drugs were used in the case of its' being contraindicated."
2876075|NCT03417596|Other|Pharmacological Therapy only|Patients were assessed by a neurologist and appropriate drug options were applied based on patients' needs and features. Propranolol was selected primarily and other prophylactic drugs were used in the case of its' being contraindicated.
2876076|NCT03417583|No Intervention|Clinical Standard Care Group|These patients will continue to be seen by their regular neurology provider for Huntington's disease. They will not be treated explicitly according to the protocol, though they may be prescribed some of the same medications.
2876077|NCT03417583|Experimental|Protocol Intervention Group|These participants will transfer their clinical care to the study provider for the duration of the study, and their symptom treatment will be guided by the study protocol.
2876078|NCT03417570|Experimental|Arm 1: EGD with cap first, followed by EGD without cap|-Participants in the first arm will undergo EGD with cap first, followed by EGD without cap.
2876079|NCT03417570|Experimental|Arm 2: EGD without cap first, followed by EGD with cap|-Participants in the second arm will undergo EGD without cap first, followed by EGD with cap
2876080|NCT03417544|Experimental|ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB|"Patients will receive the following treatment:~Atezolizumab (IV) every 3 weeks (q3w)]~Pertuzumab (loading dose ), followed q3w thereafter by a predetermined dose in the protocol via IV)~High-dose Trastuzumab weekly for the first 24 weeks, and thereafter trastuzumab q3w)."
2876081|NCT03417531|Active Comparator|Protein Supplement plus Active Exercise|Participants will ingest twice daily 23.7 g of L-leucine-enriched whey protein isolate powder (equivalent to 20 g of Protein) and perform a simple home exercise strength program (3x30 minutes/week)
2876082|NCT03417531|Active Comparator|Protein-free Supplement plus Active Exercise|Participants will ingest twice daily 23.7 g of a protein-free, isocaloric powder blend and perform a simple home exercise strength program (3x30 minutes/week)
2876083|NCT03417531|Active Comparator|Protein Supplement plus Control Exercise|Participants will ingest twice daily 23.7 g of L-leucine-enriched whey protein isolate powder (equivalent to 20 g of Protein) and perform a joint flexibility home exercise program (3x30 minutes/week)
2876084|NCT03417531|Sham Comparator|Protein-free Supplement plus Control Exercise|Participants will ingest twice daily 23.7 g of a protein-free, isocaloric powder blend and perform a joint flexibility home exercise program (3x30 minutes/week)
2876085|NCT03417518|Active Comparator|Desflurane Inhalant Product Group|general anesthesia with desflurane
2876086|NCT03417518|Experimental|Propofol Group|general anesthesia with propofol
2876087|NCT03417505|Experimental|Treated followed by untreated|Patients wear the Hydra-PEG treated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the untreated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered prior to the control treatment (untreated scleral lenses).
2876088|NCT03417505|Experimental|Untreated followed by treated|Patients wear the untreated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the Hydra-PEG treated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered after the control treatment (untreated scleral lenses).
2876089|NCT03417492|Experimental|Sildenafil Citrate|Open label treatment with forced titration of sildenafil citrate.
2876090|NCT03417479||1:1 Randomization|Patients will be randomized to either a single dose of 15mg/kg up to 600 mg of gabapentin or a placebo equivalent at a 1:1 ratio. The subjects will be enrolled in the study at the orthopedic surgeon's office with randomization occurring on the day of surgery by the hospital pharmacist. The method for the randomization will be the creation of a sequence of sealed envelopes containing assignment information for a dose of 600 mg of gabapentin or placebo.
2876091|NCT03417466|Experimental|Study arm|Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-4, or 6).
2876092|NCT03417453|Active Comparator|Eye Drop Dispenser TYPE Opticare|subject will assess TYPE 1 dispenser
2876093|NCT03417453|Active Comparator|Eye Drop Dispenser Autodrop|subject will assess Autodrop dispenser
2876123|NCT03417271|Active Comparator|30us stimulation then 60us stimulation|All patients will receive both types of stimulation in a randomised crossover design. This arm will receive 30us stimulation for 4 weeks then will be switched to 60us stimulation for 4 weeks.
2876095|NCT03417440|Other|PA App + On Your Feet + Coach Me|"Participants in this arm will use a basic physical activity (PA) app in conjunction with the following 2 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); and (2) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers)."
2876096|NCT03417440|Other|PA App + On Your Feet + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 2 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); and (2) Proof Positive (explicit and implicit messaging to promote positive aging views)."
2876097|NCT03417440|Other|PA App + On Your Feet|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions)."
2876098|NCT03417440|Other|PA App + Coach Me + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 2 features: (1) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers); and (2) Proof Positive (explicit and implicit messaging to promote positive aging views)."
2876099|NCT03417440|Other|PA App + Coach Me|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers)."
2876100|NCT03417440|Other|PA App + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) Proof Positive (explicit and implicit messaging to promote positive aging views)."
2876101|NCT03417440|Other|PA App|Participants in this arm will use a basic physical activity (PA) tracker app without any additional features.
2876102|NCT03417427|Active Comparator|Decitabine and Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive decitabine (15mg/m2 d1-5) combined with high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
2876103|NCT03417427|Placebo Comparator|Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
2876104|NCT03417414||B-CLL|Patients with B-Cell CLL
2876105|NCT03417414||B-NHL|Patients with B-Cell NHL
2876106|NCT03417401|Experimental|RVC with tPA for CRVO|Single arm phase I open label study were CRVO patients will have a vitrectomy with retinal vein cannulation and a single infusion of tPA (0.25mg/ml) intravenously with a maximum dose of 1mg.
2876107|NCT03417388|Experimental|Intensive Medical Treatment (IMT)|"The IMT-assigned women will receive high dose potent statin, and moderate dose of an ACE-I (lisinopril) or ARB (losartan). PCSK9 Inhibitor will be available to women who have an LDL <100, or intolerance to statins. Aspirin will also be recommended to IMT women without contraindications or bleeding risk. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and face-time with site staff to reduce bias."
2876108|NCT03417388|Active Comparator|Usual Care (UC)|"The UC-assigned women will maintain standard of care. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and face-time with site staff to reduce bias."
2876109|NCT03417375|Experimental|Osteocel Plus|Experimental product will be placed in one sinus while the control product will be placed in the contralateral sinus. (Randomized)
2876110|NCT03417375|Active Comparator|alloOss|The control product will be placed in one sinus while the control product will be placed in the contralateral sinus. (Randomized)
2876111|NCT03417362|Other|Animation|Animation describing process of early medical abortion, what to expect, how to take medicines. This is prior to consultation.
2876112|NCT03417362|No Intervention|Standard|Standard of Care - no animation ,standard consultation only.
2876113|NCT03417349||Aspiration thrombectomy|Patients with acute ischmic stroke of the anterior circulation whom the treating physician deemed eligible to be treated with SOFIA™/ SOFIA™ as a first line treatment technique
2876114|NCT03417336|Experimental|brachytherapy + External radiotherapy|Prostate booster, HDR brachytherapy with 15Gy in 1 fraction + external radiotherapy 25Gy in 5 fractions
2876115|NCT03417336|Active Comparator|External radiotherapy|Exclusive external radiotherapy. 25Gy in 5 fractions + a 40Gy prostate boost in stereotaxic conditions.
2876116|NCT03417323|Experimental|Compressive garment|Groups wear compression garment after WB-EMS induced muscle soreness
2876117|NCT03417323|No Intervention|No compression garment|Groups wear no compression garment after WB-EMS induced muscle soreness
2876118|NCT03417310|Experimental|"H joystick"|"Patients are treated with the H joystick on a traction table"
2876119|NCT03417310|Active Comparator|Common reduction methods|Patients are treated with common reduction methods on a traction table
2876120|NCT03417297|Experimental|high intensity focused ultrasound|Initially, 3 patients will be enrolled and followed for 3 months to assess the safety of study intervention which is unilateral MR guides focused ultrasound thalamotomy (anterior nucleus). These data will be reviewed by the Data and Safety Monitoring Committee (DSMC) and the FDA. If approval is granted by the DSMC and FDA, then up to an additional 7 participants will be enrolled.
2876121|NCT03417284|Experimental|Group 1: Evomela For 30 Minutes to 60 minutes|"Participants receive Evomela by vein over 30 to 60 minutes on Day -2. The first sets of participants receive the lowest dose level. Each new set receives a higher dose than the set before it, if no intolerable side effects were seen. This continues until the highest tolerable dose of Evomela is found.~Participants receive Palifermin by vein on Days -5, -4, -3, +1, +2, and +3.~On Day 0, participants receive the stem cell transplant by vein over about 30-60 minutes.~Starting on Day +5, participants receive G-CSF (filgrastim) as an injection just under the skin."
2876122|NCT03417284|Experimental|Group 2: Evomela For 8 to 9 Hours|"Participants receive Evomela by vein over 8 to 9 hours on Day -2. The first sets of participants receive the lowest dose level. Each new set receives a higher dose than the set before it, if no intolerable side effects were seen. This continues until the highest tolerable dose of Evomela is found.~Participants receive Palifermin by vein on Days -5, -4, -3, +1, +2, and +3.~On Day 0, participants receive the stem cell transplant by vein over about 30-60 minutes.~Starting on Day +5, participants receive G-CSF (filgrastim) as an injection just under the skin."
2876160|NCT03417037|Active Comparator|Arm C|Chemotherapy administered alone
2876124|NCT03417271|Active Comparator|60us stimulation then 30us stimulation|All patients will receive both types of stimulation in a randomised crossover design.This arm will receive 60us stimulation for 4 weeks then will be switched to 30us stimulation for 4 weeks.
2876125|NCT03417258||Patients with polyps|urinary phytoestrogen excretion and intestinal microbiota evaluation
2876126|NCT03417258||Patients without polyps|urinary phytoestrogen excretion and intestinal microbiota evaluation
2876127|NCT03417245|Experimental|fitusiran|
2876128|NCT03417245|Active Comparator|On Demand factor VIII or IX|
2876129|NCT03417232|Experimental|Split Full Split Elevation of CAF|The central portion of the flap apical to the recession was elevated full thickness by the use of a small periostium elevator inserted into the probable sulcus
2876130|NCT03417232|Sham Comparator|Split Elevation of CAF|The flap was fully elevated with a split thickness approach: the blade of the knife was inserted into the sulcus
2876131|NCT03417219|Experimental|Mobile Media Education and Skill-Building Rehabilitation Int|The investigators' ESBR-m intervention consists of four, 90-minute group (= 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.
2876132|NCT03417219|Active Comparator|Usual Care|"Usual Care (plus supplemental educational materials). Participants randomized to the Usual Care (UC) group will receive supplemental educational materials (e.g., VA Caregiver Support Program; Veterans Crisis Line; National Institute on Aging's Understanding Memory Loss)."
2876133|NCT03417206|Experimental|SEVOFLURANE INHALATIONAL ANAESTHESIA|concentration of sevoflurane in the exhalation gas will be maintained to ensure target SE between 40, remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
2876134|NCT03417206|Experimental|DESFLURANE INHALATIONAL ANAESTHESIA|concentration of desflurane in the exhalation gas will be maintained to ensure target SE 40, remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
2876135|NCT03417206|Experimental|TIVA USING PROPOROL|Infusion of propofol will be adjusted at target of SE 40,remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
2876136|NCT03417193|Active Comparator|Opioid based Anesthesia|General anesthesia will be induced using Propofol , fentanyl , and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with Remi-fentanyl , sevoflurane and nitrous oxide.
2876137|NCT03417193|Active Comparator|Opioid Free Anesthesia|-General anesthesia will be induced using dexmedetomidine and lidocaine started 10 minutes before induction, Propofol and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with IV infusion of dexmedetomidine , lidocaine , sevoflurane and nitrous oxide.
2876138|NCT03417180|Experimental|SEVOFLURANE INHALATIONAL ANAESTHESIA|concentration of sevoflurane in the exhalation gas will be maintained to ensure target SE 40, remifentanil will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
2876139|NCT03417180|Experimental|DESFLURANE INHALATIONAL ANAESTHESIA|concentration of desflurane in the exhalation gas will be maintained to ensure target SE 40,remifentanil will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
2876140|NCT03417180|Experimental|TIVA USING PROPOROL|infusion of propofol will be adjusted at target of SE 40, remifentanyl infusion will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
2876141|NCT03417154|Experimental|Stage 1 Arms 1&2: Nivolumab and Cyclophosphamide|
2876142|NCT03417154|Experimental|Stage 2: Nivolumab and Cyclophosphamide|
2876143|NCT03417141|Experimental|Valchor treatment of Lichen Planopilaris|Assess the potential effectiveness of once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.
2876144|NCT03417128|No Intervention|Control|Participants in the control group will receive a one-time personalised nutrition and lifestyle advised based from the Malaysian Dietary Guideline 2010. They will be assured to be followed up twice for the next six month.
2876145|NCT03417128|Experimental|Peer support|This group will receive a continuous three-months, peer-led nutrition and lifestyle behaviour intervention through a series of peer gathering.
2876146|NCT03417115||Her2 positive|Patients with Her2 positive tumors
2876147|NCT03417115||triple negative|Patients with triple negative tumors
2876148|NCT03417115||HR positive, Her2 negative|Patients with HR positive, Her2 negative tumors
2876149|NCT03417102|Experimental|fitusiran|
2876150|NCT03417102|Active Comparator|On demand bypassing agents|
2876151|NCT03417089|Experimental|falciform ligament suspension|routine suspension of falciform ligament during mini gastric bypass,
2876152|NCT03417089|Active Comparator|No suspension|working without suspension of the falciform ligament
2876153|NCT03417076|Experimental|Bexagliflozin|Each subject will receive a single oral dose of bexagliflozin tablets, 20 mg, followed by a single IV dosing of < 30 ug 14C-bexagliflozin in 0.9% saline solution).
2876154|NCT03417050||Randomized CABG patients|Patients which were randomized to undergo CABG.
2876155|NCT03417050||Randomized PCI patients|Patients which were randomized to undergo PCI.
2876156|NCT03417050||Registry CABG|Patients for whom only one treatment option was suitable were included into a parallel, nested registry: the CABG registry for PCI-ineligible patients.
2876157|NCT03417050||Registry PCI|Patients for whom only one treatment option was suitable were included into a parallel, nested registry: the PCI registry for CABG-ineligible patients.
2876158|NCT03417037|Experimental|Arm A|BMS-986205 and Nivolumab administered in combination
2876161|NCT03417024||All Subjects|All subjects will undergo scanning with both Automated Breast Ultrasound and Digital Breast Tomosynthesis devices.
2876162|NCT03416998|Active Comparator|Phototherapy Active|Phototherapy active group will be administered 30 minutes prior to the soccer match as well as 48 h after the match in direct contact with the skin with light pressure at predetermined sites: nine on the knee extensor muscles, six on the knee flexor muscles and two on the gastrocnemius muscle on both lower limbs.
2876163|NCT03416998|Placebo Comparator|Placebo Phototherapy|"Phototherapy placebo group will be administered 30 minutes prior to the soccer match as well as 48 h after the match in direct contact with the skin with light pressure at predetermined sites: nine on the knee extensor muscles, six on the knee flexor muscles and two on the gastrocnemius muscle on both lower limbs.~For placebo treatment, the same procedures and treatment times will be employed, but the equipment will be set in placebo mode. Only the researcher in charge of programming the device will have knowledge regarding which treatment is being used. However, the programmer will not participate in the execution of the treatment, evaluations or data analysis"
2876164|NCT03416985|Active Comparator|Manual Toothbrush|Patients will be asked to use a manual toothbrush for 30 days
2876165|NCT03416985|Active Comparator|Sonic Toothbrush|Patients will be asked to use a sonic toothbrush for 30 days
2876166|NCT03416985|Active Comparator|Pulsating Toothbrush|Patients will be asked to use a pulsating toothbrush for 30 days
2876167|NCT03416972||Stage I-III NSCLC patients|Stage I/II NSCLC patients receiving standard stereotactic body radiation therapy and Stage III patients receiving Standard platinum-based chemoradiotherapy will receive PET/MRI, DCE-CT, ECG/EKG, and bloodwork before and six weeks post treatment.
2876168|NCT03416946|Active Comparator|Custom Block Instrumentation|Patients-specific custom cutting blocks using the Smith and Nephew Visionaire system
2876169|NCT03416946|Active Comparator|Traditional Instrumentation|Traditional cutting methods for Total Knee Replacement
2876170|NCT03416933|Experimental|Biological|
2876171|NCT03416920|Experimental|Wellframe|Subjects in this arm will use the Wellframe application for 90 days
2876172|NCT03416907|Active Comparator|Original|Participants will review the full-length, original consent form for the clinical trial.
2876173|NCT03416907|Experimental|Shortened|Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
2876174|NCT03416907|Experimental|Reordered|Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
2876175|NCT03416907|Experimental|Highlighted|Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
2876176|NCT03416907|Experimental|Interactive|Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
2876177|NCT03416894|Experimental|Deep Brain Stimulation|
2876178|NCT03416868|Experimental|Week 3 start|"For the first two weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In the following 3 weeks of voice therapy (weeks 3 through 5), patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
2876179|NCT03416868|Experimental|Week 4 start|"For the first three weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In voice therapy weeks 4 and 5, patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
2876180|NCT03416868|Experimental|Week 5 start|"For the first four weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In voice therapy week 5, patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
2876181|NCT03416855||Overall population|Participants will be decided to be treated with Ryzodeg® FlexTouch® by physicians before the enrolment in the study based on clinical judgement in the diabetes management.
2876182|NCT03416842|Experimental|Training with 4D Motion Capture Device|Participants will be given access to a tablet-based application and non-invasive sensors that will track movements of the upper extremity and will prompt daily exercise. Participants will be encouraged to use the device daily for 30 consecutive days, up to one hour per day.
2876183|NCT03416829|Experimental|100% frequency|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (100% frequency - vibrotactile cueing every time the participant exceeds a vocal intensity threshold). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
2876207|NCT03416660|Active Comparator|High density|Fractional carbon dioxide laser : Lesion C or part C parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 300 µm spacing (25.6% density).
2876208|NCT03416647|Experimental|SMAS patients|
2876184|NCT03416829|Experimental|25% frequency|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (25% frequency - vibrotactile cueing every 4th time the participant exceeds a vocal intensity threshold). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
2876185|NCT03416829|Experimental|Summary feedback|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (summary - no cueing, statistics shown every 2 minutes of voicing). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
2876186|NCT03416816|Experimental|DSP-0337|In Part 1 - Up to six dose levels will be investigated in dose-escalating cohorts to identify a maximum tolerated dose (MTD). An additional subset of patients will be treated to assess the effect of food intake on the PK of DSP-0337 administration at the MTD level. Once the recommended Phase 2 dose (RP2D) has been established, patients will be treated with the RP2D to explore preliminary antitumor activity and safety profile.
2876187|NCT03416803|Experimental|Radiotherapy|Patients in the experimental group, who were at high risk for lymph node metastasis, underwent radiotherapy in the lymphatic drainage area. Radiotherapy was started in lymphatic drainage areas about 1 month after HCC surgery. The range of radiotherapy was hepatic portal area, pancreas circumference, celiac trunk and abdomen Around the aortic lymph drainage area, the dose of radiation 45Gy, conventional segmentation.
2876188|NCT03416803|No Intervention|Blank control|Patients in the control group , who were at high risk for lymph node metastasis，were followed up.
2876189|NCT03416777|Active Comparator|Meat-based diet (MBD)|Behavioral intervention with diet including 4 servings per week of red meat, 3 servings per week of processed meat, and 1 servings per week of poultry, for a total amount of 900 g per week of meat.
2876190|NCT03416777|Experimental|Meat-based alpha-tocopherol (MBD-T)|Behavioral intervention including diet with 4 servings per week of red meat, 3 servings per week of processed meat, and 1 servings per week of poultry, for a total amount of 900 g per week of meat with a dietary supplement of 100 mg/day of alpha-tocopherol in the form of tablet
2876191|NCT03416777|Experimental|Pesco-vegetarian (PVD)|Behavioral intervention with diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish
2876192|NCT03416764|Experimental|EFP-NF during LOW estrogen phase|EFP-NF training, twice a week, during low-estrogen phases only (days 21-28 of a cycle and days 1-7 of the following cycle,based on a 28-day cycle), for a total of 10 sessions.
2876193|NCT03416764|Experimental|EFP-NF during HIGH estrogen phase|EFP-NF training, twice a week, during high-estrogen phases only (days 7-21 of a 28-day cycle), for a total of 10 sessions.
2876194|NCT03416764|No Intervention|No EFP-NF treatment|Participant will receive no EFP-NF training, and continue their treatment in the Lotem Clinic as usual (TAU)
2876195|NCT03416751|Experimental|Fecal Microbial transplantation|Patients will get one-dose of 90ml of FMT enema on day 1 that has been received from OpenBiome using a rational donor
2876196|NCT03416751|Placebo Comparator|Placebo|Patients will get one-dose of 90ml of saline enema on day 1
2876197|NCT03416738|Active Comparator|Semantically focused treatment|This treatment will focus on improving word finding and comprehension of information.
2876198|NCT03416738|Active Comparator|Phonologically focused treatment|This treatment will focus on training speech sound production, targeting overall production abilities.
2876199|NCT03416725||Patients with chronic suppurative otitis media.|patients of the age group 18-60 years with Chronic suppurative otitis media (CSOM) planned for tympanoplasty.
2876200|NCT03416712|No Intervention|Control|"To obtain baseline socioeconomic data on all children (intervention and control), study participants will utilize the Children's HealthWatch Survey (www.childrenshealthwatch.org), which is a standardized, validated survey designed to collect demographics and information on child health and development, parental health, and socioeconomic factors income, education level, financial literacy, childcare, and government assistance).~The control group will not complete the WE CARE HOUSTON survey and will not receive any referrals to community resources from the study team at the time of enrollment (they may be referred to resources by their medical/clinical team as per standard of care during their hospitalization at Texas Children's Hospital). The study investigators will offer control participants information on community resources at the end of the study. Study participants will be called for a 6 month follow up structure telephone survey."
2876201|NCT03416712|Experimental|Intervention|The intervention group will complete a short survey called the WE CARE HOUSTON survey. The WE CARE HOUSTON survey has been designed to quickly assess patient need for local services that address the social determinants of health. The WE CARE HOUSTON survey will be administered on paper or verbally if family is not able to read. Based on the parent's responses to the screening survey, the study investigators will use an algorithm to direct families to appropriate services and community resources. Families who screen positive for social needs will receive a handout on resources. For the families that screen positive for depression/ mental health needs, domestic violence, or alcohol and drug abuse, the study investigators will notify the medical/clinical team and recommend an inpatient social work prior to discharge. Intervention participants will be called 1 week-2 months after enrollment to follow up on resources and will be called for a 6 month follow up structured telephone survey.
2876202|NCT03416686|Experimental|Radiofrequency|
2876203|NCT03416673|Active Comparator|CTG+CAF|The surgical procedure will include a connective tissue graft harvested from the palate and used under a coronally advanced flap
2876204|NCT03416673|Experimental|peCTG+CAF|A papillary extended connective tissue graft reshaped after harvested from the palate will be used under a coronally advanced flap
2876205|NCT03416660|Active Comparator|Low density|Fractional carbon dioxide laser: Lesion A or part A parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 900µm spacing (7.4% density).
2876206|NCT03416660|Active Comparator|Medium density|Fractional carbon dioxide laser : Lesion B or part B parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 600µm spacing (12.6% density).
2876273|NCT03416192|Experimental|MCO-HD|Hemodialysis with Medium Cut-Off filter
2876209|NCT03416634|Active Comparator|App Alone|Participants randomized to use the Microsoft Band app to track daily activity
2876210|NCT03416634|Experimental|App Plus Automated Motivational Message|Participants randomized to use the Microsoft Band app to track daily activity, and to receive automated, motivational text messages
2876211|NCT03416634|Experimental|App Plus Personalized Motivational Message|Participants randomized to use the Microsoft Band app to track daily activity, and to receive personalized, motivational text messages
2876212|NCT03416634|Active Comparator|Wearable Device Alone|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity
2876213|NCT03416634|Experimental|Wearable Device Plus Automated Motivational Message|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity, and to receive automated, motivational text messages
2876214|NCT03416634|Experimental|Wearable Device Plus Personalized Motivational Message|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity, and to receive personalized, motivational text messages
2876215|NCT03416621|Experimental|Cognitive behavioral cessation counseling|Standard smoking cessation plus support text messages
2876216|NCT03416621|Placebo Comparator|Counseling and placebo drug intervention|enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo
2876217|NCT03416621|Active Comparator|Counseling and active drug intervention|enhanced cue exposure treatment (lab-based + interactive SMS texting) + active DCS. In addition to an in-person screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
2876218|NCT03416595|Active Comparator|N1115 Probiotic Supplement|A probiotic supplement containing Lactobacillus paracasei N1115 [Junlebao Lp. N1115] Participators, who met inclusion criteria, will receive following product during 8 weeks: N1115 Probiotic Supplement in the form of powder packaged in sachet (one sachet containing 10^9 CFU Lp. N1115).
2876219|NCT03416595|Placebo Comparator|Placebo control|Dietary Supplement: Placebo Participators, who met inclusion criteria, will receive an identical N1115 Probiotic Supplement looking and tasting placebo.
2876220|NCT03416582|Experimental|SMENC Group|"The Symptom Management Education and Nurse Coaching (SMENC) intervention is a one hour in-person face-to-face education session followed by twice weekly telephone calls conducted all throughout the patient's chemoradiation treatment regimen.~During the telephone call, the patient will report the use of the Drinks Diary."
2876221|NCT03416569|Experimental|Nicotine-Prazosin Interaction Study|Over four test days, each participant will be tested with placebo, nicotine alone, prazosin alone, and nicotine + prazosin, in a double-blind sequence.
2876222|NCT03416556|Experimental|Mobilization to the glenohumeral joint|This condition consisted on the application of a passive rhythmic AP mobilization to the glenohumeral joint of the affected shoulder
2876223|NCT03416556|Sham Comparator|The manual contact condition|In this condition the therapist positioned the patient in a mid-range position of glenohumeral abduction and internal rotation and applied the hands to the same contact point as in the treatment condition.
2876224|NCT03416556|No Intervention|No-contact condition|There was no manual contact between the therapist and the participant
2876225|NCT03416543||Puncture|Patient with RA or gout and performing a puncture. The aim is evaluate the cellular composition of synovial fluid then evaluate the response to a new BI-specifiC Antibody Towards Dendritic Cells.
2876226|NCT03416530|Experimental|ONC201 in relapsed/refractory H3 K27M glioma|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy. Evidence of progression is not required so that ONC201 may be administered to patients in the maintenance setting or to patients with recurrent/refractory disease.
2876227|NCT03416530|Experimental|ONC201 in newly diagnosed DIPG|Pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. If H3 K27M status of tumor is unknown or archival tumor tissue is not available, then patients must agree to submit a post-mortem biopsy specimen.
2876228|NCT03416517|Experimental|Anlotinib Hydrochloride and Irinotecan|Anlotinib 8 or 12mg/d PO on days 1-14 q3w. Irinotecan 15mg/m^2/d IV over 60 minutes on days 1-5 and 8-12 q3w. Vincristine 1.4mg/m^2/d IV on days 1,8 q3w. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
2876229|NCT03416504|Experimental|Gradual Exposure Group|The gradual exposure group received the Gradual Exposure (EXP-G) Intervention.
2876230|NCT03416504|Experimental|Variable Exposure Group|The variable exposure group received the Variable Exposure (EXP-V) Intervention.
2876231|NCT03416491|Experimental|NC_30|Non-cirrhotic subjects were medicated with KW-136 capsules 30 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
2876232|NCT03416491|Experimental|NC_60|Non-cirrhotic subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
2876233|NCT03416491|Experimental|LC_60|Cirrhotic subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
2876234|NCT03416478||ctDNA test group|
2876235|NCT03416452|Experimental|PD patients no|PD patients without freezing of gait
2876236|NCT03416452|Placebo Comparator|Healthy|HV using Mobile Gait Trainer
2876237|NCT03416452|Experimental|PD patients|pd patients using vibratory cueing device
2876238|NCT03416452|Experimental|PD patients 1|PD patients with freezing of gait
2876239|NCT03416452|Experimental|Healthy Volunteers|Age and gender matched healthy volunteers.
2876240|NCT03416439|Experimental|intervention arm|lifestyle intervention program carried out by trained professionals
2876241|NCT03416439|No Intervention|control arm|standard, unstructured information given by the family physicians
2876242|NCT03416426||patients undergone PFO closure|patients with ischemic stroke and PFO documented by bubble contrast TEE with no other identifiable cause of the ischemic event who undergone PFO closure using Amplatzer® PFO occluder or Gore® Septal Occluder
2876243|NCT03416413|Active Comparator|Ambulatory Phlebectomy|Ambulatory phlebectomy of varicose vein tributaries
2876244|NCT03416413|Active Comparator|Foam Sclerotherapy|Injection of foam sclerosant into varicose vein tributaries
2900907|NCT03242239|Active Comparator|US-licensed Herceptin|
2876245|NCT03416400||Immature oocytes vitrified before In Vitro Maturation|Immature oocytes were vitrified using closed system vitrification. After warming, they were cultured during 36 hours in IVM medium and fixed for cellular analysis
2876246|NCT03416400||Immature oocytes cultured in vitro before vitrification|Immature oocytes were cultured in vitro in IVM medium during 36 hours. After IVM, they were vitrified. After warming, they were fixed for cellular analysis.
2876247|NCT03416400||Fresh oocytes|Immature oocytes were cultured in vitro in IVM medium during 36 hours and subsequently, fixed for cellular analysis.
2876248|NCT03416387|Other|OTHER: 3D PRINTING AND 3D DIGITAL IMAGE RECONSTRUCTION|
2876249|NCT03416374|Experimental|Combination Therapy + Ixazomib Therapy|Bortezomib + Lenalidomide + Dexamethasone, or Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)
2876250|NCT03416361|Experimental|Vitamin D|4000IU Vitamin D3 as two 50mcg tablets per day
2876251|NCT03416361|Placebo Comparator|Control|Placebo - two chewable blackcurrant flavoured tablets per day
2876252|NCT03416348|Placebo Comparator|Placebo Comparator AIM 1|Aim 1: Demonstration of a strong association of the Sweating Intensity Visual Scale (SIVS) score with the HDSS would provide validation for use of the SIVS in interpreting the iodine-starch test and would establish the value of the iodine-starch test in clinical practice guidelines for diagnosing hyperhidrosis in amputees, just as it is in dermatology practice.
2876253|NCT03416348|Active Comparator|Aluminum Chloride vs Placebo in Amputees|Aim 2: The investigators will have completed the first clinical trial of Aluminum Chloride for residual limb hyperhidrosis. The investigators will then have a solid foundation of data that demonstrates the rates of adverse effects such as skin irritation, and rates and magnitudes of improvement in subjective and objective measures of sweating.
2876254|NCT03416335|Experimental|DSP-0509|Up to five dose levels will be investigated in dose-escalating phase to identify a maximum tolerated dose (MTD). Dose levels will be selected in a pharmacokinetic (PK)-guided manner for overdose protection to maximize patient safety. Once the recommended Phase 2 dose (RP2D) has been established, patients will be treated with the RP2D to explore preliminary antitumor activity and safety profile in dose-expansion phase.
2876255|NCT03416322|No Intervention|Second Examination of the right colon|Second forward view examination of the right colon once the right colon (cecum to hepatic flexure) has been examined
2876256|NCT03416322|Experimental|Water exchange|"Water infusion during colonoscope insertion in the right colon (from hepatic flexure to cecum) and remove water during withdrawn (Exchange method)."
2876257|NCT03416296||normal placenta|TA , TV ,TP us
2876258|NCT03416296||placenta previa and MAP|TA,TV.TP us
2876259|NCT03416283|Experimental|Remote Monitoring (RM)|Remote Monitoring subjects will receive a blood pressure cuff and bidirectional text messaging regarding blood pressure and medication adherence.
2876260|NCT03416283|Experimental|Remote Monitoring + Social Support (RM+SS)|Remote Monitoring + Social Support subjects will receive a blood pressure cuff and bidirectional text messaging regarding blood pressure and medication adherence, as well as a social support partner to provide additional feedback to the participant on their monitoring and adherence practices.
2876261|NCT03416283|No Intervention|Usual Care|Usual care subjects will not receive a blood pressure cuff or bidirectional text messaging. They will be asked to take their medication and monitor BP as usual with no additional contact from study staff until the 4 month study follow-up.
2876262|NCT03416270|Experimental|Ertuglifozin Treatment Arm|Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) for 12 weeks
2876263|NCT03416270|Placebo Comparator|Placebo Arm|Placebo Matching Ertugliflozin Tablet for 12 weeks
2876264|NCT03416257||WIHS|Women's Interagency HIV Study
2876265|NCT03416257||MACS|Multicenter AIDS Cohort Study
2876266|NCT03416244|Experimental|A: Nivolumab / Ipilimumab combination treatment|Nivolumab 240 mg fixed dose IV every 2 weeks; Additionally, after 7 week safety assessment Ipilimumab 1mg/kg IV every 6 weeks
2876267|NCT03416244|Experimental|B. Nivolumab monotherapy|Nivolumab 240 mg fixed dose IV every 2 weeks
2876268|NCT03416231|Experimental|apatinib plus docetaxel|apatinib combine with docetaxel， 4~6 cycles
2876269|NCT03416218|Experimental|Intervention|All participants enrolled in the study will play Prognosis, the intervention being assessed in this study.
2876270|NCT03416205|Experimental|EST|EST is an operation using the Erbao electric knife and Three-cavity incision knife to make a large incision to the duodenal nipples，and the incision scope is the nipple mouth uplift length of 4/5. It has been used since 1974. The technique is intuitive and intact. However, EST cut too small to achieve the purpose of treatment and will affect the next step, and if the incision is too large it may be easier to occur gastrointestinal perforation and bleeding.The EST will also damage the anatomy of the Oddi sphincter structure,which causes bacterial reflux to the bile duct, the recurrence of CBD.Some surgeons prefer it because it's postoperative pancreatitis rate is lower and it may be easier to find the lesion position if bleeding or perforation occurs.
2876271|NCT03416205|Experimental|EPBD|EPBD is an operation using the Columnar expansion balloon to expand duodenal to achieve the purpose of using the basket and other instruments to take stone out. Balloon expansion may retain part of the sphincter not destroyed, and basically retain the normal physiological function of the nipple sphincter.Thus it may reduce the risk of recurrence of stones and bacterial reflux. However,the postoperative pancreatitis rate is high(4.8% -19.5% ), and nipple sphincter tear is uncontrollable in EPBD.If the digestive tract perforation or bleeding occur after EPBD,it is hard to accurately find the lesion position.Some surgeons prefer it for it's lower bleeding and perforation rate.
2876272|NCT03416205|Experimental|sEST+EPBD|sEST+EPBD is an operation combining EST and EPBD. Investigators use the Erbao electric knife and Three-cavity incision knife to make a small incision to the duodenal nipples, and the incision length is less than 5mm while the incision scope is less than the nipple mouth uplift length of 1/2. Then, Investigators match the appropriate Columnar expansion balloon according to the diameter of the common bile duct and gradually expand the duodenal nipples.This method allows the nipple sphincter to be cut in a small range, then the balloon can guide the direction of the nipple sphincter tearing after the expansion , so that the digestive tract bleeding, perforation may be smaller and more controllable. Besides,it may reduce postoperative pancreatitis rate and the recurrence rate of stones.
2876276|NCT03416179|Placebo Comparator|Arm B (Intensive Study)|Placebo + '7+3' Induction(s)
2876277|NCT03416179|Experimental|Arm A (Non-intensive study)|Glasdegib + azacitidine
2876278|NCT03416179|Placebo Comparator|Arm B (Non-intensive study)|Placebo + azacitidine
2876279|NCT03416153|Active Comparator|Standard Treatment|Patients will receive a single prescription of 70 Gy in 35 fractions with RT given once daily, 5 days a week along with weekly cetuximab (standard therapy)
2876280|NCT03416153|Experimental|De-escalation Treatment|Patients will initially receive a single prescription of 70 Gy in 35 fractions with RT given once daily, 5 days a week along with weekly cetuximab (standard therapy). If certain parameters are met radiation therapy will be reduced to 54Gy to high risk Planned Target Volume (PTV) and 43.2Gy to low risk PTV all in 27 fractions.
2876281|NCT03416140|Experimental|Therapeutic exercise|
2876282|NCT03416140|No Intervention|Control|
2876283|NCT03416127|Experimental|Propolis|Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
2876284|NCT03416127|Experimental|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
2876285|NCT03416127|Placebo Comparator|Placebo|Placebo capsules, two times per day before break-fast and dinner during 12 weeks.
2876286|NCT03416088|Experimental|Liquid volume|Drink 300ml wine (alcohol concentration:13%) or 300ml coffee (caffeine concentration 1.2%).
2876287|NCT03416062|Experimental|Remaxol® 400 ml + Placebo 400 ml|Treatment with Remaxol® 400 ml IV + Ringer solution 400 ml IV for 10 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
2876288|NCT03416062|Experimental|Remaxol® 800 ml|Treatment with Remaxol® 800 ml IV for 10 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
2876289|NCT03416062|Placebo Comparator|Control|Treatment with Ringer's solution 800 ml IV for 7 days. Drug: Ringer's solution
2876290|NCT03416049||High-power PEMF device|20 participants with VSLU will receive PEMF therapy with a high-power PEMF device for 10 minutes twice a day for each VSLU area.
2876291|NCT03416049||Medium-power PEMF device|20 participants with VSLU will receive PEMF therapy with a medium-power PEMF device for 15 minutes twice a day per VSLU area.
2876292|NCT03416049||Low-power PEMF device|20 participants with VSLU will receive PEMF therapy with a low-power PEMF device for 30 minutes twice a day per VSLU area..
2876293|NCT03416049||Sham PEMF device|20 participants with VSLU will receive PEMF therapy with a sham PEMF device identical to the low-power PEMF device and will treat each VSLU area for 15 minutes twice a day.
2876294|NCT03416036|Experimental|Arm 1: TV003 + rDEN2Δ30-7169|Participants will receive a single dose of TV003 at study entry (Day 0) and rDEN2Δ30-7169 on Day 28.
2876295|NCT03416036|Experimental|Arm 2: TV003 + rDEN3Δ30|Participants will receive a single dose of TV003 at study entry (Day 0) and rDEN3Δ30 on Day 28.
2876296|NCT03416036|Placebo Comparator|Arm 3: Placebo + rDEN2Δ30-7169|Participants will receive placebo at study entry (Day 0) and rDEN2Δ30-7169 on Day 28.
2876297|NCT03416036|Placebo Comparator|Arm 4: Placebo + rDEN3Δ30|Participants will receive placebo at study entry (Day 0) and rDEN3Δ30 on Day 28.
2876298|NCT03416010|No Intervention|Control|In addition to standard prenatal care the PregnancyPlus attention control group for 6 weeks will receive 1.5 hours of ACOG-designed patient education pamphlets. Material will include prenatal and post-partum education.. Dr. Gennaro will conduct the training of the attention control group midwives. The same protocol for assessing fidelity for COPE-P also will be used for assessing fidelity to the attention control intervention
2876299|NCT03416010|Active Comparator|Intervention|In addition to standard prenatal care the COPE-P intervention group will also receive 1.5 hours each week for 6 weeks the cognitive-behavior skills building program driven by CBT as the theoretical framework by health care providers trained in COPE-P by Dr. Melnyk. The content of the COPE program is driven by the literature review, the theoretical framework, previous studies of COPE interventions with mothers of preterm infants and prior work with pregnant minority women by our team.
2876300|NCT03415997|Active Comparator|Total Body Weight|
2876301|NCT03415997|Active Comparator|Lean Body Weight|
2876302|NCT03415984||Exposed patients|Patients with Parkinson's disease treated with L-DOPA
2876303|NCT03415984||Non exposed patients|Patients with Parkinson's disease not treated with L-DOPA
2876304|NCT03415971|Active Comparator|ASTRA TECH implants|implant restoration(replace of a missing tooth) - 35 patients
2876305|NCT03415971|Active Comparator|CROWN|to fixed denture restorations in own teeth - 32 patients
2876306|NCT03415971|Placebo Comparator|non-edontulos|control group will consist 38 non-edotulos patients
2876307|NCT03415958||Open reduction internal fixation|Patients with displaced midshaft clavicle fractures will be offered operative treatment which involves open reduction and internal fixation.
2876308|NCT03415958||Conservative care|Patients will be treated in a sling for the acute phase of two weeks with progressive physiotherapy.
2876309|NCT03415945|Experimental|CRT implantation|In cardiac resynchronization therapy (CRT), biventricular pacing is performed by pacing the right ventricle (RV) and epicardium of the left ventricular (LV) posterolateral wall.
2876310|NCT03415932|Experimental|Health education|Assessment of healt care Contacts Before and after intervention
2876311|NCT03415919||IBD patients|Patients suffering from IBD scheduled to have a biopsy by colonoscopy.
2876312|NCT03415919||CRC patients|Patients suffering from CRC scheduled to have a biopsy by colonoscopy, or surgical resection of colon.
2876313|NCT03415906|Experimental|sacubitril+valsartan|Combined angiotensin receptor and neprilysin inhibition
2876314|NCT03415906|Active Comparator|valsartan|Angiotensin receptor inhibition alone
2876315|NCT03415880|Other|Control group|Participants attend 4 workshops and undergo all measurements at t=0, t=3, t=6, and t=12 months.
2876316|NCT03415880|Experimental|Intervention group|Participants attend 4 workshops, receive a wrist-worn feedback physical activity monitor, a smartphone app, and telephone coaching. All participants undergo all measurements at t=0, t=3, t=6, and t=12 months.
2876317|NCT03415867|Experimental|Dose escalation sequential cohorts|Glasdegib will be self-administered orally once daily in the morning as monotherapy in continuous 28-day treatment cycles for a maximum of 12 cycles.
2876405|NCT03415282|Experimental|Open-label treatment arm|Open-label treatment arm - patients will receive RVT-501 0.5% twice daily (BID) for 4 weeks.
2876318|NCT03415854|Experimental|Paricalcitol (Zemplar)|Participants will be treated with the regimen according to the study protocol. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization and undergo imaging to determine response, if any.
2876319|NCT03415841|Experimental|mHealth|"50 patients who are randomized to the intervention group (mHealth remote monitoring devices) will be enabled with remote monitoring devices (Blood Pressure and wearable vital signs monitor, Biovotion) and Kardia mobile application, for home-based rehabilitation program followed by review in the outpatient Cardiology clinics."
2876320|NCT03415841|No Intervention|Control|The control group (50 patients) will just be monitored at fixed intervals in the outpatient Cardiology clinics
2876321|NCT03415828|Experimental|Ethanol gel|CE-marked medical device used according to its instructions for use: GELSCOM® Single injection in the selected disc(s) of 0.6 to 2.2 ml
2876322|NCT03415828|Active Comparator|Steroid infiltration|Authorized drug used according to its summary product characteristics: HYDROCORTANCYL 2,5 POUR CENT Single injection in the selected disc(s) of 0.2 to 2.0 ml
2876323|NCT03415815||T1-T3 esophageal cancer|Pathologically diagnosed patients with T1-T3 esophageal cancer who received surgeries
2876324|NCT03415802|Experimental|Nab-paclitaxel Plus S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) S-1 (40mg BID for body surface area<1.25 m2; 50mg BID for body surface area of 1.25-1.5m2; and 60mg BID for body surface area>1.5 m2; D1-14, q3w)
2876325|NCT03415789||80 patients non ischemic DCM|"A cohort of 80 patients with nonischemic dilated cardiomyopathy in sinus rhythm with left ventricle ejection fraction (EF) less than 45%.~In the first 24 hours after enrollment a coagulation blood test, an electrocardiogram, a Doppler echocardiogram exam and a clinical examination (including neuropsiquiatric evaluation) will be performed.~A cardiac magnetic resonance and a brain magnetic resonance will be performed within 10 days after the enrollment."
2876326|NCT03415776|Experimental|Twice weekly|Two sessions of hemodialysis per week
2876327|NCT03415776|Experimental|Thrice weekly|Three sessions of hemodialysis per week
2876328|NCT03415763|No Intervention|Observation|Observation for patients with pathological complete response or yp stage I(According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil)
2876329|NCT03415763|Experimental|5-fluorouracil|Capecitabine for patients with pathological complete response or yp stage I Capecitabine 1250 mg/m2 twice daily for 14 days in a 3-week cycle to be administered orally after food, three cycles(According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil )
2876330|NCT03415763|Experimental|5-fluorouracil alone|5-fluorouracil alone for patients with yp stage II or III Capecitabine 1250 mg/m2 twice daily for 14 days in a 3-week cycle to be administered orally after food, three cycles(According to the postoperative pathological stage, the present study was designed as a superiority trail for patients with yp stage II or III to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone)
2876331|NCT03415763|Experimental|mFOLFOX6 or CAPOX|Oxaliplatin combined with 5-fluorouracil for patients with yp stage II or III mFOLFOX6 (leucovorin 400 mg/m2 as a 2-hour infusion, and the concurrent administration of oxaliplatin 85 mg/m2 as a 2-hour infusion, followed by a bolus of 5-FU 400 mg/m2 within 15 min and 46-hour infusion of 5-FU 2400 mg/m2 on day 1 every 2 weeks), three cycles or CAPOX (oxaliplatin 130 mg/m2 as a 2-hour infusion on day 1, followed by capecitabine 1000 mg/m2 twice daily for 14 days every 3 weeks), three cycles( According to the postoperative pathological stage, the present study was designed as a superiority trail for patients with yp stage II or III to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone)
2876332|NCT03415750|Experimental|Everolimus arm|Patients will be converted from Tacrolimus + Mycophenolate mofetil to Everolimus + Tacrolimus 'Conversion from Mycophenolate mofetil to Everolimus'
2876333|NCT03415750|Active Comparator|Mycophenolate arm|Patients will remain in Tacrolimus + Mycophenolate mofetil combination
2876334|NCT03415724|Active Comparator|1.8 ml Lignocaine plus adrenaline|The study subjects will receive conventional inferior alveolar nerve block with 1.8 ml of 2% inj lignocaine with adrenaline 1:80000.
2876335|NCT03415724|Active Comparator|3.6 ml Lignocaine plus adrenaline|The study subjects will receive conventional inferior alveolar nerve block with 3.6 ml of 2% inj lignocaine with adrenaline 1:80000.
2876336|NCT03415724|Active Comparator|1.8 ml Lignocaine plus dexmedetomidine|conventional inferior alveolar nerve block with1.8 ml of injection lignocaine plus injection dexmedetomidiene 1micromol/ ml.
2876337|NCT03415724|Active Comparator|3.6 ml Lignocaine plus dexmedetomidine|conventional inferior alveolar nerve block with3.6 ml of injection lignocaine plus injection dexmedetomidiene 1micromol/ ml.
2876338|NCT03415711|Experimental|Mesalamine plus high-probiotic preparation VSL#3®|Mesalamine 2.4 g/day in once daily administration plus VSL#3® 450 billion sachets, two sachets per day (900 billion of bacteria per day) for 12 months.
2876339|NCT03415711|Experimental|Mesalamine plus low-probiotic preparation VSL#3®|Mesalamine 2.4 g/day in once daily administration plus VSL#3® 450 billion sachets, two sachets twice a day (1800 billion of bacteria per day) for 12 months.
2876340|NCT03415711|Active Comparator|Mesalamine plus Placebo|Mesalamine 2.4 g/day in once daily administration plus placebo for 12 months.
2876341|NCT03415698|Active Comparator|Standard Medical Therapy|Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required)
2876342|NCT03415698|Active Comparator|G-CSF + Standard Medical Therapy|G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
2876343|NCT03415685|Active Comparator|Group A: PicoPlus for unwanted tattoos.|Subjects receiving PicoPlus laser system treatment for unwanted tattoos.
2876344|NCT03415685|Active Comparator|Group B: PicoPlus for other dermatological conditions|Subjects receiving PicoPlus laser system treatment for unwanted benign pigmented lesions, melasma or other dermatological conditions such as skin rejuvenation.
2876406|NCT03415269|Experimental|20 mg ambroxol|20 mg ambroxol lozenge delivered once on one day
2877038|NCT03410433|Experimental|PP 5.0|Non-absorbable polypropylene monofilament
2876345|NCT03415672|Active Comparator|Group 1|Subjects included in Group 1 are adults who are non-responders (did not achieve seroprotection after 3 or more vaccinations with a Hepatitis B vaccine. They will receive three doses of HBVaxPro-10μg at 0, 1, and 2 months. The HBVaxPro-10μg vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
2876346|NCT03415672|Experimental|Group 2|"Subjects included in Group 2 are adults who are non-responders (did not achieve seroprotection after 3 or more vaccinations with a Hepatitis B vaccine). They will receive three doses of HBAI20 at 0, 1, and 2 months.~The HBAI20 vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly."
2876347|NCT03415659|Experimental|HWH340 monotherapy|HWH340 tablet, oral administration
2876348|NCT03415646|Active Comparator|Block Group|Erector Spinae Plane Block administered group
2876349|NCT03415646|Sham Comparator|Control Group|Control group
2876350|NCT03415633|Active Comparator|Diagnostic Randomizing|Randomizing to start with home respiratory polygraphy (APNIA) or Standard Polysomnography (PSG)
2876351|NCT03415633|Active Comparator|Therapeutic Randomizing|Randomizing for therapeutic decision taken with home respiratory polygraphy (APNIA) or Standard Polysomnography (PSG)
2876352|NCT03415620|Experimental|Music|"The recruiter will give the patient an ipod with earphone, in which the ipod is equipped with saved playlist of different music genres. Patient will choose the desired playlist and listen to the music for about 30 minutes, seated in a quiet environment in pre-operative waiting area before her turn for the scheduled surgery. Hospital Anxiety and Depression Scale (HADS) and EQ-5D-3L questionnaire will be conducted during this period.~Patient will be sent to the recovery room after the surgery, and will start the music listening again for 30 minutes once she is ready and feel comfortable to start the session. Pain score, HADS and EQ-5D-3L will be collected from the patient, as well as interview on her satisfaction and experience on the music listening."
2876353|NCT03415594|Experimental|FE203799 25 mg|FE203799 GLP-2 analogue, once weekly, subcutaneous administration
2876354|NCT03415594|Placebo Comparator|Placebo 25 mg|Placebo FE203799 GLP-2 analogue, once weekly, subcutaneous administration
2876355|NCT03415581|Placebo Comparator|Doxazosin 0 mg (Placebo)|Maintenance on a daily dose of oral doxazosin (0 mg) for 4 weeks. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
2876356|NCT03415581|Active Comparator|Doxazosin 16 mg|Maintenance on a daily dose of oral doxazosin (16 mg) for 4 weeks. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
2876357|NCT03415568|Placebo Comparator|LCT consumption|Muffin that contains 15g of long-chain triglyceride (LCT) oils were provided to conduct 6-h meal tolerance test.
2876358|NCT03415568|Experimental|MCDG consumption|Muffin that contains 15g of the mixture of medium-chain triglyceride and diacylglycerol (MCDG) oils were provided to conduct 6-h meal tolerance test.
2876359|NCT03415555|Experimental|ESP|Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
2876360|NCT03415555|Experimental|PCA|Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose. ESP will not be done in this arm.
2876361|NCT03415542|Other|Exercise Intervention|Participants receive a print-based exercise promotion program across 12 weeks and are asked to monitor their exercise behavior using an app on their cell phone.
2876362|NCT03415529||4500 patients with ARDS|This is a secondary analysis of data from the LUNG SAFE database to determine the impact of alterations in arterial carbon dioxide tensions in patients with ARDS.
2876363|NCT03415516|Experimental|Gluma Universal, self-etch mode (GSE)|
2876364|NCT03415516|Experimental|Gluma Universal, selective etching (GSL)|
2876365|NCT03415516|Experimental|Gluma Universal, etch&rinse (GER)|
2876366|NCT03415516|Experimental|All Bond Universal, self-etch (ASE)|
2876367|NCT03415516|Experimental|All Bond Universal, selective etching (ASL)|
2876368|NCT03415516|Experimental|All Bond Universal, etch&rinse (AER)|
2876369|NCT03415516|Experimental|Single Bond2, etch&rinse (SBU)|
2876370|NCT03415503|Placebo Comparator|placebo|The placebo capsules only contained pullulan and maltodextrin.During the trial period, the participants were instructed to consume 2 Medox® placebo capsules twice daily (30 min after breakfast and supper).
2876371|NCT03415503|Experimental|40mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum). To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume one Medox® anthocyanin capsules and one Medox® placebo capsules 30 min after breakfast and consume two Medox® placebo capsules 30 min after supper.The anthocyanin capsules (40 mg anthocyanins per capsule) will provid a total daily intake of 40 mg anthocyanins.
2876372|NCT03415503|Experimental|80mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum).To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume one Medox® anthocyanin capsules and one Medox® placebo capsules 30 min after breakfast and consume two Medox® placebo capsules 30 min after supper.The anthocyanin capsules (80 mg anthocyanins per capsule) will provid a total daily intake of 80 mg anthocyanins.
2876373|NCT03415503|Experimental|160mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum). To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume two Medox® anthocyanin capsules 30 min after breakfast and consume two Medox® placebo capsules 30 min after supper.The anthocyanin capsules (80 mg anthocyanins per capsule,2 per day) will provid a total daily intake of 160 mg anthocyanins.
2876552|NCT03414216|Experimental|Group1 - early off-loading surgery|"Within 1 week of randomization, offloading surgery:~Tip of toe ulcers will be treated by percutaneous tenotomy. Ulcers under metatarsal heads will be offloaded with minimally invasive floating metatarsal osteotomy.~Ulcers plantar to the interphalangeal joint of the hallux will be treated by a modified Keller resection arthroplasty."
2876374|NCT03415503|Experimental|320mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum).To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume two Medox® anthocyanin capsules 30 min after breakfast and after supper.The anthocyanin capsules (80 mg anthocyanins per capsule,4 per day) will provid a total daily intake of 320 mg anthocyanins.
2876375|NCT03415490|Active Comparator|Classic technique of self-adherent wrap|"over 16 years old~free of any symptoms in the eyes~classic technique of self-adherent wrap after surgery"
2876376|NCT03415490|Experimental|Folded technique of self-adherent wrap|"over 16 years old~free of any symptoms in the eyes~folded technique of self-adherent wrap after surgery"
2876377|NCT03415477|Experimental|denosumab (Xgeva) treatment|Patients with aneurismal bone cysts received perioperative denosumab(Xgeva).
2876378|NCT03415464|Experimental|Functional training|15 weeks of structured exercise intervention in the form of functional training. We have divided 15 weeks into 5 cycles each cycle lasting 3 weeks. Intervention will be administered twice per week, and each session will last 45 minutes.Each 45 minutes will be further divided into 10 minutes of functional warm-up, 30 minutes of neuromuscular training (strength, agility, balance, coordination) and 5 minutes of cool down. During the 3 week period the intensity of exercise will be increased with different form of same exercise, different number of repetitions and exercise duration.
2876379|NCT03415464|No Intervention|Regular army training|Regular military training.
2876380|NCT03415451|Experimental|Fiberscope-Guided Nasogastric tube|Fiberscope-Guided Nasogastric tube insertion
2876381|NCT03415438||Group 1|Assessments will be done for 30 patients diagnosed as subacromial impingement syndrome in physical medicine and rehabilitation department of Baskent University.
2876382|NCT03415438||Group 2|Assessments will be done for 30 healthy volunteers
2876383|NCT03415425|Active Comparator|Usual Care|The current version of the alert will fire for this arm of the study.
2876384|NCT03415425|Active Comparator|Alert Iteration|A modified version of the alert will fire for this arm of the study.
2876385|NCT03415412|Experimental|Group CU (Clearfil Universal)|Clearfil Univesal Bond (Kuraray Dental, New York, United States of America), adhesive system
2876386|NCT03415412|Experimental|Group IU (Ibond Universal)|IBond Universal (Heraeus Kulzer GmbH, Hanau, Germany), adhesive system
2876387|NCT03415412|Experimental|Group GP (G-Premio)|G-Premio Bond (GC Coorporation, Tokyo, Japan), adhesive system
2876388|NCT03415399|Experimental|i.v. arm|ET190L1 ARTEMIS™ T cells administered by intravenous (IV) infusion
2876389|NCT03415386|Experimental|aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2)|
2876390|NCT03415386|Experimental|aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid|
2876391|NCT03415386|Experimental|aspirin100mg qd+ticagrelor60mg bid+warfarin(INR1.8-2.2)|
2876392|NCT03415386|Experimental|aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid|
2876393|NCT03415373|Experimental|Intervention arm|Each subject will undergo ID administration by Microneedle Adapter (Model UAR-2S) and hypodermic needle + syringe of 100 μL injectable saline into 3 different regions: the inner forearm, the deltoid and the thigh, at three (3) study visits. A total of 4 injections (2 x 50 μL saline and 2 x 100 μL saline) will be administered to each study participant in the injection sites (2 injections per inner forearm/deltoid/thigh and 2 injection per device).
2876394|NCT03415360|Other|cryoablation|peripheral nerve cryoablation
2876395|NCT03415347|Active Comparator|Abscess de-roofing and curettage|Abscess de-roofing and curettage. The patient will be placed in the lateral position with the buttocks spread apart using tape. The cleft of the buttocks will be shaved prior to cleaning and preparation of the skin. A spindle-shaped (elliptical) excision will be performed to the lateral aspect of the abscess formation with a scalpel staying away from the midline. Once the pus has been drained through this lateral incision the wound cavity will then be curetted and washed out with hydrogen peroxide. The wound size will be measured by the operating surgeon who will record the maximal length and width of the wound. Once haemostasis (cessation of any bleeding) is achieved the wound will be packed with Kaltostat ribbon and the wound dressed with blue gauze and mefix tape. The wound is therefore left open.
2876396|NCT03415347|Active Comparator|Abscess wide local excision|Wide local excision. Patients will be placed in the prone position with the buttocks spread apart using tape. The cleft of the buttocks will be shaved prior to cleaning and preparation of the skin. Diluted methylene blue will be injected in all visible pits and a wide spindle-shaped (elliptical) midline excision of the skin and the underlying subcutaneous tissue down to the coccygeal (pre-sacral) fascia including all sinuses will be performed with electrocautery. The specimen will be sent for histology as per routine surgical practice. The wound will be washed with hydrogen peroxide. The wound size will be measured by the operating surgeon who will record the maximal length and width of the wound. Once haemostasis (cessation of any bleeding) is achieved the wound will be packed with Kaltostat ribbon and the wound dressed with blue gauze and mefix tape. The wound is therefore left open.
2876397|NCT03415334|Other|behavioral change|two approaches for behavior changes : social marketing and behavioral development
2876398|NCT03415321|Experimental|Intervention group|Postpartum Mobile Support Application
2876399|NCT03415321|No Intervention|Control Group|Routine care
2876400|NCT03415308||Patient Focus Groups|Identify patient preferences for constructs, and related outcomes, that reflect the expression of implicit bias in clinical encounters. I
2876401|NCT03415308||Stakeholders Cognitive Interviews|Investigators will conduct a series of semi-structured interviews.
2876402|NCT03415308||Pilot Testing of Implicit Bias Training|Refined intervention emerging from Aim 2. T
2876403|NCT03415295||Gestational diabetes mellitus|"Gestational diabetes mellitus (GDM) was diagnosed according to the American Diabetes Association criteria, which is based on the one-step approach recommended by the International Association of Diabetes and Pregnancy Study Groups. All women underwent a 75g OGTT in the morning after an overnight fast, with plasma glucose measurement fasting and at 1 and 2 hours. The criteria for GDM diagnosis was to have at least one abnormal value: Fasting glucose ≥ 5.1 mmol/L (92 mg/dL), 1 h glucose ≥ 10.0 mmol/L (180 mg/dL), 2 h glucose ≥ 8.5 mmol/L (153 mg/dL)."
2876404|NCT03415295||Healthy pregnant control|Pregnant women with fasting glucose ＜ 5.1 mmol/L (92 mg/dL), 1 h glucose ＜ 10.0 mmol/L (180 mg/dL) and 2 h glucose ＜ 8.5 mmol/L (153 mg/dL) were considered as healthy controls.
2876407|NCT03415256|Experimental|passive vibration group|The passive vibration group patients will receive passive vibration (50 Hz, one cycle= 60 seconds working time with 2 seconds rest time) on their calf in supine position for ten minutes. The total number of sessions will be nine. Passive vibration will be given to the treatment group twice a week for four weeks (eight sessions) and the ninth session will be the follow up. At every session, the skin blood flow will be measured before, immediately, and 15 minutes after passive vibration.
2876408|NCT03415256|Active Comparator|no passive vibration group|The control group will not receive any treatment and continue their usual lifestyle. Balance, sensory measurement and skin blood flow will be taken at the beginning of the study, prior to the 5th treatment, and 1 week after the last intervention .
2876409|NCT03415243|Experimental|Treatment A Group|Participants will receive a single dose (1 sachet) of the investigational product (Acetaminophen 650 mg + Dextromethorphan 20 mg + Phenylephrine 10 mg).
2876410|NCT03415243|Experimental|Treatment B Group|Participants will receive a single dose (2 caplets) of the investigational product (Acetaminophen 325 mg + Dextromethorphan 10 mg + Phenylephrine 5mg).
2876411|NCT03415230|Experimental|Therapeutic massage|Women will undertake sessions of therapeutic massage
2876412|NCT03415230|Sham Comparator|Sham massage|Women will undertake sessions of sham massage
2876413|NCT03415217|Other|Neighbourhood Team Development|Neighbourhood Team Development consisted of a 30-month standardised training and implementation plan to promote inter-professional team collaboration and enhanced resident centeredness.
2876414|NCT03415204|Experimental|acupuncture|
2876415|NCT03415204|No Intervention|no acupuncture|
2876416|NCT03415191|Experimental|Ketamine Group|Five minutes before thoracotomy incision, Ketamine Group received a bolus dose of ketamine 1 mg/kg intravenously
2876417|NCT03415191|Placebo Comparator|Placebo Group|Five minutes before thoracotomy incision, Placebo Group received a bolus dose of normal saline 1 mg/kg intravenously
2876418|NCT03415178|Experimental|AI / SYDNEY|Alirocumab self-administered using the current 1 mL alirocumab auto-injector device (AI) on Week 0 (Day 1), then the new 2 mL auto-injector device (SYDNEY) on Week 4, 8, 12
2876419|NCT03415178|Experimental|SYDNEY / SYDNEY|Alirocumab self-administered using the new 2 mL auto-injector device (SYDNEY) on Week 0 (Day 1) then Week 4, 8, 12
2876420|NCT03415165|Active Comparator|green tea buccal tablet|buccal tablet 3 times aday
2876421|NCT03415165|Sham Comparator|corticosteroids topical|topical steroids 3 times aday
2876422|NCT03415152||Omacor (Omega-3-acid ethyl esters)|Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who having been prescribed Omacor for at least 6 months.
2876423|NCT03415139||MRD HCT Recipients|Patients undergo 2 oral glucose tolerance tests (OGTTs) with and without a 2.0 pmol/kg/min intravenous infusion of GLP-1 for 2.5 hours and a standard hyperglycemic clamp procedure prior to HCT. Patients then repeat the 2 OGTTs (with and without a 2.0 pmol/kg/min intravenous infusion of GLP-1 for 2.5 hours) and a standard hyperglycemic clamp procedure once after HCT between days 80-100.
2876424|NCT03415126|Experimental|ASN007 ascending doses|Patients will receive escalating doses of ASN007 to identify the best dose.
2876425|NCT03415126|Experimental|ASN007 RD: KRAS mutant Melanoma|Patients with BRAF mutant metastatic melanoma will receive the recommended dose from Part A.
2876426|NCT03415126|Experimental|ASN007 RD: NRAS mutant Melanoma|Patients with NRAS and HRAS mutant solid tumors will receive the recommended dose from Part A.
2876427|NCT03415126|Experimental|ASN007 RD: KRAS mutant metastatic CRC|Patients with KRAS mutant CRC will receive the recommended dose from Part A
2876428|NCT03415126|Experimental|ASN007 RD: KRAS mutant NSCLC|Patients with KRAS mutant NSCLC will receive the recommended dose from Part A
2876429|NCT03415126|Experimental|ASN007 RD: Metastatic Pancreatic Cancer|Patients with pancreatic adenocarcinoma will receive the recommended dose from Part A
2876430|NCT03415100|Experimental|CAR-NK cells targeting NKG2D ligands|
2876431|NCT03415087|Active Comparator|sequential intrathecal injection of fentanyl and bupivacaine|intrathecal injection drug: fentanyl 25 μg (0.5 ml), IV,once drug: hyperbaric bupivacaine 0.5%10 mg IV,once both syringes were injected slowly sequentially
2876432|NCT03415087|Experimental|rapid sequential intrathecal injection of fentanyl and bupiva|intrathecal injection drug: fentanyl 25 μg (0.5 ml), IV, injected rapidly and mixed by CSF, once drug: hyperbaric bupivacaine 0.5%10 mg IV injected slowly once.
2876433|NCT03415074|Active Comparator|Supplemented low protein diet (sLPD)|Protein restriction to a low level (0.6 g/kg-day, mainly vegetarian) + ketoanalogues of essential amino-acids supplementation (Ketosteril 1 tb/10 kg dry bw)
2876434|NCT03415074|Active Comparator|Mild protein restriction diet (MPD)|Mild restriction in dietary protein intake (0.8 g/kg-day)
2876435|NCT03415061|Experimental|Intranasal Insulin 40 IU|40 IU of Humulin-R via nose Before surgery and everyday after surgery up to postoperative day 7
2876436|NCT03415061|Placebo Comparator|Intranasal Normal Saline|Normal Saline via nose Before surgery and everyday after surgery up to postoperative day 7
2876437|NCT03415035||Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with diagnosed CLL and eligible to venetoclax as per label
2876438|NCT03415022|Experimental|4-week computer-based treatment|A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.
2876439|NCT03415022|Experimental|8-week computer-based treatment|An 8-week (12-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks, and then once a week for the subsequent four weeks.
2876440|NCT03415009||HCV genotype 1 and genotype 2/3|DNA extracted from whole blood sample will be used as template for real-time PCR amplification. It will be analyzed for the genotypes of IL28B SNPs (genotype CC/CT/TT for rs12979860 and TT/GT/GG for rs8099917).
2876441|NCT03414996|Experimental|High-intensity interval training|Following 5 min warm-up at 30 % of maximal aerobic power (MAP) obtained at the cardiopulmonary exercise test, patients performed 2 sets of 10 minutes of repeated phases of 15 seconds at 100 % MAP alternating with 15 seconds of passive recovery. The 2 sets were separated by 4 min of passive recovery (no pedalling). Patients performed 5-minutes of recovery period at 30 % MAP after the second set. Total time duration was 34 minutes.
2876605|NCT03413917||Control group|patients who are admitted for repeat cesarean delivery with bilateral tubal ligation who do not develop uterine atony
2877039|NCT03410433|Experimental|APG 5.0|Antibacterial Vicryl suture
2876442|NCT03414996|Active Comparator|Moderate-intensity continuous exercise training|Duration was adjusted to match total energy expenditure of the high-intensity interval training session. Following 5 min warm-up at 30 % of maximal aerobic power (MAP), patients performed continuous exercise at 60 % MAP during 24 minutes. Patients performed 5-minutes of recovery period at 30 % MAP after the second set. Total time duration was 34 minutes.
2876443|NCT03414983|Experimental|Arm A|Nivo + SOC
2876444|NCT03414983|Active Comparator|Arm B|SOC
2876445|NCT03414970|Active Comparator|Group I (radiation therapy)|Patients undergo radiation therapy daily on Monday-Friday for 5-6 weeks.
2876446|NCT03414970|Experimental|Group II (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy daily on Monday-Friday for 3-4 weeks.
2876447|NCT03414957||Malay PCOS women with Metabolic Syndrome|Malay women underwent clinical assessment, followed by pelvic ultrasound scan, biochemical and hormonal blood tests. Using the Rotterdam criteria, women with PCOS were then checked for Metabolic Syndrome (IDF). Those PCOS women with Metabolic Syndrome were inducted in this group.
2876448|NCT03414957||Malay PCOS without Metabolic Syndrome|Those women with PCOS who did not have Metabolic Syndrome were included in this cohort. Hormonal and biochemical blood tests and ultrasound scanning
2876449|NCT03414957||Non-PCOS with Metabolic Syndrome|From the initial group of malay women who underwent clinical assessment, blood tests and ultrasound assessment, women without PCOS were then identified for Metabolic Syndrome and included in this group. Hormonal and biochemical blood tests and ultrasound scanning
2876450|NCT03414957||Non-PCOS and no Metabolic Syndrome|The remaining Malay women without PCOS and without Metabolic Syndrome were inducted in this group. Hormonal and biochemical blood tests and ultrasound scanning
2876451|NCT03414944|Experimental|SMART-Brain|selective brain radiotherapy based on SIB and hippocampus, inner ear avoidance.
2876452|NCT03414931|Experimental|NMDAE|An NMDA enhancer
2876453|NCT03414931|Active Comparator|SSRI|Sertraline
2876454|NCT03414931|Placebo Comparator|Placebo|Placebo
2876455|NCT03414918|Experimental|Clarithromycin|250 mg clarithromycin diluted in 250 ml saline will be administered as a slow infusion (45 min) in a peripheral vein during AVS. This dose of clarithromycin should yield peak plasma concentrations of 2.78 mcg/mL (on average)13, which are higher than the IC50 measured in vitro (0.53-1.29 mcg/mL).
2876456|NCT03414905|Experimental|Aspira Catheter & Drainage System|"Participants will have standard of care ultrasound and placement of the Aspira Catheter and Drainage System on Day 1~The removal of the Aspira Catheter and Drainage System will be dependent upon future ultrasound assessment and fluid output"
2876457|NCT03414892|Experimental|Globalagliatin Hydrochloride (SY-004)|If subjects tolerate 20mg of Globalagliatin Hydrochloride (SY-004) for 7 days, dose escalation will occur in the following order of 40mg, 80mg and 120mg at weekly intervals until patients get intolerant or blood glucose controlled well or reach the maximal dose 120mg.
2876458|NCT03414892|Placebo Comparator|Placebo|If subjects tolerate 20mg of Placebo for 7 days, dose escalation will occur in the following order of 40mg, 80mg and 120mg at weekly intervals until patients get intolerant or blood glucose controlled well or reach the maximal dose 120mg.
2876459|NCT03414879|Active Comparator|Ketamine group|Nebulization with ketamine
2876460|NCT03414879|Active Comparator|Lidocaine group|Nebulization with with lidocaine
2876461|NCT03414866||Acute thoracic aortic syndrome|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
2876462|NCT03414866||Subacute/chronic dissection of the aorta|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
2876463|NCT03414866||Aortic aneurysm|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
2876464|NCT03414853||With algorithm use|
2876465|NCT03414853||No algorithm use|
2876466|NCT03414814|Experimental|Osimertinib|Osimertinib at 80mg dose will be administered orally once daily.
2876467|NCT03414801|Active Comparator|Cohort 1|Cat Allergic Subjects
2876468|NCT03414801|Active Comparator|Cohort 2|Non-Allergic Subjects will
2876469|NCT03414788|Experimental|Treatment Arm - PF 06687234 and [124I]IB PF 06687234|PF 06687234 and [124I]IB PF 06687234
2876470|NCT03414775|Active Comparator|Pediasure|Patients assigned to this arm will receive Pediasure
2876471|NCT03414775|Active Comparator|Nourish|Patients assigned to this arm will receive Nourish
2876472|NCT03414762|Experimental|PICO Dressing|PICO Negative Pressure Wound Therapy (Smith and Nephew Healthcare, Hull, United Kingdom) is a non-significant-risk, FDA Class II, medical device commercially available in the USA. The PICO unit is a single patient use, battery-powered, disposable unit that can provide continuous 80 - 125 mmHg negative pressure over a 5 to 7-day therapy period.
2876473|NCT03414762|Active Comparator|Standard Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing.
2876474|NCT03414749|Experimental|Lower Extremity First|Treatment was a non-specific long-axis distraction to the ankle, knee, and hip provided was at the discretion of the clinic doctor (over 25 years experience).
2876475|NCT03414749|Experimental|Upper Extremity First|Treatment was a non-specific long-axis distraction to the shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
2876476|NCT03414736|Experimental|Cohort 1|Daily dose escalation (click-by-click): Starting at dose 1 in the morning with daily increments to dose 2. During the escalation phase, the dose will only be increased if the patient is feeling fine.
2876477|NCT03414736|Experimental|Cohort 2|Weekly dose escalation in 6 escalation steps (7 dose levels): Starting at dose 1 injected in the morning with weekly increments to dose 2. In case a dose level is not well tolerated by a patient, the treatment should continue at the same dose level for another 7 days before the next dose escalation.
2876478|NCT03414736|Experimental|Cohort 3|Weekly dose escalation in 4 escalation steps (5 dose levels): Starting at dose 3 with weekly increments to dose 2. In case a dose level is not well tolerated by a patient, the treatment should continue at the same dose level for another 7 days before the next dose escalation.
2876479|NCT03414723|Experimental|SAR439954 with or without ramipril|"On Period 1, following an overnight fast, subjects will receive once daily single morning oral intake of sotagliflozin from Day 1 to Day 5 followed by the first meal that has to be started within 10 min after dosing.~On Day 1 of the Period 2, study subjects will begin a 10-day ramipril regimen following an overnight fast. From Day 6 to Day 10, subjects will receive once daily single morning oral intake of ramipril concomitantly to the sotagliflozin dosing."
2876480|NCT03414710|Experimental|Intervention group|"Health education booklet plus video plus brief counseling~In addition to the educational booklet received by the control group, the intervention group will receive the following health promotion:~Watch a 10-minute video promoting VMMC~Receive a brief counseling promoting VMMC If the participants are willing to take up VMMC, the counselors will facilitate them to make an appointment for check-up and surgery."
2876481|NCT03414710|Active Comparator|Control group|"Health education booklet only After randomization took place, the control group will receive an education booklet introducing voluntary medical male circumcision.~If the participants are willing to take up VMMC, the counselors will facilitate them to make an appointment for check-up and surgery."
2876482|NCT03414697|Other|Control group|Routine rehabilitation treatments
2876483|NCT03414697|Experimental|Intravenous UC-MSCs group|Injection of UC-MSCs via the peripheral vein.
2876484|NCT03414697|Experimental|Intrathecal UC-MSCs group|Injection of UC-MSCs via the intrathecal route.
2876485|NCT03414697|Experimental|Intranasal UC-MSCs group|Injection of UC-MSCs via the nasal route.
2876486|NCT03414684|Experimental|Carboplatin + Nivolumab|"Nivolumab is administered every three weeks intravenously~Nivolumab dosage is 360mg~Carboplatin is administered every three weeks intravenously~Carboplatin dosage is pre-determined by the PI"
2876487|NCT03414684|Experimental|Carboplatin|"Carboplatin is administered every three weeks intravenously~Carboplatin dosage is pre-determined by the PI"
2876488|NCT03414671||historical control|All infants born < 30 weeks gestation admitted to the Swedish Hospital NICU from 11/30/2015-11/30/2017 (historical control, pre-standardized defined CSCPE
2876489|NCT03414671||Standardized|All infants born < 30 weeks gestation admitted to the Swedish Hospital NICU from 6/1/2018 - 12/31/20 (the group following implementation of the standardized defined CSCPE)
2876490|NCT03414658|Experimental|Trastuzumab + Vinorelbine|"Trastuzumab is administered intravenously twice per cycle~Vinorelbine is administered intravenously 3 times per cycle"
2876491|NCT03414658|Experimental|Trastuzumab + Vinorelbine + Avelumab|"Trastuzumab is administered intravenously twice per cycle~Vinorelbine is administered intravenously 3 times per cycle~Avelumab is administered intravenously twice per cycle~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab"
2876492|NCT03414658|Experimental|Trastuzumab + Vinorelbine + Avelumab + Utomilumab|"Trastuzumab is administered intravenously twice per cycle~Vinorelbine is administered intravenously 3 times per cycle~Avelumab is administered intravenously twice per cycle~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab~Utomilumab is administered intravenously once per cycle"
2876493|NCT03414658|Experimental|Trastuzumab + Avelumab + Utomilumab|"This is a crossover arm~Avelumab is administered intravenously twice per cycle~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab~Utomilumab is administered intravenously once per cycle~Trastuzumab is administered intravenously twice per cycle"
2876494|NCT03414645|Experimental|CAM-101 10%|FD hPL 10 vol/vol %
2876495|NCT03414645|Experimental|CAM-101 30%|FD hPL 30 vol/vol %
2876496|NCT03414645|Placebo Comparator|Vehicle Control|PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
2876497|NCT03414632|Other|SPECT/CT|99mTc-PYP single-photon positive emission computed tomography with computed tomography
2876498|NCT03414619|Experimental|Intrusive Thoughts Group|Clinically significant intrusive thought in the domain of obsessions, worries, or depressive ruminations with a score at least 1 standard deviations (SD) above the mean (≥ 41) on the trait repetitive negative thinking measure (Perseverative Thinking Questionnaire, PTQ). These participants will receive the Cognitive Control Tasks and Script Driven Imagery Intervention.
2876499|NCT03414619|Experimental|Non-psychiatric Control Group|A score below 1 SD of mean (≤ 15) on the trait repetitive negative thinking measure (Perseverative Thinking Questionnaire, PTQ). These participants will also receive the Cognitive Control Tasks and Script Driven Imagery Intervention.
2876500|NCT03414593|Experimental|preoperative blocked leg: group preB|ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml Before surgical incision
2876501|NCT03414593|Active Comparator|postoperative blocked leg: group postB|ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml After surgical incision
2876502|NCT03414580||Ulcerative colitis|Patients with ulcerative colitis whose diagnosis had established on clinical, endoscopic, histologic, and/or radiological criteria. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
2876503|NCT03414580||Crohn's disease|Patients with crohn's disease whose diagnosis had established on clinical, endoscopic, histologic, and/or radiological criteria. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
2876504|NCT03414580||Healthy control|Subject with no intestinal symptoms or no known gastrointestinal disorders. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
2876505|NCT03414567||Control Group|Non-smoker
2876506|NCT03414567||Study Group|Smoker
2876507|NCT03414554||HCV patients receiving DAAs|Patients with HCV-related liver cirrhosis (eligible for treatment) who will recieve DAAs therapy with one year follow up.markers: miR121, miR122, miR124will be assessed in both groups before and after DAAs
2876508|NCT03414541|Placebo Comparator|Placebo|Participants in this group will receive matching placebo capsules twice daily.
2876509|NCT03414541|Experimental|500mg DS102|Participants in this group will receive 500 mg DS102 capsules twice daily.
2876510|NCT03414541|Experimental|1000mg DS102|Participants in this group will receive 1000 mg DS102 capsules twice daily.
2876511|NCT03414528||Patients with PID|
2876512|NCT03414515||Patients with peripheral artery disease|located in the common and external iliac artery, the common and superficial femoral artery, the popliteal artery and/or the below-the-knee (BTK) arteries (anterior tibial artery, posterior tibial artery or peroneal artery).
2877040|NCT03410433|Experimental|ePTFE 5.0|expanded polytetrafluoroethylene
2876513|NCT03414502|Other|Single arm Methotrexate|"This study is a 16-week, open-label study designed to identify the subset of RA patients that respond to methotrexate monotherapy. All patients will receive methotrexate at a starting dose of 15 mg once weekly plus folic acid 1 mg daily. If a patient is not in remission by 8 weeks, then the dose will be escalated as tolerated to 20 mg once weekly. Both oral and injectable methotrexate are acceptable.~If the patient is unable to tolerate the Methotrexate at 15 mg, it is allowed to titrate the dose as tolerated as long as patient remains on Methotrexate."
2876514|NCT03414476|Experimental|ET group|Sampling : Hair follicles sampling on the scalp in women with Telogene Effluvium
2876515|NCT03414476|Experimental|Control group|Sampling: Hair follicles sampling on the scalp in women without Telogene Effluvium
2876516|NCT03414463|Experimental|TREAT|A 4-week one-to-one intervention between the clinical RA (cRA) and participant. Comprised of eight sessions, it involves psycho-educational lessons and skill-building exercises to achieve objectives based on the characteristics of alexithymia.
2876517|NCT03414463|Experimental|Waitlist Control|After Time 1 testing in Week 1, participants randomized to WLC will not receive any treatment during Weeks 2-5. The only staff interaction during this no treatment time period will be to schedule Time 2 testing appointment for week 6. After Time 2 testing, WLC will receive TREAT (weeks 14-17), followed up with testing.
2876518|NCT03414450|Experimental|Dose Escalation (Phase 1A)|An adaptive design using the ordinal Continual Reassessment Method (oCRM) will be used to determine the MTD and RD of ETC-1907206 in combination with dasatinib.
2876519|NCT03414450|Experimental|Dose Expansion (Phase 1B)|Once the MTD and/or RD has been determined in Phase 1A, an expansion cohort will be enrolled in order to characterize the safety, PK and preliminary clinical activity of ETC-1907206 in combination with dasatinib. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, withdrawal of consent or it is judged not to be in the patient's interest to continue on the study.
2876520|NCT03414424|Experimental|All subjects|All subjects undergo same full protocol, including CES at rest and CES plus active hand or wrist movements.
2876521|NCT03414398||Experimental|Qualitative interview
2876522|NCT03414385|Experimental|Exercise group|Research volunteers will be asked to undergo an acute bout of aerobic exercise at moderate intensity for ~120 minutes. Before and after the exercise the volunteer will undergo leg biopsy.
2876523|NCT03414372|Experimental|Tough Talks Online|Participants will use Tough Talks Online
2876524|NCT03414372|Experimental|Tough Talks Clinic|Participants will use receive Tough Talks in a clinic
2876525|NCT03414372|Placebo Comparator|Standard of Care|Participants will receive the standard of care (SOC).
2876526|NCT03414359|Experimental|2% Lidocaine|
2876527|NCT03414359|Active Comparator|3% Chloroprocaine|
2876528|NCT03414346|Experimental|Exclusively ice pack:|Ice pack application: 500 grams of crushed ice.
2876529|NCT03414346|Experimental|Ice pack added 10% of water:|Wetted ice pack application: 500 grams of crushed ice added to 50 mL of water at room temperature.
2876530|NCT03414346|Experimental|Ice pack added 100% of water:|Wetted ice pack application: 500 grams of crushed ice added to 500 mL of water at room temperature.
2876531|NCT03414333|Experimental|Roux-en- Y gastric bypass (RYGB)|Roux-en- Y gastric bypass (RYGB) is the most popular bariatric procedure and it has been associated with improvements in glycemic control and cognitive function. It works by decreasing the amount of food you can eat at one sitting and by changing the hormones released at the bottom of the stomach and duodenum.we propose that RYGB is a model of chronic elevation of GLP-1 providing an opportunity to explore relationship between changes in the circulating hormone and brain glucose metabolism, cognitive function and neuroplasticity.
2876532|NCT03414333|Active Comparator|GLP-1|GLP-1 is an intestinal hormone secreted in response to nutrients.
2876533|NCT03414320|Experimental|Study Arm|We will gather data from this group of patients.
2876534|NCT03414307|Experimental|Intracerebral hemorrhage|Patients with ICH meeting inclusion/exclusion criteria undergo ROSA stereotactic robot-assisted intracerebral catheter placement to evacuate intracerebral or intracranial hemorrhage
2876535|NCT03414294|Experimental|K-755 Part A (SAD)|
2876536|NCT03414294|Placebo Comparator|Placebo Part A (SAD)|
2876537|NCT03414294|Experimental|K-755 Part B (MAD)|
2876538|NCT03414294|Placebo Comparator|Placebo Part B (MAD)|
2876539|NCT03414294|Experimental|K-755 Part C (FE)|
2876540|NCT03414281|Experimental|TMQLB group 1|0.4ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
2876541|NCT03414281|Experimental|TMQLB group 2|0.6ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
2876542|NCT03414281|Active Comparator|TPVB group|0.4ml/kg ropivacaine is injected into the thoracic paravertebral space (T10) using TPVB approach.
2876543|NCT03414268|Experimental|Micronized dHACM|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
2876544|NCT03414268|Placebo Comparator|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
2876545|NCT03414255|Experimental|Micronized DHACM|1mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM)
2876546|NCT03414255|Placebo Comparator|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
2876547|NCT03414242|Experimental|Cervical spine musculature|
2876548|NCT03414229|Experimental|UPS, Liposarcoma or pleomorphic liposarcoma|Undifferentiated Pleomorphic Sarcoma (UPS) or Liposarcoma (dedifferentiated or pleomorphic liposarcoma) Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
2876549|NCT03414229|Experimental|Leiomyosarcoma|Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
2876550|NCT03414229|Experimental|Vascular Sarcoma Subtypes|Including angiosarcoma and Epithelioid Hemangioendothelioma (EHE). Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
2876551|NCT03414229|Experimental|Other|Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
2876848|NCT03411902|Placebo Comparator|Placebo|Active comparator: Identical 150 mg placebo capsules once every 4 weeks for 24 weeks.
2876553|NCT03414216|Active Comparator|Group 2 - off-loading in fiberglass cast|"Tip of toe ulcers and ulcers plantar to the interphalangeal joint of the big toe will be casted in a fiberglass cast with a heel, ending under the metatarsal heads, leaving the toes in the air.~Ulcers under metatarsal heads will be casted in a full foot fiberglass cast with a heel with a window below the ulcer designed to relieve pressure under the metatarsal heads."
2876554|NCT03414203|Active Comparator|active tDCS|Active tDCS for 15 minutes for 10 days over 2 weeks. Intensity: 2 milliampere. Placement: anode - left DLPFC; cathode - right supraorbital region
2876555|NCT03414203|Experimental|active tDCS with interval|Active tDCS for 15 minutes, interval of 20 minutes and more 15 minutes for 10 days over 2 weeks. Intensity: 2 milliampere. Placement: anode - left DLPFC; cathode - right supraorbital region
2876556|NCT03414203|Sham Comparator|sham tDCS|Sham tDCS for 15 minutes for 10 days over 2 weeks. The stimulation is non-active. Placement: anode - left DLPFC; cathode - right supraorbital region
2876557|NCT03414190|Experimental|Experimental|Automated semi-personalized mobile phone text message-based intervention for secondary prevention plus usual care.
2876558|NCT03414190|No Intervention|No Intervention|Usual Care
2876559|NCT03414177|Active Comparator|Telemedicine Group|Telemedicine participants will have asthma subspecialty follow-up visits conducted via real-time audio and video conferencing in conjunction with electronic examination peripherals and remote pulmonary function testing (PFT). Participants will receive a survey link to complete an electronic survey to assess Asthma Control Test (ACT) score, healthcare utilization, and satisfaction.
2876560|NCT03414177|Active Comparator|In-Person Group|In-Person participants will have asthma subspecialty follow-up visits at a subspecialty clinic. They will receive pulmonary function testing (PFT). Participants will receive a survey link to complete an electronic survey to assess Asthma Control Test (ACT) score, healthcare utilization, and satisfaction.
2876561|NCT03414164|Experimental|procyanidine group|
2876562|NCT03414164|No Intervention|control group|
2876563|NCT03414151||Observational|All participants will be placed in one group (there is no randomization procedure)
2876564|NCT03414138|Experimental|Mindfulness Meditation Group|"Research volunteers will participate in four sessions (20 min/session) of mindfulness training. Participants are taught that perceived sensory events are momentary and fleeting, requiring no further evaluation. They will be asked to close their eyes, relax and focus on the flow of their breathing by simply letting go of discursive thoughts."
2876565|NCT03414138|Active Comparator|Book Listening Control|Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 4 session sequence is meant to match features of the experimental meditation sessions, including attention to the recording, room setting, social support, conditioning, and time elapsed during the sessions. We do not expect that this group will demonstrate significant blood oxygenation changes as a function of the intervention.
2876566|NCT03414125|Active Comparator|FIT Screening Strategy|"Mailed outreach invitation to complete FIT. FIT Strategy invitation includes: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
2876567|NCT03414125|Experimental|Choice Screening Strategy|"Mailed outreach invitation offering patients the choice to complete either a FIT or schedule a colonoscopy.~Letter will discuss advantages and disadvantages of FIT vs. colonoscopy but will not recommend a particular test, allowing patients to choose a screening option based on their own preferences.~Choice Strategy outreach invitation includes: 1) invitation letter, 2) option grid comparing FIT and colonoscopy 3) telephone number for scheduling colonoscopy, and 4) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
2876568|NCT03414112|Placebo Comparator|Intranasal Oxytocin Placebo|Intranasal placebo
2876569|NCT03414112|Experimental|Intranasal Oxytocin|Intranasal oxytocin
2876570|NCT03414099|Experimental|Ketum|Each participant will consume a sequence of active ketum or placebo drinks. Pain tolerance will be measured using the cold pressor task after consuming each drink.
2876571|NCT03414099|Placebo Comparator|Placebo|Each participant will consume a sequence of active ketum or placebo drinks. Pain tolerance will be measured using the cold pressor task after consuming each drink.
2876572|NCT03414086||Myositis in Remission|Subjects who are in remission with their myositis diagnosis.
2876573|NCT03414086||Healthy Controls|Subjects who do not have a myositis diagnosis.
2876574|NCT03414073|Sham Comparator|Group A Phase 1|"Conventional flossing technique using commercially available Reach® Floss One third of sample are randomly assigned to Group A and are to utilise conventional finger flossing technique in the first phase of 4-weeks. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
2876575|NCT03414073|Active Comparator|Group B Phase 1|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss One third of sample are randomly assigned to Group B and are to utilise knotted floss technique in the first phase of 4-weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
2876576|NCT03414073|Sham Comparator|Group C Phase 1|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes One third of sample are randomly assigned to Group C and are to utilise conventional interdental brushing technique in the first phase of 4-weeks twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
2876606|NCT03413917||Study group|Patients who develop uterine atony either during cesarean delivery or who require surgical management of atony after delivery
2876577|NCT03414073|Active Comparator|Group A Phase 2|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss After a washout period of 2 weeks, those from Group A will use the knotted floss technique in the second phase for a period of 4 weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
2876578|NCT03414073|Sham Comparator|Group B Phase 2|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes After a washout period of 2 weeks, those from Group B will use the conventional interdental brushing technique in the second phase for a period of 4 weeks, twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
2876579|NCT03414073|Sham Comparator|Group C Phase 2|"Conventional flossing technique using commercially available Reach® Floss After a washout period of 2 weeks, those from Group C will use the conventional finger flossing technique in the second phase for a period of 4 weeks, twice daily. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
2876580|NCT03414073|Sham Comparator|Group A Phase 3|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes After a washout period of 2 weeks, those from Group A will use the conventional interdental brushing technique in the third phase for a period of 4 weeks, twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
2876581|NCT03414073|Sham Comparator|Group B Phase 3|"Conventional flossing technique using commercially available Reach® Floss After a washout period of 2 weeks, those from Group B will use the conventional finger flossing technique in the third phase for a period of 4 weeks, twice daily. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
2876582|NCT03414073|Active Comparator|Group C Phase 3|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss After a washout period of 2 weeks, those from Group C will use the knotted floss technique in the third phase for a period of 4 weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
2876583|NCT03414060|Experimental|Intervention (Menstrual Cup)|The menstrual cup is a 100% silicone, flexible reservoir cup that, when inserted correctly in the vagina, is sanitary and efficacious in preventing leakage of menstrual blood and in eliminating odor.
2876584|NCT03414047|Experimental|Prexasertib Cohort 1|Participants with platinum-resistant disease that are breast cancer susceptibility gene (BRCA) negative and have received ≥3 lines of prior therapy.
2876585|NCT03414047|Experimental|Prexasertib Cohort 2|Participants with platinum-resistant disease that are BRCA negative and have received <3 lines of prior therapy.
2876586|NCT03414047|Experimental|Prexasertib Cohort 3|Participants with platinum-resistant disease that are BRCA positive and received a prior poly ADP ribose polymerase (PARP) inhibitor.
2876587|NCT03414047|Experimental|Prexasertib Cohort 4|Participants with platinum refractory disease.
2876588|NCT03414034|Experimental|PCM-075 + abiraterone and prednisone|PCM-075, 24 mg/m2, administered orally Day 1 through Day 5 every 21 days (1 cycle) in combination with the standard dose of abiraterone (1000 mg orally once daily; four 250 mg tablets or two 500 mg film-coated tablets) and prednisone (5 mg orally once daily).
2876589|NCT03414021||Thyroid Diseases|SPECT-CT Scan
2876590|NCT03414021||Heart Diseases|SPECT-CT Scan
2876591|NCT03414021||Bone Diseases|SPECT-CT Scan
2876592|NCT03414021||Brain Diseases|SPECT-CT Scan
2876593|NCT03414021||Kidney Diseases|SPECT-CT Scan
2876594|NCT03414008|Experimental|Active Drug Group|Single rising dose
2876595|NCT03414008|Placebo Comparator|Placebo Group|
2876596|NCT03413995|Experimental|Rucaparib 600 mg BID, continuous dosing|Rucaparib 600mg by mouth twice daily, continuous dosing
2876597|NCT03413982||BC Patients|Patients with bladder cancer. This registry involves no intervention. Blood, urine, and tissue samples will be collected to be used for research.
2876598|NCT03413969|Experimental|Behavioral Intervention|The study subjects will be recruited for approximately six weeks prior to the projected start date. The participants will attend the two-day weekend retreat. Follow-up assessments will be administered three months and six months after the retreat. The investigators will analyze the data and complete the study one month after the final assessment is administered.
2876599|NCT03413956||NSCLC patients with lymph metastases|Pathologically diagnosed patients with T1 non-small cell lung cancer complicated with lymph metastases after surgeries
2876600|NCT03413943|Experimental|explicit gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
2876601|NCT03413943|Experimental|implicit gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
2876602|NCT03413943|Sham Comparator|sham gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
2876603|NCT03413930|Experimental|TaTME|Patients with mid or low rectal cancer undergo transanal total mesorectal excision.（assisted by laparoscopy to control the IMA）
2876604|NCT03413930|Active Comparator|LaTME|Patients with mid or low rectal cancer undergo laparoscopic total mesorectal excision.
2876607|NCT03413904|Experimental|transanal TME|Study procedure will consist in 2-team (combined) LAR with transanal TME using laparoscopic abdominal assistance.Transanal TME is performed either at the same time or following the above steps. Transanal endoscopic TME dissection will proceed circumferentially until the peritoneal cavity is entered anteriorly. Following complete mobilization of the rectosigmoid, the specimen is extracted transanally or using a Pfannenstiel incision followed by colorectal anastomosis, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
2876608|NCT03413904|Active Comparator|laparoscopic TME|Procedure will consist in 1 team performing laparoscopic TME. Following stapled closure of the rectum below the tumor, and complete mobilization of the rectosigmoid, the specimen is extracted using a Pfannenstiel incision . A stapled (knight-Griffen) colorectal anastomosis or coloanal anastomosis will be created and a temporary diverting stoma will be fashioned which is standard of care following surgery for this type of cancer.
2876609|NCT03413891|Placebo Comparator|Control Group|10mL water as mouthwash with white cherry flavor in oral syringes. Once before tooth extraction and 3 times daily during 3 days post-extraction (starting day after extraction).
2876610|NCT03413891|Experimental|Tranexamic Acid Group|10mL tranexamic acid mouthwash 10% in oral syringes. Once before tooth extraction and 3 times daily during 3 days post-extraction (starting day after extraction).
2876611|NCT03413878|Experimental|Wet snow/Small air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet avalanche snow with a small air pocket
2876612|NCT03413878|Experimental|Dry snow/Small air pocket|Breathing in the simulated avalanche snow. Breathing into model of dry avalanche snow with a small air pocket
2876613|NCT03413878|Experimental|Wet snow/Large air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet avalanche snow with a large air pocket
2876614|NCT03413878|Experimental|Dry snow/Large air pocket|Breathing in the simulated avalanche snow. Breathing into model of dry avalanche snow with a large air pocket
2876615|NCT03413865|Experimental|OTN virtual clinic|Pharmacist and nurse led OTN based remote teleconference based clinic (OTN) The OTN clinic will be conducted by providing the patient with a link via email which will allow the patient to access OTN teleconferencing and meet virtually with a pharmacist and nurse during a previously scheduled appointment. Virtual clinic appointments will be 30 minutes long and will consist of a patient assessment and open ended questions about the patient health status using a modified version of the validated MOATT (MASCC Oral Agent Teaching Tool) created by the Multidisciplinary Association of Supportive Care in Cancer.
2876616|NCT03413865|No Intervention|In person Visits|Patients are followed in person at the cancer clinic based on standard of care guidelines
2876617|NCT03413839|Experimental|PSSE Group|Individuals will receive at least 6 sessions of physiotherapeutic scoliosis specific exercises (PSSE) (Schroth) physical therapy. Patients will also be required to perform exercises 5x/wk for 15 minutes at home. Compliance will be monitored by written log and weekly phone check-in after 8 weeks.
2876618|NCT03413839|Other|Conventional PT Group|Individuals will receive at least 6 sessions of conventional physical therapy (PT). Patients will also be required to perform exercises 5x/wk for 15 minutes at home. Compliance will be monitored by written log and weekly phone check-in after 8 weeks.
2876619|NCT03413826|Experimental|6 Days per week|This group will exercise 6 days per week and expend 3,000 kcal per week for 12 weeks
2876620|NCT03413826|Experimental|2 Days per week|This group will exercise 2 days per week and expend 3,000 kcal per week for 12 weeks
2876621|NCT03413826|No Intervention|control|This group will remain sedentary for 12 weeks
2876622|NCT03413800|Experimental|Lenalidomide-Dexamethasone-DLI|"Patients will receive Len (10 mg in the presence of ≤ grade I acute GVHD or absence of chronic GVHD; 5 mg in presence of controlled mild or moderate chronic GVHD) daily x 21 days with Dex 40 mg once weekly for a total of 6 cycles of 28 days each~For grade ≥III non hematologic or grade IV hematologic toxicity, Len can be reduced to 5 mg~In absence of these toxicities, acute GVHD (using Glucksberg modified criteria) or severe chronic GVHD (using NIH criteria), Len dose can be increased by 5 mg per cycle to a maximum of 25 mg~If eligibility is confirmed, sibling and unrelated donor transplant recipients will both receive 3 donor lymphocyte infusions (DLIs) at the following doses: 5 x 106 CD3+/kg; 1 x 107 CD3+/kg; 5 x 107 CD3+/kg~Patient will be followed for 5 years post relapse."
2876623|NCT03413774||Abortion group|910 women attended Fayoum University hospital outpatient gynecology clinic with recent first trimesteric spontaneous miscarriage
2876624|NCT03413774||Control group|940 women attended Fayoum University hospitalpresented for any other gynecological complaint
2876625|NCT03413748|Active Comparator|Peritoneal irrigation|Irrigation with 500 - 1000 ml of warm normal saline will be done after closure of visceral peritoneum
2876626|NCT03413748|Active Comparator|Non peritoneal irrigation|No Irrigation with 500 - 1000 ml of warm normal saline will be done after closure of visceral peritoneum
2876627|NCT03413735|Placebo Comparator|Placebo Confection|Confection without green tea extract consumed daily for 4 weeks
2876628|NCT03413735|Experimental|Green Tea Extract-Confection|Confection with green tea extract consumed daily for 4 weeks
2876629|NCT03413722||Conversion Group|Kidney transplant recipients at the University of Kansas Medical Center (KUMC) who are currently on tacrolimus (CNI), and will be undergoing conversion to Everolimus + low dose CNI. Potential participants will be asked to participate in the study after the decision to convert CNI to Everolimus + low dose CNI has been made.
2876630|NCT03413722||Control Group|Kidney transplant recipients at KUMC on tacrolimus (CNI). These will be patients not planning to undergo any change in immunosuppression.
2876631|NCT03413709|Active Comparator|Treatment Group (n=350)|The sample for the treatment group for the impact evaluation will only include fathers who are receiving the full 240 hour Family Formation Program (and not the abbreviated 80 hour program). The treatment group will receive FSC's Family Formation Program, which is a six week, 240 hour program implementing a set of curricula focusing on responsible parenting, healthy relationships,and economic stability and mobility. In addition, participants will receive case management and a variety of employment, legal and support services for up to one year following the completion of the curriculum.
2876632|NCT03413709|No Intervention|Comparison Group (n=350)|The sample comparison group will receive only the abbreviated 80 hour program. Which consist of economic stability and mobility only. These participants will receive employment case management and legal services for up to one year following the completion of the curriculum.
2876633|NCT03413696||Not referred for HCV therapy|
2876636|NCT03413657|Other|Fluid responders|Patient's identified to have a significant increase in their cardiac output following a fluid bolus.
2876637|NCT03413657|Other|Fluid non-responders|Patient's identified to NOT have a significant increase in their cardiac output following a fluid bolus.
2876638|NCT03413631|Experimental|Prenatal mentalization intervention|The intervention group participants were offered three mentalization-focused 4D interactive ultrasounds at 24, 30 and 34 gestational weeks and a mentalization-focused week-by-week pregnancy diary combined with three prenatal sessions and option for one session after delivery in addition to obstetric care as usual (see Prenatal obstetric treatment as usual).
2876639|NCT03413631|Active Comparator|Prenatal obstetric treatment as usual|The control group received obstetric care as usual in a tertiary setting. The comprehensive treatment as usual was conducted at the hospital antenatal outpatient clinic, including regular obstetric ultrasounds. The multidisciplinary treatment team, consisting of an obstetrician, a midwife, a social worker and a psychiatric nurse, assess and support health and psychosocial situation of the pregnant woman. The pregnant woman was referred to addiction and psychiatric treatment when needed.
2876640|NCT03413618|Experimental|Study group|treatment of DVT with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
2876641|NCT03413618|Active Comparator|Control group|standard treatment of DVT with anticoagulation (rivaroxaban) and elastic compression stockings
2876642|NCT03413605|Experimental|a multilevel CBPR intervention|The intervention will be delivered in group-based education workshop format. The education session is a curriculum-based group education; each group will be having about 15-20 participants. We will allow 5-7 minutes for participants to get to know each other and to get comfortable talking to the group. Education will have two major topics.(a) CDC's standard Clinical Preventive Services Guidelines for adults 50+ (CPS). (b) culturally tailored CRC information discussion. This session is to increase knowledge, change cultural beliefs and attitudes on risks of CRC and benefits of screening by using interactive discussion approaches, visual aids, motivation video and print materials.
2876643|NCT03413605|No Intervention|control group|the standard CDC's Clinical Preventive Services Guidelines for adults 50+ (CPS) will be provided to control groups.
2876644|NCT03413592|Other|Driving test|
2876645|NCT03413579|Experimental|Nimotuzumab|200 mg of Nimotuzumab (weekly during 18 weeks), in combination with chemotherapy (6 cycles, every 21 days: 70 mg / m2 Cisplatin and Vinorelbine 60 mg / m2 (Per Os) at day 1 and day 8
2876646|NCT03413579|Placebo Comparator|Placebo|Placebo (weekly during 18 weeks), in combination with chemotherapy (6 cycles, every 21 days: 70 mg / m2 Cisplatin and Vinorelbine 60 mg / m2 (Per Os) at day 1 and day 8
2876647|NCT03413566||Children with clinical diagnosis of CP|All children residing in Norway with a validated diagnosis of cerebral palsy.
2876648|NCT03413566||Children without CP|All children residing in Norway without a diagnosis of cerebral palsy.
2876649|NCT03413553|Active Comparator|control group|patient will receive immediate implant alone.
2876650|NCT03413553|Other|intervention group|immediate implant combined with connective tissue graft and platelet rich fibrin .
2876651|NCT03413540|Experimental|Group 1|10-cm step, 10 reps
2876652|NCT03413540|Experimental|Group 2|10-cm step, 50 reps
2876653|NCT03413540|Experimental|Group 3|10-cm step, 100 reps
2876654|NCT03413540|Experimental|Group 4|20-cm step, 10 reps
2876655|NCT03413540|Experimental|Group 5|20-cm step, 50 reps
2876656|NCT03413540|Experimental|Group 6|20-cm step, 100 reps
2876657|NCT03413540|Experimental|Group 7|30-cm step, 10 reps
2876658|NCT03413540|Experimental|Group 8|30-cm step, 50 reps
2876659|NCT03413540|Experimental|Group 9|30-cm step, 100 reps
2876660|NCT03413540|No Intervention|Group 10|Control
2876661|NCT03413527|Experimental|rTMS Treatment|
2876662|NCT03413514|Experimental|experiment group|Neoadjuvant chemotherapy(NACT) are performed for locally advanced gastric cancer. The clinical response is evaluated by MRI and enhanced CT. The cycle of neoadjuvant chemotherapy is decided by the doctor and the patents together with shared decision making(SDM). Radical gastrectomy with D2 lymph node dissection are performed after neoadjuvant chemotherapy. Adjuvant chemotherapy(ACT) are preformed after surgery. Questionnaires are preformed to evaluate the involvement emotion and reason for the decision of stopping neoadjuvant chemotherapy.
2876663|NCT03413501|No Intervention|Treatment as usual|Receives treatment as usual at the clinic
2876664|NCT03413501|Experimental|MUD-PI|Receives multi-disciplinary pain intervention, agroup-based, multi-disciplinary treatment
2876665|NCT03413488|Experimental|Kinesio taping|subject with shoulder impingement syndrome
2876666|NCT03413488|Active Comparator|Exercise|subject with shoulder impingement syndrome
2876667|NCT03413462|Active Comparator|HS-25|20mg, QD, 12 weeks
2876668|NCT03413462|Placebo Comparator|Placebo of HS-25|20mg, QD, 12 weeks
2876669|NCT03413449||Resections|Frailty model for patients undergoing esophagectomy and pneumonectomy/lobectomy for cancer
2876670|NCT03413436|Experimental|Lobaplatin group|i) thoracic ESCC stage II to III; ii) without any preoperation treatment for ESCC; iii) underwent R0 resection; iv) received at least one cycle ajuvant chemotherapy of Lobaplatin plus Docetaxel; v) without ajuvant radiotherapy/chemoradiotherapy; vi) without history of other type of cancer. Completed clinical, pathological and follow up data.
2876671|NCT03413436|Active Comparator|Cisplatin group|i) thoracic ESCC stage II to III; ii) without any preoperation treatment for ESCC; iii) underwent R0 resection; iv) received at least one cycle ajuvant chemotherapy of Cisplatin plus Docetaxel; v) without ajuvant radiotherapy/chemoradiotherapy; vi) without history of other type of cancer. Completed clinical, pathological and follow up data.
2876672|NCT03413423|Experimental|BAT-CS|Participants will receive standard smoking cessation plus Behavioral Activation based mood management. Will be offered the nicotine patch if medically cleared.
2876673|NCT03413423|Active Comparator|Smoking Cessation and Health & Wellness|Participants will receive standard smoking cessation plus health and wellness education. Will be offered the nicotine patch if medically cleared.
2876674|NCT03413410|Experimental|Metoprolol interventional group|"This is a multi-center, prospective, open label, single-arm interventional study.~Patients hospitalized for ACS, fulfilling all of the inclusion criteria and none of the exclusion criteria can be enrolled in this study."
2877152|NCT03409497|Active Comparator|Concord Grape Juice|Concord Grape Juice
2876675|NCT03413384|Experimental|Ceftriaxone|"Name: Ceftriaxone~Dosage form: crystalline powder for intramuscular injection~Dose(s): 1 g~Dosing schedule: 1 g ceftriaxone with around 2.0 ml of lidocaine solvent per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle"
2876676|NCT03413384|Placebo Comparator|Placebo|same amount volume of placebo will be given on Day 1, Day 3, and Day 5 per cycle on a 2 weekly cycle
2876677|NCT03413371|Experimental|0,5 % bupivacaine with of 2% lidocaine|in group BL patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
2876678|NCT03413371|Experimental|0,5 % bupivacaine|in group B patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)
2876679|NCT03413371|Experimental|1 % ropivacaine with of 2% lidocaine|in group RL patients in group BF will receive regional peribulbar block using a solution of 1% ropivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
2876680|NCT03413371|Experimental|1 % ropivacaine|in group RL patients in group BF will receive regional peribulbar block using a solution of 1% ropivacaine (5 ml)
2876681|NCT03413371|Experimental|paracetamol|in P group patients will receive preemptive analgesia using 1 gram of paracetamol before induction of general anaesthesia
2876682|NCT03413358|Experimental|Treatment group|Platinum-based two medicine (carboplatin / cisplatin) plus Sheng Bai oral liquid.
2876683|NCT03413358|Experimental|Control group|Blank control and Platinum-based two medicine (carboplatin / cisplatin) .
2876684|NCT03413345||subjects without a history of cardiac disease|
2876685|NCT03413345||subjects with a history of cardiac disease|
2876686|NCT03413332|Experimental|E-Talkcare Group|use the web-based patient education tool
2876687|NCT03413332|Placebo Comparator|Usual Care Group|receive usual care
2876688|NCT03413319|Experimental|ABBV-8E12|ABBV-8E12 administered by intravenous (IV) infusion.
2876689|NCT03413306|Experimental|Eltrombopag + IST (ATG + CsA)|
2876690|NCT03413306|Active Comparator|IST (ATG + CsA)|
2876691|NCT03413293||Nosocomial infected cirrhotic patients|
2876692|NCT03413280|Experimental|preoperative Rectus sheath block: group Pre|ultrasound guided Rectus sheath block block with 0.2% ropivacaine 40ml Before surgical incision
2876693|NCT03413280|Active Comparator|postoperative Rectus sheath block: group Post|ultrasound guided Rectus sheath block block with 0.2% ropivacaine 40ml After surgical incision
2876694|NCT03413267|Experimental|Custard|The food matrix ingested (once by each volunteer) is a custard containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
2876695|NCT03413267|Experimental|Flan|The food matrix ingested (once by each volunteer) is a flan containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
2876696|NCT03413267|Experimental|Sponge cake|The food matrix ingested (once by each volunteer) is a sponge cake containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
2876697|NCT03413267|Experimental|Biscuit|The food matrix ingested (once by each volunteer) is biscuits containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
2876698|NCT03413254|Active Comparator|2nd look DLS + routine FU|Follow-up after curatively resected pT4 colon cancer, consisting of second look DLS after negative CT abdomen at 6-9 months and normal CEA, with subsequent routine follow-up according to the Dutch colorectal cancer guideline until 5 years.
2876699|NCT03413254|Experimental|2nd and 3rd DLS + routine FU|Follow-up after curatively resected pT4 colon cancer, consisting of second look DLS after negative CT abdomen at 6-9 months and normal CEA, with subsequent routine follow-up and third look DLS after negative CT abdomen at 18 months and normal CEA. Third look DLS is not performed in patients with evidence of disease that is not curable, or in those already diagnosed with PM in the preceding period.
2876700|NCT03413228||Influenza-like illness group|
2876701|NCT03413215|No Intervention|Standard Care|Patients randomized to the standard care group will receive usual care, which consists of clinic visits 4 monthly for review of BP, HbA1c and other investigations, and titration of medications;counseling with the diabetes nurse educator (DNE), and provision of educational materials on diabetes.
2876702|NCT03413215|Experimental|Intensive|Patient randomized to the intensive group will receive additional counselling and education by the DNE, medical social worker (MSW) on self-care and coping strategies for diabetes, and see the renal pharmacist for more intensive titration of antihypertensive medication between doctor visits. They will also be loaned blood pressure monitors and glucometers with test strips to perform self-monitoring at home in between outpatient visits. Smartphone and online technologies will be utilized to improve remote monitoring, education and self-care.
2876703|NCT03413202|Experimental|butylphthalide(NBP)|Based on the standard medical care, 25mg of NBP injection, and 100ml of 0.9% saline; NBP capsule
2876704|NCT03413202|Placebo Comparator|placebo|Based on the standard medical care, 100ml of 0.9% saline as the placebo; starch capsule as the placebo
2876705|NCT03413189||PREDICT participants|This cohort is obtained from the PREDICT study enrolment (approx. 500) and a review of their medical records will be conducted
2876706|NCT03413189||PREDITCABLE participants|This is a nested cohort of patients recruited into PREDICT (approx. 40) that consent for a physiotherapist home visit to assess their physical and cognitive function and perform and interview to obtain themes regarding recovery
2876707|NCT03413163|Sham Comparator|control|"Peroperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.~Intervention: Other: Standard Pain Followup and Monitorization"
2876708|NCT03413163|Experimental|ESP block|"In addition to routine analgesic protocol; before anaesthesia induction; bilateral ultrasound guided erector spinae plane block (ESP) (intervention) will be performed via USG guidance at Th9 level.Standard Pain Followup and Monitorization will be performed.~Interventions:~Procedure: Ultrasound guided erector spinae plane block Other: Standard Pain Followup and Monitorization"
2876709|NCT03413150||severely ill patients receiving amiodarone for ATs|cohort study was conducted from January 2007 to April 2012 in the 18-bed medical ICU of a tertiary teaching hospital.Data were extracted from the files of 80 consecutive critically ill patients who had received at least one dose of amiodarone to treat or prevent atrial tachycardia during their hospitalization in the ICU.
2877153|NCT03409497|Sham Comparator|Low flavonoid low essence beverage|Low flavonoid low essence beverage
2876710|NCT03413137|Active Comparator|Arm A|A Transperineal mpMRI-US Fusion prostate biopsy followed by a Transrectal mpMRI-US Fusion prostate biopsy
2876711|NCT03413137|Active Comparator|Arm B|A Transrectal mpMRI-US Fusion prostate biopsy followed by a Transperineal mpMRI-US Fusion prostate biopsy
2876712|NCT03413124|Active Comparator|Capsule then Tablet|MGL-3196 Capsule on Day 1 followed by MGL-3196 Tablet on Day 5
2876713|NCT03413124|Active Comparator|Tablet then Capsule|MGL-3196 Tablet on Day 1 followed by MGL-3196 Capsule on Day 5
2876714|NCT03413111|Experimental|Modified double wire technique|A sphincterotome was used for standard wire-guided cannulation. If the difficult biliary cannulation occurred and guidewire inadvertently entered PD, a tiny cut of opening, with the length of 5mm, was performed with the sphincterotome. Then the guidewire was left in PD and the sphincterotome withdrew. The same sphincterotome was re-inserted in the working channel alongside the first guidewire, another wire is used for wire-guided selective cannulation of CBD. If the cannulation of CBD was not successful within 5 attempts, other cannulation techniques (e.g. transpancreatic precut, needle knife (NK) precut or over-the stent precut) would be tried at the discretion of endoscopists. A 5Fr, unflanged PD stent was placed before the ending of ERCP.
2876715|NCT03413111|No Intervention|Standard double wire technique|A sphincterotome was used for standard wire-guided cannulation. If the difficult biliary cannulation occurred and guidewire inadvertently entered PD, the guidewire was left in PD and the sphincterotome withdrew. The same sphincterotome was re-inserted in the working channel alongside the first guidewire, another wire is used for wire-guided selective cannulation of CBD. If the cannulation of CBD was not successful within 5 attempts, other cannulation techniques (e.g. transpancreatic precut, NK precut or over-the stent precut) would be tried at the discretion of endoscopists. A 5Fr, unflanged PD stent was placed before the ending of ERCP.
2876716|NCT03413098|Experimental|Trial nasal Continuous Positive Airway Pressure (CPAP) mask|Trial nasal CPAP mask
2876717|NCT03413085|Other|Group A|"Intervention name: multifocal soft contact lens/single vision soft contact lens~Left eye: multifocal soft contact lens Right eye: single vision soft contact lens"
2876718|NCT03413085|Other|Group B|"Intervention name: multifocal soft contact lens/single vision soft contact lens~Left eye: single vision soft contact lens Right eye: multifocal soft contact lens"
2876719|NCT03413059|Active Comparator|morphine sulfate group|patients in this arm will receive : morphine dose 0.1mg /kg with 9 ml of 0.25 % bupivacaine with through epidural catheter on admission Then continuous epidural infusion of bupivacaine (0.1 mg.kg-1.h) 1st 72 hours
2876720|NCT03413059|Active Comparator|triamcinolone acetonide group|patients in this arm will receive will receive a mixture of 9 ml of 0.125 % bupivacaine with 80mg of triamcinolone ( 10 ml total volume) through epidural catheter on admission
2876721|NCT03413046||ALL|30 children with a recent diagnosis of PreB ALL
2876722|NCT03413046||Control|30 healthy children
2876723|NCT03413033||Group 1|24 participants will produce the vowel /a:/ as baseline during 10 seconds in habitual, comfortable speaking pitch and loudness. Thereafter, participants will produce 3 series of two semi-occluded vocal tract exercises (resonance tube, tongue trill). Electroglottographic and Stroboscopic signals will be captured with each task.
2876724|NCT03413020|Experimental|Tailored Therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole, amoxicillin and one sensitive of clarithromycin, metronidazole and levofloxacin.If isolates were resistant to all three tested antibiotics, give esomeprazole, bismuth potassium citrate, metronidazole and amoxicillin for 14 days.
2876725|NCT03412994|Experimental|Apatinib group|"Apatinib combined with second-line chemotherapy (5-Fu combined with irinotecan or oxaliplatin standard regimen ) Apatinib tablets: 500 mg po qd . Continuous medication, the cycle is consistent with the chemotherapy cycle.~Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.（Take CAPEOX for example）"
2876726|NCT03412994|Placebo Comparator|Control group|Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.（Take CAPEOX for example）
2876727|NCT03412968|Experimental|Polysulfone Filter Group|The purpose of the research is to determine whether, by controlling the patient's hemodilution level and, therefore, the acute anaemia caused by the Cardiopulmonary Bypass (CPB) priming fluid, continuous conventional ultrafiltration (CUF) can decrease serum lactate levels during normothermic CPB by increasing the haematocrit and, consequently, the supply of oxygen to the tissues, and whether the haemofiltration membrane can remove lactate molecules in situations of hyperlactataemia in CPB.
2876728|NCT03412968|Active Comparator|Control Group|The purpose of the research is to determine serum lactate levels during normothermic cardiopulmonary bypass procedure (CPB) without continuous hemofiltration of the patient during the CPB.
2876729|NCT03412955|Experimental|Eribulin|Patients enrolled into the study will receive Eribulin 1.4mg/m2 on days 1 and 8 of a 21-day treatment cycle till disease progression or non-tolerable toxicity.
2876730|NCT03412942|Other|Treatment with FISH device|Vascular closure to be performed with FISH device.
2876731|NCT03412929|Experimental|Honey Impregnated Dressing|Honey Impregnated Dressing
2876732|NCT03412916|Experimental|p3RP|The p3RP uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The p3RP sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal & coping, and growth enhancement). The format is a 10-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions.
2876733|NCT03412916|Experimental|p3RP-DMD|The p3RP-DMD is identical to that of the p3RP with the addition of a digital monitoring device (i.e., Fitbit) for recording of physical activity.
2876734|NCT03412903||Control group|First observational period: Standard care without an advising pharmacist, 140 patients
2876735|NCT03412903||Implementation group|Second observational period: Standard care with an advising pharmacist, 140 patients
2876736|NCT03412903||Learning success group|Second observational period: Standard care without an advising pharmacist, 30 patients
2876737|NCT03412890|Experimental|Relugolix + Low-Dose Hormonal Add-Back|
2876738|NCT03412877|Experimental|1-Experimental Therapy|non-myeloablative lymphocyte depleting chemotherapy regimen of cyclophosphamide and fludarabine + Individual Patient TCR-Transduced PBL + high or low-dose aldesleukin
2876741|NCT03412838|Active Comparator|Cortico-Cancellous|Graft surgery with cortico-cancellous block, freeze dried bone allograft (FDBA) for treatment the atrophic maxilla prior implant placement
2876742|NCT03412838|Active Comparator|Cancellous|Graft surgery with cancellous block, freeze dried bone allograft (FDBA) for treatment the atrophic maxilla prior implant placement
2876743|NCT03412825|Experimental|Nutrition Supplementation|
2876744|NCT03412825|No Intervention|Control|
2876745|NCT03412812|Experimental|Dose Escalated 5 Fraction Stereotactic Radiosurgery|Patients will undergo dose escalated five fraction stereotactic radiosurgery for diagnosed brain metastases. Tumors must fall into one of two categories: 2.1-4.0cm diameter or 4.1-6.0 cm diameter. Only single largest tumor will be treated with dose escalation. All other tumors (if present) will be treated with standard of care five fraction stereotactic radiosurgery.
2876746|NCT03412786|Experimental|Arm A: IM followed by IP|Will be administered first 3 vaccines biweekly IM and thereafter 3 vaccines biweekly IP.
2876747|NCT03412786|Experimental|Arm B: IP followed by IM|Will be administered first 3 vaccines biweekly IP and thereafter 3 vaccines biweekly IM.
2876748|NCT03412773|Experimental|Arm A: BGB-A317 & Safety Run-In Substudy [Japan Only]|
2876749|NCT03412773|Active Comparator|Arm B: Sorafenib|
2876750|NCT03412747|Experimental|Bimekizumab Arm 1|Subjects will receive bimekizumab dose regimen 1 for 56 weeks. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
2876751|NCT03412747|Experimental|Bimekizumab Arm 2|Subjects will receive bimekizumab dose regimen 1 for 16 weeks and will proceed with bimekizumab dose regimen 2 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
2876752|NCT03412747|Active Comparator|Adalimumab Arm|Subjects will receive adalimumab for 24 weeks and will then receive bimekizumab dose regimen 1 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
2876753|NCT03412734|Experimental|Chlorhexidine group|
2876754|NCT03412734|Active Comparator|Iodine group|
2876755|NCT03412721|Experimental|Laser analgesia|Procedure: Laser analgesic procedure Performing protocol for pre-emptive laser analgesia with Er:YAG laser (Litetouch, Syneron) switched on.
2876756|NCT03412721|Placebo Comparator|Placebo analgesia|Procedure: Placebo analgesic procedure Performing imitation of laser analgesic protocol with Er:YAG laser (Litetouch, Syneron) switched off - no pulse energy applied.
2876757|NCT03412708|Active Comparator|Vestibular Rehabilitation|"Vestibular Rehabilitation Program Exercises for Eye Movements: Smooth- Pursuit Eye Movements and Saccadic eye movements Exercises for Gaze Stability : Training of Vestibulo-ocular reflex and Cervico-ocular reflex Exercises for Postural Stability: In sitting or standing up position and walking~Duration of treatment: 3 weeks. Number of sessions: 15 Session frequency: 5 times a week. Session duration: 2 sets of 15 minutes, with a 5 minute break between sets, for a total of 35 minutes."
2876758|NCT03412708|Experimental|Vestibular Rehabilitation supported with Virtual Reality|"Patients will perform the exercises in a virtual reality environment using a virtual reality goggle and a smartphone.The virtual environments consist of 2 media provided by the videos taken with a 360 camera . 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full. Exercises conducted while sitting and standing on a soft ground will happen in the 1st environment, and the ones on the treadmill will happen in the 2nd environment.~Exercises for Eye Movements: Smooth- Pursuit Eye Movements and Saccadic eye movements Exercises for Gaze Stability : Training of Vestibulo-ocular reflex and Cervico-ocular reflex Exercises for Postural Stability: In sitting or standing up position and walking~Duration of treatment: 3 weeks. Number of sessions: 15 Session frequency: 5 times a week. Session duration: 2 sets of 15 minutes, with a 5 minute break between sets, for a total of 35 minutes."
2876759|NCT03412695|Experimental|Arm A|Use of the MyFood tool among patients and nurses (intervention group)
2876760|NCT03412695|No Intervention|Arm B|No intervention. Regular hospital routines
2876761|NCT03412682|Experimental|FE 999315 (6 mg)|
2876762|NCT03412682|Experimental|FE 999315 (9 mg)|
2876763|NCT03412682|Active Comparator|Mesalazine (3,600 mg)|
2876764|NCT03412669|Experimental|Counselling|Supporting Addiction Affected Families Effectively is a contextually adapted version of the 5-Step Method, a psychosocial intervention based on the principles of the Stress-Strain-Coping-Support model. The intervention is manualised, and is delivered by lay counsellors over 5 sessions at a weekly basis. The 5 steps (covered in the 5 steps) include: 1) Exploring stresses and strains, 2) Providing relevant information, 3) Exploring and discussing coping behaviours, 4) Exploring and enhancing social support, and 5) Exploring additional needs, and further sources of help. The intervention is delivered in settings based on convenience of the participant: which might be a place outside the home (e.g. field office, neighbour's home), or the participant's home.
2876765|NCT03412669|Active Comparator|Enhanced Usual Care|In the study setting, usual care for affected family members is no care at all, as detection rates of stress/strain in affected family members are extremely low. Hence, Enhanced Usual Care for the control group consists of a minimal intervention, namely a leaflet. The leaflet focuses on the burden that affected family members experience in relation to a relative who drinks alcohol, and on various informal and formal sources of support that are available in the local community.
2876766|NCT03412656|Experimental|Patient|
2876767|NCT03412630|Experimental|Diagnostic (computed tomography perfusion imaging)|Patients undergo computed tomography perfusion imaging at baseline and on day 15 after initiation of standard of care bevacizumab treatment and before the second dose.
2876768|NCT03412604|Experimental|tACS|Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 20 sessions on consecutive weekdays. The tACS intervention (20 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and MRI and cognitive function.
2876769|NCT03412591|Other|Open label trial of suvorexant in SUDs|It is an open label trial to study the efficacy of suvorexant in a group of opioid use and alcohol use disorder subjects.
2876770|NCT03412578|No Intervention|Control|Infants in this group will receive ordinary supportive care and will not receive Massage Therapy
2876771|NCT03412578|Active Comparator|Massage group|"Infants in this group will receive Massage Therapy Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).~During massage therapy, infant's behavioural reaction was observed for signs of distress (e.g., yawning, finger splaying, crying)."
2876772|NCT03412565|Experimental|Daratumumab(D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)|Participants will receive daratumumab 1800 milligram (mg) by subcutaneous (SC) injection on Days 1, 8 and 15 of Cycles 1 to 3 (each cycle of 21 days) and on Day 1 of Cycle 4; bortezomib 1.3 milligram per square meter (mg/m^2) SC injection on Days 1, 4, 8 and 11 of Cycles 1 to 4; lenalidomide 25 mg orally on Day 1 through Day 14 of Cycles 1 to 4 and dexamethasone 20 mg orally or intravenously on Days 1, 2 ,8, 9, 15 and 16 of Cycle 1 to 4.
2876773|NCT03412565|Experimental|D + Bortezomib + Melphalan + Prednisone (D-VMP)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15, 22, 29 and 36 of Cycle 1 then on Days 1 and 22 in Cycles 2 to 9 and Day 1 of Cycle 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; bortezomib 1.3 mg/m^2 SC injection on Day 1, 4, 8, 11, 22, 25, 29 and 32 of Cycle 1 and on Days 1, 8, 22 and 29 of Cycles 2 to 9; melphalan 9 mg/m^2 orally on Day 1 through Day 4 of Cycles 1 to 9; prednisone 60 mg/m^2 orally on Days 1 to 4 of cycles 1 to 9.
2876774|NCT03412565|Experimental|Daratumumab + Lenalidomide + Dexamethasone (D-Rd)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; lenalidomide 25 mg orally on Day 1 through Day 21 of each cycle until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or intravenously weekly until documented progression of disease, unacceptable toxicity, or end of study.
2876775|NCT03412552||severe preeclampsia without HELLP syndrome|severe preeclampsia if they met one or more of the following criteria of The American College of Obstetricians and Gynecologists (10): systolic blood pressure >160 mm/ Hg or diastolic blood pressure >110 mm/Hg, headache, epigastric or right-upper-quadrant pain, visual disturbances,pulmonary edema, and proteinuria (urinary protein level >5 g/24 h).Women with severe preeclampsia selected for analysis also met all of the following laboratory criteria: platelet count ≥150,000/ mm3, serum lactate dehydrogenase <600 IU /dL, serum total bilirubin <1.2 mg/dL and serum aspartate aminotransferase <70IU/L
2876776|NCT03412552||eclampsia without HELLP syndrome|Eclampsia was defined as tonic-clonic seizures occurring in patient diagnosed by preeclampsia patient. Any causes for convulsion other than eclampsia were excluded
2876777|NCT03412552||eclampsia with HELLP syndrome|Eclampsia was defined as tonic-clonic seizures occurring in patient diagnosed by preeclampsia patient. Any causes for convulsion other than eclampsia were excluded.HELLP syndrome was defined by the clinical presentation of PET in association with thrombocytopenia (<150.000 cells/ul), hemolysis and elevated liver enzmes (elevated transaminases and lactic dyhydrogenases activities)
2876778|NCT03412552||HELLP syndrome without eclampsia|HELLP syndrome was defined by the clinical presentation of PET in association with thrombocytopenia (<150.000 cells/ul), hemolysis and elevated liver enzmes (elevated transaminases and lactic dyhydrogenases activities)
2876779|NCT03412526|Experimental|ACT TIL|"Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Fludarabine (25 mg/m2 for 3 days) followed by Total Body Radiation (TBR) (2 Gray as a single treatment) for 1 day~Preparation and administration of unselected or 4-1BB enriched TIL~Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
2876780|NCT03412513|Active Comparator|Mirabegron|1:1 randomization to receive Mirabegron 50mg daily or placebo at visit 2. At visit 4 all subjects will receive Mirabegron 50mg.
2876781|NCT03412513|Placebo Comparator|Placebo|1:1 randomization to receive Mirabegron 50mg daily or placebo at visit 2. At visit 4 all subjects will receive Mirabegron 50mg.
2876782|NCT03412500|Active Comparator|Vancomycin trough concentration method|vancomycin dosage will be adjusted by the trough concentration method
2876783|NCT03412500|Experimental|Vancomycin equation-based method|vancomycin dosage will be adjusted by the equation-based method
2876784|NCT03412487|Active Comparator|premature ovarian failure|women under 40 years old with History of oligomenorrhea or amenorrhea for 1 year or more FSH level >20 IU/L at least 2 occasions 4-6 weeks apart (FSH level 20-40 IU/L indicates ovarian insufficiency, while level above 40 IU/L indicates complete failure).
2876785|NCT03412487|Active Comparator|Control group|A group of female patients presented with infertility but with regular menses and normal ovarian function (according to history, general examination, gynecological examination and FSH level).
2876786|NCT03412474|Active Comparator|Bupivacaine|Patients will receive 0.2 ml/kg/side of bupivacaine (0.125%).
2876787|NCT03412474|Active Comparator|Dexmedetomidine|Patients will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
2876788|NCT03412461|Experimental|Thought Spot Application|Participants randomly assigned to the experimental arm will have access to the Thought Spot application. The Thought Spot application is a mobile app and website. This digital platform was designed and produced in partnership with transition aged youth in post-secondary education. The platform maps out wellness and mental health services across the Greater Toronto Area. This group will continue to have access to usual care.
2876789|NCT03412461|Active Comparator|Resource pamphlet|Participants randomly assigned to the active comparator will receive a pamphlet that outlines mental health services and wellness services across the Greater Toronto Area. This group will continue to have access to usual care.
2876790|NCT03412435||Myocardial infarction|diagnosed as acute myocardial infarction and treated with medical treatment, coronary artery bypass surgery and percutaneous coronary intervention.
2876791|NCT03412422||Acute circulatory failure|Mechanically ventilated patients with acute circulatory failure, monitored with PiCCO method, who need fluid responsiveness assessment.
2876849|NCT03411889|Experimental|functional lacrimal delay|Participants shown to have functional delay on DSG will be included. The intervention will be an MRI scan during tear drainage
2877154|NCT03409497|Sham Comparator|Low flavonoid beverage|Low flavonoid beverage
2876792|NCT03412409|Experimental|RIC regimen|"Old patients or those have high comorbidity burden without identical sibling donor or unrelated donor would receive RIC haplo-HSCT.~RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days −10 to −9), busulfan (3.2 mg/kg/day on days −8 to −6), cyclophosphamide (1.0 g/m2/day, days −5 to −4), fludarabine (30 mg/m−2/day, days −6 to −2), semustine (250 mg/m−2, day −3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days −5 to −2; Sanofi, France)."
2876793|NCT03412396|Experimental|Apalutamide|"Participants take 4 tablets of Apalutamide by mouth each day for a total of 24 weeks (about 6 months) leading up to standard-of-care prostate surgery.~Participants undergo prostatectomy about 2 weeks after the last dose of study drug.~Questionnaires completed at baseline, at weeks 17, 24, 30 days after surgery, 6 months and 12 months after surgery."
2876794|NCT03412370||Observational (questionnaires, cognitive assessment)|Patients complete questionnaires and cognitive assessments over 45-60 minutes within 3 weeks following mammography and at about 3 months in patients for whom biopsy is not required, before biopsy and at about 3 months in patients for whom biopsy is required, and at 4-6 weeks after first chemotherapy infusion in patients receiving chemotherapy.
2876795|NCT03412357|Experimental|pleurectomy/decortication|
2876796|NCT03412357|Experimental|indwelling pleural catheter|
2876797|NCT03412331|Active Comparator|Control Group|NPT including scaling and root planing was applied to 12 subjects with ultrasonic and hand instruments until the operator feels that root surface is clean, hard and smooth.
2876798|NCT03412331|Experimental|Test Group|Following NPT, toluidine blue O mediated PDT was performed with a LED source (625-635 nm wavelength) (FotoSan®, CMS Dental, Denmark) to 12 subjects. The dye (0.1 mg/ml) was applied with a canula into the periodontal pockets. After 3 minutes, the subjects rinsed their mouths with sterile saline solution for removal of excessive dye. Then, the applicator of photosensitizer was inserted until the bottom of the periodontal pocket and photoinactivation was performed in 6 sites per tooth for 10 seconds of each sites with a total of 60 seconds per tooth.
2876799|NCT03412318|Experimental|Twisted file|Use of twisted file during cleaning and shaping of root canals
2876800|NCT03412318|Active Comparator|Mpro|Use of Mpro file during cleaning and shaping of root canals
2876801|NCT03412305|Active Comparator|Amoxicillin oral tablets|2 g amoxicillin tablets orally 1 hour before implant placement
2876802|NCT03412305|Placebo Comparator|Placebo|Placebo tablets orally 1 hour before implant placement
2876803|NCT03412292|Experimental|MAX-40279|"MAX-40279 is provided as a capsule for oral use at 5mg, 25mg. In the dose-escalation phase, patients will be enrolled sequentially into the 5 dose levels of MAX-40279 designated in this study: 20, 40, 70, 100 and 120 mg/day (3-6 patients per cohort),bid.For each dose level, a single dose of MAX-40279 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle).~After completion of the dose escalation, additional patients will be enrolled into dose expansion at the Maximum tolerated dose(MTD), up to 12 patients will be enrolled into expansion cohorts."
2876804|NCT03412266|Other|RIC regimen|"Low- and intermediate MDS patients without identical sibling donor or unrelated donor would receive RIC haplo-HSCT.~RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days −10 to −9), busulfan (3.2 mg/kg/day on days −8 to −6), cyclophosphamide (1.0 g/m2/day, days −5 to −4), fludarabine (30 mg/m−2/day, days −6 to −2), semustine (250 mg/m−2, day −3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days −5 to −2; Sanofi, France)."
2876805|NCT03412240|Experimental|Anti tachycardia pacing|
2876806|NCT03412227|Other|Principal Anxiety Disorder|Youth with a principal anxiety disorder
2876807|NCT03412227|Other|Principal Depressive Disorder|Youth with a principal unipolar depressive disorder
2876808|NCT03412201|Active Comparator|Usual Care|Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards
2876809|NCT03412201|Experimental|High Intensity Care|Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 2 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.
2876810|NCT03412188|Experimental|group 1 Eltrombopag arm|"Group 1 (eltrombopag arm n=20 patients): Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy. patients will receive a total daily dose of eltrombopag of (25-50mg/d). Dose adjustments may be made based on platelets count with an increment of 25mg once per day at 2 weeks intervals (Maximum dose: 75 mg orally once a day).~Patients, who responded poorly to eltrombopag in 6 months or developed adverse effects, were asked to discontinue the medication. Those who responded were followed for further 6 month period."
2876811|NCT03412188|Active Comparator|group 2 conventional Treatment|"Group 2 (n=20 patients) Patients who are currently receiving other lines of treatment (steroids, IVIG, azathioprine, and rituximab).~patients will continue on the conventional line of treatment"
2876812|NCT03412175|Experimental|Behavioral Intervention|Participants in the lifestyle intervention arm will receive 6 individual visits with a CREATION Health Specialist over a 3 month period, and one follow up visit at 6 months. The visits include one 2 hour-long initial assessment, four 60-minute motivational interview sessions, and two 60-minute reassessments. Visits will focus on tailoring the intervention care plan to each individual, goal-setting, action plans, self-monitoring, identification of personal and social barriers to change, self-regulatory techniques, and provision of psychosocial support using motivational interviewing techniques.
2876813|NCT03412175|No Intervention|Control Group|Participants in the control group will receive usual care as provided by their primary care physician. Participants in the control group will complete biometrics, surveys, and assessments at Visits 0, 5 and 6.
2876814|NCT03412162|Experimental|Ethnic and Racial Identity Promotion|"Students will participate in 8, 1 hour and 15 minute classroom based intervention sessions at their local high school, during which a facilitator will lead them through a series of lectures, group activities, and individual homework activities designed to promote a positive ethnic and racial identity (positive feelings about ones' ethnic and racial heritage and ethnic and racial group membership). They will also participate in 3, 1 hour and 15 minute long booster sessions during which the information they learned in the 8-week Ethnic and Racial Identity Promotion intervention are reinforced and additional stress reduction and sleep hygiene skills are taught."
2877155|NCT03409484|Active Comparator|Concord Grape Juice|100% Concord Grape Juice
2876815|NCT03412162|Active Comparator|Academic Skills Promotion|"Students in this active comparison group will participate in an 8-week, 1 hour and 15 minute classroom based intervention, during which a facilitator will lead them through a series of lectures, group activities, and individual homework activities designed to provide information regarding college and career planning, and promote college and career planning as well as study skills and strategies. They will also participate in 3, 1 hour and 15 minute long booster sessions during which the information they learned in the 8-week Academic Skills Promotion Intervention is reinforced. This condition receives the same amount of facilitator time and attention as the Experimental condition."
2876816|NCT03412149|Active Comparator|Mini Gastric Bypass|Mini Gastric Bypass: The gastric pouch will be performed starting below the incisura angularis (transverse resection 4 cm) on the lesser curvature (18).Then the stomach will be transected against a 36 Fr bougie up to the gastro-esophageal junction Then 1/3 of the small bowel will be excluded (approximately 200cms) and 3.5-4 cm gastro-jejunostomy will be performed by linear stapler.
2876817|NCT03412149|Active Comparator|Roux en Y Gastric Bypass|Roux en Y Gastric Bypass: The steps of the standard double loop RYGB technique will be followed (17). The gastric pouch will be created 7 cm from the gastro-esophageal junction to obtain a volume of 30-40 ml, and the length of the alimentary limb will be 150 cm and 3.5-4 cm gastro-jejunostomy will be performed by linear stapler. The length of the biliopancreatic limb will be from 65 to 75 cm beyond the ligament of Treitz. The lengths of both limbs should carefully measured with a graduated instrument. The mesenteric defects will be closed.
2876818|NCT03412136|Experimental|Control|
2876819|NCT03412136|Experimental|Glucose|
2876820|NCT03412136|Experimental|Protein|
2876821|NCT03412123|Experimental|gLiFE pilot group|
2876822|NCT03412084|Experimental|Stand up intervention|four week behavioral intervention based on self-regulation theory which is designed to facilitate the development of action plans to break up prolonged sitting
2876823|NCT03412084|No Intervention|Control|No behavioral intervention - the control group will go about their daily life, but come in for assessments at the same time points as the intervention group
2876824|NCT03412071|No Intervention|Control group|25 HIV-uninfected, uncircumcised men will be immediately circumcised following enrollment. This group will serve as the comparison to the four intervention groups.
2876825|NCT03412071|Active Comparator|Oral tinidazole group|25 HIV-uninfected, uncircumcised men will be randomized to receive oral tinidazole 2g once a day for two days.
2876826|NCT03412071|Active Comparator|Topical metronidazole (0.75%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply topical 0.75% metronidazole cream to the foreskin twice a day for one week, and then twice a week for three weeks.
2876827|NCT03412071|Active Comparator|Topical clindamycin (2%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply topical 2% clindamycin cream to the foreskin twice a day for one week, and then twice a week for three weeks.
2876828|NCT03412071|Active Comparator|Topical hydrogen peroxide (1%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply 1% hydrogen peroxide cream to the foreskin twice a day for one week, and then twice a week for three weeks.
2876829|NCT03412058|Experimental|Melanoma|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
2876830|NCT03412058|Experimental|NSCLC|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
2876831|NCT03412058|Experimental|HNSCC|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
2876832|NCT03412045|Experimental|treatment|this preliminary study will be a convenience sample of patients admitted to hospital for vaso-occlusive sickle cell crisis to be treated with hyperbaric oxygen in an effort to ameliorate pain and shorten the length of stay. In this sense, hyperbaric oxygen will be used as a treatment drug. Results will be compared with historical controls
2876833|NCT03412032|Other|ERC|Assessment as used by the European Resuscitation Council
2876834|NCT03412032|Other|AHA|Assessment as used by the American Heart Association
2876835|NCT03412019|No Intervention|Control group|baseline hemodynamics and anxiety screen; no music. Satisfaction will be measured.
2876836|NCT03412019|Experimental|Intervention group - Mozart|A study investigator will turn on a playlist of pre-selected Mozart music. Hemodynamics and anxiety screen. Satisfaction will be measured.
2876837|NCT03412006|Experimental|Fulacimstat (BAY1142524)|Patients have to have a clinical diagnosis of diabetic kidney disease and have to be treated with standard of care for this condition
2876838|NCT03412006|Placebo Comparator|Placebo|Patients have to have a clinical diagnosis of diabetic kidney disease and have to be treated with standard of care for this condition
2876839|NCT03411980|Experimental|Subjects with moderately decreased renal function|Subjects with moderate renal impairment with an estimated glomerular filtration rate (eGFR) of 30 to 59 mL/min/1.73 m*2 according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
2876840|NCT03411980|Experimental|Subjects with severely decreased renal function|Subjects with severe renal impairment not on dialysis with an eGFR <30 mL/min/1.73 m*2 (CKD-EPI formula).
2876841|NCT03411980|Experimental|Control subjects with normal renal function|Subjects with an eGFR ≥90 mL/min/1.73 m*2 (CKD-EPI formula) who are matched based on sex, age, race and weight.
2876842|NCT03411967|Experimental|apatinib combine with docetaxel|Docetaxel, 60 mg / m2, d1, iv + apatinib 500mg, po, qd
2876843|NCT03411954||HP-RT|Hippocampus avoidance: decrease the dose to hippocampus as low as possible without affecting the target volumes and other normal tissues
2876844|NCT03411941||Treatment-naïve nAMD patients|Patient data for whom treatment with IVT aflibercept injection was initiated as first-line treatment according to the SmPC and the SERV Guideline, in treatment-naive patients with newly diagnosed of nAMD in routine clinical practice.
2876845|NCT03411928|Experimental|Tracheolator|Tracheal dilatation using the study device as per the protocol.
2876846|NCT03411915|Experimental|XmAb18087|XmAb18087 administered on days 1, 8, 15, and 22 of each 28-day cycle for a total of 3 cycles
2876847|NCT03411902|Active Comparator|Risedronate|Experimental: Risedronate sodium,150 mg capsule once every 4 weeks for 24 weeks.
2876850|NCT03411876|Experimental|First ESWT with Oxymizer, second ESWT with CNC|Patients in this study arm first perform the first endurance shuttle walk test (ESWT) with the Oxymizer and the second ESWT with a conventional nasal cannula (CNC).
2876851|NCT03411876|Experimental|First ESWT with CNC, second ESWT with Oxymizer|Patients in this study arm first perform the first endurance shuttle walk test (ESWT) with the CNC and the second ESWT with the Oxymizer.
2876852|NCT03411863|Experimental|All subjects|All subjects undergo same full protocol, including CES at rest and CES plus active hand or wrist movements.
2876853|NCT03411850|Active Comparator|Orencia (Abatacept)|Orencia (Abatacept) Intravenous (IV) or Subcutaneous (SQ) injection
2876854|NCT03411850|Placebo Comparator|Placebo|Placebo (saline solution) given Intravenous (IV) or Subcutaneous (SQ)
2876855|NCT03411837||Dupilumab|Patients with moderated-to-severe atopic dermatitis who are receiving dupilumab as a standard of care
2876856|NCT03411811|Active Comparator|Usual Care|
2876857|NCT03411811|Experimental|Dextrose|
2876858|NCT03411798|Experimental|Experimental|Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR & CRP reduce to normal and BASDAI＜4) maintenance.
2876859|NCT03411785|Experimental|CPC+ practices|This is the intervention group, and includes the practices that were selected and agreed to participate in the CPC+ model.
2876860|NCT03411785|No Intervention|Comparison practices|Comparison practices are the control group. This group includes practices not participating in the model that were matched to the CPC+ practices and whose outcomes will be compared to those of the CPC+ practices.
2876861|NCT03411772|Active Comparator|TAP block|Patients undergoing bariatric surgery having TAP block upon completion of the procedure
2876862|NCT03411772|Sham Comparator|Non TAP block|Patients undergoing bariatric surgery without having TAP block
2876863|NCT03411733||acne vlugaris group|Included recruited patients with acne vulgaris Intervention: Blood and stool samples collection
2876864|NCT03411733||Control group|Included healthy participants Intervention: Blood and stool samples collection
2876865|NCT03411720|Experimental|FES-row-training|Subjects will perform 4 months of FES-row-raining
2876866|NCT03411720|Other|Wait-list time control|Subjects will wait 4 months before performing being allowed to engage in 4 months of FES-row-training
2876867|NCT03411720|Active Comparator|Arms-only-row-training|Subjects will perform 4 months of arms-only row training before being allowed to engage in 4 months of FES-row-training
2876868|NCT03411707||Mutiple screening test group|
2876869|NCT03411681|Active Comparator|Normal Weight|
2876870|NCT03411681|Experimental|Obese|
2876871|NCT03411668|Experimental|EBP Educational Programme|The educational EBP programme will include 12 hours of classroom lessons regarding EBP more 6 hours of mentorship made to a small groups of students (2 or 3 students per group).
2876872|NCT03411668|No Intervention|Usual Educational Programme|Without intervention. The participants in this group will be maintain usual educational programme.
2876873|NCT03411655|Active Comparator|Ambu® Aura-ITM|
2876874|NCT03411655|Active Comparator|Ambu Aura GainTM|
2876875|NCT03411603||INCA2 2006-07|"French National Dietary Intake Survey, conducted in 2006-2007 by the French Agency for Food, Environmental and Occupational Health Safety.~Adults aged 18y and over, n=1918 included in the analyses."
2876876|NCT03411603||NHANES 2011-12|Wave 2011-12 of the National Health and Nutrition Examination Survey, the US national dietary intake Survey, conducted by the Centers for Disease Control and Prevention (CDC) Adults aged 18y and over, n=5073 included in the analyses.
2876877|NCT03411590|Other|200ml|Toddlers will be allocated to the 200 ml group
2876878|NCT03411590|Other|400ml|Toddlers will be allocated to the 400 ml group
2876879|NCT03411590|Other|600ml|Toddlers will be allocated to the 600 ml
2876880|NCT03411577|Experimental|Behavioral Intervention|The adolescent HIV/STI risk-reduction intervention aims to: (a) increase knowledge of HIV risk and prevention; (b) strengthen behavioral beliefs regarding abstinence and safer sex; (c) increase self-efficacy and intentions to avoid unsafe sex; and (d) increase sexual communication and refusal skills. The mother component includes much of the same prevention knowledge and addresses parent-teen sexual risk communication, monitoring, and sexual role modeling. Interventions are held on two consecutive Saturdays for 6 hours each day. Mothers' groups meet separately from daughters' groups, although the groups will come together for the last module of each day.
2876881|NCT03411577|No Intervention|Control Group|"The control / comparison group is essentially a no intervention / wait-list control group. However, during pilot testing, participants expressed a strong desire to engage in some type of health activity. As a result, the control group members, both mothers and daughters, participated in a brief educational activity on reducing risk for cardiovascular disease. The educational activity was limited to a few hours on one Saturday. Participants returned the following week to complete post-test questionnaires along with the participants in the experimental group."
2876882|NCT03411564|Experimental|Group 1|Students enrolled in one or two targeted secondary schools in each city who are going to receive the intervention (workshop)
2876883|NCT03411564|No Intervention|Grup 0|Students from other centers with similar socioeconomic characteristics (relating to social characteristics and school location) to the centers.
2876884|NCT03411551|Active Comparator|Forearm Bier's block|Forearm intravenous regional anesthesia (Bier's block)
2876885|NCT03411551|Experimental|Peripheral Nerve Block|Ultrasound-guided peripheral nerve block (regional anesthesia)
2876886|NCT03411538||Hospital-acquired bacterial infection|
2876887|NCT03411525|Experimental|Commitment invitation at time 1|In the stepped wedge cluster randomized design, the first clinic will remain in the control period (no intervention) for 1 month, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 8 months.
2876888|NCT03411525|Experimental|Commitment invitation at time 2|In the stepped wedge cluster randomized design, the second clinic will remain in the control period (no intervention) for 2 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 7 months.
2876920|NCT03411343|Active Comparator|Interscalene Block|Patients randomized to receive an intesrcalene block.
2900908|NCT03242226|Experimental|two spectacles|
2876889|NCT03411525|Experimental|Commitment invitation at time 3|In the stepped wedge cluster randomized design, the third clinic will remain in the control period (no intervention) for 3 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 6 months.
2876890|NCT03411525|Experimental|Commitment invitation at time 4|In the stepped wedge cluster randomized design, the fourth clinic will remain in the control period (no intervention) for 4 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 5 months.
2876891|NCT03411525|Experimental|Commitment invitation at time 5|In the stepped wedge cluster randomized design, the fifth clinic will remain in the control period (no intervention) for 5 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 4 months.
2876892|NCT03411525|Experimental|Commitment invitation at time 6|In the stepped wedge cluster randomized design, the sixth clinic will remain in the control period (no intervention) for 6 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 3 months.
2876893|NCT03411525|Experimental|Commitment invitation at time 7|In the stepped wedge cluster randomized design, the seventh clinic will remain in the control period (no intervention) for 7 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 2 months.
2876894|NCT03411525|Experimental|Commitment invitation at time 8|In the stepped wedge cluster randomized design, the eighth clinic will remain in the control period (no intervention) for 8 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 1 month.
2876895|NCT03411512||CHD|Newborns with structural congenital heart defects. The exclusion criteria were pulmonary or neurological disease, perinatal asphyxia, acute illness, prematurity and congenital abnormality other than CHD.
2876896|NCT03411512||Healthy controls|The control group comprised of healthy matched newborns without a diagnosed CHD.
2876897|NCT03411499|Experimental|Early surgery|Surgery within 72 hours from endocarditis diagnosis
2876898|NCT03411499|Active Comparator|Conventional therapy|Medical treatment and a possible delayed surgical intervention according to the current guidelines
2876899|NCT03411473|Experimental|AGEN1884 with pembrolizumab|AGEN1884 in combination with pembrolizumab
2876900|NCT03411460|Experimental|Interstitial glucose|Glucose level tested by continuous monitoring device
2876901|NCT03411460|Active Comparator|Blood glucose|Glucose level tested on glucose monitor using standard finger prick
2876902|NCT03411447|Active Comparator|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
2876903|NCT03411447|Active Comparator|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
2876904|NCT03411434|Experimental|ADHD patients|90 patients will be enrolled and assessed (i.e., neurocognitive and oculomotor tests) at baseline ; after a single low dose of methylphenidate (10 mg orally); and after 6 months of adequate dose of methylphenidate oral tablet
2876905|NCT03411421|Experimental|Part 1 (AL-794 or Placebo)|Participants will receive AL-794 or placebo in 2:1 ratio in Cohorts 1 to 3. AL-794 will be administered at a 100 milligram (mg) loading dose (LD) on the morning of Day 1, followed by a 50 mg maintenance dose (MD) on the evening of Day 1 and twice-daily (BID) on Day 2 through Day 5. The duration of dosing may be extended (maximum duration 10 days), at the discretion of the Sponsor and Principal Investigator (PI).
2876906|NCT03411421|Experimental|Part 2 (AL-794 or Placebo)|Participants will receive AL-794 or placebo in 2:1 ratio. AL-794 will be administered as 100 mg LD on the morning of Day 1, followed by a 50 mg MD on the evening of Day 1 and BID on Day 2 through Day 5. The duration of dosing may be extended (maximum duration 10 days). Based on the results of Part 1, the duration of dosing may be modified.
2876907|NCT03411408|Experimental|HBO and RT|Hyperbaric oxygenation therapy and Accelerated Hypofractionated intensity - modulated radiotherapy
2876908|NCT03411395|Placebo Comparator|Placebo drink|A standardized breakfast meal will be provided together with carbonated water containing aroma
2876909|NCT03411395|Experimental|5AA+CrPic Water Dose 1|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA and CrPic
2876910|NCT03411395|Experimental|5AA+CrPic Water Dose 2|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA (1/2 of Dose 1) and CrPic
2876911|NCT03411395|Experimental|5AA+CrPic Water Dose 3|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA (1/4 of Dose 1) and CrPic
2876912|NCT03411382|Experimental|Sit muscle strength training|Sit muscle strength training using a sand bag grip ball conducted twice a week. Each exercise session will begin and end with a 5-15 minute warm-up and cool-down routine. The exercise program consists of 20-40 minute chair-based resistance exercises.
2876913|NCT03411382|Experimental|Game training|Game training (including ball activities, clay courses, massage, puzzles, painting conducted four times a week). Each section 30-60 minutes.
2876914|NCT03411382|Experimental|Sitting strength + game training|Sitting strength training (using sandbag training conducted twice a week) and game training (such as ball activities and clay courses) conducted twice a week).
2876915|NCT03411382|Placebo Comparator|Health education|Health education (conducted once a month). Each section 50-60 minutes. The topics are oral hygiene, medicine safe, living safe, food safe.
2876916|NCT03411369|Experimental|Creatine, D-Ribose, B1 Vitamin, and B6 vitamin|Water-soluble powder in sachets of 4 grams. Each sachet contains 1 gram of Creatine, 2.5 grams of D-Ribose, 0.33 mg of B1 vitamin and 0.42 mg of B6 vitamin.
2876917|NCT03411369|Placebo Comparator|Placebo|Water-soluble powder in sachets of 4 grams containing inert product consisting of starch powder.
2876918|NCT03411356|Active Comparator|Daily Caloric Restriction (DCR)|Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.
2876919|NCT03411356|Experimental|Intermittent Fasting (IMF)|Participants in this group will focus on modified intermittent fasting as their dietary weight loss strategy.
2876921|NCT03411343|Experimental|Costoclavicular Infraclavicular Block|Patients randomized to receive a costoclavicular infraclavicular block.
2876922|NCT03411330|Active Comparator|Group H (Hyaluronidase added to local anaesthetics)|"group H scalp block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg , Hyaluronidase will be added in in a dose of 1500 IU . The scalp block technique includes infiltrating local anaesthetic to 7 nerves on either side. This is an anatomical block and not just a ring block. At the end of the scalp block further local anesthetic can be infiltrated locally to the pin sites and 7 nernes supraorbital nerve, a branch of the trigeminal nerve,supratrochlear nerve, a branch of the trigeminal nerve.~zygomaticotemporal nerve,auriculotemporal nerve, lesser occipital nerve, greater occipital nerve and greater auricular nerve"
2876923|NCT03411330|Active Comparator|Group A (local anaesthetics alone)|"Group A :scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum dose of 175 mg The scalp block technique includes infiltrating local anaesthetic to 7 nerves on either side. This is an anatomical block, and not just a ring block. At the end of the scalp block; further local anesthetic can be infiltrated locally to the pin sites and 7 nernes Supraorbital nerve, a branch of the trigeminal nerve.~supratrochlear nerve, a branch of the trigeminal nerve. zygomaticotemporal nerve, auriculotemporal nerve, lesser occipital nerve, greater occipital nerve, greater auricular nerve"
2876924|NCT03411291||Diet: MRI/MR Spectroscopy/MR Perfusion|Healthy candidates for statin therapy to lower cholesterol pre-electing to lower cholesterol by diet for three months. Candidates in this arm have pre-elected to lower cholesterol by diet as described under the care of their treating physicians. Candidates will have 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at baseline and 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at 3 (three) months.
2876925|NCT03411291||Statin: MRI/MR Spectroscopy/MR Perfusion|Healthy candidates for statin therapy pre-electing to lower their cholesterol using atorvastatin (Lipitor) 20 mg per day as prescribed by their treating physician per standard of care. There are no research-related interventions for this group. Candidates will have 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at baseline and 1 brain MRI / MR spectroscopy/MR resonance perfusion scan at 3 months.
2876926|NCT03411278|Experimental|Deep Oscillation (DO) self treatment|"DO self treatment with the device mobile (Physiomed, Laipersdorf, Germany; U.S. patent 7,343,203 B2). The device produces an alternating electrostatic field, which results in a low-frequency vibration penetrating the tissue. The Field is pulsed at a frequency of 90 Hz. For self-treatment, each volunteer is given an apparatus to take home. An applicator with a diameter of 9 cm is used. The treatment will be carried out in the morning and evening for 15 minutes each in supine position on a sofa. In accordance with the technique of classical manual lymphatic drainage, stroking and circular movements in the upper and lower leg and the inguinal area take place in a fixed order."
2876927|NCT03411278|No Intervention|No intervention, control|No intervention
2876928|NCT03411265|Experimental|RETAIN|Participants who meet criteria will receive the RETAIN self-administered, e-health application intervention.
2876929|NCT03411252|Experimental|Mirabegron|Patients will receive 50 mg of oral Mirabegron daily for 4 weeks and then switch to placebo by mouth daily for an additional 4 weeks.
2876930|NCT03411252|Placebo Comparator|Placebo|Patients will receive placebo by mouth daily for 4 weeks and then switch to oral Mirabegron 50 mg daily for an additional 4 weeks.
2876931|NCT03411239|Other|Interventional arm|Patients recruited will have OBC inserted under general anaesthesia and various pressure measured
2876932|NCT03411226||re-TREPP|Patients who presented with a recurrent inguinal hernia after previous TREPP repair.
2876933|NCT03411213|Experimental|Vascular function|Diffuse optical tomography detection of differences in vascular function between healthy volunteers and patients with proven heart disease or diabetes.
2876934|NCT03411213|Experimental|Coronary artery disease|Diffuse optical tomography prediction of presence or severity of coronary artery disease on angiography.
2876935|NCT03411200|Experimental|Intervention group (n=50)|Participants in the intervention group will receive usual care and the multimodal and exercise-based intervention.
2876936|NCT03411200|No Intervention|Control group (n=50)|Participants in the control group will receive usual care.
2876937|NCT03411187|Active Comparator|foot-control exhaust group|The foot-control exhaust group used of the Pressure adjustable foot-control method by the way of adjustable Pressure to intermittent exhaust
2876938|NCT03411187|Placebo Comparator|direct exhaust group|direct exhaust group exhaust through the Trocar hole.and without use of the Pressure adjustable foot-control method
2876939|NCT03411174|Experimental|HF-PBI|Hypofractionated partial breast irradiation was delivered to the tumor bed areas for low recurrence risk breast cancer patients, with prescription dose 40Gy in 15 fractions in 3 weeks.
2876940|NCT03411161|Experimental|Combination therapy (S81694 + paclitaxel) phase I|Phase I: Single arm, non-randomized study in metastatic breast cancer patients. S81694 given intravenously at different doses on D1, D8 and D15 last for 28 days. The participants will also receive paclitaxel intravenously on D1, D8 and D15 last for 28 days.
2876941|NCT03411161|Active Comparator|paclitaxel|"Phase II: Randomised phase II part , two-arm, in untreated metastatic triple negative breast cancer patients.~Paclitaxel given intravenously on D1, D8, and D15 at 80 mg/m²."
2876942|NCT03411161|Experimental|Combination therapy (S81694 + paclitaxel) phase II|"Phase II: Randomised phase II part , two-arm, in untreated metastatic triple negative breast cancer patients.~S 81694 given intravenously on D1, D8 and D15 at recommended phase 2 dose (RP2D). paclitaxel given intravenously on D1, D8, and D15 at RP2D."
2876943|NCT03411148|Experimental|Exercise Group A|Weekly exercise sessions with physical therapist and psychologist
2876944|NCT03411148|Placebo Comparator|Exercise Group B|Home-based exercises
2876945|NCT03411122|Experimental|Single-sequence 3-period|Period 1: napabucasin 240 mg BID on days 1-2 Period 2: cytochrome P450 probe drugs during days 1-4 Period 3: napabucasin 240 mg BID on days 1-11, cytochrome P450 probe drugs during days 6-9
2876946|NCT03411109||Opioid Only Intrathecal|
2876947|NCT03411109||Opioid + Local Anesthetic Intrathecal|
2876948|NCT03411096|Experimental|Quadratus lumborum block|Quadratus lumborum block with 0.75% ropivacaine
2876949|NCT03411096|Placebo Comparator|Placebo|Quadratus lumborum block with normal saline
2876950|NCT03411083||Knee replacement|Patients assigned for total or unicompartmental knee replacement surgery
2876951|NCT03411070|Experimental|Treatment (radiofrequency tagged surgery)|Patients undergo image-guided placement of the radiofrequency tag within 4 weeks before standard of care neoadjuvant chemotherapy. Patients undergo standard of care surgery 3-6 weeks after chemotherapy.
2876952|NCT03411057||Mindfulness Based Stress Reduction (MBSR)|Inflammatory Arthritis (Rheumatoid Arthritis, Psoriatic Arthritis) participants in this group will attend an 8 week MBSR course. The MBSR course meets once per week for 2.5 hours with a 4-hour retreat on week 8.
2876953|NCT03411057||Control|Rheumatoid Arthritis, Psoriatic Arthritis participants in this group will watch an educational stress reduction video (10 minutes).
2876954|NCT03411044||Subjects with a Fitmore Hip Stem|Subjects in need of a total hip arthroplasty who met the inclusion/exclusion criteria and who received the Fitmore Hip Stem
2876955|NCT03411031|Active Comparator|A: Elotuzumab + Lenalidomide at 25 mg|"Elotuzumab 10 mg/kg intravenously (IV) weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab.~Lenalidomide 25 mg by mouth (PO) daily days 1-21 out of a 28-day schedule."
2876956|NCT03411031|Active Comparator|B: Elotuzumab + Lenalidomide at 10 mg|"Elotuzumab 10 mg/kg IV weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab.~Lenalidomide 10 mg PO daily days 1-21 out of a 28-day schedule."
2876957|NCT03411018||Conventional respiratory managed group.|Preterm infants born with less than 32 weeks gestational age (wGA) that entered in the neonatal Intensive care unit (NICU) from January 1 2012 to December 31 2013. These preterm infants were managed according to prior ventilatory protocol: Prophylactic Continuous positive airway pressure (CPAP) in delivery room, early surfactant administration by INSURE technique and volume target mechanical ventilation with rescue high frequency ventilation when needed. Mechanical ventilation exposure will be analyzed
2876958|NCT03411018||Less invasive managed group|Preterm Infants born with less than 32wGA that entered the NICU from January 1 2014 to December 31 2017. This infants are managed according to the actual ventilatory protocol. Prophylactic CPAP in delivery room, early surfactant administration by less invasive technique, nasal Synchronized positive pressure ventilation for CPAP failure and early rescue high frequency ventilation with minimally target volume.Mechanical ventilation exposure will be analyzed
2876959|NCT03411005|Experimental|Metabolic availability of lysine in Sorghum|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or cooked sorghum with or without lentils, which will all be provided by the investigators."
2876960|NCT03410992|Experimental|Bimekizumab cohort|Subjects will receive bimekizumab for 16 Weeks. Subjects who achieve certain predefined response criteria will be re-randomized to either receive bimekizumab or placebo until Week 56. Subjects who do not achieve predefined response criteria will enter the bimekizumab escape arm.
2876961|NCT03410992|Placebo Comparator|Placebo|Subjects will receive placebo for 16 Weeks. Subjects who achieve certain predefined response criteria will proceed with placebo until Week 56. Subjects who do not achieve certain predefined response criteria will enter the bimekizumab escape arm.
2876962|NCT03410979|Experimental|GLPG2737 single dose|Single doses of GLPG2737 oral suspension at up to 5 dose levels in ascending order
2876963|NCT03410979|Placebo Comparator|Placebo single dose|Single doses of Placebo oral suspension
2876964|NCT03410979|Experimental|GLP2737 multiple dose|Multiple doses of GLPG2737 oral suspension at up to 3 dose levels in ascending order
2876965|NCT03410979|Placebo Comparator|GLPG2737 multiple dose|Multiple doses of Placebo oral suspension
2876966|NCT03410966|Experimental|Intervention group|All patients affected by paroxysmal symptomatic atrial fibrillation, and anti-arrhythmic drug refractory atrial fibrillation will receive a trans catheter ablation therapy (intervention).
2876967|NCT03410940||Subjects who received a CLS Brevius Kinectiv stem|Subjects in need of a total hip arthroplasty who met the inclusion/exclusion criteria and received the CLS Brevius Kinectiv stem.
2876968|NCT03410927|Experimental|TAS0728|Group 1: Urothelial cancer with HER2 or HER3 mutation Group 2: Biliary tract cancer with HER2 or HER3 mutation Group 3: Breast cancer with HER2 or HER3 mutation Group 4: Breast cancer with HER2 amplification or overexpression as per American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) 2013 guidelines Group 5: Non-small cell lung cancer (NSCLC) with HER2 or HER3 mutation Group 6: Colorectal cancer (CRC) with HER2 mutation or amplification Group 7: Other tumors with HER2 or HER3 mutation, amplification, or overexpression (eg, gastric or gastroesophageal junction (GEJ), endometrial)
2876969|NCT03410914|Experimental|Hemopatch|Application of hemopatch to the divided end of the pancreas during surgery
2876970|NCT03410901|Experimental|Treatment (radiation therapy, SD-101, BMS-986178)|Patients receive radiation therapy on days 1-2, TLR9 agonist SD-101 and anti-OX40 antibody BMS-986178 intratumorally on days 2, 9, 16, 23, and 30, and anti-OX40 antibody BMS-986178 IV on days 2, 30, 58, 86, 114, and 142 in the absence of disease progression or unacceptable toxicity.
2876971|NCT03410888|Experimental|popliteal approach|Blockade of the sciatic nerve at the level of the popliteal fossa.
2876972|NCT03410888|Active Comparator|infragluteal approach|Blocking the sciatic nerve at the subgluteal level.
2876973|NCT03410875|Experimental|Untreated Hairy Cell Leukemia|Participants with HCL with no prior treatment for the disease
2876974|NCT03410862|Experimental|Elderberry Extract|Patients will be supplied a liquid Elderberry Extract used to treat their confirmed human influenza. The dosage of the assigned medication will be 15 ml, or 1 tablespoon. Participants aged 5-12 will be asked to take the medication 2 times per day (morning/night) for a period of 5 days. Participants aged 13 and above will be asked to take the medication 4 times per day (morning/noon/afternoon/night) for a period of 5 days.
2876975|NCT03410862|Placebo Comparator|Placebo|Patients will be supplied a liquid Placebo medication (similar in appearance and taste of Elderberry Extract) used to treat their confirmed human influenza. The dosage of the assigned medication will be 15 ml, or 1 tablespoon. Participants aged 5-12 will be asked to take the medication 2 times per day (morning/night) for a period of 5 days. Participants aged 13 and above will be asked to take the medication 4 times per day (morning/noon/afternoon/night) for a period of 5 days.
2876976|NCT03410849|Active Comparator|Gastric Bypass|A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic gastric bypass
2876977|NCT03410849|Active Comparator|Sleeve Gastrectomy|A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic sleeve gastrectomy
2876978|NCT03410836|Experimental|intravenous lidocaine (IVL)|Will receive during the colorectal surgery under General Anesthesia intravenous lidocaine bolus 1.5mg/kg at the beginning of anesthesia (induction) and 1.5mg/kg/h until the end of anesthesia.
2876979|NCT03410836|Placebo Comparator|Placebo|Will receive the same volume of normal saline for the entire duration of anesthesia.
2876980|NCT03410823|Experimental|PUSH Plus Protein and Nutrition|Participants will be given a whey-based protein supplement containing 27.6g of protein daily for 16 weeks and receive the PUSH intervention. PUSH is a specific multi-component intervention based on improving specific precursors to community ambulation. The intervention addresses endurance with continuous upright exercise for 20 min.; function by improving fast walking, standing from a chair, and stair negotiation; muscle performance by exercising to enhance lower extremity strength; and balance by performing unilateral activities and activities with decreased base of support. Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive two visits a week, on non-consecutive days, for 16 weeks. Visits take place in the participant's place of residence. Participants also receive the nutritional intervention for the duration of the 16-week study.
2876981|NCT03410810||Infant Control Group|The control arm (term born Infants) will receive an MRI at neonatal age and neurodevelopmental follow-up assessments, investigators will then compare significant morphological and diffusion properties within the brain to those of a Preterm brain.
2876982|NCT03410810||Infant Preterm Group|The experimental group will consist of preterm infants, who will receive an MRI at neonatal age and neurodevelopmental assessments. This groups scans will then be compared to those of the control arm. Significant biomarkers will then be identified.
2876983|NCT03410810||Childhood Control Group|The experimental group will consist of preterm born children aged 6-8 years, who received an MRI at neonatal age and will be called back for a neuropsychological assessment. This groups scans will then be compared to those of the children control arm. Significant biomarkers will then be identified.
2876984|NCT03410810||Childhood Preterm Group|The experimental group will consist of term born children aged 6-8 years, who received an MRI at neonatal age and will be called back for a neuropsychological assessment. This groups scans will then be compared to those of the children preterm group. Significant biomarkers will then be identified.
2876985|NCT03410797|Other|Voice Disorder Requiring Voice Therapy|Individuals with a voice disorder such as muscle tension dysphonia (MTD), vocal fold atrophy or vocal fold lesions recommended for voice therapy as treatment.
2876986|NCT03410784|Other|First-line chemotherapy with pembrolizumab|"Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks for up to 22 cycles~Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles~Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles"
2876987|NCT03410771||ICU patients on amoxicillin/clavulanic acid|
2876988|NCT03410771||ICU patients on piperacillin/tazobactam|
2876989|NCT03410771||ICU patients on meropenem|
2876990|NCT03410771||ICU patients on vancomycin|
2876991|NCT03410745|Experimental|Exercise group|
2876992|NCT03410745|No Intervention|Control group|
2876993|NCT03410732|Experimental|Radical surgery plus activated DCs|In 21 days after a radical surgery, activated DCs are iv infused
2876994|NCT03410732|Active Comparator|Radical surgery only|Radical surgery only group as a control group
2876995|NCT03410719|Experimental|<55 (Low-GI group)|intervention weeks 1-12 the subjects in each group will be counseled to follow their weight maintaining assigned diet using a combination of prescribed menus (breakfast, lunch, and snack eating occasions) and an item specific version of the Pasta Recipe Builder (dinner). The two group-specific diet plans will mostly contain the same foods and beverages typically included in Mediterranean-style diets, except for substitutions of major sources of carbohydrate in their meals:Low-GI - pasta, barley, parboiled rice, legumes.
2876996|NCT03410719|Experimental|>70 (Hi-GI group).|intervention weeks 1-12 the subjects in each group will be counseled to follow their weight maintaining assigned diet using a combination of prescribed menus (breakfast, lunch, and snack eating occasions) and an item specific version of the Pasta Recipe Builder (dinner). The two group-specific diet plans will mostly contain the same foods and beverages typically included in Mediterranean-style diets, except for substitutions of major sources of carbohydrate in their meals: Hi-GI - rice, potato,
2876997|NCT03410706||Rivaroxaban|Anticoagulation with rivaroxaban
2876998|NCT03410693|Experimental|Rogaratinib|"Rogaratinib treatment study arm, comprising~Pre-treatment period, including FGFR testing and screening,~Treatment period, and~Follow-up period, including active follow-up and long-term follow-up. Patients will be considered on study during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered off study."
2876999|NCT03410693|Active Comparator|Chemotherapy|"Chemotherapy treatment study arm, comprising~Pre-treatment period, including FGFR testing and screening,~Treatment period, and~Follow-up period, including active follow-up and long-term follow-up. Patients will be considered on study during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered off study."
2877000|NCT03410680|No Intervention|Control arm|Patients will receive the standard of care at the clinic. Questionnaires will be applied 4 times in a period of 10 months
2877001|NCT03410680|Experimental|Intervention arm|"Each participant will receive FUERTES for a period of 4 months. It consists of receiving a habit-formation kit, which include an information and habit-formation tool that can be accessed through a web platform, a mobile app and a booklet; b) pill cases; c) a fidget cube; and f) a notebook. Patients will have the option of contacting a MD though WhatsApp regarding questions related to their treatment.~After completing baseline a questionnaire, patients with a score of 2 for barriers that might affect their ART adherence will be assigned a coach. The coach will have 7 one-on-one sessions with the patient in a period of 4 months in order to catalyze ART adherence. MSM living with HIV who have been taking ART for >3 years will provide a one-time one-on-one peer support session"
2877002|NCT03410667|Other|Standard Care|Standard of care arm
2877003|NCT03410667|Experimental|Intervention Arm|Intervention arm
2877004|NCT03410654|Experimental|adult kidney transplant recipients|Adult kidney transplant recipients on tacrolimus immediate release for at least six months who are being converted to tacrolimus extended release Envarsus XR® (TAC XR) for any reason by a transplant nephrologist and are willing to participate in cognitive assessment will be offered the opportunity to participate in the study. An assessment is also made at the 3 month point as baseline.
2877005|NCT03410641||Diet and antismoking advice|Dietary and antismoking advice, aiming to reduce participant's risk of cardiovascular diseases
2877006|NCT03410641||Control|No intervention
2877007|NCT03410628|Experimental|gammaCore Active Device|open label
2877008|NCT03410615|Active Comparator|Radiation/Cisplatin|"All patients will receive standard fractionation radiation therapy (RT) scheme: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)~Cisplatin IV 100 mg/m2 days 1, 22, 43 concurrently with RT"
2877009|NCT03410615|Experimental|Radiation/Durvalumab + Adjuvant Durvalumab|"All patients will receive standard fractionation radiation therapy (RT) scheme: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)~Concurrent Phase: Durvalumab IV 1500 mg, days -7 and 22 (the second dose is given concurrently with RT).~Adjuvant Phase (to start 4 weeks after completion of concurrent phase): Durvalumab IV 1500 mg q4 weekly for 6 doses."
2877010|NCT03410615|Experimental|Radiation/Durvalumab + Adjuvant Durvalumab/Tremelimumab|"All patients will receive standard fractionation radiation therapy (RT) scheme: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)~Concurrent Phase: Durvalumab IV 1500 mg, days -7 and 22 (the second dose is given concurrently with RT).~Adjuvant Phase (to start 4 weeks after completion of concurrent phase): Tremelimumab IV 75 mg q4 weekly for 4 doses + Durvalumab IV 1500 mg q4 weekly for 6 doses"
2877011|NCT03410602|Placebo Comparator|Supragingival and subgingival scaling|Supragingival and subgingival scaling group comprised of 15 orthodontic patients treated with routine full-mouth supragingival scaling and subgingival scaling only around all banded first molars. Parameters such as radiographic evidence of alveolar crestal bone level, gingival index, probing pocket depth and clinical attachment level around the banded first molars and full-mouth plaque index were recorded as a change from baseline to 12th month.
2877012|NCT03410602|Active Comparator|Subgingival irrigation|Subgingival irrigation group comprised of 15 orthodontic patients treated with full-mouth supragingival scaling and subgingival scaling only around all banded first molars followed by irrigation with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent. Parameters such as radiographic evidence of alveolar crestal bone level, gingival index, probing pocket depth and clinical attachment level around the banded first molars and full-mouth plaque index were recorded as a change from baseline to 12th month.
2877013|NCT03410589||Single arm|
2877014|NCT03410576||Carotid artery stenting|Patients undergo carotid artery stenting.
2877015|NCT03410576||Carotid endarterectomy|Patients receive elective carotid endarterectomy.
2877016|NCT03410563||Healthy participants|
2877017|NCT03410550|Experimental|Exoskeleton Training|Twenty men with complete and incomplete SCI will be enrolled in the trial.
2877018|NCT03410537|Experimental|Taurine Supplementation|Taurine 2.4mg/d for 12 weeks
2877019|NCT03410537|Placebo Comparator|Placebo|Placebo 2.4mg/d for 12 weeks
2877020|NCT03410524|Active Comparator|Simethicone with PEG-3350 bisacodyl preparation|"Treatment arm:~200 mg Simethicone in 3 mL of liquid formulation mixed with low volume PEG-3350 bisacodyl combination preparation. Bowel preparation taken as per directions including the evening before and the day of the procedure."
2877021|NCT03410524|Placebo Comparator|Placebo with PEG-3350 bisacodyl preparation|"Placebo arm:~3 mL of water mixed with low volume PEG-3350 bisacodyl combination preparation. Bowel preparation taken as per directions including the evening before and the day of the procedure."
2877022|NCT03410511|Experimental|Nicotine free intake|The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
2877023|NCT03410511|Experimental|Nicotine intake|The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol/nicotine (mix 50:50) intake.
2877024|NCT03410511|Experimental|Cessation intake|The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off.
2877025|NCT03410498|Other|MS group|This group will perform walking trials in various conditions, i.e. normal walking, walking whilst performing an attention demanding task and walking while being physically tired.
2877026|NCT03410485|Active Comparator|Control (C Group )|Intervention for intraoperative analgesic administration will be based on heart rate and blood pressure variations. Intervention for intraoperative hypnotice/desflurane administration will based on keeping the MAC at 0.8.
2877027|NCT03410485|Experimental|Monitoring (M Group )|Intervention for intraoperative analgesic administration will be based on the NOL index (to keep it below 25). Intervention for the desflurane administration will be based on the BIS index (to keep it between 40-60).
2877028|NCT03410472|Experimental|Web based diet application|This arm entails the subject to record their diet into an online web program to monitor calories. The calorie goal will be given to the subjects in this group prior to the study based on dual x-ray absorptiometry test that will test resting metabolic rate.
2877029|NCT03410472|No Intervention|Control|This group will have body composition tested at week 1 and then repeat this test at 8 weeks having no intervention.
2877030|NCT03410459|Active Comparator|Gastric Bypass|Patients ≥ 5 years after laparoscopic gastric bypass receive DEXA (= Dual-energy x-ray absorptiometry) in order to measure bone mass density
2877031|NCT03410459|Active Comparator|Sleeve gastrectomy|Patients ≥ 5 years after laparoscopic sleeve gastrectomy receive DEXA (= Dual-energy x-ray absorptiometry) in order to measure bone mass density
2877032|NCT03410446|Experimental|Ketamine|"Three doses of ketamine will be given intranasal:~Dose 1 will be 50 mg on Day 1~Dose 2 will be between 50-100 mg on Day 4~Dose 3 will be between 50-150 mg on Day 7"
2877033|NCT03410433|Active Comparator|Silk 4.0|Silk suture
2877034|NCT03410433|Active Comparator|PG910 4.0|Vicryl Rapid suture
2877035|NCT03410433|Experimental|PP 4.0|Non-absorbable polypropylene monofilament
2877036|NCT03410433|Active Comparator|Silk 5.0|Silk suture
2877041|NCT03410420|Active Comparator|Non aneurysmal|Intervention: four non-aneurysmal patients undergoing coronary artery bypass graft or aortic valve replacement will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time.
2877042|NCT03410420|Experimental|Aneurysmal|Intervention: four patients who are candidates for aortic replacement due to aneurysm will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time.
2877043|NCT03410407||AML patients|AML patients according to the French-American-British (FAB) criteria, previously enrolled in GIMEMA Studies for AML treatment. AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.
2877044|NCT03410394||registry of endocrine tumors|"Patients who undergo thyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-22.~Patients who undergo parathyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-23~Patients who undergo adrenal surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-24~Patients who undergo pancreatic and digestive surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-26"
2877045|NCT03410381|Experimental|Group using the application EMMA|Patients with personal history of suicide attempt or with suicidal ideation, will use the application during 6 months. Assessment of the predictive value of the algorithm for suicidal risk, acceptbability and satisfaction
2877046|NCT03410368|Experimental|autologous natural killer cells|Infusion of 1-2×10^9 NK cells every 14 days in the absence of progression or unacceptable toxicity until the 6 courses of treatment.
2877047|NCT03410368|No Intervention|routine follow-up|According to present guideline, no special treatment is advised for patients with SCLC after first-line therapy.They will be followed-up regularly.
2877048|NCT03410355|Experimental|BMAC/PRP Injection Group|This group will receive an injection of BMAC/PRP for treatment of OA
2877049|NCT03410355|Active Comparator|Cortisone Injection Group|This group will receive an injection of cortisone for treatment of OA
2877050|NCT03410342|Placebo Comparator|Low Fruits and Vegetables (LFV)|"1 portion of fruits plus 1 portion of vegetables, of commonly consumed types per day.~Intakes are at 25th percentile of UK consumption (NDNS) and will exclude citrus fruits, cruciferous and allium vegetables."
2877051|NCT03410342|Experimental|High Fruits and Vegetables (HFV)|4 portions of fruits plus 4 portions of vegetables, of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
2877052|NCT03410342|Experimental|High Citrus fruits and Cruciferous vegetables (CC)|4 portions of citrus fruits plus 4 portions of cruciferous vegetables per day excluding any other types of fruits and vegetables including allium vegetables.
2877053|NCT03410329|Experimental|High weekly training frequency|three sessions a week of resistance training
2877054|NCT03410329|Experimental|Low weekly training frequency|one workouts per week
2877055|NCT03410316||Participants of the NEO study|Men and women aged 45 oy 65 years, with an oversampling of individuals with a BMI of 27 kg/m2 or higher
2877056|NCT03410303|Other|Intraoperative ultrasound|An ultrasound of the position of the prosthesis during surgery, under general anesthesia, is performed. A follow-up visit will be carried out 2 months (± 1 month) after the surgery as part of the usual care. An ultrasound of the position of the prosthesis is performed without anesthesia, either as part of the treatment or as part of the research. This measurement is performed without the intraoperative measurement by an independent sonographer.
2877057|NCT03410290||Group 1|The online questionnaire includes questions about factors that impacted a patients diagnosis of vasculitis.
2877058|NCT03410277|Experimental|All Subjects|Experimental hypoglycemia
2877059|NCT03410264|Experimental|CR-EXP|Cognitive restructuring before exposure with response prevention (45 minute intervention).
2877060|NCT03410264|Experimental|EXP-CR|Exposure with response prevention before cognitive restructuring (45 minute intervention).
2877061|NCT03410264|Active Comparator|Stress Management|Stress management skills.
2877062|NCT03410238|Experimental|Treatment|Participants receive Saferteens Brief Intervention and a brochure containing psycho-education and resources.
2877063|NCT03410238|No Intervention|Control|Participants receive a brochure containing psycho-education and resources only.
2877064|NCT03410225|Experimental|CAMI-TPP|Young men, ages 15 to 24 years, will be receiving a modified CAMI aimed at Teen Pregnancy Prevention (CAMI-TPP).
2877065|NCT03410225|Active Comparator|CAMI-Fitness|Young men, ages 15 to 24 years, will be receiving CAMI aimed at healthy diet, physical activity and tobacco avoidance (CAMI-Fitness).
2877066|NCT03410212|Active Comparator|Ketorolac Tromethanine|In the experimental group, 30mg/mL, ketorolac tromethamine will be injected as same as the first IANB and 5 minutes following it.
2877067|NCT03410212|Sham Comparator|No injection|In the control group, 5 minutes following the IANB, the sham injection will be provided at the same place of the first injection.
2877068|NCT03410173|Experimental|Taurine|2.4mg/d for 12 weeks
2877069|NCT03410173|Placebo Comparator|Placebo|2.4mg/d for 12 weeks
2877070|NCT03410160||High frequency of adrenal crisis|Patients with a high frequency of adrenal crisis in the past. Intervention: Clinical and biochemical examination (physical examination and blood-sampling before and after oral ingestion of glucocorticoids).
2877071|NCT03410160||Low frequency of adrenal crisis|Patients with no adrenal crisis or a low frequency of AC in the past. Intervention: Clinical and biochemical examination (physical examination and blood-sampling before and after oral ingestion of glucocorticoids).
2877072|NCT03410147|Other|Concentration A|Concentration of 13C-sodium octanoate in enteral nutrition is 0.3 mg/ml
2877073|NCT03410147|Other|Concentration B|Concentration of 13C-sodium octanoate in enteral nutrition is 1.0 mg/ml
2877074|NCT03410147|Other|Concentration C|Concentration of 13C-sodium octanoate in enteral nutrition is 3.0 mg/ml
2877075|NCT03410134|Experimental|NeoMTA|Vital pulp therapy with NeoMTA
2877076|NCT03410121|Other|Standard 1 : Thoracic location|The intervention is characterized by the randomization into thoracic arm which means that patients will have an implantable Venous Access Device implanted into thoracic location
2877077|NCT03410121|Other|Standard 2 : Humeral location|The intervention is characterized by the randomization into humeral arm which means that patients will have an implantable Venous Access Device implanted into humeral location
2877078|NCT03410108|Experimental|Brigatinib 90 mg + Brigatinib 180 mg|90 mg of Brigatinib tablets, once daily for 7 days, followed by 180 mg of Brigatinib tablets, once daily in a 28-days cycle.
2877079|NCT03410095||Sleep apnea patients|80 patients recently diagnosed with severe sleep apnea will participate in the Brain Changes in Sleep Apnea Study.
2877080|NCT03410082|Active Comparator|OAA/S|The patients in the control group will receive MAC titrated according to observer's assessment of anesthesia/sedation(OAA/S) score.
2877081|NCT03410082|Active Comparator|BIS|The patients in the control group will receive MAC titrated according to bispectral index(BIS).
2877082|NCT03410069|Experimental|IKORUS UP|
2877083|NCT03410056|Experimental|AMG 592|The phase 1b part of the study is a double-blind, placebo controlled, MAD study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AMG 592 in subjects with active RA. The phase 2a part of the study will commence after a RP2D is identified in the phase 1b part of the study.
2877084|NCT03410056|Placebo Comparator|Placebo|The phase 1b part of the study is a double-blind, placebo controlled, MAD study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AMG 592 in subjects with active RA. The phase 2a part of the study will commence after a RP2D is identified in the phase 1b part of the study.
2877085|NCT03410043|Experimental|Group 1: Osimertinib + Local Consolidation Therapy (LCT)|Participants receive LCT after treatment with Osimertinib during Induction Therapy. Study doctor decides if participant has radiation alone, surgery alone, or radiation combined with surgery.
2877086|NCT03410043|Experimental|Group 2: Osimertinib|Participants continue treatment with Osimertinib after Induction Therapy.
2877087|NCT03410030|Experimental|Ascorbic Acid|Some human studies of high-dose IV vitamin C in patients with cancer have shown improved quality of life, as well as improvements in physical, mental, and emotional functions, symptoms of fatigue, nausea and vomiting, pain, and appetite loss. Intravenous high-dose ascorbic acid has caused very few side effects in clinical trials
2877088|NCT03410017||Normally-hearing|Children with normal hearing
2877089|NCT03410004|Experimental|Experimental|Drug: Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
2877090|NCT03409991|Experimental|Experimental|Receives the 12-week Opening Doors group sessions, and up to 8 individual career counseling sessions.
2877091|NCT03409991|No Intervention|Waitlist Control|Offered non-vocational classes at the Boston University Center for Psychiatric Rehabilitation, and offered the chance to attend the Opening Doors program at the end of their enrolled 12-month study period.
2877092|NCT03409978||In-Motion app for movement analysis|Participants will be recruited from infants referred to the high-risk follow-up clinic at the hospital. These at-risk children are included in the regular clinical follow-up program comprising a standard examination at 3 months corrected age (fidgety general movements period). Infant/families from St. Olavs Hospital (n= 15), in Norway, Lurie Children's Hospital (n=15), Chicago, USA, Christian Medical College (n=15), Vellore, India, University of Ghent (n=15), Belgium, and Hillerød Hospital (n=30), Copenhagen, Denmark will be invited to participate.
2877093|NCT03409965|Experimental|Lutronic Systems Combination Treatment|Combination treatment of the face and/or neck using the Lutronic Infini System and Lutronic LaseMD System.
2877094|NCT03409952|Active Comparator|Group A: LaseMD and DUAL 1927nm Laser|Group A subjects will receive split-side study treatments comparing two devices: LaseMD compared to the DUAL 1927nm laser.
2877095|NCT03409952|Active Comparator|Group B: LaseMD Optimized|Group B subjects will receive LaseMD Optimized Treatments based on Group A treatment data.
2877096|NCT03409939|Experimental|Aromatic Amino Acid Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
2877097|NCT03409926|Active Comparator|Microcrystalline Cellulose (MCC) 10 grams/day|non-fermentable active control
2877098|NCT03409926|Experimental|Acacia Gum 5 grams/day|fermentable dietary fiber
2877099|NCT03409926|Experimental|Acacia Gum 10 grams/day|fermentable dietary fiber
2877100|NCT03409913||GCA cases|In a cohort of patients suspected of GCA based on the following inclusion criteria were 1) age ≥50 years, 2) CRP>15mg/l or ESR>40mm/h, 3) either a) cranial symptoms, b) new-onset extremity claudication or c) weight loss >5 kilograms or fever>38oC for >3 weeks, patients with a clinical diagnosis of GCA is identified.
2877101|NCT03409913||controls|Age-(+/- 3 years) and sex-matched malignant melanoma (MM) patients who had a follow-up metastatic-disease-free FDG PET/CT ≥6 months after MM resection
2877102|NCT03409900|Experimental|LPB Unilateral DAA THA|Patients will be randomized to receive either a LPB or QLB for post-operative analgesia. Randomization to either LPB or QLB will occur via block randomization using sealed sequentially numbered opaque envelopes that will correspond to the order with which patients are enrolled. Patients and research assistants will be blinded to their randomization by administration of intravenous sedation (titrated to patient comfort), utilization of ultrasonography to visualize pertinent structures for both blocks, and by the nature of the block technique themselves both being in close proximity on the posterior lower back.
2877103|NCT03409900|Experimental|QLB Unilateral DAA THA|Patients will be randomized to receive either a LPB or QLB for post-operative analgesia. Randomization to either LPB or QLB will occur via block randomization using sealed sequentially numbered opaque envelopes that will correspond to the order with which patients are enrolled. Patients and research assistants will be blinded to their randomization by administration of intravenous sedation (titrated to patient comfort), utilization of ultrasonography to visualize pertinent structures for both blocks, and by the nature of the block technique themselves both being in close proximity on the posterior lower back.
2877104|NCT03409887|Experimental|Intraorifice Group|Intraorifice barrier of GIC.
2877105|NCT03409887|Experimental|Base Group|Base of GIC
2877106|NCT03409887|Active Comparator|Control Group|Direct composite restoration
2877107|NCT03409874|Experimental|Dry Needling and Spinal Manipulation|
2877108|NCT03409874|Active Comparator|Interocclusal Appliance, NSAIDs and TMJ Mobs|
2877156|NCT03409484|Sham Comparator|Low flavonoid low essence beverage|Low flavonoid low essence beverage
2877157|NCT03409484|Sham Comparator|Low flavonoid beverage|Low flavonoid beverage
2877109|NCT03409848|Experimental|A: Chemo-free immunotherapy|Week 1-12 Trastuzumab 6mg/kg d1 every 3 weeks (loading dose 8mg/kg) Nivolumab 1mg/kg i.v. d1 every 3 weeks Ipilimumab 3mg/kg i.v. d1 every 3 weeks Week 13 till EOT (max treatment period 12 months) Trastuzumab 4mg/kg d1 every 2 weeks Nivolumab 240mg i.v. d1 every 2 weeks
2877110|NCT03409848|Experimental|B: Chemo- / immunotherapy|"Trastuzumab 4mg/kg d1 every 2 weeks (loading dose 6mg/kg) Nivolumab 240mg i.v. d1 every 2 weeks mFOLFOX6 every 2 weeks Oxaliplatin at a dose of 85 mg/m2 IV over two hours (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv over two hours (day 1) 5-FU at a dose of 2400 mg/m2 IV over 46 hours (day 1-3)~Max Treatment period 12 months"
2877111|NCT03409835|Experimental|Ramosetron|
2877112|NCT03409835|Placebo Comparator|Control|
2877113|NCT03409822|Other|Placenta previa|
2877114|NCT03409809|Experimental|Training Alone|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website.
2877115|NCT03409809|Experimental|Training and Technical Assistance|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website. This condition additionally contains a 1/2 day implementation training to articulate goals, needs, leadership structure, adoption options, recruitment strategies, and communication.
2877116|NCT03409809|Experimental|Training, Tech. Assist., Qual. Assurance|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website. This condition additionally contains a 1/2 day implementation training to articulate goals, needs, leadership structure, adoption options, recruitment strategies and communication. Furthermore, this condition will have 1 year of technical assistance, coaching, and quality assurance to enhance implementation skills and sustainability.
2877117|NCT03409796|Other|Group A: Gluten 3 gm|Gluten 3 gram (gm), powder, orally, once daily up to 14 days.
2877118|NCT03409796|Other|Group B: Gluten 10 gm|Gluten 10 gm, powder, orally, once daily up to 14 days.
2877119|NCT03409783|Active Comparator|Active or ENSO Group|Active ENSO device use for two weeks, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
2877120|NCT03409783|Sham Comparator|Sham Group|Sham device use for two weeks, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
2877121|NCT03409770|No Intervention|Usual care|Usual care (normothermia) arm
2877122|NCT03409770|Experimental|Therapeutic hypothermia - 24 h|Whole body cooling (33 to 34 C) for 24 hours
2877123|NCT03409770|Experimental|Therapeutic hypothermia - 48 h|Whole body cooling (33 to 34 C) for 48 hours
2877124|NCT03409770|Experimental|Therapeutic hypothermia - 72 h|Whole body cooling (33 to 34 C) for 72 hours
2877125|NCT03409757||hemodialysis patients with hyperphosphatemia|"dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool~Velphoro® medication"
2877126|NCT03409757||control group|- dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool
2877127|NCT03409744|Experimental|evinacumab|
2877128|NCT03409731|Other|Absorb GT1 BVS|Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.
2877129|NCT03409718||Biomet Comprehensive Shoulder System|Subjects in need of a total shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Shoulder System.
2877130|NCT03409705|Experimental|Skate Skin group|3,000 mg of low-molecular collagen peptide was orally administered per day for 12 weeks.
2877131|NCT03409705|Placebo Comparator|Control group|3,000 mg of placebo was orally administered per day for 12 weeks.
2877132|NCT03409679|Experimental|Murepavadin|Murepavadin IV + one anti-pseudomonal antibiotic
2877133|NCT03409679|Active Comparator|Two anti-pseudomonal antibiotics|Association of 2 anti-pseudomonal antibiotics
2877134|NCT03409666|Experimental|Taperloc Complete Microplasty stem|Subjects in need of a total hip artthroplasty who received the Taperloc Complete Microplasty stem.
2877135|NCT03409666|Active Comparator|Taperloc Complete Reduced Distal stem|Subjects in need of a total hip arthroplasty who received the Taperloc Complete Reduced Distal stem.
2877136|NCT03409627|Experimental|Group 1|Single infusion of INXN-4001, Dose 1
2877137|NCT03409627|Experimental|Group 2|Single infusion of INXN-4001, Dose 2
2877138|NCT03409614|Other|Standard-of-Care (SOC)|Chemotherapy
2877139|NCT03409614|Experimental|Dose 1|REGN2810/chemo
2877140|NCT03409614|Experimental|Dose 2|Drug: REGN2810/abbrev chemo/ipi
2877141|NCT03409601|Experimental|100% Portion Size|Test meal consists of baseline (100%) portion size of meal.
2877142|NCT03409601|Experimental|125% Portion Size|Test meal consists of food portion size that is 125% the size of baseline portion.
2877143|NCT03409601|Experimental|150% Portion Size|Test meal consists of food portion size that is 150% the size of baseline portion.
2877144|NCT03409601|Experimental|175% Portion Size|Test meal consists of food portion size that is 175% the size of baseline portion.
2877145|NCT03409588|Experimental|Study Drug|Riociguat (Adempas) 0.5mg to 2.5 mg three time daily - oral medication
2877146|NCT03409575|Other|5 minutes stimulation|The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 5 minutes.
2877147|NCT03409575|Other|10 minutes stimulation|The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 10 minutes.
2877148|NCT03409562|Experimental|Pain Neurophysiology Education and motor control training|This group will undergo two pain neurophysiology education sessions prior to motor control training.
2877149|NCT03409562|Active Comparator|motor control training alone|This group will only perform motor control training.
2877150|NCT03409536||SSEP Monitoring|participants will receive a brachial plexus block for their surgery and will be monitored for brachial plexus injury using the automated SSEP monitor.
2877151|NCT03409510|Experimental|Long-term UVB radiation|All participants received repeated UVB radiation for nine weeks. The treatment was identical for all participants.
2877158|NCT03409458|Experimental|PT-112 in combination with avelumab|"PT-112, administered by intravenous infusion avelumab, administered by intravenous infusion~Patients with all listed conditions are eligible for treatment during the dose escalation phase of the study. Patients with NSCLC and mUC are eligible for the dose confirmation phase of the study."
2877159|NCT03409432|Experimental|Treatment (brentuximab vedotin, lenalidomide)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on day 1-21. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
2877160|NCT03409419||pre cohort|Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans with each visit taking up to 4 hours. The 18F-Clofarabine PET/CT scans will be performed before the treatment interventions.
2877161|NCT03409419||post cohort|Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans with each visit taking up to 4 hours. The 18F-Clofarabine PET/CT scans will be performed after the treatment interventions.
2877162|NCT03409406|Experimental|Caregiver Intervention + ST Intervention|Parents/caregivers receive web-based tablet protocol containing sequenced communication information for working with their child at home in addition to the Standard of Care Intervention.
2877163|NCT03409406|Active Comparator|ST Intervention|This intervention is the once monthly standard of care intervention 30-minutes speech therapy (ST) session that the child receives at the hospital.
2877164|NCT03409393|Experimental|Intervention Group|The COPUS intervention plus usual care (OPUS treatment).
2877165|NCT03409393|Other|Control Group|Usual care (OPUS treatment).
2877166|NCT03409380|Experimental|Arginine|Arginine drink provided 1 time. There is about 10 g of arginine in the product.
2877167|NCT03409380|Placebo Comparator|Placebo|Placebo drink provided 1 time.
2877168|NCT03409367|Experimental|Daily Emollient|Parents assigned to the intervention arm will receive a lipid-rich emollient and educational materials promoting once daily full-body emollient use until their infant is 24 months old. Parents will select one of five emollients to be mailed to the dyad's home at enrollment and approximately every six months for the duration of the study. These emollients include (1) CeraVe Healing Ointment, (2) Vaseline, (3) Cetaphil cream, (4) CeraVe cream, and (5) Vanicream.
2877169|NCT03409367|No Intervention|Natural Skin|Parents assigned to the control arm will receive educational materials promoting general infant skin care guidelines only and will be asked to refrain from emollient use unless dry skin develops (current standard of care guidelines).
2877170|NCT03409354|Experimental|Tele-rehabilitation|Tele-rehabilitation via iPad.
2877171|NCT03409354|Active Comparator|Usual care|Usual rehabilitation care, prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
2877172|NCT03409328|Experimental|HIV and substance use prevention|Participants in the intervention condition will receive an HIV and substance use prevention program for self-identified bisexual adolescent men. The intervention content will be developed through formative research during the initial phase of the study.
2877173|NCT03409328|No Intervention|Waitlist|The control condition will be a waitlist.
2877174|NCT03409315||Moxifloxacin, prospective|Prospective included patients (n=60) receiving centralized therapeutic drug monitoring of moxifloxacin.
2877175|NCT03409315||Levofloxacin, prospective|Prospective included patients (n=60) receiving centralized therapeutic drug monitoring of levofloxacin
2877176|NCT03409315||Moxifloxacin, historical controls|Historical controls (n=120) matched to prospective patients, did not receive centralized therapeutic drug monitoring of moxifloxacin.
2877177|NCT03409315||Levofloxacin, historical controls|Historical controls (n=120) matched to prospective patients, did not receive centralized therapeutic drug monitoring of levofloxacin.
2877178|NCT03409302|Experimental|The ALGEapp (Brief i-ACT intervention)|The intervention builds on a previously unpublished face-to-face protocol for greek-speaking chronic pain sufferers (developed by Karekla & Vasiliou, 2013) and has been simplified and modified to produce a self-help digital internet-based modality, namely the ALGEApp. ALGEApp consists of a total of 4 approximately one-hour sessions, which are structured to be completed by the users in sequence within a time frame of 2-8 weeks (depending on the rate of completion by each user). The intervention is guided, which implies that an animated character (an Avatar) guides the user throughout the whole duration of the intervention. ALGEApp contains experiential and audiovisual psycho-educational material based on ACT, adopted for the Greek-Cypriot culture.
2877179|NCT03409302|Active Comparator|Active Control group|The Active control group will have access only to limited component of the ALGEApp intervention, namely the Bonus section, which contains limited psycho-educational information regarding pain management.
2877180|NCT03409289||ROSC RUSH Exam|The study population will include out of hospital cardiac arrest (both traumatic and non-traumatic causes) with return of spontaneous circulation after the cardiac arrest while in the emergency department .
2877181|NCT03409276|Experimental|Group 1 (Treatment): Protein Vaccine/GLA-SE|Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0 and Month 2.
2877182|NCT03409276|Placebo Comparator|Group 1 (Control)|Participants will receive placebo at Day 0 and Month 2.
2877183|NCT03409276|Experimental|Group 2 (Treatment) DNA Vaccine+Placebo+Protein Vaccine/GLA-SE|Participants will receive 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and placebo at Day 0 and Months 1 and 3. Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant and a placebo vaccine at Months 6 and 8.
2877184|NCT03409276|Placebo Comparator|Group 2 (Control)|Participants will receive placebo at Day 0 and Months 1, 3, 6, and 8.
2877185|NCT03409276|Experimental|Group 3 (Treatment): DNA Vaccine+Protein Vaccine/GLA-SE|Participants will receive 2 mg of the env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0 and Months 1, 3, 6, and 8.
2877186|NCT03409276|Placebo Comparator|Group 3 (Control)|Participants will receive placebo at Day 0 and Months 1, 3, 6, and 8.
2877187|NCT03409250|Other|1-Arm study|prospective, 1-arm, monocenter, investigator initiated study Intravitreal injection with Lucentis (Ranibizumab)
2877188|NCT03409237||Group 1|Mannitol 0.2-0.3 g/kg 4 times/day.
2877189|NCT03409237||Group 2|Hypertonic saline solution 3%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
2877190|NCT03409237||Group 3|Hypertonic solution saline 4%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
2877191|NCT03409237||Group 4|Hypertonic saline solution 7%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
2877192|NCT03409224||Adults 18-99|Adults who are undergoing cryoablation
2877193|NCT03409211|Active Comparator|Pso|with or without PsA
2877194|NCT03409211|Active Comparator|Healthy Subjects|Without PsA
2877195|NCT03409198|Active Comparator|Arm A|Chemo only (pegylated liposomal doxorubicin + cyclophosphamide)
2877196|NCT03409198|Experimental|Arm B|Chemo + ipilimumab + nivolumab
2877197|NCT03409185|Experimental|Alcon lens group|Alcon 1 piece SA60AT lens
2877198|NCT03409185|Active Comparator|AMO lens group|AMO 1 piece Sensar AABOO lens
2877199|NCT03409172|Experimental|Control group (CTr)|No counseling or nutritional therapy and no exercise
2877200|NCT03409172|Experimental|Moderate intensity continuous training (MICT)|"Follow-up during a period of 8 weeks of supervised ergometer-based moderate-intensity continuous training based on HRmax (MICT).~MICT:~3 sessions per week~intensity at 65-75% HRmax~time-effort per session: 50 min"
2877201|NCT03409172|Experimental|High Intensity Interval Training (HIIT)|"Procedures: Follow-up during a period of 8 weeks of supervised ergometer-based high intensity interval training based on HRmax (HIIT).~HIIT:~3 sessions per week~10 bouts of one minute at 90% HRmax interspersed by one minute at 40% HRmax~time-effort per session: 25 min"
2877202|NCT03409146||Term Patients|"Approximately 80 pregnant women monitored in labor between 37 and 42 weeks' gestation will be necessary to complete the study. Subjects will have a singleton >37 week pregnancy.~Subjects will be recruited for the study in the following groups :~At least 10 patients with Body Mass Index (BMI) < 30 kg/m2 At least 10 patients with BMI 30-34.9 kg/m2 At least 10 patients with BMI ≥ 35 kg/m2"
2877203|NCT03409133|Experimental|Multi contact electrode implant|"Ten subjects with lower limb amputation will receive implanted multicontact stimulating nerve cuff electrodes connected to temporary percutaneous leads.~During experimental testing, a small amount of stimulation will be applied to the nerves through the contacts of the multichannel cuff electrode."
2877204|NCT03409120|Experimental|Dystonia Severity Assessment|We will measure the effects of DBS on dystonia by assessing changes in the Burke-Fahn-Marsden Dystonia Rating Scale at 2, 4, 6, and 12 months after surgery to implant the Boston Scientific Vercise PC IPG with directional DBS lead versus preoperative baseline.
2877205|NCT03409107|Experimental|Daprodustat receivers|Subjects will receive oral daprodustat once daily
2877206|NCT03409107|Placebo Comparator|Placebo receivers|Subjects will receive oral placebo once daily
2877207|NCT03409068|Experimental|C2-C4 compartment block|Experimental: the C2-C4 compartment anesthetic block is performed by injecting Levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenous muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.
2877208|NCT03409068|Active Comparator|Costagliola block|Active Comparator: the Costagliola anesthetic block is performed by injecting Levobupivacaine 0.375% 20 mL injected in the posterior margin of the sternocleidomastoid muscle and along the anterior border of the same muscle.
2877209|NCT03409055||Group 0|patients without pleural effusion
2877210|NCT03409055||Group 1|patients with pleural effusion
2877211|NCT03409055||Group 2|patients with pleural Effusion and need of drainage
2877212|NCT03409029|Experimental|MRI Scan|As part of the study patients will undergo 4 MRI scans during radiotherapy treatment. These will take place during the 1st, 2nd, 3rd and 4th week of treatment
2877213|NCT03409016||Immune Checkpoint Inhibitor Therapy|Patients starting treatment with ipilimumab, nivolumab, pembrolizumab, or atezolizumab, alone or in combination, for treatment of a metastatic solid tumor cancer will be enrolled. Patients will receive checkpoint inhibitor therapy per standard protocol. There are no study-related medications or interventions beyond blood testing.
2877214|NCT03409016||Control|An additional 18 patients starting standard chemotherapy will be enrolled as a control population. Patients will receive chemotherapy per standard protocol
2877215|NCT03408990||Sleep study for clinical reasons|Children referred to sleep study for clinical reasons
2877216|NCT03408990||Healthy|Healthy children, no relevant pathologies
2877217|NCT03408977|Experimental|Men|
2877218|NCT03408977|Experimental|Women|
2877219|NCT03408964||Group 1a (control)|Patients who underwent biopsies for suspected Prostate Cancer (PC), with a negative result for invasive cancer
2877220|NCT03408964||Group 1|Patients with a first diagnosis of localized biopsy-proven PC, untreated, planned to undergo radical surgery/radical radiotherapy
2877221|NCT03408964||Group 2|Patients with a diagnosis of locally advanced unresectable, recurrent or metastatic PC planned to receive first-line hormono therapy
2877222|NCT03408964||Group 3|Patients with recurrent/progressive/metastatic CRPC planned to receive chemotherapy
2877223|NCT03408951||Interventions (recording)|Patients requiring Intracardiac defibrillator (ICD) implantation or Defibrillation Test (DFT) or Electrophysiology (EP) study with high probability of supra ventricular tachyarrhythmia.
2877224|NCT03408938||Continuous Hb monitoring with Masimo Radical|"Plethysmography Variability Index (PVI) is a measure of the dynamic changes in the perfusion index (PI) that occur during the respiratory cycle . PVI = ﴾PI Max - PI Min﴿ ÷ PI Maxx 100 %.~PVI has the potential to provide useful information concerning changes in the balance between intrathoracic airway pressure and intravascular fluid volume. Trending of PVI may be useful in monitoring surgical patients, both intraoperatively and postoperatively, for appropriate hydration states. For example, a rising PVI may indicate developing hypovolemia and gives an alarm for the need of appropriate fluid and or blood products transfusion supported by the patient hemoglobin level"
2877225|NCT03408925|Experimental|Intervention|The intervention consists of an exercise program developed by the medical team of the National Federation of Orienteering. Specifically, it consists of four exercises targeting strength, flexibility and coordination of the lower extremity. The orienteerers are asked to perform the exercises four times a week throughout the entire study period. The exercises are heel rises, runners pose, single leg stance and one-leg jumps with three difficult levels aiming to mainly improve lower extremity strength and neuromuscular function (online supplement). Each second week the exercises' difficulty level is increased.
2877226|NCT03408925|No Intervention|Control|Normal training, no intervention
2877227|NCT03408912|Other|CMR and angiography FFR|Patients will undergo both CMR and angiography to acquired FFR.
2877228|NCT03408899|Experimental|PC-1005|All participants will receive 3 single escalating doses of PC-1005 gel during Visits 3, 5, and 7, with a 2-to-6-week washout period between dosing visits. Each participant will be on study for approximately 3 to 5 months.
2877229|NCT03408886|Experimental|Group A|Group A receives treatment in Part 1 and Part 2
2877230|NCT03408886|Other|Group B|Group B receives no treatment in Part 1, but does receive treatment in Part 2
2877231|NCT03408873|Experimental|Patient Noncompliance|Subjects enrolled in the study will receive both Abilify Miantena and the Customized Adherence Enhancement (CAE) intervention
2877232|NCT03408860|Other|2-week baseline|Patients complete assessment only for a duration of 2-weeks prior to starting the intervention: Countering Emotional Behaviors Module from the Unified Protocol.
2877233|NCT03408860|Other|4-week baseline|Patient complete assessment only for a duration of 4-weeks prior to starting the intervention: Countering Emotional Behaviors Module from the Unified Protocol.
2877234|NCT03408847|Active Comparator|MC-EVOO in addition to steroid therapy|Oral beclomethasone dipropionate at dose of 10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks plus MC- EVOO for 12 weeks at a dose of 2 tablespoons per day (1 before lunch and 1 before dinner). Each spoon will contain 10 grams of oil containing 5 mg of biophenols.
2877235|NCT03408847|Placebo Comparator|Refined olive oil and steroid therapy|Oral beclomethasone dipropionate (10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks) plus placebo consisting of refined olive oil with low biophenols.
2877236|NCT03408834|Active Comparator|pulse variability index|fluid management performed by pulse variability index
2877237|NCT03408834|Placebo Comparator|conventional fluid management|fluid management performed by conventional fluid management
2877238|NCT03408821|Experimental|Problem Solving Therapy|All participants will attend 8 weekly sessions of Case Manager delivered Problem Solving Therapy.
2877239|NCT03408808|Active Comparator|Aspiration alone|The patients will have their dorsal wrist ganglion aspirated and then pressure dressing for 48 hours.
2877240|NCT03408808|Experimental|Aspiration plus platelet rich plasma|The patients will have their dorsal wrist ganglion aspirated, and then injected with platelet rich plasma (derived from a blood sample taken at the same visit) and then pressure dressing for 48 hours.
2877241|NCT03408795|Other|GOALS-DG Group|Participants in GOALS-DG Group score the performance of procedure after LDG.
2877242|NCT03408782||No drainage|Those patients that underwent surgery and no drain was inserted at the end of the procedure
2877243|NCT03408782||Drainage|Those patients that underwent surgery and one or several drains were inserted at the end of the procedure.
2877244|NCT03408756|Active Comparator|Oral Methotrexate|Participants will receive methotrexate through oral route of administration
2877245|NCT03408756|Active Comparator|Subcutaneous Methotrexate|Participants will receive methotrexate through subcutaneous route of administration
2877246|NCT03408743|Experimental|Knowledge alone|Participants will have access to the knowledge module for a period up to 3 weeks.
2877247|NCT03408743|Experimental|Self-efficacy alone|Participants will have access to the knowledge module plus the self-efficacy module for a period up to 3 weeks.
2877248|NCT03408743|Experimental|Perceived benefits alone|Participants will have access to the knowledge module plus the perceived benefits module for a period up to 3 weeks. *Also referred to as 'benefits' in other arm descriptions**
2877249|NCT03408743|Experimental|Benefits and self-efficacy|Participants will have access to the knowledge module plus perceived benefits and self-efficacy modules for a period up to 3 weeks.
2877250|NCT03408743|Experimental|Injunctive norms alone|Participants will have access to the knowledge module plus the injunctive norms module for a period up to 3 weeks.
2877251|NCT03408743|Experimental|Injunctive norms and self-efficacy|Participants will have access to the knowledge module plus injunctive norms and self-efficacy modules for a period up to 3 weeks.
2877252|NCT03408743|Experimental|Injunctive norms and benefits|Participants will have access to the knowledge module plus injunctive norms and perceived benefits modules for a period up to 3 weeks.
2877253|NCT03408743|Experimental|Injunctive norms, benefits, self-efficacy|Participants will have access to the knowledge module plus the injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2877254|NCT03408743|Experimental|Descriptive norms alone|Participants will have access to the knowledge module plus the descriptive norms modules for a period up to 3 weeks.
2877255|NCT03408743|Experimental|Descriptive norms and self-efficacy|Participants will have access to the knowledge module plus the descriptive norms and self-efficacy modules for a period up to 3 weeks.
2877256|NCT03408743|Experimental|Descriptive norms and perceived benefits|Participants will have access to the knowledge module plus the descriptive norms and perceived benefits modules for a period up to 3 weeks.
2877257|NCT03408743|Experimental|Descriptive norms, benefits, self-efficacy|Participants will have access to the knowledge module plus the descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2877258|NCT03408743|Experimental|Descriptive norms and injunctive norms|Participants will have access to the knowledge module plus the descriptive norms and injunctive norms modules for a period up to 3 weeks.
2877259|NCT03408743|Experimental|Descriptive and injunctive norms, self-efficacy|Participants will have access to the knowledge module plus the injunctive norms and self-efficacy modules for a period up to 3 weeks.
2877260|NCT03408743|Experimental|Descriptive and injunctive norms, and benefits|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
2877261|NCT03408743|Experimental|Descriptive & injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2877262|NCT03408743|Experimental|Expectancies alone|Participants will have access to the knowledge module plus the expectancies module for a period up to 3 weeks.
2877263|NCT03408743|Experimental|Expectancies and self-efficacy|Participants will have access to the knowledge module plus the expectancies and self-efficacy modules for a period up to 3 weeks.
2877264|NCT03408743|Experimental|Expectancies and perceived benefits|Participants will have access to the knowledge module plus the expectancies and perceived benefits modules for a period up to 3 weeks.
2877265|NCT03408743|Experimental|Expectancies, benefits, self-efficacy|Participants will have access to the knowledge module plus the expectancies, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2877266|NCT03408743|Experimental|Expectancies and injunctive norms|Participants will have access to the knowledge module plus the expectancies and injunctive norms modules for a period up to 3 weeks.
2877267|NCT03408743|Experimental|Expectancies, injunctive norms, self-efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
2877268|NCT03408743|Experimental|Expectancies, injunctive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
2877269|NCT03408743|Experimental|Expectancies, injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2877270|NCT03408743|Experimental|Expectancies and descriptive norms|Participants will have access to the knowledge module plus the expectancies and descriptive norms modules for a period up to 3 weeks.
2877271|NCT03408743|Experimental|Expectancies, descriptive norms, self-efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and self-efficacy modules for a period up to 3 weeks.
2877272|NCT03408743|Experimental|Expectancies, descriptive norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and perceived benefits modules for a period up to 3 weeks.
2877273|NCT03408743|Experimental|Expectancies, descriptive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2877274|NCT03408743|Experimental|Expectancies, descriptive and injunctive norms|Participants will have access to the knowledge module plus the expectancies , descriptive norms, and injunctive norms modules for a period up to 3 weeks.
2877275|NCT03408743|Experimental|Expectancies, descriptive & injunctive norms, efficacy|Participants will have access to the knowledge module plus the expectancies , descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
2877276|NCT03408743|Experimental|Expectancies, descriptive & injunctive norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
2877277|NCT03408743|Experimental|Expectancies, descriptive & injunctive, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2877278|NCT03408730|Experimental|Sci-B-Vac Lot A Hep B Vaccination|Sci-B-Vac Lot A Hepatitis B Vaccination
2877279|NCT03408730|Experimental|Sci-B-Vac Lot B Hep B Vaccination|Sci-B-Vac Lot B Hepatitis B Vaccination
2877280|NCT03408730|Experimental|Sci-B-Vac Lot C Hep B Vaccination|Sci-B-Vac Lot C Hepatitis B Vaccination
2877281|NCT03408730|Active Comparator|Comparator: ENGERIX-B Hep B Vaccination|Active Comparator: ENGERIX-B Hepatitis B Vaccination
2877282|NCT03408717||Control|Questionnaires, Mechanical Temporal Summation assessment and pain threshold assessment will be assigned to patient. Patients will be assigned to this group when no significant pain is noted during the follow-up evaluations at 4 and 6 months.
2877283|NCT03408717||Persistent post surgical pain (PPSP)|Questionnaires, Mechanical Temporal Summation assessment and pain threshold assessment will be assigned to patient. Patients will be assigned to this group when high pain score is recorded during the follow-up evaluations at 4 and 6 months.
2877284|NCT03408704|Experimental|ASP-arm|This group of primary health care centers get the internal education (ASP).
2877285|NCT03408704|No Intervention|Control-arm|No intervention at all.
2877286|NCT03408691|Active Comparator|Test product|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) BID for 6 weeks
2877287|NCT03408691|Placebo Comparator|Control product|Acidified dairy drink without ferment consumed as follows: one bottle (100g) BID for 6 weeks
2877288|NCT03408691|No Intervention|No product|no product
2877289|NCT03408665|Experimental|SBRT|Stereotaxic Body Radiation Therapy administred in 3 to 6 fractions.
2877290|NCT03408652|Experimental|Arm A|bone targeted treatment (denosumab or zoledronic acid)
2877291|NCT03408652|No Intervention|Arm B|no specific treatment
2877292|NCT03408639|Experimental|CinnaPoietin®|"The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.~In addition to main intervention, Nephrovit tablet/day and vitamine B12 100 mcg/month will be prescribed for patients."
2877293|NCT03408639|Active Comparator|Eprex®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response. In addition to main intervention, Nephrovit tablet/day and vitamine B12 100 mcg/month will be prescribed for patients.
2877294|NCT03408626|Experimental|papain chemomechenical caries removal agent (brix 3000)|papain chemomechenical caries removal agent (Birx 3000) and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action
2877295|NCT03408626|Placebo Comparator|conventional|conventional 330 bur
2877296|NCT03408613|Experimental|Positive Airway Pressure (PAP)|A registered polysomnographic technologist will perform a titration starting at 4 cm water (H2O) and adjust this value as needed to identify the optimal pressure to achieve an Apnea Hypopnea Index (AHI) <5 (including rapid eye movement sleep in the supine position). After PAP titration, subjects will be instructed to use the machine at the optimal pressure every night for 3 months. Compliance will be defined as: ≥4 hours use on 70% of nights and average use ≥6 hours per night.
2877321|NCT03408392|Experimental|Reference followed by Test Formulation|Subjects will be randomized to receive single dose of Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 1 and Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
2877297|NCT03408613|Experimental|Supplemental Oxygen (O2)|Subjects randomized to night-time supplemental oxygen will complete an overnight oxygen titration protocol in the clinical research unit. Initially, subjects will receive 0.5 liters oxygen (O2)/min; the delivery rate will then be increased by 0.5 l/min until oxygen saturation (SaO2) is ≥88%. The optimal O2 delivery rate determined during this study will be used for the intervention. The oxygen concentrators used at home will record cumulative hours of use to provide an objective measure of adherence (monitored weekly). Compliance will be defined as ≥6 h average use per night..
2877298|NCT03408613|Sham Comparator|Sham|Subjects in the sham treatment group will complete the oxygen titration protocol described for the night-time supplemental oxygen group, except that their oxygen concentrator will have been covertly modified to deliver room air at a rate of 0.5 l/min.
2877299|NCT03408613|No Intervention|Controls|Subjects without OSA will be recruited and complete all testing for primary outcome measures, but will not undergo any intervention.
2877300|NCT03408587|Experimental|CVA21 / Ipilimumab|Subjects will receive up to 8 cycles (Day 155) of intravenous CVA21 and 4 doses of ipilimumab (Days 8, 29, 50 and 71).
2877301|NCT03408574|Experimental|Older Adults|Healthy adults aged 65-75 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, placebo and perform a working memory task during the fMRI. BOLD signal is the outcome measure.
2877302|NCT03408574|Experimental|Younger Adults|Healthy adults aged 18-30 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, or placebo and perform a working memory task during the fMRI.BOLD signal is the outcome measure.
2877303|NCT03408561|Experimental|Health Services Research (message via Twitter)|Patients who mention specific cancer disease keywords and/or hashtags are identified and receive a message via Twitter. Patients are then contacted for recruitment into a clinical trial.
2877304|NCT03408548|Placebo Comparator|Placebo|Scaling root planning + two lozenge per day not containing Bifidobacterium animalis lactis HN019 for 30 days.
2877305|NCT03408548|Experimental|Probiotic|Scaling root planning + two lozenge per day containing Bifidobacterium animalis lactis HN019 (10x9 colony-forming units) for 30 days.
2877306|NCT03408535|Other|Eriksholm Guide to Better Hearing|The Eriksholm Guide to Better Hearing is an online rehabilitation program. The program is made up of 5-weekly modules that cover different topics. Each module includes self-studies, training, and professional video coaching in hearing loss, hearing aids, and communication strategies.
2877307|NCT03408509|Experimental|Cognitive training|
2877308|NCT03408496|Experimental|Myofascial release|"Eight consecutive weekly sessions lasting 40-45 minutes of myofascial release of the trunk physiological chains. The connective tissue of the flexion chain and the posterior static chain will be released. The myofascial release will be obtained through the mechanical effect produced by the friction of the therapist's hand with a surface of the patient's body, which is performed through traces executed with the fingers (thumb supported or middle finger on the indicator to achieve effect local) following as addressed chains. The release will be repeated until the feeling of local relaxation of the tissue."
2877309|NCT03408496|Experimental|Muscle Stretching|The muscle stretching protocol described by Bressan (2008) will be followed, which consists of 8 consecutive weekly sessions, lasting 40-45 minutes. In dorsal decubitus or sitting, the triceps surae, hamstring, gluteal, paravertebral, latissimocondyloideus, pectoral, trapezius and respiratory muscles will be stretched. The exercises will be performed in a series of five repetitions for 30 seconds.
2877310|NCT03408496|Active Comparator|Control|It will perform only the treatment prescribed by the responsable doctor, wich can be the use of drug and/or psychological treatment, and will be followed clinically by a rheumatologist during four medical appointments to monitor medication and follow in the analgesic's diary, according the standard procedure of attending the hospital where the patients will be recruited.
2877311|NCT03408483|Experimental|quadratus lumborum block (QLB)|"Patients will be placed in the lateral decubitus position w/non-operative side recumbent. Pillow or blankets will be placed btw patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.~Standard skin sterilization, prepping and draping will be applied to the area. Under ultrasound guidance, needle will be advanced to posterior border of quadratus lumborum muscle. After negative aspiration, a bolus of 40 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots.~After QLB is placed, patients will have THA under spinal anesthesia."
2877312|NCT03408483|Active Comparator|Standard of Care|"Patients will be placed in the lateral decubitus position with non-operative side recumbent. A pillow or blankets placed between patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.~Standard skin sterilization, prepping and draping applied to the area. Ultrasound probe used to identify quadratus lumborum muscle. No local anesthetic injected."
2877313|NCT03408470|Experimental|TD-1473 Oral Capsule & [14C]-TD-1473 IV bolus|Cohort 1 - One oral dose and IV bolus administered 1 hr after oral dose of TD-1473
2877314|NCT03408470|Experimental|[14C]-TD-1473 Oral Capsule|Cohort 2 - One oral dose
2877315|NCT03408431|Experimental|Group E|After the placement of Ambu® AuraGain™, blind intubation will be performed in patients assigned group E with neck extension positioning.
2877316|NCT03408431|Active Comparator|Group C|After the placement of Ambu® AuraGain™, blind intubation will be performed in patients assigned group E with neutral head and neck position.
2877317|NCT03408418|Experimental|L-PRF group|The use of autologous leucocyte- and platelet-rich fibrin in alveolar sockets after dental extraction.
2877318|NCT03408418|No Intervention|Control|Conventional tooth extraction without any bone substitute.
2877319|NCT03408405|Experimental|Acthar Gel treatment group|Participants will be treated with 'Acthar Gel 80 UNT/ML Injectable Solution'. Initial dose for week 1 will be 50% of 80 units, injected twice per week. Week 2 is 75% of 80 units, week 3 and throughout treatment period (6 months in total) will be 80 units/ml twice per week.
2877320|NCT03408392|Experimental|Test followed by Reference Formulation|Subjects will be randomized to receive single dose of Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 1 and Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
2877421|NCT03407664||Men Screened for AAA in England|Men invited into the NHS AAA Screening programme in England in the years 2013-2017.
2877322|NCT03408366|Experimental|Women having a Laparotomy|The first 10 patients enrolled will undergo skin closure with staples. The next 10 patients enrolled will undergo skin closure with a running subcuticular suture.to evaluate skin perfusion using the Spectrum NIR imaging system following intravenous injection of ICG in all patients. Patients will be assigned skin closure with either running subcuticular suture or skin staples in a sequential, nonrandomized fashion before the procedure. After the planned surgical procedure is complete, ICG will be injected intravenously. Video of the incision will be recorded. After skin closure is complete, a second intravenous bolus of ICG (same dose as previously injected) will be given. Video of the incision will again be recorded. Measurement of perfusion will subsequently be performed by video analysis at the previously described three predefined points along the incision after surgery is complete and again after skin closure.
2877323|NCT03408353||Breast cancer screening patients|Participants recruited at the time of their scheduled screening mammography appointment at the MDACC Breast Imaging Center will complete questionnaire, health measurements and biospecimen collection
2877324|NCT03408340|Experimental|Paravertebral Nerve Block|Participants in the experimental arm will undergo an anesthetic that includes the regional anesthetic technique, paravertebral nerve block.
2877325|NCT03408340|Active Comparator|Standard of Care Anesthesia|Participants in the control arm will undergo an anesthetic consistent with the standard of care.
2877326|NCT03408327|Experimental|Experimental group|"Wearable technology (fitness wristband & App)~4 times group activities (2 hr / each times)~LINE group interaction~Reminder and feedback form researcher"
2877327|NCT03408327|Active Comparator|Control group|"Wearable technology (fitness wristband + App)~Health promotion manual"
2877328|NCT03408314|Experimental|PediQUEST Response|"Weekly PediQUEST surveys are automatically assigned to parents and children (if 5 years old or older) and sent 48 hours prior to participant's usual clinic day~Once a PediQUEST survey is assigned, automated email reminders/app notifications are sent daily for two days~After 48 hours, unanswered or incomplete surveys are auto-submitted~PQ-feedback report generated automatically after a PQ Survey is answered~A pdf of the report is automatically emailed/available on mobile App to designated recipients~Will also receive oncology-PC integrated care through the Response team~Duration of follow-up: 18 weeks (2-week run-in period, followed by a 16-week post-randomization follow-up)"
2877329|NCT03408314|Other|Usual Cancer Care|"Will receive the usual cancer care provided at the participating sites~Will complete weekly PQ-Surveys (no feedback reports will be generated)~Can receive regular palliative care consultations following the site's usual referral procedures~Same follow-up (18 weeks)"
2877330|NCT03408301||Tourniquet deflation|Tourniquet deflation after insertion of the prosthetic components during total knee replacement arthroplasty under spinal anesthesia
2877331|NCT03408288||Nurses|
2877332|NCT03408288||Urologists|
2877333|NCT03408275||Pregnant women|Pregnant women enrolled in ALSPAC
2877334|NCT03408262|Active Comparator|Group A|Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
2877335|NCT03408262|Experimental|Group B|Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
2877336|NCT03408262|Experimental|Group C|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
2877337|NCT03408262|Experimental|Group D|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo
2877338|NCT03408262|Active Comparator|Group E|Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
2877339|NCT03408262|Experimental|Group F|Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
2877340|NCT03408262|Experimental|Group G|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
2877341|NCT03408262|Experimental|Group H|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54
2877342|NCT03408249|Experimental|IBD patients|IBD patients performing IBDoc calprotectin test and ease-of-use questionnaires
2877343|NCT03408236|Experimental|Botulax|Single dose
2877344|NCT03408236|Active Comparator|Botox|Single dose
2877345|NCT03408223|Active Comparator|total body irradiation|Patient receives preparative therapy including cyclophosphamide and total body irradiation (TBI) of 10 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
2877346|NCT03408223|Experimental|total marrow and lymphoid irradiation|Patient receives preparative therapy including cyclophosphamide and total marrow and lymphoid irradiation of 12-20 Gy on Days -8 through -2, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
2877347|NCT03408210|Active Comparator|total body irradiation|Patient receives preparative therapy including cyclophosphamide and total body irradiation (TBI) of 10 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
2877348|NCT03408210|Experimental|total marrow and lymphoid irradiation|Patient receives preparative therapy including cyclophosphamide and total marrow and lymphoid irradiation of 12 Gy on Days -6 through -2, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
2877349|NCT03408197|Experimental|EasyWarm|
2877350|NCT03408197|Active Comparator|BairHugger|
2877422|NCT03407651|Experimental|Part 1a|Coagulation Factor VIIa variant, 18 µg/kg by intravenous route
2877423|NCT03407651|Experimental|Part 1b|Coagulation Factor VIIa variant, 30 µg/kg by subcutaneous route
2877424|NCT03407651|Experimental|Part 2|Coagulation Factor VIIa variant, 30, 60, 90, 120 µg/kg by subcutaneous route
2877573|NCT03406546|Experimental|Group LMA|General anesthesia was applied using laryngeal mask.
2877351|NCT03408184|Active Comparator|Lumbar paravertebral group|After general anesthesia, the patient is placed prone. To establish the level of the block, we used US-counting of vertebrae. After determining the lumbar one level, the block performed at a parallel line 2 cm lateral to the spinous process, the transducer is moved until the corresponding transverse process is identified. Utilizing an in-plane approach from lateral to medial, a spinal needle is advanced until contact with the transverse process. The needle is withdrawn and redirected caudally under the transverse process helped by the loss of resistance technique. the solution is slowly injected after negative aspiration for blood.
2877352|NCT03408184|Active Comparator|The field block group|The ilioinguinal nerve block was done at one fingerbreadth from the anterior superior iliac spine in a line with the pubic tubercle, The injection was done after the bob of the needle after passing the external oblique aponeurosis and muscle and 5ml of the solution is injected. The rest of the solution is injected in the incision line.
2877353|NCT03408171|Active Comparator|19-gauge FNA needle|A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.
2877354|NCT03408171|Active Comparator|19-gauge FNB needle|A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
2877355|NCT03408158|No Intervention|HPA antigen and antibodies|Investigate the positive rate of HPA antibodies, the distribution and the specificity of HPA antigen and antibodies in Chinese blood disease patients.
2877356|NCT03408158|No Intervention|necessity of HPA antibodies screening|Investigate the connection between times of platelet transplantation and HPA antibody titer, which providing statistical data for evaluating the necessity and setting screening time and standards of HPA antibodies screening.
2877357|NCT03408158|Experimental|matched platlet infusion|Enable platelet donors'common HPA antigen to be typed and blood disease patients to be same type infusion of main HPA antigen as possible as early.The investigators compare the differences of platelet count between patients with same type infusion of main HPA antigen and not.
2877358|NCT03408145|Placebo Comparator|Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml and 1ml of Saline) comprising a total volume of 8.5ml fluid during one procedure.
2877359|NCT03408145|Active Comparator|Hyaluronic Acid & Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Hyaluronic Acid and 1ml Saline) comprising a total of 8.5mL fluid during one procedure.
2877360|NCT03408145|Active Comparator|Amniotic Tissue & Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Saline and 1ml Amniotic Tissue Allograft) comprising a total of 8.5mL fluid during one procedure.
2877361|NCT03408145|Experimental|Amniotic Tissue & Hyaluronic Acid|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Hyaluronic Acid and 1ml Amniotic Tissue Allograft) comprising a total of 8.5mL fluid during one procedure.
2877362|NCT03408132|Experimental|FE203799 25 mg|FE203799 25 mg subcutaneous injection
2877363|NCT03408119|Experimental|Group A|100g daily dried plum consumption, plus 800 IU vitamin D and 450 mg elemental calcium
2877364|NCT03408119|Experimental|Group B|50g daily dried plum consumption, plus 800 IU vitamin D and 450 mg elemental calcium
2877365|NCT03408119|Placebo Comparator|Group C|800 IU vitamin D and 450 mg elemental calcium
2877366|NCT03408093||Interferon beta-1b|Patients with CIS, RRMS or SPMS who had more than 6 months in treatment
2877367|NCT03408080|Experimental|Open Arm|All subjects will receive the same dosage throughout the study.
2877368|NCT03408054|No Intervention|Control group|No oxytocin desensitization (pretreatment), no nitroglycerin
2877369|NCT03408054|Active Comparator|Oxytocin desensitized - no nitroglycerin|Pretreated with oxytocin, no nitroglycerin exposure
2877370|NCT03408054|Active Comparator|Oxytocin desensitized - plus nitroglycerin|Pretreated with oxytocin followed by nitroglycerin exposure
2877371|NCT03408054|Active Comparator|Non oxytocin desensitized - plus nitroglycerin|No oxytocin pretreatment, followed by nitroglycerin exposure
2877372|NCT03408041||Alzheimer Disease|Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria
2877373|NCT03408028||Cognitive impairment|Geriatric patients with a cognitive impairment
2877374|NCT03408015|Experimental|Normal, asymptomatic non-lens wearers|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
2877375|NCT03408015|Experimental|Dry eye subjects, non-lens wearers|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
2877376|NCT03408015|Experimental|Contact lens wearers with discomfort|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
2877377|NCT03408002|No Intervention|control group|no intervention
2877378|NCT03408002|Experimental|Psychological intervention|"Psychological intervention using the Four elements technique elaborated by Shapiro and reported in M. Luber (2009) during a psychological consultation conducted the day before surgery."
2877379|NCT03407976|Experimental|Apatinib and Pembrolizumab, all patients|
2877380|NCT03407963|Experimental|Prostate cancer patients|
2877381|NCT03407950|Other|Group IPT+|2 sessions of IPT+ by week during 6 months
2877382|NCT03407950|Other|Control Group|group without specific therapy (Treatment as usual) but same number and duration of each sessions than IPT+
2877383|NCT03407937|Other|Intervention|Receiving the conditioned pain modulation intervention during the first session and receiving the placebo and the hypnosis or meditation interventions during the second session.
2877459|NCT03407365|Active Comparator|DVD Program|Weeks 1-10, subjects will not be prescribed exercise at home. If the DVD program shows to help participants in Group 1, the program and DVD will be provided to Group 2 participants
2877460|NCT03407352|Active Comparator|Passive Video Game Play|Participants will play video games in a seated position for 60 minutes.
2877574|NCT03406533|Experimental|Group F|Sedated with midazolam and fentanyl
2877384|NCT03407924|Experimental|Intervention aerobic exercise (AER)|Participants with traumatic brain injury (TBI) that are enrolled in a comprehensive rehabilitation program (R) will be engaged in an aerobic exercise program (AER). These participants will also receive standard rehabilitation which includes exercise within the physical therapy session. Given that the duration of the rehabilitative program is variable the period of AER training will be no less than 4 weeks and will not exceed 30 weeks. Activity levels will be monitored.
2877385|NCT03407924|Active Comparator|rehabilitation (R)|Participants with traumatic brain injury that are enrolled in a comprehensive rehabilitation program. These participants will receive standard rehabilitation. Given that the duration of the rehabilitative program is variable the duration of participation will be no less than 4 weeks and will not exceed 30 weeks. Activity levels will be monitored.
2877386|NCT03407924|No Intervention|control (C)|Healthy volunteers' responsiveness to exercise and activity levels will be determined to detect TBI effects.
2877387|NCT03407911||Peri-implant microbiota|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
2877388|NCT03407911||Periodontal pocket microbiota|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
2877389|NCT03407911||healthy teeth|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
2877390|NCT03407898||C-mac D blade used for intubation|
2877391|NCT03407898||mcgrath X blade used for intubation|
2877392|NCT03407885|Experimental|Experimental|Bundled payments for knee and hip replacement
2877393|NCT03407885|No Intervention|Control|No intervention
2877394|NCT03407872|Experimental|PART A|6 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.
2877395|NCT03407872|Experimental|PART B|4 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.
2877396|NCT03407872|Experimental|PART C|4 cohorts will receive multiple dose of Esketamine DPI in two weeks' time administered with dose escalation between cohorts.
2877397|NCT03407872|Placebo Comparator|PART C placebo|4 cohorts will receive multiple dose of matching placebo in two weeks' time.
2877398|NCT03407859|Experimental|Sequential therapy with different CART|Sequential therapy With different CART including one kind of CD20/CD22/CD10-CART After CD19-CART therapy in CD19-negative relapse ALL patients, subjects will receive 1-5 x 10^6/Kg transduced CAR T cells at one time.
2877399|NCT03407846|Active Comparator|Total laparscopic hystrectomy|
2877400|NCT03407846|Experimental|Total abdominal hystrectomy|
2877401|NCT03407833||Obese, surgery|Obese subjects recruited from the Center for Surgical Weight loss who are undergoing weight loss surgery as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at surgical visits.
2877402|NCT03407833||Obese, nonsurgery|Obese subjects recruited from the Vanderbilt Endoscopy Clinic who are undergoing upper endoscopy or colonoscopy as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at day of procedure.
2877403|NCT03407833||Lean control|Lean control subjects recruited from the Vanderbilt Endoscopy Clinic who are undergoing upper endoscopy or colonoscopy as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at day of procedure.
2877404|NCT03407820|Active Comparator|1st random 50% of cohort|Absorbable Chromic gut sutures
2877405|NCT03407820|Active Comparator|2nd random 50% of cohort|Non-absorbable Nylon sutures
2877406|NCT03407794|No Intervention|Control|Participants randomized into the control group will be asked to follow their usual diet during the 6 weeks of the intervention.
2877407|NCT03407794|Experimental|Fermented vegetable|Participants randomized into the fermented vegetable group will receive 1/2 cup per day of fermented vegetables, including cabbage, carrots or pickles, for 6 weeks.
2877408|NCT03407794|Active Comparator|Non-fermented vegetable|Participants randomized into the non-fermented vegetable group will receive 1/2 cup per day of non-fermented vegetables, including cabbage, carrots or pickles, for 6 weeks.
2877409|NCT03407781|Experimental|68Ga-BBN-IRDye800CW PET/NIRF|The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 or 2.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.
2877410|NCT03407768|Other|Individualized interventions|Exercise, Yoga, massage therapy, acupuncture, and others
2877411|NCT03407755|Active Comparator|Air|Intraocular 100% atmospheric air (anterior chamber).
2877412|NCT03407755|Experimental|SF6|Intraocular 20% sulphur hexaflouride (anterior chamber).
2877413|NCT03407742|Experimental|Intervention|CAPAS Youth Parenting Intervention
2877414|NCT03407742|No Intervention|Wait-list control|Participants allocated to this condition were offered the parenting intervention until all T2 assessments of the intervention arm were completed
2877415|NCT03407729||Post-hypoxic former preterm|Born in the years 2005-2009 with birth gestational age between 23-28 weeks and birth weight appropriate for gestational age (AGA). Part of a research cohort with available oxygen saturation level data recorded continuously from the first day of life to 8 weeks postnatal age (n=20).Children will undergo Magnetic Resonance Imaging, Electroencephalography, and Cognitive Performance Testing.
2877416|NCT03407729||Healthy term-born children|Born in the years 2005-2009 with birth gestational age ≥ 38 weeks gestation and birth weight appropriate for term gestation (n=10) matched by age/sex/race to participating cohort children with no history of respiratory difficulty suggesting hypoxic exposure. Children will undergo Magnetic Resonance Imaging, Electroencephalography, and Cognitive Performance Testing.
2877417|NCT03407716|Experimental|Group I (North American ginseng extract AFX-2)|Patients receive North American ginseng extract AFX-2 PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2877418|NCT03407716|Placebo Comparator|GROUP II (placebo)|Patients receive placebo PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. At the end of course 2, patients may optionally crossover to Group I to receive ginseng for an additional 28 days.
2877419|NCT03407690||PIN2 study participants|All those giving swabs for the study
2877420|NCT03407677|Other|ROTO Track|The individual patient will serve as his/her own control before intervention with ROTO Track
2877425|NCT03407638|Active Comparator|PROUD Intervention|Primary care clinics randomized to the PROUD Intervention will implement the Massachusetts (MA) Model of collaborative care for opioids use disorders (OUDs). The PROUD trial provides financial support to cover the nurse case manager (NCM) salary and technical assistance for the duration of the study, but the health systems—not investigators—implement the MA Model as part of quality improvement, and the health system and its clinicians provide all clinical care.
2877426|NCT03407638|No Intervention|Usual Primary Care|Clinics randomized to usual primary care do not receive any resources or support from the study but are free to improve opioid use disorder (OUD) care in any way they choose.
2877427|NCT03407625|Experimental|Foley bulb plus Oral Misoprostol|Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
2877428|NCT03407625|Active Comparator|Oral Misoprostol|Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
2877429|NCT03407612|Active Comparator|CPM|These subjects received a continuous passive motion (CPM) device and were instructed to use it for 4-6 hours daily throughout the first two postoperative weeks following their arthroscopic labral repair. They were provided adequate education on how to operate the device. The subjects recorded their average usage of the CPM, as well as their personal perception of the CPM, at the postoperative 2 day, 7 day, and 14 day marks.
2877430|NCT03407612|No Intervention|No CPM|No CPM was administered to these subjects.
2877431|NCT03407599|Experimental|Faster aspart followed by insulin aspart (NovoRapid®)|Participants will receive single dose of fast-acting insulin aspart followed by single dose of NovoRapid® on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days.
2877432|NCT03407599|Experimental|Insulin aspart (NovoRapid®) followed by faster aspart|Participants will receive single dose of NovoRapid® followed by single dose of fast-acting insulin aspart on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days.
2877433|NCT03407586|Other|Diagnostic STI care|All participants underwent point-of-care STI testing, and if diagnosed with a STI were offered immediate therapy, and expedited therapy if indicated.
2877434|NCT03407573|Active Comparator|Restrictive|Restrictive transfused when Hb at or below 70
2877435|NCT03407573|Active Comparator|Liberal|Will receive blood transfusion when Hb drops below or equal to 90
2877436|NCT03407560|Experimental|SintLife|Use of SintLife putty as bone substitute for spinal fusion in lumbar spine surgery for degenerative diseases.
2877437|NCT03407521|Active Comparator|study group|misoprostol tab 200mcg 2 tab at first then one every 4 hours with isosorbide mononitrate 20mg once
2877438|NCT03407521|Placebo Comparator|control group|misoprostol tab 200mcg 2 tab at first then one every 4 hours with placebo
2877439|NCT03407508|Placebo Comparator|Baseline|No dietary changes.
2877440|NCT03407508|Placebo Comparator|Comparison of Diets|Okinawan-based Nordic Diet or Control Diet.
2877441|NCT03407495|Experimental|single arm: IOP injection|single group treatment
2877442|NCT03407482|Experimental|GDC-0853|Participants will receive GDC-0853 twice daily (BID) for 48 weeks, followed by a safety follow-up period of 8 weeks.
2877443|NCT03407469||Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE).
2877444|NCT03407443|Experimental|Exposure to Make the Connection messages|
2877445|NCT03407443|Active Comparator|Active Control group|
2877446|NCT03407443|No Intervention|No exposure control group|
2877447|NCT03407430|Experimental|Pregabalin, then Placebo|"Pregabalin in cycle 1; placebo in cycle 2.~Pregabalin or matching placebo will be administered at 75 mg twice a day (BID) for 4 days, to patients receiving pegfilgrastim for hematologic malignancies or breast cancer patients on myelosuppressive chemotherapy . Starting the day of pegfilgrastim, the dose of study medication will be increased to 150 mg PO BID provided the patient is tolerating the lower dose (ie, they are not experiencing any pregabalin associated toxicities >Grade 1). This will be determined by the research team on the day of pegfilgrastim administration."
2877448|NCT03407430|Experimental|Placebo, then Pregabalin|"Placebo in cycle 1; pregabalin in cycle 2.~Pregabalin or matching placebo will be administered at 75 mg BID for 4 days, to patients receiving pegfilgrastim for hematologic malignancies or breast cancer patients on myelosuppressive chemotherapy . Starting the day of pegfilgrastim, the dose of study medication will be increased to 150 mg PO BID provided the patient is tolerating the lower dose (ie, they are not experiencing any pregabalin associated toxicities >Grade 1). This will be determined by the research team on the day of pegfilgrastim administration."
2877449|NCT03407417|Experimental|Fit Testing|Patients who self selected to receive FIT screening after interaction with the Application
2877450|NCT03407417|Active Comparator|Non-FIT testing|Patients who elected not to have FIT testing after interaction with the application
2877451|NCT03407404|Experimental|Ketamine-midazolam|Continous intravenous sedation with a colorless drug mixture in 50ml syringe containing 900mg ketamine and 36mg midazolam.
2877452|NCT03407404|Active Comparator|Morphine-Midazolam|Continous intravenous sedation with a colourless drug mixture in 50ml syringes containing 54mg morphine and 36mg midazolam.
2877453|NCT03407391||Picky eater|Identified as a very picky eater from parental questionnaire
2877454|NCT03407391||Not a picky eater|Identified as not a picky eater from parental questionnaire
2877455|NCT03407391||Somewhat picky eater|Identified as a somewhat picky eater from parental questionnaire
2877456|NCT03407378|Experimental|Assessments ON regular PD treatment|IPT803 Questionnaires Motor assessments on regular PD treatment Optional pharmacogenetic assessments Optional Blood-Oxygen-level Dependent Functional-MRI
2877457|NCT03407378|Experimental|Assessments OFF regular PD treatment|IPT803 Questionnaires Motor assessments before taking regular PD treatment Optional pharmacogenetic assessments Optional Blood-Oxygen-level Dependent Functional-MRI
2877458|NCT03407365|Experimental|Home Exercises|Patients will be given a set of home exercises to perform as part of their rehabilitation home exercise program. They will be initially trained by a research team member and will be given a DVD home exercise video with instructions on how to perform the exercises.
2877461|NCT03407352|Experimental|Active Video Game Play|Participants will play dance dance revolution (video game that requires lower body movement) for 60 minutes.
2877464|NCT03407326|Experimental|Alternative|Participants will receive approximately 190 kcal/kg/day of alternative RUTF till recovery or up to 12 weeks of treatment.
2877465|NCT03407326|Active Comparator|Standard|Participants will receive approximately 190 kcal/kg/day of standard RUTF till recovery or up to 12 weeks of treatment.
2877466|NCT03407313|Experimental|Rotational fractional resection|Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
2877467|NCT03407300|Active Comparator|Docetaxel|Stage III-IV NSCLC patients who failed first-line chemotherapy will be treated with Docetaxel alone.
2877468|NCT03407300|Active Comparator|Docetaxel plus XH1|Stage III-IV NSCLC patients who failed first-line chemotherapy will be treated with Docetaxel plus Chinese traditional medicine XH1.
2877469|NCT03407287|Experimental|Systemic inflammatory response syndrome|
2877470|NCT03407287|Experimental|Distributive shock|
2877471|NCT03407287|Experimental|Vasoactive and inotropic agents|
2877472|NCT03407287|Experimental|Decompensated congestive heart failure|
2877473|NCT03407287|Experimental|Atrial fibrillation|
2877474|NCT03407287|Experimental|Patients undergoing high risk non-cardiac surgery|
2877475|NCT03407287|Experimental|Healthy Subjects|
2877476|NCT03407261|Experimental|Micro-osteoperforations|Minimally invasive micro-osteoperforations procedure used to achieve accelerated orthodontic tooth movement. Topical and local anesthetic will be delivered in the area to be treated in accordance with standard practice
2877477|NCT03407261|No Intervention|Control|Anterior retraction after premolars extraction will be done conventionally (sliding mechanics)
2877478|NCT03407235|Other|Laparoscopic Novices|"Four laparoscopic task will be undertaken on a computerized laparoscopic trainer and box trainer with eye patch.~Time to completion is recorded."
2877479|NCT03407222|Active Comparator|Intervention group|Intervention group receives weekly text messages which encourage the increment of daily step count
2877480|NCT03407222|No Intervention|Control group|Control group does not receive text message
2877481|NCT03407209|Sham Comparator|PEIB - Use of local levobupivacaine anesthetics: 0.625 mg / ml|"automatic hourly bolus: 8ml (5mg) on 3 min~patient controlled bolus: 8ml (5mg) on 3 min~refractory period: 8min~continuous infusion: 0~maximum dose: 65mg/4h"
2877482|NCT03407209|Experimental|FREE programming - levobupivacaine anesthetics: 0.625 mg / ml|"Epidural analgesia totally controlled by the patient~automatic hourly bolus: 0~patient controlled bolus: 8ml (5mg) on 3 min~refractory period: 8min~continuous infusion: 0~maximum dose: 65mg/4h"
2877483|NCT03407183||spastic neurogenic bladder|intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) in patients with spastic neurogenic bladder is 200 U of onabotulinumtoxinA once, then follow up after three months.
2877484|NCT03407170|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion every 3 weeks (Q3W) for up to 24 months
2877485|NCT03407157|Experimental|Intervention|Probiotic supplementation
2877486|NCT03407157|Placebo Comparator|Control|Placebo
2877487|NCT03407144|Experimental|Pembrolizumab + AVD (Group 1)|After receiving 2 4-week cycles of ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) induction therapy, SER participants in Group 1 will receive pembrolizumab 2 mg/kg up to a maximum of 200 mg (3 to 17 years of age) or 200 mg (18 to 25 years of age) on Day 1 of each 3-week cycle (Q3W) in combination with 2 cycles of AVD chemotherapy (doxorubicin 25 mg/m^2, vinblastine 6 mg/m^2 and dacarbazine 375 mg/m^2 on Days 1 and 15; cycle frequency every 4 weeks [Q4W]). All SERs in Group 1 will receive radiotherapy (RT) after completing AVD chemotherapy.
2877488|NCT03407144|Experimental|Pembrolizumab + COPDAC-28 (Group 2)|After receiving 2 4-week cycles of OEPA (vincristine, etoposide/etopophos, prednisone/prednisolone and doxorubicin) induction therapy, SER participants in Group 2 will receive pembrolizumab 2 mg/kg up to a maximum of 200 mg (3 to 17 years of age) or 200 mg (18 to 25 years of age) Q3W, in combination with 4 cycles of COPDAC-28 chemotherapy (cyclophosphamide 500 mg/m^2 on Days 1 and 8, vincristine 1.5 mg/m^2 with maximum single dose 2 mg on Days 1 and 8, prednisone/prednisolone 40 mg/m^2/day divided in 3 doses on Days 1 to 15, dacarbazine 250 mg/m^2 on Days 1 to 3; cycle frequency Q4W). SERs in Group 2 will receive RT if they have a positive Positron Emission Tomography (PET) response after completing COPDAC-28 chemotherapy.
2877489|NCT03407131|Experimental|Joint replacement|Intertrochanteric fracture patients were treated with joint replacement surgery.The postoperative drainage volume, blood transfusion volume, intraoperative blood loss, operative time, early weight bearing time will be recorded, and postoperative pulmonary infection, urinary tract infection, bedsore incidence and postoperative functional rehabilitation will be observed.
2877490|NCT03407131|Active Comparator|Intramedullary nail fixation|Intertrochanteric fracture patients were treated with intramedullary nail fixation surgery.The postoperative drainage volume, blood transfusion volume, intraoperative blood loss, operative time, early weight bearing time will be recorded, and postoperative pulmonary infection, urinary tract infection, bedsore incidence and postoperative functional rehabilitation will be observed.
2877491|NCT03407118|Experimental|LY900014|LY900014 administered subcutaneously (SC) in one of two study periods.
2877492|NCT03407118|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro administered SC in one of two study periods.
2877493|NCT03407105|Experimental|Arm 2|Specified dose on specified days
2877494|NCT03407092||Stentriever Cohort|
2877495|NCT03407092||ADAPT cohort|
2877496|NCT03407079|Experimental|Study Arm 1|Participants will receive sucralose capsules (approximately 4mg/kg/day) by mouth for 28 days.
2877497|NCT03407079|Placebo Comparator|Study Arm 2|Participants will receive placebo capsules by mouth for 28 days.
2877498|NCT03407066||1|200 in-person participants and up to 10,000 on-line volunteers.
2877499|NCT03407053||1|Adult men and women
2877500|NCT03407040||Patients|Patients with a cancer diagnosis
2877501|NCT03407027|Experimental|Quadratus triamcinolone|Quadratus lumborum muscle and fascia infiltration with 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
2877502|NCT03407027|Experimental|Gluteus triamcinolone|Gluteus maximus and fascia infiltration with 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
2877503|NCT03407027|Active Comparator|Quadratus without triamcinolone|Quadratus lumborum muscle and fascia infiltration with 10ml of levobupivacaine 0,25%.
2877540|NCT03406780|Experimental|CAP-1002|Patients will receive 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for a total of 4 doses.
2877504|NCT03407001|Experimental|Ultrasound + Lumason|"Participant has a standard ultrasound performed on abdomen without using a contrast agent.~Participant then has another ultrasound performed in the same way. However, before this ultrasound, the contrast agent Lumason injected into arm vein.~The 2 ultrasounds take about an hour to complete."
2877505|NCT03406988|Experimental|Autologous fat grafting|Implantation of 0.5-1 ml of autologous AT at the base of the finger with DU.
2877506|NCT03406988|Placebo Comparator|Sham procedure|False liposuction followed by the injection of 0.5-1 ml of 0.9% saline solution at the base of the affected finger.
2877507|NCT03406975|Placebo Comparator|Control Group|Participants randomized to the control group (lifestyle intervention only) in Year 1 will undergo a standard moderate intensity life-style intervention during the first 12 months of participation. Control group participants who were compliant with at least 75% of visits in Year 1, have not achieved ≥25% EWL measured at the week 52 visit, and have no new psychosocial contraindications as deemed by the treatment team to the procedure will cross over to receive the Overstitch ESG in Year 2, in addition to the standard moderate intensity lifestyle intervention program for 12 months.
2877508|NCT03406975|Active Comparator|Treatment Group|Participants randomized to the treatment group will proceed to have the Overstitch ESG at the start of Year 1 and will undergo a standard moderate intensity life-style intervention during the first 12 months of participation. All patients undergoing ESG will go on a 6 weeks transitional diet.ESG patients will undergo a standard moderate intensity life-style intervention administered over 15 12 visits in the first year after ESG. All ESG patients in Year 1 will undergo a repeat upper endoscopy at 52 to 60 weeks to assess the durability of the plications. Patients will continue follow-up with a modified lifestyle intervention program administered over 6 visits in the second year
2877509|NCT03406962|Experimental|MGTA-456|MGTA-456 is an expanded umbilical cord blood product used during single umbilical cord blood transplantation.
2877510|NCT03406949|Experimental|MGD009 + MGA012|B7-H3 x CD3 DART protein + anti-PD-1 antibody
2877511|NCT03406936|Active Comparator|Daily interruption of sedation|Daily interruption of sedation will be done at 7 am daily by stoppage of midazolam infusion
2877512|NCT03406936|No Intervention|No Sedation|No sedation will be given after initiation of mechanical ventilation
2877513|NCT03406923|No Intervention|Usual care|Receive usual care only.
2877514|NCT03406923|Experimental|Health literacy-psychosocial support|Receive 6-week sessions of individual health literacy-psychosocial support in addition to usual care. The health literacy-psychosocial support intervention includes 45-minute face-to-face counseling at week 1 and week 6 as well as weekly phone calls (week 2 to week 5.)
2877515|NCT03406910||Seventh day Adventist adults|Seventh day Adventist adults recruited from the USA and Canada. Approximately 65% female and 35% male. Composed of participants with different dietary patterns and a wide variation in egg and meat intake ranging from non-consumptive to daily consumption.
2877516|NCT03406897|Active Comparator|Omega-3 and Vitamin D Combination|The treatment arm A includes Omega-3 Fatty Acids and Cholecalciferol (Vitamin D) supplement.
2877517|NCT03406897|Active Comparator|Vitamin D Only|The treatment arm B (control group) will receive only Cholecalciferol (Vitamin D) supplement.
2877518|NCT03406884|Experimental|Group A - c-kit+ cells|Group A - c-kit+ / Ten (10) subjects will be treated with c-kit+ cell treatment.
2877519|NCT03406884|Experimental|Group B - c-kit+ cells|Group B - c-kit+ / Five (5) subjects will be treated with c-kit+ cell treatment.
2877520|NCT03406884|Placebo Comparator|Group B - Placebo|Group B - Placebo / Ten (10) subjects will be treated with placebo.
2877521|NCT03406871|Experimental|Nivolumab + Regorafenib|Nivolumab and Regorafenib
2877522|NCT03406858|Experimental|Treatment (pembrolizumab, HER2Bi-armed activated T cells)|Patients receive pembrolizumab IV over 30 minutes every 3 weeks. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. Beginning at least 1 week after pembrolizumab, patients receive HER2Bi-armed activated T cells IV over 5-15 minutes 2 times a week for 4 weeks in the absence of disease progression or unacceptable toxicity.
2877523|NCT03406845|Experimental|Chair-side mindfulness intervention|Consists of individually conducted meditative practices, lasting 20 minutes/session, 3 times per week for 8 weeks. The interventions will be conducted during their dialysis sessions. The mindfulness meditation sessions include well-described meditations such as the body scan (being aware of bodily sensation), gentle arm movements, guided and silent breath meditations.
2877524|NCT03406845|Active Comparator|Health Enhancement Plan (HEP)|Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
2877525|NCT03406832|Experimental|Nitroprusside group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Nitroprusside Sodium via guide-catheter was performed. Then repeated administration of Nitroprusside Sodium was done prior to coronary stent implantation or post dilatation.
2877526|NCT03406832|Experimental|Tirofiban group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Tirofiban Hydrochloride via guide-catheter was performed.
2877527|NCT03406832|Placebo Comparator|Control group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of heparinized saline via guide-catheter was performed.
2877528|NCT03406819|Experimental|Nitroprusside group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Nitroprusside Sodium via guide-catheter was performed. Then repeated administration of Nitroprusside Sodium was done prior to coronary stent implantation or post dilatation.
2877529|NCT03406819|Experimental|Tirofiban group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Tirofiban Hydrochloride via guide-catheter was performed.
2877530|NCT03406819|Placebo Comparator|Control group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of heparinized saline via guide-catheter was performed.
2877541|NCT03406780|Placebo Comparator|Placebo|Patients will receive a placebo solution via intravenous infusion every 3 months for a total of 4 doses.
2877542|NCT03406767|Experimental|GLA:D Canada Program|GROUP 1: GLA:DTM CANADA GROUP (STANDARDIZED EXERCISE PROGRAM)
2877543|NCT03406767|Experimental|JointEffort Program|GROUP 2: JOINTEFFORT GROUP (INDIVIDUALIZED EXERCISE PROGRAM)
2877544|NCT03406754||Ezera LaMarpeh rehabilitation programs|Participation in a rehabilitation program for 8 weeks
2877545|NCT03406741|Experimental|Child with Hirschsprung's disease|Neuropsychological assessment at elementary school
2877546|NCT03406728|Active Comparator|PDSAFEX GROUP|Parkinson's Disease Sensory Attention Focused Exercise (PDSAFEX) is an exercise intervention developed in light of research which focuses on utilizing sensory integration and proprioception to improve balance. This intervention will be administered to one group of my participants. The protocol will be followed and led by trained volunteers.
2877547|NCT03406728|Active Comparator|CONTROL GROUP|The control group in this study will be asked to maintain their daily lifestyle as closely as possible for the 12-week duration of the study.
2877548|NCT03406728|Experimental|VIRTUAL REALITY GROUP|Virtual reality intervention will be assigned to this group. They will complete activities aimed at improving their dynamic balance. These activities are specifically developed based on previous literature and geared towards mirroring day to day activities/scenarios that individuals with PD may come into contact with.
2877549|NCT03406715|Experimental|Combination Immunotherapy Plus Vaccine|Combination immunotherapy with Ipilimumab and Nivolumab plus a Dendritic Cell based p53 Vaccine (Ad.p53-DC). Induction Immunotherapy, followed by Maintenance Immunotherapy and potentially Retreatment. During retreatment, participants would receive the combination of Ipilimumab and Nivolumab or Nivolumab alone every three weeks for a maximum of one additional year.
2877550|NCT03406702|Experimental|CX-8998|T-type calcium channel blocker
2877551|NCT03406689|Active Comparator|Nepafenac 0.1% Oph Susp|One drop of Nepafenac 0.1% will be administered 45' prior to the injection
2877552|NCT03406689|Active Comparator|Nepafenac 0.3% Oph Susp|One drop of Nepafenac 0.3% will be administered 45' prior to the injection
2877553|NCT03406689|Placebo Comparator|Artificial tears|One drop of Artificial Tears will be administered 45' prior to the injection
2877554|NCT03406676|Experimental|Methylene blue|2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.
2877555|NCT03406676|No Intervention|saline|50ml of saline is administrated I.V before anesthesia induction.
2877556|NCT03406663|Experimental|Group 1|"In group 1, the dose of Gla-300 will be titrated by the patients by 1 unit per day until achieving a fasting SMPG in the target range of 4.4 to 5.6 mmol/L (INSIGHT algorithm).~Titration algorithms:~Patients will be instructed to daily adjust their dose of Gla-300 based on fasting SMPG values. Fasting SMPG will be measured daily by the patient before breakfast and any intake of antihyperglycemic agents.~Fasting SMPG in the range of~≥ 5.6 mmol/L, increase 1 unit of Gla-300 dose~> 4.4 and ≤ 5.6 mmol/L, no change~< 4.4 mmol/L, reduce 1 unit of Gla-300 dose"
2877557|NCT03406663|Active Comparator|Group 2|"In group 2, the dose of Gla-300 will be titrated by the patients based on the SMPG values of the last 3 days at least weekly, but no more often than every 3 days to achieve a fasting SMPG in the target range of 4.4 to 5.6 mmol/L (EDITION algorithm).~Fasting SMPG (median of the last 3 days including current day) in the range of~≥ 7.8 mmol/L, increase 6 units of Gla-300 dose~> 5.6 and < 7.8 mmol/L, increase 3 units of Gla-300 dose~> 4.4 and ≤ 5.6 mmol/L, no change~≥ 3.3 and < 4.4 mmol/L, reduce 3 units of Gla-300 dose~< 3.3 mmol/L or occurrence of ≥ 2 symptomatic or 1 severe hypoglycemic episode in the preceding week, reduce 3 units of Gla-300 dose or at the discretion of the investigator"
2877558|NCT03406650|Experimental|Durvalumab in combination with standard therapy|Combination of standard therapy consisting (4 cycles cisplatin/ gemcitabin followed by surgery) with 4 cycles of neoadjuvant durvalumab and 10 cycles of adjuvant durvalumab
2877559|NCT03406624||Spinal fusion with modic changes|Patients scheduled for surgery with lumbar spinal fusion with procedures involving moderate to extensive removal of the disc, and with modic changes seen on MRI at the actual level for surgery
2877560|NCT03406624||Spinal fusion without modic changes|Patients scheduled for surgery with lumbar spinal fusion with procedures involving moderate to extensive removal of the disc, but with no modic changes seen on MRI at the actual level for surgery
2877561|NCT03406624||Disc herniation surgery with modic changes|Patients scheduled for disc herniation surgery, and with modic changes seen on MRI at the actual level for surgery
2877562|NCT03406624||Disc herniation surgery without modic changes|Patients scheduled for disc herniation surgery, but with no modic changes seen on MRI at the actual level for surgery
2877563|NCT03406611|Active Comparator|Active drug|
2877564|NCT03406611|Placebo Comparator|Placebo|
2877565|NCT03406598||Patients in shock|Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
2877566|NCT03406585|Experimental|Allogeneic transplantation with WJMSCs (batch 1)|
2877567|NCT03406585|Experimental|Allogeneic transplantation with WJMSCs (batch 2)|
2877568|NCT03406585|Placebo Comparator|Sham transplantation (placebo)|
2877569|NCT03406572|Experimental|HFHO Group|Patients will receive a first NIV session (for 2 hours) with predefined parameters, and ABG will be performed between one and two hours of starting NIV. NIV will be extended according to ABG result (i.e. extended if pH < 7.30). Switch from NIV to oxygen will require predefined criteria. In-between each NIV session, oxygen will be delivered using a high flow nasal cannula, with a flow of 50-60L/min and a FiO2 set to reach a targeted SpO2: 88%≤SpO2 ≤ 92%. Predefined criteria will be used to resume NIV.
2877570|NCT03406572|Active Comparator|Standard O2 Group|NIV will be initiated based on the same criteria and with the same parameters as the HFHO group. ABG will also be performed between one and two hours and NIV extended according to ABG result (i.e. extended if pH < 7.30). Switch from NIV to oxygen will require the same predefined criteria as the HFHO group. In-between each NIV session, oxygen will be delivered using standard low flow O2 to reach the same targeted SpO2: 88% ≤SpO2 ≤ 92%. Similar criteria will be used to resume NIV
2877571|NCT03406559|Other|orthodontic treatment|fixed orthodontic treatment in adolescent males initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion.
2877572|NCT03406546|Experimental|Group DR|Patients sedated with dexmedetomidine and remifentanil.
2877645|NCT03406013|Active Comparator|Group I|Written Information
2877575|NCT03406533|Experimental|Group DR|Sedated with midazolam, dexmedetomidine and remifentanil
2877576|NCT03406533|Experimental|Group DF|Sedated with midazolam, dexmedetomidine and fentanyl
2877577|NCT03406533|Experimental|Group PR|Sedated with midazolam, propofol and remifentanil
2877578|NCT03406520|Experimental|Chlorhexidine-impregnated disk|The chlorhexidine-impregnated disk, will be applied to the peritoneal dialysis catheter exit-site and the disk will be changed once a week
2877579|NCT03406507|Experimental|ALXN1210|
2877580|NCT03406494|Experimental|intervention group|Early multicomponent physical therapy program plus sepsis standard therapy
2877581|NCT03406494|No Intervention|control group|Sepsis standard therapy, including early initiation of intravenous antibiotics, infection source debriding, appropriate fluid therapy, minimum sedation, protocolized weaning procedure, blood glucose control and early enteral feeding, etc.
2877582|NCT03406468|Experimental|Radiotherapy|Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
2877583|NCT03406455||Primary TKA|A cohort of 25 patients undergoing primary TKA for osteoarthritis at our hospital will be enrolled into the study, which will receive IRB approval and be registered on ClinicalTrials.gov and RedCap. Patients will download the mobile application onto their personal smartphones (iOS) to record baseline activity and PROMs in the 2-4 weeks leading up to surgery. During the hospital admission, the knee sleeve will be fitted to the patient. The patient cohort will be followed for three months and four data points (both passive and active) will be extracted from the dashboard: PROMs, mean daily steps, ROM (particular attention to 2 weeks postoperatively), and home exercise plan (HEP) compliance.
2877584|NCT03406442|Other|patients|The patient who have lesions affecting pterygopalatine fossa, lateral recess of the sphenoid sinus, petrous apex, Meckel's cave, cavernous sinus, infratemporal fossa and lateral nasopharynx and can be treated by endonasal endoscopic transptergoid approaches
2877585|NCT03406429|Experimental|PPA patients|All study participants will carry a diagnosis of Primary Progressive Aphasia (PPA), either the logopenic or the non-fluent variant. All participants will receive the same study interventions in a within-subject crossover design.
2877586|NCT03406416|Experimental|Suprachoroidal retinal prosthesis|Prototype wide view suprachoroidal retinal prosthesis
2877587|NCT03406403|Active Comparator|Laryngeal mask airway group|20 slips of papers will be taken and labeled as group L (LMA) These slips will be placed in an envelope and one slip will be raised for each patient.
2877588|NCT03406403|Active Comparator|Magensium sulphate group|20 slips of papers will be taken and labeled as group M (Mgso4) These slips will be placed in an envelope and one slip will be raised for each patient
2877589|NCT03406403|Active Comparator|Control group (closure of anesthetics)|20 slips of papers will be taken and labeled as group C (Control) These slips will be placed in an envelope and one slip will be raised for each patient.
2877590|NCT03406390||primary pterygium|Observe the contrast sensitivity of primary pterygium patients and healthy control by quick CSF methods, and the pterygium group would achieve the pterygium surgery by the same surgeon (Jin Yuan) and then be performed the contrast sensitivity test on the 1st, 3rd and 6th month postoperatively.
2877591|NCT03406377|Placebo Comparator|Placebo|
2877592|NCT03406377|Experimental|OPK-88003|
2877593|NCT03406364|Experimental|MG005|Cohort 1 :3 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours)] Cohort 2 :6 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours)] Cohort 3 :3 × 250 mgMG005+1 × 200 mgSorafenib; 3 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours); 8:00 PM (±2 hours)]
2877594|NCT03406351||Asthma|
2877595|NCT03406351||Healthy|Matched controls
2877596|NCT03406338|Active Comparator|Surgical fasciectomy|Fasciectomy according to usual care (surgery), implying excision of Dupuytren's cords and tissues to release the finger joint contractures
2877597|NCT03406338|Experimental|Collagenase Clostridium Histolyticum|Injection of 0.8 mg collagenase clostridium histolyticum into multiple spots in the Dupuytren cords followed by finger manipulation 1-2 days later to release the finger joint contractures
2877598|NCT03406325||urticaria|Patients with this condition
2877599|NCT03406325||asthma|Patients with this condition
2877600|NCT03406325||eczema|Patients with this condition
2877601|NCT03406325||food allergy|Patients with this condition
2877602|NCT03406325||anaphylaxis|Patients with this condition
2877603|NCT03406325||mastocytosis|Patients with this condition
2877604|NCT03406325||mast cell activating syndrome|Patients with this condition
2877605|NCT03406312||Gastric Bypass Surgery population|liquid mixed meal tolerance test, solid mixed meal tolerance test, continuous glucose monitoring
2877606|NCT03406312||Control population|liquid mixed meal tolerance test, solid mixed meal tolerance test, continuous glucose monitoring
2877607|NCT03406299|Experimental|SLOG regimen|Arm 1 interventions : SLOG regimen: treatment for every 14 days as one cycle Tegafur (S-1) 35 mg/m2/b.i.d., day 1 - 7 (maximum dose: 120 mg/day) Leucovorin 30 mg/b.i.d., day 1-7; Oxaliplatin 85 mg/m2 in 250 mL of 5% Glucose, given as 2-hour intra- venous infusion, day 1; Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate (FDR, 10 mg/m2/min) infusion, day 1; After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin
2877608|NCT03406299|Active Comparator|GC regimen|Arm 2 interventions : GC regimen: treatment for every 21 days as one cycle Gemcitabine 1000 mg/m2 in 100 mL of normal saline, IV drip for 30 mins on D1 and D8 Cisplatin 25 mg/m2 in 250ml of normal saline, IV drip for 2 hours on D1 and D8
2877609|NCT03406273|Experimental|≥ 5 years of age|Cerebral Spinal (CS) radiation
2877610|NCT03406273|Experimental|< 5 yo and ≥ 3 yo and CSF +|Cerebral Spinal (CS) radiation
2877611|NCT03406273|Experimental|All < 3 yo & < 5 yo/≥ 3 yo CSF neg|Focal radiotherapy (SRS)
2877612|NCT03406260|Experimental|Lasmiditan Dose 1 (Treatment A)|Lasmiditan Dose 1 administered orally in one of three treatment periods.
2877613|NCT03406260|Experimental|Lasmiditan Dose 2 (Treatment B)|Lasmiditan Dose 2 administered orally in one of three treatment periods.
2877614|NCT03406260|Placebo Comparator|Placebo (Treatment C)|Placebo administered orally in one of three treatment periods.
2877615|NCT03406247|Experimental|Nivolumab|Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months
2877616|NCT03406247|Experimental|Nivolumab + Ipilimumab|"Patients in cohorts 2 and 2bis will be administered~nivolumab 240 mg every 2 weeks during 6 months~ipilimumab 1mg/kg IV every 6 weeks during 6 months"
2877617|NCT03406234||A group of participants|
2877618|NCT03406221|Experimental|Intervention arm|
2877619|NCT03406221|Active Comparator|Control Arm|
2877620|NCT03406208|Experimental|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
2877621|NCT03406208|Experimental|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
2877622|NCT03406195|Experimental|healthy older adults|Healthy older adults who will receive TMS
2877623|NCT03406169|Active Comparator|Sildenafil 25mg Oral Tablet|25mg sildenafil citrate twice daily
2877624|NCT03406169|Active Comparator|Pentoxifylline|400mg pentoxifylline twice daily
2877625|NCT03406169|Placebo Comparator|Placebo|placebo twice daily
2877626|NCT03406156|Experimental|Obinutuzumab +/- bendamustine then obinutuzumab + venetoclax|"Debulking Period: Obinutuzumab with or without bendamustine (bendamustine administered in participants with high tumor load as described in the protocol) during the debulking period (up to 6 cycles).~Treatment Period: Venetoclax + obinutuzumab regimen initiated when participant achieves low tumor burden during debulking period, or if the participant has not achieved low tumor burden status after 6 cycles of debulking, the participant may proceed to venetoclax per the discretion of the treating provider after discussion with the study physician. During this regimen period, participants to receive obinutuzumab in combination with venetoclax for 5 months then venetoclax therapy alone to continue for a total duration of 52 weeks."
2877627|NCT03406143|Experimental|CGF injection group|Concentrate Growth Factors(CGF) will be harvested through centrifugation afte intravenous blood collection. Venous blood was collected in tube and then centrifuged in Medifuge system（Thermo Scientific）. About 2ml liquid CGF can be harvested from 9ml venous blood. Patients will receive autologous CGF injection subdermally to expanded skin at the density of 0.02 ml/cm2.
2877628|NCT03406143|Sham Comparator|Control group|0.9% saline will be injected into expanded skin for control study. Patients will receive saline injection subdermally to expanded skin at the density of 0.02 ml/cm2.
2877629|NCT03406130|Active Comparator|Insignia orthodontic treatment|
2877630|NCT03406130|Experimental|Piezocision-assisted Insignia orthodontic treatment|
2877631|NCT03406117|Experimental|HAT1-EPBF2|"CIT was conducted over a period of approximately 15 days for each subject to determine the irritation and/or sensitization potential of a test material(s) under occlusion by 14 repeated closed occlusive patch application every 24 hrs. A final grade was taken 24 hours following the last patch application.~PT was conducted over a period of approximately 6 days for each subject to determine the phototoxicity of the test product.~HRIPT was conducted over a period of approximately 6-8 weeks for each subject to confirm that the test substances will not produce evidence of delayed contact sensitization following external contact with the skin by means of a repeated patch application procedure."
2877632|NCT03406117|Experimental|HAT1-HMF3|"CIT was conducted over a period of approximately 15 days for each subject to determine the irritation and/or sensitization potential of a test material(s) under occlusion by 14 repeated closed occlusive patch application every 24 hrs. A final grade was taken 24 hours following the last patch application.~PT was conducted over a period of approximately 6 days for each subject to determine the phototoxicity of the test product.~HRIPT was conducted over a period of approximately 6-8 weeks for each subject to confirm that the test substances will not produce evidence of delayed contact sensitization following external contact with the skin by means of a repeated patch application procedure."
2877633|NCT03406117|Active Comparator|Saline Solution: Sodium Chloride|Saline, Sodium Chlorine (NaCl; 0.9%), was used as the negative irritant control in the CIT portion of the study
2877634|NCT03406091||Poor Mobilizer (PM) in Multiple Myeloma (MM) patients|
2877635|NCT03406078|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
2877636|NCT03406078|Placebo Comparator|Placebo|Placebo subcutaneous injection
2877637|NCT03406065|Experimental|Sodium bicarbonate supplementation|Group taking oral NaHCO3 supplementation in a progressive-dose regimen.
2877638|NCT03406065|Placebo Comparator|Placebo treatment|Group taking oral supplementation with placebo (maltodextrin with NaCl) in a similar tablet form prepared by the same producer as NaHCO3 tablets.
2877639|NCT03406052|Experimental|Smartphone-Assisted MB-CBT|Online intervention accessed through smartphone or online accessed computer comprised of Mindfulness-Based Cognitive Behaviour content
2877640|NCT03406052|No Intervention|Control|Standard psychiatric care
2877641|NCT03406039|Experimental|Integrated Online CBT and MI|Participants in this arm will be given access to the online integrated treatment.
2877642|NCT03406039|No Intervention|Psychoeducation (Control)|The control group will be provided with psychoeducational resources about alcohol and mental illness.
2877643|NCT03406026|Experimental|Balance System Protocol Stroke|Balance System Protocol Stroke differentiates 2 levels of difficulty in relation to the patient's condition and progressively according to their evolution. If the patient maintains stability in standing for at least 30 s, he starts in Level 2 and otherwise he will remain in Level 1 until he acquires it. In level 1 the progression of exercises is: 1.Pressure stimulation of the foot support points; 2.Proprioceptive ankle work; 3.Sit-to-stand work and vice versa; 4.Sit-to-stand work with delayed affection. In level 2, the progression of exercises is: 1.Standing unbalances; 2.Standing on Balance-pad; 3.Work to get monopodal support; 4.Balance pad in monopodal support; 5.Monopodal support work with closed eyes.
2877644|NCT03406026|Active Comparator|Control Stroke|The program of Control Stroke arm is based on an integral and rehabilitative approach in which the patient follows a personalized plan of exercises and therapies according to the deficits of each patient, the previous situation, the personal concerns with In order to perform a person-centered approach.
2877647|NCT03406013|Experimental|Group III|Written Information Prescription Technology
2877648|NCT03406013|Experimental|Group IV|Written Information Prescription Technology Coaching
2877649|NCT03406000|Experimental|Insulin glargine (U300)|Self-administered subcutaneously once daily in the morning, at the same time.The initial dose for patients switching from insulin glargine is 80% of the total daily dose of basal insulin agent that was discontinued. Thereafter, insulin glargine (U300) will follow a titration algorithm for dose adjustment.
2877650|NCT03405987||ECV < median|
2877651|NCT03405987||ECV ≥ median|
2877652|NCT03405974|Experimental|Aspirin|"Aspirin 100 mg~1 tablet/ day for 2 years"
2877653|NCT03405974|Placebo Comparator|Placebo|"Placebo~1 tablet/ day for 2 years"
2877654|NCT03405961||Manual PAR score|Patient will receive upper and lower impressions, which will be cast to produce plaster models. A calibrated individual will PAR score the casts in the traditional manner (regular care pathway)
2877655|NCT03405961||Direct digital PAR score|Patient will receive upper and lower intra-oral scans which will be PAR scored directly by the computer
2877656|NCT03405961||Indirect digital PAR score|Patient will receive upper and lower impressions which will be cast to produce plater models (regular care pathway). The casts will be scanned with Carestream 3600 intra oral scanner and scored digitally by the computer.
2877657|NCT03405948|Experimental|botulinum toxin|injection of Botulinum toxin
2877658|NCT03405948|Placebo Comparator|placebo|Injection of saline serum (placebo)
2877659|NCT03405935|Experimental|B/F/TAF FDC|B/F/TAF FDC for 48 weeks
2877660|NCT03405922|Placebo Comparator|Placebo|Placebo 40 mL Saline 0.9%
2877661|NCT03405922|Active Comparator|Ropivacain|40 mL Ropivacain 0.5%
2877662|NCT03405909||Patients at risk for HCC|"Patients with any of the following conditions:~liver cirrhosis of any origin chronic hepatitis B infection chronic hepatitis C infection with advanced fibrosis non-alcoholic steatohepatitis (NASH) hemochromatosis~Interventions: B-mode ultrasound, contrast enhanced ultrasound (CEUS); MRI / histology"
2877663|NCT03405896|Experimental|Normal subjects|
2877664|NCT03405883||RIF (women with repeated implantation failure)|Transfer of at least 5 good quality embryos in IVF or ICSI cycles, without achieving pregnancy
2877665|NCT03405883||NF (normal fertile women)|Spontaneous conception or conception after max 9 IUI cycles
2877666|NCT03405870|Experimental|Lipid|Infusion of drug (Smoflipid) will occur over a 16.5 hour period given once per day for the first two days of study enrollment.
2877667|NCT03405870|No Intervention|Control|Control patients will receive no experimental drug (ie, usual care)
2877668|NCT03405857|Experimental|Group 1|Cognitive rehabilitation program will be administered for 4 weeks, three times a week, 30 minutes a day
2877669|NCT03405857|No Intervention|Group 2|No intervention will be administered
2877670|NCT03405831|Active Comparator|Ivabradine|Study participants in this arm will receive ivabradin 5 mg bid for a period of 12 weeks.
2877671|NCT03405831|Placebo Comparator|Placebo|Study participants in this arm will receive placebo bid for a period of 12 weeks.
2877672|NCT03405818|Experimental|Tavaborole 5% Topical Solution|All study participants apply study drug
2877673|NCT03405805||3+1|Healthy infants will receive 4 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4,6 and 12 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
2877674|NCT03405805||3+0|Healthy infants will receive 3 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4 and 6 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
2877675|NCT03405805||2+1|Healthy infants will receive 3 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4 and 12 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
2877676|NCT03405792|Experimental|Optune System combined with Temozolomide (TMZ) + Pembrolizumab|Patients with newly-diagnosed GBM who undergo maximal safe resection (biopsy alone is eligible) followed by chemoradiation consisting of concomitant TMZ daily and radiation therapy (RT) with minimal RT will be eligible for this trial. Four to six weeks after finishing chemoradiation, patients will start monthly cycles of adjuvant TMZ. Treatment with Optune will start at approximately the same time as the first cycle of adjuvant TMZ and continue until second disease progression or a maximum of 2 years. Within one week after starting Cycle 2 of adjuvant TMZ and Optune therapy, patients will begin open-label treatment with pembrolizumab every 3 weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.
2877677|NCT03405792|Other|Historical Control|Historical control data of patients treated with Optune System combined with Temozolomide alone will be compared with the Optune System combined with Temozolomide (TMZ) + Pembrolizumab arm.
2877678|NCT03405753|Active Comparator|Aroia|
2877679|NCT03405753|Placebo Comparator|Placebo|
2877680|NCT03405740|Active Comparator|Remote Patient Management|Patients will be followed by remote monitoring only.
2877681|NCT03405740|Placebo Comparator|Standard of Care|Remote monitoring at 6 month intervals, alternating with yearly in-clinic visits at their usual site.
2877682|NCT03405727|No Intervention|Standard treatment|
2877683|NCT03405727|Experimental|Oral dietary supplements|
2877684|NCT03405714|Experimental|Brivaracetam|Brivaracetam will be administered to various age-based cohorts. Cohort 1: Subjects >=12 to <16 years; Cohort 2: Subjects >=6 to <12 years; Cohort 3: Subjects >=2 to <6 years; Cohort 4: Subjects 1 month to <2 years. Enrollment will be sequential by descending age beginning with Cohort 1. For each cohort, the first half will receive a 15-minute iv infusion. The Data Monitoring Committee (DMC) will then review safety and, as available, PK data to make the following recommendations: the progression of the current cohort (up to 2-minute iv bolus infusion) and progression to initiate enrollment in the preceding cohort.
2877685|NCT03405701|Active Comparator|IVM (in vitro maturation)|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred
2877721|NCT03405454|Experimental|durvalumab|Patients on durvalumab will be given at 1500mg fixed dose every 4 weeks for 24 months
2877686|NCT03405701|Active Comparator|IVF (in vitro fertilization)|Undergoing controlled ovarian hyperstimulation for in vitro Fertilization (IVF) with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist triggering will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
2877687|NCT03405688|Experimental|Acute transfusion|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
2877688|NCT03405688|Other|Control - Acute transfusion|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
2877689|NCT03405688|Experimental|Chronic transfusion|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
2877690|NCT03405688|Other|Control - Chronic transfusion|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
2877691|NCT03405688|Experimental|Transfusion prior to surgery|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
2877692|NCT03405688|Other|Control - Transfusion prior to surgery|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
2877693|NCT03405675||SLAS 1|The subjects (N=2800) are recruited from all residents aged 55 years and above in Singapore in the areas covered by the South-East Community Development Council: Geylang, Aljunied, MacPherson, Marine Parade and Bedok (SLAS-I).
2877694|NCT03405675||SLAS 2|An additional 3200 subjects are recruited from residents in the Bukit Merah and Jurong (SLAS-II).
2877695|NCT03405662|Active Comparator|Acitve PBM|This arm will receive active photobiomodulation (PBM), delivered with the Vielight Neuro Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes for 16 weeks.
2877696|NCT03405662|Sham Comparator|Sham PBM|This arm will not receive active photobiomodulation (PBM). Instead, they will use a sham Vielight Neuro Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes for 16 weeks.
2877697|NCT03405649|Experimental|Group A|Participants train 60 min per session for 10 weeks on non-consecutive days. All training sessions will be supervised by a qualified exercise instructor. Each training session will include a warm up phase of 5 minutes of dynamic and static stretching and a cool down phase consisting of 5 minutes of static stretching. Whole-body exercises and weights, elastic bands and balls will be used. Babies less than 20 weeks of age will be included in the exercise routine. Participants will perform 1-3 sets per exercise, 8-12 repetitions per set and a 90-s rest interval between sets.
2877698|NCT03405649|Experimental|Group B|Participants train 60 min per session for 10 weeks on non consecutive days. All training sessions will be supervised by a qualified exercise instructor. Each training session will include a warm up phase of 5 minutes of dynamic and static stretching and a cool down phase consisting of 5 minutes of static stretching. Whole-body exercises and different equipment such as weights, elastic bands and balls will be used. Babies older than 20 weeks will be included in the exercise routine. Participants will perform 1-3 sets per exercise, 8-12 repetitions per set and a 90-s rest interval between sets.
2877699|NCT03405636|Experimental|Xeltis Pulmonary Valved Conduit|PV Conduit for RVOT reconstruction
2877700|NCT03405623|Active Comparator|Dynamic needle tip positioning|In DNTP, SAX is used, and additionally, when the needle tip is imaged in the screen as an hyper-echoic point, the practitioner (a) moves the US probe proximally a bit, and (b) the needle is advanced until the needle tip reappears in the screen. In this manner, the practitioner repeats (a) and (b) until the needle is inserted 1 cm into the lumen of vessel, and then the catheter is inserted to finish the procedure.
2877701|NCT03405623|Active Comparator|Conventional long-axis|
2877702|NCT03405610|Experimental|Toolkit for Optimal Recovery after Injury|The Toolkit for Optimal Recovery after Injury (ToR) is a mind body skills based program delivered individually via secure live video. The format is a 4-week program with weekly meetings and a focus on teaching skills to optimize recovery and prevent chronic pain and disability.
2877703|NCT03405610|No Intervention|Usual Care|The Usual Care (UC) group will continue with their current medical care.
2877704|NCT03405597|Experimental|Healthy control|Commercial Hepatitis B vaccine
2877705|NCT03405597|Experimental|Chronic hepatitis B with vaccination|Commercial Hepatitis B vaccine
2877706|NCT03405597|Active Comparator|Chronic hepatitis B without vaccination|Standard treatment
2877707|NCT03405584|Experimental|Bismuth Plus Dual Therapy|Esomeprazole 40mg bid, Amoxicillin 1.0g tid and Bismuth Potassium Citrate 600mg bid for 14 days.
2877708|NCT03405584|Active Comparator|Dual Therapy|Esomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days.
2877709|NCT03405545|Experimental|HIIT+carbohydrate-rich beverage|This group of subjects will perform High Intensity Interval training while consuming a insulinogenic, carbohydrate-rich beverage
2877710|NCT03405545|Experimental|HIIT+water|This group of subjects will perform High Intensity Interval training while consuming water.
2877711|NCT03405519|Other|Radiotherapy planning|Radiotherapy planning using both CT and MRI scans
2877712|NCT03405493|Experimental|Wake and Light Therapy|This consists of (a) Total Sleep Deprivation with group support on days one and two; (b) Phase Advance of Sleep over 5 days and daily Light Therapy. (c) Light Therapy is given daily
2877713|NCT03405493|Active Comparator|Sleep and Light Therapy|Participants will be given information on sleep hygiene and getting a good night's sleep. They are then given Light Therapy daily for 1 week.
2877714|NCT03405480|Experimental|Rehabilitation|Physiotherapist-supervised outpatient rehabilitation program 2 times a week for a total of 8 weeks.
2877715|NCT03405480|No Intervention|No rehabilitation|Patients will receive usual care, including information pamphlets with information on the disease and the general importance of exercise.
2877716|NCT03405467||lightning accident|patients suffered injuries due to lightning strike
2877717|NCT03405467||frostbite|patients suffered injuries due to local hypothermia leading to frostbite injuries
2877718|NCT03405467||cpr and aed|patients suffered cardiac arrest in alpine region treated with or without automated external defibrillatior
2877719|NCT03405467||flight accident|patients suffered injuries due to use of a flying vehicle in mountainous regions.
2877720|NCT03405454|Active Comparator|standard chemotherapy|Patients on physician's choice of chemotherapy are allowed to receive any systemic chemotherapy either as a single agent or in combination. However, biologics( including bevacizumab) and oral tyrosine kinase inhibitors will not be allowed for patients on this arm
2877722|NCT03405441|Experimental|Part 1 (Panel 1): JNJ-55375515 and placebo|Participants will receive dose level (DL) 1 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 3 (period 2) and a maximum of DL 5 (period 3) based on the safety and tolerability profile and pharmacodynamic (PD) profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations.
2877723|NCT03405441|Experimental|Part 1 (Panel 2): JNJ-55375515 and placebo|Participants will receive DL 2 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 4 (period 2) and a maximum of DL 6 (period 3) based on the safety and tolerability profile and PD profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations.
2877724|NCT03405441|Experimental|Part 2: JNJ-55375515 and placebo|Participants will randomly be assigned to one of four treatment sequences 1, 2, 3 or 4. In the first 3 sequences, participants will receive 2 doses of JNJ-55375515 and placebo. Participants assigned to sequence 4 will receive placebo only in all periods. 3 dose levels will be tested in Part 2 based on Part 1 and will not exceed those evaluated in Part 1. A wash-out period of at least 10 days will be maintained between study drug administrations in period 1, 2, 3 and 4. In period 4 (open-label pharmacokinetic (PK) assessment period) participants will be randomly assigned to one of two dose levels tested in periods 1 to 3.
2877725|NCT03405428|Other|All patients|
2877726|NCT03405402|Experimental|Experimental group|Allo-immunization detected (positive response for irregular antibodies 2 to 4 weeks after a blood transfusion)
2877727|NCT03405402|Other|Control group|Allo-immunization not detected
2877728|NCT03405389||Patients|Patients diagnosis of a mandibular fracture requiring Open Reduction and Internal Fixation (ORIF) and use of Mandibulo-Maxillary fixation (MMF) during or subsequent to surgical intervention for a minimum of two weeks
2877729|NCT03405376|Experimental|Branch retinal vein occlusion|Center-involved macular edema secondary to branch retinal vein occlusion for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit)
2877730|NCT03405363||new users of Olodaterol|COPD patients using Olodaterol for the first time
2877731|NCT03405363||new users of other LABAs|COPD patients using other long-acting beta2 agonists for the first time
2877732|NCT03405350|Active Comparator|Study Group|The treatment included a comprehensive therapy: redon-sulfide baths, partial mud baths, kinesiotherapy, terrain therapy, dry massage, laser therapy, low-frequency magnetic field, ultrasonotherapy, cryotherapy, electrotherapy, light therapy. On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: VAS scale and anxiety and depression levels - HADS scale.
2877733|NCT03405350|No Intervention|Control Group|On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: VAS scale and anxiety and depression levels - HADS scale.
2877734|NCT03405337||FVIII products (prospective)|"Qualitative patient/caregiver study:~Hemophilia A patients/caregivers (N=30) having initiated a FVIII products with improved half-life"
2877735|NCT03405337||Conventional FVIII replacement therapies|"Qualitative patient/caregiver study:~Hemophilia A patients/caregivers (N=30) receiving conventional FVIII replacement therapy for at least 6 months who are considering switching to a FVIII product with improved half-life within the next 1 year"
2877736|NCT03405337||FVIII products (retrospective)|"Quantitative physician interview/ chart review study:~Hemophilia A patients (N=100) who have switched from conventional FVIII replacement therapy to FVIII products with improved half-life."
2877737|NCT03405324|Active Comparator|active tDCS|a single session over the primary motor cortex with constant current of 2mA intensity was applied for 20 minutes with a 5-second ramp phase at the beginning applied to the participant patient before chemotherapy .
2877738|NCT03405324|Sham Comparator|sham tDCS|a single session over the primary motor cortex with constant current of 2mA intensity was applied for 20 minutes with a 5-second ramp phase at the beginning applied to the participant patient before chemotherapy switched off after 30 second without the patient knowledge .
2877739|NCT03405311|Active Comparator|Palpation|The control group (Group 2: Epidural) will receive the 'Blind/standard approach', which is the current standard of care using palpation in administering labor epidural analgesia. Additionally, an anesthesiologist will scan patient's back with Accuro device in turn off mode.
2877740|NCT03405311|Experimental|Rivanna Accuro 3D Ultrasound Device|The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device.
2877741|NCT03405298|Active Comparator|Educational Material with Collaborative Care available|In addition to the material described below, these patients are seen in clinics with behavioral health collaborative care (BHCC), which includes a care manager in the primary care provider's office along with a consulting psychiatrist. If a patient receives the brochure and would like to taper their benzodiazepine, their provider can refer them to the BHCC care manager who can provide education and anxiety and insomnia self-management strategies, while the BHCC psychiatrist will make recommendations regarding the medication taper back to the primary care provider.
2877742|NCT03405298|Active Comparator|Educational Material Only|Patients will receive an 8-page educational brochure that presents information about potential harms of these medications and a vignette about a patient that successfully stopped. It does NOT suggest patients to stop on their own, but rather suggests they speak with their provider.
2877743|NCT03405285|Experimental|Connected Catheter Feasibility Study|Clinical Feasibility Evaluation of Connected Catheter Wireless Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
2877844|NCT03404661||Pancreas Cancer Subjects|Patients with pancreas cancer will receive Synthetic Human Secretin during an endoscopy procedure.
2877744|NCT03405272|Experimental|recombinant anti-EGFR monoclonal antibody（SCT200）|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
2877745|NCT03405259|Experimental|Super Seal® Desensitizer|Professionally Applied
2877746|NCT03405259|Sham Comparator|Acclean® Fluoride Varnish|Professionally Applied
2877747|NCT03405246|Active Comparator|KIDFIT SAFE|The Control Group will be provided 12 web-based monthly Homestyles Safe Guides about safe home environments for raising children and related material emailed monthly to the moms. KIDFIT Safe web site targets environmentally safe childcare related topics such as use of sun screen, avoidance of choking hazards, pet safety, protection from electrical appliances, etc. KIDFIT Safe participants will attend both baseline and 12 month clinical visits.
2877748|NCT03405246|Experimental|KIDFIT HEALTHY|The KIDFIT intervention group combines traditional in-person and electronic participant contacts, including two scheduled individual visits with a nutrition coach, coaching calls throughout the year, and monthly group videoconferencing-type sessions. KIDFIT Healthy participants will attend both baseline and 12 month clinical visits.
2877749|NCT03405233|Experimental|Group A|Double vein cuff PTFE graft both at the inflow and outflow ends
2877750|NCT03405233|Active Comparator|Group B|Single vein cuffed PTFE graft at the outflow end
2877751|NCT03405233|Active Comparator|Group C|PTFE graft without vein cuff will be used
2877752|NCT03405220|Experimental|Self-affirm, No examples, Study 1|Behavioral: Self affirmation, 10 items, no examples
2877753|NCT03405220|Active Comparator|Self-affirm, Write examples, Study 1|Behavioral: Self affirmation, 10 items, written examples
2877754|NCT03405220|Experimental|Self-affirm, Imagine examples, Study 1|Behavioral: Self affirmation, 10 items, imagined examples
2877755|NCT03405220|No Intervention|Opinion survey, No examples, Study 1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will not be asked to provide examples for any items they respond yes to."
2877756|NCT03405220|No Intervention|Opinion survey, Write examples, Study 1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will be asked to provide written examples for each item they respond yes to."
2877757|NCT03405220|No Intervention|Opinion survey, Imagine examples, Study1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will be asked to imagine examples for each item they respond yes to."
2877758|NCT03405220|Experimental|Self-affirm, 10-item, No ex, Study 2|Behavioral: Self affirmation, 10 items, no examples
2877759|NCT03405220|Experimental|Self-affirm, 5-item, No ex, Study 2|Behavioral: Self affirmation, 5 items, no examples
2877760|NCT03405220|Experimental|Self-affirm, 3-item, No ex, Study 2|Behavioral: Self affirmation, 3 items, no examples
2877761|NCT03405220|Active Comparator|Self-affirm, 10-item, Write ex, Study 2|Behavioral: Self affirmation, 10 items, written examples
2877762|NCT03405220|Experimental|Self-affirm, 5-item, Write ex, Study 2|Behavioral: Self affirmation, 5 items, written examples
2877763|NCT03405220|Experimental|Self-affirm, 3-item, Write ex, Study 2|Behavioral: Self affirmation, 3 items, written examples
2877764|NCT03405220|Experimental|Self-affirm, 10-item, Imagine ex, Study2|Behavioral: Self affirmation, 10 items, imagined examples
2877765|NCT03405220|Experimental|Self-affirm, 5-item, Imagine ex, Study 2|Behavioral: Self affirmation, 5 items, imagined examples
2877766|NCT03405220|Experimental|Self-affirm, 3-item, Imagine ex, Study 2|Behavioral: Self affirmation, 3 items, imagined examples
2877767|NCT03405207|Active Comparator|active drug receiving group|the drug is vitamin D3 50000 UNT oral capsule prescribing under Holick's protocol, which is every week for 8 weeks then every month for long life
2877768|NCT03405207|Placebo Comparator|placebo receiving group|the same as active comparator unless the drug is the identical placebo oral capsule
2877769|NCT03405194|Experimental|Elvitegravir-Cobicistat-TAF-FTC|Elvitegravir 150mg po QD Cobicistat 150 mg po QD TAF 10 mg po QD FTC 200 mg QD
2877770|NCT03405194|Active Comparator|EFV-TDF-3TC|EFV 600 mg po QD TDF 300 mg po QD 3TC 300 mg po QD
2877771|NCT03405181|Experimental|Training with additional weight|The infants will be submitted to a reaching behavior training program of 4 weeks, two times per week (totaling 8 sessions). During this training program, infants will use a bracelet with an additional weight characterized by 20% of the total mass of the upper limb placed on both wrists. This training will be adopted for the adequate weight intervention group and low weight intervention group.
2877772|NCT03405181|Placebo Comparator|Training without additional weight|The infants will be submitted to a reaching behavior training program of 4 weeks, two times per week (totaling 8 sessions). During this training program, infants will use a bracelet without additional weight, placed on both wrists. This training will be adopted for the adequate weight placebo group and low weight placebo group.
2877773|NCT03405168|Experimental|treatment arm|antibiotic drug(choosed by Physicians, dosage: according to the Instructions) plus TPC (Treatment of Physician's Choice).
2877774|NCT03405155|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2877775|NCT03405142|Experimental|Diagnostic (panitumumab IRDye800, Lymphoseek)|Beginning 2-5 days before surgery, patients receive panitumumab IRDye800 IV over 60 minutes. On the day before surgery, patients also receive technetium Tc 99m-labeled tilmanocept via injection and undergo lymphoscintigraphy and SPECT/CT.
2877776|NCT03405129|Active Comparator|Factoid Group|The Factoid group will receive a smartphone app that delivers 2 factual messages per day
2877777|NCT03405129|Experimental|Phoenix Group|The Phoenix group will receive a smartphone app that includes multiple components that vary based upon the participant's smoking cessation stage
2877778|NCT03405129|Experimental|Phoenix + NRT Group|"The Phoenix + (Nicotine Replacement Therapy) NRT group will receive a smartphone app that is identical to the Phoenix group, with one additional feature. Participants will be able to click an Order Nicotine Patches and Gum button to order NRT."
2877779|NCT03405103|Experimental|Striving|Striving vs Boning-up & Personal Choice
2877780|NCT03405103|Active Comparator|Boning-up Standard Education|Boning-up vs Striving and Personal Choice
2877781|NCT03405103|Sham Comparator|Personal Choice|Personal Choice vs Striving & Boning-up
2900909|NCT03242226|Active Comparator|single vision spectacles|
2877782|NCT03405090|Active Comparator|Fentanyl Citrate|Single dose, nebulized 100 mcg fentanyl citrate. This is a randomized, double-blind, two-treatment crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate with a constant fraction of 30% inhaled oxygen to that of a nebulized bronchodilator (Combivent). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and combivent at the second treatment visit, patients in the other arm will receive Combivent first and fentanyl second.
2877783|NCT03405090|Active Comparator|Combivent Bronchodilator|Single dose, nebulized Combivent bronchodilator (0.5 mg ipratropium bromide + 2.5 mg salbutamol). This is a randomized, double-blind, two-treatment crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate with a constant fraction of 30% inhaled oxygen to that of a nebulized bronchodilator (Combivent). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and combivent at the second treatment visit, patients in the other arm will receive Combivent first and fentanyl second.
2877784|NCT03405077|Experimental|IPT Online Training|"Therapists in this study will be trained in IPT using an online platform. The program is self-paced but will have a deadline; the suggested pace is at least 12 hours spaced over 2 months. The guided online training program was developed in collaboration with 3C institute, an award-winning research and development company that creates web- and evidence-based programs. Content will be adapted from gold-standard training."
2877785|NCT03405064|Experimental|levonadifloxacin|oral levonadifloxacin (1000 mg BID) or IV levonadifloxacin (800 mg BID)
2877786|NCT03405064|Active Comparator|linezolid|oral linezolid (600 mg BID) or IV linezolid (600 mg BID)
2877787|NCT03405025|Other|Safety and Feasibility|All patients will undergo endoscopic US guided radiofrequency ablation, to assess safety and feasibility.
2877788|NCT03404999|No Intervention|clinical decision support NOT activated|Prior to activation of the hypertension decision-support system, providers identify, diagnose, evaluate, and treat high blood pressures/hypertension per usual practice
2877789|NCT03404999|Experimental|clinical decision support activated|"TWO MED ASSIST ALERTS~Enter height (when missing)~Repeat BP (when high)~ONE PROVIDER ALERT~BP high & prior BP/BP%s~Defines elev. BP, HTN stage 1-2 with button to enter diagnosis~Link to tailored ordersets~TAILORED ORDERSETS~Elevated BP~Button to schedule f-up <6 m~Button for diet/lifestyle counseling/check-out instructions~HTN stage 1~Buttons to order labs/studies pre-checked for stage 1 recs~Button for nephrology referral~Button to schedule f-up in 1-2 wk/<1 m~Button for diet/lifestyle counseling/check-out instructions~HTN stage 2~Buttons to order labs/studies for stage 2~Button for nephrology referral (pre-checked)~Button to f-up 1 wk~Button for diet/lifestyle counseling/check-out instruction"
2877790|NCT03404986|Other|Standardized ureteroscopy group|
2877791|NCT03404986|Other|Ultrasonography ureteroscopy group|
2877792|NCT03404960|Experimental|Arm A|Niraparib + Nivolumab
2877793|NCT03404960|Experimental|Arm B|Niraparib + Ipilimumab
2877794|NCT03404947|Experimental|Ethanol|Participants will ingest ethanol (in the form of 40% ethanol) at an ingestion rate of 0.1 grams/kg lean body mass/hour in a solution with water.
2877795|NCT03404947|No Intervention|No Ethanol|Participants will ingest a volume matched beverage of water only.
2877796|NCT03404934|Experimental|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid and C-REX DMH/DMHC included in the C-REX Ring-locking Procedure.
2877797|NCT03404921|Experimental|ESTD group|Use tunnelling method during ESD operation
2877798|NCT03404921|Other|ESD group|Use traditional method during ESD operation
2877799|NCT03404908|Experimental|TAP|Ultrasound-guided transversus abdominis plane block at the end of cesarean section
2877800|NCT03404908|Experimental|QLB|Ultrasound-guided quadratus lumborum block at the end of cesarean section
2877801|NCT03404895|Sham Comparator|Conventional Therapy|Conventional therapy of DFU comprises of four components: local wound care, antibiotic therapy, debridement and amputation, and pressure offloading.
2877802|NCT03404895|Active Comparator|Conventional Therapy + venous stent(s)|Patients will receive a venous stent in addition to conventional therapy
2877803|NCT03404882|Experimental|text messaging plus peer support arm|Patients will be assigned a peer support worker who will visit them during the last week of their inpatient stay to introduce themselves and build rapport before patients are discharged into the community. The peer support workers will visit the participants up to eight times over a six month period. The peer support workers will offer the opportunity for interactive text message support for six months. In addition to peer support, participants in this arm of the study will receive daily supportive text messages from an automated
2877804|NCT03404882|Active Comparator|supportive/reminder text message only arm|Patients in the supportive/reminder text message only arm of the study will receive daily supportive text messages from the automated online application and reminder text messages for their community clinic/program appointments.
2877805|NCT03404882|No Intervention|Control arm|Patients in the control arm of the study will receive the usual follow-up appointment offered to all patients who are discharged from acute care. However, they will not receive peer support or supportive/reminder text messages.
2877806|NCT03404882|Active Comparator|peer support only arm|Patients will be assigned a peer support worker who will visit them during the last week of their inpatient stay to introduce themselves and build rapport before patients are discharged into the community. The peer support workers will visit the participants up to eight times over a six month period. The peer support workers will offer the opportunity for interactive text message support for six months. Patients will not receive daily supportive/reminder text messages
2877807|NCT03404869|Other|Treatment with ORL-1M|
2877808|NCT03404856|Other|Treatment with ORL-1G.|
2877809|NCT03404843|Experimental|Fasudil hydrochloride|Participants will receive a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to measurements of vascular function and ATP release.
2877810|NCT03404843|Placebo Comparator|Saline|Participants will receive a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to measurements of vascular function and ATP release.
2877811|NCT03404830|Experimental|HIIT group|This group receives physical training based on HIIT
2877812|NCT03404830|Experimental|MICT group|This group receives physical training based on MICT
2877813|NCT03404830|No Intervention|No intervention group|This group does not receive any treatment.
2877814|NCT03404817|Active Comparator|Sequence 1|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:~Period 1: EMB-001 new formulation under fed condition Period 2: EMB-001 new formulation under fasted conditions Period 3: EMB-001 original formulation under fed conditions"
2877815|NCT03404817|Active Comparator|Sequence 2|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:~Period 1: EMB-001 original formulation under fed conditions Period 2: EMB-001 new formulation under fed conditions Period 3: EMB-001 new formulation under fasted conditions"
2877816|NCT03404817|Active Comparator|Sequence 3|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:~Period 1: EMB-001 new formulation under fasted conditions Period 2: EMB-001 original formulation under fed conditions Period 3: EMB-001 new formulation under fed conditions"
2877817|NCT03404804|Experimental|Oral Challenge|Patients getting amoxicillin
2877818|NCT03404804|No Intervention|No-oral challenge|Patients randomized to not get amoxicillin
2877819|NCT03404791|Experimental|Radical Cystectomy Ineligible|TAR-200 is placed into the bladder through an Inserter and gradually releases gemcitabine during the 21-day indwelling period before being removed. Subjects will undergo an 84-day induction period comprised of four consecutive 21-day dosing cycles. Subjects may undergo up to 3 additional dosing cycles as maintenance.
2877820|NCT03404778||Biomet Comprehensive Reverse Shoulder|Subjects in need of a reverse shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Reverse Shoulder System.
2877821|NCT03404765|Experimental|Tai Chi group|The Tai Chi group (i.e. the intervention group) received a 16-week Tai Chi program, of 32 sessions (2 sessions per week), each being one hour long.
2877822|NCT03404765|No Intervention|Ususal care group|The control group received the usual care offered by the respective centers. No intervention had been arranged for the control group during the study period. Participants in the control group were advised to attend different kinds of recreational activities provided by their community centers and to continue with their daily activities, including their usual general physical mobility and social activities.
2877823|NCT03404752|Experimental|Peg-Neutropine®|Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
2877824|NCT03404752|Active Comparator|Neulastim®|Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
2877825|NCT03404739|Experimental|Single-dose group|Ceftazidime 2g at the start of POEM
2877826|NCT03404739|Active Comparator|Multiple-dose group|Ceftazidime 2g at the start of POEM plus additional 2 doses given every 12 hours after the procedure
2877827|NCT03404726|Experimental|BAY2402234/ Dose Escalation|Dose escalation with sequential cohorts enrolling patients with AML, MDS, or CMML. Patients will be treated in 28 day cycles with once daily oral administration of BAY2402234
2877828|NCT03404726|Experimental|BAY2402234/ Dose Expansion: AML|After completion of dose escalation, an expansion cohort comprised of patients with AML will start. These patients will be treated in 28 day cycles with once daily oral administration of BAY2402234 at the maximum tolerated dose or pharmacologically active dose.
2877829|NCT03404726|Experimental|BAY2402234/ Dose Expansion: MDS|After completion of dose escalation, an expansion cohort comprised of patients with MDS will start. These patients will be treated in 28 day cycles with once daily oral administration of BAY2402234 at the maximum tolerated dose or pharmacologically active dose.
2877830|NCT03404713|Active Comparator|Standard Behavioral Weight Loss (BWL) Treatment|All participants will participate in 4 weeks of group based behavioral weight lost treatment in the intervention called Pathways to Health. Based on early treatment response (improvement in binge eating), participants will be assigned to either continue in this arm for the remaining 12 weeks of treatment (early strong responders) or be assigned to the 2nd arm of this study.
2877831|NCT03404713|Experimental|Acceptance-Based Binge Eating Treatment|After 4 weeks of standard BWL treatment, early weak responders will be assigned to individual acceptance-based treatment for the remaining 12 weeks of treatment.
2877832|NCT03404700|Experimental|Group 1:Test breakfast A and B|"*Please note: Part I of the study does not have separate groups. All subjects will undergo RFPM. The description of groups presented below is for part II of the study.~Subjects will have egg breakfast(test breakfast A) and egg breakfast with high saturated fat (test breakfast B) in any order."
2877833|NCT03404700|Experimental|Group 2:Test breakfast A and C|Subjects will have egg breakfast and (test breakfast A) and cereal breakfast (test breakfast C) in any order.
2877834|NCT03404700|Experimental|Group 3:Test breakfast A and D|Subjects will have egg breakfast (test breakfast A) and cereal breakfast (test breakfast C) in any order.
2877835|NCT03404700|Experimental|Group 4:Test breakfast B and C|Subjects will have egg breakfast with high saturated fat (test breakfast B) and cereal breakfast (test breakfast C) in any order.
2877836|NCT03404700|Experimental|Group 5:Test breakfast B and D|Subjects will have egg breakfast with high saturated fat (test breakfast B) and cereal breakfast with high saturated fat (test breakfast D) in any order.
2877837|NCT03404700|Experimental|Group 6:Test breakfast C and D|Subjects will have cereal breakfast (test breakfast C) and cereal breakfast with high saturated fat (test breakfast D) in any order
2877838|NCT03404687||Patients with adnexal masses|
2877839|NCT03404674|Experimental|Group A|3 intramuscular injections of 5ug CssBA (5 participants) or 100ng dmLT (5 participants)
2877840|NCT03404674|Experimental|Group B|3 intramuscular injections of 5ug CssBA + 100ng dmLT (10 participants)
2877841|NCT03404674|Experimental|Group C|3 intramuscular injections of 5ug CssBA + 500ng dmLT (10 participants)
2877842|NCT03404674|Experimental|Group D|3 intramuscular injections of 15ug CssBA + 100/500ng dmLT (10 participants) (dose of dmLT dependent upon previous groups)
2877843|NCT03404674|Experimental|Group E|3 intramuscular injections of 45ug CssBA + 100/500ng dmLT (10 participants) (dose of dmLT dependent upon previous groups)
2877845|NCT03404661||Control Subjects|Controls will receive Synthetic Human Secretin during an endoscopy procedure. Controls are at an elevated risk of pancreas cancer, including pancreatic cystic neoplasms.
2877846|NCT03404661||Familial Pancreatic Cancer Subjects|Subjects who have a family history of pancreas cancer will receive Synthetic Human Secretin during an endoscopy procedure.
2877847|NCT03404648|Experimental|High Risk Prostate Cancer Patients|Subjects will receive C-11 choline PET Tracer and Gadobutrol prior to the one time Positron emission tomography (PET/MR scanner) imaging and Multiparametric Magnetic resonance imaging (mpMRI).
2877848|NCT03404635||Apixaban for VTE|
2877849|NCT03404622|Active Comparator|Postplacental IUCD Insertion during Cesarean section|IUCD inserted postplacental removal
2877850|NCT03404622|Active Comparator|6 Week Post-Cesarean Insertion of IUCD|IUCD inserted after six weeks post Cesarean section delivery
2877851|NCT03404609|Experimental|rTMS|Participants in the rTMS group will receive MagPro X100 by MagVenture (Active) cortical stimulation condition.
2877852|NCT03404596|Experimental|Smoking Cessation Therapy|Participants will receive 6 weeks of the nicotine patch therapy and brief counseling sessions. Participants will also receive mindfulness strategies for 10 days during both the pre- and post-quit periods via smartphone to aid in their cessation attempt. AutoSense will be worn to detect stress and lapse throughout the 10 day period.
2877853|NCT03404583|Experimental|Person-centred care at distance|Person-centred care at distance through an eHealth platform
2877854|NCT03404583|No Intervention|Usual Care|Evidence-based care
2877855|NCT03404570|Experimental|High Dose (4 mg)|Oral tablet containing 2 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
2877856|NCT03404570|Experimental|Low Dose (2 mg)|Oral tablet containing 1 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
2877857|NCT03404570|Placebo Comparator|Placebo|Oral tablet containing no active drug. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
2877858|NCT03404557||Crohn's Disease patients group|44 patients
2877859|NCT03404557||Ulcerative Colitis patients group|22 patients
2877860|NCT03404557||Healthy volunteers group|22 patients
2877861|NCT03404544|Active Comparator|Carbetocin bolus|Patients in this arm will receive both syringes : the 3 ml and the 10 ml. The carbetocin 100 mcg will be in the 3 ml syringe over 2 sec and the 10 ml syringe will contain only normal saline given as infusion over 10 min.
2877862|NCT03404544|Experimental|Carbetocin infusion|Patients in this arm will receive both syringes : the 3 ml and the 10 ml. The carbetocin 100 mcg will be in the 10 ml syringe as an infusion over 10min and the 3 ml syringe will contain only normal saline given iv over 2 sec as a bolus.
2877863|NCT03404531|Experimental|Social Media Messages Intervention Group|Participants randomized to this condition will have access to a newly developed, culturally-tailored interactive website and theoretically-grounded social media messages.
2877864|NCT03404531|Active Comparator|Website Only Group|Participants randomized to this condition will have access to a newly developed, culturally-tailored interactive website only.
2877865|NCT03404518|Experimental|Norco and Ibuprofen|"This group will take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for pain control as first line intervention.~If pain is not controlled after 60 minutes then can take Ibuprofen 600mg every 6 hours as needed for additional pain control."
2877866|NCT03404518|Active Comparator|Ibuprofen and Norco|"This group will take Ibuprofen 600mg every 6 hours as needed for pain control as first line intervention.~If pain is not controlled after 60 minutes then can take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for additional pain control."
2877867|NCT03404505|Experimental|Infant Achievements|Families randomized to the IA condition will receive 17 in-home sessions. These include a one-time start up session followed by twice-weekly visits in which they will be coached on how to implement the IA strategies. Families will receive a set of developmentally appropriate toys.
2877868|NCT03404505|Experimental|Caregiver Education|In this condition, parents will receive 17 sessions with a trained study team member focused on promoting child development and well-being. Sessions include a one-time start-up visit followed by one in-home visit and one phone contact per week. Families will receive a set of developmentally appropriate toys.
2877869|NCT03404492|Other|Patients with pulmonary hypertension|
2877870|NCT03404479|Experimental|Co-administration group|Co-administration of Diacerein 50mg, Celecoxib 100mg.
2877871|NCT03404479|Active Comparator|Single administration group 1|Single administration of Diacerein 50mg and placebo.
2877872|NCT03404479|Active Comparator|Single administration group 2|Single administration of Celecoxib 100mg and placebo.
2877873|NCT03404466|Experimental|experimental group one|10 mg of Hypidone Hydrochloride tablets
2877874|NCT03404466|Experimental|experimental group two|20 mg of Hypidone Hydrochloride tablets
2877875|NCT03404453||Paediatric patients at preanaesthetic visi|Difficult airway incidence and prediction:Paediatric patients at preanaesthetic visit scheduled for surgery under general anaesthesia
2877876|NCT03404440|Active Comparator|L.Reuteri|Lactobacillus reuteri DSM 17938 + Lactobacillus reuteri ATCC PTA 6475 one tablet by mouth 7 times per day + Pantoprazole 20 mg twice a day for 28 days
2877877|NCT03404440|Placebo Comparator|Placebo|Placebo one tablet by mouth 7 times per day + Pantoprazole 20 mg twice a day for 28 days
2877878|NCT03404427|Sham Comparator|Normal sleep night|The first endurance test is the endurance motor control test after a normal sleep night.
2877879|NCT03404427|Experimental|Sleepless night|The first endurance test is the endurance motor test after a sleepless night.
2877880|NCT03404414|Experimental|18F-FDG PET/MRI and 18F-FDG PET/CT|The patients were injected with 370 MBq of 18F-FDG in one dose intravenously and underwent PET/MRI or PET/CT scan 1 hour later
2877881|NCT03404401|Experimental|BLI4700 Bowel Preparation|
2877882|NCT03404401|Active Comparator|FDA Approved Bowel Preparation|
2877883|NCT03404388|Experimental|Experimental|Balance Training
2877884|NCT03404375|Other|Term patients|This study only has one arm: term pregnant patients scheduled for cesarean sections. The surgeon will clinically estimate blood loss and the research team will estimate blood loss using the Gauss Triton system. This will be done on all 242 patients.
2878397|NCT03400735|Experimental|Cefdinir/clavulanic acide 300/125 mg Film Coated Tablets|
2877885|NCT03404362|Active Comparator|MRgFUS|"The treatment process begins with the physician acquiring a set of MR images, identifying target volume(s) of tissue to ablate, and then drawing the treatment contours.~The therapy planning software computes the type and number of sonications required to treat the defined region while minimizing total treatment time. MR images taken during the sonication provide a diagnostic quality image of the target tissue and a quantitative, real-time temperature map overlay to confirm the therapeutic effect of the treatment"
2877886|NCT03404362|Active Comparator|EBRT|Patient would undergo single fraction of external beam radiation to a dose of 8Gy or a session of 10 fractions of external beam radiations at 3Gy per fraction for two weeks.
2877887|NCT03404349|Experimental|Mindfulness for Adolescence Course|Participants will attend mindfulness classes to include deep breathing, yoga, listening to music and meditation.
2877888|NCT03404336|Experimental|Well-being therapy|WBT will be used as the only non-pharmacological therapeutic strategy and 8 sessions will be delivered every other week with a duration of 60 minutes each. The manualized WBT will be used (Fava, 2016). Thus, the initial phase will be concerned with self-observation of psychological well-being. Once the instances of well-being will be properly recognized, the patient will be encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of well-being (intermediate phase). The final part will involve cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
2877889|NCT03404336|Placebo Comparator|Control condition|The control condition will include 8 be-weekly sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) guidelines (https://www.nice.org.uk/guidance/lifestyle-and-wellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle). These sessions will inform participants about well-being and which lifestyles can influence it.
2877890|NCT03404310|Placebo Comparator|Treatment|Zinc Sulfate 220mg twice daily for three months.
2877891|NCT03404310|Placebo Comparator|Placebo|Gelatin Placebo tablet twice daily for three months.
2877892|NCT03404297|Experimental|Immediate Compression Therapy Arm|Patients in this arm will receive a locally sourced version of compression therapy while concurrently receiving chemotherapy
2877893|NCT03404297|Placebo Comparator|Delayed Compression Therapy Arm|Patients in this arm will receive a locally sourced version of compression therapy after completing ~ 14 weeks of chemotherapy.
2877894|NCT03404284||Intervention facilities|Includes 43 health facilities and their associated outreach sites
2877895|NCT03404271|Placebo Comparator|Normal Diet|Participants in the normal diet (ND) group will follow a traditional dietary pattern, consisting of eating breakfast and continuing to eat throughout the day until the evening. Participants in this group will receive placebo capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
2877896|NCT03404271|Experimental|Time-Restricted Feeding|Participants in the time-restricted feeding (TRF) group will consume all calories within an 8-hour period of time each day. Participants in this group will receive placebo capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
2877897|NCT03404271|Experimental|Time-Restricted Feeding plus HMB|Participants in the time-restricted feeding plus HMB (TRF+HMB) group will consume all calories within an 8-hour period of time each day. Participants in this group will receive HMB capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
2877898|NCT03404258||Study Patients|Infants between 1 month and 2 years of age undergoing evaluation for SCPA candidacy.
2877899|NCT03404258||Control Patients|Infants between 3 months and 12 months of age with no known cardio-pulmonary disease, no active infection, and no known genetic abnormality undergoing elective surgery for a non-cardiac indication.
2877900|NCT03404245|Active Comparator|Immediate Intervention Group|Education, Fitbit/self-management web app, physiotherapist counselling. These 3 components will be delivered to the participants in Months 1 and 2. The session will include a short presentation about physical activity in everyday life, an individual goal-setting session with a registered PT, and an orientation to the Fitbit device and the web app. Participants will be provided access to a Fitbit and an app account. The PT will review physical activity goals with participants via bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will continue using Fitbit and the app and have access to a PT via email as needed, but no phone call. In Months 7-12, participants may keep their Fitbit and app account, but will not have access to a PT.
2877901|NCT03404245|Placebo Comparator|Delayed Intervention Group|Same intervention with a 6 month delay: The full intervention will be initiated in Month 7 and 8 with a brief education session, use of a Fitbit paired with the self-management web app, and counseling by a PT. In Month 9-12, participants will continue the intervention without the PT phone calls, but will have email access to PT, if needed.
2877902|NCT03404232|Active Comparator|Group 1|patients with their first surgical intervention at the lumbar spine receive the Dynesys DTO device (Zimmer Spine, Inc.).
2877903|NCT03404232|Active Comparator|Group 2|patients with a previous surgical decompression but non-fusion procedure after lumbar spinal stenosis surgery receive the Dynesys DTO device (Zimmer Spine, Inc.).
2877904|NCT03404232|Active Comparator|Group 3|patients with the medical history of PLIF-/TLIF-technique and later onset of symptomatic ASD within the superior adjacent segment receive the Dynesys DTO device (Zimmer Spine, Inc.).
2877905|NCT03404206|Experimental|Naproxen Sodium (Aleve, BAY117031)|3/7 subjects receive total dose of 440mg Naproxen sodium (220 mg Naproxen Sodium/ orally, 2 tablets), single dose
2877906|NCT03404206|Active Comparator|Ibuprofen (Advil)|3/7 subjects receive total dose of 400mg Ibuprofen (200 mg Ibuprofen/ orally, 2 tablets), single dose
2877907|NCT03404206|Placebo Comparator|Placebo|1/7 subjects receive placebo orally, 2 tablets, single dose
2877908|NCT03404193|Experimental|Decitabine + Venetoclax|"Participants receive Decitabine by vein over about 1 hour on Days 1-10 of each 28-day study cycle.~Participants take Venetoclax by mouth on Days 1-28 of the first cycle and Days 1-21 of all other cycles."
2877941|NCT03403946|Experimental|Intervention|"All patients received the same treatment.~Laryngscopy with C-MAC PM + Macintosh blade~Laryngscopy with C-MAC PM + D-Blade~Intubation with C-MAC PM + D-Blade"
2878005|NCT03403478|Experimental|Aquatic exercise training|The participants will be submitted to a 12-weeks of aquatic exercise program, twice a week, for 1 hour each day.
2877909|NCT03404180|Experimental|Peripheral nerve block|"Prospectively evaluate peripheral nerve blocks as a primary anesthetic in the setting of above-the-knee amputations.~All enrollees will be administered Intravenous sedatives using propofol or dexmedetomidine and have ultrasound-guided femoral and sciatic nerve blocks placed per current practice at research site. Single-injection obturator nerve blocks and lateral femoral cutaneous nerve blocks will also be performed."
2877910|NCT03404167|Experimental|Zoliflodacin|4 g (2 sachets of 2 g) of zoliflodacin orally in the morning of Day 1 after 8 hours of fasting, n=8
2877911|NCT03404141|Experimental|Experimental group|The intervention administered to the experimental group will be a cognitive-behavior therapy applied by two specifically trained psychologists
2877912|NCT03404141|Active Comparator|Control group|The intervention administered to the control group will consist on a regular parent craft classes offered by the community midwife
2877913|NCT03404128|Other|Questionnaires|Questionnaire for patient Questionnaire for neurologist
2877914|NCT03404115|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
2877915|NCT03404115|Experimental|Reproxalap Ophthalmic Solution (0.1%)|
2877916|NCT03404115|Placebo Comparator|Vehicle Ophthalmic Solution|
2877917|NCT03404102||university clinic|"Enrollment: 200 Subjects will be enrolled from women attending family planning clinic for Cu- IUD insertion~Informed Consent: All participants will give their informed consent prior to enrollment.~Data collection & recording: Data of each patient will be recorded in a Case Record Form (CRF).~Follow up visits /questionnaire: will be conducted from each subject at 6 months and 12 months after Cu-IUD insertion. User satisfaction score and haemoglobin serum level will be included in the questionnaire."
2877918|NCT03404102||primary healthcare unit clinic|"Enrollment: 200 Subjects will be enrolled from women attending family planning clinic for Cu- IUD insertion~Informed Consent: All participants will give their informed consent prior to enrollment.~Data collection & recording: Data of each patient will be recorded in a Case Record Form (CRF).~Follow up visits /questionnaire: will be conducted from each subject at 6 months and 12 months after Cu-IUD insertion. User satisfaction score and haemoglobin serum level will be included in the questionnaire."
2877919|NCT03404089|Experimental|pharmacokinetic device|MON4STRAT system
2877920|NCT03404076||GIST patients under TKI treatment|GIST patients under TKI treatment are subjected to Dual Energy CT
2877921|NCT03404063|Experimental|Active Group|Patients randomized to the active treatment group will receive 30 000 000 WJMSCs suspended in 20mL 0.9% NaCl and 5% albumin administered via the IRA.
2877922|NCT03404063|Placebo Comparator|Control Group|Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.
2877923|NCT03404050|Experimental|Music and dance movement therapy group|Music and dance movement therapy group
2877924|NCT03404037||Group I|Fifty-five coronary artery disease patients without type 2 DM
2877925|NCT03404037||Group II|Fifty-five coronary artery disease patients with type 2 DM
2877926|NCT03404024|Experimental|Stage 1-Low dose VM202RY|Patients in this group will receive total 1mg of VM202RY. (4 sites of 0.25mg/0.5 mL VM202RY)
2877927|NCT03404024|Experimental|Stage 1-Middle dose VM202RY|Patients in this group will receive total 2mg of VM202RY. (8 sites of 0.25mg/0.5 mL VM202RY)
2877928|NCT03404024|Experimental|Stage 1-High dose VM202RY|Patients in this group will receive total 3mg of VM202RY. (12 sites of 0.25mg/0.5 mL VM202RY)
2877929|NCT03404024|Placebo Comparator|Stage 2-Placebo|Patients in this group will receive 6mL of VM202RY vehicle. (12 sites of 0.5mL 0.9% NaCl, 1.1% sucrose)
2877930|NCT03404024|Experimental|Stage 2-Low dose VM202RY|Patients in this group will receive total 6mL of VM202RY and VM202RY vehicle. (The dose of VM202RY can be one of the three candidate-0.5mg VM202RY/1mg VM202RY/1.5mg VM202RY based on the tolerated dose result from Stage 1.)
2877931|NCT03404024|Experimental|Stage 2-High dose VM202RY|Patients in this group will receive total 6mL of VM202RY and VM202RY vehicle. (The dose of VM202RY can be one of the three candidate-1mg VM202RY/2mg VM202RY/3mg VM202RY based on the tolerated dose result from Stage 1.)
2877932|NCT03404011|Experimental|Propylene glycol and Glycerol intake|One gram intake of a Propylene glycol/Glycerol mix (50:50)
2877933|NCT03404011|Placebo Comparator|Mimicking intake|Mimicking Propylene glycol/Glycerol intake with the device turns off
2877934|NCT03403998|Experimental|Exercises|Neck flexors Training: Each patient will initially perform cranio-cervical flexion to sequentially reach 5 pressure targets in 2 mmHg increments from a baseline of 20 mmHg to the final level of 30 mmHg. For each target level, the contraction duration will be increased to 10 s, and the participant trained to perform 10 repetitions with brief rest periods between each contraction. Once one set of 10 repetitions of 10 s is achieved at one target level, the exercise will be progressed to train at the next target level up to the final target. Neck extensors training: Patients will perform cranio-cervical extension and upper cervical rotation in a prone on elbows position while maintaining the cervical spine in a neutral position, progressing to a 4-pt kneeling position.
2877935|NCT03403998|Placebo Comparator|Placebo|"The placebo group will receive placebo TENS (switched-off TENS apparatus with no perceptible stimulation). Four electrodes, 50 x 35 mm, will be placed on the neck muscles. The participant will be informed that this therapy is called a subthreshold current and they might not be able to feel any sensation underneath the electrodes during the treatment. The placebo treatment will be for 30 min twice a week for 8 weeks, as for the intervention group."
2877936|NCT03403985|Experimental|calcium hydroxide direct pulp capping|calcium hydroxide (Ca(OH)2 direct pulp capping will be performed in this group
2877937|NCT03403985|Experimental|MTA direct pulp capping|Mineral Trioxide Aggregate (MTA) direct pulp capping will be performed in this group
2877938|NCT03403972|Experimental|Group|Intervention: vancomycin 500 mg tid for 7 days (Vancozin 250 mg capsule)
2877939|NCT03403959|Experimental|SAD|Persons with visual impairment and SAD are assessed by clinical interview, depression rating, diurnal saliva melatonin and cortisol and chromatic pupillometry during symptomatic winter phase and asymptomatic summer phase. Winter assessment is followed by a 6 week light therapy protocol ending with assessment of depression severity and repeated pupillometry.
2877940|NCT03403959|No Intervention|non-SAD|Control participants with similar visual impairment but without SAD/sSAD are assessed by clinical interview, depression rating, diurnal saliva melatonin and cortisol and chromatic pupillometry in winter and summer.
2878032|NCT03403283||Group 1|Diabetic
2877942|NCT03403933|Experimental|cardiopathic patients in hypovitaminosis|Didrogyl 10 ml: 10 drops a day to obtain levels of vitamin D > 30 ng /ml. Once these values are obtained lower the dose to 4-5 drops a day, with the aim, however, of keeping the plasma values between 30 and 60 ng/ml during 6 months of the study
2877943|NCT03403907|Experimental|Probiotic|Probiotic administration
2877944|NCT03403881|Active Comparator|Physical activity promotion + TAU|"Physical activity promotion based on:~Pedometers use;~Weekly contact (telephone or face-to-face);~Contact based on a self-determination theory.~TAU:~Treatment as usual, which include medications. Medications were prescribed by psychiatrists not involved in the study participation."
2877945|NCT03403881|Placebo Comparator|Control|"Weekly calls with general health content.~TAU:~Treatment as usual, which include medications. Medications were prescribed by psychiatrists not involved in the study participation."
2877946|NCT03403868|Other|Conductance catheter|Contractility-measurement with conductance catheter (pressure-volume-catheter)
2877947|NCT03403855|Experimental|Rocket® IPC- Long External Length|"Intervention Rocket® IPC- Long External Length: a regular full length (long catheter) Rocket catheter inserted at baseline, with an external length of 16cm. Catheter length will be modified at 2 weeks in clinic, shortened to an external length of 5cm (short catheter). Patient satisfaction will be collected at 2 weeks prior to the modification, and at 4 weeks when the patient has a shorter catheter.~The modification is easily done without any use of anesthesia as it is external to the patient using the tool kit that comes along with the catheter.~Patients will be referred to palliative home care services for assistance with drainage. The drainage catheters to be used in this study will be samples supplied by Rocket Medical Inc., for Dr. Amjadi to evaluate their product."
2877948|NCT03403855|Experimental|Rocket® IPC- Short External Length|"Intervention Rocket® IPC- Short External Length : a regular full length (long catheter) Rocket catheter inserted at baseline, with an external length of 16cm. Catheter length will be modified at 2 weeks in clinic, shortened to an external length of 5cm (short catheter). Patient satisfaction will be collected at 2 weeks prior to the modification, and at 4 weeks when the patient has a shorter catheter.~The modification is easily done without any use of anesthesia as it is external to the patient using the tool kit that comes along with the catheter.~Patients will be referred to palliative home care services for assistance with drainage. The drainage catheters to be used in this study will be samples supplied by Rocket Medical Inc., for Dr. Amjadi to evaluate Rocket's product."
2877949|NCT03403842|Active Comparator|PERIDURAL|Peridural catheter positioning with a continuous infusion of ropivacaine 0,2% 99 ml+ sufentanil 50 mcg at an infusion rate of 4-6 ml/h
2877950|NCT03403842|Active Comparator|PCA MORPHINE|Patient controlled analgesia of endovenous morphine, injection dose 1 mg, lock-out time 10 minutes, maximum dosage for hour 4 mg
2877951|NCT03403842|Experimental|SSTS|Patients controlled analgesia of sublingual sufentanil tablet system, 15 mcg sufentanil tablets, lock out time 20 minutes
2877952|NCT03403829|Experimental|maintenance arm|Gemcitabine maintenance treatment
2877953|NCT03403829|Sham Comparator|control arm|observe and follow-up
2877954|NCT03403816|Active Comparator|Intervention|Students in grades K-6 at 7 schools in two communities participating in a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions.
2877955|NCT03403816|No Intervention|Comparison|Students in grades K-6 at the same 7 schools in two communities as the intervention participants, but who did not participate in the before school physical activity program.
2877956|NCT03403803||Control Group|
2877957|NCT03403803||Optune Only|
2877958|NCT03403803||Optune and TMZ|
2877959|NCT03403790||Patients with depression in bipolar disorder|Patients with depression in bipolar disorder who are treated with quetiapine extended-release tablets for the first time
2877960|NCT03403777|Experimental|Avelumab|AVELUMAB will be administered intravenously 10mg/kg every 2 weeks. Courses will be repeated every 14 days until progression or unacceptable toxicity. AVELUMAB will be administered as a 1-hour (-10 minutes / +20 minutes, i.e., 50-80 minutes) intravenous (i.v.) infusion. The dose of AVELUMAB will be calculated based on the weight of the subject determined on the day prior to or the day of each drug administration.
2877961|NCT03403764|Experimental|Wellness Intention Transmission Groups|"Aim of this part of the study is to examine whether intention broadcasted from an Intention Host Device (a device which stores and transmits an intention) will affect self-compassion, general wellness, and awakening. 300 trial participants will be randomly allocated to 1/3 in control and 2/3 in the experimental IHD group, respectively. Differences in outcomes between control and experimental groups are expected.~To address potential bias, those who enter the study but drop out are compared to those who complete the study to gauge potential differences between the two groups, and will report on this potential bias in the published manuscript."
2877962|NCT03403764|No Intervention|Independent Control Group|"Due to the global, emergent entanglement phenomenon, the investigators are curious if the investigators can test this idea within the context of the proposed study. The investigators added an additional but smaller control group which will complete the same three questionnaires for the first 6 months only and will be unaware of the larger study being conducted. These 50 subjects will be told they are completing the questionnaires in the context of a distinct, separate study and will be unaware of the Consciousness Field Project."
2877963|NCT03403751|Experimental|Reltecimod|Single dose
2877964|NCT03403751|Placebo Comparator|0.9% Sodium Chloride Injection|Single dose
2877965|NCT03403738|Active Comparator|Enhanced usual Care|usual care plus comprehensive resource list
2877966|NCT03403738|Experimental|BBN|Bounce Back Now intervention
2877967|NCT03403725|Experimental|MEN1309 (Step 1-Solid Tumors)/(Step 2-NHL)|"Step1: Accelerated Titration Design with 1 single pt per cohort and double dose level per cohort until grade ≥ 2 drug related toxicity. Then, study reverts to 3+3 design. Any cohort in which 1 pt experiences a DLT (along ATD or 3+3) will be expanded up to 6 pts.~Step2: MTD defined in Step 1, 3 MEN1309 dose levels will be tested (MTD-2, MTD-1, and MTD), with 6 pts per each dose level. A further MTD-3 level will be explored if 2 DLTs occur at the MTD-2 dose level."
2877968|NCT03403712|Experimental|Test group|"intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination, administered as a 30-minute infusion of a 50 mL solution, on Day 1 of each cycle.~Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)"
2878033|NCT03403283||Group 2|Healthy Controls
2877969|NCT03403712|Active Comparator|Control group|"oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.~Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)"
2877970|NCT03403699||nondiabetics|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) the subject must be a healthy control and b) the subject be willing and have the ability to cooperate with the eye exam and blood draw.
2877971|NCT03403699||Diabetic|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) carry the diagnosis of diabetes and b) the subject be willing and have the ability to cooperate with the eye exam and blood draw.
2877972|NCT03403686||Controls|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require that the subject must carry the diagnosis of healthy control.
2877973|NCT03403686||Diabetic no retinopathy|Patients with diabetes but with no evidence of diabetic retinopathy
2877974|NCT03403686||Diabetic with mild retinopathy|Diabetics with mild non proliferative diabetic retinopathy (NPDR).
2877975|NCT03403686||Diabetic with moderate retinopathy|Diabetics with moderate NPDR
2877976|NCT03403686||Diabetics with severe retinopathy|Diabetic with severe NPDR.
2877977|NCT03403686||Diabetics with proliferative diabetic retinopathy (PDR)|Diabetics with proliferative diabetic retinopathy (PDR)
2877978|NCT03403660|Experimental|non white coat rounding|The postpartum physician rounding in this group will be performed wearing white coat.
2877979|NCT03403660|Placebo Comparator|White coat rounding|The postpartum physician rounding in this group will be performed not wearing white coat.
2877980|NCT03403647|Experimental|Vitamin D deficient|Vitamin D supplementation and close everolimus trough levels monitoring with oral dose adjustments
2877981|NCT03403647|No Intervention|No vitamin D deficiency|Regular and routine monitoring
2877982|NCT03403634|Experimental|Treatment (celecoxib, interferon alfa-2b, rintatolimod)|Patients receive celecoxib orally PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV on days 1-3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
2877983|NCT03403621|Experimental|Topical agent A|Topical Pentamidine Isethionate will be randomized to be applied to either the proximal or distal end of the incision. The patient is his/her own control.
2877984|NCT03403621|Placebo Comparator|Topical agent B|Silicone Gels base will be randomized to be applied either to the proximal or distal end of the incision. The patient is his/her own control
2877985|NCT03403595|Experimental|177Lu-EB-PSMA-617 dosimetry calculation|All patients were intravenous injected with single dose 0.80-1.1 GBq (21.5-30 mCi) of 177Lu-EB-PSMA-617, then monitored at 2, 24, 72, 120 and 168 hours post-injection.
2877986|NCT03403582|No Intervention|Control arm|A high-fat break fast meal with no raspberries.
2877987|NCT03403582|Experimental|Raspberry arm|A high-fat break fast meal with raspberries (250g frozen)
2877988|NCT03403569|Experimental|Triptolide Wilfordii Group|150 patients will be enrolled and be administrated with Triptolide Wilfordii 20mg three times a day(TID) per os combined with appropriate ART for 12 months.
2877989|NCT03403569|Placebo Comparator|Placebo Oral Tablet Group|150 patients will be enrolled and be administrated with placebo per os combined with appropriate ART for 12 months.
2877990|NCT03403556|Experimental|Rosuvamibe ® Tab.|Rosuvastatin 10mg/Ezetimibe10mg
2877991|NCT03403556|Active Comparator|Monorova ® Tab.|Rosuvastatin 20mg
2877992|NCT03403543||1|This cohort study only set up a group. We will follow up and observe the pregnant women's lifestyle during pregnancy in order to find the risk factors of adverse pregnancy outcomes. We will divide the participants into more than one group according to the variables（e.g. age, smoking status, drinking status, sleep pattern .etc.）
2877993|NCT03403530|Active Comparator|case group|'IgM rich immunoglobulin' intravenous infusion in the dose of 5 ml/ kg/ dose over 3 hours once a day for 3 days.
2877994|NCT03403530|Placebo Comparator|control group|antibiotics only
2877995|NCT03403517|Experimental|Methylprednisolone|10 mg/kg, single preoperative infusion
2877996|NCT03403517|Active Comparator|Dexamethasone|8 mg dexamethasone, single preoperative infusion
2877997|NCT03403504|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 10 mg
2877998|NCT03403504|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 10 mg
2877999|NCT03403491|Other|Sequence 1|Usual care for 2 weeks followed by using patientMpower application [+digital weighing scales & BP monitor] for 4 weeks followed by sham application (without digital scales or BP monitor) for 4 weeks.
2878000|NCT03403491|Other|Sequence 2|Usual care for 2 weeks followed by sham application (without digital scales or BP monitor) for 4 weeks followed by using patientMpower application [+digital weighing scales & BP monitor] for 4 weeks.
2878001|NCT03403478|No Intervention|Control group|The volunteers will be instructed to remain in an orthostatic position immersed in water up to the imaginary line of the xiphoid process for 45 minutes without performing jerky body movements.
2878002|NCT03403478|Experimental|LICE|The light-intensity continuou exercise (LICE) session comprises a 45-minute of guide walking into the pool at 55-60% of maximum heart rate (HRmax). The HR will be checked every 2 minutes during the whole session.
2878003|NCT03403478|Experimental|MICE|The moderate-intensity continuous exercise (MICE) will bem performed divided into 3 phases: warm-up (10 minutes), main part (30 minutes) and cool down (5 minutes). The warm-up and cool down will be performed at 55-60% HRmax. The main part will last 30 minutes and will be performed by 3 sets of 5 exercises lasting 2 minutes each one at 70-75% HRmax. For all phases, HR will be measured every 2 minutes during the whole session.
2878004|NCT03403478|Experimental|HIIE|The high-intensity intervaled exercise (HIIE) will bem performed divided into 3 phases: warm-up (10 minutes), main part (15 minutes) and cool down (5 minutes). The warm-up and cool down will be performed at 55-60% HRmax. The main part will last 15 minutes and will be performed by 2 sets of 5 exercises lasting 30 seconds to each exercise combined with 1 minute of active recovery. The exercise moment will be performed at 80-85% HRmax and the 1-minute active recovery at 55-60% HRmax. For both warm-up and cool down, HR will be measured every 2 minutes. For main part, HR will be measured at the end of each 30-seconds from exercise.
2878398|NCT03400735|Active Comparator|Cefdinir 300 mg Capsules|
2878006|NCT03403465|Other|Single arm interventional study|Research FDG-PET scan obtained before radiation therapy; a second research FDG-PET scan is obtained at about 3-5 weeks after treatment has started.
2878007|NCT03403452|Experimental|arm for Apatinib|500 mg,p.o.,qd
2878008|NCT03403439|Experimental|All Subjects|Reference Treatment - BI 1015550 alone followed by Test Treatment (itraconazole + BI 1015550)
2878009|NCT03403426|Experimental|Wingman Crossing Catheter|Use of the device to support CTO crossing
2878010|NCT03403413|Experimental|Feasibility|Test feasibility of muscle vibration of tibialis anterior, rectus femoris, short head of biceps and tensor fasciae latae bilaterally during walking for 1 hour 3 times per week for 12 weeks to improve walking speed through improved coordination of hip, knee and ankle flexion.
2878011|NCT03403400|Experimental|VRWP Group|Vestibular Rehabilitation plus Walking with Pedometer Groupd
2878012|NCT03403400|Active Comparator|VRW Group|Vestibular Rehabilitation plus Walking without Pedometer Group
2878013|NCT03403400|No Intervention|VR Group|Vestibular Rehabilitation Only Group. The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
2878014|NCT03403387|Experimental|GlutenShield|3 capsules of GlutenShield supplement/day for 28 days
2878015|NCT03403387|Placebo Comparator|Placebo|3 capsules of the placebo (Avicel and bentonite powder (for color))/ day for 28 days
2878016|NCT03403374|Experimental|Repatha® (evolocumab)|Single arm, all subjects receive Repatha administered by subcutaneous injection via autoinjector(AI)/pen
2878017|NCT03403361|Active Comparator|Arm A: Conventional SECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine single-energy computed tomography (SECT) or DECT scans~In Arm A, patients are treated with treatment plans optimized and calculated on the SECT data. Plan dose is re-calculated for every patient with the clinical plan in a Monte Carlo dose calculation engine for better accuracy. The investigators will use TOPAS, an extension of Geant4 simulation toolkit, as the dose calculation engine.~An additional 2 or 3 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating proton therapy and at approximately two and four weeks after initiating therapy as well as at the conclusion of radiation therapy.~Scans can be performed on the Phillips or Siemens scanners"
2878018|NCT03403361|Experimental|Arm B1: DECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine SECT or DECT scans~In Arm B1, DECT data is used to estimate the actual dose delivered using the clinical plan based on SECT data.~An additional 2 or 3 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating proton therapy and at approximately two and four weeks after initiating therapy as well as at the conclusion of radiation therapy.~Scans can be performed on the Phillips or Siemens scanners"
2878019|NCT03403361|Experimental|Arm B2: DECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine SECT or DECT scans~In Arm B2, the plan is re-optimized on DECT data with the conventional uncertainty margin of 3.5% of proton range.~An additional 2 or 3 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating proton therapy and at approximately two and four weeks after initiating therapy as well as at the conclusion of radiation therapy.~Scans can be performed on the Phillips or Siemens scanners"
2878020|NCT03403361|Experimental|Arm B3: DECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine SECT or DECT scans~In Arm B3, the plan is re-optimized on DECT data with the SPR uncertainties derived from the patient-specific uncertainty model developed.~An additional 2 or 3 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating proton therapy and at approximately two and four weeks after initiating therapy as well as at the conclusion of radiation therapy.~Scans can be performed on the Phillips or Siemens scanners"
2878021|NCT03403348|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will be enrolled in 6 cohorts and receive one of the 6 corresponding SADs of JNJ-64417184, starting from 40 milligram (mg), or placebo in a fasted state. Dose escalation in the subsequent cohorts will depend on the human maximum observed plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) in previous cohorts.
2878022|NCT03403348|Experimental|Part 2: Food Effect|Participants enrolled in cohort 3 of part 1 will roll-over in Part 2 and will receive a single oral dose (the same dose as received in Part 1) of JNJ-64417184 or placebo with a high-fat meal.
2878023|NCT03403348|Experimental|Part 3: Multiple Ascending Dose (MAD)|Participants will be enrolled in 3 cohorts and will receive one of the 3 corresponding MADs of JNJ-64417184 or placebo, dosed once daily for 7 days. Dosing will either occur in the fasted or the fed state, depending on the outcome of Part 2. Dose selection and dose escalation in the MAD cohorts will depend on the observed human Cmax and AUC in previous (SAD) cohorts. Additional cohorts may be evaluated at the discretion of the Sponsor and the Principal Investigator (PI).
2878024|NCT03403348|Experimental|Part 4: Human RSV Challenge (Proof-of-Concept Study Part)|Based on emerging pharmacokinetics (PK) and safety data from Part 3 (MAD), the participants inoculated with respiratory syncytial virus (RSV) -A Memphis 37b and confirmed positive by polymerase chain reaction (PCR) will either receive JNJ-64417184 or placebo once daily OR receive JNJ-64417184 (low dose), JNJ-64417184 (high dose) or placebo once daily.
2878025|NCT03403335|Experimental|Mindfulness Based Practices for Health Care Professionals|
2878026|NCT03403335|No Intervention|Control Group|
2878027|NCT03403322|Other|First test|All measures were evaluated
2878028|NCT03403322|Other|Second test|All measures were evaluated
2878029|NCT03403309|Experimental|Inosine 5'-monophosphate arm|Subjects are treated with inosine 5'-monophosphate to increase serum uric acid level.
2878030|NCT03403309|Placebo Comparator|Placebo arm|Subjects are treated with placebo not to increase serum uric acid level.
2878031|NCT03403296||CLASSIC cohort|Patients with stage II-III GC who underwent D2 resection were randomized (1:1) after surgery to receive adjuvant capecitabine and oxaliplatin (eight three-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or observation alone. Assessment whether patients were disease free were done by abdominal CT or MRI and chest radiograph at regular intervals as planned by protocol.
2878034|NCT03403270|Experimental|ENCOURAGE App Intervention|Users will download the ENCOURAGE mobile app. The App uses a time management technique (i.e. Pomodoro technique) as a strategy to provide prompts for users to engage in an activity. The App can be customized by the users to set prompts at intervals that fit into their schedule. For example, these activities can range from a stretching activity (e.g., a neck stretch), a standing activity (e.g., stand and read), or a physical activity (e.g., fill up the printer with paper, do a squat). Additionally, the App will use Behaviour Change Techniques as a strategy to support participants as they reduce their sedentary behaviour and improve their physical activity levels. The App uses a series of Behavior Change Techniques shown to be effective in promoting a more active lifestyle.
2878035|NCT03403257||Subjects with cognitive impairment|Subjects with MoCA <26
2878036|NCT03403257||Caregivers|Primary caregivers of subjects
2878037|NCT03403244|Experimental|US-MR image fusion-guided PTED|US-MR image fusion-guided PTED: the puncture procedure during PTED was performed under the guidance of ultrasound-MR fusion technique.
2878038|NCT03403244|Active Comparator|fluoroscopy-guided PTED|fluoroscopy-guided PTED: the puncture procedure during PTED was performed under the guidance of fluoroscopy.
2878039|NCT03403231|Active Comparator|Arm 1: Stock messages only|Participants will only receive the stock messages that encourage following recommended behaviors for reducing the risk for developing diabetes.
2878040|NCT03403231|Experimental|Arm 2: Urgency frame message strategy|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the urgency frame message strategy.
2878041|NCT03403231|Experimental|Arm 3: Social norm message strategy|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the social norm messaging strategy.
2878042|NCT03403231|Experimental|Arm 4: Urgency frame and social norm strategies|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the urgency frame and social norm messaging strategies.
2878043|NCT03403231|Experimental|Arm 5: Implementation Intentions and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the implementation intentions and urgency frame messaging strategies.
2878044|NCT03403231|Experimental|Arm 6: Implementation Intentions and Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the implementation intentions and social norm messaging strategies.
2878045|NCT03403231|Experimental|Arm 7: Implementation Intentions, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the implementation intentions, urgency frame, and social norm messaging strategies.
2878046|NCT03403231|Experimental|Arm 8: Implementation Intentions|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the implementation intentions messaging strategy.
2878047|NCT03403231|Experimental|Arm 9: Preference Checklists and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the preference checklists and urgency frame messaging strategies.
2878048|NCT03403231|Experimental|Arm 10: Preference Checklists and Social Norms|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the preference checklists and social norm messaging strategies.
2878049|NCT03403231|Experimental|Arm 11: Preference Checklists, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the preference checklists, urgency frame, and social norm messaging strategies.
2878050|NCT03403231|Experimental|Arm 12: Preference Checklists|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the preference checklists messaging strategy.
2878051|NCT03403231|Experimental|Arm 13: Tailored Aspirations and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the tailored aspirations and urgency frame messaging strategies.
2878052|NCT03403231|Experimental|Arm 14: Tailored Aspirations and Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the tailored aspirations and social norm messaging strategies.
2878053|NCT03403231|Experimental|Arm 15: Tailored Aspirations, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the tailored aspirations, urgency frame, and social norm messaging strategies.
2878054|NCT03403231|Experimental|Arm 16: Tailored Aspirations|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the tailored aspirations messaging strategy.
2878055|NCT03403218|Experimental|case group|BESTest, mini-BESTest, Berg scale and FES (falls efficacy scale) (in Spanish version is administrated in case group.
2878056|NCT03403205|Experimental|15-60 mg WTX101 to subjects treated >28 days with SOC|Subjects treated for >28 days with chelation or zinc (Zn) therapy or a combination of both chelation and Zn therapy will be treated with 15 mg every other day (QOD) to 60 mg once daily (QD) of WTX101 by oral administration.
2878057|NCT03403205|Active Comparator|SOC for subjects treated with SOC >28 days prior|Subjects treated for >28 days with chelation or Zn therapy or a combination of both chelation and Zn therapy will continue to receive the SOC therapy.
2878058|NCT03403205|Experimental|15-60 mg WTX101 to subjects treated ≤28 days with SOC|Subjects who are treatment naïve or have been previously treated with chelation or Zn therapy or a combination of both chelation and Zn therapy for ≤28 days will be treated with 15 mg QOD to 60 mg QD of WTX101 by oral administration.
2878059|NCT03403205|Active Comparator|SOC for subjects treated with SOC ≤28 days prior|Subjects who are treatment naïve or have been previously treated with chelation or Zn therapy or a combination of both chelation and Zn therapy for ≤28 days will initiate or continue SOC therapy.
2878209|NCT03402074|Experimental|Group Hypnosis|5 sessions of group hypnosis, each 90 minutes; plus CDs/MP3 recordings to train at home
2878060|NCT03403192|Active Comparator|EZ-Blocker in the left lung|This arm will receive the EZ-Blocker in the left lung of their body, which functions as a bronchial blocker.
2878061|NCT03403192|Active Comparator|EZ-Blocker in right lung|This arm will receive the EZ-Blocker in the right lung of their body, which functions as a bronchial blocker.
2878062|NCT03403192|Active Comparator|DLT in left lung|This arm will receive the DLT in the left lung of their body, which functions as a bronchial blocker.
2878063|NCT03403192|Active Comparator|DLT in right lung|This arm will receive the DLT in the right lung of their body, which functions as a bronchial blocker.
2878064|NCT03403179|Experimental|Receiving Psychosocial Intervention|Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.
2878065|NCT03403166||DASH diet|The DASH diet consisted of a high intake of fruits, vegetables, and low-fat dairy products. It included a wide range of sources of protein, such as meat, fish, poultry, nuts, and beans. Sugar-sweetened beverages, desserts, and red meat were restricted. In terms of nutrients, the DASH diet had a high amount of fiber and protein; low amounts of saturated fat, total fat, and cholesterol; and intake of potassium, magnesium, and calcium at levels close to the 75th percentile of U.S. consumption.
2878066|NCT03403166||Fruits and vegetables diet|Potassium and magnesium intake was similar to the 75th percentile of U.S. consumption. Fiber intake was high. The fruits and vegetables diet consisted of more fruits and vegetables and fewer snacks and desserts than the control diet, but otherwise was similar to the control diet.
2878067|NCT03403166||Control diet|For the control diet, macronutrient intake was similar to average U.S. consumption and intake of potassium, magnesium, and calcium were similar to the 25th percentile of U.S. consumption. Sodium intake was approximately 3 g/day in each diet.
2878068|NCT03403153|Other|Pilot and Open Trial|All Participants will complete the 8-week parenting support intervention and will provide satisfaction and acceptability ratings of the intervention. In the pilot trial, participants will make these ratings after each session, in the open trial the ratings will be made pre and post intervention.
2878069|NCT03403140|Experimental|Single arm|"Enerceptan®. Injectable Solution in prefilled syringes~Source: GEMABIOTECH S. A. Formulation per unit:~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week"
2878070|NCT03403101|Experimental|SIRIOX regimen|5-FU and leucovorin in the FOLFIRINOX regimen were replaced with oral S-1, forming the SIRIOX regimen(S1 plus irinotecan and oxaliplatin)
2878071|NCT03403088|Experimental|Group LA|INTERVENTION: to apply Laser (780 nm and 70mW) at the cementum-enamel junction fat the teeth affected by sensitivity
2878072|NCT03403088|Placebo Comparator|Group LA-P|INTERVENTION: to apply Laser (780 nm and 70mW) at the cementum-enamel junction at the teeth affected by sensitivity with the laser device having no effective laser emission, only guided by light
2878073|NCT03403088|Experimental|Group DE|INTERVENTION: to brush teeth with a blinded dentifrice with 0,45% of stannous fluoride and a soft-bristled manual toothbrush (Johnson & Johnson®).
2878074|NCT03403088|Placebo Comparator|Group DE-P|INTERVENTION: to brush teeth with a blinded dentifrice with 1500 ppm of available fluoride and a soft-bristled manual toothbrush (Johnson & Johnson®).
2878075|NCT03403088|Experimental|Group RGI|INTERVENTION: to apply a thin layer of resin based glass-ionomer product on the cervical surface of the affected teeth affected by sensitivity following the manufacturer instructions.
2878076|NCT03403088|Experimental|Group RX|INTERVENTION: to apply Adper Single Bond Plus Adhesive in accordance with the manufacturer instructions, at the teeth affected by sensitivity
2878077|NCT03403075|Active Comparator|Usual Care|"Control Group will be offered usual care (UC), which includes two sessions of therapeutic education delivered in small groups. In these educational sessions, patients are provided with useful information on communication strategies, problem solving strategies, recognition and management of symptoms and the management of any aids/orthoses provided in everyday life, etc. In the meetings, it will be emphasized the importance of maintaining an active lifestyle as much as possible by encouraging involvement in physical activity even during the cancer treatment period.~Written information material that summarizes the concepts addressed during group meetings will be provided."
2878078|NCT03403075|Experimental|ETAF: Therapeutic Education Physical Activity|"Intervention group will perform UC, plus 6 individual sessions of therapeutic education and physical activity held by physiotherapists dedicated to the study, according to the patients' needs and objectives.~In these sessions, the topics discussed in group will be deepened, personalizing them according to the patient's characteristics. Furthermore, personalized physical activity is planned, taking into account the context of execution, the clinical condition and the patient's preferences. The patient will be trained to build an action plan aimed at self-plan physical activities and a diary will be provided to monitor the physical activity carried out autonomously.~Written information material that summarizes the concepts addressed during group and individual sessions will be provided."
2878079|NCT03403049|Experimental|Arm 1|Dose-escalation phase I clinical study. In the initial dose levels, 'dose-escalation' refers to an increase in the radiotherapy dose delivered using carbon ion radiotherapy along with a corresponding decrease in the dose delivered using photons.
2878080|NCT03403036|Experimental|Brodalumab|Brodalumab (210 mg) via subcutaneous injection using prefilled syringes
2878081|NCT03403023|Experimental|DES treated patients|This single group of patients is imaged by the Tear Film Imager (TFI) device before and after treatment with Restasis, the treatment indicated for their condition.
2878082|NCT03403010|No Intervention|Control period|In this group conventional physiotherapy of the child will be continued and the therapist will be asked not to use any gaming activities. Also during the control period, the frequency and duration of the therapy sessions will not be influenced by the researchers.
2878111|NCT03402854|Experimental|Active tDCS + bimanual training|In this arm, participants will engage in 120 min of bimanual training. Bimanual training involves using both hands to play with toys and games during the study. During the first 20 min of bimanual training, participants will receive active tDCS via sponges over the scalp.
2878083|NCT03403010|Active Comparator|Intervention period|In this group the usual individual physiotherapy program of the child will be continued as performed before the study and will be executed by the child's usual, familiar physiotherapist. The therapist will be asked to use the rehabilitation-specific gaming software every therapy session, for at least 15 to 20 minutes. The therapist will receive an extensive introduction and demonstration of the software and the researchers will participate in at least one therapy session.
2878084|NCT03403010|No Intervention|Wash-out period|The wash-out period is considered after each intervention period. As during the control period, therapy will be continued as usual during the washout-period but no gaming is allowed during therapy.
2878085|NCT03402997||Resistivity measurements|The resistivity measurements will be done by introducing the needle-probe into fresh healthy, peritumoral, and tumoral ex vivo tissues
2878086|NCT03402984|Experimental|Acotiamide|Acotiamide 100 mg t.i.d. for 3 weeks. Intake of medication 10 minutes before meal.
2878087|NCT03402984|Placebo Comparator|Placebo|Placebo tablets, t.i.d. for 3 weeks. Intake of placebo 10 minutes before meal.
2878088|NCT03402971||healthy pregnant+healthy fetus|healthy pregnant women with suspected healthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
2878089|NCT03402971||non healthy pregnant|non healthy women with suspected healthy or unhealthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
2878090|NCT03402971||non healthy fetus|healthy or non healthy pregnant women with suspected non healthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
2878091|NCT03402945|Active Comparator|Arm 1|"cefazolin prophylaxis plus Prevena negative-pressure wound management system . Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h.~Prevena will be applied to all diabetic and/or obese patients (BMI >30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 day"
2878092|NCT03402945|Active Comparator|Arm 2|"cefazolin and vancomycin prophylaxis plus Prevena negative-pressure wound management system. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hrs after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose.~Prevena will be applied to all diabetic and/or obese patients (BMI >30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 days."
2878093|NCT03402945|Active Comparator|Arm 3|"cefazolin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h.~Standard wound dressing: non-negative wound dressing as standard of care at the study site."
2878094|NCT03402945|Active Comparator|Arm 4|"cefazolin and vancomycin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose.~Standard wound dressing: non-negative wound dressing as standard of care at the study site."
2878095|NCT03402932|Experimental|Group1|
2878096|NCT03402932|Experimental|Group2|
2878097|NCT03402932|Experimental|Group3|
2878098|NCT03402919||Normal healthy elderly|participants with no subjective or objective cognitive deficits or decline.
2878099|NCT03402919||Subjective Cognitive Decline|Participants with a complaint of subjective cognitive impairment, but no objective evidence of such.
2878100|NCT03402919||Mild Cognitive Impairment (MCI)|Participants with objective evidence of cognitive impairment, but it does not impact on daily function.
2878101|NCT03402919||Vascular MCI|Participants meeting criteria of MCI who also show signs of cerebrovascular disease on imaging but have no history of stroke.
2878102|NCT03402919||Alzheimer's Disease|Participants with dementia of the Alzheimer's type according to the National Institute of Aging-Alzheimer's Association criteria
2878103|NCT03402919||Dementia of Mixed Etiology|Participants with dementia and evidence of more than one etiology.
2878104|NCT03402919||Lewy Body/Parkinson's spectrum|Participants with Parkinson's disease who show mild or moderate cognitive impairment and/or dementia.
2878105|NCT03402919||Frontotemporal dementia (FTD) spectrum|Participants with behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, or corticobasal syndrome
2878106|NCT03402906|Experimental|Family-Clinician Collaboration|"Experimental group which will be performing the Family-Clinician Collaboration Program. Family members will work closely with the Clinician to understand the status and goals of the stroke survivor, and family members will integrate Family-Mediated Treatment Procedures into their time spent with the patient.~Intervention: Behavioral - Family-Clinician Collaboration Program; Behavioral - Standard Care at KIR"
2878107|NCT03402906|Sham Comparator|Control|"Control group in which patient will receive the standard treatment provided at Kessler Institute for Rehabilitation (KIR).~Intervention: Behavioral - Standard Care at KIR"
2878108|NCT03402893|Experimental|single arm Onexton gel application|Onexton gel will be supplied to all subjects and applied once daily to the face
2878109|NCT03402880|Experimental|Treatment (pembrolizumab, epacadostat)|Patients receive pembrolizumab IV on day 1 and epacadostat PO BID on days 1-21. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. Patients benefiting from treatment may continue for an additional 17 courses.
2878110|NCT03402867|Experimental|Intervention|Deep dry needling applied on active myofascial trigger points in the shoulder and neck regions
2878145|NCT03402542||Cholecystectomy|Patients with a symptomatic vesicular lithiasis, having undergone cholecystectomy during a scheduled hospitalization in the CHU Brugmann Hospital between May 2016 and November 2017.
2878112|NCT03402854|Experimental|Sham tDCS + bimanual training|In this arm, participants will engage in 120 min of bimanual training. Bimanual training involves using both hands to play with toys and games during the study. During the first 20 min of bimanual training, participants will wear the tDCS device that is worn by the active tDCS group, but in the sham group, participants will not receive stimulation during this 20 min period.
2878113|NCT03402841|Experimental|Olaparib|"Olaparib will be supplied as film-coated tablets containing 150 mg or 100 mg of olaparib.~Patients will be administered olaparib orally twice daily (bid) at 300 mg."
2878114|NCT03402815|Experimental|A|Patients received Maraviroc 300 mg/day in addition to current ART for 24 weeks. At the end of the first 24-week period patients were switched to ART with no additional treatment.
2878115|NCT03402815|Experimental|B|Patients received ART with no additional treatment for 24 weeks. At the end of the first 24-week period patients were switched to Maraviroc 300 mg/day in addition to current ART.
2878116|NCT03402789|Experimental|Docosahexaenoic acid (DHA) arm|Participants will receive a pill of docosahexaenoic acid 1,200mg daily in addition to 2 hours of daily eye patching of the affected eye.
2878117|NCT03402789|Placebo Comparator|Placebo arm|Participants will receive a placebo pill daily in addition to 2 hours of daily eye patching of the affected eye.
2878118|NCT03402776|No Intervention|good resp. after 3 vacc. inject.|no randomization for a 4th dose.
2878119|NCT03402776|Experimental|bad resp. after 3 vacc. inj., 4th inj|After randomization, these patients will receive a 4th dose one month after the 3rd dose.
2878120|NCT03402776|No Intervention|bad resp. after 3 vacc. inj., no 4th inj|After randomization, these patients will not receive a 4th dose one month after the 3rd dose.
2878121|NCT03402763|No Intervention|Control Arm|Participants receive a short informational handout on the process and choices involved in advance care planning.
2878122|NCT03402763|Experimental|Intervention|Participants are shown a 6-minute video that describe CPR, breathing tube placement, and mechanical breathing support in addition to the general process of advance care planning.
2878123|NCT03402750|Experimental|Meds to Beds|Patients receive medication in-hand at discharge from the hospital
2878124|NCT03402750|Active Comparator|Standard Care|Electronic prescription with patient pickup at the pharmacy
2878125|NCT03402737|Experimental|Stereotactic body radiotherapy + IM|Single arm phase I trial with 3 Stereotactic Body Radiation Therapy dose-escalation arms.
2878126|NCT03402711||Bleeding Risk in Chinese ACS II|1.This is an observational study，there is no intervention to be administered. 2.5500 ACS patients who meet the inclusion criteria for PCI treatment will be consecutively enrolled according to random number sampling.
2878127|NCT03402698|Experimental|cholecalciferol|cholecalciferol at a dose 1000 IU /day for 3 months
2878128|NCT03402685|No Intervention|NIBP-Group|NIBP will be shown, ClearSight will be covered.
2878129|NCT03402685|Experimental|ClearSight-Group|ClearSight will be shown, NIBP will be covered.
2878130|NCT03402672|Experimental|AWAITS|Participants who meet criteria will receive the AWAITS self-administered, e-health application intervention.
2878131|NCT03402659|Experimental|neflamapimod|40 mg hard gelatin capsules, taken twice daily with food.
2878132|NCT03402659|Placebo Comparator|placebo|hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food.
2878133|NCT03402646|Experimental|Reminder module (SMS and Phone call)|"Intervention will consist of a Reminder module delivered via SMS and telephone calls by an automated, customized software application. This will include standardized SMS reminder 3 days prior to scheduled immunization clinic appointments, telephone call reminders a day prior to scheduled clinic appointment (4 to 6pm) (in addition to standard care - routine paper-based appointment scheduling and counselling by care providers) for routine immunization. Reminders will be provided consistently for all immunization clinic appointments until the child turns 12 months of age."
2878134|NCT03402646|Experimental|Photovoice|In two small groups of 15 participants each per state, purposively selected pregnant women in their third trimester and parents of infants aged 0-12 months in the community, as well as community leaders, service providers and policy makers will be exposed to photographs (taken from other sources) of debilitating consequences of non-immunization, which will form the basis of the group discussions, knowledge sharing and consensus-building sessions, each lasting about 45 minutes to 1 hour. Each community cluster will be linked to a PHC.
2878135|NCT03402646|No Intervention|Control|Respondents in control clusters will receive standard care only - comprising routine paper-based appointment scheduling
2878136|NCT03402620|Active Comparator|four ampoules group|gonadotropin starting dose is 4 ampoules daily
2878137|NCT03402620|Active Comparator|six ampoules group|gonadotropin starting dose is 6 ampoules daily
2878138|NCT03402607|Active Comparator|Percutaneous Local Abalation (PLA)|A PLA procedure uses high-energy radio waves to treat liver tumors. Using CT and ultrasound guidance the doctor inserts a thin, needle-like probe into the liver tumor A high-frequency current is then passed through the tip of the probe, which heats the tumor with the goal to destroy the cancer cells. This may be done as an outpatient procedure or a short (1-2 day) hospital stay. PLA is the standard treatment for patients with liver cancer who cannot undergo liver surgery.
2878139|NCT03402607|Active Comparator|Hypofractionated Image-Guided Radiation Therapy (HIGRT)|HIGRT is an emerging treatment option for patients with HCC; it utilizes external radiation where multiple beams enter the body from multiple angles to treat the liver cancer over typically 5-10 treatments while minimizing radiation to normal tissues. You will receive between 5-10 fractions (treatments) of radiation. Fraction size will be either 5 or 10 Gy (pronounced Gray, a standard unit of radiation measurement) depending on your tumor size and location or underlying liver function. The total dose of radiation is 50 Gy.
2878140|NCT03402594|No Intervention|No oxygen|No oxygen supplementation given
2878141|NCT03402594|Active Comparator|Low flow oxygen|Oxygen cannula with a flow rate of 2 liter/minute
2878142|NCT03402594|Experimental|High flow oxygen|Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
2878143|NCT03402581||c-mac used for intubation|obese patients intubated with c-mac videolaryngoscope
2878144|NCT03402581||mc-grath used for intubation|obese patients intubated with mc-grath videolaryngoscope
2878146|NCT03402529|Other|CESM|
2878360|NCT03400969|Active Comparator|Aequasyal (OGT)|Oral moisturizer
2878147|NCT03402516|Experimental|18.5Fr resector|Used of a 18.5Fr bipolar resector for hysteroscopic myomectomy. Cervical dilatation would be performed until Hegar bougie number 7 and then a classic hysteroscopic resection will be performed with a 18.5Fr bipolar resector.
2878148|NCT03402516|Active Comparator|26Fr resector|Used of a 26Fr bipolar resector for hysteroscopic myomectomy. Cervical dilatation would be performed until Hegar bougie number 10 and then a classic hysteroscopic resection will be performed with a 24Fr bipolar resector.
2878149|NCT03402503|Experimental|Group A|Montelukast buccal film given daily for 26 weeks
2878150|NCT03402503|Placebo Comparator|Group B|Placebo buccal film given daily for 26 weeks
2878151|NCT03402490|Experimental|Motivational interviewing|Over a time span of 6 months, participants in the intervention group received up to 7 sessions of motivational counseling, lasting 15-30 minutes each, to enhance physical activity.
2878152|NCT03402490|No Intervention|Usual care|Participants who served as controls received usual care.
2878153|NCT03402464|Experimental|Icotinib combined dihydroaremisinin|
2878154|NCT03402438|Experimental|Normal (healthy subjects)|Healthy subjects matched for age, body weight and gender to the groups with renal impairment
2878155|NCT03402438|Experimental|Mildly renal impaired|Subjects with renal impairment and an estimated glomerular function rate between equal or above 60 and below 90 ml/min/1.75 m*2
2878156|NCT03402438|Experimental|Moderately renal impaired|Subjects with renal impairment and an estimated glomerular function rate between equal or above 30 and below 60 ml/min/1.75 m*2
2878157|NCT03402438|Experimental|Severely renal impaired|Subjects with renal impairment and an estimated glomerular function rate between below 30 ml/min/1.75 m*2
2878158|NCT03402425|Experimental|All included patients|A 18F-FET PET scan is performed
2878159|NCT03402412|Experimental|Study Arm|Narrow-band UVB will be given to a small part of the patients skin with eczema. The rest of the skin surface serves as control.
2878160|NCT03402399|Other|Primary Myelofibrosis|Blood test
2878161|NCT03402399|Other|Secondary Myelofibrosis|Blood test
2878162|NCT03402386|Experimental|MT-6548|
2878163|NCT03402373|Experimental|Lycoderm|soft gel contains nutritional supplement
2878164|NCT03402373|Placebo Comparator|Placebo|Soft gel without active ingredients
2878165|NCT03402360|Experimental|Virtual Reality rehabilitation group|The Virtual Reality group will perform upper extremity motor rehabilitation and neurocognitive rehabilitation based on virtual reality training.
2878166|NCT03402360|Active Comparator|Control group|The Control group will perform the same motor and neurocognitive rehabilitation but with the virtual reality turned off.
2878167|NCT03402347|Experimental|Laser irradiation regimes|Non-ionising radiation intervention will be applied to skin explants
2878168|NCT03402334|Experimental|CVD risk factor counseling|"This arm will receive intervention 'Patient counseling for HCV associated CVD risk factors' in addition to standard of care Hepatitis C counseling.~Cardiovascular risk factor counseling will include:~Increased risk for atherosclerosis with chronic HCV infection~Increased risk of heart attack and stroke~Treatment of HCV infection and reduction of viral load reducing risk of stroke and heart attack"
2878169|NCT03402334|No Intervention|Standard of care counseling|"This arm will receive standard of care Hepatitis C counseling:~HCV infection poses an increased risk for hepatocellular carcinoma~Hepatitis C is a curable disease~Hepatitis C is transmitted through blood to blood contact, primarily through sharing needles~HCV+ individuals should be vaccinated for Hepatitis A (HAV) and Hepatitis B (HBV)~HCV+ individuals should reduce alcohol intake and shellfish consumption"
2878170|NCT03402321|Active Comparator|control group|Gelatin Sponge Sheet is a heamostatic agent act as a mechanical barrier to protect the palatal donor site
2878171|NCT03402321|Experimental|intervention group|alvogyl in a paste form with analgesic action to protect the palatal donor site and help to relief pain
2878172|NCT03402308|Experimental|Schisandra chinensis extract group|This group takes Schisandra chinensis extract for 12 weeks
2878173|NCT03402308|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
2878174|NCT03402295|Active Comparator|Vcd- (Bortezomibe, cyclophosphamide and dexamethasone)|"Intervention - Bortezomib 1.3mg/m2 Intra venous or Subcutaneous once a week (D1-8-15-22) 35days cycle Intervention- Dexamethasone 40mg once a week for four weeks orally or Intravenously- total dose per cycle was 160mg.~Intervention- Cyclophosphamide 900-2000mg- intravenously or orally- total dose monthly Total of four cycles"
2878175|NCT03402295|Active Comparator|Ctd- Cyclophosphamide, thalidomide and dexamethasone|"Intervention- Cyclophosphamide 900-2000mg intravenously or orally total dose monthly Intervention- Thalidomide 100-200mg orally- daily dose Intervention -Dexamethasone 40mg once a week for four weeks each month- total dose per cycle was 160mg Total of four cycles (cycles of 28 each one)~28 days each cycles- total of four cycles"
2878176|NCT03402282|Experimental|embolization|upper rectal artery embolization
2878177|NCT03402282|Active Comparator|surgical treatment|surgical repair through the classic technique (Milligan and Morgan technique)
2878178|NCT03402269||Adolescents with displaced clavicle fractures|Adolescents (11 to 17 years old) with displaced clavicle fractures will be enrolled in this study.
2878179|NCT03402256|Experimental|Text Message (TM)|"Participants will receive daily text messages and all elements of standard care. They received 3 text messages per day for the first four weeks of the study and 3 messages per week for the last four weeks. Key domains of message topics were chosen based on the content of evidence-based, relapse prevention treatment. Daily messages determined current level of functioning and provide intervention messages in response. Text messages will be sent via Google Voice on a research computer. Participants will respond to the text messages either with a specified response (e.g. YES/NO) or a generic response (e.g. 1). Some messages will ask for a specific reply in response to a question. Based on the participant's response (e.g. high, med, low), the research assistant will respond with a text message tailored to the participant's message. All text messages will be sent to the HIC in an amendment to this protocol for approval."
2878206|NCT03402100|Experimental|0.01% atropine plus 0.25% Ketorolac|children who received 0.01% atropine plus 0.25% Ketorolac for myopia
2878207|NCT03402100|Experimental|0.005% atropine plus 0.25% Ketorolac|children who received 0.005% atropine plus 0.25% Ketorolac for myopia
2878208|NCT03402087|Experimental|BMS-986165+Methotrexate+Leucovorin|Three treatments administered
2878361|NCT03400969|Active Comparator|Salient (new product)|Oral moisturizer
2878180|NCT03402256|No Intervention|Standard Care (SC)|"Participants will receive only standard care provided by the liver transplantation team. No additional behavioral or psychosocial interventions will be provided. All aspects of care received by SC participants will also provided to the TM condition participants. Medical care will be managed by medical specialty providers. SC condition participants will receive behavioral treatment within the liver transplantation clinic by psychology fellows and/or psychologists/psychiatrists. Treatment schedules and session topics will be determined by individual providers, per usual practice.~These participants will receive only study-specific assessments. Participants in this condition will complete assessments at baseline, 4-weeks and 8-weeks that measure self- reported substance use, stress, and coping skills. At each in-person assessment, participants will provide urine for EtG analysis and will be compensated."
2878181|NCT03402243|Experimental|Menthol ban only for cigarettes|Participants will have available to them non-menthol cigarettes, menthol and tobacco flavored versions of a cigarette-like e-cigarette, menthol and tobacco flavored versions of a tank like e-cigarette and nicotine gum and lozenge
2878182|NCT03402243|Experimental|Menthol ban for cigarettes and e-cigarettes|Participants will have available to them non-menthol cigarettes, tobacco flavored version of a cigarette-like e-cigarette, tobacco flavored version of a tank like e-cigarette and nicotine gum and lozenge
2878183|NCT03402243|Other|No Menthol Ban|Participants will have available to them menthol and non-menthol cigarettes, menthol and tobacco flavored versions of a cigarette-like e-cigarette, menthol and tobacco flavored versions of a tank like e-cigarette and nicotine gum and lozenge
2878184|NCT03402230|Experimental|Arm I (Avmacol lower dose, Avmacol higher dose)|Participants receive lower dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days. After 10-14 days, participants receive higher dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days.
2878185|NCT03402230|Experimental|Arm II (Avmacol higher dose, Avmacol lower dose)|Participants receive higher dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days. After 10-14 days, participants receive lower dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days.
2878186|NCT03402204|Experimental|Simvastatin 10 mg|Simvastatin 10 mg
2878187|NCT03402204|Experimental|Simvastatin 40 mg|Simvastatin 40 mg
2878188|NCT03402191|Active Comparator|L-arginine|l-arginine for pulmonary hypertension in patients with thalassemia.
2878189|NCT03402191|Active Comparator|Sildenafil|Sildenafil for pulmonary hypertension in patients with thalassemia.
2878190|NCT03402191|No Intervention|Control|No pulmonary hypertension
2878191|NCT03402178|Experimental|E2082|E2082 will be administered as a 0.2 milligram (mg) solution, a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg E2082 solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, and 2.5 mg E2082 tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg E2082 under fasted conditions, and then they will receive 5 mg E2082 under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg, 15 mg, 25 mg, 40 mg, and 10 mg E2082 tablets under fasted conditions. Part B: Participants in Cohorts 1 to 3, respectively, will receive 2.5 mg, 5 mg, and 10 mg tablets once daily for 10 days. E2082 will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.
2878192|NCT03402178|Placebo Comparator|E2082-matched placebo|Matched placebo will be administered as a 0.2 mg solution, a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg matched placebo solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, and 2.5 mg matched placebo tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg matched placebo under fasted conditions, and then they will receive 5 mg matched placebo under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg, 15 mg, 25 mg, 40 mg, and 10 mg matched placebo tablets under fasted conditions. Part B: Participants in Cohorts 1 to 3, respectively, will receive 2.5 mg, 5 mg, and 10 mg matched placebo tablets once daily for 10 days. Matched placebo will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.
2878193|NCT03402165|Experimental|Normal Alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
2878194|NCT03402165|Experimental|Mild elevation of alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
2878195|NCT03402165|Experimental|High elevation of alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
2878196|NCT03402152|Experimental|NRX-101 vs. Placebo|Following study enrollment and randomization, subjects will undergo two treatment sessions, 3 days apart. Each treatment session will be conducted while the subject is undergoing Magnetic Resonance Spectroscopy to measure Glx in the ACC. In one treatment session the subject will receive oral placebo and in the other treatment session the subject will receive oral NRX-101. Following the second treatment session, the subject will participate in a four week open study of NRX-101, at the end of which a third session of Magnetic Resonance Spectroscopy will be conducted.
2878197|NCT03402152|Experimental|NRX-101 vs. lurasidone HCl|Following study enrollment and randomization, subjects will undergo two treatment sessions, 3 days apart. Each treatment session will be conducted while the subject is undergoing Magnetic Resonance Spectroscopy to measure Glx in the ACC. In one treatment session the subject will receive oral lurasidone and in the other treatment session the subject will receive oral NRX-101. Following the second treatment session, the subject will participate in a four week open study of NRX-101, at the end of which a third session of Magnetic Resonance Spectroscopy will be conducted.
2878198|NCT03402139||IUGR infants|Intrauterine growth restricted infants will be enrolled. There are no interventions.
2878199|NCT03402139||AGA infants|Appropriate for gestational age infants will be enrolled. There are no interventions.
2878200|NCT03402126||TPD RAMWare Download|Subjects who qualify and consent to participate in the TPD study will have TPD RAMWare injected into their device to collect data.
2878201|NCT03402113|Experimental|Dexmedetomidine group|Dexmedetomidine consistent infusion as sedative.
2878202|NCT03402113|Active Comparator|Midazolam group|Midazolam consistent infusion as sedative.
2878203|NCT03402100|Experimental|0.01% atropine|children who received 0.01% atropine for myopia
2878204|NCT03402100|Experimental|0.005% atropine|children who received 0.005% atropine for myopia
2878205|NCT03402100|Experimental|0.25% Ketorolac|children who received 0.25% Ketorolac for myopia
2878210|NCT03402061||Community living seniors|Approximately 50 seniors will taste test each nutrient enhanced recipe and determine acceptability and palatability.
2878211|NCT03402061||LTC cognitively well|Approximately 15 seniors living in long term care who do not have cognitive impairment will taste test each nutrient enhanced recipe and determine acceptability and palatability.
2878212|NCT03402061||LTC persons living with dementia|Approximately 15 seniors living in long term care with cognitive impairment will taste test each nutrient enhanced recipe and determine acceptability and palatability.
2878213|NCT03402048|Active Comparator|control arm|"At discretion of the treating phisician. Common chemotherapic regimens include:~Gemcitabine at 1000 or 1250 mg/m2 IV (in the vein) on day 1 and 8 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on day 1 of each 21 day cycle plus Gemcitabine at 1000 mg/m2 IV on Day 1 and 8 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on Day 1 of each 21 day cycle plus Pemetrexed 500mg/m2 on day 1 IV on Day 1 of each 21 day cycle.~Vinorelbine 30 mg/m2 IV on day 1 and day 8 every 3 of each 21 day cycle.~Number of Cycles: to a maximum of 6 cycles until progression or unacceptable toxicity."
2878214|NCT03402048|Experimental|experimental arm|"Treatment prescriptions will be based on gene analysis:~Carboplatin at an AUC of 6 IV (in the vein) on day 1 of each 21 day cycle.~Gemcitabine at 1000 mg/m2 IV on day 1 and 8 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on day 1 of each 21 day cycle plus Gemcitabine at 1000 mg/m2 IV on Day 1 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on Day 1 of each 21 day cycle plus Pemetrexed at 500 mg/m2 IV on Day 1 of each 21 day cycle.~Pemetrexed 500mg/m2 IV on Day 1 of each 21 day cycle.~Docetaxel 75 mg/m2 IV on Day 1 of each 21 day cycle. Or Vinorelbine 30 mg/m2 IV on day 1 and day 8 of each 21 day cycle.~Number of Cycles: to a maximum of 6 cycles until progression or unacceptable toxicity."
2878215|NCT03402035||Whole Blood|Subjects at enrolling centers that utilize whole blood for hemorrhagic shock
2878216|NCT03402035||Component Therapy|Subjects at enrolling centers that utilize component therapy for hemorrhagic shock
2878217|NCT03402009|Experimental|Experimental|independent meditation using web-based tools, apps, and EEG neurofeedback
2878218|NCT03402009|Active Comparator|Active Control|independent meditation using web-based tools and apps
2878219|NCT03401996|Experimental|Real tDCS|
2878220|NCT03401996|Sham Comparator|Sham tDCS|
2878221|NCT03401983|Experimental|PFMT + AT|Pelvic Floor Muscle Training and Abdominal Training
2878222|NCT03401983|Active Comparator|PFMT|Pelvic Floor Muscle Training
2878223|NCT03401970|Active Comparator|Acellular carbohydrate diet|Prescribed dietary pattern. Carbohydrates from acellular sources, e.g., refined flour/bakery products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population.
2878224|NCT03401970|Experimental|Cellular carbohydrate diet|Prescribed dietary pattern. Carbohydrates from cellular sources, e.g., root vegetables, fruits, whole-grain rice, non-flour grain products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population similar to the acellular carbohydrate diet.
2878225|NCT03401970|Experimental|Low-carbohydrate high-fat diet|Prescribed dietary pattern. Energy largely from fat, cellular carbohydrate sources, and otherwise similar food types as in the acellular/cellular carbohydrate diets including at least 500 grams of fruits/vegetables per day.
2878226|NCT03401957||RAS wild-type colorectal cancer|RAS mutation of patients who are pathologically diagnosed as metastatic colorectal cancer with RAS wild type genotyping will be evaluated using liquid biopsy during cetuximab treatment.
2878227|NCT03401944|Active Comparator|Total Parenteral Nutrition (TPN)|Overnight infusion of Parenteral Nutrition supplied in all-in one bag -format. Infusion-rate of 0.16 gram Nitrogen/kg/day.
2878228|NCT03401944|Placebo Comparator|Control (saline infusion)|Overnight infusion of physiological saline at the same infusion-rate; ml/kg as intervention (TPN).
2878229|NCT03401918|Experimental|Comparing the microbiome and ERA in RPL and infertility|"In this arm we will assess the uterine environment at the time of implantation in recurrent pregnancy loss patients and unexplained infertility patients and compare the environment in these patient populations to healthy parous controls.~We will test the uterine endometrial gene expression using the ERA test and the uterine micro biome."
2878230|NCT03401918|Experimental|The impact of progesterone and antibiotics/probiotics|In this arm, recurrent pregnancy loss and unexplained infertility patients who have abnormal results (an abnormal microbiome or an abnormal ERA) will have the option to undergo treatment followed by retesting of the uterine environment. For an abnormal ERA suggesting a pre-receptive result, luteal phase vaginal progesterone supplementation will be offered prior to re-testing of the ERA. For an abnormal microbiome a combination of oral antibiotics and vaginal probiotics will be offered prior to re-testing the uterine microbiome.
2878231|NCT03401905|Experimental|Low frequency|Percutaneous electrical nerve stimulation with frequency of 2 Hz and 120 microseconds of pulse width will be applied.
2878232|NCT03401905|Active Comparator|High frequency|Percutaneous electrical nerve stimulation with frequency of 120 Hz and 200 microseconds of pulse width will be applied.
2878233|NCT03401892|Experimental|Patients with a history of NAION|patients with a history of non-arteritic anterior ischemic optic neuropathy (NAION) in one eye
2878234|NCT03401892|Experimental|Healthy control subjects|healthy age-and sex- matched control subjects
2878235|NCT03401879|Experimental|Patients with MS|Patients with Multiple Sclerosis
2878236|NCT03401879|Experimental|Healthy control subjects|Healthy age- and sex- matched control subjects
2878237|NCT03401866|Other|DSC-MRI scan|All subjects will receive a double dose injection protocol that will be split into multiple doses for sequential DSC-MRI scans.
2878238|NCT03401853|Experimental|Treatment (pembrolizumab, rituximab)|"INDUCTION: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 and on day 1 of course 2. Courses repeat every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~EXTENDED THERAPY: Patients with at least a partial response receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years (35 doses) in the absence of disease progression or unacceptable toxicity."
2878239|NCT03401840|Experimental|postoperative SBRT|SBRT consists of a total dose of 36 Gy in 6 fractions over 11-13 days
2878240|NCT03401827|Experimental|Gemcitabine + nab-paclitaxel|Case with chemotherapy (Gemcitabine + nab-paclitaxel)
2879103|NCT03395977|Experimental|Febuxostat PO and Placebo IV|240 mg a day for 3 days
2878241|NCT03401801|Active Comparator|4 ml of 1% lidocaine|Procedure: 4 ml of 1% lidocaine is injected for stellate ganglion block using the Ultrasound(US)-guided lateral approach at the sixth cervical vertebral level.
2878242|NCT03401801|Active Comparator|6 ml of 1% lidocaine|Procedure: 6 ml of 1% lidocaine is injected for stellate ganglion block using the US-guided lateral approach at the sixth cervical vertebral level.
2878243|NCT03401801|Active Comparator|8 ml of 1% lidocaine|Procedure: 8 ml of 1% lidocaine is injected for stellate ganglion block using the US-guided lateral approach at the sixth cervical vertebral level.
2878244|NCT03401788|Experimental|Open Label PT2977|PT2977 is a small molecule inhibitor of HIF-2α, which impairs hypoxic and pseudo-hypoxia signaling in cancer cells.
2878245|NCT03401775|Experimental|Group1|Cognitive rehabilitation program will be administered for 4 weeks, three times a week, 30 minutes a day
2878246|NCT03401775|No Intervention|Group2|No intervention will be administered
2878247|NCT03401762|Experimental|Chronic stroke MCI Electromyogram (EMG) pairs|Decoupling 2 muscles at a time with MCI
2878248|NCT03401762|Experimental|Chronic stroke MCI EMG triplets|Decoupling 3 muscles at a time with MCI
2878249|NCT03401762|Experimental|Chronic stroke MCI while reaching|Decoupling muscles with MCI while reaching to targets
2878250|NCT03401762|Sham Comparator|Chronic stroke Sham MCI|Sham control group
2878251|NCT03401762|Experimental|Acute stroke MCI|Decoupling muscles with MCI in acute stroke subjects
2878252|NCT03401762|Sham Comparator|Acute stroke Sham MCI|Acute stroke subjects sham comparator
2878253|NCT03401749|No Intervention|Control Group|Usual preadmission surgery instructions (shower the night before).
2878254|NCT03401749|Experimental|Theraworx Group|Usual preadmission surgery instructions (shower the night before) plus theraworx skin wipe system use the night before surgery and 1 hour before surgery.
2878255|NCT03401749|Experimental|CHG Group|Usual preadmission surgery instructions (shower the night before) plus chlorhexidine gluconate (CHG) skin wipe system use the night before surgery and 1 hour before surgery.
2878256|NCT03401736|Experimental|Group M：received midazolam|Patients who requires the mechanical ventilation allocated to the midazolam group (group M) were treated with an infusion bolus of 0.05 mg/kg and continuous infusion of 0.04 to 0.20 mg/kg/hour, with the dosage adjusted to achieve the desired level of sedation.
2878257|NCT03401736|Active Comparator|Group D: received dexmedetomidine|Patients who requires the mechanical ventilation allocated to the dexmedetomidine group (group D) received an infusion bolus of 1 ug/kg within 10 minutes and continuous infusion of 0.25 to 0.75 ug/kg/hour, with the dosage adjusted to achieve the desired level of sedation.All patients maintained BIS between 65~85 and the Ramsay score was 3 to 4.
2878258|NCT03401723|Other|Novices|"Any physician who has no experience of endoscopies or has done no more than 50 colonoscopies.~Each subject included are to perform on the Endoscopy Training System (ETS) during which data for 3D-Colonoscopy Progression Score and 3D-Colonoscopy Retraction Score is gathered."
2878259|NCT03401723|Other|Experienced|"Includes any physician who have succeeded more than 140 colonoscopies. Professional backgrounds include surgeons and gastroenterologists.~Each subject included are to perform on the ETS during which data for 3D-Colonoscopy Progression Score and 3D-Colonoscopy Retraction Score is gathered."
2878260|NCT03401710|Experimental|Group 1|Recombinant human erythropoietin 4000 UI will be administered subcutaneously every other day
2878261|NCT03401710|No Intervention|Group 2|No recombinant human erythropoietin will be administered to this group
2878262|NCT03401697||HIV/HCV Co-infected|Patients with HIV/HCV co-infection
2878263|NCT03401697||Type 2 Diabetes|Patients with Type 2 Diabetes
2878264|NCT03401684|Experimental|Resilient Minds|Four comprehensive, skill-building learning modules in the areas of psychological trauma, mental health problems, resiliency and workplace stress.
2878265|NCT03401671|Experimental|Japanese|Healthy subjects of Japanese descent will receive a single dose of 300 milligrams (mg) lanadelumab subcutaneous (SC) injection in the abdomen.
2878266|NCT03401671|Experimental|Non-Hispanic Caucasians|Healthy Non-Hispanic Caucasian subjects will receive a single dose of 300 mg lanadelumab SC injection in the abdomen
2878267|NCT03401645|Experimental|Treatment (Alarm Active)|"Participants will be wearing the wrist device with an alarm timer that sends out signals every 5 minutes. The alarm is a buzzing noise and a vibration. Participants must turn off the alarm then perform a series of visuomotor tasks. This will be done for one hour, twice a day for two weeks.~Intervention: Device - Wrist Alarm; Behavioral - Home-based Arm and Hand Exercise"
2878268|NCT03401645|Sham Comparator|Control (Sham Control)|"Participants will perform the same tasks as the Alarm/Treatment group, but without the alarm timer. This is a series of visuomotor tasks for one hour, twice per day for two weeks.~Intervention: Behavioral - Home-based Arm and Hand Exercise"
2878269|NCT03401619||Osteoporosis With Cognitive impairment|
2878270|NCT03401619||Osteoporosis With Arterial stiffness|
2878271|NCT03401619||Osteoporosis|
2878272|NCT03401619||Normal|
2878273|NCT03401606|Active Comparator|Remifentanil|remifentanil and dexmedetomidine, 0.25 ng/mL, given intravenous, infusion, until surgery finished.
2878274|NCT03401606|Active Comparator|Dexmedetomidine|dexmedetomidine and remifentanil, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished
2878275|NCT03401593|Active Comparator|ablation|Patients in this group are treated with radio-frequency catheter ablation.
2878276|NCT03401593|No Intervention|non-ablation|Patients in this group are treated with rate control medications (e.g., beta blocker, calcium channel blocker, and digitalis) and anti-arrhythmic drugs. They also can be treated with DC cardio-version.
2878277|NCT03401580|Experimental|Viena II - 160/10|Fixed-dose, 160mg +10 mg, orally, once daily.
2878278|NCT03401580|Experimental|Viena II - 190/10|Fixed-dose, 190mg + 10 mg, orally, once daily.
2878279|NCT03401580|Experimental|Viena II - 160/12|Fixed-dose, 160mg + 12 mg, orally, once daily.
2878280|NCT03401580|Experimental|Viena II - 190/12|Fixed-dose, 190mg + 12 mg, orally, once daily.
2878281|NCT03401567|Experimental|Exercise group|Elbow bending exercises with blood flow restriction will be performed to the exercise group.
2878282|NCT03401567|No Intervention|Control group|Control group will continue daily activities and a brochure on strengthening exercises and protection from injuries.
2879200|NCT03395262|Active Comparator|Active without caffeine|Novel formula without caffeine
2878283|NCT03401554|Active Comparator|collagen membrane group|Sinus floor elevation with simultaneous implant placement and closure of the osteotomy with collagen membrane
2878284|NCT03401554|Experimental|titanium mesh group|Sinus floor elevation with simultaneous implant placement and closure of the osteotomy with titanium mesh
2878285|NCT03401541|Experimental|Fat-Mal, calcifediol then calciferol|Participants with diagnosed fat malabsorption syndrome will initially receive one capsule of calcifediol for the first round of blood draws and then receive one capsule of calciferol for the second round.
2878286|NCT03401541|Experimental|Fat-Mal, calciferol then calcifediol|Participants with diagnosed fat malabsorption syndrome will initially receive one capsule of calciferol for the first round of blood draws and then receive one capsule of calcifediol for the second round.
2878287|NCT03401541|Experimental|Non Fat-Mal, calcifediol then calciferol|Participants that do not have a diagnosed fat malabsorption syndrome will initially receive one capsule of calcifediol for the first round of blood draws and thenreceive one capsule of calciferol for the second round.
2878288|NCT03401541|Experimental|Non Fat-Mal, calciferol then calcifediol|Participants that do not have a diagnosed fat malabsorption syndrome will initially receive one capsule of calciferol for the first round of blood draws and then receive one capsule of calcifediol for the second round.
2878289|NCT03401528|Experimental|Single Ascending Dose - AVB-S6-500|Four sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
2878290|NCT03401528|Placebo Comparator|Single Ascending Dose - placebo|Four sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
2878291|NCT03401528|Experimental|Repeat Dose - AVB-S6-500|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
2878292|NCT03401528|Placebo Comparator|Repeat Dose - placebo|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
2878293|NCT03401515|Active Comparator|Intervention|Adminstration of propranolol hydrochloride ( 1 MG /ml) 1 mg every 6 hrs .
2878294|NCT03401515|Placebo Comparator|Control|Adminstration of normal saline 1 mg every 6 hrs
2878295|NCT03401502|Experimental|Treatment groups|Ranolazine 1000 mg
2878296|NCT03401502|Placebo Comparator|Control group|Placebos
2878297|NCT03401489|Experimental|PACESETTER|
2878298|NCT03401489|No Intervention|Healthy Lifestyle Intervention Group|
2878299|NCT03401476|Active Comparator|Morphine sulfate - Visit 1|Patients who are randomized to this group will be administered a fixed 5mg dose of oral morphine sulfate prior to performing their 6MWT at Visit 1.
2878300|NCT03401476|Active Comparator|Morphine sulfate - Visit 2|Patients who are randomized to this group will be administered a fixed 5mg dose of oral morphine sulfate prior to performing their 6MWT at Visit 2.
2878301|NCT03401463|Active Comparator|once a day|Cuff pressure checks once a day.
2878302|NCT03401463|Active Comparator|three times a day|Cuff pressure checks three times a day
2878303|NCT03401450|Active Comparator|ACB within true AC with bupivacaine|The patients will receive an ultrasound-guided single injection adductor canal block with 20 mL of 0.5% bupivacaine
2878304|NCT03401450|Active Comparator|ACB proximal to true AC with bupivacaine|The patients will receive an ultrasound-guided single injection femoral triangle block with 20 mL of 0.5% bupivacaine
2878305|NCT03401424|Experimental|improved Warren-type style|Minimally invasive treatment improved Warren-type cholangiocarcinoma reconstruction is easy
2878306|NCT03401424|Active Comparator|Roux-en-Y style|Early open cholecystectomy reconstruction surgery using Roux-en-Y style
2878307|NCT03401411|Experimental|Standard SCCMP|Health care provider completes triage survey of 15 fictional patient case scenarios using the standard SCCMP to prioritize each for admission.
2878308|NCT03401411|Experimental|SCCMP + Algorithm-based Triage Tool|Health care provider completes triage survey of 15 fictional patient case scenarios using SCCMP in addition to a newly designed flowchart-based triage guide to prioritize each for admission.
2878309|NCT03401398|Active Comparator|Treatment|Approximately half of the subjects randomized into SHIPSS will be randomized into the Treatment Group and will receive hydrocortisone sodium succinate according to a predetermined dosing schedule.
2878310|NCT03401398|Placebo Comparator|Placebo|Approximately half of the subjects randomized into SHIPSS will be randomized into the Placebo Group and will receive equivalent study drug volumes of normal saline.
2878311|NCT03401385|Experimental|Dose Escalation - All Participants|All participants enrolled in the dose escalation part
2878312|NCT03401385|Experimental|Dose Expansion - All Participants|All participants enrolled in the dose expansion part
2878313|NCT03401372|Experimental|Doxycycline/BCD chemotherapy|Doxycycline combined with bortezomib-cyclophosphamide-dexamethasone chemotherapy
2878314|NCT03401372|Active Comparator|BCD chemotherapy|Bortezomib-cyclophosphamide-dexamethasone chemotherapy
2878315|NCT03401346|Experimental|INP104|Single dose 1.45 mg Dihydroergotamine Mesylate (DHE), administered by I123 Precision Olfactory Delivery (POD) device nasal spray (INP104)
2878316|NCT03401346|Active Comparator|D.H.E. 45 Injection (IV)|Single dose 1 mg Dihydroergotamine Mesylate (DHE) for intravenous injection
2878317|NCT03401346|Active Comparator|Migranal Nasal Spray|Single dose 2 mg Migranal Nasal Spray Dihydroergotamine Mesylate (DHE)
2878318|NCT03401333|Experimental|Text messaging and brief intervention|Brief motivational interview and 4-weeks of text messaging.
2878319|NCT03401320|Experimental|Cohort 1: Letrozole ISM 50 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 50 mg Letrozole ISM
2878320|NCT03401320|Experimental|Cohort 2: Letrozole ISM 100 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 100 mg Letrozole ISM
2878321|NCT03401320|Experimental|Cohort 3: Letrozole ISM 200 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 200 mg Letrozole ISM
2878322|NCT03401320|Experimental|Cohort 4: Letrozole ISM 400 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 400 mg Letrozole ISM
2878362|NCT03400956|Experimental|Vilaprisan|Vilaprisan: 2 treatment periods of 12 weeks, separated by 1 bleeding episode.
2878363|NCT03400956|Experimental|Placebo+Vilaprisan|Placebo: 1 treatment period of 12 weeks; and Vilaprisan: 1 treatment period of 12 weeks; separated by 1 bleeding episode.
2878323|NCT03401307||Responders to Fampridine Treatment|Participants, who are classified as responders to Fampridine treatment, have already been identified in the MS-centers in the Region of Southern Denmark, where they undergo outpatient treatment and clinical controls. A 2-week Fampridine treatment phase, as described in the trial outline section, has been used to identify responders to Fampridine. Participants who improve with ≥20% on the T25FW are categorized as responders.
2878324|NCT03401307||Non-Responders to Fampridine Treatment|Participants, who are classified as non-responders to Fampridine treatment, have already been identified in the MS-centers in the Region of Southern Denmark, where they undergo outpatient treatment and clinical controls. A 2-week Fampridine treatment phase, as described in the trial outline section, has been used to identify non-responders to Fampridine. Participants who do not improve with ≥20% on the T25FW are categorized as non-responders.
2878325|NCT03401294|Other|Single arm|FOLFOXIRI and Bevacizumab
2878326|NCT03401281|Active Comparator|Coconut oil|50g extra virgin coconut oil to be consumed daily for four weeks
2878327|NCT03401281|Active Comparator|Butter|50g Butter to be consumed daily for four weeks
2878328|NCT03401281|Active Comparator|Olive oil|50g extra virgin olive oil to be consumed daily for four weeks
2878329|NCT03401268|Experimental|Patient cohort|The study population will include 24 patients, that are either already on IVIG or are eligible for ScIG as initial Ig replacement, that will undergo Ig replacement with subcutaneous immunoglobulin (ScIG) for a total of 6 months.
2878330|NCT03401229|Experimental|Benralizumab 30mg SC + MF|SC - subcutaneously MF - Mometasone Furoate
2878331|NCT03401229|Placebo Comparator|Placebo SC + MF|
2878332|NCT03401216|Experimental|SYNERGY 48 PCI + 3 month OCT follow-up|Synergy 48 mm stent implantation followed by 3 month OCT imaging
2878333|NCT03401216|Experimental|SYNERGY 48 PCI + 6 month OCT follow-up|Synergy 48 mm stent implantation followed by 6 month OCT imaging
2878334|NCT03401203|Experimental|rotational atherectomy followed by balloon angioplasty|
2878335|NCT03401203|Active Comparator|balloon angioplasty|
2878336|NCT03401190|Experimental|Low Dose Female|Cohort 1 will consist of 4 female patients who will be randomized 3:1 to receive CM4620-IE plus supportive care versus supportive care alone. Planned doses for patients who are randomized to receive CM4620-IE are 1.0 mg/kg on Days 1 and 1.4 mg/kg on Days 2-4.
2878337|NCT03401190|Experimental|Low Dose Male|Cohort 2 will consist of 4 male patients who will be randomized 3:1 to receive CM4620-IE plus supportive care versus supportive care alone. Planned doses for patients who are randomized to receive CM4620-IE are 1.0 mg/kg on Days 1 and 1.4 mg/kg on Days 2-4.
2878338|NCT03401190|Experimental|High Dose Female|Cohort 3 will consist of 8 female patients who will be randomized 3:1 to receive CM4620-IE plus supportive care versus supportive care alone. Planned doses for patients who are randomized to receive CM4620-IE are 2.08 mg/kg of CM4620-IE on Days 1 and 2, and 1.6 mg/kg on Days 3 and 4.
2878339|NCT03401190|Experimental|High Dose Male|Cohort 4 will consist of 8 male patients who will be randomized 3:1 to receive CM4620-IE plus supportive care versus supportive care alone. Planned doses for patients who are randomized to receive CM4620-IE are 2.08 mg/kg of CM4620-IE on Days 1 and 2, and 1.6 mg/kg on Days 3 and 4.
2878340|NCT03401177|Experimental|Naproxen & Heavy resistance training|Naproxen: 500 mg x 2 daily for 7 days, HRT: 3 months physiotherapy guided training.
2878341|NCT03401177|Placebo Comparator|Placebo & Heavy resistance training|Placebo oral tablet: pill manufactured to mimic naproxen tablet x 2 daily for 7 days, HRT: 3 months physiotherapy guided training.
2878342|NCT03401125||Sickle cell disease patients (SS genotype)|Sickle cell disease patients with a SS genotype having an history of blood transfusions within the CHU Brugmann and the Queen Fabiola Children's Hospitals.
2878343|NCT03401112|Placebo Comparator|PBO|
2878344|NCT03401112|Experimental|Dose 1|IMR-687
2878345|NCT03401112|Experimental|Dose 2|IMR-687
2878346|NCT03401099|Active Comparator|Radiofrequency ablation of CTI|Radiofrequency ablation of CTI (cavo-tricuspid isthmus), which is the 'conventional' treatment of atrial flutter
2878347|NCT03401099|Active Comparator|Cryoballoon PVI|Cryoballoon PVI (Pulmonary Vein Isolation), which is the 'novel treatment'
2878348|NCT03401086|Active Comparator|Study group|Kinesio Taping
2878349|NCT03401086|No Intervention|Control group|No intervention
2878350|NCT03401073|Placebo Comparator|0.9% Sodium Chloride|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The placebo will consist of 0.9% Sodium Chloride per day over 2 days. Followed by 0.9% Sodium Chloride over 1 day every 3 weeks for a total of 6 treatments. Participants who are randomized to placebo will receive the same volume as they would if they were randomized to IVIG (i.e.: as if receiving IVIG at 2gm/kg) through a peripheral IV line.
2878351|NCT03401073|Experimental|Intravenous Immunoglobulin|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. Treatment will consist of IVIG administered at an initial dose of 2 grams/kg over 2 days followed by 1 gram/kg over 1 day every 3 weeks for a total of 6 treatments
2878352|NCT03401060|Experimental|Experimental medication 1|Denosumab 60 mg subcutaneously injection with prefilled syringe
2878353|NCT03401060|Placebo Comparator|Experimental medication 2|NaCl 0.9%, 20ml phial, solution for injection
2878354|NCT03401047|Experimental|Transdermal Estradiol|Subjects will undergo estradiol administration for up to 9 days. Transdermal estradiol patches will be applied each day by study staff during study days two through nine (patches deliver 0.1 mg/day for a total dose of up to 0.6 mg/day).
2878355|NCT03401021||Male smokers cohort|"Male smokers met the inclusion criteria below will be invited to fill in the questionnaires set, part of them will be invited to attend a semi-structured interview(optional).~All male smokers should be aged 18 or above;~All male smokers should be married;~All male smokers should be smoking at least one cigarette per day averagely during the past 3 months;~All male smokers should be able to communicate in Mandarin (including reading Chinese)."
2878356|NCT03401008||Acromegalic patients|patients with a proven diagnosis of acromegaly achieved by an IGFA assay and a GH measure.
2878357|NCT03400995|Experimental|Intervention Arm|Each subject will receive a single oral administration of a solution containing 300 mg radiolabeled AK0529 in the fasted state.
2878358|NCT03400982|Experimental|Bone Mineral Density|Bone densitometry measurement: measurement of bone mineral densitometry with bone densitometry
2878359|NCT03400969|Active Comparator|Glycerol 17 %|Oral moisturizer
2878364|NCT03400956|Experimental|Vilaprisan+Placebo|Vilaprisan: 1 treatment period of 12 weeks; and Placebo: 1 treatment period of 12 weeks; separated by 1 bleeding episode.
2878365|NCT03400943|Experimental|Vilaprisan_A1|vilaprisan (2 mg), 2 treatment periods of 12 weeks, separated by 1 bleeding episode
2878366|NCT03400943|Experimental|Vilaprisan_A2|vilaprisan (2 mg), 2 treatment periods of 12 weeks without a break
2878367|NCT03400943|Experimental|Vilaprisan_B1|placebo, 1 treatment period of 12 weeks, and vilaprisan (2 mg), 1 treatment period of 12 weeks, separated by 1 bleeding episode
2878368|NCT03400943|Experimental|Vilaprisan_B2|vilaprisan (2 mg), 1 treatment period of 12 weeks, and placebo, 1 treatment period of 12 weeks, separated by 1 bleeding episode
2878369|NCT03400930||OptiDiag-Cohort, Liberia|A respresentative population of 275 Liberian children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC < 115, 75 of which have a WHZ < -3 and 75 of which have both a MUAC < 115 mm and a WHZ < -3).
2878370|NCT03400930||OptiDiag/MANGO-Cohort, Burkina Faso|A respresentative population of 275 Burkinabé children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC < 115, 75 of which have a WHZ < -3 and 75 of which have both a MUAC < 115 mm and a WHZ < -3).
2878371|NCT03400930||OptiDiag-cohort, Bangladesh|A respresentative population of 275 Bangladeshi children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC < 115, 75 of which have a WHZ < -3 and 75 of which have both a MUAC < 115 mm and a WHZ < -3).
2878372|NCT03400917|Experimental|AV-GBM-1|Autologous dendritic cells loaded with tumor associated antigens from a short-term cell culture of autologous tumor cells. AV-GBM-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
2878373|NCT03400891|Experimental|Intervention|This group received 14 sessions (one every 15 days) of one hour in the classroom, to work TPB constructs: attitude; subjective norms; perceived behavioural control and intention.
2878374|NCT03400891|No Intervention|Control|2 session of 1 hour each to give general information about fruit and vegetables intake and health.
2878375|NCT03400878|Active Comparator|BCG-JAPAN|Infants randomised to receive BCG-JAPAN at discharge from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated BCG-JAPAN vaccine (Japan BCG Laboratory, Tokyo, Japan) by intradermal injection in the left deltoid region.
2878376|NCT03400878|Active Comparator|BCG-RUSSIA|BCG-RUSSIA Infants randomised to receive BCG-RUSSIA at discharge from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-RUSSIA (Serum Institute of India, Pune, India) by intradermal injection in the left deltoid region.
2878377|NCT03400865|Experimental|HCQ/CQ and CAB combined treatment|Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.
2878378|NCT03400852|Experimental|Treatment A, MNK1411 High Dose|Cosyntropin suspension 0.5/0.4 mL for up to 48 weeks
2878379|NCT03400852|Experimental|Treatment B, MNK1411 Low Dose|Cosyntropin suspension 0.25/0.2 mL for up to 48 weeks
2878380|NCT03400852|Placebo Comparator|Treatment C, Placebo High Dose|Placebo suspension 0.4/0.5 mL for up to 24 weeks
2878381|NCT03400852|Placebo Comparator|Treatment D, Placebo Low Dose|Placebo suspension 0.25/0.2 mL for up to 24 weeks
2878382|NCT03400839||Patients with ILD|"Patients with a medical diagnosis of interstitial lung disease.~Patients will be submitted to the assessment of:~Daily physical activity levels;~6-minute walk test;~Cardiopulmonary exercise testing;~Muscle Function;~Lung Function;~Body composition;~HRQoL - SGRQ-I;~HRQoL - SF36;~Anxiety and depression;~Symptoms - mMRC~Symptoms - UCSD/SOBQ;~Sleep quality;~Sleepiness;~Inflammatory markers and oxidative stress."
2878383|NCT03400839||Control Group|"Age-matched peers without lung diseases.~Participants will be submitted to the assessment of:~Daily physical activity levels;~6-minute walk test;~Cardiopulmonary exercise testing;~Muscle Function;~Lung Function;~Body composition;~HRQoL - SF36;~Anxiety and depression;~Sleep quality;~Sleepiness;~Inflammatory markers and oxidative stress."
2878384|NCT03400826|Experimental|Treatment Group|The 30 participants randomized in this group will intake Simvastatin 40mg / day of orally at the same time in the evening, every day for the study duration of 12 weeks prior to undergoing hysterectomy/ myomectomy. The fibroid samples will be collected after the surgery to evaluate the effects of the study medication on the fibroid tissue.
2878385|NCT03400826|Placebo Comparator|Placebo Group|The 30 participants randomized in this group will intake Placebo 40mg / day orally at the same time in the evening every day for the study duration of 12 weeks prior to undergoing hysterectomy/ myomectomy. The fibroid samples will be collected after the surgery to evaluate the effects of the study medication on the fibroid tissue.
2878386|NCT03400813|No Intervention|Control|Patients in this group continue their usual care without intervention.
2878387|NCT03400813|Experimental|R-TEP EMDR|Patients in R-TEP EMDR group will receive the intervention.
2878388|NCT03400800|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 milliliters (mL) will be administered as a SC injection on Day 1, Day 90, and then every 6 months
2878389|NCT03400800|Placebo Comparator|Saline Solution|Placebo (1.5 mL) will be administered as a SC injection of saline solution on Day 1, Day 90, and then every 6 months
2878390|NCT03400787|Sham Comparator|Sham Control Arm|"Subjects in the Sham Control arm will undergo the same preoperative assessments as those in the Latera Treatment arm up to and including anesthesia for the implant, however, no implant will be placed.~Crossover - Subjects will be unblinded after the 3-month assessment is complete. Eligible subjects in the Sham Control arm will be treated with the Latera Implant if they still meet all eligibility criteria. Follow up will continue to 24 months post-implant. Subjects who no longer meet the eligibility criteria will exit the study."
2878391|NCT03400787|Experimental|Latera Treatment Arm|Subjects in the active treatment arm will receive the Latera Implant using standard techniques. Follow up continues for 24 months post-implant.
2878392|NCT03400774|Other|Control|Oral glucose tolerance test with no stair-climbing
2878393|NCT03400774|Experimental|1 minute|Oral glucose tolerance test with 1 minute of stair-climbing
2878394|NCT03400774|Experimental|3 minutes|Oral glucose tolerance test with 3 minutes stair-climbing
2878395|NCT03400774|Active Comparator|10 minutes|Oral glucose tolerance test with 10 minutes stair-climbing
2878396|NCT03400748|Experimental|RF Ablation|Single-arm study where subjects receive RF ablation prior to a scheduled surgical resection.
2878399|NCT03400722|Experimental|DUOSTIM group|Pergoveris 150 -300 IU start from day 2 of the cycle up to the day of trigger, GnRH antagonist 0,25 mg start from day 7-8 of the cycle up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, stop period for 5 days, after stop period start Pergoveris 150 - 300 IU start up to the day of trigger, GnRH antagonist 0,25 mg start from day 6 of ovarian stimulation up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
2878400|NCT03400722|Experimental|Modified Shanghai Protocol group|Clomiphene 50 mg start from day 2-3 of the cycle up to the day of trigger, Pergoveris 150 - 300 IU - 6,8, 10 days of the cycle, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, after stop period for 2-3 days start Pergoveris 150 - 300 IU up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
2878401|NCT03400709|Experimental|N-acetylcisteine group|
2878402|NCT03400709|Placebo Comparator|Control group|
2878403|NCT03400696|Experimental|Randomized- Lower carbohydrate diet|
2878404|NCT03400696|Experimental|Randomized- Higher fiber diet|
2878405|NCT03400696|Experimental|Randomized- Exercise focused|
2878406|NCT03400696|Experimental|Participant chooses- Lower carbohydrate diet|
2878407|NCT03400696|Experimental|Participant chooses- Higher fiber diet|
2878408|NCT03400696|Experimental|Participant chooses- Exercise focused|
2878409|NCT03400683|Active Comparator|misoprostol only group|given 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), in sublingual every four hours for a maximum of five doses
2878410|NCT03400683|Active Comparator|misoprostol with letrozole group|group received 15mg( letrozole2.5mg) on three successive day patient take doses of letrozole for daily oral three successive day at home by herself and forth day admitted to our hospital followed by sublingual misoprostol 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), every four hours for a maximum of five doses
2878411|NCT03400683|Active Comparator|misoprotol with Foley's catheter group|the transcervical 16F Foley's catheter with 30 ml balloon capacity (Euromed for Medical Industries, Cairo, Egypt, under license of Kanglite, USA), inserted under aseptic conditions withsublingual misoprostol 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), every four hours for a maximum of five doses
2878412|NCT03400670|Active Comparator|Ventilator NCPAP|neonatal ventilator (SLE; Specialised Laboratory Equipment, UK) PEEP: 5 cmH2O
2878413|NCT03400670|Active Comparator|Infant Flow-driver NCPAP|infant flow-driver device (Infant Flow System, Viasys Corp., USA) PEEP:5-8 cmH2O, This group receive variable flow
2878414|NCT03400657||fully implemented to the MDT decision|group of patients fully implemented to the MDT decision
2878415|NCT03400657||not completly implemented to the MDT-decision|group of patients not completly implemented to the MDT decision
2878416|NCT03400657||not implemented to the MDT decision|group of patients not implemented to the MDT decision
2878417|NCT03400644|Active Comparator|With Collar|Subjects are prescribed with custom-made rigid cervical collar which are to be worn for 3 weeks postoperatively
2878418|NCT03400644|No Intervention|Without Collar|Subjects do not need to wear any cervical collar postoperatively
2878419|NCT03400631|Experimental|Dextrose 0. Aspiration 1 week.|Dextrose injection given at time 0, at 1 week aspiration only, and then open label injection of dextrose at 0, 1, 2, 3, 4, 5, and 6 months.
2878420|NCT03400631|Experimental|Aspiration 0. Dextrose 1 week.|Aspiration only at time 0. Dextrose injection given at 1 week, and then open label injection of dextrose at 0, 1, 2, 3, 4, 5, and 6 months.
2878421|NCT03400618|Experimental|Moderate carbohydrate diet|A healthy diet containing 30 E % carbohydrates
2878422|NCT03400618|Experimental|Higher carbohydrate diet|A healthy diet containing 50 E % carbohydrates
2878423|NCT03400605||Program Clients|Parkdale Parents' Primary Prevention Project (5P's) clients
2878424|NCT03400592|Experimental|irinotecan and nimotuzumab|Administration of irinotecan 180 mg/m2 IV once every 2 weeks and nimotuzumab 400 mg IV once weekly
2878425|NCT03400579|Experimental|Remote Ischemic Conditioning|RIC procedure (i.e., four cycles of alternating 5-min inflation and 5-min deflation) administered by the autoRIC® device
2878426|NCT03400566|Experimental|Narrative (target)|Children will receive the story featuring the target vegetable and NO sensory experience.
2878427|NCT03400566|Experimental|Narrative+ experiential (target)|Children will receive the story featuring the target vegetable and experiential learning with the target vegetable.
2878428|NCT03400566|Active Comparator|Narrative (control)|Children will receive the story featuring the control vegetable and NO sensory experience.
2878429|NCT03400566|Active Comparator|Narrative+ experiential (control)|Children will receive the story featuring the control vegetable and experiential learning with the control vegetable.
2878430|NCT03400553|Experimental|non-traumatic thoracic pain|Patients with out-of-hospital non-traumatic thoracic pain admitted to the emergency unit via ambulance or MUG will be screened for enrolment. Blood analysis for troponin-T will be performed by 3 different devices as explained earlier.
2878431|NCT03400540|Experimental|Group A|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:~squeeze the pelvic floor muscles~squeeze and lift the pelvic floor muscles as if stopping the flow of urine~Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.~contract all of the above together"
2878432|NCT03400540|Experimental|Group B|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:~squeeze the pelvic floor muscles~squeeze the anus~Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.~contract all of the above together"
2878433|NCT03400527|Experimental|Exercise|Participant will be pedaling a stationary exercise bicycle
2878434|NCT03400501|Experimental|subjects receiving insulin degludec|Youth aged 8-18 years with T1D whose diabetes is poorly-controlled (A1c ≥8.5%) will receive insulin degludec injections.
2878435|NCT03400501|Active Comparator|Subjects receiving insulin glargine|Youth aged 8-18 years with T1D whose diabetes is poorly-controlled (A1c ≥8.5%) will receive insulin glargine injections.
2878436|NCT03400488|Experimental|AZD5718|Randomized subjects will receive orally once daily dose of AZD5718 oral suspension on Day 1 (SAD) and MAD from Days 3 to 10. On Day 2, no dose will be given. These procedures will be repeated in all cohorts.
2878437|NCT03400488|Placebo Comparator|Placebo|Randomized subjects will receive orally once daily dose of placebo matching AZD5718 oral suspension on Day 1 (SAD) and MAD form Days 3 to 10. On Day 2, no dose will be given. These procedures will be repeated in all cohorts.
2878438|NCT03400475|Experimental|Test group|Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil®), Poloxamer 407 gel (Polox Gel 20%®) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
2878439|NCT03400475|Placebo Comparator|Control group|Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil®), Poloxamer 407 gel (Polox Gel 20%®) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
2878440|NCT03400462|Experimental|dry needling + oral appliance|Three visits are needed in this therapy method. Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd) Equipment: acupuncture needle 0,6*13 e.g. Dragon Medical Device, solution for skin disinfection, sterile gauze. Exposition time : 30 minutes once a week
2878441|NCT03400462|Experimental|antiinflammatory drugs + splint therapy|"Patient's instruction for NSAID use:~Nimesulide 2*100 mg/ 24 h- twice a day one pill of the 100 mg Nimesulide during 14 days"
2878442|NCT03400462|Active Comparator|splint therapy|"Splint therapy is an useful treatment method for several group of patients e.g TMD patients, patients with retrodiscitis, patients with muscle pain disorders like local muscle soreness or chronic myalgia.~The patients have been instructed to use the appliance during nighttime. After 7 days the patient had to came back for a control visit."
2878443|NCT03400449|Active Comparator|Video counseling|The video group watched a 13.75 minute video of a local Colombian counselor reading a script of the same information provided by conversational counseling and had a chance to ask questions at the end.
2878444|NCT03400449|Active Comparator|Conversational counseling|The conversation group participated in a structured, face-to-face conversation with a trained counselor.
2878445|NCT03400423|Experimental|Non-caffeine exercise|Exercise cognition score
2878446|NCT03400423|Active Comparator|Non-caffeine cognition|Caffeine cognition score
2878447|NCT03400423|Experimental|Caffeine consumption exercise|Exercise cognition score
2878448|NCT03400423|Active Comparator|Caffeine consumption cognition|Caffeine cognition score
2878449|NCT03400423|Experimental|Deprived Caffeine consumers exercise|Exercise cognition score
2878450|NCT03400423|Active Comparator|Deprived caffeine consumers cognition|Caffeine administration cognition score
2878451|NCT03400410|Experimental|Education Arm|"This group will take a survey and be asked some sexual history questions including their contraceptive practices with their sexual partner(s). They will then watch the educational video on hormonal contraception and then be asked a few questions about the video. Then they will be asked for an email and phone number for follow up.~They will then be followed up 3 months from their visit through their contact option of choice (email, text, or call) to take an additional survey with similar sexual history questions and current contraceptive practices including if they have discussed hormonal contraception with their female partners, if their female partners are now using hormonal contraception, and impregnation rates of female partners."
2878452|NCT03400410|No Intervention|No Education Arm|"This group will take a survey and be asked some sexual history questions including contraceptive practices with their sexual partner(s). They will then be asked for an email and phone number for follow up.~They will then be followed up 3 months from their visit through their contact option of choice (email, text, or call) to take an additional survey with similar sexual history questions and current contraceptive practices including if they have discussed hormonal contraception with their female partners, if their female partners are now using hormonal contraception, and impregnation rates of female partners."
2878453|NCT03400397||Intervention|Treatment with the Cool Kids programme. The Cool Kids programme is a manualised cognitive behavioural treatment programme for children with anxiety disorders.
2878454|NCT03400384|Experimental|Direct-to-consumer educational brochure|The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
2878455|NCT03400384|No Intervention|Control wait list|This arm will receive the intervention at the completion of the six-month follow-up period for the intervention group.
2878456|NCT03400371||Patients diagnosed with JME|People who meet the eligibility requirements and have been diagnosed with juvenile myoclonic epilepsy.
2878457|NCT03400371||Controls|People without a lifetime history of seizures.
2878458|NCT03400358||Medical abortion|150 singleton multiparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were multiparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
2878459|NCT03400332|Experimental|Dose Finding|BMS-986253 administered in combination with Nivolumab
2878460|NCT03400332|Experimental|Dose Expansion|BMS-986253 administered in combination with Nivolumab
2878461|NCT03400319||Thoracic Aortic Aneurysm|Patients with Thoracic Aortic Aneurysm: Women: at the level of the sinus of valsalva ≥39mm, or ascending aorta ≥42mm. Men: at the level of the sinus of valsalva ≥44mm, or ascending aorta ≥46mm.
2878462|NCT03400319||No Thoracic Aortic Aneurysm|Patients without Thoracic Aortic Aneurysm: Women: at the level of the sinus of valsalva <39mm, or ascending aorta <42mm. Men: at the level of the sinus of valsalva <44mm, or ascending aorta <46mm.
2878463|NCT03400306|Experimental|Part 1, Bioequivalence Sequence Group 1|Veliparib 400-mg doses administered orally on Day 1 of each 2-3 day period in Part 1 with the following sequence for the 3 dosing days: four 100 mg capsules under fasting conditions, followed by one 400-mg tablet under fasting conditions, then one 400 mg tablet under non-fasting conditions.
2878464|NCT03400306|Experimental|Part 2, Extension|Veliparib as monotherapy or in combination with carboplatin and paclitaxel, per investigators' discretion.
2879201|NCT03395262|Placebo Comparator|Placebo|Dextrose
2878465|NCT03400306|Experimental|Part 1, Bioequivalence Sequence Group 2|Veliparib 400-mg doses administered orally on Day 1 of each 2-3 day period in Part 1 with the following sequence for the 3 dosing days: one 400-mg tablet under fasting conditions, followed by four 100 mg capsules under fasting conditions, then one 400 mg tablet under non-fasting conditions.
2878466|NCT03400293||Subjects living with HIV|Subjects living with HIV will be recruited via digital advertising. These subjects will participate in completing various PRO instruments and targeted questions.
2878467|NCT03400280|Experimental|Best practice|Postoperative care according to a best practice algorithm for postoperative care focussing on early detection and minimally invasive management of postoperative pancreatic fistula.
2878468|NCT03400280|No Intervention|Current practice|Postoperative care according to current usual practice.
2878469|NCT03400267|Active Comparator|paracetamol|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
2878470|NCT03400267|Active Comparator|fentanyl|
2878471|NCT03400254|Experimental|Arm A|Patients will receive HCQ, 600 mg BID, for 24 weeks.
2878472|NCT03400254|Experimental|Arm B|Arm B: Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 2 weeks administered weekly, as an intravenous dose of 150 mg.
2878473|NCT03400254|Experimental|Arm C|Arm C: Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 6 weeks administered weekly, as an intravenous dose of 150 mg.
2878474|NCT03400254|Experimental|Arm D|Arm D: Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 12 weeks administered weekly, as an intravenous dose of 150 mg.
2878475|NCT03400241|Experimental|Tiotropium Easyhaler Product A|tiotropium bromide monohydrate 2 inhalations as a single dose
2878476|NCT03400241|Experimental|Tiotropium Easyhaler Product B|tiotropium bromide monohydrate 2 inhalations as a single dose
2878477|NCT03400241|Experimental|Tiotropium Easyhaler Product C|tiotropium bromide monohydrate 2 inhalations as a single dose
2878478|NCT03400241|Active Comparator|Spiriva HandiHaler|tiotropium bromide monohydrate 2 Spiriva capsules inhaled via HandiHaler
2878479|NCT03400228|Experimental|Protics|Patients in the intervention group were to drink 2 sachets of 1g of probiotic daily for 24 weeks
2878480|NCT03400228|Placebo Comparator|Placebo|Patients in the intervention group were to drink 2 sachets of 1g of maltodextrin daily for 24 weeks
2878481|NCT03400215|Active Comparator|Breast cancer confirmed by biopsy|Cases will be women first diagnosed with invasive breast cancer confirmed by biopsy
2878482|NCT03400215|Active Comparator|Women without any history of breast cancer|No known malignancy confirmed by at least 1-year follow up exams.
2878483|NCT03400202||Group A: Dark Circles None|Group A includes participants with Dark Circle Severity Scale score 0 (None). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
2878484|NCT03400202||Group B: Dark Circles Mild|Group B includes participants with Dark Circle Severity Scale score 1 to 3 (Mild). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
2878485|NCT03400202||Group C: Dark Circles Moderate|Group C includes participants with Dark Circle Severity Scale score 4 to 6 (Moderate). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
2878486|NCT03400202||Group D: Dark Circles Severe|Group D includes participants with Dark Circle Severity Scale score 7 to 9 (Severe). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
2878487|NCT03400189|Other|Single arm|"Single oral dose of sulthiame (Ospolot® tablets)~Period I: 50 mg~Period II: 100 mg~Period III: 200 mg given 3 weeks apart"
2878488|NCT03400176|Experimental|Dose Escalation|Increasing doses of VAY736 in combination with a fixed dose of ibrutinib.
2878489|NCT03400176|Experimental|Dose expansion|Evaluation of the MTD/RD of the combination of VAY736 and ibrutinib that was identified in dose escalation.
2878490|NCT03400163|Experimental|Treatment Group D:|Administered as specified on specified days
2878491|NCT03400163|Placebo Comparator|Treatment Group E:|Administered as specified on specified days
2878492|NCT03400150|Experimental|ProSpace group|IMRT + marking + ProSpace implantation
2878493|NCT03400150|Sham Comparator|Control group|IMRT + marking
2878494|NCT03400137|Active Comparator|Healthy Volunteers|No family history (first degree relative) of glaucoma.
2878495|NCT03400137|Active Comparator|Glaucoma suspects|oEither IOP between 25 to 30 mmHg with central corneal thickness < 550µm, or a difference ≥ 0.2 in cup to disc ratio between eyes.
2878496|NCT03400137|Active Comparator|Glaucoma|Rim thinning, notching, undermining (excavation) or diffuse or localized RNFL defects that are characteristic of glaucoma.
2878497|NCT03400124|Active Comparator|ISBCS|The intervention group will undergo cataract surgery of both eyes on the same day (ISBCS)
2878498|NCT03400124|Active Comparator|DSBCS|The usual care / control group will undergo cataract surgery of both eyes on separate days, with a time period of at least two weeks between surgeries (DSBCS).
2878499|NCT03400111|Experimental|Low-level laser therapy|Patients upper and lower jaws will be irradiated with low-level laser therapy at specific points on the alveolus around the teeth from the vestibular and lingual sides. This group of patients will be followed up till the end of treatment.
2878500|NCT03400111|Experimental|Panadol-extra|Patients will be given Panadol-extra (565 mg: 500 mg paracetamol and 65 mg caffeine) at specific time points to control pain and discomfort during orthodontic treatment. This group of patients will be followed up till the end of treatment.
2878501|NCT03400111|No Intervention|Traditional Treatment|Patients will not undergo any actual irradiation therapy or take any active tablets during orthodontic treatment.
2878502|NCT03400085|No Intervention|Standard of Care|The control participants will be instructed to attend required follow-up as is standard of care, and will not receive the mHealth application.
2878503|NCT03400085|Experimental|mHealth application|Participants in the intervention arm will receive the mHealth application at their first post-donation clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the application and explain its functioning. Participants will then use the application to complete their required 6-month, 1-year, and 2-year follow-up.
2878504|NCT03400072|Experimental|Unsupervised APA program|usual care plus a 6-month unsupervised APA program
2878505|NCT03400072|Experimental|Supervised APA program|usual care plus a 6-month supervised APA program
2878506|NCT03400072|No Intervention|Usual care|Usual care
2878507|NCT03400059|Experimental|Active Treatment|
2878508|NCT03400059|Sham Comparator|Sham Treatment|
2878509|NCT03400033|Experimental|Daprodustat|Subjects randomized to this arm will receive daprodustat tablets titrated doses from 2 to 48 milligrams orally three-times weekly along with saline by IV route for the 52 weeks treatment period.
2878510|NCT03400033|Active Comparator|Epoetin alfa|Subjects randomized to this arm will receive matching placebo tablets to daprodustat orally three-times weekly and Epoetin alfa by IV route for the 52 weeks treatment period.
2878511|NCT03400020|Experimental|Ascorbic acid|Ascorbic acid 1000 mg in normal saline IV 2 hours before the operation and thereafter 500 mg in normal saline IV daily for three days.
2878512|NCT03400020|Placebo Comparator|Normal saline|Normal saline IV infusion 2 hours before the operation and for three days after operation.
2878513|NCT03400007||Prolapse surgery|
2878514|NCT03399994|Experimental|ABLUMINUS DES+|device implantation during coronary angioplasty
2878515|NCT03399994|Active Comparator|Everolimus-eluting DES|device implantation during coronary angioplasty
2878516|NCT03399981||Tysabri (TOUCH Cohort)|Patients from the Tysabri TOUCH prescribing programme who have switched to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate).
2878517|NCT03399981||Tysabri (EU MS Cohort)|Patients from the EU MS registry who have switched to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate).
2878518|NCT03399968|Experimental|ESWT|Application of shockwaves non-invasively at the level of injury
2878519|NCT03399968|Placebo Comparator|Placebo ESWT|Positioning of the therapy head at the injury level without application of shockwaves
2878520|NCT03399955|Experimental|Arm 1: Paromomycin + Miltefosine|Paromomycin 20 mg/kg/d IM for 14 days combined with Miltefosine allometric BID PO dosing for 42 days
2878521|NCT03399955|Experimental|Arm 2: Ambisome + Miltefosine|AmBisome® 5mg/kg/d IV infusion at D1, D3, D5 and D7 (20 mg/kg total dose) combined with Miltefosine allometric BID PO dosing for 28 days
2878522|NCT03399942|Experimental|DBS-ACC ON|Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is ON and the second period, between M7 and M10 is OFF
2878523|NCT03399942|Experimental|DBS-ACC OFF|Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is OFF and the second period, between M7 and M10 is ON
2878524|NCT03399929||TBI + Rehabilitation|Traumatic Brain Injury patients that received post acute rehabilitation
2878525|NCT03399929||TBI + No Rehabilitation|Traumatic Brain Injury patients that did not receive post acute rehabilitation
2878526|NCT03399929||CVA + Rehabilitation|Stroke patients that received post acute rehabilitation
2878527|NCT03399929||CVA + No Rehabilitation|Stroke patients that did not received post acute rehabilitation
2878528|NCT03399916|Experimental|Prompt|"An email based prompt was sent- containing either a stand or move message. Exploratory variations of the prompt were designed to include the addition of a goal e.g., stand for the next 5-minutes, and/or employer support e.g., PTS says stand for the next 5 minutes."
2878529|NCT03399916|No Intervention|No Prompt|Prompt delivery was sequentially randomized to be sent (ST) or not sent (NST) to all participants (probability of 0.5), at eight decision points per day (between 9am and 5pm), to achieve a total of 3200 randomizations across participants (160 per participant). Therefore 50% of the time, no prompt was sent.
2878530|NCT03399903|Experimental|Pentasa|30 participants will be randomized to take 1 gram of Pentasa, twice daily for 8 weeks
2878531|NCT03399903|Active Comparator|Align|30 participants will be randomized to take Align tablets, once daily for 8 weeks
2878532|NCT03399890||Group S|Group S: Group sugammadex Patients in this group received sugammadex at the end of the surgery, as neuromuscular reversal agent. Neurological physical exam time was recorded.
2878533|NCT03399890||Group N|"Group N: Group Neostigmine~Patients in this group received neostigmine at the end of the surgeryas neuromuscular reversal agent. Neurological physical exam time was recorded."
2878534|NCT03399877|Active Comparator|Combining electromygraphy with uroflowmetry|Children who assigned group A perform uroflowmetry-electromyography for the first and subsequently perform uroflowmetry-electromyography
2878535|NCT03399877|Active Comparator|Uroflowmetry|Children who assigned Group B perform uroflowmetry-electromyography for the first, and subsequently perform uroflowmetry solely.
2878536|NCT03399877|Experimental|Uroflowmetry-Combining electromygraphy with uroflowmetry|Children who assigned Group C firstly perform uroflowmetry solely. and subsequently perform uroflowmetry-electromyography.
2878537|NCT03399864|Experimental|Experimental group|Apart from receiving scheduled medical follow-up, the subjects in the experimental group will receive a weekly 45-minute lesson on musical training for 52 weeks. The musical training will be conducted by the Music Children Foundation and be implemented in a ratio of one subject to one qualified orchestral performer at the subjects' homes. A musical instrument will be assigned to each subject based on their interests and the results of the prior assessment of subjects' expiratory function and fine motor skills. The musical training will start at the lowest level, such as hitting simple notes and end at the highest level, such as playing an entire song.
2878538|NCT03399864|Other|Control group|The subjects will receive usual care, such as medical follow-up according to the schedule of the oncology units.
2878539|NCT03399851|Active Comparator|Amplatzer Amulet|Left atrial appendage closure (LAAC) with Amplatzer Amulet implantation will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
2878540|NCT03399851|Active Comparator|Watchman|Left atrial appendage closure (LAAC) with Watchman implantation will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
2878541|NCT03399838|Experimental|Dexmedetomidine|Application of single dose of 4mcg/kg dexmedetomidine intranasally for pediatric procedural sedation at the emergency department
2879309|NCT03394508|Placebo Comparator|Placebo|ALK diluent 0,3% human albumin'
2878542|NCT03399838|Active Comparator|Midazolam|0.5mg po/pr midazolam for pediatric sedation at the emergency department
2878543|NCT03399825||Healthy controls|Children without eye disease
2878544|NCT03399825||Retinopathy of prematurity (ROP)|Previously preterm children with a history of ROP
2878545|NCT03399825||Diabetic retinopathy|Children with diabetes
2878546|NCT03399812|Experimental|Whey protein isolate|
2878547|NCT03399812|Active Comparator|Pea protein isolate|
2878548|NCT03399799|Experimental|Dose Escalation (JNJ-64407564)|Participants will receive intravenous (IV) infusion of JNJ-64407564 at minimum anticipated biologic effect level (MABEL)-based starting dose until the completion of the end of treatment visit. Subsequent dose levels will be selected based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and preliminary antitumor activity data.
2878549|NCT03399786|Experimental|evinacumab|
2878550|NCT03399786|Experimental|Placebo|
2878551|NCT03399773|Experimental|Treatment (chemotherapy, TBI, NLA101)|"Patients receive either regimen A or regimen B.~REGIMEN A: Patients (18 through 45 years old) receive fludarabine IV over 30 minutes on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1. Patients receive unmanipulated cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0.~REGIMEN B: Patients (18 through 65 years old) receive fludarabine IV over 30-60 minutes on days -6 to -3 and IV over 30 minutes on day -2, cyclophosphamide IV on day -6, and thiotepa IV over 4 hours on days -5 and -4. Patients receive unmanipulated cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0."
2878552|NCT03399760|Experimental|i-PRF assisted upper canine retraction|I-PRF assisted upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
2878553|NCT03399760|Experimental|conventional upper canine retraction|Conventional upper canine retraction will be performed in the other side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
2878554|NCT03399747|Experimental|Abb-R-CHOP|
2878555|NCT03399734|Experimental|Treatment A|4 milligrams (mg) perampanel tablet
2878556|NCT03399734|Experimental|Treatment B|4 mg perampanel fine granules
2878557|NCT03399721|Active Comparator|Chordate S101 Active|Active treatment With Device Chordate S101
2878558|NCT03399721|Placebo Comparator|Chordate S101 Placebo|Placebo treatment With Device Chordate S101
2878559|NCT03399695|Active Comparator|control|spontaneous breathing through a face mask connected to the anaesthesia machine delivering 100% oxygen gas flow (15l/min)
2878560|NCT03399695|Experimental|ohd|spontaneous breathing through a nasal cannula connected to an humidifier device delivering warm (37°C) high flow oxygen(60l/min)
2878561|NCT03399682||Incidence of Post Cystography Urinary Tract Infections|all children less than 16 years having cystography
2878562|NCT03399669|Experimental|gefitinib|Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
2878563|NCT03399656|Placebo Comparator|Placebo|4 placebo tablets
2878564|NCT03399656|Active Comparator|Low Dose Avmacol|2 tablets Avmacol and 2 placebo tablets
2878565|NCT03399656|Active Comparator|High Dose Avmacol|4 Avmacol tablets
2878566|NCT03399630|Active Comparator|Injection of Autologous Adipose Tissue|Treatment knee receives injection of 1.5 cc's of adipose tissue mixed with 1.5 cc's of Lactated Ringers
2878567|NCT03399630|Placebo Comparator|Injection of Lactated Ringers|Placebo control group receives injection of 3 cc's of Lactated Ringers with no adipose tissue
2878568|NCT03399617|Experimental|Standard Counseling and Micronutrients|"Participants will receive standard services provided by the Ministry of Health, including powder micronutrients including Chispitas. Children receive 1 gram of powdered micronutrientes for 60 days between 6 and 12 months of age, and 60 daily packets per year from the time they are 1 year old until 5 years old."
2878569|NCT03399617|Experimental|SPOON Counseling and SQ-LNS|Participants will receive small quantity lipid nutrient supplements and Mejores Familias, a social communication strategy. SQ-LNS consists of a 20 g package that is to be consumed daily from when the child turns 6 months old until he or she turns 2 years old.
2878570|NCT03399604|Experimental|LIQ861 Inhaled Treprostinil|"LIQ861 inhaled treprostinil at capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg.~LIQ861 will be administered using the RS00 Model 8 dry powder inhalation (DPI) device (Plastiape S.p.A.; Osnago, Italy) at dose levels of 25 μg to 150 μg treprostinil QID in individual patients."
2878571|NCT03399578|Experimental|Group 1|Group 1 volunteers (n= 6) will be administered ChAdOx1 MERS, 5 x 10^9 vp through intramuscular route.
2878572|NCT03399578|Experimental|Group 2|Group 2 volunteers (n= 9) will be administered ChAdOx1 MERS, 2.5 x 10^10 vp through intramuscular route.
2878573|NCT03399578|Experimental|Group 3|Group 3 volunteers (n= 9) will be administered ChAdOx1 MERS, 5 x 10^10 vp through intramuscular route.
2878574|NCT03399552|Experimental|Avelumab|The treatment will consist of one dose of avelumab every other week as well as a short course of SBRT after the first two doses of avelumab.
2878575|NCT03399539|Experimental|Treatment (venetoclax, ixazomib citrate, dexamethasone)|Patients receive venetoclax PO daily on days 1-28, ixazomib citrate PO once weekly on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22 for courses 1-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2878576|NCT03399526|Experimental|Mapracorat|10 µL of mapracorat was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of mapracorat was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
2878577|NCT03399526|Active Comparator|Prednicarbate|10 µL of prednicarbate was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of prednicarbate was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
2878578|NCT03399526|Active Comparator|Clobetasol|10 µL of clobetasol was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of clobetasol was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
2878579|NCT03399526|Active Comparator|Calcipotriene|10 µL of calcipotriene was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of calcipotriene was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
2878580|NCT03399526|Active Comparator|Calcipotriene/Betamethasone dipropionate|10 µL of calcipotriene/betamethasone dipropionate was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of calcipotriene/betamethasone dipropionate was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
2878581|NCT03399513|Experimental|Ibrutinib and R-CHOEP chemotherapy|"All patients will receive 8 cycles of R-CHOEP immunochemotherapy every two weeks with the following doses per cycle: rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m² (dose capped at 2 mg), etoposide 300 mg/m², prednisolone 500 mg.~In addition, ibrutinib capsules will be administered orally once daily at a dose of 560 mg (4 x 140 mg hard capsules) for 112 days."
2878582|NCT03399500|Active Comparator|Usual Case Management (UCM)|Group receives standard case management at the shelter
2878583|NCT03399500|Experimental|UCM + Smartphone|Group receives standard case management and an unlimited smartphone
2878584|NCT03399500|Experimental|Smartphone Based Case Management (SPCM)|Group receives standard case management and an unlimited smartphone with the SPCM app
2878585|NCT03399487|Experimental|Arm 1|"This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.~This clinical study is targeted for the patients who harbor ROS1 rearrangement and all patients will be treated with LDK378 750mg daily. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.~Patients will be continued to receive study drug until the end of study unless the patients in disease progression, unacceptable toxicity, withdrawn consent, or by the investigator's judgment."
2878586|NCT03399474|Active Comparator|Lidocaine only|"Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline for intravenous regional anesthesia.~Nalbuphine 5 mg intravenously increments up to 0.1 mg/kg~paracetamol (Perfalgan®) 1gm IV drip~Diclofenac sodium (Voltaren®) 75 mg IM"
2878587|NCT03399474|Experimental|0.5 ug/kg dexmedetomidine|"Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline (maximum dose200 mg)+~Dexmedetomidine intravenous in a dose of 0.5 ug/kg ,with the total volume diluted to 40 ml with normal saline 0.9%. The solution will be injected at a rate 20 ml/min for intravenous regional anesthesia.~Nalbuphine 5 mg intravenously increments up to 0.1 mg/kg~Paracetamol (Perfalgan®) 1gm IV drip~Diclofenac sodium (Voltaren®) 75 mg IM ."
2878588|NCT03399474|Experimental|0.25 ug/kg dexmedetomidine|"1 Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline (maximum dose200 mg)+ 2- Dexmedetomidine intravenous in a dose of 0.25 ug/kg ,with the total volume diluted to 40 ml with normal saline 0.9%. The solution will be injected at a rate 20 ml/min.for intravenous regional anesthesia.~3-Nalbuphine 5 mg intravenously increments up to 0.1 mg/kg 4- Paracetamol (Perfalgan®) 1gm IV drip 5- Diclofenac sodium (Voltaren®) 75 mg IM"
2878589|NCT03399461||Group 1|Approximately 8 subjects with WAS between ages of 12 to 30 years will be included in Group 1.
2878590|NCT03399461||Group 2|Approximately 8 primary caregivers of subjects with WAS between ages 8 to 30 years will be included in Group 2.
2878591|NCT03399461||Group 3|Approximately 5 primary caregivers of subjects with WAS under the age of 8 years will be included in Group 3.
2878592|NCT03399448|Experimental|Multiple Myeloma (MM)|Recruitment at UPenn currently on hold.
2878593|NCT03399448|Experimental|Synovial Sarcoma (SS) and Myxoid/Round Cell Liposarcoma (MRCL)|
2878594|NCT03399448|Experimental|Melanoma|Not Recruiting at the UPenn Site
2878595|NCT03399435|Experimental|Part A|8 cohorts are planned to be treated.
2878596|NCT03399435|Experimental|Part B|Part B will start at the earliest after 4 cohorts of Part A have been treated. Up to 8 cohorts are planned to be treated.
2878597|NCT03399435|Experimental|Part C|Part C will comprise 4 treatment groups. The neosaxitoxin dose will be the same in all 4 treatment groups.
2878598|NCT03399422|Experimental|i-PRF assisted upper canine retraction|I-PRF assisted upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
2878599|NCT03399422|Experimental|conventional upper canine retraction|Conventional upper canine retraction will be performed in the other side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
2878600|NCT03399409|Experimental|Motivational Interviewing|
2878601|NCT03399409|Active Comparator|Anti-inflammatory information program|
2878602|NCT03399396|Experimental|Web-Based Coaching|Web-based delivery of practice facilitation for HPV vaccine
2878603|NCT03399396|Experimental|In-Person Coaching|In-person delivery of practice facilitation for HPV vaccine
2878604|NCT03399383|Other|Patient education (longitudinal analysis)|Patients with adrenal insufficiency complete a questionnaire before and 6 months after participation in a standardised patient education.
2878605|NCT03399370|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90, then every 6 months.
2878606|NCT03399370|Placebo Comparator|Saline Solution|Placebo will be administered as a SC injection of saline solution on Day 1, Day 90, then every 6 months.
2878607|NCT03399357||≥ 65 Years old|Healthy community-dwelling elderly (men and women) age 65 and above who are eligible for influenza vaccine and fulfil inclusion and exclusion criteria
2878608|NCT03399344|Other|DW-MRI|Patients with undergo an additional diffusion-weighted MRI in addition to the standard diagnostic work-up
2878609|NCT03399331|Experimental|group 1|Efficacy of Manuka honey on severity and pain of OM compared to placebo (standard care) and to assess which of the two interventions is more beneficial.
2878610|NCT03399331|Experimental|Group 2|Efficacy of olive oil on severity and pain of OM compared to placebo (standard care) and to assess which of the two interventions is more beneficial.
2878611|NCT03399331|Placebo Comparator|Group 3|The control group at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine
2878612|NCT03399318|Experimental|Aggressive Antipyretics|regardless of temperature, children allocated to this arm will receive acetaminophen (30mg/kg load then 15mg/kg Q6 hours) and ibuprofen (10mg/kg Q 6 hours) for 72 hours. Pediatric syrup formulations of both agents will be administered orally or via nasogastric tube. For temperatures over 38.5 degrees Celsius, placebo will be added and if the fever persists, a cooling fan will be added.
2878613|NCT03399318|Placebo Comparator|Usual Care|will receive placebo for acetaminophen and placebo for ibuprofen. If they have a temperature over 38.5 degrees Celsius, they will receive acetaminophen (15mg/kg, Q6 hours), as needed. If the fever persists, a cooling fan will be added.
2878614|NCT03399292||Group 1|10 male and female healthy subjects receive Cationorm MD sine eye drops once
2878615|NCT03399292||Group 2|10 male and female volunteers with dry eye disease receive Cationorm MD sine eye drops once
2878616|NCT03399292||Group 3|10 male and female volunteers with Maibomian gland disease receive Cationorm MD sine eye drops once
2878617|NCT03399292||Group 4|10 male and female volunteers with receive Cationorm MD sine eye drops once
2878618|NCT03399279|Experimental|Open flap debridement & perforated&Nano|Perforated collagen membrane and nano-hydroxyapatite and open flap debridement
2878619|NCT03399279|Active Comparator|Open flap debridment &Occlusive&Nano|Occlusive membrane and nano-hydroxyapatite and open flap debridement
2878620|NCT03399266|Experimental|Double balloon catheter for induction of labor|in this group a trans-cervical double balloon catheter will be inserted. Following device insertion, 20 minutes of external monitoring is performed. The patient will be transferred to the Ob/Gyn ward for hospitalization. 12 hours after insertion of the device the balloons are deflated and the device removed. At this stage the patient is assessed for a second Bishop score and expectant management is resuming.
2878621|NCT03399266|No Intervention|Expectant management|Women in the expectant management group will be transferred to the Ob/Gyn ward for hospitalization and conservative management until spontaneous labor ensues.
2878622|NCT03399253|Active Comparator|Chemotherapy|chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
2878623|NCT03399253|Experimental|Surgery+Chemotherapy|D2 Gastrectomy and Metastasectomy + chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
2878624|NCT03399240|Experimental|Vitastiq device|Vitastiq device is used for about 2 months to perform Vitastiq readings every day, preferably in the morning.
2878625|NCT03399227||Liver transplantation recipients|Venipuncture (6x) Bone mineral density measurement: lumbar spine, hip region (3x) high resolution peripheral quantitative CT: radius, tibia (3x)
2878626|NCT03399227||Control group|Venipuncture (1x) Bone mineral density measurement: lumbar spine, hip region (1x) high resolution peripheral quantitative CT: radius, tibia (1x)
2878627|NCT03399214|Experimental|IOP Injection, Phase 1b, Cohort 1|IV injection, 0.27 mg/kg
2878628|NCT03399214|Experimental|IOP Injection, Phase 1b, Cohort 2|IV injection, 0.54 mg/kg
2878629|NCT03399201|Active Comparator|General Anesthesia|Standard General Anesthesia will be applied.The change of the pulmonary functions will be evaluated via spirometer.
2878630|NCT03399201|Active Comparator|Neuraxial Anesthesia|Neuraxial anesthesia will be applied. The change of the pulmonary functions will be evaluated via spirometer.
2878631|NCT03399188|Experimental|FMT group|Group who received fecal microbiome transplantation
2878632|NCT03399175|Other|Treatment group|Early high-dose corticosteroid and immunosuppressive therapy
2878633|NCT03399162|Experimental|PREHAB Group|"Patients in this arm will receive the usual standard of care prior to surgery, which includes a PREHAB workshop; consultations with a surgeon, anaesthesiologist, and nurse; referrals to diabetes counselling and/or smoking cessation, as appropriate; and the usual diagnostic work-up.~Patients in this group will also complete an 8-week PREHAB exercise program, with weekly exercise classes and a list of exercises to complete at home."
2878634|NCT03399162|Active Comparator|Standard of care group|Patients in this arm will receive the usual standard of care prior to surgery, which includes a PREHAB workshop; consultations with a surgeon, anaesthesiologist, and nurse; referrals to diabetes counselling and/or smoking cessation, as appropriate; and the usual diagnostic work-up.
2878635|NCT03399149||"Before phase"|Retrospective study of ICU admissions of hematology patients for respiratory and hemodynamic reasons Time period: January 2012 to March 2017
2878636|NCT03399149||"After Phase: Systematic evaluation by an intensivist"|"Corresponding to the period after the implementation of a systematic intensivist evaluation Daily screening of systolic blood pressure, oxygen saturation and oxygen requirements of all patients hospitalized in hematology wards. Systematic evaluation of any patient presenting the inclusion criteria by an intensivist and collegial care planning.~Time period: From March 2017 to end of study"
2878637|NCT03399136|Experimental|Moderate-intensity aerobic exercise|In the moderate-intensity aerobic exercise group, participants performed a self-paced 1-mile walk (3-5 METs) on an indoor track in the same exercise center as the high-intensity exercise group. Initial sessions lasted 20-30 minutes and were increased weekly to 45 minutes in parallel to the duration of the high-intensity exercise group.
2878670|NCT03398915||Freehand Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of the conventional freehand technique.
2878710|NCT03398681|Placebo Comparator|Normal saline|Normal saline (0.9% weight/volume (w/v) NaCl) administered as per the instructions for active therapy.
2879458|NCT03393377|Placebo Comparator|control group|received placebo for 30 days
2878638|NCT03399136|Experimental|High-intensity aerobic exercise|In the high-intensity aerobic exercise group, exercise training was performed on a motorized treadmill with occasional substitution with the elliptical machine as needed for joint pain. Target heart rate was based on the baseline treadmill test and was calculated as percentage of the heart rate reserve (HRR=maximal HR-resting HR). Initially, participants trained for 20-30 minutes at 50-60% of HRR. Duration and intensity was increased by 10% weekly so that within 5-7 weeks the aerobic exercise sessions lasted 30-45 minutes at 70-85% of HRR and at the end of the 16 weeks lasted 40-45 minutes at 75-90% of HRR.
2878639|NCT03399123|Experimental|Low tidal volume group|Use a low tidal volume(6`8ml/kg) ventilation mode during liver segmentation。
2878640|NCT03399123|Active Comparator|Standard tidal volume group|Use a standard tidal volume(10`12ml/kg) ventilation mode during operation.
2878641|NCT03399110|Experimental|XELOX for 4 months|Adjuvant chemotherapy with capecitabine and oxaliplatin after surgery (five 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 4 months or progress of disease
2878642|NCT03399110|Active Comparator|XELOX for 6 months|Adjuvant chemotherapy with capecitabine and oxaliplatin after surgery(eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
2878643|NCT03399097||non-obese|non-obese
2878644|NCT03399097||obese|obese
2878645|NCT03399097||previously obese|previously obese
2878646|NCT03399084|Experimental|Ferric carboxymaltose (test)|Patients will receive a single dose of Ferric carboxymaltose
2878647|NCT03399084|Active Comparator|Ferric carboxymaltose (reference)|Patients will receive a single dose of Ferric carboxymaltose
2878648|NCT03399071|Experimental|FLOT plus Avelumab (FLOT-A)|"Avelumab 10mg/kg (or Maximum Administered Dose established in safety run-in) iv infusion over 1 hour.~Followed by FLOT: Oxaliplatin 85mg/m2 iv infusion day 1 over 2 hours, Folinic acid 200mg/m2 iv infusion day 1 over 2 hours, Docetaxel 50mg/m2 iv day 1 over 1 hour, Fluorouracil 2600mg/m2 over 24 hours iv"
2878649|NCT03399058|Other|Group 1 5+5+5 (Control)|The standard of care in Cambodia is known as the basic health and nutrition service package or 5+5+5. The participants in the first group will be the control group and will only be implementing the standard of care, 5+5+5 package (Group 1).
2878650|NCT03399058|Other|Group 2: 5+5+5 & PDH|The participants in the second group will receive contextualized Hearth messages through on-going PDH programs in addition to the basic standard of care (Group 2). The Hearth messages are contextualized messages on child feeding practices that women in the community have found helpful to successfully prevent child malnutrition. This program will be delivered through in person community meetings.
2878651|NCT03399058|Other|Group 3: 5+5+5 & PDH lite+mHealth|The participants in the third group will receive a similar program as group 2 with contextualized child feeding messages (PDH lite program) and receive follow-up through mobile support phone calls (Group 3).
2878652|NCT03399045|Experimental|9-minute withdrawal group|Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw. A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included in the 9 minutes.
2878653|NCT03399045|Active Comparator|6-minute withdrawal group|Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw. A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy willwill not be included in the 9 minutes.
2878654|NCT03399032||Caspofungin|Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day
2878655|NCT03399019|Experimental|Dexmedetomidine|"Dexmedetomidine~: initial loading 0.5- 1 mng/kg for 10 minutes and maintenance 0.2-0.7mng/kg/hr~Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
2878656|NCT03399019|Active Comparator|Propofol|"Propofol~: 0.75-3 mg/kr/hr continous infusion Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
2878657|NCT03399019|Active Comparator|Midazolam|"Midazolam~: initial loading 0.5- 1 mng/kg for 10 minutes and maintenance 0.2-0.7mng/kg/hr~Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
2878658|NCT03399006||preeclampsia|women who developed preeclampsia. Preeclampsia was defined as a blood pressure 140/90 mmHg and proteinuria of 300 mg in 24 hours, or two readings of at least 2+ on dipstick analysis of midstream urine specimens if no 24-hour urine collection was available in absence of urinary tract infection
2878659|NCT03399006||Normal pregnancy|women with normal blood presure
2878660|NCT03398993|Active Comparator|Scratch group|"Induction of ovulation will be done by clomophine citrate from 3rd day of cycle till 7th day of cycle and HMG 75IU (MerionaL) given from 6th day of cycle till 8th of cycle once daily. folliculometry done regularly during induction of ovulation till dominant follicle reached 18_20mm in size.~Then endometrial injury performed in pre ovulatory day by a thin pipelle (a fine, flexible, sterile, plastic tube) The procedure was carried out in preovulatory day (known when dominant follicle reached 18_20 mm in diameter), usually, done around day 14-day of the cycle"
2878661|NCT03398993|Active Comparator|Non scratch group|They will receive the same induction of ovulation as first group but without performing endometrial injury in preovulatory day
2878662|NCT03398980||survivors treated with CRT|Childhood and Adolescent Nasopharyngeal Carcinoma survivors who were treated with convention radiotherapy (CRT).
2878663|NCT03398980||survivors treated with IMRT|Childhood and Adolescent Nasopharyngeal Carcinoma survivors who were treated with intensity-modulated radiotherapy (IMRT).
2878664|NCT03398941|Experimental|Combined group|
2878665|NCT03398928|Experimental|Acupuncture|Acupuncture for delirium treatment
2878666|NCT03398928|Sham Comparator|Sham procedure|Ear stimulation with plastic tape
2878667|NCT03398928|No Intervention|Standard care|Standard conventional delirium care at the discretion of the department medical staff
2878668|NCT03398915||Robot-Guided Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of a robotic guidance system (SpineAssist or Renaissance, Mazor Robotics, Ltd., Caesarea, Israel or ROSA Spine, Medtech, Montpellier, France).
2878669|NCT03398915||Navigated Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of navigation (computer assistance using CT, O-arm or 3D-fluoroscopic imaging).
2878671|NCT03398902|Experimental|Sleep extension|Participants in the sleep extension group will keep daily sleep diaries. Sleep diaries will be reviewed with the participant and an instructor trained in Cognitive Behavioral Therapy for Insomnia (CBTI) on a weekly basis. These weekly sessions will take place by telephone or videoconferencing.
2878672|NCT03398902|Active Comparator|Habitual sleep|Participants in the habitual sleep group will be instructed to keep their habitual bedtimes and wake times. Participants will keep daily sleep diaries that will we reviewed by a study team member each week. These weekly sessions will take place by telephone or videoconferencing.
2878673|NCT03398889||Unexplained Atherosclerosis phenotype|Residual score in linear regression >2
2878674|NCT03398889||Explained Atherosclerosis phenotype|Residual score in linear regression <-2, <2
2878675|NCT03398889||Protected Atherosclerosis phenotype|Residual score <-2
2878676|NCT03398876|Experimental|Part 1; Treatment Sequence ABDC|Participants will receive Treatment A (one spray of oromucosal nicotine spray [ONS]) at Visit 1, then Treatment B (2 consecutive sprays of ONS at Visit 2, then Treatment D (1 cigarette [10 puffs]) at Visit 3, followed by Treatment C (nicotine gum) at Visit 4. The visits will be separated by a period of at least 7 calendar days.
2878677|NCT03398876|Experimental|Part 1; Treatment Sequence BCAD|Participants will receive Treatment B at Visit 1, then Treatment C at Visit 2, then Treatment A at Visit 3 followed by Treatment D at Visit 4. The visits will be separated by a period of at least 7 calendar days.
2878678|NCT03398876|Experimental|Part 1; Treatment Sequence CDBA|Participants will receive Treatment C at Visit 1, then Treatment D at Visit 2, then Treatment B at Visit 3 followed by Treatment A at Visit 4. The visits will be separated by a period of at least 7 calendar days. The visits will be separated by a period of at least 7 calendar days.
2878679|NCT03398876|Experimental|Part 1; Treatment Sequence DACB|Participants will receive Treatment D at Visit 1, then Treatment A at Visit 2, then Treatment C at Visit 3 followed by Treatment B at Visit 4. The visits will be separated by a period of at least 7 calendar days.
2878680|NCT03398876|Experimental|Part 2; Treatment Sequence EF|Participants who complete Part 1 will be selected for Part 2 based on the results of genetic polymorphism test and other examinations. Selected participants will receive Treatment E (two consecutive sprays of ONS once every 30 minutes until 11.5 hours) at Visit 5, followed by Treatment F (two consecutive sprays of ONS once every 1 hour until 11 hours) at Visit 6. The visits will be separated by a period of at least 7 calendar days.
2878681|NCT03398876|Experimental|Part 2; Treatment Sequence FE|Participants who complete Part 1 will be selected for Part 2 based on the results of genetic polymorphism test and other examinations. Selected participants will receive Treatment F at Visit 5 followed by Treatment E at Visit 6. The visits will be separated by a period of at least 7 calendar days.
2878682|NCT03398863|Active Comparator|Cleaning of uterine cavity|Cleaning of uterine cavity: participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
2878683|NCT03398863|No Intervention|Not cleaning of uterine cavity|These participants will have their uterine cavities left alone after complete delivery of the placenta. The placenta will be inspected after delivery to make sure it is complete, including the membranes.
2878684|NCT03398837|Experimental|Cohort 1|Lenabasum 5 mg BID
2878685|NCT03398837|Experimental|Cohort 2|Lenabasum 20 mg BID
2878686|NCT03398837|Placebo Comparator|Cohort 3|Placebo BID
2878687|NCT03398824|Experimental|Treatment arm|Receive metformin HCl
2878688|NCT03398811|Other|"Group I the depot medroxy-progesterone acetate group"|where they will use Depot Medroxyprogesterone Acetate 150 mg injection every 3 month,
2878689|NCT03398811|Other|"Group II Implanon group"|where they will have Implanon (etonogestrel implant) 68 mg implant
2878690|NCT03398811|Other|group III (Microlut group)|where they are using Microlut pills (0.5 mg levonorgestrel) one pill every day for 35 days without pill-free interval.
2878691|NCT03398798|Active Comparator|".014 with twin brackets"|".014 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia Metal Twin brackets."
2878692|NCT03398798|Active Comparator|".016 with twin brackets"|".016 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia Metal Twin brackets."
2878693|NCT03398798|Active Comparator|".014 with self-ligating brackets"|".014 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia SL (self-ligating) brackets."
2878694|NCT03398798|Active Comparator|".016 with self-ligating brackets"|".016 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia SL (self-ligating) brackets."
2878695|NCT03398785|Experimental|Intevention|Adrenal Artery Ablation
2878696|NCT03398785|No Intervention|Control|No intervention, but treated with standard anti-hypertensive drigs
2878697|NCT03398772|Experimental|Experiment|Comprehensive Health Coaching Program
2878698|NCT03398772|No Intervention|Control|Guideline-based usual care
2878699|NCT03398759|Experimental|Butorphanol|Butorphanol 20ug/kg , anesthesia induction，Intravenous injection
2878700|NCT03398759|Placebo Comparator|Placebo|Normal saline 5ml ， anesthesia induction，Intravenous injection
2878701|NCT03398746|Experimental|LOOP Technique|Placement of subcutaneous loop drain
2878702|NCT03398746|Active Comparator|Incision and Drainage|Standard Incision and Drainage Technique
2878703|NCT03398733|Other|continuous positive airway pressure|The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively.
2878704|NCT03398720|Experimental|Cohort 1|One participant will receive HTI-1066 at the starting dose.
2878705|NCT03398720|Experimental|Cohort 2|Participants will receive HTI-1066 at dose level 2.
2878706|NCT03398720|Experimental|Cohort 3|Participants will receive HTI-1066 at dose level 3.
2878707|NCT03398720|Experimental|Cohort 4|Participants will receive HTI-1066 at dose level 4.
2878708|NCT03398694|Experimental|Arm 1|This is a single arm study so this arm will include all eligible subjects. All subjects will have radiosurgery 1-3 days prior to surgical resection.
2878709|NCT03398681|Active Comparator|Intravenous ferric carboxymaltose|Ferric Carboxymaltose solution [Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)] will be given as a perfusion of 20 mL (which is the amount of FCM that is equivalent to 1000 mg of iron) diluted in a sterile saline solution (0.9% weight/volume (w/v) NaCl) administered over at least 15 min.
2878711|NCT03398668|Active Comparator|Relievion device- Treatment stimulation|Relievion Device- Treatment combined occipital and supraorbital transcutaneous nerve stimulation
2878712|NCT03398668|Sham Comparator|Sham Comparator: Relievion device- Sham Stimulation|Relievion Device- Sham combined occipital and supraorbital transcutaneous nerve stimulation
2878713|NCT03398655|Experimental|Arm 1|VB-111 + Paclitaxel
2878714|NCT03398655|Active Comparator|Arm 2|Paclitaxel
2878715|NCT03398642|Experimental|French Lifestyle Redesign|16 older adults, 10 without and 6 with disabilities, participated to weekly 2-hour group sessions, including outings, and monthly 1-hour individual sessions led by a occupational therapist over 6-month period and promoting healthy lifestyle and involvement in meaningful activities.
2878716|NCT03398629||IUGR group|Estimated fetal weight below10th percentile for gestational age associated with Abnormal Doppler flow in the umbilical cord (umbilical artery pulsatility index (PI)>95th percentile).
2878717|NCT03398629||Structural anomaly group|Fetus/neonates/infants who are diagnosed as congenital malformations, deformations, disruptions, dysplasias by ultrasound.
2878718|NCT03398629||Chromosomal anomaly group|Fetus/neonates/infants diagnosed by genetic amniocentesis or chorionic villus sampling for increased risk for fetal aneuploidy or fluorescence in situ hybridization.
2878719|NCT03398603||Group 1|25 women with age of 18-25 years
2878720|NCT03398603||Group 2|25 women with age of 26-40 years
2878721|NCT03398590|Experimental|mHealth Intervention for Older Adults|"Pilot study to test the feasibility and acceptability of a self-regulation theory-based mHealth behavior intervention for overweight or obese older adults with T2DM.~This is a one Group Pretest-Posttest Designed study. Ten participants will be recruited from Joslin Diabetes Center, Boston, MA. They will receive a 3-month, self-regulation theory-based weight loss intervention (five 60-minute, biweekly group sessions) and will be provided with a technology toolkit for self-monitoring including an (1) iPhone Plus, (2) the Lose It! app for self-monitoring of dietary intake, (3) Fitbit for self-monitoring of physical activity, (4) Bluetooth-enabled scale for daily weight, and (5) Bluetooth-enabled blood glucose monitor for testing blood glucose levels."
2878722|NCT03398577|Experimental|Intervention group|Eligible patients (HbA1C ≥ 7% and ≤ 9%) , who were allocated to the Intervention group will receive Dapagliflozin 10 mg in addition to oral anti-diabetic medication administered prior to study enrollment.
2878723|NCT03398577|Placebo Comparator|Control group|Eligible patients (HbA1C ≥ 7% and ≤ 9%) , who were allocated to the Control group will receive placebo in addition to oral anti-diabetic medication administered prior to study enrollment.
2878724|NCT03398564|Placebo Comparator|Group I (Control)|ultrasound guided Bilateral Erector Spinae Plan Block using isotonic saline
2878725|NCT03398564|Active Comparator|Group II (ESP)|ultrasound guided Bilateral Erector Spinae Plan Block with bupivacaine 0.25%
2878726|NCT03398538|Experimental|Mirragen Wound Matrix Dressing|MIRRAGEN™ Advanced Wound Matrix is intended for the use in the management of wounds including diabetic ulcers. Wound matrix dressing to be used per manufacturer instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing
2878727|NCT03398538|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
2878728|NCT03398525|Active Comparator|Usual care|After patient information, appropriate skin antisepsis according to local procedures, surgical hand antisepsis by the operator, use of sterile drapes, gowns and gloves, insertion of a central venous catheter after after local anesthesia with 2% lidocaine, using ultrasound guidance.
2878729|NCT03398525|Experimental|Musical intervention|"After patient information, appropriate skin antisepsis according to local procedures, surgical hand antisepsis by the operator, use of sterile drapes, gowns and gloves, insertion of a central venous catheter after after local anesthesia with 2% lidocaine, using ultrasound guidance.~In addition, a U-shaped music program (MUSIC CARE, trade mark) will be delivered to the patient through headphones throughout the catheter insertion procedure beginning with the operator's hand washing and ending once the dressing is put on the catheter insertion site."
2878730|NCT03398512|Experimental|Experimental|HIPEC with Raltitrexed at the time of fist surgery and twice repeat within one week after the surgery, following 3 cycles of 3-week Oxaliplatin/Capecitabine chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.
2878731|NCT03398499|Experimental|Magnetoledotherapy|Active ELF EMF Participants will receive active transcranial low frequency elec-tromagnetic field and magnetic induction (ELF EMF) and high energy LED light were used stimulation,Using the Viofor JPS device (Med & Live)
2878732|NCT03398486|Experimental|Kinesiotaping|Original kinesiotaping active tapes Duration: 2 times Application maintenance 5 days with a break for the weekend Muscle application on the masseter muscle area, using a tape (5 cm wide) dissected into 2 parts called tails, which included the treatment site without their tension.
2878733|NCT03398486|Experimental|inactivation of trigger points (TrP)|Duration: 10-20 minutes of surgery; 2 inactivation treatments Between the treatments 5 days break
2878734|NCT03398473|Experimental|Epoetin Hospira SDV|Epoetin Hospira Single Dose Vial (SDV)
2878735|NCT03398473|Experimental|Epoetin Hospira MDV|Epoetin Hospira Multi-Dose Vial (MDV)
2878736|NCT03398460|Other|Health Care Providers|Bellevue hospital Medical Intensive Care Unit; 30 Nurses and 50 physcians
2878737|NCT03398447|Active Comparator|High Definition colonoscopy|Subjects referred for screening or surveillance colonoscopy will be prospectively enrolled
2878738|NCT03398447|Active Comparator|High Definition colonoscopy with Endocuff Vision.|Subjects referred for screening or surveillance colonoscopy will be prospectively enrolled
2878739|NCT03398434|Experimental|MAA868 low dose regimen|patients receive dose monthly.
2878740|NCT03398434|Experimental|MAA868 middle dose regimen|patients receive dose monthly.
2878741|NCT03398434|Experimental|MAA868 high dose regimen|patients receive dose monthly.
2878742|NCT03398434|Active Comparator|Apixaban|Apixaban 5 mg b.i.d
2878845|NCT03397862|Experimental|Corplex Donepezil TDS 5 mg/day|Subjects will receive Corplex Donepezil TDS 5 mg/day during Induction, Challenge, and Re-Challenge phase.
2878846|NCT03397862|Placebo Comparator|Vehicle TDS|Subjects will receive Vehicle TDS during Induction, Challenge, and Re-Challenge phase.
2878743|NCT03398421|Experimental|Subjects receiving nemiralisib and itraconazole|Eligible subjects will receive a single dose of 100 micrograms (mcg) nemiralisib on Day 1 in Period 1. Subjects will also receive a single dose of 200 milligrams (mg) itraconazole in the morning from Day 1 to Day 10 and single dose of 100 mcg nemiralisib on Day 5, one hour after the dose of itraconazole in Period 2. There will be a washout of at least 14 days between the administration of nemiralisib in Period 1 and Period 2.
2878744|NCT03398408|Experimental|Intervention|"Patients in both groups will complete paper-pencil TMT A and B and the CWMST, the computer-based TMT A and B and Color Match, and NCPT tests upon enrollment into the study.~Participants in the intervention group will then be provided with the Lumosity cognitive flexibility training module and complete daily training for a total of five weeks. 1-3 days after completion of their training, all patients will be invited to complete the computerized versions of the TMT A and B, Color Match, and NCPT tests again on their personal computers."
2878745|NCT03398408|No Intervention|Control|"Patients in both groups will complete paper-pencil TMT A and B and the CWMST, the computer-based TMT A and B and Color Match, and NCPT tests upon enrollment into the study.~Patients in the control group will complete all tests upon enrollment and approximately five weeks after their initial testing, but will not participate in training."
2878746|NCT03398395|Active Comparator|endocrown restoration|a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
2878747|NCT03398395|Active Comparator|90° shoulder endocrown restoration|a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
2878748|NCT03398382|Placebo Comparator|Magnesium citrate tablet group|In this group patients will take magnesium citrate tablets 3 days postoperatively, so 400 mg magnesium citrate tbl (Solgar) /per day will be taken at the same time that will correspond to the time the first tablets were taken, 2 hours preoperatively.
2878749|NCT03398382|Placebo Comparator|Placebo tablet group|"In this group patients will take placebo tablets 3 days postoperatively, so 400 mg /per day placebo tbl will be taken at the same time that will correspond to the time the first tablets were taken, 2 hours preoperatively.~Placebo tablets will be identical to the right drug (Magnesium citrate tbl.Solgar)"
2878750|NCT03398382|Placebo Comparator|Magnesium citrate lozenge group|In this group patients will take 100 mg. magnesium citrate lozenge (Diasporal) 30 min. before the procedure and continue to take up to 4 lozenges per day over the next 3 days in the same time intervals as it was on the day of surgery.
2878751|NCT03398382|Placebo Comparator|Placebo lozenge group|"In this group patients will take 100 mg. placebo lozenge 30 min. before the procedure and continue to take up to 4 pastilles per day over the next 3 days in the same time intervals as it was on the day of surgery.~Placebo lozenges will be identical to the right drug (Magnesium citrate tbl.(Diasporal)"
2878752|NCT03398369|Experimental|Intervention|MRI-Guided CRT
2878753|NCT03398369|No Intervention|Control|Standard CRT
2878754|NCT03398356|Other|group A|metformin dose 3 x 500 mg
2878755|NCT03398356|Other|group B|metformin dose 3 x 1000 mg
2878756|NCT03398330|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 40 mg
2878757|NCT03398330|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 40 mg
2878758|NCT03398317|Experimental|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection
2878759|NCT03398317|Active Comparator|MACS|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with annexin V microbeads followed by separation on MACS Column, the eluted fraction contains non apoptotic sperm suitable for Oocyte injection.
2878760|NCT03398304|Experimental|Exercise|Upon arrival to an appointment the participant will be seated for 10 minutes prior to measuring their baseline heart rate. A 2.0 mL blood sample will be collected prior to initiation of exercise. The participant will then exercise for 60 minutes at the Vanderbilt Orthopedics fitness center at moderate intensity (running, goal 70-80% maximum HR). Immediately after completion of exercise, a 2.0mL blood draw will be completed every 30 minutes post-exercise for 3 hours (12mL total drawn over 3 hours) from a new site.
2878761|NCT03398291|Active Comparator|Standard treatment|Patients continue to receive standard chemotherapy.
2878762|NCT03398291|Experimental|Surgical exploration|Patients receive surgical exploration and synchronous resection of primary pancreatic cancer and liver oligometastasis will be performed.
2878763|NCT03398278|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 40 mg
2878764|NCT03398278|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 40 mg
2878765|NCT03398265|Experimental|Intervention|Initial discussion regarding opioid treatment options followed by 6 months of treatment navigation.
2878766|NCT03398265|Other|Control|Referrals to treatment from corrections staff.
2878767|NCT03398252|Experimental|Doxazosin XL|Participants will receive increasing doses of doxazosin XL (0, 4, and 8 mg).
2878768|NCT03398252|Placebo Comparator|Placebo|Participants will be randomized to receive a placebo for doxazosin XL.
2878769|NCT03398239|Active Comparator|BPAP ST/T|Non-invasive Ventilation with BPAP ST/T mode
2878770|NCT03398239|Experimental|AVAPS|Non-invasive Ventilation with AVAPS mode
2878771|NCT03398226||Control group|
2878772|NCT03398226||Distal Gastrectomy (DG) group|38 patients planing distal gastrectomy due to gastric cancer
2878773|NCT03398226||Total Gastrectomy (TG) group|38 patients planing total gastrectomy due to gastric cancer
2878774|NCT03398213|Experimental|Acupuncture|Acupuncture for treatment of COPD exacerbation + standard conventional care for COPD exacerbation
2878775|NCT03398213|Sham Comparator|Sham procedure|Ear stimulation with plaster + standard conventional care for COPD exacerbation
2878776|NCT03398213|No Intervention|Standard care|Standard conventional care for COPD exacerbation
2878777|NCT03398200|Experimental|Hyperbaric Oxygen Therapy|Subjects on the experimental arm will receive 90 minutes of hyperbaric oxygen therapy approximately six hours prior to hematopoietic stem cell infusion.
2878778|NCT03398200|Active Comparator|No Hyperbaric Oxygen Therapy|Subjects on the reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell infusion.
2878779|NCT03398174|Experimental|Motor Control Exercise and Patient Education|"Participants will receive a total of 12 sessions (2 sessions per week) of exercise program consisting of motor control training and patient education session once a week at interval of 1-week over 6-weeks (3 sessions).~The motor control training will be aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~The patient education program will be aiming to provide non-threatening information to enable patients to better understand their pain, change any unhelpful beliefs about LBP, and integrate self-management and active coping strategies that deals with fear avoidance behavior and catastrophic thought.~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
2878780|NCT03398174|Active Comparator|Motor Control Exercise|"Participants will receive the same motor control exercise program described in the patient education and motor control exercise group.~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
2878781|NCT03398174|Active Comparator|Patient Education|"Participants will receive the same patient education program described in the motor control exercise plus patient education group.~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
2878782|NCT03398161|Experimental|Low Dose Radiation Therapy|"Radiation applied directly to the lesion on the skin. Radiation delivered in 1 or 2 fractions.~Symptom questionnaire completed at baseline, 4-6 weeks after radiation, 1-14 weeks after radiation, 6-8 months after radiation, then every 6-12 months after radiation for 2 years.~Photographs taken of the affected area(s) at baseline, at 4-6 weeks after radiation, 6-8 months after radiation, then every 6-12 months after radiation for 2 years.~The lesion and unaffected skin swabbed for microbiome analysis at baseline, and at 10-14 weeks after radiation,"
2878783|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 2|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Induction 2.
2878784|NCT03398148|Experimental|Substudy 2, Induction 1: Open-label Risankizumab Dose 2|Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.
2878785|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 1(a)|Participants who received placebo with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
2878786|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 3|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Induction 2.
2878787|NCT03398148|Experimental|Substudy 1, Induction 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
2878788|NCT03398148|Experimental|Substudy 1, Induction 1: Double-blind Risankizumab Dose 2|Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.
2878789|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 1(a)|Participants who received placebo with inadequate response in Induction 1 receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
2878790|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 1(b)|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
2878791|NCT03398148|Experimental|Substudy 2, Induction 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
2878792|NCT03398148|Experimental|Substudy 1, Induction 1: Double-blind Risankizumab Dose 3|Participants randomized to receive risankizumab dose 3 administered by intravenous (IV) infusion.
2878793|NCT03398148|Placebo Comparator|Substudy 1, Induction 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
2878794|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 2|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Induction 2.
2878795|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 3|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Induction 2.
2878796|NCT03398148|Placebo Comparator|Substudy 2, Induction 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
2878797|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 1(b)|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
2878798|NCT03398148|Experimental|Substudy 1, Induction 1: Open-label Risankizumab Dose 3|Participants receive risankizumab dose 3 administered by intravenous (IV) infusion.
2878799|NCT03398135|Experimental|Substudy 2: Open-label Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
2878800|NCT03398135|Experimental|Substudy 1: Double-blind Risankizumab Dose 2|Participants randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection.
2878801|NCT03398135|Experimental|Substudy 2: Open-label Risankizumab Dose 2|Participants randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection.
2878802|NCT03398135|Experimental|Substudy 3: Open-label Extension Risankizumab|Participants who completed Sub-study 1 or 2 receive open-label risankizumab in Sub-study 3.
2878803|NCT03398135|Placebo Comparator|Substudy 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by subcutaneous (SC) injection.
2878804|NCT03398135|Experimental|Substudy 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
2878805|NCT03398122|Experimental|Apatinib combined with TACE|patients received Aptinib, 250 mg daily after TACE treatment, for 4-6 weeks
2878806|NCT03398122|Placebo Comparator|chemoemtranscatherer arterial bolization|epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
2878807|NCT03398109|Experimental|Customized toric IOL|Customized toric IOL for post-Dalk atigmatism in cataract patients
2878808|NCT03398096|Experimental|Cardiac shock wave therapy (CSWT) group|The CWST group were performed with a CSWT equipment (Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan with respect to the shockwave output and the number of shots implemented to each spot and the protocol developed by the University of Essen, Germany.
2878809|NCT03398096|No Intervention|Control group|No CWST treatment.
2878810|NCT03398083|Active Comparator|CBD (500 mg)|CBD (500 mg) capsule by mouth one time during the 18 day treatment period
2878811|NCT03398083|Active Comparator|CBD (1000 mg)|CBD (1000 mg) capsule by mouth one time during the 18 day treatment period
2878812|NCT03398083|Active Comparator|THC (2.5 mg)|THC 2.5 mg capsule by mouth one time during the 18 day treatment period
2878813|NCT03398083|Active Comparator|THC (30 mg)|THC 30 mg capsule by mouth one time during the 18 day treatment period
2878814|NCT03398083|Active Comparator|Alprazolam|Alpraxolam 1.5 mg capsule by mouth one time during the 18 day treatment period
2878815|NCT03398083|Placebo Comparator|Placebo Oral Capsule|Placebo capsule by mouth one time during the 18 day treatment period
2878816|NCT03398070||Motor Functional Neurological Disorder.|"The cohort will consist of patients with clinically established motor functional neurological disorder, which includes individuals with functional movement disorders, psychogenic nonepileptic seizures and functional limb weakness.~Patients will be receiving the standard of care within the Massachusetts General Hospital (MGH) Functional Neurological Disorders Clinic.~The updated standard of care that patient's receive in the MGH Functional Neurological Disorders Clinic includes the following:~Delivery of a positive rule-in diagnosis of functional neurological disorder~Individuals are provided with educational materials on functional neurological disorders~Referred to physical therapy and/or occupational therapy as clinically indicated~FND related cognitive behavioral therapy (CBT) referral when appropriate~Psychotropic medication management based on standard psychiatric care"
2878817|NCT03398057|Experimental|Health education group(intervention group)|Standardized heath education Program(SHEP) applied to this group participants .
2878818|NCT03398057|Placebo Comparator|Control group|Placebo health education.
2878819|NCT03398044|Experimental|Dexamethasone|Patients randomised into the Dexamethasone arm will be administered active studied drug during anaesthesia induction.
2878820|NCT03398044|Placebo Comparator|Placebo|Patients randomised into the control Placeboarm will be administered placebo during anaesthesia induction.
2878821|NCT03398031|Active Comparator|Magnesium supplement|90 female pregnant after ICSI after biochemical diagnosis of pregnancy will receive 500 mg magnesium supplement
2878822|NCT03398031|Placebo Comparator|placebo|90 female pregnant after ICSI after biochemical diagnosis of pregnancy will receive placebo oral tablet
2878823|NCT03398018|Experimental|Treatment|Treated with repository corticotropin injection
2878824|NCT03398005|Experimental|CaPre|
2878825|NCT03398005|Placebo Comparator|Placebo|
2878826|NCT03397992|Active Comparator|Group A|Treatment with high dialysate temperature first followed by low dialysate temperature and alternating thereafter.
2878827|NCT03397992|Active Comparator|Group B|Treatment with low dialysate temperature first followed by high dialysate temperature and alternating thereafter
2878828|NCT03397979|Active Comparator|Infrequent soaking baths|Infrequent soaking baths, in this study, is defined as twice a week soaking baths for 10 minutes or less, over 2 weeks. However, this is a crossover study design with two interventions: 1) Infrequent soaking baths, as defined above, and 2) Frequent soaking baths (defined as twice daily soaking baths for 15-20 minutes, over 2 weeks). All subjects in the study will undergo both interventions, but in different order. Thus, this is a study comparing Infrequent Versus Frequent Soaking Baths. Each subject serves as their own control.
2878829|NCT03397979|Active Comparator|Frequent soaking baths|Frequent soaking baths, in this study, is defined as twice daily soaking baths for 15-20 minutes, over 2 weeks. However, this is a crossover study design with two interventions: 1) Infrequent soaking baths, as defined in the first arm description above, and 2) Frequent soaking baths, as defined above in this arm description. All subjects in the study will undergo both interventions, but in different order. Thus, this is a study comparing Infrequent Versus Frequent Soaking Baths. Each subject serves as their own control.
2878830|NCT03397966|Experimental|BNP infusion|Subjects will receive an IV infusion of recombinant human b-type natriuretic peptide (BNP (1-32)) for 240 minutes.
2878831|NCT03397966|Placebo Comparator|saline infusion (control)|Subjects will receive an IV infusion of normal saline for 240 minutes. The volume of saline delivered will be equivalent to the volume of saline that the subject receives during the BNP infusion visit.
2878832|NCT03397953|Experimental|Vinorelbine monotherapy treatment|Patients will be treated by Vinorelbine. Four weeks as a course. There are 20 courses in total.
2878833|NCT03397940||Year Round School|Children attending year round school
2878834|NCT03397940||Traditional School|Children attending a traditional school with a traditional calendar school year
2878835|NCT03397927|Experimental|orthosis|
2878836|NCT03397914|Other|Group A Regimen:|- Loading dose 2.5 mg/kg followed by maintenance dose 1.25mg/Kg every 12 hours in accordance with manufacturer insert
2878837|NCT03397914|Other|Group B Regimen:|- Loading dose 5 mg/kg followed by maintenance dose 2.5 mg/Kg every 12 hours in accordance with manufacturer insert
2878838|NCT03397901|Experimental|transverse colostomy|Diverting transverse colostomy were conducted under general or epidural anesthesia in the operating room. The transverse colon was pulled out through one 2*2cm incision. The omentum was dissected from transverse colon, and a double-cavity stoma of transverse colon was then created.
2878839|NCT03397888|Experimental|Cohort 1|Mild Impairment, Child-Pugh Category A
2878840|NCT03397888|Experimental|Cohort 2|Moderate Impairment, Child-Pugh Category B
2878841|NCT03397888|Experimental|Cohort 3|Essentially Healthy man or woman without liver disease matched to Cohorts 1 & 2 for age, sex and weight.
2878842|NCT03397875|Active Comparator|Zinc oxide based sealer|After root canal treatment obturation with gutta percha will be done using zinc oxide based sealer.
2878843|NCT03397875|Experimental|Epoxy resin based sealer|After root canal treatment obturation with gutta percha will be done using epoxy resin based sealer.
2878844|NCT03397875|Experimental|Bioactive silicone based sealer|After root canal treatment obturation with gutta percha will be done using bioactive silicone based sealer.
2900910|NCT03242213|No Intervention|Usual Care|Standard of Care
2878847|NCT03397849|Active Comparator|intervention using mobile technology (IMT) plus usual care|Each study patients that are randomized to IMT plus usual care group will receive a group of smart devices including mobile phone (Vestel Venus e2) (Vestel, Manisa, Turkey), wristband (Xiaomi band 2) (Beijing Xiaomi Technology Co., Beijing, China), weight scale (Bluecat, Yongkang Tiansheng Electronic Co., Zhejiang, China) and blood pressure monitor (Clever Chek TD-3250) (TaiDoc Technology Co., Taipei County, Taiwan).
2878848|NCT03397849|No Intervention|Only usual care|Patients that are randomized to only usual care group will receive guideline-standardized medications and lifestyle recommendations. Cardiovascular risk management and compliance to medication and lifestyle recommendation will be assessed and controlled by three cardiologists in clinical visits performed at 6 and 12 months. For the necessary cases counseling to other specialities will be performed for smoke cessation and weight management.
2878849|NCT03397836|Experimental|Health TAPESTRY Intervention|This patient group will begin receiving the TAPESTRY interventions from time zero
2878850|NCT03397836|Active Comparator|Usual Care|This patient group will receive the intervention after a 6 month waiting period. In the first 6 months they will receive usual care and they will be used as a comparison group.
2878851|NCT03397823||head and neck cancer pre RT|head and neck cancer patients before and after RT
2878852|NCT03397823||head and neck cancer treated|head and neck cancer patients treated with radiotherapy
2878853|NCT03397823||healthy control|subjects matched in gender and age without cancer
2878854|NCT03397810|Experimental|Singe arm|Subjects will receive a low dose radiotherapy focused to the heart
2878855|NCT03397797|Active Comparator|Group with muscle relaxant|Rocuronium is used during the operation to maintain moderate relaxation.
2878856|NCT03397797|No Intervention|Group without muscle relaxant|Rocuronium is not used during the operation for the eletrophysiological monitoring.
2878857|NCT03397784||fluid responders|Patients whose stroke volume index increase by ≥15% in response to a 500-ml fluid bolus was defined as fluid responders.
2878858|NCT03397784||fluid non-responders|Patients whose stroke volume index increase by <15% in response to a 500-ml fluid bolus was defined as fluid non-responders.
2878859|NCT03397771|Experimental|Litoxetine oral capsules|oral experimental study medication litoxetine
2878860|NCT03397771|Placebo Comparator|Placebo oral capsules|oral comparator
2878861|NCT03397758|Experimental|Study population|They were treated with AGNES micro-insulated needles with RF applicators in two separate sessions, at intervals of four weeks.
2878862|NCT03397745|Other|BIS group|Patients who received the esophageal surgery
2878863|NCT03397732||Aorto-bifemoral bypass|Patients scheduled for elective aorto-bifemoral bypass surgery by vascular surgeons and consented to participate in the study.
2878864|NCT03397732||Aorta stentgraft|Patients scheduled for elective aorta stentgraft implantation by vascular surgeons and consented to participate in the study.
2878865|NCT03397719|Active Comparator|Control Group|This group will receive treatment as usual. Each participant will receive three hours of in-vivo parent coaching per week for 6 months.
2878866|NCT03397719|Experimental|Treatment Condition|This group will receive an additional component which will involve videotaping parent/child interactions at home for thirty minutes a week. Each week, the therapist will select sections of the video to review with the parent during one of the parent coaching sessions.
2878867|NCT03397706|Experimental|Phase 1b Dose Escalation|"VRx-3996 (cohort 1) and valganciclovir~VRx-3996 (cohort 2) and valganciclovir~VRx-3996 (cohort 3) and valganciclovir~VRx-3996 (cohort 4) and valganciclovir~VRx-3996 (cohort 5) and valganciclovir"
2878868|NCT03397706|Experimental|Phase 2 Dose Expansion|VRx-3996 (RP2D: recommended phase 2 dose) and valganciclovir
2878869|NCT03397693||1|Women with unexplained infertiltiy with no treatment given
2878870|NCT03397693||2|Women with Poly Cystic Ovary Syndrome (PCOS) who are being treated with different drugs of ovulation induction.
2878871|NCT03397693||3|Control fertile women with no treatment given.
2878872|NCT03397680|Active Comparator|Rabeprazole-levofloxacin based quadruple therapy for 7 days|Participant will received 7-day once daily dose regimen of 1-tablet 750-mg Levofloxacin after meal, 2-tablet 500-mg Clarithromycin MR after meal, 3-tablet 20-mg Rabeprazole before meal and 1-tablet 1,048-mg Gastro bismol after meal.
2878873|NCT03397680|Active Comparator|Rabeprazole-levofloxacin based quadruple therapy for14 days|Pparticipant will received 14-day once daily dose regimen of 1-tablet 750-mg Levofloxacin after meal, 2-tablet 500-mg Clarithromycin MR after meal, 3-tablet 20-mg Rabeprazole before meal and 1-tablet 1,048-mg Gastro bismol after meal
2878874|NCT03397667|Other|Control|Primary Care
2878875|NCT03397667|Experimental|Intervention|Primary Care plus ABC ANSWERS intervention
2878876|NCT03397654|Experimental|TACE followed by pembrolizumab|Trans-arterial chemoembolization (TACE) using doxorubicin solution (60 mg dose) and gelatin sponge particles; followed, at least 30 or 45 days later, by pembrolizumab solution (200 mg dose) every 3 weeks for a maximum of 1 year
2878877|NCT03397641|Active Comparator|Active|x mg HBI-3000 as x mL of a 50 mg/mL solution for intravenous infusion. Doses of HBI-3000 (Cohorts A to G) may range from 20 mg to a level at which it is expected that the drug exposure will not exceed an AUC(0-t) of 20 µg.h/mL and Cmax of 20 µg/mL (based on the NOAEL) in both 14-day repeat-dose toxicology species rat and minipig) and the expected therapeutic dose.
2878878|NCT03397641|Placebo Comparator|Placebo|Matching placebo for x mg HBI-3000 as x mL of a 50 mg/mL solution for intravenous infusion.
2878879|NCT03397628|No Intervention|Control|
2878880|NCT03397628|Experimental|Intervention|
2878881|NCT03397615|Active Comparator|Betadine douches|subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery
2878882|NCT03397615|No Intervention|Non betadine douches|subjects didnot received a vaginal preparation prior to caesarean delivery
2878883|NCT03397602|No Intervention|standard care|Participants do not participate in a on site structured exercise training program.
2878884|NCT03397602|Experimental|standard care + MICE|standard care + moderate-intensity continuous exercise training (MICE)
2878885|NCT03397602|Experimental|standard care + HIIT|standard care + high-intensity interval training (HIIT)
2878919|NCT03397277|Sham Comparator|Screened positive control video|Pregnant women who screen positive for IPV using the AAS who are randomized into viewing the control video
2878886|NCT03397589|Experimental|CHW Arm|The intervention is community health worker (CHW) services. CHWs trained in oral health will be assigned to half of the sites. Participants in these sites will be offered four in-person visits and follow-up phone calls over 12-months. These visits can occur at the location of the family's preference (recruitment site, home, or mutually-agreed upon other location). A core curriculum of oral health topics will be covered during visits, with an emphasis on developing and sustaining healthy oral health management routines for the entire family.
2878887|NCT03397589|No Intervention|Wait-list Control Arm|This arm will receive usual care. After completion of the final data collection at one year, participants and sites allotted to this arm will be offered CHW services.
2878888|NCT03397576|Experimental|ATHENA|Subjects in the experimental arm will participate in monthly group medication adherence counseling sessions within prison led by a nurse and peer educator. After prison release, subjects in the experimental group will participate in four home visits during which intervention staff (nurses and peer educators working in teams) will deliver individualized medication adherence counseling based on the Freirian educational model.
2878889|NCT03397576|No Intervention|Control|Subjects in the control group will receive standard care, which includes a referral for HIV care and ART if prescribed ART within prison.
2878890|NCT03397563|Experimental|CPAP treatment|Continuous Positive Airway Pressure (CPAP)
2878891|NCT03397563|Sham Comparator|Sham-CPAP treatment|sham Continuous Positive Airway Pressure (sham-CPAP)
2878892|NCT03397537|Other|the postmenopausal|2.5 mg letrozole every day for six months
2878893|NCT03397537|Experimental|the premenopausal|2.5 mg letrozole daily along with a GnRH analogue for ovarian suppression, which was administered as an intramuscular injection of 3.75 mg triptorelin every 28 days for 6 months.
2878894|NCT03397524|Experimental|optima4BP|optima4BP will receive several types of data to personalize the participant's medication treatment. The data include: remotely measured blood pressure (BP), and information on current medication treatment as well as health updates posted in Epic Electronic Record.
2878895|NCT03397524|No Intervention|Standard of Care|The participants randomized to the Standard of Care will follow usual care, as currently followed at the University of California San Francisco.
2878896|NCT03397511|Experimental|Usual Care+Financial Incentive|Smoking cessation counseling couples with financial incentives
2878897|NCT03397498|Experimental|Computerized cognitive training|Received the Computerized cognitive training program, CogniFit™
2878898|NCT03397498|Active Comparator|Control-games|Received the Computerized games program
2878899|NCT03397485|Experimental|Growing Milk|"Experimental Fortified milk has energy from fatty acids, protein and carbohydrates. This milk has probiotics and essential micronutrients such as Zn, Fe, vitamins ( A, D, E, K, C and B complex), selenium and Copper among others.~Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Bottles were used to facilitate measuring in milliliters and were weighted before and after preparing milk in a diet measuring scale. Mothers were given the amount of milk necessary to prepare 480 ml per day during the weekend."
2878900|NCT03397485|Active Comparator|Fortified Milk|Fortified milk has no energy from fatty acids nor micronutrients such as vitamin B12, Selenium and Copper. This milk was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Bottles were used to facilitate measuring in milliliters and were weighted before and after preparing milk in a diet measuring scale. Mothers were given the amount of milk necessary to prepare 480 ml per day during the weekend.
2878901|NCT03397472||treatment group|use the sleep pillow with the magnetic field modulation treatment
2878902|NCT03397472||placebo group|use the sleep pillow without magnetic field modulation treatment
2878903|NCT03397446|Experimental|Lisdexamfetamine dimesylate|A central nervous system stimulant, specifically, a prodrug of dextro-amphetamine
2878904|NCT03397433|Experimental|Intervention|"In this arm, an Information Technology physician assist tool will be used to predict best available therapy for patients coming to the hospital with either pneumonia, cellulitis, intraabdominal infection, or complicated urinary tract infection.~Intervention: After review of the information technology recommendation by a board certified Infectious Disease physician, the recommendation will be discussed with the primary care physician and treatment implemented."
2878905|NCT03397433|No Intervention|Control|In the two control hospitals there will be no use of the information technology tool for implementation of initial treatment (No intervention). No notes will be placed in the electronic health record and no contact as a result of this research will be made with the medical care team.
2878906|NCT03397420|Experimental|FAM-CARE|"Two facility clusters (one hospital and one health center, with their filter clinics) will be randomized to initiate the FAM-CARE program (where all HIV-positive family members are seen together as a unit and receive care together) with viral load monitoring"
2878907|NCT03397420|Active Comparator|Control Standard of Care|"Two clusters (one hospital and one health center, with their filter clinics) will be control standard-of care (usual practice) sites. Standard HIV care and treatment services, (drug resupply, clinical assessments etc.), including viral load monitoring, will be provided to adults and children in separate adult and pediatric clinics, even though they many be from the same family."
2878908|NCT03397394|Experimental|Rucaparib|Oral rucaparib (monotherapy)
2878909|NCT03397342|No Intervention|standard breath hold|
2878910|NCT03397342|Experimental|CPAP intervention|
2878911|NCT03397329|Active Comparator|Sequence A|
2878912|NCT03397329|Active Comparator|Sequence B|
2878913|NCT03397316|No Intervention|Marginal bone loss without grafting.|immediate implant placement in upper esthetic zone.
2878914|NCT03397316|Active Comparator|marginal bone loss with xenograft.|xenograft placement (Geistlich Bio-Oss) in immediate implant placement in upper esthetic zone between the residual labial bone and implant surface.
2878915|NCT03397303|Experimental|patients with peripheral neuropathies|This project aims to understand how nerve mechanical properties are altered in patients with rare peripheral neuropathies . Stiffness of various peripheral nerves will be measured using ultrasound shear wave elastography. Patients will be compared with age-matched controls.
2878916|NCT03397303|Other|controls|
2878917|NCT03397290|Experimental|Ultrasound Imaging|A Single Ultrasound Imaging to diagnose of pneumothorax post transthoracic lung biopsy.
2878918|NCT03397277|Experimental|Screened positive intervention video|Safety behaviour promoting video
2878920|NCT03397264|Experimental|Ph 1b: 2.0 mg aflibercept with 0.3 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 0.3 mg OPT-302 intravitreal injection (0.05 mL)
2878921|NCT03397264|Experimental|Ph 1b: 2.0 mg aflibercept with 1.0 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 1.0 mg OPT-302 intravitreal injection (0.05 mL)
2878922|NCT03397264|Experimental|Ph 1b: 2.0 mg aflibercept with 2.0 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 2.0 mg OPT-302 intravitreal injection (0.05 mL)
2878923|NCT03397264|Experimental|Ph 2a: 2.0 mg aflibercept with highest tested or MTD OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed highest tested or MTD from Phase 1b OPT-302 intravitreal injection (0.05 mL)
2878924|NCT03397264|Sham Comparator|Ph 2a: 2.0 mg aflibercept with sham|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by sham intravitreal injection
2878925|NCT03397251|Experimental|Ascyrus Medical Dissection Stent|Ascyrus Medical Dissection Stent placement
2878926|NCT03397238||Non-metastatic TC|
2878927|NCT03397238||Metastatic TC|
2878928|NCT03397238||MNG surgery|
2878929|NCT03397238||MNG RAI treatment|
2878930|NCT03397238||Healthy volunteers|
2878931|NCT03397225|Experimental|Intervention group|The lifestyle intervention, including educational sessions were given to the intervention group of diabetes patients. The educational sessions were scheduled every two weeks and a total of four sessions was provided to the intervention group, the session held in the lecture room at the polyclinic. Also, they were received two individual sessions including dietary and physical activity advice during the consultation session in the diabetic clinic at the beginning and at the end of the study.
2878932|NCT03397225|Active Comparator|Control group|Lifestyle intervention, including individual lifestyle consultation, including dietary and physical activity consultation at the beginning and the end of the study, two sessions. This is done after the screening of the participants in the diabetic clinic at the beginning and at the end of the study.
2878933|NCT03397225|No Intervention|Anonymous data|The patients, n = 60, were recruited randomly and anonymously from the same diabetes clinic, and the HbA1c data was taken from the anonymous patients at two points over the 12-month study duration.
2878934|NCT03397212|Experimental|NADA and Clonidine|NADA acupuncture and treatment with tbl Clonidine
2878935|NCT03397212|Sham Comparator|Sham acupuncture and Clonidine|Sham ear acupuncture and treatment with tbl Clonidine
2878936|NCT03397199|Experimental|Apatinib + S-1|Apatinib + S-1
2878937|NCT03397186|Other|Basic science (trabectedin, biopsy)|Patients undergo a biopsy at baseline and then receive trabectedin for up to 4 courses. Beginning 1 week after completion of course 2 and prior to course 3, patients undergo a second biopsy. Patients who achieve clinical benefit (CR, PR, SD) after the first post-treatment scan and who continue trabectedin for 4 courses undergo a third biopsy after course 4.
2878938|NCT03397173|Experimental|Azacitidine + Ascorbic acid|Azacitidine will be administered intravenously or subcutaneously at a fixed dose of 75mg/m2/day for 7 consecutive days, (allowing for weekends, and holidays) of each 28-day cycle. Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle.
2878939|NCT03397160|No Intervention|Usual care|Participants assigned to the control arm will receive usual care, including whatever information materials are provided to them by their urologist.
2878940|NCT03397160|Active Comparator|Decision Support Intervention (DSI)|"Participants assigned to the intervention will receive Decision Support Intervention in the form of a decision aid plus health coaching. The decision aid (delivered by internet and as a PDF document) provides participants with a report on options and outcomes as described in the literature; along with more tailored risk information. The tailored risk information will include their estimated risk of harboring more aggressive prostate cancer based on their clinical/pathologic features (i.e., My Clinical Risk). The DSI was developed and piloted at UCSF according to the International Patient Decision Aid Standards (see http://ipdas.ohri.ca/) (IRS# 14-13332), and incorporates tailored risk models developed and validated."
2878941|NCT03397147|No Intervention|Usual Care|Usual Care
2878942|NCT03397147|Experimental|Sleep Coach Jr.|Parents randomized to the intervention condition will receive a binder with the treatment manual, and the intervention will be administered in person (first session) and via telephone (second session) on an individual basis. The first session will focus on parent education and developing a positive bedtime routines, and the second session will be used to address barriers specific to the individual child.
2878943|NCT03397134|Experimental|Roluperidone 64 mg|Roluperidone 64 mg for entire study
2878944|NCT03397134|Experimental|Roluperidone 32 mg|Roluperidone mg for entire study
2878945|NCT03397134|Placebo Comparator|Placebo-1|Placebo for 12 weeks followed by Roluperidone 64 mg during open-label extension
2878946|NCT03397134|Placebo Comparator|Placebo-2|Placebo for 12 weeks followed by Roluperidone 32 mg during open-label extension
2878947|NCT03397121|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90 then every 6 months.
2878948|NCT03397121|Placebo Comparator|Placebo|Placebo will be administered as SC injections of saline solution on Day 1, Day 90 then every 6 months.
2878949|NCT03397108||Women with IBD|This group is composed of breastfeeding women aged over 18 years and in their first 6-month postpartum period, who are diagnosed with Crohn's disease or Ulcerative Colitis.
2878950|NCT03397108||Healthy breastfeeding women|This group is composed of healthy breastfeeding women aged over 18 years and in their first 6-month postpartum period.
2878951|NCT03397095|Experimental|CSWT+BMMSCs|Patients in CSWT+BMMSCs group will receive a 3-month cardiac shock wave therapy and then a total of 1 million/kg BMMSCs will be infused using the stop-flow technique through an over-the-wire balloon catheter positioned in a coronary artery or bypass graft supplying the targeting viable myocardium.
2878952|NCT03397095|Sham Comparator|CSWT+Sham operation|Placebo group will receive a 3-month CSWT and a sham procedure.
2878953|NCT03397082|Experimental|Lidocaine + Paracervical blockade|5 minutes previous to endouterine manual aspiration, 5mL of lidocaine gel was applied plus standard paracervical blockade.
2878954|NCT03397082|Placebo Comparator|Placebo + paracervical blockade|5 minutes previous to endouterine manual aspiration, standard paracervical blockade was applied plus placebo gel (KY).
2902793|NCT03229408|Placebo Comparator|Placebo-Treated Obese PCOS|n=15
2878955|NCT03397069|Placebo Comparator|Group C(control)|Peribulbar block without midazolam (peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml)
2878956|NCT03397069|Experimental|Group M1|Peribulbar block with midazolam 50 µg (peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 50 µg/ml)
2878957|NCT03397069|Experimental|Group M2|Peribulbar block with midazolam 100 µg(peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 100 µg/ml
2878958|NCT03397056||The study population|"The target population corresponds to patients with a respiratory disease already included in a biomedical research protocol.~Intervention: Questionnaire"
2878959|NCT03397043|Experimental|Healthy females|All participants receive the intervention: Protein intake (dose). This consists of varying levels of dietary protein intakes, in the form of crystalline amino acids, ranging from 0.2-3.0 g/kg/d
2878960|NCT03397030|Experimental|Home-Based Exercise Program|Participants will complete a prescribed home-based exercise program and will follow up with research staff at the UT Health San Antonio School of Nursing.
2878961|NCT03397030|No Intervention|Waitlist-Control Group|Participants assigned to this group will be asked to maintain normal activity and visit the UT Health San Antonio School of Nursing for research appointments.
2878962|NCT03397004|Active Comparator|doxycycline Hyclate|subjects will be treated with a 6-month course of doxycycline oral capsule at a dose of 100mg twice daily
2878963|NCT03397004|Placebo Comparator|Placebo|subjects will be given a placebo oral capsule twice daily for 6-months
2878964|NCT03396991||Study Group|In the study Group the investigators enrolled 26 patients scheduled for hallux valgus surgery and treated with a new analgesici approach. After sub-gluteal sciatic nerve block with short acting local anesthetic (mepivacaine 2%, 15 ml), each patient received an ultrasound-guided Posterior Tibial Nerve Block (PTNB) with levobupivacaine 0,5% (7-8 ml). The investigators measured: the intensity of pain at the baseline (before the surgery) and at 3, 6, 12 and 24 hours (h) using a Visual Analogue Scale (VAS); the consumption of oxycodone in the first 24 hours after surgical treatment and the motor recovery using modified Bromage score.
2878965|NCT03396991||Control group|The investigators compared the study group with a control group of 26 patients previously scheduled for the same surgery and treated with another post-operative analgesia technique more frequently used in our hospital: local infiltration (Local Infiltration Anesthesia, LIA) with levobupivacaine 0, 5% (15 ml) performed by the surgeon directly on the operative site.
2878966|NCT03396978|Experimental|GnRHag|Participants will undergo 6 months of gonadotropin releasing hormone agonist (GnRHag) therapy (intramuscular injection of leuprolide acetate 3.75 mg for depot suspension; Lupron; TAP Pharmaceutical Products, Inc.; Lake Forest, IL) to chronically suppress ovarian hormones. A single injection of leuprolide acetate produces an initial stimulation (for up to 3 wk) followed by a prolonged suppression of pituitary gonadotropins and ovarian hormones. Repeated monthly dosing suppresses ovarian hormone secretion.
2878967|NCT03396965|Experimental|Mini-c-arm|Fluoroscopically aided reductions
2878968|NCT03396965|No Intervention|Standard|
2878969|NCT03396952|Experimental|Treatment (pembrolizumab, ipilimumab, aspirin)|Patients receive pembrolizumab IV over 30 minutes on day 1, ipilimumab IV over 60 minutes on day 1 for courses 1-4, and aspirin PO BID (orally, twice a day) on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
2878970|NCT03396939|Experimental|Orthosis|The intervention will be performed individually and will run for 12 weeks both at the community rehabilitation unit (3 times a week for 3 weeks) and at home (9 weeks). The group will receive an orthotic device for use during the study-specific exercises.
2878971|NCT03396939|No Intervention|Control|The group will receive the same amount of a study-specific training program without the orthotic device.
2878972|NCT03396926|Experimental|Treatment (pembrolizumab, bevacizumab, capecitabine)|Patients receive pembrolizumab IV over 30 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 35 courses in the absence of disease progression or unacceptable toxicity.
2878973|NCT03396913|Experimental|IPL followed by MGX|Subjects in the experimental arm with receive IPL followed by MGX: IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
2878974|NCT03396913|Sham Comparator|Sham IPL followed by MGX|Subjects in the sham comparator arm with receive Sham IPL followed by MGX: Sham IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following Sham IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
2878975|NCT03396900|Active Comparator|RhBMP-2 Protein, Recombinant|15 subjects treated with corticotomy with rhBMP-2 (C+BMP)
2878976|NCT03396900|Experimental|Conventional Corticotomy|15 subjects treated with conventional corticotomy (C) as in the PAOO protocol
2878977|NCT03396887|Experimental|Smartphone Application Users|"The experimental group will receive the smartphone intervention along with treatment as usual for 3-months. The smartphone application (UControlDrink) includes twice daily text message recovery support, relapse prevention cognitive behavioural therapy, 12 sessions in total, drinking and recovery activity logs where participants detail their abstinence, drinking and recovery activity engagement on a daily basis. Craving intervention in the form of a calm button to deal with cravings and prevent relapse and gamification, a system of encouraging positive behaviour with the awarding of points to achieve various status levels, is used to increase adherence and compliance with treatment recommendations."
2878978|NCT03396887|Active Comparator|Control Group|The control group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
2878979|NCT03396874|Experimental|68Ga-PSMA|PET/CT imaging
2878980|NCT03396861|Experimental|Subconjunctival aflibercept|Subconjunctival aflibercept 2 milligrams (mg) /0.05 milliliters (mL) administered at baseline visit and possibly again at Month 1 visit depending on initial response.
2878981|NCT03396848|Experimental|SHAReClinic|All participants will have access to the online clinic
2878982|NCT03396809|Experimental|Punctal Plugs|This arm of the study receives punctal plug intervention.
2878983|NCT03396796|Experimental|Vagus nerve-preserving group|Every patient of vagus nerve-preserving group will receive the modified vagus nerve-preserving laparoscopic azygoportal disconnection procedure.
2878984|NCT03396796|No Intervention|Conventional group|Every patient of conventional group will receive the conventional laparoscopic azygoportal disconnection procedure.
2878985|NCT03396783|Experimental|SPP|during the visit, nurse will make a blood test for biological and immunological analysis, electromyogram and walk test
2878986|NCT03396783|Other|Control|during the visit, nurse will make a blood test for biological and immunological analysis
2878987|NCT03396770|Active Comparator|Control group|Standard clinical routine
2878988|NCT03396770|Experimental|Nephrocheck group|Nephrocheck test
2878989|NCT03396757|Active Comparator|Standard strategy|RRT will be initiated within 12 hours after documentation of serum urea concentration >40 mmol/l and/or an oliguria/anuria for more than 72 hours (identical to the delayed strategy in AKIKI).
2878990|NCT03396757|Experimental|Delayed strategy|RRT will be considered only if one potentially severe following situation occurs (noticeable hyperkalemia, or acidosis or pulmonary edema due to fluid overload resulting in severe hypoxemia which do not respond rapidly to medical treatment) or if serum urea concentration reaches 50 mmol/L.
2878991|NCT03396744|Active Comparator|Morning group|Exposition at 8 a.m +/- 30 min, during 10 active weeks, and assessed 6 months after this intervention
2878992|NCT03396744|Active Comparator|Mid-day group|Exposition at 8 a.m +/- 30 min, during 10 active weeks, and assessed 6 months after this intervention.
2878993|NCT03396731|No Intervention|Standard care alone (control)|Multilayer/multi component high-level compression bandaging treatment
2878994|NCT03396731|Active Comparator|6 hours geko™|geko™ device 6 hours daily for 4 weeks treatment phase, to be used in conjunction with Standard of care.
2878995|NCT03396731|Active Comparator|12 hours geko™|geko™ device 12 hours daily for 4 weeks treatment phase, to be used in conjunction with Standard of care.
2878996|NCT03396718|Experimental|Interventional Arm A - HPV(+)|De-escalation Radio(chemo)therapy - Level 1
2878997|NCT03396718|Experimental|Interventional Arm B - HPV(+)|De-escalation Radio(chemo)therapy - Level 2
2878998|NCT03396718|Active Comparator|Observational Arm A - HPV(-)|Standard Radio(chemo)therapy
2878999|NCT03396718|Active Comparator|Observational Arm B - HPV(+)|Standard Radio(chemo)therapy
2879000|NCT03396692|Active Comparator|Control Arm|Pain management use intravenous morphine patient-controlled analgesia (PCA)
2879001|NCT03396692|Experimental|Posterior exo-thoracic fascia block arm|Pain management use intravenous morphine patient-controlled analgesia (PCA) and a block of the posterior exo-thoracic fascia with Ropivacaine
2879002|NCT03396692|Experimental|Paravertebral block arm|Pain management use intravenous morphine patient-controlled analgesia (PCA) and a block of paravertebral space with Ropivacaine
2879003|NCT03396679||CASPAR criteria agreement|PsA patients fulfilling CASPAR criteria in remission as determined by physician with patient and physician's global assessment of disease activity in agreement compare to Ultrasound examination
2879004|NCT03396679||CASPAR criteria disagreement|PsA patients fulfilling CASPAR criteria in remission as determined by physician with patient and physician's global assessment of disease activity in disagreement compare to Ultrasound examination
2879005|NCT03396666|Experimental|Telemouv|Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
2879006|NCT03396666|No Intervention|No intervention|Regular follow-up with advice on physical activity and nutrition
2879007|NCT03396653|Active Comparator|Peer-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month patient-delivered behavioral weight maintenance intervention. Specifically, group sessions will be delivered by a mentor (i.e., successful weight loser) and weekly coaching will be delivered by a peer (other member of their weight maintenance group).
2879008|NCT03396653|Active Comparator|Professionally-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month reduced intensity behavioral weight maintenance intervention, delivered by a professional. The intervention will consist of 24 group sessions.
2879009|NCT03396640|Experimental|Unicondylar Knee Arhtroplasty|Operation with insertion of a knee arthroplasty using a unicompartmental device (Oxford phase 3, mobile bearing, uncemented)
2879010|NCT03396640|Active Comparator|Total Knee Arthroplasty|Operation with insertion of a knee arthroplasty using a total condylar device (PCR, nexgen with resurfacing, cemented)
2879011|NCT03396627||muller muscle|muller muscle and conjunctiva excised during muller muscle conjunctival resection
2879012|NCT03396614||EEG, ECG, CT, MRI|
2879013|NCT03396601|Experimental|NRX-100 infusion|Infusion of IV NRX-100 (ketamine)
2879014|NCT03396601|Experimental|Saline (placebo) infusion|Infusion of IV Saline
2879015|NCT03396588|Active Comparator|Clonidine|Babies randomized to clonidine will receive 1mcg/kg/dose (with a dosing interval of 3 or 4 hours).
2879016|NCT03396588|Active Comparator|Morphine|Babies randomized to morphine will receive 0.06 mg/kg/dose (with a dosing interval of 3 or 4 hours).
2879017|NCT03396575|Experimental|Group A|TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs) during cycles of Dose-intensified TMZ
2879018|NCT03396575|Experimental|Group B|TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs) with Cyclophosphamide + Fludarabine Lymphodepletive Conditioning
2879019|NCT03396562||SCT Conditions|"Sex Chromosome Trisomies Conditions including Klinefelter (XXY), Trisomy X (XXX), XXY Syndromes.~Interventions: Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 5 or 6 years."
2879020|NCT03396549|Experimental|real tDCS|20 min of 2 mA tDCS over the right and left dorsolateral prefrontal cortex
2879021|NCT03396549|Sham Comparator|new sham tDCS|20 min 2 mA tDCS over the left and right sensorimotor cortex
2879022|NCT03396536||Group 1|Group 1 will be implants with keratinized mucosa (KM).
2879023|NCT03396536||Group 2|Group 2 implants without keratinized mucosa (KM). Alveolar mucosa (AM) directly present around the implant.
2879024|NCT03396523|Experimental|Losartan group|
2879025|NCT03396523|Placebo Comparator|Placebo group|
2879100|NCT03395990|Active Comparator|chloroprocaine|15 ml of 2% chloroprocaine via a femoral nerve block technique
2906233|NCT03205020||women delivered at full term|
2879026|NCT03396510|Experimental|IMPROVED intervention|Patients randomized to the IMPROVED intervention will self-report their symptoms each day using a tablet computer. If any patient refuses or is unable to complete the symptom assessment on the computer, the study team will permit them to use paper versions. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden. Patients randomized to IMPROVED will have their symptoms presented to their inpatient oncology team, but the study team will not provide guidance about what actions to take in response to patients' symptoms.
2879027|NCT03396510|No Intervention|Usual Care|Usual Care per hospital standard will be administered. Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports.
2879028|NCT03396497|Experimental|LYC-55716 + pembrolizumab|Subjects will receive combination treatment until disease progression or unacceptable toxicity, or up to a maximum of 24 months.
2879029|NCT03396484|Experimental|Methyldopa|"Adults: methyldopa 500mg twice daily for one week and then increased to 500mg three times a day~Children: methyldopa dose based on weight twice daily for one week then increased to three times a day"
2879030|NCT03396484|Placebo Comparator|Placebo|Inactive agent to match active drug in appearance and dose frequency.
2879031|NCT03396471|Experimental|Single Arm Assignment|Pembrolizumab + External Beam Radiation Therapy
2879032|NCT03396458||Hepatitis B group|Hepatitis B serology and questionnaire
2879033|NCT03396445|Experimental|MK-5890|Participants receive escalating doses of MK-5890 via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
2879034|NCT03396445|Experimental|MK-5890 + Pembrolizumab|Participants receive escalating doses of MK-5890 via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
2879035|NCT03396432|Active Comparator|Video Laryngoscopy for endotracheal (ET) Placement|"Device:~Storz C-MAC Video Laryngoscope"
2879036|NCT03396432|Active Comparator|Direct Laryngoscopy for ET Placement|"Device:~Miller Laryngoscope"
2879037|NCT03396419||Acute Isch. Stk pts treat. w/SPG stimul.|"Following implantation (according to the ImpACT-24B protocol), subjects will be transferred to the angio suite. A baseline brain digital subtraction angiography (DSA) will then be performed by a trained physician prior to initiation of SPG stimulation according to the ImpACT-24B protocol.~Following the first SPG stimulation cycle of 4 minutes, a post-stimulation DSA will be performed.~Based on the results of the post-stimulation DSA, the physician may perform an additional DSA following the second SPG stimulation cycle.~The subject will then be transferred to the stroke department and will continue treatment according the ImpACT-24B protocol."
2879038|NCT03396406|Experimental|PCRF group|received Pulsed radiofrequency (PRF) at 42°C for 8 minutes followed by CRF at 60°C for 270s
2879039|NCT03396406|Experimental|CRF group|received sole thermocoagulation at 70°C for 270 s
2879040|NCT03396393|Experimental|Dihydroartemisinin 40mg|Randomized 30 patients will be received Dihydroartemisinin tablets 40mg in oral continuously from Week 0 to Week 24 in addition to SOC.
2879041|NCT03396393|Experimental|Dihydroartemisinin 80mg|Randomized 30 patients will be received Dihydroartemisinin tablets 80mg in oral continuously from Week 0 to Week 24 in addition to SOC.
2879042|NCT03396393|Experimental|Dihydroartemisinin 120mg|Randomized 30 patients will be received Dihydroartemisinin tablets 120mg in oral continuously from Week 0 to Week 24 in addition to SOC.
2879043|NCT03396393|Placebo Comparator|placebo|Randomized 30 patients will be received placebo tablets in oral continuously from Week 0 to Week 24 in addition to SOC.
2879044|NCT03396380|Active Comparator|vitamin D|93 women who will receive clomiphene citrate for induction of ovulation with vitamin D and calcium supplement
2879045|NCT03396380|Placebo Comparator|placebo|93 women who will receive clomiphene citrate for induction of ovulation with placebo and calcium supplement
2879046|NCT03396367|Experimental|PARTNER Intervention|This intervention is a four-session intervention designed to increase PrEP uptake, increase PrEP adherence, and reduce drug use and HIV transmission risk behaviors of individuals in relationships.
2879047|NCT03396367|Active Comparator|Education Intervention|This intervention is a four-session intervention that discussed drug use and its effect on physiological social functioning.
2879048|NCT03396354|Experimental|Integrated robotic surgery|
2879049|NCT03396354|Active Comparator|Conventional laparoscopic surgery|
2879050|NCT03396341||patients receiving a positive BRCA1/2 mutation result|All interested participants will provide a saliva sample for genetic risk modifier testing, and will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system
2879051|NCT03396328|Active Comparator|Conventional education|
2879052|NCT03396328|Experimental|Low salt dietary education by smartphone application|
2879053|NCT03396315|Active Comparator|alendronate|Subjects will receive oral alendronate
2879054|NCT03396315|Active Comparator|zoledronic acid|Subjects will receive zoledronic acid
2879055|NCT03396302|Experimental|Experimental|The experimental group will receive access to the web-based lifestyle intervention (exercise and nutritional education).
2879056|NCT03396302|No Intervention|Control|The control group will receive Hospital treatment as usual.
2879057|NCT03396289|Active Comparator|Control Group|Patients in this group will receive conventional physiotherapy programme including balance exercises, 3 times a week for 8 weeks. One exercise session will be performed under the supervision of a physiotherapist, other 2 sessions will be performed at home.
2879058|NCT03396289|Experimental|Training Group|In addition to conventional physiotherapy programme, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be performed under the supervision of a physiotherapist, other sessions will be performed at home.
2879059|NCT03396276|Experimental|Suboxone induction into MAT in the ED|Suboxone induction into medication-assisted treatment (MAT) in the emergency department (ED)
2879101|NCT03395990|Sham Comparator|saline|15 ml of 0.9% saline via a femoral nerve block technique
2879060|NCT03396263|Experimental|Online personalised advice|Online (web-based) delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive online personalised reports.
2879061|NCT03396263|Experimental|Face-to-face personalised advice|Face-to-face delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive nutritional advice face-to-face (in person or via video chat).
2879062|NCT03396263|Placebo Comparator|Control|Non-personalised advice Control group. Online (web-based) delivery of non- personalised dietary, weight and physical activity advice based on the UK general health guidelines. This arm will be using the e-Nutri web application. Participants in this group will receive online general recommendations (non- personalised).
2879063|NCT03396250|Experimental|Test product + Reference product|Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK (Pharmacokinetic) blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.
2879064|NCT03396250|Experimental|Reference product + Test product|Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.
2879065|NCT03396237||Group A|Case group contain cases of unexplained infertility women
2879066|NCT03396237||Group B|Control group contain fertile pregnant women
2879067|NCT03396224||Patients who received the Avenir® Cemented Hip Stem|Patients suffering from severe hip pain and disability requiring total hip arthroplasty and who meet the inclusion/exclusion criteria
2879068|NCT03396211|Experimental|Apatinib (also known as rivoceranib) with Nivolumab|Oral daily doses of apatinib (as its mesylate salt) with a fixed dose of nivolumab given intravenously every 2 weeks
2879069|NCT03396185|Experimental|Icotinib|Patients with EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.
2879070|NCT03396172|Other|Control|The intervention is an hospitalization with usual care. The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
2879071|NCT03396172|Active Comparator|FreeDom|"FreeDom strategy (early discharge, automated weaning at home, telemedicine, telereadaptation):~-initial conventional hospitalization before discharge home, O2 flow rate automatically titrated by FreeO2 (based on a SpO2 target). The hospital discharge will be possible if the definite criteria are met.~After hospital discharge, patient will have home hospitalisation. Automated oxygen flow titration, patient education will be conducted for using the telemedicine system, for questionnaires and for the tele-rehabilitation program will be initiated for home hospitalization,"
2879072|NCT03396159|Experimental|mini fluid challenge|mini fluid will be given and stroke volume will be assessed before and after
2879073|NCT03396146|Experimental|Type1diabetes with exocrine pancreatic function insufficiency|12 ml total blood tubes volume Fecal sample
2879074|NCT03396146|Experimental|Type1diabetes without exocrine pancreatic function insuficienc|12 ml total blood tubes volume Fecal sample
2879075|NCT03396146|Active Comparator|Type 3c diabetes|12 ml total blood tubes volume Fecal sample
2879076|NCT03396133|Experimental|Dyno group|individuals in this arm used Dyno according to the instruction on time and screened at the symptomatic
2879077|NCT03396133|No Intervention|RC group|patients in the RC arm accepted normal methods
2879078|NCT03396107|Active Comparator|Dexamethasone|Dexamethasone 6mg, IM, 48 hours before cesarean section
2879079|NCT03396107|Placebo Comparator|Placebo|Placebo 6mg, IM, 48 hours before cesarean section
2879080|NCT03396094|Experimental|Intervention|High-flow nasal cannula oxygenation at 60L/min for pre-oxygenation and apnoeic oxygenation
2879081|NCT03396094|Active Comparator|Control|Pre-oxygenation using non-rebreather mask and apnoeic oxygenation via nasal cannulae at 15L/min
2879082|NCT03396081|Experimental|PRADO-IC|
2879083|NCT03396081|Other|Usual care|
2879084|NCT03396068|Experimental|NRX-101|Subjects will be treated with oral NRX-101 (fixed dose combination of D-Cycloserine/lurasidone) that will be titrated to a combined dose of 950mg/66mg per day.
2879085|NCT03396068|Active Comparator|Lurasidone comparator|Subjects will be treated with oral lurasidone in a matched placebo capsule that will be titrated to a dose of 66 mg per day
2879086|NCT03396055|Experimental|Treatment group|Specific rehabilitation exercise
2879087|NCT03396055|No Intervention|Control|No intervention
2879088|NCT03396042||Group 1|5 Patient target, ages 3 to 5 yr, with visual acuity Light Perception (LP) to <=20/200
2879089|NCT03396042||Group 2|5 Patient target, ages 3 to 5 yr, with visual acuity >20/200 to <=20/60
2879090|NCT03396042||Group 3|5 Patient target, ages 6 to 11 yr, with visual acuity LP to <=20/200
2879091|NCT03396042||Group 4|5 Patient target, ages 6 to 11 yr, with visual acuity >20/200 to <=20/60
2879092|NCT03396042||Group 5|5 Patient target, ages 12 to 17 yr, with visual acuity LP to <=20/200
2879093|NCT03396042||Group 6|5 Patient target, ages 12 to 17 yr, with visual acuity >20/200 to <=20/60
2879094|NCT03396042||Group 7|5 Patient target, ages 18yr and older, with visual acuity LP to <=20/200
2879095|NCT03396042||Group 8|5 Patient target, ages 18yr and older, with visual acuity >20/200 to <=20/60
2879096|NCT03396029|Experimental|Individually tailored lifestyle feedback|Written, standardized individually tailored lifestyle feedback based on participants responses to a lifestyle questionnaire, and a leaflet on healthy lifestyle mailed to the participant.
2879097|NCT03396029|Experimental|Standard leaflet|A leaflet on healthy lifestyle mailed to the participant.
2879098|NCT03396029|No Intervention|Control|No contact with the participant.
2879099|NCT03396016||Factor V|liver transplant patients having Factor V levels measured during their first postoperative week.
2879102|NCT03395977|Placebo Comparator|Placebos PO and IV|PO : per os IV : intraveinously
2879104|NCT03395977|Experimental|Febuxostat PO And Rasburicase IV|Febuxostat : 240 mg a day for 3 days. Uricase : 3 mg once.
2879105|NCT03395977|Experimental|Placebo PO And Rasburicase IV|Placebo : for 3 days. Uricase : 3 mg once.
2879106|NCT03395964|Active Comparator|Preoperative CT scan-guided localization|Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo GIA II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
2879107|NCT03395964|Experimental|Hybrid Dyna-CT guided localization|Patients will be brought into the Hybrid OR, and placed in the lateral decubitus position. A C-arm CT scan of the pre-determined ﬁeld of view that included the nodule position will be acquired during an end-inspiratory hold maneuver using a 5 sec scan protocol with 0.36mGy/projection and 248 projections acquired over 200°. The radiologist reviewed the C-arm CT scan to localize the nodule and plan trajectories for percutaneous hook-wire placement using Syngo iGuide needle guidance software. The planned needle pathways will be integrated into the C-arm fluoroscopic imaging system, which provided laser crossbar and guidance markers on fluoroscopy images to direct the needle pathway for hook wire placement.
2879108|NCT03395938|Placebo Comparator|Current practice|"Intervention A depicts current practices by having the research team educate the participants on the Ministry of Health Singapore screening guidelines akin to counselling sessions carried out during the patient's clinical consultation."
2879109|NCT03395938|Active Comparator|Proactive engagement|"Intervention B involves a series of proactive engagements in hope to spur patients into contacting their siblings and improve their receptiveness towards colorectal cancer screening."
2879110|NCT03395925|Experimental|Celon Pro Surge|Ablation of thyroid tissue
2879111|NCT03395912|Experimental|Intervention|Infiltration of the subcutaneous layer with local anesthetic and combined with adrenaline.
2879112|NCT03395912|No Intervention|control|Abdominal layers will be closed without Infiltration .
2879113|NCT03395899|Active Comparator|Atezolizumab alone|1200mg of Atezolizumab D1 C1
2879114|NCT03395899|Experimental|Atezolizumab + Cobimetinib|Atezolizumab (1200mg IV D1 C1) + Cobimetinib (60mg PO D1 - 21 of C1)
2879115|NCT03395899|Experimental|Atezolizumab + Ipatasertib|Atezolizumab (1200mg IV D1 C1)+ Ipatasertib (400mg OD D1 - 21 of C1)
2879116|NCT03395899|Experimental|Atezolizumab + Ipatasertib + Bevacizumab|Atezolizumab (1200mg IV D1 C1)+ Cobimetinib (60mg PO D1 - 21 of C1) + Bevacizumab (10mg/kg IV D1 C1)
2879117|NCT03395886|Experimental|remifentanil group|Eligible patients will receive a continuous infusion of remifentanil starting with 0.05 μg/kg/min. The doses will be adjusted according to the sedation satisfaction (sedation target is to achieve NIV-intolerance score 1-2), and the maximum dose is 0.12 μg/kg/min.
2879118|NCT03395886|Active Comparator|dexmedetomidine group|Eligible patients will receive an IV infusion of dexmiditomidine with a loading dose of 0.5-1 μg/kg/h for 10 mins, and then the dosage will be adjusted according to the sedation satisfaction. The maximum maintenance dose for dexmedetomidine is 1 μg/kg/h.
2879119|NCT03395873|Experimental|Single arm|"Decitabine 20mg/m2 IV day 1-5, every 28 days~Avelumab 10mg/kg IV, day 1, every 14 days"
2879120|NCT03395860|Experimental|group A|low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
2879121|NCT03395860|Experimental|group B|low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
2879122|NCT03395847|Experimental|Arm1: Pembrolizumab|Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of each 21-day cycle.
2879123|NCT03395834|Experimental|O3 monitor|tissue oxygenation comparison of O3 & INVOS
2879124|NCT03395821|Active Comparator|Conventional training|Residents will receive the traditional training for laparoscopic surgery according to their residency program.
2879125|NCT03395821|Experimental|Virtual Reality+conventional training|Residents will receive 12 weeks of virtual training for laparoscopy and their traditional training for laparoscopic surgery according to their residency program.
2879126|NCT03395808|Other|AVE-901 50mg|IV Tramadol
2879127|NCT03395795|Other|Single arm|Single arm trial, every patient enroll in this study will follow the same protocol with classic and NAVA mode non-invasive ventilation.
2879128|NCT03395782||Age group 40-49|30 patients will be stratified to this age group.
2879129|NCT03395782||Age group 50-59|30 patients will be stratified to this age group.
2879130|NCT03395782||Age group 60-69|30 patients will be stratified to this age group.
2879131|NCT03395782||Age group 70-79|30 patients will be stratified to this age group.
2879132|NCT03395756|Active Comparator|12-14 mm follicle size group|Once the participant's leading follicle reaches 12-14mm, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
2879133|NCT03395756|Active Comparator|15-17 mm follicle size group|Once the participant's leading follicle reaches 15-17mm, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
2879134|NCT03395756|Active Comparator|18 mm or greater follicle size group|Once the participant's leading follicle reaches 18mm or greater, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
2879135|NCT03395730|Experimental|"• Group (A) Study Group 1:"|"In the labor room women in Group A (n = 50):~Clamping and cutting the placental cord after delivery of the baby.~Immediate intraumbilical vein injection of Oxytocin (Syntocinon®) 20 units diluted in 20 ml of 0.9% saline solution"
2879136|NCT03395730|Experimental|"• Group (B) Study Group 2:"|"In the labor room women in Group B (n = 50):~Clamping and cutting the placental cord after delivery of the baby.~Immediate unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes."
2879137|NCT03395730|Active Comparator|"• Group (C) Control Group:"|"In the labor room women in Group C (n = 50):~Clamping and cutting the placental cord after 2 minutes of delivery of the baby.~Placenta will be delivered spontaneously after appearance of clinical signs of placental separation"
2879138|NCT03395717|Experimental|Exoskeleton-Assisted Gait Training|Patients conduct sessions of gait training, each lasting 60 minutes, using the powered wearable exoskeleton (Ekso) in addition to conventional therapy. Before the treatment's beginning, a PT checks the correct alignment of the subject's joints with Ekso and the areas of greater pressure between body's skin and device, to set a proper Ekso fit as to customize the padding as well. The best individualized exoskeleton settings should be verified to plan a tailored robotic treatment. During treatment, subjects are trained to interface with the Ekso, with optimal postural arrangement and weight shifting strategies. No strength is required from the patient; only an appropriate balance and weight shifts are necessary to achieve walking, since steps are triggered by the user's lateral weight shift.
2879139|NCT03395717|No Intervention|Traditional Over ground Gait Training|"The Control Group (CG) performs 60 minutes. lasting sessions of Traditional Over ground Gait Training with a senior PT. In the starting phase, the gait task facilitation is allowed by the Pt's assistance or by using aids, such as walkers, tripods etc.~Traditional Over ground Gait Trainings include:~Sit-to-Stand tasks~Exercises for upright position control (right/left load shift): these tasks will allow to include people who are unable to walk in the CG.~CG patients will not use any other robots or treadmill for gait training."
2879140|NCT03395704|Active Comparator|LJPC-401|LJPC-401 solution for subcutaneous injection only, 5mg/1 mL (5mg/mL) single use vial
2879141|NCT03395704|Placebo Comparator|Placebo|0.9% Sodium Chloride Injection, USP, or equivalent
2879142|NCT03395691|Active Comparator|The distal approach|The first 3 attempts via the distal approach will be performed . If the first 3 attempts failed, the subsequent attempts of venipuncture were performed using the proximal approach.
2879143|NCT03395691|Active Comparator|The proximal approach|The first 3 attempts via the proximal approach will be performed . If the first 3 attempts failed, the subsequent attempts of venipuncture were performed using the distal approach.
2879144|NCT03395678|Experimental|Microneedling|Participants in this arm will receive 5 treatments of microneedling.
2879145|NCT03395678|Active Comparator|Fractional non-ablative 1,540nm laser|Participants in this arm will receive 5 treatments of fractional non-ablative1,540nm laser.
2879146|NCT03395639|Experimental|Edoxaban|Two out of three participants will be randomized for treatment with edoxaban solution or tablets
2879147|NCT03395639|Active Comparator|Standard of Care (SOC)|One out of three participants will be randomized for treatment with the institution's SOC regimen
2879148|NCT03395626|Experimental|ID-JPL934|probiotics 20%, corn starch 80%
2879149|NCT03395626|Placebo Comparator|placebo|corn starch 100%
2879150|NCT03395613|No Intervention|Standard management|Standard sterile gauze dressing on surgical groin wound.
2879151|NCT03395613|Experimental|NPWT management|Negative Pressure Wound Therapy dressing on surgical groin wound.
2879152|NCT03395600|Active Comparator|0.1%bupivacaine+10µg sufentanyl|Epidural labour analgesia was initiated with 10µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose.If there were no untoward effects after 3 min, then they were given the 10 ml bupivacaine 0.1%.
2879153|NCT03395600|Active Comparator|0.125%bupivacaine+5µg sufentanyl|Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose.If there were no untoward effects after 3 min, then they were given the 10 ml bupivacaine 0.125%.
2879154|NCT03395600|Active Comparator|0.1%bupivacaine+5µg sufentanyl|Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose.If there were no untoward effects after 3 min, then they were given the 10 ml bupivacaine 0.1%.
2879155|NCT03395587|Experimental|Experimental intervention|Fluorescence-guided surgery (day 0) Leukapheresis (wk4) Fractionated radiotherapy (60 Gy: 2 Gy/d, 5/7 d, 6 wks; wk5 10) and concomitant TMZ chemotherapy (75 mg/m2/d; 6 wks; wk5-10) vaccination with autologous, tumor lysate-loaded, mature dendritic cells (DC) (7x, 2 - 10 x 106 DC each, intradermal injection, weekly wk11-14, wk17, 21, 25)Adjuvant TMZ chemotherapy (150-200 mg/m2/d, 6x, days 1 5 of 28 d cycle: wk15, 19, 23, 27, 31, 35)
2879156|NCT03395587|Other|Control intervention|"Standard therapy:~Fluorescence-guided surgery (day 0) Fractionated radiotherapy (60 Gy: 2 Gy/d, 5/7 d, 6 wks; wk5 10) and concomitant TMZ chemotherapy (75 mg/m2/d; 6 wks; wk5-10) Adjuvant TMZ chemotherapy (150-200 mg/m2/d, 6x, days 1 5 of 28 d cycle: wk15, 19, 23, 27, 31, 35)"
2879157|NCT03395574|Experimental|terlipressin group|group will receive terlipressin infusion one mg in 50 ml normal saline will be given over 30 minute as loading dose then will be maintained as infusion of 160 μg per hour (8 ml/h).
2879158|NCT03395574|Placebo Comparator|saline (control) group|group will receive normal saline infusion 50 ml normal saline will be given over 30 minute as loading dose then will be maintained as infusion of (8 ml/h).
2879159|NCT03395561|Active Comparator|green coffe|2 capsuls of green coffe
2879160|NCT03395561|Placebo Comparator|control|2 capsuls
2879198|NCT03395275|Experimental|Intrathecal Pump Therapy Participants|Patients eligible for intrathecal pump therapy will undergo quantitative sensory tests and PROMIS surveys during various stages of the treatment process.
2879161|NCT03395548|Active Comparator|Inflammatory bowel disease|"The aim is to recruit 20 persons suffering from Crohn's disease or ulcerative colitis with stable medication and stable control of the disease.~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
2879162|NCT03395548|Active Comparator|Irritable bowel syndrome|"The aim is to recruit 20 persons suffering from irritable bowel syndrome (IBS) fulfilling rome criteria.~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
2879163|NCT03395548|Active Comparator|Healthy|"The aim is to recruit 20 persons without known illnesses with a comparable age to the other two groups.~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
2879164|NCT03395535|Experimental|'Laser-1st'|"Initial Selective Laser Trabeculoplasty (SLT) [PROCEDURE] followed by conventional medical therapy (eye-drops) as required.~All participants in this arm start their treatment pathway with SLT. If this does not reach the predefined, patient-specific target IOP then repeat laser (once only) is given. If the IOP target is then not reached additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy with mitomycin C) as needed."
2879165|NCT03395535|Active Comparator|Medicine-1st|"Conventional medical therapy [DRUG] without laser. All participants in this arm start their treatment pathway medical treatment. If the IOP target is then not reached, additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy with mitomycin C) as needed.~During this pathway of treatment all commercially available medical treatments (eye-drops) are permitted according to a pre-specified step-wise intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
2879166|NCT03395522|Experimental|Device|ITind device implant
2879167|NCT03395496|Experimental|Biodentine|Dental materials
2879168|NCT03395496|Experimental|ProRoot MTA|Dental Materials
2879169|NCT03395483||Elective, adult colorectal surgical patients|All patients will be monitored by the non-invasive Masimo Radical7 pulseoximeter (Masimo, Irvine, CA, USA) measuring PPI and the MoorVMS-LDF (Moor Instruments Ldt., Axminster, UK) measuring mesenteric tissue blood flow using doppler flowmetry. Patients will be subjected to a haemodynamic challenge using anti-trendelenburg position.
2879170|NCT03395470|Experimental|Group A1|Dose 1 or placebo
2879171|NCT03395470|Experimental|Group A2|Dose 2 or placebo
2879172|NCT03395470|Experimental|Group A3|Dose 3 or placebo
2879173|NCT03395470|Experimental|Group A4|Dose 4 or placebo
2879174|NCT03395470|Experimental|Group A5|Dose 5 or placebo
2879175|NCT03395470|Experimental|Group B|Dose + Rosuvastatin
2879176|NCT03395457|Active Comparator|Care as usual|This is the care provided by the neurologist for chronic migraine.
2879177|NCT03395457|Experimental|Care as usual plus manual therapy|Other
2879178|NCT03395444|Active Comparator|Study Group|Pulsed shortwave therapy device used as an adjunct therapy immediately on the completion of the operation
2879179|NCT03395444|Sham Comparator|Control Group|Sham pulsed shortwave therapy device used as an adjunct therapy immediately on the completion of the operation
2879180|NCT03395431|Active Comparator|FAB group|Arm A - Finger prick autologous blood (FAB) plus conventional treatment The patients will use FAB alongside conventional therapy as recommended by their treating ophthalmologist. A fingertip of the hand will be wiped with an alcohol steret and self-pricked using a standard diabetic lancet. The drop of blood is produced as normal and applied to the lower fornix of the affected eye(s) with the lower lid pulled down slightly by the patient. The blood will be applied 4 times a day. A fresh finger should be used for each eye. FAB should be applied at least 15 minutes after any artificial tears and no other drops applied for at least half an hour afterwards
2879181|NCT03395431|No Intervention|Control group|Arm B - Conventional treatment only The patients will use conventional therapy (artificial tears, cyclosporin drops and punctal plugs/cautery) as recommended by their treating ophthalmologist
2879182|NCT03395405|Experimental|Nitazoxanide Arm|500 mg (one tablet) nitazoxanide by mouth twice daily with food for 28 consecutive days. N=80
2879183|NCT03395405|Placebo Comparator|Placebo Arm|Placebo (one tablet) by mouth twice daily with food for 28 consecutive days. N=80
2879184|NCT03395392|Experimental|NRX-101|Following study enrollment and randomization, subjects will receive twice daily NRX-101
2879185|NCT03395392|Active Comparator|Lurasidone|Following study enrollment, subjects will receive twice daily lurasidone
2879186|NCT03395379||Group 1|RFA without air dissection protection
2879187|NCT03395379||Group 2|RFA with air dissection protection
2879188|NCT03395366|Active Comparator|Group 1|Multifaceted Educational / Cognitive Behavioral Intervention
2879189|NCT03395366|No Intervention|Group 2|Standard of Care + Dialysis Education without the Cognitive Behavioral component
2879190|NCT03395353|Experimental|Duloxetine hydrochloride|Duloxetine hydrochloride administered orally.
2879191|NCT03395314|Placebo Comparator|midazolam|Midazolam IV; 0.04mg/kg over 40 minutes
2879192|NCT03395314|Active Comparator|Very low dose ketamine|ketamine IV; 0.25 mg/kg over 40 minutes
2879193|NCT03395314|Active Comparator|low dose ketamine|ketamine IV; 0.5 mg/kg over 40 minutes
2879194|NCT03395301|Experimental|tubal occlusion|Fiber coils were inserted into the interstitial part of fallopian tubes, and IVF-ET was taken out in the following.
2879195|NCT03395288|Experimental|RCT treatment arm|Participants in this arm will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days.
2879196|NCT03395288|No Intervention|RCT control arm|Participants in this arm will not use any additional intervention.
2879197|NCT03395288|Experimental|Observational arm|Participants in this arm will either take a total of 1000 mg D-mannose in capsule form every 12 hours OR they will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days. Participants in this arm of the study have different home medications prior to study enrollment than participants in the RCT treatment arm.
2879199|NCT03395262|Experimental|Active with caffeine|Novel formula with caffeine
2879202|NCT03395249|Experimental|SPR994, FI, F2, F3, F4 Oral Tablets|"SPR994 is active against multidrug-resistant Gram-negative and Gram-positive pathogens that cause serious and life-threatening infections, including extended spectrum beta-lactamase (ESBL) producers as well as strains resistant to levofloxacin and trimethoprim/sulfamethoxazole. SPR994 is administered in tablet form orally. Up to five different time released formulations of SPR994 will be studied in this protocol at 100 mg, 300 mg, 600 mg and 900 mg dosages.~SAD Cohorts: One dose (two for food effect cohort) MAD Cohorts: Twenty-seven (27) doses administered twice daily (BID) over a period of 14 days or forty doses administered three times daily (TID) over period of 14 days"
2879203|NCT03395249|Placebo Comparator|Placebo Oral Tablet|"Placebo tablets (100, 300, and 600 mg) are pressed from a single placebo blend consisting of the same inactive ingredients; the active pharmaceutical ingredient (API) is replaced by Mannitol 200SD.~SAD Cohorts: One dose (two for food effect cohort) MAD Cohorts: Twenty-seven (27) doses administered BID over a period of 14 days or forty doses administered TID over a period of 14 days"
2879204|NCT03395249|Other|Optional Orapenem Open-Label Control|"A single, optional, open-label, control cohort that may enroll, in which all 8 subjects receive Orapenem.~SAD Cohort: One dose under fasted conditions and one dose under fed conditions."
2879205|NCT03395236|Experimental|Treatment|StellarexTM 0.014 OTW Drug-coated Angioplasty Balloon (Stellarex Balloon)
2879206|NCT03395223|Experimental|ProvayBlue (Methylene Blue) arm|"Methylene Blue 0.5% will be administered.~1 mg/kg will be administered intravenously over 5-30 minutes. If methemoglobin level remains above 30% or if clinical symptoms persist, give a repeat dose of up to 1 mg/kg one hour after the first dose."
2879207|NCT03395210|Experimental|PRN1008 Daily|Up to 12 weeks open-label treatment with PRN1008 daily, dose ranging from 200mg QD to 400mg BID; safety and dose evaluation, up-titration every 4 weeks
2879208|NCT03395197|Experimental|Combination arm|Talazoparib plus enzalutamide
2879209|NCT03395197|Active Comparator|Monotherapy arm|Ezalutamide plus placebo
2879210|NCT03395184|Experimental|PF-06700841 or placebo|
2879211|NCT03395184|Experimental|PF-06651600 or placebo|
2879212|NCT03395171|Experimental|Treatment: Cholecalciferol (Vitamin D3)|Athletes with Vitamin D levels lower than 30ng/mL will be treated with the supplement for eight weeks.
2879213|NCT03395171|No Intervention|Prospective Control Group|Athletes with Vitamin D levels higher than 30ng/mL were enrolled and compared but not treated.
2879214|NCT03395158||Prior alert criteria|Patients who activated full, limited or no alert criteria according to the prior alert criteria
2879215|NCT03395158||Present alert criteria|Patients who activated full, limited or no alert criteria according to the present alert criteria
2879216|NCT03395145|Experimental|Bio-Oss Collagen and Mucograft Seal|Bone volume Changes after socket preservation using Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal
2879217|NCT03395145|No Intervention|Natural healing|Evaluation of Bone volume Changes after tooth extraction (natural healing)
2879218|NCT03395132|Experimental|Fucicort® Lipid cream|Fucicort® Lipid cream is a combination of the antibiotic fusidic acid (20 mg/g) and the corticosteroid betamethasone (1 mg/g (as 17-valerate)). Twice daily for two weeks.
2879219|NCT03395132|Active Comparator|Fucidin cream +betamethasone cream|The combination treatment with Fucidin® cream followed by betamethasone (Lianbang Beisong®) cream. Twice daily for two weeks.
2879220|NCT03395132|Placebo Comparator|Vehicle cream|The vehicle cream, also named as Fucicort® Lipid cream vehicle, is the identical cream of Fucicort Lipid cream but without the active ingredient. Twice daily for two weeks.
2879221|NCT03395119|Sham Comparator|No Supplements|The control group includes 20 healthy volunteers who will receive no supplements in the study. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
2879222|NCT03395119|Experimental|Fish oil|Twenty healthy young adults will receive fish oil supplements for 4 weeks. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
2879223|NCT03395119|Experimental|Olive oil|Twenty healthy young adults will receive olive oil supplements for 4 weeks. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
2879224|NCT03395106|Experimental|Parent source + intuitive story content|
2879225|NCT03395106|Experimental|Doctor source + intuitive story content|
2879226|NCT03395106|Experimental|Parent source + deliberative content|
2879227|NCT03395106|Experimental|Doctor source + deliberative content|
2879228|NCT03395093|Experimental|FB with fentanyl|In the Bispectral Index monitoring,our study will use midazolam, propofol and fentanyl in the conscious sedation of FB
2879229|NCT03395093|Active Comparator|FB without fentanyl|In the Bispectral Index monitoring, our study will use midazolam, propofol in the conscious sedation of FB
2879230|NCT03395080|Experimental|Group 1|DKN-01 monotherapy in recurrent EEC
2879231|NCT03395080|Experimental|Group 2|DKN-01+paclitaxel in recurrent EEC
2879232|NCT03395080|Experimental|Group 3|DKN-01 monotherapy in recurrent EOC
2879233|NCT03395080|Experimental|Group 4|DKN-01+paclitaxel in recurrent EOC
2879234|NCT03395067|Active Comparator|Lifestyle counseling|
2879235|NCT03395067|No Intervention|Control group|
2879236|NCT03395054|Other|the stabilization group|the stabilization group performed cervical stabilization exercises in lying, sitting, standing and on a swisball 3times a week during 8 weeks.
2879237|NCT03395054|Other|the control group|the control group performed conventional exercises including neck isometric, isotonic and posture exercises 3 times a week during 8 weeks.
2879238|NCT03395041||ATD - SG 01|"Patients with acute coronary syndrome in whom dental examination performed in the first 7 days after the index event revealed the presence of periodontal disease.~They will undergo complex cardiac imaging tests to assess plaque vulnerability and severity of coronary artery disease."
2879239|NCT03395041||ATD - SG 02|"Patients with acute coronary syndrome in whom dental examination performed in the first 7 days after the index event did not reveal the presence of periodontal disease.~They will undergo complex cardiac imaging tests to assess plaque vulnerability and severity of coronary artery disease."
2879240|NCT03395015||Full-face 3-D images|3-D images acquisition of CLP patients' faces at rest is set at different timepoints: 1 week preoperative, 1- and 6-months postoperative. Therefore, laypeople's assessment of the facial appearance of CLP patients is based on full facial views.
2879241|NCT03395015||Nasolabial 3-D images|The control group is composed of cropped 3-D images of CLP patients' faces at rest, which show isolated nasolabial regions of CLP patients. The judgement of these pictures warrants an assessment based solely on the nasolabial appearance.
2879242|NCT03395002|Experimental|Tiotropium/Salmeterol/Fluticasone|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Discair®
2879243|NCT03395002|Active Comparator|Tiotropium + Salmeterol/Fluticasone|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler® + Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus®
2879244|NCT03394989|Experimental|Test|Fluticasone propionate/salmeterol 100/50 µg
2879245|NCT03394989|Active Comparator|Comparator|Fluticasone propionate/salmeterol 100/50 µg
2879246|NCT03394989|Other|Placebo|Test Placebo
2879247|NCT03394976||Study population|Participants will be enrolled passively at health centres. Passive enrolment will include patients referred to or presenting directly at the health facilities.
2879248|NCT03394950|Experimental|Butyphthalide combined with rtPA|Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
2879249|NCT03394950|Active Comparator|rtPA|only received thrombolysis with r-tpa (0.9mg/kg), followed by other treatments according to guidelines.
2879250|NCT03394937|Experimental|Low dose ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 5 doses of low dose ECI-006
2879251|NCT03394937|Experimental|High dose ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 5 doses of high dose ECI-006
2879252|NCT03394924|Experimental|EDP-305 Dose 1|Subjects will take 2 tablets once a day orally for 12 weeks
2879253|NCT03394924|Experimental|EDP-305 Dose 2|Subjects will take 2 tablets once a day orally for 12 weeks
2879254|NCT03394924|Placebo Comparator|Placebo|Subjects will take two tablets once a day orally for 12 weeks
2879255|NCT03394911|Experimental|Experimental Group|250mg p.o. of healthy adult male facial skin surface lipid liquid pheromone on fresh, new, just-purchased, un-chewed Wrigley's Rain #5 sugarless chewing gum vehicle. 15 pieces or divided as tolerated.
2879256|NCT03394911|Placebo Comparator|Placebo Group|Placebo identical to Experimental dose with randomly assigned identification numbers on unopened, unsealed key. Placebo and Experimental doses kept together and undifferentiable without the key being opened. Key available for opening 24/7 w/pharmaceuticals tech onsite. Keep pheromone/placebo doses under a fume hood. Wear 3M Versaflo activated charcoal filter supplied air respirator or equivalent to access.
2879257|NCT03394885|Experimental|Atezolizumab with Carboplatin and Paclitaxel|"Atezolizumab administered over 90 (± 15) minutes (for the first infusion, shortening to 60 (± 15) minutes and 30 ± 15) minutes for subsequent infusions as described below) followed by~Paclitaxel 70-80mg/m2 IV administered over approximately one hour followed by~Carboplatin IV administered over 15-30 minutes to achieve an initial target AUC of 5-6 mg/mL/Min (Calvert formula dosing)."
2879258|NCT03394872||Drainage group|Patients under mechanical ventilator support due to acute respiratory failure who had significant pleural effusion and drainage plan according to the intensive Care Unit (ICU) protocols decided by primary physician
2879259|NCT03394846|Experimental|Pilot Test of MI Prototype|We will pilot test a Movement Integration product prototype with 60 elementary classroom teachers.
2879260|NCT03394833|Experimental|Preoperative fluids|40 individuals receiving preoperative colloid fluid bolus at 6 ml/kg LBW, (Gelofusine™, Fresenius Kabi AB, Sweden) before anesthesia induction by TCI (n = 20) or RSI (n =20).
2879261|NCT03394833|No Intervention|No preoperative fluids|40 individuals anesthetized by TCI (n = 20) or RSI (n =20) without preoperative fluids.
2879262|NCT03394820|Active Comparator|dexamethasone 1 hour prior to block|The patient will receive dexamethasone through IV one hour prior to receiving their block. During the patient's block, 1 hour after and 2 hours after the block the patient will receive infusions of normal saline to maintain the blind.
2879263|NCT03394820|Experimental|dexamethasone during the block|The patient will receive dexamethasone through IV at the same time the patient has the SCB done. One hour prior to the block, one hour after the block and 2 hours after the block the patient will receive infusions of normal saline to maintain the blind.
2879264|NCT03394820|Active Comparator|dexamethasone 1 hour after block|The patient will receive dexamethasone through IV one hour after the block has been administered. One hour prior to block, during the block and two hours after the block the patient will receive normal saline to maintain the blind.
2879265|NCT03394820|Active Comparator|dexamethasone 2 hours after block|The patient will receive dexamethasone 2 hours after the block has been administered. One hour prior to the block, during the block and one hour after the block the patient will receive normal saline to maintain the blind.
2879266|NCT03394807|Experimental|LaGRA|regional anaesthesia of the right upper quadrant by injection of levobupivacaine 0.25% to the transversus abdominis plane and the rectus sheath under laparoscopic guidance immediately following specimen removal
2879267|NCT03394807|Placebo Comparator|Placebo|Sham regional anaesthesia of the right upper quadrant by injection of Saline 0.9% to the transversus abdominis plane and the rectus sheath under laparoscopic guidance immediately following specimen removal
2879268|NCT03394794|Active Comparator|Kegel exercises|Pelvic floor exercises designed in the 1950s' by Arnold Kegel.
2879269|NCT03394794|Experimental|biofeedback|Biofeeback therapy to improve neuromuscular coordination and strengthen sphincter contractility.
2879270|NCT03394794|Experimental|electrostimulation|Administration of electric current with a specific device (stimulator) and through a vaginal prove, in order to improve pelvic floor contractility.
2879271|NCT03394794|Experimental|transcutaneous neuromodulation|Stimulation of tibial nerve with a specific electric current through a stimulator and surface electrodes
2879272|NCT03394781|Experimental|DUR-928 10 mg|10 mg oral suspension
2879273|NCT03394781|Experimental|DUR-928 50 mg|50 mg oral suspension
2879310|NCT03394508|Experimental|Active treatment|Intervention: Drug ALK Alutard birch or 5-grasses Grass pollen suspension or birch pollen suspension
2879354|NCT03394131|Experimental|Hyalase|injection and hydro-dissection of median nerve using hyaluronidase followed by 10 cc normal saline ultrasonic guided
2879274|NCT03394768||NICOM Cheetah®|Patients will be treated as per department protocols and no additional intervention will be performed. Each patient will have an arterial catheter inserted as per our usual practice. All patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The NICOM CO monitor involves the application of non-invasive sensor strips. In this study, it will be applied to patients receiving the FloTrac (standard of care), on top of the standard care of monitoring with Flotrac.
2879275|NCT03394768||FloTrac®|Same patient population as the NICOM Cheetah® group as described above as all patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The FloTrac CO monitor is the current standard of care for cardiac output monitoring in the SICU of CGH. All patients deemed to require cardiac output monitoring will receive the FloTrac (as per departmental practice).
2879276|NCT03394755|Experimental|Thrombosomes|
2879277|NCT03394742|Experimental|Intervention group|Peer support group received, in addition to usual care, peer support via telephone 1-5 times according to their own preference. Peer support was started at the time between diagnosis and the beginning of treatments.
2879278|NCT03394742|No Intervention|Control group|The control group received usual care only. For ethical reasons, participants in the control group were not discouraged from seeking peer support by themselves if they felt a need for it.
2879279|NCT03394729|Experimental|Propolis tablet to limit dental biofilm|Individuals will be instructed to consume the tablet with propolis and xilytol to control dental biofilm, twice a day (at 10am and 5pm) for 7 days, giving a 30 day interval between the test and the control tablet.
2879280|NCT03394729|Active Comparator|Xilytol tablet to limit dental biofilm|Individuals will be instructed to consume the tablet with xilytol to control dental biofilm, twice a day (at 10am and 5pm) for 7 days, giving a 30 day interval between the test and the control tablet.
2879281|NCT03394716||Patient brain tumor treated with fractionated radiotherapy|
2879282|NCT03394690|Active Comparator|green coffe|green coffe 2 capsuls of green coffe
2879283|NCT03394690|Placebo Comparator|control|2 capsuls of placebo
2879284|NCT03394677|Experimental|RVT-501 0.5% ointment|Subjects will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.
2879285|NCT03394677|Placebo Comparator|RVT-501 vehicle ointment|Subjects will receive RVT-501 vehicle ointment twice daily (BID) for 4 weeks.
2879286|NCT03394664|Experimental|Very-Low Carbohydrate Diet|Feeding study. Dietary composition (approximately): 75% fat
2879287|NCT03394664|Experimental|High-Carbohydrate Low-Sugar Diet|Feeding study. Dietary composition (approximately): 25% fat 0% added sugars.
2879288|NCT03394664|Experimental|High-Carbohydrate High-Sugar Diet|Feeding study. Dietary composition (approximately): 25% fat, 20% added sugars.
2879289|NCT03394651||Oral medication group|Patients in this group will receive oral medications to treat lower urinary tract symptoms
2879290|NCT03394651||Surgical treatment group|Patients in this group receive minimal invasive transurethral prostate procedures.
2879291|NCT03394638|Active Comparator|Conventional group|"Treatment includes:~10 individual and 3 group consultations at the outpatient department by several disciplines in the first postoperative year.~Additional visits if necessary~No further access to the BePATIENT website"
2879292|NCT03394638|Experimental|Online group|"Treatment includes:~Added to conventional group: Continuation of access to the BePATIENT website with:~eLearning programs~Informative videos~Patient network~Video consulting"
2879293|NCT03394638|Experimental|Device group|"Added to Online group:Four wireless devices, which are~Weight Scale~Blood Pressure~Oximeter~Activity Tracker"
2879294|NCT03394625|Experimental|immediate implant placement using socket shield technique|Socket shield technique is a recent technique which is by sectioning the root and extraction of palatal part and leaving buccal part of the root with its attachment of periodontal ligament and vascularization still intact then placing implant in palatal socket.
2879295|NCT03394625|Active Comparator|immediate implant placement using xenograft material|placing xenograft material in gap between implant and buccal bone
2879296|NCT03394612|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
2879297|NCT03394599|Active Comparator|TheraTrainer Only|The 30 clients (15 per site) will have the opportunity to engage in cycling on the TheraTrainer only for the duration of their participation at the Geriatric program. Their carers will also be recruited.
2879298|NCT03394599|Experimental|TheraTrainer + Motiview|The 30 clients (15 per site) will have the opportunity to engage in cycling on the TheraTrainer with the addition of Motiview (engaging videos to watching while cycling). Their carers will also be recruited.
2879299|NCT03394586||UC patients with golimumab|We will retrospectively analyze all ulcerative colitis patients from the Swiss IBD cohort study treated with golimumab.
2879300|NCT03394573|Active Comparator|OCT guided treatment arm|OCT guided
2879301|NCT03394573|Active Comparator|VA guided treatment arm|VA guided
2879302|NCT03394560|Experimental|high-frequency rTMS + BWSTT|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with the combination between body weight-support treadmill training combined and high-frequency rTMS in improving the sensory-motor function of adult patients with chronic incomplete thoracolumbar spinal cord injury. The sessions will be performed three times a week for a month.
2879303|NCT03394560|Sham Comparator|sham rTMS + BWSTT|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with the combination between body weight-support treadmill training combined and high-frequency rTMS in improving the sensory-motor function of adult patients with chronic incomplete thoracolumbar spinal cord injury. The sessions will be performed three times a week for a month.
2879304|NCT03394547|Active Comparator|Active Treatment|Treatment for 2 menstrual cycles using the pulsed shortwave therapy Allay® device (BioElectronics Corp, Frederick USA)
2879305|NCT03394547|Placebo Comparator|Placebo|Treatment for 2 menstrual cycles using a placebo device which is identical in appearance to the active device but does not emit any pulsed shortwave therapy.
2879306|NCT03394547|No Intervention|No treatment|No intervention is given and a menstrual diary is completed for 2 cycles.
2879307|NCT03394534|Experimental|CGA group|
2879308|NCT03394534|No Intervention|Treatment as Usual|
2879311|NCT03394495|Experimental|BCE Combination group|"16-week BCE programme with exercise training.~Six 1-hour sessions of BCE programme and a weekly 45-60 minute centre-based exercise programme from week 4 to week 16."
2879312|NCT03394495|No Intervention|Exercise group|"16-week programme with health talks and exercise training.~Six 1-hour sessions of health talks and a weekly 45-60 minutes centre-based exercise programme from week 4 to week 16."
2879313|NCT03394495|No Intervention|Control group|Six sessions of centre-based health talks on the management of different health issues with the exception of fatigue.
2879314|NCT03394482|Experimental|Lu AF35700 5 mg clinical formulation|
2879315|NCT03394482|Experimental|Lu AF35700 5 mg commercial formulation|
2879316|NCT03394482|Experimental|Lu AF35700 10 mg clinical formulation|
2879317|NCT03394482|Experimental|Lu AF35700 10 mg commercial formulation|
2879318|NCT03394482|Experimental|Lu AF35700 20 mg clinical formulation|
2879319|NCT03394482|Experimental|Lu AF35700 20 mg commercial formulation|
2879320|NCT03394469|Other|cohort|Collection of clinical and paraclinical data (biological and anthropometric) for evaluation of sarcopenic obesity in obese patients.
2879321|NCT03394456|Experimental|Intervention|Receive diabetes group visits
2879322|NCT03394456|No Intervention|Control|Receive usual care in the clinic, followed by group visits (wait list control)
2879323|NCT03394430|Placebo Comparator|Group A|
2879324|NCT03394430|Experimental|Group B|
2879325|NCT03394430|Experimental|Group C|
2879326|NCT03394417|No Intervention|standard clinical practice (control)|aqueous cream
2879327|NCT03394417|Active Comparator|StrataXRT (intervention)|silicon-based gel
2879328|NCT03394404|Experimental|ECG-I mapping and PVI|ECG-I mapping and PVI
2879329|NCT03394391|Experimental|Intervention group|Daily ART-adherence SMS reminder
2879330|NCT03394391|Active Comparator|Control group|Standard adherence counselling/Patient experience group chat
2879331|NCT03394365|Experimental|tabelecleucel|Tabelecleucel will be administered in cycles lasting 5 weeks (35 days). During each cycle, subjects will receive intravenous (IV) tabelecleucel at a dose of 2×10^6 cells/kg on Days 1, 8, and 15, followed by observation through Day 35.
2879332|NCT03394352|Experimental|Activity on Board|Blinded CGM data will be collected prior to the Experimental Admission to determine the insulin bolus that will be determined by the activity on board calculator. Subjects will wear a continuous glucose monitor during the study admission.
2879333|NCT03394352|Placebo Comparator|Usual Diabetes Care|Subjects will use their usual diabetes care, including basal rate, correction factor and carbohydrate-insulin ratio. Subjects will determine their own insulin usage during the Control Admission. Subjects will wear a continuous glucose monitor during the study admission.
2879334|NCT03394326|Experimental|LOW-ED|In the LOW-ED condition each participant will consume at least 10 low-ED foods/day (ED ≤1.0 kcal/g) and no more than 2 high ED foods/day (ED ≥3.0 kcal/g). Foods with an ED >1.0 kcal/g and <3.0 kcal/g will be unlimited; however, lowering the overall ED of the diet will be encouraged.
2879335|NCT03394326|Active Comparator|STANDARD|In the STANDARD condition participants will consume the recommendations for calories, fruits, vegetables and whole grains based on age and sex corresponding with MyPlate. The daily caloric recommendations from MyPlate are for weight maintenance.
2879336|NCT03394287|Experimental|SHR-1210 +Apatinib daily dosing|SHR-1210 200mg(3mg/kg for patient whose weight is below 50kg) iv Q2W combination With Apatinib 250mg, po, daily dosing (d1-d14)
2879337|NCT03394287|Experimental|SHR-1210+Apatinib intermittent dosing|SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) iv Q2W combination With Apatinib 250mg, po, intermittent dosing(Continuous administration for 7 days every 14 days, d1-d7)
2879338|NCT03394274||Transfusion|Patients (n:892) were enrolled who underwent elective major surgery between the 01/01/2016-31/12/2016, and over the age of 18 years. They separated subgroups as restrictive and liberal blood transfusion groups
2879339|NCT03394261|Experimental|Patient Decision Aid|Patients in this arm will receive Patient Decision Aid for Medication Assisted Treatment for opioid use disorder.
2879340|NCT03394261|No Intervention|Record-only control group|Treatment records of patients receiving treatment in the same clinic in the prior 3 months will be abstracted for comparison purposes.
2879341|NCT03394235|Experimental|Long-pulsed, 1064nm Nd-YAG laser|All participants will receive long-pulsed, 1064nm Nd-YAG laser treatments with three different parameters at the occipital area.
2879342|NCT03394222|Experimental|Budesonide inhalation group|This group of participants were to receive 2mg/4ml of preoperative budesonide inhalation (Khartoum Road NORTH RYDE NSW 2113 Australia. AstraZeneca Pty Ltd) for 10 to 15min.
2879343|NCT03394222|Placebo Comparator|Normal saline inhalation group|This group of participants were to receive4ml of preoperative normal saline inhalation for 10 to 15min.
2879344|NCT03394209|Experimental|Favipiravir+oseltamivir|Favipiravir+oseltamivir will be given twice daily for a 10-day period.
2879345|NCT03394196|Experimental|No HIV-2 resistance|
2879346|NCT03394196|Experimental|HIV-2 NRTI resistance only|
2879347|NCT03394196|Experimental|HIV-2 NRTI and PI resistance|
2879348|NCT03394183|Experimental|Peripheral Artery Disease Participants|Patients diagnosed with peripheral artery disease will undergo a 6 month cardiac rehabilitation program that is standard of care at the Toronto Rehabilitation Institute Rumsey Centre.
2879349|NCT03394183|Active Comparator|Coronary Artery Disease Participants|Patients diagnosed with coronary artery disease will undergo a 6 month cardiac rehabilitation program that is standard of care at the Toronto Rehabilitation Institute Rumsey Centre. The responses to cardiac rehabilitation for participants with coronary artery disease will be compared to participants with peripheral artery disease.
2879350|NCT03394170||Osteoarthritis|Participants who are undergoing unicompartmental knee replacement will be considered OA status
2879351|NCT03394170||Non-Osteoarthritis|"Participants with an acute injury (occurring no more than 90 days prior to surgery) with no history of knee injury or surgery, will be considered Non-OA status"
2879352|NCT03394157|Other|Diabetes Mellitus Type 2 in Obese patients|obese patients had metabolic surgery for the treatment for DMT2 .Preoperative data , which including SASI bypass , MGB and Sleeve gastrectomy
2879353|NCT03394144|Experimental|C1:AZD9150, C2:AZD9150+Durvalumab|After confirmed safety with Cohort 1, Cohort 2 will open
2879355|NCT03394131|Placebo Comparator|Placebo|injection and hydro-dissection of median nerve hydro-dissection using 10 cc saline injection ultrasonic guided
2879356|NCT03394131|Active Comparator|Insilin|injection and hydro-dissection of median nerve hydro-dissection using 10 IU insuline followed by 10 cc normal saline ultrasonic guided
2879357|NCT03394118|Experimental|Group_TAGRISSO|Each subject will continue the study drug(Osimertinib) until disease progression or manifestation of unacceptable toxicity during the study period. The study drug will be administered orally as one 80 mg tablet once a day. The initial dose of the study drug 80 mg daily can be reduced to 40 mg once daily.
2879358|NCT03394105|Experimental|intrapleural docetaxel administration|Docetaxel will be administed to interpleural space using medical pleuroscopy in malignant effusion with lung cancer.
2879359|NCT03394092||STEMI|The study population consists of 50 patients with ST-elevated acute myocardial infarction (STEMI) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded. Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
2879360|NCT03394092||Control|50 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as control group.Quantitative changes of IgG glycosylation be measured only once on admission.
2879361|NCT03394079|Experimental|OCT-guided|
2879362|NCT03394079|Active Comparator|IVUS-guided|
2879363|NCT03394066|Active Comparator|TMS|All participants will receive TMS
2879364|NCT03394053||1|People ages 0 75 with a PID
2879365|NCT03394053||2|Healthy biological relatives the same ages
2879366|NCT03394053||3|Healthy volunteers ages 18 75
2879367|NCT03394040||1|People already enrolled in an active NIH protocol who have diarrhea
2879368|NCT03394027|Experimental|Arm 1|Single arm divided in three cohorts, each cohort with a different type of metastatic disease: ER + breast cancer, triple negative breast cancer, and endometrial cancer
2879369|NCT03394014|Active Comparator|popliteal sciatic nerve block|injecting 25 ml of bupivacaine 0.5 % (Sunnypivacaine, 20 ml vial contains Bupivacaine HCL Monohydrate 105.5 mg eq. to 100 mg Bupivacaine HCL, Sunny Pharmaceutical, Badr city- Cairo- Egypt) once circumferentially around the sciatic nerve at the popliteal fossa using ultrasound device (S-Nerve ultrasound system, Fujifilm Sonosite Inc., Bothell, WA)
2879370|NCT03394014|Active Comparator|subgluteal sciatic nerve block|injecting 25 ml of bupivacaine 0.5 % (Sunnypivacaine, 20 ml vial contains Bupivacaine HCL Monohydrate 105.5 mg eq. to 100 mg Bupivacaine HCL, Sunny Pharmaceutical, Badr city- Cairo- Egypt) circumferentially around the sciatic nerve at the subgluteal region using ultrasound device (S-Nerve ultrasound system, Fujifilm Sonosite Inc., Bothell, WA).
2879371|NCT03394001|Active Comparator|Lidocaine Hydrochloride|Wound infiltration with Lidocaine
2879372|NCT03394001|Active Comparator|Ketorolac tromethamine|Wound infiltration with Ketorolac
2879373|NCT03393988|Active Comparator|Group F|Fentanyl infusion (0.5 µg/kg/hr)
2879374|NCT03393988|Active Comparator|Group (TAP-Dex)|"Ultrasound guided TAP block and Dexmedetomidine~Ultrasound guided subcostal oblique TAP block with 0.25 % bupivacaine~Dexmedetomidine infusion(200 µg in 2 ml diluted in 48 ml of saline)~Fentanyl infusion (0.5 µg/kg/hr)."
2879375|NCT03393975|Experimental|Prophylaxis Cohort Arm 1|(1) Pharmacokinetic (PK) Assessments: PK 1 = Investigator-recommended Standard of Care (SoC) then PK 2 = BAX930. (2) Period 1 Prophylaxis (Prophy) = BAX930; Period 2 Prophy = SoC; Period 3 Prophy = BAX930. (4) PK3 = BAX930
2879376|NCT03393975|Experimental|Prophylaxis Cohort Arm 2|(1) Pharmacokinetic (PK) Assessments: PK 1 = BAX930 then PK 2 = Investigator-recommended Standard of Care (SoC). (2) Period 1 Prophylaxis (Prophy) = SoC; Period 2 Prophy = BAX930; Period 3 Prophy = BAX930. (4) PK3 = BAX930
2879377|NCT03393975|Experimental|SoC On-Demand Cohort (Then prophylaxis) Arm 1|(1) On-Demand Cohort = Standard of Care (SoC). (2) Period 1 Prophylaxis (Prophy) = BAX930; Period 2 Prophy = SoC; Period 3 Prophy = BAX930. (3) Pharmacokinetic (PK) Assessment = BAX930
2879378|NCT03393975|Experimental|SoC On-Demand Cohort (Then prophylaxis) Arm 2|(1) On-Demand Cohort = BAX930. (2) Period 1 Prophylaxis (Prophy) = SoC; Period 2 Prophy = BAX930; Period 3 Prophy = BAX930. (3) Pharmacokinetic (PK) Assessment = BAX930
2879379|NCT03393962|Experimental|OC-EIEs|Autologous ovarian cancer antigen-specific cytotoxic lymphocytes
2879380|NCT03393949|Experimental|Group M|Patients in Group M received methylprednisolone 1mg•kg-1
2879381|NCT03393949|Experimental|Group C|Patients in Group C received methylprednisolone 0.5mg•kg-1
2879382|NCT03393936|Experimental|CCT301-59|The safety and efficacy of CCT301-59 will be evaluated for subjects with ROR2 positive biopsy in a standard 3+3 dose escalation approach. 3 CAR T dosage will be tested in this study: 1×10^5/kg, 1×10^6/kg, 1×10^7/kg CAR+ T cells.
2879383|NCT03393936|Experimental|CCT301-38|The safety and efficacy of CCT301-38 will be evaluated for subjects with AXL positive but ROR2 negative biopsy in a standard 3+3 dose escalation approach. 3 CAR T dosage will be tested in this study: 1×10^5/kg, 1×10^6/kg, 1×10^7/kg CAR+ T cells.
2879384|NCT03393923|No Intervention|Control Group|Patient will undergo gait analysis
2879385|NCT03393923|Experimental|Experimental group|Patient will undergo gait analysis with use of anterior wedge
2879386|NCT03393910|No Intervention|Observational|Normal pelvic exam exposures: External exam followed by speculum exam, followed by bimanual exam
2879387|NCT03393910|Active Comparator|Experimental Pelvic Exam|Changing the order of the pelvic exam Intervention: External exam, bimanual exam,speculum exam
2879388|NCT03393897||Hemodynamic instability with hypotension|
2879389|NCT03393884|Experimental|NACT + GEN-1|The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles. GEN-1 100 mg/m2 IP will be administered on Days 8 and 15 of the first NACT cycle and then on Days 1, 8, and 15 of the subsequent 21 day NACT cycles for a total of 17 treatments.
2879390|NCT03393884|Active Comparator|NACT Alone|The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles.
2879391|NCT03393858|Experimental|Immunotherapy plus Hyperthermia|
2879392|NCT03393845|Experimental|Pembrolizumab + Fulvestrant|Pembrolizumab 200m IV q3W + Fulvestrant. Loading dose 500mg IV IM q2W x3 followed by 500mg IM q4W
2879393|NCT03393832|Placebo Comparator|Oral Care with Sterile Water|The Placebo group will receive oral care with sterile water.
2879394|NCT03393832|Experimental|Oral Care with all Breast Milk|The Experimental group will receive oral care with all breast milk. Mother's milk will be used first. When mother's milk is not available, pasteurized donor breast milk will be used.
2879395|NCT03393819|Experimental|Duraprep Surgical Solution|Surgical site (hip) is prepared with Duraprep (iodine-alcohol) prior to surgery according to package instructions.
2879396|NCT03393819|Experimental|Chloraprep Surgical Solution|Surgical site (hip) is prepared with Chloraprep (chlorhexidine-alcohol) prior to surgery according to package instructions.
2879397|NCT03393806|Experimental|Participants receiving GSK3772847|Participants will be randomized to receive GSK3772847 as IV infusion. Participants will receive three doses ( Day 1, Day 29 and Day 57) of GSK3772847 every 4 weeks
2879398|NCT03393806|Placebo Comparator|Participants receiving placebo|Participants will be randomized to receive matching placebo as IV infusion
2879399|NCT03393767|Other|prospective 1- Arm|OCT-guided high frequency intravitreal ranibizumab 0.5mg
2879400|NCT03393754|Experimental|Sci-B-Vac Hepatitis B Vaccination|Sci-B-Vac (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 10ug, IM injection at Days 0, 28, and 168.
2879401|NCT03393754|Active Comparator|Engerix-B Hepatitis B Vaccination|Engerix-B® (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 20ug, IM injection at Days 0, 28, and 168.
2879402|NCT03393741||Taxane (nab-paclitaxel or paclitaxel)|"Up to 10 participants will be enrolled on the Taxane arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
2879403|NCT03393741||Eribulin|"Up to 5 participants will be enrolled on the Eribulin arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
2879404|NCT03393741||Vinorelbine|"Up to 5 participants will be enrolled on the Vinorelbine arm. TThe dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
2879405|NCT03393741||Ixabepilone|"Up to 5 participants will be enrolled on the Ixabepilone arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
2879406|NCT03393741||Control Arm|"Up to 10 participants will be enrolled on the control arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
2879407|NCT03393728|Experimental|Intervention|72-hour propanolol before specific treatment of hyperthyroidism
2879408|NCT03393715|Experimental|Perindopril morning|10 mg of perindopril oral tablet once daily in the morning for 56 days
2879409|NCT03393715|Active Comparator|Perindopril evening|10 mg of perindopril oral tablet once daily in the evening for 56 days
2879410|NCT03393702|Experimental|Gabapentin|"Single dose preoperative gabapentin.~After surgery gabapentin 2 times per day for 3 days."
2879411|NCT03393702|Placebo Comparator|Placebo Control|"Single dose preoperative placebo control.~After surgery placebo 2 times per day for 3 days."
2879412|NCT03393689|Experimental|Angiogenesis PET/MR|One injection of the radioligand 68Ga-NODAGA-E[c(RGDyK)]2 followed by PET/MR
2879413|NCT03393676||chronic pain|preoperative pain duration > 1 months
2879414|NCT03393676||acute pain|preoperative pain duration < 1 months
2879415|NCT03393650|Active Comparator|Exercise + Placebo group|50 subjects will receive a placebo supplementation with an exercise intervention (EX group)
2879416|NCT03393650|Active Comparator|Exercise + Protein group|50 subjects will receive a protein supplementation combined with an exercise intervention (PROTEX group)
2879417|NCT03393637|Experimental|M-O-M-S Intervention|M-O-M-S intervention is 10, 1 hour prenatal mentored support groups
2879418|NCT03393637|No Intervention|Routine Prenatal Care|Routine prenatal care in accordance with the Department of Defense Pregnancy Guidelines
2879419|NCT03393624||Cases: patients with dark circles|Patients who believe they have periorbicular hyperchromia and have a confirmatory physical examination performed by a dermatologist.
2879420|NCT03393624||Controls: patients without dark circles|Patients who believe that they do not have periorbicular hyperchromia under their eyes and have physical examination that excludes dark circles carried out by a dermatologist.
2879421|NCT03393611|Experimental|CPX-351 Salvage Therapy and Transplant|Subjects will receive CPX-351 salvage chemotherapy on Day -21, -19, and -17 as a bridge to allogeneic stem cell transplantation using a Fludarabine/Melphalan/rATG conditioning regimen and a haplo-cord graft.
2879422|NCT03393598|Experimental|pre-expansion using Kiwi® VAC-6000M|Expansion will be performed using a complete vacuum delivery system called Kiwi® VAC-6000M with the PalmPumpTM (Clinical Innovations, South Murray, Utah, USA).
2879423|NCT03393598|Experimental|pre-heating using Hilotherm Calido®.|Pre-Heating will be preformed using a Hiloterm Calido® System.
2879424|NCT03393598|Experimental|pre-expansion-heating|Both preconditioning methods Hilotherm Calido® plus Kiwi® VAC-6000M- will be applied.
2879425|NCT03393598|No Intervention|Control|No preconditioning methods will be applied.
2879426|NCT03393572|Active Comparator|Group BM|bupivacaine 0.25% plus magnesium sulphate.
2879427|NCT03393572|Active Comparator|Group BN|bupivacaine 0.25% plus nalbuphine
2879428|NCT03393559|Experimental|Group L|leg elevation during the beach chair position
2879429|NCT03393559|No Intervention|Group C|Patients' leg will be straightened without any intervention.
2879430|NCT03393546|Experimental|Auricular Point Acupressure|Auricular Point Acupressure includes 4 weekly treatments (the tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day).
2879431|NCT03393546|Placebo Comparator|Education|Education Control will serve as the control group for any improvement over time, with education and interaction with study staff. Participants in the Education Control will be given three Alzheimer's Association publications (i.e., Basics of AD; Take Care of Yourself; and Behaviors) with one office visit, and then home visits weekly or four weeks (i.e., blood draws and questionnaires), which is the same schedule as those for APA Group.
2879432|NCT03393533|Other|Group I|Extraction third molar with pre and postoperative evaluation of edema, pain and trismus
2879433|NCT03393533|Active Comparator|Group II|Extraction third molar with therapeutic bandage pre and postoperative evaluation of edema, pain and trismus
2879434|NCT03393520|Placebo Comparator|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
2879435|NCT03393520|Experimental|AVP-786; Dose 1|Participants will receive AVP-786 (Dose 1) capsules administered twice a day over a 12-week period.
2879436|NCT03393520|Experimental|AVP-786; Dose 2|Participants will receive AVP-786 (Dose 2) capsules administered twice a day over a 12-week period.
2879437|NCT03393507|Experimental|apatinib combine with chemotherapy|
2879438|NCT03393507|Active Comparator|chemotherapy|
2879439|NCT03393494|Experimental|Perrigo active|Test product
2879440|NCT03393494|Active Comparator|Reference active|RLD product
2879441|NCT03393494|Placebo Comparator|Perrigo placebo|placebo product
2879442|NCT03393481|Experimental|MAA868 dose 1|MAA868 dose 1, single administration, subcutaneous
2879443|NCT03393481|Experimental|MAA868 dose 2|MAA868 dose 2, single administration, subcutaneous
2879444|NCT03393481|Active Comparator|Enoxaparin|Enoxaparin 40mg, once daily (o.d.) for 10 days
2879445|NCT03393468|Experimental|Sequence A: Dapivirine gel|Participants will receive 2.5 g of dapivirine gel administered rectally via an applicator, followed by a 2- to 4-week washout period. Participants will then receive a second dose of up to 10 g of dapivirine gel administered rectally via a coital simulation device.
2879446|NCT03393468|Experimental|Sequence B: Dapivirine gel|Participants will receive up to 10 g of dapivirine gel administered rectally via a coital simulation device, followed by a 2- to 4-week washout period. Participants will then receive a second dose of 2.5 g of dapivirine gel administered rectally via an applicator.
2879447|NCT03393442|Experimental|1. Gd-exposed subjects|Diagnostic Test: Brain MRI scan Female subjects at high risk for breast cancer that previously underwent more than 6 Gd-based contrast enhanced MRI exams of the breast.
2879448|NCT03393442|Active Comparator|2. Healthy subjects|Diagnostic Test: Brain MRI scan Age-matched female control subjects that never received Gd-based contrast agents.
2879449|NCT03393429|Active Comparator|DAVID assisted training|Group I: Training assisted by DAVID devices
2879450|NCT03393429|Placebo Comparator|training recommendation|"Group II: Training based on stay active recommendations"
2879451|NCT03393416|Experimental|MASCT-I or MASCT-I +PD1 antibody|"This study is divided into three stages:~The first, second stage is the stage of the dose climbing, and the third stage is the dose expansion stage. The first stage is MASCT-I, using 3+3 design. The second stage is divided into two groups: MASCT-I+PD1 antibody in low dose group and MASCT-I+PD1 antibody in high dose group, using 3+3 design. The third stage is the dose expansion stage , 10 patients in the low or high dose group were treated with the corresponding dose group."
2879452|NCT03393403|Experimental|Dexmedetomidine_iv group|Dexmedetomidine 0.5mcg/kg (diluted in normal saline) intravenously infusion for 30min
2879453|NCT03393403|Experimental|Dexmedetomidine_adj group|Dexmedetomidine 0.5mcg/kg (adding to local anesthetic) perineural single bolus for subcostal TAP block 0.9% sodium chloride 0.125ml/kg intravenously infusion for 30min
2879454|NCT03393403|Active Comparator|Control group|0.9% sodium chloride 0.125ml/kg intravenously infusion for 30min No dexmedetomidine use
2879455|NCT03393390||Healthy Controls|Subjects in this group will be defined as healthy controls after meeting with a clinician and determining that they do not meet the diagnostic criteria for any externalizing disorders or other psychiatric disorders.
2879456|NCT03393390||Externalizing|Subjects in this group will be defined as externalizing if the clinician determines that they meet the diagnostic criteria for one or more externalizing disorders, such as ADHD, ODD, or CD.
2879457|NCT03393377|Experimental|intervention group|received fluvastatin 10 mg and valsartan 20 mg (low-flu/val) for 30 days
2879459|NCT03393364|Experimental|Opioid arm|Patients receive opioid medication, oxycodone, after outpatient urologic surgery.
2879460|NCT03393364|Experimental|Non-opioid arm|Patients receive a non-opioid medication, ketorolac, after outpatient urologic surgery.
2879461|NCT03393351|Experimental|Shared decision-making program|
2879462|NCT03393351|Active Comparator|Usual care|
2879463|NCT03393338|Experimental|DM I-TEAM|DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months. During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs). In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
2879464|NCT03393338|No Intervention|Usual Medical Care|Usual medical care
2879465|NCT03393312|Experimental|Bifrontal tDCS|20 minutes of 2 mA transcranial direct current stimulation (tDCS), with the anode placed over the left dorsolateral prefrontal cortex and the cathode placed over the right dorsolateral prefrontal cortex (F3 and F4 according to the 10/20 international EEG system, respectively).
2879466|NCT03393312|Sham Comparator|Sham tDCS|Participants receive 20 minutes of sham tDCS, with the anode placed over the left dorsolateral prefrontal cortex and the cathode placed over the right dorsolateral prefrontal cortex (F3 and F4 according to the 10/20 international EEG system, respectively). In sham tDCS, stimulation starts with 8s fade in followed by 30s direct current followed by 5s fade out followed by 870s without any stimulation.
2879467|NCT03393299|Experimental|STOPP/START|Use of STOPP/START criteria during medication reconciliation
2879468|NCT03393299|No Intervention|CONTROL|Medication reconciliation done as usual, without the consideration of the STOPP/START criteria
2879469|NCT03393273|Experimental|Elotuzumab|This is a single arm phase II trial to assess the Very Good Partial Response rate of a strategy involving autologous hematopoietic stem cell transplantation, after intensive treatment and followed by consolidation phase, with elotuzumab, dexamethasone, velcade, and thalidomide in elderly patients.
2879470|NCT03393247|Active Comparator|infliximab and azathioprine at week 0|infliximab and azathioprine combination at week 0
2879471|NCT03393247|Active Comparator|infliximab and azathioprine at week 14|infliximab and azathioprine combination at week 14
2879472|NCT03393234|Experimental|A group|Patients who receive interphincteric resection (ISR) in this group will be given extra intraoperative radiation by INTRBEAM using low energy X-ray.
2879473|NCT03393234|No Intervention|B group|Patients who only receive interphincteric resection (ISR) in this group without intraoperative radiation.
2879474|NCT03393221|Experimental|SBWC+ER|Participants randomized to the Standard Behavioral Weight Control and Emotional Regulation (SBWC+ER) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16. They receive the same information as the Standard Behavioral Weight Control group, but weekly sessions also include elements of TRAC, and it is designed to help teach emotion regulation skills to decrease overeating and sedentary behaviors and increase the likelihood of maintaining diet and exercise behaviors that are taught as part of SBWC interventions.
2879475|NCT03393221|Active Comparator|SBWC|Participants randomized to the Standard Behavioral Weight Control (SBWC) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16. The intervention includes a dietary plan, a fitness plan, behavioral weight control management that includes self-monitoring, goal-setting, stimulus control strategies, and planning, as well as parental involvement.
2879476|NCT03393208|Experimental|First Test GIR (Fasting), Then Reference GIR (Fasting)|Test GIR in fasting state in Treatment Period 1 followed by reference GIR in fasting state in Treatment Period 2.
2879477|NCT03393208|Experimental|First Reference GIR (Fasting), Then Test GIR (Fasting)|Reference GIR in fasting state in Treatment Period 1 followed by test GIR in fasting state in Treatment Period 2.
2879478|NCT03393208|Experimental|First Test GIR (Fed), Then Reference GIR (Fed)|Test GIR in fed state in Treatment Period 1 followed by reference GIR in fed state in Treatment Period 2.
2879479|NCT03393208|Experimental|First Reference GIR (Fed), Then Test GIR (Fed)|Reference GIR in fed state in Treatment Period 1 followed by test GIR in fed state in Treatment Period 2.
2879480|NCT03393195|Experimental|Time-restricted eating plan|Participants in this group will be instructed to fast every day from 8pm until 12pm the following day. From 12pm until 8pm, participants can eat and drink whatever they want. During fasting hours, participants can drink water and black coffee.
2879481|NCT03393195|Active Comparator|Consistent Meal Timing Plan|Participants in this group will be instructed to eat three daily meals during specified eating times. Their first meal will be between 7am-11am. Second meal between 11am and 3pm, and third meal between 4pm-10pm. Participants will be encouraged to eat small snacks if needed so that they can eat their next meal during the specified window.
2879482|NCT03393182|Experimental|TLDG arm|"TLDG arm(Totally laparoscopic distal gastrectomy)~: After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy."
2879483|NCT03393182|Experimental|LADG arm|"LADG arm(Laparoscopy-assisted distal gastrectomy)~: After lymphadenectomy, gastrectomy and reconstruction procedure are performed through mini-laparotomy"
2879484|NCT03393156|Experimental|Internet-based metracognitive therapy|"The internet-based metacognitive therapy group receives a ten-week long treatment, which is based on the book Metacognitive therapy for depression and anxiety by Adrian Wells (2011)."
2879485|NCT03393156|No Intervention|Wait-list|When the active treatment groups have finished treatment (W11), the WL group will be able to start active treatment and be assessed at post-treatment, 6 and 12 months later using the same questionnaires as the treatment group.
2879486|NCT03393143||Oregon patients|Patients with back pain who get their care in community health clinics in Oregon
2879487|NCT03393143||California patients|Patients with back pain who get their care in community health clinics in California
2879488|NCT03393130||Participants possessing APOE-ε4|Young adults who have suffered a severe burn injury necessitating intensive care admission 5 to 10 years previously, who possess at least one copy of the APOE-ε4 allele.
2879623|NCT03392220|Experimental|undergo bilateral neck dissection (II-IV)|patient undergo bilateral neck dissection, along with the excision of the laryngeal primary tumor
2879489|NCT03393130||Participants not possessing APOE-ε4|Young adults who have suffered a severe burn injury necessitating intensive care admission 5 to 10 years previously, who do not possess a copy of the APOE-ε4 allele.
2879490|NCT03393117|Experimental|Liposomal Bupivacaine + Bupivacaine|This group will receive a long-acting pain medicine, Liposomal Bupivacaine, injected into the breast muscles during surgery. All patients will receive patient-controlled analgesia pump and oral narcotics as indicated post surgery.
2879491|NCT03393117|Active Comparator|Bupivacaine|This group will receive the same pain medication, Bupivacaine, but in the standard formulation, injected into the breast muscles during surgery. All patients will receive patient-controlled analgesia pump and oral narcotics as indicated post surgery.
2879492|NCT03393104|Experimental|Motor Control Exercise and Patient Education|"Participants will receive a total of 16 sessions (2 sessions per week) of motor control exercise and 4 sessions (1 session per week) of patient education program as described in respective protocol.~In addition, they will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
2879493|NCT03393104|Experimental|Motor Control Exercise|"Participants will receive a total of 16 sessions (2 sessions per week) of motor control exercise aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~They will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
2879494|NCT03393104|Experimental|Patient Education|"Participants will receive patient education session once a week at interval of 1-week over 8-weeks (4 sessions). The program will be aiming to provide non-threatening information to enable patients to better understand their pain, change any unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.~They will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
2879495|NCT03393104|Active Comparator|Control|Segmental stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP. In addition, participants will be instructed to perform aerobics in the form of continuous overground walk at desirable speed at home for the minimum of 30 minutes per day or 5 times per week.
2879496|NCT03393091||Incidence of possible anaphylaxis|Data will be collected on 1000 consecutive general anaesthetic procedures in Assiut University Hospitals. After each elective operating list the anaesthetist will be asked to complete a form in which they will document the number of patients receiving general anaesthesia on the list and the number of those patients who developed any of the following features: unexpected, unexplained hypotension; unexpected bronchospasm resistant to treatment; angioedema; urticaria; severe itching; widespread erythema
2879497|NCT03393078|Active Comparator|Real Stimulation|The repetition transcranial magnetic stimulation(rTMS) lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 110% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
2879498|NCT03393078|Sham Comparator|Sham Stimulation|The procedure of this protocol was performed by a placebo coil, lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 110% of the rest motor threshold (RMT). No actual magnetic stimulation was applied on the head of the volunteers. MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
2879499|NCT03393065|Experimental|intervention group pulmonary congestion|in the intervention group pulmonary congestion, as assessed by the BLS will guide the diuretic and fluid management, with a target of below 15 BLS. Furthermore, in the active arm, in the patients who will require a renal replacement therapy (RRT), BLS will be used to further guide the dialysis fluid prescription.
2879500|NCT03393065|No Intervention|Control group|control group the fluid management will not be LUS guided
2879501|NCT03393052|Active Comparator|Left Radial access|Left Radial approach for coronary angiography in patients with prior history of CABG surgery
2879502|NCT03393052|Active Comparator|Femoral access|Femoral approach for coronary angiography in patients with prior history of CABG surgery
2879503|NCT03393039|Experimental|Behavioral|Negative Affect Task
2879504|NCT03393026|Experimental|Lurasidone 40-160 mg|Lurasidone 40-160 mg
2879505|NCT03393013|Experimental|KZR-616 Dose Level 1 + standard therapy|1 of 2 dose levels of KZR-616 selected based on data from the Phase 1 dose escalation and administered in combination with Mycophenolate Mofetil and prednisone
2879506|NCT03393013|Experimental|KZR-616 Dose Level 2 + standard therapy|1 of 2 dose levels of KZR-616 selected based on data from the Phase 1 dose escalation and administered in combination with Mycophenolate Mofetil and prednisone
2879507|NCT03393013|Placebo Comparator|Placebo + standard therapy|Placebo administered with Mycophenolate Mofetil and prednisone
2879508|NCT03393000|Experimental|Trans Sodium Crocetinate plus SOC|Trans Sodium Crocetinate plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
2879509|NCT03393000|Active Comparator|Standard of Care (SOC)|Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
2879510|NCT03392987|Experimental|Subjects receiving GSK2696274 gene therapy|Eligible subjects will receive intravenous (IV) infusion of GSK2696274 gene therapy for approximately 20-30 minutes. Subjects will also receive conditioning regimen with busulfan.
2879511|NCT03392974|Experimental|Valoctocogene Roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 4E13 vg/kg
2879512|NCT03392961|Experimental|IN-105 (Insulin Tregopil)|"Cohort1: Treatments A, B, and C: IN-105 administered at 30, 20 or 10 minutes before the ADA meal, respectively; Treatment D: Placebo administered at 20 minutes before the ADA meal.~Cohort 2: Treatments A, B, and C: IN-105 administered at 4, 5, and 6 hours after the previous ADA meal, respectively; Treatments D, E, and F: Placebo administered at 4, 5, and 6 hours after the previous ADA meal, respectively.~Cohort 3: For the first meal, IN-105 30 mg administered at the optimal pre meal time determined from Cohort 1 with ADA meal (Treatments A and D) or high fat meal (Treatments B and E) or high fiber meal (Treatments C or F)."
2879582|NCT03392558|Active Comparator|Control Regimen|"Control Skin Care Regimen (Control Regimen, CR):~Cetaphil Gentle Skin Cleanser (to be used day and night)~Cetaphil Moisturizing Lotion (to be used day and night)"
2906940|NCT03200392|Active Comparator|B-DGG|blade DGG harvesting
2879513|NCT03392961|Placebo Comparator|Placebo tablet|"Cohort1: Treatments A, B, and C: IN-105 administered at 30, 20 or 10 minutes before the ADA meal, respectively; Treatment D: Placebo administered at 20 minutes before the ADA meal.~Cohort 2: Treatments A, B, and C: IN-105 administered at 4, 5, and 6 hours after the previous ADA meal, respectively; Treatments D, E, and F: Placebo administered at 4, 5, and 6 hours after the previous ADA meal, respectively.~Cohort 3: For the first meal, IN-105 30 mg administered at the optimal pre meal time determined from Cohort 1 with ADA meal (Treatments A and D) or high fat meal (Treatments B and E) or high fiber meal (Treatments C or F)."
2879514|NCT03392935|Experimental|All Subjects|All subjects will be treated with the laser at week 0 and week 4. Only assessors will be blinded and rate the dermatofibromas in photographs, they will not know which photos were taken pre-treatment vs. post-treatment to determine efficacy.
2879515|NCT03392922|Experimental|Uniblocker|The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery
2879516|NCT03392922|Experimental|Left-sided Double-lumen Tube|the double-lumen tube (DLT) is the most commonly used device for OLV
2879517|NCT03392909|Experimental|Intravenous Gentamicin|Intravenous gentamicin (7.5 mgs/kg) daily for for either 14 days and then stopped or twice weekly for three months and then stopped.
2879518|NCT03392896|Experimental|Group A Active (DCR-PHXC)|NHVs, single ascending doses of DCR-PHXC.
2879519|NCT03392896|Placebo Comparator|Group A Placebo|NHVs, normal saline 0.9% injection to match active doses.
2879520|NCT03392896|Experimental|Group B Active (DCR-PHXC)|PH1 and PH2 patients, open label, single ascending doses of DCR-PHXC.
2879521|NCT03392883|Experimental|Digital Health Assisted Mental Healthcare|This Digital Health Assisted Mental Healthcare intervention will be based on the novel mobile-based platform (Laddr® from Square2 Systems).
2879522|NCT03392870|Experimental|TAVA-ACTIVE|Integrative interventional programme. It involves high-frequency multidisciplinary intervention: nursing, psychology, psychiatry and social services. A psychotherapeutic group would be offered to those patients with an intelligence quotient>70, verbal communication and no behavioural alterations.
2879523|NCT03392870|Active Comparator|CONTROL|As usual
2879524|NCT03392844|Experimental|Intervention: Bed after 7 days|Caregiver-child dyads in this condition will receive a bed, bedding, and sleep education from the Beds for Kids program 7 days after initiating daily diary/actigraph procedures.
2879525|NCT03392844|Experimental|Wait-list: Bed after 14 days|Caregiver-child dyads in this condition will receive a bed, bedding, and sleep education from the Beds for Kids program 14 days after initiating daily diary/actigraph procedures.
2879526|NCT03392831|Experimental|Peripherally inserted central catheter|The peripherally inserted central catheter (PICC) with 3 to 6 French calibers, with one, two or three lumens Groshong and PowerPICC models. These calibers are dependent on the amount of lumens, which are used for single or concomitant infusions.
2879527|NCT03392831|Active Comparator|Central venous catheter|The central venous catheter (CVC), with a short stay of 3 to 7 French gauges with one or more lumens.
2879528|NCT03392818|Experimental|formula|Calculate the depth of intubation according to the formula of 0.1977* patient's height - 4.2423
2879529|NCT03392818|Experimental|Fiberoptic bronchoscope|intubation of Uniblocker under the Under the guidance of Fiberoptic bronchoscope
2879530|NCT03392818|Experimental|The measured distance|To measure the distance between the upper edge of the thyroid cartilage to the upper edge of the sternum add the distance from the upper edge of the sternum to the carina calculated according to the chest CT scans as a guide to the placement of Uniblocker without the aid of FOB.
2879531|NCT03392805|Experimental|sedentary life style|
2879532|NCT03392805|No Intervention|physically active life style|
2879533|NCT03392792|Active Comparator|tissue plasmnogen activator|
2879534|NCT03392792|Active Comparator|thrombectoy|
2879535|NCT03392779|Experimental|ZSP1601(single dose)-25 mg while fasted(Cohort 1)|ZSP1601 25 mg /Placebo
2879536|NCT03392779|Experimental|ZSP1601(single dose)-50 mg while fasted(Cohort 2)|"ZSP1601 50 mg/Placebo~Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1."
2879537|NCT03392779|Experimental|ZSP1601(single dose)-100 mg while fasted(Cohort 3)|"ZSP1601 100 mg/Placebo~Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2."
2879538|NCT03392779|Experimental|ZSP1601(single dose)-175 mg while fasted(Cohort 4)|"ZSP1601 175 mg/Placebo~Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3."
2879539|NCT03392779|Experimental|ZSP1601(single dose)-275 mg while fasted(Cohort 5,i.e.Group A)|"ZSP1601 275 mg/Placebo~Enrollment into Cohort 5 will begin upon assurance of safety for Cohort 4."
2879540|NCT03392779|Experimental|ZSP1601(single dose)-350 mg while fasted(Cohort 6)|"ZSP1601 350 mg/Placebo~Enrollment into Cohort 6 will begin upon assurance of safety for Cohort 5."
2879541|NCT03392779|Experimental|ZSP1601(food effect)-100 mg (Cohort FE)|"Period 1 (Day1 to Day4): Group A and Group B receive ZSP1601 100 mg/Placebo under the fasting or fed condition ,respectively on Day1.~Period 2 (Day 8 to Day11): Group A and Group B receive ZSP1601 100 mg/Placebo under the fed or fasting condition ,respectively on Day8."
2879542|NCT03392779|Experimental|ZSP1601(multiple doses)-50 mg (Cohort 7)|"50 mg ZSP1601 will be administrated while fasted or fed according to the results of Cohort FE~ZSP1601 50 mg/Placebo for 14 Days."
2879543|NCT03392779|Experimental|ZSP1601(multiple doses)-100 mg (Cohort 8)|"Enrollment into Cohort 8 will begin upon assurance of safety for Cohort 7.~ZSP1601 100 mg/Placebo for 14 Days."
2879544|NCT03392766|Experimental|Single lumen tube and bronchial blocker|neck collar apply. fibreoptic intubation with single lumen tube and brochial blocker
2879545|NCT03392766|Experimental|Double lumen tube|neck collar apply. fibreoptic intubation with double lumen tube
2879546|NCT03392753|Active Comparator|Mechanochemical ablation (MOCA)|Mechanochemical ablation using the ClariVein® mechanochemical ablation (MOCA) device (Vascular Insights, Madison, CT, USA).
2879547|NCT03392753|Active Comparator|Cyanoacrylate adhesive (CAE)|Cyanoacrylate using the VenaSealTM Closure System (Medtronic, Minneapolis, Minnesota, USA).
2879581|NCT03392558|Experimental|Nature-Based Sensitive Skin Regimen|"Burt's Bees Skin Care Regimen (Nature Based Sensitive Skin Regimen, NBSSR):~Burt's Bees Sensitive Facial Cleanser (to be used day and night)~Burt's Bees Sensitive Daily Moisturizing Cream (to be used in the day)~Burt's Bees Sensitive Night Cream (to be used at night)"
2906941|NCT03200366|Active Comparator|DVD|Tailored digital video disc (DVD)
2879548|NCT03392740|Experimental|Lisinopril treatment|These patients will be initiated at 5mg lisinopril daily by the research nurse at the time of enrollment. The drug will then be titrated up by the research nurse in a stepwise fashion from 5mg, to 10mg, and then to 20mg once a day every 1 to 3 weeks according to their regular/scheduled next office visits. Blood pressure will be monitored at every visit by the research nurse if it is less than or equal to 90 mmHg
2879549|NCT03392740|Placebo Comparator|Placebo Oral Tablet|These patients will be started on the placebo medication at the time of enrollment. According to their regular scheduled visits every 1 to 3 weeks, they will meet with the research nurse and be given a new placebo medication to take once a day.
2879550|NCT03392727|Experimental|Study Box & Education Session|Parents are provided a baby box and infant health and safety products and participate in a face to face educational session
2879551|NCT03392727|Active Comparator|Community Box & Online Education|Parents are informed how to receive a free box from a community site and are provided a guide to online resources for prenatal and infant health promotion
2879552|NCT03392714|Experimental|R-B(O)AD|Intravenous R-B(O)AD every 4 weeks for up to 4 cycles
2879553|NCT03392701|Experimental|LPS infusion|infusion of LPS 2 ng/kg over 5 minutes
2879554|NCT03392701|Placebo Comparator|Placebo|NaCl
2879555|NCT03392688|Experimental|Patellofemoral pain group|"Diagnosis of PFP was established based on symptoms, physical examination performed by an orthopedic surgeon. Patients were also screened through physical examination to rule out ligamentous or meniscal injuries, patellar tendinitis and knee joint effusion by an orthopedic surgeon. All patients also underwent a radiologic examination consisting of AP, lateral and tangential radiograms.~Surface EMG, Kujala patellofemoral pain scale, Q angle measurement were administered to the PFP group."
2879556|NCT03392688|Active Comparator|Control Group|"Control group had similar demographic characteristics with PFP group, and neither one of the controls had any knee pathology or current knee pain or effusion that would effect the gait.~Surface EMG, Q angle measurement were administered to the control group."
2879557|NCT03392675|Experimental|Self-monitoring of BF and intervention|Self-monitoring and regulation skills will be provided to mothers at discharge. Aside from daily diaries outlining, infant feeding behaviors and pain, mothers will be instructed to watch several 5-minute video modules to assist with self-management of breast and nipple pain. These videos include: pain neurophysiology; non-pharmacological strategies; common BF issues and intervention; catastrophizing; stress reactivity; deep breathing; guided imagery and support (informational and instrumental). These mothers will also be asked to complete study questionnaires and measures at specified time points.
2879558|NCT03392675|No Intervention|Control|Usual care and asked to complete measures at follow-up time points.
2879559|NCT03392662||Hemopatch Sealant Use with Hepatobiliary Surgery|
2879560|NCT03392662||Hemopatch Sealant Use with General Surgery|
2879561|NCT03392662||Hemopatch Sealant Use with Lung Surgery|
2879562|NCT03392662||Hemopatch Sealant Use with Cardiovascular Surgery|
2879563|NCT03392662||Hemopatch Sealant Use with Neurological/Spinal Surgery|
2879564|NCT03392662||Hemopatch Sealant Use with Urologic Surgery|
2879565|NCT03392649|No Intervention|Sham Group|At the end of cardiac surgery, the Parasym alligator clip will be placed on the subject's tragus, but the Parasym will not be turned on and the subject will not receive any stimulation. The clip will be switched to the other ear every 4 hours for a total of 48 hours.
2879566|NCT03392649|Experimental|Stimulation Group|At the end of cardiac surgery, the Parasym alligator clip will be placed on the subject's tragus, and the subject will receive continuous stimulation for 48 hours. The clip will be switched to the other ear every 4 hours.
2879567|NCT03392636|Experimental|Group A|Mitchell Banks Herniotomy
2879568|NCT03392636|Experimental|Group B|Fergusson Gross Herniotomy
2879569|NCT03392623|Other|Control group|Macules of melasma without any treatment
2879570|NCT03392623|Experimental|Niacinamide group|Macules of melasma treated with topical Niacinamide cream 4% for 8 weeks
2879571|NCT03392623|Experimental|Retinoic acid group|Macules of melasma treated with topical retinoic acid 0.05% for 8 weeks
2879572|NCT03392623|Placebo Comparator|Sunscreen group|Macules of melasma treated with sunscreen cream with a 50 sun protection factor for 8 weeks
2879573|NCT03392610||Bronchial endoscopy|Compare quality procedures performed with reusable versus disposable bronchoscopes in respiratory endoscopy unit
2879574|NCT03392610||Critical care unit|Compare quality procedures performed with reusable versus disposable bronchoscopes in critical care unit
2879575|NCT03392610||Anesthesia department|Compare quality procedures performed with reusable versus disposable bronchoscopes in anesthesia department
2879576|NCT03392597|Experimental|Brothers as Allie|Brothers as Allies is a strengths-based group approach to promote boys' and young men's safe and healthy passage through the pre-teen and adolescent years by addressing rigid beliefs and norms about masculinity that are harmful to the health, safety, relationships and opportunities of boys and young men. Groups of six to ten boys of similar age and development meet weekly with one or two facilitators for 1.5 to 2 hours for ten or more weeks. Meetings include warm up activities, an opportunity for check-in, experiential activities that address gender relevant topics (e.g., group challenges, games, skits, role plays), and a reflection and group dialogue component.
2879577|NCT03392597|Active Comparator|Programming-as-Usual|Usual programming implemented in afterschool programs.
2879578|NCT03392584||APR|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR)
2879579|NCT03392584||APR with VRAM|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR) and subsequent reconstruction of the perineum with a vertical rectus abdominis myocutaneous flap (VRAM)
2879580|NCT03392571|Experimental|Resectable and borderline restable|"Potentially operable or borderline resectable pancreatic adenocarcinoma as assessed by standard CT criteria and histologically confirmed.~Patients receive 3 cycles of preoperative chemotherapy (NGC-triple regimen). The regimen consists of gemcitabine 800 mg/m2, Nab-paclitaxel 100 mg/m2and Cisplatin 25 mg/m2 given IV weekly x 2, every 3 weeks (one cycle).~Patients will be evaluated for adjuvant therapy within 12 weeks of surgery which will consist of Nab-paclitaxel, gemcitabine, and Cisplatin IV weekly x 2, every 3 weeks (one cycle) x 3 cycles."
2879625|NCT03392207||Elderly|Elderly (age 60 or more) receiving the seasonal influenza vaccine (2018) produced by Butantan Institute.
2879583|NCT03392545|Experimental|Combined immune adjuvants and radiation|Patients with recurrent GBM will receive combined immune adjuvants (GM-CSF, TLR ligands) and radiation. The safety and efficacy will be analyzed.
2879584|NCT03392532|Other|Lens 1, then Lens 2|Toric contact lenses 1, followed by Toric contact lenses 2, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
2879585|NCT03392532|Other|Lens 2, then Lens 1|Toric contact lenses 2, followed by Toric contact lenses 1, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
2879586|NCT03392519||Chronic stroke|More than 3 months post-stroke Ischemic or hemorrhagic stroke
2879587|NCT03392506|Experimental|EBUS-TBNA-RTE|Patients do CT、 PETCT examination and EBUS-TBNA-RTE
2879588|NCT03392493|Experimental|Group A|In the phase 1 :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week); In the phase 2 :12 training sessions of Standard treatment only. (60 minutes a time, 2 times a week)
2879589|NCT03392493|Active Comparator|Group B|In the phase 1 :12 training sessions of Standard treatment only(60 minutes a time, 2 times a week) ; In the phase 2 :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week)
2879590|NCT03392480||Adult non-haptoglobin 2-2 group|Patients are 45 to 65 years old.
2879591|NCT03392480||Adult haptoglobin 2-2 group|Patients are 45 to 65 years old.
2879592|NCT03392480||Elder non-haptoglobin 2-2 group|Patients are elder than 65 years.
2879593|NCT03392480||Elder haptoglobin 2-2 group|Patients are elder than 65 years.
2879594|NCT03392467|Experimental|PNEUMOSTEM|human umbilical cord blood derived mesenchymal stem cell (hUCB-MSC)
2879595|NCT03392467|Placebo Comparator|Placebo|normal saline
2879596|NCT03392454||T+LRTI Patients|Patients who received Trapeziectomy with Ligament Reconstruction and Tendon Interposition.
2879597|NCT03392454||PT+TI Patients|Patients who received the Partial Trapeziectomy and Tendon Interposition
2879598|NCT03392441|Experimental|Insulin Deprivation|Insulin Deprivation in Type 1 Diabetic Patients will be performed for a short time period (4-6 hours). Changes to Age, Sex, and Gender matched controls will be compared.
2879599|NCT03392428|Experimental|177Lu-PSMA617|"Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression."
2879600|NCT03392428|Active Comparator|Cabazitaxel|"Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment."
2879601|NCT03392415|Active Comparator|Initial conservative treatment|Optimal medical therapy and option for crossover after 6 months or fulfillment of certain conditions
2879602|NCT03392415|Experimental|initial interventional treatment|CTO PCI attempt as initial strategy with medical optimization simultaneously
2879603|NCT03392389|Experimental|mRNA-1653|
2879604|NCT03392389|Placebo Comparator|Placebo|
2879605|NCT03392376|Experimental|Haloperidol injection|"Haloperidol 2,5mg x 3 daily, with additional as needed doses to a maximum of 20mg/daily.~Other name: Serenase"
2879606|NCT03392376|Placebo Comparator|Normal Saline|Saline (0,9%)
2879607|NCT03392350|Active Comparator|Behavioral Intervention arm|"A behavioral intervention consisting of a physician body scan consultation with a radiologist which included viewing self imagery followed by an 18 month behavioral intervention which included educational modules covering:~Responding to Stress More Effectively Enhancing the effects of Relaxation Nourishing your immune system Energizing your Body Welcoming Others and Strengthening Relationships"
2879608|NCT03392350|Active Comparator|Control Group|No Intervention
2879609|NCT03392337|Experimental|Open Label Narrowband UVB phototherapy|Open Label Narrowband UVB phototherapy for 12 weeks.
2879610|NCT03392324|Experimental|PRIMA|Implantation of PRIMA device
2879611|NCT03392311|Experimental|AD-MSCs plus Calcipotriol ointment group|AD-MSCs（adipose-derived multipotent mesenchymal stem cells ） intravenous injection at a dose of 0.5 million cells/kg at week 0,week 4，week 8 with a duration for treatment for 12 weeks. The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
2879612|NCT03392298|Experimental|CCA group|Participants in CCA group will be treated with 15g of Colla corii asini granule( produced by Dong-E E-Jiao Co., Ltd)， once daily for 4 weeks.
2879613|NCT03392298|No Intervention|Control group|Participants in Control group will be treated with nothing, but followed up for 4 weeks.
2879614|NCT03392285||Internal fixation|Patients above 65years old with an undisplaced femoral neck fractures treated with primary internal fixation with screws.
2879615|NCT03392285||Hip arthroplasty|Patients above 65years old with a displaced femoral neck fractures treated with primary hip arthroplasty.
2879616|NCT03392272|Experimental|Tisseel|Müller's Muscle-Conjunctival Resection (MMCR) using glue instead of sutures
2879617|NCT03392272|Active Comparator|Sutures|Müller's Muscle-Conjunctival Resection (MMCR) using the usual procedure
2879618|NCT03392259|No Intervention|Control group|conventional treatment
2879619|NCT03392259|Experimental|App group|conventional treatment + use of smartphone app.
2879620|NCT03392246|Experimental|Osimertinib + Selumetinib|"Selumetinib are to be administered orally intermittently (4 days on, 3 days off)~Osimertinib are to be administered orally on a daily basis"
2879621|NCT03392233|Experimental|Phase II open lable Study|Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time.
2879622|NCT03392220|Experimental|undergo unilateral (affected side) neck dissection (II-IV)|patient undergo affected side neck dissection, along with the excision of the laryngeal primary tumor
2879624|NCT03392207||Health Care Professionals|Health care professionals receiving the seasonal influenza vaccine (2018) produced by Butantan Institute.
2879626|NCT03392194|Experimental|Sleep hygiene & Yoga (SH+Y)|Participants will receive the sleep hygiene intervention, which includes 2 sleep hygiene sessions and 10 weeks of maintenance assessment. After completing the SH sessions, they will receive 10 weeks of the yoga intervention (8 in-person yoga sessions and 2 weeks of yoga home practice maintenance assessment).
2879627|NCT03392194|Active Comparator|Sleep hygiene (SH)|Participants will receive the sleep hygiene intervention, which includes 2 sleep hygiene sessions and 10 weeks of maintenance assessment.
2879628|NCT03392181|Experimental|18F-DCFPyL|
2879629|NCT03392168|Experimental|Cohort 1 - PK and Safety|Open Label ARQ-151 cream 0.5%
2879630|NCT03392168|Active Comparator|Cohort 2 - ARQ-151 cream 0.5%|Blinded
2879631|NCT03392168|Active Comparator|Cohort 2 - ARQ-151 cream 0.15%|Blinded
2879632|NCT03392168|Placebo Comparator|Cohort 2 - ARQ-151 cream placebo|Blinded
2879633|NCT03392155|Experimental|Training & Nutrition|Participants receive performance training twice a week for 12 weeks and group and individual nutritional counseling during the 12 weeks.
2879634|NCT03392142|Experimental|tabelecleucel|Tabelecleucel will be administered in cycles lasting 5 weeks (35 days). During each cycle, subjects will receive intravenous (IV) tabelecleucel at a dose of 2 x 10^6 cells/kg on Days 1, 8 and 15, followed by observation through Day 35. Treatment will continue until maximal response, unacceptable toxicity, initiation of non-protocol therapy, or failure of multiple tabelecleucel cell products.
2879635|NCT03392129|Experimental|Ai Chi|Children in the intervention group will perform 12 sessions (twice a week, 40 minutes each session) of treatment with the Ai Chi Method and educational interventions in relation to asthma.
2879636|NCT03392129|Active Comparator|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
2879637|NCT03392116|Experimental|Part A: NGM120|Single Dose
2879638|NCT03392116|Placebo Comparator|Part A: Placebo|Single Dose
2879639|NCT03392116|Experimental|Part B: NGM120|Multiple Dose
2879640|NCT03392116|Placebo Comparator|Part B: Placebo|Multiple Dose
2879641|NCT03392103|Experimental|postoperative CRT|postoperative CRT: Treatment including postoperative radiotherapy (IMRT) with concurrent chemotherapy of Raltitrexed. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on w1 and w4).
2879642|NCT03392090|Experimental|More Good Days video&brief questionnaire|"Participants will watch the More Good Days video and will be given a brief questionnaire and wallet card to help identify their goals and preferences about information and care~The More Good Days video is developed to help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments.~The 3-page brief questionnaire is designed to help patients identify their preferences about information and care and to help encourage a conversation between patients and their doctors and health care team about their goals and preferences~The wallet card will help patients think about questions they may want to ask their providers when considering treatments."
2879643|NCT03392077||Group A: cervical dilatation|patients who will have cervical dilatation during Caesarean section
2879644|NCT03392077||Group A: non cervical dilatation|patients who will have not cervical dilatation during Caesarean section
2879645|NCT03392064|Experimental|AMG 119 Treatment|AMG 119 administered as a one-time intravenous infusion at different cell dose levels
2879646|NCT03392051|Experimental|Clopidogrel Dosing|Multiple doses of Clopidogrel to obtain pharmacokinetic information.
2879647|NCT03392051|Experimental|Clopidogrel in combination with ISIS 681257|Multiple doses of clopidogrel administered with 2 doses of ISIS 681257 at 2 individual timepoints to obtain pharmacokinetic information.
2879648|NCT03392038|Experimental|Thin ADM|Periodontal root coverage surgery using a coronally positioned tunnel and thin acellular dermal matrix (ADM GBR)
2879649|NCT03392038|Active Comparator|Thick ADM|Periodontal root coverage surgery using coronally positioned tunnel surgery and thick acellular dermal matrix graft (ADM)
2879650|NCT03392025|Active Comparator|Flaxseed|Daily consumption of 30 grams flaxseed for 3 months
2879651|NCT03392025|Active Comparator|Flaxseed and the Mediterranean-like diet|Daily consumption of 30 grams flaxseed in adjunct to the Mediterranean-like diet for 3 months
2879652|NCT03392025|Placebo Comparator|Placebo|Daily consumption of Placebo for 3 months
2879653|NCT03391986|Active Comparator|Pyonex needles|This arm will receive modified battlefield auricular acupuncture using SEIRIN® Pyonex™ Acupuncture Needles.
2879654|NCT03391986|Placebo Comparator|Placebo adhesives|This arm will receive placement of adhesives using the modified battlefield auricular acupuncture placement points using 12 mm Plasters.
2879655|NCT03391986|No Intervention|Routine Care|This arm will receive no intervention.
2879656|NCT03391973|Experimental|Arm 1|Arm 1 - Pembrolizumab injection dosed at 200 mg given Q3 weeks by IV infusion on Day 1 of each 3 week cycle.
2879657|NCT03391947|Experimental|semilunar coronally positioned flap|A semilunar incision will be done following the curvature of the gingival margin and ending about 2 to 3 mm short of the tip of the papillae. The most apical distance of this incision to the gingival margin will be obtained by adding the bone sounding measurement to the recession height. Perform a split-thickness dissection coronally from the incision, and connect it to an intrasulcular incision. The tissue will be collapsed coronally, covering the denuded root. The coronally repositioned gingival margin will be stabilized by coronally anchored suture with composite stops on the buccal surface of the tooth using flowable composite. Finally, the area will be covered with a periodontal dressing. This is called semilunar coronally positioned flap.
2879694|NCT03391713|Active Comparator|Intervention|During the second half of the study (two weeks), there will be an education poster in the waiting room of the clinic, fashioned after the Face, Arms, Speech, Time (FAST) poster developed by the American Heart Association (AHA), but in Malay.
2879695|NCT03391700|Active Comparator|Moderate muscle relaxation|Rocuronium is administered to maintain moderate relaxation during operation. This is conventional muscle relaxation level of this institute.
2879696|NCT03391700|Experimental|Deep muscle relaxation|Rocuronium is administered to maintain deep relaxation during operation.
2879697|NCT03391687||Amylase Test|gastric cancer patients receiving radical gastrectomy
2879658|NCT03391947|Active Comparator|coronally advanced flap|Coronally positioned flap will be initiated with two vertical incisions, extending from a mesial and distal linear angle at the cementoenamel junction (CEJ) and go beyond the mucogingival junction. A split thickness flap will be prepared by sharp dissection mesial and distal to the recession and connected with an intra crevicular incision. On the facial aspect of the tooth, a full thickness flap, approximately 3-4 mm apical to crest of alveolar bone. Then, the flap will be returned and sutured it at 1 mm coronal to the CEJ after de-epithelize the papillae. The coronally repositioned gingival margin will be stabilized by coronally anchored suture with composite stops on the buccal surface of the tooth using flowable composite and sutured in the papilla region and releasing incision. Finally, the area will be covered with a periodontal dressing.
2879659|NCT03391934|Experimental|Cetuximab+ FOLFIRI|Cetuximab (Produced by CinnaGen Co.): 400 mg/m2 weekly in the first dose and 250 mg/m2 in the next doses Irinitecan: 180 mg/m2 biweekly Leucovorin: 400 mg/m2 biweekly Fluorouracil: 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly
2879660|NCT03391934|Active Comparator|Cetuximab + FOLFIRI|Erbitux® (Produced by Merk Co.): 400 mg/m2 weekly Irinitecan: 180 mg/m2 biweekly Leucovorin: 400 mg/m2 biweekly Fluorouracil: 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly
2879661|NCT03391921|Other|Vaccine|All patients will receive the 9-valent vaccine against HPV (Gardasil9) 3 doses at 0,2 and 6 months intramuscularly
2879662|NCT03391908||MP - SG 01|Patients with unstable angina type acute coronary syndrome: patients aged at least 18 years, who have signed the informed consent, and present an unstable angina-type acute coronary syndrome with maximum 48h before presentation, defined as the presence of typical angina pain, with duration of more than 5 minute, accompanied by ECG changes.
2879663|NCT03391908||MP - SG 02|Patients with acute myocardial infarction (STEMI or NSTEMI) that occurred 30 days before randomization: patients aged at least 18 years, who have signed the informed consent, and present with acute myocardial infarction (STEMI or NSTEMI) defined as typical changes on the ECG (ST elevation of minimum 1 mm in at least 2 consecutive leads - STEMI; ST-T changes for NSTEMI) accompanied by increased levels of cardiac troponin I or T, or CK-MB of more than 2x the normal reference value of the laboratory.
2879664|NCT03391895|Active Comparator|Control Group|Patients in this group will receive a home based exercise program. Home based exercise program includes deep diaphragmatic breathing exercises, resistive local expansion exercise on the collapsed areas in scoliosis concave sides, dynamic lumber stabilization, strengthening of inter scapular muscles, posture and stretching exercises once a day for 8 weeks. One of the exercise sessions was supervised by physiotherapist each week.
2879665|NCT03391895|Experimental|Training Group|In addition to home based exercise program, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be supervised in our clinic per week, other sessions will be performed at home.
2879666|NCT03391882|Experimental|APL-130277|APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
2879667|NCT03391882|Active Comparator|subcutaneous apomorphine|subcutaneous apomorphine , Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
2879668|NCT03391869|Experimental|Arm A: Ipilimumab + Nivolumab|"Each study cycle is 6 weeks (42 days).~Induction: All participants receive 2 cycles of Ipilimumab and Nivolumab treatment alone.~After Induction, participants receive Nivolumab on Days 1, 15, and 29 of each cycle (about every 2 weeks) and Ipilimumab on Day 1 of each cycle (about every 6 weeks) until progression or up to 2 years."
2879669|NCT03391869|Experimental|Arm B: LCT + Ipilimumab + Nivolumab|"Each study cycle is 6 weeks (42 days).~Induction: All participants receive 2 cycles of Ipilimumab and Nivolumab treatment alone.~After Induction, participants receive LCT within 14 days after last dose of Nivolumab during Induction. The study doctor, surgeon, and radiation oncologist will decide if participant will have surgery and/or radiation therapy."
2879670|NCT03391856|Experimental|intervention arm|NAC 400mg p.o tid from day 60 to day 90 post transplant
2879671|NCT03391856|Other|controlled arm|Supportive therapy including platelet infusion:prophylactic platelet transfusion was given when platelet count <20000/ul
2879672|NCT03391843|Experimental|FOLFOXIRI+Cetuximab|FOLFOXIRI+Cetuximab regimen:Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h and cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle for 4-6 cycles.
2879673|NCT03391830|Active Comparator|Atorvastatin-Ascorbic acid|atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
2879674|NCT03391830|Placebo Comparator|Placebo|Placebo
2879675|NCT03391817|Active Comparator|Intervention arm|Fecal transplant from a thin donor
2879676|NCT03391817|Placebo Comparator|Placebo arm|Fecal transplant made from patients own feces
2879677|NCT03391804|Experimental|ALLN-177|ALLN-177 7,500 units (2 capsules)
2879678|NCT03391791||Genetically engineered T Cell Receptor- treated|Long term follow-up of subjects with solid or hematological malignancies who have received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial
2879679|NCT03391778||NY-ESO-1ᶜ²⁵⁹T- treated|Long term follow-up of subjects with solid or hematological malignancies who have received NY-ESO-1ᶜ²⁵⁹T in a previous trial
2879680|NCT03391765|Experimental|Group 2|Dose 2 ABBV-8E12
2879681|NCT03391765|Experimental|Group 1|Dose 1 ABBV-8E12
2879682|NCT03391752||Royal Alexandria|Administrative records
2879683|NCT03391752||Pasqua Regional hospital|Administrative records
2879684|NCT03391752||Concordia Hospital|Administrative records
2879685|NCT03391752||Niagara General Hospital|Administrative records
2879686|NCT03391752||Hospital 6|Administrative Records
2879687|NCT03391752||Hospital 7|Administrative Records
2879688|NCT03391752||Hospital 8|Administrative Records
2879689|NCT03391752||Hospital 9|Administrative Records
2879690|NCT03391752||Hospital 10|Administrative records
2879691|NCT03391739|Experimental|Arm 1|CART-19 cells treat
2879692|NCT03391726|Experimental|Arm 1|CART-19 cells treat
2879693|NCT03391713|No Intervention|Control|No exposure to waiting room posters
2879735|NCT03391388|Experimental|Cohort II (proton APBI)|Patients undergo proton beam radiation therapy APBI for 3-5 days.
2879736|NCT03391388|Experimental|Cohort III (brachytherapy APBI)|Patients undergo brachytherapy ABPI for 3-5 days.
2879698|NCT03391674|Experimental|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
2879699|NCT03391674|No Intervention|Observational|Observational
2879700|NCT03391661|Experimental|Chronic Pain and the Brain|This condition is a 10-minute exercise that patients complete in which they examine variables in themselves that suggest that their pain is driven by central nervous system processes / their brains.
2879701|NCT03391661|Placebo Comparator|Health Behavior Control|This 10-minute exercise is designed as a control condition that has face validity as helpful and that relates to health. Thus, patients are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections).
2879702|NCT03391648||Cesarean|
2879703|NCT03391635|Experimental|Electroacupuncture|"The treatment consists of 3 times a week for 8 weeks.Huatuo Brand needles (0.30×50mm or 0.30×70mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used for ST25, SP14 and ST37.After acupuncture，the needle handle will be connected with the electrode in the electroacupuncture instrument.~The parameters of the electric acupuncture apparatus：Dilatational wave，the frequency is 2/10Hz，the electric current intensity is 0.1mA-1.0mA."
2879704|NCT03391635|Active Comparator|TranscutaneousElectricNerveStimulation|"The treatment consists of 3 times a week for 8 weeks.Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used for ST25, SP14 and ST37.~The parameters of the electric acupuncture apparatus：Dilatational wave，the frequency is 2/10Hz，the electric current intensity is 2mA-5mA."
2879705|NCT03391609|Placebo Comparator|control group|Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
2879706|NCT03391609|Active Comparator|Dex. group|Caesarian section will be performed under standard general anesthesia plus pre and intra operative Dexmedetomidine infusion in a dose of 0.5mic/kg/hour starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
2879707|NCT03391596|Experimental|Internet-based ACT intervention|"Group Internet-based ACT intervention will receive a 12-week Internet-based, acceptance and commitment therapy intervention"
2879708|NCT03391596|Active Comparator|Standardized rehabilitation|"Group Standardized rehabilitation will receive a standardized rehabilitation program in the rehabilitation center"
2879709|NCT03391596|Other|Support by caregiver associations|"Group Support by voluntary caregiver associations will receive support given by caregiver associations"
2879710|NCT03391583|Experimental|Standard of Care plus Education|Educational material will be provided at three time points along with the current standard of care provided in tertiary health care setting
2879711|NCT03391583|No Intervention|Standard of Care|Current standard of care provided in tertiary health care setting
2879712|NCT03391570|Active Comparator|COX-2 inhibitor (Celecoxib)|Celebrex; COX-2 inhibitor
2879713|NCT03391570|Placebo Comparator|Placebo drug (Ramnos)|Ramnos; Lactobacillus casei variety rhamnosus
2879714|NCT03391557|Experimental|Patients with the UE examination|Patients with enlarged intrathoracic lymph nodes(≥1cm) and/or 18-FDG high uptake (SUV Max > 2.5) without bleeding tendency, abnormal coagulation function and serious cardiac dysfunction were finally selected.
2879715|NCT03391544|Experimental|V4c toric ICL implantation Group|V4c toric ICL implantation Group
2879716|NCT03391531|Active Comparator|levobupivacaine|Echo-guided bilateral subcostalTAP block will be performed using levobupivacaine [Chirocaine®] 0.375% Epi 1/200000.
2879717|NCT03391531|Placebo Comparator|Saline|Echo-guided bilateral subcostal TAP block will be performed with saline Epi 1/200000 in the control group.
2879718|NCT03391505|Experimental|Treatment Group 1|The small-sided soccer game consists of a single bout (two times ten minutes) of small-sided soccer game (3v3) interspersed with a five minutes break.
2879719|NCT03391505|Experimental|Treatment Group 2|The walking soccer game consists of a single bout (two times ten minutes) of small-sided walking soccer game (3v3) interspersed with a five minutes break.
2879720|NCT03391505|Placebo Comparator|Control Group|The rest group watching soccer consists of watching a soccer game on a laptop (two times ten minutes) interspersed with a five minutes break.
2879721|NCT03391492||influenza group|All consecutive patients older than 18 years ,admitted to the ICU with respiratory distress with microbiologically confirmed diagnosis of influenza
2879722|NCT03391492||control group|All consecutive patients older than 18 years, admitted to the ICU for respiratory distress due to community-acquired pneumonia (CAP) and with a microbiologically confirmed absence of influenza,
2879723|NCT03391479|Experimental|Avelumab and Best Supportive Care|"Avelumab will be given intravenously (by vein) at a dose of 10 mg/kg, once every 2 weeks~Best supportive care will be provided as required."
2879724|NCT03391466|Experimental|Axicabtagene Ciloleucel Treatment|
2879725|NCT03391466|Active Comparator|Standard of Care Therapy|
2879726|NCT03391440|Experimental|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
2879727|NCT03391427|Experimental|Lidocaine|This group will receive lidocaine infusion perioperatively
2879728|NCT03391427|Experimental|Ketamine|This group will receive ketamine infusion perioperatively
2879729|NCT03391427|Experimental|Lidocaine+ketamine|This group will receive a combination of lidocaine and ketamine infusion, perioperatively
2879730|NCT03391427|Placebo Comparator|placebo|This group will receive saline infusion as placebo perioperatively
2879731|NCT03391414|Experimental|hypertonic bicarbonate|subjects will be administered a solution of 8.4% hypertonic bicarbonate by nebulizer
2879732|NCT03391414|Active Comparator|hypertonic saline|subjects will be administered a solution of 7% sodium chloride by nebulizer
2879733|NCT03391401||Adip1|Patients with morbid obesity (i.e. BMI >35 kg/sqm) and age >18 scheduled for bariatric surgery (all standard procedures included)
2879734|NCT03391388|Experimental|Cohort I (3D-CRT APBI)|Patients undergo 3D-CRT APBI for 3-5 days.
2879737|NCT03391375|Experimental|DNA-Protein|Co-administration of DNA-HIV-PT123 and AIDSVAX B/E at week 0, 4 and 24
2879738|NCT03391362|Experimental|Stereotactic Radiation|"Stereotactic radiation will begin within 14 days of the MRI used for radiation planning~Lesions <2 cm in maximum diameter will be treated with stereotactic radiosurgery, generally 20 Gy in 1 fraction~Lesions between 2.0 and 3.0 cm in maximum diameter will generally be treated to 18 Gy in 1 fraction~Lesions >3 cm will be generally be treated with stereotactic radiotherapy to 30 Gy in 5 fractions"
2879739|NCT03391349||Group I|GROUP I: 35 generalized severe chronic periodontitis subjects without type II diabetes mellitus and systemically healthy.
2879740|NCT03391349||Group II|GROUP II: 35 generalized severe chronic periodontitis subjects diagnosed with type II diabetes mellitus.
2879741|NCT03391323|Other|Medacta GMK Sphere® Medial-Pivot Knee Prosthesis|
2879742|NCT03391323|Other|Medacta GMK PS Posterior Stabilized Knee Prosthesis|
2879743|NCT03391310|Experimental|Honey dressing group|In this group, the wound will be cleaned with normal saline and then honey (medicated ) will be applied to cover the wound surface. The dressing will be changed once soiled (alternate day in most cases). The dressing will be applied for a maximum period upto 8 weeks (in cases of stage IV ulcers) or till healthy granulation tissue appears, whichever is earlier.
2879744|NCT03391310|No Intervention|Standard treatment group|In this group, the wound will be first cleaned with 'povidone iodine' and then covered with hydrocolloid dressing changed alternate day for maximum period upto 8 weeks (in cases of stage IV ulcers) or till healthy granulation tissue appears, whichever is earlier.
2879745|NCT03391297|Experimental|60-minute Prolonged Exposure Therapy|This condition is a modified version of Prolonged Exposure Therapy for PTSD. It consists of weekly 60-minute sessions, with at least 20 minutes imaginal exposure.
2879746|NCT03391297|Active Comparator|90-minute Prolonged Exposure Therapy|This condition is standard Prolonged Exposure Therapy. It consists of 10 to 15 weekly sessions, each lasting about 90 minutes, with 40-60 minutes imaginal exposure.
2879747|NCT03391284|Experimental|Oral|1000 mg acetominophen oral
2879748|NCT03391284|Active Comparator|Intravenous|1000 mg acetominophen intravenous
2879749|NCT03391271|Experimental|photobiomodulation therapy (PBMT)|During photobiomodulation therapy (PBMT) or low-level laser therapy, visible and/or (near)-infrared laser light is used at the affected area to improve tissue repair and thereby promote functional recovery of peripheral nerves
2879750|NCT03391271|Placebo Comparator|Placebo group|No PBMT
2879751|NCT03391258|Experimental|Bone Regeneration with GLAM technique|At the beginning of each surgery, a venipuncture will be performed, to obtain the L-PRF membranes. Also, two white topped tubes will be centrifuged for 3 minutes to obtain PRP. After implant placement, achieving a primary stability of at least 45 Ncm, the stiff bone-block (L-PRF membranes and PRP combined with bovine xenograft) will be used in the buccal plate of the pre-maxilla, to enhance bone volume in the esthetic area.
2879752|NCT03391245||Cirrhotic patients with or without infection|"We will include admitted patients with liver cirrhosis irrespective of the underlying etiology during 6 months in Al Rajhi Tertiary Liver Hospital, Assiut, Egypt. They will be divided into 2 Groups. Group I: Cirrhotic patients with evidence of infections at any site and Group II: Cirrhotic patients without evidence of infections.~Diagnosis of infection will based on related clinical symptoms and signs with laboratory and radiological findings."
2879753|NCT03391232|Experimental|PolyPEPI1018 CRC Vaccine|The vaccine contains 6 synthetic peptides mixed with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 epitopes from 7 cancer testis antigens (CTAs), which are the most frequently expressed CTAs in colorectal cancer. The 6 peptides were optimized with the PEPI biomarker to induce long lasting CRC specific T cell responses.
2879754|NCT03391219|Active Comparator|intravitreal Bevacizumab|
2879755|NCT03391219|Active Comparator|intravitreal Bavacizumab and Fasudil|
2879756|NCT03391206||presence of BCRL|presence of breast cancer related lymphedema after surgical treatment using Inbody 720 and arm circumference measurement
2879757|NCT03391206||absence of BCRL|absence of breast cancer related lymphedema after surgical treatment using Inbody 720 and arm circumference measurement
2879758|NCT03391193|Experimental|Multi-dose Quadrivalent Influenza Vaccine|Quadrivalent influenza vaccine (split-virion, inactivated, 2017-2018 formulation, thiomersal containing) in multi-dose presentation. Participants aged 9 to 17 years will receive 1 dose and subjects aged 6 months to 8 years will receive 2 doses 28 days apart
2879759|NCT03391193|Active Comparator|Single-dose Quadrivalent Influenza Vaccine|Quadrivalent influenza vaccine (split-virion, inactivated, 2017-2018 formulation, thiomersal free) in single-dose syringe presentation. Participants aged 9 to 17 years will receive 1 dose and subjects aged 6 months to 8 years will receive 2 doses 28 days apart
2879760|NCT03391180|Experimental|ICON Remineralization|Firstly, Conditioning of the WSL surface by 15% HCL gel (Icon-Etch, DNG) and subsequent application of the drying solution (Icon-Dry, DMG), Numbers of additional etching intervals have been determined by visual assessment after each of the etch/dry intervals to achieve individual, customized intensities of WSL surface conditioning.
2879761|NCT03391180|Active Comparator|CPP-ACPF|Participants in group 2 (CPP-ACPF) were treated with applying a pea sized amount of ACC-ACPF plus on a gloved finger of the examiner and rubbed the surface of the labial tooth for 4 minutes with advising the patient to avoid drinking and eating for the next 30 minutes of application.
2879762|NCT03391167|Sham Comparator|Control|Peroperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
2879763|NCT03391167|Experimental|ESP Block|In addition to routine analgesic protocol; before anaesthesia induction; bilateral ultrasound guided erector spinae plane block (ESP) (intervention) will be performed via USG guidance at Th9 level.Standard Pain Followup and Monitorization will be performed.
2879764|NCT03391154|Active Comparator|levothyroxine|100 pregnant female with TSH of> 2.5 mU/L but less than 4 mU/L after biochemical diagnosis of pregnancy will receive 50 ug of levothyroxine (eltroxin 50) aspen,Egypt throughout the pregnancy
2879765|NCT03391154|Placebo Comparator|placebo|100 pregnant female with TSH of> 2.5 mU/L but less than 4 mU/L after biochemical diagnosis of pregnancy will receive placebo throughout the pregnancy
2879766|NCT03391115||Inpatient Participants|"Patients admitted to University of Colorado Hospital with at least one of the following diagnoses:~Heart Failure~COPD~Cancer"
2879767|NCT03391115||Nurse Participants|"Bedside nurses who provide care at the inpatient level for the following diseases:~Heart Failure~COPD~Cancer"
2879768|NCT03391089|Experimental|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
2879769|NCT03391076|Experimental|FilmArray group|Patients in this group will use FilmArray Respiratory Panel to test potential viral pathogens.
2879770|NCT03391076|No Intervention|Routine test group|Patients in this group will use clinical routine methods to test potential viral pathogens.
2879771|NCT03391063|Experimental|reinforced polyamide denture base|metal reinforced polyamide denture base
2879772|NCT03391063|Active Comparator|conventional acrylic resin denture base|conventional heat cured acrylic resin denture base
2879773|NCT03391050|Experimental|APR-246 + Dabrafenib|
2879774|NCT03391037||Intervention|diagnostic criteria for volume assessment were heart rate (HR), mean arterial blood pressure (MABP), central venous pressure (CVP), and urine output hourly (UOP) in ml/hr. During period of hypovolemia, all enrolled patients had left IJV scanned (T0) and measured by one anesthesiologist experienced in point-of-care ultrasound. This point-of-care anesthesiologist is not involved in the anesthetic management of the patient and blinded to the volume status of the patient values. Hypovolemic patients were given a fluid bolus in the form of ringer acetate 5 ml / Kg. Ultrasonic and hemodynamic measurements are reassessed 10 minutes (T 10) after the fluid resuscitation.
2879775|NCT03391024|Experimental|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
2879776|NCT03391011|Experimental|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
2879777|NCT03390998||Peripartum SCAD|Female patients who experienced any SCAD event that occurred during pregnancy or up to 1 year post-delivery
2879778|NCT03390998||Non-peripartum SCAD|Female patients who experienced any SCAD with event onset outside of the pregnancy period
2879779|NCT03390972|Experimental|Dexmedetomidine|Volunteers are given an intravenous infusion with dexmedetomidine, with an effect-site target concentration of 0.6 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests the effect-site target concentration is raised to 1.2 ng/ml and the swallowing series is repeated.
2879780|NCT03390972|Placebo Comparator|Placebo|Volunteers are given an intravenous infusion with saline 0,9% with target controlled infusion pump in corresponding doses as in the dexmedetomidine arm.
2879781|NCT03390959|Experimental|Proprioceptive Training|The group participates in proprioceptive training that promotes sensory integration.
2879782|NCT03390959|Other|Control Group|The group continues in their daily lives with phone monitoring.
2879783|NCT03390946|Experimental|four-drug interval-compressed regimen|"Interventions for 'four-drug interval-compressed regimen': Drug: methotrexate, cisplatin, doxorubicin, ifosfamide.~Newly diagnosed oseteosarcoma patients under 40 years are eligible. Neoadjuvant chemotherapy with four drugs in an interval-compressed schedule will be done as a single arm.~Duration of neoadjuvant chemotherapy will be 10 weeks like that of conventional three-drug regimen, although four-drugs are employed in the current protocol.~After tumor resection operation, participants will be divided to poor responder group and good responder group based on 90% necrosis rate of a tumor specimen.~Poor responder group and will be assigned to 'Poor responder group adjuvant chemotherapy' and good responder will be assigned to 'Good responder group adjuvant chemotherapy'."
2879784|NCT03390933|Experimental|Fluoxetine Group|Approximately 96 patients will be enrolled into the intervention (Phase II) over the duration of the entire study.
2879785|NCT03390920|Experimental|Amniotic|The study is nonrandomized with one arm. Depending on the body area being treated, the amount of the amniotic product utilized will be either 0.5 cc's or 1.0cc's.
2879786|NCT03390907|Experimental|Hybrid APC|Hybrid APC ( Erbe Hybrid APC) design for ablation of abnormal tissue in GI tract.
2879787|NCT03390881|Experimental|Fasting condition|Effects of cumulated negative energy balance (fasting over 480 min) on breath acetone changes
2879788|NCT03390881|Active Comparator|Sugar condition|Effects of sugar consumption on breath acetone changes
2879789|NCT03390881|Active Comparator|Fat condition|Effects of fat consumption on breath acetone changes
2879790|NCT03390868|Experimental|Intervention arm|Phase 1, participants in the intervention group will take part in an web-based training for staff working with people with intellectual disabilities and challenging behaviour aiming to in a more effective way communicate to prevent challenging behaviour. The participants (staff) will by their own, go through the web-based training program during working hours. Measurement are conducted before intervention, at intervention completion an average of 12 weeks, and for a 3 month follow up after completed intervention
2879791|NCT03390868|Other|control arm|Control arm: participants in the control-group will maintain regular care and have the opportunity to receive the web-based training for staff working with people with intellectual disabilities and challenging behaviour in phase 2.
2879792|NCT03390855|Experimental|Broccoli sprout and follow up|Daily consumption of 30 g of raw, fresh, broccoli sprouts, not cooked, during 10 weeks (70 days), followed by other 90 days of no ingestion of broccoli sprouts
2879793|NCT03390842|Experimental|TRC101|Administered once daily (QD) for 40 weeks
2879794|NCT03390842|Placebo Comparator|Placebo|Administered once daily (QD) for 40 weeks
2879795|NCT03390829||Patients|
2879796|NCT03390829||Doctors|
2879797|NCT03390816||Transversal|Elderly people, who are more than 70 years old, suffering from cancer, waiting for a treatment decision and taken care of in a hospital
2879798|NCT03390816||Longitudinal|Elderly people, who are more than 70 years old, suffering from cancer, waiting for a treatment decision and taken care of in a hospital Forward-looking follow-up of 6 months of a sub-sample during the first year
2879799|NCT03390803||patients with hemifacial spasm|
2879800|NCT03390803||healthy control subjects|
2879801|NCT03390790|Experimental|Lidocaine gel|If assigned to this arm, participants have lidocaine gel 2% applied to their external urethra and vagina one time prior to the urodynamics procedure.
2879802|NCT03390790|Placebo Comparator|Lubricant gel|If assigned to this arm, participants will have a standard lubricant gel applied to their external urethra and vagina prior to the urodynamics procedure.
2879803|NCT03390777|Active Comparator|surgery only|Surgery consisting in debridement/removal of affected tissue/s will be performed.
2879873|NCT03390374|No Intervention|Control group|Sterile water 1 mL three times a day for oral hygiene
2879804|NCT03390777|Active Comparator|surgery and PRGF|Surgery consisting in debridement/removal of affected tissue/s will be performed. Platelet Rich Growth Factor (device) will be produced by a venous blood sampling of the patient and applied to the treated area
2879805|NCT03390764|Active Comparator|4:1 closure group|Patients randomized to and receiving the intervention small stitch 4:1 technique for closure of the abdominal wall.
2879806|NCT03390764|Active Comparator|RTL plus 4:1 closure group|Patients randomized to and receiving the intervention reinforced tension-line suture plus small stitch 4:1 technique for closure of the abdominal wall.
2879807|NCT03390751||Aged patients|Data collection of patients admitted to the orthopedic department of the University Hospital of Toulouse for surgical management of a fracture of the upper end of the femur in emergency or for the installation of a hip or knee prosthesis.
2879808|NCT03390738|Experimental|Intravenous nivolumab 240mg|Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal.
2879809|NCT03390725|Experimental|A Healthy School Start Plus intervention|The intervention consists of 4 components given to all participants in the experimental group: 1) A health information brochure regarding child's health; 2) Motivational Interviewing with the parents by the school nurse concerning the child; 3) classroom activities for the children with home assignments; and 4) a web-based self-test of type-2 diabetes risk by parents with recommendation to contact primary health care in case of elevated risk.
2879810|NCT03390725|Active Comparator|Control|Treatment as usual in school health services plus the health information brochure regarding child's health (component 1 of the intervention)
2879811|NCT03390712||Paliperidone Palmitate|Patients who have received a minimum of 3 months of treatment with an injection of paliperidone palmitate.
2879812|NCT03390712||Risperidone Long-acting injection.|Patients who have received a minimum of 3 months of treatment with Risperidone long-acting injection.
2879813|NCT03390699|Experimental|before and after partial maxillectomy|Microbial profile among patients before and after partial maxillectomy
2879814|NCT03390686|Experimental|HD204 (Bevacizumab biosimilar)|HD204 + Carboplatin/Paclitaxel
2879815|NCT03390686|Active Comparator|Avastin (Bevacizumab)|Avastin® + Carboplatin/Paclitaxel
2879816|NCT03390673|Experimental|HD204|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
2879817|NCT03390673|Active Comparator|EU-licensed Avastin|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
2879818|NCT03390673|Active Comparator|US-licensed Avastin|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
2879819|NCT03390660||birth cohorts|born in 1994-1997, 1998-2001, 2002-2005, 2006-2009, 2010-2014
2879820|NCT03390647|Experimental|Cohort A1|Japanese participants will receive a single oral dose of E6130 on Day 1 and Day 7 administered in the specified order (fasted/fed or fed/fasted) to evaluate the food effect.
2879821|NCT03390647|Experimental|Cohort B1|Caucasian participants will receive a single oral dose of either E6130 or placebo on Day 1.
2879822|NCT03390647|Experimental|Cohorts A2-A4|Japanese participants will receive multiple oral doses of E6130 or placebo on Days 1 to 5, administered in a randomized, dose-ascending manner.
2879823|NCT03390608||Women with T1ab breast cancer.|
2879824|NCT03390595|Experimental|Avelumab plus gemcitabine/carboplatin|2 cycles of induction avelumab 10mg/kg every 2 weeks followed by 6 cycles of carboplatin/gemcitabine plus avelumab (carboplatin 5AUC day +1, gemcitabine 1000mg/m2 day +1 and +8 and avelumab 10mg/kg day +15) every 3 weeks followed by avelumab monotherapy 10mg/kg every 2 weeks until progressive disease or intolerance.
2879825|NCT03390595|Active Comparator|Gemcitabine/carboplatin alone|patients will receive 6 cycles of carboplatin/gemcitabine (carboplatin 5AUC day +1, gemcitabine 1000mg/m2 day +1 and +8) every 3 weeks.
2879826|NCT03390582||Hashimoto's thyroiditis|Hashimoto's thyroiditis (HT) is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers.
2879827|NCT03390582||healthy controls|healthy controls are all from normal volunteers
2879828|NCT03390582||treatment_naive GD|GD is primarily a humoral disease where autoantibodies are generated against the thyroid stimulating hormone receptor (TSHR) leading to hyperthyroidism.
2879829|NCT03390582||treated GD|GD patients treated by Methimazole Pill
2879830|NCT03390569|Experimental|Exercise in GBM|All patients will be assigned a three-month exercise intervention according to their own capabilities and current activity levels
2879831|NCT03390556|Experimental|Asthma education|
2879832|NCT03390543|Experimental|Device group (Group D)|Arm Description: Patients in this group are assigned to receive internal jugular vein catheterization guided by ultrasound and simple needle guide device.
2879833|NCT03390543|Placebo Comparator|sono only group (Group S)|Patients in this group are assigned to receive internal jugular vein catheterization guided by ultrasound without simple needle guide device.
2879834|NCT03390530|Active Comparator|Thyroxine treatment|Intravenous thyroxine in a dose of 8 µg/kg/day divided into two doses (every 12 hours)
2879835|NCT03390530|Placebo Comparator|Placebo treatment|Intravenous placebo treatment every 12 hours.
2879836|NCT03390517|Experimental|ICG group|A sigmoid and rectum resection with colorectal anastomosis will be performed according to the surgeons standard practice with the addition of intraoperative imaging using fluorescence angiography with indocianyne green to assess colon and rectal tissue perfusion.
2879837|NCT03390517|No Intervention|Standard|A sigmoid and rectum resection with colorectal anastomosis will be performed according to the surgeons standard practice.
2879838|NCT03390504|Experimental|Cohort 1 (Arm 1A): Erdafitinib|Participants will be screened based on Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA) to determine molecular eligibility and participants who meet molecular eligibility criteria will be enrolled. Participants (treated with prior anti-anti-programmed cell death protein [PD][L]1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 milligram (mg), once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustment are based on phosphate level and observed toxicity (adverse events [AEs]).
2879874|NCT03390361|Active Comparator|LCS|Laser cataract surgery will be performed. 5-minutes after LCS aqueous humour will be collected and frozen in -80° celsius.
2879839|NCT03390504|Experimental|Cohort 1 (Arm 1B): Vinflunine or Docetaxel|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be enrolled. Participants (treated with prior anti-PD[L]1 agent) will receive vinflunine 320 milligram per meter square (mg/m^2) as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m^2 as a 1 hour intravenous infusion every 3 weeks. Treatment with either agent (choice of investigator) will be administered until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities.
2879840|NCT03390504|Experimental|Cohort 2 (Arm 2A): Erdafitinib|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be enrolled. Participants (no prior treatment with anti-PD(L)1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 mg, once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on phosphate level and observed toxicity (AEs).
2879841|NCT03390504|Experimental|Cohort 2 (Arm 2B): Pembrolizumab|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be enrolled. Participants (no prior treatment with anti-PD(L)1 agent) will receive pembrolizumab 200 mg as a 30-minute intravenous infusion once every 3 weeks, until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment or the completion of 2 years of pembrolizumab therapy. Dose adjustments are based on observed toxicities.
2879842|NCT03390491|Experimental|OnTrack>TheGame (OTG)|The intervention condition will consist of 2 components: (1) provision of the game to the participating clients via an email link, and (2) brief interactions with their mental health provider with respect to reactions they may have when playing the game. Components of the game are described in the Innovation section. The participant will be reminded via email once a week to play the game/visit the website for a period of 2 months. After that time, reminders to play the game/visit website will no longer be sent, but the participant may continue to play if they wish.
2879843|NCT03390491|Other|Recovery Videos (RV)|The comparator will consist of access to a website that will contain the recovery videos and the static information that is contained in the game. In this condition, mental health providers will also ask about possible reactions to viewing the recovery videos and information on the website. At the end of the study (after the follow-up assessment), the RV participants will be provided access to the game.
2879844|NCT03390478|No Intervention|Control Group|The participants that will be assign to the control group will receive institutional usual care.
2879845|NCT03390478|Experimental|Combined Intervention Group|The participants that will be assigned to the experimental group will receive the Combined Intervention Program
2879846|NCT03390465|Other|Arm1(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
2879847|NCT03390465|Other|Arm2(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
2879848|NCT03390465|Other|Arm3(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
2879849|NCT03390465|Other|Arm4(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
2879850|NCT03390465|Other|Arm5(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
2879851|NCT03390465|Other|Arm6(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
2879852|NCT03390452|Experimental|Intervention|"The parents will receive Mobile phone messages about oral hygiene and healthy dieting of their children through teachers.~The message format will be text and images, depending upon the education/ literacy level of the parents. Parents will be reminded and information reinforced, at frequent intervals for a period of six months.~Oral hygiene of School children will be assessed before intervention, after 6 months interval"
2879853|NCT03390452|No Intervention|Control|The primary school children in the control group will not receive any intervention via their parents or teachers (in-active controls) but will be observed on selected outcome measures for baseline data, then at six month interval to compare for differences (if any) with intervention group.
2879854|NCT03390439|Active Comparator|Nd-Yap 1340nm laser|The randomly assigned segment of the abdomen will receive 5 sessions with monthly intervals of Nd-yap 1340nm laser.
2879855|NCT03390439|Experimental|Microneedling|The randomly assigned segment of the abdomen will receive 5 sessions with monthly intervals of dermaroller 2,5mm.
2879856|NCT03390426|Experimental|Mepivacaine Block Group|Injection of local anesthetic (mepivacaine) above and beside the femoral artery.
2879857|NCT03390426|Placebo Comparator|Saline Sham Group|Injection of salt water (saline) above and beside the femoral artery.
2879858|NCT03390413|Active Comparator|Robot|
2879859|NCT03390413|Experimental|Cryo|
2879860|NCT03390400|Active Comparator|Anterior Capsulotomy before Lens Fragmentation|Anterior capsulotomy will be performed by femtosecond laser before lens fragmentation
2879861|NCT03390400|Active Comparator|Lens Fragmentation before Anterior Capsulotomy|Lens fragmentation will be performed by femtosecond laser before anterior capsulotomy
2879862|NCT03390387|Experimental|Dexa intermittent|Induction therapy with intermittent Dexamethasone administration (1-15 days - 6 mg/m2, 15-22 day - pause, 22-29 days - 6 mg/m2).
2879863|NCT03390387|Active Comparator|Dexa constant|Induction therapy with continuous Dexamethasone administration (6 mg/m2 1-29 days).
2879864|NCT03390387|Active Comparator|Dexa|Therapy with Dexamethasone (6 mg/m2) as basic glucocorticoid preparation.
2879865|NCT03390387|Experimental|Medrol|Therapy with Methylprednisolone (60 mg/m2) as basic glucocorticoid preparation.
2879866|NCT03390387|Experimental|IDA|Induction and consolidation therapy with Idarubicin
2879867|NCT03390387|Active Comparator|DNR|Induction and consolidation therapy with Daunorubicin
2879868|NCT03390387|Experimental|Protocol Ib+|Two-phase induction therapy (additional second phase of induction - protocol Ib)
2879869|NCT03390387|Active Comparator|Protocol Ib-|Standard induction therapy (without second phase)
2879870|NCT03390387|Active Comparator|Bortezomib-|Consolidation therapy without Bortezomib
2879871|NCT03390387|Experimental|Bortezomib+|Consolidation therapy with Bortezomib 1.3 mg/m2 N12 (N4 in each reinduction)
2879872|NCT03390374|Experimental|Nystatin group|Nystatin oral 1 mL (0.5 mL coated in oral cavity and the rest was given through orogastric tube) three times a day
2879928|NCT03389971|Experimental|USAT catheter|
2879875|NCT03390361|Placebo Comparator|MCS|Manual cataract surgery will be performed. Aqueous humour will be collected and frozen in -80° celsius before MCS starts.
2879876|NCT03390335|Experimental|Altitude Dive Altitude profile|Subjects are exposed to Pressure profiles (Altitude followed by a Dive with a return to Altitude) and Breathing Gases during dive exposures.
2879877|NCT03390322|Experimental|Duodenal Glycemic Control™|
2879878|NCT03390309|Other|Partially Hydrolyzed Formula|Infant was identified and got 1 or more scores by using infant feeding & stool pattern questionnaire at Visit 1 will be assigned into experimental group randomly
2879879|NCT03390309|Placebo Comparator|Normal Formula|Normal Formula
2879880|NCT03390296|Experimental|Arm A: PF-04518600|Phase I Dose Escalation: PF-04518600 given on Days 1 and 14 of a 28 day cycle to identify the dose to be taken forward in the subsequent combination cohorts.
2879881|NCT03390296|Experimental|Arm B: PF-04518600 + Avelumab|"Phase II: Starting dose of PF-04518600 determined by Phase I given on Day 1 and 14 of a 28 day cycle.~Avelumab given by vein on Days 1 and 14 of each 28-day cycle."
2879882|NCT03390296|Experimental|Arm C: PF-04518600 + Azacitidine|"Phase II: Starting dose of PF-04518600 determined by Phase I given on Day 1 and 14 of a 28 day cycle.~Azacitidine given either by vein or as an injection under the skin on Days 1-7 or Days 1-5 and 8-9 of each 28 day cycle."
2879883|NCT03390296|Experimental|Arm D: PF-04518600 + Utomilumab|"Phase II: Starting dose of PF-04518600 determined by Phase I given on Day 1 and 14 of a 28 day cycle.~Utomilumab given by vein on Days 1 and 14 of each 28 day cycle."
2879884|NCT03390296|Experimental|Arm E: Avelumab + Utomilumab|"Avelumab given by vein on Days 1 and 14 of each 28 day cycle.~Utomilumab given by vein on Days 1 and 14 of each 28 day cycle."
2879885|NCT03390296|Experimental|Arm F: PF-04518600 + Azacitidine + Avelumab|"Phase II: Starting dose of PF-04518600 determined by Phase I given on Day 1 and 14 of each 28 day cycle.~Azacitidine given either by vein or as an injection under the skin on Days 1-7 or Days 1-5 and 8-9 of each 28 day cycle.~Avelumab given by vein on Days 1 and 14 of each 28 day cycle."
2879886|NCT03390296|Experimental|Arm G: Gemtuzumab Ozogamycin (GO) + Glasdegib|"Gemtuzumab ozogamicin given by vein on Days 1, 4, and 7 of each 28 day cycle.~Glasdegib tablets taken by mouth every morning of each 28 day cycle."
2879887|NCT03390296|Experimental|Arm H: Glasdegib + Avelumab|"Glasdegib tablets taken by mouth every morning of each 28 day cycle.~Avelumab given by vein on Days 1 and 14 of each 28 day cycle."
2879888|NCT03390283||Parents/Caregivers|Parents/caregivers of children in the Pediatric Supportive Care Clinic at MD Anderson Cancer Center.
2879889|NCT03390270||Patients with NSTEMI|All patients admitted to Duke University Hospital with an NSTEMI
2879890|NCT03390257|Experimental|3NT flexible endoscope|Evaluation of 3NT flexible endoscope in terms of access and evaluation of the nasal anatomy
2879891|NCT03390244|Experimental|FCVB Implant|All subjects in this study are in the experimental treatment arm and will receive the FCVB implant
2879892|NCT03390231|Experimental|Stem Cell Educator|"The Stem Cell Educator (SCE) technology involves a closed-loop system that circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SCs in vitro, and returns only the educated immune cells to the patient's circulation. Several mechanistic studies with clinical samples and animal models have been conducted to demonstrate the proof of concept and clinical safety of SCE therapy. They suggest that SCE therapy may function via CB-SC induction of immune tolerance in the autoimmune T cells and pathogenic monocytes/macrophages that are encountered through the action of the autoimmune regulator (AIRE) and other molecular mechanisms. Following induction of immune tolerance in the immune cells, the immune balance and homeostasis may be restored when treated cells are returned in vivo."
2879893|NCT03390218|Experimental|TAO (Therapy Assisted Online)|TAO participants will attend a once weekly group in a computer lab. Each participant will complete an interactive educational module using an evidence based protocoled treatment for anxiety and/or depression, and have a brief session with the group leader to discuss application of the content. Participants will have access to a companion app they may use between sessions to practice skills and reinforce learning.
2879894|NCT03390218|Active Comparator|Treatment as usual|After the completion of a psychosocial assessment, and development of a treatment plan, clients are offered individual and group therapy sessions, case management services, and medication management services depending on the diagnoses. Individual and group therapy is often generic in nature as well, although some structured, evidence-based treatments are offered such as Psycho-Education Multi-Family Group and Illness Management Recovery.
2879895|NCT03390205||Patients|
2879896|NCT03390205||Controls|
2879897|NCT03390192|Experimental|Dual-mode stimulation|"Dual-mode stimulation is applied over the bilateral primary motor cortex (M1) using active rTMS and active tDCS. 1 Hz of rTMS is applied over the contralesional M1 for 20 minutes with simultaneous application of anodal tDCS on the ipsilesional M1.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
2879898|NCT03390192|Active Comparator|Single sham stimulation|"Single sham stimulation is applied over the bilateral primary motor cortex (M1) using active rTMS and sham tDCS. 1 Hz of rTMS over the contralesional M1 was applied for 20 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the ipsilesional M1.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
2879899|NCT03390179||diabetes|Patient with non insulin diabetes
2879900|NCT03390179||control|Patient without diabete
2879901|NCT03390166|Active Comparator|GPO Tri Fluvac vaccine|630 volunteers will receive a single dose of the seasonal trivalent inactivated influenza vaccine (consisting of A/Michigan/45/2015 (H1N1)pdm-09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) produced by GPO Thailand. To be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
2879902|NCT03390166|Active Comparator|Licensed Influenza vaccine|315 volunteers will receive acLicensed Influenza vaccine (seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2017 (consisting of A/Michigan/45/2015 (H1N1)pdm-09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) 0.5 mL administered intramuscularly (IM) in the deltoid muscle of the non-dominant arm.
2880024|NCT03389243|Experimental|metamizole & paracetamol|analgesic drugs
2879903|NCT03390153|Experimental|semi flexible socket group|A new form of residuum containment is the semi-flexible carbon fiber prosthetic socket. A semi-flexible carbon fiber socket is constructed with the same security for the subject in mind, and is even more lightweight than a rigid socket. The carbon fiber and resin used in a semi-flexible socket may provide the same durability and stability as previous designs, but will deform, intentionally, without failing (breaking). This distinct feature of semi-flexible sockets makes them a potential option for people living with limb loss. By moving slightly with the residual limb, the socket-user-interface should experience fewer forces/stresses, and yield greater comfort for the prosthetic user.
2879904|NCT03390153|Active Comparator|rigid fiber socket group|A rigid carbon fiber socket is constructed for security and is mechanically lightweight to ensure stability and efficient build height. Carbon is used for its durability and stability. It proves to be a detriment in comfort and flexibility. The standard for carbon fiber weaves come in two forms: Unidirectional (UD) and Bidirectional (BD). UD carbon fiber has a zero-degree alignment, which is highly durable when compressed, but has low torsional durability. The BD carbon fibers are aligned in a 90 degree angle allowing for moderate compression and torsional strength. When oriented at 45 degrees to the line of progression, fibers become more flexible and exhibit greater torsional strength. Resins and glass composites are added to ensure security and sturdiness.
2879905|NCT03390140|Experimental|Group|ReInventing Yourself after SCI structured group CBT and ReInventing Yourself after SCI study-specific workbook
2879906|NCT03390140|Active Comparator|Indiv|ReInventing Yourself after SCI study-specific workbook and ReInventing Yourself after SCI YouTube videos
2879907|NCT03390140|No Intervention|Control|No group sessions, no YouTube videos, no workbook
2879908|NCT03390127|Experimental|Group P|After LMA Supreme™ insertion, PEEP of 7 cmH2O would apply during general anesthesia with mechanical ventilation.
2879909|NCT03390127|No Intervention|Group Z|After LMA Supreme™ insertion, PEEP would not apply during general anesthesia with mechanical ventilation.
2879910|NCT03390114|Experimental|SHUTi Cognitive Behavioral Therapy|SHUTi (www.myshuti.com) is an evidence-based, cognitive-behavioral, online intervention for insomnia.
2879911|NCT03390114|No Intervention|Usual Care|Patients randomized to the Usual Care group will be encouraged to follow-up with their primary care or HIV provider. There will be no formal interaction with the participants between the Entry Visit and the Week 10 Visit. However, the participants will be encouraged to contact the study team for any changes in their condition. There will be no restrictions on the care that can be received, although we will assess changes in care during the trial.
2879912|NCT03390101|Experimental|BCD-085 Q2W|"Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 1 will be given BCD-085 every 4 weeks through Week 50."
2879913|NCT03390101|Experimental|BCD-085 Q4W|"Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 6 and Day 1 of Week 10. For the purpose of blind design, patients will receive a placebo (2 injections) on day 1 of week 4 and week 8.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will continue BCD-085 every 4 weeks through Week 50."
2879914|NCT03390101|Placebo Comparator|Placebo|"Patients in this arm (43 subjects) will be given two SC injections of placebo (1.0 mL each) on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2, Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 on Day 1 of Week 12, Day 1 of Week 13, Day 1 of Week 14 (induction), then every 4 weeks through Week 50."
2879915|NCT03390075||ResearchNow NuVal shoppers|a convenience sample of 665 shoppers at two NuVal chains.
2879916|NCT03390062|Experimental|apatinib|apatinib 500 mg orally daily until the untolerabale toxicities、desease progress or death
2879917|NCT03390049|Active Comparator|Fractional CO2 Laser Treatment|Fractional CO2 laser will be applied to the entire vestibule, anteriorly to the fourchette, and laterally to the labia majora. This takes approximately 5 minutes to complete. A treatment cycle will consist of three laser sessions separated by 6 weeks +/- 1 week. The procedures will take place in the outpatient clinic. EMLA cream will be applied to the introitus for 20 minutes and wiped clean and dried prior to each laser session. Subjects will be advised to avoid intercourse for at least 3 days after each laser session because a mild inflammatory reaction may last up to 48 hours after a laser session. Topical lidocaine 5% ointment may be used for any vulvar discomfort post-procedure.
2879918|NCT03390049|Sham Comparator|Sham Laser Treatment|A treatment cycle will consist of three laser sessions separated by 6 weeks +/- 1 week. The procedures will take place in the outpatient clinic. Subjects assigned to sham laser will undergo the same pre-treatment with EMLA cream and will receive the same post-treatment instructions as the fractional CO2 laser subjects.
2879919|NCT03390036|Experimental|Cingal|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH).
2879920|NCT03390036|Active Comparator|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose
2879921|NCT03390036|Active Comparator|Triamcinolone Hexacetonide (TH)|A 1 mL unit dose of Triamcinolone Hexacetonide (TH) supplied as 20 mg/ml.
2879922|NCT03390023||Hispanic Women|Hispanic women who have been pregnant within the past 5 years.
2879923|NCT03390023||Close Family Member|Close family member of participants in Group 1 - Hispanic Women.
2879924|NCT03390010|Active Comparator|Extra medication group|"-Procedure : Giving misoprostol plus syntocinon and methergibe drugs during CS~this group in which prevention of uterine atony is made by intrauterine misotac plus the usual syntocinon and methergine during cesarean section"
2879925|NCT03390010|Active Comparator|Active management of labour group|"Procedure: Giving syntocinon and methergine drugs during cesarean section~this group in which prevention of uterine atony is made by the usual active management of labour syntocinon and methergine during cesarean section"
2879926|NCT03389984|Experimental|Adalimumab|
2879927|NCT03389971|Active Comparator|multi-sidehole catheter|
2879929|NCT03389945|Active Comparator|25G Dural Puncture Epidural Block|Patients will receive a dural puncture epidural block with a 25 gauge spinal needle.
2879930|NCT03389945|Experimental|27G Dural Puncture Epidural Block|Patients will receive a dural puncture epidural block with a 27 gauge spinal needle.
2879931|NCT03389932|No Intervention|Standard of Care (Control)|For patients who are randomized to the control condition and who are or become potentially eligible for transplant during their enrollment in the study, they will not receive any additional interventions during the study period. Patients in this condition will only receive the education that is administered by the KPSC Kidney Transplant Program and will not receive any educational materials designed for the intervention group of this study.
2879932|NCT03389932|Experimental|Patient-Guided|Patients in the ET@Home study condition will receive four modules of video and print transplant education over a 6-month period. After each module is mailed, 3 postcards are mailed weekly that recap important transplant educational content covered within the videos. Patients will have the opportunity to participate in a texting component of ET@Home that also sends small pieces of educational content and learning reminders by phone each week.
2879933|NCT03389906|Experimental|Gold|Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants).
2879934|NCT03389893|Experimental|Dupilumab w/OLE|"Participants will receive a loading dose of dupilumab (two 300 mg subcutaneous (subcut) injections (total of 600 mgs)) on Day 0, followed by 300 mg dose of dupilumab by subcut injection every 2 weeks (Days 14 and 28).~Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of two subcut administered injections (one 300 mg dose of dupilumab and one dose of placebo, in order to protect prior masking/blind).Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98.~The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose."
2879935|NCT03389893|Placebo Comparator|Placebo Comparator w/OLE|"Participants will receive a loading dose of placebo (two placebo subcutaneous (subcut) injections) on Day 0 followed by one dose of placebo by subcut injections every 2 weeks (Days 14 and 28).~Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of dupilumab (two 300 mg subcut injections (total of 600 mgs)-protection of prior masking/blind maintained). Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98.~The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose."
2879936|NCT03389880|Active Comparator|Patellar denervation|
2879937|NCT03389880|Experimental|Non-patellar denervation|
2879938|NCT03389867|Experimental|Male Sexual Health Formulation|Kaempferia parviflora extract 100mg daily
2879939|NCT03389854|Sham Comparator|Group 1 - Control|No treatment will be administered for the initial 3 months. This are is necessary as Peyronie's disease may result in changes in length and curvature as a function of the disease process. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.
2879940|NCT03389854|Experimental|Group 2 - PTT 1x daily x 3 months|Men will utilize penile traction therapy for 30 minutes once daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
2879941|NCT03389854|Experimental|Group 3 - PTT 2x daily x 3 months|Men will utilize penile traction therapy for 30 minutes twice daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
2879942|NCT03389854|Experimental|Group 4 - PTT 3x daily x 3 months|Men will utilize penile traction therapy for 30 minutes three times daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
2879943|NCT03389841|Active Comparator|Intervention|Education of the caregiver
2879944|NCT03389841|No Intervention|No intervention|Usual care
2879945|NCT03389828||1|The study population will consist of approximately 340 focus groups participants.
2879946|NCT03389815|Experimental|WX-0593 Tablets|The first part is a dose-escalation design in patients with ALK/ROS1-positive solid tumor. The second part is an expansion in non-small cell lung Cancer (NSCLC) characterized by abnormalities in ALK expression.
2879947|NCT03389802|Experimental|Stratum 1|The recurrent, progressive, or refractory primary malignant non-brainstem CNS tumor patients will be treated with APX005M.
2879948|NCT03389802|Experimental|Stratum 2|The newly diagnosed diffuse intrinsic pontine gliomas (DIPGs) patients will be treated with APX005M.
2879949|NCT03389789|Experimental|Oral glucose solution + maternal holding|Infants will receive 2 mL of oral glucose solution two minutes before the heel-prick and will be held in the mothers' lap (maternal relationship) throughout the painful procedure.
2879950|NCT03389789|Experimental|Breastfeeding|Infants will be breastfed two minutes before the heel-prick and throughout the painful procedure.
2879951|NCT03389789|Active Comparator|Oral glucose solution|Infants will receive 2 mL of oral glucose solution given two minutes before the heel-prick on a changing table.
2879952|NCT03389789|Active Comparator|Oral expressed breastmilk|Infants will receive 2 mL of expressed breastmilk given two minutes before the heel-prick on a changing table.
2879953|NCT03389763|Experimental|SPI-guided remifentanyl|remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50%
2879954|NCT03389763|Experimental|PRD-guided remifentanyl|solution remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50%
2879955|NCT03389763|Experimental|BBS-guided remifentanyl|BBS assessment every 5 minutes, solution remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute; when BBS>2, infusion speed of remifentanyl will be increased by 50%
2879956|NCT03389750|Active Comparator|Intravenous Challege Drug: Oxymorphone|Intravenous (IV) Dose Range: 0, 18, 32, 56 mg/70kg of the participant's body weight
2879957|NCT03389750|Active Comparator|Intravenous Challege Drug: Oxycodone|IV Dose Range: 0, 18, 32, 56 mg/70kg of the participant's body weight
2879958|NCT03389750|Active Comparator|Intravenous Challege Drug: Morphine|IV Dose Range: 0, 18, 32, 56 mg/70kg of the participant's body weight
2879959|NCT03389750|Active Comparator|Intravenous Challege Drug: Hydromorphone|IV Dose Range: 0, 5.6, 10, 18 mg/70kg of the participant's body weight
2879960|NCT03389750|Placebo Comparator|Intravenous Challege Drug: Placebo|IV saline
2879961|NCT03389737|Experimental|Experimental|Experimental group will have monthly contact with the physicians, during which the athletes will receive individualized care and guidance in support of their performance goals.
2879962|NCT03389737|Active Comparator|Control|Control group will not have monthly contact with the physicians.
2879963|NCT03389724|Experimental|Group capoten (Intervention arm)|Patients will receive prophylactic ACE-I(Capoten®) at day 1 of initiation of chemotherapy and is to be continued for 1 year after the end of treatment. Patients will remain on this arm until they experience any of the study primary or secondary end-point where they will be off-study and will receive cardiotoxicity treatment independently.
2879964|NCT03389724|No Intervention|Group standard treatment (Control arm)|Patients will not receive ACE-I as prophylaxis, and will be monitored and evaluated for first signs of cardiotoxicity based on the above mentioned end-points.
2879965|NCT03389698|Active Comparator|Heatlthy Control Group|cognitively normal (CN) subjects in two age groups: young(20-40) and old (65-85)
2879966|NCT03389698|Active Comparator|Amnestic mild cognitive impairment (aMCI)|32 participants who have aMCI.
2879967|NCT03389685|Experimental|Platelet Rich Plasma|Platelet Rich Plasma will be prepared using Genesis CS EmCyte PurePRP II system.
2879968|NCT03389685|Placebo Comparator|Saline Placebo|Unmarked syringe with 5 ml of saline
2879969|NCT03389672||spinal anesthesia|The anesthesia technique were applied with modified approach and conventional approach
2879970|NCT03389672||epidural anesthesia|The anesthesia technique were applied with modified approach and conventional approach
2879971|NCT03389672||combined spinal-epidural anesthesia|The anesthesia technique were applied with modified approach and conventional approach
2879972|NCT03389659|Experimental|Vitamin D3 group|vitamin D3 2000IU (400IU*5pills） po. qd continue to disease progression plus XELOX (oxaliplatin 130mg/m2 d1; capecitabine 1000mg/m2 bid po. d1-14; q3w) or mFOLFOX (oxaliplatin 85mg/m2，d1; leucovorin 400mg/m2，d1；5-fluorouracil 400mg/m2，d1; 5-fluorouracil 2400mg/m2 continue 46h, q2w)
2879973|NCT03389659|Placebo Comparator|control group|placebo 5 pills po. qd continue to disease progression plus XELOX (oxaliplatin 130mg/m2 d1; capecitabine 1000mg/m2 bid po. d1-14; q3w) or mFOLFOX (oxaliplatin 85mg/m2，d1; leucovorin 400mg/m2，d1；5-fluorouracil 400mg/m2，d1; 5-fluorouracil 2400mg/m2 continue 46h, q2w)
2879974|NCT03389646|Active Comparator|Treated with Device: Including sham|"Treated with CERAMENTTM|G or V for filling of bone defects in the tibia and/or femur and/or the acetabulum."
2879975|NCT03389646|No Intervention|Control|Control without CERAMENT device
2879976|NCT03389633|Experimental|Rehabilitation group|this group follows a 3 months rehab program
2879977|NCT03389633|No Intervention|No rehabilitation|This group does not follow a rehab program
2879978|NCT03389620|Active Comparator|Transforaminal Cervical Epidural Corticosteroid Injections|
2879979|NCT03389620|Experimental|Lateralized Interlaminar Epidural Corticosteroid Injections|
2879980|NCT03389607||diabetic|the patients must have diabetic disease
2879981|NCT03389607||control|the patients must not have diabetic
2879982|NCT03389594|No Intervention|Surgical guide designed from voxel size 0.2mm|Surgical guide will be designed based on CBCT voxel size 0.2mm
2879983|NCT03389594|Active Comparator|Surgical guide designed from voxel size 0.4m|Surgical guide will be designed based on CBCT voxel size 0.4 mm
2879984|NCT03389568|Experimental|Intervention for caregivers of ICU patients|
2879985|NCT03389555|Experimental|Vitamin C, Vitamin B1, Corticosteroids|"The combination of vitamin C, vitamin B1, hydrocortisone :~Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days~Vitamin B1 (thiamine) 100mg every 6 hours x 4-days~Hydrocortisone 50mg every 6 hours x 4-days"
2879986|NCT03389555|Placebo Comparator|Placebo|Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components
2879987|NCT03389542|Experimental|Early mitral valve repair|Surgery will be performed within 3 months after randomization. Clinical interview will be performed at discharge, at 6 months and afterwards yearly until the end of follow-up. Echocardiography will be performed at discharge, at 6 months and at the end of follow-up.
2879988|NCT03389542|Active Comparator|Conservative management|Patients will be followed up by clinical interview and echocardiography every 6 months.
2879989|NCT03389516|Active Comparator|Polymem breast pads|
2879990|NCT03389516|Active Comparator|Lanolin|
2879991|NCT03389503|Active Comparator|Right radial approach|Right radial approach for coronary angiography and coronary intervention
2879992|NCT03389503|Active Comparator|Left radial approach|Left radial approach for coronary angiography and coronary intervention
2879993|NCT03389490|Experimental|Active|Insulin glargine 300U/ml
2879994|NCT03389490|Active Comparator|Control|Neutral Protamine Hagedorn insulin
2879995|NCT03389477|Experimental|Cohort 1: 1: palbociclib, 2: Cisplatin & IMRT, 3: palbociclib|"Step 1: Neoadjuvant palbociclib monotherapy (125 mg/day, Days 1-21 of a 28-day cycle for two cycles)~Step 2: Cisplatin 100 mg/m^2 given on Days 1 and 22 with accelerated IMRT 70 Gy to be administered over 6 weeks~Step 3: Adjuvant palbociclib 125 mg/day, days 1-21 of each 28-day cycle for six cycles. Adjuvant palbociclib will begin 16 to 22 weeks following completion of cisplatin & IMRT"
2879996|NCT03389477|Experimental|Cohort 1: 1: palbociclib, 2: Cetuximab & IMRT, 3: palbociclib|"Step 1: Neoadjuvant palbociclib monotherapy (125 mg/day, Days 1-21 of a 28-day cycle for two cycles)~Step 2: Cetuximab given one week before RT and then weekly with accelerated IMRT 70 Gy to be administered over 6 weeks~Step 3: Adjuvant palbociclib 125 mg/day, days 1-21 of each 28-day cycle for six cycles. Adjuvant palbociclib will begin 16 to 22 weeks following completion of cetuximab & IMRT"
2879997|NCT03389464|Experimental|confrontation group|computer-based confrontation with dysfunctional beliefs
2879998|NCT03389464|No Intervention|control group|no computer-based confrontation with dysfunctional beliefs
2879999|NCT03389451|Experimental|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET
2880000|NCT03389438|Experimental|Experimental arm|Participants who were treated with autologous Tcm cells immunotherapy.
2880001|NCT03389438|No Intervention|No intervention arm|Participants who were treated with no autologous Tcm cells immunotherapy.
2880002|NCT03389425|Experimental|SIMPLE weightloss group|
2880003|NCT03389412|Experimental|Treatment without evaluating the home recordings, medicin.|Children will receive desmopressin without evaluating the home recordings.
2880004|NCT03389412|Experimental|Treatment without evaluating the home recordings, alarm.|Children will receive conditional alarm without evaluating the home recordings.
2880005|NCT03389412|Active Comparator|Treatment based on home recordings, polyuria.|Children with polyuria based on the home recordings will receive desmopressin.
2880006|NCT03389412|Active Comparator|Treatment based on home recordings, reduced bladder capacity.|Children with reduced bladder capacity based on the home recordings will receive the conditional alarm.
2880007|NCT03389412|Active Comparator|Treatment based on home recordings, both.|Children with polyuria and reduced bladder capacity based on the home recordings will receive desmopressin and the conditional alarm.
2880008|NCT03389412|Active Comparator|Treatment based on home recordings, none.|Children with neither nocturnal polyuria nor reduced bladder capacity based on the home recordings will be randomized to either desmopressin or alarm treatment. If there is no effect of the treatment, the treatment can be switched.
2880009|NCT03389399||Brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days|This is a single-arm study of patients who plan on starting brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days to brigatinib 180 mg QD. Study procedures include PFTs, 6minute walk test, Modified Borg dyspnea scale (mBDS), and phlebotomy before participants commence brigatinib and on days 2 and 8 of brigatinib treatment. Participants that develop a peak reduction in DLCO of 20% or more from baseline whose DLCO does not return to their baseline level on day 8 may, at the discretion of the investigator, undergo repeated testing on a subsequent time point (e.g., day 15) for serial observation to ensure resolution of EOPE if that is the suspected cause of DLCO reduction.
2880010|NCT03389386||Congestive Heart Failure (NYHA I-IV)|"N=90~Patients with a clinically documented diagnosis of congestive heart failure (CHF), as assessed per New York Heart Association (NYHA) functional classification will be prospectively enrolled in this group. Patients will be of both sexes, enrolled in 1:1 ratio.~All subjects in this group will undergo blood withdrawal for laboratory analysis, transthoracic echocardiography (TTE) examination and will be treated with the Standard-of-care treatment according to their clinical condition."
2880011|NCT03389386||Healthy Control Group|"N= 50~Healthy volunteers (both sexes, enrolled in 1:1 ratio) with a negative history of cardiovascular diseases will be enrolled in this group that will serve as a study control.~All subjects in this group will undergo blood withdrawal for laboratory analysis and transthoracic echocardiography (TTE) examination."
2880012|NCT03389373|Other|Child with full primary dentition|All children who match inclusion criteria are eligible to have a saliva sample obtained which will act as a proxy for bacterial levels. High bacteria levels are correlated with a higher risk of developing cavities.
2880013|NCT03389347|Experimental|Device feasibility (high-throughput assay, sequencing)|Patients undergo collection of bone marrow aspirate and blood for high-throughput drug sensitivity assay and mutational analysis using next generation sequencing. Patients and their treating physicians receive the results of the tests. Treatment decisions are then made by the patients and their treating physicians.
2880014|NCT03389334|Experimental|massage group|Subjects will complete the SF-36, ODI, demographics surveys and then will receive pre-treatment range of motion, muscle strength and visual analogue pain scale prior to massage. Then will have a 45-minute myofascial release massage. Then they will fill out the visual analogue pain scale again. (Approximately 90-minutes) The second and third visits: visual analogue scale prior to the treatment; 45-minute massage, by the same therapist who treated them during the initial visit, and will fill out a second visual analog pain scale following the treatment. (Approximately 60-minutes) The fourth visit: visual analogue pain scale and 45-minute massage; post-treatment SF-36, ODI surveys, visual analogue pain scale, post-treatment range of motion and muscle strength.
2880015|NCT03389321|Experimental|Treatment A-B|All subjects will receive treatment A followed by treatment B. Treatment A consists of a single oral dose (1 mg) of riociguat (Adempas) on Day 1. Treatment B consists of a loading oral dose of 30 mg macitentan (Opsumit) (3 tablets of 10 mg) on Day 5, then 10 mg of macitentan once daily from Day 6 to Day 15, with a concomitant administration of riociguat (1 mg) on Day 10.
2880016|NCT03389308|Experimental|Treatment period|"Subjects with active lesions as determined Investigator's clinical assessment, will initiate a cycle of applying Diacerein 1% Ointment once-daily, study medication, at home to their EBS lesions for 8 weeks.~Following the Treatment Period, subjects will go Off Treatment for 8 weeks using only investigator approved bland, non-medicated emollient/moisturizer, routine cleansing products and sunscreens. As determined Investigator's clinical assessment, subjects may enter into another Treatment Period of 8 weeks.~The duration of a subject's participation in the extension study may be as short as 32 weeks or as long as 52 weeks depending on the cycle initiation schedule for each individual subject."
2880017|NCT03389295|Experimental|Reduced Target Delineation Chemoradiotherapy|All patients were assigned to receive induction chemotherapy (IC) followed by IMRT with adjuvant chemotherapy (AC). IMRT was administered 2 weeks after IC, and AC was administered 1 month after IMRT. IC or AC (TPF regimen) comprised docetaxel (60 mg/m2/day, day 1), cisplatin (25 mg/m2/day, days 1-3), and 5-fluorouracil (500 mg/m2/day with a 120-h infusion) administered once every 3 weeks for two cycles. During radiotherapy, involved retropharyngeal lymph nodes and intracavity lesions of the primary tumor were delineated according to the post-IC volume, whereas the remainder of the involved tissues (eg, pterygopalatine fossa) of the primary tumor were delineated according to the pre-IC volume of the primary tumor as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for delineation.
2880018|NCT03389269||Obese patients treated with AspireAssist|Healthy, obese with BMI > 27, treated with AspireAssist for weight management, the postprandial glucose metabolism will be tested with a meal test
2880019|NCT03389269||Matched controls|Healthy, obese with BMI > 27, the postprandial glucose metabolism will be tested with a meal test
2880020|NCT03389256|Experimental|apatinib combine with EGFR-TKI|Every 4 weeks 1 cycle, evaluated the efficacy and safety once every 2 cycles, treat until disease progression or intolerable toxicity
2880021|NCT03389256|Active Comparator|EGFR-TKI|Every 4 weeks 1 cycle, evaluated the efficacy and safety once every 2 cycles, treat until disease progression or intolerable toxicity
2880022|NCT03389243|Experimental|metamizol|analgesic drug
2880023|NCT03389243|Experimental|paracetamol|analgesic drug
2880025|NCT03389230|Experimental|STRATUM I (Intratumoral/Intracavitary delivery)|Patients receive autologous HER2(EQ)BBζ/CD19t+ Tcm cells via intratumoral/intracavitary catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to alternative delivery routes for the optional infusions.
2880026|NCT03389230|Experimental|STRATUM II (Intraventricular delivery)|Patients receive autologous HER2(EQ)BBζ/CD19t+ Tcm cells via intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Patients who progress on intraventricular administration may move to alternative delivery routes for the optional infusions.
2880027|NCT03389230|Experimental|STRATUM III (Dual delivery)|Patients receive autologous HER2(EQ)BBζ/CD19t+ Tcm cells via intratumoral/intracavitary catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
2880028|NCT03389217|Experimental|Real-tDCS + rehabilitation programme|The real transcranial Direct Current Stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 minutes over the the left dorsolateral prefrontal cortex and rehabilitation programme for prevention and management of pain.
2880029|NCT03389217|Active Comparator|Sham-tDCS + rehabilitation programme|The sham transcranial Direct Current Stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over left dorsolateral prefrontal cortex and rehabilitation programme for prevention and management of pain.
2880030|NCT03389204||Breast surgery and exercise|Patient that underwent breast surgery only without other intervention with exercise of the upper limb and instruction to continue after discharge.
2880031|NCT03389204||Breast surgery and no exercise|Patient after breast surgery alone are discharged without exercise and instructions.
2880032|NCT03389204||Breast, axilar surgery with exercise|Patients that underwent surgery of the breast and axilar lymph node surgery with exercise of the upper limb and instruction to continue after discharge.
2880033|NCT03389204||Breast, axillar surgery without exercise|The patients that underwent surgery of the breast and axilar nodes samples or dissection are discharged without exercise and instructions.
2880034|NCT03389204||Reconstructive breast with exercise|Patients that underwent breast cancer surgery and immediate reconstruction with exercises of the upper limb and instruction to continue after discharge.
2880035|NCT03389204||Reconstructive breast without exercise|Patients that underwent breast cancer surgery and immediate reconstruction without exercise and discharged without instructions.
2880036|NCT03389191|Experimental|Patients with Viral Uveitis|Oral acyclovir 100 mg three times a day (TID).
2880037|NCT03389178||stress group (SG)|"We will identify prospective subjects according with the inclusion criteria of the study, consistent on singleton pregnant women between 18 to 45 years of age in their third trimester (at least 28 weeks gestation). Upon acceptance participants will enter to Phase I-IV.~Women and participants will be categorized as stressed or controls after scoring the Cohen Perceived Stress Scale-10 (PSS-10). The PSS-10 has been validated in German speaking populations and will be a quick tool for screening stress among prospective subjects. For the purposes of the current study, a participant with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. Recruitment will continue until reaching the aimed cohort of n=75 subjects/group."
2880038|NCT03389178||control group (CG)|"For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score < 19 will be entered into Phase II as control.~Recruitment will continue until reaching the aimed cohort of n=75 subjects/group."
2880039|NCT03389165|Experimental|Elderly adults|Stair climbing with and without a wearable hip assist robot
2880040|NCT03389139|Active Comparator|spinal anesthesia|Patients in this group were randomized to receive spinal anesthesia. (Near infrared spectroscopy (spinal anesthesia))
2880041|NCT03389139|Active Comparator|general anesthesia|Patients in this group were randomized to receive general anesthesia. (Near infrared spectroscopy (general anesthesia)).
2880042|NCT03389126|Experimental|Avelumab|Avelumab 10 mg/kg every 2 wks until disease progression or unacceptable toxicity
2880043|NCT03389113|Experimental|Whole body vibration group|Whole body vibration group performed five sessions of whole body vibration exercise via a vibrating platform (Galileo® Advanced Plus, Novotec Medical, Pforzheim, Germany) with a magnitude of 20 Hz and an amplitude of 4 mm.
2880044|NCT03389113|Active Comparator|Exercise only group|The control group performed the same session without vibration.
2880045|NCT03389100|Experimental|18F-MK6240 injection|intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), IV, total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
2880046|NCT03389087|Experimental|Apatinib + Etoposide Capsule|Apatinib + Etoposide Capsule
2880047|NCT03389061|Active Comparator|sofosbuvir/velpatasvir tablet|Single-dose sofosbuvir/velpatasvir as a whole tablet in a fasted state.
2880048|NCT03389061|Experimental|sofosbuvir/velpatasvir crushed|Single-dose crushed sofosbuvir/velpatasvir in a fasted state.
2880049|NCT03389048|Experimental|degenerative lumbar spine disease|patients who suffer from unilateral degenerative lumbar spine disease, undergo SLR test while being recorded by PMD-200
2880050|NCT03389035|Experimental|CARCIK-CD19|
2880051|NCT03389022|Active Comparator|Treatment|0,15mg/kg (LBM) of intravenous single pre-incisional injection of ketamine given for bariatric patients in the operating room.
2880052|NCT03389022|Placebo Comparator|Control|The same amount of intravenous single pre-incisional injection of saline for bariatric patients in the operating room.
2880081|NCT03388840|Placebo Comparator|conventional follicular unit extraction|normal saline will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia
2880082|NCT03388827|Experimental|Laminaria|Laminaria tent was introduced in the cervical canal
2880083|NCT03388827|Active Comparator|Laminaria plus Misoprostol|Laminaria and Misoprostol were introduced
2880053|NCT03389009||smartphone abusers|"Auto refractometer without cycloplegia Uncorrected visual acuity (logMAR conversion). Anterior segment slit lamp examination UBM examination settings :Supine decubitus position.5150 Vumax (Sonomed, USA) under standard illumination Parameters that will be measured: corneal thickness, anterior chamber depth, angle to angle distance, cornea-posterior capsular lens distance, lens thickness, pupillary diameter, angle of anterior champer and trabecular-ciliary process distance.~Cycloplegic refraction UBM examination will be repeated after cycloplegia with the same settings. The patients found to have spasm of accommodation will be subjected to ways to relief the spasm of accommodation and repetition of UBM if possible"
2880054|NCT03389009||smartphone non users|"Auto refractometer without cycloplegia Uncorrected visual acuity (logMAR conversion). Anterior segment slit lamp examination UBM examination settings :Supine decubitus position.5150 Vumax (Sonomed, USA) under standard illumination Parameters that will be measured: corneal thickness, anterior chamber depth, angle to angle distance, cornea-posterior capsular lens distance, lens thickness, pupillary diameter, angle of anterior champer and trabecular-ciliary process distance.~Cycloplegic refraction UBM examination will be repeated after cycloplegia with the same settings. The patients found to have spasm of accommodation will be subjected to ways to relief the spasm of accommodation and repetition of UBM if possible"
2880055|NCT03388996||Benign ovarian disease|The group consists of patients of benign ovarian diseases and health conditions (eg infertility), who would accept the tests of pelvic microbiomes.
2880056|NCT03388996||Malignant ovarian disease|The group consists of patients of high grade serous carcinoma, who would accept the tests of pelvic microbiomes.
2880057|NCT03388983|Experimental|6-week prehabilitation group|6-week prehabilitation
2880058|NCT03388983|No Intervention|Control group|Patients will receive standard preoperative care (including information about the surgery from an orthopedic surgeon, and a pamphlet summarizing tips of maintaining proper posture and staying active). The usual postoperative care does not include routine rehabilitation program though a short course of rehabilitation may be given based on orthopedic surgeons' discretion.
2880059|NCT03388970|Experimental|research group|normal saline 100ml+ vitamin K1 20mg ivgtt qd day0 and day1。
2880060|NCT03388970|Placebo Comparator|placebo group|normal saline100ml + normal saline 2 ml ivgtt qd day0 and day1
2880061|NCT03388957|Experimental|Propranolol|Patients in this group will be given Propranolol 0.5 mg/Kg orally.
2880062|NCT03388957|Experimental|Midazolam|Patients in this group will be given Midazolam 0.5 mg/Kg orally.
2880063|NCT03388957|Experimental|Propranolol and Midazolam|Patients in this group will be given Propranolol and Midazolam with a dose of 0.5 mg/Kg orally for each drug.
2880064|NCT03388957|No Intervention|Placebo|A placebo drug will be given in this group.
2880065|NCT03388944|Experimental|PCT group|PCT group
2880066|NCT03388944|No Intervention|Standard practice group|No intervention
2880067|NCT03388931|Experimental|Study group|Increased dose of radiation therapy for locally advanced squamous cell carcinoma of the larynx or hypopharynx. Patients will also receive standard-of-care chemotherapy with the treatment regimen to be determined by the treating physicians.
2880068|NCT03388918|Experimental|Intervention group|"The intervention group has three steps:~Step I: Titration of medicine ( 0-3 months)~Step II: Telerehabilitation program at healthcare center or by call center ( 3 months)~Step III: Rehabilitation in everyday life ( 6 months)~The patients is monitoring vital signs such as blood pressure, pulse, weight, steps, respiration, and sleep. Have access to a Heart Portal that is an information cite on heart failure. Via the portal patients can see measured values & communicate with staff. Every other week the patients fill in an online questionnaires on symptoms, sleep and well being."
2880069|NCT03388918|No Intervention|Traditional rehabilitation group|"This group follows the International Cardiac Guidelines. There are three steps in this arm:~Step I: Titration of medicine (3 months).~Step II: Traditional rehabilitation at the healthcare center ( 3 months).~Step III: Everyday life with HF ( 6 months)~The participants do not have access to the Heart Portal and is not monitoring any vital signs."
2880070|NCT03388905|Experimental|Wearable Cardioverter Defibrillator group|
2880071|NCT03388892|Experimental|Drug-Eluting Balloon|PTA with DEB at venous anastomotic stenosis of AVG
2880072|NCT03388892|Active Comparator|Plain Balloon|PTA with PCB at venous anastomotic stenosis of AVG
2880073|NCT03388879|Experimental|Circular frame external fixator|A Taylor Spatial Frame should consist of 2 rings with 4 half pins/K-wire attached to each ring. If possible 3, not hydroxyapatite-coated, half pins and one K-wire should be attached to each ring. The half pins/K-wire should be spread in distance and direction for optimum stability.
2880074|NCT03388879|Active Comparator|Intramedullary nail|Nailing technique according to Karladani and Styf published technique (ref: Karladani AH, Styf J. Percutaneous intramedullary nailing of tibial shaft fratures: a new approach for prevention of anterior knee pain. Injury, Int. J. Care Injury 32 (2001) 736-39)
2880075|NCT03388866|Active Comparator|Mite extract sublingual immunotherapy|"Use of mite extract sublingual immunotherapy (SLIT) with increasing weekly doses of extracts of mites Dermatophagoides pteronyssinus and Dermatophagoides farinae (60% and 40% respectively), as represented below:~Weekly dose schedule Monday Wednesday Friday~st week 1 drop 2 drops 4 drops~nd week 6 drops 8 drops 8 drops~Monthly Dilution Schedule Dilution of mite extract~1st and 2nd weeks (1st month) 1: 1000000 v: v 3rd and 4th weeks (1st month) 1: 100000 v: v~1st and 2nd weeks (2nd month)1: 10000 v: v 3rd and 4th weeks (2nd month) 1:1000 v: v~1st and 2nd weeks (3rd month) 1: 100 v:v 3rd and 4th weeks (3rd month) 1:10 v:v 3rd to 18th month 1:10 v: v"
2880076|NCT03388866|Placebo Comparator|SLIT placebo|"Patients in the control group will be submitted to the same administration schedule, but with allergen extract diluent (doubly distilled water solution and glycerin), as described below:~Weekly dose schedule Monday Wednesday Friday~st week 1 drop 2 drops 4 drops~nd week 6 drops 8 drops 8 drops~Intervention: Placebo - Immunotherapy allergen diluent"
2880077|NCT03388853|Experimental|Acetylcysteine/Doxofylline|Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily for four weeks.
2880078|NCT03388853|Placebo Comparator|Placebo|Placebo once daily for four weeks
2880079|NCT03388840|Experimental|Adipose derived stem cells suspention|suspension rich in adipose derived stem cells will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia
2880080|NCT03388840|Active Comparator|Platelet rich plasma|platelet rich plasma will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia
2880084|NCT03388814|Active Comparator|Bupivacaine Group|Those patients randomized to surgeon infiltration will have a skin wheal performed with lidocaine at the site where an actual pectoralis nerve block would be performed as visualized using ultrasound. Surgeons performing infiltration techniques will be blinded to the contents of the injectate and those patients randomized to surgeon infiltration will receive pharmacy study drug labeled bupivacaine injected in the same fashion and volume as the saline group for oncologic and plastic surgery.
2880085|NCT03388814|Experimental|Pectoralis Nerve block Group|Those patients who are randomized to pectoralis nerve block will have randomization immediately preoperatively and will undergo the nerve block procedure using local anesthetic in the standard fashion. Those patients randomized to pectoralis block will have a standard volume of normal saline injected for oncologic and plastic surgery.
2880086|NCT03388801|Experimental|Spa therapy|Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).
2880087|NCT03388788|Experimental|Normal Weight|Healthy lean controls [18.5<BMI<25 kg/m2 and WC <94/80 (men and women respectively)] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).
2880088|NCT03388788|Experimental|Overweight|Healthy obese [30≤BMI<40 and waist circumference (WC) ≥94/80 (men and women respectively)] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).
2880089|NCT03388775||Patients with deep venous thrombosis|"Five-year prospective records of deep venous thrombosis have been collected by the RHEUNI group of five public schools in the State of São Paulo.~Demographic data of patients will be evaluated along with the main risk factors, clinical picture, diagnostic methods, use of different drugs to treat the disease and its complications."
2880090|NCT03388762|Active Comparator|GlucoSupreme™ Herbal|Each daily serving of four GlucoSupreme™ Herbal tablets includes extracts from: cinnamon bark (Cinnamomum cassia) 500 mg, banaba leaf (Lagerstroemia speciosa standardized to 1% corosolic acid) 200 mg, kudzu root (Pueraria lobata standardized to 40% isoflavones) 200 mg, fenugreek seed (Trigonella foenum-graceum standardized to contain 60% saponins) 200 mg, and gymnema leaf (Gymnema sylvestre standardized to contain 25% gymnemic acid). Additionally, American ginseng root (Panax quinquefolius standardized to contain 5% ginsenosides) 200 mg, and berberine HCl derived from bark (Berberis aristata) 500 mg. Other ingredients include Cellulose (capsule), microcrystalline cellulose, silicon dioxide, and vegetable stearate.
2880091|NCT03388762|Placebo Comparator|Control|The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
2880092|NCT03388749|Experimental|Liposomal annamycin|
2880093|NCT03388736|No Intervention|No lavender|No mist will be diffused into the environment.
2880094|NCT03388736|Active Comparator|0,1 lavender|0,1 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
2880095|NCT03388736|Active Comparator|0,3 lavender|0,3 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
2880096|NCT03388723||Arm 1: Discovery phase|"Approximately 150 women with Gestational Diabetes Mellitus (GDM) and 150 controls, and their offspring will be recruited in Pune (from KEM Hospital and Vadu). The objective will be:~Identification of epigenetic signatures~Measurements of B vitamins and 1-C metabolites in mothers' blood and cord blood~Glucose, insulin and lipids in mothers during pregnancy~Anthropometry and blood pressure"
2880097|NCT03388723||Arm 2: Validation phase|Approximately 200 women with Gestational Diabetes Mellitus (GDM) and 200 controls, and their offspring will be recruited in Punjab, and 150 stored cord blood samples of GDM offspring in Pune will be investigated to validate the epigenetic signatures discovered in Arm 1.
2880098|NCT03388723||Arm 3: Stability phase|"Approximately 500 offspring of women with Gestational Diabetes Mellitus (GDM) from Pune (~ half below 10 years and the rest over 10 years) will be investigated to study:~Stability of epigenetic signatures in offspring through childhood and adolescence~Relation of these signatures with phenotype"
2880099|NCT03388671|Active Comparator|TAB Block|Patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Transversus abdominis plane block.
2880100|NCT03388671|Active Comparator|Psoas Block|Patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided psoas block.
2880101|NCT03388645|Experimental|1-Low Dose RSV challenge|The first four volunteers will receive a dose of 10^3PFU of RSV A2. This will be followed by daily clinical assessments and collection of nasal fluid and blood samples for virologic and immunologic assays. Subjects will have 2 follow-up outpatient visits at Day 28 and 56. Intervention: Single intranasal dose of 10^6.3 PFU of RSV A2 using a nasal atomizer on Day 0
2880102|NCT03388645|Experimental|2-4 - High Dose RSV A2|The volunteers for the following 3 cohorts of 7 volunteers will receive 10 PFU of RSV A2. This will be followed by daily clinical assessments and collection of nasal fluid and blood samples for virologic and immunologic assays. Subjects will have 2 follow-up outpatient visits at Day 28 and 56. Intervention: Single intranasal dose of RSV A2 at 10^7 PFU using a nasal atomizer on Day 0.
2880103|NCT03388632|Experimental|Lead-in doublet A|Lead-in doublet for initial safety evaluation: rhIL-15 given SC days 1-8 and 22- 29 + ipilimumab (anti- CTLA-4) given IV on day 8 (IL-15 doses are limited to first 4 cycles only)
2880104|NCT03388632|Experimental|Lead-in doublet B|Lead-in doublet for initial safety evaluation: rhIL-15 given SC days 1-8 and 22- 29 + nivolumab (anti-PD1) given IV on days 8, 22, and 36 (IL-15 doses are limited to first 4 cycles only)
2880105|NCT03388632|Experimental|Triplet|Triplet combination
2880106|NCT03388619|Experimental|1|Dose to prostate bed with integrated boost
2880107|NCT03388619|Experimental|2|Dose to prostate bed
2880108|NCT03388606|Experimental|1|GMI (Growth Mindset Intervention)
2880109|NCT03388606|Sham Comparator|2|Interactive video on emotion expression, structurally equivalent to GMI
2880110|NCT03388593|Placebo Comparator|Placebo|Placebo in addition to standard therapy
2880111|NCT03388593|Experimental|rhNRG-1|rhNRG-1 in addition to standard therapy
2880113|NCT03388567|Experimental|Staff pharmacy whith intervention|Staff pharmacy who will receive continuous education through technology and communication tools, as well as accompaniment and advice from a pharmaceutical chemist
2880114|NCT03388567|No Intervention|Staff pharmacy without intervention|Staff pharmacy who will receive only pharmacy information
2880115|NCT03388554|Active Comparator|Active tDCS|Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). The anode was placed with the middle of the electrode over a point midway between F3 and FP1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The cathode was located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients in the active tDCS group were maintained on their antipsychotic medications throughout the study period.
2880116|NCT03388554|Sham Comparator|Sham tDCS|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham tDCS group were maintained on their antipsychotic medications throughout the study period.
2880117|NCT03388541|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered at 0.4ug/kg/h (5mL/h) starting at the closure of the chest and continued during 10h.
2880118|NCT03388541|Placebo Comparator|Placebo|NaCl 0.9% will be administered at 5mL/h starting at the closure of the chest and continued during 10h.
2880119|NCT03388528|Experimental|Treatment Group|This is a single arm study where forty patients with a genetically or biochemically proven diagnosis of mitochondrial disease will be recruited from the mitochondrial CRESTA clinic and / or Medical Research Council Mitochondrial Disease Patient Cohort Study in Newcastle. All forty patients will be assessed prior to and following a 12 week low residue diet study intervention.
2880120|NCT03388515|Experimental|SSS11, 1.5mg|SSS11, 1.5mg, iv, single dose at Day 1;
2880121|NCT03388515|Experimental|SSS11, 3.0mg|SSS11, 3.0mg, iv, single dose at Day 1;
2880122|NCT03388515|Experimental|SSS11, 6.0mg|SSS11, 6.0mg, iv, single dose at Day 1;
2880123|NCT03388515|Experimental|SSS11, 12.0mg|SSS11, 12.0mg, iv, single dose at Day 1;
2880124|NCT03388515|Experimental|SSS11, 24.0mg|SSS11, 24.0mg, iv, single dose at Day 1;
2880125|NCT03388502|Experimental|Text Messaging (SMS) Bot|Patients undergoing total joint (hip & knee) arthroplasty will be enrolled in their physician's automated 'Text Messaging (SMS) Bot' in addition to receiving the routine perioperative education and instructions.
2880126|NCT03388502|Active Comparator|Routine Perioperative Instructions|Patients undergoing total joint (hip & knee) arthroplasty will receive only their 'Routine Perioperative Instructions'.
2880127|NCT03388489|Experimental|Mind-Body Walking|breathing, walking and meditation
2880128|NCT03388489|No Intervention|Usual care|maintain their daily activity
2880129|NCT03388476|Other|Suspicion of pulmonary hypertension|At Patients with suspicion of pulmonary hypertension, which get a right heart catheterization, in the context of the study the exhaled air, precious the endtidal carbon dioxide (CO2), before or after the right heart catheterization will be measured through capnography.
2880130|NCT03388463|Active Comparator|Omeprazole group|Patients received intravenous bolus of 80 mg omeprazole followed by 8mg/h infusion for the whole period of ICU stay.
2880131|NCT03388463|Placebo Comparator|Placebo group|Patients received intravenous omeprazole 40mg bolus dose once daily followed by normal saline infusion.
2880132|NCT03388450|Active Comparator|Omega 3|Patients received enteral nutrition supplemented with 1000 mg omega-3.
2880133|NCT03388450|Placebo Comparator|Placebo|Patients received enteral nutrition supplemented without 1000 mg omega-3.
2880134|NCT03388437|Experimental|NI-NAVA|Initial setting; NAVA level of 2; PEEP of 5-6 cm H 2 O, apnea time 5-10 seconds, target Edi maximum between 10-15 and minimum < 5 for 72 hours post extubation
2880135|NCT03388437|Active Comparator|NIPPV|Initial setting; PIP can be increased by 2 cm H 2 O from the pre-extubation PEEP of 5-6 cm for 72 hours post extubation
2880136|NCT03388424||Control|Healthy people of both sex
2880137|NCT03388424||quantification of microbiota in Brain|Patients of both sex with neural disorders and diseases
2880138|NCT03388424||quantification of microbiota in GI|Patients of both sex with gastrointestinal diseases
2880139|NCT03388424||quantification of microbiota in Lung|Patients of both sex with Respiratory diseases
2880140|NCT03388424||quantification of microbiota Metabolic|Patients of both sex with Metabolic Diseases
2880141|NCT03388424||quantification of microbiota in UG|Patients of both sex with Uro-genital Diseases
2880142|NCT03388411||Obese children|Children ≥95 ‰ between age 7 and 12 years
2880143|NCT03388411||Non-obese children|5‰< BMI <85 ‰ for children between the ages of 7 and 12 years
2880144|NCT03388398||Mother-Infant Pairs|Mothers or caregivers (at least 16 years of age) and their infants who are 9 to 18 months of age at the time of their survey.
2880145|NCT03388398||Mothers or caregivers|Mothers or caregivers (at least 16 years of age) who are 19 to 36 months postpartum at the time of the survey.
2880146|NCT03388398||Healthcare staff|Healthcare staff (employed staff and volunteers at least 18 years of age) at all participating healthcare facilities.
2880147|NCT03388398||Providers|Health care providers (at least 18 years of age) at select participating healthcare facilities.
2880148|NCT03388398||Patients|Patients (at least 18 years of age) receiving care at select participating healthcare facilities.
2880149|NCT03388385|Placebo Comparator|Placebo|Intervention: 250 mL Sodium Chloride 0.9% Intravenous Solution, representing control infusion, over 30 minutes.
2880150|NCT03388385|Active Comparator|Ferric carboxymaltose|Intervention: 1000 mg Ferinject in 250 mL 0.9%NaCl, representing medication in study infusion, over 30 minutes.
2880151|NCT03388372|Experimental|Nimotuzumab plus RT and temozolomide.|Nimotuzumab, administered once a week intravenously in addition to radiotherapy with concomitant and adjuvant temozolomide (TMZ) after surgery.
2880181|NCT03388164|Placebo Comparator|Escitalopram + Placebo|10mg escitalopram + 5mg placebo will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the active comparator by a local compounding pharmacy in Tulsa, Oklahoma.
2880182|NCT03388151|Active Comparator|Midazolam|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation
2880152|NCT03388359|Experimental|Allergic asthma|Bronchial asthma and sensitization to D. pteronyssinus allergen Interventions: Bronchial challenge with allergen (Dermatophagoides pteronyssinus, Dosimeter ProvoX (Ganshorns)); Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation (eosinophils, fibrobralst, airway smooth muscle cells); Inhibition of Wnt and Smad signaling pathways; Extracellular matrix turnover and deposition assessment.
2880153|NCT03388359|Active Comparator|Healthy subjects|"Healthy subjects without allergic and other chronic respiratory diseases (control group).~Interventions: Bronchial challenge with allergen (Dermatophagoides pteronyssinus, Dosimeter ProvoX (Ganshorns)); Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation (eosinophils, fibrobralst, airway smooth muscle cells); Inhibition of Wnt and Smad signaling pathways; Extracellular matrix turnover and deposition assessment."
2880154|NCT03388346|Experimental|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET
2880155|NCT03388333||Atrial fibrillation ablation group|Patients undergoing catheter ablation for the treatment of atrial fibrillation.
2880156|NCT03388333||Electrophysiological study group|Patients undergoing a diagnostic electrophysiological study without ablation.
2880157|NCT03388333||Atrial flutter ablation group|Patients undergoing catheter ablation of right atrial flutter at the cavotricuspid isthmus.
2880158|NCT03388320|Experimental|Participants receiving A-CHESS|Participants will be provided access to the smartphone application A-CHESS (intervention) that will be downloaded to their phone.
2880159|NCT03388307|Experimental|unilateral laminotomy|patients with lumbar canal stenosis who undergo unilateral laminotomy for bilateral decompression
2880160|NCT03388307|Experimental|decompressive laminectomy|patients with lumbar canal stenosis who undergo decompressive laminectomy
2880161|NCT03388294|Experimental|PC followed by SR|Parents will be coached for 6 weekly sessions in the Parents and Infants Engaged (PIE) intervention pre-linguistic (PC) domain to identify their child's pre-linguistic communication bids during daily routines and respond to those bids in ways that optimize parent-child engagement. After posttest 1, they will be coached for 6 weekly sessions on sensory reactivity bids.
2880162|NCT03388294|Experimental|SR followed by PC|Parents will be coached for 6 weekly sessions in the Parents and Infants Engaged (PIE) intervention sensory reactions (SR) domain to identify their child's sensory reactions to daily activities and respond to those reactions or modify the environment in ways that optimize parent-child engagement. After posttest 1, they will be coached for 6 weekly sessions on pre-linguistic communication bids.
2880163|NCT03388281||Patients with implanted pacemaker|Patients with implanted cardiac pacemaker registered in pacemaker database of the Department of Cardiology at the Medical University Vienna were included.
2880164|NCT03388268|Active Comparator|Oral vancomycin|125mg of oral vancomycin four times per day
2880165|NCT03388268|Placebo Comparator|Placebo|Placebo four times per day
2880166|NCT03388255|Experimental|Polydeoxyribonucleotides|"PLACENTEX: Polydeoxyribonucleotides 5.625 mg/3 ml for parenteral use i.m.~The study period consists of the following phases:~Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).~Follow up period: 3 months after end of active treatment, without study medication."
2880167|NCT03388242||Normal control people|These people are age-matched with the patients with MCI. No intervention is applied.
2880168|NCT03388242||Patients with MCI|These patients have met the criteria for diagnosing MCI. No intervention is applied.
2880169|NCT03388242||Patients with AD|These patients are diagnosed with AD. No intervention is applied.
2880170|NCT03388216|Experimental|Stage I - Drug: INM004 Dose 1|
2880171|NCT03388216|Placebo Comparator|Stage I - Placebo Dose 1|
2880172|NCT03388216|Experimental|Stage I- Drug: INM004 Dose 2|
2880173|NCT03388216|Placebo Comparator|Stage I- Placebo Dose 2|
2880174|NCT03388216|Experimental|Stage II- Drug: INM004 Repeated Dose|
2880175|NCT03388216|Placebo Comparator|Stage II- Placebo Repeated Dose|
2880176|NCT03388190|Active Comparator|Control Arm|The control arm will consist of intermittent treatment with the Nordic FLOX regimen in terms of 8 cycles before break until disease progression, when therapy is reintroduced and administered for another 8 cycles before a new break. This schedule will be continued until progressive disease on ongoing therapy (PFS), unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
2880177|NCT03388190|Experimental|Experimental Arm|The experimental arm will consist of repeat 2 cycles of the Nordic FLOX regimen followed by 2 cycles of nivolumab for a total of 8 individual cycles before break until disease progression, when therapy is reintroduced and administered for another total of 8 individual cycles before a new break. This schedule will be continued until progressive disease on ongoing therapy (PFS), unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
2880178|NCT03388177|Experimental|Treatment as usual + Yoga-based therapy|The yoga-based therapy (YBT) group will receive YBT in addition to treatment-as-usual (TAU). YBT will be administered with a manualized protocol and delivered in a group format consisting of nine weekly sessions of 1,5 hours. Group sessions consist of hatha yoga practices of physical postures, breathing practices, and meditation. Each session has a different theme. The practices will primarily consist of yoga exercises (80%) and meditation (e.g., breathing practices) (20%). Between sessions, participants complete an online module with additional psychoeducation and a practice video to encourage home practice for 30-45 minutes a day. YBT will be delivered by a psychologist who is also a trained yoga teacher.
2880179|NCT03388177|Other|Treatment as usual|The treatment as usual (TAU)-only condition will consist of interventions recommended by the Dutch guidelines for depression. These include the combination of pharmacotherapy (antidepressant medications) and psychotherapy (e.g., cognitive behavioral therapy [CBT], interpersonal psychotherapy). Lentis mental health clinicians will administer TAU. In order to improve ability to interpret study results, the investigators will record frequency, content (e.g., cognitive restructuring), format (group versus individual), and intensity of contact within TAU. Such quantification of TAU will allow us to address alternative explanations (e.g., contact time) in the case of positive results for YBT.
2880180|NCT03388164|Active Comparator|Escitalopram + RT2CK17|10mg escitalopram + 5mg RT2CK17 will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the placebo comparator by a local compounding pharmacy in Tulsa, Oklahoma.
2908189|NCT03192020|Active Comparator|Percutaneous needle fasciotomy|
2880183|NCT03388151|Active Comparator|Propofol|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation
2880184|NCT03388125|Active Comparator|Injection Sclerotherapy|5% ethano lamine oleate
2880185|NCT03388125|Active Comparator|N-butyl-2-cyanoacrylate|N-butyl-2-cyanoacrylate injection group
2880186|NCT03388112|No Intervention|antibiotics|the patients in this arm will not receive probiotics.
2880187|NCT03388112|Experimental|probiotics concurrent with antibiotic|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks concurrent with antibiotic.
2880188|NCT03388112|Experimental|probiotics after antibiotic|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks after antibiotic.
2880189|NCT03388099||patients with FSH/LH polymorphisms|Infertile patients will undergo an ovarian stimulation with FSH and/or hMG. Doses will be chosen according to BMI, Antral follicle count, AMH and age.
2880190|NCT03388099||patients without FSH/LH polymorphisms|Infertile patients will undergo an ovarian stimulation with FSH and/or hMG. Doses will be chosen according to BMI, Antral follicle count, AMH and age.
2880191|NCT03388086||Onabotulinum 300 units|
2880192|NCT03388086||Onabotulinum 200 units|
2880193|NCT03388073|Experimental|Berry extract I|Plant-based antioxidant-rich berry-based extract.
2880194|NCT03388073|Experimental|Berry extract II|Plant-based antioxidant-rich berry-based extract.
2880195|NCT03388073|Experimental|Berry extract blend|Blend of plant-based antioxidant-rich berry-based extracts.
2880196|NCT03388073|Placebo Comparator|Placebo|
2880197|NCT03388060|Active Comparator|Ultrasound guided SWL|ultrasound guided SWL for Radiolucent stone
2880198|NCT03388060|Active Comparator|Dissolution therapy|Dissolution therapy for Radiolucent stone
2880199|NCT03388060|Active Comparator|Combined ultrasound guided SWL and dissolution therapy|Combined treatment for Radiolucent stone.
2880200|NCT03388047|Experimental|Barrett's Esophagus patients|Multi-Spectral Endoscopic Imaging
2880201|NCT03388034||Index case (WP1a)|"Infant under 6 months old with clinical signs of whooping cough syndrome.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by swabbing"
2880202|NCT03388034||Control case (WP1b)|"Contact cases of infant with a positive diagnosis for whooping cough.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by swabbing~Blood sampling:~A blood sample collected by fingerprick"
2880203|NCT03388034||Seroepidemiological cohort (WP2)|"Children between 3 and 15 years old with complete primo-vaccination against B.Pertussis~Blood sampling:~A blood sample collected by fingerprick"
2880204|NCT03388021|Experimental|routine use of completion angiography after thromboembolectomy|"this group will undergo surgical revascularization followed by routine completion angiography assisted with one of these adjuvant techniques as:~Thromboembolectomy under fluoroscopic guidance using Fogarty over the wire~Balloon angioplasty and/or stenting~Intraarterial thrombolysis~Aiming to correct any residual angiographic lesion as:~Residual thrombus~Retained embolus~Atheromatous plaque"
2880205|NCT03388021|Active Comparator|if the results were not satisfactory intraoperatively as fail|this group will undergo surgical thromboembolectomy. if the results were not satisfactory intraoperatively as failure to advance the Fogarty catheter or to get satisfactory inflow or backflow or Extraction of intimal fragments.patient will undergo diagnostic angiography and endovascular or surgical intervention according to result of diagnostic angiography.
2880206|NCT03388008|Active Comparator|Standard of care|Tacrolimus + Mycophenolate mofetil + prednisone from day 0 through day 365
2880207|NCT03388008|Experimental|Belatacept-based immunosuppression|Belatacept + Tacrolimus + prednisone from day 0 through day 89, then Belatacept + Mycophenolate mofetil + prednisone from day 90 through day 365
2880208|NCT03387995||Anterior communicating artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
2880209|NCT03387995||Middle cerebral artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
2880210|NCT03387995||Posterior communicating artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
2880211|NCT03387995||Internal carotid artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
2880212|NCT03387995||Vertebrobasilar system aneurysms|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
2880213|NCT03387982||Balloon Cryotherapy Treatment Group|Subjects will undergo endoscopic balloon cryotherapy for dysplastic Barrett's Esophagus as per standard of care. The treatment type (balloon cryotherapy vs RFA) is determined by the endoscopy physician at the time of the procedure and is based on several clinical factors including co-existing medical conditions, the anatomy of the esophagus, and the length and amount of tissue affected with Barrett's.
2880214|NCT03387982||RFA Treatment Group|Subjects will undergo radio frequency ablation treatment for dysplastic Barrett's Esophagus as per standard of care. The treatment type (balloon cryotherapy vs RFA) is determined by the endoscopy physician at the time of the procedure and is based on several clinical factors including co-existing medical conditions, the anatomy of the esophagus, and the length and amount of tissue affected with Barrett's.
2880215|NCT03387969||meningitic group|Children suffering from fever , disturbed consciousnessand convulsion admitted in emergency department attending to assiut University Children Hospital aged between 2-18 years old
2880216|NCT03387956|Active Comparator|Atropine group|Atropine group (A): Patients received intrathecal heavy Marcaine, 2 ml, 0.5% plus 300 µg morphine and 100 µg atropine (0.5ml), and intravenous injection of 2ml normal saline.
2880217|NCT03387956|Active Comparator|Dexamethasone group|Dexamethasone group (D): Patients received intrathecal heavy Marcaine 2 ml, 0.5% plus 300 µg morphine (0.5ml), and intravenous 8 mg dexamethasone (2ml).
2880218|NCT03387956|Active Comparator|Dexamethasone and Atropine group|Dexamethasone and Atropine group (DA): Patients received intrathecally as group A, plus intravenous injection of 2 ml, dexamethasone 8 mg. Postoperative follow-up of both nausea and vomiting was done over 24 hours postoperative.
2880219|NCT03387943|Experimental|PLD plus Cisplatin|liposomal doxorubicin(PLD) 35 mg/m2,iv,d1, plus cisplatin 75 mg/m2,drip,d1-3, once every 21days, for 6 cycles, to progression or intolerance.
2909283|NCT03184675|Other|General action observation training group|
2880220|NCT03387930||Low back pain group|Participants will be followed up over 2 years to monitor the course of low back pain
2880221|NCT03387930||Asymptomatic group|Participants will be followed up over 2 years to monitor the incidence and course of low back pain
2880222|NCT03387917|Experimental|TLD-1|"Duration of treatment~1 cycle: 21 days,~until progression or occurrence of unacceptable toxicity or withdrawal, but~maximum 9 cycles for patients previously not treated with anthracyclines~maximum 6 cycles for patients previously treated with anthracyclines.~Dose: i.v., according to DL on day 1 of each cycle"
2880223|NCT03387904|Experimental|Anlotinib Plus Irinotecan|Anlotinib QD po.and Irinotecan Day 1,8 ivgtt. Both should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2880224|NCT03387904|Active Comparator|Irinotecan|Irinotecan Day 1,8 ivgtt and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2880225|NCT03387891||Cancer patients|Cancer patients admitted to hospital for treatment or monitoring of health condition
2880226|NCT03387878|Other|Single Arm Study|This is a single arm study with no comparator
2880227|NCT03387852|Experimental|SAR440340/REGN3500 Monotherapy|SAR440340/REGN3500 administered by subcutaneous (SC) injections every 2 weeks for 12 weeks and coadministration of dupilumab placebo by SC injection every 2 weeks for 12 weeks
2880228|NCT03387852|Other|Dupilumab Monotherapy|Dupilumab administered by SC injection every 2 weeks for 12 weeks and coadministration of SAR440340/REGN3500 placebo by SC injections every 2 weeks for 12 weeks
2880229|NCT03387852|Experimental|SAR440340/REGN3500 and Dupilumab Coadministration|SAR440340/REGN3500 administered by SC injections every 2 weeks for 12 weeks and coadministration of dupilumab administered by SC injection every 2 weeks for 12 weeks
2880230|NCT03387852|Placebo Comparator|Placebo|Coadministration of matching placebos for SAR440340/REGN3500 and dupilumab administered by SC injections, respectively, every 2 weeks for 12 weeks
2880231|NCT03387839||Medial-Pivot Knee Prosthesis|
2880232|NCT03387839||Posterior-Stabilized Knee Prosthesis|
2880233|NCT03387839||Cruciate-Stubstituting Knee Prosthesis|
2880234|NCT03387826|Experimental|Ticagrelor|Ticagrelor 60mg twice daily followed by Prasugrel 5mg once daily
2880235|NCT03387826|Active Comparator|Prasugrel|Prasugrel 5m once daily followed by Ticagrelor 60mg twice daily
2880236|NCT03387813|Experimental|Randomized Arm - Treatment Group|"Management of subjects based on pulmonary artery (PA) pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
2880237|NCT03387813|Experimental|Randomized Arm - Control Group|"Management of subjects per standard of care (signs, symptoms, weight etc.) without knowledge of PA pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
2880238|NCT03387813|Experimental|Single Arm|"Management of subjects based on PA pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
2880239|NCT03387800|Experimental|WeChat interactive peer support group|Participants will be grouped together by the researcher to form closed online peer support groups (with group names they choose). Activities on the WeChat groups serve two functions: i) It enhances social support among peer members toward smoking cessation. ii) The online support group also enhances the participants' positive affect.
2880240|NCT03387800|Active Comparator|Basic health education messages|Members of the control group will receive health education messages that will also be sent to the intervention group through WeChat. The messages include topics on physical and psychological aspects of perceived severity of smoking and perceived benefits of smoking cessation, and tips/skills on resisting situational temptations that may lead to relapse.
2880241|NCT03387787|Experimental|GlucoTab Treatment Arm|Recruited patients will be treated with insulin degludec and insulin aspart. insulin doses will be calculated by the GlucoTab system
2880242|NCT03387774|Experimental|Concurrent chemoradiotherapy and ulinastatin|"Concurrent chemoradiotherapy (CCRT) and intravenous drip of ulinastatin, the details are as follows:~Intensity modulated radiation therapy combined with concurrent chemotherapy of cisplatin 100mg/m2 on day 1 and day 22 of RT;~Ulinastatin through intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline, 3 times every radiation day, until the end of radiotherapy."
2880243|NCT03387774|Active Comparator|Concurrent chemoradiotherapy|"Concurrent chemoradiotherapy (CCRT) alone:~Intensity modulated radiation therapy combined with concurrent chemotherapy of cisplatin 100mg/m2 on day 1 and day 22 of RT."
2880244|NCT03387761|Experimental|Ipilimumab + Nivolumab|Day 1: Ipilimumab 3 mg/kg i.v. Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v. Day 43: Nivolumab 3 mg/kg i.v.
2880245|NCT03387748|Experimental|Gesture elicitation|Observation: hand gesture elicitation task
2880246|NCT03387735|Placebo Comparator|Treatment as usual (TAU) + Internet|Patients will be given access to helpful websites such as NIH SeniorHealth.
2880247|NCT03387735|Experimental|Treatment as usual (TAU) + C-CHESS|Patients will be given access to the C-CHESS website for 12 months which provides tools, motivation, and social support to help them manage their specific set of chronic conditions and communicate with peers and their primary care physician.
2880248|NCT03387709|Experimental|Pistachio-enriched diet|Participants in this group will be individually counseled on a lower calorie diet, receive pistachios to be consumed daily for four months, and receive print materials on incorporating pistachios into their diet.
2880249|NCT03387709|Active Comparator|General dietary guidance diet|Participants in this group will receive general dietary guidance as part of a 4-month long group intervention.
2880250|NCT03387683|Placebo Comparator|placebo|placebo tablets once daily
2880251|NCT03387683|Experimental|dapagliflozin 10mg|dapagliflozin 10mg tablets once daily
2880252|NCT03387670|Active Comparator|Simvastatin|
2880253|NCT03387670|Placebo Comparator|Placebo|
2880254|NCT03387657|Experimental|Sotagliflozin + Hydrochlorothiazide (HCTZ)|Sotagliflozin to be administered alone in Period 1. HCTZ to be given in Period 2 for 4 days followed immediately by HCTZ and sotagliflozin for 5 days.
2880255|NCT03387644|Active Comparator|Pregabalin (PG)|Patients received 150 mg pregabalin one hour before the procedure.
2880256|NCT03387644|Placebo Comparator|Control placebo (C)|Patients received placebo tablet one hour before surgery.
2880257|NCT03387618|Experimental|Investigational Scan|new-generation digital PET/CT imaging technology
2880258|NCT03387605|Active Comparator|Ivabradine|Initiation at dose 5 mg PO x 1 dose and further increased in 12 hours to 7.5 mg PO twice per day if patient is stable with mean BP≥ 60 mmHg, systolic blood pressure ≥ 90 mmHg and HR ≥100 bpm
2880259|NCT03387605|Placebo Comparator|Placebo|Matching placebo given PO twice per day
2880260|NCT03387592|Active Comparator|FOLFIRI regimen|CPT-11 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by Calcio levofolinate 200 mg/m2, given as a 2h i.v. infusion on days 1 every 2 weeks followed by 5-Fluorouracil 400 mg/m2 given as bolus, and then 5-Fluorouracil 2400 mg/m2 given as a 48 h continuous infusion on day 1, every 2 weeks, until progression or for a maximum of 12 cycles
2880261|NCT03387592|Experimental|CAPTEM regimen|Capecitabine 750 mg/m2 twice a day on days 1-14 in combination with Temozolomide 200 mg/m2 daily on days 10-14, every 4 weeks, until progression or for a maximum of 6 cycles
2880262|NCT03387579|Active Comparator|Composite fish oil lipid (Smoflipid)|Patients randomized to this arm will receive the composite fish oil lipid, Smoflipid, at standard dosing up to 2 - 3 g/kg/day. Patients will be started on a dose of 1 g/kg/day and titrated up to maximum dose. As enteral nutrition is advanced the lipid dose will be weaned per study protocol and dietary recommendations.
2880263|NCT03387579|Active Comparator|Soy-based lipid reduction|Patients randomized to this arm will receive soy-based lipid (Intralipid) at a dose of 1 g/kg/day throughout their enrollment in the study.
2880264|NCT03387566|Experimental|HB002.1M 0.3mg|Participants received a 0.3mg dose of HB002.1M via intravitreal (IVT) injection.
2880265|NCT03387566|Experimental|HB002.1M 0.5mg|Participants received a 0.5mg dose of HB002.1M via intravitreal (IVT) injection.
2880266|NCT03387566|Experimental|HB002.1M 1.0mg|Participants received a 1.0mg dose of HB002.1M via intravitreal (IVT) injection.
2880267|NCT03387566|Experimental|HB002.1M 2.0mg|Participants received a 2.0mg dose of HB002.1M via intravitreal (IVT) injection.
2880268|NCT03387566|Experimental|HB002.1M 3.0mg|Participants received a 3.0mg dose of HB002.1M via intravitreal (IVT) injection.
2880269|NCT03387553|Active Comparator|Lead In Phase - Arm A|Arm A: One Dendritic Cell Vaccine (DC1) per week x 3 weeks.
2880270|NCT03387553|Active Comparator|Lead In Phase - Arm B|Arm B: Two DC1 vaccinations per week (given 3 days apart i.e., Mon and Thurs or Tues and Friday) x 3 weeks.
2880271|NCT03387553|Experimental|Expansion Phase|DC1 vaccinations according to optimal vaccination schedule. Participants will receive a booster intranodal study vaccine at week 25 prior to receiving surgery. Participants will then undergo definitive curative surgery following completion of the neoadjuvant therapy, additional adjuvant locoregional/systemic therapy (as deemed appropriate by their treating physicians).
2880272|NCT03387540||Myocarditis induced by Immune check point inhibitor|Case reported in the World Health Organization (WHO) of myocarditis of patient treated by ICI, with a chronology compatible with the drug toxicity
2880273|NCT03387527|Experimental|Prostate Cancer Decision Aid|The research intervention will be exposure to the screening decision aid. Patients will receive standardized counseling including population based risks and benefits of prostate cancer screening. Then, patients will be given opportunity to review the screening decision aid prior to offering a decision on whether or not to undergo prostate cancer screening. The patient decision aid will be a computer application that generates predicted risks associated with prostate cancer.
2880274|NCT03387514|Experimental|18F-DCFPyL whole body PET/CT scan|18F-DCFPyL whole body PET/CT scan at three time-points
2880275|NCT03387501|Experimental|PRGF|Plasma rich in growth factors (PRGF) administration
2880276|NCT03387488|Experimental|Treatment|StingrayTM, Medtronic®
2880277|NCT03387475|Experimental|Deferasirox|efficacy of 3.5mg/kg/day
2880278|NCT03387462|Experimental|DOT Diary Optimization Intervention|DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet
2880279|NCT03387449|Experimental|Bimanual Arm Training|Children in the study will all receive the same treatment, which includes 9 weeks of training on the bimanual arm trainer robotic device.
2880280|NCT03387436|No Intervention|1.) Treatment as usual (TAU)|Patients assigned to this arm will receive palliative treatment as usual.
2880281|NCT03387436|Sham Comparator|2.) Sham-Intervention|Patients assigned to this arm will receive an sham intervention with unspecific supportive therapy (i.e. listening, empathy etc., but no specific intervention rationale) and palliative treatment as usual.
2880282|NCT03387436|Experimental|3.) Study-Intervention|Patients assigned to this arm will receive the study-intervention and palliative treatment as usual.
2880283|NCT03387410|Experimental|Intravenous IRDye 800BK|Patients undergoing laparoscopic bowel resection & laparoscopic donor nephrectomy
2880284|NCT03387397|Other|TEAMH program|The study includes one intervention arm and no control arm. All enrolled patients will be given the TEAMH smartphone application intervention for a period of 6 months. Enrolled patients will be grouped into two mutually exclusive cohorts according to the number of daily prescribed chronic medications (both ART and non-ART). Patients will be assigned to the Lower Medications (LM) cohort group (N=85) if they received a drug regimen of less than five different medications/day during the study period. Whereas, patients will be assigned to the Higher Medications (HM) cohort group (N=85) if they received a drug regimen of more than 5 different chronic medications/day during the study period.
2880285|NCT03387371|Active Comparator|Ultrasonics & Gracey Curettes|Scaling and root planning is done with ultrasonics and gracey curettes in 24 hours with two visits.
2880286|NCT03387371|Experimental|Ultrasonics & Gracey Curettes & Laser|Scaling and root planning is done with ultrasonics, gracey curettes and Er:YAG laser in 24 hours with two visits.
2880287|NCT03387358||Historical Comparison Group|This group includes patients who were admitted to St. Paul's Hospital ICU (Vancouver BC, Canada) from September 2014 to September 2015, and had a small bore feeding tube in place at some point during their ICU admission, and were matched to key variables to the prospective observational treated group.
2880288|NCT03387358||Prospective Observational Treated Group|This group includes all patients who were admitted to St. Paul's Hospital ICU from Nov. 2017 to Dec. 2018, and nasal bridle securement device for small bore feeding tubes at some point during their ICU admission. The clinical indicators for a nasal bridle securement device outlined in our nursing practice standards include one or more of the following: recurrent nasoenteric tube dislodgement; confused and/or agitated patients; fluoroscopically or endoscopically placed nasoenteric tube; history of difficult tube placement; facial burn victims with nasoenteric tube; and/or oily skin causing decreased adhesion of traditional securement.
2880289|NCT03387345|Experimental|bread-50/50-steelcut-80/20-flake-rice|25 g of available carbohydrate was delivered to participants via (1) white bread, followed by (2) 50/50 rice-barley mix, followed by (3) 100% steel cut barley, followed by (4) 80/20 rice-barley mix, followed by (5) 100% barley flakes, followed by (6) 100% rice
2880290|NCT03387345|Experimental|50/50-steelcut-80/20-flake-rice-bread|25 g of available carbohydrate was delivered to participants via (1) 50/50 rice-barley mix, followed by (2) 100% steel cut barley, followed by (3) 80/20 rice-barley mix, followed by (4) 100% barley flakes, followed by (5) 100% rice, followed by (6) white bread
2880291|NCT03387345|Experimental|steelcut-80/20-flake-rice-bread-50/50|25 g of available carbohydrate was delivered to participants via (1) 100% steel cut barley, followed by (2) 80/20 rice-barley mix, followed by (3) 100% barley flakes, followed by (4) 100% rice, followed by (5) white bread, followed by (6) 50/50 rice-barley mix
2880292|NCT03387345|Experimental|80/20-flake-rice-bread-50/50-steelcut|25 g of available carbohydrate was delivered to participants via (1) 80/20 rice-barley mix, followed by (2) 100% barley flakes, followed by (3) 100% rice, followed by (4) white bread, followed by (5) 50/50 rice-barley mix, followed by (6) 100% steel cut barley
2880293|NCT03387345|Experimental|flake-rice-bread-50/50-steelcut-80/20|25 g of available carbohydrate was delivered to participants via (1) 100% barley flakes, followed by (2) 100% rice, followed by (3) white bread, followed by (4) 50/50 rice-barley mix, followed by (5) 100% steel cut barley, followed by (6) 80/20 rice-barley mix
2880294|NCT03387345|Experimental|rice-bread-50/50-steelcut-80/20-flake|25 g of available carbohydrate was delivered to participants via (1) 100% rice, followed by (2) white bread, followed by (3) 50/50 rice-barley mix, followed by (4) 100% steel cut barley, followed by (5) 80/20 rice-barley mix, followed by (6) 100% barley flakes
2880295|NCT03387332|Experimental|APG-1252|The starting dose for this study was 40 mg and 1 patient would be enrolled at this dose level. The dose escalation will convert to a standard 3+3 design following the occurrence of DLT or two ≥ Grade 2 adverse event or at doses 80 mg.
2880296|NCT03387319|Experimental|Racialized Stressful Event Recall|Participant presents stressful event (1) related to race then (2) unrelated to race.
2880297|NCT03387319|Experimental|Non-racialized Stressful Event Recall|Participant presents stressful event (1) unrelated to race then (2) related to race then
2880298|NCT03387306||Patient group|This grup included 38 patients with NTG.
2880299|NCT03387306||Control group|This group included 38 healthy controls.
2880300|NCT03387293|Experimental|LGI-LII Breakfast|Low glycemic index, low insulin index (LGI-LII) breakfast as a test meal
2880301|NCT03387293|Experimental|LGI-HII Breakfast|Low glycemic index, high insulin index (LGI-HII) breakfast as a test meal
2880302|NCT03387280||proximal RCA stenosis|The stenosis site is before the the right ventricular branch of right coronary artery (RCA) according to the coronary angiograms.
2880303|NCT03387280||distal RCA stenosis|The stenosis site is after the the right ventricular branch of right coronary artery (RCA) according to the coronary angiograms.
2880304|NCT03387280||left circumflex coronary artery stenosis|The stenosis site is located at the left circumflex coronary artery according to the coronary angiograms.
2880305|NCT03387267|Other|single-arm Dysphagia Detection System|An operationally seamless single-arm, prospective, multicenter, single-blinded for central outcomes assessors trial to test DDS in assessing swallowing safety and efficiency in patients at risk of oropharyngeal dysphagia.
2880306|NCT03387254|Experimental|VR + active brain stimulation|Exposure to a virtual reality world with active transcranial electric stimulation
2880307|NCT03387254|Sham Comparator|VR + sham brain stimulation|Exposure to a virtual reality world with sham transcranial electric stimulation
2880308|NCT03387241|Experimental|Fluticasone/ Formoterol (Flutiform)|"Dosage Form:2 puffs~Unit Strength:~Low dose: 50/5 µg Mid dose: 125/5 µg High dose 250/10 µg Dosing Frequency:BID Mode of Administration:Inhaled"
2880309|NCT03387241|Active Comparator|Fluticasone/ salmeterol (Seretide)|"Dosage Form:2 puffs~Unit Strength:~Low dose: 50/25 µg Mid dose: 125/25 µg High dose 250/25 µg Dosing Frequency:BID Mode of Administration:Inhaled"
2880310|NCT03387228|Experimental|Pain education group (PEG)|Pain education based on Explain Pain developed by Moseley and Butler in 2003.
2880311|NCT03387228|Active Comparator|Control group (CG)|Evidence based physiotherapy care brief education, superficial heat, massage, and exercise.
2880312|NCT03387215|Experimental|10 mg ITI-214|Single oral dose
2880313|NCT03387215|Experimental|30 mg ITI-214|Single oral dose
2880314|NCT03387215|Experimental|75 mg - 150 mg ITI-214|Single oral dose
2880315|NCT03387215|Placebo Comparator|Placebo|Single oral dose
2880316|NCT03387202||pelvic organ prolapse|"Participants received Laparoscopic lateral suspension with mesh as part of routine medical care in apical prolapse, thus, the investigator does not assign a intervention but studies the effects.Vaginal length, bladder neck mobility and pelvic floor biometry with AP hiatal diameter and pelvic organ descent measurements are measured by Transperineal ultrasound to assess anatomic success in the preoperative and at postoperative 18th months. POP-Q assessment and translabial usg for objective success; Female Sexual Function Index (FSFI), Michigan Incontinence Severity Index (M-ISI), Prolapse Quality of Life questionnaire (PQoL), Pelvic Organ Prolapse Symptom Score (POP-SS) and Visual Analog Score (VAS) are used to assess subjective success."
2880317|NCT03387189||Quality Improvement Project|Quality Improvement Project: Regions Hospital
2880318|NCT03387189||No Quality Improvement Project|No Quality Improvement Project: The comparison group is Methodist Hospital, where the Quality Improvement project is not occurring.
2880319|NCT03387176||zonulin ≤17.5 ng/ml|Pediatric patients with difficult-to-manage nephrotic syndrome will be stratified based on the plasma zonulin concentration into two groups
2880320|NCT03387176||zonulin >17.5 ng/ml|Pediatric patients with difficult-to-manage nephrotic syndrome will be stratified based on the plasma zonulin concentration into two groups
2880321|NCT03387163||Sacubitril/Valsartan|Chronic systolic heart failure patients newly prescribed in mg. twice daily.
2880322|NCT03387163||ACEi/ARB|Chronic systolic heart failure patients receiving ACEi/ARB and no s/v
2880323|NCT03387150|Experimental|Group 1: VRC07-523LS|Participants in Group 1 will receive 2.5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
2880324|NCT03387150|Experimental|Group 2: VRC07-523LS|Participants in Group 2 will receive 5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
2880325|NCT03387150|Experimental|Group 3: VRC07-523LS|Participants in Group 3 will receive 20 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
2880326|NCT03387150|Experimental|Group 4: VRC07-523LS|Participants in Group 4 will receive 2.5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
2880327|NCT03387150|Experimental|Group 5: VRC07-523LS|Participants in Group 5 will receive 5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
2880328|NCT03387150|Experimental|Group T6 VRC07-523LS|Participants in Group T6 will receive 2.5 mg/kg of VRC07-523LS by IM injection at Weeks 0, 16, 32, 48, and 64.
2880329|NCT03387150|Placebo Comparator|Group P6: Placebo|Participants in Group P6 will receive 2.5 mg/kg of placebo by IM injection at Weeks 0, 16, 32, 48, and 64.
2880330|NCT03387137|Experimental|Group 1: RSV 6120/∆NS2/1030s Vaccine|RSV-seropositive children will receive a single dose of 10^5.7 plaque-forming units (PFUs) of RSV 6120/∆NS2/1030s vaccine at study entry (Day 0).
2880331|NCT03387137|Placebo Comparator|Group 1: Placebo|RSV-seropositive children will receive a single dose of placebo at study entry (Day 0).
2880332|NCT03387137|Experimental|Group 2: RSV 6120/∆NS2/1030s Vaccine|RSV-seronegative infants and children will receive a single dose of 10^5.0 PFUs of RSV 6120/∆NS2/1030s vaccine at study entry (Day 0).
2880333|NCT03387137|Placebo Comparator|Group 2: Placebo|RSV-seronegative infants and children will receive a single dose of placebo at study entry (Day 0).
2880334|NCT03387111|Experimental|NANT Squamous Cell Carcinoma (SCC) Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, avelumab, bevacizumab, capecitabine, cetuximab, cisplatin, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, necitumumab, SBRT.
2880335|NCT03387098|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011, GI-4000, haNK, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ehtyl esters, oxaliplatin, SBRT.
2880336|NCT03387085|Experimental|NANT triple negative breast cancer (TNBC) Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, SBRT.
2880337|NCT03387072||Patients affected with CIQTP|Patients affected with catecholamine-induced QT prolongation (CIQTP)
2880338|NCT03387072||Healthy relatives of patients affected with CIQTP|Healthy relatives of patients affected with CIQTP identified during the familial screening
2880339|NCT03387059|Experimental|Forielle Endometrial Washing|
2880340|NCT03387059|No Intervention|No Endometrial Washing|
2880341|NCT03387046|Experimental|IFN beta-1a+Methylprednisolone+D-aspartate (MS with relapse)|
2880342|NCT03387046|Placebo Comparator|IFN beta-1a+Methylprednisolone+Placebo (MS with relapse)|
2880343|NCT03387046|Experimental|IFN beta-1a+D-aspartate (MS without relapse)|
2880344|NCT03387046|Placebo Comparator|IFN beta-1a+Placebo (MS without relapse)|
2880345|NCT03387033|Experimental|VR intervention session|The patients will give a pain score as well as fill out GAD-7 and PHQ-9 scores initially. The VR intervention session consists of relaxation narration WITH Virtual Reality session for 20 minutes while wearing the VR device. They will then be again asked to give a pain score and fill out GAD-7, PHQ-9, and PGIC.
2880346|NCT03387020|Experimental|Treatment (ribociclib, everolimus)|Patients receive ribociclib PO QD on days 1-21 of course 1 and subsequent courses and days 2-21 of course 2, and everolimus PO QD on days 3-28 of course 1 and days 1-28 of subsequent courses. Patients who are undergoing surgery also receive ribociclib PO QD on days 7-10 before surgery. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 13 courses may continue receiving ribociclib and everolimus every 28 days for up to 13 additional courses in the absence of disease progression or unacceptable toxicity.
2880347|NCT03387007|Experimental|Intervention|Two teachers from each of the schools included in this arm received training on providing psycho-social support to their students to be implemented in their regular routine school activities
2880348|NCT03387007|No Intervention|Control|The teachers from the schools in this arm did not receive training on psycho-social support
2880349|NCT03386994||Idiopathic Pulmonary Fibrosis patients|all IPF patients
2880350|NCT03386981||1|Professional athletes: Professional athletes belonging to different discipline
2880351|NCT03386968|Experimental|Video gaming|A child's usual physical therapy session will be replaced with a session utilizing Active video games and the Rutger's V-step.
2880352|NCT03386968|Active Comparator|Usual care|Children will receive their usual care in the physical therapy program at Blythedale.
2880353|NCT03386955|Experimental|BPI-7711 treatment|Patients in dose escalation group will receive single dose of BPI-7711 capsule PO on day -7 and start receive the 21 days/cycle continuous treatment once a day after 7 day washout period. Patients in the extension group will receive BPI-7711 once a day with the selected doses.
2880354|NCT03386942|Experimental|MORAb-202|"Part 1 (Dose-escalation): The initial dose level of MORAb-202 will be 0.3 milligrams per kilogram (mg/kg) every 3 weeks in the first cohort with 1 participant for dose-limiting toxicity (DLT) evaluation. DLTs will be evaluated in successive dose level cohorts with a single participant until a drug-related Grade 2 or higher toxicity is observed. If such a toxicity is observed, the cohort will be expanded to enroll a total of 3 participants.~Part 2 (Treatment Phase): MORAb-202 will be administered every 3 weeks during the treatment phase at the dose determined in Part 1 until participants meet any of the criteria for discontinuation. Criteria for discontinuation include: withdrawal of consent, major protocol violations, unable to continue due to adverse events, pregnancy, progressive disease, Investigator decision, or infusion reactions."
2880355|NCT03386929|Experimental|Avelumab, Axitinib, Palbociclib|"For the Phase 1:~Avelumab is administered intravenously (IV) on Day 1 and Day 15 of each Cycle (one cycle = 28 days) in combination with axitinib po bid and palbociclib po (7 days off; 21 days on).~For the Phase 2:~Avelumab, axitinib and palbociclib are administered at the recommended dose (RP2D) as determined during the phase 1 part of the study."
2880356|NCT03386916||Patient with a CT scan guide percutaneous biopsy of lytic bone|Patient with a CT scan guide percutaneous biopsy of lytic bone metastases register on CHU Grenoble Alpes radiology software between January 2010 and June 2017
2880357|NCT03386903|Experimental|Ture acupuncture group|After recruiting, patients are assigned to the ture acupuncture group by randomization,and then receive ture acupuncture treatment. patients are scanned by MRI at the baseline and 3 month post-treatment respectively.
2880358|NCT03386903|Placebo Comparator|Sham acupuncture group|After recruiting, patients are assigned to the sham acupuncture group by randomization,and then receive sham acupuncture stimulation. patients are scanned by MRI at the baseline and 3 month post-treatment respectively.
2880359|NCT03386903|No Intervention|Healthy group|Healthy subjects without intervention except scanned brain image by MRI at the baseline.
2880360|NCT03386877|Experimental|Dental pulp stem cells|Test sites (n=15) Periodontal regeneration using micro-grafts of Dental pulp stem cells seeded onto collagen sponge
2880361|NCT03386877|Active Comparator|coagulum|control sites (n=14) Periodontal regeneration using coagulum and collagen sponge alone
2880362|NCT03386864||Control|
2880363|NCT03386864||Insulin Resistant|
2880364|NCT03386864||Type 2 Diabetes|
2880365|NCT03386838|Experimental|Nivolumab and BMS-986205|Nivolumab administered in combination with BMS-986205
2880366|NCT03386838|Active Comparator|EXTREME study regimen|Cetuximab + Cisplatin/Carboplatin + Fluorouracil
2880367|NCT03386825||Regorafenib_DoT<4 months|DoT < 4 months
2880368|NCT03386825||Regorafenib_4 months ≤ DoT < 12 months|4 months ≤ DoT < 12 months
2880369|NCT03386825||Regorafenib_DoT ≥ 12 months|DoT ≥ 12 months
2880370|NCT03386799||Patient in wheelchair|Patient in wheelchair with E-motion device
2880371|NCT03386786|Experimental|Intervention (Health Partner)|The mobile health (mHealth) product, Health Partner for Knees and Hips (Health Partner), is a combination of a mobile application (app) and a web-based portal.
2880372|NCT03386786|Other|Control|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
2880373|NCT03386773|Experimental|Intervention|Intervention patients will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Intervention patients will be asked to track patient generated health data (PGHD) elements related to weight management through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
2880374|NCT03386773|Active Comparator|Control|Control patients will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Patient-reported outcomes measures will be collected pre-and-post-intervention.
2880375|NCT03386760|Experimental|A- Ultra-Speed Picosecond laser|Utilisation of Ultra-speed Picosecond laser for tattoo depigmentation
2880376|NCT03386760|Active Comparator|B- Nanosecond laser|Utilisation of Nanosecond laser for tattoo depigmentation
2880377|NCT03386747|Experimental|Home Visiting Group|Intervention: Home visits to improve parenting behaviors
2880378|NCT03386747|Experimental|Center based parenting group|Intervention: Center based parenting groups
2880379|NCT03386747|No Intervention|control group|The rest of pregnant women and their children who will not receive the intervention
2880380|NCT03386734|Experimental|SLN biopsy only|Sentinel lymph node (SLN) biopsy only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
2880381|NCT03386734|Active Comparator|SLN biopsy + PLN dissection|SLN biopsy + full pelvic lymph node dissection (PLN) will be performed. The radical hysterectomy or trachelectomy will be done.
2880382|NCT03386721|Experimental|Cohort A in Part I|Checkpoint Inhibitor (CPI)-Naïve Participants who have not received CPI therapy previously will receive RO6874281 intravenous (IV) infusion once in a week (QW) for first 4 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Starting dose will be 10 milligrams (mg), and will be up-titrated to 15 mg from second administration onwards. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: collection of fresh tumor biopsies (at baseline and on-treatment) will be optional.
2880383|NCT03386721|Experimental|Cohort B in Part I|CPI-Experienced Participants who have received CPI therapy previously will receive RO6874281 IV infusion QW for first 4 doses, and Q2W for remaining doses up to maximum 36 months. Starting dose will be 10 mg, and will be up-titrated to 15 mg from second administration onwards. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.
2880384|NCT03386721|Experimental|Cohort C in Part I|"This is a mandatory biopsy cohort based on the treatment's safety and preliminary activity analysis to enroll CPI-Naive Participants.~Participants will receive RO6874281 intravenous (IV) infusion once in a week (QW) for first 4 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Starting dose will be 10 milligrams (mg), and will be up-titrated to 15 mg from second administration onwards. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: collection of fresh tumor biopsies (at baseline and on-treatment) will be optional."
2880385|NCT03386721|Experimental|Cohort D Arm I in Part I|"CPI Experienced Participants who were previously treated with platinum and docetaxel.~Participants will receive RO6874281 intravenous (IV) infusion once in a week (QW) for first 4 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Starting dose will be 10 milligrams (mg), and will be up-titrated to 15 mg from second administration onwards. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg."
2880386|NCT03386721|Experimental|Cohort D Arm 2 in Part I|"CPI Experienced Participants who were previously treated with platinum and docetaxel.~Participants will receive RO6874281 intravenous (IV) infusion once in 3 weeks (Q3W) up to maximum 36 months. Dosage will be 10 milligrams (mg). Atezolizumab IV infusion will be administered in combination Q3W at a dose of 1200 mg."
2880387|NCT03386721|Experimental|Cohort D Arm 3 in Part I|CPI Experienced Participants who were previously treated with platinum and docetaxel will receive a single-agent gemcitabine or vinorelbine as per approved protocol.
2880557|NCT03385499|Other|negative control group|blood additional samples on negative control group
2880388|NCT03386721|Experimental|Cohort E Arm 1 in Part II|This cohort will enroll participants with High-Tumor PD-L1 Expression who have not received any prior systemic therapy. Participants will receive RO6874281 IV infusion QW in combination with atezolizumab Q2W for 4 weeks followed by RO6874281 in combination with atezolizumab Q2W. Starting dose of RO6874281 will be 15 mg and will up-titrated to 20 mg from second administration onwards. Atezolizumab IV infusion will be administered at a dose of 840 mg.
2880389|NCT03386721|Experimental|Cohort E Arm 2 Part II|This cohort will enroll participants with High-Tumor PD-L1 Expression who have not received any prior systemic therapy. Participants will receive RO6874281 IV infusion in combination with atezolizumab Q3W. Dosage of RO6874281 will be 15 mg. Atezolizumab IV infusion will be administered at a dose of 1200 mg.
2880390|NCT03386708|Experimental|hUC-MSC intrauterine injection group|Human umbilical cord mesenchymal stem cells (hUC-MSC) (SCLnow 19#)
2880391|NCT03386708|Placebo Comparator|NS intrauterine injection group|Normal saline (NS) (2ml)
2880392|NCT03386708|Experimental|hUC-MSC intravenous injection group|Umbilical cord mesenchymal stem cells (SCLnow 19#)
2880393|NCT03386708|Placebo Comparator|NS intravenous injection group|Normal saline (NS) (30ml)
2880394|NCT03386695|Other|Education by Pamphlets|Half of the women in each group will be provided an information pamphlet on the risk factors, methods of early detection, prevention, signs and symptoms of cervical cancer and how to use the self samplers at home.
2880395|NCT03386695|Other|Health education programme|Half of the women in each group will be invited to specially organised camps in their neighbourhood for Health Education and distribution of self samplers.
2880396|NCT03386682|Experimental|ESTYME MATRIX|Participants who meet the requirements for breast augmentation or breast reconstruction surgeries and have been implanted with one or two ESTYME® MATRIX Breast Implant(s)
2880397|NCT03386669|Experimental|F-18 AV-45 THK-5351|F-18 AV-45 THK-5351 imaging
2880398|NCT03386656|Experimental|Amchafibrin|Estimated total blood loss, measured using the formula described by Nadler. A difference in estimated blood loss greater than or equal to 245 ml will be considered clinically relevant.
2880399|NCT03386656|Placebo Comparator|Saline Solution 0,9%.|Comparator of tranexamic acid
2880400|NCT03386643|Experimental|Bifidobacterium animalis subsp. lactis|"Intervention:~Bifidobacterium animalis subsp. lactis HN019"
2880401|NCT03386643|Active Comparator|Clobetasol propionate 0.05%|"Intervention:~Clobetasol propionate 0.05%"
2880402|NCT03386630|Experimental|Hyperbaric bupivacaine+Sufentanil|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
2880403|NCT03386630|Experimental|Hyperbaric bupivacaine+morphine|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
2880404|NCT03386617|Experimental|NEPA|"Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded."
2880405|NCT03386604|Experimental|Whey protein + Rehabilitation|Pulmonary rehabilitation will last 8 weeks covering 3 weekly sessions of supervised exercise and a weekly educational session. Patients will receive whey protein and will be instructed to take it daily for breakfast, diluted in milk or water (if they do not drink milk).
2880406|NCT03386604|Placebo Comparator|Placebo + Rehabilitation|Pulmonary rehabilitation will last 8 weeks covering 3 weekly sessions of supervised exercise and a weekly educational session. Patients will receive placebo (maltodextrin) and will be instructed to take it daily for breakfast, diluted in milk or water (if they do not drink milk).
2880407|NCT03386591|Experimental|Mucosal Atomization (1 administration)|One Intranasal administration of 2 mL naloxone using a mucosal atomization device and syringe (1 mL/nostril)
2880408|NCT03386591|Experimental|Mucosal Atomization (2 administrations)|Two Intranasal administrations of 2 mL naloxone using mucosal atomization device and syringe (1 mL/nostril) 2 minutes apart
2880409|NCT03386591|Experimental|Narcan 2mg|One Intranasal administration of 2 mg naloxone using Narcan nasal spray
2880410|NCT03386591|Experimental|Narcan 4mg|One Intranasal administration of 4 mg naloxone using Narcan nasal spray
2880411|NCT03386591|Experimental|Intramuscular auto injector|One Intramuscular administration of 2 mg naloxone using Evzio auto-injector
2880412|NCT03386578|Experimental|Pharmacokinetics Component: Group 1|Participants will be enrolled during singleton pregnancy at 14-24 weeks' gestation. Participants will receive a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) once daily under direct observation from Day 0 through Week 12.
2880413|NCT03386578|Experimental|Pharmacokinetics Component: Group 2|Participants will be enrolled postpartum within 6-12 weeks after delivery. Participants will receive a fixed-dose combination of FTC/TDF once daily under direct observation from Day 0 through Week 12.
2880414|NCT03386578|Experimental|PrEP Comparison Component: Cohort 1|Participants will receive daily oral PrEP (FTC/TDF) from Day 0 through Week 26. Participants will also receive behavioral HIV risk reduction package, including cohort-appropriate SMS messages, from Day 0 through Week 26.
2880415|NCT03386578|Active Comparator|PrEP Comparison Component: Cohort 2|Participants will receive a behavioral HIV risk reduction package, including cohort-appropriate SMS messages, from Day 0 through Week 26.
2880416|NCT03386565|Active Comparator|control group|"Sodium chloride solution 10 mL IV just before induction of anesthesia~IV infusion during the surgery"
2880417|NCT03386565|Active Comparator|lidocaine group|"lidocaine 2 mg ̸ kg slowly IV just before induction of anesthesia~IV infusion during the surgery"
2880418|NCT03386552|Experimental|Isifera+|Subjects are pertubated with Isifer+ solution containing lidocaine 0.5 mg/ml
2880419|NCT03386552|Placebo Comparator|Buffer|Subjects are pertubated with a buffer solution without lidocaine
2880420|NCT03386539|Experimental|Everolimus/Low-Dose Tacrolimus|"Everolimus approximately 0.6 mg/m2/dose taken by mouth every 12 hours for 30 months. Everolimus dose will be adjusted to achieve a trough concentration of 3-8 ng/ml.~Tacrolimus 0.0125 mg/kg/dose by mouth every 12 hours for 30 months. (Tacrolimus dose will be adjusted to achieve a trough concentration of 3-5 ng/ml until subjects are 1 year post-heart transplant. After 1 year post-heart transplant the tacrolimus dose will be adjusted to achieve a trough concentration of 2.5-4.5 ng/mL.)"
2880558|NCT03385499|Other|positive control group|blood additional samples on positive control group
2880421|NCT03386539|Active Comparator|Tacrolimus/Mycophenolate Mofetil|"Tacrolimus 0.05 mg/kg/dose by mouth every 12 hours for 30 months. (Tacrolimus dose will be adjusted to achieve a trough concentration of 7-10 ng/ml until subjects are 1 year post-heart transplant. After 1 year post-heart transplant the tacrolimus dose will be adjusted to achieve a trough concentration of 5-8 ng/mL.)~Mycophenolate mofetil 600 mg/m2/dose by mouth every 12 hours for 30 months."
2880422|NCT03386526|Experimental|APG-1387 for Injection|APG-1387 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 20 patient per group at the dose expansion phase.
2880423|NCT03386513|Experimental|Escalation and Expansion|"Escalation: IMGN632 will be administered by IV on Day 1 of each cycle, with cycles repeating every 21 days for patients with relapsed/refractory AML or BPDCN.~Expansion: IMGN632 will be administered by IV on Day 1 of each cycle, with cycles repeating every 21 days, across four expansion cohorts, for patients with relapsed BPDCN, AML, ALL, and other CD123+ hematologic malignancies"
2880424|NCT03386500|Other|Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001|One arm includes all enrolled patients.
2880425|NCT03386487|Active Comparator|PF-04457845|Subjects will be randomized to Fatty Acid Amide Hydrolase (FAAH) Inhibitor; 4 mg PF-04457845 QD x 8 weeks
2880426|NCT03386487|Placebo Comparator|Placebo|Subjects will be randomized to placebo
2880427|NCT03386474|Experimental|Brolucizumab|Brolucizumab 6 mg solution for IVT injection, single injection at Day 1 (baseline), Week 8, and Week 16 or Week 20
2880428|NCT03386474|Active Comparator|Aflibercept|Aflibercept 2 mg solution for IVT injection, single injection at Day 1 (baseline), Week 8 and Week 16
2880429|NCT03386461|Experimental|Exercise + Omega 3 supplementation|Subjects will be enrolled in physical activity program that consists of combined aerobic and resistive training 3 times a week for 4 months. Training will be supervised by physiotherapists experienced in exercise training of elderly (Senior Fitness, and Faculty of Physical Education and Sport). Subjects will take 5 capsules od Calanus oil (containing approx. 250 mg EPA and DHA per day).
2880430|NCT03386461|Placebo Comparator|Exercise + placebo|Subjects will be enrolled in physical activity program that consists of combined aerobic and resistive training 3 times a week for 4 months. Training will be supervised by physiotherapists experienced in exercise training of elderly. Subjects will take 5 capsules od placebo per day (provided by Calanus oil company, containing sunflower oil).
2880431|NCT03386448|Placebo Comparator|control|Participants will receive placebo medication
2880432|NCT03386448|Experimental|Active|participants will receive active medications scopolamine and naltrexone
2880433|NCT03386435|Active Comparator|RIPC group|received remote ischemic preconditioning
2880434|NCT03386435|No Intervention|control group|no intervention
2880435|NCT03386422|Experimental|Mindfulness Self-Compassion Intervention MSC|"Mindfulness Self-Compassion (MSC) is a standardized program to increase self-compassion. It has been developed by Neff and Germer. The structure of the program is similar to de Mindfulness-Based Stress Reduction program (MBSR), with duration of sessions between 2 and 2 hours and a half. The frequency of the sessions is one per week for 8 weeks, with practical and experiential exercices in sessions and between sessions.~The MSC program focuses primary on helping patients to develop self-compassion, and it includes Mindfulness just as a secondary component.~The MSC program will be conducted by a clinician trained in this specific program."
2880436|NCT03386422|Active Comparator|Cognitive-Behavioural Intervention CBT|"It has been adapted a Cognitive-Behavioural Intervention for Chronic Pain by Moix and Kovacs. Our program will have 8 sessions, with duration of sessions between 2 and 2 hours and a half. The frequency of the sessions is one per week for 8 weeks, with homework between sessions.~During these 8 sessions we will train the following techniques: psychoeducation about pain, relaxation training, cognitive restructuring training, solving problem training, psychoeducation about emotions, interpersonal skills and time organization."
2880437|NCT03386409|No Intervention|Baseline|Participants receive the standard of care recommendations for safe firearm storage device usage.
2880438|NCT03386409|Experimental|Free Device|Participants receive the standard of care recommendations for safe firearm storage device usage In addition, the study intervention is provision of a free safe firearm storage device (lock box, trigger lock and/or cable lock) for firearm storage at the time of enrollment.
2880439|NCT03386409|Experimental|Low Cost Device|Participants receive the standard of care recommendations for safe firearm storage device usage. In addition, the study intervention is the provision of a low cost ($5) firearm storage device (lock box, trigger lock and/or cable lock) for firearm storage at the time of enrollment.
2880440|NCT03386396|Experimental|High protein/low carbohydrate|A breakfast shake will be made with high protein/low carbohydrate mixture.
2880441|NCT03386396|Experimental|High carbohydrate/low protein|A breakfast shake will be made with high carbohydrate/low protein mixture.
2880442|NCT03386383|Experimental|Intervention|Participants will receive an initial individual session, physical activity tracker, weekly behavioral lessons, tailored feedback summaries, and access to a Facebook group immediately after baseline assessments.
2880443|NCT03386383|No Intervention|Wait List Control|Participants will receive a physical activity tracker and be advised to maintain their current activity. After 3 months, participants will receive an initial individual session, weekly behavioral lessons, tailored feedback summaries, and access to a Facebook group.
2880444|NCT03386370|Other|"Treatment by Indigo mechanical thrombectomy system"|Acute or Chronic clot: if chronic (> 14 days) no intervention given via Indigo
2880445|NCT03386357|Experimental|A (pembrolizumab+RT)|Pembrolizumab (200mg absolute, q3w) combined with radiotherapy (12x3Gy) of one, two or three metastases.
2880446|NCT03386357|Active Comparator|B (pembrolizumab)|Pembrolizumab (200mg absolute, q3w) without radiotherapy
2880447|NCT03386344|Experimental|Dose 1|Sotagliflozin dose 1 given as two (2) dose 2 sotagliflozin tablets on top of baseline antidiabetic therapy
2880448|NCT03386344|Experimental|Dose 2|Sotagliflozin dose 2 given as one (1) dose 2 sotagliflozin tablet and one (1) sotagliflozin matching placebo tablet on top of baseline antidiabetic therapy
2880449|NCT03386344|Placebo Comparator|Placebo|Placebo, given as two (2) sotagliflozin matching placebo tablets on top of baseline antidiabetic therapy
2880450|NCT03386331|Other|Diet and Exercise|
2880451|NCT03386318||day surgery patients|20 patients female 30-60 years of age
2880554|NCT03385512|Experimental|OPEN High Touch|Participants in this arm will experience the OPEN High Touch intervention.
2880452|NCT03386305|Experimental|EnvarsusXR arm|Patients are converted to once daily EnvarsusXR (study drug). The patients continue taking this medication for 9 months of the study. Initial dosage will be 0.8 times the total daily dose of tacro bid, due to higher bioavailability. All subsequent dose adjustments will be based on maintenance of target tacro trough levels within range of 5-12 ng/ml.
2880453|NCT03386305|Active Comparator|Standard of care arm|Post Liver Transplant patients take Tacrolimus twice daily as a part of standard of care. Those participating in the study will continue to take tacrolimus twice daily, as apart of their regular care. As a part of the study, they will complete the medication adherence and quality of life instruments.
2880454|NCT03386279|Other|Sequence 1|Sequential allocation to PF-04965842 600 mg (oral, single dose), placebo (oral, single dose), and moxifloxacin 400 mg (oral, single dose)
2880455|NCT03386279|Other|Sequence 2|Sequential allocation to PF-04965842 600 mg (oral, single dose), moxifloxacin 400 mg (oral, single dose), and placebo (oral, single dose)
2880456|NCT03386279|Other|Sequence 3|Sequential allocation to placebo (oral, single dose), PF-04965842 600 mg (oral, single dose), and moxifloxacin 400 mg (oral, single dose).
2880457|NCT03386279|Other|Sequence 4|Sequential allocation to placebo (oral, single dose), moxifloxacin 400 mg (oral, single dose), and PF-04965842 600 mg (oral, single dose)
2880458|NCT03386279|Other|Sequence 5|Sequential allocation to moxifloxacin 400 mg (oral, single dose), PF-04965842 600 mg (oral, single dose), and placebo (oral, single dose)
2880459|NCT03386279|Other|Sequence 6|Sequential allocation to moxifloxacin 400 mg (oral, single dose), placebo (oral, single dose) and PF-04965842 600 mg (oral, single dose)
2880460|NCT03386253|Experimental|active tDCS|Participants receive active tDCS for five consecutive days before attempting to quit smoking
2880461|NCT03386253|Sham Comparator|sham tDCS|Participants receive sham tDCS for five consecutive days before attempting to quit smoking
2880462|NCT03386240|Experimental|Plus group (Triclosan-coated Sutures)|Use of Monocryl Plus, Vicryl Plus and PDS Plus Suture (Triclosan-coated sutures) will be used exclusively throughout the entire procedure.
2880463|NCT03386240|Placebo Comparator|Control group|Use of Monocryl, Vicryl and PDS Suture (equivalent uncoated sutures) will be used exclusively throughout the whole procedure.
2880464|NCT03386227|No Intervention|Prophylactic antibiotics|Current standard of care in our practice for a fresh in vitro fertilization cycle is to administer one dose of 1 gram oral azithromycin on day one of the IVF cycle start to both the male and female partner. In cases of same-sex couples, only the female undergoing the embryo transfer receives prophylaxis. This will serve as our control arm entitled: prophylactic antibiotics.
2880465|NCT03386227|Experimental|No antibiotic prophylaxis.|Couples randomized to the no-antibiotic treatment group will not be prescribed oral antibiotic prophylaxis.
2880466|NCT03386214|Experimental|Arm 1: Starting Dose - 5 mg/m^2 pevonedistat + ruxolitinib|"Pevonedistat will be given as an IV infusion at the assigned dose over the course of 60 minutes on Days 1, 3, and 5 of each 28-day cycle.~Ruxolitinib will be continued at the same dose as prior to enrollment and will be administered as standard of care outside the study protocol."
2880467|NCT03386214|Experimental|Arm 2: Dose Level 2 - 10 mg/m^2 pevonedistat + ruxolitinib|"Pevonedistat will be given as an IV infusion at the assigned dose over the course of 60 minutes on Days 1, 3, and 5 of each 28-day cycle.~Ruxolitinib will be continued at the same dose as prior to enrollment and will be administered as standard of care outside the study protocol."
2880468|NCT03386214|Experimental|Arm 3: Dose Level 3 - 20 mg/m^2 pevonedistat + ruxolitinib|"Pevonedistat will be given as an IV infusion at the assigned dose over the course of 60 minutes on Days 1, 3, and 5 of each 28-day cycle.~Ruxolitinib will be continued at the same dose as prior to enrollment and will be administered as standard of care outside the study protocol."
2880469|NCT03386201|Experimental|Intravenous methylene blue|
2880470|NCT03386188|Experimental|Healthy arm|posterior parietal cortex (PPC) transitory inactivation
2880471|NCT03386162|Experimental|Experimental arm (Arm A3)|fulvestrant (500 mg intramuscular [as two 5 mL injections] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days± 3 days.
2880472|NCT03386162|Active Comparator|Control arm (Arm B3)|maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
2880473|NCT03386149|Experimental|Experimental Group|In the experimental group, 2.5g of Bosinji granule (Tsmura Co., Tokyo, Japan) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.
2880474|NCT03386149|Active Comparator|Control Group|In the control group, Loxonine tab. (loxoprofen 60mg, Dong Wha Pharm Co., Ltd, Seoul, Korea) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.
2880475|NCT03386136|Experimental|Hospitalized Ileus or Pseudo-Obstruction Patient|Hospitalized inpatient diagnosed with ileus, bowel obstruction or colonic pseudo-obstruction [clinician interpretation or small bowel diameter ≥3.5 cm, cecal diameter ≥ 9 cm, sigmoid colon diameter ≥ 6 cm] provided with 100% oxygen via non-rebreather face mask, for 6 hours
2880476|NCT03386123|Experimental|Cognitive Behaviour Therapy for Insomnia (CBTi)|"A standard CBTi programme for the treatment of primary insomnia, with six, 2 hour, group sessions over eight weeks. There will be minor adaptations for tinnitus, including making specific reference to tinnitus and psycho-education about tinnitus. Every session concludes with provision of a homework task and a sleep diary to complete over the next week. The CBTi course will be supported by providing participants with a CD with some relaxation exercises and a booklet that covers the information given in the session.~CBTi includes: Sleep restriction, stimulus control, Sleep hygiene, Relaxation training, Paradoxical intention, Cognitive therapy: Targeting unhelpful beliefs about sleep and worry, Behavioural experiments: Testing unhelpful beliefs and adjusting sleep related behaviour."
2880507|NCT03385902|Active Comparator|late start group|the DIFE will be used as the assessment of initiation time of dialysis. Patients in this group will start dialysis when their results of the DIFE less than 30, which defined as late start time.
2880555|NCT03385512|Experimental|OPEN High Tech|Participants in this arm will experience the OPEN High Tech intervention.
2880477|NCT03386123|Active Comparator|Standard Audiological Care (SAC)|"A group intervention that fits with reported audiological treatment of people with tinnitus and significant sleep impairment. This involves psycho-education about tinnitus, habituation, sleep and sleep hygiene. Relaxation will be advised and information provided. A bedside sound generator, as used in routine clinical practice will be provided. Information will be based on standard advice given by hearing therapists/audiologists and will not include specific psychological techniques which are not part of SAC. The group will be generally supportive.~SAC tends not to involve repeated meetings; after the initial session, there will be one follow up session 8 weeks later. Follow up will allow for question and answer, and reports on what has been useful. Both sessions will last for 2 hours"
2880478|NCT03386123|Placebo Comparator|Sleep Support Group (SSG)|"Participants will meet in a group, which will offer equivalent contact with therapists and a supportive group milieu as CBTi. It will focus on the potential benefits of a supportive group and will not include specific advice.~Participants will complete 2-week sleep diaries as baseline and outcome measures at the four time-points, which will be checked within the session to ensure that participants know how to complete them correctly. The SSG will meet in a group for six sessions, over eight weeks, each of 2 two hours duration."
2880479|NCT03386110|Experimental|Couples Health Project (CHP)|The CHP intervention is a three session intervention that occurs once a week for three weeks. The CHP intervention will be delivered by MI-trained mental health counselors. The CHP intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.
2880480|NCT03386110|Active Comparator|Education|The Education intervention is a attention-matched control three-session intervention that occurs once a week for three weeks. The education intervention will be delivered by trained health educators. The education intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.
2880481|NCT03386097||Type 2 diabetes patients|
2880482|NCT03386097||Healthy controls|
2880483|NCT03386084|Experimental|direct application of microwave diathermy and motor control|
2880484|NCT03386084|Placebo Comparator|application of microwave diathermy without therapeutic effects|
2880485|NCT03386058|Experimental|Intervention|Temporary device deactivation
2880486|NCT03386045|Active Comparator|Optimal SBRT|Participants in this group will be randomised to either SBRT ( 36 to 45 GY in 5 fractions) or standard radiotherapy (60 Gy in 20 fractions). The allocation is 2 to 1. This means that two thirds of the participants on the trial will get the SBRT (5 treatments) and one third will get the standard fractions.
2880487|NCT03386045|Active Comparator|Optimal Booster|Participants in this group will be randomised to either standard radiotherapy plus SBRT (45 Gy in 20 fractions plus 20-30 Gy in 2 fractions-Booster) or standard radiotherapy (60 Gy in 20 fractions). The allocation is 2 to 1. This means that two thirds of the participants on the trial will get the Booster arm and one third will get the standard fractions.
2880488|NCT03386032|Experimental|Investigational OTC Cream|Investigational Over the Counter (OTC) Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
2880489|NCT03386032|Sham Comparator|Placebo Cream|Placebo Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
2880490|NCT03386032|Active Comparator|0.05% Desonide Cream|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions."
2880491|NCT03386019|Experimental|Sprinters|Sprinters will be recruited from the track and field team of National Taiwan Normal University (NTNU) in this study. After individuals' enrollments and baseline data collections, all subjects will receive all three different treatments (massage, cold water immersion and static stretching) in randomized orders a week apart, respectively. Outcome measures are: visual analogue scale (VAS) score, lower leg volume, pressure pain threshold and horizontal jump distance. All measurements will be recorded at baseline, immediately after exercise, immediately after treatment, and 10 minutes after treatment as the follow up.
2880492|NCT03386006|Experimental|Noom Coach for Bariatric Health|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app.
2880493|NCT03386006|No Intervention|Usual Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period."
2880494|NCT03385993|Experimental|Mediation and Relaxation Intervention|Patients will undergo a technology based guided meditation and relaxation exercise through use of an application on a tablet or virtual reality headset.
2880495|NCT03385980||Post-mortem patients|Post-mortem oncological patients (within 2-6 hrs from death, maximum time for tissue preservation).
2880496|NCT03385967|Active Comparator|ropivacaine only|0.5% ropivacaine
2880497|NCT03385967|Active Comparator|ropivacaine with dexmedetomidine|25ml of 0.5%ropivacaine with 0.25mcg/kg of dexmedetomidine
2880498|NCT03385954|Experimental|Intervention|distance education curse with 8 hours to be accomplished in 2 weeks,
2880499|NCT03385954|Experimental|Control|Wiil receive a lecture of 30 minutes
2880500|NCT03385941||Osteoporotic|Femal, 50-80 years of age with established diagnosis of osteoporosis, based on prior DXA scan with T-score <-2.0 at any site and/or history of fragility fracture
2880501|NCT03385941||Non-osteoporotic|Female, 27-40 years of age, no established history of osteoporosis
2880502|NCT03385928|Active Comparator|Tranexamic acid|Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
2880503|NCT03385928|Placebo Comparator|Normal Saline (0.9% NaCl)|100 mls intravenous 0.9%NaCl over 10 minutes followed by 500 ml intravenous 0.9% NaCl infusion over 8 hours.
2880504|NCT03385915||TAVI cohort|Patients who underwent transcatheter aortic valve implantation for aortic valve stenosis
2880505|NCT03385915||SAVR cohort|Patients who underwentsurgical aortic valve replacement for aortic valve stenosis
2880506|NCT03385902|Experimental|optimal start group|The DIFE will be used as the assessment of initiation time of dialysis. Patients in this group will start dialysis when their results of the DIFE reaching to 30-35, which defined as the optimal start time.
2880556|NCT03385512|Experimental|ASK|Participants in this arm will experience the ASK intervention.
2880508|NCT03385889|Experimental|Cervical Spine Mobilization Group|Subjects with cervicogenic headache who will be assigned to cervical spine mobilization group and receive intervention directed to C1/2 of ipsilateral side of unilateral dominant headache.
2880509|NCT03385889|Experimental|Cervical Spine Manipulation Group|Subjects with cervicogenic headache who will be assigned to cervical spine manipulation group and receive intervention directed to C1/2 of ipsilateral side of unilateral dominant headache.
2880510|NCT03385889|No Intervention|Control Group|No intervention. Subjects in this groups will wait for 5 minutes between pre- and post-testing of dependent variables.
2880511|NCT03385876|Experimental|Enrollees|Enrollment of healthy and affected subjects to collect samples and data for a pediatric genomic biorepository. Data includes genomic sequencing and resultant molecular diagnostic results, if any.
2880512|NCT03385863||early preterm infants with RDS|gestational age<34 weeks
2880513|NCT03385863||near term infants with RDS|34 weeks≤gestational age< 37 weeks
2880514|NCT03385863||term infants with RDS|Gestational age ≥ 37 weeks
2880515|NCT03385850|Experimental|early enteral nutrition|
2880516|NCT03385850|Active Comparator|delayed enteral nutrition|
2880517|NCT03385837||Heart Failure Patients|Cardiac Rehabilitation in Advanced Heart Failure Patients
2880518|NCT03385824|Experimental|Self-Advocacy for Independent Life (SAIL)|10 week treatment program to improve self-advocacy skills. Includes 4 in-person group sessions (3 hours per session) and two supportive phone calls; workbook and home assignments.
2880519|NCT03385824|No Intervention|Control|SAIL workbook provided at the conclusion of the study.
2880520|NCT03385811||Medical Professionals|no intervention, only questionnaire survey
2880521|NCT03385798|Active Comparator|Endo-GIA|
2880522|NCT03385798|Experimental|Endo-wrist|
2880523|NCT03385759|Active Comparator|UKA|Medial unicompartmental knee arthroplasty
2880524|NCT03385759|Active Comparator|TKA|Total knee arthroplasty
2880525|NCT03385746|Experimental|polyamide|metal reinforced polyamide denture base material
2880526|NCT03385746|Active Comparator|heat cured acrylic resin|conventional heat cured acrylic resin denture base
2880527|NCT03385733|Experimental|Inspiratory muscle training group|Patients will continue 8 weeks, 5 days, 2 times 15 minutes training program with %30 MIP at home.
2880528|NCT03385733|No Intervention|control group|Patients will continue 8 weeks, 5 days, 2 times 15 minutes training program with 9 cmH2O pressure at home.
2880529|NCT03385720|Experimental|Experimental group|
2880530|NCT03385720|Active Comparator|Control group|
2880531|NCT03385707|Experimental|CGM and Microbiota|Participants will wear a Dexcom continuous glucose monitor (CGM) and activity monitor for two weeks. They will not be aware of sensor glucose values. A stool sample will be collected. The investigators will evaluate relationships between patterns of postprandial glycemia, recorded by CGM, food intake, and microbiome composition.
2880532|NCT03385694||Assessment|All the patients operated on Van Nes Rotationplasty for bone tumors at IOR and long term surviving
2880533|NCT03385681|Experimental|Intervention Group|The study will be conducted by nurses at 3 postoperative units with children and adolescents after surgery. All nurses working with patients in these units will be asked to participate. Tailored Educational Intervention is administered to this group.
2880534|NCT03385681|No Intervention|Control Group|The study will be conducted by nurses at 3 postoperative units with children and adolescents after surgery. All nurses working with patients in these units will be asked to participate in the study.
2880535|NCT03385668|Experimental|Pirfenidone|All patients will receive Pirfenidone
2880536|NCT03385655|Experimental|wee-I inhibitor|
2880537|NCT03385655|Experimental|cMET inhibitor|
2880538|NCT03385655|Experimental|novel non-steroidal androgen receptor (AR) antagonist|
2880539|NCT03385642||Chondromimetic|Treatment of osteochondral defect in the knee with Chondromimetic device(s) in previous study 0MCM0107
2880540|NCT03385629|Experimental|CSM theory-based Arm|CSM theory-based didactic education and skills training Practice EMR changes
2880541|NCT03385629|Active Comparator|AAP-based Arm|AAP-based didactic education
2880542|NCT03385616|Experimental|Treatment with GATS|Gala Airway Treatment System (GATS)
2880543|NCT03385603|Experimental|Fear-based Dilator Progression group|Participants in this group will complete a home dilator program using levels of pain-related fear to progress through the program.
2880544|NCT03385603|Active Comparator|Standard Dilator Progression Group|Participants in this group will complete a standard home program based on dilator manufacturer instructions for use.
2880545|NCT03385590|Experimental|Soy-fiber-maize|Complementary food composed of soybean, soy fiber and maize flours.
2880546|NCT03385590|Active Comparator|Maize|Complementary food composed of maize flour.
2880547|NCT03385577|Experimental|Yoga Intervention|"The intervention, Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer, is a 10-week, manualized, group yoga program. Sessions are 60 minutes in duration, once a week, across the course of 10 weeks. The 10-week program is comprised of five modules, each of which will take two sessions to complete: (1) Getting Started, (2) Cultivating a Mindful Attitude, (3) Self-Care and Compassion, (4) Finding Peace and Acceptance, and (5) The Power of the Present Moment."
2880548|NCT03385564|Experimental|BI 655064|
2880549|NCT03385564|Placebo Comparator|Placebo|
2880550|NCT03385551|Active Comparator|ARM 1|10 micrograms of estradiol vaginal tablets. One tablet intravaginally once daily for two weeks. Thereafter one tablet twice per week with at least a 3-days interval between treatments to maintain therapeutic response
2880551|NCT03385551|Active Comparator|ARM 2|Promestriene 10 mlligrams / grams vaginal cream. 1 gr. One application once daily intravaginally for two weeks. Thereafter one application twice per week with at least a 3-days interval between treatments to maintain therapeutic response
2880552|NCT03385538|Experimental|Clopidogrel non-responders|Increasing doses og Clopidogrel depending on PRU values measured on VerifyNow
2880553|NCT03385525|Experimental|BIIB074 150 mg and Valproic Acid 500 mg|Participants will receive BIIB074 in tablet form in 150 mg doses. BIIB074 will be taken once daily (QD) on Days 1-16 after an 8-hour fast. Valproic Acid will be given in capsule form in 500 mg doses on prescription (TID) every 8 hours on Days 8-22. The morning dose on Day 16 will be coadministered with BIIB074 following an 8-hour fast.
2880559|NCT03385499|Other|seroconversion group|blood additional samples on seroconversion group
2880560|NCT03385486|Experimental|TBX-3400|TBX-3400 by intravenous infusion
2880561|NCT03385473|Active Comparator|Pharmacological Adequation (PA)|Pharmacological adequation based on the Pharmacogenomic Index and therapeutic drug monitoring results.
2880562|NCT03385473|No Intervention|Standard of Care (SOC)|Without pharmacological adequation
2880563|NCT03385460|Experimental|ESWL BOTOX|Each patient will be subjected to Low Energy Shock Waves.The target dose of low energy shock waves will be 3000 shock delivered into SP region in 3 horizontal points at SP transverse crease . all patients will be catheterized using nylaton catheter 16 ch, the study group will be injected with 100 IU botulinium toxin A. vial will be dissolved in saline half of the estimated bladder capacity. All patients will be kept for 2 hours without micturation giving a chance of BOTOX absorption .
2880564|NCT03385447|Experimental|Physical Activity|Participants were subjected to a 12-week exercise program targeting the federal physical activity guidelines.
2880565|NCT03385434|Experimental|Endorings-assisted screening colonoscopy|146 patients with an indication for screening endoscopy will receive an Endorings-2-assisted colonoscopy.
2880566|NCT03385434|No Intervention|Standard screening colonoscopy|146 patients with an indication for screening endoscopy will receive a standard colonoscopy.
2880567|NCT03385408|Experimental|HILT group|High-intensity laser therapy application through HIRO 3.0 device
2880568|NCT03385408|Sham Comparator|Placebo group|Sham high-intensity laser therapy application through HIRO 3.0 device
2880569|NCT03385395|Experimental|OctaAlpha1|
2880570|NCT03385395|Active Comparator|Glassia®|
2880571|NCT03385382||Dexamethasone group|Patients with diabetic macular edema receiving dexamethasone
2880572|NCT03385382||ranibizumab|Patients with diabetic macular edema receiving ranibizumab
2880573|NCT03385369|Experimental|Cohort 1 (Japanese)|Single low dose of MEDI0382 or placebo
2880574|NCT03385369|Experimental|Cohort 2 (Japanese)|Single intermediate - low dose of MEDI0382 or placebo
2880575|NCT03385369|Experimental|Cohort 3 (Japanese)|Single intermediate - high dose of MEDI0382 or placebo
2880576|NCT03385369|Experimental|Cohort 4 (Japanese)|Single high dose of MEDI0382 or placebo
2880577|NCT03385369|Experimental|Cohort 5 (Chinese)|Single intermediate - low dose of MEDI0382 or placebo
2880578|NCT03385356|Active Comparator|1000 IU of vitamin D per day|Half of randomized patients will receive 1000 IU of vitamin D per day
2880579|NCT03385356|Active Comparator|4000 IU of vitamin D per day|Half of randomized patients will receive 4000 IU of vitamin D per day
2880580|NCT03385343|Experimental|VLE imaging of stage EAC|All subjects will receive VLE imaging for staging EAC. Volumetric laser endomicroscopy (VLE) is an imaging platform that uses infrared light to generate cross-sectional views of the human esophagus with microscopic resolution.
2880581|NCT03385330|Active Comparator|LOWER oxygen saturation target group|Oxygen saturation target range 90--94%. The study intervention will begin in the hospital and will continue at home until 6 months CA. Overnight continuous oximetry will be transmitted wirelessly to the study team. In hospital, inspired oxygen will be adjusted as needed to maintain target SpO2. Monitoring will continue after discharge, and oxygen flow will be titrated monthly according to a standardized algorithm.
2880582|NCT03385330|Active Comparator|HIGHER oxygen saturation target group|Oxygen saturation target range greater than or equal to 96%.The study intervention will begin in the hospital and will continue at home until 6 months CA. Overnight continuous oximetry will be transmitted wirelessly to the study team. In hospital, inspired oxygen will be adjusted as needed to maintain target SpO2. Monitoring will continue after discharge, and oxygen flow will be titrated monthly according to a standardized algorithm.
2880583|NCT03385317|Experimental|Mindfulness|
2880584|NCT03385304|Experimental|10% povidone-iodine (1% free iodine) in purified water|The povidone-iodine solution will contain 10% povidone-iodine (1% free iodine) in purified water as the only active ingredient. Operating room personnel will apply the solution to the operative site as the final preoperative skin antisepsis preparation immediately prior to commencing surgical fixation. They will apply the solution as per manufacturer's directions for use (e.g., technique of application, duration of application, drying time, drying techniques, replacement of draping, etc.).
2880585|NCT03385304|Experimental|4% chlorhexidine gluconate (CHG) in purified water|The CHG solution will contain 4% CHG in purified water as the only active ingredient. Operating room personnel will apply the solution to the operative site as the final preoperative skin antisepsis preparation immediately prior to commencing surgical fixation. They will apply the solution as per manufacturer's directions (e.g., technique of application, duration of application, drying time, replacement of draping, etc.).
2880586|NCT03385291|Experimental|patients with disorders of consciousness|3 minutes stimulation with music,name,and noise separately,each are separated with a 5 minutes washout period.
2880587|NCT03385291|Experimental|healthy control group|3 minutes stimulation with music,name,and noise separately,each are separated with a 5 minutes washout period.
2880588|NCT03385278|Experimental|real-sham|the group first received real rTMS,then sham one.
2880589|NCT03385278|Experimental|sham-real|the group first received sham rTMS,then real one.
2880590|NCT03385265|Experimental|DIPPer Academy|Families randomized to this group will participate in the DIPPer Academy curriculum.
2880591|NCT03385265|Active Comparator|Standard of Care Control|
2880592|NCT03385252|Experimental|Egg Group|Egg Intervention: Provision of eggs to caregivers of enrolled infants, with instructions to prepare and feed one egg to the infant each day for 6 months time. Households will be visited twice weekly to provide eggs and monitor intake.
2880593|NCT03385252|Active Comparator|Control Group|Control Group: Caregivers will receive a food basket at the end of the study. Throughout the trial, households will be visited twice weekly and asked about food intake.
2880594|NCT03385239|Experimental|ISIS 678354 Dose 1|Cohort A
2880595|NCT03385239|Experimental|ISIS 678354 Dose 2|Cohort B
2880596|NCT03385239|Experimental|ISIS 678354 Dose 3|Cohort C
2880597|NCT03385239|Experimental|ISIS 678354 Dose 4|Cohort D
2880598|NCT03385239|Placebo Comparator|Placebo Comparator: Placebo: Sterile Normal Saline|Sterile Normal Saline (0.9% NaCl) by volume to match dose and regimen of active comparator depending on Cohort assignment
2880958|NCT03383029|Experimental|iEAT|Children with food refusal will participate in the iEAT program.
2880599|NCT03385226|Experimental|Pembrolizumab with radiotherapy|"All patients will receive~single 200mg pembrolizumab IV infusions given 3-weekly until 2 years post study entry, termination of treatment, disease progression or unacceptable toxicity~radiotherapy, 12Gy in 3 fractions"
2880600|NCT03385213||Relapse|Patients who suffered colorectal cancer relapse after curative surgery
2880601|NCT03385213||Remission|Patients who get remission after curative surgery
2880602|NCT03385200|Active Comparator|A|Application and measurement of tumor size using contrast agent-enhanced diagnostic and therapy supporting (with SonoVue®) ultrasound
2880603|NCT03385200|No Intervention|B|Application and measurement of tumor size using contrast agent-enhanced diagnostic ultrasound
2880604|NCT03385187|Other|NightOwl HSAT|Patient undergoes a NightOwl sleep apnea test whilst simultaneously undergoing a sleep study with a Type I sleep monitor (Lab-PSG) and optionally a Type IV sleep monitor.
2880605|NCT03385174|Other|Carbon monoxide|Each participant receives CO inhalation
2880606|NCT03385161|Active Comparator|botulinum toxin A|"Intraprostatic injection of botulinum toxin A (onabotulinumtoxinA; 100 IU) through transrectal ultrasonography.~One vial (100 IU) is dissolved in 10 ml saline and injected in the transition zone of each lobe of the prostate in 3 sites; basal, middle and apical.~one gm intramuscular ceftriaxone started and continued 3 days. A rectal enema performed the night before the procedure. The anal area sterilized A 21 gauge needle was introduced to the prostate."
2880607|NCT03385161|Active Comparator|Ethanol|"Intraprostatic injection of dehydrated ethanol through transrectal ultrasonography.~An amount equal to 25% of prostate volume was injected distributed over 6-8 sites among both prostatic lobes with an average of 2 ml per site.~one gm intramuscular ceftriaxone started and continued 3 days. A rectal enema performed the night before the procedure. The anal area sterilized A 21 gauge needle introduced to the prostate."
2880608|NCT03385148|Experimental|colorectal patients|the colorectal patients undergo 68Ga-Sgc8 PET/CT
2880609|NCT03385135|Active Comparator|Allopurinol group|Optimal medical therapy associated with allopurinol. The dose of allopurinol is 300 mg for 4 weeks then 600 mg for 4 weeks
2880610|NCT03385135|No Intervention|No Allopurinol group|Optimal medical therapy alone
2880611|NCT03385109||Senhance Treated|All patients enrolled who go on to have a surgery in which the Senhance system is used
2880612|NCT03385096|Experimental|BUCY+VP-16|For MM patients undergoing auto-HSCT，BUCY+VP-16 conditioning regimen was BU 3.2 mg/kg/day on days -8 and -6；CY 60 mg/kg/day on days -5 and -4; VP-16 10mg/kg/day on days -3 and -2.
2880613|NCT03385096|Active Comparator|Melphalan|For MM patients undergoing auto-HSCT，Melphalan conditioning regimen was Melphalan 200mg/m2 on day -2.
2880614|NCT03385083|Experimental|ACTIVITY TRACKER|Subjects in Cohort A will receive standard of care treatments in addition to a Fitbit Flex 2 activity tracker for six weeks and recommendation for daily step counts at initial visit. Cohort A will then meet with researchers via telehealth at 2 weeks and 4 weeks with researchers to review step counts and reaffirm targets. Subjects in Cohorts A will be reassessed in person at the conclusion of the six week period.
2880615|NCT03385083|Placebo Comparator|Control|Subjects in Cohort B will receive standard of care treatments in addition to a Fitbit Flex 2 activity tracker for six weeks and recommendation for daily step counts at initial visit. Subjects in Cohorts B will be reassessed in person at the conclusion of the six week period.
2880616|NCT03385070||Salt-sensitive group|"Patients (n:163)with HT who presented at the emergency service at least once with a minimum increase in their systolic and diastolic blood pressure of 10% after consuming salty foods were included in the SSH group.~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
2880617|NCT03385070||Salt resistance group|"Patients(n:142) who did not exhibit this increase were included in the SRH group~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
2880618|NCT03385070||Control group|"Sex- and age-matched patients(n:124) without a HT diagnosis were included in the control group.~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
2880619|NCT03385057|Active Comparator|Ibuprofen Arm|
2880620|NCT03385057|Active Comparator|Acetaminophen|
2880621|NCT03385044|Active Comparator|Cuff sealing by MOVT|MOVT (minimal occlusive volume technique). The cuff sealing will be confirmed with MOVT, then the intracuff pressure will be measured.
2880622|NCT03385044|Active Comparator|Cuff sealing by VE/VI ratio|VE/VI ratio of Spirometer. The cuff sealing will be confirmed with VE/VI ratio of a spirometer, then the intracuff pressure will be measured.
2880623|NCT03385031||group 1|whole breast irradiation, CBCT imaging at first and last fraction of radiotherapy treatment
2880624|NCT03385031||group 2|simultaneous integrated boost, CBCT imaging at first and last fraction of radiotherapy treatment
2880625|NCT03385031||group 3|patients with seroma at start radiation treatment (whole breast irradiation or simultaneous integrated boost), CBCT imaging at first and last fraction of radiotherapy treatment
2880626|NCT03385018|Experimental|Laparoscopic group|Arm Description: Laparoscopic radical total gastrectomy with D2 (or D2-#10) lymph node dissection
2880627|NCT03385018|Active Comparator|Open group|Open radical total gastrectomy with D2 (or D2-#10) lymph node dissection
2880628|NCT03385005|Active Comparator|Healthy Volunteers|This arm consists of healthy volunteers receiving electrical stimulation of the muscles within the forearm via an investigational (not FDA approved) neuromuscular stimulator.
2880629|NCT03385005|Active Comparator|Spinal Cord Injury Participants|This arm consists of spinal cord injury participants receiving electrical stimulation of the muscles within the forearm via an investigational (not FDA approved) neuromuscular stimulator.
2880630|NCT03384992|Experimental|Group 1|Participants were exposed to the following conditions: general health for week 1, diet-general information for week 2, and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
2880631|NCT03384992|Experimental|Group 2|Participants were exposed to the one of the following usual care conditions: general health for week 1, diet-general information for week 2, and diet-BCSS information (breast cancer survivor-specific) for week 3.
2880632|NCT03384992|Experimental|Group 3|Participants were exposed to the following conditions: cognitive restructuring for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
2909733|NCT03181360|Other|Control|No tenecteplase + Best standard treatment
2880633|NCT03384992|Experimental|Group 4|Participants were exposed to the following conditions: cognitive restructuring for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3.
2880634|NCT03384992|Experimental|Group 5|Participants were exposed to the following conditions: scheduled worry practice for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
2880635|NCT03384992|Experimental|Group 6|Participants were exposed to the following conditions: scheduled worry practice for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3.
2880636|NCT03384992|Experimental|Group 7|Participants were exposed to the following conditions: cognitive restructuring for week 1, worry practice for week 2, and General Health and Diet (General and BCSS) for week 3. Telephone coaching was given.
2880637|NCT03384992|Experimental|Group 8|Participants were exposed to the following conditions: cognitive restructuring for week 1, scheduled worry practice for week 2, and General Health and Diet (General and BCSS) for week 3.
2880638|NCT03384992|Experimental|Group 9|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, general health for week 2, and Diet - General and BCSS for week 3. Telephone coaching was given.
2880639|NCT03384992|Experimental|Group 10|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, general health for week 2, and Diet - General and BCSS for week 3.
2880640|NCT03384992|Experimental|Group 11|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, cognitive restructuring for week 2, and General health and Diet (General and BCSS) for week 3. Telephone coaching was given.
2880641|NCT03384992|Experimental|Group 12|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, cognitive restructuring for week 2, and General health and Diet (General and BCSS) for week 3.
2880642|NCT03384992|Experimental|Group 13|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, worry practice for week 2, and General health and Diet (General and BCSS) for week 3. Telephone coaching was given.
2880643|NCT03384992|Experimental|Group 14|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, scheduled worry practice for week 2, and General health and Diet (General and BCSS) for week 3.
2880644|NCT03384992|Experimental|Group 15|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, worry practice for week 2, and cognitive restructuring for week 3. Telephone coaching was given.
2880645|NCT03384992|Experimental|Group 16|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, scheduled worry practice for week 2, and cognitive restructuring for week 3.
2880646|NCT03384979|Placebo Comparator|TBW protocol|Patients will receive a contrast agent dose based on their TBW as a standard clinic protocol.
2880647|NCT03384979|Experimental|LBW protocol|Patients will receive a contrast agent dose based on their calculated LBW.
2880648|NCT03384966|Experimental|ACT-246475 8 mg|Single s.c. administration
2880649|NCT03384966|Experimental|ACT-246475 16 mg|Single s.c. administration
2880650|NCT03384966|Placebo Comparator|Placebo|Single s.c. administration
2880651|NCT03384953|Experimental|Clinical Hypnosis - Group Treatment|Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in a group setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
2880652|NCT03384953|Experimental|Clinical Hypnosis - Individual Treatment|Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in an individual, 1:1 setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
2880653|NCT03384940|Experimental|DS-8201a Cohort A|"Cohort A is comprised of participants with HER2-positive (IHC 3+ or IHC 2+/ISH +) who will receive DS-8201a once every 3 weeks~This cohort is active at study start."
2880654|NCT03384940|Experimental|DS-8201a Cohort B|"Cohort B is comprised of participants with HER2 IHC 2+/ISH - who will receive DS-8201a once every 3 weeks~The sponsor will inform investigators if, and when, this cohort becomes active."
2880655|NCT03384940|Experimental|DS-8201a Cohort C|"Cohort C is comprised of participants with HER2 IHC 1+ who will receive DS-8201a once every 3 weeks~The sponsor will inform investigators if, and when, this cohort becomes active."
2880656|NCT03384914|Active Comparator|Dendritic Cell (DC1) Vaccine|"The vaccine will be administered in two phases: a vaccination phase and a booster phase.~Approximately 6 months from the initiation of the first vaccine, patients will receive the first of 3 booster vaccines."
2880657|NCT03384914|Active Comparator|pUMVC3-IGFBP2-HER2-IGF1R (WOKVAC)|"The vaccine will be administered in two phases: a vaccination phase and a booster phase.~Approximately 6 months from the initiation of the first vaccine, patients will receive the first of 3 booster vaccines."
2880658|NCT03384888|Experimental|ano-M1-cat-SO5 tDCS|Participants will receive active transcranial direct current stimulation (tDCS) (active tDCS). The electrodes will be placed on left M1 for anodic stimulation and on the right supraorbital region for cathodic stimulation on 5 consecutive days.
2880659|NCT03384888|Experimental|ano-M1-cat-SO10 tDCS|Participants will receive active transcranial direct current stimulation (active tDCS). The electrodes will be placed on left M1 for anodic stimulation and on the right supraorbital region for cathodic stimulation on 10 consecutive days.
2880660|NCT03384888|Sham Comparator|Sham tDCS|Participants who receive stimulation of the simulated type (sham tDCS), following the protocol of the ano-M1-cat-SO5 group.
2880661|NCT03384875|Experimental|CytoSorb Device|Standard of care plus treatment with CytoSorb device installed on the Cardiopulmonary bypass (CPB) machine
2880662|NCT03384875|Placebo Comparator|Control|Standard of care
2880663|NCT03384862|Experimental|Nutritional Intervention Arm|5 μg vitamin B12 plus 400 μg folic acid
2880664|NCT03384862|Placebo Comparator|Control Arm|Placebo
2880665|NCT03384849||MRI patients|Up to 200 patients of different age, weight and sex, which undergo MRI examinations.
2880705|NCT03384602|No Intervention|Control group|no change in the daily activities, no exercise intervention
2880706|NCT03384589|Active Comparator|Group 1: 3 doses of PCV13|PCV13, 0.5ml intramuscular at 2, 4 and 12 months of age
2880666|NCT03384836|Experimental|Treatment (propranolol hydrochloride, pembrolizumab)|Patients receive propranolol hydrochloride PO BID and pembrolizumab IV over 30 minutes of day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
2880667|NCT03384823|Experimental|EDP-938 SAD Cohorts|EDP-938 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration
2880668|NCT03384823|Experimental|EDP-938 MAD Cohorts|EDP-938 Dose 1, Dose 2, Dose 3, and Dose 4 oral suspension, once daily for 7 days
2880669|NCT03384823|Placebo Comparator|EDP-938 SAD Placebo Cohort|Matching placebo, oral suspension, once daily in one single administration
2880670|NCT03384823|Placebo Comparator|EDP-938 MAD Placebo Cohort|Matching placebo, oral suspension, once daily for 7 days
2880671|NCT03384797||Healthy Volunteers|
2880672|NCT03384784|Experimental|Galantamine|"This study follows the FDA-recommended dosing regimen for galantamine extended release (GAL ER): 4 weeks at 8 mg (once a day), 4 weeks at 16 mg (once a day), and 4 weeks at 24 mg (once a day).~The University of Pennsylvania Investigational Drug Service (IDS) will oversee the randomization of all study medication, purchase study medication, manufacture matched placebo, encapsulate and package them in blister packs to maintain double-blind procedures."
2880673|NCT03384784|Placebo Comparator|Placebo|"12-week placebo-controlled medication period~Placebo ingredients will be purchased, encapsulated, and packaged into blister packs by the IDS at the University of Pennsylvania. Both active medication and placebo will look identical.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take galantamine during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by galantamine during the second medication period."
2880674|NCT03384771||MBSR Students|community-dwelling adults who register for relevant MBSR courses at UMass CFM, UCSF, or participating community sites
2880675|NCT03384771||MBSR Teachers|those teaching MBSR courses at UMass CFM, UCSF, or participating community sites
2880676|NCT03384771||Raters|experience mindfulness teachers, recruited by invitation, who will participate in MBI-TAC training
2880677|NCT03384758|Active Comparator|mild to moderate PAD|
2880678|NCT03384758|Active Comparator|Diabetes mellitus|
2880679|NCT03384758|Placebo Comparator|Healthy volunteers|
2880680|NCT03384745|Experimental|M1095 30mg|M1095, 30 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
2880681|NCT03384745|Experimental|M1095 60mg|M1095, 60 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
2880682|NCT03384745|Experimental|M1095 120mg - regimen 1|M1095, 120 mg, given at Week 0, 2, 4, 8, 12 and every eight weeks.
2880683|NCT03384745|Experimental|M1095 120mg - regimen 2|M1095, 120 mg, given at Week 0, 2, 4, 6, 8, 10, 12 and every four weeks.
2880684|NCT03384745|Placebo Comparator|Placebo / M1095 120mg|Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10, then M1095, 120mg, given at Week 12, 14, 16, and every four weeks.
2880685|NCT03384745|Active Comparator|Secukinumab|Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, 8, 12 and every four weeks.
2880686|NCT03384719|Experimental|35 g protein (30% milk + 70% rapeseed)|35 g protein per day (30% milk + 70% rapeseed) provided as a powder to be consumed every morning and evening
2880687|NCT03384719|Experimental|35 g protein (54% milk + 46% rapeseed)|35 g protein per day (54% milk + 46% rapeseed) provided as a powder to be consumed every morning and evening
2880688|NCT03384719|Active Comparator|35 g protein (100% milk)|35 g protein per day (100% milk) provided as a powder to be consumed every morning and evening
2880689|NCT03384706|Active Comparator|Cognitive Processing Therapy (CPT)|PTSD Psychotherapy CPT will be implemented using the Cognitive-Only version, excluding the trauma account.
2880690|NCT03384706|Experimental|Accelerated Resolution Therapy (ART)|PTSD Psychotherapy
2880691|NCT03384706|No Intervention|Wait List Control|Wait List control will include a 7 week minimal attention control period with weekly check-in calls to ensure that the participant has not experienced any significant worsening in their symptoms that might require interventions, (e.g. suicidal intent).
2880692|NCT03384693|Experimental|Prophylactic Defibrotide|6.25mg/kg administered intravenously every 6 hours for 28 to 35 days, starting on the day before conditioning is initiated.
2880693|NCT03384667|Experimental|MMDT group|
2880694|NCT03384667|Placebo Comparator|Placebo group|
2880695|NCT03384654|Experimental|Cohort 1: B-Cell Acute Lymphoblastic Leukemia (ALL)/LL|Cohort 1 will include participants with B cell ALL/LL in second or greater relapse or refractory to at least 2 prior induction regimens. Participant will receive daratumumab in combination with vincristine and prednisone.
2880696|NCT03384654|Experimental|Cohort 2: T-Cell ALL/LL|Cohort 2 will include participants with T-cell ALL/LL in first relapse or refractory to at least 1 prior induction/consolidation regimen. Participant will receive daratumumab in combination with vincristine, prednisone, doxorubicin and peg-asparaginase in Cycle 1 and daratumumab in combination with cyclophosphamide, cytarabine, 6- mercaptopurine and methotrexate in Cycle 2.
2880697|NCT03384641|Experimental|Bedaquiline|Participants will receive bedaquiline 200 (milligram) mg (2*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet three times a week (tiw) for 6 weeks with at least 48 hours between doses.
2880698|NCT03384628|Active Comparator|First Pair Senofilcon A contact lens|The first pair of Senofilcon A contact lenses is applied (according to the fitting schedule), allowed to settle before assessment of the first pair Senofilcon A contact lens and subsequent removal.
2880699|NCT03384628|Active Comparator|Second pair Senofilcon A contact lens|The second pair of contact lenses is applied (according to the fitting schedule), allowed to settle before assessment of the second pair Senofilcon A contact lens and subsequent removal.
2880700|NCT03384628|Active Comparator|Third pair Senofilcon A contact lens|The third pair of Senofilcon A contact lens is applied (according to the fitting schedule), allowed to settle before assessment of the third pair Senofilcon A contact lens and subsequent removal.
2880701|NCT03384615|Experimental|Compassion-focused therapy|
2880702|NCT03384615|No Intervention|Waitlist control group|
2880703|NCT03384602|Active Comparator|Dalcroze Eurhythmics program|music-based multi-task exercise intervention
2880704|NCT03384602|Active Comparator|home exercise strength program|simple strength training program to perform individually at home
2880707|NCT03384589|Experimental|Group 2: 2 doses of PCV13|PCV13, 0.5ml intramuscular at 2 and 12 months of age
2880708|NCT03384576|Experimental|Music intervention|Participants listen to music in the waiting room
2880709|NCT03384576|Active Comparator|No music|Participants will not have music in the waiting room
2880710|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 1-6 months|
2880711|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 1-6 months|
2880712|NCT03384563|Placebo Comparator|Placebo 1-6 months|
2880713|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 6-12 months|
2880714|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 6-12 months|
2880715|NCT03384563|Placebo Comparator|Placebo 6-12 months|
2880716|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 1-3 years|
2880717|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 1-3 years|
2880718|NCT03384563|Placebo Comparator|Placebo 1-3 years|
2880719|NCT03384550|Active Comparator|Control|"Participants in this arm receive no incentives.~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
2880720|NCT03384550|Experimental|Financial Incentives|"Participants in this arm receive financial incentives.~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
2880721|NCT03384550|Experimental|Charity Incentives|"Participants in this receive charity incentives.~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
2880722|NCT03384537|Experimental|Listerine total care zero|Listerine total care zero
2880723|NCT03384537|Active Comparator|Chlorhexidine Mouthwash (0.2%).|Chlorhexidine Mouthwash (0.2%).
2880724|NCT03384524|Active Comparator|Combination regiment|A combination regiment of Bromocriptine (2.5 mg/day), Metoprolol (25 mg/day) and Tamsulosin (0.4 mg/day)
2880725|NCT03384524|Placebo Comparator|Placebo|Three placebo pills, matching the external appearance of active drugs
2880726|NCT03384511|Experimental|Apatinib & RGD PET/CT|All of the patients will receive apatinib at oral dose of 250 mg twice daily (500 mg/day) at least 30 days.One treatment cycle is defined as 4 weeks.18F-ALF-NOTA-PRGD2 PET/CT scan will be performed berore and after one cycle of therapy. Treatment interruptions or dose reductions to 250 mg/day will be allowed for the management of adverse events. The maximum allowable period of treatment interruption is 1 week during each treatment cycle, and the dose should be re-escalated to 500 mg/day after adverse events mitigation. Treatment will not stop until disease progression, intolerable toxicity, or patients' request for withdrawal from the study.
2880727|NCT03384485|Other|antiphospholipid syndrome|blood test in patients that diagnosed with antiphospholipid syndrome to diagnose Fabry's disease
2880728|NCT03384459|Experimental|Experimental group|"For a total period of 12 months, perform the 308-nm excimer laser treatment once a month.~At this time, the dose of the 308-nm excimer laser is based on the 50% of the maximum dose that the patient received for the treatment.~Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
2880729|NCT03384459|No Intervention|Control group|"Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
2880730|NCT03384446|Active Comparator|Tooth-borne treatment|A cleaning aid that resembles tooth cleaning instruments and is empirically used for implant surface cleaning.
2880731|NCT03384446|Experimental|Implant-specific treatment|A cleaning aid that has been specifically designed for implant surface cleaning.
2880732|NCT03384433|Experimental|exosome or vesicle|CVA patients who have disability, will receive 200 microgram total protein of allogenic MSC-generated exosome transfected by miR-124, one month after attack, via Stereotaxis
2880733|NCT03384420|Experimental|Intervention 'CD34+ cells enriched with MNV-BLD'|Intervention 'CD34+ cells enriched with MNV-BLD'
2880734|NCT03384407|Experimental|Open label|Red cell recovery/survival analysis of untreated and INTERCEPT treated RBC concomitantly
2880735|NCT03384394|Placebo Comparator|Conventional oxygen therapy|oxygen by a standard nasal cannula or nonrebreather mask
2880736|NCT03384394|Active Comparator|High-flow Nasal Cannula Oxygen Therapy|High-flow Nasal Cannula Oxygen Therapy
2880737|NCT03384368|Placebo Comparator|Screw-Distraction (SD) group|six pedicle screws were implanted firstly, then distraction was achieved.
2880738|NCT03384368|Experimental|Distraction-Screw (DS) group|four pedicle screws were implanted firstly, then distraction was achieved, two additional screws were introduced at the fracture level at last.
2880739|NCT03384355||Class 0|no visible or palpable varicose veins
2880740|NCT03384355||Class 1|telengiectasia ( thread veins, spider veins, broken veins)
2880741|NCT03384355||Class 2|varicose veins
2880742|NCT03384355||Class 3|edema
2880743|NCT03384355||Class 4|skin changes (pigmentation, eczema, lipodermatosclerosis, atrophie blanche)
2880744|NCT03384355||Class 5|healed venous ulcer
2880745|NCT03384355||Class 6|active venous ulcer
2910472|NCT03176537|Placebo Comparator|Placebo|Gel, daily
2880746|NCT03384342|Experimental|Experimental group|"For a total period of 12 months, perform Narrow-band UV-B therapy treatment once a month.~At this time, the dose of Narrow-band UV-B therapy therapy is based on the 50% of the maximum dose that the patient received for the treatment."
2880747|NCT03384342|No Intervention|Control group|"Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
2880748|NCT03384329|Experimental|Resveratrol Pill|
2880749|NCT03384329|Placebo Comparator|Placebo|
2880750|NCT03384316|Experimental|1-Dose De-Escalation|Dose De-Escalation
2880751|NCT03384316|Experimental|2-Dose Expansion|Dose Expansion
2880752|NCT03384303|Other|LBPL-RYGB|
2880753|NCT03384303|Other|S-RYGB|
2880754|NCT03384290|Placebo Comparator|Placebo|
2880755|NCT03384290|Experimental|PRS-060|
2880756|NCT03384277|Experimental|Steroid+Rituximab|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）+Rituximab 375mg/m2 for one dose.
2880757|NCT03384277|Active Comparator|Steroid +Cyclophosphamide|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks （ then tapering gradually, 8 weeks in total）+ Cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)
2880758|NCT03384264|Experimental|TG|
2880759|NCT03384264|No Intervention|CG|the CG maintained their normal physical activity habits over the study
2880760|NCT03384251|Experimental|Intervention group|This group shall be given a comprehensive sex education in approximately six sessions.
2880761|NCT03384251|No Intervention|Control group|This group will not be given any form of education.
2880762|NCT03384238|Experimental|Diagnostic (panitumumab, panitumumab-IRDye800, imaging)|Patients receive a loading dose of panitumumab IV over 60 minutes, and after 15 minutes of observation, patients then receive panitumumab-IRDye800 IV over 60 minutes on day 0. Patients then undergo surgical resection 2-5 days after panitumumab-IRDye800 administration with imaging using the Novadaq SPY/LUNA, Novadaq IR9000 fluorescence imaging system with open field handheld fluorescence imaging camera, and/or pinpoint endoscopic fluorescence imaging camera, and SurgVision Explorer Air multi spectral fluorescence reflectance system.
2880763|NCT03384225|Experimental|CBA group|"CBA as HSCT conditioning:~cladribine 5mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
2880764|NCT03384225|Active Comparator|FBA group|"FBA as HSCT conditioning:~fludarabine 30mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
2880765|NCT03384212|Experimental|CBA group|"CBA as HSCT conditioning:~cladribine 5mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
2880766|NCT03384212|Active Comparator|FBA group|"FBA as HSCT conditioning:~fludarabine 30mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
2880767|NCT03384199|Experimental|Dose escaltion|insertion of 3 fiducial markers, prostate will receive 78 Gy with dose escalation to prostate focal lesion up to 87 Gy
2880768|NCT03384186|Experimental|ACH-0144471 Modified Release Prototypes|
2880769|NCT03384173|Experimental|NIRS monitoring|These infants will be monitored with NIRS
2880770|NCT03384160|Active Comparator|Group 1-Pain monitor|Use of the anesthetic Mepivacaine 2% in third molar extraction
2880771|NCT03384160|Active Comparator|Group 2 -Pain monitor|Use of the anesthetic Articaine 4% in third molar extraction
2880772|NCT03384147|Experimental|Drinking|"Occasional drinkers assigned to start with a 3week drinking period (women 1 u/day - men 2 u/day)~Followed by crossover without washout to 3 week abstaining period"
2880773|NCT03384147|Experimental|Abstaining|"Habitual drinkers assigned to start 2 weeks of abstaining from alcohol~Followed by crossover without washout to 3 weeks drinking (women 1 u/day - men 2 u/day)"
2880774|NCT03384134|Experimental|Pain Buddy|Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily diaries using Pain Buddy and will also be taught cognitive and behavioral coping skills, like deep breathing, imagery, and relaxation, to deal with pain and symptoms. The skills will be taught through the electronic tablet. Pain and symptom information, collected daily by Pain Buddy, will be sent to a health care provider on the oncology treatment team, who will contact patients when certain thresholds are reached and will instruct the patients on best ways to control pain and symptoms.
2880775|NCT03384134|No Intervention|Control|Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily pain diaries using Pain Buddy, but will not receive skills training or remote monitoring of data.
2880776|NCT03384121|Experimental|Rifampin|All subjects
2880777|NCT03384108|Experimental|In Vivo|Infusion of 5-13C-Glutamine intravenously in healthy subjects prior to undergoing a bone marrow aspiration.
2880778|NCT03384108|Placebo Comparator|Ex Vivo|Healthy subjects will undergoing a bone marrow aspiration and then the plasma cells acquired will be cultured ex vivo in cell culture media containing 5-13C-Glutamine.
2880779|NCT03384095|Experimental|Hyaluronic Acid|Subjects in this arm will be given 100 mg of hyaluronic acid in capsule form. Subject in this arm will be asked to 1 capsule take twice daily for 26 weeks.
2880780|NCT03384095|Placebo Comparator|Placebo|Subjects in this arm will be given a placebo comparator capsule that is identical to the hyaluronic capsule containing microcrystalline cellulose as the sole ingredient. Subjects in this arm will be asked to take 1 capsule twice daily for 26 weeks.
2880781|NCT03384082|Experimental|Hysteroscopic treatment|Hysteroscopic surgery
2880782|NCT03384082|No Intervention|Control group|No treatment
2880783|NCT03384069|Experimental|Group-based Cognitive Behavioral Therapy (CBT)|The Group-based CBT will incorporate psycho-education about cognitive behavioral skills and written materials to support learning and application of the psycho-educational content. The intervention will be culturally tailored to incorporate beliefs/attitudes, health literacy, effective communication, and motivational strategies, which focus on African Americans.
2880919|NCT03383211||Healthy Control|Healthy pregnant women without HIV or LTBI. No intervention beyond the standard of care provided for such cohort.
2880784|NCT03384069|Experimental|Phone-based Cognitive Behavioral Therapy (CBT)|This intervention will follow the same protocol as the group-based CBT, but without the opportunity for group-interaction. It will incorporate psycho-education about cognitive behavioral skills and written materials to support learning and application of the psycho-educational content. The intervention will be culturally tailored to incorporate beliefs/attitudes, health literacy, effective communication, and motivational strategies, which focus on African Americans.
2880785|NCT03384069|No Intervention|Standard of care|Participants will continue to receive care and follow up from their primary care providers, that incorporates general education regarding lifestyle activities and AD prevention.
2880786|NCT03384056|Active Comparator|Self Pressurized Airway Device with Blocker|
2880787|NCT03384056|Active Comparator|Proseal Laryngeal Mask Airway|
2880788|NCT03384043|Experimental|Smartphone Personal Assistant|"Participants will use the personal assistant feature of the smartphone (Cortana) to provide reminders to perform prospective memory tasks at the appropriate time and location. In the current study, participants will press a button and verbally state Cortana, I need to remember to... for time based time--based tasks (...take my medicine at 7pm), person--based tasks (tell [my daughter] I got a new phone), and event--based tasks (pick-up milk at the grocery store)."
2880789|NCT03384043|Active Comparator|Implementation Intention|"The implementation intention is a memory strategy, in which individuals verbally state when/where they will perform a prospective memory intention. In the current study, participants will verbally specify an external cue in a When…then format and record doing so using the smartphone's voice recorder app. They will use the implementation intention strategy for time--based tasks (When it is 7pm, then I will remember to take my medicine), person--based tasks (When I talk to [my daughter], then I will tell her I got a new phone), and event--based tasks (When I am at the grocery store, then I will remember to pick--up milk)."
2880790|NCT03384030|Experimental|adapted STMST|Participants are subjected to the adapted STMST to induce emotional sweating.
2880791|NCT03384017|Experimental|TSCS and gait training|
2880792|NCT03384004|Experimental|Irrigation Technique 1|Patients randomized into this group will be treated using EndoVac Pure followed by Ultrasonic Irrigation.
2880793|NCT03384004|Experimental|Irrigation Technique 2|Patients randomized into this group will be treated using EndoVac Pure only.
2880794|NCT03383991|Experimental|Reverse Total Shoulder Arthroplasty|
2880795|NCT03383991|Active Comparator|Hemiarthroplasty|
2880796|NCT03383978|Experimental|NK-92/5.28.z (HER2.taNK)|Intracranial application of NK-92/5.28.z (HER2.taNK), 1x10E7-1x10E8
2880797|NCT03383965|Experimental|ICAR30 T cells|anti-CD30 CAR-T cells. Patients receive ICAR30 T cells infusion.
2880798|NCT03383952|Experimental|ICAR19 CAR-T cells|Immunotherapy offers an extremely precise approach with the potential to eliminate cancer cells specifically. The newly designed CD19 targeted ICAR19 T cells can specifically kill CD19+ tumor cells. ICAR19 CART used the second generation of CART designation. In this study, the participants will receive several doses of autologous ICAR19 CAR-T cells and the investigators will determine the safety and therapeutic effects of these cells.
2880799|NCT03383939|Experimental|group A|"10 patients randomly allocated received nebulised alpha1-antitrypsin 250mg (diluted in 10ml injectable solution) once a day during 1 month.~Intervention: nebulised alpha1-antitrypsin 250mg (diluted in 10ml injectable solution) once a day during 1 month"
2880800|NCT03383939|Placebo Comparator|group B|"9 patients randomly allocated received 10ml 0.9%NaCl saline solution nebulised once daily during 1 month.~intervention: 10ml 0.9% Sodium Chloride saline solution nebulised once daily during 1 month."
2880801|NCT03383939|No Intervention|Control|10 patients without bronchiectasis were initially compared wiht bronchiectasis patients (group A + B) to define baseline levels of A1-AT and neutrophil elastase in BAL
2880802|NCT03383926|Experimental|Group 1|Suture confection of theTobacco-pouch of 4.5cm from the anal margin.
2880803|NCT03383926|Experimental|Group 2|Suture confection of theTobacco-pouch of 6cm from the anal margin.
2880804|NCT03383913|Experimental|Intervention|The intervention arm baseline visit will include: Institutional Review Board (IRB) consent, PROMIS measure baseline and outcome assessments, instructions on placement of Firstbeat device and use of Firsbeat journal, resting HRV recording using Firsbeat software for 15 minutes, saliva collection, and distribution of actigraph watch to quantify sleep quality. Participants placed in the intervention arm will receive 4-6 weeks of Heart Rate Variability Biofeedback training. All measures will be repeated at the end of the six week period.
2880805|NCT03383913|No Intervention|Control|The control arm baseline visit will include: Institutional Review Board (IRB) consent, PROMIS measure assessments, instructions on placement of Firstbeat device and use of Firsbeat journal, resting HRV recording using Firstbeat software for 15 minutes, saliva collection, and distribution of actigraph watch to quantify sleep quality. The control group will receive their usual care for SCD and complete baseline and post-baseline outcome assessments without any HRV-B training. All measures will be repeated at the end of the six week period.
2880806|NCT03383900|Experimental|G-IMT|The experimental group will first carry out a diaphragmatic reeducation program, followed a posteriori by an inspiratory muscle training program use progressive resistance loads up to 80% of the PImax during the 12 weeks
2880807|NCT03383900|Placebo Comparator|Gn-IMT|The Gn-IMT will use by an inspiratory muscle training program use resistance loads up to 10% PImax during the 12 weeks.
2880808|NCT03383887|Placebo Comparator|Placebo|Placebo capsule 30 minutes before sleep
2880809|NCT03383887|Active Comparator|DAW1033D|DAW1033D capsule 30 minutes before sleep
2880810|NCT03383874|Placebo Comparator|Placebo|Participants will receive capsules containing placebo for 24-weeks.
2880811|NCT03383874|Experimental|Probiotic-Probio-Tec BG-VCap-6.5|Participants will receive capsules containing approximately 10^9 colony forming units of the probiotic organisms, Lactobacillus GG and Bifidobacteria lactis strain Bb12 for 24-weeks.
2880812|NCT03383861||SSRI long-term user|Adults, 655 with an SSRI prescription ≥180 days and identified in the National Health and Nutrition Examination Survey (NHANES) data.
2880813|NCT03383861||Non-user|Adults, 12,372 non-users, were identified in the National Health and Nutrition Examination Survey (NHANES) data.
2880844|NCT03383640|Other|Intervention|Intervention Group: Early active exercises of the replanted digits started between day 5 and 7 after surgery, as instructed by hand therapist
2880954|NCT03383042|Experimental|Cohort 5|Single-ascending cohort 5
2880814|NCT03383848|Experimental|Experimental Software Group|Subjects in the experimental group will be provided with free access to the medication management software online, which will be able to be accessed on the SmartPhone/SmartDevice and home tablet(s) or computer(s) of their choice, through any browser. They will also be provided with links to the surveys to be filled out in the REDCap secure web application throughout the study.
2880815|NCT03383848|No Intervention|Control Group|Subjects in the control group will receive standard of care, and will receive emails with links to the surveys to be filled out in the REDCap secure web application throughout the study.
2880816|NCT03383835|Experimental|Omega-3 Supplementation|Participants will take the dose of omega-3 supplementation (600mg DHA and 300mg EPA) daily for 6 months.
2880817|NCT03383822|Experimental|Intranasal insulin|40 IU of intranasal insulin
2880818|NCT03383822|Placebo Comparator|Intranasal placebo|Placebo comparator to intranasal insulin
2880819|NCT03383809|Experimental|Strawberry juice with inulin|One dose of 300 g of strawberry with 10 g of inulin will be given to subjects in the form of juice
2880820|NCT03383809|Experimental|Strawberry juice|One dose of 300 g of strawberry juice will be given to subjects in the form of juice
2880821|NCT03383809|Experimental|Inulin|One dose of 10 g of inulin will be given to subjects in the form of a drink
2880822|NCT03383796|Experimental|3D approach|Three dimensional laparoscopic resection for pCCA
2880823|NCT03383796|Experimental|open approach|Open resection for pCCA
2880824|NCT03383783|Other|Treatment Period 1|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
2880825|NCT03383783|Other|Treatment Period 2|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
2880826|NCT03383783|Other|Treatment Period 3|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
2880827|NCT03383783|Other|Treatment Period 4|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
2880828|NCT03383770|Active Comparator|Tuohy|"After a careful disinfection of the puncture site, under sterile conditions and under ultrasonographic control with the application of nerve stimulation (settings: stimulation current primary 2.0 mA with stepwise reduction over 1.0 mA to 0.5 mA, pulse width 0.1 ms, pulse frequency 2 Hz) of the N. ischiadicus blocked by 20 ml ropivacaine 0.75 %. (electrical nerve stimulation and ultrasound) If no motor response can be triggered by stimulation, the closest possible needle-nerve distance is generated at a pulse strength of 1mA and regional anesthesia is performed. (protective nerve stimulation) Subsequently, the transplantation into the supine position and the further procedure specific to the operation (use of other regional procedures in combination or general anaesthesia).~A tuohy needle is used."
2880829|NCT03383770|Active Comparator|Facet|"After a careful disinfection of the puncture site, under sterile conditions and under ultrasonographic control with the application of nerve stimulation (settings: stimulation current primary 2.0 mA with stepwise reduction over 1.0 mA to 0.5 mA, pulse width 0.1 ms, pulse frequency 2 Hz) of the N. ischiadicus blocked by 20 ml ropivacaine 0.75 %. (electrical nerve stimulation and ultrasound) If no motor response can be triggered by stimulation, the closest possible needle-nerve distance is generated at a pulse strength of 1mA and regional anesthesia is performed. (protective nerve stimulation) Subsequently, the transplantation into the supine position and the further procedure specific to the operation (use of other regional procedures in combination or general anaesthesia).~A facet needle is used."
2880830|NCT03383757|Experimental|SpO2 Sensor Application & Blood draw|All subjects will undergo the same study procedures of having their SpO2 levels measured with an external sensor applied to the skin and blood SpO2 level measured
2880831|NCT03383744|Experimental|Vitamin A supplementation 1|Vitamin A status assessed at Baseline and one month after the administration of 200,000 IU of vitamin A
2880832|NCT03383744|Experimental|Vitamin A supplementation 3|Vitamin A status assessed at Baseline and three months after the administration of 200,000 IU of vitamin A
2880833|NCT03383731|Active Comparator|Group 1|Group 1: The patients in Group 1 are treated by the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + air-fluid exchange + silicone oil infusion
2880834|NCT03383731|Experimental|Group 2|Group 2: The patients in Group 2 are treated by the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + inverted internal limiting membrane insertion + air-fluid exchange
2880835|NCT03383718||DSE+/FFR+|Patients with positive Dobutamine Stress Echocardiography and with positive Fractional Flow Reserve Revascularisation
2880836|NCT03383718||DSE+/FFR- or DSE-/FFR+ or DSE-/FFR-|"Patients with positive Dobutamine Stress Echocardiography and with negative Fractional Flow Reserve~Patients with negative Dobutamine Stress Echocardiography and with positive Fractional Flow Reserve~Patients with negative Dobutamine Stress Echocardiography and with negative Fractional Flow Reserve~Optimal Medical Treatment/OMT"
2880837|NCT03383705|Experimental|Treatment arm|
2880838|NCT03383692|Experimental|Cohort 1: DS-8201a + Ritonavir|DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Ritonavir twice daily (BID) on Day 17 of Cycle 2 until Day 21 of Cycle 3
2880839|NCT03383692|Experimental|Cohort 2: DS-8201a + Itraconazole|DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Itraconazole BID on Day 17 of Cycle 2 until Day 21 of Cycle 3
2880840|NCT03383679|Experimental|Arm 1 Darolutamide|Darolutamib: 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally, continuously until disease progression
2880841|NCT03383679|Other|Arm 2 Capecitabine|"according to the 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC3) capecitabine monotherapy is one of the recommended options even in first line (Cardoso et al, 2017).~According to each center policy (minimum 1000 mg/m²) twice daily for 2 weeks followed by 1-week rest period, until progression or unacceptable toxicity"
2880842|NCT03383666|Experimental|Treatment Group|PulseRider® Aneurysm Neck Reconstruction in conjunction with coil embolization for unruptured wide-neck intracranial aneurysms.
2880843|NCT03383640|No Intervention|Control|Control Group: Standardized post operative rehabilitation, where active exercises of the replanted digits is postponed until radiologic healing of the amputated bone.
2880845|NCT03383627|Experimental|Continuous glucose monitoring|"If subjects meet inclusion criteria then they will return to the research site on Day 1 to place Freestyle Libre Pro device by the research staff for 14-day monitoring.~Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis. On Day 14, blood will be drawn for HbA1c and fructosamine, The blood drawn for this research will be approximately 10-15 milliliters.~There are no drug washout periods. Subjects will continue to take all their medications and/or insulins as prescribed by their doctor.~Baseline data including age, race, ethnicity, past medical history, home medication list, and diabetes related laboratory data will be collected."
2880846|NCT03383614|Experimental|cohort 1 (8 subjects)|6 subjects with LSF emodepside 5mg, OD 2 subjects with matching placebo
2880847|NCT03383614|Experimental|cohort 2 (8 subjects)|6 subjects with LSF emodepside 10mg, OD 2 subjects with matching placebo
2880848|NCT03383614|Experimental|cohort 3 (8 subjects)|6 subjects with LSF emodepside 10mg, BID 2 subjects with matching placebo
2880849|NCT03383601||Users of IQOS with HeatStick|Individuals (men and women) between the ages of 40 and 59 (inclusive) with a minimum of 10 pack-year smoking history who switched to and predominantly (>70%) use Heated Tobacco product IQOS/heatstick
2880850|NCT03383601||Smokers of combustible cigarettes|Individuals (men and women) between the ages of 40 and 59 (inclusive) who are currently smoking combustible cigarettes with a minimum of 10 pack-year smoking history
2880851|NCT03383588|Active Comparator|bupivacaine 0.25%|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25%
2880852|NCT03383588|Active Comparator|bupivacaine 0.25% + epinephrine|tandard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25% with Epinephrine
2880853|NCT03383588|Placebo Comparator|Saline Solution|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous NACL 0.9% (placebo)
2880854|NCT03383575|Experimental|Arm A: Azacitidine + Enasidenib|"Participants that have never received a hypomethylating drug (such as azacitidine or decitabine), assigned to Arm A.~Participants in Arm A receive Azacitidine and Enasidenib."
2880855|NCT03383575|Experimental|Arm B: Enasidenib|"Participants that have received a hypomethylating drug (such as azacitidine or decitabine) and have relapsed or refractory MDS, assigned to Arm B.~Participants in Arm B receive Enasidenib alone."
2880856|NCT03383562||morning group|patients in the morning group are operated during 8:30 a.m. to 2:00 p.m.
2880857|NCT03383562||afternoon group|patients in the morning group are operated during 2:00 p.m. to 8:00 p.m.
2880858|NCT03383562||night group|patients in the morning group are operated during 8:00 p.m. to 12:00 p.m.
2880859|NCT03383549|Experimental|Tele-rehabilitation|Tele-rehabilitation arm undergo a home-based rehabilitation combined protocol, made up of cognitive and physical exercises
2880860|NCT03383549|No Intervention|Control group|Control group receives only verbal instructions to train cognitive and physical conditions. Instructions will aim to promote daily and leisure activities.
2880861|NCT03383536||Phase 1|Healthy control participants will provide neuroeconomic game responses to form a pool of potential responses for participants to interact with during Phase 2.
2880862|NCT03383536||Phase 2: PTS-SA|posttraumatic spectrum-socially anhedonic
2880863|NCT03383536||Phase 2: PTS-nonSA|posttraumatic spectrum-non-socially anhedonic
2880864|NCT03383536||Phase 2: HC|healthy controls
2880865|NCT03383523|Experimental|Part 1a - treatment A|5 mg emodepside LSF, fasted
2880866|NCT03383523|Experimental|Part 1a - treatment B|5 mg emodepside IR-tablet #406, fasted
2880867|NCT03383523|Experimental|Part 1a - treatment C|5 mg emodepside IR-tablet #416, fasted
2880868|NCT03383523|Experimental|Part 1b - treatment D|5 mg emodepside IR-tablet #406, fed
2880869|NCT03383523|Experimental|Part 1b - treatment E|5 mg emodepside IR-tablet #416, fed
2880870|NCT03383523|Experimental|Part 2 - treatment F|2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
2880871|NCT03383523|Experimental|Part 2 - treatment G|2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
2880872|NCT03383510|Experimental|Climate friendly group|The climate friendly group will receive instructions to eat according to a climate friendly diet, i.e., to replace the majority of their intake of animal based products with plant based food.
2880873|NCT03383510|Experimental|Organic group|The organic group will receive instructions to eat an organic diet, i.e., to replace at least 50% of their normally consumed food with organic equivalents.
2880874|NCT03383510|Experimental|Climate friendly and organic group|The climate friendly and organic group will receive instructions to consume a climate friendly and organic diet, i.e, to replace the majority of their intake of animal based products with plant based food AND to consume at least 50% organic food products.
2880875|NCT03383510|Placebo Comparator|Control group|The control group will receive instructions to eat according to the Nordic Nutrition Recommendations.
2880876|NCT03383497||Idiopathic Parkinson Disease|
2880877|NCT03383497||Other Parkinsonian syndromes|
2880878|NCT03383484|No Intervention|No intervention|No OMT, yoga, acupuncture, or other interventions.
2880879|NCT03383484|Experimental|OMT intervention|Weekly OMT for 3 months
2880880|NCT03383484|Experimental|Yoga intervention|Yoga 3 times per week for 3 months
2880881|NCT03383471|Experimental|Invossa K Inj.|Invossa K Inj.
2880882|NCT03383471|Placebo Comparator|Placebo|Placebo control
2880883|NCT03383458|Experimental|Arm A|
2880884|NCT03383458|Placebo Comparator|Arm B|
2880885|NCT03383445|Other|TAVR|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local abesthesia, Imaging guidance during the TAVR procedure, and post-procedural TAVR management.
2880886|NCT03383445|Other|SAVR|SAVR procedure will be performed using standard techniques, with no limitation in terms of type and size of the valve prosthesis or surgical procedure (e.g. enlargement of the aortic root).
2880918|NCT03383211||HV+/LTBI|Pregnant women diagnosed with HIV and LTBI co-infection. No intervention beyond the standard of care provided for such cohort.
2880887|NCT03383432|Other|Trans-abdominal ultrasound intrauterine device group.|Those will be subjected to intrauterine device insertion under trans-abdominal ultrasound guidance. In this method the participant will be asked to have a full bladder. Full bladder helps to displace the bowel out of the pelvis and acts as an acoustic window for high frequency sound waves and to straighten the angle between the uterine body and cervix in anteverted uterus, performing the function of the tenaculum. Then, then ultrasound will be done and the intrauterine device will be introduced vaginally under ultrasound vision.
2880888|NCT03383432|Other|Uterine Sounding Sparing intrauterine device group|The sonographer performs ultrasound using transvaginal probe to evaluate the uterine position and the endometrial length in the sagittal view of the uterus. The intrauterine device was inserted directly into the uterine cavity without using uterine sounding.
2880889|NCT03383419|Experimental|Treatment|Epclusa® will be started within 14 days of quantifiable viremia and continued for 12 weeks. Within 24 hours prior to first-dose of treatment, HCV genotype will be sent from transplant recipient.
2880890|NCT03383406|Experimental|I Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM)|
2880891|NCT03383393||adenosine|Intracoronary bolus of adenosine (adenocor)
2880892|NCT03383393||GP IIb/IIIa|Intracoronary bolus of Integrilin (eptifibatide)
2880893|NCT03383393||Nitroglycerine|Intracoronary bolus of nitroglycerine (nitronal)
2880894|NCT03383380|Experimental|Rapamycin|Treatment for patients with activated phosphoinositide 3-kinase δ syndrome
2880895|NCT03383367|Experimental|Tempo Colo|
2880896|NCT03383341|Experimental|Cricket powder protein|Participants were provided with frozen 70 gram breakfast muffins and pre-mixed powder packets to prepare smoothies. Participants were asked to consume one muffin package and one smoothie (mixed with water or choice of milk/milk substitutes) daily for 14 days. The amount of intervention food consumed daily contained 25 grams of cricket protein powder.
2880897|NCT03383341|Placebo Comparator|Placebo Control|Participants were provided with a placebo comparator that included frozen 70 gram breakfast muffins and pre-mixed powder packets to prepare smoothies. Participants were asked to consume one muffin package and one smoothie (mixed with water or choice of milk/milk substitutes) daily for 14 days. These foods were formulated to taste and appear similar to the cricket intervention foods but did not consume any cricket powder.
2880898|NCT03383328|Active Comparator|NSAID + prednisolone, preoperative|"Combination of NSAID- and prednisolone eye drops. Treatment is initiated 3 days prior to surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day Prednisolone acetate 1% w/v, eye drops, 1 drop 3 times pr. day"
2880899|NCT03383328|Active Comparator|NSAID + prednisolone, postoperative|"Combination of NSAID- and prednisolone eye drops. Treatment is initiated on the day of surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day Prednisolone acetate 1% w/v, eye drops, 1 drop 3 times pr. day"
2880900|NCT03383328|Experimental|NSAID, preoperative|"NSAID eye drops as monotherapy. Treatment is initiated 3 days prior to surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day"
2880901|NCT03383328|Experimental|NSAID, postoperative|"NSAID eye drops as monotherapy. Treatment is initiated on the day of surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day"
2880902|NCT03383328|Experimental|Drop-less surgery|"A depot of dexamethasone is administered subtenonally during surgery.~Dexamethason Krka 4 mg/ml solution for injection/infusion. 0,5 ml equivalent to 2 mg of dexamethasone is administered once."
2880903|NCT03383315|Experimental|Group 1|Intravenous tramadol 50mg + intravenous metoclopramide 10mg
2880904|NCT03383315|Active Comparator|Group 2|Intravenous tramadol 50mg + placebo (normal saline)
2880905|NCT03383302|Experimental|Arm 1 Tolerabilty|This is a single arm study of nivolumab administered on completion of stereotactic body radiotherapy (SBRT) to patients with early stage NSCLC. The first 5 patients to enroll must have Eastern Co-operative Oncology Group (ECOG) performance status < 2 at the time of first dose of investigational medical product (IMP). An Independent Data Monitoring Committee (IDMC) will meet when the first 5 patients have reached 3 months follow up from their 1st dose of nivolumab or have withdrawn consent to follow-up. The IDMC, if satisfied with the safety data from the initial 5 patients, may recommend escalation to include recruitment of patients with ECOG performance status of 2.
2880906|NCT03383289|Experimental|R-REM training|3 module training for frontline staff in assisted living facilities related to recognizing and management of resident-to-resident elder mistreatment
2880907|NCT03383289|No Intervention|Control condition|Usual care
2880908|NCT03383276|Experimental|IL-1Ra|
2880909|NCT03383263||Children with juvenile arthritis|Children with diagnosed polyarticular juvenile arthritis according to International League of Associations for Rheumatology (ILAR) criteria treated with HUMIRA (adalimumab) in the routine clinical settings in the Russian Federation
2880910|NCT03383250|Experimental|Meal ingestion|
2880911|NCT03383237|Experimental|Apatinib|Apatinib 500mg/d,q.d.,p.o.
2880912|NCT03383224|Experimental|Genotype-guided (A allele carriers)|CHRNA5 rs16969968 genotype will be determined. Genotype-guided therapy will be given (A allele carriers will be given pharmacologic therapy (nicotine replacement therapy --NRT; nicotine patch used according to FDA labelling).)
2880913|NCT03383224|Experimental|Genotype-guided (GG homozygotes)|CHRNA5 rs16969968 genotype will be determined. Genotype-guided therapy will be given (GG homozygotes will be given smoking cessation counseling)
2880914|NCT03383224|Active Comparator|Standard (non-genotype guided) - NRT|1/2 of patients in this arm will be given nicotine replacement therapy (NRT; nicotine patch used according to FDA labeling) but this will NOT be based on the patient's genotype. Note that both nicotine replacement therapy and counseling are accepted treatments for smoking cessation in patients with coronary artery disease.
2880915|NCT03383224|Active Comparator|Standard (non-genotype guided)- counseling|1/2 of patients in this arm will be given smoking cessation counseling but this will NOT be based on the patient's genotype. Note that both nicotine replacement therapy and counseling are accepted treatments for smoking cessation in patients with coronary artery disease.
2880916|NCT03383211||HIV+|Pregnant women diagnosed with HIV infection during pregnancy. No intervention beyond the standard care provided for such cohort.
2880917|NCT03383211||LTBI|Pregnant women diagnosed with Latent form of TB infection (LTBI). No intervention beyond the standard of care provided for such cohort.
2880920|NCT03383198|Active Comparator|Liposomal Bupivacaine Left|Liposomal Bupivacaine left injection. Liposomal Bupivacaine is injected on the left, Bupivacaine plus Dexamethasone on the right
2880921|NCT03383198|Active Comparator|Liposomal Bupivacaine Right|Liposomal Bupivacaine right injection. Liposomal Bupivacaine injected on the right, Bupivacaine plus Dexamethasone on the left
2880922|NCT03383185||Non-hormonal contraceptive|Users of non- hormonal intrauterine device during the 5 years follow-up
2880923|NCT03383185||Hormonal contraceptives|Users of combined oral contraceptive, progestin-only pills, depot-medroxyprogestereone acetate during 5 years follow-up
2880924|NCT03383172|Experimental|ICPS with internal school facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by the early educator of the class, who is part of the school personnel.This internal facilitator will be trained in the program. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
2880925|NCT03383172|Active Comparator|ICPS with external facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by an external trained early educator, who is part of the research team. The early educator of the class, who is part of the school personnel, will also be trained to collaborate with all the program activities with the external facilitator. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
2880926|NCT03383172|No Intervention|Control Group|School in the control group will continue to carry out their normal academic and prevention activities.
2880927|NCT03383159||Observation group 1|Patients who suffered metachronous adenoma after proximal colorectum cancer surgery.
2880928|NCT03383159||Control group 1|Patients who do not suffere metachronous adenoma after proximal colorectum cancer surgery.
2880929|NCT03383159||Observation group 2|Patients who suffered metachronous adenoma after distal colorectum cancer surgery.
2880930|NCT03383159||Control group 2|Patients who do not suffered metachronous adenoma after distal colorectum cancer surgery.
2880931|NCT03383146|Experimental|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily for 52 weeks.
2880932|NCT03383146|Placebo Comparator|Placebo|Placebo injected twice daily for 52 weeks.
2880933|NCT03383133|Experimental|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (1.0 g)) or dehydroepiandrosterone (75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (0.75 g).
2880934|NCT03383120|Experimental|Laser|Mechanical debridement of the implant surface using an ultra-sonic device with saline irrigation and plastic curettes, followed by soft tissue curettage using a metallic curette. Adjunctive sub-mucosal diode laser application according to the instructions of the manufacturer (settings: 810 nm, 2.5 W, 50 Hz, 10 ms), 3x for 30 seconds, using a 400-µm thick fiber (Doctor Smile Wiser diode laser, Orcos Medical AG, Küsnacht, Switzerland), will be performed three times at one week intervals (days 0, 7, and 14).
2880935|NCT03383120|Active Comparator|Surgery|Active control includes mechanical debridement of the implant surface using an ultra-sonic device with saline irrigation and plastic curettes, followed by soft tissue curettage using a metallic curette at day 1. An open flap debridement procedure is performed at day 14 using normal saline for implant decontamination. Adjunctive systemic antimicrobials will be prescribed; Amoxi-mepha 500mg 3x/day and Metronidazole 500mg 3x/day, for 1 week. A chlorhexidine 0.2% mouth rinse will also be prescribed 2x/day for one week. Suture removal and prophylaxis are performed 7-10 days post-operatively.
2880936|NCT03383107||Cohort 1a - Prostate Cancer|Standard fractionation RT to 81 Gy in 45 fx over 9 weeks
2880937|NCT03383107||Cohort 1b - Prostate Cancer|Hypofractionated RT to 36.25 Gy in 5 fx over 1-2 weeks
2880938|NCT03383107||Cohort 2a - Breast cancer|Standard fractionation breast and nodal RT to 50 Gy in 25 fx over 5 weeks
2880939|NCT03383107||Cohort 2b - Breast Cancer (Partial Breast )|Partial breast RT to 30 Gy in 5 fx over 2 weeks
2880940|NCT03383094|Active Comparator|Control-radiotherapy/cisplatin|Intensity-modulated radiation therapy to 70 Gy in 35 fractions over 6.5 weeks plus concurrent cisplatin 40 mg/m2 weekly
2880941|NCT03383094|Experimental|Experimental-Radiotherapy/pembrolizumab|Intensity-modulated radiation therapy to 70 Gy in 35 fractions over 6.5 weeks plus concurrent and adjuvant Pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles
2880942|NCT03383081|Experimental|Low dose mesenchymal stem cells|Low dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)
2880943|NCT03383081|Experimental|High dose mesenchymal stem cells|High dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)
2880944|NCT03383081|No Intervention|Control groups|No intervention
2880945|NCT03383068|Other|control|metformin(1000-1500mg/d) treated for 6 months, reverse to normal glucose tolerance
2880946|NCT03383068|Experimental|acarbose|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with acarbose (100mg tid ) for 3 months
2880947|NCT03383068|Experimental|Exenatide|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with Exenatide 10μg/bid ) for 3 months
2880948|NCT03383068|Experimental|Orlistat|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with Orlistat(0.12mg/tid ) for 3 months
2880949|NCT03383055|Experimental|CMV-MVA Triplex|
2880950|NCT03383042|Experimental|Cohort 1|Single-ascending cohort 1
2880951|NCT03383042|Experimental|Cohort 2|Single-ascending cohort 2
2880952|NCT03383042|Experimental|Cohort 3|Single-ascending cohort 3
2880953|NCT03383042|Experimental|Cohort 4|Single-ascending cohort 4
2880959|NCT03383016||Men at high-rik of prostate cancer|Lifestyle questionnaires such as diet questionnaire, physical activities questionnaires, quality of life , Follows up 1 year and 2 years after the enrollment, Anthropometric measures during the first visit , Blood withdrawal for laboratory biomarkers analysis After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.
2880960|NCT03383003|Experimental|High dose dual therapy|Esomeprezole (Nexium)40 mg tid. and amoxicillin (Amolin) 750 mg qid. for 14 days
2880961|NCT03383003|Active Comparator|Non-bismuth quadruple therapy|Esomeprezole (Nexium) 40 mg bid.,clarithromycin (Klaricid) 500 mg bid., amoxicillin (Amolin) 1 g bid. and metronidazole (Flagyl) 500 mg bid. for 7 days
2880962|NCT03382990||STEMI|Patients with STEMI treated with PCI and stent placement (DES or BMS)
2880963|NCT03382990||NSTEMI|Patients with NSTEMI treated with PCI and stent placement (DES or BMS)
2880964|NCT03382977|Experimental|Dose Level 1|VBI-1901 low dose (0.4 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
2880965|NCT03382977|Experimental|Dose Level 2|VBI-1901 intermediate dose (2 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
2880966|NCT03382977|Experimental|Dose Level 3|VBI-1901 high dose (10 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
2880967|NCT03382964|Active Comparator|VLA1553 low dose|VLA1553 with 3.2x10^3 TCID50/ 100 µL (microliter). Re-vaccination at Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL (milliliter)
2880968|NCT03382964|Active Comparator|VLA1553 medium dose|VLA1553 with 3.2x10^4 TCID50/ 1 mL Re-vaccination at Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL
2880969|NCT03382964|Active Comparator|VLA1553 high dose|VLA1553 with 3.2x10^5 TCID50/ 1 mL Re-vaccination at Month 6 or Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL
2880970|NCT03382951||Healthy children|Each study is an observational study with no group assignments and no control/placebo.
2880971|NCT03382938|Active Comparator|Dexmedetomidine|Drug: dexmedetomidine (Dexmed) 20 mL solution of dexmedetomidine used for wound infiltration
2880972|NCT03382938|Active Comparator|Ropivacaine|Drug: ropivacaine 20 mL solution of ropivacaine 0.375% used for wound infiltration
2880973|NCT03382938|Active Comparator|Dexmedetomidine - Ropivacaine|Drug: dexmedetomidine (Dexmed) combined with Drug: ropivacaine 20 mL solution of dexmedetomidine 1γ/kg within ropivacaine 0.375% used for wound infiltration
2880974|NCT03382938|Placebo Comparator|0.9 % saline|Drug:0.9 % saline solution (Normal saline). 20 ml with 0.9 % saline solution used for wound infiltration
2880975|NCT03382925|Active Comparator|cervical interlaminar with lidocaine|Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).
2880976|NCT03382925|Active Comparator|cervical interlaminar with normal saline|Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).
2880977|NCT03382912|Experimental|1|AM0010 self-administered as a SQ injection QD (≤ 80kg body weight = 0.8mg or [0.2mL] > 80kg body weight = 1.6mg [0.4mL]). Nivolumab will be administered as intravenous (IV) infusion on Day 1 of a 14-day cycle (240mg over 30 minutes (± 10min))
2880978|NCT03382912|Active Comparator|2|Nivolumab will be administered as an intravenous (IV) infusion on Day 1 of a 14-day cycle (240mg over 30 minutes (± 10min))
2880979|NCT03382899|Experimental|1|AM0010 self-administered as a SQ injection QD (≤ 80kg body weight = 0.8mg or [0.2mL] > 80kg body weight = 1.6mg [0.4mL]). Pembrolizumab will be administered as intravenous (IV) infusion on Day 1 of a 21-day cycle (200mg over 30 minutes (± 10min))
2880980|NCT03382899|Active Comparator|2|Pembrolizumab will be administered as an intravenous (IV) infusion on Day 1 of a 21-day cycle (200mg over 30 minutes (± 10min))
2880981|NCT03382886|Experimental|Nivolumab and bevacizumab, all patients|
2880982|NCT03382873|Active Comparator|Group Lifestyle Balance (GLB)|Implement the first 4-sessions of the core 16-session phase of the GLB intervention for diabetes prevention to all participants. Determine percent weight change at week 5. Those who achieve >2.5% weight loss at week 5 will remain in the GLB arm.
2880983|NCT03382873|Experimental|Group Lifestyle Balance Plus (GLB+)|Implement the first 4-sessions of the core 16-session phase of the GLB intervention for diabetes prevention to all participants. Determine percent weight change at week 5. Those who fail to achieve >2.5% weight loss at week 5 will transfer to the GLB+ arm.
2880984|NCT03382860||Ventriculoperitoneal dysfunction|Patients with suspected ventriculo-peritoneal (VP) shunt dysfunction are admitted to the neurosurgical department for intracranial pressure monitoring for 24 hours. The patients are approached within this time frame.
2880985|NCT03382860||Normal Pressure Hydrocephalus (NPH)|Patients with suspected NPH (triad of cognitive dysfunction, urine incontinence of urge type, abnormal gait) are admitted to the neurosurgical department for intracranial pressure monitoring for 24 hours. The following day an infusiontest is performed, where data is collected.
2880986|NCT03382847|Experimental|Intervention arm|HCV negative patients will receive a heart transplant from a HCV positive donor. Post-transplant, there will be surveillance for the development of viremia, and treatment of viremia. Following treatment, there will be surveillance for a sustained virologic response to HCV treatment.
2880987|NCT03382834|Experimental|Arm A: Tamoxifen + Vorinostat|From Day 0 to Day 38, participants will receive tamoxifen orally once a day. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
2880988|NCT03382834|Active Comparator|Arm B: Vorinostat alone|Day 0 to Day 38 will be an observation period with no tamoxifen. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
2880989|NCT03382821|Active Comparator|Transforaminal ESI with dexamethasone|Group 1: Transforaminal cervical ESI with dexamethasone sodium phosphate
2880990|NCT03382821|Active Comparator|Transforaminal catheter-targeted ESI with triamcinolone|Group 2: Catheter-targeted cervical ESI with triamcinolone acetonide
2880991|NCT03382808|Experimental|SEE Training|The training sequence comprises four weekly sessions using a modified dote-probe paradigm (fearful vs. neutral expression).
2880992|NCT03382808|Active Comparator|GAZE Training|The GAZE training sequence comprises four weekly sessions using a modified dote-probe paradigm (averted vs. directed gaze).
2880993|NCT03382795|Experimental|EGFR retreat group|
2910473|NCT03176537|Experimental|TRT|Testosterone Replacement Therapy
2880994|NCT03382782|Active Comparator|Behavioral Weight Loss Intervention|"Participants will enroll in the BWLI program for 8 months. BWLI consists of a 6-month initial intervention phase followed by 2-month maintenance phase. The initial intervention phase comprises four types of contact:~2 hour, group weight-management class led by facilitator (once per week);~45 minute, physical activity led by facilitator (one-two times per week);~20 minute, monthly individual visit with facilitator to address barriers to goals and appropriate skills; and~weigh-in during weight management group and individual visits (once each week).~During the maintenance phase, 8 weight management review classes take place weekly. Other activities remain the same."
2880995|NCT03382782|Experimental|BWLI & Peer Navigator|"Participants randomly assigned to this condition will begin simultaneously with BWLI and run concurrently across the eight months of the intervention. Peer navigators will meet individually and face-to-face with research participants in time and places convenient to the person as needed. Specific practices are determined by the research participant with the peer navigator and may include:~partnering with participant on BWLI homework;~meeting with participant and BWLI facilitator individually;~attending all other health care appointments; and~partnering on tasks that arise out of those appointments."
2880996|NCT03382782|Active Comparator|Integrated Care (Treatment as Usual)|Participants in this arm will receive integrated care from their usual provider, which is treatment as usual. Integrated care is mental health specialty and general medical care providers working together to address the physical and behavioral health care needs of patients. One-third of research participants will be randomized to integrated care alone.
2880997|NCT03382769|Experimental|Group A|Group A will consist of 30 individuals who are candidates for cochlear implantation. They will be unilaterally implanted immediately after initial study testing has been completed and then be followed for 12 months after device activation.
2880998|NCT03382769|Active Comparator|Group B|Group B will consist of 30 individuals who are candidates for cochlear implantation. They will continue to wear hearing aids after enrolling in the study and then be unilaterally implanted and followed for 6 more months after device activation.
2880999|NCT03382756|Experimental|Group A|"Period 1: 1 capsule of test drug(CKD-337) administered under fasting condition~Period 2: 1 capsule of test drug(CKD-337) under high fat diet condition"
2881000|NCT03382756|Experimental|Group B|"Period 1: 1 capsule of test drug(CKD-337) under high fat diet fed condition~Period 2: 1 capsule of test drug (CKD-337) administered under fasting condition"
2881001|NCT03382743|Active Comparator|Group A (Lidocaine group)|5 sprays of endocervical Lidocaine 10% spray ( AstraZeneca, bedforshire) are used 3 minutes before office hysteroscopy
2881002|NCT03382743|No Intervention|Group B (control group)|office hysteroscopy is done without analgesia
2881003|NCT03382730|Other|Oral Chlorhexidine Mouth Rinse|Application of chlorhexidine gluconate mouth rinse per unit protocol.
2881004|NCT03382730|Experimental|De-Adoption of Oral Chlorhexidine Mouth Rinse|No application of chlorhexidine gluconate mouth rinse. Oral care bundle.
2881005|NCT03382717|Experimental|Excilor Forte|
2881006|NCT03382717|Active Comparator|Loceryl 5%|
2881007|NCT03382704||Patients undergoing biopsy|Patients undergoing biopsy (incisional or excisional) of peri-ocular lesions. Pre-operative examination for presence or absence of lanugo hairs
2881008|NCT03382691|Experimental|EXPERIMENTAL|Blood pressure check using mobile device and control device
2881009|NCT03382652||Patients who received the Continuum Metal on Metal System|Patients requiring total hip arthroplasty, who meet the inclusion/exclusion criteria and received the Continuum Metal on Metal System
2881010|NCT03382639|Experimental|Double-blind: TAK-831 50 mg|TAK-831 50 milligram (mg), tablets, orally, once daily up to 14 weeks.
2881011|NCT03382639|Experimental|Double-blind: TAK-831 125 mg|TAK-831 125 mg, tablets, orally, once daily up to 14 weeks.
2881012|NCT03382639|Experimental|Double-blind: TAK-831 500 mg|TAK-831 500 mg, tablets, orally, once daily up to 14 weeks.
2881013|NCT03382639|Placebo Comparator|Double-blind: Placebo|TAK-831 placebo-matching tablets, orally, once daily up to 14 weeks.
2881014|NCT03382626|Active Comparator|tDCS plus Computer-assisted training|Patients will receive 10 sessions of active anodal tDCS on the left prefrontal cortex dorsolateral (F3 area using International 10-20 system for electroencephalogram (EEG) electrode placement) plus Computer-assisted cognitive training (games to improve memory, attention and executive function).
2881015|NCT03382626|Sham Comparator|tDCS sham plus Computer-assisted training|Patients will receive 10 sessions of sham anodal tDCS on the left prefrontal cortex dorsolateral plus Computer-assisted cognitive training (games to improve memory, attention and executive function).
2881016|NCT03382613||Quality Improvement (QI) Program|Hospitals assigned to the QI program arm will begin the 4-month Preparatory Phase which is designed to introduce the institutional baseline reporting tools and materials related to performance improvement, and gain insight into their gaps in treatment, followed by 15 month Implementation Phase, which will consist of education, process, and engagement activities that are targeted at the hospital and healthcare provider level and then the Measurement Period at which time hospitals will complete a final survey to document specific interventions that were successfully implemented and perform a final retrospective chart review on selected patients.
2881017|NCT03382613||Usual Care|Hospitals assigned to the Usual Care arm will not participate in the structured QI program but will continue with their standard hospital practice in treating patients with atrial fibrillation (AF) at risk for ischemic stroke. Hospitals will also complete a final survey and final retrospective chart reviews during the Measurement Period.
2881018|NCT03382600|Experimental|Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1)|Participants receive Pembrolizumab 200 mg every 3 weeks (Q3W) plus oxaliplatin 130 mg/m^2 Q3W by intravenous (IV) infusion plus TS-1 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Study treatment will be started on Day 1 of each 3-week course.
2881019|NCT03382600|Experimental|Pembrolizumab + Cisplatin +TS-1 (Cohort 2)|Participants receive Pembrolizumab 200 mg Q3W plus cisplatin 60 mg/m^2 Q3W by IV infusion plus TS-1 BID by continuous oral administration for 14 days, followed by a recovery period of 7 days. Study treatment will be started on Day 1 of each 3-week course.
2881020|NCT03382587||Aflibercept|Treatment-naive wet age-related macular degeneration patients under routine intravitreal aflibercept treatment in a treat-and-extend scheme
2881064|NCT03382249|Experimental|OMC and SDT|OMC and sonodynamic therapy (SDT) are administrated in this arm.
2881065|NCT03382236|Experimental|Real osteopathy|
2881021|NCT03382574|Experimental|Arm I (denosumab, risk-reducing salpingo-oophorectomy)|Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 3-4 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.
2881022|NCT03382574|Active Comparator|Arm II (risk-reducing salpingo-oophorectomy)|Patients receive no treatment for 6 months and then undergo risk-reducing salpingo-oophorectomy.
2881023|NCT03382561|Experimental|Arm A (nivolumab, CE)|Patients receive nivolumab IV over 30 minutes on day 1, carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients continue to receive nivolumab IV over 30 minutes every 2 weeks for up to 2 years.
2881024|NCT03382561|Experimental|Arm B (CE)|Patients receive carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2881025|NCT03382548|Active Comparator|Short antibiotic treatment duration for VAP (7 days or less)|
2881026|NCT03382548|Active Comparator|Long antibiotic treatment duration for VAP ( 8 days or more)|
2881027|NCT03382535|Active Comparator|Voice therapy|An individually tailored voice therapy where the order and length of voice treatment methods will depend on the nature of each subject's voice problems. The intervention will take eight weeks and average of eight sessions (a' 45 min).
2881028|NCT03382535|Experimental|Voice therapy with carryover strategies|A voice therapy as described above and an enhanced carryover program. By carryover we mean the process of extending new vocal skills outside the clinic. It includes supplementary tasks and reminders that will be tailored individually out of those direct and indirect methods that the subjects have adopted during therapy sessions. Additionally, the teachers will be doing vocal warm-up and relaxation exercises together with their pupils int the beginning and in the middle of a school day. The intervention will take eight weeks.
2881029|NCT03382535|Other|Control group|No intervention during eight weeks since this group will act as a temporary control group. After eight weeks, half of the participants in this group will be provided with Voice therapy and half with Voice therapy with carryover strategies.
2881030|NCT03382509|Experimental|Single Dose Group|
2881031|NCT03382509|Experimental|Multiple Dose Group|
2881032|NCT03382496||Lung Cancer patients in France|Lung Cancer patients treated by nivolumab in real life condition in France from October 2016 to October 2017
2881033|NCT03382483||EXOGEN Treated|Patients prescribed EXOGEN and treatment initiated
2881034|NCT03382483||Non-EXOGEN Treated|Patients in insurance claims database who have not been treated with a bone growth stimulator; derived via propensity score subclassification
2881035|NCT03382457|Experimental|Treatment|Treatment with the Edwards Cardioband Tricuspid Valve Reconstruction System
2881036|NCT03382431|Experimental|PC786|Repeat dose
2881037|NCT03382431|Placebo Comparator|Placebo/vehicle|Repeat dose
2881038|NCT03382418|Experimental|Group 1: gp145 C.6980 (high dose)|Participants will receive 300 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
2881039|NCT03382418|Experimental|Group 2: gp145 C.6980 (low dose)|Participants will receive 100 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
2881040|NCT03382418|Placebo Comparator|Group 3: Placebo|Participants will receive placebo at Day 0 and Months 2 and 6.
2881041|NCT03382405|Experimental|mRNA-1647|
2881042|NCT03382405|Experimental|mRNA-1443|
2881043|NCT03382405|Placebo Comparator|Placebo|
2881044|NCT03382392||ALS|
2881045|NCT03382392||control 1|
2881046|NCT03382392||control 2|
2881047|NCT03382379|Experimental|Active|Participants in the active arm will receive 2 milliamp anodal transcranial Direct Current Stimulation (tDCS) over the Dorso-Lateral Pre-Frontal Cortex (DLPFC).
2881048|NCT03382379|Placebo Comparator|Sham|Participants in the Sham arm will receive sham transcranial Direct Current Stimulation (tDCS) over the Dorso-Lateral Pre-Frontal Cortex (DLPFC).
2881049|NCT03382366|Other|Sarcopenic Group|"This group is composed by 20 osteoporotic postmenopausal women, previously (pre-recruitment) classified as sarcopenic by the DXA.~This group will undergo the same evaluations/intervention of the second group."
2881050|NCT03382366|Other|Non-sarcopenic Group|"This group is composed by 20 osteoporotic postmenopausal women, previously (pre-recruitment) classified as non-sarcopenic by the DXA.~This group will undergo the same evaluations/intervention of the first group."
2881051|NCT03382353|Active Comparator|No Treatment (NT)|Educational training
2881052|NCT03382353|Experimental|Partial Treatment (PT)|Nutritional supplementation & Counselling on a brain-healthy diet
2881053|NCT03382353|Experimental|Full Treatment (FT)|Nutritional supplementation & Counselling on a brain-healthy diet & Physical exercise training & Computerized cognitive training
2881054|NCT03382340|Experimental|Imx-110|
2881055|NCT03382327|Experimental|Surgical planning|Two surgical plans will be established preoperatively. The first plan will be based on standard preoperative images (CT-scan, MRI) review. The second plan will be based on the 3D model review.
2881056|NCT03382314|Experimental|HDDO-1614|Bazedoxifene + Cholecalciferol combination drug
2881057|NCT03382314|Active Comparator|Bazedoxifene + Cholecalciferol|Co-administration of Bazedoxifene and Cholecalciferol
2881058|NCT03382301|Experimental|Ciclosporin A preconditioning|Ciclosporin A preconditioning before renal artery stenosis dilation
2881059|NCT03382301|Placebo Comparator|NaCl preconditioning|
2881060|NCT03382288|Experimental|Examination of participants|Examination of participants by means of the investigational device as well as the comparative devices.
2881061|NCT03382262|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
2881062|NCT03382262|Active Comparator|TAcs 40 mg|Single intra-articular (IA) injection of TAcs 40 mg
2881063|NCT03382249|Placebo Comparator|OMC and pseudo-SDT|Optimal medical care (OMC) and pseudo-SDT are administrated in this arm. OMC is established according to the standards established by the 2017 China Guidelines for the Diagnosis and Treatment of Carotid Artery Stenosis in order to promote best practices for risk factor management. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
2881067|NCT03382210||ERP group|A prospective series of patients (N=100) undergoing elective colorectal resection and completing a standardized enhanced recovery protocol in 2013-2015 (ERP group) at the S. Anna University Hospital in Ferrara (Italy).
2881068|NCT03382210||Pre-ERP group|A retrospective series of patients (N=100) operated on at the the S. Anna University Hospital in Ferrara (Italy) in 2009-2011 (Pre-ERP group), before the introduction of ERP methodology.
2881069|NCT03382197|Experimental|Nebulization|control intervention, will only perform nebulization;
2881070|NCT03382197|Experimental|Positive expiratory pressure valve|Intervention, will perform nebulization associated with positive expiratory pressure valve in the airways (EPAP)
2881071|NCT03382197|Experimental|Nonivasive ventilation|intervention, will perform nebulization associated with non-invasive ventilation Bi-level mode;
2881072|NCT03382184|Experimental|Fraxel DUAL 1550 nm|The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth. 25 patients with alopecia will be part of this group.
2881073|NCT03382184|Experimental|Halo Hybrid Laser 1550 nm|The Halo laser will be used per protocol due to the dynamic thermal optimization technology for hair regrowth. 25 patients with alopecia will be part of this group.
2881074|NCT03382171|Experimental|FoodforCare group|The intervention group will receive meals from FoodforCare at Home. The FoodforCare at Home concept consists of five to six small protein and energy enriched meals that will be delivered twice a week. After an individual intake, the composition of the dishes will be tailored to the needs of the patient in terms of composition, diet, taste, flavor and portion size. Besides the meals, patients in the intervention group will also receive an information leaflet about the importance of protein during treatment and how to reach their protein requirements.
2881075|NCT03382171|No Intervention|Usual care group|The control group will continue their usual diet for 3 weeks and have no restrictions to their diet.
2881076|NCT03382158||Type I PPB|Type I PPB is an early manifestation of this malignant disease, cured in some cases by surgery. Surgical guidelines are presented. It is unknown whether adjuvant chemotherapy improves cure rates for individuals with Type I PPB. If the treating physicians select adjuvant chemotherapy treatment, chemotherapy options include a 22-week regimen: 4 courses of vincristine, actinomycin D and cyclophosphamide (VAC) followed by 3 courses of vincristine and actinomycin D (VA). Therapy decisions are the responsibility of the treating institution.
2881077|NCT03382158||Types II and III PPB|Types II and III PPB are aggressive sarcomas. Surgery and chemotherapy are necessary in all cases. Surgical guidelines are presented. Many children with Types II or III PPB receive a single-arm multi-agent chemotherapy neo-adjuvant/adjuvant regimen of IVADo (ifosfamide, vincristine, actinomycin, doxorubicin) for 36 weeks. Second and possible 3rd look surgery may be considered for local control. Radiation therapy may be considered. Specific therapy decisions are the responsibility of the treating institution.
2881078|NCT03382158||Type Ir PPB|Type Ir (regressed) PPB is a unique, purely cystic tumor which lacks a primitive cell component. The International PPB Registry for PPB, DICER1 and Associated Conditions will enroll and follow participants with Type Ir PPB, regardless of age.
2881079|NCT03382158||DICER1 Gene or Cond Assoc with DICER1|PPB and the associated conditions found in PPB families suggest a familial tendency to formation of tumors. The International PPB Registry for PPB, DICER1 and Associated Conditions study will enroll and follow participants who have the DICER1 gene mutations or conditions associated with PPB or DICER1.
2881080|NCT03382145||postmenopausal bleeding women|Retrospective review on outcome of One stop Postmenopausal bleeding clinic in New Territorial Eastern Cluster, Hong Kong. Single group study, no intervention.
2881081|NCT03382132|Experimental|momHealth|Participants will receive support and information via the momHealth program.
2881082|NCT03382132|Active Comparator|Control|Participants will receive the normal support they would normally receive if they were not in a study.
2881083|NCT03382119|Experimental|Patients having Fontan cardiac surgery|"This group includes pediatric patients, aged 2-5 years, who have had a Fontan operation. This surgery corrects a heart defect found at birth in which the heart has only one ventricle.~Patients will have an Ultrasound with ARFI imaging."
2881084|NCT03382119|Experimental|Patients with Liver disease|"This group includes pediatric patients, aged 2-5 years, who have chronic liver disease caused by biliary atresia.~Patients will have an Ultrasound with ARFI imaging."
2881085|NCT03382106|Experimental|Smoking Cessation Group 1|80 normal smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews), between the ages of 25 and 65 will be studied to assess inflammation and heterogeneity of Perfused Blood Volume prior to and following a 3 month smoking cessation program. In 40 of the 80 subjects during the smoking cessation program, we will provide three times per day Sildenafil 20 milligrams (MG) (Viagra) for the full 3 months of the smoking cessation period. We select a three-month cessation program to maximize the likelihood of compliance with cessation yet providing enough time for a resolution of lung injury to take place.
2881086|NCT03382106|Placebo Comparator|Smoking Cessation Group 2|80 normal smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews), between the ages of 25 and 65 will be studied to assess inflammation and heterogeneity of Perfused Blood Volume prior to and following a 3 month smoking cessation program. In 40 of the 80 subjects during the smoking cessation program, we will provide three times per day placebo oral tablet for the full 3 months of the smoking cessation period. We select a three-month cessation program to maximize the likelihood of compliance with cessation yet providing enough time for a resolution of lung injury to take place.
2881087|NCT03382093|Active Comparator|Personalized Feedback Intervention|A brief, personalized computer-delivered transdiagnostic intervention (PFI) that addresses smoking and anxiety sensitivity (AS) to reduce smoking, increase quit attempts, reduce perceived barriers to cessation, reduce AS and negative affective symptoms, and increase adaptive coping skills.
2881088|NCT03382093|Active Comparator|Smoking Information Control|Standard, computer-delivered smoking cessation treatment/information.
2881089|NCT03382080|Experimental|Dream School Program (DSP)|The Dream School Program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
2881163|NCT03381521|Experimental|Group A|Ultrasound-guided nerve hydrodissection with 10cc normal saline
2881164|NCT03381521|Active Comparator|Group B|Ultrasound-guided nerve hydrodissection with 5cc normal saline
2911043|NCT03172650||study group|non alcoholic fatty liver disease patients
2881090|NCT03382080|Experimental|DSP and Mental Health Support Team|"A combination of the universal Dream Schoop Program (see description above) and the selective/indicative intervention Mental Health Support Team which is aimed at specific students at risk of dropping out of upper secondary school. It is a systematization of the student services through~Co-location of services and staff working in services~One open door to increase accessibility to the services and staff for students~Focus on the transition from lower to upper secondary school~Close follow-up of students at risk to ensure tailored help to each student~Early intervention and follow up when students starts being absent from school"
2881091|NCT03382080|No Intervention|Control|The control group are upper secondary schools who run classes and the school as usual, and do not introduce new programs similar to the Dream School or Mental Health Support Team during the project period.
2881092|NCT03382067|Active Comparator|High Epicatechin/ Melissa|Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa ® chocolate + 7.2g caster sugar + 5g Melissa containing 374 mg (-)-Epicatechin/100g chocolate and 2,69% of rosmarinic acid in Melissa leaves
2881093|NCT03382067|Placebo Comparator|Low Epicatechin/ Oat bran|Single consumption of a 55g bar of white chocolate containing: 50g Lindor ® chocolate + 5g oat bran containing < 0,0009 mg (-)-Epicatechin/100g
2881094|NCT03382054||Older surgical patients|Male and female patients with age 65 years and above scheduled for surgery
2881095|NCT03382041|Experimental|Carbon Fiber Implant|There is an alternative to the standard treatment, which is carbon fiber implants (tibial nails), especially in the prophylactic reinforcement of bones susceptible to pathological fractures following metastatic tumors. The new carbon fiber has also been used in the treatment of tibial non-union (non- healing bone); which has shown satisfactory outcomes.
2881096|NCT03382041|Active Comparator|Titanium Implant|The standard of practice in the treatment of fractures of the tibial shaft and other long bones has been the intramedullary nailing using titanium or stainless steel implants.
2881097|NCT03382015|Active Comparator|Group 1|Receives 28 days of active test product (BKR-013) in Part 1 of the study and receives 28 days of placebo in Part 2 of the study, following a washout period.
2881098|NCT03382015|Placebo Comparator|Group 2|Receives 28 days of placebo in Part 1 of the study and receives 28 days of active test product (BKR-013) in Part 2 of the study, following a washout period.
2881099|NCT03381989|Experimental|Study arm 1|The BASILICA procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TAVR.Laceration of the aortic valve leaflet using electrosurgery energy.
2881100|NCT03381976|Active Comparator|Intervention 2X/week (G2X)|This group performed resistance training twice a week (Tuesdays and Thursdays)
2881101|NCT03381976|Active Comparator|Intervention 3X/week (G3X)|This group performed resistance training three sessions a week (Mondays, Wednesdays, and Fridays).
2881102|NCT03381976|No Intervention|Control group (GC)|This group did not perform any type of organized physical exercise during the study period.
2881103|NCT03381963||Aromatase inhibitors|
2881104|NCT03381963||Tamoxifen|
2881105|NCT03381937|No Intervention|Spontaneous breathing|Spontaneous breathing without mechanical ventilation
2881106|NCT03381937|Experimental|Conventional mechanical ventilation|Conventional mechanical ventilation, with patient ventilator usual parameters
2881107|NCT03381937|Experimental|Speech specific mechanical ventilation|Mechanical ventilation with specific parameters to improve speech
2881108|NCT03381924|Experimental|Intervention group|Neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
2881109|NCT03381924|Placebo Comparator|Control group|Routine clinical practice
2881110|NCT03381911|No Intervention|E-Consent|This arm is the standard of care, where the consent form is presented to the subject on a computer screen and he/she can scroll ahead and back as needed. There is also an option to have each screen read aloud.
2881111|NCT03381911|Experimental|ECA Consent|"In this arm an Embodied Conversational Agent (ECA) which is a computer generated character reads the consent form aloud to the subject, and also describes each section using a pre-loaded script. In addition, the character performs teach-back, where she asks the subject a question about the section that was just described, and then repeats the section if the question is answered incorrectly."
2881112|NCT03381898|Experimental|Telehealth Coordinated Allied Health|rural persons with Parkinson's disease will receive telehealth exercise, speech therapy, medication management for 8 weeks. Exercise, speech therapy, and medication management are usual care for persons with Parkinson's disease. Having the 3 areas coordinated in delivery via telehealth is the new delivery that our aims address
2881113|NCT03381885|Experimental|Intervention Group|"A nudge grounded in behavioral economic theory (nudge=gentle incentive, preserving freedom of choice)"
2881114|NCT03381885|Placebo Comparator|Control|"No nudge"
2881115|NCT03381872|Active Comparator|Intravascular imaging arm|The choice of intravascular imaging devices such as IVUS or OCT during PCI will be left to the operator's discretion. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended. Use of intravascular imaging devices will be allowed at any step of PCI (pre-PCI, during PCI and post-PCI), but intravascular imaging evaluation after stent implantation will be mandatory.
2881116|NCT03381872|Active Comparator|Angiography arm|The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended.
2881117|NCT03381859|Experimental|Treatment Arm|Patients to receive 12 weeks of Elbasvir (50mg) / Grazoprevir (100mg)
2881118|NCT03381846|Experimental|MOHS treatment arm|Patients who have their dermatofibrosarcoma protuberans excised with MOHS surgery.
2881119|NCT03381833|Active Comparator|Group A - Delayed therapy|standard chelation therapy alone for 26 weeks followed by standard chelation therapy plus LJPC-401 for 26 weeks
2881120|NCT03381833|Active Comparator|Group B - Immediate therapy|standard chelation therapy plus LJPC-401 for 52 weeks
2881234|NCT03380988|Experimental|Fiber-enriched buckwheat pasta|Acute test meal
2881121|NCT03381820|Experimental|music listening|Participants who were randomized into intervention group were assigned to listen to the music everyday (day 1st to day 30th), at anytime of day that was suitable with their lifestyles but not at the time of BP measurement. During day 31st -120th, participants did not listen to the music. Other treatment was the same as the control arm.
2881122|NCT03381820|No Intervention|control|control arm received conventional hypertension treatment.
2881123|NCT03381807|Experimental|TCRA and intrauterine infusion of hAECs|100 million hAECs is infused into uterine cavity after TCRA.
2881124|NCT03381794||Patients with corneal transplantation|Aim is to include all patients in Germany treated with the different types of corneal transplantation with an interim-assessment of the period between 2001 and 2016.
2881125|NCT03381781|Experimental|Experimental group|Patients with p53 mutations will be treated with Decitabine,Arsenic Trioxide and Cytarabine.
2881126|NCT03381768|Experimental|Study group|3 vaccines of PD-L2 peptide followed by 12 vaccines of PD-L2 and PD-L1 peptide, over the course of one year.
2881127|NCT03381755|Experimental|half-dose ticagrelor|
2881128|NCT03381755|Active Comparator|standard-dose ticagrelor|
2881129|NCT03381742|Experimental|ticagrelor 45mg bidpo.|To observe ticagrelor 45mg bidpo. on platelet aggregation in patients with acute coronary syndrome.
2881130|NCT03381742|Experimental|ticagrelor 90mg qdpo.|To observe ticagrelor 90mg qdpo. on platelet aggregation in patients with acute coronary syndrome.
2881131|NCT03381742|Active Comparator|ticagrelor 90mg bidpo.|To observe standard-dose ticagrelor on platelet aggregation in patients with acute coronary syndrome.
2881132|NCT03381742|Active Comparator|clopidogrel 75mg qdpo.|To observe standard-dose clopidogrel on platelet aggregation in patients with acute coronary syndrome.
2881133|NCT03381729|Experimental|Dose A|Intrathecal administration 6.0 X 10^13 vg of AVXS-101
2881134|NCT03381729|Experimental|Dose B|Intrathecal administration 1.2 X 10^14 vg of AVXS-101
2881135|NCT03381716||male|Drug:Beta-blocker,Angiotensin II receptor blocker,Angiotensin-converting enzyme,Calcium-channel blocker,Aspirin,Statin
2881136|NCT03381716||female|Drug:Beta-blocker,Angiotensin II receptor blocker,Angiotensin-converting enzyme,Calcium-channel blocker,Aspirin,Statin
2881137|NCT03381703|Experimental|Part 1|Investigate the absorption, metabolism, and excretion of YH12852
2881138|NCT03381703|Experimental|Part 2|Investigate the absolute bioavailability of YH12852
2881139|NCT03381690||Epidural (ED) emergent C-sec|
2881140|NCT03381690||Non-ED emergent C-sec|
2881141|NCT03381690||Non-ED elective C-sec|
2881142|NCT03381677|Experimental|Pedicle Lengthening Osteotomy|Lumbar decompressive surgery via Pedicle Lengthening Osteotomy Procedure with the Altum® Device
2881143|NCT03381677|Active Comparator|Control group|"Decompressive surgery via open surgical decompression and Transforaminal Lumbar Interbody Fusion (TLIF) with implantation of bilateral pedicle screws (4 screws) and rods (2 rods) and an interbody fusion cage (1 PEEK fusion cage, coated or uncoated):~DePuy Synthes Expedium® 5.5 System or Medtronic CD Horizon Solera 5.5 System or Innovative Surgical Designs True System for fixation; and~DePuy Synthes TLIF cage, Metronic TLIF cage or Meditech Talos TLIF cage."
2881144|NCT03381664|Experimental|AVP-923-20/10 capsule|Participants will receive a single AVP-923-20/10 (dextromethorphan hydrobromide [DM] 20 milligram [mg]/quinidine sulfate [Q] 10 mg) capsule administered orally.
2881145|NCT03381664|Experimental|AVP-923-20/10 via applesauce|Participants will receive the contents from a single AVP-923-20/10 capsule mixed and consumed in 1 tablespoon of applesauce.
2881146|NCT03381664|Experimental|AVP-923-20/10 via nasogastric feeding tube|Participants will receive the contents from a single AVP-923-20/10 capsule solubilized in feeding solution and administered through a nasogastric feeding tube.
2881147|NCT03381651|Active Comparator|Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation|Neoadjuvant chemoradiation: RT: 50.4Gy/28F/5.6W; CT: paclitaxel 50mg/m2 d1, qw + CBP AUC2 d1, qw, weekly for 6 wks; Surgery: 4-6 weeks after nCRT
2881148|NCT03381651|Active Comparator|Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation|Neoadjuvant chemoradiation: RT: 41.4Gy/23F/4.6W; CT: paclitaxel 50mg/m2 d1, qw + CBP AUC2 d1, qw, weekly for 5 wks; Surgery: 4-6 weeks after nCRT
2881149|NCT03381638||Normal Volunteer|Volunteers who report to have never had a concussion and are not at high risk of getting a concussion are scanned to obtain a baseline of all ages, sex, race, etc. All patients will be scanned with the Blink Reflexometer.
2881150|NCT03381638||Concussion Protocol|Athletes who had a potential concussion and will go through any stage of the approved protocol, are scanned by the Blink Reflexometer device. Results are then analyzed prior to unblinding the clinical diagnosis from an Athletic Trainer and/or Neurologist.
2881151|NCT03381625|Experimental|BMX-010 0.03%|200 subjects will receive BMX-010 0.03% twice daily for 7-28 days applied to psoriasis or atopic dermatitis lesions.
2881152|NCT03381625|Placebo Comparator|Placebo|100 subjects will receive placebo twice daily for 7-28 days applied to psoriasis or atopic dermatitis lesions.
2881153|NCT03381599|Experimental|Bone marrow aspirate|This study will utilize one group of participants. This group of participants will have bone marrow aspirate and a blood sample collected from the iliac crest and subsequently analyzed with the Arthrex Angel system. Thirty days following bone marrow aspiration, participants will receive a subcutaneous Filgrastim injection on four serial days. On the fifth day, a peripheral blood sample sample will be obtained.
2881154|NCT03381586|Experimental|Group A|1.0 mg/ml ALT-803
2881155|NCT03381586|Experimental|Group B|2.0 mg/ml ALT-803
2881156|NCT03381573||Roflumilast exposed|Patients with COPD ever exposed to Roflumilast
2881157|NCT03381573||Roflumilast unexposed|Patients with COPD never exposed to Roflumilast
2881158|NCT03381547|Active Comparator|A|AM0010: Dose level depending on weight will be 0.8 mg or 1.6 mg, dose formulation 4 mg/mL.
2881159|NCT03381547|Active Comparator|B|AM0010: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 4 mg/mL.
2881160|NCT03381547|Active Comparator|C|AM0010: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 2 mg/mL.
2881161|NCT03381534|Placebo Comparator|stent assisted angioplasty|patient randomly assigned to this group would be undergone stenting of vertebral artery origin without embolic protection device
2881162|NCT03381534|Experimental|stenting with EPD|patient randomly assigned to this group would be undergone stenting of vertebral artery origin with embolic protection device
2881165|NCT03381521|Placebo Comparator|Group C|Ultrasound-guided nerve hydrodissection with 0.5cc normal saline
2881166|NCT03381508||The study population|"The study population corresponds to patients with obstructive sleep apnea syndrome treated via continuous positive pressure and monitored according to usual practice with the latest Brizzy device.~Intervention: Brizzy continuous positive pressure device"
2881167|NCT03381495|Experimental|Epidural analgesia during labor|The epidural analgesia technique was used to maintain analgesia for parturients who request labor analgesia.First, we injected a test dose of 5ml 1% lidocaine . If not adverse effects were observed 10 minutes after the test dose, the parturient then received a bolus injection of an initial dose of 8-10 ml mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate. We then connected the epidural catheter with a patient-controlled epidural analgesia (PCA) pump, which provided patients the same mixed solution at 8-10ml/h until the delivery of neonates.
2881168|NCT03381495|No Intervention|Non-epidural analgesia during labor|Women who refused epidural labor analgesia were included in the non-epidural analgesia group, and they don't receive epidural analgesia during labor
2881169|NCT03381482||Controls|Group 1: the 4ml of CSF collected in the surgery context will be kept for the study, and 6x5ml of blood will be added to the usual samples.
2881170|NCT03381482||Asymptomatic cases with high risk to develop AD|Group 2: 10ml of CSF and 6x5ml of blood will be collected
2881171|NCT03381482||Cases with isolated cognitive complaint|Group 3: 10ml of CSF and 6x5ml of blood will be collected
2881172|NCT03381482||Prodromal AD|Group 4: 10ml of CSF and 6x5ml of blood will be collected
2881173|NCT03381482||Mild to moderate probable AD-type dementia|Group 5: 10ml of CSF and 6x5ml of blood will be collected
2881174|NCT03381469|Experimental|Periodontitis patients undergoing NSPT|Case group participants will receive comprehensive periodontal treatment also known as non-surgical periodontal therapy (NSPT) that will be completed by the end of week 20-21 of gestation.
2881175|NCT03381469|Active Comparator|Periodontitis Patients undergoing supragingival scaling|The control group participants with periodontitis will receive oral hygiene instruction and single visit supragingival scaling of all teeth at their baseline visit.
2881176|NCT03381469|Active Comparator|Without Periodontitis undergoing supragingival scaling|Placebo group participants without periodontitis will receive oral hygiene instruction and single visit supragingival scaling of all teeth at their baseline visit.
2881177|NCT03381456|Experimental|Healthy subject|LICI
2881178|NCT03381456|Experimental|Dystonic subject|LICI
2881179|NCT03381443||ERC|all students assessed by the methods used by the European Resuscitation Council
2881180|NCT03381443||AHA|all students assessed by the methods used by the American Heart Association
2881181|NCT03381430|Experimental|Gefitinib + Radiotherapy|Experimental: Gefitinib Gefitinib 250 mg/day oral daily Radiotherapy Total dose 50-54Gy, divided dose 1.8-2Gy
2881182|NCT03381417|Experimental|Pegcyte (Nanogen pegfilgrastim)|6 mg in each cycle
2881183|NCT03381417|Active Comparator|Neulastim (Roche pegfilgrastim)|6 mg in each cycle
2881184|NCT03381404|Experimental|[14C] MT-8554|
2881185|NCT03381391|Experimental|Feedback intervention condition|
2881186|NCT03381391|No Intervention|Assessment-only control condition|
2881187|NCT03381365|Experimental|investigational arm|
2881188|NCT03381352|Experimental|Chemo-radiotherapy with IMRT technique|Radiotherapy with IMRT technique concurrent with Capecitabine and MMC chemotherapy
2881189|NCT03381339|Experimental|Powered toothbrush intervention|Subjects will be provided an oscillating rotating powered toothbrush as the experimental intervention, and given written instructions on its proper use. Efficacy of overnight plaque reduction will be assessed at baseline and both gingivitis and plaque reduction will be assessed as change from baseline at 2, 4 and 12 weeks. Subjects will be given a standard fluoride toothpaste and asked to refrain from daily interproximal plaque control for the duration of the study.
2881190|NCT03381339|No Intervention|Manual toothbrush|Subjects will be provided a manual toothbrush as the control group and given written instructions on its proper use. Efficacy of overnight plaque reduction will be assessed at baseline and both gingivitis and plaque reduction will be assessed as change from baseline at 2, 4 and 12 weeks. Subjects will be given a standard fluoride toothpaste and asked to refrain from daily interproximal plaque control for the duration of the study.
2881191|NCT03381313|Experimental|Anomic Patients|Pure Anomic Patients underwent to conditioned word repetition training or traditional one.
2881192|NCT03381300|Other|Single cohort|
2881193|NCT03381287|Experimental|500mg HTD1801|
2881194|NCT03381287|Experimental|1000mg HTD1801|
2881195|NCT03381287|Experimental|2000mg HTD1801|
2881196|NCT03381274|Experimental|Arm A|MEDI9447 and osimertinib
2881197|NCT03381274|Experimental|Arm B|MEDI9447 and AZD4635
2881198|NCT03381261|Experimental|Botulinum toxin type A injection arm|All patients will be injected with Botulinum toxin on one side of the back of the head.
2881199|NCT03381248|Experimental|Cooled Radiofrequency|Cooled radiofrequency energy will be delivered to study subjects' knees to ablate culprit sensory nerves and reduce knee pain
2881200|NCT03381248|Active Comparator|Hyaluronic Acid Injection|Hyaluronic acid injections will be administered to study subjects' knees to reduce knee pain
2881201|NCT03381235|Experimental|Moderate exercise|Subjects in the moderate exercise group will participate in Spin exercise designed by Dr. Nocera.
2881202|NCT03381235|No Intervention|Mild exercise|Sessions will be focused on balance and stretching.
2881203|NCT03381209|Experimental|Group A|Sugammadex given in a dose of 2mg/kg based on ideal body weight
2881204|NCT03381209|Experimental|Group B|Sugammadex given in a dose of 2mg/kg based on adjusted body weight
2881205|NCT03381209|Experimental|Group C|Sugammadex given in a dose of 2mg/kg based on actual body weight
2881235|NCT03380988|Active Comparator|Corn pasta|Acute test meal
2881236|NCT03380975|Experimental|Montelukast 10 mg|Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis.
2881426|NCT03379688||Cardiac surgery patients|Patients undergoing cardiac surgery at Charité Campus Mitte
2881206|NCT03381196|Experimental|Treatment Arm 1 (pimodivir + SOC treatment)|Participants will receive pimodivir 600 milligram (mg), orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6) along with Standard-of-Care (SOC) treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected adverse event (AE).
2881207|NCT03381196|Placebo Comparator|Treatment Arm 2 (placebo + SOC treatment)|Participants will receive placebo matching to pimodivir orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6) along with SOC treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
2881208|NCT03381183|Experimental|Phase 1 - Dose Escalation|The dose escalation phase of the study will enroll 3 to 6 patients per dose level using a standard 3+3 design. Cohort 1 will be 3 participants enrolled at dose level 1. If no dose-limiting toxicities are observed during first 8 weeks of treatment, the enrollment will continue in dose expansion phase (expansion cohort at dose level 1). A dose limiting toxicity (DLT) will be defined as any Grade 3 or higher toxicity that occurs during the DLT evaluation period and are considered related to the combination of the IRX-2 regimen, durvalumab and tremelimumab (IDT) occurred during Cycle 1 Day 1 and Cycle 2 Day 28 (= 8 weeks). Toxicity that is clearly and directly related to the primary disease or to another etiology is excluded from this definition.
2881209|NCT03381183|Experimental|Phase 2 - Dose Expansion|14-17 participants will be enrolled at the recommended dose level from the dose escalation phase, for a total enrollment of 20 participants; however, investigators will replace participants with any missing tumor sample collection and continue to the enrollment until there are 20 pre- and post-treatment paired tumors. The 3-6 participants treated at the maximum tolerated dose (MTD) in the dose escalation portion of the study will be counted as part of the dose expansion population.
2881210|NCT03381170|Experimental|Ublituximab|Ublituximab IV infusions on Weeks 1E, 24E, 48E, 72E and (6E
2881211|NCT03381157||Cystic Fibrosis Group|
2881212|NCT03381157||Control Group|
2881213|NCT03381144|Experimental|Part 1: GDC-0334|Participants in up to 7 cohorts will receive single, ascending doses of GDC-0334 under fasting conditions.
2881214|NCT03381144|Placebo Comparator|Part 1: Placebo|Participants in up to 7 cohorts will receive single doses of placebo under fasting conditions.
2881215|NCT03381144|Experimental|Part 2: GDC-0334|Participants in up to 3 cohorts will receive single doses of GDC-0334 under fasting or fed conditions.
2881216|NCT03381144|Placebo Comparator|Part 2: Placebo|Participants in up to 3 cohorts will receive single doses of placebo under fasting or fed conditions.
2881217|NCT03381144|Experimental|Part 3: GDC-0334|Participants in up to 4 cohorts will receive multiple, ascending doses of GDC-0334 under fasting or fed conditions.
2881218|NCT03381144|Placebo Comparator|Part 3: Placebo|Participants in up to 4 cohorts will receive multiple doses of placebo under fasting or fed conditions.
2881219|NCT03381118|Experimental|Ara-C+HaploLymphocyte+Nivo|"Patients treated with nivolumab, intermediate dose cytarabine and haploidentical lymphocyte infusion:~[Cytarabine 500-1000 mg/m2 bid D-4, -3, -2 + G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells infusion D0~+ Nivolumab 40 mg D+5] х 2-3 cycles"
2881220|NCT03381118|Experimental|Ara-C+ Nivo|"Patients treated with nivolumab and intermediate dose cytarabine:~[Cytarabine 500-1000 mg/m2 bid D+1, +2, +3 + Nivolumab 40 mg D+1] х 2-3 cycles"
2881221|NCT03381092||invasive breast cancer|Patients with invasive breast cancer who have clinically negative axilla and receive neoadjuvant treatment followed by sentinel lymph node biopsy are eligible for this study.
2881222|NCT03381079|Experimental|Surgical group|In this arm, the adults with high myopia will be given posterior scleral reinforcement.
2881223|NCT03381079|No Intervention|Control group|In this arm, the adults with high myopia will not be given any surgical treatment.
2881224|NCT03381066|Experimental|Intercalating arm|gefitinib, pemetrexed,cisplatin
2881225|NCT03381066|Active Comparator|chemotherapy alone arm|Vinorelbine, cisplatin
2881226|NCT03381053||Treatment observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose postoperative Imatinib treatment are labeled treatment group.
2881227|NCT03381053||Control observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose no Imatinib treatment are labeled observation group.
2881228|NCT03381040|Active Comparator|Group A|Poor structural support/volume (atrophy of soft tissues, leading to loss of projection) with adequate skin envelope (normal or thick skin). Treated with Restylane Lyft.
2881229|NCT03381040|Active Comparator|Group B|Poor structural support/volume (atrophy of soft tissues, leading to loss of projection) with poor skin envelope (thin skin). Treated with Restylane Volyme.
2881230|NCT03381027|Experimental|Interventional Arm- Baby Massage|Interventional Arm= Baby Massage
2881231|NCT03381027|No Intervention|Control Arm- no Baby Massage|Control Arm= no Baby Massage
2881232|NCT03381001|Active Comparator|embryo transfer after embryo thaw|Embryos will be transferred at the same day of the thawing procedure
2881233|NCT03381001|Experimental|embryo transfer after thaw and culture|Embryos will be transferred one day after thawing procedure
2881237|NCT03380962|Experimental|Clazakizumab|All ten patients will receive clazakizumab monthly. Patients will receive up to 6 doses pre-transplantation. If patients are transplanted during the study, they will then receive 6 doses of clazakizumab (monthly) and a 6 month protocol biopsy will be performed. Based on the biopsy results and clinical labs PI will determine if patients should continue monthly doses for up to another 6 doses and day 330 post-transplantation. Patients who received 12 post-transplant doses of clazakizumab will then undergo a 12 month protocol biopsy.
2881238|NCT03380949|Experimental|PPI (Pain Pupillary Index)|Opioid administration (remifentanil) in intervention group is guided by PPI derived from video-pupillometry performed with the AlgiScan™ by IDMed, Marseille, France. The device measures the degree of pupillary reflex dilation (PRD) following a nociceptive stimulation. It automatically increases the intensity of the electric stimulation from 10 to 60 mA and displays the PPI as numerical index between 0 and 10. A low PPI score indicates deep, a high score light analgesia. A PPI score of 2-3 is supposed to represent an optimal level of analgesia. A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if PPI score is calculated more than 3. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is <1.
2881239|NCT03380949|Experimental|SPI (Surgical Pleth Index)|Opioid administration (remifentanil) in intervention group is guided by SPI derived from photoplethysmography performed by the device CARESCAPE™ B650 Patient Monitor by GE Healthcare, Helsinki, Finland. Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger plethysmography. The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone). A SPI score between 20 and 50 has been proposed as the target range. A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if SPI score is calculated more than 50. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 20.
2881240|NCT03380949|Experimental|NOL (Nociception Level)|Opioid administration (remifentanil) in intervention group is guided by NOL derived from finger photoplethysmography performed with the device PMD200™ manufactured by Medasense, Ramat Gan, Israel. The device continuously calculates the NOL with a multi-parametric approach from pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level and fluctuations, skin temperature and finger motion. It is presented on a scale from 0 (no pain) to 100 (extreme pain). A NOL score between 10 and 25 has been proposed as the target range. A remifentanil bolus of 30 µg will be administered and the infusion rate will be increased by 0.03 µg/kg/min if NOL score is calculated more than 25. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 10.
2881241|NCT03380949|Active Comparator|Control|Opioid administration (remifentanil) in control group is guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation and sweating of the patient.
2881242|NCT03380936|Active Comparator|Arm 1 - conversion to Envarsus XR|Optimize: conversion to Envarsus XR (Tacrolimus Extended Release Oral Tablet [Envarsus]) with goal trough tac level > 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol
2881243|NCT03380936|Active Comparator|Arm 2 - plasma exchange and IVIG|Treat clinical AMR: Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.
2881244|NCT03380923|Experimental|Moderate Intensity (MOD)|"Endurance Training (ET): 3 d/wk x 30 minutes (min) of steady-state, moderate-intensity exercise on a treadmill or stationary cycle ergometer at target heart rate (HR) = 65-75% of maximum oxygen consumption rate (VO2max). The two modes (treadmill, bicycle) are offered for variety, and each subject is required to use each mode at least 1 d/wk to prevent bias.~Resistance training (RT): 2 d/wk consisting of a prescription engaging all major muscle groups in 10 movements. Excluding abdominal crunches, target intensity is 12 repetitions/set to volitional fatigue. Subjects complete 3 sets of each movement, with ~60 seconds (s) rest between sets. For each movement, resistance increases when 14 repetitions are achieved for 2 of 3 sets.~HR is monitored throughout each session and stored for analysis."
2881245|NCT03380923|Experimental|High Intensity (HI)|"RT: The 2 d/wk RT prescription differs from the MOD arm only in intensity and rest intervals. The same approach to progression applies, but HI RT intensity targets 8-10 repetitions per set; thus, resistance loads increase when 10 repetitions are achieved for 2 of 3 sets. The HI arm performs superset training, pairing movements stressing different muscle groups, with only 30-45 s between.~ET: In lieu of steady-state endurance exercise, the HI arm performs high-intensity interval training (HIIT) 3 d/wk using a mix of challenging, explosive movements at maximal intensity. 10 x 30 s maximal intensity intervals are separated by 30 s rest intervals.~HR is monitored throughout each session and stored for analysis."
2881246|NCT03380910|Experimental|Ready to Quit|Current patients who speak Spanish, smoke cigarettes, and are ready to quit will be included. The intervention includes an interdisciplinary team approach using pharmacy and behavioral health trainees to provide smoking cessation services.
2881247|NCT03380910|Other|Not Ready to Quit|Current patients who speak Spanish, smoke cigarettes, and are not ready to quit will be included. The intervention includes an interdisciplinary team approach using pharmacy and behavioral health trainees to provide smoking cessation services.
2881248|NCT03380897|Active Comparator|Outpatient group|"After insertion of induction catheter for labor, women of the outpatient group can go home and assess their pain with VAS scale at home. The intervention is to go home.~Intervention for outpatient group was to go home."
2881249|NCT03380897|Placebo Comparator|Inpatient group|"After insertion of induction catheter for labor, women of the inpatient group assess their pain with VAS scale in the ward. The intervention is to stay at ward.~Intervention for inpatient group was to stay at ward."
2881250|NCT03380884|No Intervention|Control|Control group will remain in their habitual life style and no vibration used
2881251|NCT03380884|Experimental|Vibration Group|The intervention group will undergo Low-magnitude high-frequency vibration (LMHFV) at 35Hz, 0.3g (peak to peak magnitude), displacement of <0.1mm, 20 min/day, at least 3 times per week, for 6 months in community centres
2881285|NCT03380663|Active Comparator|BFRE - HF|Heart failure patients undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
2881464|NCT03379415|Experimental|Footwear|4 Different types of trainers will be used to see the difference in gait in meniscectomy patients
2881252|NCT03380871|Experimental|NEO-PV-01/Adjuvant + pembrolizumab + chemotherapy|Pembrolizumab at a dose of 200 mg administered by intravenous infusion (IV) plus chemotherapy with carboplatin (AUC 5) + pemetrexed (500 mg/m2) every 3 weeks for 4 cycles. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously (one vial of pooled peptides per injection site) in up to four distinct sites (each extremity or flanks) while continuing therapy with pembrolizumab.
2881253|NCT03380845|Active Comparator|Fraxel Restore|"Multiple published studies have demonstrated that erbium-doped 1,550-nm non-ablative fractional laser (NAFL) can be successfully utilized in the treatment of all forms of atrophic acne scarring - ice-pick, boxcar, and rolling scars - with a very favorable safety profile in all skin types, and thus, has been cleared by Food and Drug Administration (FDA) for that particular indication. According to the manufacture manual (reference attached in the Documents and Attachments section), NAFL is indicated for use in skin resurfacing procedures as well as treatment of acne scars, surgical scars, lentigos (age spots), solar lentigos (sun spots), actinic keratosis, and melasma.~Fraxel Restore to be done on one side of the face monthly for three months."
2881254|NCT03380845|Active Comparator|Fractora|"Fractional radiofrequency is not a laser. Instead, these devices use an array of electrodes that allows for zones of thermal wounds to be created between areas of unaffected zones, thus stimulating dermal remodeling and allowing for a supply of reservoir cells to promote healing. Great interest has been culminating over the recent years for the use of such devices in acne scars due to the absence of light scattering and the absence of chromophore-specific targets traditionally needed with laser treatments. As melanin is not a target, it is felt to have a higher safety profile in darker skin phototypes.~Fractora to be done on one side of the face monthly for three months."
2881255|NCT03380832||Type 2 diabetes for at least 10 years|This is an observational study in which we will quantify vestibular thresholds in individuals who have had type 2 diabetes for at least 10 years. Normative data has recently been published and subjects with diabetes will be compared to a model that includes age effects.
2881256|NCT03380819|Experimental|Genome sequencing|Patients undergo exome or whole-genome sequencing, and their patients receive an interpreted clinical report.
2881257|NCT03380806|Active Comparator|Arm 1|Conventional Radiotherapy (CRT) Prostate Boost Pelvic Radiation LHRH agonist
2881258|NCT03380806|Experimental|Arm 2|Stereotactic Body Radiotherapy (SBRT) Prostate Boost Pelvic Radiation LHRH agonist
2881259|NCT03380793|Experimental|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
2881260|NCT03380780|Experimental|Emicizumab|
2881261|NCT03380767|Experimental|POC group|In this group, patients will be treated according to the information gathered by TEG or ROTEM assays.
2881262|NCT03380767|Experimental|Conventional group|In this group, patients will be treated according to the information gathered by conventional laboratory assays (platelet count, fibrinogen level, PT or INR and d dimer for fibrinolysis)
2881263|NCT03380754|Experimental|Carbohydrate Rich Drink|Group A will receive the carbohydrate rich drink, Nutricia preOp. This is the intervention group.
2881264|NCT03380754|Placebo Comparator|Placebo Drink|Group B will receive placebo, Nestle Splash Lemon Flavor Water (Placebo) (similarly flavored and appearing water, however with no calorie, carbohydrate or nutritional content).
2881265|NCT03380754|No Intervention|No Drink|Group C will not receive any drink. This group will follow normal protocol.
2881266|NCT03380741||Group1|Tumour present on histology and MRI following biopsy/LLETZ
2881267|NCT03380741||Group 2|Tumour absent on MRI following biopsy/LLETZ
2881268|NCT03380741||Group 3|Tumour recurrence present at the vaginal vault on MRI
2881269|NCT03380741||Group 4|Tumour recurrence absent at the vaginal vault on MRI
2881270|NCT03380741||Group 5|Normal cervix at colposcopy
2881271|NCT03380728|Experimental|Group 1|Ibogaine Hydrochloride 240 mg on day 1, placebo on day 4, placebo on day 7
2881272|NCT03380728|Experimental|Group 2|Ibogaine Hydrochloride 240 mg on day 1, Ibogaine Hydrochloride 320 mg on day 4, placebo on day 7
2881273|NCT03380728|Experimental|Group 3|Ibogaine Hydrochloride 240 mg on day 1, Ibogaine Hydrochloride 320 mg on day 4, Ibogaine Hydrochloride 400 mg on day 7
2881274|NCT03380715|Active Comparator|right nostril in patients with rhinitis|Intervention : Administration of either 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity or
2881275|NCT03380715|No Intervention|Left nostril in patients with rhinitis|No nasal decongestion administration into the left nostril
2881276|NCT03380715|Active Comparator|Right nostril in patients with rhinitis|400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.
2881277|NCT03380702|Active Comparator|whitening photoactivation gel|exposure to hydrogen gel and photoactivation for teeth whitening
2881278|NCT03380702|Placebo Comparator|placebo|exposure to gel without active whitening substance and the same photoactivation source as active comparator
2881279|NCT03380689|Experimental|SIRB2|Biweekly combination therapy with S-1, Irinotecan, and Bevacizumab
2881280|NCT03380676||Oromandibular dystonia group|Patients with idiopathic oromandibular dystonia, either focal or associated to other dystonic features including generalized dystonia
2881281|NCT03380676||Healthy subjects|Healthy subjects (normal neurological examination), each being age-matched to a subjet of the oromandibular dystonia group
2881282|NCT03380663|Active Comparator|RIC - Healthy|Healthy subjects undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet.
2881283|NCT03380663|Active Comparator|RIC - HF|Heart failure patients undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet.
2881284|NCT03380663|Active Comparator|BFRE - Healthy|Healthy subjects undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
2881286|NCT03380663|Active Comparator|TRT - Healthy|Healthy subjects undergoing heavy intensive resistance training (TRT) undergoing 4 sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes).
2881287|NCT03380663|No Intervention|Control - Healthy|No intervention.
2881288|NCT03380663|No Intervention|Control - HF|No intervention.
2881289|NCT03380650|Other|durg-coated balloon dilation|The drug-coated balloon will be used to treat the femoropopliteal occlusion.
2881290|NCT03380650|Other|directional atherectomy and LDD|The directional atherectomy and local drug delivery will be used to treat the femoropopliteal occlusion.
2881291|NCT03380637||Pregnant and non-pregnant females|The pregnant females posted for elective lower segment cesarean section and non-pregnant females posted for elective surgeries are scanned by ultrasound in the pre recovery room. The visibility of the gastric antrum is assessed. The qualitative and quantitative assessment is made and is compared.
2881292|NCT03380624|Experimental|Refresh Optive|The subjects are randomly assigned to Arm one or Arm two such as in the first arm, subjects are assigned to be treated with one drop of Refresh Optive at 15 minutes, 1, 2 and four hours After which there is a washout period before proceeding to the second arm
2881293|NCT03380624|Experimental|Refresh Optima OMEGA 3|The subjects are randomly assigned to Arm one or Arm two such as in the first arm, subjects are assigned to be treated with one drop of Refresh Optima OMEGA 3 at 15 minutes, 1, 2 and four hours After which there is a washout period before proceeding to the second arm
2881294|NCT03380611|Experimental|Wakame|Subjects will receive capsules containing wakame
2881295|NCT03380611|Experimental|Spirulina|Subjects will receive capsules containing spirulina
2881296|NCT03380611|Placebo Comparator|Control|Subjects will receive capsules containing microcrystalline cellulose
2881297|NCT03380598|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic during 6 months.
2881298|NCT03380598|Active Comparator|CLOSS|Usual care plus using a web based support system for self-monitoring weight at physical activity.
2881299|NCT03380585|Experimental|Reciproc|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit. In this group, intervention will be carried out by the Reciproc motor (VDW, Germany) and Reciproc single-file system. The intervention is foraminal enlargement with the Reciproc single-file system.
2881300|NCT03380585|Active Comparator|ProTaper Next|The active comparator is foraminal enlargement with the ProTaper Next multi-file system. Endodontic treatment is identical to experimental group except file systems used. In this group, ProTaper Next multi-file system will be used in enlarging apical foramina.
2881301|NCT03380572|Experimental|Senhance Cholecystectomy|Cholecystectomy operation performed using Senhance robotic system
2881302|NCT03380572|Active Comparator|Laparoscopic Cholecystectomy|Cholecystectomy operation performed using standard laparoscopic instruments
2881303|NCT03380559|Experimental|Group A : Association (botulinum toxin + corticoid)|
2881304|NCT03380559|Placebo Comparator|Group C : placebo of toxin + corticoid :|
2881305|NCT03380559|Active Comparator|Group T : botulinum toxin + placebo corticoid|
2881306|NCT03380546|Experimental|acarbose|The women will receive acarbose with a progressive increase of dose according to post prandial glucose values and digestive tolerance, with a maximal dose of 3 x 100 mg /day
2881307|NCT03380546|Active Comparator|prandial insulin|The women will receive prandial insulin according to usual practice (routine care according to French recommendations): before each meal, with dose titration according to post prandial values.
2881308|NCT03380533|Active Comparator|Buprenorphine|"Buprenorphine 10mg Patch + Multimodal Oral Scheme~Multimodal Oral Scheme:~Diclofenac 75mg c 12h Tramadol 50mg c 12h. Rescues with tramadol 50 mg (maximum rescue dose 100mg, minimum frequency between rescues 4hs)"
2881309|NCT03380533|Placebo Comparator|Placebo|"Placebo Patch + Multimodal Oral Scheme~Multimodal Oral Scheme:~Diclofenac 75mg c 12h Tramadol 50mg c 12h. Rescues with tramadol 50 mg (maximum rescue dose 100mg, minimum frequency between rescues 4hs)"
2881310|NCT03380520|Experimental|Ferric carboxymaltose|Ferric carboxymaltose according to SmPC
2881311|NCT03380520|Placebo Comparator|Placebo|Normal saline (0.9%)
2881312|NCT03380507|Experimental|Triple therapy group|"Experimental group will receive usual care according to Hamad Medical Corporation Adult Sepsis Care Pathway (CPW 10311, May 2017) PLUS triple therapy.~Triple therapy regimen:~Intravenous vitamin C (1.5 gm q 6 hourly for 4 days or until ICU discharge, whichever is earlier), hydrocortisone (50 mg q 6 hourly for 7 days or until ICU discharge, whichever is earlier, followed by a taper over 3 days) as well as intravenous thiamine (200 mg q 12 hourly for 4 days or until ICU discharge, whichever is earlier)."
2881313|NCT03380507|No Intervention|Control group|Control group will receive usual care only according to Hamad Medical Corporation Adult Sepsis Care Pathway (CPW 10311, May 2017).
2881314|NCT03380494|Experimental|Overhead perturbation training technique|Patients will undertake a series of exercise positions with the arm elevated above shoulder level with a stimulus applied with a weight and resistance band- such that the glenohumeral joint is exposed to a perturbed stimulus and has to utilise proprioception and motor control to correct arm position. The exercise session will be 45mins in length and occur once per week for 6 weeks.
2881315|NCT03380494|Active Comparator|Non-perturbed exercise|Patients will undertake a series of exercise positions with the arm elevated above shoulder level with a stimulus applied via a weight held in the hand- such that the glenohumeral joint is exposed to a load but without a perturbation of joint position. The exercise session will be 45mins in length and occur once per week for 6 weeks.
2881316|NCT03380481||SECRETS-TCM|Stroke patients who treated by western medicine and/or traditional Chinese medicine in southern China
2881317|NCT03380468|Experimental|Cisplatin plus pemetrexed|Drug: cisplatin 75mg/m2 iv Drug: pemetrexed 500mg/m2 iv
2881318|NCT03380468|No Intervention|Observation|Observation and follow up only
2881350|NCT03380195|Active Comparator|Sport drink|
2881351|NCT03380195|Active Comparator|Sugar water|
2881352|NCT03380195|Placebo Comparator|Water|
2911044|NCT03172650||Control group|fatty liver patients
2881319|NCT03380455|Experimental|Treatment period A & B|"Treatment period A: Subjects receive a single oral dose of 500 mg lucerastat on Day 1 under fasted conditions.~Treatment period B: From Day 3 to Day 9, subjects receive a b.i.d. (every 12 h) oral dose of 800 mg cimetidine under fasted conditions (Treatment period B1; from Day 3 to Day 5). On Day 6, subjects receive a single oral dose of 500 mg lucerastat concomitantly with the morning dose of 800 mg cimetidine under fasted conditions (Treatment period B2; from Day 6 to Day 10)."
2881320|NCT03380442|Experimental|Psilocybin group|This group will receive a single oral 25mg dose of psilocybin under surveilled and safe conditions.
2881321|NCT03380442|Active Comparator|Ketamine group|This group will receive a single intranasal 125mg dose of ketamine under surveilled and safe conditions.
2881322|NCT03380442|No Intervention|No-treatment group|This group will be included in the study as a no-treatment group, so that natural time-dependent changes in depressive symptoms can be controlled for and thus the antidepressive effects of ketamine and psilocybin treatment can be verified
2881323|NCT03380429|Experimental|Data on Maintenance use supplied to Subject and HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensor attached to RELVAR/BREO ELLIPTA will be fed back to the subject via an app on smart phone and to the subject's HCP via an online dashboard.
2881324|NCT03380429|Experimental|Data on Maintenance use supplied to Subject|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensor attached to RELVAR/BREO ELLIPTA will be fed back to the subject via an app on smart phone.
2881325|NCT03380429|Experimental|Data on Maintenance and Rescue use supplied to Subject and HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensors attached to RELVAR/BREO ELLIPTA and salbutamol MDI will be fed back to both subject and HCP. The data will be fed back to the subject through an app and to HCP through an online dashboard.
2881326|NCT03380429|Experimental|Data on Maintenance and Rescue use supplied to Subject|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensors attached to RELVAR/BREO ELLIPTA and salbutamol MDI will be fed back to subject through an app.
2881327|NCT03380429|Active Comparator|No data supplied to Subject or HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Subjects will be provided with a home hub through which their data will be uploaded during the study but the subjects and their HCP will not be able to view the data.
2881328|NCT03380416|Experimental|Portfolio Diet|The participants will follow a weight-maintaining diet characterized by whole-grain, polyphenol-rich foods, omega 3- rich foods, MUFA-rich foods (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 26%/total energy, fiber 24 g/1000Kcal) polyphenols 2715/day, omega-3 2.6 g/day and omega-6 9.6 g/day)
2881329|NCT03380416|Active Comparator|MUFA Diet|The participants will follow a weight-maintaining diet characterized by MUFA-rich food (olive oil) (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 28%/total energy, fiber 10 g/1000Kcal) polyphenols 376/day, omega-3 1.1 g/day and omega-6 7.4 g/day)
2881330|NCT03380403|Active Comparator|PDT|Methylene blue and Photon Irradiation , every each week, until total ulcer healing.
2881331|NCT03380403|Active Comparator|Ciprofloxacin|Diabetic foot patients were treated on conventional way, using antibiotics and surgery.
2881332|NCT03380390|Experimental|Oxymetazoline + Energy-Based Therapy|Participants will receive energy-based therapy (Potassium Titanyl Phosphate [KTP], Pulsed Dye Laser [PDL], or Intense Pulsed Light [IPL]) plus once daily application of oxymetazoline hydrochloride (HCl) cream 1.0%.
2881333|NCT03380377|Experimental|Clazakizumab (Anti-IL-6 Monoclonal)|All ten patients will be receiving clazakizumab (Anti-IL-6 Monoclonal) monthly for six months. Then patients will be scheduled for six month protocol biopsy. If biopsy and all clinical labs show benefit or stability (up to PI discretion), patients will continue receiving clazakizumab monthly for another six months. All patients completing twelve doses of clazakizumab will be scheduled for a twelve month protocol biopsy and last study visit. If at the 6 month protocol biopsy, no improvement was seen, PI will have patient come for their last study visit on month 12 post enrollment.
2881334|NCT03380364|Experimental|Group Undergoing Hysterosopy|This group will include 75 women with unexplained infertility. 5 mm rigid sheath Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.
2881335|NCT03380351||SCDIC interventions|Careful detail the intervention components and the implementation strategies (i.e., the mechanisms by which the interventions are being delivered in usual care) being developed by the consortium.
2881336|NCT03380351||SCDIC control groups|Careful detail the control conditions of each of the SCDIC sites for each of the interventions being developed.
2881337|NCT03380338|Experimental|Exercise program|Twice weekly exercise program, combined aerobic and strenght training
2881338|NCT03380325|Experimental|Iloprost first|Cross-over starts with iloprost intervention, then second clamp without iloprost.
2881339|NCT03380325|Experimental|Iloprost second|Cross-over starts without iloprost intervention, then second clamp with iloprost.
2881340|NCT03380286||Coronary Stenosis|
2881341|NCT03380273|No Intervention|pre-intervention|The number of SSI are collected in this phase. Patients with fractures are enrolled and their standard of care treatment is observed.
2881342|NCT03380273|Other|post-intervention|Here the same observations are made as in the first arm, however this is after the hospital staff was thought the prevention measures (all by themselves approved) and enforced to be applied.
2881343|NCT03380260|Experimental|Paranoia Induction|Behavioral procedure involving social exclusion and negative feedback to induce paranoia
2881344|NCT03380260|No Intervention|Control Condition|No manipulation of paranoid ideation
2881345|NCT03380234|Experimental|Intervention|8 worksheets and around 15 online quizzes and 30 WhatsApp messages.
2881346|NCT03380234|Other|Control|Control students will receive the following minimal intervention to reduce their intention to smoke and SHS - a leaflet on smoking and SHS published by the Department of Health.
2881347|NCT03380221|Experimental|Watermelon|
2881348|NCT03380221|Active Comparator|Low fat cookies|
2881349|NCT03380195|Experimental|Watermelon juice|
2881353|NCT03380182|Experimental|Acupuncture/Acupressure Group|Bilateral P6 point acupuncture will be performed intra-operatively by the PI, who has UC Davis Medical Center privilege for this specific acupuncture, while the patient is under anesthesia. Patient will be sent home with an acupressure band, which is to remain on for 24 hours post operatively.
2881354|NCT03380182|Sham Comparator|Control Group|Bilateral sham point acupuncture will be performed intra-operatively. Patient will be sent home with a wrist sham band matching in appearance of acupressure bands without the acupressure function, which is to remain on for 24 hours post operatively.
2881355|NCT03380169|Experimental|Advance dressing|Prophylactic advance wound dressing
2881356|NCT03380169|Active Comparator|Conventional gauze dressing|Prophylactic conventional wound dressing
2881357|NCT03380156|Experimental|Interventional|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour.
2881358|NCT03380156|Placebo Comparator|Control|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour.
2881359|NCT03380143|Experimental|Wellscapes Intervention|The wellness landscape intervention (Wellscapes) will establish a multi-level system infrastructure (Community Hub, Organization Wellness Teams, Activity Setting/Leaders) and provide training and support for population health quality improvement cycle processes targeting two evidence-based practices (EBPs): (1) stacking time segments of PA episodes within an organization's daily routine, and (2) improving the quality of PA episodes (% time in PA).
2881360|NCT03380143|Active Comparator|Standard Practice|The standard collective impact public health practice intervention will establish a multi-level system infrastructure and provide training on community development.
2881361|NCT03380130|Experimental|SIRT and Nivolumab|SIRT (selective internal radiation therapy) will be performed in a single session using SIR-Spheres resin microspheres. After 3 weeks, nivolumab 240 mg every 2 weeks will be initiated
2881362|NCT03380117|Experimental|eBridge Online Counseling|In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students have the opportunity to engage with eBridge counselors via online dialogues, in which students and counselors exchange messages using a secure website.
2881363|NCT03380117|No Intervention|Control|In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.
2881364|NCT03380104|Experimental|Single Arm|Intradural Spinal Cord Stimulation; Administration of Questionnaires
2881365|NCT03380091|Experimental|Metformin|Metformin 1000 mg PO bid
2881366|NCT03380091|Experimental|Vitamin D (Cholecalciferol)|Cholecalciferol 5,000 IU PO daily
2881367|NCT03380078|Active Comparator|Standard|Programs assigned to the Standard condition will receive standard EBI training only
2881368|NCT03380078|Experimental|TEAMS Leadership Institute (TLI) ONLY|Programs assigned to the TLI ONLY condition will receive standard EBI training for providers and leaders will participate in TLI.
2881369|NCT03380078|Experimental|Motivational Enhancement (TIPS for Training) ONLY|Programs assigned to the TIPS ONLY condition will receive enhanced TIPS EBI training for providers.
2881370|NCT03380078|Experimental|TIPS + TLI|Programs assigned to the TIPS + TLI condition will receive TIPS EBI training for providers and leaders will participate in TLI
2881371|NCT03380065|Active Comparator|Late deflation of TR band|"first 3ml of air removed from the TR band after TWO hour of sheath removal. Then, 3ml of air removed every 15minutes.~Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 3ml of air is pushed back into the device until bleeding stops. Then wait for another 15minutes for the next deflation."
2881372|NCT03380065|Active Comparator|Early deflation of TR band|"First 2ml of air is removed from the TR band ONE hour after sheath removal. Then, 2ml of air is removed every 30minutes.~Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then push the 2ml of air back into the device until bleeding stops. Then wait for another 30minutes for the next deflation."
2881373|NCT03380052||Gastric cancer|Patients who were diagnosed with gastric cancer
2881374|NCT03380052||Control|Healthy participants or benign disease patients such as benign gastric ulcers, duodenal ulcers, reflux esophagitis, or non-erosive reflux disease
2881375|NCT03380039|Experimental|CAR-BCMA T cells|"In this study, autologous T cells transduced with a BCMA-targeted chimeric antigen receptor (CAR-BCMA T cells) are used to treat patients with refractory or relapsed multiple myeloma.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to CAR-BCMA T cells infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
2881376|NCT03380026|Experimental|Valchlor 0.016% Topical Gel|0.016% w/w topical mechlorethamine gel applied over a minimum of 8 cm2, nightly, over a period of 4 months.
2881377|NCT03380026|Active Comparator|Valchlor plus Triamcinolone|0.016% w/w topical mechlorethamine gel (once, nightly) and Triamcinolone acetonide 0.1% ointment (up to three times daily) applied in over a minimum of 8 cm2, over a period of 4 months.
2881378|NCT03380013|Experimental|OMT group|Osteopathic Manipulative Therapy (OMT); two treatments between day 4 and 7 of life
2881379|NCT03380000|Active Comparator|Nitrate rich beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
2881380|NCT03380000|Placebo Comparator|Nitrate depleted beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.
2881381|NCT03379987|Experimental|PVB morphine|
2881382|NCT03379987|Active Comparator|PVB bupivacaine|
2881383|NCT03379974|Experimental|ARM A: DDAVP followed by exercise|"Intervention #1: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: Exercise intervention"
2881424|NCT03379701||allergic rhinitis|Patients with allergic rhinitis
2881425|NCT03379701||Control|Healthy subjects.
2911045|NCT03172637||Group A|50 female end stage renal disease patients
2881384|NCT03379974|Active Comparator|ARM B: DDAVP alone|"Intervention #1: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: no further intervention (rest)"
2881385|NCT03379974|Experimental|ARM C: Exercise intervention|"Intervention #1: Exercise intervention~Intervention #2: no further intervention (rest)"
2881386|NCT03379974|Experimental|ARM D: Exercise followed by DDAVP|"Intervention #1: Exercise intervention~Intervention #2: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril)."
2881387|NCT03379948||Group 1 with central venous line|lab investigation Complete blood count blood culture
2881388|NCT03379948||Group 2 with only peripheral line|lab investigation Complete blood count blood culture
2881389|NCT03379935||Bipolar radial head arthroplasty|Patients treated with bipolar head arthroplasty due to radial head fracture
2881390|NCT03379935||Unipolar radial head arthroplasty|Patients treated with unipolar head arthroplasty due to radial head fracture
2881391|NCT03379922|Experimental|Stress balls|The first arm will be given stress balls to squeeze during their treatment and will also receive standard care (the offer of oral analgesia)
2881392|NCT03379922|Experimental|Headphones|The second arm will be given headphones to listen to music during their treatment and will also receive standard care.
2881393|NCT03379922|No Intervention|Control|The control group will receive standard care (the offer of oral analgesia)
2881394|NCT03379909|Experimental|Treatment arm|Metformin orally at doses up to 1500 mg twice daily for 3 months.
2881395|NCT03379896||Sepsis|Patient diagnosed with sepsis according to the new sepsis definition (infection+SOFA≥2).
2881396|NCT03379896||Control|Age-matched healthy control
2881397|NCT03379883|Placebo Comparator|Pulsed radiofrequency (P-RF)|Patients will receive both intra articular RF and genicular nerve RF ablation
2881398|NCT03379883|Experimental|Platelet rich plasma (PRP)|Patients will receive intra-articular platelet rich plasma (PRP)
2881399|NCT03379870|Experimental|Arm 1|"Subjects who receive a CI and present with a post-operative LFPTA of ≤ 75 dB HL.~Electric Acoustic Speech Processor: EAS fitting. They will be evaluated in the EAS condition and a traditional fully electric condition."
2881400|NCT03379870|Experimental|Arm 2|"Subjects with pre-operative low frequency hearing who receive a CI and present with a post-operative LFPTA of > 75 dB HL.~Electric Acoustic Speech Processor: Electric only fitting They will be evaluated in the traditional fully electric condition only."
2881401|NCT03379857|Other|Cannabis User|
2881402|NCT03379844|Experimental|Holmium-166 radioembolization|
2881403|NCT03379818|Experimental|Specific word training intervention|This training programme will be similar to a typical word learning intervention. Infants will be introduced to 28 real objects and their names (e.g. biscuit, trousers). These objects will be divided into 7 sets of four words, and during each session, infants will be presented with one of this sets. Each session will consist of a 15 min play session in which each object will be presented at least 10 times and each object name will be mentioned at least 10 times. Additionally, techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used.
2881404|NCT03379818|Experimental|Shape training intervention|In the shape training intervention, infants will be presented with four novel words paired with four novel sets of objects. Each set consists of two exemplars with the same shape but with different colors and textures, and a contrasting object. Each set will be presented in a play session, and the name of the objects will be mentioned at least 10 times. The other three sets of exemplars will be presented in the same way. Each session will last 15 minutes. This intervention is based on a study conducted by Smith and colleagues (2002), where they found that typically developing infants that are taught to attend to shape at 17 months old, can enhance significantly their word learning.
2881405|NCT03379805||Fontan-Kreutzer operated patients|Patients with a Fontan-Kreutzer circulation. No interventions are done. (The intervention is the operation done 15-20 years ago)
2881406|NCT03379805||Healthy Control subjects|Age, gender and weight matched control subjects
2881407|NCT03379792|Active Comparator|Lean T1D|
2881408|NCT03379792|Active Comparator|Obese T1D|
2881409|NCT03379792|Active Comparator|Non-diabetic|
2881410|NCT03379779||Pneumonia patient with respiratory failure|Sputum and stool sampling day 1, 3 and 7 after enrolling into study
2881411|NCT03379766|Experimental|Successor of Phonak Audéo B-Direct|The successor of Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
2881412|NCT03379766|Active Comparator|Phonak Audéo B-Direct|The Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
2881413|NCT03379753|Experimental|Intervention group|Those patients randomized to intervention group will be exposed to the diad of music and positive images in a private hospital room in addition to receiving standard care.
2881414|NCT03379753|No Intervention|Control group|Those patients randomized to control group will receiving standard care in a private hospital room with an un-modified post operative environment.
2881415|NCT03379740|Experimental|Product Exposure Sequence 1|"Subjects will be randomized to follow a sequence of product exposure comprised of :~E-cigarette; P4M3-1.7%; P4M3-1.7%LA; P4M3-3%LA; and P4M3-4%LA"
2881416|NCT03379740|Experimental|Product Exposure Sequence 2|"Subjects will be randomized to follow a sequence of product exposure comprised of :~E-cigarette; P4M3-1.7%LA; P4M3-1.7%; P4M3-3%LA; and P4M3-4%LA"
2881417|NCT03379727|Experimental|Midostaurin|Induction phase - D8 to D28 in combination with standard of care (7+3 or 5+2 chemotherapy) up to 2 cycles Consolidation phase - D8 to D28 in combination with cytarabine up to 4 cycles Maintenance phase - D1 to D28 up to 12 cycles
2881418|NCT03379714||Patients with ruptured or unruptured intracranial aneurysms|
2881419|NCT03379701||CRSwPolyps with no Eosonophilia|CRS patients with nasal polyposis, and no eosonophilia.
2881420|NCT03379701||CRSwPolyps with Eosonopholia|CRS patients with nasal polyposis and eosonophilia.
2881421|NCT03379701||CRS without Polyps|Patients with chronic rhinosinusitis and no nasalpolyposis.
2881422|NCT03379701||PCD|Patients with Primrary ciliary dyskinesia .
2881423|NCT03379701||AFRS|Patients with allergic fungal rhinosinusitis.
2881427|NCT03379675|Experimental|Treatment A: JNJ-53718678 500 mg|Participants will receive 500 mg dose of JNJ-53718678 once daily for 7 days.
2881428|NCT03379675|Experimental|Treatment B: JNJ-53718678 80 mg + Placebo|Participants will receive 80 mg dose of JNJ-53718678 along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
2881429|NCT03379675|Placebo Comparator|Treatment C: Placebo|Participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
2881430|NCT03379662|Experimental|Erchonia HLS Laser|The Erchonia HLS Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
2881431|NCT03379662|Placebo Comparator|Placebo Laser|The Placebo Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
2881432|NCT03379649|Experimental|PRP|Receives intrauterine infusion of platelet rich plasma
2881433|NCT03379649|Placebo Comparator|Placebo|Receives intrauterine infusion of embryo culture media
2881434|NCT03379636|No Intervention|no tape|tests are realised without any shoulder tape
2881435|NCT03379636|Experimental|kinesiotape|tests are realised with a kinesiotape applied according to Dr Kase model, over the deltoid muscle and over the acromioclavicular joint
2881436|NCT03379636|Sham Comparator|sham tape|tests are realised with a sham tape, applied transversally under the deltoid tuberosity with no tension and with no direct influence on shoulder area
2881437|NCT03379623|Experimental|Intervention group|
2881438|NCT03379623|No Intervention|Usual care group|
2881439|NCT03379597|Experimental|Probiotics Group|"Probiotics treatment :（live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules, Oral）, each capsule contain more then 1.0*10^7 CFU.~Bifico: 210mg Bid."
2881440|NCT03379597|No Intervention|Control Group|Non-probiotics group
2881441|NCT03379584|Experimental|SGN-CD48A|SGN-CD48A every 3 weeks
2881442|NCT03379558||Cohort 1 : alirocumab exposed|Pregnant women diagnosed with primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and exposed to alirocumab during the current pregnancy.
2881443|NCT03379558||Cohort 2 : disease matched comparison|Pregnant women diagnosed of primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and unexposed to alirocumab during the current pregnancy.
2881444|NCT03379558||Cohort 3 : non disease comparison|Healthy pregnant women who do not have a known diagnosis of primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and have no known exposure to a known human teratogen.
2881445|NCT03379545|Other|Shoulder Arthroplasty (SA)|3D computed tomography (CT) and 3D non-contrast magnetic resonance (MR)
2881446|NCT03379532|Active Comparator|BCI-NMES|Electrical stimulation of paretic upper limb is triggered contigent to voluntary motor cortex activation of the patient, as detected by the brain-computer interface.
2881447|NCT03379532|Sham Comparator|Sham-NMES|Electrical stimulation of paretic upper limb is applied independently of motor cortex activation of the patient by using a prerecorded session of another patient.
2881448|NCT03379519|Experimental|Multi-domain Attention Training (MAT)|Training sessions of the MAT group is 45 minutes/day, 3 sessions/week, for 12 weeks (36 sessions).
2881449|NCT03379519|Active Comparator|Passive information activities (PIA)|The training sessions of PIA is the same as MAT group (45 min/day, 3 days/week, for 12 weeks, for a total of 36 sessions).
2881450|NCT03379506|Experimental|EBR/GZR|Ages 12 to less than 18 years will receive Fixed Dose Combination (FDC) EBR/GZR tablets once daily for 12 weeks; and ages 3 to less than 12 years will receive a pediatric formulation of EBR/GZR once daily for 12 weeks. There will be 24 weeks of follow-up.
2881451|NCT03379493|Experimental|ET190L1 ARTEMIS™ T cells|ET190L1 ARTEMIS™ T cells administered by intravenous (IV) infusion
2881452|NCT03379480|Active Comparator|Yoga arm|Patients with Schizophrenia will undergo 12 sessions of yoga. According to randomization one group of patients will start yoga immediately after recruitment ,whereas another group will go into wait list for 12 weeks after which they will also undergo Yoga treatment.
2881453|NCT03379480|No Intervention|Control arm|Healthy volunteers who will not receive yoga.
2881454|NCT03379467|Experimental|SMS Reminder|"Single SMS at each of the following times:~3 days before immunization~1 day before immunization~Day of immunization"
2881455|NCT03379467|Experimental|Interactive Reminder|"Single SMS at each of the following times:~3 days before immunization~1 day before immunization~Day of immunization On the day of immunization, study participants are required to respond back through SMS notifying us that child got vaccinated or if not, the reason for delay in immunization. In case of no response, 2 additional reminders will be sent at:~1 day after scheduled immunization date~1 week after scheduled immunization date"
2881456|NCT03379467|No Intervention|Control|Subjects in this arm will not receive any intervention
2881457|NCT03379441|Experimental|Experimental|"Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3 week cycle until:~PD,~unacceptable toxicity,~investigator choice,~patients IC withdrawal,~up to a maximum of 24 months (35 administrations) Experimental"
2881458|NCT03379441|No Intervention|Observation|
2881459|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 560 mg|In Phase I, starting dose of Ibrutinib will be 560 mg orally per day. 3 patients will be enrolled first. If none of these have DLTs, 3 new patients will be enrolled at the next higher Ibrutinib dose level (840 mg orally per day). If 1 of these 3 patients have a DLT, expand this arm to 6 patients. If 2 or more of these 6 patients have a DLT, enroll 3 patients in lower dose lever (420 mg).
2881460|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 840 mg|If no patients in 560 mg arm have DLTs, this arm will be opened in Phase I to see how this higher dose is tolerated.
2881461|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 420 mg|If 2 or more patients in 560 mg arm have DLTs, this arm will be opened in Phase I to see how this lower dose is tolerated.
2881462|NCT03379428|Experimental|Phase II- Trastuzumab plus Maximum Tolerated Dose|Maximum tolerated dose from Phase I will be used here in Phase II.
2881463|NCT03379415|Experimental|Meniscus Injured|These meniscus patients will be recruited to participate in a single session to wear 4 different pairs of shoes
2883249|NCT03366805|Active Comparator|Wound Care Video|Wound Care Patient Education Video
2881465|NCT03379402||Adult patients presenting with sepsis|Adult patients, both males and females, presenting with sepsis will be approached for participation in the study.
2881466|NCT03379389|Experimental|Methenamine + Methylthioninium|Dosage: Methenamine (120mg) + Methylthioninium (20mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days
2881467|NCT03379389|Active Comparator|Methenamine+Methylthioninium+Acriflavine+Atropa belladona|Dosage: Methenamine (250mg) + Methylthioninium (20mg) + Acriflavine hydrochloride (15mg) + Atropa belladonna L. (15mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days
2881468|NCT03379376|Experimental|Supportive Care (eMMB)|Participants receive a self-directed 20-minute eMMB video and are instructed to practice eMMB at least once before surgery and daily for 2 weeks after surgery. Participants may also request additional guidance from a yoga instructor via telephone and video conference before surgery and again 1 day after surgery or as soon as feasible.
2881469|NCT03379363||Pediatric Cushing Syndrome Patients|Pediatrics patients with endogenous Cushing syndrome who received at least one dose of Korlym
2881470|NCT03379350|Experimental|clamping group|Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
2881471|NCT03379350|No Intervention|control group|Patients in control group are managed with gravity drainage (water seal only, without suction) all the time after operation.
2881472|NCT03379337|Experimental|Dental imaging|4 incisors and 4 canine teeth of subjects were imaged with the experimental and the commercial device.
2881473|NCT03379324|Active Comparator|Superiority of augmented repairs|Assess pain, function, and structural integrity of the rotator cuff at 3 months, 6 months, 1 year, and 2 years post-operation
2881474|NCT03379324|Active Comparator|Fat degeneration of supraspinatus muscle|MRI assessment the quantity and disposition of fat within the supraspinatus muscle body compared to pre-operation MRI, at 1 year and 2 years post-operation
2881475|NCT03379259|Experimental|Phase 1A: BGB-A333 monotherapy dose escalation|
2881476|NCT03379259|Experimental|Phase 2A: BGB-A333 monotherapy dose expansion|
2881477|NCT03379259|Experimental|Phase 1B: BGB-A333 and BGB-A317 dose confirmation|
2881478|NCT03379259|Experimental|Phase 2B: BGB-A333 and BGB-A317 dose expansion|
2881479|NCT03379233|Active Comparator|Usual Care|Concept2 inhaler
2881480|NCT03379233|Experimental|Telehealth|Concept2 inhaler with patient application
2881481|NCT03379220||Subdural ECoG (Group 1)|For patients who require craniotomy to treat TBI, a subdural electrode strip will be placed intraoperatively following evacuation of a hematoma or contusion, as required. Electrode strips will be used for subsequent electrocorticography (ECoG) during intensive care. Patients will also undergo continuous scalp EEG monitoring.
2881482|NCT03379220||Burr Hole ECoG (Group 2)|For patients who do not require surgery but do require invasive monitoring, an intraparenchymal ECoG electrode array will be placed through a cranial burr hole. Depending on other monitoring needs, the location of injuries, and other clinical considerations, the burr hole may be the same as used for placement of other probes or may be separate. In cases of focal injury, the burr hole will be placed to allow electrode targeting to a lobe with significant primary lesion(s). Patients will also undergo continuous scalp EEG monitoring.
2881483|NCT03379220||EEG (Groups 1-3)|Continuous EEG recordings will be made using Ag/AgCl electrodes placed on or beneath the scalp (subdermal wire) according to standard practice. The default montage will employ eight lead electrodes for each hemisphere following the 10/20 system (Right: Fp2, F4, C4, P4, O2, F8, T4, T6; left: Fp1, F3, C3, P3, O1, F7, T3, T5). Other montages with more dense placement of electrodes in the region of ECoG monitoring may also be used.
2881484|NCT03379207||"Community Acquired Pneumonia group"|"Participants admitted to Intensive Care Unit (ICU) of University Hospital of Tours (France) for Community Acquired Pneumonia.~Interventions:~Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose, at inclusion, day 3, 8, and 15 during ICU stay Tracheal Aspirates for research purpose: only for mechanically ventilated participants, at inclusion, day 3, 8, and 15 during ICU stay~Surplus of Broncho-alveolar lavage fluid: only if performed for diagnosis purpose by the treating investigator (indication left at his discretion)"
2881485|NCT03379207||"Control group"|"Participants admitted to Intensive Care Unit of University Hospital of Tours (France) for whom invasive mechanical ventilation is required for an estimated duration of at least 48h, without diagnosis of pneumonia or shock.~Interventions:~Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose, at inclusion, day 3, 8, and 15 during ICU stay Tracheal Aspirates for research purpose: at inclusion, day 3, 8, and 15 during invasive mechanical ventilation period,~Surplus of Broncho-alveolar lavage fluid: only if performed for diagnosis purpose by the treating investigator (indication left at his discretion)"
2881486|NCT03379194|Experimental|'Antibiotic stewardship program'|Physicians receive quarterly over 24 months, first in January 2018 postal mail a feedback on their antibiotic prescriptions and updated antibiotic resistance information from the community. With the first letter, educational material, evidence-based guidelines for conditions leading to most outpatient prescriptions in primary care and leaflets for on using antibiotics wisely are provided. Additional material is made available on a study website that can be accessed by each physician in the intervention group by an unique access code.
2881487|NCT03379194|No Intervention|Control|No intervention
2881488|NCT03379181|Experimental|Propranolol 80 mg|Patients receive a single dose of 80 mg propranolol p.o.
2881489|NCT03379168|Placebo Comparator|Placebo Injection|Patients who are randomized to the placebo group will receive an injection of 7cc of sterile saline in the affected knee.
2881490|NCT03379168|Active Comparator|Corticosteroid Injection|Patients who are randomized to the corticosteroid group will receive an injection of 2cc (80mg) of triamcinalone acetonide injectable suspension mixed with 5 cc of 1% plain lidocaine for a total of 7cc of fluid injected in the affected knee.
2881522|NCT03378908|Experimental|Intervention Treatment 3 meals|Diet will be distributed in 3 meals (breakfast, lunch and dinner). Each meal will consist of the addition of the conventional meal and the next snack. Energy intake will be distributed: 30% breakfast (25% breakfast + 5% snack), 40% lunch (30% lunch + 10% snack) and 30% dinner (25% dinner and 5% snack).
2881523|NCT03378895|Experimental|adults aged 35 to 55 years|
2911046|NCT03172637||Group B|50 normal female patients
2881491|NCT03379168|Experimental|Lipogems Injection|Patients who are randomized to the Lipogems treatment group will undergo a lipoaspiration from their abdomen and autologous injection of the harvested adipocytes into their knee. It is standard to harvest three to four times more adipose tissue than is planned to be injected to account for tissue processing by the Lipogems device. The investigators plan to inject 7cc of autologous adipose tissue. Thus, the investigators will harvest between 25 and 30 cc of adipose tissue from each patient. The tissue will be processed immediately and 7cc will be injected. Any remaining adipose tissue will be disposed of immediately in biohazardous waste.
2881492|NCT03379155|Experimental|Active Group|Internet-based self-help
2881493|NCT03379155|No Intervention|Waiting List Group|
2881494|NCT03379142|Other|Behavioral: Faith-Based messages|We will send faith-based messages one week prior to Ramadan and twice a day during Ramadan.
2881495|NCT03379103|Active Comparator|GP - sevoflurane|GP - patients will be anesthetized with sevoflurane associated with subarachnoid anesthesia and will be preconditioned with 1 MAC sevoflurane for 15 minutes before the installation of ischemia by tourniquete
2881496|NCT03379103|Placebo Comparator|GC - control|GC - patients will be anesthetized with sevoflurane associated with subarachnoid anesthesia and will be preconditioned with intravenous propofol for 15 minutes before the installation of ischemia by tourniquete.
2881497|NCT03379077|Experimental|LTP Plus Supported Implementation|LTP Plus Supported Implementation group participants will receive intervention by trained LHWs of HANDS, co-facilitated and supervised by senior trained PILL researchers, expert in delivering LTP plus intervention
2881498|NCT03379077|Active Comparator|LTP Plus|Participants in LTP Plus arm will receive LTP plus intervention by trained LHWs of Health and Nutrition Development Society (HANDS).
2881499|NCT03379064|Experimental|culturally adapted Cognitive Behavior Therapy|We will use The STreSS CBT manual developed by Schroder and his colleagues
2881500|NCT03379064|No Intervention|Treatment As Usual|The Treatment As Usual (TAU) group will receive regular treatment they have been receiving already as prescribed by the physician.
2881501|NCT03379051|Experimental|Ublituximab + Umbralisib + Venetoclax|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Venetoclax oral daily dose
2881502|NCT03379038|Experimental|Progressive Physical Therapy (PPT)|"Duration: Each child was given 40-minute session. Frequency: Two sets were performed, 5-10 active assisted sit-ups in each set at least once a day. Furthermore, the subjects were advised to use CP chair and standing frame/wall corner for sitting/standing position respectively for at least 15-30 minutes once a day. These exercises were followed by reflex inhibiting postures in sitting and lying positions.~Total 42 sessions were performed in 6 weeks (7 days/week). Intensity: The aim of the PPT was to improve the patient's level of spasticity, strength and activity level."
2881503|NCT03379038|Placebo Comparator|Maintenance Physical Therapy (MPT)|"Duration: Each child was given 40-minute session. Frequency: Two sets were performed, 5-10 active assisted sit-ups in each set at least once a day. Furthermore, the subjects were advised to use CP chair and standing frame/wall corner for sitting/standing position respectively for at least 15-30 minutes once a day. These exercises were followed by reflex inhibiting postures in sitting and lying positions. Total 42 sessions were performed in 6 weeks (7 days/week).~Intensity:The aim of the MPT was to maintain the patient's current level of spasticity, strength and activity level."
2881504|NCT03379025|Experimental|Early Intervention Group|National Institute on Drug Abuse Standardized Research Electronic Cigarettes, nicotine concentration 15mg/ml, to replace all cigarette use for 12 weeks
2881505|NCT03379025|Other|Delayed Intervention Group|After a 12 week period of no electronic cigarette use, National Institute on Drug Abuse Standardized Research Electronic Cigarettes, nicotine concentration 15mg/ml, to replace all cigarette use for 12 weeks
2881506|NCT03379012|Experimental|Testosterone and Targeted therapy|Testosterone undecanoate (Nebido®) and Targeted therapy (sunitinib or pazopanib)
2881507|NCT03379012|Active Comparator|Control|Targeted therapy (sunitinib or pazopanib) only
2881508|NCT03378999|Placebo Comparator|Control|Placebo capsules containing microcrystalline cellulose
2881509|NCT03378999|Experimental|Rhodospirillum rubrum 0.25 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 0.25 gram/day
2881510|NCT03378999|Experimental|Rhodospirillum rubrum 0.5 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 0.5 gram/day
2881511|NCT03378999|Experimental|Rhodospirillum rubrum 1.0 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 1.0 gram/day
2881512|NCT03378986||Unilateral THA|Patients who underwent to unilateral total hip arthroplasty
2881513|NCT03378986||Bilateral THA|Patients who underwent to simultaneous bilateral total hip arthroplasty
2881514|NCT03378973|Experimental|High dose dexmedetomidine|Patients will receive dexmedetomidine 0.5 mcg/kg/hr plus propofol 50 mcg/kg/min
2881515|NCT03378973|Active Comparator|Low dose dexmedetomidine|Patients will receive dexmedetomidine 1.0 mcg/kg/hr plus propofol 25 mcg/kg/min
2881516|NCT03378960|Other|omeprazole|omeprazole 20 mg
2881517|NCT03378934|Experimental|Berberine Arm|In the Berberine Arm, patients will receive berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4±1 weeks (Stage 3) in addition to standard treatment. Patients will also take aspirin 100 mg once daily and clopidogrel 75 mg once daily for 12±1 weeks.
2881518|NCT03378934|Active Comparator|Control Arm|In the Control Arm, patients will receive standard treatment for 12±1 weeks. Patients will also take aspirin 100 mg once daily and clopidogrel 75 mg once daily for 12±1 weeks.
2881519|NCT03378921|Experimental|donors feces|Fecal microbiota transplantation is performed by experienced endoscopists through flexible sigmoideoscopy into the afferent limb. The second FMT is installed via catheter into the pouch 3 weeks after the first FMT.
2881520|NCT03378921|Placebo Comparator|patients own feces|Fecal microbiota transplantation is performed by experienced endoscopists through flexible sigmoideoscopy into the afferent limb. The second FMT is installed via catheter into the pouch 3 weeks after the first FMT.
2881521|NCT03378908|No Intervention|Conventional Treatment 6 meals|Diet will be distributed with 6 meals (breakfast, lunch, dinner and 3 snacks). This is the usual diet prescribed for women with GDM at the Department of Endocrinology and Nutrition of both Centers. Energy intake distribution: 25% breakfast, 5% snack, 30% lunch, 10% snack, 25% dinner and 5% snack.
2883250|NCT03366805|Experimental|Pain Management Video Group|Pain Management Patient Education Video
2881524|NCT03378817|Active Comparator|Conventional cold storage|Conventional static cold storage (CCS) on temperature 0-4 °C from organ procurement (historical case matched group)
2881525|NCT03378817|Experimental|Hypothermic oxygenated perfusion (HOPE)|HOPE for 2 hours via the renal artery in a recirculating and pressure controlled system, Belzer (UW) machine perfusion solution, perfusate temperature 0-4 °C, perfusate oxygenation pO2 of 60-80 kPa Other Name: Hypothermic machine perfusion (HMP)
2881526|NCT03378804|Experimental|PIEB-PCEA|"Programmed intermittent epidural bolus (PIEB) application of ropivacaine 0.2% with patient-controlled epidural analgesia:~The background rate is set at 6ml per hour. The patient-controlled bolus function is programmed with 4ml at a lock-out interval of 30min."
2881527|NCT03378804|Active Comparator|CEI-PCEA|"Continous epidural analgesia with patient-controlled analgesia using ropivacaine 0.2%:~The background rate is set at 6 ml / h continuously. The patient-controlled bolus function is programmed in with 4ml at a lock-out interval of 30min."
2881528|NCT03378791|Experimental|Group A|Iron bisglycinate (27mg of elemental iron)
2881529|NCT03378791|Active Comparator|Group B|Ferrous fumarate (115mg of elemental iron)
2881530|NCT03378778||Less than 33% Tooth Structure remaining|Root canal treatment followed by CAD CAM restoration
2881531|NCT03378778||33%-50% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
2881532|NCT03378778||50% -66% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
2881533|NCT03378778||More than 66% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
2881534|NCT03378765||African origin adults|African origin adults from Ghana, Jamaica, Seychelles, South Africa and USA between the ages of 30- 50.
2881535|NCT03378752||Atelectasis formation using HFJV|Computed tomography scans are performed every 15 minute during the first 45 minutes during general anaesthesia using high frequency jet ventilation.
2881536|NCT03378726|Experimental|Standard Counseling and Micronutrients|Participants will receive standard services provided by the Ministry of Health, including powder micronutrients. Children receive 1 gram of powdered micronutrientes for 60 days between 6 and 12 months of age, and 60 daily packets per year from the time they are 1 year old until 5 years old.
2881537|NCT03378726|Experimental|SPOON Group Counseling with SQ-LNS|Participants will receive the supplement SQ-LNS in addition to SPOON group counseling, which is a new form of social communication in which participants will learn relevant lessons in a group format. SQ-LNS consists of a 20g nutrient supplement package that is to be consumed daily between 6 and 24 months of age.
2881538|NCT03378726|Experimental|Group, Interpersonal Counseling, SQ-LNS|Participants will receive the supplement SQ-LNS in addition to SPOON group and interpersonal counseling, which will consist of both participants learning relevant lessons in group format as well as in formats in which participants will work one-on-one with an instructor. SQ-LNS consists of a 20g nutrient supplement package that is to be consumed daily between 6 and 24 months of age.
2881539|NCT03378713|Experimental|GROUP 1: Long testosterone|Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application.
2881540|NCT03378713|Active Comparator|GROUP 2: Short testosterone|Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.
2881541|NCT03378713|Active Comparator|GROUP 3: Control|The COS starts directly on the second day of the cycle without prior medication.
2881542|NCT03378700|Experimental|Brief Hope Intervention Group|In addition to the pre-dialysis educational programme on self-care and treatment options for ESRF patients as per the control group, brief hope intervention will be offered: a four-weeks individual intervention. Two face-to-face sessions (1-hour) and two telephone follow up sessions (30 minutes) in between. A booklet modified from the goal worksheet in Lopez et al. (2000) will be prepared for the participants for reviewing their planned goals, recording achieved targets and successful experiences.
2881543|NCT03378700|Active Comparator|Pre-dialysis Education Group|Pre-dialysis educational class and standard care such as clinic follow up and normal hospital care will be provided. This session is led by clinicians with renal nursing training. The educational class aims at providing information on the treatment modalities for patients with ESRD, signs and symptoms of their illness and the basic advice on the importance of adherence to healthy lifestyle, nutrition and medications. Logistic call and social communication will be offered and initiated by trained nurses in the second week and the third week
2881544|NCT03378687||status epileptius|Cases were patients 29 days to 18 years who were diagnosed with status epileptius in 35 hospitals in China between January 1， 2013 and December 31，2015.
2881545|NCT03378674|Experimental|Group A|remifentanil infusion of 0,15 mcg/Kg/min
2881546|NCT03378674|Active Comparator|Group B|remifentanil infusion of 0,3 mcg/Kg/min
2881547|NCT03378661|Experimental|BZN STD Regimen|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 8 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
2881548|NCT03378661|Experimental|BZN 300 mg - 4 wks|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
2881549|NCT03378661|Experimental|BZN 300 mg - 2 wks|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 2 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 6 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
2881550|NCT03378661|Experimental|BZN 150 mg - 4 wks|"Benznidazole (100 mg and 50 mg) tablets and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in two separate daily doses for 4 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
2881743|NCT03377257|Active Comparator|Active group|The treatment with oral zolmitriptan is 2.5mg when headache attack.
2881551|NCT03378661|Experimental|BZN 150 mg - 4 wks / E1224 300 mg|"Benznidazole (100 mg and 50 mg) tablets and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in two separate daily doses for 4 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.~Three E1224 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks. (total dose: 3000 mg)."
2881552|NCT03378661|Experimental|BZN 300 mg (weekly) 8 wks / E1224 300 mg|"Benznidazole (100 mg and 50 mg) tablets by mouth, once weekly for 8 weeks (total 8 days of intermittent treatment) and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in the other 6 days of the week for 8 weeks~Three E1224 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks. (total dose: 3000 mg)."
2881553|NCT03378661|Placebo Comparator|Placebo|"Benznidazole Placebo (100 mg and 50mg) tablets by mouth, every 12 hours for 8 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
2881554|NCT03378648|Experimental|CHF6366 active|
2881555|NCT03378648|Placebo Comparator|CHF6366|
2881556|NCT03378648|Active Comparator|Comparator|
2881557|NCT03378635|Experimental|Dasiglucagon|Single fixed dose (s.c.injection) of dasiglucagon
2881558|NCT03378635|Placebo Comparator|Placebo|Single fixed dose (s.c.injection) of placebo
2881559|NCT03378635|Active Comparator|GlucaGen®|Single fixed dose (s.c.injection) of GlucaGen®
2881560|NCT03378622|Experimental|Anchor|Anchor used for mesh attachment
2881561|NCT03378622|Active Comparator|Suture|Suture used for mesh attachment
2881562|NCT03378609|Other|Vocal Fatigue Index (VFI)|Standardized Questionnaire assessing vocal fatigue
2881563|NCT03378596|Experimental|L-citrulline & L-arginine|L-citrulline (6 grams) L-arginine (8 grams)
2881564|NCT03378596|Active Comparator|L-citrulline & Placebo|L-citrulline (6 grams) Placebo (6 grams)
2881565|NCT03378596|Active Comparator|L-arginine & Placebo|L-arginine (8 grams) Placebo (6 grams)
2881566|NCT03378596|Active Comparator|Placebo|Placebo (6 grams)
2881567|NCT03378583||control,|control normal ventilation
2881568|NCT03378583||sellick,|ventilation while sellick manoeuvre is applied
2881569|NCT03378583||low paratracheal esophagus compression|ventilation while low paratracheal esophagus compression is applied
2881570|NCT03378570|Active Comparator|5.5cm Rule Group|rTMS will be targeted at a left prefrontal target 5.5cm anterior to the primary motor strip identified on the scalp during motor threshold testing.
2881571|NCT03378570|Active Comparator|F3 Group|rTMS will be targeted at the left prefrontal scalp target identified as F3 according to the 10-20 EEG system.
2881572|NCT03378544|Experimental|Experimental arm|Patients with suicidal ideation and depression will receive psychosocial interventions adapted from the WHO mental health Global Action Programme Intervention Guide (mhGAP-IG). The intervention will involve psycho-education to patients on the importance of maintaining interest in activities that they used to do, regular sleep cycles, physical activity and social activity.
2881573|NCT03378544|No Intervention|Control group|Patients with suicidal ideation and depression will be trained on how to refer patients suffering from depression, using a referral note to the nearest health centre for further treatment
2881574|NCT03378531|Experimental|AEB1102|Each patient may receive AEB1102 administered IV for up to approximately 3 years.
2881575|NCT03378505|Experimental|Mobile App|Half of the students randomly assigned
2881576|NCT03378505|Experimental|Reflection|Half of the students randomly assigned
2881577|NCT03378492|Active Comparator|Standard Epidural|Participants in this group will have epidurals placed using standard practice.
2881578|NCT03378492|Experimental|Ultrasound Guided Epidural|Participants in this group will have epidurals placed using standard practice with the assistance of ultrasound.
2881579|NCT03378479|Other|SOC + 'Posaconazole 18 MG/ML'|standard of care (SOC) treatment for influenza pneumonia +posaconazole 2*300mg/d IV on day 1, followed by 1*300mg/d IV from day 2 for 7 days; vials containing 18mg posaconazole /mL, 300mg posaconazole/vial in total)
2881580|NCT03378479|Other|Standard of Care|standard of care treatment for influenza pneumonia (at the investigators discretion)
2881581|NCT03378466|Experimental|Unfractionated Heparin (UFH)|UFH initiated at 18 IU/kg/hr
2881582|NCT03378466|Other|Venous thromboprophylaxis (VTE)|as per local standard
2881583|NCT03378453|Other|NarCo|Narcolepsy type 1 over 65 years old
2881584|NCT03378453|Other|CoS|Cognitevement healthy controls
2881585|NCT03378427|Experimental|Tedizolid Phosphate 200 MG [Sivextro]|All included patients will receive prolonged (>= 6 weeks) tedizolid treatment given orally.
2881586|NCT03378414|Experimental|Intravenous infusion group|Umbilical cord mesenchymal stem cells (SCLnow 19#)
2881587|NCT03378414|Experimental|Intrathecal injection group|Umbilical cord mesenchymal stem cells (SCLnow 19#)
2881588|NCT03378414|No Intervention|Control groups|No intervention
2881589|NCT03378401|Experimental|Octenidine Mouthwash|0.1% Octenidinedihydrochlorid Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
2881590|NCT03378401|Placebo Comparator|Placebo|Placebo Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
2881591|NCT03378388||Vedolizumab|Participants diagnosed with UC or CD, who fail or are intolerant to a previous biologic treatment or with contra-indication to anti-tumor necrosis factor alpha (TNF alpha) after failure of conventional treatments regardless of the line of treatment, and are potentially eligible for a treatment with vedolizumab will be observed from the first prescription during consultation over a period of 24 months.
2881592|NCT03378362|Experimental|Partial denervation of the wrist joint|Patients will be operated with a partial denervation of the wrist through a single dorsal approach.
2881655|NCT03377894|Active Comparator|• Group (B) sharp incision|100 primigravidas, at term who underwent elective transverse lower segment Cesarean section for the first time among the age group of 20 ̶ 37 years with a singleton pregnancy undergoing sharp uterine incision expansion
2881656|NCT03377881|Other|Traditional|The traditional/control arm consists of PSA testing and if PSA>3ng/ml a systematic biopsy of the prostate is performed.
2882154|NCT03374579|Experimental|CO2 gap|The patients will receive fluid bolus and observe changes in co2 gap and gap/ ratio in them.
2881593|NCT03378349|Experimental|Internet-delivered CBT over 10 weeks|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that aim to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
2881594|NCT03378349|Placebo Comparator|Treatment as usual wait list|Patients randomized to the treatment as usual wait list arm will receive standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health. Thus, the treatment as usual arm will control for the provision of basic patient information, but without the guidance of a psychologist or any CBT interventions.
2881595|NCT03378336||Observational Group|This is an observational study with only one group/cohort with no intervention
2881596|NCT03378323|Active Comparator|Multiple injection local anesthetic|Ultrasound guided axillary plexus block with multiple injections of local anesthetic
2881597|NCT03378323|Experimental|Single injection local anesthetic|Ultrasound guided axillary plexus block with a single injection of local anesthetic
2881598|NCT03378310|Experimental|Reference tablet followed by BMS-986205 tablet with free base|BMS-986205 reference tablet (treatment period 1) followed by BMS-986205 tablet with free base (treatment period 2).
2881599|NCT03378310|Experimental|BMS-986205 tablet with free base followed by reference tablet|BMS-986205 tablet with free base (treatment period 1) followed by BMS-986205 reference tablet (treatment period 2).
2881600|NCT03378297|No Intervention|Feasibility study cohort|
2881601|NCT03378297|Experimental|Metformin|850 mg
2881602|NCT03378297|Experimental|Acetylsalicylic acid|160 mg
2881603|NCT03378297|Experimental|Olaparib|300 mg x 2
2881604|NCT03378297|Experimental|Letrozol|2.5 mg
2881605|NCT03378284|Experimental|Tegoprazan(Test drug)|Tegoprazan drug QD for 7 days
2881606|NCT03378284|Active Comparator|Active comparator drug|Active comparator drug QD for 7 days
2881607|NCT03378271|Experimental|FGM/CGM|"each patient will have a CGM and a FGM, subcutaneous glucose sensors, the data will be compared to the time-matched reference blood glucose measurements.~Each ambulatory patient will sample capillary blood with the HemoCue meter and measure the concentration of glucose minimum 3 times per day for 14 days. The concentration of finger-stick capillary blood glucose will be measured using the self-monitoring blood glucose (SMBG) hemocue meter in their daily living. The subjects will record SMBG, in a written diary. Subjects will dose insulin according to their routine methods throughout the 14 day study"
2881608|NCT03378245|Experimental|Telemedicine Intervention|Multidisciplinary telemedicine education of staff and providers on best practices for behavioral modification as well as education on best practices for pharmacologic therapies.
2881609|NCT03378232|Placebo Comparator|Placebo Olive Oil|Placebo supplement with olive oil
2881610|NCT03378232|Experimental|High EPA Supplement|Supplements providing up to 3g per day of Omega-3, with increased EPA
2881611|NCT03378232|Experimental|High DHA Supplement|Supplements providing up to 3g per day of Omega-3, with increased DHA
2881612|NCT03378219||Cohort 1|Sarilumab-Exposed Cohort: Pregnant women exposed to Kevzara (sarilumab) for the treatment of an approved Kevzara (sarilumab) indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
2881613|NCT03378219||Cohort 2|Disease-matched Comparison Cohort: Pregnant women diagnosed with Kevzara (sarilumab) approved indication. Approximate frequency matched to the exposed group by disease indication, validated by medical records, who have not been exposed to Kevzara (sarilumab) any time in the current pregnancy, and have taken another biologic DMARD medication for their disease within 2 years before the current pregnancy and have an indication for such treatment at enrollment
2881614|NCT03378219||Cohort 3|Non-diseased Comparison Cohort: Healthy pregnant women not diagnosed with a Kevzara (sarilumab) indication and unexposed to Kevzara (sarilumab) during the course of the pregnancy
2881615|NCT03378206|Experimental|Hinged 8-figure plate|Hinged 8-figure plate is a novel devise that has modifications in order to improve the treatment effect of conventional 8-figure plate. This arm will be used to verify the effectiveness and feasibility of the modification.
2881616|NCT03378206|Active Comparator|conventional 8-figure plate|Conventional 8-figure plate is widespread method to treat genu varum and valgus. This arm, as a comparator, will be the control group to verify the feasibility of the novel hinged 8-figure plate.
2881617|NCT03378167|Experimental|MICROBIOTA|Patients randomized to the INTERVENTION arm will receive a baseline fecal microbiota transplant (FMT) colonoscopic infusion at Week 0, followed by twice-weekly oral microbiota capsule (OMC) therapy for 6 weeks (including Week 0).
2881618|NCT03378167|Placebo Comparator|PLACEBO|Patients randomized to the CONTROL arm will receive a baseline normal saline (NS) colonoscopic infusion at Week 0, followed by twice-weekly dextrose-containing oral placebo capsule (OPC) therapy for 6 weeks (including Week 0).
2881619|NCT03378154|Experimental|Tracheal Intubation in infants using Macintosh laryngoscopes|Children < 1 year of age posted for elective or emergency surgical procedure will be administered general anaesthesia by means of orotracheal intubation with the help of the Macintosh laryngoscope
2881620|NCT03378154|Experimental|Tracheal Intubation in infants using King vision|Children < 1 year of age posted for elective or emergency surgical procedure will be administered general anaesthesia by means of orotracheal intubation with the help of the King vision videolaryngoscope
2881621|NCT03378141|Experimental|A&T- intensive|A&T-intensive arm receive standard MNCH services and intensified maternal nutrition behavior change intervention. Intervention includes provision of IFA and calcium supplements, interpersonal counseling on diet during pregnancy and consumption of IFA and calcium, community mobilization, and adequate weight-gain monitoring during pregnancy
2881622|NCT03378141|No Intervention|A&T-non intensive|A&T-non intensive aim only receive MNCH services
2881623|NCT03378128|Experimental|diagnostic laparoscopic assessment after neoadjuvant chemo|All patients will undergo a diagnostic laparoscopic assessment of disease following neoadjuvant chemotherapy
2881741|NCT03377270|No Intervention|Standard of Care|Standard of Care Arm
2881624|NCT03378102|Experimental|Interferon (IFN)-gamma-secreting HAdV antigen specific T cells|Virus-specific, antigen selected cells will be obtained using the CliniMACS® Prodigy System. the donor will be screened for their ability to produce an IFN-gamma- secretion response to HAdV by testing the donor's mononuclear cells with the Miltenyi Rapid Cytokine Inspector kit. Donors with appropriate IFN-gamma secretion response will undergo a steady state leukapheresis. The investigational product (IP) will be generated using the CCS-IFN enrichment program with an approximate duration time of 15 hours. After the IP passes release criteria, the IP will be suspended in 0.9 normal saline + 2.5% albumin and distributed for infusion. The IP will be infused within 4 hours as a bolus on day 0.
2881625|NCT03378089|Experimental|Music Therapy|Participants in the experimental group will be given choices about how to proceed with the session: active or passive, improvisation, re-creative or receptive songs, or receptive (relaxation). Three music therapy sessions will be completed, the first within 24 hours of admission, the second 24-96 hours of session 1, and the final session the day before stem cell infusion.
2881626|NCT03378089|Active Comparator|No Music Therapy|Participants randomized to the standard care group will be asked to rate the same symptoms as those in the experimental group. This will mark the beginning of a 45-minute control condition period during which the participants may fill the 45-minute time-period in whatever ways they choose.
2881627|NCT03378076|Experimental|FX006 32 mg|Two intra-articular (IA) injections of FX006 32 mg (total dose of 64 mg)
2881628|NCT03378076|Active Comparator|TAcs 40 mg|Two intra-articular (IA) injections of TAcs 40 mg (total dose of 80 mg)
2881629|NCT03378063|Experimental|transplantation of mesenchymal stem cell|transplantation of mesenchymal stem cell will be given to the infants with BPD.
2881630|NCT03378063|Active Comparator|no transplantation of mesenchymal stem cell|transplantation of mesenchymal stem cell will be not given to the infants with BPD.
2881631|NCT03378050|Experimental|Intervention group|"The intervention group will receive a multi-component individualized support intervention HEART, which will consist of 12 sessions in four stages."
2881632|NCT03378050|Active Comparator|Control group|"Participants is the control group will be placed on a waiting list for 12 weeks. They will receive the intervention, after they complete the 12-week follow-up assessment. Caregivers in the control group will receive 12 week follow-up as usual (FU) including two brief check-in calls and an outcome measures call during the study period."
2881633|NCT03378037|Experimental|Acupuncture group|Disposable acupuncture needles will be inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.
2881634|NCT03378037|Sham Comparator|Control group|Streitberger's non-invasive placebo acupuncture needles will be used in the control group; blunt-tipped needles will touch the skin quickly without being inserted. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.
2881635|NCT03378024||diabetic mellitus patients|"Measure the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) of pre-exercise and post-exercise by the oscillometric (Omron Colin co.).~And follow up for 3 years to identify of the correlation with PAD outcome."
2881636|NCT03378011|Active Comparator|UVA1 phototherapy|UVA1 phototherapy in acral vitiligo
2881637|NCT03378011|Active Comparator|Topical PUVA|Topical PUVA in acral vitiligo
2881638|NCT03377998|Experimental|vitiligo patients|lesional skin biopsy to measure ERDR1 level
2881639|NCT03377998|Experimental|controls|normal skin biopsy to measure ERDR1 level
2881640|NCT03377985|Active Comparator|axillary brachial plexus block group|Patients placed in the supine position with arm to be blocked abducted and externally rotated. After sterilization of the axilla ultrasound device with high frequency of 8-12 MHZ, linear transducer was put parallel to the anterior axillary fold at axilla to identify the axillary artery, lateral, medial and posterior cords of the brachial plexus in relation to the axillary artery. Lidocaine 1% was infiltrated subcutaneously 1 cm lateral to the probe, 7-10 ml of bupivacaine 0.5% was injected around each cord of the brachial plexus
2881641|NCT03377985|Active Comparator|supraclavicular brachial plexus block group|patients placed in the supine position with the head of the bed elevated 30 degrees and patient's head turned away from the side to be blocked after skin disinfection, ultrasound device was put transversely parallel to and above the middle third of the clavicle, the probe was tilted till identification of the subclavian artery, 1st rib, pleura and brachial plexus lateral to the subclavian artery and above the 1st rib. Lidocaine 1% was infiltrated subcutaneously 1 cm lateral to the lateral side of the probe. A needle was inserted in plane 1 cm lateral to the probe when adjacent to brachial plexus 25 ml of bubivacaine 0.5% was injected around the brachial plexus
2881642|NCT03377972||WHO diagnostic standard|
2881643|NCT03377972||Japan diagnostic standard|
2881644|NCT03377959|Experimental|Pilates Group|Pilates Method Mat classes and Ballet Classes three times a week, totaling 24 session of each.
2881645|NCT03377959|Other|Ballet Group|Ballet Classes three times a week, totaling 24 sessions.
2881646|NCT03377946|Experimental|probiotics on type 2 diabetes|take probiotics
2881647|NCT03377946|Experimental|probiotics on pre-diabetes|take probiotics
2881648|NCT03377946|Placebo Comparator|placebo on type 2 diabetes|take placebo
2881649|NCT03377946|Placebo Comparator|placebo on pre-diabetes|take placebo
2881650|NCT03377933|Experimental|probiotics and quadruple therapy|Patients are given two-week compound Lactobacillus acidophilus probiotic (1 g t.i.d.), followed by a quadruple antibiotic regimen (esomeprazole [20 mg b.i.d.] + bismuth potassium citrate [220 mg b.i.d.] + tetracycline [750 mg b.i.d.] + furazolidone [100 mg b.i.d.]) for 10 days as rescue therapy.Meanwhile perform endoscopy and take gastric mucosa specimens for gene sequencing before and after the application of probiotic.
2881651|NCT03377920|Experimental|Severe asthma patients; COPD patients|Cross sectional study Lung function measurement
2881652|NCT03377907|Active Comparator|Ketamine in hematoma block|Ketamine will be used in hematoma block
2881653|NCT03377907|Active Comparator|ketamine intravenous anesthesia|ketamine will be used in local intravenous anesthesia
2881654|NCT03377894|Active Comparator|• Group (A) blunt incision|"100 primigravidas at term who underwent elective transverse lower segment Cesarean section for the first time among the age group of 20 ̶ 37 years with a singleton pregnancy.~undergoing blunt uterine incision expansion"
2881742|NCT03377270|Other|Home Practice Arm|RST + Home Practice Arm
2881657|NCT03377881|Experimental|STHLM3+MRI/Fusion|The experimental arm consists of a Stockholm3 bloodiest and if elevated, an MRI is recommended with targeted biopsies to prostate lesions.
2881658|NCT03377868|Other|Patients with Amyotrophic lateral sclerosis|Patients diagnosed with amyotrophic lateral sclerosis
2881659|NCT03377868|Other|Control|Parallel cohort of healthy age and sex matched subjects
2881660|NCT03377855|Experimental|Default Prescribing Change|In the e-prescribing system, the default opioid dosage/duration is changed to the minimum recommended dosage from the CDC guidelines for short acting opioids.
2881661|NCT03377842|Active Comparator|FOLFOX regimen|FOLFOX regime alone.
2881662|NCT03377842|Experimental|Apatinib and FOLFOX regimen|Apatinib combine with FOLFOX regimen.
2881663|NCT03377829|Experimental|Percutaneous laser ablation(PLA)|Eligible participants with PTMC will be randomly assigned to this group and undergo percutaneous laser ablation(PLA). All the process is under the detection of real-time ultrasound.After surgery, all the patients will accept contrast-enhanced ultrasound(CEUS), regular ultrasound follow-up, thyroid functional detection, fine-needle aspiration biopsy(FNAB), neck CT.Per and post-operative complications, need of drug treatment, length of hospital admission and customer satisfaction will be registered.
2881664|NCT03377829|Active Comparator|Surgery|Eligible participants with PTMC will be randomly assigned to this group and undergo total/subtotal thyroid surgery.
2881665|NCT03377816|Experimental|Art Therapy|The AT intervention is an 8-week group intervention comprised of 8 1.5 hour weekly sessions conducted by an experienced Art Therapist who received special training in conducting the treatment protocol as designed.
2881666|NCT03377816|Sham Comparator|Mandala group|The comparison group will color prefabricated shapes. The same art materials as in the intervention group will be on the table as will the same instrumental music.
2881667|NCT03377803|Active Comparator|VP-102|VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days
2881668|NCT03377803|Placebo Comparator|Placebo|Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days
2881669|NCT03377790|Active Comparator|VP-102|VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days
2881670|NCT03377790|Placebo Comparator|Placebo|Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days
2881671|NCT03377777||Infants|Outwardly healthy male and female infants at 6-7 months or 12-13 months. No intervention.
2881672|NCT03377764||Landmark Technique|Control group
2881673|NCT03377764||Ultrasound guided technique|Neuroaxial block using Ultrasound guidance
2881674|NCT03377751|Experimental|Additional posterior wall isolation|Operator will perform pulmonary vein isolation (PVI) and additional posterior wall isolation if low voltage area exists more than 10% of the left atrium
2881675|NCT03377751|Experimental|Voltage-guided substrate homogenization|Operator will perform pulmonary vein antrum isolation (PVI) and additional substrate modification based on the degree of low voltage area.
2881676|NCT03377751|Active Comparator|PVI only group|Operator will perform PVI only
2881677|NCT03377738|No Intervention|anti-smoking therapy|All patients will be given only an intervention for tobacco cessation which will depend on the individual's cessation phase
2881678|NCT03377738|Experimental|anti-smoking therapy + spirometry|All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase. In addition, in this group will be given a spirometry test as a motivational element for dishabituation.
2881679|NCT03377725|Experimental|Experimental group|MDS patients of the experimental group will be treated with decitabine and arsenic trioxide.
2881680|NCT03377725|Active Comparator|Controlled group|MDS patients of the controlled group will be treated with decitabine alone.
2881681|NCT03377712||Brachial Plexus Injury group|Patients who will be submitted to the surgical procedure and monitored for the repercussions of the surgery. Interventions: optoelectronic plethysmography, diaphragmatic ultrasound, postural evaluation, functional capacity, pain evaluation, function and quality of life
2881682|NCT03377712||Paired group|Healthy individuals who will be matched by sex and age with the group of patients who will effectively undergo the surgical process. Interventions: optoelectronic plethysmography, diaphragmatic ultrasound, postural evaluation and functional capacity.
2881683|NCT03377699|Experimental|Insulin Degludec|Insulin Degludec once daily and Insulin Aspart 2-4 times daily
2881684|NCT03377699|Active Comparator|Insulin Determir|Insulin Determir once daily or twice daily and Insulin Aspart 2-4 times daily
2881685|NCT03377686||Asthma|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years with doctor's diagnosed asthma
2881686|NCT03377686||Cystic fibrosis|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years with CF
2881687|NCT03377686||Healthy|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years old without respiratory diseases
2881688|NCT03377660||Sandostatin|This cohort will be the group who are undergoing routine clinical treatment with a long-acting somatostatin analogue to minimise abnormal gut hormone signalling, and thus reduce early satiety.
2881689|NCT03377660||Mirtazapine|This cohort will be the group who are undergoing routine clinical treatment with a tetracyclic antidepressant to stimulate appetite.
2881690|NCT03377647||Year two intervention|Both interventions will occur in the Tuba City Agency during year two.
2881691|NCT03377647||Year three intervention|Both interventions will occur in the Chinle Agency during year three.
2881692|NCT03377647||Year four intervention|Both interventions will occur in the Fort Defiance during year four.
2881693|NCT03377634|Experimental|Intervention|Participants receive the MORPH intervention.
2881694|NCT03377634|No Intervention|Control|The wait list control participants receive usual care and are offered intervention materials on completion of the study.
2881695|NCT03377621|Experimental|Whole Body Vibration|OSA subjects will be asked to use whole body vibration machine for 30 minutes, 3 times a week for 6 weeks in between visits.
2881696|NCT03377608||Depo-Provera|
2881697|NCT03377608||Non-hormonal contraception|
2881698|NCT03377595|Experimental|TAP (Transversus Abdominis Plane) block|20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL m.A 2-point classic TAP block will be performed under ultrasound guidance within 1 hour (± 30 minutes) following skin incision closure of the C-section.
2881699|NCT03377595|Experimental|Wound infiltration|20 mL of EXPAREL 266 mg expanded in volume with 40 mL normal saline for a total volume of 60 mL, infiltrated in the fascia prior to skin closure with attention to infiltrate the angles of the incision.
2881700|NCT03377582|Active Comparator|Conventional therapy|Exercise-based cardiac rehabilitation
2881701|NCT03377582|Experimental|Virtual reality based therapy|Exercise-based virtual reality
2881702|NCT03377569||Group #1|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring prior to DBS surgery and in patient polysomnography with neural recording after DBS surgery.
2881703|NCT03377569||Group #2|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring after DBS surgery with DBS stimulation on at night, and in patient polysomnography after DBS surgery.
2881704|NCT03377569||Group #3|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring after DBS surgery with DBS stimulation off at night, and in patient polysomnography after DBS surgery.
2881705|NCT03377556|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2881706|NCT03377543|Experimental|Control Sleep/Non-Active Placebo or 81mg Aspirin Pill|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
2881707|NCT03377543|Experimental|Sleep Restriction/81mg Aspirin Pill|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
2881708|NCT03377543|Experimental|Sleep Restriction/Non-Active Placebo|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
2881709|NCT03377530||Premature neonates infected with bacillus Species|The investigators studied retrospectively eleven cases of these infections in our NICU and reviewed series and report cases in literature.
2881710|NCT03377517|Experimental|ResearchTreatment Plan|Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
2881711|NCT03377504|Experimental|mirror group|Routine physical therapy and exercise program will be applied to all patients for a total of 4 weeks, 5 days a week, 1 hour/day. Mirror therapy will be applied to the mirror group for 30 minutes per day in addition to this routine treatment.
2881712|NCT03377504|Active Comparator|control group|Routine physical therapy and exercise program will be applied to all patients for a total of 4 weeks, 5 days a week, 1 hour/day. A total of 20 sessions of treatment will be given to each patient.
2881713|NCT03377491|Experimental|NovoTTF-100L(P)|Patients receive TTFields using the NovoTTF-100L(P) System together with gemcitabine and nab-Paclitaxel
2881714|NCT03377491|Active Comparator|Best Standard of Care|Patients receive best standard of care with gemcitabine and nab-Paclitaxel
2881715|NCT03377478|Experimental|Lung Transplant|Patients will be transplanted with HCV positive lung. Recipients whom test positive for HCV viremia for 2 consecutive tests at any point will complete 12 weeks of Epclusa (Sofosbuvir/velpatasvir).
2881716|NCT03377465|Experimental|Experimental Group|Patients with stroke of undetermined cause age 18-65
2881717|NCT03377465|Active Comparator|Comparative group|Healthy patients age 18-65
2881718|NCT03377452|Experimental|Behavioral Education Intervention I|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
2881719|NCT03377452|Experimental|Behavioral Education Intervention II|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
2881720|NCT03377439||Group A|Participants with platelet counts ＜32×10^9/L.
2881721|NCT03377439||Group B|Participants with platelet counts between 32×10^9/L and 132×10^9/L.
2881722|NCT03377439||Group C|Participants with platelet counts ＞132×10^9/L.
2881723|NCT03377426|Experimental|LYS228|IV infusion
2881724|NCT03377426|Active Comparator|Standard of care|IV infusion of standard of care antibiotics for at least 5 days
2881725|NCT03377400|Experimental|study arm|Concurrent radiotherapy with chemotherapy (5FU/CDDP) and immune checkpoint inhibitors (durvalumab/tremelimumab), and followed by consolidation immune checkpoint inhibitors
2881726|NCT03377387|Experimental|capecitabine 7/7 with neratinib|In the phase I portion of the study, a 3+3 design will be used. Once the MTD is reached, the phase II portion will enroll up to 24 patients. Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Patients will be seen on Day 1 of each cycle (+/- 3 days).
2881727|NCT03377374|Experimental|Probiotic|L. reuteri ATCC PTA 5289 + L. reuteri DSM 17938 at a dose of 2x10^8 Colony Forming Units (CFU)
2881728|NCT03377374|Placebo Comparator|Placebo|Five drops of Placebo taken twice a day (in the morning and in the evening).
2881729|NCT03377361|Experimental|Previously Treated Metastatic Colorectal Cancer Doublet|Treatment of mCRC participants
2881730|NCT03377361|Experimental|Previously Treated Metastatic Colorectal Cancer Triplet|Treatment of mCRC participants
2881731|NCT03377348|Other|subconjunctival injection of triamcinolone acetonide|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
2881732|NCT03377335|Experimental|Dapagliflozin|"Dapagliflozin (10mg daily) as add-on to metformin (stable doses ranging from 1500 to 3000 mg daily).~The total duration of treatment is 6 months."
2881733|NCT03377335|Placebo Comparator|Metformin alone|"Metformin alone (stable doses ranging from 1500 to 3000 mg daily).~The total duration of treatment is 6 months."
2881734|NCT03377322|Active Comparator|Treatment|Probiotic Agent contains Bifidobacterium lactis
2881735|NCT03377322|Placebo Comparator|Placebo|Placebo pill containing maltodextrin
2881736|NCT03377309|Experimental|Fycompa|
2881737|NCT03377296|Experimental|Plasmodium Vivax infection|"Both volunteers will be infected with Plasmodium Vivax (as described below in full in Interventions). i.e., there is only one arm to this study."
2881738|NCT03377283|Active Comparator|AP-KTx/LTx|Transplant recipients receiving an rATG-perfused kidney or liver
2881739|NCT03377283|Placebo Comparator|CP-KTx/LTx|Transplant recipients receiving a control-perfused kidney or liver.
2881740|NCT03377270|Experimental|RST|Respiratory Swallow Training Arm
2881744|NCT03377257|Experimental|Experimental group|The treatment with zolmitriptan by sublingual administration is 2.5mg when headache attack.
2881745|NCT03377244||Healthy Bodies, Healthy Souls intervention|Participants in Diabetes Prevention Program Lifestyle Intervention (DPP-LI) with Healthy Bodies Healthy Souls (HBHS) intervention which includes the enhancement of working with Marshallese churches to implement organizational/institutional level changes to support the individual behavioral intervention of the DPP-LI.
2881746|NCT03377244||Diabetes Prevention Program Lifestyle Intervention|Diabetes Prevention Program Lifestyle Intervention at Marshallese churches with a focus on individual change without the implementation of organizational/institutional level changes to support the individual behavioral intervention of the DPP-LI.
2881747|NCT03377231|Experimental|Prevention|
2881748|NCT03377231|Experimental|Treatment|
2881749|NCT03377218|No Intervention|Control|Without additional iodine supplementation.
2881750|NCT03377218|Experimental|Iodine|Receiving iodine.
2881751|NCT03377218|Experimental|Iodine + Selenium|Receiving iodine and selenium.
2881752|NCT03377205|Active Comparator|Plate|Compression screws and neutralization plate.
2881753|NCT03377205|Experimental|Intramedullary nail|Acumed Fibular Rod System
2881754|NCT03377179|Experimental|ABC294640 treatment|All participants will be receiving ABC294640, 500 mg twice a day (BID), continuously in 28 day cycles
2881755|NCT03377166|Active Comparator|Vertigo|Participants with vestibular disorder
2881756|NCT03377166|Active Comparator|Control|Participants without vestibular disorder
2881757|NCT03377153|Active Comparator|Hesperidin and Flaxseed|
2881758|NCT03377153|Placebo Comparator|control|
2881759|NCT03377140|Active Comparator|Hesperidin|2 capsuls of Hesperidin
2881760|NCT03377140|Placebo Comparator|control|2 capsuls of placebo
2881761|NCT03377127|Active Comparator|SOC|The control group patients will be managed by their assigned PCPs, per Standard of Care (SOC), per American Diabetes Association Guidelines. Management per standard of care includes referrals to ophthalmology for dilated eye exam, nephrology for nephropathy management, cardiology for macrovascular complications management, neurology for neuropathy or neurologic complications, diabetic education, laboratory studies, and vaccinations and will be ordered or performed at the discretion of each patient's PCP
2881762|NCT03377127|Experimental|SOC and PMDC|The intervention group patients will be managed by their assigned primary care physicians (PCPs), per American Diabetes Association Guidelines for Standard of Care (SOC) and will have scheduled six extra face-to-face visits with the pharmacists for the 6 month duration of the intervention. The pharmacy managed diabetes clinic (PMDC) visit encounters will focus on patient identified goals for the management of their diabetes. Pharmacists have the discretion to make medication adjustments and initiate new medications pertinent to the management of diabetic comorbidities. The model is a collaborative practice agreement between the pharmacist and the primary care physician.
2881763|NCT03377114|Active Comparator|Neutral|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head and neck in neutral position.
2881764|NCT03377114|Experimental|Head tilting|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head in head-tilting position.
2881765|NCT03377101|Active Comparator|Arm I (fulvestrant, palbociclib)|Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses and palbociclib PO on days 1-21. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.
2881766|NCT03377101|Experimental|Arm I (fulvestrant, palbociclib, copanlisib)|Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses, palbociclib PO on days 1-21, and copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.
2881767|NCT03377088|Placebo Comparator|Almond Oil|Patients will be given Almond Oil for inhalation on cotton balls as a control. Almond Oil has been shown to act as a placebo when compared to our variable, Rosa Damascena oil. To ensure blinding, this arm will act to always deliver a scent to a patient, blinding them to whether they are receiving a known aromatherapy or a common scent.
2881768|NCT03377088|Experimental|Rose Oil|Patients will be given Rosa Damascena oil on cottons balls as a variable. This oil has been shown to significantly lower acute pain levels on the visual analog pain scale when compared to placebo of distilled water or Almond Oil.
2881769|NCT03377075||Healthy subjects|
2881770|NCT03377062||EEG monitoring|Patients arriving to the emergency room with decreased consciousness, severe headaches or dizziness
2881771|NCT03377049||Acetazolamide Challenge|Subjects entered into the study as a cohort, will because of their participation, undergo only two additional digital subtraction angiogram (DSA) imaging acquisitions. These will be done in conjunction with their standard diagnostic DSA evaluation and consist of two CBCTPs, one before and one after administration of 1 g acetazolamide through a peripheral IV line. Each CBCTP will require administration of 75-100 mL iodinated contrast medium also through an intravenous line. Neither of these imaging studies will be used for clinical decision making, but would be processed and evaluated at later date for a formal analysis of the results. Following completion of diagnostic imaging subjects will receive the usual standard of care for treatment of their ruptured aneurysm i.e. endovascular embolization or open surgical clipping.
2881772|NCT03377036|Experimental|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
2881773|NCT03377036|Active Comparator|2D-FFDM|2D full-field digital mammography
2881774|NCT03377023|Experimental|Phase 1 - Dose Escalation|"Nivolumab + Ipilimumab + Nintedanib dose escalation.~Nivolumab: 3 mg/kg IV Q2 weeks.~Ipilimumab: 1 mg/kg Q6 weeks.~Nintedanib Level -1: 100 mg by mouth (PO) once a day (QD) Days 1-28 (Daily dose =100 mg).~Nintedanib Level 1: 100 mg PO twice daily (BID) Days 2-28 (Daily dose = 200 mg).~Nintedanib Level 2: 150 mg PO BID Days 2-28 (Daily dose = 300 mg).~Nintedanib Level 3: 200 mg PO BID Days 2-28 (Daily dose = 400 mg)."
2881775|NCT03377023|Active Comparator|Phase 2 - Arm A|"Arm A: Newly diagnosed or treatment-naïve patients, with a target overall response rate (ORR) of 50%.~Nivolumab + Ipilimumab + Nintedanib at RP2D."
2881776|NCT03377023|Active Comparator|Phase 2 - Arm B|"Arm B: Patients who have been previously exposed to immunotherapy, such as anti-PD-1, anti-PD-L1 or anti-CTLA-4, with a target ORR of 20%.~Nivolumab + Ipilimumab + Nintedanib at RP2D."
2883251|NCT03366792|Experimental|MRI Targeted Biopsy|
2881777|NCT03377010||Hematopoietic Stem Cell Transplant (HSCT) Survivor|Study participants will be administered a Dietary Intake - Food Frequency Questionnaire and a Receptivity to Participating in Diet Interventions Questionnaire.
2881778|NCT03376997|Experimental|Perampanel: 30-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 milligram (mg) dose of perampanel intravenous (IV) infusion (30-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
2881779|NCT03376997|Experimental|Perampanel: 60-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 mg dose of perampanel IV infusion (60-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
2881780|NCT03376997|Experimental|Perampanel: 90-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 mg dose of perampanel IV infusion (90-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
2881781|NCT03376984|Active Comparator|Gutta Percha|Subjects in both arms of the study will be receiving standard of care RCT and routine follow-up examinations/assessments at 6 months, 1 year, and 2 years post RCT. For all the patients into the control arm of the study, the root canals will be filled with gutta percha (current standard of care), using the vertical condensation obturation technique (standard of care RCT technique).
2881782|NCT03376984|Experimental|ND and Amox modified Gutta Percha|Subjects in both arms of the study will be receiving standard of care RCT and routine follow-up examinations/assessments at 6 months, 1 year, and 2 years post RCT. The difference between the two arms will be the root canal filler material used. The root canals for the treatment arm of the study will be filled with gutta percha at the apical third, gutta percha modified with nanodiamonds and amoxicillin (NDGX) will be used for the middle and coronal thirds.
2881783|NCT03376971|Experimental|Diagnostic (lung biopsy)|Patients undergo extraction of up to 3 additional lung biopsies from target lesions that are at least 2-3 cm in diameter using the 19 gauge SuperCore biopsy needle or the 20 gauge Rotax needle. The extracted tissue is imaged via confocal fluorescence microscopy using a variety of fluorescent contrast agents, such as fluorescein sodium, methylene blue, indocyanine green and then undergo hematoxylin and eosin processing.
2881784|NCT03376958|Experimental|Apatinib+ESHAP regimen|Drug: Apatinib+ESHAP regimen ESHAP regimen (etoposide，cytarabine, cisplatinum,dexamethasone) etoposide (VP-16) 60mg/m2,ivgtt（intravenously guttae）,d1-5;cytarabine(Ara-C) 100mg/m2,ivgtt d1-5;cisplatinum 25mg/m2, ivgtt, d1-3;dexamethasone(Dex) 20mg, ivgtt, d1-5; apatinib, p.o,250mg, qd, continued use to the end of chemotherapy. Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
2881785|NCT03376958|No Intervention|ESHAP regimen|Drug: ESHAP regimen ESHAP regimen (etoposide，cytarabine, cisplatinum,dexamethasone) etoposide (VP-16) 60mg/m2,ivgtt（intravenously guttae）,d1-5;cytarabine(Ara-C) 100mg/m2,ivgtt d1-5;cisplatinum 25mg/m2, ivgtt, d1-3;dexamethasone(Dex) 20mg, ivgtt, d1-5. Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
2881786|NCT03376945||trail cohort|n-3 FAs
2881787|NCT03376945||control cohort|Structolipid
2881788|NCT03376932|Experimental|Subjects receiving FF/UMEC/VI (100/62.5/25) mcg+ CIS|Eligible subjects will receive SITT of FF/UMEC/VI based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving mid-dose of ICS during pre-study will be administered with FF/UMEC/VI (100/62.5/25) mcg inhalation powder via ELLIPTA DPI, once daily in the morning or evening with the CIS. Subjects will also receive albuterol/salbutamol metered dose inhalers (MDIs) as a rescue medication throughout the study.
2881789|NCT03376932|Experimental|Subjects receiving FF/UMEC/VI (200/62.5/25) mcg+ CIS|Eligible subjects will receive SITT of FF/UMEC/VI based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving high-dose of ICS during pre-study will be administered with FF/UMEC/VI (200/62.5/25) mcg inhalation powder via ELLIPTA DPI, once daily in the morning or evening with the CIS. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
2881790|NCT03376932|Active Comparator|Subjects receiving FP/SAL(250/50) mcg + TIO 5 mcg|Eligible subjects will receive MITT of FP/SAL+ TIO based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving mid-dose of ICS during pre-study will be administered with FP/SAL (250/50) mcg inhalation powder via DISKUS DPI with sensor, twice daily in the morning or evening plus TIO 5 mcg via RESPIMAT inhaler without sensor, once daily in the morning or evening. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
2881791|NCT03376932|Active Comparator|Subjects receiving FP/SAL(500/50) mcg + TIO 5 mcg|Eligible subjects will receive MITT of FP/SAL+ TIO based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving high-dose of ICS during pre-study will be administered with FP/SAL (500/50) mcg inhalation powder via DISKUS DPI with sensor, twice daily given in the morning or evening plus TIO 5 mcg via RESPIMAT inhaler without sensor, once daily in the morning or evening. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
2881792|NCT03376919|Experimental|CLs++|CLs ++ gait training
2881793|NCT03376906|Experimental|Obese Subjetcs|The subjects were welcomed for a visit to the Laboratory of Studies of Physical Training Applied to Health, where they performed an evaluation of body composition, maximal ergospirometric exercise test, and three experimental sessions (HIIE 1, HIIE 3 and Control) in a random order, which were performed with a 96 h interval between them.
2881794|NCT03376893||SCA with overt stroke|Participants have sickle cell anemia and a history of overt stroke.
2881795|NCT03376893||SCA with silent stroke|Participants have sickle cell anemia and a history of silent stroke.
2881796|NCT03376893||SCA with no stroke|Participants have sickle cell anemia and no history of stroke.
2881797|NCT03376880||Obese Boys|Obese boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.
2881831|NCT03376815||cervical ,traditional sample method|Samples from 100 patients with cervical carcinoma were obtained by traditional sampling method.
2881798|NCT03376880||Obese Girls|Obese girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.
2881799|NCT03376880||Normal Weight Boys|Normal weight boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI between 16th and 84th percentile.
2881800|NCT03376880||Normal Weight Girls|Normal weight girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI between 16th and 84th percentile.
2881801|NCT03376880||Obese Boys Misdiagnosed with Asthma|Obese boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.This group will have a prior diagnosis of asthma without confirmation by lung function testing.The absence of asthma will be confirmed by a negative response (<10% increase in FEV1) to spirometry before and after bronchodilator (and on visit 2 by a negative bronchial challenge test [<10% decrease in FEV1]; i.e., EVH).
2881802|NCT03376880||Obese Girls Misdiagnosed with Asthma|Obese girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.This group will have a prior diagnosis of asthma without confirmation by lung function testing.The absence of asthma will be confirmed by a negative response (<10% increase in FEV1) to spirometry before and after bronchodilator (and on visit 2 by a negative bronchial challenge test [<10% decrease in FEV1]; i.e., EVH).
2881803|NCT03376867||Healthy volunteers|Conditionned pain modulation (2 stimuli test: heat and pressure points) before and after conditioning stimuli (cold water bath).
2881804|NCT03376867||Volunteers with chronic pain|Conditionned pain modulation (2 stimuli test: heat and pressure points) before and after conditioning stimuli (cold water bath).
2881805|NCT03376854|Experimental|Hypothermia|Surface temperature management to maintain core temperature between 34 and 35°C for 48, then rewarm to 36°C at 0.33°C per h.
2881806|NCT03376854|Active Comparator|Standard of care|Acetaminophen and surface temperature management to maintain core temperature between 37°C and 38°C.
2881807|NCT03376841|Experimental|Severe hepatic impairment|Cenicriviroc tablet; single-dose oral administration
2881808|NCT03376841|Experimental|Normal Hepatic function|Cenicriviroc tablet; single-dose oral administration
2881809|NCT03376828|Active Comparator|Hypertensive T group|Hypertensive T group: Patients participating in the study were randomly assigned hypertensive (preoperative systolic blood pressure <180 mmHg and diastolic blood pressure <100 mmHg) Macintosh laryngoscopy using intubated
2881810|NCT03376828|Active Comparator|Hypertensive VL group|Hypertensive VL group: Patients participating in the study were randomly assigned hypertensive (preoperative systolic blood pressure <180 mmHg and diastolic blood pressure <100 mmHg) C-Mac Videolaryngoscope using intubated
2881811|NCT03376828|Sham Comparator|Non-hypertensive T group|Non-hypertensive T group: (Preoperative systolic blood pressure < 140 mmHg and diastolic blood pressure < 100 mmHg) Macintosh laryngoscopy using intubated
2881812|NCT03376828|Sham Comparator|Non-hypertensive VL group|Non-hypertensive VL group: Preoperative systolic blood pressure < 140 mmHg and diastolic blood pressure < 100 mmHg C-Mac Videolaryngoscope using intubated
2881813|NCT03376815||prostate ,traditional sample method|Samples from 100 patients with prostate carcinoma were obtained by traditional sampling method
2881814|NCT03376815||prostate ,landscape sample method|Samples from 100 patients with prostate carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2881815|NCT03376815||liver, traditional sample method|Samples from 100 patients with liver cancer were obtained by traditional sampling method.
2881816|NCT03376815||liver,landscape sample method|Samples from 100 patients with liver cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2881817|NCT03376815||esophageal ,traditional sample method|Samples from 100 patients with esophageal carcinoma were obtained by traditional sampling method.
2881818|NCT03376815||esophageal ,landscape sample method|Samples from 100 patients with esophageal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2881819|NCT03376815||GIST,traditional sample method|Samples from 100 patients with gastrointestinal stromal tumor were obtained by traditional sampling method.
2881820|NCT03376815||GIST,landscape sample method|Samples from 100 patients with gastrointestinal stromal tumor were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2881821|NCT03376815||colorectal ,traditional sample method|Samples from 100 patients with colorectal carcinoma were obtained by traditional sampling method.
2881822|NCT03376815||colorectal ,landscape sample method|Samples from 100 patients with colorectal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2881823|NCT03376815||pancreatic ,traditional sample method|Samples from 100 patients with pancreatic carcinoma were obtained by traditional sampling method.
2881824|NCT03376815||pancreatic,landscape sample method|Samples from 100 patients with pancreatic carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2881825|NCT03376815||lung cancer,traditional sample method|Samples from 100 patients with lung cancer were obtained by traditional sampling method.
2881826|NCT03376815||lung cancer,landscape sample method|Samples from 100 patients with lung cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2881827|NCT03376815||Renal ,traditional sample method|Samples from 100 patients with renal carcinoma were obtained by traditional sampling method.
2881828|NCT03376815||Renal carcinoma,landscape sample method|Samples from 100 patients with renal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2881829|NCT03376815||Breast cancer,traditional sample method|Samples from 100 patients with breast cancer were obtained by traditional sampling method.
2881830|NCT03376815||Breast cancer,landscape sample method|Samples from 100 patients with breast cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2912013|NCT03166098||Healthy control (HC) comparison group|
2881832|NCT03376815||cervical ,landscape sample method|Samples from 100 patients with cervical carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2881833|NCT03376802|Experimental|SAR425899|Repeated once daily subcutaneous (SC) doses of SAR425899 administered over 19 days
2881834|NCT03376802|Placebo Comparator|Placebo|Repeated once daily SC doses of placebo administered over 19 days
2881835|NCT03376789|Active Comparator|MYL-1501D (Process V Product)|MYL-1501D (Process V Product)
2881836|NCT03376789|Active Comparator|MYL-1501D (Process VI Product)|MYL-1501D (Process VI Product)
2881837|NCT03376776||Eyes with epiretinal proliferation|The eyes with epiretinal proliferation around the macular hole detected with optical coherence tomography
2881838|NCT03376776||Eyes without epiretinal proliferation|The eyes without epiretinal proliferation around the macular hole detected with optical coherence tomography
2881839|NCT03376763|Experimental|Group 1|Schizophrenia patients who are taking oral aripiprazole will be switched to Abilify maintena
2881840|NCT03376763|Experimental|Group 2|Schizophrenia patients who are taking other oral atypical antipsychotics will be switched to Abilify maintena
2881841|NCT03376750|Experimental|CO - OP via telerehabilitation + standard care|10 CO-OP videoconferencing sessions from an occupational therapist . Each session will be utilized to guide the participants to achieve their self-identified goals, focusing on problem-solving for daily life situations and on the ability to implement the discussed strategies for a variety of activities.
2881842|NCT03376750|Experimental|CO - OP via face to face + standard care|10 CO - OP face to face sessions from an occupational therapist. Each session will be utilized to guide the participants to achieve their self-identified goals, focusing on problem-solving for daily life situations and on the ability to implement the discussed strategies for a variety of activities.
2881843|NCT03376750|No Intervention|control group - standard care|standard care as given from public health service
2881844|NCT03376737|Experimental|Apatinib + Pemetrexed|Apatinib + Pemetrexed
2881845|NCT03376724|Experimental|Functional exercise|
2881846|NCT03376724|Active Comparator|Control Group|
2881847|NCT03376711|No Intervention|Standard Care Group|Participants in this arm of the study will not have access to the online peer support program until the end of the 12-week trial.
2881848|NCT03376711|Experimental|Online Peer Support Program|Participants in the online peer support program arm of the intervention will have access to the website for 12 weeks.
2881849|NCT03376698|Active Comparator|Colchicine 0.5 mg|
2881850|NCT03376698|Active Comparator|Colchicine 0.25 mg|
2881851|NCT03376698|Placebo Comparator|Placebo|
2881852|NCT03376685|Experimental|Endurance Training (END)|This group is performing END training for 6 weeks in duration. Intervention: Behavioral: Endurance Exercise Training (END)
2881853|NCT03376685|Experimental|Sprint Training (SIT)|This group is performing SIT training for 6 weeks in duration. Intervention: Behavioral: Sprint Exercise Training (SIT)
2881854|NCT03376685|Experimental|Combined Training (COMB)|This group is performing COMB training for 6 weeks in duration. Intervention: Behavioral: Combined Endurance-Sprint Exercise Training (COMB)
2881855|NCT03376672|Experimental|Ixazomib,lenalidomide,dexamethasone|Ixazomib capsules 4Mg Oral capsule on days 1, 8 and 15 in 28d cycle, lenalidomide 25 milligram capsules on days 1-21 in 28d cycle, dexamethasone 40 milligram capsules on days 1, 8, 15, 22 in 28d cycle
2881856|NCT03376672|Experimental|High risk maintenance arm|Ixazomib capsules 4Mg Oral capsule on days 1, 8, 15, lenalidomide 10 milligram on days 1-21 in 28d cycle
2881857|NCT03376672|Experimental|Standard and low risk maintenance arm|Lenalidomide
2881858|NCT03376659|Experimental|Phase I - Safety|"MVA-BN-CV301 (prime) - Day 1 and Day 29.~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.~Durvalumab - q2 weeks~Capecitabine - twice a day, Monday - Friday Weekly~Bevacizumab - q2weeks (colorectal cancer patients only)"
2881859|NCT03376659|Experimental|Phase II - Colorectal Cancer Arm|"MVA-BN-CV301 (prime) - Day 1 and Day 29.~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.~Durvalumab - q2 weeks~Capecitabine - twice a day, Monday - Friday Weekly~Bevacizumab - q2weeks"
2881860|NCT03376659|Experimental|Phase II - Pancreatic Cancer Arm|"MVA-BN-CV301 (prime) - Day 1 and Day 29.~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.~Durvalumab - q2 weeks~Capecitabine - twice a day, Monday - Friday Weekly"
2881861|NCT03376646|Experimental|Cohort A: Dissolve™|
2881862|NCT03376646|Active Comparator|Cohort A: Resolute™ Integrity|
2881863|NCT03376646|Experimental|Cohort B: Dissolve™-2.00mm|Cohort B is single arm.
2881864|NCT03376633|No Intervention|Control group|These youth will not receive Working on Womanhood (WOW) services during academic years 2017-18 and 2018-19 and will not have contact with WOW clinicians. Control youth will be able to receive all other services available through their school as they normally would, such as access to the school counselor and after school programs.
2881865|NCT03376633|Experimental|WOW Group and Individual Counseling|These youth will receive Working on Womanhood (WOW) services during academic years 2017-18 and 2018-19. These young women will participate in weekly group therapy and skill-building sessions, led by master's level clinicians, and will also receive individual support and therapy from their clinicians as-needed.
2881866|NCT03376620|Sham Comparator|10% Urea cream|Opposite breast scars treated OD at hs simultaneously using sham 10% Urea cream
2881867|NCT03376620|Active Comparator|Active cream with 1,4 diaminobutane|Other breast scar treated daily with active cream with 1,4 diaminobutane topically OD at hs
2881868|NCT03376607|Experimental|Intervention group 1|Intervention group 1 will receive access to the newly-established HBCP programme.
2881869|NCT03376607|Experimental|Intervention group 2|Intervention group 2 will receive access to the newly-established HBCP programme, and facilitated access to a mobile health application.
2881870|NCT03376607|No Intervention|Control group|The control group will receive routine practice.
2881871|NCT03376594|Active Comparator|Benjakul Extract|Benjakul Extract 100 mg capsule by mouth 3 times a day for 42 days
2881872|NCT03376594|Placebo Comparator|Loratadine|Loratadine 10 mg capsule by mouth 3 times a day for 42 days
2881873|NCT03376581|Experimental|Prospective treatment|
2881874|NCT03376568||Narcolepsy with RBD & Control|Narcolepsy with REM sleep disorder lable(20) and Control subjects lable(20)
2881875|NCT03376568||Narcolepsy with /without RBD|Narcolepsy with REM sleep disorder lable(20) and Narcolepsy without REM sleep disorderlable (20)
2881876|NCT03376555|Active Comparator|Baseline|Subjects on normal personal diet Acetylcholine (ACh) Dose Response, Local heating (LH), and Flow Mediated Dilation with nitroglycerin experiments
2881877|NCT03376555|Experimental|Low Sodium, No Cheese|"Diet contains 1,500 mg sodium per day Diet does not contain dairy cheese~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
2881878|NCT03376555|Experimental|Low Sodium, Cheese|"Diet contains 1,500 mg sodium per day Diet contains 6 oz dairy cheese per day~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
2881879|NCT03376555|Experimental|High Sodium, No Cheese|"Diet contains 5,500 mg sodium per day Diet does not contain dairy cheese~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
2881880|NCT03376555|Experimental|High Sodium, Cheese|"Diet contains 5,500 mg sodium per day Diet contains 6 oz dairy cheese per day~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
2881881|NCT03376542|Experimental|Cardiopulmonary exercise testing|All patients included in the study will perform cardiopulmonary exercise testing prior to surgery
2881882|NCT03376529|Experimental|SPR741/Ceftazidime (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + ceftazidime1.0 gram IV over 1 hour, and ceftazidime 1.0 gram IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
2881883|NCT03376529|Experimental|SPR741/Piperacillin/tazobactam (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + piperacillin/tazobactam 4.5 grams IV over 1 hour, and piperacillin/tazobactam 4.5 grams IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
2881884|NCT03376529|Experimental|SPR741/Aztreonam (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + aztreonam 1.0 gram IV over 1 hour, and aztreonam 1.0 gram IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
2881885|NCT03376516|Experimental|All patients|All patients will receive Wilate for prophylactic treatment. Patients will also receive Wilate for treatment of breakthrough bleeding events as required
2881886|NCT03376503|Experimental|Pegcyte (Nanogen pegfilgrastim)|pegcyte 6 mg in the first cycle
2881887|NCT03376503|Active Comparator|Neulastim (Roche pegfilgrastim)|Neulastim 6 mg in the first cycle
2881888|NCT03376477|Experimental|Lenalidomide plus GM-CSF Vaccine|"Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment.~Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter."
2881889|NCT03376477|Active Comparator|Lenalidomide Only|Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment
2881890|NCT03376464|Experimental|single injection technique (SIT)|40 U of Xeomin Cosmetic delivered directly into the region where the three masseter heads overlap.
2881891|NCT03376464|Experimental|multi-injection technique (MIT)|A distribution of 40 U (8 U distributed in 5 different areas) of Xeomin Cosmetic over the width of the masseter while respecting the upper limit of the anterior border of the masseter and the inferior insertion of the masseter. The injections are separated by a 1cm distance and the dose is equally distributed across these sites.
2881892|NCT03376451|Other|Patients in EndoSearch|EndoSearch will conduct on only one cohort divided in two groups : patients affected by endometriosis and patient unaffected (controls). All of these patients need a laparoscopic surgery for endometriosis indication (endometriosis group) or another indication which is not endometriosis (controls). However, nothing in the surgery or the patient medical care will be different between the two groups : patients will be treated exactly the same.
2881893|NCT03376438||Prospective observational cohorts|1) Atrial flutter without fetal hydrops; 2) Atrial flutter with fetal hydrops; 3) Supraventricular tachycardia without fetal hydrops; and 4) Supraventricular tachycardia with fetal hydrops
2881894|NCT03376412|Experimental|Single Arm Treatment.|All patients will be unilaterally implanted in the non-dominant eye with the Raindrop Near Vision Inlay for the compensation of presbyopia.
2881895|NCT03376386|Other|HNSCC receiving (chemo)radiotherapy|Imaging
2881896|NCT03376373|Experimental|active|Neurofeedback for FER
2881897|NCT03376373|No Intervention|control|waiting list
2881898|NCT03376347|No Intervention|Conventional arm|Institutional Standard of Care with intention to keep MAP> 65 mmHg. The FlotracIQ will be connected, but fully covered.
2881899|NCT03376347|Active Comparator|Treatment arm|FlotracIQ with HPI algorithm.
2881900|NCT03376334|Experimental|Motor Imagery (MI)|Those meeting the inclusion criteria were selected (n=22). Each participant was necessary to complete the Movement Imagery Questionnaire in a quiet room. Finally, each participant assigned a score by using a 7-point scale regarding the ease/difficulty associated with representing each movement mentally. Next their baseline balance measurement was performed using the SEBT. Later this group had 9 motor imagery sessions, each session for 15 minutes, 3 sessions (alternate days) per week for a total of 3 weeks. Reassessment of balance was done after every 3 sessions.
2881901|NCT03376334|No Intervention|Control (C)|Those meeting the inclusion criteria were selected (n=10). Baseline measurement of SEBT was done on day 1, end of week 1, end of week 2 and end of week 3.
2881936|NCT03376048|Experimental|Wound infiltration plus TAP|Wound infiltration placed by surgeon + TAP-LAP placed laparoscopically guided by surgeon
2881937|NCT03376048|Active Comparator|Wound infiltration|Wound infiltration placed by surgeon
2881938|NCT03376035|Active Comparator|Unilateral breast reconstruction|Temperature measurements are obtained from the reconstructed breast and compared to the non-reconstructed breast.
2881939|NCT03376035|Experimental|Bilateral breast reconstruction|Temperature measurements are obtained from both reconstructed breasts and the core temperature is measured as well for comparison.
2882215|NCT03374189|Active Comparator|Carter Thomason arm|Carter Thomason used for port-site closure.
2881902|NCT03376321|Experimental|Treatment Arm 1 (pimodivir + Standard-of-Care [SOC] treatment)|Participants will receive pimodivir 600 milligram (mg) orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in the protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment is determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of SOC cannot be changed (example, switching one influenza antiviral for another) during either treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in case of suspected adverse event (AE).
2881903|NCT03376321|Placebo Comparator|Treatment Arm 2 (placebo + SOC treatment)|Participants will receive placebo matching to pimodivir orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than day of first study drug intake. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either treatment period/extension phase, with the exception that an influenza antiviral may be discontinued in case of a suspected AE.
2881904|NCT03376308||Group 1|"Venous diameter measurements were made via the USG in the hand dorsum. Transverse venous diameter ≤2mm was defined group 1.~Anesthesia induction drugs were all treated in the same order and dose. Pain score, withdrawal movement score and hemodynamic response was recorded."
2881905|NCT03376308||Group 2|"Venous diameter measurements were made via the USG in the hand dorsum.Transverse venous diameter >2mm was defined group 2.Anesthesia induction drugs were all treated in the same order and dose.~Pain score, withdrawal movement score and hemodynamic response was recorded."
2881906|NCT03376295||Subjects diagnosed with COPD|Chronic obstructive pulmonary disease
2881907|NCT03376282|Other|HBOT treatment|HBOT treatment: 60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
2881908|NCT03376282|No Intervention|Standard treatment|follow up with the standard recommended treatment
2881909|NCT03376269|Active Comparator|Combined HBOT/psychotherapy|combined concurrent intervention of HBOT and creative art psychotherapy.
2881910|NCT03376269|Other|psychotherapy|single intervention with creative art psychotherapy
2881911|NCT03376256|Experimental|Phase A - Thoracic ES with LOR|Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until loss of resistance (LOR) is perceived to identify the thoracic epidural space (ES). The Compuflo Epidural Instrument will be used to record pressure readings. The thoracic epidural procedure will then continue per standard of care.
2881912|NCT03376256|Experimental|Phase B - Thoracic ES with Compuflo|Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until the Compuflo Epidural Instrument indicates that pressure has decreased. The loss of resistance technique will then be used to identify the thoracic epidural space. The thoracic epidural procedure will then continue per standard of care.
2881913|NCT03376243|Experimental|Emollient (LIPIKAR BAUME AP+)|Daily application of Lipikar Baume AP+ emollient AND Structured parent education
2881914|NCT03376243|No Intervention|Control|Only structured parent education
2881915|NCT03376230||Control patients|
2881916|NCT03376230||Crohn's disease patients|
2881917|NCT03376230||Ulcerative colitis patients|
2881918|NCT03376217|No Intervention|Control|IPTp delivered at antenatal clinic
2881919|NCT03376217|Experimental|Intervention|IPTp delivered by HSAs
2881920|NCT03376204||Adult subjets|Adult subjets diagnosed with bronchiectasis by high-resolution computed tomography with symptomatology in stable phase, matched by by sex and age with healthy subjects.
2881921|NCT03376178|Experimental|six-hole group|lidocaine and ropivacaine injection through catheters
2881922|NCT03376178|Active Comparator|end-hole group|lidocaine and ropivacaine injection through catheters
2881923|NCT03376152|Active Comparator|Treatment Arm|"Poverty households invited to attend cluster-level electric kettle promotion events and offered free kettles, information, and promotional materials 450 households in 15 clusters (30 households per cluster)"
2881924|NCT03376152|No Intervention|Control Arm|450 households in 15 clusters (30 households per cluster)
2881925|NCT03376139|Experimental|Zonisamide (up to 400 mg/day)|Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
2881926|NCT03376139|Placebo Comparator|Placebo|Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
2881927|NCT03376126||MI-ILP|
2881928|NCT03376113|Experimental|VHS group|Patients will be asked to make links between critical situations and appropriate solutions in the volitional help sheet (VHS).
2881929|NCT03376113|No Intervention|Control group|Patients will be asked to read the VHS. This is an active control group. That means all patients in this study will be exposed to situations and solutions in the VHS.
2881930|NCT03376100|Active Comparator|Control Group|Patients with distal forearm fractures randomized to Hematoma Block.
2881931|NCT03376100|Active Comparator|Intervention Group|Patients with distal forearm fractures randomized to Ultrasound guided nerve block
2881932|NCT03376074|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 2 hours
2881933|NCT03376074|Active Comparator|Conventional cold storage|
2881934|NCT03376061|Active Comparator|TA Topical|1 syringe of 50ml of topical Tranexamic Acid (5g) or placebo. The topical will be poured into the pericardial mediastinal cavities in 2 equal doses, 25ml when the pt comes off-pump and the other 25ml before sternotomy is closed.
2881935|NCT03376061|Active Comparator|TA Intravenous|2 syringes of 50ml (5mg) Tranexamic Acid for intravenous injection or placebo.
2912498|NCT03162757|Experimental|Subclavian vein access|
2881940|NCT03376009||Liver transplant assessment patients|"Adult patients admitted to the Scottish Liver Transplant Unit for liver transplant assessment, over a 6 month study period will be considered for recruitment.~Interventions:~Blood sample for serum and plasma biomarkers:~Urine sample for biomarkers Cardiac bio-impedance (Cardioscreen Medis) Aortic pulse wave velocity (APWV) (TensioMed and SphygmoCor) Optical Coherence Tomography (Spectralis OCT) Arterial Spin Labelling Magnetic Resonance Imaging"
2881941|NCT03375996||FLACS group|Patient presenting cataract and scheduled for laser-assisted cataract surgery
2881942|NCT03375983|Experimental|Blood-stage infection of P.vivax|This is a single arm study that plans to enroll 20 patients and each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1.0 × 10^7 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.
2881943|NCT03375970|Experimental|Collaborative Care of TCM and Western Medicine|
2881944|NCT03375970|Active Comparator|Western Medicine|
2881945|NCT03375957|Experimental|ATx201 2% Gel|
2881946|NCT03375957|Experimental|ATx201 4% Gel|
2881947|NCT03375957|Placebo Comparator|ATx201 Gel Placebo|
2881948|NCT03375944|No Intervention|control group|Cardiac supervision
2881949|NCT03375944|Other|study group|Cardiac supervision and rehabilitation
2881950|NCT03375931|Experimental|prayer group|
2881951|NCT03375931|Active Comparator|non-prayer group|
2881952|NCT03375918|Other|Healthcare Trainees - Cluster 1|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
2881953|NCT03375918|Other|Healthcare Trainees - Cluster 2|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
2881954|NCT03375918|Other|Healthcare Trainees - Cluster 3|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
2881955|NCT03375918|Other|Healthcare Trainees - Cluster 4|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
2881956|NCT03375918|Other|Healthcare Trainees - Cluster 5|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
2881957|NCT03375905|Experimental|cNEP|cNEP treatment
2881958|NCT03375892|Experimental|Prone Position and Supine Position|
2881959|NCT03375879|Active Comparator|Bandage contact lens|Placing a bandage contact lens in one eye.
2881960|NCT03375879|No Intervention|Sham contact lens (immediate removal)|Sham contact lens will be placed on other eye, placing it and immediately removing it so patient does not know which eye will have a bandage contact lens.
2881961|NCT03375866|Active Comparator|Pretzels|
2881962|NCT03375866|Experimental|Mixed nuts|
2881963|NCT03375853|Active Comparator|Control Condition|Participants will complete computer based response training tasks that will incorporate pictures of birds, flowers, and mammals. As part of the computer based training, participants will be instructed to respond or inhibit response to certain of these stimuli in order to bring about a change in the participant response to certain stimuli. These tasks will be structured identically to those presented in the experimental condition, only the appearance and context of the stimuli will be different (i.e., non-food versus food items). The computer tasks described above comprise the Generic Response Training Control Intervention.
2881964|NCT03375853|Experimental|Experimental Condition|Participants will complete computer based response training tasks that will incorporate pictures of healthy food, unhealthy food, and glasses of water. As part of the computer based training, participants will be instructed to respond or inhibit response to certain of these stimuli in order to bring about a change in the participant response to certain stimuli. These tasks will be structured identically to those presented in the control condition, only the appearance and context of the stimuli will be different (i.e., food versus non-food items). The computer tasks described above comprise the Computer Based Response Training Weight Loss Intervention.
2881965|NCT03375840|Experimental|Text-only PWL, immediate post|"Exposure to 9 FDA-mandated warning labels~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
2881966|NCT03375840|Experimental|Text-only PWL, delay posttest|"Exposure to 9 FDA-mandated warning labels~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
2881967|NCT03375840|Experimental|Low-emot PWL, immediate posttest|"Exposure to 9 warning labels paired with image that elicited little emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
2881968|NCT03375840|Experimental|Low-emot PWL, delay posttest|"Exposure to 9 warning labels paired with image that elicited little emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
2881969|NCT03375840|Experimental|High-emot PWL, immediate posttest|"Exposure to 9 warning labels paired with image that elicited high emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
2881970|NCT03375840|Experimental|High-emot PWL, delay posttest|"Exposure to 9 warning labels paired with image that elicited high emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
2881971|NCT03375827|Experimental|Survey QOL|"Study participants will be provided with the Individualized Goals of Care Discussion Guide (IGCDG) consisting of a brief pamphlet and the IGCDG questionnaire.~Participants will be asked to complete the IGCDG questionnaire prior to their next visit.~Participants will also complete an 8-week follow-up survey after the clinic visit to evaluate the impact on patient satisfaction with care, communication, and care received."
2912499|NCT03162757|Experimental|Internal jugular vein access|
2881972|NCT03375814|Experimental|Experimental group|The group that takes the main drug. They received the conventional treatment group and crocin.
2881973|NCT03375814|Placebo Comparator|Placebo group|The group that takes the Placebo.
2881974|NCT03375801|No Intervention|control group/pre intervention|the first 164 patients will receive care as usual and will make the decision together with their clinician without support of the decision aid. They will be asked to fill out the questionnaires.
2881975|NCT03375801|Experimental|intervention arm|another 164 patients will receive the decision aid as support for the decision making process with their clinician.
2881976|NCT03375788|Experimental|Tesamorelin|tesamorelin (brand name Egrifta) 2mg daily given subcutaneously
2881977|NCT03375788|Placebo Comparator|Placebo|identical placebo given subcutaneously daily
2881978|NCT03375775|Experimental|Treatment group|Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy
2881979|NCT03375775|Active Comparator|Control group|No immunotherapy, symptomatic treatment These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.
2881980|NCT03375762|Experimental|Usual care plus RIPerC|Usual care for stroke code patients, with or without revascularization therapies, with Remote ischemic perconditioning (RIPerC) using an electronic tourniquet.
2881981|NCT03375762|Sham Comparator|Usual care plus Sham RIPerC|Usual care for stroke code patients, with or without revascularization therapies, with Sham remote ischemic conditioning (RIPerC)
2881982|NCT03375749|Experimental|Standing Desk Intervention|Each participant allocated to the experimental group will receive a low-cost, cardboard, fixed-height standing desk converter (https://oristand.co/) that will be placed in their regular office environment, along with their usual sitting desk. The participants will be instructed on how to use the fixed-height standing desk converter (herein referred to as standing desk) as a way to break up sitting time every 30 minutes. In addition, each participant will be provided with information about the health benefits of breaking up sitting time.
2881983|NCT03375749|Other|Waitlist Control|Control group participants will not encounter any changes to their regular office environment. They will be provided with the standing desk and behaviour change strategies 6-months post-intervention.
2881984|NCT03375736|Experimental|Intervention arm|Whole body vibration will be provided by an equipment, GalileoTM Med L Plus (Novotech Medical GmbH). The study participant will stand still on the vibration platform with both knees slightly flexed.
2881985|NCT03375723|Experimental|Information on anatomy and physiology, and breathing technique|"Information on anatomy and physiology, and breathing technique~Information about anatomy~Information about physiology~Breathing technique"
2881986|NCT03375723|Active Comparator|Usual care treatment|Usual care treatment given to patients with respiratory associated pain in acute PE, which is treatment with analgesics. The information on anatomy and physiology in acute PE is the usual information given by the physician at the ward that the patient is treated.
2881987|NCT03375710|Experimental|Cordella™ Heart Failure System|Cordella™ Heart Failure System and implant of Cordella™ Pulmonary Artery Sensor System (CorPASS)
2881988|NCT03375697|Experimental|SAD (Part 1): Healthy Subjects|In Part 1, single ascending intravenous (IV) doses of JNJ-63733657 or placebo will be administered to sequential cohorts (Cohorts 1 to 5) of healthy subjects on Day 1. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. Here, SAD indicates single ascending dose.
2881989|NCT03375697|Experimental|MAD (Part 2): Subjects With Alzheimer's Disease (AD)|In Part 2, multiple ascending IV doses of JNJ-63733657 or placebo will be evaluated at three dose levels in sequential cohorts in subjects with prodromal or mild AD; 3 doses will be administered over a period of 8 weeks (Day 1, Day 29, Day 57). The starting dose will be decided based on the data from Part 1. Escalations will be done based on safety and tolerability similar to Part 1. Doses will not exceed those tested in Part 1. Here, MAD indicates multiple ascending dose.
2881990|NCT03375684|Active Comparator|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 7 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
2881991|NCT03375684|Experimental|Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
2881992|NCT03375671|Experimental|Ketamine|Single administration of Ketalar® (ketamine hydrochloride injection, USP); 5 mg/kg, IM
2881993|NCT03375671|Active Comparator|Midazolam + haloperidol|Single administration of combination of: Midazolam injection (5 mg, IM) and haloperidol injection (5mg, IM)
2881994|NCT03375658|Experimental|Intervention arm|All vital signs registered as part of usual care are used for modelling patients state and trajectories and made available to clinicans via the Patient Deterioration Warning System in nursing and physician offices.
2881995|NCT03375658|No Intervention|Control arm|Usual care
2881996|NCT03375632|Experimental|Uric acid-overproduction Type|
2881997|NCT03375632|Experimental|Uric acid-underexcretion Type|
2881998|NCT03375619||Patients who received CAR-20/19-T cells|
2881999|NCT03375606|Experimental|CSL730|
2882000|NCT03375606|Placebo Comparator|Placebo|
2882001|NCT03375593|Experimental|Narcotic|Hydrocodone 5mg/Acetaminophen 500 mg Tab
2882002|NCT03375593|Experimental|Non Narcotic|Ibuprofen 600mg Tab + acetaminophen 500 mg Tab
2882003|NCT03375580|Placebo Comparator|TLC group|transform life custom (TLC) group
2882004|NCT03375580|Active Comparator|TLC + metformin group|transform life custom (TLC) combined with 0.5g metformin, PO tid
2882005|NCT03375580|Experimental|TLC + CZT capsules group|transform life custom (TLC) combined with 2.52 Compound Zhenzhu Tiaozhi capsules (four tablets), PO tid
2882006|NCT03375580|Active Comparator|TLC + simvastatin group|transform life custom (TLC) combined with 20mg simvastatin, PO qn
2882007|NCT03375567|Experimental|Guided Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
2882047|NCT03375281|Experimental|No touch group|RFA for small HCC would be done by using no touch technique
2914166|NCT03150589|Active Comparator|Lucentis (ranibizumab)|
2882008|NCT03375567|Active Comparator|Standard Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
2882009|NCT03375541|No Intervention|Control|Natural discussion of disease modifier selection conducted without augmentation by risk aversion calculator
2882010|NCT03375541|Experimental|Calculator|Natural discussion of disease modifier selection conducted with augmentation by risk aversion calculator
2882011|NCT03375528|Experimental|coronary artery disease patients|To define the Matrix metalloproteinases expression level in the neointimal hyperplasia induced by DES implantation
2882012|NCT03375515|Experimental|PCA IV Hydromorphone titration|Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. The titration will be done on the patient's request (manipulation by the patient hiself/herself) in 24hrs.
2882013|NCT03375515|Active Comparator|non-PCA IV Hydromorphone titration|Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. Increasal dose of hydromorphone by 50%-100% if pain unchanged or increased, or repeat same dose if pain decrease to 4-6. The titration will be done on the patient's request (manipulation by a nurse) in 24hrs.
2882014|NCT03375502|Experimental|MG1111(Varicella vaccine)|A single injection of 0.5ml MG1111 will be administered subcutaneously at Visit 1
2882015|NCT03375502|Active Comparator|Comparator(Varicella vaccine)|A single injection of 0.5ml comparator will be administered subcutaneously at Visit 1
2882016|NCT03375489|Experimental|Telehealth|"Patients will meet with the PC clinician in person within four weeks of enrollment~Subsequent visits with the PC clinician will be conducted with the patients in their home or other location using video at least every four weeks~Patients may be scheduled to meet with the PC clinician in the clinic if requested by the patient or a clinician"
2882017|NCT03375489|Active Comparator|In Person PC|"Patients will be scheduled for their first In-person PC visit within four weeks of enrollment and then at least every four weeks thereafter until the patient is no longer coming into the clinic~PC visits will be scheduled on the same day as an oncology visit if possible"
2882018|NCT03375476||Vascular surgical patients|Patients undergoing elective vascular non-cardiac surgery in general anesthesia
2882019|NCT03375463|Experimental|LY3298176 Test Part A|SC dose of LY3298176 solution formulation
2882020|NCT03375463|Experimental|LY3298176 Reference Part A|SC dose of LY3298176 lyophilized formulation
2882021|NCT03375463|Experimental|LY3298176 Formulation Part B|IV dose of LY3298176 formulation
2882022|NCT03375463|Experimental|LY3298176 Part C|Titrated SC doses of LY3298176 solution formulation
2882023|NCT03375463|Placebo Comparator|Placebo Part C|SC dose of placebo matching LY3298176 dose
2882024|NCT03375450||Observation|Cohort of patients with COPD
2882025|NCT03375437|Experimental|NTRK, ROS and ALK molecular screening|
2882026|NCT03375424||1st subpopulation|IBD-patients (age at enrollment: 18-80 years) receiving a newly introduced Vedolizumab (VDZ) therapy (n=1.800). A former therapy with other biologics is allowed. More than 30% of these Vedolizumab patients will be biologics-naiv.
2882027|NCT03375424||2nd subpopulation|IBD-patients (age at enrollment: 18-80 years) receiving a newly introduced anti-TNF-alpha therapy other than VDZ (n=350) in biologics-naiv patients.
2882028|NCT03375424||3rd subpopulation|IBD patients (age at enrollment: 18-80 years) with an early disease (n=350), who were first diagnosed <2 years before the start of documentation in the Investigator initiated non-interventional study (NIS) but have not yet received and are not planned to receive biologics in the near future.
2882029|NCT03375411|Experimental|INC1-Bare metal stent|Percutaneous coronary implantation of the device (Stent INC-1) following the standard procedure of stent placement
2882030|NCT03375398|Experimental|3 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice consumed with 3 tablets Sugardown™
2882031|NCT03375398|Placebo Comparator|Rice only|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice
2882032|NCT03375398|Experimental|6 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice consumed with 6 tablets Sugardown™
2882033|NCT03375385|Other|Hemodynamic parameters|
2882034|NCT03375385|Other|Ramsay sedation score|
2882035|NCT03375385|Other|Intraoperative side effects|
2882036|NCT03375385|Other|recovery of sedation|
2882037|NCT03375372|Active Comparator|Group 1 (Treatment Group)|Subjects receive intervention of Scaling and Root Planing (S&RP) procedure under local anesthesia, plus a specified Oral Hygiene Regimen (OHR)
2882038|NCT03375372|No Intervention|Group 2 (Delayed treatment)|Subjects have delayed treatment scaling and root planing procedure and OHR at 36 weeks (Final visit) These subjects are not followed beyond completion of the treatment.
2882039|NCT03375359||cfDNA screening|Pregnant women who are referred for FTS or for further follow-up examinations in case of a suspected anomaly or increased nuchal translucency at 11-13 weeks' gestation can be recruited for this study.
2882040|NCT03375346|Experimental|Whole body vibration group|Whole body vibration group performed a single session of whole body vibration exercise via a vibrating platform (Galileo® Advanced Plus, Novotec Medical, Pforzheim, Germany) with a magnitude of 20 Hz and an amplitude of 4 mm.
2882041|NCT03375346|Active Comparator|Exercise only group|The control group performed the same session without vibration.
2882042|NCT03375333||20GPs|20 general practitioners, who use ultrasound in the examination of patients.
2882043|NCT03375320|Experimental|Arm I (cabozantinib S-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2882044|NCT03375320|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2882045|NCT03375307|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2882046|NCT03375294|Experimental|Nitrous Oxide|PTSD patients in this arm will receive a single inhalation dose of 50% nitrous oxide and 50% oxygen for 1 hour
2882048|NCT03375255|Experimental|SRP-5051|"Patients will be sequentially assigned to receive one of the 5 escalating dose levels of SRP-5051 on Day 1.~Patients who complete the study and continue to meet safety eligibility criteria will have the opportunity to enroll in an open-label extension study to continue to receive SRP-5051."
2882049|NCT03375242||crizotinib|
2882050|NCT03375229|Active Comparator|Group On|This group will be composed of 20 subjects. The application of dry needling and Low-Level Laser Therapy (LLLT) turned on will be directly on the trigger point. The intervention will be administered one time.
2882051|NCT03375229|Active Comparator|Group Off|This group will be composed of 20 subjects. The application of dry needling and LLLT turned off will be directly on the trigger point. The intervention will be administered one time.
2882052|NCT03375229|Placebo Comparator|Placebo group|This group will be composed of 20 subjects. The application of dry needling and LLLT turned off will be 1.5 cm medially from the trigger point. The intervention will be administered one time.
2882053|NCT03375216|Active Comparator|taper|participants undergoing a taper as directed by their pain physician. Interventions include sensory testing ( heat, cold, and pressure) and PROMIS surveys.
2882054|NCT03375216|Placebo Comparator|non taper systemic <90|participants on systemic opioids < 90 MEDD (morphine equivalent daily dose) and no taper
2882055|NCT03375216|Placebo Comparator|non taper systemic >90|participants on systemic opioids > 90 MEDD and no taper
2882056|NCT03375216|Placebo Comparator|non taper intrathecal|Participants on intrathecal therapy and no taper
2882057|NCT03375216|Sham Comparator|non opioids|Participants on non-opioid therapy will undergo behavioral tests and PROMIS surveys
2882058|NCT03375203|Placebo Comparator|Placebo|Participants will receive matching placebo to JNJ-42847922 as oral capsules at normal study bedtime on Nights 1 through 14.
2882059|NCT03375203|Experimental|JNJ-42847922 5 milligram (mg)|Participant will receive JNJ-42847922 5 mg dose as oral capsules at normal study bedtime on Nights 1 through 14.
2882060|NCT03375203|Experimental|JNJ-42847922 10 mg|Participant will receive JNJ-42847922 10 mg as oral capsule and one placebo capsule at normal study bedtime on Nights 1 through 14.
2882061|NCT03375203|Experimental|JNJ-42847922 20 mg|Participant will receive JNJ-42847922 20 mg as oral capsule and one placebo capsule at normal study bedtime on Nights 1 through 14.
2882062|NCT03375203|Experimental|Zolpidem|Participants will receive Zolpidem 5 mg plus one placebo capsule or 10 mg dose as oral capsule at normal study bedtime on Nights 1 through 14.
2882063|NCT03375190|Experimental|Dressing|Transparent film dressing (TegadermTM CHG Chlorhexidine Gluconate IV Securement Dressing, 3M Health Care, St. Paul, MN, USA) alone
2882064|NCT03375190|Experimental|Dressing + adhesive|Transparent film dressing + topical skin adhesive (SwiftSetTM Topical Skin Adhesive, CovidienTM, Devon, UK) at insertion site
2882065|NCT03375190|Experimental|Dressing + adhesive + strips (parallel)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed parallel to long axis of catheter
2882066|NCT03375190|Experimental|Dressing + adhesive + strips (perpend)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed perpendicular to long axis of catheter
2882067|NCT03375190|Experimental|Dressing + adhesive + strips + benzoin|Transparent film dressing + topical skin adhesive + skin closure strips + topical benzoin (Compound Tincture of Benzoin USP 10%, Professional Disposables International, Inc., Orangeburg, NY, USA) spread in a 12 centimeter by 14 centimeter area around the insertion site
2882068|NCT03375190|Experimental|Dressing + adhesive + strips + spray|Transparent film dressing + topical skin adhesive + skin closure strips + medical adhesive spray (AdaptTM Medical Adhesive, Hollister Incorporated, Libertyville, IL, USA) in a 12 centimeter by 14 centimeter area around the insertion site
2882069|NCT03375164|Experimental|Cohort A|"(n=6) is between 3 months to 3 years of age, will receive intravenous rAAVrh74.MHCK7.micro-dystrophin vector (2X1014 vg/kg in 10 mL/kg).~One-day prior to gene transfer subjects in Cohort A will be started on prednisolone (prednisone or deflazacort acceptable) 1 mg/kg and maintained for 30 days while monitoring immune response. If negative at day 30, steroids will be weaned over 1 week. If T cell response to AAV or micro-dys is >125 SFC/106 PBMCs, steroids will be maintained until levels drop below this threshold."
2882070|NCT03375164|Experimental|Cohort B|(n=6) is between 4 to 7 years of age, will receive intravenous rAAVrh74.MHCK7.micro-dystrophin vector (2X1014 vg/kg in 10 mL/kg). will be maintained on stable dose of corticosteroids throughout trial but may be increased for short time if T cell response to AAV or micro-dystrophin is >125 SFC/106 PBMCs.
2882071|NCT03375151|Experimental|EEG based feedback|The therapist will give feedback to the participants during the exercise based on their performance.and use the feedback from the EEG analyzed data to direct cognitive therapy based on the therapist's guidance to maximize the intensity and duration of the patient's high brain engagement Index (BEI) during exercise.
2882072|NCT03375151|Other|Standard practice based feedback|The therapist will give feedback to the participants during the exercise based on their performance.
2882073|NCT03375151|Other|No feedback|The participants will perform the exercise without feedback during practice.
2882074|NCT03375138|Experimental|Process E PPQ belatacept|10 mg/kg, single dose by intravenous (IV) infusion.
2882075|NCT03375138|Experimental|Process C belatacept|10 mg/kg, single dose by intravenous (IV) infusion.
2882076|NCT03375125|Experimental|Probiotic|L. reuteri DSM 17938 + L. reuteri ATCC PTA 5289), dose of 2x10^8 Colony Forming Units (CFU). One lozenges will be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day
2882077|NCT03375125|Placebo Comparator|Placebo|Placebo will have identical appearance, taste, and flavor, except for lacking the bacteria. One lozenges will be taken twice per day (one in the morning and one in the afternoon)
2882078|NCT03375112|Experimental|Fascia Iliaca Compartment Block|A Fascia Iliaca Compartment Block will be administered in the block room.
2882079|NCT03375112|Placebo Comparator|Control|The patients will be brought back to the block room, prepped, and a blunt needle will be touched to the skin. A band aid will be applied over the site.
2882117|NCT03374865||Face-to-face consultation|Traditional face-to-face consultations
2882216|NCT03374176|Active Comparator|AMX-MET|"AMX-MET Amoxicillin 500 mg + Metronidazole 250 mg. Capsules.~1 capsule tid during 7 days."
2914829|NCT03145883|No Intervention|Control group|Control group
2882080|NCT03375099|Experimental|Lethal Means Counseling|National Guard Personnel will receive a single 15-25 minute session of lethal means counseling. The session will focus on increasing the safety of current storage practices for personal firearms (e.g., storing unloaded in a secure location separate from ammunition) as well as planning to voluntarily and temporarily store firearms away from the home during any future hypothetical suicidal crisis. This intervention utilizes a motivational interviewing framework in an effort to remain sensitive to the views and culture of firearm owners.
2882081|NCT03375099|Active Comparator|Lethal Means Counseling plus Gun Locks|National Guard Personnel will receive a single 15-25 minute session of lethal means counseling. The session will focus on increasing the safety of current storage practices for personal firearms (e.g., storing unloaded in a secure location separate from ammunition) as well as planning to voluntarily and temporarily store firearms away from the home during any future hypothetical suicidal crisis. This intervention utilizes a motivational interviewing framework in an effort to remain sensitive to the views and culture of firearm owners. Individuals in this condition will also receive a free gun (cable) lock for each of their personal firearms.
2882082|NCT03375099|Active Comparator|Health and Stress Reduction|Individuals in this condition will take part in a single 15-25 minute session focused on reducing health vulnerabilities in one of four areas: diet, exercise, sleep, or stress. This condition is designed to control for the effects of active interaction with a clinicians (e.g. common factors). As with the experimental condition, this session will utilize a motivational interviewing framework.
2882083|NCT03375099|Active Comparator|Health + Stress Reduction plus Gun Locks|Individuals in this condition will take part in a single 15-25 minute session focused on reducing health vulnerabilities in one of four areas: diet, exercise, sleep, or stress. This condition is designed to control for the effects of active interaction with a clinicians (e.g. common factors). As with the experimental condition, this session will utilize a motivational interviewing framework. Individuals randomized to this condition will also receive a free gun (cable) lock for each of their personal firearms. This will control for whether the effect of the provision of gun locks is accounted for by the simultaneous use of lethal means counseling.
2882084|NCT03375086|Experimental|Single arm|Patients will receive APX3330 orally, twice per day until disease progression
2882085|NCT03375073|Experimental|Positive communication|Positive communication during medical transmission
2882086|NCT03375073|No Intervention|Non-optimized communication|Medical transmission with non-optimized communication.
2882087|NCT03375047|Experimental|Low Dose|Low dose of MRT5005
2882088|NCT03375047|Experimental|Mid Dose|Mid dose of MRT5005
2882089|NCT03375047|Experimental|High Dose|High dose of MRT5005
2882090|NCT03375047|Placebo Comparator|Placebo Comparator|Normal Saline 0.9% USP
2882091|NCT03375034|Experimental|NDMC 20mg|oral single dose
2882092|NCT03375034|Experimental|NDMC 60mg|oral single dose
2882093|NCT03375034|Active Comparator|Clonazepam 1.5mg|oral single dose
2882094|NCT03375034|Placebo Comparator|Placebo|oral single dose
2882095|NCT03375021|Experimental|Sequence 1 PL|Eligible subjects were randomized to Sequence 1 PL in which they received placebo (P) followed by crossover to CX717 200 mg low dose (L) of active treatment
2882096|NCT03375021|Experimental|Sequence 2 PH|Eligible subjects were randomized to Sequence 2 PH in which they received placebo (P) followed by crossover to CX717 800 mg High dose (H) of active treatment
2882097|NCT03375021|Experimental|Sequence 3 LP|Eligible subjects were randomized to Sequence 3 LP in which they received CX717 200 mg Low dose (L) of active treatment followed by crossover to placebo (P)
2882098|NCT03375021|Experimental|Sequence 4 HP|Eligible subjects were randomized to Sequence 2 PH in which they received CX717 800 mg High dose (H) of active treatment followed by crossover to placebo (P)
2882099|NCT03375008|Experimental|Imaging diagnostic and biopsy|40 subjects who are suspected NASH from June 2016 to December 2017.
2882100|NCT03374995|Experimental|Group I (topical keratin)|Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks).
2882101|NCT03374995|Active Comparator|Group II (standard of care)|Patients receive standard of care as directed by radiation oncologist until the end of radiation therapy (approximately 3-6 weeks).
2882102|NCT03374982|Experimental|DentalVibe On|DentalVibe will be turned on during local anesthetic injection at one appointment.
2882103|NCT03374982|No Intervention|DentalVibe Off|DentalVibe will be be turned off during local anesthetic injection at one appointment.
2882104|NCT03374969|Experimental|Attachment and Biobehavioral Catch-Up|
2882105|NCT03374969|Active Comparator|Developmental Education for Families|
2882106|NCT03374956|Experimental|Intervention group|Phenotype-guided pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine plus Exercise
2882107|NCT03374956|Active Comparator|Control Group|Randomly assigned pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine
2882108|NCT03374943|Experimental|KB004 dose escalation|Patients will be entered at each KB004 dose level sequentially until 3-6 patients are evaluable for safety. Three sequential cohorts are planned in this study (3.5mg/kg, 5.25 mg/kg, 7.9 mg/kg) Additional dose levels may be explored based on the emerging data in the study.
2882109|NCT03374917|Experimental|ABBV-951|ABBV-951 administered by continuous subcutaneous infusion (CSCI) for 4 weeks.
2882110|NCT03374904|Active Comparator|Control Group|Patients in control group will attend to four session of Play Therapy plus inpatient treatment as usual during four weeks
2882111|NCT03374904|Experimental|Video Feedback|Once a week, after play therapy, individual or group video feedback session will be done.
2882112|NCT03374891|No Intervention|Participants will fill out surveys|These participants will fill out surveys in regard to their experiences, opinions, and knowledge of the defibrillator process.
2882113|NCT03374891|Active Comparator|Educational video and/or handout|These participants will receive an educational video and/or handout about the defibrillator process. Then they will fill out surveys in regard to their experiences, opinions, and knowledge of the defibrillator process.
2882114|NCT03374878|Experimental|oral contraceptive and training|Users of oral contraceptive training for 10 weeks
2882115|NCT03374878|Placebo Comparator|no oral contraceptive and training|Non-users of oral contraceptive training for 10 weeks
2882116|NCT03374865||Video-mediated consultation|Consultations using Facetalk videocommunication software
2882118|NCT03374852|Experimental|CPI-613 + mFOLFIRNOX|"CPI-613: 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port mFOLFIRNOX (given immediately after CPI-613 administration): Oxaliplatin (Eloxatin) at 65 mg/m2 given as a 2-hr IV infusion via a central venous port~Folinic acid at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin, and concurrently with irinotecan (Camptosar).~Irniotecan at 140 mg/m2 given as a 90-min IV infusion via a central venous port via a Yconnector.~Flurouracil (5FU) at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan"
2882119|NCT03374839|Experimental|TIL + IL-2 + Nivolumab|"A first cohort of 3 patients will be done to ensure that the combined treatment (TIL + IL-2 + Nivolumab) would not cause severe autoimmunity pathologies.~For this first cohort, a dose of 0.5 billion of TILs per injection will be administered. After the opinion of the Data and Safety Monitoring Committee (DSMC), the sponsor will make the decision of the second cohort of 8 patients who will receive between 1 and 20 billion of TIL."
2882120|NCT03374826|Experimental|Dedicated axillary hybrid PET-MRI axilla|
2882121|NCT03374813|Experimental|MimetikOss|Ridge preservation bone grafting after tooth extraction
2882122|NCT03374813|Active Comparator|Bio-Oss|Ridge preservation bone grafting after tooth extraction
2882123|NCT03374800|Placebo Comparator|Placebo (0.9% saline)|Withholding Stress ulcer prophylaxis (intravenous 0.9% saline as placebo)
2882124|NCT03374800|Active Comparator|Stress Ulcer Prophylaxis (Pantoprazole)|pantoprazole 40mg powder for injection reconstituted with 0.9% saline
2882125|NCT03374787|Experimental|Fusion sound processor|The sound processor picks up the sound and transfer it to the implant that convert the sound to vibrations that are transmitted to the inner ear.
2882126|NCT03374774||Participants with Type 2 Diabetes Mellitus|Participants will be prescribed and treated with commercially available BIAsp 30 according to routine clinical practice at the discretion of the treating physician, independent of this study. The study will gather data over the course of routine treatment on willingness to pay for BIAsp 30 in FlexPen® or Penfill®.
2882127|NCT03374761|Experimental|Families First Home Visiting Program|10 group sessions conducted weekly and 4 home visits for the duration of the program. Sessions and visits of the Families First Home Visiting Program cover child development, parenting skills, parent-child communications, and positive discipline practices. The intervention is delivered by para-professional community facilitators, trained in the program.
2882128|NCT03374761|No Intervention|Control Group|The control group receives the standard, government run, services provided by community health workers in West Java. Once the evaluation of the intervention arm is completed, participants in the control arm will be offered the intervention.
2882129|NCT03374735|Experimental|SETALUM™ Sealant|SETALUM™ Sealant to be applied on the suture line
2882130|NCT03374722||Mechanically ventilated critically ill patients|Mechanically ventilated critically ill patients who receive opioid as continuous infusion for more than 24 hours
2882131|NCT03374709|Experimental|Treatment Group|This arm includes subjects who have been prescribed Oxtellar XR 150Mg Extended Release Tablets.
2882132|NCT03374696|Experimental|Intervention group|The intervention SAFETY was performed in school facilities by professional actors and staff from the municipality`s youth guidance center within the county. The actors first enacted a play portraying youths and problems with condom use. Next, a value exercise was held by the youth guidance center staff. The class continued with chlamydia games held by the youth guidance center staff, providing information on symptoms, protection, how to get tested, treatment and consequences. The youth guidance center staff and the actors, playing students, then held a condom school. Lastly, the students came up with new endings to the play. All replays were enacted and the students gave feedback on the new endings. The class ended with condoms being handed out.
2882133|NCT03374696|Active Comparator|Control group|The intervention in the control group contained standard education from school staff, based on the sex education guidelines of the Swedish National Agency for Education. Students got education on human sexuality, reproduction, menstruation, love, sex, pregnancy and how STIs and unwanted pregnancy are prevented.
2882134|NCT03374683|Experimental|Risk Reframing (RR) Digital Tool|
2882135|NCT03374683|Active Comparator|RR In-Person Workshop|
2882136|NCT03374683|Sham Comparator|Position Statement Active Outdoor Play|
2882137|NCT03374670|Experimental|Cohort 1|Zimura dosage 1 + Eylea 2 mg
2882138|NCT03374670|Experimental|Cohort 2|Zimura dosage 2 + Eylea 2 mg
2882139|NCT03374657|Experimental|CPK Dose 1 (lowest dose)|CPK850, one subretinal injection to the study eye
2882140|NCT03374657|Experimental|CPK Dose 2 (next lowest dose)|CPK850, one subretinal injection to the study eye
2882141|NCT03374657|Experimental|CPK Dose 3 (third lowest dose)|CPK850, one subretinal injection to the study eye
2882142|NCT03374657|Experimental|CPK Dose 4 (next to highest dose)|CPK850, one subretinal injection to the study eye
2882143|NCT03374657|Experimental|CPK Dose 5 (highest dose)|CPK850, one subretinal injection to the study eye
2882144|NCT03374644|Experimental|ETCO2 monitoring with nasal cannula|SentriTM ETCO2 adult nasal cannula (Intersurgical ® code 1144002) will be placed into patient's nostril following radial artery catheter insertion. A baseline (without oxygen flow) ETCO2, PaO2, SPO2, RR and PaCO2 will be recorded. Oxygen will then be administered at 2,4, and 6 liters per minute for a period of five minutes.ETCO2, PaCO2 and PaO2 will be recorded for each level of oxygen administration.Sedation will be given during intra-operative period with the target of Observer Assessment of alertness/sedation scale (OAA/S) score of 3. During intraoperative period, oxygen will be administered at 2 and 4 liters per minute for a period of five minutes. ETCO2, PaCO2 and PaO2 level will be recorded during each level of oxygen administration.
2882145|NCT03374631|Experimental|Active anodal tDCS|Active anodal tDCS followed by behavioral testing
2882146|NCT03374631|Sham Comparator|Sham tDCS|Sham tDCS followed by behavioral testing
2882147|NCT03374618|Experimental|systemic lupus erythematosus|adult with systemic lupus erythematosus
2882148|NCT03374618|Experimental|systemic sclerosis|adult with systemic sclerosis
2882149|NCT03374618|Other|healthy volunteers|healthy volunteer (adult)
2882150|NCT03374605|Experimental|Active tDCS|
2882151|NCT03374605|Sham Comparator|Sham tDCS|
2882152|NCT03374592|Active Comparator|Conventional Radiotherapy|8Gy in 1 fraction or 20Gy in 5 fractions
2882153|NCT03374592|Experimental|Volumetric Intensity-Modulated Arc Therapy|8Gy in 1 fraction or 20Gy in 5 fractions
2882155|NCT03374566||Screened patients|Immunodeficiency screening: Heparinized peripheral blood is obtained from patients with severe EBV infections for immunological function assays and genetic analysis, when current screening is performed after parents' information and consent.
2882156|NCT03374553|Experimental|MINIject 636 implant|"MINIject 636 implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
2882157|NCT03374540||Rivaroxaban|Patients who initiated Oral anticoagulant (OAC) treatment with rivaroxaban
2882158|NCT03374540||Vitamin K antagonist(VKA)|Patients who initiated OAC treatment with VKA
2882159|NCT03374527||Psoriasis|Patients with psoriasis vulgarism without clinical signs of PsA
2882160|NCT03374527||Psoriatic Arthritis (PsA)|Patients with a diagnosis of psoriatic arthritis and cutaneous psoriasis
2882161|NCT03374527||Control group|Healthy subjects
2882162|NCT03374514|Experimental|DEX|Topical dexamethasone will be placed at a concentration of 20mg / ml in a single dose in the tympanic cavity of the middle ear through posterior tympanotomy in the cochlear implant surgery, paying special attention to the round window membrane completely submerged in the liquid, to the insertion of the electrode assembly
2882163|NCT03374514|Placebo Comparator|SF|Sterile isotonic saline solution will be placed in a single dose in the tympanic cavity of the middle ear through posterior tympanotomy during cochlear implant surgery, paying special attention to the fact that the round window membrane is completely submerged in the liquid, prior to insertion of the electrode array
2882164|NCT03374501|Experimental|2 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink consumed with 2 tablets of Sugardown™
2882165|NCT03374501|Experimental|4 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink consumed with 4 tablets of Sugardown™
2882166|NCT03374501|Placebo Comparator|Soft drink|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink
2882167|NCT03374488|Experimental|Treatment Group 1|Pembrolizumab + epacadostat
2882168|NCT03374488|Active Comparator|Treatment Group 2|Pembrolizumab + placebo
2882169|NCT03374475|Placebo Comparator|Lead-in period: Placebo|Participants who successfully complete the baseline examination visit at the clinical site/unit, will be treated with placebo (2 capsules taken orally) for the duration of the lead-in period which will last up to 3 weeks. Investigators and participants will be blinded to exact duration of each participant-specific lead-in period throughout the study.
2882170|NCT03374475|Experimental|Treatment period: JNJ-42847922 or Placebo|Placebo lead-in period responders and non-responders will be randomized to receive either placebo or 20 milligram (mg) JNJ-42847922 or 40 mg JNJ‑42847922 for 5 Weeks. Participants will swallow JNJ-42847922 20 mg (2*10-mg capsules) or JNJ-42847922 40 mg (2*20-mg capsules) or 2 matching placebo capsules once daily for 5 Weeks.
2882171|NCT03374475|Placebo Comparator|Withdrawal period: Placebo|Participants who will complete the treatment period prior to the end of Week 8 will enter the withdrawal period where they will be treated with placebo (2 capsules taken orally) for the remaining time of the double-blind phase of the study. Investigators and participants will be blinded to exact duration of each participant-specific withdrawal period.
2882172|NCT03374462|Experimental|Telemedicine Intervention|All participants will receive the study intervention, which consists of home-based telemedicine visits with a diabetes specialist, at a frequency determined by the patient's degree of glycemic control (every 4, 6, or 8 weeks).
2882173|NCT03374449|Experimental|continuation of the RAS-inhibitors|in the continuation of the RAS-inhibitors arm the treatment will be continued until the morning the day of surgery.
2882174|NCT03374449|Active Comparator|discontinuation of the RAS-inhibitors|In this arm : discontinuation of the RAS-inhibitors 48 hours before surgery Patients won't receive the drug on the morning of the day of the surgery.
2882175|NCT03374436|Experimental|High-Carbohydrate Sedentary|Participants will remain seated for 9 hours (except for using the restroom) while consuming a high-carbohydrate diet (3 meals)
2882176|NCT03374436|Experimental|High-Carbohydrate Active|"Participants will remain seated for 9 hours (except for using the restroom) while consuming a high-carbohydrate diet (3 meals) but will complete 8 stair climbing sprint snacks once per hour involving ascending 3 flights of stairs at a vigorous pace (~20 seconds each)."
2882177|NCT03374436|Active Comparator|Low-Carbohydrate Sedentary|Participants will remain seated for 9 hours (except for using the restroom) while consuming a low-carbohydrate diet (3 meals)
2882178|NCT03374423|Active Comparator|intercostal nerve group|pulsed radiofrequency on intercostal nerves (2-5)
2882179|NCT03374423|Active Comparator|dorsal root ganglion group|pulsed radiofrequency on dorsal root ganglion (2-5)
2882180|NCT03374397|Active Comparator|SurgiGuard|Surgiguard Non-woven Drug : SurgiGuard Non-woven 6g during surgery
2882181|NCT03374397|No Intervention|Bipolar electrocauterization|Bipolar electrocauterization during surgery Drug(-)
2882182|NCT03374371||S. epidermidis Infection (CASE)|Patients with confirmed infection at S. epidermidis
2882183|NCT03374371||S. epidermidis Contamination (CONTROL)|Patients with confirmed contamination at S. epidermidis
2882184|NCT03374358|No Intervention|No intervention arm.|Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).
2882185|NCT03374358|Experimental|Raltegravir arm.|Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).
2882186|NCT03374345|Experimental|SDT group|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
2882187|NCT03374345|Placebo Comparator|Placebo group|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
2882188|NCT03374332|Experimental|Treatment 1: Gemtuzumab Ozogamicin and DLI >or =70 years old|"Patients > 70 years of age will be given gemtuzumab ozogamicin 6mg/m2 (2mg/m2 each day, capped at 4.5mg) from Day 1, 4, 7.~Day 8: The product will be administered unprocessed on day 8 (same day as leukapheresis) with a minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg irrespective of the number of CD34+ cells."
2882217|NCT03374176|Experimental|Clindamycin|"Clindamycin Clindamycin 300 mg + placebo. Capsules.~1 capsule tid during 7 days."
2882189|NCT03374332|Experimental|Treatment 1 : Gemtuzumab Ozogamicin and DLI < 70 years old|"Patients > 70 years of age will be given gemtuzumab ozogamicin 9mg/m2 (3mg/m2 each day,capped at 4.5mg) from Day 1, day 4, day 7~Day 8: The product will be administered unprocessed on day 8 (same day as leukapheresis) with a minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg irrespective of the number of CD34+ cells."
2882190|NCT03374332|Experimental|Treatment #2: Gemtuzumab Ozogamicin and DLI|"Patients who show a transient response to therapy can receive up to two additional donor leukocyte infusions with GO 6mg/m2 (2mg/m2 day,capped at 4.5mg) for all patients regardless of age administered day 1, 4, 7, no sooner than 35 days status post their last cellular infusion.~Day 8: The product will be administered unprocessed on day 8 (same day as leukapheresis) with a minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg irrespective of the number of CD34+ cells."
2882191|NCT03374332|Experimental|Treatment #3: Gemtuzumab Ozogamicin and DLI|"Patients who show a transient response to therapy can receive up to two additional donor leukocyte infusions with GO 6mg/m2 (2mg/m2 each day, capped at 4.5mg) for all patients regardless of age administered day 1,4,7, no sooner than 35 days status post their last cellular infusion.~Day 8: The product will be administered unprocessed on day 8 (same day as leukapheresis) with a minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg irrespective of the number of CD34+ cells."
2882192|NCT03374319|Experimental|Intervention group|Modified amputation procedure
2882193|NCT03374319|Active Comparator|Control group|Standard amputation procedure
2882194|NCT03374306|Experimental|Atropine 0.01%|Group receiving atropine treatment for 18 months
2882195|NCT03374306|Placebo Comparator|Artifical tear|Group receiving placebo for 18 months
2882196|NCT03374293|Experimental|Experimental Group|Radiation to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody . Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes.
2882197|NCT03374280|Experimental|pemetrexed/cisplatin intercalating gefitinib|"pemetrexed 500mg/m2 d1; cisplatin 30mg/m2 d1-2 ;gefitinib 250mg d3-20d, to 4 cycles.~pemetrexed 500mg/m2 d1; gefitinib 250mg d2-20d to disease progression or untolerable"
2882198|NCT03374280|Active Comparator|pemetrexed/cisplatin|pemetrexed 500mg/m2 d1; cisplatin 30mg/m2 d1-2 to 4 cycles. pemetrexed 500mg/m2 d1 to disease progression or untolerable
2882199|NCT03374254|Experimental|Pembrolizumab + Binimetinib (Cohort A)|During Part 1, participants in Cohort A will receive a standard dose (DL1) of pembrolizumab (200 mg) intravenous (IV) every 3 weeks (Q3W) plus binimetinib orally at a starting dose of 30 mg twice a day (BID). Based on dose-limiting toxicities (DLT) assessed during the initial 21 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (Dose Level 2 [DL2]). Once a preliminary RP2D for binimetinib is identified in Part 1 for Cohort A, participants will receive pembrolizumab 200 mg IV Q3W plus binimetinib orally at the preliminary RP2D during Part 2.
2882200|NCT03374254|Experimental|Pembrolizumab + mFOLFOX7 (Cohort B)|During Part 1, participants in Cohort B will receive a standard dose (DL1) of pembrolizumab 200 mg IV Q3W plus mFOLFOX7 (oxaliplatin 85 mg/m^2; leucovorin [calcium folinate] 400 mg/m^2; fluorouracil [5-FU] 2400 mg/m^2 over 46-48 hours) IV every 2 weeks (Q2W). Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of mFOLFOX7 may be de-escalated to oxaliplatin 70 mg/m^2; leucovorin (calcium folinate) 400 mg/m^2; 5-FU 2000 mg/m^2 over 46-48 hours] IV Q2W. Once a preliminary RP2D for mFOLFOX7 is identified in Part 1 for Cohort B, participants will receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the preliminary RP2D during Part 2.
2882201|NCT03374254|Experimental|Pembrolizumab + mFOLFOX7 + Binimetinib (Cohort C)|After an RP2D for mFOLFOX7 is identified in Part 1 for Cohort B, participants may enroll in Cohort C and receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the preliminary RP2D Q2W in combination with binimetinib orally at a starting dose of 30 mg BID during Part 1. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (DL2). Once a preliminary RP2D for binimetinib is identified in Part 1 for this cohort, participants in Part 2 will receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the RP2D determined for Cohort B Q2W plus binimetinib orally at the RP2D determined for Cohort C in Part 1.
2882202|NCT03374254|Experimental|Pembrolizumab + FOLFIRI (Cohort D)|During Part 1, participants in Cohort D will receive a standard dose (DL1) of pembrolizumab 200 mg IV Q3W plus FOLFIRI (irinotecan 180 mg/m^2; leucovorin [calcium folinate] 400 mg/m^2; 5-FU 2400 mg/m^2 over 46-48 hours) IV Q2W. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of FOLFIRI may be de-escalated to irinotecan 150 mg/m^2; leucovorin (calcium folinate) 400 mg/m^2; 5-FU 2000 mg/m^2 over 46-48 hours) IV Q2W. Once a preliminary RP2D for FOLFIRI is identified in Part 1 for Cohort D, participants will receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the preliminary RP2D during Part 2.
2882203|NCT03374254|Experimental|Pembrolizumab + FOLFIRI + Binimetinib (Cohort E)|After an RP2D for FOLFIRI is identified in Part 1 for Cohort D, participants may enroll in Cohort E and receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the preliminary RP2D Q2W in combination with binimetinib orally at a starting dose of 30 mg BID during Part 1. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (DL2). Once a preliminary RP2D for binimetinib is identified in Part 1 for this cohort, participants in Part 2 will receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the RP2D determined for Cohort D Q2W plus binimetinib orally at the RP2D determined for Cohort E in Part 1.
2882204|NCT03374241|Experimental|Cohort 1|HM15211 or Placebo (single dose, subcutaneous injection)
2882205|NCT03374241|Experimental|Cohort 2|HM15211 or Placebo (single dose, subcutaneous injection)
2882206|NCT03374241|Experimental|Cohort 3|HM15211 or Placebo (single dose, subcutaneous injection)
2882207|NCT03374241|Experimental|Cohort 4|HM15211 or Placebo (single dose, subcutaneous injection)
2882208|NCT03374241|Experimental|Cohort 5|HM15211 or Placebo (single dose, subcutaneous injection)
2882209|NCT03374228|Experimental|BMS-986205|Single oral dose of BMS-986205 tablet on the morning of Day 1 followed by a 15-minute infusion of [13C]BMS-986205 solution for intravenous administration starting 01:45 hours after the oral dose administration
2882210|NCT03374215||1|People ages 18-70 who are Black, African American, or of Caribbean descent and have difficult to control blood pressure or primary aldosteronism.
2882211|NCT03374202|Experimental|Group 1|5x10(10)vg/kg dose of AAV8-VRC07
2882212|NCT03374202|Experimental|Group 2|5x10(11)vg/kg dose of AAV8-VRC07
2882213|NCT03374202|Experimental|Group3|2.5x10(12) vg/kg dose of AAV8-VRC07
2882214|NCT03374189|Experimental|EZ Close arm|EZ close used for port-site closure.
2882218|NCT03374163|Experimental|treatment group who recived intralipid|71 patients who recived intralipid on day of embryo transfer day, pregnancy day.
2882219|NCT03374163|No Intervention|control group|71 patient not recived intralipid
2882220|NCT03374150|Experimental|high protein|High protein (HP) group were given counseling about weight loss program by applying low calorie-high protein diet with diet menu composition of 22-30% protein, along with instructions for allowed cooking method.
2882221|NCT03374150|Active Comparator|standard protein|Active comparator receiving standard protein (SP) proportion were counseled about weight loss program by means of low calorie-balanced composition diet with menu comprised of 12-20% protein.
2882222|NCT03374137||obinutuzumab|Participants with follicular lymphoma or previously untreated chronic lymphocytic leukemia will be treated with obinutuzumab.
2882223|NCT03374124||postoperational CRS|observe the symptoms and endoscopic appearance
2882224|NCT03374111|Experimental|Experimental group|15g of Colla corii asini granule( produced by Dong-E E-Jiao Co., Ltd) ， taken once daily for 8 weeks
2882225|NCT03374111|Placebo Comparator|Control group|a Simulate Agent of Colla corii asini granule， similar in size, shape，color and taste to Colla corii asini granule, taken once daily for 8 weeks
2882226|NCT03374098|Experimental|Education|Attend an hour-long classes once per week for three weeks
2882227|NCT03374098|Experimental|Home Visitation|Receive home visits that focus on the social determinants of health and attend hour-long classes once per week for three weeks
2882228|NCT03374085|Experimental|Administration of CC-92480 and Dexamethasone|Escalating doses of CC-92480 in combination with a fixed dose of dexamethasone administered according to two different dosing schedules
2882229|NCT03374072|Experimental|Siblings FORWARD|Siblings who participate in the Siblings FORWARD program will participate in videoteleconference sessions with an Arc community provider. The content and format of the program is still being finalized. In the initial conception of the program, we proposed 6 sessions: Session 1 will focus on assessment and motivation (Sibling and adult with ASD). In Session 2, the sibling will learn family communication strategies. Session 3 will provide the sibling with information about adult services and how to navigate the service system. Session 5 will be a joint session with the family members with ASD. In the final session, the sibling will develop a plan of action outlining their involvement in family future planning.
2882230|NCT03374072|Active Comparator|Information Only Condition|We will create an information packet for siblings in the control condition. Siblings in the control condition will receive the same tip sheets and packet of information about resources for adults with ASD as those distributed in Session 3 of the Siblings FORWARD program.
2882231|NCT03374059|Experimental|Exercise|Exercise group received a home exercise program treatment for 4 weeks including isometric exercises for neck muscles and postural correction exercises for neck region.
2882232|NCT03374059|Experimental|Exercise and Life modification|This group received life modification suggestions additional to home exercise treatment program for 4 weeks.
2882233|NCT03374059|No Intervention|Control Group|Control group did not receive any treatments
2882234|NCT03374046|No Intervention|Control Group|Standard care
2882235|NCT03374046|Experimental|Apneic Oxygenation Group|"During apneic period of intubation attempt, patient will be placed on nasal cannula~If 0-2 years: 3L/min NC of 100% FiO2~If > or = to 2 through17 years: 5L/min NC of 100% FiO2"
2882236|NCT03374033|No Intervention|NUTR (Nutrition) 0_STIMUL(Stimulation) 0|Standard Nutrition and no Physical Stimulation
2882237|NCT03374033|Experimental|NUTR 0_STIMUL +|Standard Nutrition and Physical Stimulation
2882238|NCT03374033|Experimental|NUTR +_STIMUL 0|Enhanced Nutrition, and no Physical Stimulation
2882239|NCT03374033|Experimental|NUTR +_STIMUL +|Enhanced Nutrition and Physical Stimulation
2882240|NCT03374020||Intermediate AMD|
2882241|NCT03374020||Advanced AMD|
2882242|NCT03374020||DR without macular edema|
2882243|NCT03374020||DR with macular edema|
2882244|NCT03374007|Experimental|GB226 1mg/kg single-dose|GB226 1mg/kg single-dose
2882245|NCT03374007|Experimental|GB226 3 mg/kg single-dose|GB226 3mg/kg single-dose
2882246|NCT03374007|Experimental|GB226 10mg/kg single-dose|GB226 10mg/kg single-dose
2882247|NCT03374007|Experimental|GB226 1mg/kg multiple dosing, every 2 weeks|GB226 1mg/kg every 2 weeks
2882248|NCT03374007|Experimental|GB226 3mg/kg multiple dosing,every 2 weeks|GB226 3mg/kg every 2 weeks
2882249|NCT03374007|Experimental|GB226 10mg/kg multiple dosing, every 2 weeks|GB226 10mg/kg every 2 weeks
2882250|NCT03374007|Experimental|GB226 3mg/kg multiple dosing, every 3 weeks|GB226 3mg/kg every 3 weeks
2882251|NCT03374007|Experimental|GB226 10mg/kg multiple dosing, every 3 weeks|GB226 10mg/kg every 3 weeks
2882252|NCT03373994||18F-FDG PET/CT initial-time imaging|PET/CT imaging was underwent 5min after 18F-FDG injection.
2882253|NCT03373994||18F-FDG PET/CT balanced-time imaging|PET/CT imaging was underwent 60min after 18F-FDG injection.
2882254|NCT03373981|Experimental|intervention|rTMS
2882255|NCT03373968|Experimental|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
2882256|NCT03373955||Immunotherapy,chemotherapy,radiotherapy|Pembrolizumab will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent.The peripheral blood will be collected at 3 weeks,2 months, 6 months,an average of 1 year
2882257|NCT03373942||Primary Open Angle Glaucoma (POAG)|The study included 30 eyes of 30 patients diagnosed with POAG who presented to Glaucoma Unit of İzmir Katip Çelebi University Atatürk Training and Research Hospital
2882258|NCT03373942||Pseudoexfoliation Syndrome (PEX)|The study included 30 eyes of 30 patients diagnosed with PEX glaucoma who presented to Glaucoma Unit of İzmir Katip Çelebi University Atatürk Training and Research Hospital
2882259|NCT03373942||Control|The control group included 30 eyes of 30 healthy individuals with similar age distribution with POAG and PEX group
2882260|NCT03373929|Other|PFO Closure Rate|Evaluate closure rate of clinically relevant septal defects including PFO, ASD (less than 1 cm with redundant septal tissue), trans septal puncture sites, repair of ASA (when an appropriate PFO or small ASD defect is present) and rate of recurrent neurologic embolic event in patients with cryptogenic stroke and PFO
2882261|NCT03373929|Other|Published PFO Device Closure|Compare PFO closure rate and safety of closure of septal occluders in published PFO clinical trials.
2882262|NCT03373916|Experimental|Peer Mentorship intervention|A Peer Specialist will be making weekly follow-up contact with study participants in the community or by telephone for 3 months following hospital discharge. The content of the peer mentorship interactions will be based on the manual developed by the study team and will address protective factors such as hope and belongingness.
2882263|NCT03373916|Active Comparator|Enhanced Usual Care|"The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts."
2882264|NCT03373903|Placebo Comparator|Placebo once daily for 16 weeks|
2882265|NCT03373903|Experimental|BEZ235 once daily for 16 weeks|
2882266|NCT03373903|Experimental|BEZ235 twice daily for 16 weeks|
2882267|NCT03373903|Experimental|BEZ235 plus RAD001 once daily for 16 weeks|
2882268|NCT03373890|Experimental|Short burst Interval Treadmill Training|All participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 5x/week for 4 weeks or 2x/week for 10 weeks.
2882269|NCT03373877|Experimental|Dose 1: PU-H71 225 mg/m2 + ruxolitinib|Cohort 1
2882270|NCT03373877|Experimental|Dose 2: PU-H71 300 mg/m2 + ruxolitinib|Cohort 2
2882271|NCT03373877|Experimental|Dose 3: PU-H71 400 mg/m2 + ruxolitinib|Cohort 3
2882272|NCT03373877|Experimental|Dose 4: PU-H71 600 mg/m2 + ruxolitinib|Cohort 4
2882273|NCT03373864|Experimental|Unilateral spinal anesthesia|In this arm, the patients will have a hypobaric lateral spinal anesthesia. Sedation can be added for the patients comfort.
2882274|NCT03373864|Active Comparator|General anesthesia|In this arm, the patients will have a general anesthesia.
2882275|NCT03373851||Zalviso|Patient willing to participate to the study, and scheduled for major functional surgery (arthroplasty, valgisation osteotomy, DIEP flap surgery, total body lift procedures) will be consented to use the Zalviso device in postoperative period as a main analgesia method.
2882276|NCT03373838||Census|Epidemiological study. Sociodemographic and medical survey.
2882277|NCT03373838||Qualitative interview|Individual qualitative interview.
2882278|NCT03373825|Experimental|Arm 1|50 participants will receive a kit containing 10 Rapid Response fentanyl test strips. We will ask participants to use the take-home rapid drug test to test their urine for presence or absence of fentanyl.
2882279|NCT03373825|Experimental|Arm 2|50 participants will receive a kit containing 10 Rapid Response fentanyl test strips. We will ask the participants to use the take-home rapid drug test to test the residue of their drug (ie. instruct them to test bags, cookers, spoons, etc.) for the presence or absence of fentanyl.
2882280|NCT03373812|Active Comparator|anterior approach|patients having involutional ptosis undergoing anterior approach surgical ptosis repair (Levator advancement)
2882281|NCT03373812|Active Comparator|posterior approach|patients having involutional ptosis undergoing posterior approach surgical ptosis repair (mullerectomy)
2882282|NCT03373799|Experimental|Group 1|Video-Based Rehabilitation Group
2882283|NCT03373799|Active Comparator|Group 2|Physiotherapist-Supervised Rehabilitation Group
2882284|NCT03373786|Experimental|RG-012 Single Dose|1.5 mg/kg RG012 subcutaneous injection
2882285|NCT03373786|Experimental|RG012 Every Other Week|1.5 mg/kg RG012 subcutaneous injections every other week
2882286|NCT03373773|Active Comparator|Home Removal|"Patients will be randomly allocated to two groups: subjects in one group will remove their indwelling Foley catheter at home and will have voiding assessment remotely based on their voiding characteristics (a Force of Stream of >5/10 indicates that the patient has adequate bladder function), and the other group will follow up in the office for Foley catheter removal and voiding trial.~Subjects in this arm will remove the Foley catheter at home."
2882287|NCT03373773|Active Comparator|Office Removal|"Patients will be randomly allocated to two groups: subjects in one group will remove their indwelling Foley catheter at home and will have voiding assessment remotely based on their voiding characteristics (a Force of Stream of >5/10 indicates that the patient has adequate bladder function), and the other group will follow up in the office for Foley catheter removal and voiding trial.~Subjects in this arm will remove the Foley catheter in a medical office."
2882288|NCT03373760|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes on day 1 for courses 1-4 and durvalumab IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2882289|NCT03373747|Experimental|Reliability of IET|In phase 1, the first of familiarization is to the participants understand the test and familiarize with the equipment after 24 to 48 hours, the participants will do the test applied twice at the same day with 10 minutes of rest. For realization of the IET the participants will be instructe to make the maximum effort as possible and mantain until they can't resiste. After one week the retest session will be doing. The order between the evaluators will be changed in the test and retest sessions.
2882290|NCT03373747|Experimental|Physiological analysis of IET|In phase 2, the participants will be submitted two sessions, familiarization session and test session. In the test session there is be two teste applied in the same day with approximately 20 minutes of rest. In the first test, thers is gas analysis during all the test until seven minutes after the test and blood lactat concentrate will be colected before the test with 10 minutes of rest, immediately after the teste and in the first, in the third, fifth and seventh minutes after the test. In the second test will be assess the muscular activation porcentage of lateral vastus muscle by means of twitch interpolation technique there is be performe before and after the test.
2882291|NCT03373708|Experimental|EC follow T group|Epirubicin 100mg/m2 on day 1 cyclophosphamide 600mg/m2 on day1 every 2 weeks for four cycles followed by docetaxel 100mg/m2 on day 1 every 3 weeks for four cycles
2882292|NCT03373708|Experimental|TC follow endocrine|Docetaxel 75mg/m2 on day 1 and cyclophosphamide 600mg/m2 on day 1 every 3 weeks for four cycles followed by goserelin acetate+tamoxifen for young patients/ letrozole for postmenopausal patients
2882293|NCT03373695|Experimental|Dissolve™|
2882294|NCT03373695|Active Comparator|SeQuent®Please|
2882295|NCT03373669|Active Comparator|Shanchol Dose-interval Group 1|Participants in Dose-Interval Group 1 (DIG-1) will receive the oral cholera vaccine, Shanchol, according to the manufacturer instructions: in 2 doses at Day 0 and two weeks later (Day 14).
2882296|NCT03373669|Experimental|Shanchol Dose-Interval Group 2|Participants in Dose-Interval Group 2 (DIG-2) will receive the Adjusted Dose oral cholera vaccine, Shanchol, with a delayed second dose. The vaccine will be given at Day 0 and six months later.
2882297|NCT03373656|Experimental|low antibody titers|Antibody titers lower than protection level
2882298|NCT03373656|Other|high antibody titers|Antibody titers higher than protection level
2882299|NCT03373643|Experimental|Patient suspected for NAFLD|
2882300|NCT03373630|Experimental|Midline catheter|
2882301|NCT03373617||General anesthesia group|Patients in general anesthesia group are scheduled to undergo RIRS under general anesthesia.
2882302|NCT03373617||Spinal anesthesia group|Patients in general anesthesia group are scheduled to undergo RIRS under spinal anesthesia without sedation.
2882303|NCT03373617||Spinal anesthesia with sedation group|Patients in general anesthesia group are scheduled to undergo RIRS under spinal anesthesia with sedation.
2882304|NCT03373604|Experimental|Cognitive impairment|Alzheimer's disease (mild cognitive impairment or mild stage Alzheimer's disease dementia)
2882305|NCT03373604|Active Comparator|No cognitive impairment|Healthy controls
2882306|NCT03373591|Experimental|Liposomal Bupivacaine TAP block|73 patients will be randomized to receive an intraoperative transverse abdominis peritoneal (TAP) block with liposomal bupivacaine (LB). The solution used to perform the TAP block with LB will comprise of 20mL of liposomal bupivacaine solution, 30mL of 0.25% bupivacaine, and 100mL of normal saline.
2882307|NCT03373591|Active Comparator|Regular Bupivacaine TAP block|73 patients will be randomized to receive an intraoperative transverse abdominis peritoneal (TAP) block with regular bupivacaine (RB).The solution used to perform the TAP block with RB will comprise of 50mL of 0.25% bupivacaine and 100mL of normal saline.
2882308|NCT03373591|No Intervention|No TAP block|73 patients will be randomized to receive no TAP block as a control group.
2882309|NCT03373578|Active Comparator|earmuffs|Preterm newborns with earmuffs during the Quiet time
2882310|NCT03373578|No Intervention|control|Preterm newborns without earmuffs during de Quiet time
2882311|NCT03373565|Active Comparator|Radial|Coronary angiography using radial approach
2882312|NCT03373565|Experimental|palmar|Coronary angiography using palmar approach
2882313|NCT03373552||non responder Group|"Platelet function assay:~High platelet reactivity: PRU>230"
2882314|NCT03373552||responder Group|"Platelet function assay:~PRU<230"
2882315|NCT03373526|Active Comparator|Aerobic Physical Training|Aerobic Training
2882316|NCT03373526|Experimental|Combined Physical Training|Inspiratory Muscle Training Aerobic Training
2882317|NCT03373513|Active Comparator|Robotic single-site hysterectomy|Robotic single-site hysterectomy is performed in this arm
2882318|NCT03373513|Active Comparator|Multiport Laparoscopy|Multiport Laparoscopic hysterectomy is performed in this other arm
2882319|NCT03373500|Experimental|Low Salt Diet|Dietary salt reduction: Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
2882320|NCT03373500|No Intervention|Standard Treatment|Patients will be instructed to continue with their usual diet, therefore no advice will be given about salt reduction.
2882321|NCT03373487|Experimental|Early-intervention group|Patients follow the evidence-based cognitive rehabilitation program ReMind, which is provided via an iPad. It incorporates psychoeducation, strategy training and retraining. The intervention commenced 3 months after surgery and patients were advised to spend 3 hours per week on the program for 10 weeks.
2882322|NCT03373487|Other|Waiting-list control group|The waiting-list control group will be offered the same cognitive rehabilitation program after they have undergone all study assessments one year after surgery.
2882323|NCT03373474|Experimental|local distribution points association|Participants will receive warm acupuncture with the local distribution acupoints association on the affected arm only.
2882324|NCT03373474|Experimental|local-distal points association|Participants will receive warm acupuncture with the local-distal acupoints association on the affected arm, unaffected arm, abdomen, and legs.
2882325|NCT03373474|Active Comparator|exercise with compression sleeve|Participants will follow a program that involves the performance of 5 exercises with the wearing of compression sleeve on the affected limb.
2882326|NCT03373461|Placebo Comparator|Placebo|Placebo to LNP023
2882327|NCT03373461|Experimental|LNP023 dose 1|Dose 1 of LNP023
2882328|NCT03373461|Experimental|LNP023 dose 2|Dose 2 of LNP023
2882329|NCT03373461|Experimental|LNP023 dose 3|Dose 3 of LNP023
2882330|NCT03373448|Active Comparator|Labrida BioClean|Labrida BioClean- chitosan device.The brush bristles of the test device (Labrida BioClean® LABRIDA AS, Oslo Norway) are made of the biopolymer chitosan. Any debris left from the chitosan bristles is completely biocompatible and will dissolve or be resorbed thus not causing harm to the tissues surrounding the implant. Chitosan is made from chitin derived from shell of marine crustaceans such as shrimp and crab, however chemically modified and thus not even considered to be animally derived. Chitosan has been approved for use in e.g., surgical bandages, as a haemostatic agent and as dietary supplement used in a wide range of nutritional and health products. Chitosan has also been documented to be non-allergenic and it has been suggested that chitosan has anti-inflammatory properties.
2882331|NCT03373448|Other|Titanium curettes|Peri-implant pockets will be debrided with titanium curettes.
2882332|NCT03373435|Experimental|Treatment Group 1|patients will receive two dose regimens of exendin 9-39 and one placebo
2882333|NCT03373435|Experimental|Treatment Group 2|patients will receive two dose regimens of exendin 9-39 and one placebo (in a different sequence than Treatment Group 1)
2882334|NCT03373422|Experimental|BAY1128688 (dose 1)|One BAY1128688 tablet (lowest dose) in the morning, one placebo tablet in the evening
2882335|NCT03373422|Experimental|BAY1128688 (dose 2)|One BAY1128688 tablet (first intermediate dose) in the morning, one placebo tablet in the evening
2882336|NCT03373422|Experimental|BAY1128688 (dose 3)|One BAY1128688 tablet (second intermediate dose) in the morning, one placebo tablet in the evening
2883317|NCT03366311|Active Comparator|epiglottis lift|with epiglottis lift or without
2882337|NCT03373422|Experimental|BAY1128688 (dose 4)|One BAY1128688 tablet (second intermediate dose) in the morning and one in the evening
2882338|NCT03373422|Experimental|BAY1128688 (dose 5)|One BAY1128688 tablet (highest dose) in the morning and one in the evening
2882339|NCT03373422|Placebo Comparator|Placebo|One placebo tablet in the morning and one in the evening
2882340|NCT03373409|Experimental|Albuterol DPI 90mcg|Participants will receive albuterol 90mcg via the albuterol DPI
2882341|NCT03373409|Experimental|Albuterol DPI 180mcg|Participants will receive albuterol 180mcg via the albuterol DPI
2882342|NCT03373409|Active Comparator|Albuterol HFA MDI|Participants will receive albuterol 180mcg via the HFA MDI inhaler
2882343|NCT03373396|Other|Case group with Metavir score between F1 and F4|Patient with Metavir score between F1 and F4 will be assigned to the case group. Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage.
2882344|NCT03373396|Other|Control group with Metavir score of between F0|Patient with Metavir score of F0 will be assigned to the control group. Collected data will contain epidemiological and biological data. Blood samples with chlordecone dosage will be performed.
2882345|NCT03373383|Experimental|Padsevonil dosing regimen 1|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
2882346|NCT03373383|Experimental|Padsevonil dosing regimen 2|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
2882347|NCT03373383|Experimental|Padsevonil dosing regimen 3|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
2882348|NCT03373383|Experimental|Padsevonil dosing regimen 4|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
2882349|NCT03373383|Placebo Comparator|Placebo|Subjects randomized to the placebo group will receive a combination of several Placebo tablets to maintain the blinding.
2882350|NCT03373357|Other|Patient not SAHOS|The medical follow-up of patients no SAHOS will be assured by the investigators of the unity of cardiovascular explorations: phone consultation in 1 month, 3mois, then every 6 months, and an annual visit.
2882351|NCT03373357|Other|Patient SAHOS sailed by the ventilation in PPC and not sailed|The patients who have a SAHOS sailed by the ventilation in PPC will be estimated and followed in 3 months then every 6 months by the investigators of the service of pneumology and the unity of cardiovascular explorations. The control of the material and its tolerance, the data supplied by the service providers (bodies of ventilation at home) will be estimated by the investigator of the service of pneumology. IDE the unity of cardiovascular explorations will plan and will realize a 2nd one MAPA after 3 months of ventilation in PPC.
2882352|NCT03373344|Experimental|Experimental Group|Participants in the experimental group will receive emotional processing training exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
2882353|NCT03373344|Placebo Comparator|Control Group|"Participants in the control group will meet with the examiner the same frequency and for the same duration as those in the experimental group.~They will receive placebo control exercises administered on a laptop computer."
2882354|NCT03373331|Experimental|Experimental Group|Participants in the experimental group will receive emotional processing training exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
2882355|NCT03373331|Placebo Comparator|Control Group|"Participants in the control group will meet with the examiner the same frequency and for the same duration as those in the experimental group.~They will receive placebo control exercises administered on a laptop computer."
2882356|NCT03373318|Experimental|Experimental|Human Albumin
2882357|NCT03373318|Active Comparator|Control|Plasmalyte
2882358|NCT03373305|Experimental|Treatment (brentuximab vedotin, lenalidomide)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
2882359|NCT03373292|Experimental|Venous stenting (Group-1)|Patients in this group will undergo venous stenting treatment at once after enrollment.
2882360|NCT03373292|Experimental|Stenting one-month after routine medical treatment (Group-2)|Patients in this group will undergo routine medical treatment for one month, followed by venous stenting intervention.
2882361|NCT03373266|Active Comparator|Sevoflurane|anesthesia was maintained with Sevoflurane 1-2%.
2882362|NCT03373266|Active Comparator|isoflurane|anesthesia was maintained with isoflurane 1-2%.
2882363|NCT03373253||Participants With Diagnosis of Depression|This study will evaluate participant's socio-demographic, disease-related and treatment-related characteristics along with outcomes in routine clinical practice across the European region. Only data available within clinical practice, through routine therapeutic procedures and diagnostic assessments, will be recorded. Individual participant information will be recorded from participant's medical records or by use of specific questionnaires.
2882364|NCT03373240|Experimental|TAU plus Cognitive Remediation Program|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on learning and decision making.
2882365|NCT03373240|Placebo Comparator|TAU plus Control Tasks|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.
2882366|NCT03373227|Experimental|Prospective|25 adult male or female recipients of a heart transplant will be prospectively enrolled to once-daily therapy with Envarsus tablets. Time of initiation will follow current standard of care.
2882367|NCT03373227|No Intervention|Retrospective|25 age/gender-matched subjects who are receiving twice daily dosing with Prograf will be identified from the transplant center database and contacted to be consented, after which their results will be analyzed retrospectively.
2882368|NCT03373214|Experimental|30 µg Na-GST-1 + CPG 10104|
2882369|NCT03373214|Experimental|100 µg Na-GST-1 + CPG 10104|
2882370|NCT03373214|Experimental|100 µg Na-GST-1|
2882371|NCT03373201|Experimental|Tasimelteon|
2882372|NCT03373201|Placebo Comparator|Placebo|
2882373|NCT03373188|Active Comparator|Arm I (surgery)|Patients undergo surgery.
2882374|NCT03373188|Experimental|Arm II (VX15/2503, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
2882375|NCT03373188|Experimental|Arm III (VX15/2503, ipilimumab, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
2882376|NCT03373188|Experimental|Arm IV (VX15/2503, nivolumab, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
2882377|NCT03373175|Experimental|Ventilator 1 vs Ventilator 2|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record PS10 record PS15 record PS 20 record
2882378|NCT03373175|Experimental|Ventilator 3 vs Ventilator 4|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed.Interventions: Basal record PS10 record PS15 record PS 20 record
2882379|NCT03373175|Experimental|Ventilator 5 vs Ventilator 6|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record PS10 record PS15 record PS 20 record
2882380|NCT03373175|Experimental|Ventilator 7 vs Ventilator 8|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record PS10 record PS15 record PS 20 record
2882381|NCT03373162|Experimental|Pre-Post|Participants will receive MRI scans pre and post-Botox injection
2882382|NCT03373149|Experimental|Growth hormone/HPuFSH/GnRH antagonist|The patients receive growth hormone
2882383|NCT03373149|Active Comparator|HPuFSH/GnRH antagonist|Growth hormone is not used
2882384|NCT03373136|Experimental|Cold snaring|Polypectomy will be done without electrocautery
2882385|NCT03373136|Active Comparator|Hot snaring|Polypectomy will be performed with electrocautery
2882386|NCT03373123|Experimental|Single arm study|Patients will receive CTA, Endoscopy, and rEndosc per protocol. Intervention: Procedure: Endoscopy
2882387|NCT03373110|Experimental|Online Mindfulness Based Cognitive Therapy +Fitbit|A central aspect of MBCT is the concept of awareness. Participants practice a variety of meditation types (e.g. breath awareness) and learn to bring mindfulness to everyday situations. Awareness will be directed to elements in participants' lives that interfere with living a more productive, physically active life (e.g. thoughts and feelings that interfere with becoming more physically active; stressful situations and circumstances that prevent them from engaging in exercise). Two hundred participants will be randomized into this group.
2882388|NCT03373110|Experimental|Online Cognitive Behavioral Therapy +Fitbit|1)identifying and setting realistic exercise-based goals and intermediate goals (to maximize success to increase motivation); (2) behavioral scheduling to optimize when to exercise, identify rewards for exercising, and problem solve obstacles to exercising; and (3) identify dysfunctional, maladaptive thoughts about exercise (which decrease motivation) and skills to identify more adaptive, positive thoughts (to overcome thoughts of being too tired or too stressed to exercise). Two hundred participants will be randomized into this group.
2882389|NCT03373110|Active Comparator|Fitbit Alone|Participants assigned to the Fitbit-only control study group you will not be receiving therapy. However, they will receive a Fitbit, which they will be asked to wear over the course of 16 weeks as well as to complete the same schedule of assessments as the therapy arms. One hundred participants will be randomized into this group.
2882390|NCT03373097|Experimental|GD2-CART01|After a lymphodepleting regimen the patients will receive 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells.
2882391|NCT03373084||hamstring muscle lesions|Patients with hamstring muscle lesions in sport will be included. As usual practice they will have Magnetic Resonance Imaging (MRI) or ultrasound, and will answer to self-questionnaire
2882392|NCT03373071|Experimental|CD19-CART01|Following the lymphodepleting treatment, with patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose
2882393|NCT03373058|Experimental|Experimental group|"Cytoreductive surgery~Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession~5 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks"
2882394|NCT03373058|Active Comparator|Control group|"Cytoreductive surgery~6 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks"
2882395|NCT03373045||Cohort of US adults with severe asthma|To describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.
2882396|NCT03373032|Active Comparator|Stiper|Stiper,patients with breast cancer diagnosis during chemotherapy cycles, 1 a week, 10 weeks
2882397|NCT03373032|Active Comparator|Acupuncture|Acupuncture with needles, patients with breast cancer diagnosis during chemotherapy cycles, 1 a week, 10 weeks
2882398|NCT03373032|Placebo Comparator|Control|Control Exercise,patients with breast cancer diagnosis during chemotherapy cycles, 1 a week, 10 weeks
2882399|NCT03373019|Experimental|Chidamide combined with R-GDP|Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
2882400|NCT03373006|Experimental|Men with Gleason Score 7 prostate cancer|Men seeking focal therapy for Gleason Score 7 prostate cancer will receive Axumin PET/CT imaging to detect metastasis which will result in exclusion from laser focal therapy.
2882401|NCT03372967||Comprehensive Vaccination History Review|Patients who receive a comprehensive vaccination history review at a participating pharmacy site will be eligible to: a) receive a vaccination forecast review, b) be evaluated for unmet vaccination needs, c) receive patient education, and d) have vaccination needs met.
2882402|NCT03372954|Experimental|Bone marrow autologous cells concentrate (BMAC)|retrograde administration on non-selected BMAC via coronary sinus
2882403|NCT03372954|Placebo Comparator|Control|standard treatment o heart failure
2882467|NCT03372473|Experimental|Montelukast mixed with Loratadine|Montelukast 5mg mixed with Loratadine 5mg one dose a day
2882404|NCT03372941|Active Comparator|Alternative treatment strategy|Patient will receive a single dose of dalbavancin administered in the BJH ED or ED observation unit for ABSSSI followed by discharge w/ close Infectious Disease outpatient clinic follow-up.
2882405|NCT03372941|No Intervention|Usual care|"Patients will receive usual care (i.e., hospital admission for intravenous antibiotics - typically, vancomycin) - antibiotic and doses to be determined at the discretion of the treating clinician (both in the BJH ED and on the BJH inpatient ward)."
2882406|NCT03372928|Active Comparator|Low EAA|EAA dose provided at 0.10 g/kg body mass
2882407|NCT03372928|Experimental|High EAA|EAA dose provided at 0.30 g/kg body mass
2882408|NCT03372915|Active Comparator|Standard Exposure|This arm will receive exposure therapy conducted according to standard care practices.
2882409|NCT03372915|Experimental|Exposure + Inhibitory Learning|This arm will receive exposure therapy conducted according to principles of inhibitory learning.
2882410|NCT03372902||normal mammograms (BI-RADS 1 or 2)|
2882411|NCT03372902||suspicious lesion group (BI-RADS 4)|
2882412|NCT03372889|Active Comparator|Patient educaiton materials Print based|Patients are randomly assigned to view print based educational material.
2882413|NCT03372889|Active Comparator|Patient educaiton materials Media Based|Patients are randomly assigned to view media based educational material.
2882414|NCT03372876|Experimental|Protein-carbohydrate (PC) (protein intake after exercise)|ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon. The resistance exercise was performed equally by both groups.
2882415|NCT03372876|Placebo Comparator|Carbohydrate-protein (CP) (protein intake far to exercise)|ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. The resistance exercise was performed equally by both groups.
2882416|NCT03372863||Cardiac surgery patients|
2882417|NCT03372850|Experimental|Sequence Group 1|Period 1: Reference Drug(HGP1705) Period 2: Test Drug(HIP1601)
2882418|NCT03372850|Experimental|Sequence Group 2|Period 1: Test Drug(HIP1601) Period 2: Reference Drug(HGP1705)
2882419|NCT03372837|Experimental|SyB L-0501|"The administration of SyB L-0501 at 120 mg/m^2/day by intravenous infusion on Day 2 and Day 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m^2, 90 mg/m^2 or 120 mg/m^2/day on Day 2 and Day 3 will be followed by 18 days of observation."
2882420|NCT03372824||Pregnant women|Primiparas above 25 years of age, singleton pregnancy
2882421|NCT03372811|Active Comparator|TC cream (10%)|
2882422|NCT03372811|Placebo Comparator|Vehicle|
2882423|NCT03372785|Experimental|Active Intervention|Complete Revascularization of CTO and non-CTO lesions
2882424|NCT03372785|Other|Conventional Intervention|Non-CTO vessel revascularization
2882425|NCT03372772|No Intervention|Control group|Control group - patients with only levothyroxine therapy
2882426|NCT03372772|Experimental|Intervention group|Intervention Group- Patients with levocarnitine supplementation in addition to levothyroxine therapy
2882427|NCT03372759|Active Comparator|study group air|airtamponade
2882428|NCT03372759|Sham Comparator|study group saline|saline
2882429|NCT03372746||1|Participants across multiple sites with AMD from the original cohort of study participants enrolled in the AREDS2
2882430|NCT03372733|Experimental|Group 1|Subjects randomized to the control olive oil armwill take the equivalant to 3g of control /day in twodivided doses (4 capsules a day) for 8 +/- 2 weeks andcross-over to the palmitoleate-rich oil
2882431|NCT03372733|Experimental|Group 2|Subjects randomized to the Subjects randomizedto the control olive oil arm will take the equivalant to3g of control /day in two divided doses (4 capsulesa day) for 8 +/- 2 weeks and cross-over to thepalmitoleate-rich oil arm will take the equivalant to3g of control /day in two divided doses (4 capsulesa day) for 8 +/- 2 weeks and cross-over to the contrololive oil
2882432|NCT03372720|Experimental|Arm I (fractional CO2 laser therapy)|Patients undergo fractional CO2 laser therapy at 3 time points 30 days apart.
2882433|NCT03372720|Sham Comparator|Arm II (sham laser therapy)|Patients undergo sham laser therapy at 3 time points 30 days apart. Patients may then crossover to Arm I.
2882434|NCT03372707|Experimental|Intervention Arm|Patients randomized to the intervention arm will have the results of the Cuff Leak Test (CLT) (whether failed or passed) communicated to the treating physician; the treating physician will decide whether to proceed with extubation or not based on the CLT results. It is at the discretion of the treating physician to provide corticosteroids (4-5 mg of intravenous dexamethasone every six hours for up to 24 hours, with the last dose given one hour preceding extubation) and/or delay extubation by 24 hours should the patient fail the CLT.
2882435|NCT03372707|No Intervention|Control Arm|In the control arm of this trial; the treating physicians and healthcare workers will be blinded to the results of the Cuff Leak Test (CLT); therefore, the Respiratory Therapist (RT) will proceed with extubation without delay or administering systemic steroid, regardless to the CLT results.
2882436|NCT03372694|Experimental|Chemotherapy+Training+TCM|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Rehabilitation training is mainly composed of gymnastic qigong, which will be started in one month after operation.~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe, detoxication and resolving masses recipe. Patients will take harmonizing stomach recipe granules for the first week after chemotherapy and syndrome differentiation granules in TCM for second weeks from the end of chemotherapy. The patient will take TCM granules for 3 months."
2882437|NCT03372694|Experimental|Chemotherapy+Education+TCM|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Patients who received rehabilitation education will not accept rehabilitation training.~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe, detoxication and resolving masses recipe. Patients will take harmonizing stomach recipe granules for the first week after chemotherapy and syndrome differentiation granules in TCM for second weeks from the end of chemotherapy. The patient will take TCM granules for 3 months."
2882468|NCT03372473|Active Comparator|Montelukast|Montelukast 5mg one dose per day
2882683|NCT03371030|Experimental|Pronator quadratus reparation|Surgical Intervention: Radius fracture teated with plate and pronator quadratus muscle repair.
2882438|NCT03372694|Placebo Comparator|Chemotherapy+Education+Placebo|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Patients who received rehabilitation education will not accept rehabilitation training.~Patients who received rehabilitation education will not accept rehabilitation training.~We compromise the raw materials for the placebo including food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages. The patient will take placebo granules for 3 months."
2882439|NCT03372681|Experimental|Antiperistaltic|In this group patients undergo the distal gestrectomy with antiperistaltic Billroth II + Braun anastomosis
2882440|NCT03372681|Active Comparator|Isoperistaltic|In this group patients undergo the distal gestrectomy with isoperistaltic Billroth II + Braun anastomosis
2882441|NCT03372668|Other|All Participants|Each study participant will progress through the three, 4-week study periods in the ABA withdrawal design in the same, designated order. The first and third 4-week study periods (or the A periods) have no intervention and only consist of twice weekly data collection. The second 4-week study period (or the B period) will include the twice weekly delivered massage therapy combined with components of mirror therapy intervention.
2882442|NCT03372642||Subtalar endorthesis|Patients who underwent subtalar endorthesis for flexible pediatric flatfoot
2882443|NCT03372629|Experimental|ID-085, single ascending dose (Part A)|ID-085 administered at different single dose levels in a sequential manner, and in a maximum of 6 dose levels starting from 10 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort)
2882444|NCT03372629|Placebo Comparator|Placebo, single ascending dose (Part A)|Matched placebo administered as single ascending doses in parallel to ID-085
2882445|NCT03372629|Experimental|ID-085 multiple ascending dose (Part B)|ID-085 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be either 10 or 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A
2882446|NCT03372629|Placebo Comparator|Placebo, multiple ascending dose (Part B)|Matched placebo administered as single ascending doses in parallel to ID-085
2882447|NCT03372616||All participants|Aortic blood pressure, LV filling pressrue, and LV volume will be measured in all participants. Meanwhile, echocardiography and non-invasive aortic blood presure measurement will be performed. Three devices will be used in non-invasive aortic blood presure measurement, including Sphygmocor (AtCor Medical, Australia), PulsePen (DiaTecne SRL, Italy), and Mobil-O-Graph (IEM, Germany). In conclusion, all participants will receive invasive and non-invasive left ventricular diastolic function assessment, together with invasive and non-invasive aortic blood pressure assessment.
2882448|NCT03372603|Experimental|Treatment Sequence AB|Subjects will receive GSK2798745 matching placebo tablets (two tablets on Day 1 followed by one tablet once daily for 6 days), via oral route (treatment period of total 7 days). After a washout period of 14 to 21 days, subjects will then receive 4.8 mg (two tablets of 2.4 mg) GSK2798745 on Day 1, followed by 2.4 mg GSK2798745 tablets once daily for 6 days via oral route (treatment period of total 7 days).
2882449|NCT03372603|Experimental|Treatment Sequence BA|Subjects will receive 4.8 mg (two tablets of 2.4 mg) GSK2798745 on Day 1, followed by 2.4 mg GSK2798745 tablets once daily for 6 days via oral route (treatment period of total 7 days). After a washout period of 14 to 21 days, subjects will then receive GSK2798745 matching placebo tablets (two tablets on Day 1 followed by one tablet once daily for 6 days), via oral route (treatment period of total 7 days).
2882450|NCT03372590|Experimental|NICU-based rehabilitation bundle|Patients identified to be at high risk for cerebral palsy will be enrolled after parental consent is obtained to the NICU rehabilitation program. This program consists of maternal-driven evidence based intervention that include: vocal soothing, scent exchange, comforting touch, kangaroo care, and infant massage. These intervention will be provided at GA-appropriate intervals.
2882451|NCT03372590|Other|Standard of care|Infants not participating in the intervention study will be provided with standard or care. Interventions include kangaroo care, physical therapy and infant massage provided by NICU staff.
2882452|NCT03372577|Experimental|patient and partner|
2882453|NCT03372577|Experimental|patient ,partner and cardiac rehabilitation team|
2882454|NCT03372577|Active Comparator|Treatment as usual|
2882455|NCT03372564|Experimental|Hip Capsule Repair|Patients in the intervention group (Hip capsule repair) will undergo initial diagnostic arthroscopy of the hip. Two to three standard portals (anterolateral, mid anterior, distal antero-lateral, posterolateral) will be used during the entire procedure to assess and treat the patient. After establishing standard portals, an interportal capsulotomy is completed to allow for complete evaluation of the central compartment of the hip. In the central compartment, significant and obvious pathologies will be addressed accordingly. Following addressing central compartment pathologies, cam impingement type lesions in the peripheral compartment will be treated. Once all pathologies are addressed, the interportal capsulotomy10 will be repaired by using simple interrupted sutures with absorbable suture (Number 1 Vicryl). Three to four simples sutures will be placed and tied using arthroscopic technique.
2882456|NCT03372564|No Intervention|No Hip Capsule Repair (Control)|Patients in the control group (no hip capsule repair) have the same portals utilized and will have the same interportal capsulotomy performed. They will have all central and peripheral compartment pathologies addressed in the same way that the study group does. At the conclusion of the case, the hip capsule will be left open and not repaired.
2882457|NCT03372538||multidisciplinary team group|500 patients of placenta accreta managed by obstetricans and urologists
2882458|NCT03372538||obstetricians only group|500 patients of placenta accreta managed by obstetricans only
2882459|NCT03372525|Experimental|HFOV|Ventilated infants were randomized to HFOV.
2882460|NCT03372525|Active Comparator|CMV|Ventilated infants were randomized to CMV.
2882461|NCT03372512||Fluid overload (Liters) ≥ median|
2882462|NCT03372512||Fluid overload (Liters) < median|
2882463|NCT03372499|Experimental|nutritional management group|diet management strategy for encephalopathy
2882464|NCT03372499|No Intervention|control group|Current ordinary guidance for patients after TIPS placement performed by trained nurse in the inpatient department
2882465|NCT03372486|Active Comparator|Bupivacaine plus naloxone|Patients will receive brachial plexus block using bupivacaine plus naloxone.
2882466|NCT03372486|Placebo Comparator|Bupivacaine|Patients will receive brachial plexus block using bupivacaine.
2882469|NCT03372460|Active Comparator|Active Stimulation|Active stimulation (tDCS) will be used in the dose of 2mA /25 min per day, for 6 sessions over the course of 2 weeks (3 sessions per week).
2882470|NCT03372460|Sham Comparator|Sham Stimulation|Sham tDCS will include a 30-second ramp up to 1mA, 30 seconds of stimulation at 1mA, followed by a 30-second ramp down to off. The device will remain off for the remainder of the session. This process will be used for each of the 6 sessions during a 2 week period.
2882471|NCT03372447|Experimental|Megadose multivitamin complex|Intramuscular injection of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg
2882472|NCT03372421|Experimental|Social Story|Participants will read information about what to expect from the assessment in the format of a Social Story
2882473|NCT03372421|Active Comparator|Standard Information|Participants will read standard information about what to expect from the assessment.
2882474|NCT03372408||Program Clients|Parkdale Parents' Primary Prevention Project (5P's) clients
2882475|NCT03372395|Other|Group 1|Standard treatment plus short-term (3 months) vaginal Lactobacillus rhamnosus BMX 54 implementation
2882476|NCT03372395|Experimental|Group 2|Standard treatment plus long-lasting (6 months) Lactobacillus rhamnosus BMX 54 administration
2882477|NCT03372382|Active Comparator|ibuprofen plus acetaminophen|women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen
2882478|NCT03372382|Experimental|ibuprofen plus acetaminophen/hydrocodone|women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen/hydrocodone (Norco)
2882479|NCT03372369|Active Comparator|CDC Poster|After collecting baseline contraceptive knowledge, method preference, if participant were to switch methods during the next year, and current perceived pregnancy risk, participants will view CDC poster for contraceptive effectiveness.
2882480|NCT03372369|Experimental|Patient-Centered Poster|After collecting baseline contraceptive knowledge, method preference, if participant were to switch methods during the next year, and current perceived pregnancy risk, participants will view Patient-Centered poster for contraceptive effectiveness.
2882481|NCT03372356||Neuroendocrine tumors|Patients with neuroendocrine tumors will be given access to an application that monitors distress, anxiety, depression, self-perceived burden, and resilience at regular intervals for 3 months lasting for 24 months.
2882482|NCT03372330||Sepsis with PAD|"Patients admitted to the intensive care unit with the diagnosis of sepsis (quick SOFA score >=2) and with ankle-brachial index < 0.9 or vascular Duplex confirmed peripheral artery disease.~* Standard care for sepsis and PAD"
2882483|NCT03372330||Sepsis without PAD|"Patients admitted to the intensive care unit with the diagnosis of sepsis (quick SOFA score >=2) and with ankle-brachial index >= 0.9 or vascular Duplex found no evidence of peripheral artery disease.~* Standard care for sepsis"
2882484|NCT03372317||Non-demented elders|Participants aged 55-90 that are cognitively normal or have mild cognitive impairment will receive 18F-MK-6240 to identify the presence of tau protein in the brain.
2882485|NCT03372304|Experimental|API+PCA|Infusion of ropivacaine 0.2 %, 10 mL, every 8th hour. Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
2882486|NCT03372304|Active Comparator|CI+PCA|Continuous infusion of ropivacaine 0.2 %, 6 mL/hour. Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
2882487|NCT03372304|Active Comparator|PCA only|Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
2882488|NCT03372291|Experimental|Psychological app|"Psychological intervention consist of four components~Supportive psychotherapy interventions to help patients deal with the initial shock of diagnosis, cope with the loss of independence and abrupt life disruptions, and provide validation and reassurance;~Psychoeducation to manage expectations and enhance preparedness for extended hospitalization and mobilize social supports;~Psychosocial skill-building to promote effective coping strategies and facilitate acceptance while living with uncertainty;~Self-care to promote positive health behaviors and enhance patients' sense of control especially as they transition from the hospital to outpatient care.~The psychological intervention will consist of five sessions (20-25 minutes each) that patients will start during their first week of admission for intensive chemotherapy and continue weekly for five weeks after diagnosis"
2882489|NCT03372291|Active Comparator|Usual Care|"Participants receiving usual care will not have access to the psychological intervention app. -They will receive usual leukemia care with all the supportive care measures instituted by the leukemia team.~Patients in usual care will also meet with the leukemia social worker based on their request or at the discretion of the treating leukemia team"
2882490|NCT03372278||Patients who received the Maxera Cup|Subjects in need of a total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Maxera Cup.
2882491|NCT03372265|Experimental|API+PCA|Infusion of ropivacaine 0.2 %, 15 mL, every 10th hour. Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
2882492|NCT03372265|Active Comparator|CI+PCA|Continuous infusion of ropivacaine 0.2 %, 6 mL/hour. Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
2882493|NCT03372265|Active Comparator|PCA only|Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
2882494|NCT03372252|Experimental|Successful weaning|Patients extubated after the success of the breathing test in spontaneous ventilation under artificial nose and always extubated after seven days.
2882495|NCT03372252|Experimental|Failure to wean|Patients who failed the breathing test in spontaneous ventilation under artificial nose and not extubated or patients extubated after the success of the weaning test in spontaneous ventilation under artificial nose but reintubated within seven days.
2882496|NCT03372239|Experimental|Part 1: Bioavailability and Food Effect|"Subjects will be randomized to receive the following 3 regimens in randomized sequence:~Single dose of Indoximod base formulation under fasting conditions~Single dose of Indoximod HCL (salt) formulation under fed conditions~Single dose of Indoximod HCL (salt) formulation under fasting conditions"
2882497|NCT03372239|Experimental|Part 2: Single Ascending Dose|
2882536|NCT03371953|Active Comparator|Atracurium group|Atracurium 0.6 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
2882537|NCT03371953|Active Comparator|Vecuronium-Atracurium group|Vecuronium 0.04 mg/kg + atracurium 0.3 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
2882684|NCT03371030|Active Comparator|No pronator quadratus reparation|Surgical Intervention: Radius fracture with plate without pronator quadratus muscle repair.
2882498|NCT03372226|Experimental|Online self-help program|"The intervention group receives the login data for the online program directly following the baseline assessment. The program consists of 10 modules with many interactional exercises and homework-sheets.~Themes that are addressed in the online-program are for example self-esteem, sleep hygiene, problem solving strategies, mindfulness-based relaxation and attention exercises as well as gambling-specific topics such as money/debt management and impulse control. In addition, the user learns to modify negative and gambling-specific thought distortions, to integrate positive activities into his/her daily routine, strategies to deal with the urge to play as well as ways to regulate debts and to prevent relapse."
2882499|NCT03372226|No Intervention|Wait-list control group|The participants of the wait-list control condition do not receive any new intervention during the intervention period of 8 weeks, but may continue any treatment that has already been started before, including medication. Participants in the wait-list control condition receive full access to the program after completion of the post-assessment.
2882500|NCT03372213||2003-2004|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
2882501|NCT03372213||2005-2006|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
2882502|NCT03372213||2011-2012|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
2882503|NCT03372213||2013-2014|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
2882504|NCT03372200|Experimental|FYU-981|
2882505|NCT03372200|Active Comparator|Febuxostat|
2882506|NCT03372187|Experimental|DIET-MS|This group will follow a low glycemic load diet plan prescribed to them by a health coach and will receive information on exercise as well. This group will have weekly calls with the telehealth coach and will be provided access to the eHealth platform.
2882507|NCT03372174|Experimental|Mechanical ventilation group|patients with mechanical ventilation during cardiopulmonary bypass for cardiac surgery
2882508|NCT03372174|Active Comparator|Control group|patients without mechanical ventilation during cardiopulmonary bypass for cardiac surgery
2882509|NCT03372161|Experimental|SP-102|SP-102
2882510|NCT03372161|Placebo Comparator|Placebo|Placebo
2882511|NCT03372148|Experimental|pHRMi in evaluation of swallowing function|Pharyngeal High Resolution Manometry and Impedance (pHRMi) evaluation of swallowing function at baseline, 3 months post radiation, then at 9 months
2882512|NCT03372135||Trendelenburg group|Patients in trendelenburg group take trendelenburg position and have CO2 pneumoperitoneum. Cerebral oxygen monitor will be needed. Take notes per hour for HR, MAP, CVP, SpO2, SrO2 and etCO2.Preoperative and postoperative ABG, S-100beta , CRP and cognitive dysfunction scales will be tested.
2882513|NCT03372135||Control group|Patients in control group take horizontal position. Cerebral oxygen monitor will be needed. Take notes per hour for HR, MAP, CVP, SpO2, SrO2 and etCO2.Preoperative and postoperative ABG, S-100beta , CRP and cognitive dysfunction scales will be tested
2882514|NCT03372122|Active Comparator|SAGE Chlorhexidine Gluconate Cloth|Ready to use disinfectant cloth
2882515|NCT03372122|Active Comparator|HUBS with Hibiclens|Dry cloths to be used with water and disinfectant
2882516|NCT03372109|Active Comparator|Modified Fasting Arm|Dietary Supplements administered daily for 52 days with a meal replacement shake administered two days per week for the study duration
2882517|NCT03372109|Placebo Comparator|Placebo|Multivitamin tablet administered daily for 52 days
2882518|NCT03372096|Experimental|All patients|Patients will receive the Prostatic Artery Embolization procedure.
2882519|NCT03372083|Experimental|Deferasirox|Crushed deferasirox (ICL670) FCT for oral use daily. Deferasirox FCT dosing is based on subject's weight
2882520|NCT03372070|Experimental|cNEP|silicone collar applied to anterior neck
2882521|NCT03372057|Experimental|Dose Optimization Phase: Cohort 1|Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a per-patient basis to 50 mg and then 75 mg, based on the patient's response to and tolerance of therapy, in 28-day cycles.
2882522|NCT03372057|Experimental|Dose Optimization Phase: Cohort 2|Duvelisib 75 mg PO BID, administered in 28-day cycles.
2882523|NCT03372057|Experimental|Expansion Phase|Duvelisib administered in 28-day cycles (dose determined in Optimization Phase)
2882524|NCT03372044|Experimental|PF-06865571|Treatment
2882525|NCT03372031|Experimental|Active-Passive|Active Piano training (8 sessions in two weeks) followed by listening to piano training (8 sessions in 2 weeks) (Passive condition)
2882526|NCT03372031|Experimental|Passive-Active|Passive piano training listening (8 sessions in two weeks) followed by active piano training (8 sessions in two weeks)
2882527|NCT03372018|Experimental|Promotora-led intervention (PLI)|PLI -DPP protocol was developed from original DPP materials and culturally tailored for the target population based on formative research. The core PL-DPP curriculum includes 14 group sessions of 90 minutes duration. One promotora will lead each session in Spanish using behavioral strategies to discuss lifestyle behaviors, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
2882528|NCT03372018|Active Comparator|Usual care (UC)|UC participants will receive standard educational materials in Spanish discussing mental health and diabetes prevention. UC participants will be encouraged to continue all routine medical care during the study.
2882529|NCT03372005|Experimental|Floorball|The subjects in this group are set to play floorball three times pr. week for 39 weeks.
2882530|NCT03372005|No Intervention|Control|This group functions as a control group, that will continue the normal lifestyle throughout the study.
2882531|NCT03371992|Other|Lung Cancer Patients|Lung cancer patients receiving one of three standard of care immunotherapy drugs including nivolumab, pembrolizumab or atezolizumab. 3D-EX will be performed on biopsies from patients enrolled in the study to correlate with the patient's evaluation of response by RECIST.
2882532|NCT03371979|Experimental|Pegzilarginase plus Pembrolizumab|Phase 1 & 2
2882533|NCT03371966|Active Comparator|High Nitrate Beetroot Juice|Beetroot juice high in nitrate will contain approximately 10.0 mmole nitrate per 120 ml.
2882534|NCT03371966|Placebo Comparator|Low Nitrate Beetroot Juice|Beetroot juice low in nitrate will contain approximately 0.5 mmole nitrate per 120 ml.
2882535|NCT03371953|Active Comparator|Vecuronium group|Vecuronium 0.08 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
2882538|NCT03371940|Experimental|Talk therapy (CBT)|"Participants randomized the talk therapy arm received 10 weeks of CBT or talk therapy. The goal of CBT was to provide individuals with skills and concepts that they may use to: 1) manage and reduce depressive symptoms; 2) prevent the onset and severity of future depressive episodes; and 3) generalize these skills to diabetes management.~CBT interventionists facilitated patient management of depressive symptoms by providing participants with:~Education about depression and the cognitive-behavioral therapy model;~A safe relationship for participants to explore their symptom patterns and try to new tools to address them;~Coaching as participants fully engage emotional and behavioral strategies."
2882539|NCT03371940|Experimental|Exercise (EXER)|Participants randomized to the exercise arm were enrolled in a 12-week physical activity intervention designed to increase aerobic physical activity. Participants were asked to complete 100 minutes of aerobic activity in Week 1, 125 minutes in Week 2, and 150 minutes per week of physical activity in Weeks 3-12. In addition, participants received 6 exercise training classes in which safe exercise practices were introduced and practiced, free access to a local exercise facility, use of a pedometer, completion of activity logs each week, and received an exercise workbook that addressed social and motivational aspects of physical activity.
2882540|NCT03371940|Experimental|Talk therapy + exercise (CBT+EXER)|Participants randomized to the combination therapy received both talk therapy and exercise as detailed above.
2882541|NCT03371940|Placebo Comparator|Usual care (UC)|Participants randomized to usual care received no study intervention.
2882542|NCT03371927|No Intervention|Standard Feeding|The control group consisted of prescribed volumes of oral and/or gavage feedings at 2 or 3-hour intervals, with feeding time restricted to ≤30 minutes per feeding.
2882543|NCT03371927|Experimental|SINC Feeding Protocol|Safe individualized nipple-feeding competence (SINC) protocol
2882544|NCT03371914|Experimental|Treatment: Management + data training|"The treatment group in the study will receive a 5-day training. The first two days of the training will consist of introducing the data collection tools and collecting baseline data. Days three through five of the training will consist of a variety of management topics.~On a monthly basis, the treatment group will receive data visualizations that will compare their site's performance that month to pervious performance and to other sites in the study. Both treatment and control groups will collect information regarding input costs and number of services provided on a monthly basis."
2882545|NCT03371914|No Intervention|Control: data training only|The control group will receive only a 2-day training which will focus on data collection alone. Both treatment and control groups will collect information regarding input costs and number of services provided on a monthly basis.
2882546|NCT03371901|Experimental|Physical therapy with BFR-LLST|
2882547|NCT03371888|Experimental|PRP injections|Intramuscular injection of Platelet-Rich Plasma into the masseter and temporalis muscle
2882548|NCT03371888|Placebo Comparator|0,9% NaCl injections|Intramuscular injection of 0,9% NaCl into the masseter and temporalis muscle
2882549|NCT03371875|Experimental|Transition Clinics|Clinics in this arm will assess the adolescent's readiness for youth-to-adult transition using the TRAQ questionnaire. Physicians will then be given reminders based on the subject's deficiencies in transition management, and given the opportunity to intervene.
2882550|NCT03371875|No Intervention|Control Clinics|Clinics in this arm will assess the adolescent's readiness for youth-to-adult transition using the TRAQ questionnaire. No reminders will be provided to providers for care transition.
2882551|NCT03371862|Experimental|Test group|
2882552|NCT03371849|Experimental|Group 1|Reference Drug → Test Drug
2882553|NCT03371849|Experimental|Group 2|Test Drug → Reference Drug
2882554|NCT03371836|Other|open label single treatment arm|open label
2882555|NCT03371823|Other|Normotensive|Normotensive PMW will complete an experimental visit to assess vascular function. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visit to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
2882556|NCT03371823|Experimental|Hypertensives|Hypertensive women will be tested at baseline and then administered Losartan 50 mg once a day at night for 14 days. Vascular function is measured at baseline and again after 2 weeks of losartan. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visits to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
2882557|NCT03371810|Experimental|Bright light therapy|"Mobile therapeutic light (10.000 LUX), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total.~Additional treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise) is allowed."
2882558|NCT03371810|Experimental|Physical exercise|"Aerobic exercise of moderate-to-vigorous intensity three days a week plus muscle-strengthening exercises two days a week during 10 weeks in total.~Additional treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise) is allowed."
2882559|NCT03371810|No Intervention|Treatment as usual|Stable treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise).
2882560|NCT03371797||Treatment group|Valsartan, Amlodipine single pill combination.The recommended dosage of AVSAR (Valsartan/Amlodipine) is one tablet per day.
2882561|NCT03371784|Active Comparator|Hydrocortisone|Patients who meet the inclusion criteria, with a CWP above the derived cutoff, with continuous elevation of the pressure line, who are randomized to i.v hydrocortisone administration.
2882562|NCT03371784|Placebo Comparator|Placebo|Patients who meet the inclusion criteria, with a CWP above the derived cutoff, with continuous elevation of the pressure line, who are randomized to placebo (sodium chloride 0.9%).
2882563|NCT03371771|Experimental|Volunteer-delivered Behavioral Activation|
2882567|NCT03371745|Active Comparator|PGS-FET|The PGS-FET arm involves deferred transfer of embryos following cryopreservation at the blastocyst stage following pre-implantation genetic screening. This arm will culture embryos to day 5/6/7 (blastocyst stage). The embryos will be cryopreserved following trophectoderm biopsy. A subsequent frozen embryo transfer cycle will be performed during which 1 euploid (chromosomally normal) embryo will be thawed and transferred.
2882568|NCT03371745|Active Comparator|FET|"The Freeze only arm involves the deferred transfer of embryos following cryopreservation. In this arm embryos will be cryopreserved. A subsequent frozen embryo transfer cycle will be performed during which one or more embryos will be thawed and transfered based on local clinical site, age-specific embryo number transfer guidelines."
2882569|NCT03371745|Active Comparator|Fresh|The Fresh arm will have an immediate embryo(s) transfer based on local clinical site, age-specific embryo number transfer guidelines within the stimulation cycle.
2882570|NCT03371732|Other|Groupe 1|G1 : Motivational Intervention group
2882571|NCT03371732|Other|Groupe 2|G2 : Educational advises group
2882572|NCT03371719|Placebo Comparator|Arm 1 (Radiation Therapy + Placebo)|Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive placebo PO QD on Days 1-30. Treatment repeats every 30 days for up to 6 courses (6 months) in the absence of disease progression or unacceptable toxicity.
2882573|NCT03371719|Experimental|Arm 2 (Radiation Therapy + Apalutamide)|Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive apalutamide PO QD on Days 1-30. Treatment repeats every 30 days for up to 6 courses (6 months)in the absence of disease progression or unacceptable toxicity.
2882574|NCT03371706|Experimental|Evidence-Based Treatment 1|
2882575|NCT03371706|Active Comparator|Evidence-Based Treatment 2|
2882576|NCT03371693|Experimental|HIPEC|"Patients will undergo a CRS plus HIPEC and IVCT. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the abdominal cavity is bathed in a warm solution of anti-cancer medications for 60 minutes.~A single drug lobaplatin(30mg/m2)will be administered in normal saline via HIPEC and it will be continued for 60 minutes in the hyperthermic phase (41°C-43°C). HIPEC will be performed at the 1st, 3rd and 5th day after CRS. The intravenous chemotherapy(IVCT) will start from 7th-14th day after CRS."
2882577|NCT03371693|Other|Non HIPEC|Patients will undergo only CRS and IVCT. Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS.
2882578|NCT03371680|Experimental|Injection of stable isotopes|Injection of 1-13 Carbon Leucine and deuterated water: all patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
2882579|NCT03371667|Experimental|Methotrexate|"5mg/Kg/day methotrexate for 4 weeks then 3 mg/m2 every two weeks for 12 weeks~2mg/kg/day PO prednisone prednisone (or 1.6 mg/kg/day IV methylprednisolone) once daily.~10 mg po or iv lederfolin after each MTX administration"
2882580|NCT03371667|Placebo Comparator|Placebo|"Once a week placebo for 4 weeks then every two weeks for 12 weeks~2 mg/kg/day PO prednisone (or 1.6 mg/kg/day IV methylprednisolone) once daily.~10 mg po or iv lederfolin after each placebo administration"
2882581|NCT03371654|Experimental|Estradiol 2mg|Women will be randomized and asked to take the study drug (2mg E2 dose) at home 5 hours before their appointment on Day 2.
2882582|NCT03371654|Experimental|Estradiol 4mg|Women will be randomized and asked to take the study drug (4mg E2 dose) at home 5 hours before their appointment on Day 2.
2882583|NCT03371654|Placebo Comparator|Placebo|Women will be randomized and asked to take the study drug (Placebo) at home 5 hours before their appointment on Day 2.
2882584|NCT03371641|Other|Alcoholic exposure group|Blood sample (mother) Cord blood sample Placenta sample ASQ parental questionnaire WPPSI - IV and NEPSY development scales Scale of Conners SCQ questionnaire
2882585|NCT03371641|Other|Control|Blood sample (mother) Cord blood sample Placenta sample ASQ parental questionnaire WPPSI - IV and NEPSY development scales Scale of Conners SCQ questionnaire
2882586|NCT03371628|Experimental|Group VNI 1h|Intervention: Non invasive ventilation, applied for 1 hour
2882587|NCT03371628|No Intervention|Group O2|Oxygen therapy
2882588|NCT03371615|Active Comparator|Fermented IF + LBG + Gos Fos|Fermented infant formula with Locust bean gum and Gos Fos
2882589|NCT03371615|Placebo Comparator|Fermented IF +LBG|Fermented infant formula with Locust bean gum
2882590|NCT03371602|Experimental|control group|non-septic mesocolic programmed abdominal or thoracic surgery: gastrectomy, esophagectomy, pancreatectomy, hepatectomy
2882591|NCT03371602|Experimental|sepsis group|Abdominal or thoracic surgery in a septic context (peritonitis, mediastinitis, pleural abscess)
2882592|NCT03371602|Experimental|mechanical ventilation group|Patient in brain death for whom a multi-organ sampling is planned
2882593|NCT03371602|Experimental|mechanical ventilation - sepsis group|Patient under controlled mechanical ventilation to undergo abdominal or thoracic surgery in a septic context (peritonitis, mediastinitis, pleural abscess)
2882594|NCT03371589|Experimental|no P.O corticosteroids|Steroids injection
2882595|NCT03371576||2 different torical intraocular lenses|
2882596|NCT03371563||elderly patients|
2882597|NCT03371563||younger adult patients|
2882598|NCT03371563||controls|
2882599|NCT03371550|Experimental|Radiochemotherapy|Induction chemotherapy with docetaxel and cisplatine and concomitant radiotherapy
2882600|NCT03371537||Hepatectomy|Patient undergoing laparotomy for liver resection. The aim is to measure the flow rates in the portal vein and the hepatic artery.
2882601|NCT03371524||Native valves_30 seconds loops|Patient with calcified aortic stenosis on native valve: record of a 30 second loop during routine cardiac echography.
2882602|NCT03371524||Native valves_30 and 60 seconds loops|Patient with calcified aortic stenosis on native valve: record of a 30 second loop and a 60 second loop during routine cardiac echography.
2882603|NCT03371524||Bioprosthesis_30 seconds loops|Patient with calcified aortic stenosis on bioprosthesis: record of a 30 second loop during routine cardiac echography.
2882685|NCT03371017|Experimental|Atezolizumab|Participants will receive Atezolizumab on day 1 of each 3-week treatment cycle
2882604|NCT03371511||MiLC Cohort|"Participants donated HM from two consecutive pumping sessions at home. Women pumped once with their own pump and milk collection kit, and once with a sterile and sterile collection kit. Both pumping sessions occurred at participants' homes between 0700 and 1100 hours. The second pumping session occurred within 3 hr (+/- 30 min) after the beginning of the first. Randomization was used to determine which pump was used first. Women elected from which breast they donated their HM and were asked not to nurse on that side 2 hr before the first pumping session and not until after the second. Before women pumped with their own pump, swabs were taken of the breast from which HM was donated, the women's dominant hand, their own bottle/flange, their own pumps (port of pump and tubing), and their babies' mouths.~There was only one group but stratified enrollment was used to ensure equal numbers of women whose infants consumed HM only and women whose infants consumed HM and complementary foods."
2882605|NCT03371498|Experimental|Methylprednisolone Group|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L will receive methylprednisolone
2882606|NCT03371498|Placebo Comparator|Control Group|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L will receive placebo
2882607|NCT03371485|Active Comparator|Arm A|Patients with advanced NSCLC, to receive AST-VAC2.
2882608|NCT03371485|No Intervention|Arm B|Patients with advanced NSCLC, receiving no AST-VAC2 treatment and serving as a control for Arm A.
2882609|NCT03371485|Active Comparator|Arm C:|Patients with previously treated NSCLC, currently disease free, to receive AST-VAC2 in the adjuvant setting.
2882610|NCT03371485|No Intervention|Arm D:|Patients with previously treated NSCLC, currently disease free, receiving no AST-VAC2 treatment and serving as a control for Arm C.
2882611|NCT03371472|Other|VALE - PVL leak sizing balloon - mitral|Placement and inflation of PVL leak sizing balloon for visualisation and measuring of paravalvular leak located in mitral position - Balton developed investigational balloon
2882612|NCT03371472|Other|VALE - PVL leak sizing balloon - aortic|'Placement and inflation of PVL leak sizing balloon for visualisation and measuring of paravalvular leak located in aortic position - Balton developed investigational balloon
2882613|NCT03371459|Experimental|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
2882614|NCT03371459|Active Comparator|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
2882615|NCT03371446||Smokers/Non-smokers|It was an experimental study with parallel controls, comparing two groups, a group with patients who smoked for more than 10 years, consuming 10 more cigarettes per day and diagnosing chronic periodontitis (case) and another group (control) were non-smokers with chronic periodontitis, according to the standard of World Health Organization (WHO) definition of the smoking population
2882616|NCT03371420|Experimental|124I-PU-AD|A single dose of 124I-PU-AD will be administered by intravenous (IV) injection
2882617|NCT03371407||Parkinsonian patient under dopaminergic medication|
2882618|NCT03371407||Parkinsonian patient without dopaminergic medication|
2882619|NCT03371407||Control participants|
2882620|NCT03371394||median 1|
2882621|NCT03371394||median 2|
2882622|NCT03371381|Experimental|Nivolumab + JNJ-64041757|Phase 1b and Phase 2 Group A/Arm 1: Participants will receive separate intravenous (IV) infusions of nivolumab and JNJ-64041757 over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
2882623|NCT03371381|Active Comparator|Nivolumab|Phase 2 Group B/Arm 2: Participants will receive intravenous (IV) infusions of nivolumab over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
2882624|NCT03371368|Active Comparator|Gastric Bypass Non-diabetic|Roux-en-Y gastric bypass surgery
2882625|NCT03371368|Active Comparator|Sleeve Gastrectomy Non-diabetic|sleeve gastrectomy surgery
2882626|NCT03371368|Active Comparator|Very Low Calorie Diet Non-diabetic|very low calorie diet
2882627|NCT03371368|No Intervention|Obese Control|Non-diabetic obese subjects
2882628|NCT03371368|No Intervention|Lean Control Group|Non-diabetic lean subjects
2882629|NCT03371355|Experimental|ISIS 703802 Dose 1|Cohort A
2882630|NCT03371355|Experimental|ISIS 703802 Dose 2|Cohort B
2882631|NCT03371355|Experimental|ISIS 703802 Dose 3|Cohort C
2882632|NCT03371355|Placebo Comparator|Placebo: Sterile Normal Saline|Sterile Normal Saline (0.9% NaCl) by volume to match dose and regimen of active comparator depending on Cohort assignment
2882633|NCT03371342|Experimental|MEDITOXIN|
2882634|NCT03371342|Active Comparator|BOTOX|
2882635|NCT03371329|Experimental|Group 1 MSC dose .5 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose .5 x 10^6/kg for 3 participants.
2882636|NCT03371329|Experimental|Group 2 MSC dose 1 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose 1 x 10^6/kg for next 3 participants.
2882637|NCT03371329|Experimental|Group 3 MSC dose 2 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose 2 x 10^6/kg for next 3 participants.
2882638|NCT03371329|Experimental|Group 4 MSC dose 0.5 x 10^6/kg I|Intraventricular infusion of MSC (mesenchymal stem cell) dose .5 x 10^6/kg for final 3 participants.
2882639|NCT03371316|Experimental|Hemicraniectomy Surgery with Viashield|All patients requiring a hemicraniectomy surgery will receive the anti-adhesion barrier of amnion patch.
2882640|NCT03371303||diabetology|
2882641|NCT03371303||cardiology|
2882642|NCT03371303||rheumatology|
2882643|NCT03371303||geriatrics|
2882644|NCT03371290|Experimental|Mirror Therapy Intervention|
2882645|NCT03371290|Active Comparator|Control Intervention|
2882646|NCT03371277|Experimental|Arm1|patients with Parkinson's disease treated with deep brain stimulation.
2882647|NCT03371277|Experimental|Arm2|patients with Parkinson's disease treated without deep brain stimulation.
2882648|NCT03371264||Cohort R1 and Cohort T1|Cohort R1 (patients on the waiting list between 2009 and 2013) and Cohort T1 (transplanted patients between 2009 and 2013)
2882649|NCT03371264||Cohort R2 and Cohort T2|Cohort R2 (patients on the waiting list in 2014) and Cohort T2 (transplanted patients in 2014)
2882650|NCT03371251|Experimental|Phase 1: BOS161721 20, 60, 120 mg|Participants will be randomized to receive a 20 milligram (mg), 60 mg, or 120 mg subcutaneous (SC) dose of BOS161721. Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180 followed by a 90-day safety follow-up visit.
2882651|NCT03371251|Placebo Comparator|Phase 1: Placebo 20, 60, 120 mg|Participants will be randomized to receive a 20 mg, 60 mg, or 120 mg SC dose of placebo. Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180 followed by a 90-day safety follow-up visit.
2882652|NCT03371251|Experimental|Phase 2: BOS161721|Participants will be randomized to receive a SC dose of BOS161721 as determined from Phase 1 of the study. Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180 followed by a 90-day safety follow-up visit.
2882653|NCT03371251|Placebo Comparator|Phase 2: Placebo|Participants will be randomized to receive a SC dose of placebo as determined from Phase 1 of the study. Participants may receive a total of 7 SC monthly doses of placebo of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180 followed by a 90-day safety follow-up visit.
2882654|NCT03371238|Experimental|Floorball|
2882655|NCT03371238|No Intervention|Control|
2882656|NCT03371225|Experimental|Active tDCS and Active Exercise|Active tDCS for 20 min Active exercise (60-70% max HR) for 30 min
2882657|NCT03371225|Active Comparator|Sham tDCS and Active Exercise|Sham tDCS for 20 min Active exercise (60-70% max HR) for 30 min
2882658|NCT03371225|Active Comparator|Active tDCS and Sham Exercise|Active tDCS for 20 min Sham exercise (within 5% baseline HR) for 30 min
2882659|NCT03371225|Sham Comparator|Sham TDCS and Sham Exercise|Sham tDCS for 20 min Sham exercise (within 5% baseline HR) for 30 min
2882660|NCT03371212|Active Comparator|Conventional Cohort|Patients in this group will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components > 52mm), polyethylene bearing, and G7 acetabular shell.
2882661|NCT03371212|Experimental|Modular Dual Mobility Cohort|Patients in this group will receive a Taperloc femoral stem, inner ceramic femoral head (28mm), mobile polyethylene bearing, cobalt alloy liner, and G7 acetabular shell.
2882662|NCT03371199|Active Comparator|Sodium arm|Sodium tablets
2882663|NCT03371199|Placebo Comparator|Placebo arm|Placebo tablets
2882664|NCT03371186|Experimental|Bundled RMNCH Intervention|Stepped wedge, cluster-controlled implementation science trial of 5 bundled intervention components (1. Community Health Worker, 2, Continuous Surveillance, 3. CB-Integrated Management of Newborn and Childhood Illness, 4. Group Antenatal and Postnatal Care, and 5. Balanced Post-Partum Contraceptive Counseling) implemented across 40 village clusters in Achham District, Nepal and 40 village clusters in Dolakha District, Nepal (covering a total population of approximately 300,000) in coordination with district authorities and study staff. The investigators anticipate the experimental arm will enroll approximately 12,000 women and their children over the 18mo enrollment period.
2882665|NCT03371173|Experimental|Ferric maltol 30 mg (Feraccru®)|Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks
2882666|NCT03371147|Experimental|CancerLife|Arm A will be asked to download a mobile application called CancerLife. CancerLife is a stand-alone application that is NOT integrated into the patient's electronic health record and will NOT trigger symptom alerts to the treatment team. Participants will be instructed to use the after-visit instructions provided to them by their treatment team for any symptoms or conditions that will require an evaluation by a healthcare provider.
2882667|NCT03371147|No Intervention|Usual care|Arm B will receive usual care provided for in the clinics. Usual care may vary between institutions, practices, and providers. Usual care may consist of but is not limited to any combination of the following: history and physical examination, review of systems, distress screening, symptom assessment measures, and/or interval quality of life measures.
2882668|NCT03371134||Sarcopenic group|Harvesting of muscular biopsies Muscular biopsies will be harvested from old sarcopenic patients undergoing hip replacement surgery
2882669|NCT03371134||Control group|Harvesting of muscular biopsies Muscular biopsies will be harvested from young patients undergoing Anterior Cruciate Ligament (ACL) reconstruction surgery
2882670|NCT03371121|Other|Chondro-gide - Geistlich|Arthroscopic use of chondro-gide to treat symptomatic osteochondral talar lesion
2882671|NCT03371108|Experimental|Gan & Lee Insulin Glargine Injection|Gan & Lee Insulin Glargine Injection solution for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0 mL prefilled Gan & Lee injector pen. Subjects randomized to the Gan & Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
2882672|NCT03371108|Active Comparator|Lantus®|Lantus® solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL prefilled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
2882673|NCT03371095|Experimental|Infliximab|Infliximab 5mg/kg intravenously at week 0, 2, 6, 12, and 18
2882674|NCT03371095|Active Comparator|Cyclophosphamide|Cyclophosphamide 0.7g/m2 intravenously at week 0, 4, 8, 12, 16 and 20
2882675|NCT03371082|Experimental|Gan & Lee Insulin Glargine Injection|Gan & Lee Insulin Glargine Injection for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0-mL prefilled Gan & Lee injector pen. Subjects randomized to the Gan & Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
2882676|NCT03371082|Active Comparator|Lantus®|Lantus® solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL prefilled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
2882677|NCT03371069||users of methylphenidate|Children and adolescents who are users of methylphenidate, 2010 to 2015
2882678|NCT03371056|Experimental|Woman at low risk of infection|Women with systematic vaginal sample for detection of GBS will be included.
2882679|NCT03371056|Experimental|Woman with high risk of infection > 37 SA|Women with premature rupture of membranes (> 12 hours before labor) but > 37 SA will be included.
2882680|NCT03371056|Experimental|Women with premature rupture of membranes (<37SA)|Woman with high risk of infection <37SA
2882681|NCT03371056|Experimental|Women with premature delivery or premature delivery threat|Woman with high risk of infection <37SA and Women with premature delivery or premature delivery threat
2882682|NCT03371043||users of analgesic medications|Children and adolescents who are users of analgesic medications, 2012 to 2015
2914888|NCT03145480|Experimental|Frail arm|ibrutinib and obinutuzumab
2882686|NCT03371017|Placebo Comparator|Placebo|Participants will receive Placebo on day 1 of each 3-week treatment cycle
2882687|NCT03371004|Experimental|DM-CHOC-PEN + Radiation|4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) - 39-89.7 MG/M2 iv once and then 3-weeks later radiation - 15-30 Gy will be administered
2882688|NCT03370991|Experimental|Blueberry|22 g/day freeze-dried blueberry powder for 12 weeks
2882689|NCT03370991|Placebo Comparator|Control|22 g/day placebo powder for 12 weeks
2882690|NCT03370978|Experimental|Text Messaging|Receives text messages to remind of upcoming follow-up appointment with primary care doctor. Also provides opportunity for subjects to text ED staff for follow-up care concerns or to reschedule primary care appointment.
2882691|NCT03370978|No Intervention|Usual Care|Received usual care including follow-up phone calls if clinically indicated.
2882692|NCT03370965|Experimental|Patients with optic neuritis|
2882693|NCT03370952|Active Comparator|new approach|"Under general anaesthesia, the patient is placed in the modified dorsal lithotomy position a 10-mm umbilical trocar is inserted. A panoramic view of the pelvis was obtained together with full assessment of the ovarian mass(es).~Aspiration of the cyst:~Delivery of affected ovary outside the abdominal cavity:~A transverse mini-laparotomy is done (2-3 cm) in the midline 2 cm above the symphysis pubis.~Ovarian cystectomy:~Re-introduction of the ovary to inside the abdominal cavity:"
2882694|NCT03370952|Active Comparator|Laproscopic ovarian cystectomy|classic laparoscopic ovarian cystectomy
2882695|NCT03370913|Experimental|valoctocogene roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg
2882696|NCT03370900|No Intervention|Learning and Assessment at 12 months|Study participants will complete an 80 case learning set followed by a 20-case post test. The study intervention in this group is a 20-case test at 12 months.
2882697|NCT03370900|Experimental|Testing Every Two Months|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests without any feedback at 2, 4, 6, 8, 10, 12 months.
2882698|NCT03370900|Experimental|Low Bolus Feedback|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests at 2, 4, 6, 8, 10, 12 months. At 6 months, the 20-case post-test will be delivered with feedback.
2882699|NCT03370900|Experimental|High Bolus Feedback|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests at 2, 4, 6, 8, 10, 12 months. At 4, 8, and 12 months, the 20-case post-test will be delivered with feedback.
2882700|NCT03370887|Experimental|Low dose AZD8601 (3 mg)|8 patients will be randomised to receive 3 mg AZD8601
2882701|NCT03370887|Experimental|High dose AZD8601 (30 mg)|8 patients will be randomised to receive 30 mg AZD8601
2882702|NCT03370887|Placebo Comparator|Placebo|8 patients will be randomised to receive placebo injections
2882703|NCT03370874|Experimental|ALLO-ASC-DFU|Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
2882704|NCT03370874|Placebo Comparator|Vehicle Sheet|Hydrogel sheet without Allogenic mesenchymal stem cell
2882705|NCT03370848|Experimental|Psyllium plus Aspirin and Niacin ER|"Niacin ER 500mg tablet - take 1 niacin ER 500mg tablet at least two hours before bedtime for two weeks, then increase niacin ER to two 500mg tablets (1,000 mg total) for two weeks, then increase to three niacin ER 500mg tablets (1,500 mg total) for two weeks.~Aspirin 325mg tablet - take 1 aspirin 325 mg tablet 30 minutes prior to niacin ER~Psyllium 1.7gm wafers - take 2 wafers (3.4 grams total) along with aspirin 30 minutes prior to niacin ER"
2882706|NCT03370848|Active Comparator|Aspirin and Niacin ER|"Niacin ER 500mg tablet - take 1 niacin ER 500mg tablet at least two hours before bedtime for two weeks, then increase niacin ER to two 500mg tablets (1,000 mg total) for two weeks, then increase to three niacin ER 500mg tablets (1,500 mg total) for two weeks.~Aspirin 325mg tablet - take 1 aspirin 325 mg tablet 30 minutes prior to niacin ER"
2882707|NCT03370835|Experimental|Sequence 1|"Metoprolol-succinate-ER 25mg daily weeks 0-2, 50mg daily weeks 2-4, 100mg daily weeks 4-6, 200mg daily weeks 6-8, 100mg daily week 9, 50mg daily week 10~Carvedilol 3.125mg twice daily weeks 10-12, 6.25mg twice daily weeks 12-14, 12.5mg twice daily weeks 14-16, 25mg twice daily weeks 16-18"
2882708|NCT03370835|Active Comparator|Sequence 2|"Carvedilol 3.125mg twice daily weeks 0-2, 6.25mg twice daily weeks 2-4, 12.5mg twice daily weeks 4-6, 25mg twice daily weeks 6-8, 12.5mg twice daily week 9, 6.25mg twice daily week 10~Metoprolol-succinate-ER 25mg daily weeks 10-12, 50mg daily weeks 12-14, 100mg daily weeks 14-16, 200mg daily weeks 16-18"
2882709|NCT03370822||Study Participants|Women who have continuous fetal monitoring using the MONICA AN24 device. The MONICA AN24 is a wearable monitor with five adhesive electrodes placed on the mother's abdomen. This records the fetal heart rate, maternal heart rate and uterine contractions.
2882710|NCT03370809|Experimental|patients over 75 years old with cancer discovery|Elderly patients with cancer have a 18F-FDG PET whole body performed routinely in the initial assessment . A cerebral recording is added 45 minutes after the 18F-FDG injection and just before the registered whole body
2882711|NCT03370796|Experimental|Reminiscence Therapy|The Reminiscence program will consist of a set of sessions thematically sequenced topics that address the life course of the participant. Each session will integrate a group of activities that will be developed in group and will have a didactic character, privileging subjective interests and interpersonal communication.
2882712|NCT03370796|No Intervention|Control Group|The control group shall participate in the institutional care provided by the professionals of each RSE.
2882713|NCT03370770||patients with EGFR mutation-positive NSCLC|(Non-Small Cell Lung Cancer) (Epidermal Growth Factor Receptor)
2882714|NCT03370757|Active Comparator|3-hour bundled care|Infants in this group will have their diaper changed every 3 hours during 3-hour bundled care.
2882715|NCT03370757|Active Comparator|6-hour bundled care|Infants in this group will have their diaper changed every 6 hours.
2882716|NCT03370744||Subjective cognitive decline|Individuals with subjective cognitive decline (SCD) are elderly people who self-report persistent decline in cognitive capacity without measurable cognitive impairment according to results of standard assessments.
2882717|NCT03370744||Normal control|
2882718|NCT03370731|Experimental|Adenotonsillectomy|Surgical management, i.e. adenotonsillectomy, including adenoidectomy, tonsillectomy or adenoidectomy combined tonsillectomy
2882719|NCT03370731|Other|Nonsurgical management|Nonsurgical management, including nasal irrigation, inhaled corticosteroids etc.
2882720|NCT03370718|Experimental|Cabozantinib|Participants take Cabozantinib tablets by mouth 1 time each day.
2882721|NCT03370705|Active Comparator|CT group|78 patients will be treated by conventional treatment : antiplatelet therapy + ACE inhibitor +/- Statin in patients with cholesterol total level > 1,35 g/l
2882722|NCT03370705|Experimental|Sulodexide + CT group|"78 patients will be treated by :~Sulodexide (250ULS, twice daily , oral administration)~Conventional treatment : antiplatelet agents + ACE inhibitor +/- Statin in patients with cholesterol total level > 1,35 g/l"
2882723|NCT03370666|Experimental|HFNT|HFNT performed with any available device. The flow will be initially set at 60 liters per minute and temperature at 37° C. The target will be an oxygen saturation (SpO2) of 88-92%. In case of patient not tolerating these settings, flow and temperature will be titrated to the maximum tolerated level.
2882724|NCT03370666|Active Comparator|NIV|NIV must be delivered by full or oronasal mask with any available ventilator. The ventilator settings will be decided according to the usual practice: maximal tolerated inspiratory pressure to obtain a measured or estimated expired tidal volume of 6-8 mL·kg-1 of body weight and a positive end expiratory pressure (PEEP) between 3 and 5 cmH2O. An interface rotational strategy will be allowed among only different types of masks.
2882725|NCT03370653|Experimental|Double-blind - odiparcil 1000 mg per day|2 tablets of odiparcil 250 mg per os, twice daily (BID)
2882726|NCT03370653|Experimental|Double-blind - odiparcil 500 mg per day|1 tablet of placebo and 1 tablet of odiparcil 250 mg per os, twice daily (BID)
2882727|NCT03370653|Placebo Comparator|Double-blind - placebo|2 tablets of placebo per os, twice daily (BID)
2882728|NCT03370653|Experimental|Open Label - odiparcil 1000 mg per day|2 tablets of odiparcil 250 mg per os, twice daily (BID)
2882729|NCT03370640|Experimental|SEP-363856 Part 1 Cohort 1|An oral 25 mg dose of SEP 363856 once daily for 3 days, then 50 mg dose of SEP-363856 once daily for 7 days.
2882730|NCT03370640|Experimental|SEP-363856 Part 1 Cohort 2|An oral 50 mg dose of SEP 363856 once daily for 3 days, then 75 mg dose of SEP-363856 once daily for 7 days.
2882731|NCT03370640|Experimental|SEP-363856 Part 2 Cohort 3|An oral 25 mg dose of SEP 363856 once daily for 3 days, 50 mg dose of SEP 363856 once daily for 4 days, and then 75 mg dose of SEP-363856 once daily for 7 days.
2882732|NCT03370627|Experimental|Patient|
2882733|NCT03370614||IBS Group|Participants will complete initial baseline and follow up IBS evaluations and questionnaires. Pre and Post FDG-PET-MR scans will be conducted to evaluate changes at baseline and approximately 2 months after dietary and nutritional counseling.
2882734|NCT03370614||Healthy Control Group|Participants will complete initial baseline evaluations and questionnaires. Participants will also receive a FDG-PET-MR scan.
2882735|NCT03370601|Other|Optimisation strategy|increase of Infliximab dose from 5mg/kg every 8 weeks to Infliximab 10 mg/kg every 8 weeks
2882736|NCT03370601|Other|Addition strategy|same dose of Infliximab ( 5mg/kg every 8 weeks) with addition of immunosuppressive agent: Azathioprine or Mercaptopurine
2882737|NCT03370588|Experimental|dexmedetomidine infusion group|
2882738|NCT03370588|Active Comparator|normal saline infusion group|
2882739|NCT03370575|Experimental|ethiodized poppyseed oil|
2882740|NCT03370575|Active Comparator|the second-generation non-ionic monomer contrast|
2882741|NCT03370562|Active Comparator|Dexmedetomidine|Patient will receive 10 mcg of dexmedetomidine in 5 ml of normal saline, administered by slow intravenous injection
2882742|NCT03370562|Placebo Comparator|Placebo|Patient will receive 5 ml of normal saline, administered by slow intravenous injection
2882743|NCT03370549|Experimental|AWARE intervention|Group psychotherapy intervention for Asian-American women
2882744|NCT03370549|Other|Waitlist control|Delayed AWARE intervention for Asian-American women
2882745|NCT03370536|Experimental|Patients with AF|Patients with AF and planned to undergo first catheter procedure
2882746|NCT03370510|Experimental|Pivotal Response Treatment (PRT)/oxytocin (OXT) nasal spray|Participants will receive oxytocin nasal spray 45 minutes prior to each PRT session.
2882747|NCT03370510|Placebo Comparator|Pivotal Response Treatment (PRT)/placebo nasal spray|Participants will receive a placebo nasal spray 45 minutes prior to each PRT session.
2882748|NCT03370497|Active Comparator|Whey protein hydrolysate|Whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
2882749|NCT03370497|Experimental|Whey protein hydrolysate plus milk mineral supplement|Milk mineral supplement (equating to 1000 mg calcium) plus whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
2882750|NCT03370484|Placebo Comparator|Control|Water with artificial sweetener
2882751|NCT03370484|Experimental|Milk mineral supplement|Milk Minerals containing 1000 mg calcium with artificial sweetener and water
2882752|NCT03370471|Active Comparator|Study Only|Subject uses their own strategy for learning words; no active retrieval during learning.
2882753|NCT03370471|Active Comparator|Retrieval Practice|Subject actively retrieves words as prompted during learning.
2882754|NCT03370458|Experimental|Lactobacillus plantarum DR7|"Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum DR7, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 weeks.~Intervention: Dietary Supplement: Lactobacillus plantarum DR7"
2882755|NCT03370458|Placebo Comparator|Placebo|"Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks.~Intervention: Dietary Supplement: Placebo"
2882756|NCT03370445|Active Comparator|"Control Attention Intervention"|"This injury prevention program will act as an attention placebo to control against the added attention provided to the intervention group. In addition this injury prevention program will act as an incentive for Pediatric Resident Clinics to participate and maximize retention throughout the study period - as they will know that they will be randomized to one of two beneficial resident education programs."
2882785|NCT03370263||Benlysta subcutaneous (SC)|This arm will include subjects who will receive BENLYSTA SC. Observation period per subject will be for 52 weeks from start of Benlysta administration.
2882757|NCT03370445|Experimental|Greenlight Intervention|The intervention includes the following components: (1) training of pediatric resident physicians in improved health communication skills and (2) a low literacy and numeracy-oriented educational toolkit which promotes healthy diet and physical activity practices.
2882758|NCT03370432||Colorectal cancer cases|1038 participants diagnosed with colorectal cancer from the Diet, Cancer and Health cohort.
2882759|NCT03370432||Sub-cohort members|1857 persons randomly selected within the full cohort at time of entry into the Diet, Cancer and Health cohort. These participants serve as controls for the colorectal cancer cases.
2882760|NCT03370419|Experimental|TReatment arm|Participants are asked to participate in five health-coaching sessions and to return in Week 20 for follow-up data collection. The initial face-to-face coaching session lasts approximately 90 minutes with subsequent telephone sessions lasting approximately 20 minutes. Coaching sessions will include education about MetS, weight loss, dietary and physical activity recommendations, and the principles of habit development, guidance in forming implementation intentions for each self-selected habit, and identifying routines and contextual cues that could be modified to support habit development Coaching sessions are augmented with a participant workbook. Participants' also receive individually tailored study text messages to maintain their motivation.
2882761|NCT03370406|No Intervention|Control Group|Control group will receive neither 5-fluorouracil (5FU) injection nor topical Imiquimod 5% cream. This group will receive standard of care only. Lesion will be surgical resected on day 21 of study.
2882762|NCT03370406|Experimental|5FU Group|5-fluorouracil (5FU) Group participants will receive a 1ml intralesional injection of 5FU 50mg/ml aqueous injectable solution. One injection will be administered weekly for 3 weeks. Injections will occur on d0, d7, and d14. Standard of care will be administered on d21 of study and lesion will be surgical resected.
2882763|NCT03370406|Experimental|5FU + Imiquimod 5% Group|5-fluorouracil (5FU) + Imiquimod 5% cream Group participants will receive intralesional 5FU as in the previous group, additionally participants will also receive three-times-weekly topical application of 5% imiquimod to the same lesion. Standard of care will be administered on d21 of study and lesion will be surgical resected.
2882764|NCT03370393|Experimental|Pathways for African-Americans' Success|Subjects will complete a 6-week Pathways for African-Americans' Success (PAAS) intervention. This is a weekly, 1.5 hour/session, family intervention for 6 weeks.
2882765|NCT03370393|No Intervention|Wait-list|Subjects will be on waiting list for active intervention and will receive the PAAS intervention at the end of the study (same as active intervention).
2882766|NCT03370367|Experimental|Arm A|13-cis retinoic acid will be dispensed in 3.75 mg and 5 mg gelatin capsules. Take 2 capsules once a day for up to 2 years.
2882767|NCT03370367|Placebo Comparator|Arm B|Take 2 placebo pills once a day for up to 2 years.
2882768|NCT03370354||Control group|First questionnaire (spiegel questionnaire) will allow a score on 30. If the score is > 18, the patient will be in the control group.
2882769|NCT03370354||troubled sleeping patterns group|First questionnaire (spiegel questionnaire) will allow a score on 30. If the score is < 18, the patient will be in the troubled patterns group.
2882770|NCT03370341|Experimental|Active anodal tDCS|Active anodal tDCS followed by behavioral testing Intervention: Device: active anodal tDCS
2882771|NCT03370341|Sham Comparator|Sham tDCS|Sham tDCS followed by behavioral testing Intervention: Device: sham tDCS
2882772|NCT03370328|Experimental|Peppermint oil|post-op surgical patients
2882773|NCT03370328|Experimental|Ginger oil|post-op surgical patients
2882774|NCT03370328|Experimental|Peppermint and ginger oil|post-op surgical patients
2882775|NCT03370315|Experimental|Dance Group|"This group will be undergo dance classes two times a week, for 12 weeks. 24 sessions.~Intervention administered: Dance classes inspired by the rhythm of Forró and Samba."
2882776|NCT03370315|Experimental|Walking Group|"This group will be undergo walking training two times a week, for 12 weeks. 24 sessions.~Intervention administered: Walking program with 3 different moments."
2882777|NCT03370302|Experimental|TAK-228 Once Daily|TAK-228, milled capsule, orally, once daily, on an empty stomach in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 2 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 2 mg, once daily, is safe and tolerable, then the dose will be escalated to 4 mg, once daily, until RP2D is determined.
2882778|NCT03370302|Experimental|TAK-228 Once Weekly|TAK-228, milled capsule, orally, once weekly, on an empty stomach in Cycle 1 of a 28-day treatment cycle and following a light meal from Cycle 2 for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 20 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 20 mg, once weekly, is safe and tolerable, then the dose will be escalated to 30 mg, once weekly, until RP2D is determined.
2882779|NCT03370289|Experimental|BLB-750 Qinghai RG strain|Two doses of BLB-750 Qinghai reverse genetics (RG) strain at a vaccination dose of 0.5 mL (HA antigen level of 7.5 µg per strain) will be injected into the upper arm muscle (the deltoid muscle) at 3-week intervals (Day 1, Day 2 and Day 43).
2882780|NCT03370276|Experimental|Phase I - Affiliate Sites Only|"Nivolumab and dose escalation of Cetuximab.~Dose Level 1:~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 500 mg/m^2; Nivolumab 240 mg.~Dose Level -1:~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 250 mg/m^2; Nivolumab 240 mg."
2882781|NCT03370276|Experimental|Phase I - Moffitt Site Only|"Nivolumab and dose escalation of Cetuximab.~Dose Level 1:~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 500 mg/m^2; Nivolumab 240 mg.~Dose Level -1:~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 250 mg/m^2; Nivolumab 240 mg."
2882782|NCT03370276|Experimental|Phase II - Affiliate Sites Only|Nivolumab and Cetuximab at recommended Phase II dose (RP2D).
2882783|NCT03370276|Experimental|Phase II - Moffitt Site Only|Nivolumab and Cetuximab at recommended Phase II dose (RP2D).
2882784|NCT03370263||Benlysta intravenous (IV)|This arm will include subjects who will receive Benlysta IV. Observation period per subject will be for 52 weeks from start of Benlysta administration.
2882826|NCT03369938|Experimental|exercise training intervention|
2882786|NCT03370224|Experimental|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
2882787|NCT03370224|Placebo Comparator|Placebo|The placebo group will receive placebo control memory exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
2882788|NCT03370211|Experimental|experimental intervention|The training group performed the resistance training (RT) program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, wirh 3 sets of 10-15 repetition maximums (RM).The RT program was performed in the following order: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl, , and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
2882789|NCT03370211|No Intervention|control group|The control group did not perform any type of physical exercise during the intervention period.
2882790|NCT03370198|Experimental|Dose-level 1|The dose-level 1 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
2882791|NCT03370198|Experimental|Dose-level 2|The dose-level 2 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
2882792|NCT03370198|Experimental|Dose-level 3|The dose-level 3 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
2882793|NCT03370185|Experimental|Duvelisib|Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles
2882794|NCT03370172|Experimental|Cohort 1|Low dose
2882795|NCT03370172|Experimental|Cohort 2|High dose
2882796|NCT03370159|Experimental|Treatment (CPI-613, docetaxel)|Patients receive CPI-613 IV over 2 hours on days 1 and 3, and docetaxel IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients that achieve stable disease after 6 courses then receive CPI-613 alone on days 1and 3. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2882797|NCT03370146||TKA patients - Experimental Group|
2882798|NCT03370146||TKA patients - Control Group 1|
2882799|NCT03370146||Healthy subjects - Control Group 2|
2882800|NCT03370133|Experimental|Bimekizumab cohort|Subjects will receive bimekizumab for 52 weeks.
2882801|NCT03370133|Active Comparator|Ustekinumab cohort|Subjects will receive ustekinumab (dose 1 or dose 2 depending on subjects weight) for 52 weeks. Placebo will be administered at pre-specified time points to maintain the blinding.
2882802|NCT03370133|Placebo Comparator|Placebo|Subjects will receive placebo up to week 16 and bimekizumab starting at week 16 through week 52.
2882803|NCT03370120|Experimental|Padsevonil|"Padsevonil will be administered in an open-label manner. The individual starting dose of each subject will be the one at the end of the parent study.~Once subjects enter EP0093 further individual dose adjustments are allowed after 1 week to the extent possible with the combination of tablet strengths available."
2882804|NCT03370107|Active Comparator|Active rTMS and H coil|
2882805|NCT03370107|Placebo Comparator|sham rTMS and Hcoil|
2882806|NCT03370094||patients with suspected stroke|patients with suspected stroke due to paramedic's initial evaluation of face, arm, and speech function will be diagnosed with audio-video-streaming of suspected stroke symptoms and signs
2882807|NCT03370081|Experimental|CAPNO+|END TIDAL CO2(EtCO2) is monitoring and PACU nurses can see the values delivered by the capnography device
2882808|NCT03370081|No Intervention|CAPNO-|END TIDAL CO2(EtCO2) is monitoring but PACU nurses cannot see the values delivered by the capnography device
2882809|NCT03370068|Experimental|ICSI|All the oocytes in this group (from one ovary) will undergo insemination by ICSI.
2882810|NCT03370068|Active Comparator|Conventional IVF|All the oocytes in this group (from the other ovary) will undergo insemination by conventional IVF.
2882811|NCT03370055|Active Comparator|LeucoPatch®|Usual wound care and LeucoPatch® treatment for 8 weeks, with the offer of additional 8 weeks treatment with LeucoPatch®
2882812|NCT03370055|Placebo Comparator|Control|Usual wound care for 8 weeks, with the offer of 8 weeks of LeucoPatch® treatment after the first 8 weeks
2882813|NCT03370042|Active Comparator|SCPF + FGG|semilunar coronally positioned flap with free gingival graft
2882814|NCT03370042|Sham Comparator|SCPF|semilunar coronally positioned flap alone
2882815|NCT03370029||Primary ciliary dyskinesia patients|Primary ciliary dyskinesia patients will be included in study. Inclusion and exclusion criteria were considered.
2882816|NCT03370029||Healthy individuals|Those without diagnosed chronic disease will be included in study. Inclusion and exclusion criteria were considered.
2882817|NCT03370016|Experimental|Reduction in pressure|This group receives 8mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy.
2882818|NCT03370016|Active Comparator|Stand Amount of Pressure|This group receives 12mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy (RARP). This pressure is the standard amount used for all RARP procedures.
2882819|NCT03369990|Experimental|Botulinum toxin type A|DWP450
2882820|NCT03369990|Placebo Comparator|Placebo|Normal Saline
2882821|NCT03369977|Experimental|BioGlue Surgical Adhesive|Subjects in the BioGlue group will receive BioGlue as an adjunct for traditional surgical repair of the sinus of Valsalva.
2882822|NCT03369977|No Intervention|Traditional Surgical Repair|Subjects in the control group will receive traditional surgical repair of the sinus of Valsalva.
2882823|NCT03369964|Experimental|Atezolizumab + Emactuzumab|Participants will receive Atezolizumab and Emactuzumab on Day 1 of each 21- day cycle
2882824|NCT03369964|Active Comparator|Atezolizumab + Emactuzumab + Obinutuzumab|"Participants will receive Atezolizumab, Emactuzumab, and Obinutuzumab on Day 1 of each- 21 day cycle (starting in cycle 2)~(Atezolizumab starting in cycle 2); and Obinutuzumab on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2-8."
2882825|NCT03369951|Experimental|Minocin® IV|200 mg minocycline hydrochloride IV infusion over approximately 60 minutes, n=50
2882832|NCT03369886|Other|Early glaucoma group|Patients whose visual field mean deviation is > -6dB OCT angiography will be taken but there are no difference between patients' group. The same OCT angiography protocol will be applied to all patients' group.
2882833|NCT03369886|Other|Advanced glaucoma group|Patients whose visual field mean deviation is < -6dB OCT angiography will be taken but there are no difference between patients' group. The same OCT angiography protocol will be applied to all patients' group.
2882834|NCT03369873|Experimental|Nursing Orientation with guidance manual|The patients received the nursing orientation with validated guidance manual of cardiac catheterization.
2882835|NCT03369873|No Intervention|Routine Nursing Orientation|The patients received the routine nursing orientation about cardiac catheterization.
2882836|NCT03369860|Experimental|Healthy Subjects|Healthy Subjects take part in the experimental manipulation
2882837|NCT03369847|Experimental|Inhaled Corticosteroids|"Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer x 28 days.~Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer x 28 days"
2882838|NCT03369847|No Intervention|Standard Care|Patients allocated to this group will not receive an asthma controller medication from the emergency department. The intervention group will receive prescriptions for inhaled albuterol and oral corticosteroids as per standard treatment.
2882839|NCT03369834|No Intervention|Control Group|the volunteers of this group will not be submitted to the intervention.
2882840|NCT03369834|Experimental|Red LED group|in the volunteers of this group will be applied Red Light-emitting diode device with the length 620nm wave along the entire tibialis anterior muscle and bilateral sural triceps.
2882841|NCT03369834|Active Comparator|LED group infrared|in the volunteers of this group will be applied Infrared Light-emitting diode device with the wavelength of 940nm throughout the tibialis anterior muscle and bilateral sural triceps.
2882842|NCT03369821||Study 1: Existing EET1D (Case)|"Aged 0 to 70 years~Clinical diagnosis of diabetes <12 months (+ evidence of WHO diabetes criteria)~Negative genetic test for mutations causing neonatal diabetes~Type 1 diabetes genetic risk score >50th centile of T1D reference group."
2882843|NCT03369821||Study 1: T1D (Control)|"Age 0-70 years (matched to above)~Clinical diagnosis of T1D (diagnosed age 1-20 years)~Insulin treated from diagnosis."
2882844|NCT03369821||Study 2: Newly diagnosed EET1D (Case)|"Aged 0 to 18 months at recruitment~Clinical diagnosis of diabetes <12 months (+ evidence of WHO diabetes criteria)~Negative genetic test for mutations causing neonatal diabetes~Type 1 diabetes genetic risk score >50th centile of T1D reference group"
2882845|NCT03369821||Study 2: NDM (Control)|"Diagnosis of diabetes <12 months~Age 0 to 18 months at recruitment~Diagnosis of NDM (confirmed by Exeter Molecular Genetics Laboratory)."
2882846|NCT03369808|Experimental|7.5μg H7N9 Vaccine|Participants will receive 2 doses of 7.5μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
2882847|NCT03369808|Experimental|15μg H7N9 Vaccine|Participants will receive 2 doses of 15μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
2882848|NCT03369808|Experimental|30μg H7N9 vaccine|Participants will receive 2 doses of 30μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
2882849|NCT03369808|Placebo Comparator|Aluminum hydroxide adjuvant|Participants will receive 2 doses of aluminum hydroxide adjuvant at 21-day intervals.
2882850|NCT03369808|Placebo Comparator|Phosphate buffer solution|Participants will receive 2 doses of phosphate buffer solution at 21-day intervals.
2882851|NCT03369795|Experimental|Study Drug|Methotrexate 10mg
2882852|NCT03369795|Placebo Comparator|Placebo|Pills equivalent to other study arm (10 mg)
2882853|NCT03369782|Placebo Comparator|Placebo|Placebo alternative for rocuronium and for sugammadex
2882854|NCT03369782|Active Comparator|Rocuronium|Rocuronium as bolus and in syringe pump Sugammadex just before reduction of the joint
2882855|NCT03369769|Experimental|Canine & Adult Handler Activity|Unstructured 10-minute small group interaction with canine & handler
2882856|NCT03369769|Active Comparator|Toy and Adult Handler Activity|Unstructured 10-minute small group interaction with toy & handler
2882857|NCT03369756|Other|Prontosan Solution and Gel|Treatment with Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel over 4 week period
2882858|NCT03369717|Experimental|Antibiotics|To receive postoperative antibiotics
2882859|NCT03369717|No Intervention|No antibiotics|Will not receive any postoperative antibiotics
2882860|NCT03369704|Experimental|Omalizumab|Eligible patients randomized to this arm will receive omalizumab subcutaneously for 12 weeks
2882861|NCT03369704|Placebo Comparator|Placebo|Eligible patients randomized to this arm will receive placebo subcutaneously for 12 weeks
2882862|NCT03369665|Experimental|Mavenclad®|
2882863|NCT03369652|Experimental|Intervention|Medication history by pharmaconomist. Medication review by pharmacist, patient interview, and conference with physician in hospital, telephone contact to general practitioner after discharge, medication report sent to primary care.
2882864|NCT03369652|No Intervention|Control|Medication history by pharmaconomist. Usual care by physicians.
2882865|NCT03369626|Other|FareWell Program|All participants receive the FareWell Program intervention in this evaluation study
2882866|NCT03369613|Active Comparator|MRI - HC tDCS|Healthy controls in Phase 1 transcranial electrical stimulation set to direct current
2882867|NCT03369613|Active Comparator|MRI - HC tACS|Healthy controls in Phase 1- transcranial electrical stimulation set to alternating current
2882868|NCT03369613|Active Comparator|MRI - CD tCDS|Cervical dystonia in Phase 1 transcranial electrical stimulation set to direct current
2882869|NCT03369613|Active Comparator|MRI - CD tACS|Cervical dystonia in Phase 1 transcranial electrical stimulation set to alternating current
2882870|NCT03369613|Active Comparator|Phase II - Stim|Cervical dystonia in Phase 2 transcranial electrical stimulation setting is active
2882871|NCT03369613|Sham Comparator|Phase II - Sham|Cervical dystonia in Phase 2 transcranial electrical stimulation setting is sham
2882872|NCT03369600|Experimental|Study Group|Women receiving Supersonic Imagine Aixplorer SWE Ultrasound Imaging prior to surgery
2882901|NCT03369392|Experimental|Feasibility Cycle 2|Participants use the PANDA application after modifications are made based on suggestions from participants in cycle 1.
2883318|NCT03366298|Active Comparator|1|Visit 1: Emerade 300mcg then Epipen 0.3mg Visit 2: Emerade 500mcg
2882873|NCT03369587|Experimental|Diverging lines|What: Handwriting practice at home delivered through handwriting workbooks. The workbook consists of diverging lines. Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines. Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines. They will be asked to do this daily, but at least 5 days a week for 6 weeks. Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.
2882874|NCT03369587|Active Comparator|Parallel lines|What: Handwriting practice at home delivered through handwriting workbooks. The workbook consists of parallel lines. Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines. Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines. They will be asked to do this daily, but at least 5 days a week for 6 weeks. Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.
2882875|NCT03369574||chronic rhinosinusitis and eosinophilic asthma|Adults over the age of 18, diagnosed with poorly controlled moderate to severe asthma with an eosinophilic phenotype (defined by blood eosinophil count of 150 µL or greater within 6 weeks of enrollment) who are initiating/undergoing reslizumab therapy and also carry a physician diagnosis of chronic rhinosinusitis with nasal polyposis
2882876|NCT03369561||normal cardiac patient|"Full history and clinical examination ECG on the left and right side Echocardiography and measurement of both left and right ventricular functions Laboratory investigation including cardiac enzymes, CK, CK MB, and cardiac troponin I.~Serum urea and creatinine and the calculated e GFR"
2882877|NCT03369548|Experimental|Apple/ Polyphenol|Participants will be asked to consume 2 Renetta Canada apples (with skin) and 2 placebo capsules every day for 8 weeks.
2882878|NCT03369548|Experimental|Oats / Prebiotic|Participants will be asked to consume 40g jumbo rolled oats with semi-skimmed milk and 2 placebo capsules every day for 8 weeks.
2882879|NCT03369548|Experimental|Lactobacillus reuteri NCIMB 30242 / Probiotic|Participants will be asked to consume 2 probiotic capsules and 40g cornflakes with semi-skimmed milk every day for 8 weeks.
2882880|NCT03369548|Placebo Comparator|Placebo / cornflakes|Participants will be asked to consume 40g cornflakes with semi-skimmed milk and 2 placebo capsules every day for 8 weeks.
2882881|NCT03369535|Placebo Comparator|Baseline|Baseline corresponds to typical American diet
2882882|NCT03369535|Active Comparator|PROT rich diet|Protein rich diet for 6 weeks
2882883|NCT03369535|Active Comparator|MUFA rich diet|MUFA rich diet for 6 weeks
2882884|NCT03369535|Active Comparator|CARB rich diet|CARB rich diet for 6 weeks
2882885|NCT03369522||Construction|100 recordings that will be used for the algorithm development
2882886|NCT03369522||Validation|100 recordings for the validation of the algorithm
2882887|NCT03369509||hypersensitivity drug reaction|Patient followed in the allergology department for the realization of immunoallergological test after suspicion of hypersensitivity drug reaction.
2882888|NCT03369496||MoNNET-HA Panel|Adults 25 years and older residing in the Montreal Metropolitan Area
2882889|NCT03369483||CPAP|At the end of the abdominal surgical procedure, mechanical ventilation withdrawal and extubation, patients will receive Continuous Positive Airway Pressure CPAP). CPAP will be be delivered using any commercially available CPAP equipment. CPAP will be started as soon as possible after the end of surgery. The starting airway pressure (PEEP) will be 5 cmH2O. PEEP may be changed at the discretion of the responsible physician. The maximum permissible PEEP during the trial intervention period will be 10 cmH2O. CPAP may be continued after the four-hour trial intervention period has finished, at the discretion of the responsible physician.
2882890|NCT03369470|Experimental|App Dexterity|
2882891|NCT03369470|Active Comparator|Theraband|
2882892|NCT03369444|Experimental|FLT180a Treatment|Participants receiving gene therapy vector
2882893|NCT03369431|Other|Group A|Group A starts with Vivomixx probiotic for the first 12 weeks then crosses over to have the placebo after a 4-week washout.
2882894|NCT03369431|Other|Group B|Group B starts with the placebo for the first 12 weeks then crosses over to have Vivomixx probiotic after a 4-week washout.
2882895|NCT03369418|Active Comparator|Active|Subjects will be given an Alpha-Stim active device for daily treatment. The electrodes attached to the device will be active. The device frequency is preset to 0.5 Hz and 100 microampere and treatment is one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur.
2882896|NCT03369418|Sham Comparator|Inactive|"Subjects will be given an Alpha-Stim inactive device for daily treatment. The electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive. The frequency on the device will state 0.5 Hz and 100 microampere but it will not actually emit anything. Subjects in this group will receive treatment one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur."
2882897|NCT03369405||Periodontally healthy patients|Patients that have no history of periodontal treatment and that have been scheduled for routine prophylaxis appointments in the predoctoral clinics at the School of Dental Medicine, University at Buffalo.
2882898|NCT03369405||Periodontitis, group 1|Patients that have been referred from the pre-doctoral dental clinics to the Postgraduate Periodontics clinic for advanced periodontal disease. Clinical attachment loss, pain, mobility, bleeding, suppuration, and probing depths > 4 mm more likely to be prevalent.
2882899|NCT03369405||Periodontitis, group 2|Patients referred to a faculty practice periodontist over the course of his clinical career due to chronic periodontitis that could not be treated by the referring general dentist. Clinical attachment loss, pain, mobility, bleeding, suppuration, and probing depths > 4 mm more likely to be prevalent.
2882900|NCT03369392|Experimental|Feasibility Cycle 1|Participants use the initial PANDA application.
2882902|NCT03369392|Experimental|Feasibility Cycle 3|Participants use the PANDA application after modifications are made based on suggestions from participants in cycle 1 and 2.
2882903|NCT03369379|Active Comparator|D3 Vitamin|In this group subjects will receive 1 vitamin D3 capsule of 50,000 units, each week, for 12 weeks.
2882904|NCT03369379|Placebo Comparator|Placebo|In this group the subjects will receive 1 placebo capsule each week for 12 weeks.
2882905|NCT03369366|Experimental|Reconstruction and Dental Rehabilitation|Placement of NobelActive dental implants (minimum of three) using integrated osteotomy and implant placement guide.Placement of provisional screw-retained prosthesis (all while flap is still pedicled to vascular supply). Inset of flap/implant/prosthesis/custom plate construct (KLS Martin Mandibular Reconstruction Implant).
2882906|NCT03369340|Active Comparator|Product Sequence 1|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 2 on Day 2; P3P 4 on Day 3; P3P 1 on Day 4"
2882907|NCT03369340|Active Comparator|Product Sequence 2|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 4 on Day 2; P3P 1 on Day 3; P3P 2 on Day 4"
2882908|NCT03369340|Active Comparator|Product Sequence 3|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 1 on Day 2; P3P 2 on Day 3; P3P 4 on Day 4"
2882909|NCT03369340|Active Comparator|Product Sequence 4|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 1 on Day 2; P3P 4 on Day 3; P3P 2 on Day 4"
2882910|NCT03369340|Active Comparator|Product Sequence 5|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 2 on Day 2; P3P 1 on Day 3; P3P 4 on Day 4"
2882911|NCT03369340|Active Comparator|Product Sequence 6|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 4 on Day 2; P3P 2 on Day 3; P3P 1 on Day 4"
2882912|NCT03369327|Experimental|sofosbuvir/daclatasvir|Once daily fixed-dose combination pill of sofosbuvir and daclatasvir for 12 weeks if the patient is non cirrhotic and for 24 weeks if cirrhotic
2882913|NCT03369314||Patients Receiving octaplasLG®|The data will be collected in all patients who have received at least one infusion of octaplasLG®
2882914|NCT03369301||Gammanorm|Patients on Gammanorm per standard of care
2882915|NCT03369301||Other Subcutaneous Immunoglobulin|Patients on subcutaneous immunoglobulin treatments other than Gammanorm
2882916|NCT03369275|Experimental|Mesenchymal Stromal Cells (MSCs)|Intravenous infusion of 300 million Allogeneic, Bone Marrow-Derived Human Mesenchymal Stromal Cells
2882917|NCT03369275|Placebo Comparator|Placebo|Intravenous infusion of Placebo, with excipients
2882918|NCT03369262|Experimental|Active|The dose from Part A. Plus Atosiban as per label.
2882919|NCT03369262|Experimental|Placebo|OBE022 matching placebo. Plus Atosiban as per label.
2882920|NCT03369249|Experimental|Link2CARE|This arm is comprised of participants randomized to the 4-session Link2CARE intervention.
2882921|NCT03369249|No Intervention|Standard of Care|This arm is comprised of participants who will not receive the 4-session Link2CARE intervention.
2882922|NCT03369236|Placebo Comparator|Placebo|Placebo tablets 3 times daily (TID) for the first 2 weeks (Dose Adjustment Period) with the opportunity for dose adjustment, then continued for an additional 6 months (Treatment Period). At the time of treatment completion, drug will be tapered as appropriate.
2882923|NCT03369236|Experimental|ACH-0144471|ACH-0144471 tablets at a starting dose of 100 mg TID for the first 2 weeks (Dose Adjustment Period) with the opportunity for dose adjustment, then continued for an additional 6 months (Treatment Period). At the time of treatment completion, drug will be tapered as appropriate.
2882924|NCT03369223|Experimental|Arm A|BMS-986249
2882925|NCT03369223|Experimental|Arm B|BMS-986249 in combination with nivolumab
2882926|NCT03369210|Experimental|Liberal|Liberal group (patients receive a RBC unit each time Hb falls ≤ 9 g/dl (≤ 5.6mmol/l) with a target range for the post-transfusion Hb level of 9-10.5 g/dl (5.6-6.5 mmol/l)).
2882927|NCT03369210|Active Comparator|Restrictive|Restrictive group (patients receive a single RBC unit each time Hb falls ≤ 7.5 g/dl (≤ 4.7 mmol/l) with a target range for the post-transfusion Hb level of 7.5-9 g/dl (4.7-5.6 mmol/l).
2882928|NCT03369197|Experimental|Intervention: Nasal Mask|Nasal anesthesia mask with positive pressure
2882929|NCT03369197|Active Comparator|Control: Nasal cannula|Nasal Cannula with standard care
2882930|NCT03369184|Experimental|Supplemental oxygen|Inhalation of oxygen 6 L/min through an open face mask
2882931|NCT03369184|Sham Comparator|Ambient air|Breathing ambient air through an open face mask
2882932|NCT03369171|Experimental|patients with MYO armband|
2882933|NCT03369158|Experimental|MySpine|"Patients operated for spinal stabilization through patient specific pedicle screw guide MySpine"
2882934|NCT03369158|Active Comparator|Free hand technique|Patients operated for spinal stabilization through standard free hand technique
2882935|NCT03369145|Experimental|High-fat diet|Participants will consume a hypercaloric, high-fat diet. Participants will be provided with all the food during the week and will be instructed to consume all of the foods provided and no extra calorie containing food or drink. In the event of leftover food, participants will be asked to return the food for measurement and subsequent subtraction from their total energy intake.
2882936|NCT03369145|No Intervention|Control diet|Participants will consume their normal 'habitual' diet for seven days which will be compared to their habitual diet recorded by a three day food diary before commencing the two diets. Participants will be instructed to carry on as normal and eat their usual diet and this period will be used as a comparator to the high-fat diet. They will also be told to record their food intake for 3 days during the diet to quantify their control diet.
2882937|NCT03369132|Experimental|Angiflash|
2882938|NCT03369132|Placebo Comparator|Placebo|
2882939|NCT03369119|Active Comparator|Montelukast|Children received 4 mg oral montelukast granule daily until discharge.
2882940|NCT03369119|Placebo Comparator|Placebo|Children receive 4 mg oral placebo montelukast granule daily until discharge
2882941|NCT03369106||Multiple Sclerosis siblings|Group of siblings having multiple sclerosis, n=120 Composite severity score calculation for all subjects
2914925|NCT03145207|Other|generic patch|generic lidocaine patch
2882942|NCT03369093|Active Comparator|Ampicillin arm|Ampicillin arm: Patients will receive four doses of parenteral Ampicillin and single dose of Gentamicin daily for 3-5 days
2882943|NCT03369093|Experimental|Amoxicillin arm|Amoxicillin arm: Patients will receive two doses of Amoxicillin and single dose of Gentamicin daily for 3-5 days
2882944|NCT03369080||Danish National Cohort|This study includes all patients with a new Spinal Cord Injury hospitalized at Clinic for Spinal Cord Injuries, Rigshospitalet or Spinal Cord Injury Center of Western Denmark
2882945|NCT03369067|Experimental|Artificial Pancreas Therapy|Subjects will use the Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
2882946|NCT03369067|Placebo Comparator|Sensor Augmented Pump Therapy|Subjects will use a Dexcom CGM G5 and their Continuous Subcutaneous Insulin Infusion devices (insulin pumps) to modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
2882947|NCT03369054|Experimental|Minority Stress|"The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?)."
2882948|NCT03369054|Active Comparator|Treatment as Usual|Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
2882949|NCT03369028||2d and 3D image|A 2D and 3D image of the participants` face will be taken. It will at least last 2-3 sec.
2882950|NCT03369015|Experimental|Placebo, then 10 mg d-amphetamine, then 20mg d-amphetamine|
2882951|NCT03369015|Experimental|Placebo, then 20 mg d-amphetamine, then 10mg d-amphetamine|
2882952|NCT03369015|Experimental|10 mg d-amphetamine, then placebo, then 20mg d-amphetamine|
2882953|NCT03369015|Experimental|10 mg d-amphetamine, then 20mg d-amphetamine, then placebo|
2882954|NCT03369015|Experimental|20 mg d-amphetamine, then 10mg d-amphetamine, then placebo|
2882955|NCT03369015|Experimental|20 mg d-amphetamine, then placebo, then 10mg d-amphetamine|
2882956|NCT03369002|Experimental|Normal|"Child-Pugh Score: N/A~Subjects will receive a single 10 mg oral dose of seladelpar"
2882957|NCT03369002|Experimental|Mild Impairment|"Child-Pugh Score: A (5 to 6 points)~Subjects will receive a single 10 mg oral dose of seladelpar"
2882958|NCT03369002|Experimental|Moderate Impairment|"Child-Pugh Score: B (7 to 9 points)~Subjects will receive a single 10 mg oral dose of seladelpar"
2882959|NCT03369002|Experimental|Severe Impairment|"Child-Pugh Score: C (10 to 15 points)~Subjects will receive a single 10 mg oral dose of seladelpar"
2882960|NCT03368989||treatment with radium-223 Dichloride (Xofigo)|
2882961|NCT03368976||Interscalene|
2882962|NCT03368976||Supraclavicular|
2882963|NCT03368976||Infraclavicular|
2882964|NCT03368976||Transversus Abdominus Plane|
2882965|NCT03368976||Paravertebral Space|
2882966|NCT03368976||Fascia Iliaca|
2882967|NCT03368976||Femoral Nerve|
2882968|NCT03368976||Saphenous Nerve via Adductor Canal|
2882969|NCT03368976||Popliteal Sciatic Nerve|
2882970|NCT03368963|Experimental|Treatment (Nal-IRI, TAS-102)|Patients receive nanoliposomal irinotecan IV over 90 minutes on day 1 and combination of trifluridine and tipiracil hydrochloride combination agent TAS-102 PO BID on days 1-5. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
2882971|NCT03368950|Experimental|Intervention|Participants in this arm are invited to undertake an 8-week online mindfulness course
2882972|NCT03368950|Active Comparator|Wait list|Participants in this arm are informed they are on a wait list and are required to wait 8 weeks, before being invited to take part in the intervention itself (an 8-week online mindfulness course).
2882973|NCT03368937|Experimental|Tandem t:slim X2 with Control-IQ Technology|Subjects will use the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
2882974|NCT03368924|Other|SCA patients (SS genotype)|"To compare the level of anti band 3 antibodies in steady state and during vaso-occlusive crises in SCA patients.~To assess the relationship between level of biomarkers of oxidation of SS RBCs, altered hemorheological parameters, biomarkers of cellular activation (microparticles) and anti band 3 antibodies rate, taking into account the alpha-globin genes status.~To study the relationship between level of anti band 3 antibodies and severity of these VOC using an index of clinical severity (IS2) calculated at the end of SCA patients hospitalization for VOC.~To study early clinical (including the activity of the autonomic nervous system activity) and biological items to evaluate the relationship between these items and severity of VOC."
2882975|NCT03368911|Experimental|Reinforced tube group|use an reinforced endotracheal tube for endotracheal intubation during general anesthesia undergoing thyroidectomy
2882976|NCT03368911|Active Comparator|Conventional tube group|use an conventional endotracheal tube for endotracheal intubation during general anesthesia undergoing thyroidectomy
2882977|NCT03368898||Estradiol valerate|Women who were treated with E2V for HMB for 3 months.
2882978|NCT03368898||LNG-IUD|Women who were treated with LNG-IUD for HMB for 4 years.
2882979|NCT03368898||Micronized Progesterone|Women who were treated with Micronized Progesterone for HMB for 3 months.
2882980|NCT03368885|Experimental|Experimental area PCI|"In this arm, in addition to the standard care for Polio eradication program activities of CGPP project, the following interventions are added:~Maternal dietary diversity; Diet diversity in complementary feeding; Exclusive breast feeding; Community mobilization; Capacity building; Convergence;Use of existing platforms VHSND; Strategic Use of Data"
2882981|NCT03368885|No Intervention|Control area PCI|This arm will receive standard care with respect to Polio eradication program activities of CGPP such as awareness generation around Polio and routine immunization, hand washing and sanitation
2915220|NCT03143140|Other|tumor ablation|ablation of tumor directly
2882982|NCT03368872|Experimental|Astaxanthin and exercise|Astaxanthin formulation intake for one month followed by a 3-month exercise training program with astaxanthin formulation intake.
2882983|NCT03368872|Placebo Comparator|Placebo and exercise|Placebo intake for one month followed by 3-month exercise training with placebo intake.
2882984|NCT03368859|Experimental|ABT-165 plus FOLFIRI|ABT-165 plus FOLFIRI (irinotecan, leucovorin, fluorouracil).
2882985|NCT03368859|Active Comparator|Bevacizumab plus FOLFIRI|Bevacizumab plus FOLFIRI (irinotecan, leucovorin, fluorouracil).
2882986|NCT03368846|Experimental|[14C]-Varlitinib|
2882987|NCT03368833||Caudal block|Patients that receive regional anesthesia in the form of a caudal block prior to surgery as part of their standard of care.
2882988|NCT03368833||Control|Patients who do not receive a caudal block.
2882989|NCT03368807||Blinded Study Period 1|Insulin lispro doses as prescribed delivered via the pen. CGM data blinded.
2882990|NCT03368807||Unblinded Study Period 2|Insulin lispro doses as prescribed delivered via the pen. CGM data unblinded.
2882991|NCT03368794|Experimental|Intervention|Telephone alert signal from ambulance staff to out-patient substance use disorder treatment facility, for active outreach aiming to locate and include the patient in long-term evidence-based treatment for the substance use disorder.
2882992|NCT03368794|Active Comparator|Control|Information-only. Ambulance staff hand over written information to the individual about how to seek treatment for the substance use disorder.
2882993|NCT03368781|Experimental|AcQMap Imaging and Mapping|Use of the AcQMap Imaging and Mapping System as a diagnostic modality in an ablation retreatment procedure for recurrent atrial fibrillation following a failed AF ablation.
2882994|NCT03368768||Contact group email of Mahidol-Oxford Research Unit (MORU)|The investigator aims to have at least 100 adult people who could provide information for the total of one year. This expects that at least 20 of those 100 people would have common cold or diarrhea at least one time over one year period. This should provide more than 80% power to detect whether the proportion of having antibiotics when they have common cold or diarrhea was lower than 50% or not. The hypothesized proportion was 20% as stated by the national strategy against AMR in Thailand
2882995|NCT03368755|Experimental|Cases (IUGR)|50 school-aged children (7-10 years old) exposed to IUGR (birth weight <10th percentile & fetal ultrasound documentation) and of comparable gestational age with controls Intervention: Cardiopulmonary Exercise Testing and Respiratory Muscle Strength and Endurance
2882996|NCT03368755|Active Comparator|Controls|"100 school-aged children (7-10 years old) not exposed to IUGR (birth weight <10th percentile & fetal ultrasound documentation) and of comparable gestational age with cases.~Intervention: Cardiopulmonary Exercise Testing and Respiratory Muscle Strength and Endurance"
2882997|NCT03368742|Experimental|SGT-001 - Dose Level 1|Single IV infusion of SGT-001 at starting dose
2882998|NCT03368742|Experimental|SGT-001 - Dose Level 2|Single IV infusion of SGT-001 at next ascending dose
2882999|NCT03368742|Experimental|SGT-001 - Dose Level 3|Single IV infusion of SGT-001 at selected dose
2883000|NCT03368742|No Intervention|Untreated Control|Untreated control group. After 1 year, treatment-eligible control patients will receive SGT-001 at the selected dose.
2883001|NCT03368729|Experimental|Phase 1: 300 mg/kg Niraparib + 6 mg/kg Trastuzumab|In phase 1 patients in this first arm will receive 300 mg/kg Niraparib in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.
2883002|NCT03368729|Experimental|Phase 1: 200 mg/kg Niraparib + 6 mg/kg Trastuzumab|In phase 1 patients in this second arm will receive 200 mg/kg Niraparib in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.
2883003|NCT03368729|Experimental|Phase 2: 200 or 300 mg/kg Niraparib + 6 mg/kg Trastuzumab|The dosage of Niraparib in phase 2 will be determined by the response of patients in Phase 1. A dosage of 300 mg/kg Niraparib will be given along with 6 mg/kg Trastuzumab IV unless a dose limiting toxicity occurs in Phase 1. If so, 200 mg/kg Niraparib will be given with the 6 mg/kg Trastuzumab (instead of 300 mg/kg Niraparib.)
2883004|NCT03368716|Experimental|Acceptance-based Behavioral Treatment|Family acceptance-based behavioral treatment (ABBT) will be piloted with 16 child-caregiver pairs. At months 0 (pre-treatment), 3 (mid-treatment), and 6 (post-treatment), feedback regarding the feasibility and acceptability will be collected from participants through surveys and semi-structured group interviews to refine the family ABBT protocol.
2883005|NCT03368703|Experimental|COPD patients|COP patients group
2883006|NCT03368703|Active Comparator|Healthy subjects|Healthy subject group, matched with COPD patients group on age, weight and BMI
2883007|NCT03368690|Experimental|Oligopin®|"Dietary supplement, Polyphenolic extract from pine bark. This group receives a nutritional supplement for a period of 10 weeks.~Children and adolescent 20-50 kg body weight: 25 mg Oligopin®/day; > 50 kg body weight: 50 mg Oligopin®/day Adults 40-60 kg body weight: 100 mg Oligopin®/day; > 60 kg body weight: 150 mg Oligopin®/day"
2883008|NCT03368690|Placebo Comparator|Placebo|Placebo treatment ( identical capsules containing maltodextrin and magnesium stearate )
2883009|NCT03368677||Teriflunomide group|20 MS patients who are using teriflunomide medication under the supervision of their treating neurologist.
2883010|NCT03368677||No disease modifying treatment|10 MS-patients who do not use any regular disease modifying MS treatment of their own volition
2883011|NCT03368664|Experimental|alemtuzumab|Dose 1 (initial course) of alemtuzumab will be administered intravenously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, prednisolone, H1 antagonist [antihistamine], H2 antagonist, paracetamol, acyclovir) will be administered prior alemtuzumab administration.
2883012|NCT03368651|Experimental|treatment group|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
2883013|NCT03368651|No Intervention|control group|no neo-adjuvant treatment before operation
2883014|NCT03368638|Experimental|Intervention|
2883015|NCT03368625|Other|Arm 1|Neoadjuvant SRS
2883016|NCT03368599|Experimental|Bronchoscope guide group|DLT is advanced into the main bronchus through the guide of fiberoptic bronchoscope (Bronchoscope guided advancement).
2883017|NCT03368599|Active Comparator|Conventional group|DLT is advanced blindly to the main bronchus level (Conventional advancement).
2883044|NCT03368404|Experimental|CBL-102 eye drops|CE marked medical device, tear substitute containing 0.24% hyaluronic acid salt, carbomer and medium chain triglycerides
2915694|NCT03139981|Experimental|ASN002 40 mg|40 mg ASN002
2883018|NCT03368573|No Intervention|Control Arm|Participants in the control arm will undergo standard treatment as usual for ADHD. This will involve the clinician reviewing the child's symptom improvement once on medication and altering the dose according to their clinical judgement which may be informed by rating scales (completed by the parent, teacher and/or young person) and interviews with the parent and young person.
2883019|NCT03368573|Experimental|Experimental Arm|Participants in the experimental arm (QbTest) protocol will also undergo standard assessment as usual plus a QbTest. If a QbTest was not conducted within 12 weeks prior to starting medication (as part of the ADHD diagnostic assessment procedure) the young person will sit a QbTest at baseline (off medication). Once on medication they will sit another QbTest 2-4 weeks after commencing medication and again 8-10 weeks later (and no later than 12 weeks).
2883020|NCT03368560|Active Comparator|Sudarshan Kriya Yoga|Thirty participants with treatment-resistant late life depression (TR-LLD) will attend 5 instructional days of Sudarshan Kriya Yoga (SKY), followed by 3 weekly follow-ups, and 8 weeks of bimonthly follow-ups. Participants will also practice SKY for 25 minutes per day at home. These participants will attend 4 mental health assessments at weeks 0, 4, 8, and 12. Thirteen of the recruited TR-LLD will attend an MRI at baseline and post-intervention.
2883021|NCT03368560|No Intervention|Control|The seven recruited age-matched controls will complete a screening appointment and an MRI only for comparison. Demographic information will also be collected from the control participants. These individuals will not undergo the study intervention.
2883022|NCT03368547|Experimental|Diagnostic (68Ga-PSMA-11, PET/CT)|Patients receive 68Ga-PSMA-11 IV and undergo a single PET/CT scan over 45-60 minutes at week 1
2883023|NCT03368534|Experimental|Skin Wound Patients|Patients will receive ART for wound healing and will be followed for 28 days to determine success of the procedure.
2883024|NCT03368521|Other|Back pain screening group|Includes the Group of patients where the care giver has used the back pain screening tests studied in order to judge how to proceed with rehabilitation, which level of rehabilitation is appropriate.
2883025|NCT03368521|No Intervention|treatment as usual|The Group get treatment as usual, where the care giver base the rehabilitation plan without taking the scorings from the screening tool into consideration.
2883026|NCT03368508|Experimental|Experimental group|To view a 360-degree simulating video on physiotherapy assessment in lumbar spine
2883027|NCT03368508|Active Comparator|Control group|To view a conventional video on physiotherapy assessment in lumbar spine
2883028|NCT03368495|Experimental|Co-administration of MMR/YF|Participants randomized to this arm will receive both MMR and yellow fever vaccines on Day 0.
2883029|NCT03368495|Active Comparator|MMR followed by YF|Participants randomized to this arm will receive MMR vaccine on Day 0 followed by yellow fever vaccine on Day 28.
2883030|NCT03368495|Active Comparator|YF followed by MMR|Participants randomized to this arm will receive YF vaccine on Day 0 followed by MMR vaccine on Day 28.
2883031|NCT03368482|Experimental|Brain Gym Exercises|Brain Gym® (BG) is a movement-based program originally designed to improve learning capabilities through the performance of mind-body exercises. BG can be considered as an interesting field of research due to the need of identifying novel therapies which might be more pleasant for older adults who tend not to be prone to participating in conventional exercise programs and might have a positive effect on their cognitive function. In spite of this, scientific evidence regarding the effects of BG on people with cognitive impairment is scarce.
2883032|NCT03368482|Active Comparator|Standard Exercises|A traditional physical exercise program designed for institutionalized elderly people aimed at increasing their range of mobility and coordination, specifically focused on the lower limbs.
2883033|NCT03368469|Experimental|transcranial direct current stimulation|Transcranial direct current stimulation (35 sq cm anode over left dorsolateral prefrontal cortex, 35 sq cm cathode over right supraorbital area, 1 mA current, 20 min per treatment session, 1 session per day, 10 treatment sessions over two weeks)
2883034|NCT03368456|Experimental|S4E App Intervention|Participants in the S4E condition will first receive the intervention in the waiting area via iPads provided for them. Content includes the theoretically driven components of Storytelling for Empowerment: (a) Storytelling scenarios, (b) drug use and HIV/STI knowledge development, (c) interactive activities, (d) increasing self-efficacy to prevent/reduce sexual risk and drug use behaviors, and increase HIV/STI testing, (e) clinician-youth communication, and (f) highlighting prevention principles
2883035|NCT03368456|Placebo Comparator|Usual Care Condition|Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.
2883036|NCT03368443|Active Comparator|Single-room group|The participants assigned to the Single-room group will receive treadmill training and overground gait training in one room (Room A) throughout the training sessions.
2883037|NCT03368443|Experimental|Two-room group|The participants in the Two-room group will receive treadmill training and overground gait training in 2 rooms (Room A and B) in an alternating order.
2883038|NCT03368443|Experimental|Three-room group|The participants assigned to the Three-room group will receive treadmill training and overground gait training in 3 different rooms (Room A, B, and C) in a pseudorandom order so that the participants will not practice in the same room for two consecutive sessions.
2883039|NCT03368430|Experimental|Melatonin|10 mg melatonin capsule was given to participants in the test group once per day for only 2 months after performing scaling and root planing (SRP) during the whole 6- month period of the study.
2883040|NCT03368430|Placebo Comparator|Placebo|Matching placebo capsule was given to the control group once daily for 2 months after receiving scaling and root planing (SRP) during the whole 6- month period of the study.
2883041|NCT03368417|Active Comparator|Usual Care|Usual care from SingHealth Polyclinics which includes non-wireless HBPM. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
2883042|NCT03368417|Experimental|Wireless HBPM System|Usual care from SingHealth Polyclinics with wireless HBPM system. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
2883043|NCT03368417|Experimental|Wireless HBPM System and Incentives|Usual care from SingHealth Polyclinics with wireless HBPM system and BP monitoring incentives. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
2883045|NCT03368404|Active Comparator|Vismed Multi eye drops|CE marked medical device, tear substitute containing 0.18% sodium hyaluronate
2883046|NCT03368391|Other|Sequence 1|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.~Sequence 1 participants will receive the drugs in the following sequence: 1) tetracaine HCl and oxymetazoline HCl 2) 3% mepivacaine 3) 2% lidocaine with 1:100,000 epi"
2883047|NCT03368391|Other|Sequence 2|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.~Sequence 2 participant will receive the drugs in the following sequence: 1) 2% lidocaine with 1:100,000 epi 2) tetracaine HCl and oxymetazoline HCl 3) 3% mepivacaine"
2883048|NCT03368391|Other|Sequence 3|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.~Sequence 3 participants will receive the drugs in the following sequence: 1) 3% mepivacaine 2) 2% lidocaine with 1:100,000 epi 3) tetracaine HCl and oxymetazoline HCl"
2883049|NCT03368378|Experimental|Group 1|During robot-assisted radical prostatectomy after the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
2883050|NCT03368378|Active Comparator|Group 2|After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The bladder neck will be then incised and preserved when possible. An inter-fascial or intra-fascial nerve-sparing technique will be then performed and the posterolateral aspect of the neurovascular bundles will be preserved. The DVC will be then isolated and selectively ligated using a V-lok 3/0 barbed suture. The anterolateral fibers of the neurovascular bundles will be then identified and preserved when possible. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
2883051|NCT03368365|Other|Ventilotel ®|Using of the spirometer of Aqsitania company, Ventilotel ®.
2883052|NCT03368352|No Intervention|Normoxia|Sleep in normal room air with no drug
2883053|NCT03368352|Placebo Comparator|Hypoxia with Placebo|Sleep in hypoxic tent after taking Placebo 1 hour before bed.
2883054|NCT03368352|Experimental|Hypoxia with Melatonin|Sleep in hypoxic tent after taking 5 mg Melatonin before bed.
2883055|NCT03368339|Active Comparator|PR013 topical Ophthalmic Drops (0.045%)|
2883056|NCT03368339|Active Comparator|PR013 topical Ophthalmic Drops (0.06%)|
2883057|NCT03368339|Placebo Comparator|Vehicle|
2883058|NCT03368313|Experimental|Compression arm|The compression arm will receive an adjustable velcro compression device for the calf (Circaid Juxtalite® Lower Leg; Medi Gmbh, Bayreuth, Germany), thigh and knee (Circaid Juxtafit; Medi Gmbh, Bayreuth, Germany). The Circaid device will be applied with an average pressure of more than 40 mmHg, verified through a BPS (built-in pressure system).
2883059|NCT03368313|No Intervention|Control arm|No compression
2883060|NCT03368300|Other|Patients|Parkinson's patient
2883061|NCT03368300|Other|witnesses: without parkinson's disease|Subjects without parkinson's disease
2883062|NCT03368287|Experimental|activity tracker|In this study, Fitbit One, the activity tracker, will be used for every participants to evaluate the daily steps before and after surgery for one year
2883063|NCT03368274|Experimental|Signal arm study|Patients with mild symptom IgG4-RD are enrolled and inject one dosage of diprospan ,then take Iguratimod (T614), 25mg, Bid orally for three months. Firstly, we evaluate IgG4-RD responder index of patients at baseline and follow-up time.We collect the laboratory parameters and blood for lymphocytes subpopulations by flowcytometry.
2883064|NCT03368261|Other|HTAP/ clinical complications in the sickle cell disease|Supply epidemiological data on this detected HTAP, and allow the characterization of the clinico-biological paintings and the mortality which are associated to them.
2883065|NCT03368248||All neonatal resuscitation services.|All professionals in contact with children were interviewed: doctors (senior and intern), paramedics (managers, pediatric nurses, auxiliaries and nurses, psychomotor therapists) and psychologists. The survey was based on a questionnaire, which was offered to all professionals, both medical and non-medical.
2883066|NCT03368235|Experimental|AZD9567|oral suspension of 40 mg AZD9567 once daily (OD) for two weeks
2883067|NCT03368235|Active Comparator|Prednisolone|oral OD treatment of 20 mg prednisolone administered as capsules
2883068|NCT03368222|Experimental|Dose Escalation / Expansion|"Part A - Dose escalation cohort. DOSE LEVEL 1: 200mg pembrolizumab week 1 (then 3 weekly) + Sterotactic Body Radiotherapy (SBRT) dosed at 30 Gy in 3 fractions (#) (Monday, Wednesday & Friday) in week 3.~DOSE LEVEL 2: 200mg pembrolizumab in week 1 (then 3 weekly) + SBRT dosed at 54 Gy in 3# (Monday, Wednesday & Friday) in week 3.~Part B - Expansion cohort. 12 patients 200mg of pembrolizumab week 1 (then 3 weekly) + SBRT in week 3, dosed at MTD determined in Part A (3# - Monday, Wednesday & Friday)."
2883069|NCT03368209|Experimental|OUH protocol|"The protocol constituted two outpatient visits in the clinic within one week. Each visit had a duration of approximately 2,5 hours. Prior to study, optical screenings were conducted:~Optical Coherence Tomography (OCT)~Optical screening on measuring site with WM3.4.~Subjects were measured by the following scheme: ABL measurement, two optical measurements on WM3.4 #1 followed by two optical measurements on WM3.4 #2."
2883070|NCT03368209|Experimental|Home 1 protocol|"Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue was used for reference."
2883071|NCT03368209|Experimental|Home 2 protocol|"Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue and CGM/FGM was used for reference."
2883072|NCT03368196|Experimental|DS-8201a|DS-8201a administered by intravenous infusion on Day 1 of each cycle, once every 3 weeks (Q3W)
2883073|NCT03368183|Experimental|SCAMP arm|The SCAMP is a clinical decision support tool. See Mendu et al. CJASN 2017.
2883210|NCT03367104||Normal healthy controls|
2883074|NCT03368183|Active Comparator|"Control arm SHAM SCAMP"|The control arm will be a form that asks questions about indications for renal replacement therapy but does not provide suggestions about when to initiate renal replacement therapy, as is being done in the active SCAMP arm. The goal of the control group is to test whether the SCAMP clinical decision support influences provider practice patterns and improves care.
2883075|NCT03368170|Experimental|IRL790|Capsule 2.5 mg, oral administration
2883076|NCT03368170|Placebo Comparator|Placebo|Identical capsule, oral administration
2883077|NCT03368144|Experimental|ClearLumen II Peripheral Thrombectomy System|Patients treated with the ClearLumen II Peripheral Thrombectomy System
2883078|NCT03368131|Experimental|Trastuzumab XELOX and radiotherapy|Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle. XELOX：Capecitabine 825~1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45 Gray (unit)Gy/25f （1.8Gy/f/d，5 f/w）
2883079|NCT03368131|Active Comparator|XELOX and radiotherapy|Capecitabine：825~1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
2883080|NCT03368118|Experimental|ABX464 Treatment arm|All subjects will receive ABX464 at 50 mg o.d for an overall period of 12 months.
2883081|NCT03368105|Experimental|LP299v group|Participants: one capsule of LP299v orally per a day during the entire period of antibiotic therapy.
2883082|NCT03368105|Placebo Comparator|Placebo group|Participants: one capsule of placebo orally per a day during the entire period of antibiotic therapy.
2883083|NCT03368092|Experimental|Dornase alfa|Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.
2883084|NCT03368092|Placebo Comparator|Placebo|NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.
2883085|NCT03368079|Experimental|Negative Pressure Suction Device|
2883086|NCT03368066|Experimental|Hospitalized cirrhosis patients|Administration of cortisol stimulation test to assess for presence or absence of adrenal insufficiency
2883087|NCT03368053|Experimental|GSKSB732461 Group|Healthy HIV uninfected volunteers who participated in study PRO HIV-002 between February 2003 and February 2005 and who were vaccinated with at least 3 doses of the GSKSB732461 vaccine candidate.
2883088|NCT03368027|Experimental|Stress management program|A cognitive-behavioral program of coping with psychological stress for 3 months (with a total of 12 sessions), one session per week, with a duration of 90 minutes per session.
2883089|NCT03368027|Active Comparator|Standard intervention|Usual activities performed in the association where they attend (supervised by a psychologist) for 3 months (with a total of 12 sessions), one session per week, with a duration of 90 minutes per session.
2883090|NCT03368014|Experimental|Lyrics-writing and singing show|The one-hour lyrics-writing and singing workshop was conducted first at the beginning of the programme for the intervention group, followed by two small workshops teaching lyrics-writing skills and the lyrics-writing competition after the workshop. A lyrics writing and singing show and an award ceremony will be held at the end.
2883091|NCT03368014|No Intervention|Waitlist control|The workshops will not be provided to the control schools during the evaluation period and will be provided after the evaluation period.
2883092|NCT03368001|Experimental|SENSE Theatre|SENSE Theatre is a peer-mediated, theatre-based intervention targeting social competence in youth with autism spectrum disorder. The 40 hour intervention is comprised of 10 sessions in which trained typically peers are paired with children with autism spectrum disorder (ASD).
2883093|NCT03368001|Active Comparator|Tackling Teenage Together|The Tackling Teenage Together is a psychosocial and sexual education program developed for youth with ASD. It is comprised of 10 sessions.
2883094|NCT03367988|Experimental|Opioid-free Anesthesia|Patients will receive no intraoperative narcotics as part of their anesthesia regimen
2883095|NCT03367988|Active Comparator|Opioid Anesthesia|Patients will receive intraoperative narcotics as part of their anesthesia regimen
2883096|NCT03367962|Experimental|Highly suspected to already have aGVHD|Patients highly suspected to have aGVHD. These patients will undergo a [18F]F-AraG PET-CT scan following a biopsy taken to confirm aGVHD.
2883097|NCT03367962|Experimental|High risk of developing aGVHD|Patients at high risk of developing aGVHD will undergo a [18F]F-AraG PET-CT scan on day 4 +/- 2 days post transplant. Additionally these patients will be scanned again between day 14-21 post transplant.
2883098|NCT03367962|Experimental|Healthy Subjects|Healthy subject volunteers will undergo preliminary evaluation to ensure eligibility, receive and sign an informed consent, be enrolled in the trial, and then have a [18F]F-AraG PET-CT scan.
2883099|NCT03367949|No Intervention|Accuracy of surgical guide from Model optical scan|
2883100|NCT03367949|Active Comparator|Accuracy of surgical guide from Impression inversion Technique|
2883101|NCT03367936|Active Comparator|Self-monitoring group|All subjects will use a smartphone to self-monitor diet (LoseIt!), Fitbit Charge HR to monitor physical activity, and a Withings digital scale for weight. Following randomization, participants will be oriented to Self-monitoring and provided a tutorial with images shown on the laptop and devices as well as printed materials showing the screen shots. At this baseline session, each participant will have a one-on-one session with the project interventionist, which covers the core principles of behavioral weight loss. The participant also will be given personalized fat, calorie, and PA goals for weight loss and information about how to access the intervention materials from the Diabetes Prevention Program (DPP) online which is publically available(https://www.diabetesprevention.pitt.edu/).
2883102|NCT03367936|Experimental|Self-monitoring+Feedback group|All subjects will be asked to do everything the self-monitoring group is ask to do. Subjects will receive up to 4 Feedback messages per day (messages will be delivered between the hours set by the participants on the participant's phone, e.g., 8 AM and 9:30 PM). Messages will be delivered automatically, remotely and in real-time. it will be tailored to each participant's progress based on standardized algorithms. The Feedback program will be explained to them and how this is responsive to information entered on the self-monitoring diaries.
2883103|NCT03367923|Experimental|Arm I (exercise counseling, Fitbit, phone call)|Participants undergo an exercise counseling session at baseline and wear Fitbit tracker daily for 9 months. Participants receive a short phone call at 2, 4, 6, and 8 weeks, and at 4 and 5 months to discuss the average number of daily steps over the past 2 weeks and to encourage a goal of a 10% increase over the next 2-4 week time period.
2883104|NCT03367923|Experimental|Arm II (exercise counseling, Fitbit, email/text)|Participants undergo an exercise counseling session at baseline and wear Fitbit tracker daily for 9 months. Participants receive an electronic communication (email/text) of their choice at 2, 4, 6, and 8 weeks, and at 4 and 5 months stating the average number of daily steps over the past 2 weeks and encouraging a goal of a 10% increase over the next 2-4 week time period.
2883105|NCT03367910|Experimental|FMT for MDRO UTI|Participants with eligible MDRO UTIs will receive FMT (150mL of RBX2660) via enema.
2883106|NCT03367897||Bleeding ulcer/erosions|Patients with hematemesis and/or melena, anemia or positiv FOBT that during gastroscopy are diagnosed with ulcer and/or erosions of the ventricle and/or duodenum. Gastroscopy must be performed within 72 hours of the findings above.
2883107|NCT03367897||Peptic ulcer without bleeding|Control group for H. pylori will be patients with peptic ulcer without bleeding. These patients are systematically registered at SØ from August 2013 through the ongoing European registration study - HpEuReg study. SØ participate in this study, together with 9 other Norwegian hospitals, which is approved by REK.
2883108|NCT03367884|Experimental|Neck dissection group|Neck dissection followed by radiotherapy(50Gy) according to risk factors
2883109|NCT03367884|Active Comparator|Radiotherapy group|Definitive radiotherapy (70Gy)
2883110|NCT03367871|Experimental|Pembrolizumab, Chemotherapy, Bevacizumab|"On day 1 of each 21 day cycle, for 3 cycles. Participants achieving at least stable disease after 3 cycles will continue to receive the same regimen every 21 days until disease progression, unacceptable toxicity or complete resolution of the disease:~Pembrolizumab 200mg (IV),~Standard of Care: Paclitaxel 175mg/m2 or 135 mg/m2 (IV), and~Standard of Care: Cisplatin 50mg/m2 (IV) or Carboplatin AUC 5, after Paclitaxel~Bevacizumab 15mg/kg (IV) after Cisplatin/Carboplatin"
2883111|NCT03367858|Experimental|Motivational Interviewing (MI)|
2883112|NCT03367858|Active Comparator|Brief Adolescent Mindfulness (BAM)|
2883113|NCT03367845|Experimental|Control|Phone contacts with content not focusing on sensitivity or couples' relationships
2883114|NCT03367845|Experimental|Sensitivity Intervention|Home visits to enhance mother-infant and father-infant parental sensitivity
2883115|NCT03367845|Experimental|Couples Intervention|Home visits to enhance constructive couples' communication
2883116|NCT03367845|Experimental|Sensitivity and Couples Intervention|Home visits combining sensitivity and couples' interventions
2883117|NCT03367832||Paediatric surgical patients|All patients < 16 years, admitted to participating centres during the study period who undergo elective and non-elective surgery
2883118|NCT03367819|Experimental|Phase 1: mCRPC/NSCLC|Isatuximab dose 1 and REGN2810 predefined dose
2883119|NCT03367819|Experimental|Cohort A-1: mCRPC, isatuximab and REGN2810 combination|Patients with mCRPC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
2883120|NCT03367819|Experimental|Cohort A-2: mCRPC, isatuximab monotherapy|Patients with mCRPC will be given isatuximab dose 2
2883121|NCT03367819|Experimental|Phase 2 Cohort B: NSCLC|Patients with NSCLC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
2883122|NCT03367819|Experimental|Phase 2 Cohort C: mCRPC|Isatuximab dose 3 will be given in combination with REGN2810 predefined dose or isatuximab dose 3 will be given as monotherapy in patients with mCRPC
2883123|NCT03367819|Experimental|Phase 2 Cohort D: NSCLC|Isatuximab dose 3 will be given in combination with REGN2810 predefined dose
2883124|NCT03367793|Experimental|Clinical, then Metric #1, then Metric #2|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the clinically derived prescription first, followed by the metric-derived #1, and lastly the metric-derived #2.
2883125|NCT03367793|Experimental|Clinical, then Metric #2, then Metric #1|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the clinically derived prescription first, followed by the metric-derived #2, and lastly the metric-derived #1.
2883126|NCT03367793|Experimental|Metric #1, then Clinical, then Metric #2|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #1 prescription first, followed by the clinically derived prescription, and lastly the metric-derived #2 prescription.
2883127|NCT03367793|Experimental|Metric #2, then Clinical, then Metric #1|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #2 prescription first, followed by the clinically derived prescription, and lastly the metric-derived #1 prescription.
2883128|NCT03367793|Experimental|Metric #1, then Metric #2, then Clinical|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #1 prescription first, followed by the metric-derived #2 prescription, and lastly the clinically derived prescription.
2883129|NCT03367793|Experimental|Metric #2, then Metric #1, then Clinical|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #2 prescription first, followed by the metric-derived #1 prescription, and lastly the clinically derived prescription.
2883130|NCT03367780||RT with curative intent for HNSCC|several schemes for radical (chemo)radiotherapy, administered in 30‐35 fractions over 6‐7 weeks
2883131|NCT03367767||1|Former AREDS2 and AREDS2 Follow-On participants
2883132|NCT03367754|Experimental|1|Single dose of 200 mg (IV infusion)
2883133|NCT03367754|Placebo Comparator|2|Single dose (IV infusion)
2883134|NCT03367741|Experimental|Arm A (cabozantinib, nivolumab)|Patients receive cabozantinib PO QD on days 1-28 and nivolumab IV over 60 minutes on days 1 and 15, then on day 1 beginning course 5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2883135|NCT03367741|Experimental|Arm B (nivolumab)|Patients receive nivolumab as in Arm A. Patients may cross-over to Arm A at the time of disease progression. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2883136|NCT03367728|Placebo Comparator|TAP and Rectus Sheath Normal Saline|TAP and Rectus Sheath Block of 60 mL Normal Saline divided into 4 injections administered as in Experimental Arm.
2883137|NCT03367728|Experimental|TAP and Rectus Sheath ropivacaine|The block will be administered in the anterior abdominal wall. For the TAP block, the standard technique will be followed- at the anterior axillary line midway between the subcostal margin and iliac crest. For the rectus sheath block, a bilateral sub-xiphoid approach will be used. There will be 4 injection sites in total and the size of the needle will be standardized to an 18g spinal needle 10cms. Using laparoscopic visualization, the transversus abdominis muscles were identified lateral to the semilunar line. Ropivacaine to be infiltrated will be divided into 4 equal amounts. The procedure is then repeated 2 times in the transversus abdominis plane (20mL each) and 2 times as a Rectus Sheath Block (10mL each) with a total amount of 60 mL.
2883138|NCT03367715|Experimental|Nivolumab + Ipilimumab + Short-course radiation therapy|within 6 weeks of the first diagnostic surgery for glioblastoma, all subjects will initiate study treatment on Day 1
2883139|NCT03367702|Active Comparator|Intensity-Modulated Radiation Therapy (IMRT)|Patients undergo Intensity-Modulated Radiation Therapy (IMRT) once daily 5 fractions per week for 28 fractions over less than 32 business days.
2883140|NCT03367702|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients undergo Stereotactic Body Radiation Therapy (SBRT) at least every other day for 2-3 fractions per week for 5 fractions over less than 12 business days.
2883141|NCT03367689|Experimental|Olaparib 300 mg|Patients whose tumours are identified as Homologous Recombination Deficient, will receive olaparib 300 mg (two tablets of 150mg) orally twice daily (bid) on days 1-28 each 28 days.
2883142|NCT03367676|Experimental|Experimental Arm|12 weeks adjuvant docetaxel plus trastuzumab
2883143|NCT03367663|Experimental|low dose|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
2883144|NCT03367663|Experimental|high dose|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
2883145|NCT03367650|Other|ALS's patients in Guadeloupe and Martinique|"We shall determine:~Impact of ALS in Guadeloupe and Martinique~Prevalence of the ALS in Guadeloupe and Martinique on the duration of the study~The distribution of ALS various phenotypes in our population of patients.~We shall collect the date of the beginning of the symptoms of the SLA, the date of diagnosis of ALS, the date of death for the same individual and the origin of the death, the weight, the size, the albumin, CRP; in order to establish the forecast of the various clinical forms, the description of the evolution of the nutritional state.~Search for transfers of genes TARDBP, VCP, SOD1 known and involved in the disease~Search for possible environmental factors"
2883146|NCT03367637|Active Comparator|Standard Care|"Patients in this arm will receive standard palliative care currently provided at the Rwanda Palliative and Hospice Care Organization (RPCHO).~Standard care also includes regular follow-up phone calls and home visits by the RPCHO staff, though the timing of these calls is variable and is selected by the discretion of the team. In addition, patients can contact providers on a landline number available during business hours and staffed by an on-call palliative care provider as and when needed."
2883147|NCT03367637|Experimental|Intervention|Patients in this arm, in addition to the standard palliative care currently provided at the RPCHO, will receive biweekly frequency reminders to fill out the African Palliative Care Outcomes Scale (APCA POS) on the new smart phone based symptom evaluation application on their phones. It is a short symptom assessment questionnaire with responses on 5-point severity scale. In addition to bi-weekly, patients can complete the symptom assessment at any time they feel their symptoms are poorly controlled. The team at RPCHO will be able to track all enrolled patients on a desktop dashboard. Any score of 2 or higher will be flagged. The providers at RPCHO will respond to such patients during business hours via call or text and will advise the patients as indicated or triage to a fellow team member.
2883148|NCT03367611|Experimental|Immunochemical faecal occult blood test|All participants will collect a single faecal sample for haemoglobin measurement (immunochemical faecal occult blood test, iFOBT), and be examined by colonoscopy.
2883149|NCT03367598||Normal weight|nondiabetic and nonobese individuals (18.5 kg/m2 ≤ BMI < 25 kg/m2, n=349)
2883150|NCT03367598||Overweight|nondiabetic and nonobese individuals (25 kg/m2 ≤ BMI < 30 kg/m2, n=154)
2883151|NCT03367585|Experimental|Experimental|The experimental group, which will supplement vitamin D3 50,000 IU / week, being in two capsules (25,000 IU / week each),
2883152|NCT03367585|Placebo Comparator|Placebo|The placebo group will inject two capsules of equal size, volume and coloration, composed of lactose, without the vitamin D3 supplement.
2883153|NCT03367572|Experimental|Group I (netupitant/palonosetron hydrochloride, dexamethasone|Within 1 hour prior to chemotherapy, patients receive netupitant/palonosetron hydrochloride PO on day 1. Within 30 minutes prior to chemotherapy, patients also receive dexamethasone PO on days 1-4. Patients also receive placebo PO with chemotherapy Q8H on days 1-4.
2883154|NCT03367572|Experimental|Group II (net/pal hydro, dexa, prochlorperazine, placebo)|Patients receive netupitant/palonosetron hydrochloride and dexamethasone as in Group I. Patients also receive prochlorperazine PO Q8H and placebo PO with chemotherapy on days 1-4.
2883155|NCT03367572|Experimental|Group III (net/pal hydro, dexa, olanzapine, placebo)|Patients receive netupitant/palonosetron hydrochloride and dexamethasone as in Group I. Patients also receive olanzapine PO and placebo PO Q8H with chemotherapy on days 1-4.
2883211|NCT03367104||Heart failure patients|
2883156|NCT03367559|Experimental|Rotavirus Vaccine|3 dose, interval for each dose is 4 weeks. The first dose will be received at 6-8 weeks of age.
2883157|NCT03367546|Experimental|rATG, FLU/CY/TBI, & Thiotepa|Anti-Thymocyte Globulin - Rabbit (rATG), Fludarabine (Fludara), Cyclophosphamide (Cytoxan, Neosar), Total Body Irradiation (TBI), & Thiotepa
2883158|NCT03367533|Experimental|ketamine plus perampanel|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive 6 milligrams (mg) oral perampanel and intravenous ketamine. Participants will then undergo a 2-hour magnetic resonance imagining (MRI) scan. The following day, participants will return for an additional scan and symptom assessment.
2883159|NCT03367533|Placebo Comparator|ketamine plus placebo|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive an oral placebo (in lieu of 6 mg oral perampanel) and intravenous ketamine. Participants will then undergo a 2-hour MRI scan. The following day, participants will return for an additional scan and symptom assessment.
2883160|NCT03367520|Experimental|StayQuit|StayQuit offers 3 meetings during hospitalization and up 13 telephone calls. StayQuit begins in the hospital with an assessment of motivation to remain quit after discharge and a brief intervention to develop discrepancy between values and behaviors and generate change talk. Participants are also encouraged to try nicotine replacement therapy during the hospitalization and after discharge. Telephone counseling is brief and focused on managing withdrawal from nicotine, coping with cravings, and supporting use of NRT. The investigators will work with hospital staff as needed to ensure that nicotine replacement therapy is offered to participants during the inpatient stay and prescribed at discharge.
2883161|NCT03367507|Experimental|80% Sub-symptom threshold aerobic exercise|The moderate intensity intervention group will exercise at 80% of the maximum symptom free heart rate identified by their most recent graded treadmill test. The target heart rate zone will be within of the heart rate at which they experienced an increase in symptoms. The participants will be instructed to follow a program of moderate intensity activity in the form of their choice, we will recommend the following: stationary cycling, brisk walking, light jogging or the use of any available cardiovascular exercise equipment where they can control and monitor their heart rate wearing both the Actigraph and Polar HR monitor provided.
2883162|NCT03367507|Active Comparator|60% Sub-symptom aerobic exercise|The light (conservative) intensity intervention group will exercise at 60% of the maximum symptom free heart rate identified by their most recent graded treadmill test. The target heart rate zone will be within of the heart rate at which they experienced an increase in symptoms. The low intensity group will perform their exercise program at their own discrepancy however we will advise either of the following activities: light walking, stationary cycling or the use of any available cardiovascular exercise equipment where they can control and monitor their heart rate while simultaneously wearing both the Actigraph and polar HR monitor.
2883163|NCT03367494|Other|Subjects with Cystic Fibrosis|Diagnostic
2883164|NCT03367494|Other|Healthy Volunteers|Diagnostic
2883165|NCT03367481|Active Comparator|Control - Toothbrush type: soft|The participants will use a toothbrush with soft bristles.
2883166|NCT03367481|Experimental|Test - Toothbrush type: medium|The participants will use a toothbrush with medium bristles.
2883167|NCT03367468|Active Comparator|Physiotherapy group|Strengthening and stretching exercises,cross friction massage (supervised by physiotherapist) Mobilization techniques Daily usage of prescribed orthotic insole
2883168|NCT03367468|Active Comparator|Home exercise group|Strenthening and stretching exercises Daily usage of prescribed orthotic insole
2883169|NCT03367468|No Intervention|Control group|Follow ups Daily usage of prescribed orthotic insole
2883170|NCT03367455||ARIC and JHS participants|A combined cohort of Atherosclerosis Risk in Communities (ARIC) Study and Jackson Heart Study (JHS) participants
2883171|NCT03367429|Experimental|Exp 2 & 3 - Arm 1|"If within-subject design is adopted, subjects will receive one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic LGM and one standard BT injection of of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic MGM.~If between-subjects design is adopted, subjects will receive one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic LGM."
2883172|NCT03367429|Experimental|Exp 2 & 3 - Arm 2|"If within-subject study design is adopted, subjects will receive one standard BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic LGM and one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic MGM.~If between-subjects design is adopted, subjects will receive one standard BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic LGM."
2883173|NCT03367416||Intervention|This study will test the NIATx model, an evidence-based behavioral intervention for implementing organizational change and quality improvement in community based health settings with a high proportion of underserved individuals. The goal of the study will be to use the model to identify and implement organizational changes in dental practices that will improve the no-show rate in underserved populations.
2883174|NCT03367403|Experimental|LY3002813|LY3002813 administered intravenously (IV) in combination with placebo administered orally.
2883175|NCT03367403|Experimental|LY3002813 + LY3202626|LY3002813 administered IV in combination with LY3202626 administered orally.
2883176|NCT03367403|Placebo Comparator|Placebo|Placebo administered IV in combination with placebo administered orally.
2883177|NCT03367390|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
2883178|NCT03367377|Experimental|LY3209590|Escalating doses of LY3209590 administered by subcutaneous (SC) injection
2883179|NCT03367377|Active Comparator|Insulin glargine|Insulin glargine administered by SC injection
2883180|NCT03367364|Active Comparator|Patient education bundle (PEB)|A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.
2883181|NCT03367364|Placebo Comparator|Nurse feedback and coaching (NFC)|Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
2883182|NCT03367351|Experimental|Web-Based Educational Intervention|Participants receiving the Web-Based Educational Intervention will be enrolled to the research protocol for six weeks of module-based learning and online discussion sessions and followed for a total of 3-months post CGM implementation to collect study measures.
2883183|NCT03367351|Placebo Comparator|Standard of Care|Participants will receive standard clinical care. Similar study measures will be collected to compare between groups.
2883184|NCT03367338|Active Comparator|Group A|Participants in group A will receive 2-day low-phosphate diet with known phosphate content of 600 mg/day, followed by 5-day washout period and then receive another 2-day diet with 800 mg/day of phosphate.
2883185|NCT03367338|Active Comparator|Group B|"Compared with group A, the opposite order of low-phosphate diets will be prescribed in group B.~Participants in group B will receive 2-day low-phosphate diet with known phosphate content of 800 mg/day, followed by 5-day washout period and then receive another 2-day diet with 600 mg/day of phosphate."
2883186|NCT03367325|Experimental|CDS-NVAF benefiting group|CDS-NVAF = Clinical decision support (CDS) tool for improving the adequacy of the anticoagulant therapy adequacy in non-valvular atrial fibrillation (NVAF)
2883187|NCT03367325|No Intervention|CDS-NVAF not-benefiting group|
2883188|NCT03367312|Experimental|Pulmonary Hypertension Patients on Inhaled Prostacyclin|10 subjects will Pulmonary Hypertension on a stable dose of Inhaled Prostacyclin for treatment of PH.
2883189|NCT03367299|Experimental|Chemotherapy + Blinatumomab|Treatment sequence consists of eight chemotherapy courses and two blinatumomab courses. Patients not in CR after chemotherapy course 2 will go off-study.
2883190|NCT03367286||Computed Tomography Perfusion (CTP)|
2883191|NCT03367286||Magnetic Resonance Perfusion (MRP)|
2883192|NCT03367273|Experimental|vitiligo patients|
2883193|NCT03367273|Experimental|controls|
2883194|NCT03367247|Experimental|Bolster|"Bolster provides participants with longitudinal nursing support across care settings,~A smartphone-based symptom management app,~A print and web-based symptom management toolkit,~Advance care planning to ensure that the patient receives care that is congruent with her informed preferences~BOLSTER includes a total of 12 contacts with a study nurse over 10 weeks~Daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice"
2883195|NCT03367234|Experimental|Personalized Addiction-to-Health (PATH)|Cognitive Behavioral Therapy (CBT) sessions with a behavioral health consultant twice weekly for weeks 1-13, once weekly for weeks 14-26, as needed weeks 27-52; Contingency management rewards for specified recovery behaviors which could include medication adherence, attendance at CB/RP sessions and/or CB/RP exercise participation; Medication-assisted treatment, either extended-release naltrexone once monthly or buprenorphine once daily; Peer recovery specialist support twice weekly for weeks 1-13, once weekly for weeks 14-26, as needed for weeks 27-52; Psychiatric consultation as needed.
2883196|NCT03367234|Active Comparator|Standard Care|Treatment may differ slightly by treatment program, but addiction specialty Intensive Outpatient Treatment (ASAM Level 2.1) will generally include individual therapy sessions with a counselor 1 hour per week for week; Medication-assisted treatment, either extended-release naltrexone once monthly or suboxone once daily; Group therapy sessions 9 hours per week then decreasing to 3 hours per week; Psychiatric consultation as needed.
2883197|NCT03367221|Experimental|NAVA group|NAVA ventilation
2883198|NCT03367195|Active Comparator|Treatment 1|1 Omeprazole capsule 20 mg and 1 placebo caplet of DLBS2411, twice daily
2883199|NCT03367195|Experimental|Treatment II|1 DLBS2411 caplet 250 mg and 1 placebo capsule of Omeprazole, twice daily
2883200|NCT03367182||Weekly paclitaxel + bevacizumab|
2883201|NCT03367182||Topotecan + bevacizumab|
2883202|NCT03367182||Pegylated liposomal doxorubicin + bevacizumab|
2883203|NCT03367169|Active Comparator|minimally invasive method|The patients are treated with minimally invasive method
2883204|NCT03367169|Active Comparator|open reduction method|The patients are treated with open reduction method
2883205|NCT03367156|Experimental|Group 1: Dexamethasone|"Participants receive Dexamethasone on Days 1-14 of the study.~After 14 days, no matter which group assigned to, participants take dexamethasone for 14 days.~Questionnaires about shortness of breath, symptoms, and quality of life completed at baseline, Day 7, and Day 14."
2883206|NCT03367156|Placebo Comparator|Group 2: Placebo|"Participants receive a Placebo on Days 1-14 of the study.~After 14 days, no matter which group assigned to, participants take dexamethasone for 14 days.~Questionnaires about shortness of breath, symptoms, and quality of life completed at baseline, Day 7, and Day 14."
2883207|NCT03367143|Experimental|L-ICE|Lenalidomide 25mg/d po d1-10, Ifosfamide 1500mg/m2/d iv d1-3, Carboplatin 5*[GFR(ml/min)+25]mg/d iv d2, Etoposide 100mg/m2/d iv d1-3, Frequency every 21 days, Total cycles 4
2883208|NCT03367130|Experimental|Intervention|HIV-positive individuals will receive the standard HIV care following the national ART guidelines. In addition, the intervention group will receive mobile phone calls. A mobile phone reminder will be made two days prior to their scheduled appointment for pills pick up. Trained research assistants will remind them of their scheduled clinic appointment of pills pick up. If the first call is missed, the second call will be made within the same day, if the second call is also missed, the final call will be made next day. The intervention will be delivered over the period of six months. Outcome assessors will not be involved in the phone calls.
2883209|NCT03367130|Placebo Comparator|Control|Control group will also receive the standard HIV care following the national ART guidelines and phone calls educating them on healthy living. Phone calls will be made once a month.
2883212|NCT03367091|Experimental|Ekso GT gait training|"Participants will be measured during three Ekso GT gait trainings:~20-minute Ekso GT gait training with high swing assistance~20-minute Ekso GT gait training with neutral swing assistance~20-minute Ekso GT gait training with high swing resistance.~Each training will be performed on a separate day in a randomized order (within one week and controlled for time of day)."
2883213|NCT03367078||tDCS cohort|DOC patients treated according to usual care, plus anodal tDCS (prospective cohort)
2883214|NCT03367078||Historical control cohort|DOC patients treated according to usual care only (retrospective cohort of patients matched for demographic and clinical characteristics, admitted at the Montecatone Rehabilitation Institute no more than 3 years before the introduction of tDCS)
2883215|NCT03367065|Experimental|Dynamic contrast enhanced computerised tomography|
2883216|NCT03367052|Experimental|Two level Prodisc-C vivo|Two level Prodisc-C vivo cervical artificial disc replacement.
2883217|NCT03367052|Active Comparator|Hybrid|This group of patients will be treated with hybrid construct, i.e., one level of Prodisc-C vivo and one level of anterior cervical discectomy fusion (ACDF).
2883218|NCT03367039|Experimental|ProDisc-C vivo|This group of patients will be treated with ProDisc-C vivo disc replacement (single segment).
2883219|NCT03367039|Active Comparator|Anterior cervical discectomy fusion|This group of patients will be treated with anterior cervical discectomy fusion (ACDF) procedure (single segment).
2883220|NCT03367026|Active Comparator|Ivabradine oral product|Patients in the ivabradine treatment arm receive interventions:an additional enteral preparation (orally, via nasogastric tube or Jejunum tube) of ivabradine for 4 days.
2883221|NCT03367026|No Intervention|control group|All patients receive established medical therapy according to current guidelines and therapeutic standards.
2883222|NCT03367013|Experimental|Intervention Group|The intervention group will receive a daily dose of 200 mg/kg of bovine lactoferrin in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
2883223|NCT03367013|Sham Comparator|Control Group|The control group will receive daily study feed with no bovine lactoferrin added in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
2883224|NCT03367000|Experimental|Ceprolac|Received supplementation which added 27.6g protein and 114kcal to daily nutritional intake as well as standard diet counselling for 6 months
2883225|NCT03367000|Placebo Comparator|Dietary counseling (DC)|Received standard diet counselling only for 6 months.
2883226|NCT03366974|Experimental|CYP inhibition + IV/PO midazolam|"Period 1: Administration of Midazolam (IV) on day 1, Co-administration of Midazolam (IV) and Grapefruit juice on day 2~Period 2: Administration of Midazolam (PO) on day 8, Co-administration of Midazolam (PO) and Grapefruit juice on day 9~Period 3: Self-administration of Clarithromycin (PO) bid regimen on day 12-14, Co-administration of Midazolam (IV) and Clarithromycin (PO) on day 15, Co-administration of Midazolam (PO) and Clarithromycin (PO) on day 16"
2883227|NCT03366961|Other|Conversion surgery|Palliative chemotherapy followed by radical gastrectomy
2883228|NCT03366935|Experimental|EPL and CEI|Those with receive a standard epidural (EPL) and continuous epidural infusion(CEI) + patient-controlled epidural analgesia (PCEA)
2883229|NCT03366935|Active Comparator|DPE and CEI|Those with receive a dural puncture labor epidural (DPE) and continuous epidural infusion(CEI) + patient-controlled epidural analgesia (PCEA)
2883230|NCT03366935|Active Comparator|DPE and PIEB|Those with receive a dural puncture labor epidural (DPE) and programmed intermittent epidural boluses(PIEB) + patient-controlled epidural analgesia (PCEA)
2883231|NCT03366922|Active Comparator|Control Arm|Participants will be on routine HAART only. No Artemisia Annua, Moringa oleifera will be given.
2883232|NCT03366922|Experimental|Intervention Arm 1|Participants will be given HAART and Artemisia annua leaf powder 4 g per day. They will only receive Artemisia Annua, Moringa oleifera will not be given.
2883233|NCT03366922|Experimental|Intervention Arm 2|Participants will be given HAART with Artemisia annua leaf powder of 4 grams per day and Moringa oleifera leaf powder of 10 grams per day. Both Artemisia Annua, Moringa oleifera will be given.
2883234|NCT03366909|Experimental|MBRP group|20 patients 2 groups of 10 patients
2883235|NCT03366909|Active Comparator|classic care in addictology center|20 patients
2883236|NCT03366896|Experimental|Delirium|Diagnosis of delirium according to 5th Edition of The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) by Psychiatrist.
2883237|NCT03366883|Experimental|"Paclitaxel, Cisplatin Plus 5-FU (TCF)"|preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks
2883238|NCT03366883|Experimental|Preoperative radiochemotherapy|preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week
2883239|NCT03366870|Experimental|Computerized Intervention 1|A web-based program will deliver components of CBT-I on a time and event-based schedule. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
2883240|NCT03366870|Experimental|Computerized Intervention 2|A web-based program will deliver components of sleep education via an Internet platform. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
2883241|NCT03366857|Active Comparator|30%|Participants allocated to these groups will receive a FiO2 of 0.3 during the operation and for two hours postoperatively.
2883242|NCT03366857|Active Comparator|80%|Participants allocated to these groups will receive a FiO2 of 0.8 during the operation and for two hours postoperatively.
2883243|NCT03366844|Experimental|Pembrolizumab with RT Boost|"Study drug plus tumor boost before standard of care treatment"
2883244|NCT03366831|Active Comparator|15 minute version without questions|15 minute version of the TMW-Newborn intervention video without questions interspersed
2883245|NCT03366831|Active Comparator|15 minute version with questions|15 minute version of the TMW-Newborn intervention video with questions interspersed
2883246|NCT03366831|Active Comparator|7 minute version without questions|7 minute version of the TMW-Newborn intervention video without questions interspersed
2883247|NCT03366831|Active Comparator|7 minute version with questions|7 minute version of the TMW-Newborn intervention video with questions interspersed.
2883252|NCT03366779|Other|Surgery with 6mm ACD|CE marked ACD medical device (non-experimental). Surgical device implantation after standard lumbar discectomy.
2883253|NCT03366766|Experimental|Cohort I (nivolumab, cisplatin, pemetrexed disodium)|Patients with non-squamous lung cancer receive nivolumab IV over 60 minutes, cisplatin IV over 60-120 minutes, and pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity
2883254|NCT03366766|Experimental|Cohort I (nivolumab, cisplatin, gemcitabine hydrochloride)|Patients with squamous lung cancer receive nivolumab IV over 60 minutes on day 1, cisplatin IV over 60-120 minutes on day 1, and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
2883255|NCT03366753|Experimental|Acute normovolemic hemodilution|acute normovolemic hemodilution by using hydroxyethyl starch
2883256|NCT03366753|Experimental|In-vitro hemodilution|adding additional hydroxyethyl starch for achieving further 30% dilution of whole blood sample which already underwent ANH of 4-6 ml/kg.
2883257|NCT03366740|Experimental|GB mixed full strength rice suji|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn`t resolve, the child will be enrolled in the study and after randomization will get the GB mixed full strength rice suji.~The allocated diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
2883258|NCT03366740|Experimental|Full strength rice suji alone|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn`t resolve, the child will be enrolled in the study and after randomization will get full strength rice suji alone.
2883259|NCT03366740|Active Comparator|3/4th strength rice suji|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn`t resolve, the child will be enrolled in the study and after randomization will get 3/4th strength rice suji.
2883260|NCT03366727|Experimental|DCB group|this group treated with drug coated balloon catheter, Orchid
2883261|NCT03366727|Experimental|PTA group|this group treated with plain balloon catheter, Admiral Xtreme
2883262|NCT03366714|Experimental|RAM cannula|nasal CPAP support with RAM cannula
2883263|NCT03366714|Active Comparator|Hudson cannula (short binasal cannula)|nasal CPAP support with Hudson cannula
2883264|NCT03366701||Patient during rehabilitation program|Patient performing a 5 weeks inpatient pulmonary rehabilitation program
2883265|NCT03366701||Patient after the rehabilitation program|Patient in their domicile after the 5 weeks program
2883266|NCT03366688|Active Comparator|IBI306|Subcutaneous or intravenous injection of a single dose of IBI306, dose level according to ascending dose design
2883267|NCT03366688|Placebo Comparator|placebo|Subcutaneous or intravenous injection of a single dose of placebo, dose level according to ascending dose design
2883268|NCT03366675|Experimental|AZD2811|AZD2811 200mg IV QD CnD1 & D4 every 4weeks
2883269|NCT03366649|Other|UMA (Group 1)|Participants in the UMA group will receive an undersizing mitral annuloplasty (UMA).
2883270|NCT03366649|Other|UMA + PMA (Group 2)|Participants in the UMA + PMA group will receive an undersizing mitral annuloplasty (UMA) with papillary muscle approximation (PMA).
2883271|NCT03366649|No Intervention|Retrospectively identified patients|Retrospectively identified patients, who already underwent the standard of care surgery for the lesion of interest at Emory, within 6 months (± 1 month) after the date of their surgery, and are suitable for recruitment to the study for their post-operative research.
2883272|NCT03366636|No Intervention|Control|"The control/comparison group will be receiving only their usual services which are offered at the agencies they frequent, including mental health services, case management, job training, educational services, and, in specific venue contexts, may receive HIV risk reduction or other sex education interventions such as Street Smart. These same services are also open to the intervention group. Usage of these services varies by site (residential vs drop-in; city (San Diego vs Los Angeles) and type of service (case management, mental health, health care, etc.)."
2883273|NCT03366636|Experimental|Project Legacy|The experimental/intervention arm will receive the Project Legacy intervention
2883274|NCT03366623|Other|Hospital clown intervention|"The performance of the hospital clown included creating a relation with the child by using different techniques in the venipuncture procedure.~The hospital clown used distraction techniques with music, songs, toys, fake tattoos (a small sticker/label with a picture applied to the skin with water), dream journeys, storytelling and making agreements in collaboration with the child, parents and healthcare personnel."
2883275|NCT03366623|Other|No hospital clown intervention|The clinical staff, defined as pediatric nurses and biomedical laboratory technologists, assisted the child in the venipuncture procedure with conventional communication, comfort and care techniques.
2883276|NCT03366610||Patients Previously Treated with Daclatasvir-Based Regimens|Patients in China Previously Treated with Daclatasvir-Based Regimens
2883277|NCT03366597|Experimental|Sevoflurane|Sevoflurane will be used as a narcotic drug in one group during cardiac surgery.
2883278|NCT03366584|Experimental|Intervention|"beta carotene 25,000 IU~vitamin D3 50,000 IU~zinc 50 mg~dexamethasone 6 mg"
2883279|NCT03366584|Active Comparator|Control|dexamethasone 6 mg
2883280|NCT03366571||Anti-viral therapy group|"Subjects who have completed the 3 years research Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis"
2883281|NCT03366571||Non anti-viral therapy group|History study from literature
2883282|NCT03366558||PD patients: early stage|Parkinson Disease patients with early stage of the disease: potentially hypokinesia, but no dyskinesia and motor fluctuations
2883283|NCT03366558||PD patients: developed stage|"PD patients having dyskinesia and motor fluctuations (described as developed stage of the disease)"
2883284|NCT03366558||No PD|Subjects not having diagnosed Parkinson Disease
2883285|NCT03366532||Nurses' Health Study|The NHS began in 1976 when 121,700 female nurses aged 33-55 years and residing in the United States responded to a baseline questionnaire.
2883286|NCT03366532||Nurses' Health Study II|The NHSII was initiated in 1989 with the recruitment of 116,671 younger female registered nurses, 24 to 44 years of age, from 14 states
2883319|NCT03366298|Active Comparator|2|Visit 1: Epipen 0.3mg then Emerade 300mcg Visit 2: Emerade 500mcg
2883287|NCT03366532||Health Professionals Follow-Up Study|The Health Professionals Follow-up Study (HPFS) was established in 1986 and was comprised of 51,529 US male health professionals ranging in age from 40 to 75 years at enrollment from 50 states
2883288|NCT03366519||patients with pulmonary embolism|patients with pulmonary embolism confirmed by tomography scan in emergency department
2883289|NCT03366506||ALS patients|"ALS patients ( suspected, possible, probable or definite per El-Escorial criteria).~Observation"
2883290|NCT03366493|Experimental|FRD, Cyctology, HPV testing|Subjects will be asked to have the FRD, Cytology, and HPV test performed on them by the study doctor or staff.
2883291|NCT03366493|Experimental|Colposcopy Examination (and ECC if necessary)|Subjects with abnormal cytology (≥ ASCUS/AGC), positive FRD test in either the cervix or cervical canal, and/or positive HPV test will be referred to colposcopy. Subjects with a positive FRD test for the cervical canal, unsatisfied colposcopy (type II-III), and/or detection of AGC during cytology will also have to complete an ECC procedure. In addition, 10% of the subjects who tested negative for all three tests and are ≥ 25 years old will be randomly selected to complete a colposcopy as well.
2883292|NCT03366493|Experimental|Biospy|According to the colposcopy assessment, if the results show satisfied (type I) then a biopsy will be taken. Finally, a histopathological examination will be done and used as the gold standard. Subjects with a histopathological examination result of < CIN2 will be asked to come back for a follow up visit within 6 months or 1 year, according to the investigator's discretion.
2883293|NCT03366480|Experimental|Endometrial cancer|Sodium 2-hydroxylinoleic (starting 1,300 mg tid orally) in combination with paclitaxel and carboplatin will be given to patients with advanced endometrial cancer, up to 12 months from initiation.
2883294|NCT03366480|Experimental|Squamous lung cancer|Sodium 2-hydroxylinoleic (starting 1,300 mg tid orally) in combination with paclitaxel and carboplatin will be given to patients with squamous NSCLC, up to 12 months from initiation.
2883295|NCT03366467|Experimental|SADE first|SADE first will initially be treated under SADE (Time 1) and receive RDE on the second encounter (Time 2)
2883296|NCT03366467|Experimental|RDE first|RDE first will initially be treated under RDE (Time 1) and receive SADE on the second encounter (Time 2)
2883297|NCT03366441|Experimental|Telephone call group|The telephone call intervention group received telephone calls. All non-response and refusing donors were included for further follow-up as described below. Donors who answered the phone call and agreed to be interviewed were asked for the reasons why they had stopped donating according to a pre-designed questionnaire.
2883298|NCT03366441|Experimental|SMS group|The SMS intervention group received the following text message: 'Dear Donors, thank you for your donation which brought hope to patients. Please give blood again to save lives if you are available. Thank you for your support'. All donors either receiving or not receiving the message were included for further follow-up as described below.
2883299|NCT03366441|No Intervention|Control group|No intervention will be giving to this group.
2883300|NCT03366428|Experimental|All Participants|All participants will receive DS-8201a by intravenous infusion
2883301|NCT03366415|Experimental|Induction chemotherapy+IMRT+adjuvant chemotherapy|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), followed by gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles.
2883302|NCT03366415|Active Comparator|Induction chemotherapy+IMRT and concurrent cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 30 mg/m² every week.
2883303|NCT03366402||Influenza A|
2883304|NCT03366402||Influenza B|
2883305|NCT03366389||Case|patients with irritable bowel syndrome
2883306|NCT03366389||Control|Healthy subjects without any gastrointestinal disorders, chronic diseases and malignancy.
2883307|NCT03366376|Experimental|Experimental|WBRT with hippocampus-sparing and SIB
2883308|NCT03366363|Experimental|Electro-acupuncture|"5 compulsory acupoints (ST35、EX-LE5、LR8、GB33 and Ashi) and 3 optional matching acupoints (stomach meridian syndrome：ST34、ST36、ST32、ST40、EX-LE2；gallbladder meridian syndrome：GB31、GB36、GB34、GB39、GB41；bladder meridian syndrome：BL39、BL40、BL57、BL60；San Yin meridian syndrome：LR7、SP9、SP10、KI10、SP4、SP6、LR3、KI3) will be chosen. Needles will be stimulated manually to achieve De Qi sensation and an electrical apparatus (Nanjing Jisheng Medical Co., Ltd., wave of 2/100Hz) will be then connected to the needles with alligator clips in pairs LR8-GB33 and two other matching acupoints. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity. Patients will receive 30-minute, 24 sessions intervention over eight weeks."
2883309|NCT03366363|Experimental|manual acupuncture|Participants in the manual acupuncture group have the same schedule as the Electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
2883310|NCT03366363|Sham Comparator|sham acupuncture|Those in the sham acupuncture group receive shallow acupuncture at non-acupoints without manipulation，Deqi or actual current output.
2883311|NCT03366350|Experimental|CAR-T therapy bridging to HSCT|Once the patient achieves remission through Second generation CAR-T cells, he/she will be transferred to Hematological stem cell transplantation within 30 days.
2883312|NCT03366337|Experimental|Patients with baseline ACR > 300 mg/g but ≤ 2,500 mg/g|Patients will receive bardoxolone methyl throughout the study. Patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg of bardoxolone methyl. They will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, 20 mg at week 4, and then to 30 mg at Week 6.
2883313|NCT03366337|Experimental|Patients with baseline ACR ≤ 300 mg/g|Patients will receive bardoxolone methyl throughout the study. Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg of bardoxolone methyl. They will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2 and 20 mg at week 4.
2883314|NCT03366324|Experimental|Combination of CAR-T therapy and HSCT|After patients achieve MRD- remissions through Second generation CAR-T cells, they will subsequently receive hematological stem cell transplantations within 30 days.
2883315|NCT03366311|Active Comparator|holding position|different holding position of endotracheal tube
2883316|NCT03366311|Active Comparator|stylet shapes|banana shape versus straight-to-cuff shape
2915695|NCT03139981|Experimental|ASN002 80 mg|80 mg ASN002
2883320|NCT03366298|Active Comparator|3|Visit 1: Emerade 500mcg Visit 2: Emerade 300mcg then Epipen 0.3mg
2883321|NCT03366298|Active Comparator|4|Visit 1: Emerade 500mcg Visit 2: Epipen 0.3mg then Emerade 300mcg
2883322|NCT03366285||Fullterm infants|Quality of bonding is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from the local elementary school.
2883323|NCT03366285||Moderate to late preterm infants|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the trauma and depression in late preterm parents study (TraDelPP) conducted 2010 to 2011."
2883324|NCT03366285||Preterm infants with skin to skin contact|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the delivery room skin to skin study (deisy) who were randomized into the skin to skin contact group. The study was conducted from 2012 to 2015."
2883325|NCT03366285||Preterm infants with visual contact|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the delivery room skin to skin study (deisy) who were randomized into the visual contact group. The study was conducted from 2012 to 2015."
2883326|NCT03366272|Active Comparator|(R)-GemOx|eight cycles of (R)-GemOx (Gemcitabine 1000 mg/m2, d1, Oxaliplatin 100 mg/m2, d1, Rituximab 375 mg/m2 in case of B-cell lymphoma disease, repeated every 2 wks)
2883327|NCT03366272|Experimental|Nivo-(R)-GemOx|eight cycles of nivolumab (3 mg/kg) plus (R)-GemOx in 2-wk intervals followed by additional 18 infusions of Nivolumab (3 mg/kg) in 2-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
2883328|NCT03366259|Active Comparator|Group A (Misoprostol group)|200 mcg rectal Misoprostol administration before cesarean section
2883329|NCT03366259|Placebo Comparator|Group B (control group)|No prostaglandins administration before cesarean section
2883330|NCT03366246|Active Comparator|lidocaine / prilocaine cream|according to randomization 2g topical nano anesthetic ( lidocaine 25mg/g and prilociane 25mg/g )was applied to one side ( left or right ) of the forehead 20 minutes before laser therapy.
2883331|NCT03366246|Placebo Comparator|placebo|according to randomization 2g of the placebo( nano anesthetic vehicle with no active ingredient ) was applied to one side ( left or right) of the forehead 20 minutes before laser therapy.
2883332|NCT03366233|Experimental|Mentally fatiguing task|A modified Stroop task of 90 min, partitioned in 8 blocks of 252 stimuli, will be used as mentally fatiguing task.
2883333|NCT03366233|Placebo Comparator|Control task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial for 90 min.
2883334|NCT03366220|Experimental|initial resuscitation with plasma|Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
2883335|NCT03366220|Active Comparator|initial resuscitation with balanced crystalloids|Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
2883336|NCT03366207|Experimental|Ciprofloxacin|Ciprofloxacin for the treatment of uncomplicated urinary tract infection
2883337|NCT03366181||heart failure patients|
2883338|NCT03366168||Group 1 - 18-39 years|thirty participants between the ages 18-39 years. Of the thirty participants, fifteen will be men and fifteen will be women.
2883339|NCT03366168||Group 2 - 40-59 years|thirty participants between the ages 40-59 years. Of the thirty participants, fifteen will be men and fifteen will be women.
2883340|NCT03366168||Group 3 - 60 years and older|thirty participants ages 60 years and older. Of the thirty participants, fifteen will be men and fifteen will be women.
2883341|NCT03366155|Experimental|1/Arm 1|HAIP + Systemic chemotherapy
2883342|NCT03366142|Experimental|1|Weights up to 60 kg will receive 0.75 mg/kg, more than 60kg up to 100kg will receive 45 mg, and more than 100kg will receive 90mg via subcutatneious injection once every 12 weeks for a total of 5 doses.
2883343|NCT03366129||1|a cohort of stroke patients with white matter hyperintensities (WMH)
2883344|NCT03366116|Experimental|1|Aza-TdCyd will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles
2883345|NCT03366103|Experimental|Treatment (navitoclax, vistusertib)|Patients receive navitoclax PO QD and vistusertib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2883346|NCT03366090||IBD patients|Biopsies for immunological analyses
2883347|NCT03366090||healthy controls|Biopsies for immunological analyses
2883348|NCT03366077|Active Comparator|Active|
2883349|NCT03366077|Placebo Comparator|Placebo|
2883350|NCT03366064|Experimental|Pemetrexed and donor NK cell infusion|Eligible patients with stage 4 non-small cell lung cancer receive NK cells derived from HLA-haploidentical family donors. One week prior to NK cell infusion, patients receive pemetrexed (500 mg/m2) intravenous infusion
2883351|NCT03366051|Active Comparator|Sentinel Node Mapping plus Lymphadenectomy|Patients with high risk endometrial cancer will undergo Sentinel Node Mapping followed by Systematic Pelvic and Para-Aortic Lymphadenectomy
2883352|NCT03366051|Experimental|Sentinel Node Mapping|Patients with high risk endometrial cancer will undergo Sentinel Node Mapping per NCCN algorithm
2883353|NCT03366038||Modified Pancreaticojejunostomy|Shark Mouth Modified Pancreaticojejunostomy is performed following pancreaticoduodenectomy.
2883354|NCT03366025||Oocyte donors|Healthy oocyte donors undergoing ovarian stimulation with recombinant Follicular stimulating hormone
2883355|NCT03366012|Other|Cytosponge Test|This arm will include individuals without formal diagnosis of Barrett's esophagus.
2883400|NCT03365726|No Intervention|NDST (no-dobutamine-stress-test)|patients refused the dobutamine stress test and transesophageal echocardiography measured the troponin level in first 24 hours after surgery
2883356|NCT03365999|Active Comparator|Oral Tranexamic Acid|"Tranexamic acid will be administered orally three times (administering 2 tablets each time). In the case of tranexamic acid tablets are 650 mg each.~The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.~For the tranexamic acid a total dose of 3.9 grams (6 tablets) divided between the 3 administrations (1.3 grams each, ie 2 tablets of 650 mg) will be administered."
2883357|NCT03365999|Experimental|Oral Aminocaproic Acid|"Aminocaproic acid will be administered orally three times (administering 2 tablets each time). In the case of aminocaproic acid tablets are 500 mg each.~The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.~For the aminocaproic acid, a total dose of 3 grams (6 tablets) divided between the 3 administrations (1 gram each, ie 2 tablets of 500 mg) will be administered."
2883358|NCT03365973||Spinal metastases of breast cancer|Patients with potentially unstable spinal metastases of breast cancer
2883359|NCT03365960|Active Comparator|Active1|watermelon rind
2883360|NCT03365960|Active Comparator|Active2|watermelon flesh
2883361|NCT03365960|Active Comparator|Active3|watermelon seeds
2883362|NCT03365960|Placebo Comparator|Control Comparator|placebo
2883363|NCT03365947|Active Comparator|ARO-HBV Injection|
2883364|NCT03365947|Placebo Comparator|Placebo|
2883365|NCT03365934|Experimental|ADHESIVE BANDAGE #1|bandage applied to wounded site.
2883366|NCT03365934|Experimental|ADHESIVE BANDAGE #2|bandage applied to wounded site.
2883367|NCT03365934|Experimental|ADHESIVE BANDAGE #3|bandage applied to wounded site
2883368|NCT03365934|Experimental|Antibacterial Bandage with 0.8% BZK|bandage with 0.8% Benzalkonium Chloride (BZK) applied to wounded site
2883369|NCT03365934|Other|Intact and No Bandage|This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
2883370|NCT03365934|Other|Wounded and No Bandage|This test site will be wounded and no bandage applied, serving as a positive control site.
2883371|NCT03365921|Experimental|Hepatitis E vaccine lot 1|
2883372|NCT03365921|Experimental|Hepatitis E vaccine lot 2|
2883373|NCT03365921|Experimental|Hepatitis E vaccine lot 3|
2883374|NCT03365908|Experimental|Adductor Canal Nerve Block|Participant will receive an adductor canal nerve block via 15 mL 0.5% ropivacaine injection prior to OR for ACL reconstruction. Participant will receive pre-op oral medications.
2883375|NCT03365908|No Intervention|No Nerve Block|Participant will receive pre-op oral medications but no nerve block prior to OR for ACL reconstruction.
2883376|NCT03365895|Experimental|Diagnostic (non-enhanced MRI using MRN and DTI)|Patients undergo non-enhanced MRI of both lower extremities using MRN and DTI prior to initiation and after completion of standard of care chemotherapy.
2883377|NCT03365882|Experimental|Arm I (pertuzumab, trastuzumab)|Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2883378|NCT03365882|Experimental|Arm II (cetuximab, irinotecan hydrochloride)|Patients receive cetuximab IV over 60-120 minutes and irinotecan hydrochloride IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may optionally crossover to Arm I.
2883379|NCT03365869|Active Comparator|Sirolimus|Add sirolimus according to the protocol. Sirolimus active: 2mg po. QD
2883380|NCT03365869|Placebo Comparator|placebo|sirolimus placebo: 2mg po. QD
2883381|NCT03365856||RA patients|As routinary clinical practice and observational study
2883382|NCT03365843|Experimental|Montage bone putty|Sternal closure with conventional wire cerclage plus Montage bone putty
2883383|NCT03365843|Active Comparator|Conventional Sternal Closure|Conventional wire cerclage sternal closure only -- standard care.
2883384|NCT03365817|Experimental|Taper off|Decrease of opioid daily dose until discontinuation for up to six months.
2883385|NCT03365817|Active Comparator|Control Group|No changes on opioids and adjuvant medication for up to six months.
2883386|NCT03365804|Experimental|3D Printed Brace|This group will receive 3D printed brace
2883387|NCT03365804|No Intervention|Traditional Brace|This group will receive the traditional brace
2883388|NCT03365791|Experimental|PDR001 and LAG525|PDR001 will be supplied as powder for solution for infusion. LAG525 will be supplied as a liquid formulation. PDR001 and LAG525 will be administered via i.v. infusion over 30 minutes once every 3 weeks. LAG525 will be given first followed by PDR001.
2883389|NCT03365778|Active Comparator|Educational intervention group|Patients receive educational materials regarding selective laser trabeculoplasty (SLT) versus topical medication (ophthalmic eye drops) to lower eye pressure.
2883390|NCT03365778|Placebo Comparator|Usual care group|Patients receive standard of care.
2883391|NCT03365765|Experimental|mFOLFOX6 & apatinib|oxaliplatin 85mg/m2 intravenous infusion for 2 hours, intravenous infusion of leucovorin 400mg/m2 for 2 hours, intravenous infusion of 5- fluorouracil 400mg/m2, first days; 5- fluorouracil 2400mg/m2 continuous intravenous infusion for 46-48 hours, repeated 1 time every two weeks, a total of 12 cycles, 24 weeks. Patients also take apatinib, 1 time daily, 500mg each time, lasting 1 year, from the first chemotherapy of mFOLFOX6.
2883392|NCT03365765|Active Comparator|mFOLFOX6|oxaliplatin 85mg/m2 intravenous infusion for 2 hours, intravenous infusion of leucovorin 400mg/m2 for 2 hours, intravenous infusion of 5- fluorouracil 400mg/m2, first days; 5- fluorouracil 2400mg/m2 continuous intravenous infusion for 46-48 hours, repeated 1 time every two weeks, a total of 12 cycles, 24 weeks.
2883393|NCT03365752|Experimental|Chloroprocaine|
2883394|NCT03365752|Active Comparator|Mepivacaine|
2883395|NCT03365752|Active Comparator|General Anesthesia|
2883396|NCT03365739|Active Comparator|Active Comparator 1|Treatment - Mango (pulp/flesh-500 g)
2883397|NCT03365739|Active Comparator|Active Comparator 2|Mango (500 g) + Vitamin C (100 mg)
2883398|NCT03365739|Placebo Comparator|Control Comparator|Vitamin C (100 mg)
2883399|NCT03365726|Experimental|DST (dobutamine-stress-test)|dobutamine stress echocardiography performed to patients undergoing major surgery
2883401|NCT03365700|Active Comparator|Cryoballoon ablation|Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line.
2883402|NCT03365700|Active Comparator|Radiofrequency Ablation|Contact force-sensing radiofrequency left atrial ablation with 3D mapping system.
2883403|NCT03365687|Active Comparator|Vitamin D|Vitamin D supplement (100,000 IU) orally at baseline and at 3.5 months with daily 400 IU vitamin D for 7 months
2883404|NCT03365687|Placebo Comparator|Placebo|Placebo orally at baseline and at 3.5 months with daily placebo during 7 months
2883405|NCT03365674|Experimental|Vibration group|Vibrator head was applied (100Hz) on the popliteal fossa, during the trigger point injection
2883406|NCT03365674|Placebo Comparator|Placebo group|In placebo group, vibrator head was applied with switch-off sate, during the trigger point injection
2883407|NCT03365661|Experimental|ALT-803|
2883408|NCT03365648|Experimental|Lertal® + standard therapy|Lertal® double-layer tablets (1 tab/day for 4 weeks) plus standard therapy (antihistamine)
2883409|NCT03365648|Placebo Comparator|Placebo + standard therapy|Placebo tablets (1 tab/day for 4 weeks) plus standard therapy (antihistamine)
2883410|NCT03365635|Experimental|Genotype 1a -Rx naive -no NS5A polymorph|Genotype 1a - treatment naive without NS5A polymorphism - Drug Intervention : Oral administration Elbasvir (50mg)/Grazoprevir (100mg) one tablet per day for 12 weeks
2883411|NCT03365635|Experimental|Genotype 1a, Rx naive + NS5A polymorph|Genotype 1a - treatment naiive with NS5A polymorphism - Oral administration of Elbasvir/Grazoprevir one tablet daily and ribavirin (200 mg) daily for 16 weeks weeks
2883412|NCT03365635|Experimental|Genotype 1b - Rx naive|Genotype 1b-treatment naive - Oral administration of Elbasvir/Grazoprevir one daily for 12 weeks
2883413|NCT03365635|Experimental|Genotype 1a/1b -prior INF or NS3/4A|Genotype 1a or 1b - prior treatment with INF or HCV NS3/4A protease inhibitor - oral administration of Elbasvir/Grazoprevir and ribavirin each once daily for 12 weeks
2883414|NCT03365635|Experimental|Genotype4 - treatment naive|(e) Genotype 4 - treatment naive - oral administration of Elbasvir/Grazoprevir one daily for 12 weeks
2883415|NCT03365635|Experimental|Genotype 4- prior treatment|Genotype 4 -prior treatment - oral administration of Elbasvir/Grazoprevir and ribavirin each once per day for 16 weeks
2883416|NCT03365622|Active Comparator|IV acetaminophen and placebo pills|
2883417|NCT03365622|Placebo Comparator|placebo IV (normal saline) + oral acetaminophen|
2883418|NCT03365609|Experimental|T-group|T-group(triple therapy)
2883419|NCT03365609|Experimental|S-group|S-group( sequential therapy)
2883420|NCT03365609|Experimental|B-group|B-group( bismuth quadruple therapy )
2883421|NCT03365609|Experimental|C-group|C-group( concomitant therapy)
2883422|NCT03365596|Experimental|Subacute stroke|
2883423|NCT03365583||Vitamin B12 deficiency|"No intervention will be administered for this study. Serum vitamin B12 <203 pg/mL is considered as vitamin B12 deficiency.~Fecal microbiota composition will be analyzed with 16S rRNA sequencing. In a subgroup of infants (n=11), fecal samples will be recollected after the treatment as usual"
2883424|NCT03365583||Vitamin B12 sufficient|Serum vitamin B12 ≥203 pg/mL is considered as vitamin B12 sufficient Fecal microbiota composition will be analyzed with 16S rRNA sequencing.
2883425|NCT03365557|Experimental|Intracuff pressure set by airway peak pressure|
2883426|NCT03365557|Other|Intracuff pressure set at 60 mmHg|
2883427|NCT03365544|Experimental|6am-2pm eating window|4 weeks of time restricted eating between 6am-2pm.
2883428|NCT03365544|Experimental|2pm-10pm eating window|4 weeks of time restricted eating between 2pm-10pm.
2883429|NCT03365531|Experimental|Alternate Daily Fasting (ADF)|Participants randomized to the ADF group will alternate between a day of ad lib feeding and a day of nearly no energy intake. Participants will be prescribed a core diet for feeding days that meets 110% of their estimated calorie needs within the fixed macronutrient distribution of 50% CHO, 20% PRO, and 30% FAT. In accordance with the ad lib feeding protocol, optional modules of similar macronutrient content will be prescribed, each providing an additional 200 kcals. Meal timing will not be restricted on these days. On fasting days, participants will be asked to consume 16 oz. of G2 Gatorade (40 kcal) in the morning and then only water or non-caloric beverages for the rest of the day.
2883430|NCT03365531|Active Comparator|Caloric Restriction|Participants randomized to the CR group will consume a diet of fixed energy designed to yield a 500 kcal/d deficit with a macronutrient distribution of 50% CHO, 20% PRO, and 30% FAT. Meal timing and caloric distribution will not be restricted.
2883431|NCT03365518|Experimental|Cognitive Behavioural Therapy (CBT)|Treatment will consist of a 4-week group lead by a trained clinician. Sessions are 2 hours in length and take place in consecutive weeks, with daily homework recommended between sessions.
2883432|NCT03365518|Experimental|Mindfulness-Based Therapy|Treatment will consist of a 4-week group lead by a trained clinician. Sessions are 2 hours in length and take place in consecutive weeks, with daily homework recommended between sessions.
2883433|NCT03365518|No Intervention|Control - Usual Care|Participants who are randomized to the control group will not receive mindfulness or CBT treatment. They will proceed with the course of treatment they were receiving prior to enrollment in the study. As resources for couples dealing with changes to their sexual lives after prostate cancer are limited, it is anticipated that the majority of these patients will have no treatment targeting sexual intimacy during the 6-week period between completing the first and second questionnaire.
2883434|NCT03365492|Experimental|Treatment Arm|Patients with CAD who receive the BioFreedom™ Biolimus A9™ stent.
2883435|NCT03365479|Experimental|Study cohort|The study comprises a 1-day Screening period, followed by a right heart catheterization with a single administration of inhaled iloprost 2.5 μg delivered via Breelib nebulizer
2883436|NCT03365466||Group A|Patients who received a daily dose of 75mg LDA per day after menstruation prior to ET.
2883437|NCT03365466||Group B|Patients who received a daily dose of 5000u LMWH after menstruation prior to ET.
2883438|NCT03365466||Group C|Patients who received a daily dose of 75 mg LDA plus 5000u LMWH after menstruation prior to ET.
2883439|NCT03365466||Group D|Patients who did not receive any treatment.
2883440|NCT03365453|Experimental|frailty evaluation|all consecutive patients admitted to hospital for valvular disorders more than 69 years will be evaluated with several frailty and comorbidities scores.
2915696|NCT03139981|Experimental|ASN002 20 mg|20 mg ASN002
2883441|NCT03365440||EP study with transseptal passage|"15-30 minute esophageal ECG (using esoECG-3D catheter) & respiration recording during elective EP study and/or ablation procedure~Focal pacing maneuvers"
2883442|NCT03365440||EP study without transseptal passage|- 15-30 minute esophageal ECG (using esoECG-3D catheter) & respiration recording during elective EP study and/or ablation procedure
2883443|NCT03365440||Healthy participants|- 60 minute esophageal ECG (using esoECG-3D catheter) & respiration recording
2883444|NCT03365427|Experimental|Application Group|People in this arm will be introduced to an APP on smart phone, and receive lessons on how to use it on their own phones. The APP will be installed and prepare to use before surgery. People will be asked and monitored on-line to regularly use the APP.
2883445|NCT03365427|No Intervention|Convention Group|People in this arm receive exactly the same treatment and lessons on post-operative rehabilitation except the reach of the APP.
2883446|NCT03365414|Other|Phase I|Placebo ( Normal Saline 0.9% Infusion Solution Bag) or active comparator (Albumin (Human) 5%, USP)
2883447|NCT03365414|Other|Phase II|Placebo ( Normal Saline 0.9% Infusion Solution Bag) or active comparator (Albumin (Human) 5%, USP), whichever was not not administered in Phase I
2883448|NCT03365401|Experimental|grade 1|Decompression surgery
2883449|NCT03365401|Active Comparator|grade 2|nonsurgical treatment
2883450|NCT03365388|Experimental|Sodium Hyaluronate group|Treatment of periarthritis of shoulder with Sodium Hyaluronate
2883451|NCT03365388|Active Comparator|Aerzhi group|Treatment of periarthritis of shoulder with Aerzhi
2883452|NCT03365375|Active Comparator|Usual Care Referral|Subjects will be referred for primary care provider (PCP) follow up and/or to psychiatry for further management and treatment of elevated anxiety levels according to standard of care.
2883453|NCT03365375|Experimental|MBSR Referral|Referral to a local mindfulness-based stress reduction course in addition to referral to their PCP.
2883454|NCT03365362|Experimental|Long-Term Varenicline|Participants will receive 24 weeks of varenicline at standard doses (0.5 mg/day for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily)
2883455|NCT03365362|Active Comparator|Short-Term Varenicline|Participants will receive 12 weeks of varenicline at standard doses (0.5 mg/day for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily), followed by matching placebo twice daily through week 24.
2883456|NCT03365362|Experimental|Directly Observed Therapy|Participants receiving directly observed therapy (DOT) will receive varenicline from opioid treatment program nurses at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.
2883457|NCT03365362|Active Comparator|Self Administered Therapy|Patients receiving varenicline self administered therapy (SAT) will self-administer all varenicline doses.
2883458|NCT03365349|Experimental|living theatre|One session consisting for the patient of telling a story about his/her own life with diabetes , which is first written and then transformed to a script to be played by professional actors co-directed by the patient with the support of the Director to create a little play.
2883459|NCT03365349|Active Comparator|writing workshop|"one session consisting for the patient of writing a Letter to his/her own diabetes and then to read it to the group of patients and the healthcare providers."
2883460|NCT03365336|Experimental|Intervention Group|Each Flu Care capsule consists of combination of seven polyherbal formulation (350 mg). Participant will be instructed to take one capsule thrice daily at a fixed time in the day for the study duration of 7 days along with 75 mg of Oseltamivir.
2883461|NCT03365336|Active Comparator|Standard Care Group|Standard of care consist of 75 mg of Oseltamivir for five days and any other required provision of care. These will be determined on case by case basis by research clinician.
2883462|NCT03365323||infectious group|Patients who met the criteria according of Periprosthetic Joint Infection were identified as the infectious group.
2883463|NCT03365323||non-infectious group|Patients who didn't meet the criteria according of Periprosthetic Joint Infection were identified as the non-periprosthetic joint infection group.
2883464|NCT03365310|Experimental|Intervention Group|Participants will receive turmeric and tulsi capsule with milk(100 ml) along with standard of care treatment as determined by research physician...Each participants has to take two capsules of turmeric formula and tulsi twice daily for the study period of 3 months
2883465|NCT03365310|Active Comparator|Standard Care Group|Participants will only receive the standard of care treatment as determined by research physician
2883466|NCT03365297|Experimental|Treatment|apalutamide, 240mg (4x60mg tablets) orally, daily for a max. duration of 90 continuous days.
2883467|NCT03365284|Experimental|Smart Kneebrace|Smart Kneebrace with a smart phone app will be used during the rehabilitation after surgery for three months
2883468|NCT03365284|Placebo Comparator|without Smart Kneebrace|regular rehabilitation procedure will be applied after surgery
2883469|NCT03365271|Experimental|drainage|A drainage will be applied in this group.
2883470|NCT03365271|Active Comparator|without drainage|Non-drainage will be applied in this group.
2883471|NCT03365258|Other|High Nutritional Risk|modified NUTRIC score ≥ 5
2883472|NCT03365258|Other|Low Nutritional Risk|modified NUTRIC score < 5
2883473|NCT03365245|Other|study arm|Microperimetry and automated visual field are performed at three different days
2883474|NCT03365232|Experimental|non custom base attachment|
2883475|NCT03365232|Active Comparator|custom base attachment|
2883476|NCT03365219|Experimental|Alexis Retractor|This group received an Alexis O-Ring Wound Retractor during cesarean delivery.
2883477|NCT03365219|Active Comparator|Standard Surgical Retractors|This group received routine hand-held metal retractors as needed by the surgical team during cesarean delivery.
2883478|NCT03365180|Experimental|The Starter Kit Algorithm|Basal insulin initiation and titration using the Starter Kit Algorithm at two weeks, followed by standard of care titration during the following the next 10 weeks (maximum), or until optimal daily dose is considered identified.
2883479|NCT03365167|Active Comparator|LANAP|LANAP (Laser Assisted New Attachment Procedure)
2883480|NCT03365167|Placebo Comparator|LANAP off|laser therapy in off mode
2883481|NCT03365154|Experimental|Treatment Group|Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.
2915697|NCT03139981|Experimental|ASN002 120 mg|120 mg ASN002
2883482|NCT03365141|Experimental|Experimental group|"All lesions will treated with NBUVB or excimer laser weekly and application of topical tacrolimus ointment twice daily for a total of 12-week period.~Intervention: Intralesional injection of triamcinolone acetonide (0.4mg/cc) will be performed weekly."
2883483|NCT03365141|Active Comparator|Control group|All lesions will treated with NBUVB or excimer laser weekly and application of topical tacrolimus ointment twice daily for a total of 12-week period.
2883484|NCT03365115|Active Comparator|intrathecal fentanyl|
2883485|NCT03365115|Active Comparator|intrathecal morphine|
2883486|NCT03365115|Experimental|intrathecal morphine and fentantyl|
2883487|NCT03365102|Experimental|anodal tDCS over the rIFG,|anodal tDCS over the rIFG,
2883488|NCT03365102|Experimental|anodal tDCS over the lOFC|anodal tDCS over the lOFC
2883489|NCT03365102|Placebo Comparator|sham tDCS stimulation|sham tDCS stimulation
2883490|NCT03365089|Experimental|Collateral vein ligation|Ligation of collateral veins under sonographic guidance
2883491|NCT03365089|No Intervention|Control|No collateral vein ligation.
2883492|NCT03365076|Experimental|Physical aerobic intervention|The exercise program will be varying between different aerobic activities indoor or outdoor as walking uphill and in stairs in intervals that will differ from session to session to build up the load and progression for these patients. In total, each session will be lasting approximately 45-60 minutes and a physiotherapist or personal trainer will supervise each session. Depending on the participants starting point, there will be 3 supervised session per week and two sessions where the participants do activity with low intensity (walk) by themselves and keep a log with duration (time) and intensity (using Borg scale).
2883493|NCT03365076|No Intervention|Controls|These patients will be acting as controls by not been instructed to physical activity. We will not monitor their activity either as this has been shown to increase activity by itself.
2883494|NCT03365063|Experimental|Active Knowledge Translation Group|Primary care clinics receiving the active knowledge translation intervention.
2883495|NCT03365063|No Intervention|Control Group|Primary care clinics receiving the current standard of care. Information on personalized risk and risk-based referral will not be provided.
2883496|NCT03365037|Experimental|Electret electrostatic physiotherapyFilm|Patients with acute soft tissue injury treated with electret electrostatic physiotherapyFilm
2883497|NCT03365037|Active Comparator|Fracture healing film|Patients with acute soft tissue injury treated with fracture healing film
2883498|NCT03365024|Experimental|Computerized Intervention 1|A web-based program will deliver components of CBT-I on a time and event-based schedule. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
2883499|NCT03365024|Active Comparator|Computerized Intervention 2|A web-based program will deliver components of sleep education via an Internet platform. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
2883500|NCT03365011|Placebo Comparator|Placebo|"Placebo was defined as 50% nitrogen and 50% oxygen for 40 minutes.~Participants are blinded to the order of interventions administered. Participants have been informed prior to consent that one session will contain the nitrous oxide gas mixture, and the other session will contain the placebo gas mixture."
2883501|NCT03365011|Experimental|Nitrous oxide|"Nitrous oxide treatment was defined as 50% nitrous oxide and 50% oxygen for 40 minutes.~Participants are blinded to the order of interventions administered. Participants have been informed prior to consent that one session will contain the nitrous oxide gas mixture, and the other session will contain the placebo gas mixture."
2883502|NCT03364998|Experimental|Treatment A|BAY 94-9027, 60 IU/kg, single infusion to analyze pharmacokinetics
2883503|NCT03364998|Other|Treatment B|Elocta, 60 IU/kg, single infusion to analyze pharmacokinetics
2883504|NCT03364985|Experimental|Cohort 1: DWP16001 Amg|DWP16001 Amg, tablets, orally, single dose administration
2883505|NCT03364985|Experimental|Cohort 2: DWP16001 Bmg|DWP16001 Bmg, tablets, orally, single dose administration
2883506|NCT03364985|Experimental|Cohort 3: DWP16001 Cmg|DWP16001 Cmg, tablets, orally, single dose administration
2883507|NCT03364985|Experimental|Cohort 4: DWP16001 Dmg|DWP16001 Dmg, tablets, orally, single dose administration
2883508|NCT03364985|Experimental|Cohort 5: DWP16001 Emg|DWP16001 Emg, tablets, orally, single dose administration
2883509|NCT03364985|Experimental|Cohort 6: DWP16001 Fmg|DWP16001 Fmg, tablets, orally, single dose administration
2883510|NCT03364985|Placebo Comparator|Cohort 1-6: Placebo|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, single dose administration
2883511|NCT03364985|Active Comparator|Cohort 1-6: Dapagliflozin|Forxiga® tablets, orally, single dose administration
2883512|NCT03364985|Experimental|Cohort 7: DWP16001 Gmg|DWP16001 Gmg, tablets, orally, single dose administration
2883513|NCT03364985|Experimental|Cohort 8: DWP16001 Hmg|DWP16001 Hmg, tablets, orally, single dose administration
2883514|NCT03364985|Experimental|Cohort 9: DWP16001 Img|DWP16001 Img, tablets, orally, single dose administration
2883515|NCT03364985|Placebo Comparator|Cohort 7-9: Placebo|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
2883516|NCT03364985|Active Comparator|Cohort 7-9: Dapagliflozin|Forxiga® tablets, orally, repeated dose administration(for 15days)
2883517|NCT03364972|Experimental|Experimental intraocular lens implant|'Alcon Clareon' : New monofocal, hydrophobic acrylic intraocular lens implant
2883518|NCT03364972|Active Comparator|Standard intraocular lens implant|Abbott Tecnis PCB00- Standard monofocal,hydrophobic acrylic intraocular lens implant
2883519|NCT03364959|Experimental|Flixotide|Patients inhale first Flixotide and then Qvar
2883520|NCT03364959|Experimental|Qvar|Patients inhale first Qvar and then Flixotide
2883521|NCT03364946||High Nasal Flow Therapy|Every patient in the ICU that requires High Nasal Flow Therapy
2883522|NCT03364933|Experimental|Primary intensivist and nurses|Patients randomized to the experimental arm will have a primary intensivist and a team of primary nurses assigned to them.
2883523|NCT03364933|No Intervention|Control|Patients who are randomized to the control group will receive usual care and not be assigned a primary intensivist or nurses.
2883524|NCT03364920||normal level of serum maresin-1|
2883525|NCT03364920||abnormal level of serum maresin-1|
2915726|NCT03139747|Experimental|Single Arm|
2883526|NCT03364907||HIPEC patients|Patients with a diagnosis of peritoneal carcinomatosis who undergo HIPEC treatment with oxaliplatin.
2883527|NCT03364868|Experimental|oral insulin capsule (dose escalation using 3 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 22.5 mg rH-insulin crystals; dose 3 is 67.5 mg rH-insulin crystals. The insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) and contained in hard gelatine capsules. The study treatment will be given orally.
2883528|NCT03364868|Placebo Comparator|Placebo capsule|Daily treatment with placebo capsules containing filling substance (microcrystalline cellulose).
2883529|NCT03364855|Active Comparator|SEBT exercise group|Star Excursion Balance Test will be used
2883530|NCT03364855|Active Comparator|KAT 2000 exercise group|Kinesthetic ability trainer will be used
2883531|NCT03364855|Active Comparator|combined exercise group|Both star Excursion Balance Test exercise and Kinesthetic ability trainer will be used.
2883532|NCT03364842|Experimental|F group|Furosemide group
2883533|NCT03364842|No Intervention|C group|Control group
2883534|NCT03364829|Experimental|COPD on Indacaterol/Glycopyrronium|COPD on indacaterol/glycopyrronium for 1 month
2883535|NCT03364816||TDR with Prodisc-C|participant underwent total disc replacement with Prodisc-C artificial disc
2883536|NCT03364816||TDR with Mobi-C|participant underwent total disc replacement with Mobi-C artificial disc
2883537|NCT03364816||TDR with Prestige-LP|participant underwent total disc replacement with Prestige-LP artificial disc
2883538|NCT03364803||Participants with Cushing's Syndrome|
2883539|NCT03364790|Experimental|group1|participant with posterior lumbar interbody fusion(PLIF or PLF)
2883540|NCT03364790|Experimental|group2|participant with total knee arthroplasty (TKA)
2883541|NCT03364790|Experimental|group3|participant with PLIF and TKA on one stage
2883542|NCT03364790|No Intervention|group4|participant without operation
2883543|NCT03364777||lumbar surgery patients|patients undergoing lumbar surgery with or without anxiety or depression emotional state
2883544|NCT03364764|Experimental|efficiency of sirolimus on PRCA|A prospective research of the sirolimus efficiency on refractory PRCA patients On refractory PRCA patients, sirolimus was tried. Dosage: 2mg QD for the first day, then 1 mg QD. Medication time should last at least 6 months.
2883545|NCT03364751|Active Comparator|IQOS arm|~86 patients, switching from cigarette smoking to IQOS use.
2883546|NCT03364751|Active Comparator|Cigarette arm|~86 patients, continuing cigarette smoking.
2883547|NCT03364738|Experimental|rhPTH(1-84)|Participants will receive rhPTH(1-84) subcutaneous (SC) injection in the thigh (alternate thigh every day) once daily (QD) of an escalating dose from 50 microgram (mcg) to a maximum of 100 mcg increased in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining albumin-corrected serum calcium (ACSC) levels in the range of 2-2.25 millimoles per liter (mmol/L) (8.0-9.0 milligrams per deciliter [mg/dL]). Once a participant achieves a stable ACSC (2-2.25 mmol/L [8.0-9.0mg/dL]) and has minimized supplement doses, they will be maintained at that dose of rhPTH(1-84). If ACSC is greater than (>) 2.25 mmol/L (>9.0 mg/dL), a starting dose of 25 mcg will be administered.
2883548|NCT03364725|Experimental|Open Label Treatment Arm|Treatment arm using Glecaprevir-pibrentasvir for treatment of all patients
2883549|NCT03364712||pregnant|Pregnant women receiving routine medical care, including venipuncture.
2883550|NCT03364712||non-pregnant|Women not pregnant receiving routine medical care, including venipuncture.
2883551|NCT03364699|Active Comparator|dietary supplementation|The volunteers ingested 3 g daily of Soybean lecithin or fish oil rich in docosa-hexanoic acid (DHA) containing 1.5 g DHA and 0.3 g EPA (DHA:EPA = 5:1) or fish oil rich in eicosapentaenoic acid (EPA) containing 1.6 g EPA and 0.3 g DHA (EPA:DHA = 5.4:1) during 60 days.
2883552|NCT03364699|Experimental|Exercise|All volunteers performed two half-marathons. In the first half-marathon, all participants were not supplemented. In the second half-marathon, participants were supplemented. Blood samples were collected before and after both half-marathon race.
2883553|NCT03364686|Experimental|Biotin-Labeled Red Blood Cells Infusion|Each participant will receive 2 transfusions of biotin labeled red blood cells.
2883554|NCT03364673|Experimental|Fitness Tracker + Social Incentive Intervention|Participants will enroll with a teammate (i.e. family or friend) and collaborate together. Teams will set a daily step goal, receive daily feedback on whether they achieved their goal, and receive a social incentive intervention.
2883555|NCT03364660|Experimental|Voluntary Movement Epidural Stimulation|Participants assigned to this group will receive epidural stimulation specific for voluntary movement.
2883556|NCT03364660|Experimental|Cardiovascular Epidural Stimulation|Participants assigned to this group will receive epidural stimulation specific for cardiovascular function.
2883557|NCT03364660|Experimental|Stand Epidural Stimulation|Participants assigned to this group will receive epidural stimulation specific for standing.
2883558|NCT03364660|Experimental|Voluntary Movement ES + Stand Training|Participants assigned to this group will receive epidural stimulation specific for voluntary movement and will also receive stand training.
2883559|NCT03364660|Experimental|Cardiovascular ES + Stand Training|Participants assigned to this group will receive epidural stimulation specific for cardiovascular function and will also receive stand training.
2883560|NCT03364660|Experimental|Stand ES + Stand Training|Participants assigned to this group will receive epidural stimulation specific for standing and will also receive stand training.
2883561|NCT03364647|Experimental|Arm A - Blood flow restriction training|Group will use blood flow restriction training and standard of care
2883562|NCT03364647|Sham Comparator|Arm B - standard of care plus sham|Group will receive standard of care plus a sham version of blood flow restriction training
2883563|NCT03364621||Metastatic Colorectal Cancer with Isolated Liver Metastasis|Patients with advanced colorectal cancer with isolated liver metastasis. Primary cancer must be resectable (if no archival exists) and patient must be planned for liver resection with at least 3 cycles of chemotherapy prior to liver surgery.
2883564|NCT03364608|Experimental|• AS MDI 90 µg|(2 actuations of 45 µg/actuation)
2883565|NCT03364608|Experimental|• AS MDI 180 µg|(2 actuations of 90 µg/actuation)
2883566|NCT03364608|Placebo Comparator|• Placebo MDI|(2 actuations)
2883567|NCT03364608|Active Comparator|• Proventil 90 µg|(1 actuation of 90 µg/actuation)
2883568|NCT03364608|Active Comparator|• Proventil 180 µg|(2 actuations of 90 µg/actuation)
2883569|NCT03364595||Plate Fixation|The operating surgeon will determine the positioning of the patient for surgery. ORIF of the radial head fracture will be carried out
2883570|NCT03364595||Replacement|The operating surgeon will determine the positioning of the patient for surgery. During the surgery, they take out the the comminuted radial head and proceed replacement using artificial.
2883571|NCT03364582||Men-observed dietary pattern|Health Professionals Follow-up Study: a prospective cohort of male health professionals
2883572|NCT03364582||Women-observed dietary pattern|Nurses' Health Study: a prospective cohort of female registered nurses
2883573|NCT03364569||Participant with tranexamic acid.|The investigators followed the recommendations of one gram, two times a day, starting at the end of the surgery so as to avoid any adverse effects. The participants received two grams of Spotof ® (C.C.D laboratory, Portugal) as an oral liquid solution during three days.
2883574|NCT03364569||Participant without tranexamic acid.|This group concerns participants followed without acid tranexamic treatment. Investigators will observe the postoperative practices and complications observed, according to the surgical habits.
2883575|NCT03364543|Experimental|Medical-Legal Partnership Group|The Medical-Legal Partnership Group are lawyers in clinics who address health-harming legal needs. This group will also have access to access to a social worker and a community worker.
2883576|NCT03364543|Active Comparator|Usual Care|Access to a social worker and a community worker, but no systematic process for addressing health-harming legal needs.
2883577|NCT03364517|Experimental|Experimental group SPIA|The regulator will be asked to systematically use the tool Predictor score of the imminence of a childbirth (SPIA). This tool is used to evaluate the means to be sent following a call for imminent delivery outside the hospital.
2883578|NCT03364517|No Intervention|Control group|The classic care will be made according to the usual practices of the doctor and the center.
2883579|NCT03364504|Experimental|PXE patients|urine collection and culture of renal cells
2883580|NCT03364491|Experimental|Tranexamic Acid|Tranexamic Acid for intravenous administration
2883581|NCT03364491|Placebo Comparator|Placebo|Normal saline for intravenous administration
2883582|NCT03364478|Experimental|DML group|The group underwent laparoscopic right hemicolectomy with dorsal and medial hybrid approach. In DML group, the dissecting based on CME is performed with dorsal approach and medial approach hybridized.
2883583|NCT03364478|Active Comparator|MLA group|The group underwent laparoscopic right hemicolectomy with traditional medial-to-lateral approach. In MLA group,the dissecting based on CME is performed with meidial-to-lateral approach.
2883584|NCT03364465|No Intervention|GruopFix|one-lung ventilation with constant tidal volume
2883585|NCT03364465|Active Comparator|GroupVariable|one-lung ventilation with variable tidal volume Intervention: change of ventilatory settings
2883586|NCT03364439|Experimental|One arm for all patients|Patients eligible for the study will receive 6 courses of R-CHOP14 or R-CHOP21.
2883587|NCT03364413||Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).
2883588|NCT03364400|Experimental|VT1021|Escalating Doses of VT1021
2883589|NCT03364374||Stroke survivors|Individuals that experienced uni-hemispheric ischemic or hemorrhagic stroke
2883590|NCT03364374||Controls|Healthy controls with no history of stroke
2883591|NCT03364361|Other|Acupuncture|Feasibility Study
2883592|NCT03364348|Experimental|Cohort 1 (trastuzumab emtansine + utomilumab)|"Participants receive trastuzumab emtansine intravenously (IV) over 30 minutes on Day 0 of Cycle and Day 1 of subsequent cycles, and utomilumab IV over 1 hour on day 1.~Treatment cycles are 21 days, and may repeat for up to 24 cycles, in the absence of disease progression or unacceptable toxicity."
2883593|NCT03364348|Experimental|Cohort 2 (trastuzumab + utomilumab)|Participants receive trastuzumab intravenously (IV) over 90 minutes on Day 0 of Cycle 1 and Day 1 of subsequent cycles, and utomilumab IV over 1 hour on day 1. Treatment cycles are 21 days, and may repeat for up to 24 cycles, in the absence of disease progression or unacceptable toxicity.
2883594|NCT03364335|Placebo Comparator|Placebo|
2883595|NCT03364335|Experimental|Leu Sil 1.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
2883596|NCT03364335|Experimental|Leu Sil 4.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
2883597|NCT03364335|Experimental|Leu Met Sil 1.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
2883598|NCT03364335|Experimental|Leu Met Sil 4.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
2883599|NCT03364322||Dry eye syndrome|
2883600|NCT03364309|Experimental|Ixekizumab Dose Schedule 1|Ixekizumab given subcutaneously (SC).
2883601|NCT03364309|Experimental|Ixekizumab Dose Schedule 2|Ixekizumab given SC. Placebo given SC to maintain blind.
2883602|NCT03364309|Placebo Comparator|Placebo|Placebo given SC
2883603|NCT03364296|Other|Patients hospitalized for stroke|
2883604|NCT03364283||Sitting Position|Sitting and semi-sitting
2883605|NCT03364283||Horizontal Position|Prone, lateral and park bench.
2883606|NCT03364270|Experimental|[F-18] RDG-K5|PET/CT with administration of [F-18] RGD-K5
2883607|NCT03364244||Sildenafil|Pediatric patients receiving Revatio
2883608|NCT03364231|Experimental|Umbralisib|Umbralisib oral daily dose
2883609|NCT03364218|Experimental|Treatment group|
2883610|NCT03364218|No Intervention|non treatment group|
2883611|NCT03364205|Experimental|intervention|solution-focused interview techniques
2883612|NCT03364205|No Intervention|control|This group did not apply solution-focused interview techniques.
2883613|NCT03364192|Experimental|Peer-delivered Whole Health Coaching|Whole Health Coaching is a Veterans Health Administration variation of integrative health coaching. For this study it will be administered by a peer support specialist.
2883614|NCT03364179||young onset dementia|
2883615|NCT03364179||late onset dementia|
2884378|NCT03358589|Other|MESTAR|All patients will have the same scans performed
2883616|NCT03364166|Active Comparator|buccinator muscle excision with skin|surgical excision of the buccinator muscle with the skin in buccal squamous cell carcinoma and neck dissection also done
2883617|NCT03364166|Active Comparator|buccinator muscle excision without skin|surgical excision the buccinator muscle without the skin in buccal squamous cell carcinoma and neck dissection also done.
2883618|NCT03364153|Experimental|Cohort 1|Zimura dose group
2883619|NCT03364153|Sham Comparator|Cohort 2|Sham dose group
2883620|NCT03364127|Active Comparator|Experimental: Active Acupuncture|Active Acupuncture two times per week for 5 weeks
2883621|NCT03364127|Placebo Comparator|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
2883622|NCT03364114|Experimental|EndoRotor Resection|Intervention: A prospective, multi-center, randomized study to compare the safety and performance of the EndoRotor® Mucosal Resection System in 110 subjects with refractory dysplastic Barrett's Esophagus. The subjects are randomized and treated (up to 2 times) with either the EndoRotor® or control.
2883623|NCT03364114|Active Comparator|Continued Ablation (Control)|Intervention: A prospective, multi-center, randomized study to compare the safety and performance of the EndoRotor® Mucosal Resection System with continued ablative therapy in 110 subjects with refractory dysplastic Barrett's Esophagus. The subjects are randomized and treated (up to 2 times) with continued ablation using either cryotherapy or ablative therapy or the EndoRotor Resection Arm.
2883624|NCT03364101|Experimental|PowerOff|PowerOff is a nutraceutical and a blend of nine ingredients for sleep, including: melatonin; California Poppy; L-Cystine; Glycine; and Magnolia Officinalis
2883625|NCT03364101|Placebo Comparator|Placebo|The placebo pill will be manufactured at the same facility and appear identical in all aspects. However, the control agent will feature non-active ingredients with regards to sleep.Capsules will be instructed to commence on day 7 of the study after baseline appointment
2883626|NCT03364088|Active Comparator|Spinal anesthesia with tourniquet|"This group will be operated under spinal anesthesia (15 mg of bupivacaine) and in continuous light propofol sedation. Surgical tourniquet (with the pressure of 250 mmHg or > 100 mmHg higher than systolic blood pressure) is used during the operation.~Local infiltration analgesia (LIA) will be administered during the operation. Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the removal of the tourniquet.~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
2883627|NCT03364088|Active Comparator|Spinal anesthesia without tourniquet|"This group will be operated under spinal anesthesia (15 mg of bupivacaine) and in continuous light propofol sedation. Surgical tourniquet is not used during the operation.~Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the surgical incision. Local infiltration analgesia (LIA) will be administered during the operation.~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
2883628|NCT03364088|Active Comparator|General anesthesia with tourniquet|"This group will be operated under general anesthesia (propofol and remifentanil are used with target-controlled infusion (TCI) mode) and surgical tourniquet (with the pressure of 250 mmHg or > 100 mmHg higher than systolic blood pressure) is used during the operation.~Local infiltration analgesia (LIA) will be administered during the operation. Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the removal of tourniquet. Intravenous bolus of oxycodone 0.1 mg/kg (ideal body weight) is given when the closure of surgical wound begins.~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
2883629|NCT03364088|Active Comparator|General anesthesia without tourniquet|"This group will be operated under general anesthesia (propofol and remifentanil are used with target-controlled infusion (TCI) mode) without the use of surgical tourniquet.~Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the surgical incision. Local infiltration analgesia (LIA) will be administered during the operation. Intravenous bolus of oxycodone 0.1 mg/kg (ideal body weight) is given when the closure of surgical wound begins.~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
2883630|NCT03364075|Active Comparator|Duloxetine Treatment|patients treated with Duloxetine
2883631|NCT03364075|Active Comparator|Propranolol Treatment|patients treated with Propranolol
2883632|NCT03364075|Placebo Comparator|Placebo Treatment|patients treated with placebo
2883633|NCT03364062||cemented shoulder replacement patients|A total of 350 cases of proximal humeral fracture receiving cemented shoulder replacement in Department of Orthopedics and Trauma
2883634|NCT03364049|Experimental|MK-7162+Pembrolizumab|Cycle 1: Participants receive MK-7162 (at a daily dose of between 25 mg and 400 mg) via oral tablets once daily (QD) throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 (at a daily dose of between 25 mg and 400 mg) via oral tablets QD PLUS pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (every 3 weeks [Q3W]).
2883635|NCT03364036|Experimental|Mavenclad®|
2883636|NCT03364023||Acute Ischemic Stroke Patients|Acute Ischemic Stroke (AIS) patients treated with Medtronic Market-Released Neurothrombectomy Device
2883637|NCT03364010|Experimental|Dyslexic and non dyslexic Children|Children aged 10-12 Evaluation of proprioception Evaluation of motor learning Evaluation of written language
2883638|NCT03363997|Experimental|Test 1 vaginal ring|Single vaginal application of 1 vaginal ring containing 100 mg estriol, with delivery rate of 0.125 mg/day over 21 days
2883639|NCT03363997|Experimental|Test 2 vaginal ring|Single vaginal application of 1 vaginal ring containing 300 mg estriol, with delivery rate of 0.250 mg/day over 21 days
2883640|NCT03363997|Experimental|Test 3 vaginal ring|Single vaginal application of 1 vaginal ring containing 600 mg estriol, with delivery rate of 0.500 mg/day over 21 days
2883641|NCT03363984|Experimental|Midazolam & ID-082|Single oral administration of 2 mg midazolam on Day 1, Day 2, and Day 11. Administration of ID-082 from Day 2 through Day 11.
2883642|NCT03363971|Experimental|Experimental group|Zhi Kang Capsule, 0.3g/capsule, oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery,treatment for 6 weeks.
2883643|NCT03363971|Placebo Comparator|Control group|Simulant agent for Zhi Kang Capsule,consistent with the appearance, color, odor, and usage of the Zhi Kang capsule, so that it can not be distinguished.oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery, treatment for 6 weeks.
2883670|NCT03363815|Experimental|Part 2- Rosuvastatin and CC-90001|Patients will receive CC-90001 and 10mg of Rosuvastatin
2883644|NCT03363958|Experimental|RIC Group|Three cycles of remote ischemic conditioning (5minutes ischemia and 5minutes reperfusion; lower leg ischemia achieved by pressure cuff inflation and deflation); First three cycles the patient will receive 24 hours preoperatively, second three cycles the patient will receive after the induction of general anesthesia but before skin incision shortly before CABG. Remote ischemic postconditioning (5minutes ischemia and 5minutes reperfusion; lower leg ischemia achieved by pressure cuff inflation and deflation) will be administered to the patient within 60 minutes after the completion of all coronary artery bypass grafts and the restoration of coronary blood flow.
2883645|NCT03363958|Sham Comparator|Control Group|Control group will receive sham procedure near identical to intervention. That will be afforded by inflation of pressure cuff on artificial leg hidden under the draping by an assistant who is not included in the research team and does not have any connection to study design and data analysis.
2883646|NCT03363945|Active Comparator|MDR-101|A single dose will be administered via IV infusion post-kidney transplant.
2883647|NCT03363945|No Intervention|Control Arm|Subjects randomized to this arm will receive the standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study.
2883648|NCT03363932||Perimembranous VSD with high pulmonary flow rate|"It is an observational study, no intervention or examination will be realized for the sole purpose of the study. Patient management will be at the discretion of referral cardiologists according to the practices of the centers.~As part of the usual follow-up of these patients, the participating centers collect the clinical and echocardiography data from inclusion and the following year, as well as data from a functional assessment at baseline and at one year. and the collection of cardiovascular events at 5 years and 10 years of follow-up.~Data from a possible percutaneous or surgical closure procedure will be collected. The indication of VSD closure will be left to the discretion of participating centers. There will be no recommendation for percutaneous or surgical closure of VSD for the sole purpose of this observatory."
2883649|NCT03363919|Active Comparator|Phase I Low Intracortical facilitation (ICF) and 1 Hz|Participants with Low ICF. Defined as < or equal to 1.5 testing at baseline, will receive 1 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) using the NeuroStar TMS Therapy® System and the NeuroStar XPLOR®
2883650|NCT03363919|Active Comparator|Phase I Low Intracortical facilitation (ICF) and 10 Hz|Participants with Low ICF. Defined as < or equal to 1.5 testing at baseline, will receive 10 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) using the NeuroStar TMS Therapy® System and the NeuroStar XPLOR®
2883651|NCT03363919|Active Comparator|Phase I High Intracortical facilitation (ICF) and 1 Hz|Participants with High ICF. Defined as > 1.5 testing at baseline, will receive 1 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) using the NeuroStar TMS Therapy® System and the NeuroStar XPLOR®
2883652|NCT03363919|Active Comparator|Phase I High Intracortical facilitation (ICF) and 10 Hz|Participants with High ICF. Defined as > 1.5 testing at baseline, will receive 10 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) using the NeuroStar TMS Therapy® System and the NeuroStar XPLOR®
2883653|NCT03363919|Active Comparator|Phase II Low Intracortical facilitation (ICF)|Phase II is a trial of Phase I participants who did not have an adequate clinical response in Phase I. Participants will be assigned to 2 weeks of Intermittent Theta Burst Stimulation (iTBS) if their ICF (baseline assessment for TBS extension trial) is < 1.5. Participants assigned to iTBS will receive 10 daily sessions (5 sessions per week for two weeks) with 2 second trains every 10 seconds for a total of 570 seconds for 1800 pulses. Using the NeuroStar TMS Therapy® System and the NeuroStar XPLOR®
2883654|NCT03363919|Active Comparator|Phase II High Intracortical facilitation (ICF)|Phase II is a trial for Phase I participants who did not have an adequate clinical response in Phase I. Participants will be assigned to 2 weeks of Continuous Theta Burst Stimulation (cTBS) if their ICF (baseline assessment for TBS extension trial) is > 1.5. Participants will receive 10 daily sessions (5 sessions per week for two weeks) with 120 second trains of uninterrupted TBS for 1800 pulses at 80% MT using the NeuroStar TMS Therapy® System and the NeuroStar XPLOR®
2883655|NCT03363906|Experimental|Dulaglutide (Reference)|Dulaglutide administered subcutaneously (SC) in 3 prefilled syringes in one of two study periods
2883656|NCT03363906|Experimental|Dulaglutide (Test)|Dulaglutide administered SC in 1 single dose pen in one of two study periods
2883657|NCT03363893|Experimental|Module 1 Monotherapy|Module 1 CT7001 Monotherapy
2883658|NCT03363880|Experimental|experimental group|The trauma treatment team will be established in the experimental group
2883659|NCT03363880|Active Comparator|control group|The trauma treatment team will not be established in this group，just establish the basic experimental settings
2883660|NCT03363867|Experimental|Atezolizumab, Bevacizumab and Cobimetinib (ABC)|
2883661|NCT03363854|Experimental|Tralokinumab(initial)responders-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
2883662|NCT03363854|Experimental|Tralokinumab(initial)responders-> Tralokinumab(continuation B)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen B."
2883663|NCT03363854|Experimental|Tralokinumab(initial)non-respon-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
2883664|NCT03363854|Experimental|Placebo (initial)non-respon-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
2883665|NCT03363854|Placebo Comparator|Placebo(initial)responders-> Placebo(continuation A)|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 32 (continuation period):~Placebo continuation SC injection regimen A."
2883666|NCT03363841|Experimental|SCY-078|SCY-078
2883667|NCT03363828||Normal microbiota|Based on qPCR and Next gen sequencing
2883668|NCT03363828||Abnormal microbiota|Based on qPCR and Next gen sequencing
2883669|NCT03363815|Experimental|Part1:Omeprazole + Midazolam + Warfarin + Vitamin K + CC-90001|Patient will receive CC-90001, 20mg Omeprazole, 2mg Midazolam 10mg Warfarin and 10mg Vitamin K
2883804|NCT03362853|Experimental|Nemonoxacin 750Mg Capsule|
2883671|NCT03363815|Experimental|Part 3: Metformin + Digoxin and CC-90001|Patients will receive CC-90001, 500mg Metformin and 0.25mg, Digoxin
2883672|NCT03363815|Experimental|Part 4: Nintedanib and CC-90001|Patients will receive CC-90001 and 100mg of Nintedanib
2883673|NCT03363789|Active Comparator|Brisement|Patients will receive a series of brisement injections for treatment of non insertional Achilles tendinosis.
2883674|NCT03363789|Active Comparator|Physical Therapy|Patients will undergo physical therapy for treatment of non insertional Achilles tendinosis.
2883675|NCT03363776|Experimental|Monotherapy|BMS-986277 administered alone
2883676|NCT03363776|Experimental|Combination Dose Escalation Therapy|BMS-986277 administered in combination with Nivolumab
2883677|NCT03363776|Experimental|Combination Expansion Therapy|BMS-986277 monotherapy with option for subsequent Nivolumab therapy
2883678|NCT03363763|Active Comparator|Arm 1|Sirolimus 0.2% ointment applied topically hs x 12 weeks
2883679|NCT03363763|Active Comparator|Arm 2|Sirolimus 0.4% ointment applied topically hs x 12 weeks
2883680|NCT03363763|Placebo Comparator|Arm 3|Placebo ointment applied topically hs x 12 weeks
2883681|NCT03363750|Experimental|mind-body-skills intervention|mind-body-skills group intervention offered weekly for 10 weeks
2883682|NCT03363737|Active Comparator|Static|
2883683|NCT03363737|Experimental|Dynamic|
2883684|NCT03363724||HaGuide version 1.0 software module|Patients diagnosed with Parkinson's Disease who underwent implantation of DBS electrode in the STN for the treatment of Parkinson's Disease, using the Neuro-Omega device for navigation and procedure's MER digital recorded data is available.
2883685|NCT03363685||Low risk|For NSCLC spinal metastasis patients with 0-3 of novel survival prediction algorithm.
2883686|NCT03363685||Intermediate risk|For NSCLC spinal metastasis patients with 4-6 of novel survival prediction algorithm.
2883687|NCT03363685||High risk|For NSCLC spinal metastasis patients with 7-10 of novel survival prediction algorithm.
2883688|NCT03363672||Patients receiving surgery|No intervention will be administered. Patients included will be asked to return a questionnaire regarding chronic postoperative pain via app.
2883689|NCT03363659|Experimental|DSF-Cu with temozolomide and radiation|Disulfiram (DSF; oral) / copper gluconate (Cu; oral) dosed at 125 mg / 2 mg, twice daily. Temozolomide will be administered following the standard Stupp protocol at a dose of 75 mg/m2 for 42 days with concurrent radiation therapy. Temozolomide maintenance dose will be 150 mg/m2 once daily on Days 1-5 of every 28-day cycle while DSF-Cu is continued twice daily, as tolerated, for the duration of the Temozolomide adjuvant treatment. Patients demonstrating continued benefit from the adjuvant temozolomide after 6 cycles can continue treatment to a maximum of 12 cycles
2883690|NCT03363633|No Intervention|Observation|
2883691|NCT03363633|Experimental|Injection + Compression|
2883692|NCT03363633|Active Comparator|Compression|
2883693|NCT03363620|Experimental|self ligation brackets damon ormco®|the self ligation bracket (damon system) in the orthodontic treatment, was used in the experimental group with the recommended protocol damon arches sequence.
2883694|NCT03363620|Active Comparator|conventional brackets orthos ormco®|the conventional bracket (orthos system) in the orthodontic treatment, was used in the active comparator group with the recommended protocol damon arches sequence as used in the experimental group.
2883695|NCT03363607|Experimental|3D printed transfer tray group|Indirect bonding using digital 3D printed transfer tray
2883696|NCT03363607|Active Comparator|Thermoformed transfer tray group|Indirect bonding using Thermoformed transfer tray
2883697|NCT03363594||1|Diabetes Mellitus
2883698|NCT03363581||Control|Normal Weight Healthy Controls
2883699|NCT03363581||Gastric bypass|Obese patients due to undergo gastric bypass surgery
2883700|NCT03363568|Experimental|Adaptive Inhibitory Control Training|Participants played a set of three modified stop-signal reaction time tasks designed by NeuroScouting, LLC at home for approximately 5 days a week (25 min/day) for 4-weeks. This condition involved real-time adaptive gameplay that increased in difficulty as performance increased.
2883701|NCT03363568|Active Comparator|Non-Adaptive Inhibitory Control Training|Participants played a set of three modified stop-signal reaction time tasks designed by NeuroScouting, LLC at home for approximately 5 days a week (25 min/day) for 4-weeks. This condition had no change in difficulty (non-adaptive gameplay).
2883702|NCT03363555|Experimental|SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.
2883703|NCT03363542|Active Comparator|Fruits and vegetables rich diet|dietary education to increase fruits and vegetable consumption
2883704|NCT03363542|Active Comparator|Whole grain fiber rich diet|dietary education to increase whole grain fiber consumption
2883705|NCT03363542|Active Comparator|Fruits and vegetables and whole grain fiber rich diet|dietary education to increase fruits and vegetable and whole grain fiber consumption
2883706|NCT03363542|No Intervention|Control group|Routine care
2883707|NCT03363529|Placebo Comparator|Standard|This study arm utilizes a standard lighting condition in the patient room
2883708|NCT03363529|Experimental|Dynamic|This study arm utilizes a dynamic lighting from special designed lightfixtures in the ceiling and window sill.
2883709|NCT03363516||Cases|Glucose normotolerant subjects with 1-h post-load plasma glucose >155 mg/dL
2883710|NCT03363516||Controls|Glucose normotolerant subjects with 1-h post-load plasma glucose <155 mg/dL
2883711|NCT03363503|Experimental|Salmeterol/Fluticasone Capsair®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks
2883712|NCT03363503|Active Comparator|Salmeterol/Fluticasone Diskus®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks
2883713|NCT03363490|Other|Control|The patients in this group will only receive health education intervention.
2883714|NCT03363490|Other|Neuromuscular exercise therapy|The patients in this group will receive exercise therapy intervention.Besides, health education will be performed for every group.
2883715|NCT03363490|Other|Self-management program|The patients in this group will receive self-management intervention.Besides, health education will be performed for every group.
2883716|NCT03363490|Other|Exercise therapy+self-management|The patients in this group will receive exercise therapy and self-management intervention.Besides, health education will be performed for every group.
2883717|NCT03363477|Experimental|AB treatment sequence|Period 1-Test Treatment A: enoxaparin (100 mg/mL) 100-mg SC injection, manufactured by Rovi (Spain) Period 2-Reference Treatment B: Clexane (100 mg/mL) 100-mg SC injection, manufactured by Sanofi (EU)
2883718|NCT03363477|Active Comparator|BA treatment sequence|Period 1-Reference Treatment B: Clexane (100 mg/mL) 100-mg SC injection, manufactured by Sanofi (EU) Period 2-Test Treatment A: enoxaparin (100 mg/mL) 100-mg SC injection, manufactured by Rovi (Spain)
2883719|NCT03363464||patients with T2DM initiating empagliflozin|Type 2 diabetes mellitus
2883720|NCT03363464||patients with T2DM initiating a DPP-4 inhibitor|dipeptidyl peptidase-4 inhibitor treated patients
2883721|NCT03363451||Infection Group|Patients with end stage liver disease with infection
2883722|NCT03363451||Non-infection Group|Patients with end stage liver disease without infection
2883723|NCT03363438||martinique|
2883724|NCT03363438||guadeloupe|
2883725|NCT03363425|Active Comparator|Lidocaine|
2883726|NCT03363425|Active Comparator|Dexmedetomidine|
2883727|NCT03363425|Placebo Comparator|Normal Saline 0,9%|
2883728|NCT03363412|Experimental|Underdilated TIPS|Patients will be treated with PTFE-covered stent grafts balloon-dilated to less than 8 mm.
2883729|NCT03363386|Experimental|Proprioceptive Exercise Group (PG)|Aerobic Exercise Proprioceptive Exercises
2883730|NCT03363386|Active Comparator|Resistive Exercise Group (RG)|Aerobic Exercise Resistive Exercises
2883731|NCT03363373|Experimental|GM-CSF + hu3F8|Each investigational cycle is started with 5 days of GM-CSF administered at 250 µg/m2/day in advance of the start of hu3F8 administration. GM-CSF is thereafter administered at 500 µg/m2/day on days 1 to 5. As standard treatment, hu3F8 is administered at 3 mg/kg/day on days 1, 3, and 5 totalling 9 mg/kg per cycle. After 15 cycles at week 101 participants will enter a long-term follow up for up to five years after first dose.
2883732|NCT03363347||Radioiodine refractory papillary thyroid cancer|Patients with radioiodine refractory papillary thyroid cancer who received redifferentiation therapy with retinoid acid.
2883733|NCT03363347||Radioiodine sensitive papillary thyroid cancer|Patients who were in remission after one or two radioiodine therapies.
2883734|NCT03363321|Experimental|PF-06741086 (Cohort 1)|
2883735|NCT03363321|Experimental|PF-06741086 (Cohort 2)|
2883736|NCT03363321|Experimental|PF-06741086 (Cohort 3)|
2883737|NCT03363321|Experimental|PF-06741086 (Cohort 4)|
2883738|NCT03363321|Experimental|PF-06741086 (Cohort 5)|
2883739|NCT03363321|Experimental|PF-06741086 (Cohort 6)|
2883740|NCT03363308|Experimental|Phase 1|training for health care workers supplemented by QI teams
2883741|NCT03363308|No Intervention|Phase 2|
2883742|NCT03363295|Experimental|Intracameral moxifloxacin|Injection of 0,03ml of moxifloxacin in the anterior chamber following phacoemulsification surgery
2883743|NCT03363295|No Intervention|No - Intracameral moxifloxacin|This group won't receive any prophylaxis after phacoemulsification surgery
2883744|NCT03363282|Experimental|Mini-SLET|Simple Limbal Epithelial Transplantation
2883745|NCT03363282|Experimental|Limbal-Conjunctival Autograft|Patients treated with limbal-conjunctival autograft
2883746|NCT03363269|Experimental|ID1201 100mg|
2883747|NCT03363269|Experimental|ID1201 200mg|
2883748|NCT03363269|Experimental|ID1201 400mg|
2883749|NCT03363269|Placebo Comparator|Placebo|
2883750|NCT03363256|Experimental|TAU+TES-NAV|Standard outpatient addiction treatment plus Therapeutic Education System adapted for AI/AN
2883751|NCT03363256|Active Comparator|TAU|Standard outpatient addiction treatment
2883752|NCT03363243|Experimental|STOP Therapy Treatment group|Self-regulation Treatment for Opioid addiction and Pain (STOP) is a 12-week, rolling entry group therapy protocol that underwent initial development in a previous K23 study. Treatment consists of weekly 90-minute CBT+SR (Self Regulation) treatment with skill building exercises for co-morbid opioid addiction and pain. STOP will be provided in lieu of TAU (Treatment as Usual) group therapy.
2883753|NCT03363243|Active Comparator|Treatment as usual (TAU) group|Psychotherapy for Addiction in conjunction with medication assisted treatment. Standard community treatment for opioid addiction consists of 90-minute weekly rolling entry addiction treatment for 12 weeks to allow for the learning and rehearsal of skills designed to reduce relapse.
2883754|NCT03363230|Experimental|Mindfulness skills|
2883755|NCT03363230|Active Comparator|Interpersonal effectiveness skills|
2883756|NCT03363217|Experimental|Neurofibromatosis Type 1 (NF1) with low-grade glioma|Patients presenting with Neurofibromatosis Type 1 (NF1) and a progressing/refractory low-grade glioma.
2883757|NCT03363217|Experimental|Neurofibromatosis Type 1 (NF1) with Plexiform Neurofibroma|Patients presenting with Neurofibromatosis Type 1 (NF1) and a plexiform neurofibroma
2883758|NCT03363217|Experimental|Progressing/refractory low grade-glioma, KIAA1549-BRAF fusion|Patients presenting with a progressing/refractory low-grade glioma with a KIAA1549-BRAF fusion.
2883759|NCT03363217|Experimental|Progressing/Refractory central nervous system (CNS) glioma.|Patients presenting with a progressing/refractory central nervous system glioma with an activation of the MAPK/ERK pathway who do not meet criteria for inclusion in other study groups.
2883760|NCT03363204|Experimental|BRUXENSE|Patients corresponding to selection criteria will use the BRUXENSE occlusal splint for 10 consecutive nights.
2883761|NCT03363191|Experimental|Subjects received Fluticasone Furoate/Vilanterol|Subjects will receive fluticasone furoate/vilanterol 100/25 mcg inhalation powder via ELLIPTA dry powder inhaler (DPI) once daily for the 12 week treatment period. Subjects will receive salbutamol/albuterol as rescue medication on an as-needed basis.
2883762|NCT03363191|Active Comparator|Subjects received Fluticasone Furoate|Subjects will receive fluticasone furoate 100 mcg inhalation powder via ELLIPTA DPI once daily for the 12 week treatment period. Subjects will receive salbutamol/albuterol as rescue medication on an as-needed basis.
2883763|NCT03363178|Experimental|GC3107|BCG Vaccine, 0.1mL
2883764|NCT03363165|Active Comparator|VM202|Participants will receive injections of VM202 (4 mgs) in calf skeletal muscle every 14 days for a total of four treatment days.
2883765|NCT03363165|Placebo Comparator|Placebo|Participants will receive injections of placebo in calf skeletal muscle every 14 days for a total of four treatment days.
2883805|NCT03362853|Placebo Comparator|Placebo oral capsule|
2883766|NCT03363139||Patients with T790M mutation|Patient who has progressed to Tyrosin Kinase inhibitors and has the mutation of the gen T790M
2883767|NCT03363100|Experimental|Intervention|
2883768|NCT03363100|No Intervention|Control|
2883769|NCT03363087|Experimental|Mapping and ablation|Automated high density biatrial scar mapping Pacing confirmation of scar Collection of impedance data during clinical ablation
2883770|NCT03363074|Experimental|Orthotic Insole|Device: Orthotic Insole 8-week follow-up with Orthotic Insole
2883771|NCT03363074|Experimental|Low-level Laser Therapy|Low-Level Laser 5-week follow-up
2883772|NCT03363061||Antithrombotics|The patients should be on antithrombotics on the day of colonoscopy arrangement
2883773|NCT03363048|Experimental|Restricted|
2883774|NCT03363048|Experimental|Restriction plus Incentive|
2883775|NCT03363048|No Intervention|Control|
2883776|NCT03363035|Experimental|Rivaroxaban 2.5 mg|One 2.5 mg rivaroxaban tablet twice daily
2883777|NCT03363035|Experimental|Rivaroxaban 5 mg|One 5 mg rivaroxaban tablet twice daily
2883778|NCT03363035|Active Comparator|enoxaparin|Enoxaparin 1mg/kg twice daily SC twice daily
2883779|NCT03363022|Experimental|Standard Medical Treatment+Fecal Microbiota Transplant|
2883780|NCT03363022|Active Comparator|Standard Medical Treatment+Placebo|
2883781|NCT03363009|Experimental|Connected device with close following|Data from connected devices (arm wrist watch, connected monitor of blood pressure, connected thermometer and pulse oximeter) will be analyzed every day and used for coaching
2883782|NCT03363009|Other|Connected device with standard coaching|Data from connected devices (arm wrist watch, connected monitor of blood pressure, connected thermometer and pulse oximeter) will be saved but not used for coaching
2883783|NCT03362996|Experimental|Experimental Group|"50 patients Freshly-Pressed Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days.~Dietary Supplement: Freshly-Pressed Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)"
2883784|NCT03362996|Placebo Comparator|Control group 1|50 patients Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days. Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)
2883785|NCT03362996|Other|Control Group 2|50 patients that will have the same dietary habits and a Mediterranean dietary protocol
2883786|NCT03362983|Experimental|Care HND Intervention|Integrated, multidisciplinary, person centered care at HND-centrum.
2883787|NCT03362983|No Intervention|Standard care|Standard care at separate specialty clinics and primary care as needed.
2883788|NCT03362970|Active Comparator|Standard of Care|For children randomized to the standard of care arm, the treating physician will be informed to proceed as per their usual practice and treatment patterns. If stool is unavailable a rectal swab will be collected and sent to Calgary Laboratory Services (CLS) for routine culture. A routine stool specimen for back-up culture will still be requested as per standard of care. Home stool collection will be performed for those unable to provide a sample at enrolment and will be achieved by providing families with collection kits.
2883789|NCT03362970|Experimental|BioFire Gastrointestinal Panel FilmArray|For children randomized to the BioFire FilmArray arm, stool, if available, will be sent STAT to Calgary Laboratory Services (CLS) for the performance of the BioFire FilmArray test and routine culture. If stool is unavailable, a rectal swab will be performed and sent to CLS for the performance of the BioFire FilmArray test and routine culture. A routine stool specimen for back-up culture will still be requested as per standard of care once it is available. Treatment decisions will be at the sole discretion of the ED treating physician who receives the result.
2883790|NCT03362957|Experimental|GAE Procedure|Patients will be randomized to receive the Geniculate Artery Embolization Procedure
2883791|NCT03362957|Sham Comparator|Sham Procedure|Patients will be randomized to a sham procedure.
2883792|NCT03362957|Experimental|Crossover Arm|If after 1 month patients see no improvement, they will be unblinded and crossover to receive the Geniculate Artery Embolization Procedure
2883793|NCT03362944|Experimental|Active Music Therapy|
2883794|NCT03362944|Experimental|Passive Music Therapy|
2883795|NCT03362931|Experimental|XEN45 Glaucoma Treatment System (hereafter referred to as XEN)|XEN45 unilaterally implanted in the study eye
2883796|NCT03362918|No Intervention|Control Group|"Participants randomized to the control group will continue with their usual level of physical activity. They will track their menstrual cycles and perform daily ovulation tests.~Once all post-intervention assessments are complete, they will have the option to begin an exercise program with three supervised sessions of either high-intensity interval training or continuous aerobic exercise training free of charge. They will be given a Polar heart rate (HR) monitor as a gift for their participation in the study."
2883797|NCT03362918|Experimental|High-Intensity Interval Training|Participants randomized to this group will complete three high intensity interval training sessions per week, two of which will be supervised. They will exercise for a total of 30 minutes per session. Each session will begin with a five-minute warm-up and end with a five-minute cool-down.
2883798|NCT03362918|Experimental|Continuous Aerobic Exercise Training|Participants randomized to this group will complete three continuous aerobic training sessions per week, two of which will be supervised. They will exercise for a total of 50 minutes per session. Each session will begin with a five-minute warm-up and end with a five-minute cool down.
2883799|NCT03362905|Experimental|Lidocaine spray Arm|This arm will receive lidocaine spray (Lidocaine topical aerosol ®, 10%, Arab drug co., Egypt) with dose four puffs (50 ml, 10 mg/puff) will be applied to the cervical canal and cervix.
2883800|NCT03362905|Active Comparator|Lidocaine cream Arm|This arm will receive topical cream (Pridocaine ®, Global Napi, Egypt) with a dose of 2g lidocaine cream will be applied to the cervix via cotton swab.
2883801|NCT03362905|Active Comparator|Lidocaine injection Arm|This arm will receive lidocaine injection (Debocaine®, 2%, Sigma-Tec, Egypt) with a dose of 80-200 mg equivalent to 10 ml lidocaine (20 mg/ml) is injected at four and eight o'clock of the cervico-vaginal junction, and 2 ml to the area to be grasped with the tenaculum for paracervical block.
2883802|NCT03362879||Patients with Advanced Parkinson's Disease|Patients with advanced Parkinson's Disease on current treatment with levodopa-carbidopa intestinal gel (LCIG) for at least 12 months.
2883803|NCT03362853|Experimental|Nemonoxacin 500Mg Capsule|
2883807|NCT03362840|Experimental|Early Start Denver Model (ESDM) group|The ESDM is a manualized comprehensive treatment model for young children (12-48 months). In the preschool based ESDM, learning objectives are guided by the ESDM curriculum checklist, which includes developmental skills in language, play, motor skills, personal independence, imitation and cognition.
2883808|NCT03362840|Active Comparator|Eclectic preschool intervention group|The eclectic approach consists of a combination of methods from several treatment-models. Individualized educational plans are based on multi-disciplinary assessment, and include objectives in several domains - communication, social-skills, play, emotional adjustment, adaptive daily skills, motor skills and cognition. They are presented to parents at the beginning of the year and are reviewed by the staff three times a year.
2883809|NCT03362827||Chronic low back pain patients|People must have experienced low back pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
2883810|NCT03362827||Subjects without chronic low back pain|Participants must not have presented episodes of low back pain for more than 7 days in the last 12 months.
2883811|NCT03362814|Experimental|Experimental Group|Ravidasvir + Danoprevir + Ritonavir + Ribavirin
2883812|NCT03362814|Placebo Comparator|Placebo Group|Ravidasvir placebo + Danoprevir placebo + Ritonavir placebo + Ribavirin placebo
2883813|NCT03362801|Other|Sarcopenic|sarcopenic status the day before cystectomy.
2883814|NCT03362801|Other|not sarcopenic|sarcopenic status the day before cystectomy.
2883815|NCT03362788||VKA|"Patients receiving VKA as anticoagulant treatment plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.~Treatment will be at operator's discretion or, post discharge, at prescribing physician's discretion."
2883816|NCT03362788||NOAC|"Patients receiving a NOAC as anticoagulant treatment plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.~Treatment will be at operator's discretion or, post discharge, at prescribing physician's discretion."
2883817|NCT03362775|Other|All subjects|EEG will be recorded in all subjects before (0.0 µL/mL) and during a target controlled infusion of propofol (0.5 µL/mL and 1.0 µL/mL).
2883818|NCT03362723|Experimental|Treatment Sequence 1: ABCD|Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 1 (one cycle is 28 days). Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 8. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 15. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
2883819|NCT03362723|Experimental|Treatment Sequence 2: ABDC|Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 1 (one cycle is 28 days). Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 8. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 15. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
2883820|NCT03362723|Experimental|Treatment Sequence 3: BACD|Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 1 (one cycle is 28 days). Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 8. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 15. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
2883821|NCT03362723|Experimental|Treatment Sequence 4: BADC|Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 1 (one cycle is 28 days). Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 8. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 15. Treatment C: A single dose of new tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
2883822|NCT03362723|Experimental|Optional Treatment Extension Arm|Following completion of the BE/rBA cycle (Cycle 1), participants who have no clinically defined progressive disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and who recover from any prior treatment toxicity to Grade </=1 may enter the optional treatment extension phase. Participants will receive 200 mg idasanutlin orally (200-mg tablet reference formulation) daily for 5 days, followed by 23 days of rest. This extension phase will continue for additional 28-day cycles or until disease progression or unacceptable toxicity is observed.
2883823|NCT03362710|Experimental|PAD patients|"Patients referred for an arterial doppler assessment of lower limbs will be included.~Intervention is a series of examination, followed by the measurement of the ABI and an arterial echo-doppler of the lower limbs +/- transcutaneous oxygen pressure measurements in case of suspected critical limb ischemia.~A technician will perform the evaluation with simplified tools blinded to the results of vascular specialised investigations"
2883824|NCT03362697|Experimental|Probiotic|5*10^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 & Lactobacillus reuteri DSM 17938, PAC-A and Zinc
2883825|NCT03362697|Active Comparator|Antibiotic|Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick
2883826|NCT03362684|Experimental|FOLFOX-4 plus Cetuximab|
2883827|NCT03362684|Active Comparator|FOLFOX-4|
2883877|NCT03362333|Active Comparator|Exercise|This group received exercise directed at the neck and shoulder regions once a week over 4 weeks
2885154|NCT03353077|Experimental|Alpha DaRT|Alpha DaRT Seeds, Diffusing alpha-emitters Radiation Therapy.
2883828|NCT03362671|Experimental|Treatment Group|Participants will be treated with a novel experimental implant supported mandibular advancement oral appliance, which uniquely attaches to orthodontic mini implants (OMIs) in the jaw. Participants will be fitted with OMIs per standard clinical practice prior to treatment with the novel oral appliance.
2883829|NCT03362658||Patients|ALS patients (as well as patients with other related disorders such PLS, PMA, and ALS-FTD) will be recruited from ALS clinics under the direction of neurologists who are participating in this study. ALS patients should meet research criteria for suspected, possible, probable, probable laboratory supported, or definite ALS.
2883830|NCT03362658||Controls|Healthy controls who are age and gender matched to patients.
2883831|NCT03362645||Fabry cardiomyopathy|
2883832|NCT03362645||Hypertrophic cardiomyopathy|
2883833|NCT03362632||Infection Group|Patients with end stage liver disease with SBP
2883834|NCT03362632||Non-infection Group|Patients with end stage liver disease without SBP
2883835|NCT03362619|Experimental|CC-EIEs|Autologous cervical cancer specific engineered immune effectors (EIEs)
2883836|NCT03362606|Experimental|OC-CTLs|Autologous ovarian cancer specific cytotoxic lymphocytes
2883837|NCT03362593|Experimental|MEDI7219|Experimental Drug
2883838|NCT03362593|Placebo Comparator|Placebo|Placebo
2883839|NCT03362593|Placebo Comparator|Formulation without Active Drug|Formulation without Active Drug
2883840|NCT03362580||Group A|Patients diagnosed with diabetes mellitus, type 1 or type 2, aged 15 years or older
2883841|NCT03362580||Group B|Patients non-diagnosed with diabetes mellitus, aged 15 years or older
2883842|NCT03362567|Experimental|SNAGS Group|Subjects in SNAGS group were treated with application of sustained natural apophyseal glides, twice weekly for six weeks
2883843|NCT03362567|Experimental|MCT Group|subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks
2883844|NCT03362554|Experimental|Intervention|
2883845|NCT03362554|No Intervention|Control|
2883846|NCT03362541|Experimental|MS INFoRm group|Participants in the MS INFoRm group will be given a login and password that will take them to the MS INFoRm webpage. Access will be granted for 3-months, starting on the date of the first login. Participants can access the website at any time, at their own volition over the 3-months.
2883847|NCT03362541|Active Comparator|Usual care control group|Participants in the usual care group will be given a login and password that will take them to a usual care webpage. Access will be granted for 3-months, starting on the date of the first login. Participants can access the website at any time, at their own volition over the 3-months.
2883848|NCT03362528|Experimental|Short term collection of IMD data|Subjects will collect spectral raman data on WM3.4NR four times a day for 30 days distributed over a time period of 60 days. Each timepoints are conducted in duplicate. Spectral data will be compared to standard BG measurements.
2883849|NCT03362528|Experimental|Long term collection of IMD data|Subjects will collect spectral raman data on WM3.4NR four times a day for the initial 30 days, distributed over a time period of 60 days. Subjects will for the remaining 60 days of measurements, distributed over 120 days collect spectral data twice a day. Each timepoints are conducted in duplicate. Spectral data will be compared to standard BG measurements.
2883850|NCT03362515|Experimental|Furosemide|
2883851|NCT03362515|Placebo Comparator|Placebo|
2883852|NCT03362502|Experimental|PF-06939926|
2883853|NCT03362489|Other|IVF / IVF-ICSI|In Vitro Fertilization / In Vitro Fertilization - Intracytoplasmic Sperm Injection (ICSI)
2883854|NCT03362489|Other|IUI|Intrauterine insemination
2883855|NCT03362476|Experimental|Computer-based alcohol reduction intervention.|CBT4CBT is a computer-based version of cognitive behavioral therapy (CBT) used in conjunction with standard clinical care for current substance users.
2883856|NCT03362476|Other|Standard-of-care.|Routine counseling to avoid alcohol and drugs.
2883857|NCT03362463||Acute Coronary Syndrom|acute coronary syndrome in a real-life setting for patients hospitalized with an ACS (i.e. STEMI, NSTEMI, unstable angina)
2883858|NCT03362450||Pregnant patients seen for second or third trimester|Foetus with diagnosis of prenatal volvulus based on post-natal findings and prenatal imaging findings
2883859|NCT03362437|Experimental|Treatment A|Receive 200 mg BMS-986177 Form A without food
2883860|NCT03362437|Experimental|Treatment B|Receive 200 mg BMS-986177 Form B without food
2883861|NCT03362437|Experimental|Treatment C|Receive 200 mg BMS-986177 Form B with food
2883862|NCT03362424|Experimental|Mesenchymal stem cell group|rotator cuff repair stem cells
2883863|NCT03362424|Active Comparator|Control group|rotator cuff repair
2883864|NCT03362411|Experimental|BMS-986205 intact tablet orally then crushed tablet orally|Single, 100 mg dose
2883865|NCT03362411|Experimental|BMS-986205 crushed tablet orally, then intact tablet orally|Single, 100 mg dose
2883866|NCT03362411|Experimental|BMS-986205 intact tablet orally then suspension via NG tube|Single, 100 mg dose
2883867|NCT03362411|Experimental|BMS-986205 suspension via NG tube then intact tablet orally|Single, 100 mg dose
2883868|NCT03362398|Active Comparator|Omarigliptin|Drug: Omarigliptin 25 mg
2883869|NCT03362398|Active Comparator|Trelagliptin|Drug: Trelagliptin 100 mg
2883870|NCT03362385||OSA|
2883871|NCT03362385||Non-OSA|
2883872|NCT03362372|Experimental|INTERVENTION GROUP: MEDITERRANEAN DIET COUNSELING|During 2 years a nutritional intervention will be carried out to increase adherence to DiMet based on: annual visit of personalized nutritional education, a telephone contact for intervention reinforcement and computer access to a nutrition blog
2883873|NCT03362372|No Intervention|CONTROL GROUP: WITHOUT CHANGES IN DIET|The participants of health centers will carry out the same 5 visits (3 individual visits and 2 phone calls), although no changes are induced in their usual diet and they will not be offered access to the nutritional blog.
2883874|NCT03362359|Experimental|Ga-68-PSMA-11|
2883875|NCT03362346||Neurocritical patients|Patients with brain injury from trauma, ischemic stroke, hemorrhage stroke (intracerebral hemorrhage, subarachnoid hemorrhage), brain tumor with increased intracranial pressure, brain infection, hydrocephalus, among others.
2883876|NCT03362333|Experimental|pain neuroscience education and exercise|This group received pain neuroscience education and exercise once a week over 4 weeks
2884062|NCT03361046||Transcatheter Aortic Valve-in-Valve Implantation Cohort|
2883878|NCT03362320|Experimental|double layer fixation|Patients with torn infraspinatus and supraspinatus tendon undergoing arthroscopy rotator cuff repair with double layer fixation
2883879|NCT03362320|Experimental|single layer fixation|Patients with torn infraspinatus and supraspinatus tendon undergoing arthroscopy rotator cuff repair with single layer fixation
2883880|NCT03362307|Active Comparator|Laser Emitting group|subjects received Low-Level Laser and Light-Emitting Diodes after implant placement
2883881|NCT03362307|Placebo Comparator|Non Emitting group|In laser emitiiing group, subjects received Low-Level Laser and Light-Emitting Diodes after implant placement and in Non-emitting group,the same device was used while device was off.
2883882|NCT03362294|Experimental|GA Depot 40mg once monthly|Monthly IM injection
2883883|NCT03362281|Experimental|Ilaprazole|
2883884|NCT03362281|Active Comparator|omeprazole|
2883885|NCT03362268|Experimental|Ilaprazole|
2883886|NCT03362268|Active Comparator|omeprazole|
2883887|NCT03362255|Active Comparator|Rapid speed of injection|Rapid speed of injection (3cc/sec) during thoracic epidurography thoracic epidural catheterization
2883888|NCT03362255|Active Comparator|Slow speed of injection|Slow speed of injection (1cc/sec) during thoracic epidurography thoracic epidural catheterization
2883889|NCT03362242|Active Comparator|ARO-AAT|
2883890|NCT03362242|Placebo Comparator|Placebo|
2883891|NCT03362229|Active Comparator|FIXATION|Medial malleolus fixation, with the method of fixation left to the surgeons discretion.
2883892|NCT03362229|Active Comparator|NON-FIXATION|A well reduced medial malleolus fracture is then left without fixation ie, non-operative management.
2883893|NCT03362216|Experimental|experimental group|Treated with Compound Methyl Salicylate Liniment group
2883894|NCT03362216|Active Comparator|Control group|Treated with Diclofenac Sodium Liniment group
2883895|NCT03362203||Patients with chronic neck pain|Patients,aged 21-80 years, must have experienced neck pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
2883896|NCT03362203||Subjects without chronic neck pain|Subjects,aged 21-80 years, must not have presented episodes of chronic neck pain for more than 7 days in the last 12 months.
2883897|NCT03362190|Experimental|Cohort 1|Zimura dosage 1 + Lucentis 0.5 mg
2883898|NCT03362190|Experimental|Cohort 2|Zimura dosage 2 + Lucentis 0.5 mg
2883899|NCT03362190|Experimental|Cohort 3|Zimura dosage 3 + Lucentis 0.5 mg
2883900|NCT03362190|Experimental|Cohort 4|Zimura dosage 4 + Lucentis 0.5 mg
2883901|NCT03362177|Experimental|Romiplostim|The study in a 2:1 randomization ratio(108 subjects to romiplostim). Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
2883902|NCT03362177|Placebo Comparator|Placebo|The study in a 2:1 randomization ratio (54 subjects to placebo) Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
2883903|NCT03362151|Experimental|Regular pasta|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of regular pasta. They will consume this meal on two separate occasions.
2883904|NCT03362151|Experimental|High protein pasta|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of high protein pasta. They will consume this meal on two separate occasions.
2883905|NCT03362151|Experimental|White rice|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of white rice. They will consume this meal on two separate occasions.
2883906|NCT03362138||Dermoscopy|Dermoscopic imaging of a lesion decided to be biopsied
2883907|NCT03362099|No Intervention|Group Varenicline|Patients randomized to this group will collect polymorphisms at time zero and will receive varenicline for smoking cessation. The polymorphism result will only be known at the end of the protocol. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
2883908|NCT03362099|Active Comparator|Group Genetic|"The patients randomized to this arm will collect polymorphisms and could receive varenicline or bupropion or both depending on genetic polymorphisms for each one these drugs.~Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve."
2883909|NCT03362073|Experimental|Ketamine|continuous intravenous infusion of ketamine
2883910|NCT03362060|Experimental|PVX-410|"PVX-410 vaccine at W0, 1, 2, 3, 4, and 5 followed by booster PVX-410 vaccine doses at W10 and 28~Pembrolizumab will be administered every 3 weeks intravenously starting with week 1"
2883911|NCT03362047|Experimental|Riciguat Group|15 PAH patients will be administered Riciguat according to standard of care. RV function will be evaluated 90 mintutes after first medication intake and 12 weeks after first medication intake.
2883912|NCT03362047|Experimental|Macitentan Group|15 PAH patients will be administered Macitentan according to standard of care. RV function will be evaluated 90 mintutes after first medication intake and 12 weeks after first medication intake.
2883913|NCT03362034|Active Comparator|single transfer tray|
2883914|NCT03362034|Experimental|double transfer trays|
2883915|NCT03362021||DEX|Sedation with dexmedetomidine (solution 4 γ/ml) continuously infused at a dose of 1 γ/kg/ and fentanyl 100γ iv. Dexmedetomidine infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure.
2883916|NCT03362021||MZM|Sedation with remifentanil (solution 50γ/ml) continuously infused at a dose of 0.2 γ/kg/min and midazolam 1 mg iv. Remifentanil infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure.
2883917|NCT03362008|Experimental|Group I|Period I: administration of Zeropix Period II: administration of Champix®
2883918|NCT03362008|Experimental|Group II|Period I: administration of Champix® Period II: administration of Zeropix
2883919|NCT03361995|Experimental|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after PCI.
2916505|NCT03134300|Placebo Comparator|Normal/high SES|
2883920|NCT03361995|Active Comparator|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
2883921|NCT03361982|No Intervention|Fresh surgical testicular sperm|Fresh, surgically obtained testicular sperm
2883922|NCT03361982|Experimental|Frozen surgical testicular sperm|Surgically obtained testicular sperm that will undergo slow freezing and thawing
2883923|NCT03361969|Active Comparator|estetrol|
2883924|NCT03361969|Placebo Comparator|placebo|
2883925|NCT03361956|Experimental|Part A: Arm 1 (JNJ-56136379) (open label)|Participants with hepatitis B virus (HBV) currently not being treated will receive JNJ-56136379 tablet orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2883926|NCT03361956|Placebo Comparator|Part A: Arm 2 (Placebo+NA [ETV] or [TDF])|Participants with HBV currently not being treated will receive matching placebo along with nucleos(t)ide analog (NA) (entecavir [ETV] or tenofovir disoproxil fumarate [TDF]) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2883927|NCT03361956|Experimental|Part A: Arm 3 (JNJ-56136379 + NA [ETV or TDF])|Participants with HBV currently not being treated will receive JNJ-56136379 along with NA (ETV or TDF) tablet orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2883928|NCT03361956|Placebo Comparator|Part A: Arm 4 (Placebo + NA [ETV or TDF])|Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2883929|NCT03361956|Experimental|Part A: Arm 5 (JNJ-56136379 + NA [ETV or TDF])|Virologically suppressed participants will receive JNJ-56136379 along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2883930|NCT03361956|Experimental|Part B: Arm 6 (JNJ-56136379) (open label)|Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose, orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2883931|NCT03361956|Placebo Comparator|Part B: Arm 7 (placebo + NA [ETV or TDF])|Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2883932|NCT03361956|Experimental|Part B: Arm 8 (JNJ-56136379 + NA [ETV or TDF])|Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2883933|NCT03361956|Placebo Comparator|Part B: Arm 9 (placebo + NA [ETV or TDF])|Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2883934|NCT03361956|Experimental|Part B: Arm 10 (JNJ-56136379 + NA [ETV or TDF])|Virologically suppressed participants will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2883935|NCT03361930|Experimental|CP participants|Single-day data collection for walking conditions; barefoot, with plain ankle-foot orthosis (flat foot plate) on involved side, with tone-reducing ankle-foot orthosis on involved side.
2883936|NCT03361917|No Intervention|Control Arm (Standard Colonscopy)|Standard colonoscopy with no device attachments
2883937|NCT03361917|Experimental|Endocuff Vision|Colonoscopy with Endocuff Vision attached to distal end of scope
2883938|NCT03361891|No Intervention|Control|Patients receive no intervention
2883939|NCT03361891|Experimental|WalkMORE group|WalkMORE Ambulation program. Patients will ambulate with a trained WalkMORE Volunteer Coach two times per day; once in the morning (0900-1200hrs) and once in the afternoon (1300-1700hrs), Monday- Friday, until hospital discharge.
2883940|NCT03361878|Active Comparator|Metformin Tolerant|
2883941|NCT03361878|Active Comparator|Metformin Intolerant|
2883942|NCT03361865|Experimental|Treatment Group 1|Pembrolizumab + epacadostat
2883943|NCT03361865|Active Comparator|Treatment Group 2|Pembrolizumab + placebo
2883944|NCT03361852|Experimental|Neo Vax|"Neo Vax is injected into up to 4 different anatomic site.~NeoVax may be administered within +/- 1 day of the scheduled administration date for days 4 and 8,~Within +/-3 days of the scheduled administration date for days 15 and 22~Within +/-7 days of days 78 and 134.~Participants will receive Rituximab weekly x 4 weeks per institutional standard"
2883945|NCT03361839|Active Comparator|1|patients with RIF
2883946|NCT03361839|Placebo Comparator|2|fertile arm as r reference for result
2883947|NCT03361826|Other|DBT Only|Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder.
2883948|NCT03361826|Experimental|MagPro MST + DBT|Magnetic Seizure Therapy (MST) involves the induction of a seizure by applying magnetic stimulation to the brain.100% machine output at 25 Hz, with coil directed over frontal or vertex region of the brain, until adequate seizure achieved. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
2883949|NCT03361813|Active Comparator|trans-cutaneous ultrasound guided peritonsillar infiltration|
2883950|NCT03361813|Placebo Comparator|trans-oral ultrasound guided peritonsillar infiltration|
2883951|NCT03361800|Experimental|Entinostat|Nine days prior to their scheduled surgery, entinostat 5mg PO given once weekly on day 1 and day 8
2883952|NCT03361787|Experimental|Parentship coaching intervention|
2883953|NCT03361774|Experimental|Test dentifrice|Participants in this arm will receive experimental dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 parts per million [ppm] fluoride).
2883954|NCT03361774|Active Comparator|Control dentifrice|Participants in this arm will receive comparator dentifrice containing 0.454% SnF2 (1100ppm fluoride).
2883955|NCT03361761||experimental|therapeutic coordination apartments with formalized/official Health education program
2883956|NCT03361761||active comparator|therapeutic coordination apartments without formalized/official Health education program
2883957|NCT03361748|Experimental|Administration of bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 15 - 45 x 10^7 CAR+ T cells after receiving lymphodepleting chemotherapy.
2883958|NCT03361735|Experimental|Treatment (hormone therapy, SBRT, radium Ra 223 dichloride)|Beginning 4 weeks (28 days) prior to radiation therapy, patients receive leuprolide acetate or goserelin acetate, for up to 32 weeks. Patients also undergo 3-5 fractions of SBRT every 40 hours over 7-21 days beginning on day 1 of course 1, and receive radium Ra 223 dichloride IV over 1 minute on day 1 of courses 2-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
2883959|NCT03361709|Active Comparator|Dexamethasone group|Dexamethasone injected at conclusion of Phacoemulsification
2883960|NCT03361709|Placebo Comparator|Non-dexamethasone group|No dexamethasone will be injected at the conclusion of Phacoemulsification
2883961|NCT03361683|Experimental|High-flow nasal oxygen|Randomized patients will receive oxygen through a high flow nasal device capable of delivering humidified, heated air at an output rate of 40 L/min
2883962|NCT03361683|Active Comparator|Conventional oxygen|Randomized patients will receive oxygen through a Venturi mask at an air flow of 15 L/min
2883963|NCT03361670||Specimens that meet inclusion criteria|
2883964|NCT03361657|Active Comparator|Group I|IAP 8mmHg Laparoscopic surgeries will be performed according to the standard surgical and anesthesia protocols. Pneumo-peritoneum will be achieved using non-heated non-humidified CO2 with the intra-abdominal pressure (IAP) maintained at 8mmHg
2883965|NCT03361657|Active Comparator|Group II|IAP 10mmHg Laparoscopic surgeries will be performed according to the standard surgical and anesthesia protocols. Pneumo-peritoneum will be achieved using non-heated non-humidified CO2 with the intra-abdominal pressure (IAP) maintained at 10 mmHg
2883966|NCT03361657|Active Comparator|Group III|IAP 12mmHg Laparoscopic surgeries will be performed according to the standard surgical and anesthesia protocols. Pneumo-peritoneum will be achieved using non-heated non-humidified CO2 with the intra-abdominal pressure (IAP) maintained at 12 mmHg
2883967|NCT03361644|Experimental|High-Intensity Interval Training|Brief periods of vigorous physical activity separated by short periods of rest.
2883968|NCT03361644|Active Comparator|Moderate-Intensity Continuous Training|Physical activity at a sustained moderate heart rate.
2883969|NCT03361631|Experimental|arm treated with MSC|"Type 1 diabetic man~Aged from 18 to 50 years~Having a diabetes evolving for at least 10 years~Presenting at least one severe manifestation of microangiopathy, with or without dysautonomia: diabetic retinopathy, diabetic or vascular nephropathy, diabetic neuropathy, diabetic foot~Presenting an erectile dysfunction refractory to oral treatment (sildenafil, tadalafil ...)~IIEF-5 score less than or equal to 10"
2883970|NCT03361618|Experimental|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
2883971|NCT03361618|No Intervention|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment.
2883972|NCT03361605|Experimental|Propofol Administration|
2883973|NCT03361592|Experimental|Spinal Manipulative Therapy|The participants assigned to the intervention group received the procedure Lumbar (SMT) was performed after baseline measurements, using Diversified techniques, aiming to correct vertebral dysfunctional segments after clinical assessment. Participants were asked to lay down prone on, to perform spinal motion palpation analysis was performed in order to evaluate the presence of dysfunction in vertebral segments of lumbar spine.
2883974|NCT03361592|Sham Comparator|Sham pre-load positioning SMT|"The participants assigned to the control group received the procedure Sham (pre-load positioning MVT). The Sham (SMT) was performed with participant body positioning in the lateral position, as the SMT intervention. The doctor followed the participant through the same position of (SMT) intervention, using the maintenance of set-up position, but no manipulative thrust was delivered. The therapist applied minimal pressure and slid their hands across the skin to mimic the manipulative trust. The position was maintained for approximately 1 minute in total, 30 seconds on each side, and none of force or researcher body weight were putted in this procedure, only minimal pressure common to stabilize the set up position of (SMT)."
2883975|NCT03361579|Other|Placebo education group|Prior to the intervention during the Placebo is given, the volunteer receives a detailed information about the effect and the strength of an open-label placebo. This education is performed via a slide show and a news report video. The important terms for Placebo analgesia: positive expectations, conditioning, communication are discussed
2883976|NCT03361579|Other|Placebo non education group|No detailed Information about open-label placebo prior to the intervention. The volunteer is told about the possible strength of the Placebo effect on pain directly before the application.
2883977|NCT03361566|Experimental|low energy flux at ad libitum energy intake|physical activity: inactive energy intake: ad libitum
2883978|NCT03361566|Experimental|medium energy flux at ad libitum energy intake|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: ad libitum
2883979|NCT03361566|Experimental|high energy flux at ad libitum energy intake|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: ad libitum
2883980|NCT03361566|Experimental|Low energy flux at energy balance|physical activity: inactive energy intake: individual energy balance
2883981|NCT03361566|Experimental|medium energy flux at energy balance|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: individual energy balance
2883982|NCT03361566|Experimental|high energy flux at energy balance|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: individual energy balance
2883983|NCT03361566|Experimental|low energy flux at caloric restriction|physical activity: inactive energy intake: caloric restriction -25%
2883984|NCT03361566|Experimental|medium energy flux at caloric restriction|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: caloric restriction -25%
2883985|NCT03361566|Experimental|high energy flux at caloric restriction|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: caloric restriction -25%
2883986|NCT03361566|Experimental|low energy flux at overfeeding|physical activity: inactive energy intake: overfeeding +25%
2883987|NCT03361566|Experimental|medium energy flux at overfeeding|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: overfeeding +25%
2883988|NCT03361566|Experimental|high energy flux at overfeeding|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: overfeeding +25%
2883989|NCT03361540|Experimental|Single dose of ASP8302 dose-1|Subjects will receive a single dose of ASP8302.
2883990|NCT03361540|Experimental|Single dose of ASP8302 dose-2|Subjects will receive a single dose of ASP8302.
2883991|NCT03361540|Experimental|Single dose of ASP8302 dose-3|Subjects will receive a single dose of ASP8302.
2883992|NCT03361540|Experimental|Single dose of ASP8302 dose-4|Subjects will receive a single dose of ASP8302.
2883993|NCT03361540|Placebo Comparator|Single dose of Placebo|Subjects will receive a single dose of Placebo.
2883994|NCT03361540|Experimental|Multiple dose of ASP8302 dose-5|Subjects will receive once daily dosing of ASP8302 for 14 consecutive days at the same dose level.
2883995|NCT03361540|Experimental|Multiple dose of ASP8302 dose-6|Subjects will receive once daily dosing of ASP8302 for 14 consecutive days at the same dose level.
2883996|NCT03361540|Placebo Comparator|Multiple dose of Placebo|Subjects will receive once daily dosing of Placebo for 14 consecutive days.
2883997|NCT03361514|Active Comparator|Supported Protocolized Discontinuation|Supported Protocolized Discontinuation (SPD) Patients will receive guidance of their GP and can have supportive meetings with the mental health assistant.
2883998|NCT03361514|Experimental|SPD + Mindfulness (MBCT)|In addition to the SPD (as mentioned above) patients are offered Mindfulness Based Cognitive Therapy (MBCT)
2883999|NCT03361501|Experimental|CaPre|
2884000|NCT03361501|Placebo Comparator|Placebo|
2884001|NCT03361488|Experimental|Trained anesthesiologist|Patient interview by anesthesiologists having obtained training to optimize structured communication
2884002|NCT03361488|No Intervention|Control anesthesiologist|Patient interview by control anesthesiologists
2884003|NCT03361475|Experimental|Intervention school|One school workshop and a small talk were conducted first at the beginning of the programme, which was to promote SME and introduce the function of SME App for students, followed by downloading and using immediately to connect family members, then let them continue to use for one month with system reminder.
2884004|NCT03361475|No Intervention|Waitlist control schools|The intervention won't be provided during evaluation period and will be provided after the evaluation period
2884005|NCT03361462|Experimental|Intervention group|Two joyful adventure days in the form of physical activities and competitions with adventure games and short interactive talk on SME.
2884006|NCT03361462|No Intervention|Waitlist control group|The intervention won't be provided during evaluation period and will be provided after the evaluation period
2884007|NCT03361449|Active Comparator|Group 1|training with kinesthetic ability trainer.
2884008|NCT03361449|Active Comparator|Group 2|Flamingo exercise
2884009|NCT03361449|Active Comparator|Group 3|training with kinesthetic ability trainer and Flamingo exercise
2884010|NCT03361436|Experimental|Treatment (eribulin mesylate, IMRT, surgery)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8 and undergo intensity-modulated radiation therapy QD 5 days a week beginning on day 8 of course 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo surgery within 3-10 weeks after radiation therapy.
2884011|NCT03361423|Active Comparator|treatment of migraine with active device|Treatment of acute migraine with an active form of Nerivio migra-1 device
2884012|NCT03361423|Sham Comparator|treatment of migraine with sham device|Treatment of acute migraine with a sham form of the Nerivio Migra-1 device
2884013|NCT03361410|Experimental|Grape Powder|
2884014|NCT03361410|Placebo Comparator|Placebo Powder|
2884015|NCT03361397|Active Comparator|Lidocaine nebulization|Inhalation of 10 mL nebulized lidocaine hydrochloride via mask nebulizer 5 min before laryngeal mask insertion.
2884016|NCT03361397|Placebo Comparator|Distilled water nebulization|Inhalation of 10 mL of nebulized distilled water solution via mask nebulizer 5 min before laryngeal mask insertion in the preoperative period.
2884017|NCT03361384|Experimental|Alcohol condition|The amount of alcohol received in the alcohol condition will be determined by an algorithm developed by Curtin (Curtin, 2000). Participants in the alcohol condition will receive a dose of alcohol (target BAC = .08%), administered in a chilled beverage of 80-proof vodka mixed with tonic water and lime juice in a 1:4 ratio.
2884018|NCT03361384|Placebo Comparator|Placebo condition|Placebo participants will receive tonic water and lime juice served to enhance alcohol cues in an amount comparable to the amount that they would have received if assigned to the alcohol condition.
2884019|NCT03361384|No Intervention|Control (water)|Participants in the water control condition will receive a glass of chilled water in volume of liquid comparable to the amount that they would have received if assigned to the alcohol or placebo condition.
2884020|NCT03361371|Experimental|Interventional group|All participants will receive standard of care treatment for bronchiolitis in the ED. Participants in this group will go home with standard discharge instructions and in addition they will receive a battery operated nasal aspirator and the caregiver will be instructed and trained to suction prior to each feed for one week at home.
2884021|NCT03361371|No Intervention|Control group|Participants in this group will receive the bronchiolitis standard of care treatment in the ED and will go home with standard discharge instructions.
2884022|NCT03361345|Experimental|Right Side of Face|Patients will apply topical tranexamic acid to the dark spots on the one side of their face.
2884023|NCT03361345|Sham Comparator|Left Side of Face|Patients will apply the vehicle cream without any medication to the dark spots on one side of their face.
2884024|NCT03361332||Healthy subjects|
2884025|NCT03361332||Patients with Gilles de la Tourette Syndrome|
2884026|NCT03361319|Experimental|Part 1: (Phase Ib) Dose Escalation|"A dose-finding study of nintedanib (Vargatef) with nab-paclitaxel (Abraxane) with a standard 3+3 design. In the dose escalation part there will be 3 dose cohorts of nintedanib:~Dose level -1: 100mg po BID d2-7, 9-21, q21 Dose level 1: 150mg po BID d2-7, 9-21, q21 Dose level 2: 200mg po BID d2-7, 9-21, q21"
2884027|NCT03361319|Experimental|Part 1: Dose Expansion|In the dose expansion part, 6 additional patients will be enrolled at the maximum tolerated dose (MTD) of nintedanib (Vargatef) with nab-paclitaxel (Abraxane), prior to proceeding to part 2.
2884925|NCT03354572|Active Comparator|NAC|receive 150 mg/kg acetylcysteïne in 200 ml saline (NaCl0,9%) prior to surgery
2884028|NCT03361319|Placebo Comparator|Part 2: (Phase II)|"A placebo-controlled, randomised, double-blind, 2-arm, phase 2 multi-centre clinical trial of nab-paclitaxel (Abraxane) with nintedanib (Vargatef) and nab-paclitaxel alone.~Arm A: nab-paclitaxel + placebo Arm B: nab-paclitaxel + nintedanib"
2884029|NCT03361306|Experimental|KRd-Elotuzumab|
2884030|NCT03361293|Active Comparator|Cognitive Training and Active tDCS|5 sessions of computerized cognitive training on tasks of attention, concentration, set-shifting, and memory - plus active tDCS (also 5 sessions).
2884031|NCT03361293|Sham Comparator|Cognitive Training and Sham tDCS|"5 sessions of computerized cognitive training on tasks of attention, concentration, set-shifting, and memory - plus sham tDCS (also 5 sessions) which consists of placebo stimulation with tDCS (ramp-up, but no actual stimulation)."
2884032|NCT03361280|Experimental|Atenolol|Atenolol (50 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
2884033|NCT03361280|Experimental|Bisoprolol|Bisoprolol (5 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
2884034|NCT03361280|Experimental|Metoprolol|Metoprolol (50 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
2884035|NCT03361280|Experimental|Carvedilol|Carvedilol (6.25 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
2884036|NCT03361267|Active Comparator|Bismuth containing quadruple therapy|If CLO test is positive, Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 5100 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) are prescribed for 7 days If CLO test is negative, no intervention is needed
2884037|NCT03361267|Experimental|tailored therapy|If H. pylori PCR is negative, no intervention is needed If H. pylori PCR is positive and mutation is negative, triple regimen (rabeprazole 20 mg bid, amoxacillin 1000 mg bid, clarithromycin 500mg bid) are prescribed for 7 days is given If H. pylori PCR is positive and mutation is positive, Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 5100 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) are prescribed for 7 days is given
2884038|NCT03361241|Experimental|No Physiotherapeutic Intervention|Virtual reality training without physiotherapeutic intervention
2884039|NCT03361241|Active Comparator|Physiotherapeutic Intervention|Virtual reality training with physiotherapeutic intervention
2884040|NCT03361228|Experimental|INCB001158 + Epacadostat + Pembrolizumab|
2884041|NCT03361228|Experimental|INCB001158 + Epacadostat|
2884042|NCT03361202||Atrial fibrillation group|blood sampling
2884043|NCT03361202||control group|blood sampling
2884044|NCT03361189|Experimental|CLS-On|Subjects in this arm will programmed to CLS-on to received closed loop stimulation-based pacing.
2884045|NCT03361189|No Intervention|CLS-Off|Subjects in this arm, will be placed in a standard pacing mode (i.e. AAIR or DDDR).
2884046|NCT03361176|Active Comparator|Control|Control Group (5 patients per site): Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline delivered in up to 50 injections per treatment session.
2884047|NCT03361176|Experimental|w/ Triamcinolone|Experimental Group (10 patients per site): Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate and 0.2 mL of 1% lidocaine with no epinephrine delivered in up to 50 injections per treatment session.
2884048|NCT03361163|Experimental|GAS oropharyngeal challenge|"Biological: emm75 Streptococcus pyogenes (GAS M75, strain 611024)~Direct oropharyngeal application using a sterile-tipped Dacron swab after immersion for 10 seconds in a 1mL vial containing 1-3x10^5 to 1-3x10^8 colony forming units (CFU) of the challenge strain (depending on dose group allocation)."
2884049|NCT03361150|Experimental|HIT|Preoperative nutrition, relaxation strategies + high intensity interval training (HIT). HIT alternates a series of high-intensity bouts with relief period. This will be a personalized, 3 times per week, 40-min exercise. Protein supplement will be prescribed if needed to achieve a daily intake of 1.5 g protein/kg.
2884050|NCT03361150|Active Comparator|MCT|Preoperative nutrition, relaxation strategies + high intensity interval training (MCT). MCT is continuous exercise with a constant intensity below anaerobic threshold. This will be a personalized, 3 times per week, 40-min exercise. Protein supplement will be prescribed if needed to achieve a daily intake of 1.5 g protein/kg.
2884051|NCT03361137|Experimental|Emicizumab|All eligible participants will receive emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continue to derive sufficient benefit. Participants must have received all loading doses prior to surgery and plan to continue emicizumab for a minimum of 1 month after surgery. Dosing should be adjusted if the participant has a significant change in body weight.
2884052|NCT03361124|Placebo Comparator|Control|Patient will receive standard post-partum Oxytocin (20 mU in 1 L LR) and 1 L LR over 8 hours following delivery.
2884053|NCT03361124|Experimental|Treatment|Patient will receive standard post-partum Oxytocin(20 mU in 1 L LR) an additional 20 mU Oxytocin in 1 L LR over 8 hours following delivery.
2884054|NCT03361098|Experimental|SGLT2 inhibitor + GLP-1 receptor agonist|dapagliflozin 10 mg tablet /day and exenatide twice daily subcutaneous injection (week 1-4; 5 microgram, week 5 -16; 10 microgram)
2884055|NCT03361098|Active Comparator|GLP-1 receptor agonist (exenatide) and placebo|GLP-1 receptor agonist exenatide twice daily in combination with placebo dapagliflozin
2884056|NCT03361098|Active Comparator|SGLT2 inhibitor (dapagliflozin) and placebo|SGLT2 inhibitor dapagliflozin 10 mg tablet /day in combination with placebo GLP-1 receptor agonist exenatide twice daily
2884057|NCT03361098|Placebo Comparator|double placebo|placebo dapagliflozin and placebo exenatide twice daily
2884058|NCT03361085|Experimental|Intervention|nvHAP-Prevention Bundle
2884059|NCT03361072|Experimental|Milk allergy|Milk oral immunotherapy intervention for milk allergy
2884060|NCT03361072|Experimental|Peanut allergy|Peanut oral immunotherapy intervention for peanut allergy
2884061|NCT03361072|Experimental|Egg allergy|Egg oral immunotherapy intervention for egg allergy
2884063|NCT03361033||Medulloblastoma|Participants who are survivors of pediatric medulloblastoma and who meet eligibility criteria will be approached for their consent to participate in this study. Observational data will be collected through the administration of standard psychological questionnaires. If the participant consents, their parents, teachers and best friends will also be asked to complete questionnaires. In addition, participants will complete an online daily diary assessment of their social interactions for seven days.
2884064|NCT03361033||Other Brain Tumors|Participants who are survivors of other pediatric brain tumors (excluding medulloblastoma and craniopharyngioma), who have not been treated with craniospinal irradiation (CSI), and who meet eligibility criteria will be approached for their consent to participate in this study. Observational data will be collected through the administration of standard psychological questionnaires. If the participant consents, their parents, teachers and best friends will also be asked to complete questionnaires. In addition, participants will complete an online daily diary assessment of their social interactions for seven days.
2884065|NCT03361020||Hodgkin Lymphoma|Participants will be survivors of Hodgkin Lymphoma (HL) who were treated with thoracic radiation during the course of their HL, who meet eligibility criteria, and who consent to this study.
2884066|NCT03361020||Control Group|The Comparison or control group members will be recruited from healthy parents, sibling, relative or friends who accompany the participant for follow-up at SJCRH and who meet eligibility criteria.
2884067|NCT03361007||Common carotid artery access for TAVI|Patients in whom femoral artery could not be used to deliver the bioprosthesis for any reason.
2884068|NCT03360994|Experimental|WATChmAN|Patients randomized to the WATChmAN Active Surveillance arm will receive their active surveillance testicular cancer care via an online virtual clinic. Importantly, patients will follow the same surveillance schedule as patients in the standard of care arm. However, patients in the WATChmAN arm will be able to see their upcoming tests and virtual appointments online, request requisitions to perform their required testing at outside institutions, and indicate any concerns for physicians to review during the virtual visit.
2884069|NCT03360994|Active Comparator|Standard of Care|Patients randomized to the standard of care arm (in-person active surveillance) will follow the current active surveillance protocol in place at Princess Margaret Cancer Centre's Multidisciplinary Testicular Cancer Clinic. This protocol involves the same schedule of testing as the WATChmAN arm, but will require patients to come into the clinic to receive their test results (as in current practice).
2884070|NCT03360981|Active Comparator|diabetics incretin-users (arm 1)|epicardial tissue biopsy, and than treated by incretin therapy plus standard anti ischemic therapy.
2884071|NCT03360981|Placebo Comparator|diabetics never-incretin-users (arm 2)|epicardial tissue biopsy, and than treated by standard hypoglycemic drug therapy plus standard anti ischemic therapy.
2884072|NCT03360981|No Intervention|non diabetics (arm 3)|non diabetics, treated by coronary artery bypass grafting (CABG), receiving epicardial tissue biopsy, and than treated by standard anti ischemic therapy.
2884073|NCT03360968|Experimental|Treatment A-B|Patient is treated with 1 hour SPN-CPAP/PS followed by 1 hour of Variable-PS ventilation mode
2884074|NCT03360968|Experimental|Treatment B-A|Patient is treated with 1 hour Variable-PS followed by 1 hour of SPN-CPAP/PS ventilation mode
2884075|NCT03360955||Total Intravenous Anesthesia|Patients with total intravenous anesthesia during the cardiac surgery
2884076|NCT03360955||Spinal Anesthesia|Patients with spinal anesthesia with minimal opioid dose.
2884077|NCT03360942||DBS Long Term Follow Up|5 participants who were in a prior study to receive DBS are enrolled to have their progress and DBS devices monitored for a period of 12 years.
2884078|NCT03360929|Experimental|experimental group|"Study drug: AZD3759 Strength: 50mg/tablet, 100mg/tablet Dose escalation:A treatment cycle consists of consecutive 21 days of dosing. Three dose cohorts are planned for dose escalation, including: 150, 200 and 250 mg twice daily.~RP2D in dose expansion."
2884079|NCT03360916|Placebo Comparator|Placebo & Exercise Group|Participants randomized to this group will undergo placebo treatment and an aerobic exercise program.
2884080|NCT03360916|Experimental|Low Statin & Exercise Group|Participants randomized to this group will undergo low statin treatment (Lipitor 20Mg Tablet) and an aerobic exercise program.
2884081|NCT03360916|Experimental|High Statin & Exercise Group|Participants randomized to this group will undergo high statin treatment (Lipitor 80Mg Tablet) and an aerobic exercise program.
2884082|NCT03360903|Placebo Comparator|Placebo|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
2884083|NCT03360903|Active Comparator|Caffeine|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
2884084|NCT03360890|Experimental|Cohort 1: salivary gland tumors without SOC treatment option|All patients will receive pembrolizumab and docetaxel. First pembrolizumab and docetaxel will be given together. After which patients will receive pembrolizumab alone until disease progression or up to 35 cycles (about 2 years).
2884085|NCT03360890|Experimental|Cohort 2: 'aggressive' thyroid cancer without SOC treatment op|All patients will receive pembrolizumab and docetaxel. First pembrolizumab and docetaxel will be given together. After which patients will receive pembrolizumab alone until disease progression or up to 35 cycles (about 2 years).
2884086|NCT03360877|Other|Health-care associated infection|
2884087|NCT03360864|Experimental|Therapeutic Education Program|"Patient randomized in this arm will attend a 1 day long validated Therapeutic Education Program.~This program will take place within 6 months after biologic treatment initiation."
2884088|NCT03360864|No Intervention|No therapeutic Education Program|Patient randomized in this arm will not attend a Therapeutic Education Program within 12 months after biologic treatment initiation.
2884136|NCT03360474|Experimental|Intervention|Patients will be placed on the delirium screening intervention protocol arm. They will be screened for delirium twice per day. If positive, they will follow the treatment algorithm and assessed at 4 hour intervals until they reach 4 negative screens. Once 4 negative screens have been reached, they will be assessed twice daily.
2884137|NCT03360461|Experimental|EMI-137|Ten participants to receive the IMP - EMI-137 1 to 3 hours before laparoscopic colonic resection surgery. Dose range 0.02mg/kg to 0.13mg/kg will be administered.
2884138|NCT03360448|Experimental|Experimental|Ad5.hAC6: Intracoronary delivery of adenovirus encoding human adenylyl cyclase type 6
2884089|NCT03360851|Experimental|Low-dose CT|A low-dose chest CT-scan will be performed either directly from the ER or from the medical ward as soon as possible but within 24 hours of admission. The CT will be performed with a radiation dose <0.5 mSv for a 70kg patient, as a replacement or in addition to the chest radiograph. Pregnancy will be an exclusion criterion for CT because of unwanted radiation exposure. CT interpretation will be performed by a radiologist. Test results will be communicated to the treating physician. Recommendations based on the CT may be to discontinue antibiotics in case of a noninfectious diagnosis that explains the presented signs and symptoms and to start treatment for the alternative diagnosis if needed, or to re-evaluate the CAP diagnosis if no signs of lobar or bronchopneumonia are detected on the CT.
2884090|NCT03360851|Experimental|PoC-PCR|The FilmArray real-time multiplex PCR (Biofire; bioMérieux) is a Point-of-Care PCR with a panel of respiratory viruses (adenovirus, coronavirus, human metapneumovirus, human rhinovirus/enterovirus, influenza A and B, parainfluenza virus, and respiratory syncytial virus), and three atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Bordetella pertussis), which will be performed on nasopharyngeal swab samples. Test results will be made available to the treating physician immediately. The treatment recommendation could be adaptation of antibiotic treatment for a documented atypical pathogen, a recommendation to not start or discontinue antibiotics when a virus is the only detected pathogen, or a recommendation to discontinue coverage of atypical pathogens.
2884091|NCT03360851|No Intervention|Standard care|All hospitals will continue the antibiotic stewardship activities employed during the baseline period as part of standard care. A representative of the Antibiotics-team (Team consisting of clinical microbiologists, infectious diseases specialist and clinical pharmacists supervising in-hospital antibiotic use) will monitor the empirical antibiotic treatment of patients hospitalized with CAP to non-ICU wards and provide feedback if indicated.
2884092|NCT03360838||CogCheck application|Performance in the application
2884093|NCT03360812|Experimental|Intervention group|The intervention is an online training resource to improve the recognition of imminent death in palliative care patients. The intervention should take approximately 15 minutes to complete. During this time, the participants who are in the intervention arm will be shown the results of a previous study which identified how expert palliative care doctors recognise imminently dying palliative care patients. The intervention will be implemented via the website, immediately after participants have completed the first set of vignettes.
2884094|NCT03360812|No Intervention|Control group|The participants assigned to the control group will not receive this additional information and will simply be informed that they are approximately half way through the task and will be asked to continue on to the next set of vignettes.
2884095|NCT03360799||Medical Marijuana Questionnaire|Participants (inpatient or outpatient) seen by the Palliative Care team at Banner MD Anderson or UT MD Anderson.
2884096|NCT03360786|Experimental|Specific Protocol|The intervention group will work with the study physiotherapist and perform a 10-20 minute progressive exercises twice per week. The intervention will include a series of exercises including dynamic balance, adaptation, cervical spine strength, cervical spine neuromotor control and divided attention exercises. Exercises will begin at a lower level and progress to increasingly difficult levels of each exercise type over the course of the intervention. Concussion education and injury identification will also be completed.
2884097|NCT03360786|Active Comparator|Control Protocol|The control group will continue with their standard warm up and practice schedule but have the addition of contact time with the study physiotherapist for education regarding concussion education and injury identification.
2884098|NCT03360760|Experimental|Pre surgical Chemotherapy|Immediate pre surgical chemotherapy treated with four drugs including doxorubicin, cisplatin, high-dose methotrexate (MTX) and ifosfamide in eleven weeks, and then definitive surgery followed by adjuvant chemotherapy according to chemotherapy regimen in Peking University People's Hospital(PKUPH).
2884099|NCT03360760|Other|Immediate Surgery|Immediate definitive surgery, and then post operative chemotherapy based on doxorubicin, cisplatin, high-dose MTX and ifosfamide according to chemotherapy regimen in PKUPH.
2884100|NCT03360747|Experimental|AKCEA-ANGPTL3-LRX Dose 1|
2884101|NCT03360734|Experimental|Combination|Combination of Gatipotuzumab and Tomuzotuximab
2884102|NCT03360721|Experimental|Abiraterone Acetate + Apalutamide|Abiraterone acetate 1,000 mg (4 x 250 mg tablets each) orally, Apalutamide 240 mg (4 x 60 mg tablets) orally and Prednisone 5 mg orally, all daily for four week course.
2884103|NCT03360708|Experimental|Treatment (cytokine-induced killer cells and vaccine therapy)|Patients receive cytokine-induced killer cells IV over 1 hour on day 13 of course 1. Patients also receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 1, 3, and 5 of courses 2 and 3, and on day 1 of subsequent courses. Treatment with malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine repeats every 21 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
2884104|NCT03360695|Experimental|Proactive Psychiatry Consultation (PPC)|"Proactive Psychiatry Consultation and Case Management is:~Patient-centered: Based on the patient's needs, the team aims to build a relationship, increase engagement, and promote continuity.~Team-based: A psychiatrist and case manager identify goals for cancer treatment, assess psychiatric history and symptoms with a focus on impact on cancer care, collaborate with community-based clinicians and caregivers, and address barriers to care.~Integrated into cancer care delivery: The psychiatry and oncology teams collaborate starting at cancer diagnosis to support patient through cancer treatment.~Systematic: The team monitors psychiatric and cancer-related symptoms and cancer care delivery to measure progress toward goals and rapidly adjust treatment as needed."
2884105|NCT03360682|Experimental|HIV-1-infected solid organ transplant patients 1|"The patient or donor is not a carrier of genetic characteristics that predispose to a severe allergy to Abacavir or the patient is not a carrier of the hepatitis B virus.~treatment 48 weeks"
2884106|NCT03360682|Experimental|HIV-1-infected solid organ transplant patients 2|"The patient or donor is a carrier of genetic characteristics that predispose to a severe allergy to Abacavir or the patient is a carrier of the hepatitis B virus.~treatment 48 weeks"
2884139|NCT03360448|Placebo Comparator|Placebo Comparator|Placebo: Intracoronary delivery of formulation buffer ( 3% sucrose)
2884140|NCT03360435||Participants with transdermal patches|All study subjects will belong to the same group. This group will undergo bariatric surgery and will use a transdermal patch for vitamin and mineral supplementation post operatively. The transdermal patch will be the Patch MD MultiVitamin Plus patch
2884107|NCT03360669|Experimental|Sequence: Clinical/Research|Participants assigned to this arm will have their blood pressure measured in a clinical setting first, and in a research setting second. The sequence randomization corresponds to the intervention. Visits will be at least a day apart but within a two-week period. During the clinical visit, they will have their blood pressure measured with the Omron HEM-907, an automated office blood pressure (AOBP) device. During the research setting, participants will be guided through a series of research-driven steps such as study questionnaires and completion of consent forms. They will have their blood pressure measured in both arms with a mercury sphygmomanometer, and then 3 measurements with a mercury sphygmomanometer. AOBP measurements (Omron HEM-907) will be performed at the end of the visit.
2884108|NCT03360669|Active Comparator|Sequence: Research/Clinical|Participants assigned to this arm will go through the same measurements and procedures exception made of the research-first and clinical-second sequence. The intervention to which they are randomized corresponds to the sequence of the visits.
2884109|NCT03360656|Experimental|Transnasal Thermal Regulating Device|Consented subjects will undergo cooling via transnasal thermal regulating device for a period of 8 to 24 hours
2884110|NCT03360643|Active Comparator|Point-of-care ultrasound prior to radiology ultrasound|
2884111|NCT03360643|Active Comparator|Radiology-performed ultrasound|
2884112|NCT03360630|Experimental|Anti-PD-1 plus DC-CIK|
2884113|NCT03360630|Active Comparator|Anti-PD-1 alone|
2884114|NCT03360617|Experimental|Syringe Arm|IV antibiotics will be delivered by syringe IV push over 2-3 minutes
2884115|NCT03360617|Sham Comparator|Piggyback Arm|IV antibiotics will be delivered by IV piggyback over 30 minutes
2884116|NCT03360604|Experimental|Low GI diet|This diet consists of three meals (breakfast, lunch, snack) which all have a low glycaemic index. This is the Low Glycaemic Diet intervention.
2884117|NCT03360604|Experimental|High GI diet|This diet consists of three meals (breakfast, lunch, snack) which all have a high glycaemic index. This is the High Glycaemic Diet intervention.
2884118|NCT03360591|Experimental|Physiologically-guided strategy|"Patients randomized in this group will undergo stenting of coronary lesions showing FFR values ≤0.80 only.~Lesions showing positive FFR measurements (<0.80) must be treated with PCI, before or after TAVI.~Lesions showing clearly negative values (FFR >0.80) will not be treated with PCI before TAVI, and repeated FFR and iFR measurements after TAVI are strongly recommended.~Lesions showing borderline FFR measurements before TAVI (FFR 0.80-0.83), should be measured again (both FFR and iFR) after TAVI, and the decision of treating of deferring treatment in a given lesion will be based on the FFR value obtained after TAVI.~In all cases iFR values will be recorded for a post hoc analysis and for validation of the study endpoints according to iFR values."
2884119|NCT03360591|Other|Angiographically-guided strategy|Patients allocated in this group will undergo stenting of all coronary stenosis ≥50% as assessed by visual estimation in vessels ≥2.5mm. PCI can be performed before in a previous procedure, or after TAVI, but always within one month, ± 5 days of the valve implantation.PCI in the group randomized to the angio-guided procedure can be performed therefore, either before or after valve implantation, in the same or in different procedures. Implantation of second-generation drug eluting stents (DES) in all interventions is advised, but not mandatory, and the brand of the stent is left to the operators and center's choice.
2884120|NCT03360552|Experimental|the multidimensional score of fragility (RAI CA)|A general practitioner (MG) management strategy guided by a multidimensional evaluation (RAI-CA) on the multidimensional score of fragility (RAI-HC) of patients with mild to moderately severe dementia.
2884121|NCT03360552|Placebo Comparator|Usual care|support for patients without multidimensional evaluation (RAI-CA)
2884122|NCT03360539|Experimental|Treatment-NFP|NFP is a prenatal and infancy home visiting program for low-income, first-time mothers and their families. Registered nurses begin visiting their clients as early in the pregnancy as possible, helping the mother-to-be make informed choices. The nurses continue visiting regularly until the child is two years old.
2884123|NCT03360539|No Intervention|Control|Control group members have access to the standard of care and whatever other programs and services are available in the community.
2884124|NCT03360526|Active Comparator|PICSI|Physiological ICSI
2884125|NCT03360526|Experimental|TESA|Testicular sperm aspiration
2884126|NCT03360513||general group|Comprised 70 caucasian Brazilian individuals with normal occlusion and at least four of Andrew's six keys.
2884127|NCT03360500|Experimental|EXERCISE PROTOCOL + CRYOTHERAPY|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
2884128|NCT03360500|Experimental|EXERCISE PROTOCOL|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
2884129|NCT03360500|Placebo Comparator|EXERCISE PROTOCOL + PLACEBO|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
2884130|NCT03360487|Sham Comparator|Sham photobiomodulation in the sublingual region|A disposable plastic wrap will cover the application pen for the purposes of hygiene, and the laser will be placed for 10 minutes, without being turned on.
2884131|NCT03360487|Active Comparator|Photobiomodulation in the sublingual region|A disposable plastic wrap will cover the application pen for the purposes of hygiene, and the region will be irradiated for 10 minutes.
2884132|NCT03360487|Sham Comparator|Sham photobiomodulation along the spinal cord|Transcutaneous irradiation of the spinal cord will be pretended on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be wakely irradiated for 30 seconds (total treatment time: 10 minutes).
2884133|NCT03360487|Active Comparator|Photobiomodulation along the spinal cord|Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).
2884134|NCT03360487|Sham Comparator|Sham Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific turned-off bracelet of the DMC laser Therapy EC model.
2884135|NCT03360487|Active Comparator|Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.
2884141|NCT03360422|Active Comparator|Survey group|Collect alcohol and sexual activity data via web survey from 683 young MSM to yield normative data for the alcohol and HIV preventive intervention in a follow-up study
2884142|NCT03360422|Active Comparator|Focus Group|30 young MSM who drink regularly to inform the content of the alcohol and HIV preventive intervention tested in the UH3 phase and ensure the intervention is culturally appropriate for MSM.
2884143|NCT03360422|Active Comparator|Usability Study|10 young adult MSM will test the mobile intervention in development for 30 days in order to establish usability, acceptability and correct any functionality issues.
2884144|NCT03360409|Experimental|grade 1|ACD
2884145|NCT03360409|Active Comparator|grade 2|ACDF
2884146|NCT03360409|Active Comparator|grade 3|ACDA
2884147|NCT03360396|Experimental|Endobronchial Coils|
2884148|NCT03360396|No Intervention|Control|
2884149|NCT03360383|Experimental|grade 1|percutaneous vertebroplasty
2884150|NCT03360383|Active Comparator|grade 2|conservative treatment
2884151|NCT03360370||6 to 66 months children with significant CHD|"Children with significant congenital heart disease (CHD) aged from 6 to 66 months at the time of the study and fulfilling inclusion criteria for whom an age-appropriate questionnaire completed by parents (Ages & Stages Questionnaires, Third Edition in French (ASQ-3™) will be used to screen developmental delays."
2884152|NCT03360357|Experimental|guided drills|These people will be going through all the guided drills before being evaluated.
2884153|NCT03360357|No Intervention|Self-trained|These people will watch a video and be able to practice by themselves without having any direction regarding how and what to practice.
2884154|NCT03360344|Experimental|Kinesio Tape|"Dorsal application of Kinesio Tape to the affected extremity: Approximately 12 inches of Kinesio tape will be applied from the musculotendinous junction of the participant's forearm over digits 1 and 5. Two - 2 inch strips of Kinesio Tape will be applied to the participant's wrists over the volar and dorsal aspects. The Kinesio Tape will remain in place for three days, with the participants returning for skin check by the researchers and re-application by the researchers four times during the course of the study.~A tape removal form will be provided should the participants want to remove it prior to the next visit."
2884155|NCT03360344|Sham Comparator|Control group|Approximately 4 inch strip of Kinesio Tape will be applied to the scapular spine of the same side as the affected extremity. The Kinesio Tape will remain in place for three days, with the participants returning for skin check by the researchers and re-application four times during the course of the study by the researcher. A tape removal form will be provided should the participants want to remove it prior to the next visit.
2884156|NCT03360344|Active Comparator|Standard of Care|Currently, the standard of care is a general cock-up splint and lumbrical exercises. A general cock-up splint will be supplied, fitted, and checked on each of the four return visits by the researchers. Lumbrical exercises are also used and consist of active joint ranges for the wrist and hand. The exercises will be demonstrated by the researchers for 3-sets of 10 times each, daily, to be recorded in a log by the participants.
2884157|NCT03360318|Active Comparator|Elbow cast|Device: Elbow cast
2884158|NCT03360318|Experimental|Removable elbow brace|Device: Removable elbow brace
2884159|NCT03360305|No Intervention|Usual care|The ED clinician will perform a standard medical evaluation. This evaluation includes a focused history and exam to identify injuries. Laboratory tests and radiologic imaging may be ordered. If necessary, the patient will receive consultation with specialty services (e.g., orthopedics). The research assistant (RA) will read the CDC STEADI brochure to the patient and provide them with a printed copy at the conclusion of their visit. The RA will solicit feedback from the clinician and the patient at the conclusion of the visit using the post-visit survey.
2884160|NCT03360305|Experimental|Intervention|"ED clinician will perform standard medical evaluation, including focused history and exam to identify injuries. RA will solicit feedback from clinician and patient via post-visit survey at conclusion of visit.~PT will perform services, including integrative mobility training and lower extremity strength training and recommending outpatient services/referrals. Specific assessments and treatments will be tailored to patient.~Pharmacist will perform a medication review using the updated BEERS criteria and CDC's STEADI instrument and recommend changes to potential fall risk increasing medication. Recommendations will be communicated to ED treatment team.~Seniors will return home with standardized checklist containing details of their assessment and action plan. The checklist addresses patient's personal risk factors for the fall and required further actions."
2884161|NCT03360292|Experimental|Higher target range|Infants will be targeted to 92-97% oxygen saturation
2884162|NCT03360292|No Intervention|Standard target range|Infants will be targeted to 90-95% oxygen saturation, which is the range used as routine in the Neonatal Unit involved in the study
2884163|NCT03360279|Active Comparator|Regular balloon|Use the regular balloon to perform standard balloon angioplasty.
2884164|NCT03360279|Active Comparator|DCB (paclitaxel-coated balloon)|Use DCB (paclitaxel-coated balloon) to perform additional balloon angioplasty.
2884165|NCT03360266|Active Comparator|Profluorid group|5% Sodium Fluoride varnish (Profluorid varnish) applied over white spot lesions on maxillary anterior teeth
2884166|NCT03360266|Experimental|Enamel Pro|Sodium Fluoride with ACP varnish (Enamel Pro varnish) applied over white spot lesions on maxillary anterior teeth
2884167|NCT03360266|Experimental|MI varnish|Sodium Fluoride with CPP-ACP varnish (MI varnish) applied over white spot lesions on maxillary anterior teeth
2884168|NCT03360253|Experimental|HMilkProb|L. reuteri DSM 17938 in drops will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together to give the product the correct rheological properties
2884169|NCT03360253|Placebo Comparator|HMilkPlacebo|The placebo consists of an identical formulation except that the L. reuteri is not present
2884170|NCT03360253|Experimental|IFormProb|L. reuteri DSM 17938 in drops will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together to give the product the correct rheological properties
2884171|NCT03360253|Placebo Comparator|IFormPlacebo|The placebo consists of an identical formulation except that the L. reuteri is not present
2884231|NCT03359694|Experimental|DT group|Pegylated liposomal doxorubicin and Docetaxel Treatment group Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
2884172|NCT03360240||Cases|Cases: patients with pregnancy that starts before the age of 19 that develops preeclampsia (mild), severe preeclampsia, gestational hypertension and eclampsia, that is 24 and more weeks pregnant with prenatal control started before 20 weeks of pregnancy.
2884173|NCT03360240||controls|Are patients with pregnancy that starts before the age of 19 that without develops (preeclampsia mild), severe preeclampsia, gestational hypertension or eclampsia) that is 24 and more weeks pregnant with prenatal control started before 20 weeks of pregnancy.
2884174|NCT03360214|Other|Active PEMF + Treatment PIB|Participants will receive an active device (Pulsed Electromagnetic Field (PEMF) Device) and active drug (Bupivacaine Hydrochloride).
2884175|NCT03360214|Other|Active PEMF + Sham PIB|Participants will receive an active device (Pulsed Electromagnetic Field (PEMF) Device) and placebo drug.
2884176|NCT03360214|Other|Sham PEMF + Treatment PIB|Participants will receive a placebo device and active drug (Bupivacaine Hydrochloride).
2884177|NCT03360214|Other|Sham PEMF + Sham PIB|Participants will receive placebo drug and placebo device.
2884178|NCT03360201|Experimental|Intervention: Tuko Pamoja|The intervention, Tuko Pamoja, is delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. The content and structure has been adapted in both content and implementation model based on formative research in this context. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection.
2884179|NCT03360175||Thoracic Surgery Patients|"Inclusion criteria include: Patients scheduled to undergo thoracic surgery at Brigham and Women's Hospital, between the ages 18-85 years old. Exclusion criteria are: pre-existing chronic pain or opioid use; current treatment with corticosteroids; evidence of active infection; chronic liver disease; end-stage renal disease (CKD-5); chronic inflammatory disorders; recent major surgery or illness within 30 days; use of immunosuppressive medication; history of organ transplantation.~Pro-inflammatory eicosanoid and pro resolving lipid mediator temporal profiles will be determined pre-operatively, on post-operative day 1 and on post-operative day 14. In addition, daily pain scores will be recorded for 60 days after surgery and at 3, 6 and 12 months."
2884180|NCT03360136|Other|Multi-professional CBT-rehabilitation|24 weeks CBT-based multi-professional rehabilitation.
2884181|NCT03360123|Active Comparator|Midazolam Hydrochloride 2Mg/mL Syrup|"The participants in this arm will receive midazolam+nitrous oxide at the 1st dental appointment.~Dosage: Midazolam: Midazolam HCl Syrup 0.5mg/kg (Max: 15mg) taken 10-15 minutes prior to dental treatment."
2884182|NCT03360123|Active Comparator|Triazolam 0.125 MG|The participants in this arm will receive triazolam+nitrous oxide at the 1st dental appointment. Dosage: Triazolam: 0.125mg tablet taken 30 minutes prior to dental treatment.
2884183|NCT03360097|No Intervention|Fresh ET|The best available embryo is at expansion grade <4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and transferred regardless of expansion grade. Arrested blastocysts are discarded.
2884184|NCT03360097|Experimental|Frozen Embryo Transfer|The best available embryo is at expansion grade <4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and vitrified regardless of expansion grade. Arrested blastocysts are discarded. The single best available embryo is transferred under a cryo-synthetic cycle.
2884185|NCT03360071|Experimental|Allergen Immunotherapy Group|
2884186|NCT03360071|Placebo Comparator|Control Group|
2884187|NCT03360058|Experimental|Immediate access to STBD training|Immediate access to training materials and print pieces to support implementation
2884188|NCT03360058|Placebo Comparator|Delayed access to STBD training|Delayed access to training materials and print pieces
2884189|NCT03360045|Active Comparator|Tranexamic acid group|500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
2884190|NCT03360045|Placebo Comparator|Placebo group|5ml normal saline is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
2884191|NCT03360045|Active Comparator|Merocel Group|Merocel packing is applied.
2884192|NCT03360032||All participants|All patients will be asked to undertake an incremental shuttle walk test and a cardiopulmonary exercise test and the results will be compared.
2884193|NCT03360019|Active Comparator|Residents in memory care or skilled nursing Facility|
2884194|NCT03360019|Active Comparator|Resident in independent living setting|
2884195|NCT03360019|Other|Care Partners|
2884196|NCT03360006|Experimental|ABBV-744|ABBV-744 will be administered at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
2884197|NCT03359993||Preterm infants intubated|All participants were preterm infants intubated in the delivery room for Infantile Respiratory Distress Syndrome (IRDS). The purpose of this research is to determine a premedication of intubation. This consists of describing a simple and effective method for premedication in the delivery room, using the umbilical vein, directly perforated through the Wharton jelly.
2884198|NCT03359980|Experimental|treated patients|Treated with Fecal Microbiota Transfer (FMT)
2884199|NCT03359954|Experimental|Preoperative Boost Radiotherapy (RT)|"Participants receive preoperative boost RT after completion of neoadjuvant systemic therapy. Participants then undergo definitive oncologic breast surgery followed by standard of practice breast or chest wall RT.~Preoperative boost RT scheduled to occur 6-8 days prior to the date of the participant's definitive breast surgery. Radiation boost delivered to a dose of 7.5Gy in 1 fraction using conformal treatment."
2884200|NCT03359941|Experimental|Integrative Treatments|This study's arm is single, so all participants will receive acupuncture treatments.
2884201|NCT03359928|Experimental|Boxing|"In each of the three sessions a different exercise modality will be conducted, in a randomised sequence. Non-contact boxing involves boxing punch pads that will be held by the one of the researchers, while wearing protective boxing gloves. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest). During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed."
2884202|NCT03359928|Experimental|Stair stepping|Participants will complete 3 sessions of exercise. In each of the three sessions a different exercise modality will be conducted in a randomised sequence. Stair stepping involves stepping on to and off a 35 cm Reebok exercise bench, repeatedly. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest). During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed.
2884203|NCT03359928|Experimental|Stair climbing|"In each of the three sessions a different exercise modality will be conducted, in a randomised sequence. Stair climbing involves continuously ascending the stairs located in a public access staircase. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest).~During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed."
2884204|NCT03359915|Experimental|Intervention Group|Patient education in use of a COPD self-management action plan supported by monthly visits from, and access to, a CHW who has been trained in the use of a COPD self-management action plan.
2884205|NCT03359915|No Intervention|Control Group|COPD 'standard' care in local setting - Bhaktapur, Nepal; Lima, Peru; Nakaseke, Uganda
2884206|NCT03359902|Experimental|Initial tVNS|This group will receive transcutaneous vagal nerve stimulation, initially. Participants will be randomized between the two arms of the crossover sessions (initial tVNS vs. initial Sham). Behavioral portions of the testing will then be carried out twice, with at least 72 hours between sessions (to avoid carryover effects).
2884207|NCT03359902|Experimental|Initial Sham|This group will receive sham stimulation, initially. Participants will be randomized between the two arms of the crossover sessions (initial tVNS vs. initial Sham). Behavioral portions of the testing will then be carried out twice, with at least 72 hours between sessions (to avoid carryover effects).
2884208|NCT03359889||patients administered with PraxbindTM|
2884209|NCT03359876||Rivaroxaban|NVAF patients with renal dysfunction newly initiated on rivaroxaban 15 mg for stroke prevention
2884210|NCT03359876||Warfarin|NVAF patients with renal dysfunction newly initiated on vitamin K antagonist (warfarin) for stroke prevention
2884211|NCT03359863|Experimental|Treatment Arm|Subjects will receive Pirfenidone as part of treatment for their restrictive chronic lung allograft dysfunction (RCLAD).
2884212|NCT03359850|Experimental|Normal hepatic function (Group 1):|To evaluate the pharmocokinetics and safety of niraparib
2884213|NCT03359850|Experimental|Moderate hepatic impairment (Group 2):|To evaluate the pharmocokinetics and safety of niraparib
2884214|NCT03359837|Experimental|Glargine based therapy|Once daily glargine plus prandial oral anti-hyperglycemic drugs
2884215|NCT03359837|Active Comparator|Premixed insulin|Twice daily premixed insulin
2884216|NCT03359824|Other|Exercise|Arm: Exercise: Combination of moderate intensity continuous training, high intensity interval training and endurance training 5 times per week for a total of 6 weeks. Out of 5 sessions three were supervised by trainer and two sessions were performed by subjects on their own.The duration of the exercise was increased progressively. The first two weeks was 30 minutes that increased to 45 minutes in the third and fourth week. It was 60 minutes for the last two weeks.
2884217|NCT03359811|Experimental|Standard-of-Care Thoracic Epidural Analgesia (TEA)|An epidural catheter placed before induction of anesthesia by an anesthesiologist. A bolus or infusion of the local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
2884218|NCT03359811|Active Comparator|4Q-TAP Blocks|Participants have an ultrasound guided 4Q-TAP block. A maximum of 80 cc of a solution consisting of 30 mg of bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) and 65 mg of liposomal bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
2884219|NCT03359798|Experimental|Narcotic counseling script|Study participants will be read a script regarding post-cesarean section narcotic use.
2884220|NCT03359798|Sham Comparator|Post-partum depression counseling script|Study participants will be read a script of the same length, and much of the same wording as the experimental script. However, this script's content is focused on post-partum depression.
2884221|NCT03359785|Experimental|TAK-831 500 mg + TAK-831 50 mg|TAK-831 500 milligrams (mg) or matching Placebo tablets, orally, once daily for 8 days in period 1, followed by 14-21 day washout period, followed by TAK-831 50 mg or matching Placebo tablets, orally, once daily for up to 8 days in period 2.
2884222|NCT03359785|Experimental|TAK-831 50 mg + TAK-831 500 mg|TAK-831 50 mg or matching Placebo tablets, orally, once daily for 8 days in period 1, followed by 14-21 day washout period, followed by TAK-831 500 mg or matching Placebo tablets, orally, once daily for up to 8 days in period 2.
2884223|NCT03359772|No Intervention|Group 1|Exercise Only Group
2884224|NCT03359772|Active Comparator|Group 2|Kinesthetic Ability Trainer Group
2884225|NCT03359746|Experimental|Treatment Group|This is a prospective, interventional, case-control study at King Faisal Specialist Hospital & Research Centre in post-renal transplant patients who are receiving Grazoprevir/Elbasvir combination. Data will be compared with matched historical controls, which will be selected according to the following matching criteria: age, time from transplant to initiation of therapy. Only patients who completed at least 48 weeks of pegylated Interferon + Ribavirin therapy in the control group and 12 weeks of therapy on the case group will be enrolled. Any patient who received at least one dose of Grazoprevir/Elbasvir combination will be included in the safety analysis.
2884226|NCT03359733|Experimental|TAK-659 100 mg Fasted + TAK-659 100 mg Fed|TAK-659 100 milligram (mg), tablet, orally under fasted state, once on Day 1, followed by TAK-659 100 mg, tablet, orally under fed state, once on Day 8 of a 15-day food effect treatment period.
2884227|NCT03359733|Experimental|TAK-659 100 mg Fed + TAK-659 100 mg Fasted|TAK-659 100 mg, tablet, orally under fed state, once on Day 1, followed by TAK-659 100 mg, tablet, orally under fasted state, once on Day 8 of a 15-day food effect treatment period.
2884228|NCT03359720||guyane|
2884229|NCT03359720||martinique|
2884230|NCT03359720||guadeloupe|
2884232|NCT03359694|Active Comparator|ET group|Conventional doxorubicin and Docetaxel Treatment group Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
2884233|NCT03359694|Experimental|NX group|Navelbine and Xeloda treatment group in group of Non-pCR patients Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d×4
2884234|NCT03359694|No Intervention|Control group|"no treatment group of Non-pCR patients after DT or ET neoadjuvant chemotherapy.~No drugs treatment in this group."
2884235|NCT03359681|Active Comparator|metformin hydrochloride|metformin, encapsulated tablet, 500mg 3 times a day for 30 days.
2884236|NCT03359681|Placebo Comparator|placebo oral capsule|placebo, encapsulated tablet, 500mg 3 times a day for 30 days.
2884237|NCT03359668|Experimental|Non-contrast-enhanced CT|Comparison of non-contrast CT to the standard-of-care contrast-enhanced CT of the head and neck in detection of suspicious lymph nodes
2884238|NCT03359668|Active Comparator|Contrast-enhanced CT|Comparison of non-contrast CT to the standard-of-care contrast-enhanced CT of the head and neck in detection of suspicious lymph nodes
2884239|NCT03359655|Active Comparator|Rectal misoprostol|200 mcg of misoprostol will be administered rectally- 2 hours previously. This intervention will be performed by a third party health professional who will be blinded to the procedure.
2884240|NCT03359655|Active Comparator|Rectal hyoscine butyl bromide|10 mg hyoscine butyl bromide administered rectally- 2 hours previously. This intervention will be performed by a third party health professional who will be blinded to the procedure.
2884241|NCT03359655|No Intervention|Sham administration|A rectal examination will be performed by a third party health professional who will be blinded to the procedure. No drug will be administered
2884242|NCT03359642|Experimental|Patients with anti-TNF alpha|12 spondyloarthritis and 24 inflammatory bowel diseases patients (12 Crohn's disease and 12 ulcerative colitis), in which a first anti-TNF alpha treatment is indicated.
2884243|NCT03359642|Active Comparator|mirror group|"A mirror group of 12 spondyloarthritis and 24 inflammatory bowel diseases patients (12 Crohn's disease and 12 ulcerative colitis), in which an all but anti-TNF alpha or biotherapy treatment is indicated will be included to distinguish the specific effects on microbiota of anti-TNF alpha."
2884244|NCT03359616|Experimental|transanal total mesorectal excision|Transanally, the rectum is mobilized through the mesorectal plane according to the TME principles, assisted by the transanal surgical platform (Transanally curable surgical resection).
2884245|NCT03359616|Active Comparator|laparoscopic total mesorectal excision|By standard laparoscopic techniques, the rectal cancer will be resected by the conventional laparoscopic TME (LaTME).
2884246|NCT03359603|Experimental|Group A|After recruiting, patients are assigned to the group by randomization,and then receive electro-acupuncture treatment. Patients in the group will receive EA 3 sessions per week for 8 weeks. The EA stimulation lasted for 30 minutes with a dilatational wave of 2/100 Hz and a current intensity depending on the patient's comfort level (preferably with skin around the acupoints shivering mildly without pain).
2884247|NCT03359603|Experimental|Group B|After recruiting, patients are assigned to the group by randomization,and then receive electro-acupuncture treatment. Patients in the group will receive EA once per week for 8 weeks. The EA stimulation lasted for 30 minutes with a dilatational wave of 2/100 Hz and a current intensity depending on the patient's comfort level (preferably with skin around the acupoints shivering mildly without pain).
2884248|NCT03359590|Experimental|Sitagliptin arm|Drug: Sitagliptin
2884249|NCT03359590|Experimental|Placebo arm|Placebo comparator
2884250|NCT03359577|Experimental|Psorax35|Food supplement Psorax35 capsules containing fish roe extract high in eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) phospholipid. Dose: 10 capsules of 590 mg. Route of administration: oral.
2884251|NCT03359577|Placebo Comparator|MCT oil|Placebo capsules containing coconut oil high in caprylic acid C8:0 and capric acid C10:0 (Medium Chain triglycerides (MCT) oil). Dose: 10 capsules of 590 mg: Route of administration: oral.
2884252|NCT03359564||micro endoscopic discectomy|the patients with lumbar disc herniation
2884253|NCT03359538|Placebo Comparator|placebo|Patients assigned to this arm will take Riluzole as usual + placebo tablets
2884254|NCT03359538|Active Comparator|Rapamycin 1 mg/m2|Patients assigned to this arm will take Riluzole as usual + tablets corresponding to a Rapamycin dose of 1 mg/m2/day
2884255|NCT03359538|Active Comparator|Rapamycin 2 mg/m2|Patients assigned to this arm will take Riluzole as usual + tablets corresponding to a Rapamycin dose of 2 mg/m2/day
2884256|NCT03359525|Experimental|Group A|Group A: Intravenous Tranexamic acid at a dose of 1 gram administered 30 min prior to skin incision and 1 gram 3 hours after the procedure. (Total dose administered is 2 grams)
2884257|NCT03359525|Experimental|Group B|Group B: Topical Tranexamic acid at a dose of 1 gram injected in to the periarticular tissues prior to closure and 1 gram injected into the joint through the drain following wound closure. (Total dose administered is 2 grams)
2884258|NCT03359525|Experimental|Group C|Group C: Combined Intravenous 1 gram given intravenous 30 min prior to skin incision and topical tranexamic acid (1 gram) injected in to the periarticular tissues prior to closure. (Total dose administered is 2 grams)
2884259|NCT03359512|Experimental|qCON monitor|Simultaneous measurement of BIS and qCON
2884260|NCT03359499|Experimental|Bacillus clausii|Bacillus clausii administered orally for two weeks plus standard dietary advice for non-constipated irritable bowel syndrome
2884261|NCT03359499|Other|Antispasmodic|Trimebutine administered orally for two weeks plus standard dietary advice for non-constipated irritable bowel syndrome
2884262|NCT03359486|Experimental|Group problem management plus|Five sessions of group low intensity psychological intervention
2884263|NCT03359486|Active Comparator|Enhanced treatment as usual|Referral to primary health care workers trained in mental health Gap Action Programme.
2884264|NCT03359473|Experimental|Male subjects receiving GSK2881078-Cohort 1|Male subjects between the age of 50 and 75 years will be administered GSK2881078 at a dose of 2 mg once daily by the oral route.
2884265|NCT03359473|Placebo Comparator|Male subjects receiving Placebo-Cohort 1|Male subjects between the age of 50 and 75 years will be administered GSK2881078 matching placebo once daily by the oral route.
2884266|NCT03359473|Experimental|Female subjects receiving GSK2881078-Cohort 2|Post-menopausal female subjects between the age of 50 and 75 years will be administered GSK2881078 at a dose of 1 mg once daily by the oral route.
2884267|NCT03359473|Placebo Comparator|Female subjects receiving Placebo-Cohort 2|Post-menopausal female subjects between the age of 50 and 75 years will be administered GSK2881078 matching placebo once daily by the oral route.
2884268|NCT03359460|Experimental|Treatment (lenalidomide, ibrutinib)|Patients receive lenalidomide PO QD on days 1-21 and ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
2884269|NCT03359447|Experimental|Weekly Iron|Weekly ferrous sulfate: one dose (4mg/kg/week).
2884270|NCT03359447|Active Comparator|Daily Iron|Daily ferrous sulfate: one dose (1 mg/kg/day). Maximum daily dose: 40 mg
2884271|NCT03359434|Experimental|Two measuring methods of blood pressure|
2884272|NCT03359421||Aeromedical transport|Patients transported to trauma center by helicopter
2884273|NCT03359421||Ground transport|Patients transported to trauma center by ground ambulance
2884274|NCT03359408|No Intervention|Care as usual|Care as usual, no intervention, just observation of natural change/ trajectories over time
2884275|NCT03359408|Experimental|Dementia Care Management (DCM)|"Subjects in this arm will be provided with Dementia Care Management adapted to the intersectoral setting."
2884276|NCT03359395|Active Comparator|Alfentanil|
2884277|NCT03359395|Placebo Comparator|placebo|
2884278|NCT03359382|No Intervention|control|
2884279|NCT03359382|Experimental|exercise|
2884280|NCT03359369||Septic Patients|
2884281|NCT03359369||Non Septic Patients|
2884282|NCT03359356|Experimental|Dupilumab|An initial dose of 600 mg (two 300 mg subcutaneous injections), followed by 300 mg given every other week
2884283|NCT03359356|Placebo Comparator|Placebo|Matching placebo in prefilled syringes identical to the dupilumab syringes
2884284|NCT03359343||experts|In this group, two experts distinguish a set of polyps on LCI images as adenoma or non-adenoma.
2884285|NCT03359343||non-experts|In this group, two non-experts distinguish the set of polyps(the same to experts group) on LCI images as adenoma or non-adenoma.
2884286|NCT03359343||Computer-aided diagnosis system|In this group, a newly developed computer-aided diagnosis system will be used to distinguish a set of polyps as adenoma or non-adenoma.
2884287|NCT03359330||Degradable conduit small gap tublization|patients with fresh peripheral nerve injury in the upper extremities,repaired with degradable conduit small gap tublization
2884288|NCT03359317|Experimental|jogging|At least 5 times/week
2884289|NCT03359291|Experimental|Sequence AB|Subjects participate in two study periods: During the first period (treatment A), they receive a single oral dose of rosuvastatin on Day 1. During the second period (treatment B), they receive a single oral loading dose of macitentan on Day 5 and oral doses of macitentan from Day 6 to Day 16 (i.e., 11 doses). Subjects receive a single oral dose of 10 mg rosuvastatin concomitantly with macitentan in the morning of Day 10.
2884290|NCT03359278||open reduction and internal fixation|The volar approach was used for open reduction and internal fixation of distal radius fractures
2884291|NCT03359265|Active Comparator|Test|The test group used underpants made of precious metal fibers (germanium, titanium and phosphorus), developed by Green Energy Nano Technology Co., Ltd.
2884292|NCT03359265|Placebo Comparator|Control|The control group used commercially available underpants.
2884293|NCT03359252|Active Comparator|non-stent assisted coiling|patients treated with non-stent assisted coiling of unruptured intracranial aneurysms
2884294|NCT03359252|Experimental|stent assisted coiling|patients treated with stent assisted coiling of unruptured intracranial aneurysm
2884295|NCT03359239|Experimental|PGV 001 with Atezolizumab|Atezolizumab: programmed death-ligand 1 PGV001:personalized cancer vaccine PGV 001 - vaccine Poly ICLC- adjuvant The product is prepared within the Icahn School of Medicine at Mount Sinai (ISMMS) . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.
2884296|NCT03359226|Experimental|Submandibular gland biopsy|No treatment is being used in this study. Study participants will have bilateral submandibular gland biopsies.
2884297|NCT03359213|Experimental|JR-141 1.0 mg/kg/week|
2884298|NCT03359213|Experimental|JR-141 2.0 mg/kg/week|
2884299|NCT03359213|Experimental|JR-141 4.0 mg/kg/week|
2884300|NCT03359187|Active Comparator|Normal saline with salt/Soda|Normal saline with salt/soda rinse 4 times a day/everyday and for each time 15 ml.
2884301|NCT03359187|Experimental|Clinacanthus nutans|Clinacanthus nutans in form of mouth wash rinse 4 times a day/everyday and for each time 15 ml.
2884302|NCT03359187|Experimental|Boesenbergia rotunda|Boesenbergia rotunda in form of mouth wash 4 times a day/everyday and for each time 15 ml.
2884303|NCT03359174|Experimental|All-trans retinoic acid (ATRA) therapy|Fixed low dose of ATRA 10 mg twice daily for 24 weeks.
2884304|NCT03359161|Experimental|In-Home Subcutaneous Furosemide Treatment ARm|Prospective, open-label arm to evaluate the clinical effectiveness of a novel formulation of furosemide delivered by subcutaneous administration.
2884305|NCT03359148||Disposable ventilator system|The experimental study group will be assigned to a disposable ventilator system combined with an auto-filled heated humidifier (HH), a closed suction catheter, and a closed aerosol therapy procedure with a valved T-adaptor.
2884306|NCT03359148||Conventional reused ventilator system|According to clinical commonly used system, the control study group will be assigned to use with conventional reused ventilator system, combined with a manually filled HH, an open suction catheter, and a conventional aerosol therapy procedure.
2884307|NCT03359135||group1|hEDS treated with rehabilitation only
2884308|NCT03359135||group 2|hEDS treated with rehabilitation associated to compression garments wearing
2884309|NCT03359109||Stainless Steel Devices|10 patients with stainless steel devices implanted
2884310|NCT03359109||Titanium or Titanium-alloy Based Devices|30 patients with titanium or titanium-alloy implanted devices
2884311|NCT03359109||De Novo Titanium Implant|10 patients undergoing de novo titanium implant placement who have had no previous orthopedic procedures
2884312|NCT03359096|Experimental|Therapeutic HGNS|Therapeutic Hypoglossal Nerve Stimulation (HGNS). Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study.
2884379|NCT03358576|Experimental|Sulopenem|Sulopenem 1000 mg IV once daily for at least 5 days, followed by Sulopenem-Etzadroxil/Probenecid 500 mg PO twice daily to complete 7-10 days of treatment
2884313|NCT03359096|Sham Comparator|Subtherapeutic 'Sham' HGNS|"Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds."
2884314|NCT03359070|Experimental|Group 1 - dapaconazole cream 2%|Topical application of dapaconazole cream 2%, twice a day (7 to 8 a.m. and 6 to 7 p.m.) for 14 days.
2884315|NCT03359070|Active Comparator|Group 2 - miconazole cream 2%|Topical application of miconazole cream 2%, twice a day (7 to 8 a.m. and 6 to 7 p.m.) for 14 days.
2884316|NCT03359057|Experimental|Estradiol + levonorgestrel + folic acid|Coated tablet of the test product - ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days.
2884317|NCT03359057|Placebo Comparator|Folic acid|Coated tablet of placebo coated tablet containing folic acid 0.4 mg only on the last 7 days of the cycle.
2884318|NCT03359044||Sedation + topical anesthesia|midazolam 0.1～0.2 mg/kg for sedation, 2%lidocaine for topical anesthesia
2884319|NCT03359044||General anesthesia+ topical anesthesia|propofol 4～5mg/kg、Remifentanil2～3μg/kg for induction ,insert Laryngeal Mask Airway(LMA) , 2%lidocaine for topical anesthesia
2884320|NCT03359031|No Intervention|No patient education|This group of patients will not receive any additional information beyond standard of care educational pamphlets provided by the hospital.
2884321|NCT03359031|Other|Patient education|This group of patients will be given a pamphlet on pain control, narcotic medication, and compartment syndrome including its pathophysiology, signs/symptoms, and treatment.
2884322|NCT03359018|Experimental|apatinib plus anti-PD1 therapy arm|Every patients will received apatinib 250mg or 500mg orally daily and SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
2884323|NCT03359005|Experimental|irinotecan and temozolomide|Irinotecan 20mg/m2/d IV over 60 minutes on days 1-5 and 8-12. Temozolomide 100mg/m2/d PO on days 1-5. Vincristine 1.4mg/m^2/d IV on days 1,8 Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
2884324|NCT03358979||Severe eye dryness|
2884325|NCT03358979||absence of eye dryness|
2884326|NCT03358966||Early to moderate CKD (stage 1-3)|40 patients with CKD stage 1-3. All subjects performed a comprehensive metabolic analysis including measurement of Resting Energy Expenditure using indirect calorimetry, bioimpedance, doubly-labelled water technique and body size measures. Physical activity was assessed using a Stanford 7 day recall questionnaire.
2884327|NCT03358966||Advanced CKD (stage 4-5)|40 patients with CKD stage 4-5. All subjects performed a comprehensive metabolic analysis including measurement of Resting Energy Expenditure using indirect calorimetry, bioimpedance, doubly-labelled water technique and body size measures. Physical activity was assessed using a Stanford 7 day recall questionnaire.
2884328|NCT03358953|Other|Electronic Cigarettes|Participants wishing to quit tobacco smoking have an equal chance of being assigned to the electronic cigarette arm. They are supplied with a second generation e-cigarette to support their quit attempt with standard of care once weekly support sessions from NHS smoking cessation services.
2884329|NCT03358953|Other|Nicotine replacement patches|Participants wishing to quit tobacco smoking have an equal chance of being assigned to the nicotine replacement patch arm (standard care). They are supplied with a second generation e-cigarette to support their quit attempt with standard of care once weekly support sessions from NHS smoking cessation services.
2884330|NCT03358940|Other|patient with miscarriage complications or not|The day of inclusion, for patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
2884331|NCT03358927|Active Comparator|Standard Group|Deferred fast-track care
2884332|NCT03358927|Experimental|Immediate Fast-Track Group|Immediate fast-track care
2884333|NCT03358914||Adolescents with psoriasis|No assigned intervention: completion of PsoTeenQOL and other instruments for assessment of psychometric properties and further refinement of the PsoTeenQOL.
2884334|NCT03358914||Parents of adolescents with psoriasis|No assigned intervention: completion of proxy-version of the PsoTeenQOL for validation purposes
2884335|NCT03358914||Adolescents without psoriasis|No assigned intervention: completion of non-psoriasis control-version of the PsoTeenQOL for validation purposes
2884336|NCT03358901|Experimental|YC-6|6 volunteers in each level will be infused 100, 200, 400, or 600 mg of YC-6 over 7 consecutive days: BID within 30 minutes for the first 6 days and QD on the 7th day.
2884337|NCT03358901|Placebo Comparator|Vehicle|2 volunteers in each level will be infused 2, 4, 8, or 12 g of vehicle over 7 consecutive days: BID within 30 minutes for the first 6 days and QD on the 7th day.
2884338|NCT03358888|Active Comparator|Standard of Care|
2884339|NCT03358888|Active Comparator|Multi-modal with as needed opioids|
2884340|NCT03358888|Active Comparator|Multi-modal with one week of opioids offered|
2884341|NCT03358875|Experimental|BGB-A317|BGB-A317, 100 mg per vial, 200mg IV, Q3W
2884342|NCT03358875|Experimental|Docetaxel|Docetaxel 75 mg/m2 IV Q3W
2884343|NCT03358862||Myopes|Children, adolescents and young adults with existing progressive myopia equal to or exceeding -0.50 D in the year prior to beginning the use of the NaturalVue contact lens.
2884344|NCT03358849|Experimental|experimental group|
2884345|NCT03358836||Group A|Episodic treatment with FIX concentrates for bleeding episodes
2884346|NCT03358836||Group B|Prophylaxis using any FIX concentrate with an intended trough of 1-5%
2884347|NCT03358836||Group C|Prophylaxis with an extended half-life (EHL) FIX with an intended trough of >10%
2884375|NCT03358628||Osteosarcoma|Osteosarcoma patients with metastatic relapsed or unresectable progressive disease (total n= up to 20) following resection of the primary lesion and adjuvant chemotherapy.
2884376|NCT03358602|Experimental|Radiotherapy|Radiotherapy & open partial supraglottic laryngectomy(primary tumor)
2884377|NCT03358602|Active Comparator|Elective neck dissection|Elective neck dissection & open partial supraglottic laryngectomy(primary tumor)
2884348|NCT03358823||Angelman syndrome|Cases were children with the diagnosis meet the all 4 major criteria developmental delay, speech impairment, movement or balance disorder, and behavioral characteristics, as well as the presence of 3 of 6 minor criteria, including postnatal deceleration of head growth, seizures, abnormal EEG, sleep disturbance, attraction to or fascination with water, and drooling (summary by Tan et al., 2011). all patients meet the 4 known genetic mechanisms can cause Angelman syndrome (AS).,including maternal deletions involving chromosome 15q11.2-q13;paternal uniparental disomy of 15q11.2-q13;imprinting defectsand mutations in the gene encoding the ubiquitin-protein ligase E3A gene (UBE3A; 601623)
2884349|NCT03358810|Active Comparator|Active group|patients randomized to receive active PES
2884350|NCT03358810|Sham Comparator|Sham treatmment|Patients randomized to sham will not receive any PES.
2884351|NCT03358797|Experimental|Intervention|Community participants will participate in a group-based lifestyle intervention based on the CDC Diabetes Prevention Program, and adapted to the Arabic language, Arab culture, Mediterranean Diet, and adapted to include empowerment, leadership and emotion regulation.
2884352|NCT03358797|No Intervention|Comparison|No intervention, other than baseline measurement.
2884353|NCT03358784||PHILOS Plate|three or four-part fractures of proximal humerus treated with internal fixation
2884354|NCT03358784||Hemi-shoulder arthroplasty|three or four-part fractures of proximal humerus treated with hemi-shoulder arthroplasty
2884355|NCT03358771|No Intervention|Usual Care|"During the initial stepped wedge phase, all sites will receive usual care. There is currently no standardized discharge care bundle for COPD in Alberta. Some electronic patient information sheets do exist; however, their content is general and use is limited. It is expected that a vast majority of patients will transition to the community on a sub-optimal medication regimen, with limited referral to additional outpatient programs and no formal follow-up organized with a primary care provider (e.g., F/U prn or F/U with Fam MD)."
2884356|NCT03358771|Active Comparator|COPD discharge care bundle|"COPD discharge care bundle:~Ensure patient has demonstrated adequate inhaler technique~Send discharge summary to family physician office and arrange follow-up~Optimize and reconcile prescription of respiratory medications~Provide a written discharge management plan, and assess patient's and care giver's comprehension of discharge instructions~Refer to pulmonary rehabilitation~Screen for frailty and comorbid condition(s)~Assess smoking status, provide counseling and refer to smoking cessation program, where appropriate"
2884357|NCT03358771|Experimental|COPD discharge care bundle & coordinator|COPD discharge care bundle as listed for active comparator arm enhanced with care coordinator support.
2884358|NCT03358745|Experimental|Standard meal, bread/butter as starter|"Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal and consists of bread and butter, soup, salad and cheese. The participants eat the bread and butter portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).~Blood samples are taken before the lunch and every 30 min postprandial for 4 h."
2884359|NCT03358745|Experimental|Standard meal with soup as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the soup portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
2884360|NCT03358745|Experimental|Standard meal with cheese as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the cheese portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
2884361|NCT03358745|Experimental|Standard meal with salad as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the salad portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
2884362|NCT03358732|Experimental|Mock embryo transfer|The patients underwent a mock embryo transfer one day before the scheduled actual transfer
2884363|NCT03358732|No Intervention|No mock embryo transfer|The patients did not undergo mock embryo transfer one day before the scheduled actual transfer
2884364|NCT03358719|Experimental|Treatment (CDX-1401, poly ICLC, decitabine, nivolumab)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 intracutaneously and poly ICLC SC on day -14, on day 15 of courses 1-4, and then on day 1 of every 4 courses thereafter. Patients also receive nivolumab IV over 60 minutes on days 1 and 15 and decitabine IV over 1 hour on days 1-5. Courses with nivolumab and decitabine repeat every 4 weeks in the absence of disease progression or unaccepted toxicity.
2884365|NCT03358706|Experimental|Crohn's Disease Participants: Ustekinumab + Probe Cocktail|Participants will receive a single Intravenous (IV) infusion dose of ustekinumab (dosage to be decided based on body weight) on Day 8 and a ustekinumab 90 milligram (mg) maintenance dose via subcutaneous (SC) route on Day 64. A second optional maintenance dose may be administered on Day 120 based on participants clinical response assessed by investigator. The probe cocktail (2 milligram [mg] of midazolam, 10 mg of warfarin plus 10 mg of vitamin K, 20 mg of omeprazole, 30 mg dextromethorphan, and 100 mg of caffeine) will be administered orally on Days 1, 22, and 113.
2884366|NCT03358706|Experimental|Healthy Participants: Probe Cocktail|Participants will receive the probe cocktail (2 mg of midazolam, 10 mg of warfarin plus 10 mg of vitamin K, 20 mg of omeprazole, 30 mg dextromethorphan, and 100 mg of caffeine) orally on Day 1.
2884367|NCT03358693||Psoriasis patients receiving ustekinumab|Ustekinumab
2884368|NCT03358693||Psoriasis patients receiving infliximab|Infliximab
2884369|NCT03358693||Psoriasis patients receiving secukinumab|Secukinumab
2884370|NCT03358693||Atopic dermatitis patients receiving dupilumab|Dupilumab
2884371|NCT03358667||group A|single edentulism implant insertion tent screw 2mm augmentation peri-implant soft tissue
2884372|NCT03358667||group B|single edentulism implant insertion cover screw and membrane augmentation peri-implant soft tissue
2884373|NCT03358654|Experimental|mesenchymal stem cells|Inject mesenchymal stem cells from umbilical cord. The patients will be followed up at 1, 2, 3, and 6 months after the injection
2884374|NCT03358641||Wuchuan residents|All residents that meet the criteria can be enrolled in this group, receiving a home interview (including IPA-Q to assess the level of physical activity) and a weight-bearing posteroanterior semiflexed view of radiographs at tibiofemoral (TF) joints at baseline and 3 years later.
2884380|NCT03358576|Active Comparator|Ertapenem|Ertapenem 1000 mg IV once daily for at least 5 days, followed by ciprofloxacin 500 mg PO twice daily along with metronidazole 500 mg PO four times daily. If patient is found to have causative pathogens that are resistant to ciprofloxacin they will receive amoxicillin-clavulanate 875 mg PO twice daily instead
2884381|NCT03358563|Experimental|Degarelix SC + bicalutamide + docetaxel|Degarelix SC monthly x3 + bicalutamide 50mg orally QD x 14 wks + Docetaxel 75mg/m2 IV q 21 days x 3
2884382|NCT03358550|Experimental|Accommodation in scotopic luminance|
2884383|NCT03358537|Active Comparator|Clear Liquid Diet|110 subjects received clear liquid diet 24 hours before colonoscopy
2884384|NCT03358537|Active Comparator|Low-residue Diet|105 subjects received a prespecified low-residue diet 24 hours before colonoscopy
2884385|NCT03358524|Experimental|Vitamin E 400 IU|Vitamin-E Capsule (alpha-tocopherol) 400 IU once per day orally for 8 weeks
2884386|NCT03358524|Placebo Comparator|Placebo|Placebo capsule once per day orally for 8 weeks
2884387|NCT03358511|Experimental|Breast Cancer Patients|All subjects will be given 2-4 weeks of probiotics prior to surgery in operable stage I-III breast adenocarcinoma tumors ≥1.0 cm. Subjects will take the probiotic three times a day.
2884388|NCT03358498||β-thalassemia group|"SICT It is a questionnaire to assess patient satisfaction with ICT regimens. It comprises 19 items assessing four domains: perceived effectiveness of ICT (PE), burden of ICT (BD), acceptance of ICT (AC), and side effects of ICT (SE). Patients rate all items on scale from 1 very dissatisfied to 5 very satisfied.~Lab methods :~full history and thorough clinical evaluation.~. Complete blood count. .3- Serum ferritin .~4-Renal function tests. 5-liver function tests."
2884389|NCT03358485|Experimental|Aolanti Weikang tablets|3，6 or 8 Aolanti Weikang tablets each time,tid
2884390|NCT03358485|Placebo Comparator|Placebo|3,6 or 8 tablets each time,tid
2884391|NCT03358472|Experimental|Group 1|Pembrolizumab + Epacadostat
2884392|NCT03358472|Experimental|Group 2|Pembrolizumab
2884393|NCT03358472|Active Comparator|Group 3|EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil)
2884394|NCT03358459||EP|For diagnosis non-acquired epilepsy;
2884395|NCT03358446||A group|"Based on the presence of non-overlapping range between femoral artery and vein from the initial observation, the patients were divided into following two groups.~A group is the patients with non-overlapping range"
2884396|NCT03358446||S group|S group is the patients without non-overlapping range
2884397|NCT03358433|Experimental|Exercise|
2884398|NCT03358433|Active Comparator|Antidepressants|
2884399|NCT03358407|Experimental|Part A: Cohort 1|Cohort 1 will be 5-way crossover with 5 treatment periods. Subjects will be randomized in the ratio 4:1 to receive either single dose of GSK2983559 or placebo.
2884400|NCT03358407|Experimental|Part A: Cohort 2 fasting|Cohort 2 will be 4-way crossover design with one additional period of open-label. Subjects will be randomized in the ratio 3:1 to receive either single dose of GSK2983559 or placebo in fasted conditions
2884401|NCT03358407|Experimental|Part A: Cohort 2 fed|In Cohort 2, treatment period 5 will be open-label period. This open-label period is to determine food effect and subjects will receive GSK2983559 under fed conditions.
2884402|NCT03358407|Experimental|Part B|Part B is repeat ascending dose sequential period. There will four cohorts (3-6) of 10 healthy subjects. In each cohort subjects will be randomized to receive GSK2983559 or placebo in ratio 4:1. Subjects will receive GSK2983559 or placebo QD and twice daily dose will be decided based upon the pharmacokinetic, safety and tolerability observed in Part A.
2884403|NCT03358394|Experimental|Intervention group|The intervention group will be asked to complete the outcomes measures anxiety, depression and mindfulness questionnaires at baseline, a week before the start of the intervention and at the end of the intervention time period(i.e., after five weeks).
2884404|NCT03358394|Experimental|Control group|"The control group will be asked to complete the outcomes measures anxiety, depression and mindfulness questionnaires at baseline, a week before the start of the intervention and at the end of the intervention after six weeks.~At the end of the pilot trial, control group will receive the full intervention. They would be sent the materials week by week as same as the intervention group."
2884405|NCT03358381|Experimental|gap balance group|The type of total knee arthroplasty will be the balance gap.The gap balance type of total knee arthroplasty will be performed.
2884406|NCT03358381|Active Comparator|measured resection group|The type of total knee arthroplasty will be the measured resection.The measured resection type of total knee arthroplasty will be performed.
2884407|NCT03358355|Experimental|Intervention|Subcutaneous injection of unacylated ghrelin: Doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg
2884408|NCT03358342||ED Patients treated using ePneumonia CDS|ED patients with community-acquired pneumonia treated in ED's after roll out of ePneumonia
2884409|NCT03358342||Usual care|ED patients with pneumonia receiving usual care without electronic CDS
2884410|NCT03358329|Experimental|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
2884411|NCT03358316||cuff tear patients|Patients with cuff tear
2884412|NCT03358303|Experimental|Telemonitoring (Medly)|Medly is a smartphone application allows heart failure (HF) patients to measure and record their daily weight, blood pressure (BP), heart rate, and self-reported symptoms. This monitoring information is then transmitted wirelessly to a data server where an algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated self-care message based on their measurements and reported symptoms.
2884413|NCT03358303|No Intervention|Control|Standard of care: Control groups will receive standard medical care when discharged from hospital, including discharge instructions, home medications as well as follow-up in a heart failure clinic or with a primary care doctor.
2884414|NCT03358290|Experimental|JTE-051 Dose 1|JTE-051 dose 1 for 12 weeks
2884415|NCT03358290|Experimental|JTE-051 Dose 2|JTE-051 dose 2 for 12 weeks
2884416|NCT03358290|Experimental|JTE-051 Dose 3|JTE-051 dose 3 for 12 weeks
2884417|NCT03358290|Experimental|JTE-051 Dose 4|JTE-051 dose 4 for 12 weeks
2884418|NCT03358290|Experimental|Placebo|Placebo for 12 weeks
2884419|NCT03358277|Experimental|ADHD+DMDD Group|The subjects with comorbid ADHD and DMDD received pharmacological intervention with combination treatment of MPH+ APZ with flexible dosage according to clinical judgment for six weeks.
2884420|NCT03358264|Experimental|Type 2 diabetic patients|L-citrulline at a dose of 2000 mg per day for a period of 1 month will be administered to type 2 diabetic patients with HbA1c>6
2884421|NCT03358264|Experimental|Healthy volunteers|L-citrulline at a dose of 2000 mg per day for a period of 1 month will be administered to non-diabetic healthy volunteers
2884422|NCT03358251|Active Comparator|Pocket-X Gel treatment group|Participants in this group will receive treatment with an in-situ gelling product, Pocket-X Gel, following scaling and root planing on the entire mouth. The product will be inserted during several visits into periodontal pockets present in one/two mouth segment(s) of each participant, while the rest of the mouth will not undergo further intervention.
2884423|NCT03358251|Active Comparator|Pocket-X Chip treatment group|Participants in this group will receive treatment with a periodontal film, Pocket-X Chip, following scaling and root planing on the entire mouth. The product will be inserted during several visits into periodontal pockets present in one/two mouth segment(s) of each participant, while the rest of the mouth will not undergo further intervention.
2884424|NCT03358238|Placebo Comparator|No weekly review|Individuals will not review self-report and activity tracker data with an interviewer on a weekly basis over the phone.
2884425|NCT03358238|Experimental|Weekly review|Individuals will review self-report and activity tracker data with an interviewer on a weekly basis over the phone.
2884426|NCT03358225||Anterior Cervical Discectomy and Fusion|The patients undergoing anterior cervical discectomy and fusion surgery
2884427|NCT03358225||Cervical Artificial Disc Replacement|The patients undergoing cervical artificial disc replacement surgery
2884428|NCT03358225||Hybrid surgery|The patients undergoing hybrid surgery(1-level ADR plus 1-level ACDF) surgery
2884429|NCT03358212||denosumab used postoperatively|the postoperative denosumab group, including patients receiving denosumab after piecemeal intralesional curettage aided by digital subtraction angiography(DSA) and balloon occlusion of abdominal aorta;
2884430|NCT03358199||Study group|PCOS women with AMH level (≥ 7 ng/ml) who underwent LOD in the preceding 3 months prior to IVF/ICSI
2884431|NCT03358199||Control group|PCOS women with AMH level (≥ 7 ng/ml) who did not undergo LOD in the preceding 3 months prior to IVF/ICSI
2884432|NCT03358186||revision of periprosthetic fracture|patients with surgically treated periprosthetic femur fracture
2884433|NCT03358173||Conservative Treatment|Standard protocol for conservative treatment will consist of the implementation of a sling and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
2884434|NCT03358173||Operative Plate Fixation|The operating surgeon will determine the positioning of the patient for surgery. ORIF of the humeral shaft fracture will be carried out
2884435|NCT03358160||TKA|Orthopaedic patients who underwent surgical operation for total knee arthroprothesis.
2884436|NCT03358160||Rizoarthrosis|Orthopaedic patients who underwent surgical operation to treat chronic arthrosis of the thumb.
2884437|NCT03358160||Healthy Controls|Healthy age-matched controls.
2884438|NCT03358147|Experimental|GP MDI 28.8 μg|GP MDI 14.4 μg per actuation taken as 2 inhalations BID
2884439|NCT03358147|Experimental|GP MDI 14.4 μg|GP MDI 7.2 μg per actuation taken as 2 inhalations BID
2884440|NCT03358147|Experimental|GP MDI 7.2 μg|GP MDI 3.6 μg per actuation taken as 2 inhalations BID
2884441|NCT03358147|Placebo Comparator|Placebo MDI|Taken as 2 inhalations BID
2884442|NCT03358147|Other|Spiriva Respimat 2.5 μg|Open Label Spiriva Respimat 2.5 μg
2884443|NCT03358134|Experimental|Secukinumab|All patients will be treated with active treatment. (anti-IL17)
2884444|NCT03358121||Diabetics without hypoglycemia awareness|Diabetic patients without impaired hypoglycemia awareness. No interventions were performed, the study is purely observational.
2884445|NCT03358121||Diabetics with hypoglycemia awareness|Diabetic patients with impaired hypoglycemia awareness. No interventions were performed, the study is purely observational.
2884446|NCT03358108||Group A: interferon group|formerly interferon group (including interferon alone or interferon combined with other drugs)
2884447|NCT03358108||Group B:nucleoside analogue group|formerly nucleoside analogue treatment group. Each group was followed for five years
2884448|NCT03358095|No Intervention|Early surgery|Patients in this group proceed to pancreatic resection within 2 week of recruitment.
2884449|NCT03358095|Active Comparator|Preoperative biliary drainage|Endoscopic retrograde cholangiopancreatography (ERCP) is used to place an endoprosthesis to the biliary ducts to drain biliary stasis, and the patients proceed to pancreatic resection within 6 weeks of recruitment.
2884450|NCT03358082|Active Comparator|Tacrolimus group|Tacrolimus 0.03% ointment twice daily for 6 months
2884451|NCT03358082|Active Comparator|Hydrocortisone group|hydrocortisone acetate 1% ointment twice daily for 6 months
2884452|NCT03358069||deep anesthetic state|technique of Anesthesia at the time of airway device removal
2884453|NCT03358069||awake|technique of Anesthesia at the time of airway device removal
2884454|NCT03358069||emergence time (clinical): min|The duration from the time of anesthestic medications stop and the time that patient spontaneously open their eyes
2884455|NCT03358069||Emergence time (entropy): min|time from Entropy value above 60 to 90
2884456|NCT03358056|Experimental|Mindfulness-based Cognitive Therapy|
2884457|NCT03358030|Placebo Comparator|Cohort A, B and C|"Subjects will be stratified based on the diagnosis of documented atrial fibrillation at screening, and then subjects will be randomized to 1 of 3 dose cohorts in a 1:1:1 ratio (Cohort A, Cohort B and Cohort C).~Cohort A: Approximately 68 subjects will be randomized 3:1 to either Dose #1 of ISIS 416858 or placebo.~Cohort B: Approximately 68 subjects will be randomized 3:1 to either Dose #2 of ISIS 416858 or placebo.~Cohort C: Approximately 68 subjects will be randomized 3:1 to either Dose # 3 of ISIS 416858 or placebo.~Cohort A, B and C will include a 4 week screening period and a 26-week treatment period followed by a 12-week post-treatment evaluation period.~Cohort A, B and C will receive Study Drug (ISIS 416858 or placebo) once a week for the 26 week treatment period. All doses of Study Drug will be administered subcutaneously (SC) post-dialysis within 2 hours."
2884458|NCT03358030|Placebo Comparator|Pharmacokinetic Subgroup|The pharmacokinetic subgroup will include approximately 12 subjects in each of the 3 cohorts.
2884494|NCT03357679|Active Comparator|Glidescope assisted intubation|Glidescope is used for laryngoscopy, followed by intubation
2884459|NCT03358030|Placebo Comparator|Platelet Function/Activation Subgroup|The platelet subgroup will include approximately 12 subjects in each of the 3 cohorts, platelet function and/or activation will be assessed.
2884460|NCT03358017|Active Comparator|ARM A - standard NACT|Standard anthracyclines/taxanes based neoadjuvant chemotherapy chosen by the investigator and administered according to clinical practice, for 6 months, or 4.5 months in case of dose dense schedule (unless disease progression, unacceptable toxicity, patient's refusal or investigator's decision)
2884461|NCT03358017|Experimental|ARM B - standard NACT + Zol + atorvastatin|Standard anthracyclines/taxanes based neoadjuvant CT chosen by the investigator and administered according to clinical practice + Zoledronate 4 mg i.v. every 3-4 weeks and Atorvastatin 80 mg/die administered for 6 months, or 4.5 months in case of dose dense schedule (unless disease progression, unacceptable toxicity, patient's refusal or investigator's decision)
2884462|NCT03358004|Experimental|ARM A|Vinorelbine 50 mg, thrice a week
2884463|NCT03358004|Experimental|ARM B|Vinorelbine 40 mg thrice a week + capecitabine 500 mg thrice a day
2884464|NCT03357978|Other|A-T patients|"A-T patients aged 2 to 45 years with and without immunoglobulin G Substitution~bioelectrical impedance Analysis~blood draw~transient elastography (FibroScan)~ataxia score~Five-Times-Sit-to-Stand Test"
2884465|NCT03357952|Experimental|Part 1: JNJ‑63723283 + Daratumumab|Participants in Safety Run-in cohort will receive daratumumab IV and JNJ‑63723283 IV for 1 cycle (28 days). Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met.
2884466|NCT03357952|Experimental|Part 2 and Part 3: Daratumumab/ JNJ‑63723283 + Daratumumab|Participants in Treatment Arm A will receive daratumumab IV and in Treatment Arm B will receive daratumumab IV and JNJ‑63723283 IV for cycles of 28 days each. All participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met.
2884467|NCT03357939|Experimental|HLX03|sub-cutaneous injection with single dose of 40 mg in 0.8mL
2884468|NCT03357939|Active Comparator|Humira|sub-cutaneous injection with single dose of 40 mg in 0.8mL in a pre-filled syringe
2884469|NCT03357926||Observation Group|
2884470|NCT03357913||Co morbidities after lung transplantation in cystic fibrosis|The population studied is the cohort of cystic fibrosis patients who received a bipulmonary transplant between 2004 and 2014 in one of the two transplantation centers in the Rhône-Alpes region.
2884471|NCT03357900|Experimental|Orthotopic liver transplantation|
2884472|NCT03357874|Experimental|Clopidogrel group|
2884473|NCT03357874|Experimental|Ticagrelor group|
2884474|NCT03357848||Study group|Surgical patients receiving nutritional support (enteral and/or parenteral nutrition) pre and/or after surgery
2884475|NCT03357848||Control group|Surgical patients without nutritional support during the perioperative period
2884476|NCT03357835||Normal Triage|Triage scoring determined by the Ministry of Health (SB ), routinely performed by an emergency medical technician (att), will be applied when the patients are admitted to emergency services. According to this scoring, patients who need urgent care and who should not wait less than 15 minutes will be considered red coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded.
2884477|NCT03357835||Software Triage|"triage maintenance / evaluation will be done with computer software called Trauma Decision System (TraumaDS) developed by us. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes. According to this scoring, patients who need urgent care and who should not wait will be considered red code, patients who should wait less than 15 minutes will be considered orange coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded."
2884478|NCT03357822|Experimental|Sequential combination therapy group|Patients are treated with pegylated Interferon (180ug, subcutaneously, once a week) plus entecavir (0.5mg, orally, every day) or tenofovir disoproxil fumarate (300mg, orally, every day) for 48/72/96 weeks
2884479|NCT03357822|Active Comparator|Nucleoside therapy group|Patients are treated with entecavir (0.5mg, orally, every day) or tenofovir disoproxil fumarate (300mg, orally, every day) for 96 weeks
2884480|NCT03357809|Experimental|Endoscopic treatment|ENDOSCOPIC MUCOSAL RESECTION AT DAY 1
2884481|NCT03357796|Experimental|Group A: LY03005 cross-over to Pristiq®|Subjects in Group A will receive an 80 mg oral dose of LY03005 and the subjects will stay in the CRU for 4 days (Period 1). After a washout period of up to 4 days, the subjects will be switched and will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) comparator followed by a 4-day stay in the CRU (Period 2).
2884482|NCT03357796|Experimental|Group B: Pristiq® cross-over to LY03005|Subjects in Group B will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) comparator and the subjects will stay in the CRU for 4 days (Period 1). After a washout period of up to 4 days, the subjects will be switched and will receive an 80 mg oral dose of LY03005 followed by a 4-day stay in the CRU (Period 2).
2884483|NCT03357770|Experimental|low dose of mesenchymal stem cells|Three groups of patients were enrolled in this study. Every group includes three patients. The three groups of patients were treated with high, medium and low dose of cytokine.The low-dose is 1 × 10^7cells / 3mL
2884484|NCT03357770|Experimental|medium dose of mesenchymal stem cells|the medium-dose is 5 × 10^7cells / 3mL
2884485|NCT03357770|Experimental|high dose of mesenchymal stem cells|the high dose is 1 × 10^8cells / 3mL
2884486|NCT03357757|Experimental|Avelumab with VPA|Valproic Acid (VPA, 12.5 mg/kg) once per day and Avelumab (10 mg/kg IV) every 2 weeks for up to 2 years.
2884487|NCT03357731|Experimental|HNO Donor, NTG, Placebo|administered in a cross over design with 5-hour infusions and 7-28 day wash-out periods
2884488|NCT03357718|Experimental|Dexmedetomidine|2 µg/kg Precedex
2884489|NCT03357718|Active Comparator|Midazolam|0.5 mg/kg dormicum
2884490|NCT03357705|Experimental|synthetic|alveolar ridge preservation with synthetic bone
2884491|NCT03357705|Active Comparator|collagen|alveolar ridge preservation with bovine collagen
2884492|NCT03357692|Experimental|maxillary total edentulism|all on four implant rehabilitation with trans-sinusal implants
2884493|NCT03357679|Active Comparator|Bed up head elevated intubation|Patients positioned in the bed up head elevated position, followed by tracheal intubation
2884495|NCT03357666|Experimental|HUDC_VT(Glucose 200mg/Sodium chloride 200mg)|Glucose 200mg/Sodium chloride 200mg, once a day, two tablets at a time for 7 days
2884496|NCT03357666|Experimental|HUDC_VT(Glucose 400mg/Sodium chloride 200mg)|Glucose 400mg/Sodium chloride 200mg, once a day, two tablets at a time for 7 days
2884497|NCT03357666|Experimental|HUDC_VT(Glucose 400mg)|Glucose 400mg, once a day, two tablets at a time for 7 days
2884498|NCT03357666|Experimental|HUDC_VT(Sodium chloride 200mg)|Sodium chloride 200mg, once a day, two tablets at a time for 7 days
2884499|NCT03357666|Placebo Comparator|Placebo|Placebo, once a day, two tablets at a time for 7 days
2884500|NCT03357653|Experimental|Losartan group|Losartan 50 mg daily
2884501|NCT03357653|Placebo Comparator|Placebo group|Placebo 1 pill daily which has same size, color and taste with losartan
2884502|NCT03357640|Placebo Comparator|no intervention|The women will receive one package of placebo. They also will receive a diary card for recording oral contraception intake to be returned to the physician on the next period. An appointment for the women in this group will be scheduled at one month of treatment for the second ultra-sonography. If the ovarian cyst does not show remission, the women will continue the same treatment and will follow up in another month by transvaginal ultra-sound. If the ovarian cyst still persists or progresses at the second month, the women will be followed up for third month.
2884503|NCT03357640|Active Comparator|combined oral contraception pills|The women will receive intervention of one package of combined oral contraception pills and will be counseled about how to take oral contraception and informed of possible side effects. They also will receive a diary card for recording oral contraception intake to be returned to the physician on the next period. An appointment for the women in this group will be scheduled at one month of treatment for the second ultra-sonography. If the ovarian cyst does not show remission, the women will continue the same treatment and will follow up in another month by transvaginal ultra-sound. If the ovarian cyst still persists or progresses at the second month, the women will be followed up for third month.
2884504|NCT03357627|Experimental|Dose Escalation: TAK-659 60 mg + Venetoclax 400 mg|TAK-659 (60 mg, tablet, orally, once daily, up to 35 days in Cycle 1) along with venetoclax (tablet, orally, once daily, in a ramp-up dose schedule in Cycle 1). After Cycle 1, TAK-659 and venetoclax will be administered once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant.
2884505|NCT03357627|Experimental|Safety Expansion: Diffuse Large B-cell Lymphoma (DLBCL) Cohort|TAK-659 tablet, orally, once daily along with venetoclax tablet, orally, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant. TAK-659 and venetoclax MTD/RP2D will be determined from the dose escalation phase.
2884506|NCT03357627|Experimental|Safety Expansion: Follicular Lymphoma (FL) Cohort|TAK-659 tablet, orally, once daily along with venetoclax tablet, orally, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant. TAK-659 and venetoclax MTD/RP2D will be determined from the dose escalation phase.
2884507|NCT03357614|Experimental|Sulopenem|Sulopenem 1000 mg IV once daily for a minimum of 5 days, followed by sulopenem-etzadroxil/probenecid 500 mg PO twice daily to complete 7-10 total days of treatment
2884508|NCT03357614|Active Comparator|Ertapenem|Ertapenem 1000 mg IV once daily for a minimum of 5 days, followed by ciprofloxacin 500 mg PO twice daily or amoxicillin-clavulanate 500 mg PO twice daily to complete 7-10 total days of treatment
2884509|NCT03357601|Experimental|High Intensity Interval Training|six 20 second bouts of high intensity interval exercise (HIIT) separated by 2 minutes of active recovery with 3 minutes and warm up and cool down on the treadmill, three times per week for five weeks
2884510|NCT03357601|Experimental|MCEET|14 minutes of Moderate Endurance Training with 3 minutes and warm up and cool down on the treadmill, three times per week for five weeks
2884511|NCT03357588|Active Comparator|Control|Standard of Care monitoring
2884512|NCT03357588|Experimental|Intervention|Intensified monitoring
2884513|NCT03357575|Experimental|Mesenchymal Stem Cells from adipose|Mesenchymal Stem Cells from adipose will be injected.
2884514|NCT03357575|Active Comparator|hyaluronic acid|Hyaluronic acid will be injectied.
2884515|NCT03357562|Experimental|lung MRI|lung MRI without contrast injection
2884516|NCT03357549|Experimental|Brief Motivational Intervention|The women of this group will receive a Brief Motivational Intervention during 20 or 30 minutes.
2884517|NCT03357549|Active Comparator|Breastfeeding education|The women of this group will receive a standard education about breastfeeding during 20-30 minutes
2884518|NCT03357536|Experimental|Patients with Listeriosis|"Patients with Listeriosis.~Human biological samples :~Blood sample~Skin biopsy~Saliva"
2884519|NCT03357536|Experimental|Volunteers related with patients with Listeriosis|"Volunteers related with patients with Listeriosis.~Human biological samples :~Blood sample~Skin biopsy~Saliva"
2884520|NCT03357523|Experimental|Red LED|Light emitting diodes, 633 nm, 70 mW/cm2, Omnilux new-U (Red LED) (Photomedex, Horsham, PA, USA); RESPeRATE; Heating bag
2884521|NCT03357523|Active Comparator|Near Infrared LED|Light emitting diodes, 830 nm, 55 mW/ cm2, Omnilux new-U (Near infrared LED) (Photomedex, Horsham, PA, USA); RESPeRATE metronome; Heating bag
2884522|NCT03357497|Experimental|Very early mobilization|This group will be mobilized in the post-operative unit by a designated physiotherapist. The intervention will be conducted accordingly with the SOMS protocol.
2884523|NCT03357497|No Intervention|Standard post-operative care|This group will receive standard post-operative care. Mobilization will only take place if the patient request it or to facilitate god post-operative care.
2884524|NCT03357484|Experimental|L-PRF|Third molar extraction sockets were filled with two leukocyte- and platelet rich fibrin (L-PRF) clots
2884525|NCT03357484|Active Comparator|Blood clot|Third molar extraction sockets allowed to form a natural blood clot and undergo natural healing
2884526|NCT03357471|Experimental|Certolizumab Pegol Q2W injection by e-Device|Subjects will self-inject Certolizumab Pegol 200 mg (1 x 200 mg injection) using the e-Device every 2 weeks.
2884527|NCT03357471|Experimental|Certolizumab Pegol Q4W injection by e-Device|Subjects will self-inject Certolizumab Pegol 400 mg (2 x 200 mg injection) using the e-Device every 4 weeks.
2884528|NCT03357458|Experimental|Family Integrated Care|Study participants receive FICare, a dynamic psycho-educational intervention, while their infant(s) was/were admitted to a Level II NICU.
2917629|NCT03126422|Experimental|Dexmedetomidine 0.06 μg/kg/min|
2884529|NCT03357458|No Intervention|FICare Control Group|Study participants received standard care while their infant(s) was/were admitted to a Level II NICU.
2884530|NCT03357445|Other|Subgroup 1|Prospective non Controlled to Document long term performance of AVANTAGE® RELOAD
2884531|NCT03357445|Other|Subgroup 2|Randomized Controlled Trial to Evaluate wear rate of E1 liner in comparison to ArCom® liner
2884532|NCT03357432|Experimental|effects of gelatin, collagen on PINP levels|The study is aimed at determining if the same dose of gelatin, hydrolyzed collagen (administered in a beverage form) or a mixture gelatin/hydrolyzed collagen (administered in a gummy form) with a standard dose of vitamin C (50 mg) has a similar effect a marker of collagen synthesis (PINP). In a randomized, crossover design subjects consume 3 different nutritional supplements: (a) 15 of gelatin, (b) 15 hydrolyzed collagen (administered in a beverage form) or (c) 15 g of gelatin/hydrolyzed collagen mixture all with a standard dose of vitamin C (50 mg) 1 hour prior to exercise stimulus (6 minutes of jump rope). A baseline assessment with only the jump rope and no intervention will also be conducted prior to the interventions. Each intervention will be separated by a >24 hr washout. Following completion of exercise, subjects will remain in the lab in a rested state for the subs
2884533|NCT03357419|Active Comparator|prophylactic antibiotic|"Each active arm patient will be given the tested drug on admission, 30-60 minutes before the surgery, by the nurses.~2 g dose of cephalexin (or Clindamycin 600 mg for patients suffering from allergy) will be given once, orally, 30-60 minutes prior to skin lesion excision"
2884534|NCT03357419|Placebo Comparator|placebo oral capsule|Each placebo arm patient will be given the placebo drug on admission, 30-60 minutes before the surgery, by the nurses
2884535|NCT03357406|Experimental|edentulism side 1|ultrasound implant site preparation
2884536|NCT03357406|Active Comparator|edentulism side 2|conventional implant site preparation
2884537|NCT03357393|Active Comparator|Midazolam and morphine-scopolamine|Sedation during bronchoscopy with midazolam and morphine-scopolamine as premedication.
2884538|NCT03357393|Experimental|PCS (propofol) with morphine-scopolamine|Sedation during bronchoscopy with propofol using PCS and morphine-scopolamine as premedication
2884539|NCT03357393|Experimental|PCS (propofol) with glycopyrronium bromide|Sedation during bronchoscopy with propofol using PCS and glycopyrronium bromide as premedication.
2884540|NCT03357380|Experimental|Semaglutide|Semaglutide will be initiated with a starting dose of 0.05 mg/day for the first 4 weeks. The dose will be increased every 4 weeks until the target dose of 0.4 mg/day has been reached.
2884541|NCT03357380|Placebo Comparator|Placebo|Placebo will be initiated with a starting volume corresponding to 0.05 mg/day of semaglutide for the first 4 weeks. The volume will then be increased every 4 weeks until the target volume corresponding to 0.4 mg/day of semaglutide has been reached.
2884542|NCT03357367|Experimental|PAD patients|"Experimental: PAD patients Patients referred for vascular ultrasound investigation for suspicion of peripheral artery disease (PAD).~Intervention is measurement of microvascular response to current application on the skin by TiVi system"
2884543|NCT03357354|Experimental|Obese Children in precarious situations|
2884544|NCT03357341||COPD cohort|Approximately 100 subjects with COPD identified through integrated EHR records will be enrolled.
2884545|NCT03357341||Asthma cohort|Approximately 100 subjects with asthma identified through integrated EHR records will be enrolled.
2884546|NCT03357328|Active Comparator|Therapy light room|This group (4 NH units, about 35 patients) will receive light therapy administered via LED technology. The light will vary in intensity and colour temperature throughout the day. Ceiling-mounted LED-lights are installed in the living rooms of participating nursing home units. Between 07:00 and 10:00 light of 400 lux at eye level, with 4000 K, will be provided. Between 10:00 and 15:00 the light will comprise 1000 lux at eye level, with 6000 K. From 15:00 to 18:00 the light will comprise 400 lux at eye level and 4000 K. When light is on from 18:00 to 07:00, standard light (about 100 lux at eye level, 3000K) will be administered.
2884547|NCT03357328|Placebo Comparator|Standard light|"This group (4 NH units, about 35 patients) will receive standard light (100 lux at eye level, 3000K). The light will be administered between 07:00 and 18:00; and the same when light is on between 18:00 to 07:00. This represents the placebo light intervention, which at the same time ensures a constant standard light condition in all control units."
2884548|NCT03357315|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2884549|NCT03357315|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2884550|NCT03357289|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2884551|NCT03357289|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2884552|NCT03357276|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2884553|NCT03357276|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2884554|NCT03357263|Experimental|GC3114|Pre-filled syringe inj., 0.5ml, Once, IM
2884555|NCT03357263|Active Comparator|GCFLU Quadrivalent|Pre-filled syringe inj., 0.5ml, Once, IM
2884556|NCT03357237|Experimental|XYLOGLUCAN|treatment regimen with oral rehydration solution and xyloglucan
2884557|NCT03357237|Placebo Comparator|PLACEBO|rehydration solution and placebo.
2884558|NCT03357224|Experimental|Experimental: Atezolizumab|The treatment will be given for a maximum of 1-year unless confirmed disease progression or unless other criteria for treatment discontinuation are met as specified in the protocol.
2884625|NCT03356691|Other|Non-fluidic water|individuals receive water without fluidification (no laying on of hands hands on the glass of water).
2884559|NCT03357198||cough peak flow measurement|All enrolled patients will undergo measurement of cough peak flow by two methods, i.e. using a handheld electronic spirometer, and using the ventilator flowmeter, in a randomized order.
2884560|NCT03357172|Experimental|Recipient|
2884561|NCT03357172|Experimental|Donor|
2884562|NCT03357159|Experimental|cyclophosphamide and ATLG|The study will include 2 phases. In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg administered on day +3 and +4 (target dose) will be added to a standard GVHD prophylaxis consisting of anti-human T-lymphocyte immunoglobulin (ATLG, Grafalon®, formerly ATG-Fresenius S, Neovii Pharmaceuticals) 15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation in order to find the maximally tolerated dose (MTD) of post-transplant cyclophosphamide (PTCy) in combination with pre-transplant immunosuppression by ATLG. The second phase will use the MTD cyclophosphamide dose identified in the first phase.
2884563|NCT03357146||CRA|Patients with chronic retinal artery occlusion
2884564|NCT03357146||Control|Healthy
2884565|NCT03357133|Experimental|Tirofiban and alteplase|
2884566|NCT03357133|Placebo Comparator|Alteplase|
2884567|NCT03357120|Other|Follow-up after neoadjuvant chemotherapy|Patients with an invasive breast cancer on neoadjuvant chemotherapy (with the exception of cT2cN0 tumors) are preselected before the surgical procedure. They are definitely included during the post-surgery visit following the analysis of the surgical specimen (only patients whose tumor did not achieve a complete pathological response are included).
2884568|NCT03357081||CEUS|Adult patients over the age of 18 who have a clinical suspicion of an actively bleeding soft-tissue hematoma as determined by the treating emergency provider. Enrollment will be for one year or until a target of 20 patients is enrolled.
2884569|NCT03357068|Active Comparator|Control|Autogenous bone block surgery without treatment of bone surfaces.
2884570|NCT03357068|Experimental|Acid|Autogenous bone block surgery with citric acid treatment of bone block and recipient site
2884571|NCT03357055|Experimental|Ketamine arm|Ketamine group will receive an IV infusion of 0.25mg/kg of ketamine in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure patients will receive 0.25mg/kg of ketamine infusion at 10ml/hour until the end of operation.
2884572|NCT03357055|Placebo Comparator|Control arm|Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation.
2884573|NCT03357042|Experimental|Persistent post-concussive symptoms|Participants who report post-concussive symptoms. 20 participants will receive the aerobic exercise and balance training intervention, 20 participants will receive standard of care treatment for concussions.
2884574|NCT03357042|Active Comparator|Healthy control|Persons without post-concussive symptoms. No intervention.
2884575|NCT03357029|Active Comparator|Gammacore Device|The GammaCore Device is a non-Invasive vagus nerve stimulator. One stimulation dose bilaterally to the cervical vagal neck area, three times per day (morning 8 am., afternoon 2 pm, and evening 8 pm) for two weeks
2884576|NCT03357029|Sham Comparator|Sham Device|"The Sham GammaCore device looks and operates like the Active GammaCore device, but does not deliver a therapeutic stimulation treatment.~One stimulation dose bilaterally to the cervical vagal neck area, three times per day (morning 8 am., afternoon 2 pm, and evening 8 pm) for two weeks."
2884577|NCT03357016|Experimental|High Intensity Interval Training program (HIIT)|Subjects perform three sessions of training during 12 weeks: 35 min at 50% maximal aerobic power on bicycle.
2884578|NCT03357016|Experimental|Moderate Intensity Continuous Training program (MICT)|Subjects perform three sessions of training during 12 weeks: repeated cycles of sprinting for 8s and pedaling slowly for 12s (between 20 and 30 rpm) for a maximum of 60 repeats per session.
2884579|NCT03357016|Experimental|HIIT + Resistance Training program (RT)|Subjects perform three sessions of training during 12 weeks: Each subject performed HIIT protocol and then a single set of 8 exercises with 1 ou 2min resting period between exercises. Each set consisted of 8-12 repetitions at about 80% maximum repetition.
2884580|NCT03356990|Experimental|Resistant Starch|"Intervention:~Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose of Hi-Maze 260 or High RS Gummy Chews in the morning and the other half dose in the evening~Adult participants are asked to introduce in their diet 30 grams of high RS supplement each day of the diet period (2 weeks).~Children of age included between 5 and 9 years are asked to introduce in their diet 10 grams of high RS supplement each day of the diet period (2 weeks).~Children of age included between 10 and 17 years are asked to introduce in their diet 15 grams of high RS supplement each day of the diet period (2 weeks)."
2884581|NCT03356977|Experimental|Crisaborole ointment 2%|Subjects will be dosed for 28 days. A thin layer of ointment will be applied to all areas designated for treatment.
2884582|NCT03356964|Active Comparator|Control group|Follicle stimulating Hormone will be applied, starting from day 3 of the cycle, the dosage will be choosen between Gonal F 150 - 225 IU, according to the ovarian reserve parameters (13). The stimulation dosage will remain unchanged until the criteria for final oocyte maturation are met (≥ 3 follicles of ≥ 17 mm).
2884583|NCT03356964|Experimental|Study group|Follicle stimulating Hormone will be applied, starting from day 3 of the cycle, the dosage will be choosen between Gonal F 150 - 225 IU, according to the ovarian reserve parameters (LaMarca et al.). As soon as ≥ 3 follicle of a size of 14mm are seen, the stimulation dosage will be reduced daily by 12.5 IU recFSH until the criteria for final oocyte maturation are met (≥ 3 follicles of ≥ 17 mm).
2884584|NCT03356951||Lateral approach group|TAR through lateral approach and subtalar fusion
2884585|NCT03356951||Anterior approach group|TAR through anterior approach and subtalar fusion
2884586|NCT03356938|No Intervention|Baseline recording|
2884587|NCT03356938|Experimental|Sleep restriction|
2884588|NCT03356938|Experimental|Sleep deprivation|
2884589|NCT03356925|No Intervention|Centralised Xpert®Ultra testing|Patients are selected to receive the standard of care for TB diagnosis at a centralised laboratory facility
2884590|NCT03356925|Active Comparator|Xpert Ultra Point of Care testing|Patients are selected to receive the point of care for TB diagnosis at the clinic facility they are visiting
2884626|NCT03356665|Experimental|Clinical suspect|Diagnostic tests: Rapid diagnostic test (RDT); Serological and molecular tests on DBS
2884591|NCT03356912|Active Comparator|Cabazitaxel plus prednisone|Cabazitaxel 25 mg/m² intravenously (Day 1) every 3 weeks, plus prednisone 10 mg orally given daily. Premedication must be administered according to Cabazitaxel Package Insert.
2884592|NCT03356912|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously (Day 1) every 3 weeks. Premedication must be administered according to Cabazitaxel Package Insert.
2884593|NCT03356899|Active Comparator|Low dose bupivacaine 0.5% (8mg)|Bupivacaine 0.5% for spinal anesthesia
2884594|NCT03356899|Active Comparator|High dose bupivacaine 0.5% (10mg)|Bupivacaine 0.5% for spinal anesthesia
2884595|NCT03356886|Experimental|Spinal Manipulative Technique (SMT)|This protocol of combined manipulation and mobilization techniques was adopted in view of the previous findings of a systematic review in which the combination of thrust mobilization and non-thrust techniques showed greater (moderate) evidence for chronic low back pain when compared to each technique alone (limited evidence). In addition, the thrust manipulation will be administered at the thoracic spine considering that a previous study found no differences in pain intensity after lumbar spine high-velocity manipulation versus non-region-specific manipulation in patients with chronic low back pain.
2884596|NCT03356886|Active Comparator|SMT + Pain Neuroscience Education|Content: 1) Contextualization on the importance of the program; 2) Initial concepts on neuroscience and pain, 3) How context can influence pain perception; 5) human beings as a multisensory complex; 6) Pain and memory; 7) Nociception and nociceptors; 8) The incorrect concepts on pain; 9) Concepts on pain neurophysiology; 10) Types of sensitization; 11) Descending inhibitory system; 12) The danger message and the brain processing; 13) The sensitized brain and its relationship to chronic pain; 14) The contribution of other systems to pain experience; 15) How bone, muscles and nerves send sensory information all the time; 16) Fear avoidance model revisited; 17) Encouragement to change; 18) How to develop positive attitudes and 19) Concepts of gradual exposition and gradual activity
2884597|NCT03356873|Experimental|Active|Vitamin D 5000 units capsules, 20 capsules per week during four weeks (total 400,000 units)
2884598|NCT03356873|Placebo Comparator|Placebo|Identical placebo capsules, 20 capsules per week during four weeks
2884599|NCT03356860|Experimental|Durvalumab|"Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.~Durvalumab will be administered at 1500 mg IV at week 14 and week 18."
2884600|NCT03356860|Active Comparator|Standard|Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.
2884601|NCT03356847|Experimental|SISA implant|
2884602|NCT03356834|Experimental|TDF switch to TAF|Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Tenofovir Alafenamide(TAF) 25mg daily
2884603|NCT03356834|Active Comparator|Maintaining on TDF|Maintaining on Tenofovir Disoproxil Fumarate(TDF) 300mg daily
2884604|NCT03356821|Experimental|Mesenchymal Stem Cells|All (near-)term newborns ≥36 weeks of gestation with or without clinical symptoms of PAIS but with a magnetic resonance imaging (MRI) confirmed PAIS (in the Middle Cerebral Artery region) will be eligible for this study. Following written parental consent, 10 patients will be included in our study.
2884605|NCT03356808|Experimental|Lung cancer-specific T cells|Peripheral blood mononuclear cells (PBMCs) of patients, who have cancer antigen identified lung cancer, will be obtained through apheresis, and T cells will be activated and ex vivo engineered.
2884606|NCT03356795|Experimental|Cervical cancer-specific CAR-T cells|Peripheral blood mononuclear cells (PBMCs) of patients who have GD2, PSMA, Muc1 or Mesothelin positive cervical cancer will be obtained through apheresis, and T cells will be activated and modified to cervical cancer-specific CAR-T cells.
2884607|NCT03356782|Experimental|Sarcoma-specific CAR-T cells|Peripheral blood mononuclear cells (PBMCs) of patients who have CD133, GD2, Muc1, CD117 or other marker positive sarcoma will be obtained through apheresis, and T cells will be activated and modified to sarcoma-specific CAR-T cells.
2884608|NCT03356769|Experimental|experimental：asprin & AEDS|Aspirin 5mg/kg，maximum 300mg; once a day plus AEDS
2884609|NCT03356769|Placebo Comparator|control: placebo & AEDS|placebo 5mg/kg，maximum 300mg; once a day plus AEDS
2884610|NCT03356756||PET MRI exam|simultaneous combined 18F-FDG PET and cardiac MRI imaging (PET MRI) performed immediately after the PET CT exam.
2884611|NCT03356743|Experimental|Ex-Vivo|
2884612|NCT03356730|Experimental|Arm vitamin D|Vitamin D 5.000 IU a day for 2 months (10 drops after lunch)
2884613|NCT03356730|Placebo Comparator|Arm placebo|Placebo for 2 months (10 drops after lunch)
2884614|NCT03356717|Experimental|educational intervention - observer tool|"Participants in this arm will be given the observer tool (OT) before the scenario and will be explained how to use it, i.e. observe all details of the scenario on the screen and tick on the OT all actions which are done by active participants.The observer tool will also be used to engage observers during the debriefing session.~The scenario will then be observed in a screen (i.e. the scenario is played by active participants in an adjacent room using direct video-recording and transmission."
2884615|NCT03356717|Active Comparator|without observer tool|Participants in this arm will not be given the observer tool (OT) before the scenario but will be asked to observe all details of the scenario on the screen.The observers will also be asked to participate during the debriefing session.
2884616|NCT03356704||General anaesthesia|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had general anesthesia
2884617|NCT03356704||continued spinal anesthesia|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had continued spinal anesthesia
2884618|NCT03356704||peripheral nerve blocks|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had peripheral nerve blocks
2884619|NCT03356691|No Intervention|Control group|No intervention.
2884620|NCT03356691|Experimental|Complementary Spiritist Therapy|"Prayer, Spirit education, Spiritist passe and magnetized water"
2884621|NCT03356691|Other|Prayer|Prayer during 1-2 minutes
2884622|NCT03356691|Other|"Spiritist passe"|"Spiritist passe during 5-10 minutes."
2884623|NCT03356691|Placebo Comparator|Laying on of hands with intent to heal|laying on of hands with intent to heal during 5-10 minutes.
2884624|NCT03356691|Other|Fluid water or magnetized water|Spiritist healers laying on of hands hands on the glass of water and desire health, restoration of balance and health for the patient.
2884627|NCT03356652|Experimental|Tailor-made CRT delivery|Patient undergoes acute noninvasive electrical dyssynchrony study with various CRT configurations. CRT device is then implanted with optimal configuration.
2884628|NCT03356639|Experimental|ASP6981 low dose, then matching Placebo|Participants in Sequence AB will first receive ASP6981 capsules orally (low dose) during period 1. After a 14 day washout period, participants receive matching placebo during period 2. Participants will receive ASP6981 capsules or matching placebo capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, ASP6981 or matching placebo will be administered under fasting conditions.
2884629|NCT03356639|Experimental|Matching Placebo, then ASP6981 low dose|Participants in Sequence BA will first receive matching placebo capsules orally during period 1. After a 14 day washout period, participants receive ASP6981 capsules (low dose) during period 2. Participants will receive matching placebo or ASP6981 capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, matching placebo or ASP6981 will be administered under fasting conditions.
2884630|NCT03356639|Experimental|ASP6981 high dose, then matching Placebo|Participants in Sequence CD will first receive ASP6981 capsules orally (high dose) during period 1. After a 14 day washout period, participants receive matching placebo during period 2. Participants will receive ASP6981 capsules or matching placebo every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, ASP6981 or matching placebo will be administered under fasting conditions.
2884631|NCT03356639|Experimental|Matching Placebo, then ASP6981 high dose|Participants in Sequence DC will first receive matching placebo capsules orally during period 1. After a 14 day washout period, participants receive ASP6981 (high dose) during period 2. Participants will receive matching placebo or ASP6981 capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, matching placebo or ASP6981 will be administered under fasting conditions.
2884632|NCT03356626|Experimental|ULTRACISION Harmonic Scalpel|Patients group randomized to use ULTRACISION Harmonic Scalpel when receives laparoscopic gastrectomy
2884633|NCT03356626|Experimental|Ligasure Maryland|Patients group randomized to use Ligasure Maryland when receives laparoscopic gastrectomy
2884634|NCT03356626|Experimental|Thunderbeat|Patients group randomized to use Thunderbeat when receives laparoscopic gastrectomy
2884635|NCT03356613||focus group of paramedical staff from Nancy|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
2884636|NCT03356613||focus group of paramedical staff from Metz|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
2884637|NCT03356613||focus group of paramedical staff from Dijon|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
2884638|NCT03356613||focus group of paramedical staff from Bar-le-Duc|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
2884639|NCT03356613||Test of the tool by paramedical staff center 1|Paramedical staff who didn't participate to the focus group, will test the GenI tool to generate research ideas.
2884640|NCT03356613||Test of the tool by paramedical staff center 2|Paramedical staff who didn't participate to the focus group, will test the GenI tool to generate research ideas.
2884641|NCT03356600|Experimental|Apatinib plus radiotherapy|"Apatinib:~Within 1 week before radiotherapy, the dose of Apatinib were 500mg/daily .During radiotherapy,the dose of Apatinib were 250mg/daily.~After radiotherapy, if the subject did not have a level 3 or above adverse reaction, investigators consider increasing doses to 500mg.~Radiotherapy:~The subjects with 1 to 4 metastases receive stereotactic radiosurgery or stereotactic radiation therapy ,and the subjects with more than 4 metastases receive stereotactic radiosurgery plus whole-brain radiation therapy."
2884642|NCT03356587|Experimental|Arm4: Abemaciclib|Abemaciclib represents a selective and potent small molecule CDK4 and CDK6 dual inhibitor with broad antitumor activity in preclinical pharmacology models.(oral class) Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day
2884643|NCT03356561|Experimental|Group 1: Ad26.ZIKV.001 5*10^10 Viral Particles (vp)|Participants will receive Ad26.ZIKV.001 at 5*10^10 viral particles (vp) via intramuscular (IM) route on Days 1 and 57.
2884644|NCT03356561|Experimental|Group 2: Ad26.ZIKV.001 5*10^10 vp and Placebo|Participants will receive Ad26.ZIKV.001 5*10^10 vp on Day 1 and placebo on Day 57 via IM route.
2884645|NCT03356561|Experimental|Group 3: Ad26.ZIKV.001 1*10^11 vp|Participants will receive Ad26.ZIKV.001 at 1*10^11 vp via IM route on Days 1 and 57.
2884646|NCT03356561|Experimental|Group 4: Ad26.ZIKV.001 1*10^11 vp and Placebo|Participants will receive Ad26.ZIKV.001 1*10^11 vp on Day 1 and placebo on Day 57 via IM route.
2884647|NCT03356561|Placebo Comparator|Group 5: Placebo|Participants will receive placebo via IM route on Days 1 and 57.
2884648|NCT03356509|Experimental|Exercise|They will do a 26-min bout of high intensity interval exercise.
2884649|NCT03356509|No Intervention|No exercise|They will sit quietly for 26 minutes without access to electronic devices or reading materials.
2884650|NCT03356496|Experimental|Intervention|Patient provided with instructions and video for the use of oscillating positive expiratory pressure (OPEP) device. Patient instructed to use OPEP device set at the median resistance at least 4 times daily for at least 20 breathing cycles for 1-3 weeks before surgery. Patient instructed to record usage and any physical complaints in a diary.
2884651|NCT03356496|No Intervention|Control|Patient receives only usual care as provided by perioperative healthcare providers.
2884652|NCT03356483|Experimental|Psilocybin|Psilocybin (0.25mg/kg)
2884653|NCT03356483|Placebo Comparator|Niacin|Niacin (250mg)
2884654|NCT03356470||FLT/PET + biopsy|F-FDG and FLT PET/CT imaging will be obtained prior to anti-cancer treatment and 10-12 weeks after starting treatment with anti-PD-1 antibody.
2884686|NCT03356223|Experimental|Abemaciclib|
2884687|NCT03356210|No Intervention|Treatment as usual (TAU)|This control group will receive treatment as usual; conventional counseling
2884688|NCT03356210|Experimental|Neurofeedback + TAU|20 sessions of symptom-based NF training in conjunction with traditional therapy
2884655|NCT03356457|Active Comparator|DCA in T1DM with severe hypoglycemia|12 T1DM subjects (C-peptide negative, HbA1c <7.5%) with a history of severe hypoglycemia and hypoglycemia unawareness as assessed by the Guy's and Thomas' Minimally Modified Clarke Hypoglycemia Survey, the Gold Score and the Edinburgh Hypoglycemia Survey and as evidenced by interview and glucose log and/or continuous glucose monitoring will receive a single dose of 12.5mg/kg dichloroacetate (DCA).
2884656|NCT03356457|Placebo Comparator|Placebo in T1DM with severe hypoglycemia|12 T1DM subjects (C-peptide negative, HbA1c <7.5%) with a history of severe hypoglycemia and hypoglycemia unawareness as assessed by the Guy's and Thomas' Minimally Modified Clarke Hypoglycemia Survey, the Gold Score and the Edinburgh Hypoglycemia Survey and as evidenced by interview and glucose log and/or continuous glucose monitoring will receive a placebo oral capsule.
2884657|NCT03356457|Active Comparator|DCA in healthy control subjects|12 non-diabetic healthy subjects (fasting plasma glucose < 100 mg/dL, HbA1c < 6.0%), who are matched for age, gender, and weight to T1DM subjects, to serve as controls for the study. Each subject will receive a single dose of 12.5mg/kg dichloroacetate (DCA).
2884658|NCT03356457|Placebo Comparator|Placebo in healthy control subjects|12 non-diabetic healthy subjects (fasting plasma glucose < 100 mg/dL, HbA1c < 6.0%), who are matched for age, gender, and weight to T1DM subjects, to serve as controls for the study will receive a placebo oral capsule.
2884659|NCT03356444|Experimental|Abiraterone group|Abiraterone acetate is administered in this arm.
2884660|NCT03356444|Active Comparator|Docetaxel group|Docetaxel is administered in this arm.
2884661|NCT03356431|Experimental|Supervised group exercise|The supervised exercise group will receive a lower extremity exercise treatment, under physiotherapist supervision for 60 min, two times a week (12 sessions).
2884662|NCT03356431|Experimental|Home-based exercise|"For the home-based exercise group, exercises will be demonstrated to the patient with the supervision and guidance of a physiotherapist in an exercise session. These patients will perform the same exercise protocol at home at least twice a week.~In addition to the initial session, subjects will perform further two supervised sessions (at one week and four weeks after the initial session).~The exercise program are the same as the supervised group exercise."
2884663|NCT03356418|Experimental|WBV exercise group|Subjects will perform an isometric semi-squat exercise associated with the vibratory platform. The exercise will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will be connected at the beginning of each series, set at a vibration frequency of 40 Hertz (Hz) and peak-to-peak amplitude of 4 millimeters (mm) resulting in a peak acceleration of 128 ms2 (12.8 g). This should provide the equivalent of 3600 vertical vibrations, totaling 14400 vibrations per training session
2884664|NCT03356418|Sham Comparator|Sham WBV exercise group|Subjects will perform an isometric semi-squat exercise associated with the vibratory platform. The exercise will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
2884665|NCT03356392||stroke patients|acute stroke patients treated with endovascular treatment combined with thrombolysis or without previous thrombolysis Intervention: telephone call on day 90 to assess the primary outcome (mRs d90)
2884666|NCT03356379|Experimental|Patients|Patients suspected of PES will have a transcutaneous oximetry test during tiptoeing
2884667|NCT03356379|Sham Comparator|Controls|Healthy asymptomatic athletes will have a transcutaneous oximetry test during tiptoeing
2884668|NCT03356366|Experimental|Principal study|Patients pathological process will be assessed using MRI 3T
2884669|NCT03356366|Experimental|Ancillary study 1|Patients pathological process will be assessed using MRI 1,5T
2884670|NCT03356366|Experimental|Ancillary study 2|Patients pathological process will be assessed using MRI 7T
2884671|NCT03356353|Experimental|sildenafil citrate|Following enrolment, participants will be given an initial dose of sildenafil 20 mg. If tolerated, a schedule of 20 mg three times daily (tid) will be initiated. Dosage will be titrated over 3-4 days to the target dose of 40 mg tid. If the initial dose is not tolerated, the participant will be exited from the trial.
2884672|NCT03356327|Experimental|Group 1|Group 1 consisting of 30 children treated with Actitan F and standard oral rehydration (SOR)
2884673|NCT03356327|Active Comparator|Group 2|Group 2 consisting of 30 children who received only SOR.
2884674|NCT03356301|Experimental|Triathletes|Every triathlete will realize three cardiac MRI exams.The second of those will be done at the fitness peak, 2-3 weeks before the main objective of the sports season. Training will be increased between the study beginning and the first MRI, and the second exam. After each cardiac MRI, an applanation tonometry examination will aslo be performed.
2884675|NCT03356301|Experimental|Controls|Every control subject will also realize three cardiac MRI exams if possible at the same time as the triathletes.They must be not engaged in physical activity more than 150 minutes a week on average. After each cardiac MRI, an applanation tonometry examination will aslo be performed.
2884676|NCT03356288||Asthma|20 Participants with moderate to severe asthma, as defined by British Thoracic Society (BTS) guidelines
2884677|NCT03356288||Chronic heart failure|10 Participants with a diagnosis of chronic heart failure
2884678|NCT03356288||Breathing Pattern Disorder|10 Participants with a diagnosis of Breathing Pattern Disorder
2884679|NCT03356288||Pneumonia|10 participants with a radiologically confirmed diagnosis of pneumonia
2884680|NCT03356288||Motor Neurone Disease|10 participants with a diagnosis of motor neurone disease with known hypercapnic failure.
2884681|NCT03356288||Healthy|10 Participants who have no known lung, cardiac or neuromuscular condition.
2884682|NCT03356275|Experimental|Mobile application|Psychosocial support for parents, including: brief audio mindfulness recordings, videos, and psychoeducational materials.
2884683|NCT03356249||Sepsis Group|Patients (n=500) with suspected or proven sepsis or septic shock (according to the Sepsis-3 definitions).
2884684|NCT03356236||Observation group 1|All treatments of patients after Local Ablation are prescribed by a physician on the basis of usual clinical practice.Patients who maybe receive Huaier Granule are as observation group 1
2884685|NCT03356236||Observation group 2|All treatments of patients after Local Ablation are prescribed by a physician on the basis of usual clinical practice.Patients who maybe not receive Huaier Granule are as observation group 2
2884689|NCT03356171|Experimental|Cardiac Coherence|Patients participate to Adapted physical activity sessions and to cardiac coherence sessions
2884690|NCT03356171|Active Comparator|Adapted Physical Activity|Patients only participate to Adapted physical activity sessions
2884691|NCT03356158|Experimental|CPGJ 602 low dose|Part 1: CPGJ602, IV over 2 hours, 100 mg/m2 X 1;
2884692|NCT03356158|Experimental|CPGJ 602 normal dose|Part 1: CPGJ602, IV over 2 hours, 400 mg/m2 X 1; Part 2: CPGJ602, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time;
2884693|NCT03356158|Active Comparator|Cetuximab normal dose|Part 1: Cetuximab, IV over 2 hours, 400 mg/m2 X 1. Part 2: Cetuximab, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time.
2884694|NCT03356145|Experimental|12 mL arm|"Intervention:~Syringe loaded with 12 mL of 1% lidocaine (120 mg); 22-gauge spinal needle~2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix~The tenaculum is immediately placed at the previously injected site~The remaining 10 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)~No wait time between injection and dilator insertion"
2884695|NCT03356145|Active Comparator|20 mL arm|"Intervention:~Syringe loaded with 20 mL of 1% lidocaine (120 mg); 22-gauge spinal needle~2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix~The tenaculum is immediately placed at the previously injected site~The remaining 18 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)~No wait time between injection and dilator insertion"
2884696|NCT03356132||Textured Group|Women undergoing primary breast augmentation with Silimed® Textured Silicone Gel-Filled Breast Implant.
2884697|NCT03356132||Polyurethane Group|Women undergoing primary breast augmentation with Silimed® Polyurethane Foam Covered Silicone Gel-Filled Breast Implant
2884698|NCT03356119|Experimental|RemovAid arm|New IMD Subjects with contraceptive implants to be removed, are subjected to the novel device by personnel skilled in traditional removal.
2884699|NCT03356106|Experimental|CPAP|Nocturnal administration of continuous positive airway pressure treatment (CPAP) until delivery
2884700|NCT03356106|No Intervention|Control|Usual antenatal care for high risk pregnancy
2884701|NCT03356093||Patients with head and neck cancer|No intervention was provided. The patients were only asked to complete a set of questionnaire at baseline, and week 1, 2, 3, 4, 5 and 6 after starting of postoperative radiotherapy.
2884702|NCT03356080|Experimental|DLAAG|"All patients receive 1-2 cycles of induction chemotherapy,that is DLAAG,which is expected to be 6 weeks/cycle,including decitabine,cytarabine, all-transretinoic acid,and Granulocyte Colony-Stimulating Factor(G-CSF).~patients with CR after the first course of induction therapy (DLAAG) will continue to receive 1 cycle of consolidation therapy, while those with therapy failure will continue the second course of induction therapy. If CR is not achieved, quit the study.~Patients who achieve CR after induction therapy will be in accordance with the guidelines, such as the proposed active treatment of allogeneic hematopoietic stem cell transplantation"
2884703|NCT03356067|Sham Comparator|Esophago-gastro-duodenoscopy|Standard endoscopic examination of the upper GI tract with flexible endoscope.
2884704|NCT03356067|Experimental|Gastric endoscopic peroral pyloromyotomy|Experimental per-oral endoscopic myotomy of the pyloric sphincter
2884705|NCT03356054|Experimental|Brentuximab vedotin-R-DHAP|Brentuximab vedotin added to R-DHAP
2884706|NCT03356041|Active Comparator|Intervention Group|The intervention group will receive the three months' lifestyle modification program by a clinical pharmacist.
2884707|NCT03356041|No Intervention|Usual care Group|The usual care group will be provided the standard medical services
2884708|NCT03356028|Other|impacted by the attack of 14 July 2016|characterize the psycho-social factors of risk and / or protection interfering in the children's future with questionnaire following the mass trauma of 14 July 2016 in Nice on a sample of exposed pediatric population
2884709|NCT03356028|Other|control group|characterize the psycho-social factors of risk and / or protection interfering in the children's future with questionnaire of children controls
2884710|NCT03356015|Experimental|4L Polyethylene Glycol|4L-group received 4 bags of PEG and were instructed to drink 2L at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes, and to drink the remaining 2L 4 to 6 h before colonoscopy at the same rate.
2884711|NCT03356015|Active Comparator|3L Polyethylene Glycol|3L-group received 3 bags of PEG and were instructed to drink 1L at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes, and to drink the remaining 2L 4 to 6 h before colonoscopy at the same rate.
2884712|NCT03356002|Active Comparator|High risk subjects|"Each subject will ingest the C-Scan System capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~Subjects to be enrolled in this study are indicated and scheduled to undergo optical colonoscopy based on the following symptoms or by being classified as higher than average risk based on one or more of the following:~c. Surveillance - Significant findings in previous optical colonoscopy d. Diagnostic - Polyps detected in virtual colonoscopy referred for polypectomy e. Diagnostic - Polyps detected in previous optical colonoscopy (community setting) referred for polypectomy f. Diagnostic - Positive FIT test g. Diagnostic - one or more of the typical symptoms:"
2884713|NCT03356002|Experimental|Average risk|"Each subject will ingest the C-Scan System capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~Average risk based on their age and demographics referred for screening for polyps."
2884714|NCT03355989|Experimental|Low Flat Rate without Lottery|The intervention consists of receiving a small cash incentive of $0.80 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
2884715|NCT03355989|Experimental|Low Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a small cash incentive of $4.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
2884716|NCT03355989|Experimental|Low Sharp Rate without Lottery|The intervention consists of receiving a small cash incentive of $0.75 on the BCG/Penta-1/Penta-2 vaccine and $1.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
2884717|NCT03355989|Experimental|Low Sharp Rate with Lottery|The intervention consists of a 20% chance of receiving a small cash incentive of $3.75 on the BCG/Penta-1/Penta-2 vaccine and $5.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
2884718|NCT03355989|Experimental|High Flat Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.40 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
2884719|NCT03355989|Experimental|High Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $12.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
2884720|NCT03355989|Experimental|High Sharp Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.25 on the BCG/Penta-1/Penta-2 vaccine and $3.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
2884721|NCT03355989|Experimental|High Sharp Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $11.25 on the BCG/Penta-1/Penta-2 vaccine and $15.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
2884722|NCT03355989|Experimental|Easypaisa Flat Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.40 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile money transfer i.e. easypaisa
2884723|NCT03355989|Experimental|Easypaisa Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $12.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile money transfer i.e. easypaisa
2884724|NCT03355989|Experimental|SMS Reminder Only|The intervention consists of only sending 3 SMS reminders before, at and after the due date.
2884725|NCT03355989|No Intervention|Control|No intervention will be provided either in the form of cash incentive or reminder SMS. Vaccination facilities will be provided as per usual.
2884726|NCT03355976|Experimental|Arm 1 Nivolumab Ovarian|Nivolumab 240 mg Day 1 Cycle = 2 weeks
2884727|NCT03355976|Experimental|Arm 2 Nivolumab and Ipilimumab Ovarian|Nivolumab 240 mg every 2 weeks Ipilimumab 1mg/kg day 1 Cycle=6 weeks
2884728|NCT03355976|Experimental|Arm 1 Nivolumab Extra-renal|Nivolumab 240 mg Day 1 Cycle = 2 weeks
2884729|NCT03355976|Experimental|Arm 2 Nivolumab and Ipilimumab Extra-renal|Nivolumab 240 mg every 2 weeks Ipilimumab 1mg/kg day 1 Cycle=6 weeks
2884730|NCT03355963|Placebo Comparator|Group A|The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
2884731|NCT03355963|Active Comparator|Group B|The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
2884732|NCT03355963|Active Comparator|Group C|"The treatment group C:~intervention: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test."
2884733|NCT03355950|Active Comparator|TEP group|Patients who undergo totally extraperitoneal hernia repair, TEP Repair.
2884734|NCT03355950|Active Comparator|Lichtenstein group|Patients who undergo Lichtenstein repair.
2884735|NCT03355937|Active Comparator|UEI Sperm Chip (-)|Conventional IVF treatment and using conventional sperm selection
2884736|NCT03355937|Experimental|UEI Sperm Chip (+)|Conventional IVF treatment and using sperm chip for sperm selection
2884737|NCT03355937|Active Comparator|RIF sperm chip (-)|Conventional IVF treatment and using conventional sperm selection
2884738|NCT03355937|Experimental|RIF sperm chip (+)|Conventional IVF treatment and using sperm chip for sperm selection
2884739|NCT03355872|Experimental|HLX01|
2884740|NCT03355872|Active Comparator|Rituximab|
2884741|NCT03355859|Experimental|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 4 CAR T dosage will be tested in this study: 1×10^7, 2.5×10^7, 5×10^7, 1×10^8 CAR+ T cells.
2884742|NCT03355846|Experimental|AAF treated with Centella® Complex|Centella® Complex 1 cps 60 mg per os
2884743|NCT03355846|Experimental|AAF treated with Proctocella® cream|Proctocella® Complex cream to be applied in anal area and anal canal
2884744|NCT03355846|Experimental|AAF treated with Flavonil® cps|Flavonil® 1 cps 300 mg per os
2884745|NCT03355846|Experimental|AAF treated with Flavonil® Cream|Flavonil® Cream Cream to be applied in anal region and anal canal
2884746|NCT03355846|Experimental|AAF treated with Rectalgan Mousse|Rectalgan Mousse cleansing cleanser for anal and perineal region
2884747|NCT03355820|Experimental|HPV Group|Healthy Chinese female subjects, including and above 17 years of age at the time of enrollment, who received all three doses of the HPV-16/18 vaccine in the HPV-058 study.
2884748|NCT03355807|Experimental|Group MgSO4|The magnesium group (group Mg, n _ 40) received an additional infusion of MgSO4 (30 mg/kg by bolus and 10 mg/kg/h by infusion for 24 hours)
2884749|NCT03355807|No Intervention|Group Control|the control group (group C, n _ 40) received the same amount of IV saline
2884750|NCT03355794|Experimental|Dose level 1 (starting dose level) (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 300mg daily (DIPG only); </=21 yrs of age 120 mg/m2/day) Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; dose calculation age dependent (>21yrs 2.5mg/day (DIPG only); </=21yr 1.2 mg/m2/day) BSA >/=0.75m2
2884751|NCT03355794|Experimental|Dose level 2 (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 170 mg/m2/day Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 1.2 mg/m2/day BSA >/=0.45m2
2884752|NCT03355794|Experimental|Dose level 3 (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 170 mg/m2/day Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 1.5 mg/m2/day BSA >/=0.45m2
2884753|NCT03355794|Experimental|Dose level 1 (DIPG participants > 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 300mg daily Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 2.5mg/day
2884754|NCT03355781||Schizophrenic patients|Patients will have clinical psychiatric evaluation, brain imaging and blood sample
2884926|NCT03354572|Placebo Comparator|placebo|receive only NaCl 0.9% prior to surgery (volume identical to active comparator)
2884755|NCT03355781||Related volunteers (first degree relative of patient)|Related volunteers will have clinical psychiatric evaluation, brain imaging and blood sample
2884756|NCT03355781||Healthy volunteers|Healthy volunteers will have clinical psychiatric evaluation, brain imaging and blood sample
2884757|NCT03355768|Experimental|Romidepsin Arm|Control Arm: Subjects will receive Romidepsin 14 mg/m2 on Days 1, 8, 15.
2884758|NCT03355768|Experimental|Romidepsin + Pralatrexate Combination Arm|Combination Arm: Subjects will receive Romidepsin 12 mg/m2 and Pralatrexate 25 mg/m2.
2884759|NCT03355755|Experimental|Interventional Group|All participants will be included in the interventional group. Intervention will consist of walking exercise using the EksoGT exoskeleton for supported walking, running SmartAssist software.
2884760|NCT03355742|Experimental|XIENCE|XIENCE + Short duration (1 month) of DAPT
2884761|NCT03355716|Placebo Comparator|Group A (placebo):|instillation of bupivacaine alone: Bupivacaine 25 ml (0.25%) after surgery completion
2884762|NCT03355716|Active Comparator|Group B|Instillation of bupivacaine and morphine: Bupivacaine 25 ml (0.25%) + Morphine (3.0 mg)
2884763|NCT03355716|Active Comparator|Group C|Instillation of bupivacaine and fentanyl: Bupivacaine25 ml (0.25%) + fentanyl (30.0 Mc)
2884764|NCT03355716|Active Comparator|Group D|Instillation of bupivacaine and Ketamine: Bupivacaine25 ml (0.25%) + ketamine (0.5 mg/kg).
2884765|NCT03355690||Stroke patients|Stroke patients are treated according to the clinical practice which can be divided into: anti-aggregation, thrombectomy and/or thrombolysis
2884766|NCT03355677|Active Comparator|Case finding clinics|The visit will be a minimum 90 minutes long at the participants own GP surgery. This will include a respiratory assessment including spirometry will performed by a RT Respiratory Nurse Specialist (RNS) and where possible a Practice Nurse or Nurse Practitioner will attend. The visit will consist of objective measurements, investigations and questionnaires
2884767|NCT03355677|Placebo Comparator|Case finding Usual care|In the control arm of the study, practices will continue with usual care according to national guidance for case finding for COPD (NICE, 2010). Matched practices will have their eligible population identified through electronic searches based on data routinely recorded in primary care run in the HHRa. Case finding yield will be measured as the percentage of patients from the eligible population identified with a respiratory diagnosis in the 12 months from study beginning to study end.
2884768|NCT03355677|Active Comparator|At Risk Case clinics|The complex case clinic will be a minimum 120 minute appointment at the participants own GP surgery. The intervention will include an initial assessment by a RT Respiratory Nurse Specialist (RNS) and followed by a joint assessment by a respiratory physician (RP) working alongside a practice clinician (GP and/or Practice Nurse/Nurse Practitioner). The visit will consist of objective measurements, investigations and questionnaires as outlined in section 3 below. A personalised disease management and action plan will be agreed jointly between the RT, practice clinician and participant. The practice clinician will undertake the necessary tasks required for the agreed management plan. The clinical responsibility for the participant will remain with the GP practice.
2884769|NCT03355677|Placebo Comparator|At Risk Usual Care|In the control arm of the study, practices will continue with usual care according to national guidance for the management of COPD and asthma . A cohort of patients matched for practice and for age, sex, disease condition and, where possible, disease control will be identified. This cohort will be monitored against markers of sub-optimal disease (medication usage, exacerbations, unscheduled visits to the practice, attendance or admission to hospital).
2884770|NCT03355664|Active Comparator|ACT|Artemether-lumefantrine for 3 days plus primaquine at hour 24
2884771|NCT03355664|Experimental|TACT|Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days plus primaquine at hour 24
2884772|NCT03355651|Active Comparator|PROGEN Group|PROGEN + Standard Rehabilitation + ACL reconstruction
2884773|NCT03355651|No Intervention|Control Group|Standard Rehabilitation + ACL reconstruction
2884774|NCT03355638|Active Comparator|aflibercept monotherapy|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata
2884775|NCT03355638|Experimental|aflibercept plus pranoprofen|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients also self- administered one drop of pranoprofen (Pranoflog; Sifi SpA, Aci Sant'Antonio, CT, Italy) three times a day for 12 months. All patients were followed up for 12 months.
2884776|NCT03355638|Experimental|aflibercept plus nutraceutical|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients were given daily tablets of Omega-3 supplementation (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).
2884777|NCT03355612|Experimental|experimental group|Drug:Apatinib with XELOX(Capecitabine and Oxaliplatin)
2884778|NCT03355612|Active Comparator|active comparator|Drug:XELOX(Capecitabine and Oxaliplatin)
2884779|NCT03355599|Other|3d camera|3d camera
2884780|NCT03355586||Suspected lung cancer|"Patients referred as part of a first diagnostic evaluation of newly detected pulmonary lesion(s) or when an indication for an invasive diagnostic procedure is found during follow-up of earlier detected pulmonary lesion.~Patients identified during per protocol CT imaging follow-up of known lesions when growth of the lesion is found and an indication for biopsy is determined by the treating physician and/or multidisciplinary board.~Patients identified when referred for surgical biopsy in case of nodule location inaccessible for CT-guided TTNA.~These will be subjected to a combined approach of modalities with the main intervention being electromagnetic navigation."
2884781|NCT03355573|Experimental|Bimekizumab|Subjects will receive bimekizumab up to 4 years.
2884782|NCT03355560|Experimental|Nivolumab|Nivolumab starting 4-11 weeks after surgery for 12 doses.
2884783|NCT03355547||no URI (upper respiratory tract infection) symptoms|Patients without upper respiratory tract infection symptoms
2884784|NCT03355547||URI (upper respiratory tract infection) symptoms|Patients with upper respiratory tract infection symptoms
2884785|NCT03355534|Experimental|nasal dexmedetomidine|dexmedetomidine is given nasally, saline is given intravenously
2884786|NCT03355534|Experimental|intravenous dexmedetomidine|saline is given nasally, dexmedetomidine is given intravenously
2884787|NCT03355534|Placebo Comparator|normal saline|saline is given nasally and intravenously
2917630|NCT03126422|Experimental|Dexmedetomidine 0.09 μg/kg/min|
2884788|NCT03355521|Experimental|Nordic walking Experimental|Experimental: Nordic walking Training The total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Nordic walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (NW); (c) return to the calm and ultimate stretching.
2884789|NCT03355521|Active Comparator|Free walking|Free walking Training The total period of training was composed by 9-week of walking without poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
2884790|NCT03355508|Other|puncture bevel up|
2884791|NCT03355508|Other|puncture bevel domn|
2884792|NCT03355495|No Intervention|Left Lateral Decubitus Position|Gold standard positioning for colonoscopy
2884793|NCT03355495|Active Comparator|Right Lateral Decubitus Position|Comparing positioning in Right Lateral Decubitus (intervention) for visualization in colonoscopy to the gold standard of Left Lateral Decubitus.
2884794|NCT03355482|Active Comparator|Depomedrol arm|Patients are treated with new or ascending doses of subcutaneous methotrexate, and receive a single intramuscular dose of Depomedrol (160mg) at baseline.
2884795|NCT03355482|Sham Comparator|Placebo arm|Patients are treated with new or ascending doses methotrexate, and receive a single intramuscular placebo injection at baseline.
2884796|NCT03355469|Placebo Comparator|LoEx+placebo|Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions and receive placebo.
2884797|NCT03355469|Placebo Comparator|HiEx+placebo|Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions and receive placebo.
2884798|NCT03355469|Active Comparator|LoEx+metformin|If subjects are assigned to this group they will participate in the same LoEx exercise program as outlined above. But, here they will be provided metformin. Metformin is a common medication routinely used to treat high blood sugar and has secondary effects on vascular health. Subjects will not be able to find out if you are on metformin until the study is done. If their doctor needs to know, the people doing this study can find out.
2884799|NCT03355469|Active Comparator|HiEx+metformin|If subjects are assigned to this group you will participate in the same HiEx exercise program and receive metformin as outlined above.
2884800|NCT03355456|Active Comparator|Pulmonary vein isolation (PVI) alone|Radiofrequency ablation procedure to isolate pulmonary veins without other intervention performed..
2884801|NCT03355456|Active Comparator|PVI+Total LT Atrial low voltage ablation|"PVI radiofrequency ablation along with ablation of areas of low voltage identified."
2884802|NCT03355456|Active Comparator|PVI + Posterior wall ablation|PVI radiofrequency ablation along with ablation of the posterior wall.
2884803|NCT03355443|Active Comparator|Re-examination Group|Routine intubation is performed. After cecal intubation, the cecum and ascending colon is examined with colonoscope tip in forward direction for the first time. Re-intubation is performed after the first examination of the cecum and ascending colon, and then this region of the large bowel is re-examined in the same fashion. After that, the rest of the colon is examined in routine method.
2884804|NCT03355443|Experimental|Retroflexion Group|Routine intubation is performed. After cecal intubation, the cecum and ascending colon is examined with colonoscope tip in forward direction for the first time. Re-intubation is performed after the first examination of the cecum and ascending colon, and then this region of the large bowel is re-examined with the colonoscope tip in reverse direction (retroflexion fashion). After that, the rest of the colon is examined in routine method.
2884805|NCT03355430||moderate keratoconus group|moderate keratoconus group underwent combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK) and accelerated corneal collagen cross-linking (CXL) after intracorneal ring segment (ICRS) implantation
2884806|NCT03355417|Experimental|OT-SI|Occupational therapy using a sensory integration approach
2884807|NCT03355404|Experimental|"Standing Patient"|
2884808|NCT03355404|No Intervention|"Standardized management in stretcher"|
2884809|NCT03355391||Screening participants|Individuals aged 50 to 65 years who were included in the screening program of Cancer Hospital of Barretos
2884810|NCT03355378|Experimental|study group|gum chewing during spinal anesthesia and early ambulation
2884811|NCT03355378|No Intervention|Control group|no gum chewing
2884812|NCT03355365|Experimental|lumbar puncture with MSC-NP injection|Intrathecal MSC-NP injection
2884813|NCT03355365|Placebo Comparator|lumbar puncture with no injection|Lumbar puncture placebo control
2884814|NCT03355352||Patients treated with conventional i.v. PCA|
2884815|NCT03355352||Patients treated with Zalviso|
2884816|NCT03355339|Experimental|Binasal occlusion|Participants will be fitted with glasses covered with occlusive tape from the inner canthi to the nasal border on each lens.
2884817|NCT03355339|Active Comparator|No binasal occlusion|Participants will be fitted with non-occluded glasses.
2884818|NCT03355326|Experimental|Glycerin Suppository Group|
2884819|NCT03355326|No Intervention|Non-suppository Group|
2884820|NCT03355313|Experimental|Low level light therapy 1|
2884821|NCT03355313|Experimental|Low level light therapy 2|
2884822|NCT03355313|Experimental|Low level light therapy 3|
2884823|NCT03355300|Experimental|Cannabidiol Oral Solution|Cannabidiol Oral solution, dose as assigned in INS-17-103.
2884824|NCT03355287|Placebo Comparator|Traditionally Threshed Teff (TTT)|The control group will consume injera based on teff threshed under the hooves of cattle. We plan to have a certain number of teff flour suppliers, where the teff is traditionally threshed and contains at least 50 mg Fe per 100 g flour.
2884825|NCT03355287|Experimental|Lab Threshed Teff (LTT)|The intervention group will consume injera based on teff flour that has been lab threshed using a modern teff threshing machine.
2884888|NCT03354832||Birth control for foetal death|Same gender child born, and alive, in the same hospital, and born on time (37-41 amenorrhea weeks old).
2920687|NCT03104946||Respiratory Distress Syndrome|
2884826|NCT03355287|Active Comparator|Fortified Lab Threshed Teff (FTT)|This arm will be the positive control group consuming Ferrous Sulphate drops ( with injera that consist of lab-threshed teff. The Fe drops have to be consumed with the meal and will provide an additional 6 mg of Ferrous sulfate to the diet of the children.
2884827|NCT03355274|Experimental|Patients|Patients suspected of thoracic outlet syndrome Transcutaneous oximetry during upper arm manoeuvers
2884828|NCT03355274|Sham Comparator|controls|healthy asymptomatic subjects Transcutaneous oximetry during upper arm manoeuvers
2884829|NCT03355261|Experimental|complete remission (CR) group|According to the RECIST 1.1, 9 patients were allocated into the complete remission (CR) group based on their responses to neoadjuvant chemotherapy (NAC).
2884830|NCT03355261|Experimental|partial remission (PR) group|According to the RECIST 1.1, 18 patients were allocated into the partial remission (PR) group based on their responses to neoadjuvant chemotherapy (NAC).
2884831|NCT03355261|Experimental|stable disease (SD) group|According to the RECIST 1.1, 4 patients were allocated into the stable disease (SD) group based on their responses to neoadjuvant chemotherapy (NAC).
2884832|NCT03355261|Experimental|progressive disease (PD) group|According to the RECIST 1.1, 2 patients were allocated into the progressive disease (PD) group based on their responses to neoadjuvant chemotherapy (NAC).
2884833|NCT03355248|Active Comparator|Control Group - 28|The control group (post-operative cesarean section) will be prescribed 28 Oxycodone Acetaminophen at the time of discharge. Both groups will also be provided with a handout on non-opioid analgesia. The groups will be assigned randomly in blocks. Specifically, the first half of the patients will automatically be placed in the experimental arm and the second half into the control arm of the study
2884834|NCT03355248|Experimental|Experimental - 20|The experimental group (post-operative cesarean section) will be prescribed 20 Oxycodone Acetaminophen at the time of discharge. Both groups will also be provided with a handout on non-opioid analgesia. The groups will be assigned randomly in blocks. Specifically, the first half of the patients will automatically be placed in the experimental arm and the second half into the control arm of the study
2884835|NCT03355235||Cognitive assessment using standardized tools|cognitive assessment using standardized tools pre and post transplant.
2884836|NCT03355222|No Intervention|No Intervention|No intervention: The community receives no chickens and no special education is provided.
2884837|NCT03355222|Experimental|Experimental: providing chickens|"Experimental: Two chickens are given to each family so that eggs are available for children and of eggshell powder for mothers and children.~The community receives these chickens so each designated family has an egg to give to young child. In a subgroup the mother will receive ESP (1000 mg calcium). The community receives information on using egg and has help on caring for chickens."
2884838|NCT03355209|Experimental|ZX008 0.2 and 0.8 mg/kg/day|Part 1: ZX008 is supplied as an oral solution. Subjects will be randomized to receive 1 of 2 doses of ZX008 (0.2 mg/kg/day, 0.8 mg/kg/day or placebo.
2884839|NCT03355209|Placebo Comparator|Matching Placebo|Part 1: Matching ZX008 placebo is supplied as an oral solution.
2884840|NCT03355209|Placebo Comparator|Open-Label|Part 2: ZX008 is supplied as an oral solution. Study medication will be administered twice a day (BID) in equally divided doses.
2884841|NCT03355196|Experimental|LRX712|LRX712 given intra-articularly
2884842|NCT03355196|Placebo Comparator|Placebo|Placebo given intra-articularly
2884843|NCT03355183|Experimental|Healthy athletes|Muscular strength of healthy athletes who are not physically disabled and doing sports for 3 years as a professional will be measured by isokinetic dynamometer.
2884844|NCT03355170|Experimental|Lansoprazole/Domperidone|Patient will be administered lansoprazole/domperidone 30/30 mg capsules (brand name: Duolans) half an hour before breakfast for eight weeks according to randomisation scheme.
2884845|NCT03355170|Active Comparator|Lansoprazole|Patient will be administered lansoprazole 30 mg capsules (brand name: Lasotab) half an hour before breakfast for eight weeks according to randomisation scheme.
2884846|NCT03355157|Experimental|Palbociclib + endocrine therapy|Experimental arm for testing palbociclib + endocrine therapy.
2884847|NCT03355157|Active Comparator|Chemotherapy +/- endocrine maintenance therapy|Chemotherapy +/- endocrine maintenance as comparator arm.
2884848|NCT03355144|Experimental|Internal Medicine residents at NYU|effect of supplying Internal Medicine residents at NYU with free coffee on self reported features of psychological health, energy and burnout
2884849|NCT03355131|Experimental|Adapted NASA's Mission X program|Adapted NASA's Mission X program for the intervention group
2884850|NCT03355131|No Intervention|Mission X Control|no intervention
2884851|NCT03355105|Experimental|Objective adjustment of the MI/E exsuflation pressure|Objective adjustment of the MI/E exsuflation pressure based on the flow-volume curve generated during the cough.
2884852|NCT03355105|Active Comparator|Subjective adjustment of the MI/E exsuflation pressure|Subjective adjustment of the MI/E exsuflation pressure based on the clinical judgment of the therapist and the patient.
2884853|NCT03355092|Experimental|vBloc Therapy + Usual Care for Type 2 Diabetes|
2884854|NCT03355092|No Intervention|Usual Care for Type 2 Diabetes|
2884855|NCT03355079|Experimental|SmofKabiven® E + standard oral nutrition|SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit® will be administered at 5-7 days per week for up to 9 +/-1 weeks in addition to standard of care oral nutrition as per routine dietary counseling, to reach the patient's target energy intake.
2884856|NCT03355079|No Intervention|Standard oral nutrition|The patients will consume standard of care oral nutrition as per routine dietary counseling, to reach their target energy intake.
2884857|NCT03355066|Experimental|Active Treatment|SM08502 tablet, dosed once per day in 28-day cycles, dose determined by dose escalation scheme (10 mg, 20 mg, 40 mg, 60 mg, 80 mg, 120 mg, 160 mg, 200 mg)
2884858|NCT03355053|Active Comparator|Dexmedetomidine (Dex) slow-bolus group|"Study drug will be administered by the patient's nurse. Two 60 mL syringes will be supplied for each patient, containing 50 mL of Dex HCl at 4 ug/ ml Dex HCl or 50 ml normal saline (NS)), depending on randomized assignment. An initial bolus dose will be given over 45 min at 0.33 ml/kg/h (provides 1 mcg/kg/h for Dex patients) at 8PM, followed by continuous overnight infusion at 0.025 ml/kg/h (for Dex patients, provides 0.1 mcg/kg/h), for 7 consecutive nights (or until leaving the ICU), as follows:~1) Dex slow-bolus group: Dex slow bolus at 8PM over 45 min, then overnight NS until 8AM"
2884859|NCT03355053|Active Comparator|Dexmedetomidine (Dex) continuous infusion group|"Study drug will be administered by the patient's nurse. Two 60 mL syringes will be supplied for each patient, containing 50 mL of Dex HCl at 4 ug/ ml Dex HCl or 50 ml normal saline (NS)), depending on randomized assignment. An initial bolus dose will be given over 45 min at 0.33 ml/kg/h (provides 1 mcg/kg/h for Dex patients) at 8PM, followed by continuous overnight infusion at 0.025 ml/kg/h (for Dex patients, provides 0.1 mcg/kg/h), for 7 consecutive nights (or until leaving the ICU), as follows:~2) Dex continuous infusion group: NS slow bolus at 8PM over 45 min, then overnight Dex until 8AM"
2884860|NCT03355053|Placebo Comparator|Usual care + placebo group|"Study drug will be administered by the patient's nurse. Two 60 mL syringes will be supplied for each patient, containing 50 mL of Dex HCl at 4 ug/ ml Dex HCl or 50 ml normal saline (NS)), depending on randomized assignment. An initial bolus dose will be given over 45 min at 0.33 ml/kg/h (provides 1 mcg/kg/h for Dex patients) at 8PM, followed by continuous overnight infusion at 0.025 ml/kg/h (for Dex patients, provides 0.1 mcg/kg/h), for 7 consecutive nights (or until leaving the ICU), as follows:~3) NS slow bolus at 8PM over 45 min, then overnight NS until 8AM"
2884861|NCT03355027|Experimental|Alirocumab Treatment Arm|30 patients with stable cardiovascular disease to receive Alirocumab 150mg & prescribed one of the following: Atorvastatin 40mg/80mg or Simvastatin 80mg or Rosuvastatin 20mg/40mg. Dosing and dispensing to be performed at V3, V4, V5 and V6.
2884862|NCT03355027|Active Comparator|Comparator Treatment Arm|30 patients with stable cardiovascular disease to receive Ezetimibe 10mg & prescribed one of the following: Atorvastatin 40mg/80mg or Simvastatin 80mg or Rosuvastatin 20mg/40mg. Dosing and dispensing to be performed at V3, V4, V5 and V6.
2884863|NCT03355014|Experimental|Gemigliptin+Metformin combination therapy group|"Part I (Fasted) Combination therapy of gemigliptin/metformin sustained release 50/1000mg(25/500mg 2tablets), for 1day~Part II (High fat diet) Combination therapy of gemigliptin/metformin sustained release 50/1000mg(25/500mg 2tablets), for 1day"
2884864|NCT03355014|Experimental|Gemigliptin and Metformin coadministration therapy group|"Part I (Fasted) Coadministration therapy of gemigliptin 50mg and metformin HCL extended relese 1000mg~Part II (High fat diet) Coadministration therapy of gemigliptin 50mg and metformin HCL extended relese 1000mg"
2884865|NCT03355001||Skin Closure|Monosyn® Quick will be used for skin closure for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
2884866|NCT03355001||Urology|Monosyn® Quick will be used in urology for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
2884867|NCT03355001||Gynecology|Monosyn® Quick will be used in gynecology for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
2884868|NCT03354988|Active Comparator|physical exercise group|For the exercise group, Intervention by doing physical exercise. systematic physical activity programs consisting of range-of-motion exercises with gentle compression, extension and flexion of all joints of both bilateral upper extremities; including the shoulder, elbow, and wrist and lower extremities; including the hip, knee and ankle, with a total of 12 joints. Each activity was about 10 min a day and was carried out 5 times per week for 4 weeks. This program was started after 1 week of birth. Physical activity continued until discharge from hospital.
2884869|NCT03354988|Other|Control group|Other routine care activities such as bathing (every day) and kangaroo care (30 minutes/day), will be done for both the control
2884870|NCT03354975|Experimental|Experiential Training|
2884871|NCT03354975|Active Comparator|Training-as-usual|
2884872|NCT03354962|Active Comparator|ARM A|
2884873|NCT03354962|Experimental|ARM B|
2884874|NCT03354949||Positioning hemiplegic.|"Positioning all hemiplegic by stroke requiring a single wheelchair even at the exit of the SSR and hemiplegic patient with sequelae.~Measurement of sitting postural control of the adult (MCPAA). Assessment of wheelchair pain in the spine and ischia by a self-evaluation scale (EVA).~Propulsion speed of a wheelchair."
2884875|NCT03354923|Experimental|immediate intervention group|Immediate PEERS intervention
2884876|NCT03354923|Other|delayed intervention|delayed PEERS intervention to begin after experimental group
2884877|NCT03354910|No Intervention|Usual Care|All enrolled patients will receive Usual Care for transplant candidates at our two centers, which includes individual meetings with transplant providers, attendance at a patient group education session in the transplant center (focused on the specifics of the transplant experience), and a transplant education binder.
2884878|NCT03354910|Active Comparator|Usual Care (UC) + House Calls (HC)|Patients and their invited guests will be scheduled for one House Call. A house call is meeting done at a patient's home with transplant health educators facilitating a discussion on topics related to living kidney donation. Patients and guests also receive an information packet containing several brochures providing information about the living donation process, common concerns and misperceptions, and donation resources and information about our transplant center (e.g., copy of our quarterly newsletter, contact information). Patients in the group will also receive Usual Care, the regular education on living donation, provided as part of their routine transplant care.
2884879|NCT03354910|Experimental|UC + HC + Peer Mentorship|Patients in this condition will receive the Usual Care and the House Calls intervention as described previously. In addition, participants will receive access to a Peer Mentor trained by the National Kidney Foundation following their House Call.
2884880|NCT03354897|Other|Treatment|16 weeks treatment 5mg/day
2884881|NCT03354884|Experimental|Cabozantinib|All subjects will receive open label Cabozantinib 60 mg orally once daily
2884882|NCT03354858||Follicular flushing|One ovary will be aspirated using follicular flushing (up to 5 times per follicle).
2884883|NCT03354858||No flushing|One ovary will be aspirated using direct aspiration (no flushing).
2884884|NCT03354845|No Intervention|Control (usual care) group|In the control group, doctors maintained the usual practice of medication review, altering and discontinuing medications as necessary, without receiving deprescribing recommendations from pharmacists.
2884885|NCT03354845|Other|Deprescribing intervention group|The five-step patient-centred deprescribing process was utilized in the intervention group.
2884886|NCT03354832||Foetal death|In-utero dead foetus weighting at least 500 g or 22-amenorrhea weeks old. In utero death means that death occurs during delivery or per partum
2884887|NCT03354832||New-born death|New-born dead during post-birth hospital stay and at least 23-amenorrhea weeks old.
2920688|NCT03104933||Patients with septic shock|
2884889|NCT03354832||Birth control for new-born death|"Same gender infant born, and alive, in the same hospital, and:~for 23-amenorrhea weeks old new-born death: control new-born are born on time (37-41 amenorrhea weeks old).~for 24 to 31-amenorrhea weeks old new-born death: control new-born are premature infant (24-31 amenorrhea weeks old), and are included when their hospital stay ends.~for 32 and more-amenorrhea weeks old new-born death: control new-born are 32 and more-amenorrhea weeks old infant"
2884890|NCT03354819|Experimental|Modified MBCT|A group-based, 10-week, 7-session modified Mindfulness Based Cognitive Therapy (MBCT) will be adopted in the MBCT intervention group with a group size of 15-20. The program includes different mindfulness activities (such as mindful eating and mindful walking) and peer sharing.
2884891|NCT03354819|Active Comparator|SIRE on dementia|The frequency of the Social Interactions and Routine Education (SIRE) program is the same as that of modified MBCT which consists of seven sessions (weekly for the first four sessions and bi-weekly for the last three sessions) and each session will last about two hours for 10 weeks with group size 15-20.
2884892|NCT03354806|Experimental|Continuous peripheral nerve blocks|Ropivacaine-continous treatment using catheters for continous sciatic nerve blocks
2884893|NCT03354806|Active Comparator|Analgesic treatment|Pharmacological pain management in accordance with WHO's pain relief ladder
2884894|NCT03354793||endometriosis|Survey on first pregnancy after endometriosis diagnosis
2884895|NCT03354793||non endometriosis|Survey on first pregnancy
2884896|NCT03354780||endometriosis|Survey on first pregnancy after endometriosis diagnosis
2884897|NCT03354780||non endometriosis|Survey on first pregnancy
2884898|NCT03354767||Wasting patients|Patients with >10% loss of skeletal muscle one week after major aortic surgery
2884899|NCT03354767||Non-wasting patients|Patients with <10% loss of skeletal muscle one week after major aortic surgery
2884900|NCT03354754|Experimental|LYS228|IV infusion every 6 hours for at least 5 days
2884901|NCT03354754|Active Comparator|Standard of care|IV infusion of standard of care antibiotics for at least 5 days
2884902|NCT03354741|Other|Laser then Sham therapy|2nd cycle of chemotherapy : administration of laser therapy 3th cycle of chemotherapy : administration of a sham laser according to the same modalities
2884903|NCT03354741|Other|Sham therapy then laser|2nd cycle of chemotherapy : administration of a sham laser 3th cycle of chemotherapy : administration of laser therapy according to the same modalities
2884904|NCT03354728|Experimental|Treatment (multi-antigen CMV-modified vaccinia ankara vaccine)|Patients receive multi-antigen CMV-modified vaccinia ankara vaccine IM on days 28 and 56 post-HCT.
2884905|NCT03354715|Sham Comparator|Rapid prototyping Denture base|Complete Denture Using Rapid Prototyping method for fabrication of the complete denture depending on
2884906|NCT03354715|Sham Comparator|Heat Cured Conventional Complete Denture|Complete Denture using heat cured Denture base using flasking and deflasking method
2884907|NCT03354702|Experimental|Group aerobic activity (experimental)|Group aerobic exercise (experimental). Patients perform aerobic exercise per 30 minutes (moderate intensity: 70% to 85% of estimated maximum heart rate), more 10 minutes stretching, once a week monitored and once without monitoring and patients have medical appointment with psychiatrist and make psychotherapy sessions.
2884908|NCT03354702|Active Comparator|Group stretching (control)|Group stretching (control). Patients perform stretching per 30 minutes, once a week monitored and once without monitoring and patients have medical appointment with psychiatrist and make psychotherapy sessions
2884909|NCT03354676||MetS+|Obese group with metabolic syndrome/Data processing from Patient Medical Files
2884910|NCT03354676||MetS-|Obese group without metabolic syndrome/Data processing from Patient Medical Files
2884911|NCT03354663|Experimental|TactiCath SE|Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.
2884912|NCT03354650||complete blood count|blood sample is collected from infant to detect presence of sepsis
2884913|NCT03354650||c reactive protein|measuring c reactive protein in blood sample to determine neonatal sepsis
2884914|NCT03354637|Active Comparator|ATI-50002 high dose Topical Solution|High dose active
2884915|NCT03354637|Active Comparator|ATI-50002 low dose Topical Solution|low dose active
2884916|NCT03354637|Placebo Comparator|Vehicle Topical Solution|placebo
2884917|NCT03354624|Experimental|Nerve growth factor group|Three injections of sterile solutions of recombinant human nerve growth factor (NGF) will be performed in the right extensor carpi radialis muscle to induce muscle hyperalgesia.
2884918|NCT03354624|Experimental|Nerve growth factor group + delayed onset muscle soreness|Injections of nerve growth factor and eccentric exercise of the extensor carpi radialis muscle will be performed to induce muscle hyperalgesia.
2884919|NCT03354611|Experimental|Diagnostic Workup|The subjects will first have a pre-contrast CBBCT scan. Iodinated contrast will be injected intravenously, and then another CBBCT scans will be performed to capture the tumor vasculature enhancement.
2884920|NCT03354598|Experimental|Sulopenem-etzadroxil/probenecid|Sulopenem-etzadroxil/probenecid 500 mg PO twice daily for 5 days
2884921|NCT03354598|Active Comparator|Ciprofloxacin|Ciprofloxacin 250 mg PO administered twice daily for 3 days
2884922|NCT03354585|Experimental|Mindfulness Group|"Study volunteers will participate in a twelve-session mindfulness training regimen. In brief, subjects will be taught that perceived sensory events are momentary and fleeting and do not require further evaluation. There will be an emphasis on breath focus and altering one's perspective of discursive sensory events. This intervention has been found to reliably attenuate the subjective experience of pain."
2884923|NCT03354585|Active Comparator|Meditation Group|Study volunteers will participate in a twelve-session meditation training regimen. In brief, subjects will be taught to take deep breaths every few minutes to facilitate hypothesized descending inhibition of discursive sensory events. There will be an emphasis on breathing rate focus throughout each intervention session. This intervention has been found to reliably attenuate the subjective experience of pain.
2884924|NCT03354585|Active Comparator|Book Listening Control Group|Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 12 session intervention is meant to provide the control attention to the facilitator, room setting, social support, conditioning, and the time elapsed during the other respective interventions. We do not expect that this group will demonstrate significant cerebral blood flow changes as a function of the intervention.
2884927|NCT03354559||pre-ECS group|Data collection from 01-01-2011 to 31-12-2012. Patients were treated according to a massive transfusion protocol with the following targets: fresh frozen plasma(FFP)/packed red blood cells(PRBCs) ratio ≥ 1:1.5, target platelet count > 100.000 x 10 9/L
2884928|NCT03354559||ECS group|Data collection from 01-01-2013 to 31-12-2014. Patients were treated according to the ECS protocol.
2884929|NCT03354546||Elective noncardiac surgery|Individuals having major noncardiac surgery following an elective hospital admission
2884930|NCT03354546||Emergency general surgery|Individuals having general surgery following an urgent hospital admission
2884931|NCT03354533|Other|Treatment with ORL-1F.|
2884932|NCT03354520|Active Comparator|Tailored Videos|
2884933|NCT03354520|Active Comparator|Standard Videos|
2884934|NCT03354520|Active Comparator|OSA Treatment|
2884935|NCT03354507|Experimental|Sodium Bicarbonate|"Patients will receive sodium bicarbonate for 4 weeks, based on pre-calculated weight based doses. Patients are selected if they have metabolic acidosis at baseline.~< 24 kg : 1/4 teaspoon bid. 24 - 42 kg : 1/2 teaspoon bid. > 42kg : 3/4 teaspoon bid."
2884936|NCT03354507|No Intervention|Control|Patients will not receive treatment if they do not have metabolic acidosis at baseline.
2884937|NCT03354494||DSG-CTP|
2884938|NCT03354481|Experimental|Behavioral recording of arithmetic and associated information|The experiment will contain several behavioral tasks in which solving time and correct answer will be recorded. The main one will be a computerized task on arithmetic facts. There will also be three additional tasks as described below.
2884939|NCT03354468||fall prevention program time 1|orthopedic department in Kristiansund hospital before implementation of a fall prevention program
2884940|NCT03354468||no fall prevention program time 1|orthopedic department in Ålesund hospital without fall prevention program
2884941|NCT03354468||fall prevention program time 2|orthopedic department in Kristiansund hospital after implementation of a fall prevention program
2884942|NCT03354468||no fall prevention program time 2|orthopedic department in Ålesund hospital without fall prevention program
2884943|NCT03354455|Experimental|REAL TMS|30 minutes of repetitive transcranial magnetic stimulation with 100% of the patients' individual resting motor threshold.
2884944|NCT03354455|Sham Comparator|SHAM TMS|30 minutes of repetitive transcranial magnetic stimulation with 30% of the patients' individual resting motor threshold.
2884945|NCT03354442|Experimental|Modified Fixed Mandibular Retractor|All patients in this group will be treated using Modified Fixed Mandibular Retractor Appliance. This appliance will be used full-time.
2884946|NCT03354442|No Intervention|Untreated control group|All patients in this group will be observed during the period of treating the patients in the other group to assess the growth changes.
2884947|NCT03354429|Experimental|TICAGRELOR|
2884948|NCT03354429|Placebo Comparator|TICAGRELOR PLACEBO|
2884949|NCT03354416||Cohort 1|Subjects with a diagnosis of prostatic cancer or suspicious for prostatic cancer lesions.
2884950|NCT03354403||Patients|Up to 50 mothers of sons of all ages diagnosed with XLRS are eligible to participate in this study. Up to 50 fathers of sons of all ages with XLRS are also eligible to participate and will serve as a comparison group.
2884951|NCT03354390|Experimental|1|1 x 10e6 HERV-E TCR transduced CD8/CD34 cells per kg body weight
2884952|NCT03354390|Experimental|2|5 x 10e6 HERV-E TCR transduced CD8/CD34 cells per kg body weight
2884953|NCT03354390|Experimental|3|1 x 10e7 HERV-E TCR transduced CD8/CD34 cells per kg body weight
2884954|NCT03354390|Experimental|4|5 x 10e7 HERV-E TCR transduced CD8/CD34 cells per kg body weight
2884955|NCT03354377|Experimental|Vegan Diet|"Participants in this group will follow a plant-based vegan diet. The vegan group diet will be based on investigators' pilot work, which instructs participants to favor a diet built around whole grains, fruits, vegetables, and legumes. This group will be supplemented by the Oldways African Heritage and Health program, which includes a food pyramid guide. A Taste of African Heritage (ATAH) six-lesson nutrition and cooking program and an online course for health professionals and cooking instructors (all research and restaurant team members will complete this course.~Interventions include intervention meetings, physical activity, and podcasts/mailings."
2884956|NCT03354377|Experimental|Omnivorous (Omni) Diet|"Participants in this group will follow a low-fat omni diet. The diet intervention for the omni group will be supplemented by the Oldways African Heritage and Health program, which includes a food pyramid guide, A Taste of African Heritage (ATAH) six-lesson nutrition and cooking program and an online course for health professionals and cooking instructors (all research and restaurant team members will complete this course).~Interventions include intervention meetings, physical activity, and podcasts/mailings."
2884957|NCT03354364|Active Comparator|Group 1|Receives pea hull fiber snack for the first 4 weeks and then control snack for the last 4 weeks of the study with 4-week washout between them.
2884958|NCT03354364|Active Comparator|Group 2|Receives control snack for the first 4 weeks and then pea hull fiber snack for the last 4 weeks of the study with 4-week washout between them
2884959|NCT03354351||NB-Group|Stepped-care model comprising a hierarchy of interventions, from the least to the most intensive, matched to the cardiac man's needs. The model involves three steps: Step 1 (therapist-guided and self-guided 3-session psychoeducational program), Step 2 (Group sessions involving care partners), and Step 3 (individual or dyadic (patient and care Partner) sessions. As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
2884960|NCT03354351||ON-Group|Stepped-care model where men will need to follow a sequential treatment (Step 1 (self-guided), Step 2 (Group sessions), and Step 3 (individual or couple sessions). As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
2884993|NCT03354169|Experimental|Delayed Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 1200 and 2300.
2920805|NCT03104153|Active Comparator|Early-removal|
2884961|NCT03354351||QC-Group|Standard Stepped-care model where men will need to follow a sequential treatment (Step 1 (self-guided), Step 2 (Group sessions), and Step 3 (individual or couple sessions). As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
2884962|NCT03354338|Experimental|Experimental Group|Intensive Periodontal treatment and pre-medication with 2 gr of oral amoxicilline 1 hour before treatment
2884963|NCT03354338|Placebo Comparator|PLACEBO|Intensive Periodontal treatment with 2 gr of Placebo 1 hour before treatment
2884964|NCT03354325|Active Comparator|Scheduled PCP follow-up|Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician (PCP) within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
2884965|NCT03354325|Experimental|As needed PCP follow-up|At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician (PCP). Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
2884966|NCT03354312|Experimental|Lidocaine/Articaine|Lidocaine Hydrochloride 1% Gel anesthesia / Articaine hydrochloride/epinephrine (adrenaline) hydrochloride anesthesia
2884967|NCT03354312|Experimental|Articaine/Lidocaine|Articaine hydrochloride/epinephrine (adrenaline) hydrochloride anesthesia / Lidocaine Hydrochloride 1% Gel anesthesia
2884968|NCT03354299|Experimental|Group I|Group I patients received 25 gram of sugar (pudding) and 50 cc of coconut milk as late night snack for a month
2884969|NCT03354299|Active Comparator|Group II|Group II patients received 50 gram of sugar (25 gram pudding and 25 gram syrup) as late night snack for a month
2884970|NCT03354286|Experimental|Developmental & Technological Demands|Provide education on using diabetes technology in various settings and formats in this age group, and increase ability for real-time problem-solving. Identify and troubleshoot barriers to keeping young children in Auto Mode.
2884971|NCT03354286|Experimental|Distress Reduction|Identify and reduce parent distress symptoms and worries. Provide strategies for obtaining social support.
2884972|NCT03354286|Experimental|Nutrition, Set Point, & C:I Ratio|Provide education on a variety of properties of food and how they affect blood glucose levels. Optimize the use of carbohydrate to Insulin ratios, insulin duration of action, and use of temporary target glucose set point in the 670G pump and the Quick bolus feature to gain better glycemic control.
2884973|NCT03354286|Experimental|Hypoglycemia management|Focus on hypoglycemia management to avoid hyperglycemia, review fear of hypoglycemia
2884974|NCT03354286|Placebo Comparator|Minimal Intervention|A short communication detailing the percentage of time spent in range and in Auto Mode and if the goals have been met.
2884975|NCT03354273|Experimental|1|Flurpiridaz PET MPI (following off-study SPECT MPI)
2884976|NCT03354260|Experimental|intervention|Optimized personalized oral nutrition in ICU and nutritional follow up with therapeutic educational after exit of ICU
2884977|NCT03354260|No Intervention|Control|
2884978|NCT03354247|No Intervention|Healthy Control|
2884979|NCT03354247|No Intervention|NAFLD Control|
2884980|NCT03354247|Experimental|NAFLD Intervention|
2884981|NCT03354234|Experimental|Stimuli of slowly increasing intensities|"300-s check before the stimuli~LBNP is applied stepwise with 11.1 mmHg/15 s decrement to -100 mmHg, and then this value is sustained for 120 s~180-second phase of rest between stimuli~75°-HUT (5°/s) for 120 s after a 15-s reversing of the gravity vector (-30°)~180-second phase of rest between stimuli~75°-HUT (5°/s) accompanied by an exposure to an LBNP of -60 mmHg increased linearly by -4 mmHg/s, and then this value is sustained for 120 s during HUT~120-s check after the stimuli"
2884982|NCT03354234|Experimental|Stimuli of rapidly increasing intensities|"120-s check before the stimuli~75°-HUT (45°/s) for 60 s after a 3-s reversing of the gravity vector (-30°)~180-second phase of rest between stimuli~LBNP decreases linearly by -20 mmHg/s to -100 mmHg, and then this value is sustained for 60 s.~180 second phase of rest between stimuli~push-pull, i.e., 3 x 75°-HUT (45°/s) preceded by -30°-HDT (45°/s) and accompanied by an exposure to an LBNP of -60 mmHg decreased linearly by -20 mmHg/s, and then this value is sustained for 30 s during HUT~120-s check after the stimuli"
2884983|NCT03354221|Experimental|Cytosponge, Diet, EEsAI Pro, Likert Scoring Scale|Patients going through the six food elimination diet (clinically) for EoE will be asked to participate. During the initial 6 week elimination period, participants will return at 2, 4 and 6 weeks to swallow the cytosponge. The cytosponge is a 10 minute procedure done in the office. This will be sent for histology, <15 phf would be considered a responder. Results of the histology will help the investigator to direct the future of the 6 food elimination diet to determine if a period of 6 weeks of initial elimination is necessary. The EEsAI Pro questionnaire measures symptomatic response to the elimination of the foods. The Likert Scoring Scale measures patient experience of the cytosponge and the upper endoscopy.
2884984|NCT03354208||Group 1|patients with hypoxic-ischemic encephalopathy (HIE) receiving hypothermia therapy
2884985|NCT03354208||Group 2|patients with suspected HIE, non-confirmed
2884986|NCT03354208||Group 3|healthy, retrospectively classified as such
2884987|NCT03354195|Active Comparator|Group 1|"Group 1 - intact ACL ligament will be accepted as functionally intact~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
2884988|NCT03354195|Active Comparator|Group 2|"Group 2 - intact but fibrillated (frayed) ligament) will be accepted as functionally intact~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
2884989|NCT03354195|Active Comparator|Group 3|"Group 3 - nearly completely torn ligament (>50% and disrupted) will be deemed as having functionally absent ACLs~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
2884990|NCT03354182|Active Comparator|Control group|Open flap surgery on mandibular type II furcations treated with Bio-oss collagen + Bio-gide
2884991|NCT03354182|Active Comparator|Test group|Open flap surgery on mandibular type II furcations treated with Bio-oss collagen alone
2884992|NCT03354169|Experimental|Daytime Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 0800 and 1900.
2884994|NCT03354156||High-LDL|patients with LDL cholesterol levels of >4.9 mmo/l, who have not been treated with statins in the past years, and who have an indication for treatment with statins.
2884995|NCT03354156||Control|control subjects with an LDL cholesterol level of <3.5 mmol/l
2884996|NCT03354143|Active Comparator|Standard Care|Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
2884997|NCT03354143|Experimental|Intensive Treatment|Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
2884998|NCT03354130|Active Comparator|Tofu control|Volunteers will consume a vegetarian diet containing tofu during 3 days for 5 meals in total
2884999|NCT03354130|Experimental|Non-processed pork diet|Volunteers will consume a diet containing non-processed pork during 3 days for 5 meals in total
2885000|NCT03354130|Experimental|Bacon diet|Volunteers will consume a diet containing bacon during 3 days for 5 meals in total
2885001|NCT03354130|Experimental|Sausage diet|Volunteers will consume a diet containing sausage during 3 days for 5 meals in total
2885002|NCT03354130|Experimental|Dry-cured sausage diet|Volunteers will consume a diet containing dry-cured sausage during 3 days for 5 meals in total
2885003|NCT03354117|Experimental|Ulipristal 30mg plus Meloxicam 15mg|Each study participant will complete one menstrual cycle without medication. Her second menstrual cycle, each study participant will receive ulipristal acetate plus meloxicam at peak fertility.
2885004|NCT03354104|Experimental|Recession coverage with connective tissue graft + Emdogain®|A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The root surfaces are applied with 24% EDTA (PrefGel®, Straumann, Basel, Switzerland) for 2 minutes and then washed with saline. Subsequently, EMD (Emdogain®, Straumann, Basel, Switzerland) is applied on root surfaces. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
2885005|NCT03354104|Active Comparator|Recession coverage with connective tissue graft|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
2885006|NCT03354091|Experimental|Intervention|Patient education program and the use of an Fitbit where the users can monitore their activity and receive minor feedback regarding physical activity.
2885007|NCT03354091|No Intervention|Control|Patient education program only.
2885008|NCT03354078|Active Comparator|interrupted sutures group|This group in which closure of the subcutaneous layer is closed by interrupted sutures
2885009|NCT03354078|Active Comparator|Continous sutures group|subcutanous tissue layer is closed by continous sutures in this group
2885010|NCT03354065|Active Comparator|Early oral feeding|TIME OF FEEDING. 48 hours after pancreatitis general management is started ( liquid diet)
2885011|NCT03354065|Experimental|Immediate oral feeding|TIME OF FEEDING: 8 hours of after pancreatitis general management is started (enteral formula)
2885012|NCT03354052|Experimental|Real-rTMS + Gloreha device|
2885013|NCT03354052|Active Comparator|Sham-rTMS + Gloreha device|
2885014|NCT03354039|Experimental|Tamoxifen 20 mg once daily|DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of TAM daily.
2885015|NCT03354039|Placebo Comparator|Matching placebo once daily|Patients randomised to placebo will be administered matching placebo.
2885016|NCT03354026|Experimental|Experimental: AICH-PXZY|Removing Blood Stasis medicine with folium sennae , Polygonum cuspidatum and so on, 8 herbals, Tong-fu-xing-shen. The intervention in this group includes po AICH-PXZY bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
2885017|NCT03354026|Experimental|Experimental: AICH-without PXZY|Removing Blood Stasis medicine without folium sennae and Snakegourd seed, 6 herbals, without the effect of Poxuezhuyu. The intervention in this group includes po AICH-without PXZY bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
2885018|NCT03354026|Placebo Comparator|Placebo: AICH-placebo|The placebo is made up of Starch, bitter taste and cyclodextrin. The intervention in this group includes po AICH-placebo bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
2885019|NCT03354013|Experimental|AOA, genetic screening, calcium pattern|"Clinical setting: Patients will undergo 100% ICSI-AOA if less than 6 mature oocytes are collected upon oocyte retrieval. If 6 or more mature oocytes are retrieved, 50%ICSI and 50%ICSI-AOA will be applied.~Furthermore, patients will give a saliva sample to do genetic screening. Genes important during oocyte activation and embryo development will be investigated.~Also, calcium pattern analysis of the patients' spermatozoa will be executed."
2885020|NCT03354000|Placebo Comparator|Take-home online training|Participants received a link to access the online tutorial videos on their own.
2885021|NCT03354000|Active Comparator|In-person online training|Participants received an in-person tutorial of how to use the patient portal website with a trained research assistant.
2885022|NCT03353987|No Intervention|Control|Preoperative counselling will be given upon recruitment Patients will be given instructions to continue their normal routine.
2885023|NCT03353987|Experimental|Cognitive Training|Preoperative counselling will be given upon recruitment Patients are taught cognitive training and are asked to perform a prescribed set of one-hour cognitive training daily for a minimum of 10 days and up to 1 month prior to surgery.
2885050|NCT03353818|Placebo Comparator|Placebo|No intervention given. No restrictions on physical activity.
2885281|NCT03352245|No Intervention|Control Group|Usual care group will receive standard of care management from their Oncologist.
2885024|NCT03353974|Experimental|Video game therapy|Subjects belonging to the experimental group will receive a Video Game Therapy (VGT) protocol using the Xbox console. They will receive 18 sessions of treatment within 6 weeks (3 sessions per week); each session will last 1 hour. Patients will be required to concentrate in games whose major purposes are increasing balance, selective attention and attention shifting. During sessions the patient will be carefully controlled by a researcher who will prevent the risk of falling
2885025|NCT03353974|Active Comparator|Balance platform therapy|"Subjects belonging to the control group will receive the same amount of therapy (18 sessions) using a balance platform (Biodex Medical Systems, Inc., Shirley, NY). Balance/rebalancing, postural stability and weight-shifting exercises ill be administered with and without visual feedback. During the first session, the tasks will be performed at an entry level, and the exercise progression will be adjusted over time according to the patients' functional level (intermediate and difficult level). Balance platform therapy offered visual feedback and knowledge of performance (augmented feedback). The physiotherapist, as during VGT, provided additional external feedback."
2885026|NCT03353961|Experimental|Adjunctive Internet-delivered ERITA|Participants will receive 11 weeks of internet-delivered emotion regulation individual therapy with therapist support adjunctive to treatment as usual as provided in the community. The caregiver(s) will receive 6 modules of internet-delivered parent program with therapist support.
2885027|NCT03353961|Active Comparator|Treatment as usual|Participants will receive treatment as usual for 11 weeks of treatment as usual as provided in the community.
2885028|NCT03353948|Active Comparator|Metfrormin group (MET)|Drug: Metformin
2885029|NCT03353948|Active Comparator|COMBI group (COMBI)|Drug: liraglutide
2885030|NCT03353935||NERVE SPARING|Patients who underwent surgery for deep endometriosis were submitted to surgical procedures aiming at sparing the pelvic ortho- and parasympathetic nerves. The subjects were then followed with interviews using validated questionnaires, to assess the possible changes in post-operative urinary sexual and fecal function.
2885031|NCT03353922|Experimental|Tolperisone HCl 150 mg|150 mg tolperisone tablets or cyclobenzaprine 10 mg oral tablet administered by mouth every 8 hours for 3 days
2885032|NCT03353922|Placebo Comparator|Placebo Oral Tablet|sugar pills administered by mouth every 8 hours for 3 days
2885033|NCT03353922|Active Comparator|Cyclobenzaprine 10 mg oral tablet|10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days
2885034|NCT03353909|Experimental|Treatment|At the end of the dilatation and curettage, new crosslinked hyaluronan gel (3ml) was applied to the uterine cavity in women assigned to the treatment group through a 15-cm sterile cannula.
2885035|NCT03353909|No Intervention|Control|At the end of the dilatation and curettage, nothing was applied to the uterine cavity in women assigned to the control group.
2885036|NCT03353896|Experimental|Treatment (medical device)|Beginning 4-8 weeks after standard of care treatment, patients wear NovoTTF-200A device over 18 hours QD. Treatment continues for up to 24 months in the absence of disease progression or unacceptable toxicity.
2885037|NCT03353883|Active Comparator|(Group A) Midluteal Triptorelin depot|infertile women with impaired ovulation who will be subjected to Triptorelin sustained release(Decapeptyl depot 375 mg one injection )at D-21 of previous menstrual cycle Hormon Replacement Therapy (HRT)Cyclo-Progynova (estradiol, norgestrel)(Group A). All patients received the same luteal support in the form of intravaginal progesterone two day before embryos transfer until blood pregnancy test was performed 14 days later. The classic Testart slow freezing and rapid thawing protocol was applied on stage-2 PN embryos. Endometrial thickness was measured in the midsagittal plane using transvaginal ultrasound (TVU). Clinical pregnancy was diagnosed by measurement of β-HCG level and was confirmed 2-weeks later by TVU.
2885038|NCT03353883|Active Comparator|(Group B)first day Triptorelin depot|infertile women with impaired ovulation who will be subjected toTriptorelin sustained release(Decapeptyl depot 375 mg one injection) at D-1 of menses then Cyclo-Progynova (estradiol, norgestrel) (Group B). All patients received the same luteal support in the form of intravaginal progesterone two day before embryos transfer until blood pregnancy test was performed 14 days later. The classic Testart slow freezing and rapid thawing protocol was applied on stage-2 PN embryos. Endometrial thickness was measured in the midsagittal plane using transvaginal ultrasound (TVU). Clinical pregnancy was diagnosed by measurement of β-Human Chorionic Gonadotropin level and was confirmed 2-weeks later by TVU.
2885039|NCT03353870||qualitative interview|This study has only one arm
2885040|NCT03353857|Experimental|levonorgestrel|levonorgestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
2885041|NCT03353857|Experimental|norethindrone|norethindrone and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
2885042|NCT03353857|Experimental|desogestrel|desogestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
2885043|NCT03353857|Experimental|dienogest|dienogest and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
2885044|NCT03353857|Experimental|Drospirenone/ ethinylestradiol|"drospirenone/ethinylestradiol and midazolam will be administered on Day 1, Day 15 and Day 26.~rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29."
2885045|NCT03353844|Experimental|Intradialytic exercise group|These patients will get intradialytic exercise every sessions of hemodiafiltration
2885046|NCT03353844|No Intervention|Standard dialysis group|regular and standard of care in every hemodiafiltration sessions (as usual) without intradialytic exercise.
2885047|NCT03353831|Placebo Comparator|Arm A: Chemotherapy + Bevacizumab + Placebo|Chemotherapy: Paclitaxel 80 mg/m² d1, 8, 14, 22 q28 or pegylated liposomal doxorubicin 40 mg/m² q28 + Bevacizumab 10 mg/kg q14 + Placebos q14
2885048|NCT03353831|Experimental|Arm B: Chemotherapy + Bevacizumab + Atezolizumab|Chemotherapy: Paclitaxel 80 mg/m² d1, 8, 14, 22 q28 or pegylated liposomal doxorubicin 40 mg/m² q28 + Bevacizumab 10 mg/kg q14 + Atezolizumab 840 mg q14
2885049|NCT03353818|Active Comparator|Golf|In three different golf clubs patients will be introduced how to play golf. They will be taught techniques and recieve basic golf equipment. A total of 1 year membership free membership in the golf clubs will be given.
2885051|NCT03353792|Active Comparator|CL/AP system|To improved glycemic control and strict avoidance of hypoglycemia via 8-week use of a CL/AP system (closed-loop/artificial pancreas) reverses brain metabolic adaptations in older adult T1DM patients.
2885052|NCT03353792|Placebo Comparator|usual care|Subjects in this control group will continue their usual diabetic care (insulin pump therapy) along with CGM recording.
2885053|NCT03353766|Experimental|Early crossbite correction|Early crossbite correction with Q-H Device
2885054|NCT03353766|No Intervention|Crossbite correction in mixed dentition|Later crossbite correction, during mixed dentition
2885055|NCT03353753|Active Comparator|Arm 1|150 mg QD DCC-2618
2885056|NCT03353753|Placebo Comparator|Arm 2|Placebo
2885057|NCT03353740|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
2885058|NCT03353727|Experimental|Orthoptic rehabilitation|
2885059|NCT03353714|Placebo Comparator|Pudendal block with saline|Pudendal block with normal saline
2885060|NCT03353714|Active Comparator|Pudendal block with bupivacaine|Pudendal block with bupivacaine
2885061|NCT03353701|Other|Adults with or without HIV infection|Participants will be asked to stop drinking for at least 30 and up to 90 days. The study will use Contingency Management (CM) with financial incentives to encourage participants to maximally reduce alcohol consumption.
2885062|NCT03353688|Active Comparator|Directional DBS guided by behavior|Directional stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by behavioral assessments during device activation.
2885063|NCT03353688|Placebo Comparator|Omnidirectional DBS guided by behavior|"Omnidirectional (ring mode) stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by behavioral assessments during device activation."
2885064|NCT03353688|Active Comparator|Directional DBS guided by biomarkers|Directional unilateral subthalamic stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by electrophysiology biomarkers measured during surgery (nested exploratory treatment arm).
2885065|NCT03353675|Experimental|TG4010/Chemotherapy/Nivolumab|
2885066|NCT03353662||Women of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Gamo Gofa between 15-49 years
2885067|NCT03353662||Children of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Gamo Gofa between 6 - 59 months
2885068|NCT03353662||Women of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of West Gojjam between 15-49 years
2885069|NCT03353662||Children of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of West Gojjam between 6 - 59 months
2885070|NCT03353662||Women of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Kamashi between 15-49 years
2885071|NCT03353662||Children of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Kamashi between 6 - 59 months
2885072|NCT03353649|Experimental|Binge Eating Group|"(1) exposing subjects to specific stimulus sets relevant to the sample that may promote engagement of appetitive drives (images of highly palatable foods for obese individuals), and (2) exposing them to an instructional manipulation designed to engage self-regulatory processes in the presence of these stimulus sets. Specifically, participants in this sample will be exposed to images of food and control non-food images. In different trials, subjects will be given a now cue instructing them to engage with the immediate hedonic properties of the stimulus or a later cue instructing them to imagine the long-term consequences of using the stimulus.~This arm includes fMRI and the now vs. later cue intervention"
2885073|NCT03353649|Experimental|Smoking Group|"(1) exposing subjects to specific stimulus sets relevant to the sample that may promote engagement of appetitive drives (tobacco-related images or smokers), and (2) exposing them to an instructional manipulation designed to engage self-regulatory processes in the presence of these stimulus sets.~A similar approach to the Binge Eating sample will be used for the smoking sample using two stimulus sets. Instead of foods and non-food control images, smokers will see smoking-related images and the same control non-food non-smoking images as the Binge Eating sample.~This Arm includes fMRI and the now vs. later cue intervention"
2885074|NCT03353636|Experimental|Natural Calm Magnesium|150mg elemental magnesium in a single oral dose
2885075|NCT03353636|Active Comparator|Magnesium Bis-glycinate|150mg elemental magnesium in a single oral dose
2885076|NCT03353636|Active Comparator|MAGSmart|150mg elemental magnesium in a single oral dose
2885077|NCT03353636|Active Comparator|Magnesium citrate|150mg elemental magnesium in a single oral dose
2885078|NCT03353636|Placebo Comparator|Placebo|
2885079|NCT03353623|Experimental|ISG-Group (Immediate Serious Game)|Children in the ISG-Group first participated in the VR-assisted rehabilitation, which consisted in 8 sessions with immersive virtual environment and wearable haptic devices, and were then crossed over and followed during an intended duration of 6 hours of conventional therapy.
2885080|NCT03353623|Experimental|DSG-Group (Delayed Serious Game)|Children from DSG-Group were followed during an intended duration of 6 hours of conventional therapy before receiving VR-assisted rehabilitation with immersive virtual environment and wearable haptic devices.
2885081|NCT03353610||Patient-reported PSVT.|Participants who recorded a PSVT diagnosis.
2885082|NCT03353610||Suspected PSVT.|Participants who do not record a PSVT diagnosis.
2885083|NCT03353610||Other subgroups.|Subgroups also may be examined ( PSVT-episode characteristics, use of a self-management technique for PSVT at home (on their own) to return heart rate back to normal).The sample size, however, may limit the extent of any subgroup analyses.
2885084|NCT03353597|Experimental|Plasma Transfusion|Plasma Transfusions with 2 units of plasma per dose, for a total of 6 doses
2885085|NCT03353584|No Intervention|Standard Care|Participants receive standard care treatment for their vaso-occlusive crisis. Participants will be randomized by age.
2885086|NCT03353584|Active Comparator|Virtual Reality|Participants receive standard care treatment for their vaso-occlusive crisis. In addition, they will have a 15-minute Virtual Reality Therapy session. Participants will be randomized by age.
2885125|NCT03353324|Active Comparator|intravitreal injection of bevacizumab+ targeted laser|Intervention intravitreal bevacizumab injection + targeted laser photocoagulation of retinal non perfused areas
2924721|NCT03077399||control|patients without stroke, application of SCALA
2885087|NCT03353571|Other|C3 PATIENT PARTICIPANTS|This single arm prospective study is designed to produce valid scientific evidence regarding safety and efficacy of the C3 in establishing urinary drainage and allowing the control of micturition when indwelling for up to 7 days in patients. The total study population will initially include 50 subjects with open enrollment of additional subjects.
2885088|NCT03353558||Study Group (CML group)|"This group will be CML patients. In this group each participant will be asked to wear a watch Actigraph for one week.~He will be asked to fill the appropriate questionnaires, and a daily sleep diary."
2885089|NCT03353558||Control Group|"The control group will be non-CML patients, also without any known malignancy or known sleep disturbances.~They will be asked to wear the watch Actigraph for one week, and to fill the appropriate questionnaires and a daily sleep diary."
2885090|NCT03353532||Cohort|Adult patients with SSI after any surgical procedure.
2885091|NCT03353532||Case-Control|"Cases: Patients establishing S. aureus SSI Controls: Patients from the same center who did not undergo S. aureus SSI, matched by the following criteria~Type of procedure~Age~ASA score~BMI~Duration of procedure (as percentile for this procedure)~Diabetes~Sex"
2885092|NCT03353519|Experimental|Primary care model|The new model of care incorporates a multi-factorial package of service aimed at providing a review of patient needs, facilitated self-management of longer-term stroke care needs for survivors and their carers, optimised communication between patients and health and social care services, optimised communication between the different care services, and increased awareness of and access to national and local community and charity provided services.
2885093|NCT03353519|No Intervention|Usual care|The control arm will consist of the usual care currently provided for stroke survivors registered with each general practice.
2885094|NCT03353506|Active Comparator|LFMT|Lyophilized fecal microbiota transplant capsules
2885095|NCT03353506|Experimental|LSFF|Lyophilized sterile fecal filtrate capsules
2885096|NCT03353493|Experimental|MBCT + TAU|Mindfulness-based Cognitive Therapy (MBCT) a 8 week group based intervention delivered according to the protocol by Segal, Williams and Teasdale (2013) plus treatment as usual (TAU) . TAU is restricted to antidepressant medication and no psychological therapy.
2885097|NCT03353493|Other|TAU|Treatment as Usual (TAU). TAU is restricted to antidepressant medication and no psychological therapy.
2885098|NCT03353480|Other|Reference|250mg Azithromycin tablet manufactured at Pfizer Barceloneta, Puerto Rico, US
2885099|NCT03353480|Experimental|Experimental|250mg Azithromycin tablet manufactured at Pfizer Dalian, China
2885100|NCT03353467|Experimental|Group in endoscopic surgery|Stage I patients were only treated with endoscopic surgery without additional chemotherapy. Endoscopic nasopharyngectomy included endoscopic resection , with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.
2885101|NCT03353467|Active Comparator|Group in IMRT|Stage I patients were only treated with radical intensity-modulated radiotherapy without additional chemotherapy. IMRT was delivered with a dynamic multileaf intensity-modulating collimator (NOMOS, Sewickley, PA) by a slice-by-slice arc rotation approach.
2885102|NCT03353454|Experimental|Maralixibat (SHP625)|Participants will be randomized to Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks.
2885103|NCT03353454|Placebo Comparator|Placebo|Participants will recieve placebo matched to maralixibat oral solution twice daily for 26 weeks.
2885104|NCT03353441|Active Comparator|Glycine (MSG)|Microencapsulated Sublingual Glycine (MSG): 1 tablet prior to TSST; 1 tablet after the TSST
2885105|NCT03353441|Placebo Comparator|Placebo|Lactose: 1 tablet prior to TSST; 1 tablet after the TSST
2885106|NCT03353441|No Intervention|No treatment|
2885107|NCT03353428|Experimental|LC-CTLs|Autologous lung cancer specific cytotoxic lymphocytes
2885108|NCT03353415|Experimental|CGM Use|Each participant will wear the DexCom continuous glucose monitor for four weeks. During the first two weeks, participants will not be able to read the sensor glucose levels. In the second two weeks, participants will be able to read the sensor glucose levels. Frequency of hypoglycemia will be compared between the two phases of the study.
2885109|NCT03353402|Experimental|Fecal Microbiota Transplant (FMT)|FMT includes a colonoscopy conducted by a gastroenterologist followed by stool capsules which will be swallowed by the patient. Both interventions will be conducted in an outpatient setting
2885110|NCT03353389||No AKI|Adult admissions without Acute Kidney Injury during their stay
2885111|NCT03353389||CA-AKI|Adult admissions with Acute Kidney Injury diagnosed within 48 hours during their stay (Community-acquired Acute Kidney Injury)
2885112|NCT03353389||HA-AKI|Adult admissions with Acute Kidney Injury diagnosed after 48 hours during their stay (Hospital-acquired Acute Kidney Injury)
2885113|NCT03353376|Experimental|group care with empowerment model|4 group visits a year according to empowerment model in a tertiary diabetes clinic
2885114|NCT03353376|Active Comparator|individual usual care|individual visits according to disponibility in the diabetes clinic and needs of the patients
2885115|NCT03353363|Placebo Comparator|Normal Saline|Subject will receive 20ml of normal saline infiltration
2885116|NCT03353363|Experimental|Plain Bupivacaine|Subject will receive 20ml of 0.5% plain bupivacaine infiltration (100mg)
2885117|NCT03353363|Experimental|Liposomal Bupivacaine|Subject will receive 20ml of liposomal bupivacaine infiltration (266mg) non-expanded
2885118|NCT03353350|Experimental|Efpeglenatide low dose|Efpeglenatide low dose (Prefilled syringe) administered once weekly for 56 weeks
2885119|NCT03353350|Experimental|Efpeglenatide middle dose|Efpeglenatide middle dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
2885120|NCT03353350|Experimental|Efpeglenatide high dose|Efpeglenatide high dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
2885121|NCT03353350|Placebo Comparator|Placebo|Matching placebo (Prefilled syringe) administered once weekly for 56 weeks
2885122|NCT03353337|Experimental|aerobic exercise|Cycling at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 1 month.
2885123|NCT03353337|Placebo Comparator|Placebo controlled group|General intensity activities of recreation therapy, including Handicraft manufacture, reading activity, singing entertainment, walking.
2885124|NCT03353324|Active Comparator|intravitreal injection of bevacizumab|
2885153|NCT03353103|Active Comparator|asymptomatic|
2885126|NCT03353311||Enhanced Recovery After Surgery|"Patients undergoing elective colorectal surgical resection for benign/malignant disease.~A multidisciplinary validated approach based on 24 items including Preadmission information, education and counselling Preoperative optimization (increasing exercise, stop smoking and alcohol consumption should 4 weeks before surgery) No preoperative bowel preparation Use of preoperative carbohydrate drinks Pre-anesthetic medication Prophylaxis against thromboembolism Antimicrobial prophylaxis and skin preparation Standard anesthetic protocol for rapid awakening PONV Mini-invasive surgery No nasogastric dreinage Prevention of intraoperative hypothermia Perioperative fluid management No drains in the peritoneal cavity after colonic anastomosis Early remouval of urinary drainage (24-48 hrs) Prevention of postoperative ileus (including use of postoperative laxatives) Postoperative analgesia Perioperative nutritional care Postoperative control of glucose Early mobilization Auditing"
2885127|NCT03353298|Active Comparator|Arm A|Allopurinol 300 mg
2885128|NCT03353298|Placebo Comparator|Arm B|Placebo Oral tablets
2885129|NCT03353285||Group I|Group I= egg retrieved in the follicular fluid of the first aspirate (no flushing)
2885130|NCT03353285||Group II|Group II= egg retrieved in the 1st-2nd flush
2885131|NCT03353285||Group III|Group III= egg retrieved in the 3rd-5th flush
2885132|NCT03353272|No Intervention|Impairment Based Treatment|an impairment-based conservative intervention that has been created by compiling the evidence associated with established, effective treatment interventions for rotator cuff related shoulder pain.
2885133|NCT03353272|Experimental|Impairment Based Treatment PLUS PEERC|Participants assigned to the impairment-based care plus PEERC condition will also receive the PEERC protocol. This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
2885134|NCT03353259|No Intervention|SS-TG|Standard surgery using burr-hole procedure, irrigation and drainage.
2885135|NCT03353259|Active Comparator|SS-TXA-TG|Standard surgery using burr-hole procedure, irrigation and drainage combined withTranexamic acid (Cyklokapron) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day until complete hematoma disappearance.
2885136|NCT03353259|Active Comparator|SS-TXA-RoA|Standard surgery using burr-hole procedure, irrigation and drainage combined with Tranexamic acid (Cyklokapron) and Tocilizumab (RoActemra) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day combined with RoActemra subcutaneous injection of 162 mg once a week until complete hematoma disappearance.
2885137|NCT03353246|Experimental|InfraScanner 2000™|All patients entered onto the trial will undergo at least one cranial scanning using the InfraScanner 2000™ within 30 minutes of CT. Patients will be scanned using the InfraScanner 2000™ within 30 minutes of each subsequent CT. Patients will know the results of the CT but not the InfraScanner 2000™. The standard for comparison will be determined as follows. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative. In cases where the results of the CT are negative for hematoma and the results of the InfraScanner 2000™ are positive consideration of further follow-up will be given on a case-by-case basis.
2885138|NCT03353233|Experimental|iPACK Block Group|A nerve block technique using a numbing medication called ropivacaine.
2885139|NCT03353233|Placebo Comparator|Sham Group|The same nerve block technique as above, however using an inactive solution of salt water.
2885140|NCT03353220|Experimental|Arm A|Participants receive lorcaserin (Belviq) 10 mg twice a day for 7 days followed by a 3 week washout period. These participants will then be crossed over to receive placebo twice a day for 7 days.
2885141|NCT03353220|Experimental|Arm B|Participants receive placebo twice a day for 7 days followed by a 3 week washout period. These participants will then be crossed over to receive lorcaserin (Belviq)10 mg twice a day for 7 days.
2885142|NCT03353207||health Control|"No family history of RBD;~Age- and sex- matched with isolated RSWA subjects~Absence of dream enactment behaviors;~A score of RBDQ-HK less than 19;~Absence of RSWA as measured by v-PSG;~for those individuals with moderate obstructive sleep apnea (AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
2885143|NCT03353207||Case with isolated RSWA|"First degree relatives of patients with iRBD;~Age 45 years or above;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the cut-off suggestive of a diagnosis of RBD;~Presence of RSWA as measured by v-PSG; RSWA is defined as the percentage of increased EMG activity (phasic or tonic) at least 10% during REM sleep for any channel.~for those individuals with moderate to severe obstructive sleep apnea (apnea-hypopnea index, AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
2885144|NCT03353207||Case without isolated RSWA|"First degree relatives of patients with iRBD;~Age- and sex- matched with isolated RSWA subjects;~Absence of dream enactment behaviors;~A score of RBDQ-HK less than 19;~Absence of RSWA as measured by v-PSG;~for those individuals with moderate obstructive sleep apnea (AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
2885145|NCT03353181|Experimental|Endoscopic scissors|Endoscopic nasobiliary drainage for malignant hilar biliary strictures at first， and application of endoscopic cutting technique followed.
2885146|NCT03353181|Active Comparator|Stent|Standard placement of biliary stent for malignant hilar biliary strictures.
2885147|NCT03353155|Active Comparator|Usual Care|Telephone and/or home visits at 1 week, and thereafter, monthly for 6 months, to check on medication compliance and/or medical social problems and/or physical therapy needs and/or health-related financial challenges by the relevant service departments as recommended by the discharging physician.
2885148|NCT03353155|Active Comparator|CareHub|Telephone follow-up by a nurse care coordinator acting as single point of contact for medication compliance and/or medical social problems and/or physical therapy needs and/or health-related financial challenges based on automatic enrollment using ACE score cut-off at admission.
2885149|NCT03353142|Experimental|Equal Breathing|
2885150|NCT03353116|Active Comparator|maxilla first group|the maxillary osteotomy is going to be done and fixed first
2885151|NCT03353116|Experimental|mandible first group|the mandibular osteotomy is going to be done and fixed first
2885152|NCT03353103|Active Comparator|symptomatic|
2885155|NCT03353064|Active Comparator|Vivify + EMS|This arm will have the Telemedicine kits and get scheduled EMS home visits. The subjects will complete daily biometrics / surveys / care plans through the telemedicine kit, as specified in the activity schedule Apart from the tablet device, EMS home visits will be scheduled on Day 7, Day 21 and Day 42 from discharge. During these home visits, the EM personnel will perform a check of the NIV/NIPPV device. They are able to adjust pressures according to your Pulmonologist / Sleep doctor's prescription, and troubleshoot any issues with the mask, the humidifier, etc. They will also measure End-tidal CO2 via nasal cannula.
2885156|NCT03353064|Active Comparator|Vivify Only|"This group will receive the telemedicine tablet and kit, with the same protocol as defined above.~No EMS home visits will be set up"
2885157|NCT03353051||Group A: other - observational study|neonates ≥2000-<2500g and born with a gestation age <37 weeks.
2885158|NCT03353051||Group B: other- observational study|Group B will contain neonates >2500g and born with a gestation age <37 weeks.
2885159|NCT03353051||Group C: other - observational study|Group C will contain neonates ≥2000-<2500g but with a gestation age >37 weeks.
2885160|NCT03353051||Group D1:other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 30-48hrs.
2885161|NCT03353051||Group D2: other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 42-60hrs
2885162|NCT03353051||Group D3: other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 144-192hrs.
2885163|NCT03353038|Active Comparator|Off-The-Shelf Pillbox vs 3D Printed Pillbox|Participants in the study were pillbox users at baseline. Participants described their experiences and preferences with their own pillbox. Then participants will be given a 3D printed pillbox. Researchers will compare participants' experiences and preferences between their off-the-shelf pillbox used at baseline and the customized 3D printed pillbox delivered to participants as part of the study.
2885164|NCT03353025|Experimental|transsphenoidal surgery treatment|Transsphenoidal surgery treat non-invasive prolactinoma by experienced neurosurgeon
2885165|NCT03353025|Experimental|dopamine agonist treatment|Minimum effective dose of dopamine agonist, bromocriptine, treat non-invasive prolactinoma
2885166|NCT03353012|Experimental|Levonorgestrel immediate post-partum|Breast-feeding postpartum woman who receive Levonorgestrel drug implant (75 mg) between 48-72 hr after child delivery
2885167|NCT03353012|Experimental|Etonogestrel immediate post-partum|Breast-feeding postpartum woman who receive Etonogestrel drug implant (68 mg) between 48-72 hr after child delivery
2885168|NCT03353012|Active Comparator|Levonorgestrel delayed post-partum|Breast-feeding postpartum woman who receive Levonorgestrel drug implant (75 mg) between 5-7 weeks after child delivery
2885169|NCT03353012|Active Comparator|Etonogestrel delayed post-partum|Breast-feeding postpartum woman who receive Etonogestrel drug implant (68 mg) between 5-7 weeks after child delivery
2885170|NCT03352999|Other|ROHCA rescued by vaECMO|Patients experiencing a ROHCA despite advanced CPR and finally rescued with a va ECMO device.
2885171|NCT03352986||osteonecrosis|Sickle cell patients with osteonecrosis as a vascular main complication
2885172|NCT03352986||leg ulcer|Sickle cell patients with leg ulcer as a vascular main complication
2885173|NCT03352986||microalbuminuria|Sickle cell patients with microalbuminuria as a vascular main complication
2885174|NCT03352986||pulmonary hypertension|Sickle cell patients with pulmonary hypertension as a vascular main complication
2885175|NCT03352986||stroke|Sickle cell patients with strocke as a vascular main complication
2885176|NCT03352986||priapism|Sickle cell patients with priapism as a vascular main complication
2885177|NCT03352973|Experimental|tDCS on the DLPFC|Dorsolateral prefrontal cortex (DLPFC) target will be identified by the baseline fMRI study for regulation of craving. During the intervention, each participant will receive a transcranial direct current stimulation (tDCS) intervention on this DLPFC region.
2885178|NCT03352973|Active Comparator|tDCS on the motor area|Each participant will also receive a control tDCS intervention on the motor area of the brain, which is not directly related to regulation of craving.
2885179|NCT03352947|Active Comparator|Continuous (Standard)|Dabrafenib 150mg twice daily 12 hours apart, on days 1-28 of a 28 day cycle plus Trametinib 2mg once daily, on days 1-28 of a 28 day cycle
2885180|NCT03352947|Experimental|Intermittent (experimental)|Dabrafenib 150mg twice daily 12 hours apart, on days 1-21 of a 28 day cycle plus Trametinib 2mg once daily, on days 1-14 of a 28 day cycle
2885181|NCT03352934|Experimental|Avelumab|10 mg/kg Avelumab every 2 weeks
2885182|NCT03352921|Experimental|clinical pilates exercises|The experimental group will receive clinical pilates exercise training in group form for 3 weeks a week for 8 weeks. The training will be done 40-50 minutes per one day. The exercise session will be started with a 10 minute warming program, 30 minutes with the core stabilization training and the clinical pilates exercises with the postural alignment exercises will be applied and the exercise session will be ended with the 10 minutes cooling period.
2885183|NCT03352921|Active Comparator|Home exercises program|For 8 weeks the member in comparison group will be ask to do the exercise program 3 days a week at home. This group will receive a program of stretching, strengthening, and posture exercises. All the exercises in the program will be illustrated on a descriptive form with images. In terms of the follow-up during 8-week duration, the individuals will be called frequently and in the interview by the end of the study.
2885184|NCT03352908||YSP|The Yale Swallow Protocol (YSP) consists of a brief cognitive screen, a brief oral motor exam, and a 3oz water challenge (subjects instructed to drink 3oz of water without stopping). Pass/fail is determined based on the subjects ability to drink the 3oz of water uninterrupted without immediate cough.
2885185|NCT03352908||FEES|Flexible Endoscopic Evaluation of Swallowing (FEES) uses a flexible endoscope that will be passed transnasally into the pharynx by a speech pathologist specializing in dysphagia management. FEES will be treated as a placebo comparator.
2885186|NCT03352895|Placebo Comparator|control|Control group will receive placebo medication therapy
2885187|NCT03352895|Experimental|test group|resveratrol group will receive oral resveratrol (100 mg per day)
2885188|NCT03352882|Other|Open Label|All enrolled participants will undergo hepatic ultrasound with acoustic radiation force impulse (ARFI) before and 30 days after creation of TIPS.
2927288|NCT03059212|Sham Comparator|Sham rTMS|Sham stimulation
2885189|NCT03352869|Experimental|Exenatide|Drug: Byetta Generic name: Exenatide Dosage form: 5ug and 10ug Dosage: 10-20ug/day Frequency: twice a day Duration: 3 months
2885190|NCT03352869|Active Comparator|Metformin|Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
2885191|NCT03352869|Experimental|Combination|Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months
2885192|NCT03352856|Active Comparator|Active|Highly purified barley starch packed in sachets; Increasing doses given at clinic as follows: 0.6 g, 2 g, 6 g and 18 g. If required, continued at home with 2 x 18 g daily for 5 days.
2885193|NCT03352856|Placebo Comparator|Placebo|Maize starch packed in sachets; Increasing doses given at clinic as follows: 0.6 g, 2 g, 6 g and 18 g. If required, continued at home with 2 x 18 g daily for 5 days.
2885194|NCT03352843|Experimental|Single arm|
2885195|NCT03352830|No Intervention|Control|All individuals in each arm will receive a new LPG cookstove. The control arm will receive an orientation for safe operation of the new LPG stove. They will, however, receive no other intervention.
2885196|NCT03352830|Experimental|No Delivery, Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives a health promotion intervention based on the Risks, Attitudes, Norms, Ability, and Self-Regulation (RANAS) model.
2885197|NCT03352830|Experimental|Delivery, No Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives free direct delivery of their LPG cylinder refills upon demand.
2885198|NCT03352830|Experimental|Agent Delivery, Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives free direct delivery of their LPG cylinder refills upon demand. They also receive a health promotion intervention based on the Risks, Attitudes, Norms, Ability, and Self-Regulation (RANAS) model.
2885199|NCT03352817||Patients in cardiac rehabilitation|Eligible patients must have reached the age of majority, participate in a CR program at one of the centers cited, and agreed to respond to the study questionnaire voluntarily
2885200|NCT03352804||Patients hospitalized in internal medicine ward|Patients included are patients hospitalized in internal medicine ward.
2885201|NCT03352791|Active Comparator|DSM-H Hospice Edition|training, assigning of champions to serve as mentors and performance improvement leads, and workflow changes including caregiver education pamphlets, interdisciplinary care plans, treatment algorithms, and assessment instruments.
2885202|NCT03352791|Active Comparator|Control Arm|Usual Care
2885203|NCT03352778||IMRT|
2885204|NCT03352778||2DRT|
2885205|NCT03352765|Experimental|rituximab, bendamustine & melphalan and ASCT|This is a phase I/II study of rituximab, bendamustine and melphalan (RBM) conditioning followed by ASCT in elderly patients with B-cell NHL. Conditioning regimen consist of rituximab 375 mg/m2 on days -11 and -4, bendamustine 160 mg/m2 intravenously on days -3 and -2; melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0. The conditioning timeline can be modified if there are patient scheduling conflicts.
2885206|NCT03352752|Experimental|Possess HTC Vive before the operation|The experimental group was wearing VR helmet before operation, and the immersion experience was selected from the video content library pre-selected. After 3 minutes of the VR experience, the surgeon started the fractional laser operation (Notify the patient). The operating area is continuous 10 maximum square spot areas.The parameters for the DEEP FX mode:35mj, 5% density, 300Hz.
2885207|NCT03352752|Experimental|Without HTC Vive before the operation|The control group was wearing a blindfold before operation. The operating area is continuous 10 maximum square spot areas. The parameters for the DEEP FX mode:35mj, 5% density, 300Hz.
2885208|NCT03352739|Experimental|DBS of the fornix, power on|
2885209|NCT03352739|Experimental|DBS of the NbM, power on|
2885210|NCT03352739|Sham Comparator|DBS of the fornix, power off|
2885211|NCT03352739|Sham Comparator|DBS of the NbM, power off|
2885212|NCT03352739|No Intervention|Control group|The patients are going to prescribe stable dosage of donepezil during observation period without surgical interference.
2885213|NCT03352726|Experimental|DBV712 Solution for Skin Prick Test|DBV712 In-House Reference Skin Prick Test preparation
2885214|NCT03352713|Experimental|Laddr|All participants in the study will be invited to use Laddr, described in the intervention section.
2885215|NCT03352700|Placebo Comparator|3L PEG|only used 3L PEG
2885216|NCT03352700|Experimental|3L PEG+Dyclonine Hydrochloride Mucilage|used 3L PEG+Dyclonine Hydrochloride Mucilage
2885217|NCT03352687|Experimental|Anterior SSAX|patients receiving suprascapular and axillary nerve block (SSAX) whose approach to the SS nerve is performed by anterior route
2885218|NCT03352687|Experimental|Posterior SSAX|patients receiving suprascapular and axillary nerve block (SSAX) whose approach to the SS nerve is performed by posterior route
2885219|NCT03352674|Experimental|Insulin Glargine Ezelin|Drug product Insulin Glargine, Ezelin 100 U/mL (PT Kalbe Farma, Tbk)
2885220|NCT03352674|Active Comparator|Insulin Glargine Lantus|Insulin Glargine Pen Injector [Lantus]
2885221|NCT03352661||Endometriosis|No drugs are administered. It is an observational study. Collect retrospectively data
2885222|NCT03352661||No endometriosis|No drugs are administered. It is an observational study. Collect retrospectively data
2885223|NCT03352635||Native Hawaiians|One parent of Hawaiian descent.
2885224|NCT03352635||Japanese Americans|Two parents of Japanese descent.
2885225|NCT03352635||Non-Hispanic Whites|Two parents of non-Hispanic white descent.
2885226|NCT03352622|Active Comparator|CASES|Patients with RA with methotrexate therapy and inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; That present problems of effectiveness
2885227|NCT03352622|Active Comparator|CONTROLS|Patients with RA with methotrexate therapy inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; No problems of effectiveness
2885228|NCT03352609|Experimental|Active rTMS|5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
2885322|NCT03351998|Placebo Comparator|Placebo|Participants receiving matching placebo oral tablet.
2885229|NCT03352609|Sham Comparator|Sham|5 session of sham rTMS delivered with Magpro (MagVenture) double blind rTMS system to mimic active intervention.
2885230|NCT03352596|Experimental|intervention group|Eight weeks of low fructose diet with a maximum of 12 g of fructose
2885231|NCT03352596|No Intervention|control group|Eight weeks of regular diabetic diet with a 15%pro 30%fat 55%CHO
2885232|NCT03352583|Active Comparator|Day|Group receives casein protein during the day (greater than 6 hours before bed).
2885233|NCT03352583|Experimental|Night|Group receives casein protein immediately before going to bed.
2885234|NCT03352570|Experimental|COLOVAC device|colorectal surgery performed per standard of care with deployment of the Colovac device to protect the anastomosis site
2885235|NCT03352557|Experimental|Low-dose BIIB092|Intravenous (IV) infusion once every 4 weeks OR once every 12 weeks and placebo at the other 4-week dosing visits to maintain the treatment blind.
2885236|NCT03352557|Experimental|Medium-dose BIIB092|Intravenous (IV) infusion once every 4 weeks.
2885237|NCT03352557|Experimental|High-dose BIIB092|Intravenous (IV) infusion once every 4 weeks.
2885238|NCT03352557|Placebo Comparator|Placebo|Intravenous (IV) infusion once every 4 weeks.
2885239|NCT03352544|Experimental|Exercise|Exercise training for 12 weeks (aerobic and resistance training trice a week).
2885240|NCT03352544|No Intervention|Usual treatment|Usual treatment during 12 weeks, coinciding with exercise intervention time frame.
2885241|NCT03352531|Experimental|AK-105|Single-arm
2885242|NCT03352518|Experimental|IMD data collection|Subjects will intensively collect spectral raman data in a home-based setting for 5 days using WM3.4NR and comparators.
2885243|NCT03352505||control|healthy walking control participants
2885244|NCT03352505||wheelchair dancer|wheelchair users, who are performing wheelchair dancing
2885245|NCT03352505||wheelchair marathon participants|wheelchair users, who are participants in wheelchair/ handbike Marathon competitions
2885246|NCT03352505||sedentary wheelchair patients|wheelchair users, who conduct exercise bouts less than 2 times per month
2885247|NCT03352492|Experimental|Bilateral iridotomy|Each subject in this single-arm study undergoes bilateral laser peripheral iridotomy surgery. Each participant will undergo superior laser peripheral iridotomy in one eye and temporal laser peripheral iridotomy in the fellow eye.
2885248|NCT03352479|Other|Opioids Prescribed|Each participant in the study will be given an envelope for return of unused opioids. The percentage of returned number of opioids will be calculated based on the number prescribed
2885249|NCT03352466|Experimental|NasoShield very low dose|Single intranasal spray (Part A)
2885250|NCT03352466|Experimental|NasoShield low dose|Single intranasal spray (Part A)
2885251|NCT03352466|Experimental|NasoShield medium dose|Single intranasal spray (Part A)
2885252|NCT03352466|Experimental|NasoShield high dose|Single intranasal spray (Part A) or two intranasal sprays 21 days apart (Part B)
2885253|NCT03352466|Placebo Comparator|Placebo|Normal saline, single intranasal spray (Part A) or two intranasal sprays 21 days apart (Part B)
2885254|NCT03352466|Active Comparator|BioThrax|Three intramuscular injections 15 days apart (Part A)
2885255|NCT03352453|Experimental|Rapastinel 450mg|Rapastinel 450 milligram (mg) weekly intravenous (IV) injections.
2885256|NCT03352453|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections.
2885257|NCT03352440|Experimental|Cerebral Palsy - Kinect|Group with Cerebral Palsy that will perform the task on Kinect
2885258|NCT03352440|Experimental|Cerebral Palsy - Touchscreen|Group with Cerebral Palsy that will perform the task on Touchscreen
2885259|NCT03352440|Active Comparator|Control Group - Kinect|Group with typical development that will perform the task on Kinect
2885260|NCT03352440|Active Comparator|Control Group - Touchscreen|Group with typical development that will perform the task on Touchscreen
2885261|NCT03352427|Experimental|Dasatinib+Everolimus|"Dasatinib = 60 mg/m2 orally twice daily~Everolimus = starting dose of 3.0 mg/m2, with titration of dosing after first cycle to keep everolimus trough level of 5-15 ug/ml~Both agents will be taken daily for 28 day cycles. Cycles will be repeated every 28 days and patients may receive up to 24 cycles."
2885262|NCT03352414|Experimental|Alvimopan|
2885263|NCT03352414|Placebo Comparator|Placebo|
2885264|NCT03352388|Experimental|Snack|Dairy- and berry-based snacks
2885265|NCT03352388|No Intervention|Reference|No snacks
2885266|NCT03352375|Active Comparator|Orotracheally Intubation|Intervention:orotracheally intubation
2885267|NCT03352375|Active Comparator|Laryngeal Mask Airway|Intervention: Laryngeal Mask Airway
2885268|NCT03352362|Experimental|caldolor|intravenous caldolor injection during intraoperative period
2885269|NCT03352362|Active Comparator|denogan|intravenous denogan injection during intraoperative period
2885270|NCT03352362|Experimental|combination|intravenous denogan and caldolor injection during intraoperative period
2885271|NCT03352349|Experimental|Terlipressinum|If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
2885272|NCT03352323|Experimental|oxymetazoline cream|
2885273|NCT03352310|Experimental|Study Group|autologous UCB transfusion
2885274|NCT03352310|Other|Control Group|standard care
2885275|NCT03352284|Experimental|Straumann Pure Ceramic Implant|Replacement of single tooth gaps with a Zirconia implant
2885276|NCT03352271|Experimental|Individualized Incremental hemodialysis|ESRD patients starting an individualized (twice/week, once/week, once/10 days or less frequent) incremental hemodialysis program.
2885277|NCT03352271|Active Comparator|Thrice weekly dialysis|ESRD patients initiating a conventional thrice weekly hemodialysis program
2885278|NCT03352258|No Intervention|Observation|Subjects in this arm will only be followed and not treated (observational arm)
2885279|NCT03352258|Experimental|Treatment arm|Subjects will receive a low dose brain radiotherapy
2885280|NCT03352245|Experimental|Intervention Group|Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).
2885282|NCT03352232|Experimental|Subacute Ischemic Stroke|Subacute stroke patients post stroke within 3 months of enrollment, have persistent neurological deficits despite conventional rehabilitation
2885283|NCT03352232|Experimental|Chronic Ischemic Stroke|Chronic stroke patients more than 6 months from stroke with persistent neurological deficits despite conventional rehabilitation
2885284|NCT03352219|Experimental|Reality Check|Received streamed 13-episode HIV risk reduction serial drama, Reality Check, developed based on Social Cognitive Theory integrated with findings from focus groups and community advisory boards. Each character has a behavioral trajectory related to HIV. For example, one character modeled negotiating condom use with his partner when she was against it. Messages in the serial drama showed that the characters had normative support for HIV testing and condom use. One character modeled a mastery experience when she overcame her fear and got tested for HIV. Homophobia is addressed when a mother discovers that her son is gay. Over the course of the episodes, the interweaving storylines play out, with all the characters eventually achieving their positive goals.
2885285|NCT03352219|Placebo Comparator|Physical Activity Attention Control|Received streamed physical activity promotion videos designed to control for Hawthorne effects, including special attention, consisting of a series of 13 videos from YouTube on physical activity and exercise. The videos, selected to be appropriate for African Americans 18 to 24 years of age, were tailored to be gender specific and hence varied between men and women. The videos focused on the importance of physical activity, coping strategies for lack of motivation to engage in physical activity, and other challenges faced in becoming more physically active, provided specific knowledge and skills regarding how to engage in aerobic and muscle-strengthening exercises, and model aerobic and muscle-strengthening exercises in a variety of settings.
2885286|NCT03352206||2-Drug Treated Communities|"Communities who were treated with diethylcarbamazine and albendazole (DA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis."
2885287|NCT03352206||3-Drug Treated Communities|"Communities who were treated with ivermectin, diethylcarbamazine and albendazole (IDA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis."
2885288|NCT03352193||SOTI group|
2885289|NCT03352193||Historical control group|
2885290|NCT03352180|Active Comparator|subscapularis tendon repair|arthroscopic reapir of subscapularis tendon
2885291|NCT03352180|Active Comparator|subscapularis tendon debridement|arthroscopic debredement of subscapularis tendon
2885292|NCT03352167||ED Hjoerring|
2885293|NCT03352167||ED Aalborg|
2885294|NCT03352167||ED Aarhus|
2885295|NCT03352167||ED Herning|
2885296|NCT03352167||ED Aabenraa|
2885297|NCT03352167||ED Odense|
2885298|NCT03352167||ED Slagelse|
2885299|NCT03352167||ED Koege|
2885300|NCT03352154|Experimental|patients with unilateral cochlear implants submitted to P300|Patients with unilateral cochlear implants, using the speech processor at least 6 months, submitted to P300 exam before CI surgery, on speech processor activation and after 06 months.
2885301|NCT03352141|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced along the jawline with Cryolipolysis.
2885302|NCT03352128|Experimental|Creatine supplementation|7-day creatine supplementation
2885303|NCT03352128|Placebo Comparator|Placebo supplementation|7-day calcium lactate supplementation
2885304|NCT03352115|Experimental|Steroid group|Will recieve 5 day course of oral prednisolone post-operatively
2885305|NCT03352115|Placebo Comparator|Control|Will receive placebo syrup for 5 days post-operatively
2885306|NCT03352102|Experimental|Diaphragm Group (DG)|"subjects who received conventional physical therapy once a day, plus a daily session of electrical stimulation in the diaphragm.~Intervention: Electrical stimulation of the diaphragm."
2885307|NCT03352102|Active Comparator|Quadriceps Group (QG)|"subjects who also received conventional physical therapy once a day, plus a daily session of electrical stimulation in the quadriceps.~Intervention: Electrical stimulation of the quadriceps."
2885308|NCT03352102|No Intervention|Control Group (CG)|subjects who received regular treatment, i.e., conventional physical therapy, which included gross motor therapy and respiratory therapy twice a day every day, including weekend, during their stay in the ICU.
2885309|NCT03352089||Aortic stenosis group|Patients with severe aortic stenosis >70 years of age referred for aortic valve intervention
2885310|NCT03352089||Healthy volunteer group|Patients with no history of symptoms to suggest current cardiovascular disease >70 years of age
2885311|NCT03352076|Active Comparator|Oral Danatrol|200 mg orally TDS (600 mg daily) for 5-7 days
2885312|NCT03352076|Experimental|Vaginal Danazol|100 mg of Danazol Cream to be applied vaginally for 5-7 days on a single daily dose
2885313|NCT03352063|Active Comparator|Sitting with Exercise|Subjects will complete a short term training protocol while sitting >11 hours per day. This training will be preceded by a VO2max test to aid in setting the correct intensity for training. Subjects will be asked to complete three high fat tolerance tests. One to establish a baseline, the second to determine the acute effects of training, and a third at the completion of training to determine the cumulative effect of exercise training.
2885314|NCT03352063|Active Comparator|Walking with exercise|Subjects will complete a short term training protocol while sitting <5 hours per day. This training will be preceded by a VO2max test to aid in setting the correct intensity for training. Subjects will be asked to complete three high fat tolerance tests. One to establish a baseline, the second to determine the acute effects of training, and a third at the completion of training to determine the cumulative effect of exercise training.
2885315|NCT03352050|Active Comparator|ground beef|ground beef instead of mushrooms
2885316|NCT03352050|Active Comparator|Mushroom|2 servings of mushrooms
2885317|NCT03352037|Other|Single Arm|In this project, there is only one study group which comprises of patients with pancreatic cystic neoplasms who will undergo pancreatic PET/MRI.
2885318|NCT03352024|Other|Standard Care|Relational care used to help the patient by reducing the fear and anxiety
2885319|NCT03352024|Other|Hypnosis|Hypno-analgesia is used to help the patient by reducing the fear and anxiety
2885320|NCT03352011|Experimental|Primary Care Brief Mindfulness Training|
2885321|NCT03352011|Active Comparator|PTSD Psychoeducational Class|
2885323|NCT03351998|Active Comparator|Low dose statin|Participants will receive Lipitor 20Mg Tablet to take daily.
2885324|NCT03351998|Active Comparator|High dose statin|Participants will receive Lipitor 80Mg Tablet to take daily.
2885325|NCT03351985||Delirium Group|The cardiac surgery patients with delirium receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
2885326|NCT03351985||Non-delirium Group|The cardiac surgery patients without delirium receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
2885327|NCT03351972|Active Comparator|Bowel Prep routine|Participants randomised to this arm will receive their bowel prep (Klean Prep) with the routine guidance of taking the contents the day before their capsule endoscopy
2885328|NCT03351972|Active Comparator|Bowel Prep Split|Participants randomised to this arm will receive their bowel prep (Klean Prep) with the guidance stating to take the first dose the day before the capsule endoscopy and the second dose the morning of the capsule endoscopy
2885329|NCT03351972|Experimental|No bowel prep|Participants randomised to this arm will be advised to drink clear liquids only ahead of their capsule endoscopy procedure
2885330|NCT03351959||ypT0 rectal cancers|Rectal cancer patients who underwent neo-adjuvant treatment followed by surgical resection and had a final pathologic diagnosis of absence of residual viable tumoral cells within the rectal wall specimen (pathologic complete response, pCR - ypT0).
2885331|NCT03351946|Active Comparator|ZEEP at awakening|"Controlled ventilation with tidal volume of 7 mL/kg of ideal body weight and respiratory frequency 10. Fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure (PEEP) is set to 7 or 9 cm H20 (9 if BMI≥25) until start of emergence preoxygenation.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.~First CT scan after completion of surgery, before emergence. After the first CT scan and immediately before start of emergence preoxygenation, this group will have the PEEP exchanged for zero PEEP (ZEEP). ZEEP will remain until the study subjects are extubated. Second CT scan approx. 30 min after extubation."
2885332|NCT03351946|Active Comparator|PEEP at awakening|"Controlled ventilation with tidal volume of 7 mL/kg of ideal body weight and respiratory frequency 10. Fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure (PEEP) is set to 7 or 9 cm H20 (9 if BMI≥25) even after start of emergence preoxygenation.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.~First CT scan after completion of surgery, before emergence. After the first CT scan, this group will have PEEP remained until the study subjects are extubated. Second CT scan approx. 30 min after extubation."
2885333|NCT03351933|Experimental|Immune Globulin (Human) GamaSTAN|The healthy subjects will receive a single IM dose of GamaSTAN (0.2 mL/kg), followed by a PK sampling period of 150 days.
2885334|NCT03351894|Placebo Comparator|Conventional|Conventional phacoemulsification surgery
2885335|NCT03351894|Active Comparator|Femtosecond laser|Ziemer femtosecond laser assisted cataract surgery Intervention: Ziemer femtosecond laser assisted cataract surgery
2885336|NCT03351881|Active Comparator|Opt Out|
2885337|NCT03351881|Active Comparator|Opt In|
2885338|NCT03351881|Active Comparator|Opt Neutral|
2885339|NCT03351868|Experimental|Gene-modified autologous stem cells|Autologous hematopoeitic stem cells and mesenchymal stem cells transduced with lentiviral vector carrying the FANCA gene ex vivo
2885340|NCT03351855|Experimental|HPV-CTLs|Autologous or allogenic HPV specific cytotoxic lymphocytes
2885341|NCT03351842|Active Comparator|Arm I|Undergo surgery, followed by observation. Patients receive no further therapy
2885342|NCT03351842|Experimental|Arm II|Undergo surgery, followed by chemotherapy (cis Platinum/Carboplatin, Pemetrexed Disodium). Patients receive chemotherapy comprising cisplatin 75mg/m2 or Carboplatin AUC=5mg/ml/min, and pemetrexed 500mg/m2 in day 1. Treatment continues every 3 weeks for 4 courses.
2885343|NCT03351829|Experimental|Gene-modified autologous stem cells|Autologous stem cells transduced with lentiviral vector carrying the related gene ex vivo
2885344|NCT03351816|Experimental|Cardioversion group|Patients with persistent atrial fibrillation who are oriented for cardioversion in the course of routine care.
2885345|NCT03351816|Experimental|Ablation group|Patients with persistent or paroxystic atrial fibrillation who are oriented for ablation of AF in the course of routine care.
2885346|NCT03351803||Participants with Ashkenazi ancestry|
2885347|NCT03351790||All included participants|Patients that complete study questionnaire and have endoscopy recorded.
2885348|NCT03351777|Experimental|PR022 topical gel, 0.05%|Applied twice daily for 28 days
2885349|NCT03351777|Experimental|PR022 topical gel, 0.1%|Applied twice daily for 28 days
2885350|NCT03351777|Placebo Comparator|PR022 topical gel vehicle|Applied twice daily for 28 days
2885351|NCT03351764||1|Healthy Volunteers 18-65 years of age
2885352|NCT03351751|Placebo Comparator|Placebo|Subjects receiving placebo
2885353|NCT03351751|Experimental|PF-06372865|Subjects receiving PF-06372865
2885354|NCT03351738|Experimental|Cohort 1|Dose 1 MEDI5884
2885355|NCT03351738|Experimental|Cohort 2|Dose 2 MEDI5884
2885356|NCT03351738|Experimental|Cohort 3|Dose 3 MEDI5884
2885357|NCT03351738|Experimental|Cohort 4|Dose 4 MEDI5884
2885358|NCT03351738|Experimental|Cohort 5|Dose 5 MEDI5884
2885359|NCT03351738|Placebo Comparator|Cohort 6|Placebo
2885360|NCT03351725||Peripheral venous catheter indwell time more than 48 hours|
2885361|NCT03351712|Active Comparator|Gold Standard Intervention + Activity Tracker WITHOUT Feedback|Gold Standard Intervention + Activity Tracker WITHOUT Feedback (Medical Rehabilitation, Motivational Support and Psycho-Education) During the in-patient phase, participants will participate in the intensive four-week hospital-based and medically-managed rehabilitation program for weight reduction. All patients will be placed on a hypocaloric nutritionally balanced diet tailored to the individual after consultation with a dietitian. Furthermore, they will receive nutritional counseling provided by dietitians, have physical activity training provided by physiotherapists and motivational support with elements of psycho-education provided by physicians trained and informed by psychologists-psychotherapists.
2885588|NCT03350217|Active Comparator|Eleview|This arm will be administered the Eleview Injectate (up to 50 mL's) solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
2885362|NCT03351712|Experimental|Gold Standard Intervention and Activity Tracker WITH Feedback|In this experimental condition, will be provided the same rehabilitation program for the 4-weeks in-patient phase. In addition, for these subjects will be implemented a Stepped Protocol using wearable devices / activity trackers to collect information about daily physical activity and providing meaningful and informative feedbacks. The additional procedure starts during the in-patients phase, delivering and explaining the use of the wearable devices. In this meeting, longer than the one previously described for the control condition, experimenters provide information, set individualized goals and explain feedbacks which will be delivered after ending in-patients phase by the electronic wearable devices.
2885363|NCT03351712|Experimental|ACT-Based Intervention and Activity Tracker WITHOUT Feedback|In this experimental condition, the subjects followed the normal medical rehabilitation program described above for the first experimental condition. For the out-patient phase the ACT intervention includes monthly 30 minutes skype-telephone sessions. The ACT-based interventions includes different processes: 1) Acceptance, that involves the active awareness of difficult private experiences without attempts to control or avoid unpleasant emotions. 2) Mindfulness, refers to engaging in present moment experience and adopting an open and curious attitude. 3) Defusion: Participants will be encouraged to defuse from thoughts and feelings by turning attention toward the 'noticing-self', instead of becoming attached to thoughts and 'run' through life on 'auto-pilot'. 4) Values and Commitment: encouraging participants to live in accordance with their values, participants can engage in meaningful activities despite experiencing unwanted emotions/ sensations.
2885364|NCT03351712|Experimental|ACT-Based Intervention and Activity Tracker WITH Feedback|ACT-Based Intervention and Activity Tracker WITH Feedback (Combining ACT and Behavioral Change) In the last experimental condition, obese individuals will follow the same rehabilitation program in the in-patients phase of the Behavioral Change condition, with the addition of the brief ACT intervention of 4 45-minutes sessions for a total amount of 3 hours one-to-one therapy sessions, exactly as in the ACT condition. In the out-patient phase of 16 weeks, each participant receive feedback from activity tracker following the same stepped protocol but message and feedbacks are informed by ACT therapist, including Value-based goal setting, prompt for including defusion from difficult thoughts, mindfulness cues and a set of ACT-consistent metaphors and messages.
2885365|NCT03351699|Experimental|Panel A: MK-4250 150 mg|Participants will receive MK-4250 150 mg tablet by mouth on Day 1 after an 8-hour fast.
2885366|NCT03351699|Experimental|Panel B: MK-4250 600 mg|Participants will receive MK-4250 600 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel B and the dose selected (i.e., ≤600 mg) will be made based on evaluation of pharmacokinetics and 7-day safety and viral load data from Panel A.
2885367|NCT03351699|Experimental|Panel D: MK-4250 900 mg|Participants will receive MK-4250 900 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel D will be made upon completion of Panels A and B and evaluation of safety and viral load data from those panels.
2885368|NCT03351699|Experimental|Panel E: MK-4250 ≤900 mg with a Low-fat Meal|Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a low-fat meal. The decision to enroll Panel E will be made upon completion of Panel D and evaluation of safety and viral load data from that panel.
2885369|NCT03351699|Experimental|Panel F: MK-4250 ≤900 mg with a Moderate-fat Meal|Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a moderate-fat meal. The decision to enroll Panel F will be made upon completion of Panel D and evaluation of safety and viral load data from that panel. The decision to enroll Panel F will be made based on evaluation of PK and safety data from other studies with MK-4250.
2885370|NCT03351686|Experimental|tranexamic acid group|
2885371|NCT03351686|No Intervention|non tranexamic (control) group|
2885372|NCT03351673|Experimental|endometrial volume 2D TVS|perimenopausal women who bleed are examined by 2D TVS and the calculated endometrial volume using a specific formula and followed by endometrial biopsy for correlation with the pathological findings
2885373|NCT03351647||Group Ustekinumab|Patients presenting an active crohn's disease (HBI score ≥ 4) with an indication of treatment by ustekinumab because of failure or unacceptable side effects of previous treatments, and who have already been treated by at least one anti TNF The patients must be 18 years old or older.
2885374|NCT03351634|Experimental|Children with neurogenic incontinence with spinal dysraphism|
2885375|NCT03351608|Experimental|Sugammadex 2 mg/kg (Part A)|Single intravenous (i.v.) bolus of sugammadex at 2 mg/kg.
2885376|NCT03351608|Experimental|Sugammadex 4 mg/kg (Part A)|Single i.v. bolus of sugammadex at 4 mg/kg.
2885377|NCT03351608|Experimental|Sugammadex 2 mg/kg (Part B)|Single i.v. bolus of sugammadex at 2 mg/kg.
2885378|NCT03351608|Experimental|Sugammadex 4 mg/kg (Part B)|Single i.v. bolus of sugammadex at 4 mg/kg.
2885379|NCT03351608|Active Comparator|Neostigmine (Part B)|Single i.v. bolus containing neostigmine (50 μg/kg; up to 5 mg maximum dose) in combination with either glycopyrrolate (10 μg/kg) or atropine sulfate (20 μg/kg).
2885380|NCT03351582|Experimental|Grief and Communication One Session|Group one will meet with a family therapist for one 90 minute session where the main focus will be on providing psychoeducation on grief and communication to both children and parents. This arm receives only the first session of the grief and communication family intervention.
2885381|NCT03351582|Experimental|Grief and Communication Three Sessions|Thie Group will receive all three sessions of the grief and communication family intervention.
2885382|NCT03351582|No Intervention|Control|Group three will be the control group and will not receive the grief and communication family intervention.
2885383|NCT03351569|Experimental|Immunoglobulin|Intravenous immunoglobulin 25 grams (five 100 ml bottles, 5g/100ml), in 3 hours, once a month for one year.
2885384|NCT03351569|Placebo Comparator|Saline solution|Intravenous saline solution 500 ml (five 100 ml bottles), in 3 hours, once a month for one year.
2885385|NCT03351556|No Intervention|Comparison Arm|Participants in the comparison group will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS.
2885386|NCT03351556|Experimental|Active Intervention 1|Participants will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month (~$4.50) for up to 6 months conditional on visit attendance.
2885661|NCT03349658|Active Comparator|spinal anesthesia|Patients in this group were randomized to receive spinal anesthesia.
2885387|NCT03351556|Experimental|Active Intervention 2|Participants will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month (~$10.00) for up to 6 months conditional on visit attendance.
2885388|NCT03351543|Experimental|Exposed group|these volunteers receive microbial inoculate
2885389|NCT03351543|No Intervention|control|these volunteers do not receive microbial inoculate
2885390|NCT03351530||Pre-diabetes|
2885391|NCT03351530||Diabetes|
2885392|NCT03351530||Diabetes with periodontal disease|
2885393|NCT03351530||Periodontal patient|
2885394|NCT03351530||Healthy person|
2885395|NCT03351517|Experimental|Tapentadol arm|Single dose of 100 mg of extended release oral tapentadol will be administered 1 hour before surgery.
2885396|NCT03351517|Placebo Comparator|Placebo arm|A comparable placebo will be administered 1 hour before surgery.
2885397|NCT03351504|No Intervention|Control (usual lighting)|Participants will continue to use their usual lighting sources.
2885398|NCT03351504|Experimental|Intervention (solar lighting)|Participants will receive an indoor solar lighting system
2885399|NCT03351478|Experimental|Sotagliflozin|Sotagliflozin will be given as two tablets and one placebo capsule (identical to empagliflozin capsule in appearance), once daily before the first meal of the day.
2885400|NCT03351478|Active Comparator|Empagliflozin|Empagliflozin will be given as two placebo tablets (identical to sotagliflozin in appearance) and one capsule of empagliflozin, once daily before the first meal of the day.
2885401|NCT03351478|Placebo Comparator|Placebo|Placebo given as two placebo tablets (identical to sotagliflozin) and one placebo capsule (identical to empagliflozin) once daily before the first meal of the day.
2885402|NCT03351465|Experimental|CALM|The intervention for this study, CALM Tools for Living-Il, is a computer-assisted cognitive-behavioral therapy for anxiety and depression that guides both the patient and CALM specialist. It is a reformulation of CALM Tools for Living that directly incorporates our previously optional modules for depression into the main program. The computerized/internet format is designed to retain the fidelity of CBT when delivered by novice clinicians. The program is intended to be delivered in 6 to 8 sessions, although flexibility is allowed. Participants in the intervention group will be visited by the calm specialist weekly between 6 and 8 times prenatally;postpartum visits will vary based on continuing assessment of symptoms.
2885403|NCT03351465|No Intervention|Treatment as Usual|Participants will receive pre-natal care as usual, and will be visited at 4 time points by the graduate student researchers: baseline, 12 weeks post baseline, and 10 weeks postpartum.
2885404|NCT03351452|Experimental|Real tDCS|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the VLPFC (current density: 0.057 mA/cm2) and cathodal 10x10 rubber electrode over supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
2885405|NCT03351452|Experimental|Real tACS|20 min of 2 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm and 10x10 cm rubber electrodes over the VLPFC (current density: 0.057 mA/cm2) and supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
2885406|NCT03351452|Sham Comparator|Sham tES|30 s of 2 mA sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the VLPFC (current density: 0.057 mA/cm2) and supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase of the memory task.
2885407|NCT03351439|Active Comparator|Group 1|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily x 3 weeks
2885408|NCT03351439|Experimental|Group 2|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Zopiclone 7.5 mg nightly for 7 days
2885409|NCT03351439|Experimental|Group 3|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Gabapentin 600 mg pre-operatively for one dose and 600 mg post-operatively for one dose
2885410|NCT03351439|Experimental|Group 4|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Celebrex 400 mg pre-operatively for one dose
2885411|NCT03351426|Active Comparator|Active tDCS Group|Subjects will receive a total of eight tDCS sessions: 1st week five daily sessions (Monday to Friday), followed by 2nd week three sessions only (Monday, Wednesday, Friday). tDCS sessions will consist of 20 minutes stimulation at 2mA. Target: left dorsolateral prefrontal cortex (DLPFC). Montage: 5x5 sponge electrodes placed over EEG 10:20 system location F3 (anode) and right supraorbital area (cathode).
2885412|NCT03351426|Sham Comparator|Sham tDCS Group|Subjects will receive a total of eight tDCS sessions: 1st week five daily sessions (Monday to Friday), followed by 2nd week three sessions only (Monday, Wednesday, Friday). tDCS sessions will be sham stimulation (30-second ramp up and down). Target: left dorsolateral prefrontal cortex (DLPFC). Montage: 5x5 sponge electrodes placed over EEG 10:20 system location F3 (anode) and right supraorbital area (cathode).
2885413|NCT03351413|Experimental|Intervention|"LIVE-LiFE to Prevent Falls Among Older Fallers Intervention, which is an individually tailored program at the participant's home spaced across 12 weeks including:~Home safety assessment and risk reduction strategies; incorporating strength and balance training into daily habits vision screening and referral; and education about fear of falling and falls~Home repairs, modifications, and low cost assistive devices to address unsafe home environments increasing fall risk~Medication review and feedback concerning medications with increased fall risk"
2885414|NCT03351413|No Intervention|Control|- An individualized fall risk assessment provided to participant and their primary care provider
2885415|NCT03351400|Experimental|Treatment group|Stem cells administered to participants
2885416|NCT03351387||SPY Intra-operative Angiography|The SPY Fluorescent Imaging System
2885417|NCT03351374||Temple Physicians Incorporated|A community-based provider, operating 32 primary care sites
2885418|NCT03351374||WhiteBark|For profit entity created by the Indiana Rural Health Association
2885662|NCT03349645|Experimental|Ampion|4 mL Ampion (<5 kilodatlon (kDa) ultrafiltrate of 5% Human Serum Albumin (HSA)), solution
2885663|NCT03349619|Experimental|Resveratrol plus Carboxymethyl-β-Glucan|
2885419|NCT03351374||Drexel Family Intervention Science|Academic center that developed and deployed Attachment Based Family Therapy (ABFT) assessment, treatment, and prevention models with an interest in adolescents struggling with substance abuse, depression, trauma, and suicidality.
2885420|NCT03351374||Bon Secours Health System|A primary care clinic in Baltimore that provides care services to a population in a lower socioeconomic status in downtown Baltimore.
2885421|NCT03351374||Howard University Hospital CARES|A project provides free outpatient medical, dental, mental health, nutrition and social services for HIV positive uninsured and underinsured residents of the District of Columbia.
2885422|NCT03351361|Experimental|Nivolumab + Ipilimumab|
2885423|NCT03351361|Active Comparator|Chemotherapy|carboplatin and pemetrexed or carboplatin and paclitaxel
2885424|NCT03351348|Placebo Comparator|Placebo|The intervention in this study is the insertion of 20cc of saline via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- axillary dissection, +/- sentinel lymph node biopsy.
2885425|NCT03351348|Experimental|Bupivacaine|The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- axillary dissection, +/- sentinel lymph node biopsy.
2885426|NCT03351335|Experimental|Ultherapy®, energy level 3|Group 1: Subjects will receive Ultherapy® treatment at energy level 3 (EL3).
2885427|NCT03351335|Experimental|Ultherapy®, energy level 4|Group 2: Subjects will receive Ultherapy® treatment at energy level 4 (EL4).
2885428|NCT03351335|Experimental|Ultherapy®, energy level 2|Group 3: Subjects will receive Ultherapy® treatment at energy level 2 (EL2).
2885429|NCT03351322|Experimental|ENERGI-F701|ENERGI-F701, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks
2885430|NCT03351322|Active Comparator|Regaine|Regaine, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks
2885431|NCT03351309|Experimental|Telephone-based cognitive behavioral therapy|Telephone-based cognitive behavioral therapy (CBT) intervention - Four session protocol plus routine perioperative management.
2885432|NCT03351309|No Intervention|Treatment as Usual|Treatment as Usual (TAU) - Routine perioperative management.
2885433|NCT03351296|Experimental|LV5FU2 + streptozotocin +/- Bevacizumab|
2885434|NCT03351296|Experimental|Capecitabine + temozolomide +/- Bevacizumab|
2885435|NCT03351283|Experimental|Severe sodium restriction|"Patients will be assigned to a diet with two grams of sodium. The nutritionist will be responsible for calculating diets appropriate to the needs of each patient. The diet will not have the intention to modify the weight of the patient but only to indicate the menus that the patients will follow. All the patients will be explained the diet. Patients will be allowed a maximum intake of 1.5 liters of water per day, including the liquid of soups, juices and drinks; This will be explained in detail to the patients.~The diets will be identical in calories according to the weight of the patient. The only difference in diets will be the sodium content, which will be 2 grams of sodium vs. 3 grams of sodium."
2885436|NCT03351283|Active Comparator|Moderate sodium restriction.|Patients will be assigned to a diet with three grams of sodium.
2885437|NCT03351244|Experimental|BI 409306 high dose|
2885438|NCT03351244|Experimental|BI 409306 low dose|
2885439|NCT03351244|Placebo Comparator|Placebo|
2885440|NCT03351231|Experimental|Dose Escalation|BMS-986242 administered in combination with Nivolumab
2885441|NCT03351231|Experimental|Dose Expansion|BMS-986242 administered in combination with Nivolumab
2885442|NCT03351218|Other|Patients|25 patients with cervical and 25 patients with myoclonus dystonia
2885443|NCT03351218|Other|Controls|50 healthy volunteers matched to patents ( age, sex)
2885444|NCT03351205|Experimental|Uterine cavity barrier only|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.
2885445|NCT03351205|Experimental|hormone|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ amnion membrane+hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
2885446|NCT03351179||AMI patients with HFpEF|
2885447|NCT03351179||AMI patients without HF|
2885448|NCT03351166|Experimental|Molidustat (BAY85-3934)|Molidustat group
2885449|NCT03351153|Other|X-ray group|In the X-ray group, the changes in femoral head height were measured with X-ray in an anteroposterior position of the pelvis (healthy and affected sides of the hip) at preoperative 1 week.
2885450|NCT03351153|Other|CT group|In the CT group, changes of femoral head height were measured with CT scan on bilateral hips (healthy side and affected side) at preoperative 1 week.
2885451|NCT03351153|Other|Specimen group|In the specimen group, femoral head on the affected side was resected during surgery and directly measured with a ruler and vernier caliper.
2885452|NCT03351140||Subjects with breast cancer|Approximately 30 subjects who have confirmed diagnosis of breast cancer will be included in the study
2885453|NCT03351140||Subjects with prostate cancer|Approximately 30 subjects who have confirmed diagnosis of prostate cancer will be included in the study
2885454|NCT03351140||Subjects with NSCLC|Approximately 30 subjects who have confirmed diagnosis of NSCLC will be included in the study
2885455|NCT03351140||Subjects with multiple myeloma|Approximately 30 subjects who have confirmed diagnosis of multiple myeloma excluding smoldering/asymptomatic multiple myeloma will be included in the study
2885456|NCT03351140||Subjects with DLBCL or follicular lymphoma|Approximately 30 subjects who have confirmed diagnosis of DLBCL or follicular lymphoma will be included in the study
2885457|NCT03351127||18-29 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 18-29 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
2885458|NCT03351127||30-39 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 30-39 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
2885459|NCT03351127||40-49 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 40-49 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
2885664|NCT03349619|Placebo Comparator|Placebo|
2885460|NCT03351127||50-59 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 50-59 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
2885461|NCT03351127||60-69 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 60-69 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
2885462|NCT03351127||70-79 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 70-79 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
2885463|NCT03351114|Experimental|Crisaborole 2% ointment|Crisaborole 2% ointment applied to affected skin twice per day.
2885464|NCT03351101|Experimental|Acuvue Vita|Contact Lense
2885465|NCT03351101|Experimental|Ultra|contact lense
2885466|NCT03351088|Other|Preventive ligation|Preventive ligation of DVC is done after the opening of endopelvic fascia and before bladder neck dissection. DVC is ligated at the level of the apex with a 8-fashion single stich (1-0 Monocryl® CT-1 stich) trying to preserve puboprostatic ligaments and the muscle fibres of the rabdosphincter. DVC is then dissected at the end of prostatectomy before the section of the urethra.
2885467|NCT03351088|Other|Delayed ligation|Delayed ligation is done after the section of the urethra and once the prostatectomy is completed with a single stich (3-0 Monocryl® UR-6).
2885468|NCT03351075|Experimental|Intervention group|Standard physical therapy program + Modern educational program
2885469|NCT03351075|Active Comparator|Control group|Standard physical therapy program + Traditional biomedical educational program
2885470|NCT03351062|Active Comparator|Tamoxifen treatment group|Patients in this group will receive tamoxifen treatment.
2885471|NCT03351062|Active Comparator|Toremifene treatment group|Patients in this group will receive Toremifene treatment.
2885472|NCT03351049|Experimental|Reactive, Low air loss support surface|Participants in this arm will use a reactive support surface with a low air loss feature
2885473|NCT03351049|Active Comparator|Reactive, non-low air loss|Participants in this arm will use a reactive support surface without a low air loss feature
2885474|NCT03351023||Nurses' Health Study II|Nurses' Health Study II, an ongoing cohort study of 116,430 female registered nurses in the US, aged 25-42 at enrollment in 1989. Participants have been followed by biennial mailed questionnaires that elicit updated information on diet, lifestyle, and various health outcomes; the follow-up rate over 26 years exceeds 90% of the eligible person-time.
2885475|NCT03351010|Experimental|Mindfulness|Receiving education program and mindfulness training
2885476|NCT03351010|Active Comparator|Control|Receiving education program
2885477|NCT03350997|Experimental|Trial 1|Subjects will have two CGM devices placed on either side of the abdomen, near the belly button. Trial 1 Exercise - subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for ~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
2885478|NCT03350997|Experimental|Trial 2|Subjects will have one CGM device placed on one side of the abdomen. Trial 2 Exercise - subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).
2885479|NCT03350984|Experimental|NPH insulin group|Patients receiving NPH twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose >180 mg/dL. If subjects were not eating, they shouldn't receive dose of NPH insulin. Intervention Drug: NPH insulin
2885480|NCT03350984|Active Comparator|Glargine and Lispro insulin group|"Half of the total of Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose will be given as Lispro; doses were divided equally for breakfast, lunch, and dinner. An additional correctional dose of Lispro will be given for any blood glucose >180 mg/dL. If subjects were not eating, they received glargine once daily and they shouldn't receive doses of lispro.~Intervention drug: Glargine and Lispro"
2885481|NCT03350971|Experimental|Virtual reality training|Training with ergometer associated with training on wii videogame during 4 days
2885482|NCT03350971|Active Comparator|Control|chest physical therapy
2885483|NCT03350958|Experimental|Group 1|Participants received experimental test meal first and placebo comparator meal at the next study visit. Participants to fill out visit questionnaire prior to meal and every 30 minutes thereafter for 5 hours. Samples of ileostomy fluid taken at these time-points, along with blood samples in a subset of participants
2885484|NCT03350958|Placebo Comparator|Group 2|Participants received placebo comparator meal first and experimental test meal at the next study visit. Participants to fill out visit questionnaire prior to meal and every 30 minutes thereafter for 5 hours. Samples of ileostomy fluid taken at these time-points, along with blood samples in a subset of participants
2885485|NCT03350945|Active Comparator|Device:Titanium Clips|Device: Tumor localization. Preoperative endoscopic localization with titanium clips
2885486|NCT03350945|Active Comparator|Device:Intra-operative Endoscopy|Device: Tumor localization. During the laparoscopic surgery,tumor is localized using intra-operative endoscopy detection.
2885487|NCT03350945|Experimental|Device:Carbon Nanoparticles|Device: Tumor localization. During the laparoscopic surgery,tumor is localized using carbon nanoparticles.
2885488|NCT03350932|No Intervention|Control|This group of children, will have to perform a sensory imagination task about neutral facts before choosing the portion size of a food.
2885489|NCT03350932|Experimental|Food sensory imagination|"This group, the food sensory imagination group, will have to perform a sensory imagination task foods (being the intervention) before choosing the portion size of a food."
2885490|NCT03350919|Experimental|Training in the blind field|Training in the blind field using software
2885491|NCT03350919|Experimental|Training in the intact field|Training in the intact field using software
2885665|NCT03349606|Experimental|Cocaine dependence|[C-11]FLB 457 PET at baseline and post d-amphetamine
2885666|NCT03349606|Experimental|Controls|[C-11]FLB 457 PET at baseline and post d-amphetamine
2885492|NCT03350906|Experimental|n3-PUFA|Participants will be instructed to swallow 2 Docosahexaenoic acid (DHA)/EPA soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day. The DHA/EPA soft gels will each contain ~465mg of EPA and ~375mg of DHA for a total daily dosage of 3.4g/day. The duration of the intervention will be 6 months.
2885493|NCT03350906|Placebo Comparator|Placebo|Patients in this group will be supplemented with placebo capsules containing soybean oil. Participants will be instructed to swallow 2 placebo soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day. The duration of the intervention will be 6 months.
2885494|NCT03350893|Placebo Comparator|Control Group|Emulsion base without probiotics
2885495|NCT03350893|Experimental|Active Group|Emulsion base with probiotics
2885496|NCT03350880|Experimental|PNF in Water - PNFW|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
2885497|NCT03350880|Active Comparator|PNF on Land - PNFL|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
2885498|NCT03350867|Experimental|Personalized Insole Group|The participants will use insole with personalized support directed to your biomechanics necessities.
2885499|NCT03350867|Placebo Comparator|Placebo Group|The participants will use plane insoles.
2885500|NCT03350854|No Intervention|The non-intervention control group|In the non-intervention control group, providers are blind to the patient's preferred decision making role.
2885501|NCT03350854|Experimental|The intervention group|The provider will be informed of the patient preference in treatment decision making (preferred role) and have a discussion about this with the patient in the intervention group.
2885502|NCT03350841|Experimental|Revascularization|platelet rich plasma injected in the canals
2885503|NCT03350841|Active Comparator|root canal treatment|endodontic treatment obturated with gutta percha
2885504|NCT03350815|Active Comparator|Responders|Patients achieving an Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (total score <1.3) at both Week 12 and Week 16.
2885505|NCT03350815|Active Comparator|Inadequate responders|Patients who have active disease, defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) total score of >1.3 at both Week 12 and Week 16, and who do achieve a decrease (improvement) from baseline in total ASDAS score at both Week 12 and Week 16.
2885506|NCT03350815|Active Comparator|Non-responders|"Patients who exhibit no change or an increase (worsening) from baseline in total Ankylosing Spondylitis Disease Activity Score (ASDAS) score at either Week 12 or Week 16.~Non-responders will not enter Treatment Period 2. Non-responders will be discontinued from the study at Week 16."
2885507|NCT03350802||procalcitonin pneumonia cohort|Patients who are suspected of acute pneumonia due to symptoms and imaging findings compatible with pneumonia can be enrolled in this cohort.
2885508|NCT03350789|Experimental|Real acupuncture|manual acupuncture + electroacupuncuture on acupoints, twice a week, for 4 weeks
2885509|NCT03350789|Sham Comparator|Sham acupuncture|sham acupuncture (no skin penetration) + placebo electroacupuncture without electrical stimulation on acupoints, twice a week, for 4 weeks
2885510|NCT03350763|Experimental|Plastic biliary stent|A plastic (ie Tannenbaum 10 Fr) biliary stent is used to achieve biliary decompression
2885511|NCT03350763|Experimental|Self-expandable metallic biliary stent|A self-expandable metallic biliary stent is used to achieve biliary decompression
2885512|NCT03350750|Active Comparator|Open Shunt Group|FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve setting to active (open shunt group)(setting 4)(110 mm H2O) at time of shunt implantation
2885513|NCT03350750|Sham Comparator|Closed Shunt Group|FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve setting to placebo (closed shunt group)(setting 8)(>400 mm H2O) at time of shunt implantation followed by setting to active (setting 4) (110 mm H2O) four months after the procedure.
2885514|NCT03350737|Experimental|Heparin-primed physical rehabilitation|2 exercise sessions per day for 5 days a week for 2 weeks with 100 IU/kg of Heparin i.v. (up to a maximum of 5000 IU) 10 minutes prior to exercise
2885515|NCT03350737|Placebo Comparator|Placebo-primed physical rehabilitation|2 exercise sessions per day for 5 days a week for 2 weeks with placebo (2 ml of Sodium Chloride 0.9% i.v.) 10 minutes prior to exercise
2885516|NCT03350724|Experimental|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
2885517|NCT03350724|Active Comparator|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
2885518|NCT03350711||Microbiota Enrichment Program (MEP)|Patients who are seeking a fecal microbiota transplant (FMT), for any reason, who will be part of a registry of patients to potentially screen for a FMT study.
2885519|NCT03350698|Experimental|active drug|Human Papilloma virus ,Gardasil, 9 valent vaccine
2885520|NCT03350685||Classic Whipple's disease (CWD)|"Classic Whipple's disease (CWD), defined as~duodenal biopsy positive by PAS/immunohistochemistry~or blood positive by PCR"
2885521|NCT03350685||Focal Whipple's disease (FWD)|"Focal Whipple's disease (FWD), defined as~joint fluid positive by PCR~but duodenal biopsy negative by PAS/immunohistochemistry"
2885522|NCT03350685||Chronic T. whipplei-associated arthritis (CTWA)|"Chronic T. whipplei-associated arthritis (CTWA) defined as chronic arthritis and~duodenal biopsy, stool, or saliva positive by PCR~duodenal biopsy negative by PAS/immunohistochemistry~joint fluid negative by PCR"
2885523|NCT03350672|Experimental|Cohort 1a|"Age 18 or older at the time of signed informed consent~Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP~Willing and able to independently provide written informed consent~Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test"
2885524|NCT03350672|Experimental|Cohort 1b|"Age 18 or older at the time of signed informed consent~Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP~Willing and able to independently provide written informed consent~Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test"
2885718|NCT03349099|Active Comparator|Boston Scientific Navigator HD|ureteral access sheath
2885729|NCT03349021|Experimental|Bougiecap|Treatment with Bougiecap instead of Savary Bougie
2885525|NCT03350672|Active Comparator|Cohort 2|"Age 18 or older at the time of signed informed consent~Willing and able to independently provide written informed consent~Last viral load < 20 copies/mL within the last four weeks of screening~Must be on combination antiretroviral therapy that includes TAF/FTC for at least 6 months~Undetectable viral load, as defined by < 50 copies/ml, for at least 6 months"
2885526|NCT03350659|Experimental|Atomoxetine|Atomoxetine 18mg once a day.
2885527|NCT03350659|Active Comparator|Midodrine|midodrine 2.5mg twice a day (increase to 5mg three times a day if necessary)
2885528|NCT03350646|Other|Low volume (20-25 μl)|Low volume (20-25 μl)
2885529|NCT03350646|Other|High volume (40-45 μl)|High volume (40-45 μl)
2885530|NCT03350633|Experimental|Tocilizumab|Tocilizumab Injection (ACTEMRA®) , a IL-6 receptor blockade
2885531|NCT03350633|Active Comparator|Azathioprine|Imuran
2885532|NCT03350620|Experimental|NVK-002 Concentration 1|"Stage 1: Subjects will be randomized to NVK-002 Concentration 1~Stage 2: Subjects will be re-randomized to one of the three treatment arms."
2885533|NCT03350620|Experimental|NVK-002 Concentration 2|"Stage 1: Subjects will be randomized to NVK-002 Concentration 2~Stage 2: Subjects will be re-randomized to one of the three treatment arms."
2885534|NCT03350620|Placebo Comparator|Vehicle (Placebo)|"Stage 1: Subjects will be randomized to Vehicle (Placebo)~Stage 2: Subjects will be re-randomized to one of the two experimental NVK-002 treatment arms"
2885535|NCT03350594|Active Comparator|Systemic Family Therapy|"SyFT involves the patient, the parents, and siblings over the age of 6 living at home. Therapists do not manage the issues relating to AN, which are taken on by referent psychiatrist who can be called on in case of any concern. Without denying personal suffering and its intra-psychic and meta-psychological impact, or the somatic and biological aspect of the pathology, the emphasis is on interactions around the symptom.~There will be free exchanges along the lines between therapist and family, within the family and between therapists.~Session is possible with sibling alone or the parents alone or in inter-generational mode (other family relatives)"
2885536|NCT03350594|Experimental|Multiple Family Therapy|"Each session will involve 5 families of patients suffering from AN including the parents and non-systematically the siblings. There will be exchanges in groups and mediation via different exercises involving different sub-groups according to the theme: complete families, patients on their own for problems specific to them, or  cross-parenting  exercises whereby parents adopt another patient for the duration of the exercise. This organization enables mutual support and social propping, favoring the emergence of family resources. Direct exchanges between families (between parents, siblings, or mixes) with and between therapists are also sought."
2885537|NCT03350581|Active Comparator|FAM-CT 3D map group|Operator will perform radiofrequency catheter ablation using 3D map which is constructed by integration of FAM with CT or MRI.
2885538|NCT03350581|Experimental|FAM 3D map group|Operator will perform radiofrequency catheter ablation using 3D map which is constructed by integration of FAM alone.
2885539|NCT03350555|Experimental|ERCP with additioned endoscopy|This arm will include participants undergoing ERCP with assistance of additioned endoscopy.
2885540|NCT03350555|No Intervention|ERCP without additioned endoscopy|This arm will include participants undergoing ERCP without assistance of additioned endoscopy as negative controls.
2885541|NCT03350542|Experimental|SYNERGY 48 mm|SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)
2885542|NCT03350529|Experimental|Localised PC prior to RP|MRI guided transurethral HIFU ablation is targeted to MRI visible, biopsy proven, index lesion(s) within prostate and if possible with 5mm angular extension (imaging based healthy tissue marginal) to both sides from the tumour boundary in transverse plane and 5 mm in coronal plane. The ablative effect is aimed to reach prostate capsule by heating the control boundary (3 mm from capsule) to temperature 57 °C. The focal approach is intended to be radical as for index lesion.
2885543|NCT03350529|Experimental|Symptomatic locally advanced PC|MRI guided transurethral HIFU ablation is targeted to main prostatic malignant tumour squeezing and/or invading the prostatic urethra and/or bladder neck. The approach is intended to be palliative.
2885544|NCT03350529|Experimental|Locally recurrent PC after EBRT|"MRI guided transurethral HIFU ablation is targeted to MRI visible, biopsy proven, local recurrent index lesion(s) within and/or surrounding prostate and if possible with 5 mm angular extension to either side from the tumour boundary in transverse plane and 5 mm in coronal plane. The approach is intended to be focal and salvage.~The whole-gland HIFU ablation approach will be considered in case of extensive organ confined recurrent prostate cancer (positive biopsies for malignancy from extensive/multiple area in prostate and/or extensive/multiple lesion(s) at baseline MRI) to cover whole prostate."
2885545|NCT03350529|Experimental|Symptomatic BPH|MRI guided transurethral HIFU ablation is targeted to adenomas of the prostate. The HIFU sector encompasses bilateral (anterolateral) transitional zones between bladder neck and verumontanum (colliculus seminalis).
2885546|NCT03350516|Experimental|Daily 500 mg Calcium|
2885547|NCT03350516|Active Comparator|Daily1500 mg Calcium (Standard dose)|
2885548|NCT03350503|Experimental|Acrysof IQ Toric A-code IOL|IOL implanted during cataract surgery
2885549|NCT03350490|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2885550|NCT03350490|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2885551|NCT03350490|Experimental|Combination therapy|"In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(>2cm),then drink QilishengImmunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2885552|NCT03350490|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2885553|NCT03350477|Active Comparator|Cancer ablation|In this group,the patients will receive ablation therapy(e.g.cryosurgery or irrreversible electroporation) first for big tumors (>2cm).The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2885554|NCT03350477|Active Comparator|Life information rehabilitation therapy|"In this group,the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2885555|NCT03350477|Experimental|Combination therapy|"In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(>2cm),then drink QilishengImmunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2885556|NCT03350477|No Intervention|Control|In this group,the patients will recieve no special treatment and as a control group.The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2885557|NCT03350464|Experimental|Pain in PD Arm|This arm will receive a total 10 sessions of TMS stimulation over 10 weeks. Pre and post intervention scales will be performed on week one and week 10.
2885558|NCT03350451|Experimental|ALN-GO1|
2885559|NCT03350438||PTSD Patients|patients ranging 18-60, diagnosed with PTSD following a trauma that occured over one year before the current study and do not have other health problems that may affect their everyday participation.
2885560|NCT03350438||healthy adults|healthy adults, ranging 18-60, without any health problems that may affect their everyday participation.
2885561|NCT03350425||Recently vaccinated patients|Patients who recently received pneumococcal vaccination.
2885562|NCT03350425||Patients vaccinated >2 years ago|Patients who received pneumococcal vaccination more than two years ago.
2885563|NCT03350399||level of placenta growth factor in IUGR|
2885564|NCT03350386|Experimental|Single dose|Single administration of FYU-981
2885565|NCT03350386|Experimental|Concomitant administration|Concomitant administration of FYU-981 with oxaprozin at steady state
2885566|NCT03350373|Experimental|Fasted dosing followed by fed dosing|Dosing of FYU-981 in the fasted state followed by fed dosing
2885567|NCT03350373|Experimental|Fed dosing followed by fasted dosing|Dosing of FYU-981 in the fed state followed by fasted dosing
2885568|NCT03350360|Experimental|Attention Control Training Clinic|"Attention Control Training Clinic will consist of:~6 sessions in the clinic lasting approximately 10 minutes each.~Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
2885569|NCT03350360|Experimental|Attention Control Training Web-delivery|"Attention Control Training Web-delivery will consist of:~6 sessions lasting approximately 10 minutes each logged into via the internet from the participants' home.~Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard).~Ideally participants will complete 2 sessions per week, allowing them to complete the trial in less than one month's time"
2885570|NCT03350360|Placebo Comparator|Comparison Task Clinic|"6 sessions in the clinic of a presumably inactive neutral-neutral stimuli intervention lasting approximately 10 minutes each.~Each session will consist of 128 presentations of pairs of faces, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard).~(Note that those receiving this arm, are invited to repeat the attention control training web-delivery arm at the end of their participation)."
2885571|NCT03350347|Experimental|Molidustat (BAY85-3934)|Molidustat group
2885572|NCT03350347|Active Comparator|Darbepoetin alfa|Darbepoetin alfa group
2885573|NCT03350334|Active Comparator|Duloxetine|The patients who will be given 60 mg duloxetine 2 hours before surgery and 24 hours after surgery.
2885574|NCT03350334|Placebo Comparator|Placebo Control|The patients who will be given 60 mg placebo 2 hours before surgery and 24 hours after surgery.
2885575|NCT03350321|Experimental|Molidustat (BAY85-3934)|Molidustat group
2885576|NCT03350321|Active Comparator|Darbepoetin alfa|Darbepoetin alfa group
2885577|NCT03350308||Patients with chronic end-stage renal failure|
2885578|NCT03350295|Experimental|GRP1 - Assess relative bioavailability(3-way cross-over)|"GROUP 1 (Treatments A, B, C) All treatments in Group 1 consist of a dose of 120 mg nifurtimox (4 x 30 mg tablets).~In Treatment A, dose administration with fast in vitro dissolution characteristics In Treatment B, dose administration with medium in vitro dissolution characteristics In Treatment C, dose administration with slow in vitro dissolution characteristics"
2885579|NCT03350295|Experimental|GRP2 - Assess relative bioavailability (2-way cross-over)|GROUP 2 (Treatments D and E) In Treatment D Single dose 30 mg nifurtimox dose with medium in vitro dissolution characteristics In treatment E, subjects will receive single dose of 120 mg nifurtimox
2885580|NCT03350282|Experimental|Mixture GAA-creatine|Mixture of guanidinoacetic acid and creatine monohydrate
2885581|NCT03350282|Active Comparator|Creatine|Creatine monohydrate
2885582|NCT03350269|Experimental|Intervention|Kidney transplant recipient candidates who are informed that their living donor candidates can receive reimbursement for lost wages incurred during the evaluation, donation surgery and recuperation
2885583|NCT03350269|No Intervention|Control|Kidney transplant recipient candidates who receive standard of care (donors are not offered wage reimbursement)
2885584|NCT03350256|Experimental|Microdosing group|Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
2885585|NCT03350243|Experimental|CCENT Intervention group|Participants will be assigned a dedicated key worker that will support families through the child's first year, in addition to standard medical care, which involves neonatal follow-up at routine times.
2885586|NCT03350243|No Intervention|Control group|Participants will receive the current standard of care. All infants in the control are will followed in the neonatal follow-up clinic and will be seen at routine times (6 weeks, 4 months, 12 months, and 18 months corrected age).
2885587|NCT03350230||oncofertility patients|oncofertility patients undering controlled ovarian hyperstimulation and embryo cryopreservation who carry a present or past cancer diagnosis
2927357|NCT03058757|No Intervention|Control arm|No intervention applied.
2885589|NCT03350217|Active Comparator|Hetastarch|This arm will be administered Hetastarch (w/Methylene blue as a contrast agent) as the injection solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
2885590|NCT03350204|Experimental|Meniscus Injured|These participants will come in pre and post operation
2885591|NCT03350204|Experimental|Healthy|These participants will be used as a standardised comparison for the patient group
2885592|NCT03350191|Experimental|SAR425899 high dose|Repeated once daily subcutaneous (SC) doses of SAR425899 administered over 20 days
2885593|NCT03350191|Experimental|SAR425899 low dose|Repeated once daily SC doses of SAR425899 administered over 20 days
2885594|NCT03350178|Experimental|treated patients|Treated wit FMT
2885595|NCT03350165|Experimental|Treatment Group|K-877 (pemafibrate) tablet twice daily.
2885596|NCT03350165|Placebo Comparator|Control Group|placebo tablet twice daily.
2885597|NCT03350152||LAM group|Have a diagnosis of AML according to World Health Organization (WHO) classification Are at least 70 years of age
2885598|NCT03350139||Patients treated with gamma knife radiosurgery|Collection of non-genetic, chronobiological, therapeutic and co-morbidities
2885599|NCT03350126|Experimental|Experimental arm|Therapy induction (12 weeks) Nivolumab (IV) and Ipilimumab (IV) - every 21 days - 4 cycles Then Nivolumab (IV) alone every 15 days - 20 cycles - until 12 months
2885600|NCT03350113|Experimental|HemoSpec|Blood Sampling for analysis in the HemoSpec device
2885601|NCT03350100|Experimental|Birhi date cultivar|A 48.46 g of freeze dried powder of Birhi date Cultivar which is equivalent to a 115g of fresh dates, contains 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and a total phenolic content of 162.8 mg/100 g of GAE. and 0.80 g of fibres, will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
2885602|NCT03350100|Experimental|Khassab date cultivar|A 34.5 g of freeze dried powder of Khassab date Cultivar which is equivalent to A 115g of fresh dates, contains 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and a total phenolic content of 91.52 mg/100 g of GAE. and 0.80 g of fibres,will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
2885603|NCT03350100|Placebo Comparator|placebo|A 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and 0.80 g of fibres, will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
2885604|NCT03350087|Experimental|iTBS group|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
2885605|NCT03350087|Experimental|cTBS group|In continuous theta burst stimulation (cTBS group), they received cTBS (80% of active motor threshold) on unaffected hemisphere.
2885606|NCT03350087|Experimental|iTBS+cTBS group|Continuous theta burst stimulation (cTBS group) at first followed by intermittent theta burst stimulation (iTBS group).
2885607|NCT03350087|Sham Comparator|sham TBS group|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
2885608|NCT03350087|Experimental|VCT group|VCT group received the VCT training in addition to traditional rehabilitation. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise.
2885609|NCT03350087|Experimental|VCT+optimal rTMS group|VCT+optimal rTMS group received the VCT training and optimal rTMS in addition to traditional rehabilitation.
2885610|NCT03350061|Experimental|SENSY benefit|Sensory feedback elicited by intraneural stimulation will be provided by SENSY with and without the leg prosthesis to improve walking ability, increase embodiment, and reduce metabolic cost, cognitive load and phantom pain.
2885611|NCT03350048||Training Set|"First 500 participants recruited for the Training Set:~Blood collection for optimization and validation (vs ELISA) of TransDot point-of-care test at LUMC and later for lab-based TransDot at local site laboratory~Blood, sputum, saliva and urine collection for secondary objectives and repository"
2885612|NCT03350048||Test Set|"Subsequent 300 participants to be used for the Test Set:~Fingerprick TransDot point-of-care test performed at field site after symptom screen and clinical evaluation and before CXR~Blood, sputum, saliva and urine collection for secondary objectives and repository"
2885613|NCT03350035|Experimental|IV Ganaxolone active|Ganaxolone IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by a 24-hour taper.
2885614|NCT03350035|Placebo Comparator|IV Placebo, non-active|Placebo IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by a 24-hour taper.
2885615|NCT03350022|Experimental|Sham Feeding|
2885616|NCT03350009||High and low grade embryos|The distribution for the high and low grade embryos is based on common morphological grading criteria.
2885617|NCT03350009||High and low quality follicles|The distribution for the high and low grade oocytes is based on common morphological grading criteria and on different features of the participants such as age.
2885618|NCT03349996|Experimental|LifeStream Peripheral Stent Graft System|Patients treated with the LifeStream Peripheral Stent Graft System
2885619|NCT03349983|Experimental|MVA-BN-Brachyury/ FPV-Brachyury|
2885620|NCT03349970||TEE vs PAC|we will compare the SV measurements obtained by PAC thermodilution technique to those obtained by different TEE methods in 60 patients undergoing coronary artery bypass grafting (CABG) and/or aortic valve (AV) or aortic surgery with cardiopulmonary bypass (CPB) in 2 different cardiac centres. The LV cardiac deformation, expressed as global longitudinal strain (GLS) will be calculated off-line from the acquired images. We will also determine the intra and inter-observer reproducibility of each TEE method.
2885621|NCT03349944|Active Comparator|Moderate intensity training|Moderate continuous exercise three times pr. week for 50 min.
2885622|NCT03349944|Experimental|High intensity training|High intensity interval training three times pr. week for 15 min.
2885623|NCT03349931||Hematological patients|Hematological patients at high risk for invasive aspergillosis
2885719|NCT03349086|Active Comparator|Voice Exercise|Randomized participants in this group will undergo 45 minutes of voice exercise, including sustained pitches and pitch glides on a variety of different vocal facilitators.
2885720|NCT03349086|No Intervention|Voice Rest|Randomized participants in this group will undergo 45 minutes of voice rest.
2885624|NCT03349918|Experimental|Mobile Health Monitoring|Participants will monitor their blood pressure using a wireless-enabled blood pressure cuff or mood using a mobile health application once per week at baseline. The investigators will monitor their medical records to determine if a medication change has occurred. After this, the investigators will increase the frequency of notifications to monitor the participant's specific health condition to once daily for 1 month. This monitoring will continue for a study duration of 6 months.
2885625|NCT03349905|Active Comparator|Fresh transfer|"Women randomized in the non experimental group will have:~Antagonist stimulation protocol~Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France)~All of their embryo kept in prolonged culture~A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage)~Supernumerary blastocysts cryopreserved"
2885626|NCT03349905|Experimental|Deferred-frozen embryo transfer|"Women randomized in the experimental group will have:~Antagonist stimulation protocol~Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France)~All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture.~A frozen-thawed single embryo transfer at blastocyst stage, is planned 4-5 weeks after cryopreservation"
2885627|NCT03349879||Vitamin D deficiency|serum 25(OH)D < 30 nmol/L
2885628|NCT03349879||Vitamin D insufficiency|serum 25(OH)D between 30 and 49 nmol/L
2885629|NCT03349879||Vitamin D sufficiency|serum 25(OH)D ≥ 50 nmol/L
2885630|NCT03349866|Experimental|apatinib XELOX and radiotherapy|apatinib：250mg qd po XELOX：Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
2885631|NCT03349866|Active Comparator|XELOX and radiotherapy|XELOX：Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
2885632|NCT03349840|Active Comparator|Insulin glargine U100|Intervention: half of the subjects will be randomised to insulin glargine U100 basal insulin treatment (or continued on glargine if already treated) that will be administered daily in the evening
2885633|NCT03349840|Active Comparator|insulin degludec U100|Intervention: half of the subjects will be randomised to insulin degludec U100 basal insulin treatment that will be administered daily in the evening
2885634|NCT03349827|Experimental|Experimental|HIPEC with Docetaxel/ Lobaplatin at the time of fist surgery and twice repeat within one week after the surgery, following 2 cycles of 3-week Oxaliplatin/S1 chemotherapy combined with Apatinib and 1 cycles of 3-week Oxaliplatin/S1 chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.
2885635|NCT03349814||Appendicitis group|"Patients, who undergo a diagnostic laparoscopy, which because of the operative findings leads to an appendectomy, and the appendix is found to be inflamed in the pathology report.~A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed."
2885636|NCT03349814||Normal appendix group|"Patients, who undergo a diagnostic laparoscopy, that either because of the operative findings (mesenteric lymphadenitis or normal diagnostic laparoscopy) does not lead to appendectomy, or leads to appendectomy, but the appendix is not found to be inflamed in the pathology report.~A diagnostic laparoscopy where the appendix is not found to be inflamed, and therefore is not removed.~OR~A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed, but is not found to be inflamed in the pathology report."
2885637|NCT03349801||no AMD|No interventions
2885638|NCT03349801||early AMD|No interventions.
2885639|NCT03349801||intermediate AMD|No interventions.
2885640|NCT03349801||late AMD|No interventions.
2885641|NCT03349788|Experimental|LCA-nP|The group underwent laparoscopic radical rectectomy without preserving left colic artery. In IMA group, the dissecting based on TME is performed without preserving left colic artery. Surgeon should dissect the lymph nodes and ligated the vessel in the root of inferior mesenteric artery.
2885642|NCT03349788|Active Comparator|LCA-P|The group underwent laparoscopic radical rectectomy with preserving left colic artery. In LCA group, the dissecting based on TME is performed with preserving left colic artery. The relationship of inferior mesenteric artery, inferior mesenteric vein and LCA should be identified and ligated separately without LCA.
2885643|NCT03349775|Active Comparator|Metformin|Metformin: 500mg twice daily for 1 week, followed by 1g twice daily for a total of 3 months.
2885644|NCT03349775|Placebo Comparator|Placebo|Placebo: 500 mgh twice daily for 1 week, followed by 1g twice daily for a total of 3 months.
2885645|NCT03349762||Observational 1|Radiotherapy or Chemotherapy
2885646|NCT03349762||Observational 2|Huaier Granule & Radiotherapy or chemotherapy
2885647|NCT03349762||Observational 3|Huaier Granules
2885648|NCT03349749||Patients undergoing fluid resuscitation|Adult patients in the intensive care unit (ICU) undergoing fluid resuscitation guided by the LiDCOplus haemodynamic monitor.
2885649|NCT03349736|Experimental|Pelvic Floor Muscle Training|"Women visiting antenatal (up to16 weeks of gestation) will be enrolled for the study. The women will be follow up 4 times during the antenatal visit until 37 weeks of gestation. Questionnaire data and clinical measurements(strength of PFM by Electromyograph biofeedback) will be registered at baseline and and follow-up at week 37 of pregnancy.~The treatment program will include~1) Information, education material (leaflets, posters and videos) and individual/group exercise on PFM exercise on the 1st day of the visit. Counseling about the importance of performing PFM exercise will be provided.Women are advised to perform home PFM exercise and record in the exercise diary."
2885650|NCT03349723|Experimental|BI 1265162|BI 1265162
2885651|NCT03349723|Placebo Comparator|Placebo|Placebo
2885652|NCT03349710|Experimental|Arm A|Cohort 1
2885653|NCT03349710|Experimental|Arm B|Cohort 1
2885654|NCT03349710|Experimental|Arm C|Cohort 2
2885655|NCT03349710|Experimental|Arm D|Cohort 2
2885656|NCT03349697|Experimental|Active Product then Placebo|
2885657|NCT03349697|Experimental|Placebo then Active Product|
2885658|NCT03349684|Experimental|Acarbose plus metformin arm|Loose combination of acarbose and metformin given 3 times daily (together with main meals; breakfast, lunch, dinner). Acarbose dose will be started at a low dose and increased within 2 weeks to the target dose.
2885659|NCT03349684|Active Comparator|Metformin plus placebo arm|Loose combination of placebo and metformin given 3 times daily (together with main meals; breakfast, lunch, dinner).
2885660|NCT03349658|Active Comparator|general anesthesia|Patients in this group were randomized to receive general anesthesia.
2885667|NCT03349580|Experimental|The training group|The training group performed rehabilitation program twice per week over 9 weeks. The group commenced rehabilitation 3 weeks after the surgery. During the phase one training (week 1 to week 5), the isometric exercises were preformed on the trunk extension, flexion and lateral flexion muscles. During the phase 2 (week 6 to week 9), the exercises were performed on the strength machines and duration of the exercises were maintained and prolonged to 30 seconds. The leg adduction and hip extension exercises were added. The patients were instructed to perform abdominal bracing (IAP) and maintain the neutral position of their lumbar spine before and during the exercises.
2885668|NCT03349580|No Intervention|The control group|The control group followed the hospital's standard protocol. These do not include exercises or physiotherapy before 3 months after surgery.
2885669|NCT03349567|Experimental|Audit-and-feedback|The experimental arm will consist of Emergency Department providers who do receive the intervention.
2885670|NCT03349567|No Intervention|Control|The control arm will consist of providers who do not receive the intervention.
2885671|NCT03349554|Experimental|"standardized meditation technique body-scan"|
2885672|NCT03349541|Experimental|Complex Care Curriculum Intervention|Paediatric residents who are randomized to the intervention group will participate in the complex care curriculum during an academic half-day prior to the Objective Structured Clinical Examination (OSCE).
2885673|NCT03349541|No Intervention|No intervention|Paediatric residents who are randomized to the control group will attend the regular academic half-day unrelated to complex care prior to the Objective Structured Clinical Examination (OSCE).
2885674|NCT03349528|Experimental|Probiotic Supplement|The probiotic supplement will consist of capsules containing approximately 1 billion (1.0 x 10^9) colony forming units of the probiotic organisms, Lactobacillus rhamnosus LGG® (LGG®) and Bifidobacterium animalis subsp. lactis BB-12® (BB-12®). The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. Participants will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.
2885675|NCT03349528|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.
2885676|NCT03349515|Active Comparator|Group A - povidone-iodine ophthalmic solution.|Group A will receive three drops of povidone-iodine ophthalmic solution in each eye, with the right eye to receive the drops first.
2885677|NCT03349515|Active Comparator|Group B - ophthalmic balanced salt solution.|Group B will receive three drops in each eye of ophthalmic balanced salt solution, with the right eye to receive the drops first.
2885678|NCT03349502|Experimental|MG4101|"MG4101 administration (Not yet commercialized)~Dosage Bwt<50 : 2.0 x109 cells (2 bags) 50≤Bwt<70 : 3.0 x109 cells (3 bags) 70≤Bwt<100 : 4.0 x109 cells (4 bags) Bwt≥100 : 5.0 x109 cells (5 bags)~Duration and frequency~Intravenous over 1 hour~Day 4, Day 11, Day 18 of each cycle"
2885679|NCT03349489|Active Comparator|Reduction of insulin basal rate 40 minutes prior to exercise|
2885680|NCT03349489|Active Comparator|Reduction of insulin basal rate 90 minutes prior to exercise|
2885681|NCT03349476|Experimental|MFAM|"The mFAM Workstation is a computerized system used to reconstruct the shape of the left atrium of the heart, by fitting a parametric shape model to points data acquired by a catheter.~The mFAM Workstation uses recorded catheter positions and other data inputs collected from various types of multi-electrode catheters and generates output data files that can be displayed as a 3D anatomic structure."
2885682|NCT03349463|Experimental|18F-Fluciclovine|
2885683|NCT03349450|Experimental|Single Arm-Investigational|"DPX-Survivac Priming dose of 0.5ml. DPX-Survivac Booster dose of 0.1ml.~Pembrolizumab 200mg Intravenously.~Cyclophosphamide 50mg Twice daily orally."
2885684|NCT03349424|Experimental|Stilamin group|Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin in addition to postoperative conventional treatment.
2885685|NCT03349424|No Intervention|Control group|Patients in the control group will receive the postoperative conventional treatment, without addition of any new medicines.
2885686|NCT03349411||Acute Ischemic Stroke Sample|45 acute patients with first ever ischemic stroke on the right side of the brain will be recruited at NYC Health + Hospitals/Bellevue . They will undergo testing with the Confusion Assessment Method (CAM), Behavioral Inattention Test (BIT), Montreal Cognitive Assessment (MOCA) and Geriatric Depression Scale (GDS)
2885687|NCT03349411||Subacute Ischemic Stroke Sample|30 patients with first ever ischemic stroke on the right side of the brain who are within 3 months of their stroke will be recruited at Kessler Institute for Rehabilitation. They will undergo testing with the Confusion Assessment Method (CAM), Behavioral Inattention Test (BIT), Florida Mental Status Examination (FMSE); Kessler Foundation Neglect Assessment Process (KF-NAP); and Geriatric Depression Scale (GDS). These participants will also complete a research Magnetic Resonance Imaging (MRI) scan.
2885688|NCT03349398|Active Comparator|the group of Roux-en-Y|
2885689|NCT03349398|Experimental|the group of Uncut Roux-en-Y|
2885690|NCT03349346|Experimental|Cohort 1- Participants 12 to less than 18 years of age|"Participants will receive idelalisib monotherapy (from day 1 to day 21), followed by combination therapy with RICE. Upon enrollment, participants will be assigned to one of the 3 dose levels during idelalisib monotherapy (Dose level 1 = 55 mg/m^2 twice daily (BID), Dose level 2 = 85 mg/m^2 BID, Dose level 3 = 125 mg/m^2 BID) administered as 50 mg, 100 mg or 150 mg tablets as appropriate, or as 10 mg dispersible tablets for oral suspension for participants who cannot swallow tablets.~Day 1: single dose of idelalisib~Day 2 up to Day 21: initiate and continue idelalisib BID dosing~Day 22 for up to 12 months: idelalisib twice per day in combination with RICE. Cycles of RICE will be administered over 5 days every 3 weeks (Day 1: rituximab; Day 3: rituximab, ifosfamide, carboplatin, etoposide; Days 4 and 5: ifosfamide, etoposide) starting day 22 (or earlier if there is evidence of clinical progression while on idelalisib monotherapy) for up to 12 months."
2885721|NCT03349073|Experimental|T-1101 (Tosylate)|
2885722|NCT03349060|Experimental|PF-04965842 100 mg|
2885723|NCT03349060|Experimental|PF-04965842 200 mg|
2885724|NCT03349060|Placebo Comparator|Placebo|
2885725|NCT03349047|Active Comparator|Behavioral Intervention|Behavioral Intervention Group - Education regarding nut allergy and will also have contact with nut.
2885726|NCT03349047|Placebo Comparator|Control|Education regarding nut allergy
2885727|NCT03349034|Experimental|Test Group|Local Ropivicaine Infusion
2885728|NCT03349034|Placebo Comparator|Control Group|Local Saline Infusion
2885691|NCT03349346|Experimental|Cohort 2- Participants 1 to less than 12 years of age|"Participants will receive one of the 3 doses of idelalisib monotherapy (from day 1 to day 21) followed by combination therapy with RICE. Idelalisib will be administered as as 50 mg, 100 mg or 150 mg tablets as appropriate, or as 10 mg dispersible tablets for oral suspension for participants who cannot swallow tablets. Participants will will be enrolled at dose level 1 once tolerability is demonstrated in the older cohort (Cohort 1). Thereafter, both age cohorts will be dose escalated independently.~Day 1: single dose of idelalisib~Day 2 up to Day 21: initiate and continue idelalisib BID~Day 22 for up to 12 months: idelalisib twice per day in combination with RICE. Cycles of RICE will be administered over 5 days every 3 weeks (Day 1: rituximab; Day 3: rituximab, ifosfamide, carboplatin, etoposide; Days 4 and 5: ifosfamide, etoposide) starting day 22 (or earlier if there is evidence of clinical progression while on idelalisib monotherapy) for up to 12 months."
2885692|NCT03349333|Experimental|pralatrexate|Vitamin B12 and folic acid will be taken concurrently with pralatrexate
2885693|NCT03349307|Experimental|No Intervention|
2885694|NCT03349281|Experimental|Dose Level 1: Pevonedistat 15 + VXLD|"Pevonedistat: 15 mg/m2 intravenously (IV)~Vincristine: 1.5 mg/m2/dose IV push~Dexamethasone: 10 mg/m2/day divided twice daily~PEG-asparaginase: 2500 IU's/m2/day~Doxorubicin: 60 mg/m2/day IV"
2885695|NCT03349281|Active Comparator|Dose Level -1: Pevonedistat 10 + VXLD|"Pevonedistat: 10 mg/m2 IV~Vincristine: 1.5 mg/m2/dose IV push~Dexamethasone: 10 mg/m2/day divided twice daily~PEG-asparaginase: 2500 IU's/m2/day~Doxorubicin: 60 mg/m2/day IV"
2885696|NCT03349281|Active Comparator|Dose Level 2: Pevonedistat 20 + VXLD|"Pevonedistat: 20 mg/m2 IV~Vincristine: 1.5 mg/m2/dose IV push~Dexamethasone: 10 mg/m2/day divided twice daily~PEG-asparaginase: 2500 IU's/m2/day~Doxorubicin: 60 mg/m2/day IV"
2885697|NCT03349268|Active Comparator|Pulsed UV Device Emitting Germicidal UV|Pulsed UV Device to be used to disinfect rooms following post-discharge terminal cleaning
2885698|NCT03349268|Sham Comparator|Sham Device - Non Emitting Germicidal UV|Sham Device to be run in rooms following post-discharge terminal cleaning. No Germicidal UV is emitted.
2885699|NCT03349255|Experimental|intravenous (i.v.) arm|autologous ET1402L1-CART cells administered by intravenous (IV) infusion
2885700|NCT03349255|Experimental|intra-hepatic artery (i.a.) arm|autologous ET1402L1-CART cells administered by intra-hepatic artery (IA) infusion
2885701|NCT03349216|Experimental|Intravenous regional Analgesia|in this arm patients will receive intravenous regional anesthesia as infusion of mini dose (that is 1.5 mg/kg ) lidocaine 0.5% and immediately after procedure their torniquettes will be deflated (hence named Rapid MiniBier's block).
2885702|NCT03349216|Experimental|Systemic Analgesia|In this arm patients will receive ketamine 1-2 mg/kg IV slow as a systemic analgesia. ketamine as a PCP derivative has both hypnotic and analgesic effects.
2885703|NCT03349203|Experimental|Icotinib|Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks before surgery and 2 years as adjuvant therapy after surgery or till progressive disease or unaccepted toxicity.
2885704|NCT03349177|Experimental|FEC group|Fluorouracil 500mg/m2 on day 1, epirubicin 100mg/m2 on day 1 and cyclophosphamide 500mg/m2 on day 1 every 3 weeks for six cycles
2885705|NCT03349177|Experimental|EC-T group|Epirubicin 100mg/m2 on day 1 cyclophosphamide 600mg/m2 on day1 every 2 weeks for four cycles followed by docetaxel 100mg/m2 on day 1 every 3 weeks for four cycles
2885706|NCT03349177|Experimental|TC group|Docetaxel 75mg/m2 on day 1 and cyclophosphamide 600mg/m2 on day 1 every 3 weeks for six cycles
2885707|NCT03349151|Active Comparator|Early feeding|This group will be served soft meal diet served on postoperative 2nd hour on return to the ward.
2885708|NCT03349151|Placebo Comparator|On- demand feeding|This group will be served soft meal diet served whenever they wanted to eat on return to the ward.
2885709|NCT03349138|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different standard motor training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
2885710|NCT03349138|Experimental|Robotic Glove|Robotic Glove & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the robotic glove system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
2885711|NCT03349138|Experimental|Electrical Stimulation|Electrical Stimulation & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the electrical stimulation system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
2885712|NCT03349138|Experimental|Electrical Stimulation and Robotic Glove|Electrical Stimulation & Robotic Glove & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the electrical stimulation system plus 60 minutes of conventional therapy or 30-minute training with the robotic glove system plus 60 minutes of conventional therapy. Half of the sessions are allocated to the electrical stimulation system, and half are allocated to the robotic glove system. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
2885713|NCT03349125||Collar On|Individuals who have been referred for videoflouroscopic swallow study (VFSS) as per standard of care, with a stable cervical injury, will have trials of liquids and solids with the Cervical Brace (Collar) on.
2885714|NCT03349125||Collar Off|Individuals who have been referred for videoflouroscopic swallow study (VFSS) as per standard of care, with a stable cervical injury, will have trials of liquids and solids with the Cervical Brace (Collar) off.
2885715|NCT03349112|Active Comparator|Anesthetized|A study team member will apply 1 mL of 2% viscous lidocaine to each nares prior to the passage of the catheter, Participants in this group will additionally receive .8 mL of a 4% Lidocaine spray to both nares prior to HRPM.
2885716|NCT03349112|Placebo Comparator|Non-Anesthetized|A study team member will apply 1 mL of 2% viscous lidocaine to each nares prior to the passage of the catheter. Randomized participants in this group will not receive .8 mL of a 4% Lidocaine spray prior to HRPM .
2885717|NCT03349099|Active Comparator|Cook Flexor|ureteral access sheath
2885730|NCT03349008|Placebo Comparator|Control group|Entecavir treatment with placebo, Magnesium Isoglycyrrhizinate placebo followed by Diammonium Glycyrrhizinate placebo
2885731|NCT03349008|Experimental|Experimental group|Entecavir combined with glycyrrhizin, Magnesium Isoglycyrrhizinate Injection followed by Diammonium Glycyrrhizinate
2885732|NCT03348982|Experimental|Intervention group|The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session) in a hall/gymnasium of each participating school.Each intervention session will be conducted in the morning by a trained research assistant assisted by student helpers. Each intervention session will be conducted in an identical format, comprising three activities: warm-up (5 min), jogging (20 min), and cool-down (5 min). In the jogging activity, participants will be asked to jog side-by-side with the research staff around an activity circuit (57m x 50m) marked with 4 red cones.
2885733|NCT03348982|No Intervention|Control group|Participants in the control group will receive no physical intervention and will be required to follow their daily routine without participating in any additional physical activity/exercise program throughout the whole study period (T1-T3).
2885734|NCT03348969|Experimental|Intervention|Neoadjuvant Mitomycin C
2885735|NCT03348969|Active Comparator|Control|Adjuvant Mitomycin C
2885736|NCT03348956|Experimental|EPR Oximetry|All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points (pre-exposure, during-exposure or CIPN incidence, and post exposure), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing.
2885737|NCT03348943|Active Comparator|Right hemiparesis, right upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
2885738|NCT03348943|Experimental|Right hemiparesis, left upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
2885739|NCT03348943|Active Comparator|Left hemiparesis, left upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
2885740|NCT03348943|Experimental|Left hemiparesis, right upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
2885741|NCT03348930|Experimental|Tolcapone|Each subject will have a 4 week treatment phase with Tolcapone
2885742|NCT03348930|Placebo Comparator|Placebo|4 week placebo phase before or after Tolcapone phase depending on randomization.
2885743|NCT03348917|Active Comparator|Treatment sequence Group 1|"Treatment Sequence Group 1 = A -> B -> C~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)"
2885744|NCT03348917|Active Comparator|Treatment sequence Group 2|"Treatment Sequence Group 2 = B -> C -> A~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)"
2885745|NCT03348917|Active Comparator|Treatment sequence Group 3|"Treatment Sequence Group 3 = C -> A ->B~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)"
2885746|NCT03348904|Experimental|Arm A|Nivolumab plus epacadostat in combination with platinum doublet chemotherapy.
2885747|NCT03348904|Active Comparator|Arm B|Platinum doublet chemotherapy
2885748|NCT03348904|Experimental|Arm C|Nivolumab plus placebo in combination with platinum doublet chemotherapy.
2885749|NCT03348891|Other|Subgroup 1|Patients treated with anti-PD-1 alone (nivolumab or pembrolizumab)
2885750|NCT03348891|Other|Subgroup 2|Patients treated with the combined treatment anti-PD-1+anti-CTLA-4 (nivolumab + ipilimumab)
2885751|NCT03348878|Other|cohort of uncontrolled hypertensive patients|
2885752|NCT03348865|Experimental|Fertility Life Counselling Aid (FeLiCiA)|"Patients to undergo weekly Felicia counselling interventions for 6 weeks; making a total of 6 sessions.~Each session is expected lasts 30 mins to 1 hour."
2885753|NCT03348865|No Intervention|Control|Patients are to undergo treatment as usual.
2885754|NCT03348852|Active Comparator|Active tDCS|Active transcranial direct current stimulation
2885755|NCT03348852|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
2885756|NCT03348839|Experimental|Cluster 1|NeLLY service is implemented after 8 months.
2885757|NCT03348839|Experimental|Cluster 2|NeLLY service is implemented after 12 months.
2885758|NCT03348839|Experimental|Cluster 3|NeLLY service is implemented after 16 months.
2885759|NCT03348839|Experimental|Cluster 4|NeLLY service is implemented after 20 months.
2885760|NCT03348839|Experimental|Cluster 5|NeLLY service is implemented after 24 months.
2885761|NCT03348839|Experimental|Cluster 6|NeLLY service is implemented after 28 months.
2885762|NCT03348839|Experimental|Cluster 7|NeLLY service is implemented after 32 months.
2885763|NCT03348826|Experimental|Alteplase then Sodium Bicarbonate|Alteplase will first be administered to restore flow. If flow is not restored, then sodium bicarbonate will be administered.
2885764|NCT03348826|Experimental|Sodium Bicarbonate then Alteplase|Sodium bicarbonate will first be administered to restore flow. If flow is not restored, then alteplase will be administered.
2885765|NCT03348813|Experimental|HIV/STI Prevention Intervention|Two-session, small group HIV/STI prevention intervention.
2885766|NCT03348813|Active Comparator|General Health Control Intervention|Two-session, small group general health promotion intervention.
2885767|NCT03348800|Experimental|Test Side|The side in which computer controlled anesthetic delivery system will be used as dental anesthesia before dental surgery
2885768|NCT03348800|Active Comparator|Control Side|The side in which conventional syringe will be used as dental anesthesia before dental surgery
2885769|NCT03348787|Experimental|Behavioral and Cognitive Therapies|Chronic psychotic patients will have Behavioral and Cognitive Therapies
2885800|NCT03348579||The second period|"The second period will consist of all consecutive patients admitted to the participating ICUs after the publication of the national guidelines publication concerning healthcare associated pneumonia.~Afterward, an interphase will occur during which all physicians, residents, physiotherapists and nurses will receive a formal training for the processes and procedures related to the new guidelines published in september 2017."
2885770|NCT03348761|Experimental|rTMS Group|20 sessions of neuronavigation rTMS to lDLPFC over a 4-week period. Individual sessions consist of 30 minutes of 10 Hz rTMS (3000 pulses; 30-second cycles, 5 seconds on, 25 seconds off). A magnetic device is used with a 70-mm double air film coil and manually centered at MNI coordinates -46, 45, 38. Resting motor threshold (MT) is defined as the minimum TMS intensity that elicits a motor-evoked potential (MEP) of peak to peak in the contralateral abductor pollicis brevis in 5 out of 10 trials. MT is measured before the first treatment and re-checked every 10 days. The stimulation output is 120% of MT
2885771|NCT03348748|Experimental|Study 1 (highest-dose of SBRT, surgery)|Patients with stage I or II NSCLC in the peripheral lung undergo highest-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
2885772|NCT03348748|Experimental|Study 2 (lowest-dose of SBRT, surgery)|Patients with stage I or II NSCLC in the central lung undergo lowest-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
2885773|NCT03348748|Experimental|Study 3 (lowest- or higher-dose of SBRT, surgery)|Patients with stage IIIA NSCLC in the any lung location undergo lowest- or higher-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
2885774|NCT03348735|Experimental|Lidocaine patch 5%|Lidocaine 5% medicated plasters will be applied daily, during 12 consecutive hours.
2885775|NCT03348735|Experimental|Capsaicin 8% patch|Capsaicin 8% patches need to applied in a hospital setting during 1 hour. Re-application of these capsaicin patches will be performed upon re-occurrence of painful symptoms (mostly after 12 weeks - so not after a fixed time interval). Application of capsaicin patches will be carried out in a hospital setting (+/- 3 hours procedure).
2885776|NCT03348735|Active Comparator|Pregabaline|Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe. In European clinical practice, up-titration of the dose is often carried out over a longer time-period. This study thus includes up-titration schedule for pregabalin over a period of 4 weeks. If patients develop side-effects during the intake/uptitration of pregabalin this treatment can be stopped and switched to gabapentin (300mg capsules). Gabapentin will always be the back-up treatment for failed systematic treatment with pregabalin. Dose of gabapentin will be uptitrated to maximum 1200mg per day.
2885777|NCT03348722||Active surveillance|Newly diagnosed low risk prostate cancer patients managed according to an active surveillance program
2885778|NCT03348722||Radical prostatectomy|Newly diagnosed low risk prostate cancer patients undergoing radical prostatectomy
2885779|NCT03348722||Radiotherapy|Newly diagnosed low risk prostate cancer patients undergoing radiotherapy (external or brachitherapy)
2885780|NCT03348722||Other radical treatment|Newly diagnosed low risk prostate cancer patients undergoing other radical treatments (HIFU, cryotherapy, others)
2885781|NCT03348709|Experimental|Isoosmolar|Iso-osmolar oral supplement (276 mOsm/kg)
2885782|NCT03348709|Active Comparator|Hyperosmolar|Hyper-osmolar oral supplement (681 mOsm/kg)
2885783|NCT03348696|Active Comparator|dexamethasone tapering dose|standard dexamethasone pre-medication (8mg B.I.D x 3 days commencing the day before chemotherapy) then 4mg 1x/d for 2 days followed by 2mg 1x/d for 2 days
2885784|NCT03348696|Active Comparator|dexamethasone physician choice|standard dexamethasone pre-medication (i.e. 8mg B.I.D x 3 days commencing the day before chemotherapy) then physician choice interventions
2885785|NCT03348683|Experimental|Propranolol|2mg of IV push
2885786|NCT03348683|Placebo Comparator|Placebo|an equivalent quantity in milliliters of normal saline
2885787|NCT03348670|Experimental|Etoposide OS + Methotrexate OS for usual|"Combined Chemotherapy - usual group~Etoposide Capsule + Methotrexate Tablet + Topotecan Capsule~Etoposide OS + Methotrexate OS + Topotecan OS~Etoposide Capsule plus Methotrexate Tablet plus HYCAMTIN - Topotecan Capsule"
2885788|NCT03348670|Experimental|Etoposide OS + Methotrexate OS for study|"Combined Chemotherapy - study group~Etoposide Capsule + Methotrexate Tablet + Everolimus Tablet~Etoposide OS + Methotrexate OS + Everolimus OS~Etoposide Capsule plus Methotrexate Tablet plus AFINITOR - Everolimus Tablet"
2885789|NCT03348657|Other|Music intervention Group|Patients who participated to at least one music session provided by volunteers while being admitted to the geriatric assessment unit. Participation to the music sessions was voluntary.
2885790|NCT03348657|No Intervention|Control Group|Patients who did not want to participate to the music sessions provided by volunteers while being admitted to the geriatric assessment unit
2885791|NCT03348644|Experimental|Phosphate tablets.|800 mg oral phosphor supplement distributed over five times a day independently of any prior treatment dose.
2885792|NCT03348644|Active Comparator|High cheese intake.|Cheese with an estimated phosphate content of 800 mg distributed over 5 meals.
2885793|NCT03348644|Active Comparator|High milk intake.|800 ml of milk daily corresponding to approximately 800 mg phosphor per day.
2885794|NCT03348631|Experimental|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2885795|NCT03348618|Experimental|IVIG|IVIG dose at 1 g/Kg/body weight
2885796|NCT03348605|Other|First setting ON|This arm performs the Gait analysis the first time after the familiarization phase with the stimulator in the modality ON. The second time the gait analysis is performed in the OFF modality.
2885797|NCT03348605|Other|First setting OFF|This arm performs the Gait analysis the first time after the familiarization phase with the stimulator in the modality OFF. The second time the gait analysis is performed in the ON modality.
2885798|NCT03348592|Experimental|Oligofructose-enriched inulin (p-inulin)|Participants are on no treatment for 8 weeks, then the pre-biotic p-inulin for 12 weeks, then no treatment for 8 weeks. Inulin is derived from chicory root fiber. The dose is 16 grams of p-inulin powder per day.
2885799|NCT03348579||The before period|The before period (control phase) will consist of all consecutive patients admitted to the participating ICUs before the national guidelines publication concerning healthcare associated pneumonia.
2885801|NCT03348579||The third and final period|The third and final period will consist of all consecutive patients admitted to the participating ICUs after the formal training.
2885802|NCT03348553|Sham Comparator|control group|20 subjects do not receive any supplementation
2885803|NCT03348553|Active Comparator|Omega2|20 subjects receive an Omega-Fatty-acid Nutratceutical
2885804|NCT03348553|Active Comparator|Omega4|20 subjects receive an Omega-Fatty-acid Nutraceutical
2885805|NCT03348553|Active Comparator|Omega2+OGV|20 subjects receive an Omega-Fatty-acid Nutraceutical + encapsulated fruit, vegetable and berry-juice concentrate
2885806|NCT03348540|Experimental|Attention Control Training|"6 sessions in the clinic lasting approximately 10 minutes each.~Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
2885807|NCT03348540|Placebo Comparator|Comparison Task|"6 sessions in the clinic of a presumably inactive neutral-neutral stimuli intervention lasting approximately 10 minutes each.~• Each session will consist of 128 presentations of pairs of faces, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
2885808|NCT03348527|Experimental|Dose equal to 35% of prostate volume|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 35 % of their prostate volume.
2885809|NCT03348527|Experimental|Dose equal to 45% of prostate volume|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 45 % of their prostate volume.
2885810|NCT03348527|Experimental|Dose equal to 50% of prostate volume|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 50 % of their prostate volume.
2885811|NCT03348514|Experimental|Accelerated Escalation Design|
2885812|NCT03348514|Experimental|"3+3 Dose Escalation Design"|
2885813|NCT03348488|No Intervention|Standard ultrafiltration|standard ultrafiltration (fluid removal from the body by dialysis at the prescribed volume and rate) during a conventional treatment
2885814|NCT03348488|Active Comparator|High dose ultrafiltration|Intervention= Fixed rate high dose ultrafiltration (fluid removed from the body by dialysis) of 1 litre per hour over 1 hr instaed of standard ultrafiltration rate and volume.
2885815|NCT03348475|Experimental|Experimental Group|Binge Focused Therapy (BFT) Intervention
2885816|NCT03348462|Experimental|ethosomal anthralin|Group 1: included 10 psoriatic patients will be treated with ethosomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.
2885817|NCT03348462|Active Comparator|liposomal anthralin|Group 2: included 10 psoriatic patients will be treated with liposomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.
2885818|NCT03348436|Experimental|patients with atrioventricular nodal reentrant tachycardia|radiofrequency catheter ablation therapy
2885819|NCT03348436|Experimental|patients with atrioventricular tachycardia|radiofrequency catheter ablation therapy
2885820|NCT03348423|Experimental|DEX-IN 50 µg|Dexmedetomidine Intranasal Spray
2885821|NCT03348423|Active Comparator|Fentanyl 50 µg|Intravenous Fentanyl
2885822|NCT03348423|Placebo Comparator|Placebo|Placebo
2885823|NCT03348410|Experimental|Intervention|Motivational interviewing
2885824|NCT03348410|No Intervention|Control|Control group
2885825|NCT03348397||Contegra patients|
2885826|NCT03348397||Pulmonary homograft patients|
2885827|NCT03348384|Experimental|Cocaine use disorders|PET scan
2885828|NCT03348384|Experimental|Controls|PET scan
2885829|NCT03348371|Experimental|Oral day|Participant receive ethanol orally
2885830|NCT03348371|Experimental|i.v. infusion day|Participant receive ethanol in an i.v. infusion
2885831|NCT03348358|Placebo Comparator|control|No music during labor
2885832|NCT03348358|Experimental|Quiet music|Women hearing quiet music during labor
2885833|NCT03348358|Experimental|Rhythmic music|Women hearing rhythmic music during labor
2885834|NCT03348345|Experimental|Eat Breathe Thrive Intervention|A manualized program designed to prevent eating disorders using psychoeducation, group work, and yoga.
2885835|NCT03348345|No Intervention|Wait-List|Participants are placed on a wait-list receiving no intervention.
2885836|NCT03348332|No Intervention|Sedentary pregnant women|Pregnant women who do not exercise regularly during pregnancy
2885837|NCT03348332|Experimental|Exercise pregnant women|Pregnant women who participate in a supervised exercise program
2885838|NCT03348319||Cadaver organs|
2885839|NCT03348306|Experimental|All patients|
2885840|NCT03348293|Experimental|3D printing patient|Immediate breast reconstruction using 3D printing personalized scaffold
2885841|NCT03348280||Vitamin D Deficient|Type 2 diabetics with high blood pressure and 25-hydroxyvitamin D levels of <20 ng/ml
2885842|NCT03348280||Vitamin D Sufficient|Type 2 diabetics with high blood pressure and 25-hydroxyvitamin D levels of >30 ng/ml
2885843|NCT03348267|Experimental|Protein|On the match day, 25g of protein consumed immediately after the match and then 30g at 3h (+3h) and 25g at 6h (+6h). On each day of the remaining days, 20 g of protein consumed with breakfast.
2885844|NCT03348267|Active Comparator|Placebo|On the match day, 500 ml received received orally immediately post-match and then at +3h and +6h. On the remaining days, 500 ml daily with breakfast.
2885845|NCT03348254||1|Group one will consist of patients receiving a single shot antibiotic prophylaxis preoperatively before primary arthroplasty of hip or knee
2885846|NCT03348254||2|Group two will consist of patients receiving multiple shot antibiotic prophylaxis perioperatively before and after primary arthroplasty of hip or knee
2885847|NCT03348241|Experimental|Gum Arabic group|Patients of study group was received a dose of 30 grams Gum Arabic per day as oral solution (dissolved in 250 ml purified water) for six weeks along with the chemotherapy prescribed addition to verbal instructions pertaining to the optimal nutrition and daily routine for oral hygiene.
2885848|NCT03348241|Other|Control group|Patients of control group was received only chemotherapy regimen and verbal counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
2885849|NCT03348228|Placebo Comparator|Control Group|Participants willrecord a self-selected diet for 3 days and then perform two 24-hour urine collections on the last 2 days of this diet. HCA will be administered afterwards to both groups (see methods below) for 7 days
2885890|NCT03347916|Active Comparator|Gabapentin group|patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
2885850|NCT03348228|Active Comparator|Calcium Stone Formers|Participants willrecord a self-selected diet for 3 days and then perform two 24-hour urine collections on the last 2 days of this diet. HCA will be administered afterwards to both groups (see methods below) for 7 days
2885851|NCT03348215|Other|Enhanced Treadmill Training|Treadmill walking with an immersive environment and bio mechanical support (body weight, ankle-foot -orthosis and functional electrical stimulation)
2885852|NCT03348202||Focus Group Participants|Approximately 24 groups (6 per country; Finland, Norway, Spain, Italy) consisting participants aged 80+ recruited from: senior community centres, adult day care centres, nursing homes. Each focus group will comprise from 4 to 8 people. Attempts would be made to create gender-balanced groups.
2885853|NCT03348189||Observational|Healthy males and females
2885854|NCT03348176|Experimental|Vegetable exposure|Repeated exposure to a variety of vegetables from the start of complementary feeding
2885855|NCT03348176|Experimental|VIPP-Feeding Infants|Promotion of responsive feeding practices from the start of complementary feeding
2885856|NCT03348176|Experimental|Exposure + VIPP-FI|Combination of repeated exposure to vegetables and promotion of responsive feeding practices
2885857|NCT03348176|Sham Comparator|Control|Phone calls on development child with no information on complementary feeding
2885858|NCT03348163|Experimental|Switch ART|Switch from current antiretroviral therapy (ART) to B/FTC/TAF bfor 48 weeks
2885859|NCT03348163|Active Comparator|Continue Current ART|Continue current (ART) therapy (emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent) for 48 weeks
2885860|NCT03348150|Experimental|Gastrecomy + Cytoreductive surgery + HIPEC|
2885861|NCT03348150|No Intervention|palliative systemic chemotherapy|
2885862|NCT03348137||Ancillary-Correlative (questionnaire)|Patients take Progeny Genetic Pedigree and Family History Questionnaire. Results are reviewed by the site specific research coordinator and/or genetic counselor to assess whether a patient fulfills criteria for referral to the site specific cancer genetics clinic for further evaluation.
2885863|NCT03348124|Experimental|Intervention|"Educational lessons based on the conversational material Toolkit Children - what does it involve?, will be delivered in the classroom at school and caring for the RCB simulator during three days and nights."
2885864|NCT03348124|No Intervention|Control|Education as usual.
2885865|NCT03348111|Experimental|Air-polishing device|Air polishing of the implant surface and/or elimination of the intrapocket biofilm using the air abrasion device Air-Flow Master Piezon®
2885866|NCT03348098|Experimental|single arm|Apatinib Combined With Paclitaxel in Neoadjuvant Therapy of Locally Advanced Exploratory Research on Single-arm of TNBC
2885867|NCT03348072||Jehovah's witnesses|Jehovah's witnesses having undergone cardiac surgery between 1991 till 2012. Blood perfusions refused.
2885868|NCT03348072||Control|Paired control group, twice as big as the experimental group. Pairing criteria: age, sex, type of surgery performed. The control group must accept blood transfusions.
2885869|NCT03348033|Experimental|Chronic Myeloid Leukemia + NK cell|"Starting on Day -7, G-CSF daily by vein until post nadir of absolute neutrophil counts (ANC) are equal or over 1000. Day -6 to Day -2 Fludarabine administrated by vein at 30 mg/m^2. Four hours later Cytarabine administrated by vein at 2 g/m^2. Natural killer (NK) cell infusion Days 0 to 14 for 6 doses total.~NK Cell infusion on Days 0 to 14 for 6 doses total."
2885870|NCT03348020|Experimental|Baseline Clinical Trial|Before blood donation, subjects will participate in a baseline clinical trial where the research team will perform a series of metabolic tests as described in the detailed study description.
2885871|NCT03348020|Experimental|Post-Blood Donation Clinical Trial|1 month after blood donation, subjects will participate in post-blood donation clinical trial where the research team will perform a series of metabolic tests as described in the detailed study description.
2885872|NCT03348007|Experimental|HEPAR|1L of Hépar + 0.5L of low-mineral water (Hépar group).
2885873|NCT03348007|Active Comparator|VITTEL Bonne Source|1.5L of low-mineral water (Vittel Bonne Source, control group)
2885874|NCT03347994|Experimental|Minnelide 0.40 (Dose Level -1)|"Dose Level -1: 25% decrease from prior dose level~- 0.40 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
2885875|NCT03347994|Experimental|Minnelide 0.53 (Dose Level 1)|"Starting Dose Level 1:~0.53 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
2885876|NCT03347994|Experimental|Minnelide 0.67 (Dose Level 2)|"Dose Level 2: 25% increase from Dose Level 1~- 0.67 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
2885877|NCT03347994|Experimental|Minnelide 0.80 (Dose Level 3)|"Dose Level 3: 25% increase from Dose Level 2~- 0.80 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
2885878|NCT03347981|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
2885879|NCT03347981|Active Comparator|IOL implantation active comparator|hydrophilic, trifocal intraocular lens POD F
2885880|NCT03347968|Experimental|MEDI0382|All participants will receive MEDI0382.
2885881|NCT03347968|Active Comparator|Warfarin|All participants will receive Warfarin
2885882|NCT03347968|Active Comparator|Esmolol|All participants will receive Esmolol
2885883|NCT03347955|Experimental|Neural implantation group|Human embryonic dopamine neurons were implanted into brains of half the randomized participants (n = 20). Participants were evaluated at baseline, 4, 8, and 12 months after surgery.
2885884|NCT03347955|Sham Comparator|Sham Surgery group|This group (n = 20) received sham surgery with a steel frame affixed to their heads and four burr holes drilled into their foreheads without crossing the blood/brain barrier. Participants were assessed at baseline, 4, 8, and 12 months after surgery.
2885885|NCT03347942|Experimental|Intervention|During a period of 30 days the research participant in the intervention group will be instructed to wait at least 20 minutes after finishing the first portion of meals previously considered sufficient by the individual before being served again if he or she feels the need.
2885886|NCT03347942|Other|Control|The control group will also serve the dish the same way, but you can serve additional portion without waiting.
2885887|NCT03347929|Experimental|Naproxen|Naproxen 500 mg twice daily
2885888|NCT03347929|Placebo Comparator|Placebo|Placebo 1 tablet twice daily
2885889|NCT03347916|Placebo Comparator|Control group|patients received strawberry juice 5 ml volume, one hour before induction.
2885891|NCT03347890|Experimental|Liraglutide 3.0 mg|35 obese patient will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg).
2885892|NCT03347890|Placebo Comparator|Placebo|35 obese patient will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Placebo by pen injector.
2885893|NCT03347877|Experimental|autologous bone-periosteal graft|The patients in experimental group will undergo the surgery of arthroscopic repair Hepple V osteochondral lesions of the talus with autologous osteo-periosteal cylinder graft transplantation.
2885894|NCT03347877|Active Comparator|autologous osteochondral graft|The patients in control group will undergo the surgery of arthroscopic repair Hepple V osteochondral lesions of the talus with autologous osteochondral graft transplantation.
2885895|NCT03347864|Experimental|68Ga-NOTA-RM26 PET/CT|The patients were injected with 1.85 MBq per kilogram body weight of 68Ga-NOTA-RM26 in one dose intravenously and underwent PET/CT scan 30-45 min later
2885896|NCT03347851||On-X AAP|Patients with prior AVR surgery with the CryoLife On-X Ascending Aortic Prosthesis (AAP).
2885897|NCT03347851||SJM Masters or Carbomedics Carbo-seal|Patients with St. Jude Medical Masters HP Valved Graft with Gelweave Valsalva™ Technology or Carbomedics Carbo-seal (including Carbo-seal Valsalva) mechanical aortic valve prostheses patients
2885898|NCT03347838|Experimental|Nivolumab Injection [Opdivo]|240 mg IV every 2 weeks for 4 doses
2885899|NCT03347825||Robotic-assisted lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent robotic-assisted lobectomy for lung cancer.
2885900|NCT03347825||VATS (video assisted thoracic surgery) lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent VATS lobectomy for lung cancer.
2885901|NCT03347825||Open lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent open lobectomy for lung cancer.
2885902|NCT03347812||Endovascular Aortic Repair|Patients with aortic arch lesions who only received endovascular treatment, including chimney / fenestration / branch stent-grafts technique and combination of these techniques, would be assigned to this group.
2885903|NCT03347812||Total Arch Replacement|Patients with aortic arch lesions who only received traditional open surgery for total aortic arch replacement, would be assigned to this group.
2885904|NCT03347773|Experimental|Intervention|The subjects will be assigned to receive nutritional supplement consisting of one can of ReGen 18% (19.1 g protein, 425 Kcal) daily and standard care.
2885905|NCT03347773|No Intervention|Control|The subjects will be assigned to receive standard care alone.
2885906|NCT03347760|Experimental|Experimental arm|All included patients wil receive 68Ga-dotatoc-PET/CT suspected acute myocarditis in first and an other 68Ga-dotatoc-PET/CT 6 months later
2885907|NCT03347747||Photoaged Male Subjects|45-80 year old males with visible photoaging and the desired exposure profile/driving history and who also has spent (or are spending) at least 30 minutes in a car per day (as the driver), 5 days per week for at least 15 years of their adult life to ensure they have the type of asymmetrical exposure required for hypothesis validation. This is an multi-center trial, and study sites will range from northern to southern latitudes in North America, Australia and potentially other international sites. Study Photography + Personal & Medical History Collection via a study questionnaire will be obtained.
2885908|NCT03347747||Photoaged Female Subjects|45-80 year old females with visible photoaging and the desired exposure profile/driving history and who also has spent (or are spending) at least 30 minutes in a car per day (as the driver), 5 days per week for at least 15 years of their adult life to ensure they have the type of asymmetrical exposure required for hypothesis validation. This is an multi-center trial, and study sites will range from northern to southern latitudes in North America, Australia and potentially other international sites. Study Photography + Personal & Medical History Collection via a study questionnaire will be obtained.
2885909|NCT03347734|Experimental|Eye Exercises Group (EEG)|For the individuals in the group of eye exercises (GEG), 10 repetitive eye exercises protocol was organized as a home program for 6 weeks, twice a day in the morning and evening each day of the week.
2885910|NCT03347734|Experimental|Convergence Exercise Group (CEG)|For the individuals in the group of convergence exercise, 5 minutes convergence exercise protocol was organized as a home program for 6 weeks, twice a day in the morning and evening each day of the week.
2885911|NCT03347734|Experimental|Oculomotor Exercise Group (OMEG)|For the individuals in the group of oculomotor exercise, 10 repetitive, four different oculomotor exercise protocols with eye stabilization were organized as home programs for 6 weeks, twice a day in the morning and evening each day of the week.
2885912|NCT03347721|Active Comparator|Lidocaine gel|
2885913|NCT03347721|Placebo Comparator|Lubricant Gel|
2885914|NCT03347708|Experimental|High Dose IDCT|Single intradiscal injection with High Dose IDCT (9M cells).
2885915|NCT03347708|Experimental|Low Dose IDCT|Single intradiscal injection with Low Dose IDCT (3M cells).
2885916|NCT03347708|Placebo Comparator|Saline|Single intradiscal injection with saline solution.
2885917|NCT03347708|Placebo Comparator|Sodium Hyaluronate Vehicle|Single intradiscal injection with Sodium Hyaluronate Vehicle.
2885918|NCT03347695|Experimental|A modified Cox-Maze operation|Two circular incisions were performed in the left atrial wall between the pulmonary veins and the mitral annulus. with those two incisions , Circumferential resection of a strip for the left atrial was obtained . Then, the resected margin around the mitral annulus was directly anastomosed to the remnant posterior left atrium wall including the pulmonary veins. If there was enlarged in right atrium, right atrium cox-Maze procedure was performed as per usual standard.
2885919|NCT03347682||Test group: Transtibial amputees|After translation/retranslation of the Prosthesis donning and doffing questionnaire, transtibial amputees will be asked to complete a quality of life evaluation Nottingham Health Profile-NHP, a satisfaction evaluation Satisfaction with Prosthesis -SATPRO and the Turkish version of the Prosthesis donning and doffing questionnaire twice (1-3 days apart).
2885920|NCT03347669|Experimental|FM patients|50 fibromyalgia patients/50 healthy subjects
2885921|NCT03347669|Active Comparator|Healthy subjects|50 fibromyalgia patients/50 healthy subjects
2885993|NCT03347123|Experimental|Treatment Group B|Epacadostat + nivolumab + lirilumab
2885922|NCT03347643|Active Comparator|tDCS with real stimulation|A total of 25 patients will be allocated into active comparator with real stimulation with tDCS.
2885923|NCT03347643|Sham Comparator|tDCS with sham stimulation|A total of 25 patients will be allocated into sham comparator with sham stimulation with tDCS.
2885924|NCT03347630|Other|oesophagus cancer MRI|Diagnostic test
2885925|NCT03347617|Experimental|Diagnostic (Ferumoxytol MRI, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 2 years or 35 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ferumoxytol IV and undergo MRI scans at baseline, 4 weeks after the last day of standard of care stereotactic radiosurgery or chemoradiotherapy, at suspected radiographic progression, and within 4 weeks from suspected radiographic progression.
2885926|NCT03347604||Patients with abdominal obesity|Enrolling patients with abdominal obesity as defined by WHO to have waist to hop ratio of > 0.85 in women, or > 0.9 in men.
2885927|NCT03347591||Patients with rare bleeding disorders|All patients registered in Dutch Haemophilia Treatment Centers with known disorders of the coagulation factors fibrinogen, factor II, V, V & VIII, VII, X, XI, XIII, α2-antiplasmin and plasminogen activator inhibitor type 1, aged 1 years and older.
2885928|NCT03347578||Lung cancer surgery|All patients undergoing thoracic surgery for lung cancer either with thoracoscopy or thoracotomy will receive diaphragmatic Ultrasonography 2 and 24 hours after surgery
2885929|NCT03347565||Adolescents with an Eating Disorder|Females between the ages of 14-17 currently diagnosed with an eating disorder (including ARFID, Anorexia Nervosa, Bulimia Nervosa, OSFED)
2885930|NCT03347565||Healthy Controls|Females between the ages of 14-17 with no psychiatric conditions
2885931|NCT03347552|Experimental|Active Treatment|Participants in the active arm will be enrolled in the HOME Program.
2885932|NCT03347552|No Intervention|E-CARE|"Receiving enhanced care as usual. Participants at these sites are described as receiving enhanced care as usual or E-CARE because they will be recruited, enrolled and complete baseline and follow-up assessments in addition to care as usual."
2885933|NCT03347539||Nexplanon|This group is participants who choose to receive the nexplanon implant. This group will only have one study interaction in the form of filling out a survey, at the time of implant.
2885934|NCT03347539||Removal participants|This group is participants who choose to remove the nexplanon implant. This group will only have one study interaction in the form of filling out a survey, at the time of removal. Anyone with a Nexplanon implant can have the implant removed on the mobile health unit and become part of this group - removal participants do not need to be in the Nexplanon group.
2885935|NCT03347526|Experimental|Cosyntropin Injectable Suspension, 1mg/mL + vigabatrin|
2885936|NCT03347526|Experimental|Cosyntropin Injectable Suspension, 1 mg/mL|
2885937|NCT03347526|Active Comparator|Vigabatrin|
2885938|NCT03347513|Experimental|Eradication of H-pylori|"triple attack therapy (Clarithromycin 500 mg BID for 14 days, omeprazole 20 mg BID for 14 days, metronidazole 500 mg BID for 14 days).~Followed by confirmation of eradication by repeating the H-pylori stool antigen test.~Iron therapy will be given twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm, Egypt."
2885939|NCT03347513|Active Comparator|No eradication of H-pylori|Iron therapy will be given twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm, Egypt.
2885940|NCT03347500||obese OA patients|"Use of patient-derived biological samples~Inclusion Criteria:~Subscription of informed consent~BMI ≥ 30~age between 60-80 years included~Kelgrenn-Lawrence equal or superior to grade III~presence of synovitis~patients undergoing knee replacement~suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice~Exclusion criteria:~- HCV, HIV, HBV, TPHA infection"
2885941|NCT03347500||Non-obese OA patients|"Use of patient-derived biological samples~Inclusion criteria:~Subscription of informed consent~BMI ≤ 28~age between 60-80 years included~Kelgrenn-Lawrence equal or superior to grade III~presence of synovitis~patients undergoing knee replacement~suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice~Exclusion criteria:~- HCV, HIV, HBV, TPHA infection"
2885942|NCT03347487|Experimental|Active DBS|
2885943|NCT03347487|Experimental|Shame DBS|
2885944|NCT03347474|Experimental|Bilateral surgical implantation of DBS system to VC/ VS|Device：Suzhou Sceneray® DBS system
2885945|NCT03347461|Experimental|Otiprio by surgeon|Otiprio will be administered through the tympanic membrane by the otolaryngologist immediately after tympanostomy placement.
2885946|NCT03347461|Active Comparator|Ciprodex by surgeon|Ciprodex drops will be instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery.
2885947|NCT03347461|Active Comparator|Ciprodex by surgeon and parent|Ciprodex drops will be instilled by the otolaryngologist into the ear immediately after tympanostomy tube surgery. The parent or guardian will administer Ciprodex drops into the ears twice daily for five days after surgery.
2885948|NCT03347435|Experimental|Genotype/ phenotype guided group|The patients randomized to the genotype/phenotype guided group undergo genetic tests for CYP2C19*2, CYP2C19*17 and ABCB1 3435 genetic variants immediately after diagnosis of ACS and receive one of the ADP receptor antagonists (clopidogrel/prasugrel/ticagrelor) on the basis of an algorithm that consider genetic and clinical variables.
2885949|NCT03347435|Active Comparator|phenotype only guided group|The patients randomized to the phenotype only guided group receive clopidogrel or prasugrel or ticagrelor on the basis of the standard of care on the basis of clinical algorithm alone.
2885950|NCT03347422|Experimental|Part A: sutimlimab or Placebo|In Part A, participants will be randomized 1:1 to receive an intravenous (IV) infusion of sutimlimab or placebo.
2885951|NCT03347422|Experimental|Part B: Response Extension Phase (sutimlimab)|In Part B, all participants will undergo blinded cross-over loading doses to allow all participants to receive sutimlimab while maintaining Part A blinding.
2885952|NCT03347409|No Intervention|Standard Perioperative (SP) care|
2885953|NCT03347409|Experimental|ERAS protocol|
2885954|NCT03347396|Experimental|Sutimlimab|Participants will receive an intravenous (IV) infusion of sutimlimab. Participants who complete Part A per protocol through the end of treatment visit (Day 182) will participate in Part B, and continue to receive sutimlimab up to 1 year after last patient out (LPO) in Part A.
2885955|NCT03347383|Experimental|Combination therapy DCB + stent|Patients treated with the Luminor DCB and the iVolution stent
2885956|NCT03347370||SC Peginterferon beta-1a|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
2885957|NCT03347370||SC interferon beta-1a|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
2885958|NCT03347370||SC interferon beta-1b|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
2885959|NCT03347357|Experimental|tacrolimus|
2885960|NCT03347344|Experimental|RILUZOLE|Riluzole PMCS 50 mg is presented as a round, biconvex, 8 mm diameter nearly white film-coated tablet. The tablets will be held under a blister of 20 tablets.
2885961|NCT03347344|Placebo Comparator|PLACEBO|The placebo PMCS 50 mg is presented as a round, biconvex, 8 mm diameter nearly white film-coated tablet matching the appearance of the Riluzole used in this study
2885962|NCT03347331|Experimental|Input function group|Each subject underwent a 90 min acquisition PET scan with concomitant arterial blood sampling
2885963|NCT03347331|Experimental|Test-retest group|Each subject underwent 2 PET scans distant from 1 to 3 weeks
2885964|NCT03347305|Experimental|Patients Group DPA|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
2885965|NCT03347305|Experimental|Healthy Volunteers|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
2885966|NCT03347292|Experimental|Dose escalation|The regorafenib starting dose will be 120 mg q.d.(once daily) 3 weeks on / 1 week off in combination with the recommended dose of pembrolizumab (200 mg Q3W). Pembrolizumab dose will not be escalated or de-escalated.
2885967|NCT03347292|Experimental|Dose expansion|Dose expansion cohorts will continue to be expanded until the sample size of 30 patients per cohort is reached.
2885968|NCT03347279|Experimental|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
2885969|NCT03347279|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
2885970|NCT03347266|Experimental|VVZ-149 injections|VVZ-149 injections will be mixed with saline, then intravenous infusion for 10hr. The drug product will be administrated with a 1000mg for 10 hours.
2885971|NCT03347266|Placebo Comparator|Placebo|Placebo group will receive an water for injection the same volume and period of experimental group.
2885972|NCT03347240|Active Comparator|Brain lesioning group|Stereotactic lesioning of the thalamus or gloves pallidus
2885973|NCT03347240|Active Comparator|Combined rhizotomy group|Combined anterior and posterior lumbosacral rhizotomy
2885974|NCT03347240|Active Comparator|Deep brain stimulation group|Bilateral globus pallidus internus deep brain stimulation
2885975|NCT03347240|Active Comparator|Intra-thecal Baclofen infusion therapy|Intra-thecal infusion pump
2885976|NCT03347227|Active Comparator|Pulmonary Vein Isolation|Wide area circumferential catheter ablation for pulmonary vein isolation
2885977|NCT03347227|Experimental|Pulmonary Vein Isolation and scar ablation|Wide area circumferential catheter ablation for pulmonary vein isolation and scar ablation
2885978|NCT03347214||1|People who already participated in the Pediatric Cardiac Genomics Consortium (PCGC) study
2885979|NCT03347201|Experimental|Intervention Group|"Initial heparin bolus before CPB to be calculated using HMS Plus.~Following commencement of CPB further heparin requirements will be determined using the HMS Plus. ACT's will also be checked whilst on CPB and if falls below 480 seconds, additional heparin will also be given.~Following cessation of CPB the dose of protamine required to reverse residual heparin will be calculated using the HMS Plus."
2885980|NCT03347201|No Intervention|Control Group|Patients in the control arm will undergo routine heparin anticoagulation using a weight based initial dose of 400 units/kg, aiming for an ACT of >480 seconds. Further heparin doses (5000 to 10000 units) will be given if the ACT falls below 480 seconds whilst on bypass. At the end of CPB heparin will be reversed with protamine using 1:1 ratio based on the initial dose of heparin given pre-bypass. HMS Plus measures will also be conducted in this group for study purposes, but the results will not be made available to the clinicians.
2885981|NCT03347188|Experimental|Fremanezumab|675 mg of fremanezumab administered as 3 sc injections (225 mg/1.5 mL each ) at week 0, week 4, and week 8.
2885982|NCT03347188|Placebo Comparator|Placebo|675 mg of placebo administered as 3 sc injections (225 mg/1.5 mL each ) at week 0,week, and week 8.
2885983|NCT03347175|Experimental|Volume controlled ventilation|Intervention1: Ventilation with Volume controlled ventilation
2885984|NCT03347175|Active Comparator|Pressure controlled ventilation|Intervention2: Ventilation with Pressure controlled ventilation
2885985|NCT03347175|Active Comparator|CPAP mode|Intervention3: Ventilation with Continuous Positive Airway Pressure mode only
2885986|NCT03347162||Cohort 1 - Resectable patients|These patients will undergo 3 assessments: a baseline-assessment prior to surgery, a post-surgery assessment (2 week post-surgery) and a follow-up assessment 6 months after surgery (after adjuvant oncology treatment).
2885987|NCT03347162||Cohort 2 - Non-resectable patients|These patients will undergoing 3 assessments: a baseline-assessment prior to palliative treatment, an acute measurement 4 weeks after initiation of palliative treatment, and a 6-month long-term assessment.
2885988|NCT03347149||Pre-Phase (Control)|no Alarm Advisor Software installed
2885989|NCT03347149||Post-Phase (Observation)|Alarm Advisor Software implemented
2885990|NCT03347136|Active Comparator|Newborns with CPAP support|Newborn with mild to moderate respiratory distress randomly allocated to CPAP arm. CPAP started with Positive End Expiatory Pressure(PEEEP) 05 and increased up to PEEP 09 according to the severity of baby's condition.
2885991|NCT03347136|Experimental|Newborns with NIPPV support|Newborn with mild to moderate respiratory distress randomly allocated to NIPPV arm. NIPPV started with Intermittent Mandatory Ventilation rate 30, Peak Inspiratory Pressure 20 and PEEP 5.Increased the settings according to the severity of baby's condition
2885992|NCT03347123|Experimental|Treatment Group A|Epacadostat + nivolumab + ipilimumab
2885994|NCT03347110|Experimental|Bimekizumab|Subjects will receive bimekizumab up to 2 years.
2885995|NCT03347097|Experimental|PD-1-PIK T cells|10 days after the end of concurrent chemoradiotherapy，the 300ml PD-1-PIK cells ( PD-1-PIK saline + 0.25% human serum albumin) was injected intravenously 2 times every 30 days .
2885996|NCT03347084|Active Comparator|Excitation|Excitation Paradigm: LIFUP excites the activity of hippocampal neurons.
2885997|NCT03347084|Active Comparator|Inhibition|Inhibition Paradigm: LIFUP inhibits the activity of hippocampal neurons.
2885998|NCT03347071||Prevention Course Group|The Prevention Course Group is composed of female student-athletes enrolled in the 7-week prevention course. The course occurs once a week (1 hour, 40 minute sessions) for a total of 7-weeks during the academic semester. Approximately 1 hour of each class session is lecture based, leaving 40 minutes for yoga practice administered by a certified yoga instructor. The course instructor is certified in Eat Breathe Thrive Program delivery. The course teaching assistant is certified in yoga instruction.
2885999|NCT03347071||Control Group|The Control Group is composed of female student-athletes not enrolled in the 7-week prevention course. Female student-athletes in this group will not be enrolled in the course during the period of data collection, nor will they have previously completed the course.
2886000|NCT03347058|Other|Supportive programming|Access to a suite of resources, including digital tools, person-to-person support, and educational resources
2886001|NCT03347045|Experimental|Trimodal Prehab & ERP|"Trimodal prehab includes:~Guided exercise program at Repsol Place in Calgary, Alberta 2x/week, hosted by the Total Cardiology group. Home-exercise program for another 3x/week.~Nutritional optimization with a high-protein oral supplement, along with nutritional counseling and access to a Registered Dietitian on site.~Anxiety reduction workshop and take-home anxiety reduction program."
2886002|NCT03347045|Active Comparator|No Prehab; ERP Alone|The active comparator group will be given a home exercise program, nutrition education, and a take-home anxiety reduction program.
2886003|NCT03347032|Experimental|Intervention|This group will undergo remote ischemic preconditioning with serial inflations of the blood pressure cuff to 200 mmHg followed by deflation for reperfusion for a period of 5 minutes each for a total of 4 cycles.
2886004|NCT03347032|Sham Comparator|Control|This group will undergo serial inflations of the blood pressure cuff to 40 mmHg followed by deflation for a period of 5 minutes each for a total of 4 cycles.
2886005|NCT03347019|Experimental|accelerated rehabilitation after surgery|patients were included progressive rehabilitation programme first week after arthroscopic bankart repair consisting of passive shoulder range of motion exercises, scapular retraction exercises. The exercise programme progressed from active range of motion exercises to resistive and plyometric shoulder exercises. Patients were followed for six months.
2886006|NCT03347019|Experimental|delayed rehabilitation after surgery|Patients were not allowed to start passive shoulder exercises first three weeks after surgery. Patients were included progressive rehabilitation programme third week after arthroscopic bankart repair consisting of passive shoulder range of motion exercises, scapular retraction exercises. The exercise programme progressed from active range of motion exercises to resistive and plyometric shoulder exercises. Patients were followed for six months.
2886007|NCT03347006|Placebo Comparator|Placebo|Placebo control
2886008|NCT03347006|Experimental|Dose 1|1.5 g of omega-3 supplement
2886009|NCT03347006|Experimental|Dose 2|3.0 g of omega-3 supplement
2886010|NCT03347006|Experimental|Dose 3|4.5 g of omega-3 supplement
2886011|NCT03346993|Experimental|24C° 0,5% bupivacaine group|24C° 0,5% bupivacaine group will be performed USG guided infraclavicular block with 24C° 20 ml 0,5% bupivacaine
2886012|NCT03346993|Experimental|37C° 0,5% bupivacaine group|37C° 0,5% bupivacaine group will be performed USG guided infraclavicular block with 37C° 20 ml 0,5% bupivacaine
2886013|NCT03346980||Familial adenomatous polyposis|The Danish Polyposis Register is sited at Copenhagen University Hospital Hvidovre. From this registry consecutive familial adenomatous polyposis patients referred for esophagogastroduodenoscopy (EGD) will prospectively be enrolled in this single-center study. Both patients referred for endoscopic surveillance and interventional endoscopy are eligible.
2886014|NCT03346967|Experimental|Stem cell Administration for female patients|Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for female patients
2886015|NCT03346967|Experimental|Stem cell Administration for male patients|Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for male patients
2886016|NCT03346954|Experimental|Patients with Cushing's disease|Implementation of [11C]-Methionine PET/MRI
2886017|NCT03346915|Experimental|Subjects receiving WoW and BNI|The behavioral intervention (WoW and BNI) will supplement the subject's standard of care by incorporating interactive messaging, reminders, patient education, and enhanced provider communication.
2886018|NCT03346902|Placebo Comparator|Placebo|
2886019|NCT03346902|Active Comparator|EB001|
2886020|NCT03346876||Study group|patients with pectus excavatum
2886021|NCT03346876||Control group|healthy subjects without pectus excavatum
2886022|NCT03346850|Active Comparator|nasogastric tube (NGT) feeding|
2886023|NCT03346850|Active Comparator|nasoduodenal tube (NDT) feeding|
2886024|NCT03346837|Experimental|Inhibition (Cohort 1)|Single oral dose BMS-986205
2886025|NCT03346837|Experimental|Inhibition (Cohort 2)|Daily oral itraconazole doses for 24 days; single oral dose BMS-986205 on day 4
2886026|NCT03346837|Experimental|Induction (Cohort 3)|Single oral dose BMS-986205
2886027|NCT03346837|Experimental|Induction (Cohort 4)|Daily oral rifampin doses for21 days; single oral dose BMS-986205 on day 8
2886028|NCT03346811|Experimental|Experimental: icotinib|Patients diagnosed with lung cancer with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
2886029|NCT03346798|Experimental|Food Photography|On the first visit, participants will engage in food photography on their smart phones while eating. On the second visit, participants will not use their smart phones while eating.
2886030|NCT03346798|Experimental|Non-Food Photography|On the first visit, participants will engage in non-food photography on their smart phones while eating. On the second visit, participants will not use their smart phones while eating.
2886031|NCT03346785|Experimental|Food Photography|Participants will engage in food photography on their smart phones while eating
2886032|NCT03346785|Experimental|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
2886033|NCT03346785|Experimental|No Phone Use|Participants will not use their smart phones while eating
2886034|NCT03346772|Experimental|Influenza vaccination cohort|Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.
2886035|NCT03346759|Experimental|Tampon A First|Subjects were provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for the first of two consecutive menstrual cycles. Subjects were then provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the second of two consecutive menstrual cycles. For the third menstrual cycle, subject used tampons of their choosing.
2886036|NCT03346759|Experimental|Tampon B First|Subjects were provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the first of two consecutive menstrual cycles. Subjects were then provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for the second of two consecutive menstrual cycles. For the third menstrual cycle, subject used tampons of their choosing.
2886037|NCT03346746|Experimental|Low GI diet|This diet contained three Low GI meals. This was the Low Glycaemic Diet intervention.
2886038|NCT03346746|Experimental|High GI diet|This diet contained three meals, all with a high GI value. This was the High Glycaemic Diet intervention.
2886039|NCT03346720||Participants recruited into biomedical research|Participants recruited into biomedical research where data collected may be shared with the wider research community.
2886040|NCT03346720||Frontline research staff|Frontline research staff directly involved in obtaining consent from participants in the above studies e.g. study nurses, investigators
2886041|NCT03346720||Research related staff and other stakeholders|Research related staff and other stakeholders involved in the implementation of the data sharing policy e.g. study managers, data access committee members, ethics committee members, study nurses, investigators, research collaborators, data managers and other clinical trials support staff.
2886042|NCT03346720||Community advisory board members|Community advisory board members and other community members
2886043|NCT03346707||10.5 Tesla|
2886044|NCT03346694|Active Comparator|Dressing 1: Standard Island Dressing|Standard dressing that is applied on most patients with a sternotomy wound incision immediately after cardiovascular surgery before leaving the operating room. Dressing will be removed 48 hours after surgery.
2886045|NCT03346694|Active Comparator|Dressing 2: Prevena negative pressure|Prevena negative pressure wound suction machine dressing applied to sternotomy wound incision immediately after cardiovascular surgery. Dressing will be in use for 7 days or removed sooner if participant is discharged before end of 7 day post-operative time period.
2886046|NCT03346694|Active Comparator|Dressing 3: Mepilex Border Post-Op Ag|Mepilex Border PostOp AG dressing impregnated with silver ions. Dressing will be in use for 7 days or removed earlier if patient is discharged before end of 7 days post0operative time period.
2886047|NCT03346681|Experimental|NAC and albuterol|The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).
2886048|NCT03346681|No Intervention|Albuterol|Albuterol will be administered via nebulization every six hours.
2886049|NCT03346668|Experimental|Topical gabapentin|gabapentin 6% solution, 1mL applied twice daily for 12 weeks
2886050|NCT03346642|Experimental|Decitabine primed GVD and SHR-1210|
2886051|NCT03346642|Experimental|GVD and SHR-1210|
2886052|NCT03346629|Experimental|Mifepristone + Misoprostol|Intervention: 200mg mifepristone followed 24-48 h later with 400mcg misoprostol (repeat Q3)
2886053|NCT03346616|Experimental|Texting Group|"The texting group received a daily text message containing a board style multiple choice question. If the participant wanted immediate feedback, the message contained a link to a website containing the answer to the question along with an explanation, the source material, and a more complete clinical vignette. One hour after the initial text message was sent, a follow up answer text message was delivered. Text messages were sent 6 days per week (Monday through Saturday) at 2 pm and 3 pm."
2886054|NCT03346616|Active Comparator|Non Texting Group|The non-texting group received access to the journal articles from which the text message content was derived, but did not receive any text messages or any of the online material or question stems.
2886055|NCT03346590|Active Comparator|16 patients with active RA|"Women over 18 years old with proven active (DAS28 >3.2) RA, diagnosed based on ACR/EULAR 2010 criteria, receiving biological anti-TNF treatment for the first time.~Covered by social security. Capable of giving informed consent and acceding to the requirements of the study. For high-resolution echocardiography: no hypertension, diabetes or history of cardiovascular disorders."
2886056|NCT03346590|Sham Comparator|8 Healthy volunteers (control group)|Healthy volunteers (control group) The healthy female controls will be enrolled from the Centre de Recherche en Nutrition Humaine (CRNH) list of volunteers and matched to the RA patients according to age ±5 years and BMI class (<25; 25-30; >30).
2886057|NCT03346577||Patients with peripheral artery disease|located in the common and external iliac artery, the common and superficial femoral artery, the popliteal artery and/or the below-the-knee (BTK) arteries (anterior tibial artery, posterior tibial artery or peroneal artery).
2886058|NCT03346564|Experimental|Ritual training program|ritual training program for 8 weeks, biweekly
2886059|NCT03346564|Placebo Comparator|Routine care|Routine care following hospital
2886060|NCT03346551|Experimental|women with postnatal depression|
2886061|NCT03346551|Other|women without postnatal depression|
2886062|NCT03346538|Experimental|Continuous infusion high-dose group (Group H)|High-dose MCI-186 will be administered as a bolus, and then as a continuous infusion. In addition, a placebo will be administered as an intravenous infusion twice a day over 30 minutes.
2886089|NCT03346317|Experimental|dried biological amnion graft|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.
2886063|NCT03346538|Experimental|Continuous infusion low-dose group (Group L)|Low-dose MCI-186 will be administered as a bolus, and then as a continuous infusion. In addition, a placebo will be administered as an intravenous infusion twice a day over 30 minutes.
2886064|NCT03346538|Experimental|Approved dosing regimen group (control group)|A placebo will be administered as a bolus, and then as a continuous infusion. In addition, MCI-186 30 mg will be administered as an intravenous infusion twice a day over 30 minutes.
2886065|NCT03346525|Experimental|BPG Arm|Intramuscular BPG prophylaxis (600,000 IU for children <30kg, 1.2 million IU for children ≥30kg), every 28 days
2886066|NCT03346525|No Intervention|Control Arm|No prophylaxis
2886067|NCT03346512||Cardiac surgery|Patients having undergone cardiac surgery (other than the placement of a pacemaker or defibrillator) within the CHU Brugmann hospital between 2006 and 2015
2886068|NCT03346499|Experimental|NK cells and IL-2|
2886069|NCT03346486|Placebo Comparator|Control diet|Regular diet
2886070|NCT03346486|Active Comparator|Intervention diet|Brainfood diet
2886071|NCT03346473||Adolescents aged 12-15 years in LMICs|No interventions administered
2886072|NCT03346460|Experimental|Tongue scraper group (Group 1)|Fifteen patients will be included in this group. Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
2886073|NCT03346460|Experimental|aPDT group (Group 2)|Fifteen patients will be included in this group. One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
2886074|NCT03346460|Experimental|Tongue scraper and aPDT (Group 3)|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating. After, one session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
2886075|NCT03346434|Experimental|Part A (Open label Dupilumab): Age cohorts 1 & 2|"Age cohort 1: ≥2 years old to <6 years old~Age cohort 2: ≥6 months to <2 years old"
2886076|NCT03346434|Experimental|Part B (Double-blind): Dupilumab dose 1|The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.
2886077|NCT03346434|Experimental|Part B (Double-blind): Dupilumab dose 2|The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.
2886078|NCT03346434|Experimental|Part B (Double-Blind): Placebo|
2886079|NCT03346421||diet and physical activity|
2886080|NCT03346408||Patients|data collection obtained from patient (self-questionnaire) and algologist physician (questionnaire).
2886081|NCT03346395|Experimental|Problem solving based intervention|The problem solving based intervention contains a problem solving process and cooperation between the person on sick leave, his/her employer and health care professionals. The intervention consists of five steps: 1) Making an inventory of problems and/or opportunities related to return to work; 2) brainstorming about solutions; 3) writing down solutions, identifying the support needed to implement the solutions; 4) a three-party meeting with the person on sick leave, his/her employer and the rehabilitation coordinator; 5) evaluation of the action plan and implementation of solutions, relapse prevention. The intervention takes the form of two to five consultations. The first and fourth steps are key elements.
2886082|NCT03346395|Active Comparator|Care as usual|Medical treatment, or behavioral therapy or in combination. Meeting with a rehabilitation coordinator if that is a part or care as usual within primary health care.
2886083|NCT03346369|Experimental|Experimental single arm|Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period.
2886084|NCT03346356|Experimental|Teenagers as cross-age teachers|After the initial training, the teenage teachers facilitated the curricula associated with the SHCP, Discovering Healthy Choices and Cooking Up Healthy Choices, approximately twice a month. The curricula can be viewed at http://cns.ucdavis.edu/programs/shcp/curriculum.html. Each activity provided step-by-step instructions that the teenage teachers were asked to follow. Younger youth served as participants for the classroom and garden-based activities.
2886085|NCT03346356|No Intervention|Comparison group|Youth of similar ages to the intervention group completed the same assessments, but did not receive the intervention.
2886086|NCT03346343|Experimental|Non-invasive forced airway oscillometry|"Analyze lung function using forced airway oscillometry in preterm infants and term infants with and without lung disease with both cross-sectional and longitudinal comparisons.~Aim 1: Lung function in term and preterm infants without lung disease (anticipated n=264) Aim 2: Lung function in preterm infants with respiratory distress syndrome (RDS) who develop bronchopulmonary dysplasia (BPD) and preterm infants with RDS who do not develop BPD (anticipated n=264) Aim 3: Lung function measurements in infants with common neonatal lung diseases (including RDS, BPD, meconium aspiration syndrome, and transient tachypnea of the newborn) and controls without lung disease (anticipated n=570) Aim 4: Lung function in infants with lung disease before and after common therapeutic interventions"
2886087|NCT03346330|Experimental|TRK-750, single and multiple doses|
2886088|NCT03346330|Placebo Comparator|Placebo, single and multiple doses|
2886144|NCT03346031|Active Comparator|Music Therapy Group 2|Group 2 is the group listening to preoperative music
2886090|NCT03346317|Experimental|estrogen|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
2886091|NCT03346304|Experimental|PDT treatment (Intervention Arm)|Patients randomised to the PDT treatment (Intervention Arm) will have two courses of PDT treatment in total (for each lung treated). Follow-up is the same as for Control Arm patients: an AFB at 6, 12, 24, and at 36 months post-randomisation; with further AFB visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
2886092|NCT03346304|No Intervention|Surveillance (Control Arm)|Patients randomised to the surveillance (Control Arm) will have: an AFB at 6, 12, 24, and at 36 months post-randomisation; with further AFB visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
2886093|NCT03346291|Experimental|Persistence Targeted Smoking Cessation|8 weekly counseling sessions + 10 weeks of over-the-counter nicotine patch
2886094|NCT03346278|No Intervention|No Text Message Intervention|Participants will receive usual care of information on CR and clinical referral to CR.
2886095|NCT03346278|Experimental|Text Message Intervention|Participants randomized to the intervention will receive usual care plus a text messaging intervention.
2886096|NCT03346265|Experimental|Group A|"Treatment A consisted in a combined exercise program of 40 min duration RMP (Monari, 2004; Monari et al., 2016) and 20 min duration of gait training with sensory cues.~RMP. RMP protocol was based on lengthening and muscular recruitment exercises by means of complex motor skills involving muscular kinetic chains in lower limbs and trunk. Each session was divided into muscular stretching exercise, aiming to increase step length and rotating trunk movements, and tailored progressive exercise therapy."
2886097|NCT03346265|Experimental|Group B|Treatment B Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code): trunk (s760), pelvis (s750), lower extremity (s750), and upper extremity (s730) including shoulder region (s720). Domains focused on were (1) warm-up exercises, (2) trunk mobility exercises, (3) postural stability (b715), and (4) transferring oneself (d420) and changing body positions (d410).
2886098|NCT03346252|Experimental|Botulinum Toxin type A|Participants will be injected intramuscularly with total of 50 Units, 25 units of Botulinum A per temporalis muscle. The BTX injection will be prepared by dissolving 100 U vial in 2 ml of 0.9 % of Sodium Chloride (NaCl), yielding 25 U/ml. Each participant will receive 0.1 ml of BTX/NaCl mixture in 5 spots per temporalis muscle.
2886099|NCT03346239|Experimental|Gaze Contingent Music Reward Therapy|Participants will receive gaze-contingent feedback according to their viewing patterns, over a course of 12 weeks.
2886100|NCT03346239|Active Comparator|Selective Serotonin Reuptake Inhibitors|Participants will receive 10-20 mg of Escitalopram over a course of 12 weeks.
2886101|NCT03346239|Placebo Comparator|Waitlist Control|Participants will wait for treatment for 12 weeks, then receive GC-MRT for 12 weeks.
2886102|NCT03346226|Experimental|Dexmedetomidine Hydrochloride|Dex Group: 0.5 μg/kg of Dex is given 10 minutes before operation through injection pump during 15 minutes. After the operation starts, the initial pumping ratio of Dex is 0.5ug/kg/h and adjusted under BIS surveillance to keep BIS between 70-80 until 30 minutes before the end of surgery. Meanwhile, OAA/S grade is evaluated every 15 minutes to maintain OAA/S at grade 4. If discrepancy occurs, OAA/S prevails.
2886103|NCT03346226|Active Comparator|Propofol|Prop Group: Propofol is given with an initial ratio of 2-10mg/kg/h, when the operation starts. Under BIS surveillance, dripping rate is adjusted to keep BIS between 70-80 until 5 minutes before the end of surgery. Meanwhile, OAA/S grade is evaluated every 15 minutes to maintain OAA/S at grade 4. If discrepancy occurs, OAA/S prevails.
2886104|NCT03346213||Major surgery|"Adult patients undergoing elective surgery~Having a CPET as part of routine care~Patients with a Hb value of < 130 g/L who are iron deficient, iron restricted/deplete or have functional iron deficiency.~Able to provide written informed consent."
2886105|NCT03346200|Active Comparator|20 mg tamoxifen|
2886106|NCT03346200|Experimental|10 mg tamoxifen|
2886107|NCT03346200|Experimental|5 mg tamoxifen|
2886108|NCT03346200|Experimental|2.5 mg tamoxifen|
2886109|NCT03346200|Experimental|1 mg tamoxifen|
2886110|NCT03346200|Placebo Comparator|0 mg tamoxifen|
2886111|NCT03346187|Experimental|A|"Period 1: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions.~Period 2: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions."
2886112|NCT03346187|Experimental|B|"Period 1: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions.~Period 2: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions."
2886113|NCT03346174|Experimental|AAD|AAD is an airway clearance technique for infants based upon the principles of autogenic drainage. By modulating manually the functional breathing level within the vital capacity, optimal airflow will be obtained at the targeted airway generations, where secretions have been identified. A gentle increase of manual pressure on the chest during each inspiration is performed to guide the breathing of the patient towards the desired lung volume level. During expiration the breathing movement of the patient is followed gently.
2886114|NCT03346174|Experimental|BAAD|AAD is an airway clearance technique for infants based upon the principles of autogenic drainage .AAD sometimes leads to crying or resistance against therapy.Bouncing (at low amplitude:6-8 cm) in a stable upright position is a gentle up-and-down movement on a physio ball. It is not an ACT, but used to maximize the relaxation of the infant, avoiding resistance against or crying during treatment. Due to the relaxing effect of bouncing, infants appear to tolerate better AAD, increasing the effectiveness of the treatment.
2886145|NCT03346031|Active Comparator|Music Therapy Group 3|Group 3 is the preoperative and peroperative music listening group (continuous)
2886146|NCT03346018||uveitis of tuberculous etiology|Analysis of aqueous humor and plasma samples: The patients with diagnosis of uveitis of tuberculous etiology, undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
2886224|NCT03345459|No Intervention|Usual Care|Participants are notified that they have elevated distress, and additionally, they are provided a list of on-campus and community resources.
2886115|NCT03346161|Experimental|Arm 1: Decision Tool|-The investigators will recruit patients who are scheduled for a plastic/reconstruction consultation. Investigators will also identify patients who have completed a mastectomy, or are scheduled for one, and are considering reconstruction, but don't have an appointment with a plastic/reconstructive surgeon. A study team member will call the patient to determine their interest and ask them to come to their scheduled appointment 30 minutes early to meet a coordinator. Patients will be randomized using computer random assignment. If the patient does not have an appointment, she will schedule a convenient time to complete study procedures with research staff. Patients will interact with the decision tool. They will be asked to answer a survey. After the appointment, for those who have clinical appointments, the team will collect information about the duration of the consultation and measures of shared decision making. Patient participation time is expected to be approximately 30 minutes.
2886116|NCT03346161|Active Comparator|Arm 2: Usual Care Surgical Care Booklet|-The investigators will recruit patients who are scheduled for a plastic/reconstruction consultation. The investigators will also identify patients who have completed a mastectomy, or are scheduled for one, and are considering reconstruction, but do not have an appointment with a plastic/reconstructive surgeon. A study team member will phone the patient to determine their interest and ask them to come to their scheduled appointment 30 minutes early to meet a coordinator. Patients will be randomized using computer random assignment. Patients will interact with the usual care surgical information booklet. They will be asked to answer a survey containing several questions. After the appointment, the team will collect information about the duration of the consultation and outcome measures. Patient participation time is expected to be approximately 30 minutes.
2886117|NCT03346135|Experimental|Treatment (ASCT, melphalan, daratumumab)|Patients undergo standard of care ASCT with a conditioning regimen of melphalan. Beginning 60-120 days after ASCT, patients receive daratumumab IV every week for 8 weeks, every 2 weeks for 16 weeks, and then every 4 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
2886118|NCT03346122|Experimental|Cohort 1:JNJ-64991524 Dose Level (DL) 1 or Placebo(SAD Part 1)|Participants will receive a single oral dose (Dose level 1) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
2886119|NCT03346122|Experimental|Cohort 2: JNJ-64991524 DL 2 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 2) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
2886120|NCT03346122|Experimental|Cohort 3: JNJ-64991524 DL 3 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 3) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
2886121|NCT03346122|Experimental|Cohort 4:JNJ-64991524 DL 4 or Placebo (SAD Part 1:Fasted-Fed)|Participants will receive a single oral dose (Dose level 4) of either JNJ-64991524 or placebo capsules in a fasted condition on Day 1 and fed condition, on Day 7.
2886122|NCT03346122|Experimental|Cohort 5: JNJ-64991524 DL 5 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 5) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
2886123|NCT03346122|Experimental|Cohort 6: JNJ-64991524 DL 6 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 6) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
2886124|NCT03346122|Experimental|Cohort 1: JNJ-64991524 DL 7 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 7) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and pharmacokinetics (PK) from Part 1.
2886125|NCT03346122|Experimental|Cohort 2: JNJ-64991524 DL 8 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 8) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
2886126|NCT03346122|Experimental|Cohort 3: JNJ-64991524 DL 9 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 9) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
2886127|NCT03346122|Experimental|Cohort 4: JNJ-64991524 DL 6 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 6) of JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined by tolerability and PK from Part 1.
2886128|NCT03346109|Experimental|MRLN sparing group|Patients in medial group retropharyngeal node（MRLN） sparing group will not routinely receive MRLN irradiation to 56Gy/33Fr
2886129|NCT03346109|No Intervention|MRLN prophylactic irradiation group|Patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr
2886130|NCT03346096|Experimental|Thiotepa|Thiotepa for reduce toxicity and improve outcome following transplantation
2886131|NCT03346083|Experimental|Single Dose|Single oral dose 40 mg or 80 mg
2886132|NCT03346070|Experimental|Sugammadex 2 mg/kg ABW|Single intravenous (i.v.) bolus of Sugammadex at 2 mg/kg as determined utilizing participant ABW.
2886133|NCT03346070|Experimental|Sugammadex 2 mg/kg IBW|Single i.v. bolus of Sugammadex at 2 mg/kg as determined utilizing participant IBW.
2886134|NCT03346070|Experimental|Sugammadex 4 mg/kg ABW|Single i.v. bolus of Sugammadex at 4 mg/kg as determined utilizing participant ABW.
2886135|NCT03346070|Experimental|Sugammadex 4 mg/kg IBW|Single i.v. bolus of Sugammadex at 4 mg/kg as determined utilizing participant IBW.
2886136|NCT03346070|Active Comparator|Neostigmine/Glycopyrrolate|Single i.v. bolus containing both Neostigmine (50 µg/kg; up to 5 mg maximum dose) and Glycopyrrolate (10 µg/kg; up to 1 mg maximum dose) as determined utilizing participant ABW.
2886137|NCT03346057|Experimental|Sugammadex 2 mg/kg|Sugammadex 2 mg/kg administered as a single intravenous (IV) dose
2886138|NCT03346057|Experimental|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg administered as a single IV dose
2886139|NCT03346057|Experimental|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg administered as a single IV dose
2886140|NCT03346057|Active Comparator|Neostigmine + Glycopyrrolate|Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose
2886141|NCT03346044|Active Comparator|Carpentier-Edwards SAV bioprostheses|
2886142|NCT03346044|Active Comparator|Medtronic Mosaic bioprostheses|
2886143|NCT03346031|No Intervention|Group 1|Group 1 is control group that does not listen to music
2886147|NCT03346018||uveitis of suspect sarcoidosis|Analysis of aqueous humor and plasma samples:The patients with diagnosis of uveitis of suspect sarcoidosis, undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
2886148|NCT03346018||uveitis of undifferentiated origin|Analysis of aqueous humor and plasma samples:The patients with diagnosis of uveitis of undifferentiated origin (tuberculosis/sarcoidosis), undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
2886149|NCT03345992|Placebo Comparator|Placebo|After enrollment, the placebo arm will receive water for injection at a volume of 20ml diluted to a final volume of 250 ml dextrose in water 5%, infused once daily through intravenous route, within 1 hour, for a duration of four consecutive days.
2886150|NCT03345992|Active Comparator|Clarithromycin|After enrollment, the active drug arm will receive 1g of clarithromycin (500 mg powder for concentrate for solution for infusion per vial), dissolved into 20 ml water for injection and then diluted to a final volume of 250 ml dextrose in water 5%. This will be infused through intravenous route, once daily within 1 hour, for a duration of four consecutive days.
2886151|NCT03345979|Experimental|Treatment Group 1|Regular injections
2886152|NCT03345979|Active Comparator|Treatment Group 2|Regular injections
2886153|NCT03345966|Experimental|Immunohistochemistry|"In order to provide more precised data on Bmi-1 immunoexpression in OSCC, image analyzer will be used.~The data will be obtained using the software (SIS, Germany), which comprise a light microscope (Olympus B × 60 Japan) capable of performing high speed digital image processing for the purpose of cell measurements. It will be calibrated automatically to convert the measurement units (pixels) produced by image analyzer program into actual micrometer units."
2886154|NCT03345966|Experimental|Polymerase Chain Reaction PCR|"Calculation of Relative Quantification (RQ) (relative expression):~After the RT-PCR will run, the data will be expressed in Cycle threshold (Ct).PCR data sheets will include Ct values of assessed gene and the house keeping (reference) gene which will be continuously expressed in the cell- (β-actin).To measure the gene expression of certain gene, -ve control sample shall be used. So target gene expression will be assessed and related to reference (internal control) gene as follows:~Finally, RQ was calculated according to the following equation:~∆ Ct (Cycle threshold) = Ct assessed gene - Ct reference gene~∆∆ Ct = ∆ Ct sample - Ct control gene~RQ = 2-(∆∆Ct)"
2886155|NCT03345953|Experimental|BP 1.4979|15 mg tablet BID
2886156|NCT03345953|Placebo Comparator|Placebo|Matching placebo tablet
2886157|NCT03345940|Active Comparator|Fingolimod 0.5 mg/day|"The study drugs, FTY and DMT, are approved and available on the market and safety and tolerability profile of both the drugs is well known. In our study, patients will be treated according to the clinical practice.~Dose: FTY 0.5 mg/day or DMF 240 mg twice daily"
2886158|NCT03345940|Active Comparator|Dimethyl Fumarate 240 mg twice daily|"The study drugs, FTY and DMT, are approved and available on the market and safety and tolerability profile of both the drugs is well known. In our study, patients will be treated according to the clinical practice.~Dose: FTY 0.5 mg/day or DMF 240 mg twice daily"
2886159|NCT03345927||high cardiovascular risk group|no intervention
2886160|NCT03345914|Experimental|Group 1|Participants will receive dupilumab, dosing regimen 1
2886161|NCT03345914|Experimental|Group 2|Participants will receive dupilumab, dosing regimen 2
2886162|NCT03345914|Experimental|Group 3|Participants will receive matching placebo
2886163|NCT03345901|Experimental|Pemafibrate|.2 mg pemafibrate orally BID
2886164|NCT03345901|Placebo Comparator|Placebo|Placebo pill orally BID
2886165|NCT03345888||resuscitation time line group|The ETCO2 will be arrange in resuscitation time line.
2886166|NCT03345888||ETCO2 time line group|The ETCO2 will be arrange in time line which the beginning time is the time of starting to show stable ETCO2 wave.
2886167|NCT03345875|Other|HPV Screening|Study eligible participants will be screened for HPV using a self collected vaginal sample using a collection device and kit. Those who test positive for HPV will be offered visual assessment of the cervix for treatment (VAT) and treatment as appropriate.
2886168|NCT03345862|Experimental|Intervention|Non-pharmacological multicomponent intervention
2886169|NCT03345862|No Intervention|Control|Not intervention, usual attention
2886170|NCT03345849|Experimental|Arm A|Participants will receive upadacitinib dose A for 12 weeks.
2886171|NCT03345849|Experimental|Arm B|Participants will receive placebo for 12 weeks.
2886172|NCT03345836|Experimental|Arm B|Participants will receive placebo for 12 weeks.
2886173|NCT03345836|Other|Arm C|Participants will receive open-label upadacitinib dose A for 12 weeks.
2886174|NCT03345836|Experimental|Arm A|Participants will receive upadacitinib dose A for 12 weeks.
2886175|NCT03345823|Experimental|Group A - Arm B|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive dose C.
2886176|NCT03345823|Experimental|Group B - Arm C|This is a long-term extension group with 240 weeks which includes participants who complete group A.
2886177|NCT03345823|Experimental|Group B - Arm A|This is a long-term extension group with 240 weeks which includes participants who complete group A and will receive dose B.
2886178|NCT03345823|Experimental|Group B - Arm B|This is a long-term extension group with 240 weeks which includes participants who complete group A and will receive dose C.
2886179|NCT03345823|Experimental|Group A - Arm A|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive dose B.
2886180|NCT03345823|Experimental|Group A- Arm C|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive placebo.
2886181|NCT03345810|Active Comparator|Control Arm A|Frail or elderly patients with metastatic NSCLC; CARG- Score ≤ 3 Carboplatin (AUC 5.0; D1) + nab-Paclitaxel (100mg/m2 D1,D8) Q3W
2886225|NCT03345446||Patients with HF-rEF|These patients have Heart Failure with Reduced Ejection Fraction (EF < 55% per the protocol).
2886182|NCT03345810|Experimental|Experimental Arm B|"Frail or elderly patients with metastatic NSCLC; CARG- Score ≤ 3~Induction:Carboplatin (AUC 5.0; D1) + nab-Paclitaxel (100mg/m2) D1,D8; Q3W [2 cyc] followed by durvalumab (1125 mg; Q3W) [ 2 cyc] Maintenance:durvalumab (1500 mg) Q4W"
2886183|NCT03345810|Experimental|Experimental Arm C|"Frail or elderly patients with metastatic NSCLC; CARG- Score > 3~Induction: Vinorelbine (30 mg/m2; D1+D8) Q3W [ 2 cyc] or Gemcitabine (1000 mg/m2; D1+D8) Q3W [ 2 cyc] followed by durvalumab (1125 mg) Q3W [2 cyc] Maintenance:durvalumab (1500 mg; Q4W)"
2886184|NCT03345810|Active Comparator|Control Arm D|"Frail or elderly patients with metastatic NSCLC; CARG- Score > 3~Vinorelbine (30 mg/m2; D1+D8) Q3W or Gemcitabine (1000 mg/m2; D1+D8) Q3W"
2886185|NCT03345797|Experimental|Naive subjects - ARM 1|TRT naïve subjects with Tanner Stage of 0 and bone age >/= 10.5 years
2886186|NCT03345797|Experimental|Non-naive - ARM 2|non-naïve subjects (have had prior testosterone treatment), with Tanner Stage >/= 3 and bone age >/= 13 years
2886187|NCT03345784|Experimental|Treatment (radiation therapy, adavosertib, cisplatin)|Patients undergo external beam radiation therapy on days 1-5 and receive adavosertib PO on days 1, 3, and 5 or QD on days 1-5 and cisplatin IV over 1 hour on day 1 or 3. Courses repeat each week for up to 5 weeks in the absence of disease progression of unacceptable toxicity.
2886188|NCT03345771|Active Comparator|Antimicrobial Barrier Dressing|postoperative wound dressing with either anti-microbial dressing placed in the operating room from surgery to postoperative day 7
2886189|NCT03345771|Active Comparator|Closed-incision Negative Pressure Therapy|portable NPWT device placed in the operating room from surgery to postoperative day 7
2886190|NCT03345758||ECMO mode,outcome|ECMO mode includes VV-ECMO and VA-ECMO, outcome includes survive condition , physical and mental health, cognitive function and social adaptation
2886191|NCT03345745||Periodontally healthy subjects|Salivary samples
2886192|NCT03345745||Chronic periodontitis patients|Salivary samples
2886193|NCT03345745||Gingivitis patients|Salivary samples
2886194|NCT03345706|Experimental|Selective cerebral hypothermia|Selective cerebral hypothermia
2886195|NCT03345706|Active Comparator|Regular hypothermia|Regular hypothermia
2886196|NCT03345693|Experimental|Treated with MoTrack Therapy|Patients receive the MoTrack Therapy device to assist them in their at-home therapy exercises. The patient is instructed to use the MoTrack Therapy device when they want to do their at-home therapy exercises. The patients therapy in the clinic is not affected.
2886197|NCT03345680|No Intervention|Control Group|Children will be screened, both parents and children will be informed of any abnormalities in the mouth.
2886198|NCT03345680|Experimental|Interventional Group|Interventional (Dental Screening) Children will be screened for dental caries and referred to a specific hospital for treatment, namely King Saud University Dental College, treatment will be provided free of charge to the referred participants.
2886199|NCT03345667||Anti-Vegf|Use intravitreous anti-vegf
2886200|NCT03345654|Placebo Comparator|Standard-of-care hearing aid fit|
2886201|NCT03345654|Experimental|Toolset-directed hearing aid fit|
2886202|NCT03345641||dyads|dyads with babies and their mothers
2886203|NCT03345628||sedated|infants requiring intubation and ventilation who received sedatives for at least 3 days
2886204|NCT03345628||non-sedated|infants who received respiratory support by non-invasive ventilation and were not sedated
2886205|NCT03345615|Experimental|Intensive Monitoring|30-day ambulatory cardiac event monitoir
2886206|NCT03345615|No Intervention|Standard Care|Standard Care (no supplemental monitoring)
2886207|NCT03345589|Experimental|18-22mg/kg/d Ursodeoxycholic group|
2886208|NCT03345589|Placebo Comparator|13-15mg/kg/d Ursodeoxycholic group|
2886209|NCT03345576|Experimental|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
2886210|NCT03345576|Sham Comparator|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
2886211|NCT03345563|Experimental|Body Mind Training (BMT)|Body mind training
2886212|NCT03345563|Active Comparator|Body Training (BT)|Body training only
2886213|NCT03345563|Other|Usual care (UC):|Control
2886214|NCT03345550|Experimental|Omega-3 Polyunsaturated Fatty Acid Treatment Arm|Participants randomized to this study arm will receive 6g DHA+EPA for one month followed by 1.2 g DHA+EPA for two months. Capsules contain fish oil 1000 mg (contains 500 mg DHA & 100 mg EPA) or placebo capsules.
2886215|NCT03345550|Placebo Comparator|Placebo Arm|Participants randomized to this study arm will receive placebo drug for 3 months.
2886216|NCT03345524|Experimental|Peer-buddy system|Will meet with peer-buddy who will help with them with CPAP usage. Also will receive standard of care CPAP educational training
2886217|NCT03345524|Active Comparator|Usual Care|Will receive educational material at the same frequency that those in the experimental arm. Will also receive standard of care CPAP educational training.
2886218|NCT03345511|Experimental|Ultrasound Guided Caudal Block|30 minutes before benign canal anal surgery, a 18 G tuohy needle guided with an ultrasound probe to visualize the caudal space, a solution of bupivacaine 0.25%, Lidocaine 1% and dexamethasone 8mg was injected and needle removed.
2886219|NCT03345498||ETV 0.5 mg|Group of study participants who were started on 0.5 mg/day of entecavir
2886220|NCT03345498||ETV 1.0 mg|Group of study participants who were started on 1.0 mg/day of entecavir
2886221|NCT03345485|Experimental|Tinostamustine (EDO-S101)|"Phase 1:~Schedule A: Tinostamustine (EDO-S101), IV, 60mg/m2 up to 150mg/m2 Day 1 and 15 of each 28 day cycle~Schedule B: Tinostamustine (EDO-S101, IV, 60mg/m2 up to 150mg/m2 Day 1, 8 and 15 of each 28 day cycle~Phase 2:~The RP2D and selected schedule will be further investigated in patients with specific types of solid tumors: relapsed/refractory SCLC, soft tissue sarcoma, non-Kit GIST, triple negative breast, and ovarian cancers."
2886222|NCT03345472|Experimental|Treated|Enrolled subjects who are implanted with a spinal cord stimulation system that is activated.
2886223|NCT03345459|Experimental|Internet-Based Treatment (ICare)|ICare Prevent is a 7-week internet-based treatment for depression that is primarily cognitive behavior therapy but targets broad-based mechanisms related to college students.
2886226|NCT03345446||Patients with HF-pEF|These patients have Heart Failure with Preserved Ejection Fraction (EF > 55% per the protocol).
2886227|NCT03345433|Experimental|interactive group drumming sessions|Participants will be involved in four interactive group drumming sessions (10-30 minutes each) and complete surveys and questionnaires about music and quality of life.
2886228|NCT03345420|Experimental|Treatment (hypofractionated radiation therapy)|Within 12 weeks after breast conserving surgery, patients undergo hypofractionated radiation therapy for 9 fractions over 2 weeks.
2886229|NCT03345407|Placebo Comparator|placebo once daily|Eligible subjects will receive placebo ELLIPTA dry powder (blended with lactose) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
2886230|NCT03345407|Experimental|Nemiralisib 50 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 50 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
2886231|NCT03345407|Experimental|Nemiralisib 100 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 100 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
2886232|NCT03345407|Experimental|Nemiralisib 250 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 250 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
2886233|NCT03345407|Experimental|Nemiralisib 500 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 500 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
2886234|NCT03345407|Experimental|Nemiralisib 750 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 750 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
2886235|NCT03345394|Active Comparator|Standard Treatment|12 weeks of standard treatment offered by the 2 treatment facilities where the study is being conducted
2886236|NCT03345394|Experimental|Contingency Management|12 weeks of standard treatment offered by these same facilities associated with Contingency Management
2886237|NCT03345381|Experimental|SKY + ASTM + usual care|Sudarshan Kriya Yoga (SKY) followed by Automatic Self Transcending Meditation (ASTM) plus usual care
2886238|NCT03345381|Active Comparator|Usual Care|Treatment as usual
2886239|NCT03345368|Experimental|rTMS treated group|A Magstim Rapid2 Stimulator equipped with a double 70mm alpha coil P/N 3191-00 (Magstim, Wales, UK) will be used to stimulate the motor cortex. Transcranial magnetic stimulation will be applied through a coil at 10 Hz, a field intensity of 90% of the motor threshold. Stimuli will be provided in 10 trains of 100 pulses, followed by a 28 s rest period.
2886240|NCT03345368|Sham Comparator|sham rTMS group|Sham rTMS will be administered with the coil held in contact with the head but a 180 degrees from scalp, and the power parameter will be reduced by half to avoid stimulation.b
2886241|NCT03345355||patient with axial spondyloarthritis|
2886242|NCT03345342|Experimental|PP1M: Transition Phase|Participants who previously have not achieved stability with moderate to higher doses of Paliperidone palmitate 1-month (PP1M) or Paliperidone palmitate 3-month (PP3M) will enter into a transition period of up to 4 months. During transition period participants will receive 1 to 5 injections of PP1M 50 to 100 milligrams equivalent (mg eq.). The participants who achieved stability (stability is defined as at least 3 months of injections with the last 2 doses being the same strength) with PP1M 100 mg eq. will precede from transition phase to maintenance phase.
2886243|NCT03345342|Experimental|PP1M/PP3M: Maintenance Phase|All the participants will receive only 1 dose of PP1M 100 or 150 mg eq. or PP3M 350 or 525 mg eq. The participants will precede from maintenance phase to double-blind phase.
2886244|NCT03345342|Experimental|PP6M or Placebo: Double-Blind Phase|Participants will receive intramuscular injection of PP6M at dose of 700 or 1000 milligrams equivalent (mg eq.) in left gluteal muscle on Day 1 and right gluteal muscle on Day 183 with alternating placebo in right gluteal muscle on Day 92 and left gluteal muscle on Day 274 and in the same repeated pattern as needed after the first 12 months.
2886245|NCT03345342|Experimental|PP3M: Double-Blind Phase|Participants will receive intramuscular injections of PP3M at dose of 350 mg eq. or 525 mg eq. in left gluteal muscle on Day 1 and 274 and right gluteal muscle on Day 92 and 183 and in the same repeated pattern as needed after the first 12 months.
2886246|NCT03345329||Periodontal patient|
2886247|NCT03345329||Healthy person|
2886248|NCT03345329||Peri-implantitis patient|
2886249|NCT03345316|Experimental|FFI-1010|
2886250|NCT03345303|Experimental|Bortezomib treatment|'Bortezomib Injectable Solution
2886251|NCT03345303|No Intervention|supportive care|supportive care
2886252|NCT03345290|Experimental|Subjects|Subjects referred to a FDG PET scan (standard PET without cerebral step) without any oncologic setting. Patients will be included as following critera: 25% of subjects will have under 40 years old, 25% between 40 and 60 yeard old et 50% higher than 60 years old.
2886253|NCT03345277||Continuous Temperature monitoring|All residents of a long-term care facility will be considered for the study over the predetermined timeframe. Residents who choose not to participate or are determined, by their care providers, to be inappropriate for inclusion will be excluded.
2886254|NCT03345264|Experimental|Cancer patients, survivors, and partners|
2886255|NCT03345251|Experimental|manipulation of endometrium|The arm is physical manipulation to the endometrium prior to ICSI By one of these interventions )Hydrotubation , Sonohysterography or endometrial scratching
2886256|NCT03345251|Placebo Comparator|no manipulation to endometrium in ICSI|This is the control group , with no manipulation to endometrium prior to ICSI No intervention to this group
2886257|NCT03345238|Experimental|Active MTP|
2886258|NCT03345238|Experimental|Latent MTP|
2886259|NCT03345238|Experimental|Out of MTP|
2886860|NCT03340961|Placebo Comparator|Placebo Capsules|Placebo Capsules once per day for 16 weeks.
2886260|NCT03345225|Active Comparator|Control Group|Participants will be randomized to receive DEB-TACE utilizing a standard endhole microcatheter
2886261|NCT03345225|Experimental|Surefire Group|Participants will be randomized to receive DEB-TACE utilizing the Surefire Infusion System
2886262|NCT03345212|No Intervention|Control group|Patients in this group continue their sedentary life-style throughout the study period. Patients will be advised to perform no specific exercise training during the trial. After 15 weeks, the patients are offered to take part in the training program as well.
2886263|NCT03345212|Experimental|Training group|"Standard rehabilitation therapy includes dietary measures, massages and relaxation techniques. Additionally, patients perform exercise and respiratory therapy and mental gait training.~Patients will be informed about group allocation."
2886264|NCT03345199|Experimental|Inspiratory Muscle Trainer (IMT)|Inspiratory Muscle Trainer (IMT) provides resistance as a person inhales, thereby strengthening respiratory muscles.
2886265|NCT03345186|Experimental|Nurse led plus standard of care|Nurse Led Patient Management Programme to Improve Outcomes in Gout and Standard of care for gout patients, including nurse delivered patient education and follow up
2886266|NCT03345186|No Intervention|Standard of care|Standard of care for gout patients
2886267|NCT03345173|Experimental|CI-581a|"CI-581a will be administered during the washout phase when participants are experiencing moderate withdrawal, as well as the following day when the naltrexone titration is initiated.~(0.11 mg/kg 2-min bolus followed by 1.3 mg/kg over 90 min)"
2886268|NCT03345173|Placebo Comparator|CI-581b|"CI-581b will be administered during the washout phase when participants are experiencing moderate withdrawal, as well as the following day when the naltrexone titration is initiated.~(2-min saline bolus followed by 0.0125 mg/kg over 90 min)"
2886269|NCT03345160|Experimental|Peanut Flour: Open label peanut OIT|This is an open label treatment for subjects who had previously received placebo treatment in a prior peanut OIT study
2886270|NCT03345147||Normal Vitamin A intake|Normal Vitamin A intake will be assessed by a questionnaire directed to the consumption of food items with high VA content on the 7 days prior to the questionnaire. The daily consumption will be assessed on average. A child is assigned to Normal Vit. A consumption if daily Vit. A is between 250 and 600 micrograms per day.
2886271|NCT03345147||High Vitamin A intake|High Vitamin A intake will be assessed by a questionnaire directed to the consumption of food items with high VA content on the 7 days prior to the questionnaire. The daily consumption will be assessed on average. A child is assigned to High Vit. A consumption if daily Vit. A is above 900 micrograms per day.
2886272|NCT03345134|Experimental|MK-3475 and BCG|Single treatment group of high risk superficial upper urinary tract transitional cell carcinoma; combination treatment with MK-3475 and BCG
2886273|NCT03345108|Experimental|Test Denture Adhesive (Conventional Application)|Test denture adhesive will be applied to participants' dentures via conventional pattern of application.
2886274|NCT03345108|Experimental|Test Denture Adhesive (Continuous strip Application)|Test denture adhesive will be applied to participants' dentures via continuous strips pattern of application.
2886275|NCT03345108|Other|Negative Control|Participants will not apply any denture adhesive in this treatment arm.
2886276|NCT03345095|Experimental|Experimental Arm|Radiotherapy + Temozolomide + Marizomib followed by adjuvant Temozolomide + Marizomib
2886277|NCT03345095|Active Comparator|Standard Arm|Radiotherapy + Temozolomide followed by adjuvant Temozolomide
2886278|NCT03345082|Experimental|0.5 mg ranibizumab with 2.0 mg OPT-302|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 2.0 mg OPT-302 intravitreal injection (0.05 ml)
2886279|NCT03345082|Experimental|0.5 mg ranibizumab with 0.5 mg OPT-302|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 0.5 mg OPT-302 intravitreal injection (0.05 ml)
2886280|NCT03345082|Sham Comparator|0.5 mg ranibizumab with sham|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by sham
2886281|NCT03345056|Other|included cases|vitrectomy done with planned foveal separation and followed for the result
2886282|NCT03345043|Experimental|VAL-339851|
2886283|NCT03345043|Placebo Comparator|Placebo|
2886284|NCT03345030||Unexplained infertile group|Patients diagnosed as unexplained infertility (UI) were recruited to the study. UI was diagnosed after normal standard infertility evaluation according to the guideline of The Practice Committee of the American Society for Reproductive Medicine which consist of the assesment of spermiogram, ovulation, hysterosalpingogram and if indicated ovarian reserve tests and laparoscopy. If the results of all this tests were normal, patients were accepted as UI.
2886285|NCT03345030||Control group|The control group received in vitro fertilization (IVF) for tubal factor and included only those women who had salpingectomy for ectopic pregnancy or proximal tubal obstruction because of low-grade infection or fimbrial occlusion with or without mild peritubal adhesions. Tubal infertility associated with hydrosalpinx, severe pelvic adhesions, endometriosis or pelvic inflammatory disease were excluded. Patients with male factor except oligoasthenospermia were also recruited for the study.
2886286|NCT03345004|Active Comparator|Active arm|Patients will be assigned to receive i) three (3) intralymphatic injections with 4µg Diamyd (GAD-alum) on Days 30, 60, and 90 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day 1 through Day 120)
2886287|NCT03345004|Placebo Comparator|Placebo arm|Patients will be assigned to receive i) three (3) intralymphatic injections of Placebo for Diamyd (GAD-alum) on Days 30, 60, and 90 and; ii) oral Placebo for vitamin D once a day for 4 months (from Day 1 through Day 120)
2886288|NCT03344991|Active Comparator|Cardboard Cot Care|Stable infant will be transferred to cardboard cot, lined with reflective film for duration of hospital stay following weaning from radiant warmer. Infant's axillary temperature will be taken at 1 hour, 6 hours, 24 hours after being placed in the cot or crib, and then once every 24 hours until discharge.
2886289|NCT03344991|Placebo Comparator|Open Crib|Stable infant will be transferred to standard of care open crib for duration of hospital stay following weaning from radiant warmer. Infant's axillary temperature will be taken at 1 hour, 6 hours, 24 hours after being placed in the cot or crib, and then once every 24 hours until discharge.
2886290|NCT03344978|Active Comparator|Cardboard Cot Care|Stable infant will be nursed in a cardboard cot, lined with reflective film for 24 hour period of time. Infant's axillary temperature will be taken at 1 hour after randomization, at 6 hours after randomization, and 24 hours after randomization. After 24 hours, infant will be swapped to the other arm (Incubator Care), and back for a total of 2 24-hour periods in each arm.
2886291|NCT03344978|Placebo Comparator|Incubator Care|Stable infant will be nursed in an incubator for 24 hour period of time. Infant's axillary temperature will be taken at 1 hour after randomization, at 6 hours after randomization, and 24 hours after randomization. After 24 hours, infant will be swapped to the other arm (Cardboard Cot Care), and back for a total of 2 24-hour periods in each arm.
2886292|NCT03344965|Experimental|OLAPARIB QD GERMLINE MUTATION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks) during taking 2 times per day, 12 hours apart.~Tumor measurement q6 weeks x 24 weeks, then q 12 weeks"
2886293|NCT03344965|Experimental|OLAPARIB QD SOMATIC MUTATION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks) during taking 2 times per day, 12 hours apart.~Tumor measurements q6 weeks x 24 weeks, then q 12 weeks"
2886294|NCT03344926|Experimental|ACTsmart|ACT treatment via a smart phone application
2886295|NCT03344913|Active Comparator|Adults with knee Osteoarthritis|walking 30 minutes per day, three days/week for 6 weeks.
2886296|NCT03344913|Active Comparator|Healthy controls|walking 30 minutes per day, three days/week for 6 weeks.
2886297|NCT03344900||Phase I|It is estimated that 100 participants with SCD will be enrolled for the Phase I portion which will identify barriers to hydroxyurea utilization.
2886298|NCT03344900||Phase II|It is estimated that 72 participants with SCD will be enrolled for the Phase II portion of the study which will evaluate the degree of feasibility and acceptance of mHealth intervention on hydroxyurea adherence.
2886299|NCT03344887|Active Comparator|RBC Transfusion from male donor|For the treatment of anemia
2886300|NCT03344887|Active Comparator|RBC Transfusion from female donor|For the treatment of anemia
2886301|NCT03344874|Experimental|Stethee (new stethoscope)|"Test 1: Use Stethee® to auscultate and identify a set of 10 manikin-simulated heart sounds.~Test 2: After a 10-minute break, use 3MTM Littmann® Classic IIITM to auscultate and identify the same set of 10 manikin-simulated heart sounds but played in a different sequence to Test 1."
2886302|NCT03344874|Active Comparator|Littmann (conventional stethoscope)|"Test 1: Use 3MTM Littmann® Classic IIITM to auscultate and identify a set of 10 manikin-simulated heart sounds.~Test 2: After a 10-minute break, use Stethee® to auscultate and identify the same set of 10 manikin-simulated heart sounds but played in a different sequence to Test 1."
2886303|NCT03344861|Experimental|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, the laser light will be applied to the tumor.
2886304|NCT03344848|Experimental|Single Arm|Implanted with the Orion Visual Cortical Prosthesis System
2886305|NCT03344835||Prostate Cancer|Patients diagnosed with prostate cancer
2886306|NCT03344822|Experimental|68Ga-PSMA PET-CT|
2886307|NCT03344796||Focus Group|"32 subjects~Focus group: It is expected that each participant will provide comments during the 2 hours of the focus group. It will take about one month to enroll the subjects. The audio files should be transcribed and the analysis completed in 60 days."
2886308|NCT03344796||Usability testing|"10 subjects~Usability test with structured interview: Each participant will use the sensor for 14 days and transmit data with the app installed on their mobile phone. It will take about one month to enroll the subjects. The analysis of the structured interview is completed in one week."
2886309|NCT03344796||Cohort Study|"100 subjects~Cohort study: It is expected that each participant will provide wear the sensor and transmit data for 90 days in the warm weather months of June-Aug. It will take about 3 months to enroll the subjects. Data analysis should be completed by February 2019."
2886310|NCT03344783||mother-children pairs|
2886311|NCT03344770|Experimental|Active rESWT|Application of 5,000 pulses of rESWT by a pneumatic generator, with 0.16mJ/mm2 (millijoule per squared millimeter) of energy at a frequency of 20Hz on the most painful spot of the knee. The applications will be given once a week for three weeks.
2886312|NCT03344770|Sham Comparator|Sham rESWT|Application of 5,000 pulses of rESWT by a pneumatic generator, at a frequency of 20Hz on the most painful spot of the knee with 0 mJ/mm2 energy. The applications will also be given once a week for three weeks.
2886313|NCT03344757|Experimental|C-CBSM|Culturally adapted cognitive behavioral stress management
2886314|NCT03344757|Active Comparator|CBSM|Standard cognitive behavioral stress management
2886315|NCT03344744||SAH with DCI|Aneurysmal subarachnoid haemorrhage patients with delayed cerebral infarction
2886316|NCT03344744||SAH nonDCI|Aneurysmal subarachnoid haemorrhage patients without delayed cerebral infarction
2886317|NCT03344744||Control|Healthy volunteers
2886318|NCT03344731|Experimental|Experimental Group|Patient with any form ob brain damage
2886319|NCT03344731|Other|Control Group|Healthy volounteers
2886320|NCT03344705|Experimental|IM19 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
2886321|NCT03344692|Experimental|Alirocumab|Alirocumab 75 mg for subcutaneous injection via a pre-filled pen. One injection every 2 weeks during a 10-weeks period (5 injections in total)
2886322|NCT03344692|Placebo Comparator|Placebo|"Placebo matching alirocumab is prepared in the same formulation as alirocumab, without the addition of protein, for subcutaneous injection via a pre-filled pen.~One injection every 2 weeks during a 10-weeks period (5 injections in total)"
2886323|NCT03344679|Other|Control group|Bupivacaine 0.25% for pectoral nerve block.
2886324|NCT03344679|Other|Adenosine|Bupivacaine 0.25% with added Adenosine 12mg for pectoral nerve block.
2886325|NCT03344679|Other|Magnesium sulphate|Bupivacaine 0.25% with Magnesium sulphate 500 mg for pectoral nerve block.
2886326|NCT03344666|Experimental|First Treatment|Participants will be randomized to first treatment to compare Brief Intervention + Health Coach (Step 1 Treatment BI+HC) to Brief Intervention + Text Messages (Step 1 Treatment BI+TM). Participants in the BI+HC will receive a BI in the ED, followed by weekly sessions with the Health Coach for 4 weeks. Participants in the BI+TM will receive a BI in the ED, followed by daily TMs for 4 weeks.
2886353|NCT03344484|Experimental|Midline Approach|A midline surgical approach will be used for the exposure required to complete the lumbar fusion.
2886391|NCT03344198|Experimental|Firefighter (Veteran) Group|Firefighters with >10yrs experience. Exercise + Dietary intervention
2886327|NCT03344666|Experimental|Second Treatment for Responders and Non-Responders|"Beginning in week 5, all participants will be classified as Responders or Non-Responders (based on weekly assessments) and re-randomized.~Step 2 Treatment Responders: Responders will be randomized to either stay the course or be stepped down. Specifically, participants in the BI+HC will either continue to receive the HC or stepped down to receive a control brochure; participants in the BI+TM will either continue to receive the TM or stepped down to receive a control brochure.~Step 2 Treatment Non-Responders: Non-Responders will be randomized to either stay the course or be stepped up. Specifically, participants in the BI+HC will either continue to receive the HC or stepped up to receive a HC+; participants in the BI+TM will either continue to receive the TM or stepped up to receive HC."
2886328|NCT03344653|Active Comparator|Resolute Onyx stent|Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be randomly allocated in a 1:1 fashion to treatment with a Resolute Onyx stent or the BioFreedom stent followed by 1-month DAPT. Subjects implanted with the Resolute Onyx stent will be assessed for non-inferiority compared to those implanted with the BioFreedom stent using a composite safety endpoint of cardiac death, myocardial infarction, and definite/probable stent thrombosis, at 1 year post-procedure.
2886329|NCT03344653|Active Comparator|BioFreedom stent|Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be randomly allocated in a 1:1 fashion to treatment with a Resolute Onyx stent or the BioFreedom stent followed by 1-month DAPT. Subjects implanted with the Resolute Onyx stent will be assessed for non-inferiority compared to those implanted with the BioFreedom stent using a composite safety endpoint of cardiac death, myocardial infarction, and definite/probable stent thrombosis, at 1 year post-procedure.
2886330|NCT03344640|Experimental|AIN457|AIN457 subcutaneously for 12 weeks
2886331|NCT03344640|Placebo Comparator|Placebo|Placebo subcutaneously for 12 weeks
2886332|NCT03344627|Active Comparator|Meropenem standard dose|Meropenem 1 g every 8 hours
2886333|NCT03344627|Active Comparator|Meropenem high dose|Meropenem 2 g every 8 hours
2886334|NCT03344614|Experimental|raltitrexed combined with apatinib|therapeutic regimen : raltitrexed, 3 mg/㎡, ivgtt, d1, apatinib 500 mg, QD po, d1-21, Every 3 weeks for 1 cycles.
2886335|NCT03344601|No Intervention|Reference Cohort|A 12-month longitudinal evaluation of physical fitness and physical activity assessments in a cohort of individuals with HD (n=60) recruited from the Enroll-HD platform study.
2886336|NCT03344601|Experimental|Physcial Activity Intervention|Participants will be recruited from the Enroll-HD platform study and will be individually randomised (1:1) to a 12-month physical activity and coaching intervention.
2886337|NCT03344601|No Intervention|Activity as usual control|Participants will be recruited from the Enroll-HD platform study and will be individually randomised (1:1) to continue with physical activity as usual for 12 months
2886338|NCT03344588|Active Comparator|artery preserving varicocelectomy|In all patients, sub-inguinal varicocelectomy will be carried out under spinal anesthesia, by a single surgeon (KS), using surgical microscope. A 2-3 cm pre-pubic incision will be performed. The cord will be grasped with a Babcock clamp and isolated over a vessel tape. Any external cremastric veins will be identified and ligated using vicryl 3/0. After opening the spermatic fascia, the vassal compartment including the vasal, cremasteric arteries and lymphatics will be separated from the pampiniform plexus compartment and preserved. In group A (APV), testicular arteries will be spared with aid of by intraoperative Doppler US (VTI intraoperative Doppler system 20 MHz). The arteries will be carefully dissected by a micro-dissector, separated over a vessel loupe, and then the remaining veins will be ligated using vicryl 3/0.
2886339|NCT03344588|Active Comparator|artery ligation varicocelectomy|In all patients, sub-inguinal varicocelectomy will be carried out under spinal anesthesia, by a single surgeon (KS), using surgical microscope. A 2-3 cm pre-pubic incision will be performed. The cord will be grasped with a Babcock clamp and isolated over a vessel tape. Any external cremastric veins will be identified and ligated using vicryl 3/0. After opening the spermatic fascia, the vassal compartment including the vasal, cremasteric arteries and lymphatics will be separated from the pampiniform plexus compartment and preserved. In group B (ALV), all vascular channels will be ligated without identifying or sparing the internal spermatic arteries
2886340|NCT03344575|Active Comparator|Conventional defect closure|The defect is sutured with continuous PDS 2-0.
2886341|NCT03344575|Experimental|Peritoneal bridging|The peritoneum is dissected beginning 2-3 cm from the edge of the defect. The sac is dissected all the way to the opposite edge of the defect. The peritoneal flap is pulled to the opposite side and fixated with Optifix
2886342|NCT03344562|Experimental|CES Active|Active cranial electrical stimulation device
2886343|NCT03344562|Sham Comparator|CES Sham|Inactive device identical to the active device.
2886344|NCT03344549|Experimental|Teleconsultation|In the patients of the experimental group, the nutritional intervention is carried out through teleconsultation with the free technological tool chosen (the patients from home and the nutritionist from the remote clinic).
2886345|NCT03344549|Other|Face-to-face consultation|In the patients of the other group, the nutritional intervention is offered through face-to-face consultations carried out by the nutritionist of the nutrition service of the institution.
2886346|NCT03344536|Experimental|fulvestrant and Debio 1347|Fulvestrant will be administered according to its approved dose of 500 mg intramuscularly on days 1, 15, 29 and then every 28 days (+/-3 days) thereafter. Debio 1347 will be administered orally daily (1 cycle is 28 days) and the dose of Debio 1347 could be deescalated. The dosage in the phase 2 portion will be the MTD/RP2D determined in the phase 1b portion.
2886347|NCT03344523|Experimental|standard treatment + Iron succinylate|1 bottle orally, twice daily, take orally before meals
2886348|NCT03344523|Placebo Comparator|standard treatment + placebo|1 bottle orally, twice daily, take orally before meals
2886349|NCT03344510|Experimental|Kinetic anesthesia device arm|In this arm of the crossover study, participants will receive lidocaine injection in conjunction with the kinetic anesthesia device
2886350|NCT03344510|No Intervention|Control arm|In this arm of the crossover study, participants will receive lidocaine injection with no intervention
2886351|NCT03344497|Other|VC (Conventional Consultation/Video) Group|Subjects will receive conventional consultation and watch an animated video.
2886352|NCT03344497|No Intervention|CC (Conventional Consultation) Group|Subjects will receive conventional consultation only. Subjects will cross-over to receive animated video at the end.
2888084|NCT03332849|Experimental|Cohort 4|T2DM: Multiple dose subcutaneous administration
2886354|NCT03344484|Experimental|Paramedian Approach|A paramedian (i.e. Wiltse) surgical approach will be used for the exposure required to complete the lumbar fusion.
2886355|NCT03344471|Other|women with PTSD after preterm deliver|
2886356|NCT03344471|Other|women without PTSD after preterm deliver|
2886357|NCT03344458|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
2886358|NCT03344445|No Intervention|traditional vist|Patients receive traditional anesthesiologist visit
2886359|NCT03344445|Experimental|video-assisted|Patients watch the video, then an anesthesiologist visit
2886360|NCT03344432||With intraocular pressure high|Intracranial pressure equal or more than 20 mmHg
2886361|NCT03344432||Without intraocular pressure high|Intracranial pressure smaller than 20 mmHg
2886362|NCT03344419|Experimental|CI-581a+MET+MBRP|Administration of CI-581a at 0.71 mg/kg during weeks 1 and 5 combined with a 12-week course in MET and MBRP
2886363|NCT03344419|Active Comparator|CI-581b+MET+MBRP|Administration of CI-581b at 0.025 mg/kg during weeks 1 and 5 combined with a 12-week course in MET and MBRP
2886364|NCT03344406||Subjects with asthma|Subjects with moderate to severe asthma will be interviewed via telephone. Subjects will complete a daily diary including the E-RS: COPD and supplemental asthma items for 7 days.
2886365|NCT03344393|Active Comparator|ketamine hydrochloride|intravenous ketamine infusion in the intraoperative period
2886366|NCT03344393|Active Comparator|normal saline|intravenous normal saline infusion in the intraoperative period
2886367|NCT03344380||Prospective cohort|Adult patients undergoing liver transplantation will be included and followed up during the first 72 hours post-liver transplantation in order to confirm the development of acute kidney injury. The patients will be divided into two groups (AKI group vs. non-AKI group) according to the development of acute kidney injury. The GWAS will be performed with the blood obtained from enrolled patients.
2886368|NCT03344380||Retrospective cohort|In previous study performed in adult patients undergoing liver transplantation (NCT02489474, 4-2015-0411), we enrolled patients and collected data regarding the development of acute kidney injury during the first 72 hours post-liver transplantation. Among these patients enrolled in this previous study, only patients who agreed to additional use of the blood sample for research purposes will be included in the present study. The GWAS will be performed with the blood obtained from enrolled patients.
2886369|NCT03344367|Experimental|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 4 CAR T dosage will be tested in this study: 1×10^7, 2.5×10^7, 5×10^7, 1×10^8 CAR+ T cells.
2886370|NCT03344354|Active Comparator|Biogel 1|Biogel 1 (overglove) sterile surgical glove
2886371|NCT03344354|Active Comparator|Ansell|Ansell sterile surgical glove
2886372|NCT03344354|Active Comparator|Cardinal|Cardinal sterile surgical glove
2886373|NCT03344354|Active Comparator|Biogel 2|Biogel 2 (underglove) sterile surgical glove
2886374|NCT03344354|Active Comparator|Medline|Medline sterile sergical glove
2886375|NCT03344341|Experimental|Dapagliflozin|Dapagliflozin is started from 5 mg once a day, taken orally in the morning, before or after breakfast. From the third week, the dose will be increased to 10 mg once a day and last to the end of the study.
2886376|NCT03344341|Active Comparator|Acarbose|Acarbose is started from 50 mg once a day at dinner during the first week, titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
2886377|NCT03344315|Active Comparator|autologous connective tissue graft|Soft tissue harvesting from patient palate
2886378|NCT03344315|Experimental|collagen matrix|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland Device: Collagen matrix
2886379|NCT03344302|Experimental|study group|100 women were assigned to receive an intravenous infusion of oxytocin 30 units in a rate 125 mL/hour minutes diluted into 500 mL of normal 0.9% sodium chloride) immediately after opening the visceral peritoneum just before incising the uterine wall during Cesarean section
2886380|NCT03344302|Active Comparator|Control group|100 women were assigned to an intravenous infusion of oxytocin 30 units in a rate 125 mL/hour diluted into 500 mL of normal 0.9% sodium chloride) immediately after clamping the umbilical cord during cesarean section
2886381|NCT03344289|Experimental|Linked color imaging|When the patient is randomized for LCI, the imaging mode is switched to LCI and colonoscopic inspection will take place during withdrawal of the endoscope
2886382|NCT03344289|Active Comparator|High definition white light|When the patient is randomized for HD-WLE, the imaging mode is switched to HD-WLE and colonoscopic inspection will take place during withdrawal of the endoscope.
2886383|NCT03344276|Active Comparator|Control Group|Patients, as outlined by NASCET criteria, will have between 50 symptomatic stenosis or 70% asymptomatic stenosis of the carotid artery. Patients, undergoing carotid artery stenting for carotid stenosis, will undergo cognitive testing at 2 time points before intervention (1 months, and 2 months). The two preoperative time points will serve as the control group.
2886384|NCT03344276|Experimental|Intervention Group|Patients, as outlined by NASCET criteria, will have between 50 symptomatic stenosis or 70% asymptomatic stenosis of the carotid artery. Patients, undergoing carotid artery stenting for carotid stenosis, will undergo cognitive testing at 2 time points after invention (1 month and 2 months). The two postoperative time points will serve as the intervention group.
2886385|NCT03344263|Experimental|tests of attentional performance|
2886386|NCT03344250|Experimental|EGFR BATs with SOC RT and TMZ|Study participants will have cells collected by leukapheresis prior to initiating standard concurrent RT and TMZ. Participants will receive the first and second infusions of EGFR BATs on days 14 and 21 after finishing concurrent RT and TMZ and then receive an infusion on day 21 of the first six cycles of TMZ.
2886387|NCT03344224||normal blood lipid/protein group|
2886388|NCT03344224||abnormal blood lipid/protein group|
2886389|NCT03344211|Experimental|Arm I (enzalutamide, radium 223)|Patients receive enzalutamide PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive radium Ra 223 dichloride IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2886390|NCT03344211|Experimental|Arm II (enzalutamide)|Patients receive enzalutamide as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2886392|NCT03344198|Experimental|Firefighter (Novice) Group|Firefighters with <10yrs experience. Exercise + Dietary intervention
2886393|NCT03344198|Experimental|Control Non-Firefighter Group|Non-Firefighter adults. Exercise + Dietary intervention
2886394|NCT03344185|Experimental|Low GI diet|This diet contained three meals, all with a low GI value. This was the Low Glycaemic Diet intervention.
2886395|NCT03344185|Experimental|High GI diet|This diet contained three meals, all with a high GI value. This was the High Glycaemic Diet intervention.
2886396|NCT03344172|Experimental|PGHA|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine and Avelumab
2886397|NCT03344172|Experimental|PGH|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine
2886398|NCT03344159|Experimental|Spironolactone|Participants with chronic right-sided heart failure will receive spironolactone 12.5mg daily up to a maximum dose of 50 mg daily for a total duration of 12 weeks.
2886399|NCT03344159|Placebo Comparator|Placebo|Participants with chronic right-sided heart failure will receive placebo daily for a total duration of 12 weeks.
2886400|NCT03344146|Other|Group 1|Intake reminders followed by crossover to no intake reminders
2886401|NCT03344146|Other|Group 2|No intake reminders followed by crossover to intake reminders
2886402|NCT03344133|Experimental|Exercise|4-week moderate intensity exercise programme
2886403|NCT03344133|No Intervention|Control|4 weeks of habitual life style
2886404|NCT03344120|Active Comparator|Vortek double-J stent|Vortek double-J stent positioning after ureteroscopy. Intervention: administration of USSQ questionnaire.
2886405|NCT03344120|Active Comparator|Silicone double-J stent|Silicone double-J stent positioning after ureteroscopy. Intervention: administration of USSQ questionnaire.
2886406|NCT03344107|Active Comparator|Vortek double-J stent after RIRS|Vortek double-J stent positioning after RIRS. USSQ questionnaire administration.
2886407|NCT03344107|Active Comparator|Polaris Loop stent after RIRS|Polaris Loop ureteral stent positioning after RIRS. USSQ questionnaire administration.
2886408|NCT03344094||MS-ocrelizumab treated|ocrelizumab 600 mg IV over 5 hours, twice a year, with loading dose of 300 mg 2 weeks apart x 2 at start
2886409|NCT03344094||MS untreated|age- and sex-matched untreated MS controls
2886410|NCT03344094||Healthy control|age- and sex-matched untreated healthy controls
2886411|NCT03344094||MS interferon-treated|MS with ongoing interferon-beta therapy
2886412|NCT03344081||Meditators|Meditators will have practiced meditation for at least the 5 years, at least 90 minutes weekly. They will have completed at least 14 days of retreat practice in the past 5 years. At least half of their meditation practice will include attention to the breath and body. All participants will be MRI-compatible, healthy with no health conditions that affect breathing, have no current psychiatric disorder, and not be taking psychotropic medications.
2886413|NCT03344081||Controls|Control participants will be age- and gender-matched to each meditators. They will have little to no previous meditation experience. All participants will be MRI-compatible, healthy with no health conditions that affect breathing, have no current psychiatric disorder, and not be taking psychotropic medications.
2886414|NCT03344068|Experimental|Experimental Group|The patients in the Experimental Group are allocated to receive radical radiotherapy with or without chemotherapy plus Nutren® Optimum of 7 scoops tid at begin of radiotherapy.
2886415|NCT03344068|Active Comparator|Controlled Group|The patients in the Controlled Group are allocated to receive radical radiotherapy with or without chemotherapy plus routine diet guidance at begin of radiotherapy.
2886416|NCT03344055|Active Comparator|Colonoscopy with Endocuff Vision (ECV)|ECV-assisted colonoscopy ( with the use of Endocuff Vision (ECV) Second generation)
2886417|NCT03344055|No Intervention|Standard colonoscopy|Standard colonoscopy (without the use of Endocuff Vision (ECV) Second generation)
2886418|NCT03344042|Active Comparator|Fentanyl|100mcg Fentanyl administered into epidural space during regular contractions before cervical dilation
2886419|NCT03344042|Active Comparator|Sufentanyl|10mcg sufentanyl administered into the epidural space during regular contractions before cervical dilation
2886420|NCT03344042|No Intervention|Control|No epidural analgesia
2886421|NCT03344029|Experimental|SP Shz TIV|Participants aged 18 to 59 years will receive a single injection of SP Shz TIV.
2886422|NCT03344029|Active Comparator|Hualan TIV|Participants aged 18 to 59 years will receive a single injection of Hualan TIV.
2886423|NCT03344016|No Intervention|Standard care follow-up group|Patients will receive an information leaflet (see appendix), which advises on recommended routine follow-up according to international guidelines.
2886424|NCT03344016|Active Comparator|Special care follow-up group|In addition to the information leaflet patients will be actively contacted by the clinical center to increase the likelihood that patients meet recommended follow-up schedules.
2886425|NCT03344003||Wilate prospective cohort|Evaluable haemophilia A patients with an inhibitor against FVIII enrolled prospectively
2886426|NCT03344003||Wilate retrospective cohort|Evaluable haemophilia A patients with an inhibitor against FVIII enrolled retrospectively
2886427|NCT03343990||group A|Interlocking multi-twisted wires techniqe in sternal closure
2886428|NCT03343990||group B|Eight Figure techniqe in sternal closure
2886429|NCT03343977|Experimental|Every two weeks docetaxel|50 mg/m2 of docetaxel will be given on day 1 every 14 days over one hour IV infusion for up to 9 cycles (1 cycle = 14 days)
2886430|NCT03343977|Active Comparator|Every three weeks docetaxel|75 mg/m2 of docetaxel will be given on day 1 every 21 days over one hour IV infusion for up to 6 cycles (1 cycle = 21 days)
2886431|NCT03343964||Children with moderate to severe TBI|
2886432|NCT03343951||Shoulder patients|Shoulder patients referred to examination at the shoulder clinic, Silkeborg Regional Hospital.
2886433|NCT03343938|Experimental|Closed Station|Embryo handling is performed inside a closed station with a controlled environment: 6% CO2 and 37 degrees.
2886434|NCT03343938|No Intervention|Open flow cabinet|Embryo handling is performed inside a conventional open flow cabinet without a controlled environment.
2886435|NCT03343912|Experimental|Test 1 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.400 mg/day and Trimegestone 0.06 mg/day (Test 1) over 21 days
2886436|NCT03343912|Experimental|Test 2 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.300 mg/day and Trimegestone 0.12 mg/day (Test 2) over 21 days
2927709|NCT03056560|Experimental|Video Bystander Program|TakeCARE video
2886437|NCT03343912|Experimental|Test 3 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.200 mg/day and Trimegestone 0.18 mg/day (Test 3) over 21 days
2886438|NCT03343873|Experimental|Midarolam|midarolam sensation group
2886439|NCT03343873|Experimental|Propofol|propofol sensation group
2886440|NCT03343873|Experimental|Ketamine|ketamine sensation group
2886441|NCT03343873|Experimental|dexmedetomidine|dexmedetomidine sensation group
2886442|NCT03343873|Placebo Comparator|Saline|saline control group
2886443|NCT03343860|Active Comparator|Conventional|PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps.
2886444|NCT03343860|Active Comparator|Non inducibility|PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT) .
2886445|NCT03343847|Experimental|Romiplostim|the study in a 2:1 randomization ratio(108 subjects to romiplostim)
2886446|NCT03343847|Placebo Comparator|Placebo|the study in a 2:1 randomization ratio (54 subjects to placebo)
2886447|NCT03343834|Other|EBV+ allograft population|"Retrospective study (n=80) : Patient who underwent HSCT, in Saint-Antoine hospital, between 2010-2015, treated by rituximab for high level EBV-DNAemia (above 3.3 log copies/mL).~Prospective study (n=58) : Patients who underwent HSCT, in Saint-Antoine hospital and la Pitié-Salpêtrière, in 2016-2017, treated by rituximab for high level EBV-DNAemia (above 10 000c/mL), And/or having post-transplant lymphoproliferative diseases(PTLD) Concerned population Allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients with a high Epstein-Barr virus (EBV) viral load"
2886448|NCT03343821||Frail elderly patient|
2886449|NCT03343795|Experimental|study group 1|oral progesterone
2886450|NCT03343795|Active Comparator|study group 2|intramuscular progesterone
2886451|NCT03343782|Experimental|Intravenous injection|Intervention: 15 patients will be transplanted autologous bone marrow-derived mesenchymal stem cells by using intravenous injection and undergoing 2 treatment with 6 months interval
2886452|NCT03343782|Experimental|Dorsal pancreatic artery infusion|Intervention: 15 patients will be transplanted autologous bone marrow-derived mesenchymal stem cells by using the dorsal pancreatic artery and undergoing 2 treatment with 6 months interval
2886453|NCT03343769||Patient|
2886454|NCT03343769||Control|
2886455|NCT03343743|Other|Hydration|Patients were instructed to drink at least 2 L/day of a hypotonic, oligomineral water low in sodium and minerals (fixed residue at 180°C <200 mg/L) for at least 12 months
2886456|NCT03343730|Experimental|Non-mydriatic color fundus photography|All participants will receive Non-mydriatic color fundus photography with the RetinaVue camera at an already scheduled annual physical exam or follow up clinic visit with their primary care provider (PCP).
2886457|NCT03343730|Active Comparator|Standard of Care (Control)|All patients will also receive a referral for a dilated eye exam with an eye care professional. A yearly dilated exam as referred by the PCP.
2886458|NCT03343717|Experimental|rehabilitation|"Phase 1 passive mobilization with 10 repetitions on each joint motion and muscle stretching to the upper.~Phase 2 - ability to respond to 3 of 5 simple verbal commands. Beginning with passive, active-assisted or active exercises with 5 repetitions in each joint movement in the MMSS and MMII, following the sequence of phase 1.~Phase 3 - exercises of MMSS with cycle ergometer - 1 series of 1 minute or passive, active-assisted, active or active-resistidos with 5 repetitions in each joint movement, following the sequence of phase 1."
2886459|NCT03343717|Active Comparator|chest physical therapy|respiratory exercises that include techniques of bronchial hygiene maneuvers with the objective of airway clearance, pulmonary reexpansion techniques for reversal of atelectasis, passive mobilization techniques with the aim of reducing deformities and preserving joint mobility
2886460|NCT03343704|Experimental|Idarucizumab|
2886461|NCT03343691||Screening Population|"Cohort 1:Screening Population - Women presenting for routine XRM and / or breast US.~Participants will be followed for one year and the outcome of those who undergo an annual XRM / breast ultrasound will be recorded."
2886462|NCT03343691||Breast Cancer Population|Cohort 2:Breast Cancer Population - Women who were diagnosed with malignant breast tumors, as determined by biopsy, and have not yet begun any treatment for the disease.
2886463|NCT03343678|Experimental|Venetoclax + BI 836826|
2886464|NCT03343665|Experimental|Nivolumab 40 mg|Experimental: Nivolumab Nivolumab 40 mg IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
2886465|NCT03343652|Experimental|NB|Nivolumab 3 mg/kg IV infusion on day 1,14 + Bendamustine hydrochloride 90 mg/kg IV infusion on day 1,2 up to 3 cycles. Duration of cycle 28 days
2886466|NCT03343639|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
2886467|NCT03343639|Placebo Comparator|Matching Placebo Tablets|Placebo Tablets
2886468|NCT03343626|Placebo Comparator|Placebo|TAK-426 placebo-matching injection, intramuscular, once on Days 1 and 29.
2886469|NCT03343626|Experimental|Low Dose: PIZV 2 microgram (mcg)|PIZV 0.5 milliliter (mL), 2 mcg antigen, injection, intramuscular, once on Days 1 and 29.
2886470|NCT03343626|Experimental|Medium Dose: PIZV 5 mcg|PIZV 0.5 mL, 5 mcg antigen, injection, intramuscular, once on Days 1 and 29.
2886471|NCT03343626|Experimental|High Dose: PIZV 10 mcg|PIZV 0.5 mL, 10 mcg antigen, injection, intramuscular, once on Days 1 and 29.
2886472|NCT03343613|Experimental|LY3381916 Escalation|LY3381916 administered orally.
2886473|NCT03343613|Experimental|LY3381916 + LY3300054 Escalation|LY3381916 administered orally and LY3300054 administered intravenously (IV).
2886474|NCT03343613|Experimental|LY3381916 Expansion|LY3381916 administered orally.
2886475|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion (NSCLC)|LY3381916 administered orally and LY3300054 administered IV in NSCLC (PD-L1/PD-1 naive).
2886476|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion (SCCHN)|LY3381916 administered orally and LY3300054 administered IV in SCCHN (PD-L1/PD-1 naive).
2886477|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion|LY3381916 administered orally and LY3300054 administered IV in PD-L1/PD-1 resistant NSCLC, SCCHN and bladder, and NSCLC with brain metastasis.
2886478|NCT03343600|Experimental|Imatinib|Imatinib (100 mg/tablet) 2# per day till D+100 after allo-HSCT or prophylaxis failure.
2886479|NCT03343600|Placebo Comparator|Placebo|Placebo 2# per day till D+100 after allo-HSCT or prophylaxis failure.
2886480|NCT03343587|Experimental|LY3375880 Single Dose|Single dose of LY3375880 administered IV or SC
2886481|NCT03343587|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered IV or SC
2886482|NCT03343587|Experimental|LY3375880 Multiple Dose|Multiple doses of LY3375880 administered IV or SC
2886483|NCT03343587|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered IV or SC
2886484|NCT03343574|Experimental|Abdominal Strengthening Exercise|All participants in this arm shall perform exercises for the strengthening of abdominal muscles for a period of three months in addition to the routine care provided to them for the management of Parkinson's Disease. The exercises are structured and need to be performed on a routine basis.
2886485|NCT03343574|No Intervention|Routine Care|All participants in this group shall continue to obtain routine care for the management of Parkinson's Disease.
2886486|NCT03343561|No Intervention|Control|Subjects would have subjects' own diet as usual
2886487|NCT03343561|Experimental|Intervention diet 1|Nutrition advice will be given to subjects to consume a healthy diet and select food with Polyunsaturated fatty acids like fish and nuts to replace subjects' own food in high fat
2886488|NCT03343561|Experimental|Intervention diet 2|Nutrition advice will be given to subjects to consume a healthy diet and select food with whole grains to replace subjects own food in carbohydrate
2886489|NCT03343561|Experimental|Intervention diet 3|Nutrition advice will be given to subjects to consume a healthy diet and select food with healthy choices in fat and carbohydrate to replace subjects' own food choice
2886490|NCT03343548|Active Comparator|Group I|magnesium group (Mg)
2886491|NCT03343548|Placebo Comparator|Group II|control group (C)
2886492|NCT03343535|Experimental|OCS|OCS Lung Preservation
2886493|NCT03343522|No Intervention|Sedentarism|Patients assigned to this arm shall not perform regular exercise training.
2886494|NCT03343522|Experimental|Exercise Training|Patients assigned to this arm will be enrolled in exercise training program.
2886495|NCT03343509|Experimental|Group A - Oral|Oral metronidazole 400mg 3 times a day for 7 days Placebo ointment applied 3 time times a day for 7 days to affected region
2886496|NCT03343509|Experimental|Group B - Topical|Topical metronidazole ointment 10% 3 times a day for 7 days Oral placebo tablets 3 times a day for 7 days
2886497|NCT03343483|Experimental|Volunteering|Structured social volunteering program providing peer companionship to frail, homebound older adults for at least 16 hours per month for 12 months.
2886498|NCT03343483|Active Comparator|Life Review|Self-guided program of life review for 12 months.
2886499|NCT03343470||Cushing Syndrome (active phase)|Patients displaying biochemical and clinical features of active Cushing's syndrome
2886500|NCT03343470||Cushing Syndrome (during remission)|Patients at 3-6 months from remission with cortisol levels in the normal range
2886501|NCT03343457|Experimental|Acceptance Commitment Therapy|Acceptance Commitment Therapy. Cognitive therapy
2886502|NCT03343457|Experimental|Multidisciplinary assessment|Assessment of a team. Cognitive therapy
2886503|NCT03343457|No Intervention|Control|Control group
2886504|NCT03343444|Active Comparator|Arm 1|Treatment-naïve is defined as having never received treatment for HCV with any interferon (IFN), ribavirin , or other approved or experimental HCV specific direct acting antivirals.
2886505|NCT03343444|Active Comparator|Arm 2|"Treatment-experienced is defined as:~IFN Intolerant~Non-response~Relapse/Breakthrough"
2886506|NCT03343444|Experimental|Short Track|Treatment-naïve or Treatment-experienced who achived very rapid virological responce - Negative HCV PCR after treatment with (Sofosbuvir 400mg/Ledipasvir 90mg) for 1 week
2886507|NCT03343418|Active Comparator|desmopressin|Patients randomized to this group receive desmopressin 0,3 microgram.kg-1 as an intravenous infusion given during 20 min.
2886508|NCT03343418|Placebo Comparator|Placebo|Patients randomized to the control group will receive the infusion of 100 mL 0.9% saline (SF0,9%).
2886509|NCT03343405|Experimental|Intervention: Online Mind/Body|Participants randomized to the intervention group (i.e., Online Mind/Body Program for Fertility) were provided the 10 online modules provided weekly (one module per week), intended to be completed over 10 weeks. Additionally, participants received weekly therapeutic feedback.
2886510|NCT03343405|No Intervention|Wait-List|After 10-weeks being in the wait-list group, participants had the potential to participate in the intervention protocol if they desire.
2886511|NCT03343392|Experimental|acetam/ketoro tromet group|One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
2886512|NCT03343392|Placebo Comparator|Placebo group|One hour before in-office bleaching patients received either placebo.
2886513|NCT03343379|Other|Healthy cohort|Core stability test
2886514|NCT03343366|Experimental|Test Group 1|The participants in this group will receive a combination of ultrasonic scaling and hand instrumentation required for planing of the root surfaces (SRP) followed by systemic AAT followed by routine warm salt water rinses for 3-5 days and OHI. SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth. Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days. OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
2886515|NCT03343366|Active Comparator|Test Group 2|The participants in this group will receive a combination of Scaling Root Planing followed by routine warm salt water rinses for 3-5 days and OHI. Same procedure for SRP and OHI will be followed as that followed in Test Group 1
2886538|NCT03343197|Experimental|AG-881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-881.
2886516|NCT03343366|Other|Control Group 3|The participants in this group will receive only routine warm salt water rinses for 3-5 days and Oral Hygiene Instructions as that followed in Test Group 1 and Test Group 2. However, after completing six (6) months of evaluation they will be provided DT either in the form of SRP+MET or SRP only in addition to OHI, whichever would be found to have a significant beneficial effect on CP.
2886517|NCT03343353|Experimental|LED red group (630nm)|The leds will initially be measured in the photobiophysics laboratory of the University of São Paulo - Ribeirão Preto, regarding wavelength parameters, beam divergence, nominal power and fluency. The application will be in the graft donor area (scalp) of burn patients. The applied fluence will be 4J / cm2.
2886518|NCT03343353|Experimental|LED infrared group (940nm)|The leds will initially be measured in the photobiophysics laboratory of the University of São Paulo - Ribeirão Preto, regarding wavelength parameters, beam divergence, nominal power and fluency. The application will be in the graft donor area (scalp) of burn patients. The applied fluence will be 4J / cm2.
2886519|NCT03343353|Sham Comparator|Group Sham|This group will not receive irradiation by led light. You will only receive the routine care of the hospital unit to which you are hospitalized. These patients will be evaluated in the same way as the other two intervention groups, and also by a blind evaluator.
2886520|NCT03343340|Experimental|Early CRRT|Early Continous Renal Replacement Therapy within 6 hours + Standard Medical Therapy
2886521|NCT03343340|Active Comparator|Late CRRT|Late Continous Renal Replacement Therapy + Standard Medical Therapy
2886522|NCT03343327|Experimental|Chronocort®|Single dose of 20mg Chronocort®
2886523|NCT03343327|Active Comparator|Cortef®|Single dose of 20mg Cortef® Immediate Release Hydrocortisone Tablets
2886524|NCT03343314||Hospitalized patients due to a severe, symptomatic aortic sten|Patients who agreed to participate in the study, aged ≥75 years, with severe and symptomatic aortic stenosis, and hospitalized in one of the medical and surgical centers participating in the study
2886525|NCT03343301|Other|Phase 1 Study of FPA144 + mFOLFOX6|"Phase 1 dose escalation of FPA144 administered intravenously over approximately 30 minutes in cohorts of 3-6 patients to evaluate for the recommended dose (RD) of FPA144 for phase 3. mFOLFOX6 administered 30 minutes after the end of the FPA144 infusion as follows:~Oxaliplatin 85 mg/m2 intravenously over 2 hours on day 1~Leucovorin 400 mg/m2 intravenously over 2 hours. Can be administered concurrently with oxaliplatin using a Y-connector on day 1~Immediately after completion of oxaliplatin and leucovorin, administer 5-fluorouracil (5-FU) 400 mg/m2 intravenously over 5 minutes~Immediately after the 5-FU bolus, 5-FU 2400 mg/m2 as a continuous intravenous infusion over 46 hours.~Treatment is repeated every 2 weeks."
2886526|NCT03343288|Experimental|Silver HA coated implants|Silver doped hydroxyapatite coated implants
2886527|NCT03343275|Experimental|Experimental|"Dietary supplement : Lit-Control® pH Down~Pharmaceutical form: capsules~Administration : oral~Dose: 3 capsules/day.~• Sanitary product : Lit-Control® pH Meter~In vitro diagnosis sanitary product~Use:Urinary pH evaluation"
2886528|NCT03343275|Placebo Comparator|Placebo|"Placebo:~Pharmaceutical form: capsules~Administration : oral~Dose: 3 capsules/day.~• Sanitary product : Lit-Control® pH Meter~In vitro diagnosis sanitary product~Use:Urinary pH evaluation"
2886529|NCT03343262|Experimental|"ta-VNS yidan-pi"|"Device:ta-VNS & Electro-acupuncture(yidan-pi auricular acupoints):2 times per day,2 days per week for 12 weeks"
2886530|NCT03343262|Placebo Comparator|"ta-VNS jian"|"Device:ta-VNS & Electro-acupuncture(jian auricular acupoints):2 times per day,2 days per week for 12 weeks"
2886531|NCT03343249|Experimental|Study Visits|"The Short form of the Rapid Estimate of Adult Literacy in Medicine (REALM) will be administered to ensure that all participants are able to read at > sixth grade level. Expired carbon monoxide (CO) will be measured.~Assessment: Participants will complete self-report questionnaires; and expired CO, weight, and height will be measured. Participants will be provided with a Samsung Galaxy Light Android smart phone and instructed on how to: 1) use the phone features, 2) complete EMAs, and 3) use the adjunctive Smart-T phone based treatment. Participants will receive 4 random prompts and 1 daily diary prompt during their normal waking hours each day for three consecutive weeks. Random assessments will take approximately 1 min to complete and daily diary assessments will take approximately 5 mins to complete."
2886532|NCT03343236||Patients with head and neck cancer|All patients with newly diagnosed and untreated head and neck cancer. Exclusion criteria: previous treatment for malignant disorder except for skin cancer, severe alcohol abuse, psychiatric disorder, inability to understand Swedish
2886533|NCT03343223|Experimental|Intervention Group|"Public health personnel identify PrEP-eligible clients.~PrEP-eligible clients are given a list of PrEP providers in Iowa and a brochure with info on getting PrEP. Clients are referred to a PrEP navigator, who facilitates linkage to clients' choice of TelePrEP or to community PreP providers.~Public health clients choosing TelePrEP complete a video visit with the tele-pharmacist and obtain PrEP relevant lab tests.~PrEP medication is mailed to the client and follow up video visits and lab testing are performed.~Within 7 days of enrollment, the subject will complete a survey regarding PrEP beliefs (20 minutes).~30 to 40 days after enrollment, the subject will complete a second survey with 4 questions about initiation of PrEP since study enrollment (10 minutes).~6 months following enrollment, a study team member will obtain medical records for the subject from PrEP providers in Iowa to determine if the subject has initiated and been retained in PrEP."
2886534|NCT03343223|No Intervention|Control Group|"Public health personnel identify PrEP-eligible.~Public health personnel give PrEP-eligible clients a list of PrEP providers in Iowa, and a brochure with information on getting PrEP.~The client initiates contact with a PrEP provider in Iowa and schedules an appointment.~PrEP medication is mailed to the client and follow up video visits and lab testing are performed.~Within 7 days of enrollment, the subject will complete a survey regarding PrEP beliefs (20 minutes).~30 to 40 days after enrollment, the subject will complete a second survey with 4 questions about initiation of PrEP since study enrollment (10 minutes).~6 months following enrollment, a study team member will obtain medical records for the subject from PrEP providers in Iowa to determine if the subject has initiated and been retained in PrEP."
2886535|NCT03343210|Experimental|cancer patient|cancer patient
2886536|NCT03343210|Active Comparator|no cancer patient|no cancer patient
2886537|NCT03343197|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 .
2886595|NCT03342859|Active Comparator|Ulipristal group|Ulipristal 5 mg oral daily over 8-12 weeks
2886539|NCT03343197|No Intervention|No Treatment Pre-Surgery|Subjects will not receive treatment prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 or AG-881.
2886540|NCT03343184|Active Comparator|SEE and incremental restoration|50 teeth will receive restorations using SEE Strategy and Incremental Restoration
2886541|NCT03343184|Experimental|SEE and bulk restoration|50 teeth will receive restorations using SEE Strategy and Bulk Fill Restoration
2886542|NCT03343184|Experimental|SET and incremental restoration|50 teeth will receive restorations using SET Strategy and Incremental Restoration
2886543|NCT03343184|Experimental|SET and bulk restoration|50 teeth will receive restorations using SET Strategy and Bulk Fill Restoration
2886544|NCT03343145|Experimental|Test Drug Group|Leucostim 5µg/kg/day
2886545|NCT03343145|Active Comparator|Reference Drug Group|Neupogen 5µg/kg/day
2886546|NCT03343132||Subacute SCI|
2886547|NCT03343132||Chronic SCI|
2886548|NCT03343132||Controls|
2886549|NCT03343119||Hospitalised patients|No intervention
2886550|NCT03343119||Healthy volunteers|No intervention
2886551|NCT03343119||Dog owners (healthy volunteers)|No intervention
2886552|NCT03343119||Veterinarians (healthy volunteers)|No intervention
2886553|NCT03343119||Pig farmers (healthy volunteers)|No intervention
2886554|NCT03343106|Experimental|ACT plus ERP|Sessions 1 and 2 involved information-gathering, discussion of the ACT model of OCD and ERP, and introduction to self-monitoring of rituals. Session 3 involved the development of an exposure hierarchy and response prevention plan, and further explanation of the ACT-based approach to ERP which focuses on learning flexible responding in the presence of obsessions, anxiety, and urges to ritualize. Exposure practices (sessions 4-16) were procedurally similar to the ERP condition, but focused on the facilitation of ACT processes rather than on fear extinction. Homework exposure practice was linked to the participant's goals and values. Session 16 included an ACT model of relapse prevention focusing on following one's values in the presence of obsessive thoughts and compulsive urges.
2886555|NCT03343106|Experimental|ERP alone|ERP followed Kozak and Foa's treatment manual. Sessions 1 and 2 included information-gathering, psychoeducation about the cognitive-behavioral model of OCD and rationale for ERP, and introduction to self-monitoring of rituals. Session 3 was dedicated to developing the treatment plan (exposure hierarchy, response prevention plan). Sessions 4-16 included in-session prolonged and repeated gradual exposure therapy (in vivo and imaginal as needed), the assignment of daily exposure practices for between-sessions, and instructions to refrain from rituals (response prevention in session and between sessions), along with self monitoring of any rituals that were performed. Session 16 also addressed discontinuation and relapse prevention.
2886556|NCT03343093|Experimental|Intervention Evaluation Control Group|Surveys at 3 month intervals
2886557|NCT03343093|Experimental|Intervention Evaluation Test Group|We will evaluate the effects of an educational, tailored, online rehabilitation program addressing sexual and urinary outcomes after treatment by surveying at 3 month intervals
2886558|NCT03343080|Experimental|Buffered Lidocaine|"At the induction of anesthesia, patients will be breathing 100% oxygen via a face mask and then, become anesthetized according to a standard protocol and at the discretion of the attending anesthesiologist.~For cardiac surgery patients randomized to the buffered lidocaine arm, the OR RRT will inflate the endotracheal tube cuffs with the study drug containing 1.8% lidocaine plus 0.76% sodium bicarbonate until abatement of the air leak at 20 cm of water.~The intervention will take place while in the operating room. The room nurse anesthetist (CRNA) or anesthesiologist will be aware of the amount of solution instilled in the ETT cuff. The patient will remain intubated after the surgery is complete and will be taken to the cardiac surgical ICU."
2886559|NCT03343080|Placebo Comparator|Air|"At the induction of anesthesia, patients will be breathing 100% oxygen via a face mask and then, become anesthetized according to a standard protocol and at the discretion of the attending anesthesiologist.~For cardiac surgery patients randomized to the air arm, the OR RRT will inflate the endotracheal tube cuffs with air until abatement of the air leak at 20 cm of water.~The intervention will take place while in the operating room. The room nurse anesthetist (CRNA) or anesthesiologist will be aware of the amount of air in the ETT cuff. The patient will remain intubated after the surgery is complete and will be taken to the cardiac surgical ICU."
2886560|NCT03343067|Experimental|Arm C|Incomplete efficacy responders to elagolix dose A at Month 3 and randomized to elagolix dose B plus E2/NETA
2886561|NCT03343067|Experimental|Arm A|Efficacy responders to elagolix dose A at Month 3
2886562|NCT03343067|Experimental|Arm E|Incomplete efficacy responders to elagolix dose A at Month 3, randomized to elagolix dose A treatment group and are efficacy responders at Month 6 continue the same treatment through Month 24
2886563|NCT03343067|Experimental|Arm B|Incomplete efficacy responders to elagolix dose A at Month 3 and randomized to elagolix dose A.
2886564|NCT03343067|Experimental|Arm D|Incomplete efficacy responders to elagolix dose A at Month 3, randomized to elagolix dose A treatment group and are incomplete efficacy responders at Month 6, and dose increased to elagolix dose B plus E2/NETA through Month 24
2886565|NCT03343054|Experimental|talazoparib|0.75 mg/day or 1.0 mg/day
2886566|NCT03343041|Active Comparator|low carbohydrate nutrition|"We will use a low-carbohydrate nutrition (LCN) formulated by the MICU registered dietitian and pharmacy staff, who routinely prepare enteral and parenteral nutrition which will provide:~5% carb, 41% protein, 54% lipid."
2886567|NCT03343041|Active Comparator|standard enteral nutrition|"The standard enteral nutrition (SEN) and per cent contribution of carbohydrates used in the Yale MICU is as follows:~Jevity 1.2 56% carb, 29.5% lipid, 18.5% protein Diabetisource 33% carb, 44% lipid, 20% protein Promote 55% carb, 25% lipid, 25% protein Vital AF 37% carb, 40% lipid, 25% protein Peptamin Intense 29% carb, 34% lipid, 37% protein Osmolite 1.5 54% carb, 29.5% lipid, 16.5% protein"
2886596|NCT03342859|No Intervention|Control group|Patients undergoing surgery without any prior treatment, as control group
2886597|NCT03342846|Active Comparator|High Frequency rTMS in PD|The first group received 20 Hz rTMS on M1 daily for 10 days 5 sessions every week.
2886598|NCT03342846|Active Comparator|Low Frequency rTMS in PD|The second group received 1 Hz rTMS on M1 daily for 10 days 5 sessions every week.
2886599|NCT03342833|Active Comparator|Blood flow restriction|
2886600|NCT03342833|Sham Comparator|Usual training|
2886601|NCT03342820|Experimental|Quadriceps muscle fatigue|Quadriceps muscle fatigue
2886568|NCT03343028||Psychotherapy|The investigators will assess and acquire data on these Veterans across the course of the project prior to and after receiving Prolonged Exposure (PE) or Cognitive Processing Theory (CPT) treatment at VA Palo Alto (VAPAHCS) and the Albuquerque VA. They will acquire fMRI, behavioral, EEG, TMS/EEG, and saliva at baseline on these Veterans and again 3 months after treatment to assess prediction and durability of the clinical and brain/behavioral metrics. All study assessments will take place at Stanford University/VAPAHCS. Subjects will be recruited through VAPAHCS and Albuquerque VA. Subjects will complete a clinical assessment including: neuroimaging, self-report questionnaires completed via computer or paper-and-pencil, cognitive testing, saliva, and TMS and EEG assessments.
2886569|NCT03343015||Traditional CR establishing|establishing a CR in traditional way with occlusal wax rims during complete dentures therapy
2886570|NCT03343015||Gothic arch method|establishing a CR with gothic arch tracing device during complete dentures therapy
2886571|NCT03343002|Experimental|fentanyl at 10-15 min before end of surgery|
2886572|NCT03343002|Active Comparator|fentanyl at end of surgery|
2886573|NCT03342989|Experimental|Speed of Processing Training|Training involves detection, localization, and discrimination of briefly displayed stimuli (17-500 milliseconds) using tasks with varying demands on visual attention. Cognitive processing speed is defined as response accuracy at a given display duration, regardless of motor speed. Training involves detection, localization, and discrimination of briefly displayed stimuli (17-500 milliseconds) using tasks with varying demands on visual attention. Speed of processing is defined as response accuracy at a given display duration, regardless of motor speed. Training consists of 10 lab-based sessions over 5 weeks, followed by home-based practice on a tablet computer for 24 months with supportive home visits.
2886574|NCT03342989|Active Comparator|Internet-Based Contact Control|Training involves mentally stimulating activity and consists of three levels: (1) using a computer (e.g., mouse training, pull-down menus, selecting options), (2) internet search engine training, and (3) search engine proficiency tasks. Training consists of 10 lab-based sessions over 5 weeks, followed by home-based practice on a tablet computer for 24 months with supportive home visits.
2886575|NCT03342976|Active Comparator|Cases|"Pre-frail subjects will use an ICT platform (my-AHA platform) embedded in a mobile phone and a fit-band that will continuously monitor physical and cognitive activities.~Interventions regarding physical, cognitive, psychological and social domains will be prescribed and monitored through the my-AHA platform. In addition, sleep and dietary habits will be investigated and tailored interventions will be suggested."
2886576|NCT03342976|Placebo Comparator|Controls|"Pre-frail subjects will be followed according to best standard of care protocols. Interventions regarding physical, cognitive, psychological and social domains will be prescribed. In addition, sleep and dietary habits will be investigated and tailored interventions will be suggested."
2886577|NCT03342963|Experimental|ASC-01 in period 1, Aripiprazole and sertraline in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.~At Day 1 in Period II, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting."
2886578|NCT03342963|Experimental|Aripiprazole and sertraline in period 1, ASC-01 in period 2|"At Day 1 in Period I, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting.~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting."
2886579|NCT03342963|Experimental|Fasting in period 1, After breakfast in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast."
2886580|NCT03342963|Experimental|After breakfast in period 1, Fasting in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast.~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting."
2886581|NCT03342950|Active Comparator|Active drug group|Treatment with the topical solution of clonidine + pentoxifylline (0.1%/5%)
2886582|NCT03342950|Placebo Comparator|Placebo group|Treatment with placebo solution with out active drug ingredients
2886583|NCT03342937|Experimental|Oxaliplatin+Capecitabine+Pembrolizumab|
2886584|NCT03342924|Experimental|Flanker test and physical fitness test|Participants performed a computer-based Flanker Task measuring cognitive control and physical fitness tests: two-minute walk, vertical jump, one-minute curl-ups, and handgrip strength. Body composition variables included: body mass index, percent body fat, waist circumference, and sagittal abdominal height. General linear models were performed to evaluate impacts of physical fitness and body composition on cognition, adjusting for age and sex.
2886585|NCT03342911|Experimental|Treatment (nivolumab, paclitaxel, carboplatin)|Patients receive nivolumab IV over 60 minutes on day 1, paclitaxel IV on days 1 and 8, and carboplatin IV on days 1 and 8. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
2886586|NCT03342898|Experimental|Group 1|YF-17D vaccine, 0.6 mL, injection, subcutaneously plus placebo, 0.5 mL, injection, subcutaneously on Day 1, followed by TDV, 0.5 mL, injection, subcutaneously (first dose) on Day 90, followed by TDV, 0.5 mL, injection, subcutaneously on Day 180 (second dose).
2886587|NCT03342898|Experimental|Group 2|TDV, 0.5 mL, injection, subcutaneously plus placebo, 0.5 mL injection, subcutaneously on Day 1 (first dose), followed by TDV, 0.5 mL, injection, subcutaneously on Day 90 (second dose), followed by YF-17D vaccine, 0.6 mL, injection, subcutaneously on Day 180.
2886588|NCT03342898|Experimental|Group 3|TDV, 0.5 mL, injection, subcutaneously plus YF-17D vaccine, 0.6 mL, injection, subcutaneously on Day 1 (first dose), followed by TDV, 0.5 mL, injection, subcutaneously on day 90 (second dose), followed by placebo, 0.5 mL, injection, subcutaneously on Day 180.
2886589|NCT03342885|Experimental|Intervention group|Participants enrolled into the intervention group receive specific sleep ergonomics guidance
2886590|NCT03342885|Active Comparator|Control group|Participants enrolled into the control group will receive general sleep ergonomics guidance
2886591|NCT03342872|Experimental|Core Training|
2886592|NCT03342872|Experimental|Core Training & Facilitation|
2886593|NCT03342872|No Intervention|Control|
2886594|NCT03342859|Experimental|Vilaprisan group|Vilaprisan 2 mg oral daily over 8-12 weeks
2886604|NCT03342794|Other|preexisting posterior capsule defects|congenital cataracts with a preexisting posterior capsule defect
2886605|NCT03342781|Active Comparator|Diffuser-mask group|The patients received oxygen therapy (8-15 L/min) from an OxyMask (Southmedic, Inc., Barrie, ON, Canada) to maintain oxygen saturation (SpO2) > 92%. Oxygen therapy was halted if SpO2 was maintained at a level greater than 92% for more than 4 h. The oxygen flow rate was then decreased to 2 L/min and the patient was monitored while breathing room air.
2886606|NCT03342781|Active Comparator|HFNC group|The patients received oxygen therapy at a high flow rate from a Precision Flow nasal cannula (Vapotherm, Inc., Stevensville, MD, USA). We selected a 1.9 mm pediatric cannula, which can dispense 1-20 L/min of oxygen. The initial oxygen flow rate was 1 L/kg/min and the FiO2 was 100%. The initial flow rate was increased by 1 L/kg/min until the SpO2 reached 92%. The initial FiO2 was decreased once the SpO2 was greater than 92% and the oxygen flow rate was maintained. HFNC therapy was halted if SpO2 was maintained at a level greater than 92% for more than 4 h at a FiO2 value of 21%, and the patient was transferred to a ward.
2886607|NCT03342768|Experimental|TID|Messages will be sent 1-2 times per week containing information that aims to denormalise the tobacco industry.
2886608|NCT03342768|Other|Sugar sweetened beverages|Messages will be sent 1-2 times per week containing information on the adverse health effects of sugar sweetened beverages.
2886609|NCT03342742|Experimental|Daily Caloric Restriction|The daily caloric restriction group will be instructed to reduce energy intake by a 30% daily energy deficit from baseline individual weight maintenance energy requirements.
2886610|NCT03342742|Experimental|Intermittent Fasting|Participants in the intermittent fasting group will be instructed to reduce energy intake to ~25% of estimated energy requirement (delivered as a single meal) three non-consecutive days per week, resulting in a weekly energy deficit of ~30% (similar to the daily caloric restriction group).
2886611|NCT03342729|Experimental|Intervention Group|Immediate exposure to the 10-week Aging Mastery Program (AMP)
2886612|NCT03342729|Placebo Comparator|Wait-list Group|Class to start 3 months after the Intervention Group
2886613|NCT03342716||Main cohort|Patients with a clinical or radiological diagnosis of acute pancreatitis (AP)
2886614|NCT03342716||Nested cohort|Subgroup of patients with a clinical or radiological diagnosis of acute pancreatitis (AP) who will undergo additional assessments and scans
2886615|NCT03342703||Patients with Liver Disease|Patients will undergo an Ultrasound to correlate cirrhosis and/or steatosis measurements obtained using standard-of-care MRI.
2886616|NCT03342690||Eplerenone|Patients with CHF receiving Selara (eplerenone)
2886617|NCT03342677|Other|Single Arm|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo Liver MRI with Primovist before hepatic transplantation.
2886618|NCT03342664|Experimental|Artemis + Medical Management (MIS)|Minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management
2886619|NCT03342664|Active Comparator|Best Medical Management Alone (MM)|Best medical management alone per standard of care at treating institution
2886620|NCT03342651|Other|Observational research|Vitamin D levels and respiratory complications; observational research.
2886621|NCT03342638|Experimental|Control Arm|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, MESNA, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant.
2886622|NCT03342638|Experimental|IVIg Arm|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, MESNA, rATG (rabbit), and methylprednisolone. IVIg and G-CSF will be administered post-transplant.
2886623|NCT03342625|Experimental|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound for the treatment of breast tumors, guided by MRI
2886624|NCT03342612|Experimental|Brain Magnetic Resonance Imaging (MRI)|Neuroimaging protocol to assess brain changes after minor head trauma and over the time.
2886625|NCT03342599|Experimental|GNC Alpha Lipoic Acid Supplement|600mg/daily ingestion of GNC alpha lipoic acid with no change in lifestyle for 8 weeks
2886626|NCT03342599|Placebo Comparator|Cellulose Fiber Placebo|600mg/daily ingestion of Vital Nutrients placebo (cellulose starch) with no change in lifestyle for 8 weeks
2886627|NCT03342586||Central Nervous System Lymphoma|Participants will have non-Hodgkins lymphoma involving the brain (primary or secondary)
2886628|NCT03342573|Experimental|Single Arm|Patients with a biopsy proven diagnosis of PRP
2886629|NCT03342560|Experimental|30 Patients with known liver biopsy results|Patients with chronic liver disease with known biopsy results
2886630|NCT03342547|Experimental|Intestinal stem cell-derived enteroids|Duodenal biopsy samples and saliva will be collected from participants and then processed in laboratory to generate intestinal stem cell-derived enteroids.
2886631|NCT03342534|Active Comparator|Anodal tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the contralesional supraorbital front of the patient.
2886632|NCT03342534|Active Comparator|High definition (HD) anodal tDCS|A single HD anode is placed over the primary motor cortex of the stroke affected hemisphere, 4 HD cathodes are placed over the affected hemisphere around the anode.
2886633|NCT03342534|Active Comparator|Bihemispheric tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the primary motor cortex of the contralesional hemisphere.
2886634|NCT03342534|Sham Comparator|Sham tDCS|The electrodes are placed as in one of the active arms, but only a ramp up current is applied during 30 seconds and then switched off. This induces similar sensations for the patients, but no change in excitability.
2886635|NCT03342508|Experimental|Fetal Pillow Inflated (FPI)|"A Fetal Pillow will be inserted vaginally by the obstetrician after catheterization of the bladder (if it has not been previously performed). Once the Fetal Pillow is in place, the woman's legs will be placed flat on the operating table. The anesthesiologist will then inflate the Fetal Pillow. The obstetrician will not be aware to inflation of Fetal Pillow~Cesarean delivery will then be performed~The circulating nurse will deflate the Fetal Pillow following delivery. The obstetrician will remove the Fetal Pillow at the end of the procedure. The obstetrician will then fill out a survey regarding the delivery."
2886721|NCT03341923|Other|AMMF, then DT1MF|Etafilcon A multifocal contact lenses, followed by delefilcon A multifocal contact lenses. Each product will be worn in both eyes for 14 +/- 3 days.
2886636|NCT03342508|No Intervention|Fetal Pillow Not Inflated (FPNI)|"A Fetal Pillow will be inserted vaginally by the obstetrician after catheterization of the bladder (if it has not been previously performed). Once the Fetal Pillow is in place, the woman's legs will be placed flat on the operating table. The Fetal Pillow will not be inflated.~Cesarean delivery will then be performed. The obstetrician will continue to be able to use conventional methods for delivery of a second stage arrest including hand from below and reverse breech extraction.~The circulating nurse will deflate the Fetal Pillow following delivery. The obstetrician will remove the Fetal Pillow at the end of the procedure. The obstetrician will then fill out a survey regarding the delivery."
2886637|NCT03342495|Experimental|Patient Navigator Arm|"Patient Navigator (Social Worker) will assist youth adapt and attach to adult delivered healthcare for up to 24 months.~Participants will receive 5 issues of a provincial generic newsletter on topics around transition.~Participants will be asked to complete a health questionnaire at baseline and 4 more times during 24 months.~Participants will be asked to complete a transition readiness questionnaire at baseline and 4 more times during 24 months.~Participants will be provided the opportunity to journal online about their experiences.~Up to 100 participants will be provided the opportunity to be interviewed at baseline and end of study about their transition experience."
2886638|NCT03342495|Other|Usual Care Arm|"Youth will receive usual care from their pediatric clinics in preparation and transfer to adult care.~Participants will receive 5 issues of a provincial generic newsletter on topics around transition.~Participants will be asked to complete a health questionnaire at baseline and 4 more times during 24 months.~Participants will be asked to complete a transition readiness questionnaire at baseline and 4 more times during 24 months.~Participants will be provided the opportunity to journal online about their experiences."
2886639|NCT03342482|Placebo Comparator|Placebo|5 g of placebo (sugar and salt) will be administered in veggie capsules
2886640|NCT03342482|Experimental|MSG|5 grams of MSG will be administered in veggie capsules
2886641|NCT03342469|Active Comparator|Artificial Food Colorings Challenge|A high consumer child dose totaling of 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) will be mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). The chocolate will mask the food coloring.
2886642|NCT03342469|Placebo Comparator|Placebo Challenge|The participants will consume chocolate cookies with no food coloring.
2886643|NCT03342456|Experimental|group 1|week1 to week2：Doxycycline Hyclate Enteric-Coated Capsules 0.1g,orally,twice daily,taken with meals, Ilaprazole Enteric-Coated Tablets 5mg,orally,twice daily, Furazolidone Tablets 0.1g,orally,twice daily,taken with meals, Bismuth Potassium Citrate Tablets 220mg,orally,twice daily week3 to week4：Ilaprazole Enteric-Coated Tablets 5mg,orally,once daily
2886644|NCT03342456|Active Comparator|group 2|"Amoxicillin Capsules 1g,orally,twice daily,taken with meals, Ilaprazole Enteric-Coated Tablets 5mg,orally,twice daily, Furazolidone Tablets 0.1g,orally,twice daily,taken with meals, Bismuth Potassium Citrate Tablets 220mg,orally,twice daily.~week3 to week4：Ilaprazole Enteric-Coated Tablets 5mg,orally,once daily"
2886645|NCT03342443|Experimental|memantine|Patients receive memantine with a dosage of 5 microgram at 8 am daily for one week (Week 1), then 5 microgram at 8 am and 5 microgram at 5 pm for one week (Week 2), then 10 microgram at 8 am and 5 microgram at 5 pm for one week (Week 3), then 10 microgram at 8 am and 10 microgram at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
2886646|NCT03342443|Placebo Comparator|placebo|Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
2886647|NCT03342430||Early Dieting in Girls cohort|A cohort of 197 non-Hispanic white girls, observed from age 5 to age 15 years
2886648|NCT03342417|Experimental|Neoadjuvant Breast Cancer|"Newly diagnosed patients who have Stage II-III breast cancer, with the primary cancer in place. These patients have not received prior therapy for their breast cancer and intend to undergo surgery after completion of investigational neoadjuvant therapy.~Each patient will be treated with two 6-week treatment cycles of Nivolumab 240 mg administered by intravenous (IV) infusion over 30 minutes and Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes. Nivolumab is given every two weeks (q2w) whereas Ipilimumab is given every 6 weeks (q6w), both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1 and 43. On these days, Ipilimumab is to be given immediately after Nivolumab."
2886649|NCT03342417|Experimental|Platinum-resistant ovarian cancer|Platinum-resistant/refractory ovarian cancer (PRROC) patients. Each patient will be treated with four 6-week treatment cycles of Nivolumab 240 mg administered by IV infusion over 30 minutes and Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes. Nivolumab is given q2w whereas Ipilimumab is given q6w, both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1, 43, 85 and 127. On these days, Ipilimumab is to be given immediately after Nivolumab.
2886650|NCT03342417|Experimental|Advanced gastric cancer patients|"Advanced gastric cancer patients who are recurrent/refractory to a prior therapy not involving herceptin.~Each patient will be treated with four 6-week treatment cycles of Nivolumab and Ipilimumab . Nivolumab is given q2w whereas Ipilimumab is given q6w, both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1, 43, 85 and 127. On these days, Ipilimumab is to be given immediately after Nivolumab."
2886651|NCT03342404|Experimental|Luspatercept (ACE-536) plus Best Supportive Care (BSC)|Arm Description: Luspatercept, subcutaneous(ly) (SC) once every 21 days
2886652|NCT03342404|Placebo Comparator|Placebo plus Best Supportive Care (BSC)|normal saline solution subcutaneous(ly) (SC) once every 21 days
2886653|NCT03342391|Other|Treatment Phase|Treatment Phase will evaluate the effectiveness of Transnasal Esophagoscopy (TNE) as an acceptable form of monitoring Eosinophilic Esophagitis
2886654|NCT03342378||Oropharynx Cancer Patients|Patients with OPSCC will be treated with comprehensive head and neck RT to 70 Gy in 33 fractions with concurrent weekly cisplatin at 40 mg/m2 and at the University of Wisconsin.
2886655|NCT03342352|Experimental|Arm A|Nivolumab plus epacadostat in combination with platinum (carboplatin/cisplatin) plus 5-fluorouracil.
2886656|NCT03342352|Active Comparator|Arm B|EXTREME regimen.
2886657|NCT03342352|Experimental|Arm C|Nivolumab plus placebo for epacadostat in combination with platinum (carboplatin/cisplatin) plus 5-fluorouracil.
2886658|NCT03342339|Other|patients with Parkinson's disease|"cognitive examination : mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test~viewing of video : scale of differential emotions and Positive and Negative Affect Scale~Test of Iowa Gambling Task"
2886659|NCT03342339|Other|witnesses|"cognitive examination : mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test~viewing of video : scale of differential emotions and Positive and Negative Affect Scale~Test of Iowa Gambling Task"
2886660|NCT03342326|Other|patient with Alzheimer's Disease|"Exposure to familiar songs : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.~Music Experience Questionnaire : questions about the past music training~Implicit tasks memory : a) Completion of trigrams : freely complete the first 3 letters of a word. b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not."
2886661|NCT03342326|Other|healthy volunteer|"Exposure to familiar songs : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.~Music Experience Questionnaire : questions about the past music training~Implicit tasks memory : a) Completion of trigrams : freely complete the first 3 letters of a word. b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not.~For volunteer over 65 years : Mini Mental State Examination, 5 words by Dubois and fluence verbal test"
2886662|NCT03342313|Experimental|healthy weight|BMI (kg/m2) ≥ 18.5 and < 23
2886663|NCT03342313|Experimental|Overweight|BMI (kg/m2) ≥23 chewing 15 times and 50 times per bite
2886664|NCT03342300|Experimental|Arm A|participants will recieve pegylated liposomal doxorubicin (50 mg/m²d1) plus ifosfamide (2 g/m²/d d2-3), dacarbazine (300 mg/m²/d d2-3).
2886665|NCT03342300|Placebo Comparator|Arm B|participants will recieve pirarubicin (60 mg/m²d1) plus ifosfamide (2 g/m²/d d2-3), dacarbazine (300 mg/m²/d d2-3).
2886666|NCT03342274|Experimental|Lifestyle Program Intervention|Participants receive usual care and group weight loss sessions adapted from the Diabetes Prevention Program delivered by Community Health Workers.
2886667|NCT03342274|Other|Wait list|Participants receive usual care and after 1 year receive the Lifestyle Program intervention
2886668|NCT03342261||HCV patients with mixed cryoglobulinemia|HCV patients with or without HIV presenting a mixed cryoglobulinemia and treated with direct-acting antiviral agents
2886669|NCT03342248|Experimental|access to the social network|This group is made up of carers who have access to the social network via a digital platform developed during step 1. This network will offer features from step 1 (sharing experiences on a forum, monitoring health status )
2886670|NCT03342248|No Intervention|no access to the network|"This group consists of caregivers who do not have access to the social network via a digital platform developed during step 1.~Access to the social network will be offered to all carers at the end of the study, especially those assigned in the control group to limit their refusal to participate."
2886671|NCT03342235|Experimental|Surgical Group|Participants randomized to PRK surgery will be referred to a study surgical center. The participant will have a preoperative exam within 7 days prior to surgery and surgery within 60 days after randomization. Participants will continue prescribed 2 hours per day of patching between randomization and the day of surgery.
2886672|NCT03342235|Active Comparator|Non-surgical Control Group|For participants assigned to the non-surgical control group, patching will be prescribed for 2 hours per day with optical correction, and will continue until the 8-month primary outcome visit.
2886673|NCT03342222|Experimental|PEEK Interference Screws|PEEK Interference Screws provided by Ruijin Hangzhou Martins Medical Equipment Co., Ltd.
2886674|NCT03342222|Active Comparator|Biosure PK interference screw|Biosure PK interference screw from Smith & Nephew plc.
2886675|NCT03342209|Experimental|HFNC therapy|Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy will be implemented to CO-poisoned patients. Oxygen flow rate will be started 60 L/min and be decreased as the patient has requested.
2886676|NCT03342196|Experimental|Thiotepa + Fludarabine + Melphalan|Melphalan 100 mg/m2 on day −8 Thiotepa 10 mg/kg on day -7 Fludarabine 160 mg/m2 in divided doses given on days −6, −5, −4 and −3.
2886677|NCT03342183|Experimental|Intervention Arm|RIPC stimulus will be applied prior to the first intervention visit, using a previously validated (for cardiac protection in HD patients) standard dose (four cycles of cuff inflation to the lower limb of the patient and inflating at 200mmHg for five minutes, with five minutes' deflation). To be administered on a monthly basis from the baseline visit to the year 1 visit.
2886678|NCT03342183|Sham Comparator|Control Arm|Sham procedure in which the blood pressure cuff will be applied to the lower limb and inflated to 40mmHg for five minutes and deflated for five minutes with the cycle repeated a total of four times prior to dialysis. To be administered on a monthly basis from the baseline visit to the year 1 visit.
2886679|NCT03342170||CIRRAL|alcoholic cirrhosis
2886680|NCT03342170||CIRVIR|Viral cirrhosis
2886681|NCT03342157|Experimental|High-dose|8.6/50 mg of senna/docusate, oral, twice daily
2886682|NCT03342157|Experimental|Low-dose|8.6/50 mg of senna/docusate, oral, once daily
2886683|NCT03342144||Participants Receiving Venetoclax|Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.
2886684|NCT03342131||STEMI group|The study population consists of 150 patients with ST-elevated acute myocardial infarction (STEMI) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded. Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA at 0 , 7days and 12 months after admission.
2886719|NCT03341936|Experimental|Nivolumab+Lirilumab|"The drugs will be administered intravenously. A single dose of Nivolumab and Lirilumab will be administered prior Salvage surgical resection.~In Cycle 1-3: Nivolumab will be administered on Days 1 and 15 and lirilumab will be administered on Day 1 of each 28 day long cycle~In Cycle 4-6 and beyond: Nivolumab and lirilumab will be administered on Day 1 of each 28 day long cycle."
2927710|NCT03056560|No Intervention|Control Video|Study Skills Video
2886685|NCT03342131||NST-ACS group|The study population consists of 150 patients with non-ST elevated acute myocardial infarction (NST-ACS) including unstable angina pectoris (UAP),who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA at 0 , 7days and 12 months after admission.
2886686|NCT03342131||Control group|150 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Control group. Circulation wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission.
2886687|NCT03342118|Experimental|Phloroglucin group|patients taken Phloroglucin(Flospan®)
2886688|NCT03342118|Placebo Comparator|Normal saline placebo group|patients taken normal saline placebo
2886689|NCT03342105|Experimental|Cettum (Electrical moxibustion)|The patients in this group will receive Cettum (Electrical moxibustion) treatment applied by a certified Korean Medicine Doctor with more than 6 years of traditional Korean medicine college education.
2886690|NCT03342105|Active Comparator|Acupuncture|The patients in this group will receive acupuncture treatment applied by a certified Korean Medicine Doctor with more than 6 years of traditional Korean medicine college education.
2886691|NCT03342092||Questionnaire|Questionnaires distributed to the families 15 days before child's medical consultation
2886692|NCT03342079|Experimental|Group 1|local anesthetic + placebo
2886693|NCT03342079|Experimental|Group 2|local anesthetic + nitrous oxide
2886694|NCT03342079|Placebo Comparator|Group 3|Placebo + nitrous oxide
2886695|NCT03342066||A|Cariogram
2886696|NCT03342066||B|CAMBRA
2886697|NCT03342053|Experimental|IONIS HTTRx Cohort A|IONIS HTTRx is administered intrathecally for 14 months at dose level A.
2886698|NCT03342053|Experimental|IONIS HTTRx Cohort B|IONIS HTTRx is administered intrathecally for 14 months at dose level B.
2886699|NCT03342040|Experimental|TAP block|Patients undergoing laparoscopic ventral hernia repair with TAP block with 0.2% ropivacaine under ultrasound guidance
2886700|NCT03342040|Active Comparator|No TAP block|Patients undergoing laparoscopic ventral hernia repair without TAP block
2886701|NCT03342027|Experimental|Bupropion + Positively Smoke Free|Positively smoke free-- an 8 session tailored behavioral treatment for smoking cessation bupropion--used for smoking cessation
2886702|NCT03342027|Experimental|Bupropion + Standard of Care|Standard of Care--brief advice to quit provided in a standardized format bupropion--used for smoking cessation
2886703|NCT03342027|Experimental|Placebo + Positively Smoke Free|Placebo--matched to bupropion Positively smoke free-- an 8 session tailored behavioral treatment for smoking cessation
2886704|NCT03342027|Placebo Comparator|Placebo + Standard of Care.|Placebo--matched to bupropion Standard of Care--brief advice to quit provided in a standardized format
2886705|NCT03342014|Experimental|All patients|All patients will have the same intervention (3DPD and UAD acquisitions ; blood sample)
2886706|NCT03342001|Experimental|Treatment group, open label|calcitonin nasal spray, 200 mcg daily
2886707|NCT03341988|Other|Ombitasvir (25 mg ), Paritaprevir (150 mg ) once daily|Ombitasvir (25 mg once daily), Paritaprevir (150 mg once daily), Ritonavir (100 mg once daily)Ribavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) given to 50 chronic HCV infected patients with renal impairment for 12 week
2886708|NCT03341975|Experimental|Intervention|They will receive the same pamphlet as controls and the enhanced ED SexHealth intervention with the educator. Based on behaviors, CDS system recommendations (generated from screening survey responses only for intervention participants), and discussions, participants may be offered testing (for pregnancy, gonorrhea/chlamydia, and /or HIV), hormonal birth control, condoms, emergency contraception (for immediate or future use), treatment for previously diagnosed (yet untreated) infection with gonorrhea/chlamydia, and a scheduled appointment at Adolescent Clinic (for ongoing care, including repeat STI/HIV testing if needed). All services will be provided at point of care, costs will be covered by the study.
2886709|NCT03341975|No Intervention|Control|They will receive a printed health pamphlet and a list of local resources with the phone number for Adolescent Clinic. Participants will then be referred back to their ED provider, who will provide their standard care.
2886710|NCT03341962|Experimental|10 mg IMU-838 (Induction)|Two 5 mg tablets once daily of IMU-838 for 10 to 22 weeks (Period 1) followed by an additional 10 to 22 weeks (Period 2) depending on the results of an interim analysis.
2886711|NCT03341962|Experimental|30 mg IMU-838 (Induction)|Two 15 mg tablets once daily of IMU-838 for 10 to 22 weeks (Period 1) followed by an additional 10 to 22 weeks (Period 2) depending on the results of an interim analysis.
2886712|NCT03341962|Experimental|45 mg IMU-838 (Induction)|Two 22.5 mg tablets once daily of IMU-838 for 10 to 22 weeks (Period 1) followed by an additional 10 to 22 weeks (Period 2) depending on the results of an interim analysis.
2886713|NCT03341962|Placebo Comparator|placebo (during induction)|The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging.
2886714|NCT03341962|Experimental|10 mg IMU-838 (Maintenance)|Two 5 mg tablets once daily of IMU-838 until Week 50 or ulcerative colitis relapse.
2886715|NCT03341962|Experimental|30 mg IMU-838 (Maintenance)|Two 15 mg tablets once daily of IMU-838 until Week 50 or ulcerative colitis relapse.
2886716|NCT03341962|Experimental|30 mg IMU-838 (Open-label)|Two 5 mg tablets once daily of IMU-838 for up to 10 years
2886717|NCT03341962|Placebo Comparator|placebo (during maintenance)|The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. Patients who have received placebo during the induction phase will be 're-randomized' to continue to receive placebo (in a blinded fashion).
2886718|NCT03341949|Experimental|Patient with chronic kidney disease|Determination of the Cluster of Differentiation 146 (CD146)
2886720|NCT03341923|Other|DT1MF, then AMMF|Delefilcon A multifocal contact lenses, followed by etafilcon A multifocal contact lenses. Each product will be in both eyes for 14 +/- 3 days.
2886759|NCT03341650|Experimental|Low Pasta|Habitual pasta consumption equal or lower than 3 times/week.
2886722|NCT03341910|Experimental|DFD-03 Lotion, 0.1%|DFD-03 Lotion, 0.1% to be applied twice daily approximately 12 hours apart, for 1 minute and rinsed off
2886723|NCT03341910|Active Comparator|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% to be applied once in the evening and left overnight for approximately 12 hours
2886724|NCT03341910|Placebo Comparator|Vehicle Lotion|Vehicle Lotion to be applied twice daily for 1 minute and rinsed off
2886725|NCT03341910|Placebo Comparator|Vehicle Cream|Vehicle Cream to be applied once in the evening and left overnight for approximately 12 hours
2886726|NCT03341897|Experimental|Surgical varicocelectomy|
2886727|NCT03341884|Experimental|Normal Hepatic Function|Participants with normal hepatic function will be administered a single oral dose of ipatasertib (100 mg).
2886728|NCT03341884|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of ipatasertib (100 mg).
2886729|NCT03341884|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of ipatasertib (100 mg).
2886730|NCT03341884|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15, inclusive) will be administered a single dose of ipatasertib (100 mg).
2886731|NCT03341871||HCV Genotypes 1, 2, 3, 4, 5, or 6 participants|Participants receiving combination therapy with the glecaprevir plus pibrentasvir (GLE/PIB) regimen according to the current local label.
2886732|NCT03341845|Experimental|axitinib and avelumab|axitinib 5MG BID and avelumab 10mg/kg Q2W
2886733|NCT03341832|Experimental|NVP-1203|NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose
2886734|NCT03341832|Active Comparator|NVP-1203-R|NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose
2886735|NCT03341832|Placebo Comparator|Placebo|NVP-1203 placebo plus NVP-1203-R placebo for up to 7 days, oral dose
2886736|NCT03341819|Active Comparator|Retained Urinary Catheter|
2886737|NCT03341819|Experimental|Non-retained Urinary Catheter|
2886738|NCT03341806|Experimental|Patients with Recurrent Glioblastoma|Part A - Avelumab Part B - Avelumab + MRI-guided LITT therapy
2886739|NCT03341793|Experimental|Muscle secretion|Characterize the changes in muscle secretion induced by bariatric surgery and determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by B cell responsible for the remission of diabetes mellitus.
2886740|NCT03341767|Experimental|Clofazimine|Subjects >/=50 kg: Clofazimine two 50mg gelatin capsules taken orally every 8 hours for 5 days Subjects <50 kg: Clofazimine 50mg gelatin capsule taken orally every 8 hours for 5 days
2886741|NCT03341767|Placebo Comparator|Placebo|Placebo gelatin capsule(s) taken orally every 8 hours for 5 days.
2886742|NCT03341767|Experimental|Clofazimine, no diarrhea|Subjects >/=50 kg: Clofazimine two 50mg gelatin capsules taken orally every 8 hours for 5 days Subjects <50 kg: Clofazimine 50mg gelatin capsule taken orally every 8 hours for 5 days
2886743|NCT03341754|Experimental|Group 1 (D/ChAd63-CA)|"(2-antigen): 3 doses at 4 week intervals (Week 0, 4, and 8) of DNA prime with D-C + D-A at 2 mg total (1 mg per construct) per dose as two 1 mL IM injections of the blended D-CA, one in each arm, via Biojector 2000 needle-free injection device or an equivalent disposable syringe needle-free injection device. This will be followed after 16 weeks (Week 24) by 1 dose of ChAd63-C + ChAd63-A boost, at a total dose of 1 x 1011 virus particles (vp) (5 x 1010 vp/construct) as a single IM injection of 0.65mL, using a needle and syringe.~Week 0 = Prime with D-CA Week 4 = Prime with D-CA Week 8 = Prime with D-CA Week 24 = Boost with ChAd63-CA Week 28 = Controlled Human Malaria Infection (CHMI)"
2886744|NCT03341754|Experimental|Group 2 (D/ChAd63-CAT)|"(3-antigen): 3 doses at 4 week intervals (Week 0, 4, and 8) of DNA prime with D-C + D-A + D-T at 3 mg total (1 mg per construct) per dose as two 1 mL intramuscular (IM) injections of the blended D-CAT, one in each arm, via Biojector 2000 needle-free injection device or an equivalent disposable syringe needle-free injection device. This will be followed after 16 weeks (Week 24) by 1 dose of ChAd63-C + ChAd63-A + ChAd63-T boost, at a total dose of 1.5 x 1011 vp (5 x 1010 vp/construct) as a single IM injection of 1.0mL, using a needle and syringe.~Week 0 = Prime with D-CAT Week 4 = Prime with D-CAT Week 8 = Prime with D-CAT Week 24 = Boost with ChAd63-CAT Week 28 = Controlled Human Malaria Infection (CHMI)"
2886745|NCT03341754|Active Comparator|Infectivity Control (IC)|"Subjects will be exposed to the bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.~Week 28 = Controlled Human Malaria Infection (CHMI)"
2886746|NCT03341741|Experimental|Tobramycin powder / Colistin|TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off); and Colistin solution 2 x daily 1 Mega continuously for 112 days
2886747|NCT03341741|Active Comparator|Colistin|Colistin solution 2 x daily 1 Mega continuously for at least 30 days
2886748|NCT03341728|Experimental|Older Fallers|Older adults with a history of falls will walk during exposure to optical flow perturbations
2886749|NCT03341728|Experimental|Older Non-Fallers|Older adults without a history of falls will walk during exposure to optical flow perturbations
2886750|NCT03341715|Experimental|Mavoglurant (AFQ056)|The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
2886751|NCT03341715|Placebo Comparator|Placebo|The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
2886752|NCT03341689|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
2886753|NCT03341689|Experimental|Placebo/High Dose Psilocybin|Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
2886754|NCT03341689|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
2886755|NCT03341689|Experimental|High Dose Psilocybin/Placebo|Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.
2886756|NCT03341676|Experimental|Dexamethasone|8ml IV 3.3mg/mL dexamethasone
2886757|NCT03341676|Placebo Comparator|Placebo|8ml IV 0.9% w/v saline
2886758|NCT03341650|Experimental|High Pasta|Habitual pasta consumption equal or higher than 5 times/week.
2886760|NCT03341637|Experimental|Tetravalent Dengue Vaccine (TDV)|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose)
2886761|NCT03341637|Placebo Comparator|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
2886762|NCT03341624|Experimental|cataract surgery cataract extraction and intraocular implanta|
2886763|NCT03341611||Adults 55 and younger|
2886764|NCT03341611||Adults 55 and older|
2886765|NCT03341598|Active Comparator|CAF+R|First of all, a sterile rubber dam will be placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M- St. Paul, Minnesota, USA), following the manufacturer's instructions. CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures will be placed to stabilize the flap in a coronal position 2 mm above the cementoenamel junction (CEJ), followed by interrupted sutures to close the releasing incisions.
2886766|NCT03341598|Experimental|CAF+R+MC|First of all, a sterile rubber dam will be placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M - St. Paul, Minnesota, USA), following the manufacturer's instructions. CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous collagen matrix graft (Geistlich) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
2886767|NCT03341585|Experimental|Expiration Lente Prolongée|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of 'Expiration Lente Prolongée (ELPr)' . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
2886768|NCT03341572|Experimental|high response group|patients undergo 5,10 and 15cmH2O positive end expiratory pressure ,the change of central venous pressure is more than 2.5cmH2O
2886769|NCT03341572|Placebo Comparator|low response group|the change of CVP is less than 2.5cmH2O
2886770|NCT03341559||With Existing Diabetic Ulcers|
2886771|NCT03341559||Diabetic Ulcers in remission|
2886772|NCT03341546||Patient cohort|20 patients referred to Ninewells Hospital radiology department for an anterior-posterior abdomen x-ray examination. All of these patients will have a measurement of their anterior-posterior depth before undergoing their x-ray examination. An estimate of their anterior-posterior depth will then be made from their x-ray image using the computational model.
2886773|NCT03341533|Experimental|Ice packs plus usual post-op analgesia|Ice pack applied to the abdomen and maintained continuously for the first 12 hours post-operatively. Standard standard post-operative analgesia orders will be followed in addition to use of ice.
2886774|NCT03341533|Active Comparator|Usual post-op analgesia|Standard post-operative analgesia only, no ice use.
2886775|NCT03341520|Experimental|interventional arm|Obinutuzumab Injection [Gazyva] 1000mg flat i.v. on week 1, 2, 3, 4, 8, 12, 16; Low dose radiation Therapy (LDRT) involved site 2 x 2 Gy in week 9
2886776|NCT03341507|Experimental|laryngoscopy and tracheal intubation|Tracheal intubation with the rigid tube for laryngoscopy for patients with difficult airway. Prior the use of rigid tube for laryngoscopy, a classical laryngoscopy with a Mc Coy laryngoscope will be performed.
2886777|NCT03341494|Experimental|Gefitinib 250mg qd thalidomide 200mg qn|
2886778|NCT03341494|Active Comparator|Gefitinib 250mg qd|
2886779|NCT03341481|Experimental|Femaltiker|7.7 g of Femaltiker twice a day for 14 days of the trial.
2886780|NCT03341481|Placebo Comparator|placebo|7.7 g placebo 14 days of the trial.
2886781|NCT03341468|Experimental|Urethral catheter immobilization|Subjects randomized to the intervention group will undergo radical prostatectomy with placement of the urethral catheter per the standard of care. The urethral catheter immobilization device will be applied in the operating room prior to the patient being transported to the recovery room. Subjects will be informed on safe use of the device and must demonstrate competency in removing and replacing the device prior to discharge. Subjects will also be given an elastic leg strap, which they may use concurrently with the device. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial per standard of care, at which the device will no longer be needed.
2886782|NCT03341468|No Intervention|No urethral catheter immobilization|Subjects randomized to the control group will undergo radical prostatectomy with placement and securing of the urethral catheter per the standard of care. The catheter will be secured to the leg using cloth tape. Subjects will also be given an elastic leg strap that they may use following discharge, as is routine. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial per standard of care.
2886783|NCT03341455|Other|Intervention preschools|"Capacity building to support families affected by IPV & substance misuse will be provided to the intervention preschools.~Specifically, capacity building, training and support will be provided to~selected mothers on the provision of safe, confidential and relevant community-based referral and support services for women affected by IPV.~selected fathers on the provision of safe, confidential and relevant community-based referral and support to men seeking support for substance misuse problems.~intervention preschool teachers on provision of IPV and substance misuse prevention educational messages and referral pathways to services for these issues."
2886784|NCT03341455|No Intervention|Control preschool|No intervention or training will not be provided to the control group in order to assess the impact of the intervention between the control and intervention arms of the study.
2886785|NCT03341442|Experimental|No hip precautions|No hip precautions practiced after THA surgery
2886786|NCT03341442|No Intervention|Hip precautions|Hip precautions practiced per standard of care after THA surgery
2886823|NCT03341195|Active Comparator|2. Two Way SMS messages|Parents/caregiver will receive two way (interactive) educational/reminder/proactive SMS messages related to routine immunization once a week till 20 weeks of age-parents will have the option to reply and receive more information related to immunization through text messages.
2886787|NCT03341429|Experimental|Treatment|"Daily subcutaneous injection of liraglutide 3.0 mg~Study dosing of liraglutide:~Week 1: 0.6 mg once daily Week 2: 1.2 mg once daily Week 3: 1.8 mg once daily Week 4: 2.4 mg once daily Week 5-24: 3.0 mg once daily~In addition to the daily injection of liraglutide/placebo, participants in both groups will be advised to cut down approximately 500 calories from their usual food intake and to achieve a minimum of 150 minutes per week of physical activity."
2886788|NCT03341429|Placebo Comparator|Control|"Daily subcutaneous injection of placebo; the same dosage regimen as treatment to be followed.~In addition to the daily injection of liraglutide/placebo, participants in both groups will be advised to cut down approximately 500 calories from their usual food intake and to achieve a minimum of 150 minutes per week of physical activity."
2886789|NCT03341416|Experimental|Device - deep brain stimulation ON|"Intervention type: device (deep brain stimulation of the dentate nucleus in cerebellum). The intervention is a device called deep brain stimulation bilaterally placed in the sub thalamic nucleus.~The stimulation will remained turned ON during 3 months - phase 1 - blinded and continuous during the open-label phase"
2886790|NCT03341416|Sham Comparator|Device - deep brain stimulation Sham|"Sham stimulation: device (deep brain stimulation of the dentate nucleus in cerebellum). Intervention type: device (deep brain stimulation of the dentate nucleus in cerebellum). The intervention is a device called deep brain stimulation bilaterally placed in the sub thalamic nucleus.~During the sham stimulation the intervention will remained turned OFF during 3 months"
2886791|NCT03341403|Active Comparator|Synbiotic group|"severe asthmatic patients (ACQ> 1.5 and beclomethasone > 200 µg per day) will receive Probiotical ® (3 pills a day, content: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill) during 3 months."
2886792|NCT03341403|Placebo Comparator|Placebo group|severe asthmatic patients (ACQ> 1.5 and beclomethasone > 200 µg per day) will receive a placebo (3 pills a day) during 3 months.
2886793|NCT03341390|Active Comparator|Aspirin|325 mg tablet, once daily for 5 days (Day -5 to -1)
2886794|NCT03341390|Experimental|BMS-986177 plus aspirin|200 mg BMS-986177 twice daily and 325 mg tablet aspirin once daily (Day 1-7)
2886795|NCT03341390|Placebo Comparator|Placebo plus aspirin|200 mg Placebo twice daily and 325 mg tablet aspirin once daily (Day 1-7)
2886796|NCT03341377||Perioperative lung cancer cohort|Symptom management for surgical patients with lung cancer
2886797|NCT03341364|Experimental|ACT group treatment|Participants receiving the ACT-based group therapy.
2886798|NCT03341364|Active Comparator|ACT individual|Participants receiving individual ACT-based therapy.
2886799|NCT03341351|Active Comparator|Instructional video|The modified beef tongue video group will be given an instructional video created using the modified beef tongue model to show anatomy and proper repair of the laceration.
2886800|NCT03341351|Active Comparator|Instructional workshop|The group randomized to the modified beef tongue instructional workshop will undergo an interactive workshop using the modified beef tongue model to show anatomy and proper repair of the laceration.
2886801|NCT03341325|Experimental|animal-assisted intervention|the intervention is a real animal is presented in different forms to the participants
2886802|NCT03341325|Active Comparator|control intervention|the control intervention is a stuffed toy animal and a spickey massage ball is presented in different forms to the participants
2886803|NCT03341312|Experimental|LY900014 Before Meal|Individualized dose of LY900014 administered subcutaneously (SC) immediately before meal in one of four study periods.
2886804|NCT03341312|Experimental|LY900014 After Meal|Individualized dose of LY900014 administered SC 20 minutes after start of meal in one of four study periods.
2886805|NCT03341312|Active Comparator|Insulin Lispro (Humalog) Before Meal|Individualized dose of insulin lispro administered SC immediately before meal in one of four study periods.
2886806|NCT03341312|Active Comparator|Insulin Lispro (Humalog) After Meal|Individualized dose of insulin lispro administered SC 20 minutes after start of meal in one of four study periods.
2886807|NCT03341299|Experimental|LY900014 Before Meal|Individualized dose of LY900014 administered subcutaneously (SC) immediately before meal in one of four study periods.
2886808|NCT03341299|Experimental|LY900014 After Meal|Individualized dose of LY900014 administered SC 20 minutes after start of meal in one of four study periods.
2886809|NCT03341299|Active Comparator|Insulin Lispro (Humalog) Before Meal|Individualized dose of insulin lispro administered SC immediately before meal in one of four study periods.
2886810|NCT03341299|Active Comparator|Insulin Lispro (Humalog) After Meal|Individualized dose of insulin lispro administered SC 20 minutes after start of meal in one of four study periods.
2886811|NCT03341286|Experimental|TK3|This is a oral supplement combination of tryptophan and thiamine called TK3 to be taken three times a day
2886812|NCT03341286|Placebo Comparator|Placebo|Placebo orally, to be taken three times a day
2886813|NCT03341273|Experimental|Azithromycin|210 subject to receive Azithromycin 500 mg as a single dose on Day 1, followed by Azithromycin 250 mg once daily Day 2 through Day 5
2886814|NCT03341273|Placebo Comparator|Placebo|210 subject to receive 2 capsules of placebo as a single dose on Day 1, followed by 1 capsule of placebo once daily Day 2 through Day 5
2886815|NCT03341260|Experimental|Diclofenac Potassium 50mg tab|Diclofenac Potassium 50mg tablet to be administered one hour before treatment.
2886816|NCT03341260|Placebo Comparator|Placebo|Placebo to be administered one hour before treatment.
2886817|NCT03341247||Low-risk of obesity|Children whose biological mother and biological father have a body mass index between 18.5 - 25 kg/m2.
2886818|NCT03341247||High-risk of obesity|Children whose biological mother has a body mass index greater than or equal to 30 kg/m2 and whose biological father have a body mass index greater than or equal to 25 kg/m2.
2886819|NCT03341234|Active Comparator|Group SPB|Ultrasound guided serratus plane block with 30 ml %0,25 bupivacaine
2886820|NCT03341234|Active Comparator|Group Control|Ultrasound guided sham block with 2 ml saline subcutaneously
2886821|NCT03341221||One group|Diagnosis of ascites in infants and children by history, examination and investigations
2886822|NCT03341195|Active Comparator|1. One way SMS messages.|Parents/caregiver will receive one way educational/reminder/proactive SMS messages related to routine immunization once a week till 20 weeks of age.
2886859|NCT03340961|Experimental|Oraycea® (doxycycline) Capsules|Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.
2886824|NCT03341195|Active Comparator|3. One way automated calls.|Parents/caregiver will receive one way educational/reminder/proactive automated phone call related to routine immunization once a week till 20 weeks of age.
2886825|NCT03341195|Active Comparator|4.Two way interactive automated calls|Parents/caregiver will receive two way (interactive) educational/reminder/proactive automated phone call related to routine immunization once a week till 20 weeks of age-parents will have the option to reply and receive more information related to immunization through phone call.
2886826|NCT03341195|No Intervention|5. Control Arm|One time counseling at the baseline survey.
2886827|NCT03341182|Active Comparator|normal method group (group A)|A mirror is not used in tunnel view technique (conventional manner)
2886828|NCT03341182|Experimental|mirror use group (group B)|A mirror is used in tunnel view technique
2886829|NCT03341169|Experimental|Glutamine|Intravenous glutamine infusion perioperatively for 18 hours (8 hours before surgery and 10 hours after induction of anesthesia)
2886830|NCT03341169|Placebo Comparator|Placebo|
2886831|NCT03341156|Experimental|Kcentra (PCC)|Half of subjects enrolled will be randomized to the Kcentra (PCC) group.
2886832|NCT03341156|Active Comparator|Frozen Plasma Product, Human|Half of subjects enrolled will be randomized to the standard transfusion group and receive fresh frozen plasma intra-operatively.
2886833|NCT03341143|Experimental|Fecal Microbiota Transplant (FMT) with Pembrolizumab|"The FMT will be performed as outpatient by a gastroenterologist. The FMT is infused into the colon by performing a colonoscopy. FMT will be performed on Cycle 1 Day 1 and will take 15 to 30 minutes.~Pembrolizumab, 200mg, through an IV over 30 minutes on Cycle 1 Day 1 (same day as the FMT), and then again on Day 1 of each 21-day cycle for an additional 3 cycles (Cycles 2 - 4)."
2886834|NCT03341130|Experimental|Treatment Group|The treatment group will will be treated a mandibular advancement oral appliance following standard practices. The treatment group will also receive a mandibular repositioning splint to wear in the mornings for a minimum of 1 hour following removal of their mandibular advancement oral appliance, in an effort to reduce the side effects resulting from use of the mandibular advancement oral appliance.
2886835|NCT03341130|Experimental|Positive Control Group|The positive control group will will be treated a mandibular advancement oral appliance following standard practices. The positive control group will not receive any additional oral appliances. Side effects resulting from use of the mandibular advancement oral appliance will be managed using standard practices, including jaw stretching exercises as needed for comfort.
2886836|NCT03341130|No Intervention|Negative Control Group|The negative control group is comprised of 15 healthy individuals recruited specifically from faculty members at the UBC Faculty of Dentistry. This group will undergo the same clinical data collection as the treatment group and the negative control group but will not receive any treatment.
2886837|NCT03341117|Active Comparator|Acetylsalicylic acid|The patients were randomly assigned to received Acetylsalicylic acid 300 mg once daily for 90 days
2886838|NCT03341117|Placebo Comparator|calcined magnesia|"The patients were randomly assigned to received placebo (calcinaned magnesia),~1 capsule 300 mg before each meal for a period of 90 days."
2886839|NCT03341091|Experimental|Tai-chi group|"16-week 10-step simplified Tai-chi programme.~Two 1-hour sessions of centre-based Tai-chi training and a minimum of three 30-minute Tai-chi sessions at home on a weekly basis."
2886840|NCT03341091|No Intervention|Control group|"Group recreational activities and continue their usual lifestyles and levels of physical activity as usual for 16 weeks.~Two 1-hour sessions of group recreational activities on a weekly basis."
2886841|NCT03341078|Placebo Comparator|Placebo|Placebo Group will be dosed with a placebo oral tablet twice daily for 6 weeks. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
2886842|NCT03341078|Active Comparator|Ibudilast|Ibudilast Group will be dosed with ibudilast twice daily for 6 weeks. The first 2 weeks will be 20 mg twice daily followed by 4 weeks of 50 mg twice daily. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
2886843|NCT03341078|No Intervention|Controls|Healthy controls will only undergo baseline evaluations and will not be enrolled in the drug portion of the study.
2886844|NCT03341065|Experimental|exoskeleton type robot|exoskeleton type robot assisted gait training (Lokomat orthosis)
2886845|NCT03341065|Experimental|end-effector type robot|end-effector type robot assisted gait training (G-EO system)
2886846|NCT03341052|Active Comparator|Obese Participants|Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
2886847|NCT03341052|Active Comparator|Normal Weight Participants|Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
2886848|NCT03341026|Other|Induction day 1, 4, 7, 14|Patient will come to the hospital on day 1, 4, 7 and 14. A hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
2886849|NCT03341026|Other|Induction day 1, 7, 10, 14|Patient will come to the hospital on day 1, 7, 10 and 14. A hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
2886850|NCT03341013|Experimental|Sequence 1|formulation 2 on Day 1 and formulation 3 on Day 10
2886851|NCT03341013|Experimental|Sequence 2|formulation 3 on Day 1 and formulation 2 on Day 10
2886852|NCT03341000|Experimental|DISCSS Device|This pilot feasibility study will explore and help determine optimal settings and configuration of the DISCSS™ System with patients that have completed a percutaneous trial with a commercially available SCS trial system.
2886853|NCT03340987|Experimental|Vista technique with SCTG|vestibular incision subperiosteal tunnel access combined with subepithelial connective tissue graft
2886854|NCT03340987|Active Comparator|coronally advanced flap with SCTG|coronally advanced flap combined with subepithelial connective tissue graft
2886855|NCT03340974|Experimental|Arm A: SBRT + GC4419|
2886856|NCT03340974|Placebo Comparator|Arm B: SBRT + Placebo|
2886857|NCT03340961|Experimental|DFD-29 Extended Release Capsules (40 mg)|DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.
2886858|NCT03340961|Experimental|DFD-29 Extended Release Capsules (20 mg)|DFD-29 (minocycline HCl) Extended Release Capsules (20 mg) once per day for 16 weeks.
2927711|NCT03056547|Experimental|Induced dyspnea|
2886861|NCT03340948|Experimental|MBSR participation|Participation in the 8 week Mindfulness Based Stress Reduction (MBSR) course.
2886862|NCT03340935|Experimental|Fasting mimicking diet|Fasting mimicking diet (FMD)
2886863|NCT03340922|Experimental|Automatic annotation of LAT (WF-method)|The annotation of LAT in each acquired point will be automatically performed using the LAT annotation tool integrated into CARTO navigation system, called Wavefront (WF). Automatic annotation of LAT performed by the CARTO system uses the maximum negative slope of the distal U-EGM to set the timing of the mapping annotation, displayed on the corresponding B-EGM. Additionally, the automatic annotation of LAT will be aided by an ECG recognition pattern algorithm (included in the last version of CARTO), which is intended to avoid wrong annotation of ventricular complexes other than the clinical PVC.
2886864|NCT03340922|Active Comparator|Manual annotation of LAT (M-method)|A detailed electrocardiogram (ECG)-gated activation map of the chamber of interest will be acquired using the CARTO navigation system. An experienced electrophysiologist will perform the annotation of LAT in each acquired point. The LAT will be measured from the onset of B-EGM (earliest positive or negative deflection) of the distal dipole of the mapping catheter to the defined reference. The use of the U-EGM as a guidance to identify the real onset of B-EGM will be decided under electrophysiologist criteria.
2886865|NCT03340909|Experimental|Prednisolone|Prednisolone tablets 5 mg
2886866|NCT03340909|Placebo Comparator|Placebo|Placebo tablets with identical appearance to the experimental drug.
2886867|NCT03340896|Active Comparator|TPF followed by radiotherapy|"Induction chemotherapy by Docetaxel 75 mg/m² day 1,cisplatin 75 mg/m² day 1 and 5 fluorouracil 750mg/m²(day 1 to day 5) 3 cycles day1, day 22, day 43 followed (for responders or stable disease patients) by radiotherapy~Radiotherapy ;70 gray fractionization: 2Gy/day, 5days/week, for 7 weeks."
2886868|NCT03340896|Experimental|Cisplatin and radiotherapy|"Drug and radiation • Cisplatin: 100 mg / m² administered IV at J1, J22 and J43 of radiotherapy~. Radiotherapy 70 gray fractionization: 2Gy/day, 5days/week, for 7 weeks."
2886869|NCT03340883|Experimental|BION-1301|BION-1301 will be administered once every 2 weeks as an intravenous (IV) infusion.
2886870|NCT03340870|Experimental|Sonazoid™ 0.12 microliter (µl)|Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 µl microbubbles (MB)/kilogram (kg) body weight.
2886871|NCT03340870|Experimental|Sonazoid™ 0.60 µl|Participants will receive single I.V bolus injection of Sonazoid™ 0.60 µl MB/kg body weight.
2886872|NCT03340857|Experimental|Intelligent electric bicycle (VELIS) sessions|Intelligent electric bicycle (VELIS) sessions with an instructor, twice a week for 6 weeks
2886873|NCT03340844|Experimental|No Touch (NT)|Pancreatic and Periampullary Tumors resection by no-touch technique
2886874|NCT03340844|Active Comparator|Superior Mesenteric Artery First (SMA)|Pancreatic and Periampullary Tumors resection by superior Mesenteric Artery First technique
2886875|NCT03340831||CGM/BGM Group|single-group, whereby participant is their own control. Use of a Blood Glucose Meter (BGM) for 6 months is compared to use of the G5 CGM System for 6 months, with collection of major diabetes related events (mild/severe hypoglycemia and DKA).
2886876|NCT03340818|Experimental|Bone Marrow Concentrate|Patients in this group will receive injection of autologous bone marrow concentrate into the suspected painful intervertebral discs.
2886877|NCT03340818|Sham Comparator|Placebo Group|Patients in this group will receive an injection of normal saline dorsal to the transverse process. The bone marrow aspiration will be simulated for these patients.
2886878|NCT03340805|Experimental|Lactated Ringer's fluid (LR)|Lactated Ringer's (LR) fluid will be administered to patients randomized to the experimental arm. LR will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team.
2886879|NCT03340805|Active Comparator|"0.9% normal saline fluid (NS)"|"0.9% normal saline (NS) fluid will be administered to patients randomized to the active comparator (control) arm. NS will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team."
2886880|NCT03340792|Experimental|Exoskeleton robot ambulation training|Ambulation training utilizing an exoskeleton robot
2886881|NCT03340779|Experimental|Norepinephrine alone|Administration of norepinephrine with increasing dose
2886882|NCT03340779|Active Comparator|Norepinephrine plus Dobutamine|Administration of norepinephrine and dobutamine
2886883|NCT03340766|Experimental|COHORT Ib|Blinatumomab 9 to 28 microgram plus Pembrolizumab (day 1).
2886884|NCT03340766|Experimental|COHORT IIb|Blinatumomab 9 to 28 to 112 microgram plus Pembrolizumab (day 1).
2886885|NCT03340766|Experimental|COHORT IIIb|Blinatumomab 9 to 28 to 56 microgram plus Pembrolizumab (day 1).
2886886|NCT03340766|Experimental|COHORT Ia|Blinatumomab 9 to 28 microgram plus Pembrolizumab (day 15).
2886887|NCT03340766|Experimental|COHORT IIa|Blinatumomab 9 to 28 to 112 microgram plus Pembrolizumab (day 19).
2886888|NCT03340766|Experimental|COHORT IIIa|Blinatumomab 9 to 28 to 56 microgram plus Pembrolizumab (day 19).
2886889|NCT03340766|Experimental|Expansion Cohort|This cohort will test the Maximum Tolerated Dose of Blinatumomab in combination with Pembrolizumab identified using cohort design from cohorts Ia/b, IIa/b and IIIa/b tested in Part 1 of the study.
2886890|NCT03340753|Active Comparator|KBP-5074 Capsule|KBP-5074 (0.5 mg or 1.0 mg) in capsule formulation in a 2-period crossover design with a 2-week washout/follow-up period
2886891|NCT03340753|Experimental|KBP-5074 Tablet|KBP-5074 (0.5 mg or 1.0 mg) in tablet formulation in a 2-period crossover design with a 2-week washout/follow-up period
2886892|NCT03340740|Experimental|Cetirizine|Cetirizine 10mg (10ml) (patients age 12-17) or cetirizine 5mg (5ml) (patients age 6-11) x 1 dose at beginning of course in emergency department.
2886893|NCT03340740|Placebo Comparator|Placebo|Placebo 10ml (patients age 12-17) or 5ml (patients age 6-11) x 1 dose at beginning of course in the emergency department.
2886894|NCT03340727|Experimental|Caffeine Citrate|Caffeine citrate at 10 mg/kg/dose (5 mg/kg caffeine base) daily, in hospital. Infants will continue at home on the same dose of caffeine citrate for the first 28 days after hospital discharge.
2886895|NCT03340727|Placebo Comparator|Placebo|Placebo contains all of the excipients except for the active ingredient, caffeine citrate, (a volume equivalent to 10 mg/kg of caffeine citrate) and given daily. Infants will be continued at home on the same dose of placebo for the first 28 days after hospital discharge.
2886896|NCT03340714|Experimental|Device Feasibility (ADAMM)|Patients wear the Automated Device for Asthma Monitoring and Management (ADAMM) from the time of computed tomography (CT) simulation for radiation therapy (RT) planning throughout the entire RT course and for 4 weeks post-RT
2886897|NCT03340701|Other|Vaginal Progesterone|micronized progesterone vaginal suppository 200mg
2886898|NCT03340688|Active Comparator|Cervical cerclage + vaginal progesterone|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤15mm and Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
2886899|NCT03340688|No Intervention|Vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
2886900|NCT03340675|Experimental|Oral Ifetroban - Low Dose|Weight based, once daily oral ifetroban
2886901|NCT03340675|Experimental|Oral Ifetroban - High Dose|Weight based, once daily oral ifetroban
2886902|NCT03340675|Placebo Comparator|Placebos|Matching Placebo
2886903|NCT03340662|Experimental|CC-122 Alone under fasted conditions|Single oral dose of 3 mg CC-122 administered alone under fasted conditions
2886904|NCT03340662|Experimental|CC-122 plus Itraconazole|Single oral dose of 3 mg CC-122 alone and with multiple doses of itraconazole.
2886905|NCT03340662|Experimental|CC-122 plus Fluvoxamine|Single oral dose of 3 mg CC-122 alone and with multiple doses of fluvoxamine.
2886906|NCT03340662|Experimental|CC-122 plus Rifampin|Single oral dose of 3 mg CC-122 alone and with multiple doses of rifampin
2886907|NCT03340623||Mammary reconstruction by DIEP with venous coupler|
2886908|NCT03340623||Mammary reconstruction by DIEP without venous coupler|
2886909|NCT03340610|Other|Open Label Single Arm Trial|Evaluating the efficacy of Alflibercept Injections in DME Following Treatment With Bevacizumab and Ranibizumab
2886910|NCT03340597|Experimental|A1; F901318 (10 days)|F901318 : 10 days dosing orally
2886911|NCT03340597|Experimental|A2; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
2886912|NCT03340597|Experimental|A3; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
2886913|NCT03340597|Experimental|A4; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
2886914|NCT03340584|Experimental|The intervention group|The intervention group will be received the Nine Castle Net Format taping and the traditional rehabilitation throughout all hospitalization period.We will exchange the new taping for Every two days.
2886915|NCT03340584|Other|The control group|The control group will be received the traditional rehabilitation during the hospitalization period.The traditional rehabilitation included occupational therapy and physical therapy.
2886916|NCT03340571||Alzheimer's Patients|
2886917|NCT03340571||Healthy Volunteers|
2886918|NCT03340558|Experimental|Monotherapy Cohort|The first 10 subjects will receive Atezolizumab 840 mg IV on Day 1 and Day 15 of each 28-day cycle. Subjects will be treated for 2 cycles before undergoing metastatectomy within 42 days of completion of Cycle 2. No study treatment is administered while subjects are healing after surgery.
2886919|NCT03340558|Experimental|Combination Cohort|The next 15 subjects will receive Atezolizumab 840 mg IV on Day 1 and Day 15 and Cobimetinib 60 mg PO on Days 1-21 of each 28-day cycle. Cobimetinib must be held for the 7 days prior to metastatectomy. Subjects will be treated for 2 cycles before undergoing metastatectomy within 42 days of completion of Cycle 2.
2886920|NCT03340545|Other|Healthy Individuals|Healthy individuals will be imaged for comparison purposes
2886921|NCT03340545|Other|Disc Herniation|Subjects diagnosed with Intervertebral Disc Herniation will be imaged to evaluate sensitivity of the proposed method.
2886922|NCT03340532|Experimental|Sleep hygiene video|Participants will watch a sleep hygiene video
2886923|NCT03340532|Experimental|Information video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
2886924|NCT03340532|Experimental|Information + Appearance video|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
2886925|NCT03340519||Healthy Controls|Healthy Controls will undergo MR imaging to optimize MR techniques for bowel assessment and to acquire normative data
2886926|NCT03340519||Newly Diagnosed Crohns Patients|MR imaging will be performed in newly diagnosed CD patients prior to initiation of infliximab therapy in order to obtain baseline measures in the setting of active intestinal inflammation
2886927|NCT03340506|Experimental|dabrafenib and/or trametinib|"Patients in this study may receive one of the following treatments received in the parent study which are:~Patients who received monotherapy of either of dabrafenib or trametinib solid dose forms~Patients who received combination of dabrafenib and trametinib solid dose forms~Patients who received suspensions of dabrafenib and/or trametinib"
2886928|NCT03340493|Active Comparator|Assigned Interventions|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).
2886929|NCT03340493|Experimental|Tenecteplase|Patients will receive intravenous tenecteplase (0.4mg/kg, maximum 40mg, administered as a bolus over ~10 seconds).
2886930|NCT03340480|Experimental|NVP-1402-1|NVP-1402 was administered once a day for 24 hours
2886931|NCT03340480|Experimental|NVP-1402-2|NVP-1402 was administered once a day for 24 hours
2886932|NCT03340467|Experimental|CGM patch|Patient receives four models of CGM patches. Adhesion sites are randomly allocated (1 on each upper arm, 2 on the abdomen).
2886933|NCT03340454|Active Comparator|Health systems-level intervention|using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies;
2886934|NCT03340454|Active Comparator|CHW-led patient navigation program|a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability
2886935|NCT03340428|Experimental|TCAC|Participants in this arm will be referred to join a facilitated group setting for HIV on release from incarceration. This arm will provide HIV care services in a facilitated group setting to provide medical and psychosocial needs of participants.
2886936|NCT03340428|No Intervention|CAU|Care as usual participants will be referred to routine clinic HIV care on release from corrections.
2886937|NCT03340415|No Intervention|Control Rehab|Follow existing rehabilitation protocol of Non-weight bearing walking for 6 weeks followed by heel walking for 6 weeks; then the resumption of normal full weight-bearing walking in normal shoes at 12 weeks post-operation
2886938|NCT03340415|Experimental|Accelerated Rehab|Accelerated rehabilitation protocol of non-weight bearing walking for 2 weeks followed by heel walking for 10 weeks; then the resumption of normal full weight-bearing walking in normal shoes at 12 weeks post-operation
2886939|NCT03340402|Experimental|Accelerated Partial Breast Irradiation|"Accelerated partial breast irradiation using proton beam scanning will consist of;~5 daily treatments using custom prone patient immobilization, contrast-enhanced CT planning, and daily image guidance~Radiation therapy may be delivered with photons if proton treatments cannot be delivered~Dose will be prescribed such that the gross tumor (GTV) receives the prescription dose per institutional policy and standard of care~Daily target localization will also be confirmed using AlignRTTM"
2886940|NCT03340389|Experimental|cataract surgery|cataract extraction and intraocular implantation
2886941|NCT03340376|Experimental|atezolizumab monotherapy|A fixed dose of 1200 mg atezolizumab will be administered intravenously on Day 1 of each 21-day cycle until progressive disease
2886942|NCT03340376|Experimental|atezolizumab combined with doxorubicin|A fixed dose of 1200 mg atezolizumab will be administered intravenously on Day 1 of each 21-day cycle. Doxorubicin will be administered on Day 1 of each 21-day cycle at a dose of 75mg/m² for a total of 6 cycles or until progressive disease
2886943|NCT03340376|Active Comparator|doxorubicin monotherapy|Doxorubicin will be administered on Day 1 of each 21-day cycle at a dose of 75mg/m² for a total of 6 cycles or until progressive disease
2886944|NCT03340363|Experimental|environmental change|Shoppers were exposed to modifications to the supermarket environment to encourage selection of low-cost, kid-friendly meals
2886945|NCT03340363|Experimental|environmental change and messaging|Shoppers were exposed to modifications to the supermarket environment and weekly messages via text or email to encourage selection of low-cost, kid-friendly meals
2886946|NCT03340350|Experimental|Minocycline|Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
2886947|NCT03340337|Experimental|Neo-Russian Electrical Stimulation|The subjects will receive Neo-Russian electrical stimulation.
2886948|NCT03340337|Experimental|Aussie Electrical Stimulation|The subjects will receive Aussie electrical stimulation.
2886949|NCT03340337|Experimental|RBS Electrical Stimulation|The subjects will receive RBS electrical stimulation.
2886950|NCT03340337|Experimental|Fatigue Test|The subjects will receive, randomly, a fatigue test with the three types of current.
2886951|NCT03340324|Experimental|One arm open label V-Endo recepients|This is single arm open label trial wherein active drug is V-Endo
2886952|NCT03340311|Other|Pre-Post|"(Phase one): Each participant will receive usual care (four weeks). Four weeks of glucose logs will be collected at patient's provider visits and completeness recorded.~(Phase two): Each participant will receive a BG5 wireless glucose meter with supplies enough for four weeks. Each participant will download the iGluco application to their smartphone. Education will be given on the monitor and iGluco application use. Four weeks of glucose logs will be collected at patient's provider visits and completeness recorded.~At the conclusion of phase 2, the participants will be asked to complete a satisfaction survey about the care received and their preference of monitors."
2886953|NCT03340298|Experimental|grain|25 gram fiber from whole grain products and 10 gram fiber from fruits and vegetables
2886954|NCT03340298|Experimental|fruits and vegetables|25 gram fiber from fruits and vegetables as main supplier and the remaining 10 grams from whole grain sources
2886955|NCT03340298|Experimental|grain-fruits and vegetables|15 gram fiber from whole grain and 15 gram fiber from fruits and vegetables
2886956|NCT03340285|Experimental|AkP06|first two weeks: Placebo + prescribed Diet then 4 weeks AkP06 two tablet/day before meals + Diet
2886957|NCT03340285|Placebo Comparator|Placebo|first two weeks: Placebo + prescribed Diet then 4 weeks Placebo two tablet/day before meals + Diet
2886958|NCT03340259||Newborn infants with enterostomy|Infants with enterostomy after surgery due to congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation
2886959|NCT03340246|Active Comparator|Immediate phlebectomy|Mechanochemical ablation of main trunk and immediate phlebectomy of varicosities
2886960|NCT03340246|Experimental|Delayed treatment|Mechanochemical ablation of main trunk. Evaluation of varicosities at 3 months with sclerotherapy if required
2886961|NCT03340233|Experimental|Group 1|Group 1 includes 25 healthy subjects recruited in Year 1 to undergo cardiac MRI without contrast.
2886962|NCT03340233|Experimental|Group 2|Group 2 includes 25 healthy subjects recruited in Year 2 to undergo cardiac MRI without contrast.
2886963|NCT03340233|Experimental|Group 3|Group 3 includes 33 patients with Heart Failure with Preserved Ejection Fraction (HFpEF) who will undergo cardiac MRI at baseline and at six months to assess diagnostic sensitivity of MRI measurement.
2886964|NCT03340220|Experimental|XPF-008|"Single ascending dose: Single oral dose for each cohort~Multiple ascending dose: 7 days of single oral dose daily for each cohort"
2886965|NCT03340220|Placebo Comparator|Placebo - Microcrystalline cellulose|"Single Ascending Dose: Single oral dose for each cohort~Multiple Ascending Dose: 7 days of single oral dose daily for each cohort"
2886966|NCT03340207|Experimental|Pneumaglide|After induction of anesthesia Pneumaglide device will be placed in the mouth of the pneumaglide assigned patients.
2886967|NCT03340207|No Intervention|non-pneumaglide|The patients in non-pneumaglide will not have Pneumaglide insertion prior to intubation.
2886968|NCT03340194||Systemic sclerosis patients|
2886969|NCT03340181|Experimental|RIPC|4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb.
2886970|NCT03340181|Sham Comparator|control|patient in control group using a blood pressure cuff on an upper limb without inflating
2886995|NCT03339999|Experimental|AGN-242428 Medium Dose|AGN-242428, oral administration, once-daily for 16 weeks
2886996|NCT03339999|Experimental|AGN-242428 Higher Dose|AGN-242428, oral administration, once-daily for 16 weeks
2886997|NCT03339999|Placebo Comparator|Placebo|Placebo, oral administration, once-daily for 16 weeks
2886971|NCT03340168|Experimental|Bisphenol-S kinetics - oral exposure|Six female volunteers will be exposed orally acute at the reference dose level(0.1 mg / kg bw). For the administration, the product will be dissolved in ethanol (100 mg / ml equivalent to 10 mg / 100 μl) and the solution will be deposited on a cookie (deposit of about 70 μl of solution on a cookie for an individual of 70 kg) and the ethanol is allowed to evaporate before giving each volunteer, with the subsequent consumption of 100 ml of water.
2886972|NCT03340168|Experimental|Bisphenol-S kinetics - dermal exposure|volunteers will be exposed dermally acute at a dose of 1 mg / kg bw. The solution will be applied to an area of 40 cm2 of the forearm and delimited by the indelible marker. The BPS will be added in suspension in an aqueous solution containing 1% of carboxymethylcellulose and administered in the form of drops (70 .mu.l for an individual of 70 kg). The treated area will be left uncoated and unwashed for a period of 4 hours. After 4 hours, the application area will be washed with water and soap. This type of application is therefore similar to an exposure of the general population via the skin (manipulation of cash receipts).
2886973|NCT03340142|Experimental|Single Arm|All patients will undergo standard of care ablation procedures. VIVO™ results will be compared to that of standard of care results, but will not be used in diagnosis or treatment.
2886974|NCT03340129|Other|Nivolumab and Ipilimumab|"Induction: Intravenous nivolumab 1mg/kg every 3 weeks for 4 doses with intravenous ipilimumab 3mg/kg every 3 weeks for 4 doses.~Maintenance: From week 12, nivolumab 240mg every 2 weeks. After week 52, optional change to nivolumab 480 mg every 4 weeks."
2886975|NCT03340129|Active Comparator|Immunotherapy + SRS|Stereotactic radiotherapy 16 to 22 Gray in 1 fraction.
2886976|NCT03340129|Active Comparator|Immunotherapy + WBRT|Whole brain radiotherapy at 30 Gray over 10 fractions.
2886977|NCT03340116||Pre-operative cohort|This cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 prior to any surgical intervention
2886978|NCT03340116||Post-operative cohort|This cohort will consist of the same study participants in the pre-operative cohort. The only difference is that this cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 AFTER burn surgery.
2886979|NCT03340103|Experimental|Experimental group A|Group A (25 newborns) will be treated with LUTEIN ofta 0,5 drops, (1 ml per Kg equal to 0,5 mg of lutein and 0,05 of zeaxantin) additionaly to the standard hospital treatment foreseen. The first dose will be given within 36 hours of life, the least to 30th day of life.
2886980|NCT03340103|Placebo Comparator|Control group B|Group B (25 newborns) treated with Placebo solution additionaly to the standard hospital treatment foreseen. The first dose will be given within 36 hours of life, the least to 30th day of life.
2886981|NCT03340090|Experimental|Intervention|First group of patients will undergo standard CABG procedure in CPB. In addition, two pieces of Hemopatch will be applied in one patient. One piece to improve hemostasis in the bed of left internal mammary artery (LIMA) harvesting and second piece of Hemopatch will be placed beneath the sternum.
2886982|NCT03340090|No Intervention|Control|Second group of patients will undergo standard CABG procedure in CPB only.
2886983|NCT03340077|Experimental|MOR Toolkit|Medicines Optimisation Review consultation + My clinical companion (patient questionnaire about their medications)
2886984|NCT03340077|Active Comparator|Standard of Care|Current standard of care for patients with HIV receiving antiretroviral therapy, which consists of a phamacists review of ART prescriptions.
2886985|NCT03340064|Experimental|Levetiracetam|"Subjects aged 1 month to <6 months will be started on LEV 14mg/kg/day at Visit 3. The dose may be increased by LEV 14mg/kg/day for subjects aged 1 month to <6 months at 2-week intervals to a maximum dose of 42mg/kg/day. Subjects aged 6 months to <4 years will be started on LEV 20mg/kg/day at Visit 3. The dose may be increased by LEV 20mg/kg/day at 2-week intervals to a maximum dose of 60mg/kg/day.~At Visit 6, subjects may enter the Second Period or enter the Down-Titration Period followed by a Safety Follow-Up Period. Subjects who do not enter the Second Period will be down-titrated. The dose will be decreased by LEV 14mg/kg/day for subjects aged 1 month to <6 months or by LEV 20mg/kg/day for subjects aged 6 months to <4 years at 2-week intervals to 0mg/kg/day."
2886986|NCT03340051|Active Comparator|EFT group|Episodic Future Thinking (EFT) is the intervention in this arm. EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.
2886987|NCT03340051|Placebo Comparator|ERT group|Episodic Recent Thinking (ERT) is the intervention in this arm. ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
2886988|NCT03340038|Active Comparator|Specialty Ward|Patients who have been randomized into receiving post-operative care at the Non-ICU Specialty ward (intervention) after receiving flap reconstructive surgery on their mucosal or cutaneous defect.
2886989|NCT03340038|No Intervention|Intensive Care Unit (ICU)|Patients who have been randomized into receiving post-operative care at the intensive care unit after receiving flap reconstructive surgery on their mucosal or cutaneous defect.
2886990|NCT03340025|Experimental|negative pressure wound therapy|PICO Single Use Negative Pressure Wound Therapy System
2886991|NCT03340025|Placebo Comparator|conventional dressing|traditional surgical wound dressing of xeroform gauze and padding
2886992|NCT03340012|Experimental|GTR + radiation-sterilize allogenic bone graft (TEST)|The surgical procedure will be performed in line with minimally invasive surgical technique by Cortellini and Tonetti (2007). The intrabony defects will be debrided and the roots will be planned. The required quantity of radiation-sterilized allogenic bone graft will be delivered into intrabony defects. Subsequently, a trimmed collagen membrane will be placed over graft. The flaps will be sutured with non-absorbable modified internal mattress sutures.
2886993|NCT03340012|Active Comparator|GTR + xenogenic graft (CONTROL)|The surgical procedure will be performed in line with minimally invasive surgical technique by Cortellini and Tonetti (2007). The intrabony defects will be debrided and the roots will be planned. The required quantity of xenogenic graft will be delivered into intrabony defects. Subsequently, a trimmed collagen membrane will be placed over graft. The flaps will be sutured with non-absorbable modified internal mattress sutures.
2886994|NCT03339999|Experimental|AGN-242428 Lower Dose|AGN-242428 and placebo, oral administration, once-daily for 16 weeks
2886998|NCT03339986|Experimental|Reduction|Participants will be instructed to reduce all high energy dense snacks that they serve to thier children by 50%
2886999|NCT03339986|Experimental|Replacement|Participants will be instructed to replace all high energy dense snacks with fresh fruit and vegetables
2887000|NCT03339973|Experimental|allo-APZ2-PAOD|20-30 intramuscular injections, single dose of allo-APZ2-PAOD, 150 - 225 x 10^6 cells per patient (depending on length of lower leg)
2887001|NCT03339973|Placebo Comparator|Placebo|20-30 intramuscular injections, vehicle solution (depending on length of lower leg)
2887002|NCT03339960|Active Comparator|Robotic camera controlled|
2887003|NCT03339960|Active Comparator|Human camera controlled|
2887004|NCT03339947||Travel medicine|All adult travellers who attended the consultation for travel medicine and international vaccination in Reims University Hospital.
2887005|NCT03339934|Active Comparator|Arm 1: Conventional Hypofractionation|40 Gy (RBE) / Gy in 15 daily fractions with optional 10 Gy (RBE) / Gy in 4 fractions sequential boost to a total dose of 50 Gy in 19 fractions; or a concomitant boost to total dose of 48Gy in 15 daily fractions.(n=41)
2887006|NCT03339934|Experimental|Arm 2: 5 Fraction Hypofractionation|25 Gy (RBE) / Gy in 5 daily fractions with optional concurrent boost to a total dose of 30 Gy (RBE) / Gy in 5 fractions (n=41)
2887007|NCT03339921|Experimental|Botulinum toxin injections|Botulinum toxin injections for chronic compartment syndrome
2887008|NCT03339921|Active Comparator|surgical fasciotomy|surgical fasciotomy for chronic compartment syndrome
2887009|NCT03339908|Experimental|patients with Multiple Sclerosis|Patients will benefit from unilateral thalamotomy by Gamma Knife radiosurgery
2887010|NCT03339895|Experimental|pvı-guided|pvı-guided(according to pvi value) fluid infused during whole procedure 2 ml/kg/h infusion during surgery
2887011|NCT03339895|Experimental|traditional-guided|4-8 ml/kg/h infusion during surgery
2887012|NCT03339882|Experimental|Remifemin intervention|Using Remifemin during LHRH-a treatment in breast cancer
2887013|NCT03339882|No Intervention|Control|No intervention during LHRH-a treatment in breast cancer
2887014|NCT03339869|Experimental|blood sample group|Adult patient hospitalized in intensive care unit and treated for infection.
2887015|NCT03339856|Experimental|Treatment arm|Patients received selective retina therapy
2887016|NCT03339843|Experimental|Abemaciclib|"This study contains 2 stages; during the 1st stage, a maximum of 17 patients will be enrolled in each tumour type cohort. After 13 evaluable patients have been enrolled, an interim analysis will be performed. If 3 or more patients are seen to have experienced a treatment success, then the cohort will pass into the 2nd stage in which a maximum of 20 more patients are enrolled. If 2 or less patients are seen to have experienced a treatment success, then that cohort will be closed and will not proceed into the 2nd stage.~Subjects will receive 200 mg of abemaciclib orally, twice a day, during cycles of 28 days each. The subject will undergo: A baseline FDG-PET/CT and a baseline CT scan and A blinded early FDG-PET/CT at D14 +/- 2 days of study treatment.~A treatment success is defined as a patient who has metabolic response according to PERCIST with a response cut off set at 15% at the early FDG-PET/CT and a morphological disease control after 2 cycles measured by RECIST v1.1."
2887017|NCT03339817|Other|Patients with severe MS|polysomnography and functional pulmonary testings.
2887018|NCT03339804|Experimental|Chemotherapy|Infusion of doxorubicin and cyclophosphamide
2887019|NCT03339791|Active Comparator|Sleeve|Morbid obese patients, 65 years old or more, submitted to Sleeve Gastrectomy
2887020|NCT03339791|Active Comparator|Bypass|Morbid obese patients, 65 years old or more, submitted to Gastric Bypass
2887021|NCT03339765|Experimental|Serious game intervention|Participants randomized to the intervention will receive the Strong Together serious game program on a tablet computer. The goal of this serious game is to teach the participant how to advocate for her needs relate to her cancer and treatment. The research team will send participants weekly notifications for 12 weeks to alert them that a new serious game session is available and encourage them to complete one session per week.
2887022|NCT03339765|No Intervention|Enhanced care as usual|If randomized to the enhanced care as usual arm, the research team will give participants a paper-based self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.
2887023|NCT03339752|Active Comparator|Treatment A|Rosuvastatin Day 1
2887024|NCT03339752|Experimental|Treatment B1|ACT-541468 Day 5 to Day 7
2887025|NCT03339752|Other|Treatment B2|Rosuvastatin Day 8; ACT-541468 Day 8 to Day 12
2887026|NCT03339739|Experimental|Isometric exercise Group|Group of participants which perform Isometric mandibular exercises, once a day, for 21 days
2887027|NCT03339739|Active Comparator|Isotonic exercise Group|Group of participants which perform Isotonic mandibular exercises, once a day, for 21 days
2887028|NCT03339739|Placebo Comparator|Counseling Group|Group of participants which receive education brochure and no further interventions.
2887029|NCT03339726|Experimental|New Formulation Phenylephrine HCl|
2887030|NCT03339726|Active Comparator|Marketed Phenylephrine HCl|
2887031|NCT03339726|Placebo Comparator|Placebo|
2887032|NCT03339713|Experimental|Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1|Participants will receive intramuscular injection of 1*10^11 viral particles (vp) of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on 1 arm administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on the other arm at Day 1, and intramuscular injection of placebo on Day 29.
2887033|NCT03339713|Experimental|Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2|Participants will receive intramuscular injection of placebo administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on Day 1, and 1*10^11 vp of Ad26.RSV.preF on Day 29.
2887034|NCT03339700|Experimental|Unique|Patients will receive reduced BUCY 2 conditioning regimen, consisting in the administration of two medications: Busulfan and Cyclophosphamide Plus: Gemcitabine. Then they will undergo an Allogeneic Hematopoietic Stem Cell Transplantation.
2887035|NCT03339687|Experimental|Induction of Open Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce a Deliberative Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
2887036|NCT03339687|Experimental|Induction of a Closed Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce an Implemental Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
2887037|NCT03339674|Experimental|Intervention|Psychoeducational Group Intervention on Alcohol Drinking Related to Stress: Psychological group intervention with 3 sessions of 60 min (Odenwald & Semrau, 2012). Contains psychoeducation on alcohol drinking related to stress and PTSD.
2887038|NCT03339674|Active Comparator|Control|Cognitive Training: Psychological group intervention with 3 sessions of 60 min. The content is paper-and-pencil based cognitive training of memory and attention functions.
2887039|NCT03339661|Experimental|Group 1_ No proph treatment|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated will depend on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if γδ T cell expansion occurs, no secondary prophylaxis treatment will be introduce, and curative treatment stops.
2887040|NCT03339661|Experimental|Group 2A_Proph treatment and γδ T cells expansion|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated depends on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if no γδ T cell expansion will occur, a secondary prophylaxis will be initiated during 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
2887041|NCT03339661|Experimental|Group 2B_Proph treatment and no γδ T cells expansion|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated depends on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if no γδ T cell expansion will occur, a secondary prophylaxis will be initiated during 3 months maximum. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
2887042|NCT03339648|Experimental|Professional Development Enhancement|"During the measurement period, this group will receive the intervention, described below:~Content using three of UF Lastinger Center's innovations for cost-effective teaching and learning - e-Content Clinics, Coaching, and Communities of Practice. Elements of the professional development model are as follows:~E-Content Clinics- Content Clinics are offered online using digital video technology.~Coaching- Coaching develops strong cadres of leaders that have profound expertise and substantial success in advancing teaching and learning outcomes. This approach uses existing personnel to reinforce and deepen learning through online professional development by embedding it in day-to-day activities.~Online Community of Practice- This scalable online platform allows users to create virtual communities of practice designed to strengthen the learning and collaboration network."
2887043|NCT03339648|Active Comparator|Control- Delayed Intervention|This arm will continue business as usual during the measurement period. They will receive the exact same intervention described above once data collection is complete.
2887044|NCT03339635|Experimental|Testosterone gel|Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
2887045|NCT03339635|Placebo Comparator|Placebo gel|Patients will be randomized to treatment with placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
2887046|NCT03339622|Experimental|smoked cannabis (PPP001)|280 mg dried cannabis pellet -(9% THC / 2% CBD per pellet)
2887047|NCT03339622|Placebo Comparator|THC free placebo|280 mg dried extracted cannabis pellet (0% THC / 0.6% CBD per pellet)
2887048|NCT03339609||Immediate uroflow/EMG testing|Participants performed two direct repetitions of uroflowmetry in combination with EMG.
2887049|NCT03339609||uroflow measurement beforehand|Participants performed a preceding measurement of isolated uroflowmetry, followed by two randomized measurements of either isolated uroflowmetry or uroflowmetry with EMG.
2887050|NCT03339596|Experimental|Erythropoietin|4 intravenous infusions of recombinant human erythropoietin (EPO)
2887051|NCT03339596|Placebo Comparator|Saline|4 intravenous infusions of saline (1 ml NaCl)
2887052|NCT03339583|Experimental|zopiclone first group|underwent the medication therapy (zopiclone) for the first two weeks followed by brief behavioral therapy
2887053|NCT03339583|Experimental|BBT-I first group|received two-week brief behavioral therapy followed by medication therapy (zopiclone).
2887054|NCT03339557|Active Comparator|PFC Total Knee Replacement|PFC, Conventional design Perioperative treatment will be carried out according to routine protocol of the hospital.
2887055|NCT03339557|Active Comparator|NexGen Total Knee Replacement|NexGen, Conventional design Perioperative treatment will be carried out according to routine protocol of the hospital.
2887056|NCT03339557|Active Comparator|Persona Total Knee Replacement|Persona, Novel design Perioperative treatment will be carried out according to routine protocol of the hospital.
2887057|NCT03339544|Experimental|Celebrex premedication|Celebrex is a NSAID with selective COX-2 inhibition properties, is given as an intervention to assess the pain
2887058|NCT03339544|Placebo Comparator|Placebo tablets|placebo tablets to compare the efficacy of Celebrex on the intra-operative and post-operative pain accompanying endodontic treatment of teeth with irreversible pulpits
2887059|NCT03339531|Experimental|2D radiotherapy|Patients with prostate cancer were treated with 2D-radiotherapy
2887060|NCT03339518|Experimental|BRIM3 Educational intervention|Individuals will receive a booklet and counseling about risk.
2887061|NCT03339518|Other|Wait list Control|At the completion of the study, individuals in the wait list condition will receive a booklet.
2887062|NCT03339505|Active Comparator|Treatment group|Patients in treatment group will receive Salovum according to g/kg body weight/24 hours/divided into 6 doses, during a maximum of 5 days
2887063|NCT03339505|Placebo Comparator|Placebo group|Patients in treatment group will receive Placebo (egg yolk powder) according to g/kg body weight/24 hours/divided into 6 doses, during a maximum of 5 days
2887064|NCT03339492|Active Comparator|Active PEMF|Subjects have 2 out of 3 chance to get the active device which emits a pulsed electromagnetic field (PEMF) from the RCStim Model 1114 device (right and left side models available). Double-blind randomization.
2887065|NCT03339492|Sham Comparator|Control/placebo PEMF|Subjects have a 1 out of 3 chance to get the control/placebo device which does not emit a pulsed electromagnetic field (PEMF) from the RCStim Model 1114 device (right and left side models available). Double-blind randomization.
2887066|NCT03339479|Experimental|dielectric property test|The patient with lung nodules/mass is firstly arranged to be tested for dielectric property after the nodules/mass resection and cutting open.
2887067|NCT03339479|Placebo Comparator|frozen pathological examination|The resected lung nodules/mass will be sent for frozen pathological examination after dielectric property test.
2887068|NCT03339479|Other|final pathological examination|The resected lung nodules/mass will undergo the final pathological examination for final diagnosis after dielectric property test and frozen pathological examination.
2887069|NCT03339453|Experimental|Glucagon Nasal Powder|Single dose of glucagon nasal powder
2887070|NCT03339453|Active Comparator|Glucagon Hydrochloride Solution|Single IM dose of glucagon hydrochloride solution
2887071|NCT03339440|Experimental|Intervention Group|Patients in this group will be receiving the Hearts and Parks intervention.
2887072|NCT03339440|No Intervention|Control Group|Patients in this group will continue receiving standard of care.
2887073|NCT03339427|Active Comparator|vitamin D,capsule|A total of 150 subjects were recruited in the vitamin D supplementation group.
2887074|NCT03339427|Other|control|A total of 150 subjects were recruited in the control group.
2887075|NCT03339401|Experimental|Brincidofovir (BCV)|BCV
2887076|NCT03339401|Other|Standard of Care (SOC)|SOC
2887077|NCT03339375||control|Monitoring arterial pressure, central venous pressure and pulse pressure variation
2887078|NCT03339375||esophagela Doppler|Monitoring arterial pressure, central venous pressure Insertion of esophageal Doppler probe to patient Monitoring stroke volume, cardiac output, corrected flow time from esophageal Doppler Use stroke volume optimization goal directed therapy protocol
2887079|NCT03339362|Active Comparator|Active Procedure|"All patients will receive 6 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 1% Lidocaine. This a test procedure to identify the patient has a 50% pain reduction from baseline pain numerical score. If patients pass this test injection, they will be randomised to the active or sham procedure.~4 X-ray guided intra-articular facet-joint injections via a spinal needle at 2 bilateral lumbar levels, using 0.5ml 0.5% bupivacaine + 20mg methylprednisolone per joint"
2887080|NCT03339362|Sham Comparator|Sham procedure|"All patients will receive 6 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 1% Lidocaine. This a test procedure to identify the patient has a 50% pain reduction from baseline pain numerical score. If patients pass this test injection, they will be randomised to the active or sham procedure.~4 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml normal saline per injection"
2887081|NCT03339349|Experimental|Enoxaparin Metabolism|Eligible patients will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.2-0.4 IU/mL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
2887082|NCT03339336|Experimental|BIIB074 350 mg|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 350 mg tablets orally BID Double-Blind Treatment Period.
2887083|NCT03339336|Experimental|BIIB074 200 mg|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 200 mg tablets orally BID Double-Blind Treatment Period.
2887084|NCT03339336|Placebo Comparator|Placebo|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 placebo-matching tablets orally BID Double-Blind Treatment Period.
2887085|NCT03339323|No Intervention|Control|Standard rehabilitation procedure
2887086|NCT03339323|Experimental|Exercise|Aerobic exercise combined with resistance training; Concentric resistance training; Eccentric resistance training
2887087|NCT03339310|Experimental|Optimizer Smart System with 2-leads|All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
2887088|NCT03339297|Experimental|Defibrotide Prophylaxis|Standard of Care Immunoprophylaxis + Defibrotide
2887089|NCT03339297|Active Comparator|Standard of Care|Standard of Care Immunoprophylaxis Alone
2887090|NCT03339284|Active Comparator|QLB with dexamethasone|Single sided US-guided QLB using ropivacaine 3,75 mg/ml 20 ml and dexamethasone 5 mg/ml 0,4 ml
2887091|NCT03339284|Active Comparator|QLB without dexamethasone|Single sided US-guided QLB using ropivacaine 3,75 mg/ml 20 ml and isotonic natriumchloride solution (NaCl 0,9%) 0,4 ml
2887092|NCT03339284|Placebo Comparator|Placebo|Single sided US-guided QLB using isotonic natriumchloride solution (NaCl 0,9%) 20,4 ml
2887093|NCT03339271|Active Comparator|Technology-Enhanced Group|Family caregivers will have daily visits from the study nurse while the patient is in the hospital and will receive weekly technology-enhanced support (video chats) from the study nurse for 8 weeks after the patient is discharged from the hospital.
2887094|NCT03339271|Active Comparator|Usual Care Group|Family caregivers will have usual care support from the doctors and nurses to plan for taking care of the patient upon return home and will receive a weekly telephone call for 8 weeks after the patient is discharged from the hospital.
2887095|NCT03339258|Experimental|Doxazosin Mesylate, Extended Release|Subjects will undergo a 4-week titration phase during which doxazosin may be increased to a maximum dose of 16mg at bedtime based on symptoms and tolerability. After the 4-week titration phase, subjects will continue at stable dose of study medication for a 4-week stable dose phase.
2887096|NCT03339258|Placebo Comparator|Placebo|Subjects will undergo a 4-week titration phase during which the placebo may be increased to a maximum dose of 16mg at bedtime based on symptoms and tolerability. After the 4-week titration phase, subjects will continue at stable dose of study placebo for a 4-week stable dose phase.
2887097|NCT03339245|Experimental|Glucose, Then Fructose|Participants first receive Glucose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Fructose Solution (75 Grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.
2887117|NCT03339089||Participants with Rheumatoid Arthritis (RA)|This group/ cohort includes participants with RA.
2927792|NCT03056014|Active Comparator|PUFA 2000 mg|
2887098|NCT03339245|Experimental|Fructose, Then Glucose|Participants first receive Fructose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Glucose Solution (75 grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.
2887099|NCT03339232|No Intervention|Usual Care|Participants will receive standardized information about a healthy diet, including the potential benefit of small, frequent meals and nighttime snacking . In addition, the treating hepatologist will counsel participants on the benefits of increased physical activity. These recommendations will be provided at the beginning of the study. The usual care arm reflects current clinical practice. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity.
2887100|NCT03339232|Other|BCAA Supplement|BCAA powder (Bulk Supplements®) will be provided as the powder was found to be easier to swallow. Each teaspoon contains 1788 mg of BCAA and participants will take 7 teaspoons (12.5 grams of BCAA) per day divided into three separate servings. Each teaspoon contains L-leucine, isoleucine and valine in a 2:1:1 ratio. BCAA will be provided by the study investigators and half will be provided at baseline study visit and the second half at the week 6 visit. In addition, the treating hepatologist will provide standardized information about the potential benefits of small, frequent meals, nighttime snacking and increased physical activity at the beginning of the study. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity.
2887101|NCT03339232|Other|BCAA supplement plus supervised physical activity|BCAA supplement will be as described for group 2, above. Study coordinators will supervise the physical activity program for study participants at the Loyola Fitness Center. Participants will attend the fitness center one hour each week; the fitness session will consist of low-impact aerobic physical activity, beginning with walking on the indoor track and possibly building to a recumbent exercise bicycle and light resistance training. Participants will be given a list of exercises to perform at home at least two times during the week with a goal of >90 minutes of physical activity per week. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity which they will return during the weekly fitness center sessions. In addition, the treating hepatologist will provide standardized information about the potential benefits of small, frequent meals, nighttime snacking and increased physical activity at the beginning of the study.
2887102|NCT03339219|Experimental|Cabozantinib|Cabozantinib 60 mg, tablet, orally, once daily in the fasted state.
2887103|NCT03339206|Experimental|Constituent message with FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
2887104|NCT03339206|Experimental|Constituent message without FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
2887105|NCT03339206|Other|Littering message (Control)|Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
2887106|NCT03339193||Patients having LAAC|Patients who meet current clinical criteria for left atrial appendage closure (LAAC), ie have atrial fibrillation, a CHA2DS2-VASc score of 3 or more and a contraindication to long-term oral anticoagulation therapy and who have been approved by the OUH NHS Foundation Trust LAAC Multidisciplinary Team (MDT) as suitable for left atrial appendage occlusion in accordance with National Health Service (NHS) guidelines.
2887107|NCT03339167|Experimental|metabolic availability of lysine in millet|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or cooked millet with or without lentils, which will all be provided by the investigators."
2887108|NCT03339154|Experimental|Methionine bioavailability in chickpeas|"Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods).~You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or chickpeas with or without rice, which will be provided by the investigators"
2887109|NCT03339141|Placebo Comparator|supine position|Patients are placed in the supine position at 0° from arrival in the room until intubation
2887110|NCT03339141|Active Comparator|25° head-up position|Patients are placed in the 25° head-up position (half-seat or whole body proclive) from arrival in the room until intubation.
2887111|NCT03339128|Experimental|Eluxadoline 25mg|Eluxadoline 25mg, oral administration, twice daily
2887112|NCT03339128|Experimental|Eluxadoline 50mg|Eluxadoline 50mg, oral administration, twice daily
2887113|NCT03339128|Experimental|Eluxadoline 100mg|Eluxadoline 100mg, oral administration, twice daily
2887114|NCT03339128|Experimental|Placebo|Dose-matched placebo, oral administration, twice daily
2887115|NCT03339115|Experimental|Cardiovalve Transfemoral Mitral Valve|Replacement valve delivered through a transfemoral access and transseptal approach
2887116|NCT03339102||Participants who received Humira®|Non-infectious intermediate, posterior, or panuveitis patients who received Humira®
2927793|NCT03056014|Placebo Comparator|Placebo|
2887118|NCT03339089||Participants with Plaque Psoriasis (Ps)|This group/ cohort includes participants with Ps.
2887119|NCT03339089||Participants with Ankylosing spondylitis (AS)|This group/ cohort includes participants with AS.
2887120|NCT03339076|Other|For a single-arm trial|"Inclusion Criteria with intervention replacing either a foley catheter or self intermittent catheter with the M3 Mini Catheter~Males > 50 years of age~Signed subject informed consent~Patients with actual urinary retention dependent on Foley Catheter or Intermittent Catheter~Inclusion will start once the M3 is placed and a functioning bladder is demonstrated.~Exclusion Criteria~Inability to undergo bladder catheterization with the M3 due to anatomical challenges (i.e. urethral stricture, bladder neck contracture, false passage or false passages or other history of urethral stricture)~Gross hematuria~Hypotonic Neurogenic Bladder (the placement of the M3 may isolate the cause of the retention with the bridging of the prostate as bladder dysfunction rather than prostate obstruction)."
2887121|NCT03339050|Experimental|Health for Hearts United|Health for Hearts United (HHU) is a 18-month church-based intervention to reduce CVD risk in mid-life and older African Americans.
2887122|NCT03339037|Active Comparator|Hyperbaric oxygen therapy|"60 Hyperbaric oxygen sessions in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). each session 1.5 ATA of 100% oxygen for 1 hour.~1 meter per minute compression and decompression."
2887123|NCT03339037|Sham Comparator|Normobaric air SHAM|"60 sessions in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session at 1 ATA of 21% oxygen (air) for 1 hour.~1 meter per minute compression and decompression. after 3 months, patients will be crossed over and treated with 60 sessions of treatment"
2887124|NCT03339024|Experimental|oxytocin|"intranasal oxytocin spray Day 1-3: Twice daily intranasal oxytocin spray administered by health personnel.~Day 3-30:Self-administered intranasal spray as needed, max thrice daily"
2887125|NCT03339024|Placebo Comparator|Placebo|"intranasal spray without oxytocin Day 1-3: Twice daily intranasal spray without oxytocin, administered by health personnel.~Day 3-30: Self-administered intranasal spray as needed, max thrice daily"
2887126|NCT03339011|Experimental|SMS text message|"The content of the text messages is developed based on recommendation and advice from the Danish Health Authority about the importance of regular daily physical activity.~For 6 weeks, the text messages will be send three times per week, twice during the week days and once in the weekend, based on previous experience with SMS as motivation for chronic pain patients."
2887127|NCT03339011|No Intervention|No intervention|No attention from the study
2887128|NCT03338998|Experimental|BAF312|"Days 1 - 7, IV uptitration; days 8 - 14, final daily dose administered orally"
2887129|NCT03338998|Placebo Comparator|Placebo|Days 1 through 7: i.v. matching placebo Days 8 through 14: p.o. matching placebo QD
2887130|NCT03338985|Experimental|"Group cases patients"|patients with endometrial hyperplasia or endometrial cancers
2887131|NCT03338972|Experimental|Treatment (chemotherapy, BCMA CAR-T cells)|Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes intravenously (IV) over 20-30 minutes on day 0. Patients may receive a second BCMA-specific CAR-expressing T lymphocytes infusion at the highest cell dose or the next highest dose level.
2887132|NCT03338959|Experimental|Treatment (pembrolizumab, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 3 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy daily for 5-6 weeks.
2887133|NCT03338946||CIED subjects|CIED interrogation
2887134|NCT03338933||Control Group|No history of addiction to any substance or gambling. Less than 20 lifetime cigarettes or equivalent.
2887135|NCT03338933||Nicotine Group|Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V) criteria for Nicotine Use Disorder. Current smoker, at least 10 cigarettes per day. No history of addiction to any other substance
2887136|NCT03338933||Nicotine and Alcohol Group|DSM-V criteria for Nicotine Use Disorder and Alcohol Use Disorder. At least 8 heavy drinking episodes in the past month. Current smoker. Alcohol free from 2 to 4 weeks. No history of addiction to other substances or gambling.
2887137|NCT03338933||Alcohol Group|DSM-V criteria for Alcohol use Disorder. At least 8 heavy drinking episodes in the past month. Abstinent for at least 2 weeks and no more than 4 weeks. Less than 20 lifetime cigarettes or equivalent. No history of addiction to any other substances or gambling.
2887138|NCT03338920|Experimental|Sumatriptan nasal powder|Participants will be dosed with 22 milligrams (mg) sumatriptan nasal powder via two nosepieces (11 mg per nosepiece).
2887139|NCT03338920|Placebo Comparator|Placebo|Participants will be dosed with matching placebo via nosepieces containing capsules filled with lactose instead of sumatriptan.
2887140|NCT03338907|Experimental|Oxycarbon (5% CO2 + 95% O2)|Patients will be mechanical ventilated with Oxycarbon (5%CO2 +95% O2) after normocapnia is reached until FeO2 is stable for at least 1 min ≥ 80%. At timepoint 1 immediately prior apnea NIRS and vital parameters will be registered and an bloodsample will be drawn.
2887141|NCT03338907|Placebo Comparator|Control (95% O2)|"Same procedure as arm active comparator"
2887142|NCT03338894|Other|Yoga group|Each subject will serve as their own control
2887143|NCT03338881|Experimental|[14C]-TAK-659 100 mg|[14C]-TAK-659 100 mg, solution, orally, once, in the fasted state on Day 1. Participant will have the option to continue treatment with TAK-659 100 mg, tablets, orally, once daily in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, or the start of another anticancer therapy in post-ADME study period.
2887144|NCT03338868||Patients with MetS|To be a volunteer patient with a chronic non-specific musculoskeletal pain disorder, including knee osteoarthritis, rotator cuff tear, adhesive capsulitis, and non-specific low back, back or neck pain for more than 6 months.
2887145|NCT03338868||Patients without MetS|To be a volunteer patient with a chronic non-specific musculoskeletal pain disorder, including knee osteoarthritis, rotator cuff tear, adhesive capsulitis, and non-specific low back, back or neck pain for more than 6 months.
2887146|NCT03338855|Active Comparator|Dapagliflozin|"Patients will receive dapagliflozin 10 mg in tablet for a maximum of 40 days based on randomization sequence in Period 1.~Patients that received 10 mg dapagliflozin in the first treatment period will receive matching placebo in the second treatment period for a maximum of 40 days."
2887220|NCT03338361|Sham Comparator|AAT sham - VPT sham|Approach avoidance training sham condition and visual probe training sham condition
2887147|NCT03338855|Placebo Comparator|Placebo matching to dapagliflozin|"Patients will receive matching placebo in tablet for a maximum of 40 days based on randomization sequence.~Patients who received placebo in the first treatment will receive 10 mg dapagliflozin in the second treatment period, for a maximum of 40 days"
2887148|NCT03338842|Experimental|Distractor and Lower limb VR|The training sessions consist of Phase 1 (Distractor VR) in which patients will explore VR environments and Phase 2 (Lower limb VR) in which they will play games using their VR lower-limbs.
2887149|NCT03338829|No Intervention|Control|The control arm will received compensation at time of enrollment for agreeing to participate.
2887150|NCT03338829|Experimental|Positive Incentive|The positive incentive arm will receive compensation per prescribed test, payable every month based on testing adherence.
2887151|NCT03338829|Experimental|Loss Aversion|"The loss aversion arm will have compensation deposited into a University of Iowa Women's Health account. The participant will then lose compensation depending on actual adherence to recommended testing"
2887152|NCT03338816|Experimental|Givosiran|
2887153|NCT03338816|Placebo Comparator|Placebo|Normal Saline (0.9% NaCl)
2887154|NCT03338803||Patients with a written prescription for linagliptin|
2887155|NCT03338790|Experimental|Arm A|Nivolumab in combination with Rucaparib
2887156|NCT03338790|Experimental|Arm B|Nivolumab in combination with Docetaxel
2887157|NCT03338790|Experimental|Arm C|Nivolumab in combination with Enzalutamide
2887158|NCT03338777|Experimental|Suicide plus immunogene therapy|Intra and peritumoral infiltrates with multiple injections of lipoplexes carrying the HSVtk suicide gene co-administered with GCV and subcutaneous vaccine produced with formolized allogeneic tumor extracts and lipoplexes carrying hIL-2 and hGM-CSF genes.
2887159|NCT03338764|Experimental|Experimental (SM-1)|Drug: SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
2887160|NCT03338764|Placebo Comparator|Placebo|Drug: Placebo Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials.
2887161|NCT03338751|Active Comparator|Hearing Assistance Device (HAD) First|Tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second. Participants randomized to HAD first will use a Hearing Aid Device.
2887162|NCT03338751|Active Comparator|No Hearing Assistance Device (HAD) First|Sham hearing aid device
2887163|NCT03338738|Experimental|Patients with ESBL, antibiotic pressure|Patients with ESBL, antibiotic pressure will be included. On the day of inclusion, a stool culture is performed on the first stool issued after the start of antibiotic therapy in order to evaluate the initial flora and the relative initial faecal abundance of multidrug-resistant bacteria. In the absence of stool emission by the patient, a rectal swab will be performed. 72 hours after initiation of antibiotic therapy, a blood sample (5 ml) will be taken to determine plasma concentrations of antibiotics. In addition, a stool sample will be taken at 72 hours after the start of antibiotic therapy, at the end of antibiotic therapy and 60 days after this end to evaluate the change in initial flora and relative faecal abundance of ESBL-producing enterobacteria.
2887164|NCT03338725|Active Comparator|Patients without intervention|Patients without follow-up by clinical pharmacy model
2887165|NCT03338725|Experimental|Patients with intervention|Patients who are being monitored by a clinical pharmacy model
2887166|NCT03338699|Experimental|ShangRing|Topical anesthesia based, no-flip ShangRing circumcision.
2887167|NCT03338699|Active Comparator|Mogen clamp|Mogen clamp circumcision.
2887168|NCT03338686|Active Comparator|Free Gingival Graft|Free Gingival Graft (FGG)
2887169|NCT03338686|Experimental|Connective Tissue Graft followed by Laser Gingivoplasty|Connective Tissue Graft (CTG) followed by Laser Gingivoplasty
2887170|NCT03338673|Experimental|Dual Therapy First|Participants receive 10 sessions of non-invasive brain stimulation (tDCS) plus 10 hours of computerized cognitive exercises (BrainHQ), followed by 10 hours of computerized cognitive exercises alone
2887171|NCT03338673|Experimental|Mono Therapy First|Participants complete 10 hours of computerized cognitive exercises (BrainHQ) alone, followed by 10 sessions of non-invasive brain stimulation (tDCS) plus 10 hours of computerized cognitive exercises
2887172|NCT03338660|Placebo Comparator|Control (Placebo)|Subjects will receive infusion of placebo (saline).
2887173|NCT03338660|Active Comparator|Platelet storage routine|Subjects will receive infusion of platelets stored by routine method.
2887174|NCT03338660|Experimental|Platelet storage experimental|Subjects will receive infusion of platelets stored by a novel methodology.
2887175|NCT03338647|Active Comparator|TACE|Transarterial chemoembolization with drug eluted beads or doxorubicin/lipoidol
2887176|NCT03338647|Experimental|SBRT|Stereotactic radiation therapy with risk adapted dose prescription
2887177|NCT03338634||Children 6 to 10|Children must be between the ages of 6-10 years-old at the time they participate. All children will be physically healthy and without diagnosed learning disorders. A parent or legal guardian must be able to accompany the child.
2887178|NCT03338621|Experimental|Drug Sensitive BPaMZ|Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 9 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 17 weeks (Total treatment duration 4 months
2887179|NCT03338621|Active Comparator|Drug Sensitive Standard Treatment|isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9 to 26
2887180|NCT03338621|Experimental|Drug Resistant BPaMZ|Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 18 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 26 weeks (Total treatment duration 6 months)
2887181|NCT03338608|Experimental|Vertical Platysma Incision|Patients in this arm who have anterior cervical decompression and fusion will receive the vertical platysma incision.
2887182|NCT03338608|Experimental|Transverse Platysma Incision|Patients in this arm who have anterior cervical decompression and fusion will receive the transverse platysma incision.
2887183|NCT03338569|Sham Comparator|Placebo|Placebo designed to mimic intervention
2887184|NCT03338569|Active Comparator|Intervention|Vitamin C
2887185|NCT03338556|Active Comparator|Cohort A - PrEP-001|PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
2887186|NCT03338556|Placebo Comparator|Cohort A - Placebo|Placebo matching PrEP-001, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
2887187|NCT03338556|Active Comparator|Cohort B- PrEP-001|PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 4 and Day - 3 prior to intranasal challenge with HRV-16 (Day 0).
2887188|NCT03338556|Placebo Comparator|Cohort B - Placebo|Placebo matching PrEP-001, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 4 and Day - 3 prior to intranasal challenge with HRV-16 (Day 0).
2887189|NCT03338543|Experimental|percutaneous stimulation|PENS in 2/100 hertz (HZ), 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
2887190|NCT03338543|Experimental|transcutaneous stimulation|TENS in 2/100 HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
2887191|NCT03338543|No Intervention|Control|Conventional analgesic medication is offered.
2887192|NCT03338530|Experimental|Comprehensive School-Based Intervention|Children with HFASD assigned to the CSBI received social skills groups, computer instruction in emotion recognition, therapeutic activities, and a behavioral reinforcement system (individual daily note) during the school year and their parents participated in monthly parent training. School staff received training prior to the school year and demonstrated fidelity with the protocol. Fidelity was also monitored during the school year by research assistants.
2887193|NCT03338530|No Intervention|Business-As-Usual (BAU) Control|Children with HFASD in the BAU schools received their typical special education programming as legally-mandated. The programming received by each was carefully monitored per the following: 1) Each student's IEP was reviewed to document the legally mandated services received; 2) For those receiving counseling or speech-language services, the related-service provider completed a survey indicating specific treatment targets and the protocol for service provision; 3) Parents completed a monthly survey of any external therapeutic programming their child may have received; and 4) Fidelity measures designed for the intervention group (with sequencing requirements removed) were completed for the control condition during two 60-minute classroom observations per week by research assistants.
2887194|NCT03338517|Active Comparator|Study group|Helium Neon Laser
2887195|NCT03338517|No Intervention|Control group|No intervention
2887196|NCT03338504||Suspected type 2 myocardial infarction|The investigators will identify consecutive patients with acute myocardial injury (defined as a rise and or fall in cardiac troponin concentration on serial testing, with at least one value >99th centile) where the likely mechanism of injury is thought to be myocardial oxygen supply and demand imbalance (e.g secondary to hypoxia, hypotension, tachycardia or anaemia). Patients will be identified through screening of cardiac troponin measurements. Patients who meet both the inclusion and exclusion criteria, will be approached and those who provide consent will comprise the study population. All patients will have a Cardiac MRI scan, with invasive coronary angiography or CT coronary angiography dependent on baseline fitness. The investigators will record demographic and clinical information from the electronic patient record for patients who meet inclusion criteria but have one or more exclusion criteria.
2887197|NCT03338491|Experimental|Induction of Implemental Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce an Implemental Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
2887198|NCT03338491|Experimental|Induction of Deliberative Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce a Deliberative Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
2887199|NCT03338491|No Intervention|Control|Participants will revive no induction of any mindset.
2887200|NCT03338478|Experimental|Epilepsy Patients|Patients being tapered off of levetiracetam or lamotrigine monotherapy during epilepsy video monitoring. Patients will receive the Wii Balance Board and computerized reaction time testing.
2887201|NCT03338478|Experimental|Healthy Control Group|Patients without a diagnosis of epilepsy. Control participants will receive the Wii Balance Board and computerized reaction time testing.
2887202|NCT03338465|Active Comparator|Group A|3 weekly sessions of focused extracorporeal shockwave treatment (2.000 impulses at 0.20 millijoules/mm2 per session)
2887203|NCT03338465|Active Comparator|Group B|3 weekly sessions of focused extracorporeal shockwave treatment (2.000 impulses at 0.01 millijoules/mm2 per session)
2887204|NCT03338452|Experimental|participants|The participants will be subjected to low energy ketogenic diet.
2887205|NCT03338439||CSII|CSII: patients with continuous subcutaneous insulin infusion
2887206|NCT03338439||MDI|MDI: patients with multi-daily injections
2887207|NCT03338426|Experimental|Experimental|Co-administration of a fixed dose combination of Fimasartan 120mg and Atorvastatin 40mg
2887208|NCT03338426|Active Comparator|Active Comparator 1|Co-administration of Fimasartan 120mg and Placebo for Atorvastatin 40mg
2887209|NCT03338426|Active Comparator|Active Comparator 2|Co-administration of Atorvastatin 40mg and Placebo for Fimasartan 120mg
2887210|NCT03338413|Experimental|Goal Management Training|
2887211|NCT03338413|Experimental|Computerized Cognitive Training|
2887212|NCT03338400|Active Comparator|Dexamethasone|Patients in the Dexamethasone arm will be administered the drug at the time of induction.
2887213|NCT03338400|Placebo Comparator|Normal Saline|The placebo arm patients will receive normal saline at the time of induction.
2887214|NCT03338387|Experimental|Acipimox|Other Names: Olbetam
2887215|NCT03338387|Placebo Comparator|Placebo|"Other Names:~Placebo (for Olbetam)"
2887216|NCT03338374|Experimental|Biventricular Pacemaker|All subjects to be in a single study group experiencing all interventions.
2887217|NCT03338361|Experimental|AAT active - VPT sham|Approach avoidance training active intervention and visual probe training sham intervention
2887218|NCT03338361|Experimental|VPT active - AAT sham|Visual probe training active condition and approach avoidance training sham condition
2887219|NCT03338361|Experimental|AAT active - VPT active|Approach avoidance training active condition and visual probe training active condition
2887334|NCT03337516|Experimental|Patients treated with Cytarabine|
2887221|NCT03338348|Other|Azacitidine + Vosaroxin|"Cycle 1-8:~Azacitidine: 75 mg/m²/d subcutaneously, d 1-7; Vosaroxin: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .~Patients who have completed 8 cycles of azacitidine and vosaroxin are scheduled to maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression."
2887222|NCT03338322|Experimental|Twisted file adaptive|Files that are used in root canal preparation in adaptive motion
2887223|NCT03338322|Active Comparator|Reciproc|Reciproc files are used in root canal preparation with reciprocation motion
2887224|NCT03338309||iFR-guied strategy group|1,200 patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, non ST-segment elevation MI, or ST-segment elevation MI with non-culprit stenosis who underwent iFR measurement and enrolled at 5 centers in Republic of Korea.
2887225|NCT03338296|Experimental|Lorcaserin hydrochloride XR 20 mg QD|Participants will receive lorcaserin hydrochloride extended release (XR) 20 milligrams (mg) once daily (QD) for up to 52 weeks.
2887226|NCT03338296|Placebo Comparator|Placebo|Participants will receive placebo QD for up to 52 weeks.
2887227|NCT03338283|Experimental|Electromassage|"Electromassage and conservatory treatment. All subjects will be received a conservatory treatment (1h and 40 min) and electro-massage (10min).~The protocol will consist of six sessions, twice a week for three weeks. The duration will be 1 hour and 40 min for the conservatory treatment and 10 min for the electro-massage."
2887228|NCT03338283|Active Comparator|Conservatory Treatment|The control protocol will combine: (a) thermotherapy with infrared application; (b) active, self-assisted and isometric shoulder exercises, including Codman's pendulum exercises; (c) manual therapy, always in a pain-free range of movement; and (d) ultrasound in pulsatile mode over the acromium and scapulohumeral area.
2887229|NCT03338257|Experimental|Husky Reads Intervention|The Husky Reads curriculum includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and sometimes food tasting to complement the learning objectives. Undergraduate students enrolled in the Husky Reads service-learning course at UCONN or college students participating in a paid summer internship deliver the program. Each team of 2-3 students is assigned 2-3 early care classrooms to visit and deliver Husky Reads on a weekly basis.
2887230|NCT03338257|No Intervention|Wait list Control|Programs on the wait list for Husky Reads, participate in the pre and post intervention testing but do not receive the program.
2887231|NCT03338244|Active Comparator|Biannual mass oral azithromycin: 2 years|Continued biannual azithromycin Communities that had received four rounds of biannual mass azithromycin distributions during the MORDOR trial will receive two more rounds of biannual mass azithromycin.
2887232|NCT03338244|Active Comparator|Biannual mass oral azithromycin: 1 year|Newly started biannual azithromycin Communities that had received four rounds of biannual mass placebo distributions during the MORDOR trial will receive two rounds of biannual mass azithromycin.
2887233|NCT03338218|Experimental|Volulyte 6%|Volulyte 6% solution for infusion
2887234|NCT03338218|Active Comparator|Ionolyte|Ionolyte solution for infusion
2887235|NCT03338205|Experimental|Ketamine Treatment|"Everyone enrolled in study presenting in status asthmaticus to pediatric emergency department at Augusta University will receive a ketamine treatment, who include:~Patients with a Clinical Asthma SCore (CAS) of greater than or equal to 10 on presentation and have received at least two (appropriately dosed based on weight) albuterol treatments prior to arrival~OR~Patients with a CAS of ≥ greater than or equal to 10 that have not received treatment prior to arrival and after receiving 1 hour of treatment per the severe asthma pathway do not have a decrease in CAS of greater than 2~OR~Patients with a CAS above > 6 but less than < 10 when as measured 1 hour after initiation of standard treatment per Augusta University's moderate asthma pathway"
2887236|NCT03338192||African American/Black QST|This group will consist of a full range of socioeconomic status in African American/Black individuals with chronic low back pain.
2887237|NCT03338192||Caucasian/White QST|This group will consist of a full range of socioeconomic status in Caucasian/White individuals with chronic low back pain.
2887238|NCT03338179|Experimental|Adult Patients|Schizophrenia patients aged between 18 and 45 years old
2887239|NCT03338179|Experimental|Aged Patients|Schizophrenia patients aged 59.5 years and above
2887240|NCT03338179|Active Comparator|Adult Controls|Controls aged between 18 and 45 years old
2887241|NCT03338179|Active Comparator|Aged Controls|Controls aged 59.5 years and above
2887242|NCT03338166||Group A|Patients with Hepatocellular carcinoma who treated with sorafenib and measure LDH serum level one month pre and post treatment
2887243|NCT03338166||Group B|Patients with Hepatocellular carcinoma who treated with trans catheter arterial chemo embolization (TACE) and measure LDH serum level one month pre and post treatment
2887244|NCT03338166||Group C|Patients with Hepatocellular carcinoma who treated surgically and measure LDH serum level one month pre and post treatment
2887245|NCT03338166||Group D|Patients with Hepatocellular carcinoma who don't receive treatment and asses LDH serum level for 3months
2887246|NCT03338153||controlled diabetes|diabetic patients with HbA1C level below 7.0%
2887247|NCT03338153||uncontrolled diabetes|diabetic patients with hbA1C level above 7%
2887248|NCT03338153||non-diabetic|patients who does not have diabetes at the time of PCI
2887249|NCT03338127||Participants|all patients recruited in the trial will be investigated for renal function test
2887250|NCT03338114|Experimental|FLX-787-ODT (orally disintigrating tablet)|FLX-787-ODT (orally disintigrating tablet)
2887251|NCT03338075||CRT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy plus concomitant Temozolomide.
2887252|NCT03338075||RT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy alone.
2887253|NCT03338062|Experimental|HIDA and MRI Scan|Two imaging scans will be added to the standard radiation planning, treatment and follow up process; a Hepatobiliary Iminodiacetic Acid (HIDA) scan and an MRI scan with Eovist contrast
2887254|NCT03338049|Other|Veran System|Staged biopsy sampling methodology. If lymph node staging is negative, EMN-bronchoscopy will be performed. If EMN-bronchoscopy is negative, EMN-TTNA will be performed
2888085|NCT03332836|Experimental|Cohort 1|Single dose subcutaneous administration (Dose A)
2887255|NCT03338036|Experimental|Heart Rate Variability Biofeedback|Participants in this arm of the study will only receive HRV biofeedback. This constitutes initial training with the android device and application, and HRV training performed at home. This training will occur twice daily, and each session will take five minutes. Participants in this arm will meet with the co-investigator bi-weekly to review progress and express feedback.
2887256|NCT03338036|Experimental|Heart Rate Variability/Neurofeedback|Participants in this arm of the study will receive HRV biofeedback and neurofeedback. HRV biofeedback will occur twice daily, using an android device and application. Additionally, three times per week they will have one-hour long neurofeedback sessions.
2887257|NCT03338036|No Intervention|Post-Concussed Control Group|Age-matched, previously concussed individuals that have completed the same concussion rehabilitation program (Brain Ex 90) will be recruited for this arm.
2887258|NCT03338036|No Intervention|Non-Concussed Control Group|Age-matched individuals who have not been diagnosed with a concussion in the previous two years
2887259|NCT03338023|Experimental|LY2963016 + Insulin Lispro|LY2963016 administered subcutaneously (SC) with insulin lispro administered SC.
2887260|NCT03338023|Active Comparator|Lantus® + Insulin Lispro|Lantus® administered SC with insulin lispro administered SC.
2887261|NCT03338010|Experimental|LY2963016|LY2963016 administered subcutaneously (SC). Participants will continue their pre-study oral antihyperglycemic medication (OAMs) throughout the study.
2887262|NCT03338010|Active Comparator|Lantus®|Lantus® administered SC. Participants will continue their pre-study OAMs throughout the study.
2887263|NCT03337997|Experimental|Study group|All patients in this pilot study are in the same group. All receive Irreversible Electroporation.
2887264|NCT03337971|Placebo Comparator|PLACEBO|"Intervention: Dietary Supplement: PLACEBO A group of subjects ingesting a liquid beverage (0.3g per kg body mass ; 1.2kcal/kg body mass) at 10:00pm, 3h post-absorptive of a standardised evening meal.~Samples for the measurement of biomarkers of change in the rate of bone turnover appearing in the blood to be collected for the immediate 4h, and excreted in urine, 24h post-ingestion"
2887265|NCT03337971|Active Comparator|Milk-based protein matrix|"Intervention: Dietary Supplement: MBPM A group of subjects ingesting a liquid beverage (0.3g per kg body mass ; 1.2kcal/kg body mass) at 10:00pm, 3h post-absorptive of a standardised evening meal.~Samples for the measurement of biomarkers of change in the rate of bone turnover appearing in the blood to be collected for the immediate 4h, and excreted in urine, 24h post-ingestion"
2887266|NCT03337958|No Intervention|CONTROL GROUP|Received the standard medical and pharmacological care provided by the hospital
2887267|NCT03337958|Experimental|INTERVENTION GROUP|The group received the standard medical and pharmacological care provided by the hospital. In addition, an educational program on the use of inhalers, which included an explanation of the use of inhalers together with a ventilatory re-education program, furthermore, the technique of inhaler use was trained.
2887268|NCT03337945|Experimental|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
2887269|NCT03337932|Active Comparator|MEM-7 days doxycycline|
2887270|NCT03337932|Active Comparator|MEM-14 days doxycycline|
2887271|NCT03337932|Placebo Comparator|Controls|
2887272|NCT03337919|Experimental|Nivolumab|Up to 8 x 2-weekly cycles of nivolumab 240mg IV. Interim PET-CT scan to be performed after 4 cycles, and centrally reviewed. Patients will stop treatment after 4 cycles if they have complete metabolic response or progressive metabolic disease. If they have partial metabolic response or stable disease, they will continue to 8 cycles.
2887273|NCT03337906||Participants infected with HIV-1|Persons who become HIV-1 infected after enrollment in HIV-1 vaccine trials
2887274|NCT03337893||Breastfed|The kids who breastfed
2887275|NCT03337893||non-breastfed|The kids who did not breastfed
2887276|NCT03337880||Cases|newborns who were delivered with an extractor
2887277|NCT03337880||Controls|newborns who were not delivered with an extractor
2887278|NCT03337867|Active Comparator|Real-iTBS|
2887279|NCT03337867|Sham Comparator|Sham-iTBS|
2887280|NCT03337841|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV once only in the neoadjuvant phase. Pembrolizumab 200 mg IV every 3 weeks in the adjuvant phase.
2887281|NCT03337828|Active Comparator|Alcohol-free beer with regular composition|Two cans (33 cl.) per day of an alcohol-free beer with regular carbohydrates composition.
2887282|NCT03337828|Experimental|Alcohol-free beer with modified composition|Two cans (33 cl.) per day of alcohol-free beer with modified carbohydrates composition. This include the substitution of regular maltose by isomaltulose and the addition of maltodextrin (fiber).
2887283|NCT03337815|Active Comparator|Treatment of MTX and TwHF placebo|Patients were treated with Methotrexate (MTX) and Tripterygium wilfordii Hook F（TwHF）placebo.
2887284|NCT03337815|Experimental|Treatment of TwHF and MTX placebo|Patients were treated with Tripterygium wilfordii Hook F（TwHF）and Methotrexate (MTX) placebo.
2887285|NCT03337802|No Intervention|Pregnant women at standard diet|
2887286|NCT03337802|Experimental|Pregnant women at mediterranean diet|
2887287|NCT03337789|Experimental|Polygonatum sibiricum|
2887288|NCT03337789|Placebo Comparator|Placebo|
2887289|NCT03337776|Active Comparator|WhatsApp message|WhatsApp messages will be sent to invite subjects to participate CRC screening
2887290|NCT03337776|Active Comparator|Telephone call|Telephone call will be made to invite subjects to participate CRC screening
2887291|NCT03337750|Experimental|Web-PE|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
2887292|NCT03337737|Placebo Comparator|Placebo|Placebo will be composed of microcrystalline cellulose in a gel capsule
2887293|NCT03337737|Active Comparator|Extreme Endurance|Dietary Supplement manufactured by LifeSpan International LLC
2887294|NCT03337724|Experimental|Ipatasertib + Paclitaxel|
2887295|NCT03337724|Experimental|Placebo + Paclitaxel|
2887296|NCT03337698|Experimental|Atezolizumab|"Patients in the Atezo arm will receive treatment until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria"
2887297|NCT03337698|Experimental|Atezolizumab + Cobimetinib|"Patients in the Atezo + Cobi arm will receive treatment until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.~Participants who progressed on 3L treatment, may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Docetaxel treatment, provided they meet the eligibility criteria"
2887298|NCT03337698|Experimental|Atezolizumab+ RO6958688|"Patients in the Atezo + RO6958688 arm will receive treatment until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.~Participants who progressed on 3L treatment, may have the option of receiving Atezolizumab + Docetaxel treatment, provided they meet the eligibility criteria"
2887299|NCT03337698|Active Comparator|Docetaxel|"Patients in the Docetaxel arm will receive treatment until unacceptable toxicity or disease progression.~Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6958688 treatment, provided they meet the eligibility criteria"
2887300|NCT03337698|Experimental|Atezolizumab + BL-8040|"Patients in the Atezo + BL-8040 arm will receive treatment until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Docetaxel treatment, provided they meet the eligibility criteria"
2887301|NCT03337698|Experimental|Atezolizumab + Tazemetostat|"Patients in the Atezolizumab + Tazemetostat arm will receive treatment until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Docetaxel treatment, provided they meet the eligibility criteria"
2887302|NCT03337698|Experimental|Atezolizumab + CPI-444|"Patients in the Atezo + CPI-444 arm will receive treatment until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Docetaxel treatment, provided they meet the eligibility criteria."
2887303|NCT03337698|Experimental|Atezolizumab + Pemetrexed + Carboplatin|Patients in the Atezolizumab + Pemetrexed + Carboplatin arm will receive treatment until unacceptable toxicity or loss of clinical benefit
2887304|NCT03337698|Experimental|Atezolizumab + Gemcitabine + Carboplatin|Patients in the Atezolizumab + Gemcitabine + Carboplatin arm will receive treatment until unacceptable toxicity or loss of clinical benefit
2887305|NCT03337698|Experimental|Atezolizumab + Docetaxel|Patients in the Atezolizumab + Docetaxel arm will receive treatment until unacceptable toxicity or loss of clinical benefit
2887306|NCT03337672|Experimental|Dexmedetomidine group|Subjects who receive dexmedetomidine for prevention of emergence delirium
2887307|NCT03337672|Active Comparator|Midazolam group|Subjects who receive midazolam for prevention of emergence delirium
2887308|NCT03337659|Experimental|FICare Intervention Group|Study participants received Family Integrated Care (intervention) while their infant(s) was/were admitted to a Level II NICU.
2887309|NCT03337659|No Intervention|FICare Control Group|Study participants received standard care while their infant(s) was/were admitted to a Level II NICU.
2887310|NCT03337646|Other|Lisdexamphetamine|All participants will receive Lisdexamfetamine Dimesylate (LDX) at an optimized dose based on protocol
2887311|NCT03337633|Active Comparator|Experiment 1 Easy|"For the first experiment, subjects in this arm received the easy menu during the protocol."
2887312|NCT03337633|Active Comparator|Experiment 1 Hard|"For the first experiment, subjects in this arm received the hard menu during the protocol."
2887313|NCT03337633|Active Comparator|Experiment 2 Easy|"For the second experiment, subjects in this arm, who qualified as restrained eaters and were asked to fast for 8 hours overnight, received the easy menu during the protocol."
2887314|NCT03337633|Active Comparator|Experiment 2 Hard|"For the second experiment, subjects in this arm, who qualified as restrained eaters and were asked to fast for 8 hours overnight, received the hard menu during the protocol."
2887315|NCT03337620|Active Comparator|Bupivacaine|Bupivacaine is a local anesthestic that will be delivered to the SPG by the Tx360 device.
2887316|NCT03337620|Placebo Comparator|saline|Saline is being used as a placebo treatment that will be delivered to the SPG by the Tx360 device.
2887317|NCT03337607|Active Comparator|rESWT plus C-E drugs|Patients will receive rESWT, Celecoxib and Eperisone
2887318|NCT03337607|Active Comparator|rESWT alone|Patients will receive rESWT
2887319|NCT03337607|Active Comparator|C-E drugs alone|Patients will receive Celecoxib and Eperisone
2887320|NCT03337594||Control|Pediatric patients who have not been exposed to gadolinium-based contrast agent administration and who require cardiac surgery as part of their standard clinical treatment.
2887321|NCT03337594||Dotarem|Pediatric patients who have undergone routine contrast-enhanced MRI using only Dotarem contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.
2887322|NCT03337594||MultiHance|Pediatric patients who have undergone routine contrast-enhanced MRI using only MultiHance contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.
2887323|NCT03337581|Sham Comparator|group 1.1|Normal saline group
2887324|NCT03337581|Experimental|group 1.2|0.25μg/kg dexmedetomidine group
2887325|NCT03337581|Experimental|group 1.3|0.5μg/kg dexmedetomidine group
2887326|NCT03337581|Experimental|group 1.4|0.75μg/kg dexmedetomidine group
2887327|NCT03337581|Experimental|group 1.5|1.0μg/kg dexmedetomidine group
2887328|NCT03337555|Active Comparator|Macintosh|intubation using Macintosh direct laryngoscope
2887329|NCT03337555|Experimental|McGrath|intubation using McGrath MAC®
2887330|NCT03337555|Experimental|Pentax|intubation using Pentax-airway scope®
2887331|NCT03337542|Other|Treatment arm description|Subjects will receive maintenance dosing with AR101.
2887332|NCT03337529|Experimental|Vitamin C|RLS positive patients will be assessed for the severity. They will be given 200 mg Vitamin C for 8 weeks duration. Patients will be re-assessed for the severity of restless leg syndrome.
2887333|NCT03337529|Placebo Comparator|Placebo|RLS positive patients will be assessed for the severity. They will be given 200 mg placebo for 8 weeks duration. Patients will be re-assessed for the severity of restless leg syndrome.
2887335|NCT03337503|Experimental|THC and CDB in a 1 to 1 ratio|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.~2.5 mg THC with 2.5 mg CBD capsule"
2887336|NCT03337503|Experimental|THC and CBD in a 1 to 2 ratio|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.~2.5 mg THC with 5 mg CBD capsule"
2887337|NCT03337503|Experimental|high CBD with trace THC|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.~20 mg CBD with traces of THC"
2887338|NCT03337503|Placebo Comparator|placebo|"Post a self-titrating schedule of carrier oil, subjects take 1 capsule three times a day at 6 hour intervals.~carrier oil capsule"
2887339|NCT03337490|Experimental|Ivermectin 0.5% Lotion|Ivermectin 0.5% lotion, topical, 117g, single dose
2887340|NCT03337490|Active Comparator|Ivermectin 0.5% Lotion [SKLICE]|Sklice 0.5% Lotion, topical, 117g, single dose
2887341|NCT03337490|Placebo Comparator|Placebo 0% Lotion|0% lotion, 117g, single dose
2887342|NCT03337477|Experimental|ZS+insulin+glucose|ZS will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
2887343|NCT03337477|Placebo Comparator|Placebo+insulin+glucose|Placebo will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
2887344|NCT03337464|Experimental|Parkinson's disease|Subjects with Parkinson's disease
2887345|NCT03337464|Active Comparator|Control|Subjects without Parkinson's disease
2887346|NCT03337451|Experimental|OPN-305|
2887347|NCT03337438|Other|Values-PFI|
2887348|NCT03337438|Other|Traditional-PFI with values assessment|
2887349|NCT03337438|Other|Traditional PFI no values assessment|
2887350|NCT03337425|Experimental|psychoeducational groups|Psychoeducational group therapy and standard treatment (ADHD treatment as usual)
2887351|NCT03337425|Active Comparator|Waiting list|Waiting list and standard treatment (ADHD treatment as usual)
2887352|NCT03337412|Experimental|Patients|initial assessment of physical capacities, determination of personalized objectives on the occasion of 1 to 2 workshops during the hospital checkup. Telephone Contact by the APA educator at 6 months. One-year medical visit.
2887353|NCT03337412|Experimental|Employees|"initial assessment of physical capacities, participation in 10 to 20 physical activity workshops over 6 months on working time, then employees oriented towards autonomous activities over the following 6 months.~Evaluation by computer-filled questionnaires."
2887354|NCT03337399|Experimental|Stepped PC|"Patients will receive Stepped PC~During step 1, patients will be scheduled to meet with the outpatient PC clinician within four weeks of study enrollment and after they are admitted to the hospital or have a change in their cancer treatment~Patients will complete the Functional Assessment of Cancer Therapy-Lung (FACT-L) to monitor their quality of life every six weeks and if their quality of life deteriorates substantially, they will step up to step 2 of the protocol~Patients who transition to step 2 will then meet with the PC clinician at least every four weeks for the remainder of their illness"
2887355|NCT03337399|Experimental|Early Integrated PC|"Patients will receive Early Integrated PC~Patients will meet with the PC clinician within four weeks of enrollment and at least every four weeks throughout their course of illness"
2887356|NCT03337373|Experimental|Cisatracurium|Patients who require paralysis with cisatracurium as part of their clinical care in ICU
2887357|NCT03337360|Active Comparator|Impryl|One tablet daily for 6 months
2887358|NCT03337360|Placebo Comparator|Placebo|One tablet daily for 6 months
2887359|NCT03337334|Other|Non-Focused stimulation|Stimulation frequency is set similar to that of the tremor and the amplitude is set up to 2 mA peak amplitude (reduced if not uncomfortable). One 5*5 cm2 square patch electrodes are placed over the Motor cortex and the Prefrontal cortex respectively and a common return electrode of 10*10 cm2 over the ankle. Each subject follows three sessions of 12 min length each. During each session the tremor is measured while interleaving between Motor cortex stimulation, Prefrontal cortex stimulation and No stimulation. By the end of each session we get 4 min of Motor Cortex stimulation, 4 min of Prefrontal Cortex stimulation and 4 min of No stimulation.
2887360|NCT03337334|Other|Focused stimulation|Stimulation frequency is set similar to that of the tremor and the amplitude is set up to 5 mA peak amplitude (with the help of local anesthetic cream and amplitude is reduced if not uncomfortable). A set of 4*1 gel-filled cup-electrodes is placed over each of motor cortex and the occipital cortex respectively. Each subject follows three sessions of 12 min length each. During each session the tremor is measured while interleaving between Motor cortex stimulation, Occipital cortex stimulation and No stimulation. By the end of each session we get 3 min of Motor Cortex stimulation, 3 min of occipital Cortex stimulation and 6 min of No stimulation.
2887361|NCT03337321||ETvalid|Pregnant women attending maternal care services and having access to computational device
2887362|NCT03337308|Experimental|BA 180 mg + EZE 10 mg FDC|Bempedoic acid (BA) + ezetimibe (EZE) fixed-dose combination (FDC) 180 mg/10 mg tablets taken orally once daily for 12 weeks
2887363|NCT03337308|Experimental|BA 180 mg|Bempedoic acid (BA) 180 mg tablets taken orally once daily for 12 weeks
2887364|NCT03337308|Active Comparator|EZE 10 mg|Ezetimibe (EZE) 10 mg overencapsulated tablets taken orally once daily for 12 weeks
2887365|NCT03337308|Placebo Comparator|Placebos|Placebos to match identical bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or identical bempedoic acid 180 mg tablet, or identical ezetimibe 10 mg capsule, taken orally, once daily for 12 weeks
2887366|NCT03337295||Low-MGD|
2887367|NCT03337295||High-MGD|
2887368|NCT03337282||Observational cohort|Adults 70 years of age or older undergoing major noncardiac surgery under protocolized general anesthesia
2887369|NCT03337269|Other|Control|Subject does not receive an educational intervention
2887370|NCT03337269|Other|Educational video|Subject watches an educational video
2887371|NCT03337269|Other|Educational handout|Subject reads an educational handout
2887372|NCT03337256|Experimental|GI bleeding score|Early endoscopy in emergency department + other clinical parameters
2887373|NCT03337243|Experimental|HAM and HUMCWJ Injections (Group 1)|Participants who self-select into the Group 1 (Immediate Treatment) will be scheduled to undergo the HAM and HUMCWJ injections to the OA affected knee at the same visit.
2887374|NCT03337243|No Intervention|Control (Group 2)|Participants who self-select into Group 2 will choose to delay their HAM and HUMCWJ injection to the OA affected knee for at least 3 months or choose not to have the injections at all. Participants will be asked to keep track of pain management and therapy throughout the 3 months.
2887375|NCT03337230|Experimental|Physical Activity + Diet + Social media|Educational materials for the proposed study will be delivered via a secret social media Facebook group. These materials will promote simple, attainable forms of Physical Activity and lasting diet changes. A study moderator will deliver weekly communications to the Facebook group providing intervention content including social support, social competition and comparison, and social rewards
2887376|NCT03337217|Experimental|Prone Position|Position during colonoscopy
2887377|NCT03337217|Active Comparator|Left lateral decubitus position|Position during colonoscopy
2887378|NCT03337204|Experimental|Engaged4Life|"Participants randomly assigned to this group receive: 1) technology-assisted self-monitoring of daily activity via a Fitbit Zip worn daily (for 8 weeks) and a daily tablet self-report survey (completed for a 7-day period at baseline and a second 7-day period 4-weeks later); and 2) a one-time, 3hr workshop and peer mentoring (via phone 2X/week for 3 weeks). The workshop includes psychoeducation on the relationship between active engagement and health and well-being and a goal setting activity focused on carefully assessing and then make improvements upon existing activity portfolios. Peer mentors provide support as participants implement their goals."
2887379|NCT03337204|Active Comparator|Technology-assisted self-monitoring only|Participants randomly assigned to this group receive: 1) technology-assisted self-monitoring of daily activity via a Fitbit Zip worn daily (for 8 weeks) and a daily tablet self-report survey (completed for a 7-day period at baseline and a second 7-day period 4-weeks later). While it is expected that wearing the Fitbit and raising consciousness of activity engagement may initially result in behavior change, it is not expected to have a sustained impact on outcomes over time.
2887380|NCT03337191|Active Comparator|ultrasound guided caudal block|Caudal block was performed by ultrasound guided with %0,125 levobupivacaine + 10 mq/kg morphine
2887381|NCT03337191|Active Comparator|conventional caudal block|Caudal block was performed by conventional method with %0,125 levobupivacaine + 10 mq/kg morphine
2887382|NCT03337178|No Intervention|Control|Standard of care
2887383|NCT03337178|Experimental|Blinded Fitbit|Blinded Fitbit, no step goal, and no activity feedback
2887384|NCT03337178|Experimental|Fitbit|Fitbit plus step goal and activity feedback
2887385|NCT03337165|Experimental|tolerogenic dendritic cells|Each dose of autologous monocyte-derived dendritic cells generated in the presence of IFN-α/GM-CSF and tolerized with Dexamethasone (1x106, 3x106, 5x106, 8x106 and 10x106 cells in 2.0 mL sodium chloride 0.9% solution) will be administered in RA patients through intra-articular injection (into the knee joint).
2887386|NCT03337152|Other|1A: primaquine|Twelve males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD deficiency will be randomized to arm 1A. Participants in arm 1A will receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
2887387|NCT03337152|Other|1B: chloroquine + primaquine|Twelve males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD deficiency will be randomized to arm 1B. Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
2887388|NCT03337139|Active Comparator|Lifestyle Modification|Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on self-report.
2887389|NCT03337139|Experimental|Lifestyle Modification + Share|Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on digital data shared with clinicians.
2887390|NCT03337126|Active Comparator|Fasting Condition|Single dose of ATI-1501(oral suspension) administered under fasting conditions; BioAvailability and PK parameters will be measured and analyzed. These parameters will be compared to the BA and PK parameters measured after administration of a single Metronidazole Tablet
2887391|NCT03337126|Active Comparator|Fed Condition|Single dose of ATI-1501(oral suspension) administered under fed condition; BioAvailability and PK parameters will be measured and analyzed. These parameters will be compared to the BA and PK parameters measured after administration of a single Metronidazole Tablet
2887392|NCT03337113|Experimental|WMT + rTMS|WMT + rTMS is the Working Memory Training + repetitive Transcranial Magnetic Stimulation arm. Both conditions are active.
2887393|NCT03337113|Active Comparator|Sham WMT + rTMS|Sham WMT + rTMS is the sham Working Memory Training + repetitive Transcranial Magnetic Stimulation arm. This condition isolates the effects of rTMS. WMT is inactive.
2887394|NCT03337113|Active Comparator|WMT + sham rTMS|WMT + sham rTMS is the Working Memory Training + sham repetitive Transcranial Magnetic Stimulation arm. This condition isolates the effects of WMT. rTMS is inactive.
2887395|NCT03337113|Sham Comparator|Sham WMT + sham rTMS|sham WMT + sham rTMS is the sham Working Memory Training + sham repetitive Transcranial Magnetic Stimulation arm. Both are inactive in this arm.
2887396|NCT03337100|Experimental|Co-Dispensing|Early implementation of a naloxone co-dispensing pharmacy program. Pharmacies in the phase 1 (early) naloxone co-dispensing arm will be assigned to implement the pharmacy based naloxone co-dispensing program first relative to the phase 2 arm.
2887397|NCT03337100|No Intervention|Usual Care|"Usual care/Phase 2 naloxone co-dispensing:~Pharmacies in the usual care/phase 2 naloxone co-dispensing arm will provide usual pharmacy services to patients receiving chronic opioid therapy (no naloxone co-dispensing). After 10 months, they may implement the pharmacy-based naloxone co-dispensing program."
2887398|NCT03337087|Experimental|Treatment (nal-IRI, leucovorin, fluorouracil, rucaparib)|Patients receive liposomal irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV over 46 hours on days 1 and 15. Patients also receive rucaparib PO BID on days 4-13 and 18-27. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
2887399|NCT03337074||Sperm Epigenome arm/healthy men|Men with no significant health problems.
2887400|NCT03337074||Sperm Epigenome arm/cholestatic men|Men with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis.
2887510|NCT03336346||EFV group|Reproductive-aged HIV-infected women taking efavirenz-based ART and using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
2887401|NCT03337074||Outcomes arm/Cholestatic fathers|Fathers who were diagnosed with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis either before or after the conception of their child who is now aged 16 - 25 years of age.
2887402|NCT03337074||Outcomes arm/Children of cholestatic fathers|16 - 25 years-old children of fathers who were diagnosed with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis either before or after their conception.
2887403|NCT03337061|Experimental|Experimental (Mindfulness)|This arm will receive mindfulness-based interventions through a mobile application
2887404|NCT03337061|No Intervention|Control (Sleep Advice)|This is the control arm that will receive usual care
2887405|NCT03337048|Experimental|Measurement of endpoints|"In healthy volunteers the endpoint are measured while spontaneous voiding of the bladder and while emptying the bladder using a standard intermittent catheter (SpeediCath).~In subjects with spinal cord injury or enlarged prostata the endpoint are measured while emptying the bladder using a standard intermittent catheter."
2887406|NCT03337035|Active Comparator|oral probiotics and oxytocin spray|Subjects will receive oral probiotics, 1 pill per day, for 24 weeks. For the last 12 weeks, subjects will also receive intranasal oxytocin spray at the following dose: 4 IU in week 1, 8 IU in week 2, 16 IU in week 3, and 24 IU in weeks 4-12.
2887407|NCT03337035|Placebo Comparator|vitamin C and oxytocin spray|Subjects will receive oral placebo (vitamin C), 1 pill per day, for 24 weeks. For the last 12 weeks, subjects will also receive intranasal oxytocin spray at the following dose: 4 IU in week 1, 8 IU in week 2, 16 IU in week 3, and 24 IU in weeks 4-12.
2887408|NCT03337022|Experimental|CC-90006; Dose level 1|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
2887409|NCT03337022|Experimental|CC-90006; Dose level 2|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
2887410|NCT03337022|Experimental|CC-90006; Dose level 3|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
2887411|NCT03337022|Experimental|CC-90006; Dose level 4|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
2887412|NCT03337022|Placebo Comparator|Placebo|Placebo (saline) will be administered subcutaneously (SC) on days 1, 15, and 29.
2887413|NCT03337009|Experimental|Naloxone Navigator|"Targeted, web-based animated video (Naloxone Navigator [NN]):~This arm is a web-based intervention targeted to patients receiving chronic opioid therapy identified in the electronic health record. Participants in this arm have access to naloxone under standing orders from the pharmacy or with a prescription from their providers."
2887414|NCT03337009|No Intervention|Usual Care|Participants in the usual care arm will receive usual care from their health plan, pharmacy and clinicians. As part of usual care, participants can access naloxone through physician prescription or standing orders.
2887415|NCT03336996|Experimental|evaluation|To characterize and evaluate functional and anatomical changes of nerve fiber injuries after umbilical cord mesenchymal stem cells transplantation with BOLD drived-DTI
2887416|NCT03336996|Experimental|BOLD-fMRI and DTI|To determine the therapeutic efficiency of umbilical cord mesenchymal stem cells and also the utility of the integration of BOLD-fMRI and DTI.
2887417|NCT03336996|Experimental|correlate the imaging results|To correlate the imaging results with the electrophysiology outcomes
2887418|NCT03336983|Other|LHRH-A + Enzalutamide|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide until patient's progression, consent withdrawal or unacceptable toxicity
2887419|NCT03336983|Experimental|LHRH-A + Enzalutamide + Zoledronic Acid|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide + Zoledronic Acid until patient's progression, consent withdrawal or unacceptable toxicity
2887420|NCT03336970|Active Comparator|Single visit root canal treatment|The teeth were treated in single-visit (SV) root canal treatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation.
2887421|NCT03336970|Active Comparator|Multiple visit root canal treatment|The teeth were treated in multiple visit (MV) root canal treatment. After completion of root canal instrumentation, calcium hydroxide paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
2887422|NCT03336957|Experimental|Pregnant group|Test group, non-surgical periodontal therapy (NPT) consisted of scaling and oral hygiene instruction was applied. IL- 1β AND IL-10 in the GCF and Cg A in saliva samples were taken before and after periodontal treatment.
2887423|NCT03336957|Active Comparator|Non-Pregnant|Control group, non-surgical periodontal therapy (NPT) consisted of scaling and oral hygiene instruction was applied. IL- 1β AND IL-10 in the GCF and Cg A in saliva samples were taken before and after periodontal treatment.
2887424|NCT03336931||High-risk childhood cancers|Expected survival < 30%
2887425|NCT03336918||Bipolar Disorder I or II Depressed|DSM-V Bipolar I or II Depressed treated with lithium
2887426|NCT03336918||Healthy Controls|Healthy Controls with no psychiatric history
2887427|NCT03336905|Experimental|Physical Activity and Prevention|"co-construction of supervised and non-supervised physical activity sessions with a physical activity trainer~balance sheet (at diagnosis and 4 monthes+/- 2 months later) : IPAQ, QLQC30, 6-min walk test, anthropometric evaluation~meetings and phone calls after the physical activity program to assess patient perception and satisfaction, and provide information and recommendations for cancer prevention"
2887428|NCT03336892|Experimental|Intervention|Enhanced usual care with written mental health resources and system navigation information in addition to individualized mental health care coordination by a dedicated specially trained mental health care coordinator.
2887429|NCT03336892|No Intervention|Control|Enhanced usual care with written mental health resources and system navigation information.
2887474|NCT03336567||Subjects with hematological malignancies|It will include subjects with Refractory Diffuse Large B-cell Lymphoma and Multiple Myeloma, Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) and/or who participated in a CAR-T clinical trial or autologous treatment. Subjects will undergo a telephonic interview for up to 90 minutes.
2887475|NCT03336567||Subjects with NSCLC or soft-tissue sarcoma|It will Include subjects with NSCLC on second or later-line therapy or soft-tissue sarcoma on second or later line therapy. Subjects will undergo a telephonic interview for up to 90 minutes.
2928020|NCT03054337|Experimental|Vadadustat, Dose 3|Daily oral dose
2887430|NCT03336879|Experimental|Active rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive active stimulation targeting the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 15 Hz and 100% of the individual resting motor threshold, for a total of 40 trains (60 stimuli per train, inter-train interval of 15 second, total duration 13 minutes). Each session will be repeated twice/daily for 10 consecutive days for 2 weeks, during the continued treatment phase. Following this, the participants will receive the maintenance intervention of 2 sessions per week for 3 months (rTMS follow-up), at the same parameters described above. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
2887431|NCT03336866|Placebo Comparator|Placebo|Normal saline
2887432|NCT03336866|Experimental|IXT-m200|Single 6 or 20 mg/kg intravenous dose of IXT-m200
2887433|NCT03336853|Experimental|HybenX ®|1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
2887434|NCT03336853|Placebo Comparator|Control|5 cc of sterile saline water for 20 sec
2887435|NCT03336840|Experimental|Metformin|
2887436|NCT03336840|Experimental|Probiotics|
2887437|NCT03336840|Experimental|Metformin and Probiotics|
2887438|NCT03336827|Other|Experimental Group|Patients include in the experimental group (EG) will receive one individual pre-group session and 8 sessions of group intervention combining cognitive-behavioral therapy and hypnosis after the first assessment (T1) (i.e., before the second assessment taking place 4 months later (T2)). They will resort to usual care only after the second assessment (T2) (i.e., before the third assessment taking place 4 months later (T3)).
2887439|NCT03336827|Other|Waiting-List Control Group|Patients include in the waiting-list control group (CG) will resort to usual care only after the first assessment (T1) (i.e., before the second assessment taking place 4 months later (T2)). They will receive one individual pre-group session and 8 sessions of group intervention combining cognitive-behavioral therapy and hypnosis after the second assessment (T2) (i.e., before the third assessment taking place 4 months later (T3)).
2887440|NCT03336814|Experimental|terlipressin associated with norepinephrine|
2887441|NCT03336814|Placebo Comparator|placebo (physiologic serum) associated with norepinephrine|
2887442|NCT03336801|Active Comparator|Sevoflurane|Intervention Back surgery and sevoflurane.
2887443|NCT03336801|Active Comparator|Propofol|Intervention Back surgery and propofol.
2887444|NCT03336788|Placebo Comparator|TMS|
2887445|NCT03336788|Active Comparator|TMS with virtual reali|
2887446|NCT03336775|Experimental|acupuncture|Patients receive acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks). These patients also received corticosteroid for 4 weeks, methylprednisolone 80mg ivdrip. for 3 days, 60mg ivdrip. for 3 days, 40mg ivdrip. for 3 days, 30mg po. for 7 days, 20mg po. for 7 days, 10mg po. for 5 days and maintain.
2887447|NCT03336775|No Intervention|control|Patients receive no acupuncture. The use of corticosteroid is the same with Arm I.
2887448|NCT03336749|Experimental|Sensory group|Sensory re-learning in combination with task-specific training
2887449|NCT03336749|Active Comparator|Control group|Traditional task-specific training
2887450|NCT03336736||Pulmonary Sarcoidosis|Self-reported and self-referred self-reported medically diagnosed pulmonary sarcoidosis.
2887451|NCT03336736||Control|Healthy age-matched control group with no known lung disease.
2887452|NCT03336723|Experimental|Experimental Group|Two piece zirconia dental implants place subcrestally with a healing abutment at baseline (T0) and rehabilitated with a zirconia dental crown T3 3 Measures on the IL1b and IL6 at T0 baseline , T2 2 month and T3 at crown placement.Microbiological samples at T2 and T3.
2887453|NCT03336723|Active Comparator|Control Group|Two piece titanium dental implants place subcrestally with a healing abutment at baseline (T0) and rehabilitated with a zirconia dental crown T3 3 Measures on the IL1b and IL6 at T0 baseline , T2 2 month and T3 at crown placement.Microbiological samples at T2 and T3.
2887454|NCT03336710||Primary sample|Community sample of adults (18-65) from the greater Buffalo, NY region, oversampling people who are seeking mental health treatment.
2887455|NCT03336697||Parkinson's disease subjects|Patients with untreated or treated Parkinson's disease ages 45-75.
2887456|NCT03336697||Healthy control subjects|Healthy control subjects ages 45-75.
2887457|NCT03336684|Experimental|Patient Education Group|Patients will be provided with disease education literature
2887458|NCT03336684|No Intervention|Normal Group|Patients will not be provided with disease education literature
2887459|NCT03336671|Active Comparator|Adenoidectomy|Current standard of care for pediatric chronic rhino sinusitis.
2887460|NCT03336671|Experimental|Adenoidectomy plus Endoscopic Sinus Surgery|endoscopic sinus surgery in addition to adenoidectomy
2887461|NCT03336645|Experimental|SHP615|Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
2887462|NCT03336632|Experimental|Chidamide|Chidamide, tablets, 5 mg/tablet, 20 mg orally twice weekly from D-7~+14 Cyclophosphamide: 50 mg/Kg intravenously D+3, +4 Cyclosporine A: intravenously then orally 3 mg/Kg D+5~D+100
2887463|NCT03336619|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
2887464|NCT03336619|Placebo Comparator|Placebo|Two Placebo tablets orally twice daily (b.i.d.) for 5 days
2887465|NCT03336606|Active Comparator|Cohort I|MEDI0562 administration (90mg on day 1) followed by surgical resection (day 15)
2887466|NCT03336606|Active Comparator|Cohort II|MEDI0562 administration (30mg on days 1, 3, 5) followed by surgical resection (day 15)
2887467|NCT03336593|Experimental|QIV batch 1|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 1
2887468|NCT03336593|Experimental|QIV batch 2|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 2
2887469|NCT03336593|Experimental|QIV batch 3|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 3
2887470|NCT03336593|Active Comparator|Trivalent Influenza Vaccine|1 dose of 0.5 ml of trivalent influenza vaccine
2887471|NCT03336593|Experimental|QIV (subjects 6-35 months)|2 dose of 0.25 ml of quadrivalent influenza vaccine
2887472|NCT03336593|Experimental|QIV (subjects 3-8 years)|2 dose of 0.5 ml of quadrivalent influenza vaccine
2887473|NCT03336580|Experimental|3+3 Cohort Study|This is a Phase 1 3+3 design Cohort Study
2887476|NCT03336567||Oncologists from academic centers with CGT experience|It will include oncologists using TCR therapies, CAR-T or participating in CAR-T or TCR therapy clinical trials. Oncologists will undergo a telephonic interview for up to 60 minutes.
2887477|NCT03336567||Oncologists from community clinics|It will include oncologists from community clinics who evaluate, prescribe, treat, and actively interact with subjects with NSCLC or soft tissue sarcoma, who have used immuno-oncology (IO) therapies. Oncologists will undergo a telephonic interview for up to 60 minutes.
2887478|NCT03336554||observation group|One group of participants are under observation. This trial has two phase. Phase I: 40 participants will be enrolled. Only if epigenetic cfDNA library has been built, investigators would move on to Phase II. Another 60 participants will be enrolled for further analysis.
2887479|NCT03336541|Experimental|Ketamine group|Low-dose ketamine (0.5 mg/kg in 100 ml normal saline) is intravenously infused in 40 minutes after childbirth during cesarean delivery.
2887480|NCT03336541|Placebo Comparator|Placebo group|Placebo (100 ml normal saline) is intravenously infused in 40 minutes after childbirth during cesarean delivery.
2887481|NCT03336528|Experimental|Degludec inpatient|Study participants treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as a basal bolus regimen with degludec once daily plus rapid-acting aspart insulin before meals. Degludec insulin 100 Units/mL, average dose: 30-45 U/day. aspart (U-100) insulin 100 Units/mL, average dose: 20-30 U/day.
2887482|NCT03336528|Active Comparator|Glargine U100 inpatient|"Study participants treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as basal bolus regimen with glargine once daily plus rapid-acting aspart insulin before meals. Glargine (U-100) insulin 100 Units/mL, average dose: 30-45 U/day.~Aspart (U-100) insulin 100 Units/mL, average dose: 20-30 U/day."
2887483|NCT03336528|Experimental|Degludec post-discharge|Patients with poorly controlled diabetes (HbA1c >7.5%) enrolled in the degludec inpatient arm will be invited to participate in the prospective outpatient study. At hospital discharge, patients will be treated following an HbA1c based algorithm for a total duration of the outpatient follow-up of 3 months. Patients with an HbA1c between 7.5% and 10% will be discharged on preadmission oral antidiabetic agents plus degludec once daily. Patients with an admission A1C ≥ 10% will be discharged on basal bolus regimen with degludec and aspart insulin before meals.
2887484|NCT03336528|Active Comparator|Glargine U100 post-discharge|Patients with poorly controlled diabetes (HbA1c >7.5%) enrolled in glargine inpatient arm will be invited to participate in this open label prospective outpatient study. At hospital discharge, patients will be treated following an HbA1c based algorithm for a total duration of the outpatient follow-up of 3 months. Patients with an HbA1c between 7.5% and 10% will be discharged on preadmission oral antidiabetic agents plus glargine once daily. Patients with an admission A1C ≥ 10% will be discharged on basal bolus regimen with glargine and aspart insulin before meals.
2887485|NCT03336515|Other|Group A-General Recommendation|General recommendation not sleeping in supine position without the postural device
2887486|NCT03336515|Placebo Comparator|Group B-Postural device no activated|General recommendation not sleeping in supine position and the postural device without any activation (placebo)
2887487|NCT03336515|Experimental|Group C-Postural device activated|General recommendation not sleeping in supine position and the postural device activated (intervention group).
2887488|NCT03336502|Experimental|Posaconazole|All participants will receive posaconazole 300 mg intravenous (IV) infusion twice on Day 1 followed by 300 mg IV infusion once daily on Days 2 to 10 (±1). At the discretion of the investigator, participants will received posaconazole 300 mg IV infusion once daily or 200 mg oral solution three times daily for up to 18 additional days.
2887489|NCT03336476|Experimental|Videolaryngoscopy|Videolaryngoscopy the trachea will be intubated using a videolaringoscop
2887490|NCT03336476|Active Comparator|Direct laryngoscopy|Direct laringoscopy the trachea will be intubated using a laringoscope
2887491|NCT03336463||Controls|No intervention
2887492|NCT03336463||Cases|No intervention
2887493|NCT03336450|Experimental|SHP615|Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
2887494|NCT03336437|Active Comparator|Estrogen Vaginal Ring|At the time of initial study visit, a estrogen vaginal ring (Estring) will be placed. Participants will retain this ring for 12 weeks.
2887495|NCT03336437|Placebo Comparator|Inactive Vaginal Placebo Ring|At the time of initial study visit, a placebo vaginal ring will be placed. Participants will retain this ring for 12 weeks.
2887496|NCT03336424|Experimental|Non-invasive investigations group|Non-invasive investigations include: ultrasound, blood exam, urine analysis and culture, uroflowmetry
2887497|NCT03336424|Experimental|Invasive investigations group|urodynamic study including: cystomanometry, pressure flow study, EMG
2887498|NCT03336411|Active Comparator|mHealth|
2887499|NCT03336411|Experimental|Personalized mHealth|
2887500|NCT03336398|Experimental|Tinnitus Distressed Patients|Tinnitus distressed patients are patients who experience symptoms of anxiety or depression with tinnitus. This group will receive both 0.5 mg/kg ketamine hydrochloride in saline and placebo, saline, with Magnetic Resonance Spectroscopy scans and audiometry testing and scales.
2887501|NCT03336398|Experimental|Tinnitus Patients|Tinnitus patients are patients who do not experience symptoms of anxiety or depression with tinnitus. This group will receive both 0.5 mg/kg ketamine hydrochloride in saline and placebo, saline, with Magnetic Resonance Spectroscopy scans and audiometry testing and scales.
2887502|NCT03336385|Placebo Comparator|Placebo|Maltodextrin 12 gram used as placebo
2887503|NCT03336385|Active Comparator|Naxus|Naxus contains the wheat-derived prebiotic fibre Arabinoxylan
2887504|NCT03336385|Active Comparator|Oatwell|Oatwell contains an oat-derived prebiotic beta-glucan fibre
2887505|NCT03336372|Experimental|Picato topical gel|
2887506|NCT03336359|Active Comparator|LCI|Tandem colonoscopy with Linked Color Imaging system
2887507|NCT03336359|Active Comparator|NBI|Tandem colonoscopy with Narrow band imaging system
2887508|NCT03336346||DTG group|Reproductive-aged HIV-infected women taking dolutegravir-based ART and using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
2887509|NCT03336346||No ART group|Reproductive-aged HIV-uninfected women using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
2888086|NCT03332836|Experimental|Cohort 2|Single dose subcutaneous administration (Dose B)
2887511|NCT03336333|Experimental|BGB-3111 (patients without del[17p])|Approximately 210 subjects in Cohort 1 to receive BGB-3111
2887512|NCT03336333|Experimental|B+R|Approximately 210 subjects in Cohort 1 to receive bendamustine plus rituximab
2887513|NCT03336333|Experimental|BGB-3111 patients with del[17p])|Approximately 47 subjects in Cohort 2 to receive BGB-3111
2887514|NCT03336320|Experimental|Multidomain Intervention Group|Home-based multidomain intervention composed of nutritional counselling, exercise (balance, gait, , and cognitive training provided using ICT solutions. A web platform, containing information, questionnaires, videos, games, and tests related to each one of the three components of the multidomain intervention will be made available to participants in this group.
2887515|NCT03336320|Active Comparator|Control Group|"Participants from CG will also be equipped with wrist worn accelerometers (that will record daily activity data continuously) but contrary to MIG, participants won't have access to the password encrypted application, and therefore, to the multidomain intervention. However, they will be able to access the study website with overall information on the eMIND study and links to the website of health authorities (such as http://www.mangerbouger.fr/PNNS or the World Health Organization http://www.who.int/topics/ageing/fr/) regarding healthy ageing topics. Plus, in order to control for the social aspect of MIG, participants in CG will receive monthly phone calls from the research team."
2887516|NCT03336307||Patients with Parkinson's disease|"All participants could walk independently without walking devices. All patients were taking oral administrations of levodopa (18 patients), dopamine agonists (5 patients), or both (13 patients) and were recorded in on phase. Medication was kept constant throughout the trial, and all interventions were performed at the same time of day for each patient during ON phase.~Severity of parkinsonism was evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS-II and III) and the Hoehn and Yahr staging system.~All patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease"
2887517|NCT03336294|Other|Old group|Subjects involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
2887518|NCT03336294|Other|Young group|Subjects involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
2887519|NCT03336281||Participants with Psoriatic Arthritis: Dermatologist Cohort|Participants who will receive ustekinumab (as a first or second line of biologic disease modifying anti-rheumatic drug [bDMARD] therapy) along with other co-medications as per clinical dematologist's discretion will be observed in this study. Ustekinumab will not be provided by the sponsor. The treatment by ustekinumab must have been decided by the physician prior to the decision to include the participant in the study. Only data available from a participant's source medical records will be collected. Additionally investigators will be asked to obtain (or record where available) Patient-Reported Outcome (PRO) data from participants participating in this study.
2887520|NCT03336281||Participants with Psoriatic Arthritis: Rheumatologist Cohort|Participants who will receive ustekinumab (as a first or second line of bDMARD therapy) along with other co-medications as per clinical rheumatologist's discretion will be observed in this study. Ustekinumab will not be provided by the sponsor. The treatment by ustekinumab must have been decided by the physician prior to the decision to include the participant in the study. Only data available from a participant's source medical records will be collected. Additionally investigators will be asked to obtain (or record where available) PRO data from participants participating in this study.
2887521|NCT03336268|Experimental|POINT|This arm will be offered both POINT services (in addition to standard emergency care) and enrollment in study data collection. If they choose to enroll in POINT, they may choose whether or not to enroll in data collection, as it is not required. Should they enroll in data collection, they will be consented and enrolled in the research study as a participant in the POINT study arm.
2887522|NCT03336268|No Intervention|Standard Care|This arm will only be offered enrollment in study data collection, as they will receive standard emergency care. If they choose to enroll, they will be consented in the research study as the Standard Care arm.
2887523|NCT03336255|No Intervention|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
2887524|NCT03336255|Experimental|SAHELI Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 16 to 20 participants who will attend 16 weekly, 90 minute group education sessions at Metropolitan Asian Family Services or Skokie Health Department. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management.
2887525|NCT03336242|Experimental|Cohort 1: Cannabidiol Oral Solution 20 mg/kg/day|Treatment Period: Cannabidiol Oral Solution 20 milligrams per kilogram per day (mg/kg/day) divided twice daily (BID) for 4 weeks.
2887526|NCT03336242|Experimental|Cohort 2: Cannabidiol Oral Solution 30 mg/kg/day|"Titration Period: Cannabidiol Oral Solution 20 mg/kg/day divided BID for 5 days.~Treatment Period: Cannabidiol Oral Solution 30 mg/kg/day divided BID for 4 weeks."
2887527|NCT03336242|Experimental|Cohort 3: Cannabidiol Oral Solution 40 mg/kg/day|"Titration Period: Cannabidiol Oral Solution 20 mg/kg/day divided BID for 5 days, followed by 30 mg/kg/day divided BID for 5 days.~Treatment Period: Cannabidiol Oral Solution 40 mg/kg/day divided BID for 4 weeks."
2887528|NCT03336229|Active Comparator|Intervention|
2887529|NCT03336229|No Intervention|Control|
2887530|NCT03336216|Active Comparator|Arm A|"Investigator choice of chemotherapy either gemcitabine/nabpaclitaxel (ABRAXANE) or 5-fluorouracil/leucovorin/irinotecan Liposome (ONIVYDE)~ONIVYDE-based regimen can be substituted with FOLFIRI (leucovorin, fluorouracil, irinotecan hydrochloride)"
2887531|NCT03336216|Experimental|Arm B|Cabiralizumab and Nivolumab
2887532|NCT03336216|Experimental|Arm C|cabiralizumab and nivolumab in combination with gemcitabine and abraxane
2887533|NCT03336216|Experimental|Arm D|cabiralizumab and nivolumab in combination with oxaliplatin/5-Fluorouracil/leucovorin
2887534|NCT03336203|Active Comparator|Hyperurecemia with gout|90 patients with high SUA level (>8 mg/dL; 480 µmol/L) with gout (EULAR's criteria) are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA <3 mg/dL (180 µmol/L)
2887585|NCT03335917|Placebo Comparator|Normobaric Normoxia|This will serve as the exercise only control trial
2888087|NCT03332836|Experimental|Cohort 3|Single dose subcutaneous administration (Dose C)
2887535|NCT03336203|Active Comparator|Hyperurecemia without gout|90 patients with high SUA level (>8 mg/dL; 480 µmol/L) withot gout (EULAR's criteria) but with CKD are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA <3 mg/dL (180 µmol/L)
2887536|NCT03336190|Experimental|Experimental|Receives the full program, including the toolkit training and avatar interaction
2887537|NCT03336190|Other|Control|Receive the avatar PLUS additional self-care (toolkit and avatar PLUS extra self-care)
2887538|NCT03336164|Experimental|Front-of-pack labelling Nutri-Score|"Introduction of the Nutri-Score front-of-pack nutrition label on every food and beverage sold in the same campus university restaurant after the control period without food labelling.~The implementation of the label is accompanied by a communication campaign towards students in the form of posters and leaflets."
2887539|NCT03336151|Experimental|Front-of-pack labelling Nutri-Score|"Introduction of the Nutri-Score front-of-pack nutrition label on every food and beverage in the campus cafeteria after a control period without food labelling.~The implementation of the label is accompanied by a communication campaign towards students in the form of posters and leaflets."
2887540|NCT03336138|Active Comparator|AMA group|Patient with telephone follow-up modality called AMA (Assistance for ambulatory patients)
2887541|NCT03336138|No Intervention|Control group|Patient with standard follow-up with no specific assistance for ambulatory patients
2887542|NCT03336125|Experimental|Vitamin D group|Intervention is vitamin D supplement
2887543|NCT03336125|Placebo Comparator|Control group|Placebo capsule contains olive oil
2887544|NCT03336112|Experimental|Intervention group|5 weeks guided internet-delivered cognitive behavioral therapy program The program consists of psychoeducation, exposure to physical activity, and awareness (mindfulness) training.
2887545|NCT03336112|Active Comparator|Control group|Information program delivered by the Internet during 5 weeks.
2887546|NCT03336099|Experimental|Spa Treatment|Bicarbonate and sulfurated water cares in Vals-les-Bains thermal cure center, massage, cataplasm.
2887547|NCT03336086|Other|experimental|This group underwent a weight loss program
2887548|NCT03336086|No Intervention|control|This group underwent adlibitum diet + physical activity
2887549|NCT03336073|Experimental|carfilzomib, dexamethasone and cyclophosphamide|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose of 20 mg (10 mg for patients >75 years) days 1, 2, 8, 9, 15 and 16 and cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15, in 28 days cycles
2887550|NCT03336073|Active Comparator|carfilzomib and dexamethasone|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose of 20 mg (10 mg for patients >75 years) days 1, 2, 8, 9, 15 and 16 , in 28 days cycles
2887551|NCT03336060||Healthy Control|Age matched healthy subjects. Inclusion criteria for healthy controls are: male (18 - 40 years, right-handed); sportive (preferably ball game sports, e.g. soccer); no acute injury or life-quality impairing diseases; no medication
2887552|NCT03336060||Subjects with ACL reconstruction|"Unilateral, primary anterior cruciate ligament tear and reconstruction (1 to 10 years ago); no serious concomitant injuries, e.g. unhappy triad); no kinesiophobia; symmetric single leg jump performance (>85 %); male (18 - 40 years, right-handed); sportive (preferably ball game sports, e.g. soccer); no acute injury or life-quality impairing diseases; no medication"
2887553|NCT03336047|Active Comparator|10,000 steps daily|Subjects will be encouraged to obtain 10 000 steps a day, monitored by a step counter (fit bit zip)
2887554|NCT03336047|Experimental|using personal activity intelligence|Subjects will be encouraged to obtain 100 PAI points per week, monitored by Mio Slice and the Mio Pai 2.0 smart phone application
2887555|NCT03336034||IBS-C|Constipation-predominant irritable bowel syndrome
2887556|NCT03336021|Experimental|Intervention|FAS program
2887557|NCT03336021|No Intervention|Comparison|Comparison group
2887558|NCT03335982|Other|transendoscopic enteral tubing in mid-gut|A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia. The feasibility, safety, success rate, and satisfaction with TET placement were evaluated for enteral nutrition or fecal microbiota transplantation.
2887559|NCT03335969|Active Comparator|pre colon irrigation diaries|4 week bowel movement and rescue medication diaries
2887560|NCT03335969|Experimental|colon irrigation followed by diaries|HyGIeaCare colon irrigation followed by 4 week bowel movement and rescue medication diaries
2887561|NCT03335956|Placebo Comparator|SAD Part 1 Placebo Cohort 1 Period 1|
2887562|NCT03335956|Experimental|SAD Part 1 Active Cohort Period 1|
2887563|NCT03335956|Placebo Comparator|SAD Part 1 Placebo Cohort 1 Period 2|
2887564|NCT03335956|Experimental|SAD Part 1 Active Cohort 1 Period 2|
2887565|NCT03335956|Placebo Comparator|SAD Part 1 Placebo Cohort 1 Period 3|
2887566|NCT03335956|Experimental|SAD Part 1 Active Cohort 1 Period 3|
2887567|NCT03335956|Placebo Comparator|SAD Part 2 Placebo Cohort 2 Period 4|
2887568|NCT03335956|Experimental|SAD Part 2 Active Cohort 2 Period 4|
2887569|NCT03335956|Placebo Comparator|SAD Part 2 Placebo Cohort 2 Period 5|
2887570|NCT03335956|Experimental|SAD Part 2 Active Cohort 2 Period 5|
2887571|NCT03335956|Placebo Comparator|SAD Part 2 Placebo Cohort 2 Period 6|
2887572|NCT03335956|Experimental|SAD Part 2 Active Cohort 2 Period 6|
2887573|NCT03335956|Placebo Comparator|MAD Placebo Cohort 1|
2887574|NCT03335956|Experimental|MAD Active Cohort 1|
2887575|NCT03335956|Placebo Comparator|MAD Placebo Cohort 2|
2887576|NCT03335956|Experimental|MAD Active Cohort 2|
2887577|NCT03335956|Placebo Comparator|MAD Placebo Cohort 3|
2887578|NCT03335956|Experimental|MAD Active Cohort 3|
2887579|NCT03335956|Placebo Comparator|MAD Placebo Cohort 4|
2887580|NCT03335956|Experimental|MAD Active Cohort 4|
2887581|NCT03335943|Experimental|CDA-2 (Cell Differentiation Agent 2)|Patients will be given CDA-2 therapy.
2887582|NCT03335930|Experimental|Morning exercise|To exercise at morning (08:00-10:00)
2887583|NCT03335930|Active Comparator|Afternoon exercise|To exercise at afternoon (14:00-16:00)
2887584|NCT03335930|Active Comparator|Evening exercise|To exercise at evening (18:00-20:00)
2887586|NCT03335917|Experimental|Normobaric Hypoxia|This arm will provide hypoxia by reducing the amount of oxygen concentration without changing the barometric pressure
2887587|NCT03335917|Experimental|Hypobaric Hypoxia|This arm will provide hypoxia by reducing the barometric pressure without changing the oxygen concentration (terrestrial altitude exposure)
2887588|NCT03335904|Placebo Comparator|Placebo|Participants will ingest microcrystalline cellulose by mouth on two consecutive days. The first tablet will be consumed on day 1 at 0700 hrs. The second tablet will be consumed at 1900 hrs and the final tablet will be consumed at 0700hrs on day 2. Participants will undergo a Hyperoxic Hypercapnic Ventilatory Response Test, a Hypoxic Hypercapnic Ventilatory Response Test, and Repeated Hypoxic Apneas before and after a Hypoxic Sleep Study.
2887589|NCT03335904|Experimental|Losartan|Participants will ingest 50 mg of losartan, an angiotensin receptor blocker, by mouth on two consecutive days. The first tablet will be consumed on day 1 at 0700 hrs. The second tablet will be consumed at 1900 hrs and the final tablet will be consumed at 0700hrs on day 2. Participants will undergo a Hyperoxic Hypercapnic Ventilatory Response Test, a Hypoxic Hypercapnic Ventilatory Response Test, and Repeated Hypoxic Apneas before and after a Hypoxic Sleep Study.
2887590|NCT03335891|Experimental|Training Group|Asthma Education Program Breathing Exercises Core Stabilization Exercises
2887591|NCT03335891|Active Comparator|Control Group|Asthma Education Program Breathing Exercises
2887592|NCT03335878||Type 1 Diabetes Mellitus Group|T1DM Group - 150 otherwise healthy children, ages 4-16 years old, diagnosed with T1DM within 3 months prior to their initial study visit. This is not a treatment study therefore there is no intervention in this study.
2887593|NCT03335878||Healthy Control Sibling Group|Sibling Control Group - 50 age and gender matched healthy siblings without a diagnosis of T1DM. This is not a treatment study therefore there is no intervention in this study.
2887594|NCT03335852|Experimental|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection
2887595|NCT03335839|Experimental|Intracoronary tPA 10 mg|
2887596|NCT03335839|Experimental|Intracoronary tPA 20 mg|
2887597|NCT03335839|Placebo Comparator|Placebo|saline
2887598|NCT03335826|Experimental|Combined Epi-GA/PCEA|Patients assigned to this group (experimental group) received combined epidural-general anesthesia (combined Epi-GA) and patient-controlled epidural analgesia (PCEA). An epidural catheter was placed before anesthesia induction. General anesthesia was induced and maintained in the same manner as in the control group, with the addition of a continuous infusion or intermittent boluses of 0.5%-0.75% ropivacaine given through the epidural catheter for anesthesia maintenance. Patient-controlled epidural analgesia was used for postoperative analgesia (0.12% ropivacaine and 0.5 ug/mL sufentanil in 250 mL normal saline, programmed to deliver a 2-mL bolus with a lockout interval of 20 minutes and a background infusion of 4 mL/hr).
2887599|NCT03335826|Active Comparator|GA/PCIA|Patients assigned to this group (control group) received general anesthesia (GA) and patient-controlled intravenous analgesia (PCIA). General anesthesia was induced with midazolam, sufentanil, propofol and rocuronium. Anesthesia was then maintained by inhalation of oxygen-nitrous oxide mixture (1:1-2) and sevoflurane, and/or continuous intravenous infusing of propofol. Sufentanil and rocuronium were given when needed. Other types of opioids and muscle relaxants were also provided when necessary. Patient-controlled intravenous analgesia was used for postoperative analgesia (50 mg morphine in 100 mL normal saline, programmed to deliver a 2-mL bolus with a 6-10 minutes lockout interval and a 1 mL/hr background infusion).
2887600|NCT03335813|Experimental|brachytherapy with multichannel balloon applicator|6 channel balloon re-positioning, multichannel brachytherapy applicator used to deliver localized radiation therapy to esophageal tumors
2887601|NCT03335800|Experimental|Apple Heart Study App|
2887602|NCT03335787|Experimental|Intervention|Taping will be applied three times and will be reapplied one and two weeks later prior to first application for two weeks.
2887603|NCT03335787|Other|Control|Control group would not receive any taping in order to prevent sham taping sensory stimulation effect.
2887604|NCT03335774|Active Comparator|Hydrocortisone Acetate Suppository, 25 mg|One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
2887605|NCT03335774|Placebo Comparator|Placebo (Vehicle) Suppository|One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
2887606|NCT03335761|Experimental|Amplitude Setting #1|InterStim Therapy will be set to amplitude parameter #1.
2887607|NCT03335761|Experimental|Amplitude Setting #2|InterStim Therapy will be set to amplitude parameter #2.
2887608|NCT03335761|Experimental|Amplitude Setting #3|InterStim Therapy will be set to amplitude parameter #3.
2887609|NCT03335748|Active Comparator|active control group|The program for the active control group is the same as for the experimental group, except that the degree of difficulty of the exercises remains low and invariable across trials, with three items needing to be recalled throughout.
2887610|NCT03335748|Experimental|the Cogmed program|12 exercises proposed in the Cogmed program. Eight of these target visuospatial WM and four target verbal WM. Eight exercises are preprogrammed for each session, for a total of 90 trials (Pearsons, 2014). The degree of difficulty of the trials increases as a function of the participant's performance. For each trial, the participant receives feedback on their performance.
2887611|NCT03335735|Experimental|Loss-Framed Text Messages|Loss-framed text message
2887612|NCT03335735|No Intervention|Control|Participants in this arm will not receive any intervention.
2887613|NCT03335735|Experimental|Gain-Framed Messaging Group|Gain-framed text message
2887614|NCT03335722|Active Comparator|Active TDCS and Fluency Intervention|Participants will receive 1-mA tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes a day for five consecutive days. he stimulation will be applied for the first half of a 40-minute speech fluency training paradigm, using metronome-timed speech.
2887643|NCT03335514||STEMI|The study population consists of 20 patients with ST-elevated acute myocardial infarction (STEMI,n = 20) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
2887615|NCT03335722|Sham Comparator|Sham TDCS and Fluency Intervention|Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes a day for five consecutive days. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session. he stimulation will be applied for the first half of a 40-minute speech fluency training paradigm, using metronome-timed speech.
2887616|NCT03335709|Experimental|ADL intervention|The participants are assigned to an eight-week intervention program aiming at enhancing ADL ability. The program consists of a minimum of five and a maximum of eight sessions; Session one - First meeting and occupational therapy evaluation (mandatory), Session two - Goal setting and clarifying reasons for problems related to ADL (mandatory), Session three- seven - Interventions aiming at enhancing ADL ability (Number of sessions can vary. However, a minimum of two sessions are mandatory), Session eight - Re-evaluation (Mandatory)
2887617|NCT03335683|Experimental|Phytoterapy agent|Subjects were allocated to receive 1 h and 12 h after surgery: group 1, Lenidase® (Enfarma SRL, Misterbianco, Italy)
2887618|NCT03335683|Placebo Comparator|Placebo|Subjects were allocated to received 1 h and 12 h after surgery: placebo (Sugar pill, Sucratol - Placebo Capsules).
2887619|NCT03335670|Experimental|[68Ga]Pentixafor PET scan|4 mCi (range 3-5 mCi) of [68Ga]Pentixafor is administered intravenously over 1 minute using an infusion pump. PET imaging is performed from time of infusion for about 90 minutes. Approximately 12 blood samples (~ 1 tsp) will be taken for pharmacokinetic analysis.
2887620|NCT03335657|Experimental|CBPT Treatment|The CBPT intervention delivers a patient-oriented cognitive-behavioral self-management program to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy. The program consists of six weekly telephone sessions with a trained physical therapist. Sessions cover an introduction and rationale for treatment in addition to techniques such as deep breathing, graded activity plan and goal-setting, distraction techniques, automatic thoughts, coping self-statements, being present-minded, and relapse prevention and symptom management plans. At the end of the 6th week, patients will build individualized recovery plans with selected strategies and details on frequency of practice.
2887621|NCT03335657|Placebo Comparator|Education Treatment|The education program provides a postoperative recovery and is based on education that would typically be provided by a treating physician or a physical therapist in an outpatient setting. The education program is matched to the CBPT treatment in terms of session frequency and contact with the study therapist. The therapist will call weekly to check in with the patient and encourage him/her to read the manual. Manuals contain educational information on injury patterns and symptoms, stress and recovery, benefits of physical therapy, and importance of daily exercise, and ways to promote healing. Education on sleep hygiene, energy management, healthy eating, and preventing future injury are also provided.
2887622|NCT03335631|Experimental|Group-supervised|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
2887623|NCT03335631|Experimental|Home-based|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as the supervised group). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
2887624|NCT03335618|Experimental|Active Coaching and Monitoring|
2887625|NCT03335618|Sham Comparator|Passive Monitoring|
2887626|NCT03335605||Antibody deficiency (CVID)|Subjects with antibody deficiency (CVID)
2887627|NCT03335605||Healthy controls|Age and gender-matched control subjects
2887628|NCT03335579||non-MACE|patients without major postoperative cardiac or cerebral complications
2887629|NCT03335579||MACE|patients with major postoperative cardiac or cerebral complications
2887630|NCT03335566|Experimental|Sonazoid™|Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 microliter (µL) microbubbles (MB)/kilogram (kg) body weight.
2887631|NCT03335566|Active Comparator|SonoVue®|Participants will receive single I.V bolus injection of SonoVue® 2.4 milliliter (mL).
2887632|NCT03335553|Experimental|Single ascending dose (SAD): BMS-986235 or Placebo|BMS-986235 or Placebo oral dose
2887633|NCT03335553|Experimental|Multiple ascending dose (MAD): BMS-986235 or Placebo|BMS-986235 or Placebo oral dose
2887634|NCT03335540|Experimental|Arm A|Combination therapy determined by biomarker assessment
2887635|NCT03335540|Experimental|Arm B|Combination therapy determined by biomarker assessment
2887636|NCT03335540|Experimental|Arm C|Combination therapy determined by biomarker assessment
2887637|NCT03335540|Experimental|Arm D|Combination therapy determined by biomarker assessment
2887638|NCT03335540|Experimental|Arm E|Combination therapy determined by biomarker assessment
2887639|NCT03335540|Experimental|Arm F|Combination therapy determined by biomarker assessment
2887640|NCT03335540|Experimental|Arm G|Combination therapy determined by biomarker assessment
2887641|NCT03335527|Experimental|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1 ug/kg/h during mechanical ventilation, for a maximum of 3 days
2887642|NCT03335527|Placebo Comparator|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group during mechanical ventilation, for a maximum of 3 days
2887672|NCT03335345|Other|maintaining calorie intake|maintaining enteral caloric intake at the same rate. No aspiration in the gastric tube
2887696|NCT03335202||cf patients at the cf centre Kiel|microbiome of cf patients at the cf centre Kiel will be analyzed and correlated to standard cf care.
2887644|NCT03335514||NSTE-ACS|The study population consists of 30 patients with non-ST elevated acute myocardial infarction (NSTE-ACS,n=30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
2887645|NCT03335514||SAP|The study population consists of 30 patients with stable angina pectoris (SAP, n = 30). The diagnosis is made according to the criteria of the American Heart Association (AHA, 2014 and 2015). Patients who had autoimmune diseases, malignancies,chronic or acute infections, severe heart failure (NYHA class 3and 4) and advanced liver or renal diseases are excluded.
2887646|NCT03335514||CONTROL|20 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Normal group
2887647|NCT03335501|Active Comparator|Rapid-acting Aspart|Rapid-acting Aspart will be used to regulate glucose levels
2887648|NCT03335501|Active Comparator|Faster insulin Aspart|Faster insulin Aspart will be used to regulate glucose levels
2887649|NCT03335488|Experimental|Arm 1, RAVICTI|Used for Baseline, Treatment, Transition, Maintenance, and Safety. Dosing will be based on participants disease and treatment status at entry to the study. RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose.
2887650|NCT03335488|Active Comparator|Arm 2, NaPBA (sodium phenylbutyrate)|"Used for Baseline and Treatment. Sodium Phenylbutyrate (NaPBA). Dosing will be based on participants disease and treatment status at entry to the study.~NaPBA in patients weighing < 20 Kg - 600 mg/Kg, maximum total daily dose~NaPBA in patients weighing > 20 Kg - 13 g/m2, maximum total daily dose"
2887651|NCT03335475|Active Comparator|Fitbit Only|In the Fitbit Only arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, and a Fitbit. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
2887652|NCT03335475|Experimental|Fitbit + Coaching Sessions|In the Fitbit + Coaching Sessions arm, participant will receive their exercise prescription, as devised from their baseline exercise stress test results, a Fitbit, and will have 8 sessions with a coach (interventionist) over the course of 20 weeks. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
2887653|NCT03335462|Experimental|Paravertebral injections|Lumbar paravertebral injections containing contrast will be performed. The needles are kept in their position and afterwards followed by CT scan.
2887654|NCT03335449|Experimental|Protective ventilation group|Protective ventilation (PV group) (Vt 6 ml/Kg of ideal body weight, PEEP 8-10 cmH 2 O and repeated recruitment maneuvers.
2887655|NCT03335449|No Intervention|Standard ventilation group|Standard ventilation (SV group) (Tidal Volume, Vt 10 ml/Kg of ideal body weight, Positive End Expiratory Pressure, PEEP 5 cmH 2 O, no recruitment maneuvers)
2887656|NCT03335436|Experimental|Gabapentin|Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery
2887657|NCT03335436|Placebo Comparator|Placebo|Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery
2887658|NCT03335423|Experimental|Oral Metformin|Oral metformin 1000mg will be given as a single dosis
2887659|NCT03335423|Experimental|Intravenous metformin|Intravenous metformin 500mg will be injected as a single dosis
2887660|NCT03335423|Experimental|Oral codeine and oral metformin|Codeine 25 mg will be given at 5 occasions with approximately 6 hours between each dosing. The fifth and last dose will be given together with 1000 mg oral metformin
2887661|NCT03335423|Experimental|Oral codeine and intravenous metformin|Codeine 25 mg will be given at 5 occasions with approximately 6 hours between each dosing. The fifth and last dose will be given together with 500 mg metformin administrated as an injection.
2887662|NCT03335410||shoulder surgery|18-85 years, undergoing day case shoulder surgery during 15th Sept- 15th Oct 2017, possibility to e-mail and an internet connection, understands Finnish,
2887663|NCT03335397|Experimental|M-learning group|Participants receive mobile app (m-learning application) with interactive content (quiz).
2887664|NCT03335397|Other|Control group|Participants receive traditional learning process (books, journals available in the University library).
2887665|NCT03335384|Experimental|Measurement of Pdi|Two small balloons, which are attached to small, flexible tubes, will be put into the esophagus (food tube) and stomach through the nose. Each balloon is about 2 inches long (deflated) and about the width of a pencil tip. A gastric balloon will be inserted into subject's stomach while an esophageal balloon will be inserted into the subject's esophagus. To reduce any discomfort with this procedure, lidocaine gel or spray will be put into the subject's nose and administered to the back of the throat before the balloon. In addition, swallowing water during the procedure will help to reduce any gagging sensation and will assure that the balloon goes into the esophagus.
2887666|NCT03335384|Experimental|Measurement of SNIPs|While the gastric and esophageal balloon catheters are in place, the subject will be asked to perform a maximal sniff maneuver (SNIP) while one nostril is occluded with a plug containing a nasal pressure transducer to measure airway pressure during maximal inspiration. The distal end of the pressure catheter will be connected to a hand held pressure meter to display peak pressure and to provide you visual feedback. This maneuver will be performed 10 times.
2887667|NCT03335371|Experimental|TTP399 400 mg|
2887668|NCT03335371|Placebo Comparator|Placebo|
2887669|NCT03335358|Experimental|Positive Psychology Intervention|Participants complete baseline assessments and receive a 20min training on the positive psychology activities. They are instructed to engage in at least 2 positive psychology activities alone and at least 2 as a couple each week for 8 weeks. Self-administered activities include expressing gratitude, practicing acts of kindness, focusing on the positive, fostering relationships, working toward a goal, spirituality, savoring. Post-intervention and 3-month follow-up assessments are completed.
2887670|NCT03335358|Other|Waitlist control|Participants complete a baseline assessment and are waitlisted for 4-6 weeks. They then complete another assessment, receive the 20min training on activities, and then complete the 8-week self-administered intervention (same as the experimental arm). Post-intervention and 3-month follow up assessments are also completed.
2887671|NCT03335345|Other|maximum gastric void|stopping enteral feeding at least 6 hours before extubation. Suction in the gastric tube (if its size permits) continuously for 6 hours before extubation.
2887673|NCT03335332|Experimental|High intensity exercise|A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions will supervised at our hospital based fitness centre until the subject is confident to complete the training independently. All HIIT sessions will be supervised over the intervention.
2887674|NCT03335332|Active Comparator|Moderate intensity exercise|
2887675|NCT03335319|Experimental|Periodized Exercise Training Regime|The ET program will be carried out 3 times a week (60 minutes per session) on non-consecutive days for 48 weeks and supervised for both groups. Exercise prescription will be gradually progressed through various combinations of duration, frequency and/or intensity of training. Over the 1st-15th exercise sessions: MCT and anatomical resistance training; from the 16th-30th session: combined ET with HIIT and hypertrophy; from the 31st-45th exercise session, after the adjustments of the respectively time point assessments: MCT and maximal strength; from the 46th-60th exercise sessions: HIIT with hypertrophy; at the end of the 60th session until the end (6 months has passed): the same exercise prescription will repeat all over again at the same order.
2887676|NCT03335319|Active Comparator|Non Periodized Exercise Training Regime|participants will do a combined ET regime (aerobic and RT). Aerobic component: combine moderate to vigorous exercises 3 d.wk-1 on nonconsecutive days, for 20 min per session, involving major muscle groups using the available ergometers to perform continuous and rhythmic activities in nature. Resistance component: RT should be performed after the aerobic component of the exercise session to allow for adequate warm-up. Initial load should be trained initially with one set of 10-15 repetitions that can be lifted without straining (~30%-40% 1RM for the upper body; ~50%-60% 1 RM for the lower body). Each major muscle group should be trained initially with one set; multiple set regimens may be introduced later as tolerated. It will be performed 8-10 exercises of the major muscle groups.
2887677|NCT03335306||Healthy subjects in Hong Kong|
2887678|NCT03335293|Placebo Comparator|Placebo|normal saline vehicle added to subarachnoid block
2887679|NCT03335293|Experimental|100 mcg epinephrine|100 mcg epinephrine added to subarachnoid block
2887680|NCT03335293|Experimental|200 mcg epinephrine|200 mcg epinephrine added to subarachnoid block
2887681|NCT03335280||Positive for PTEN deletion|Confirmed by immunohistochemistry of tissue biopsy
2887682|NCT03335280||Negative for PTEN deletion|Confirmed by immunohistochemistry of tissue biopsy
2887683|NCT03335267|Experimental|CPX-351 (Cytarabine:Daunorubicin) Injection|"Dosing for first induction: CPX-351~• CPX-351 at 100u/m2 will be administered on study days 1, 3 and 5~Dosing for second induction:~• CPX-351 at 100 u/m2 will be administered on days 1 and 3~Dosing for consolidation:~• CPX-351 at 65 u/m2 will be administered on days 1 and 3"
2887684|NCT03335254|Experimental|Period 1: Single Dose|Period 1. Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
2887685|NCT03335254|Experimental|Period 2: Twice Daily Dose|380 mg TSX-011 twice daily dosing period of 15 days in fed conditions.
2887686|NCT03335254|Experimental|Period 3, Day 16-25: Once Daily Dose|"If Period 2 Day 8 total testosterone is >800 ng/dL, subjects randomized in a 1:1 ratio to receive:~Schedule A: 317 mg (TU) TSX-011 twice daily OR~Schedule B: 507 mg (TU) TSX-011 once daily."
2887687|NCT03335254|Experimental|Period 3, Day 16-25: Twice Daily Dose|"If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~If Period 2 Day 8 total testosterone is >350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~If Period 2 Day 8 total testosterone is >800 ng/dL, randomize subjects in a 1:1 ratio to receive:~Schedule A: 317 mg (TU) TSX-011 twice daily OR~Schedule B: 507 mg (TU) TSX-011 once daily."
2887688|NCT03335254|Experimental|Period 3, Day 26-30: Once Daily Dose|"If Period 3 Day 19 total testosterone is >350 ng/dL and <500 ng/dL:~Dose adjust subjects on once-daily dosing from 507 mg TU daily to 570 mg TU daily.~If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose of 507 mg TU daily.~If Period 3, Day 19 total testosterone is >800 ng/dL, decrease TSX-011 dose as follows: Dose adjust subjects on once-daily dosing from 507 mg TU daily to 380 mg TU daily."
2887689|NCT03335254|Experimental|Period 3, Day 26-30: Twice Daily Dose|"If Period 3 Day 19 total testosterone is >350 ng/dL and <500 ng/dL:~Dose adjust subjects on twice daily dosing as follows:~If dose is 570 mg TU twice daily, increase to 633 mg TU twice daily.~If dose is 443 mg TU twice daily, increase to 507 mg TU twice daily.~If dose is 380 mg TU twice daily, increase to 443 mg TU twice daily.~If dose is 317 mg TU twice daily, increase to 380 mg TU twice daily.~If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose twice daily.~If Period 3 Day 19 total testosterone is >800 ng/dL, decrease TSX-011 dose as follows:~For the twice-daily dosing group:~If dose is 570 mg TU twice daily, decrease to 507 mg TU twice daily.~If dose is 443 mg TU twice daily, decrease to 380 mg TU twice daily.~If dose is 380 mg TU twice daily, decrease to 317 mg TU twice daily.~If dose is 317 mg TU twice daily, decrease to 253 mg TU twice daily."
2887690|NCT03335254|Experimental|Period 3, Day 26-30: Thrice Daily Dose|If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
2887691|NCT03335241|Experimental|Arm 1: Fludarabine and Pegylated liposomal doxorubicin|
2887692|NCT03335241|Active Comparator|Arm 2: Pegylated liposomal doxorubicin|
2887693|NCT03335228|Experimental|Eclipse Easy Spin for PRP Treatment|Assessing the safety and efficacy of platelet rich plasma for treating frontal fibrosing alopecia. This will be accomplished by the production of platelet rich plasma by the Eclipse Easy Spin centrifuge. Subjects will receive treatment once a month for 6 months. Platelet rich plasma will be administered via injections into the affected areas of the scalp.
2887694|NCT03335215|Experimental|cognitive remediation|The innovative nature of this cognitive remediation program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation. Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains. The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context.
2887695|NCT03335215|No Intervention|usual care|
2887697|NCT03335189|Experimental|ASyMS-Can|TParticipants assigned to the experimental group will be provided with the encrypted, secure, pre-programmed ASyMS-Can android phone, and instructed of its use; how to report their symptomatology on a twice daily basis using the CTAQ for the first 14 days of each treatment cycle until end of the final cycle of treatment (or up to 16 weeks).
2887698|NCT03335189|No Intervention|Control|Control group will be asked to complete the study questionnaires at your clinic visits. Also, research staff will contact participants at 1 to 14 days following each chemotherapy, mid and end of each chemotherapy appointment and again within week 8 and 16 of your participation to collect information about participants' symptoms.
2887699|NCT03335176|Experimental|Endurance and Resistance Training Exercise|
2887700|NCT03335176|No Intervention|Control group|Usual care
2887701|NCT03335163|Experimental|ENG Implant Users|Healthy women using an ENG implant for at least 12 months and no greater than 36 months will be administered a 6 week titration schedule of topiramate to a max dose of 200mg bid by the final week.
2887702|NCT03335150|Active Comparator|Supportive Care|Support Group for PD-MCI
2887703|NCT03335150|Experimental|CogSMART-PD|Cognitive Rehabilitation for PD-MCI
2887704|NCT03335137||ICU Patients with Severe Burns|Patients suffering from severe burns treated on a burn unit - Drug Level Monitoring Piperacillin/Tazobactam
2887705|NCT03335137||ICU Patients without Burns - Drug Level Monitoring|Patient suffering from disease treated on an ICU - Drug Level Monitoring Piperacillin/Tazobactam
2887706|NCT03335124|Experimental|Active substances|"Vitamin C: Vitamin C will be mixed as 1500 mg vitamin C in 50ml container, which will then be infused over 30 minutes to 1 hour. The bag will be labeled by the pharmacy as Vitamin C. The dosing schedule is 1500mg every 6 hours for 4 days or until discharge from the ICU.~Hydrocortisone: Hydrocortisone will be mixed as 50 mg of Hydrocortisone in 50 ml of 0.9 % Sodium Chloride. Patients will be treated with hydrocortisone 50mg IV q 6 hourly for 4 days or until ICU discharge.~Thiamine: Intravenous thiamine will be given in a dose of 200mg q 12 hourly for 4 days or until ICU discharge."
2887707|NCT03335124|Placebo Comparator|Control|Vitamin C placebo will consist of an identical container of 50cc normal saline (0.9% Sodium Chloride Injection) (but with no vitamin C) and will be labelled vitamin C. Placebo will be infused over 30-60 minutes as per the infusion instructions of the active vitamin. Hydrocortisone placebo will be provided in an identical 50 ml bag of 0.9% Sodium Chloride Injection. Placebo patients will receive a matching vial of 0.9% Sodium Chloride Injection.
2887708|NCT03335111|Experimental|ACI with BAIPC|Beside of routine treatment for Anterior circulation infarction(ACI) patients, BAIPC group patients are admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation). All subjects will take BAIPC for 1 week using 'Remote Ischemic Conditioning Equipment' .Intravenous blood collection with anticoagulant and 5ml total blood will be administered at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
2887709|NCT03335111|Sham Comparator|ACI without BAIPC|ACI patients in this group only recieve routine treatment for ischemic stroke and are admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation using pressure 0 mmHg , followed by 5-minute cuff deflation). All subjects will take BAIPC for 1 week using 'Remote Ischemic Conditioning Equipment' .Intravenous blood collection with anticoagulant and 5ml total blood will be administered at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
2887710|NCT03335098|Experimental|Study arm|Subcutaneous bortezomib 1.3mg/m2 on days 1, 4, 8, and 11 (every 4 weeks, up to 6 cycles) Oral thalidomide 50mg daily on days 1-28 (every 4 weeks, up to 6 cycles) Intravenous or oral dexamethasone 40mg on days 1-4 (every 4 weeks, up to 6 cycles)
2887711|NCT03335085|Active Comparator|Oxytocin|Single dose of intranasally administered 24 IU of Oxytocin (Syntocinon-Spray Novartis, Switzerland)
2887712|NCT03335085|Placebo Comparator|Placebo|All ingredients except for oxytocin.
2887713|NCT03335072|Active Comparator|WHO-recommended|Annual mass azithromycin distribution of all residents
2887714|NCT03335072|Experimental|Age-based core group|Annual mass treatment of everyone plus quarterly treatment of children
2887715|NCT03335072|Experimental|PCR infection-based core group|Annual mass treatment plus quarterly treatment of a PCR-based cohort that would be a subset of the age-based core group.
2887716|NCT03335072|Experimental|TI-based core group|Annual mass treatment plus quarterly treatment of a conjunctival photography-based cohort that would be a subset of the age-based core group
2887717|NCT03335059|Experimental|Synergo® RITE + MMC|Bladder radiofrequency-induced hyperthermia will be delivered in combination with each instillation of MMC in accordance with the Sponsor operational guidelines.
2887718|NCT03335046|Experimental|Intervention|The intervention arm will receive the home visit intervention, consisting of 2 visits to the home by a team consisting of a pediatric medical provider and a school teacher or school support staff member. This team will evaluate the child's home environment to assess for potential asthma triggers that may lead to school absenteeism, and provide strategies and material goods to help reduce those triggers.
2887719|NCT03335046|Other|Wait-List Control|The control group will receive standard interventions carried out by the school system for students at risk for chronic absenteeism. Following the study observation period, this control group will then receive the home visits performed for the intervention group.
2887720|NCT03335033|Active Comparator|Carotid Plaques with >70% Stenosis|Subjects being seen in the Mayo Clinic Gonda Vascular Center who have a plaque causing a > 70% stenosis will be approached for recruitment to receive an ultrasound examination including duplex imaging, shear wave elastography and contrast-enhanced ultrasound.
2887721|NCT03335033|Active Comparator|Carotid Plaques with 50-69% Stenosis|Cardiovascular high-risk patients with moderate (50-69% diameter) stenosis carotid plaques from the Mayo Clinic Gonda Vascular Center will be approached for recruitment to receive an ultrasound examination including duplex imaging, shear wave elastography and contrast-enhanced ultrasound.
2887722|NCT03335020|Placebo Comparator|Normal|Healthy volunteers. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
2887723|NCT03335020|Active Comparator|Fibromuscular Dysplasia (FMD)|Subjects with diagnosis of FMD. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
2887947|NCT03333694|Placebo Comparator|Placebo|Placebo Cutaneous Cream application twice daily
2887724|NCT03335020|Active Comparator|Atherosclerosis|Subjects with diagnosis of atherosclerosis. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
2887725|NCT03335020|Active Comparator|Spontaneous Coronary Artery Dissection (SCAD)|Subjects with diagnosis of SCAD. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
2887726|NCT03335020|Active Comparator|Segmental Arterial Mediolysis (SAM)|Subjects with diagnosis of SAM. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
2887727|NCT03335007|Experimental|Aceclofenac|Aceclofenac 100 mg tablet
2887728|NCT03335007|Placebo Comparator|Placebo|Placebo
2887729|NCT03334994|Active Comparator|Control group: immediate implant alone|Patient will be treated with immediate implant alone.
2887730|NCT03334994|Active Comparator|(Group A) immediate implant alone|Patient will be treated with immediate implant alone.
2887731|NCT03334981||exposed mother and child|mother and child who have been exposed to methadone or to buprenorphine during pregnancy
2887732|NCT03334968||Patient group|Acute ischemic stroke patients
2887733|NCT03334968||Control group|Those served as control group
2887734|NCT03334955|Experimental|polycystic ovary syndrome patients|patients with polycystic ovary syndrome performed laparoscopic ovarian drilling to induce ovulation
2887735|NCT03334942|Experimental|CFTSI|Youth and parents randomized to the Violence Intervention Program (VIP) and Child and Family Traumatic Stress Intervention (CFTSI) arm will receive 4 to 6 CFTSI sessions with a trained clinician and be enrolled in VIP. VIP is the standard clinical service offered to assault injured patients treated in the CHOP ED. Participants in this arm will also complete follow-up assessments approximately 4 and 10 months following the ED visit.
2887736|NCT03334942|No Intervention|Violence Intervention Program|Youth and parents randomized to the VIP-only condition will complete a baseline assessment prior to randomization and then be enrolled in the Violence Intervention Program (VIP). VIP is the standard clinical service offered to assault injured patients treated in the CHOP ED. Participants in this arm will also complete follow-up assessments approximately 4 and 10 months following the ED visit.
2887737|NCT03334929|Experimental|Virtual Reality intervention|Participants will be wearing Virtual Reality headset called Oculus gear equipped with Samsung galaxy S7 during the trigger point injections. The VR app chosen is called Relax VR - Rest, Relaxation & Meditation, which will provide a calm beach scene with waves and soothing musics.
2887738|NCT03334929|No Intervention|control|Participants in this group will receive trigger point injections without any intervention. The trigger point injections will be performed in daily manner.
2887739|NCT03334916|Experimental|YMC026|108 subjects will be assigned in this group. They will be administered 20mL of YMC026 three times a day for 6 days.
2887740|NCT03334916|Placebo Comparator|Placebo|108 subjects will be assigned in this group. They will be administered 20mL of placebo three times a day for 6 days.
2887741|NCT03334903|No Intervention|Standard of Care|Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.
2887742|NCT03334903|Experimental|Postoperative Gabapentin Regimen|Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.
2887743|NCT03334877||β -human chorionic gonadotropin|Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation to predict preterm labour in asymptomatic high risk patients
2887744|NCT03334864||I Retrospective cohort|Diagnosis of advanced non-small cell lung cancer from 2012-2016
2887745|NCT03334864||II Prospective cohort|Advanced non-small cell lung cancer with driver gene mutations
2887746|NCT03334864||III Prospective cohort|Non-small cell lung cancer in immuno-therapy;
2887747|NCT03334864||IV Prospective cohort|Non-small cell lung cancer with wild-type driver gene or unknown driver gene status;
2887748|NCT03334864||V Prospective cohort|Advanced non-small lung cancer with wild-type gene treated with anti-Vascular Endothelial Growth Factor (VEGF) drug.
2887749|NCT03334851|Experimental|Part A, Cohort 1|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration
2887750|NCT03334851|Experimental|Part A, Cohort 2|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
2887751|NCT03334851|Experimental|Part A, Cohort 3|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
2887752|NCT03334851|Experimental|Part A, Cohort 4|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
2887753|NCT03334851|Experimental|Part A, Cohort 5|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
2887754|NCT03334851|Experimental|Part A, Cohort 6|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
2887755|NCT03334851|Experimental|Part A, Cohort 7|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
2887756|NCT03334851|Experimental|Part A, Cohort 8|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
2887757|NCT03334851|Experimental|Part B, Cohort 1|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
2887758|NCT03334851|Experimental|Part B, Cohort 2|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
2887759|NCT03334851|Experimental|Part B, Cohort 3|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
2887760|NCT03334851|Experimental|Part B, Cohort 4|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
2887761|NCT03334851|Experimental|Part B, Cohort 5|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
2887762|NCT03334851|Experimental|Part B, cohort 6|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
2887763|NCT03334838|Experimental|GRP 1 - Assess relative bioavailability (4-way crossover)|"GROUP 1 (Treatments A, B, C, D) All treatments in Group 1 consist of a dose of 120 mg nifurtimox (4 x 30 mg tablets).~In Treatment A, dose administration will be in a fasted state.~For the other treatments, dose administration will be in a fed state:~Treatment B after a low-fat breakfast; Treatment C after a breakfast consisting of dairy products (yogurt+milk); and Treatment D after a high-calorie and high-fat breakfast."
2887764|NCT03334838|Experimental|GRP 2 - Assess relative bioavailability (2-way crossover)|"All subjects in Group 2 will receive a single dose of nifurtimox in each of the Treatments D and E.~In Treatment D, subjects will receive 120 mg nifurtimox (4 x 30 mg tablets), and in Treatment E, subjects will receive 240 mg nifurtimox (8 x 30 mg tablets). Both treatments will be administered in a fed state, after a high-calorie and high-fat breakfast."
2887765|NCT03334825|Experimental|Enhanced housing placement assistance|assistance in the rapid (fast-track) acquisition of permanent housing; and participation in a 12-month support services program designed to prevent PLWHA from relapsing into homelessness, with services focused on increasing clients' capacity to live independently and maintain housing stability
2887766|NCT03334825|Active Comparator|Standard housing placement assistance|standard connections to services and housing programs offered by HASA, HOPWA, or Ryan White
2887767|NCT03334812|Experimental|LNA043|LNA043 20mg/3ml single dose
2887768|NCT03334812|Placebo Comparator|Matching placebo to 20mg|Matching placebo to 20mg/3ml, single dose
2887769|NCT03334812|Experimental|LNA043 40mg/ml|LNA043 40mg/4ml single dose
2887770|NCT03334812|Placebo Comparator|Matching placebo to 40mg|Matching placebo to 40mg/4ml, single dose
2887771|NCT03334799|Other|Sacroiliac belt on and off|Belt on and belt off
2887772|NCT03334786|Experimental|FLX-787-ODT (orally disintegrating tablet)|Single dose
2887773|NCT03334773|Experimental|Intervention group|Nutrition education (group inclusive of education materials)
2887774|NCT03334773|No Intervention|Control group|Only receives education materials
2887775|NCT03334747|Experimental|Treatment arm 1: KAE609 10 mg Single Dose (SD)|COHORT 1_Treatment arm 1: KAE609 10 mg once daily (QD) for 1 day
2887776|NCT03334747|Active Comparator|Treatment arm 2:Coartem Control|COHORT 1_Treatment arm 2: Coartem® twice a day (BID) for 3 days
2887777|NCT03334747|Experimental|Treatment arm 3:KAE609 25 mg SD|COHORT 2_Treatment arm 3: KAE609 25 mg once daily (QD) for 1 day
2887778|NCT03334747|Experimental|Treatment arm 4:KAE609 10 mg 3 Days|COHORT 2_Treatment arm 4: KAE609 10 mg (QD) for 3 days
2887779|NCT03334747|Active Comparator|Treatment arm 5:Coartem Control|COHORT 2_Treatment arm 5: Coartem® twice a day (BID) for 3 days
2887780|NCT03334747|Experimental|Treatment arm 6:KAE609 50 mg SD|COHORT 3_Treatment Arm 6: KAE609 50 mg once daily (QD) for 1 day
2887781|NCT03334747|Experimental|Treatment arm 7:KAE609 25 mg 3 Days|COHORT 3_Treatment Arm 7: KAE609 25 mg once daily (QD) for 3 days
2887782|NCT03334747|Active Comparator|Treatment arm 8:Coartem Control|COHORT 3_Treatment arm 8: Coartem® twice a day (BID) for 3 days
2887783|NCT03334747|Experimental|Treatment arm 9:KAE609 75 mg SD|COHORT 4_Treatment Arm 9: KAE609 75 mg once daily (QD) for 1 day
2887784|NCT03334747|Experimental|Treatment arm 10:KAE609 50 mg 3 Days|COHORT 4_Treatment Arm 10: KAE609 50 mg once daily (QD) for 3 days
2887785|NCT03334747|Active Comparator|Treatment arm 11:Coartem Control|COHORT 4_Treatment Arm 11: Coartem® twice a day (BID) for 3 days
2887786|NCT03334734|Experimental|PBTZ169, 160 mg|2 capsules 80 mg of PBTZ169 once a day for 14 days
2887787|NCT03334734|Experimental|PBTZ169, 320 mg|4 capsules 80 mg of PBTZ169 once a day for 14 days
2887788|NCT03334734|Experimental|PBTZ169, 640 mg|8 capsules 80 mg of PBTZ169 once a day for 14 days
2887789|NCT03334734|Active Comparator|Isoniazid, 600 mg|2 tablets 300 mg of Isoniazid once a day for 14 days
2887790|NCT03334721|Experimental|Gabapentin|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
2887791|NCT03334721|Placebo Comparator|Placebo Oral Capsule|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
2887792|NCT03334708||Locally Advanced or Metastatic Pancreatic Cancer Cohort|For patients with locally advanced or metastatic PDAC, blood will be collected pre-treatment initiation (baseline), after first chemotherapy cycle, every 8-12 weeks while under treatment to coincide with restaging CT scan and at time of disease progression.
2887793|NCT03334708||Acute Benign Pancreatic Pathology Control Cohort|For patients with acute pancreatitis, blood specimens will be drawn at the time of acute pancreatitis and every 6-12 months thereafter
2887794|NCT03334708||Chronic Benign Pancreatic Path,IPMC & Pancreatic Cyst Ctrl|For patients with chronic pancreatitis, IPMN, or cysts, blood specimens will be drawn every 6-12 months.
2887795|NCT03334708||Healthy Control|For normal controls, blood specimens will be drawn once at study baseline.
2887796|NCT03334695|Experimental|Group 1: Ad26.RSV.preF|Participants will receive single intramuscular injection of 1*10^11 virus particles (vp) of Ad26.RSV.preF during Day -90 to Day -28. On Day 0, intranasal challenge with respiratory syncytial virus (RSV)-A Memphis 37b virus will occur for all participants.
2887797|NCT03334695|Placebo Comparator|Group 2: Placebo|Participants will receive single intramuscular injection of placebo as sterile 0.9 percent (%) saline for injection during Day -90 to Day -28. On Day 0, intranasal challenge with RSV-A Memphis 37b virus will occur for all participants.
2887798|NCT03334682|Experimental|spironolactone|Spironolactone ARROW ® 75 mg, 150mg, orally, once a day during all the trial (12 months: 6 months on double-blinded spironolactone then 6 months on open-label spironolactone), + topical therapy during all the trial (benzoyl peroxide 5%)
2887799|NCT03334682|Active Comparator|doxycycline|(Doxycycline Sandoz 100 mg), 100mg/day during 3 months followed by placebo during 3 months, on double-blinded + topical therapy during all the trial (benzoyl peroxide 5%
2887800|NCT03334669|Experimental|Intervention|"Sites randomized to the intervention group will receive the following:~Parents Connect for Healthy Living (PConnect)~Enhanced Nutrition Support~Media Resources"
2887801|NCT03334669|No Intervention|Control|Control sites will not receive any intervention components (i.e., standard practice).
2887948|NCT03333681|Experimental|Refractory rheumatoid arthritis patients|Autologous mesenchymal stem cells
2887802|NCT03334656|Experimental|Biological Dressing|"It is a cellularized dressing of 100 cm² composed of fetal skin cells associated to a bovine collagen matrix:~Fetal skin cells were obtained from a single fetal skin sample and consist in two clinical grade banks of keratinocytes (reference BKF07 K CB1) and fibroblasts (reference BKF07 WCB F d P3) produced at the UTCG. These two clinical grade cells banks were fully characterized and secure.~The matrix is a customized type I calf collagen produced by the company Symatese. Symatese's collagen is in compliance with the European requirements"
2887803|NCT03334656|Active Comparator|Paraffin Gauze Dressing|"It is a low-adherent, sterile paraffin Tulle Gras dressing made from open weave gauze. The gauze has interlocking threads which minimize fraying when the dressing is cut to shape. JELONET® dressings are non-medicated and are used as a primary wound contact layer with paraffin present to reduce the adherence of the product to the surface of a granulating wound.~JELONET® is a product of Smith-Nephew, it has the CE-mark (n°0086) and the class of this medical device is IIa.~The features of this dressing are: Soft paraffin base, Sterile leno weave presentation, Comprehensive size range."
2887804|NCT03334643|Experimental|Non-Diabetes|Participants without clinical diagnosis of impaired glucose tolerance or type 2 diabetes and with fasting blood glucose less than 100 mg/dL. They will consume white bread or fiber mix for multiple times over a span of 2 weeks. Changes in blood glucose levels will be monitored.
2887805|NCT03334643|Experimental|Prediabetes/Diabetes|Participants who are clinically diagnosed with impaired glucose tolerance or type 2 diabetes, and those without the above diagnosis but with fasting blood glucose equal to or greater than 100 mg/dL. They will consume white bread or fiber mix for multiple times over a span of 2 weeks. Changes in blood glucose levels will be monitored.
2887806|NCT03334630|Experimental|DiamondTemp Ablation Catheter|Catheter ablation to treat paroxysmal atrial fibrillation using temperature-controlled ablation catheter
2887807|NCT03334630|Active Comparator|TactiCath Quartz Ablation Catheter|Catheter ablation to treat atrial fibrillation using contact-force sensing ablation catheter
2887808|NCT03334617|Experimental|Durvalumab + olaparib|Durvalumab given in combination with olaparib .
2887809|NCT03334617|Experimental|Durvalumab + AZD9150|Durvalumab given in combination with AZD9150.
2887810|NCT03334617|Experimental|Durvalumab + AZD6738|Durvalumab given in combination with AZD6738.
2887811|NCT03334617|Experimental|Durvalumab + vistusertib|Durvalumab given in combination with Vistusertib (AZD2014).
2887812|NCT03334604|Experimental|Multispecies probiotic group|175 participants.
2887813|NCT03334604|Placebo Comparator|Control group|175 participants.
2887814|NCT03334591|Experimental|Apatinib 5 days' continuous use and 2 days' off|Apatinib 500mg 5 days' continuous use and 2 days' off with Docetaxel60mg/m2 to treat advanced gastric cancer
2887815|NCT03334591|Active Comparator|Apatinib 500mg continuous use|Apatinib 500mg continuous use with Docetaxel60mg/m2 to treat advanced gastric cancer
2887816|NCT03334578|Experimental|Drug: Gastrografin|"Patient will receive 30ml of Gastrografin (diluted at 1:3 ratio with water) as recommended by the manufacturer for a single dose in our population. The dose will be given via the nasogastric tube, which will then be clamped for 1 hour. Gastrografin will only be given if there is evidence of a bowel obstruction. Additionally, Gastrografin will only be given when the patient is hemodynamically stable, not receiving any inotropes, and off of invasive respiratory support. Once administered the patient will receive an x-ray at 48 hours. If Gastrografin can be viewed past the obstruction than another dose of Gastrografin (30ml at 1:3 dilution ratio with water via NG tube) can be given. If gastrografin is not viewed past the obstruction than another dose will not be given.~Generic name: Diatrizoate Meglumine, Diatrizoate Sodium"
2887817|NCT03334578|No Intervention|Control: Standard care|This group will be recruited from an ongoing observational study at our centre. The patients in this group have all received the standard care for treating gastroschisis and any potentially associated bowel obstruction. They have not received Gastrografin. They will be recruited between May 2010 and May 2019.
2887818|NCT03334565|Sham Comparator|Sham|Participants were exposed to unfiltered ambient air (sham) filtered air using air filtration systems in the bedroom and main living space of each residence.
2887819|NCT03334565|Active Comparator|Low efficiency|"Participants were exposed to low-efficiency (LE) HEPA-type filtered air using air filtration systems in the bedroom and main living space of each residence."
2887820|NCT03334565|Active Comparator|High efficiency|"Participants were exposed to high-efficiency (HE) true-HEPA filtered air using air filtration systems in the bedroom and main living space of each residence."
2887821|NCT03334539|Experimental|0.10% HL036 Ophthalmic Solution|0.10% HL036 Ophthalmic Solution, BID for 8weeks
2887822|NCT03334539|Experimental|0.25% HL036 Ophthalmic Solution|0.25% HL036 Ophthalmic Solution, BID for 8weeks
2887823|NCT03334539|Placebo Comparator|Placebo|Placebo vehicle Solution, BID for 8weeks
2887824|NCT03334526|Experimental|healthy volunteers|
2887825|NCT03334513||ROP group|children with retinopathy of prematurity received either bevacizumab or ranibizumab
2887826|NCT03334500|Experimental|Cohort 1 Gleason 6 (n=10)|
2887827|NCT03334500|Experimental|Cohort 2 Gleason 7-8 (n=10)|
2887828|NCT03334500|Experimental|Cohort 3 Gleason 9 or oligometastic disease (n=10)|
2887829|NCT03334487|Experimental|Rovalpituzumab tesirine + dexamethasone|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle plus oral dexamethasone 8 mg twice daily on Day -1, Day 1, and Day 2 of 6-week each cycle.
2887830|NCT03334474||young|18-35 years old
2887831|NCT03334474||middle|35-65 years old
2887832|NCT03334474||aged|65-85 years old
2887833|NCT03334461|Experimental|Mirafluor K gel cola 6150ppm F pH 5.1|Exposure to enamel remineralisation agent
2887834|NCT03334461|Experimental|Curasept ADS 212 a 200ml 0,12%|Exposure to oral antiseptics
2887835|NCT03334461|No Intervention|Placebo|Without exposure to oral antiseptic or enamel remineralisation agent
2887836|NCT03334448|Experimental|LY900014-U200|Single subcutaneous (SC) dose of LY900014 U-200 containing 15 units of insulin lispro (Humalog) in two of four study periods
2887837|NCT03334448|Experimental|LY900014-U100|Single SC dose of LY900014 U-100 containing 15 units of insulin lispro in two of four study periods
2887838|NCT03334435|Experimental|Baricitinib High Dose Nonresponders|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2887949|NCT03333668|Active Comparator|Lisdexamfetamine - Placebo|
2887839|NCT03334435|Experimental|Baricitinib High Dose Nonresponders Rescued|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2887840|NCT03334435|Experimental|Baricitinib Mid Dose Nonresponders Rescued|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2887841|NCT03334435|Experimental|Baricitinib High Dose Responders|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2887842|NCT03334435|Experimental|Baricitinib Mid Dose Responders|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2887843|NCT03334435|Experimental|Baricitinib Low Dose Responders|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2887844|NCT03334435|Placebo Comparator|Placebo Responders|Placebo administered orally.
2887845|NCT03334435|Experimental|Baricitinib Open Label Extension|Baricitinib administered orally.
2887846|NCT03334422|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2887847|NCT03334422|Experimental|Baricitinib Mid Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2887848|NCT03334422|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2887849|NCT03334422|Placebo Comparator|Placebo|Placebo administered orally.
2887850|NCT03334409|Experimental|Arm A (pazopanib hydrochloride, ascorbic acid)|Patients receive pazopanib hydrochloride PO QD on days 1-28 and ascorbic acid IV three times per week. Treatment repeats every 28 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
2887851|NCT03334409|Active Comparator|Arm B (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
2887852|NCT03334396|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2887853|NCT03334396|Experimental|Baricitinib Mid Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2887854|NCT03334396|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2887855|NCT03334396|Placebo Comparator|Placebo|Placebo administered orally.
2887856|NCT03334383|Experimental|Sponge group|Patients offered surgery with the retractor sponge
2887857|NCT03334383|No Intervention|Control group|Patients receiving standard care: surgery in Trendelenburg position
2887858|NCT03334370||DM subjects in Hong Kong|
2887859|NCT03334357|No Intervention|Control|Non-Exercise group. We will provide general advices to control group participants thought an information meeting performed by a graduate in Sport Sciences. It will recommended to follow the physical activity recommendations for adults provided by World Health Organization
2887860|NCT03334357|Experimental|PAR group|"The volume in PAR is based on the minimum physical activity recommended (150min/week at moderate intensity).~Intensity selected for PAR aerobic training is 60-65% HRres. Strength intensity selected was 40-50% of 1 RM.~Frequency. PAR group will train 3 days/week, the minimum frequency recommended. Exercises programmed for the aerobic exercise are treadmill, cycle-ergometer and elliptical ergometer in aerobic training part and weight bearing and guided pneumatic machines (involved major upper and lower body muscle group) in resistance training.~Training load variation. We propose a gradual progression to control the exercise dose Training periodization divided in two phases of 5 weeks each one, starting with a familiarization phase (2 weeks).~Training sessions. Sessions start with a dynamic standardized warm up, which include several muscle activation exercises. Aerobic sessions include compensatory exercises. Training session will be ended with a cooling-down protocol"
2887861|NCT03334357|Experimental|HIIT group.|"The volume in HIIT 40-65 min/week at high intensity. Intensity. Two different protocols: HIIT with long intervals (Type A session), which intensity will be >95% VO2max and HIIT with short intervals (Type B session), >120% VO2max.~Training frequency two times/week. Type of exercise. Type A session are walking in treadmill with personalized slopes. Eight weight-bearing exercises in circuit form, type B session.~Training load variation. Gradual progression to control the exercise dose. Training periodization divided in: familiarization phase, phase I, phase II. Training sessions. Type A: 5 minutes in treadmill at 60% VO2max. After warm-up, participants complete sets corresponding to each training session following the corresponding characteristics. Type B: eight weight-bearing exercises (in circuit form) two times/set with an active rest (walking at 60%VO2max) as many times at as defined. Training session will be ended with a cooling-down protocol"
2887862|NCT03334357|Experimental|WB-EMS group.|"WB-EMS training program will be the same than HIIT intervention related to volume, intensity, frequency, type of exercise, training load variation, training periodization and training session. However, electrical impulse will be included in order to assess if WB-EMS training will produce an added effect compared to HIIT.~Electrical parameters:~We will apply a frequency of 15-33 Hz in type A session. And, we will apply a frequency of 35-75 Hz in type B session.~Intensity will be 80-100 mA. Impulse Width adjusted in relation to body segment: thigh zone (400μsec), glute zone (350μsec), abdominal zone (300μsec), dorsal zone (250μsec), cervical (200μsec), chest zone (200μsec) and arm zone (200μsec).~Duty cycle. We have programmed a duty cycle of 50-67% in type B session, but duty cycle in type A session will be 99%.~RPE impulse: the impulse intensity was individually adapted to generate similar values of rate of perceived exertion (RPE) in Borg CR-10 Scale 5 of 9"
2887863|NCT03334344|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in connection with the in addition to the source CT/MR image
2887864|NCT03334344|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case
2887865|NCT03334318||Allopurinol-treated|Participants in the PERL Clinical Trial (NCT02017171) randomized to allopurinol
2887866|NCT03334318||Placebo-treated|Participants in the PERL Clinical Trial (NCT02017171) randomized to placebo
2887867|NCT03334305|Experimental|Group A|Dose-intensified TMZ with TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine without Autologous Hematopoietic Stem cells (HSCs)
2887868|NCT03334305|Experimental|Group B|Dose-intensified TMZ with TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs)
2887869|NCT03334279||non smokers|
2887870|NCT03334279||cigarette smokers|Cigarette smokers to be included in the study must be frequent smokers (at least 10 cigarettes a day) for a period not less than 5 years.
2887871|NCT03334279||simultaneous cigarette and cannabis smokers|frequent cigarette smokers (at least 10 cigarettes a day) and frequent cannabis smoker (at least 3 times/week) for not less than 5 years.
2887872|NCT03334266|Experimental|Family Spirit Nurture (FSN)|The intervention group (n=169) will receive the Family Spirit Nurture (FSN) + Optimized Standard Care (OSC). The FSN home-visiting module consists of 36, 60-minute lessons delivered by trained local Family Health Coaches (FHCs), from 28 weeks gestation to 18 months postpartum. Lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
2887873|NCT03334266|Other|Control Program|The control group will receive Injury Prevention Education (IPE) + Optimized Standard Care (OSC). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. The lessons will be delivered at the following assessment time points: 36 weeks gestation, 2 weeks, 2 months, 4 months, 6 months, 9 months, 12 months, and 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities but that will not overlap in anyway with FSN content, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
2887874|NCT03334253|Experimental|Atropine Group|0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops
2887875|NCT03334253|Placebo Comparator|Placebo Group|Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops
2887876|NCT03334240|Experimental|CLS003|Digoxin and Furosemide topical formulation
2887877|NCT03334240|Placebo Comparator|Vehicle|Inactive vehicle
2887878|NCT03334227|Experimental|High-Flow nasal cannula (HFNC)|"Treatment with HFNC will be adjusted for SpO2 >92%, even with FiO2 of 0.21, if needed.~The rationale for this HFNC dosage is that minute ventilation can be already reduced with 30 L/min, but functional residual capacity and oxygenation maximally improve at higher flow. On the contrary, flow >50 L/min is uncomfortable for many patients.~In the case of clinical intolerance, flow will be reduced to 40, 30 or 20 L/min. Yet it is not tolerated, HFNC will be stopped and patients will receive conventional oxygen if required, but will be evaluated as in the HFNC group by intention to treat."
2887879|NCT03334227|No Intervention|Conventional therapy|"Patients assigned to the conventional treatment will receive the standard care given at hospital which consists of adding oxygen on nasal prongs or Venturi mask only if hypoxemia is suggested by SpO2 < 92% by pulse oximetry.~Target for oxygenation in both arms is SpO2 between 92% and 95%. SpO2 >95% without oxygen supply is acceptable. On the contrary, SpO2 <92% may be acceptable when needed for medical reasons, mainly chronic hypercapnic patients."
2887880|NCT03334214|Experimental|IONIS DGAT2Rx|Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
2887881|NCT03334214|Placebo Comparator|Placebo (sterile saline 0.9)|Calculated volume to match active comparator administered subcutaneously once weekly for 13 weeks
2887882|NCT03334201|Other|Western diet first|To receive Western diet controlled feeding first, followed by non-Western diet controlled feeding
2887883|NCT03334201|Other|Non-Western diet first|To receive non-Western diet controlled feeding first, followed by Western diet controlled feeding
2887884|NCT03334188|Other|Control|Patients will receive care-as-usual. The only study procedures patients will be exposed to will be a baseline survey at time of enrollment about their sense of engagement around their HFrEF medication prescribing, as well as a follow-up survey with the same general content one month after their next clinic appointment. Medical record review will occur at baseline (enrollment), 1 month after the next clinic appointment post-enrollment, and at 12 months from enrollment.This arm will include 'No Intervention--Usual Care'.
2887885|NCT03334188|Active Comparator|Intervention|Patients will receive the patient engagement video and HFrEF medication checklist by email one week prior to their next clinic appointment after enrollment. Patients in the intervention arm will also receive a baseline survey at time of enrollment about their sense of engagement around their HFrEF medication prescribing, as well as a follow-up survey with the same general content one month after their next clinic appointment. Medical record review will occur at baseline (enrollment), 1 month after the next clinic appointment post-enrollment, and at 12 months from enrollment. This arm will include the 'Intervention :Behavioral: Patient engagement materials.'
2887886|NCT03334175|Experimental|Walnuts Now|Will receive and be instructed to consume 1-oz individually wrapped daily walnut supplement packages for 12 weeks during intervention.
2887887|NCT03334175|No Intervention|Walnuts Later|Will receive diet and exercise guidance at beginning of study. At end of study, will receive 12 weeks of a walnut supply to be consumed at their discretion after the study is complete.
2887888|NCT03334162|Experimental|Intervention group|Patients in the intervention group will perform a standardized, age-adjusted, specific playful sensorimotor training (SMT) program twice a week for 12 weeks in addition to usual care.
2887889|NCT03334162|No Intervention|Control group|Children in the control group will receive treatment as usual. The control group will be given the opportunity to participate in the intervention after study completion
2887890|NCT03334149|Experimental|Self-Monitoring of Blood Pressure|BUMP 1: using a validated home blood pressure monitor at least 3 times a week to record blood pressure BUMP 2: using a validated home blood pressure monitor daily to record blood pressure Women in the intervention groups will be encouraged to use a simple mobile tele monitoring system.
2887891|NCT03334149|No Intervention|Usual Care|Women randomised to usual care will continue to have all their BP monitoring completed by the clinical team at their antenatal assessments.
2887892|NCT03334136|Active Comparator|Vitamin D|25-hydroxyvitamin D 20.000 IU capsule given orally. Five capsules the first day and thereafter one capsule every week for 4 months.
2887893|NCT03334136|Placebo Comparator|Placebo|Placebo oral capsules. Five capsules the first day and thereafter one capsule every week for 4 months.
2887950|NCT03333668|Active Comparator|Guanfacine - Placebo|
2887951|NCT03333668|Experimental|Lisdexamfetamine - Guanfacine|
2887953|NCT03333642|Experimental|Duodenal Ileal interposition|Duodenal Ileal Interposition with Sleeve Gastrectomy.
2887894|NCT03334123|Experimental|Functional training and cycling|Participants in this group will perform 20 minutes of functional training before dialysis (in the first 8 weeks) and intradialysis cycling exercise during dialysis. Participants will also receive exercise counselling; investigators will teach them how to practice at home by practice and examples given during the 20 minutes of functional training pre-dialysis. In the second phase of additional eight weeks participants will perform the functional training at home on non-dialysis days in addition to intradialysis cycling. Kinesiologist will monitor, advice and motivate them.
2887895|NCT03334123|Active Comparator|Cycling|This active control comparator group will perform intradialytic cycling on an adapted ergometer 3 times per week for 4 months without functional training prior to dialysis procedure and without exercise counselling.
2887896|NCT03334110|Experimental|LIMA-GSV-SCVBG Group|Experimental group: The intervention：we apply a new operation on the patients with diffuse coronary artery disease(DCAD), we choose LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein.
2887897|NCT03334110|Other|BIMA-SCVBG Group|The other group：The intervention: We choose bilateral internal mammary artery composited LIMA-Right Mammary Internal Artery（RIMA） y graft， and anastomose the RIMA with selective coronary vein.
2887898|NCT03334097|Experimental|Experimental arm|There will only one experimental arm in order to study test-retest validity after having validate the questionnaire. The beginning of the maternal education takes place between 26 and 30 weeks of gestation and ends between 32 and 36 weeks of gestation. Hence, to study responsiveness, questionnaires will be filed at the beginning of the maternal education and after the two educational sessions related to childbirth.
2887899|NCT03334084|Experimental|1|Scheme 1
2887900|NCT03334084|Experimental|2|Scheme 2
2887901|NCT03334084|Experimental|3|Scheme 3
2887902|NCT03334071|Active Comparator|Exercise Intervention|Patients in the intervention arm will participate in a supervised in-hospital, exercise training program on a cycle ergometer before and during chemotherapy. At week 5-6 there will be a transition period of in-hospital to home-based exercise training (at this point we will perform the exercises that they will perform at home in the in-hospital environment to ensure that the patient understands the home-based exercise training programme) and then week 7-12 will be home-based exercise training only with telephone support.
2887903|NCT03334071|No Intervention|Negative Control|Patients in the control arm will not undergo an exercise training program.
2887904|NCT03334071|No Intervention|Observational|Patients who do not enrol in RCT will be enrolled in the observational arm
2887905|NCT03334058|Experimental|ARGX-113|
2887906|NCT03334045||Stress patients|Patients diagnosed with work-related Adjustment disorder
2887907|NCT03334045||Controls|Healthy controls
2887908|NCT03334032||Inpatient treatment for Anorexia nervosa|"Adolescents with anorexia nervosa assessed~at baseline: on admission to inpatient treatment~at follow-up: 6 months after admission on outpatient basis"
2887909|NCT03334032||Controls|Adolescent healthy and normal weight controls (matched for gender and age), assessed at one point of time
2887910|NCT03334019||subjects|Data collected on general population, farmers and veterinarians though questionnaires and blood samples.
2887911|NCT03334006|No Intervention|A: Control group|Standard of Care
2887912|NCT03334006|Active Comparator|B: Pentaglobin®|Standard of Care + Pentaglobin®
2887913|NCT03333993|Experimental|Intervention Group|Patients in this group will be submitted to 10 sessions of Mat Pilates exercises, performed twice a week, lasting 60 minutes, for a period of 5 weeks (from the beginning to the end of radiotherapy). The program will consist of group sessions of up to 4 patients, supervised by a specialized physiotherapist. In addition, they will be guided to follow with the home exercises, according to the institutional routine.
2887914|NCT03333993|Active Comparator|Control Group|Patients assigned to this group will not participate in the Mat Pilates exercises and will be instructed to maintain the home exercises for upper limbs, guided by physiotherapists in the postoperative period, according to the institutional routine.
2887915|NCT03333941||RES (Regenerative Epithelial Suspension)|
2887916|NCT03333928|Active Comparator|500mg HTD1801, bid|
2887917|NCT03333928|Active Comparator|1000mg HTD1801, bid|
2887918|NCT03333928|Placebo Comparator|placebo, bid|
2887919|NCT03333915|Experimental|Phase 1|
2887920|NCT03333902|Experimental|QLB type 2|"Ultrasound-guided, Inject at the point posterior to quadratus lumborum muscle, 0.2% ropivacaine 30mL in each side for a total of 60mL.~Subjects also receive an intravenous patient-controlled analgesia pump of 0.5mg/mL morphine for 48 hours."
2887921|NCT03333902|Experimental|QLB type 3|"Ultrasound-guided, Inject at the point between the quadratus lumborum and the psoas major muscle, 0.2% ropivacaine 30mL in each side for a total of 60mL.~Subjects also receive an intravenous patient-controlled analgesia pump of 0.5mg/mL morphine for 48 hours."
2887922|NCT03333902|Experimental|QLB type 2+3|"Ultrasound-guided, conduct both QLB type 2 and 3, 0.2% ropivacaine 15mL in each point of injection, for a total of 60mL.~Subjects also receive an intravenous patient-controlled analgesia pump of 0.5mg/mL morphine for 48 hours."
2887923|NCT03333902|Experimental|TAP block|"Ultrasound-guided, inject at the point between the transversus abdominis and internal oblique muscle from lateral side, 0.2% ropivacaine 30mL in each side for a total of 60mL.~Subjects also receive an intravenous patient-controlled analgesia pump of 0.5mg/mL morphine for 48 hours."
2887924|NCT03333902|Active Comparator|epidural|"An epidural catheter was placed when finishing spinal anesthesia. After surgery we used a single bolus of 0.15% ropivacaine + 2 mg morphine (diluted in 6ml saline) via epidural cathether.~Subjects also receive an intravenous patient-controlled analgesia pump of 0.5mg/mL morphine for 48 hours."
2887925|NCT03333889|Active Comparator|E-max hybrid crown|E-max hybrid crown Lithium Disilicate based ceramic which is characterized by high strength and optimum esthetics and considered a gold standard in anterior restorations
2887926|NCT03333889|Experimental|Vita Enamic hybrid crown|Vita Enamic hybrid crown polymer infilltrated ceramic network(hybrid ceramic) characterized by low modulus of elasticity that acts as cushion on implants.
2887952|NCT03333655|Other|Checkpoint Inhibitor Therapy|Pre-treatment (archival) and at progression biopsy for participants with a demonstrated clinical benefit on CPI therapy will be asked to participate in the study. In addition, retrospective enrollment of patients who progressed on CPI therapy after documented response and for whom an at-progression biopsy is available, is also possible.
2887927|NCT03333850|Experimental|Visual feedback of physical activity|Participants in the exposure cohort will receive usual hospital care and continuous measurement of physical activity by sensors collecting physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level, in terms of time spent bedridden, sitting, standing and walking. This information will be visible to the health personnel, the patients and their relatives.
2887928|NCT03333850|Active Comparator|No feedback of physical activity|The participants in the non-exposure cohort will receive usual hospital care and continuous measurement of physical activity by sensors collecting physical activity level during hospitalisation. No visual feedback is provided.
2887929|NCT03333837|Active Comparator|Dance Group|The Dance Group will participate in 1-hour group improvisational dance lessons 2x/week for 12 weeks. Improvisational dance classes are grounded in 4 principles that shape the tone of the class and result in a sense of social belonging: non-judgment, non-competitiveness, curiosity, and playfulness. The following training strategies are used to maintain: active imagination, variability, and pacing.
2887930|NCT03333837|Active Comparator|Non-group Dance|The Non-group dance intervention is designed to capture the same dance movement and auditory stimuli as the group class without social interaction. Recordings of the dance instructor teaching a dance class will be played. This will ensure participants hear comparable music and receive comparable verbal auditory cues to prompt dance movements that students in the group class will hear, without interacting with other people. Improvisational dance is particularly suited for this means of delivery because the primary method of instruction is verbal auditory cueing. Participants will be asked to follow the same schedule as participants in the Dance Group arm and complete 2 one-hour dance sessions each week.
2887931|NCT03333837|Active Comparator|Social Group|The social group will consist of improvisational party games to foster curiosity and playfulness, use imagery, and encourage non-judgment. Games that may be used include 'Balderdash', 'Wise and Otherwise', 'Charades', 'Pictionary', and 'Tell Me A Story' cards. These games will also use the same core strategies as the dance group. Games will be varied within an hour-long session to incorporate pacing and variability into the social group, akin to the dance group. The social group will occur 2x/week for 1 hour each time and be led by the same instructors who lead the Dance Group, to control for effects of personality of the group leader.
2887932|NCT03333837|Sham Comparator|No Contact|A No Contact condition captures the condition of no added social contact and no added dance movement. Participants randomized to the No Contact condition will be asked to continue their current disease management and lifestyle for 12 weeks
2887933|NCT03333824|Experimental|Wee-1 kinase inhibitor AZD1775|To evaluate the effect of multiple doses of AZD1775 on the PK of substrates for CYP3A (midazolam), CYP2C19 (omeprazole), CYP1A2 (caffeine) and to evaluate the effect of multiple doses of AZD1775 on QT interval
2887934|NCT03333798|Experimental|Cognitive-Behavioral Intervention|Cognitive-Behavioral Intervention with community worker support.
2887935|NCT03333798|Active Comparator|Standard psychosocial care|Standard psychosocial care delivered by health services.
2887936|NCT03333785|Experimental|Intervention group|Primary care providers whose patients have been randomized to the intervention group will receive an invitation from their patient's cancer specialist provider to communicate using eOncoNote. Primary care providers and cancer specialist providers will use eOncoNote in addition to usual methods of communication.
2887937|NCT03333785|No Intervention|Control group|Primary care providers whose patients have been randomized to the control group will receive usual care (i.e. their primary care providers will not access eOncoNote to communicate with the cancer specialist providers and vice versa) and will be able to contact each other via telephone, fax, and mail consultation letters and progress notes, as per usual care.
2887938|NCT03333772|Experimental|REAL-T Intervention|The current feasibility study will evaluate the feasibility of implementing the REAL-T RCT by enrolling 10 participants who are 18-30 years of age, conducting the REAL-T intervention with all participants over a 3-month period, evaluating pre-to-post changes in their health and quality of life, and assessing the process of implementing the study (feasibility and participant satisfaction).
2887939|NCT03333759|Experimental|Laser Treatment|"Patients will receive one laser treatment (week 0) with the Erbium YAG laser at a 2940nm wavelength (Alma - Harmony XL Laser) and parameters corresponding with their acne scar severity. They will then return to the clinic 1, 4 and 8 weeks (7, 30, and 56 days + 7 days) after the treatment for their scars to be evaluated under optical coherence tomography.~Laser parameters are as follows:~iPixelEr 2940nm Erbium:YAG Module: mild scars: 7 by 7 (7X7) mm tip, energy 1400-1600 millijoules/P (mJ), pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap moderate scars: 7X7 mm tip, energy 1600-1800 mJ/P, pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap severe scars: 7X7 mm tip, 1800-2000 mJ/P, pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap"
2887940|NCT03333746|Experimental|Treatment (lenalidomide, nivolumab)|Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 1 hour on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2887941|NCT03333733|Experimental|HENRY|Children's Centres within local authorities that have been randomised to the experimental arm, HENRY, will receive staff training to deliver the training and be asked to implement at least two programmes per year. Parents enrolled to attend HENRY programmes will then be invited to take part in the research.
2887942|NCT03333733|No Intervention|Waiting list control|Children's Centres within local authorities that have been randomised to the control arm will continue with usual practice. Parents attending another programme (Stay and Play) will be invited to take part in the research. At the end of the follow-up period, they will be offered training to deliver HENRY programmes although this will not be compulsory.
2887943|NCT03333720|Experimental|Intervention|Intervention is phenylalanine-free protein substitute. Following a 7 day baseline period, all recruits will receive the new phenylalanine-free protein substitute daily for 28 days in addition to routine nutritional management. The study product prescription will be specified on an individual basis by the metabolic Dietitian responsible for the patient's nutritional management and will be dependent on age, bodyweight and medical condition of the patient, but will wholly replace their currently prescribed tablet protein substitute and multivitamin supplements.
2887944|NCT03333707|Experimental|Active|Participants will be provided will full access to the Pacifica app.
2887945|NCT03333707|No Intervention|Wait List|Participants will be placed on a wait list and will receive access to the app after 1 month.
2887946|NCT03333694|Experimental|CLL442|Cutaneous Cream application twice daily
2887954|NCT03333629|Experimental|Enhanced early detection|Providers will receive training to administer enhanced early detection strategies.
2887955|NCT03333629|No Intervention|Usual care|Providers will not change their early detection strategies, but will be monitored.
2887956|NCT03333616|Experimental|Nivolumab+Ipilimumab|"Nivolumab and Ipilimumab are administered intravenously every 3 weeks for a total of 4 maximum doses. After combination therapy, nivolumab will be administered as monotherapy every 4 weeks.~Doses are determined per protocol."
2887957|NCT03333603|Experimental|esomeprazole|esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56
2887958|NCT03333590|Experimental|Cohort 1 (Minimal Efficacious Dose) rAAVrh74.MCK.GALGT2|N = 3 [2.5 x E13 vg/kg per leg, delivered bilaterally (total 5.0 x E13 vg/kg)]
2887959|NCT03333590|Experimental|Cohort 2 (Dose Escalation) rAAVrh74.MCK.GALGT2|N=3 [5 x E13 vg/kg per leg, delivered bilaterally (total 1.0 x E14 vg/kg)]
2887960|NCT03333577|Experimental|Experimental SoundArc study group|all subjects will receive the SoundArc intervention
2887961|NCT03333564|Experimental|VD3 group|treated with 50,000 IU VD3 / week
2887962|NCT03333564|Experimental|omega3-FA group|1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
2887963|NCT03333564|Experimental|VD3 and Omega-3FA group|50,000 IU VD3 / week and 1000 mg wild salmon and fish oil complex (contains 300 mg of omega-3FA) once daily
2887964|NCT03333564|Other|Control group|No intervention was given
2887965|NCT03333551|Experimental|Patients with AL cardiac amyloid|Patients enrolled will be patients > 18 years of age with a clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis) with plans to undergo plasma cell directed chemotherapy.
2887966|NCT03333538|Experimental|Stage 1 (component A)|a single administration of component A (VSV) of vaccine
2887967|NCT03333538|Experimental|Stage 1 (component B)|a single administration of component B (Ad5) of vaccine
2887968|NCT03333538|Experimental|Stage 2 (Primary Group)|150 people who will receive the vaccine in the therapeutic scheme: the sequential introduction of components A and B with an interval of 21 days
2887969|NCT03333538|Placebo Comparator|Stage 2 (Controll Group)|50 people who will receive placebo in the therapeutic scheme: the sequential introduction of components A (placebo) and B (placebo) with an interval of 21 days
2887970|NCT03333525|Experimental|Insulin dose-CARB counting HPM group|HPM (high protein meal), contained 36 g protein,17 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
2887971|NCT03333525|Experimental|Insulin dose-CARB counting HPFM group|HPFM (high protein-high fat meal), contained 36 g protein,30 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
2887972|NCT03333525|Experimental|Insulin dose-CARB+FPU counting-HPFM|HPFM (high protein-high fat meal), contained 36 g protein,30 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting plus fat-protein counting (insulin-to-carbohydrate ratio-ICR and fat-protein unit-FPU).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
2887973|NCT03333525|Active Comparator|Insulin dose-CARB counting SM group|SM (standart meal), contained 24 g protein,17 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR and fat-protein unit-FPU).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
2887974|NCT03333512|Experimental|Nap|After each night with a 5-hour sleep opportunity, participants have a daytime nap opportunity of 1.5 hours.
2887975|NCT03333512|No Intervention|No nap|After each night with a 6.5-hour sleep opportunity, participants do not have a daytime nap opportunity, but instead watch documentaries.
2887976|NCT03333499|Placebo Comparator|the control group|YanXinShi placebo pills
2887977|NCT03333499|Experimental|YanXinShi group|YanXinShi pills
2887978|NCT03333499|Active Comparator|Trimetazidine group|Trimetazidine pills
2887979|NCT03333499|Other|YangXinShi and Trimetazidine group|YanXinShi and Trimetazidine pills
2887980|NCT03333486|Experimental|Treatment (fludarabine, cyclophosphamide, TBI, PBSCT)|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 2 hours on days -6 and -5. Patients undergo TBI on days -1 and PBSCT on day 0.
2887981|NCT03333473|Experimental|Intervention|The intervention will be applied to health facilities in one district in Indonesia and one county in Kenya. The intervention package will work within existing public and private health facilities to strengthen and assess the effectiveness of facility and provider level PPFP service provision and counseling, and expand method choice for women during antenatal, early labor, and post-pregnancy pre-discharge periods. Training within the intervention package include provider-lever PPFP counseling and service provision (PPFP Clinical and Counseling Skills), as well as provider and facility-level leadership management and governance training (Facility-Level Leadership Management and Governance Training).
2887982|NCT03333473|No Intervention|Control|The health facilities control district in Indonesia and county in Kenya will continue with their standard counseling and service provision throughout the study period. At the conclusion of the study period, the facilities in these areas will receive the same intervention that Intervention facilities received prior to study startup.
2888021|NCT03333252|Placebo Comparator|Control Condition|Exposing caregivers to Nutrition and Health promotional material. The care recipients are exposed to plain words games from computer.
2888022|NCT03333239|Experimental|psychodynamic psychotherapy|
2888023|NCT03333239|Experimental|cognitive behavioral psychotherapy|
2888024|NCT03333239|Active Comparator|psychodynamic family intervention|
2887983|NCT03333460|Experimental|Active Comparator: Active rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive active stimulation targeting the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 15 Hz and 100% of the individual resting motor threshold, for a total of 40 trains (60 stimuli per train, inter-train interval of 15 second, total duration 13 minutes). Each session will be repeated twice/daily for 10 consecutive days for 2 weeks, during the continued treatment phase. Following this, the participants will receive the maintenance intervention of 2 sessions per week for 3 months (rTMS follow-up), at the same parameters described above. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
2887984|NCT03333460|Placebo Comparator|Sham Comparator: Sham rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation (Sham). rTMS will be used with the software necessary for the operator to remain blind to the stimulation condition. Also, the software will be pre-programmed by a staff member that will not be involved in data collection and analysis. The sham condition will match the number of pulses delivered during the 15Hz session and will use the same coil placement but the intensity of stimulation will be set a 3% of the individual resting motor threshold so to ensure that the participant will feel similar scalp sensations experienced by participants receiving active rTMS, but brain tissue will not be stimulated. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
2887985|NCT03333447||Study Population|Patients of any age or gender with confirmed diagnosis of type 1 Gaucher disease, treated with VPRIV® at the beginning of the study. Patients should have one MRI data in the 5 previous years before starting VPRIV® treatment (up to 3 months after initiation of VPRIV®.
2887986|NCT03333434|Other|AFO - Ankle_7 group|AFO is active comparator, ANKLE7 is the experimental treatment
2887987|NCT03333434|Other|Ankle-7 - AFO group|AFO is active comparator, ANKLE7 is the experimental treatment
2887988|NCT03333408|Active Comparator|Group A (Antibiotic)|Group A will receive postoperative oral antibiotics for 10 - 14 days (Clindamycin or Augmentin) upon discharge.
2887989|NCT03333408|No Intervention|Group B (no Antibiotic)|Group B will not be given postoperative oral antibiotics upon discharge.
2887990|NCT03333395|Active Comparator|HS Group (study group)|
2887991|NCT03333395|Active Comparator|S Group (control group)|
2887992|NCT03333382|Active Comparator|Plastic Biliary Stent|Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary plastic biliary stent placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
2887993|NCT03333382|Active Comparator|FCSEMS|Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary fully covered self-expanding metal stent (FCSEMS) placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
2887994|NCT03333369|Active Comparator|Madopar Arm|A single dose of a cachet filled with 200 mg levodopa/50 mg benserazide
2887995|NCT03333369|Placebo Comparator|Placebo Arm|A single dose of a cachet filled with Dextrose
2887996|NCT03333356|Experimental|Experimental Arm|adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction /day (duration of RT is 38 days).
2887997|NCT03333356|No Intervention|Standard Arm|Surveillance
2887998|NCT03333343|Experimental|Arm 1|EGF816+ trametinib in escalation phase
2887999|NCT03333343|Experimental|Arm 2|EGF816 + ribociclib in escalation phase
2888000|NCT03333343|Experimental|Arm 3|EGF816 + LXH254 in escalation phase
2888001|NCT03333343|Experimental|Arm A|EGF816 + INC280 in expansion phase (patients with no known resistance mechanism)
2888002|NCT03333343|Experimental|Arm B|EGF816 + trametinib in expansion phase
2888003|NCT03333343|Experimental|Arm C|EGF816 + ribociclib in expansion phase
2888004|NCT03333343|Experimental|Arm D|EGF816 + LXH254 in expansion phase (patients with no known resistance mechanism)
2888005|NCT03333343|Experimental|Arm E|EGF816 + LXH254 in expansion phase (patients with known resistance mechanism)
2888006|NCT03333343|Experimental|Arm F|EGF816 + gefitinib in expansion phase
2888007|NCT03333343|Experimental|Arm G|EGF816 + INC280 in expansion phase (patients with known resistance mechanism)
2888008|NCT03333330|Experimental|Carotid imaging with Visipaque 320 and SonoVue|"Patients undergo to brain MRI, carotid contrast-enhanced CTA, duplex ultrasound, CEUS, blood sampling, clinical structured interview.~Intervention is related to the administration of contrast agents:~Visipaque 320 for contrast-enhanced CTA, and SonoVue for CEUS"
2888009|NCT03333317|Experimental|Regimen A (Low-Dose Lumicitabine)|Participants will receive a single 40 milligram per kilogram (mg/kg) loading dose (LD) (Dose 1) followed by nine 20 mg/kg maintenance doses (MDs) (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.
2888010|NCT03333317|Experimental|Regimen B (High-Dose Lumicitabine)|Participants will receive a single 60 mg/kg LD (Dose 1) followed by nine 40 mg/kg MDs (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.
2888011|NCT03333317|Placebo Comparator|Regimen C (Placebo)|Participants will receive either a single 40 mg/kg placebo LD (Dose 1) followed by nine 20 mg/kg maintenance dose (MDs) (Doses 2 to 10) of placebo twice daily or single 60 mg/kg placebo LD (Dose 1) followed by nine 40 mg/kg placebo MDs (Doses 2 to 10), twice daily up to Day 5/6.
2888012|NCT03333304|Experimental|PCT group|Procalcitonin measurement and Discontinuation of antimicrobials according to Procalcitonin kinetics
2888013|NCT03333304|No Intervention|Standard of care|Standard practice
2888014|NCT03333291|Experimental|Fecal transplantation|Duodenal transfer of healthy donor fecal suspension
2888015|NCT03333278|Active Comparator|Vitamins|intravenous: Ascorbic acid (Vitamin C: 1.5g every 6 hours) Thiamine (Vitamin B1: 200mg every 12 hours) Hydrocortisone (50mg every 6 hours)
2888016|NCT03333278|Other|Control|Hydrocortisone (50mg every 6 hours)
2888017|NCT03333265|Experimental|100mg Berberine hydrochloride group|Berberine hydrochloride 100mg tablet by mouth, two times per day for 6 months
2888018|NCT03333265|Experimental|300mg Berberine hydrochloride group|Berberine hydrochloride 300mg tablet by mouth, two times per day for 6 months
2888019|NCT03333265|Placebo Comparator|Placebo oral tablets|identical-appearing placebo tablets by mouth, two times per day for 6 months
2888020|NCT03333252|Experimental|Intervention Condition|Exposing caregivers to caregiving-related information and care recipients to cognitive training tasks
2888320|NCT03331458|Experimental|subjects with prostate cancer|
2888025|NCT03333226|Experimental|ARM lymph node preservation|All patients will be sent to both rSLNB and photodynamic Axillary Reverse Mapping (ARM) to evaluate the crossover between SLN and ARM lymph node. In case of SLN metastases, an ALND with ARM lymph node preservation will be performed.
2888026|NCT03333226|Active Comparator|ARM lymph node removal|All patients will be sent to both rSLNB and photodynamic Axillary Reverse Mapping (ARM) to evaluate the crossover between SLN and ARM lymph node. In case of SLN metastases, an ALND with ARM lymph node removal will be performed.
2888027|NCT03333213|Experimental|Gua Sha therapy|Patients' backs were first covered with Tumarol N Balsam. The study physician then applied a round-edged instrument (the inside smooth edged lip of a metal cap) to patients' skin in downward strokes. Patients were treated twice with a 7-day interval.
2888028|NCT03333213|No Intervention|Waitlist control group|Treatments in the control group were not regulated but patients were asked to continue their self-directed medical care. They were offered the Gua Sha therapy once the trial was concluded.
2888029|NCT03333187|Experimental|Arm A|Treatment with Allogeneic Stem cell Transplantation after 3 months of Ruxolitinib induction therapy
2888030|NCT03333187|Active Comparator|Arm B|Treatment with Ruxolitinib continuous therapy
2888031|NCT03333174|Experimental|Servo-controlled Oxygen Environment|Oxygen will be provided by servo-controlled oxygen environment with adjustment of oxygen concentration (FiO2) to keep infant's oxygen saturation target range at 91-95% in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
2888032|NCT03333174|Active Comparator|Nasal Cannula Oxygen|Oxygen will be provided by nasal cannula with adjustment of flow rate and FiO2 to keep infant's oxygen saturation target range at 91-95% in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
2888033|NCT03333161|Experimental|Higher TcCO2|"The investigators will evaluate the effects of attempts to increase blood carbon dioxide levels within a narrow range of 5 mm Hg (well within the range of usual clinical practice) in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.~The investigators will attempt to adjust PCO2 by 5 mm Hg higher from baseline (to max of 70 mm Hg), as long as pH is >7.2. The first 24 hours of the data collection will be the baseline data. Over the next 72 hours, the investigators will evaluate 3 interventions in a cross-over manner, with the initial intervention randomly assigned: Intervention 1 (24-48h of data; Increase TcCO2 by 5 mm Hg), Intervention 2 (48-72h; TcCO2 back to baseline), and Intervention 3 (72-96h; increase TcCO2 again by 5 mm Hg)."
2888034|NCT03333161|Active Comparator|Lower TcCO2|"The investigators will evaluate the effects of attempts to decrease blood carbon dioxide levels within a narrow range of 5 mm Hg (well within the range of usual clinical practice) in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.~The investigators will attempt to adjust PCO2 by 5 mm Hg lower than baseline (to minimum of 40 mm Hg), as long as pH is <7.45."
2888035|NCT03333148|Experimental|Arm A - Nestle IMPACT Immunonutrition|Treatment Arm A (n=146) — Nestlé IMPACT Advanced Recovery:Along with standard of care nutritional therapy patients will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
2888036|NCT03333148|Other|Arm B- Standard of Care|No intervention standard of care nutrition (n=146).
2888037|NCT03333135|Experimental|HK100 Pulsed Electromagnetic Field|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Hong Kong 100 races. In addition, these athletes will use the pulsed electromagnetic field (PEMF) for the two weeks prior to the race.
2888038|NCT03333135|Sham Comparator|HK100 Pulsed Electromagnetic Field Sham|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Hong Kong 100 races. In addition, these athletes will use a PEMF device that doesn't produce electromagnetic fields (sham) for the two weeks prior to the race.
2888039|NCT03333135|Experimental|UTMB Pulsed Electromagnetic Field|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Ultra Trail du Mont Blanc (UTMB) races. In addition, these athletes will use the pulsed electromagnetic field (PEMF) for the two weeks prior to the race.
2888040|NCT03333135|Sham Comparator|UTMB Pulsed Electromagnetic Field Sham|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Ultra Trail du Mont Blanc (UTMB) races. In addition, these athletes will use a PEMF device that doesn't produce electromagnetic fields (sham) for the two weeks prior to the race.
2888041|NCT03333122||Breast Conserving Therapy|Patient who undergo breast conserving therapy or breast conserving therapy with oncoplastic therapies will complete the BREAST-Q Lumpectomy survey module.
2888042|NCT03333122||Mastectomy|Patients who undergo mastectomy will complete the BREAST-Q Mastectomy survey module.
2888043|NCT03333122||Mastectomy with Reconstruction|Patient who undergo breast reconstruction will complete the BREAST-Q Reconstruction survey module. This group will be further subdivided based on implant or autologous tissue reconstruction.
2888044|NCT03333109|Experimental|AMG334 (erenumab) Dose 1|AMG334 Dose 1, administered by pre-filled syringe
2888045|NCT03333109|Experimental|AMG334 (erenumab) Dose 2|AMG334 Dose 2, administered by pre-filled syringe
2888046|NCT03333109|Placebo Comparator|Placebo|Placebo administered by pre-filled syringe
2888047|NCT03333096|Other|Glaucoma and mild cognitive impairment|"Device: Ocusweep test battery Neuropsychological test battery~Ocusweep system compared to neuropsychological testing"
2888048|NCT03333083|Experimental|Raltegravir + Lamivudine|
2888049|NCT03333070|Active Comparator|Treatment Arm|"25 consecutive children diagnosed with functional constipation will be treated with full dose PEG (Polyethylene glycol 3350) treatment (dose of ~1g/kg/day) for 12 weeks.~After 12 weeks of treatment they will be randomized: treated arm will receive probiotic containing Lactobacillus reuteri for 12 weeks while tapering the PEG dose Dose of 5 drops per day for 48 weeks"
2888050|NCT03333070|Placebo Comparator|Placebo Arm|"25 consecutive children diagnosed with functional constipation will be treated with full dose PEG (Polyethylene glycol 3350) treatment (dose of ~1g/kg/day) for 12 weeks.~After 12 weeks of treatment they will be randomized: control arm will receive placebo for 12 weeks while tapering the PEG dose Dose of 5 drops per day for 48 weeks"
2888321|NCT03331445|Experimental|160 ppm Nitric Oxide|
2888051|NCT03333057|Experimental|NOV03 4 times daily (QID)|100% Perfluorohexyloctance solution 4 times daily (QID)
2888052|NCT03333057|Experimental|NOV03 2 times daily (BID)|100%Perfluorohexyloctance solution 2 times daily (BID)
2888053|NCT03333057|Placebo Comparator|Placebo 4 times daily (QID)|Saline solution (0.9% sodium chloride solution) 4 times daily (QID)
2888054|NCT03333057|Placebo Comparator|Placebo 2 times daily (BID)|Saline solution (0.9% sodium chloride solution) 2 times daily (BID)
2888055|NCT03333044|Experimental|CHW-led health coaching|Group sessions
2888056|NCT03333044|Experimental|HIT-enabled & CHW led|Supportive care enabled by mobile devices.
2888057|NCT03333044|Experimental|CHW & Physician Feedback|Patient setting progress communicated to physician via PHI
2888058|NCT03333031|Experimental|HS-196|HS-196 will be administered intravenously as a single dose
2888059|NCT03333018||Aclidinium bromide monotherapy|In DUS1, all new users of aclidinium either on monotherapy or with concomitant formoterol will be included. In addition, in DUS2, all new users of the fixed-dose combination of aclidinium/formoterol and any other new fixed-dose combinations of LAMAs and LABAs that become available during the study and that are captured in each database will be included.
2888060|NCT03333018||Aclidinium bromide and formoterol|In DUS1, all new users of aclidinium either on monotherapy or with concomitant formoterol will be included. In addition, in DUS2, all new users of the fixed-dose combination of aclidinium/formoterol and any other new fixed-dose combinations of LAMAs and LABAs that become available during the study and that are captured in each database will be included.
2888061|NCT03333018||New users of other COPD medication|New users of other COPD medications (tiotropium, other LAMAs, LABA, LABA/ICS, LAMA/LABA), prescribed as recorded in the database.
2888062|NCT03333005|Experimental|APX001 with Standard of Care Anti-fungal agent|
2888063|NCT03332992|Experimental|Viral changes + General intentions|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a general question asking whether the respondent intends to get a flu shot (general intentions).
2888064|NCT03332992|Experimental|Viral changes + Behavioral intentions|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a question asking when / where the respondent will get a flu shot (behavioral intention).
2888065|NCT03332992|Experimental|Viral changes + Accountability|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a question that implies the patient's care team will be notified of intent to vaccinate (accountability to providers).
2888066|NCT03332992|Experimental|Protect others + General intentions|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a general question asking whether the respondent intends to get a flu shot (general intentions).
2888067|NCT03332992|Experimental|Protect others + Behavioral intentions|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a question asking when / where the respondent will get a flu shot (behavioral intention).
2888068|NCT03332992|Experimental|Protect others + Accountability|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a question that implies the patient's care team will be notified of intent to vaccinate (accountability to providers).
2888069|NCT03332966||Participants|"The adolescent psychiatric organizations of the Helsinki University Central Hospital (serving the capital region's 1.1 million inhabitants), the Tampere University Hospital (catchment area of 500.000 inhabitants), and the Oulu University Hospital (catchment area of 500.000 inhabitants) have agreed to implement the data collection as part of routine intake assessments for patients aged 15-17. All consenting patients will be enrolled; the only exclusion criterion is a previous diagnosis of psychotic disorder.~The participants will fill in psychiatric self-report questionnaires, and their structured diagnostic interview data will be collected with their permission."
2888070|NCT03332953|Other|E-cigarette|Subjects will be asked to vape various e-cigarettes at three concentrations of nicotine and sweet flavor (9 stimuli per subject). The subject will be asked to make ratings for the overall liking or disliking of the e-cigarette, followed by ratings on perceived intensities of sensations.
2888071|NCT03332940|Experimental|Tc99m-sulfur colloid + Tc99m-tilmanocept|All subjects will receive a single IV injection of unfiltered sulfur colloid radiolabeled with 8 mCi Tc99m on study day 0. All subjects will receive a single IV injection of 200 mcg tilmanocept radiolabeled with 8 mCi Tc99m on study day 3.
2888072|NCT03332927|Experimental|Egg based breakfast foods|Study products delivering two eggs/day, 6 days per week, will be administered for the 4-week treatment period.
2888073|NCT03332927|Active Comparator|Non-egg based breakfast foods|Study products delivering non-egg based control breakfast foods will be administered 6 days per week for the 4-week treatment period.
2888074|NCT03332914|Active Comparator|First group|control group fisrt and after washing out Microcurrent therapy: Channel A: 100µA; 200 Hz Duration of each treatment session: 30 minutes Number of sessions: 10
2888075|NCT03332914|Active Comparator|Second group|"Microcurrent therapy: Channel A: 100µA; 200 Hz Duration of each treatment session: 30 minutes Number of sessions: 10~after washing out control group"
2888076|NCT03332888|Experimental|Interventional Group|For this trial, HMA-CD20 will be given as an intravenous infusion of 1000 mg I.V twice in a month separating them by fourteen days starting at the baseline visit. The dose for both HMA-CD20 dosages willbe identical at the screening visit after the participant's eligibility has been established, and it will remain thesame for both infusions. The standard dose for HMA-CD20 is 1,000 mg per intravenous infusion on day 1 and day 15.
2888077|NCT03332875|Experimental|OurRelationship - 1 Coach Call|OurRelationship online program plus a single call with a coach.
2888078|NCT03332875|Experimental|OurRelationship - 4 Coach Calls|OurRelationship online program plus four calls with a coach.
2888079|NCT03332862|Experimental|Discontinuous ablation|perform discontinuous ablation of ipsilateral pulmunary veins.
2888080|NCT03332862|Active Comparator|Continuous ablation|perform continuous ablation of ipsilateral pulmunary veins.
2888081|NCT03332849|Experimental|Cohort 1|T1DM: Multiple dose subcutaneous administration
2888082|NCT03332849|Experimental|Cohort 2|T1DM: Multiple dose subcutaneous administration
2888083|NCT03332849|Experimental|Cohort 3|T2DM: Multiple dose subcutaneous administration
2888088|NCT03332823|Experimental|SME Ambassadors training & program|- SME Ambassadors will participate in train-the-ambassador workshops and provide voluntary services and promote mental well-being activities to vulnerable groups.
2888089|NCT03332810|Experimental|SME family based physical activity|Adults and family members will participate into one core session and one booster session
2888090|NCT03332810|Active Comparator|Gathering activity|Adults and family members will participate into two gathering activities
2888091|NCT03332797|Experimental|Dose Escalation: GDC-9545|During dose escalation, participants will be assigned sequentially to escalating doses of GDC-9545, up to the maximum tolerated dose (MTD) or maximum administered dose (MAD).
2888092|NCT03332797|Experimental|Dose Escalation: Cohort B0: GDC-9545 + Palbociclib|GDC-9545 will be administered at a dose lower than the MTD or MAD determined in single-agent dose escalation along with the label-recommended dose of Palbociclib.
2888093|NCT03332797|Experimental|Dose Expansion: Cohort A1: GDC-9545 Dose 1|GDC-9545 will be administered as a single-agent at a dose lower than the MTD/MAD (Dose 1).
2888094|NCT03332797|Experimental|Dose Expansion: Cohort A2: GDC-9545 Dose 1 + LHRH|GDC-9545 will be administered at a dose lower than the MTD or MAD (Dose 1) along with an approved LHRH agonist.
2888095|NCT03332797|Experimental|Dose Expansion: Cohort A3: GDC-9545 Dose 2|GDC-9545 (Dose 2) will be administered as a single-agent at a dose at or below the MTD/MAD and above Dose 1.
2888096|NCT03332797|Experimental|Dose Expansion: Cohort A4; GDC-9545 Dose 2 + LHRH|GDC-9545 will be administered at Dose 2 along with an LHRH agonist.
2888097|NCT03332797|Experimental|Dose Expansion: Cohort B1: GDC-9545 + Palbociclib|GDC-9545 will be administered at a dose that is at or below MTD/MAD along with Palbociclib.
2888098|NCT03332797|Experimental|Dose Expansion: Cohort B2: GDC-9545 + Palbociclib + LHRH|GDC-9545 will be administered at or below MTD/MAD along with Palbociclib and an approved LHRH-agonist.
2888099|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 1)|TAK-925, Intravenous single administration. Healthy adults will be enrolled in double blind manner.
2888100|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 2)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 2). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
2888101|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 3)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 3). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
2888102|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 4)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 4). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
2888103|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
2888104|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 6)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 6). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
2888105|NCT03332784|Placebo Comparator|Part 1: Placebo (Cohort 1-2)|TAK-925 Placebo, Intravenous single administration. Healthy adults will be enrolled in double blind manner.
2888106|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 3; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Healthy elderly participants will be enrolled in double blind manner.
2888107|NCT03332784|Placebo Comparator|Part 1: Placebo (Cohort 3)|TAK-925 Placebo, Intravenous single administration. Healthy elderly participants will be enrolled in double blind manner.
2888108|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 4; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Healthy adults will be enrolled in non-blinded manner.
2888109|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 5)|TAK-925, Intravenous single administration. Dose in Cohort 5 will be based on safety and tolerability in the Part 1. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
2888110|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 6)|TAK-925, Intravenous single administration. Dose in Cohort 6 TBD based on safety, tolerability, PK data, and results of the Maintenance Wakefulness Test (MWT) from previous Cohorts. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
2888111|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 7)|TAK-925, Intravenous single administration. Dose in Cohort 7 TBD based on safety, tolerability, PK data, and results of the Maintenance of Wakefulness Test (MWT) from previous Cohorts. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
2888112|NCT03332784|Placebo Comparator|Part 2: Placebo (Cohort 5-7)|TAK-925 Placebo, Intravenous single administration. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
2888113|NCT03332771|Experimental|Sotagliflozin dose 1|Sotagliflozin dose 1, given as two tablets, and two glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day
2888114|NCT03332771|Experimental|Sotagliflozin dose 2|Sotagliflozin dose 2, given as one tablet and one sotagliflozin-matching placebo tablet, and two glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day
2888115|NCT03332771|Active Comparator|Glimepiride|Two sotagliflozin-matching placebo tablets, and combination of 2 glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day
2888116|NCT03332771|Placebo Comparator|Placebo|Two sotagliflozin-matching placebo tablets and two glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day
2888117|NCT03332758||RD treated with vitrectomy|Vitreous fluid from retinal detachment treated with pars plana vitrectomy
2888118|NCT03332758||RD treated with external drainage|Subretinal fluid from retinal detachment treated with external drainage.
2888119|NCT03332758||Macular holes treated with vitrectomy|Vitreous fluid from patients treated for macular hole
2888120|NCT03332758||ERM treated with vitrectomy|Vitreous fluid from patients treated for epiretinal membrane
2888121|NCT03332745||Severe aortic stenosis|Patients with severe aortic stenosis who are scheduled to undergo aortic valve replacement surgery
2888122|NCT03332745||Control group|Patients scheduled to undergo non-aortic valve cardiac or elective ascending aortic surgery
2888123|NCT03332732|Experimental|Part 1A|In Part 1A, subjects will receive single doses of VNRX-5133 and VNRX-5022 alone and in combination. All subjects will receive all treatments in the sequence specified by the randomization schedule..
2888124|NCT03332732|Experimental|Part 1B|In part 1B, subjects from Part 1A will receive metronidazole with or without VNRX-5133 + VNRX-5022. All subjects will receive all treatments in the sequence specified by the randomization schedule.
2888125|NCT03332732|Experimental|Part 2 - 2A|Multiple dose administration of Low Dose VNRX-5133 + VNRX-5022
2888126|NCT03332732|Experimental|Part 2 - 2B|Multiple dose administration of High Dose VNRX-5133 + VNRX-5022
2888127|NCT03332732|Placebo Comparator|Part 2 - 2C|Multiple dose administration of Placebo (matching VNRX-5133 + VNRX-5022)
2888128|NCT03332719|Active Comparator|Enbrel®|Enbrel® 50 mg injectable solution in autoinjector SureClick® contains: 50 mg etanercept and excipients/Once a week Methotrexate 15 to 25 mg /Once a week
2888129|NCT03332719|Experimental|Enerceptan®.|Enerceptan®. Injectable Solution in prefilled syringes Source: GEMABIOTECH S. A. Formulation per unit: 1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg /Once a week
2888130|NCT03332706||SG|Study Group is the group where the patients during observation suffer from spontaneous abortion or missed abortion,
2888131|NCT03332706||CG|Control Group is where the patients carry the normal live fetal for at least 8 weeks
2888132|NCT03332693|Active Comparator|No exercise|Volunteers will not participate in exercise
2888133|NCT03332693|Active Comparator|Light exercise|Volunteers will participate in one short exercise
2888134|NCT03332693|Active Comparator|Heavy exercise|Volunteers will participate in heavy exercise
2888135|NCT03332680|Experimental|EmbryoGlue® (laboratory culture medium)|"laboratory culture medium~laboratory embryo culture medium, embryos are placed in this media prior to transfer into uterus via embryo transfer procedure to facilitate IVF. EmbryoGlue contains Hyaluronic acid."
2888136|NCT03332680|Active Comparator|Standard control medium|"laboratory culture medium~In standard procedure embryos are placed in a media prior to transfer into uterus via embryo transfer procedure to facilitate IVF."
2888137|NCT03332667|Experimental|131I-MIBG with Dinutuximab|Patients will receive 131I-MIBG on day 1. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab and 131I-MIBG dose will be based on the dose level assigned at the time of patient registration. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
2888138|NCT03332654||Multiple sclerosis|Prevalence and risk factor of stress urinary incontinence in women with multiple sclerosis and included in the database over 15 years from December 1999 to June 2014, who had undergone a urodynamic test
2888139|NCT03332641|Experimental|Citron peel Extract|Citron peel extract for 12 weeks
2888140|NCT03332641|Placebo Comparator|Placebo|Placebo for 12 weeks
2888141|NCT03332628|Other|Microneedle application|This is the only arm of the study. Nine sites on the upper arm will be identified, and baseline measurements of trans-epidermal water loss, electrical resistance, sebum content, hydration, color, and pH of the skin will be made at every site. At three of the sites a small microneedle patch will be applied to the skin. Microneedle application will only occur once on the first day of the study, and the microneedle patches will then be discarded. The sites will be covered with a small patch secured in place with medical tape; three of the other sites that did not receive microneedle application will also be covered with patches. The last three sites will not have any microneedle application and will not be covered with patches. Measurements will be repeated daily at all nine sites for four consecutive days after the day of microneedle application (trans-epidermal water loss measurements will only be made on day 1).
2888142|NCT03332615|Active Comparator|Clinicians with MI coaching|Clinicians in the intervention arm will be taught Motivational Interviewing via a coaching model in which a didactic session is followed by feedback through review of clinicians' audio-recorded encounters.
2888143|NCT03332615|Placebo Comparator|Wait-list control|After consent, clinicians in the wait-list control arm will complete a survey to self-assess their motivational interviewing skills and burnout.
2888144|NCT03332602|Experimental|free FeSO4|wheat bread fortified with free FeSO4
2888145|NCT03332602|Experimental|free FeSO4 and empty microspheres|wheat bread fortified with free FeSO4, and empty microspheres
2888146|NCT03332602|Experimental|free FeSO4 with eudragit polymer|wheat bread fortified with free FeSO4, and eudragit polymer
2888147|NCT03332602|Experimental|free FeSO4 with Hyaluronic Acid|wheat bread fortified with free FeSO4, and hyaluronic acid
2888148|NCT03332602|Experimental|encapsulated FeSO4 3.2%|wheat bread fortified with encapsulated FeSO4 in a microsphere with 3.2% Fe loading
2888149|NCT03332602|Experimental|encapsulated FeSO4 20%|wheat bread fortified with encapsulated FeSO4 in a microsphere with 20% Fe loading
2888150|NCT03332602|Experimental|encapsulated FeSO4 3.2%, encap. Vitamin A|wheat bread fortified with encapsulated FeSO4 in a microsphere with 3.2% Fe loading, and encapsulated Vitamin A as microspheres
2888151|NCT03332602|Experimental|encapsulated FeSO4 3.2%, encap. Vitamin A, free folicacid|wheat bread fortified with encapsulated FeSO4 as microsphere with 3.2% Fe loading, encapsulated Vitamin A as microspheres and free folic acid
2888152|NCT03332602|Experimental|FeSO4 embedded in Hyaluronic Acid|wheat bread fortified with FeSO4 that is embedded in hyaluronic acid.
2888153|NCT03332589|Experimental|E6201 320 mg/m2 twice weekly (max)|320 mg/m2 E6201 for injection 250 ml over 120 min twice weekly, repeated weekly for 3 weeks in a 28 day cycle. In the event of drug related toxicities, dose reductions of 240 mg/m2 and 160 mg/m2 can be used in sequential dose lowering to alleviate symptoms of toxicity.
2888154|NCT03332589|Experimental|E6201 240 mg/m2 twice weekly (-1 dose)|240 mg/m2 E6201 for injection 250 ml over 120 min twice weekly. Used only in the event of drug related toxicities at 320 mg/m2.
2888155|NCT03332589|Experimental|E6201 160 mg/m2 twice weekly (-2 dose)|160 mg/m2 E6201 for injection 250 ml over 120 min twice weekly. Used only in the event of drug related toxicities at 240 mg/m2.
2888156|NCT03332576|Experimental|Cohort 1|"6 Doses DPX-Survivac (2 prime q3w, 4 boost q8w)~Low dose cyclophosphamide"
2888157|NCT03332576|Experimental|Cohort 2|"6 Doses DPX-Survivac (2 prime q3w, 4 boost q8w)~Low dose cyclophosphamide"
2888158|NCT03332576|Experimental|Cohort 3|"3 Doses DPX-Survivac (1 prime, 2 boost q8w)~Low dose cyclophosphamide"
2888159|NCT03332576|Experimental|Cohort 4|"5 Doses DPX-Survivac (2 prime q6w, 3 boost q6w)~Low dose cyclophosphamide"
2888160|NCT03332576|Experimental|Cohort 5|"5 Doses DPX-Survivac/DPX-Survivac(Aqueous) (2 prime q4w, 3 boost q4w)~Low dose cyclophosphamide"
2888161|NCT03332563|Experimental|WebMAP Mobile|Adolescent participants assigned to this arm will receive access to the WebMAP mobile program delivering cognitive-behavioral intervention for chronic pain. Parents of adolescents will receive access to cognitive-behavioral strategies for parents on the WebMAP parent web site.
2888162|NCT03332563|No Intervention|Usual care|Participants assigned to this arm will receive usual care from the pain or specialty clinic during the non-exposure periods in the stepped wedge design.
2888163|NCT03332550||purulent peritonitis|Hinchey 3
2888164|NCT03332550||faecal peritonitis|Hinchey 4
2888165|NCT03332537|No Intervention|Control|Participants will be provided an online interactive platform to access electronic modules (total of 10) on: IBS-related pain neurophysiology and the brain-gut axis and self-management strategies. There is no additional intervention.
2888166|NCT03332537|Experimental|Personalized IBS Pain SM|Participants will be enrolled in the online platform. After completion of the modules, they will be scheduled for a consultation with a research nurse about their level of peripheral and central sensitivity, self-evaluation of IBS-pain SM, goal setting and self-monitoring of IBS-pain and physical activity. They will be asked to document their pain and all symptom SM behaviors daily for the next 10 weeks. At the 6-week follow-up visit, the researcher will review the online activities of the participant, go over the previously selected goals with the participants. The study nurse will acknowledge accomplishment of goals and assist in problem-identification and solving.
2888167|NCT03332524|Experimental|Arm 1 Product SP160412|oral route, 9 doses (Capsule) of SP160412 (Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg combined) in the 72 hours-period from first dose to last dose.
2888168|NCT03332524|Placebo Comparator|capsules Ibuprofen&placebo|2 capsules Ibuprofen and 1 placebo, oral route, 9 doses of Ibuprofen 400 mg with Placebo (Capsule) in the 72 hours-period from first dose to last dose,
2888169|NCT03332524|Placebo Comparator|Capsule Chlorpheniramin&placebo|capsule Chlorpheniramine 4mg and 1 Placebo, 3/72 hours-period from first dose to last dose, oral route
2888170|NCT03332511|Experimental|Investigational arm|Oral nilotinib 300mg twice daily with a 12-hour interval
2888171|NCT03332498|Experimental|Pembrolizumab and Ibrutinib|"Pembrolizumab intravenously (IV): 200 mg every 3 weeks (Q3W).~Ibrutinib by mouth (PO): Phase I Dose Escalation at doses of 420 mg daily (cohort 0) and 560 mg daily (cohort 1);. Phase II treatment at Recommended Phase II dose."
2888172|NCT03332485|Experimental|ECP Colon Prep Kit|
2888173|NCT03332485|Active Comparator|MoviPrep®|
2888174|NCT03332472|Experimental|Telemedicine group|Telematics visit in front of the conventional visit face to face
2888175|NCT03332472|Placebo Comparator|Conventional group|Group with conventional medical visit
2888176|NCT03332459|Experimental|Lumicitabine|Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing lumicitabine for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage.
2888177|NCT03332459|Placebo Comparator|Placebo|Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing placebo for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of placebo, frequency and type of respiratory infections and medical resource usage.
2888178|NCT03332446|Experimental|cooling|strength training and cold water immersion
2888179|NCT03332446|No Intervention|control|strength training and no cold water immersion
2888180|NCT03332433|No Intervention|Control group|Oxygen(2L/min) supplied with nasal catheter
2888181|NCT03332433|Experimental|High-flow nasal cannula group|Oxygen(up to 60L/min) supplied with high-flow nasal cannula
2888182|NCT03332420||Observational 1|Huaiqihuang Granule
2888183|NCT03332420||Observational 2|Standard treatment+Huaiqihuang Granule
2888184|NCT03332420||Observational 3|Standard treatment
2888185|NCT03332394||Healthcare Professionals|Includes nurses, physicians, and allied health professionals who care for patients on the 6NW (Respirology ward) of the General campus at TOH who have implemented and worked with the COPD care pathway during the study duration.
2888186|NCT03332394||COPD Patients|Adult patients admitted to the 6NW (Respirology ward) of the General campus at TOH with a primary diagnosis of acute exacerbation of COPD (AECOPD). The diagnosis is based on the admitting physician's assessment of the patient in the emergency room.
2888187|NCT03332381|Active Comparator|Attention training technique|
2888188|NCT03332381|Active Comparator|Mindful self-compassion|
2888189|NCT03332368||TCM exposure group|TCM exposure group were treated with traditional Chinese medicine while the other do not treated with that
2888190|NCT03332355|Experimental|PAC-1 in combination with temozolomide|Temozolomide (PO) will be dosed at 150 mg (adjusted for body size area [m2]) daily for 5 days starting on day 8 at cycle 1, and then for each successive cycle. In Component 2, the first PAC-1 dose will be 1 dose level lower than the PAC-1 MTD established in Component 1, and the maximum dose will not exceed 450 mg. PAC-1 will be taken in the morning on days 1-21 in each 28-day cycle.
2888191|NCT03332342|Experimental|Daily rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed daily.
2888192|NCT03332342|Active Comparator|Weekly rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed weekly.
2888193|NCT03332342|Experimental|Occasional rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed on two separate occasions
2928021|NCT03054337|Placebo Comparator|Placebo|Daily oral dose
2888194|NCT03332329|Experimental|Sequential combination arm|Drug: Entecavir for 60 weeks Drug: HBV vaccine (60ug/month, every four weeks) for 24 weeks Drug: Granulocyte Macrophage Colony Stimulating Factor (75 μg/day, first 5 days each month, subcutaneous) from baseline to week 16 and from week 60 to week 84 Drug: Y peginterferon alfa-2b (180 μg/week, subcutaneous) from week 16 to week 108
2888195|NCT03332316|Placebo Comparator|DEXA0|Ropivacaine Hydrochloride Inj 2mg/ml 20 ml and Sodium Chloride 9mg/mL 1 ml perineurally
2888196|NCT03332316|Experimental|DEXA1|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,2 ml and Sodium Chloride 9mg/mL 0,8 ml perineurally
2888197|NCT03332316|Experimental|DEXA2|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,4 ml and Sodium Chloride 9mg/mL 0,6 ml perineurally
2888198|NCT03332316|Experimental|DEXA4|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,8 ml and Sodium Chloride 9mg/mL 0,2 ml perineurally
2888199|NCT03332303|Experimental|Experimental: Estradiol Vaginal Cream, USP, 0.01% (Prasco LLC)|"Estradiol Vaginal Cream, USP, 0.01%, administered once daily for 7 days.~Intervention: Drug: Estradiol Vaginal Cream, USP, 0.01%"
2888200|NCT03332303|Active Comparator|Active Comparator: Estrace® Cream|"Estrace® Cream (Estradiol Vaginal Cream, USP, 0.01%), administered once daily for 7 days.~Intervention: Drug: Estrace® Cream (Estradiol Vaginal Cream, USP, 0.01%)"
2888201|NCT03332303|Placebo Comparator|Placebo Comparator: Placebo (Test vehicle cream) Vaginal Cream|"Placebo (Test vehicle cream) Vaginal Cream, administered once daily for 7 days.~Intervention: Drug: Placebo (Test vehicle cream) Vaginal Cream"
2888202|NCT03332290|Active Comparator|sport training|training course lasting 10 days. It included 10 days of multisports practice once (2h) per day.
2888203|NCT03332290|Experimental|diving|diving course lasting 10 days. It included 10 days of diving once (2h) per day. Diving will be carried out using air at a maximum depth of 30-meters
2888204|NCT03332277|Experimental|Active Bodysuits|The potential materials that can provide support are 3D printable rigid materials, semirigid foam padding, Velcro tape and stretchable wide waistbands. The 3D printable materials can be very versatile in terms of properties and can be further finished with an epoxy resin or thermoplastics. Different compositions and structures of knitted fabrics will be used in different areas of the proposed bodysuits to provide a close fit, high breathability and effective pain management due to extra support. The fastening system includes a magnetic zipper and pulley system that can be adjusted by pulling on knobs. The pulley system contains a microadjustable dial, super-strong lightweight lacing, and low friction lacing guides.
2888205|NCT03332264|Experimental|Drug coated balloon catheter|"PTA with paclitaxel coated SeQuent Please OTW"
2888206|NCT03332264|Active Comparator|Drug coated stent|"PTA with paclitaxel coated Eluvia Vascular Stent System"
2888207|NCT03332264|Active Comparator|Uncoated stent|PTA with bare nitinol stent (as commonly used in site)
2888208|NCT03332251|Experimental|Posture Correction Girdle|The design of posture correction girdle will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system, d) axial rotation or coupled motion by using a system with uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure
2888209|NCT03332251|No Intervention|Control|No treatment will be provided for control participants.
2888210|NCT03332238|Placebo Comparator|Placebo|Patients will receive an injection of vehicle (Ringer's solution) into their supraspinatus muscle and tendon at the time of rotator cuff repair
2888211|NCT03332238|Active Comparator|Cell Therapy|Patients will receive an injection of stromal vascular fraction material suspended in vehicle (Ringer's solution) into their supraspinatus muscle and tendon at the time of rotator cuff repair
2888212|NCT03332225|Experimental|Anakinra|Treatment with iv anakinra 200 mg three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
2888213|NCT03332225|Placebo Comparator|IV Placebo|Treatment with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
2888214|NCT03332225|Experimental|Recombinant human interferon-gamma|Treatment with sc recombinant human interferon-gamma every other day for a total of 15 days and with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days
2888215|NCT03332212|Experimental|Cohort A (Empagliflozin + Placebo)|Heart Failure with Reduced Ejection Fraction
2888216|NCT03332212|Experimental|Cohort B (Empagliflozin + Placebo)|Heart Failure with Preserved Ejection Fraction
2888217|NCT03332199|No Intervention|Control|Participants in the control group received standard treatment from oncologists and nurses at Hanoi Medical University Hospital.
2888218|NCT03332199|Experimental|Intervention|In addition to standard care provided by oncologists and nurses at Hanoi Medical University Hospital as described above, participants assigned to the intervention group received the psychoeducational intervention delivered by the nurse researcher.
2888219|NCT03332186|Experimental|Mild Renal Impairment|Mild renal impairment defined as eGFR 60 to <90 mL/min/1.73 m^2
2888220|NCT03332186|Experimental|Moderate renal impairment|Moderate renal impairment defined as eGFR 30 to <60 mL/min/1.73 m^2
2888221|NCT03332186|Experimental|Severe renal impairment|Severe renal impairment defined as eGFR <30 mL/min/1.73 m^2, not requiring dialysis
2888222|NCT03332186|Experimental|Normal renal function|Normal renal function defined as eGFR ≥90 mL/min/1.73 m^2
2888223|NCT03332173|Experimental|BGB-3111|
2888224|NCT03332160|Active Comparator|Standard of Care|Standard home lymphedema care
2888225|NCT03332160|Experimental|Flexitouch head and neck lymphedema treatment system|Daily treatment with Flexitouch® pneumatic compression device for treatment of head and neck lymphedema and standard home lymphedema care
2888226|NCT03332134|Experimental|Married Couple Dyad|Husband-wife dyads will receive the intimate partner violence (IPV) intervention program over the course of six weeks.
2888227|NCT03332134|No Intervention|Control Group|Husband-wife dyads in the control group will not receive an intervention.
2888228|NCT03332121|Experimental|B001,B001 dose escalation|5 groups with different dose: 350mg/700mg/1000mg/1500mg/2000mg
2888322|NCT03331432|Placebo Comparator|Placebo|Taking daily placebo capsules for 4 weeks
2888461|NCT03330509|Experimental|Cluster 2|Control: 1-8 months; SPARK intervention: 9-20 months
2888229|NCT03332108|Experimental|Intervention|Those allocated to the intervention arm will be enrolled in the mHealth intervention (EpxBreastfeeding) for six months, and will also be asked about breastfeeding status at their six-week postpartum follow up visit (standard of care) as well as during phone interviews at three and six months postpartum.
2888230|NCT03332108|Other|Control|Those in the control arm will be asked about breastfeeding status (exclusive, supplementing, or formula only) at their six-week postpartum follow up visit (standard of care) as well as during phone interviews at three and six months postpartum.
2888231|NCT03332095|Experimental|Cohort 1: DOR|Participants will receive a single dose of DOR at study entry (Day 0).
2888232|NCT03332095|Experimental|Cohort 2: DOR/3TC/TDF|Participants will receive DOR/3TC/TDF from Day 0 through Week 96.
2888233|NCT03332082|Experimental|Tooth positioner treatment group|The participants that meet the inclusion criteria will be treated with tooth positioner.
2888234|NCT03332069|Experimental|Study|50 Gy external beam radiation administered in fractions of 2 Gy 3 Doses of 8 Gy High Dose Rate brachytherapy up to 3 doses of 80mg/m2 of Cisplatin 10 modulated electro-hyperthermia treatments (55 minutes at a maximum of 150W)
2888235|NCT03332069|Active Comparator|Control|50 Gy external beam radiation administered in fractions of 2 Gy 3 Doses of 8 Gy High Dose Rate brachytherapy up to 3 doses of 80mg/m2 of Cisplatin
2888236|NCT03332056|Active Comparator|Belladonna and Opium (B&O) suppository|A single belladonna and opium suppository, dose-weight calculated, administered immediately following patient positioning prior to instrumentation. The pharmacologically active ingredients that are present in the belladonna extract consist of atropine and scopolamine. Opium is compound drug that is composed of 20 alkaloids. The principle alkaloid that derives the majority of its effect is its morphine content and acts as a narcotic analgesic by increasing the pain threshold or the magnitude of stimulus required to evoke pain.
2888237|NCT03332056|Placebo Comparator|Placebo Suppository|placebo suppository
2888238|NCT03332043|Experimental|HIRREM|Subjects in the experimental arm will receive an in-office, open-label course of acoustic stimulation linked to brain activity (High-resolution, relational, resonance-based, electroencephalic mirroring, HIRREM).
2888239|NCT03332043|Active Comparator|Ambient Nature Sounds|Subjects in the active comparator arm will receive an in-office, open-label course of acoustic stimulation not linked to brain activity (ambient natures sounds).
2888240|NCT03332017|Experimental|Arm A|Approximately 140 subjects to receive BGB-3111 and obinutuzumab
2888241|NCT03332017|Experimental|Arm B|Approximately 70 subjects to receive obinutuzumab
2888242|NCT03332004|Experimental|Indocyanine Green arm|All the enrolled patients met the inclusion criteria. No patients have been excluded from the study. All patient have been subjected, during laparoscopy, to an accurate inspection of the abdomen and all the visible endometriotic lesions have been described. Subsequently, 0.25 mg /(kg BW) Indocyanine Green were administered intravenously during surgery and a second look of the abdomen and pelvis with the Near Infrared Vision has been made, in order to identify the fluorescent lesions. All the lesions has been described and localized pre and post the Indocyanine Green injection and then removed and properly cataloged
2888243|NCT03331978|Experimental|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if <85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
2888244|NCT03331978|No Intervention|Control - No Treatment Education|The Usual Care control group will only receive standard of care through their HIV clinics.
2888245|NCT03331965|Experimental|Metoclopramide|A one-time dose of promotility agent (2 mL of Metoclopramide 5 MG/ML Injectable Solution in 8 mL saline IV) will be administered at the time of GJ placement. After administration of the pro-motility drug, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
2888246|NCT03331965|Placebo Comparator|Saline|A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement. After administration of the placebo, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
2888247|NCT03331952||Invasive pneumococcal disease study (PCV-D)|"Prospective study of children with invasive pneumococcal disease / probable bacterial meningitis (PCV-D)~Clinical procedures~At study enrolment:~Admission clinical findings / laboratory results will be recorded.~A questionnaire will be administered to the parent / guardian or caretaker to assess the child's immunisation status, household structure, environmental exposures, and recent antimicrobial use.~Radiology procedures As part of routine clinical management at AHC, a digital chest radiograph (CXR) may be performed as part of a child's diagnostic work up. CXRs will be read and interpreted primarily by the AHC radiologists. All CXR will subsequently be re-read by two study clinicians and interpreted according to the WHO paediatric radiologic pneumonia criteria.~Laboratory procedures~• Residual routine clinical specimens further analysed as part of the study protocol:~Blood and cerebrospinal fluid culture specimens.~EDTA / serum specimens.~Urine."
2888248|NCT03331952||Pneumonia study (PCV-P)|"Prospective study of children hospitalised with clinical and/or radiologic pneumonia (PCV-P)~Clinical procedures As described for PCV-D.~Radiology procedures As part of routine clinical management at AHC, a digital chest radiograph (CXR) is performed on all children with an admission diagnosis of pneumonia. CXRs will be handled as described for PCV-D.~Laboratory procedures~Study specific specimens:~o Nasopharyngeal swab at enrolment.~Residual routine clinical specimens further analysed as part of the study protocol:~As described for PCV-D."
2888323|NCT03331432|Experimental|Tauroursodeoxycholic acid|Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks
2888357|NCT03331224|Experimental|OTSC|Initial treatment with the OTSC for non-variceal upper GI-bleedings with high risk of recurrency.
2888249|NCT03331952||Pneumococcal colonisation study (PCV-C)|"Cross-sectional pneumococcal colonisation surveys in children attending the AHC out-patient department (PCV-C)~Three annual surveys, enrolling 450 children each year, will be done to identify and characterise pneumococcal nasopharyngeal colonisation in AHC out-patient department (OPD) attendees.~Clinical procedures~• Subjects will be recruited from the OPD waiting area after nurse triage. A questionnaire will be administered to the parent / guardian or caretaker to assess the child's immunisation status (by review of the handheld immunisation card where possible), household structure, environmental exposures, and recent antimicrobial use.~Laboratory procedures • Study specific specimens:~o Nasopharyngeal swab at enrolment. A nasopharyngeal swab will be collected from each participant and these will be processed as described for PCV-P."
2888250|NCT03331939|Experimental|No stimulation|All patients will receive three different stimulations
2888251|NCT03331939|Other|Beta (25-30 Hz)|Vagal nerve stimulator will be set to Beta (25-30 Hz)
2888252|NCT03331939|Other|Theta (5 Hz)|Vagal nerve stimulator will be set to Theta (5 Hz)
2888253|NCT03331913|Active Comparator|intradermal / submucosal injection group|intradermal / submucosal injection at pain area
2888254|NCT03331913|Experimental|intra-masseter injection group|intra-masseter injection on the ipsilateral of pain involved
2888255|NCT03331900|Placebo Comparator|Placebo|
2888256|NCT03331900|Active Comparator|COR388 TBD mg|
2888257|NCT03331887|Active Comparator|E-max CAD crowns retained with Fiber Reinforced Composite Post|"The modulus of elasticity of FRC post is (18-22 GPa) resembling that of dentin. Ideally the remaining tooth, the fiber post and the composite cement create a monoblock in which the loads are uniformly dissipated, ensuring a behavior similar to healthy teeth with a lower risk of root fracture. Using lithium disilicate e.max restorations is documented in literature as a successful restoration."
2888258|NCT03331887|Experimental|E-max CAD Endocrowns|Endocrowns have several advantages over conventional crowns like adequate function and esthetic with less chair time reduced number of interfaces in the restorative system. Stress concentration is less because of the reduction in the nonhomogenous material present. The preparation design is conservative compared to the traditional crown. Supragingival margin prevents interferences with periodontal tissues so involvement of the biological width is minimal. The application and polymerization of resins is also better controlled. Emax ceramic material have a high mechanical strength and are capable of being acid etched, with the adhesive capacity of adhesive systems and resinous cements, made it possible to restore endodontically treated teeth, without cores and intraradicular posts.
2888259|NCT03331874||Basal Cell Carcinoma|Diagnosis of Basal Cell Carcinoma by Reflectance confocal microscopy
2888260|NCT03331861|Experimental|Metformin|Metformin for 4 months
2888261|NCT03331861|Placebo Comparator|Placebo|Matched placebo for 4 months
2888262|NCT03331848|Placebo Comparator|PLACEBO|
2888263|NCT03331848|Experimental|PXT002331 - 20mg|
2888264|NCT03331835|Experimental|Brodalumab|Kyntheum® (brodalumab) pre-filled syringe 210 mg/1.5 mL solution for subcutaneous injections. First 3 injections are administered weekly, and hereafter every two weeks (Q2W).
2888265|NCT03331835|Active Comparator|Fumaric acid esters|"Fumaderm® initial dose tablets (30 mg dimethyl fumarate, 67 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt) Fumaderm® tablets (120 mg dimethyl fumarate, 87 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)~Fumaderm® tablets are administered orally up to 3 times daily in accordance with the dosing scheme in the label."
2888266|NCT03331822|Experimental|Light|High illuminance ,white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux.
2888267|NCT03331822|No Intervention|No Light|Ambient, standard white fluorescent environmental light will serve as control.
2888268|NCT03331809|Active Comparator|Control|
2888269|NCT03331809|Experimental|Two-hand|
2888270|NCT03331796|Experimental|Active rTMS (Bilateral DLPFC)|One-third of participants will receive active rTMS to the right and left dorsolateral prefrontal cortex (DLPFC).
2888271|NCT03331796|Experimental|Active rTMS (Bilateral LPC)|One-third of participants will receive active rTMS to the right and left lateral parietal cortex (LPC).
2888272|NCT03331796|Placebo Comparator|Placebo rTMS (Inactive)|One-third of participants will receive placebo/inactive rTMS, either to the DLPFC or the LPC. Those receiving placebo rTMS will serve as the control group.
2888273|NCT03331783|Experimental|Test of new adhesive strips|"On the peristomal skin 4 different patches are applied to the skin (Standard hydrocolloid adhesive patch; LT-2, LT21 and 33-20. There is a bag welded to each patch. Tthe bag contains real output.~The difference between the four patches is that they are made of four different adhesives.~The primary endpoint is measured after 8 hours and 24 hours."
2888274|NCT03331770|Experimental|BAK-free latanoprost ophthalmic emulsion|Patients with primary open-angle glaucoma who were using BAK-containing latanoprost ophthalmic solution for ≥ 6 months (baseline), switched to a new formulation of latanoprost ophthalmic product
2888275|NCT03331757|Experimental|Glucose as reference food|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from D-glucose, tested three times, in different weeks as reference food along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
2888276|NCT03331757|Experimental|Fir honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from fir honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
2888277|NCT03331757|Experimental|Heather honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from heather honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
2888324|NCT03331419||Males with Chronic Fatigue Syndrome|Two brief high effort exercise tests on consecutive days in our laboratory in order to provoke abnormalities in ME/CFS patients with respect to autonomic function, symptom exacerbation, and activity limitations.
2888533|NCT03330223||Ticagrelor|ticagrelor 90mg bid; aspirin 100mg qd, n=30
2888278|NCT03331757|Experimental|Citrus honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from citrus honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
2888279|NCT03331757|Experimental|Pine honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from pine honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
2888280|NCT03331757|Experimental|Thyme honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from thyme honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
2888281|NCT03331757|Experimental|Chestnut honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from chestnut honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
2888282|NCT03331731|Experimental|Single arm|Single Arm
2888283|NCT03331718|No Intervention|Control|Pancreaticojejunostomy with duct-to-mucosa anastomosis is performed as usual.
2888284|NCT03331718|Active Comparator|PGA felt reinforcement|In addition to usual pancreaticojejunostomy, PGA felt is used in duplicate.
2888285|NCT03331705||Use of new cystoscope|Patients in which the cystoscope is used.
2888286|NCT03331692|Other|TIVA group|"The participants scheduled for elective ENT procedures or for elective discectomy. The surgery was performed under totally intravenous anesthesia.~During procedure, monitoring of the proper level of general anesthesia both clinical and instrumental was performed."
2888287|NCT03331692|Other|VA group|The participants scheduled for elective ENT procedures or for elective discectomy. The surgery was performed under volatile anesthesia. During procedure, monitoring of the proper level of general anesthesia both clinical and instrumental was performed.
2888288|NCT03331679|Experimental|2 Wk HIIT|2 weeks of High Intensity Interval Training
2888289|NCT03331666|Active Comparator|Evolocumab|Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 88.
2888290|NCT03331666|Placebo Comparator|Placebo|Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 88.
2888291|NCT03331653|Experimental|Dry Needling and Ischemic Compression at the Trigger Point|Dry Needling and Ischemic Compression at the Trigger Point
2888292|NCT03331653|Active Comparator|Intervention at 1.5 cm from the Trigger Point|Dry Needling and Ischemic Compression at 1.5 centimeters from the Trigger Point
2888293|NCT03331640|Experimental|OFF|
2888294|NCT03331640|Experimental|FOLFIRI|
2888295|NCT03331627|Active Comparator|STR001-IT/STR001-ER|
2888296|NCT03331627|Active Comparator|STR001-IT/STR001-ER Placebo|
2888297|NCT03331627|Placebo Comparator|STR001-IT placebo/STR001- ER placebo|
2888298|NCT03331614|No Intervention|Control Group|This group will continue with their current treatment regimen during the course of the study. They will be monitored with daily questionnaires, and at the end of trial visit will also undergo a QST evaluation.
2888299|NCT03331614|Active Comparator|Active Treatment Group|This group will continue with their current treatment regimen during the course of the study. In addition they will be given an active intervention with the Flowaid FA-100 SCCD device to utilize at home daily. They will be monitored with daily questionnaires, and at the end of trial visit will also undergo a QST evaluation.
2888300|NCT03331588|Active Comparator|Subxiphoid uniportal VATS|Standard Subxiphoid single-port video assisted thoracic surgery, no use of rib-spreader.
2888301|NCT03331588|Active Comparator|Intercostal uniportal VATS|Standard Intercostal single-port video assisted thoracic surgery, no use of rib-spreader.
2888302|NCT03331575|Experimental|Arm1(Hypofractionated Radiotherapy)|Hypofractionated Radiotherap（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
2888303|NCT03331575|Placebo Comparator|Arms2（Conventional Radiotherapy）|Conventional Radiotherapy（PTV-G60Gy/30Fx,2Gy/Fx; PTV-C 50.4Gy/30Fx, 1.8Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
2888304|NCT03331562|Active Comparator|pembrolizumab & paricalcitol|pembrolizumab 200 mg IV q 3 weeks and paricalcitol 25 mcg IV 3 xs per week
2888305|NCT03331562|Placebo Comparator|pembrolizumab & placebo|pembrolizumab 200 mg IV q 3 weeks & placebo- normal saline IV 3 xs per week
2888306|NCT03331549||Myocardial infarction|
2888307|NCT03331549||Control group|
2888308|NCT03331536||Roux en Y Gastric Bypass Pre-menopausal|Pre-menopausal women undergoing Roux en Y Gastric Bypass
2888309|NCT03331536||Roux en Y Gastric Bypass Post-menopausal|Post-menopausal women undergoing Roux en Y Gastric Bypass
2888310|NCT03331536||Sleeve Gastrectomy Pre-menopausal|Pre-menopausal women undergoing Sleeve Gastrectomy
2888311|NCT03331536||Sleeve Gastrectomy Post-menopausal|Post-menopausal women undergoing Gastric Sleeve
2888312|NCT03331523|Experimental|Calcipotriene/betamethasone dipropionate|
2888313|NCT03331523|Active Comparator|Taclonex®|
2888314|NCT03331523|Placebo Comparator|Placebo|
2888315|NCT03331497|Experimental|Tonsillotomy|The patients diagnosed with PFAPA will have tonsillotomy performed in one month from randomisation.
2888316|NCT03331497|No Intervention|Follow up|The patients diagnosed with PFAPA will be monitored for 3 months time. If the symptoms still persist, tonsillectomy will be performed
2888317|NCT03331484|Other|Ticagrelor and Rivaroxaban|All participants will be prescribed ticagrelor 90 mg twice daily and rivaroxaban 15 mg once daily for a year.
2888318|NCT03331471|Active Comparator|alveolar recruitment maneuver|FIO2 0.5, TV 6 ml/kg of ideal body weight, PEEP 5 cmH2O and applying alveolar recruitment maneuver (PEEP 10 cmH2O for 3 breath - PEEP 15 cmH2O for 3 breath and PEEP 20 cmH2O for 10 breath) immediate before and after pneumoperitoneum
2888319|NCT03331471|Experimental|conventional ventilation|FIO2 0.5, TV 6 ml/kg of ideal body weight, PEEP 5 cmH2O applying during anesthesia
2888325|NCT03331419||Females with Chronic Fatigue Syndrome|Two brief high effort exercise tests on consecutive days in our laboratory in order to provoke abnormalities in ME/CFS patients with respect to autonomic function, symptom exacerbation, and activity limitations.
2888326|NCT03331406|Experimental|12-week physical activity program|"The physical activity program is of moderate intensity and consists of aerobic, strength, flexibility, and balance training with a target duration of 150 minutes per week.~At study start, participants will be provided with a pedometer to objectively monitor their aerobic activity, variable weight ankle weights and a medical journal to record physical activity.~Exercise Trainer --A exercise trainer will be assigned to design a physical activity program."
2888327|NCT03331393||RA patients treated with Abatacept|Treated with Abatacept as a first-line biologic
2888328|NCT03331393||RA patients treated with TNFi|Treated with Tumor necrosis factor inhibitor (TNFi) as a first-line biologic
2888329|NCT03331380|Other|Group A|Group A includes 150 healthy adult volunteers of both sexes with-out known cardiovascular disease; MRI Scan x 1 for 60 healthy volunteers; MRI Scan x 2 in 60 healthy volunteers
2888330|NCT03331380|Other|Group B|Group B includes 100 adult subjects of both sexes with known stable cardiovascular disease including adults with stable coronary artery disease after myocardial infarction; adults with heart failure and reduced left ventricular systolic function; adults with pulmonary artery hypertension; adults with congenital heart disease including cardiac shunts; adults with valvular heart disease including aortic stenosis, mitral regurgitation, and tricuspid regurgitation; and adults with metallic cardiovascular implants (such as coronary and peripheral artery stents) known to be safe for CMR at 1.5T.
2888331|NCT03331380|Other|Group C|Group C includes 100 adult subjects of both sexes with known non-cardiovascular disease
2888332|NCT03331367|Active Comparator|Total Cyrotherapy of the Prostate|Patients who will undergo total cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
2888333|NCT03331367|Active Comparator|Focal Cryotherapy of the Prostate|Patients who will undergo focal cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
2888334|NCT03331367|Active Comparator|Cyberknife SBRT of the Prostate|Patients who will undergo Cyberknife SBRT of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post Cyberknife, 3 months post Cyberknife)
2888335|NCT03331367|Active Comparator|Radical Prostatectomy|Patients who will undergo a radical prostatectomy will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post surgery, 3 months post surgery)
2888336|NCT03331354|Active Comparator|Self-help resources|a self-help vocational manual
2888337|NCT03331354|Experimental|Compass|a distant learning vocational program
2888338|NCT03331341|Experimental|Treatment (APVD)|Patients receive doxorubicin hydrochloride IV, pembrolizumab IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2888339|NCT03331328|Sham Comparator|Control/sham|The CO2 laser will not be activated but the same procedure of moving the probe inside the vagina in a systematic manner including depressing the foot pedal at similar frequency will be performed. The smoke evacuator will also be activated, laser eye glasses and masks worn by the laser team and the subject. However, the laser will remain in the standby mode.
2888340|NCT03331328|Active Comparator|Treated|Active arm subjects will be treated intravaginally with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μs, dot spacing 1000 μm and the smart stack parameter from 1 to 3. For the vulva, the dot power will be reduced to 26 watts, dwell time 800 μs, dot spacing 800 μm and the smart stack parameter of 1.
2888341|NCT03331315|Active Comparator|Ketorolac|Patients receiving scheduled ketorolac postoperatively
2888342|NCT03331315|Experimental|Celecoxib|Patients receiving celebrex preoperative and postoperatively for 7 days
2888343|NCT03331302|Active Comparator|COPD patients - Xe-133|COPD patients who will be assessed with Xenon-133 scintigraphy (Standard diagnostic study)
2888344|NCT03331302|Experimental|COPD patients - Hyperpolarized Xe-129|COPD patients crossed over from the Active Comparator Arm who will be assessed with hyper polarized Xenon-129 MRI (Experimental diagnostic study)
2888345|NCT03331289|Placebo Comparator|Placebo|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
2888346|NCT03331289|Active Comparator|Exenatide|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
2888347|NCT03331289|Active Comparator|Dapagliflozin|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
2888348|NCT03331289|Active Comparator|Exenatide and Dapagliflozin|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
2888349|NCT03331276|Experimental|Formula B|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age with high Sn-2 Palmitate, Alpha Lactalbumin and Osteopontin to better mimic human milk.
2888350|NCT03331276|Active Comparator|Formula A|A Commercially available Infant Formula, for healthy term infants 0 to 12 months of age (Enfamil TM, Milk-Based Powder with Iron)
2888351|NCT03331263|Experimental|Abdominal application of 2% CHG|
2888352|NCT03331263|Experimental|Groin application of 2% CHG|
2888353|NCT03331263|No Intervention|Control treatment with no application|
2888354|NCT03331250|Experimental|Eribulin|"Eribulin administered twice per cycle intravenously~Each cycle contains 21 days~Dosing is per the FDA label for other cancers"
2888355|NCT03331237|Active Comparator|LVS group|interscalene injection
2888356|NCT03331237|Active Comparator|ISO group|in this group all patients will receive ISO block.
2888358|NCT03331224|Active Comparator|Standard therapy|Endoscopic standard therapy (two techniques e.g. clip and injection)
2888359|NCT03331211||Chmotherapy combined with TKIs|Patients with ALL were treated by chmotherapy and TKIs(PDT-NFH-2016)
2888360|NCT03331198|Experimental|Phase 1 JCAR017 monotherapy|Subjects will be assigned to receive JCAR017 (lisocabtagene maraleucel)
2888361|NCT03331198|Experimental|Phase 1 JCAR017 + ibrutinib|Subjects receiving ibrutinib at baseline will be assigned to receive JCAR017 (lisocabtagene maraleucel) at the recommended dose + ibrutinib
2888362|NCT03331198|Experimental|Phase 2 JCAR017|Subjects will receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm
2888363|NCT03331198|Active Comparator|Phase 2 control|Subjects will receive standard of care treatment
2888364|NCT03331185|Active Comparator|Freeze Dried Bone Allograft|Socket filled with Mineralized Cortical Freeze Dried Bone Allograft
2888365|NCT03331185|Experimental|L-PRF Clot|Socket filled with L-PRF Clot
2888366|NCT03331172|Experimental|High Intensity Focused Ultrasound|
2888367|NCT03331159|Experimental|NanoBone|The participants were treated with anterior lumbar interbody fusion (ALIF) with a new nanocrystalline hydroxyapatite embedded in a silica gel matrix (NH-SiO2)
2888368|NCT03331159|Active Comparator|Homologous bone|The participants were treated with anterior lumbar interbody fusion (ALIF) with homologous bone
2888369|NCT03331146|Placebo Comparator|Control group|saline infusion will be administered after induction of general anesthesia
2888370|NCT03331146|Active Comparator|Sodium Nitrite|sodium nitrite will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
2888371|NCT03331133||Identical Twins|Twins develop from one zygote with no intervention
2888372|NCT03331133||Dizygotic Twins|Twins develop from two different zygote with no intervention
2888373|NCT03331120|Active Comparator|Control Group|"1--Control group~. Conventional treatment:~moist hot pack.~Soft Tissue mobilization.~manual therapy.~Therapeutic Exercise.~Home program routine."
2888374|NCT03331120|Experimental|Study or Experimental Group|"2--Experimental or study group:~moist hot pack.~Soft Tissue mobilization.~manual therapy.~Therapeutic Exercise.~Home program routine.~ambulatory mirror image functional re-training through wearing 3D adjustable cervical thoracic Posture Corrective orthosis (CTPCO) For 10 weeks.(3Times/week for 20 minutes)"
2888375|NCT03331094||surgery with graft|The procedure is to place a metal instrumentation (rods and screws) in contact with the spine to correct the deformity. Added to this is a graft between the vertebrae that will allow a bone bridge of ankylosis making the spine completely rigid.
2888376|NCT03331094||surgery without graft|Adult scoliosis surgery is performed with instrumentation without grafting: the teams use variable stiffness rods made of metal or PEEK.
2888377|NCT03331081|Experimental|Group Bladder Training|Patients will receive verbal instructions on bladder function (filling and bladder emptying phases), pelvic floor musculature on bladder function; orientation on urinary positioning and habits (urinary frequency); and the definition and major risk factors responsible for urinary incontinence.
2888378|NCT03331081|Active Comparator|Group TMAP|In this group the patients will perform TMAP in isolation. The training protocol aims at the work of strength and muscular hypertrophy, with concentric-isometric muscular action and load of 100% of the maximum voluntary contraction.
2888379|NCT03331081|Active Comparator|Group Bladder Training + TMAP|In this group, the patients should perform the proposed exercises for the Bladder Training Group and the exercises proposed for the TMAP Group. The training protocol of this group will consist of exercises that have as objectives: to improve the control over the urgency and urge-incontinence; increase bladder capacity, and thus prolong the intervals between urinations; to restore confidence in bladder control; and improve MAP strength and hypertrophy.
2888380|NCT03331068||Patients with prostate cancer|online questionnaire of MAX-PC
2888381|NCT03331055|Experimental|percutaneous stimulation|PENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
2888382|NCT03331055|Experimental|trancutaneous stimulation|TENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
2888383|NCT03331055|No Intervention|Control|Conventional analgesic medication is offered.
2888384|NCT03331042|Experimental|Sequence 1|SM-1 (Treatment Period 1), D+Z (Treatment Period 2), D+L (Treatment Period 3), Placebo (Treatment Period 4).
2888385|NCT03331042|Experimental|Sequence 2|D+Z (Treatment Period 1), D+L (Treatment Period 2), Placebo (Treatment Period 3), SM-1 (Treatment Period 4).
2888386|NCT03331042|Experimental|Sequence 3|D+L (Treatment Period 1), Placebo (Treatment Period 2), SM-1 (Treatment Period 3), D+Z (Treatment Period 4).
2888387|NCT03331042|Experimental|Sequence 4|Placebo (Treatment Period 1), SM-1 (Treatment Period 2), D+Z (Treatment Period 3), D+L (Treatment Period 4).
2888388|NCT03331029|Other|transesophageal echocardiography|Comparison of 3D Ultrasound with transesophageal echokardiography
2888389|NCT03331016|Other|Waitlist Control Group|Waitlist Control Group will serve as control group for 6 months, receiving no intervention during that time but completing periodic surveys to assess outcomes among controls (knowledge, attitudes, behaviors). They will also later receive the intervention (training program) and be followed for 6 more months.
2888390|NCT03331016|Experimental|Intervention Group|Intervention Group will receive the intervention (training program) right away, then will be followed for 6 months.
2888391|NCT03331003|Experimental|low level light therapy|1 group uses the investigational device on the left side, and the subjects will have half part receiving low level light therapy (red light-emitting diode and laser irradiation)
2888392|NCT03331003|Placebo Comparator|non-LLLT wavelength group group|the control device on the right side, other half with non-low-level laser therapy wavelength (white light-emitting diode light bulb coating with red paint to make the irradiating light close to the red).
2888393|NCT03330990|Other|Entrectinib / Midazolam|
2888394|NCT03330977|Other|Before and after use of pressure garments|"At inclusion, patients will only have medication prescription as usual but without pressure garments, and thus, for 4 months.~4 months after inclusion, patients will continue medication but will also be prescribed pressure garments Then every 6 months, until 26 months, patients will come back to have new pressure garments (as usual practice)"
2888460|NCT03330509|Experimental|Cluster 1|Control: 1-4 months; SPARK intervention: 5-20 months
2888395|NCT03330964|Experimental|electroacupuncture group|The experimental group adopted chemotherapy combined with electro-acupuncture stimulated related acupoints for 3 days running.
2888396|NCT03330964|No Intervention|control group|The control group received chemotherapy only(same as the experimental group),but no electroacupuncture treatment.
2888397|NCT03330938|Experimental|CBI and Resilience|8 sessions total, once a week, 2 hours long each, consistent of 6 sessions of Cognitive-behavioral Intervention (CBI) plus 2 sessions to improve resilience strengths.
2888398|NCT03330938|Active Comparator|Cognitive-behavioral Intervention|8 sessions total, once a week, 2 hours long each. Cognitive-behavioral Intervention (CBI) without resilience strengthening.
2888399|NCT03330925|Experimental|ElastiMed's SACS|Healthy Subjects which the Elastimed's SACS will be tried on
2888400|NCT03330912|Experimental|Seat Height Intervention|"Randomly assigned 5 wheelchair seat heights ranging from very low (2 below) to very high (2 above) the lower leg length of the participant."
2888401|NCT03330899|Active Comparator|15 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (15 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 15 mcg of the monovalent H7N9 antigen per dose"
2888402|NCT03330899|Active Comparator|7.5 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (7.5 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 7.5 mcg of the monovalent H7N9 antigen per dose"
2888403|NCT03330899|Active Comparator|3.75 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (3.75 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 3.75 mcg of the monovalent H7N9 antigen per dose"
2888404|NCT03330899|Active Comparator|15 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (15 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 15 mcg of the monovalent H7N9 antigen per dose"
2888405|NCT03330899|Active Comparator|7.5 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (7.5 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 7.5 mcg of the monovalent H7N9 antigen per dose"
2888406|NCT03330899|Active Comparator|3.75 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (3.75 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 3.75 mcg of the monovalent H7N9 antigen per dose"
2888407|NCT03330899|Active Comparator|15 mcg H7N9 without adjuvant|"Participants in this arm will receive one dose of the 15 mcg H7N9 antigen without adjuvant at Day 0 and another dose at Day 28.~Each dose = 0,5 ml"
2888408|NCT03330899|Placebo Comparator|Placebo (PBS)|"Participants in this arm will receive one dose of Placebo (PBS) at Day 0 and another dose at Day 28.~Each dose = 0,5 ml"
2888409|NCT03330873|Experimental|Foley catheter|After the completion of hysteroscopic adhesiolysis, Foley catheter was inserted and inflated with normal saline which was removed on the 7th day after surgery.
2888410|NCT03330873|Experimental|Disposable balloon uterine stent|After the completion of hysteroscopic adhesiolysis, disposable balloon uterine stent was inserted and inflated with normal saline which was removed on the 7th day after surgery.
2888411|NCT03330860|Experimental|Neuromarketing strategy|Twelve clips regarding maternal and neonatal health topics, designed with mixed 2D and 3D elements, each one about 45 seconds long (prepared based on the best available evidence and validated by clinical experts).
2888412|NCT03330860|Active Comparator|No-capsule group|Control clip with 2D elements about 45 seconds long, containing information on prenatal control and presented in conventional format (narration, static images and on screen text).
2888413|NCT03330847|Active Comparator|Olaparib monotherapy|All randomized patients will receive Olaparib monotherapy 300 mg twice daily (BD).
2888414|NCT03330847|Active Comparator|Olaparib+AZD6738|All randomized patients will receive Olaparib 300 mg twice daily+AZD6738 160 mg once daily (OD).
2888415|NCT03330847|Active Comparator|Olaparib+AZD1775|All randomized patients will receive Olaparib 200 mg BD +AZD1775 175 mg BD.
2888416|NCT03330834|Experimental|Single Arm|CAR-T cells to treat advanced lung cancer. This study has only one arm. All participators will attend the screening and meet the set criteria for the clinical treatment. PD-L1 CAR-T cells are infused on day 0 with 10%, day 3 with 30% and day 7 with 60% , (1-2)×10^6/kg PD-L1 CAR-T cells total.
2888417|NCT03330821|Experimental|Treatment (idarubicin, cytarabine, pevonedistat)|"INDUCTION: Patients receive idarubicin IV over 10-15 minutes on days 1-3, cytarabine IV over 1-3 hours on days 1-7, and pevonedistat IV over 60 minutes on days 1, 3, and 5. Patients with gross residual disease on day 14 bone marrow may receive a second course of induction chemotherapy.~CONSOLIDATION: Patients who achieve CR and will not undergo bone marrow transplant receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats every 28-35 days for 4 courses in the absence of disease progression or unaccepted toxicity."
2888418|NCT03330808|Experimental|Epidural with general anesthesia|Epidural anesthesia with 0.2% ropivacaine 10 ml
2888419|NCT03330808|No Intervention|General anesthesia alone|Sevoflurane and nitrous oxide.
2888420|NCT03330795|Experimental|CD3/CD19 neg allogeneic BMT|All participants will receive a double lung transplant followed by a bone marrow (hematopoietic stem cells) transplant. The lungs and allogeneic hematopoietic stem cells will be from the same partially HLA-matched cadaveric donor. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
2888421|NCT03330782|Experimental|Elderly|Remifentanil was infused at predetermined effect-site concentration before propofol infusion in elderly patients.
2888422|NCT03330782|Active Comparator|Adult|Remifentanil was infused at predetermined effect-site concentration before propofol infusion in adult patients.
2888423|NCT03330769||Patients with active Psoriatic Arthritis|Patients with clinically diagnosed PsA with clinically active joint disease starting a new course of treatment.
2888424|NCT03330756|Active Comparator|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
2888425|NCT03330756|Experimental|Laparoscopic Mini Gastric Bypass|laparoscopic Mini gastric bypass
2888426|NCT03330743|No Intervention|Usual care|
2888427|NCT03330743|Placebo Comparator|Parent Mentor|
2888428|NCT03330743|Active Comparator|Parent Mentor with Positive Deviance|
2928022|NCT03054311|Experimental|Lifestyle Matters intervention|
2888429|NCT03330730|Experimental|Experimental|"Patients with oncological follow up and home-care service package IsereADOM:~Objects connected to patients' home (thermometer, weight scale, tensiometer +/- oximeter, glucose meter or pedometer) with graduated protocol for medical platform support.~Digital linkbook (different from the medical file) accessible to the patient and the standard care actors.~Referent sentinel: a field actor to coordinate the care. Preferred contact of the patient outside the center Motivational coaching: 1 to 2 axes to be defined by the investigator among the following axes (physical activity, nutrition and hydration, drug compliance, medical follow-up, chronic and moral pain, acceptance of the disease and treatments)."
2888430|NCT03330730|No Intervention|Control|Patients with oncological follow up only
2888431|NCT03330717|Placebo Comparator|General anesthesia|Patients will undergo oncologic breast surgery on general anesthesia.
2888432|NCT03330717|Experimental|Hypnosis sedation|Patients will undergo oncologic breast surgery on hypnosis sedation.
2888433|NCT03330717|Experimental|General anesthesia with preoperative session of hypnosis|Patients interested in hypnosis but too anxious to have surgery while on hypnosis sedation will undergo surgery on general anesthesia but will have a preoperative session of hypnosis relaxation using technology of virtual reality
2888434|NCT03330704|Active Comparator|Standard Therapy|This group will receive 3% hypertonic sodium chloride for the management of their cerebral edema. 3% Sodium Chloride is the generic name of this intravenous fluid preparation.
2888435|NCT03330704|Experimental|Balanced Therapy|This group will undergo two simultaneous infusions. 23.4% sodium chloride and 8.4% sodium bicarbonate will be infused at the same time in various ratios for management of cerebral edema with a balanced approach
2888436|NCT03330691|Experimental|Patient-derived CD19- and CD22 specific CAR|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
2888437|NCT03330678|Experimental|Probiotic (VSL#3)|Probiotics will be given to women included in study arm
2888438|NCT03330665|No Intervention|Control|No meditation
2888439|NCT03330665|Experimental|Intervention|Meditate using headspace app 3 times a week
2888440|NCT03330639|Experimental|Experimental Group|This group will receive the capsaicin. The Study Drug ICX72 or sinus buster which is a homeopathic blend of capsicum annum and eucalyptol, that is readily available over the counter.
2888441|NCT03330639|Placebo Comparator|Placebo Group|This group will receive saline. The Placebo formulation contained saline and eucalyptol in a concentration that matched the control.
2888442|NCT03330626|Active Comparator|IO group|Fluid overload will be removed in the patients who received continuous renal replacement therapy, but the amount of fluid removal are guided by the intake-output balance.
2888443|NCT03330626|Experimental|InBody group|Fluid overload will be removed in the patients who received continuous renal replacement therapy, but the amount of fluid removal are guided by the bioimpedance analysis (InBody S10).
2888444|NCT03330613|Other|Inhalational anesthesia|Inhalational anesthesia is an anesthesia procedure using by respiratory tract. PAEDS used to for postanesthesia pediatric patients.
2888445|NCT03330613|Active Comparator|Total intravenous anesthesia|Total intravenous anesthesia (TIVA) is an anesthesia procedure using vascular infusion method.PAEDS used to for postanesthesia pediatric patients.
2888446|NCT03330600|Experimental|aquatic physicotherapy group|For the experimental group, we will associate kinesiotherapy with immersion in water.
2888447|NCT03330600|Placebo Comparator|immersion group|The control group will be submitted to immersion in the water, contained in flexion with the towel and maintaining the same care as the experimental one.
2888448|NCT03330574||Variability of the device|We will study the repeatability and reliability of the Diopsys® ERG Vision Testing Systems in normal non-glaucomatous people and in those with suspicion of glaucoma or confirmed glaucoma.
2888449|NCT03330574||Diagnosis and progression of glaucoma|Patients who have a suspicion of glaucoma and patients with confirmed glaucoma will be included. PERG data obtained by the Diopsys® ERG Vision Testing Systems will be analyzed to study the PERG changes in different clinical situations, such as early glaucoma and progression of glaucoma.
2888450|NCT03330574||Effect of medical/surgical intervention|Patients will undergo standard treatment based on their medical history and we will observe the PERG changes induced by these treatments (eye drops, laser or surgery) with the Diopsys® ERG Vision Testing Systems.
2888451|NCT03330561|Experimental|PRS-343|
2888452|NCT03330548|Active Comparator|TeleMOVE!|Veterans randomized to the control arm will participate in TeleMOVE!, an arm of the Management of Overweight Veterans (MOVE!) program. TeleMOVE! is telehealth treatment program within the VA designed to improve the lives of Veterans by assisting with weight management and health promotion. This program includes daily interaction with in-home messaging technologies and clinician contact as needed
2888453|NCT03330548|Experimental|Culinary Rx|Veterans randomized to the experimental arm will participate in Culinary Rx. Culinary Rx is an online instructional cooking and nutrition course that healthcare professionals can prescribe to patients who need to transition away from a Standard American Diet to a more health-supportive, whole foods, plant-based lifestyle. In partnership with The Plantrician Project, this course will focus on teaching the foundational cooking skills needed for long-term behavioral change, coupled with lifestyle education around nutrition and resources that will help users successfully face the many challenges inherent to dietary change.
2888454|NCT03330535|Active Comparator|Verbal oral hygiene instructions|Participants will receive verbal oral hygiene instructions during routine orthodontic visits.
2888455|NCT03330535|Experimental|Reminders once a week|Participants will receive active reminders once a week.
2888456|NCT03330535|Experimental|Reminders three times a week|Participants will receive active reminders three times a week.
2888457|NCT03330535|Experimental|Daily reminders|Participants will receive active reminders daily.
2888458|NCT03330522|Experimental|Intervention|"The active intervention is Love, Sex, & Choices, a 12-episode, online HIV prevention intervention video series accessed on study provided smartphones. Each episode is up to 20 minutes in length. Study participants receive one episode per week for 12 weeks on study provided smartphones."
2888459|NCT03330522|Active Comparator|Control Comparison Group|The control comparison intervention is twelve messages in text that promote HIV prevention behaviors and open communication with male sex partners. Study participants receive one message per week for 12 weeks on study provided smartphones.
2928268|NCT03052517|Experimental|QAW039 Dose 1|QAW039 Dose 1 once daily
2888462|NCT03330509|Experimental|Cluster 3|Control: 1-12 months; SPARK intervention: 13-20 months
2888463|NCT03330509|Experimental|Cluster 4|Control: 1-16 months; SPARK intervention: 17-20 months
2888464|NCT03330496||Preterm infants|preterm neonates (34-37 weeks gestational age, n=30)
2888465|NCT03330496||Term infants|term newborns (37-42 weeks gestation, n=30)
2888466|NCT03330496||Small infants|1-3 month-old infants (n=30)
2888467|NCT03330496||Older infants|3-6 month-old infants (n=30)
2888468|NCT03330483||Female Speedicath nelathon|Evaluation of pain or discomfort in female patients at/during/after Speedicath nelathon-tip catheter insertion
2888469|NCT03330483||Female nelathon|Evaluation of pain or discomfort in female patients at/during/after standard nelathon-tip catheter insertion
2888470|NCT03330483||Male Speedicath tiemann|Evaluation of pain or discomfort in male patients at/during/after Speedicath tiemann-tip catheter insertion
2888471|NCT03330483||Male tiemann|Evaluation of pain or discomfort in male patients at/during/after standard tiemann-tip catheter insertion
2888472|NCT03330470|Experimental|exercise and carnosine supplementation|exercise: participants will be subjected to 3 months supervised exercise intervention carnosine supplementation: participants will be instructed to take carnosine 2 times daily
2888473|NCT03330470|Experimental|exercise and supplementation with placebo|exercise: participants will be subjected to 3 months supervised exercise intervention supplementation with placebo: participants will be instructed to take placebo 2 times daily
2888474|NCT03330470|Experimental|stretching controls and carnosine supplementation|stretching controls: participants will be subjected to 3 months supervised stretching program carnosine supplementation: participants will be instructed to take carnosine 2 times daily
2888475|NCT03330470|Experimental|stretching controls and supplementation with placebo|stretching controls: participants will be subjected to 3 months supervised stretching program supplementation with placebo: participants will be instructed to take placebo 2 times daily
2888476|NCT03330457|Experimental|Arm 1|Betrixaban 80 mg PO QD + Andexanet 800 mg IV Bolus
2888477|NCT03330457|Experimental|Arm 2|Betrixaban 80 mg PO QD + Andexanet 800 mg IV Bolus followed by 960 mg continuous IV infusion
2888478|NCT03330457|Experimental|Arm 3|To be determined
2888479|NCT03330457|Experimental|Arm 4|To be determined
2888480|NCT03330444||LD microbiome receptive to the ERA test|Receptive patients by the ERA test with an endometrial microbiota mainly composed of different species of the genus Lactobacillus, determined by NGS sequencing.
2888481|NCT03330444||NLD microbiome receptive to the ERA test|Receptive patients by the ERA test with an endometrial microbiota composed of different pathogenic bacteria such as Streptococcus and Gardnerella, or not dominated by bacteria of the genus Lactobacillus, determined by NGS sequencing.
2888482|NCT03330431|Experimental|Experimental group 1 (personal expert)|Participants watch a video of an expert describing the positive effects of Progressive Muscle Relaxation (PMR) with personalized examples and stories before undergoing a PMR session.
2888483|NCT03330431|Experimental|Experimental group 2 (factual expert)|Participants watch a video of an expert describing the positive effects of Progressive Muscle Relaxation (PMR) with factual information (not personal) before undergoing a PMR session.
2888484|NCT03330431|Active Comparator|Control group|Participants read a neutral text before undergoing a Progressive Muscle Relaxation (PMR) session.
2888485|NCT03330418|Experimental|Placebo Comparator|Participants received placebo weekly administered subcutaneously for 48 times in the double-blind treatment period.Once the participants relapse,they should advance to the open phase.All participants were treated with the test drugs.
2888486|NCT03330418|Experimental|RC18 160 mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 48 times.Starting with the forty-ninth dose,the trial went into the open phase . All participants were treated with the test drugs.
2888487|NCT03330405|Experimental|Dose Level 0 Phase 1b|"Drug: Avelumab~Drug: Talazoparib"
2888488|NCT03330405|Experimental|Dose Level -1 Phase 1b|"Drug: Avelumab~Drug: Talazoparib"
2888489|NCT03330405|Experimental|Dose Level -2 Phase 1b|"Drug: Avelumab~Drug: Talazoparib"
2888490|NCT03330405|Experimental|A1. NSCLC Phase 2|"Drug: Avelumab~Drug: Talazoparib"
2888491|NCT03330405|Experimental|A2. NSCLC PD-L1+ Phase 2|"Drug: Avelumab~Drug: Talazoparib"
2888492|NCT03330405|Experimental|B1. TNBC Phase 2|"Drug: Avelumab~Drug: Talazoparib"
2888493|NCT03330405|Experimental|B2. HR+BC DDR Defect +Assay Phase 2|"Drug: Avelumab~Drug: Talazoparib"
2888494|NCT03330405|Experimental|C1. Ovarian CA Recurrent Plat-Sensitive Phase 2|"Drug: Avelumab~Drug: Talazoparib"
2888495|NCT03330405|Experimental|C2.Ovarian CA Recurrent Plat-Sensitive BRCA defect Phase 2|"Drug: Avelumab~Drug: Talazoparib"
2888496|NCT03330405|Experimental|D.Urothelial CA Phase 2|"Drug: Avelumab~Drug: Talazoparib"
2888497|NCT03330405|Experimental|E1. CRPC Phase 2|"Drug: Avelumab~Drug: Talazoparib"
2888498|NCT03330405|Experimental|E2. CRPC DDR Defect +Assay Phase 2|"Drug: Avelumab~Drug: Talazoparib"
2888499|NCT03330405|Experimental|F: Advanced Solid Tumors with BRCA or ATM defect Phase 2|"Drug: Avelumab~Drug: Talazoparib"
2888500|NCT03330392|Experimental|AGP|take two tablets per day (500 mg/day) for 8 weeks.
2888501|NCT03330392|Placebo Comparator|Placebo|take two tablets per day for 8 weeks.
2888502|NCT03330379|Experimental|continuous adjustment strategy|patients assigned to the continuous adjustment strategy, in addition to standard care, the Tracoe Smart CuffmanagerTM will be connected to the tracheal cuff
2888503|NCT03330379|No Intervention|usual care|patients with usual care
2888504|NCT03330366|Experimental|Allium hookeri extract|take two capsules per day (486 mg/day) for 8 weeks
2888505|NCT03330366|Placebo Comparator|Placebo|take two capsules per day for 8 weeks
2888506|NCT03330353||Neurodegenerative Diseases|Individuals with neurodegenerative diseases
2888534|NCT03330197|Experimental|Ad-RTS-hIL-12 +veledimex|Intratumoral Ad-RTS-hIL-12 injection after tumor resection and oral veledimex (activator ligand) in pediatric patients with brain tumors (supratentorial tumors and DIPG)
2888535|NCT03330184|Experimental|Berberine Hydrochloride group|2/day, 16 weeks
2888536|NCT03330184|Experimental|Bifidobacterium group|2/day, 16 weeks
2888537|NCT03330184|Experimental|Berberine Hydrochloride and Bifidobacterium group|2/day, 16 weeks
2928269|NCT03052517|Experimental|QAW039 Dose 2|QAW039 Dose 2 once daily
2888507|NCT03330340||Percutaneous vertebroplasty|All PVPs are performed by experienced spine surgeons under optimal fluoroscopic guidance. The procedure takes place under sterile conditions. Local anesthesia is administered to the periosteum of the targeted pedicle via skin. Polymethylmethacrylate bone cement is injected under continuous fluoroscopic guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. Patients are encouraged to stand up and walk with brace immediately after operation and the brace are required to be worn for 3 months. Furthermore, all patients will take oral bisphosphonates treatment together with supplemental calcium and vitamin D.
2888508|NCT03330340||Conservative treatment|In conservative treatment group, the patients were required horizontal bed rest for the initial 2 weeks after diagnosis. Then, they were encouraged to stand up and walk with brace and assistance. The bed rest time was extended if the back pain worsened when they stood up and walked. The brace should be worn in 3 months. For pain medication, nonsteroidal anti-inflammatory drugs (NSAIDs) were prescribed for every patient. Additional analgesics, such as tramadol and morphine, would be added in case NSAIDs were not effective. Two weeks after diagnosis, physical therapy was started. All patients are put on osteoporosis medication, bisphosphonates together with supplemental calcium and vitamin D.
2888509|NCT03330327|Experimental|Part 1|Intravenous (IV) infusion of HM12470
2888510|NCT03330327|Experimental|Part 2: Sequence 1|Intravenous (IV) infusion of HM12470
2888511|NCT03330327|Experimental|Part 2: Sequence 2|Intravenous (IV) infusion of HM12470
2888512|NCT03330314|Experimental|Part 1|Intravenous (IV) infusion
2888513|NCT03330314|Experimental|Part 2: Cohort A|Intravenous (IV) infusion (Dose A)
2888514|NCT03330314|Experimental|Part 2: Cohort B|Intravenous (IV) infusion (Dose B)
2888515|NCT03330314|Experimental|Part 2: Cohort C|Intravenous (IV) infusion (Dose C)
2888516|NCT03330301||Exposed|"Individuals born between June1983 and May1985 were exposed to the mandatory vitamin D margarine fortification during fetal life.~Cases: individuals defined as having one of the aforementioned diseases of interest from the registers"
2888517|NCT03330301||Non-exposed|"Individuals born between September1986 and August 1988 were not exposed to the mandatory vitamin D margarine fortification during fetal life.~Controls: cohort of matched disease-free individuals"
2888518|NCT03330288||Patients with Hip OA stage I to III|Male and female patients from 45 to 75 of age with Hip osteoarthritis stage I to III
2888519|NCT03330288||Patients with Knee OA stage I to III|Male and female patients from 45 to 75 of age with knee osteoarthritis stage I to III
2888520|NCT03330275|Experimental|Test/Control 1/Control 2|Subjects will be randomized to 1 of 3 lenses (Test/Control 1/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
2888521|NCT03330275|Experimental|Test/Control 2/Control 1|Subjects will be randomized to 1 of 3 lenses (Test/Control 2/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
2888522|NCT03330275|Experimental|Control 1/Test/Control 2|Subjects will be randomized to 1 of 3 lenses (Control 1/Test/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
2888523|NCT03330275|Experimental|Control 1/Control 2/Test|Subjects will be randomized to 1 of 3 lenses (Control 1/Control 2/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
2888524|NCT03330275|Experimental|Control 2/Test/Control 1|Subjects will be randomized to 1 of 3 lenses (Control 2/Test/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
2888525|NCT03330275|Experimental|Control 2/Control 1/Test|Subjects will be randomized to 1 of 3 lenses (Control 2/Control 1/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
2888526|NCT03330262|Experimental|BALCAP prosthesis|Participants will be asked to perform a series of appropriate exercises daily at home wearing the BALCAP prosthesis for a period of 6 weeks. The training exercises will include: (1) standing on a firm surface with feet apart, eyes open and closed; (2) standing on a firm surface with feet together, eyes open and closed; (3) standing on thick footing (e.g., multiple pairs of socks) with feet apart, eyes open and closed; (4) standing on thick footing with feet together, eyes open and closed; (5) standing in a modified Romberg position on a firm surface, eyes open and closed; (6) standing in a Romberg position on a firm surface, eyes open and closed; (7) walking on a firm surface eyes open; (8) walking with thick footing, eyes open; (9) walking with head turns and tilts, eyes open; and (10) walking around a room, incorporating turns and movements other than straight forward walking, eyes open.
2888527|NCT03330262|No Intervention|Control|Participants will be asked to perform a series of appropriate exercises daily at home for a period of 6 weeks. The training exercises will include: (1) standing on a firm surface with feet apart, eyes open and closed; (2) standing on a firm surface with feet together, eyes open and closed; (3) standing on thick footing (e.g., multiple pairs of socks) with feet apart, eyes open and closed; (4) standing on thick footing with feet together, eyes open and closed; (5) standing in a modified Romberg position on a firm surface, eyes open and closed; (6) standing in a Romberg position on a firm surface, eyes open and closed; (7) walking on a firm surface eyes open; (8) walking with thick footing, eyes open; (9) walking with head turns and tilts, eyes open; and (10) walking around a room, incorporating turns and movements other than straight forward walking, eyes open.
2888528|NCT03330249|Experimental|Split Cisplatin and radiotherapy|25 mg/m2/day IV infusion at D1 to D4, at D22 to D25, at D43 to D46 during the radiotherapy
2888529|NCT03330249|Active Comparator|Cisplatin and radiotherapy|100 mg/m2/day IV infusion at D1, D22 and D43 during the radiotherapy
2888530|NCT03330236|Experimental|SedLine EEG monitoring|All recruited patients from the intervention group will receive SedLine EEG Brain Function Monitoring.
2888531|NCT03330236|No Intervention|Control arm|Participants randomized to the control arm will receive no placebo intervention- receiving only standard of care procedures.
2888532|NCT03330223||Clopidogrel|clopidogrel 75mg qd;aspirin 100mg qd, n=30
2888538|NCT03330184|Placebo Comparator|placebo|bifidobacterium mimetic capsules berberine mimetic tablets,2/day, 16 weeks
2888539|NCT03330171|Other|HIV-unexposed children|HIV-unexposed children enrolled in a randomized open label study on the pneumococcal conjugate vaccine (PCV1+1) will be invited to participate in this study. Children enrolled in the PCV1+1 study will receive all vaccines included in the South African public immunization program. Measles vaccine (0.5 mL, subcutaneous injection) will be adminstered at 6 months of age and 12 months of age. Varicella vaccine (0.5 mL, subcutaneous injection) or Hepatitis-A vaccine (0.5 mL, intra-muscular injection) will be administered to the participants at 18 months of age as an additional benefit for participating in the study.
2888540|NCT03330171|Other|HIV-exposed children|A cohort of HIV-exposed children will be recruited. Measles vaccine (0.5 mL, subcutaneous injection) will be adminstered at 6 months of age and 12 months of age. Varicella vaccine (0.5 mL, subcutaneous injection) or Hepatitis-A vaccine (0.5 mL, intra-muscular injection) will be administered to the participants at 18 months of age as an additional benefit for participating in the study.
2888541|NCT03330158|Experimental|ASTS device|Implantation of device ASTS (for ACTIVE TREATMENT SCOLIOSIS SYSTEM ) in children between 4 and 10
2888542|NCT03330145|Experimental|children who lost a parent to cancer|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
2888543|NCT03330145|Active Comparator|children who lost a parent not to cancer|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
2888544|NCT03330132|Active Comparator|Standard vaccine|Once-annual administration of standard vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2888545|NCT03330132|Experimental|Alternating standard vaccine & adjuvanted vaccine|Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2888546|NCT03330132|Experimental|Alternating adjuvanted vaccine & standard vaccine|Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2888547|NCT03330132|Experimental|Alternating standard vaccine and high-dose vaccine|Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2888548|NCT03330132|Experimental|Alternating high-dose vaccine and standard vaccine|Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2888549|NCT03330132|Experimental|Alternating adjuvanted vaccine and high-dose vaccine|Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2888550|NCT03330132|Experimental|Alternating high-dose vaccine and adjuvanted vaccine|Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2888551|NCT03330132|Experimental|High-dose vaccine|Once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2888552|NCT03330132|Experimental|Adjuvanted vaccine|Once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2888553|NCT03330132|Experimental|Recombinant vaccine|Once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2888554|NCT03330119|Experimental|Alternate Management|
2888555|NCT03330119|Placebo Comparator|Control|The regular Lankenau cesarean section order set.
2888556|NCT03330106|Experimental|Part A: Pevonedistat 25 mg/m^2 + Pevonedistat 50 mg/m^2|Pevonedistat 25 mg/m^2, infusion, intravenously, once on Day 1 of Cycle 1, followed by pevonedistat 50 mg/m^2, infusion, intravenously, once on Day 8 of Cycle 1.
2888557|NCT03330106|Experimental|Part A: Pevonedistat 50 mg/m^2 + Pevonedistat 25 mg/m^2|Pevonedistat 50 mg/m^2, infusion, intravenously, once on Day 1 of Cycle 1, followed by pevonedistat 25 mg/m^2, infusion, intravenously, once on Day 8 of Cycle 1.
2888558|NCT03330106|Experimental|Part B: Pevonedistat|Pevonedistat 25 mg/m^2 in combination with docetaxel 75 mg/m^2 or pevonedistat 20 mg/m^2 in combination with carboplatin plus paclitaxel 175 mg/m^2, infusion, intravenously, once on Day 1 in each 21-day treatment cycle followed by pevonedistat 25 mg/m^2 or 20 mg/m^2 infusion, intravenously, once on Days 3 and 5 in each 21-day treatment cycle for up to 12 cycles or symptomatic deterioration or PD, treatment is discontinued for another reason, or until the study is stopped. The combination and dose of pevonedistat will be based on investigator discretion.
2888559|NCT03330093|Experimental|Sleep Extension|1-month educational and problem solving behavioral intervention about sleep.
2888560|NCT03330093|Active Comparator|Health and Safety|1-month educational and problem solving behavioral intervention about health and safety.
2888561|NCT03330080||Ecological momentary assessment (EMA)|The ecological momentary assessment (EMA) will be used for participants to complete surveys from home on two occasions each day over seven days.
2888562|NCT03330067|Sham Comparator|Cold and dry CO2 pneumoperitoneum|Pneumoperitoneum is created by insufflation of standard cold (19-21°C) and nonhumidified (0%) CO2 directly from a standard CO2 tank or wall source.
2889050|NCT03326817|Active Comparator|Control Group|This group will receive standard care.
2888563|NCT03330067|Experimental|Warm and humidified CO2 pneumoperitoneum|The humidification and warming device to be used is the Insuflow Synergy Port (Lexion Company, FDA approved) which is a specialized 5 mm port that delivers warmed (95° F) and humidified (95% relative humidity) CO2, the source of which is a standard CO2 tank or wall source.
2888564|NCT03330054||Group A|50 patients Type 2 Diabetes without renal impairment will be examined using fundoscope
2888565|NCT03330054||Group B|25 patients Type 2 Diabetes with chronic kidney disease not on replacement therapy (stage I-IV) will be examined using fundoscope
2888566|NCT03330054||Group C|25 patients Type 2 Diabetes with end stage renal disease on haemodialysis will be examined using fundoscope
2888567|NCT03330041|Experimental|Fast absorbing gut suture placed 2 mm apart|Wound closed with sutures spaced 2 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern
2888568|NCT03330041|Experimental|Fast absorbing gut suture placed 5 mm apart|Wound closed with sutures spaced 5 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern
2888569|NCT03330028|Experimental|Hyperthermic Intraperitoneal Chemoperfusion (HIPEC)|Participants receive heated Mitomycin, Cisplatin, and Paclitaxel as a liquid that is injected through 3 to 4 small incisions into the abdomen over about 1 hour.
2888570|NCT03330002||CE-marked MANTA vascular closure devices per IFU|Transcatheter Aortic Valve Replacement (TAVR), Endovascular aneurysm repair (EVAR), TEVAR, etc.
2888571|NCT03329989|Experimental|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
2888572|NCT03329976||patient|any person about to undergo combined surgery for cataract and ERM
2888573|NCT03329963|Experimental|Lifestyle intervention Group|Behavioral therapy for weight loss and Exercise Training
2888574|NCT03329963|Active Comparator|Healthy lifestyle intervention Group|Group education sessions that focus on diet exercise and social support.
2888575|NCT03329950|Experimental|CDX-1140|"Part 1: Dose-escalation phase: Eligible patients will receive treatments, based on cohort assigned, in 4 week cycles until progression or intolerance.~Expansion phase: To further study the safety, tolerability, and efficacy of CDX-1140. Patients enrolled in the expansion phase of the study will receive CDX-1140 at the dose level(s) chosen during the escalation phase."
2888576|NCT03329950|Experimental|CDX-1140 and CDX-301|"Part 2: Dose-escalation phase: Eligible patients will receive CDX-1140 in 4 week cycles until progression or intolerance. CDX-301 is injected once a day for five days before cycles 1 and 2 of CDX-1140.~Expansion Phase: To further study the safety, tolerability, and efficacy of CDX-1140 and CDX-301. Patients enrolled in the expansion phase of Part 2 will receive CDX-1140 at the dose level(s) chosen during the escalation phase."
2888577|NCT03329937|Experimental|Safety and Antitumor Evaluation|To evaluate the antitumor activity and safety of Niraparib therapy.
2888578|NCT03329924||Pre-implementation cohort|These patients are being exposed to the current standard of care, which does include some early mobilization practices, but not a formalized program.
2888579|NCT03329924||post-implementation cohort|These patients will have been exposed to the fully executed early mobilization program.
2888580|NCT03329911|Active Comparator|EU Avastin®|"Drug:EU Avastin® 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months.~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
2888581|NCT03329911|Experimental|BAT1706|"BAT1706 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with BAT1706 up to a maximum of 8 months.~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
2888582|NCT03329898|Experimental|dried biological amnion graft|dried biological amnion graft patients, who are with IUA, treated by uterine application of dried biological amnion graft + disposable balloon uterine stent + hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
2888583|NCT03329898|Sham Comparator|disposable balloon uterine stent only|disposable balloon uterine stent patients, who are with IUA, treated by uterine application of disposable balloon uterine stent only + hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
2888584|NCT03329885|Experimental|Part A Single Ascending Dose (SAD) in Healthy Patients|Healthy patient will receive single escalating oral doses of BMS-986251 or placebo
2888585|NCT03329885|Experimental|Part B Multiple Ascending Dose (MAD) in Healthy Patients|Healthy patients will receive daily escalating oral doses of BMS-986251 or placebo
2888586|NCT03329885|Experimental|Part C Multiple Dosing in Psoriasis Patients|Psoriasis patients will receive daily escalating oral doses of BMS-986251 or placebo
2888587|NCT03329872||Patients group|Patients follow-up in hospital will have data collection
2888588|NCT03329859|Experimental|Interventional arm|"High resolution standardized laparoscopic cholecystectomy Patients in which laparoscopic cholecystectomy was performed after high Resolution standardization and Training of the OR Team according to the Standard."
2888589|NCT03329859|Active Comparator|Control arm|No 'High resolution standardized laparoscopic cholecystectomy' Patients in which laparoscopic cholecystectomy was performed in the conventional way without prior standardization
2888590|NCT03329846|Active Comparator|Nivolumab + Placebo|"Specified dose on specified day~Participants will no longer receive BMS-986205 Placebo"
2888591|NCT03329846|Experimental|Nivolumab + BMS-986205|"Specified dose on specified day.~Participants have the option to discontinue BMS-986205, and continue nivolumab monotherapy, at investigator discretion"
2888592|NCT03329833|Experimental|Motivational Interviewing|Participants will talk to a coach on the phone who will employ Motivational Interviewing as a coaching style.
2888593|NCT03329833|Experimental|Web-Based Application|Participants will use a Web-Based Application to track their daily physical activity.
2888594|NCT03329833|Experimental|Combination MI and App|Participants will have both a coach by phone who will employ Motivational Interviewing as a coaching style and use a Web-Based Application to track their daily physical activity.
2888595|NCT03329833|No Intervention|Educational Program|Participants will get to use a website that contains information relevant to patients with Parkinson's Disease.
2889396|NCT03324295||impaired renal functions|patients with impaired renal functions and are not on dialysis
2888596|NCT03329820||1 Uncomplicated CHB|Patients with chronic CHB infections but normal liver function and without cirrhosis or hepatocellular carcinoma
2888597|NCT03329820||2 CHB with impaired liver function (LF) or CC w/o tx|CHB with impaired liver function or compensated cirrhosis, not on anti-viral treatment
2888598|NCT03329820||3 CHB with impaired LF or CC with tx|CHB with impaired liver function or compensated cirrhosis, on anti-viral treatment.
2888599|NCT03329820||4 Decompensated cirrhosis|Patients with CHB infection and cirrhosis complicated by one or more of the following: variceal bleeding, hepatic encephalopathy or ascites.
2888600|NCT03329820||5 Hepatocellular carcinoma|Patients with confirmed diagnosis of hepatocellular carcinoma
2888601|NCT03329807|Experimental|Experimental rTMS and conventional sensory therapy|"Device: Repetitive Transcranial Magnetic Stimulation (rTMS) The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the somatosensory cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 10Hz on the injured hemisphere by stroke; 1500 pulses with an intensity of 120% of MT 10 sessions of rTMS, one per day, always before conventional sensory therapy. rTMS it will be applied for about 20 minutes, five days per week.~Behavioral: conventional sensory therapy All patients will receive the same protocol of Sensory Therapy that will consist of the behavioral methods of Active Sensory Reeducation, Mirror Therapy and passive method that will consist in the administration of electric current by TENS (sensitive threshold). Participants will be instructed not to perform active muscular contraction during Interventions. The protocol it will be applied for about 60 minutes, five days per week."
2888602|NCT03329807|Sham Comparator|Sham Comparator|"control The control group received rTMS sham stimulation (same area as the experimental group) in 10 sessions, 5 days per week, and Sham conventional sensory therapy in the paretic upper limb The sham stimulation will be applied so that it is perceived by the patient as real. Thus during the rTMS sessions the same procedures of the active rTMS sessions will be applied, however the stimulation will be performed with two coils: a coil coupled to the stimulator positioned away from the patient's scalp, yet not visible to the patient so that the patient Perceive only the characteristic sound of the stimulation, and the other coil, disconnected from the stimulator positioned on the volunteer's head.~For the SHAM group, all sensory therapy activities will be performed, however only with the non-affected member. Patients will be convinced that a transfer of skills from one member to another can occur through the connections between the hemispheres."
2888603|NCT03329781|Experimental|Trial|350 mg of BCM-95, 1 capsule per day, for 21 days.
2888604|NCT03329781|Placebo Comparator|Control|350 mg of starch, 1 capsule per day, for 21 days
2888605|NCT03329755|Experimental|Experimental|
2888606|NCT03329755|Other|Standard|
2888607|NCT03329742|Placebo Comparator|Control protein diet arm|20% protein content
2888608|NCT03329742|Experimental|Low protein diet arm|10% protein content
2888609|NCT03329729||Hyperlipidemic patients|
2888610|NCT03329716|Other|Immediate Brace Weaning|Immediate weaning of brace
2888611|NCT03329716|Other|Gradual Brace Weaning|Nocturnal brace wearing for 6 months prior to stopping brace
2888612|NCT03329703|Experimental|Immediate-Treatment|This group will receive Project UPLIFT immediately after completing surveys.
2888613|NCT03329703|Active Comparator|Waitlist Control|This group will receive Project UPLIFT after waiting approximately 3 months to begin the intervention.
2888614|NCT03329690|Experimental|Parallel: DS-8201a|Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive DS-8201a once every 3 weeks.
2888615|NCT03329690|Active Comparator|Parallel: Physician's Choice|Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive monotherapy prescribed by the physician before enrollment.
2888616|NCT03329690|Other|Exploratory: Naïve HER2 IHC 2+/ISH-|A maximum of 20 non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every three weeks.
2888617|NCT03329690|Other|Exploratory: Naïve HER2 IHC 1+|A maximum of 20 non-randomized patients with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every 3 weeks.
2888618|NCT03329677|Experimental|Transference-focused Psychotherapy (TFP)|Transference-focused psychotherapy is a psychodynamic talk therapy utilized in treating borderline personality disorder in men and women.
2888619|NCT03329664|Experimental|CIK Intervention plus routine treatment|Patients who receive their routine treatment (chemotherapy, radiation therapy) + Cytokine-induced killer cell infusion
2888620|NCT03329664|Active Comparator|Control|Patients who receive routine treatments only (chemotherapy, radiation therapy)
2888621|NCT03329651|Experimental|Metformin treatment|
2888622|NCT03329651|Placebo Comparator|Placebo treatment|
2888623|NCT03329638|Experimental|DE-127 Ophthalmic Solution low dose|
2888624|NCT03329638|Experimental|DE-127 Ophthalmic Solution medium dose|
2888625|NCT03329638|Experimental|DE-127 Ophthalmic Solution high dose|
2888626|NCT03329638|Placebo Comparator|Placebo Ophthalmic Solution|
2888627|NCT03329625|Experimental|Pathways Triple P|Families randomized to the Pathways Triple P received a 14 week home based intervention.
2888628|NCT03329625|Active Comparator|Services as Usual|Families randomized to the services as usual condition received services as usual through the Missouri Children's Division
2888629|NCT03329612|Experimental|Intervention|This group will undergo remote ischemic preconditioning with serial inflations of the blood pressure cuff to 200 mmHg followed by deflation for reperfusion for a period of 5 minutes each for a total of 4 cycles.
2888630|NCT03329612|Sham Comparator|Control|This group will undergo serial inflations of the blood pressure cuff to 40 mmHg followed by deflation for a period of 5 minutes each for a total of 4 cycles.
2888631|NCT03329599|Experimental|Polypill|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
2888632|NCT03329599|No Intervention|Usual Care|Will continue to take separate, individual secondary preventive medications as prescribed
2888633|NCT03329586|Experimental|Training|
2889397|NCT03324282|Experimental|Arm A: GC + avelumab group|
2889398|NCT03324282|Active Comparator|Arm B: GC group|
2888634|NCT03329573|Experimental|AB treatment sequence receivers in fasting group|Eligible subjects will receive a single dose of Paroxetine IR tablets A in Period 1 followed by Paroxetine IR tablets B in Period 2 in fasting state.
2888635|NCT03329573|Experimental|BA treatment sequence receivers in fasting group|Eligible subjects will receive a single dose of Paroxetine IR tablets B in Period 1 followed by Paroxetine IR tablets A in Period 2 in fasting state.
2888636|NCT03329573|Experimental|AB treatment sequence receivers in fed group|Eligible subjects will receive a single dose of Paroxetine IR tablets A in Period 1 followed by Paroxetine IR tablets B in Period 2 in fed state.
2888637|NCT03329573|Experimental|BA treatment sequence receivers in fed group|Eligible subjects will receive a single dose of Paroxetine IR tablets B in Period 1 followed by Paroxetine IR tablets A in Period 2 in fed state.
2888638|NCT03329560|Experimental|Oral fecal microbiota transplantation|All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.
2888639|NCT03329547|Experimental|Subjects receiving treatment sequence AB|Eligible subjects will receive treatment sequence AB; A= SKF101804 cefixime 400 mg test capsules and B= cefixime 400 mg reference capsules. Subjects will receive single oral dose of treatment A in treatment period 1 on Day 1 and treatment B in treatment period 2 on Day 1. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days.
2888640|NCT03329547|Experimental|Subjects receiving treatment sequence BA|Eligible subjects will receive treatment sequence BA; B= cefixime 400 mg reference capsules and A= SKF101804 cefixime 400 mg test capsules. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days. Subjects will receive single oral dose of treatment B in treatment period 1 on Day 1 and A in treatment period 2 on Day 1. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days.
2888641|NCT03329534|Experimental|Subjects with GRDs|An intervention of a change in diet, specifically a gluten free diet taught by a health care professional will be administered for one month's time.
2888642|NCT03329534|Active Comparator|Subjects without GRDs|An intervention of a change in diet, specifically a gluten free diet taught by a health-care professional will be administered for one month's time.
2888643|NCT03329521|Experimental|Multicomponent Initiative|A number of quality improvement initiatives will be provided at the CKD programs.
2888644|NCT03329521|No Intervention|Routine Care|CKD programs will continue to support access to kidney transplantation and living kidney donation as they usually do for CKD patients.
2888645|NCT03329508|Experimental|P2B001|Fixed dose combination once daily capsule of pramipexole and rasagiline
2888646|NCT03329508|Experimental|rasagiline capsule|rasagiline Once daily capsule
2888647|NCT03329508|Experimental|Pramipexole capsule|Pramipexole once daily capsule
2888648|NCT03329508|Active Comparator|Pramipexole Extended Release|pramipexole ER tablet titrated to optimal dose of 1.5, 3.0 or 4.5mg
2888649|NCT03329495|Active Comparator|SMA-orientated right hemicoloectomy|SMA-orientated right hemicoloectomy
2888650|NCT03329495|Experimental|SMV-orientated right hemicoloectomy|SMV-orientated right hemicoloectomy
2888651|NCT03329482|Experimental|Pulse Ultrasound Group A|This is the Pulse Ultrasound group. Twenty five patients will be in this group.
2888652|NCT03329482|Experimental|Kneading Massage Group B|This is kneading massage group . Also 25 patients will be in this group.
2888653|NCT03329469|Experimental|Experimental: 1: Toshiba CT-FFR Arm|All patients who consent will receive Toshiba CT-FFR and medically acceptable care based on the study protocol, commonly accepted standards of care, and the patients condition.
2888654|NCT03329456|Other|Ropivacaine|Single arm intervention
2888655|NCT03329443|Placebo Comparator|placebo|
2888656|NCT03329443|Active Comparator|Spironolactone|
2888657|NCT03329430|Experimental|Foot orthoses|Customize foot orthoses
2888658|NCT03329417|Active Comparator|Traditional occupational therapy|The program includes 30 minutes of traditional occupational therapy (sensorimotor facilitation techniques, such as: Rood, Bobath and propriocetive-neuromuscular-facilitation), followed by 20 minutes of motor task specific training in each treatment session.
2888659|NCT03329417|Active Comparator|Mirror therapy using a mirror box|The program includes 30 minutes of mirror therapy, followed by 20 minutes of regular motor task specific training in each treatment session.
2888660|NCT03329417|Experimental|Virtual reality based mirror therapy|The program includes 30 minutes treatment session of virtual reality mirror therapy, followed by 20 minutes of motor task specific training in each treatment session.
2888661|NCT03329404|Experimental|Mirasol Red Blood Cells (MIR RBCs)|MIR RBCs: RBCs will be derived from WB collected in CPD solution, treated with the Mirasol System for WB, LR, and stored in AS-3 for ≤ 21 days at 1 6°C
2888662|NCT03329404|Active Comparator|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs); LR apheresis RBCs or WB-derived RBCs will be per site standard inventory
2888663|NCT03329391|Experimental|Intervention Group|The intervention group will receive a 6-week nurse-led psychosocial care group,which involve 90 minutes session every week.
2888664|NCT03329391|No Intervention|Control Group|The control group will receive usual care, which refers to the pharmacological therapy provided by psychiatrists in the Psychiatric Department.
2888665|NCT03329378|Active Comparator|ddACTHP|"Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Pegfilgrastim 6mg SC, day 2 of AC~Cycled every 14 days for 4 cycles, followed by, Paclitaxel 80 mg/m2 IV x 1 hour infusion on days 1, 8, and 15 Trastuzumab 8 mg/kg IV day 1, followed by 6mg/kg Pertuzumab loading dose 840 mg IV followed by 420 mg IV every 3 weeks~Cycled every 21 days for 4 cycles, followed by, Trastuzumab 6mg/kg every 21 days to complete 1 year"
2888666|NCT03329378|Active Comparator|TCHP|TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Pegfilgrastim ) institutional practice is to titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.
2888667|NCT03329365||ESUS/ETUS|Patients with embolic ischemic stroke or transient ischemic attack of undetermined source
2888668|NCT03329365||SSS-CVTUS|Patients with superior sagittal sinus cerebral venous thrombosis of undetermined source
2888669|NCT03329339|No Intervention|2 L PEG with ascorbic acid group|
2888670|NCT03329339|Experimental|1 L PEG with ascorbic acid with PLD|
2888671|NCT03329313|Active Comparator|Low sodium concentration|Concentration of sodium in dialysate at 140 mmol/l ( Lowering sodium concentration dialysate)
2888672|NCT03329313|Sham Comparator|High Sodium Concentration|Concentration of sodium in dialysate at 145 mmol/l (Highing sodium concentration dialysate)
2888673|NCT03329300|Other|All participants|Family-based Behavioral Treatment (FBT)
2888674|NCT03329287|Experimental|SCBT + Drug|Participants receive SCBT at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
2888675|NCT03329287|Active Comparator|Psychological Placebo + Drug|Participants receive supportive and relaxation therapy at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
2888676|NCT03329287|Active Comparator|Drug|Participants only take SSRIs and/or SNRIs through the trial at a recommended dosage.
2888677|NCT03329274||Patients with Erdheim-Chester Disease|
2888678|NCT03329261|Active Comparator|Arm 1 (single dose)|Will receive a clopidogrel loading dose of 600 mg PO, then a daily dose of clopidogrel 75 mg PO until the angioplasty is performed. After coronary intervention, a daily dose of clopidogrel 150 mg PO for 7 days will be given, followed by a daily single dose of clopidogrel (75 mg PO) for 21 days. Maintenance therapy will be clopidogrel daily dose of 75 mg PO thereafter, until the end of the study.
2888679|NCT03329261|Active Comparator|Arm 2 (double dose)|Will receive a clopidogrel loading dose of 600 mg PO, then a daily dose of clopidogrel 75 mg PO until the angioplasty is performed. After coronary intervention, a daily dose of clopidogrel 150 mg PO for 7 days will be given, followed by a daily double dose of clopidogrel (150 mg PO) for 21 days. Maintenance therapy will be clopidogrel daily dose of 75 mg PO thereafter, until the end of the study.
2888680|NCT03329248|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: ALT-803, ETBX-011, GI-4000, haNK, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ethyl esters, oxaliplatin, SBRT
2888681|NCT03329235|Experimental|Intraosseous and intra-articular|injection of PRP 2 ml
2888682|NCT03329235|Active Comparator|intra-articular PRP|injection PRP 2 ml
2888683|NCT03329235|Active Comparator|Intra-articular injection of HA|injection of HA 2 ml
2888684|NCT03329222|Experimental|Intervention group|An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose
2888685|NCT03329222|Active Comparator|Control group|Standard cow's milk with prebiotics mixture
2888686|NCT03329209|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, infusion, intravenously over 30-minutes, once on Day 1.
2888687|NCT03329196|Experimental|MT-6548|
2888688|NCT03329196|Active Comparator|Darbepoetin alfa|
2888689|NCT03329183|Experimental|HD-FOLFIRI|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive high-dose FOLFIRI regimen (Irinotecan 260mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course.)
2888690|NCT03329183|No Intervention|SD-FOLFIRI|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive standard-dose FOLFIRI regimen (Irinotecan 180mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
2888691|NCT03329183|No Intervention|SD-FOLFOX-6|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive standard-dose FOLFOX-6 regimen (Oxaliplatin 130mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
2888692|NCT03329170|Experimental|CHD intervention|educational intervention using motivational interviewing
2888693|NCT03329170|No Intervention|CHD control|At 24 and 36 months of age the parents of the child will fill in a questionnaire via internet, designed to assess oral health behaviour. At 36 months of age the child will be offered to participate in a clinical dental examination.
2888694|NCT03329170|No Intervention|Healthy control|At 36 months of age the parents of the child will fill in a questionnaire via internet, designed to assess oral health behaviour. At 36 months of age the child will be offered to participate in a clinical dental examination.
2888695|NCT03329157|Other|Rebuilding Bridges|This is a one-group study and the group will receive the Rebuilding Bridges intervention
2888696|NCT03329144|Experimental|Cognitive Behavioural Therapy|The women in this arm will receive a 9-week CBT-based curriculum delivered by Public Health Nurses to help build resilience and optimize mood, anxiety, and emotion regulation while attending a supported school program in Niagara Region.
2888697|NCT03329131|Experimental|Cryotherapy|Each patient will receive cryotherapy administered during each neurotoxic chemotherapy agent infused treatments by Elasto gel™ Hypothermia gloves and socks. Patients will wear the glove and sock for 15 minutes prior to treatment start and 15 minutes following treatment completion, for a total of 30 minutes.
2888698|NCT03329118|Experimental|SHR3824 1Omg,Simavastatin 40mg|two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
2888699|NCT03329105|Experimental|Sea Salt Mouth Rinse|
2888700|NCT03329105|Active Comparator|Standardized Oral Health Practices|
2888701|NCT03329092|Experimental|Aztreonam-Avibactam ± Metronidazole|All patients randomised to this arm will receive ATM-AVI; all patients with cIAI will receive MTZ for anaerobic cover
2888702|NCT03329092|Active Comparator|Meropenem ± Colistin|All patients randomised to this arm will receive MER; addition of COL will be at investigator's discretion in line with local practice
2888703|NCT03329079|Experimental|Mobile Technology Plus (MT+)|Experimental arm will receive a 3-month MT+ intervention using the premium mobile phone app version with social comparison group, behavior change text messaging, and daily self-weighing via Wi-Fi scale.
2888704|NCT03329079|Active Comparator|Mobile Technology (MT)|Comparison group will receive the basic version of the mobile phone app only.
2888705|NCT03329066|Experimental|MAST - Managing Asthma & Sleep in Teens|This is an eight week intervention consisting of 4 group and 4 individual tailored coaching sessions that focuses on both asthma and sleep. In this behavioral medicine intervention, teenagers learn ways to better care for their asthma and sleep hygiene. Teen sessions are delivered in school. Their caregivers will receive four educational booklets that correspond to each group session; topics mirror the objectives of each group and the booklets are sent at the time of each group.
2888706|NCT03329066|Active Comparator|ASMA - Asthma Self-Management for Adol|ASMA is an evidence-based intervention for students, caregiver education, and education for students' medical providers. The student intervention consists of 3 group sessions & 5 individual tailored coaching sessions. All sessions are held at school. The caregiver intervention includes 3 educational booklets that correspond to the timing of the student group and 4 brief telephone-counseling sessions to review the booklets, answer questions, and provide strategies to support adolescents' steps to care for their asthma. With caregiver permission, we mail students' healthcare providers a toolkit consisting of (1) a letter informing them their patient is participating in ASMA and is being directed to them for clinical evaluation and (2) summaries of key NHLBI guidelines for treating asthma.
2888707|NCT03329066|Placebo Comparator|Information & Referral Control Group|The information-and-referral control intervention is a student-only intervention that consists of 3 group sessions and 5 individual sessions. Sessions are held once a week at school, where students will receive guideline-based information about asthma and other health topics relevant to adolescents (e.g., nutrition, safety). Students will be referred to their medical providers for asthma and other health concerns; if they do not have a provider, they are given referrals in their community.
2888708|NCT03329053|Experimental|Experimental group|Patients randomized into the experimental group will undergo behavioural counselling. During the 30-minute long consultation patients will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support system EXPERT tool.
2888709|NCT03329053|Active Comparator|Control group|Patients randomized into the control group will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, also in the domain of recommendations for physical activities.
2888710|NCT03329040||Primipara mothers|Infant to primipara mothers, i.e. the first infant to the mother - No intervention
2888711|NCT03329040||Multipara mothers|Infant to multipara mothers, i.e. not the first infant to the mother - No intervention
2888712|NCT03329027|Experimental|Vibrating Mode 1|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
2888713|NCT03329027|Experimental|Vibrating Mode 2|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
2888714|NCT03329027|Sham Comparator|Sham|Patients will receive sham capsule for 8 weeks of treatment (5 capsules/week)
2888715|NCT03329014|Experimental|Intravenous Remimazolam|4 mg intravenous remimazolam as an intravenous control
2888716|NCT03329014|Experimental|10 mg Powder Remimazolam|Powder containing 10 mg remimazolam for intranasal administration
2888717|NCT03329014|Experimental|10 mg Solution Remimazolam|Solution containing 10 mg remimazolam for intranasal administration
2888718|NCT03329014|Experimental|20 mg Powder Remimazolam|Powder containing 20 mg remimazolam for intranasal administration
2888719|NCT03329014|Experimental|20 mg solution Remimazolam|Solution containing 20 mg remimazolam for intranasal administration
2888720|NCT03329014|Experimental|40 mg Powder Remimazolam|Powder containing 40 mg remimazolam for intranasal administration
2888721|NCT03329014|Experimental|40 mg Solution Remimazolam|Solution containing 40 mg remimazolam for intranasal administration
2888722|NCT03329014|Placebo Comparator|Placebo Powder|Powder containing 20 mg placebo for intranasal administration
2888723|NCT03329014|Placebo Comparator|Placebo solution|Solution containing 20 mg placebo for intranasal administration
2888724|NCT03329001|Experimental|Tablet-Capsule Sequence|Single dose Niraparib Tablet (1x300mg) followed by single dose Niraparib Capsule (3x100mg) followed by optional daily dosing extension phase
2888725|NCT03329001|Experimental|Capsule-Tablet Sequence|Single dose Niraparib Capsule (3x100mg) followed by single dose Niraparib Tablet (1x300mg) followed by optional daily dosing extension phase
2888726|NCT03328988|Experimental|Quadratus lumborum block|Single shot bilateral QLB, ropivacaine 75 mg (20 mL) per side, placed under ultrasound control, at the end of surgery. 22 patients will be allocated in this group.
2888727|NCT03328988|No Intervention|Epidural|"Epidural catheter (placed before anesthesia induction), ropivacaine 75 mg in 50 mL isotonic saline (1,5 mg/mL), induction bolus after surgery 1 mL/10 kg ideal weight and there on continuous infusion 2-8 mL/h according to analgesic need. 22 patients will be allocated in this group.~This is the current standard for postoperative pain relief in cystectomy patients in our hospital"
2888728|NCT03328975|Active Comparator|Dexamethasone|Group 1 will receive an injection of 4mg of dexamethasone 4 mL of 1% lidocaine.
2888729|NCT03328975|Placebo Comparator|Placebo|Group 2 will receive an injection of 5 mL of 1% lidocaine (placebo).
2888730|NCT03328962|No Intervention|Control group|Newly diagnosed cancer patients at their first consultation for treatment at an oncological hospital Department, who report to be smoking, recruited from 15/09/17 to 15/3/18. Their smoking status will be observed over a period of six months.
2888731|NCT03328962|Experimental|Intervention group|Newly diagnosed cancer patients at their first consultation for treatment at an oncological hospital Department, who report to be smoking, recruited from 15/09/18 to 15/3/19. The intervention group will receive structured smoking cessation counselling based on MI and adapted for the cancer setting combined with provision of smoking cessation medication (nicotine replacement therapy) while in the control group there will be standard care which may vary from hospital to hospital. Their smoking status will be observed over a period of six months.
2888732|NCT03328949|Experimental|IVL Coronary Lithotripsy System|All enrolled patients will receive treatment from the IVL coronary lithotripsy system prior to coronary stent placement.
2888733|NCT03328936|Experimental|Arm I (melphalan hydrochloride for 3-day severe neutropenia)|Patients receive personalized dose of melphalan hydrochloride IV on day -2 for for predicted 3-day duration of severe neutropenia and undergo standard of care autologous stem cell transplant on day 0.
2888734|NCT03328936|Experimental|Arm II (melphalan hydrochloride or 5-day severe neutropenia))|Patients receive personalized dose of melphalan hydrochloride IV on day -2 for predicted 5-day duration of severe neutropenia and undergo standard of care autologous stem cell transplant on day 0.
2888735|NCT03328923|Experimental|500mg brown seaweed powder|2 x 250mg capsules InSea2® (brown seaweed powder)
2888736|NCT03328923|Placebo Comparator|Placebo|2 x capsules microcrystalline cellulose (bulking agent) (0mg InSea2®)
2888840|NCT03328143|Experimental|Treatment with Lavender|Lavender (Lavandula angustifolia) aromatherapy will be administered at regular intervals using a nasal inhaler.
2888737|NCT03328910||Analgesia monitoring|After anesthesia induction, all participants received standard anesthesia monitoring, SPI monitor (GE Healthcare, Helsinki, Finland) and bispectral index (BIS). BIS was kept between 40-60, whereas no specific target was determined for SPI. At the end of surgery, anesthesia was terminated and the patients were stimulated to wake up. After the participants were able to breathe spontaneously and obey verbal commands, extubation was carefully performed, and the monitoring of SPI was stopped.
2888738|NCT03328897|Experimental|omalizumab 300mg s.c.|omalizumab 300 mg s.c. every 4 weeks.
2888739|NCT03328897|Experimental|omalizumab 150mg s.c.|Omalizumab 150 mg s.c. every 4 weeks.
2888740|NCT03328897|Placebo Comparator|placebo s.c.|Placebo s.c. every 4 weeks.
2888741|NCT03328884|Other|nal-IRI|This is a single arm study. After signing the informed consent form, patients will start treatment with nal-IRI. nal-IRI will be administered at a fixed dose of 60 mg/m2 on D1 of a 14-day cycle in monotherapy.
2888742|NCT03328871|Experimental|Fractional CO2 Laser and PRP injection|One of the striae gravidarum areas will be treated by fractional laser once every three months for 2 times combined with PRP injection once a month for 6 times.
2888743|NCT03328871|Experimental|Nanofat grafting and PRP injection|Another area will be treated by nanofat grafting once every three months for 2 times and PRP therapy once a month for 6 times.
2888744|NCT03328858|Other|Ketogenic Diet|Participants will be provided a consultation with a ketogenic dietitian, and test the tolerance to the diet in an inpatient mode
2888745|NCT03328845|Other|Tresiba & NovoRapid|Patients treated with Tresiba insulin and NovoRapid insulin
2888746|NCT03328845|Other|Toujeo SoloStar & NovoRapid|Patients treated with Toujeo SoloStar insulin and NovoRapid insulin
2888747|NCT03328845|Other|Tresiba & Humalog Kwikpen|Patients treated with Tresiba insulin and Humalog kwikpen insulin
2888748|NCT03328845|Other|Toujeo SoloStar & Humalog Kwikpen|Patients treated with Toujeo SoloStar insulin and Humalog kwikpen insulin
2888749|NCT03328845|Other|Tresiba & Apidra|Patients treated with Tresiba insulin and Apidra insulin
2888750|NCT03328845|Other|Toujeo SoloStar & Apidra|Patients treated with Toujeo SoloStar insulin and Apidra insulin
2888751|NCT03328832|Active Comparator|Combined topical TXA and Floseal|Floseal® was applied on potential bleeding sites before prosthesis implantation, and intraarticular application of topical tranexamic acid after capsule closure Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
2888752|NCT03328832|Active Comparator|Topical TXA alone|Intraarticular application of topical tranexamic acid after capsule closure Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
2888753|NCT03328819|Experimental|Acupuncture for Depression/Acupuncture for pain|
2888754|NCT03328819|Experimental|Acupuncture for pain/Acupuncture for Depression|
2888755|NCT03328793|Experimental|Music Intervention (Intervention Group)|"The patients will assist to a live music session of 30 minutes which will be given by musicians (volunteers) and will undergo:~mood assessment~emotion assessment~mobility assessment~communication assessment"
2888756|NCT03328793|Active Comparator|Documentary watching (Control Group)|"The patients will watch a documentary for 30 minutes in the presence of a volunteer and will undergo:~mood assessment~emotion assessment~mobility assessment~communication assessment"
2888757|NCT03328780||Hemoglobin determination|In this study classical laboratory determination, determination with HemoCue® and Rad-67™ will be performed to compare precision of those three methods as well as their correlation.
2888758|NCT03328767|Experimental|Early activity and Mobilisation intervention|Patients will be randomised within 48 hrs of commencing ECMO. Patients unable to initially receive active physical training will receive passive physical training for a minimum of 20 minutes and a maximum of one hour per day to maintain joint and muscle activity until active physical training is commenced. The intervention involves a progression of exercises with the objective of rehabilitating the patient at the highest level of exercise possible for the patient for the longest period of time that can be tolerated (up to 60 minutes) at each session, based on our published ICU mobility scale now used internationally in ICU trials. This is performed with or without IMV (including both endotracheal tubes or tracheostomies).
2888759|NCT03328767|No Intervention|Standard Care|The control group will receive standard care from physiotherapy staff not involved in delivering the intervention. We have previously established that standard care in Australia for a patient receiving prolonged IMV (control group intervention) frequently involves no active exercise out of bed.
2888760|NCT03328754|Experimental|Group 1 Powerscope|Powerscope placed bilaterally for class II correction
2888761|NCT03328754|Experimental|Group 2 Forsus|Forsus placed bilaterally for class II correction
2888762|NCT03328741|Experimental|Joint Academy|Online osteoarthritis treatment
2888763|NCT03328741|Active Comparator|The BOA program|Face-to-face osteoarthritis treatment
2888764|NCT03328728|Experimental|Cellular Matrix / A-CP HA Kit|One intra-articular injection of a combination of PRP and non-crosslinked HA
2888765|NCT03328728|Active Comparator|Synvisc-One|One intra-articular injection of a crosslinked HA
2888766|NCT03328715|Active Comparator|study group|only patients with diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
2888767|NCT03328715|Sham Comparator|controll group|only patients without diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
2888768|NCT03328702|Experimental|Continue Positive Airway Pressure|Continue Positive Airway Pressure during VFSE
2888769|NCT03328689|Experimental|Physical activity in the community|The physical activity program will include an individualized exercise program delivered in community exercise facility plus education..
2888770|NCT03328689|Active Comparator|Control group standard care|Participants from the control group will receive no additional intervention other than being encouraged to continue with their physiotherapists or chiropractor recommendation which will often include recommendation to keep activity, home exercise programs and advice to engage in physical activity.
2888771|NCT03328676|Experimental|"Avidekel  cannabis oil 20:1 CBD:THC"|The cannabis oil will be mad out of extract from the Avidekel strain and olive oil. Avidekel oil containing Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.
2888772|NCT03328676|Placebo Comparator|placebo oil|Patients in the control group will receive placebo.
2888773|NCT03328663|Experimental|CARE intervention|"Six psychological intervention sessions in-person or via video conferencing conducted by a trained psychologist~The CARE intervention contain 3 component~a psychoeducational component to address preparednessmanage expectations, and develop caregiving skills~a psychosocial component focusing on coping strategies, mindfulness, and facilitating acceptance while living with uncertainty~a self-care component to promote caregiver health and well-being"
2888774|NCT03328663|Active Comparator|Standard transplant care|"Standard Transplant Care~Social work consults to help caregivers only upon request"
2888775|NCT03328650|Experimental|Reference Point Indentation|Participants who have elected to participate in the optional, interventional arm of this study will undergo routine proximal humeral plate fixation for their proximal humerus fracture. Once the participant has been anesthetized prior to stabilizing the fracture with a ALPS proximal humerus plate, the participant's arm will be secured and the orthopaedic surgeon will indent the proximal humeral metaphysis, distal to the site of the fracture, at 10 to 15 locations ((~2 mm apart) using the OsteoProbe-RPI. The indent size is approximately ~300 μm in diameter and ~300 μm in depth.
2888776|NCT03328637|Experimental|Intervention|Patients in the intervention group will be provided Cognitive Behavioral Therapy (CBT). CBT is a common psychological intervention based on the notion that thoughts trigger the emotions. In CBT patients are trained to monitor their thoughts and identify those that trigger addictive feelings and actions while they learn new coping skills and ways to prevent a relapse (Beck, Wright, Newman & Liese, 2001). The treatment period of CBT is three months consisting of a weekly session and total 12 sessions. Initial stage of therapy is behavioral, centering on specific behaviors and situations. Latter on there is more of a focus on the cognitive assumptions and distortions that have developed and the effects of these on behavior.
2888777|NCT03328637|No Intervention|Control|Control group will not receive CBT however, primary care service providers and mental health professionals will provide any required routine care according to their clinical judgment and available resources.
2888778|NCT03328624|Other|Recovery Force's DVT II cuff|
2888779|NCT03328598|Experimental|Positive psychology therapy group|This arm will be given a positive psychological group intervention developed from an foreign psychotherapy.
2888780|NCT03328598|Experimental|Resilience promotion therapy group|This arm will be given a resilience group intervention developed from our pervious research results.
2888781|NCT03328598|Active Comparator|Controlled routine activity group|This arm will continue to participate in conventional community activities.
2888782|NCT03328585|Active Comparator|CBT-I in person|
2888783|NCT03328585|Experimental|CBT-I via telemedicine|
2888784|NCT03328585|Other|Waitlist Control|Patients in this arm will receive in person CBT-I treatment after conclusion of the study.
2888785|NCT03328572|Active Comparator|E-max Endocrowns|all patients in this arm will receive e-max endocrowns
2888786|NCT03328572|Experimental|Cerasmart Endocrowns|all patients in this arm will receive Cerasmart endocrowns
2888787|NCT03328559|Other|early stage bronchial cancer|Early stage which can benefit from a surgical resection. A taking will be made in preoperative then in every consultation of follow-up after the intervention
2888788|NCT03328559|Other|advanced stage bronchial cancer|Patients locally moved forward or at a metastatic stage handled by chemotherapy
2888789|NCT03328533|Active Comparator|Phenylephrine|Will receive spinal anesthesia using Bupivacaine. Then, phenylephrine infusion by a starting rate of 0.75 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure. The infusion will stop in case of reactive hypertension. The infusion will start again when blood pressure returns to normal reading. Infusion will be increased by 20% if hypotension occurred.
2888790|NCT03328533|Experimental|Norepinephrine|Will receive spinal anesthesia using Bupivacaine. Then, norepinephrine bitartrate infusion by a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min). The rate will be then adjusted according to the patient blood pressure. The infusion will stop in case of reactive hypertension. The infusion will start again when blood pressure returns to normal reading. Infusion will be increased by 20% if hypotension occurred.
2888791|NCT03328520|Experimental|First Year Students in Wellness FYIs|
2888792|NCT03328507|Experimental|BLI4900|BLI4900 Bowel Preparation
2888793|NCT03328507|Active Comparator|PEG Control|Polyethylene glycol-based bowel preparation
2888794|NCT03328494|Experimental|Part A: Monotherapy (BOS172722)|BOS172722 will be administered on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycles in participants with histopathologically confirmed advanced nonhaematologic malignancies.
2888795|NCT03328494|Experimental|Part A: Combination therapy (BOS172722 + Paclitaxel)|BOS172722 will be administered on Cycle 0 Day 1 and on Days 1, 2, 8, 9, 15, and 16 in Cycle 1 and subsequent 28-day cycles in participants with histopathologically confirmed advanced nonhaematologic malignancies. The participants will also receive 80 milligrams per meters squared (mg/m^2) paclitaxel as an intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle.
2888796|NCT03328494|Experimental|Part B: Combination therapy (BOS172722 + Paclitaxel)|Participants with triple-negative breast cancer will be treated with oral BOS172722 at the recommended Phase 2 dose (RP2D) established in Part A on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle and IV paclitaxel at 80 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.
2888797|NCT03328481|Experimental|Loss-of-resistance|Patients in this group will receive Loss-of-resistance Quadratus lumborum block with 30 ml bupivacaine 0.25% in addition to general anesthesia.
2888798|NCT03328481|Active Comparator|Ultrasound-guided|Patients in this group will receive Ultrasound-guided Quadratus lumborum block type-II with 30 ml bupivacaine 0.25% in addition to general anesthesia.
2888799|NCT03328468|Experimental|Breathing Exercise|
2888800|NCT03328455|Experimental|Active training|Adaptive training tailored to each individual's thresholds will be used. Specifically, a two-alternative forced-choice TOJ task will be used, where participants will be asked to judge the temporal order of the stimulus pair (an auditory beep and a visual flash) with varying SOAs. On each training day, the range of SOAs will be established for individuals based on their thresholds determined from the pre-training TOJ assessment given on the same day. The maximum SOA will be 0.2 log units greater than their estimated threshold and will be used for both visual leading (positive SOA) and auditory leading (negative SOA) stimuli. Feedback will be provided after each response.
2888956|NCT03327402|Experimental|SHP465|Participants will receive SHP465 capsule at a dose of 6.25 mg, orally once daily for 4 weeks.
2888801|NCT03328455|Sham Comparator|Passive training|To control for pure practice or exposure effects, a second group of elderly participants will undergo passive training. Participants will be exposed to the stimulus pair with varying SOAs, similarly as in the active training group. The maximum SOA for each individual will be likewise determined by his or her threshold from the TOJ assessment. However participants will not be asked to perform the TOJ task and no feedback will be provided. Instead, participants will perform an oddball task in which they are asked to detect a stimulus that occurs less frequently than the standard one. Having an oddball task in both auditory and visual modalities will ensure that participant's attention is divided between the two modalities as required in the active training task.
2888802|NCT03328442|Experimental|Vista technique|The vista technique with PRF membrane uses a Vestibular incision subperiosteal tunnel access in combination with Platelet rich fibrin membrane to treat gingival recession defects.
2888803|NCT03328442|Active Comparator|modified coronally advanced flap|A modified coronally advanced flap utilising Platelet rich fibrin membrane to treat gingival recession defects.
2888804|NCT03328429|Other|Marsupialization|Bartholin gland marsupialization will be done to all patients with Bartholin abscess.
2888805|NCT03328429|Other|Excision|Bartholin gland excision will be done to all patients with Bartholin abscess.
2888806|NCT03328416|Experimental|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
2888807|NCT03328403|Experimental|Aspiration First|Aspiration thrombectomy with large bore catheters
2888808|NCT03328403|Experimental|Stent retriever first|Thrombectomy with a licensed stent retriever device
2888809|NCT03328390|Experimental|Quadratus lumborum block Group|ultrasound guided
2888810|NCT03328390|Active Comparator|Transversus abdominis plane block Group|ultrasound guided
2888811|NCT03328364||enzalutamide (mCRPC pre-chemo)|Patients treated with enzalutamide prior to chemotherapy
2888812|NCT03328364||enzalutamide and chemotherapy (mCRPC post chemo)|Patients treated with enzalutamide who have previously undergone treatment with chemotherapy (docetaxel)
2888813|NCT03328351|Experimental|manual group|"The Manual therapy (Mobilization):~Cervical postero-anterior vertebral mobilization glides: the mobilization was grade 3 for 2 min 3 set~Cervical lateral vertebral glides: the mobilization was grade 3 for 1 min 3 set.~Strengthening Exercises for deep neck flexor muscle"
2888814|NCT03328351|Sham Comparator|sham group|"Superficial soft tissue massage~Strengthening Exercises: for deep neck flexor muscles for 10 seconds and repeating it for 10 times ."
2888815|NCT03328325|Experimental|Fluarix|0.5 mL dose of IIV-4 vaccine administered intramuscularly, n=240
2888816|NCT03328312|Active Comparator|Sugammadex|For reversal of rocuronium neuromuscular- block we will use Sugammadex
2888817|NCT03328312|Placebo Comparator|neostigmine+atropine|For reversal of rocuronium neuromuscular- block we will use Neostigmine (Miostin®; Stigmosan®) 0.05 mg/kg and atropine 1 mg/ dose.
2888818|NCT03328312|Experimental|neostigmine+atropine+sugammadex|For reversal of rocuronium neuromuscular- block we will use Neostigmine (Miostin®; Stigmosan®) 0.025 mg/kg and atropine 0.5 mg/dose followed within 3 min by Sugammadex 1 mg/kg.
2888819|NCT03328299|Active Comparator|Dexmedetomidine group|patients were given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine + dexmedetomidine 1 μg•kg-1 diluted in 20 ml saline
2888820|NCT03328299|Placebo Comparator|bupivacaine group|patients will given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine
2888821|NCT03328286|Experimental|Weekly group meeting w/psychotherapist|All the participants fulfilling the eligibility criteria are asked to take part in an additional Intervention. The Intervention is a weekly group Meeting with a psychotherapist to discuss issues or Problems the Group members have
2888822|NCT03328273|Experimental|Arm A Part 1|AZD6738 monotherapy
2888823|NCT03328273|Experimental|Arm B Part 1|AZD6738 + acalabrutinib in combination
2888824|NCT03328260|Experimental|Treatment|
2888825|NCT03328247|No Intervention|Control|Control group will attend their routine melanoma follow-ups
2888826|NCT03328247|Experimental|Intervention|The intervention group will use the ASICA app in addition to their routine follow-ups
2888827|NCT03328234|Active Comparator|SIB-IMRT with combined chemotherapy ENI|
2888828|NCT03328234|Active Comparator|SIB-IMRT with ENI|
2888829|NCT03328234|Experimental|SIB-IMRT combined chemotherapy with IFI|
2888830|NCT03328234|Experimental|SIB-IMRT with IFI|
2888831|NCT03328208|Experimental|Comfort Talk® App Group|Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.
2888832|NCT03328208|Active Comparator|White Noise Group|Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
2888833|NCT03328195|Active Comparator|Neuro RX Gamma|Neuro RX Gamma device delivering near infra-red light through four diodes positioned over the scalp and one positioned inside the nostril.
2888834|NCT03328195|Sham Comparator|Sham light therapy|Sham Neuro RX Gamma device having the same appearance and sound as the Neuro RX Gamma device but does not emit the near-infrared light.
2888835|NCT03328182|Experimental|New oral endotracheal tube holder|Single Study Product Arm
2888836|NCT03328169|Active Comparator|CBT-I|Cognitive Behavioral Therapy for Insomnia
2888837|NCT03328169|Experimental|Mindfulness|Mindfulness-Based Therapy
2888838|NCT03328156||patient with STEMI will treated by PPCI|Primary angioplasty procedure The procedure will be performed using a standard angioplasty technique. A bolus of100 IU kg of heparin will be administered intra-arterially after insertion of the vascular catheter. The target lesions will initially treated with appropriate balloon predilatation as necessary, followed by intracoronary stenting. After stent implantation, heparin will be routinely administered. The sheaths will be removed the same day.
2888839|NCT03328156||patient with STEMI will treated by Thrombolytic therapy|oral clopidogrel (300 mg), Low-flow nasal oxygen, oral acetylsalicylic acid (325 mg), Will be given to each patient. Streptokinase will be given intravenously at 1.5 million units over approximately 60 min. Reperfusion afterTT will be assessed according to clinical criteria .
2888841|NCT03328130|Experimental|Cohort 1 - Low Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the lowest dose. Dose-escalation will be performed after DSMC assessment.
2888842|NCT03328130|Experimental|Cohort 2 - High Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the highest dose. Confirmatory dose will be determined after DSMC assessment.
2888843|NCT03328130|Experimental|Cohort 3 - Confirmatory Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the confirmatory dose.
2888844|NCT03328117|Active Comparator|Intervention|
2888845|NCT03328117|Placebo Comparator|Placebo|
2888846|NCT03328104|Experimental|Everolimus in combination with standard chemotherapy|A treatment course lasts 28 days, during which participants take everolimus by mouth every day and also get standard chemotherapy via IV on certain days.
2888847|NCT03328091|Active Comparator|Traditional pre-test genetic counseling|"In-person consultation with licensed genetic counselor at the Center for Cancer Genetics and Prevention before genetic testing~Participant is given a pamphlet introducing prostate cancer genes, genetic testing~Participant is sent electronic family history tool~Participant is given the Genetic Testing Information for Decision Making packet. After the genetic counseling session, patient is asked if they would like to proceed with genetic testing."
2888848|NCT03328091|Experimental|Pre-test video education|"Participant is given a pamphlet that describes the basics of prostate cancer genes, genetic testing~Participant is sent electronic family history tool~Participant is approached in clinic by research staff at a pre-planned time~The patient is given the Genetic Testing Information for Decision Making packet~The pre-test video education is a short video. Information will be provided about the basics of genetics and mutations, the potential benefits, risks, and limitations of genetic testing, and the possible results the participant may receive"
2888849|NCT03328078|Experimental|CA-4948|"Part A: Dose-level cohorts with up to 6 patients each will be used to define the Maximum Tolerated Dose (MTD) for CA-4948.~Part B: The expansion phase of the study will be conducted in patients with Relapsed or Refractory Non-Hodgkin Lymphoma with and without MYD88 mutations. Patients will be treated with CA-4948 at the Recommended Phase 2 Dose (RP2D) or the MTD (or highest dose tested if MTD is not reached)."
2888850|NCT03328065||Patients|
2888851|NCT03328065||Caregivers|
2888852|NCT03328065||Doctors|
2888853|NCT03328052|Experimental|MYnd Analytics PEER Online directed therapy|Patients in this arm will receive anti-depressants as recommended by the PEER Online algorithm as described below.
2888854|NCT03328052|Sham Comparator|Conventional therapy|Patients in this arm will receive anti-depressants as chosen by the physician without guidance by the PEER Online algorithm.
2888855|NCT03328026|Experimental|Pembrolizumab SV-BR-1-GM combination|Patients with tumors that express PD-L1 or PD-L2 will be treated with the SV-BR-1-GM regimen (including pre-treatment with low dose cyclophosphamide and post-treatment Interferon inoculation) in combination with pembrolizumab with cycles every 3 weeks
2888856|NCT03328026|Experimental|Ipilimumab SV-BR-1-GM combination|Patients with tumors that do not express PD-L1 or PD-L2 will be treated with the SV-BR-1-GM regimen (including pre-treatment with low dose cyclophosphamide and post-treatment Interferon inoculation) in combination with ipilimumab with cycles every 3 weeks
2888857|NCT03328013||Women aged 25 to 33 years in 2017|"Women aged 25 to 33 years in 2017 and having performed an analyzed smear at the Brest University Hospital.~They are invited to fill out an online questionnaire asking them about :~vaccine status against HPV~if vaccinated, the name of the vaccine and the number of injection~age of first sexual intercourse~do they have a gynecological pathology"
2888858|NCT03327987||31-90 days|Patient 31-90 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
2888859|NCT03327987||91-180 days|91-180 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
2888860|NCT03327987||181-365 days|181-365 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
2888861|NCT03327974|Other|depressed patients|"All patients performed the same evaluation : ecological momentary assesement throught smartphone and 3 sheduled visits.~All patients are depressed patients."
2888862|NCT03327961||scaffold|Patients receiving during PCI the implantation of at least one scaffold
2888863|NCT03327948|Experimental|Treatment group|Urinary Urgency Incontinence
2888864|NCT03327935|Experimental|Nutrition|Oral nutritional supplements and dietetic advice
2888865|NCT03327935|Experimental|Nutrition and exercise|Oral nutritional supplements, dietetic advice and exercise training
2888866|NCT03327935|No Intervention|Control|Standard Hospital Procedure
2888867|NCT03327922|Experimental|Vicryl absorbable suture placed 2 cm apart|Wound closed with sutures spaced 2 centimeters apart will be treated in a simple, interrupted subdermal suture pattern
2888868|NCT03327922|Experimental|Vicryl absorbable suture placed 1 cm apart|Wound closed with sutures spaced 1 centimeter apart will be treated in a simple, interrupted subdermal suture pattern
2888869|NCT03327909|Experimental|TAKE|Participants in TAKE units will be advised to take all antihypertensive medications as prescribed, including on the morning of dialysis.
2888870|NCT03327909|Experimental|HOLD|Participants in the HOLD units will advised to hold the dose of the antihypertensive medications prior to the dialysis session on the morning of the dialysis days. Participants can choose whether they wish to take the antihypertensive medication that was held at any time after the dialysis session has ended.
2888871|NCT03327896||OCHIN EHR|"Patients who were established patients at OCHIN Primary Care Clinics in 2015 and had a face to face visit at the clinic in 2015.~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
2888872|NCT03327896||OneFlorida EHR|"Patients who were established patients at OneFlorida Primary Care clinics in 2015 and had a face to fact visit at the clinic in 2015.~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
2888873|NCT03327896||Oregon Medicaid|"Clients who were continuously insured through Oregon Medicaid in 2015 and had a claim with an Evaluation and Management Current Procedure Terminology (CPT) code indicating an office visit listing a Primary Care provider as the performing provider.~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
2889051|NCT03326817|Experimental|Soft Robotic Glove Group|This group will receive standard care and soft robotic therapy (continuous passive motion device developed by National University of Singapore).
2888874|NCT03327896||Florida Medicaid|"Clients who were continuously insured through Florida Medicaid in 2015 and had a claim with an Evaluation and Management Current Procedure Terminology (CPT) code indicating an office visit listing a Primary Care provider as the performing provider. Florida Medicaid data is limited to clients who were 22 years or younger.~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
2888875|NCT03327883||Patients with metastatic bladder cancer|a chart review of the diagnostic imaging and management of patients with metastatic bladder cancer who have undergone PET MRI.
2888876|NCT03327870||1|Sjogren's Syndrome
2888877|NCT03327870||2|Sicca
2888878|NCT03327870||3|Incomplete Sjogren's Syndrome
2888879|NCT03327870||4|Healthy Volunteers
2888880|NCT03327870||5|Excluded by 2016 ACR/EULAR Classificastion Criteria
2888881|NCT03327857|Experimental|AbGn-168H (Neihulizumab)|intravenous doses of AbGn-168H (Neihulizumab)
2888882|NCT03327844|Active Comparator|RET using bi-Antibiotics|Interventions: Bi-antibiotics (Ciprofloxacin and Metronidazole) placed into the root canal during first treatment stage (disinfection stage)
2888883|NCT03327844|Active Comparator|RET using non-setting Calcium Hydroxide|Interventions: non-setting calcium hydroxide placed into the root canal during first treatment stage (disinfection stage)
2888884|NCT03327831|Experimental|Open Label Treatment Arm|This study has a single, open label treatment arm. Patients will have topical aminolevulinic acid applied to the actinic keratoses in the treatment area (face/scalp) and will spend 2 hours outdoors in the shade to activate the medication. The patient then follow up in clinic 3 months and 6 months after their treatment to have the number of actinic keratoses counted.
2888885|NCT03327818||conservative surgery group|
2888886|NCT03327818||hysterectomy group|
2888887|NCT03327805|Experimental|Short Term Choline Supplementation|Participants will be asked to consume 1000 mg of choline bitartrate for 2 weeks prior to and during the testing period.
2888888|NCT03327805|Placebo Comparator|Short Term Placebo Supplementation|Participants will be asked to consume 1000 mg of placebo (maltodextrin) for 2 weeks prior to and during the testing period.
2888889|NCT03327805|Experimental|Acute Choline Supplementation|Participants will be asked to consume 1000 mg of choline bitartrate 8 hours prior to the third testing session at baseline testing.
2888890|NCT03327805|Placebo Comparator|Acute Placebo Supplementation|Participants will be asked to consume 1000 mg of placebo 8 hours prior to the third testing session at baseline testing.
2888891|NCT03327792|Experimental|200 mg Mavoglurant|200 mg mavoglurant once daily for 8-11 days
2888892|NCT03327792|Placebo Comparator|Placebo|Placebo once daily for 8-11 days
2888893|NCT03327766||RPL group|history of unexplained recurrent pregnancy loss (defined as two or more consecutive missed miscarriage before 14 weeks of gestation).
2888894|NCT03327766||Control group|womens coming for contraception after normal pregnancy outcome.
2888895|NCT03327753|Experimental|Motor control exercises|A primary goal of the motor control exercise program is to regain control and coordination of the spine and pelvis using principles of motor learning such as segmentation and simplification. The whole intervention is based on assessment of the individual patient's motor control impairments and the patient's individual treatment goals (set collaboratively with the therapist).
2888896|NCT03327753|Experimental|Graded activity|A primary goal of the graded activity program is to increase activity tolerance by performing individualized and submaximal exercises in addition to ignoring illness behaviors and reinforcing well behaviors. The intervention uses cognitive behavioral approaches to deal with fear of movement and self efficacy.
2888897|NCT03327740||Subjects on DTG based ARV with ABC|These are subjects who begin a DTG based ARV regimen that includes ABC
2888898|NCT03327740||Subjects that start DTG based ARV regimen but without ABC|These are subjects who begin a DTG-based ARV regimen that does not contain ABC
2888899|NCT03327740||Subjects on other integrase inhibitor based regimen with ABC|These are subjects who begin other integrase inhibitor based regimens (RAL and EGV) that contains ABC
2888900|NCT03327740||Subjects on other integrase inhibitor based regimen but no ABC|These are subjects that start non-ABC containing RAL or EGV based regimens
2888901|NCT03327740||Subjects that start any other DTG based ARV regimen|These are subjects who begin any other DTG based ARV regimen that will include DTG as monotherapy or two-drug regimens
2888902|NCT03327727|Experimental|VL-2397|Investigational agent VL-2397 600 mg IV infusion administered every day for 28 days (4 weeks) followed by 2 weeks of standard treatment
2888903|NCT03327727|Active Comparator|Standard (First-Line) Treatment|Investigator selected standard treatments of voriconazole, isavuconazole, or liposomal amphotericin B administered every day for 42 days (6 weeks) per product package insert
2888904|NCT03327714|Experimental|Mindfulness and compassion|Children aged between 6-16 years old will perform 5-10 minutes daily mindfulness and compassion training in school. The intervention will last for 10 weeks.
2888905|NCT03327714|No Intervention|Control group|The control group consists of children who do not perform mindfulness in school.
2888906|NCT03327701|Active Comparator|Experimental|Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
2888907|NCT03327701|Placebo Comparator|Placebo|Subjects will receive placebo 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
2888908|NCT03327688|Active Comparator|POCUS group|Point-of-care ultrasound
2888909|NCT03327688|No Intervention|Radiologist group|Traditional diagnostic way
2888910|NCT03327688|Active Comparator|DVT POCUS group|DVT group after POCUS education
2888911|NCT03327688|No Intervention|DVT traditional group|DVT group traditional diagnostic way before educational intervention
2888912|NCT03327675|Experimental|68Ga-PSMA PET/MR|Hybrid 68Ga-PSMA PET/MR scan
2888913|NCT03327662|Experimental|Interventional|Active CTC assessment: Patients will receive first line docetaxel until progression by CTC, and/or disease progression according to treating clinician or completion of 10 cycles. CTC results will be available to the treating clinician to guide decision-making. A progressing CTC count on Day 1 will require confirmation with a second CTC count performed on Day 15 (-/+ 5 days) of that cycle. If a patient is found to have two successive CTC determinations showing progression by CTCs, the clinician will receive a recommendation to discontinue docetaxel on the following cycle.
2888914|NCT03327662|No Intervention|Control|Patients will receive first line docetaxel until disease progression according to treating clinician or completion of 10 cycles. Patients and treating clinicians will not be disclosed to the results of CTC determinations.
2888915|NCT03327649|Sham Comparator|Sham control|Patients will receive 1 hour of sham transcutaneous low level vagal stimulation daily for 3 months
2888916|NCT03327649|Experimental|Active treatment|Patients will receive 1 hour of active transcutaneous low level vagal stimulation daily for 3 months
2888917|NCT03327636|Experimental|High Intensity Focused Ultrasound|Apply the machine 'Echopulse' with High Intensity Focused Ultrasound to treat the papillary thyroid microcarcinoma.
2888918|NCT03327636|No Intervention|Active surveillance|The participants will be monitored by the doctors actively, like more frequent in follow-up to observe their current situation.
2888919|NCT03327623||Hypertrophic Cardiomyopathy (HCM)|Subjects with a diagnosis of Hypertrophic Cardiomyopathy
2888920|NCT03327623||Control|Subjects who are healthy volunteers
2888921|NCT03327610|No Intervention|BASELINE|The subjects were kept in their current ventilatory mode.
2888922|NCT03327610|Experimental|VC-CMV20|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow of 20Lpm.
2888923|NCT03327610|Experimental|VC-CMV50|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow of 50Lpm.
2888924|NCT03327610|Experimental|PC-CMV1|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1) with an inspiratory time of 1 second.
2888925|NCT03327610|Experimental|PC-CMV3|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1) with an inspiratory time of 3 seconds.
2888926|NCT03327610|Experimental|PSV10|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV) with a cycling off of 10% of peak inspiratory flow.
2888927|NCT03327610|Experimental|PSV25|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV) with a cycling off of 25% of peak inspiratory flow.
2888928|NCT03327597|Active Comparator|Abnormal Non-MGUS|Participants previously diagnosed with MGUS, multiple myeloma or other lymphoproliferative disease.
2888929|NCT03327597|Experimental|MGUS group arm 1|Participants diagnosed with MGUS, randomized to group 1.
2888930|NCT03327597|Experimental|MGUS group arm 2|Participants diagnosed with MGUS, randomized to group 2.
2888931|NCT03327597|Experimental|MGUS group arm 3|Participants diagnosed with MGUS, randomized to group 3.
2888932|NCT03327597|Active Comparator|Normal group|Participants without MGUS.
2888933|NCT03327597|Active Comparator|Controls|Participants without MGUS, matched to MGUS participants by age and gender.
2888934|NCT03327584|Active Comparator|Ultrasound Guided Arthrocentesis|The patients in this group will have ultrasound guided arthrocentesis.
2888935|NCT03327584|Active Comparator|Landmark Guided Arthrocentesis|The patients in this group will have landmark guided arthrocentesis.
2888936|NCT03327571||Group 1: cHL|Participants diagnosed with high-risk stage IIb-IV cHL, received frontline treatment with chemotherapy with or without radiotherapy between 01 January 2010 and 31 December 2013 from the 13 participating countries will be observed for various treatments received for cHL, associated adverse events and resources used from the date of cHL diagnosis until the date of first documented relapse or disease progression after frontline therapy. Participants will be continue to be observed for overall survival until the date of death or data collection, whichever occurs first.
2888937|NCT03327571||Group 2: RRHL|Participants diagnosed with RRHL, between 01 January 2010 and 31 December 2013 from the 13 participating countries will be observed for various treatments received for RRHL, detailed data on treatment pathways, clinical outcomes, associated adverse events and resources used from the date of RRHL diagnosis until the date death or data collection, whichever occurs first. Participants will be continue to be observed for overall survival until the date of death or data collection, whichever occurs first.
2888938|NCT03327558|Experimental|Apriso 0.375G ER CAP|Apriso 0.375G ER Cap
2888939|NCT03327558|Active Comparator|APRISO 375 mg extended-release capsules|APRISO 375 mg ER cap
2888940|NCT03327545|Experimental|Experimental Group 1|Neural mobilization for a total of 12 minutes
2888941|NCT03327545|Experimental|Experimental Group 2|Soft tissue techniques and Stretching right side of the craniocervical for a total of 12 minutes
2888942|NCT03327545|Placebo Comparator|Control group|Control group
2888943|NCT03327532|Experimental|Patients hospitalized for acute heart failure|"One arm study.~Patients hospitalized for acute heart failure will undergo the following evaluations:~Clinical examination centered on congestion~Cardiopulmonary and peritoneal ultrasound~Blood sample retrieved for biological assessment and biobanking~Telephone interview"
2888944|NCT03327519|Experimental|SHUTi|Self-guided, automated, interactive, and tailored web-based program
2888945|NCT03327519|Experimental|Emmi|A program that is an animated online video that walks patients through important information about a health topic, condition or procedure.
2888946|NCT03327506|Experimental|hypnosis group|Intervention: hypnosis session the eve of the surgery
2888947|NCT03327506|Active Comparator|premedication|alprazolam 0,5 mg the eve and the morning of the surgery
2888948|NCT03327493|Other|Refractory cardiogenic shock under ECLS|
2888949|NCT03327480|Experimental|neoprene CMC orthosis|We will prescribe a neopren CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2
2888950|NCT03327480|Experimental|thermoplastic CMC orthosis|We will prescribe a neoprene CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2
2888951|NCT03327454||Benepali|Treatment of participants with the Benepali pre-filled pen takes place in accordance with the prescribing information and standard medical practice.
2888952|NCT03327441|Experimental|Almonds|
2888953|NCT03327441|Active Comparator|Omelette|
2888954|NCT03327428||Patients with Sickle Cell Disease|Patients with any sickling condition, including among others Sickle Cell Anemia, HbSC Disease, HbS-betaThal, excluding Sickle Cell Trait.
2888955|NCT03327415||Age groups|Eleven age groups that took into account the previous surveys and the key stages of child development were defined: 15 days to 3 months, 4, 5, 6, 7, 8-9, 10-11, 12- 17, 18-23, 24-29, and 30-35 months.
2888957|NCT03327389|Experimental|Dexmedetomidine (Group D)|Dexmedetomidine infusion during surgery Dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
2888958|NCT03327389|Placebo Comparator|Control (Group C)|0.9% NaCl infusion during surgery 0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
2888959|NCT03327376||Characteristic and regularity of CRT|The patients who have a central venous catheterization conduct the daily ultrasound-screening for CVC-related Thrombosis (DUCT).
2888960|NCT03327363|Experimental|ICT base monitoring group|In the ICT-based centralized monitoring group, both subjects and medical staff receive feedback regarding decreased lung function and exacerbation in asthma symptoms in the form of text messages
2888961|NCT03327363|Placebo Comparator|control group|Use standard asthma treatment
2888962|NCT03327350||WATCHMAN transplantation|This group will receive WATCHMAN device implantation.Device implantation included concomitant antithrombotic medication to facilitate device endothelialization: warfarin and aspirin for 45 days. To assess for device stability, peridevice leaks, and device-related thrombus, transesophageal echo (TEE) imaging was performed at 45 days, 6 months, and 12 months. When the 45-day TEE revealed minimal residual peridevice flow (jet width ≤5 mm) and no device-related thrombus, warfarin will be stopped and replaced by clopidogrel, 75 mg daily, until the 6-month visit, after which only aspirin was continued. If an adequate seal is not obtained or a thrombus is detected, patients continue taking warfarin until an adequate seal is attained or thrombus is resolved before transitioning to aspirin.
2888963|NCT03327350||Oral anticoagulant therapy|"This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).~For patients taking warfarin, international normalized ratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Follow-up visits occurred twice annually after the first year, with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected."
2888964|NCT03327337|Experimental|experimental group|operate with Arthroscopic Assisted Balloon Tibioplasty on this group patients
2888965|NCT03327337|Other|control group|operate with open reduction and internal fixation on this group patients
2888966|NCT03327324|Other|Resident of the Skilled Nursing Facility|
2888967|NCT03327311||Bellafill 1 week post-injection|n=2. Histopathology conducted 1 week post-injection
2888968|NCT03327311||Bellafill 1 month post-injection|n=2. Histopathology conducted 1 month post-injection
2888969|NCT03327311||Bellafill 2 months post-injection|n=2. Histopathology conducted 2 months post-injection
2888970|NCT03327311||Bellafill 3 months post-injection|n=2. Histopathology conducted 3 months post-injection
2888971|NCT03327311||Bellafill 6 months post-injection|n=2. Histopathology conducted 6 months post-injection
2888972|NCT03327298|Other|accuracy of pedicle screw insertion|postoperative CT lumbar spine axial and sagittal views.
2888973|NCT03327285|Experimental|C-CAR011|The amount of cells received：1.0-5.0×10^6 CAR+T cells/kg
2888974|NCT03327272|Active Comparator|Local injection of methylprednisolone|Drug: methylprednisolone Injection of 80mg methylprednisolone injectable suspension at surgical site prior to incision closure
2888975|NCT03327272|Placebo Comparator|Local injection of saline|Administration of saline at surgical site prior to incision closure.
2888976|NCT03327259|Active Comparator|Activity Planning Only|
2888977|NCT03327259|Experimental|Enhanced Activity Planning|Activity planning with therapist guided activity practice.
2888978|NCT03327246|Experimental|Intervention group|Implementing the Connecare system to support integrated care for complex patients who are plan to undergo a major elective surgery in Assuta Ashdod and are discharged back to the community with an emphasis on Connecare self managment system for the patient and close follow up and coordination of all of the medical, health and social care in the community for two periods of time: (1) Pre habilitation plan for a month prior to surgery (2) a period of 3 months post discharge.
2888979|NCT03327246|No Intervention|No Intervention: Matched control group|The control group will be selected from Maccabi's database and will be patients who are matched 1:1 with the intervention sample and live in another community similar to Ashdod in socioeconomic characteristics who undergo the same elective major surgery in other hospitals
2888980|NCT03327233|Experimental|Intervention group|Implementing the Connecare system to support integrated care for complex patients with an unplanned admission to Assuta Ashdod who are discharged back to the community with an emphasis on Connecare self managment system for the patient and close follow up and coordination of all of the medical, health and social care in the community by a Maccabi integrated care nurse for a period of 3 months post discharge.
2888981|NCT03327233|No Intervention|Matched control group|The control group will be selected from Maccabi's database and will be patients who are matched 1:1 with the intervention sample and live in another community similar to Ashdod in socioeconomic characteristics who undergo the same elective major surgery in other hospitals
2888982|NCT03327220|Experimental|iovera° Treatment Group|Subjects are treated with the iovera° device 3-7 days prior to Total Knee Arthroplasty
2888983|NCT03327220|No Intervention|Standard of Care Total Knee Arthroplasty|Subjects undergo the standard Total Knee Arthroplasty
2888984|NCT03327207||Study group|Children who receive Growth hormone treatment. Non Interventional
2888985|NCT03327207||Control group|Healthy children . Non Interventional
2888986|NCT03327194|Experimental|ADHEAR Audio processor|
2888987|NCT03327181|Experimental|COPD|The subject will arrive fasted. A catheter will be inserted in the arm for stable tracer SCFA infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable tracers will be administered by the research nurse. Stable tracers are given to measure SCFA metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet, and a variety of functional measurements.
2889018|NCT03326986|Experimental|Panel B: Sequence 1|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated: Placebo→MK-7252 12 mg→MK-7252 48 mg→MK-7252 72 mg→MK-7252 162 mg. There is a minimum of a 7-day washout period between each treatment period or dose administration.
2888988|NCT03327181|Active Comparator|Healthy older adults|The subject will arrive fasted. A catheter will be inserted in the arm for stable tracer SCFA infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable tracers will be administered by the research nurse. Stable tracers are given to measure SCFA metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet, and a variety of functional measurements.
2888989|NCT03327168|Active Comparator|Adenosine|Perfusion is measured using PET/CT during intravenous infusion (0.14 mg/kg/min) of adenosine.
2888990|NCT03327168|No Intervention|Room temperature|Perfusion and A2A receptor density is measured using PET/CT in resting room temperature conditions.
2888991|NCT03327168|Experimental|Cold exposure|Perfusion and A2A receptor density is measured using PET/CT during controlled cold exposure.
2888992|NCT03327155|Experimental|TDF/FTC (300mg/200mg) once daily|Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) (300mg/200mg) on tablet once daily with food.
2888993|NCT03327129||Healthy Controls|Subjects will have no personal or family psychiatric history and no suicide attempts.
2888994|NCT03327129||Patients with SI and low acquired capability|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported low acquired capability for suicide (Acquired Capability for Suicide Scale <20)
2888995|NCT03327129||Patients with SI and high acquired capability|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported high acquired capability for suicide (Acquired Capability for Suicide Scale >60)
2888996|NCT03327116|Experimental|Methotrexate|
2888997|NCT03327103|No Intervention|Enhanced Usual Care|Receive standard care
2888998|NCT03327103|Experimental|Decision Intervention|Receives decision aid intervention that encompasses balance sheets, navigation, audio files, and interaction -- Cancer Health Aid to Manage Preferences and Improve Outcomes through Navigation (CHAMPION)
2888999|NCT03327090|Experimental|Experimental Kinesio Tape|"The Kinesio Tape original brand was used in this study (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque). The application of the experimental Kinesio Tape was as Dr. Kenzo Kase demonstration for muscle facilitation (Kase. et al., 2003):~Gluteal maximus muscle.~Quadriceps muscle.~Gastrocnemius muscle and soleus muscle (triceps surae).~The tape was in tension (15%- 35%) and the muscles were stretched during the application."
2889000|NCT03327090|Sham Comparator|Sham Kinesio Tape|"Same tape brand was used, but different application techniques were utilized for the three muscles.~Gluteal maximus muscle.~Quadriceps muscle.~Gastrocnemius muscle and soleus muscle (triceps surae).~There were no tension on the tape and no muscle stretching during the application."
2889001|NCT03327077|No Intervention|Control Group|
2889002|NCT03327077|Experimental|Intervention Group|Music group
2889003|NCT03327064|Active Comparator|Renal Transplant subjects receiving UAB30|Generally healthy renal transplant subjects receive UAB30 for 28 days with increased risk of non-melanoma skin cancer as evidenced by a history of prior squamous or basal cell skin cancer, ongoing or history of actinic keratoses and presence at baseline of at least 8 actinic keratosis on the face, neck, scalp and arms.
2889004|NCT03327064|Placebo Comparator|Renal Transplant subjects receiving placebo|Generally healthy renal transplant subjects receive placebo for 28 days with increased risk of non-melanoma skin cancer as evidenced by a history of prior squamous or basal cell skin cancer, ongoing or history of actinic keratoses and presence at baseline of at least 8 actinic keratosis on the face, neck, scalp and arms.
2889005|NCT03327051|Active Comparator|Omeprazole and VSL #3|15 healthy volunteers will receive a proton pump inhibitor (Omeprazole) and VSL #3
2889006|NCT03327051|Placebo Comparator|Placebo and VSL #3|15 healthy volunteers will receive placebo and VSL #3
2889007|NCT03327038|Experimental|Psychological Intervention|Patients will be randomized to the intervention group after they have complete the study screening form. Patients randomized to the intervention group will receive a multifaceted intervention consisting of the following components (administered over an 8 week period): (1) Web-Based Cognitive Behavioral Therapy: (2) Short Questionnaires; (3) Ongoing Nurse Monitoring.
2889008|NCT03327038|Active Comparator|Control|Patients will be randomized to the control group after they have completed the study screening form. Patients randomized to the control group will receive the usual standard of care that is available to patients with moderate anxiety or depression. Additionally, control patients will completed detailed questionnaires for assessment of primary and secondary outcomes.
2889009|NCT03327025|Experimental|Intervention|
2889010|NCT03327012|Experimental|Treatment of Panlongqi Tablet|Patients were treated with Panlongqi Tablet.
2889011|NCT03327012|Placebo Comparator|Treatment of Panlongqi Placebo|Patients were treated with Panlongqi Placebo Tablet.
2889012|NCT03326999|Experimental|Investigational arm|Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine
2889013|NCT03326999|Sham Comparator|Control arm|Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with saline
2889014|NCT03326986|Experimental|Panel A: Sequence 1|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated: Placebo→MK-7252 6 mg→MK-7252 24 mg→MK-7252 72 mg→MK-7252 108 mg. There is a minimum of a 7-day washout period between each treatment period or dose administration.
2889015|NCT03326986|Experimental|Panel A: Sequence 2|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated: MK-7252 1 mg→Placebo→MK-7252 24 mg→MK-7252 72 mg→MK-7252 108 mg. There is a minimum of a 7-day washout period between each treatment period or dose administration.
2889016|NCT03326986|Experimental|Panel A: Sequence 3|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated: MK-7252 1 mg→MK-7252 6 mg→Placebo→MK-7252 72 mg→Placebo. There is a minimum of a 7-day washout period between each treatment period or dose administration.
2889017|NCT03326986|Experimental|Panel A: Sequence 4|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated: MK-7252 1 mg→MK-7252 6 mg→MK-7252 24 mg→Placebo→MK-7252 108 mg. There is a minimum of a 7-day washout period between each treatment period or dose administration.
2889019|NCT03326986|Experimental|Panel B: Sequence 2|Participants receive either a single dose of MK-7252 or Placebo in a fasted stated in each of five alternating treatment dosing periods as indicated: MK-7252 3 mg→Placebo→MK-7252 48 mg→MK-7252 72 mg→MK-7252 162 mg. There is a minimum of a 7-day washout period between each treatment period or dose administration.
2889020|NCT03326986|Experimental|Panel B: Sequence 3|Participants receive either a single dose of MK-7252 or Placebo in a fasted stated in each of five alternating treatment dosing periods as indicated: MK-7252 3 mg→MK-7252 12 mg→Placebo→MK-7252 72 mg→Placebo. There is a minimum of a 7-day washout period between each treatment period or dose administration.
2889021|NCT03326986|Experimental|Panel B: Sequence 4|Participants receive either a single dose of MK-7252 or Placebo in a fasted stated in each of five alternating treatment dosing periods as indicated: MK-7252 3 mg→MK-7252 12 mg→MK-7252 48 mg→Placebo→MK-7252 162 mg. There is a minimum of a 7-day washout period between each treatment period or dose administration.
2889022|NCT03326986|Experimental|Panel C: Sequence 1|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated: Placebo→MK-7252 240 mg→MK-7252 360 mg→MK-7252 540 mg→Placebo. There is a minimum of a 7-day washout period between each treatment period or dose administration.
2889023|NCT03326986|Experimental|Panel C: Sequence 2|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated: MK-7252 120 mg→Placebo→MK-7252 360 mg→MK-7252 540 mg→MK-7252 120 mg fed. There is a minimum of a 7-day washout period between each treatment period or dose administration.
2889024|NCT03326986|Experimental|Panel C: Sequence 3|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated: MK-7252 120 mg→MK-7252 240 mg→Placebo→MK-7252 540 mg→MK-7252 120 mg fed. There is a minimum of a 7-day washout period between each treatment period or dose administration.
2889025|NCT03326986|Experimental|Panel C: Sequence 4|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated: MK-7252 120 mg→MK-7252 240 mg→MK-7252 360 mg→Placebo→MK-7252 120 mg fed. There is a minimum of a 7-day washout period between each treatment period or dose administration.
2889026|NCT03326973||online or telephone survey|This is a cross-sectional survey. Our main method of communication with patients will be email. Participants will complete a single online or telephone survey at a minimum of 12 months post initial treatment of checkpoint inhibitors and remain on maintenance therapy.
2889027|NCT03326960||Sevoflurane|Patients in Sevoflurane group are maintained with sevoflurane (1%~4% inhalation), remifentanil (0.1~0.3μg•kg-1•min-1, intravenous administration) and cisatracurium (0.1mg•kg-1•h-1 intravenous administration).
2889028|NCT03326960||Propofol|Patients in propofol group are maintained with propofol (1-3μg/ml plasma target controlled infusion), remifentanil (0.1~0.3μg•kg-1•min-1, intravenous administration), and cisatracurium (0.1mg•kg-1•h-1 intravenous administration).
2889029|NCT03326947|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed with surgery and radiotherapy/chemoradiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
2889030|NCT03326947|No Intervention|Control group|The patients in the control group received the radical surgery and radiotherapy/chemoradiotherapy.
2889031|NCT03326934|Sham Comparator|Milk Chocolate|Each subject consumes a Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
2889032|NCT03326934|Experimental|Dark Chocolate|Each subject consumes a Trader Joe's 72% Cacao Dark Chocolate bar: 47g, 34g cacao, total flavanols: 316.3 mg.
2889033|NCT03326921|Experimental|Treatment (CD4+ and CD8+ HA-1 TCR T cells)|Patients receive fludarabine phosphate for 1-3 doses 7-14 days prior to HA-1 TCR T cell administration. Patients then receive CD4+ and CD8+ HA-1 TCR T cells IV over 1 hour.
2889034|NCT03326908|Other|Normal conditions of light exposure|"Spectral Domain Optical Coherence Tomography (SD-OCT):~Five SD-OCTs will be produced under the same lighting conditions (photopic).~At baseline~20 minutes after baseline~25 minutes after baseline~45 minutes after baseline~60 minutes after baseline"
2889035|NCT03326908|Other|Light variations|"Spectral Domain Optical Coherence Tomography (SD-OCT):~Five SD-OCT will be performed:~at baseline, in a room with photopic artificial lighting (400 lux)~after a period of adaptation to the dark (20 minutes in the dark: 0 lux)~after 5 min of retinal glare, obtained by means of a projection of light of 1000 lux on the fundus of eye~15 minutes after this period of retinal glare, in photopic artificial lighting~30 minutes after the period of retinal glare, in photopic artificial lighting"
2889036|NCT03326895||Stage 1|Manual circular stapler used to complete anastomosis of colon
2889037|NCT03326895||Stage 2|Powered circular stapler used to complete anastomosis of colon
2889038|NCT03326882|Active Comparator|Glidescope|A device for endotracheal intubation
2889039|NCT03326882|Active Comparator|Macintosh laringoscope|A device for endotracheal intubation
2889040|NCT03326869|Experimental|Delayed|"Intervention: Raindrop Near Vision Inlay~In the delayed approach, the corneal pocket is created and dissected but the corneal inlay is not implanted. After one to three months, the corneal inlay is implanted on a second surgical day."
2889041|NCT03326869|Active Comparator|Non-Delayed|"Intervention: Raindrop Near Vision Inlay~In the non-delayed approach, the corneal pocket is created and inlay implanted on the same surgical day."
2889042|NCT03326856|Placebo Comparator|Vehicle|Vehicle
2889043|NCT03326856|Experimental|Dose 1|botulinum toxin, Type A, Dose 1
2889044|NCT03326856|Experimental|Dose 2|botulinum toxin, Type A, Dose 2
2889045|NCT03326856|Experimental|Dose 3|botulinum toxin, Type A, Dose 3
2889046|NCT03326856|Experimental|Dose 4|botulinum toxin, Type A, Dose 4
2889047|NCT03326843|Experimental|Avatrombopag 60 mg|Open-label: oral avatrombopag
2889048|NCT03326830|Active Comparator|Standard oxygen therapy|Standard oxygen therapy will be delivered using any device or combination of devices that are part of usual care: nasal oxygen, and mask with or without a reservoir bag and with or without the Venturi system. The flow will be tapered to target an SpO2 ≥ 95%
2889049|NCT03326830|Experimental|High-flow nasal oxygen (HFNO)|Experimental: High-flow nasal oxygen (HFNO) group Device that delivers humidified and warmed high-flow oxygen at flows between 30-60L/min HFNO will be initiated at a flow rate between 30-60 L/min and FiO2 titrated for a target of SpO2 ≥ 95%.
2889052|NCT03326804||Cohort 1 - Safety|"Cohort 1 will consist of the first 20 participants recruited into the study for H1 Hip Resurfacing Arthroplasty. These patients will receive additional CT scans preoperatively and then post-operatively at these time points: immediately postoperatively (2days), at 6 weeks, 3 months, 6 months, 1 year and 2 years. They will have metal-ion measurements for safety analysis. Blood samples will be taken preoperatively and postoperatively at 3 months, 6 months, 1 year and 2 years.~A safety analysis of Cohort 1 will be performed at the 6 week, 3 month and 6 month post-operative stage by independent assessors. Yearly clinical evaluations will be performed until 10 years, and radiographs at 3,5,10 years. If the investigation supports the safety of the implant, the study will proceed with recruitment into Cohort 2."
2889053|NCT03326804||Cohort 2 - Efficacy|Cohort 2 will consist of the remaining target size population of 230 patients for H1 Hip Resurfacing Arthroplasty. They will undergo the same intervention as previously described for Cohort 1, but will not undergo metal-ion testing and reduced frequency CT-scans.
2889054|NCT03326791|Experimental|Intervention group|Acetylsalicylic acid 160 mg once daily until recurrent disease or a total period of 3 years.
2889055|NCT03326791|Placebo Comparator|Control group|Placebo Oral Tablet once daily until recurrent disease or a total period of 3 years.
2889056|NCT03326778||AVR + CABG|Patient receiving AVR combined with CABG
2889057|NCT03326765|Other|Children|Questionnaires electroencephalogram (EEG) Actigraphy polysomnography
2889058|NCT03326765|Other|Adults|Questionnaires electroencephalogram (EEG) Actigraphy polysomnography
2889059|NCT03326752|Experimental|Dose Escalation Cohort 1-5|"Cohort 1-5~DV281 - Dose level 1-5~DV281 in combination with approved anti-PD-1 Inhibitor.~DV281 is administered via a breath actuated nebulizer"
2889060|NCT03326752|Experimental|Dose Expansion (RP2D)|"Preliminary Recommended Phase 2 dosing of DV281 in combination with an approved anti-PD-1 Inhibitor~- DV281 is administered via a breath actuated nebulizer."
2889061|NCT03326739|Active Comparator|Ultrasound Guided A-Line Placement|Patients in this group will have ultrasound guided arterial line placement.
2889062|NCT03326739|Active Comparator|Landmark Guided A-line Placement|Patients in this group will have landmark guided arterial line placement.
2889063|NCT03326726|Experimental|Chlorhexidine Gluconate|2% CHG
2889064|NCT03326713|Experimental|Telephone Counseling & Navigation (TCN)|Telephone Counseling
2889065|NCT03326713|Active Comparator|Mailed Targeted Print (TP)|Mailed Targeted Print
2889066|NCT03326713|Other|Usual Care (UC)|Control
2889067|NCT03326700|Active Comparator|Laparoscopic hernia repair.|Intervention: inguinal hernia repair.
2889068|NCT03326700|Active Comparator|Open hernia repair.|Intervention: inguinal hernia repair.
2889069|NCT03326687|Experimental|Treatment ABAB|Participants will receive anomia treatment in isolation and will perform a physical endurance task in isolation during A phases. They will receive anomia treatment in combination with performing a physical endurance task during B phases.
2889070|NCT03326687|Experimental|Treatment BABA|Participants will receive anomia treatment in isolation and will perform a physical endurance task in isolation during A phases. They will receive anomia treatment in combination with performing a physical endurance task during B phases.
2889071|NCT03326674|Experimental|Arm A: Tesetaxel and Capecitabine|Tesetaxel (27 mg/m2) orally once every 21 days on Day 1 of each 21-day cycle; and Capecitabine (825 mg/m2) orally twice daily (in the morning and evening after a meal, for a total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle
2889072|NCT03326674|Active Comparator|Arm B: Capecitabine|Capecitabine (1,250 mg/m2) orally twice daily (in the morning and evening after a meal, for a total daily dose of 2,500 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle
2889073|NCT03326661|Active Comparator|Needle aspiration|Patients treated with aspiration will receive standard antibiotic treatment according to clinical guidelines: Penicillin and metronidazole or Clindamycin alone in case of penicillin allergy. These patients will be treated in the outpatient clinic and will be examined again the day after inclusion. Aspiration will be done if necessary. At this first control visit the clinician will schedule the next visit based on findings.
2889074|NCT03326661|Active Comparator|Tonsillectomy a chaud|Patients treated with tonsillectomy a chaud are admitted for intra-venous treatment with penicillin and metronidazole until surgery. Antibiotic treatment is discontinued after surgery and the patient may be discharged from the hospital the day after surgery.
2889075|NCT03326648|Experimental|Strength training + protein supplement|Two sessions of strength training each week in addition to daily protein supplementation for 10 weeks.
2889076|NCT03326648|Experimental|Protein supplement|Daily protein supplementation for 10 weeks.
2889077|NCT03326635||frailty group|frailty score ≤ 3
2889078|NCT03326635||non-frailty group|frailty score >3
2889079|NCT03326622|Experimental|moderate exercise + standard care|This group performed a moderate exercise protocol with training zone determined by Cardiopulmonary Exercise testing added to standard care program based on American Academy of Neurology guidelines.
2889080|NCT03326622|Active Comparator|Standard care|This group performed a standard care program based on American Academy of Neurology guidelines, without exercise intensity control.
2889081|NCT03326609|Experimental|Volume: 2.5 mL|Perineural injection of ropivacaine 10 mg, 2.5 mL. Concentration: Ropivacaine 4 mg/mL.
2889082|NCT03326609|Experimental|Volume: 5 mL|Perineural injection of ropivacaine 10 mg, 5 mL. Concentration: Ropivacaine 2 mg/mL
2889083|NCT03326609|Experimental|Volume: 10 mL|Perineural injection of ropivacaine 10 mg, 10 mL Concentration: Ropivacaine 1 mg/mL
2889084|NCT03326609|Experimental|Volume: 15 mL|Perineural injection of ropivacaine 10 mg, 15mL Concentration: Ropivacaine 0.67 mg/mL
2889085|NCT03326609|Experimental|Volume: 20 mL|Perineural injection of ropivacaine 10 mg, 20mL Concentration: Ropivacaine 0.5 mg/mL
2889086|NCT03326596|Experimental|ProphylacticTranexamic Acid|Once consented, patients to receive 1000mg/10ml normal saline infusion of TXA with the delivery of the infant's anterior shoulder.
2889087|NCT03326583|No Intervention|No Intervention: Pre-Treatment|This arm is the 2 week observation period before the start of the Patiromer treatment phase.
2889118|NCT03326375|Experimental|SBRT (Stereotatic body radiotherapy)|Treatment of SBRT in HCC patients who have incomplete response after first TACE
2890001|NCT03319732|Experimental|AERT 80 mg|Arbaclofen extended release tablet, 20 mg
2889088|NCT03326583|Experimental|Intervention: Treatment|This arm is the 12 week treatment phase. Participants will take 8.4 grams of Patiromer once daily for one week, during which serum potassium and gastrointestinal symptoms will be evaluated. If tolerated and in the absence of hypokalemia, the dose will be up-titrated to 16.8 grams once daily for the remaining 11 weeks.
2889089|NCT03326583|No Intervention|No Intervention: Post-Treatment|This arm is the 2 week observation period after the Patiromer treatment phase.
2889090|NCT03326570||Bronchoscopy Data Collection|Medical information collected after bronchoscopy for up to 2 years.
2889091|NCT03326557|Active Comparator|Membrane sweeping|Membrane sweeping involves the insertion of a digit past the internal cervical os followed by three circumferential passes of the digit causing separation of the membranes from the lower uterine segment. When the cervix is closed, a massage of the cervical surface for 15 to 30 seconds will be performed instead. Membrane sweeping will be undertaken twice a day at 8 to 10 hours apart.
2889092|NCT03326557|Active Comparator|Transcervical Foley catheter insertion|Transcervical Foley catheter No. 18 F will be inserted under aseptic technique into the endocervical canal surpassed beyond the internal os. The balloon will be inflated with 60 ml of sterile water and the catheter is plastered to patient's thigh with gentle traction. The catheter will be checked for its position and the traction at 6 hours interval. If it were expelled spontaneously, it would not be re-inserted. Otherwise, the catheter will be removed after 24 hours.
2889093|NCT03326544|Experimental|Saphenous nerve block group|Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
2889094|NCT03326544|Experimental|Platelet rich plasma group|Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
2889095|NCT03326518|Experimental|Lumentin® 44|Contrast agent
2889096|NCT03326518|Active Comparator|Diluted Omnipaque®|Contrast agent
2889097|NCT03326518|Active Comparator|Movprep®|Contrast agent
2889098|NCT03326505|Active Comparator|Injection of Umbilical cord derived UC- MSCs|Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients
2889099|NCT03326505|Active Comparator|injection of UC- MSCs and SPT|Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients along with a supervised physical therapy program
2889100|NCT03326505|Active Comparator|Supervised Physical Therapy (SPT)|Supervised physical therapy program without stem cells
2889101|NCT03326492||Patients bitten by a snake|"Any patient over 5 years old going to a participating center for curative care following a snake bite.~Participation to the study does not change usual follow-up of patients. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient."
2889102|NCT03326479||Retrospective|Subject who have previously had MI Profiling performed prior to 11/11/2016 are eligible for this study. No drug intervention is required for this study.
2889103|NCT03326466||Patients with SAP|
2889104|NCT03326466||Healthy Controls|
2889105|NCT03326453|Experimental|Mini Dental implant|2 mini dental implant of diameter 2.8 mm with length 10 mm will be inserted mandiblular ridge ≥5 mm mesial to the mental foraminato support overdentures for the intervention group.
2889106|NCT03326453|No Intervention|conventional implant|two slandered implant diameter 3.7 mm and length 10 mm will be placed in interforaminal region of mandiblular ridge support overdenture for the compartor group.
2889107|NCT03326440|Other|Study Arm|Patients with a histological diagnosis of prostate cancer are shown how Radiotherapy is planned and given using 3D images on the VERT (Virtual Environment Radiotherapy) system prior to the start of Radiotherapy.
2889108|NCT03326440|Other|Control Arm|Patients with a histological diagnosis of prostate cancer who are shown how Radiotherapy is planned and given using 3D images on the VERT (Virtual Environment Radiotherapy) system following completion of Radiotherapy.
2889109|NCT03326427|Experimental|Skill Training Group|A twelve sessions protocol of the Skill Training Group of the Dialectical Behavior Therapy.
2889110|NCT03326427|Active Comparator|Treatment as Usual|Patients will have one psychiatric session to control their medication adherence.
2889111|NCT03326414|Other|Constant PEEP - low tidal volume|PEEP is 10mbar, tidal volume is set to 4-5ml/kg IBW
2889112|NCT03326414|Other|Constant PEEP - high tidal volume|PEEP is 10mbar, tidal volume is set to 8-10ml/kg IBW
2889113|NCT03326414|Other|constant tidal volume - low PEEP|tidal volume is 8ml/kg IBW, PEEP is set to 3mbar
2889114|NCT03326414|Other|constant tidal volume - high PEEP|tidal volume is 8ml/kg IBW, PEEP is set to 12mbar
2889115|NCT03326401||Case (AMD group)|Case group including 100 patients diagnosed with age-related macular degeneration (50 women, 50 men).Demographic data and dietary intake of different food groups were assessed by a standardized interviewer-assisted questionaire with the method of face-to-face interview. The body weight of the individuals were measured with a calibrated electronic scale,anthropometric measurements were measured by the researcher. Participants' dietary intake was assessed using food frequency questionaire (FFQ). The FFQ included 65 food items traditionally consumed in Turkey. Foods were classified into the following food categories: milk and dairy products, meat and meat products, fruits, vegetables, breads and cereals, beverages, and desserts.
2889116|NCT03326401||Control (Non-AMD group)|Case group including 100 patients not diagnosed with age-related macular degeneration (50 women, 50 men).Demographic data and dietary intake of different food groups were assessed by a standardized interviewer-assisted questionaire with the method of face-to-face interview. The questionaire form, prepared to determine socio-demographic features of individuals participating in the research, was applied by the research with the method of face-to-face interview. The body weight of the individuals were measured with a calibrated electronic scale,anthropometric measurements were measured by the researcher. Participants' dietary intake was assessed using food frequency questionaire (FFQ). The FFQ included 65 food items traditionally consumed in Turkey. Foods were classified into the following food categories: milk and dairy products, meat and meat products, fruits, vegetables, breads and cereals, beverages, and desserts.
2889117|NCT03326388|Experimental|Selumetinib Intermittent Dosing|Phase 1 of the study to evaluate Intermittent Dosing (Selumetinib given twice daily on 5 out of 7 days) in children with NF1 and inoperable plexiform neurofibromas. The Maximum tolerated dose will define the Recommended phase 2 dose of selumetinib.
2889545|NCT03323164|Active Comparator|Timolol|Timolol maleate 0.5% ophthalmic solution Instillation of one drop in each eye, once.
2889119|NCT03326375|No Intervention|TACE (Transarterial chemoembolization)|Treatment of repeated TACE in HCC patients who have incomplete response after first TACE
2889120|NCT03326362|Experimental|High intensity resistance training (HIRT)|"12 weeks of two weekly training sessions, with at least 48 hours of interval between sessions. The HIRT performed the squat, deadlift and lunge exercises, as these exercises induce high core muscles activity. HIRT started with two weeks of low intensity exercises emphasizing the activation of core muscles (pelvic elevation with feet on the floor, superman, static supine bridge on bosu), and the technique of the selected resistance exercises (e.g. squat, deadlift, and lunges). Participants performed 3 sets of 10 repetitions per exercise. In the third and forth weeks, participants performed the exercises from the previous weeks and also static unipedal forward flexion on bosu and dynamic unipedal forward flexion and the main exercises with a load corresponding to (50% of the 1 RM load (Brzycki, 1993).~From the 5th to the 12th week, participants performed only the selected resistance exercises with progressive higher intensities (from 12RM to 8RM)."
2889121|NCT03326362|Active Comparator|Low intensity resistance training (LIRT)|12 weeks of two weekly training sessions, with at least 48 hours of interval between sessions.The LIRT group performed very low intensity and volume exercises (i.e. 1 set per exercise). Exercises started with participants lying on a firm surface, with the back supported, knees bent and feet flat on the floor. Then, participants performed the following exercises: 1) inhaling and exhaling and then isometrically contract in gluteal and abdominal muscles for 20 seconds and relax; 2) raising the head, lifting the chin and shoulders toward the chest for 20 seconds and relax; 3) raising one knee towards the chest and raising the head and shoulders likewise in the second exercise for 20s, relaxing, and changing the leg.; 4) raising both knees towards the chest in the same time that raise the head and shoulder off the floor during 20 seconds and relax.
2889122|NCT03326349|Experimental|Guttmann, NeuroPersonalTrainer|Guttmann NeuroPersonalTrainer (GNPT) 5 days per week over 6 weeks.
2889123|NCT03326349|Sham Comparator|Ictus.online|Itus.online 5 days per week over 6 weeks
2889124|NCT03326336|Other|Cohort|3 dose escalation cohorts (low, medium and high dose) with 3 subjects per cohort followed by an extension cohort at the highest-well tolerated dose with 3 to 9 subjects.
2889125|NCT03326323||Patients undergoing ANH during CABG|Patients undergoing Acute Normovolemic Hemodilution during CABG surgery.
2889126|NCT03326310|Experimental|Azacitidine and selumetinib|Subjects will receive azacitidine subcutaneously on days 1-7. Selumetinib will be administered on days 8-21. Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression.
2889127|NCT03326297|Experimental|Osteopathy manual therapy|Osteopathy manual therapy applying the following treatment: Technique for the treatment of parasympathetic innervation, Techniques for the treatment of sympathetic innervation of the digestive system, Functional visceral techniques.
2889128|NCT03326297|Active Comparator|Measures to support and education to the family|Measures to support and education to the family that consist on pedagogical intervention in parents, health education.
2889129|NCT03326297|No Intervention|No specific intervention|No specific intervention, prescriptions by pediatrician
2889130|NCT03326284|Experimental|15g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 15g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
2889131|NCT03326284|Experimental|35g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 35g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
2889132|NCT03326284|Experimental|60g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 60g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
2889133|NCT03326284|Experimental|35g protein energy balanced diet|Following a 5-day energy balanced diet the subjects (n=10) will ingest 35g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
2889134|NCT03326271||Lubinus SP2 stem|Patients treated with a cemented Lubinus SP2 stem for a femoral neck fracture. Both total hip arthroplasty and hemiarthroplasty are included.
2889135|NCT03326271||Exeter stem|Patients treated with a cemented Exeter stem for a femoral neck fracture. Both total hip arthroplasty and hemiarthroplasty are included.
2889136|NCT03326258|Experimental|Treatment (glembatumumab vedotin, nivolumab, ipilimumab)|Patients receive glembatumumab vedotin IV over 90 minutes and nivolumab IV over 60 minutes on day 8 of course 1 and on day 1 of subsequent courses. Patients in melanoma expanded cohort also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 21 days for 4 courses in the absence of disease progression or unaccepted toxicity and courses with glembatumumab vedotin and nivolumab repeat every 21 days in the absence of disease progression or unaccepted toxicity.
2889137|NCT03326245|Experimental|1|Dynamic changes in D2R
2889138|NCT03326245|Experimental|2|Dynamic changes in D2R
2889139|NCT03326245|Experimental|3|Dynamic changes in D2R
2889140|NCT03326232|Experimental|Blinded continuous glucose monitoring|The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter).
2889141|NCT03326232|Experimental|Real time continuous glucose monitoring|The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)
2889142|NCT03326219|Other|Aethoxysklerol clarivein during leg amp|Clarivein treatment with Aethoxysklerol in 5 patients during lower or upper leg amputation
2889143|NCT03326206||COPE participants|Individuals living with diabetes seen at a study site who were enrolled in the COPE programmatic intervention during the study period. Participation in COPE consists of receiving home visits by a Navajo Community Health Representative (CHR) once or twice a month for a period of at least 12 months. CHRs use structured patient coaching materials to support behavior change. CHRs also check vital signs, monitor blood glucose levels through finger sticks, and facilitate access to appointments and medical refills. CHRs communicate regularly with providers through electronic health record documentation and case management rounds. In-person or telephone communication is be used to address acute issues that may arise.
2889144|NCT03326206||Non-COPE participants|Individuals living with diabetes seen at a study site, did not participate in the COPE programmatic intervention, and had comparable baseline characteristics.
2889546|NCT03323164|Active Comparator|Brimonidine|Brimonidine tartrate 0.2% Instillation of one drop in each eye, once.
2889145|NCT03326180|Experimental|Liposomal bupivacaine (EXPAREL)|266mg/20ml EXPAREL mixed with 80ml 0.9% normal saline and 100mg/20ml 0.5% plain bupivacaine hydrochloride. Administered as a single dose intra-operatively by periarticular infiltration.
2889146|NCT03326180|Active Comparator|Bupivacaine hydrochloride alone|"100ml 0.9% normal saline mixed with 100mg/20ml 0.5% plain bupivacaine hydrochloride.~Administered as a single dose intra-operatively by periarticular infiltration."
2889147|NCT03326167||Patients with or suspected coronary heart disease|
2889148|NCT03326141|Active Comparator|Otago+PAM+Health / Wellness topics|"Condition 1:~Otago Exercise Program adapted for delivery to small groups; a physical activity monitor such as a Fitbit (PAM); and, information about health and wellness (8) topics guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
2889149|NCT03326141|Experimental|Otago + PAM + Interpersonal strategies|"Condition 2:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g.,Fitbit); 5 Interpersonal behavior change strategies; and, information about health and wellness topics (1) guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
2889150|NCT03326141|Experimental|Otago, PAM, Intrapersonal strategies|"Condition 3:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g.,Fitbit); 5 Intrapersonal behavior change strategies; and, health and wellness topics (1) guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
2889151|NCT03326141|Experimental|Otago,PAM, Inter+Intra strategies|"Condition 4:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g., Fitbit); 5 Interpersonal behavior change strategies; and, 5 Intrapersonal behavior change strategies"
2889152|NCT03326128|Active Comparator|BUP-300|Participants will receive Bupropion hydrochloride extended release for 12 weeks and titrate to a maximum dose of 300 mg/day and will also receive standard smoking cessation counseling for 8 weeks.
2889153|NCT03326128|Experimental|BUP-450|Participants will receive Bupropion hydrochloride extended release for 12 weeks and titrate to a maximum dose of 450 mg/day and will also receive standard smoking cessation counseling for 8 weeks.
2889154|NCT03326115|Experimental|Peer Visitation Program (PVP)|Participants in this group will begin participation in the Peer Visitation Program (PVP) beginning at amputation date with the initiation window ranging from immediately pre-operative to 7 days post operative.
2889155|NCT03326115|No Intervention|Delayed Peer Visitation (NoPVP)|Not participating in a Peer Visitation Program for 60 days post-operatively, followed by participation and completion in a PVP 60 days later than the PVP group for a total of 120 days.
2889156|NCT03326102|Experimental|DHP107|"The 12 eligible subjects will receive DHP107 and be taken blood samples for PK analysis on Day 1, 8 of cycle 1.~Total 48 subjects (including PK subjects) will receive DHP107 200 mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days."
2889157|NCT03326102|Experimental|IV paclitaxel|Total 24 subject will receive IV paclitaxel 80 mg/m2 weekly.(3 weeks on/1 week off)
2889158|NCT03326089|Active Comparator|High flow oxygen supplementation|Pulmonary rehabilitation with constant high flow supplementary oxygen supply FiO2 50% for 2 months (Group A).
2889159|NCT03326089|Placebo Comparator|Oxygen supplementation upon hypoxemia|Pulmonary rehabilitation without oxygen supply unless upon resting or exercise induced hypoxemia for 2 months (Group B).
2889160|NCT03326076||Primary donor-derived cell-free DNA|300 patients with planned renal surveillance biopsies at 12 months post-transplantation
2889161|NCT03326076||Control|A matched control cohort of 300 patients with planned renal surveillance biopsies at 12 months post-transplantation but were not managed with donor-derived cell-free DNA (AlloSure®) will be retrospectively selected
2889162|NCT03326076||Secondary donor-derived cell-free DNA|700 patients without planned renal surveillance biopsies at 12 months post-transplantation
2889163|NCT03326063|Active Comparator|Ifetroban|Subjects will be randomized to receive ifetroban (200 mg dose per day) for 4 weeks.
2889164|NCT03326063|Placebo Comparator|Placebo|Subjects will be randomized to receive placebo for 4 weeks.
2889165|NCT03326050|Placebo Comparator|gemifloxacin and Rifampicin|first group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once dailygroup will be given the usual regimen given for free by the Ministry of Health in Egypt; Rifampicin 300 mg twice daily for three months..
2889166|NCT03326050|Placebo Comparator|gemifloxacin and ciprofloxacin|. group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once daily group will be given a short course (four weeks) of oral Ciprofloxacin 750 mg twice daily
2889167|NCT03326050|Placebo Comparator|gemifloxacin and placipo|.group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once daily
2889168|NCT03326024||A|Patients with Polycystic Ovary Syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and underwent laparoscopic ovarian drilling from more than two years.
2889169|NCT03326024||B|Patients with Polycystic Ovary Syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and didn't undergo laparoscopic ovarian drilling
2889170|NCT03326011|Experimental|Gait training group|Gait training with Samsung Hip Assist v1 All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions.
2889171|NCT03325998|Experimental|Gait training group|"Gait training with Samsung Hip Assist v1~All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions."
2889172|NCT03325985|Active Comparator|Cancer|
2889173|NCT03325985|Active Comparator|End-stage organ failure|
2889174|NCT03325972|Experimental|IV dexmedetomidine|Dexmedetomidine is an alpha-2-adrenergic agonist. It is commonly used for sedation and as an adjunct to general anesthetics.
2889175|NCT03325972|Placebo Comparator|Placebo|saline placebo
2889176|NCT03325959|Active Comparator|Hyperbaric oxygen therapy|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes Crossover: After 3 months of either pharmaceuitical or HBOT, once the 2nd evaluation is completed, all patients in both groups will be offered to switch to the alternative treatment group.
2889223|NCT03325673|Placebo Comparator|TrueTear Sham Control|TrueTear sham device, which is not electrically active, should be used intranasally on contact lens (CL) wear days; it may also be used on non-CL wear days if participant chooses. The number of applications is determined by participant.
2889224|NCT03325660|Active Comparator|study group|whole body vibration
2889177|NCT03325959|Active Comparator|Pharmacotherapy|"patients will be offered pharmacological treatment with one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg at bedtime while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning). After a period of 6 weeks patients will be evaluated and dose will be adjusted as necessary. Patients may also be switched from one medication to the other based according to clinical judgment.~Crossover: After 3 months of either pharmaceuitical or HBOT, once the 2nd evaluation is completed, all patients in both groups will be offered to switch to the alternative treatment group."
2889178|NCT03325946||Children and Adults with Cerebral Palsy|
2889179|NCT03325946||Children and Adults with Microcephaly|
2889180|NCT03325946||Children and Adults with other Neuromotor Impairments|
2889181|NCT03325933|Experimental|Resistance Training 1|Participants will perform resistance training with high training loads and low repetitions (high load/low rep resistance training).
2889182|NCT03325933|Experimental|Resistance Training 2|Participants will perform resistance training with low training loads and high repetitions (Low load/high rep resistance training).
2889183|NCT03325933|No Intervention|Wait-list control|This group will be offered the option of participating in either experimental group after the study is completed.
2889184|NCT03325920|Experimental|Sleep bruxism group|25 sleep bruxism subjects wear the DIABRUX for five consecutive nights.
2889185|NCT03325920|Experimental|non-sleep bruxism group|25 non-sleep bruxism subjects wear the DIABRUX for five consecutive nights.
2889186|NCT03325907|Experimental|template-guided biopsy|Participants receive transthoracic lung biopsy guided by navigational template.
2889187|NCT03325894|Experimental|SHP465|Group A participants who have been rolled-over from antecedent SHP465 studies and Group B participants who will be newly enrolled into the study will receive SHP465 capsule 6.25 mg orally once daily for 360 days.
2889188|NCT03325881|Experimental|SHP465|Participants will be randomized to receive SHP465 capsule 6.25 milligram (mg) orally once daily for 4 weeks.
2889189|NCT03325881|Placebo Comparator|Placebo|Participant will receive placebo matching to SHP465 capsule orally once daily for 4 weeks.
2889190|NCT03325868|Experimental|Ulipristal|Ulipristal acetate 5mg daily for 12 weeks
2889191|NCT03325842||Cerebral palsy|ASKp will be submitted to children of 5 to 15 years with hemiplegia or diplegia due to Cerebral Palsy, with normal or slightly impaired cognitive level.
2889192|NCT03325842||Healthy individuals|ASKp will be submitted to children of 5 to 15 years with typical development
2889193|NCT03325829||Patients with colonic diverticula|No interventional study
2889194|NCT03325816|Experimental|Phase II - Arm 1|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.~The Phase II dose of 177Lu-DOTA0-Tyr3-Octreotate will be the maximum tolerated dose as determined in the Phase I portion."
2889195|NCT03325816|Experimental|Phase I - Dose Level -1|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.~177Lu-DOTA0-Tyr3-Octreotate dose will be 3.7 GBq (100 mCi) every 8 weeks for 4 doses."
2889196|NCT03325816|Experimental|Phase I - Dose Level 0|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.~177Lu-DOTA0-Tyr3-Octreotate dose will be 7.4 GBq (200 mCi) every 8 weeks for 4 doses."
2889197|NCT03325816|No Intervention|Phase II - Arm 2|Patients randomized to this arm will be followed (observation). Cross-over to Phase II Arm 1 at the time of disease progression will be allowed
2889198|NCT03325803|Experimental|150μm-AFL-PDT|
2889199|NCT03325803|Experimental|350μm-AFL-PDT|
2889200|NCT03325803|Experimental|500μm-AFL-PDT|
2889201|NCT03325790|Placebo Comparator|Placebo|Placebo
2889202|NCT03325790|Experimental|200mg SPI-1005 BID|200mg SPI-1005 BID
2889203|NCT03325790|Experimental|400mg SPI-1005 BID|400mg SPI-1005 BID
2889204|NCT03325777|Experimental|Approach Bias Retraining Group|Individuals in this condition will receive seven sessions of ABR training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the training may weaken automatic cigarette-approach and strengthen automatic cigarette-avoidance. Furthermore, they will be told that the opposite effect will be true for the stimuli not related to cigarettes (i.e., the positive stimuli).
2889205|NCT03325777|Sham Comparator|Control Group|Individuals in this condition will receive seven sessions of SHAM training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the purpose of the training is to improve control over these automatic tendencies and that following the training sessions, they will easily be able to push or pull the stimuli regardless of content.
2889206|NCT03325764|Other|PRE group|candidates seeking sleeve gastrectomy
2889207|NCT03325764|Other|POST group|patients 6 months after sleeve gastrectomy
2889208|NCT03325751||Healthy subjects|
2889209|NCT03325751||Glaucoma subjects|Patients with primary open-angle-, pseudoexfoliation- or primary angle-closure glaucoma
2889210|NCT03325725|Experimental|NewBreez LD Intra-laryngeal implant|
2889211|NCT03325712|Experimental|Dose Group 1|
2889212|NCT03325712|Experimental|Dose Group 2|
2889213|NCT03325712|Experimental|Dose Group 3|
2889214|NCT03325712|Experimental|Dose Group 4|
2889215|NCT03325712|Experimental|Dose Group 5|
2889216|NCT03325712|Placebo Comparator|Placebo|
2889217|NCT03325712|Experimental|Dose Group 8|
2889218|NCT03325699|Experimental|Intervention|Participants assigned to the intervention group will have access to the SMART4MD health application and participate in clinical visits every 6 months
2889219|NCT03325699|No Intervention|Control|Participants assigned to the intervention group will NOT have access to the SMART4MD health application and participate in clinical visits every 6 months
2889220|NCT03325686|Experimental|vitamin D supplement|D
2889221|NCT03325686|Placebo Comparator|control|P
2889222|NCT03325673|Experimental|TrueTear|TrueTear Device should be used intranasally on contact lens (CL) wear days; it may also be used on non-CL wear days if participant chooses. The number of applications is determined by participant.
2889226|NCT03325647|Experimental|Visit 1 Drug, Visit 2 Placebo|Subjects in this group will be randomized to receive Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution every 4 weeks x 3 doses, beginning at visit 1, and Placebo Injectable Saline beginning at visit 2.
2889227|NCT03325647|Experimental|Visit 1 Placebo, Visit 2 Drug|Subjects in this group will be randomized to receive Placebo Injectable Saline beginning at visit 1, and Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution every 4 weeks x 3 doses beginning at visit 2.
2889228|NCT03325634|Experimental|Treatment (SBRT)|Patients undergo Stereotactic Body Radiation Therapy (SBRT) every other day for 3 fractions.
2889229|NCT03325621|Active Comparator|PRS-080#022-DP|Experimental: PRS-080#022-DP Hepcidin antagonist, repeated administrations, ascending doses
2889230|NCT03325621|Placebo Comparator|PRS-080-Placebo#001|Experimental: PRS-080-Placebo#001 Comparator treatment, repeated administrations
2889231|NCT03325608|Experimental|Intervention|The POISED care management team consisting of specially-trained nurses functioning as care managers (CMs) and para-professionals in the role of care manager assistants (CMAs) will conduct a biopsychosocial/environmental needs assessment by phone within 48 hours of emergency room discharge if not possible during the ED stay.
2889232|NCT03325608|Placebo Comparator|Usual Care|will receive referrals to services at the time of enrollment.
2889233|NCT03325595|Active Comparator|Experimental: AEF0117|Subjects in Cohorts 1 through 4 receive active treatments. Subjects in Cohorts 1 through 4 will receive a single dose of 0.2, 0.6, 2 and 6mg respectively of AEF0117 on Day1.
2889234|NCT03325595|Placebo Comparator|Placebo Comparator: Placebo|Subjects in Cohorts 1 through 4 will be randomly assigned in an 6:2 allocation to receive active or placebo treatments.
2889235|NCT03325569|Active Comparator|NGT|NGT - normal glucose tolerance. Women with PCOS and normal glucose tolerance
2889236|NCT03325569|Active Comparator|IGH|IGH - impaired glucose homeostasis Women with PCOS and impaired glucose homeostasis - that means impaired fasting glucose or impaired glucose tolerance.
2889237|NCT03325556|Placebo Comparator|Placebo|
2889238|NCT03325556|Experimental|Drug - Pimavanserin|
2889239|NCT03325543|Experimental|Intervention Group|The treatment program is based on the motor learning concepts of PFMs. The steps of learning a correct muscle contraction will be separate into four levels: 1. Understand 2. Search 3. Find 4. Learn. Feedback from the PF is mandatory. The intervention program will last four weeks, and will contain four outpatient consultations (1 session per week) lasting 60 minutes each session.
2889240|NCT03325543|Active Comparator|Control Group|The control group will receive only verbal instructions about the anatomy and function of the PFM, and to perform the contraction of the PFMs.
2889241|NCT03325530||Focus Group|
2889242|NCT03325504|Experimental|hBM-MSCs-Low Dose|Autologous Cultured Mesenchymal Cells +Biomaterial (Low Dose): 100x106 cells
2889243|NCT03325504|Experimental|hBM-MSCs-High Dose|Autologous Cultured Mesenchymal Cells+Biomaterial (High Dose): 200x106 cells
2889244|NCT03325504|Active Comparator|Autollogous Illiac crest graft|Autologous Iliac Crest Grafting
2889245|NCT03325491|Experimental|Acipimox plus exercise training|The active supplement will contain the prescription drug Acipimox (250 mgs) , a nicotinic acid precursor traditionally used to lower blood lipid levels. The supplement will be administered 3 times per day, for 6 weeks.
2889246|NCT03325491|Placebo Comparator|Placebo plus exercise training|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
2889247|NCT03325465|Experimental|Pembrolizumab and epacadostat|"Patients will receive neoadjuvant immunotherapy either with anti-PD-1 (pembrolizumab) alone or anti-PD-1 in combination with IDO1 inhibition (epacadostat). Patients will receive Pembrolizumab every 3 weeks over a period of 8 weeks as well as epacadostat starting on day 1 for the duration of pembrolizumab treatment.~All patients will undergo baseline biopsy (mandatory, sampling ≥ 4 areas to represent the tumor), as well as baseline imaging (and for exploratory analysis collection of blood for baseline ctDNA testing and TCR analysis)."
2889248|NCT03325452|Experimental|cardio-respiratory arrest|
2889249|NCT03325439|Experimental|Brivaracetam (BRV)|Exploratory Cohort and Confirmatory Cohorts
2889250|NCT03325426|No Intervention|Usual care|
2889251|NCT03325426|Experimental|Physical activity tracker|
2889252|NCT03325413|No Intervention|Control|Usual care with assessment only (no study-related intervention)
2889253|NCT03325413|Other|Implementation|Implementation of intervention measures
2889254|NCT03325413|Other|Full-scale intervention|
2889255|NCT03325400|Other|Non-fluoride toothpaste|Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation.
2889256|NCT03325400|Active Comparator|Fluoride toothpaste|Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation.
2889257|NCT03325387|Experimental|LY3305677|Escalating doses of LY3305677 administered by subcutaneous (SC) injection
2889258|NCT03325387|Placebo Comparator|Placebo|Saline solution administered by SC injection
2889259|NCT03325374||BLB patients|Patients admitted for urgent MRI with possible cauda equina syndrome will be consented for questionnaires and examination.
2889260|NCT03325361|Experimental|TD|
2889261|NCT03325361|No Intervention|NTD|
2889262|NCT03325348|Experimental|Oral Nifedipine|Nifedipine 10mg oral tablet & 1ml 0.9%N/Saline will be given every 15 minutes up till one hour
2889263|NCT03325348|Active Comparator|IV Labetalol|IV labetalol 20 mg and mint tablet will be given every 15 minutes up till one hour
2889264|NCT03325335|Active Comparator|Midazolam premedication group (Group P)|Patients of group P were premedicated with intramuscular midazolam 0.05 mg/kg 30 minutes before surgery.
2889265|NCT03325335|Other|Control group (Group N)|Patients of group N were not premedicated with midazolam (Do not use placebo). [Treatment of Glycopyrrolate (0.2 mg, IM) 30 minutes prior to surgery is not intervention because it is a routine practice of this center. (-> removed from interventions)]
2889266|NCT03325322|Experimental|Treatment|Fisetin 20 mg/kg/day, orally for 2 consecutive days
2889267|NCT03325322|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days
2889268|NCT03325309||Home-based cycling|A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
2889269|NCT03325296|Experimental|LEO 124249 ointment 30 mg/g|Ointment to be applied on the eyebrow twice daily.
2889270|NCT03325296|Placebo Comparator|LEO 124249 ointment vehicle|Ointment to be applied on the eyebrow twice daily.
2889271|NCT03325283|Experimental|Protembo device treatment|Patients who consent to participate in the PROTEMBO SF Trial and in whom the ProtEmbo Cerebral Protection System is used or is attempted to be used.
2889272|NCT03325270|Experimental|ferrous fumarate|labeled iron as Ferrous Fumarate
2889273|NCT03325270|Experimental|ferrous fumarate and GOS|labeled ferrous fumarate + prebiotics
2889274|NCT03325270|Experimental|ferrous sulfate and GOS|labeled ferrous sulfate + prebiotics
2889275|NCT03325244||All participants|All participants will use a portable EEG monitor and FITBIT to monitor sleep and activity before and after night call
2889276|NCT03325231||Bladder Cancer Patients|Participants will be recruited from those who have had advanced bladder cancer (grade pT1 and above) and undergone either IC or NB procedures within the last five years. No form of payment will be offered for participation, but participants will be reimbursed for travel expenses. There will be no other inclusion or exclusion criteria in order to access a wide range of patients with potentially different values and lifestyles, and to aid in the recruitment of adequate sample sizes.
2889277|NCT03325218||Questionnaire Set A|
2889278|NCT03325218||Questionnaire Set B|
2889279|NCT03325205|Experimental|Active tDCS|Participants receive anodal tDCS over DLPFC. Each sessions lasts for 20 minutes, with a total of 15 stimulations: 6 acute sessions, 9 maintenance sessions.
2889280|NCT03325205|Sham Comparator|Sham tDCS|Participants receive sham tDCS over DLPFC. Each sessions lasts for 20 minutes, with a total of 15 stimulations: 6 acute sessions, 9 maintenance sessions.
2889281|NCT03325192|Placebo Comparator|Standard of care|Subjects in this arm will receive placebo only (100mL of normal saline) into the pleural space delivered via the newly placed tunneled intrapleural catheter
2889282|NCT03325192|Experimental|Rapid pleurodesis protocol|Subjects in this arm will receive the chemical pleurodesing agent of 10% iodopovidone solution delivered to the pleural space via the newly placed tunneled intrapleural catheter
2889283|NCT03325179|Experimental|participants received treatment|100 participants who are diagnosed as simple obesity under the standards of... are planned to enrolled in the trial. Each will receive Thread-embedding therapy.
2889284|NCT03325166|Experimental|Treatment (pembrolizumab, ferumoxytol MRI)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years (or up to 32 courses) in the absence of disease progression or unacceptable toxicity. Patients also receive ferumoxytol IV and undergo MRI at baseline, 12 weeks after radiation, at suspected radiographic progression, and 6 weeks after suspected radiographic progression.
2889285|NCT03325127||Radium-223 concomitant with Abiraterone or Enzalutamide|Approximately 150 medical charts from mCRPC patients within the network will be collected
2889286|NCT03325114|Other|Chlorthalidone|Chlorthalidone 12.5-50 mg by mouth daily for 4 weeks
2889287|NCT03325101|Experimental|Treatment (apheresis, pembrolizumab, cryosurgery, mDCs)|Patients undergo apheresis over 4 hours on day 1 or course 1. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses with pembrolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Within 36 hours after receiving pembrolizumab, patients undergo cryosurgery over 45 minutes on day 1 or 2 of courses 2 and 3. Patients also receive mature dendritic cells IT on day 1 or 2 of courses 2 and 3 after cryosurgery.
2889288|NCT03325088|Other|Severe Asthma|patients affected with severe asthma s defined by ERS-ATS (European Respiratory Society - American Thoracic Society) without long term oral corticosteroids treatment
2889289|NCT03325088|Other|Mild to moderate Asthma|patients affected with untreated mild to moderate asthma
2889290|NCT03325088|Other|Controlled Sample|smooth muscle cells from Tracheobronchial rings of non-asthmatic cadaveric donor
2889291|NCT03325075|Experimental|VAL-181388|
2889292|NCT03325075|Placebo Comparator|Placebo|
2889293|NCT03325062|Experimental|Experimental: MOVE|Movement pattern training in addition to contemporary progressive rehabilitation
2889294|NCT03325062|Active Comparator|CONTROL|Contemporary progressive rehabilitation
2889295|NCT03325049|Experimental|The health-promoting conversations|In the intervention group, there were 3 health-promoting conversations with each family after the discharge. The health-promoting conversations were held within an approximately 4- to 8-week period with an interval of 2 weeks between conversations. A closing letter was sent 2 to 3 weeks after the final conversation that summarized all of the conversations and that provided further opportunities for reflection.
2889296|NCT03325049|Active Comparator|Control Arm|Usual Care
2889297|NCT03325023|Active Comparator|Active Comparator:|Dietary modification + Probiotic supplementation (Sanprobi Super Formula)
2889298|NCT03325023|Placebo Comparator|Placebo Comparator|Dietary modification + placebo.
2889299|NCT03325010|Placebo Comparator|Placebo|Capsule, administered once daily for 12 weeks.
2889300|NCT03325010|Experimental|Valbenazine|Capsule, administered once daily for 12 weeks.
2889301|NCT03324997|Experimental|Restylane|half the chest to be treated with Restylane Silk
2889302|NCT03324997|Placebo Comparator|Placebo|half-chest injections with saline as a placebo to Restylane Silk.
2889303|NCT03324984|Experimental|2-Chloroprocaine (PF)|2-Chloroprocaine is an ester-linked local anesthetic with the shortest duration of action of all local anesthetics.
2889304|NCT03324984|Active Comparator|0.75% bupivacaine|0.75% bupivacaine is a amino-amide anesthetic local anesthetic. It is hyperbaric in nature due to addition of dextrose.
2889305|NCT03324971|Experimental|Diabetic patients with non-adherence and poly-pharmacy|Medications review. Elimination of all unnecessary prescription to cut down the number of medications to the least possible number.
2889306|NCT03324958|Experimental|Virtual Reality Helmet|Patients will use a virtual reality helmet during brachytherapy applicator's setting up. The use of virtual reality helmet has already been assessed during oncologic treatments, and seems to reduce pain and anxiety. The use of virtual reality helmet has never been assessed to reduce the pain or anxiety associated with brachytherapy applicators' setting up.
2889307|NCT03324958|Active Comparator|No Virtual Reality Helmet|Patient wont use virtual reality helmet during brachytherapy applicator setting up, as in current practice.
2889308|NCT03324945|Experimental|Neurocognitive Assessment +/- FMRI|All participants receive pre- and post-chemotherapy neurocognitive assessments. A sequentially-assigned subset also receive pre- and post-chemotherapy Functional Magnetic Resonance Imaging (FMRI) procedures.
2889309|NCT03324932|Other|AI+denosumab VS only AI|We compare AI intake+denosumab injection and AI intake only in patients with normal BMD to whom Letrozole or Arimidex will be administered as postoperative endocrine therapy, and we assess the efficacy of denosumab injection on bone loss by adjuvant endocrine therapy.
2889310|NCT03324919||Psoriasis, HRQL|Patients with a medical diagnosis of Psoriasis were enclosed.
2889311|NCT03324919||Urticaria, HRQL|Patients with a medical diagnosis of Urticaria were enclosed.
2889312|NCT03324919||Lupus erythematodes, HRQL|Patients with a medical diagnosis of Lupus were enclosed.
2889313|NCT03324906|Active Comparator|tDCS active Prader-Willi Syndrome|The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
2889314|NCT03324906|Active Comparator|tDCS active Obese Subjects|The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation). The start ramp, when the current will be changed from zero to 2mA (two milli amps), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes.
2889315|NCT03324893|Experimental|[F18]-FCH PET/MRI|Patients with primary hyperparathyroidism planned for parathyroidectomy
2889316|NCT03324880|Experimental|rhPTH(1-84)|Participants will receive rhPTH(1-84) 50 microgram (mcg) subcutaneous (SC) injection once daily (QD), titrated within the dose range of 25-100 mcg QD as an adjunctive treatment with active vitamin D and calcium supplements based on metabolic response.
2889317|NCT03324880|Placebo Comparator|Placebo|Participants will receive placebo matched to rhPTH(1-84) as SC injection QD with active vitamin D and calcium supplements.
2889318|NCT03324867|Experimental|Intranasal Insulin 40 IU|40 IU of Humulin-R via nose Before surgery and everyday after surgery up to POD 7
2889319|NCT03324867|Placebo Comparator|Intranasal Normal Saline|Normal Saline via nose Before surgery and everyday after surgery up to POD 7
2889320|NCT03324854|Experimental|mosquito net mesh|The open ventral hernia repair were carried out with rives technique, followed by the placement of the mosquito net mesh, and left active-close drainage, 30 minutes before the incisión, prophylactic antibiotic 1gm of cefalotin was administered.
2889321|NCT03324854|Active Comparator|prolene mesh|The open ventral hernia repair were carried out with rives technique, followed by the placement of the prolene mesh, and left active-close drainage, 30 minutes before the incisión, prophylactic antibiotic 1gm of cefalotin was administered.
2889322|NCT03324841||MI Profiling|Subjects must have undergone Caris MI Profiling in order to be eligible for the study. No required intervention is dictated by the protocol.
2889323|NCT03324828|Active Comparator|Hydroxyzine+no clowns|Patients will receive hydroxyzine solution and no additional intervention
2889324|NCT03324828|Experimental|Hydroxyzine+clowns|Patients will receive hydroxyzine solution and clowns intervention
2889325|NCT03324828|Active Comparator|Placebo+clowns|Patients will receive placebo solution and clowns intervention
2889326|NCT03324828|No Intervention|Placebo+no clowns|Patients will receive placebo solution and no additional intervention
2889327|NCT03324815|Active Comparator|Morphine- Methadone|Morphine 5mg/6h plus metadone: 2,5mg/12h
2889328|NCT03324815|Active Comparator|Morphine|Morphine: 5mg/6h
2889329|NCT03324802|Experimental|Arm 2 (hypofractionated radiation therapy, 5 fractions)|Within 12 weeks of breast cancer surgery or adjuvant chemotherapy, patients undergo hypofractionated radiation therapy in 5 daily fractions for 5 days.
2889330|NCT03324802|Experimental|Arm I (radiation therapy, 15 fractions)|Within 12 weeks of breast cancer surgery or adjuvant chemotherapy, patients undergo standard radiation therapy in 15 daily fractions for 10 days.
2889331|NCT03324789|Experimental|Single Implant Partial Over-denture|The design will be as follows; two rests on principle abutments and lingual plate major connector, single implant in the symphyseal region.
2889332|NCT03324789|Active Comparator|Conventional Partial Denture|patients will receive conventional partial denture with double Aker clasp on mandibular second premolar and first molar, with no indirect retention and lingual plate as major connector .
2889333|NCT03324776|Other|Afrezza Inhalant Product|Patients will be instructed to follow a Weekly Treat-to-Target BG Testing Regimen and make Afrezza dose changes according to an Afrezza Titration Algorithm
2889334|NCT03324763||stool sampling|
2889335|NCT03324737|No Intervention|Standard Care Arm|Subjects in the standard care arm will be informed of their increased risk of developing type 2 diabetes in the future, and given general lifestyle verbal advice to maintain a healthy weight, eat a well-balanced diet and do regular exercise during their 6 week postnatal visit. Women found to have impaired fasting glucose (6.1-6.9 mmol/L) or impaired glucose tolerance (2H post glucose of 7.8-11.0 mmol/L) will be issued a letter reinforcing lifestyle changes namely weight loss (if raised BMI), diet, exercise, and encouragement to consult a family physician to discuss the appropriateness of starting medications that can prevent the progression to type 2 diabetes, or restore the blood glucose to normal levels. Those with a normal OGTT result will just be informed that it is normal.
2889362|NCT03324503|Experimental|Glucocorticoid ≥ 30 mg/day|≥ 30 mg/day prednisone or prednisolone as per local clinical practice of sarcoidosis initial induction therapy will be taken orally preferably before, during, or immediately after meals or with food or milk, at approximately the same time of day for 8 weeks.
2889336|NCT03324737|Active Comparator|Interactive Smartphone App Arm|"Participants will download the INTERACTIVE SMARTPHONE APP and will be briefed on its use by our team of nutritionists/dieticians, exercise physiologists and life style coaches. Weight: Participants will be reminded that the goal is satisfactory weight loss.~NUH occupational therapist-trained lifestyle coaches, exercise physiotherapists, and clinical nutritionist/ dietician will interact with participants through real-time chats channels via the APP; all culturally appropriate and customized to the Singapore context."
2889337|NCT03324724|Experimental|Adolescents with Eating Disorder|Adolescents with bulimia nervosa or binge eating disorder, with one or more of their parents, will receive integrative cognitive-affective therapy for adolescents (ICAT-A).
2889338|NCT03324711|Other|Elderly patient (65 and more)|Ederly patients seen in geriatric day hospital, from creole culture.
2889339|NCT03324685|Experimental|BIIB074 150 mg and Oral Contraceptive|Participants will receive BIIB074 in tablet form in 150 mg doses every 8 hours on prescription (TID) on days 1-7 and on days 26-32. OC will be taken in tablet form (ethinyl estradiol 30 micrograms and levonorgestrel 150 micrograms) once daily (QD) on days 12-32.
2889340|NCT03324672|Active Comparator|TRIGGER|
2889341|NCT03324672|Experimental|TRIGGER+CURETAPE|
2889342|NCT03324659|Experimental|Exercise and Meditation|The Exercise and Meditation group will practice mindfulness meditation immediately before walking treadmill exercise, five days per week for four weeks.
2889343|NCT03324659|Sham Comparator|Control|The Control group will listen to an audio book followed by quiet rest, five days per week for four weeks.
2889344|NCT03324646||Healthy Volunteers|Healthy adult female and male volunteers age 18 or older
2889345|NCT03324620|Experimental|pre active HSCT|"Candidates for transplantation of hematopoietic progenitors since May 12, 2012, regardless of sex and age, who agree to participate in the study and sign informed consent.~In the pre-transplantation visit with the physiotherapist: Measures of muscle mass and strength, quality of life questionnaires, program presentation, fitness assessment and lifestyle determination. The exercises will be personalized, stimulating your practice before admission and involving the family. During admission, the team will encourage the patient to remain active by adapting to the symptoms. At discharge, measures of resistance, exercise tolerance and quality of life at discharge, in the month after discharge, 3 months after discharge, 6 months after discharge and 12 months after discharge."
2889346|NCT03324620|No Intervention|control group|"Patients' candidates for transplantation of hematopoietic progenitors prior to May 12, 2012, regardless of gender and age, who meet the inclusion criteria and are collected correlatively until completing 104 subjects.~Clinical history review to calculate the days of hospitalization in the different hospitalization units during the transplant. As well as the number and type of complications and the use of health resources. Status vitae. Baseline review of functional tests and exercise tolerance."
2889347|NCT03324594|Active Comparator|Group A|Participants will be first given (1) WONDALEAF-CAP, followed by (2) WONDALEAF-ON-MEN, and last with (3) durex-TOGETHER after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
2889348|NCT03324594|Active Comparator|Group B|Participants will be first given (1) WONDALEAF-CAP, followed by (2) durex-TOGETHER, and last with (3) WONDALEAF-ON-MEN after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
2889349|NCT03324594|Active Comparator|Group C|Participants will be first given (1) WONDALEAF-ON-MEN, followed by (2) durex-TOGETHER, and last with (3) WONDALEAF-CAP after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
2889350|NCT03324594|Active Comparator|Group D|Participants will be first given (1) WONDALEAF-ON-MEN, followed by (2) WONDALEAF-CAP, and last with (3) durex-TOGETHER after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
2889351|NCT03324594|Active Comparator|Group E|Participants will be first given (1) durex-TOGETHER, followed by (2) WONDALEAF-ON-MEN, and last with (3) WONDALEAF-CAP after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
2889352|NCT03324594|Active Comparator|Group F|Participants will be first given (1) durex-TOGETHER, followed by (2) WONDALEAF-CAP, and last with (3) WONDALEAF-ON-MEN after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
2889353|NCT03324581|Experimental|OPC-64005|20 mg tablet dose, titrated up to a max of 30 mg, daily, oral
2889354|NCT03324581|Active Comparator|Atomoxetine|40 mg capsule titrated up to 80 mg, daily, oral
2889355|NCT03324581|Placebo Comparator|Placebo|tablet/capsule, daily, oral
2889356|NCT03324568|Other|Educational handout|
2889357|NCT03324568|Experimental|Video plus educational handout|
2889358|NCT03324555|Experimental|ORIC-101|
2889359|NCT03324529|Experimental|Participants in the NYU takotsubo registry|"10 patients with a confirmed history of takotsubo syndrome~10 age- and sex-matched healthy controls with no significant history of cardiac or neurological illness"
2889360|NCT03324516|Experimental|Experimental Group|Patients included in this arm will undergo a traditional bony pterional approach for their craniotomy. A superior cuff of temporal muscle will be left attached to the temporal bone.
2889361|NCT03324516|Active Comparator|Control|Patients included into this arm will receive a traditional pterional approach for their craniotomy. The temporal muscle will be detached in its entirety.
2889395|NCT03324295||ocular problems|systemically healthy subjects with ocular problems other than cataract
2889363|NCT03324490|Active Comparator|TSA group|Thoracic Spinal Anesthesia; Bupivacaine 0.5% (hyperbaric) 7.5mg, Fentanyl 25 µg & Dexmedetomidine 5 µg by intrathecal injection
2889364|NCT03324490|Active Comparator|TEA group|Thoracic Epidural Anesthesia; Bupivacaine 0.5% (isobaric) 25-50 mg & Fentanyl 10-20 µg by epidural injection
2889365|NCT03324477|Experimental|preload group|Patients will receive 4 ml/kg of hypertonic saline 3% via G14 cannula over 15-20 min before the induction of spinal anaesthesia.
2889366|NCT03324477|Experimental|coload group|Patients will receive 4 ml/kg of hypertonic saline 3% via G14cannula at the maximal possible rate at the time of identification of C.S.F .
2889367|NCT03324464|Experimental|CET-Working Memory (WM)|Central Executive Training: Working Memory
2889368|NCT03324464|Active Comparator|CET-Behavioral Inhibition (BI)|Central Executive Training: Inhibitory Control
2889369|NCT03324451|Experimental|Intervention arm|"The arm that receives TTM Intervention for Insulin Initiation. The intervention contains three parts: (1) individual intervention; (2) insulin injection follow-up management; (3) motivational group activities."
2889370|NCT03324451|Placebo Comparator|Control arm|The arm that receives usual care from the hospital that hosts the control arm. Participants in the control arm receives regular patient education.
2889371|NCT03324438|Active Comparator|Home Telehealth T1D (CoYoT1-HR)|Home Telehealth T1D (C2oYoT1-HR), standard of care delivered via Telehealth for high-risk youth
2889372|NCT03324438|Experimental|Personalized Adherence Feedback|C2oYoT1-HR+Personalized Adherence Intervention
2889373|NCT03324438|Experimental|Personalized Behavioral Health|C2oYoT1-HR+Personalized Behavioral Health
2889374|NCT03324438|Experimental|C2oYoT1-HR + Adherence + Behavioral|C2oYoT1-HR + both Personalized Adherence Feedback + Personalized Behavioral Health (C2oYoT1-HR + Adherence + Behavioral)
2889375|NCT03324425|Experimental|Simvastatin|Simvastatin 40 mg in combination with anti-HER2 therapy regimen
2889376|NCT03324412|Active Comparator|Treatment of MTX|Patients were treated with methotrexate (MTX)and Tripterygium wilfordii Hook F（TwHF）placebo.
2889377|NCT03324412|Experimental|Treatment of MTX and TwHF|Patients were treated with methotrexate (MTX)and Tripterygium wilfordii Hook F（TwHF).
2889378|NCT03324399|Experimental|High Amino Acid levels|"Comparison between high amino acid levels and low amino acid levels of clinical global assessments, muscle strength and spasticity and functional assessments.~Patients taking proprietary probiotic"
2889379|NCT03324399|Experimental|Low Amino Acid levels|"Comparison between high amino acid levels and low amino acid levels of clinical global assessments, muscle strength and spasticity and functional assessments.~Patients taking proprietary probiotic"
2889380|NCT03324386|Experimental|Individual Orientation|This was a prospective randomized clinical study conducted with the following 4 groups of hypertensive patients: Experimental: individual orientation: receiving individual orientation required by an embracement strategy characterized by 7 nursing visits at 20-day intervals, for 4 months);The ntervention is composed by relational strategies characterized by interpersonal relationships
2889381|NCT03324386|Experimental|VLE for Distance Learning|This was a prospective randomized clinical study conducted with the following 4 groups of hypertensive patients:Experimental: a technological education strategy for distance learning (DL), using a technological education strategy (E-Care of Hypertension) for Distance Learning (DL) characterized by 7 nursing visits at 20-day intervals, for 4 months). The intervention is composed by the use of equipment-oriented techniques or audio-visual aids in educational environments remotely accessed for health education specifically for hypertensive patients
2889382|NCT03324386|Experimental|E-blended Learning|This was a prospective randomized clinical study with the patient received experimental intervention: a technological education strategy with E-blended Learning modality with E-Care of Hypertension, associated with face-to-face consultation with the health professional and making 7 nursing visits at 20-day intervals, for 4 months. The intervention is composed by the use of equipment-oriented techniques or audio-visual aids in presential educational environments intended for health education specifically for hypertensive patients
2889383|NCT03324386|No Intervention|No intervention|No type of intervention was performed making 2 nursing visits at baseline and 1 after 120 days (No intervention)
2889384|NCT03324373|Experimental|Lenvatinib and Everolimus prior to cytoreductive nephrectomy|Eligible patients will start treatment with lenvatinib 18 mg PO daily (administered as one 10 mg capsule and two 4 mg capsules) and everolimus 5 mg PO daily for 4 weeks constituting one cycle. Two cycles of treatment will be administered and after 2 weeks wash out period, the patients will go for nephrectomy.
2889385|NCT03324360|Experimental|Healthy Particpants|A single MRI with injeciton of hyperpolarized 13C pyruvate.
2889386|NCT03324360|Experimental|Intracranial Metastasis Part II|MRI with injection of hyperpolarized 13C pyruvate prior to radiation treatment.
2889387|NCT03324360|Experimental|Intracranial Metastasis Part III|MRI with injection of hyperpolarized 13C pyruvate prior to radiation treatment. MRI with injection of hyperpolarized 13C pyruvate1-5 days following radiation treatment.
2889388|NCT03324347|Experimental|Therapydog|A certified therapydog (together with a certified dog-handler) will be present in the dental clinic while the child will undergo a clinical dental examination by licenced pediatric dentist.
2889389|NCT03324347|No Intervention|No therapydog|No therapydog will be present in the dental clinic while the child will undergo a clinical dental examination by licenced pediatric dentist.
2889390|NCT03324334||Study group|Patients with ulcerative colitis Interventions to be administered: Thyroid antibodies and Thyroid sonography
2889391|NCT03324334||Control group|normal control subjects selected from general population at random Interventions to be administered: Thyroid antibodies and Thyroid sonography
2889392|NCT03324321|Experimental|Hyperventilation Protocol|This will involve sustained periods of 90-seconds of hyperventilation at two levels (-5mmHg and -10mmHg below baseline EtCO2) to a maximum lower level threshold of EtCO2 24mmHg/CBFV 33cm/s regulated using a metronome. Two-minute washout periods of normal respiration will be allowed between successive measurements. Each incremental reduction in pCO2 will be repeated on two occasions during the same session. Further assessments will be conducted 10-14 days following baseline assessments.
2889393|NCT03324308|Experimental|Interventional Group|"Participants undergoing dynamic computed tomography myocardial perfusion imaging.~Intervention: Diagnostic Test: Dynamic Computed Tomography Angiography Imaging"
2889394|NCT03324295||cortical cataract|patients with age related cortical cataracts who are otherwise healthy
2889399|NCT03324269|Other|NOL|"After tracheal intubation and before surgical incision, a calibration Tetanus test of 100Hz, 60 mAmp during 30 sec at remifentanil level (Ce) of 4 ng/ml will be done (starting NOL below 10).~According to the NOL response, there will be an increment of 1 ng/ml of RemiCe if NOL gradient ≥ 10 or decrement of 1 ng/ml if NOL gradient < 10. Ideal remifentanil Ce is the remifentanil Ce at which the variation of NOL index will be less than 10 units at a NOL starting value below 10. Thus this individual remifentanil Ce will be the remifentanil level programmed before surgical incision and sternotomy. NOL and hemodynamic responses will be recorded during the entire duration of thyroid surgery and until the cardiopulmonary bypass during cardiac surgery."
2889400|NCT03324256|Active Comparator|Energy drink and placebo gum|Commercially-available energy drink (16oz) + 2 pieces of placebo gum
2889401|NCT03324256|Active Comparator|Caffeinated drink and placebo gum|Commercially-available caffeinated drink (16oz) + 2 pieces of placebo gum
2889402|NCT03324256|Active Comparator|Control drink and energy gum|Control drink (16oz) + 2 pieces of energy gum
2889403|NCT03324256|Placebo Comparator|Control drink and placebo gum|Control drink (16oz) + 2 pieces of placebo gum
2889404|NCT03324256|Active Comparator|Energy drink and total sleep deprivation|Commercially-available energy drink (16oz) + 2 pieces of placebo gum following total sleep deprivation
2889405|NCT03324243|Experimental|Crenolanib|
2889406|NCT03324217|Experimental|Motor Imagery Group|The participants in the motor imagery group were given instructions to perform a daily training composed of two sets of activities. The main set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions. In the first set, the participant only had to imagine that he was performing that task, placed in the standard position with the tennis ball in the hand. Once the first set was completed, the participant had to take a 2-minute break before starting the second set, in which they had to complete the set both imagining and actively performing the isometric contractions with the tennis ball.
2889407|NCT03324217|Experimental|Action Observation Group|The participants in the action observation group were given instructions to perform a daily training comprised of two sets of activities. The main set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions. In the first set, the participant simply watched a video that showed a forearm performing the task, placed in the standard position and with the tennis ball in the hand. Once that first set was completed, the participant took a 2-minute break before starting the second set, in which they performed the 10 isometric contractions with the tennis ball while they watched the video.
2889408|NCT03324217|Active Comparator|Control Group|The participants in the control group were given instructions to perform a daily training of a single set. The set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions.
2889409|NCT03324204|Experimental|Neuromuscular Training|Each session lasted 30 minutes and consisted of three sets of exercises with 20-30 repetitions. Emphasis is placed on proper knee alignment during exercise. Most of the women exhibit excessive medial rotation and adduction of the femur, resulting in knee valgus. The women will be instructed how to correct their abnormalities using mirrors as visual feedback. All exercises will be completed without pain. If the exercises are too easy, the level of difficulty will be increased individually in accordance with the rehabilitation protocol
2889410|NCT03324204|Active Comparator|Shock Wave Therapy|The ESWT group will will meet the therapist twice in the first week, and once a week after it. ESWT will be applied to the iliotibial band and tensor fascia latae with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session.
2889411|NCT03324191|Placebo Comparator|Placebo|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and placebo drink within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
2889412|NCT03324191|Experimental|Tea beverage|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and tea within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
2889413|NCT03324191|Experimental|Tea extract (medium concentration)|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and concentrated tea extract at a medium concentration within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
2889414|NCT03324191|Experimental|Tea extract (high concentration)|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and concentrated tea extract at a high concentration within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
2889547|NCT03323151|Experimental|Phase I: Ixazomib & Ibrutinib|Ixazomib and Ibrutinib will be given by mouth until progression or unacceptable toxicity.
2889415|NCT03324178|Experimental|Neurofeedback training|Sixteen 30-minute sessions of neurofeedback training performed once a day over the course of four weeks (four sessions each week)
2889416|NCT03324178|Active Comparator|Video game control group|Sixteen 30-minute sessions of playing video games once a day over the course of four weeks (four sessions each week)
2889417|NCT03324165|No Intervention|Usual Care Arm|Patients randomized to Usual Care Arm will be managed as per current best practice that is based on the individual doctor's discretion.
2889418|NCT03324165|Experimental|Intervention Arm|Patients randomized to Intervention Arm will be managed as per the proposed algorithm, which is based on the computation of Alvarado Score.
2889419|NCT03324152|Experimental|High-intensity interval training (HIIT) - myositis|12-week, 3d/w, HIIT
2889420|NCT03324152|Active Comparator|Standard low-intensity home exercise control (CG)|12-week, 5 d/w, home exercise.
2889421|NCT03324152|Active Comparator|High-intensity interval training (HIIT) - healthy|12-week, 3d/w, HIIT.
2889422|NCT03324139|Experimental|Study Group|Treatment with low molecular weight Heparin.
2889423|NCT03324139|Placebo Comparator|Control Group|Treatment with Placebo.
2889424|NCT03324126||Targeted fortification|In the targeted protein fortification group, breast milk samples were analyzed daily via mid-infrared spectroscopy and additional protein was provided to maintain an intake of 4.5 g/kg/day.
2889425|NCT03324126||Adjustable fortification|"In the adjustable protein fortification group, blood urea nitrogen (BUN) levels were monitored weekly, and if the level was < 5 mg/dL, the amount of protein fortification was gradually increased to an estimated maximum level of 4.5 g/kg/day"
2889426|NCT03324113|Experimental|SAR408701 Monotherapy|SAR408701 Dose escalation administered as a single agent intravenously, on Day 1 and once every two weeks, to patients with malignant solid tumors
2889427|NCT03324113|Experimental|SAR408701 + TAS-102 Combination|SAR408701 administered intravenously at the maximum tolerated dose (MTD), once every two weeks in combination with TAS-102 given orally to patients with colorectal cancer
2889428|NCT03324100||Allergic Rhinitis Patients|
2889429|NCT03324100||Healthy Controls|
2889430|NCT03324087||Adult patients with ITP|The investigators are undertaking a multi-center, prospective trail of 1000 adult ITP patients and use SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.
2889431|NCT03324061|Experimental|Fulvestrant for Injectable Suspension|Fulvestrant for Injectable Suspension (500 mg/vial)
2889432|NCT03324061|Active Comparator|Faslodex (R)|Faslodex (250 mg/mL)
2889433|NCT03324048|Other|Patients anxious|Patients anxious will be perform relaxation session.
2889434|NCT03324035|Experimental|Treatment|Patients on this arm will receive amitriptyline on flexible doses, starting from 25mg (1 capsule) and titrated to 50mg (2 capsules) or 75mg (3 capsules), based on brief pain inventory (BPI) questionnaire, applied weekly for 3 consecutive weeks. All patients will receive tramadol as a supportive drug for the treatment of neuropathic pain, they are instructed to take 50mg every 8 hours, if pain present.
2889435|NCT03324035|Placebo Comparator|Placebo|Patients on this arm will receive placebo on flexible doses, starting from 1 capsule and titrated to 2 capsules or 3 capsules, based on brief pain inventory (BPI) questionnaire, applied weekly for 3 consecutive weeks. All patients will receive tramadol as a supportive drug for the treatment of neuropathic pain, they are instructed to take 50mg every 8 hours, if pain present.
2889436|NCT03324009|Experimental|2-stage screen|All patients will be enrolled in the two-stage cervical cancer screening protocol
2889437|NCT03323996||Health Professionals|Health Professionals attending a training in therapeutic education
2889438|NCT03323996||Patients|Patients of the health Professionals recruited for the study
2889439|NCT03323983||Normal lung clearance index|
2889440|NCT03323983||Elevated lung clearance index|
2889441|NCT03323970||Physicians|
2889442|NCT03323957||Patients|all infants admitted for care
2889443|NCT03323944|Experimental|Cohort 1: huCART-meso cells only|Subjects will receive a single dose of 1-3x10^7/m^2 lentiviral transduced huCART-meso cells without any conditioning chemotherapeutic regimen.
2889444|NCT03323944|Experimental|Cohort 2: huCART-meso cells only|Subjects will receive a single dose of 1-3x10^8/m^2 lentiviral transduced huCART-meso cells without any conditioning chemotherapeutic regimen.
2889445|NCT03323944|Experimental|Cohort 3: huCART-meso cells after chemo|Subjects will receive a single dose of 1-3x10^8/m^2 lentiviral transduced huCART-meso cells following a flat dose of 1 gram/m^2 cyclophosphamide as lymphodepleting chemotherapy.
2889446|NCT03323931|Active Comparator|(1) standard therapy|Standard therapy based on Applied Behavioral Analysis (ABA) and Cognitive-Behavior-Therapy (CBT). It implies structured activities in which the therapist reinforces the adaptive behavior of the child.
2889447|NCT03323931|Experimental|(2) robot--enhanced intervention|A treatment developed on the same principles as standard therapy, based on Applied Behavioral Analysis (ABA) and Cognitive-Behavior-Therapy (CBT). It implies structured activities in which the robotic agent reinforces the adaptive behaviors of the child, under the supervision of the therapist.
2889448|NCT03323918|Experimental|ImPACT|Project ImPACT will be provided in 18 weekly intervention sessions, during which parents will learn how to stimulate their children's social imitation, social engagement, language and play skills. First, parents are taught techniques that promote interaction with the child (one technique per session, through demonstration and coaching). In the second half of the intervention, parents are taught direct teaching techniques, e.g., to promote language or play, again by means of demonstration and coaching. After completion of the program, families will receive guidance every 2-3 weeks for an additional 12 weeks, during which the support will generally not focus on social-communicative abilities, although ImPACT follow-up sessions might be given if necessary.
2889449|NCT03323918|Active Comparator|TAU|Treatment as usual (TAU) will be provided at the typical frequency, which is every 2-3 weeks. TAU can include targeting eating and sleeping problems, adaptive skills, or other goals. TAU will not include forms of intervention explicitly targeting social communicative skills. However, limited guidance on social communication development can be given if explicitly asked by parents.
2889450|NCT03323905|Experimental|MR Guided High Intensity Focused Ultrasound|
2889713|NCT03321968|Experimental|Lot 2|Quadrivalent VLP Influenza Vaccine
2889451|NCT03323892|Active Comparator|'normal' abstinence duration|Patients follow the normal abstinence duration as asked by the physician (2-7 days). This sperm will be used to inject half of the oocytes Intervention = second sperm sample
2889452|NCT03323892|Experimental|short abstinence duration|"Patients will be asked to produce a second sperm sample, 2 hours after the first. This sperm will be used to inject the other half of the oocytes.~Intervention = second sperm sample"
2889453|NCT03323879|Experimental|LDR/HDR|MRI planned LDR boost to DIL with concurrent whole gland 19 Gy HDR. LDR dose will be sequentially escalated from 50 Gy to 80 Gy
2889454|NCT03323866|Active Comparator|Mometasone nasal spray|Mometasone nasal spray 50 mcg/dose, 2 sprays/nostril twice daily x 3 months Patients will also be taking Sinus Rinse once daily throughout the study period
2889455|NCT03323866|Experimental|Budesonide irrigation|2 cc budesonide nebule (0,5 mg/cc) incorporated to 240 of saline water (Sinus Rinse) to be taken on a daily basis x 3 months
2889456|NCT03323853|Experimental|CARS Report|
2889457|NCT03323853|No Intervention|No CARS report|
2889458|NCT03323840|Experimental|Incentivized Care|Patients will meet with the pharmacist up to 2 times/month for blood pressure measurement. Patients will receive a $10 gift card for each measurement.
2889459|NCT03323827||Aim 2a|"Specific Aim 2. To determine how the cytosolic and mitochondrial protein acetylomes are regulated by muscle contraction in insulin sensitive and resistant human volunteers.~Protocol 2a. Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) nondiabetics 20 subjects will be enrolled"
2889460|NCT03323827||Aim 2b|"Specific Aim 2. To determine how the cytosolic and mitochondrial protein acetylomes are regulated by muscle contraction in insulin sensitive and resistant human volunteers.~Protocol 2b (muscle contraction and acetylation) Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) 32 subjects will be enrolled"
2889461|NCT03323827||Aim 3|"Specific Aim 3. To determine how acetylation of the mitochondrial inner membrane adenine nucleotide translocase ANT1 regulates protein structure and function.~Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) 20 subjects will be enrolled."
2889462|NCT03323814||short-sleepers|subset of participants will be recruited who report less than typical work/ weekday sleep in order to examine whether enhancing sleep with stimulation will reduce the amount of extra sleep subjects usually get on the weekends.
2889463|NCT03323814||shift-workers|An additional subset of participants will be recruited who work evening shifts to see if enhanced sleep can counteract some of the effects of schedule shifting.
2889464|NCT03323814||normal-sleepers|The first cohort will be used to optimize the the type and duration of sensory stimuli that will optimally enhance slow-waves.
2889465|NCT03323801|Experimental|13-cis retinoic acid|20 mg 13-cis retinoic acid twice daily (BID) with means for 32 weeks
2889466|NCT03323788||Aim 1|Aim 1. To determine whether the transcription factor expression response to exercise is dysregulated in muscle from type 2 diabetic patients. We will test the hypothesis that MZF1, NFKB1, RELA, SP1/KLF and EGR1 responses to an acute exercise bout are reduced in insulin resistant patients with type 2 diabetes.
2889467|NCT03323788||Aim 2|"Aim 2. To determine how insulin resistance changes the response of post-translational modifications of SP1/KLF family and MZF1 transcription factors to acute exercise in muscle from type 2 diabetic patients. We will test the hypothesis that:~SP1/KLF2, 4, and 6 and phosphorylation/acetylation and MZF1 phosphorylation is altered in response to acute exercise.~The response of SP1/KLF2, 4, and 6 phosphorylation and acetylation and MZF1 phosphorylation to acute exercise is abnormal in patients with type 2 diabetes."
2889468|NCT03323788||Aim 3|"Aim 3. To define the response of miRNAs to acute exercise in healthy and insulin resistant muscle from obese and type 2 diabetic patients. We will test the hypotheses that:~The exercise-induced increases in expression of miR-378 members and miR-128 are lower in obese and type 2 diabetic muscle than in lean healthy controls.~FOXO1 expression, a target of miR-378 and miR-128, is higher in obese and type 2 diabetic muscle and this is accompanied by decreased FOXO1 phosphorylation.~The exercise-induced increases in expression of miR-30 family members, miR-10a, miR-422a, and miR-532 are lower in obese and type 2 diabetic muscle.~There are novel miRNAs that regulate the transcriptional program induced by acute exercise and are dysregulated in insulin resistance."
2889469|NCT03323788||Aim 4|Aim 4. To determine whether treatment with PPAR-Alpha agonist fibrate derivatives suppresses the normal gene expression response to acute exercise. We will test the hypothesis that Gemfibrozil treatment inhibits the normal transcriptional response to exercise.
2889470|NCT03323762|Experimental|RIC|"RIC treatment arm The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflated to 200 mmHg for 5 minutes followed by 5 minutes of deflation. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes.~The treatment will be carried out on the morning of day 2 to day 7 by the participants themselves at their home."
2889471|NCT03323749|Experimental|Part 1: Elamipretide|Subjects will be randomized to receive either elamipretide or placebo for 24 weeks. For the elamipretide arm, subjects will administer daily 40 mg (0.5mL) subcutaneous injections of elamipretide.
2889472|NCT03323749|Placebo Comparator|Part 1: Placebo|Subjects will be randomized to receive either elamipretide or placebo for 24 weeks. For the placebo arm, subjects will administer daily 40 mg (0.5 mL) subcutaneous injections of placebo for 24 weeks.
2889473|NCT03323749|Experimental|Part 2: Elamipretide open label|Once subjects complete part 1, and meet continuation criteria, they will have the option to continue into an open-label treatment extension. Subjects will receive 40 mg (0.5 mL) subcutaneous injections of elamipretide for up to 144 weeks.
2889474|NCT03323723|Other|RS-2 SUI Device|Comparing use of device to non-treatment phase
2889475|NCT03323710|Experimental|Propranolol plus Sunitinib|
2889476|NCT03323697|Experimental|Herbal|SZ-05 (2.5 gr; 3 capsules twice a day)
2889477|NCT03323697|Active Comparator|Selective serotonin reuptake inhibitor|Escitalopram (10 mg capsule plus 5 placebo capsules)
2889478|NCT03323684|Experimental|Quadratus lumborum block Group (QL)|Quadratus lumborum block will be performed
2889479|NCT03323684|Experimental|Transversus abdominis plane Group (TAP)|Subcostal transversus abdominis plane will be performed
2889480|NCT03323684|Experimental|Control group (C)|Postoperative analgesia will be accomplished with conjunction of paracetamol and ketorolac
2889714|NCT03321968|Experimental|Lot 3|Quadrivalent VLP Influenza Vaccine
2889481|NCT03323671|Experimental|premenstruation group|preemptive mefenamic acid 500mg tablets every 8 hours starting 2 days before anticipated menstruation and during the first 2 days of the cycle
2889482|NCT03323671|Experimental|menstruation group|mefenamic acid 500mg tablets every 8 hours during the first 2 days of the cycle
2889483|NCT03323658|Experimental|Prevention (bexarotene)|Group 1 will apply 10mg bexarotene topically to one breast QOD for 4 weeks; Group 2 will apply 10mg bexarotene topically to one breast QOD for 1 week and then daily for 3 weeks after confirmation that toxicity is at an acceptable range; Group 3 will apply 10mg bexarotene topically to one breast QOD for 1 week, then daily for 1 week, and then 20mg daily for 2 weeks after confirmation that toxicity is at an acceptable range.
2889484|NCT03323645||Patients with penile prostheses|
2889485|NCT03323632|Experimental|MyndMove|The MyndMove system is a neuromodulation device that delivers short electrical pulses to stimulate muscle contractions and enhance motor recovery following Stroke or Spinal Cord Injury. MyndMove delivers therapeutic stimulation sequences called protocols, which are coded therapeutic algorithms which assist muscle movement allowing the brain and central nervous system to be retrained restoring voluntary reaching and grasping functions lost following neurological injury. The MyndMove system comprises the hardware device, stimulation electrodes and cables, hand and foot switches, and integrated software.
2889486|NCT03323619||GA|No intervention. General anesthesia is decided by the physicien according to his usual practice
2889487|NCT03323619||LASed|No intervention. Local anesthesia with sedation is decided by the physicien according to his usual practice
2889488|NCT03323606|Active Comparator|Gambling Internet Intervention|The gambling only Internet intervention (G-only) will consist of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
2889489|NCT03323606|Experimental|Gambling Internet Intervention + CYD|The G+A intervention condition will consist of the G-only intervention and an online intervention for drinking. The online drinking intervention chosen is Check Your Drinking, a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
2889490|NCT03323593|Active Comparator|iv|
2889491|NCT03323593|Active Comparator|drip|
2889492|NCT03323593|Active Comparator|atomizer|
2889493|NCT03323580|Experimental|SVV-based GDFT group|The patients will receive fluid therapy under SVV-directed goal.
2889494|NCT03323580|Sham Comparator|non-SVV-based GDFT group|The patients will receive fluid therapy without SVV-directed goal.
2889495|NCT03323567|Experimental|MD Muscle Collagen group|Group with collagen intramuscular injections
2889496|NCT03323567|Experimental|Lidocaine 2% group|Group with 2% Lidocaine intramuscular injections
2889497|NCT03323567|Placebo Comparator|Saline|Group with 0,9% NaCl intramuscular injections
2889498|NCT03323554|Experimental|Ustrap®|Ustrap is a new adjustable-pressure 4-arm device
2889499|NCT03323554|Active Comparator|AMS 800®|Artificial sphincter currently considered the gold standard device in this field
2889500|NCT03323541||Group of patients treated with Zarxio|All consecutive patients, treated for lymphoma or myeloma, which underwent autologous stem cell transplantation in the University Hospital of Brest. All these patients were treated with biosimilars of Filgrastim: Zarzio®.
2889501|NCT03323528|Active Comparator|Dorithricin|"Dorithricin throat lozenges is a fixed combination of three active substances: Benzalkonium Chloride-Benzocaine Topical plus tyrothricin. Lozenge has to be sucked slowly until it fully dissolves in the mouth and dosed up to 8 lozenges per day. Test product without mint oil.~Intervention: The initial dose is administered at the study site. Patients administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
2889502|NCT03323528|Placebo Comparator|Placebo|"Placebo Oral Tablet is taken orally. Placebo consists of a lozenge with matched appearance and the same excipients as those of the Dorithricin lozenge. The initial dose (2 lozenges simultaneously) is administered at the study site.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
2889503|NCT03323502|Experimental|ACP Specialist Program|The ACP Specialist will work with nursing home leaders to: i. Consolidate nursing home ACP procedures; ii. Train and educate staff; and iii. Facilitate ACP with patients who have Alzheimer's Disease/related dementias and their family caregivers.
2889504|NCT03323502|No Intervention|Usual Care|Facility will followed usual ACP procedures.
2889505|NCT03323489|Experimental|celiac radiosurgery, single fraction|Celiac Plexus Radiosurgery
2889506|NCT03323476|Experimental|Discontinuation of maintenance treatment|
2889507|NCT03323476|Active Comparator|Maintenance of immunosuppressive treatment|
2889508|NCT03323463|Experimental|HPV associated oropharyngeal carcinoma|HPV associated oropharyngeal carcinoma subjects who also have no evidence of hypoxia
2889509|NCT03323450|Experimental|High grade gliomas(WHO grade III or IV; n=15)|The two groups will follow identical study timelines. Participants will receive a 1 hour training session on CogMed® (PI or trained graduate student). Participants will complete 5 weeks of CogMed® training within their own home. It consists of 25 training sessions. Each session lasts 30-45 minutes.The study team will check in with participants once a week via phone or email. Brief neuropsychological evaluations will be conducted at 4 time points. Each assessment will take approximately 30-60 minutes. Each participant will receive a $25 gift card to the VCU medical center gift shop at two time points.
2889510|NCT03323450|Experimental|Low grade gliomas(WHO grade II; n=15)|The two groups will follow identical study timelines. Participants will receive a 1 hour training session on CogMed® (PI or trained graduate student). Participants will complete 5 weeks of CogMed® training within their own home. It consists of 25 training sessions. Each session lasts 30-45 minutes.The study team will check in with participants once a week via phone or email. Brief neuropsychological evaluations will be conducted at 4 time points. Each assessment will take approximately 30-60 minutes. Each participant will receive a $25 gift card to the VCU medical center gift shop at two time points.
2889511|NCT03323437|Experimental|Patient|Medication-free individuals during first-episode of psychosis who will receive 4 weeks of treatment with risperidone
2889512|NCT03323437|No Intervention|Control|Healthy, psychosis-free controls who will not receive risperidone
2889513|NCT03323424|Experimental|Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)|Patients with metastatic breast, colorectal or head or neck cancers and corresponding with the inclusion criteria will receive a systemic treatment, according to the usual practice, but also a Stereotactic Body Radio-Therapy (SBRT).
2889514|NCT03323424|Active Comparator|Systemic treatment|Patients with metastatic breast, colorectal or head or neck cancers and corresponding with the inclusion criteria will receive a systemic treatment, according to the usual practice.
2889515|NCT03323411||Intervention and attention control|the Advance Care Treatment Plan experimental group received education on dementia cardiopulmonary resuscitation and tube feeding. The attention control group received education on exercise stress control diabetes and hypertension
2889516|NCT03323398|Experimental|mRNA-2416|
2889517|NCT03323385|Experimental|N1539 30 mg|N1539 (meloxicam injection for IV use) 30 mg every 24 hours
2889518|NCT03323385|Placebo Comparator|IV Placebo|IV Placebo every 24 hours
2889519|NCT03323372|Active Comparator|control group|In group 1 (G1-control), the operator applied a desensitizing gel based on 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2% ®, FGM , Joinville, Santa Catarina, Brazil) with the aid of a custom silicone tray, which was made from a model obtained from the patient, with a vacuum plasticizer. A small layer of the gel was placed on the surface of the tray that was in contact with the vestibular face of the upper anterior teeth of the participants. The tray remained in position in the mouth for 10 minutes, according to the manufacturer's specifications.
2889520|NCT03323372|Experimental|experimental group|In group 2 (G2-intervention group), the operator applied a desensitizing gel containing 3% potassium nitrate and 0.25% sodium fluoride (Ultra EZ®, Ultradent Products Inc, South Jordan, UT, Estados Unidos) with the help of a tray in which the material is stored on the vestibular surfaces of the upper anterior teeth of the participants. The tray remained in position in the mouth for 15 minutes, according to the manufacturer's specifications.
2889521|NCT03323359|Experimental|Hemopatch 45x90 mm - CE 0297 Class III|Hemopatch + Common surgical techniques
2889522|NCT03323359|Other|Standard Surgery Technique|Common surgical techniques
2889523|NCT03323346|Experimental|Disulfiram with copper|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed. Patients will take disulfiram after their evening meal.~Patients will avoid alcohol and other disulfiram-drug interactions will be considered.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
2889524|NCT03323333|Experimental|Intervention|
2889525|NCT03323307|Experimental|OCT imaging|OCT device images retina
2889526|NCT03323294||Healthy Lean|Healthy lean individuals (n=20) defined with a Body Mass Index (BMI) ≥ 5th percentile and <85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
2889527|NCT03323294||Healthy Obese|Healthy obese individuals (n=20) defined with a Body Mass Index (BMI) ≥ 95th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
2889528|NCT03323294||Obese Insulin Resistant|Obese insulin resistant individuals (n=70) as defined with a Body Mass Index (BMI) ≥ 95th percentile for age/sex and will be recruited. Participants will be asked to complete a total of 2 study visits. The second study visit will occur at 12 months (± 2 weeks) after the initial study visit.
2889529|NCT03323294||Type 2 Diabetes or Insulin Resistant with Metformin|Obese individuals with Type 2 Diabetes or insulin resistance (n=20) and who are prescribed metformin as part of their clinical care will be asked to complete an additional study visit to occur at 6 months (± 2 weeks) after beginning metformin therapy.
2889530|NCT03323281||Diabetic Type 1 or Type 2 with foot wound|Type 1 or type 2 diabetic patients with hospitalization for foot wounds having an interview with a neuropsychologist or a physician trained in neuropsychological assessments
2889531|NCT03323281||Diabetic Type 1 or Type 2 without a foot wound or antecedent|Type 1 or Type 2 diabetic patients with no foot wounds or history of foot wounds having an interview with a neuropsychologist or a physician trained in neuropsychological assessments
2889532|NCT03323255|Active Comparator|cTBS stimulation|continuous theta-burst TMS stimulation (1200 pulses, 50Hz, separated in two sequences of 600 pulses)
2889533|NCT03323255|Sham Comparator|SHAM stimulation (placebo)|SHAM stimulation
2889534|NCT03323242|No Intervention|Control group|Recipient hepatectomy using conventional bipolar coagulation devices, surgical suture ligatures, and surgical clips (or any dissecting / coagulating device other than LS)
2889535|NCT03323242|Experimental|LS group|Recipient hepatectomy applying LigaSure.
2889536|NCT03323242|Experimental|USD group|Recipient hepatectomy applying Harmonic Ultrasonic dissector.
2889537|NCT03323229|No Intervention|Usual care (control group)|Patient receives care as usual.
2889538|NCT03323229|Experimental|Enhanced communications & ultrasound|The paramedic will record a brief video summary of the patient's condition, then remotely supported point of care ultrasound scans will be performed, and both file types sent to the hospital for review and feedback from the consultant.
2889539|NCT03323216||No diabetes|Patients without diabetes
2889540|NCT03323216||Type 2 diabetes|Patients with diagnosis of type 2 diabetes (new/established)
2889541|NCT03323216||Prediabetes|Patients with an intermediate state of hyperglycemia with glycemic parameters above normal but below the diabetes threshold.
2889542|NCT03323190|Experimental|Inpatient COPD patient|All COPD patients meeting the inclusion criteria of this study will be exposed to inpatient COPD education and tested at a later date to determine if knowledge on COPD was gained.
2889543|NCT03323177|Experimental|Nutritional supplementation gender specific formula|Patients at this arm will continue to consume the study formula until final height. The formula is a gender specific powder added to water containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
2889544|NCT03323177|Other|Follow-up only|Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
2890002|NCT03319706|Experimental|Test|Torrent's Olmesartan Medoxomil Tablets 40 mg
2889548|NCT03323151|Experimental|Phase II: Ixazomib & Ibrutinib-Naive|Patients who are Ibrutinib-Naive will receive Ixazomib and Ibrutinib by mouth until progression or unacceptable toxicity.
2889549|NCT03323151|Experimental|Phase II: Ixazomib & Ibrutinib Pre-Treated|Patients previously treated with Ibrutinib will receive Ixazomib and Ibrutinib by mouth until progression or unacceptable toxicity.
2889550|NCT03323138|Experimental|Ex-PRESS and phacoemulsification|A treatment session of PACG coexisting cataract treated with phacoemulsification combined with P50 Ex-PRESS miniature glaucoma device (Alcon Laboratories, Fort Worth, Texas, USA).
2889551|NCT03323112||Influenza vaccine recipients|Health care workers vaccinated by their occupational health care according to the routine praxis.
2889552|NCT03323099|Experimental|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
2889553|NCT03323099|Placebo Comparator|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
2889554|NCT03323086|Experimental|Brief Intervention (BI) with Technology Extender|Participants assigned to BI condition will receive a face to face session lasting 45-60 minutes delivered by a health coach. Following the session, participants will be given access to a study website and receive texts-of-the day on study topics.
2889555|NCT03323086|Other|Brochure|Participants assigned to the Brochure condition will receive materials prepared by the CDC on the study topics.
2889556|NCT03323073|Active Comparator|Bipolar disorder type I or II|a single resting state fMR for patients with bipolar disorder type I or II with acute depressive state
2889557|NCT03323073|Active Comparator|Unipolar disorder|a single resting state fMR for patients with monopolar disorder with acute depressive state
2889558|NCT03323073|Other|Healthy volunteers|a single resting state fMRI for subjects without psychiatric disorders assessed by the SCID
2889559|NCT03323060||Male and/or females ≥ 22 yrs old|≥ 22 years of age requiring transanal procedures in the areas of the anus, rectum, and distal colon Transanal endoscopic surgical procedure
2889560|NCT03323047|Experimental|Group 1|Acetaminophen and High-dose dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia.
2889561|NCT03323047|Active Comparator|Group 2|Acetaminophen and Low-dose Dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
2889562|NCT03323047|Placebo Comparator|Group 3|Placebo oral tablet and Low-dose Dexamethasone: an oral placebo given 1 hr pre-operatively and intravenous administration of low dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia.
2889563|NCT03323034|Experimental|Treatment (pevonedistat, temozolomide, irinotecan)|Patients receive pevonedistat IV over 60 minutes on days 1, 8, 10, and 12, temozolomide PO daily on days 8-12, and irinotecan hydrochloride IV over 90 minutes on days 8-12 of course 1. Beginning at course 2, patients receive pevonedistat IV over 60 minutes on days 1, 3, and 5, temozolomide PO daily on days 1-5, and irinotecan hydrochloride IV over 90 minutes on days 1-5. Treatment repeats every 28 days for course 1 and 21 days for subsequent courses for up to 17 courses in the absence of disease progression or unacceptable toxicity.
2889564|NCT03323021|Experimental|Treatment with DHACM|Partial nephrectomy patched with DHACM
2889565|NCT03323021|Active Comparator|Control without DHACM|Partial nephrectomy without DHACM.
2889566|NCT03323008|Experimental|Training Prototype|Testing of 3 modules
2889567|NCT03322995|Experimental|Restaging: Response to Treatment|After the first restaging evaluation, further treatment will be based on treatment response. Patients who demonstrate a response ([decline in CA19-9 values] and radiographic response, along with preserved performance status) will be maintained on the first line chemotherapy for an additional two months.
2889568|NCT03322995|Experimental|Restaging: Patients with Stable Disease|Patients who do not have a significant decline in CA19-9 values will be changed to a second-line therapy for an additional two months.
2889569|NCT03322995|Experimental|Restaging: Local Disease Progression|After the first restaging evaluation, further treatment will be based on treatment response. If, at the initial restaging, the patient has local disease progression amenable to surgical resection, he or she will receive chemoradiation, rather than continued chemotherapy, so the window of opportunity for surgical resection is not lost.
2889570|NCT03322982|Experimental|MS Diet|34 people with MS following low-fat diet
2889571|NCT03322982|No Intervention|MS Wait-List|34 people with MS following usual diet
2889572|NCT03322982|No Intervention|Diet Healthy Control|20 controls with no diagnosis of MS, age and sex-matched to members of the MS Diet group
2889573|NCT03322982|No Intervention|Wait-List Healthy Control|20 controls with no diagnosis of MS, age and sex-matched to members of the MS Wait-List group
2889574|NCT03322969|Experimental|receiving modified chemotherapy|Paclitaxel/DDP
2889575|NCT03322969|Active Comparator|receiving the original chemotherapy|XELOX/SOX
2889576|NCT03322956|Experimental|experimental group (EGR)|"Physical therapy intervention.~In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises)."
2889577|NCT03322956|Sham Comparator|Sham group (SGR)|"Physical therapy intervention.~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze and Evidence Based Practice Therapy. The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
2889578|NCT03322930||RP|patients with a diagnosis of retinitis pigmentosa
2889579|NCT03322930||AMD|patients with a diagnosis of intermediate AMD
2889580|NCT03322891|Experimental|Educational Supplement|Participants diagnosed with prostate cancer will receive education for treatment options and treatment side effects.
2889716|NCT03321942|Active Comparator|Treatment group|Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure.
2889581|NCT03322878|Experimental|Intravenous magnesium group (Group IV)|Group IV (n=30) will receive intravenous (IV) 20 ml magnesium SO4 (50 mg/ kg 10% MgSO4(magnesium sulphate) diluted in normal saline to a total volume of 20 ml(milliliter) ) and caudal anaesthesia using (bupivacaine 0.25% diluted in normal saline with total volume of 1 mL/kg) .
2889582|NCT03322878|Active Comparator|Caudal magnesium group (Group CA)|Group CA (n=30) will receive IV 20 ml normal saline and caudal anaesthesia using (bupivacaine 0.25% and 50 mg Magnesium SO4 diluted in normal saline with total volume of 1mL/kg).
2889583|NCT03322878|Placebo Comparator|Placebo group (Group P)|Group P (n=30) ) will receive IV 20 ml normal saline and caudal anaesthesia using (bupivacaine 0.25% diluted in normal saline with total volume of 1 mL/kg).
2889584|NCT03322865|Experimental|One Arm|Obinutuzumab i.v.
2889585|NCT03322839|Experimental|Multifaceted implementation strategies|The school-management will participate in a one-day training. In addition each intervention school will form an implementation team that is responsible for the implementation of the guideline within their school. The implementation teams will participate in 4-5 workshops in order to support the implementation process.
2889586|NCT03322839|Active Comparator|Single implementation strategy|The control-schools will only receive training to the school-management.
2889587|NCT03322826|Active Comparator|Lymphadenectomy|systematically Lymphadenectomy of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side
2889588|NCT03322826|Experimental|systematic sampling of the lymph nodes|systematic sampling of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side
2889589|NCT03322813|Experimental|ExAblate 4000 - Type 2|ExAblate BBBD
2889590|NCT03322800|Experimental|AK0529 100 mg, Pilot|This is an open pilot arm and male subjects enrolled into this arm will be only administered with an oral single dose of 100 mg AK0529. The dose group begins treatment on Day 1.
2889591|NCT03322800|Experimental|AK0529 100 mg|Subjects will be administered with an oral single dose of 100 mg AK0529 or placebo. The dose group begins treatment on Day 1.
2889592|NCT03322800|Experimental|AK0529 300 mg, food effect|A 3x3 cross-over study is designed in this group to evaluate the food effect following a standard Chinese meal or a high fat meal in the same subjects, comparing with the PK profile of AK0529 under fasted condition. Subjects will be administered with an oral dose of 300 mg AK0529 or placebo on Day 1 of each cycle.
2889593|NCT03322800|Experimental|AK0529 600 mg|Subjects will be administered with an oral single dose of 600 mg AK0529 or placebo. The dose group begins treatment on Day 1.
2889594|NCT03322800|Experimental|AK0529 300 mg, MAD|Subjects will be administered with the multiple doses of 300 mg AK0529 or placebo on Day 1-7.
2889595|NCT03322800|Other|Placebo|For assessment of the Adverse Event (AE) profile, there are placebo controls in each dose group (except the pilot group). The placebo is administered at the same time (and of the same dosage) as the AK0529 subjects.
2889596|NCT03322787|No Intervention|Oxygen|The training will be performed using oxygen by the Venturi mask with the FiO2 set during the run - in session.
2889597|NCT03322787|Experimental|HFO|The training will be performed using the HFO device during the run - in session at iso_FiO2 as in the Control Group (Oxygen by Venturi mask).
2889598|NCT03322774|Sham Comparator|Attention Control|This group receives sleep hygiene education, which serves as a credible control intervention to digital cognitive behavioral therapy for insomnia (dCBT-I). This intervention mimics the web-based patient contact inherent in dCBT-I but is inert with respect to sleep outcomes.
2889599|NCT03322774|Experimental|Stepped Care Model|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Following initial treatment with dCBT-I, individuals who do not experience remission of their insomnia will begin treatment with face-to-face Cognitive Behavioral Therapy for Insomnia with a trained staff member in behavioral sleep medicine."
2889600|NCT03322774|Sham Comparator|Stepped Care Model Control|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Following initial treatment with dCBT-I, individuals who do not experience remission of their insomnia will receive sleep hygiene education, serving as a credible control intervention for comparison to the Stepped Care Model."
2889601|NCT03322774|Experimental|digital CBT-I|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Treatment includes weekly sessions of CBT-I administered over the internet in hour-long video sessions. Daily sleep diaries are recorded online for individual tailoring of treatment."
2889602|NCT03322761|Experimental|Systematic exercise training|Two weekly supervised aerobic exercise trainings for 48 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
2889603|NCT03322761|Active Comparator|Educational program|Educational program on physical activity and health, consisting of four educational sessions in the intervention period.
2889604|NCT03322761|No Intervention|Standard treatment alone|Data from The Danish MS Registry will serve as control-data for standard treatment alone.
2889605|NCT03322748|Experimental|Experimental group|Usual physical therapy+ strengthening of lower limbs muscles
2889606|NCT03322748|Other|Control group|Usual physical therapy
2889607|NCT03322735|Experimental|anti-tumor response of BCMA CAR-T|"Drug: Cyclophosphamide patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days.~Drug: Fludarabine Fludarabine 25-30mg/m2/day IV for 3 days. Biological: BCMA CAR-T BCMA CAR-T cells will be administered after completion of the chemotherapy."
2889608|NCT03322709||Robotic-assisted kidney transplant|Adult patients undergoing robotic kidney transplantation. The transplant operation will be undertaken using the da Vinci systems robot in minimally invasive fashion.
2889609|NCT03322709||Open kidney transplant|Adult patients undergoing kidney transplantation via an open approach.
2889610|NCT03322709||Donor nephrectomy|Adult patients undergoing donor nephrectomy will have a scan of their abdominal wound to compare wound healing.
2889611|NCT03322696||Cirr-PVT|Cirrhotic patients developing over 1 yr period thrombosis of portal vein or collaterals
2889612|NCT03322683|Experimental|EXPERIMENTAL GROUP|The intervention for this group consisted of 5 massage sessions with the PHYSIUM device for a month.
2889613|NCT03322683|Experimental|CONTROL GROUP|"The multimodal physical therapy program includes 10 sessions of:~ultrasound pulsatil therapy (US) for 10 minutes.~transcutaneous electric nerve stimulation (TENS) for 20 minutes.~massage for 20 minutes."
2889614|NCT03322670||Signs of CAP and a positive chest X-Ray|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and a chest X-Ray not compatible with CAP
2889615|NCT03322670||Patients directly hospitalized|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and who are directly hospitalized before complementary examinations
2889616|NCT03322670||Control patients|Healthy Patients (age-matched with a radiologically confirmed CAP patient)
2889617|NCT03322670||Patients with partial participation|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and who can not or do not want to perform all the complementary examinations of the study
2889618|NCT03322670||Signs of CAP and a negative Chest X-Ray|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and a chest X-Ray not compatible with CAP
2889619|NCT03322657|Active Comparator|Neostigmine with glycopyrrolate|Neostigmine 0. 07 mg/kg with glycopyrrolate 0.01 mg/kg with ceiling dose of 5 mg neostigmine with 1 mg of glycopyrrolate at the end surgery
2889620|NCT03322657|Experimental|Sugammadex|Sugammadex 4 mg/kg at the end surgery
2889621|NCT03322644|Experimental|Internet-based CBT intervention|In addition to standard medical care, participants in the Internet-based CBT group will receive access to the Pancreatitis Pain Course and will be asked to complete all online modules over 2 months using their own smartphone or computer. A coach will guide participants through the weekly lessons.
2889622|NCT03322644|No Intervention|Wait list control group|Participants assigned to the Wait list control group will be asked to continue with any recommendations made by their clinic provider and will not be offered any internet-based content until after they complete the 5 month assessments (i.e. Months 5-7).
2889623|NCT03322631|Experimental|LY3298176|LY3298176 administered subcutaneously (SC).
2889624|NCT03322631|Placebo Comparator|Placebo|Placebo administered SC.
2889625|NCT03322618|Experimental|SpA HLA-B27 +,|
2889626|NCT03322618|Experimental|SpA HLA-B27-|
2889627|NCT03322618|Active Comparator|healthy subject|
2889628|NCT03322592|Active Comparator|EUS-FNB with ROSE|Intervention: Rapid on-site evaluation (ROSE) In the EUS-FNB with ROSE arm, the material obtained with the first pass will be processed for ROSE using the touch imprint technique. The biopsy specimen is carefully pressed onto the slide, allowing the superficial cells to adhere, and then gently lifted with forceps thereby creating a touch imprint of the specimen on the slide. In case of inadequate sample, a second pass will be done and the touch imprint technique will be repeated up to a maximum of 3 passes. In case of adequate ROSE at the first or the second pass, the additional passes will be performed as EUS-FNB and the material obtained placed directly into formalin or other fixative for subsequent histopathological evaluation.
2889629|NCT03322592|Active Comparator|EUS-FNB without ROSE|Intervention: histologic evaluation In the FNB alone arm, 3 needle passes will be performed and the samples obtained will be placed directly in a vial containing formalin (or other fixative according to the local individual protocol). Macroscopic on-site evaluation (MOSE) of acquired sample will be then performed by the endoscopist.
2889630|NCT03322579|Experimental|Patients with Eustachian tube dysfunction|
2889631|NCT03322566|Experimental|Arm 1|Epacadostat + pembrolizumab + platinum-based chemotherapy
2889632|NCT03322566|Active Comparator|Arm 2|Placebo + pembrolizumab + platinum-based chemotherapy
2889633|NCT03322553|Experimental|Plication group|In patients allocated to endoscopic plication, endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of GE junction around the GERD-X device
2889634|NCT03322553|Sham Comparator|Sham Group|In sham procedure, identical technique will be followed by positioning the plicator inside the stomach but sutures will not be applied.
2889635|NCT03322540|Experimental|Treatment 1|Pembrolizumab + epacadostat
2889636|NCT03322540|Active Comparator|Treatment 2|Pembrolizumab + matching placebo
2889637|NCT03322514|Experimental|experimental group|10 g of Inulin-Propionate Esters will be administered per day
2889638|NCT03322514|Active Comparator|Inulin|10 g of Inulin will be administered per day
2889639|NCT03322501|Experimental|Intervention|The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
2889640|NCT03322488|Experimental|Patients with Crohn's Disease|20 patients with Crohn's Disease. Intervention: Fistulodesis
2889641|NCT03322488|Experimental|Patients without IBD|20 patients without underlying Inflammatory Bowel Disease. Intervention: Fistulodesis
2889642|NCT03322475|Experimental|Facial skin rejuvenation|Facial skin rejuvenation using PiQo4 laser system
2889643|NCT03322462|Experimental|Subjects with Early Symptomatic AD|Patients who receive 18F-AV-1451 dose after being successfully screened and are interested in participating in AD therapeutic clinical trials (and are not known to meet any exclusion criteria for those AD therapeutic clinical trials).
2889644|NCT03322449|Experimental|Animal Diet|during this Arm, the participants will receive a diet enriched in animal products
2889645|NCT03322449|Experimental|Plant Diet|during this Arm, the participants will receive a diet enriched in plant products
2889646|NCT03322436||AMI patients developping Heart Failure|
2889647|NCT03322423|Active Comparator|Test 1 Multifocal/Test 2 Multifocal OR Test 2 Alternative|Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 1 Multifocal then Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power), for approximately 8-12 days of wear with an approximately 4-8 day washout period.
2889715|NCT03321955|Experimental|Subjects with Painful Neuropathy|All subjects will be implanted with the Medtronic Synchromed II pump, and treated with the same algorithm for dose adjustment for painful neuropathy with Ziconotide 100 micrograms/ml.
2889648|NCT03322423|Active Comparator|Test 2 Multifocal OR Test 2 Alternative/Test 1 Multifocal|Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power) then Test 1 Multifocal, for approximately 8-12 days of wear with an approximately 4-8 day washout period.
2889649|NCT03322410|Experimental|Patients|
2889650|NCT03322397|Experimental|Kindness to Others|Participants will complete the 'Other-Focused Acts of Kindness Intervention' by performing acts of kindness for others. They be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
2889651|NCT03322397|Active Comparator|Kindness to Self|Participants will complete the 'Self-Focused Acts of Kindness Intervention' by performing acts of kindness for themselves. They be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
2889652|NCT03322397|Sham Comparator|Daily Report|Participants will complete the 'Daily Reports' and be asked to report their daily activities throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will list activities from their day.
2889653|NCT03322384|Experimental|Experimental|All patients will begin epacadostat on day 1 of radiotherapy, which will consist of three threatments over one week. Epacadostat will continue until disease progression or intolerance occurs. On days 1, 8, 15, 22, 29, intralesional injectinons of SD101 will be given to patients.
2889654|NCT03322371|Other|Health Subjects in Sleep Lab|Adult patients (> 18yrs old) scheduled for a standard of care PSG (sleep study) lasting at least 8 hours for any condition. Patients will undergo simultaneous 2-lead limited EEG recording with experimental device.
2889655|NCT03322371|Other|ICU patients, not sedated or ventilated|Adult ICU patients (> 18yrs old) anticipated to stay in the ICU overnight (minimum 8 hours) with a Glasgow Coma Scale of 13 or greater, not intubated and not sedated. Patients will undergo simultaneous 2-lead limited EEG recording with experimental device.
2889656|NCT03322371|Other|ICU patients, sedated and ventilated|Adult ICU patients (> 18yrs old) who are intubated, sedated, ventilated, and anticipated to stay in the ICU overnight (minimum 8 hours). Patients will undergo simultaneous 2-lead limited EEG recording with experimental device.
2889657|NCT03322358|No Intervention|Control|No changes to normal sleep habits.
2889658|NCT03322358|Experimental|Naps only|"After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days."
2889659|NCT03322358|Experimental|Home sleep aids only|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.
2889660|NCT03322358|Experimental|Home sleep aids + Sleep incentives|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful. In addition, they will be given a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.
2889661|NCT03322358|Experimental|Naps + Home sleep aids|"After a baseline period, participants in this condition will be provided with: 1) the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days, 2) a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful."
2889662|NCT03322358|Experimental|Naps + Home sleep aids + Sleep incentives|"After a baseline period, participants in this condition will be provided with: 1) the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days, 2) a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish, and 3) a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period. The sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful."
2889663|NCT03322345||Dopamine Added|Patients with protein losing enteropathy (PLE) that have an exacerbation such that their treating physicians decide to add continuous dopamine infusion to their current therapies.
2889664|NCT03322345||No dopamine added (control)|Patients with protein losing enteropathy (PLE) that have an exacerbation such that their treating physicians decide to add new therapies to their current therapies but that do not require the addition of continuous dopamine infusion.
2889665|NCT03322332||NonDM-0|Nondiabetics without significant stenoses (> 50%) in the coronary arteries
2889666|NCT03322332||NonDM-L|Nondiabetics with significant stenosis in the left anterior descending (LAD) coronary artery or in the Left main (LM) coronary artery, but without significant stenosis in the right coronary artery (RCA)
2889667|NCT03322332||NonDM-R|Nondiabetics without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA
2889668|NCT03322332||NonDM-LR|Nondiabetics with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA
2889669|NCT03322332||DM-0|Patients with type 2 diabetes mellitus (T2DM) without significant stenoses in the coronary arteries
2889670|NCT03322332||DM-L|T2DM patients with significant stenosis in the LAD or in the LM, but without significant stenosis in RCA
2889671|NCT03322332||DM-R|T2DM patients without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA
2889672|NCT03322332||DM-LR|T2DM patients with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA
2889673|NCT03322319|Experimental|left Ventricular Hypertrophy|Patients with left ventricular wall thickness measuring 15mm or more, or patients with a suggestive left ventricular echogenicity. Procedure/surgery will be performed following a diagnostic tree.
2889802|NCT03321227|Experimental|Egg whites|2 egg whites as a snack
2889674|NCT03322293|Active Comparator|A. Conventional arm|"This is considered the standard of care arm for photodynamic therapy for the treatment of actinic keratosis. This treatment arm includes: Acetone preparation, ALA topical application, 1 hour incubation, 16 minutes 40 seconds (16:40) BLU-U exposure, application of sunscreen.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: BLU-U blue light phototherapy illuminator"
2889675|NCT03322293|Experimental|B. Combination arm|"This treatment arm combines standard of care BLU-U exposure and daylight exposure. This treatment arm includes: Acetone preparation, ALA topical application, 15 minute incubation, 16:40 BLU-U exposure, application of sunscreen, 45 minute daylight exposure.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: BLU-U blue light phototherapy illuminator"
2889676|NCT03322293|Experimental|C. Daylight arm|"This is the experimental arm. This treatment arm includes: Acetone preparation, ALA topical application, 15 minute incubation, application of sunscreen, 1 hour daylight exposure.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: none"
2889677|NCT03322280|Experimental|TACE+I-125 seeds|TACE combined with iodine-125 seeds implantation
2889678|NCT03322280|Active Comparator|TACE alone|TACE alone
2889679|NCT03322267|Experimental|Pembrolizumab|Adjuvant cisplatin-chemoradiotherapy followed by pembrolizumab
2889680|NCT03322228|Experimental|Music Therapy|1 music therapy session, lasting approximately 45 min-1 hr
2889681|NCT03322215|Experimental|Palbociclib and fulvestrant|"Combination of palbociclib and fulvestrant~Palbociclib:~125 mg capsule administered orally once daily for 21 consecutive days followed by 7 days off treatment. Dose modification is recommended based on individual safety and tolerability.~Fulvestrant:~500 mg administered intramuscularly on days 1 and 15 of cycle 1, and then on day 1 of each subsequent 28-day cycle."
2889682|NCT03322215|Active Comparator|Capecitabine|1,000 mg/m2 tablet administered orally twice daily for 2 weeks followed by one week of rest. Depending on adverse reactions, both dose escalation and dose reductions will be performed.
2889683|NCT03322202|Experimental|Motivational Interviewing|Physical and Occupational Therapists will have 16 hours of training in Motivational Interviewing and use these techniques during sessions with patients.
2889684|NCT03322202|No Intervention|Control|Therapists will not participate in additional training.
2889685|NCT03322150|Active Comparator|Atropine group|Patients that receive atropine 0.01 mg/kg (max 0.5mg) before spinal anesthesia
2889686|NCT03322150|Active Comparator|Glycopyrrolate group|Patients that receive glycopyrrolate 0.004mg/kg (max 0.2 mg) before spinal anesthesia
2889687|NCT03322137|Active Comparator|SNA-120 (0.05% )|Pegcantratinib Ointment
2889688|NCT03322137|Active Comparator|SNA-120 (0.5%)|Pegcantratinib Ointment
2889689|NCT03322137|Placebo Comparator|Vehicle|
2889690|NCT03322124|Experimental|Octenidine Mouthwash|0.1% Octenidinedihydrochlorid Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
2889691|NCT03322124|Placebo Comparator|Placebo|Placebo Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
2889692|NCT03322111|Experimental|Cyclofusion|
2889693|NCT03322098|Active Comparator|Atropine group|Patients that receive atropine 0.01 mg/kg (max 0.5mg) before spinal anesthesia
2889694|NCT03322098|Active Comparator|Glycopyrrolate group|Patients that receive glycopyrrolate 0.004mg/kg (max 0.2 mg) before spinal anesthesia
2889695|NCT03322085|Experimental|paroxysmal AF with radiofrequency ablation|radiofrequency catheter ablation therapy
2889696|NCT03322085|Experimental|persistent AF with radiofrequency ablation group|radiofrequency catheter ablation therapy
2889697|NCT03322085|Experimental|paroxysmal AF with cryoballoon group|cryoballoon ablation therapy
2889698|NCT03322072|Experimental|Real-Time Position Transponder Beacons|Patients in this arm will each be receiving 3 implanted real-time position transponder beacons (Calypso beacons)
2889699|NCT03322059|Active Comparator|Control|"The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.~Participants will receive a weekly email with a step goal that will increase 10% beyond the previous weeks values."
2889700|NCT03322059|Experimental|Intervention|"The core intervention will include educational materials, access to a basic smartphone app and a Fitbit. Participants will receive a weekly email with a step goal that will increase 10% beyond the previous weeks values.~Participants will be in the form of a charitable donation in their name to a cancer charity."
2889701|NCT03322046||Therapeutic Lifestyle Change (TLC) Intervention Group|TLC group received CVD risk lecture, enrolled in lifestyle program, received follow-up visits from team practitioner after each blood draw, access to food journaling portal for 12 month period, telephonic coaching
2889702|NCT03322046||Control Group|Control group received CVD risk lecture, then baseline, 3, 6, 12 month blood draws and 3 day food journals prior to each blood draw.
2889703|NCT03322033|Experimental|Type A Dissection|High risk subjects with ascending thoracic aortic pathologies including type A aortic dissection who are suitable for endovascular repair
2889704|NCT03322020|Experimental|CK 18 Gy|Patients who receive Cyberknife boost dose of 18 Gy in 3 fractions
2889705|NCT03322020|Experimental|CK 21 Gy|Patients who receive Cyberknife boost dose of 21 Gy in 3 fractions
2889706|NCT03322007|Experimental|Open label treatment|Usual FDA-cleared pain management with Scrambler Therapy
2889707|NCT03321994|Experimental|Stereotaxic unit, navigation|
2889708|NCT03321994|Active Comparator|Conventional biopsy technique|
2889709|NCT03321981|Experimental|Cohort 1 doublet|two step evaluation with safety review after 4-6 patients receiving combination of MCLA-128, 750mg 2hour intravenous infusion in combination with trastuzumab, 8mg/kg first cycle, 6mg/kg other cycles, 90minute intravenous infusion; once per cycle of 21 days.
2889710|NCT03321981|Experimental|Cohort 1 triplet|two step evaluation with safety review after 4-6 patients receiving combination of MCLA-128, 750mg 2hour intravenous infusion once per cycle of 21 days in combination with trastuzumab, 8mg/kg 90minute first cycle, 6mg/kg other cycles, intravenous infusion once per cycle of 21 days and vinorelbine, 25 mg/M2 10minute intravenous infusion twice per cycle of 21 days;
2889711|NCT03321981|Experimental|Cohort 2|MCLA-128, 750mg 2hour intravenous infusion once per cycle of 21 days in combination with same dose and regimen of endocrine therapy prior to study entry and on which the patient progressed.
2889712|NCT03321968|Experimental|Lot 1|Quadrivalent VLP Influenza Vaccine
2889717|NCT03321942|Placebo Comparator|Control group|Treatment of chronic renal failure patients with conventional methods.
2889718|NCT03321929|Experimental|LUM Imaging System|Single dose of LUM015 (1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. All subjects will have intraoperative imaging using the LUM Imaging Device
2889719|NCT03321916|Experimental|Subthreshold Photothermal Therapy|
2889720|NCT03321916|Sham Comparator|Sham|
2889721|NCT03321903||1: Intraoral Squamous Cell Carcinomas|Intraoral squamous cell carcinomas that are resected and receive adjuvant radiation therapy. These patients may receive a Carlo Erba Ink injection before surgical tumor resection, after tumor resection (in the postsurgical radiation field), or in both instances. Patients whose tumor is within 5 mm of the surface will have injections of India ink into the tumor itself and measurements made in the tumor prior to surgery. Patients whose tumor is deeper than 5 mm of the surface could participate only in the measurements of the postsurgical radiation field. EPR Oximetry measurements will be made in the tumor and/or, if applicable, over the course of radiation in the postsurgical radiation field as appropriate.
2889722|NCT03321903||2: Cutaneous Malignant Tumors|Patients with primary cutaneous malignant tumors (including but not limited to squamous cell carcinoma, basal cell carcinoma, or melanoma) whose tumor is within 5 mm of the surface and whose treatment plan includes surgical resection and/or postsurgical radiation therapy. These patients may receive a Carlo Erba Ink injection before surgical tumor resection, after tumor resection (in the postsurgical radiation field), in both the tumor and the postsurgical radiation field, or in the tumor prior to radiation therapy. EPR Oximetry measurements will be made in the tumor and/or, if applicable, over the course of radiation in the tumor or postsurgical radiation field as appropriate.
2889723|NCT03321903||3: Breast Cancers|Breast cancer patients whose treatment plan includes surgical resection followed by radiation therapy. All patients who receive a surgical resection will receive a Carlo Erba Ink injection in the radiation field after sufficient healing has occurred to the area to be injected, as determined in consultation with the treating physicians, and using topical anesthetic or local anesthetic, if the patient so desires. All patients in this cohort will be expected to agree to a minimum of one EPR Oximetry measurement in the planned radiation field prior to radiation and a minimum of one measurement made over the course of radiation therapy.
2889724|NCT03321903||4: Other tumors|Other tumors within 5 mm of the surface, whose planned treatment includes radiotherapy of the tumor and does not include a planned resection of the tumor. As these other qualifying malignancies are expected to occur only rarely, they will be grouped into a single cohort despite potential varied histology. These patients will receive a Carlo Erba Ink injection in their tumor prior to radiation therapy. All patients in this cohort will be expected to agree to a minimum of one EPR Oximetry measurement in the planned radiation field prior to radiation and a minimum of one measurement made over the course of radiation therapy.
2889725|NCT03321890|Experimental|Combination therapy regimen|Chidamide + prednisone+cyclophosphamide+etoposide+methotrexate
2889726|NCT03321877|Experimental|Study group|All included patients underwent dose reduction.
2889727|NCT03321864|Experimental|Study arm|All patients recruited to the study (this arm) will have an additional transrectal ultrasound whilst already under GA for TP biopsy.
2889728|NCT03321851|Other|V-Sensor Device User|This diagnostic medical device is designed to detect the user's 5 vital signs. Each user tests two sensors, each sensor is mounted on a smartphone. Each vital sign is compared to an equivalent reference device obtained by the healthcare provider.
2889729|NCT03321838|Experimental|Accommodative/vergence therapy|Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
2889730|NCT03321825|Experimental|Belotero® Volume Lidocaine|Subdermal injection
2889731|NCT03321825|No Intervention|No treatment|
2889732|NCT03321812|Experimental|decalcification bone scaffold|Decalcification bone scaffold is a novel tissue engineered acellular matrix scaffold with the closest biomechanics and structure to normal cartilage.
2889733|NCT03321812|Active Comparator|Microfracture|Microfracture is a conventional treatment for cartilage lesions of the knee.
2889734|NCT03321799|Active Comparator|Sterile Antimicrobial Dressings|Control group, current hospital standard. AQUACEL is left in place for 7 days unless it becomes saturated over 50%, which requires a premature dressing change.
2889735|NCT03321799|Experimental|NPWT|"Experimental group. Negative pressure wound therapy bandage applied intra-operatively by a physician on the treatment team.~The dressing will be removed after 7 days postoperatively, or if the battery power stops earlier."
2889736|NCT03321786||Legionnaires' Disease Volunteers|Volunteers who have been diagnosed/survivors of Legionnaire's Disease
2889737|NCT03321786||Healthy Volunteers|Volunteers who are healthy.
2889738|NCT03321773|Experimental|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
2889739|NCT03321773|Active Comparator|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
2889740|NCT03321760|Experimental|Run-In Dose 1|10 Gy dose delivered to the primary tumor & 10 Gy to the hilar (N1) node over 5 fractions
2889741|NCT03321760|Experimental|Run-In Dose -1|10 Gy dose delivered to the primary tumor & 9 Gy to the hilar (N1) node over 5 fractions
2889742|NCT03321760|Experimental|Run-In Dose -2|10 Gy dose delivered to the primary tumor & 8 Gy to the hilar (N1) node over 5 fractions
2889743|NCT03321760|Experimental|Phase 2|The maximum tolerated radiation dose to the hilar (N1) node from the run-in period will be used during Phase 2.
2889744|NCT03321747|Experimental|Phase 1/Dose Level 1|11 Gy will be given in 5 fractions for a total dose of 55 Gy
2889745|NCT03321747|Experimental|Phase 1/Dose Level 2|12 Gy will be given in 5 fractions for a total dose of 60 Gy
2889746|NCT03321747|Experimental|Phase 1/Dose Level 3|13 Gy will be given in 5 fractions for a total dose of 65 Gy
2889747|NCT03321747|Experimental|Phase 1/Dose Level 4|14 Gy will be given in 5 fractions for a total dose of 70 Gy
2889803|NCT03321227|Experimental|Egg yolks|2 egg yolks as a snack
2889748|NCT03321747|Experimental|Phase 2|The maximum tolerated radiation dose determined during Phase 1 (i.e. 11, 12, 13, or 14 Gy) will be given in 5 fractions for a total dose of 55, 60, 65, or 70 Gy.
2889749|NCT03321734|Experimental|Extended Caffeine Treatment|Infants in the extended caffeine treatment arm will, beginning the next day after stopping routine caffeine treatment, receive 10 mg/kg/day of caffeine citrate to 36 weeks post menstrual age (PMA), and increase to 10 mg/kg/BID of caffeine citrate beginning at 36 weeks PMA through 42 weeks PMA.
2889750|NCT03321734|Placebo Comparator|Placebo|Infants in the placebo arm will, beginning the next day after stopping routine caffeine treatment, receive a placebo through 42 weeks PMA.
2889751|NCT03321721|No Intervention|conservative|patient fulfilling entry criteria will be randomized to the conservative arm - no suturing
2889752|NCT03321721|Active Comparator|suture|patient fulfilling entry criteria will be randomized to the suture arm for repair with nylon suture material
2889753|NCT03321682|Experimental|Functional Training|Patients in the functional training group, in addition to maintaining their usual care, will perform functional training including exercises for core strength, power training, knee dominance, hip dominance, horizontal pressure, vertical pressure, horizontal pull and vertical pull, using unstable surfaces.
2889754|NCT03321682|Active Comparator|Strength Training|These group, in addition to maintaining their usual care, will perform the exercise protocol as recommended by the American Heart Association.
2889755|NCT03321669|Active Comparator|Increased Fat Diet|
2889756|NCT03321669|Sham Comparator|Low Fat Diet|
2889757|NCT03321656|Active Comparator|Tacrolimus|0.1 - 0.2 mg/kg/day in 2 divided doses every 12 hours orally
2889758|NCT03321656|Experimental|Envarsus XR|0.07-0.14 mg/kg/day every morning orally
2889759|NCT03321643|Experimental|Treatment (rituximab, gemcitabine, oxaliplatin, atezolizumab)|"INDUCTION PHASE: Patients receive rituximab IV, gemcitabine IV, and oxaliplatin IV every 2 weeks. Starting course 2, patients also receive atezolizumab IV over 30-60 minutes every 2 weeks. Treatment repeats every 14 days of course 1 and every 28 days for up to 4 courses in the absence of disease progression or unaccepted toxicity.~MAINTENANCE PHASE: Patients receive rituximab IV and atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unaccepted toxicity."
2889760|NCT03321630|Other|Lenvatinib & Pembrolizumab|
2889761|NCT03321617|Experimental|POMA 40mg BID (80mg)|Subject will take 40mg pomaglumetad methionil (POMA) twice a day for 14 days.
2889762|NCT03321617|Experimental|POMA 80mg BID (160 mg)|Subject will take 80 mg pomaglumetad methionil (POMA) twice a day for 14 days
2889763|NCT03321617|Experimental|POMA 120mg BID (240mg)|Subject will take 120 mg pomaglumetad methionil (POMA) twice a day for 14 days
2889764|NCT03321617|Experimental|POMA 160 mg BID (320 mg)|Subject will take 160 mg pomaglumetad methionil (POMA) twice a day for 14 days
2889765|NCT03321552|Experimental|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
2889766|NCT03321539|Experimental|CCRT+GP|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during radiotherapy followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21days for three cycles
2889767|NCT03321539|Active Comparator|CCRT+PF|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during radiotherapy followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles
2889768|NCT03321526|Experimental|JNJ-42847922|Participants will receive 20 mg of JNJ-42847922 as a starting dose and matching placebo (1 capsule of 20 mg JNJ-42847922 and 1 capsule of matching placebo) once daily for 14 days. After Day 14, if needed, JNJ-42847922 dose can be increased to 40 mg (2*20 mg capsules) and flexible dose of JNJ-42847922 (20 or 40 mg) will be taken once daily until Day 167. Dose of JNJ-42847922 (20 or 40 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
2889769|NCT03321526|Active Comparator|Quetiapine Extended-Release (XR)|Participants will receive 1 capsule of quetiapine XR 50 mg along with 1 capsule of matching placebo once daily for 2 days, followed by 1 capsule of quetiapine XR 150 mg along with 1 capsule of matching placebo once daily from Day 3 to Day 14. After Day 14, if needed, quetiapine XR dose can be increased to 300 mg (2*150 mg capsules) and flexible dose of quetiapine (150 or 300 mg) will be taken once daily until Day 167. Dose of quetiapine XR (150 or 300 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline SSRI/SNRI antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
2889770|NCT03321513|Active Comparator|Aflibercept Group|2.0 mg intravitreous aflibercept
2889771|NCT03321513|Experimental|Bevacizumab + Deferred Aflibercept Group|1.25 mg intravitreous bevacizumab + deferred intravitreous 2.0 mg aflibercept if eye meets switch criteria
2889772|NCT03321500|Experimental|Versacyl soft liner|Versacryl soft liner are flexible biocompatible materials with a reported predictable long term performance, durable bonding to acrylic denture bases, high fatigue endurance, excellent wear characteristics and solvent resistance with almost no free monomer in the processed material
2889773|NCT03321500|Active Comparator|Silicone-based soft liner|Resilient liners were introduced in the1950s and have been used since then as a gold standard material to increase the tolerance, retention and comfort of complete dentures. Resilient liners also known as 'soft liners' can be classified as temporary or permanent, cold-cured or heat-cured.Resilient liners can be divided into two main types: plasticized acrylic resins and silicone elastomers.
2889774|NCT03321487|Experimental|Stage I Cohort|Blood-Brain Barrier opening with MRgFUS. BBB opening of a small volume of the primary motor cortex
2889775|NCT03321487|Experimental|Stage II Cohort|Blood-Brain Barrier opening with MRgFUS. BBB opening of a larger volume of the primary motor cortex
2889804|NCT03321227|Active Comparator|Yogurt|Full fat yogurt as a snack
2890003|NCT03319706|Active Comparator|Reference|Daiichi Sankyo Inc's Benicar Tablets 40 mg
2889776|NCT03321474|Experimental|modified gull wing preparation|Gullwing preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally. The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation
2889777|NCT03321474|Active Comparator|conventional preparation|"In conventional preparation of veneer it circumvents the contact areas and extends palatally in the incisal third of the tooth only. The preparation thickness is defined by a 0.5 mm facial and 1.5-2.0 mm incisal reduction with the proximal finish lines placed facially to the proximal contacts~Gull wing (dog leg) preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally. This preparation design helps to hide the restoration margin when viewed from an angle, especially in discoloration.~The preparation thickness is defined by a 0.5 mm facial and 1.5-2.0 mm incisal reduction with the proximal finish lines The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation."
2889778|NCT03321461|Experimental|TMTP1|The TMTP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. Then TMTP1-ICG spray was applied thoroughly to the ectocervix for 30 minutes. After cleaned by NS, fluorescent detected sites will be removed.
2889779|NCT03321461|Active Comparator|ICG|The ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. ICG spray was applied thoroughly to the ectocervix for 30 minutes. After cleaned by NS, fluorescent detected sites will be removed.
2889780|NCT03321448|Experimental|TMTP1|The TMTP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of this TMTP1-ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
2889781|NCT03321448|Active Comparator|ICG|The ICG powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
2889782|NCT03321435||placenta previa group|
2889783|NCT03321435||Normal control group|
2889784|NCT03321409||The general population|People who take the physical examination in Renji Hospital between 18 to 80 years old without any previously confirmed serious medical conditions or mental disorders.
2889785|NCT03321409||The patients with suspected CAD|Patients with suspected CAD between 18 to 80 years old without any previously confirmed serious medical conditions or mental disorders.
2889786|NCT03321396|Experimental|Endoscopic submucosal dissection|All participants in the study received Endoscopic submucosal dissection with Sodium Alginate mixed with Calcium Lactate prior to endoscopic resection.
2889787|NCT03321344|Experimental|Test Arm|Focused Ultrasound Thermal ablation of the Medial Nerve Branch
2889788|NCT03321331|Experimental|Lark (JITAI)|"Participants in the intervention arm will use for 12 weeks the pro version of a mHealth app called Lark, developed by Lark Technologies Ltd. Lark is a coach app, which uses several variables to generate smart and empathic conversations. Variables include activity, sleep, meals, weight, and height data, weight goal set by the user/Lark coach, activity goal set by user/Lark coach, starchy food goal set by user/Lark coach. Lark uses all these variables to create a dynamic coaching system, constantly changing and adapting to the user in the moment and over time. For these features, Lark provides a just in time adaptive intervention (JITAI)."
2889789|NCT03321331|Active Comparator|MyFitnessPal (no JITAI)|"Participants in the control arm will be assigned to use MyFitnessPal. Similar to the intervention arm, they will be instructed to use the app for 12 weeks. MyFitnessPal does not include JITAI components, but allows users to keep track of their caloric intake and energy expenditure. MyFitnessPal has features that can be associated with effective behavior change techniques, including: self-monitoring of behavior and outcomes, goal setting and feedback (similar to Lark). In MyFitnessPal, social support is limited to comments and 'likes' from friends of its restricted user community, therefore tackling the techniques of social comparisons and social reward."
2889790|NCT03321318|Experimental|A group|AK-R215, test drug
2889791|NCT03321318|Active Comparator|B group|reference drug, Bazedoxifene 20mg, Cholecalciferol 800IU
2889792|NCT03321292|Experimental|L-arginine and Acetylesalicylic acid|L-arginine 1000mg capsules( manufactured by Putriant Pride,INC Holbrook,NY 11741 U.S.A.) every 8 hours Acetylesalicylic acid 75 mg tablet(manufactured by Multi_Apex Pharma , Egypt) once daily will be given for patients of group A starting from diagnosis till birth
2889793|NCT03321292|Active Comparator|Acetylesalicylic acid75mg|acetylsalicylic acid 75 mg tablet(manufactured by Multi_Apex Pharma , Egypt) orally once daily will be given for patients of group B starting from diagnosis till birth
2889794|NCT03321279|No Intervention|Control|Participants' daily step counts will be for weeks 2-13 after hospital discharge. Participants will be asked to complete surveys at 5, 9 and 13 weeks post-discharge.
2889795|NCT03321279|Experimental|Intervention|Participants' daily step counts will be monitored for weeks 2-13 after hospital discharge. Participants will have a weekly step goal that increases from baseline by 10% each week of the intervention (12 weeks). Participants will engage in a social incentive-based gamification based on points and levels that leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. Participants will receive daily feedback for the step counts and weekly feedback for levels. Participants will be asked to identify a support partner, who will receive weekly reports with the the participant's points and levels balance.
2889796|NCT03321266||Patients treated for a anorectal fistula|Patients who were treated for a anorectal fistula with a Biodesign Fistula plug
2889797|NCT03321253|Experimental|Nd: YAG laser posterior capsulotomy|Posterior capsulotomy was performed by using Nd: YAG laser and macular pigment optical density, intra ocular pressure, choroidal thickness, macular thickness and anterior chamber parameters were measured before Nd: YAG laser, at 1 week, 1 month and 2 months
2889798|NCT03321240||The SEEG group|Group with the SEEG analysis
2889799|NCT03321240||The direct surgery group|Group with a direct surgery
2889800|NCT03321227|Experimental|Snack skipping|No snack provided
2889801|NCT03321227|Experimental|Whole eggs|2 whole large eggs as a snack
2889805|NCT03321214|Experimental|Light use of Nima|Ten participants will be randomized to receive 12 capsules every other month (18 capsules for the 3 months which is considered light use).
2889806|NCT03321214|Experimental|Moderate use of Nima|Ten participants will be randomized to receive 12 capsules per month (36 capsules for the 3 months which is considered moderate use).
2889807|NCT03321214|Experimental|Heavy use of Nima|Ten participants will be randomized to receive 24 capsules per month (72 capsules for the 3 months which is considered heavy use).
2889808|NCT03321201|Experimental|Cauterization|
2889809|NCT03321201|Active Comparator|Fibrin glue|
2889810|NCT03321188|Experimental|HIPEC + adjuvant IV chemotherapy|"HIPEC~HIPEC will be administered intraoperatively one time only.~*HIPEC cisplatin will be administered at rate of 100 milligram per meter squared (mg/m2)~Administration of HIPEC will have a duration of 90 minutes.~Adjuvant IV chemotherapy~IV Paclitaxel~Dose: 80mg/m2 IV over 1 hour~Schedule: Days 1, 8 and 15~Cycle Length: 3 weeks (21 days)~IV Carboplatin~Dose: Area under the curve (AUC) 6 IV~Schedule: Day 1~Cycle Length: 3 weeks (21 days)"
2889811|NCT03321175|Experimental|Subcutaneous irrigaton|Patients will receive 200 cc subcutaneous saline irrigation before skin incision closure.
2889812|NCT03321175|No Intervention|Subcutaneous no irrigation|Patients will not receive subcutaneous saline irrigation before skin incision closure.
2889813|NCT03321162||double scan protocol|In C1(double scan technique) , after CT scan for patient wearing scan appliance , two optical scan for the model with and without scan appliance.
2889814|NCT03321162||triple scan protocol|In C2 (triple scan technique) , after CT scan for patient wearing scan appliance , CT scan for scan appliance alone .
2889815|NCT03321149|Experimental|RiseTx|Participants were given access to the RiseTx application and an activity monitor to participate in the five phase intervention.
2889816|NCT03321136|Placebo Comparator|Placebo, LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2889817|NCT03321136|Placebo Comparator|LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2889818|NCT03321136|Placebo Comparator|LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2889819|NCT03321136|Placebo Comparator|LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2889820|NCT03321136|Placebo Comparator|LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2889821|NCT03321136|Placebo Comparator|LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100, LSD-200|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2889822|NCT03321123|Experimental|CRA treatment|"The drug for this trial is autologous T cells transduced with the lentiviral vector pLTG1563 (MB-CART19.1). The dose is 2x10e6 ~2x10e7 MB-CART19.1/kg.~A leukapheresis for the patient will be performed for MB-CART19.1 generation. All patients will receive lymphodepleting chemotherapy with fludarabine 30 mg/m2/d intravenously (iv) on days -5,-4,-3 and -2 cyclophosphamide 500 mg/m2/d iv on day -3,-2 before CAR T cell transfer to enhance the in vivo expansion of CAR T cells."
2889823|NCT03321110|Experimental|Placebo|Placebo
2889824|NCT03321110|Experimental|Q10-150|coenzyme Q10 150 mg/d.
2889825|NCT03321110|Experimental|Q10-300|coenzyme Q10 300 mg/d.
2889826|NCT03321097|Experimental|condensed RT group|Training session included 45 minutes RT, followed by 30-minute functional training. The condensed group will receive 4 sessions per week, for 6 weeks.
2889827|NCT03321097|Experimental|distributed RT Group|Training session included 45 minutes RT, followed by 30-minute functional training. The distributed group 2 sessions per week, for 12 weeks.
2889828|NCT03321084|Experimental|MatPilates|In the beginning was nominated Contrology, but today is known as Pilates. Created by Joseph Humbertus Pilates. This technique is based on respiration, balance, flexibility, proprioception and muscular strength. One of the main work is on the power house (core), biomechanical axis of the body, composed of muscles: rectus abdominis, paravertebral, multifidus, diaphragm, and those of the perineal center.
2889829|NCT03321084|Other|Control|It continues in your daily life with phone monitoring.
2889830|NCT03321071|Experimental|Health Summer Learners|Similar to typical summer day camp procedures, students attending Healthy Summer Learners will be dropped-off and picked-up at camp. The physical activity component of the program was designed with the expertise and input from B&G Club youth program staff. The academic component was informed by school district personnel. The program was also designed to be analogous to typical summer day camp program in terms of operating weeks (10 weeks) length of program day (i.e., 8am-5pm), and program component time blocks (~45min-1hr time blocks).
2889831|NCT03321071|Active Comparator|21st Century Learning Center|Children in this condition will attend a 21st Century Summer Learning Program.
2889832|NCT03321045|Experimental|[89Zr]-Df-Trastuzumab|[89Zr]-Df-Trastuzumab [89Zr]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab. 5-6 days post injection the patients will undergo PET/MRI imaging.
2889833|NCT03321032|Experimental|Amphilimus-eluting stents|Polymer-free Amphilimus-eluting stents
2889834|NCT03321032|Active Comparator|Zotarolimus-eluting stents|Biolinx Polymer-based zotarolimus-eluting stents
2889835|NCT03321019||Healthy controls|Men and women between the ages of 45 and 85 years without Parkinson's disease, or any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
2889836|NCT03321019||Parkinson's disease|Men and women between the ages of 45 and 85 years with Parkinson's disease, and without any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
2889837|NCT03321006|Active Comparator|AD + full amplification hearing aids|
2889838|NCT03321006|Sham Comparator|AD + Low amplification (sham) hearing aids|
2889839|NCT03320993|Active Comparator|Low Protein-Low Fat study|Subjects will receive a mixed meal with carbohydrates (70g) plus a low content of proteins and fats
2889840|NCT03320993|Experimental|High Protein-High Fat study|Subjects will receive a mixed meal with the same carbohydrates content of arm 1 (70g), but a greater amount of fats and proteins
2889937|NCT03320343||Patients recruited for pelvic imaging examination|
2889841|NCT03320993|Experimental|High Protein-High Fat & alcohol study|Subjects will receive the same mixed meal of the High Protein-High Fat study plus 0,7g of alcohol per Kg of weight
2889842|NCT03320980||RALPPS|Patients with initial volume of FLR < 40% which underwent RALPPS and major liver resection (as the second stage of RALPPS) for hilar and intrahepatic cholangiocarcinoma
2889843|NCT03320980||Portal vein embolization (PVE)|Patients with initial volume of FLR < 40% undergoing PVE and major liver resection for hilar and intrahepatic cholangiocarcinoma
2889844|NCT03320954|Experimental|Anomia treatment|Phase 2 portion of the research during which participants with acquired brain injury will perform intervention activities.
2889845|NCT03320941|Experimental|LIK066 Dose 1|Eligible patients randomized to this arm will receive LIK066 dose regimen Dose 1 orally for 12 weeks.
2889846|NCT03320941|Experimental|LIK066 Dose 2|Eligible patients randomized to this arm will receive LIK066 dose regimen Dose 2 orally for 12 weeks.
2889847|NCT03320941|Experimental|LIK066 Dose 3|Eligible patients randomized to this arm will receive LIK066 dose regimen Dose 3 orally for 12 weeks.
2889848|NCT03320941|Experimental|LIK066 Dose 4|Eligible patients randomized to this arm will receive LIK066 dose regimen Dose 4 orally for 12 weeks.
2889849|NCT03320941|Placebo Comparator|Placebo|Eligible patient randomized to this arm will receive LIK066 matching placebo orally for 12 weeks.
2889850|NCT03320915|Experimental|Cholecalciferol|Cholecalciferol 5mg (200,000 IU)
2889851|NCT03320915|No Intervention|Usual care|Usual care
2889852|NCT03320902|Active Comparator|Sudden death counselling|The emergency physician of the prehospital EMS who intervenes at the scene will systematically give the family member allocated to the intervention the option to attend a sudden death counselling during the first month after the event.
2889853|NCT03320902|No Intervention|Usual practice|The physician will act as usual. The relatives will not systematically benefit from this option.
2889854|NCT03320889|Other|Pamphlets plus Review with Expert Educator|Educational Intervention includes Pamphlets plus Review with Expert Educator
2889855|NCT03320889|Other|Pamphlets only|Educational Intervention includes Pamphlets only
2889856|NCT03320876|Experimental|filgotinib|
2889857|NCT03320863|Active Comparator|Active or Enso Group|Active Enso device use for one month, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
2889858|NCT03320863|No Intervention|Sham Group|Sham device use for one month, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
2889859|NCT03320850|Experimental|100U cohort - BOTOX® plus Hydrogel admixture|100U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
2889860|NCT03320850|Placebo Comparator|100U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
2889861|NCT03320850|Experimental|300U cohort - BOTOX® plus Hydrogel admixture|300U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
2889862|NCT03320850|Placebo Comparator|300U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
2889863|NCT03320850|Experimental|400U cohort - BOTOX® plus Hydrogel admixture|400U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
2889864|NCT03320850|Placebo Comparator|400U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
2889865|NCT03320850|Experimental|500U cohort - BOTOX® plus Hydrogel admixture|500U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
2889866|NCT03320850|Placebo Comparator|500U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
2889867|NCT03320837||Breastfeeding group|Infant are exclusively fed with breast milk
2889868|NCT03320837||Mixed feeding group|Infants are fed with mixed nutrition with breast milk and Rontamil Complete 1®
2889869|NCT03320837||Infant formula group|Infant are fed exclusively with Rontamil Complete 1®
2889870|NCT03320811||"group celiac disease"|
2889871|NCT03320811||"group no celiac disease"|
2889872|NCT03320798||"group Bullous pemphigoid"|Patients consulting at dermatology department of Reims Teaching Hospital for bullous pemphigoid between 1997 and 2011.
2889873|NCT03320772|Experimental|TMVP1|The TMVP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of TMVP1-ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
2889874|NCT03320772|Active Comparator|ICG|The ICG powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of this ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
2889875|NCT03320759|No Intervention|No rehabilitation|
2889876|NCT03320759|Experimental|Rehabilitation|
2889877|NCT03320746|Experimental|Activity trackers|
2889878|NCT03320746|No Intervention|No activity trackers|
2889879|NCT03320733|Experimental|Surgical|"Includes patients who will undergo surgery for their pancreatic cysts.~In addition to the routine pre-operative CT abdomen performed for surgical planning purposes, these patients will receive Dual Energy CT scan with subtraction imaging before surgery."
2889880|NCT03320733|Experimental|Surveillance|"Includes patients who are undergoing surveillance for their pancreatic cysts.~Dual Energy CT scan with subtraction imaging will be performed in addition to the standard-of-care surveillance method of MRI scans."
2889881|NCT03320720|Experimental|Home Treatment|Patients with acute mental illness are treated at their houses by a mobile and multiprofessional care team instead of being treated as inpatients if their medical condition permits.
2889882|NCT03320720|Active Comparator|Treatment-as-usual|Patients with acute mental illness are treated as inpatients in a psychiatric clinic.
2928270|NCT03052517|Placebo Comparator|Placebo|Placebo once daily
2889883|NCT03320707|Experimental|Daratumumab|Participants will receive a single subcutaneous (SC) dose of daratumumab, within one of 6 dose cohorts. Doses will be escalated based on review of pharmacokinetic, pharmacodynamic, and safety data of previous cohort.
2889884|NCT03320707|Placebo Comparator|Placebo|Participants will receive placebo as a single SC dose in all 6 cohorts.
2889885|NCT03320694|Experimental|metformin|Metformin will be given until 2500mg in divided doses till normoglycemia is achieved and will be continued till delivery
2889886|NCT03320694|Active Comparator|Insulin|Insulin will be give as 3 regular injection and one intermediate acting injection at bedtime till normoglycemia is achieved and will be continued till delivery
2889887|NCT03320681|Active Comparator|Active Stimulation|Acupuncture needles will be inserted into the auricular zones and electrical stimulation will be given for 20 minutes.
2889888|NCT03320681|Other|Dry Needling|Acupuncture needles will be inserted into the auricular zones for 20 minutes. However, no electrical stimulation will be given
2889889|NCT03320668|No Intervention|Individual OEP|"Randomized subjects (65 to 80-year-old) receiving individual Otago Exercise Program (OEP) training in a total of nine Primary Care Centers.~An OEP leader trained nurse/physiotherapist will perform in its community consult individual education to each participant in five sessions: In the 1st, 2nd, 4th and 8th week and one reinforcement session after six months. A telephone call to each participant (following a predefined telephonic interview protocol) will be carried out in the months without training session to perform the follow-up."
2889890|NCT03320668|Experimental|Group OEP|65-80 year-old randomized subjects receiving group Otago Exercise Program (OEP) training in a total of nine Primary Care Centers.
2889891|NCT03320655|Active Comparator|Combined Aerobic Training|The subjects will perform in ST part, always only 1 set in the 6 machines early mentioned. During the first and second week they will do 12 repetitions at 40% - 50% of 1 RM. In the third and fourth week progress to 10 repetitions at 60%-70% of 1 RM, and in the second and third month, 8 repetitions at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of 10 interval training periods (2 min of high intensity at 85% - 90% of heart rate reserve (HRreser) and 9 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 5 intervals of HIIT, and in the second and third months they are doing the 10 stages of HIIT.
2889892|NCT03320655|Experimental|Combined Strength Training|During the first and second week subjects will perform 1 sets with 12 repetitions at 40% - 50% of 1 RM in the 6 machines mentioned before. In the third and fourth week strength exercises progress to 2 sets of 10 repetitions, at 60%-70% of 1 RM, and in the second and third month consists of 3 sets at 8 repetitions, at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of of 5 interval training periods (2 min of high intensity: 85% - 90% of HRreser) and 4 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 3 intervals of HIIT, and after the third/fourth week they are doing the 5 stages of HIIT.
2889893|NCT03320642|Experimental|Itacitinib + Calcineurin Inhibitor (CNI) -Based Interventions|Itacitinib in combination with a CNI-based intervention.
2889894|NCT03320629|Experimental|apatinib and S-1 radiotherapy|apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
2889895|NCT03320629|Active Comparator|S-1 radiotherapy|S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
2889896|NCT03320616|Experimental|Sequence 1|4 single doses of EYP001a: Period 1 first dose morning fasted, second dose morning fed; Period 2 first dose evening fasted, second dose evening fed
2889897|NCT03320616|Experimental|Sequence 2|4 single doses of EYP001a: Period 1 first dose evening fasted, second dose evening fed; Period 2 first dose morning fasted, second dose morning fed
2889898|NCT03320616|Experimental|Sequence 3|4 single doses of EYP001a: Period 1 first dose morning fed, second dose morning fasted; Period 2 first dose evening fed, second dose evening fasted
2889899|NCT03320616|Experimental|Sequence 4|4 single doses of EYP001a: Period 1 first dose evening fed, second dose evening fasted; Period 2 first dose morning fed, second dose morning fasted
2889900|NCT03320603|Other|Phase 1|Prospective collection of data on a standard eCRF (without reminders of recommendations). Prothrombin Complex Concentrate given as standard of care.
2889901|NCT03320603|Other|Phase 2|Prospective collection of data on expert data collection tool (expert eCRF reminding recommendations at each step of the management of severe bleeding). Prothrombin Complex Concentrate given as standard of care.
2889902|NCT03320590||Couple|Couple with female aged under 37 years
2889903|NCT03320577|Active Comparator|Class instruction of breathing exercises|Class participation/instruction weekly for 6 weeks and requested to practice Pranayama breathing exercises of 15 minute duration for an additional 4x during the week; completed log that indicated time/date/duration of practice; weekly blood pressure measurements and turn in logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
2889904|NCT03320577|Active Comparator|DVD instruction of breathing exercises|Received DVD with instructions and 15 minute Pranayama breathing exercises of 15 minute duration. Participants requested to practice breathing exercises 5x during the week for 6 week intervention; completed log that indicated time/date/duration of practice; weekly blood pressure measurements and turn in logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
2889905|NCT03320577|Placebo Comparator|Control|Completed log that indicated time of eating dinner; weekly blood pressure measurements for the 6 week intervention; control participants also turned in dinner time logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
2889906|NCT03320564|Experimental|Infiltration|Repeat F-18 FDG PET
2889907|NCT03320551|Experimental|Nutrition Education Immersion Program|Assessing if a one week lifestyle interventions can lead to long term health benefits.
2889938|NCT03320330|Experimental|Treatment (VX15/2503)|Patients receive VX15/2503 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 13 courses in the absence of disease progression or unacceptable toxicity.
2889939|NCT03320317||Colorectal cancer|
2890004|NCT03319693||Mucosal melanoma|Incident Mucosal melanoma in the Champagne-Ardenne region 2004-2014
2889908|NCT03320538|Experimental|Hou Gu Mi Xi|"Basic treatment period (0 to 2nd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive Jiangzhong Hou Gu® Mi Xi™ (once 10 g, twice a day).~Recuperation period (7th to 52th week): Patients in this arm receive Jiangzhong Hou Gu® Mi Xi™ (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
2889909|NCT03320538|Experimental|Jiangzhong Hou Gu® Mi Xi™ + rabeprazole|"Basic treatment period (0 to 2nd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive Jiangzhong Hou Gu® Mi Xi™ (once 10 g, twice a day) plus rabeprazole (once 10 mg, once a day).~Recuperation period (7th to 52th week): Patients in this arm receive Jiangzhong Hou Gu® Mi Xi™ (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
2889910|NCT03320538|Placebo Comparator|Placebo + rabeprazole|"Basic treatment period (0 to 2nd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive Placebo of Jiangzhong Hou Gu® Mi Xi™ (once 10 g, twice a day) plus rabeprazole (10 mg/d, qd).~Recuperation period (7th to 52th week): Patients in this arm receive Jiangzhong Hou Gu® Mi Xi™ (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
2889911|NCT03320538|Placebo Comparator|Placebo|"Basic treatment period (0 to 2nd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive placebo of Jiangzhong Hou Gu® Mi Xi™ (once 10 g, twice a day).~Recuperation period (7th to 52th week): Patients in this arm receive Jiangzhong Hou Gu® Mi Xi™ (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
2889912|NCT03320525|Experimental|Experimental|The active substance used in the T-ChOS capsule formulation is a chitooligosaccharide blend.
2889913|NCT03320512|Experimental|P3|Participants will use P3
2889914|NCT03320512|Experimental|P3+|Participants will use P3+
2889915|NCT03320512|Placebo Comparator|Control|Participants will receive the standard of care
2889916|NCT03320499||echo doppler at the bed|
2889917|NCT03320499||echo doppler in the vascular exploration platform|
2889918|NCT03320486|Experimental|Group 1 - dapaconazole cream 2%|Topical application of dapaconazole cream 2%, once daily, during 42 days.
2889919|NCT03320486|Active Comparator|Group 2 - ketoconazole cream 2%|Topical application of ketoconazole cream 2%, once daily, during 42 days.
2889920|NCT03320473|Experimental|IC-8 IOL|IC-8 IOL implantation after removal of KAMRA ACI 7000 PDT inlay
2889921|NCT03320460|Experimental|Photobiomodulation|Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ =660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
2889922|NCT03320460|Active Comparator|Propionate clobetasol gel 0.05%|Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days. Laser device will be positioned over the lesion but will be switched off to mask the treatment. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
2889923|NCT03320447|Experimental|MAL-PDT|Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT
2889924|NCT03320447|Experimental|AFL-PDT|Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT
2889925|NCT03320434|Experimental|PRT 0.5%|
2889926|NCT03320434|Experimental|PRT 1%|
2889927|NCT03320434|Active Comparator|Patanol|
2889928|NCT03320434|Active Comparator|Pred-forte|
2889929|NCT03320434|Placebo Comparator|PRT 0%|
2889930|NCT03320421|Experimental|SIB group|"Radiation therapy:~daily 5 days per week for 3 weeks. 43.5 Gy in 15 fractions to the whole breast 49.5 Gy in 15 fractions to the tumor bed boost"
2889931|NCT03320408||Asymptomatic AAA|These patients will be included while their AAA is asymptomatic and while they are under surveillance by their vascular surgeon.
2889932|NCT03320408||Acute AAA|These are the patients that are included while they presented in the participating hospitals because either a symptomatic or ruptured AAA. For this group, a different recruitment procedure exists which has been approved by the appropriate medical ethical committee.
2889933|NCT03320408||Repaired AAA|These patients are included while they already had had AAA repair (both elective and emergency repair).
2889934|NCT03320395|Experimental|Small bowel RFA treatment|Five small bowel samples each of the duodenum, jejunum and ileum will be recruited treated.
2889935|NCT03320369|Other|Treatment|Treatment Phase will evaluate the effectiveness of elemental diet Intervention: Elemental Diet Therapy
2889936|NCT03320356||shoulder pain|Patients presenting inflammatory, degenerative, or post-traumatic shoulder pain and consulting at Orthopaedic Department, Reims Teaching Hospital.
2889940|NCT03320304||Vagal Nerve Simulation (VNS) Therapy|"The aim of this study is to include patients with difficult to treat depression from a global real world (standard of care) population who are referred for treatment with VNS Therapy."
2889941|NCT03320291|Experimental|Regjoint|
2889942|NCT03320278||SPIDS,TMH|There will be two tests in this study for evaluation. Both of them will be measured in same group. (155 patients)
2889943|NCT03320265|Experimental|PC-mAb|Phosphorylcholine human monoclonal antibody, i.v. infusions
2889944|NCT03320265|Placebo Comparator|Placebo|Placebo to PC-mAb, i.v. infusions
2889945|NCT03320239|Experimental|the online-RASSL intervention group|HIV risk assessment and tailored suggestions, free HIV testing link
2889946|NCT03320239|Experimental|intervention group 2|HIV risk behavior investigation and routine education
2889947|NCT03320239|Placebo Comparator|the control group|The placebo control: HIV/AIDS knowledge assessment, routine education
2889948|NCT03320226|Other|Probiotic 10 (Nature's Bounty)|The suggested dose will be two (2) pills of Probiotic 10 (Nature's Bounty) after dinner daily. Subjects will be asked to take probiotics for six (6) days after providing baseline fecal specimen. Subjects will self-report their daily GI function including the frequency of nausea, vomiting, and bowel movement(s). Then, the subjects will stop taking probiotics for two (2) days and resume taking probiotics for another six (6) days. This six (6)-day on and two (2)- day off cycle is repeated two (2) times.
2889949|NCT03320200|Experimental|CNS-focused treatment|Group of subjects receiving a 10 week CNS (Central Nervous System) -focused treatment program for frozen shoulder in addition to 5 days per week home treatment program
2889950|NCT03320200|Experimental|Standard Care Treatment|Group of subjects receiving a 10 week standard care treatment program for frozen shoulder in addition to 5 days per week home treatment program based on conventional physiotherapy
2889951|NCT03320187|Experimental|Group A|Nitroglycerin as Nitroderm TTSⓇ skin patch is applied on the upper chest alongside with regular induction of labor protocol ( 3gm/ 8 hours DinoprostoneⓇ vaginal tablet in the posterior vaginal fornix)
2889952|NCT03320187|Placebo Comparator|Group B|Placebo patch is applied on the upper chest alongside with regular induction of labour protocol ( 3gm/ 8 hours DinoprostoneⓇ vaginal tablet in the posterior vaginal fornix)
2889953|NCT03320174|Active Comparator|Tafenoquine 200 mg (2 x 100 mg tablets)|Tafenoquine 200 mg (2 x 100 mg tablets) daily for three consecutive days, followed by study treatment (tafenoquine 200 mg or placebo) once per week for 51 weeks
2889954|NCT03320174|Placebo Comparator|Placebo|Placebo daily for three consecutive days, followed by study treatment (tafenoquine 200 mg or placebo) once per week for 51 weeks
2889955|NCT03320148|Experimental|Physiotherapist-led primary care model for back pain|The PT-led primary care model for back pain will involve incorporating a PT within the primary care team at the first point of contact for people with back pain at no cost to the patient. Patients in this model will be given the choice of seeing the PT or family doctor. They will be encouraged to book with the PT except when the primary reason for visit is for medication renewals or when the patient has additional health concerns that need attention from their physician in the same visit. There will be 4 key components of the PT led primary care intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at the first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need.
2889956|NCT03320148|Active Comparator|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada. This usually includes a visit to a primary care physician, who would perform a history and physical examination, provide LBP education, and prescribe medications and/or refer based on their assessment findings and patient preferences.
2889957|NCT03320135|Active Comparator|Enamel matrix derivative proteins|Open flap debridement to enamel matrix derivative application in proximal class-II furcation.
2889958|NCT03320135|Active Comparator|Open Flap Debridement|Open flap debridement in proximal class-II furcation.
2889959|NCT03320122|Experimental|Telemedicine|Medical Direction will be provided by pediatric physiatrists using telemedicine.
2889960|NCT03320122|Active Comparator|In-Person Pediatric Physiatrist|Medical Direction will be provided by pediatric physiatrists in-person.
2889961|NCT03320122|Active Comparator|In-Person Non-Pediatric Physiatrist|Medical Direction will be provided by contracted physicians (i.e., non-pediatric physiatrists) in-person care.
2889962|NCT03320096|Experimental|Microfocused ultrasound with visualization|
2889963|NCT03320083|Active Comparator|Educational care derived from POSSUMS|Intervention group were offered a sleep education session using behavioral change counseling communication skills, derived from the POSSUMS approach developed by Douglas P and Whittingham K. However we could not use Acceptance and Commitment Therapy (ACT), because none of the investigators had sufficient training on ACT at the time the study was conducted.
2889964|NCT03320083|No Intervention|Usual Care|General anticipatory guidance given
2889965|NCT03320070|Experimental|Acthar, 1 mL (80 U)|
2889966|NCT03320070|Placebo Comparator|Placebo, I mL|
2889967|NCT03320057|Experimental|Medication abortion patients|Oral mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)
2889968|NCT03320031|Experimental|combined group|Drug: linagliptin&premixed insulin Treated with linagliptin 5mg/d combined with premixed insulin for 12 weeks.
2889969|NCT03320031|Active Comparator|linsulin group|Drug: premixed insulin Treated with premixed insulin for 12 weeks.
2889970|NCT03320018|Experimental|Hydrogen/Minocycliine|"Hydrogen will be infused into aqueous solution (normal saline or water) at as high a concentration as possible (saturation = 1.6 ppm), and administered intravenously or orally respectively, q 8 hours for 3 days.~Similarly, Minocycline will be administered either i.v. or p.o. once daily for 5 days."
2889971|NCT03320018|Placebo Comparator|Placebo Hydrogen/Placebo Minocycline|Normal saline will be substituted for both Hydrogen and Minocycline for intravenous administration. Water will be substituted for hydrogen when administered p.o., and placebo capsules will be substituted for minocycline.
2889972|NCT03320005|Active Comparator|ResistanceTraining Group|The RT program has the following features: 05 classes performing two weekly sessions; day shift; sessions with maximum duration of 1 (one) hour; 02 series; 08 to 12 repetitions; interval between sets of 01 to 02 minutes; exercises: bench press, seated leg press 45°, pull forward, Earth, rowing standing calf standing, power lifting, abdominal and development.
2889974|NCT03319992|No Intervention|Conventional treatment|The conventional treatment arm was conducted according to a set of exercises that were specifically designed in order to match the robotic treatment. Patients received both physical therapy (PT) and occupational therapy (OT) session, administered by the physiotherapists of the hospital. The therapist will provide a specific conventional treatment comparable with the robotic treatment in terms of session time and therapeutic goals.
2889975|NCT03319992|Experimental|Robotic treatment|The patients enrolled in the robotic arm are going to be undergone a series of passive, assisted and active mobilization in upper limb task-oriented exercises implemented in 3d virtual environments. Briefly speaking, these tasks promote the upper arm multi-joints coordination during the execution of reaching movements and grasping actions of fixed virtual objects displaced in the space.
2889976|NCT03319966||Oculomotor Dysfunction|This group consists of subjects with mTBI who have been diagnosed with OMD by objective OD measurements. These subjects will undergo neurovision rehabilitation used to treat oculomotor dysfunction following traumatic brain injury per usual clinical standard of care at the HCMC TBI Clinic.
2889977|NCT03319953|Experimental|TAK-041 40 mg + Placebo|TAK-041 40 milligram (mg), suspension, orally on Day 1 of treatment period 1, followed by 35 days wash-out period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of treatment period 2. All participants will take a stable dose of antipsychotics throughout the duration of the treatment period.
2889978|NCT03319953|Experimental|Placebo + TAK-041 40 mg|TAK-041 placebo-matching, suspension, orally on Day 1 of treatment period 1, followed by 35 days wash-out period, followed by TAK-041 40 mg, suspension, orally on Day 1 of treatment period 2. All participants will take a stable dose of antipsychotics throughout the duration of the treatment period.
2889979|NCT03319940|Experimental|AMG 757 Treatment|
2889980|NCT03319927|Experimental|Integrated pest management|The intervention consists of an integrated pest management (IPM) educational workshop and consultation. The child care health consultants (CCHCs) conduct the educational workshop for child care center directors and providers on IPM policies and practices including the providers' practices and beliefs. The workshop includes IPM videos, IPM Toolkit, and IPM toolbox. The (CCHCs) meet with center directors to review the results of the Baseline observational Checklists and to identify center-specific intervention goals. The intervention also includes 7 monthly child care health consultation visits where the CCHC and director review the center's progress towards the intervention goals, discuss problems, and share resources.
2889981|NCT03319927|Active Comparator|Physical activity|The intervention consists of a physical activity educational workshop and consultation. The child care health consultants (CCHCs) conduct the educational workshop for the child care center directors and providers on physical activities center policies and best practices over 7 months. The workshop includes a Physical Activity Toolkit and toolbox. The (CCHCs) meet with center directors to review the results of the Baseline observational Checklists and to identify center-specific intervention goals. The intervention also includes 7 monthly child care health consultation visits where the CCHC and director review the center's progress towards the intervention goals, discuss problems, and share resources.
2889982|NCT03319914||ST-003 Observational|Calciphylaxis patients who participated in the ST-001 CALISTA
2889983|NCT03319901|Experimental|Venetoclax + Chemotherapy|"Venetoclax is administered orally once daily for 21 days in each cycle~Standard Chemotherapy will be administered every 28 days"
2889984|NCT03319888|Experimental|cpap group|CPAP treatment plus conservative treatment with lifestyle modifications.
2889985|NCT03319888|Active Comparator|control group|Conservative treatment with lifestyle modifications.
2889986|NCT03319849|Experimental|Renexus®|
2889987|NCT03319849|Sham Comparator|Sham|
2889988|NCT03319836||Pre-very high protein enteral nutrition|20 enterally fed critically ill adult patients prior to the introduction of a very high protein enteral nutrition formula [2015].
2889989|NCT03319836||Post-very high protein enteral nutrition|20 enterally fed critically ill adult patients post the introduction of a very high protein enteral nutrition formula [2016].
2889990|NCT03319823|Experimental|Thiazide Therapy Group|• Group (1): Thiazide Therapy Group: Men without diabetes, and mild hypertension - a sleeping systolic blood pressure of 125-139 mm Hg, and an awake average blood pressure of < 160 mm Hg
2889991|NCT03319823|Experimental|Combination Therapy Group|• Group (2): Combination Therapy Group: Men with diabetes, or with more severe hypertension - a sleeping blood pressure of ≥ 140 mm Hg, or an awake average blood pressure of ≥ 160 mm Hg.
2889992|NCT03319810|Experimental|infusion of IVIG|
2889993|NCT03319797|Other|Treatment with NOVOCART® Inject plus|Treatment with NOVOCART® Inject plus (Autologous chondrocyte transplantation)
2889994|NCT03319784|Active Comparator|Ketorolac (Toradol) Injection Group|Patients will be randomized into two patient groups: Ketorolac (Toradol) injection group (n=30) and or Steroid injection group (n=30). Patients assigned to Ketorolac group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000. Patients will be blinded to the kind of injection they receive, but the physicians who perform the injection will not be blinded for the medical record purposes. The injection will be done under ultrasound guidance to the subacromial space.
2889995|NCT03319784|Active Comparator|Steroid Injection Group|Patients will be randomized into two patient groups: Ketorolac (Toradol) injection group (n=30) and or Steroid injection group (n=30). Patients assigned to Steroid group will receive a single dose of 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000. Patients will be blinded to the kind of injection they receive, but the physicians who perform the injection will not be blinded for the medical record purposes. The injection will be done under ultrasound guidance to the subacromial space.
2889996|NCT03319771|Experimental|Treadmill Walking Exercise Training|12 weeks of supervised, progressive treadmill walking exercise training
2889997|NCT03319771|Active Comparator|Stretching-and-toning Exercise Training|12 weeks of supervised, stretching-and-toning exercise training
2889998|NCT03319758|Experimental|Intact labial plate|Immediate implant placement used bone augmentation in combination with an absorbable collagen membrane without labial plate dehiscence defects.
2889999|NCT03319758|Experimental|Compromised labial plate.|Immediate implant placement used bone augmentation in combination with an absorbable collagen membrane with labial plate dehiscence defects.
2890000|NCT03319745|Experimental|Pembrolizumab|"Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of Cycles 1 and 2.~Each cycle is 3 weeks."
2890005|NCT03319680|Active Comparator|Citrate dialysate|Hemodialysis with citrate dialysate during 16 weeks
2890006|NCT03319680|No Intervention|Acetate dialysate|Hemodialysis with acetate dialysate during 16 weeks
2890007|NCT03319667|Experimental|Isatuximab/Bortezomib/Lenalidomide/Dexamethasone = IVRd arm|"Induction treatment with 4x6-week cycles with intravenous (IV) isatuximab + subcutaneous (SC) bortezomib + oral lenalidomide + IV or oral dexamethasone~Continuous treatment with 4-week cycles with IV isatuximab + oral lenalidomide + IV or oral dexamethasone"
2890008|NCT03319667|Active Comparator|Bortezomib/Lenalidomide/Dexamethasone = VRd arm|"Induction treatment with 4x6-week cycles with SC bortezomib + oral lenalidomide + IV or oral dexamethasone~Continuous treatment with 4-week cycles with oral lenalidomide + IV or oral dexamethasone"
2890009|NCT03319667|Other|Isatuximab/Lenalidomide/Dexamethasone = IRd crossover arm|4-weeks cycles with IV isatuximab + oral lenalidomide + IV or oral dexamethasone
2890010|NCT03319654|Experimental|Spontaneous cycle IUI|"DNA fragmentation by TUNEL assay~DNA fragmentation will be measured both at the time of the diagnostic work-up as at the time of insemination."
2890011|NCT03319641|Experimental|PSMA-PET/CT scan|PSMA-PET/CT imaging in advanced ACC/SDC
2890012|NCT03319628|Experimental|Dose Escalation and Confirmation|XMT-1536 treatment will be administered in groups of patients who will receive doses that increase over time. Once the maximum tolerated dose or recommended Phase 2 dose is achieved, new groups of patients will receive XMT-1536 at this fixed dose.
2890013|NCT03319615|No Intervention|Habitual dietary intake|Habitual dietary intake
2890014|NCT03319615|Experimental|Energy Restriction|Match period (to comparator) of dietary energy restriction
2890015|NCT03319602|Active Comparator|Oxygenation only with nasal canula|intervention: classical oxygenation with nasal canula (High flow)
2890016|NCT03319602|Experimental|Oxygenation with double trunk masknasal canula|oxygenationwith DTM above nasal canula
2890017|NCT03319589|Experimental|Supplement Arm|School children (age 6 to 6.5) will receive their supplement 5 days a week in the morning before school starts. They will either receive the supplement at school or at the community health center depending on the preference of the villagers after recruitment. Young children (age 24 to 30 months) will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers.
2890018|NCT03319589|No Intervention|Control Arm|Children in the active intervention village will be compared with assessment-only controls in a separate village having comparable demographic characteristics
2890019|NCT03319576|Experimental|Early feeding|Patients randomized to early feeding will be fed 4 hours following gastrostomy tube placement
2890020|NCT03319576|No Intervention|Standard feeding|Patients randomized to standard feeding will be fed 24 hours following gastrostomy tube placement
2890021|NCT03319563|Experimental|local anesthetic-epinephrine group|"after general anesthesia, the Infiltration cocktail was done by the surgeon at three levels:~Subcutaneous: before incision at a volume 20 ml/10 cm/side.~Muscular Paravertebral: before opening the thoracolumbar fascia, using the same previous volume.~Neural paravertebral: after exposure of the transverse processes. A volume of 5 ml/per each process of the same cocktail, 1 cm deep to the surface of the corresponding process before pedicular screws fixation after negative blood aspiration."
2890022|NCT03319563|Placebo Comparator|saline group|after general anesthesia, the same infiltration volume and technique using normal saline.
2890023|NCT03319550|Experimental|Casein|"LPS + 36 hour fast and bedrest + Casein (9% leucine) - 0,1 g leucine/kg bodyweight, 1/3 as bolus and 2/3 as sipping."
2890024|NCT03319550|Experimental|Whey|"LPS + 36 hour fast and bedrest + Whey (11% leucine) - 0,1 g leucine/kg bodyweight, 1/3 as bolus and 2/3 as sipping"
2890025|NCT03319550|Experimental|Leucine-enriched whey|"LPS + 36 hour fast and bedrest + Leucine-enriched whey (16% leucine) - 0,1 g leucine/kg bodyweight, 1/3 as bolus and 2/3 as sipping"
2890026|NCT03319537|Experimental|Pevonedistat|
2890027|NCT03319537|Experimental|pevonedistat in combination with pemetrexed and cisplatin|
2890028|NCT03319511|Active Comparator|paravertebral group|ultrasound guided, in sitting position, or lateral position, at T2 and T4 levels, using 22 G spinal needle, in plane technique, traversing the costo-transverse ligament
2890029|NCT03319511|Experimental|spinal group|Ultrasound guided, In the lateral decubitus or sitting position, the puncture performed via para-median approach, at the T4-T5 or T5-T6 interspace, with a 27G spinal needle. After piercing the ligamentum flavum, the needle's stylet removed and the hub observed for free flow of CSF; injection when there is a flow of clear CSF.
2890030|NCT03319498|Active Comparator|Peppermint Oil Vapor|Exposure of the perineum to the vapor of the active comparator, 2 ml peppermint oil. The perineum will NOT come into contact with the oil directly.
2890031|NCT03319498|Placebo Comparator|Mineral Oil Vapor|Exposure of the perineum to the vapor of the placebo comparator, 2 ml mineral oil. The perineum will NOT come into contact with the oil directly.
2890032|NCT03319485|Experimental|ExAblate Pallidotomy|ExAblate treatment for Advanced Idiopathic Parkinson's Disease
2890033|NCT03319485|Sham Comparator|Sham ExAblate Pallidotomy|
2890034|NCT03319472||Benign Pleural Effusion|Patients that will be diagnosed within a month from admission with any non-malignant cause of pleural effusion, including but not limited to effusions caused by common or tuberculous or fungal infection, heart failure, etc. Documentation of the etiology will be required for inclusion in this group, including but not limited to bacteriology, virology, PCR, radiology, heart echocardiogram or catheterization, as appropriate.
2890035|NCT03319472||Malignant Pleural Effusion|Patients that will be diagnosed within a month from admission with any malignant cause of pleural effusion, including but not limited to effusions caused by lung, breast, colon, ovary, mesothelial, hematopoietic, prostate, or any other cancer. Diagnosis will be based on verification of the presence of malignant cells in the pleural fluid or tissues. Patients with cancer and an effusion without such documentation will be assigned to the benign group if an alternative diagnosis is made. In any other case, they will be excluded.
2890036|NCT03319459|Experimental|Regimen A|FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies.
2890037|NCT03319459|Experimental|Regimen B|FATE-NK100 in combination with trastuzumab in subjects with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, HER2+ advanced gastric cancer or other advanced HER2+ solid tumors.
2890111|NCT03318861|Experimental|Relapsed/Refractory Muliple Myeloma Subjects|Phase 1 dose-escalation
2890038|NCT03319459|Experimental|Regimen C|Regimen C: FATE-NK100 in combination with cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC), or other epidermal growth factor receptor 1 positive (EGFR1+) advanced solid tumors.
2890039|NCT03319433||Group I (Perfusion Index <3.5)|Those parturient with perfusion index <3.5 when baseline monitors are attached while the patient is being prepared for surgery.
2890040|NCT03319433||Group II (Perfusion index >3.5)|Those parturient with perfusion index >3.5 when baseline monitors are attached while the patient is being prepared for surgery.
2890041|NCT03319420|Experimental|LO2A|1 drop of sodium hyaluronate instilled into each eye 4 times daily
2890042|NCT03319420|Active Comparator|Systane Ultra UD|1 drop of Systane Ultra UD instilled into each eye 4 times daily
2890043|NCT03319407|Other|Observation|All participants will be monitored with EPAD system
2890044|NCT03319394|Experimental|The First Twenty|TF20 group completed a structured exercise program. Once a week a trained firefighter with current CPR and First Aid certifications met with the group to assess progress and answer questions about the workouts or the program. The rest of the time, the participants completed the workouts on their own time. Workouts contained a combination of aerobic (e.g., running, rowing, jumping), body weight (e.g., air squats, pushups, situps), and weight lifting (e.g., presses, back squats, lunges) exercises with workouts designed to use equipment available in an exercise/gym facility (e.g., weight racks, benches). Sixty-minute TF20 sessions included a warm-up, workout and cool down. All sessions were able to be logged online in TF20 program.
2890045|NCT03319394|Active Comparator|Comparison|The Comparison Group followed and documented their regular workout routine for 14 weeks. Once a week, a trained firefighter with current CPR and First Aid certifications met with the group to discuss questions. Participants were able to choose when to complete their workouts.
2890046|NCT03319381||w/o SOP|Time period 1: 2000-2006, without new SOPs
2890047|NCT03319381||SOP|Time period 2: 2010-2012, after implementation of the new SOPs
2890048|NCT03319368|Experimental|Intervention: Targeted gown and glove use|Additional gowns and gloves used for high risk care activities
2890049|NCT03319342|Experimental|Group I (acts of kindness to others)|Participants perform small acts of kindness or generosity for others 3 times per week for 4 weeks and complete weekly online questionnaires.
2890050|NCT03319342|Experimental|Group II (acts of kindness to self)|Participants perform small acts of kindness for themselves 3 times per week for 4 weeks and complete weekly online questionnaires.
2890051|NCT03319342|Experimental|Group III (self-kindness meditation)|Participants direct kind, loving thoughts to themselves, via guided meditation, 3 times per week for 4 weeks and complete weekly online questionnaires.
2890052|NCT03319342|Active Comparator|Group IV (track daily activities)|Participants keep track of their daily activities, focusing on factual information rather than thoughts and feelings, on 3 separate days each week. At the end of the week, participants report on their activities and complete several online questionnaires.
2890053|NCT03319329||critically ill adult patients|"Part I: A cross-sectional study to compare validity of several predictive equations used to predict REE in critically ill adult patients for staying ≤ 5 days, 6 - 10 days and > 10 days by using indirect calorimetry (IC) as the reference standard.~Part II: To develop predictive equation for the estimation of energy requirement by identifying variables that might influence REE of mechanically ventilated critically ill patients.~Part III: To validate the newly developed predictive equation for the estimation of energy requirement by using Ten fold cross-validation approach"
2890054|NCT03319316|Experimental|Cohort 1 - Non-squamous - Arm A|Patients receive a maintenance treatment of durvalumab + tremelimumab
2890055|NCT03319316|No Intervention|Cohort 1 - Non-squamous - Arm B|Patients receive a maintenance treatment of pemetrexed
2890056|NCT03319316|Experimental|Cohort 2 - Squamous - Arm A|Patients receive a maintenance treatment of durvalumab + tremelimumab
2890057|NCT03319316|No Intervention|Cohort 2 - Squamous - Arm B|Patients will have observation
2890058|NCT03319277|Active Comparator|Routine opiate prescription|This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the standard amount of post-discharge opiate medications - 28 tablets of oxycodone 5mg.
2890059|NCT03319277|Experimental|Decreased opiate prescription|This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the decreased amount of post-discharge opiate medications - 5 tablets of oxycodone 5mg with a paper prescription for an additional 10 tablets of oxycodone 5mg as a backup for uncontrolled pain.
2890060|NCT03319264|Experimental|Patients with SpA|"Patients included in this single group study will have 3 interventions to assess the severity of muscle loss :~dynamometry exam~walking test~Dual-energy X-ray Absorptiometry (DXA) measurement Quality of life will be assessed with Sarcopenia & Quality of Life (SARQOL) questionnaire. Patients will also fill a Life habits Questionnaire."
2890061|NCT03319238||Patient cohort|Neuropathic pain patient taking ketamine
2890062|NCT03319225||Tetraplegia|Persons with Tetraplegia
2890063|NCT03319225||Paraplegia|Persons with Paraplegia
2890064|NCT03319225||Neurologically-intact|Neurologically-intact controls
2890065|NCT03319212|Other|Active Comparator|Subjects that are between the ages 18-55 and are current spherical soft contact lens wearers will be assigned to a single study lens type to be worn bilaterally for approximately 4 weeks followed by no contact lens wear for 1 week.
2890066|NCT03319199|Active Comparator|Primary treatment Arm|"patients with a diagnosis of NAFDL will be randomly receive trial product SLIM WATER that contains L-CARNITINE and MAGNESIUM for a duration of 16 weeks."
2890067|NCT03319199|Placebo Comparator|Placebo Arm|"patients with a diagnosis of NAFDL will be randomly receive placebo for the initial 8 weeks and continue another 8 weeks with the trial product SLIM WATER."
2890068|NCT03319186|Experimental|EDIT Management|
2890069|NCT03319186|Active Comparator|Standard Care|
2890108|NCT03318887||Sofosbuvir/daclatasvir|Patients with hepatitis C virus (HCV) infection treated with sofosbuvir/daclatasvir combination therapy with or without ribavirin between February and September 2014
2890109|NCT03318874|Experimental|Blephasteam|Heat delivery device, to be used according to guidelines from manufacturer.
2890110|NCT03318874|Active Comparator|THERA°PEARL Eye Mask|Heat delivery device, to be used according to guidelines from manufacturer.
2890070|NCT03319173|Experimental|Experimental group|"Dietary interventions for subjects in the experimental group include clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation. Subjects will consume 3 meals per day with the following approximate macronutrient breakdown per meal: 65% fat, 25% protein, 10% carbohydrate.~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week."
2890071|NCT03319173|Active Comparator|Control group|"Dietary interventions for subjects in the control group include the subjects' current dietary protocol (Standard American Diet-SAD). Subjects will consume 4-6 small meals per day with the following approximate macronutrient breakdown per meal: 50% carbohydrate, 35% protein, 15% fat.~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week."
2890072|NCT03319160||Retrospective|Patients who have already completed use of LifeVest before start of the study
2890073|NCT03319160||Prospective|Patients receiving a LifeVest prescription in clinical routine
2890074|NCT03319147|Placebo Comparator|Placebo|4g of maltodextrin
2890075|NCT03319147|Active Comparator|Active|4g of essential amino acids
2890076|NCT03319134|Experimental|active anodal HD-tDCS|Active anodal HD-tDCS stimulation applied during memory task
2890077|NCT03319134|Sham Comparator|sham HD-tDCS|Sham HD-tDCS stimulation during memory task for comparison
2890078|NCT03319134|Experimental|active cathodal HD-tDCS|Active cathodal HD-tDCS stimulation applied during memory task
2890079|NCT03319121|Experimental|Empirical therapy group|Participants will be given extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks
2890080|NCT03319121|Experimental|Guided therapy group|Participants will be give Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
2890081|NCT03319108|Other|Low Comorbidity Index Score|CCI; 1-3 as Group 1
2890082|NCT03319108|Other|High Comorbidity Index Score|CCI; 4 and above as Group 2
2890083|NCT03319095|No Intervention|Control|Control group: participants will receive only verbal instructions on PFM anatomy and function during the first assessment when women will be required to contract their pelvic floor muscle. The participants will have no contact with the service until the second assessment
2890084|NCT03319095|Active Comparator|Intervention|Intravaginal Electrical Nerve Stimulation: participants will be submitted to Intravaginal Electrical Nerve Stimulation
2890085|NCT03319082||CXL Group|Patients with corneal ectasia following refractive surgery who had corneal collagen cross-linking in one or both eyes according to the Photrexa Viscous and Photrexa prescribing information
2890086|NCT03319069|Experimental|group (1)|Hypofractionated radiotherapy women with T3-4 and /or 4 or more axillary nodes involvement post mastectomy. Hypofractionated radiotherapy 43,5 GY/15 fractions (f) /3w. to chest wall and supraclavicular nodal region.
2890087|NCT03319069|Active Comparator|group(2)|Conventional fractionated radiotherapy breast cancer women with T3-4 and/ or 4 or more axillary nodes involvement post mastectomy. Conventional fractionated radiotherapy 50 Gray(GY)/25 fractions (f)/5w to chest wall and supraclavicular nodal region.
2890088|NCT03319056|Active Comparator|Air purifier in active-mode|using the air purifier with a filtration
2890089|NCT03319056|Sham Comparator|Air purifier in sham-mode|using the air purifier without filtration
2890090|NCT03319043|Experimental|treatment group|patients are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation and additional Chanqin granules 10g three times a day. All granules will be taken orally with 200 ml warm water.
2890091|NCT03319043|Placebo Comparator|controlled group|patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation and Chanqin analogous granules. All granules will be taken orally with 200 ml warm water.
2890092|NCT03319030||Duchenne Muscular Dystrophy (DMD)|Enrolls boys with a genetically confirmed diagnosis of DMD.
2890093|NCT03319017||Multiple-trauma patients|The patients who are diagnosed with multiple-trauma and have blood test in an emergency room. The patients with multiple-trauma are defined as the patients who have trauma in more than two regions.
2890094|NCT03319004|Experimental|Compare bispectral index and phase lag entropy|
2890095|NCT03318991|Active Comparator|GreenLight laser|180W Greenlight laser is used for vaporesection of the prostate.
2890096|NCT03318991|Active Comparator|Thulium laser|200W Thulium laser is used for enucleation of the prostate.
2890097|NCT03318978|Experimental|25 ng dose|Capsule containing 25 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
2890098|NCT03318978|Experimental|50 ng dose|Capsule containing 50 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
2890099|NCT03318978|Experimental|100 ng dose|Capsule containing 100 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
2890100|NCT03318978|Experimental|250 ng dose|Capsule containing 100 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
2890101|NCT03318952|Experimental|lidocaine then articaine|For the first dental procedure 2% lidocaine with 1:100,000 epinephrine will be administered with a buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed. For the second dental procedure a single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
2890102|NCT03318952|Experimental|articaine then lidocaine|For the first dental procedure a single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered. For the second dental procedure 2% lidocaine with 1:100,000 epinephrine will be administered with a buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed.
2890103|NCT03318939|Experimental|Poziotinib|"Cohort 1: Patients with EGFR exon 20 insertion-mutant non-small cell lung cancer (NSCLC)~Cohort 2: Patients with HER2 exon 20 insertion-mutant non-small cell lung cancer (NSCLC)"
2890104|NCT03318913|No Intervention|Health control|Health young subjects free of diabetes mellitus and nutritional intervention
2890105|NCT03318913|Placebo Comparator|DM Placebo|Sucralose
2890106|NCT03318913|Active Comparator|DM FHP|Fish protein hydrolysates
2890107|NCT03318900|Experimental|Leukapheresis + Utomilumab|Part 1 Leukapheresis then Part 2 Treatment, Dose escalation of Utomilumab given in combination with CD8+T cells, IL-2 and Cyclophosphamide. Utomilumab begins with dose level 2.
2890112|NCT03318848|Experimental|Video during simulation|The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
2890113|NCT03318848|No Intervention|Simulation without video|The students of the control group performed the simulation of the bed bath procedure, with the aid of a tutor.
2890114|NCT03318835|Experimental|Thalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21
2890115|NCT03318835|Active Comparator|R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
2890116|NCT03318822||Q-Collar|Subjects wearing the Q-Collar
2890117|NCT03318809|Experimental|AMG 986 Treatment|Group 1: Severely Renal Impaired subjects; Group 2: Healthy Subjects
2890118|NCT03318796|Other|Interventional|Coronary artery stenting of De novo bifurcation lesions MB & SB
2890119|NCT03318783|Active Comparator|GSK2256294|10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.
2890120|NCT03318783|Placebo Comparator|Placebo|10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.
2890121|NCT03318770||All patients|All eligible patients enrolled in the GIMEMA LAL2116 study who have completed 12 months follow-up will be included in this group.
2890122|NCT03318757|Experimental|Group 1- Bupivacaine extended release liposome injection|Bupivacaine extended release liposome injection (Exparel TM) is a novel formulation of bupivacaine designed to achieve long-acting postoperative analgesia.
2890123|NCT03318757|Active Comparator|Group 2- Bupivacaine HCl|Bupivacaine HCl (Marcaine) is a local anesthetic that reduces the flow of sodium in and out of nerves which decreases the initiation and transfer of nerve signals in the area in which the drug is applied.
2890124|NCT03318744|Experimental|aspirin 100mg|Participants will be given aspirin 100mg once per day.
2890125|NCT03318744|Placebo Comparator|placebo|Participants will be given placebo oral tablets once per day.
2890126|NCT03318731|Placebo Comparator|Sugar Pill|Maltodextrin (matches the weight of the active treatment). Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
2890127|NCT03318731|Experimental|Fenugreek Extract, Low Dose|300mg Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
2890128|NCT03318731|Experimental|Fenugreek Extract, High Dose|500mg Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
2890129|NCT03318718|Experimental|TOF measurement|TOF and MEP measurement after Anesthesia with non-depolarizing NMBA Rocuronium
2890130|NCT03318692|Experimental|MySpine System|pedicle screw implantation (spondylodesis) using the MySpine System. post surgery CT.
2890131|NCT03318692|Active Comparator|free-hand|Freehand (fluoroscopically controlled) implantation of pedicle screw (spondylodesis). Post surgery CT
2890132|NCT03318666|Active Comparator|Enhanced Usual Care (EUC)|Both arms will receive this intervention
2890133|NCT03318666|Experimental|Supporting Our Valued Adolescents (SOVA)|This arm will receive the SOVA intervention in addition to Enhanced Usual Care
2890134|NCT03318653||HD - Hemodialysis|Patients with end stage renal disease treated with hemodialysis
2890135|NCT03318653||PD - Peritoneal dialysis|Patients with end stage renal disease treated with peritoneal dialysis
2890136|NCT03318640|Experimental|Mindfulness|Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month.
2890137|NCT03318640|No Intervention|Control|Patient will have usual medical care.
2890138|NCT03318627|Other|Tension Measuring|Measuring intraoperative tension of rotator cuff tendon with sterile spring Balance.
2890139|NCT03318614|Experimental|Probiotics M-63 group|Participants assigned to the M-63 group were given a sachet of B. infantis M63 (Morinaga Milk Industry Co., Ltd., Japan) to consume daily in addition to advice of good hygiene and sanitation practices.
2890140|NCT03318614|Placebo Comparator|Control group|No probiotic intervention was given to the control group over three months other than advice of good hygiene and sanitation practices.
2890141|NCT03318601|Experimental|cirrhotic patients with ascites|cirrhotic patients with ascites requiring prolonged hospitalization
2890142|NCT03318588||Case|Patients undergoing vitrectomy for primary retinal detachment
2890143|NCT03318588||Control|Patients undergoing vitrectomy for idiopathic macular hole
2890144|NCT03318575|Experimental|autoRIC|The autoRIC device will be used on subjects randomized to the treatment group.
2890145|NCT03318575|Sham Comparator|autoRIC Sham|The autoRIC Sham device will be used on subjects randomized to the control group.
2890146|NCT03318562|Experimental|TNBC Cohort|female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable TNBC and have received >=1 prior cancer therapy regimen for metastatic disease
2890147|NCT03318562|Experimental|HCC Cohort|male and female subjects who have histologically or cytologically confirmed advanced HCC not amenable to surgical resection and have failed >=1 systemic therapy, which must include sorafenib, or are intolerant to multikinase inhibitor therapies
2890148|NCT03318549||Glaucoma|Patients with diagnosed glaucoma
2890149|NCT03318549||Suspicious of having glaucoma|Patients with suspicious of having glaucoma based on intra-ocular pressure or optic nerve photographs with glaucoma appearance
2890150|NCT03318549||Non-glaucomatous optic neuropathies;|Patients with optic neuropathies that do not look glaucomatous-like
2890151|NCT03318549||Age-related macular degeneration (AMD)|Patients with diagnosed age-related macular degeneration
2890152|NCT03318549||Retinal degenerations|Patients with other retinal degenerations excluding AMD
2890153|NCT03318549||Other diseases of visual pathways|Other diseases of the visual pathway not included in the previous groups
2890154|NCT03318549||Healthy control group|Patients labeled as healthy controls for not having any other eye diseases that would be included on the other groups
2890155|NCT03318536||No Granisetron|120 Patients prior to changes of intern standards of caesarean section. Before march 2017 no patient undergoing elective caesarean section received Granisetron as a matter of routine.
2890156|NCT03318536||With Granisetron|120 Patients after changes of intern standards of caesarean section. After march 2017 all patient undergoing elective caesarean section received Granisetron as a matter of routine.
2890157|NCT03318523|Placebo Comparator|Placebo|"Year 1: Participants will receive matching placebo to BIIB054 on Day 1 and then every 4 weeks.~Year 2: Participants who received placebo in year 1 will be randomized into one of the active treatment arms in year 2 and will receive BIIB054 intravenous (IV) infusion on Week 52 and then every 4 weeks."
2890158|NCT03318523|Experimental|BIIB054 250 mg|Participants will receive BIIB054 250 mg intravenous (IV) infusion on Day 1 and then every 4 weeks.
2890159|NCT03318523|Experimental|BIIB054 1250 mg|Participants will receive BIIB054 1250 mg IV infusion on Day 1 and then every 4 weeks.
2890160|NCT03318523|Experimental|BIIB054 3500 mg|Participants will receive BIIB054 3500 mg IV infusion on Day 1 and then every 4 weeks.
2890161|NCT03318497|Experimental|Diagnostic (Interim FLT PET/CT)|"The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.~Procedure: Computed Tomography~Drug: 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT~Other: Laboratory Biomarker Analysis~Procedure: Positron Emission Tomography"
2890162|NCT03318484|Active Comparator|Optimal Medical Care|Optimal medical care (OMC) only is administrated in this arm. OMC is established according to the standards established by the 2016 ACC-AHA Guidelines for the Management of Patients with Peripheral Artery Disease in order to promote best practices for risk factor management.
2890163|NCT03318484|Experimental|Optimal Medical Care and SDT|OMC and sonodynamic therapy (SDT) are administrated in this arm.
2890164|NCT03318471|Active Comparator|Group M|received 50 mg/kg MgSo4 in 100 ml 0.9 NaCl 15 minutes prior to anesthesia induction over 15 minutes
2890165|NCT03318471|Placebo Comparator|Group S|received 100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes.
2890166|NCT03318458|Experimental|Pilates group|
2890167|NCT03318458|No Intervention|No intervention group|
2890168|NCT03318445|Experimental|Rucaparib and irinotecan|"Rucaparib will be taken twice daily by mouth for 7-14 days in 21 or 28 day cycles. Irinotecan will be administered by IV for 90 minutes every 14 days, or every 21 days if not tolerated.~During the dose escalation phase, the maximum tolerated dose for combining Rucaparib and irinotecan will be determined. The dose for rucaparib during dose escalation will range from 300 mg to 600 mg, depending on the progression of study. The dose for irinotecan during dose escalation may range from 40 mg/m2 to 150 mg/m2.~During the dose expansion phase, patients who have received prior PARP inhibitors will be given rucaparib and irinotecan at the maximum tolerated dose levels determined during the dose escalation phase."
2890169|NCT03318445|Experimental|Rucaparib only|During the dose expansion phase, patients who have not received prior PARP inhibitor therapy will take 600 mg of rucaparib by mouth daily. Patients who progress on single-agent rucaparib will be given the option to cross-over to the combination treatment arm and receive rucaparib in combination with irinotecan at the maximum tolerated dose levels determined during dose escalation.
2890170|NCT03318419|Experimental|Cladribine group|Cladribine in combination of GAP (G-CSF priming, low dose cytarabine, and Pegaspargase) will be administrated in this arm
2890171|NCT03318406||BTVA treated patients|Patients with heterogeneous upper lobe emphysema undergoing Bronchoscopic Thermal Vapor Ablation treatment
2890172|NCT03318393|Active Comparator|Unfractionated heparin group|Patients randomized to this arm will undergo usual care using unfractionated heparin as the primary anticoagulant.
2890173|NCT03318393|Experimental|Bivalirudin group|Patients randomized to this arm will receive anticoagulation with bivalirudin
2890174|NCT03318380|Experimental|Diagnostic Contrast-Enhanced Ultrasound Imaging (CEUS)|Patients receive sulfur hexafluoride IV and undergo CEUS imaging over 10 minutes.
2890175|NCT03318367|Experimental|Supportive care (virtual reality education module)|After undergoing a previously planned CT simulation scan, patients complete a virtual reality education module to learn more about radiation therapy for prostate cancer. Patients also complete questionnaires before and after the module.
2890176|NCT03318354|Experimental|Test|Torrent's Olmesartan Medoxomil Tablets 40 mg
2890177|NCT03318354|Active Comparator|Reference|Daiichi Sankyo Inc's Benicar Tablets 40 mg
2890178|NCT03318341|Experimental|TheraBracelet & Stimulation|Participants will be instructed to wear TheraBracelet on the affected wrist every day for at least 8 hours/day during their daily activity over a month. The device will apply wrist vibration at a subthreshold (imperceptible) level.
2890179|NCT03318341|Placebo Comparator|TheraBracelet & Sham|Participants will be instructed to wear TheraBracelet on the affected wrist every day for at least 8 hours/day during their daily activity over a month. The device will apply no vibration.
2890180|NCT03318315|Experimental|Group 1|3.75 mcg HA per 0.5 mL dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant and 0.5 ml dose of IIV4 vaccine, both administered intramuscularly within 15 minutes on day 1, and 3.75 mcg HA per 0.5 mL dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant intramuscularly on day 22, n=60
2890181|NCT03318315|Experimental|Group 2|0.5 ml dose of IIV4 vaccine intramuscularly on day 1 and 3.75 mcg HA per 0.5 ml dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant intramuscularly on day 22 and day 43, n=60
2890182|NCT03318315|Active Comparator|Group 3|0.5 ml dose of IIV4 vaccine intramuscularly on day 1, n=30
2890183|NCT03318289|Experimental|Ving Tsun (VT) group|Participants in the VT group will receive VT exercise intervention for 12 weeks.
2890184|NCT03318289|No Intervention|Control group|No intervention but can continue daily activities.
2890185|NCT03318276|Experimental|SID142|Patients administrate SID142 (Cilostazol 200mg, Ginkgo biloba leaf extract 160mg) once a day for 12 weeks
2890186|NCT03318276|Active Comparator|Rinexin® Tab|Patients administrate Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg) twice a day for 12 weeks
2890187|NCT03318263|Other|experimental|
2890188|NCT03318250|Active Comparator|Burst3D|"This is a device progamme setting which is being compared against DR6-LF.~Intervention for this arm is the dorsal root ganglion neurostimulation device implant which will occur at trial implant. Once device is implanted participants are assigned progammes in a randomized manner."
2890216|NCT03318029|Active Comparator|Vitamin D UK trial|Vitamin D supplementation and living in the UK
2890189|NCT03318250|Active Comparator|DRG-LF|"This is a device progamme setting which is being compared against Burst3D.~Intervention for this arm is the dorsal root ganglion neurostimulation device implant which will occur at trial implant.Once device is implanted participants are assigned progammes in a randomized manner."
2890190|NCT03318237||Patients with focal epilepsy|Patients undergoing ultra high field MRI of the brain
2890191|NCT03318211|Active Comparator|MgSO4 discontinuation|after delivery , no Extradoses of MgSO4 were given
2890192|NCT03318211|Active Comparator|MgSO4 continuation|After delivery , Mg Sop4 was given at a rate of 1 gram /hour for 24 hours after delivery
2890193|NCT03318198|Active Comparator|Intervention Arm|Attendings on the interventional arm attended daily work rounds with the resident teams in addition to established work rounds on the previously admitted patients on the care team.
2890194|NCT03318198|Placebo Comparator|Control Arm|Attendings crossed over to the control arm in which they did not attend work rounds with the team and only say new admissions with the resident team. This was usual care.
2890195|NCT03318185|Experimental|gasless single-port laparoscopic surgery|radical resection of rectal carcinoma is performed by gasless single-port laparoscopic-assisted surgery.
2890196|NCT03318185|Sham Comparator|conventional laparoscopic surgery|radical resection of rectal carcinoma is performed by conventional laparoscopic surgery.
2890197|NCT03318172|Experimental|Group C spinal cord stimulator|Spinal cord stimulator (SCS) implantation with conventional stimulation mode therapy during 2 weeks followed by 2 weeks with high-density stimulation mode therapy.
2890198|NCT03318172|Active Comparator|Group H spinal cord stimulator|Spinal cord stimulator (SCS) implantation with high-density stimulation mode therapy during 2 weeks followed by 2 weeks with conventional stimulation mode therapy.
2890199|NCT03318159|Other|posaconazole prophylaxis group|aplastic anemia / hypoplastic myelodysplastic syndrome patients undergoing antithymocyte globulin treatment and receiving posaconazole as prophylaxis antifungal agent
2890200|NCT03318146|Experimental|EXP-LP punctum plug|EXP-LP is a novel and innovative drug delivery system aiming to improve patient compliance and outcomes. EXP-LP punctum plug, is a non-invasive insert that replaces eye drops and provides sustained therapy for glaucoma, dry eye and other major eye diseases. EXP-LP is a combination of an ophthalmic prostaglandin drug (Latanoprost). The prostaglandin drug works by increasing the natural outflow of fluid from inside the eye
2890201|NCT03318146|Active Comparator|XALATAN®|XALATAN® (latanoprost ophthalmic solution) is an eye drop used to treat high eye pressure/intraocular pressure in people with open-angle glaucoma or ocular hypertension. XALATAN is administrated once a day
2890202|NCT03318133|Experimental|GA group|"general anesthesia(GA) group:~Open peripheral vein fluid infusion, radial arterial cannulation under local lidocaine anesthesia and arterial blood pressure monitoring~Propofol (1.5-3mg/kg), cis-atracurium(0.1-0.15mg/kg) and sulfentanyl(0.2-0.6μg/kg) anesthesia-induced intubation, mechanical ventilation to maintain normal PETCO2~Use sevoflurane, propofol and sulfentanyl to maintain anesthesia, and add cis-atracurium as needed~Transfer to ICU after surgery"
2890203|NCT03318133|Experimental|CLSB group|"combined lumbar plexus and sacral plexus block(CLSB) group:~Open peripheral vein fluid infusion~In lateral position (affected side upward), ultrasound-guided lumbar plexus block (0.375% ropivacaine, Lumbar 2-3 or/and 3-4vertebral space level, 25ml), then sacral plexus block (0.375% ropivacaine, 20ml)~Radial arterial cannulation under local lidocaine anesthesia and arterial blood pressure monitoring, and blockade effectiveness was evaluated 30min after nerve block~After reaching satisfactory blockade, target-controlled infusion of propofol was used to maintain Ramsay sedation score between 5-6 points, monitoring PETCO2 through nasopharyngeal airway, maintain autonomous respiration, and add small-dose fentanyl (10-20μg/time) as needed~Transfer to ICU after surgery"
2890204|NCT03318120|Experimental|Progressive Resistance Training|Participants assigned to this arm will receive progressive resistance training under the supervision of a personal trainer at a gym facility close to their home. They will be required to perform these exercises twice a week for the first six months and thereafter once a week for up to three years.
2890205|NCT03318120|Active Comparator|Standardized Exercise Training|Participants assigned to this arm will receive a set of standardized exercises comprising of stretching, balancing and strengthening under the supervision of a personal trainer at a gym facility that is close to their home. They will be required to perform these exercises twice a week for the first six months and thereafter once a week for up to three years.
2890206|NCT03318107|Experimental|Transvaginal probe (Photoacoustic + ultrasound imaging)|"A transvaginal imaging probe using ultrasound and photoacoustic imaging will be inserted into the vagina and will use different frequencies of lights to create images~This will occur before the first standard of care treatment, mid-treatment, end of treatment, and approximately 3 months after the end of treatment for a total of 4 imaging time points"
2890207|NCT03318094|Placebo Comparator|Intact Day|Saline
2890208|NCT03318094|Experimental|Blocked Day|Phentolamine
2890209|NCT03318081|Active Comparator|cognitive function rehabilitation group|The main content of cognitive function rehabilitation esecutive function,including working memory,sustained attention, response inhibition function and cognitive flexibility, 45 minutes a day over 6 weeks period.
2890210|NCT03318081|Active Comparator|cognitive bias modification group|The main content of cognitive bias modification groups were changing ATS related attention bias, 45 minutes a day over 6 weeks period.
2890211|NCT03318081|No Intervention|control group|Participants only accept the regular scheduled in the compulsory isolated detoxification center
2890212|NCT03318068|Experimental|Yoga intervention arm|The group will receive a weekly yoga session for the duration of 10 weeks. The yoga sessions will be delivered in person for 3 weeks during the intervention, coordinated with existing clinic visits. The other 7 sessions will be delivered via skype. The participant will be asked to fill out questionnaires during each of the three in-person yoga visits asking about psychological symptoms and quality of life.
2890213|NCT03318055||Single group study|"The study population will include patients presenting for elective surgery, who fulfil the inclusion criteria of all surgical disciplines undergoing elective surgery period during the period of the study.~Inclusion Criteria:~> 18 years of age Non-cardiac patients Non-obstetric patients Patients receiving general, neuraxial, regional or local/topical anaesthesia for elective surgical intervention"
2890214|NCT03318042|Experimental|Child-teenagers-walnuts-pomegranate|Intake of walnuts or pomegranate juice for 3 days
2890215|NCT03318029|Placebo Comparator|Placebo UK trial|Placebo and living in the UK
2890217|NCT03318029|Placebo Comparator|Placebo Brazil Trial|Placebo and living in the Brazil
2890218|NCT03318029|Active Comparator|Vitamin D Brazil Trial|Vitamin D supplementation and living in Brazil
2890219|NCT03318016|Experimental|Cyclophosphamide|"Cohort -1: Cyclophosphamide 500 mg/m2~Cohort 1: Cyclophosphamide 1000 mg/m2~Cohort 2: Cyclophosphamide 2000 mg/m2~Cohort 3: Cyclophosphamide 3000 mg/m2~Cohort 4: Cyclophosphamide 4000 mg/m2"
2890220|NCT03318003|Experimental|Auto-PAP Therapy|
2890221|NCT03318003|No Intervention|No Therapy|
2890222|NCT03317990|Experimental|NeuroSAFE|These patients will undergo robotic radical prostatectomy with bilateral nerve spare. The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade. The tissue sample will be snap frozen and embedded in OCT. Using a cryostat, 10 micron thick slices will be placed on slides. The entire length of the area of interest will be sampled in this way generating ≈10 frozen sections per side. The slides will be stained with H&E and will be examined by a consultant pathologist . As soon as examination is complete the pathologist will telephone the operating surgeon to give the result. Presence of cancer cells at the margin of resection constitutes a positive margin and the neurovascular bundle on that side will be resected.
2890223|NCT03317990|No Intervention|Control|These patients will undergo robotic radical prostatectomy with a nerve sparing procedure based on surgical planning performed by a consultant radiologist. The mp-MRI will be reviewed by a consultant radiologist along with the details of the prostate biopsy and DRE a decision to perform unilateral, bilateral or non-nerve sparing will be established and recorded in the clinical record form (CRF) for each patient.
2890224|NCT03317977|Experimental|Reach for Control|Reach For Control is a multi-component, home-based family therapy that targets the multiple causes of poor adolescent asthma management across individual, family and community systems.
2890225|NCT03317977|Active Comparator|Michigan MATCH|Program endorsed by the State of Michigan for treatment of poorly controlled asthma.
2890226|NCT03317964||Saliva - cardiomyopathy|Saliva sample for genetic testing from subjects who developed cardiomyopathy
2890227|NCT03317964||Saliva - no cardiomyopathy|Saliva sample for genetic testing from subjects who do not have cariomyopathy
2890228|NCT03317951|Experimental|Novel integrated care concept (NICC)|The care center is at the heart of the NICC structure. It will be available 24/7. It is the core platform to share information for all NICC patients in the care process and serves as integration point between the professional groups. The care center is utilizing the NICC platform for care coordination and patient monitoring. The NICC platform enables patient management from the distance and allows treating physicians to observe and follow the health status of patients daily. Using the NICC tablet, patients provide information from home about their health status. They will receive feedback about their therapy, measurements and reminders and motivation to follow care plans. The communication allows for a regular evaluation of the patient's situation, a review of the therapy and coordination of necessary adjustments with care providers. The general intervention rules are based on the current European Society of Cardiology (ESC) guidelines for treating AF, HF and TRH patients.
2890229|NCT03317951|Active Comparator|Standard care|Patients will be treated according to current practice as described in the guidelines of the European Society of Cardiology (ESC). For AF, this has been provided by Kirchhof et al. (2016 Eur Heart J). HF treatment will follow the 2016 ESC guideline for HF (Ponikowski et al., 2016 Eur Heart J), and TRH will be treated according to the ESC treatment guideline for arterial hypertension (Mancia et al., 2013 Eur Heart J).
2890230|NCT03317938|Experimental|Fecobionics studies|
2890231|NCT03317912|Active Comparator|Lidocaïne 2%|Bolus 0.075ml/kg/h, following by continuous infusion 0.1ml/kg/h during surgery and 0.066ml/kg/h during 24h
2890232|NCT03317912|Placebo Comparator|Placebo (for Lidocaïne)|Bolus 0.075ml/kg/h, following by continuous infusion 0.1ml/kg/h during surgery and 0.066ml/kg/h during 24h
2890233|NCT03317899|Experimental|Group I (auto HSCT tbo-filgrastim)|Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days.
2890234|NCT03317899|Experimental|Group II (auto HSCT)|Patients undergo auto Hematopoietic Cell Transplantation (HSCT).
2890235|NCT03317886|Active Comparator|mesenteric approach|mesenteric approach starts from lymph node dissection around the superior mesenteric artery and performs Kocher's maneuver finally during pancreaticoduodenectomy.
2890236|NCT03317886|Active Comparator|conventional approach|Conventional approach starts from Kocher's maneuver and finally performs lymph node dissection around the superior mesenteric artery during pancreaticoduodenectomy.
2890237|NCT03317873|Experimental|wild type AA (CC)|All participants with the wild type genotype AA (CC) will be allocated to this group
2890238|NCT03317873|Experimental|mutation VV (TT)|All participants with the mutation genotype VV (TT) will be allocated to this group
2890239|NCT03317860|Sham Comparator|Sham tDCS plus RTP|Single session of bilateral sham parietal cortex tDCS (for 30 minutes) paired with repetitive task-specific practice (RTP)
2890240|NCT03317860|Active Comparator|Active tDCS plus RTP|Single session of bilateral active parietal cortex tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP)
2890241|NCT03317847|Experimental|Bromfenac|Patients randomized to this arm will receive Bromfenac 0.09 % Ophthalmic Solution BID for 2 weeks
2890242|NCT03317847|Active Comparator|Dexamethasone|Patients randomized to this arm will receive Dexamethasone 0.1 % Ophthalmic Suspension QID for one week and BID for the following week
2890243|NCT03317834||Study Population|Total Knee Replacement with Navio Surgical Systems
2890244|NCT03317808|Active Comparator|Heavy slow resistance exercise|
2890245|NCT03317808|Placebo Comparator|Conventional exercise|
2890246|NCT03317795|Active Comparator|Levonorgestrel IUS|Levonorgestrel-releasing intrauterine system (Mirena) contains 52 mg of levonorgestrel, a progestin, and is intended to provide an initial release of approximately 20 mcg/day. Levonorgestrel intrauterine system is effective immediately upon placement in the uterus and can be kept in place for up to 5 years.
2890247|NCT03317795|Active Comparator|Tranexamic Acid|Tranexamic Acid (Lysteda) is an antifibrinolytic drug. Tranexamic Acid will be dosed at 1300mg by mouth three times a day at the start of menses and used during the days that bleeding is heaviest (not to exceed 5 days per menstrual cycle).
2890248|NCT03317769|Experimental|Experimental Treatment|Computerized cognitive training for 18 hours and structured social skills training for 9 hours over a 9 week period.
2890249|NCT03317769|Active Comparator|Active Comparator|Commercially-available computerized training for 18 hours and 9 hours of unstructured support group sessions over a 9 week period.
2890250|NCT03317756|Experimental|Patient Variation 1|Patient Educational Intervention: Patient will receive intervention videos and will be required to complete the baseline and follow-up surveys.
2890251|NCT03317756|Experimental|Patient Variation 2|Patient Control: Patients will receive an attention control and will be required to complete the baseline and follow-up surveys.
2890252|NCT03317743|Experimental|NOV140101 (IDX1197HCl)|
2890253|NCT03317730|Experimental|RT + Xtampza ER|This study will enroll patients scheduled to receive radiation therapy (RT), but RT details are not specified by this protocol. Patients taking long acting opioid analgesics prior to enrollment will be converted to an equivalent dose of Xtampza ER at the time of enrollment. For the remaining patients not previously prescribed opioid analgesics, Xtampza ER will be initiated when 2 or more daily doses of short acting opioids are required, resulting in a total daily dose of at least 30mg morphine sulfate equivalent. During RT, pain will be assessed on a weekly basis using the PI-NRS and the dose of Xtampza ER will be adjusted at the discretion of the treating physician, with recommendation to maintain an equivalent of 100% daily opioid requirement. Assessment for tapering of Xtampza ER will begin 1 month following the completion of RT at the time of first follow-up.The study period will end 3 months following the final fraction of RT.
2890254|NCT03317717|Experimental|botulinum toxin 2U|
2890255|NCT03317717|Experimental|botulinum toxin 5U|
2890256|NCT03317717|Experimental|botulinum toxin 10U|
2890257|NCT03317717|Experimental|botulinum toxin 20U|
2890258|NCT03317717|Experimental|botulinum toxin 30U|
2890259|NCT03317704|Active Comparator|speed endurance training (SET)|Training 6 weeks 3 times pr. week
2890260|NCT03317704|No Intervention|Controls|Asked to continue their usual life style
2890261|NCT03317691||ST segment Elevation Myocardial Infarction|ST segment Elevation Myocardial Infarction patients' diagnosis was confirmed by coronary artery angiography. The prior surgery electrocardiogram need to be collected.
2890262|NCT03317678|Experimental|BioKefir (BKP)|BioKefir™ (Lifeway Foods) is a lactose-free fermented milk drink containing 12 different species of bacteria within the lactobacillus, bifidobacterium, and streptococcus generas totaling approximately 20 CFU per 3.5 ounce serving. The product also contains 2 g of fiber, including pectin and inulin. These fibers, especially inulin, are prebiotics that may function along with the probiotic species to support gastrointestinal health. The product is available commercially. Participants will be asked to consume 3.5 ounces twice daily, preferably at morning and nighttime. The probiotic will be provided in individual 3.5 ounce unlabeled containers. These quantities will be started on the first day of the intervention phase of the study (day 0, visit 0) and remain unchanged until the end of the intervention phase on day 56 (visit +4). Administration will be discontinued then.
2890263|NCT03317678|Placebo Comparator|Non-fermented Milk (NFM)|The NFM is dairy-based product ultra-filtered to remove lactose. In addition to being matched to lactose, the NFM contains similar energy, fat, and protein content as the probiotic. Participants will be asked to consume 3.5 ounces twice daily, preferably at morning and nighttime. The NFM control will be provided in 11.5 ounce unlabeled containers. These quantities will be started on the first day of the intervention phase of the study (day 0, visit 0) and remain unchanged until the end of the intervention phase on day 56 (visit +4). Administration will be discontinued then.
2890264|NCT03317665||Standard of care|Mesh for hernia repair: Standard of care products used by the Investigator for open ventral hernia repair procedure
2890265|NCT03317652|Experimental|Sodium nitroprusside and CO2 reactivity|"The subject rests in the supine position throughout the study that lasts for approximately three hours.~Interventions are:~Hyperventilation~6% CO2 breathing~Infusion of sodium nitroprusside"
2890266|NCT03317639|Experimental|an intervention arm|Hospitals in the intervention arm will receive a multi-components intervention based on the Behaviour Change Wheel model
2890267|NCT03317639|No Intervention|a control arm|hospitals in the control arm will receive no intervention and maintain existing care
2890268|NCT03317626|Experimental|Cold Stimulus|The study procedure will beto use a coldstimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted
2890269|NCT03317613|Experimental|Capsaicin|Cancer patients presenting neuropathic pain secondary to their anti cancer treatments will receive patch of capsaicin (qutenza) on the painful zones..
2890270|NCT03317600|Active Comparator|Lidocaine block|
2890271|NCT03317600|Placebo Comparator|Isotonic saline block|
2890272|NCT03317587|Experimental|INSPIRE|
2890273|NCT03317574|Experimental|MEDITOXIN|
2890274|NCT03317574|Active Comparator|BOTOX|
2890275|NCT03317561||Myocardial injury|Subjects who have had an increase in troponin T level (> 99 percentile) in the perioperative period shall form the cases.
2890276|NCT03317561||Control|Subjects who do not have an increase in troponin T level (< 99 percentile) in the perioperative period shall form the controls.
2890277|NCT03317548||fresh embryo transfer|patients with fresh day 3 embryo transfer after oocyte pick up, the hormone including FSH, LH, E2 and progesterone was test before embryo transfer for analysis. The clinical outcomes including implantation and pregnancy were checked and recorded.
2890278|NCT03317548||frozen embryo transfer|"freeze-all embryo was performed after oocyte fertilization, the hormone including FSH, LH, E2 and progesterone was test before oocyte pick up and embryo transfer for analysis.~vitrification of pronuclear stage embryo (zygote) and frozen embryo transfer"
2890279|NCT03317535|Other|Local anesthesia and sedation|Patients will be injected by dexmedetomidine(adjusted by bispectral index scale ≥70 ) and /or remifentanil（0.01-0.06μg/kg/min）. Patients will maintain spontaneous breathing.
2890280|NCT03317535|Other|General anesthesia|Patients will be induced with remifentanil (0.2-0.8 μg/kg), propofol TCI 2-4 ug/ml, and rocuronium (0.6 mg/kg). Anesthesia will then be maintained keep the BIS between 40 and 60. After tracheal intubation, patients will be kept with controlled ventilation.
2890303|NCT03317353|No Intervention|Control group|Group D. No vestibular rehabilitation is developed.
2890304|NCT03317340||Patient Undergoing Urodynamics|
2890305|NCT03317327|Experimental|Nivolumab|Nivolumab, intravenous every 2nd week (1 cycle = 2 weeks), dose escalation schedule (1.0, 3.0 mg/kg), for a maximum of 12 months or until disease progression.
2890281|NCT03317522||Belfast HAPO|"All pregnant women who attended the Royal Victoria Maternity Hospital, Belfast were eligible to participate unless they met one or more exclusion criteria.~All eligible women from the Belfast centre were invited to take part in a prospective observational study involving an additional fasting serum sample for lipids at 28 weeks gestation and long term follow up of their HAPO offspring. Only those women who had remained blinded to oral glucose tolerance test (OGTT) results during pregnancy were included (fasting plasma glucose ≤5·8 mmol/L and 2-hour glucose ≤11·1 mmol/L). Offspring from these pregnancies had anthropometric measurements performed within 72 hours of birth and at age 5-7 years."
2890282|NCT03317509|Active Comparator|Real rTMS|Each patient received high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days
2890283|NCT03317509|Sham Comparator|Sham rTMS|Each patient received rTMS with the same pulse as the first group but with the coil placed perpendicular to the scalp.
2890284|NCT03317496|Experimental|Group A Cohort A1|Non-squamous non-small cell lung cancer (NSCLC) patients treated with avelumab plus pemetrexed/carboplatin
2890285|NCT03317496|Experimental|Group A Cohort A2|Cisplatin-eligible urothelial cancer patients treated with avelumab plus gemcitabine/cisplatin
2890286|NCT03317470|Active Comparator|Phase I:|"In Phase 1 of the study (first five months), the investigators will enroll new patients when they call them to remind them of their first colposcopy appointment. If patients consent, the investigators also will assess their basic needs during the call. Those who screen positive for at least one unmet basic need, will be referred to the 2-1-1 helpline at their clinic visit (or this information will be sent to them if they miss their clinic visit).~All women enrolled in our study will be asked to complete our basic needs survey and take a follow-up survey at the time of their first colposcopy visit.~For patients in phase 1, the follow-up survey will only assess acceptability of the basic needs survey (five questions)"
2890287|NCT03317470|Experimental|Phase 2:|"-In Phase 2 of the study (second five months), new colposcopy patients will be approached and consented in a similar fashion as in Phase 1 and asked to complete the basic needs survey. However, this time, patients who screen positive with at least one unmet basic need will be offered assistance by a life navigator (a trained case manager) who will contact the patients by phone within 2 business days of completing the survey.~The life navigator will connect patients with community resources in each area to help with their unmet basic needs.~All women enrolled in our study will be asked to complete our basic needs survey and take a follow-up survey at the time of their first colposcopy visit.~Patients enrolled in phase 2 will be asked the same five questions in addition to seven more assessing perceived effectiveness of the life navigator"
2890288|NCT03317457|Experimental|Durvalumab and Tremelimumab|"Cycles/courses 1-3:~Durvalumab 1.5g q4wks Tremelimumab 75 mg q4wks~Cycles/courses ≥4:~Durvalumab 1.5g q4wks Tremelimumab 75 mg q12wks"
2890289|NCT03317457|Active Comparator|Doxorubicin|Doxorubicin 75 mg/qm q3wks for 6 courses
2890290|NCT03317444|Experimental|TRC101|Administered once daily (QD) for 12 weeks
2890291|NCT03317444|Placebo Comparator|Placebo|Administered once daily (QD) for 12 weeks
2890292|NCT03317431||ventilation|patients undergoing selective operation with general anesthesia(GA) and mechanical ventilation(MV)
2890293|NCT03317405|Experimental|Cohort I (Z-endoxifen hydrochloride)|Participants apply Z-endoxifen hydrochloride gel to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
2890294|NCT03317405|Placebo Comparator|Cohort II (placebo)|Participants apply placebo to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
2890295|NCT03317392|Experimental|Arm I (radium Ra 223 dichloride, olaparib)|Patients receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also continue to receive olaparib PO BID as in Phase I.
2890296|NCT03317392|Experimental|Arm II (radium Ra 223 dichloride)|Patients receive radium Ra 223 dichloride as in Arm I.
2890297|NCT03317379|Experimental|Peer mentorship|Participants meet weekly with an adult peer mentor who has recovered from an eating disorder. The focus of meetings is on eating disorder symptoms and how to overcome them. The goal of this program is to reduce eating disorder symptoms directly by receiving support and guidance from someone who has been through it.
2890298|NCT03317379|Active Comparator|Social support mentorship|Participants meet weekly with an adult mentor who has not personally struggled with an eating disorder but who is dedicated to offering support. During weekly meetings, participants and mentors (and possibly 1-2 other mentees) engage in activities unrelated to the eating disorder. The goal of this program is to reduce eating disorder symptoms indirectly by exploring aspects of self outside the eating disorder.
2890299|NCT03317379|No Intervention|Wait list|Participants are on a wait list and then get matched with either type of mentor (of their choice) 6 months later
2890300|NCT03317353|Experimental|Vestibular rehabil.: CDP|Group A. The Smart Equitest program was used with a protocol of 10 exercises per session, which were customized depending on each patient´s deficit. The exercises involve visual biofeedback together with sensitive, real-time monitoring of movement. In some exercises, patients must maintain their center of gravity (COG) over the base of support, while in others the COG must be moved to a series of targets. In addition, the support surface and/or visual surround may also move in response to the patient´s own movement. The exercise difficulty was progressively increased throughout the rehabilitation sessions. The duration of each session was approximately 15 minutes. The distribution of sessions was one per day and five per week (2 weeks).
2890301|NCT03317353|Experimental|Vestibular rehabil.: optokinetic stimuli|Group B. Patient has to stand in a dark room, wiht optokinetic stimuli around him/her. Ten sessions (one per day, five per week, two weeks), with progressive increase of stimulus speed (from 30º/sec the first day to 100º/sec the last), duration of session (from 5 minutes the first day to 15 minutes the last), stimulus complexity (horizontal stimuli in the first sessions, progressively adding vertical and rotating stimuli) and support surface difficulty (initially hard surface, last sessions on foam).
2890302|NCT03317353|Experimental|Vestibular rehabil.: home exercises|Group C. The patient is given a list of exercises (and explained how to do them) to stabilise eye position and improve postural control. They are to be performed twice a day for two weeks. Approximate duration of each session: 15 minutes. The exercises must be supervised by a family member to verify adherence to the programme.
2890306|NCT03317301|Experimental|Experimental|Experimental: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
2890307|NCT03317301|Active Comparator|Active comparator|Comparator: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
2890308|NCT03317288|Other|SCI subjects|The subject act as his or her own control. Each subject will undergo two procedures, intervention: alternating pressure overlay on top of standard operation room overlay, vs. control: operation room overlay.
2890309|NCT03317275|Experimental|injection based on 18F-Fluoride-PET/MRI|One group will undergo facet injection(s) according to the 18F-Fluoride-PET/MRI result, with standard injections performed under CT-guidance. The Pain assessment by VAS immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
2890310|NCT03317275|Active Comparator|injection based on clinical practise|The control group will undergo facet injections blinded to the 18F-Fluoride-PET/MRI results, but based on current standard clinical practise (MRI and clinical correlation). Pain assessment by VAS immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
2890311|NCT03317249||Pregnant Healthy|Pregnant females aged between 18-45 years who do not have IST syndrome
2890312|NCT03317249||Pregnant IST|Pregnant females aged between 18-45 years who have IST syndrome
2890313|NCT03317236|Experimental|Reference - Test|A new extended release formulation containing quetiapine 50 mg (T) followed by a branded formulation (R).
2890314|NCT03317236|Experimental|Test - Reference|A branded formulation (R) followed by a new extended release formulation containing quetiapine 50 mg (T).
2890315|NCT03317223|Experimental|CJ-12420/Clarithromycin/Amoxicillin|CJ-12420 50mg /Clarithromycin 500mg /Amoxicillin 1g
2890316|NCT03317223|Active Comparator|Lansoprazole/Clarithromycin/Amoxicillin|Lansoprazole 30mg /Clarithromycin 500mg /Amoxicillin 1g
2890317|NCT03317210|Other|iron therapy with good response|Patients with an Hb level between 9.0 and 9.9 g/dl received 200 mg iron sucrose intravenously twice weekly. The maximum total iron dose was 1,600 mg, therefore therapy was stopped if the maximal iron sucrose dose was administered, or target Hb > 10.5 g/dL was achieved.
2890318|NCT03317210|Other|iron therapy with poor response|Patients with an Hb level between 9.0 and 9.9 g/dl received 200 mg iron sucrose intravenously twice weekly. If response to therapy with iron sucrose was poor (i.e. Hb increase <0.7 g/dl after 2 weeks), patients additionally received recombinant human erythropoietin (10,000 U EPREX®, Janssen-Cilag, Baar, Switzerland).
2890319|NCT03317210|Other|iron therapy and erythropoietin|Patients with an Hb between 8.0 and 8.9 g/dl received 200mg iron sucrose and recombinant human erythropoietin intravenously twice weekly.
2890320|NCT03317197|Placebo Comparator|Control Group|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only~Control group receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~Syringe No. 1 : Saline solution~Syringe No. 2 : Saline solution"
2890321|NCT03317197|Active Comparator|Experimental Group 1|"Using Vasopressin [20 IU/CPR cycle] injection until the 5th cycle~Experimental Group 1 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~Syringe No. 1 : Vasopressin~Syringe No. 2 : Saline solution"
2890322|NCT03317197|Active Comparator|Experimental Group 2|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)~Experimental Group 2 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~Syringe No. 1 : Saline solution~Syringe No. 2 : Steroid"
2890323|NCT03317197|Experimental|Experimental Group 3|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)~Experimental Group 3 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~Syringe No. 1 : Vasopressin~Syringe No. 2 : Steroid"
2890324|NCT03317184|Experimental|Periumbilical incisions|
2890325|NCT03317184|Experimental|Pfannenstiel incision|
2890326|NCT03317171|Experimental|Treated group|oral administration of flavonoids, DHA and EPA, once a day for 24 weeks.
2890327|NCT03317171|Placebo Comparator|Placebo group|oral administration of placebo compound, once a day for 24 weeks.
2890328|NCT03317158|Experimental|Phase 1: (cohort 1):|Durvalumab monotherapy (cohort 1)
2890329|NCT03317158|Experimental|Phase 1: (cohort 2a) & (cohort 2b):|"(cohort 2a) - Durvalumab plus BCG~(cohort 2b) - Durvalumab plus External Beam Radiotherapy (EBRT)"
2890330|NCT03317158|Experimental|Phase 2: (cohort 2a), (cohort 2b), & (BCG re-treatment)|"(cohort 2a) - Durvalumab plus BCG~(cohort 2b) - Durvalumab plus External Beam Radiotherapy (EBRT)~(BCG re-treatment) - Cross-over to Durvalumab Monotherapy"
2890331|NCT03317145|Active Comparator|Arm A (NMES followed by IPC)|Arm A (NMES followed by IPC). Following baseline blood flow measurements using ultrasound, the neuromuscular electrostimulation (NMES) device will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The NMES device will be removed. After a 30 minute rest period, the intermittent pneumatic compression (IPC) device will be fitted, activated for 10 minutes and then blood flow measurements repeated.
2890332|NCT03317145|Active Comparator|Arm B (IPC followed by NMES)|Arm B (IPC followed by NMES). Following baseline blood flow measurements using ultrasound, the intermittent pneumatic compression device (IPC) will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The IPC device will be removed. After a 30 minute rest period, the neuromuscular electrostimulation (NMES) device will then be fitted, activated for 10 minutes and then blood flow measurements repeated
2890333|NCT03317132|Experimental|Individual Placement and Support|One year of IPS Support
2890334|NCT03317132|No Intervention|Treatment as usual|Treatment as usual
2890335|NCT03317119|Experimental|Treatment (TAS-102, trametinib)|Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 PO BID on days 1-5 and 8-12 and trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2890336|NCT03317080||patients with lung cancer|patients with stages I-IV lung cancer eligible for surgery
2890337|NCT03317067|Experimental|dexmedetomidine|Patients in the Dexmedetomidine (interventional) group will be treated with a continuous infusion of dexmedetomidine in case of agitated delirium.
2890338|NCT03317067|Placebo Comparator|Normal Saline (NaCl 0.9%)|Patients in the Normal Saline (control) group will be treated with a continuous infusion of normal saline in case of agitated delirium.
2890339|NCT03317041|Experimental|Tecar treatment group|The capacitive-resistive electric transfer (Tecar) therapy treatment group will receive 45 minutes of Tecar therapy treatment.
2890340|NCT03317041|No Intervention|Control group|Participants will test passively in a sitting position for 30-min period
2890341|NCT03317028|Experimental|high dose of CS02|Subjects will receive 450mg of CS02 combined with a stable dose of metformin monotherapy.
2890342|NCT03317028|Experimental|middle dose of CS02|Subjects will receive 300mg of CS02 combined with a stable dose of metformin monotherapy.
2890343|NCT03317028|Experimental|low dose of CS02|Subjects will receive 150mg of CS02 combined with a stable dose of metformin monotherapy.
2890344|NCT03317028|Placebo Comparator|placebo control|Subjects will receive placebo combined with a stable dose of metformin monotherapy.
2890345|NCT03317015|Experimental|Group A - Nasacort®|Nasacort® will be sprayed twice in each nostril once every morning
2890346|NCT03317015|Active Comparator|Group B - Flixonase®|Flixonase® will be sprayed twice in each nostril once every morning
2890347|NCT03317002|Experimental|AZD5718 Dose A|AZD5718 Dose A once daily
2890348|NCT03317002|Experimental|AZD5718 Dose B|AZD5718 Dose B once daily
2890349|NCT03317002|Placebo Comparator|Placebo|Matching placebo once daily
2890350|NCT03316989||obese children|Children and adolescents with BMI according to the CDC greater that 95%ile
2890351|NCT03316989||normal weight|Children and adolescents with BMI according to the CDC less than the 85%ile
2890352|NCT03316989||obese with the MetS|obese children with metabolic syndrome compared to obese children with out the MetS and normal weight children
2890353|NCT03316976|Experimental|Group 1: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
2890354|NCT03316976|Experimental|Group 2: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
2890355|NCT03316963|Experimental|Drug-induced sleep endoscopy (DISE) with Neostigmine|Artificial sleep will be induced by intravenous administration of propofol with micro boluses until clinical sleep is achieved with spontaneous respiration and observed apneas under monitored anesthesia care. Endoscopy will be performed with visualization on a monitor and recording on a digital recorder. After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate.
2890356|NCT03316950|Experimental|IntraGen RF|Patients will undergo treatment with radiofrequency device, using the device's standard protocol. Patients will have 3 treatments space one month apart. Each treatment will be a total of 20 minutes for internal treatment only. Prior to treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
2890357|NCT03316950|Sham Comparator|IntraGen Sham|Patients will undergo all acts of receiving radiofrequency treatment, but no direct energy will be applied.Patients will have 3 sham treatments space one month apart. Each treatment session will be a total of 20 minutes. Prior to sham treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
2890358|NCT03316950|Experimental|DiVA|Patients randomized into the DiVA treatment group will receive treatment per DiVA protocol. Patients will have a total of 3 treatments, space 1 month apart. Each treatment will last approximately 10 minutes. Prior to treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
2890359|NCT03316950|Sham Comparator|DiVA Sham|Patients randomized into the DiVA sham group will undergo all acts of receiving DiVA treatment, but not direct energy will be applied. Patients will have a total of 3 treatments, spaced 1 month apart. Each treatment will last approximately 10 minutes. Prior to sham treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
2890360|NCT03316937|Experimental|Teflon Scaler|The buccal and lingual surface of the 23 participants' crowns will be randomly assigned to receive scaling and root planing with either Teflon scalers, or non-Teflon scalers after implant crown delivery. Each patient will act as their own control.
2890361|NCT03316937|Experimental|Non Teflon Scaler|The buccal and lingual surface of the 23 participants' crowns will be randomly assigned to receive scaling and root planing with either Teflon scalers, or non-Teflon scalers after implant crown delivery. Each patient will act as their own control.
2890362|NCT03316911|Experimental|MKit WebApp Intervention|The intervention arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors. In addition, they will receive access the MKit WebApp, which will give them access to content, goal setting, and resources for 14 topic areas.
2890363|NCT03316911|No Intervention|Standard of Care|The control arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors.
2890955|NCT03312738|Experimental|Everolimus + Exemestane|Everolimus 10mg/Day + Exemestane 25mg/Day
2890364|NCT03316898|Placebo Comparator|Placebo|Two placebo capsules once daily for 28 Days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
2890365|NCT03316898|Experimental|AGN-242071 5 mg|One AGN-242071 5 mg capsule plus one placebo capsule once daily for 28 days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
2890366|NCT03316898|Experimental|AGN-242071 15 mg|AGN-242071 starting at a dose of one 5 mg capsule plus one placebo capsule once daily for 5 days followed by AGN-242071 15 mg total dose (one 5 mg and one 10 mg capsules) once daily on Days 6 to 28. Dose can be adjusted based on safety and tolerability. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
2890367|NCT03316898|Experimental|AGN-242071 25 mg|AGN-242071 starting at a dose of one 5 mg capsule plus one placebo capsule once daily for 5 days followed by AGN-24071 15 mg total dose (one 5 mg and one 10 mg capsules) once daily on Days 6 to 10 followed by AGN-242071 25 mg total dose (one 5 mg and one 20 mg capsules) on Days 11 to 28. Dose can be adjusted based on safety and tolerability. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
2890368|NCT03316885|Experimental|Clareon IOL|Clareon® aspheric hydrophobic acrylic intraocular lens implanted as a replacement of the human crystalline lens during cataract surgery
2890369|NCT03316872|Experimental|Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)|"Pembrolizumab, intravenously, at a dose of 200 mg, once every 3 weeks~SBRT starting Day 2 of Cycle 1 of pembrolizumab treatment, given in 5 fractions over 10-15 days."
2890370|NCT03316859|Experimental|Naloxegol|naloxegol 25 mg pill
2890371|NCT03316859|Placebo Comparator|Placebo|placebo pill
2890372|NCT03316846|Experimental|Internet-delivered therapy|10 week, guided and individually tailored internet-delivered cognitive behavioral therapy.
2890373|NCT03316846|No Intervention|Wait list control group|Wait list control group, receives treatment at later point.
2890374|NCT03316820|Experimental|Treatment A|K0706 tablet
2890375|NCT03316820|Experimental|Treatment B|K0706 tablet
2890376|NCT03316820|Experimental|Treatment C|K0706 tablet
2890377|NCT03316820|Experimental|Treatment D|K0706 capsule
2890378|NCT03316807|Experimental|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
2890379|NCT03316807|Experimental|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
2890380|NCT03316794|Experimental|SC-005|SC-005 intravenous (IV) (various doses and dose regimens)
2890381|NCT03316781|Experimental|HLX03 group|
2890382|NCT03316781|Active Comparator|adalimumab group|
2890383|NCT03316755|No Intervention|without pamphlet|a group not exposed to pamphlet
2890384|NCT03316755|Experimental|With pamphlets|a group exposed to pamphlet
2890385|NCT03316742|Experimental|Intervention 1|Participants randomized to intervention 1 will complete baseline and endline outcomes and participate in version 1 of a weight loss program. Each participant will attend twelve one hour classes discussing weight loss adherence in addition to barriers experienced. Changes in weight will be recorded throughout the study.
2890386|NCT03316742|Experimental|Intervention 2|Participants randomized to intervention 2 will complete baseline and endline outcomes and participate in version 2 of a weight loss program. Each participant will attend 12 one hour classes discussing weight loss adherence in addition to barriers experienced. Changes in weight will be recorded throughout the study.
2890387|NCT03316729|Experimental|DS-9231|In conjunction with standard of care, participants will receive an intravenous infusion delivering DS-9231 at ascending dose levels in Cohort 1, 2, and 3
2890388|NCT03316729|Placebo Comparator|Placebo|In conjunction with standard of care, participants will receive an intravenous infusion delivering only saline solution as matching placebo comparator
2890389|NCT03316716|No Intervention|Control Group|Women randomised to the control group will receive the hospital's current standard of care which is the peri-operative administration of room-temperature (25°C) IV fluids (Hartman's solution) started before the insertion of regional anaesthesia and continued until the transfer of the woman to the postnatal ward.
2890390|NCT03316716|Experimental|active warming group|Women randomised in the intervention group will recieve warm IV fluids. The IV fluids (Hartman's solution) will be warmed to 39°C with the use of Hotline™ device.
2890391|NCT03316703|Active Comparator|Conventional open surgery|Fixation of a proximal vertebra, a vertebra distal to the fractured vertebra, and also of the fractured vertebra with a pedicle fixation system using the conventional open to implant placement without subsequent arthrodesis.
2890392|NCT03316703|Experimental|Minimally invasive percutaneous surgery|Fixation of a proximal vertebra, a vertebra distal to the fractured vertebra, and also of the fractured vertebra with a pedicle fixation system using the percutaneous minimally invasive approach to implant placement without subsequent arthrodesis.
2890393|NCT03316690|Experimental|Metformin treatment|
2890394|NCT03316690|Placebo Comparator|Placebo treatment|
2890395|NCT03316677|Other|colorectal resection and anastamosis|"Intraoperative testing of colorectal anastomoses~Insert a Foley catheter through the anus into the rectum.~Insufflate the Foley balloon with 5 cc of air.~fill the pelvic space with 500 CC of warm saline~Insufflate air into the rectum up to a pressure of 35 mmH2o as measured by external manometer~Remove the saline from the pelvic space.~Inject methylene blue in to the rectum up to a pressure of 35 mmH2o measured by external manometer~Remove the methylene blue from rectum.~NB the above procedures are standard practice for assessing the quality of colorectal anastomoses during colorectal surgery.~The purpose of the study is to compare these standard methods of evaluation to determinant which method is superior"
2890396|NCT03316664|Experimental|INT|Integrated Neurocognitive Therapy (INT) is a manualized psychological intervention that consists of 30 sessions administered by a therapist and a co-therapist in an open group of 6-8 patients. Sessions will take place twice a week, and each session should last 90 min.
2890482|NCT03315962|Experimental|Aim 1: DHO Intervention Arm|A selection of DHO or TB district supervisors that are randomized to the multicomponent SPIRIT intervention.
2892608|NCT03301181|Experimental|Arm B|Approximately 20 subjects to receive BGB-3111 and itraconazole
2890397|NCT03316664|Active Comparator|IPT|Integrated Psychological Therapy (IPT) is a manualized psychological intervention that consists of 5 modules which can be completed in a variable number of sessions that will be administered by a therapist and a co-therapist in an open group of 6- 8 patients. Sessions will take place twice a week, and each session should last 60 to 90 min.
2890398|NCT03316664|Other|CoC|COGPACK is a computer-based neuropsychological cognitive training program. It will be administered by a trainer in an open group of 6- 8 patients. Sessions will take place twice a week, and each session will last 45 - 60 minutes.
2890399|NCT03316651|Experimental|GM-CSF|"After the patients were randomly divided into two groups, they will receive whole lung lavage (WLL), and then one of the two groups with continue the next step as follows:~Induction period: The time of beginning is 1 week after whole lung lavage, aerosolized GM-CSF was given for 7 days (150ug bid), and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle, a total of 6 cycles (3 months) were known as the induction period.~Maintenance period: maintenance period came up after the induction period. The dose of aerosolized GM-CSF was reduced to 150ug/d for three times a week, and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle and maintenance period lasted for 9 months."
2890400|NCT03316638|Experimental|W0101 - Cohort A1|
2890401|NCT03316638|Experimental|W0101 - Cohort A2|Cohort A2 starts after completion of cohort A1
2890402|NCT03316638|Experimental|W0101 - Expansion Phase|
2890403|NCT03316625|Experimental|Bone mineral density|Bone densitometry measurement : Measurement of bone mineral densitometry with bone densitometry
2890404|NCT03316612|Experimental|Intervention group|"Ingredients: Vaccinium Myrtillus L. extracts, and excipients (cellulose microcrystalline, mannitol, silica, magnesium stearate, coating agent)~Brown oval tablet, 650mg per tablet with 150mg Vaccinium Myrtillus L. extracts, twice a day, 2 tablets each time.~The intervention period is about 3 months."
2890405|NCT03316612|Placebo Comparator|Placebo group|"Ingredients: excipients (cellulose microcrystalline, mannitol, silica, magnesium stearate, coating agent)~Brown oval tablet without Vaccinium Myrtillus L. extracts, 650mg per tablet, twice a day, 2 tablets each time.~The intervention period is about 3 months."
2890406|NCT03316599|Experimental|Ficlatuzumab + Gemcitabine and Nab-Paclitaxel|"Ficlatuzumab will be administered intravenously days 1 and 15 of a 28 day cycle~Gemcitabine 1000 mg/m2 and Nab-Paclitaxel 125mg/m2 will be administered IV days 1, 8, and 15 of a 28 day cycle.~Dosage of Ficlatuzumab is determined by dose level to which the patient is assigned at time of enrollment."
2890407|NCT03316586|Experimental|Nivolumab + Cabozantinib|"Nivolumab given every 4 weeks intravenously~Cabozantinib given orally once daily"
2890408|NCT03316573|Experimental|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks for 35 cycles
2890409|NCT03316560|Experimental|Group 1|Subjects at least 18 y/o treated with a lower dose of rAAV2tYF-GRK1-RPGR study drug.
2890410|NCT03316560|Experimental|Group 2|Subjects at least 18 y/o treated with a middle dose of rAAV2tYF-GRK1-RPGR study drug.
2890411|NCT03316560|Experimental|Group 3|Subjects at least 18 y/o treated with a higher dose of rAAV2tYF-GRK1-RPGR study drug.
2890412|NCT03316560|Experimental|Group 4|Subjects at least 6 y/o treated with a maximum tolerated dose of rAAV2tYF-GRK1-RPGR study drug determined for Groups 1, 2 and 3.
2890413|NCT03316547|No Intervention|Control|Infants randomized to the control group will receive standard hosptial care. This includes normal medical and therapeutic care as well as varied amounts of sensory exposure normally given via parents and/or medical staff such as: reading/talking/singing to the infant, dim lights, skin-to-skin (kangaroo) care, therapeutic exercises, etc. Nurses and therapists educate parents and aid in providing sensory stimuli.
2890414|NCT03316547|Experimental|Intervention|The sensory-based intervention group will be provided daily support to engage families in sensory-based interventions across the length of hospitalization as outlined in the manualized intervention. The sensory-based intervention will include the provision of specific amounts of auditory, tactile, vestibular, kinesthetic, and visual exposure to be conducted daily through hospitalization. This includes specifically timed and set amounts of reading/talking/singing to the infant, cycled lighting, skin-to-skin (kangaroo) care or gentle human touch, rocking the infant, and therapeutic exercises [passive range of motion (PROM), gentle stretching]. The intervention plan is intended to be implemented by parents when available, and by surrogates when the parents are unable to be present in the hosptial. Specific amounts and timing of interventions will be tailored to the current medical status and age of each infant.
2890415|NCT03316534|Placebo Comparator|Placebo|Placebo
2890416|NCT03316534|Active Comparator|Aspirin|Aspirin (100 mg/daily)
2890417|NCT03316521|Experimental|Single Ascending Dose (SAD)|"In the SAD arm subjects will be sequentially included in one of up to six cohorts (dose levels). All cohorts will include at least four subjects each. Additional subjects may be added in any cohort if necessary.~AMY-101 will be administered as a SQ or IV injection. Subjects in each cohort will be dosed sequentially, to allow for close safety monitoring. Between each cohort, safety data will be analyzed, evaluated and reviewed by the internal Safety Review Committee. Subsequent dose levels will be administered until either the maximum tolerated dose (MTD) or the study maximum dose (SMD) is reached based on specified dose escalation criteria."
2890418|NCT03316521|Experimental|Multiple Dose (MD)|Depending on the results of the SAD, multiple doses of AMY-101 will be administered at the dose which has been identified as the dose which saturates target C3, for a duration that results to an exposure level equivalent to the maximum exposure achieved in the SAD. The dose and dosing interval will be determined based on the PK data obtained in the SAD part of the study. Each MD cohort will include at least four subjects and may be expanded with additional subjects if necessary. Between each cohort, safety data will be analyzed, evaluated and reviewed by the internal Safety Review Committee.
2890419|NCT03316495|No Intervention|without pamphlet|NOT EXPOSED TO PAMPHLETS
2890420|NCT03316495|Experimental|with pamphlet|EXPOSED TO PAMPHLETS
2890421|NCT03316482|Experimental|Leuplin DPS 11.25mg s.c. every 12 weeks|
2890422|NCT03316469|Experimental|Group A: CC & ovulation|AMH level is measured before Clomiphene citrate 100 mg daily for 5 days & detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels.
2890483|NCT03315962|No Intervention|Aim 1: DHO Control Arm|A selection of DHO or TB district supervisors that are randomized to the country standard of care, but not to receive the study intervention.
2890423|NCT03316469|Experimental|Group B: CC & no ovulation|AMH level is measured before Clomiphene citrate 100 mg daily for 5 days & detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels.
2890424|NCT03316456||AL Patients Undergoing Induction Chemotherapy|Adults undergoing inpatient induction chemotherapy for newly diagnosed/relapsed acute leukemia.
2890425|NCT03316443|Active Comparator|(Group G)|Glidescope group: 45 patients will be intubated by Glidescope (Group G). For endotracheal intubation with glidoscope, size 3 blade will be used in all of the cases. Glidoscope will be advanced gently in the oral cavity (in the midline) and walked down the tongue. The scope will be further advanced into the vallecula and gentle lifting force will be applied for visualization of the glottis. Endotracheal tube will be loaded on specific rigid stylet with 60 degree bent and will be advanced into the trachea by the same operator.
2890426|NCT03316443|Experimental|(Group M)|Macintosh group: 45 patients will be intubated by Macintosh laryngoscope (Group M).The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter). In Macintosh group we will use a blade size 3 at first, the laryngoscope will be advanced in patient mouth displacing the tongue laterally till the laryngoscope reach the vallecula and then gentle lifting will be applied till visualization of the laryngeal inlet then the tube will be advanced
2890427|NCT03316430||Patients|Patients coming before 16 weeks of gestation at their first planned prenatal visit at the Hôpital Femme Mère Enfant, who planned to deliver at the Hôpital Femme Mère Enfant
2890428|NCT03316417||Patients under immunotherapy|All patients with Immune Checkpoints inhibitors treatment (Nivolumab, Pembrolizumab, ipilimumab, Atezolizumab), for dermatologic, pneumologic, or oncologic cancer treated on Centre Hospitalier Lyon Sud are included.
2890429|NCT03316404||Cohort 1|Cohort 1 of the study will collect blood samples from participants in various states of the disease. After qualification and informed consent, accepted participants will be sent a blood collection kit and will be asked to complete a study-related questionnaire.
2890430|NCT03316404||Cohort 2|Cohort 2 may be conducted at selected clinical sites where MS treatment-naïve patients who are entering a new treatment paradigm will be sought. At the clinical site, patients will be qualified, consented, and a small amount (up to 1mL) of blood will be collected. Between approximately 1 week and 6 months of treatment on the new drug, the participant will be sent another blood collection kit for microsample collection and a brief questionnaire at home. A final sample will be collected between 3 and 6 months after the start of treatment. Within 6 months of initiating treatment, the site will be asked to provide information regarding the health and treatment status of the participant.
2890431|NCT03316391||Pre-eclampsia|Patients in hospital for pre-eclampsia at the Hopital Femme-Mère-Enfant
2890432|NCT03316378|Experimental|Group with Achilles Tendinopathy|Ropivacaine injection. While looking at the Achilles tendon with ultrasound, the orthopaedic physician will inject 4 mL of 0.5% ropivacaine (numbing medicine) around the area of pain. The needle may be directed just under the skin (and above the tendon) and/or deep to the tendon.
2890433|NCT03316378|No Intervention|Group without Achilles Tendinopathy|
2890434|NCT03316365|Experimental|Continuous RAS|The experimental group (continuous treatment) trained daily with RAS for 24 weeks.
2890435|NCT03316365|Active Comparator|Intermittent RAS|The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks.
2890436|NCT03316352|Experimental|Ultrasound-assisted|Ultrasound-assisted paramedian technique spinal anesthesia will be performed. A Preprocedural ultrasound scan will be performed for skin marking of entry site of spinal needle. Spinal anesthesia will be performed via paramedian approach using the skin marking site as entry point. 0.5% heavy bupivacaine will be administered into intrathecal space.
2890437|NCT03316352|Active Comparator|Landmark-guided|In these patients, spinal anesthesia will be performed via paramedian approach using conventional landmark palpation technique. Landmark-guided paramedian technique spinal anesthesia will be performed. 0.5% heavy bupivacaine will be administered into intrathecal space.
2890438|NCT03316339|Experimental|Dexmedetomidine|
2890439|NCT03316339|Active Comparator|Control|
2890440|NCT03316326|Experimental|SIROX|Tegafur-gimeracil-oteracil potassium, irinotecan, oxaliplatin combination
2890441|NCT03316313||Date of birth|Those people born within the years 1945-1965
2890442|NCT03316300|Experimental|Renexus|
2890443|NCT03316300|Sham Comparator|Sham|
2890444|NCT03316287|Experimental|Hearing aid + mobile phone|
2890445|NCT03316287|Experimental|Hearing aid + mobile phone + biosensor|
2890446|NCT03316274|Experimental|Nivolumab|
2890447|NCT03316248|Experimental|visual feedback|participants in the experimental group were applied usual prosthetic rehabilitation with visual feedback methods. 9 sessions for three days were applied.
2890448|NCT03316248|Active Comparator|Usual prosthetic rehabilitation|participants in the control group were applied usual prosthetic rehabilitation. 9 sessions for three days were applied.
2890449|NCT03316222|Experimental|Dose escalation|Dose escalation using 3+3 design with dose limiting toxicity (DLT) observation period of 28 days.
2890450|NCT03316222|Experimental|Dose Continuation|Additional patients will be enrolled into the recommended dose. These additional patients will undergo all of the same assessments as the patients enrolled in dose escalation with the exception of PK sampling.
2890451|NCT03316196|Experimental|COGENT|Participants will be Veterans assigned to the active cognitive training (see below for details).
2890452|NCT03316196|Sham Comparator|Non-Training|Participants will be Veterans assigned to a non-training cognitive program matched for time and memory demands (see below for details).
2890453|NCT03316183|Experimental|Intervention Group|"Maintain rSO2 values at or above 75% of the baseline~Midline position~Target CO2 of ≥40 mmHg, target MAP >60 mm Hg~Maintain cerebral perfusion pressure >50 mm Hg~Target pump flow 2.5 L/m2/min~If rSO2 persistently below treatment threshold:~FiO2 is increased~or propofol 50-100 mg bolus is administered~If Hct below 20% packed red blood cells will be transfused~timeline: before induction, after time-out has been performed, and will continue until 24 hours post surgery."
2890484|NCT03315962|Experimental|Aim 2: SPC Intervention Arm|Individuals randomized to receive the Single Pill Combination (SPC) for IPT who reside in districts where the SPIRIT intervention is being implemented.
2929314|NCT03045354|Experimental|Breakfast skipping|No breakfast
2890454|NCT03316183|No Intervention|Control Group|Patients in the control group will be managed under the attending physician's discretion. Cerebral oximetry data will be collected in the same fashion as in the intervention group, but the measurements will be blinded to the physician. Blood samples will be collected for metabolomic profiling in the same fashion and at identical time points as the intervention group for later analysis.
2890455|NCT03316170|Experimental|Social Support + NRT Sampling|"The treatment group will receive:~a brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs,~a written directory of a range of social support resources delivered via mail,~a brief phone consult (10-15 minutes via phone) germane to smoking cessation,~a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and~a free, 2-week supply of nicotine patches and lozenges delivered via mail."
2890456|NCT03316170|Active Comparator|Social Support|"The control group will receive:~a brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs,~a written directory of a range of social support resources delivered via mail,"
2890457|NCT03316157|Experimental|Rehabilitation|Advanced cancer patients will receive an 8 week rehabilitation intervention consisting of physical exercise and nutritional supplementation, along with standard care
2890458|NCT03316157|No Intervention|Waiting list Control|Standard care alone for the 8 week trial period, followed by participants being offered the rehabilitation programme
2890459|NCT03316144|Experimental|1 mg/kg JS001|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg Q2w until disease progresses or unacceptable tolerability occurs
2890460|NCT03316144|Experimental|3 mg/kg JS001|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
2890461|NCT03316144|Experimental|10 mg/kg JS001|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 10mg/kg Q2w until disease progresses or unacceptable tolerability occurs
2890462|NCT03316131|Experimental|Treatment A|"Randomized patients will receive orally once daily fixed dose of the following drugs:~RDEA3170 + febuxostat + dapagliflozin;"
2890463|NCT03316131|Experimental|Treatment B|"Randomized patients will receive orally once daily fixed dose of the following drugs:~RDEA3170 + febuxostat + dapagliflozin matched placebo"
2890464|NCT03316118|Active Comparator|Group 1|Patient will receive genicular nerve block with bupivacaine
2890465|NCT03316118|Placebo Comparator|Group 2|Patient will receive normal saline as the nerve block
2890466|NCT03316105|Active Comparator|TENS unit stimulation|During this TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will take pressure readings after being placed. After four hours, subjects will again be given a second meal. Fifteen minutes of electrical stimulation will be given to subjects fifteen minutes before ingestion of lunch. After ingestion of lunch, 60 minutes of the electrical stimulation will be applied. When the test is done, the tube will be removed.
2890467|NCT03316105|Sham Comparator|No TENS unit stimulation|During this no TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will record stomach pressure readings after being placed. After four hours, subjects will again be given a second meal. The TENS unit stimulation will be placed but no electrical stimulation will be given. When the test is done, the tube will be removed.
2890468|NCT03316079|Active Comparator|Chest physiotherapy techniques|Manual chest physiotherapy techniques applied
2890469|NCT03316079|Experimental|Chest physiotherapy techniques + Mechanical in-exsufflation|Mechanical insufflation-exsufflation in addition to manual chest physiotherapy techniques
2890470|NCT03316066|Experimental|Group 5|stellate ganglion block with ropivacaine 0.2% 5 mL
2890471|NCT03316066|Active Comparator|Group 2|stellate ganglion block wit ropivacaine 0.2% 2 mL
2890472|NCT03316053||Tissue Sample for genetic testing|Biopsy sample
2890473|NCT03316040|No Intervention|Control 1|This arm represent control schools. No JIC will be implemented.
2890474|NCT03316040|Experimental|Treatment 1|This arm implements the JIC among a random subset of students within the pre-defined grade.
2890475|NCT03316040|Experimental|Treatment 2|This arm implements the JIC among indegree central students within the pre-defined grade.
2890476|NCT03316040|Experimental|Treatment 3|This arm implements the JIC among edge betweeness central students within the pre-defined grade.
2890477|NCT03316014||Adverse drug reaction|Children from 0 to 17 years inclusive with ADR notifications recorded in the French pharmaco-vigilance database by the Regional Pharmacovigilance Center of Champagne-Ardenne between 1 January 1985 and 31 December 2014
2890478|NCT03316001||cases|patients with a CT scan from January to August 2008 for which mesenteric panniculitis was diagnosed
2890479|NCT03316001||controls|"patients with a CT scan from January to August 2008 for which mesenteric panniculitis wasn't diagnosed and matched by gender and age with cases patients"
2890480|NCT03315988|Experimental|Vegan diet|"Intervention Description and Definition The participants will be asked to follow a diet that excludes foods hypothesised to support the syntheses of TMAO, particularly meat (any), eggs and fish (any). A number of studies suggest that dairy products may also have an effect in modulating TMAO production whereas other studies do not. Therefore, in order to avoid any potential contaminating or confounding effect, dairy products will also be avoided.~The diet employed in this study is broadly aligned to a vegan diet. The term vegan will be used to aid behaviour change and food choice. For example, an increasing array of products are now pack marked as vegan. The participants will be asked to keep their diet similar to their original and the Registered Dietitian involved in this study will plan their weekly menus accordingly."
2890481|NCT03315975|Experimental|Influenza vaccination cohort|Subjects will receive one dose of seasonal quadrivalent inactivated influenza vaccine intramuscularly for standard of care for prevention of influenza infection.
2890485|NCT03315962|No Intervention|Aim 2: Non-SPC Control Arm|Individuals randomized to receive the non-Single Pill Combination (SPC) for IPT who reside in districts where the SPIRIT intervention is being implemented.
2890486|NCT03315962|Experimental|Aim 2: RRF Intervention Arm|Individuals randomized to the Reduced Refill Frequency Intervention (RRF) group who reside in districts where the SPIRIT intervention is being implemented.
2890487|NCT03315962|No Intervention|Aim 2: RRF Control Arm|Individuals randomized to the Reduced Refill Frequency (RRF) control group who reside in districts where the SPIRIT intervention is being implemented.
2890488|NCT03315949|Experimental|Same-day dose group|Participants who ingest bowel cleanser on the day of colonoscopy. Participant will ingest the 4L PEG on the day of colonoscopy.
2890489|NCT03315949|Active Comparator|Split-dose group|Participants who ingest bowel cleanser by split dose. 2L PEG will be ingested 1 day before colonoscopy. Remaining 2L bowel cleanser will be ingested on the day of colonoscopy.
2890490|NCT03315936|Experimental|Single rising dose part|
2890491|NCT03315936|Experimental|Relative bioavailability (rel BA) part|
2890492|NCT03315923|Experimental|Rituximab|Patients in this group will receive 1g of rituximab in 500 cc normal saline serum through intravenous infusion for two times, with two weeks interval, which is assumed as one treatment course. The treatment course will be repeated in 6 months. Along with rituximab, 100 mg methylprednisolone, 10 mg chlorpheniramine, and 500 mg acetaminophen will also be injected to decrease side effects of rituximab.
2890493|NCT03315923|Experimental|Glatiramer acetate|Patients in this group will receive 20 mg of glatiramer acetate on a daily basis through subcutaneous injection. The medication dose can be increased up to 40 mg daily, based on the neurologist decision.
2890494|NCT03315910|Experimental|Motivational Interviewing( MI) (Yes vs. No)|Participants will receive two motivational informed cessation sessions; the first delivered face to faceor via telephone by the SC during the patient's initial lung cancer screening visit or during the shared decision making discussion or within about 1 week following their screening visit, and the second session delivered by telephone by the SC approximately 4 to 8 weeks after the first MI session.
2890495|NCT03315910|Experimental|Nicotine Replacement Therapy (NRT) Patch (Yes vs. No)|Participants will receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day and written instructions to use the patch daily starting on date they mutually agreed upon with their site coordinator. Participants who smoke fewer than 10 cigarettes per day will receive 4-weeks of the 14mg patch (2 boxes), and 2-weeks of the 7mg patch (1 box). Those who smoke 10 or more cigarettes per day will receive 4-weeks of the 21mg patch (2 boxes) and 2-weeks of the 14mg patch (1 box). Participants will receive their study medications from their site coordinator on the day of their screening appointment or via mail from Arrowhead Promotion & Fulfillment.
2890496|NCT03315910|Experimental|NRT Lozenge (Yes vs. No)|Participants will receive will receive 6 packs of NRT 2mg lozenge and written instructions to use the lozenge PRN to help manage acute nicotine withdrawal. Participants will be instructed to use the NRT lozenges no more than every 1-2 hours as needed. Participants will receive their study medications from their site coordinator on the day of their screening appointment or via mail from Arrowhead Promotion & Fulfillment.
2890497|NCT03315910|Experimental|Message Framing (Gain vs. Loss)|Overall, a robust body of health communication literature demonstrates that gain-framed messages may be more effective than loss-framed or non-framed (neutral) messages for encouraging smoking cessation. In other words, quitting messages that promote smoking cessation are more persuasive if they emphasize the benefits of quitting (gain-framed) rather than the risks (loss-framed) of persistent smoking (25, 26). Included with the written communication of their LDCT-LCS results, participants will receive a printed individualized quitting message that emphasizes either the benefits of quitting (gain-framed) or the risks of continuing to smoke (loss-framed).
2890498|NCT03315897|Active Comparator|Erythropoietin|12 intravenous infusions of recombinant human erythropoietin (EPO)
2890499|NCT03315897|Placebo Comparator|Saline|12 intravenous infusions of saline (1 ml NaCl)
2890500|NCT03315884|Experimental|Iliac segment recanalization and stenting Iliac segment CFA|Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)
2890501|NCT03315884|Active Comparator|Iliac segment recanalization, stenting and plastic CFA patch|Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch
2890502|NCT03315871|Experimental|1|Combination Immunotherapy
2890503|NCT03315832|Experimental|Valsartan|The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
2890504|NCT03315832|Placebo Comparator|Placebo Oral Tablet|The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
2890505|NCT03315819|Experimental|Bankart repair|Arthroscopic repair of anterior capsulo-labral lesions using the Bankart technique. The procedure must be performed within 15 days of dislocation.
2890506|NCT03315819|Active Comparator|Immobilization interne rotation|Immobilization of the shoulder during 3 weeks
2890507|NCT03315806|Active Comparator|Beetroot Juice|Beetroot juice containing 9 mmol of nitrate per dose
2890508|NCT03315806|Placebo Comparator|Placebo juice (nitrate depleted)|Beetroot juice nitrate-depleted
2890509|NCT03315793|Experimental|Duloxetine Hydrochloride|Duloxetine hydrochloride given orally.
2890510|NCT03315793|Placebo Comparator|Placebo|Placebo given orally.
2890511|NCT03315780|Experimental|Dulaglutide, Placebo|Dulaglutide and placebo administered subcutaneously (SQ).
2890512|NCT03315780|Experimental|Placebo, Dulaglutide|Placebo and dulaglutide administered SQ.
2890513|NCT03315767|Other|cirrhosis patients|"ARFI-elastography and portal vein flow measurement: Liver and spleen of patients with a scheduled HVPG-investigation will be examined by an ARFI-elastography-investigation. Additionally the portal vein flow will be assessed.~This examination will be done at d0 before the start of beta-blocker-administration and repeated as monitoring for portal hypertension treated by beta-blocker after 6 and 12 weeks, respectively.~HVPG-measurement: HVPG-values will be assessed at d0, after 6 and after 12 Weeks, respectively."
2890594|NCT03315338|Placebo Comparator|MAD Part 5 Placebo Cohort B|
2890514|NCT03315754|Experimental|TOOKAD Soluble 4 mg/kg|TOOKAD® Soluble VTP treatment consist of the combination of a single, 10-minute IV infusion of TOOKAD® Soluble at the dose of 4 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
2890515|NCT03315741|Experimental|Patient centered approach|Drug titration of maximum dose over 3-8 weeks
2890516|NCT03315728||Quality Improvement Strategy|First Nations communities partners are a diverse group of Indigenous communities reflecting wide variation in contextual factors: healthcare delivery and funding models; population size; remoteness; governance structures; and access to primary, secondary and tertiary care. Four diverse communities will partner in the program (two in Ontario and two in Atlantic Canada). All four communities will undertake an 18- month Quality Improvement Strategy intervention where they develop community-driven and culturally-relevant initiatives to improve diabetes care and management in their community
2890517|NCT03315702||control|venous blood samples collected from patients before mechanical ventilation
2890518|NCT03315702||mechanical ventilation|venous blood samples collected from patients with mechanical ventilation that last for at least 3 hours
2890519|NCT03315689|Placebo Comparator|Vehicle|Vehicle
2890520|NCT03315689|Experimental|Active|ATI-50002 Topical Solution
2890521|NCT03315676|Active Comparator|Oral Bonoprazan|Daily intake of Bonoprazan
2890522|NCT03315676|Active Comparator|Oral Esomeprazol|Daily intake of Esomeprazol
2890523|NCT03315663|Active Comparator|Sweetch App + DBWS|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app plus weight monitoring via digital body weight scale (DBWS).
2890524|NCT03315663|Active Comparator|Sweetch App Alone|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app alone.
2890525|NCT03315637|Experimental|Fetoscopic repair of spina bifida|This is a single arm study, all patients will receive a fetoscopic repair of the spina bifida
2890526|NCT03315624|Other|Hemodiafiltration HDF|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration sessions with the dialyzer FX CORAL 600 (TD 16-1), the dialyzer FX CorDiax 600 or the dialyzer FX 600. In each week the patient is assigned to one type of dialyzer.
2890527|NCT03315611|Active Comparator|AD, sensitized, treated|Allergen challenge chamber and Treatment for 12 day with 'Eucerin AtopiControl Lotion' (for the body) and 'Eucerin AtopiControl facial cream' (for the face): 1,2 g twice daily.
2890528|NCT03315611|Experimental|AD, not sensitized, not treated|Allergen challenge chamber
2890529|NCT03315611|Experimental|AD, sensitized, not treated|Allergen challenge chamber
2890530|NCT03315598|Experimental|An open-labeled, single-arm, exploratory pilot study|Electroacupunture for 2months
2890531|NCT03315585|Experimental|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
2890532|NCT03315572||Pediatric subject/caregiver dyads-first interview set|The first interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
2890533|NCT03315572||Pediatric subject/caregiver dyads-second interview set|The second interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
2890534|NCT03315559|Experimental|Subjects receiving GSK2269557 in treatment period 1|Eligible subjects will receive IV infusion of [14C] radiolabelled GSK2269557 with a single dose of 10 micrograms (µg) administered as single microtracer, concomitantly with an inhaled nonradiolabelled 1000 µg dose of GSK2269557. There will be a washout of at least 14 days after inhaled and IV dosing before subjects receive treatment 2.
2890535|NCT03315559|Experimental|Subjects receiving GSK2269557 in treatment period 2|Eligible subjects will receive [14C]-GSK2269557 with a single dose of 800 µg, administered as an oral solution.
2890536|NCT03315533|Experimental|Duloxetine 30 milligrams (mg)|
2890537|NCT03315533|Placebo Comparator|Placebo|
2890538|NCT03315533|Experimental|Duloxetine 60 milligrams (mg)|
2890539|NCT03315520|Experimental|Relapsed/refractory malignant lymphomas|Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation using BeEAC (Bendamustine, Cytarabine, Etoposide, Cyclophosphamide) conditioning regimen
2890540|NCT03315507|Experimental|PB1046 Injection|PB1046 Subcutaneous Injection
2890541|NCT03315494|Experimental|SKI-O-703 200 mg (once daily)|SKI-O-703 capsule (1 x 200 mg)
2890542|NCT03315494|Experimental|SKI-O-703 400 mg (once daily)|SKI-O-703 capsule (2 x 200 mg, once daily)
2890543|NCT03315494|Experimental|SKI-O-703 200 mg (twice daily)|SKI-O-703 capsule (1 x 200 mg twice daily)
2890544|NCT03315494|Placebo Comparator|Placebo|Placebo capsule
2890545|NCT03315481|Active Comparator|SAX catheter insertion|Ultrasound guided cather insertion in the short axis (SAX) of the adductor canal. Injection of lidocaine through the catheter
2890546|NCT03315481|Active Comparator|LAX catheter insertion|Ultrasound guided cather insertion in the long axis (LAX) of the adductor canal. Injection of lidocaine through the catheter
2890547|NCT03315455|Experimental|Prophylactic Emicizumab 1.5 mg/kg QW|Participants will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 1.5 mg/kg via SC injection QW up to 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study.
2890548|NCT03315455|Experimental|Prophylactic Emicizumab 6 mg/kg Q4W|Participants will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 6 mg/kg via SC injection Q4W (or 3 mg/kg Q2W if Q4W is not to be pursued) up to 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study.
2890595|NCT03315338|Experimental|MAD Part 5 Active Cohort C|CORT118335, dose to be determined
2890596|NCT03315338|Placebo Comparator|MAD Part 5 Placebo Cohort C|
2890798|NCT03313791|Experimental|50%whey-50% casein (Alternative)|portion size that contains 25 g of protein, oral, single administration
2890549|NCT03315455|Other|Control Arm: No Prophylaxis|Participants will not receive any prophylactic treatment up to 24 weeks. After 24 weeks, participants will have the opportunity to switch to receive emicizumab prophylaxis at 3 mg/kg QW via SC injection for 4 weeks, followed by 6 mg/kg Q4W (or 3 mg/kg Q2W if Q4W is not to be pursued), until marketing authorization as part of this study or a separate extension study.
2890550|NCT03315442|Sham Comparator|Caffeine Group|Caffeine group consumed 200mg of caffeine one time.
2890551|NCT03315442|Experimental|Energy Drink Group|The energy drink group consumed 1 16 ounces energy drink one time.
2890552|NCT03315429|Other|Stress testing arm|Stress testing of patients with functional mitral regurgitation.
2890553|NCT03315416||NHS Sample|Children diagnosed with speech sound disorder aged 2-5 years
2890554|NCT03315403||Patients with CAP|"Patients with a diagnosis of radiographically-confirmed CAP at the emergency department will undergo the usual diagnostics. For the study an extra nasopharynx sample, saliva sample and blood sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
2890555|NCT03315403||Related controls|"Of related controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)"
2890556|NCT03315403||Unrelated controls|"Of unrelated controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.~A questionnaire will be filled in. LytA PCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)"
2890557|NCT03315403||Patients with stable COPD|"Of stable COPD patients a nasopharynx sample, oropharynx sample and saliva sample will be collected. And if available also a sputum sample.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
2890558|NCT03315403||Patients with exacerbation of COPD|"Of patients with a diagnosis of an exacerbation of COPD at the emergency department a nasopharynx sample, oropharynx sample and saliva sample will be collected apart from the usual diagnostics. If available also a sputum sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
2890559|NCT03315390|Experimental|Intervention-group|Narrative Exposure Therapy (NET): for GP-practice adapted version of narrative exposure therapy during 3 sessions (à 45 minutes)
2890560|NCT03315390|Active Comparator|iTAU group|Improved Treatment-as-usual: 3 GP consultations with patients according to guidelines and adapted to patients' needs
2890561|NCT03315377|Active Comparator|Lunate-Capitate Fusion (LCF)|Operation with a Lunate-Capitate Fusion (LCF) for SLAC or SNAC arthritis.
2890562|NCT03315377|Active Comparator|Four Corner Fusion (4CF)|Operation with a Four Corner Fusion (4CF) for SLAC or SNAC arthritis
2890563|NCT03315364|Experimental|Liporaxel® (oral paclitaxel)|"28 days (4 weeks) will be set as one cycle of administration and Liporaxel® will be administered for 3 weeks, twice a day, every morning and evening (D1, D8, D15) and will take a week off on 4th week.~Liproaxel® 200mg/m2 will be orally administered twice a day (morning, evening) 1 hour after meal for D1, D8, D15 of every cycle. 10 hour-interval is recommended for between each administration."
2890564|NCT03315364|Active Comparator|Taxol® (IV paclitaxel)|"28 days (4 weeks) will be set as one cycle and for every 3 week administration, 1 week off dose period will be given.~Taxol® 80mg/m2 will be administered via IV and it must be diluted before drip administration. Dilute with 0.9% sodium chloride injection solution to make final concentration of 0.3-1.2 mg/mL."
2890565|NCT03315351|Experimental|Study Procedure|Brachytherapy. PET-scan.
2890566|NCT03315338|Experimental|SAD Part 1 Active Cohort A|CORT118335, 25 mg
2890567|NCT03315338|Placebo Comparator|SAD Part 1 Placebo oral capsule Cohort A|
2890568|NCT03315338|Experimental|SAD Part 1 Active Cohort B|CORT118335, 75mg
2890569|NCT03315338|Placebo Comparator|SAD Part 1 Placebo Cohort B|
2890570|NCT03315338|Experimental|SAD Part 1 Active Cohort C|CORT118335, 225mg
2890571|NCT03315338|Placebo Comparator|SAD Part 1 Placebo Cohort C|
2890572|NCT03315338|Experimental|SAD Part 1 Active Cohort D|CORT118335, 675mg
2890573|NCT03315338|Placebo Comparator|SAD Part 1 Placebo Cohort D|
2890574|NCT03315338|Experimental|SAD Part 2 Active Cohort A, Fasting|CORT118335, 600mg, is supplied as capsules for oral dosing given after an overnight fast
2890575|NCT03315338|Experimental|SAD Part 2 Active Cohort A, Fed|CORT118335, 600mg, is supplied as capsules for oral dosing given after a high-fat breakfast
2890576|NCT03315338|Placebo Comparator|SAD Part 2 Placebo PD Effect Cohort B|
2890577|NCT03315338|Experimental|SAD Part 2 Active PD Effect Cohort B: 630mg of CORT118335|
2890578|NCT03315338|Experimental|SAD Part 2 Active PD Effect Cohort B: 675mg of CORT118335|
2890579|NCT03315338|Experimental|MAD Part 3 Active Cohort A|CORT118335, 375mg qd for 14 days
2890580|NCT03315338|Placebo Comparator|MAD Part 3 Placebo Cohort A|Placebo qd for 14 days
2890581|NCT03315338|Experimental|SAD Part 4 Active Cohort A|CORT118335, 100mg
2890582|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort A|
2890583|NCT03315338|Experimental|SAD Part 4 Active Cohort B|CORT118335, 300mg
2890584|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort B|
2890585|NCT03315338|Experimental|SAD Part 4 Active Cohort C, Fasting|CORT118335, 900mg is supplied as suspension for oral dosing given after an overnight fast
2890586|NCT03315338|Experimental|SAD Part 4 Active Cohort C, Fed|CORT118335, 900mg is supplied as suspension for oral dosing given after a high-fat breakfast
2890587|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort C, Fasting|Supplied as suspension for oral dosing given after an overnight fast
2890588|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort C, Fed|Supplied as suspension for oral dosing given after a high-fat breakfast
2890589|NCT03315338|Experimental|SAD Part 4 Active Cohort Part D|CORT118335, 1500mg
2890590|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort D|
2890591|NCT03315338|Experimental|MAD Part 5 Active Cohort A|CORT118335, 150mg
2890592|NCT03315338|Placebo Comparator|MAD Part 5 Placebo Cohort A|
2890593|NCT03315338|Experimental|MAD Part 5 Active Cohort B|CORT118335, dose to be determined
2890597|NCT03315325|Experimental|Adult men|The average age was 25.80±0.37 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
2890598|NCT03315325|Experimental|Middle age men|The average age was 47.00±0.77 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
2890599|NCT03315325|Experimental|Advance age men|The average age was 73.20±0.91 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
2890600|NCT03315312|Active Comparator|Fissure sealant|
2890601|NCT03315312|Experimental|Fluoride varnish|
2890602|NCT03315286|Experimental|Device: SHADE Ultraviolet Sensor|Patients will receive an Ultraviolet (UV) sensor that will quantify their UV exposure through a linked smartphone application. Patients will also receive clinical counseling by their dermatologist regarding sun protection and avoidance
2890603|NCT03315286|Active Comparator|Standard of Care Counseling|Patients will receive clinical counseling by their dermatologist regarding sun protection and avoidance
2890604|NCT03315273|Experimental|Traumatic brain injury|"Patients who have suffered a traumatic brain injury will be assessed with a test battery including~a motor imagery ability questionnaire (MIQ-rs)~a mental rotation test~a chronometry test (TDMI)"
2890605|NCT03315273|Active Comparator|Control|"Healthy volunteers matched for age, sex and educational level will be assessed with the same test battery including~a motor imagery ability questionnaire (MIQ-RS)~a mental rotation test~a chronometry test (TDMI)"
2890606|NCT03315260||Bone metastatic CRPC patients|Japanese patients who are designated to undertake Ra-223/Xofigo therapy based on physician judgement
2890607|NCT03315247|No Intervention|Treatment as Usual|Participants assigned to the Treatment as Usual group will attend routine clinic visits at the Toronto Western Hospital Bariatrics Surgery Program (TWH-BSP). These visits generally include education on bariatric surgery and nutrition. Patients meet with select members of the multidisciplinary team at 1, 2, and 3 years post-surgery, and may attend an optional monthly support group. Participants' service utilization (i.e., attendance at optional sessions) will be documented and compared across groups.
2890608|NCT03315247|Experimental|Telephone-Based CBT|"The Tele-CBT intervention will be delivered 1 year following bariatric surgery. Participants will receive 6 weekly Telephone-based Cognitive Behavioural Therapy sessions and 1 final booster session 1 month later, all approximately 55-minutes in duration and scheduled at a time convenient for the participants."
2890609|NCT03315234||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
2890610|NCT03315234||0 < SYNTAX score < 23|Low SYNTAX group
2890611|NCT03315234||SYNTAX score ≥ 23|Intermediate-High SYNTAX group
2890612|NCT03315221|Experimental|Test product|Human Milk Fortifier (HMF) with added lipids.
2890613|NCT03315221|Active Comparator|Control product|Commercially available HMF (without lipids).
2890614|NCT03315208|Experimental|Unified Protocol + Treatment As Usual|Participants in this arm are offered 16 twice-weekly group UP sessions in addition to TAU at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
2890615|NCT03315208|Active Comparator|Treatment As Usual Alone|Participants in this arm undergo TAU at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
2890616|NCT03315195|Experimental|Preoperative oral nutritional supplement|Oral nutritional supplement 500 kcal/day for 14 days and dietary advice
2890617|NCT03315195|No Intervention|Conventional treatment|Dietary advice
2890618|NCT03315182|Experimental|Cohort 1 (Low Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:~• Cohort 1 (Low Dose): 2 X 10E13 vg/kg (n=3 subjects)"
2890619|NCT03315182|Experimental|Cohort 2 (High Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:~• Cohort 2 (High Dose): 5 X 10E13 vg/kg (n=3-6 subjects)"
2890620|NCT03315169|Active Comparator|Packing of perianal abscess cavity|Internal packing of perianal abscess cavity as per normal practice.
2890621|NCT03315169|Experimental|External dressing|External application of a non-adherent dressing to the perianal abscess cavity.
2890622|NCT03315156||Patients|patients with AOM
2890623|NCT03315143|Experimental|Sotagliflozin|Sotagliflozin dose 1 (1 tablet), once daily with possible uptitration in the first 6 months to dose 2 (2 tablets)
2890624|NCT03315143|Placebo Comparator|Placebo|Placebo dose 1 (1 tablet), once daily with possible uptitration in the first 6 months to dose 2 (2 tablets)
2890625|NCT03315130|Experimental|0.1 mg/kg RA101495|
2890626|NCT03315130|Experimental|0.3 mg/kg RA101495|
2890627|NCT03315130|Placebo Comparator|Placebo|
2890628|NCT03315104|Experimental|FLU-IGIV High Dose|Participants will receive a single infusion of high dose of FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive standard of care (SOC) antiviral treatment for flu. Administered intravenously at a dose of 450 mL of 65 g/mL FLU-IGIV.
2890629|NCT03315104|Experimental|FLU-IGIV Low Dose|Participants will receive a single infusion of low dose of FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive SOC antiviral treatment for flu. Administered intravenously at a dose of 225 mL of 65 g/mL FLU-IGIV.
2890630|NCT03315104|Placebo Comparator|FLU-IGIV Placebo|Participants will receive a single infusion of placebo for FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive SOC antiviral treatment for flu. Administered IV as 500 mL of normal saline.
2890631|NCT03315091|Experimental|Treatment sequence 1 (Fasted-Fed)|To assess the PK of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in either a fed or fasted condition.
2890632|NCT03315091|Experimental|Treatment sequence 2 (Fed-Fasted)|To assess the PK of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in either a fed or fasted condition.
2890633|NCT03315078|Experimental|Gene-Modified CD34+ HSCs|Participants will receive palifermin on Days -6, -5, and -4 and then busulfan on Days -3 and -2. On Day 0, participants will undergo the gene transfer treatment with infusion of the gene-modified CD34+ HSCs. They will receive palifermin on Days 1, 2, and 3.
2890634|NCT03315065|Other|Patients diagnosed with Lung cancer|patients diagnosed with Lung cancer and Thoracic radiotherapy
2890635|NCT03315052|Experimental|Budesonide treatment arm|Patients treated with budesonide in place of prednisone as part of immunosuppressive regimen
2890636|NCT03315052|Active Comparator|Standard immunosuppression arm|Patients treated with standard immunosuppression after liver transplant
2890637|NCT03315039|Experimental|Liposomal annamycin|
2890638|NCT03315026|Experimental|Siltuximab|Siltuximab 11mg/kg will be administered seven days before and 21 days after autologous stem cell infusion (+/-2 day).
2890639|NCT03315013|Experimental|SLATE|The SLATE arm will be administered the SLATE II algorithm and initiated on ART immediately if eligible under the algorithm. Patients not eligible under the algorithm will be referred for standard care.
2890640|NCT03315013|No Intervention|Standard|The standard arm will be referred to standard care after study enrollment.
2890641|NCT03315000|Experimental|Vilanterol|Vilanterol (25mcg)+ fluticasone (100mcg) inhaled through Ellipta® inhaler
2890642|NCT03315000|Experimental|Fluticasone|Fluticasone (100mcg) monotherapy inhaled through Ellipta® inhaler
2890643|NCT03315000|Placebo Comparator|Placebo|Lactose powder inhaled through Ellipta® inhaler
2890644|NCT03314987|Experimental|treatment group|carnosine
2890645|NCT03314987|Placebo Comparator|placebo group|placebo
2890646|NCT03314974|Experimental|TBI Regimen|
2890647|NCT03314974|Experimental|Non-TBI Regimen|
2890648|NCT03314935|Experimental|Treatment Group A|INCB001158 + FOLFOX
2890649|NCT03314935|Experimental|Treatment Group B|INCB001158 + gemcitabine/cisplatin
2890650|NCT03314935|Experimental|Treatment Group C|INCB001158 + paclitaxel
2890651|NCT03314922|Experimental|INCB050465|
2890652|NCT03314909|Experimental|Hemodialysis (HD)|Patients in this group would receive hemodialysis for 3 days consecutively besides conservative therapy.
2890653|NCT03314909|Experimental|Hemoperfusion (HP)|Patients in this group would receive hemoperfusion for 3 days consecutively besides conservative therapy.
2890654|NCT03314909|Experimental|HP-HD|Patients in this group would receive hemoperfusion and hemodialysis concurrent therapy for 3 days consecutively besides conservative therapy.
2890655|NCT03314909|No Intervention|Conservative|Patients in this group would receive basic supportive treatment, gastric lavage, glucosteroid and immunosuppressive drugs without any hemopurification.
2890656|NCT03314896|Experimental|Laparoscopic surgery for T4 colon cancers|Laparoscopic surgery for T4 colon cancers
2890657|NCT03314896|No Intervention|Conventional open surgery for T4 colon cancers|Conventional open surgery for T4 colon cancers
2890658|NCT03314883|Experimental|D-US ARF|Diaphragmatic evaluation, i.e thickening fraction (%) and excursion (millimeters), will be performed 3 times in the first two hours after acute hypoxic - hypercapnic respiratory failure (ARF) patients admission
2890659|NCT03314870|Other|Retrospective study|Tumoral tissue of 100 patients with breast cancer treated with neoadjuvant chemotherapy.
2890660|NCT03314870|Other|Prospective study|Tumoral tissue and plasma of 120 patients with breast cancer treated with neoadjuvant chemotherapy.
2890661|NCT03314857|Experimental|Patients with SAPIEN XT THV|Patients will be treated with Edwards SAPIEN XT™ Transcatheter Heart Valve and NovaFlex+ delivery system
2890662|NCT03314831||Sepsis|Patients with sepsis or septic shock admitted on Intensive Care Unit.
2890663|NCT03314831||Systemic Inflammatory Response Syndrome|Patients after cardiac surgery with Systemic Inflammatory Response Syndrome non-infectious etiology.
2890664|NCT03314818||Ultrasound 3D Imaging|To investigate natural history of subclinical atherosclerosis as determined by 3D carotid ultrasound.
2890665|NCT03314805|Placebo Comparator|Control|Placebo
2890666|NCT03314805|Experimental|Treatment|Astragalus polysaccharides 500 mg
2890667|NCT03314792|Active Comparator|Oxycodone|Active comparator drug administrated.
2890668|NCT03314792|Experimental|Tapentadol|Experimental drug administrated.
2890669|NCT03314766||IC-8 IOL|Patients previously implanted with an IC-8 IOL contralaterally or bilaterally under the protocol ACU-P14-029
2890670|NCT03314753||Cryoballoon Arm from FIRE AND ICE Trial|"No new/additional patients will be enrolled within this project. Only retrospective data will be collected on performed re-ablation procedures within the FIRE AND ICE Trial.~The FIRE AND ICE Trial collected data to compare efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus (Cryoballoon Arm) a radiofrequency ablation (RF Arm) with a ThermoCool catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AF).~Products Used within the FIRE AND ICE Trial: Arctic Front® & Arctic Front Advance® Cardiac CryoAblation Catheter System.~The purpose of this retrospective data collection on re-ablations performed in both treatment arms (Cryo arm and Radiofrequency arm) of the FIRE AND ICE Trial."
2890671|NCT03314753||Radiofrequency Arm from FIRE AND ICE Trial|"No new/additional patients will be enrolled within this project. Only retrospective data will be collected on performed re-ablation procedures within the FIRE AND ICE Trial.~The FIRE AND ICE Trial collected data to compare efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus (Cryoballoon Arm) a radiofrequency ablation (RF Arm) with a ThermoCool catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AF).~Products Used within the FIRE AND ICE Trial: NaviStar® ThermoCool® Ablation Catheter (Radiofrequency Arm; Manufacturer Biosense Webster, Inc.).~The purpose of this retrospective data collection on re-ablations performed in both treatment arms (Cryo arm and Radiofrequency arm) of the FIRE AND ICE Trial."
2890672|NCT03314740|Active Comparator|Arm A|Intravenous administration of weekly Paclitaxel (dosage: 80 mg/mq) for a maximum of 6 cycles. Cycle is defined as 4 weeks.
2890673|NCT03314740|Experimental|Arm B|"Oral administration of two experimental drugs:~Cediranib 20 mg/day given 7 days per week~Olaparib 600 mg / day (i.e. 300 mg twice a day) 7 days per week until progression, unacceptable toxicity, patient or physician decision to discontinue or death."
2890674|NCT03314740|Experimental|Arm C|"Oral administration of two experimental drugs:~Cediranib 20 mg/day given 5 days per week~Olaparib 600 mg / day (i.e. 300 mg twice a day) 7 days per week until progression, unacceptable toxicity, patient or physician decision to discontinue or death."
2890675|NCT03314727|No Intervention|Control group|Drink 200 ml soup with no added salt
2890676|NCT03314727|Experimental|High salt (NaCl) intake|Group 2: Drink 200 ml soup with 3 g added salt Group 3: Drink 200 ml soup with 3 g added salt plus 500 ml water Group 4: Drink 200 ml soup with 3 g added salt plus 750 ml water
2890677|NCT03314714|Experimental|Acute bout of endurance exercise|Intramyocellular lipid metabolism will be assessed in insulin resistant and healthy, sedentary individuals after an acute bout of endurance exercise.
2890678|NCT03314701|Active Comparator|Group 1|"Biphasic Intermittent Positive Airway Pressure (BIPAP) group:~Following endotracheal intubation BIPAP mode will be started with:~Inspiratory positive airway pressure [IPAP] at 20 cmH2O~Expiratory positive airway pressure [EPAP] at 5 cmH2O~PRESSURE SUPPORT is difference between these two pressures [IPAP]- [EPAP]~Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed"
2890679|NCT03314701|Active Comparator|Group 2|"Airway Pressure Release Ventilation (APRV) group:~high airway pressure (Phigh) will be set at 20 cmH2O~low airway pressure ( Plow) will be set at 5 cmH2O~the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min~T high at 4.5-6 seconds~T low at 0.5 to 0.8 second"
2890680|NCT03314688|Active Comparator|Usual Care Group|"Standardized breast cancer follow up care and materials regarding treatment (i.e., chemotherapy and endocrine therapy when relevant).~Lifestyle intervention book and log book for breast cancer survivors and access to the associated online videos and a pedometer at the end of the 2-year study. Women will also be offered a counselling session with a registered study dietician at the end of the study."
2890681|NCT03314688|Experimental|Dietary/Physical Activity Intervention|Eleven 30-min counseling sessions over six months (weekly, then biweekly, then monthly) with additional sessions in the latter 6 months (5 additional monthly sessions for a total of 16 sessions), timed with their oncology visit or via telephone if not coming in for oncology visit. Sessions focus on motivating health dietary choices and physical activity (home-based program).
2890682|NCT03314675|Other|CRT-D Measurements|Pre-specified measurements and additional follow-ups
2890683|NCT03314662|Experimental|aQIV|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
2890684|NCT03314662|Experimental|aTIV-1|Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
2890685|NCT03314662|Experimental|aTIV-2|MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
2890686|NCT03314649||Observational study|Patients with gastric cancer and non-cancerous disease planned to have laparotomy
2890687|NCT03314636|Experimental|PET-CT-positive patients|Carfilzomib 20/36mg/m2 days 1,2,8,9,15,16 Lenalidomide 25mg days 1-21 Dexamethasone 40mg days 1,8,15,22 28 day cycles 4 cycles
2890688|NCT03314610||Patients enrolled|Patient with parkinsonian syndromes and lower urinary tract symptoms, age > 18, able to walk without human help on 50 meters, able to hold urine at least 3 minutes. A first record of gait speed will be at strong desire to void. A second record will be after voiding or catheterization Gait records consist on : 3x 10 meter walk test, 1x double task 10 meter walk test, 1x Timed up and Go test and 1x GMT
2890689|NCT03314597|Active Comparator|Balance exercise group|Each of the ten sessions was composed of 45 minutes of balance exercises, each treatment being followed by a 15-min final phase of lower limb stretching, performed with the assistance of a physiotherapist. Sessions were repeated two or three times a week, with at least one rest day between one session and the next, over four successive weeks. Each patient was treated on-phase, at the same time of the day across sessions.
2890690|NCT03314597|Experimental|Mobile platform exercise group|Each of the ten sessions was composed of 45 minutes mobile platform training, each treatment being followed by a 15-min final phase of lower limb stretching, performed with the assistance of a physiotherapist. Sessions were repeated two or three times a week, with at least one rest day between one session and the next, over four successive weeks. Each patient was treated on-phase, at the same time of the day across sessions.
2890691|NCT03314584|Experimental|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
2890692|NCT03314584|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex.
2890693|NCT03314571||non applicable|
2890694|NCT03314558||COPD patients following a pulmonary rehabilitation program|COPD patients following a pulmonary rehabilitation program
2890695|NCT03314545|Other|laminate veneers with coronal posts|anterior endodontically treated teeth restored with laminate veneers with coronal posts
2890696|NCT03314545|Other|post, core and crown|anterior endodontically treated teeth restored with post, core and crown
2890697|NCT03314532|No Intervention|Surgery group|We will completely resection of the visible tumor and made the resection margin negative. We will use regular/irregular resection of the liver tumor tissue, hemihepatectomy or extended hepatectomy.
2890698|NCT03314532|Experimental|TILA-TACE group|After femoral artery catheterization, 5-Fr angiography catheters will be used for complete radiography of the celiac artery, the hepatic artery proper, left and right hepatic arteries and their branches, and 2.8-Fr micro-catheters will be used for complete radiography of the tumor's nutrient arteries. Lipiodol-epirubicin emulsions and 5% sodium bicarbonate injection solutions will be used for perfusion of chemotherapy drugs. Different sizes of embolic microspheres will be used alternatively for chemoembolization.
2890699|NCT03314519|Active Comparator|Ultrasonography|Patient in this group receive lung ultrasonography to detect lung collapse after insert double lumen tube and finally compare lung collapse by surgeon's visual grading scale of lung collapse when enter pleural cavity.
2890700|NCT03314519|Active Comparator|Fiberoptic bronchoscopy|Patient in this group receive fiberoptic bronchoscope to detect lung collapse after insert double lumen tube and finally compare lung collapse by surgeon's visual grading scale of lung collapse when enter pleural cavity.
2890743|NCT03314181|Experimental|Arm D, Part 2a: VenDVd Dose Escalation|Venetoclax at various doses administered orally QD in combination with daratumumab (16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection [preferred] or IV) Cycles 1-8, Days 1, 4, 8 and 11), and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.
2930557|NCT03036813|Active Comparator|Dose 2|GBT440
2890701|NCT03314506|Experimental|Trial|Subjects will need to come to the Substrate Metabolism Laboratory in the morning around 7:00 AM. After about a 15-30 minute rest, the study team will collect a blood sample from the subject's hand or forearm. The study team will also obtain a small sample of fat tissue from the area just underneath the skin near the belly button. Next, subjects will exercise on a treadmill at a moderate intensity for about 1 hour. Immediately after exercising the study team will collect a blood sample. The subject will remain resting in the laboratory for 3 hours after exercise, and then the study team will collect another blood and fat tissue sample. Upon completion, the subject will be provided a snack before leaving the laboratory.
2890702|NCT03314493|Experimental|Spironolactone group|Spironolactone oral tablet 25mg/day, for 12 months
2890703|NCT03314493|No Intervention|Control group|No spironolactone use
2890704|NCT03314480||Midfacial fracture suspected patients|Patients who are suspected of maxillofacial fracture
2890705|NCT03314480||Mandibular fracture suspected patients|Patients who are suspected of a mandibular fracture
2890706|NCT03314467||Cases DR|diabetic patients with diabetic retinopathy (DR)
2890707|NCT03314467||Cases other|diabetic patiens with other/multiple ocular disorder(s)
2890708|NCT03314467||Control|diabetic patients without ocular abnormalities
2890709|NCT03314454|Active Comparator|Elevated Mental Status|Elevated score on Patient Health Questionnaire
2890710|NCT03314454|Active Comparator|Non-elevated depressed mood|Lower score on Patient Health Questionnaire
2890711|NCT03314454|Active Comparator|Social Drinking status|The social drinker group will be those who consume alcohol regularly but with infrequent heavy drinking days.
2890712|NCT03314454|Active Comparator|Heavy drinker status|The heavy drinker group will be those who consume alcohol regularly with frequent heavy drinking days.
2890713|NCT03314441|Experimental|Yoga|Patients receiving Yoga lessons for 3 months
2890714|NCT03314428|Experimental|Gait retraining|Runners will be taught how to modify their running gait through multiple laboratory sessions and in-field training.
2890715|NCT03314415|Experimental|Early robotic intervention|Participants randomized to the early robotic intervention will attend robotic assistance sessions for a two-week period earlier in the study (during the first half of the study, approximately). Each participant will attend ten 15-minute robotic assistance sessions to interact with a robot (Aldebaraan Nao H25).
2890716|NCT03314415|Experimental|Late robotic intervention|Participants randomized to the late robotic intervention will attend robotic assistance sessions for a two-week period later in the study (during the latter half of the study, approximately). Each participant will attend ten 15-minute robotic assistance sessions to interact with a robot (Aldebaraan Nao H25).
2890717|NCT03314402|Experimental|group 1|Jaktinib Dihydrochloride Monohydrate
2890718|NCT03314402|Placebo Comparator|group 2|Placebo
2890719|NCT03314389|Experimental|Cochet bonnet esthesiometer|To examine sensation
2890720|NCT03314376|Experimental|Prehabilitation program|Individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants.
2890721|NCT03314376|No Intervention|Control group|They will be instructed to continue their current activities and not to increase objectively levels of physical activity performed during the 6-week intervention.
2890722|NCT03314363|Other|all patients|Classic CRRT with citrate predilution
2890723|NCT03314337|No Intervention|Distal Pancreatectomy without pancreatic stent|
2890724|NCT03314337|Experimental|Distal Pancreatectomy with pancreatic stent|pancreatic stent will be placed in the main pancreatic duct during the operation
2890725|NCT03314324|Experimental|ODM-201|
2890726|NCT03314324|Active Comparator|Enzalutamide|
2890727|NCT03314311|Experimental|Rehabilitation Programme|12 week multi-disciplinary intervention prescribing exercise, individual dietary counselling and education sessions.
2890728|NCT03314311|No Intervention|Control|Usual care control arm
2890729|NCT03314298|Experimental|testosterone anastrozole implant|testosterone 80mg Anastrozole 4 mg single as a subcutaneous pellet
2890730|NCT03314285|Other|Neck Pain|Patients with chronic mechanical neck pain will be evaluated for sleep quality by the Pittsburgh Sleep Quality Scale.
2890731|NCT03314285|Other|Healthy volunteers|Healthy volunteers without any disease will be evaluated for sleep quality by the Pittsburgh Sleep Quality Scale.
2890732|NCT03314272|No Intervention|Sliding scale protocol|"Consists of giving insulin every 30 minutes based on the blood glucose readings as follows:~<150 mg/dl: 0 units of insulin~150-220 mg/dl: 2 units of insulin~201-250 mg/dl: 4 units~251-300 mg/dl: 6 units~301-350 mg/dl: 8 units~351-400 mg/dl: 10 units~> 400 mg/dl: inform the MD on call"
2890733|NCT03314272|Experimental|Space Glucose Control|"Automated protocol consisting of an insulin infusion pump named The Space Glucose Control System.~Intervention:~For glucose measurement, a sample of blood gas will be taken every 30 minutes. Actrapid HM will be used in a 4IU/ ml concentration for infusion in a 50 ml syringe.~The range of glucose will be recorded throughout the intra-operative period. The number of hypoglycemic (<70mg/dl) and hyperglycemic (> 200mg/dl) events will be recorded."
2890734|NCT03314259|Experimental|Tamsulosin|Patients will then consume oral tamsulosin 0.4mg every morning daily for 5 days prior to elective surgery
2890735|NCT03314259|Placebo Comparator|Placebo|Patients will then consume placebo every morning daily for 5 days prior to elective surgery
2890736|NCT03314246|Other|Intervention|FAST user
2890737|NCT03314246|Other|Control|Standard of care
2890738|NCT03314233|Experimental|DING intervention|Delayed Cord Clamping
2890739|NCT03314220|Experimental|standard care plus preoperative preparation|experimental group received standard care plus preoperative preparation, which included a tour, a cartoon video depicting a boy's surgical journey and familiarization with medical equipment.
2890740|NCT03314220|No Intervention|standard care|
2890741|NCT03314194|Experimental|Plant Based Diet Group|Study is one cohort being tested over 6 days in two conditions: habitual diet versus plant based diet.
2890742|NCT03314181|Experimental|Arm B, Part 1b: VenDd Dose Expansion|Venetoclax at a dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (16 mg/kg intravenous [IV]) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
2890922|NCT03312920|Sham Comparator|Sham tDCS|sham tDCS with Face Name associate Memory task
2890744|NCT03314181|Experimental|Arm A, Part 1a: VenDd Dose Escalation|Venetoclax (Ven) various doses administered orally, once daily (QD) in combination with daratumumab (D) (16 mg/kg intravenous [IV]) administered in accordance with prescribing information and dexamethasone (d) (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
2890745|NCT03314181|Experimental|Arm E, Part 2b: VenDVd Dose Expansion|Venetoclax at dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8, Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.
2890746|NCT03314168|Active Comparator|Control group|Patients who are randomized in control group will receive the usual care in the physiotherapy service of Hospital Moinhos de Vento.
2890747|NCT03314168|Experimental|Single-set group|Patients who are randomized in Single-set (SS) group, will receive 12-week of combined training, twice a week, composed by 10 resistance exercises and 20-25 minutes aerobic exercise at 80-95% of the second ventilatory threshold heart rate in a cycle. One-single set will be performed per exercise at 60-80%1-RM, with 1-1,5min of rest between the exercises.
2890748|NCT03314168|Experimental|Multiple-sets group|Patients who are randomized in Multiples-set (MS) group, will receive 12-week of combined training, twice a week, composed by 10 resistance exercises and 20-25 minutes aerobic exercise at 80-95% of the second ventilatory threshold heart rate in a cycle. Regarding resistance exercises, three set will be performed per exercise at 60-80%1-RM, with 1-1,5min of rest between sets and the exercises.
2890749|NCT03314155|Experimental|Cerebral neuroinflammation evaluation|The density of TSPO (which is an inflammation maker) is evaluated by the tracer's brain distribution volume ([18F] DPA-714).
2890750|NCT03314142|Experimental|Glucose as reference food|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2890751|NCT03314142|Experimental|White bread as reference food|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2890752|NCT03314142|Experimental|Bread enriched with coarse wheat bran|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2890753|NCT03314142|Experimental|Bread enriched with fine wheat bran|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2890754|NCT03314142|Experimental|Bread enriched with fine wheat and carob|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2890755|NCT03314129|Experimental|Contrast sensitivity|UltimEyes
2890756|NCT03314129|Experimental|Perceptual organization|Contour Integration Training
2890757|NCT03314129|Experimental|Contrast sensitivity + Perceptual org.|UltimEyes + Contour Integration Training
2890758|NCT03314129|Active Comparator|Cognitive remediation|MyBrainSolutions
2890759|NCT03314116|Experimental|video group|guided by a 7-minute video that explains the importance of using ear plugs and correct installation.
2890760|NCT03314116|No Intervention|control group|instructed to use earplugs properly, including practical exercises by a medic
2890761|NCT03314103|Experimental|Vaccine|live attenuated varicella-zoster virus vaccine (with live virus >=4.3 LgPFU per dose)
2890762|NCT03314103|Placebo Comparator|Placebo|Placebo with no live virus
2890763|NCT03314090|Experimental|Silicone Gel Group|Intervention: Silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day (BID). The amount being similar in size to a grain of rice.
2890764|NCT03314077||COPD patients|
2890765|NCT03314064|Experimental|HIV positive subjects continuing DTG|HIV positive subjects who complete taking DTG in studies ING112276, ING113086, ING114915, ING111762 and those subjects who end participation in study 200304 in which they received either DTG or LPV/RTV will be included in this study.
2892724|NCT03300336|Experimental|Intervention|Implementation of STRIDE program
2890766|NCT03314025|Experimental|Tamsulosin|The patients in the Experimental group will receive Tamsulosin Hydrochloride 0.4 MG (milligrams) once a day for 5 days before the surgery, one capsule on the day of the surgery and one on the day after. The intervention will consist of a total of 7 capsules
2890767|NCT03314025|Placebo Comparator|Placebo|The patients in the Placebo group will receive a placebo oral capsule (sugar) once a day for 5 days before the surgery, one capsule on the day of the surgery and one on the day after. The intervention will consist of a total of 7 capsules
2890768|NCT03314012|Experimental|Catheter-Based Carotid Body Ablation|All subjects undergo catheter-based ablation of the carotid body using the Cibiem Transvenous Ultrasound System (CTUS).
2890769|NCT03313999|Other|Durometer Measurement|All patients participating in the study will receive standard of care treatment for their lymphedema. As part of the study they will be measured by the durometer in addition to other, standard diagnostics to further characterize their lymphedema progression.
2890770|NCT03313973|Experimental|with self stretching same muscle|
2890771|NCT03313973|Sham Comparator|with self stretching forearm muscle|
2890772|NCT03313960|Active Comparator|"One Drop | Premium with Afrezza"|
2890773|NCT03313960|Other|"One Drop | Premium without Afrezza"|
2890774|NCT03313947|Other|Difficult Airway|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
2890775|NCT03313947|Other|Obstructive Sleep Apnea|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
2890776|NCT03313947|Other|Predictive Obstructive Sleep Apnea|"The following 6 questions will be asked during the preoperative visit:~While sleeping, does your child snore more than half the time?~While sleeping, does your child always snore?~Have you ever seen your child stop breathing during the night?~Does your child occasionally wet the bed?~Did your child stop growing at a normal rate at any time since birth?~Is your child overweight"
2890777|NCT03313934|Placebo Comparator|Hyaluronic Acid Filler with Saline|For each subject, one tear trough will be injected with hyaluronic acid filler mixed with saline. This arm will act as a control to evaluate the efficacy of PRF with hyaluronic acid.
2890778|NCT03313934|Experimental|Hyaluronic Acid Filler with Platelet Rich Fibrin (PRF)|For each subject, one tear trough will be injected with hyaluronic acid filler mixed with Platelet Rich Fibrin (PRF). This study seeks to determine the efficacy of PRF in volumization of the tear trough and improvement of skin quality. This is the experimental condition.
2890779|NCT03313921|Experimental|Online Manifest Refraction|All participants will undergo three assessments of refractive error, in random order. All will perform an unsupervised manifest refraction with the use of a computer screen and their smartphone. Next, a regular manifest refraction assessment performed by an optometrist will function as active comparator. An automated refraction assessment will be performed to relate the quality and repeatability of the online refraction to another unsupervised method of refraction assessment.
2890780|NCT03313908|Experimental|breast surgery|during the breast surgery, detection of the tumor lesion with indocyanine green fluorescence and with radioactive seed localization, in each subject
2890781|NCT03313895|Active Comparator|Cycling Only|Moderate-intensity cycling, 3 times a week for 6 months, supervised by an exercise specialist
2890782|NCT03313895|Active Comparator|Cognitive Training Only|Computerized cognitive training, 3 times a week for 6 months, supervised by a specialist
2890783|NCT03313895|Experimental|ACT|Moderate-intensity cycling followed by computerized cognitive training, 3 times a week for 6 months, supervised by a specialist
2890784|NCT03313895|Sham Comparator|Stretching and Mental Stimulation Activities|Stretching and mental stimulation activities, 3 times a week for 6 months, supervised by a specialist
2890785|NCT03313882||donor|donor: normal heart samples from donor
2890786|NCT03313882||ICM|ICM: heart samples with ischemic cardiomyopathy
2890787|NCT03313882||NICM|NICM: heart samples with non-ischemic cardiomyopathy
2890788|NCT03313869|Experimental|Control|"Intervention: Reduction in daily steps up to 2000-3000 steps per day and no structured physical activity + High dose ingestion of fructose (3g/kg/day) glucose (0,5g/kg/day)in the last 10 days of the protocol No cocktail during the protocol~Healthy male volunteers in the active range of population (10000 to 15000 steps per day) aged 20-45 years, 22 BMI 27 158 cm height 190 cm, Certified as healthy by a comprehensive clinical assessment."
2890789|NCT03313869|Experimental|Cocktail intervention|"Intervention: Reduction in daily steps up to 2000-3000 steps per day and no structured physical activity + High dose ingestion of fructose (3g/kg/day) glucose (0,5g/kg/day)in the last 10 days of the protocol + Micronutrient cocktail supplementation with 560,7 mg/ day of polyphenols (3 pills/day), 2,1 g/day of omega-3 fatty-acids (3 pills/day), 168 mg/day of vitamin E and 80µg/day of selenium (1 pill/day)~Healthy male volunteers in the active range of population (10000 to 15000 steps per day) aged 20-45 years, 22 BMI 27 158 cm height 190 cm, Certified as healthy by a comprehensive clinical assessment."
2890790|NCT03313856|Placebo Comparator|Placebo|The patients were randomly assigned to received placebo (calcinaned magnesia), 1 capsule before each meal for a period of 90 days.
2890791|NCT03313856|Experimental|Guazuma ulmifolia plus Tecoma stans|The patients were randomly assigned to received the herbarium mixture (GU/TS) , 1 capsule of 400mg, before each meal for a period of 90 days.
2890792|NCT03313830|Experimental|Whey Protein Hydrolysate (WPH)|The intervention consists of Whey Protein Hydrolysate (WPH) ingestion by young healthy subjects to determine rates of muscle protein synthesis.
2890793|NCT03313830|Experimental|Intact Whey Protein (WHEY)|The intervention consists of Intact Whey Protein (WHEY) ingestion by young healthy subjects to determine rates of muscle protein synthesis.
2890794|NCT03313804|Experimental|Immune Checkpoint Inhibitor + Radiation|Immune checkpoint inhibitor (Nivolumab OR Pembrolizumab OR Atezolizumab) PLUS Radiation Therapy (Stereotactic Body Radiation Therapy OR fractionated radiation therapy)
2890795|NCT03313791|Experimental|Whey protein concentrate|portion size that contains 25 g of protein, oral, single administration
2890796|NCT03313791|Experimental|Yoghurt|portion size that contains 25 g of protein, oral, single administration
2890797|NCT03313791|Experimental|50%whey-50% casein (Standard)|portion size that contains 25 g of protein, oral, single administration
2930558|NCT03036813|Placebo Comparator|Placebo|Placebo
2890799|NCT03313791|Experimental|Micellar Casein Isolate- WPH|portion size that contains 25 g of protein, oral, single administration
2890800|NCT03313791|Experimental|Micellar Casein Isolate - Na-caseinate|portion size that contains 25 g of protein, oral, single administration
2890801|NCT03313791|Experimental|Micellar Casein Isolate|portion size that contains 25 g of protein, oral, single administration
2890802|NCT03313791|Experimental|UHT milk|portion size that contains 25 g of protein, oral, single administration
2890803|NCT03313791|Experimental|Recombined milk|portion size that contains 25 g of protein, oral, single administration
2890804|NCT03313791|Experimental|Recombined 50% whey milk|portion size that contains 25 g of protein, oral, single administration
2890805|NCT03313791|Experimental|Ca-caseinate|portion size that contains 25 g of protein, oral, single administration
2890806|NCT03313791|Experimental|Milk protein isolate|portion size that contains 25 g of protein, oral, single administration
2890807|NCT03313778|Experimental|Part A: Dose Escalation|mRNA-4157
2890808|NCT03313778|Experimental|Part B: Dose Escalation|mRNA-4157 + pembrolizumab
2890809|NCT03313778|Experimental|Part B: Dose Expansion|mRNA-4157 + pembrolizumab
2890810|NCT03313765|Experimental|Intervention|
2890811|NCT03313765|Active Comparator|Standard-of-care|
2890812|NCT03313752|Placebo Comparator|A - placebo|Green, plain, diamond shaped, film coated tablet (orally), not containing active ingredient; once daily, for 4 weeks
2890813|NCT03313752|Experimental|B - experimental drug|Dapagliflozin tablet available at dose of 10 mg, once daily, for 4 weeks
2890814|NCT03313739|Experimental|Intervention group|An Educational Program
2890815|NCT03313739|No Intervention|Control group|This group(n=30) received no intervention.
2890816|NCT03313726|Experimental|GnRh-antagonist A|
2890817|NCT03313726|Experimental|GnRh-antagonist B|
2890818|NCT03313713|Active Comparator|Beta-glucans|Beta-glucans, 3 g per day, per 8 weeks, at breakfast
2890819|NCT03313713|Placebo Comparator|Placebo|Placebo, 3 g per day, per 8 weeks, at breakfast
2890820|NCT03313700|Experimental|Robotic Assisted Distal Gastrectomy|Robotic Assisted Distal Gastrectomy will be performed for the treatment of patients assigned to this group.
2890821|NCT03313700|Active Comparator|Laparoscopic Assisted Distal Gastrectomy|Laparoscopic Assisted Distal Gastrectomy will be performed for the treatment of patients assigned to this group.
2890822|NCT03313674|Experimental|Seasonal Affective Disorder|The primary objective is to use neuroimaging paradigms to identify perturbations in neural circuits of SAD patients when they are clinically depressed in the winter, after bright light therapy treatment, and when they are healthy in the summer
2890823|NCT03313674|No Intervention|Major Depressive Disorder|SAD patients will be compared to unipolar depressed patient cohort, who will be imaged in the winter and the summer.
2890824|NCT03313674|No Intervention|Healthy Controls|SAD patients will be compared to healthy controls, who will be imaged in the winter and the summer.
2890825|NCT03313661|Experimental|Cabergoline|cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
2890826|NCT03313661|Active Comparator|Gliclazide|gliclazide (60-120 mg) once daily
2890827|NCT03313661|No Intervention|Placebo|Placebo
2890828|NCT03313648|Experimental|Laparoscopic Hepatectomy|Improvements in laparoscopic technology mean that LH now has superior short-term efficacy and similar long-term efficacy to open surgery , and LH has shown significant advantages in applications involving recurrent HCC.
2890829|NCT03313648|Active Comparator|Radiofrequency Ablation|With recent technological advances, RFA has become the most widely investigated new first-line therapeutic option for recurrent HCCs . Numerous large studies have demonstrated the advantages of RFA, which include its ease of use, safety, effectiveness, minimal invasiveness, and minimal morbidity and mortality .
2890830|NCT03313635||Men presenting with low-T|Men presenting with low-t will undergo a blood draw for evaluation of prealbumin levels.
2890831|NCT03313622||OCD group|"Day 1: Questionnaires/Assessments~Day 2: Tasks"
2890832|NCT03313596|Active Comparator|LT-only|patients received orthotopic LT and subsequent immunosuppression therapy
2890833|NCT03313596|Experimental|LT+ADV-TK|ADV-TK therapy was administered in addition to orthotopic LT and subsequent immunosuppression therapy
2890834|NCT03313583||Blood product recipients|All patients who received at least one blood product on the day of the study
2890835|NCT03313557|Experimental|Wee-1 kinase inhibitor AZD1775|To assess the safety of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in patients who have previously completed 1 of the AZD1775 clinical pharmacology studies and not have met any requirements to permanently discontinue treatment with AZD1775.
2890836|NCT03313544|Experimental|NIVOLUMAB PATIENTS|
2890837|NCT03313531||Study group 1|Patients with severe hemophilia A
2890838|NCT03313531||Study group 2|Healthy volunteers
2890839|NCT03313531||Study group 3|Healthy volunteers ) that at previous measurements have been shown to have a TGC>2SD of the median of the control population.
2890840|NCT03313531||Treated HA person|One patient with severe hemophilia A (HA) will be treated with two factor FVIII concentrates, one with standard half- life (Advate™) and one with a pro-longed half-life (Adynovate™) at two separate occasions
2890841|NCT03313518|Active Comparator|Anodal tDCS|Transcranial Direct Current Stimulation using anodal electrode, 15 patients received real anodal tDCS 2mA for 20 minutes for 10 consecutive days.
2890842|NCT03313518|Sham Comparator|sham group|Fifteen patients received sham anodal tDCS 2mA for 20 minutes for 10 consecutive days.
2890843|NCT03313505||Patients who had been tested for S100B protein|
2890844|NCT03313505||Patients who have benefited from another strategy|
2890845|NCT03313492|Active Comparator|E-Pamphlet|"A free non-interactive e-pamphlet (Skin Cancer Prevention and Early Detection from the American Cancer Society) will be accessible via our website."
2890846|NCT03313492|Active Comparator|Original UV4.me|Participants will view the original UV4.me web intervention, which includes educational modules, personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individuals, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator. The website content will remain the same, with the exception of updating photos, statistics, and cultural references for the current year.
2890847|NCT03313492|Experimental|Enhanced UV4.me2|Participants will view an enhanced version of the UV4.me website. Improvements to the website are based on user feedback from the original UV4.me trial, as well as reviews and models of effective e-Health interventions and implementation strategies.
2890848|NCT03313479||Group 1|GA and Dexmedetomidine
2890849|NCT03313479||group 2|GA and peribulbar
2890850|NCT03313479||group3|GA and xylocaine gel
2890851|NCT03313466|Experimental|iCBTI|Intervention: An internet-based cognitive behavioral therapy program for insomnia (iCBTI) that is tailored to the individual's needs based on responses to questions.
2890852|NCT03313466|Active Comparator|Usual care|Intervention: A group class on insomnia provided at each Kaiser Permanente Southern California medical center.
2890853|NCT03313453|Experimental|Aircleaner group|PuriCare (HEPA Air Cleaner) in active mode
2890854|NCT03313453|Placebo Comparator|Control comparator|Mock device of PuriCare in active mode
2890855|NCT03313440|Experimental|high fibre|A 10 day increase in daily wheat fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
2890856|NCT03313440|Experimental|low fibre|A 10 day control intervention with no additional wheat fibre. Products are provided in boxes that must be consumed each day during the intervention.
2890857|NCT03313427|Experimental|Intervention|Usual care Early physical therapy intervention at the UCIN and after discharge, at home; based on the family-centered model.
2890858|NCT03313427|Other|Control|Usual care
2890859|NCT03313414|Experimental|Treatment with Sofosbuvir/Velpatasvir|14 days of treatment with Sofosbuvir/Velpatasvir tablet
2890860|NCT03313388|Experimental|Tart Cherry Juice|290 mL per day of Tart Cherry juice for 7 days
2890861|NCT03313388|Active Comparator|Gatorade|290 mL per day of Gatorade for 7 days
2890862|NCT03313375|No Intervention|Control|Subjects will have no intervention. They will be resting in a chair for the entire length of the visit (4-5 hours) where blood pressure will be taken every 10 min, while other non-invasive cardiac measures are taken (I.E. Cardiac output, systemic vascular resistance, heart rate variability).
2890863|NCT03313375|Active Comparator|Continuous exercise|Subjects will be asked to perform a 45 min exercise bout. After a warmup, the exercise will be 30 minutes at a continuous level. After the exercise period subject will remain in the lab and blood pressure will be measured every 10 minutes for the remainder of the visit (4 hours) while other non-invasive cardiac measures are taken continuously as discussed above.
2890864|NCT03313375|Experimental|Aerobic Interval Exercise|Subjects will be asked to complete a 43 minute exercise session. After a warmup period, the subjects will complete a 4x4 protocol in that they will alternate 4, 4 minute higher intensity exercise bouts with 3, 3 minute lower intensity bouts. After the exercise, subjects will remain in the lab and blood pressure will be measured every 10 minutes for 4 hours, while other non-invasive cardiac measures are taken continuously as discussed above.
2890865|NCT03313362|Experimental|Subjects admitted to Epilepsy Monitoring Units in the VAMC|Subjects being monitored by standard of care, video EEG, in the Epilepsy Monitoring Units in the VAMC will all be placed on a Seizure Monitoring and Alerting System (SPEAC System).
2890866|NCT03313349|Other|Usual Provision (UP)|"Usual Provision~Psychotherapy: 1. cognitive therapy 2.family intervention"
2890867|NCT03313349|Other|Enhanced/Need-Based Provision (ENP)|"Enhanced/need-based Provision~Psychotherapy: 1.cognitive therapy 2.family intervention"
2890868|NCT03313336|Active Comparator|Cohort 1|EMLA Test Patch.
2890869|NCT03313336|Active Comparator|Cohort 2|EMLA Reference Patch.
2890870|NCT03313336|Placebo Comparator|Cohort 3|Placebo patch.
2890871|NCT03313323|Experimental|Zirconium-ipilimumab|Zirconium-ipilimumab is an experimental tracer and is administered at start of ipilimumab treatment and after second infusion 3 weeks later
2890872|NCT03313310|Experimental|Employment Intervention|An employment intervention (iFOUR) that has been adapted from previous piloting work of focus groups, key informant interviews and a community advisory board.
2890873|NCT03313297|Active Comparator|AZD4017|400mg oral AZD4017 twice daily for 35 days
2890874|NCT03313297|Placebo Comparator|Placebo|A placebo tablet containing microcrystalline cellulose and sodium stearyl fumarate to match the active tablets in size, shape and colour.
2890875|NCT03313284|Experimental|Study Group|
2890876|NCT03313271||a cohort of patients with lymphoma in China|establish a cohort of patients with lymphoma in China and follow up the patients for a long period of time
2890877|NCT03313258|Active Comparator|Standard of Care Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.
2890878|NCT03313258|Experimental|Active Warming Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.
2890879|NCT03313232|Experimental|Fragrance allergic patients|Patients with a previous positive patch test to oxidized R-Limonene. Patients will have an initial patch test dilution series with oxidized R-limonene performed on the back followed by twice daily exposure to oxidized R-limonene at three different concentrations and a vehicle control on the forearms for up to three weeks.
2890880|NCT03313232|Experimental|Possible fragrance allergic patients|Patients with a previous doubtful patch test to oxidized R-limonene. Patients will have an initial patch test dilution series with oxidized R-limonene performed on the back followed by twice daily exposure to oxidized R-limonene at three different concentrations and a vehicle control on the forearms for up to three weeks.
2890881|NCT03313232|Experimental|Healty controls|Healthy controls with no contact allergy to oxidized R-limonene. Healthy controls will have en initial diagnostic patch test with oxidized R-limonene performed followed by twice daily exposure to oxidized R-limonene at one concentration and a vehicle control on the forearms for up to three weeks.
2890923|NCT03312920|Experimental|active cathodal tDCS|active cathodal tDCS with Face Name associate Memory task
2890956|NCT03312738|Active Comparator|Placebo + Exemestane|Placebo of everolimus in combination with exemestane 25 mg daily
2890957|NCT03312725||Patients with ruptured or unruptured intracranial aneurysms.|
2890882|NCT03313219|Experimental|Gentuximab Injection|Patients are assigned to a dose level at the time of study entry and scheduled to receive i.v. of a single dose. The patient enter the subsequent multiple dose i.v. in a 7-day cycle if no DLT in 21 days after the first dose. The study period of each subject will be up to 4 cycles until the tumor progression or unacceptable toxicity. The MTD will be determined by assessing DLT in each cohort from cohort 1 to 6, using a 3+3 dose escalation model. Cohort A begin at 4mg/kg IV and the dose escalated in separate cohorts from 8mg/kg IV, 12mg/kg IV，16mg/kg IV and 20mg/kg IV. If there is no DLT observe in any of these 3 patients in 7 weeks, then the trial proceeds to enroll 3 patients into the next higher dose cohort. If one subject develops a DLT at a specific cohort, an additional 3 patients are enrolled into that same dose cohort. Development of DLTs in more than 1 of 6 patients in a specific dose cohort suggests that the MTD has been exceeded, and further dose escalation is not pursued.
2890883|NCT03313206|Experimental|Patients with Resectable head and neck mucosal melanomas|
2890884|NCT03313193|Experimental|Arm A|Acupressure for Children in Treatment for a Childhood Cancer + usual care
2890885|NCT03313193|No Intervention|Arm B|Usual care alone
2890886|NCT03313180|Experimental|All patients|
2890887|NCT03313167||Atrial Fibrillation-potential Patients|individuals 65 years of age or older with moderate-to-high risk of stroke
2890888|NCT03313154||Neuropsychiatric screening (treatment+)|Subjects affected by chronic hepatitis HCV-related, undergoing new antiviral drugs treatment, will be screened by psychiatric and neuropsychological questionnaires/tests
2890889|NCT03313154||Neuropsychiatric screening (treatment-)|Subjects affected by chronic hepatitis HCV-related, in wait list for new antiviral drugs treatment, will be screened by psychiatric and neuropsychological questionnaires/tests
2890890|NCT03313141|Experimental|Subjects|Only one arm is considered
2890891|NCT03313128||Historic intervention|Infants born into the historic intervention arm of sanitation trial (NCT02362932)
2890892|NCT03313128||Historic control|Infants born into the historic control arm of sanitation trial (NCT02362932)
2890893|NCT03313115||No Sleep/Wake Protocol Implementation|No implementation of the sleep/wake protocol. A subset of participants in this group will have light and sound levels in the room recorded.
2890894|NCT03313115||Sleep/Wake Protocol Implementation|The sleep/wake protocol will be implemented. A subset of participants in this group will also have light and sound levels in the room recorded.
2890895|NCT03313102|Experimental|Horton disease|
2890896|NCT03313102|Experimental|control|
2890897|NCT03313089||PSAN + MNP|"PSAN (Papas más nutritivas project) + MNP (micronutrients powders):~Children of the families beneficiaries of Community Schools of Family Agriculture of the municipalities of Cumbal, Carlosama Guachucal and Túquerres, who are part of the project Papas más nutritivas and exposed to project activities in which they work on topics related to food and nutritional security, equity and gender, production and entrepreneurship, Additionally, the home fortification with MNP that is 12 months in total, will be made 2 deliveries of 60 doses (specified in the MNP only group). After the delivery of MNP, advising, measurements of weight and height, clarification of doubts regarding fortification with MNP, nutrition education, and accompaniment by the project staff will take place."
2890898|NCT03313089||MNP only|"Cohort of exposed to MNP (micronutrients powders):~Children who will receive MNP delivered through the hospital or institutional health service providers of the municipalities of Guachucal and Carlosama, following the protocol for the home fortification with MNP that is 12 months in total, will be made 2 deliveries of 60 doses: the first period consists of the taking of MNP for 2 months, followed by a rest period of 4 months and continues again by another MNP intake for 2 months and rest for 4 months, and exposed to dissemination of basic information with regard to MNP and monitoring by growth and development that is routinely performed by health staff."
2890899|NCT03313076|Experimental|n-3 PUFA + Vitamin D3|4g fish oil in 4 softgels (n-3 PUFA) + 2000 IU Vitamin D3 in 1 capsule
2890900|NCT03313076|Experimental|n-3 PUFA Placebo + Vitamin D3|4g of corn/soy oil blend in 4 softgels + 2000 IU Vitamin D3 in 1 capsule
2890901|NCT03313076|Experimental|n-3 PUFAs + Vitamin D3 Placebo|4g fish oil in 4 softgels (n-3 PUFA) + Vitamin D3 matching Placebo, an inert white powder placebo in 1 capsule
2890902|NCT03313076|Placebo Comparator|n-3 PUFA Placebo + Vitamin D3 Placebo|4g n-3 PUFA Matching Placebo, a corn/soy oil blend in 4 softgels + inert white powder Vitamin D3 matching placebo in 1 capsule
2890903|NCT03313063||PE|Women with a history or preeclampsia, between 18 - 50 years of age, 0.5 - 20 years postpartum
2890904|NCT03313063||Control|Age-matched women without any birth complications, between 18 - 50 years of age, 0.5 - 20 years postpartum
2890905|NCT03313050|Experimental|Stage 1 multivalent (ages 50-64 years)|multivalent
2890906|NCT03313050|Active Comparator|Stage 1 Tdap (ages 50-64 years)|Tdap
2890907|NCT03313050|Experimental|Stage 2 multivalent (ages 65-85 years)|multivalent
2890908|NCT03313050|Active Comparator|Stage 2 polysaccharide (ages 65-85 years)|polysaccharide
2890909|NCT03313037|Experimental|Multivalent|Pneumococcal conjugate vaccine
2890910|NCT03313037|Active Comparator|Control|Prevnar 13 and PPSV23
2890911|NCT03313011||Progressive Apraxia of Speech|
2890912|NCT03312998|Experimental|Xrays|
2890913|NCT03312985|Experimental|ACAF surgery|Underwent anterior controllable antedisplacement and fusion
2890914|NCT03312985|Placebo Comparator|ACCF surgery|Underwentanterior controllable antedisplacement and fusion
2890915|NCT03312972|Experimental|HDR Brachytherapy|Day 1: HDR Brachytherapy implant, Up to 30 Gray (Gy) to target lesion
2890916|NCT03312959|Experimental|hyperbaric bupvacaine group|Peribulbar block will be performed using a total volume of 7 ml 6ml hyperbaric bupivacaine 0.5% + hyaluronidase (50 IU) in 1ml saline
2890917|NCT03312959|Active Comparator|isobaric bupvacaine group|Peribulbar block will be performed using a total volume of 7 ml 6ml isorbaric bupivacaine 0.5% + hyaluronidase (50 IU) in 1ml saline
2890918|NCT03312946|Experimental|Treatment oscillating vibro|treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks. Being performed twice a week, with a total duration of 50 minutes to the session, being 10 sessions total to end the treatment.
2890919|NCT03312933|Active Comparator|4 Weeks|Wears CAM Boot for 4 weeks
2890920|NCT03312933|Active Comparator|12 Weeks|Wears CAM Boot for 12 weeks
2890921|NCT03312920|Experimental|active anodal tDCS|active anodal tDCS with Face Name associate Memory task
2890924|NCT03312907|Placebo Comparator|Arm A (Control) 0-52 Weeks|Eligible subjects will receive belimumab plus rituximab-placebo. No immunosuppressant medications are allowed after week 4. Subjects may receive standard of care therapy which may include anti-malarials, Non-steroidal anti-inflammatory drugs (NSAIDs), and/or corticosteroids with presdnisone dose equivalent to <= 5 mg/day through Week 52. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study. Subjects will stop receiving Belimumab injections after week 52.
2890925|NCT03312907|Placebo Comparator|Arm A (Control) 53-104 Weeks|Eligible subjects may receive standard of care therapy which may include anti-malarials, NSAIDs, and/or corticosteroids with presdnisone dose equivalent to <= 5 mg/day in Week 53 through 104. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study.
2890926|NCT03312907|Experimental|Arm B (Combination) 0-52 Weeks|Eligible subjects will receive belimumab plus rituximab. No immunosuppressant medications are allowed after week 4 (Other than Rituximab at Week 6). Subjects may receive standard of care therapy which may include anti-malarials, NSAIDs, and/or corticosteroids with presdnisone dose equivalent to <= 5 mg/day through Week 52. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study. Subjects will stop receiving Belimumab injections after week 52.
2890927|NCT03312907|Experimental|Arm B (Combination) 53-104 Weeks|Eligible subjects may receive standard of care therapy which may include anti-malarials, NSAIDs, and/or corticosteroids with presdnisone dose equivalent to <= 5 mg/day in Week 53 through 104. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study.
2890928|NCT03312907|Experimental|Arm C (Reference) 0-52 Weeks|Eligible subjects will receive belimumab plus standard therapy including immunosuppressant which may be continued throughout the study. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study.
2890929|NCT03312907|Experimental|Arm C (Reference) 53-104 Weeks|Eligible subjects will receive belimumab plus standard therapy which may be continued throughout the study. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study.
2890930|NCT03312894|Experimental|Cohort 1 (Ketamine Responders): TAK-653 6 mg|TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 1 and 2; followed by TAK-653 tablets, orally, once daily on Days 3 and 4; followed by TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 5 to 7; followed by TAK-653 tablets, orally, once daily on Days 8 to 56.
2890931|NCT03312894|Placebo Comparator|Cohort 1 (Ketamine Responders): Placebo|TAK-653 placebo-matching tablets, orally, once daily up to Day 56
2890932|NCT03312894|Experimental|Cohort 2 (Ketamine Nonresponders): TAK-653 6 mg|TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 1 and 2; followed by TAK-653 tablets, orally, once daily on Days 3 and 4; followed by TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 5 to 7; followed by TAK-653 tablets, orally, once daily on Days 8 to 56.
2890933|NCT03312894|Placebo Comparator|Cohort 2 (Ketamine Nonresponders): Placebo|TAK-653 Placebo-matching tablets, orally, once daily up to Day 56
2890934|NCT03312881||neuropathic pain|Children with clinical diagnosis of neuropathic pain. Interventions: patient reported outcome measures, quantitative sensory testing, neuroimaging
2890935|NCT03312881||non-neuropathic pain|Children with clinical diagnosis of non-neuropathic pain. Interventions: patient reported outcome measures
2890936|NCT03312868|Experimental|Prospective Arm|Prospective arm with patients being treated with SBRT
2890937|NCT03312855|Experimental|Revacept 80 mg|single dose, intravenous
2890938|NCT03312855|Experimental|Revacept 160 mg|single dose, intravenous
2890939|NCT03312855|Placebo Comparator|Placebo|single dose, intravenous
2890940|NCT03312842|Experimental|CS1001|
2890941|NCT03312816|Placebo Comparator|Placebo|0 mg/d added POP
2890942|NCT03312816|Active Comparator|low dosage|low added POP
2890943|NCT03312816|Active Comparator|Medium dose|medium added POP
2890944|NCT03312816|Active Comparator|Hige dose|high added POP
2890945|NCT03312803|Active Comparator|Mini autogenous skin grafts|we take the autogenous skin graft from the same patient then cut it into small pieces then we spread it over the burn wound on one limb then cover these small pieces with homogenous skin graft taken from another person.
2890946|NCT03312803|Active Comparator|Autogenous skin graft|we take the regular autogenous one piece skin graft from the same patient and cover the burn wound on the other limb then we make a comparison between both limbs
2890947|NCT03312790|Experimental|augmented reality device|Tasks realized using augmented reality device
2890948|NCT03312790|Other|Real condition|Same tasks than augmented reality realized in normal/real condition
2890949|NCT03312777|Experimental|Omnitram|Oral Omnitram 20 mg (overencapsulated 10 mg tablets) administered every 6 hours for nine doses, coadministered with paroxetine.
2890950|NCT03312777|Active Comparator|Tramadol|Oral tramadol 50 mg (overencapsulated 50 mg tablet) administered every 6 hours for nine doses, coadministered with paroxetine.
2890951|NCT03312777|Placebo Comparator|Placebo|Oral placebo (overencapsulated microcrystalline) administered every 6 hours for nine doses, coadministered with paroxetine.
2890952|NCT03312764|Experimental|Online Diabetes Prevention Program|Participants will receive access to a 12-month online diabetes prevention program modeled after the CDC DPP curriculum. Participants in the online program receive paced curriculum, access to a live health coach, interactive group message forums, and connected weight scale and activity monitoring devices.
2890953|NCT03312764|Active Comparator|Enhanced Standard Care|All participants randomized to the standard-care/control group (SC) will be offered the opportunity to attend a single 90-minute diabetes prevention class with a trained health professional (MPH, RD, or related advanced degree). The class will focus on healthful eating based on the current MyPlate recommendations, guidance on gradual increases in moderate intensity physical activity, and action planning to be shared with friends and/or family. Control participants will also be given the opportunity to participate in the online digital intervention upon completion of the 12-month follow-up assessment.
2890954|NCT03312751|Experimental|Emapalumab|
2890958|NCT03312712||Participants with sarcoidosis|"Bronchoscopy, BAL collection, and PFTs* [SoC] *if required~Screening, research and safety bloods~Dynamic 18F-FDG PET/CT scan"
2890959|NCT03312712||Healthy volunteers|"Part A:~PFTs~Screening, research and safety bloods~Dynamic 18F-FDG PET/CT scan~Part B:~PFTs~Screening, research and safety bloods~Baseline and post challenge Dynamic 18F-FDG PET/CT scans~LPS/saline challenge"
2890960|NCT03312699|Experimental|Group A IIV4|Group A: Up to 30 healthy volunteers 18-40 years old, will be given seasonal quadrivalent inactivated influenza vaccine (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2890961|NCT03312699|Experimental|Group B High Dose IIV3|Group B: Up to 15 healthy volunteers 65 plus years old, will be given seasonal high dose trivalent inactivated influenza vaccine (Fluzone High Dose) Fluzone® high dose vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2890962|NCT03312699|Experimental|Group B Fluad|Group B: Up to 15 healthy volunteers 65 plus years old, will be given seasonal adjuvanted trivalent inactivated influenza vaccine Fluad®. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2890963|NCT03312699|Experimental|Group A Hepatitis A (HepA)|Group A: Up to 30 healthy volunteers 18-40 years old, will be given inactivated Hepatitis A vaccine Vaqta® in year 1 of the study and a booster 12 months post primary Vaqta vaccination. Each volunteer will complete a total of 4 visits per vaccination: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2890964|NCT03312699|Experimental|Group B Hepatitis A|Group B: Up to 30 healthy volunteers 65 plus years old, will be given inactivated Hepatitis A vaccine Vaqta® in year 1 of the study and a booster 12 months post primary Vaqta vaccination. Each volunteer will complete a total of 4 visits per vaccination: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2890965|NCT03312699|Experimental|Group A Typhoid VI|Group A: Up to 15 healthy volunteers 18-40 years old, will be randomized to either Typhoid Vi Polysaccharide Vaccine (Typhoid VI), Typhim Vi®, or Typhoid Vaccine Live Oral Ty21a, Vivotif®. This arm represents those randomized to Typhoid VI. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2890966|NCT03312699|Experimental|Group A Oral Typhoid|Group A: Up to 15 healthy volunteers 18-40 years old, will be randomized to either Typhoid Vi Polysaccharide Vaccine, Typhim Vi®, or Typhoid Vaccine Live Oral Ty21a, Vivotif® (Oral Typhoid). This arm represents those randomized to Oral Typhoid. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8 (from date of last oral dose), Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2890967|NCT03312699|Experimental|Group B Typhoid VI|Group B: Up to 30 healthy volunteers 65 plud years old, will be given Typhoid Vi Polysaccharide Vaccine (Typhoid VI), Typhim Vi® vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2890968|NCT03312686||Eosinophilic Esophagitis patients|PPI treatment
2890969|NCT03312673||Asthma population|Patients (men and women) asthmatic smokers and non-smokers followed routinely in the pulmonology department, Croix-Rousse Hospital, Hospices Civils of Lyon.
2890970|NCT03312660|Experimental|Prebiotic group.|Group of 22 families consuming a fermented dairy product with prebiotic components, once a day for 4 months.
2890971|NCT03312660|Placebo Comparator|Placebo group|Group of 22 families consuming a dairy product with similar characteristics regarding color, flavor and nutritional composition, not containing the prebiotic components, once a day for 4 months.
2890972|NCT03312647||Latent tuberculosis infection|Identified subjects with latent tuberculosis infection (LTBI) using whole-blood interferon-r release assays. All enrolled subjects were treated with one of the recommended regimens for LTBI treatment: 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid plus rifampin. Blood, urine sampling, and monitoring frequencies of adverse reactions of anti-TB drugs were performed.
2890973|NCT03312634|Experimental|Palovarotene Chronic/Flare-Up Regimen|Subjects will receive 5 mg palovarotene once daily for up to 24 months; and 20 mg palovarotene once daily for 28 days, followed by 10 mg for 56 days for flareups. (Dosing will be adjusted for weight in skeletally immature subjects.)
2890974|NCT03312621|Experimental|Intervention|The intervention group received all aspects of enhanced usual care but was also assigned a healthcare transition nurse who coordinated the delivery of specific intervention services. These services included 1) a face-to-face systematic review of the readiness assessment with the participant/caregiver 2) a status assessment of ongoing healthcare transition planning and preparation; 3) monthly phone calls with the participant/caregiver to update and fill gaps in the healthcare transition action plan.
2890975|NCT03312621|No Intervention|Control|The control group received enhanced usual care which provides standardized healthcare transition-specific written information including a written transition policy, as well as insurance and guardianship information. Participants were also provided with a transition readiness assessment and entered into a healthcare transition registry to facilitate tracking and communication.
2890976|NCT03312608||mild myelopathy (JOA>12)|40 patients (JOA>12) suffering from symptomatic or asymptomatic degenerative cervical myelopathy scheduled for surgery or conservative treatment. The radiological inclusion criteria are cervical spinal stenosis associated with or without intramedullary high signal intensity lesion on T2-weighted MRI. Exclusion criteria are other pathologies in the vicinity of the corticospinal tract above the lesion site (i.e. tumor, infarction), neuroinflammatory disease, high grade paresis of the upper extremity (BMRC<3), the existence of a cardiac pacemaker, deep brain stimulation electrodes or pregnancy. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
2890977|NCT03312608||moderate myelopathy|40 patients (JOA≤12) suffering from symptomatic degenerative cervical myelopathy scheduled for surgery (anterior and/ or posterior decompression) or conservative treatment. The radiological inclusion criteria are cervical spinal stenosis associated with or without intramedullary high signal intensity lesion on T2-weighted MRI. Exclusion criteria are other pathologies in the vicinity of the corticospinal tract above the lesion site (i.e. tumor, infarction), neuroinflammatory disease, high grade paresis of the upper extremity (BMRC<3), the existence of a cardiac pacemaker, deep brain stimulation electrodes or pregnancy. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
2890978|NCT03312608||healthy control|As a control group, 40 subjects will be included into the study. Exclusion criteria and examination protocol are identical with the patient group. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
2890979|NCT03312595|Other|Restrata TM Wound Matrix|Prospective, single armed, non-randomized study with direct assignment
2890980|NCT03312582|Experimental|Manual debridement and 1% metformin gel|
2890981|NCT03312582|Placebo Comparator|Manual debridement and placebo|
2890982|NCT03312569||Intracorporeal Anastomosis|Participants will undergo either robotic-assisted or laparoscopic surgery with an intracorporeal anastomosis due to begin or malignant Right Colon Disease.
2890983|NCT03312569||Extracorporeal Anastomosis|Participants will undergo either robotic-assisted or laparoscopic surgery with an extracorporeal anastomosis due to begin or malignant Right Colon Disease.
2890984|NCT03312556|Placebo Comparator|Placebo|Placebo pill or patch
2890985|NCT03312556|Active Comparator|CPAP|Continuous positive airway pressure during the night
2890986|NCT03312543|Experimental|Active Cell: Active Mask|Cleanser, Moisturizer, Active Mask
2890987|NCT03312543|Sham Comparator|Sham Cell: Sham Mask|Cleanser, Moisturizer, Sham Mask
2890988|NCT03312530|Experimental|A: Cobimetinib|Participants will receive the standard single-agent cobimetinib dose of 60 milligrams (mg) (3 tablets of 20 mg each) orally (PO) daily on Days 1-21 of each 28-day cycle until disease progression. Upon progression, participants will be allowed to receive treatment with cobimetinib and atezolizumab at the recommended Phase II dose of cobimetinib 60 mg PO on Days 1-21 plus atezolizumab intravenous (IV) infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
2890989|NCT03312530|Experimental|B: Cobimetinib + Venetoclax|Participants will receive cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
2890990|NCT03312530|Experimental|C: Cobimetinib + Venetoclax + Atezolizumab|Participants will receive cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase plus atezolizumab IV infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
2890991|NCT03312530|Experimental|Safety Run-In: Cobimetinib + Venetoclax|Participants will receive cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses, in 28-day cycles, to identify the dose level with acceptable safety.
2890992|NCT03312530|Experimental|Safety Run-In: Cobimetinib + Venetoclax + Atezolizumab|Participants will receive cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses and atezolizumab (on Day 1 and Day 15) at a fixed dose of 840 mg IV, in 28-day cycles, to identify the dose level with acceptable safety.
2890993|NCT03312517|Experimental|Suvorexant 10mg|Subjects will receive belsomra 10mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
2890994|NCT03312517|Experimental|Suvorexant 20mg|Subjects will receive belsomra 20mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
2890995|NCT03312517|Experimental|Placebo oral capsule|Subjects will receive placebo before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
2890996|NCT03312504|Experimental|Neuromuscular Training Warm-up|Schools randomized to the intervention arm receive a workshop outlining a neuromuscular training program to be used as a warm-up for 15 minutes at the beginning of each physical education class. The warm-up consist of high-intensity aerobic, strengthening, agility, plyometric, and balance components. The workshop is designed to last two hours, and includes a video outlining the warm-up components, practice time, and group discussions for action planning to address potential barriers to the program.
2890997|NCT03312504|Placebo Comparator|Control Standard-of-practice Warm-up|Schools randomized to the control arm receive a workshop outlining a standard-of-practice program to be used as a warm-up for 15 minutes at the beginning of each physical education class. The warm-up consists of aerobic exercises and static stretching. The workshop is designed to last one hour, and includes an explanation and demonstration of the exercises, but no video or practice time.
2890998|NCT03312478|Other|Case|Known cases of type 1 diabetes mellitus as described in the inclusion criteria for cases
2890999|NCT03312478|Other|Control|Age-matched non-diabetic controls as described in the inclusion criteria for controls
2891000|NCT03312465||AS Domelock System Subjects|Subjects that receive the Anatomical Shoulder Domelock System
2891001|NCT03312452|Experimental|Infusion pump group|Study subjects assigned to this group will receive intravenous fluid via an infusion pump (Hospira plum pump) during their surgery.
2891002|NCT03312452|Active Comparator|Gravity drip group|Study subjects assigned to this group will receive intravenous fluid via a gravity drip device during their surgery.
2891003|NCT03312439|Active Comparator|Intervention group|Will be given advice as described above
2891004|NCT03312439|No Intervention|Control group|Consisting of subjects from the general Swedish population.
2891005|NCT03312426|Experimental|BMS-986205 under fasted conditions then with high-fat meal.|Single, 100 mg dose of BMS-986205 under fasted conditions (Day 1) followed by single, 100 mg dose of BMS-986205 with a high-fat meal (Day 15).
2891006|NCT03312426|Experimental|BMS-986205 with high-fat meal then under fasted conditions.|Single, 100 mg dose of BMS-986205 with a high-fat meal (Day 1) followed by single, 100 mg dose of BMS-986205 under fasted conditions (Day 15).
2891007|NCT03312426|Experimental|BMS-986205 under fasted conditions then with light meal.|Single, 100 mg dose of BMS-986205 under fasted conditions (Day 1) followed by single, 100 mg dose of BMS-986205 with a light meal (Day 15).
2891008|NCT03312426|Experimental|BMS-986205 with light meal then under fasted conditions.|Single, 100 mg dose of BMS-986205 with a light meal (Day 1) followed by single, 100 mg dose of BMS-986205 under fasted conditions (Day 15).
2891009|NCT03312413|Experimental|Dexmedetomidine low dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.2μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
2891010|NCT03312413|Experimental|Dexmedetomidine median dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.5μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
2891011|NCT03312413|Experimental|Dexmedetomidine high dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.7μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
2891012|NCT03312413|Placebo Comparator|Control group (normal saline group)|Patients in this group are received saline iv infusion of 5mL·h-1 from incision to 20-30 minutes before the end of surgery
2891013|NCT03312400|Active Comparator|200 mg Arm|100 mg twice a day
2891014|NCT03312400|Active Comparator|400 mg Arm|200 mg twice a day
2891015|NCT03312387|Experimental|Essential Amino Acid and Exercise|Participants will be provided with essential amino acids during exercise training.
2891016|NCT03312387|Placebo Comparator|Placebo and Exercise|Participants will be provided with placebo supplement during exercise training.
2891017|NCT03312374||stage II CRC|Patients with stage II colorectal cancer
2891018|NCT03312374||stage III CRC|Patients with stage III colorectal cancer
2891019|NCT03312361|Experimental|15% Oxygen|All participants will breath in 15% oxygen for 2 hours
2891020|NCT03312348|Experimental|Infrared Imaging undertaken|Infrared imaging of Region Of Interest in study participants
2891021|NCT03312335|Experimental|Low-dose Aldesleukin (Proleukin®)|
2891022|NCT03312322|Experimental|CWT with high-frequency electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
2891023|NCT03312322|Experimental|CWT with low-frequency electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
2891024|NCT03312322|Experimental|CWT with sham electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
2891025|NCT03312309|Experimental|RIF group|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
2891026|NCT03312283|Experimental|QL1205|QL1205 injection (0.5mg) by vitreous injection once a month for three months（D1、D29、D57）
2891027|NCT03312283|Active Comparator|Lucentis|Lucentis® injection(0.5mg) by vitreous injection once a month for three months（D1、D29、D57）
2891028|NCT03312270|Experimental|Multimodality information Comprehension|Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
2891029|NCT03312257|Experimental|Multifocal D +2.50 add & 0.01% atropine|"The Biofinity Multifocal D with a +2.50 add is a soft bifocal contact lens that has a strong reading power; the 0.01% atropine is a low-dose atropine."
2891030|NCT03312244|Experimental|Pyridostigmine|Pyridostigmine 90mg/d
2891031|NCT03312244|Placebo Comparator|Placebo|Placebo
2891032|NCT03312231|Experimental|Group 1|3.75 mcg of H7N9 vaccine with PBS diluent plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
2891033|NCT03312231|Experimental|Group 2|7.5 mcg of H7N9 vaccine plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
2891034|NCT03312231|Experimental|Group 3|15 mcg of H7N9 vaccine plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
2891035|NCT03312231|Experimental|Group 4|15 mcg of unadjuvanted H7N9 vaccine on days 1 and 22, n=50 (19-64 years old) and n=30 (65 and older)
2891036|NCT03312231|Experimental|Group 5|45 mcg of unadjuvanted H7N9 vaccine on days 1 and 22, n=50 (19-64 years old) and n=30 (65 and older)
2891037|NCT03312218|Experimental|Intervention|Intervention site residents will receive alerts through an app to adaptively reinforce the learning of clinical content based on cases and test questions (spaced education).
2891038|NCT03312218|No Intervention|Control|Residents in the control group will receive the same app providing identical clinical cases and test questions-on-demand, but with alerts inactivated (no spaced education).
2891039|NCT03312205|Experimental|Autologous CAR-T cells|Patients will be be treated with autologous CAR-T cells
2891040|NCT03312192|Active Comparator|Plate and Cage|ACDF with interbody cage and anterior plating.
2891041|NCT03312192|Active Comparator|Stand Alone Cage|ACDF with stand alone interbody cage without anterior plating
2891042|NCT03312179||diabetics STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
2891110|NCT03311633|Experimental|3 week percutaneous pinning group|Percutaneous pinning time will be for three weeks and short cast immobilization for six weeks.
2892725|NCT03300336|No Intervention|Usual Care|Pre-implementation before STRIDE program
2891043|NCT03312179||non diabetics STEMI|Non diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis(Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
2891044|NCT03312179||diabetics incretin-users STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These patients were treated by incretin therapy at last 6 months before study enrollment.
2891045|NCT03312179||diabetics never-incretin-users STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These diabetic patients were never treated by incretin therapy before study enrollment.
2891046|NCT03312166|Experimental|Compression device|
2891047|NCT03312153|Experimental|Neem (Azadirachta indica)|Neem (Azadirachta indica) (alcoholic solution) used as an anti inflammatory , antibacterial irrigant
2891048|NCT03312153|Active Comparator|2.5%sodium hypochlorite|2.5% sodium hypochlorite, anti-bacterial root canal irrigant solution
2891049|NCT03312140|Other|Choline Chloride|Patients receive choline chloride (1g Choline) three times a day for 12.6 weeks as a food supply
2891050|NCT03312127|Experimental|GORE Excluder|GORE Excluder Iliac Branch Endoprosthesis arm with 'ILIAC ENDOPROSTHESIS GORE EXCLUDER'
2891051|NCT03312114|Experimental|Single arm|Avelumab and SABR
2891052|NCT03312101|Experimental|Experimental|exercise program
2891053|NCT03312101|No Intervention|Control|observation
2891054|NCT03312075||cystic fibrosis patients|Sputum and blood samples
2891055|NCT03312062|Experimental|Foam Rolling Group|The participants in this group will receive foam rolling exercise.
2891056|NCT03312062|No Intervention|Control Group|The participants in this group will receive no foam rolling. They will only be evaluated.
2891057|NCT03312036|Experimental|CPFA Patients|Patients affected by acute or acute on chronic liver failure who undergo Coupled plasma filtration and adsorption (CPFA) to recover their basal liver function or as a bridge to liver transplantation. The intervention is CPFA treatment which lasts 6 hour length. The intervention can be repeated for a maximum of 5 times.
2891058|NCT03312023|Experimental|LDV/SOF|12 weeks treatment with ledipasvir/sofosbuvir
2891059|NCT03312010|Experimental|High Frequency|Subjects receiving high frequency pulse rate treatment over T9 exiting nerve roots. Subjects and assessors blinded Randomization.
2891060|NCT03312010|Sham Comparator|Sham|Subjects receiving Sham (non-active) treatment over T9 exiting nerve roots. Subjects and assessors blinded to randomization. Subjects and assessors to be unblinded if pain scores are 30 mms or higher with VAS after 1-month follow-up. Upon this moment subjects to receive active stimulation
2891061|NCT03311997|No Intervention|Non-operative treatment|Active rehabilitation program
2891062|NCT03311997|Active Comparator|Operative treatment|Surgical reattachment of hamstring tendons using suture anchors followed by active rehabilitation program
2891063|NCT03311984||LMWH qd|receiving Low-molecular-weight Heparin（LMWH）qd
2891064|NCT03311984||LMWH q12h|receiving Low-molecular-weight Heparin（LMWH）q12h
2891065|NCT03311971|Sham Comparator|Conventional therapy|Patient undergoing conventional analgesic therapy after total knee replacement
2891066|NCT03311971|Experimental|Virtual reality glasses|treated with virtual glasses
2891067|NCT03311958|Experimental|Nivolumab|
2891068|NCT03311945|Experimental|Raltegravir + Lamivudine|Lamivudine (300 mg QD) plusRaltegravir (1200 mg QD)
2891069|NCT03311932|Active Comparator|Cortef® Tablets - fasted|Single dose of 20mg Cortef® Tablets - fasted arm
2891070|NCT03311932|Experimental|Infacort® - fasted|Single dose of 20mg Infacort® - fasted arm
2891071|NCT03311932|Active Comparator|Cortef® Tablets - fed|Single dose of 20mg Cortef® Tablets - fed arm
2891072|NCT03311932|Experimental|Infacort® - fed|Single dose of 20mg Infacort® - fed arm
2891073|NCT03311906|Experimental|Test side|Scaling and Root Planing 0.8% Hyaluronic acid gel
2891074|NCT03311906|Active Comparator|Control Side|Scaling and Root Planing
2891075|NCT03311893|Active Comparator|health personnel|natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population
2891076|NCT03311893|Placebo Comparator|population|natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population
2891077|NCT03311880|Experimental|Intervention|There is no control group for this study. Therefore all participants receive the intervention.
2891078|NCT03311867|Active Comparator|Braided Suture|Patient in this group will have a cerclage with ethibond suture material
2891079|NCT03311867|Active Comparator|Non- Braided Suture|Patient in this group will have a cerclage with prolene suture material
2891080|NCT03311854|Experimental|NI-0501|
2891081|NCT03311841|Experimental|End Stage Renal Disease|Participants requiring hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). A washout period of at least 14 days will separate dosings.
2891082|NCT03311841|Experimental|Severe Impairment|Participants with <30 mL/min/1.73m^2 estimated glomerular filtration rate (eGFR) not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
2891083|NCT03311841|Experimental|Moderate Impairment|Participants with 30 to <60 mL/min/1.73m^2 eGFR not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
2891084|NCT03311841|Experimental|Mild Impairment|Participants with 60 to <90 mL/min/1.73m^2 eGFR not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
2891085|NCT03311841|Active Comparator|Healthy Control|Participants with ≥90 mL/min creatinine clearance (CLcr). Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
2891086|NCT03311828|Experimental|Diagnostic (Copper 64Cu-DOTA-daratumumab, PET)|Patients receive daratumumab IV over 10-45 minutes, and within 6 hours, patients receive copper 64Cu-DOTA-daratumumab IV on day 0. Patients undergo PET on days 1 and 2.
2891087|NCT03311802||1|
2891088|NCT03311789|Experimental|PD-1 inhibitor + Gemcitabine+Cisplatin|Patients will be enrolled in the experimental arm and will receive Gemcitabine on day 1 and 5 (1000mg/m2 ) +Cisplatin on day 1(75mg/m2)+ PD-1 inhibitor on day 3 (Nivolumab 3mg/kg, or SHR-1210 200mg) every 3 weeks. If there is continued benefit after 6 months, PD-1 inhibitor will be administered as maintenance treatment until tumor progression or death.
2891089|NCT03311763|Active Comparator|Counseling alone|Group 1: physical activity assessment, brief counseling session + physical activity wearable
2891090|NCT03311763|Experimental|Group exercise|Group 2: Group 1 intervention components + referral to a free, community-based, EIM practitioner led group exercise program (two, 1 hour classes/week for 8 weeks).
2891091|NCT03311750|Experimental|Panitumumab|On day 1 of each cycle patients will receive panitumumab followed by 5-fluorouracil and leucovorin in combination with either irinotecan (FOLFIRI regimen) or oxaliplatin (FOLFOX regimen) or followed by irinotecan monotherapy. This treatment will be repeated every 2 weeks for FOLFIRI and FOLFOX regimens and every 3 weeks for irinotecan monotherapy.
2891092|NCT03311737|Experimental|general anesthesia group|The patients in this group receive general anesthesia preoperatively, and use patient controlled intravenous analgesia postoperatively.
2891093|NCT03311737|Active Comparator|epidural group|The patients in this group receive general anesthesia combined with epidural anesthesia, and use patient controlled epidural analgesia postoperatively.
2891094|NCT03311724|Experimental|LY3298176 Group 1|LY3298176 administered subcutaneously (SC)
2891095|NCT03311724|Experimental|LY3298176 Group 2|LY3298176 administered SC
2891096|NCT03311724|Experimental|LY3298176 Group 3|LY3298176 administered SC
2891097|NCT03311724|Placebo Comparator|Placebo|Placebo administered SC
2891098|NCT03311711|Experimental|SPIRIT-in person|Patients and surrogates who participate in the SPIRIT intervention in person.
2891099|NCT03311711|Experimental|SPIRIT-remote|Patients and surrogates who participate in the SPIRIT intervention remotely, via teleconference.
2891100|NCT03311711|Active Comparator|Usual care|Patients and surrogates who receive the standard information about advance directives that is provided at the time of diagnosis.
2891101|NCT03311698|Experimental|Intervention|Households receiving the intervention will receive (1) Interventions to promote homestead food production, increase agricultural production and food diversity, (2) nutritional counselling, including locally adapted instructions on the mix and quantity of food suitable for children of ages 6-24 months, and (3) a health-focused intervention, including information on micronutrient supplementation, integrated management of child illnesses, and prevention and management of child malnutrition with a focus on the first 1,000 days.
2891102|NCT03311698|No Intervention|Control|Households receive the standard of care in the area for agricultural and health services.
2891103|NCT03311685|Experimental|Laparoscopic POP repair|"Patients undergoing laparoscopic surgery for the repair of pelvic organ prolapse.~vaginal tactile imager"
2891104|NCT03311685|Experimental|Vaginal POP repair|Patients undergoing vaginal surgery for the repair of pelvic organ prolapse. vaginal tactile imager
2891105|NCT03311672|Experimental|Cohort 1 - Immunotherapy Alone|Approximately 10 patients will be enrolled in the immunotherapy alone cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection.
2891106|NCT03311672|Experimental|Cohort 2 - Immunotherapy with Stereotactic Radiation|Approximately 10 patients will be enrolled in the immunotherapy with stereotactic radiation therapy cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection.
2891107|NCT03311659|Experimental|dTpa group|This group will consist of subjects aged 4 years and above, who will receive a single dose of Boostrix vaccine.
2891108|NCT03311646|Experimental|Normal nicotine content|Cigarettes with a normal nicotine content will be provided
2891109|NCT03311646|Experimental|Lower nicotine content|Cigarettes with a lower nicotine content will be provided.
2891154|NCT03311347|Experimental|Air breathing|Primary aim, item 1
2891111|NCT03311633|Active Comparator|6 week percutaneous pinning group|Percutaneous pinning time will be for six weeks and also short cast immobilization.
2891112|NCT03311620|Other|Endobronchial ultrasound transbronchial needle aspirate|
2891113|NCT03311607|Other|Cohort treated with AmBisome 15 mg/kg|280 patients, receiving AmBisome
2891114|NCT03311594|Experimental|Low Alcohol Consumption and No Pain Induction|Condition 1: Low alcohol consumption Condition 2: No pain group
2891115|NCT03311594|Experimental|Low Alcohol Consumption and Pain Induction|Condition 1: Low alcohol consumption Condition 2: Pain group
2891116|NCT03311594|Experimental|Moderate Alcohol Consumption and No Pain Induction|Condition 1: Moderate alcohol consumption Condition 2: No pain group
2891117|NCT03311594|Experimental|Moderate Alcohol Consumption and Pain Induction|Condition 1: Moderate alcohol consumption Condition 2: Pain group
2891118|NCT03311594|Placebo Comparator|Placebo Alcohol Consumption and No Pain Induction|Condition 1: Placebo alcohol consumption Condition 2: No pain group
2891119|NCT03311594|Experimental|Placebo Alcohol Consumption and Pain Induction|Condition 1: Placebo alcohol consumption Condition 2: Pain group
2891120|NCT03311594|Placebo Comparator|Control and No Pain Induction|Condition 1: No alcohol consumption Condition 2: No pain group
2891121|NCT03311594|Experimental|Control and Pain Induction|Condition 1: No alcohol consumption Condition 2: Pain group
2891122|NCT03311581|Experimental|Propofol group|propofol TCI plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml
2891123|NCT03311581|Active Comparator|Sevoflurane group|sevoflurane 2~4 % plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml
2891124|NCT03311568|Experimental|surgery in general anaesthesia|10 patients. ultrasound for microcirculatory assessment applied.
2891125|NCT03311568|Experimental|open chest cardiac surgery|10 patients. ultrasound for microcirculatory assessment applied.
2891126|NCT03311568|Experimental|critical septic shock at ICU|20 patients. ultrasound for microcirculatory assessment applied.
2891127|NCT03311568|Experimental|healthy volunteers|10 subjects. ultrasound for microcirculatory assessment applied.
2891128|NCT03311555|Experimental|Recurrent PSA-only non-metastatic prostate cancer|Subjects with recurrent PSA-only prostate cancer within 4 years of prostatectomy, and a PSA of greater than 0.2 ng/mL and less than 4 ng/mL in the absence of metastatic disease on CT and bone scans.
2891129|NCT03311529|Experimental|Applied Relaxation|
2891130|NCT03311529|No Intervention|usual care|
2891131|NCT03311516|Experimental|Group A|Group A = intervention group (new functional insulin therapy) who adjusts the insulin bolus according to a dose titration algorithm taking into account the lipid and protein content in addition to that of carbohydrates. The functional insulin therapy is based on a Carbohydrate / Lipid / Protein count
2891132|NCT03311516|Other|Group B|Group B=control group (functional insulin tehrapy) who adjusts the insulin bolus taking into account only the carbohydrate content. The functional insulin therapy is based on a Carbohydrate count only.
2891133|NCT03311503|Experimental|Treatment arm|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
2891134|NCT03311490|Experimental|Intervention|Participants allocated to the intervention group will use Spraino® as a measure to prevent lateral ankle sprains.
2891135|NCT03311490|No Intervention|Control|"Participants allocated to the control group will be a do-as-usual comparator. This implies, that the participants can treat and prevent lateral ankle sprains in any way they wish, except using Spraino®."
2891136|NCT03311477|Experimental|ABBV-399|ABBV-399 via intravenous administration at escalating dose levels.
2891137|NCT03311464|Experimental|Arm A|Participants receiving adalimumab for Pyoderma Gangrenosum active ulcer(s).
2891138|NCT03311451|Other|C2 CryoBalloon 180 Ablation System|C2 CryoBalloon 180 Ablation System will be used to ablate visible Barrett's esophagus
2891139|NCT03311438|Other|Oral health intervention program|Oral Health intervention program: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
2891140|NCT03311425|Active Comparator|Local Depomedrol plus IV dexamethasone|Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone
2891141|NCT03311425|Placebo Comparator|IV dexamethasone|Intraoperative systemic (IV) steroid (dexamethasone) only.
2891142|NCT03311412|Experimental|Sym021|Sym021 will be administered at up to 3 planned dose level cohorts
2891143|NCT03311399|Experimental|Home Visit|"Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Intervention: SSI Screening Tool used in home visits by CHWs"
2891144|NCT03311399|Experimental|Phone Call|"Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone. Intervention: SSI Screening Tool used via phone call follow-up"
2891145|NCT03311399|No Intervention|Standard of Care|Individuals in Arm 3 will not have any additional contact beyond standard of care.
2891146|NCT03311386|Other|Patients in AIS receiving actilyse|the patients will receive actilyse intaravenously in a dose of 0.9mg/kg once
2891147|NCT03311373|Experimental|Treatment Period 1|Test Formulation (Regimen B or D) or Reference Formulation (Regimen A or C)
2891148|NCT03311373|Experimental|Treatment Period 2|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
2891149|NCT03311373|Experimental|Treatment Period 3|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
2891150|NCT03311373|Experimental|Treatment Period 4|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
2891151|NCT03311360||drug-coated balloon|patients with vertebral artery origin stenosis treated with drug-coated balloons
2891152|NCT03311360||bare metal stent|patients with vertebral artery origin stenosis treated with bare metal stent
2891153|NCT03311347|Experimental|100%O2 breathing|Primary aim, item 1
2891157|NCT03311321|Placebo Comparator|Placebo-Control|The placebo-control group will take four placebo softgel capsules (similar in taste and appearance to the vitamin K2 supplements) every day for 8 weeks.
2891158|NCT03311321|Experimental|Vitamin K2 (360-mcg/d)|The experimental group will take four 90-mcg of vitamin K2 (menaquinone-7; 360-mcg) softgel capsules every day for 8 weeks.
2891159|NCT03311308|Active Comparator|Pembrolizumab|Pembrolizumab (Keytruda), 200 mg, by IV, every three weeks, for up to 2 years
2891160|NCT03311308|Experimental|Pembrolizumab and Metformin Combination|Pembrolizumab (Keytruda), 200mg, by IV, every three weeks, for up to 2 years will be taken in combination with Metformin, 500mg, once a day, for nine weeks
2891161|NCT03311295|Experimental|ARTO System|
2891162|NCT03311282|Experimental|Feeding Bottle 0m+|10 infants aged 0-4 weeks (+/- 7 days): 0-4 m bottle. 0-4 months, 250 ml, 2 angled teats: newborn (also referred to as low flow) and infant (also referred to as medium flow), for infants aged 0-4 weeks (+/- 7 days) / over 9 weeks of participation.
2891163|NCT03311282|Experimental|Feeding Bottle 4m+|10 infants aged 4 months (+/- 10 days): 4-6 m bottle. 4-6 months, 250 ml, non-angled teat), for infants aged 4 months (+/- 10 days) / over 9 weeks of participation.
2891164|NCT03311282|Experimental|Feeding Bottle 6m+|10 infants aged 6-10 months (+/- 10 days): 6m+ bottle. 6 months and over, 250 ml, longer teat) for infants aged form 6 to 10 months (+/- 10 days) / over 9 weeks of participation.
2891165|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 0m+|10 infants aged 0-4 weeks (+/- 7 days)
2891166|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 4m+|10 infants aged 4 months (+/- 10 days)
2891167|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 6m+|10 infants aged 6-10 months (+/- 10 days) (at least 2 breastfeeding sessions per day)
2891168|NCT03311269|Active Comparator|ClariVein RES 1% Injection|Sodium Tetradecyl Sulfate 1% Injection single administration
2891169|NCT03311269|Active Comparator|ClariVein RES 3% Injection|Sodium Tetradecyl Sulfate 3% Injection single administration
2891170|NCT03311243|Experimental|β-Thalassemia major (TM- β)|
2891171|NCT03311243|Active Comparator|Systemically healthy controls|
2891172|NCT03311230|No Intervention|Control|Participants in this arm will receive no other interventions during the 9 month study period
2891173|NCT03311230|Experimental|Supportive social incentive|Participants will identify a family member or friend to support them during a gamification intervention.
2891174|NCT03311230|Experimental|Competitive social incentive|Participants will compete in a gamification intervention in groups of three.
2891175|NCT03311230|Experimental|Collaborative social incentive|Participants will collaborate in groups of three in a gamification intervention
2891176|NCT03311217|Experimental|Intervention group|Healthy retail strategies will be implemented in tribally owned convenience stores in these communities. Specific strategies include pricing discounts, promotional signage, incorporation of new product, and placement of healthier items on shelves.
2891177|NCT03311217|No Intervention|Control group|No intervention will be implemented in the stores in the control communities.
2891178|NCT03311204|Experimental|Microblepharon Exfoliation|This treatment is provided using BlephEx tool from Optimed Pty Ltd.
2891179|NCT03311204|Experimental|Eyelid cleansing using Lid Hygenix|Foam-based hypoallergenic cleanser used as a control treatment in this study.
2891180|NCT03311191||Younger Women|Women ages 20-30 who are not pregnant will be painted with oxygen sensing bandage
2891181|NCT03311191||Younger Men|Men ages 20-30 will be painted with oxygen sensing bandage
2891182|NCT03311191||Older Women|Women ages 55-65 who are not pregnant will be painted with oxygen sensing bandage
2891183|NCT03311191||Older Men|Men ages 55-65 will be painted with oxygen sensing bandage
2891184|NCT03311178|Experimental|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
2891185|NCT03311152|Experimental|HCC-free cirrhotic patients|"Cirrhotic patients enrolled in an HCC screening program by abdominal ultrasound and AFP every six months and followed at the Department of Hepatology of the University Hospital of Nancy. Each patient included will undergo a diagnostic test called Epi proColon 2.0 CE from Epigenomics, Inc (Berlin, Germany) also known as Plasma mSEPT9 test."
2891186|NCT03311152|Experimental|HCC-positive cirrhotic patients|"Cirrhotic patients followed at the Department of Hepatology of the University Hospital of Nancy who presents an HCC according to the AASLD guidelines. Each patient included will undergo a diagnostic test called Epi proColon 2.0 CE from Epigenomics, Inc (Berlin, Germany) also known as Plasma mSEPT9 test."
2891187|NCT03311139||AF and ACS patients: No PCI|Patients with Atrial Fibrillation and Acute Coronary Syndrom who did not undergo a Percutaneous Coronary Intervention
2891188|NCT03311139||AF and ACS patients: PCI without stent|Patients with Atrial Fibrillation and Acute Coronary Syndrom who underwent PCI without stent implantation (NOMESCO code FNG00-96 except FNG05)
2891189|NCT03311139||AF and ACS patients: PCI with stent|Patients with Atrial Fibrillation and Acute Coronary Syndrom who underwent PCI with stent implantation (NOMESCO code FNG05)
2891190|NCT03311126|Experimental|Bendamustine + Obinutuzumab (BO)|"Induction chemoimmunotherapy (28 day cycles):~Bendamustine 90 mg/m2 IV days 1 & 2 every 28 days X 4-6 cycles~Obinutuzumab:~Cycle 1: 100 mg IV day 1, 900 mg IV day 2, 1000 mg IV days 8 & 15~Cycles 2-6: 1000 mg IV day 1~Consolidation phase:~Obinutuzumab 1000 mg IV weekly X 4 doses~Maintenance phase (8 week cycles):~Obinutuzumab 1000 mg IV on day 1 of cycles 1-8"
2891191|NCT03311113||Patients with osteoarticular infection|To evaluate drug adherence to oral antibiotic therapy in patients treated for bone and joint infection for a minimum expected duration of 6 weeks.
2891192|NCT03311100||Lung cancer|
2891193|NCT03311100||Central Nervous System Cancers|
2891194|NCT03311100||Head and Neck and upper aero-digestive tract cancers|
2891195|NCT03311100||Skin cancers|
2891196|NCT03311100||Sarcomas|
2891197|NCT03311100||Urothelial cancer|
2891198|NCT03311100||Hepatocarcinoma|
2891222|NCT03310931||End and non-END groups|END was denied as NIHSS score increase of 2 or more than 2 within 7 days after admission
2892911|NCT03298945|Active Comparator|Golytely|4-L split-dose Golytely bowel prep
2891199|NCT03311074|Experimental|GSK2696273 treatment receivers|Approximately 15 subjects with ADA-SCID who were previously received GSK2696273 will be included in the analysis and a total of 5 blood samples will be collected from each subject at approximately annual interval.
2891200|NCT03311061|Experimental|DREAMS|"The experimental group will be exposed to the DREAMS curriculum including the supplemental technology based application.It is composed of 10 modules: Introduction; Self Exploration; Healthy Relationships; Adolescent Sexuality; Attitudes and Adolescent Sexual Activity; Consequences of Sex - HIV/STI; Consequences of Sex - Pregnancy; Managing Pressure to Engage in Sexual Activity through the Lens of Social Media; Financial Literacy; Careers; Post secondary Education; Wrap up and Close Out.~The technology app will include curriculum support and additional resources.~Students will have access to the mobile app after the in school programming ends. The intent is for students to have access to portions of the app that deal with self developed goals and progress monitoring for goals, and resource material. This is similar to a student having continued access to a textbook/other class materials."
2891201|NCT03311061|Active Comparator|Non DREAMS|The control group experience will include health curriculum already adopted by the school district. Continued services as usual. The control group schools, for the most part, lack any formal pregnancy prevention services. All schools claim that lessons developed by the teachers meet the Texas Essential Knowledge Standards (TEKS). No outside services are provided to students and school based services are limited. The services offered at the schools is predominately abstinence based. Students attending the schools would need to initiate any services that are available within the community. The control group will not have access to the DREAMS curriculum or the technology-based application to enhance the DREAMS curriculum. The technology-based application will be a closed, password protected, system during the research trial.
2891202|NCT03311048|Experimental|Hospital|Hospital cleaning workers Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
2891203|NCT03311048|Experimental|University|Campus (university) cleaning workers Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
2891204|NCT03311048|Experimental|Housekeeper|Housemaid (cleaning workers) Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
2891205|NCT03311048|Experimental|Control|Office workers (no relationship to cleaning) Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
2891206|NCT03311035|Experimental|Group A|patients undergoing ligation of intersphincteric fistula tract (LIFT technique)
2891207|NCT03311035|Experimental|Group B|patients undergoing Seton method
2891208|NCT03311022|Experimental|Treatment 1|One tablet of test product (Nefopam Hydrochloride 30mg Tablets) containing 30mg nefopam hydrochloride.
2891209|NCT03311022|Active Comparator|Treatment 2|One tablet of reference product (Acupan® 30mg Tablets) containing 30mg nefopam hydrochloride.
2891210|NCT03311009|Experimental|GLPG1972|
2891211|NCT03311009|Placebo Comparator|Placebo|
2891212|NCT03310996|Experimental|tDCS Active arm|The experimental arm will have the tDCS stimulation electrodes placed on the scalp and the current will be delivered over 20 minutes
2891213|NCT03310996|Placebo Comparator|tDCS Sham arm|The sham arm will have electrodes placed over the scalp and will be given the current for 10 seconds after which it will be ramped down and stopped.
2891214|NCT03310983||ADORE Participants|Participants enrolled in the ADORE study are invited to participate in this study.
2891215|NCT03310970|Active Comparator|Lidocaine Patch|Each of the 24 subjects will complete three study arms in a crossover design, with adequate washout in between arms. Lidocaine will be administered to subjects in three ways (one route per study arm): a single intravenous dose of 0.5 mg/kg lidocaine hydrochloride, wearing three Lidoderm® topical patches for 12 hours, and wearing three generic lidocaine patches for 12 hours. Twelve subjects will be randomized to Group 1 (generic lidocaine patch first, then intravenous lidocaine hydrochloride followed by the Lidoderm® topical patch), and 12 subjects will be randomized to Group 2 (Lidoderm® topical patch first, then intravenous lidocaine hydrochloride followed by a generic lidocaine patch).
2891216|NCT03310970|Active Comparator|Lidoderm® Topical Patch|Each of the 24 subjects will complete three study arms in a crossover design, with adequate washout in between arms. Lidocaine will be administered to subjects in three ways (one route per study arm): a single intravenous dose of 0.5 mg/kg lidocaine hydrochloride, wearing three Lidoderm® topical patches for 12 hours, and wearing three generic lidocaine patches for 12 hours. Twelve subjects will be randomized to Group 1 (generic lidocaine patch first, then intravenous lidocaine hydrochloride followed by the Lidoderm® topical patch), and 12 subjects will be randomized to Group 2 (Lidoderm® topical patch first, then intravenous lidocaine hydrochloride followed by a generic lidocaine patch).
2891217|NCT03310957|Experimental|SGN-LIV1A plus pembrolizumab|SGN-LIV1A followed by pembrolizumab.
2891218|NCT03310944|Active Comparator|Sotagliflozin dose 1 (reference formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
2891219|NCT03310944|Experimental|Sotagliflozin dose 2 (prototype p1 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
2891220|NCT03310944|Experimental|Sotagliflozin dose 3 (prototype p2 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
2891221|NCT03310944|Experimental|Sotagliflozin dose 4 (prototype p3 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
2891223|NCT03310918|Experimental|Collaborative palliative and oncology care|"1st palliative care visit within 96 hours of randomization in the outpatient or hospital~In outpatient setting: At least once weekly for the first 30 days and then at least twice per month thereafter palliative care clinic visits or contact via telephone~During hospital admissions to MGH: At least twice weekly palliative care visits"
2891224|NCT03310918|Active Comparator|Standard leukemia care|"Palliative care consults only upon request~Standard Leukemia care"
2891225|NCT03310905|Experimental|Abdominal Wall Transplant with Belatacept|
2891226|NCT03310905|Experimental|Abdominal Wall with Solid Organ Transplant|
2891227|NCT03310892|No Intervention|Usual Care|Participants in this arm will Usual scheduling process without any intervention
2891228|NCT03310892|Experimental|Generic Message|"Participants in this arm will receive a telephone call from a study team member, and if no answer, up to two additional attempts will be made. During the telephone call, the study team member will ask the participant a series of 7 questions then receive a generic message encouraging colonoscopy scheduling."
2891229|NCT03310892|Experimental|Tailored Message|"Participants in this arm will receive a telephone call from a study team member, and if no answer, up to two additional attempts will be made. During the telephone call, the participant will answer a series of 7 questions then receive a tailored message encouraging colonoscopy scheduling, which will be determined by their responses to the preceding questions."
2891230|NCT03310879|Experimental|Participants with CCND1, CCND2, or CCND3|"Abemaciclib will be administered orally on a daily basis~Dosage will be determine by the PI"
2891231|NCT03310879|Experimental|Participants with CDK4 or CDK6|"Abemaciclib will be administered orally on a daily basis~Dosage will be determine by the PI"
2891232|NCT03310866|Active Comparator|fiberoptic, airway|Classical fiberoptic intubation assisted by side fenestrated airway and head tilt- chin lift- jaw thrust by 2 anesthetist
2891233|NCT03310866|Experimental|fiberoptic, Machintosh|oral Fiberoptic bronchoscopic intubation assisted by Macintosh Laryngoscope, by 2 anesthetist
2891234|NCT03310853|Experimental|Probiotic|Combination of two probiotic strains in one capsule
2891235|NCT03310853|Placebo Comparator|Placebo|Non active ingredients in a capsule
2891236|NCT03310827|Experimental|Personalized Nutrition|Participant receives gene test results with diet plan (personalized nutrition)
2891237|NCT03310827|Placebo Comparator|Gene Test Report Only|Participant receives standard diet plan
2891238|NCT03310814|Experimental|Personalized nutrition intervention|Participant receives gene-test results plus personalized nutrition information from a registered dietician
2891239|NCT03310814|Placebo Comparator|Usual nutrigenomics intervention|Participant receives usual nutrigenomics intervention (direct-to-consumer)
2891240|NCT03310801||LAAO with DAPT|patients with AF who underwent PCI and treated with LAAO(either ACP or Watchman) and DAPT
2891241|NCT03310801||Conventional antithrombotic therapy|patients with AF who underwent PCI and treated with conventional antithrombotic therapy
2891242|NCT03310775|Experimental|case group|Behavioral: parent-assisted social skills training program for young adults with autism spectrum disorder The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
2891243|NCT03310775|Experimental|waitlist control group|"For this group, same intervention with the Experimental group will be provided after waiting for 16 weeks.~Behavioral: Delayed intervention Intervention is provided to Waitlist Control Group after waiting for 16 weeks"
2891244|NCT03310762|Experimental|Alma Sana Bracelet Arm|Subjects in this arm will receive a vaccine reminder and tracker bracelet developed by Alma Sana Inc. This bracelet uses a combination of symbols and numbers to denote the entire vaccine schedule a child is supposed to receive before the age of 2 years. Shapes indicate vaccines, and numbers signify the child's age.
2891245|NCT03310762|Experimental|Simple Silicon Bracelet Arm|Subjects in this arm will receive a simple silicon bracelet. This bracelet has six symbols to remind parents that their child needs to get at least six vaccination visits before he reaches 2 years of age. The first five symbols are represented by a crescent shape and the sixth symbol is represented by a star shape to denote that the child is fully immunized.
2891246|NCT03310762|No Intervention|Control Arm|Subjects in this arm will not receive any bracelet/intervention.
2891247|NCT03310749|Other|Treatment sequence A|Gemigliptin 50 mg q.d. during 7 days, metformin 1000 mg twice a day during 7 days and gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days.
2891248|NCT03310749|Other|Treatment sequence B|Gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d. during 7 days, metformin 1000 mg twice a day during 7 days
2891249|NCT03310749|Other|Treatment sequence C|Metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d. during 7 days
2891250|NCT03310723|Active Comparator|Standard Face Mask Preoxygenation|Tidal volume breathing for via a face mask set at 100% oxygen and a rate of 15L/min.
2891251|NCT03310723|Experimental|Optiflow Preoxygenation|Tidal volume breathing with the OptiFlow system applied at 100% oxygen and a flow rate of 30-70L/min.
2891252|NCT03310710|Experimental|treatment with Viabahn BX stent|Treatment with Viabahn BX stent as branch device in fenestrated EVAR
2891253|NCT03310697|Experimental|Children with afebrile seizure|"For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.~Intervention : Collection of blood and urine samples, and Clinical examination"
2891254|NCT03310684||Hypertensive|Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Antihypertensive medication type and dosage will be recorded. Blood and urine samples will be collected at baseline and yearly for three years. All subjects will receive baseline and yearly echocardiograms. Subjects with overweight/obesity (BMI >=85th percentile for age and sex) will receive baseline and yearly ultrasounds of the liver to evaluate for hepatic fat infiltration. Auscultated, continuous and ambulatory blood pressure will be measured at baseline and yearly.
2891288|NCT03310489|Experimental|Digitalized cognitive-behavioral intervention|
2891289|NCT03310489|Active Comparator|Psychoeducation about anxiety|
2891290|NCT03310476|Experimental|Baked, consumed chilled potatoes|
2891255|NCT03310684||Normotensive with Obesity|"Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Subjects will receive a baseline ultrasound of the liver to evaluate hepatic fat infiltration as per standard of care.~Blood and urine will be collected at baseline to measure liver function (AST, ALT) and uric acid, angiotensin ll, and angiotensin-(1-7)."
2891256|NCT03310684||Healthy Normotensive|Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Subjects will have baseline echocardiograms. Blood pressure will be measured at baseline and at one year. Continuous blood pressure and ambulatory blood pressure monitoring will be assessed at baseline. Blood and urine samples will be used to measure uric acid, FGF23, klotho, and albumin, as well as the predictors angiotensin ll and angiotensin-(1-7).
2891257|NCT03310671||CASES|"Cases:~Age ≥ 65 years at the time of cardiac ultrasound~Genetically diagnosed HFH or in a first-degree relative~History of hypercholesterolemia with LDLc levels> 220 mg / dL without lipid-lowering treatment"
2891258|NCT03310671||Controls|"Genetically Similar~Siblings of the normocholesterolemic case, defined by LDLc <190 mg / dl without lipid-lowering treatment.~In the absence of available siblings, first cousins may be included.~In the presence of several siblings available, the same sex will be included,~Environmentally similar~Stable partner of the case with cohabitation> 25 years"
2891259|NCT03310658|Experimental|Single Study Site: UANL|As the only study arm, 10 enrolled subjects received vaginal cuff closure with the Zip-Stitch Soft Tissue Closure System as part of Total Laparoscopic Hysterectomy.
2891260|NCT03310645|Experimental|Dose 1 of BAY1817080|"Study Part 1:~Oral dose 1 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
2891261|NCT03310645|Experimental|Dose 2 of BAY1817080|"Study Part 1:~Oral dose 2 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
2891262|NCT03310645|Experimental|Dose 3 of BAY1817080|"Study Part 1:~Oral dose 3 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
2891263|NCT03310645|Experimental|Dose 4 of BAY1817080|"Study Part 1:~Oral dose 4 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
2891264|NCT03310645|Placebo Comparator|Placebo|"Study Part 1:~Oral dose of matching placebo twice daily with a loading dose administered three times on Day 1"
2891265|NCT03310645|Experimental|Placebo+BAY1817080|"Study Part 2:~Randomized crossover design in cough patients Placebo+4 different doses of BAY1817080"
2891266|NCT03310645|Experimental|BAY1817080+Placebo|"Study Part 2:~Randomized crossover design in cough patients 4 different doses of BAY1817080+Placebo"
2891267|NCT03310632|Experimental|Antroquinonol with SOC|"Antroquinonol will first be conducted by dose escalation(200mg TID and 300mgTID) to characterize the safety of antroquinonol in combination with the standard of care (SOC) (nab-paclitaxel + gemcitabine) and to identify the MTD of antroquinonol in patients with metastatic pancreatic cancer.~At the cohort expansion part of the study, up to an additional 40 patients will be enrolled at the MTD or MFD/RD."
2891268|NCT03310619|Experimental|Arm A: JCAR017 in combination with Durvalumab|JCAR017 will be administered at a single flat dose of 5 x 10^7 CAR+T cells or 1 x 10^8 CAR+T cells. The combination agent will be administered at different doses and/ or schedules.
2891269|NCT03310619|Experimental|Arm B: JCAR017 in combination with CC-122|Will test JCAR017 in combination with CC-122 in adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 1 x 10^8 CAR+T cells. The combination agent will be administered at different doses
2891270|NCT03310606|Other|Peritonitis|"Patient received for antibiotic treatment a B lactam according to French recommendation :~type of antibiotic : cefotaxime or ceftriaxone or piperacilline/tazobactam or imipenem~dose : cefotaxime 2g / cetriaxone 2g / piperacilline 4g / imipenem 1g"
2891271|NCT03310593|Experimental|Cannabidiol|Cannabidiol 300mg per day for 12 weeks.
2891272|NCT03310593|Placebo Comparator|Placebo|Cannabidiol comparator for 12 weeks.
2891273|NCT03310580|Experimental|Netarsudil Ophthalmic Solution 0.02%|Netarsudil ophthalmic solution 0.02%; 1 drop daily to each eye for 28 days
2891274|NCT03310580|Experimental|Netarsudil Ophthalmic Solution 0.04%|Netarsudil ophthalmic solution 0.02%; 1 drop daily to each eye for 28 days
2891275|NCT03310580|Placebo Comparator|Placebo Comparator|Netarsudil ophthalmic solution placebo; 1 drop daily to each eye for 28 days
2891276|NCT03310567|Experimental|Epacadostat + pembrolizumab|
2891277|NCT03310554|Experimental|26cm suspended overlength biliary stents group|
2891278|NCT03310554|Experimental|30cm suspended overlength biliary stents group|
2891279|NCT03310554|Other|ordinary plastic biliary stents group|
2891280|NCT03310541|Experimental|Prostate, Previously treated with Enzalutamide|28-DAY CYCLE AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week + Enzalutamide 160 mg PO once daily
2891281|NCT03310541|Experimental|ER+ Breast, Previously treated with Fulvestrant|28-DAY CYCLE AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week + Fulvestrant 500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
2891282|NCT03310541|Experimental|Advanced Solid Tumors|28-DAY CYCLE AZD5363 480mg PO twice daily for 4 days on, 3 days off, every week
2891283|NCT03310528||Obeyed fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
2891284|NCT03310528||Did not obey fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
2891285|NCT03310528||Trauma - obeyed fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
2891286|NCT03310528||Trauma - did not obey fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
2891287|NCT03310515||HIV-1 uninfected high risk subjects|The study will involve HIV-1 uninfected high risk MSM and TGW subjects. They will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment. Visits will include Baseline screening for HIV followed by screenings at Day 1, Weeks 5, 9, and 8 week intervals thereafter until study conclusion. Screening for other STIs will occur at Baseline, Week 9, and every 16 weeks thereafter.
2891292|NCT03310463|Experimental|Cohort 1, Normal Renal Function|Healthy control participants matched to participants enrolled in Cohort 4 (creatinine clearance ≥90 milliliters per minute [mL/min] estimated by the Cockcroft-Gault equation) will receive ETX2514SUL as a single dose of up to 1000 milligrams (mg) ETX2514 and 1000 mg sulbactam given by concurrent 3-hour intravenous (IV) infusion.
2891293|NCT03310463|Experimental|Cohort 2, Mild Renal Impairment|Participants with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥60 to <90 mL/min/1.73 meters squared [m^2] calculated by the Modified Diet in Renal Disease [MDRD] equation) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
2891294|NCT03310463|Experimental|Cohort 3, Moderate Renal Impairment|Participants with moderate renal impairment (eGFR ≥30 to <60 mL/min/1.73 m^2 calculated by the MDRD equation) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
2891295|NCT03310463|Experimental|Cohort 4, Severe Renal Impairment|Participants with severe renal impairment (eGFR <30 mL/min/1.73 m^2 calculated by the MDRD equation) and not on hemodialysis (HD) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
2891296|NCT03310463|Experimental|Cohort 5, ESRD on a Stable HD Regimen|Participants with end-stage renal disease (ESRD) on a stable HD regimen (determined by medical history) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
2891297|NCT03310450||Group 160kms cycling|willing to participate in 160kms cycling touring of TdB 2017
2891298|NCT03310450||Group 100kms cycling|willing to participate in 100kms cycling touring of TdB 2017
2891299|NCT03310437||Primary PCI|In primary PCI we use arterial sheath , wires ,heparin ,intracoronary stents
2891300|NCT03310437||Thrombolytic|In patients recieving thrombolytics they continue on LWMH for 72h ,plus aspirin , clopedogril , BB, statins
2891301|NCT03310411|Experimental|Lasmiditan + Sumatriptan (A)|Single oral dose of lasmiditan and single oral dose of sumatriptan in one of four treatment periods.
2891302|NCT03310411|Experimental|Lasmiditan + Placebo (B)|Single oral dose of lasmiditan and single oral dose of placebo in one of four treatment periods.
2891303|NCT03310411|Active Comparator|Sumatriptan + Placebo (C)|Single oral dose of sumatriptan and single oral dose of placebo in one of four treatment periods.
2891304|NCT03310411|Placebo Comparator|Placebo + Placebo (D)|Oral doses of placebo in one of four treatment periods.
2891305|NCT03310398||Anxiety|elevated anxiety (as indicated by a GAD-7 score of 8 or higher)
2891306|NCT03310398||Depression|elevated anxiety (as indicated by a GAD-7 score of 8 or higher)
2891307|NCT03310385|Experimental|High-dose GHX02 group(1,920mg/day)|4 tablets of the GHX02, three times daily for 7 days
2891308|NCT03310385|Experimental|Standard-dose GHX02 group(960mg/day)|2 tablets of the GHX02 and 2 tablets of the placebo, three times daily for 7 days
2891309|NCT03310385|Placebo Comparator|Placebo control|4 tablets of the placebo, three times daily for 7 days
2891310|NCT03310372|Experimental|ultrafractionated brain irradiation - temozolomide|
2891311|NCT03310359|Active Comparator|Astaxanthin (12 mg)|Subjects will be given capsules containing a set oral dose of astaxanthin (12 mg) and instructed to take two capsules each morning after (up to 1 hr) the morning meal for a total of up to 24 weeks (168 days on study drug).
2891312|NCT03310359|Placebo Comparator|Placebo|Subjects will be given capsules containing placebo and instructed to take two capsules each morning after (up to 1 hr) the morning meal for a total of up to 24 weeks (168 days on study drug).
2891313|NCT03310333|Experimental|Cook cervical ripening|the device is introduced by a resident or a doctor. No traction on the probe was done. It is left in place for maximum 12 hours. Oxytocin is added at the end of the first 6 hours even if device is fallen. An epidural analgesia can be started before or after the installation of oxytocin
2891314|NCT03310333|Active Comparator|Dinoprostone vaginal group|"the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.~After 24 hours, it is removed. If they are any contraction, oxytocin is started with or without epidural analgesic."
2891315|NCT03310320|Placebo Comparator|Placebo|Placebo for AZD0284 oral solution
2891316|NCT03310320|Experimental|AZD0284|AZD0284 oral solution 2.5 mg/mL
2891317|NCT03310307|Active Comparator|vitamin D3|50,000 IU
2891318|NCT03310307|Placebo Comparator|Placebo|Similar in size, shape and color to vitamin D3
2891319|NCT03310294|Placebo Comparator|placebo|one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)
2891320|NCT03310294|Active Comparator|Prebiotics and Probiotics|one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS), 90 grams)
2891321|NCT03310281|Active Comparator|ALK-T03|AKL-T03 is a digital intervention that requires the subject to navigate a character through a game-like space, while collecting objects, in a fixed period of time.
2891322|NCT03310281|Active Comparator|AKL-T09|AKL-T09 is a digital intervention that requires the subject to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time.
2891323|NCT03310268|Experimental|Test Product|Participants will be instructed to self administer experimental dentifrice containing 0.454% SnF2 and 0.072% sodium fluoride (NaF) (1450 parts per million [ppm] fluoride in total).
2891324|NCT03310268|Active Comparator|Negative Control|Participants will be instructed to self administer negative control dentifrice containing 1400 ppm fluoride as sodium monofluorophosphate (SMFP).
2891325|NCT03310268|Active Comparator|Positive Control|Participants will be instructed to self administer positive control dentifrice containing SnCl2 and 0.15% NaF (1450 ppm fluoride in total).
2891326|NCT03310242|Experimental|Sunlight Exposure|Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks
2891327|NCT03310242|Experimental|Vitamin D Supplementation|Supplementation of vitamin D3 500 IU/day for 8 weeks
2891328|NCT03310242|Placebo Comparator|Placebo|Intake of placebo for 8 weeks
2891329|NCT03310216|Experimental|Order I of visual inspection|Participants in group I are provided AI visual inspection system first and EDTRS later.
2892912|NCT03298945|Experimental|Miralax-Gatorade prep|2-L split-dose Miralax-Gatorade bowel prep
2891330|NCT03310216|Active Comparator|Order II of visual inspection|Participants in group II are provided EDTRS first and AI visual inspection system later.
2891331|NCT03310203|Experimental|Obese women: central obesity|OGTT with iron
2891332|NCT03310203|Experimental|Obese women: peripheral obesity|OGTT with iron
2891333|NCT03310203|Experimental|Lean women|OGTT with iron
2891334|NCT03310190||Participants receiving venetoclax|Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.
2891335|NCT03310177||COPD|The smokers who are diagnosed as chronic obstructive pulmonary disease according to GOLD guideline.
2891336|NCT03310177||healthy control|The healthy controls without chronic obstructive pulmonary disease
2891337|NCT03310164||COPD|Smokers with clinically stable chronic obstructive pulmonary disease (COPD)
2891338|NCT03310164||healthy control|Age-matched subjects without chronic obstructive pulmonary disease (COPD)
2891339|NCT03310151|Experimental|Intervention|Group follows usual care plus imagined movements in a home exercise plan. The exercises will be taught to the subject by reading through an exercise booklet with them, this ensures the advice is standardised. The imagined movement programme will consist of imagined wrist movement in all planes. The frequency of approximately 10-15 minutes, four times a day has been selected as a practical compromise of previous investigations, (Moseley, 2004 and Frenkel et al., 2014), and mirrors routine advice.
2891340|NCT03310151|No Intervention|control|Follows usual care
2891341|NCT03310138|Active Comparator|Dorsolateral Prefrontal Cortex|"Intervention: Real Transcranial Magnetic Stimulation~Real Transcranial Magnetic Stimulation will be delivered to the left dorsolateral prefrontal cortex (10Hz, 110% of resting motor threshold) using a MagVenture MagPro B60 coil."
2891342|NCT03310138|Active Comparator|Motor Cortex|"Intervention: Real Transcranial Magnetic Stimulation~Real Transcranial Magnetic Stimulation will be delivered to the left primary motor cortex (10Hz, 80% of resting motor threshold) using a MagVenture MagPro B60 coil."
2891343|NCT03310138|Placebo Comparator|Sham stimulation|"Intervention: Sham Transcranial Magnetic Stimulation~Sham Transcranial Magnetic Stimulation will be delivered to the prefrontal cortex (10Hz, 110% of resting motor threshold) using the integrated sham system on the MagVenture MagPro B60 coil."
2891344|NCT03310125|Experimental|Colchicine|Oral colchicine 0.5mg
2891345|NCT03310125|Placebo Comparator|Placebo|Placebo oral tablet
2891346|NCT03310112|Experimental|4-week MBAT|Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 4 weeks.
2891347|NCT03310112|Active Comparator|2-week MBAT|Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 2 weeks.
2891348|NCT03310112|No Intervention|No training control (NTC)|Participants will receive no intervention but will be tested before and after a no-training interval.
2891349|NCT03310099|Experimental|Dietary Intervention|Dietary intervention aimed at increasing UFA consumption. The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated [MUFA] and polyunsaturated fatty acids [PUFA]), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
2891350|NCT03310086|Experimental|Traditional fixed appliance|"Fixed orthodontic appliances will be applied for aligning and leveling of lower anterior teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
2891351|NCT03310086|Experimental|Fixed appliance and corticision|"Fixed orthodontic appliances with corticison will be applied for aligning and leveling of lower anterior teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
2891352|NCT03310073|Experimental|bOPV (bivalent OPV Bio Farma)|"bOPV one dose corresponds to 2 drops (0.1ml). The vaccine shall be given orally.~The subject received bOPV, Pentabio and IPV according to the study schedule."
2891353|NCT03310060|Active Comparator|Tisseel combined Tranexamic acid|"Drug: Tisseel® Applied on potential bleeding sites. The entire content was 4 mL.~Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg before surgical incision and 3 hours after surgery"
2891354|NCT03310060|Placebo Comparator|Tranexamic acid|Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg before surgical incision and 3 hours after surgery
2891355|NCT03310047|Experimental|Right-low, left-high|"The right-side perineural catheter will be subject to intervention drug Infusion, Lidocaine, 0.5%, 5 mL Lidocaine and the left side perineural catheter will be subject to intervention Infusion, Lidocaine, 0.5%, 10 mL.~This will be repeated after 24 hours."
2891356|NCT03310047|Experimental|Right-high, left-low|"The right-side perineural catheter will be subject to intervention drug Infusion, Lidocaine, 0.5%, 10 mL Lidocaine and the left side perineural catheter will be subject to intervention Infusion, Lidocaine, 0.5%, 5 mL.~This will be repeated after 24 hours."
2891357|NCT03310034|Active Comparator|Intervention|
2891358|NCT03310034|Placebo Comparator|Control|
2891359|NCT03310021|Experimental|Cohort 1|Apixaban + low dose andexanet
2891360|NCT03310021|Experimental|Cohort 2|Rivaroxaban + high dose andexanet
2891361|NCT03310021|Experimental|Cohort 3|Edoxaban + high dose andexanet
2891362|NCT03310021|Experimental|Cohort 4|Edoxaban + high dose andexanet
2891363|NCT03310021|Experimental|Cohort 5|Apixaban + low dose andexanet
2891364|NCT03310008|Experimental|Dose level 1 (escalation|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
2891365|NCT03310008|Experimental|Dose level 2 (escalation)|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
2891366|NCT03310008|Experimental|Dose level 3 (escalation)|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
2891367|NCT03310008|Experimental|Recommended dose level (expansion)|The dose expansion arm will use the maximum tolerated dose.
2891463|NCT03309280||Cardiac surgery|All patients included in this study. A statistical analysis will be determine which factors are significant in duration of intubation.
2891368|NCT03309995|Experimental|Zinc lozenges|Each lozenge contains 13 mg elemental zinc as zinc acetate. The instruction for common cold patients is to dissolve slowly 6 lozenges per day in their mouth, which totals to 78 mg/day of elemental zinc, at most for 5 days, as early as possible from the start of the cold symptoms.
2891369|NCT03309995|Placebo Comparator|Placebo lozenges|The placebo lozenges contain sucrose octaacetate, and they are similar with the zinc lozenges in visual appearance and in taste.
2891370|NCT03309982|Experimental|Plant polyphenol blend|The study product (4 g) consists of 3 g of a mix a maltodextrins, and 1 g of anthocyanin-rich plant polyphenol blend containing: 1) 100 mg bilberry extract; 2) 300 mg black currant extract; and 3) 600 mg black rice extract.
2891371|NCT03309982|Placebo Comparator|Placebo|The placebo (4 g) consists of a mix of maltodextrins (3.85 g) and Red Dye No. 40 (0.125 g) and Blue Dye No. 1 (0.025 g).
2891372|NCT03309969||observation group|Subjects with suspicious iliac vein compression syndrome were included in the observation group.
2891373|NCT03309956|Other|Holter Monitor and Zio Patch|All subjects will wear the Holter monitor and Zio patch for a total of 48 hours.
2891374|NCT03309943|Experimental|Propranolol|Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions
2891375|NCT03309943|Placebo Comparator|Placebo|Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions
2891376|NCT03309930|Experimental|Comprehension Acquired Brain Injury|All participants will be exposed to 3 conditions: (a) written text, (b) auditory output (synthetic speech), and combined conditions for study 1. For study 2 participants will be repeatedly exposed to synthetic speech output to determine the influence on comprehension. Participants are not required to participate in both studies.
2891377|NCT03309917|Experimental|Changes in mean arterial pressure|"The study is conducted from one hour after incision and lasts for approximately half an hour. Measurements are conducted at three levels of mean arterial pressure:~MAP set at 80-85 mmHg for 5 min.~MAP set at 70-75 mmHg for 5 min.~MAP set at 60-65 mmHg for 5 min.~Blood pressure control is by infusion of noradrenaline. When the evaluations have been conducted blood pressure control is according to clinical practice. Measurements include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, frontal lobe and muscle oxygenation, depth of anesthesia, and arterial and central venous blood gas variables."
2891378|NCT03309904|Experimental|Knee Control training program|The Knee Control program is a neuromuscular training program that consists of 6 different exercises, with 4 levels of progression and one pair-exercise, for each exercise. The Knee Control program takes about 10 minute to complete after familiarization. In addition, a 5-minute running warm-up is instructed to coaches. Coaches are to perform the Knee Control program + the 5 minute warm-up at all training sessions during the season, and the 5 minute warm-up before all matches.
2891379|NCT03309904|No Intervention|Control group - usual training|The control group teams receive no intervention, and coaches are instructed to carry out their normal training and warm-up practice throughout the season.
2891380|NCT03309891|Experimental|Cohort 1|GX-H9 subcutaneous injections (weekly)
2891381|NCT03309891|Experimental|Cohort 2|GX-H9 subcutaneous injections (weekly)
2891382|NCT03309891|Experimental|Cohort 3|GX-H9 subcutaneous injections (twice-monthly)
2891383|NCT03309891|Active Comparator|Cohort 4|Genotropin subcutaneous injections (daily)
2891384|NCT03309878|Experimental|Arm I (pembrolizumab, mogamulizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 and mogamulizumab IV over 60 minutes on days 1, 8 and 15 of course 1, then day 1 of subsequent courses. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2891385|NCT03309878|Experimental|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2891386|NCT03309865|Experimental|Combined diet and vedolizumab|Intervention: vedolizumab injection (300mg, IV infusions at week 0, 2, 6, 14) and concurrently on structured semi-vegetarian diet; Duration of Therapy: 14 weeks
2891387|NCT03309839||neonates with cardiac surgery under cardiopulmonary bypass|
2891388|NCT03309826|Experimental|PAP Treatment Arm|Automated positive airway pressure titration then treatment with fixed PAP.
2891389|NCT03309826|Active Comparator|Nasal Dilator Strip|Nightly use of nasal dilator strip
2891390|NCT03309813|Experimental|Transcranial ExAblate|ExAblate Transcranial MR Guided Focused Ultrasound (MRgFUS)
2891391|NCT03309813|Sham Comparator|Sham Transcranial ExAblate|ExAblate MRgFUS Sham Procedure
2891392|NCT03309800|Experimental|Experimental|HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
2891393|NCT03309800|Placebo Comparator|Placebo comparator|HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
2891394|NCT03309787||Amulet only|As per usual care participants will receive an eHealth (Amulet + videoconferencing) intervention over a 16 week period of time.
2891395|NCT03309787||Amulet/Fitbit|As per usual care participants will receive an eHealth (Amulet/Fitbit + videoconferencing) intervention over a 16 week period of time.
2891396|NCT03309787||Fitbit only|As per usual care participants will receive an eHealth (Fitbit + videoconferencing) intervention over a 16 week period of time.
2891397|NCT03309774|Experimental|Complex Regional Pain Syndrome (CRPS)|"Children 6 to 12 years old child with Complex Regional Pain Syndrome (CRPS) type 1 will be included.~They will have questionnaires, holter electrocardiogram, blood pressure and relaxation sessions."
2891398|NCT03309761||Patients aged 55-60|
2891399|NCT03309748|Active Comparator|Dental Prophylaxis|Standard dental prophylaxis
2891400|NCT03309748|Active Comparator|Dental prophylaxis + antimicrobial photodynamic therapy|Dental prophylaxis + aPDT
2891401|NCT03309735||1|Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
2891402|NCT03309735||2|Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
2891403|NCT03309735||3|Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
2891404|NCT03309722||early stage|
2891405|NCT03309722||advanced|
2891406|NCT03309709|No Intervention|watch-and-wait patients|patients who receive a watch-and-wait approach
2893084|NCT03297645|Experimental|Arm 2|asthma education + home environment remediation
2891407|NCT03309709|Experimental|Progesterone patients|Treatment consists of 7 days of 25 mg subcutaneous progesterone administered from 18° to 25° day of the menstrual cycle and repeated for 3 cycles
2891408|NCT03309696|Experimental|Experimental: tDCS over TC and 1 Hz rTMS|
2891409|NCT03309696|Experimental|Experimental: tDCS over TC and 10 Hzr rTMS|
2891410|NCT03309696|Experimental|Experimental: tDCS over DLFC and 1 Hz rTMS|
2891411|NCT03309696|Experimental|Experimental: tDCS over DLFC and 10 Hz rTMS|
2891412|NCT03309683|Experimental|Clip group|Olympus Quick Clip Pro - Single Use Repositionable Clips will be used for Prophylactic clipping after EMR
2891413|NCT03309683|No Intervention|Control group|Standard treatment after EMR (as described in the detailed study description above)
2891414|NCT03309670||Formers young patients|all patients hospitalized between 2006 and 2010 in the Pass'Aje unit
2891415|NCT03309657|Experimental|Ceftolozane Tazobactam|Infected patients with external intraventricular drain will receive a single dose of Ceftolozane/ tazobactam (3000mg) over 1 hour and will undergo blood , csf and urine sampling at specific times over an 8 hour period.
2891416|NCT03309644||Peripheral nerve block|Peripheral nerve block
2891417|NCT03309644||No peripheral nerve block|No peripheral nerve block
2891418|NCT03309618|Experimental|Treatment group|20 participants received low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val) per orally once daily for 30 days.
2891419|NCT03309618|Placebo Comparator|Control group|16 participants received placebo per orally once daily for 30 days.
2891420|NCT03309605|Placebo Comparator|Placebo Comparator Arm|Placebo
2891421|NCT03309605|Experimental|ELX-02|ELX-02
2891422|NCT03309592|Other|Combination Therapy|Qualifying participants will begin combination therapy with ambrisentan pill 5 mg daily and tadalafil pill 20 mg. After one week of therapy, patients will increase tadalafil pill to 40 mg daily and continue ambrisentan pill 5 mg daily. On day 15, patients will increase ambrisentan pill to 10 mg daily and continue at 40 mg of tadalafil pill daily.
2891423|NCT03309579|Experimental|Liberal RBC Transfusion Strategy|Hemoglobin value of ≤100g/L
2891424|NCT03309579|Active Comparator|Restrictive RBC Transfusion Strategy|Hemoglobin value of ≤80g/L
2891425|NCT03309566|Experimental|Test - Reference|A new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).
2891426|NCT03309566|Experimental|Reference - Test|A branded formulation (R) followed by a new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T).
2891427|NCT03309553|Active Comparator|Current Primary Care Referral Process|In villages randomized to the current primary care process, families will be notified if their children screen positive in exactly the same method each school had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation. The list of referred children is also given to the Norton Sound Audiology Department, who reaches out to families to schedule appointments during the next available audiology clinic.
2891428|NCT03309553|Experimental|Expedited Telemedicine Referral|In villages randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made same-day or next-day, with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children screening positive will be transported to clinic for their appointment with adult chaperones. Parents are encouraged but not required to attend, except for children grades 2 and younger, for whom parental participation will be required. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
2891429|NCT03309540|Experimental|experimental group (EGR)|"Physical therapy intervention.~In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises)."
2891430|NCT03309540|Sham Comparator|Sham group (SGR)|"Physical therapy intervention.~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze and Evidence Based Practice Therapy. The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
2891431|NCT03309527|Experimental|e-aid Cognitive Behavior Therapy|Participants receive e-aid cognitive behavior therapy. Every week, this group will receive researcher guided individual customized sleep restriction and stimulus control therapy.
2891432|NCT03309527|Active Comparator|e-aid Sleep Hygiene Education|Participants receive e-aid sleep hygiene education which consists of general sleep health education and the guidance on questionnaires. Every week, this group will receive researcher guided sleep hygiene.
2891433|NCT03309514|Experimental|Treatment|
2891434|NCT03309501|Experimental|Tong-Luo-Qu-Tong Plaster group|Intervention: Tong-Luo-Qu-Tong Plaster, daily 1 time, conventional treatment lasted for 14 days as two courses
2891435|NCT03309501|Active Comparator|Qi-Zheng-Xiao-Tong Plaster group|Intervention: Qi-Zheng-Xiao-Tong Plaster, daily 1 time, conventional treatment lasted for 14 days as two courses
2891436|NCT03309488||Food allergic|Patients with a positive oral challenge to the food being studied.
2891437|NCT03309488||Non food allergic|Patients with a negative oral challenge to the food being studied.
2891438|NCT03309475|Experimental|SocialMind|The experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
2891527|NCT03308851|Experimental|Piezocorticision and osteoperforation group|All participants in this arm will receive the piezocorticision and osteoperforation procedures on the upper jaw on the left and the right side.
2893085|NCT03297645|Active Comparator|Arm 3|enhanced standard of care
2891439|NCT03309475|Active Comparator|Structured psychoeducation|The active comparator arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and psychoeducation group training for psychosis.There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 7 monthly sessions.
2891440|NCT03309462|Experimental|Re-biopsy tissue sample|The gene testing of re-biopsy tissue sample diagnosed with NSCLC will be performed with NGS using Illumina Miseq squencer and Cobas.
2891441|NCT03309462|Experimental|Peripheral blood sample|The peripheral blood sample will be extracted with DNA and performed with NGS using Illumina Miseq squencer and ddPCR.
2891442|NCT03309449|Other|Intramuscular administration|Participants in this arm will be provided with the training and supplies to administer intramuscular simulated naloxone using a syringe and needle to a simulated flesh pad on a mannequin.
2891443|NCT03309449|Other|Intranasal (Atomizer)|Participants in this arm will be provided with the training and supplies to administer atomized intranasal simulated naloxone to a mannequin via a syringe using an intranasal mucosal atomization device.
2891444|NCT03309449|Other|Intranasal (Spray)|Participants in this arm will be provided with the training and supplies to administer an intranasal spray simulated naloxone to a mannequin.
2891445|NCT03309436|Experimental|Use Clomiphene Citrate protocol|Ovulation induction: regular Clomiphene Citrate protocol. Start use rFSH or HMG from day 2/3 of the menstrual cycle, the initial dosage is determined by patients' age, BMI, antral follicle number, FSH, E2, AMH and past ovarian response, usually 150-225IU/d, until hCG injection. At the same time, take CC 100mg/d until hCG injection. The dosage of Gn will be adjust by serum E2, P, LH and the development of follicular.
2891446|NCT03309436|Active Comparator|Procedure|Ovulation induction: regular GnRH antagonist protocol. Start use rFSH or HMG from day 2/3 of the menstrual cycle, the initial dosage is determined by patients' age, BMI, antral follicle number, FSH, E2, AMH and past ovarian response, usually 150-225IU/d, until hCG injection. When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection. The dosage of Gn will be adjust by serum E2, P, LH and the development of follicular.
2891447|NCT03309423||Respiratory disease|Patients with acute respiratory insufficiency admitted to the ICU and with pH <7,35 or >7,45
2891448|NCT03309423||Metabolic disease|Patients with acute metabolic disease admitted to the ICU and with pH <7,35 or >7,45
2891449|NCT03309423||Sepsis|Patients with acute sepsis admitted to the ICU and with pH <7,35 or >7,45
2891450|NCT03309410||Pre-study|In the pre-study, venous samples were collected in paired 2 mL ABG syringes and 4.5 mL tubes from each of the 10 patients, to determine which blood collection method was preferred. VBG samples were collected via a butterfly needle with a three-way stopcock in conjunction with routine venous blood sampling upon admission. VBG samples were collected by the biomedical laboratory technician in the same manner as PVB samples in the normal clinical setting. Results from the pre-study were used to determine the preferred blood collection method in the main study. In this study, paired ABG and VBG samples were collected simultaneously from each of the 20 patients. The ABG samples were collected by the responsible physician. Allocation to either the pre-study or the main study was performed by simple quasi-random allocation in order of admission.
2891451|NCT03309410||Main study|In this study, paired ABG and VBG samples were collected simultaneously from each of the 20 patients. The ABG samples were collected by the responsible physician. Allocation to either the pre-study or the main study was performed by simple quasi-random allocation in order of admission. The clinical indication for ABG analysis was decided by the responsible physician in the ED upon patient admission and based on national guidelines and criteria.
2891452|NCT03309358|Experimental|Inhaled SNSP113|
2891453|NCT03309358|Placebo Comparator|Inhaled Placebo|
2891454|NCT03309345||Case group, PKU group|Children and adults (10 - 45 years old) with PKU attending the metabolic medicine clinics in the area of National Health Services (NHS) Greater Glasgow and Clyde (GGC) will be approached for recruitment. Participants will be free from history of acute and chronic illness (other than PKU) requiring regular appointments to the doctor and/or chronic use of medication or major gastrointestinal surgery where major part of the gut has been resected as these conditions are known to impact on energy expenditure and dietary intake. Pregnant or lactating women will also be excluded from participation. People with learning or mobility difficulties or those with incapacity to provide informed consent will be excluded too. The clinical treatment team will evaluate patients' capacity to consent before considering them to participate in the study.
2891455|NCT03309345||Control group, healthy control|Gender, BMI and age matched healthy people will be recruited as a control group. Pregnant or lactating women will be excluded from participation. Those with any chronic illnesses or bone injuries will also be excluded.
2891456|NCT03309332|Experimental|Device|Subjects implanted with the AMPLATZER™ PFO Occluder.
2891457|NCT03309319|Experimental|Ros|Rosiglitazone：2 times a day, 4mg each time（4mgBid）
2891458|NCT03309306|No Intervention|Phase 1: Lab Testing (Visit 1, Day 0)|Participants will test the FoodImage App and Pen-and-paper Records with in a Laboratory Kitchen. Participants will use the FoodImage app and food records to measure food waste during simulated shopping trip and kitchen clean-out. Measurements will be collected by participants with both methods while lab personnel directly weigh foods to provide the criterion value.
2891459|NCT03309306|Active Comparator|Phase 2: RCT Stress Management|Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will capture baseline data for 4-7 days. After a 1-week break, participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also receive information on stress management
2891460|NCT03309306|Experimental|Phase 2: RCT Food Waste Reduction|"Phase 2 will occur in participants' natural environment (free-living conditions). Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges. Participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also be provided with the following:~Feedback on the amount of food waste their household created during the first week,~A goal to reduce the next week's food waste by 20% or more, and~Tips on how to reduce household food waste adapted from current consumer campaigns"
2891461|NCT03309293|Other|controls|biological samples bank
2891462|NCT03309293|Experimental|cases|
2891464|NCT03309267||Intercostal block|Anesthesia induction was performed to all patients .At the end of the operation some patients were performed with intercostal block by the chest surgeon. For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
2891465|NCT03309267||Serratus anterior plane block|Anesthesia induction was performed to all patients. At the end of the operation some patients were performed SAPB under Ultrasound guidance by the same anesthetist.For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
2891466|NCT03309254|Experimental|High Glycemic Index|White Bread with Turkey breast meat (2 slices) Turkey Breast (7 slices) Chamomile Tea with 25 grams glucose Almonds 15 grams
2891467|NCT03309254|Experimental|Low Glycemic Index|Multi-grain Bread with Turkey breast meat (2 slices) Turkey Breast (6 slices) Chamomile Tea with 25 grams fructose Cashews 10 grams
2891468|NCT03309241|Experimental|Cohort 1|Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
2891469|NCT03309241|Experimental|Cohort 2|Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
2891470|NCT03309241|Experimental|Cohort 3 (optional)|Single Ascending Dose administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
2891471|NCT03309228||Qualitative Research|Semi-structured interviews with patients, relatives and general practitioners.
2891472|NCT03309215|Experimental|Patients with nickel allergy|Experimental stimulation with nickel discs
2891473|NCT03309215|Experimental|Persons without nickel allergy|Experimental stimulation with nickel discs
2891474|NCT03309202|Experimental|Cohort 1_Without impairment|Single, 25 mg dose of PF-05221304
2891475|NCT03309202|Experimental|Cohort 2_Mild impairment|Single, 25 mg dose of PF-05221304
2891476|NCT03309202|Experimental|Cohort 3_Moderate impairment|Single, 25 mg dose of PF-05221304
2891477|NCT03309202|Experimental|Cohort 4_Severe impairment|Single, 25 mg dose of PF-05221304
2891478|NCT03309176|Active Comparator|Standard group|Intervention:Medroxyprogesterone acetate (Provera) 10 mg daily for 10 days will be used prior to starting ovulation induction with clomiphene citrate (CC) and between anovulatory cycles. On cycle day (CD) 3 CC 50 mg is administered daily for 5 days. Follicle growth will be monitored by ultrasound, starting from CD11. Anovulatory patients (defined as no follicle ≥ 14 mm) on CD20, will receive Provera 10mg daily for 10 days. The CC dosage will be increased in the next cycle. On CD3 patients will receive CC 100 mg daily for 5 days with ultrasounds performed from CD11 onwards. Anovulatory patients will receive Provera 10mg daily for 10 days. In the next cycle the CC dose will be increased to 150 mg, starting from CD3, daily for 5 days with ultrasounds starting from CD11-20.
2891479|NCT03309176|Experimental|Stair Step group|Intervention: Stair step protocol without medroxyprogesterone acetate 10 mg prior to ovulation induction with clomiphene citrate (CC), nor in between anovulatory cycles. After performing an ultrasound to check for the presence of cysts or any other abnormalities and a negative pregnancy test, patients will receive CC 50 mg daily for 5 days. Ultrasounds will be performed on CD11-14. If there is no response on CD14 (no follicle ≥ 14 mm), the dose of CC is immediately increased to 100 mg CC daily for 5 days and an ultrasound is performed 1 week following the last ultrasound. If there is no response, 150 mg CC daily is initiated immediately for 5 days and the ultrasound is repeated 1 week after the previous ultrasound.
2891480|NCT03309163|Active Comparator|Group T|All patients receive the patient-controlled intravenous analgesia with Tramadol.
2891481|NCT03309163|Placebo Comparator|Group H|All patients receive the patient-controlled intravenous analgesia with Hydromorphone.
2891482|NCT03309163|Placebo Comparator|Group E|All patients receive the patient-controlled epidural analgesia with Ropivacaine.
2891483|NCT03309150|Experimental|M6620 Monotherapy or Combination Therapy|
2891484|NCT03309137|Experimental|Antiseptic device|Patients who are randomized to receive the device will receive Chlorhexidine at a dose of 0.24-0.42 mg/installation into all intravenous lines. The intervention will be administered every 24 hrs and as needed for as long as the intravenous is in place
2891485|NCT03309137|No Intervention|Routine Care|Patients who are randomized to routine care (no device, no intervention) will receive normal saline flush as per standard ICU care.
2891486|NCT03309124|Experimental|White bread|Matched for energy content and available carbohydrate content of potato treatments
2891487|NCT03309124|Experimental|Baked potato with skin|Baked russet potato
2891488|NCT03309124|Experimental|Mashed potatoes|Mashed potatoes prepared from frozen, matched for available carbohydrate content of baked potato
2891489|NCT03309124|Experimental|Fried French fries|Matched for available carbohydrate content of baked potato
2891490|NCT03309124|Experimental|Meal skipping|No food given
2891491|NCT03309111|Experimental|GBR 1342|Open-label dose escalation of GBR 1342
2891492|NCT03309098||Ankle Injury|Person who injures their ankle
2891493|NCT03309085|Experimental|Single arm|Repeated CT scan
2891494|NCT03309072|Experimental|active tDCS|active tDCS with Face Name associate Memory task
2891495|NCT03309072|Sham Comparator|sham tDCS|sham tDCS with Face Name associate Memory task
2891496|NCT03309059|Placebo Comparator|water and soap|Will be composed of elderly patients who present with fecal and / or urinary incontinence and who, therefore, need to implement measures to prevent the development of IAD with the use of soap and water in the area and subsequent diaper placement disposable. This type of procedure is standardized in the medical clinic wards of the hospital under study, and for this reason, it was defined as control.
2891497|NCT03309059|Active Comparator|zinc oxide|will be composed of elderly patients who present with fecal and / or urinary incontinence and who, therefore, need to implement measures to prevent the development of IAD with the use of soap and water sanitation and application of zinc oxide . The patient presenting with urinary and / or fecal eliminations will undergo such intervention and then the placement of the disposable diaper used by the hospital.
2891528|NCT03308851|No Intervention|Control|The participants in this arm will receive no treatment, but will have the same monitoring as the experimental group.
2891498|NCT03309059|Experimental|Non-Irritant Barrier Film|will be composed of the elderly patients who present fecal and / or urinary incontinence and that, therefore, it is necessary to implement measures to prevent the development of ICD with the use of soap and water hygiene and application of Non Irritant Barrier Film. The patient who presents with urinary and / or fecal eliminations will undergo this intervention and then the placement of the disposable diaper used by the hospital.
2891499|NCT03309046|Experimental|REACH Individual Session|The individual sessions intervention focuses on education, skills building, and support. It will be delivered in six sessions by telephone over three months. A Caregiver Notebook will include comprehensive materials for all sessions and topics. Treatment fidelity will be monitored and ensured through assessment of intervention delivery, receipt, and enactment. The intervention is targeted and individualized to the concerns of the specific caregiver and care recipient through a risk assessment. The Risk Assessment (RA) assesses the main caregiving risk areas for the specific caregiving dyad. The RA is used to tailor the intervention for care recipient behaviors or safety issues and/or caregiver centered issues/concerns related to health, physical and emotional well being, and/or social support.
2891500|NCT03309046|Active Comparator|Education Webinar|For the education webinar sessions, topics addressing each of the caregiving risk factors topics but without the skills building or cognitive restructuring components present in the individual intervention sessions will be available online in webinars. The education webinar sessions will focus on general information about post 9/11 concerns, problem behaviors, caregiver health, caregiver emotional well-being, and red flags. Education webinar session participants will not receive the Caregiver Notebook until they have completed their 6 month interviews. Parents will be able to view all 6 webinars at any time during the first 3 months. Each session will last approximately thirty minutes through PowerPoint slide presentation format with a pre-recorded script.
2891501|NCT03309033||Group 1|-Women aged 30-38 who participated in the CVT LTFU study
2891502|NCT03309020||Ebola Survivors|Up to 60 Ebola survivors will be enrolled.
2891503|NCT03309020||Controls|Up to 60 controls will be enrolled.
2891504|NCT03309007|Experimental|Metformin|Metformin started at 500 mg po twice daily (BID), and then titrated up to 1000 mg po q morning (AM) and 500 po q evening (PM) over the course of 1 month, as tolerated.
2891505|NCT03309007|Placebo Comparator|Placebo Oral Tablet|Near-identical CaCO3 as a Placebo Oral Tablet will be started at 648 mg po BID, and then titrated up to 1296 mg po q AM and 648 mg po q PM over the course of 1 month, as tolerated.
2891506|NCT03308994||Oral first line disease modifying treatments|
2891507|NCT03308994||Injectable first line disease modifying treatments|
2891508|NCT03308981|Experimental|REThink therapeutic online game|REThink group will play twice the seven levels of the game, divided into seven modules.
2891509|NCT03308981|Active Comparator|REBE group|Participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
2891510|NCT03308981|No Intervention|Wait-list|Participants will not receive any intervention.
2891511|NCT03308968|Experimental|Fremanezumab Monthly|During the double-blind period, participants with chronic migraine (CM) are administered Dosage A subcutaneous (sc) injection of fremanezumab at Week 0 (baseline) followed by Dosage B sc injections at Week 4 and Week 8 and participants with episodic migraine (EM) are administered Dosage B subcutaneous (sc) injection of fremanezumab at Week 0 (baseline), Week 4, and Week 8 then followed by an open label period where all participants are administered Dosage B sc injection of fremanezumab at Weeks 12, 16 and 20.
2891512|NCT03308968|Experimental|Fremanezumab Quarterly|During the double-blind period, participants with chronic migraine (CM) and participants with episodic migraine (EM) are administered Dosage A sc injection of fremanezumab at Week 0 (baseline) followed by placebo sc injections at Week 4 and Week 8 followed by an open label period where all participants are administered Dosage B sc injection of fremanezumab at Weeks 12, 16 and 20.
2891513|NCT03308968|Placebo Comparator|Placebo|During the double-blind period, participants with chronic migraine (CM) and participants with episodic migraine (EM) are administered 3 placebo sc injections at Week 0, and 1 placebo injection at weeks 4 and 8 followed by an open label period where all participants are administered Dosage B sc injection of fremanezumab at Weeks 12, 16 and 20.
2891514|NCT03308955|Active Comparator|Grup B|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
2891515|NCT03308955|Sham Comparator|Grup S|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
2891516|NCT03308942|Experimental|NSCLC High PD-L1 Expressing|All Non-small cell lung cancer histologies with a high expression of PD-L1 as defined as TPS greater or equal to 50%. Treated with combination of niraparib and PD-1 Inhibitor.
2891517|NCT03308942|Experimental|NSCLC Low PD-L1 Expressing|All Non-small cell lung cancer histologies with a low expression of PD-L1 as defined as TPS 1-49%. Treated with combination of niraparib and PD-1 Inhibitor.
2891518|NCT03308942|Experimental|Squamous NSCLC|Squamous non-small cell lung cancer. Treated with niraparib monotherapy.
2891519|NCT03308916|Experimental|Liver stiffness measurement|Transient elastography in fasting state
2891520|NCT03308890|Active Comparator|Arm 1|0.5mg Entecavir QD for 6 months after cessation of TDF and clinical observation for up to 6 months after the end of study follow-up.
2891521|NCT03308890|Active Comparator|Arm 2|0.5mg Entecavir QD for 12 months after cessation of TDF and clinical observation for up to 6 months after the end of study follow-up.
2891522|NCT03308890|No Intervention|Arm 3|No consolidation arm and observation only and clinical observation for up to 6 months after the end of study follow-up.
2891523|NCT03308877|Experimental|Brief Motivational Intervention (BMI)|
2891524|NCT03308877|Active Comparator|Standard Care (SC)|
2891525|NCT03308864|Experimental|Interpersonal Psychotherapy for Adolescents (IPT-A)|All adolescents who present at Child and Adolescent Outpatient Service (CAOS) for a diagnostic intake evaluation and who report any symptoms of depression.
2891526|NCT03308864|Active Comparator|Treatment as Usual|All adolescents who present at Child and Adolescent Outpatient Service (CAOS) for a diagnostic intake evaluation and who report any symptoms of depression.
2891529|NCT03308838||Cases|Cases consisted of Costa Rican adults who were diagnosed as survivors of a first acute myocardial infarction.
2891530|NCT03308838||Controls|Controls consisted of healthy individuals randomly identified from the underlying source population in Costa Rica and matched to each case by age, sex, and area of residence.
2891531|NCT03308825|Experimental|Children 6 to < 36 months|Children 6 to < 36 months of age will receive a 0.25-mL dose of the 2017-2018 formulation of Fluzone Quadrivalent vaccine on Day 0. For participants for whom 2 doses of influenza vaccine are recommended, a second dose will be administered on Day 28.
2891532|NCT03308825|Experimental|Children 3 to < 9 years|Children 3 to < 9 years of age will receive a 0.5-mL dose of the 2017-2018 formulation of Fluzone Quadrivalent vaccine on Day 0. For participants for whom 2 doses of influenza vaccine are recommended, a second dose will be administered on Day 28.
2891533|NCT03308825|Experimental|Adults 18 to < 65 years|Adults 18 to < 65 years of age will receive a 0.5-mL dose of the 2017-2018 formulation of Fluzone Quadrivalent vaccine on Day 0.
2891534|NCT03308825|Experimental|Adults ≥ 65 years|Adults ≥ 65 years of age will receive a 0.5-mL dose of the 2017-2018 formulation of Fluzone High-Dose vaccine on Day 0.
2891535|NCT03308812|Active Comparator|Health360x|Participants will use the Health360x application for 6 months.
2891536|NCT03308812|Experimental|Health360x plus health coach|Participants will use the Health360x application and received personalized health coaching for 6 months.
2891537|NCT03308799|Experimental|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
2891538|NCT03308799|Active Comparator|Cal/BDP combination|Calcipotriene/betamethasone (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.
2891539|NCT03308799|Placebo Comparator|Cream vehicle|One application daily for 8 weeks.
2891540|NCT03308786|Experimental|IL2 treatment|Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for five consecutive days every 8 weeks for 8 weeks, in addition to combination antiretroviral therapy.
2891541|NCT03308747|Experimental|High systemic inflammation|Individuals assigned in the high systemic inflammation group will be characterized by IL6: ≥ 1.7 pg/ml and hs-CRP: > 2.0 mg/L.
2891542|NCT03308747|Active Comparator|Low systemic inflammation|Individuals assigned in the high systemic inflammation group will be characterized by IL6: < 1.7 pg/ml and hs-CRP: < 1.0 mg/L.
2891543|NCT03308734|Experimental|Exercise Intervention Group|Reduced-Exertion High-Intensity Interval Training Following baseline testing, participants will start a 6-week training protocol involving reduced-exertion high-intensity training on a cycle ergometer based in a gym in Gloucestershire used by the Macmillan Cancer Support's Next Steps project.
2891544|NCT03308734|No Intervention|Control Group|Following baseline testing, participants will receive usual care only.
2891545|NCT03308721|Experimental|NNC9204-1177|Dose trial with a sequential trial design
2891546|NCT03308721|Placebo Comparator|Placebo|
2891547|NCT03308708|No Intervention|Control group|
2891548|NCT03308708|Experimental|NE group|
2891549|NCT03308682|Experimental|177Lu-DOTA-EB-TATE dosimetry calculation|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
2891550|NCT03308669|Experimental|Lasmiditan Alone|Lasmiditan administered orally, alone
2891551|NCT03308669|Placebo Comparator|Placebo Alone|Placebo administered orally, alone
2891552|NCT03308669|Experimental|Topiramate + Lasmiditan|Topiramate administered orally, alone, and co-administered with oral lasmiditan
2891553|NCT03308669|Experimental|Topiramate + Placebo|Topiramate administered orally, alone, and co-administered with oral placebo
2891554|NCT03308656||Induced labor in term pregnancies|100 singleton nulliparous patients are planning to complete the study period. Study group constitute of third trimester pregnancies between 37-40 weeks of gestation. All participants were nulliparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
2891555|NCT03308643|Experimental|Oxytocin infusion|Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
2891556|NCT03308643|Placebo Comparator|Placebo|Patients will receive pure normal saline infusion at the same rate and volume just before the surgery after the induction of general anesthesia.
2891557|NCT03308630|Experimental|Energy Alignment and Mantra|
2891558|NCT03308604|Experimental|Patients with locally advanced cervical cancer|
2891559|NCT03308591|Experimental|NACT|The patients will receive 2 courses of platinum based chemotherapy before surgery, 2-3 weeks after each course, doctors will appraise the effect of the chemotherapy. Patients who are sensitive to the treatment will undergo radical hysterectomy and pelvic lymph node dissection 3 weeks after chemotherapy. And 2-3weeks after the surgery, patients will receive adjuvant chemotherapy according to the pathological risk factors.
2891560|NCT03308591|Active Comparator|PST|The patients in this group will undergo radical hysterectomy and pelvic lymph node dissection directly, and 2-6 weeks after the surgery, they will receive adjuvant chemotherapy according to the pathological risk factors.
2891561|NCT03308578|Experimental|Atorvastatin|Subjects randomized to this arm will be started on a lower dose of atorvastatin 40 mg daily for the first 4 weeks. If they are tolerating this dose without significant problems, atorvastatin will be increased to 80 mg daily.
2891562|NCT03308578|Placebo Comparator|Placebo Oral Capsule|Subjects randomized to this arm will receive placebo capsules matching study drug.
2891563|NCT03308565|Experimental|Phase I|Patients will receive a single dose of 100 million autologous, adipose derived mesenchymal stem cells. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
2891564|NCT03308552|Active Comparator|SIB-IMRT combined chemotherapy followed by chemotherapy|"SIB-IMRT: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.~Concurrent chemotherapy: Paclitaxel and platinum based drug are administered once a week for at least 5 weeks during radiotherapy treatment days."
2891565|NCT03308552|Placebo Comparator|SIB-IMRT Alone followed by chemotherapy|SIB-IMRT: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
2891566|NCT03308539||myocardial infarction patients|transthoracic echocardiography and cardiac magnetic resonance
2891567|NCT03308500|Experimental|High-intensity intermittent games HIIG|High-intensity intermittent games (HIIG): complete a supervised 12-weeks. Twice per week child-specific games program, intensity HRmax 75% ≤ - RPE 6-8.
2891568|NCT03308500|Active Comparator|Moderate-intensity games (MIG)|Moderate intensity games (MIG): complete a supervised 12-weeks. Twice per week child-specific games program, intensity HRmax 60-74% ≤ - RPE 4-5.
2891569|NCT03308487|Active Comparator|vitamin D3 (1000 IU)|group 1
2891570|NCT03308487|Active Comparator|vitamin D3 (2000 IU)|group 2
2891571|NCT03308461|Experimental|Fecal microbiota transplantation (FMT)|Patients underwent single FMT in this studyAll patients were assessed before FMT and during 12-week follow-up after FMT.
2891572|NCT03308448|Active Comparator|Group 1|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 300 units/kg/day for three consecutive days (total:900/kg in 3 days)
2891573|NCT03308448|Active Comparator|Group 2|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 600 units/kg/day for three consecutive days (total:1800/kg in 3 days)
2891574|NCT03308448|Active Comparator|Group 3|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 600 units/kg/day for three consecutive days then repetition of the same treatment in month 1 (Total: 3600/kg in 2 set of 3-day treatment, 1 month apart)
2891575|NCT03308422||Parents of 2-6-years-old children|Parents of preschool children in Nancy agglomeration
2891576|NCT03308409|Active Comparator|Protocol 1|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six sessions, one per week, with 3000 pulses at 0.20 mj/mm2, at a frequency of 4Hz. At all of the shockwave sessions, 2000 pulses will be distributed to the body of the penis and 1000 pulses will be applied to the base.
2891577|NCT03308409|Experimental|Protocol 2|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six initial sessions, one per week, with 3000 pulses at 0.20 mj/mm2, at a frequency of 4Hz for six weeks, followed by monthly maintenance sessions (every 4 weeks) for five months. At all of the shockwave sessions, 2000 pulses will be distributed to the body of the penis and 1000 pulses will be applied to the base.
2891578|NCT03308409|Experimental|Protocol 3|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six monthly sessions in which 3000 pulses will be applied at 0.20 mj/mm2, at a frequency of 4Hz, with 2000 pulses distributed to the body of the penis and 1000 pulses applied to the base
2891579|NCT03308396|Experimental|Single Arm|"This is a non-randomized, single arm, open label Phase Ib/II study.~Phase Ib:~Days 1-5~Guadecitabine:~Dose 0: 60 mg/m^2~Dose -1: 45 mg/m^2~Phase II:~Days 1-5 Guadecitabine (at Ph II dose)~Day 8 Durvalumab (1500 mg IV) Day 8 Durvalumab (1500 mg IV)"
2891580|NCT03308383|Experimental|TRANSTHORACIC ECHOCARDIOGRAM|Individuals who visit pre-anaesthetic check up (PAC) clinic for minor surgery which includes plastic, rhino-otolaryngeal, ophthalmologic, orthopaedic, abdominal, urological, gynaecological surgeries, who are free of cardiac disease or any known risk factors for the cardiac disease like chronic alcoholism, chronic smoking, metabolic syndrome, morbid obesity
2891581|NCT03308370|Experimental|Platelet rich plasma|intradermal injection of 5 ml of autologous platelet rich plasma in the lesional skin of the face of 20 melasma patients every 4 weeks for 3 times
2891582|NCT03308357||All six subjects|2 patients with ulcerative colitis; one with active disease and one in remission. 2 patients with Crohn's disease; one with active disease and one in remission. 2 healthly controls. Single blood sample from each participant, serum collected, that serum will be spiked with known concentrations of the originator infliximab and the biosimilar infliximab and then run on a range of assays to measure infliximab drug concentrations
2891583|NCT03308344|Experimental|Mindfulness Training|Participants will engage in 15-hour mindfulness training.
2891584|NCT03308344|No Intervention|Wait-list control|Participants will be tested before and after a no-training interval and will receive training at a later time.
2891585|NCT03308331|Experimental|HIV-1 smokers|
2891586|NCT03308331|No Intervention|HIV-1 nonsmokers|
2891587|NCT03308331|Active Comparator|Healthy control smokers|
2891588|NCT03308331|No Intervention|Healthy control nonsmokers|
2891589|NCT03308331|Active Comparator|HIV-1 nonsmokers using nicotine patch|
2891590|NCT03308331|No Intervention|HIV-1 nonsmokers using placebo patch|
2891591|NCT03308331|Active Comparator|Healthy control nonsmokers using nicotine patch|
2891592|NCT03308331|No Intervention|Healthy control nonsmokers using placebo patch|
2891593|NCT03308318||the supratemporalis approach|patients operated upon with zygomaticofacial or craniofacial fractures using the supratemporalis approach
2891594|NCT03308292|No Intervention|Control Group|
2891595|NCT03308292|Experimental|Intervention Group|"A moderate-intensity aerobic physical exercise programme was carried out during the months of March to May 2017 (12 weeks), with a frequency of three sessions per week (36 sessions in total) with a duration of 45 minutes per session. The intensity was controlled through the Borg 1982 modified scale of perceived exertion (RPE). It is a scale from 0 to 10, considering 0 as nothing at all and 10 as very very strong, setting the moderate intensity as value"
2891596|NCT03308279||Asinthomatic|The only group evaluated
2891597|NCT03308266||CLP children with pain-related TMD|
2891598|NCT03308266||CLP children with no TMD|
2891599|NCT03308266||CLP children with painfree TMD|
2891600|NCT03308253|Other|Standard of Care|Patients will receive the standard of care for vascular procedures as it is provided at Hamilton General Hospital
2891601|NCT03308253|Experimental|Antibiotic Impregnated Beads|Patients will have their wound packed with calcium sulfate beads prior to closing. The beads will be infused with the antibiotics vancomycin and tobramycin.
2891602|NCT03308240|Experimental|Magic Therapy Group|"Medical student magicians who have completed MagicAid training will provide the therapy.~Three or four tricks will be performed per patient at the discretion of the magician to cater to patient age and cognition capabilities. Patients in the experimental group may be given the opportunity to learn a magic trick that has been presented to them as well."
2894259|NCT03289260|Experimental|Interventional Arm|Imiquimod 5% cream therapy Fulguration
2891603|NCT03308240|No Intervention|Standard Child Life Therapy Group|Stony Brook Child Life Specialists will provide standard therapies available to all patients, such as pet therapy, art therapy, music therapy.
2891604|NCT03308227||Experimental Group|septic shock patients;
2891605|NCT03308227||Conrol Group|non-septic shock patients;
2891606|NCT03308214||septic shock|Patients with septic shock treat with Imipenem
2891607|NCT03308214||non-septic shock|Patients with infection but not septic shock treat with Imipenem
2891608|NCT03308201|Experimental|Hemay022 and Exemestane|"Part one: Hemay022 in combination with exemestane will be taken orally once daily. Planned dose escalation of Hemay022 will be 200mg, 300mg,400mg or 500mg daily for 28 days.~Part two: Hemay022 in combination with exemestane will be taken in OTR dose until disease progression, intolerable toxicity or death."
2891609|NCT03308188|No Intervention|Treatment As Usual|Participants randomized to Treatment As Usual will receive treatment for chronic pain as typically provided by their clinician -- they will receive no extra treatment from the study.
2891610|NCT03308188|Experimental|E-Health+|Participants randomized to the E-health+ arm will receive treatment as typically provided by their clinician plus a 4-month subscription to the E-health program, which is an internet based chronic pain program.
2891611|NCT03308175|Experimental|flat fixed anterior bite plane|"Bands selection will be done for upper 6s. Alginate impressions taken and molar bands are fitted in place into the impressions. Impressions for upper and lower arches are poured with stone plaster. Mounting on simple hinge articulator will be done.~Lingual arches (diameter 1 mm) with anterior acrylic bite plates with thickness enough to separate posterior teeth 4mm .~The acrylic bite planes were in occlusion with the lower anterior teeth and extended sagittally 2-3mm beyond edges of lower incisors.~Finishing ,polishing and cementation into patient's mouth with glass ionomer cement."
2891612|NCT03308175|Experimental|modified inclined fixed anterior bite plane|"In modified inclined fixed anterior bite plane,the modification is that some indentations will be done in the acrylic part where the lower anteriors will fit such that mandible will be held in a more forward position. These indentations will be relieved lingually to overcome it's flaring effect on mandibular incisors .The inclined plane will be 60 degrees to occlusal plane.~Functional bite will be taken to position the mandible in the proper position forward.~Bite taken edge-to-edge for appliance construction. Mounting upper and lower casts on simple hinge articulator for construction of modified flat fixed anterior bite plane"
2891613|NCT03308162|Experimental|Group Intervention|Cognitive behavioral experiential group therapy for health behavior change
2891614|NCT03308136|Experimental|subcutaneous anesthesia group (group A)|
2891615|NCT03308136|Active Comparator|muscle anesthesia group (group B)|
2891616|NCT03308123||Health Care Professionals|Health care professionals
2891617|NCT03308123||Carers of hip-fracture patients with moderate/severe|Carers of hip-fracture patients with moderate/severe
2891618|NCT03308123||Discharged hip-fracture patient with memory difficulty|Discharged hip-fracture patient with memory difficulty
2891619|NCT03308110|Other|Relative Bioavailability Cohort|Relative Bioavailability cohort
2891620|NCT03308097|Experimental|PrEP Mobile Messaging Intervention|Participants from the STI/HIV testing clinic will receive Enhanced Standard of Care (described below) plus texted messages with the intervention content and follow-up questions over the next 4 weeks on their cell phones. Participants will receive approximately 8-16 interactive text messages with links to web content. Texts will be sent twice a week over the next 4 weeks. Participants will return for 2 more appointments over the next couple of months to fill out questionnaires.
2891621|NCT03308097|Active Comparator|Enhanced Standard of Care|As part of the enhanced standard of care, participants seen in the STI/HIV testing clinic are given feedback regarding PrEP eligibility and current risk behaviors. Participants are also given an informational handout about PrEP, shown a brief video, and given contact information for the PrEP Clinic Care Coordinator. Participants will return for 2 more visits over the next couple months to fill out questionnaires.
2891622|NCT03308084|Active Comparator|Local Depomedrol plus IV dexamethasone|Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone
2891623|NCT03308084|Placebo Comparator|IV dexamethasone|Standard systemic (IV) dexamethasone only
2891624|NCT03308071|Experimental|Hypnosis Group|Participants will undergo a brief hypnotic assessment, a single hypnosis session with an MD trained in hypnosis, and be given a phone number to listen to a guided self-hypnosis recording for 1 week pre-op until 2 weeks post-op.
2891625|NCT03308071|No Intervention|Usual care|These patients will be enrolled in the study and usual care will be provided.
2891626|NCT03308058|Experimental|Breastfeeding Computer education|Breastfeeding Computer education
2891627|NCT03308058|No Intervention|Printed Educational material|Printed educational material
2891628|NCT03308045|Experimental|pEYS606|Cohort 1 (pEYS606 lower dose); Cohort 2 (pEYS606 intermediate dose); Cohort 3 (pEYS606 higher dose); Extension Cohort (pEYS606 maximum tolerated dose)
2891629|NCT03308032|Experimental|Intervention|Participants assigned to the intervention arm will be invited to connect to a webpage, through either computer or tablet / iPad, where they can login to receive the SDL course. Immediately after the login, and weekly thereafter, participants will receive emails to remind them of the login passwords, to provide them with tracking data on their progress in going through the training lessons. For those who login but do not proceed to take baseline assessment for longer than two days, study staff will contact participants, via the email address or telephone number that was entered during initial registration for login, to answer any questions they might have and to provide assistance to those who have not been able to log onto the site. Those who sign up without taking any courses for 10 days will receive a reminder call by study staff. Intervention arm participants will be invited back via both
2891660|NCT03307785|Experimental|Part C: Dose Finding|Test safety and tolerability of combination therapy of Niraparib and Bevacizumab with TSR-042. To establish a Phase 2 dose (RP2D)
2891661|NCT03307785|Experimental|Part D: Safety and Tolerability Evaluation|Test the safety and tolerability of combination therapy of Carboplatin-Pacitaxel and Bevaxizumab with TSR-042. To establish a Phase 2 dose (RP2D)
2891662|NCT03307772|Placebo Comparator|placebo drink|The placebo drink consists of fermented low-fat milk with no added Lactobacillus GG.(placebo)
2891663|NCT03307772|Active Comparator|LGG Drink (|The probiotic drink consists of fermented low-fat milk with added Lactobacillus GG. (probiotics)
2891630|NCT03308032|Active Comparator|Control|"Participants assigned to the intervention arm will be invited to connect to a webpage, through either computer or tablet / iPad, where they can login to receive the SDL course.~Immediately after the login, and weekly thereafter, participants will receive emails to remind them of the login passwords, to provide them with tracking data on their progress in going through the training lessons (see below). For those who login but do not proceed to take baseline assessment for longer than two days, study staff will contact participants, via the email address or telephone number that was entered during initial registration for login, to answer any questions they might have and to provide assistance to those who have not been able to log onto the site. Those who sign up without taking any courses for 10 days will receive a reminder call by study staff. Intervention arm participants will be invited back via both"
2891631|NCT03308019|Experimental|Adjunctive photodynamic therapy|This arm will be given scaling and root planing (SRP) with adjunctive photodynamic therapy (aPDT)
2891632|NCT03308019|Active Comparator|Dental scaling|This arm will be given scaling and root planing (SRP) only
2891633|NCT03308006|Experimental|Stem cells therapy|
2891634|NCT03307993|Experimental|Idalopirdine|"Idalopirdine 60 mg once daily for 10 day (up to 14 days possible), adjunct to donezepil (patients individualized maintenance dose)~If high receptor occupancy cannot be verified, the receptor occupancy following a higher dose (up to 60 mg twice daily for 10-14 days) will be assessed in Cohort 2."
2891635|NCT03307967|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM) was developed to promote engagement in multi-modal non-pharmacological pain management among compensation-seeking Veterans with chronic pain. In SBIRT-PM, a clinician meets with the Veteran after the compensation examination to address the presenting MSD complaint. The clinician addresses Veterans' motivation for multi-modal pain care, and explains how pain can be managed using a variety of non-pharmacological pain management services. The clinician spells out how those services can be accessed at VA. Using permissive language about how pain is commonly self-medicated with substances, the clinician transitions to inquiries about use of prescription and non-prescription substances. The clinician then attempts to motivate Veterans to change their behavior if they are misusing substances. Thus, SBIRT-PM addresses the Veteran's presenting pain complaint first and nascent substance use subsequently.
2891636|NCT03307967|No Intervention|Usual Care|A Veteran who completes a Compensation examination ordinarily has no further treatment, referral or debriefing as part of the Compensation examination. Veterans will be advised that they should continue to pursue whatever counseling they need outside the study.
2891637|NCT03307954|Experimental|Ekso Therapy|Up to 12 weeks of Ekso Therapy. Three sessions per week. One hour per session
2891638|NCT03307954|Active Comparator|Control|Up to 12 weeks of usual physiotherapy care. Three sessions per week. One hour per session.
2891639|NCT03307941|Other|Single arm (classic 3+3 design)|
2891640|NCT03307928|Experimental|Cardiopulmonary Exercise Test Protocol|All subjects performed an incremental cardiopulmonary exercise test (CPET) to maximum exercise tolerance. All the procedures were performed in agreement with the American Thoracic Society/American College of Chest Physicians guidelines for cycle ergometer tests.
2891641|NCT03307928|Experimental|Polysomnography Assessment|All hypertensive subjects were submitted to a polysomnography exam to diagnose OSA. The OSA diagnose was confirmed by the apnea/hypopnea index (AHI) and classified as follows: AHI < 5 events/h, absence of OSA; 5 ≤ AHI ≤ 15 events/h, low OSA; 15 ≤ AHI ≤ 30 events/h, moderate OSA; AHI > 30 events/h, severe OSA.
2891642|NCT03307915|Experimental|Group 1: Ad26.Mos4.HIV + MVA-Mosaic/Placebo|Participants will receive adenovirus serotype 26-Mosaic 4 -Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5*10^10 virus particles (vp) as intramuscular (IM) injection at Weeks 0 and 12 (1 injection) followed by modified Vaccinia Ankara-Mosaic (MVA-Mosaic) 10^8 Plaque-forming unit (pfu) and placebo as IM injection at Weeks 24 and 36 (2 injections).
2891643|NCT03307915|Experimental|Group 2: Ad26.Mos4.HIV + Clade C gp140 + Mosaic gp140|Participants will receive Ad26.Mos4.HIV, 5*10^10 vp as IM injection at Weeks 0 and 12 (1 injection) followed by both Ad26.Mos4.HIV 5*10^10 vp plus Clade C gp140 (125 microgram [mcg]) plus Mosaic gp140 (125 mcg) IM injection at Weeks 24 and 36 (2 injections).
2891644|NCT03307915|Placebo Comparator|Group 3: Placebo|Participants will receive 0.9 percent (%) saline as IM injection at Weeks 0, 12 (one injection) and at Week 24, 36 (two injections).
2891645|NCT03307902|Experimental|Imiquimod + ID HBVv|topical imiquimod + intradermal hepatitis B vaccination
2891646|NCT03307902|Active Comparator|Aqueous + ID HBVv|topical aqueous + intradermal hepatitis B vaccination
2891647|NCT03307902|Active Comparator|Imiquimod + IM HBVv|topical imiquimod + intramuscular hepatitis B vaccination
2891648|NCT03307876||groups that are fac + and -|autologous PPP injection is given to all patients. Prior to injection, a lavage of the disc space is taken to test for FAC.
2891649|NCT03307863|Experimental|Carbamazepine-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
2891650|NCT03307863|Experimental|Topiramate-Implant|Women with epilepsy using topiramate for at least 3 months will have an etonogestrel-releasing implant inserted
2891651|NCT03307863|Active Comparator|Implant|Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted
2891652|NCT03307850|Experimental|Observation of Exercise|Observation During Exercise and Stress
2891653|NCT03307837|Experimental|CA-008|
2891654|NCT03307837|Placebo Comparator|CA-008 Placebo|
2891655|NCT03307824|Experimental|IfabondTM|Use of the synthetic glue IfabondTM
2891656|NCT03307824|Active Comparator|sutures|Glue-Free Suture Technique
2891657|NCT03307811|Experimental|22 gauge needle liver biopsy|EUS-LB will be performed using a 22 g FNB needle. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
2891658|NCT03307785|Experimental|Part A: Dose Finding|Test safety and tolerability of combination therapy of Niraparib with TSR-042. To establish a Phase 2 dose (RP2D)
2891659|NCT03307785|Experimental|Part B: Safety and Tolerability Evaluation|Test the safety and tolerability of combination therapy of Carboplatin-Pacitaxel with TSR-042. To establish a Phase 2 dose (RP2D)
2931310|NCT03031626|Experimental|Arm A: Medical air followed by oxygen|
2891664|NCT03307772|Active Comparator|FOS Drink|The prebiotics drink consists of fermented low-fat milk with fructooligosaccharides. (prebiotics)
2891665|NCT03307772|Active Comparator|LGG e FOS Drink|The probiotics and prebiotics drink consists of acidified low-fat milk with added Lactobacillus GG and fructooligosaccharides (prebiotics and probiotics)
2891666|NCT03307759|Active Comparator|SABR plus pembrolizumab|SABR followed by pembrolizumab
2891667|NCT03307759|Active Comparator|Pembrolizumab plus SABR|Pembrolizumab followed by SABR after cycle 1
2891668|NCT03307746|Active Comparator|ARM A- Rituximab and Varlilumab|Patients in ARM A willl receive Cycle1 Day 1: rituximab 375 mg/m2 IV Cycle 1 Day 2: varlilumab 3 mg/kg IV Cycles 2 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 2: varlilumab 3 mg/kg IV Cycle 4 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 2: varlilumab 3 mg/kg IV Cycle 6 Day 1: rituximab 375 mg/m2 IV
2891669|NCT03307746|Active Comparator|ARM B - Rituximab and Varlilumab|Patients in ARM B will receive Cycle 1 Day 1: rituximab 375 mg/m2 IV Cycle 1 Day 8: varlilumab 3 mg/kg IV Cycle 2 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 2: varlilumab 3 mg/kg IV Cycle 4 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 2: varlilumab 3 mg/kg IV Cycle 6 Day 1: rituximab 375 mg/m2 IV
2891670|NCT03307733|No Intervention|Control Group|Control group received usual care plus a blinded Fitbit pedometer.
2891671|NCT03307733|Active Comparator|Intervention|Intervention group received a Fitbit pedometer with individualised physical activity targets and behaviour change techniques which were delivered via a closed Facebook group
2891672|NCT03307720|Active Comparator|Poor responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.~Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment."
2891673|NCT03307720|Experimental|Poor responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)~Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment."
2891674|NCT03307720|Active Comparator|Normo responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.~Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment."
2891675|NCT03307720|Experimental|Normo responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)~Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment."
2891676|NCT03307720|Active Comparator|High responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.~Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment."
2891677|NCT03307720|Experimental|High responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)~Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment."
2891678|NCT03307707||Heart Failure (HF)|subjects with a Left Ventricular Ejection Fraction (LVEF) <50% or LVEF >50% and E/e'>10.
2891679|NCT03307707||No Heart Failure (NHF)|subjects with LVEF>50%
2891680|NCT03307694||MAC-SWEI, standard SWEI, ultrasound|Participants in this group will receive all three imaging techniques
2891681|NCT03307694||Standard SWEI, ultrasound|Participants in this group will receive two imaging techniques
2891682|NCT03307681|Experimental|White bread|Test Meal (50 g of available carbohydrates)
2891683|NCT03307681|Experimental|Baked potato with skin|Test Meal (50 g of available carbohydrates)
2891684|NCT03307681|Experimental|Mashed potato served hot|Test Meal (50 g of available carbohydrates)
2891685|NCT03307681|Experimental|Mashed potato re-heated|Test Meal (50 g of available carbohydrates)
2891686|NCT03307681|Experimental|Fried French fries|Test Meal (50 g of available carbohydrates)
2891687|NCT03307668|Experimental|CaReS-1S|
2891688|NCT03307668|Active Comparator|Microfracture|
2891689|NCT03307655|Experimental|Control (fertile semen donors)|Sperm from fertile men (donors who attend the IVI Murcia clinic) will be included in this arm.
2891690|NCT03307655|Experimental|Patients (subfertile men)|Sperm from patients (subfertile men, i.e. men who possess one altered spermiogram parameter, according to the WHO 2010 guidelines) will be included in this arm.
2891691|NCT03307642|No Intervention|SLIV + usual communication|Parents receive usual communication from school (paper consent packets & automated voice mails) about SLIV
2891692|NCT03307642|Active Comparator|SLIV + usual communication + text|Parents receive usual communication from school (paper consent packets & automated voice mails) about SLIV plus a series of text messages informing them about the usual communication for SLIV
2891693|NCT03307629|Experimental|NOX66 + Radiation treatment (combined) in cohorts 1-3|"NOX66 administered on Days 1-16 and radiation treatment given on Day 2 to 9 of 2-week cycle.~NOX66 treatment given to 3 cohorts of 4 patients as 1 of 3 doses, 400mg, 800mg and 1200 mg.~Radiation treatment of 20Gy given over 5 daily fractions to selected target lesion/s for all cohorts."
2891694|NCT03307629|Experimental|NOX66 + Radiation treatment (combined) in cohort 4|"NOX66 administered on Days 1-16 and radiation treatment given on Day 2 to 9 of 2-week cycle.~NOX66 dose will be either one of 3 doses 400mg, 800mg and 1200 mg based on interim analyses of safety data and tumour response at WEEK 6 of 3 dose cohorts of 12 total patients. The SSC will inform on dose for cohort expansion.~Radiation treatment of 20Gy given over 5 daily fractions to selected target lesion/s for all cohorts."
2891695|NCT03307616|Experimental|Arm A - Nivolumab|"Arm consists of treatment naive primary or locally recurrent dedifferentiated liposarcoma (DDLPS) of the retroperitoneum participants.~Participants receive Nivolumab by vein over about 1 hour on Days 1, 15, and 29."
2891696|NCT03307616|Experimental|Arm B - Nivolumab + Ipilimumab|"Arm consists of treatment naive primary or locally recurrent dedifferentiated liposarcoma (DDLPS) of the retroperitoneum participants.~Participants receive Nivolumab by vein over about 1 hour and Ipilimumab by vein over about 90 minutes on Day 1. Then, participants receive Nivolumab by vein over about 1 hour on Days 15 and 29."
2891760|NCT03307122|Active Comparator|Routine Infant Formula 1|Routine infant formula with probiotic
2891761|NCT03307122|Active Comparator|Routine Infant Formula 2|Routine infant formula with probiotic and prebiotic
2891697|NCT03307616|Experimental|Arm C - Nivolumab + Radiation Therapy|"Arm consists of undifferentiated pleomorphic sarcoma (UPS) of the trunk or extremities.~Participants receive Nivolumab by vein over about 1 hour on Days 1, 15, 29, and 43. Participants have radiation therapy 1 time each day, 5 days a week (Monday through Friday) from Day 15 to Day 47."
2891698|NCT03307616|Experimental|Arm D - Nivolumab + Ipilimumab + Radiation Therapy|"Arm consists of undifferentiated pleomorphic sarcoma (UPS) of the trunk or extremities.~Participants receive Nivolumab by vein over about 1 hour and Ipilimumab by vein over about 90 minutes on Day 1. Then, participants receive Nivolumab by vein over about 1 hour on Days 15, 29, and 43. Participants have radiation therapy 1 time each day, 5 days a week (Monday through Friday) from Day 15 to Day 47."
2891699|NCT03307603|Experimental|Yttrium-90 + Nivolumab|240 mg Nivolumab intravenously, beginning at 2 weeks after Yttrium-90 treatment and given every 2 weeks until progression or toxicity. Additional dose at 2 weeks prior to Y-90 will be given if the first 3 patients do not have toxicity. If any of the first 3 patients have toxicity, the schedule can be relaxed to begin 3 weeks after Y-90 treatment.
2891700|NCT03307590|Active Comparator|D group|Dexmedetomidine with bupivacaine group Caudal dexmedetomidine 1.5 microgram/kg with bupivavaine (0.25%) 1.25 ml/kg were administered
2891701|NCT03307590|Active Comparator|B group|Bupivacaine only group Caudal bupivavaine (0.25%) 1.25 ml/kg without dexmedetomidine was administered
2891702|NCT03307577|Experimental|UHE-101 cream, 1%|Cream is applied twice a day
2891703|NCT03307577|Placebo Comparator|Vehicle cream|Cream is applied twice a day
2891704|NCT03307564|Experimental|TraceIT tissue marker injection|The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments
2891705|NCT03307551|Active Comparator|CLADS group|Anaesthesia will be induced and maintained with Propofol administered by CLADS. Its administration rate will be controlled by a feedback loop facilitated by BIS monitoring. A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
2891706|NCT03307551|Active Comparator|Manual group|Anaesthesia will be induced and maintained with propofol administration by an intravenous infusion pump. Its administration rate will be controlled manually to maintain a target BIS of 50 during induction and maintenance of anaesthesia.
2891707|NCT03307538|Experimental|Stereotactic body radiation therapy|
2891708|NCT03307512|Experimental|Dance 501|Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
2891709|NCT03307512|Active Comparator|Insulin Lispro|Insulin Lispro (Humalog®) will be administered by subcutaneous injection
2891710|NCT03307499|Experimental|Treatment|NeoPatch
2891711|NCT03307486||Gestational diabetes|Women diagnosed with GDM according to the IADPSG criteria, either by abnormal fasting plasma glucose or by abnormal oral glucose tolerance test.
2891712|NCT03307473||e-bike|During 3 months in a the geographic area of Clermont-Ferrand (France), new e-bike buyers and renters are invited to take part in VELONAPS study before starting to use their e-bike
2891713|NCT03307460|Experimental|uPAR PET/MRI|68Ga-NOTA-AE105 is injected once for performing a PET/MRI scan
2891714|NCT03307447|Experimental|Treatment arm|Cosentyx (Secukinumab) 300 mg subcutaneous injection at weeks 0, 1, 2, 3 and 4 followed by every 4 weeks until 16 weeks
2891715|NCT03307434|Experimental|experimental group|experimental group is composed of athletes will be followed the Athletics Injury Prevention Program
2891716|NCT03307434|Active Comparator|control group|control group is composed of athletes will be continued their regular training
2891717|NCT03307421|Other|debriefing without instructor|Team debriefing without an instructor will be organized as follows. The pairs of participants will be placed in a room with direct access to the video recording of their passage on the simulator. Two documents will be made available to help participants structure their debriefing: one targeting non-technical skills, based on the TEAM Score, and one recalling recommendations on ACR care. Despite its absence at the time of the debriefing, the instructor will be present during the briefing and during the simulation.
2891718|NCT03307421|Other|debriefing with instructor|"The team debriefing with an instructor will begin immediately after the simulator run and will be governed by the principle of no judgment described by Rudolph .~A portion of the video of the participants' pass may be reviewed and used to support the debriefing (depending on the utility judged by the debrief). Each center will use its own team of trainers, but it will have a predefined plan and predefined objectives, which are provided in advance in order to obtain a standardized debriefing. Moreover, these trainers will not be beginners but will have some expertise in the pedagogy of simulation. They will have to have a DU in a simulation or pedagogy trainer (recommendations from SofraSim) and will have to carry out 15 debriefings per year"
2891719|NCT03307395|Experimental|Middle Meningeal Artery Embolization|
2891720|NCT03307382|Experimental|SpyGlass DS Cholangioscopy|ERCP with cholangiogram will be performed to assess the common bile duct (CBD) and intrahepatic ducts (IHD) for presence of a stricture. Once a biliary stricture is confirmed on cholangiogram during ERCP, SpyGlass DS Cholangioscopy would be performed. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy. Endoscopic stenting will be performed in standard fashion for biliary drainage to relieve the obstructive jaundice.
2891721|NCT03307356|Experimental|Uterine Transplantation|Women will undergo extensive medical and psychological screening. Five women that meet all inclusion and exclusion criteria will undergo ovarian stimulation, oocyte retrieval and will create embryos that will be stored for future use. Women will then undergo uterine transplantation from a deceased donor. Following transplant women will be closely monitored for complications (including infection and rejection). If no complications arise, or complications that do arise can be treated, attempts at pregnancy will begin approximately 12 months after transplant. Pregnancy in the setting of uterine transplant requires directly placing embryos directly into the uterus.
2891722|NCT03307343|Experimental|Intervention|The intervention will use behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts to target a 2-4 hour/day reduction in sedentary behavior.
2931311|NCT03031626|Experimental|Arm B: Oxygen followed by medical air|
2891723|NCT03307343|No Intervention|Control|Participants randomized to the control condition will receive no intervention during the study. After the 3-month assessment, control participants will be provided with a wrist-worn activity monitor and will be offered the 3-month delayed intervention if desired to aid in retention and recruitment.
2891724|NCT03307330||Obstructive Sleep Apnea|Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) >=5
2891725|NCT03307330||Non-Obstructive Sleep Apnea|Non-Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) < 5
2891726|NCT03307317||Group 1|60 typically developing infants, who will complete the imitation and neuroimaging paradigm between the ages of 9-12 months (+/- 2 weeks) and again at 12 months of age(+/- 2 weeks).
2891727|NCT03307317||Group 2|The second group includes 60 infants at increased risk for social communication disorders, including those with motor delay, language delay, preterm birth, or a sibling with an autism spectrum disorder.
2891728|NCT03307304||Patients|CLN3 participants
2891729|NCT03307278|Experimental|Steroid resistance in HDM allergic patients|
2891730|NCT03307278|Experimental|Steroid resistance in non HDM allergic subjects|
2891731|NCT03307265|Experimental|Imbalance correction|
2891732|NCT03307265|Active Comparator|Control|
2891733|NCT03307252|Experimental|Treatment Reference 1|
2891734|NCT03307252|Experimental|Treatment Reference 2|
2891735|NCT03307252|Experimental|Treatment Reference 3|
2891736|NCT03307252|Experimental|Treatment 1|
2891737|NCT03307252|Experimental|Treatment 2|
2891738|NCT03307252|Experimental|Treatment 3|
2891739|NCT03307252|Experimental|Treatment 4|
2891740|NCT03307252|Experimental|Treatment 5|
2891741|NCT03307252|Experimental|Treatment 6|
2891742|NCT03307239|Experimental|cold application (experimental group)|subjects in the experimental group (n = 30) received cold application of 600 g ice packs 15 minutes before CTR
2891743|NCT03307239|Sham Comparator|tap water packs application (sham group)|subjects in the sham group (n = 30) received tap water packs.
2891744|NCT03307226|Experimental|Youth Development Accounts (YDA)|"Youth Development Accounts (YDA)~Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development~Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)"
2891745|NCT03307226|Experimental|YDA + Multiple Family Groups (MFG)|"YDA + Multiple Family Groups (MFG)~Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development~Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs)~Multiple Family Groups sessions focused on strengthening family relationships and mental health"
2891746|NCT03307226|No Intervention|Usual Care|Usual Care consisting of curricula delivered at secondary schools in Uganda including Life Planning Skills, and Adolescent Sexual Reproductive Health
2891747|NCT03307213|Experimental|BioFreedom™CoCr|Patients with CAD will receive the BioFreedom™CoCr stent if randomised to this arm.
2891748|NCT03307213|Active Comparator|BioFreedom™ SS|Patients with CAD will receive the BioFreedom™SS stent if randomised to this arm.
2891749|NCT03307187|Experimental|GLB-AIM|GLB-AIM (Group Lifestyle Balance program, Adapted for individuals with Impaired Mobility) is a 12-month intervention that promotes 5% weight loss by reducing calories and increasing exercise (150 minutes of moderate physical activity). The 23 GLB-AIM sessions were delivered through monthly in-person and teleconference calls and participants were encouraged to self-monitor daily caloric/fat intake and physical activity using materials to accurately measure daily calories and exercise, which included a food scale, measuring cups and spoons and a loaned Garmin vívofit® activity tracker and heart rate monitor. Participants shared their logs with lifestyle coaches over the 13 core sessions and lifestyle coaches provided positive reinforcement, feedback, and problem solving techniques as needed.
2891750|NCT03307187|No Intervention|wait-list control|During the initial 6 month intervention period the control group received several contacts from the study staff via mail that included information on general health (e.g., managing stress, getting good sleep), holiday cards, and scheduling reminders for the 3 and 6 month testing.
2891751|NCT03307174|Active Comparator|Continuous epidural infusion|"At our institution, the most commonly utilized form of administration of medication through an epidural (our active comparator/control) is as follows:~Combination of 0.0625% bupivacaine with 2mcg/ml of fentanyl infused at a constant rate of 8ml/hr. The patient has the ability to self administer patient controlled epidural analgesia of 2ml of the epidural medication with a lock out period of 15 min. The total maximum volume of epidural medication each hour is 16ml. These settings are managed and controlled by a epidural medication pump.~Additional oral and intravenous analgesia medications are available as scheduled and pro re nata."
2891752|NCT03307174|Experimental|Programmed intermittent epidural bolus|"For the programmed intermittent epidural bolus group:~Combination of 0.0625% bupivacaine with 2mcg/ml of fentanyl will be administered as a bolus of 4ml every 30 minutes. The patient has the ability to self administer patient controlled epidural analgesia of 2ml of the epidural medication with a lock out period of 10 min. The total maximum volume of epidural medication each hour is 16ml. These settings are managed and controlled by a epidural medication pump.~Additional oral and intravenous analgesia medications are available as scheduled and pro re nata."
2891753|NCT03307161|Active Comparator|Parkinsons fwd posture manual treatment|Subject will receive the intervention, osteopathic manual treatment protocol.
2891754|NCT03307161|No Intervention|Parkinsons forward posture|Subjects will receive counseling.
2891755|NCT03307161|No Intervention|Parkinsons without forward posture|Subjects will receive counseling.
2891756|NCT03307148|Experimental|ATRA in combination with Gemcitabine and Nab-Paclitaxel|Patients will receive ATRA, Gemcitabine and nab-Paclitaxel in 28 day cycles. ATRA will be administered for 6 cycles whereas Gemcitabine/nab-Paclitaxel will be administered until disease progression.
2891757|NCT03307135|Experimental|Simple Assessment group|Intervention is a single evaluation with the MSPMI by two evaluators.
2891758|NCT03307135|Experimental|Hospitalization group|Evaluation with the MSPMI by two evaluators on two consultations separate by a 7 days interval.
2891759|NCT03307135|Experimental|Treatment group|Evaluation with the MSPMI by two evaluators before and after specific therapies proposed on our usual practices (Selective tibial neurotomy, anesthetic block or botulinum toxin intramuscular injection).
2891762|NCT03307109||Patients having prosthetic joint infection|The primary aim is to measure the evolution of quality of life in patients having prosthetic joint infection during their medical care and possibly psychologic assistance in the Infectious and Tropical Diseases Department of Croix-Rousse Hospital.
2891763|NCT03307096|Experimental|Microperc surgery|Patient is turned into prone position and the desired calyx is punctured by 4.8F microperc under fluoroscopic or sonographic guidance. No tract dilation is needed. A 200um holmium laser fiber will be used to break stone into less than 2mm. Pull out microperc without drainage tube left.
2891764|NCT03307096|Active Comparator|FURS|Patient is placed in the lithotomy position, pull out the pre-inserted double J, and place guidewire into the renal pelvis. A 12/14 Fr ureteral access sheath (UAS) is advanced into the proximal ureter over the guidewire, and flexible ureteroscope is passed through the UAS. The stones are fragmented smeller than 2mm using a 200um holmium laser fiber. Fragments are removed using a stone basket for stone analysis if necessary, a double J stent is placed at the conclusion of the procedure and removed post-operative 4 weeks.
2891765|NCT03307070|Active Comparator|Active Group|Participants who are randomized to begin the Cognitive Behavioral Therapy for individuals with TBI immediately after screening. This treatment is a version of Cognitive Behavioral Therapy (CBT) adapted specifically for patients who have experienced a moderate to severe Traumatic Brain Injury (TBI).
2891766|NCT03307070|Other|Waitlist Control|Participants who are randomized to be put on a waitlist after screening. After 12 weeks of being on the waitlist, participants will be offered the Cognitive Behavioral Therapy for individuals with TBI
2891767|NCT03307057|Experimental|Social Communication Growth Charts (SCGC)|Infants with a sibling who is diagnosed with ASD, who are randomized to receive the Social Communication Growth Charts (SCGC) intervention.
2891768|NCT03307057|No Intervention|Usual care|Infants with a sibling who is diagnosed with ASD, who are randomized to receive usual care.
2891769|NCT03307057|Experimental|Parent-Implemented (P-I) Condition|Participants showing early signs of ASD at 12 months of age, randomized to receive a parent-implemented (P-I) condition of a naturalistic developmental behavioral intervention (NDBI) based on the Early Social Interaction model.
2891770|NCT03307057|Experimental|Clinician-Implemented (C-I) Condition|Participants showing early signs of ASD at 12 months of age, randomized to receive a clinician-implemented (C-I) condition NDBI based on a hybrid model.
2891771|NCT03307044|Experimental|Treatment (fractional CO2 laser therapy)|Patients undergo fractional CO2 laser therapy every 4-6 weeks for 3 treatments.
2891772|NCT03307031|Experimental|High Volume Group|Performed four weekly sessions, during 10 weeks with 45 to 55 minutes per session.
2891773|NCT03307031|Experimental|Low Volume Group|Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
2891774|NCT03307031|Placebo Comparator|Control Group|Did not exercise, during 10 weeks.
2891775|NCT03307018|Experimental|Bronch|Postoperative systematic bronchial aspiration.
2891776|NCT03307018|No Intervention|Control|In this arm bronchial aspiration with bronchoscope will not be done.
2891777|NCT03307005|Experimental|Intervention|
2891778|NCT03307005|Placebo Comparator|Control|
2891779|NCT03306992|Experimental|Personalized Exercise Program|
2891780|NCT03306992|No Intervention|Standard of Care - No Exercise|
2891781|NCT03306979|Active Comparator|N-acetylcysteine|Participants randomized into the N-acetylcysteine arm will be receiving N-acetylcysteine for 24 weeks.
2891782|NCT03306979|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be receiving placebo for 24 weeks.
2891783|NCT03306966||Colon cancer patients|Patients with colon cancer (ascending colon) eligible for laparoscopic or open segmental colectomy.
2891784|NCT03306953|Active Comparator|Rectus muscle approximation|Three sutures will be done for the the purpose of rectus muscle approximation in cesarean section.
2891785|NCT03306953|No Intervention|Control|No approximation for the rectus muscle will be done for the control group in cesarean section.
2891786|NCT03306940|Placebo Comparator|unilateral injection group|Patients of unilateral group were injected botulinum toxin type A to the affected hemiface.
2891787|NCT03306940|Experimental|bilateral injection group|Patients of bilateral group were injected botulinum toxin type A to the affected hemiface and normal hemiface. The intervention of the bilateral group was that the normal side was injected.
2891788|NCT03306927|Experimental|Whole yellow pea|Chili containing 25g available carbohydrate from whole yellow peas. Intervention: Whole yellow pea chili
2891789|NCT03306927|Experimental|Split yellow pea|Chili containing 25g available carbohydrate from split yellow peas. Intervention: Split yellow pea chili
2891790|NCT03306927|Placebo Comparator|Rice-PPGR|Chili containing 25g available carbohydrate from long grain white rice. Intervention: Rice chili
2891791|NCT03306927|Placebo Comparator|Rice-Satiety|Rice chili with the same calories as the pea chili. Intervention: Rice chili
2891792|NCT03306914|Active Comparator|Albumin group|Albumin resuscitation Albumin 5%
2891793|NCT03306914|Experimental|Hydroxyethylstarch group|Hydroxyethylstarch resuscitation Hydroxyethylstarch 6%
2891794|NCT03306901|Experimental|Concurrent Chemoradiotherapy|"Patients receive 2 courses (every 3 weeks) of chemotherapy including cisplatin (45-60mg/m2) intravenously over 1 hour on day 1 and 5-fluorouracil (3,200 ~ 4,000mg/m2) intravenously for 4 to 5 days.~Patients receive a total of 45 Gy radiation therapy (5 days a week for 5 weeks)."
2891795|NCT03306901|Active Comparator|Esophagectomy|Patients receive surgical resection, including Ivor Lewis esophagectomy or McKeown esophagectomy and systematic lymphadenectomy.
2891796|NCT03306888|Experimental|Physical Activity Coaching Intervention|The intervention will entail one face-to-face coaching session (approximately 1 hour) to be held approximately 1 week following the baseline assessment, and three remote video sessions (via secure Webex connection via computer or smart phone, or phone call if internet/smart phone is not available to participant) lasting approximately 20 minutes.
2891797|NCT03306875|Experimental|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
2891798|NCT03306862|Experimental|Whole yellow pea|Soup containing 25g available carbohydrates from whole yellow peas. Intervention: Whole yellow pea soup
2891799|NCT03306862|Experimental|Split yellow pea|Soup containing 25g available carbohydrates from split yellow peas. Intervention: Split yellow pea soup
2891800|NCT03306862|Placebo Comparator|Potato|Soup containing 25g available carbohydrates from potatoes. Intervention: Potato soup
2891801|NCT03306849||Regular menstrual cycles|Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days). Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
2891802|NCT03306849||Normoandrogenic anovulation|Women will be assigned to this category if they do not have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
2891803|NCT03306849||Hyperandrogenic anovulation|Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
2891804|NCT03306836|Experimental|Standard dose group of Heparin Sodium|First infused with 5000 IU of Heparin Sodium, then continuous infusion at a rate of 18 IU / kg.h during the hybrid operation.
2891805|NCT03306836|Active Comparator|Low dose group of Heparin Sodium|infusion Heparin Sodium at a rate of 18 IU / kg.h during the hybrid operation.
2891806|NCT03306823||aneurysm|For cerebral aneurysm with hybrid operation, anticoagulation program is decided by different surgeons based on their experience and record the patient's intraoperative activated coagulation time changes in detail.
2891807|NCT03306823||arteriovenous malformations|For arteriovenous malformations with hybrid operation, anticoagulation program is decided by different surgeons based on their experience and record the patient's intraoperative activated coagulation time changes in detail.
2891808|NCT03306810|Active Comparator|AG service|"In the Active Comparator Arm: Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients in the Päijät-Häme Central hospital will be optimized and individualized in the patients in personal manner."
2891809|NCT03306810|No Intervention|Without AG service|"In the No intervention Arm: Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients follows the current protocol of Päijät-Häme Central hospital."
2891810|NCT03306797|Experimental|SONICHAND|The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises (4 weeks, daily)
2891811|NCT03306797|Other|STANDARD REHAB|The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training for 4 weeks (daily)
2891812|NCT03306771||Metabolic syndrome risk factors|Candidates for bariatric surgery who have metabolic syndrome risk factors will be evaluated by Ultrasound duplex before the bariatric surgery and 6,12 and 24 months post surgery for Intimal-Media Thickness and Carotid artery velocity
2891813|NCT03306771||No metabolic Syndrome risk factors|Candidates for bariatric surgery who lack metabolic syndrome risk factors will be evaluated by Ultrasound duplex before the bariatric surgery and 6,12 and 24 months post surgery for Intimal-Media Thickness and Carotid artery velocity
2891814|NCT03306758|Experimental|Experimental: sodium bicarbonate|
2891815|NCT03306758|No Intervention|No Intervention|
2891816|NCT03306745|Experimental|Study group|"1 soft capsule/day containing 500mg omega-3 fatty acids~one tablet/day containing 800mg folic acid, 70mg selenium, 30 mg Vitamin E, 4 mg catechin, 12 mg glycyrrhizin, and 30 mg coenzyme Q10"
2891817|NCT03306745|Placebo Comparator|Control group|200µg folic acid - two capsules per day
2891818|NCT03306732|Active Comparator|Thiamine group|
2891819|NCT03306732|Placebo Comparator|Placebo group|
2891820|NCT03306719||Study Group|The intervention group will be women with premature preterm rupture of membranes (pProm), suffering from IAI
2891821|NCT03306719||Control Group|Pregnant women without IAI
2891822|NCT03306706|Experimental|whole yellow pea|2 muffins containing 25g available carbohydrate from whole yellow peas. Intervention: Whole pea muffins
2891823|NCT03306706|Experimental|split yellow pea|2 muffins containing 25g available carbohydrate from split yellow peas. Intervention: Split pea muffins
2891824|NCT03306706|Placebo Comparator|wheat-PPGR|2 muffins containing 25g available carbohydrate from wheat flour. Intervention: Wheat muffins
2891825|NCT03306706|Placebo Comparator|wheat-satiety|"2 muffins containing wheat flour to match the calories in the whole and split pea muffins.~Intervention: Wheat muffins"
2891826|NCT03306693|Experimental|Emotional skills|3 group sessions where patients are going to learn how to identify, express and regulate their emotions
2891827|NCT03306693|Sham Comparator|Relaxation and talking group|3 group sessions where patients are going to follow relaxation instructions and after a non directive talking group about cancer
2891828|NCT03306680|Experimental|Patients with ultra-central NSCLC T1-3 (<6cm) N0 M0|"Level-1 Dose per fraction: 4Gy Number of fractions: 15 Total Dose: 60 Gy~Level 0 Dose per fraction: 6Gy Number of fractions: 10 Total Dose: 60 Gy~Level 1 Dose per fraction: 7.5 Gy Number of fractions: 8 Total Dose: 60 Gy~Level 2 Dose per fraction: 10 Gy Number of fractions: 6 Total Dose: 60 Gy~Level 3 Dose per fraction: 12 Gy Number of fractions: 5 Total Dose: 60 Gy"
2891829|NCT03306667|Experimental|Normal group|Healthy control subjects
2891830|NCT03306667|Experimental|Mild hepatic-insufficient group|Patients with mild hepatic impaired function (Child-Pugh A)
2891831|NCT03306667|Experimental|Moderate hepatic-insufficient group|Patients with moderate hepatic impaired function (Child-Pugh B)
2891832|NCT03306667|Experimental|Severe hepatic-insufficient group|Patients with severe hepatic impaired function (Child-Pugh C)
2891833|NCT03306654|Active Comparator|Unchanged Happify|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
2891834|NCT03306654|Placebo Comparator|Active control|Participants complete a Happify program that is designed to engage with specific activities, but that does not aim to promote positive emotion or reduce negative emotion. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
2891994|NCT03305588|Experimental|130 Gy Radiation & Unframed Virtual Cone|130 Gy Virtual Cone Radiosurgery Unframed (Face Mask)
2891835|NCT03306654|Sham Comparator|Distraction condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
2891836|NCT03306628|Experimental|Early Laser Therapy|a group which will receive laser therapy to one breast incision at the first post-operative visit
2891837|NCT03306628|Experimental|Late Laser Therapy|a group which will receive laser therapy to one breast incision 6 weeks after surgery
2891838|NCT03306615|Experimental|Treatment Arm|Hyaluronidase plus saline
2891839|NCT03306615|Placebo Comparator|Control Arm|Normal Saline
2891840|NCT03306602|Experimental|Bulk Fill Composite|In the experimental cavity, Filtek Bulk Fill Posterior Restorative (3M ESPE) will be placed in 5 mm increments, eliminating the need for additional layers or multiple steps.
2891841|NCT03306602|Active Comparator|Layered Composite|The control restoration will be filled with Filtek Z350 XT (3M ESPE) using the 2 mm incremental layering technique.
2891842|NCT03306589|Experimental|Subjects receiving LPS: Part I and Part II|Eligible subjects will be randomized to receive LPS in a dose-escalation manner ranging from 0.5 nanogram (ng)/kg to 4 ng/kg. Subjects will be hydrated prior to administration of LPS with normal saline at a rate of 250 mL/hour for 4 hours prior to dosing and 8 hours after dosing.
2891843|NCT03306589|Experimental|Subjects receiving GM-CSF: Part I and Part II|Eligible subjects will be randomized to receive GM-CSF in a dose-escalation manner ranging from 5 to 15 microgram (µg)/kg.
2891844|NCT03306576|Experimental|ELS Extra composite|Commercially available composite resin restorative that will be used for direct restoration as per manufacturer's instructions
2891845|NCT03306576|Active Comparator|ELS composite|Commercially available composite resin restorative that will be used for direct restoration as per manufacturer's instructions
2891846|NCT03306563|Experimental|Patients with suspected TBI|The group will consist of patients who have arrived in the hospital with head injury and suspected isolated TBI. Sample collection (up to five times) and assessment of neurological status.
2891847|NCT03306563|Active Comparator|Orthopedic patients|The group will consist of patients with orthopedic injury, but without a head injury and suspected TBI. Sample collection (once).
2891848|NCT03306563|Sham Comparator|Controls|The group will consist of healthy controls who do not have a recent trauma history. Sample collection (once).
2891849|NCT03306550|Active Comparator|aspirin arm|only take aspirin (100mg,qd) orally for 10 days treatment course
2891850|NCT03306550|Active Comparator|salvianolate injection arm|only inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course
2891851|NCT03306550|Experimental|aspirin and salvianolate injection arm|take aspirin (100mg,qd) orally and inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course
2891852|NCT03306524|Experimental|SIPPV_VG_0_08|SIPPV VG ventilation for 15 minutes slope time = 0.08 seconds inspiratory time = 0.40 seconds
2891853|NCT03306524|Experimental|PSV_VG_0_08|PSV VG ventilation for 15 minutes slope time = 0.08 seconds maximum inspiratory time = 0.60 seconds
2891854|NCT03306524|Experimental|SIPPV_VG_0_16|SIPPV VG ventilation for 15 minutes slope time = 0.16 seconds inspiratory time = 0.40 seconds
2891855|NCT03306524|Experimental|PSV_VG_0_16|PSV VG ventilation for 15 minutes slope time = 0.16 seconds maximum inspiratory time = 0.60 seconds
2891856|NCT03306524|Experimental|SIPPV_VG_0_24|SIPPV VG ventilation for 15 minutes slope time = 0.24 seconds inspiratory time = 0.40 seconds
2891857|NCT03306524|Experimental|PSV_VG_0_24|PSV VG ventilation for 15 minutes slope time = 0.24 seconds maximum inspiratory time = 0.60 seconds
2891858|NCT03306524|Experimental|SIPPV_VG_0_32|SIPPV VG ventilation for 15 minutes slope time = 0.32 seconds inspiratory time = 0.40 seconds
2891859|NCT03306524|Experimental|PSV_VG_0_32|PSV VG ventilation for 15 minutes slope time = 0.32 seconds maximum inspiratory time = 0.60 seconds
2891860|NCT03306524|Experimental|SIPPV_VG_0_40|SIPPV VG ventilation for 15 minutes slope time = 0.32 seconds inspiratory time = 0.40 seconds
2891861|NCT03306524|Experimental|PSV_VG_0_40|PSV VG ventilation for 15 minutes slope time = 0.40 seconds maximum inspiratory time = 0.60 seconds
2891862|NCT03306511||Case|Football players with a previous self-reported hamstring strain injury in the preceding 12 months
2891863|NCT03306511||Control|Football players without a previous self-reported hamstring strain injury in the preceding 12 months
2891864|NCT03306498||hepatic encephalopathy patients|The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d for 3 days
2891865|NCT03306498||hepatic encephalopathy patients-amino|The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d plus Aminoleban (8% amino acids infusion) b.i.d for 3 days
2891866|NCT03306485||Patients with GERD symptoms refractory to PPI therapy|"Patients with proven GERD (gastro-esophageal reflux disease) off PPI (proton pump inhibitor) (Los Angeles grade B, C or D esophagitis and/or esophageal acid exposure > 5% on pH monitoring performed off PPI).~These patients have persistent heartburn and/or regurgitation despite double dose proton pump inhibitor. Patients are referred for esophageal high resolution impedance manometry and ambulatory 24-h pH-impedance monitoring on proton pump inhibitor."
2891867|NCT03306472|Active Comparator|Arm A: Letrozole|Arm A: 15 days of Letrozole 2.5mg daily
2891868|NCT03306472|Experimental|Arm B: Letrozole + Megestrol Acetate (40mg)|Arm B: 15 days of Letrozole 2.5mg daily + Megestrol acetate 40mg daily
2891869|NCT03306472|Experimental|Arm C: Letrozole + Megestrol Acetate (160mg)|Arm C: 15 days of Letrozole 2.5mg daily + Megestrol acetate 160mg daily.
2891870|NCT03306459||1/PCOS|The authors will select 30 PCOS patients who met the more strict and conservative Rotterdam diagnostic criteria (Rotterdam phenotype A) which include the presence of oligo-anovulation (cycles lasting >35 days or amenorrhea) and hyperandrogenemia /hyperandrogenism (hirsutism or obvious acne or pronounced alopecia). All patients should have bilateral polycystic ovaries morphology on ultrasound. Additionally, the authors have decided to enroll PCOS patients that are all without pregnancy desire at the moment they fill out the questionnaires, in order to control for the potential confounding role of infertility on psychological outcomes. Different pituitary, adrenal, ovarian, thyroid or metabolic diseases will be excluded
2894260|NCT03289260|Placebo Comparator|Placebo Arm|Placebo cream therapy Fulguration
2891871|NCT03306459||2/CONTROL|The authors will enroll a control group of 30 women, age- matched with the PCOS women, from consecutive women controlled in the same outpatient clinic who met the following inclusion criteria: history of irregular menstrual cycle in absence of severe gynecologic and non-gynecologic diseases. This PCOS sample will be entirely constituted by women with no pregnancy desire; therefore, with the aim to limit the potential effect of the unfulfilled wish to conceive in the final results; additionally, infertile women will not admitted into the control group.
2891872|NCT03306446|Experimental|Adalimumab in monotherapy|Start Adalimumab in monotherapy at 160 mg at inclusion, 80 mg on 2nd week and 40 mg/week each other week over 12 months.
2891873|NCT03306433|Experimental|UDMA-K18|UDMA-K18 smooth surface sealant
2891874|NCT03306433|Placebo Comparator|UDMA-control|UDMA smooth surface sealant without K18
2891875|NCT03306433|No Intervention|Negative control|No intervention to provide baseline
2891876|NCT03306420|Experimental|Part IA (Dose Escalation): MS201408-0005A Monotherapy|
2891877|NCT03306420|Experimental|Part IB (Dose Escalation): MS201408-0005A + MS201408-0005C|
2891878|NCT03306420|Experimental|Part IC (Dose Escalation): MS201408-0005A + MS201408-0005B|
2891879|NCT03306407|No Intervention|Baseline Group|Group screened for colonization with ESBL-producing Enterobacteriaceae pre- and post-travel after having received standard pre-travel advice
2891880|NCT03306407|Active Comparator|Intervention Group|Group screened for colonization with ESBL-producing Enterobacteriaceae pre- and post-travel after having received pre-travel advice with special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
2891881|NCT03306394|Experimental|S95005|Film-coated tablet containing 15 mg of trifluridine and 7.065 mg of tipiracil hydrochloride, or 20 mg of trifluridine and 9.42 mg of tipiracil hydrochloride, taken orally twice a day at the dose of 35 mg/m²/dose. The treatment is given until progression of disease, unacceptable toxicity, investigator decision, patient refusal or until market authorization or reimbursement has been granted by the relevant Authority of the country where that patient is treated or until trifluridine / tipiracil is available by a doctor's prescription or can be accessed from another source or Sponsor decision.
2891882|NCT03306381|Experimental|Dietary intervention subject group|n=130. Participants on low FODMAP-similar diet during 4-week study period.
2891883|NCT03306381|No Intervention|Control group|n=20. Participants on traditional IBS diet during 4-week study period.
2891884|NCT03306368|No Intervention|Treatment as Usual (TAU)|Participants receiving treatment as usual post-residential detox. TAU clinic-based treatment receiving standard clinic-based XR-NTX.
2891885|NCT03306368|Experimental|Youth Opioid Recovery Support (YORS)|"Youth Opioid Recovery Support consists of the following component:~Home delivery of XR-NTX, family framework, assertive continuing care incorporates outreach, home delivery of evidence based psychosocial treatment and case management in a model that specifically targets engagement and motivation in youth, contingency management."
2891886|NCT03306355|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
2891887|NCT03306355|Active Comparator|IOL implantation active comparator|hydrophilic, trifocal intraocular lens POD F
2891888|NCT03306342|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
2891889|NCT03306329|Experimental|DNS-7801 (low-dose)|
2891890|NCT03306329|Experimental|DNS-7801 (high-dose)|
2891891|NCT03306329|Placebo Comparator|Placebo|
2891892|NCT03306316|Experimental|Experimental|Experimental Arm
2891893|NCT03306316|Placebo Comparator|Control|Placebo Control Arm
2891894|NCT03306303||Quartile 1 of plasma melatonin|Quartile 1 of plasma melatonin
2891895|NCT03306303||Quartile 2 of plasma melatonin|Quartile 2 of plasma melatonin
2891896|NCT03306303||Quartile 3 of plasma melatonin|Quartile 3 of plasma melatonin
2891897|NCT03306303||Quartile 4 of plasma melatonin|Quartile 4 of plasma melatonin
2891898|NCT03306290|Other|Bariatric surgery candidate|"Patients included in this study belong to this arm and put up with intervention Serum dosage of antibiotic prophylaxis CEFOXITIN"
2891899|NCT03306277|Experimental|AVXS-101|one-time Intravenous administration of AVXS-101 at the therapeutic dose
2891900|NCT03306264|Experimental|ASTX727|ASTX727 (cedazuridine + decitabine) - Cycle 1 or Cycle 2 (crossover)
2891901|NCT03306264|Active Comparator|IV decitabine|Dacogen (decitabine for injection) - Cycle 1 or Cycle 2 (crossover)
2891902|NCT03306238|Active Comparator|Open/Hasson|This group will undergo initial laparoscopic port insertion by the open or Hasson approach and then undergo the remaining laparoscopic surgery as usual
2891903|NCT03306238|Active Comparator|Closed/ Veress|This group will undergo initial laparoscopic port insertion by the closed or Veress approach and then undergo the remaining laparoscopic surgery as usual
2891904|NCT03306212|Experimental|Casting Group|Patients treated by botulinum toxin A and occupational therapy and intermittent serial casting
2891905|NCT03306212|Active Comparator|Control Group|Patients treated by botulinum toxin A and occupational therapy
2891906|NCT03306186|Experimental|HemoSpec|Diagnosis of sepsis using HemoSpec device
2891907|NCT03306173|Experimental|Ventilated cigarettes|Participants in this ARM will be assigned to ~25% filter ventilation commercially available cigarettes.
2891908|NCT03306173|Experimental|Unventilated cigarettes|Participants in this ARM will be assigned to ~0% filter ventilation commercially available cigarettes.
2891909|NCT03306147|Experimental|Chronic pain or long-acting opioid use|Education of pain and promotion of adjunct and non-pharmacologic alternative therapies will be completed to engage patients in assessing their pain and seeing the effectiveness of their treatment. Patients will receive 3 follow-up interventions: 2 phone calls with a pharmacist or student pharmacist at weeks 2 and 6, and a follow-up visit with a pain or primary care physician.
2891910|NCT03306134||BETA-BLOCKERS|Patients taking beta-blockers with or without dysphagia
2891911|NCT03306134||NO BETA-BLOCKERS|Patients not taking beta-blockers with or without dysphagia
2891912|NCT03306121|Experimental|TPF+CCRT|Patients receive induction chemotherapy with paclitaxel liposome (135mg/m2 on day 1) ,cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) .
2891913|NCT03306121|Active Comparator|CCRT+ PF|Patients receive concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) , then followed by three cycles of adjuvant chemotherapy with cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles four weeks after radiotherapy.
2891914|NCT03306095||Early refeeding group|Food Intake by patient with in 4 hours i.e <4 hours after the EVL procedure
2891915|NCT03306095||Delayed refeeding group|Food Intake by patient with in 4 hours i.e > 4 hours after the EVL procedure
2891916|NCT03306082|Experimental|Image-guided Cochlear Implant Programming (IGCIP)|Cochlear implant programming using IGCIP.
2891917|NCT03306069|Experimental|Control|Nutritional therapy / no exercise
2891918|NCT03306069|Experimental|HIIT|High-intensity interval training (HIIT) at 90% heart rate maximum (HRmax) combined with Nutritional therapy
2891919|NCT03306069|Experimental|MIIT-HR|Heart rate based moderate-intensity interval training (MIIT-HR) at 70% heart rate maximum (HRmax) combined with Nutritional therapy
2891920|NCT03306069|Experimental|MIIT-LT|Lactate threshold based moderate-intensity interval training (MIIT-LT) at 105% of lactate threshold (corresponding ~70-75% HRmax) combined with Nutritional therapy
2891921|NCT03306056|Experimental|Control|Nutritional therapy / no exercise
2891922|NCT03306056|Experimental|Standard Strength Training|Nutritional therapy combined with a Standard Strength Training program
2891923|NCT03306056|Experimental|Low-volume Strength Training|Nutritional therapy combined with a low-volume Strength Training program
2891924|NCT03306056|Experimental|Whole-body Electromyostimulation|Nutritional therapy combined with Whole-Body Electromyostimulation
2891925|NCT03306043|Experimental|Subjects who received mepolizumab|Subjects who were part of study 200622 and were randomized to receive either placebo or mepolizumab will be enrolled in this study as per study eligibility criteria. In this study, subjects will receive 300 mg of mepolizumab SC (three 100 mg SC injections) every 4 Weeks for a total of 5 doses during 20-Week treatment period.
2891926|NCT03306030|Active Comparator|Split group|Split-dose of 4l PEG was used before and on the day of colonoscopy
2891927|NCT03306030|Experimental|Three times group|Three times-dose of 4l PEG was used before and on the day of colonoscop of 4l PEG was used before and on the day of colonoscopy
2891928|NCT03306017|Experimental|LAVD implantation|Ten patients before and after LAVD implantation had blood sampling
2891929|NCT03306004||Health Care Providers|Providers answer questionaires
2891930|NCT03306004||Mothers|Mothers answer questionaires
2891931|NCT03305978|Experimental|Ultra low dose chest CT|
2891932|NCT03305978|Active Comparator|Low dose chest CT|
2891933|NCT03305965|Experimental|Patient navigation|
2891934|NCT03305965|No Intervention|Care as usual|
2891935|NCT03305952|Experimental|Compassion|CBCT was facilitated in an eight weekly, 2-h sessions format through didactics, class discussion, and guided meditation practice. Topics covered in order were: Week 1: Developing attention stability and mental clarity. Week 2. Open awareness of sensations, feelings, and emotions. Week 3: Self-Compassion. Week 4: Practice in impartiality and cultivation of social connection. Week 5: Practice in appreciation, gratitude, social interconnection, and interdependence. Session 6: Practice in affection (endearment) for developing undifferentiated affection for others. Week 7: Development of the aspirational wish that all beings be happy and free from suffering and its causes. Week 8: Active compassion
2891936|NCT03305952|Active Comparator|Treatment as usual|Treatment as usual (TAU) consisted of usual periodical visits to psycho oncologist based on hospital's regular calendar. Hospital's standard treatment was applied to participants. The standard treatment consists of counselling interventions, cognitive-behavioural interventions, family interventions, third generation interventions.
2891937|NCT03305939|Experimental|Intervention|Intervention group will be selected by randomization and we receive all the intervention contents according to the protocol ,such as group sessions, monthly phone calls ,text/ SMSs and also receive 6 monthly Follow ups.
2891938|NCT03305939|No Intervention|Control|Control group participants will be selected by randomization and will be referred to their usual doctor for ongoing management, with no attempt made to influence this. They will not get any part of the intervention but will receive the usual care (if exists). Any abnormal OGTT results during follow up will be provided to the patient and their doctor.This is entirely consistent with current usual care.
2891939|NCT03305926|Active Comparator|Conventional CVR|
2891940|NCT03305926|Experimental|eCVR|
2891941|NCT03305913|Experimental|Dose Level 1|TAS-102 25 mg/m2 BID (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)
2891942|NCT03305913|Experimental|Dose Level 2|TAS-102 35 mg/m2 BID (days 1-5 and 8‑12), Regorafenib 120 mg daily (3 weeks on, 1 week off)
2891943|NCT03305913|Experimental|Dose Level 3|TAS-102 35 mg/m2 BID, (days 1-5 and 8‑12) Regorafenib 160 mg daily (3 weeks on, 1 week off)
2891944|NCT03305913|Experimental|Dose Level -1a|TAS-102 25 mg/m2 BID, (days 1-5 and 8‑12) Regorafenib 80 mg daily (3 weeks on, 1 week off)
2891945|NCT03305913|Experimental|Dose Level -1b|TAS-102 35 mg/m2 BID, (days 1-5 and 8‑12) Regorafenib 80 mg daily (3 weeks on, 1 week off)
2891946|NCT03305913|Experimental|Dose Level -2a|TAS-102 30 mg/m2 BID (or 35 mg/m2 a.m. and 25 mg/m2 p.m.), (days 1-5 and 8‑12) Regorafenib 120 mg daily (3 weeks on, 1 week off)
2891947|NCT03305887|Experimental|Barbed suture group|The deep layer and the intermediate layer will be repaired and closed by using one STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue suture respectively. STRATAFIX Spiral PGA-PCL sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation.
2891948|NCT03305887|Active Comparator|Conventional suture group|CR8 VICRYL® PLUS sutures will be used to close the deep and the intermediate layers with interrupted suturing manner. STRATAFIX Spiral PGA-PCL sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation.
2891995|NCT03305575|Experimental|Chloroprocaine|Patients assigned to chlorprocaine will receive a single spinal injection of 40 mg of chloroprocaine PF. (other name: pure Nesacaine MPF 3% in a total volume of 2ml)
2891996|NCT03305575|Active Comparator|Bupivacaine|Patients assigned to bupivacaine will receive a single spinal injection of 7.5 mg of bupivacaine. (other name: pure Sensorcaine 0.75% diluted with normal saline to a total volume of 2ml).
2891949|NCT03305874||Study Group|Prospectively, inpatients undergoing percutaneous coronary intervention (PCI) will be consented, and the computer-based contrast induced nephropathy (CBCIN) risk score will be calculated and displayed to the operator, along with suggested standard CIN-avoidance strategies during the PCI. Following the PCI, serum creatinine will be measured as per treating physician, but those who undergo at least two consecutive daily serum creatinine measurements starting the day after the procedure will be included in the study. These patients will be called 6 months and 12 months post-procedure to determine mortality and re-hospitalization status.
2891950|NCT03305874||Comparator Group|Retrospectively, inpatients who underwent PCI and had at least two consecutive daily serum creatinine measurements will be selected. These patients will then be matched to the prospective patients, and matched by age and gender. Baseline CBCIN score will be calculated and other demographic and outcomes information will be obtained from medical records review.
2891951|NCT03305861|Active Comparator|HoLEP|Holmium laser enucleation of prostate
2891952|NCT03305861|Experimental|ThuLEP|Thulium laser enucleation of prostate
2891953|NCT03305861|Experimental|Green LEP|Greenlight laser enucleation of prostate
2891954|NCT03305848|Other|Oral nitroglycerin solution|Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes
2891955|NCT03305822|Experimental|LY900014|Single, subcutaneous (SC) dose of LY900014 in one of two study periods
2891956|NCT03305822|Active Comparator|Insulin Lispro (Humalog)|Single SC dose of insulin lispro (Humalog) in one of two study periods
2891957|NCT03305809|Experimental|LY3154207 High Dose|LY3154207 administered orally.
2891958|NCT03305809|Experimental|LY3154207 Mid Dose|LY3154207 administered orally.
2891959|NCT03305809|Experimental|LY3154207 Low Dose|LY3154207 administered orally.
2891960|NCT03305809|Placebo Comparator|Placebo|Placebo administered orally.
2891961|NCT03305783||Patients having cholecystectomy|Healthy, normal weight patients (BMI<27) undergoing elective cholecystectomy will have a meal test performed before and after surgery.
2891962|NCT03305783||Healthy controls|Healthy matched controls will have one meal test performed.
2891963|NCT03305757|Active Comparator|conventional wound closure|The skin flaps will not undergo further treatment in this group.
2891964|NCT03305757|Experimental|flap fixation with vicryl sutures|The skin flaps will be sutured on to the pectoral muscle after having performed the mastectomy.
2891965|NCT03305757|Experimental|Artiss tissue glue|ARTISS tissue glue will be applied to the skin flaps after mastectomy
2891966|NCT03305744||Endurance Athlete with Atrial Fibrillation|These are middle-aged athletes who are diagnosed with paroxysmal Atrial Fibrillation in the last 4 years, but are otherwise free of disease.
2891967|NCT03305744||Endurance Athlete without Atrial Fibrillation|These are middle-aged athletes who will serve as our control group- they have not been diagnosed with AF or any other disease.
2891968|NCT03305731|Experimental|Activating Behavior for Lasting Engagement|Participants will engage in the ABLE intervention.
2891969|NCT03305718|Experimental|Meal sequence: 3C1A2B4D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 3C1A2B4D."
2891970|NCT03305718|Experimental|Meal sequence: 2A3D4C1B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2A3D4C1B."
2891971|NCT03305718|Experimental|Meal sequence: 2D4B3A1C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2D4B3A1C."
2891972|NCT03305718|Experimental|Meal sequence: 3B2C1D4A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 3B2C1D4A."
2891973|NCT03305718|Experimental|Meal sequence: 4C2B1A3D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 4C2B1A3D."
2891997|NCT03305562||Retrospective cohort|The cohort of patients seen prior to the implementation of a standardized clinical management protocol on 10/01/2017 whose data is collected retrospectively.
2932498|NCT03023397|Other|Der f treated E-cig user|
2891974|NCT03305718|Experimental|Meal sequence:1B4D3C2A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 1B4D3C2A."
2891975|NCT03305718|Experimental|Meal sequence:4A1C2D3B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 4A1C2D3B."
2891976|NCT03305718|Experimental|Meal sequence:1D3A4B2C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 1D3A4B2C."
2891977|NCT03305718|Experimental|Meal sequence: 4D3B2C1A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 4D3B2C1A."
2891978|NCT03305718|Experimental|Meal sequence: 3A4C1B2D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 3A4C1B2D."
2891979|NCT03305718|Experimental|Meal sequence: 1C2A3D4B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 1C2A3D4B."
2891980|NCT03305718|Experimental|Meal sequence: 2B1D4A3C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2B1D4A3C."
2891981|NCT03305705|Experimental|Treatment Arm 1|Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.
2891982|NCT03305705|Experimental|Treatment Arm 2|Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.
2891983|NCT03305692|Experimental|ECG Belt|Use ECG Belt body surface mapping system to optimize CRT programming.
2891984|NCT03305692|Experimental|Echocardiography|Use mitral inflow echocardiography to optimize CRT programming.
2891985|NCT03305679|Experimental|Direct provisional technique|Patients here will be subjected to the direct provisional technique
2891986|NCT03305679|Active Comparator|Indirect Provisional technique|Patients here will be subjected to the indirect provisional technique
2891987|NCT03305666|Active Comparator|Bupivacaine indwelling catheter|Bupivacaine indwelling OnQ pain pump catheter will be placed in the subscapular space at the time of surgery, at infusion of 12 ml/hr of 0.25% bupivacaine, and left in place for a maximum of 120 hours
2891988|NCT03305666|Active Comparator|Liposomal bupivacaine injection|A single injection of liposomal bupivacaine: mixture of 20 mL liposomal bupivacaine, 20 mL 0.25% bupivacaine, and 10 mL sterile saline (50 mL total), will be delivered in the intercostal space during VATS (with a 178 mm, 22 gauge needle, at ribs 3-8).
2891989|NCT03305653|Experimental|Current/historical diagnosis of EoE|Subjects with current or historical diagnosis of EoE, or suspected of having EoE will complete the Esophageal String Test (EST) and EndoFLIP
2891990|NCT03305627|Experimental|Short PAP|Perioperative antibiotic prophylaxis will be stopped after 24h
2891991|NCT03305627|Active Comparator|Extended PAP|Perioperative antibiotic prophylaxes will be continued for 48h or more (until all indwelling urinary catheters have been removed)
2891992|NCT03305614|Active Comparator|Aphasia therapy and tDCS|
2891993|NCT03305614|Sham Comparator|Aphasia therapy and sham-tDCS|
2892033|NCT03305406||Interview Participants|One-on-one interviews
2891998|NCT03305562||Prospective cohort|The cohort of patients seen initially seen after implementation of a standardized clinical management protocol on 10/01/2017 whose data is collected prospectively.
2891999|NCT03305549|Active Comparator|TIW Dialysis Strategy|Conventional thrice-weekly acute intermittent hemodialysis treatment schedule.
2892000|NCT03305549|Experimental|Conservative Dialysis Strategy|Conservative acute intermittent hemodialysis strategy, in which hemodialysis is not continued unless specific metabolic or clinical indications for RRT are present.
2892001|NCT03305536|Active Comparator|Interventional|1000 mcg/day of Vitamin K2 + 5000 IU/day Vitamin D3 as a treatment to decalcifiy the valve
2892002|NCT03305536|Active Comparator|interventional|5000 IU/day of Vitamin D3 will be given to measure the progression of the disease along the time of the study
2892003|NCT03305523|Experimental|Thermocautery|Circumcision with thermocautery technique was applied all participants
2892004|NCT03305510||Vitamin D deficiency|The level of vitamin D is below 20ng/ml.
2892005|NCT03305510||Vitamin D insufficient|The level of vitamin D is between 20ng/ml and 30ng/ml.
2892006|NCT03305510||Vitamin D sufficient|The level of vitamin D is above 30ng/ml.
2892007|NCT03305484||Symptomatic Contact Lens Wearers|Contact lens wearers who present to the eye care practitioner's office with a symptomatic red eye
2892008|NCT03305471|Experimental|Part A: DS-2330b PIB, then Tablet|On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b PIB [Treatment A1] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b in tablet form [Treatment A2] right after breakfast.
2892009|NCT03305471|Experimental|Part A: DS-2330b Tablet, then PIB|On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b in tablet form [Treatment A2] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b PIB [Treatment A1] right after breakfast.
2892010|NCT03305471|Placebo Comparator|Part B: Placebo|Participants are given placebo three times daily [Treatment B1]
2892011|NCT03305471|Experimental|Part B: DS-2330b PIB|Participants are given 400 mg of DS-2330b PIB three times daily [Treatment B2]
2892012|NCT03305471|Experimental|Part B: DS-2330b PIB + Sevelamer|Participants are given 400 mg of DS-2330b PIB along with 1.6 grams of sevelamer three times daily [Treatment B3]
2892013|NCT03305471|Experimental|Part B: Placebo + Sevelamer|Participants are given placebo along with 1.6 grams of sevelamer three times daily [Treatment B4]
2892014|NCT03305471|Experimental|Part C: DS-2330b Tablet + Sevelamer|Participants are given one 250 mg dose of DS-2330b in tablet form along with 1.6 grams of sevelamer three times daily [Treatment C]
2892015|NCT03305458|Active Comparator|Treatment as usual|Trauma Focused Cognitive Behavioral Therapy
2892016|NCT03305458|Experimental|Tablet-Facilitated TF-CBT|Standard treatment with the addition of in-treatment/session iPad activities
2892017|NCT03305445|Experimental|Pts with Diffuse Large B Cell Lymphoma|"Patients with DLBCL not eligible for autologous stem cell transplant. All patients will receive dual checkpoint blocking antibody (DCBA) therapy of ipilimumab and nivolumab given at three week intervals, two times before, and two times following immunotransplant in which T cells (in whole PBMCs) are cryopreserved and re-infused (adoptive T cell transfer or ATCT) following lymphodepleting chemotherapy regimen, currently being employed in adoptive T cell therapies."
2892018|NCT03305432|Experimental|PPI group|take preoperative PPI for 10 days
2892019|NCT03305432|Active Comparator|Control group|take placebo for for 10 days preoperative
2892020|NCT03305419|Experimental|Subjects receiving treatment sequence ABC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence ABC in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
2892021|NCT03305419|Experimental|Subjects receiving treatment sequence ABP in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence ABP in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and P= Placebo. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
2892022|NCT03305419|Experimental|Subjects receiving treatment sequence APC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence APC in Part A; A= GSK2982772 120 mg TID, P= Placebo and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
2892023|NCT03305419|Experimental|Subjects receiving treatment sequence PBC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence PBC in Part A; P= Placebo, B= GSK2982772 240 mg TID and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
2892024|NCT03305419|Experimental|Subjects receiving GSK2982772 120 mg TID in cohort 2 : Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
2892025|NCT03305419|Experimental|Subjects receiving GSK2982772 120 mg TID in cohort 3 : Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
2892026|NCT03305419|Experimental|Subjects receiving GSK2982772 240 mg TID in cohort 4: Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 240 mg TID for 14 days in Part B.
2892027|NCT03305419|Experimental|Subjects receiving GSK2982772 360 mg BID in cohort 5: Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 360 mg BID for 14 days in Part B.
2892028|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 2 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
2892029|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 3 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
2892030|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 4 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
2892031|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 5: Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
2892032|NCT03305406||Focus Group Participants|Semi-structured focus groups
2892034|NCT03305393|Other|Adaptiv CRT|Adaptiv CRT algorithm in Medtronic FDA approved CRT devices to be programmed as ON at 6 month follow-up visit
2892035|NCT03305380||Patients with a pulmonary event|(under anti-PD1 or anti-PD-L1) This is the first group of the retrospective part of the study.
2892036|NCT03305380||Patients without a pulmonary event|(under anti-PD1 or anti-PD-L1) This is the second group of the retrospective part of the study.
2892037|NCT03305367|No Intervention|Screening/Baseline|A standard OGTT with no supplementation/intervention
2892038|NCT03305367|Experimental|Hydrolyzed pine nut oil low dose|Standard OGTT supplemented with 3 g of hydrolyzed pine nut oil
2892039|NCT03305367|Experimental|Hydrolyzed pine nut oil high dose|Standard OGTT supplemented with 6 g of hydrolyzed pine nut oil
2892040|NCT03305354|Experimental|CBTI app intervention|Cognitive Behavioral Therapy for Insomnia delivered for 6 weeks via the CBT-I Coach app with use guided by a self-management guide
2892041|NCT03305354|Active Comparator|CBTI app+Physical Activity Intervention|Cognitive Behavioral Therapy for Insomnia delivered for 6 weeks via the CBT-I Coach app with use guided by a self-management guide plus self-management guidance on increased step counts
2892042|NCT03305341|Experimental|Etoposide IV + Methotrexate IV - usual|"Combined Chemotherapy - usual group~Etoposide Injection plus Methotrexate Injection"
2892043|NCT03305341|Experimental|Etoposide OS + Methotrexate OS - study|"Combined Chemotherapy - study group~Etoposide Capsule plus Methotrexate Tablet"
2892044|NCT03305328|Experimental|Active|Participants within the Active condition receive 30 minutes of alpha-frequency Transcranial Alternating Current Stimulation (tACS) stimulation for four consecutive days. Participants are stimulated at their baseline peak alpha frequency, or the frequency at which they exhibit maximal power within the 8 to 12 Hz range. Stimulation was administered over occipitoparietal sites, where tACS current models showed maximal effect over the dorsal extrastriate.
2892045|NCT03305328|Sham Comparator|Sham Control|Participants within the Sham condition receive 30 minutes of sham Transcranial Alternating Current Stimulation for four consecutive days, during which no current was passed. To control for awareness of the Sham stimulation, all Sham control participants receive a brief, 10 second pulse of random noise stimulation at the beginning and end of the 30 minutes.
2892046|NCT03305315||Cases|Diseases of the temporomandibular joint
2892047|NCT03305315||Controls|Asymptomatic subjects
2892048|NCT03305289|Active Comparator|pulsed radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then pulsed radiofrequency will be applied for 10 patients for 10 mins
2892049|NCT03305289|Active Comparator|thermal Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then Thermal lesion will be applied for 10 patients for 2 cycles of 90 seconds
2892050|NCT03305276||general population|the study is open to all population, (14-90 years, male/female) to verify the impact of lifestyles (mediterranean style) on intermediate and hard endpoint.
2892051|NCT03305263|Experimental|Hydroxychlorochine HCQ|Women in the experimental arm will take 200 mg HCQ tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
2892052|NCT03305263|Placebo Comparator|Hydroxychlorochine HCQ Placebo|Women in the experimental arm will take 200 mg HCQ placebo tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
2892053|NCT03305250|Active Comparator|Interventional Arm|Using an Implantable Loop Recorder fo continuous rhythm monitoring and home follow-up. This will be combined with standard care procedure, which will include annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
2892054|NCT03305250|No Intervention|Standard of Care Arm|The standard of care with annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
2892055|NCT03305237|Experimental|big breakfast (BB) to big dinner (BD)|Phase 1: no intervention, habitual diet for 4 days and then 4day maintenance diet Phase 2: consumption of BB energy restriction diets for 4 weeks Phase 3: washout for 1 week, controlled maintenance diet Phase 4: consumption of BD energy restriction diets for 4 weeks
2892056|NCT03305237|Experimental|big dinner (BD) to big breakfast (BB)|Phase 1: no intervention, habitual diet for 4 days and then 4day maintenance diet Phase 2: consumption of BD energy restriction diets for 4 weeks Phase 3: washout for 1 week, controlled maintenance diet Phase 4: consumption of BB energy restriction diets for 4 weeks
2892057|NCT03305224|Other|Ra-223 + Enzalutamide|
2892058|NCT03305211|Other|Biological sample|biological sampling will be performed on patients requiring renal biopsy and well-phenotyped patients (diagnosis of renal disease)
2892059|NCT03305198|Experimental|Patients undergoing exercise oximetry|Patients with PAD referred for treadmill testing and exercise oximetry will have a capillary blood sampling from the earlobe
2892060|NCT03305185|Experimental|Schroth SSE with Bracing|Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
2892061|NCT03305185|Active Comparator|Bracing alone|Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
2892062|NCT03305172|No Intervention|Control|Subjects in the Control treatment are not given any financial incentive to achieve the goal.
2892063|NCT03305172|Experimental|Gain Treatment|Financial Incentive: Each subject in the Gain treatment will earn a certain amount of money for each day the goal is achieved. The money earned will be added to a virtual account that the subject has, and will be paid to the subject at the end of the intervention period.
2892093|NCT03304964|Experimental|200 mg FP-025 (b.i.d.)|
2892094|NCT03304964|Experimental|400 mg FP-025 (b.i.d)|
2892095|NCT03304964|Experimental|200 mg FP-025 (single dose; fasted)|
2892096|NCT03304964|Experimental|200 mg FP-025 (single dose; fed condition)|
2892064|NCT03305172|Experimental|Loss Treatment|Financial Incentive: Each subject in the Loss treatment will be given a certain amount of money in his/her virtual account at the beginning of every week. For each day that the subject does not achieve the goal, a small portion of that money will be deducted from the virtual account. The balance that is left in the virtual account will be paid to the subject at the end of the intervention period.
2892065|NCT03305172|Experimental|Gain Streak Treatment|Financial Incentive: Each subject in the Gain Streak treatment get an increasing amount of money added to his/her virtual account for every continuous day that they achieve the goal. The maximum cumulative amount per week is same as in the other treatment conditions. The payment is reset at the beginning of each week, or if the subject misses the goal on any day. The money in the virtual account will be paid to the subject at the end of the intervention period.
2892066|NCT03305172|Experimental|Loss Streak Treatment|Financial Incentive: Each subject in the Loss Streak treatment will be given a certain amount of money in his/her virtual account at the beginning of every week. An increasing amount of money will be deducted for each consecutive day the subject does not achieve the goal. The payment is reset at the beginning of each week, or when the subject achieves the goal (i.e., deductions are reset when the streak is broken). The balance that is left in the virtual account will be paid to the subject at the end of the intervention period.
2892067|NCT03305159|Active Comparator|Control (Povidone Iodine)|Patients to receive povidone iodine for the surgical preparation of the vagina.
2892068|NCT03305159|Experimental|Intervention (4% Chlorhexidine gluconate)|Patients to receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
2892069|NCT03305146|Experimental|single arm|"For inoperable patients with indeterminate cystic lesions of the pancreas,a EUS FNA will be performed and molecular biology analysis of pancreatic intra-cyst fluid collected by EUS FNA will be performed.~For operable patients, after the pancreatic surgery, molecular biology analysis of extemporaneous pancreatic tissue specimen biopsy will be conducted."
2892070|NCT03305107|Experimental|Exercise and Chocolate Milk|"Children will exercise on a cycle ergometer with a 3-min warm-up, 7 repeated bouts of 60-sec exercise at 90% of peak power output and 60-second recovery, and a 3-min cool down.~Children will then drink 240mL of chocolate milk"
2892071|NCT03305107|Experimental|Exercise and Water|"Children will exercise on a cycle ergometer with a 3-min warm-up, 7 repeated bouts of 60-sec exercise at 90% of peak power output and 60-second recovery, and a 3-min cool down.~Children will then drink 240mL of water"
2892072|NCT03305107|Experimental|Sitting and Chocolate Milk|Children will quietly sit for 20 minutes Children will then drink 240mL of chocolate milk
2892073|NCT03305107|Experimental|Sitting and Water|Children will quietly sit for 20 minutes Children will then drink 240mL of water
2892074|NCT03305094|Active Comparator|Control group|"Sham remote ischemic preconditioning on the right arm is induced with a blood pressure cuff inflation at 20 mm Hg for 5 min and followed by a 5 min reperfusion at 0 mm Hg. The sham ischemia-reperfusion cycle is performed 3 times for a total of 30 min. This procedure is done after anesthetic induction, but before the patient is placed on cardiopulmonary bypass.~A 20 mm Hg blood pressure cuff on the right arm does not induce ischemia."
2892075|NCT03305094|Experimental|Intervention group|Remote ischemic preconditioning on the right arm is induced with a blood pressure cuff inflation at 200 mm Hg for 5 min and followed by a 5 min reperfusion at 0 mm Hg. The ischemia-reperfusion cycle is performed 3 times for a total of 30 min. This procedure is done after anesthetic induction, but before the patient is placed on cardiopulmonary bypass.
2892076|NCT03305081|Experimental|Immediate or early placement|Immediate or early placement of levonorgestrel IUD, copper IUD, or etonorgestrel sub dermal implant (within 48 hours) postpartum
2892077|NCT03305081|Active Comparator|Interval placement|Interval (4-6 weeks) postpartum placement of levonorgestrel IUD, copper IUD, or etonorgestrel sub dermal implant
2892078|NCT03305068|Placebo Comparator|the use of a COX-II inhibitor in shoulder surgery.|Arm 1 shoulder replacement, both primary and reverse
2892079|NCT03305068|Placebo Comparator|the use of a COX-II inhibitor in arhroscopic shoulder surgery.|Arm 2 arthroscopic rotator cuff repair
2892080|NCT03305055|Experimental|Fentanyl Plus Ketamine|"Study drug group~Ketamine Loading Dose (Low Dose, Slow Infusion) =~• 0.3 mg/kg; Initiated approximately 10 minutes before wound care start, pump set to deliver slowly over approximately 5 minutes, … Then,~Fentanyl Loading Dose (UC, injection) =~• 1 mcg / kg. This is given to participants in both Group 1 and Group 2 initiated < 1 minute prior to wound care.~Ketamine (Study Drug, Infusion) = • 2.5 mcg/kg/min, Pump initiates infusion immediately after the fentanyl Loading Dose and continued for session duration. The nurse determines session end, then turns off infusion.~Fentanyl PRN dose* = 1 mcg / kg. Provided when participant requires additional pain medication."
2892081|NCT03305055|Active Comparator|Fentanyl Plus Saline|"Usual care group~Saline Loading Dose (Low Dose, Slow Infusion) =~• An identical volume of saline as that in 0.3 mg/kg of ketamine. Initiated approximately 10 minutes before wound care start, pump set to deliver slowly over approximately 5 minutes, (i.e., same time/rate as STUDY DRUG GROUP receives ketamine loading dose), … Then, ...~Fentanyl Loading Dose (UC, injection) =~• 1 mcg / kg: This is given to participants in both Group 1 and Group 2 initiated <1 minute prior to wound care.~Saline (Placebo, Infusion) = • Identical volume of fluid as that in 2.5 mcg/kg/min of ketamine; Pump initiates infusion immediately after the fentanyl Loading Dose and continued for session duration. The nurse determines session end, then turns off infusion.~FENTANYL PRN DOSE = 1 mcg / kg. Provided when participant requires additional pain medication."
2892082|NCT03305042||21-54 y|Ages 21-54 y
2892083|NCT03305042||55-74 y|Ages 55-74 y
2892084|NCT03305042||>75 y|Age >75 y
2892085|NCT03305029|Experimental|SCNT-hES-RPE Cells|Pars plana vitrectomy and Sub-retinal Transplantation of Human Somatic cell nuclear transfer Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells (SCNT-hES-RPE Cells) in Patients with Advanced Dry Age-related Macular Degeneration(AMD)
2892086|NCT03305016|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
2892087|NCT03305003|Active Comparator|Communication modality: spiral notebook|
2892088|NCT03305003|Experimental|Communication modality: mobile application|
2892089|NCT03304990||Family History of CA|Hereditary cancer genetic screening based on risk factors
2892090|NCT03304990||Risk Factors for CA|No dx of CA
2892091|NCT03304990||Suspected or Confirmed Diagnosis of CA|Suspected or confirmed diagnosis of cancer
2892092|NCT03304964|Experimental|100 mg FP-025 (b.i.d)|
2892241|NCT03303872||AF-pacemaker registry|
2892097|NCT03304951|Experimental|Synopsis® Lacrimal Stent|The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid sinus access
2892098|NCT03304938|Active Comparator|Lavender oil|
2892099|NCT03304938|Placebo Comparator|vehicle (Almond oil)|
2892100|NCT03304925|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the flanks with a new applicator design.
2892101|NCT03304912||Cohort|The cohort will be comprised of women who inject drugs who are eligible for PrEP.
2892102|NCT03304899|Experimental|Case group|"Severe isolated Traumatic Brain injury patients with serum fibrinogen level under 200 mg/dl that receive Fibrinogen concentrate after common emergency resuscitation. Instruction:~Airway control & breathing.~Circulation (Serum therapy, Epinephrine,Packed cell, FFP and ...).~Fibrinogen Concentrate(IV injection): Each vial contains 1gr fibrinogen concentrate. Fibrinogen concentrate will be given until serum fibrinogen level riches to 200 mg/dl.~Dose (mg/kg body weight) = ([Target level (mg/dL) - measured level (mg/dL)])/(1.7 (mg/dL per mg/kg body weight))"
2892103|NCT03304899|Active Comparator|Control group|"Severe isolated Traumatic Brain injury patients with serum fibrinogen level under 200 mg/dl that receive common emergency resuscitation. Instruction:~Airway control & breathing.~Circulation (Serum therapy, Epinephrine,Packed cell, FFP and ...)."
2892104|NCT03304886||Migraineurs|with a migraine
2892105|NCT03304886||Control|Participants without migraine
2892106|NCT03304873|Experimental|Retapamulin|Thin layer of ointment applied twice a day for five days. Study drug will be applied to the nares and peri-rectal area twice a day for 5 consecutive days.
2892107|NCT03304873|Placebo Comparator|Placebo|The placebo used will be a triple purified pharmaceutical grade white petrolatum
2892108|NCT03304860|Experimental|CRC screening Survey|Residents with parents eligible for CRC screening will be asked to provide their e-mail address, solely for the use of distributing the follow up survey so it can be linked to 2 brief (3-5 min) surveys
2892109|NCT03304847|Other|Ablation|Radio-frequency catheter ablation
2892110|NCT03304834|Experimental|ECHOPULSE|Arm of patient treated by HIFU
2892111|NCT03304821|Experimental|GM-CSF|Participants receiving 500µg of granulocyte-macrophage colony stimulating factor (GM-CSF), administered subcutaneously. Prior to randomization to a study arm, eligible participants will be trained to perform subcutaneous injections and instructed to walk at least three times a day until they develop claudication or symptomatic limitation for 4 weeks.
2892112|NCT03304821|Placebo Comparator|Placebo|Participants receiving 500µg of a placebo, administered subcutaneously. Prior to randomization to a study arm, eligible participants will be trained to perform subcutaneous injections and instructed to walk at least three times a day until they develop claudication or symptomatic limitation for 4 weeks.
2892113|NCT03304808|Experimental|device|
2892114|NCT03304808|Active Comparator|behavioral|
2892115|NCT03304808|No Intervention|waiting list|
2892116|NCT03304795||Vitamin D deficiency|Serum 25-hydroxyvitamin D level is less than 50 nmol/L.
2892117|NCT03304795||Normal|Serum 25-hydroxyvitamin D level is 50 nmol/L or greater.
2892118|NCT03304782||Preterm birth|Delivery prior to 37 weeks gestation
2892119|NCT03304782||Full-term birth|Delivery after 37 weeks gestation
2892120|NCT03304769|No Intervention|IV placement no Virtual reality|Patient will have IV placed in traditional manner, with no virtual reality headset
2892121|NCT03304769|Experimental|IV placement with Virtual Reality|Patient will have IV placed with Virtual Reality headset distraction
2892122|NCT03304756|Experimental|CAP|Cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
2892123|NCT03304743|Experimental|Post-menopausal women|
2892124|NCT03304730||facet inflammatory signs|patients with facet inflammatory signs identified on MRI
2892125|NCT03304730||no facet inflammatory signs|patients without facet inflammatory signs identified on MRI
2892126|NCT03304717|Experimental|TDF/FTC then Placebo|This is a double-blind, placebo-controlled, 2 arm, cross-over trial involving 34 children with clinical findings and molecular confirmation of Aicardi Goutieres Syndrome, who also have an abnormal interferon signature. For arm 1, half of the patients will receive TDF/FTC (a combination of Tenofovir [TDF] and Emtricitabine [FTC]) for the first 6 months of the study. There will be a one month washout period before starting on placebo for 6 months.
2892127|NCT03304717|Experimental|Placebo then TDF/FTC|For arm 2, half of the patients will receive placebo for the first 6 months of the study. There will be a one month washout period before starting on TDF/FTC (a combination of Tenofovir [TDF] and Emtricitabine [FTC]) for 6 months.
2892128|NCT03304704||Genotype Only Cohort|The Genotype Only Cohort (n=1000), which will include the vaccine trial participants, will complete a single visit to obtain a blood sample for genotyping with no additional follow up.
2892129|NCT03304704||DSF Cohort|The DSF Cohort (n=1200) will enroll subjects aged 5 to 65 years for monthly blood sampling, DSF, and mosquito collection at their household.
2892130|NCT03304704||Parasite Surveillance Cohort|The Parasite Surveillance Cohort (n=1000) will enroll subjects under the age of 5 years (as young as 6 months) and subjects of any age who are unwilling to participate in DSF; they will have monthly blood sampling and mosquito collection at their household.
2892131|NCT03304691||Children|Children of the Bandiagara region.
2892132|NCT03304678||Patients|Patients with lymphangioleiomyomatosis (LAM)
2892133|NCT03304665||Healthy Volunteers|Adult males and females in general good health who are 18 years of age and older.
2892134|NCT03304639|Active Comparator|Group I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2892135|NCT03304639|Experimental|Group II (pembrolizumab, SBRT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo SBRT for 3 doses during course 1.
2892136|NCT03304626|Experimental|Study Group|"Budesonide EC 3 mg capsule. The dose will be as follows~Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Budesonide 9 mg Days 31-45 SIS + Budesonide 6 mg Days 46-90 SIS + Budesonide 3 mg Days 90 onwards SIS1"
2892293|NCT03303443||Younger|20-40 years old patients
2892137|NCT03304613|Active Comparator|Standard Web-based Cognitive Behavioral Therapy (e-CBT)|"Patients randomized to e-CBT will undergo Standard Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management Program and meet with a study medical assistant (MA) for an orientation session. The MA provides an overview of the program, explains the rationale for treatment, and directs them to the FibroGuide website. FibroGuide features the CBT modules that will be used by both groups. Patients will complete one module per week. Materials needed for the 8-week intervention including the instructions for each activity and forms for the written aspects of an activity (worksheets) will be provided in the first visit and available online. The FibroGuide website evolved from the evidence-based website Living Well with Fibromyalgia that has established efficacy for improving functional status and reducing pain."
2892138|NCT03304613|Experimental|Resilience-Enhanced web-based CBT Program|"Patients randomized to PRISM will undergo Promoting Resilience through Innovative Self-Management (PRISM) and meet with the MA for an orientation session. The MA describes the program, explains the rationale for treatment, and directs them to the FibroGuide and PRISM websites. Materials and worksheets are provided in the first visit and available online. The e-CBT elements retained are the core elements of CBT for pain, while the resilience-based activities capitalize on the best practices for positive activities interventions including having multiple overlapping activities, making favored activities standard practice beyond the study and having a coaching component."
2892139|NCT03304613|No Intervention|Usual Care|Patients randomized to the usual care only group will have no contact with the study MAs. Usual care patients return for the same follow-up assessments (and electronic medical record review) at 8 weeks and at 6 and 12 months. Whereas major surgery including surgeries for pain, are exclusion criteria, spine and pain injections will be permitted.
2892140|NCT03304600|Experimental|Active stimulation|10 sessions (1 per day during 2 week) of active tDCS stimulation
2892141|NCT03304600|Sham Comparator|Sham Stimulation|10 sessions (1 per day during 2 week) of sham stimulation
2892142|NCT03304587|Experimental|Arm 1: Bright blue-green light|"Bright blue-green light (~515nm; 12,000 lux) for 30 minutes once a day.~For those who have scores of ≤41 (evening types) on Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ), light will be delivered within 30 minutes of waking for 14 consecutive mornings. For those who receive scores of ≥59 (morning types), light will be delivered between 1900-2000 hours for 14 consecutive evenings.~Light therapy will be self-administered using a light visor cap~Each participant will make (3) overnight visits to the sleep laboratory~On 2 randomly selected days, the participants will wear a light meter during wake time"
2892143|NCT03304587|Active Comparator|Arm 2: Dim red light|"Dim red light (5 lux) (control group) for 30 minutes once a day.~--For those who have scores of ≤41 (evening types) on Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ), light will be delivered within 30 minutes of waking for 14 consecutive mornings. For those who receive scores of ≥59 (morning types), light will be delivered between 1900-2000 hours for 14 consecutive evenings.~Light therapy will be self-administered using a light visor cap~Each participant will make (3) overnight visits to the sleep laboratory --On 2 randomly selected days, the participants will wear a light meter during wake time"
2892144|NCT03304574|No Intervention|Control|Participants will complete the electronic health assessment only and will not receive integrated personalized feedback
2892145|NCT03304574|Experimental|Intervention|Participants will complete the electronic health assessment and will receive integrated personalized feedback
2892146|NCT03304561|Experimental|traditional rehabilitation|patients in this groups is going to recieve traditional rehabilitation programme for 3 months after ACL recontsruction
2892147|NCT03304561|Experimental|Cross-over training|patients in this programme is going to recieve isokinetic exercise programme targeting unilvolved limb during rehabilitation. for the first 4 weeks after ACL reconstruction traditional rehabiitation programme is going to applied to the subjects. after 4 weeks, isokinetic strenghtening programme at 60˚/second angular velocity, between 0-90 degree knee flexion until 3 months after ACL reconstructon
2892148|NCT03304548||All subjects with PAH|A total of 8 to 10 US-English speaking PAH subjects will be recruited. They will take part in a 30-minute telephone concept elicitation interview. All interviews will be audio-recorded and transcribed verbatim.
2892149|NCT03304522|Experimental|VX-150|
2892150|NCT03304522|Active Comparator|Placebo|
2892151|NCT03304509|No Intervention|Face-to-face follow-up|Face-to-face follow-up after hospital discharge
2892152|NCT03304509|Experimental|Telematic follow-up|Telematic follow-up after hospital discharge
2892153|NCT03304496|Experimental|Nitroglycerin|"The intervention group will receive a subcutaneous cocktail with 0,5 ml of 500 mcg of nitroglycerin + 1 ml of 2% simple lidocaine."
2892154|NCT03304496|Placebo Comparator|Control|The placebo group will receive a subcutaneous injection with 0,5 ml of 0,9% saline solution + 1 ml of 2% simple lidocaine.
2892155|NCT03304483|Experimental|Athletes|246-km running
2892156|NCT03304470|Experimental|ATx201 2% CREAM|
2892157|NCT03304470|Placebo Comparator|ATx201 Cream Vehicle|
2892158|NCT03304457|Active Comparator|Olanzapine|Olanzapine will be prescribed at a dose of 10mg once daily orally for 6 weeks
2892159|NCT03304457|Experimental|Lurasidone|Lurasidone will be prescribed at a dose of 80mg/day once daily orally for 6 weeks
2892160|NCT03304444|Active Comparator|Bupivacaine HCl in TAP block|"When performing a bilateral TAP with Bupivicaine 0.25% and the incision is below the umbilicus: 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes by the anesthesiologist (need 2 vials).~When performing a bilateral TAP with Bupivicaine 0.25% and the incision extends above the umbilicus: 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes by the anesthesiologist (need 2 vials). A 3rd vial of 30 ml 0.25% bupivacaine will be drawn up and is directly infiltrated into the surgical site (above and below the fascia prior to closure of fascia) extending above the umbilicus by the surgeon."
2892161|NCT03304444|Experimental|Liposomal Bupivicaine in TAP block|When performing a bilateral TAP with liposomal bupivacaine and the incision is below the umbilicus: the 20 ml vial of liposomal bupivacaine containing 266 mg, will be diluted with 20 ml of 0.25% bupivacaine (containing 50 mg of bupivacaine) and 20 ml saline (60 ml total). That total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
2892162|NCT03304431|No Intervention|Control group(Group C)|After pre-oxygenation, anesthesia induction will be performed with intravenous administration of 2 μg / kg fentanyl, 2 mg/kg propofol, 0.6 mg/kg rocuronium bromide (Esmeron 5 mg vial, Organon Oss Holanda).
2892163|NCT03304431|Other|Group L|The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
2892164|NCT03304418|Experimental|Radium Ra 223 dichloride and radiation, all patients|
2892165|NCT03304405||Gait Analysis|All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
2892166|NCT03304392|Experimental|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
2892167|NCT03304392|Active Comparator|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
2892168|NCT03304379|Experimental|Dosing regimen 1|
2892169|NCT03304379|Experimental|Dosing regimen 2|
2892170|NCT03304379|Experimental|Dosing regimen 3|
2892171|NCT03304379|Experimental|Dosing regimen 4|
2892172|NCT03304379|Experimental|Dosing regimen 5|
2892173|NCT03304379|Experimental|Dosing regimen 6|
2892174|NCT03304366||Patients with primary pterygium|"All eyes have primary pterygium and seeking for surgery due to Cosmetic problems, ocular irritation, and, or visual impairment.~All selected patients will undergo complete ophthalmological examination including refraction, best corrected visual acuity, keratometry, and pentacam (scheimpflug imaging) preoperatively then will be followed up 2 and 6 months post pterygium excision."
2892175|NCT03304353|Experimental|Self-managed protocol|
2892176|NCT03304353|Active Comparator|Predetermined protocol|
2892177|NCT03304340|Experimental|TENS+SR|For each participant in the transcutaneous nerve stimulation (TENS) group, standard rehabilitation (SR) in addition a TENS stimulator (BioTENS, Skylark Device & Systems Co., Ltd) was applied with 0.2-ms pulses at 100 Hz in the constant mode within the subject's sensory level without muscle contraction via (5 × 3.5 cm) electrodes attached to the motor points of the tibia anterior (TA) and quadriceps muscles on the affected lower extremity. For the TENS group, the given electric stimulation treatment lasted for 30 min per session, once per day, 5 days a week, for 2 weeks.
2892178|NCT03304340|Experimental|FES + SR|For each participant in the functional electrical stimulation (FES) group, standard rehabilitation (SR) in addition two dual-channel FES stimulators (MEDTRONIC Respond Select; EmpiInc) were used. The FES was delivered with 0.3-ms pulses at 30 pps and the stimulation intensity was set to the movement threshold to induce visible muscle contractions. For the FES group, the given electric stimulation treatment lasted for 30 min per session, once per day, 5 days a week, for 2 weeks.
2892179|NCT03304340|Active Comparator|SR-only|All the participants received functional training and motor relearning physiotherapy treatment as early standard rehabilitation (SR) for 30 minutes per day, 5 days a week throughout the study. Subjects in the SR group received only SR .
2892180|NCT03304327|Experimental|Mindfullness and Yoga|Subjects will receive yoga training either at their home or at the Center for Living Campus at Duke. Subjects will complete their yoga assignments for 5 consecutive days, along with a symptom checklist. On the 6th day, subjects will complete the symptom checklist and mail all checklists to the study team
2892181|NCT03304314|Experimental|Pseudotumor cerebri (PTC) patients|
2892182|NCT03304314|Experimental|Control|
2892183|NCT03304301|Experimental|experimental group|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and expose to sunlight (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months.
2892184|NCT03304301|No Intervention|control group|Participants will receive routine care.
2892185|NCT03304288|Experimental|low-dose rituximab & ATRA|rituximab 100mg once weekly for 6 weeks and oral all-trance retinoid acid 20mg/m^2 qd for 12 weeks.
2892186|NCT03304288|Active Comparator|low-dose rituximab|rituximab 100mg once weekly for 6 weeks
2892187|NCT03304275|Experimental|Emergency Department vaccination group|Pertussis (Tdap) vaccine offered/administered in the Emergency Department
2892188|NCT03304275|Experimental|Public Health referral group|Public Health referral for Pertussis (Tdap) vaccine administration offered
2892189|NCT03304262|Active Comparator|Cathodal tDCS + rTMS|Participant will receive 10 minutes of cathodal tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2.
2892190|NCT03304262|Active Comparator|Anodal tDCS + rTMS|Participant will receive 10 minutes of anodal tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2.
2892191|NCT03304262|Sham Comparator|Sham tDCS + rTMS|Participant will receive 10 minutes of sham tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2.
2892192|NCT03304249|Experimental|iAmHealthy|Participants randomized to this arm receive the iAmHealthy Healthy Lifestyles Program.
2892193|NCT03304249|Active Comparator|Control|Participants randomized to this group receive comparable content delivered via a newsletter.
2892194|NCT03304236||Myelopathy hand|Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists).
2892195|NCT03304223|Experimental|[18F]FB-IL2 PET scan|Renal transplant recipients with a clinical suspicion for renal transplant rejection.
2892196|NCT03304210|Experimental|Abraxane 35 mg/m²|PIPAC with Abraxane (35 mg/m²) will be administered every 4 weeks for 3 cycles.
2892197|NCT03304210|Experimental|Abraxane 70 mg/m²|PIPAC with Abraxane (70 mg/m²) will be administered every 4 weeks for 3 cycles.
2892198|NCT03304210|Experimental|Abraxane 90 mg/m²|PIPAC with Abraxane (90 mg/m²) will be administered every 4 weeks for 3 cycles.
2892199|NCT03304210|Experimental|Abraxane 112.5 mg/m²|PIPAC with Abraxane (112.5 mg/m²) will be administered every 4 weeks for 3 cycles.
2892200|NCT03304210|Experimental|Abraxane 140 mg/m²|PIPAC with Abraxane (140 mg/m²) will be administered every 4 weeks for 3 cycles.
2892201|NCT03304197|Experimental|Dehydrated|90 minutes cycling, without the ingestion of any fluids, followed by a 15 minute cycling time trial test
2892202|NCT03304197|Experimental|Hypotonic|90 minutes cycling, with the ingestion of six 250 ml carbohydrate (6g sucrose, 3g glucose) drinks, followed by a 15 minute cycling time trial test
2892203|NCT03304197|Experimental|Isotonic|90 minutes cycling, with the ingestion of six 250 ml carbohydrate (6g glucose, 3g fructose) drinks, followed by a 15 minute cycling time trial test
2892204|NCT03304197|Experimental|Placebo|90 minutes cycling, with the ingestion of six 250 ml taste-matched water drinks, followed by a 15 minute cycling time trial test
2892205|NCT03304184|Placebo Comparator|Photac-fil|Participants will have a restoration placed with photac-fil in the lesion near the gum line.
2892206|NCT03304184|Experimental|Biodentine|Participants will have a restoration placed with Biodentine in the lesion near the gum line.
2892207|NCT03304158|Experimental|FCHV visit-diabetes|
2892208|NCT03304158|No Intervention|FCHV no visit-diabetes|
2892209|NCT03304132||Upper aerodigestive squamous cell cancers (UADSCC) cases|From PLCO and ACS CPS II, identified 140 UADSCC cases. These cases are frequency matched 3:1 (420 controls) by incidence density sampling for study (ACS. PLCO),
2892210|NCT03304132||Controls|From PLCO and ACS CPS II, we have identified 140 UADSCC cases. These cases are frequency matched 3:1 (420 controls) by incidence density sampling for study (ACS. PLCO),
2892211|NCT03304119||Patellar instability group|Group of patients with patellar instability stemming from a recurrent patellar dislocation
2892212|NCT03304119||Control group control|Group that has not been checked for patellar instability.
2892213|NCT03304106|Experimental|Group 1|Use of AI technology to assist in audiologist's evaluation and programming of new (standard of care-commercial) cochlear implant recipients
2892214|NCT03304106|Experimental|Group 2|Use of AI technology to assist in audiologist's evaluation and programming of existing cochlear implant recipients
2892215|NCT03304093|Experimental|Nivolumab|Nivolumab 3mg/kg every 2 weeks
2892216|NCT03304080|Experimental|HR-positive, Her2-positive Metastatic Breast Cancer|Women with HR-positive, Her2-positive Metastatic Breast Cancer on trial of anastrozole, palbociclib, trastuzumab and pertuzumab
2892217|NCT03304067|Experimental|Intervention|
2892218|NCT03304067|No Intervention|Control|
2892219|NCT03304054|Experimental|amifamapridine phosphate tablets|
2892220|NCT03304054|Placebo Comparator|placebo tablets|
2892221|NCT03304041|Experimental|low-FODMAPs diet|"The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.~low-FODMAPs diet therapy for 3 weeks"
2892222|NCT03304041|Placebo Comparator|standard diet advice|"Standard diet advice(SDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period~standard diet for 3 weeks"
2892223|NCT03304028|Other|Refusal Group|"Refusal Questionnaires Intervention:~Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal."
2892224|NCT03304028|Other|Interventionnal Group|Connected Devices for 3 months (36 patients will be equipped with CDs-spirometer, oxymeter, scales, podometer watch and AURA device for sleep quality and analyze) Educationnal Intervention Connected Devices for 12 months Interviews
2892225|NCT03304015|Experimental|Intervention: Behavioral Change Communications|
2892226|NCT03304015|No Intervention|Control: No intervention|
2892227|NCT03303989|Experimental|pegloticase + MMF|Participants randomized to this arm will receive pegloticase + mycophenolate mofetil.
2892228|NCT03303989|Placebo Comparator|pegloticase + placebo|Participants randomized to this arm will receive pegloticase + placebo
2892229|NCT03303976|Experimental|Pneumo1-low dose|Arm A: intramuscular injection monovalent bioconjugate pneumococcal vaccine
2892230|NCT03303976|Experimental|Pneumo1-mid dose|Arm B: intramuscular injection monovalent bioconjugate pneumococcal vaccine
2892231|NCT03303976|Experimental|Pneumo1-target dose|Arm C: intramuscular injection monovalent bioconjugate pneumococcal vaccine
2892232|NCT03303976|Active Comparator|Pneumovax23|Arm D: intramuscular injection multivalent plain polysaccharide vaccine
2892233|NCT03303963||Rifampicin resistant and susceptible patients|Study 1: Patients detected positive by the GeneXpert Mycobacterium tuberculosis/Rifampicin (susceptible and resistant to rifampicin)
2892234|NCT03303963||Rifampicin resistant patients|Study 2: Follow up of the rifampicin resistant patients included in the study 1 during their treatment
2892235|NCT03303950|Experimental|Treatment (busulfan, fludarabine, HSCT, cyclophosphamide)|Patients receive busulfan IV over 2 hours and fludarabine IV over 30 minutes on days -5 to -2. Patients undergo HSCT on day 0. Patients then receive cyclophosphamide IV over 60 minutes on days 3 and 4.
2892236|NCT03303924|Experimental|ETX2514 and sulbactam|Healthy male and female subjects, non-smoking, will receive multiple doses of ETX2514 1.0 g and sulbactam 1 g via intravenous (IV) infusion every 6 hours with each dose of medication infused over 3 hours.
2892237|NCT03303911|Experimental|Cytisine 1.5 mg|"Multiple doses of 1.5 mg cytisine administered per 25-day schedule:~Days 1-3 (6 times daily)~Days 4-12 (5 times daily)~Days 13-16 (4 times daily)~Days 17-20 (3 times daily)~Days 21-24 (2 times daily)~Day 25 (Once daily)"
2892238|NCT03303911|Experimental|Cytisine 3.0 mg|"Multiple doses of 3.0 mg cytisine administered per 25-day schedule:~Days 1-3 (6 times daily)~Days 4-12 (5 times daily)~Days 13-16 (4 times daily)~Days 17-20 (3 times daily)~Days 21-24 (2 times daily)~Day 25 (Once daily)"
2892239|NCT03303898|Other|asymptomatic carriers|
2892240|NCT03303898|Other|uninfected patient|
2892242|NCT03303846|Experimental|Treatment (breast MRI, biopsy)|Participants undergo standard of care high risk breast cancer screening MRIs at baseline and follow-up and blood sample collection at baseline. Participants also undergo collection of breast tissue samples at any breast biopsy or breast surgery.
2892243|NCT03303833||Persons with Lynch syndrome|
2892244|NCT03303807|Other|Extracorporeal CO2 removal|Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)
2892245|NCT03303794|Active Comparator|Bupivicaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
2892246|NCT03303794|Experimental|Bupivicaine + Exparel|0.25% bupivacaine and 1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
2892247|NCT03303781||BE + CR|Belgian ischemic heart disease patients with cardiac rehabilitation program
2892248|NCT03303781||BE-CR|Belgian ischemic heart disease patients without cardiac rehabilitation program
2892249|NCT03303781||Si + CR|Singapore (Asian) ischemic heart disease patients with cardiac rehabilitation program
2892250|NCT03303781||SI -CR|Singapore (Asian) ischemic heart disease patients without cardiac rehabilitation program
2892251|NCT03303768||Pregnant women|Pregnant woman with suspected coarctation of isolated aorta or woman followed in the last 12 for suspected coarctation of the aorta isolated during pregnancy
2892252|NCT03303742|Experimental|feather edge finish line marginal design|intervention
2892253|NCT03303742|Active Comparator|deep chamfer finish line marginal design|comparator
2892254|NCT03303729|Experimental|Meat hydrolysate & Cluster Dextrin|Meat hydrolysate containing 25g of protein given together with 75 grams of Cluster Dextrin.
2892255|NCT03303729|Active Comparator|Meat hydrolysate & placebo|Meat hydrolysate containing 25g of protein given together with 75 grams of Glucose.
2892256|NCT03303703|No Intervention|Control|Usual cardiac rehabilitation and social phone calls for attention control.
2892257|NCT03303703|Experimental|Intervention|RENEwS intervention is five 60-minute group educational sessions.
2892258|NCT03303690|Experimental|Ankle Spacer (AS)|This arm will surgically receive the to be implanted ankle spacer in their ankle.
2892259|NCT03303677|Active Comparator|Saline|Post operative endoscopic sinus surgery patients using Saline nasal sinus irrigations to be performed twice daily. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
2892260|NCT03303677|Experimental|Saline and budesonide|Post operative endoscopic sinus surgery patients using saline + budesonide nasal sinus irrigations to be performed twice daily. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
2892261|NCT03303677|Experimental|saline, budesonide, and topical antibiotic|Post operative endoscopic sinus surgery patients using saline + budesonide + topical antibiotic nasal sinus irrigations. The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
2892262|NCT03303664|Experimental|IMPROVE Protocol|The intervention is composed of 4 parts: 1) a multidisciplinary team that recommends, develops, approves, monitors the components of the intervention and training? 2) monitoring of medication sedation risk using established scale 3) restriction of medication dispensing via enhanced technology 4) health professional training on multimodality pain management including complementary and alternative therapies.
2892263|NCT03303664|No Intervention|Usual Care|Treatment of patients in the usual manner based on their diagnosis and resources available at that site.
2892264|NCT03303651|Experimental|PPI (Pain Pupillary Index)|Opioid administration guided by Pain Pupillary Index (PPI) derived from Videopupillometry performed with the device AlgiScan manufactured by IDMed, Marseille, France. The device measures the degree of pupillary reflex dilation (PRD) following an electric nociceptive stimulation. It automatically increases the intensity of the electric stimulation from 10 to 60 milliampere depending on the degree of PRD and afterwards displays the PPI. The numerical index ranges from 0 to 10. A low PPI score indicates a deep analgesia, a high PPI score indicates an insufficient or light analgesia. A PPI score of 2 or 3 is supposed to represent an optimal level of analgesia according to the manufacturer. 5 µg sufentanil will be administered every 5 minutes if PPI score is calculated more than 3.
2892265|NCT03303651|Experimental|SPI (Surgical Pleth Index)|Opioid administration (sufentanil) guided by by Surgical Pleth Index (SPI) derived from photoplethysmography performed by the device CARESCAPE B650 Patient Monitor from the manufacturer GE (General Electrics) Healthcare, Helsinki, Finland. Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger plethysmography. The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone). A SPI score between 20 and 50 has been proposed as the target range to guide analgesics (15 - 17). 5 µg Sufentanil will be administered every 5 minutes if SPI score is calculated more than 50.
2892266|NCT03303651|Experimental|NOL (Nociception Level)|Opioid administration (sufentanil) guided by Nociception Level (NOL) derived from finger photoplethysmography performed with the analgesia monitoring device PMD200 manufactured by Medasense, Ramat Gan, Israel. The device continuously calculates the NOL with a multi-parametric approach from pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level, skin conductance fluctuations, skin temperature and finger motion. The composite algorithm of the device analyses the data and the numerical index NOL is presented on a scale from 0 (no pain) to 100 (extreme pain) (18). A NOL score between 10 and 25 has been proposed as the target range to guide analgesics. 5 µg Sufentanil will be administered every 5 minutes if NOL score is calculated more than 25.
2892267|NCT03303651|Active Comparator|Control|Opioid administration (sufentanil) guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation and sweating of the patient.
2892294|NCT03303443||Elderly|over 60 years old patients
2892295|NCT03303430||Surgery group|This patient's group will benefit from a endarteriectomy in order to treat their carotid stenosis.
2892296|NCT03303430||Stenting group|This patient's group will benefit from a stenting of their carotid in order to treat their stenosis.
2892268|NCT03303638|Other|Multi-sensory Environment during bathing|The MSE intervention will be provided by an interactive waterproof fiber optic kit that includes: a light-emitting diode (LED) wall-washer light, a waterproof fiber optic cable that can be controlled by a waterproof switch held by the participant while bathing, showering, and or tub bathing, and a mobile MSE cart. The wall-washer LED light creates the illusion that the room is painted a variety of bright colors that can be changed by the veteran being bathed. The mobile MSE cart includes an LED solar projector providing visual sensory stimulation by projecting scenes on the wall, an aroma therapy diffuser and a portable bubble tube to create positive distraction during the bathing process.
2892269|NCT03303625|Experimental|Cohort 0: Adults (Ad26.RSV.preF)|Participants aged greater than or equal to (>=) 18 to lesser than or equal to (<=) 50 years will receive vector Ad26.RSV.preF at 1*10^11 viral particles (vp) via intramuscular (IM) route (Group 1) on Day 1 and 29.
2892270|NCT03303625|Placebo Comparator|Cohort 0: Adults (Placebo)|Participants aged >= 18 to <= 50 years will receive placebo via IM route (Group 2) on Day 1 and 29.
2892271|NCT03303625|Experimental|Cohort 1: RSV seropositive Toddlers (Ad26.RSV.preF)|RSV seropositive participants aged >=12 to <=24 months will receive Ad26.RSV.preF at 5*10^10 vp via IM route (Group 3) on Day 1 and 29.
2892272|NCT03303625|Placebo Comparator|Cohort 1: RSV seropositive Toddlers (Placebo)|RSV seropositive participants aged >= 12 to <= 24 months will receive placebo via IM route (Group 4) on Day 1 and 29.
2892273|NCT03303612|Other|EP-based approach/pacemaker implant|"Subjects will undergo an EP study prior to hospital discharge and will receive a pacemaker implantation if the HV interval is ≥65 msec.~In the case where the electrical slowdown is not confirmed by the electrophysiological study, the participant will not have a pacemaker implantation."
2892274|NCT03303612|Other|Compared transcutaneous cardiac monitor|Subjects will undergo a minimum of 72 hour ECG monitoring in hospital and receive transcutaneous monitoring prior to hospital discharge for a duration of 30 days.
2892275|NCT03303599||HCV Genotypes 1, 2, 3, 4, 5, or 6 participants|Participants receiving combination therapy with the glecaprevir plus pibrentasvir (GLE/PIB) regimen according to standard of care, international guidelines and in line with the current local label.
2892276|NCT03303586|Active Comparator|Asthma group|Participants will be randomized to wear compression stockings or to control group for two weeks and cross over in the end of the period. When assigned to wear compression stockings, they will be instructed to put the stockings on as soon as they get up in the morning and to remove them just prior to bedtime for two weeks. If they have become loose, a new pair will be fitted. They will be given a diary to record the time they put on and remove the compression stockings each day. They will be telephoned after one week to check the fit of the compression stockings.
2892277|NCT03303586|Active Comparator|Healthy group|Participants will be randomized to wear compression stockings or to control group for two weeks and cross over in the end of the period. When assigned to wear compression stockings, they will be instructed to put the stockings on as soon as they get up in the morning and to remove them just prior to bedtime for two weeks. If they have become loose, a new pair will be fitted. They will be given a diary to record the time they put on and remove the compression stockings each day. They will be telephoned after one week to check the fit of the compression stockings.
2892278|NCT03303573||recombinant human erythropoietin group|cerebral palsy patients who had received erythropoietin from January 2013 to November 2016
2892279|NCT03303547|Experimental|MRI-Pathology N1c matching group|MRI mapping will be used to guide pathologists to sample areas of the mesorectum where tumour deposits are likely to be present.
2892280|NCT03303534|Experimental|PCR|pre-operative protein calorie restricted (PCR) group. participants randomized to this arm will consume scandishake diet (strawberry, caramel, banana cream, vanilla) mixed with almond milk for three days inpatient prior to planned elective carotid endarterectomy. Water is ad libitum for this cohort. Nutritionists will prepare shakes so participants will achieve 30% calorie restriction and severe protein restriction during the three days on the diet.
2892281|NCT03303534|No Intervention|control regular diet|participants in this cohort are randomized to the control group and will have no dietary restriction three days in patient prior to planned elective carotid endarterectomy
2892282|NCT03303521|Experimental|Sodium Zirconium Cyclosilicate (ZS)|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days.
2892283|NCT03303521|Placebo Comparator|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
2892284|NCT03303508|Other|anti-ds DNA|anti-ds DNA
2892285|NCT03303495|Experimental|FOLFIRI +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1; CPT-11 180 mg/m2 IV 90 min Day 1; l-LV (dl-LV) 200 mg/m2 (400 mg/m2) IV 120 min Day 1; 5-FU - bolus 400 mg/m2 IV bolus Day 1; 5-FU - infusional 2400 mg/m2 IV continuous (46 hours) Day 1 - 3
2892286|NCT03303495|Experimental|CPT-11 +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1; CPT-11 180 mg/m2 IV 90 min Day 1
2892287|NCT03303482|Experimental|Intervention Group|
2892288|NCT03303482|No Intervention|Waitlist Control Group|
2892289|NCT03303469|Experimental|FMISO PET imaging post TACE and SBRT|FMISO imaging at baseline, post-TACE and post-SBRT
2892290|NCT03303456|Experimental|Clinical high risk (CHR)|Subjects at clinical high risk (CHR) for psychosis and/or bipolar disorder, aged 13-30 years. CHR participants will have no history of psychosis and will demonstrate attenuated psychotic symptoms consistent with the Structured Interview for Prodromal Syndromes (SIPS), or genetic risk (first-degree relative with psychosis) in conjunction with a substantial drop in functioning over the past year. Assigned Mobile health application - Ginger.io
2892291|NCT03303456|Experimental|First Episode Psychosis (FEP)|First Episode Psychosis (FEP) subjects aged 13-30 meeting criteria for schizophreniform disorder, schizophrenia, schizoaffective disorder or another psychotic, non-schizophrenia diagnosis including those with bipolar disorder. FEP participants will be ascertained three years or less from illness onset and have diagnoses of affective (i.e. bipolar) and non-affective psychosis (i.e. schizophrenia) according to DSM-IV criteria. Assigned Mobile health application - Ginger.io
2892292|NCT03303456|Experimental|Healthy Controls (HC)|Healthy individuals with no current/past axis I disorders according to DSM-IV criteria and no first-degree relative with a psychotic disorder. Assigned Mobile health application - Ginger.io
2892297|NCT03303417|Experimental|Kiwifruit|Participants asked to consume 2 kiwifruit twice a day for 3 days before undergoing MRI Scan
2892298|NCT03303417|Placebo Comparator|Control|Participants asked to consume a calorie-matched sugar drink twice a day for 3 days before undergoing MRI Scan
2892299|NCT03303404|Experimental|Ambulatory (24-hour) Blood Pressure|
2892300|NCT03303391|No Intervention|Standard Care|This arm of subjects will have all aspects of fluid management and dialysis management managed by the his/her individual nephrologist
2892301|NCT03303391|Experimental|IBPS Group|This group will have ultrafiltration prescriptions dictated by a pre-specified protocol that is based on monthly assessment of intradialytic blood pressure slopes obtained over a two week period.
2892302|NCT03303378|Experimental|Melatonin group|Patients will receive a total intravenous melatonin dose of 11.61 mg (aproximately 166 μg/kg).
2892303|NCT03303378|Placebo Comparator|Control group|Patients will receive the same dose of placebo.
2892304|NCT03303365|Experimental|Treatment based on SPACE MRI sequence|Cyberknife SRS of all suspect intracranial lesions visible in SPACE up to 10 simultaneous lesions
2892305|NCT03303365|Active Comparator|Treatment based on MPRAGE|Cyberknife SRS of all suspect intracranial lesions visible in MPRAGE up to 10 simultaneous lesions
2892306|NCT03303352|Experimental|Fast Pass First, Slow Pass Second|"Each patient will receive 2 EUS FNA passes, 1 fast and 1 slow, with a 22 gauge EUS needle, with suction syringe, employing the fanning technique, 10 jabs for each pass.~A fast pass has an advancing mean acceleration jab (to movement) higher than 1 g, while a slow pass has an advancing mean acceleration jab of less than 1 g (where 1 g equals 9.8 m/s2). Both movements will have a slow fro withdrawal movement, from the point of maximum advance into the lesion to the lesion entry site.~For each patient, the passes order with be either done as fast pass first, slow pass second."
2892307|NCT03303352|Experimental|Slow Pass First - Fast Pass Second|"Each patient will receive 2 EUS FNA passes, 1 fast and 1 slow, with a 22 gauge EUS needle, with suction syringe, employing the fanning technique, 10 jabs for each pass.~A fast pass has an advancing mean acceleration jab (to movement) higher than 1 g, while a slow pass has an advancing mean acceleration jab of less than 1 g (where 1 g equals 9.8 m/s2). Both movements will have a slow fro withdrawal movement, from the point of maximum advance into the lesion to the lesion entry site.~For each patient, the passes order with be either done as slow pass first, fast pass second."
2892308|NCT03303339|Experimental|Phase 1b: PCM-075 + low-dose cytarabine|PCM-075, administered in escalating doses orally Day 1 through Day 5 every 28 days (1 cycle) in combination with cytarabine, which will be administered in all cohorts as 20 mg/m2 subcutaneously, once daily on Day 1 through Day 10 every 28 days (1 cycle). PCM-075 administration, in combination with cytarabine, will be initiated at a starting dose of 12 mg/m2 orally, daily for 5 days. PCM-075 dose will be escalated in successive cohorts until Maximum Tolerated Dose/Recommended Phase 2 Dose is achieved.
2892309|NCT03303339|Experimental|Phase 1b: PCM-075 + decitabine|PCM-075 will be administered in escalating doses orally, Day 1 through Day 5 every 28 days (1 cycle) in combination with decitabine, administered consistently in all cohorts as 20 mg/m2 intravenously over 1 hour on Day 1 through Day 5 every 28 days (1 cycle). PCM-075 administration, in combination with decitabine, will be initiated at a starting dose of 12 mg/m2 orally, daily for 5 days (Day 1 through Day 5). PCM-075 dose will be escalated in successive cohorts until Maximum Tolerated Dose/Recommended Phase 2 Dose is achieved.
2892310|NCT03303339|Experimental|Phase 2: PCM-075 + cytarabine or decitabine|PCM-075 Recommended Phase 2 Dose, orally Day 1 through Day 5 every 28 days (1 cycle) and either cytarabine, 20 mg/m2 subcutaneously, once daily on Day 1 through Day 10 every 28 days (1 cycle), or decitabine, administered consistently as 20 mg/m2 intravenously over 1 hour on Day 1 through Day 5 every 28 days (1 cycle), with treatment modifications or delays based on return of hematopoietic function to baseline or Grade ≤1 toxicity for optimal subject management.
2892311|NCT03303326|Experimental|Immediate Interview|A 60-minute interview about women's health conducted immediately after baseline questionnaires.
2892312|NCT03303326|No Intervention|Delayed Interview|The interview is conducted after the follow-up questionnaires are completed, rather than after baseline.
2892313|NCT03303313|Experimental|Cemdisiran|
2892314|NCT03303287|Experimental|intervention|School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
2892315|NCT03303287|No Intervention|control|usual
2892316|NCT03303274|Experimental|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally before subclavian venous catheterization.
2892317|NCT03303274|No Intervention|Supine|Catheterization of right subclavian vein in supine position.
2892318|NCT03303248|Experimental|Web-based Educational Intervention|This group of participants will be given access to a web-based educational resource in addition to the standard of care.
2892319|NCT03303248|No Intervention|Standard of Care|This group will be given only the standard of care during their clinic visit.
2892320|NCT03303235|Experimental|IV Methergine|"IV methylergonovine group~-IM 0.9% NaCl (1 ml)) + IV methylergonovine (2 mcg/ml) infusion (100 ml)"
2892321|NCT03303235|Active Comparator|Conventional|"IM methylergonovine group~-200 mcg IM methylergonovine (1 ml) + IV 0.9% NaCl infusion (100 ml)"
2892322|NCT03303222||patients on dialysis|patients with kidney disease treated by dialysis
2892323|NCT03303222||patients with chronic kidney disease|patients with chronic kidney disease not treated by dialysis
2892324|NCT03303196|Experimental|Bihormonal Bionic Pancreas Admission|Four day inpatient admission where participants will have blood sugar managed by the Bihormonal Bionic Pancreas. Blood sugars will be monitored for safety by study staff.
2892325|NCT03303196|No Intervention|Standard Care Admission|Four day inpatient admission where participants will have blood sugar managed by the participant's home-glucose control regimen. Blood sugars will be monitored for safety by study staff.
2892326|NCT03303183|Active Comparator|Direct Ear Scanner|Digitale impression via direct ear scanner
2892327|NCT03303183|Active Comparator|Silicone Ear impression|Impression via silicone
2892328|NCT03303170|Experimental|Sebacia Microparticles|
2892329|NCT03303170|Active Comparator|Nd:Yag Laser|
2892369|NCT03302910|Experimental|Short Stay Unit|Subjects are assigned to the short stay unit (SSU) for approximately 23 hours treatment and observation period. In the SSU, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.
2892330|NCT03303144|Experimental|Triferic via Hemodialysate|Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic over 4 hrs at one hemodialysis session.
2892331|NCT03303144|Experimental|Triferic via IV infusion( pre-dialyzer)|Patients will receive a single 6.5-mg dose of Triferic iron administered IV over 3 hrs during hemodialysis via arterial blood line (pre-dialyzer)
2892332|NCT03303144|Experimental|Triferic via IV infusion (post-dialyzer)|Patients will receive a single 6.5-mg dose of Triferic iron administered IV over 3 hrs during hemodialysis via venous blood line (post-dialyzer)
2892333|NCT03303131||Period A|Children discharged as recovered from September 2007 to March 2009 with at least 15% of their weight at admission
2892334|NCT03303131||Period B|Children discharged as recovered from April 2009 to December 2011 with Children discharged as recovered from September 2007-March 2009 with MUAC ≥ 124 mm
2892335|NCT03303118|Other|Left|No product administration will be done in this study.
2892336|NCT03303105|Experimental|TEV-48125 (225 mg/1 month) group|TEV-48125 will be administered subcutaneously once every 4 weeks for a total of 13 doses to subjects of 225 mg/1 month group.
2892337|NCT03303105|Experimental|TEV-48125 (675 mg/3 month) group|TEV-48125 will be administered subcutaneously once every 12 weeks for a total of 5 doses to subjects of 675 mg/3 months group.
2892338|NCT03303092|Experimental|TEV-48125 (225/225/225 mg) group|TEV-48125 will be subcutaneously administered once monthly for 3 months (225/225/225 mg).
2892339|NCT03303092|Experimental|TEV-48125 (675 mg/placebo/placebo) group|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/placebo/placebo).
2892340|NCT03303092|Placebo Comparator|Placebo group|Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).
2892341|NCT03303079|Experimental|TEV-48125 (675/225/225 mg) group|TEV-48125 will be subcutaneously administered once monthly for 3 months (675/225/225 mg).
2892342|NCT03303079|Experimental|TEV-48125 (675 mg/placebo/placebo) group|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/placebo/placebo).
2892343|NCT03303079|Placebo Comparator|Placebo group|Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).
2892344|NCT03303066|Experimental|FG-4592 (Open Label, Double-blind, Three times a week)|Fixed starting doses (different doses for lower body weight & higher body weight); dose adjustments to hemoglobin levels are allowed during the study.
2892345|NCT03303066|Placebo Comparator|Placebo (Double-blind, Three times a week)|Fixed starting doses (different doses for lower body weight & higher body weight); dose adjustments to hemoglobin levels are allowed during the study.
2892346|NCT03303053|Experimental|Group1:Cholestyramine+standard treatment|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
2892347|NCT03303053|Experimental|Group2:Prednisolone+standard treatment|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
2892348|NCT03303053|Active Comparator|Group 3: Standard treatment alone|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
2892349|NCT03303040|Experimental|Stimulation|Electrical stimulation of hemidiaphragm
2892350|NCT03303040|No Intervention|Control|No stimulation of hemidiaphragm
2892351|NCT03303027|Experimental|6-0 fast absorbing gut suture|6-0 fast absorbing gut used to suture wound
2892352|NCT03303027|Experimental|5-0 fast absorbing gut suture|5-0 fast absorbing gut used to suture wound
2892353|NCT03303014|Experimental|5-0 Prolene|Half of the wound will be treated with 5-0 prolene
2892354|NCT03303014|Experimental|5-0 Fast Absorbing Gut|Half of the wound will be treated with 5-0 fast absorbing gut
2892355|NCT03303001|Experimental|Subacromial high volume infiltration|This group received an subacromial infiltration guided by ultrasound, of 50 mL of solution. This solution mix: 2 mL of methylprednisolone (40 mg) plus 8 mL of lidocaine simple plus 10 mL of ropivacaine 7.5% plus 30 mL of saline solution.
2892356|NCT03303001|Active Comparator|Subacromial conventional infiltration|This group received an subacromial infiltration guided by ultrasound of 10 mL of solution. This solution mix: 2 mL of methylprednisolone (40 mg) plus 3 mL of lidocaine simple plus 5 mL of ropivacaine 7.5%
2892357|NCT03302988|Experimental|Everted closure|Wound eversion will be achieved through buried vertical mattress suture or cuticular suture based on surgeon's preference, either buried vertical mattress suture or cuticular sutures
2892358|NCT03302988|Active Comparator|Planar closure|The planar side of the same wond will be closed with traditional buried simple closure and running cuticular sutures
2892359|NCT03302975|Experimental|Real time biofeedback|Real-time visual biofeedback of braking forces during a treadmill run.
2892360|NCT03302962|Experimental|Intensive Asthma Education|"One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted."
2892361|NCT03302962|No Intervention|Routine Asthma Education Literature|"The remaining 54 cases were randomized to the control arm and received written materials related to patient-centered asthma control."
2892362|NCT03302949|No Intervention|Control|Control arm will not receive the intervention, but will receive standard 6-month anti-tuberculosis regimen and nutritional supplements provided by various NGO's (on irregular basis).
2892363|NCT03302949|Experimental|Intervention|Intervention arm will receive standard 6-month anti-tuberculosis regimen, nutritional supplements provided by various NGO's (on irregular basis), and receive the study intervention of daily supplement of 62.5g Lacprodan® DI-8090
2892364|NCT03302936|Experimental|Pyridium arm|Phenazopyridine 200mg tablet, once prior to surgery
2892365|NCT03302936|No Intervention|Control arm|No intervention in this group. Routine perioperative care.
2892366|NCT03302923|Experimental|Brisk walking 1|1 time a week of 9 months brisk walking
2892367|NCT03302923|Experimental|Brisk walking 3|3 times a week of 9 months brisk walking
2892368|NCT03302923|No Intervention|Control group|No brisk walking session
2892456|NCT03302208|Placebo Comparator|placebo group|
2892370|NCT03302910|Active Comparator|Standard of Care|Subjects are assigned to inpatient hospitalization. During hospitalization, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.
2892371|NCT03302897|Experimental|2 μg LEP-F1 + 5 μg GLA-SE|Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56. Low dose of antigen.
2892372|NCT03302897|Experimental|10 μg LEP-F1 + 5 μg GLA-SE|Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56. Higher dose of antigen.
2892373|NCT03302884|Experimental|Biological sampling in ovarian carcinoma|Blood and tumor samples
2892374|NCT03302871|Experimental|İntensive Therapy Group|Children who received Botulinum toxin type A to plegic upper limb would be treated by transcranial direct current stimulation and a hybrid training model of CIMT and BIT
2892375|NCT03302871|Active Comparator|Control Group|Children who received Botulinum toxin type A to plegic upper limb would continue their usual care
2892376|NCT03302845|Experimental|Omeprazole|Subjects will receive one 40 mg omeprazole capsule per day for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
2892377|NCT03302845|Experimental|Famotidine|Subjects will receive one 40 mg famotidine tablet given twice daily for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
2892378|NCT03302832|Active Comparator|Standard Care Physical Therapy|The participants randomized to the Standard Care Physical Therapy group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of sessions will be 2-3 x per week for the initial 2 weeks, followed by 2 x per week until the culmination of physical therapy. The frequency and duration of sessions will be determined by the treating physical therapist based upon the clinical needs and progress of the specific participant.
2892379|NCT03302832|Experimental|Physical Therapy and in-Home Equipment|The participants randomized to the experimental group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of physical therapy sessions will be 1 x per week throughout the duration of the study period. In addition, this group will utilize in-home exercise equipment daily.
2892380|NCT03302819|Experimental|Breast cancer accuracy|Patients with a known or suspected (and subsequently proven) breast cancer
2892381|NCT03302819|Experimental|Imaging characteristics and performance|Patients attending the symptomatic clinic
2892382|NCT03302819|Experimental|Tumour response in neoadjuvant treatment|Patients who are being treated with neoadjuvant chemotherapy or endocrine treatment
2892383|NCT03302793|Experimental|BreEStim and tDCS sham, then combined BreEStim and tDCS|BreEStim is voluntary breathing controlled electrical stimulation.
2892384|NCT03302793|Experimental|Combined BreEStim and tDCS, then BreEStim and tDCS sham|BreEStim is voluntary breathing controlled electrical stimulation. tDCS is transcranial direct current stimulation.
2892385|NCT03302780|Experimental|BreEStim and tDCS sham, then combined BreEStim and tDCS|BreEStim is voluntary breathing controlled electrical stimulation.
2892386|NCT03302780|Experimental|Combined BreEStim and tDCS, then BreEStim and tDCS sham|BreEStim is voluntary breathing controlled electrical stimulation. tDCS is transcranial direct current stimulation.
2892387|NCT03302767|Experimental|Psychological and Social Consultation|Psychological and Social Consultation
2892388|NCT03302754|Other|Alemtuzumab|"Patients less than 15kg will be given 0.6mg/kg alemtuzumab divided over days -14, -13, and -12 (0.2mg/kg/dose).~Patients greater than 15kg will be given a 3mg test dose on day -14 in order to limit the first dose to no more than 3 mg per the manufacturer's recommendation. This will be followed by 0.23mg/kg/dose on days -13 and -12 (to equal a total dose of approximately 0.5-0.6mg/kg).~Alemtuzumab will be drawn into a sterile syringe and given to patients subcutaneously."
2892389|NCT03302741|Active Comparator|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the IZs of the entire muscle.
2892390|NCT03302741|Experimental|3-dimensional innervation zone (3DIZ) guided injection|In the IZ-guided injection technique, IZ location obtained using the 3DIZ will be first marked over the skin surface of the muscle and the depth of the IZ will be also provided. The 3DIZ will be applied to the IZ-guided injection group 1 day prior to scheduled injection. The surface location and depth information of the IZ will be used to guide where the needle tip needs to go. Currently, patients commonly receive 1 to 2 injection sites, occasionally 3 sites for biceps muscles. To standardize the procedure, we will choose 2 sites for all patients.
2892391|NCT03302728|Experimental|Lenalidomide & brentuximab vedotin|Brentuximab vedotin 1.8mg/Kg Lenalidomide 15 mg
2892392|NCT03302715|Experimental|Mucosal biopsies|Only blood samples and mucosal biopsies
2892393|NCT03302702|Other|Exercise program|Treatment group
2892394|NCT03302689|Experimental|Ropivacaine|TAP-block with Ropivacaine Solution
2892395|NCT03302689|Experimental|Levobupivacaine|TAP-block with Levobupivacaine Solution
2892396|NCT03302676|Active Comparator|Intervention|"Patients use tasteless and sugar free chewing gum up to 5 times a day for 1 month.~Daily registrations in a patient dairy."
2892397|NCT03302676|No Intervention|Control|Patients continue with daily routine to relieve oral discomfort. No chewing gum allowed.
2892398|NCT03302663|Other|Patients attending for a clinical scan|Patients attending for a clinical scan will be offered 2-4 extra sequences. The additional sequences and compare them to the currently established ones.
2892399|NCT03302663|Other|Patients who have requested a TOP|Women who have requested a termination of pregnancy (TOP) will be asked if they are willing to have a fetal MRI at 3T performed prior to the TOP. The images obtained will be compared to either images done clinically at 1.5T before the TOP request (if done and with the patients consent) or to images obtained at 1.5T of a similar gestation and pathology that the investigators obtained in a previous research study.
2892400|NCT03302663|Other|Patients with fetal heart abnormality|The investigators plan to recruit patients with a fetus with heart abnormality on ultrasound and compare the MRI findings with the ultrasound findings and the clinical outcome.
2892574|NCT03301428|Experimental|Retrain pain educational website|Participants will be invited to consult an educational website developped for patients with chronic pain
2892401|NCT03302663|Other|Patient fetal bone abnormalities|The investigators would like to ask women who have a fetus with bone abnormalities if they would be willing to have a fetal MRI. The findings will be compared to the ultrasound findings and the clinical or pathological findings after delivery.
2892402|NCT03302650|Experimental|Angiotensin group|Patients will receive Angiotensin II at a starting dose of 20 ng/Kg/min. During the first 30 minutes after randomization, the angiotensin II infusion will be titrated to achieve a mean arterial pressure of 65-75 mmHg while the norepinephrine infusion will be withdrawn and stopped. Following a stabilization of 60 minutes, the angiotensin II infusion is titrated to achieve a mean arterial pressure of 85-95 mmHg. Following a 30 minutes wash-in period and a 60 minutes stabilization period, a third set of measurements will be taken. Then, the angiotensin II infusion will be withdrawn in small steps and replaced by a norepinephrine infusion which will then be titrated to achieve a mean arterial pressure of 65-75 mmHg. Then, the final set of measurements will be taken.
2892403|NCT03302650|Placebo Comparator|Normal saline group|Patients will receive normal saline infusion in addition to norepinephrine infusion. The same mean arterial pressure levels (65-75 mmHg > 85-95 mmHg > 65-75 mmHg) will be achieved by titration of the norepinephrine infusion. Identical wash-in and stabilization periods will be kept as in the study group. Measurements will be taken at the same time points as in the study group. The maximum dose of norepinephrine applied will be 0.7 mcg/kg/min.
2892404|NCT03302637||Cases|subjects with histology-confirmed incident pancreatic cancer, with no prior history of cancer (except non-melanoma skin cancer), a valid consent, and pre-diagnostic oral wash samples.
2892405|NCT03302637||Control|selected by incidence density sampling63 among cohort members who had no cancer prior to selection, provided a valid consent and an oral wash. Controls were frequency matched to cases by cohort, age at cohort entry (5 year), sex, race, and calendar year of cohort entry.
2892406|NCT03302624||Patients who were included in ELVIS study|
2892407|NCT03302611|Experimental|Surf Therapy|Participants randomized to surf therapy will receive 6 sessions (i.e., once per week for 6 weeks). Each surf therapy session is 1.5 to 3 hours in duration and occurs in a group setting. Each service member is paired with a surf instructor who typically works with them each week for the length of the 6-week program. Participant goals are individually-tailored to the service member (based on participant's level of comfort in the water, etc.) and can incorporate both physical and psychological objectives
2892408|NCT03302611|Active Comparator|Hike Therapy|Participants randomized to hike therapy will receive 6 sessions (i.e., once per week for 6 weeks). Each hike therapy session is 1.5 to 3 hours in duration and occurs in a group setting. During hike therapy, service members may hike together or at a self-selected pace. Participant goals are individually-tailored to the service member (based on participant's limitations for hiking, etc.) and can incorporate both physical and psychological objectives
2892409|NCT03302598|Other|patients with enterocutaneous fistula|
2892410|NCT03302585|Experimental|High-Dose Vitamin D Treatment Group|"Patients in this arm will receive:~-5 days of high-dose oral vitamin D3 (50,000 IU daily x 5), followed by 85 days of moderate dose oral vitamin D3 (10,000 IU daily x 85 days)"
2892411|NCT03302585|Placebo Comparator|Placebo/Standard Vitamin D3 Group|"Patients in this arm will receive Placebo/Standard of Care Vitamin D3:~-5 days of placebo, followed by 85 days of standard of care dose of oral vitamin D3 (4,000 IU daily x 85 days)"
2892412|NCT03302572|Experimental|Brief information group|Patients will be given brief information about the existence of advance directives after resolving the reason for the visit for which they had come. This information will not last more than 3 minutes and will not be repeated on successive visits within the recruitment period. Also, an informative triptych will be given to the patient so that he can read it at home. These leaflets have been made by the regional Department of Health. They will be advised that we can extend the information or help them to do the document in the near future if they want, we will inform that we would wait for the answer 3 months. In case of interest, they can leave their information in the User Service by specifying name, telephone number and reference doctor or ask for an appointment again.
2892413|NCT03302572|No Intervention|Control group|"Patients who fall into a control group will only be attended to their reason for visiting and will be asked for the necessary data to obtain the independent variables if they do not appear in their history. If the patient in this group wants the information, he will be excluded from the study because he refuses to participate."
2892414|NCT03302559|Experimental|Retinol Complex 0.5|During a 2-week washout period the participant will use a basic skin care regimen (SkinMedica facial cleanser in the morning and in the evening, Cetaphil Fragrance Free Moisturizing Lotion in the morning and in the evening and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen in the morning and as needed), followed by the same basic skin care regimen plus SkinMedica Retinol Complex 0.5 applied topically to the face in the evening for 12 Weeks. Assessments of the participant's facial skin will be made utilizing investigator clinical grading, digital photography, a spectrophotometer and in vivo skin imaging.
2892415|NCT03302546|Active Comparator|Incremental Hemodialysis|Subjects on this arm will be treated with 2 hemodialysis sessions of at least 4 hour per week.
2892416|NCT03302546|Active Comparator|Conventional hemodialysis|Subjects on this arms will be treated with 3 hemodialysis sessions of at least 3.5 hour per week.
2892417|NCT03302533||Primary arthroplasty|All patients who received TEA for an acute trauma with fracture of the distal humerus.
2892418|NCT03302533||Secondary arthroplasty|All patients who received TEA due to a failed reconstruction or non-operative treatment after a distal humerus fracture.
2892419|NCT03302520|Experimental|Novomax|Novomax(R) ceramic glass spacer for interbody fusion
2892420|NCT03302520|Active Comparator|PEEK cage|PEEK cage for interbody fusion
2892421|NCT03302507|Experimental|BESS, biportal endoscopic spine surgery|Biportal endoscopic decompression surgery for lumbar spinal stenosis
2892422|NCT03302507|Active Comparator|ULBD, unilateral laminotomy bilateral decompression|Minimally invasive ULBD for lumbar spinal stenosis
2892423|NCT03302494|Experimental|WaveCrest|WaveCrest left atrial appendage occluder
2892424|NCT03302494|Active Comparator|Watchman (control)|Watchman left atrial appendage closure device
2892425|NCT03302481|Experimental|Experimental Group|the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
2892426|NCT03302455|Experimental|eCBTI|This group will receive a 1-week of eCBTI treatment and will receive 3 months of follow-up.
2932579|NCT03022838|Placebo Comparator|Placebo|Placebo tablets
2892427|NCT03302455|No Intervention|Control|This group does not receive any interventions during first 3 months of clinical study. If the participants still have no remission from insomnia after 3 months, will be recommended to enter the standardized insomnia treatment (medication and / or non-drug treatment).
2892428|NCT03302429|Experimental|PRF/ BCP|"Biphasic calcium phosphate (BCP)bioceramic bone substitute combined with platelet rich fibrin PRF"
2892429|NCT03302429|Active Comparator|autogenous bone graft|Autogenous bone graft involving utilizing bone obtained from the same individual receiving the graft
2892430|NCT03302416|Experimental|[C-11]NOP-1A PET Scan conditions|Baseline condition and Post-hydrocortisone (1 mg/Kg, intravenous) condition
2892431|NCT03302403|Experimental|CAR T cell|"In this study, autologous T cells transduced with a chimeric antigen receptor are used to treat patients with malignant tumors:~CAR-CD19 T cell is for the treatment of B-cell Leukaemia/Lymphoma; CAR-BCMA T cell is for the treatment of Myeloma; CAR-GPC3 T cell is for the treatment of Hepatocellular Carcinoma; CAR-CLD18 T cell is for the treatment of Pancreatic Carcinoma and Adenocarcinoma of Esophagogastric Junction.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to CAR T cell infusion, which may improve in vivo cell count and survival of T cells.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
2892432|NCT03302390||Biopsy of Skin with Psoriasis|Shave biopsy of psoriasis lesion
2892433|NCT03302377|Experimental|Physical activity intervention|Participants will receive an individual counseling session in the clinic to help them set physical activity and step goals. They will then receive a Fitbit wrist monitor and help personalizing the Fitbit app. They will send weekly emails to their physicians reporting their goals and current activity. They will return at 12 weeks to engage in a semi-structured interview to give their overall impressions of the intervention.
2892434|NCT03302364||risperidone patients|patients that are in accordance with DSM-IV-TR schizophrenia diagnostic criteria, based on concise International Neuropsychological Interview(MINI)
2892435|NCT03302351|Experimental|Dexmedetomidine|1st group will include 30 patients will receive intravenous dexmedetomidine 1 mcg/kg.
2892436|NCT03302351|Experimental|Ketamine|2nd group will include 31 patients will receive intravenous ketamine 0.4 mg/kg.
2892437|NCT03302351|Experimental|Dexmetedomidine-Ketamine combination|3rd group will include 33 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg and low dose ketamine 0.25mg/kg.
2892438|NCT03302338|Experimental|SAFE group|SAFE group: simulated amniotic fluid 20cc/kg/day enterally divided according to number of feds (syringe for every fed). This amount provides enteral 4.5μg rhG-CSF / kg/day and enteral 88IU rhEPO / kg/day.
2892439|NCT03302338|Placebo Comparator|Placebo|Placebo group: distilled water 2.5 ml/kg every 3 hours enterally given.
2892440|NCT03302325||Stage IV solid tumors|adult patients with stage IV cancer that are starting a new line of treatment
2892441|NCT03302312||Participants|Service members who received at least one SGB study procedure as part of the clinical effectiveness trial during the three months prior to qualitative data collection or service members who received at least one SGB for PTSD symptoms at a study site in the three months prior to qualitative data collection.
2892442|NCT03302312||Providers|Behavioral Health or other (e.g., Family Medicine) clinicians who have referred or could potentially have referred service members for SGB for PTSD symptoms, as well as physicians who provide SGBs.
2892443|NCT03302299|Experimental|Isoniazid & pyridoxine|Isoniazid 300 mg oral tablet: 300 mg daily by mouth for 6 months. Pyridoxine 25 mg oral tablet: 25mg daily by mouth for 6 months.
2892444|NCT03302286|Active Comparator|Mannitol Prime|This group will undergo cardiac surgery with heart-lung machine with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
2892445|NCT03302286|Active Comparator|NonMannitol Prime|This group will receive a priming solution of Ringer´s acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
2892446|NCT03302273|Experimental|Corneal Epithelial Stem Cell Transplant|The treatment will consist of transplantation (via self-administration) of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material four times daily in both eyes for a three month interval.
2892447|NCT03302260|No Intervention|Control|Participants in the control arm will receive standard postpartum clinical care through the participants' usual healthcare providers. No intervention will be administered. Participants in both arms will receive educational material about the risk of CVD, and CVD prevention for women with HDP from the Preeclampsia Foundation.
2892448|NCT03302260|Experimental|CardioPrevent® Program|In addition to standard care, participants randomized to the intervention arm will also receive the CardioPrevent® Program. This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context. Participants in both arms will receive educational material about the risk of CVD, and CVD prevention for women with HDP from the Preeclampsia Foundation.
2892449|NCT03302247|Experimental|Nivolumab+Gemcitabine|Nivolumab infusion on day 1 and 15 with the addition of gencitabine on day 1, 8 and 15 of 28 day cycle
2892450|NCT03302234|Experimental|pembrolizumab + ipilimumab|Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus 1 mg/kg of ipilimumab by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.
2892451|NCT03302234|Active Comparator|pembrolizumab + placebo|Participants receive 200 mg of pembrolizumab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus placebo by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.
2892452|NCT03302221|Other|Dexmedetomidine Group|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography ;general anesthesia combined with 0.5 μg/kg dexmedetomidine infusion before induction
2892453|NCT03302221|Experimental|Paravertebral Block Group|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography ;general anesthesia combined with paravertebral block
2892454|NCT03302221|Experimental|Epidural Block Group|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography ;general anesthesia combined with epidural block
2892455|NCT03302208|Active Comparator|pregabalin group|
2892457|NCT03302195|Active Comparator|Control group|"Heparin dose and cardiopulmonary bypass pump flow rate are calculated using total body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
2892458|NCT03302195|Experimental|Intervention group A|"Heparin dose is adjusted for lean body weight and cardiopulmonary bypass pump flow rate is calculated using total body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
2892459|NCT03302195|Experimental|Intervention group B|"Heparin dose is calculated using total body weight and cardiopulmonary bypass pump flow rate is adjusted for lean body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
2892460|NCT03302195|Experimental|Intervention group C|"Heparin dose and cardiopulmonary bypass pump flow rate are adjusted for lean body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
2892461|NCT03302182|Experimental|fasting group|"During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fasting condition.~For group1:~cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg~For group2:~cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg"
2892462|NCT03302182|Experimental|Fed group|"During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fed condition.~For group3:~cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg~For group4:~cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg"
2892463|NCT03302169|Experimental|Posterior Rhabdosphincter Reconstruction|Patients in who posterior rhabdosphincter reconstruction is performed
2892464|NCT03302169|Active Comparator|Standard Technique|Patients in who posterior rhabdosphincter reconstruction is NOT performed, Standard technique.
2892465|NCT03302156|Other|Control Group|The control group will consists of women with no imaging evidence of gynecological cancer, who are undergoing hysterectomy and salpingo-oophorectomy.
2892466|NCT03302156|Other|Patient Group|The patient group will consist of women with suspected gynecological cancers who are undergoing hysterectomy and salpingo-oophorectomy
2892467|NCT03302143|Active Comparator|Control|Guided bone regeneration with Bovine Bone Mineral
2892468|NCT03302143|Experimental|Experimental|Guided bone regeneration with freeze dried bone allograft
2892469|NCT03302130|Experimental|Imaging healthy volunteers|Mood induction: positive, negative, neutral mood (using subjects own memories) Arterial spin labeling MRI Physiological monitoring
2892470|NCT03302091|Experimental|All Subjects|
2892471|NCT03302078|Experimental|Treatment T|Fed state
2892472|NCT03302078|Experimental|Treatment R|Fasted state
2892473|NCT03302065|Experimental|Test Product 1 Tiotropium|4 inhalations
2892474|NCT03302065|Experimental|Test Product 2 Tiotropium|4 inhalations
2892475|NCT03302065|Experimental|Test Product 3 Tiotropium|4 inhalations
2892476|NCT03302065|Active Comparator|Reference Tiotropium|2 inhalations
2892477|NCT03302039|Experimental|Single shot|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, a single shot phenylephrine (1.5 ug/Kg) will be administered.
2892478|NCT03302039|Active Comparator|Fixed infusion|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, fixed infusion phenylephrine will be administered at a dose of (0.75 mcg/Kg/min). the infusion will stop if reactive hypertension occurred.
2892479|NCT03302039|Active Comparator|Variable infusion|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, variable infusion phenylephrine will be administered at a starting dose of (0.75 mcg/Kg/min). the infusion will be titrated according to blood pressure.
2892480|NCT03302026|Experimental|Real-time neurofeedback training group|We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. In this arm, participants will complete four sessions: an intake session and 3 neurofeedback scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm. Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.
2892481|NCT03302026|No Intervention|No-feedback control group|We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. In the control group arm, participants will complete four sessions: an intake session and 3 scanning visits with no neurofeeback. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm. Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.
2892482|NCT03302013|Experimental|Vanguard XP Knee Replacement Surgery|Participants randomised in this group will receive the Vanguard XP Bi-cruciate Retaining Knee Replacement System. This total knee replacement device (Vanguard XP) and surgical procedure retain the anterior cruciate ligament in the knee.
2892483|NCT03302013|Active Comparator|Vanguard CR Knee Replacement Surgery|Participants randomised to this group will receive the Vanguard CR Single Cruciate Retaining Knee Replacement Surgery. This total knee replacement device (Vanguard CR) and surgical procedure sacrifice the anterior cruciate ligament and replaces it with artificial support. This is currently the standard practice for knee replacement surgery in the NHS.
2892484|NCT03302000|Experimental|Visual stimulation|"Early visual stimulation (EVS) will be implemented by physioteraphist. Nine high contrast figures will be used. Figures will be moved in vertical, horizontal and circular directions. Figures are black and white. One card is composed by a face coloured in yellow and red.~At home: the parents will receive training to do visual stimulation at home. For 30 days, 10-minute time each day. Once a week the physiotherapist will visit infant in order to verify the presence of any doubts about the EVS."
2892575|NCT03301428|Experimental|Booklet|Participants will be invited to read an educational booklet for patients with chronic pain
2892485|NCT03302000|Other|Instruction regarding child development|"Parentswill receive instructions on how to take care of the premature child. Information will be provided on how to stimulate sensory systems and motor development. A pre-defined guide will be used.~Instructions will be provided only on the first day and then no additional information will be provided to caregivers."
2892486|NCT03301987|Experimental|Therapeutic exercise|
2892487|NCT03301974|Experimental|conjunctival autograft with fibrin glue|Conjunctival autograft with fibrin glue done for patients of group 1 after pterygium excision
2892488|NCT03301974|Experimental|sutured conjunctival autograft|Sutured conjunctival autograft done for patients of group 2 after pterygium excision
2892489|NCT03301974|Experimental|sutureless and glue-free conjunctival autograft|Sutureless, glue-free conjunctival autograft done for patients of group 3 after pterygium excision
2892490|NCT03301948|Experimental|Overfeed|Experimental trial where participants are provided with 50% higher energy intake than their estimated requirements on the first day of the trial.
2892491|NCT03301948|Experimental|Energy Balance|Experimental trial where participants are provided with an energy intake equal to their estimated requirements on the first day of the trial.
2892492|NCT03301922|Experimental|Work-focused metacognitive therapy|Work-focused metacognitive therapy
2892493|NCT03301922|Other|Waiting list|Waiting list
2892494|NCT03301909|Experimental|PillCam™ Endoscopy System|"PillCam™ Endoscopy System consists of the following subunits (the dates bellow represent the initial marketing approvals):~PillCam™ Capsule products' family (latest model):~PillCam COLON 2~PillCam UGI (upper gastrointestinal)~PillCam SB3 (small bowel 3)~PillCam Crohn's capsule~Patency capsule:~PillCam Patency capsule~All the bellow system subunits as applicable, are part of the regulatory approval status mentioned alongside each of the Pillcam and Patency systems.~PillCam Recorder~PillCam Sensor Arrays & Sensor Belt~PillCam™ Software v. 9~Workstation unit~Patency scanner"
2892495|NCT03301896|Experimental|LHC165 single agent|LHC165 intratumoral injection given alone
2892496|NCT03301896|Experimental|LHC165 in combination with PDR001|LHC165 intratumoral injection given with PDR001 infusion
2892497|NCT03301883|Experimental|Tocilizumab|Participants weighing greater than or equal to (>/=) 30 kilograms (kg) will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion every 2 weeks (Q2W), and participants weighing less than (<) 30 kg will receive tocilizumab 12 mg/kg IV infusion Q2W for 52 weeks. After Week 12, the dose of tocilizumab can be adjusted for non-transient changes in body weight (shifting from <30 to >/=30 kg) over a minimum of three consecutive dosing visits. MTX, NSAIDs, and oral corticosteroids (CSs) are permitted but not required during the study.
2892498|NCT03301870|Experimental|ATx201 GEL, 2% - intact skin|ATx201 GEL, 2% applied intact skin
2892499|NCT03301870|Experimental|ATx201 GEL, 4% - intact skin|ATx201 GEL, 4% applied to intact skin
2892500|NCT03301870|Experimental|ATx201 GEL, 2% - abraded skin|ATx201 GEL, 2% applied to abraded skin
2892501|NCT03301870|Experimental|ATx201 GEL, 4% - abraded skin|ATx201 GEL, 4% applied to abraded skin
2892502|NCT03301870|Placebo Comparator|ATx201 GEL Placebo - intact skin|ATx201 GEL Placebo applied to intact skin
2892503|NCT03301870|Placebo Comparator|ATx201 GEL Placebo - abraded skin|ATx201 GEL Placebo applied to abraded skin
2892504|NCT03301870|Active Comparator|Negative Irritant Control - intact skin|Negative (low) Irritant Control applied to intact skin
2892505|NCT03301870|Active Comparator|Negative Irritant Control - abraded skin|Negative (low) Irritant Control applied to abraded skin
2892506|NCT03301870|Active Comparator|Positive Irritant Control - intact skin|Positive (high) Irritant Control applied to intact skin
2892507|NCT03301857|Experimental|Denosumab|Trial drug - Cohort A
2892508|NCT03301857|No Intervention|Safety Follow up|Safety Follow Up - Cohort B Subjects who completed denosumab treatment in 20062004 and were in the safety follow-up (FU) at the conclusion of 20062004 will continue in long-term safety FU in this study. FU study visits will be done every 6 months (± 30 days) either via telephone or in-person clinic visit. Retreatment with denosumab (120 mg subcutaneous [SC] every 4 wks) is allowed for subjects who previously demonstrated a response to denosumab and have experienced disease recurrence while in long-term safety FU at the investigator's discretion. If more than 12 months have elapsed since the last denosumab therapy, biopsy confirmation of disease for further pathologic evaluation of the recurrence is required.
2892509|NCT03301844|Experimental|Study treatment|Blephapad Combo twice daily for one month. Blephapad is a disposable wet wipe containing Hy-Ter® solution (sodium hyaluronate acid and 4-terpineol), aloe, natural anti-inflammatories and antiseptics.
2892510|NCT03301844|Other|Standard treatment|Wet, warm gauze twice daily for one month.
2892511|NCT03301831|Experimental|Resourcefulness Training Intervention|The intervention arm will receive an intervention that includes: a face-to-face session for teaching social (help-seeking) and personal (self-help) resourcefulness skills; ongoing access to video vignettes of caregivers of technology-dependent children describing resourcefulness skill application in daily life; 4 weeks of skills' reinforcement using daily journal writing; weekly phone calls for the first 4 weeks; and booster sessions at 2 and 4 months post enrollment.
2892512|NCT03301831|No Intervention|Attention Control|The Attention Control arm will receive weekly phone calls for the first 4 weeks and at 2 and 4 months post enrollment plus any usual care.
2892513|NCT03301818|Experimental|Patients undergoing USI repair|
2892514|NCT03301805|Experimental|BLEX 404 Oral Liquid|During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Gemcitabine monotherapy among 6 patients in the Phase I study.
2892515|NCT03301792|No Intervention|Routine Prenatal Care|Subjects randomized to routine care will receive their care in the usual diabetic clinic attended by residents and faculty. They will receive consultation with the diabetes educator at diagnosis and as needed. Patients are seen every 2 weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits are 10-15 minutes and focus on routine screening tests and review of blood sugar logs/medication titration.
2892576|NCT03301428|No Intervention|Control|Participants in this group will receive the 2 educational tools at the end of the study
2892577|NCT03301415|Experimental|Confirmed congenital CMV without baseline SNHL|Valganciclovir 16 mg/kg/dose orally twice daily for four months, n=229
2892578|NCT03301402|Active Comparator|Filter|
2892516|NCT03301792|Experimental|Group prenatal care|Group visits will be held every 2 weeks in a continuous cycle through a six session curriculum. Women will have weekly visits beginning at 37 weeks with traditional prenatal visits on the weeks when the group does not meet. Groups of 2-12 women will meet for two hour visits and much of that time will be spent on pregnancy, behavioral health, diabetes and nutrition education. Groups will be co-facilitated by a health educator and an obstetric provider. Women may be instructed to have additional visits in the traditional clinic at the discretion of the obstetric provider.
2892517|NCT03301779|Experimental|Investigational Product|Blood product from these donors will be processed and stored using the Hemanext Red Blood Cell Processing System
2892518|NCT03301779|No Intervention|Control Product|Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.
2892519|NCT03301766|Experimental|Lidocaine 5% patch|"Patients will receive a 7 day supply (21 patches) of lidocaine 5% patches upon discharge from the emergency department in addition to standard therapy at the discretion of the treating emergency department physician."
2892520|NCT03301766|Active Comparator|Non-medicated patch|"Patients will receive a 7 day supply (21 patches) of non-medicated patches upon discharge from the emergency department in addition to standard therapy at the discretion of the treating emergency department physician."
2892521|NCT03301740|Experimental|UF Profiling Phase First|"First treatment phase begins with linear UF profiling during HD.~Participants randomized to starting with the experimental UF profiling phase will receive 9 HD treatments with UF profiling (1st experimental phase). Following a 3 conventional HD treatment wash-out period, participants will then cross over to 9 conventional HD treatments (1st control phase). Following a 2nd 3 conventional HD treatment wash-out period, participants will cross over to 9 HD treatments with UF profiling (2nd experimental phase). Following a 3rd conventional HD treatment wash-out period, participants will cross over to 9 conventional HD treatments (2nd control phase)."
2892522|NCT03301740|Experimental|Conventional HD Phase First|"First treatment phase begins with conventional HD.~Participants randomized to starting with the control conventional HD phase will receive 9 conventional HD treatments (1st control phase). Following a 3 conventional HD treatment wash-out period, participants will then cross over to 9 HD treatments with UF profiling (1st experimental phase). Following a 2nd 3 conventional HD treatment wash-out period, participants will cross over to 9 conventional HD treatments (2nd control phase). Following a 3rd conventional HD treatment wash-out period, participants will cross over to 9 HD treatments with UF profiling (2nd experimental phase)."
2892523|NCT03301727|Active Comparator|In-person CBT-I Treatment|Participants receive 6 in-person weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
2892524|NCT03301727|Active Comparator|Online CBT-I Treatment|Participants receive 6 online weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
2892525|NCT03301727|Other|Wait-list Control|Participants are placed on a wait-list for 6 weeks before receiving either in-person or online 6 weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
2892526|NCT03301714|No Intervention|Control|Regular dental care under the standard clinic operation
2892527|NCT03301714|Experimental|Intervention 1|Group based oral health education
2892528|NCT03301714|Experimental|Intervention 2|Individual-based motivational interviewing
2892529|NCT03301701|Experimental|Arm 1|Radical prostatectomy
2892530|NCT03301701|Active Comparator|Arm 2|Radiotherapy
2892531|NCT03301688|Experimental|A group (JS001 20161002)|The subjects of A group will use 3 mg/kg doses every 2 weeks.Drug batch number is 20161002.
2892532|NCT03301688|Experimental|B group (JS001 20161108)|The subjects of B group will use 3 mg/kg doses every 2 weeks.Drug batch number is 20161108.
2892533|NCT03301675|Experimental|Orange juice|Orange Juice: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) plus 100% orange juice (500 mL/d) during 12 weeks.
2892534|NCT03301675|No Intervention|Control|Control: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) during 12 weeks.
2892535|NCT03301649|Experimental|Ivermectin Lotion, 0.5%|Test Product, manufactured by Actavis Laboratories UT, Inc.
2892536|NCT03301649|Active Comparator|SKLICE® (ivermectin) Lotion, 0.5%|Reference product, manufactured by Arbor Pharmaceuticals, LLC
2892537|NCT03301649|Placebo Comparator|Placebo (vehicle) lotion|Placebo (vehicle) lotion, manufactured by Actavis Laboratories UT, Inc.
2892538|NCT03301636|Experimental|Pembrolizumab + Indoximiod|
2892539|NCT03301636|Active Comparator|Pembrolizumab + Placebo|
2892540|NCT03301636|Experimental|Nivolumab + Indoximiod|
2892541|NCT03301636|Active Comparator|Nivolumab + Placebo|
2892542|NCT03301623|Experimental|Clinical Decision Support|Patients within the physicians randomized to the IDM arm will receive the Clinical Decision Support alerts via the EHR when certain order criteria are triggered appropriately.
2892543|NCT03301623|Experimental|Patient Education and Activation Tools|Patients within the physicians randomized to SDM will receive the PEAT materials via REDCap two days prior to their PCP office visit. During the enrollment survey, they will be asked whether they prefer to receive the PEATS via email, text message, mail or any combination of the delivery methods and they will receive these materials every time they have an office visit with their PCP.
2892544|NCT03301610|Experimental|Mobile Education Delivery|The participants in the study arm will receive comprehensive pain management education delivered using mobile iPads at the point of care. The mobile based education modules will be inclusive of the use of the pain rating scale and assessment of pain; communication with healthcare providers; daily expectations for pain and pain management; pharmacologic and non-pharmacologic treatment options; medication side effects and safety; and discharge instructions including safe handling of opioids, disposal, tapering, and when to call the provider. It will also include an interactive pain and discomfort menu, knowledge based questions, and medication tracking log.
2892579|NCT03301402|No Intervention|No filter|
2892580|NCT03301389||Control group|
2892581|NCT03301389||Pretreatment group|Patients in pretreatment state
2892582|NCT03301389||Anthracycline-based chemotherapy (3 months)|Patients who received anthracycline-based chemotherapy 3 months ago
2892545|NCT03301610|Placebo Comparator|Standard verbal and written education|The control group will receive the current standard of care which consists of verbal instruction and pain management educational pamphlets. At a minimum, the patients will receive two educational pamphlets titled Your Pain and Discomfort Management Menu and Communicating About Your Pain. Verbal instruction is nurse dependent. At a minimum the nurse will provide the two pamphlets to the patient and follow-up with the patient to address any questions.
2892546|NCT03301597|Other|Control Arm|The Control Arm will receive standard of care (SOC) chemotherapy without the infusion of NLA101. SOC chemotherapy will be determined by local PI and must be a standard regimen for untreated de novo or secondary AML that will result in moderate to severe myelosuppression and will be given with curative intent.
2892547|NCT03301597|Experimental|Low Dose Arm|The Low Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of low-dose NLA101.
2892548|NCT03301597|Experimental|Medium Dose Arm|The Medium Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of medium-dose NLA101.
2892549|NCT03301597|Experimental|High Dose Arm|The High Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of high-dose NLA101.
2892550|NCT03301584|Active Comparator|Enhanced collaboration|"Enhanced OT and PT collaboration to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.~Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.~Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.~Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.~Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment."
2892551|NCT03301584|Active Comparator|Usual Care Treatment|Standard rehabilitation
2892552|NCT03301571|Other|All patients|"All patients will receive the treatment (CABG) and postoperatively three different interventions:~Change in preload and afterload~Change in inspired oxygen~Change in pacemaker modes"
2892553|NCT03301558|Active Comparator|Low dose sodium bicarbonate|Low dose 1500 mg sodium bicarbonate (Nephrotrans®) per day (500mg tablets 3x/day) for 14 ± 3 days. The patients will be advised to take one capsule with breakfast, one with lunch and one with dinner (schedule 1-1-1).
2892554|NCT03301558|Active Comparator|High Dose sodium bicarbonate|High dose 3000 mg of sodium bicarbonate (Nephrotrans®) per day (500mg tablets 3x/day) for 14 ± 3 days. The patients will be advised to take two capsules with breakfast, two with lunch and two with dinner (schedule 2-2-2).
2892555|NCT03301545|Active Comparator|Fast-Track to Bariatric Surgery|Patients will undergo standard of care for bariatric surgery patients in Manitoba and receive preoperative evaluation by the Centre for Metabolic and Bariatric Surgery (CMBS) team of nurses, dietitians, psychologist, and kinesiologist. Patients must attend the standard appointments and achieve the personalized program goals to be approved for laparoscopic Roux-En-Y gastric bypass surgery. Once approved, one of four surgeons performs surgery (within 12 months of randomization). Patients are followed post-operatively (by surgeon) at 6 weeks, and at 6 and 12 months. Pharmacologic glycemic control will be determined by an endocrinologist as per a standardized post-operative protocol. Post-procedural multidisciplinary follow-up occurs based on established CMBS guidelines (phone call 1 week post-operatively and an appointment at 3 and 12 months). Patients receive surgery within the current publically funded bariatric surgery program; no additional direct costs incurred by the patients.
2892556|NCT03301545|No Intervention|Best Diabetic Care Group|Patients will receive the best available medical practice for the treatment, education, and follow-up T2DM based on Manitoba Diabetes Care Recommendations and Canadian Diabetes Association's clinical practice guidelines. Patients will have access to a general physician, endocrinologist, and a diabetes education group. Endocrinologists will deliver the program to patients. Diabetes care, education and self-management support services will be provided by the Victoria General Hospital (VGH) Diabetes Education Centre; led by a registered nurse and dietitian. Patients will undergo group and individual diabetes management classes and counseling on topics including diet, exercise, smoking cessation, medications, diabetic complications, and blood sugar testing. Family supports will also be provided. Medical therapies, including pharmaceutical agents, will be determined on an individual basis as per standard protocol. There will be no direct patient-related medication costs (publicly funded).
2892557|NCT03301545|No Intervention|Retrospective Cohort|A retrospective cohort of non-Indigenous bariatric surgery patients from the Centre for Metabolic and Bariatric Surgery Program will allow comparison with the intervention group. The cohort will be age and gender matched.
2892558|NCT03301532|Experimental|Patients on a ketogenic diet|
2892559|NCT03301506|Experimental|Seladelpar 2 mg Capsule|
2892560|NCT03301506|Experimental|Seladelpar 5 mg Capsules|
2892561|NCT03301506|Experimental|Seladelpar 10 mg Capsule|
2892562|NCT03301480||No contraception/18-19 years old|
2892563|NCT03301480||Use of ENG-I/18 - 19 years old|
2892564|NCT03301480||LNG-IUS/18-19 years old|
2892565|NCT03301480||No Contraception/ 25 - 45 years old|
2892566|NCT03301480||Use of ENG-I/25 - 45 years old|
2892567|NCT03301480||LNG-IUS/25-45 years old|
2892568|NCT03301467|Experimental|Avacopan|Avacopan (formerly CCX168) 10 mg capsules x 3 administered twice daily during the blinded 26 week blinded treatment period
2892569|NCT03301467|Placebo Comparator|Avacopan Matching Placebo|Matching placebo capsules x 3 administered twice daily during the 26 week blinded treatment period period
2892570|NCT03301454|Experimental|Arm A|Pursuit of chemotherapy.
2892571|NCT03301454|No Intervention|Arm B|Interruption of chemotherapy, best supportive care
2892572|NCT03301441||Migrainers|Patients experiencing an acute brain infarction complicating the occlusion of the internal carotid artery or the first or second segment of the middle cerebral artery. Migraine status determined by the validated French short questionnaire ef-ID Migraine (Classification into migraine without or with aura)
2892573|NCT03301441||Non migrainers|Patients experiencing an acute brain infarction complicating the occlusion of the internal carotid artery or the first or second segment of the middle cerebral artery. Migraine status determined by the validated French short questionnaire ef-ID Migraine A short questionnaire validating the absence of migraine
2892607|NCT03301181|Experimental|Arm A|Approximately 20 subjects to receive BGB-3111 and rifampin
2892583|NCT03301389||Anthracycline-based chemotherapy (6 months)|Patients who received anthracycline-based chemotherapy 6 months ago
2892584|NCT03301389||Anthracycline-based chemotherapy (more than 1 year ago)|Patients who received anthracycline-based chemotherapy more than 1 year ago
2892585|NCT03301389||Other therapy group|Patients who have been treated with other therapies (other chemo-therapies, combined radiation therapy, target agent therapy, hormone therapy)
2892586|NCT03301350|Experimental|Neoadjuvant Chemotherapy|"Paclitaxel 80 mg/m2; administer intravenously on day 1, 8, 15 of cycles 1, 2, 3, 4 (every 3 weeks) Carboplatin AUC=2 (dose calculation by determining creatine clearance with Cockroft Gault using adjusted body weight); administer intravenously on day 1, 8, 15 of cycles 1, 2, 3, 4 (every 3 weeks) Doxorubicin 60 mg/m2; administer intravenously on day 1 of cycles 5, 6, 7, 8 (every 2 weeks) Cyclophosphamide 600 mg/m2; administer intravenously on day 1 of cycles 5, 6, 7, 8 (every 2 weeks) Pegfilgrastim (for use on Doxorubicin/Cyclophosphamide cycles only), filgrastim, or biosimilar support on day 2 - 3 of cycles 5, 6, 7, 8 (every 2 weeks)~Surgical intervention for management of breast cancer diagnosis; procedure and timing as determined by surgical team."
2892587|NCT03301337|Experimental|Hydrolyzed meat protein|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
2892588|NCT03301337|Experimental|Minced Meat|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
2892589|NCT03301337|Experimental|Beef|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
2892590|NCT03301311|Experimental|Specific Carbohydrate Diet (First)|Participants will be following the Specific Carbohydrate Diet (SCD). Allowed foods include meat/fish/poultry, eggs, some legumes (e.g., lentils and split peas are permitted, chickpeas and soybeans are not), fully fermented yogurt, non-starchy vegetables, ripe fruit, nuts/seeds, honey and nut flours (e.g. almond flour or coconut flour). Restricted foods include all grains, milk products aside from 24-hour fermented SCD yogurt and cheeses aged greater than 30 days, starchy vegetables, processed foods with food additives and sweeteners other than honey.
2892591|NCT03301311|Experimental|Modified Specific Carbohydrate Diet (First)|Participants will be following a modified Specific Carbohydrate Diet (MSCD). In addition to the foods in the SCD, allowed foods will expand to include organic rice, oats, sweet potatoes, grade A maple syrup and cocoa. Gluten, corn products, milk products (except yogurt and hard cheeses), sweeteners (except honey), and process foods are still restricted.
2892592|NCT03301298|Experimental|SXC-2023|Dose escalation
2892593|NCT03301298|Placebo Comparator|Placebo|Dose escalation
2892594|NCT03301285||Children with osteoporosis associated to multiple disabilities|Treated with zoledronic acid
2892595|NCT03301272|Experimental|Onabotulinumtoxin A Injection, then Placebo|Participants first receive Onabotulinumtoxin A Injection and following a 3-month washout, they receive Placebo
2892596|NCT03301272|Experimental|Placebo, then Onabotulinumtoxin A Injection|Participants first receive placebo injection and following a 3-month washout, they receive Onabotulinumtoxin A Injection.
2892597|NCT03301259|Experimental|wave -one reciprocating system|"The reciprocating single file systems WaveOne (Maillefer, Ballaigues, Switzerland) provide more flexibility of the M-wire Ni-Ti alloy, greater resistance to cyclic fatigue and better handling of narrow and curved canals than the traditional Ni-Ti instruments Root canal preparation will be done with theWaveOne System with strict adherence to the manufacturer's instructions. After coronal preflaring with File ISO 21 taper 8% instrument with 2.5% sodium hypochlorite as the irrigant, working length was determined and a glide path will created.~The Red file R 25 taper 8% will be used for preparing the mesial canal; and the Black ISO 40 taper 8% file will be used for preparing the distal canals where there is only a single canal."
2892598|NCT03301259|Experimental|OneShape|OneShape (MICRO-MEGA) rotary nickel-titanium use roation movement and available in two sizes N°30 - .06 rotary files. , N°25 - .06
2892599|NCT03301246|Experimental|Artimes Pro Low Profile Dilatation Catheter|Subjects who require initial pre-dilatation using the study device, and then undergo definitive therapy using additional PTCA catheters and stents, according to standard of care will be enrolled in this study.
2892600|NCT03301233|Active Comparator|estradiol valerate|oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma). One tablet every 12 hour from 2nd day of the cycle till the day of trigger of ovulation).
2892601|NCT03301233|Experimental|estradiol valerate and sildenafil|oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25 mg, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
2892602|NCT03301220|No Intervention|Arm A: Active Monitoring|Participants randomized to active monitoring will receive no study medication, but will undergo the same disease evaluations at the same frequency as participants randomized to daratumumab.
2892603|NCT03301220|Experimental|Arm B: Daratumumab SC|Participants will receive 1800 milligram (mg) of daratumumab co-formulated with 2000 units per milliliter (U/mL) of recombinant human hyaluronidase (rHuPH20) by subcutaneous (SC) injection until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study or study completion.
2892604|NCT03301207|Experimental|Ibrutinib + Oral Contraceptives + Probe Drugs (CYP)|Pre-treatment Phase: Participants will receive a single dose of oral contraceptive (OC) consisting of ethinylestradiol (EE) 30 microgram (mcg) and levonorgestrel (LN) 150 mcg on Study Day 1, and probe drugs (CYP) consisting of bupropion 75 milligram (mg) and midazolam 2 mg on Study Day 3, followed by a washout period from Study Days 4 to 7. Treatment Phase: Participants will receive ibrutinib 560 mg (4*140 mg capsules) once daily (QD) on Days 8 to 26 along with midazolam 2 mg once orally on Study Day 8 (Cycle 1 Day 1), OC once orally on Study Day 22 (Cycle 1 Day 15; EE and LN), and bupropion 75 mg and midazolam 2 mg once orally on Study Day 24 (Cycle 1 Day 17). From Study Day 27 (Cycle 1 Day 20) and onwards participants will continue oral treatment with ibrutinib 420 mg (3*140 mg capsules) or 560 mg QD (depending on the subtype of B-cell malignancy) up to the end of Cycle 6 (each cycle will consist of 28 days).
2892605|NCT03301194||RAMP-HT patients|HT patients who have enrolled into the RAMP-HT between 1 October 2011 and 31 March 2012 and fulfilled the inclusion criteria and without any exclusion criteria
2892606|NCT03301194||Usual care patients|HT patients receiving usual care in GOPCs who have never enrolled into RAMP-HT on or before 31 March 2017 and fulfilled the inclusion criteria and without any exclusion criteria
2892609|NCT03301168|Experimental|BPX-501 T cells and AP1903|"TCR alpha beta depleted graft infusion with addback of BPX-501 T cells.~AP1903: Dimerizer drug administered to subjects who present with Grade I-IV acute GVHD with inadequate response to steroids within 48 hours of treatment or mild to severe chronic GVHD with inadequate response to steroids within 7 days of treatment."
2892610|NCT03301155|Experimental|Anaferon for children|The product should be administered apart from meal (between meals or 15 minutes prior to meal or drinking). The tablet should be held in the mouth until complete dissolution.
2892611|NCT03301155|Placebo Comparator|Placebo|The product should be administered apart from meal (between meals or 15 minutes prior to meal or drinking). The tablet should be held in the mouth until complete dissolution.
2892612|NCT03301142|Experimental|Device laser|treatment with application of Erbium Laser: YAG 2940nm, SMOOTH mode, one session per month for three months (n=20
2892613|NCT03301142|Active Comparator|kinesiotherapy|with supervision twice a week for three months (n=20)
2892614|NCT03301129|Experimental|Traditional cigarette|smoke one Traditional cigarette (with a mean nicotine content of 0.6 mg according to package label) and in a sub-group smoke a sham cigarette (an traditional cigarette without combustion).
2892615|NCT03301129|Experimental|Electronic cigarette|smoke a tobacco-flavored Electronic cigarette (9 puffs approximately equivalent to 0.6 mg of nicotine content) and in a sub-group smoke a sham cigarette (an electronic cigarette without nicotine).
2892616|NCT03301129|Experimental|Heat-not-burn tobacco products (IQOS)|smoke one IQOS cigarette (with a mean nicotine content of 0.6 mg according to package label).
2892617|NCT03301116|Experimental|Healthy Moves|Home care aides (HCAs) will be trained to deliver Healthy Moves for Aging Well (Healthy Moves), a gentle physical activity program, to their clients. On the first home care visit after the training, HCAs will introduce the program, assess their clients' readiness for the activity and have their clients set personally meaningful goals, and teach the three chair-bound moves. Home care clients will be asked to do the three moves every day. HCAs remind clients of their activity as part of their regular home care visits throughout the 4-month intervention period.
2892618|NCT03301116|Active Comparator|Active Mind|Home care aides (HCAs) will be trained to deliver Active Mind for Aging Well (Active Mind), a gentle thinking activity program, to their clients. On the first home care visit after the training, HCAs will introduce the program, assess their clients' readiness for the activity and have their clients set personally meaningful goals, and teach the activity. Home care clients will be asked to do a word search puzzle every day. HCAs remind clients of their activity as part of their regular home care visits throughout the 4-month intervention period.
2892619|NCT03301103|Placebo Comparator|Placebo|"The placebo will consist of low-lactose isonitrogenous soy product, and will be matched in appearance and flavour to PTM202.~After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14)."
2892620|NCT03301103|Experimental|PTM202|"PTM202 is a dry powder for reconstitution, comprised of a proprietary mixture of dried bovine colostrum and dried whole egg.~After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14)."
2892621|NCT03301090|Experimental|Cohort A|REGN3048+REGN3051 3 mg/kg (1.5 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
2892622|NCT03301090|Experimental|Cohort B|REGN3048+REGN3051 10 mg/kg (5 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
2892623|NCT03301090|Experimental|Cohort C|REGN3048+REGN3051 30 mg/kg (15 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
2892624|NCT03301090|Experimental|Cohort D|REGN3048+REGN3051 50 mg/kg (25 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
2892625|NCT03301090|Experimental|Cohort E|REGN3048+REGN3051 100 mg/kg (50 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
2892626|NCT03301090|Experimental|Cohort F|REGN3048+REGN3051 150 mg/kg (75 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
2892627|NCT03301077||General population|recruited from schools and other institutions like job-centers or child and adolescent psychiatries
2892628|NCT03301064|Experimental|Intervention Condition: MET/SBCM|The combined Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM) intervention will be used in the proposed study. The intervention consists of three 1-hour sessions. The sessions are structured to provide feedback to participants about their risks associated with alcohol use and to help them identify barriers and motivators to change. The sessions will aim to reduce drinking by promoting self-efficacy to change, setting goals and fostering utilization of medical, mental health and social services as needed. A comprehensive list of referrals will be provided. Sessions will occur 1-2 weeks apart.
2892629|NCT03301064|Active Comparator|Control Condition: Alcohol education brochure|Participants randomized to the control condition will be receive a Spanish-language version of an alcohol education brochure. Participants will be encouraged to read the brochure. The brochure will provide information about defining heavy drinking, harmful effects of drinking and symptoms of an alcohol use disorder. Control group participants will also receive a list of available clinics and resources from Providence staff. After the baseline visit participants in the control group will be contacted by phone twice over the next 4 weeks by the promotores to remind them about the 3-month follow-up appointment.
2892630|NCT03301051|Experimental|Quadrivalent VLP Vaccine|Single dose - 30 µg/strain of Quadrivalent VLP Vaccine
2892631|NCT03301051|Placebo Comparator|Placebo|Single dose - Placebo
2892632|NCT03301038|Experimental|All Subjects|
2892633|NCT03301025|Active Comparator|Pregabalin group|(n=53):
2892634|NCT03301025|Placebo Comparator|placebo group|(n=53):
2892635|NCT03301012|Active Comparator|Recovery Support as Usual Control|Participants in the control and experimental condition will have access to post treatment recovery support services as usual.
2892669|NCT03300726||Normal controls|Normal cognition will be defined as cognitive performance on detailed neuropsychometric testing that falls within 1 SD of age-, gender-, and education-matched norms in all cognitive domains, and no subjective report of cognitive decline from an individual's baseline (i.e. CDR 0). All participants in this group will undergo clinical and cognitive evaluations, CSF analysis, and functional MRI during resting state and semantic memory tasks.
2892726|NCT03300323|Active Comparator|IV Fluid challenge administration _5|4ml/kg intravenous fluid challenge administered over 5 minutes
2932580|NCT03022825|Experimental|BCG+ALT-803|
2892636|NCT03301012|Experimental|Smartphone Assisted Relapse Prevention|Participants in the experimental condition will receive a smartphone, a calling/texting/data plan, and the SARC-A mobile applications for the first 6 months post treatment discharge. Experimental participants will 1) complete a 2-3 minute recovery-focused ecological momentary assessment (EMA) at 5 random times a day, receive feedback on their current answers, and provided access to behavioral charting of their past answers over time; and 2) receive continuous access to a suite of self-initiated ecological momentary interventions (EMI) to support their recovery via tool box of coping tools, apps related to getting support, and apps related to maintaining a healthy lifestyle.
2892637|NCT03300999|Experimental|Ginger Tea|"End of the second menstruation cycle - Start of the third menstruation cycle: Subjects will take ginger tea daily, avoid home remedies, refrain from taking pain medications and supplements, and keep track of ginger tea intake by placing a check mark each day in the daily log checklist.~Start of the third menstruation cycle - End of the third menstruation cycle: Subjects will drink ginger tea daily. Subjects will rate discomfort using the visual analog pain scales and the symptom checklist at the end of each day during menstruation.~After the third menstruation cycle ends: Subjects will meet with student investigators at a location convenient to the subject to turn in daily logs, visual analog pain scales, and symptom checklists."
2892638|NCT03300999|No Intervention|No Ginger Tea|"End of the first menstruation cycle - Start of the second menstruation cycle: Subjects will not take ginger tea, avoid home remedies, and refrain from taking pain medications or supplements.~Start of the second menstruation cycle - End of the second menstruation cycle: Subjects will rate discomfort using the visual analog pain scales and symptom checklist during menstruation. Subjects will meet with student investigators at a convenient location to the subject and will complete surveys and questionnaires. Subjects will be given daily logs, visual analog pain scales, symptom checklists, and supplies for the ginger tea."
2892639|NCT03300986||Functional Electrical Stimulation (FES) users|
2892640|NCT03300973|Active Comparator|urodynamics study group|65 patients with stress urinary incontinence were randomly chosen to have urodynamic study before surgery
2892641|NCT03300973|Active Comparator|surgery only group|60 patients with stress urinary incontinence were randomly chosen to have surgery without urodynamics study
2892642|NCT03300960|Experimental|Provera|
2892643|NCT03300960|Active Comparator|Orgalutrán Ganirelix (GnRH antagonist)|
2892644|NCT03300947|Experimental|High-dose Psilocybin|Psilocybin 300 mcg/kg once per week, every week, for 8 weeks
2892645|NCT03300947|Experimental|High- or Low-dose Psilocybin|Psilocybin 100 mcg/kg or psilocybin 300 mcg/kg once per week, every week, for 8 weeks
2892646|NCT03300947|Placebo Comparator|High-dose Psilocybin or Lorazepam|Psilocybin 300 mcg/kg or Lorazepam 1 mg once per week, every week, for 8 weeks
2892647|NCT03300934|Experimental|closed loop glucose control system|Closed loop glucose control system
2892648|NCT03300934|No Intervention|CSII Pump treatment|CSII Pump treatment without the integrated algorithm and glucose sensor
2892649|NCT03300921|Experimental|Arm A|Arm A: 50mcg IV weekly
2892650|NCT03300921|Experimental|Arm B|Arm B: 12mcg PO daily
2892651|NCT03300908|Experimental|Project ADHERE|Participants will receive a 3-session antiretroviral medication adherence and risk reduction intervention called Project ADHERE.
2892652|NCT03300908|Active Comparator|Control MACE|Participants will receive a one-session antiretroviral medication adherence intervention called MACE.
2892653|NCT03300895|Experimental|High-intensity interval training|
2892654|NCT03300895|Active Comparator|Moderate-intensity continuous exercise|
2892655|NCT03300882||CMV+ First Lung Transplant Recipients|Participants enrolled in one of four North American sites in clinical research study CTOT-20 (Clinical Trials.gov ID: NCT02631720) who are cytomegalovirus positive by serology (e.g., CMV Recipient positive).
2892656|NCT03300856||Chart Review|Existing records of patients within the NINDS database who have had TMS performed to measure central motor conduction time (CMCT).
2892657|NCT03300843|Experimental|Experimental Therapy|Peptide loaded dendritic cell vaccine on days 0, 14, 28, and 42
2892658|NCT03300830||Group 1|Viral-assoc. cancer; HIV-neg pts with cancer that occurs in HIV pos; KSHV-assoc. cancer or related diseases e.g. multicentric Castleman disease; retrovirus-induced cancer; Idiopathic Castleman disease.
2892659|NCT03300817|Experimental|Prevention (MUC1 peptide-Poly-ICLC vaccine)|Patients receive MUC1 peptide-Poly-ICLC vaccine SC at weeks 0, 2, and 10.
2892660|NCT03300804|Active Comparator|20-herb formulation|Active herb
2892661|NCT03300804|Placebo Comparator|Placebo|Placebo herb formulation
2892662|NCT03300791||Admitted|We will include patients who had beeb admitted by an acute heart failure in hospitalization ward
2892663|NCT03300778|Experimental|aerobic exercise|Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
2892664|NCT03300778|Placebo Comparator|Placebo controlled group|6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
2892665|NCT03300765|Experimental|Apatinib with IMRT|Participants will receive apatinib (0.5g, daily) for two cycles followed by intensity modulated radiation therapy (Primary site and lymph nodes: 66 Gy/33F, metastatic site: 40-60Gy/20-30F)
2892666|NCT03300752|Experimental|BREATHE Intervention|The patient's primary care provider (PCP) will deliver the active intervention (shared decision-making discussion of asthma control status and treatment) - BREATHE Intervention.
2892667|NCT03300752|Active Comparator|Control Intervention|The patient's primary care provider (PCP) will deliver the control intervention (discussion of healthy lifestyles).
2892668|NCT03300726||MCI due to AD or mild AD dementia|The clinical diagnoses of amnestic MCI due to AD or mild AD dementia will be made according to standard clinical criteria as described by the National Institute of Aging -Alzheimer's Association Working Group and supported by CSF biomarker data for tau, p-tau181, and Aβ42. This includes evaluation for other systemic or neurological disorders which could account for the cognitive impairment, and inclusion of results from ancillary structural imaging (CT or structural MRI), neuro-psychometric testing, and FDG-PET imaging (when available) into the diagnostic scheme. All participants in this group will undergo clinical and cognitive evaluations, CSF analysis, and functional MRI during resting state and semantic memory tasks.
2892722|NCT03300349||Fulfillment of a preventive programme|Patients who fulfil a preventive programme for axillary lymphadenectomy sequels
2892670|NCT03300713|Experimental|F+ group (Mocitraining program)|including 8 pediatricians' clusters. F+ pediatricians will attend a specific training focused on mother-child interactions, maternal psychiatric disorders, particularly PND screening and early interventions for non-psychiatric physician.
2892671|NCT03300713|Sham Comparator|F- group (usual follow-up)|grouping 8 pediatricians' clusters. They will not receive the initial training on early interactional disorders and PND screening
2892672|NCT03300687|Active Comparator|Active|Subjects will receive FX-322 as an intratympanic injection
2892673|NCT03300687|Placebo Comparator|Placebo|Subjects will receive Placebo as an intratympanic injection
2892674|NCT03300674|Active Comparator|Intravenous hydromorphone|Intravenous hydromorphone 1mg. A second dose can be administered at 30 minutes.
2892675|NCT03300674|Active Comparator|Intravenous lidocaine|Intravenous lidocaine 120 mg. A second dose can be administered at 30 minutes
2892676|NCT03300661|Experimental|Mediterranean Style|Educational intervention with personalized suggestions to improve diet and physical activity
2892677|NCT03300648|No Intervention|Unual care|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees
2892678|NCT03300648|Experimental|Mechanical ventilation|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees, along with intubation and mechanical ventilation for a maximum of 7 days
2892679|NCT03300648|Experimental|Hypertonic saline|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees, along with intravenous 3% hypertonic saline for a maximum of 7 days
2892680|NCT03300635|Other|Fibromyalgia patients|All study subjects, both patients and healthy controls, will attend all three interventions: Mental distress and relaxation test, Glucose tolerance test, and Exercise test
2892681|NCT03300635|Other|Healthy controls|All study subjects, both patients and healthy controls, will attend all three interventions: Mental distress and relaxation test, Glucose tolerance test, and Exercise test
2892682|NCT03300609|Experimental|Arm I (panitumumab, leucovorin calcium, fluorouracil)|"INDUCTION Patients receive panitumumab IV over 30-60 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE:~Patients receive panitumumab IV over 30 minutes, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
2892683|NCT03300609|Active Comparator|Arm II (capecitabine)|"INDUCTION Patients receive panitumumab IV over 30-60 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE:~Patients receive capecitabine PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
2892684|NCT03300596|Experimental|brief intervention to prevent suicide attempt|Individuals presenting to hospital following a suicide attempt who are age 18-plus and screen positive for alcohol or drug use problem
2892685|NCT03300596|Other|standard of care|Individuals presenting to hospital following a suicide attempt who are age 18-plus and screen positive for alcohol or drug use problem
2892686|NCT03300583||ILD patients|Patients from all types of ILD who are under the care of the two collaborating hospitals.
2892687|NCT03300583||Family/Carers|Family and carers of patients with ILD who are or have been treated in the two collaborating hospitals.
2892688|NCT03300583||Clinicians|Clinicians from the two collaborating hospitals and GPs from the nearby areas who treat and refer patients with ILD.
2892689|NCT03300570|Experimental|Arm A (dolcanatide)|Participants receive dolcanatide PO QD for 7 days.
2892690|NCT03300570|Placebo Comparator|Arm B (placebo)|Participants receive placebo PO QD for 7 days.
2892691|NCT03300557|Experimental|Treatment (exemestane)|Patients receive exemestane PO QD over 21-42 days in the absence of disease progression or unaccepted toxicity. Patients undergo standard of care surgery between days 22-43.
2892692|NCT03300544|Experimental|Treatment (T-VEC, capecitabine, chemoradiation)|Patients receive talimogene laherparepvec intralesionally via endoscopy on weeks 1, 2-4 and 8-9. Patients receive capecitabine PO BID, fluorouracil IV over 46 hours, oxaliplatin IV over 2 hours followed by radiation therapy for 28 fractions on weeks 2-5 and 8-13. Patients undergo resection surgery on weeks 21-25.
2892693|NCT03300531|Experimental|P-PRP|Blood will be drawn and pure platelet-rich plasma will be injected into the tendon.
2892694|NCT03300531|Experimental|PRP|Blood will be drawn and platelet-rich plasma will be injected into the tendon.
2892695|NCT03300531|Active Comparator|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) )
2892696|NCT03300518|Other|pretreatment group|the pretreatment group underwent a modified treatment protocol with pretreatment with estogen administering during the cycle preceding the IVF/ICSI cycle. daily dose of 4 mg (2 mg twice a day) estradiol valerate was given orally in the middle luteal phase which is confirmed seven days after ovulation monitoring by the ultrasound up to 2 days of the next menstrual cycle.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.
2892697|NCT03300518|Other|control groups|In the control groups standard GnRH-antagonist protocol was applied.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.
2892723|NCT03300349||No fulfillment of a preventive programme|Patients who do not fulfil a preventive programme for axillary lymphadenectomy sequels
2892698|NCT03300505|Experimental|ARRx + Pembrolizumab|"Stage 1: All registered subjects will be treated with ARRx (ASO) given intravenously in 60-minute infusions on Days 1, 4, 8, 11, 15 on cycle 1, then on days 1,8,15 in subsequent 21-day cycles until clinical or radiologic progression or unacceptable toxicity~Stage 2: At progression on ARRx, subjects will be treated with pembrolizumab immunotherapy given intravenously in 60-minute infusions in 21-day cycles until clinical or radiologic progression."
2892699|NCT03300492|Experimental|NK-DLI|"Preemptive immunotherapy with ex vivo expanded NK cells on days~+10, +15 and +20 with increasing NK cell doses following haplo-HSCT."
2892700|NCT03300479|Experimental|Clevidipine|The treatment starts at admission to the ICU for 24 hours with 2 mg to a maximum of 16 mg Clevidipine per hour infused intravenously and continuously to reach the systolic target pressure < 160 mmHg (>120 mmHg).
2892701|NCT03300479|Active Comparator|Urapidil|The treatment starts at admission to the ICU for 24 hours with 5 mg to a maximum of 40 mg Urapidil per hour infused intravenously and continuously to reach the systolic target pressure < 160 mmHg (>120 mmHg).
2892702|NCT03300466|Experimental|GP0045|Treatment with GP0045
2892703|NCT03300466|Active Comparator|Comparator|Treatment with active comparator
2892704|NCT03300453|Experimental|rAAV2/5-hNAGLU|Each patient will receive 960 µL of vector suspension. The vector suspension will be deposited simultaneously at 16 sites, each deposit containing 2.4x 1011 vg (4x1012 vg in total).
2892705|NCT03300440|Experimental|Intervention group|Probiotics and vitamin B7
2892706|NCT03300440|Placebo Comparator|Control group|Placebo and vitamin B7
2892707|NCT03300427|Experimental|sacubitril/valsartan|Participants will be randomized to two treatment arms in a 1:1, double blinded fashion. Two strengths of sacubitril/valsartan will be available for use after randomization, 49 mg sacubitril/51 mg valsartan and 97 mg sacubitril/103 mg valsartan. After randomization, subjects in this arm will receive sacubitril/valsartan 100 mg orally twice daily (BID). The dose will be then up-titrated to 200 mg BID (or maintained at the starting dose level, if up-titration is not possible). Dose modifications are allowed until week 4 after the randomization. In order to be eligible for the final assessments, the subject has to tolerate the 100 mg BID dose at the minimum. In total, participants will be on sacubitril/valsartan for a minimum of 8 weeks and a maximum of 10 weeks.
2892708|NCT03300427|Active Comparator|valsartan|Participants will be randomized to two treatment arms in a 1:1, double blinded fashion. In this arm, Valsartan 80 mg and 160 mg will be used as comparative drug, taken orally BID at home. Depending on the screening/run-in dose the subjects in this arm will get either valsartan 80 mg BID or valsartan 160 mg BID. During the treatment period the dose of valsartan will be up-titrated to the highest tolerated dose (160 mg BID) or maintained at 80 mg BID if up-titration is not possible. Dose modifications are allowed until week 4 after the randomization. In order to be eligible for the final assessments, the subject has to tolerate at least 80 mg BID dose of valsartan. The treatment phase will be a minimum of 8 weeks, and a maximum of 10 weeks.
2892709|NCT03300414||Collection of blood specimen|Collection of blood specimen from patients will be performed during the course of routine medical care at UC Davis with no prospective follow up period. The duration anticipated to enroll all 10 study subjects will be 1 year. The estimated date for the investigator to complete analysis and publication is 2 years.
2892710|NCT03300414||Liver Biopsy slides|Up to twenty (20) de-identified hepatocellular carcinoma (HCC) tissue sections on biopsy slides or frozen sections and associated information such as age, sex, race, ethnicity, treatment status, pathological diagnoses, and date of procedure will be obtained from UC Davis Cancer Center Biorepository (CCB) and outside tissue biobanks, including, but not limited to, Cooperative Human Tissue Network (CHTN). The duration anticipated to complete analysis and publication is 2 years.
2892711|NCT03300401|Experimental|Diagnostic (CEUS)|Patients receive perflutren or sulfur hexafluoride lipid microspheres and undergo CEUS at baseline, 2 and 4 weeks, and 3 and 6 months. Patients also undergo PET/CT after standard of care 90Y radioembolization at baseline.
2892712|NCT03300388|Placebo Comparator|Control|Dietary advice for a healthy diet supplemented with placebo (olive oil).
2892713|NCT03300388|Experimental|Omega-3|Dietary advice for a healthy diet supplemented with DHA-rich dietary supplement (providing 1.650 mg/day of DHA).
2892714|NCT03300388|Experimental|Resistance Training|Dietary advice for a healthy diet supplemented with placebo (olive oil) and moderate resistance training program.
2892715|NCT03300388|Experimental|Omega-3 + Resistance Training|Dietary advice for a healthy diet supplemented with a DHA-rich dietary supplement (providing 1.650 mg/day of DHA) and moderate resistance training program.
2892716|NCT03300375|Active Comparator|Home-Based Resistance Exercise Intervention Group|Participants in the HBRX group will be coached through six phases of the intervention with two weeks per phase. Exercise will use body weight and resistance exercise bands. A set of commercial elastic resistive bands and a stability pad (TheraBand, Inc.) will be provided to each participant to keep for personal use after their participation in the study. The use of elastic bands for resistance training can induce similar results in neuromuscular adaptations as well as strength to those achieved by weight machines and free-weights.
2892717|NCT03300375|Experimental|Wait-List Control Condition Group|Participants who are assigned to the CON group will wait to participate in the resistance training after a three month wait period. Participants will follow all instructions provided to them by their physician and care team, but will be asked to refrain from starting any new strengthening exercise protocols or begin any new physical therapies during this time. The participants will be contacted by phone on a monthly basis during the study period to determine if any changes in LBP symptoms have occurred. At month three, these participants will also receive the elastic resistive bands and a stability pad.
2892718|NCT03300362|Experimental|Seasonal influenza & MVA-NP+M1|Two vaccinations will be administered: Seasonal influenza vaccine & MVA-NP+M1
2892719|NCT03300362|Placebo Comparator|Seasonal influenza & saline placebo|Two vaccinations will be administered: Seasonal influenza vaccine & sodium chloride
2892720|NCT03300349||axillary lymphadenectomy sequels|Patients who have suffered from axillary lymphadenectomy due to breast cancer between 2014 and 2016 and who have developed breast cancer-related lymphedema and/or shoulder disability who fulfill or not a preventive programme
2892721|NCT03300349||No axillary lymphadenectomy sequels|Patients who have suffered from axillary lymphadenectomy due to breast cancer between 2014 and 2016 and who have not develped breast cancer-related lymphedema and/or shoulder disability who fulfill or not a preventive programme.
2892841|NCT03299439|Experimental|acupuncture at highly sensitive points|
2892727|NCT03300323|Active Comparator|IV Fluid challenge administration 20|4ml/kg intravenous fluid challenge administered over 20 minutes
2892728|NCT03300310|Experimental|with nursing visit|a nurse visit is scheduled twice a week during 3 months at patient home.
2892729|NCT03300310|Experimental|without nursing visit|no nursing visit
2892730|NCT03300297|Active Comparator|Cervical Spine Thrust Joint Manipulation|Thrust Manipulation delivered to C0/1 and C2/3 on both the right and left side
2892731|NCT03300297|Sham Comparator|Cervical Spine Sham Manipulation|Sham Manipulation delivered to C0/1 and C2/3 on both the right and left side
2892732|NCT03300284||Thyroid cancer|This study does not involve any intervention, but rather data collection on patient and physician preferences and beliefs, communication, and patient psychological outcomes.
2892733|NCT03300271|Other|No intervention (Education)|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
2892734|NCT03300271|Experimental|Mobile Application (Self monitoring)|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
2892735|NCT03300271|Experimental|Mobile Application (Personal coaching)|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
2892736|NCT03300258|Other|Non-Stroke Pilot Group|Robotic therapy. Aerobic therapy. Subjects without stroke, pilot subjects tested during early phases while the device and therapeutic task specifications are developed, and throughout the project while the device and tasks are refined.
2892737|NCT03300258|Other|Non-Stroke Comparison Group|Robotic therapy. Healthy controls enrolled (age 50-85) to contribute to a normative data set on motor learning using the robotic protocols designed for stroke.
2892738|NCT03300258|Experimental|Robotic Training Group|Robotic therapy. Subjects with Stroke who will perform the targeted training task: exercise using novel tasks on a robotic recumbent cycle.
2892739|NCT03300258|Active Comparator|Aerobic Training Group|Aerobic therapy. Subjects with Stroke who will perform aerobic pedaling, duration-matched to the Robotic group.
2892740|NCT03300245||patients with nasal septal deviation|Maxillofacial CT scan
2892741|NCT03300232|Experimental|Computer-based VC-CBT|Computer-based VC-CBT: Six, one-hour computerized therapy sessions delivered on an interactive computerized platform with two-session therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
2892742|NCT03300232|No Intervention|Treatment as Usual|Participants randomized to the treatment as usual control condition will not undergo the CBT therapy.
2892743|NCT03300219|Experimental|telerehabilitation|Telerehabilitation refers to the use of technologies to provide rehabilitation services to people in their homes. The intervention will be performed by real-time video-conferencing using an iPad® and Skype™, a software program that allows video calls over the Internet
2892744|NCT03300206||Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging.
2892745|NCT03300206||Standard of Care|Each of the participating sites will currently be using a vacuum assisted breast biopsy system along with a specimen radiography system (or other specimen imaging system).
2892746|NCT03300193||Tremor patients|Essential Tremor and Parkinson's Disease patients with Tremor refractory to pharmacological therapy who underwent Magnetic Resonance guided Focused Ultrasound Surgery (MRgFUS)
2892747|NCT03300180|No Intervention|Control|The patients in this group will receive no AD screening
2892748|NCT03300180|Active Comparator|Screening Only|The patients in this group will receive screening for AD coupled with letters sent to the dyads and the primary care PCP informing them of the results of the screening
2892749|NCT03300180|Experimental|Collaborative Dementia Care Program|The patients in this group will receive screening for AD, disclosure letters to the dyads, and the dyads in this group will be referred the Aging Brain Care Medical Home for diagnostic assessment and management if the patient screens positive
2892750|NCT03300167|Experimental|CE-marked coronary artery catheter|use of a novel CE-marked coronary artery catheter to obtain spatially-separated intravascular samples for laboratory measurement.
2892751|NCT03300154|Experimental|Financial incentives|
2892752|NCT03300154|Experimental|Framing (SMS)|
2892753|NCT03300154|No Intervention|Usual care|
2892754|NCT03300141|Active Comparator|Healthy|Healthy participants will participate in reaching activity using the Looking Glass and Leap motion tracking system
2892755|NCT03300141|Experimental|Chronic Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
2892756|NCT03300141|Experimental|Chronic Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
2892757|NCT03300141|Experimental|Acute Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
2892758|NCT03300141|Experimental|Acute Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
2892759|NCT03300128|Experimental|Incredible Years - ASD|The intervention, The Incredible Years Parent Program for Autism Spectrum and Language Delays (IY-ASD; more information is here: http://www.incredibleyears.com/programs/parent/autism-spectrum-language-delays/) is a 14-week course that meets for 2 hours every week. Ideally, an IY-ASD group will be composed of approximately 10 parents and other primary caregivers of children who have autism.
2892760|NCT03300128|Active Comparator|Circle of Parents|"Circle of Parents, the comparison condition, is an open parent support group led by a parent leader. (For more information, see http://circleofparents.org/). Participants are encouraged to share resources and other support both during groups, and between meetings."
2892761|NCT03300115|Experimental|AC0010|Each participant will be given AC0010 300mg bid.
2892762|NCT03300102||Patients with suspected or confirmed renal cell carcinoma|Patients with suspected or confirmed renal cell carcinoma who have consented will either donate tissue, or complete a structured questionnaire or a semi-structured interview. Not all patients will have all three interventions, each patient must have at least one.
2892763|NCT03300089|Active Comparator|General Anaesthesia|General Anaesthesia during surgery
2892764|NCT03300089|Experimental|Regional Anaesthesia|Regional Anaesthesia during surgery
2892765|NCT03300063|No Intervention|control|Standard Medical care
2892766|NCT03300063|Active Comparator|Low Flow Nocturnal Oxygen|This group will receive standard medical care as well as low flow oxygen during sleep.
2892767|NCT03300050|Experimental|Group 1: cH8/1N1 LAIV and cH5/1N1 IIV + adjuvant|Participants will receive 0.5mL cH8/1N1 LAIV administered as 0.25mL per nostril on D1 followed by 0.5mL cH5/1N1 IIV + AS03A administered as an injection on D85.
2892768|NCT03300050|Experimental|Group 2: cH8/1N1 LAIV and cH5/1N1 IIV|Participants will receive 0.5mL cH8/1N1 LAIV administered as 0.25mL per nostril on D1 followed by 0.5mL cH5/1N1 IIV administered as an injection on D85.
2892769|NCT03300050|Placebo Comparator|Group 3: Placebo|Participants will receive 0.5mL of normal saline administered as 0.25mL per nostril on D1 followed by 0.5mL phosphate buffered saline administered as an injection on D85.
2892770|NCT03300050|Experimental|Group 4: cH8/1N1 IIV + adjuvant and cH5/1N1 IIV + adjuvant|Participants will receive 0.5mL of cH8/1N1 IIV + AS03A administered as an injection on D1 followed by 0.5mL cH5/1N1 IIV + AS03A administered as an injection on D85.
2892771|NCT03300050|Placebo Comparator|Group 5: Placebo|Participants will receive 0.5mL phosphate buffered saline administered as an injection on D1 followed by 0.5mL phosphate buffered saline administered as an injection on D85.
2892772|NCT03300024|Active Comparator|Expanded polytetrafluoroethylene (ePTFE)|The ePTFE grafts used are the Flixene (Maquet-Atrium Medical, Hudson, NH), Advanta VXT (Maquet-Atrium), GORE-TEXStretch Vascular Graft For Vascular Access (W. L. Gore and Associates, Flagstaff, Ariz), or Venaflo (Bard Peripheral Vascular, Tempe, Ariz). The choice of graft used is at the surgeons' discretion. The graft it is offered in both large and small diameters, as well as thin-wall and rapidly-tapering designs for cases where arterial steal syndrome is a potential complication. A 6 mm graft featuring external supporting rings in 5 cm centered or 7 cm offset sections enables tight loop configurations and crossing the cubitus. A 4-7 mm tapered graft with 10 or 15 cm of removable rings allows for tailoring or exact placement of the ringed section.
2892773|NCT03300024|Experimental|Bovine carotid Artery Graft|The bovine carotid artery biological grafts (Artegraft®; Artegraft, Inc., North Brunswick, NJ) consist of a biological fibrous matrix processed to enhance long-term patency and provide a tightly woven, cross-linked conduit that is flexible and compliant.
2892774|NCT03300011|Experimental|recanalisation CTO lesion successful|Patients with CTO lesion performed PCI strategy and successfully recanalisation the CTO lesion with implanted stents .
2892775|NCT03300011|No Intervention|recanalisation CTO lesion failure|Patients with CTO lesion performed PCI strategy and failure recanalisation the CTO lesion with PCI wire and balloon..
2892776|NCT03300011|No Intervention|OMT|Patients with CTO lesion optimal medicine treatment without PCI
2892777|NCT03299998||BLOCK+|Patients who underwent maxillary and mandibulary block before surgery
2892778|NCT03299998||BLOCK -|Patients who did not undergo maxillary and mandibulary block before surgery.
2892779|NCT03299985|Experimental|Diaphragmatic myofascial release|Subjects in this arm will receive different myofascial release techniques aimed to normalize the myofascial tension of the diaphragmatic muscle
2892780|NCT03299985|Sham Comparator|Sham myofascial release|Subjects in this arm will receive the same manual techniques of the diaphragmatic myofascial release group, but without the myofascial stimulus
2892781|NCT03299972|Placebo Comparator|Control|
2892782|NCT03299972|Experimental|Whey Protein|
2892783|NCT03299972|Experimental|Resistance Exercise + Placebo|
2892784|NCT03299972|Experimental|Resistance Exercise + Whey Protein|
2892785|NCT03299959|Experimental|Agili-C|
2892786|NCT03299959|Active Comparator|Surgical Standard of Care (SSOC)|
2892787|NCT03299946|Experimental|Arm 1|
2892788|NCT03299920|Active Comparator|Intervention|Patients will receive standardized instruction from a study nurse, tailored to understanding pain management after nerve blocks and maximizing utilization of non-opioid analgesics.
2892789|NCT03299920|Other|Control|Patient will receive conventional instructions on postoperative pain management.
2892790|NCT03299907||COPD|Subject with FEV1/FVC post BD < 0.7 or LLN
2892791|NCT03299907||Non COPD|Subject with FEV1/FVC post BD >= 0.7 or LLN
2892792|NCT03299894|Experimental|systematic calculation of qSOFA|Usual procedure for patient triage AND systematic calculation of qSOFA at Emergency Department triage in patients admitted with a suspected or proven bacterial infection.
2892793|NCT03299894|No Intervention|no systematic calculation of qSOFA|Usual procedures for patient triage at Emergency Department admission and management of suspected or proven bacterial infection. No systematic calculation of qSOFA.
2892794|NCT03299881|Experimental|Treatment|The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatone for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.
2892795|NCT03299881|Active Comparator|Control|Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
2892796|NCT03299868|Experimental|Routine PICC group|PICC is initially routine insertion at the time of admission of hospice-palliative care unit
2892797|NCT03299868|Active Comparator|General IV group|PICC is inserted if 3 or more times of IV insertion trial per day is required for IV access
2892798|NCT03299842|Experimental|ZX008|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
2892842|NCT03299439|Active Comparator|acupuncture at lowly/non-sensitive points|
2892843|NCT03299439|No Intervention|no acupuncture (waiting-list)|
2892844|NCT03299426|Experimental|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Children will receive a single 0.5-ml dose of Vi-TCV administered by the intramuscular route.
2892913|NCT03298919|Experimental|Exercise Videogames|Exercise videogames 3 times weekly for 12 weeks followed by 6 months of home practice
2892799|NCT03299816|Active Comparator|Self-Shopping DASH group (S-DASH)|The Self-Shopping DASH group will receive printed patient-centered materials on the DASH diet and chronic kidney disease. Participants will also receive $30/week allowance for the purchase of food and drinks of their choosing from a local grocer (Klein's ShopRite stores of Maryland) during the first four months. During the remainder of the study (months 5-12), the participants in this group will be asked to continue to follow the dietary advice provided but will not receive the food allowance.
2892800|NCT03299816|Experimental|Coaching DASH group (C-DASH)|The C-DASH group intervention will be a patient-tailored program, delivered by a study coach that is trained by a dietitian, which emphasizes key self-management behaviors - diet and self-monitoring. This group will receive advice from the study coach and purchase $30 worth of fresh fruits, vegetables, nuts and beans that are high in potassium on a weekly basis for the first four months.
2892801|NCT03299803|Experimental|Men's Healing Pathways|Men with physical disabilities will receive a 14 session weekly peer implemented program
2892802|NCT03299803|No Intervention|Control group|Telephone contact only
2892803|NCT03299790|Active Comparator|traininggroup 1: HIIT|high-intensity interval exercise training group (T2DM patients)
2892804|NCT03299790|Active Comparator|training group 2: MIT|moderate-intensity exercise training group (T2DM patients)
2892805|NCT03299790|No Intervention|control group|Control group (T2DM patients)
2892806|NCT03299790|No Intervention|healthy controls|
2892807|NCT03299777||Control group|A control group will consist 100 normotensive women with normal pregnancy outcomes who were admitted to our fetal-maternal unit during the same period
2892808|NCT03299777||Preeclampsia group|All patients diagnosed with preeclampsia will undergo the fibroscan test.
2892809|NCT03299764|Experimental|Intervention|Non-invasive ventilation with pursed lip breathing ventilation device
2892810|NCT03299764|Active Comparator|Control|Non-invasive ventilation with standard non-invasive ventilation device
2892811|NCT03299751|Experimental|NICU newborns of at least 7 days of life with suggestive signs|
2892812|NCT03299738|Experimental|C-CAR011|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
2892813|NCT03299725|Experimental|Treatment arm|
2892814|NCT03299712|Other|ArteFill|This post-approval study will evaluate the continuing safety of ArteFill® as an injectable implant for correction of nasolabial folds over the course of five years post implantation, with a focus on determining the incidence of granuloma formation. Incidence of adverse events and subject satisfaction with respect to the subject's personal expectations will be assessed.
2892815|NCT03299686|Experimental|CJM112|Study treatment
2892816|NCT03299686|Placebo Comparator|Placebo to CJM112|Placebo
2892817|NCT03299660|Experimental|Avelumab|Long course chemoradiotherapy (LCCRT) comprised of 50.4 Gy radiotherapy in conjunction with 5FU (225mg/m2/day continuous infusion)/Capecitabine (825 mg/m2 BID on RT days) over 5. 5 weeks, followed by 4 cycles of Avelumab. This is then followed up with surgical resection
2892818|NCT03299647||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
2892819|NCT03299647||TD group|Typically development controls without lifetime diagnosis with ADHD
2892820|NCT03299621|Experimental|PLE (Phase Lag Entropy) monitoring|Investigators monitor the change of PLE value using the sensor of PLEM™ during propofol anesthesia.
2892821|NCT03299621|Experimental|Muscle relaxant injection|Investigators monitor the change for PLE value using the sensor of PLEM™ before and after the injection of muscle relaxant.
2892822|NCT03299582|Experimental|Healthy subjects (Hypothermia)|To investigate the safety and tolerability of limb hypothermia in subjects without cancer
2892823|NCT03299582|Experimental|Healthy subjects (Cryocompresion)|To investigate the safety and tolerability of cryocompression in subjects without cancer
2892824|NCT03299582|Experimental|Cancer subjects (Hypothermia)|To investigate the safety and tolerability of limb hypothermia in subjects with breast cancer being treated with paclitaxel chemotherapy.
2892825|NCT03299582|Experimental|Cancer subjects (Cryocompresion)|To investigate the safety and tolerability of cryocompression in subjects with cancer being treated with taxane-based chemotherapy.
2892826|NCT03299569||Takotsubo cardiomyopathy|All patients diagnosed with Takotsubo cardiomyopathy in Scotland since 2010.
2892827|NCT03299569||Myocardial Infarction|An equal number of myocardial infarction patients in NHS Grampian since 2010.
2892828|NCT03299556||WHT|The WHT group includes only patients newly enrolled in the Geisinger MPP program who consent to participate in the study. WHT subjects will be recruited over 1 year, with 1 year of follow-up.
2892829|NCT03299556||Historic Control|Patients who were enrolled in the MPP in the preceding year. These patients received the MPP educational program but received no WHT as part of their treatment.
2892830|NCT03299556||Concurrent Control|Patients being treated for chronic pain in the Geisinger Medical Pain Management (MPM) program over the same time period as the WHT group. These subjects do not receive the MPP educational program nor use WHT as part of their treatment
2892831|NCT03299543||Healthy adults|Healthy adults who are able to provide duplicate breath samples and pin-drop blood samples
2892832|NCT03299530||patients with corneal astigmatism|Patients who had received phacoemulsification surgery with or without implantation of toric IOL are with a certain amount of corneal astigmatism.
2892833|NCT03299517|Experimental|lidocaine|"Initial dose: antiarrythmic drugs Lidocaine (1.5 mg / kg EV in 30 minutes).~Adittional dose: Lidocaine (0.75 mg / kg EV in 30 minutes)."
2892834|NCT03299517|Experimental|amiodarone|"Initial dose: antiarrythmic drugs Amiodarone (5 mg / kg EV in 30 minutes)~Adittional dose: Amiodarone (3 mg / kg EV in 30 minutes)"
2892835|NCT03299491|Experimental|MWA+IEC intervention|
2892836|NCT03299491|Experimental|IEC intervention|
2892837|NCT03299491|No Intervention|Control|
2892838|NCT03299478||NSCLC patients|
2892839|NCT03299465|Experimental|Yoga arm|A six-week restorative yoga intervention consisting of a weekly, 60-minute yoga group class led by a certified yoga instructor along with twice-weekly home practice using yoga DVD.
2892840|NCT03299452|Experimental|PDX-guided therapy|Drugs screened by accelerated PDX model will be administered in accordance with the protocol of the drug specification or the CPSC guidelines until the patient progresses, intolerant, the patient withdrawn or the investigator determines that the medication must be discontinued.
2892845|NCT03299426|Active Comparator|Meningococcal A Conjugate Vaccine (MCV-A)|Children will receive a single dose of MCV-A administered by the intramuscular route. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
2892846|NCT03299413|Experimental|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be given as a cell suspension in aseptic buffered solution in disposable vials with no preservative agents. The cells will be injected every two weeks at a total of three doses, 120 million cells in 10mls divided on two IV boli for each dose
2892847|NCT03299400|Experimental|Contact lens sensor|Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
2892848|NCT03299387|Active Comparator|Oral Nitrofurantoin|Participants will randomized to oral nitrofurantoin
2892849|NCT03299387|Active Comparator|Intravesical Gentamicin|Participants will be randomized to intravesical gentamicin
2892850|NCT03299374|Active Comparator|Falls Group|Falls prevention intervention
2892851|NCT03299374|Experimental|Pilates Group|Pilates intervention
2892852|NCT03299348|Experimental|Active Treatment Group|This group will get the AgingPLUS intervention program which addresses negative views on aging, low internal control beliefs, and deficient goal planning skills.
2892853|NCT03299348|Placebo Comparator|Active Control Group|This group will get the Successful Aging control program. The control program will control for the effect of social contact and will not address the intervention targets of the active treatment group. The Successful Aging program will only provide generic information on how to optimize successful aging.
2892854|NCT03299335|Other|Early-stage sIMB patients|
2892855|NCT03299335|Other|Late-stage sIMB patients|
2892856|NCT03299335|Other|Control subjects|
2892857|NCT03299322|Placebo Comparator|Control Group|80 participants will take oral therapy of 9.25 g Jia Wei Yang He granule Placebo twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
2892858|NCT03299322|Experimental|High dose Treatment Group|Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 18.5g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
2892859|NCT03299322|Experimental|Low dose Treatment Group|Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 9.25g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
2892860|NCT03299309|Experimental|PEP-CMV|Cytomegalovirus (CMV)-specific peptide vaccine (PEP-CMV)
2892861|NCT03299296|Experimental|Rivaroxaban arm|Rivaroxaban 10 Milligrams
2892862|NCT03299296|Active Comparator|Enoxaparin Arm|'Enoxaparin 40 Milligrams /0.4 Milliliters Prefilled Syringe
2892863|NCT03299283||Respiratory/Pharyngitis|Subject presents with signs/symptoms of respiratory infection including but not limited to fever, cough, sore throat (pharyngitis), runny nose, myalgia, headache, chills, or fatigue
2892864|NCT03299283||Gastrointestinal|Subject presents with suspected gastroenteritis (e.g. diarrhea, vomiting, nausea, etc.) with duration of symptoms less than or equal to 7 days
2892865|NCT03299270||Group 1|Elderly patiences with solid malignancy
2892866|NCT03299257|Active Comparator|donepezil treatment|donepezil with 10 mg will be administered for 30 days.
2892867|NCT03299257|Placebo Comparator|placebo treatment|placebo with 10 mg placebo will be administered for 30 days.
2892868|NCT03299244|Experimental|Etelcalcetide|Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW, and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and the dose may be titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.
2892869|NCT03299244|Active Comparator|Cinacalcet|Participants were randomized to receive oral cinacalcet once daily and placebo intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 25 mg daily and the dose may be titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
2892870|NCT03299231|Active Comparator|Aerobika|Group of participants with COPD, hospitalized for severe exacerbation and using the active oscillating positive expiratory pressure device (OPEP). The device is a hand held one. Used mostly in subjects with bronchiectasis for mucus clearing. Estimated number of subjects in this arm is 80. The device has an adjustable resistance which will be set by a health care provider in the study team. The device is to be used three times daily from 10 to 20 minutes according to subject's effort.
2892871|NCT03299231|Sham Comparator|Sham device|Group of participants using the same looking device which is devoid from nebulizer port valve so it is not functioning (sham device). The sham arm is a control arm. It will be used as the active comparator three times daily for 10 to 20 minutes according to subject's effort
2892872|NCT03299218|No Intervention|Control|Receiving current Government of Punjab health services
2892873|NCT03299218|Experimental|Cash-based transfers|Cash-based transfers only by BISP
2892874|NCT03299218|Experimental|Cash with enhanced BCC|Cash-based transfers and enhanced behaviour change communication (BCC)
2892875|NCT03299218|Experimental|Cash with SNF (Wawamum)|Cash-based transfers and SNF (Wawamum)
2892876|NCT03299218|Experimental|Cash,SNF (Wawamum) & enhanced BCC|Cash-based transfers, SNF (Wawamum) and BCC
2892877|NCT03299205|Experimental|Exercise|Aerobic exercise program using treadmill.
2892878|NCT03299192|Experimental|Tai Chi|twice weekly classes for 12 weeks and then weekly for 6 weeks, every other week for 6 weeks and monthly for 3 months
2892879|NCT03299192|Active Comparator|Health Education|twice weekly classes for 12 weeks
2892880|NCT03299192|Active Comparator|Usual Medical Care|the usual care to which participants are entitled by their health insurance
2892881|NCT03299179||Natural cycle|15 female volunteers, not using hormonal contraception, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 3 times: during the follicular phase, during ovulation and during luteal phase.
2892910|NCT03298958|Active Comparator|Sirolimus (Rapamycin) 0.5 mg/day for 2 years|Subject will be randomized to take Sirolimus (Rapamycin) 0.5mg once daily for 2 years or until disease recurrence
2892882|NCT03299179||Anti-conception|15 female volunteers, using hormonal contraception pill Deso 20, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 2 times: during the pill-week and during the pill-free week.
2892883|NCT03299166|Experimental|BHV-4157|
2892884|NCT03299166|Placebo Comparator|Placebo|
2892885|NCT03299153|Experimental|Intervention group|patients in this group were received 200 ml/d barberry juice for tow month
2892886|NCT03299153|No Intervention|control group|patients in this group received no intervention
2892887|NCT03299140|Other|Family Focused Therapy|Only 1 arm
2892888|NCT03299127|Experimental|imagery rescripting|bibliotherapy, intervention is provided by pdf-manual (either short or long version, i.e. 2 active arms, each 1/3 of sample receives either short or long version)
2892889|NCT03299127|No Intervention|wait-list control|wait-list control, participants receive intervention manual upon completion of post-assessment (1/3 of sample)
2892890|NCT03299114|Active Comparator|Intervention Group|Treated with warm whirlpool
2892891|NCT03299114|Placebo Comparator|Placebo group|Treated with sham whirlpool
2892892|NCT03299101|Experimental|Prehabilitation|Prospective sample of patients anticipating cardiothoracic surgery.
2892893|NCT03299088|Experimental|Arm A (trametinib, pembrolizumab)|Patients receive trametinib PO daily. Beginning on day 1 of course 2, patients also receive pembrolizumab IV over 30 minutes. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
2892894|NCT03299088|Experimental|Arm B (pembrolizumab, trametinib)|Patients receive pembrolizumab IV over 30 minutes on day 1. Beginning on day 1 of course 2, patients also receive trametinib PO daily. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
2892895|NCT03299062|Active Comparator|Parkinson's Disease with Voice Dysfunction Patients|• Twenty people with Parkinson's Disease requiring evaluation of voice dysfunction by an Ear, Nose, and Throat (ENT) doctor
2892896|NCT03299062|Active Comparator|Other Neurodegenerative Disorders with Voice Dysfunction|• Twenty people with other neurodegenerative disorders requiring evaluation of voice dysfunction by an ENT doctor.
2892897|NCT03299062|Placebo Comparator|Voice Dysfunction|Twenty people with voice tremor and/or presbylarynx, but no evidence of Parkinson's other neurodegenerative disease, requiring evaluation of voice dysfunction by an ENT doctor.
2892898|NCT03299049|Experimental|Subjects in group 1 receiving study treatment once in 4 weeks|Group 1 will consist of subjects randomized from current ART SOC therapy. Subjects in group 1 will be randomized to receive CAB LA plus RPV LA Q4W via intramuscular (IM) route. All subjects will receive oral therapy with CAB 30 mg + RPV 25 mg once daily prior to randomization.
2892899|NCT03299049|Experimental|Subjects in group 1 receiving study treatment once in 8 weeks|Group 1 will consist of subjects randomized from current ART SOC therapy. Subjects in group 1 will be randomized to receive CAB LA plus RPV LA Q8W via IM route. All subjects will receive oral therapy with CAB 30 mg + RPV 25 mg once daily prior to randomization.
2892900|NCT03299049|Experimental|Subjects in group 2 receiving study treatment once in 4 weeks|Group 2 will consist of subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in Group 2 will be randomized to continue CAB LA plus RPV LA Q4W administration via IM route.
2892901|NCT03299049|Experimental|Subjects in group 2 receiving study treatment once in 8 weeks|Group 2 will consist of subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in Group 2 will be randomized to receive CAB LA plus RPV LA Q8W via IM route.
2892902|NCT03299036|Experimental|Taiwan ACE Beads with doxorubicin|The use of Taiwan ACE Beads (T-ACE) microspheres embolization with doxorubicin as a treatment for patients with hepatoma.
2892903|NCT03299010||DM patient|Patients with a documented clinical diagnosis of DM and were receiving care in the Hospital Authority (HA) primary care General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) on or before 1 July 2006 identified from the HA clinical management system (CMS) database.
2892904|NCT03298997|Experimental|Ligation and Hemorrhoidopexy|"The patient will be placed in the Lloyd-Davies position. Provision of a sterile field, using a 10% povidone iodine solution. Rectal dilatation will be performed with a 10% xylocaine gel. Introduction of a proctoscope. Identification of the hemorrhoidal nodules (3rd, 7th, 11th hour). Confirmation of the hemorrhoidal artery location, through palpation. Ligation of the hemorrhoidal nodules using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Placement of a fixative suture in the hemorrhoidal nodule and then performance of hemorrhoidopexy Placement of a hemostatic gauze in the surgical field. Prior to operation, the patients will be submitted to pudendal nerve block. Using an atraumatic 25 Gauge (G) needle, a 20ml lidocaine solution (diluted with saline in a 1:1 rate) will be administered bilaterally, medially to the ischial tuberosity.~10 minutes before the operation, the patient will receive 1-2.5mg midazolam and 0.1-0.2 mg fentanyl."
2892905|NCT03298997|Active Comparator|Ultrasound Guided Ligation of Hemorrhoidal Arteries|"The patient will be placed in the Lloyd-Davies position. Provision of a sterile field, using a 10% povidone iodine solution. Rectal dilatation will be performed with a 10% xylocaine gel. Use of a proctoscope combined with a Doppler sensor. After the hemorrhoidal artery localization, Z ligations will be placed, using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~The proper artery ligation will be confirmed by the absence of the Doppler signal.~In the presence of residual hemorrhoidal tissue hemorrhoidopexy will be performed, by applying a continuous suture.~Placement of a hemostatic gauze in the surgical field. Prior to operation, the patients will be submitted to spinal anesthesia. Using an atraumatic 25 Gauge (G) needle, a levobupivacaine 5mg/ml and fentanyl 25mg solution, will be administered at the height of lumbar (L)2-L3 or L3-L4."
2892906|NCT03298984|Experimental|Alvocidib and Cytarabine/Daunorubicin|The starting dose of alvocidib will be 20 mg/m2 as a 30-minute intravenous (IV) bolus followed by 30 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3 of Induction. Patients will have a one day drug holiday (Day 4) before initiation of the 7+3 regimen. Beginning on Day 5, cytarabine will be administered as a 100 mg/m2/day continuous IV infusion for seven consecutive days (Days 5-11) plus daunorubicin administered at a dosage of 60 mg/m2 IV on Days 5-7.
2892907|NCT03298971||Survivors of Childhood Osteosarcoma|Survivors of Childhood Osteosarcoma were invited to fill in a set of questionnaires.
2892908|NCT03298971||Healthy Subjects|Healthy Subjects were invited to fill in a set of questionnaires.
2892909|NCT03298958|Placebo Comparator|Placebo Oral Tablet|Subject will be randomized to take the Placebo once daily for 2 years or until disease recurrence
2892914|NCT03298919|Active Comparator|Standard Exercise|Exercise using aerobic equipment such as stationary bikes and treadmills 3 times weekly for 12 weeks followed by home practice
2892915|NCT03298919|No Intervention|Wellness Control|Weekly mailings on general health and wellness topics for 12 weeks followed by monthly mailings for 6 months.
2892916|NCT03298906|Experimental|Esketamine + Ticlopidine|Participants will self-administer one 14 milligram (mg) spray of intranasal esketamine into each nostril at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg (Treatment A) in Treatment Period 1. After that participants will receive 250 mg of ticlopidine tablets orally twice daily on Day -9 through Day 1, and will self-administer one 14 mg spray of intranasal esketamine into each nostril at Time 0 and again 5 minutes later in the morning of Day 1, a total dose of 56 mg (Treatment B) in Treatment Period 2. A washout period of greater than or equal to (>=)10 days will separate the esketamine self‑administrations between 2 treatment periods.
2892917|NCT03298893|Experimental|Nivolumab + radiochemotherapy|5 weeks of radiochemotherapy + nivolumab followed by 5 months of nivolumab alone
2892918|NCT03298880|Other|Four VM's|Healthy volunteers undergo repeated VM's - Device: Supine VM VAD, Supine VAD manometer Modified VM VAD, Modified VM Manonmeter
2892919|NCT03298867|Active Comparator|Teprotumumab 20 mg/kg|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
2892920|NCT03298867|Placebo Comparator|Placebo|Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
2892921|NCT03298828|Experimental|CD19 CAR|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19 CAR T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19 CAR T-cells.
2892922|NCT03298828|Experimental|CD19 CAR and PD-1 knock out|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19 CAR and PD-1 knock out engineered T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19 CAR and PD-1 knock out engineered T-cells.
2892923|NCT03298815|Active Comparator|Amniotic Fluid Eye Drops (AFED) - All participants, One eye|
2892924|NCT03298815|Placebo Comparator|Saline Solution - All participants, One eye|
2892925|NCT03298802|Active Comparator|Hydrochlorothiazide 50mg Tablet|Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
2892926|NCT03298802|Placebo Comparator|Placebo Tablet|Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for fourteen days postpartum
2892927|NCT03298789|Experimental|Experimental condition|7 series of static stretching will be conducted in the experimental condition. Activation exercises will be performed after 7th series of static stretching.
2892928|NCT03298789|Other|Control|7 series of static stretching will be conducted in the control condition.
2892929|NCT03298776|Active Comparator|standard white light endoscopy|Patients will undergo the standard of care which is standard white light endoscopy
2892930|NCT03298776|Experimental|Endoscopy and I-Scan|Patients will undergo standard of care endoscopy plus the I-Scan
2892931|NCT03298763|Experimental|Phase 1 - RP2D finding study|Phase I of the trial aims to establish the recommended MSCTRAIL dose when given in combination with cisplatin/pemetrexed chemotherapy in metastatic non-small cell lung cancer (NSCLC) patients
2892932|NCT03298763|Active Comparator|Phase 2 Intervention Arm|"Cisplatin 75mg/m2 and Pemetrexed 500mg/m2 on day 1 followed by MSCTRAIL (at the recommended phase 2 dose) on day 2. This schedule will be repeated after 21 days for 3 cycles.~Patients will then receive a further 1-3 cycles of pemetrexed/ cisplatin alone. They may then be eligible for maintenance pemetrexed according to clinical response as directed by their Oncologist in line with local standard of care."
2892933|NCT03298763|Placebo Comparator|Phase 2 Control Arm|"cisplatin 75mg/m2 and pemetrexed 500mg/m2 on day 1 and placebo on day 2. This will be repeated after 21 days for up to 3 cycles.~Patients will then receive a further 1-3 cycles of pemetrexed/ cisplatin alone. They may then be eligible for maintenance pemetrexed according to clinical response as directed by their Oncologist in line with local standard of care."
2892934|NCT03298750|Experimental|Mechanical stimulation|Mechanical stimulation of ovarian tissue
2892935|NCT03298737||Correct to normal vision population|
2892936|NCT03298724|Experimental|TAPP Intervention|The Teachers and Partners intervention will be provided
2892937|NCT03298698|Experimental|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
2892938|NCT03298698|Active Comparator|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
2892939|NCT03298685||CF patient and parents cohort in 3 CF center|All adolescents for whom the transition to the adult center is scheduled within six months and their parent will be interviewed before and after transition.
2892940|NCT03298672|Experimental|NDX-1017|NDX-1017 will be administered via subcutaneous injection
2892941|NCT03298672|Placebo Comparator|Placebo|Placebo will be administered via subcutaneous injection
2892942|NCT03298659|Experimental|Active iFR-guided revascularization|Decision to treat the nonculprit coronary stenosis if there is a significant pressure drop over the stenosis, as measured by intracoronary iFR assessment
2892943|NCT03298659|Active Comparator|Deferred CMR-guided revascularization|Decision to treat the nonculprit coronary stenosis if perfusion defect visible in corresponding coronary territory as visualized on stress perfusion CMR imaging
2892944|NCT03298646|Experimental|Lidacaine hydrochloride|"Adding 10 ml of 2% Lidocaine hydrochloride on hysteroscopic saline media during office hysteroscopy to test its efficacy in reducing pain.~22 women."
2892945|NCT03298646|Active Comparator|Diclofenac|"100 mg Diclofenac oral tablet is administered 1 hour before the procedure to test its efficacy in reducing pain.~22 women."
2892946|NCT03298633|Active Comparator|Intracytoplasmic Sperm Injection|On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in group A will undergone Intracytoplasmic Sperm Injection (ICSI) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
2892947|NCT03298633|Active Comparator|Conventional IVF|On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in this group will undergone Conventional In Vitro Fertilization (IVF) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
2892948|NCT03298620|Experimental|Intervention|Electric toothbrush
2892949|NCT03298620|Active Comparator|Control|New standard manual toothbrush
2892950|NCT03298607|Placebo Comparator|Placebo|2 capsules daily for 2 months containing inactive substances
2892951|NCT03298607|Active Comparator|Serelys PMS|2 capsules daily for 2 months containing pollen extract
2892952|NCT03298594|Experimental|specific cervicograph|Specific cervicograph, including an alert line (normal progression of cervical dilation, i.e. 1 cm per hour) and an action line 2 hours after the alert line. This should be completed after the diagnose of active labor
2892953|NCT03298594|No Intervention|Usual cervicograph|The usual cervicograph in our unit is not having lines
2892954|NCT03298581|Experimental|Halobetasol propionate spray 0.05%|Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.
2892955|NCT03298568|Experimental|DAOsin treatment|Patients suffering from histamine intolerance and a diamin oxidase activity below 10 Units/ml get a DAOsin treatment for one month 3 times a day.
2892956|NCT03298555|Experimental|Mobile phone based intervention|This group will receive the smartphone app HealthyMoms between gestational week 14 and 37. The app will contain information and support to achieve a healthy weight gain and lifestyle during pregnancy. This group will also receive standard care.
2892957|NCT03298555|No Intervention|Control|This group will only receive standard care.
2892958|NCT03298542|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
2892959|NCT03298542|Placebo Comparator|Group 2: Placebo|Participants will receive a SC matching placebo to golimumab.
2892960|NCT03298529|Experimental|Traditional egg pasta|"Traditional egg pasta. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta made with 8 eggs/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
2892961|NCT03298529|Experimental|Pasta with only eight egg whites/kg flour|"Pasta with only eight egg whites/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with only eight egg whites/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
2892962|NCT03298529|Experimental|Pasta with four eggs/kg flour|"Pasta with four eggs/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with four eggs/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
2892963|NCT03298529|Experimental|Hyperproteic pasta (with added gluten and albumin)|"Hyperproteic pasta (with added gluten and albumin). 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with added gluten and albumin. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
2892964|NCT03298529|Experimental|Pasta with only four egg whites/kg flour|"Pasta with only four egg whites/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with only four egg whites/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
2892965|NCT03298516|Experimental|Arm A: DCLL9718S|Participants will receive escalating doses of DCLL9718S intravenously (IV) in each 21-day cycle to determine MTD and RP2D in dose-escalation stage followed by DCLL9718S IV at RP2D in each 21-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
2892966|NCT03298516|Experimental|Arm B: DCLL9718S and Azacitidine|Participants will receive escalating doses of DCLL9718S (starting dose: at least one dose level below a completed and tolerated DCLL9718S monotherapy in Arm A) IV in each 28-day cycle and azacitidine 75 milligrams per square meter (mg/m^2) subcutaneously (SC) or IV on Days 1-7 of each 28-day cycle to determine MTD and RP2D of DCLL9718S in dose-escalation stage followed by DCLL9718S IV at RP2D in each 28-day cycle and azacitidine 75 mg/m^2 SC or IV on Days 1-7 of each 28-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met. Azacitidine may also be given on Days 1-5 and Days 8-9 depending on institutional preference.
2892967|NCT03298503|Active Comparator|early stage or non-freezers PD|"early stage defined as modified Hoehn and Yahr scale 1, 1.5 and 2, means that symptoms involved unilateral or bilateral without impairment of balance.~non-freezers defined as without freezing of gait, means that patients without transient inability to generate effective stepping."
2892968|NCT03298503|Experimental|moderate stage or freezers PD|"moderate stage defined as modified Hoehn and Yahr scale 2.5 and 3, means that symptoms involved unilateral or bilateral without impairment of balance.~freezers defined as with freezing of gait, means that patients have transient inability to generate effective stepping."
2892969|NCT03298477|Other|Single Arm|Single Arm Safety and Effectiveness Confirmatory Study of EVAS using the Nellix® System
2892970|NCT03298464|Experimental|NGM313|
2892971|NCT03298464|Active Comparator|Pioglitazone|
2892972|NCT03298451|Experimental|Arm 1|Durvalumab
2892973|NCT03298451|Experimental|Arm 2|Durvalumab in combination with tremelimumab (Regimen 1)
2892974|NCT03298451|Experimental|Arm 3|Durvalumab in combination with tremelimumab (Regimen 2)
2892975|NCT03298451|Active Comparator|Arm 4|Sorafenib
2893049|NCT03297918|Active Comparator|Intervention group|Patients will be asked to participate in a structured singing and respiratory training for 12 weeks.
2893050|NCT03297918|No Intervention|Control group|no intervention
2893051|NCT03297905|Experimental|Complementary and Integrative Therapies|Chiropractic, Acupuncture, Yoga, Biofeedback (if indicated), and Foam roller instruction
2893157|NCT03297190|Active Comparator|SMS|Participants will receive SMS messages on nutrition and health related topics
2892976|NCT03298425|Active Comparator|Treatment NMES|Patients allocated to the NMES group will be given an information booklet on NMES machines. The Cefar Compex three electrical stimulator will be used. Participants are expected to use the NMES machine for half an hour and complete bed exercises twice daily. Patients should relax during the NMES as completing both does not demonstrate better results, due to unsynchronised activation of the NMES (Gregory & Bickel, 2005). Using the machine once daily will allow for the recovery of the muscle. A voluntary contraction would normally be 20-30Hz but due to the high intensities of the NMES (35-75Hz) it can cause muscle fatigue (Maffiuletti, 2011).
2892977|NCT03298425|Placebo Comparator|Placebo NMES|The placebo group will act as the control group. They will be expected to complete the same regime as previously described above, however these machines will be on TENS setting (80-100Hz) as even low Hz can trigger motor stimulation (Paillard 2008). This setting is designed as a sensory stimulus therefore will have no effects on muscle strength however the patient will feel a small twitch sensation. This setting is not painful and will have no effect on muscle fatigue. The patient will not be expected to complete the bed exercises and the TENS session together.
2892978|NCT03298412|Experimental|Blinatumomab|Blinatumomab is administered as a continuous intravenous (IV) infusion.
2892979|NCT03298399|Experimental|MSC dose level 1|The first three subjects (minimum) will receive four weekly infusions of MSCs.
2892980|NCT03298399|Experimental|MSC dose level 2|If no significant side effects are encountered at dose level 1, then subsequent subjects will receive four infusions of MSCs given twice weekly.
2892981|NCT03298399|Experimental|MSC dose level 3|If dose level 2 is well tolerated, then subsequent subjects will receive six infusions MSCs given twice weekly.
2892982|NCT03298386|Experimental|"Intervention Group STOPP/START"|Training of General Practitioners with the tool STOPP/START Systematic medication review by GP with STOPP/START
2892983|NCT03298386|No Intervention|Control group|Patient's usual care by the general practitioner (who will not be trained in the STOPP/START tool)
2892984|NCT03298373|Placebo Comparator|Placebo|Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
2892985|NCT03298373|Experimental|11β-MNTDC|11β-MNTDC capsules administered orally (200 mg or 400 mg).
2892986|NCT03298347|Experimental|80mg/kg of caffeine|80mg/kg of caffeine is given to treat AOP.
2892987|NCT03298347|Active Comparator|20mg/kg of caffeine|20mg/kg of caffeine is given to treat AOP.
2892988|NCT03298334|Active Comparator|Receives Vaginal Seeding|
2892989|NCT03298334|Sham Comparator|No Vaginal Seeding|
2892990|NCT03298321||Vidaza patients|This study will be performed on adults with Acute Myeloid Leukemia and atrial fibrillation. Only patients treated for the first time with vidaza® within an hospital hematology unit will be included.
2892991|NCT03298308|Experimental|Brainwave|Brainwave analysis after cranial electric stimulation
2892992|NCT03298295|Experimental|Insertion of Insulin Infusion Catheters|Non-diabetic patients scheduled for abdominoplasty will be inserted continuous subcutaneous insulin infusion (CSII) catheters of two different materials into the part of the abdomen which will be removed during surgery.
2892993|NCT03298282||Imaging Registry|Imaging cohort: Patients with intermediate lesions
2892994|NCT03298269|Experimental|Mindfulness-Oriented Recovery Enhancement|
2892995|NCT03298269|Active Comparator|Supportive Counseling|
2892996|NCT03298256||Lenke type 1 AIS|Patients will be given a new prescription for a custom made Boston type thoracic-lumbo- sacral-orthosis (TLSO) braces. All patients will undergo low dose biplanar X-rays using the EOS ® machine system.
2892997|NCT03298243|Experimental|Stroke Cohort - Optimize Delivery|Aim 1 intervention: Vibrotactile stimulation. An optimal location and style of vibrotactile feedback for reach and stabilization behaviors will be determined.
2892998|NCT03298243|Experimental|Stroke Cohort - Extended Training|Aim2 intervention: Vibrotactile stimulation. Progressive training from simple to more complex reaching and stabilizing tasks using vibrotactile feedback to guide performance
2892999|NCT03298230|Experimental|REmotely SuPervised Exercise Training|12- week home based exercise programme consisting of bi-weekly, hourly sessions at the time and place of the participant's choosing. They will wear a fitness tracker which will automatically upload their exercise data to an online platform which can be monitored by the research team and used to provide additional motivation.
2893000|NCT03298230|Active Comparator|Supervised Exercise Training|As per NICE guidance. 12 week, bi-weekly, one hour sessions of supervised exercise training.
2893001|NCT03298217|Other|Bronchiolitis patients sverity|In patients with bronchiolitis mWCAS / 3-5 : Measurement of the peak tidal inspiratory flow (PTIF)
2893002|NCT03298204||Chemoradiotherapy|
2893003|NCT03298204||Chemoradiotherapy following chemotherapy|
2893004|NCT03298204||Chemoradiotherapy followed by chemotherapy|
2893005|NCT03298191|Experimental|Magnesium sulphate|
2893006|NCT03298191|Experimental|Ritodrine|
2893007|NCT03298191|Experimental|Calcium channel blocker|
2893008|NCT03298178||all aortic stenosis|
2893009|NCT03298165|Experimental|disinfection the cavity with diode laser|diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
2893010|NCT03298165|Placebo Comparator|no cavity disinfection|placebo is used as no cavity disinfection will be done as after excavation the restoration will be placed .
2893011|NCT03298152|Active Comparator|Emax CAD Endocrowns|Using lithium disilicate e.max restorations is documented in literature as a successful restoration. Two different ceramic crowns systems were investigated clinically for three-years and howed that patient was satisfied with the final restoration
2893012|NCT03298152|Experimental|Cerasmart Endocrowns|A new material CERASMART (Force Absorbing Flexible nano ceramic CAD/CAM block) with high density of ultrafine glass particles with 71 wt% filled nano-composite. It combines high strength and unique aesthetics. full homogeneous and even distribution nano ceramic network lead to unique physical properties for cerasmart . Uniform scuttle (very short inter-particle distance) of silanated and bonded particles is key to delivering CERASMART's™ with exceptional strength, retention, acceptable level of marginal adaptation
2893013|NCT03298139|Experimental|parabolic flights|parabolic flights in normogravity (1g), hypergravity (1.8g) and microgravity (0g).
2893083|NCT03297645|Experimental|Arm 1|school + asthma education + home environment remediation
2932868|NCT03020784|Experimental|PF-06818883|Experimental drug
2893014|NCT03298126|Active Comparator|TR BAND Protocol A|In this group, air removal from TR band was initiated after 2 hours of TR band application. 3 ml of air was removed periodically at an interval of 15 minutes until all the air is eliminated from the band. In case of bleeding or hematoma while deflating air, 4 ml of air was re-injected and observed for 30 minutes until next attempt was made to deflate the band. The data including the attempts made at deflating TR band, time and amount of air injected along with the response to each deflation i.e. occurrence of bleeding or hematoma was noted down in the proforma
2893015|NCT03298126|Active Comparator|TR BAND PROTOCOL B|In this group deflation was initiated after 2 hours of TR band application as described by Cohen and Alfonso. [6] 5 ml of air was deflated at first attempt. Next attempt was carried out after 15 minutes in which further 5 ml was removed. After 15 minutes, the remaining 2 ml of air was released from the band. In case of bleeding or hematoma at any attempt, 6 ml air was re-injected and interval for 15 minutes taken to attempt further air deflation. All the attempts and its response were recorded in the proforma filled out by the assessor.
2893016|NCT03298113|Experimental|Cavilon Advanced Skin Protectant|Product applicator contains liquid barrier and is applied according to the 3M manufacturer's instructions for use.
2893017|NCT03298113|Other|IAD Hospital Standard Care|Marketed products are applied according to the IAD hospital standard care routine.
2893018|NCT03298100||Postmenopausal women|
2893019|NCT03298087|Experimental|Experimental Arm|Radical prostatectomy (and post-operative fractionated radiotherapy for pT=3a, pN1, or positive margins), metastasis directed SBRT, and complete ADT with LHRH analog leuprolide, abiraterone acetate with prednisone, and apalutamide (ARN-509) for a total of six months of systemic therapy.
2893020|NCT03298074|Experimental|Apatinib plus Etoposide|Apatinib,500mg,PO.QD, continuous administration Etoposide,100mg, PO.QD，D1-D10, Q3W
2893021|NCT03298074|Active Comparator|Etoposide|Etoposide,100mg, PO.QD，D1-D10, Q3W
2893022|NCT03298061|Experimental|Subjects from clinical study MEA115921|Subjects who participated in clinical study MEA115921 and who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included. Eligible subjects will receive subcutaneously administered mepolizumab at a dose of 300 mg SC every 4 weeks.
2893023|NCT03298048|Active Comparator|Low fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
2893024|NCT03298048|Active Comparator|Mid fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
2893025|NCT03298048|Active Comparator|High fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
2893026|NCT03298035|Active Comparator|NCPAP as mode for apnea prevention|With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.
2893027|NCT03298035|Experimental|NIPPV as rescue mode for apnea prevention|With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
2893028|NCT03298022|Experimental|AbGn-168H|intravenous doses of AbGn-168H
2893029|NCT03298009|Placebo Comparator|Treatment 1|placebo oral capsule will be administered once daily, for 2 weeks
2893030|NCT03298009|Experimental|Treatment 2|Canagliflozine 100mg once daily, for 2 weeks
2893031|NCT03297996||SIT|Centers for Disease Control and Prevention (CDC) Study of In-home Tests for Colorectal Cancer (SIT)
2893032|NCT03297996||NYU|New York University (NYU) Human Microbiome and Colorectal Tumor study
2893033|NCT03297983|Experimental|First M7583 Tablet:Fasted, Then PiC:Fasted, Then Tablet:Fed|
2893034|NCT03297983|Experimental|First M7583 PiC:Fasted, Then Tablet:Fasted, Then Tablet:Fed|
2893035|NCT03297970||Bogota School Children Cohort|"Children are classified according to exposure levels of:~Micronutrient biomarker indicators:~Ferritin~Hemoglobin~Mean corpuscular volume~Zinc~Vitamin A~Vitamin B12~Folate~Vitamin D~Serum fatty acids~Inflammatory biomarkers:~C-reactive protein~Diet~Socioeconomic status indicators~Anthropometric indicators~Incidence of infectious morbidity symptoms~DNA biomarkers"
2893036|NCT03297957|Experimental|Arm 1: Fluorescence Imaging|"The patient will then be taken to the operating room, without deviating from normal operating procedures for this surgical procedure. Prior to starting the operation, the patient will undergo injection of ICG around the tumor per standard techniques while in the operating room~Patients will then undergo the standard SLN biopsy procedure.~After gamma probe and methylene blue identification of the SLN as per standard of care, the surgeon will put on the goggle system to attempt to identify the SLN using fluorescence guidance. After this is performed, the goggle system will be removed and the SLN biopsy will be completed per standard techniques. Lymph nodes that are fluorescent from ICG detected with the goggles will also be removed if the node identified in the dissected nodal basin. All three visualizations will be performed prior to removal and the nodes will then be sent for pathologic confirmation of node positivity or negativity."
2893037|NCT03297944|Experimental|2ALP/PLC|2mg Alprazolam administered at night, placebo administered in the morning
2893038|NCT03297944|Experimental|1ALP/PLC|1mg Alprazolam administered at night, placebo administered in the morning
2893039|NCT03297944|Experimental|0.5ALP/PLC|0.5mg Alprazolam administered at night, placebo administered in the morning
2893040|NCT03297944|Active Comparator|ZOL/PLC|10mg Zolpidem administered at night, placebo administered in the morning
2893041|NCT03297944|Placebo Comparator|PLC/PLC|Placebo administered at night, placebo administered in the morning
2893042|NCT03297944|Active Comparator|PLC/ALP|Placebo administered at night, 1mg alprazolam administered in the morning
2893043|NCT03297931|Active Comparator|Commercial corn chips + Onion dip|Corn chips + onion dip
2893044|NCT03297931|Experimental|Commercial pulse chip + pulse spread|Pinto bean chip + hummus
2893045|NCT03297931|Experimental|Novel pulse chip + pulse spread|Yellow pea chip + hummus
2893046|NCT03297931|Experimental|Commercial pulse chip + non-pulse spread|Pinto bean chip + onion dip
2893047|NCT03297931|Experimental|Novel pulse chip + non-pulse spread|Yellow pea chip + onion dip
2893048|NCT03297931|Experimental|Non-pulse chip + pulse spread|Corn chips + hummus
2893052|NCT03297905|Active Comparator|Standard Rehabilitative Care|Cognitive Behavioral Therapy (CBT) 60-minute orientation, CBT psychoeducation group, and Physical therapy/occupational therapy
2893053|NCT03297879|Experimental|exenatide group|The drug-naïve, overweight or obese patients with newly diagnosed T2D
2893054|NCT03297879|Active Comparator|metformin group|The drug-naïve, overweight or obese patients with newly diagnosed T2D
2893055|NCT03297866||Incentive schemes 1|No incentive will be given after completing the follow-up survey
2893056|NCT03297866||Incentive schemes 2|Receiving $100 supermarket coupon after completing the follow-up survey
2893057|NCT03297866||Incentive schemes 3|Receiving $200 supermarket coupon after completing the follow-up survey
2893058|NCT03297866||Incentive schemes 4|Receiving $100 supermarket coupon before completing the follow-up survey and another $100 supermarket coupon after completing the follow-up survey
2893059|NCT03297840||Treatment|Patients with Borderline Personality Disorder receiving DBT treatment. Measurement takes place at the beginning of the treatment and a second time after 12-weeks treatment.
2893060|NCT03297840||Waitlist|Patients with Borderline Personality Disorder on the waitlist for inpatient DBT treatment. Measurement takes place twice at baseline and after 12-weeks waiting.
2893061|NCT03297827||Patients with stroke|Adult stroke patients with the stroke diagnosis will be recruited on admission to the University of New Mexico Hospital. Serum and Urine measurement of cytokines from two sets of serum and urine samples will be done on the admission and at the 24-hour mark respectively, form the specimens collected for the clinical purposes and are meant to be discarded. Consent will be taken from the patients to use these samples for our study.
2893062|NCT03297827||Patients without stroke|Age/Sex matched adult control patients without the diagnosis of stroke, myocardial infarction, inflammatory flare, acute trauma, neurodegenerative or neuroinflammatory disease (AD, PD, TM, PSP, etc.) except MS will be recruited on admission to the University of New Mexico Hospital. Serum and Urine measurement of cytokines from two sets of serum and urine samples will be done on the admission and at the 24-hour mark respectively, form the specimens collected for the clinical purposes and are meant to be discarded. Consent will be taken from the patients to use these samples for our study.
2893063|NCT03297814|Active Comparator|Platelet lysate|A total of 5 ml platelet lysate will be intramuscularly injected in 4 doses with 2 week interval
2893064|NCT03297814|Placebo Comparator|placebo|A total of 5 ml of Normal Saline will be intramuscularly injected in 4 doses with 2 week interval
2893065|NCT03297801||Fish oil group|Women who chose to supplement with fish oil, rich in omega-3 polyunsaturated fatty acids, during gestation or lactation.
2893066|NCT03297801||No fish oil group|Women who chose not to supplement with fish oil during gestation or lactation.
2893067|NCT03297788|Experimental|Arm A: SRS|Patient receive stereotactic radiosurgery (SRS), dose prescription according to the size of radiated brain metastases
2893068|NCT03297788|Active Comparator|Arm B: WBRT|Patients receive whole brain radiotherapy (WBRT)
2893069|NCT03297775||Evidence of interstitial lung disease|"Subjects who screen positive for ILD will be followed annually until study closure.~Assessments are as follows:~Clinical - Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)~Physiologic - Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance~Radiologic - Assessment for airways disease, interstitial lung abnormalities~Genetic - DNA, RNA~Biologic - Serum, Plasma, Sputum"
2893070|NCT03297775||No evidence of interstitial lung disease|"Subjects who screen negative for ILD will be followed five years after the initial screen and re-screened with a chest CT scan to check for evidence of new lung disease.~Assessments are as follows:~Clinical - Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)~Physiologic - Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance~Radiologic - Assessment for airways disease, interstitial lung abnormalities~Genetic - DNA, RNA~Biologic - Serum, Plasma, Sputum"
2893071|NCT03297762|Experimental|Gamification|Use of continuous glucose monitor (Dexcom G5) with proactive intervention and incentives for time in use.
2893072|NCT03297762|Active Comparator|Standard care|Use of continuous glucose monitor (Dexcom G5) per usual care.
2893073|NCT03297736|Active Comparator|Control|Subjects receive the control device.
2893074|NCT03297736|Experimental|Investigational device|Subject receives the 3D CAD/CAM autograft prosthesis implant.
2893075|NCT03297723||Experimental arm|The experimental group will be constituted after the medical staff was trained to TPE. Cancer patients will benefit from a PEP aiming at learning how to better manage their pain.
2893076|NCT03297723||Controle arm|The control group will be constituted before the training of the medical staff to TPE. Patients' pain will be managed conventionally.
2893077|NCT03297710|Experimental|Treatment (TAS-102, radiation therapy)|Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 PO BID and undergo radiation therapy in 10 fractions on days 1-5 and 8-12 in the absence of disease progression or unacceptable toxicity.
2893078|NCT03297697||Arm 1: Lymphotrack|-Patients will be treated with frontline chemotherapy per the treating physician's discretion. Collection of the pre-treatment tumor biopsy to identify the tumor-specific clonotype and peripheral blood samples at various time points for assessment of minimal residual disease using the LymphoTrack MRD assay. The results of these studies will be performed in batches and therefore will not be available to patients and clinicians to make clinical decisions.
2893079|NCT03297671||Pregnant Women|2000 pregnant women from the communities in the catchment area of THQ Johi. Rh negative women will receive two RhIg prophylaxis injections.
2893080|NCT03297671||Lady Health Visitors (LHVs)|3-5 LHVs who are full time employees at THQ Johi. LHVs will perform ELDONCARD test.
2893081|NCT03297658|Active Comparator|electro-acupuncture (EA) intervention|Micro electrodes will be placed at PC 4 and 6 , LI 4 and ST36. subjects will receive electro-acupuncture (EA) (treatment) mixed frequency( continuous plus dense disperse) will be at 2Hz and 100 Hz the amplitude will be 1000 microA.
2893082|NCT03297658|Sham Comparator|sham electro acupuncture|Micro electrodes will be placed at PC 4 and 6 , LI 4 and ST36. subjects Receive sham (control) will not have stimulation.
2893086|NCT03297632|Experimental|Intervention Group|Receives instructor-based functional resistance exercise. 45 minutes per session. 3 times per week, during 10 weeks in total.
2893087|NCT03297632|No Intervention|Control group|Asked to normally active according to their current lifestyle
2893088|NCT03297632|Active Comparator|Home-based group|Receives home-based exercises with written instructions and digital video support. 45 minutes per session. 3 times per week, during 10 weeks in total.
2893089|NCT03297619|Experimental|ACT self-help book condition|Participants in this condition will be assigned to read The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness by Fleming and Kocovski (2013), a self-help book based on acceptance and commitment therapy.
2893090|NCT03297619|Active Comparator|CBT self-help book condition|Participants in this condition will be assigned to read The Shyness and Social Anxiety Workbook by Antony and Swinson (2008), a self-help book based on cognitive-behavioral therapy for social anxiety.
2893091|NCT03297606|Experimental|Group 1|VEGFR1, VEGFR2, VEGFR3
2893092|NCT03297606|Experimental|Group 2|BCR-ABL, SRC
2893093|NCT03297606|Experimental|Group 3|ALK, ROS1, MET
2893094|NCT03297606|Experimental|Group 4|KIT, PDGFRA, PDGFRB, ABL1
2893095|NCT03297606|Experimental|Group 5|EGFR
2893096|NCT03297606|Experimental|Group 6|high mutation burden, POLE, POLD1
2893097|NCT03297606|Experimental|Group 7|BRCA1, BRCA2, mutations in HRD.
2893098|NCT03297606|Experimental|Group 8|CDKN2A, CDK4, CDK6, CCND1
2893099|NCT03297606|Experimental|Group 9|CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL
2893100|NCT03297606|Experimental|Group 10|AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STKII, TSC1, TSC2
2893101|NCT03297606|Experimental|Group 11|ERBB2
2893102|NCT03297606|Experimental|Group 12|BRAFV600
2893103|NCT03297606|Experimental|Group 13|PTCH1, SMO
2893104|NCT03297593|Experimental|nivolumab and ipilimumab|"Patients start treatment with nivolumab (240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter).~After 2 weeks, ipilimumab (1mg/kg every 6 weeks) will be introduced. As soon as a radiographic complete response (CR) or partial response (PR) is observed, ipilimumab has to be stopped and only the single-agent treatment with nivolumab is continued. Once ipilumimab has been stopped because of a response, it will not be re-started later on."
2893105|NCT03297567|Experimental|verbal guidance and booklet|verbal guidance and a booklet on the importance and benefits of movement during hospital stay, as well as what the patients should do to increase the level of physical activity.
2893106|NCT03297567|No Intervention|No Intervention|The control group will not receive any type of intervention
2893107|NCT03297554|Experimental|m-health approach|See intervention description
2893108|NCT03297541|Experimental|m-health approach|All dyads will receive the m-health approach.
2893109|NCT03297528|Experimental|study group|Participants receive chemotherapy and donor lymphocyte infusions based on the state GvHD, even the participants have a negative result of minimal residual disease (MRD). If the participants have no GvHD,they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD.
2893110|NCT03297528|No Intervention|control group|Participants don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD,in dispite of whether or not GvHD.
2893111|NCT03297515|Experimental|Omega 3 fatty acids|Omega 3 fatty acids
2893112|NCT03297515|Placebo Comparator|Placebo|Placebo (sunflower oil)
2893113|NCT03297502|Experimental|Pimecrolimus cream, 1%|
2893114|NCT03297502|Active Comparator|Elidel (pimecrolimus) cream 1%|
2893115|NCT03297502|Placebo Comparator|placebo|
2893116|NCT03297489|Experimental|Diagnostic (intravital microscopy)|Patients receive fluorescein sodium injection IV. Patients also undergo observation of primary and metastatic tumors via microscopy over 15-20 minutes during the course of standard of care surgery.
2893117|NCT03297476||high-risk group|"Selected by High-risk subtype detection panels"
2893118|NCT03297476||non high-risk group|"Selected by High-risk subtype detection panels"
2893119|NCT03297463|Experimental|Phase Ib (Dose Escalation)|
2893120|NCT03297463|Experimental|Phase II (Dose Expansion)|
2893121|NCT03297450|Active Comparator|Aphasia therapy and tDCS|
2893122|NCT03297450|Sham Comparator|Aphasia therapy and sham-tDCS|
2893123|NCT03297450|Sham Comparator|Standard of care and sham-tDCS|
2893124|NCT03297424|Experimental|PLX2853|"Phase 1b (Dose Escalation): Up to 30 Subjects with advanced malignancies.~Phase 2a (Dose Expansion): There will be 5 total expansion cohorts. Either 10 or 29 subjects per cohort in each of 4 expansion cohorts: advanced SCLC, uveal melanoma, OCCC, and any other advanced malignancy with a known ARID1A mutation (between 40 to 116 subjects total for the solid tumor expansion phase). For the 5th expansion cohort, up to 20 subjects may be enrolled for NHL."
2893125|NCT03297411|Active Comparator|Brief Temporoparietal ECT|Brief Pulse Temporoparietal ECT
2893126|NCT03297411|Active Comparator|Ultrabrief Temporoparietal ECT|Ultrabrief Pulse Temporoparietal ECT
2893127|NCT03297411|Active Comparator|Brief Frontoparietal ECT|Brief Pulse Frontoparietal ECT
2893128|NCT03297411|Active Comparator|Ultrabrief Frontoparietal ECT|Ultrabrief Pulse Frontoparietal ECT
2893129|NCT03297398|Placebo Comparator|Other|Placebo Group
2893130|NCT03297398|Experimental|Drug Group 1|15mg, OPK-88004
2893131|NCT03297398|Experimental|Drug Group 2|25,mg OPK-88004
2893132|NCT03297385|Experimental|Prostatectomy after enzalutamide|"This is a single-arm study. Patients will have biopsies, after which they will receive enzalutamide for 3 months.~After 3 months they will have a prostatectomy."
2893133|NCT03297372|Experimental|IOL Implantation experimental|Implantation of Micropure 1.2.3. in one of the eyes of the study subject
2893158|NCT03297190|Active Comparator|Interpersonal|Participants will receive interpersonal counselling on nutrition and health related topics
2893159|NCT03297190|Active Comparator|SMS + Interpersonal|Participants will receive SMS messages on nutrition and health related topics as well as interpersonal counselling on nutrition and health related topics
2893160|NCT03297190|No Intervention|Usual Care|
2893161|NCT03297177|Experimental|Microcannula Harvest Adipose|Acquisition AD-tSVF Via Closed Syringe Microcannula
2893134|NCT03297359|Experimental|Weight adjusted dalteparin|"Participants will receive a daily subcutaneous injection of weight-adjusted dalteparin (See Table below) at a dose of approx. 200 IU/kg beginning on the day of enrolment and for a one month.~91 to 95 kg: 18,000 IU daily ( or 1 prefilled syringe of 18,000 IU) 96 to 105 kg: 20,000 IU daily ( or 2 prefilled syringes of 10,000 IU) 106 to 120 kg: 22,500 IU daily ( or 2 pre-filled syringes (10,000 and 12,500 IU)) 121 to 130 kg: 25,000 IU daily ( or 2 prefilled syringes of 12,500 IU) 131 to 145 kg: 27,500 IU daily ( or 2 pre-filled syringes (12,500 and 15,000 IU)) 146 to 150 kg: 30,000 IU daily ( or 2 prefilled syringes of 15,000 IU)~≥ 151 kg: 33,000 IU daily ( or 2 prefilled syringes (15,000 and 18,000 IU))"
2893135|NCT03297346|Other|Breast cancer patients treated with RT|"Cardiac imaging and circulating biomarkers measurements to evaluate:~myocardial dysfunction and deformation (ECHO-ST)~coronary artery lesions and coronary artery calcium score (CT)~myocardium including tissue abnormalities, cardiac morphology and function (MRI)~blood-based biomarkers of cardiovascular changes (BLOOD)"
2893136|NCT03297333|Experimental|Resistance training group|Resistance training will consist of a supervised circuit training 3 sessions/week for approximately 45-50 min/session. The circuit will include 7 strength exercises engaging the major muscle groups (leg press, rows, back squats, weighted crunches, deadlifts, bench press, and squat jumps with weights). The participants will perform 3 sets of 10 repetitions with resting periods of 30 seconds between exercises, and 2 minutes between sets. The overall OMNI-Resistance Exercise Scale per set will range between 8-10. Heart rate and exercise energy expenditure during the workout will be monitored. The load will be changed depending on the participants' perception when needed. In addition, the intensity will be monitored assessing Lactate concentrations at baseline and at the end of each session. Circuit will be repeated until meeting the targeted exercise energy expenditure of 450-500 kcal/session.
2893137|NCT03297333|Experimental|Aerobic interval training group|Aerobic interval will consist of a supervised aerobic interval training sessions 3 times/week. Duration will range between 45-50 min/session depending on the exercise energy expenditure. Each interval will have a total duration of 5 min, and it will be divided into 2 periods. The first period will consist of 3 minutes of high-intensity activity, and the second period the intensity will be reduced for 2 minutes. The speed/incline will be changed depending on the participants' heart rate and perception using the Borg's rating of perceived exertion as needed. Heart rate and exercise energy expenditure during the workout will be monitored. Intensity will be monitored assessing Lactate concentrations at the end of each session. Intervals will be repeated until meeting the targeted exercise energy expenditure (450-500 kcal/session).
2893138|NCT03297333|No Intervention|Control group|Participants in the control group will not participate in the training programs.
2893139|NCT03297320|Active Comparator|Team Referrals|In-depth conversations about Goals of Care and ACP (the intervention) will be held for the patients referred to the research team by the three healthcare teams in Internal Medicine at London Health Sciences Centre (University Campus)
2893140|NCT03297320|Active Comparator|Random selection|A random selection of patients (not referred to the research team by the healthcare team) in Internal Medicine at London Health Sciences Centre (University Campus) will be selected to have in-depth conversations about Goals of Care and ACP (the intervention)
2893141|NCT03297307|Experimental|Mother-Child with Intervention|Children will attend presurgical visits with their mother
2893142|NCT03297307|No Intervention|Mother-Child Non-Intervention|Children will not attend presurgical visits with their mother
2893143|NCT03297294|Experimental|EMA401|During the treatment epoch, patients will receive EMA401 for 12 weeks. During the treatment withdrawal epoch, patients will receive EMA401 or matching placebo for 1 week.
2893144|NCT03297294|Placebo Comparator|Placebo|Participants will receive matching placebo to EMA401 during both the treatment and treatment withdrawal epochs for a total of 13 weeks.
2893145|NCT03297281|Experimental|S1: maintenance|Maintenance of OAC in surgery of BPH by PVP.
2893146|NCT03297281|Active Comparator|S2 : discontinuation|Discontinuation of OAC in surgery of BPH by PVP.
2893147|NCT03297268||Phase 1-Controlled Validation & Study Planning|Phase 1 is focused on refining and ultimately verifying BESI's basic sensing and notification functionality and validating BESI's environmental assessments in a controlled setting - namely the laboratory and homes of two healthy volunteers. This phase also serves to support further requirements gathering to refine BESI for community-based deployment. No interventions are delivered.
2893148|NCT03297268||Phase 2 - In-situ Validation and Ethnographic Analysis|Phase 2 starts the deployment of the technology within a community context, with the goals of validating the system's ability to assess agitation and environmental events in-situ and developing the cyber-sociophysical system models based on the dyad-specific relationship between agitation and the environment. A hybrid remote ethnographic methodology will be used, combining remote BESI measurement and caregiver diaries and a time-series design for the administration of the assessment battery.
2893149|NCT03297268||Phase 3 - Intervention with Home-Based Caregivers|Phase 3 is the intervention phase and the full realization of BESI. The goal is to employ the validated assessment capabilities and the developed modeling techniques to enable real-time, dyad-specific caregiver notifications that empower a caregiver to intervene with the PWD and/or environment before agitation escalation. In addition to validation of the BESI's ability to provide such appropriate notifications, Phase 3 will also serve as a pilot study about the effect that these notifications have on caregiver empowerment (as measured by self-efficacy) and the frequency and severity of PWD agitation, thus providing proof-of-concept for BESI's potential to improve dyad outcomes and motivating a larger-scale followup study to establish proof-of-practice.
2893150|NCT03297229|Experimental|Peer mentoring|Peers will be patients with hypertension that have already been adequately controlled within the last six months. They will be selected within each center by the staff of the center and invited to participate in the study.
2893151|NCT03297229|Experimental|Self-monitoring|Each participant will receive a blood pressure monitor. The study nurse will teach the participant on how to use the device.
2893152|NCT03297229|No Intervention|Control|Usual care
2893153|NCT03297216|Active Comparator|250 mg 17P|weekly intramuscular injection of 250mg 17P
2893154|NCT03297216|Placebo Comparator|Placebo|weekly intramuscular injection of indistinguishable placebo
2893155|NCT03297203|Experimental|groupe1|patients in septic shock (group 1) in the medical intensive care unit of the Timone Hospital.
2893156|NCT03297203|Active Comparator|groupe 2|patients with a bacterial sepsis alone, during a 6 months period.
2893162|NCT03297177|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (tSVF) via enzymatic digestive isolation & concentration in Centricyte 1000 closed system to create AD-cSVF
2893163|NCT03297177|Experimental|Sterile Normal Saline Infusion|Sterile Normal Saline to Re-Suspend Autologous cSVF pellet for delivery via intravascular (IV) route
2893164|NCT03297164||optimized group|the patients in this group have been given the suggestive treatment from guideline.
2893165|NCT03297164||un-optimized group|the patients in this group have not been given the suggestive treatment from guideline.
2893166|NCT03297151|Sham Comparator|CONTROL|"Intervention: Dietary Supplement: Non-essential amino acids A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g non-essential amino acids dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry.~Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
2893167|NCT03297151|Active Comparator|PROTEIN|"Intervention: Dietary Supplement: Whey Protein Concentrate A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g of Whey Protein Concentrate dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry. Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
2893168|NCT03297151|Active Comparator|HYDROLYSATE|"Intervention: Dietary Supplement: Whey Protein Hydrolysate A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g of Whey Protein Hydrolysate dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry. Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
2893169|NCT03297125|Experimental|Imaging: Standard MRI|Anticipated Results/Interpretation Standard anatomic imaging will prove not to be reliable for evaluation of progression free survival, but may show some ability to predict overall survival.
2893170|NCT03297125|Experimental|Imaging: Advanced MRI|Anticipated Results/Interpretation Advanced MRI methods will demonstrate the ability to predict response earlier than with standard MRI methods.
2893171|NCT03297112|Experimental|contrast-enhanced subharmonic ultrasound imaging|Patients receive perflutren lipid microspheres IV. After 15 minutes, patients receive perflutren lipid microspheres IV again over 5 minutes and undergo contrast-enhanced subharmonic ultrasound imaging over 60 minutes.
2893172|NCT03297099|Experimental|Robot-assisted Laparoscopic operation|Da Vinci surgical robot can overcome limitations of conventional laparoscopic surgery in terms of vision and instrumentation flexibility, making the minimally invasive treatment of complex hepatolithiasis possible.
2893173|NCT03297099|Active Comparator|Open surgery|The indication of laparoscopic surgery is mainly for early regional type hepatolithiasis. Open surgery is the traditional treatment method for heptolithiasis.
2893174|NCT03297086|Active Comparator|Bi-Flex|Medicontur Bi-Flex 677MY IOL was implanted into 24 eyes of 12 patients during cataract surgery. Angle kappa, biometric data and IOL decantation were measured.
2893175|NCT03297086|Active Comparator|ReStor|and Alcon Acrysof Restor SN6AD1 IOL was implanted into 36 eyes of 18 patients during cataract surgery. Angle kappa, biometric data and IOL decantation were measured.
2893176|NCT03297073|Experimental|major hepatic surgery|resection greater than or equal to three hepatic segments
2893177|NCT03297073|Experimental|hepatic surgery|resection less than three hepatic segments
2893178|NCT03297073|Experimental|hepatic surgery recovery|
2893179|NCT03297060|Experimental|SSL Implementation Strategy|Science to Service Implementation Strategy for SBIRT adherence
2893180|NCT03297060|No Intervention|Standard Care|Standard Care SBIRT services
2893181|NCT03297047|Active Comparator|upper arm combi cast|standardized treatment
2893182|NCT03297047|Experimental|forearm combi cast|Treatment with a forearm combi cast should be a sufficient immobilization
2893183|NCT03297021|Placebo Comparator|Ondansetron 4mg Pre-emergence|
2893184|NCT03297021|Experimental|Ondansetron 8mg Pre-emergence|
2893185|NCT03297021|Experimental|Ondansetron Pre-Incision and Pre-emergence|4mg Ondansetron Pre-Incision and 4mg Ondansetron Pre-emergence
2893186|NCT03296995|Experimental|flash glucose monitoring system|Subjects in the arm measure blood glucose by flash glucose monitoring system.
2893187|NCT03296982||Blood Sample|Blood will be sampled by direct venipuncture on 8 occasions.
2893188|NCT03296969|Active Comparator|rectus muscle approximation|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
2893189|NCT03296969|Active Comparator|rectus muscle non approximation|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
2893190|NCT03296956|Active Comparator|Day-5 postpartum - Active dietary supplement|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.~Intervention: Full dose dietary supplement Motherwell"
2893544|NCT03294356|Experimental|FT210751 Group|7 day at-home use of electronic cigarette FT210751 followed by a 2 day in-clinic period.
2893191|NCT03296956|Placebo Comparator|Day-5 postpartum - Placebo|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.~Intervention: Placebo"
2893192|NCT03296943|Experimental|Essential oil|Essential oil is prepared from the product of Thailada with manufacture standard ID 1087/2548 by Thailand Ministry of Industry. Essential oil is extracted by a cold compressed method from the lavandula angustifolia (lavender) grown in Australia.
2893193|NCT03296943|Sham Comparator|Perfume|Perfume is the synthetic perfume of lavender flavor without essential oil.
2893194|NCT03296930|Active Comparator|first drug group|Sofosbuvir 400 MG Oral Tablet
2893195|NCT03296930|Active Comparator|second drug group|Ombitasvir/paritaprevir/ritonavir
2893196|NCT03296917|Experimental|IMP - PrEP-001|"In Viral Challenge arm cohort:~A nasal dose of 6400 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1).~In the Safety arm's first dose cohort:~A nasal dose of 6400 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1).~Then assuming no significant safety issues with the lower dose (as determined by blinded review by the DSMB team), the Safety arm's second dose cohort will consist of:~A nasal dose of 12800 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1)"
2893197|NCT03296917|Placebo Comparator|Placebo - G-004|"In the Viral Challenge arm and each Safety Arm cohort:~A nasal dose of placebo equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1)."
2893198|NCT03296904|Experimental|CLs++|Baseline assessment, intervention, final assessment
2893199|NCT03296891|Active Comparator|PoCUS Guided Resuscitation of Shock|Participants randomized to this arm of the study will undergo PoCUS guided resuscitation of shock.
2893200|NCT03296891|No Intervention|Usual Care|Participants randomized to the 'usual care' arm of the study will be suggested to have the following guide resuscitation: 1) Pulse pressure variation (PPV), stroke volume variation (SVV) and/or systolic pressure variation (SPV) on their arterial line, 2) central venous pressure (CVP) and oxygen saturation(ScvO2) measurement, 3) Passive leg raise (PLR) maneuver.
2893201|NCT03296878|Other|Own-Price Elasticity|"The price of eggs will vary (own-price elasticity) while the price of other foods in the mock grocery store will remain constant."
2893202|NCT03296878|Other|Cross-Price Elasticity|"The eggs will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
2893203|NCT03296865|No Intervention|Without taping|Evaluations without taping
2893204|NCT03296865|Experimental|Kinesio taping|Kinesio taping was apllied only one time. It was removed after intervention.
2893205|NCT03296865|Placebo Comparator|Placebo|Placebo was apllied only one time. It was removed after intervention.
2893206|NCT03296852|Experimental|Healthy Volunteers|
2893207|NCT03296839|Experimental|chemotherapy and SBRT|"Patients will receive 2 courses of chemotherapy before SBRT if no hepatic or extrahepatic progression is identified.~All liver metastases will be irradiated. 4 dose prescriptions are allowed (according to the center, and the technique used and the dosimetric constraints): 3 x 15 Gy, 4 x 15 Gy, 5 x 10 Gy or 5 x 8 Gy.~Then remaining courses of chemotherapy 2 to 3 weeks after the completion of SBRT will be administered."
2893208|NCT03296839|Active Comparator|chemotherapy|Patients will receive chemotherapy as initially scheduled.
2893209|NCT03296826||BRCA1/2 variant carriers|Japanese women who carry BRCA 1/2 variants.
2893210|NCT03296813|Active Comparator|Torsemide|Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.
2893211|NCT03296813|Active Comparator|Furosemide|"Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.~For patients receiving loop diuretics other than furosemide, conversion to furosemide equivalents will be as follows:~1 mg oral torsemide = 2-4 mg oral furosemide~1 mg oral or intravenous bumetanide = 40 mg oral furosemide"
2893212|NCT03296800|Experimental|Bexagliflozin/probenecid|
2893213|NCT03296800|Experimental|Bexagliflozin/rifampin|
2893214|NCT03296800|Experimental|Bexagliflozin/verapamil|
2893215|NCT03296787|Experimental|Group A TAK-954 0.2 mg: Healthy Participants|Participants with normal renal function receive TAK-954 0.2 milligram (mg), infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
2893216|NCT03296787|Experimental|Group B TAK-954 0.2 mg: Mild Renal Impairment|Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
2893217|NCT03296787|Experimental|Group C TAK-954 0.2 mg: Moderate Renal Impairment|Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
2893218|NCT03296787|Experimental|Group D TAK-954 0.2 mg: Severe Renal Impairment|Participants without hemodialysis or End-stage Renal Disease (ESRD) receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
2893219|NCT03296787|Experimental|Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD)|Participants with hemodialysis receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period followed by a minimum 13-day washout period, further followed by TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period.
2893220|NCT03296774|Placebo Comparator|Usual Care|Usual postpartum care
2893221|NCT03296774|Experimental|Healthy Beyond Pregnancy|Web-based program for postpartum care and education and scheduling. Incentive for committing and returning for postpartum care.
2893222|NCT03296761||ESM-1＜5ng/ml|
2893223|NCT03296761||ESM-1≥5ng/ml|
2893224|NCT03296748|Active Comparator|TOT only group|60 patients with stress incontinence and asymptomatic grade 2 cystocele.
2893225|NCT03296748|Active Comparator|concomitant repair group|63 patients with stress incontinence and asymptomatic grade 2 cystocele.
2893226|NCT03296735|Experimental|Ipsilateral tilt|Measuring the cross-sectional area of right subclavian vein in the 20 degree left tilting posture.
2893227|NCT03296735|No Intervention|Supine|Measuring the cross-sectional area of right subclavian vein in supine position.
2893228|NCT03296735|Active Comparator|Contralateral tilt|Measuring the cross-sectional area of right subclavian vein in the 20 degree left tilting posture.
2893229|NCT03296722|No Intervention|Control group|The control group comprised 41 patients, which was to go once a month to receive nutritional intervention with the prescription of a hypocaloric diet on the part of the nutritionist. The control group had a monthly monitoring for 3 months.
2893230|NCT03296722|Experimental|Intervention group|The intervention group made up of 42 patients using the transtheoretical model and MI through sessions group and sessions individual with topics of healthy eating habits taught by a nutritionist, physical activity and exercise manual taught by a physical therapist, preparation of healthy food with menu taught by graduates in gastronomy and confrontation of barriers given by a psychologist. The intervention group had a monthly monitoring for 3 months. The diet that was prescribed to the intervention group was with the characteristics of the DASH diet.
2893231|NCT03296709|Active Comparator|CPP m|
2893232|NCT03296709|Experimental|CPP z|
2893233|NCT03296696|Experimental|Dose exploration|Dose exploration of the intervention, AMG 596
2893234|NCT03296696|Experimental|Dose expansion|Dose expansion of the intervention, AMG 596
2893235|NCT03296683|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
2893236|NCT03296670|Experimental|alprostadil|alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
2893237|NCT03296670|Placebo Comparator|nitroglycerin|nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
2893238|NCT03296657|Experimental|stannous fluoride toothpaste|0.454% stannous fluoride will be used twice a day, brushing for at least 1 minute for 2 weeks
2893239|NCT03296644|Active Comparator|PowerScope2 group (G1)|Class II correction using PowerScope2
2893240|NCT03296644|Active Comparator|Forsus group (G2)|Class II correction using Forsus
2893241|NCT03296631||children|"Enrollment of 15 to 20 children (< 9 months old) at the early beginning of their entry in nursery (crèche) between August and November 2017.~This cohort will be followed during a maximum period of 36 months . Diapers with fresh stools will be collected once a week per child and then frozen.~Spontaneous personal day care informations given by the parents to the nurses and recorded in each child's daily logbook will be collected for the research. No specific interviews will be conducted."
2893242|NCT03296618|Experimental|NSI-566 neural stem cell implantation|
2893243|NCT03296605||Obesity|Patients with obesity already received bariatric surgery
2893244|NCT03296605||Healthy control|Volunteers with normal body weight and already received abdominal surgery
2893245|NCT03296592||Investigational subjects|"Patients who have been diagnosed with cervical spondylotic myelopathy and who will be undergoing surgical correction for this diagnosis.~Visit 1 Investigational subjects will undergo a clinical assessment. Patients will undergo a DBSI MRI~Visit 2. 6 months after surgery, investigational subjects will undergo a clinical assessment.~Visit 3 12 months after surgery, investigational subjects will undergo a clinical assessment~Visit 4 18 months after surgery, investigational subjects will undergo a clinical assessment.~Visit 5 24 months after surgery, investigational subjects will undergo a clinical assessment and a DBSI MRI."
2893246|NCT03296592||Control group|Healthy volunteers aged 45-65 Visit 1: DBSI MRI Visit 2: 24 months after first MRI, patient will undergo the second MRI
2893247|NCT03296579|Active Comparator|Conventional asthma therapy.|Bilevel Positive Airway Pressure group(BiPAP). BiPAP settings at 15/5 cm H2O by face mask with background rate 10 to 15/min. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 > 92%.
2893248|NCT03296579|Experimental|Non-invasive ventilation (CPAP).|Continuous Positive Airway Pressure group (CPAP). CPAP settings at 8 to 10 cm H2O. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 > 92%.
2893249|NCT03296579|Experimental|Non-invasive ventilation (BiPAP)|Standard steroid dose, hourly salbutamol, oxygen as needed, nebulized ipratropium q 6 hrly, magnesium sulfate 50 mg/kg IV (4 doses q 6 hrly), loading dose of aminophylline 6 mg/kg IV if no progress.
2893250|NCT03296566|Experimental|Patient Liaison Intervention|The participants randomized to the intervention group will be exposed to the patient liaison in receiving their colposcopy report results and recommendations. Rather than receive results from their referring/family physician, an experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients.
2893251|NCT03296566|No Intervention|Control|The control group will receive the standard of care for colposcopy results reporting via their referring physician. Following their colposcopy visit, control patients are given a slip of paper reminding them to call their family/referring physician for their colposcopy results in three weeks if they have not yet been contacted. Upon receipt of the final pathology, colposcopy reports are prepared by the colposcopists and forwarded to family/referring physicians typically within 2-3 weeks of the visit. Patients then receive the results of their colposcopy report from their family/referring physician by whatever method of communication preferred by that provider.
2893252|NCT03296553|Experimental|Valganciclovir|Oral Valgancyclovir 900 mg twice in a day during 4 weeks prior to initiation of cART (combined antirretroviral therapy) until suppression of HHV-8.
2893253|NCT03296553|Active Comparator|Antiretroviral combinations|Standard treatment with cART according to current HIV Therapy Mexican guidelines.
2893254|NCT03296540|Active Comparator|Uncrushed|6 Integral tablets Prasugrel as loading dose
2893255|NCT03296540|Experimental|Crushed|6 Crushed tablets Prasugrel as loading dose
2893256|NCT03296527|Experimental|FE 999049|rFSH. FE 999049 for subcutaneous injection
2893257|NCT03296527|Active Comparator|Gonal-F|rFSH. Follitropin alfa for subcutaneous injection
2893258|NCT03296514|No Intervention|Wait List Control|Will receive voucher for MBSR after study is concluded
2893259|NCT03296514|Other|Intervention|These people will receive the MBSR
2893260|NCT03296501|Experimental|Autologous ADRC injection|
2893261|NCT03296488|Experimental|Nalbuphine Sebacate|receive single dose of NALDEBAIN (150 mg Nalbuphine Sebacate, 75 mg/ml, 2 ml/vial) intramuscularly 24±12 hours before surgery.
2893262|NCT03296488|Active Comparator|Fentanyl Citrate|receive intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
2893263|NCT03296475|Experimental|Midline Ventral Hernia|"Main inclusion criteria:~Patients with midline hernia defects.~Patients with either a maximal ventral hernia axial width of greater than 5cm or a loss of domain of greater then 20%.~Patients aged ≥ 18 years old.~Midline hernias closed in the midline with primary fascial closure with or without mesh augmentation.~Midline ventral hernias of VHWG grade 2 or 3."
2893264|NCT03296462|Experimental|Hip external rotation exercise (alone)|Standardised hip external rotation exercise training - over 12 week period
2893265|NCT03296462|Experimental|Hip external rotation + PFM exercises|Standardised hip external rotation plus pelvic floor muscle exercises - over 12 week period
2893266|NCT03296462|Active Comparator|pelvic floor muscle exercises (alone)|Standardised pelvic floor muscle exercises - over 12 week period (usual care)
2893267|NCT03296449|No Intervention|One-Lung Ventilation|During one-lung ventilation, when the chest is open, the non-dependent lung is collapsed and manipulated by the surgeon. It is the routine procedure during video-assisted thoracic surgery.
2893268|NCT03296449|Active Comparator|CPAP to non-dependent lung|"The patient will be randomly assigned to the study arm Continuous Positive Airway Pressure (CPAP). CPAP will be applied for 20 minutes to the non-dependent lung at a pressure of 2-3cmH20 using the disposable Mallinckrodt Bronchocath CPAP system."
2893269|NCT03296449|Experimental|HFJV to non-dependent lung|"The patient is randomly assigned to the study arm High-frequency jet ventilation (HFJV). HFJV will be applied for 20 minutes to the non-dependent lung with a driving pressure of a 0.6 atm, respiratory rate 100 cycles per minute using the Monsoone III Jet Ventilator (Acutronic, Hirzel, Switzerland)."
2893270|NCT03296436|Experimental|Treatment Group|Group that will be receiving the investigational product
2893271|NCT03296423|Placebo Comparator|Placebo|One intradermal injection of 0.1ml of sodium chloride 0.9%
2893272|NCT03296423|Active Comparator|Vaccination|One intradermal injection of 0.1ml of BCG (BCG vaccine Bulgaria strain 1331; Intervax)
2893273|NCT03296410|Experimental|EV71 and two measles attenuated live vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) and two measles attenuated live vaccine at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
2893274|NCT03296410|Experimental|EV71 and attenuated Japanese encephalitis vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) and live attenuated Japanese encephalitis vaccine at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
2893275|NCT03296410|Active Comparator|two measles attenuated live vaccine|infants vaccinated with two measles attenuated live vaccine at 8 months old
2893276|NCT03296410|Active Comparator|live attenuated Japanese encephalitis vaccine|infants vaccinated with live attenuated Japanese encephalitis vaccine at 8 months old
2893277|NCT03296410|Active Comparator|EV71 vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
2893278|NCT03296397|Active Comparator|HPV Quadrivalent vaccine (QHV)|Gardasil
2893279|NCT03296397|Placebo Comparator|Placebo|Normal Saline
2893280|NCT03296384|Other|Patients with schizophrenia|
2893281|NCT03296384|Other|Relatives|
2893282|NCT03296371||Ancillary-Correlative (biospecimen collection)|Patients and their parents undergo collection of saliva or buccal mucosa samples for genetic mutational analysis. Germline DNA from saliva or buccal mucosa is evaluated via whole exome sequencing.
2893283|NCT03296358|No Intervention|Control group|Chorpheniramine 10 mg/amp ; 1 ampule Cetirizine 10 mg 7 tabs OD as home medication
2893284|NCT03296358|Experimental|Experiment 1|Chorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication
2893285|NCT03296358|Experimental|Experiment 2|Chorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication Oral prednisolone 5 mg 20 tabs ; 2*2 po pc as home medication
2893286|NCT03296345|Active Comparator|Intervention|"Prior to the second dose of IV opiates, the experiment will be to give patients a single IV bolus of ketamine at the dose of 0.2 mg/kg. Pain scores will be collected using the FACES scale currently in place. In consenting patients, chart review will be performed with the following data being collected: mg/kg/hour of morphine equivalents, pain scores on admission, during the encounter, and at discharge, the time to 50% pain reduction, whether or not the patient was discharged, and if re-presentation occurred in the subsequent 3 months.~In addition, a survey, which is attached, will be given to patients/families at the time of drug administration to determine if they experienced a subjective improvement in their pain and if they suffered any undue side effects due to drug administration."
2893287|NCT03296345|No Intervention|Historical Control|"Patient data from at least one but up to as many as are available within the last year will be summed and compared to their visit where they were given adjuvant ketamine, using the outcome measures in the Intervention arm. Since this a historical control study, patients act as their own controls in the above manner. Patients are allowed to re-enroll 4 weeks after presentation, which is typically considered a second vaso-occlusive crisis in the literature."
2893288|NCT03296319|Active Comparator|echocardiography guided fluid resuscitation|
2893289|NCT03296319|Experimental|clinically guided fluid resuscitation|
2893290|NCT03296306|Active Comparator|6 cycles arm|Patients without evidence of disease progression or unacceptable toxicities after completion of two or four treatment cycles of cisplatin based chemotherapy (GP, GP-S, MVAC, HD-MVAC with GCSF) were randomly assigned to receive additional two to four cycles of chemotherapy (totally six cycles)
2893291|NCT03296306|Experimental|4 cycles arm|Patients without evidence of disease progression or unacceptable toxicities after completion of two or four treatment cycles of cisplatin based chemotherapy (GP, GP-S, MVAC, HD-MVAC with GCSF) were randomly assigned to receive additional zero to two cycles of chemotherapy (totally four cycles)
2893292|NCT03296293|Other|Group I:IVPD≤3mmHg|Effect of PEEP at 5cmH2O on ICP in Group I:IVPD≤3mmHg Effect of PEEP at 10cmH2O on ICP in Group I:IVPD≤3mmHg Effect of PEEP at 15cmH2O on ICP in Group I:IVPD≤3mmHg
2893293|NCT03296293|Other|Group II:3mmHg<IVPD≤6mmHg|Effect of PEEP at 5cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg Effect of PEEP at 10cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg Effect of PEEP at 15cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg
2893294|NCT03296293|Other|Group III:IVPD>6mmHg|Effect of PEEP at 5cmH2O on ICP in Group III:IVPD>6mmHg Effect of PEEP at 10cmH2O on ICP in Group III:IVPD>6mmHg Effect of PEEP at 15cmH2O on ICP in Group III:IVPD>6mmHg
2893295|NCT03296280||Early Intervention|This cohort of 10 facilities will undergo early training by participating in the first 6 POCUS course sessions during FY17
2894737|NCT03285945||PET3|Post-therapeutic FDG PET/CT performed after 3 days of steroid treatment
2893296|NCT03296280||Late Intervention|This cohort of 10 facilities will undergo late training by participating in the last 6 POCUS courses during FY17.
2893297|NCT03296267|Other|gastroduodenoscopy|all participants undergo a gastroduodenoscopy to use the biopsies in an Ussing chamber experiment.
2893298|NCT03296254|Experimental|Course A|Body Mindfulness Exercised followed by Sitting Mindfulness Exercises. Written material and sound recordings will be offered as support elements.
2893299|NCT03296254|Experimental|Course B|Sitting Mindfulness Exercises followed by Body Mindfulness Exercises. Written material and sound recordings will be offered as support elements.
2893300|NCT03296241|Experimental|Laser|One session of non-ablative Er:YAG laser (2940 nm) treatment of the vaginal wall, introitus and vestibule.
2893301|NCT03296241|Sham Comparator|Sham control|The sham control group was treated with the same procedure but with zero intensity settings - without receiving therapeutic irradiation (placebo).
2893302|NCT03296228||Hong Kong|supine side-bending and fulcrum bending films
2893303|NCT03296228||Turkey|supine side-bending, fulcrum bending, and traction under GA films
2893304|NCT03296215||Observational|Patterno of admitted cases in Respiratory Intensive Care Unit at Assiut University Hospitals and Outcome
2893305|NCT03296202||HIV patients|4500 patients infected with HIV-1
2893306|NCT03296189|Active Comparator|Local anaesthetic|Post-ureteroscopy intraluminal injection of alkalinised high concentration levo-bupivicaine in the renal pelvis
2893307|NCT03296189|Active Comparator|Local anaesthetic + steroid|Post-ureteroscopy intraluminal injection of 10 mls alkalinised high concentration levo-bupivicaine with l dexamethasone in the renal pelvis
2893308|NCT03296189|Placebo Comparator|Placebo|Post-ureteroscopy intraluminal injection of 10 mls normal saline (placebo) in the renal pelvis
2893309|NCT03296176|Experimental|presymptomatic|
2893310|NCT03296176|Experimental|symptomatic|
2893311|NCT03296176|Other|controls|
2893312|NCT03296163|Experimental|MB02 (Bevacizumab Biosimilar Drug)|MB02 (Bevacizumab Biosimilar Drug) + Carboplatin/Paclitaxel
2893313|NCT03296163|Active Comparator|EU-approved Avastin®|EU-approved Avastin® + Carboplatin/Paclitaxel
2893314|NCT03296150|No Intervention|Control arm : Information|Patients will receive the usual standard information delivered to patients
2893315|NCT03296150|Experimental|Intervention arm : Therapeutic educational program|"Patients will receive the therapeutic educational program PRESTAGE"
2893316|NCT03296137|Experimental|All participants|
2893317|NCT03296098|Experimental|ulipristal acetate|Subjects will be administered ulipristal acetate in 5 mg dosages and instructed to take two pills once daily for 6 months.
2893318|NCT03296072|Experimental|Test product|Participants will apply a full ribbon of the test product (1.5 grams [g]) containing 0.254% w/w sodium fluoride and 5% KNO3.
2893319|NCT03296072|Active Comparator|Comparator Product|Participants will apply a full ribbon of the comparator product (1.5 g orally) containing 0.454% w/w stannous fluoride.
2893320|NCT03296072|Placebo Comparator|Placebo Product|Participants will apply a full ribbon of the placebo (1.5 g orally) containing 5% KNO3.
2893321|NCT03296059|Experimental|RBC transfusion with conventional treatment|Besides conventional treatment,neonates diagnosed with ARDS is treated with RBC transfusion.
2893322|NCT03296059|Active Comparator|conventional treatment|neonates diagnosed with ARDS is treated with conventional treatment.
2893323|NCT03296046||PPBL patients|
2893324|NCT03296033|Active Comparator|24 Hours group|Group one will be instructed to administer their last dose of enoxaparin at 07:00 in the morning on the day prior to their scheduled surgery date. This will mean that patients who have their surgery scheduled for 07:00 the following day will be 24-hours removed from their last dose. Patients presenting for surgery later in the day would be slightly farther removed from their last dose, however this is currently considered normal clinical practice.
2893325|NCT03296033|Experimental|36 Hours Group|Group 2 will be instructed to administer their last dose of enoxaparin at 19:00 in the evening two days prior to their scheduled surgery date. Patients presenting for surgery at 07:00 two days later will be 36-hours removed from their last dose. Patients presenting for surgery later in the day would be slightly farther removed from their last dose, but again this mimics normal clinical practice in which the timing of the last dose of self-administered enoxaparin is not routinely adjusted based on the scheduled surgical start time.
2893326|NCT03296020|No Intervention|control group|"After the surgery, during the hospitalization ,the control group would get as is customary in our ENT department :acetaminophen syrup+ syrup oxycode( as necessary).~After the discharge from the hospital - the patients would take( as is customary in our ENT department): acetaminophen syrup ( as necessary) and other painkillers ( as necessary).~The families would ask to follow treatment protocols for 7 days and will fill a questionnarie every day during the 7 days."
2893327|NCT03296020|Experimental|"case group-HONEY"|"After the surgery, during the hospitalization ,the case group would instructed to use honey twice a day( 5 ml- one tea spoon each time)+acetaminophen syrup + syrup oxycode( as necessary).~After the discharge from the hospital - the patients would take:acetaminophen syrup ( as necessary) and other painkillers+honey twice a day( 5 ml- one tea spoon each time) .~The families would ask to follow treatment protocols for 7 days and will fill a questionnarie every day during the 7 days."
2893328|NCT03296007|Experimental|Mindfulness Meditation App|Participants randomized to this arm will use a smartphone app to practice mindfulness meditation for 12 minutes.
2893329|NCT03296007|Active Comparator|Mindfulness Meditation No App|Participants randomized to this arm will not use a smartphone app, but will receive instructions to practice mindfulness meditation for 12 minutes.
2893330|NCT03295994|Active Comparator|Operative|surgery + post-operative physical therapy
2893331|NCT03295994|Active Comparator|Non-Operative|non-operative physical therapy
2893372|NCT03295708|Placebo Comparator|control group|the control group will be given 4 soybean oil capsules ( placebo capsule,1g/one capsule) twice daily after two meals at roughly the same time each day,lasting for the first 6 months.placebo capsule will be provided by the Hunan Kangqi100 Biological Technology Co.Ltd.The placebo capsule's appearance and flavor are made the exactly the same as the fish oil capsules .
2893446|NCT03295110|Experimental|Functionalities of the Lili Smart Solution activated|Lili Smart solution consists of an application for caregivers (web / mobile), a GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 / 24 and 7/7.
2893332|NCT03295981|No Intervention|Control group|The surgical procedure for all patients will include extensive curettage of the lesion to remove macroscopic tumor, high-speed burring of the residual cavity, adjuvant treatment to the residual cavity, followed by packing of the cavity with either polymethylmethacrylate (PMMA) bone cement (Simplex P; Stryker, Mahwah, New Jersey) alone or bone cement with subchondral allograft bone graft. The choice of cavity reconstruction will be at the discretion of the treating surgeon. Traditional local adjuvants (argon beam coagulation, phenol, ethanol, or cryotherapy) will be used depending on surgeon preference. In addition to the above standard treatment, the patients will be randomized into one of two study arms. In Arm 1, the control group, no additional local therapy will be utilized.
2893333|NCT03295981|Experimental|Bisphosphonate group|In Arm 2, the bisphosphonate group, 4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement.
2893334|NCT03295968|No Intervention|Water and Rest|
2893335|NCT03295968|Experimental|Water and High Intensity Exercise|
2893336|NCT03295968|Experimental|Ibuprofen and Rest|
2893337|NCT03295968|Experimental|Ibuprofen and High Intensity Exercise|
2893338|NCT03295955|Active Comparator|Postop antibiotics group|Prescribe Amoxicillin Clavulanate
2893339|NCT03295955|No Intervention|No postop antibiotics|Do not prescribe Amoxicillin Clavulanate
2893340|NCT03295942|Experimental|OMP-336B11|Intravenous (in the vein) infusions of OMP-336B11
2893341|NCT03295916|Experimental|Systemic therapy plus SBRT to OM|Stereotactic Body Radiotherapy (SBRT) up to 5 OM sites
2893342|NCT03295903|Placebo Comparator|Placebo|Sugar pill that will have no effect.
2893343|NCT03295903|Active Comparator|Cannabidiol and herbal capsules (1 dose)|Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
2893344|NCT03295903|Active Comparator|Cannabidiol (1 dose)|Only cannabidiol supplement.
2893345|NCT03295903|Active Comparator|Cannabidiol and herbal capsules (2 dose)|Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
2893346|NCT03295903|Active Comparator|Cannabidiol only (2 dose)|Only cannabidiol supplement.
2893347|NCT03295890|Sham Comparator|Sham Needling|Intervention = Sham Needling
2893348|NCT03295890|Active Comparator|Active Needling|Intervention = Active Needling
2893349|NCT03295877|Experimental|RO7171009: SAD|Patients will receive a single dose of RO7171009, in multiple escalating cohorts.
2893350|NCT03295877|Experimental|RO7171009: MD|Patients will receive RO7171009 at maximum tolerated dose (MTD), identified during the SAD stage for three doses.
2893351|NCT03295864|Experimental|Patients with Chiari type 1 malformation|Tympanometry measurement at inclusion and 6 months after surgery
2893352|NCT03295864|Experimental|Healthy volunteers|Tympanometry measurement at inclusion. Every healthy volunteer will be match with a patient for his age and his BMI (body mass index).
2893353|NCT03295851|Experimental|IV Ferric Carboxymaltose|Patients in the intervention group will receive preoperative IV ferric carboxymaltose, given as a single dose (15 mg/kg body weight, to a maximum dose of 1000 mg) over 30 minutes.
2893354|NCT03295851|Active Comparator|Oral Ferrous Fumarate|Patients will be given oral iron as per current clinical protocol, which is Ferrous fumarate 200mg twice daily
2893355|NCT03295838|Experimental|Mentalization-based Treatment|MBT was conducted according to the treatment manual developed by Bateman & Fonagy. Patients were offered individual sessions with a psychotherapist and group sessions with 6-8 participants and 1-2 group therapists for 18 months. An introductory psycho-educational component (9-12 sessions) was also offered focusing on explicit mentalising skills (i.e. understanding one's own or others' intentions). Group and individual MBT focused on implicit mentalising towards self and others.
2893356|NCT03295825|Other|Biomarker|Blood sampling
2893357|NCT03295799|Experimental|Patient Self-Management|Patients will go through a preparatory phase (creation of warfarin dosing chart, process for documentation and retrieval of labs), a practical training phase (formulate warfarin management plan with support) and then perform patient-self management of their own warfarin.
2893358|NCT03295799|No Intervention|Anticoagulation Clinic Care|Patients will not have their care altered, and will continue to be managed by our Anticoagulation Clinic.
2893359|NCT03295786|Placebo Comparator|Placebo|Patients randomized to this group will receive 6 monthly infusions of placebo/vehicle
2893360|NCT03295786|Experimental|CDNF mid-dose|Patients randomized to this group will receive 6 doses of CDNF titrated to mid-dose
2893361|NCT03295786|Experimental|CDNF high-dose|Patients randomized to this group will receive 6 doses of CDNF titrated to high-dose
2893362|NCT03295773||Symptomatic stroke patient|Patients who are found signal void in a relevant intracranial internal carotid artery or middle cerebral artery (stenosis >60%) will proceed to a 3-Dimensional rotational angiography (3DRA) at baseline and in 12 months. All recruited patients will receive dual antiplatelet agents for 4 weeks, followed by aspirin alone. The investigator or neurologists shall regularly review the patients and treat the conventional cardiovascular risk factors based on four pre-specified goals, for example, LDL <1.8, HbA1c <6.0, blood pressure <140/90 and no smoking. The morphologic changes of the cerebral plaques with the intensity of the risk factor control in pre and post will be correlated.
2893363|NCT03295760||Children with cyclic vomiting syndrome|Children followed at Children's Hospital of Nancy treated with Q10 coenzyme for cyclic vomiting syndrome
2893364|NCT03295747|Experimental|Peppermint oil soft gel|Children will be randomized to receive either 180 mg, 360 mg, or 540 mg of peppermint oil.
2893365|NCT03295734|Active Comparator|Perindopril|4 mg qd titrated to 8 mg qd perindopril + aerobic exercise
2893366|NCT03295734|Active Comparator|Losartan|50 mg qd titrated to 100 mg qd losartan + aerobic exercise
2893367|NCT03295734|Active Comparator|HCTZ|12.5 mg qd titrated to 25 mg qd HCTZ + aerobic exercise
2893368|NCT03295721|Experimental|Treatment Group 1|HTX-011
2893369|NCT03295721|Placebo Comparator|Treatment Group 2|Saline placebo
2893370|NCT03295721|Active Comparator|Treatment Group 3|Bupivacaine HCl
2893371|NCT03295708|Experimental|experimental group|the experimental group will be given 4 fish oil capsules (1g/one capsule)twice daily after two meals at roughly the same time each day,lasting for the first 6 months.fish oil capsule will be provided by the Hunan Kangqi100 Biological Technology Co.Ltd.
2893541|NCT03294382|Placebo Comparator|Normal Saline|0.1 mL normal saline, administered in the other intercanthus
2932869|NCT03020771|Active Comparator|5 mcg IM|
2893373|NCT03295695|Experimental|Cardiac Imaging - All Participants|Study agent: 2-deoxy-2-[18F]fluoro-D-glucose (FDG). Fluoro-D-glucose-positron Emission Tomography: Participants will undergo a PET-CT scan with Fluoro-D-glucose-labeled (FDG-labeled) red blood cells (RBCs) within 2 weeks of obtaining an echocardiogram prior to start of chemotherapy. A repeat FDG-RBC PET-CT scan will be completed within two weeks of obtaining their follow-up echocardiogram to determine post-therapy cardiac ejection fraction. If the participant has an echocardiogram obtained prior to completion of chemotherapy, an attempt will be made to obtain a FDG-RBC PET-CT scan within two weeks of the echocardiogram.
2893374|NCT03295656|Experimental|IV Contrast-Enhanced US|IV sulfur hexafluoride lipid-type A microspheres, 0.03 mL/kg, 2 doses per examination, total dose not to exceed 4.8 mL. Single examination per patient.
2893375|NCT03295630||Accelerometer|Ward based patients recovering from critical illness will wear two accelerometers placed on the thigh and ankle of the non-dominant leg
2893376|NCT03295617||spinal thoracic herniation|
2893377|NCT03295604|Experimental|test group|Miller class I-II gingival recession defects operated with sub epithelial connective tissue graft (SCTG) in addition with enamel matrix derivatives (EMD) (Emdogain ®, Switzerland ) in SCTG+EMD group.
2893378|NCT03295604|Experimental|control group|Miller class I-II gingival recession defects operated with only sub epithelial connective tissue graft (SCTG). No drug or something else were used
2893379|NCT03295578|Experimental|Personalized feedback group|In between the two measurement periods, the personalized feedback group will receive an explanation and personalized feedback on their self-measured data (interstitial glucose, cognition, wellbeing and food intake).
2893380|NCT03295578|Placebo Comparator|General feedback group|The generic feedback group will receive a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
2893381|NCT03295565|Active Comparator|A: Cabazitaxel|Cabazitaxel 25mg/m2 IV, once every 3 weeks
2893382|NCT03295565|Active Comparator|B: Abiraterone OR Enzalutamide|"At physician's discretion:~Abiraterone 1000mg oral, taken daily Prednisone 5mg oral, 2 times a day OR Enzalutamide 160mg oral taken daily"
2893383|NCT03295552|Experimental|DC|DNA demethylating agent decitabine plus carboplatin
2893384|NCT03295539|Other|Acute or Chronic clot|If chronic clot, no intervention given via Indigo
2893385|NCT03295526|No Intervention|Control group|IB-IIA Cervical Cancer Patients with positive lymph node metastasis confirmed by intraoperative frozen pathological examination who will undergo radical hysterectomy and systematic pelvic lymphadenectomy
2893386|NCT03295526|Experimental|Experimental group|IB-IIA Cervical Cancer Patients with positive lymph node metastasis confirmed by intraoperative frozen pathological examination who will undergo radical hysterectomy and selective enlarged lymph node dissection.
2893387|NCT03295513|Active Comparator|veneered zirconia full coverage restorations|InCoris zirconia material (TZI-Densupply sirona)
2893388|NCT03295513|Experimental|Monolithic zirconia full coverage restorations|InCoris (TZI-Densupply sirona)
2893389|NCT03295500||Experimental Group One|In this group ,the participants receive the dose fraction of 49Gy/7f (BED 83.3Gy) by cyberknife.
2893390|NCT03295500||Experimental Group Two|In this group ,the participants receive the dose fraction of 54Gy/6f(BED 102.6Gy) by cyberknife.
2893391|NCT03295500||Control Group|In this group ,the participants receive the dose fraction of 55Gy/5f(115.5Gy) by cyberknife.
2893392|NCT03295487|Active Comparator|Group A|post menopausal female with genuine stress incontinence treated by TVT-O and local estrogen cream for 3 months after surgery
2893393|NCT03295487|Active Comparator|Group B|post menopausal female with genuine stress incontinence treated by TVT-O only
2893394|NCT03295474||Rehabilitation using telehealth technology|
2893395|NCT03295461|Active Comparator|test group|SRP+ 10% Emblica officinalis irrigation
2893396|NCT03295461|Active Comparator|positive control group|SRP + 0.2% Chlorhexidine irrigation
2893397|NCT03295461|Active Comparator|negative control group|SRP + 0.9% Saline irrigation
2893398|NCT03295461|Active Comparator|test gropup|SRP +10% E. officinalis gel application
2893399|NCT03295461|Placebo Comparator|control group|received SRP+ placebo gel application.
2893400|NCT03295448|Active Comparator|Fat - Sugar - Fiber|Intervention: consuming diets rich in fat, rich in sugar, and rich in fibers during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
2893401|NCT03295448|Active Comparator|Fat - Fiber - Sugar|Intervention: consuming diets rich in fat, rich in fiber, and rich sugar during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
2893402|NCT03295448|Active Comparator|Sugar - Fiber - Fat|Intervention: Consuming diets rich in sugar, rich in fiber, and rich in fat during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
2893403|NCT03295448|Active Comparator|Sugar - Fat - Fiber|Intervention: Consuming diets rich in sugar, rich in fat, and rich in fiber during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
2893404|NCT03295448|Active Comparator|Fiber - Sugar - Fat|Intervention: Consuming diets rich in fiber, rich in sugar, and rich in fat during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
2893405|NCT03295448|Active Comparator|Fiber - Fat - Sugar|Intervention: consuming diets rich in fiber, rich in fat, and rich in fiber during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
2893406|NCT03295422|Active Comparator|RF ablation PVI alone|RF catheter ablation of pulmonary veins alone
2893407|NCT03295422|Experimental|RF ablation PVI plus LPAW|RF catheter ablation PVI plus left atrial posterior wall
2893408|NCT03295409|Experimental|Experimental: Standard self-affirmation|"Participants are asked to form a self-affirming implementation intention at the end of a questionnaire:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will…~think about the things I value about myself~remember things that I have succeeded in~think about what I stand for~think about things that are important to me~If…___________________________________________________________________"
2894738|NCT03285945||PET10|Post-therapeutic FDG PET/CT performed after 10 days of steroid treatment
2893409|NCT03295409|Experimental|Experimental: Familial self-affirmation|"Participants are asked to form a self-affirming implementation intention at the end of a questionnaire:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will…~think about the things my family and I value about ourselves~remember things that my family and I have succeeded in~think about what my family and I stand for~think about things that are important to my family and me~If…__________________________________________________________________"
2893410|NCT03295409|No Intervention|Control|Participants are asked to complete a questionnaire.
2893411|NCT03295383|Experimental|Rituximab treatment|"Rituximab at a dose of 1000 mg (or matching placebo) will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197~cyclophosphamide placebo will be administered orally once daily"
2893412|NCT03295383|Active Comparator|Cyclophosphamide treatment|"cyclophosphamide will be administered orally once daily at the following initial doses:~patients younger than 75 years: 1.5 mg/kg/day, orally. patients older than 75 years: 1 mg/kg/day, orally.~Rituximab placebo (NaCl 0.9 %) will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197"
2893413|NCT03295370|Experimental|Active Group|Needle electrical stimulation of accessory spinal nerve
2893414|NCT03295370|Sham Comparator|Sham Group|Needle of accessory spinal nerve without electrical stimulation
2893415|NCT03295357||Patients with extubation while on ECLS|
2893416|NCT03295357||Patients without extubation|
2893417|NCT03295344||Patients|
2893418|NCT03295344||Healthy volunteers|
2893419|NCT03295331||GINA-defined clinical diagnosis of Asthma|All patients with GINA-defined clinical diagnosis of Asthma seen at respiratory clinic from January to August 2016 with age 18 and above
2893420|NCT03295318|Experimental|Adjuvanted study formulation NmCV-5|"Subjects in this arm will receive adjuvanted formulation of polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
2893421|NCT03295318|Experimental|Non-adjuvanted study formulation NmCV-5|"Subjects in this arm will receive non-adjuvanted formulation of polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
2893422|NCT03295318|Active Comparator|Menactra|"Subjects in this arm will licensed quadrivalent conjugated vaccine against meningococcal serogroups A,C,Y, & W viz. Menactra.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
2893423|NCT03295305|Experimental|Action Based Cognitive Remediation|
2893424|NCT03295305|Active Comparator|Unstructured support group|
2893425|NCT03295292|Sham Comparator|Standard Surgery with Vehicle|After the standard surgical procedure (PRK/PTK or CXL), patients will receive 50uL Fibrin Sealant (sham) without cells.
2893426|NCT03295292|Experimental|Standard Surgery with Stem Cells|After the standard surgical procedure (PRK/PTK or CXL), patients will receive 50uL of a mixture of limbus derived corneal epithelial cells and limbus derived corneal stromal cells in a ratio of 2:1, at a concentration of 50000 cells/uL diluted in the thrombin component of Fibrin Sealant (TISEEL, Baxter).
2893427|NCT03295266|Experimental|Moderate Hepatic Impairment (Panel A)|Participants with moderate HI receive a single IV dose of MK-3866 (150 mg) on Day 1.
2893428|NCT03295266|Experimental|Severe Hepatic Impairment (Panel B)|Participants with severe HI receive a single IV dose of MK-3866 (150 mg) on Day 1.
2893429|NCT03295266|Experimental|Healthy Matched Controls (Panel C)|Healthy participants receive a single IV dose of MK-3866 (150 mg) on Day 1.
2893430|NCT03295253|Experimental|Female patients with Stress Incontinence|Female patients who will undergo autologous adipose tissue harvesting/grafting using Lipogems and grafting in urethra/bladder neck
2893431|NCT03295240|Experimental|BR-I in combination with VEN|The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered in combination with VEN (Venetoclax).
2893432|NCT03295227|Experimental|Pembrolizumab|"Part 1: Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of every 21 day Cycle.~Part 2: Participants received Pembrolizumab at the maximum tolerated dose from Part 1."
2893433|NCT03295214|Active Comparator|Acetaminophen 975mg Per Os|975mg of Acetaminophen given by mouth
2893434|NCT03295214|Active Comparator|Acetaminophen 1000mg Intravenous|1000mg of Acetaminophen given intravenously
2893435|NCT03295201|Experimental|Pulmonary rehabilitation+exercise group|Active cycle of breathing techniques (ACBT) and postural exercise program
2893436|NCT03295201|Active Comparator|Pulmonary rehabilitation group|Active cycle of breathing techniques (ACBT)
2893437|NCT03295188|Experimental|Intervention Group|Two 0.5 mg plasmalogen capsules per day
2893438|NCT03295188|Placebo Comparator|Placebo Group|Two placebo capsules containing no plasmalogen per day
2893439|NCT03295175||Congenital Megaprepuce|Congenital Megaprepuce
2893440|NCT03295175||Hypospadias|Hypospadias
2893441|NCT03295175||Control|Circumcision for non-medical reasons.
2893442|NCT03295162|Experimental|Sepsis A Group|neonates diagnosed with Sepsis and will receive melatonin. 10 mg product as a total dose of 20 mg .together with conventional treatment of Neonatal sepsis
2893443|NCT03295162|Sham Comparator|Sepsis B Group|neonates diagnosed with Sepsis and willnot receive melatonin., they will recieve only the conventional treatment of Neonatal Sepsis
2893444|NCT03295162|No Intervention|Control|healthy neonates, in whom sepsis will be ruled-out on the basis of absence of any clinical or laboratory evidence suggestive of infection.
2893445|NCT03295136|Experimental|Health Promotion Training for Women Employees|A group of women employees will participate in a 20 session health promotion training course. The course will include health education and health promotion knowledge and skills, as well as leadership and project building skills, including empowerment, change process, recruiting partners and more. The first 15 sessions will be weekly session, while the remaining five will take place every couple of months throughout the following year.
2893542|NCT03294369||Cohort of the study|A sample from the general population aged 18 years or older, randomly selected from a database of sanitary cards stratified by age and gender.
2893447|NCT03295110|Other|Functionalities of the Lili Smart Solution non activated|Lili Smart watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
2893448|NCT03295097|Other|Clinical Decision Support System|The Clinical Decision Support System is composed of pharmacogenomic results and a pharmacist evaluated drug to drug interaction review. This system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions.
2893449|NCT03295084|Experimental|Irinotecan|Dose escalation study in cohorts of minimum 3 patients of an Irinotecan tablet taken once daily for 14 days within 3 week treatment cycle
2893450|NCT03295084|Experimental|Irinotecan with Capecitabine|Dose escalation study in cohorts of minimum 3 patients of an Irinotecan tablet taken once daily in combination with Capecitabine tablet taken twice daily for 14 days within 3 week treatment cycle
2893451|NCT03295071||Single-group study|
2893452|NCT03295058|Experimental|severe aplastic anemia|Conditioning regimen :Fludarabine + cyclophosphamide prior to hematopoietic cell transplantation. GVHD Prophylaxis: Cyclosporine A +Steroid then will do allogenic stem cell transplantation from peripheral blood
2893453|NCT03295032|Experimental|group-based ACT|Stroke survivors were randomised into group-based ACT intervention consisting of 2hr sessions for four consecutive weeks.
2893454|NCT03295032|No Intervention|Waiting list control|Waiting list control - received treatment as usual.
2893455|NCT03295019|Experimental|Test Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
2893456|NCT03295019|Placebo Comparator|Placebo Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their placebo mouth spray, 2 times daily (morning and evening), for the 4 week duration of the study.
2893457|NCT03295006||Previous Therasphere treatment|Patients who had received TheraSphere yttrium-90 microspheres
2893458|NCT03294993|Experimental|Ultrasound assess group|The investigators designed a study to assess whether there were any blood flow indexes change before and after radial artery puncture with doppler ultrasonography
2893459|NCT03294967|Active Comparator|Caffeine|To determine the effect of caffeine on ocular circulation in high myopes by consuming 200 mg caffeine capsule
2893460|NCT03294967|Placebo Comparator|Vitamin E|To determine the effect of caffeine on ocular circulation in high myopes by consuming and 200 International Unit vitamin E control capsule, as control
2893461|NCT03294954|Experimental|GINAKIT cells + cytoxan + fludara|"Cyclophosphamide and fludarabine will be administered prior to the GINAKIT cells.~Day -4: Cyclophosphamide and Fludarabine~Day -3: Cyclophosphamide and Fludarabine~Day -2: Fludarabine~Day -1: Rest~Day 0: GINAKIT cells"
2893462|NCT03294941|Other|HepQuant SHUNT Liver Diagnostic Kit|All subjects receive HepQuant SHUNT test and DSI measurement. HepQuant SHUNT is a combination product where 13C Cholate 20mg is administered intravenously once for each test and d4 Cholate 40mg is administered once orally for each test
2893463|NCT03294928|Experimental|progressive increasing of PEEP level|four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level.
2893464|NCT03294915|Active Comparator|Resistant Starch|Green banana flour
2893465|NCT03294915|Placebo Comparator|Placebo|Maltodextrin, cellulose and guar gum
2893466|NCT03294902||Critical Limb Ischaemia (CLI) Group with tibial arterial dise|Up to 20, but at least 8 subjects with a Rutherford grade 4 or 5 critically ischemic foot, where the primary intention is to treat at least one occluded tibial vessel or 2 severely stenosed tibial vessels. The treatment of SFA stenoses of less than 70%, as confirmed by duplex or CT, is acceptable in parallel in this group.
2893467|NCT03294902||Peripheral Artery Disease (PAD) Group with SFA disease|Up to 20, but at least 8 subjects with a clinical diagnosis of claudication and duplex or CT-confirmed SFA stenoses greater than 70%, with no intention of primarily treating any tibial disease at this encounter.
2893468|NCT03294863|Experimental|Embrace Scar Therapy Device|16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive will be applied to 1/2 of the cutaneous wound
2893469|NCT03294863|Placebo Comparator|Standard of Care|Another 1/2 of cutaneous wound will be treated per standard of care
2893470|NCT03294850|Experimental|NASH group|These are individuals that have been identified as having NASH by MRE. Confirmation with liver biopsy required for continuation in the longitudinal study.
2893471|NCT03294850|Active Comparator|Non-NASH (NAFLD or normal) group|These are individuals that do not have NASH. They either have normal liver physiology or only have evidence of hepatic steatosis. This group will be studied up until the day of their bariatric surgery and will serve as a comparator population with respect to baseline measurements.
2893472|NCT03294824||patients who reactivate CMV or AdV after allogeneic HSCT|allotransplanted patients who reactivated respectively CMV (n=30) and AdV (n=10)
2893473|NCT03294824||Control group: allogeneic HSC transplanted patients|allotransplanted patients who didn't reactivate CMV
2893474|NCT03294824||Healthy donors group|healthy donors serologically + for CMV
2893475|NCT03294811|Experimental|Telemonitoring group|Recieve a smartphone with an application to coach them, a blood pressure monitor and scale.
2893476|NCT03294811|No Intervention|Control group|Control group (usual care, without telemonitoring)
2893477|NCT03294798|Experimental|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 600-900μg,once per two weeks.
2893478|NCT03294798|Active Comparator|Pegasys|Pegasys 180 mcg, once per week
2893479|NCT03294785|Experimental|Chuna manual therapy|The Chuna manual therapy group will receive Chuna manual therapy alone. Chuna manual therapy will employ a semi-standardized treatment plan of Chuna manual therapy through Chuna technique selection based on physician judgement of techniques from Chuna Medicine (Korean Society of Chuna Manual Medicine for Spine & Nerves: Chuna Medicine: Seoul: Korean Society of Chuna Manual Medicine for Spine & Nerves; 2017) and osteopathic manipulative medicine. The Chuna techniques employed in this study are divided into cervical, thoracic and rib cage, lumbar, pelvic, sacral, pubic, and hip joint area techniques. Chuna manual therapy sessions will be administered 2 sessions/week over a period of 5 weeks (total 10 sessions). The time duration of 1 Chuna manual therapy session will consist of approximately 10-20 minutes of diagnosis and approximately 10 minutes of treatment.
2893480|NCT03294785|Active Comparator|Usual care|The usual care group will receive usual care alone. Usual care will be limited to physical therapy and conventional medication in this study. Usual care will be provided with reference to a list of most frequently used treatments in neck pain-related patients from Korean Health Insurance Review and Assessment (HIRA) 2014 statistics. Frequency and types of physical therapy used will be recorded in a separate electronic case report form for outcome assessor blinding purposes.
2893481|NCT03294772|Experimental|Hand sanitizer group|DCCs received alcohol-based hand sanitizer and a program educational. Characteristics of the hydroalcoholic gel (Alco aloe gel): chlorhexidine digluconate at 0.2% solution, phenoxyethanol 1%, benzalkonium chloride 0.1%. aloe barbadensis 5%, ethyl alcohol 70%, excipients c.s.p. 100 ml. Alcohol of between 70%, ph = 7-7,5.
2893482|NCT03294772|Experimental|Liquid soap group|DCCs received soap and program educational. The liquid soaps used for handwashing in this study did not contain specific antibacterial component, ph= 5.5.
2893483|NCT03294772|No Intervention|Control group|No hand sanitizer or educational program were used.
2893484|NCT03294759|Experimental|Bio-ACL (Amion)|Intervention: ACL Autograft Reconstruction with Amion Collagen Scaffold. Stem Cells isolated from bone marrow aspirate from distal femur will be injected inside the Amion Collagen Scaffold.
2893485|NCT03294759|Active Comparator|Control|Intervention: Normal ACL Autograft Reconstruction with either patella or hamstring autograft will be performed in the control group.
2893486|NCT03294746|Other|Clinical evaluations and Thoracic CT scan scoring of DIILD|
2893487|NCT03294733|Other|Ultrasound|Ultrasound wrists to determine carpal tunnel size
2893488|NCT03294720|Experimental|Bio ACL Reconstruction|Normal ACL reconstruction with either patellar or hamstring autograft will be done and prior to fixation the graft will be wrapped in a amion collagen wrap. Bone marrow aspirate will be obtained from distal femur at the time of the arthroscopy and stem cells isolated using the Arthrex Angel System. These stem cells with be under direct visualization impregnated into the ACL autograft amion wrap complex.
2893489|NCT03294707|Experimental|AG10 single oral dose|AG10 oral tablet, administered by mouth, once
2893490|NCT03294707|Placebo Comparator|Placebo single oral dose|Placebo Oral Tablet, administered by mouth, once
2893491|NCT03294694|Experimental|Ribociclib and PDR001 (Cohort A)|"The treatment regimen is defined as ribociclib + PDR001.~Treatment will be administered on an outpatient basis.~The study will use a 3 + 3 dose escalation design to determine the MTD/RP2D.~Three to six evaluable patients will be enrolled in each cohort in the dose escalation phase.~Once the RP2D of the combination of ribociclib + PDR001 is determined, there will be an expansion cohort.~Cohort A expansion will assess the combination of ribociclib + PDR001 in 12 patients with metastatic ovarian cancer."
2893492|NCT03294694|Experimental|Ribociclib, PDR001 and Fulvestrant (Cohort B)|"The treatment regimen is defined as ribociclib + PDR001 + fulvestrant .~Treatment will be administered on an outpatient basis.~There will be a safety run-in using the MTD/RP2D of ribociclib + PDR001 from Cohort A with the addition of fulvestrant in an initial 6-12 patients.~Once the safety of the combination of ribociclib + PDR001 + fulvestrant is established, there will be an expansion cohort.~Cohort B expansion will assess the combination of ribociclib + PDR001 + fulvestrant in 24 patients with hormone receptor-positive metastatic breast cancer (HR+ MBC)."
2893493|NCT03294681||Cochlear Implant Recipients|
2893494|NCT03294668|Experimental|KONTAKT Australia|A social skills group training
2893495|NCT03294668|Active Comparator|Super Chef|A social cooking group
2893496|NCT03294655|No Intervention|No contact control|the no contact control group will do nothing
2893497|NCT03294655|Experimental|Intervention|the intervention condition will come to the lab for a 1 hour Pilot Resilience Building Intervention including a presentation on resilience and strategies to boost adherence, of which they will chose five to integrate in their daily life over the following 4 weeks
2893498|NCT03294642|Experimental|Trial 1|Water Intervention: In one of the 3 cycling trials, participants will receive only water and no carbohydrate supplementation during the 2 hour cycling challenge.
2893499|NCT03294642|Experimental|Trial 2|Carbohydrate Gel Intervention: In one of the 3 cycling trials, participants will receive carbohydrate supplementation in the form of commercially available gels (15g every 15 minutes) during the 2 hour cycling challenge.
2893500|NCT03294642|Experimental|Trial 3|Potatoes Intervention: In one of the 3 cycling trials, participants will receive carbohydrate supplementation in the form of pureed russet potato (15g every 15 minutes) during the 2 hour cycling challenge.
2893501|NCT03294629|No Intervention|APAP begins without SensAwake|Patients will receive CPAP treatment without SensAwake™ activation for two weeks, then crossed-over to CPAP treatment with SensAwake™ activation for additional two weeks.
2893502|NCT03294629|Experimental|APAP begins with SensAwake|"Patients will receive CPAP treatment with SensAwake™ activation for two weeks, then crossed-over to CPAP treatment without SensAwake™ activation for additional two weeks.~SensAwake™ modification: SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep."
2893503|NCT03294616|Experimental|scleroderma patients-0|for acute study: The experiment in patients will be performed in 4 randomized sessions on separate days (at least 3 days apart): one control session with sham-TEA and 3 TEA sessions at various parameters. TEA will be applied on both acupoints ST36 and PC6; the following sets of parameters will be tested for TEA at ST36: A) standard parameters: the set used in the previous SSc study: 25 Hz, 0.3ms, 2s-on and 3s-off; B) same as A but pulse width of 0.6ms; C) same as B but 0.1s-on and 0.4s-off. For TEA at PC6, 25 Hz will be replaced by 100Hz because TEA at PC6 is used to treat symptoms and 100Hz is believed to be better than 25Hz. The patient will be fasted overnight, and the test will last 2 hours (1 hour fasting and 1 hour postprandial).
2893504|NCT03294616|Experimental|scleroderma patient-1|for chronic study: 2 weeks of Sham transcutaneous electroacupuncture treatment, 2 weeks of wash out, 2 weeks of transcutaneous electroacupuncture/Sham transcutaneous electroacupuncture treatment. Best parameter gained from acute study will be used.
2893543|NCT03294356|Experimental|FT210771 Group|7 day at-home use of electronic cigarette FT210771 followed by a 2 day in-clinic period.
2932870|NCT03020771|Active Comparator|5 mcg SC|
2893505|NCT03294616|Experimental|scleroderma patients-2|for chronic study: 2 weeks of transcutaneous electroacupuncture treatment, 2 weeks of wash out, 2 weeks of transcutaneous electroacupuncture/Sham transcutaneous electroacupuncture treatment. Best parameter gained from acute study will be used.
2893506|NCT03294603|Experimental|[14C]-CC-220 solution|A single oral dose of 1 mg [14C]-CC-220 solution, containing approximately 1.4 μCi of radioactivity, will be administered on Day 1 under fasted conditions.
2893507|NCT03294590|Experimental|Oral health text messages (OHT)|Participants in this arm will receive the OHT parent targeted text messages to reduce caries and improve oral health behaviors among low income families visiting community-based, urban pediatric clinics.
2893508|NCT03294590|Active Comparator|Child wellness text messages (CWT)|Participants in this arm will receive the CWT parent targeted text messages to improve child wellness (e.g., reading time, safety) among low income families visiting community-based, urban pediatric clinics.
2893509|NCT03294577|Active Comparator|Pegfilgrastim (0.6 ml)|Phase 2: TAC + Pegfilgrastim (0.6 ml)
2893510|NCT03294577|Experimental|Plinabulin (10 mg/m2)|Phase 2: TAC + Plinabulin (10 mg/m2)
2893511|NCT03294577|Experimental|Plinabulin (20 mg/m2)|Phase 2: TAC + Plinabulin (20 mg/m2)
2893512|NCT03294577|Experimental|D5W placebo|"Phase 3:TAC + Pegfilgrastim (0.6 ml)+ D5W placebo~D5W Placebo: 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W"
2893513|NCT03294577|Experimental|Saline placebo|"Phase 3: TAC+ Plinabulin + saline placebo~Saline Placebo: Placebo Syringe 0.6 ml Saline to match the 0.6 ml pegfilgrastim administration"
2893514|NCT03294564|Active Comparator|Typhoid Vi Polysaccharide Vaccine|Patients will receive one intramuscular 0.5 mL injection of Typhoid Vi Polysaccharide Vaccine containing 0.025 mg purified Vi polysaccharide.
2893515|NCT03294564|Placebo Comparator|Placebo|Patients will receive one intramuscular 0.5 mL injection of saline placebo.
2893516|NCT03294551|No Intervention|Standard of Care Control|Usual source of care
2893517|NCT03294551|Experimental|HPV Vaccine Reminder Recall - Autodialer|HPV Vaccine Reminder Recall - Autodialer: Receive up to 4 reminders via telephone (live call or voicemail) - includes brief educational message + providers name + providers telephone number
2893518|NCT03294551|Experimental|HPV Vaccine Reminder Recall - Texting|HPV Vaccine Reminder Recall - Texting: Receive up to 4 reminders via text message - includes brief educational message + providers name + providers telephone number
2893519|NCT03294538|Active Comparator|Estrace® Cream|Reference Product Estrace® Cream, US Pharmacopeia (USP), 0.01%. Two grams self-administered once daily at approximately the same time of the day for 7 consecutive days.
2893520|NCT03294538|Experimental|Generic Estradiol Cream|Generic formulation of Estrace® Cream, USP, 0.01%. Two grams self-administered once daily at approximately the same time of the day for 7 consecutive days.
2893521|NCT03294538|Placebo Comparator|Vehicle Cream|Placebo formulation cream in the likeness of test and reference products. Two grams self-administered once daily at approximately the same time of the day for 7 consecutive days.
2893522|NCT03294525|Experimental|Lithium carbonate|Lithium Carbonate oral tablet, 500mg~2000mg/day, oral,8weeks
2893523|NCT03294525|Active Comparator|lithium carbonate+escitalopram|a combination of lithium carbonate oral tablet and escitalopram pill
2893524|NCT03294512|Experimental|Heart Failure Patients|Patients who are seen at Intermountain Medical Center with heart failure, based on the Intermountain-specific Heart Failure Identification and Risk Stratification, will be screened for this study. The Principal Investigator and/or his delegate will confirm the presence of heart failure, based on established standard of care criteria for diagnosis.
2893525|NCT03294486|Experimental|Combination of TG6002 and flucytosine (5-FC, Ancotil®)|All patients within a given cohort will be treated with the same dose schedule of TG6002, administred as 3 weekly IV infusions at days 1, 8 and 15. following the 1st and 2nd infusions of TG6002, patients will be given oral 5-FC for 3 days starting on day 5 and 12 . following the 3rd infusion, patients will be given oral 5-FC for 21 days starting on day 19.
2893526|NCT03294473|Experimental|Autodial R/R|R/R Autodialers:Participants in this group will receive up to 3 influenza vaccination reminders via telephone call - with a brief educational message + practice name + practice phone number
2893527|NCT03294473|Experimental|Text Message R/R|R/R Texting: Participants in this group will receive up to 3 influenza vaccination reminders via text message - with a brief educational message + practice name + practice phone number
2893528|NCT03294473|Experimental|Postcard R/R|R/R Mailed Postcard:Participants in this group will receive up to 3 influenza vaccination reminders via postcard - with a brief educational message + practice name + practice phone number
2893529|NCT03294473|No Intervention|Standard of Care Control|Participants in this group will not receive any influenza vaccination reminders
2893530|NCT03294460|Experimental|1|Alcohol self-administration (IV ethanol for sessions 1 and 3, oral for session 2)
2893531|NCT03294447|Experimental|Fall Prevention Intervention by OT|Fall prevention interventions implemented by an OT in a geriatric primary care setting for a client immediately following the provider visit within the office.
2893532|NCT03294434||High Grade Glioma|Diffusion tensor Imaging (DTI-MRI) scan to be performed pre-operatively and pre-radiotherapy
2893533|NCT03294421|Active Comparator|standard closed tympanomastoidectomy|In this group it will be performed the standard technique for closed tympanomastoidectomy, in which a surgical microscope is used.
2893534|NCT03294421|Experimental|combined access tympanomastoidectomy|In this group a closed tympanomastoidectomy with combined access will be performed. This technique combines the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation.
2893535|NCT03294408|Other|Imaging|multimodal imaging and clinical assessment
2893536|NCT03294395|Active Comparator|Ceftriaxone im|Current standard treatment. Ceftriaxone 500mg (single intramuscular dose) + placebo (single oral dose)
2893537|NCT03294395|Experimental|Ertapenem im|Ertapenem 1000mg (single intramuscular dose) + placebo (single oral dose)
2893538|NCT03294395|Experimental|Fosfomycin po|Fosfomycin oral suspension 6g (single oral dose) + placebo (single intramuscular dose)
2893539|NCT03294395|Experimental|Gentamicin im|Gentamicin sulfate, injectable 5mg/kg (single intramuscular dose) + placebo (single oral dose)
2893540|NCT03294382|Experimental|Botulinum toxin|5U Botulinum toxin in 0.1 mL normal saline, administered in one of the intercanthus
2893545|NCT03294356|Experimental|6T30134157764 Group|7 day at-home use of electronic cigarette 6T30134157764 followed by a 2 day in-clinic period.
2893546|NCT03294356|Experimental|G41A7C071 Group|7 day at-home use of electronic cigarette G41A7C071 followed by a 2 day in-clinic period.
2893547|NCT03294356|Experimental|M011161212 Group|7 day at-home use of electronic cigarette M011161212 followed by a 2 day in-clinic period.
2893548|NCT03294356|Experimental|FT21002 Group|7 day at-home use of combustible cigarette FT21002 followed by a 2 day in-clinic period.
2893549|NCT03294343|Experimental|HBOCS|For carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome), if they demand for risk-reducing surgeries, counseling, decision-making analysis, then salpingo-oophorectomy only by laparoscopy and long-term follow-up are provided.
2893550|NCT03294343|Experimental|Lynch syndromes|for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11, , if they demand for risk-reducing surgeries, counseling, decision-making analysis, then salpingo-oophorectomy with hysterectomy by laparoscopy and long-term follow-up are provided.
2893551|NCT03294343|Other|Refusal to surgery|For carriers with any mutation genes (BRCA1, BRCA2, ATM, BRIP1, RAD51, RAD51C, RAD51D, STK11, MLH1, MSH2, MSH6, PMS2 and EPCAM) but refusal to any risk-reducing surgeries, counseling, decision-making analysis, and then long-term follow-up are provided.
2893552|NCT03294330|Experimental|Patients with Melanoma or Breast Cancer|The SPY machine used in conjunction with the IC-green kit will be used exclusively to identify sentinel nodes in patients diagnosed with Melanoma or Breast Cancer who are undergoing sentinel lymph node biopsy.
2893553|NCT03294317||His Bundle Pacing|Patient will be implanted per indications for single or dual chamber pacemaker. Lead for His bundle pacing will be implanted.
2893554|NCT03294304|Experimental|Nivolumab, Cisplatin, & Gemcitabine|
2893555|NCT03294291|Active Comparator|Quadratus Lumborum block group|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.7 ml/kg bupivacaine 0.25 % injected unilaterally at the posterior border of the quadratus lumborum muscle.
2893556|NCT03294291|Active Comparator|Caudal block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory caudal block wil performe with bupivacaine 0.7 ml/kg as 0.25%.
2893557|NCT03294278|Active Comparator|Ablation plus ICD|Epicardial ablation by radio-frequency
2893558|NCT03294278|Active Comparator|ICD alone|Implantation of ICD
2893559|NCT03294265|Experimental|Peer support group|"Patients who accept to participate in the protocol and are randomized to the intervention group will be invited to five sessions, one per bimester, that will be carried out in our facilities until their next appointment to the centre (fifth visit). All of them will be coordinated by a group leader.~Interventions are made each bimester in 2 hours in peer support sessions in which the patients discuss and reinforce the following topics: grief stages, control goals, self-care activities, adequate diet planning and diminish sedentary lifestyle."
2893560|NCT03294265|Active Comparator|Control group|"Patients who accept to participate in the protocol and are randomized to the control group will receive weekly messages and reminders about self-care to their cell phones via WhatsApp.~Interventions are made by sending each week a self-care reminder via WhatsApp and questionnaires about self-care activities and drugs"
2893561|NCT03294252|Experimental|Oxaliplatin|The experimental drugs used in this protocol are Oxaliplatin, 5-Fluorouracil and L-Folinic acid. All are used as part of their marketing authorization, with the exception of Oxaliplatin as regards its mode of administration specific to the CIPPA procedure (injection and nebulisation in intraperitoneal).
2893562|NCT03294239|Experimental|Group A (Transurethal group)|Patients will have trans urethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone disintegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.
2893563|NCT03294239|Experimental|Group B (Percutaneous group)|Patients will have per cutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the mid line 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
2893564|NCT03294226|Experimental|AuraGain|After anesthetic induction, AuraGain is inserted for airway management. Size of the device is selected according to the manufacturer's recommendation; size 1.5 for 5-10kg, size 2 for 10-20kg.
2893565|NCT03294226|Active Comparator|I-gel|After anesthetic induction, I-gel is inserted for airway management. Size of the device is selected according to the patient's weight; size 1.5 for 5-10kg, size 2 for 10-20kg.
2893566|NCT03294213||aScope 4 Broncho|The only data to be obtained are evaluation forms directly related to the users' perception of the aScope™ 4 Broncho
2893567|NCT03294200|Experimental|Tricinch Coil System treatment|
2893568|NCT03294187|Experimental|Monitoring and Feedback|Subjects will use two wrist-worn wearables over a period of 6 weeks. Patients will receive multimodal (vibrotactile and visual) feedback.
2893569|NCT03294187|Placebo Comparator|Monitoring|Study subjects will use identical devices over a period of 6 weeks. Patients will *not* receive multimodal feedback.
2893570|NCT03294174||Opioid naive|Patients who have not been exposed to opioids, but will receive ropivacaine injection
2893571|NCT03294174||Opioid exposure|Patients who have been exposed to(> 6months), but not currently taking opioids, but will receive ropicacaine injection
2893572|NCT03294174||opioid tolerance|Patients who have been actively taking opioids with a tolerant dose based on FDA guideline, but will receive ropivacaine injection
2893573|NCT03294161|Experimental|Immucillin DI4G|Meglumine Antimoniate by intravenous route at 20mg/kg/day during 20 days + Immucillin DI4G 2% by topical use once a day at the ulcer for 20 days .
2893574|NCT03294161|Active Comparator|Meglumine Antimoniate|Meglumine Antimoniate by intravenous route at 20mg/kg/day during 20 days + placebo for topical use once a day at the ulcer for 20 days.
2893575|NCT03294148|Experimental|Placebo|The open-label placebo treatment the investigators will use is based on past open-label placebo trials (Kam-Hansen et al., 2014; Kaptchuk et al., 2010; Kelley et al., 2012). Prior to treatment administration, patients will view a brief (~3 min) video summarizing scientific findings regarding the therapeutic power of placebo treatments. The video will describe established findings regarding placebo and suggest that placebos may still work even when patients know the treatment is a placebo. The video will state that believing in the placebo is not necessary, and the investigators ask only that patients keep an open mind. Patients will then receive a subcutaneous injection of 1ml medical grade saline into the lower back. The injection will be administered near the location of the pain, as specified by the participant. The investigators will use a standard needle used in subcutaneous injections of 27 gauge with a length from 1in to 1.5in.
2893576|NCT03294148|Experimental|Psychotherapy|Psychotherapy will consist of one initial medical history session with Co-I Schubiner, followed by twice weekly 50 minute psychotherapy sessions for 4 weeks with a therapist, for a total of 9 sessions maximum. The purpose of the initial medical history session is to help evaluate the likelihood that the patient's back pain is caused by structural conditions in the back. Dr. Schubiner will then speak with patients for a 1 hour session in which he collects their medical history and discusses different possible causes of their back pain with them. This session will be conducted by phone, by HIPAA-compliant Zoom, or by another HIPAA-compliant videoconferencing technology in consultation with the OIT team at Dr. Schubiner's hospital.
2893577|NCT03294148|No Intervention|Waitlist|Wait-listed patients will be asked not to change their treatment regime for the 4 weeks in between their two fMRI sessions. Wait-listed patients in the placebo injection arm will be offered the opportunity to receive the placebo treatment (optional). Waitlisted participants in the psychotherapy arm will be given a copy of Dr. Schubiner's book and free access to his online self-help program (optional to accept these).
2893578|NCT03294135|Experimental|Conventional Group|Subjects will receive a second booster vaccination six months after the blood draw only in case they result to be with an NT titre below 10 and who belonged to the following vaccination schedule in the primary studies: Primary vaccination of 66 subjects in study V48P7 on Days 0, 28 (+10) and 300 (+21), booster vaccination of 55 subjects in study V48P7E1 (NCT00387634), no vaccination in study TBEV POLYGELINE FREE (V48)-023 EXT 021 (V48P7E2) (NCT01562444).
2893579|NCT03294135|Experimental|Accelerated/Rapid Group|Subjects will receive a second booster vaccination six months after the blood draw only in case they result to be with an NT titre below 10 and who belonged to the following vaccination schedule in the primary studies: Primary vaccination of 66 subjects in study V48P7 on Days 0, 7 (+3) and 21 (+7), booster vaccination of 9 subjects in study V48P7E1 (NCT00387634) 40 subjects received their booster vaccination before enrolment in study V48P7E1 (NCT00387634), no vaccination in study TBEV POLYGELINE FREE (V48)-023 EXT 021 (V48P7E2) (NCT01562444).
2893580|NCT03294135|Experimental|Accelerated Conventional Group|Subjects will receive a second booster vaccination six months after the blood draw only in case they result to be with an NT titre below 10 and who belonged to the following vaccination schedule in the primary studies: Primary vaccination of 133 subjects in study V48P7 on Days 0, 14 (+3) and 300 (+21), booster vaccination of 109 subjects in study V48P7E1 (NCT00387634), no vaccination in study TBEV POLYGELINE FREE (V48)-023 EXT 021 (V48P7E2) (NCT01562444).
2893581|NCT03294122||PCa patients - Discovery cohort|External beam radiotherapy for prostate cancer
2893582|NCT03294122||HNCa patients - Discovery cohort|External beam radiotherapy for head and neck cancer
2893583|NCT03294122||PCa patients - Validation cohort|External beam radiotherapy for prostate cancer
2893584|NCT03294122||HNCa patients - Validation cohort|External beam radiotherapy for head and neck cancer
2893585|NCT03294109|Experimental|study|liposomal bupivacain
2893586|NCT03294109|No Intervention|control|no intervention
2893587|NCT03294096|Experimental|experimental group|
2893588|NCT03294096|Active Comparator|control group|
2893589|NCT03294083|Experimental|Part 1, Dose escalation|"Pexa-Vec will be administered via IV infusion at a dose of 3 x 10^8 pfu once per week for 4 treatments. Based on the occurrence of dose-limiting toxicities, patients may subsequently be enrolled to receive Pexa-Vec on the same schedule at a dose of 1 x 10^9 pfu.~REGN2810 will be administered via IV infusion every 3 weeks."
2893590|NCT03294083|Experimental|Part 2, Pexa-Vec (IT) and REGN2810|"Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments.~REGN2810 will be administered via IV infusion every 3 weeks."
2893591|NCT03294083|Experimental|Part 2, REGN2810|"REGN2810 will be administered via IV infusion every 3 weeks.~At disease progression, Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments. REGN2810 will continue every 3 weeks."
2893592|NCT03294083|Experimental|Part 2, Pexa-Vec (IV) and REGN2810|"Pexa-Vec will be administered via IV infusion once per week for 4 treatments.~REGN2810 will be administered via IV infusion every 3 weeks."
2893593|NCT03294070|Experimental|Fimasartan 60 mg + amlodipine besylate 5 mg|Fimasartan 60 mg + amlodipine besylate 5 mg. In subjects with a DBP equal to or greater than 90 mmHg and / or SBP equal to or greater than 140 mmHg at week 8, the investigator will have the option, according to his clinical criteria, to add 12.5 mg of HCTZ QD (in these cases, the subject will receive one 60 mg Fimasartan tablet plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate tablet.
2893594|NCT03294057|Experimental|ICT programs + Tele-coaching programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH) are provided. And a trained nurse provides tele-coaching programs to subjects. After that, subjects will conduct self-management health care and tele-coaching programs for 12 weeks. After 3 months, they finish self-management ICT + coaching programs, and then they fill out the questionnaire.
2893624|NCT03293836|Active Comparator|Multilayer Compressive Bandage only|Receive only compressive treatment
2893668|NCT03293550||patients over 65 years undergoing elective surgery|patients over 65 years undergoing elective cardiac surgery or elective hip or knee surgery
2893595|NCT03294057|Experimental|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH) are provided. After that, subjects will conduct self-management health care for 12 weeks. After 3 months, they finish self-management ICT programs, and then they fill out the questionnaire.
2893596|NCT03294057|Active Comparator|A book about chronic disease|Subjects in the group get a book about chronic disease for patients. After 3 months, they finish reading the materials, they fill out the questionnaire.
2893597|NCT03294044|Experimental|ICT programs|ICT programs that include health information learning by disease, and self-management based on Smart Management Strategy for Health (SMASH) are provided. After that, subjects will conduct self-management health care for 12 weeks. After 3 months, they finish self-management ICT programs, and then they fill out the questionnaire.
2893598|NCT03294044|Active Comparator|A book about chronic disease|Subjects in the group get a book about chronic disease for patients. After 3 months, they finish reading the materials, they fill out the questionnaire.
2893599|NCT03294031|Experimental|Pilates|The Pilates program covered a 12-week period, two weekly sessions. In one session, exercises were performed on a mat (Mat Pilates), and in the second session in standing and sitting position. The programme included warm-up exercises, the main part of the session and cooling activities.
2893600|NCT03294031|Active Comparator|Conventional Exercise|The conventional exercise programme covered a 12-week period, two weekly sessions. The programme aimed at improving aerobic capacity, muscular resistance, balance and flexibility. The program combined land-based and water-based exercise sessions.
2893601|NCT03294018||Bradycardia during sugammadex administration|Recording any heart rate changes during planned administration of sugammadex.
2893602|NCT03294005||Subjects with nodular goiter|Enrolled subjects with nodular goiter had thyroid sonography and thyroidectomy from 2002 January to 2016 December in CMUH. Total enrolled subject about 2000. These subjects were confirmed by pathology. Each subject had been transverse and longitudinal views of thyroid ultrasonography with high-resolution ultrasound (7-14 MHz) (HP Image Point-HS, Toshiba SSA250, GE ,Aloka SSD-1200 and Siemens S2000) that was performed by our partners - endocrinologist in all patients. Gray scale ultrasonography was routinely performed in every subject. Color Doppler ultrasonography for blood flow and thyroid fine needle aspiration was not absolute done in routine procedure. All data at least was interpreted by 3 endocrinologists under the blind method. Each subject was analyzed under thyroid echogenicity, margin, calcification, inclusion, grooving change and size & ratio size of tall and transverse.
2893603|NCT03293992|Experimental|0.01% RO7058584 or Matching Placebo|
2893604|NCT03293992|Experimental|0.1% RO7058584 or Matching Placebo|
2893605|NCT03293992|Experimental|1% RO7058584 or Matching Placebo|
2893606|NCT03293992|Experimental|RO7058584 and Latanoprost 0.005%|
2893607|NCT03293940|Experimental|Cryoablation Group|"After an initial diagnostic visit to locate the pain causing nerve, participants randomized to this arm will receive the cryoablation procedure.~Participants will have the option to crossover to tPNB 90 days post the initial intervention."
2893608|NCT03293940|Active Comparator|Control Group|"After an initial diagnostic visit to locate the pain causing nerve, participants randomized to this arm will receive the nerve block procedure.~Participants will have the option to crossover to cryoablation treatment 90 days post the initial intervention."
2893609|NCT03293927|Experimental|Fentanyl + Dexmedetomidine|
2893610|NCT03293927|Experimental|Dexmedetomidine + Fentanyl|
2893611|NCT03293927|Experimental|Fentanyl only|
2893612|NCT03293927|Experimental|Dexmedetomidine only|
2893613|NCT03293914|Experimental|Intervention|Participants will be invited to enroll in an occupational therapy (OT) lifestyle redesign intervention focused on diabetes management. The intervention includes approximately 8 one-hour OT sessions over 4 months.
2893614|NCT03293914|No Intervention|Usual Care Control|Participants will not be contacted; outcome data will be extracted from medical records.
2893615|NCT03293901|No Intervention|Rest|
2893616|NCT03293901|Active Comparator|Exercise|Militarily relevant exercise
2893617|NCT03293875|Other|HIV testing promoted by members of the social network|Research staff will initiate the recruitment of seeds by recruiting four to six seeds per city. Counselors, at the partner organizations, will begin by administering a rapid HIV test and provide pre and post-test counseling to seeds. Counselors, who will be trained in the social network assessment methodology, will then ask seeds to list other drug users in their social network who they believe are at risk of contracting HIV. Counselors will then provide participants with 3 coupons to recruit identified network members for an HIV test. Referred participants who engage in high-risk behavior will be also provided with 3 coupons to refer their own network members for an HIV test.
2893618|NCT03293875|Other|Peer network behavioral intervention|Two peer leaders will be selected from each city to deliver the intervention sessions. Peer leaders will recruit drug users they know who will be asked, in turn, to recruit other drug users in their networks. Peer leaders will deliver the intervention to 300 drug users (150 per border city) in cycles composed of small social networks of 5-6 drug users.
2893619|NCT03293862|Active Comparator|Group A (suture only)|Patients randomized to this arm will undergo midline laparotomy closure using a PDS 0 continuous suture only, without mesh, aiming a suture length to wound length ratio higher than four. Randomization occurs after fascial closure.
2893620|NCT03293862|Experimental|Group B (prophylactic mesh).|Patients randomized to this arm will undergo midline laparotomy closure using a PDS 0 continuous suture aiming a suture length to wound length ratio higher than four AND further polypropilene onlay mesh. Randomization occurs after fascial closure.
2893621|NCT03293849|Experimental|Patient Navigation Arm|After an assessment of supportive care needs, a patient navigator will present assessment results and develop and implement a personalized supportive care intervention plan based on the findings in collaboration with a multidisciplinary supportive care team, formed by oncologists and pain and palliative care specialists. The developed plan will be sent to the treating oncologist and oncology team.
2893622|NCT03293849|No Intervention|Control Arm|Assessment results will be provided in printed and electronic form to the treating oncologist for their review. Referrals or interventions for patients allocated to the control arm will be coordinated by the treating oncologist without involvement from the patient navigator or the study team.
2893623|NCT03293836|Experimental|Radiofrequency treatment|Radiofrequency ablation of insufficient saphenous and perforating veins plus multilayer compressive bandage treatment
2893625|NCT03293823|Experimental|vision-based speed of processing (VSOP) cognitive training|use the INSIGHT online program (Posit Science), which includes five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All exercises share visual components and focus on accuracy and fast reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
2893626|NCT03293823|Active Comparator|active control|The standardized computerized leisure activities program - MLA, including crossword puzzle, Sudoku, etc. will be used
2893627|NCT03293797|Experimental|Abbreviated Mindfulness-based Therapy|5 week, abbreviated group MBT treatment for depression and anxiety
2893628|NCT03293784|Other|COHORT 1|Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
2893629|NCT03293784|Other|COHORT 2|Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
2893630|NCT03293771||Stage 1 Focus Groups|The focus groups will involve transgender women who have completed gender confirmation surgery who volunteer to discuss their postoperative experience regarding bladder function, genital complaints, and sexual function.
2893631|NCT03293771||Stage 2 Questionnaire Groups|Stage 2 participants will be asked to complete a questionnaire packet after surgery followed by a second questionnaire completion 2 weeks later. Participants' operative notes and postoperative visit records will be reviewed.
2893632|NCT03293745|Active Comparator|Face to Face CBT-I (F2F)|Participants in the F2F arm will receive a standard 6-session course of Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered in-person, one-on-one with a qualified and experienced therapist.
2893633|NCT03293745|Experimental|Telemedicine CBT-I (TM)|Participants in the F2F arm will receive a standard 6-session course of Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via the American Academy of Sleep Medicine (AASM) Sleep Telemedicine system. This telemedicine system provides an online videoconference platform in which a qualified and experienced therapist will deliver CBT-I to participants who will call in to the video therapy sessions with their provider from their homes using a webcam. All aspects of the treatment will remain identical to standard CBT-I delivered face-to-face, as described above, with the exception that the telemedicine technology will be used to deliver the treatment via video conference.
2893634|NCT03293732|Active Comparator|HA antigen only|All subjects in this group received 2 doses of 22.2 μg HA antigens
2893635|NCT03293732|Experimental|7.5 μg of DCB07010|All subjects in this group received 7.5 μg of DCB07010 in 22.2 μg HA antigens twice.
2893636|NCT03293732|Experimental|15 μg of DCB07010|All subjects in this group received 15 μg of DCB07010 in 22.2 μg HA antigens twice.
2893637|NCT03293732|Experimental|30 μg of DCB07010|All subjects in this group received 30 μg of DCB07010 in 22.2 μg HA antigens twice.
2893638|NCT03293732|Experimental|45 μg of DCB07010|All subjects in this group received 45 μg of DCB07010 in 22.2 μg HA antigens twice.
2893639|NCT03293719||Ceramic|Patients receiving BPK-S Integration UC implant made from BIOLOX delta ceramic
2893640|NCT03293719||CoCr|Patients receiving BPK-S Integration UC implant made from CoCr (metal)
2893641|NCT03293706|Active Comparator|CHO Control 1 Glucose|25 g glucose
2893642|NCT03293706|Active Comparator|CHO Control 2 Glucose|25 g glucose
2893643|NCT03293706|Experimental|CHO Experimental 1 Slowly Digested|25 g slowly-digested carbohydrate blend
2893644|NCT03293706|Experimental|CHO Experimental 2 Digestion Resistant|25 g digestion-resistant carbohydrate blend
2893645|NCT03293706|Experimental|CHO Experimental 3 Low Sugar|25 g low sugar carbohydrate blend
2893646|NCT03293706|Experimental|CHO Experimental 4 Maltodextrin|25 g maltodextrin
2893647|NCT03293693|Experimental|Test meal 1|Test meal with 0.5 g beta-glucan
2893648|NCT03293693|Experimental|Test meal 2|Test meal with 3.5 g beta-glucan
2893649|NCT03293693|Experimental|Test meal 3|Test meal with 8 g beta-glucan
2893650|NCT03293680|Experimental|Pembrolizumab Arm|1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks
2893651|NCT03293667|Other|Exploratory arm|
2893652|NCT03293654|Experimental|MB02 (Bevacizumab Biosimilar)|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
2893653|NCT03293654|Active Comparator|US licenced Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
2893654|NCT03293654|Active Comparator|EU approved Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
2893655|NCT03293641|Experimental|Zinc Sulfate Tablet|Zinc Sulfate Tablet 10 mg, 3 times a week plus Standard of Care for 6 months
2893656|NCT03293641|Placebo Comparator|Control Arm|Standard of Care for 6 months
2893657|NCT03293628|Experimental|Conization With Vaginal Packing|Experimental Arm. Haemostasis at the end of the procedure using vaginal packing and Monsel's solution.
2893658|NCT03293628|Active Comparator|Conization Without Vaginal Packing|Haemostasis at the end of the procedure using only Monsel's solution.
2893659|NCT03293615|Experimental|Dermatomyositis (DM)|Patients with dermatomyositis according to ENMC criteria
2893660|NCT03293615|Active Comparator|Non-dermatomyositis inflammatory myopathies|Patients with other inflammatory myopathy than dermatomyositis according to ENMC criteria
2893661|NCT03293615|No Intervention|No myopathy|Patients without myopathy on muscle biopsy
2893662|NCT03293602|Experimental|F-MISO PET imaging|F-MISO PET imaging will be added to the preoperative staging explorations of a patient with high risk prostate cancer candidate to radical prostatectomy. Patient will be selected during multidisciplinary meeting and urology consultation of Bordeaux and Toulouse university hospitals. Functional MRI imaging should be available before surgery. If patient consent to participate in the study, F-MISO PET imaging will be planed before prostatectomy. Results of this exam will not be considered for patient therapeutic management.
2893663|NCT03293589||OR|patients treated with open revascularization
2893664|NCT03293589||EVT|patients treated with endovascular revascularization
2893665|NCT03293576|Experimental|Intervention|Volitional help sheet
2893666|NCT03293576|No Intervention|Control|Short Zimbardo's time perspective inventory (Orosz et al. 2017)
2893669|NCT03293537|Experimental|Patients with dementia|The subject will be informed of the procedure and their task before the sensors are attached. Electrodermal activity (EDA) and heart rate (HR) will be continuously monitored while the subject views the image sequence on a PC monitor. EDA will be measured using electrodes attached to the middle (D3) and ring finger (D4). Heart rate will be measured using an infrared pulseoximeter attached to one of the free digits of the hand. A pulseoximeter is a non-invasive sensor, using tissue absorption of infrared light to determine blood-oxygen saturation (SaO2). EDA and HR will be recorded concurrently using commercial software. Data analysis will involve both commercial and in-house software.
2893670|NCT03293524|Experimental|Treatment Arm 1|Subjects will be randomized to treatment arm 1 or treatment arm 2 in a 1:1 allocation. Subjects in treatment arm 1 will receive intravitreal GS010 in both eyes.
2893671|NCT03293524|Placebo Comparator|Treatment Arm 2|Subjects will be randomized to treatment arm 1 or treatment arm 2 in a 1:1 allocation. Subjects in treatment arm 2 will receive GS010 in one eye and placebo intravitreal injection in the other eye.
2893672|NCT03293511|Experimental|Order of administration: oxytocin - placebo|Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo nasal spray
2893673|NCT03293511|Experimental|Order of administration: placebo - oxytocin|Participants first received placebo nasal spray. After a washout period of 2 weeks, they then receive oxytocin (24 IU).
2893674|NCT03293498|Experimental|Group A|Low dose NanoFlu - Day 0; Fluzone HD - Day 21
2893675|NCT03293498|Experimental|Group B|High dose NanoFlu - Day 0; Fluzone HD - Day 21
2893676|NCT03293498|Active Comparator|Group C|Fluzone HD - Day 0; Saline - Day 21
2893677|NCT03293485|Experimental|Imipenem+Cilastatin/Relebactam|Participants with cIAI or cUTI will receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours for 5 to 14 days
2893678|NCT03293472|Experimental|Ropivacaine|"Experimental: 0.5% ropivacaine (isobaric) 4.5 ml for the patients < 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml > 180 cm.~supplementary bolus doses of ropivacaine as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period"
2893679|NCT03293472|Active Comparator|Bupivacaine|"0.5% v Bupivacaine mg (isobaric) loading dose of 0.5% bupivacaine, 3.0 ml for the patients < 160 cm tall, 3.3 ml for 161-170 cm tall, 3.6 ml for 171-180 cm tall, and 4.0 ml > 180 cm.~and supplementary bupivacaine bolus dose as required, followed by 0,12% bupivacaine 1 ml/h for the postoperative period"
2893680|NCT03293459|Experimental|Balloon Retrograde Transvenous Obliteration (BRTO)+SMT|
2893681|NCT03293459|Active Comparator|Standard Medical Treatment (SMT)|
2893682|NCT03293446|Experimental|Patients with chronic kidney disease|
2893683|NCT03293446|Active Comparator|Healthy controls|
2893684|NCT03293433||Patient with lung cancer|Patient with pulmonary nodule showed in scanner (defined as a rounded picture higher than 5 mm and less than 30 mm in the lung parenchyma) presenting at one of the 3 participant services and meeting the inclusion criteria and exclusion. A blood punction will be performed in order to extract micro RNA.
2893685|NCT03293407||BAYQ6256_Ventavis|Patients with pulmonary hypertension who agree to be treated with Ventavis (Iloprost) at the discretion of physician
2893686|NCT03293394|Experimental|Real tDCS|10 days anodal bilateral motor cortex and cathodal spinal tDCS
2893687|NCT03293394|Placebo Comparator|Sham tDCS|10 days sham bilateral motor cortex and sham spinal tDCS
2893688|NCT03293368|Experimental|Platelet rich plasma|0.5 ml of autologous platelet rich plasma prepared using a double spin technique described by Mostafa et al., 2013 will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.
2893689|NCT03293368|Active Comparator|Croticosteroids|0.5 ml of triamcinolone acetonide 40 mg will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.
2893690|NCT03293355|No Intervention|Control|Standard of care
2893691|NCT03293355|Experimental|Intervention|"The VPN intervention has 2 in-person sessions:~1) Providing training on service integration and team building for CHW and tools for them to network more effectively with OPC and MMT treatment providers as well as reach out to their patients; and 2) Learning to use effective communication tools such as motivational ruler and decision balance sheet to work more effectively with their patients and use Facebook group to facilitate collaboration among providers and e-chat for patient engagements. Sessions will occur once a week for two weeks, with each session featuring a different set of themes and relevant activities."
2893692|NCT03293342|Experimental|D CBT|Dentist administered cognitive behaviioral treatment
2893693|NCT03293342|Active Comparator|Control|Treatment as usual
2893694|NCT03293329|Experimental|Diaphragm manual therapy|3 diaphragm stretching techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position. 20 people are recruited in order to the inclusion criteria for the study. They have rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
2893695|NCT03293329|Experimental|Diaphragm hipopressive exercise|Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures. 20 people are recruited in order to the inclusion criteria for the study. They have rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
2893696|NCT03293329|Active Comparator|Shoulder myofascial trigger points treatment|A ischemic compression technique in infraespinatus and supraespinatus myofascial trigger points performed by a physical therapist is employed in this group. 20 people are recruited in order to the inclusion criteria for the study. They had rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
2893697|NCT03293316|Sham Comparator|Sham Transcranial Random Noise Stimulation|The sham tRNS condition involves 30 seconds of 1.5 mA tRNS, with a ramping period of 30 seconds at the onset and offset. This procedure ensures that, in both the Active and Sham conditions, participants experience the sensations associated with the onset of transcranial electrical stimulation (e.g., tingling sensation)
2893698|NCT03293316|Experimental|1mA Transcranial Random Noise Stimulation|The 1mA tRNS condition consists of 1 mA peak-to-peak (-.5 mA to .5 mA) high frequency noise (100-500 Hz), with amplitude values that are normally distributed and have a mean of zero. The stimulation is delivered for 20 minutes, with a ramping period of 30 seconds at the onset and offset.
2893737|NCT03293069|Placebo Comparator|Placebo|Half of participants will receive the placebo Twice-daily oral placebo taken over 12 months
2894942|NCT03284450|Active Comparator|Sport specific repeated sprints (SSRS)|
2893699|NCT03293316|Experimental|2mA Transcranial Random Noise Stimulation|The only factor that varies for the 2mA tRNS condition is that the high frequency noise has a peak-to-peak of -1 mA to 1mA as opposed to -.5 mA to .5 mA. Again, the stimulation is delivered for 20 minutes, with a ramping period of 30 seconds at the onset and offset.
2893700|NCT03293303|Experimental|Stay Active at Home|One group of homecare professionals receives a training programme. In this training they learn to motivate their clients to be more active in daily and physical activities.
2893701|NCT03293303|No Intervention|Usual care|Second group of homecare professionals will get no training and their clients will receive usual homecare.
2893702|NCT03293290|Experimental|PrEP|For participants who are eligible for PrEP and willing to participate, subjects on PrEP will be followed for 1 year with quarterly assessments.
2893703|NCT03293277|Experimental|A1|20µg Dexmedetomidine or Placebo is administered intranasally on Day 1, and 20µg Dexmedetomidine or Placebo is administered intravenousally on Day 8
2893704|NCT03293277|Experimental|A2|20µg Dexmedetomidine or Placebo is administered intravenousally on Day 1, and 20µg Dexmedetomidine or Placebo is administered intranasally on Day 8
2893705|NCT03293277|Experimental|B1|40µg Dexmedetomidine or Placebo is administered intranasally on Day 1, and 40µg Dexmedetomidine or Placebo is administered intravenousally on Day 8
2893706|NCT03293277|Experimental|B2|40µg Dexmedetomidine or Placebo is administered intravenousally on Day 1, and 40µg Dexmedetomidine or Placebo is administered intranasally on Day 8
2893707|NCT03293277|Experimental|C|80µg Dexmedetomidine or Placebo is administered intranasally on Day 1
2893708|NCT03293264|Experimental|Exercise training group|The intervention group will be encouraged to perform 150 min of exercise training per week for 6 months. Subjects will be provided with individual feedback and exercise Training prescriptions. After month 6 subjects will be randomized to three different groups for follow-up observation.
2893709|NCT03293264|No Intervention|Waiting-control group|The control group will be provided with general informations on a healthy lifestyle. After 6 months wait-list-control months subjects will receive the guided exercise training intervention for 6 months.
2893710|NCT03293251||uveitic/ POAG|Outcomes, success rates, complications of trabeculectomy with MMC in Uveitic glaucoma
2893711|NCT03293251||POAG|Outcomes, success rates, complications of trabeculectomy with MMC and I stent in this groups
2893712|NCT03293238|Active Comparator|Joint Line Ultrasound|Patients assigned to this group receive a standard medial or lateral joint line injection of Euflexxa aided by ultrasound guidance while sitting up.
2893713|NCT03293238|Sham Comparator|Joint Line Landmark|Patients assigned to this group receive a standard medial or lateral joint line injection of Euflexxa without ultrasound guidance while sitting up.
2893714|NCT03293238|Active Comparator|Suprapatellar Ultrasound Guided|Patients assigned to this group receive an injection of Euflexxa while lying down into the suprapatellar pouch aided by ultrasound guidance.
2893715|NCT03293238|Sham Comparator|Suprapatellar Landmark|Patients assigned to this group receive an injection of Euflexxa while lying down into the supratpatellar pouch without ultrasound guidance.
2893716|NCT03293225||add H2RA|Add antihistamines to standard drug therapy
2893717|NCT03293225||change ns-H1RA|Change to ns-H1RA in standard medication
2893718|NCT03293225||ns-H1RA(3-4 tabs)|Standard treatment with ns-H1RA 4X dose
2893719|NCT03293225||ns-H1RA(3-4kinds)|Use of NS 4 kinds for standard treatment
2893720|NCT03293199|Active Comparator|Chest tube drainage|This group will undergo chest tube drainage as an intervention for spontaneous pneumothorax treatment.
2893721|NCT03293199|Active Comparator|Needle aspiration|This group will undergo repetitive needle aspiration as an intervention for spontaneous pneumothorax treatment.
2893722|NCT03293186|Experimental|Use MEDICLORE|use mediclore at the end of surgery
2893723|NCT03293186|No Intervention|No antiadhesive product|use no antiadhesive product at the end of surgery
2893724|NCT03293173|Experimental|Group A|Biologically low risk group, R-CHOEP-14
2893725|NCT03293173|Experimental|Group B|Biologically high risk group, DA-EPOCH-R
2893726|NCT03293160||Treatment group|The set of patients in the sample who are offered enrollment in care management services.
2893727|NCT03293160||Control group|The set of patients in the sample who are not initially offered enrollment in care management services (will be offered enrollment after six months).
2893728|NCT03293147|Experimental|Arm A|Intervention group: Non-adherent hypertensive patients randomised in Arm A will receive standard clinical care plus HPLC-MS/MS-guided intervention.
2893729|NCT03293147|Active Comparator|Arm B|Control group: Non-adherent hypertensive patients randomised in Arm B will receive clinical standard care.
2893730|NCT03293121|Experimental|Strength and Coordination Training|The strength and coordination group will perform a progression of exercises utilizing body weight and resistance bands as resistance. Exercises include squats, lunges, jumps etc. typical of a normal strength training program.
2893731|NCT03293121|Active Comparator|Walking|The walking group will be instructed to walk 3x/week, progressing from 30 to 45 min over 8 weeks.
2893732|NCT03293108|Experimental|AryoGen Pharmed Denosumab|"Dyenix (Denosumab Prefilled Syringe produced by AryoGen Pharmed) 60 mg/1 ml in a prefilled syringe.~Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12. Along with, all women will receive daily supplements containing at least 1000 mg of elemental calcium (divided into two doses) and at least 400 IU vitamin D daily during 18 months of the study."
2893733|NCT03293108|Active Comparator|Amgen Denosumab|"Prolia® (Denosumab Prefilled Syringe produced by Amgen) 60 mg/1 ml in a prefilled syringe.~Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12. Along with, all women will receive daily supplements containing at least 1000 mg of elemental calcium (divided into two doses) and at least 400 IU vitamin D daily during 18 months of the study."
2893734|NCT03293095||Acute musculoskeletal pathology patients|Musculoskeletal pathology patients that they will perform functional tasks measuring with motion sensors and motion capture.
2893735|NCT03293095||Match control|Healthy people of the same age as the acute musculoskeletal pathology subjects. They will perform functional tasks measuring with motion sensors and motion capture.
2893736|NCT03293069|Experimental|Deferiprone|Half of participants will receive twice-daily oral deferiprone taken over 12 months.
2932871|NCT03020771|Placebo Comparator|5 mcg IM control|0.9% NaCl Solution
2893738|NCT03293056|Experimental|High-intensity Interval Hydrogynmastics|High-intensity Interval training Hydrogynmastics, 2x/week, for 3 months.
2893739|NCT03293056|Active Comparator|Hydrogynmastics Continuous Moderate|Hydrogynmastics Continuous Moderate training (HCM), 2x/week, for 3 months.
2893740|NCT03293043|Experimental|Experimental Group|After initial screening, appropriately obtained informed consent and confirmation of eligibility at time of transplant, those recipients (a total of 12 subjects) who agree to continue as participants will receive reconditioned marginal lungs should the lungs on the device meet acceptable criteria to proceed with clinical transplantation.
2893741|NCT03293030|Experimental|Dupilumab treatment|15 subjects will receive dupilumab for a treatment period of 52 weeks (i.e. last injection on week 50). All subjects will undergo skin biopsies for molecular profiling.
2893742|NCT03293017|Experimental|Baclofen 30 mg/day|baclofen 30 mg/day
2893743|NCT03293017|Experimental|Baclofen 60 mg/day|
2893744|NCT03293017|Placebo Comparator|Placebo|
2893745|NCT03293004|Experimental|Hydrolyzed collagen|First, we aim to determine the optimal amount of hydrolyzed collagen with a constant dose of vitamin C in humans to increase a marker of collagen synthesis (PINP). In a randomized, double-blinded, crossover design subjects consume a nutritional supplement with varying doses of hydrolyzed collagen (control (0 g), 5 10, 20 and 30 g hydrolyzed collagen) with a constant dose of vitamin C (50 mg). Each intervention will be separated by a 6-day wash out. Subjects will be asked to consume the supplement 1 hour before 6-min of jump rope exercise. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours and 24 hours blood samples will be collected. Blood samples will be used for PINP analysis.
2893746|NCT03293004|Experimental|Vitamin C|Second, we aim to determine the optimal amount of vitamin C with the determined optimal dose of hydrolyzed collagen in humans to increase a marker of collagen synthesis (PINP). In a randomized, double-blinded, crossover design subjects consume a nutritional supplement with varying doses of vitamin C (0 (control), 50, 250 and 500 mg) with an optimized dose of hydrolyzed collagen as determined from the first arm. Each intervention will be separated by a 6-day wash out. Subjects will be asked to consume the supplement 1 hour before 6-min of jump rope exercise. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours and 24 hours blood samples will be collected. Blood samples will be used for PINP analysis.
2893747|NCT03293004|Experimental|Optimized Collagen and Vitamin C supplement|The findings from the first 2 arms of the study will be used to inform a training-based study aimed to determine whether exercise together with this optimal dose of hydrolyzed collagen and vitamin C is sufficient to improve rate of force development (RFD) and performance. A gummy food will be developed with the optimized dose of hydrolyzed collagen and vitamin C as well as a placebo. In a randomized, double-blinded, parallel design with subjects undertake a 3 week exercise protocol. The supplement will be ingested 1 hour prior to each exercise session (Monday/Wednesday/Friday). Exercise testing to assess rate of force development (RFD) will take place at the end of each week (Fridays) and these outcomes will be the basis for determining the effects of the nutrition intervention on performance.
2893748|NCT03293004|Placebo Comparator|Gummy Placebo|A gummy food will be developed with the optimized dose of hydrolyzed collagen and vitamin C as well as a placebo. In a randomized, double-blinded, parallel design with subjects undertake a 3 week exercise protocol. The supplement or placebo will be ingested 1 hour prior to each exercise session (Monday/Wednesday/Friday). Exercise testing to assess rate of force development (RFD) will take place at the end of each week (Fridays) and these outcomes will be the basis for determining the effects of the nutrition intervention on performance.
2893749|NCT03292978|Experimental|probiotics intervention|"The probiotic is provided in sachets as a 2g powder dried with corn starch.~The powder is orally taken once daily for 4 weeks.~The powder contains totally 11 log 10 colony forming units(CFU) of probiotics.~The types of probiotics are Lactobacillus.rhamnosus, Lactobacillus.acidophilus, Bifidobacteria.animalis and Bifidobacteria.longum."
2893750|NCT03292978|Placebo Comparator|non-probiotic control|The placebo is corn starch alone provided and the shape, color, weight,flavor and taste are same with the powder of probiotics intervention.
2893751|NCT03292965|Active Comparator|Neostigmine|"At the end of surgery, administrating neostigmine to participants according to the protocol below:~when train-of-four (TOF) 2-3, administrating neostigmine 50mcg/kg when TOF 4 with fade, administrating neostigmine 40mcg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg"
2893752|NCT03292965|Active Comparator|Sugammadex|"At the end of surgery, administrating sugammadex to participants according to the protocol below:~when TOF=0 and post-tetanic count (PTC)=1 or more, administrating sugammadex 4mg/kg when TOF=1 or more, administrating sugammadex 2mg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg"
2893753|NCT03292952|Experimental|Active Treatment|KP415 oral capsule 20, 30 or 40 mg
2893754|NCT03292952|Placebo Comparator|Placebo Treatment|Placebo oral capsule
2893755|NCT03292939|Other|vaginal progestrone group|cohort of patients who received 400mg vaginal progestrone .
2893756|NCT03292926|Active Comparator|Adductor Canal Block (ACB)|The adductor canal block will be ultrasound-guided sonosite. The anesthesiologist will administer 15 cc bupivacaine 0.5% with 2 mg preservative-free dexamethasone with a 22 gauge (G)/4 inch Chiba needle to the mid-thigh of the surgical limb while subject lays in the supine position post IV sedation.
2893757|NCT03292926|Active Comparator|Adductor Canal Block & IPACK (ACB/IPACK)|"The adductor canal block will be ultrasound-guided. The anesthesiologist will administer 15 cc bupivacaine 0.5% with 2 mg preservative-free dexamethasone with a 22G/4 inch Chiba needle to the mid-thigh of the surgical limb while subject lays in the supine position post IV sedation.~The IPACK will be ultrasound-guided with c60 sonosite probe (5-2Hz). While laying in the prone or supine, frog-leg position the IPACK will be administered using a 22G/4inch Chiba needle. The anesthesiologist will identify the popliteal artery at the popliteal crease and move cephalad just beyond the femoral condyles at the confluence with the femur. Then the anesthesiologist will identify the space between the femur and the popliteal artery and moving from medial to lateral place the needle in between the popliteal artery and femur with the tip ending 2-3 cm lateral to the artery and inject 25 cc bupivacaine 0.25% with 2 mg preservative-free dexamethasone."
2893758|NCT03292913|Experimental|Intervention Group|Receives the Positive Health Check intervention plus standard of care
2893759|NCT03292913|Other|Control Group|Receives standard of care
2893875|NCT03292094||White men|284 young healthy men were included (clinic normotensive, non-HIV)
2893760|NCT03292887||Elaprase Treated|Participants with Hunters Syndrome received or receiving treatment with Elaprase as prescribed by their physician following locally approved prescribing information.
2893761|NCT03292887||Elaprase Non-Treated|Participants received no treatment for Hunters Syndrome.
2893762|NCT03292874|Other|Paired imaging|Single arm, paired imaging of high resolution MRI (hrMRI) and stand MRI (sMRI)
2893763|NCT03292861|Active Comparator|Thymoglobulin®|"Thymoglobulin® (Genzyme) [rabbit anti-thymocyte globulin (ATG)] is a purified pasteurized, gamma immune globulin, obtained by immunization of rabbits with human thymocytes. This immunosuppressive product contains polyclonal cytotoxic antibodies directed against antigens expressed on human T-lymphocytes. Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 6 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4 hours.~In addition, there will be maintenance doses of mycophenolate mofetil, tacrolimus, sirolimus, and cumulative dose of corticosteroids at 12 months post-transplantation"
2893764|NCT03292861|No Intervention|No induction therapy|Patients qualifying for the study will be randomized before the transplantation surgery in a 1:1 ratio to either Thymoglobulin® or no treatment.
2893765|NCT03292848|Experimental|10 to <13 Years of Age|Two doses will be administered with a washout period of 14 days between the first dose of 1.5 mg the second dose of 3 mg.
2893766|NCT03292848|Experimental|6 to <10 Years of Age|Two doses will be administered with a washout period of 14 days between the first dose of 0.75 mg and the second dose of 1.5 mg.
2893767|NCT03292822|Experimental|Licochalcone A|Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties.
2893768|NCT03292822|Active Comparator|Paclitaxel|chemotherapeutic drug
2893769|NCT03292809|Experimental|CyclASol Ophthalmic Solution|Cylclosporine A solution in vehicle
2893770|NCT03292809|Placebo Comparator|Vehicle Ophthalmic Solution|Vehicle only
2893771|NCT03292796|Other|Stop prostaglandin eye drops post op|Stop prostaglandin eye drops post operatively. Prostaglandins either stopped or continued after cataract surgery. Latanoprost Travaprost Bimatoprost Tafluprost
2893772|NCT03292796|Other|Continue prostaglandin eye drops post op|Continue prostaglandin eye drops post operatively Prostaglandins either stopped or continued after cataract surgery. Latanoprost Travaprost Bimatoprost Tafluprost
2893773|NCT03292783|Experimental|NOV150101 (ABL001)|
2893774|NCT03292770|No Intervention|Control Group|Embryo transfer will be performed as per clinic's routine protocol, where cervical mucus is gently removed with a cotton swab. No manipulation of the cervical canal is executed.
2893775|NCT03292770|Experimental|Flushing Group|"A catheter will be used to perform a flushing of the cervical canal with culture media. The Flushing Catheter has a flared proximal end that is designed to affix to a standard Luer slip syringe and a pre-curved distal closed end, with a biseled opening on the side, 2mm from the tip, in which liquid flushes towards the outside of the cervical canal.~Device: Cook Flushing Catheter J-IUIC-352200 (3.5fr 20cm flushing catheter with positioner closed end) (CEE approval)."
2893776|NCT03292757|Experimental|Mesenteric ICG|Indocyanine green injected into the small bowel mesentery during oesophagectomy.
2893777|NCT03292757|Experimental|Feeding jejunostomy ICG (cream)|Indocyanine green mixed with cream infiltrated into the feeding jejunostomy.
2893778|NCT03292744|Experimental|Alfacalcidol|Alfacalcidol 0,5 mcg once daily for 90 days
2893779|NCT03292744|Placebo Comparator|Placebo|Amylum same capsule form, weight and colour with treatment arm
2893780|NCT03292731|Active Comparator|hydroxyprogesterone caproate 250 mg|Pregnant subject will receive 250mg of hydroxyprogesterone caproate Intramuscular injection weekly from 16 0/7-36 6/7 weeks or delivery which ever occurs first.
2893781|NCT03292731|Experimental|hydroxyprogesterone caproate 500 mg|Pregnant subject will receive 500mg of hydroxyprogesterone caproate Intramuscular injection weekly from 16 0/7-36 6/7 weeks or delivery which ever occurs first.
2893782|NCT03292718|Experimental|use of MyCyFAPP|use of MyCyFAPP during 6 months
2893783|NCT03292705|Experimental|PEP+CCI|"PEP: The PEP system is built on a picture-based touch-screen interface on tablet computers. PEP allows users to explore and participate in entertainment, educational, spiritual, and other recreational activities and content personalized according to their interests and preferences. It provides easy access to the Internet and communication applications, and has hundreds of modules spanning music, travel, trivia, games, and religious and inspirational domains.~CCI. VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention.~Intervention format and fidelity The PEP+CCI group will practice PEP for the first 4 weeks and VSOP for the following 6 weeks."
2893784|NCT03292705|Active Comparator|control+CCI|For the control + CCI group, an inert control condition, consisting of nothing outside of the ordinary, will be implemented for the first 4 weeks, and CCI for 6 more weeks.
2893785|NCT03292692|Experimental|OurRelationship|Online Intervention
2893786|NCT03292692|No Intervention|Waitlist Control|2 month waiting period before couples can receive intervention
2893787|NCT03292679|No Intervention|Control|Subjects that are randomized into Arm A will have their fractures repaired in the usual fashion i.e. using plates that are bent by free hand.
2893788|NCT03292679|Experimental|3D template|Subjects that are randomized into Arm B will have custom models of relevant portions of their facial skeleton printed and used as templates for bending and shaping plates for stabilizing the fracture(s).
2893789|NCT03292666||Extended anticoagulation|Patients with acute VTE treated with oral anticoagulants for > 3 months
2893790|NCT03292666||No extended anticoagulation|Patients with acute VTE treated with oral anticoagulants for no longer than 3 months
2893791|NCT03292653|Experimental|Sotagliflozin Cohort 1|Cohort 1 will receive sotagliflozin (SAR439954) dose 1 administered as one dose 1 tablet plus one placebo sotagliflozin tablet once daily (OD) prior to the first meal of the day for 14 days.
2893792|NCT03292653|Experimental|Sotagliflozin Cohort 2|Cohort 2 will receive sotagliflozin (SAR439954) dose 2 administered as two dose 1 tablets OD prior to the first meal of the day for 14 days.
2932872|NCT03020771|Placebo Comparator|5 mcg SC control|0.9% NaCl Solution
2893793|NCT03292653|Experimental|Sotagliflozin Cohort 3|Cohort 3 will be allocated to sotagliflozin (SAR439954) dose 1 or dose 2 administered as two tablets OD prior to the first meal of the day for 14 days.
2893794|NCT03292653|Placebo Comparator|Placebo|Placebo sotagliflozin administered as two placebo tablets (identical to sotagliflozin dose 1 tablets in appearance) OD prior to the first meal of the day for 14 days.
2893795|NCT03292640|Experimental|DFD-03 Lotion (0.1% tazarotene)|
2893796|NCT03292640|Placebo Comparator|DFD-03 Vehicle (0% tazarotene)|
2893797|NCT03292627||mid age|mid age: 50-70 years old
2893798|NCT03292627||old age|old age: age older than 70 years old
2893799|NCT03292614||Multifocal intraocular lens implantation|Patients who have undergone a cataract surgery with implantation of a multifocal intraocular lens LS313 MF30, Oculentis Berlin, will be invited for Measurements of the postoperative refraction
2893800|NCT03292601|Active Comparator|Feedback Group|Patients in the Feedback Group will receive their brace-wear (Cinch Smart Strap) compliance data via the Wellinks phone application (Cinch Mobile App). Patients will also receive their brace-wear compliance information at their standard of care follow-up visits.
2893801|NCT03292601|Sham Comparator|No Feedback Group|Patients in the Feedback Group will not receive brace-wear (Cinch Smart Strap) compliance data via the Wellinks phone application. Patients will receive their brace-wear compliance information at their standard of care follow-up visits.
2893802|NCT03292588|Experimental|Mepolizumab|Intervention: Mepolizumab plus guidelines-based standard of care asthma treatment.
2893803|NCT03292588|Placebo Comparator|Placebo|Intervention: Placebo for mepolizumab plus guidelines-based standard of care asthma treatment.
2893804|NCT03292575||Stroke related to CAAF|
2893805|NCT03292562|Active Comparator|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria (described below) pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1L flow, 30% FiO2).
2893806|NCT03292562|Active Comparator|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1L flow, 30% FiO2).
2893807|NCT03292549||Patients|Robotic partial surgery
2893808|NCT03292536|Experimental|Merestinib, all patients|
2893809|NCT03292523||Hyperventilation syndrome|
2893810|NCT03292510|Experimental|GO-OUT Group|Participants attend the walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes.
2893811|NCT03292510|Active Comparator|Workshop Group|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
2893812|NCT03292497|Experimental|Treatment algorithm|"Mitral valve will be replaced if posterior leaflet tethering angle >=25 degrees.~Mitral valve will be repaired if posterior leaflet tethering angle <25 degrees"
2893813|NCT03292497|Active Comparator|No treatment algorithm|Mitral valve will be repaired or replaced at surgeon's discretion.
2893814|NCT03292484|Other|Treatment arm description|Subjects will be assigned to one of three treatment pathways when first enrolled into ARC008, which is dependent on the treatment received (AR101 or placebo) during the parent study and their tolerance of this treatment regimen (e.g., daily or non-daily schedule).
2893815|NCT03292471|Experimental|Inhibitory only|Inhibitory 1Hz rTMS will be applied continuously for 1200 pulses (20 minutes) 5 days per week across 2 weeks (10 sessions total).
2893816|NCT03292471|Experimental|Excitatory primed|The inhibitory sequence described above will be preceded for each session by priming stimulation which will consist of intermittent 6-Hz rTMS applied in 5 second trains with 25 second intervals between trains for a total 600 pulses (10 minutes).
2893817|NCT03292458|Experimental|Clinical response to sodium oxybate|In contrast to placebo but similar to alcohol, sodium oxybate is expected to be most effective in reducing voice symptoms in alcohol-responsive SD and VT.
2893818|NCT03292458|Experimental|Primary markers of clinical response|The clinical outcome is expected to be determined by selective modulation of functional abnormalities in the brain regions controlling speech sensorimotor processing and integration in association with underlying gene variants.
2893819|NCT03292445|Experimental|Immune tolerance after kidney transplant|Immune tolerance after kidney transplant will be induced by transfusion of enriched donor blood stem cells and T cells to initiate blood cell mixed chimerism in patients conditioned with total lymphoid irradiation and rabbit anti-thymocyte globulin after kidney transplant. Patients will receive corticosteroids for 14 weeks with gradual dose reduction. They will also receive 12 months of mycophenolate mofetil and 18 months of tacrolimus with dose tapering beginning 9 months post-transplant and continuing as long as mixed chimerism is maintained and there is no evidence of graft versus host disease and no kidney rejection evident. Patients losing chimerism will continue on low dose immunosuppressive drug doses unless additional kidney rejection therapy is needed.
2893820|NCT03292432|Active Comparator|Standard of Care|Standard of Care for adherence support at Site
2893821|NCT03292432|Experimental|TERA Intervention|Triggered, escalating, real-time adherence (TERA) intervention for 12 weeks.
2893822|NCT03292406|Experimental|Group 1|Placebo followed by CD11301 (0.03%) Topical Gel
2893823|NCT03292406|Experimental|Group 2|CD11301 (0.03%) Topical Gel
2893824|NCT03292406|Experimental|Group 3|CD11301 (0.06%) Topical Gel
2893876|NCT03292094||Black women|312 young healthy women were included (clinic normotensive, non-HIV)
2893877|NCT03292094||White women|312 young healthy women were included (clinic normotensive, non-HIV)
2893825|NCT03292393|Active Comparator|Group Contingency Management|During the intervention phase, the Group Contingency Management (GCM) arm will continue to take their hypertensive medication for the four-month period and will receive a randomized phone call once a month to obtain a pill count and a home blood pressure monitoring reading using the HBPM. Participants in the GCM arm will receive a payment after each phone call, dependent on their medication adherence assessment. The GCM arm will also receive an additional payment based on their group's medication adherence.The intervention administered is the Financial Reward and Social Norms.
2893826|NCT03292393|Active Comparator|Individual Contingency Management|During the intervention phase, those in the Individual Contingency Management (ICM) arm will also continue to take their hypertensive medication for the four-month period but will receive a payment after each phone call, dependent on their medication adherence assessment.The intervention administered is the Financial Reward.
2893827|NCT03292393|Placebo Comparator|Control Arm|During the intervention phase, those in the control arm will be asked to continue to take their hypertensive medication for the four-month period and will receive a randomized phone call once a month to obtain a pill count and a blood pressure reading using the HBPM. Those in the control arm will only be paid for their participation in the study regardless of medication adherence assessment.
2893828|NCT03292380||Caffeine intake recall|All subjects completed 24-hour urine collection, and subsequently completed the 24-hour Caffeine Intake Recall (CIR-24) developed by the research group and the Caffeinated Beverage Frequency Questionnaire (CBQ) developed by the Fred Hutchison Cancer Centre. The order of completing the CIR-24 and the CBQ was alternated each day of data collection.
2893829|NCT03292367||ldTRA|Patients who are planned to perform coronary angiography will be enrolled via left distal radial artery
2893830|NCT03292354|Active Comparator|Body Weight (BW)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on body weight.
2893831|NCT03292354|Active Comparator|Cardiac output (CO)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on cardiac output.
2893832|NCT03292354|Active Comparator|Lean Body weight (LBW)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on Lean Body Weight.
2893833|NCT03292354|No Intervention|Control group|Patients in this group will be included retrospectively and have received the standard CM injection protocol previously used in our department.
2893834|NCT03292341|Experimental|Patients|"Patients diagnosed with larynx cancer and ex-larynx cancer patients:~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~Questionnaires"
2893835|NCT03292341|Experimental|Clinicians|"2.Clinicians Radiotherapy-oncologists, ENT(Ear-Nose-Throat)-specialists, General practitioners, Nurses~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~Questionnaires"
2893836|NCT03292341|Experimental|Other involved organizations|Patient Organizations and insurance companies Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid
2893837|NCT03292328|Experimental|Yoga Arm|After randomization, participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.
2893838|NCT03292328|Active Comparator|Wait List Control Arm (WLC)|Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these participants will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
2893839|NCT03292315|Experimental|Exenatide 2 MG Injection [Bydureon]|20 subjects will be randomized to receive once weekly injection of Exenatide (Bydureon 2mg) for 26 weeks.
2893840|NCT03292315|Other|No Intervention|10 subjects will be randomized to receive no intervention for 26 weeks.
2893841|NCT03292302|Placebo Comparator|Placebo Comparator Arm|
2893842|NCT03292302|Active Comparator|Active treatment|ELX-02
2893843|NCT03292289|Experimental|Study process|Pre- and post-operative consultations. Stomatherapy consultation. Questionnaires
2893844|NCT03292276|Experimental|Amadeo training|All participants will receive 40 sessions of treatment (45-minute) for 8 consecutive weeks (5 days/week). The robotic exercises will be carried in passive modality (15 minutes), passive/plus (15 minutes), assisted modality (15 minutes).
2893845|NCT03292276|Active Comparator|occupational therapy|All participants will receive 40 sessions of treatment (45-minute) for 8 consecutive weeks (5 days/week). The control group will receive the same amount of training by physiotherapist skilled in occupational tharapy.
2893846|NCT03292263|Experimental|Mel+Nivo|Autologous Stem Cell Transplant Drug: Melphalan 140-200 mg/m^2, Nivolumab100 mg iv days -3, +17
2893847|NCT03292250|Experimental|Arm1: BYL719|Experimental: BYL719 BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
2893848|NCT03292250|Experimental|Arm2: Poziotinib|Experimental:Poziotinib Poziotinib is a pan-HER tyrosine kinase inhibitor.(oral class)
2893849|NCT03292250|Experimental|Arm3: Nintedanib|Nintedanib is a potent small molecule triple receptor tyrosine kinase inhibitor (PDGFR, FGFR 1-3,VEGFR 1-3 ,VEGFR- 2) is considered to be the crucial receptor involved in initiation of the formation as well as the maintenance of tumour vasculature.(oral class)
2893850|NCT03292250|Experimental|Arm4: Abemaciclib|Abemaciclib represents a selective and potent small molecule CDK4 and CDK6 dual inhibitor with broad antitumor activity in preclinical pharmacology models.(oral class)
2893878|NCT03292081|Experimental|OFDI-guided PCI|
2893879|NCT03292081|Active Comparator|IVUS-guided PCI|
2893931|NCT03291678|Active Comparator|classic laparoscopic orchoipexy|this group will subjected to classic laparoscopic orchiopexy by delivery of abdominal undescended testis to subdartos pouch of scrotum
2932873|NCT03020771|Active Comparator|10 mcg IM|
2893851|NCT03292250|Experimental|Arm5: Durvalumab,Tremelimumab|"Durvalumab is a human immunoglobulin (Ig) G1 kappa (IgG1κ) monoclonal antibody (mAb) that blocks the interaction of PD-L1 with PD-1 on T-cells and CD80 on immune cells and is engineered to reduce antibody-dependent cell-mediated cytotoxicity.(IV class)~Tremelimumab is specific for human CTLA-4; cluster of differentiation a cell surface receptor that is expressed primarily on activated T cells and acts to inhibit their activation.(IV class)"
2893852|NCT03292237|No Intervention|Standard Nutrition Arm|"In ICU:~After enrolment, patients allocated to the standard nutrition therapy (control) group will commence or continue nutrition via an enteral tube to a target rate according to unit protocol including the use of promotility agents and the placement of nasojejunal feeding tubes if required.~PN will only be used if the above methods have been attempted, or an absolute contraindication to EN develops.~Unless there is specific indication for a compounded PN solution, the PN used in the standard care group will be the same as used in the intervention arm.~After ICU:~Nutrition management will be as per usual site management at that hospital.~Nutrition intake amounts will be recorded 3 times per week using provided study documents and assessment tools."
2893853|NCT03292237|Experimental|Intensive Arm|"Intervention~In ICU:~Supplemental PN will be commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation~The need for the intervention will be based on the adequacy of nutrition provision from both PN and EN and assessed daily until ICU discharge~If there is an actual or anticipated interruption of EN for greater than 2 hours the PN must be run at 20 kcal/kg calculated body weight until EN is recommenced. After the interruption, EN should be recommenced as per local protocol.~After ICU:~An intensive nutrition intervention will be provided on the ward in the intervention group. This will include daily review from dedicated study dietitians and a clearly protocolized hierarchical management plan which reflects best practice clinical management."
2893854|NCT03292211|Experimental|early mobilization|early mobilization group will commence rehabilitation consisting of out-of-bed mobilization (including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.)
2893855|NCT03292211|Other|early standard intervention|early standard intervention included bed exercises including the joint range of motion exercise, bridge exercise, the straight leg raising exercise, stretching exercises, and the facilitation techniques in recent 5 days after stroke.
2893856|NCT03292198|Active Comparator|Compression Group|"Subjects in the Compression Group will wear 20-30 mmHg sleeves and gauntlets daily for a maximum of 4 weeks. L-dex will be performed at the end of each week. If the L-dex score has reversed back into normal range, intervention (garment wearing) will be discontinued and the subject will resume the surveillance schedule of screenings. If the L-dex score is still abnormal, garment wearing continues. If L-dex score is abnormal even at the end of the 4 weeks, the subject will be removed from the study and referred to standard lymphedema therapy.~An abnormal L-dex is defined by 7 or more units change compared to the subject's pre-surgical baseline."
2893857|NCT03292198|Experimental|Therapy Group|"Subjects in the Therapy Group will wear 20-30 mmHg sleeves and gauntlets daily and receive Manual Lymphatic Drainage 3x/week for a maximum of 4 weeks. L-dex will be performed at the end of each week. If the L-dex score has reversed back into normal range, intervention will be discontinued and the subject will resume the surveillance schedule of screenings. If the L-dex score is abnormal, intervention continues. If L-dex score is abnormal even at the end of the 4 weeks, the subject will be removed from the study and referred to standard lymphedema therapy.~An abnormal L-dex is defined by 7 or more units change compared to the subject's pre-surgical baseline."
2893858|NCT03292185|Experimental|IDeglira-IDeg-Liraglutide|Treatment sequence first Insulin Degludec/Liraglutide, then Insulin Degludec, then Liraglutide
2893859|NCT03292185|Experimental|IDeglira-Liraglutide-IDeg|Treatment sequence first Insulin Degludec/Liraglutide, then Liraglutide, then Insulin Degludec
2893860|NCT03292185|Experimental|IDeg-Liraglutide-IDeglira|Treatment sequence first Isulin Degludec, then Liraglutide, then Insulin Degludec/Liraglutide
2893861|NCT03292185|Experimental|IDeg-IDeglira-Liraglutide|Treatment sequence first Insulin Degludec, then Insulin Degludec/Liraglutide, then Liraglutide
2893862|NCT03292185|Experimental|Liraglutide-IDeg-IDeglira|Treatment sequence first Liraglutide, then Insulin Degludec, then Insulin Degludec/Liraglutide
2893863|NCT03292185|Experimental|Liraglutide-IDeglira-IDeg|Treatment sequence first Liraglutide, then Insulin Degludec/Liraglutide, then Insulin Degludec
2893864|NCT03292172|Experimental|Group 1 - Escalation Dose: RO6870810 + Atezolizumab|Participants will be administered escalating doses of RO6870810 (0.3 milligram per kilogram [mg/kg], 0.45 mg/kg, and 0.65 mg/kg) subcutaneously (SC) once daily (QD) along with fixed dose of atezolizumab 1200 mg intravenously (IV) on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
2893865|NCT03292172|Experimental|Group 2 - Sequential Dose: RO6870810 + Atezolizumab|Participants will be administered RO6870810 monotherapy (starting dose 0.30 mg/kg) during the first 14 days of 21-day Run-in period. Following the Run-in period, participants will continue to receive RO6870810 at the same dose in combination with fixed dose of atezolizumab 1200 mg IV every 3 weeks in 21-day cycles.
2893866|NCT03292172|Experimental|Group 3 - Expansion in TNBC Group: RO6870810 + Atezolizumab|Participants will be administered dose of RO6870810 established in Group 1 (either 0.3 mg/kg, 0.45 mg/kg, or 0.65 mg/kg) SC QD along with fixed dose of atezolizumab 1200 mg IV on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
2893867|NCT03292172|Experimental|Group 4 - Expansion in OC Group: RO6870810 + Atezolizumab|Participants will be administered dose of RO6870810 established in Group 1 (either 0.3 mg/kg, 0.45 mg/kg, or 0.65 mg/kg) SC QD along with fixed dose of atezolizumab 1200 mg IV on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
2893868|NCT03292159|Experimental|RAVANS|
2893869|NCT03292159|Sham Comparator|Sham stimulation|
2893870|NCT03292146|Experimental|Active Denosumab 60mg Injection|One time Denosumab 60mg injection at baseline study visit
2893871|NCT03292146|Placebo Comparator|Placebo|One time Placebo injection at baseline study visit
2893872|NCT03292133|Experimental|EGF816 + Gefitinib|"All patients will receive gefitinib orally once daily~EGF816 will be administered orally once daily~Participant will be requested to maintain a medication diary of each dose of medication"
2893873|NCT03292120|Experimental|patients with septic shock|
2893874|NCT03292094||Black men|294 young healthy men were included (clinic normotensive, non-HIV)
2893880|NCT03292068|Experimental|Acupuncture, acupressure|"Intervention with Pyonex-needles & Usual care; applied to the acupoints LI4 , LI11, PC6 and ST36 bilaterally before surgery. Pyonex needles are embedded in a 2 mm round plastic piece sitting on a round, skin friendly patch of about 8 mm in diameter. The patch can remain for seven days. The needle can be stimulated by gently touches the plastic bubble by the patch.~Intervention Acupressure & Usual care; a 'kulplåster (1.5 mm a ball on a small piece of adhesive tape) both ears before postoperative drug administration. Kulplåster can remain for ten days or until they fall off. Children and their parents will be asked to fill in a diary of when the needle is stimulated, for what reason and when the symptoms are alleviated. In the diary is also filled in on the kulplåster remains."
2893881|NCT03292068|Experimental|Timbal diet|"Timbal diet including ice cream & Usual care.The specially designed diet, originally made for patients suffering of dysphagia, named timbalkost will be used. The specially designed food/diet, timbalkost will be given as lunch and dinner. The consistency of timbalkost is smooth. It does not require more thorough processing of the mouth. As a snack, a protein-enriched ice cream, made with egg yolks and cream, will be made available. The food will be given to the child for 3-7 days depending on how quickly the child can return to normal food. A powder that jellify liquids to facilitate swallowing will also be used if and when needed. The children or their parents will be asked to fill in a food diary during one week after surgery."
2893882|NCT03292068|Other|Extended telephone counseling|Extended telephone counseling & Usual care : A nurse will contact the child, or the child´s parents, by telephone on day 1, 3, 5 and 10 for extended telephone counseling postoperatively (POD), to provide support and information. The child's well-being will be assessed, response given to queries and concerns, advice and explanations related to the problems expressed or identified, proper interventions will be promoted and reassurance provided. The nurse will fill in a protocol on what topics the counseling was about at each call and the child and/or parent a diary.
2893883|NCT03292042|Experimental|Experimental Group|"This group will carry out the lifestyle intervention (Physical health promotion program) during 6 months.~The group will attend a session per week."
2893884|NCT03292042|No Intervention|Control group|usual care
2893885|NCT03292029|Other|T50 Calcification Inhibition Test (CIT)|Measurement of T50 CIT and fetuin-A serum values
2893886|NCT03292016|Experimental|APL-130277, sublingual thin film|APL-130277, sublingual thin film, once daily
2893887|NCT03292016|Active Comparator|Subcutaneous APO-go|Subcutaneous APO-go, once daily
2893888|NCT03292016|Active Comparator|Subcutaneous APOKYN|Subcutaneous APOKYN, once daily
2893889|NCT03292003||Journey II BCS Total Knee System|Subjects having TKA with Journey II BCS Total Knee System
2893890|NCT03291990|Experimental|5 fraction radiotherapy with standard temozolomide|5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide
2893891|NCT03291977|Experimental|Fluorescein sodique FAURE|Fluorescein (Fluorescéine sodique FAURE) will be given intravenously during the induction of the anesthesia
2893892|NCT03291977|Active Comparator|White-light surgery|"In the control arm, the surgery will be performed under classical conditions (so-called  white-light  surgery)."
2893893|NCT03291951|Experimental|Resistance training group|Participants randomized to the resistance training (RT) group will receive an in-person and telephone-based intervention to promote home-based resistance training. The exercise intervention will begin within the first 4 weeks of adjuvant chemotherapy and continue exercise through the completion of post-operative chemotherapy. Participants will work with an exercise professional with expertise working with oncology patients.
2893894|NCT03291951|No Intervention|Usual care group|Participants randomized to the usual care (U) group will be instructed to refer to their physician regarding what forms of exercise are safe for them, given their medical history. The U group will be told to continue whatever exercise program they have been undertaking up to enrolling in the study, but not to increase exercise or begin weight-lifting over the period of study participation.
2893895|NCT03291938|Experimental|IACS-010759 - Dose Escalation Cohort|"IACS-010759 administered daily on Days 1-7 of Induction Phase in a 21-day schedule.~In the first cycle, IACS-010759 administered daily.~Beginning dose of IACS-010759 depends on when participant joins this study."
2893896|NCT03291938|Experimental|Breast Cancer - TNBC Expansion Cohort|"TNBC Expansion Cohort: Subjects with advanced TNBC with no available effective conventional treatment options.~IACS-010759 administered on Day 8 and Day 15 in cycle 1. Doses administered on Days 1, 8 and 15 for all subsequent cycles.~Beginning dose of IACS-010759 is maximum tolerated dose from Dose Escalation Cohort."
2893897|NCT03291938|Experimental|Pancreatic Cancer - PDAC Expansion Cohort|"PDAC Expansion Cohort: Participants with advanced PDAC with no available effective conventional treatment options.~IACS-010759 administered on Day 8 and Day 15 in cycle 1. Doses administered on Days 1, 8 and 15 for all subsequent cycles.~Beginning dose of IACS-010759 is maximum tolerated dose from Dose Escalation Cohort."
2893898|NCT03291938|Experimental|Biopsy Expansion Cohort|"Biopsy Expansion Cohort - Participants with tumors that can be safely biopsied on several occasions.~IACS-010759 administered on Day 8 and Day 15 in cycle 1. Doses administered on Days 1, 8 and 15 for all subsequent cycles.~Beginning dose of IACS-010759 is maximum tolerated dose from Dose Escalation Cohort."
2893899|NCT03291925|Experimental|Selective invasive angiography based on CT/CCTA imaging|Patients will undergo selective invasive angiography based on CT/CCTA imaging. Decision to procede with additional invasive CA will be based on adequacy of CT/CCTA evaluation and likelihood of significant coronary artery disease.
2893900|NCT03291925|Active Comparator|Invasive Cardiac Angiography|Patients will undergo systematic invasive angiography.
2893901|NCT03291912|Experimental|Chuna Manual Therapy (CMT)|"Chuna manual therapy (CMT), 2 sessions/week, 6 weeks (12 sessions in total)~Usual care therapy (UC), 2 sessions/week, 6 weeks (12 sessions in total)~Usual care consists of physical therapy and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~Patients will be educated about cause and risk factors of cervicogenic dizziness, general neck muscle functions, self-exercising for relieving the symptoms.~CMT and UC group will receive the same UC regimen."
2893929|NCT03291691||Standard of care: AXP|Patients at Charite, with upper limb surgery undergoing a protective performed ultrasound guided axillary plexus block. N=15.
2893930|NCT03291678|Experimental|new laparoscopic orchiopexy|this group will subjected to classic laparoscopic orchiopexy by delivery of abdominal undescended testis to subdartos pouch of scrotum with closure of internal ring
2893902|NCT03291912|Active Comparator|Usual Care (UC)|"Usual care therapy (UC), 2 sessions/week, 6 weeks (12 sessions in total)~Usual care consists of physical therapy and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~Patients will be educated about cause and risk factors of cervicogenic dizziness, general neck muscle functions, self-exercising for relieving the symptoms.~CMT and UC group will receive the same UC regimen."
2893903|NCT03291899|Experimental|Experimental single arm|"Chemotherapy using the FOLFIRINOX regimen will be given every 2 weeks for a total of 12 cycles. FOLFIRINOX consist of:~Oxaliplatin-85 mg/m2 IV Day 1~Leucovorin-400 mg/m2 IV Day 1~Irinotecan-180 mg/m2 IV Day 1~Fluorouracil (FU)-400 mg/m2 IV bolus Day 1~Fluorouracil 2400 mg/m2 infused over 46 hours starting day 1"
2893904|NCT03291886|Experimental|Arm A (exemestane, Entinostat)|"5 mg KHK2375 will be administered to subjects once weekly. EXE001 will be administered at a dose of 25 mg once daily orally.~Pre/perimenopausal female patients also receive luteinizing hormone-releasing hormone (LH-RH) agonist."
2893905|NCT03291886|Placebo Comparator|Arm B (exemestane, Entinostat(placebo))|"KHK2375 Placebo will be administered to subjects once weekly. EXE001 will be administered at a dose of 25 mg once daily orally.~Pre/perimenopausal female patients also receive luteinizing hormone-releasing hormone (LH-RH) agonist."
2893906|NCT03291873|Active Comparator|topography guided PRK in one eye|Topography-guided (placido disk- based) using T-CAT Contoura treatment.
2893907|NCT03291873|Active Comparator|Q-value adjusted ( custom Q) PRK in the other eye|The target Q will be estimated according to a nomogram considering the patient's age
2893908|NCT03291847|Experimental|Buprenorphine-naloxone treated|Participants receiving buprenorphine-naloxone treatment for opioid use disorder during pregnancy
2893909|NCT03291847|Active Comparator|Methadone treated|Participants receiving methadone treatment for opioid use disorder during pregnancy
2893910|NCT03291821|Experimental|DuoStim|Two controlled ovarian stimulation within the same menstrual cycle using human menopausal gonadotropin 225 IU/day subcutaneously, GnRH antagonist in a dose of 0.25 mg/day subcutaneously and 0.2 mg of GnRH analog to induce oocyte maturation. It will be followed by ovarian puncture, oocyte isolation, intracytoplasmic sperm injection and trophectoderm biopsy at the blastocyst stage. Preimplantation genetic test and MitoScore will be performed in all the embryos prior to the embryo transfer. At this step embryos will be frozen to wait for the results. Chromossomally normal embryos will be thawed and transferred to the uterus in a deferred cycle. A pregnancy test will be performed when appropriate.
2893911|NCT03291821|Active Comparator|Conventional Stimulation|Two controlled ovarian stimulation in different menstrual cycles using human menopausal gonadotropin 225 IU/day subcutaneously, GnRH antagonist in a dose of 0.25 mg/day subcutaneously and 0.2 mg of GnRH analog to induce oocyte maturation. It will be followed by ovarian puncture, oocyte isolation, intracytoplasmic sperm injection and trophectoderm biopsy at the blastocyst stage. Preimplantation genetic test and MitoScore will be performed in all the embryos prior to the embryo transfer. At this step embryos will be frozen to wait for the results. Chromossomally normal embryos will be thawed and transferred to the uterus in a deferred cycle. A pregnancy test will be performed when appropriate.
2893912|NCT03291808|Experimental|Weight loss intervention|Such designs are widely used in efficiently informing decisions to proceed to Phase III clinical trials. This trial design is appropriate when the effect of the placebo arm can reasonably be estimated (weight loss is likely to be close to 0), and the toxicity of the treatment is minimal (no toxicity is anticipated related to weight loss).18 Therefore, this will be a single arm 6-month study of 40 participants (20 at each site). All participants will be assigned to the weight loss intervention.
2893913|NCT03291795|Experimental|Exercise Intervention|
2893914|NCT03291782|Experimental|D-0120 Dose 1|D-0120 Dose 1 Patients will get D-0120 single agent or placebo of matching size during dose escalation
2893915|NCT03291782|Experimental|D-0120 Dose 2|D-0120 Dose 2 Patients will get D-0120 single agent or placebo of matching size during dose escalation
2893916|NCT03291782|Experimental|D-0120 Dose 3|D-0120 Dose 3 Patients will get D-0120 single agent or placebo of matching size during dose escalation
2893917|NCT03291782|Experimental|D-0120 Dose 4|D-0120 Dose 4 Patients will get D-0120 single agent or placebo of matching size during dose escalation
2893918|NCT03291782|Experimental|D-0120 Dose 5|D-0120 Dose 5 Patients will get D-0120 single agent once in the fasted state and once in the fed state.
2893919|NCT03291756||Multiple Sclerosis|Multiple Sclerosis Pts presenting to enrolling sites across the US are invited to enroll if eligible
2893920|NCT03291743|Experimental|First Degree Relative|A total of 112 high risk first-degree relatives will be enrolled in total. Patients with Crohn's Disease will be given information about the study when in clinic for routine care to share with their first degree relatives (FDR). Screening will be done using capsule endoscopy.
2893921|NCT03291743|Active Comparator|Healthy Controls|This study will also enroll 35 healthy controls who will be age and sex matched to the first degree relative (FDR) population. Enrollment will begin after 20-25 FDR's have passed screening and will continue at this interval until all controls have been enrolled. Controls will be initially screened by colonoscopy. If enrolled they will undergo capsule endoscopy as well
2893922|NCT03291730|Experimental|Hand Lettering|"The participant will engage in art-therapy by tracing and coloring a detailed letter or word~Participants will also be guided through a relaxation breathing and journaling exercise that can be incorporated into the art activity."
2893923|NCT03291717|Experimental|Bridging Community Gaps Photovoice (BCGP)|The BCGP program is a 6-month photovoice-based intervention to help individuals with psychiatric disabilities enhance their community participation.
2893924|NCT03291717|No Intervention|Services as Usual|Individuals in this group continue with their regular mental health services with no additional intervention.
2893925|NCT03291704|Experimental|Thermal Therapy|Heat application using at home thermal therapy device
2893926|NCT03291691||Standard of care: SCI|Patients at Charite, with lower limb surgery undergoing a protective performed ultrasound guided sciatic nerve block. N=15.
2893927|NCT03291691||Standard of care: FEM|Patients at Charite, with lower limb surgery undergoing a protective performed ultrasound guided femoral nerve block. N=15.
2893928|NCT03291691||Standard of care: ISB|Patients at Charite, with upper limb surgery undergoing a protective performed ultrasound guided interscalene plexus block. N=15.
2894113|NCT03290274|Experimental|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation at Basal nucleus of Meynert
2893932|NCT03291652||Symptomatic stroke patient|"DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.~2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.~Diagnosis procedure: DSA/3DRA"
2893933|NCT03291652||Asymptomatic stroke patient|"DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.~2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.~Diagnosis procedure: DSA/3DRA"
2893934|NCT03291613|Experimental|Pinpoint App|Tablet application.
2893935|NCT03291600|Experimental|Virtual Psychiatric Care Group|Participants randomized to the intervention group will have the option to receive video-based psychiatrist care in addition to care as usual. Participants will be assigned to begin immediately after randomization.
2893936|NCT03291600|No Intervention|Control Group|Women allocated to the control condition will receive care as usual (in-person psychiatric care) from the study site to which they were referred.
2893937|NCT03291587|Experimental|Intervention - Key Informant|NCORP site coordinator will call each participant to administer a 5 minute telephone survey within 14 days of the lung cancer screening clinic visit. A participant contact log is appended. This assessment focuses on exposure to the intervention and subsequent quit attempts.
2893938|NCT03291587|No Intervention|Usual Care|Data collection from Patients: demographics, health status, smoking history, quitting behavior, perceptions of lung cancer risk and worry, impact of screening on tobacco use behavior, and exposure to the intervention. (baseline, <14 days, 3 months, and 6 months)
2893939|NCT03291574|Experimental|Electroacupuncture group|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu
2893940|NCT03291574|Placebo Comparator|Sham electroacupuncture group|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu
2893941|NCT03291561|Experimental|Electroacupuncture group|Electroacupuncture Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
2893942|NCT03291561|Placebo Comparator|Sham electroacupuncture group|Sham acupuncture at Baihui, Nei guan, bilateral Zu, sanli and bilateral Tian shu.
2893943|NCT03291548|Experimental|Quinoa Biscuit|The quinoa-enriched biscuits containing 7.11g quinoa flour.
2893944|NCT03291548|Placebo Comparator|Control biscuit|The placebo control biscuit: an iso-energetic, matched product in terms of appearance, taste, texture and smell.
2893945|NCT03291535|Placebo Comparator|Control|This arm will consist of the usual care of management of hypertension by a clinical pharmacist.
2893946|NCT03291535|Active Comparator|Intervention|This arm will consistent of usual care plus the addition of a blood pressure cuff that will allow patients to upload data to the electronic health record via a secure portal.
2893947|NCT03291522||Men undergoing TESE|Ultrasound-guided rete testis flushing and aspiration
2893948|NCT03291509|Active Comparator|In-person Group|Participants randomized to this group will have a health educator to their house for in-person meetings. Participants will use paper forms to track progress in other parts of the study. Participants will be asked follow the Enhanced Stop Light Diet (eSLD) and take part in structured physical activity each week.
2893949|NCT03291509|Experimental|Computer Group|Participants randomized to this group will use an iPad to talk to the health educator via video conference meetings. Participants will use the iPad to track progress in other parts of the study. Participants will be asked follow the Enhanced Stop Light Diet (eSLD) and take part in structured physical activity each week.
2893950|NCT03291496||Preterm Neonates|Blood collection Preterm. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.
2893951|NCT03291496||Term Neonates|Blood collection Term. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.
2893952|NCT03291483|Experimental|whole body vibration group|basketball players had done exercises on whole body vibration platform.
2893953|NCT03291483|Sham Comparator|plyometric training|Basketball players had done same plyometric exercises
2893954|NCT03291470|Active Comparator|Active Treatment (TG-C)|TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
2893955|NCT03291470|Placebo Comparator|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
2893956|NCT03291457||Glucocorticoids + Tocilizumab|Participants with RA who are receiving glucocorticoid treatment will be observed for up to 52 weeks after starting tocilizumab.
2893957|NCT03291444|Experimental|CAR-T cells combined with Eps8 peptide specific dendritic cell|
2893958|NCT03291444|Active Comparator|Chimeric antigen receptor T cells|
2893959|NCT03291431|Active Comparator|Active iTBS|
2893960|NCT03291431|Sham Comparator|Sham iTBS|
2893961|NCT03291418|Experimental|ATB-346 OR Placebo|Intervention: Drug: ATB-346 dosed orally at 250 mg once daily for 14 days Intervention: Drug: Placebo (for ATB-346) dosed once daily for 14 days
2893962|NCT03291418|Active Comparator|Naproxen sodium|Intervention: Drug: naproxen sodium dosed orally at 550 mg twice daily for 14 days
2893963|NCT03291405||Body Mass Index less than 30|
2893964|NCT03291405||Body Mass Index more than 30|
2893965|NCT03291392||Atherosclerosis|"Patient with intracranial stenosis or extracranial stenosis equal to or more than 70% would be invited to join the study for blood taking.~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
2893990|NCT03291223||GOS Participants|GOS is a disease specific registry open to all Gaucher patients irrespective of treatment status or type of treatment
2893966|NCT03291392||Family members|"The stroke patient who had family history of stroke, their parents and siblings would also be invited to join the study for blood taking or buccal swab/ saliva collection.~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
2893967|NCT03291392||Normal subjects|"Normal subjects without ischemic stroke or intracranial/extracranial stenosis would be invited to join the study for blood taking.~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
2893968|NCT03291379|Experimental|BTG-002814|Single arm: BTG-002814 (vandetanib-eluting radiopaque beads)
2893969|NCT03291366|Experimental|MSC|infusion of aUCMSC and conventional therapy
2893970|NCT03291366|Active Comparator|conventional|conventional therapy
2893971|NCT03291353|Experimental|AML Patients|pembrolizumab 200 mg given IV once every three weeks
2893972|NCT03291340||Cognitively normal elderly|TCD agitated saline right-to-left shunt study TCD cerebrovascular reactivity study
2893973|NCT03291340||Cognitive impaired elderly|TCD agitated saline right-to-left shunt study TCD cerebrovascular reactivity study
2893974|NCT03291327|Active Comparator|Investigational product (Lactobacillus A)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.~Lactobacillus (A) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The lactobacilli will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
2893975|NCT03291327|Active Comparator|Investigational product (Lactobacillus B)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.~Lactobacillus (B) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The lactobacilli will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
2893976|NCT03291327|Placebo Comparator|Placebo Product (P)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.~Placebo (P) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The placebo will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
2893977|NCT03291314|Experimental|Axitinib + Avelumab|On day 1 of the treatment phase, patients recruited to this arm will initiate concomitant continuous daily treatment with axitinib (InlytaTM, 5 mg comp BID) in combination with avelumab (10 mg/kg IV Q2 weeks)
2893978|NCT03291314|Experimental|Axitinib (+Avelumab)|"On day 1 of the treatment phase, patients recruited to this arm will initiate treatment with continuous daily axitinib (InlytaTM, 5 mg comp BID).~Patients who tolerate treatment with axitinib and are able to taper the dose of corticosteroids to a maximal daily dose of 8 mg methylprednisolone (or an equivalent dose of another oral corticosteroid) will initiate combination therapy with avelumab (10 mg/kg IV Q2 weeks) on day 43, following the the first MRI-based tumor response evaluation in week 6.~Patients who do not tolerate monotherapy with axitinib, or cannot decrease their daily dose of corticosteroids to a maximal daily dose of 8 mg methylprednisolone will not be allowed to initiate avelumab treatment."
2893979|NCT03291301|Experimental|CBT Group|Cognitive Behavioral Therapy for Insomnia
2893980|NCT03291301|Experimental|Combined Group|Cognitive Behavioral Therapy for Insomnia plus Acupressure
2893981|NCT03291301|No Intervention|Wait-list Control Group|
2893982|NCT03291288|Active Comparator|Part 1 - Reference treatment|On Day 1 all participants will receive a single oral dose each of midazolam (2 mg) and tolbutamide (500 mg), followed by blood draws for pharmacokinetic (PK) analysis.
2893983|NCT03291288|Experimental|Part 1 - Test Treatment 1|On Day 3 all participants will receive a single oral dose each of midazolam (2 mg) and tolbutamide (500 mg) with morning dose of pexidartinib (400 mg) followed by blood draws for PK analysis.
2893984|NCT03291288|Experimental|Part 1 - Test Treatment 2|"All participants will receive only the 400 mg pm dose of pexidartinib on Day 3 and continue twice-daily (BID) dosing of pexidartinib (400 mg for the am dose, and 400 mg for the pm dose) until Day 13.~On Day 13, all participants will receive a single oral dose of midazolam (2 mg) and tolbutamide (500 mg) with the morning dose of pexidartinib (400 mg) followed by blood draws for PK analysis."
2893985|NCT03291288|Experimental|Part 2 - Pexidartinib only|"On Day 13, all participants will receive a pm dose of 400 mg pexidartinib only.~All participants will continue to receive pexidartinib BID dosing in 28-day cycles at the 400 mg/day dose for up to one year. The dose of pexidartinib may be further modified within that year, depending upon tolerance as defined in the protocol."
2893986|NCT03291249|Placebo Comparator|Group A|Group A will receive placebo solution for 30 consecutive days
2893987|NCT03291249|Experimental|Group B|Group B will receive 0.5 mg Foralumab Solution daily for 30 consecutive days
2893988|NCT03291249|Experimental|Group C|Group B will receive 2.5 mg Foralumab Solution daily for 30 consecutive days
2893989|NCT03291249|Experimental|Group D|Group B will receive 5.0 mg Foralumab Solution daily for 30 consecutive days
2894114|NCT03290261|Experimental|Patients with reccurent cystitis|Patient perform 3 hypnosis sessions
2893991|NCT03291210|Experimental|Normoxemia|Patients randomized to the normoxemia group receives inspired oxygen fraction of 0.3 from initiation of induction of anesthesia to the end of the procedure.
2893992|NCT03291210|Active Comparator|Hyperoxemia|Patients randomized to the hyperoxemia group receives inspired oxygen fraction of 0.8 from initiation of induction of anesthesia to the end of the procedure.
2893993|NCT03291197|Experimental|Open label treatment|These patients will receive suprascapular and median nerve blocks for shoulder hand syndrome. Investigators will assess the tolerability of his procedure using pre-defined criteria (outlined elsewhere).
2893994|NCT03291171|Experimental|Intervention group|Participants will receive the e- and mHealth intervention 'MyPlan 2.0'.
2893995|NCT03291171|No Intervention|Waiting-list control group|Participants will not receive the e- and mHealth intervention 'MyPlan 2.0', but will be given access to the intervention after all testing phases.
2893996|NCT03291158|Experimental|Minocycline IV|Open label Minocin IV
2893997|NCT03291145|Experimental|Beta Blockers|With and without Beta Blockers
2893998|NCT03291145|Experimental|Spironolactone|With and without Spironolactone
2893999|NCT03291132|Other|training camp|"The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months."
2894000|NCT03291093|Experimental|18F-Flutemetamol PET/MRI dynamic|"All included patients will be patients with a recent stroke and a significant carotid plaque.~The first 5 patients will undergo a slightly longer scan protocol to determine optimal scan time for the use of 18F-Flutemetamol in atherosclerosis imaging."
2894001|NCT03291093|Experimental|18F-Flutemetamol PET/MRI CEA|10 patients will be selected from patients that will undergo carotid endarterectomy (CEA) and will undergo the the optimized (shorter) scan protocol with 18F-Flutemetamol. The decision for this operation is made by the surgeon and neurologist and based on clinical standards and is thus independent of study participation.
2894002|NCT03291093|Experimental|18F-Flutemetamol PET/MRI|The remaining 10 patients will undergo the optimized (shorter) scan protocol with 18F-Flutemetamol.
2894003|NCT03291080|Experimental|Liquid|Oral liquid formulation of 13-Cis Retinoic Acid - test product.
2894004|NCT03291080|Experimental|Capsule|Isotretinoin capsules (13-CRA extracted per standard of care)- reference product.
2894005|NCT03291067|Experimental|MT-8554 Low dose|
2894006|NCT03291067|Experimental|MT-8554 Medium dose|
2894007|NCT03291067|Experimental|MT-8554 High dose|
2894008|NCT03291067|Placebo Comparator|Placebo|
2894009|NCT03291054|Experimental|Epacadostat and pembrolizumab|Subjects will receive epacadostat and pembrolizumab
2894010|NCT03291041|Experimental|tasimelteon|tasimelteon, administered as oral capsule(s)
2894011|NCT03291041|Placebo Comparator|Placebo|Placebo, administered as oral capsule(s)
2894012|NCT03291028||Patients treated with immune check point blocker|Patients who were treated with immune checkpoint inhibitor targeting PD1 and developed metastatic lesion later
2894013|NCT03291028||Patients treated with targeted/ observational therapy|Patients who were not treated with immune checkpoint inhihibitor and developed metastatic lesion following other targeted therapy
2894014|NCT03291015|Other|radiographic guided treatment|radiographic guided treatment of kienbock disease using plain x ray for determine treatment plan
2894015|NCT03291015|Other|arthroscopic guided treatment|arthroscopic guided treatment of kienbock disease using wrist arthroscopy for determine treatment plan (Wrist arthroscopy)
2894016|NCT03291002|Experimental|Cohort A|Dose escalation of CV8102
2894017|NCT03291002|Experimental|Cohort B|Optional expansion cohorts of CV8102
2894018|NCT03291002|Experimental|Cohort C|Dose escalation of CV8102 + anti-PD-1 therapy
2894019|NCT03291002|Experimental|Cohort D|Optional expansion of CV8102 + anti-PD-1 therapy
2894020|NCT03290976|No Intervention|Control Group|The control group will consist of patients who choose not to undergo CIM treatments for their CIPN-related symptoms. Participants in this arm of the study will receive standard conventional supportive care, as provided by their oncology health care professionals (HCPs), and closely monitored for any changes in the severity of their CIPN-related symptoms.
2894021|NCT03290976|Active Comparator|Intervention Group A: Single Modality (acupuncture)|Patients choosing to undergo CIM treatments, in addition to standard conventional care: Acupuncture x2/week, for 6 weeks.
2894022|NCT03290976|Active Comparator|"Intervention Group B: Multi-modality (acupuncture plus)"|Patients choosing to undergo CIM treatments, in addition to standard conventional care: Acupuncture with additional CIM treatment modalities, x2/week, for 6 weeks.
2894023|NCT03290963|Active Comparator|Ketamine plus Lithium|Lithium will be used in conjunction to Ketamine infusions for the treatment of major depression disorder or bipolar disorder type I or II. Before the first ketamine infusion, subjects will be randomized to 2 weeks of lithium treatment. All subjects will receive three IV ketamine infusions (0.5 mg/kg, over 100 min.) over 7 days. Those who achieve positive response (>50% decrease in MADRS total score from baseline) will be given 4 additional once-weekly ketamine infusions (same dose and infusion rate) and lithium treatment .
2894024|NCT03290963|Placebo Comparator|Ketamine plus Placebo|Placebo tablets will be used in conjunction to Ketamine infusions for the treatment of major depression disorder or bipolar disorder type I or II. Before the first ketamine infusion, subjects will be randomized to 2 weeks of placebo treatment. All subjects will receive three IV ketamine infusions (0.5 mg/kg, over 100 min.) over 7 days. Those who achieve positive response (>50% decrease in MADRS total score from baseline) will be given 4 additional once-weekly ketamine infusions (same dose and infusion rate) and placebo treatment.
2894090|NCT03290456|Placebo Comparator|Placebo 5mg/day extended of 9 additional months|Placebo 5mg/day will be administered from Day 1 to Month 9
2894025|NCT03290950|Experimental|daratumumab, carfilzomib, lenalidomide, and dexamethasone|Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients.
2894026|NCT03290937|Experimental|Metastatic Wild Type (RAS-RAF) Colorectal Cancer Group|"Dose Expansion: Participants receive Irinotecan at the maximum tolerated dose from Dose Escalation Phase.~Participants receive the same dose of Cetuximab and PF-05082566.~Participants continue receiving the study drugs for as long as study doctor thinks it is in participant's best interest."
2894027|NCT03290937|Experimental|Mutated RAS Colorectal Cancer Group|"Dose Expansion: Participants receive Irinotecan at the maximum tolerated dose from Dose Escalation Phase.~Participants receive the same dose of Cetuximab and PF-05082566.~Participants continue receiving the study drugs for as long as study doctor thinks it is in participant's best interest."
2894028|NCT03290937|Experimental|Irinotecan + PF-05082566 + Cetuximab|"Dose Escalation: Participants assigned to a dose level of Irinotecan based on when joining study. Up to 3 dose levels of Irinotecan tested. Up to 6 participants enrolled at each dose level. First group of participants receive the lowest dose level. Each new group receives a higher dose than the group before it, if no intolerable side effects were seen. This continues until the highest tolerable dose of Irinotecan is found.~Participants receive the same dose of Cetuximab and PF-05082566."
2894029|NCT03290924|Experimental|Intervention|Low-dose high-frequency health worker training approach to update skilled birth attendants in key evidence-based intrapartum and immediate newborn care practices
2894030|NCT03290924|Active Comparator|Comparison|Training on data collection and reporting
2894031|NCT03290898|Active Comparator|Training group|"Supervised High intensity interval training (HIIT) 3 times a week for 6 months.~Training session:~10 minutes warm up (Low-moderate intensity) 30 minutes intervention (16 minutes HIIT) 10 minutes cool down(Low-moderate intensity)"
2894032|NCT03290898|No Intervention|Control group|Control group, usual lifestyle. Aside from training intervention, all other visits are the same as intervention group (training).
2894033|NCT03290885|Experimental|Combined use of contact aspiration and stent retriever|Combined use of contact aspiration and stent retriever mechanical thrombectomy for recanalization
2894034|NCT03290885|Active Comparator|Stent retriever mechanical thrombectomy alone|Stent retriever mechanical thrombectomy alone for recanalisation
2894035|NCT03290872|Active Comparator|Carpentier Edwards Physio 2 Complete flexible mitral ring|Mitral Valve Annuloplasty Ring Repair using Carpentier Edwards Physio 2 Complete flexible mitral ring
2894036|NCT03290872|Active Comparator|Simplici T Partial flexible mitral annuloplasty ring|Mitral Valve Annuloplasty Ring Repair using Simplici T Partial flexible mitral annuloplasty ring
2894037|NCT03290859||Training intervention|Train anesthesia providers who deliver propofol sedation for GI endoscopy procedures to follow a uniform propofol monotherapy administration guideline to titrate propofol monotherapy infusion to effect according to a standardized protocol.
2894038|NCT03290859||Effectiveness of training intervention|Compare the effectiveness of training intervention and standardized titration to effect through aggregate data for metrics of recovery times.
2894039|NCT03290846|Active Comparator|Secretin|Scanning will be performed after subject has been given a secretin hydrochloride infusion.
2894040|NCT03290846|Placebo Comparator|Placebo|Scanning will be performed after subject has been given a saline infusion.
2894041|NCT03290833|Experimental|Robotic|The experimental group will receive 30 minutes robotic training sessions, 3 times per week for a total of 30 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive schedule (1-hour sessions, 3 times/week, 30 total sessions) of conventional therapy from an occupational therapist.
2894042|NCT03290833|Active Comparator|Conventional|In conventional therapy group, participants will receive an one-hour of one-on-one treatment (1-hour sessions, 3 times/week, 30 total sessions) from an occupational therapist, focusing on arm and hand function.
2894043|NCT03290820|Active Comparator|Controlled Group|The patients in the Controlled Group are allocated to receive radiotherapy and concurrent chemotherapy.
2894044|NCT03290820|Experimental|Experimental Group|The patients in the Experimental Group are allocated to receive radiotherapy and concurrent chemotherapy plus daily aspirin.
2894045|NCT03290794||Decision to treat with intravitreal aflibercept for wet AMD|Adult patients with a diagnosis of wet AMD, as an indication approved by the local health authorities for use with intravitreal aflibercept.
2894046|NCT03290781|Experimental|SHP647 25 mg|Participants who received 25 milligram (mg) of SHP647 or placebo and achieved a clinical response in one of the induction studies (SHP647-301 or SHP647-302) will receive 25 mg of SHP647 as maintenance treatment subcutaneously using a prefilled syringe once in every 4 weeks (Q4W) up to Week 52.
2894047|NCT03290781|Experimental|SHP647 75 mg|Participants who received 75 mg of SHP647 or placebo and achieved a clinical response in one of the induction studies (SHP647-301 or SHP647-302) will receive 75 mg of SHP647 as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.
2894048|NCT03290781|Placebo Comparator|Placebo|Participants who received 25 mg or 75 mg SHP647 or placebo matched to SHP647 in the induction studies (SHP647-301 or SHP647-302) will receive placebo matched to SHP647 as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.
2894049|NCT03290768|Experimental|Diabetes Management Educational Program|Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.
2894050|NCT03290755||MSM co-infected HIV-HCV|
2894051|NCT03290742||Patients without documented infection.|Patients without infection during 30 day follow-up after radical cystectomy.
2894052|NCT03290742||Patients with documented infection.|Patients with documented any kind of infection (urinary tract infection, blood infection/septic shock, surgical site infection) during 30 day follow-up after radical cystectomy.
2894053|NCT03290729|Experimental|narrow ridge|edentulous site with crestal bone width comprised between 3,5 and 5 millimeters wedge shape implants insertion
2894054|NCT03290716|Experimental|SS+SSSC|Salt substitute plus stepwise salt supply control
2894055|NCT03290716|Experimental|SS only|Salt substitute only
2894056|NCT03290716|Experimental|SSSC only|Stepwise salt supply control only
2894057|NCT03290716|No Intervention|control|No salt substitute and no stepwise salt supply control
2894112|NCT03290274|Experimental|Deep brain stimulation (fornix)|Deep brain stimulation at fornix area
2894058|NCT03290703|Experimental|Part 1: GDC-0853 (Effect of Formulation)|Participants will receive five single oral doses of test formulations of GDC-0853 co-administered with rabeprazole in the fasted state.
2894059|NCT03290703|Experimental|Part 2: GDC-0853 (Effect of Food and Rabeprazole)|Participants will receive three single oral doses of one GDC-0853 formulations selected from Part 1 of this study. One dose will be administered in the fasted state, one dose will be administered in the fed state, and one dose will be co-administered with rabeprazole in the fed or fasted state, depending on randomization.
2894060|NCT03290703|Experimental|Part 3: GDC-0853 Optimized (Effect of Food and Rabeprazole)|Participants will receive three single oral doses of an optimized tablet formulations of GDC-0853. One dose will be administered in the fasted state, one dose will be administered in the fed state, and one dose will be co-administered with rabeprazole in the fed or fasted state, depending on randomization.
2894061|NCT03290690||All Subjects|"All subjects in this study will have their wounds imaged and assessed in the following manner:~Capture and save ST-image Capture and save FL-image Identify discrete locations of cyan (blue/green) fluorescent bacteria (FL_C) Acquire sample of tissue where cyan fluorescent bacteria are present (using curette method) Consent patient for inclusion in this study Note location of sample acquisition by annotating FL-image obtained in step 2 Send sample for microbiology analysis Note naming of microbiology sample on Case Report Form"
2894062|NCT03290677|Experimental|CT-guided Percutaneous Cryoablation of Lung Tumor|"Image-guided core needle biopsy to confirm cancer will be perform~Patients will undergo cryoablation as a standard procedure~cryoablation will be performed with a three-cycle freeze-thaw phase protocol~Non-contrast CT images will be obtained in 3 to 5 minutes intervals to visualize the evolving ablation zone"
2894063|NCT03290664|Experimental|CD3-/CD19- Infusion|
2894064|NCT03290664|Experimental|CD3-/CD56+ Infusion|
2894065|NCT03290651|Experimental|Probiotic Natural Health Product - RepHresh Pro-B|One capsule contains 2.5 billion CFU of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14.
2894066|NCT03290651|Placebo Comparator|Placebo|Placebo. It is the same composition as the active capsule, without the bacteria.
2894067|NCT03290638|Experimental|Dehydrated Human Amnion Chorion Membrane|This membrane was investigated to evaluate its use as an open barrier for guided bone regeneration (GBR) after tooth extraction and to determine whether intentional exposure of this membrane to the oral environment compromises ridge dimensions and bone vitality for implant placement.
2894068|NCT03290638|Active Comparator|Type I Bovine Collagen Membrane|This membrane has been tested as an open barrier for GBR after tooth extraction. The intentional use of this membrane to the oral environment did not compromise ridge dimensions and bone vitality for implant placement.
2894069|NCT03290625|Experimental|DexKet|Intranasal DEXMEDETOMIDINE (2.0 mcg/kg, maximum 100 mcg) + KETAMINE (1.0 mg/kg, maximum 100 mg)
2894070|NCT03290625|Active Comparator|Dex|DEXMEDETOMIDINE (2.5 mcg/kg, maximum 100 mcg)
2894071|NCT03290612|Experimental|Vitamin C then Placebo|Participants will receive a 1.5g dose of Ascorbic Acid upon wake for the first visit, and a placebo tablet on the second visit.
2894072|NCT03290612|Experimental|Placebo then Vitamin C|Participants will receive a placebo tablet upon wake for the first visit, and a 1.5g dose of Ascorbic Acid on the second visit.
2894073|NCT03290599||No Post operative cognitive dysfunction|Patients who did not have any change or a change less than 4 points between MMT1 and MMT3
2894074|NCT03290599||Post operative cognitive dysfunction|Patients with a difference more than 4 points between MMT1 and MMT3
2894075|NCT03290573|Active Comparator|Dorsum of hand group|short peripheral venous catheter place in the dorsum of the hand
2894076|NCT03290573|Experimental|Forearm group|short peripheral venous catheter place in the forearm
2894077|NCT03290560|Experimental|Recombinant human tissue kallikrein|A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.
2894078|NCT03290560|Placebo Comparator|Placebo|A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.
2894079|NCT03290547|Other|arm-1|Cutera enLighten laser treatments that allows the user to choose a wavelength between 640nm to 800nm.
2894080|NCT03290521|Experimental|A - Yes Washing (SL)|In this group, the washing process is continued. In particular, 1000cc of laced ringer is instilled by changing the position of the patient in Trendelenburg and Anti-Trendelenburg so that the liquid contacts not only the internal surgical wounds but the whole wall of the abdominal cavity.
2894081|NCT03290521|Experimental|B- No Washing (NL)|No washing was performed before the end of surgery
2894082|NCT03290508||Prolaris Testing|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
2894083|NCT03290508||No Prolaris Testing|Patients with newly diagnosed favorable intermediate-risk localized prostate cancer who DO NOT undergo Prolaris testing
2894084|NCT03290495|Active Comparator|isonly|This arm will receive spinal anesthesia. then this arm will receive saline during isoflurane anesthesia. this arm will serve as a control group.
2894085|NCT03290495|Active Comparator|isoket|this arm will receive spinal anesthesia. then will receive isoflurane inhalation. during isoflurane inhalation, this arm will receive single injection of ketamine. at end of anesthesia, effect of ketamine on recovery will be monitored.
2894086|NCT03290482||EE Study Patients 2000-2008|"All patients with the diagnosis of EE from the study period 2000 to 2008. Sixty patients participated in the 10 year follow up phone interview and questionnaire. These are the subjects we will contact to see if they are interested in participating in this study.~If interested in participating, subjects will complete:~Evaluation by the PI physical examination~Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) questionnaires~Barium Esophagram with maximal and minimal esophageal diameter measurement~EsophaCap cytology"
2894087|NCT03290469|Experimental|15 day cWGS and Standard of Care|Enrolled cohorts receive the results of the clinical whole genome sequencing (cWGS) after 15 days of the sample receipt while still undergoing standard of care (SOC).
2894088|NCT03290469|No Intervention|Standard of Care|Enrolled cohorts receive the results of the clinical whole genome sequencing (cWGS) after 60 days of the sample receipt while still undergoing standard of care (SOC).
2894089|NCT03290456|Experimental|Prednisone 5mg/day extended of 9 additional months|Prednisone 5mg/day will be administered from Day 1 to Month 9
2932874|NCT03020771|Active Comparator|10 mcg SC|
2894091|NCT03290443|Experimental|Enasidenib (CC-90007) tablet|Subjects will receive one 100 mg enasidenib (CC-90007) tablet the morning of Day 1 which will be administered in the fasted state.
2894092|NCT03290430|Experimental|Group Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 sessions over 4 week, each lasting between 1-2 hours. During these sessions, participants will learn about how to quit smoking by changing habits. Sessions may be audio or video taped.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
2894093|NCT03290430|Experimental|Individual Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 sessions over 4 week, each lasting between 30-45 minutes. During these sessions, participants will learn about how to quit smoking by changing habits. Sessions may be audio or video taped.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
2894094|NCT03290430|Experimental|Telephone Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 phone calls over 4 week, each lasting between 30-45 minutes. During these phone calls, participants will learn about how to quit smoking by changing habits. Sessions may be audio taped.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
2894095|NCT03290430|Experimental|Video Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 video calls over 4 week, each lasting between 30-45 minutes. During these video calls, participants will learn about how to quit smoking by changing habits. Sessions may be recorded.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
2894096|NCT03290417|No Intervention|Unmodified Diet|Patients are under active surveillance with no modification to their diet, as is standard of care for low risk prostate cancer
2894097|NCT03290417|Experimental|Diet modification|Patients receive Vitamin D, Omega-3 and turmeric curcumin as dietary supplements
2894098|NCT03290391|Experimental|LINC-II|LINC-II is a multi-faceted intervention combining pharmacological therapy (i.e., ART and naltrexone for opioid use disorder) and 12 months of strengths-based case management delivered to coordinate care across the narcology and HIV health care systems.
2894099|NCT03290391|No Intervention|Standard of Care|Participants randomized to the control group will receive the narcology hospital's standard of care, which is detoxification with or without stabilization. Prior to discharge, those identified as HIV-infected are given contact details for an HIV clinic, not an appointment. Upon discharge, patients are encouraged to receive outpatient narcology treatment, monthly, for 1 year. For this study, with regard to linkage to HIV medical care, patients will be given printed information about where to obtain HIV medical care and a resource card containing harm reduction information.
2894100|NCT03290378|Active Comparator|AVE-901 50 mg|
2894101|NCT03290378|Active Comparator|AVE-901 25 mg|
2894102|NCT03290378|Placebo Comparator|Placebo|
2894103|NCT03290365|Active Comparator|Platelet rich plasma + Hyaluronic acid|Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee. Patients received one dose of PRP injection. One week later, the one dose of HA is injected for intervention group.
2894104|NCT03290365|Placebo Comparator|Platelet rich plasma + normal saline|Patients received one dose of PRP injection. One week later, the one dose of normal saline is injected for control group.
2894105|NCT03290352||Head and neck cancer patients|Patients with oral cavity, tongue, gingival, pharyngeal, laryngeal, or salivary gland cancer and cervical lymph node metastasis who received free flap reconstruction would be enrolled in this study. However, we excluded the patients with distant metastasis identified in their medical records, and those undergoing reconstruction other than anterolateral thigh, fibular bone and radial forearm flaps.
2894106|NCT03290326|Experimental|tACS|Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 10 sessions on consecutive weekdays. The tACS intervention (10 sessions) will be preceded and followed by amyloid PET imaging as well as a clinical/cognitive evaluation. The assessment of adverse effects will constitute a Primary outcome measure. Changes in amyloid load in the stimulated brain region will be evaluated and constitute a secondary outcome of the study. Clinically relevant changes in cognitive and clinical scores will be also evaluated as secondary outcomes. Stimulation will be also preceded and followed by electroencephalography (EEG) recording aimed at assessing changes in spectral power in the gamma band.
2894107|NCT03290313|Experimental|shu gan yi yang capsule|4 capsules / time, 3 times / day, taking 8 weeks
2894108|NCT03290313|Placebo Comparator|shu gan yi yang capsule capsule simulation agent|4 capsules / time, 3 times / day, taking 8 weeks
2894109|NCT03290300||Long-Term Study Subjects|This cohort will consist of all subjects who were treated with the Vivaer Stylus in the 50-subject TP258 interventional study, who consent to continue to provide quality of life data.
2894110|NCT03290287||New users of aclidinium bromide|This nested cohort will be composed of patients aged 40 years or older who have previously been diagnosed with COPD and who are new users of aclidinium bromide (monotherapy; concomitant with formoterol not in fixed-dose combination; and aclidinium/formoterol)
2894111|NCT03290287||New users of other COPD medication|This nested cohort will include patients aged 40 years or older who have previously been diagnosed with COPD and who are new users of other COPD medication: tiotropium, other LAMAs, LABA, LABA/ICS and LAMA/LABA.
2894115|NCT03290248|Placebo Comparator|Vehicle|"Intranasal application:~1 pump (140ul) per nostril BID for 14 days"
2894116|NCT03290248|Active Comparator|B 244 1x (low dose)|"Intranasal application:~1 pump (140ul) per nostril BID for 14 days"
2894117|NCT03290248|Active Comparator|B244 4x (mid dose)|"Intranasal application:~1 pump (140ul) per nostril BID for 14 days"
2894118|NCT03290235|Experimental|PEG-somatropin-1|Dosage 0.2mg/kg/w
2894119|NCT03290235|Experimental|PEG-somatropin-2|Dosage 0.1-0.2mg/kg/w
2894120|NCT03290222||TRACK|Children will be followed for four weeks (3 to 5 weeks) after the inclusion in the study. Parents will complete the TRACK questionnaire in both visit and will answer additional questions about respiratory symptoms and use of medication.
2894121|NCT03290209|Experimental|Laparoscopic D1 Lymphadenectomy|Laparoscopic D1 Lymphadenectomy will be performed for the treatment of patients assigned to this group.
2894122|NCT03290209|Active Comparator|Laparoscopic D2 Lymphadenectomy|Laparoscopic D2 Lymphadenectomy will be performed for the treatment of patients assigned to this group.
2894123|NCT03290196|Other|EXPAREL 1.3 % in 20 ML Injection|"EXPAREL (bupivacaine liposome injectable suspension, 20 mL single use vial, 1.3% [13.3 mg/mL]) is a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. EXPAREL dosage is based on the following factors:~size of surgical site~volume required to cover the area~individual patient factors that may impact the safety of an amide local anesthetic~maximum doe of 266 mg (20 mL)"
2894124|NCT03290183||Intrathoracic malignancy|Patients with (strong suspicion of) intrathoracic malignancy and an indication for tissue collection by CT-guided, transthoracic or thoracoscopic approach undergo additional imaging with confocal laser endomicroscopy (CLE).
2894125|NCT03290170|Experimental|Measured resection technique|Measured resection surgical technique
2894126|NCT03290170|Experimental|Gap Balancing Technique|Gap Balancing surgical technique
2894127|NCT03290157|No Intervention|Control group|Regular colonoscopy preparation paper based information provided
2894128|NCT03290157|Other|ColoprAPP group|Regular colonoscopy preparation paper based information provided plus usage of a downloaded SPA (ColoprAPP) as a reminder system for colonoscopy preparation
2894129|NCT03290144||with diabetes|
2894130|NCT03290144||without diabetes|
2894131|NCT03290131|Active Comparator|AERT 40 mg|40 mg Arbaclofen Extended-Release Tablets
2894132|NCT03290131|Active Comparator|AERT 80 mg|80 mg Arbaclofen Extended-Release Tablets
2894133|NCT03290131|Placebo Comparator|Placebo|Placebo
2894134|NCT03290118|Experimental|Traffic Light|"Participants in this group will be provided with a survey that shows the food and beverage packages with traffic light front of pack labels only.~Intervention is the Nutrition Rating System - Traffic Light"
2894135|NCT03290118|Experimental|Star System|"Participants in this group will be provided with a survey that shows the food and beverage packages with health star rating front of pack labels only.~Intervention is the Nutrition Rating System - Health Star Rating"
2894136|NCT03290118|Experimental|Warning Label|"Participants in this group will be provided with a survey that shows the food and beverage packages with warning front of pack labels only.~Intervention is the Nutrition Rating System - Warning Labels"
2894137|NCT03290118|No Intervention|Control|Participants in this group will be provided with a survey that shows the food and beverage packages without any front of pack labels.
2894138|NCT03290105||study population|Consecutive critically-ill patients admitted to the ICU and receiving invasive mechanical ventilation for more than 48 hours
2894139|NCT03290092|Experimental|Treatment|
2894140|NCT03290079|Experimental|Pembrolizumab Treatment|"Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks. Estimated average length of treatment per participant: 4 months.~Second Course Study Treatment: Participants may be eligible for up to one year of additional pembrolizumab therapy if they progress after stopping study treatment. If they meet the criteria to be eligible for the Second Course, participants will restart treatment at the same dose and dose interval as when they last received pembrolizumab."
2894141|NCT03290066|Active Comparator|Kinesiotape|"Kinesiotape will be applied as a self-treatment. All participants will be instructed in an indvidual session and will receive a tutorial video to remember the kinesiotaping procedure. 3 band of a special and hypoallergenic tape (Kinematix Tex) will be attached to the abdominal (2 strips) and lower back (1 strip).~Patients will be taped for four days , ıt will start at the beginning of the menstruation."
2894142|NCT03290066|Active Comparator|Usual care|"Participants will use the usual self-care for primary dysmenorrhea. It will start at the beginning of the menstruation.~They will note the treatment indicating the dosage in a calendar."
2894143|NCT03290053|Experimental|CE-5S A: Treatment arm|Gets thrombolysis, transcranial ultrasound on the flow limitation and SonoVue infusion
2894144|NCT03290053|Sham Comparator|CE-5S A: Control arm|Gets thrombolysis, sham transcranial ultrasound and placebo (NaCl) infusion
2894145|NCT03290053|Experimental|CE-5S B: Treatment arm|Gets NO thrombolysis (due to contraindications), transcranial ultrasound on the flow limitation and SonoVue infusion
2894146|NCT03290053|Sham Comparator|CE-5S B: Control arm|Gets NO thrombolysis (due to contraindications), sham transcranial ultrasound and placebo (NaCl) infusion
2894147|NCT03290027|Experimental|Active|DFD-03 (0.1% tazarotene) Lotion
2894148|NCT03290027|Placebo Comparator|Vehicle|DFD-03 (0% tazarotene) Lotion
2894149|NCT03290014||Good sleepers|COPD patients with good sleep quality according to CASIS score will be studied with polysomnography, actigraphy and OSLER test
2894150|NCT03290014||Bad sleepers|COPD patients with poor sleep quality according to CASIS score will be studied with polysomnography, actigraphy and OSLER test
2894151|NCT03289988||Normal group|Normal group(control group): patients with negative colonoscopy findings (n= 238).
2894152|NCT03289988||Low risk adenoma group|Low risk adenoma group: patients having at least one low risk adenoma (n=250).
2894153|NCT03289988||High-risk adenoma group|High-risk adenoma group: patients having at least one of following criteria (more than 1 cm in size, villous or tubulovillous histologic type, high-grade dysplasia findings) (n=316).
2894154|NCT03289988||Colon cancer|Colon cancer: histologically confirmed colon cancer patients (n=160).
2894155|NCT03289962|Experimental|Phase 1a Dose-Escalation: RO7198457|Participants will receive RO7198457 at escalated dosages.
2894156|NCT03289962|Experimental|Phase 1b Dose-Escalation: RO7198457 + Atezolizumab|Participants will receive RO7198457 at escalated dosages along with atezolizumab at a fixed dose of 1200 milligrams (mg).
2894157|NCT03289962|Experimental|Phase 1b Exploration: RO7198457 + Atezolizumab|Non-small cell lung cancer (NSCLC) cancer immunotherapy (CIT)-treated participants will receive RO7198457 (at dosage lower than maximum tolerated dose [MTD] based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.
2894158|NCT03289962|Experimental|Phase 1b Expansion: RO7198457 + Atezolizumab|Participants with different indications as per inclusion criteria, will receive RO7198457 (at multiple dose levels below MTD based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.
2894159|NCT03289962|Experimental|Phase 1b Expansion: RO7198457 + Atezolizumab (Serial Biopsy)|Participants with selected tumor types who consent to optional serial biopsies will receive RO7198457 (at multiple dose levels below MTD based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.
2894160|NCT03289949|Other|Project 1|After baseline MRI & 5-HT2AR PET-imaging, participants will be allocated to undergo either one oral dose of psilocybin or one oral dose of ketanserin. After drug administration, participants will undergo two CIMBI-36 PET scans.
2894161|NCT03289949|Other|Project 2|After baseline MRI & CIMBI-36 PET-imaging, participants will receive one dose of oral psilocybin. One and 12 weeks after dosing, participants will undergo post-intervention PET-scan.
2894162|NCT03289949|Other|Project 3|After baseline MRI scanning and CIMBI-36 PET, participants will undergo one psilocybin-intervention fMRI scan and one ketanserin-intervention fMRI scan. If P2 shows there are long term effects of psilocybin on 5-HT2AR levels, psilocybin will be fixed as the second intervention. If not, interventions will be randomized.
2894163|NCT03289936|Experimental|Start ventilation with NIPPV|Alternatively vented with NIPPV and sNIPPV
2894164|NCT03289936|Experimental|Start ventilation with sNIPPV|Alternatively vented with sNIPPV and NIPPV
2894165|NCT03289923|Experimental|TMS+SST|
2894166|NCT03289923|Sham Comparator|Sham Group|
2894167|NCT03289923|Experimental|Active Group|
2894168|NCT03289910|Experimental|Arm A (veliparib, topotecan hydrochloride, carboplatin)|Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
2894169|NCT03289910|Active Comparator|Arm B (placebo, topotecan hydrochloride, carboplatin)|Patients receive topotecan hydrochloride and carboplatin as in Arm A. Patients also receive placebo PO BID on days 1-21. Treatment repeats every 28-63 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
2894170|NCT03289897|Experimental|Study Arm-LiverMultiScan|Patients will be scanned using the LiverMultiScan. Follow-up will be determined by the results of the scan.
2894171|NCT03289897|No Intervention|Control Arm|Standard of care as per guidelines of the local centre
2894172|NCT03289884||Control Group (CE1)|"All patients must have cystic lesions which must exceed 30mm in diameter.~All patients must be aged 16 or over and able to provide informed consent.~Patients will have an MRI scan (not involving ionising radiation)~Patients wil have an 'Ultrasound scan (not involving ionising radiation)'~Exclusion criteria include pregnancy and any contraindication to MRI (pacemaker, metallic implants, claustrophobia) and inability to give consent."
2894173|NCT03289884||CE group (CE2-4)|"All patients must have hepatic CE, as confirmed by positive blood tests, with lesions identified on the standard of care MRI/CT scan, one or more of which must exceed 20 mm in diameter.~All patients must be aged 16 or over and able to provide informed consent.~All patients will have an MRI scan (not involving ionising radiation)~Patients wil have an 'Ultrasound scan (not involving ionising radiation)'~Exclusion criteria include pregnancy and any contraindication to MRI (pacemaker, metallic implants, claustrophobia) and inability to give consent.~Patients from the CE group undergoing surgery or aspiration will have fluid samples sent for analysis as part of standard clinical care. These cyst fluid samples will then be transported to the MRI scanner for Ex vivo scanning."
2894174|NCT03289871|Experimental|Excilor|2 applications per day for 6 months
2894175|NCT03289871|Active Comparator|Loceryl 5%|1 application per week for 6 months
2894176|NCT03289858|Experimental|Exparel (Liposomal Bupivacaine)|"Exparel (liposomal bupivacaine) is FDA approved, with a labeled indication of single-dose infiltration into the surgical site to produce postsurgical analgesia."
2894177|NCT03289858|Placebo Comparator|Saline Control|Saline Solution (Sodium Chloride)
2894178|NCT03289845|Other|BHX implant|All patients implanted with BHX implant
2894179|NCT03289832|Active Comparator|Crucera-SGS®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a non-cruciferous diet and to ingest daily for 10 days, Crucera-SGS® as a source of glucoraphanin which is converted to sulforaphane; 9 capsules (450 mg or 1.03 mmol GR) per day.~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third days of chromometer readings, 2 biopsies will be taken from the upper buttocks for a total of 8 skin-punch biopsies per individual."
2894180|NCT03289832|Active Comparator|Meriva 500-SF®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a non-cruciferous diet and to ingest daily for 10 days, Meriva 500-SF® as a source of curcumin; 2 capsules (1000 mg or 2.72 mmol total curcuminoids) per day.~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third day of chromometer readings, 2 biopsies will be taken from the upper buttocks, for a total of 8 skin-punch biopsies per individual."
2894209|NCT03289624|No Intervention|Health Coaching|Six 30-minute weekly telephone calls to provide information and education related to the PWCC's conditions and information about services and care options will be conducted.
2894210|NCT03289611|No Intervention|Control|Usual management
2894211|NCT03289611|Experimental|Experimental|Ambulatory management if sFlt-1 / PlGF ratio is below 38 Usual management if sFlt-1/PlGF is between 38 and 85. If the ratio is > 85, monitoring will be intensified and patient hospitalization will be continued
2894212|NCT03289598|Experimental|Interventionsgroup|
2894181|NCT03289832|Active Comparator|Crucera-SGS® and Meriva 500-SF®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a cruciferous vegetable-free diet and to ingest daily for 10 days, Crucera-SGS® as a source of glucoraphanin which is converted to sulforaphane; 9 capsules (450 mg or 1.03 mmol GR) and Meriva 500-SF® as a source of curcumin; 2 capsules (1000 mg or 2.72 mmol total curcuminoids) per day.~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third day of chromometer readings, 2 biopsies will be taken from the upper buttocks for a total of 8 skin-punch biopsies per individual."
2894182|NCT03289819|Experimental|Pembrolizumab/Nab-Paclitaxel|"This is a phase II, one-arm, open label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple negative breast cancer.~All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.~Clinical and bioptic tumor assessment will be performed after each treatment phase. Study treatment will be applied until state of the art surgery, onset of unacceptable toxicities, progression or withdrawal of consent."
2894183|NCT03289806||Cases|Glaucoma surgery
2894184|NCT03289806||Controls|Strabismus surgery
2894185|NCT03289793|Experimental|Group A|"Children will be assigned to this group in a random fashion according to a ratio 2:1 with respect to group B (see below).~20 subjects will be included in this group."
2894186|NCT03289793|Active Comparator|Group B|Children will be assigned in this group in a random fashion. 10 subjects will be included in this group.
2894187|NCT03289793|Active Comparator|Group C|"Will be included in this group children who meet the inclusion criteria and who, with their families, are motivated to participate in the study but cannot claim to be part of groups A or B (because of logistical constraints: living too far away to comply with the frequency of the visits required by the training).~Group C allows to follow the natural evolution of children with ADHD with no intervention."
2894188|NCT03289767|Experimental|Curved-tube|Giving additional curve to the endotracheal tube by simple preparation.
2894189|NCT03289767|No Intervention|Control|No other manipulation of the endotracheal tube is done.
2894190|NCT03289754|Experimental|ConforMIS iTotal Knee with iPoly Insert|The tibial insert being utilized in this study will be a highly-crosslinked, Vitamin-E enriched UHMWPE (iPoly XE) instead of traditional tibial inserts.
2894191|NCT03289741|Experimental|Octreotide then Lanreotide|Each patient on study will receive three injections of intramuscular (IM) octreotide Long Acting Release (LAR). Octreotide LAR for 3 injections followed by lanreotide for 3 injections
2894192|NCT03289741|Experimental|Lanreotide then Octreotide|Each patient on study will receive three injections of deep subcutaneous (subq) lanreotide. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
2894193|NCT03289728|Experimental|Strategy guided by ischemia imaging|"Non-invasive imaging (SPECT or DSE) will be performed. High-risk Patients judged to high risk by imaging (according to ESC guidelines (5)) will undergo coronary angiography aimed at myocardial revascularization and have optimal medical treatment, according to ESC guidelines.~- Low or intermediate risk patients will receive optimal medical treatment."
2894194|NCT03289728|Active Comparator|Systematic coronary angioplasty|Patients will routinely undergo invasive coronary angiography aimed at myocardial revascularization.
2894195|NCT03289715|Experimental|arm 1|on demand humidification
2894196|NCT03289702|Experimental|CORETOX®|
2894197|NCT03289702|Active Comparator|BOTOX®|
2894198|NCT03289689|Experimental|Whole body vibration|"The subjects in the WBV group performed one series of five consecutive repetitions of 60 sec unsynchronised multidimensional WBV (Zeptoring, Scisen GmbH, Germany; 4 Hz, amplitude 3mm) with a 1-min pause between administrations, three times a week. The construction of this device is designed to perform a nonharmonious generation of oscillating movements in vertical and horizontal planes in order to prevent occurrences of resonance and habituation of receptors.~During the intervention, subjects wore thin-soled gymnastic-type shoes, carrying out in a squatting standing position, with slight flexion at the hips, knees and ankle joint, on the vibration platform."
2894199|NCT03289689|No Intervention|Control|The controls did not receive any training.
2894200|NCT03289676|Experimental|Quitting Smoking Video|This arm will receive a storytelling narrative intervention by watching a video of women living with HIV taking about their success in quitting smoking.
2894201|NCT03289676|Active Comparator|HIV Infection Video|This arm will watch an attention-control storytelling narrative intervention by watching a video of women living with HIV taking about their life after the diagnosis of HIV.
2894202|NCT03289663|Active Comparator|Control|The arm will receive bednets treated with conventional insecticide (Pyrethroid)
2894203|NCT03289663|Experimental|Experimental|The arm will receive bednets treated with new generation of insecticides (synergistic combination of insecticides)
2894204|NCT03289650|Active Comparator|Standard of care tacrolimus twice-daily|
2894205|NCT03289650|Active Comparator|Extended-release tacrolimus once-daily|
2894206|NCT03289637|Experimental|Active intervention|"In the group randomised to active treatment and with a screening level of 25-OH-vitamin D 25-50nmol/L an intervention with 1600IE daily of vitamin D will be given.~In those randomised to active treatment and with a screening level of 25-OH-vitamin D of <25nmol/L, an intervention of 2400IE of vitamin D will be given."
2894207|NCT03289637|Placebo Comparator|Placebo|In the group randomised to placebo and with a screening level of 25-OH-vitamin D <50 mol/L, the participants will be given placebo.
2894208|NCT03289624|Experimental|SHARE for Chronic Conditions|"Six weekly SHARE for Chronic Conditions (SHARE-CC) sessions will be conducted in the dyad's home or another location preferred by the participants. A care plan (the SHARE plan) is created that reflects the mutual decisions made by the dyad as a result of their participation in the SHARE-CC program. The SHARE plan is intended to help the caregiver (CG) ensure the PWCC's values and preferences are supported when decisions have to be made in an emergency or in the end stages of the disease. SHARE plans will be documented in a notebook that also contains information on key topics and provides links to local and online resources and services."
2894214|NCT03289585||HS Cohort|Patients with HS (ages 18-99 years old) will be asked to complete a series of questionnaires on how HS impacts quality of life.
2894215|NCT03289559|No Intervention|Control|
2894216|NCT03289559|Placebo Comparator|GnRH antagonist + Placebo Gel|
2894217|NCT03289559|Active Comparator|GnRH antagonist + Testosterone Gel|
2894218|NCT03289546|Experimental|Mindfulness training only|1 mindfulness training class (1 hour) every week for 8 weeks.
2894219|NCT03289546|Experimental|Aerobic training only|3 aerobic training sessions (1 hour) per week for 12 weeks.
2894220|NCT03289546|Experimental|mindfulness + aerobic training|2 aerobic training sessions + 1 mindfulness training class every week for 8 weeks, then continue with 3 aerobic training sessions/ week for 4 additional weeks.
2894221|NCT03289546|No Intervention|Usual care|
2894222|NCT03289533|Experimental|Experimental 1|Avelumab (MSB0010718C) in combination with axitinib (AG-013736)
2894223|NCT03289520|Experimental|Clopidogrel|
2894224|NCT03289520|Placebo Comparator|Placebo|
2894225|NCT03289507|Active Comparator|Treatment1|Longvida Capsule formulation A
2894226|NCT03289507|Active Comparator|Treatment 2|Longvida Capsule formulation B
2894227|NCT03289507|Experimental|Treatment3|Curcuma longa extract of Rhizomes
2894228|NCT03289494|Active Comparator|Diet A|Balanced diet high in Slowly Digestible Starch
2894229|NCT03289494|Placebo Comparator|Diet B|Balanced diet low in Slowly Digestible Starch
2894230|NCT03289481|Active Comparator|Active lozenge first|Subject will take active lozenge for one week, perform cardiac testing then take placebo lozenge for one week and perform cardiac testing.
2894231|NCT03289481|Active Comparator|Placebo lozenge first|Subject will take placebo lozenge for one week, perform cardiac testing then take active lozenge for one week and perform cardiac testing.
2894232|NCT03289468||Group1|Endometrial Benign Disease
2894233|NCT03289468||Group2|Endometrial Cancer and Precancerous Lesions
2894234|NCT03289455|Experimental|AUTO3|Paediatric patients with relapse or refractory B-cell ALL
2894235|NCT03289442|Experimental|supine position group|
2894236|NCT03289442|No Intervention|left lateral position|
2894237|NCT03289429|Experimental|Atorvastatin|Atorvastatin and intravenous placebo
2894238|NCT03289429|Experimental|Magnesium sulfate|Magnesium sulfate and tablets placebo
2894239|NCT03289429|Placebo Comparator|Control|intravenous placebo and tablet placebo
2894240|NCT03289416|Other|Platelet Rich Plasma (PRP)|Blood will be drawn from the patient using the Pure PRP II system into a syringe with anticoagulant (sodium citrate). 1 mL of blood will be separated and sent to a lab for analysis. Remaining blood will be separated into a single concentrating device and centrifuged to separate red blood cells from plasma and platelets. The plasma and platelets will be separated off with a syringe and re-centrifuged to separate the platelets from the plasma. 1 mL will be separated and sent to a lab for analysis leaving 6 mL for injection. Both the 1 mL of blood and the 1 mL of PRP will be sent to an independent lab to undergo analysis for CBC, TNC, human CD34+ hematopoietic stem/progenitor cell assay and CFU-F. Physician will then inject the PRP into the affected knee joint.
2894241|NCT03289416|Other|Bone Marrow Concentrate (BMC)|Bone marrow will be harvested from the posterior iliac crest using the PureBMC system. 50 mL of bone marrow will be drawn into one syringe containing 10 mL of sodium citrate. Marrow will be filtered and centrifuged for separation of the bone marrow concentrate. Plasma and cell concentrate will be separated off with two syringes and re-centrifuged to separate the cell concentrate from the plasma. After plasma is drawn off, BMC will be drawn into a syringe for injection into affected knee. BMC production procedure results in 7 mL of product and 1 mL will be separated and sent to a lab for analysis. Both 1 mL of BMA and 1 mL of BMC will be sent to an independent lab to undergo analysis for CBC, TNC, human CD34+ hematopoietic stem/progenitor cell assay and CFU-F.
2894242|NCT03289403|Experimental|Study group|Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D and immunomodulatory drugs(prednisolone, hydroxychloroquine, azathioprin, IV immunoglobulins)
2894243|NCT03289403|Active Comparator|Control group|Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D.
2894244|NCT03289390||Acetaminophen to close PDA|Infants with PDA treated with acetaminophen beyond 14 days of life or in whom acetaminophen is used due to contraindication to ibuprofen
2894245|NCT03289377|Experimental|RDAD training to APNs|Half-day workshop to provide APNs with all skills necessary to conduct RDAD in their clinical settings. A subset of the trained APNs will implement RDAD as part of their ongoing care of persons with ADRD.
2894246|NCT03289364|Experimental|Penguin Cold Caps|Penguin Cold-cap therapy will commence at least 50 minutes prior to chemotherapy infusion, and will continue for 4 hours following completion of chemotherapy.
2894247|NCT03289351|No Intervention|2-drug Therapy|ceftriaxone/metronidazole
2894248|NCT03289351|Experimental|1-drug Therapy|piperacillin-tazobactam
2894249|NCT03289338|Experimental|Zoledronic acid|Bisphosphonate Zoledronic acid
2894250|NCT03289338|Active Comparator|Methylprednisolone|Glucocorticoid Methylprednisolone
2894251|NCT03289338|Placebo Comparator|Placebos|Placebo normal saline
2894252|NCT03289325|Experimental|DEX group|The active drug (dexmedetomidine hydrochloride for injection) will be administered during a period from before anesthesia induction until the end of mechanical ventilation after surgery.
2894253|NCT03289325|Placebo Comparator|CTRL group|The placebo drug (normal saline, or 0.9% sodium chloride for injection) will be administered in the same rate and volume for a same duration as that in the DEX group.
2894254|NCT03289312||Sepsis|Diagnosis of new onset sepsis within 24h without history of tumor, hematological or immunological disease, and treatment with chemotherapy agents or corticosteroids within 6 months prior to or during the hospitalization.
2894255|NCT03289312||Health control|Health vonlunteers
2894256|NCT03289299|Experimental|Arm A|Non-high dose treatment in 3 phases Induction 6 cycles: carfilzomib, lenalidomide, daratumumab, dexamethasone Consolidation 6 cycles: carfilzomib, lenalidomide, daratumumab, dexamethasone Maintenance 12 cycles: lenalidomide, daratumumab
2894257|NCT03289286|Other|Patients with breast cancer operated in ambulatory|
2894258|NCT03289273||uHCC patients treated with regorafenib|Patients with a confirmed diagnosis of uHCC and for whom a decision to treat with regorafenib has been made (by the treating physician)
2894261|NCT03289247|No Intervention|Regular|"Regular closure:~The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure."
2894262|NCT03289247|Experimental|Additional tissue adhaesive|The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure. tissue adhesive (Leukosan®) is applied on top of the staples according to manufacturer instructions. One layer (one tube) of tissue adhesive is applied following air-drying for 30 seconds, followed by a placement of a second layer with a second layer (one tube), and a second air-drying period of 60 seconds
2894263|NCT03289234|Experimental|mild hepatic impairment|
2894264|NCT03289234|Experimental|moderate hepatic impairment|
2894265|NCT03289234|Experimental|normal hepatic function|
2894266|NCT03289221|Experimental|Experimental Group|Thirty (30) consecutive patients indicated for treatment of prostate cancer with HIFU (FocalOneR, Edap TMS, France) will be selected to the manometry study before the treatment together with the application of specific questionnaires (Cleveland Clinic Incontinence Score-CCIS, Fecal Incontinence Quality of Life Score-FIQLS, and Rome IV for functional constipation. This evaluaton will be conducted again after the treatment.
2894267|NCT03289208|Experimental|mild renal impairment|
2894268|NCT03289208|Experimental|moderated renal impairment|
2894269|NCT03289208|Experimental|normal renal function|
2894270|NCT03289195|Experimental|MRI biopsy|All patients enrolled will have had complete MR imaging response post Neoadjuvant Chemotherapy (NAC) and will undergo percutaneous MR guided biopsy.
2894271|NCT03289182||MabThera|Participants with NHL will be administered 1400 milligrams (mg) and those with with CLL will be administered 1600 mg MabThera subcutaneously at the discretion of the physician in accordance with local clinical practice and local labeling, and will be observed for 6 years.
2894272|NCT03289169|Experimental|MEDITOXIN|Meditoxin(Botulinum toxin type A)
2894273|NCT03289156|Active Comparator|Arousal Reappraisal|Brief educational intervention about the stress response and arousal reappraisal
2894274|NCT03289156|Active Comparator|Exercise|Three 5-minute bouts of aerobic exercise at increasing intensities
2894275|NCT03289156|Experimental|Arousal Reappraisal + Exercise|Brief educational intervention about the stress response and arousal reappraisal followed by three 5-minute bouts of aerobic exercise at increasing intensities with practice applying the arousal reappraisal learned earlier.
2894276|NCT03289156|No Intervention|Control|Time-matched rest
2894277|NCT03289143|Experimental|Dose 1 RO7105705|
2894278|NCT03289143|Experimental|Dose 2 RO7105705|
2894279|NCT03289143|Experimental|Dose 3 RO7105705|
2894280|NCT03289143|Placebo Comparator|Placebo|
2894281|NCT03289117|Experimental|Novel gel installation device procedure|"Catheter change with novel device.~Each subject will undergo catheter change with novel gel instillation device procedure"
2894282|NCT03289117|Active Comparator|Standard procedure|"Catheter change with standard procedure.~Each subject will undergo catheter change with standard procedure"
2894283|NCT03289104|Active Comparator|Steel Wires|In this arm, patients will have their sternum closed with steel wires.
2894284|NCT03289104|Experimental|ZipFix Sternal Closure System (Plastic Cables)|In this arm, patients will have their sternum closed with the ZipFix system.
2894285|NCT03289091|Experimental|water-based continuous aerobic training|Participants who will be randomized for the intervention in the continuous aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle. In the first mesocycle (weeks 1-4), participants will carry out three 4-minute series of each exercise whose intensity corresponds to the Rating of Perceived Exertion (RPE) 13. In the second mesocycle (weeks 5-8), participants will perform four 3-minute series of each exercise corresponding to RPE 14. In the third mesocycle, participants will perform six 2-minute series of each exercise at intensity corresponding to RPE 15 from weeks 9-10, whereas intensity corresponding to RPE 16 will be experienced from weeks 11-12.
2894286|NCT03289091|Experimental|water-based interval aerobic training|Participants who will be randomized for the intervention in the interval aerobic training group will carry out exercises which associate effort phases, at higher intensity and recovery phases, at lower intensity, with no interval for exercise change. Intensity will be increased every mesocycle. The first mesocycle (weeks 1-4) comprises three 4-minute series of each exercise whose intensity corresponds to the RPE 16 for 2 minutes and RPE 11 for 2 minutes. The second mesocycle (weeks 5-8) includes four 3-minute series of each exercise whose intensity corresponds to the RPE 17 for 1.5 minutes and RPE 11 for 2 minutes. The third mesocycle (weeks 9-12) comprises six 2-minute series of each exercise whose intensity corresponds to the RPE 18 for 1 minute and RPE 11 for 1 minute.
2894287|NCT03289078|Experimental|Thermal care|Spa Treatment realised daily 6 days a week during 18 days
2894288|NCT03289078|No Intervention|Standard Care|Usual care
2894289|NCT03289065||FOS Participant|FOS is a disease registry open to all Fabry participants irrespective of treatment status or type of treatment.
2894290|NCT03289052|Experimental|Restylane Volyme|Single injection and optional touch up injection with Restylane Volyme in Midface
2894291|NCT03289052|No Intervention|No intervention arm|No treatment
2894292|NCT03289039|Experimental|Neratinib|"Neratinib will be administered orally once daily~Neratinib is dosed at 240mg (six 40mg tablets)"
2894293|NCT03289039|Experimental|Neratinib + Fulvestrant|"Neratinib will be administered orally once daily~Neratinib is dosed at 240mg (six 40mg tablets)~Fulvestrant will be administered intramuscular as an injection (shot) on day 1 and 15 of cycle 1, day 1 of cycle 2, and then on day 1 of each subsequent cycle.~Fulvestrant is dosed as 250 mg/5mL (x2) for a total of 500 mg via intramuscular injection (two injections)."
2894294|NCT03289026|Experimental|aripiprazole group|Patients receive aripiprazole treatment
2894295|NCT03289013|Experimental|Testing of new adhesive strips|"Each subject will test six adhesive strips on pre-stripped skin.~Standard adhesive 1~Standard adhesive 2~LT-2~LT-21~LT-25~33-20~The six strips are applied on the abdominal skin. The order of the adhesive strips on the skin is randomized. The subjects will change the adhesive strips at home and the adhesion of adhesive strips will be measured at 5 visits."
2894296|NCT03289000||ConforMIS PS Group|Patients who have undergone a total knee replacement with the ConforMIS iTotal PS Knee Replacement System
2894297|NCT03288987|Experimental|Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)|Bevacizumab+FOLFIRI-3 (irinotecan, leucovorin, and 5-FU). Bevacizumab (AryoGen) 5 mg/kg will be administered every 2 weeks.
2894298|NCT03288987|Active Comparator|Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)|Bevacizumab+FOLFIRI-3 (irinotecan, leucovorin, and 5-FU). Bevacizumab (Avastin®) 5 mg/kg will be administered every 2 weeks.
2894299|NCT03288974||Post Marketing Survey of MM patients treated with POMALYST®|As a method of POMALYST® PMS, Drug Use Examination (DUE) is planned and designed to comply with the regulatory requirement in consequence of approval of a new drug in Korea. This DUE is a non-interventional, observational and post-marketing surveillance, which is conducted as a regulatory required procedure to evaluate product safety of a new drug treatment in clinical routine practice in Korea. And this DUE will be conducted in compliance with the local guideline [standard for Re-examination of New Drugs, etc.] as a post approval commitment.
2894300|NCT03288948|Active Comparator|Standard Contrast Increment|
2894301|NCT03288948|Experimental|Reduced Contrast Increment|
2894302|NCT03288948|Experimental|No Contrast Increment|
2894303|NCT03288935|Active Comparator|Group 1 (TICM only)|Assigned to TICM group after reception & placement.
2894304|NCT03288935|Active Comparator|Group 2 (TICO only)|Assigned to TICO group after reception & placement.
2894305|NCT03288935|Active Comparator|Group 3 (TICM & TICO)|Assigned to both TICM and TICO group after reception & placement.
2894306|NCT03288935|No Intervention|Group 4 (None)|No additional intervention after reception & placement
2894307|NCT03288922|Experimental|Limited BF OL-HDF with SHF|Limited blood flow pre-dilution online hemodiafiltration using super high-flux dialyzer which had larger pore size than standard high-flux dialyzer was assigned as the new intervention to compare the efficacy of protein-bound toxin removals with the control period.
2894308|NCT03288922|Active Comparator|High-efficiency OL-HDF|High-efficiency post-dilution online hemodiafiltration using standard high-flux dialyzer was assigned as the control period.
2894309|NCT03288909||Early onset Parkinson's disease|Idiopathic Parkinson's disease within 1 year of symptom onset
2894310|NCT03288909||Idiopathic REM Sleep Behavior Disorder|Idiopathic REM Sleep Behavior Disorder
2894311|NCT03288909||Age-matched healthy controls|Age-matched healthy controls
2894312|NCT03288896|Experimental|Alerta Alcohol|Intervention Group: The Experimental Group receives the Alerta Alcohol intervention, which consists of four sessions at school (baseline questionnaire, two sessions in three scenarios: at home, celebrations, and public places, and a final evaluation). The adolescents are provided with answers related to their views of each scenario; this information is used to provide highly specific feedback regarding their knowledge, risk perception, self-esteem, attitude, social influence (modelling, norms and social pressure), self-efficacy and action plans. In addition, two booster sessions are given at home to reinforce the contents of the three scenarios. Evaluation takes place after four months.
2894313|NCT03288896|No Intervention|Control Group|Control Group: The Control Group just completes the baseline and the evaluation questionnaires and then they are allowed to receive the intervention as well (as a waiting list control condition). Evaluation takes place after four months from baseline
2894314|NCT03288883|Active Comparator|Fractional Microablative CO2-laser|
2894315|NCT03288883|Active Comparator|Photothermal Non-ablative Erbium:YAG-laser|
2894316|NCT03288870|Experimental|BCD-100 monotherapy|Patients will receive solution of BCD-100 in a dose 3 mg/kg every 3 weeks as intravenous infusion until progression of the disease or signs of intolerable toxicity
2894317|NCT03288870|Active Comparator|Docetaxel monotherapy|Patients will receive solution of docetaxel in a dose 75 mg per square meter every 3 weeks as intravenous infusion until progression of the disease or signs of intolerable toxicity, maximum 6 cycles
2894318|NCT03288857|No Intervention|Bulb Aspirator|If randomized to the bulb aspirator group, the patient will be sent home with a bulb aspirator to use for home nasal secretion management
2894319|NCT03288857|Experimental|Nasal Oral Aspirator (NeilMed Naspira)|If randomized to the nasal oral aspirator group, patient will be sent home with a nasal oral aspirator to use for home nasal secretion management
2894320|NCT03288844||HOLOCORE Patients|Patients who completed the main HOLOCORE clinical trial will undergo to Ophthalmologic examinations, Digital pictures collection and QoL questionnaires (NEI VFQ 25 and EQ-5D-3L/Y) will be performed/administered at each study visit
2894321|NCT03288831|Active Comparator|Normal Subjects, Gluten Drink|Normal subjects will drink a solution containing 6 grams of gluten one time.
2894322|NCT03288831|Placebo Comparator|Normal Subjects, Placebo Drink|Normal subjects will drink a solution without gluten one time.
2894323|NCT03288831|Active Comparator|Celiac Subjects, Gluten Drink|Subjects with celiac disease will drink a solution containing 6 grams of gluten one time.
2894324|NCT03288831|Placebo Comparator|Celiac Subjects, Placebo Drink|Subjects with celiac disease will drink a solution without gluten one time.
2894325|NCT03288831|Active Comparator|Gluten Sensitivity, Gluten Drink|Subjects with non-celiac gluten sensitivity will drink a solution containing 6 grams of gluten one time.
2894326|NCT03288831|Placebo Comparator|Gluten Sensitivity, Placebo Drink|Subjects with non-celiac gluten sensitivity will drink a solution without gluten one time.
2894327|NCT03288818|Experimental|low dose TSEBT, mechlorethamine hydrochloride gel|Patients undergo low dose TSEBT for 2 weeks. After 30 days of observation, patients receive mechlorethamine hydrochloride gel topically daily at week 7 and then once weekly up to week 54.
2894328|NCT03288792|Experimental|RI8 device imaging|RI8 Device imaging for adjunctive detection of breast cancer
2894329|NCT03288779|Other|Theta Burst Stimulation Arm|This is a pilot open label study.
2894330|NCT03288766||PICC Placement with Study Device|PICC Placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software
2894331|NCT03288753|Experimental|Adults and children above 14 years old|"Visit 1:~Satisfaction questionnaire on Neuro 1 Speech intelligibility in quiet on Neuro 1 Speech intelligibility in noise on Neuro 1 VRB (Vocale Rapide dans le Bruit) on Neuro 1~Visit 2 (15 days after V1):~Satisfaction questionnaire on Neuro 2 Speech audiometry in quiet on Neuro 2 Speech audiometry in noise on Neuro 2 VRB (Vocale Rapide dans le Bruit) on Neuro 2~Visit 3 (3 months after V2):~Satisfaction questionnaire on Neuro 2 Speech audiometry in quiet on Neuro 2 Speech audiometry in noise on Neuro 2 VRB (Vocale Rapide dans le Bruit) on Neuro 2"
2894332|NCT03288753|Experimental|children up to 14 years old|"Visit 1 Satisfaction questionnaire on Neuro 1~Visit 2 (15 days after V1):~Satisfaction questionnaire on Neuro 2~Visit 3 (3 months after V2):~Satisfaction questionnaire on Neuro 2~The questionnaires have to be filled in by the parents. The child can participate in the completion of the questionnaire if he is willing and understands the questions."
2894333|NCT03288740|Experimental|Semaglutide 0.5 mg|Participants will enter a 13 weeks treatment with 4 weeks dosing at dose level 0.25 mg and 9 weeks at 0.5 mg semaglutide.
2894334|NCT03288740|Placebo Comparator|Semaglutide 0.5 mg placebo|Participants will enter a 13 weeks treatment with 4 weeks dosing at dose level 0.25 mg and 9 weeks at 0.5 mg semaglutide placebo.
2894335|NCT03288740|Experimental|Semaglutide 1.0 mg|Participants will have 13 weeks treatment with 4 weeks dosing at dose level of 0.25 mg, 4 weeks at 0.5 mg, and 5 weeks at 1.0 mg semaglutide.
2894336|NCT03288740|Placebo Comparator|Semaglutide 1.0 mg placebo|Participants will have 13 weeks treatment with 4 weeks dosing at dose level of 0.25 mg, 4 weeks at 0.5 mg, and 5 weeks at 1.0 mg semaglutide placebo.
2894337|NCT03288727|Experimental|Negative IF result|
2894338|NCT03288727|Experimental|Positive IF result|
2894339|NCT03288714|Experimental|Active sTMS|Synchronized Transcranial Magnetic Stimulation (sTMS) treatments to be administered using an active device 5 times per week for six treatment weeks.
2894340|NCT03288714|Sham Comparator|Sham Stimulation|Sham treatments to be administered using a sham device 5 times per week for six treatment weeks.
2894341|NCT03288701|Experimental|Body Composition Analysis|Daily measurement of the Body Composition using electrical Bioimpedance Analysis in a scale (seca mBCA 515). Including total body water and weight.
2894342|NCT03288688|Experimental|Exercise program and education|An exercise program in the form of home exercise videos will be given to the participants in this group. They will be asked to perform a minimum of two 35-minute exercise sessions per week, over a period of 11 weeks. They will also be required to attend three group exercise sessions, to confirm correct execution of the exercises. A short educational presentation on injury prevention will be offered at the beginning of the study, followed by three informative e-mails over the course of the study.
2894343|NCT03288688|No Intervention|No intervention|Participants in this group will be asked to continue their usual activities.
2894344|NCT03288675|Active Comparator|Active aiTBS - active CCT+SSRI|Patients receive active aiTBS treatment in the first week, and starting from week 3 receive active CCT for a period of 4 weeks in combination with an antidepressant (SSRI)
2894345|NCT03288675|Experimental|Active aiTBS - sham CCT+SSRI|Patients receive active aiTBS treatment in the first week, and starting from week 3 receive a control training for a period of 4 weeks in combination with an antidepressant (SSRI)
2894346|NCT03288675|Experimental|Sham aiTBS - aiTBS - active CCT+SSRI|Patients receive sham aiTBS treatment in the first week, real aiTBS treatment in the third week, and starting from the fifth week receive CCT for a period of 4 weeks in combination with an antidepressant (SSRI)
2894347|NCT03288675|Experimental|Sham aiTBS - aiTBS - sham CCT+SSRI|Patients receive sham aiTBS treatment in the first week, real aiTBS treatment in the third week, and starting from the fifth week control training for a period of 4 weeks in combination with an antidepressant (SSRI)
2894348|NCT03288662|Experimental|CT and histopathological classification|With each histopathological type of thymic epithelial tumors, we measure the maximun diameter in chest CT scan. Comparison of some characteristics of the tumor on preoperative chest CT scans and histopathological type of thymic epithelial tumors .
2894349|NCT03288649||Anorexia nervosa|adolescents with anorexia nervosa (N=20 ?), their parents (N=20), their physicians (N=20)
2894350|NCT03288649||Anxiety based school refusal|adolescents with anxiety based school refusal (N=20 ?), their parents (N=20), their physicians (N=20)
2894351|NCT03288649||Depression|adolescents with depression (N=20 ?), their parents (N=20), their physicians (N=20)
2894352|NCT03288636|Experimental|Experimental|"PKGroup:~Ravidasvir + Danoprevir/ Ritonavir"
2894353|NCT03288636|Placebo Comparator|Placebo|"Placebo Group:~Placebo"
2894354|NCT03288623|Experimental|Dark Chocolate|Dark chocolate (85% cocoa) 40 mg per day for 30 days
2894355|NCT03288623|Placebo Comparator|White/Milk Chocolate|White chocolate or Milk chocolate administration in tablet (<35% cocoa) per day for 30 days
2894356|NCT03288610||With inflammatory response|"Patients with postoperative inflammatory response as defined by the occurrence of severe SIRS and/or postoperative vasodilation syndrome.~Severe SIRS is defined by meeting at least 2 SIRS criteria during 6 consecutive hours or at least 3 SIRS criterias. Classical SIRS criteria include: temperature >38,3 or <36°C, heart rate >90/min, respiratory rate >20/min or PaCO2 <32mmHg, GB>12000 ou <4000 c/mm3.~Postoperative vasodilation syndrome is defined by the need of continuous infusion of norepinephrine (whatever the dose) to maintain the mean arterial pressure above 60 mmHg associated to a cardiac index above or egal to 2.2 L/min/m2.~Patients without postoperative severe SIRS and without postoperative vasodilation syndrome"
2894357|NCT03288597||A: advanced and metastatic neuroendocrine tumors|Advanced and metastatic neuroendocrine tumors receive syestematic treatment
2894358|NCT03288597||A: advanced and metastatic neuroendocrine carcinomas|Advanced and metastatic neuroendocrine carcinomas receive syestematic treatment
2894359|NCT03288584||Tocilizumab|Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
2894360|NCT03288584||Other biological agent|Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
2894361|NCT03288584||Corticosteroid and non-biological agents.|Enhanced treatment with corticosteroid and non-biological agents.
2894362|NCT03288571|Experimental|Wharton Jelly Mesenchymal stem cells|"Intervention: Wharton Jelly Mesenchymal stem cells Site: Renal parenchyma Route of administration: ultrasound guided- intra-parenchymal total of 3 sites in each kidney.~Number of doses: 3 doses 2 weeks apart for each kidney. Time interval between each dose: 2 weeks Total volume of cell suspension infused: 3 ml/kidney; each site will receive a 1 ml cell suspension with a total volume of 3 ml in each kidney."
2894363|NCT03288558|Experimental|Intervention Group|Subjects randomized to the intervention group will receive a comprehensive perioperative mechanical ventilation strategy that includes a bundle of protective settings (use of PEEP, recruitment maneuvers and continuation of mechanical ventilation during CPB).
2894364|NCT03288558|No Intervention|Control Group|Subjects randomized to the control group will receive mechanical ventilation according to the current usual care.
2894365|NCT03288545|Experimental|Enfortumab Vedotin + CPI|Enfortumab vedotin on days 1 and 8 plus CPI therapy (either pembrolizumab or atezolizumab) on day 1 every 21 days
2894366|NCT03288532|No Intervention|Arm A (active monitoring)|Participants randomised to Arm A will be allocated to active monitoring for 1 year, in line with current standard-of-care in resected primary RCC at high or intermediate risk of relapse
2894367|NCT03288532|Experimental|Arm B (durvalumab monotherapy)|Participants randomised to Arm B will receive durvalumab (1500mg) 4 weekly for 1 year (13 cycles maximum)
2894368|NCT03288532|Experimental|Arm C (durvalumab + tremelimumab)|Participants randomised to Arm C will receive durvalumab (administered as per arm B, i.e. 13 cycles maximum) and tremelimumab (75mg) on day 1 and week 4 visits (i.e. 2 cycles)
2894369|NCT03288506|Experimental|Google Hangout (VC) group|This group receive peer led support for depression via Google Hangouts for 8-weeks
2894370|NCT03288506|No Intervention|Waiting list control group|Waiting list
2894371|NCT03288493|Experimental|P-BCMA-101 CAR-T cells|single dose, intravenous infusion, CAR-T cells
2894372|NCT03288480|Other|PT-112|This is a single arm study of PT-112, which is administered to patients with relapsed or refractory MM
2894373|NCT03288467|Active Comparator|Root canal treatment with 5% NaOCl|Root canal treatment with 5% NaOCl: 5 ml of 5% sodium hypochlorite was used during root canal treatment after each instrument change.After root canal instrumentation, canals irrigated with 5ml of 17% EDTA solution for 1 minute followed by final wash with 5ml of 5% sodium hypochlorite.
2894374|NCT03288467|Active Comparator|Root canal treatment with 1% NaOCl|5 ml of 1% soium hypochlorite was used during root canal treatment after each instrument change.After root canal instrumentation, canals irrigated with 5ml of 17% EDTA solution for 1 minute followed by final wash with 5ml of 1% sodium hypochlorite.
2894375|NCT03288454|Experimental|Cohort 1|Administer ciraparantag or placebo Dosing schedule 1
2894376|NCT03288454|Experimental|Cohort 2|Administer ciraparantag or placebo Dosing schedule 2
2894377|NCT03288454|Experimental|Cohort 3|Administer ciraparantag or placebo Dosing schedule 3
2894378|NCT03288441||antiplatelet only|"Patients receiving antiplatelet medication, but not anticoagulation. Antiplatelet drugs include any class, dose or duration of any platelet aggregation inhibitor.~This refers to the antithrombotic regimen when the current thrombocytopenia, or risk thereof (i.e. predicted), was first identified (even if the treatment is subsequently stopped)"
2894379|NCT03288441||anticoagulant-based|"Patients receiving only anticoagulants or both anticoagulant and antiplatelet medication combined. This includes any class, dose or duration of any antiplatelet or anticoagulant drug.~This refers to the antithrombotic regimen when the current thrombocytopenia, or risk thereof (i.e. predicted), was first identified (even if the treatment is subsequently stopped)"
2894380|NCT03288428|Experimental|nalbuphine|using nalbuphine for patient controlled analgesia
2894381|NCT03288428|Active Comparator|morphine|using morphine for patient controlled analgesia
2894382|NCT03288415||SMZL|Patients newly diagnosed with Splenic Marginal Zone Lymphoma with a minimum follow-up of at least 5 years
2894383|NCT03288402|Experimental|ongoing fasted|ongoing fasted following 10 h overnight fast; series blood samples CgA over 180 min
2894384|NCT03288402|Experimental|intake of caffeine containing beverages|10 h overnight fast; intake of caffeine containing beverages; series blood samples CgA over 180 min
2894385|NCT03288402|Experimental|intake of 5 item English breakfast|10 h overnight fast; intake of 5-item English breakfast; series blood samples CgA over 180 min
2894386|NCT03288389|Placebo Comparator|Placebo|Participants will take 4 placebo wafers per day for 42 days. Subjects will be asked to take the Fibromyalgia Combined Symptom Survey (see attachments, based on validated survey instruments) on-line on Day 0 (before starting supplement/placebo) and on Days 1, 2, 3, 7, 14, 21, 30 and 42.
2894387|NCT03288389|Active Comparator|NTFactor Lipids®|Participants will take 4 NTFactor Lipid® wafers (4 g) per day for 42 days. Subjects will be asked to take the Fibromyalgia Combined Symptom Survey (see attachments, based on validated survey instruments) on-line on Day 0 (before starting supplement/placebo) and on Days 1, 2, 3, 7, 14, 21, 30 and 42.
2894388|NCT03288363|Experimental|tDCS|20 sessions tDCS (DC-Stimulator Plus -Neuroconn) during 2 Weeks on temporal cortex - each session : 30 minutes - 2 mA - 2 sessions per day - evaluation at 12 weeks post-treatment
2894389|NCT03288363|Sham Comparator|sham stimulation|the same parameters of stimulation as with real current stimulation (time, parameters to be seen on the apparatus screen) 20 sessions during 2 Weeks on temporal cortex - each session : 30 minutes - 2 sessions per day.
2894390|NCT03288350|Experimental|mDCF + Avelumab|"Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil, followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of docetaxel, cisplatin, 5-fluorouracil and avelumab.~Docetaxel as a one-hour 40 mg/m2 IV infusion on day 1. Cisplatin 40 mg/m2 IV infusion on day 1. 5-FU 1000 mg/m2/day over 2 days. Avelumab 10 mg/kg following the completion of the mDCF regimen."
2894391|NCT03288337||Hidradenitits Suppurativa Cohort|Patients with HS who are eligible to fill out the series of quality of life questionnaires
2894392|NCT03288324|Experimental|Tofacitinib Arm|open-label study
2894393|NCT03288311|Active Comparator|Protocolized Post-extubation Respiratory Support|Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning
2894394|NCT03288311|Active Comparator|Usual Care|Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
2894395|NCT03288298|Experimental|luteolin|a natural extract derived flavinoids
2894396|NCT03288298|Active Comparator|nano-luteolin|nano-particles derived from a natural extract luteolin
2894397|NCT03288272|Active Comparator|Arm 1 - WBRT 10 x 2 Gy|Arm 1 - WBRT 10 x 2 Gy Whole brain radiotherapy with a total dose of 20 Gy in single fractions of 2 Gy
2894398|NCT03288272|Active Comparator|Arm 2 - WBRT 15 x 2 Gy|Arm 2 - WBRT 15 x 2 Gy Whole brain radiotherapy with a total dose of 30 Gy in single fractions of 2 Gy
2894399|NCT03288272|Active Comparator|Arm 3 - Best Supportive Care|Symptomatic treatment includes steroids, pain medication, nutritional support etc.
2894400|NCT03288259|Experimental|Obese patients|Obese patients undergoing Local Anesthetics and Transnasal Endoscopy.
2894401|NCT03288246|No Intervention|Standard-of-care|Participants in the standard-of-care arm will receive a standard laboratory-based viral load test at baseline, 3, and 6 months.
2894402|NCT03288246|Experimental|Point-of-care|Participants in the point-of-care arm will receive a point-of-care viral load test at baseline, 3, and 6 months.
2894403|NCT03288233||Primary Group|
2894404|NCT03288220||Stroke patients|--Age 18 and over; Mild to moderate unilateral or bilateral upper limb hemiparesis; Stroke onset > 6 months prior to participation
2894405|NCT03288220||Healthy older adults|Healthy older adults--Age 60 and over
2894406|NCT03288207||Other Volunteers|targeting physical activity (PA) among at-risk African-American women in resource-limited, Washington, D.C. communities
2894407|NCT03288194|Experimental|Problem-Solving Treatment|Problem-Solving Treatment is a structured, yet flexible, form of cognitive-behavioral psychotherapy intended to increase problem-solving skills.
2894408|NCT03288194|Active Comparator|Time Management|Time Management is a structured, yet flexible, intervention intended to increase creativity.
2894409|NCT03288181|Experimental|Muscle Stretch Group|This is the group who applies the splint to stretch the calf muscles as per the described protocol for 4 weeks.
2894410|NCT03288181|No Intervention|Control Arm|This is the group who has undergone no splint for 4 weeks.
2894411|NCT03288168||0-18 y/o Patients with Medulloblastoma|Patients treated with comprehensive treatments including surgery, chemo-therapy with / without (less than 3 y/o) radiation, during the period of Jan 2008 and Dec 2012, whose tumor samples will be tested by NanoString and Histochemistry methods, are enrolled in this cohort group.
2894412|NCT03288155|Experimental|Flavonoid rich cocoa|Dark cocoa beverage rich in flavonoids
2894413|NCT03288155|Placebo Comparator|Low flavonoid cocoa|A control cocoa beverage low inn flavonoids
2894414|NCT03288142|Experimental|Intervention|"The intervention group will receive all the interventions provided to the control group. In addition, intervention group participants will install on their mobile phone the hypertension personal control program (HPCP) (Lark HTN Pro), which is a smartphone application. The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD. The HPCP has blood pressure, medication, and weight monitoring, including periodic reminders for the user to measure blood pressure, measure weight, and take their medication(s). The HPCP provides real-time feedback based on user input, such as out-of-range measurements and has additional features designed to encourage behavior change in areas such as dietary intake, physical activity, sleep, and stress reduction. Users can set goals and receive guidance and feedback through the app."
2894415|NCT03288142|No Intervention|Control|Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.
2894416|NCT03288129|Experimental|Perampanel|Perampanel will be administered orally once daily (QD) at bedtime. At the beginning of the Titration Period, oral perampanel will start at a dose of 2 milligrams (mg) QD. Doses of perampanel will then be up titrated in increments of 2 mg/day at no less than 2-week intervals according to the investigator's judgment. At the 4 mg dose, the investigator will confirm whether further dose escalation is needed based on participant response and tolerability. The investigator may adjust dosing further or leave the participant at 4 mg. The maximum dose is 12 mg. During the 39-week Maintenance Period, participants will continue to receive the perampanel dose level that was administered at the end of the Titration Period.
2894417|NCT03288116||patient|Scheimplug imaging and contrast and sensitivity test
2894418|NCT03288116||early disease|Scheimplug imaging and contrast and sensitivity test
2894419|NCT03288116||normal|Scheimplug imaging and contrast and sensitivity test
2894420|NCT03288103|Experimental|Growth Hormone Treatment for Participants with ACAN Deficiency|Pre-pubertal children with ACAN deficiency on daily growth hormone (Norditropin) regimen for 12 month period.
2894421|NCT03288090||Treated|
2894422|NCT03288090||Non-treated|
2894423|NCT03288077|Experimental|Triptophan beverage|Proprietary blend of nutritional interventions aimed at increasing sleepiness
2894424|NCT03288064|Experimental|Corinthian currant supplementation|Corinthian currant supplementation: 1.5 g CHO/kg BW prior to exercise
2894425|NCT03288064|Experimental|Glucose supplementation|Glucose drink (Top Star 100, Esteriplas, Portugal) supplementation: 1.5 g CHO/kg BW prior to exercise
2894426|NCT03288064|Placebo Comparator|Water ingestion|Water ingestion: 7 ml/kg BW prior to exercise
2894427|NCT03288051|Active Comparator|Crystalloid group|
2894428|NCT03288051|Active Comparator|Colloid group|
2894429|NCT03288038|Experimental|RSV5mg + EZE 10mg|Rosuvastatin 5mg/Ezetimibe 10mg
2894430|NCT03288038|Active Comparator|RSV5mg|Rosuvastatin 5mg
2894431|NCT03288038|Experimental|RSV10mg + EZE10mg|Rosuvastatin 10mg/ Ezetimibe 10mg
2894432|NCT03288038|Active Comparator|RSV10mg|Rosuvastatin 10mg
2894433|NCT03288038|Experimental|RSV20mg + EZE10mg|Rosuvastatin 20mg/Ezetimibe 10mg
2894434|NCT03288038|Active Comparator|RSV20mg|Rosuvastatin 20mg
2894435|NCT03288025|Experimental|Nutrition and Exercise|5 days a week of moderate exercise and biweekly diet counseling on Low Glycemic Index/ Mediterranean Diet for 12 weeks.
2894436|NCT03288025|No Intervention|Standard of Care|Counseling at baseline on diet as recommended by USDA and on the benefits of regular aerobic exercise.
2894437|NCT03287999||Haemophilia patients|Persons with haemophilia A or B - 240 to be recruited
2894438|NCT03287999||Healthy volunteers|Healthy volunteers - 10 to be recruited
2894439|NCT03287986||Suicide attempters|Depressed patients over 60 years of age with a personal history of suicide attempts scanned with MRI
2894440|NCT03287986||Patient controls|depressed patients over 60 years of age without a personal history of suicide attempt scanned with MRI
2932910|NCT03020550||GERD Patients|Subjects with active GERD symptoms.
2894441|NCT03287986||Healthy Controls|Healthy subjects over 60 years, not depressed and without personal history of severe mental illness or suicide attempts, scanned with MRI
2894442|NCT03287973|Active Comparator|Lifestyle modification program group|Patients with apnea-hypopnea index (AHI) ≥ 15/hr on home sleep study will participate in a dietitian-led lifestyle modification program (LMP) for 6 months. Patients will attend dietary consultation weekly in the first 4 months, and then monthly in the following two months.
2894443|NCT03287973|Other|CPAP group|Patients randomized into the continuous positive airway pressure (CPAP) group in each arm will be interviewed by the physician on duty and invited to start autoCPAP treatment for 6 months. They will be offered a CPAP education package. Patients will then commence autoCPAP treatment for 6 months at home.
2894444|NCT03287960|Experimental|setmelanotide|setmelanotide subcutaneous injection once daily
2894445|NCT03287960|Placebo Comparator|Placebo|Placebo subcutaneous injection once daily
2894446|NCT03287947|Experimental|A|Nintedanib
2894447|NCT03287934|Experimental|selective laser sintered stent|according to the allocation, the experimental group will receive a selective laser sintered stent for immediate implant drilling and placement after atraumatic extraction of the target tooth.
2894448|NCT03287934|Active Comparator|stereolithographic stent|according to the allocation, the intervention for the control group will be a stereolithographic stent after atraumatic extraction of the target tooth for immediately implant placement. the stereolithographic stent will be adapted and drilling will be done through the stent.
2894449|NCT03287921||mono bronchodilatation|patients with COPD and features of hyperinflation and small airway disease
2894450|NCT03287921||dual bronchodilatation|patients with COPD and features of hyperinflation and small airway disease
2894451|NCT03287908|Experimental|AMG 701|Comparison of different dosages of drug
2894452|NCT03287895|Experimental|Intervention - Decision Support|In addition to the regular conversation about CPR that a patient's physician may have with them, participants will be given a two-part intervention. First, the participant will receive a values clarification tool which helps them rate and understand which relevant values are most important to them. There are two forms of this tool, a full and simplified version. All participants in this arm will receive both, in randomized order. The second aspect of the intervention is an educational video about the potential risks and benefits of CPR, which all participants in this arm will receive.
2894453|NCT03287895|No Intervention|Control|Participants in this arm will receive usual care, the regular conversation about CPR that their physician may have with them.
2894454|NCT03287882|No Intervention|Standard of care|"Preconception period: none~Pregnancy period: daily iron (60 mg) and folic acid (400 µg) supplementation from confirmation of pregnancy; daily balanced energy protein supplements will additionally be provided to those participants who are underweight at the confirmation of pregnancy for the duration of the pregnancy~Postpartum period: daily iron and folic acid supplementation to 6 months postpartum"
2894455|NCT03287882|Experimental|MMN supplementation and life skills education|"Preconception period: twice-weekly MMN supplementation and bi-monthly group session including life skill based education materials~Pregnancy period: daily MMN supplementation from confirmation of pregnancy; daily balanced energy protein supplements will additionally be provided to those participants who are underweight at the confirmation of pregnancy for the duration of the pregnancy~Postpartum period: daily MMN supplementation to 6 months postpartum"
2894456|NCT03287869|Experimental|Brexpiprazole|Oral, tablet; starting dose of 2 mg/day, with potential to be titrated to a max of 4 mg/day
2894457|NCT03287856|Experimental|Treatment|Transcatheter Aortic Valve Implantation (TAVI) in failing surgical bioprosthesis
2894458|NCT03287843|Experimental|Early surgery group|İn this arm patients will go under surgery before eight weeks, after neoadjuvant chemoradiation therapy.
2894459|NCT03287843|Experimental|Late surgery group|İn this arm patients will go under surgery after eight weeks, after neoadjuvant chemoradiation therapy.
2894460|NCT03287830|Experimental|Intervention|Text message influenza vaccine reminders
2894461|NCT03287830|No Intervention|Usual care|"Season 2017-18: Usual care has no text message~Season 2018-19: Usual care includes on text message with a link to American Academy of Pediatrics parenting information page. The purpose is to provide those randomized to usual care with tangible benefit that is not related to the study."
2894462|NCT03287817|Experimental|AUTO3|Patient with relapsed or refractory DLBCL
2894463|NCT03287804|Experimental|AUTO2|Relapsed or refractory Myeloma patients
2894464|NCT03287791|Active Comparator|Azelaic acid (Finacea®) Foam|Reference azelaic acid drug 15% foam. Applied to the affected facial areas twice daily for 12 weeks (84 days)
2894465|NCT03287791|Experimental|Generic Azelaic Acid Foam|Test formulation of azelaic acid drug 15% foam. Applied to the affected facial areas twice daily for 12 weeks (84 days)
2894466|NCT03287791|Placebo Comparator|Vehicle Foam|Placebo formulation foam in the likeness of test and reference products.. Applied to the affected facial areas twice daily for 12 weeks (84 days)
2894467|NCT03287778|Active Comparator|Pyridoxine|Pyridoxine will be administered in dosages of 200 mg with a maximum dose of 400 mg.
2894468|NCT03287778|Placebo Comparator|Placebo|Matching placebos will be administered for each active drug.
2894469|NCT03287765|Experimental|Experimental 18F-AV-1451|
2894470|NCT03287752|Active Comparator|BASKA MASK|Patients will be anesthetized using BASKA mask after lubrication with water soluble lubricant.
2894471|NCT03287752|Active Comparator|Endotracheal tube|Patients will be anesthetized using appropriate sized cuffed oral endotracheal tube ETT.
2894472|NCT03287739||Single-group study|Assessment of behavioral biometric impairments
2894473|NCT03287726|Experimental|probiotics|
2894474|NCT03287726|Placebo Comparator|placebo|
2894475|NCT03287713|Active Comparator|Conventional oxygen (EPIDOC)|Patients randomized in conventional oxygen (EPIDOC) group will perform a Pulmonary Rehabilitation Program. Oxygen will be titrated to flow needed to maintain SpO2 ≥ 90% during training with both systems.
2894476|NCT03287713|Active Comparator|Nasal High-Flow oxygen therapy (EPIDOAF)|Patients will be randomized in nasal High-Flow oxygen therapy (EPIDOAF) group will perform a Pulmonary Rehabilitation Program. Oxygen will be titrated to FiO2 needed to maintain SpO2 ≥ 90% during training with both systems.
2894550|NCT03287284|Active Comparator|LLLT Group|Active Low Level Laser Therapy application with a dose of 240 Joules before resistance training
2894477|NCT03287700||Focus group participants|Adults who have received a cochlear implant on the National Health Service (NHS) at an auditory implant service in the United Kingdom (UK) OR Adults who have been referred to a UK auditory implant programme for assessment for cochlear implantation but who have not yet been implanted
2894478|NCT03287700||Online patient survey participants|Adults who have received a cochlear implant on the National Health Service (NHS) at an auditory implant service in the United Kingdom (UK)
2894479|NCT03287700||Online clinician survey participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
2894480|NCT03287700||Trial design workshop participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
2894481|NCT03287700||Manufacturer's forum participants|Representatives of manufacturers of cochlear implants who provide devices on the NHS
2894482|NCT03287700||Care pathway working group participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
2894483|NCT03287687|Active Comparator|Air for insufflation|In this arm of patients, air which is currently used as standard of care will be used for insufflation
2894484|NCT03287687|Experimental|Carbon dioxide gas for insufflation|in this arm of patients, carbon dioxide (CO2) will be used for insufflation during endoscopy
2894485|NCT03287674|Experimental|Patient group|"All patients receive the same treatment. All patients are treated with one dose of Ipilimumab 14 days prior to surgical removal of tumor tissue for TIL expansion. Hospitalization for TIL treatment is approximately 3 weeks.~The patients are admitted to hospital on day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine= on day -7 to day -1. The first of 4 doses of Nivolumab is administered on day -2 and every 2 weeks for at total of 4 doses.~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 13.~Interleukin-2 is administered as a daily low-dose subcutaneous injection for a total for 14 days."
2894486|NCT03287661|Experimental|Treatment Condition|An Online 8-week Acceptance-based Behavioural Therapy for chronic pain.
2894487|NCT03287661|No Intervention|Wait-list Control Condition|Wait-list Control group (8-weeks)
2894488|NCT03287635|Experimental|Acthar gel 80 U/ml|Patients who continue to experience clinically significant symptoms of dry eye disease even after utilizing traditional methods of treatment for dry eye including but not limited to artificial tears, warm compresses, topical anti-inflammatories like cyclosporine and/or lifitegrast. Patients will receive repository corticotropin intramuscular injections 80 u/ml 2-3 times weekly for up to 3 months as judged by the investigator.
2894489|NCT03287622|Experimental|Education Intervention + Nudge|This group will receive BOTH the scenario-tailored STOMP educational feedback AND the behavioral Nudge intervention
2894490|NCT03287622|Experimental|Standard of Care + Nudge|This group will receive routine, standard of care information AND the behavioral Nudge intervention
2894491|NCT03287622|Experimental|Educational Intervention no Nudge|This group will receive scenario-tailored opioid message (STOMP) feedback and NO behavioral nudge intervention.
2894492|NCT03287622|No Intervention|Standard of Care no Nudge|This group will receive only standard of care information and NO behavioral nudge intervention.
2894493|NCT03287609|Active Comparator|Evolocumab|Evolocumab 140 mg/mL, pre-filled auto-injector pen, 3 injections at day 1 and week 4
2894494|NCT03287609|Placebo Comparator|Placebo|Placebo, pre-filled auto-injector pen, 3 injections at day 1 and week 4
2894495|NCT03287596|Experimental|HEALTHY VOLUNTEERS|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium"
2894496|NCT03287596|Experimental|SPA + NON-SYMPTOMATICS|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium~3D Sequence ZTE2 DP with gadolinium~3D sequence UTE with gadolinium"
2894497|NCT03287596|Experimental|SPA + SYMPTOMATICS|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium~3D Sequence ZTE2 DP with gadolinium~3D sequence UTE with gadolinium"
2894498|NCT03287596|Experimental|MECHANIC TENDINOPATHY|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium~3D Sequence ZTE2 DP with gadolinium~3D sequence UTE with gadolinium"
2894499|NCT03287583|Experimental|SBIRT|SBIRT intervention for Gambling
2894500|NCT03287583|Other|Control|Participants randomized to the enhanced control condition will receive a handout with gambling resources.
2894501|NCT03287570|Experimental|Cettum (Electric moxibustion)|The patients in this group receive Cettum (Electric moxibustion) treatment prescribed by a certified Korean Medicine Doctor with more than 6 years of Oriental Medicine College education.
2894502|NCT03287570|Active Comparator|Traditional indirect moxibustion|The patients in this group receive traditional indirect moxibustion treatment using the same points, applied by a certified Korean Medicine Doctor with more than 6 years of Oriental Medicine College education.
2894503|NCT03287570|Other|Usual care|The patients in this group maintain the usual treatment and self-care.
2894504|NCT03287544|Experimental|Combined rehabilitation|Linguistic training as well as communication training.
2894505|NCT03287544|Active Comparator|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
2894506|NCT03287531|Experimental|conventional therapy (group I)|"Exercise therapy.~For muscles around TMJ :~Masetter Lateral Pterygoid Medial Pterygoid Temporalis Digastric~Pulsed ultrasound at 0.3 to 0.6 watts per sq cm over the lateral poles of the temporomandibular joint condyles with a small sound head for 2 to 3 minutes per side"
2894507|NCT03287531|Experimental|low level laser therapy (groupII)|LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.
2894508|NCT03287518|Active Comparator|Verum|WAK2017 One (1) ml IP should be taken with breakfast and one (1) ml with supper every day.
2894509|NCT03287518|Placebo Comparator|Placebo|"The placebo liquid is identical in colour and flavor to the verum. In order to maintain the blind with respect to the odour, the placebo will contain 3% Concentrated Aged Garlic Extract (DER 0.9-1.2:1), which is considered as inactive with respect to a potential beneficial effect.~One (1) ml IP should be taken with breakfast and one (1) ml with supper every day."
2894510|NCT03287505|Experimental|Abilify IM Depot 300mg by once|300 mg dose group: single-administration of Aripiprazole IM Depot (300 mg) in 12 subjects;
2894511|NCT03287505|Experimental|Abilify IM Depot 400mg by once|400 mg dose group: single-administration of Aripiprazole IM Depot (400 mg) in 12 subjects.
2894512|NCT03287492|Experimental|Question Prompt Sheet (QPS) Patient Group|"Participant receives the new informational material to read through.~At follow up visit, participant given both types of informational material to read through.~Questionnaires completed at baseline, after question and answer visit with physician, and at the follow up visit."
2894513|NCT03287492|Experimental|General Information Sheet (GIS) Patient Group|"Participant receives the regular informational material to read through.~At follow up visit, participant given both types of informational material to read through.~Questionnaires completed at baseline, after question and answer visit with physician, and at the follow up visit."
2894514|NCT03287492|Experimental|Question Prompt Sheet (QPS) Caregiver Group|"Participant receives the new informational material to read through.~After question and answer visit with physician, questionnaire completed."
2894515|NCT03287492|Experimental|General Information Sheet (GIS) Caregiver Group|"Participant receives the regular informational material to read through.~After question and answer visit with physician, questionnaire completed."
2894516|NCT03287479|Experimental|Gavi®|surplus or all fertilized oocytes will be cryoperserved by utilizing the closed, semi-automated Gavi® vitrification system
2894517|NCT03287479|Active Comparator|Cryotop®|surplus or all fertilized oocytes will be cryoperserved by utilizing the open, manual Cryotop® vitrification system
2894518|NCT03287466|Experimental|SpO2 88-92%|The intervention is targeted oxygen therapy (TO2T) to achieve an arterial haemoglobin oxygen saturation (SpO2) of 88-92%.
2894519|NCT03287466|Active Comparator|SpO2 96% or above|The control group will also receive TO2T, but to achieve an SpO2 of 96% or above (standard care).
2894520|NCT03287453|Experimental|Screening (educational intervention)|Participants attend educational sessions comprising of an inflatable colon interactive exhibit that allows visitors to walk through a colon while seeing images, a PowerPoint presentation that contains messages that are tailored to meet the cultural and linguistic needs of Black/African Americans, Appalachians, and Hispanics/Latinos, and or flip books/flip charts. Participants also receive a copy of the study information sheet which contains the basic elements of informed consent and a pre-education session knowledge survey.
2894521|NCT03287440|Active Comparator|COPD Wellness With Health Advocate|This arm will be given low-intensity pulmonary rehabilitation, COPD Wellness, for individuals with moderate-to-severe COPD with an additional assignment of a health advocate to address unmet social needs as an adherence strategy.
2894522|NCT03287440|Active Comparator|COPD Wellness|This arm will only be given low-intensity pulmonary rehabilitation, COPD Wellness, for individuals with moderate-to-severe COPD.
2894523|NCT03287427|Experimental|TetMYB Vaccine & BGB-A317|
2894524|NCT03287414|Experimental|VAY736|VAY736 administered subcutaneously (s.c.) every 4 weeks
2894525|NCT03287414|Placebo Comparator|Placebo|Placebo administered subcutaneously (s.c.) every 4 weeks
2894526|NCT03287401||Patients with general anesthesia|Patients with general anaesthesia are monitored with electroencephalography and the results will be associated with the risk for PACU delirium
2894527|NCT03287388|Experimental|No Rocuronium|Phase 1: no neuromuscular blockade
2894528|NCT03287388|Experimental|Rocuronium (moderate NMB)|Phase 2: moderate neuromuscular blockade (TOF 1-3)
2894529|NCT03287388|Experimental|Rocuronium (deep NMB)|Phase 3: deep neuromuscular blockade (PTC 0-1)
2894530|NCT03287375|Experimental|PIPAC|Peritoneal metastases (PM) from colorectal or appendiceal cancer will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using oxaliplatin 92 mg/m2 in 150 ml dextrose. Peritoneal metastases (PM) from other GI or gynecologic cancers will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using cisplatin 7.5 mg/m2 in 150 ml saline combined with doxorubicin 1.5 mg/m2 in 50 ml saline. PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg and the aerosolised chemotherapy will be nebulized at a maximum pressure of 200 PSI and a flow rate of 0.5 ml/min. There is no upper number of allowed PIPAC treatments, but they will be planned in series of 3 with 5 weeks interval.
2894531|NCT03287362|Experimental|ST-arm|one-third of the patients is randomized to schema therapy
2894532|NCT03287362|Active Comparator|CBT-arm|one-third of the patients is randomized to cognitive behavioral therapy
2894533|NCT03287362|Placebo Comparator|IST-arm|one-third of the patients is randomized to individualized supportive therapy
2894534|NCT03287349||Patients with severe reactions to radiation|Two 12.5 mL blood draws and photograph of severe reaction, and autoimmune testing in patients without prior testing.
2894535|NCT03287336|Experimental|Cohort 1|Dose of Tranexamic acid 5mg/kg will be administered.
2894536|NCT03287336|Experimental|Cohort 2|Dose of Tranexamic acid 10 mg/kg will be administered.
2894537|NCT03287336|Experimental|Cohort 3|Dose of Tranexamic acid 15 mg/kg will be administered.
2894538|NCT03287323|No Intervention|Usual Care Group|One hundred patients of a control group will receive standard intensive care treatment (Usual Care Group).
2894539|NCT03287323|Other|Proactive Palliative Care|One hundred patients will additionally be offered a palliative care Intervention (Proactive Palliative Care Group).
2894540|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 1|Six subjects in Cohort 1 will receive a single SC dose of 2 mg GSK3511294.
2894541|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 1|Two subjects in Cohort 1 will receive a single SC dose of placebo.
2894542|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 2|Six subjects in Cohort 2 will receive a single SC dose of 10 mg GSK3511294.
2894543|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 2|Two subjects in Cohort 2 will receive a single SC dose of placebo.
2894544|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 3|Nine subjects in Cohort 3 will receive a single SC dose of 30 mg GSK3511294.
2894545|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 3|Three subjects in Cohort 3 will receive a single SC dose of placebo.
2894546|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 4|Nine subjects in Cohort 4 will receive a single SC dose of 100 mg GSK3511294.
2894547|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 4|Three subjects in Cohort 4 will receive a single SC dose of placebo.
2894548|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 5|Six subjects in Cohort 5 will receive a single SC dose of 300 mg GSK3511294.
2894549|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 5|Two subjects in Cohort 5 will receive a single SC dose of placebo.
2894551|NCT03287284|Placebo Comparator|Placebo Group|Placebo Low Level Laser Therapy application before resistance training
2894552|NCT03287271|Experimental|Defactinib (VS-6063) +Carboplatin/Paclitaxel|
2894553|NCT03287258|Active Comparator|three program|30 patients are subjected to educational Pelvic floor dysfunction prevention program with perineal massage and Pelvic floor muscle exercise.
2894554|NCT03287258|Active Comparator|one program|60 patients are subjected to educational Pelvic floor dysfunction prevention program
2894555|NCT03287245|Experimental|Idasanutlin|150 milligrams (mg), once daily for 5 days, every 28 days, until treatment discontinuation or up to 2 years.
2894556|NCT03287232|Placebo Comparator|Placebo|
2894557|NCT03287232|Experimental|Prasterone|
2894558|NCT03287219|Active Comparator|150 mg Methylene Blue-MMX tablets|take 6 x 25mg Methylene Blue-MMX tablets equivalent to 150 mg
2894559|NCT03287219|Active Comparator|200 mg Methylene Blue-MMX tablets|take 8 x 25mg Methylene Blue-MMX tablets equivalent to 200 mg
2894560|NCT03287180|Experimental|Experimental group|Participants in the experimental group will attend one individual assessment with the study physician for combination of Buprenorphine/naloxone 4/1 prescription and urinalysis, along with one weekly Adolescent Community Reinforcement Approach (A-CRA) session (approximately 50 minutes).
2894561|NCT03287180|Active Comparator|Control group|Participants in the control condition will attend weekly individual limited counseling sessions with the MD who will also provide a prescription for combination of Buprenorphine/naloxone 4/1 (approximately 25 minutes in duration).
2894562|NCT03287167|Experimental|1 month DAPT intervention|After implantation of Firehawk coronary stents, 860 subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 1 month， then will be given aspirin and placebo for next 5 months.
2894563|NCT03287167|Active Comparator|6 months DAPT intervention|After implantation of Firehawk coronary stents, 860 subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 6 months.
2894564|NCT03287154|Experimental|Active tDCS stimulations|Patients in this arm will receive 10 tDCS active stimulations of 2 mA (1 stimulation per day from Monday to Friday during 2 weeks).
2894565|NCT03287154|Sham Comparator|Sham tDCS|"Patients in this arm will receive 10 sham stimulations (1 stimulation per day from Monday to Friday during 2 weeks).~As soon as the power will have reached the maximal intensity as in the active arm, the stimulation will be stopped."
2894566|NCT03287141|Sham Comparator|First intervention|The subjects did a shuttle walk test without any previous intervention.
2894567|NCT03287141|Experimental|Second intervention|Subjects underwent 30 minutes of noninvasive ventilation (CPAP) and then re-performed the shuttle walk test.
2894568|NCT03287141|Experimental|Third intervention|Subjects underwent 30 minutes of noninvasive ventilation (Bi-pap) and then re-performed the shuttle walk test.
2894569|NCT03287115|Experimental|Broccoli|Subjects will consume a dose of broccoli on day 11
2894570|NCT03287102|Other|Temporal inverted ILM peeling group|The internal limiting membrane is peeled from the temporal side of the fovea only
2894571|NCT03287102|Other|Complete ILM peeling group|The internal limiting membrane is completely removed around the fovea
2894572|NCT03287089|Active Comparator|Nitrofurantoin|Receives twice daily 100mg nitrofurantoin for 5 days following catheter removal
2894573|NCT03287089|Placebo Comparator|Placebo|Receives twice daily matching placebo for 5 days following catheter removal
2894574|NCT03287076|Experimental|active|Patients will receive exenatide injections
2894575|NCT03287076|No Intervention|standard care/no intervention|standard care for stroke as per hospital protocol
2894576|NCT03287050|Experimental|Pembrolizumab + SBRT|Pembrolizumab 200 mg IV q 21 days Stereotactic body radiation therapy (SBRT) administered between the second and third doses of pembrolizumab. SBRT dose and fractionation will be at the discretion of the treating radiation oncologist, but will be selected to respect the normal tissue tolerance of adjacent organs at risk.
2894577|NCT03287037|Experimental|tDCS over DLPFC|Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours.
2894578|NCT03287024|Experimental|BeGrow Stent System|All enrolled subjects will receive the BeGrow Stent System
2894579|NCT03287011|Active Comparator|Control tooth paste|controlled fluoridated toothpaste will be provided for brushing to both the groups initially
2894580|NCT03287011|Experimental|Shoplaque tooth paste|Fluoridated toothpaste with organic plaque disclosing dye will be given to the test group second visit
2894581|NCT03286998||placenta previa|pregnant women with singleton living healthy fetus diagnosed as having placenta previa by grey scale ultrasound (placental tissue covers the internal cervical os or within 2 cm from it)
2894582|NCT03286985||General ICU patients|No intervention is associated with inclusion to the study (observational study). Included will be all patients admitted to general ICU with ICU stay >72 hours, having deep venous thrombosis prophylaxis appropriate to clinical setting and following the recent guidelines. All study participants will undergo repeated noninvasive ultrasound testing for deep venous thrombosis, which is normal part of the routine care in our ICU.
2894583|NCT03286972||PET/MRI|"All participants will undergo a diagnostic PET/CT and a Radiation Treatment Planning CT per SOC procedures. In addition, all participants will undergo an additional imaging set consisting of a PET/MRI. It is anticipated that most patients will undergo the PET/MRI on the same day as their PET/CT negating the need for a second injection of the FDG radioisotope used for SOC PET imaging. All participants will receive gadolinium contrast per SOC dosing guidelines for the MRI portion of the PET/MRI. Both SOC MMRI pulse sequences and investigational sequences will be utilized in this study.~If a second dose of the radioisotope is need to complete the PET/MRI (unable to perform both PET scans on the same day) only a 50% dose of FDG will be administered due to the increased sensitivity the PET/MRI scanner."
2894584|NCT03286959|Active Comparator|PCR WITH CALCIUM HYDROXIDE|PCR WITH CALCIUM HYDROXIDE : A layer of dycal (dentsply) was placed adjacent to pulpal or axial wall after mixing as per manufacturer recommendations followed by etching and restoration with composite using incremental technique.
2894585|NCT03286959|Active Comparator|PCR WITH RMGIC|PCR WITH RMGIC: A layer of resin modified liner ( GC Fuji II ) was placed adjacent to pulpal or axial wall and light cured for 40 sec. afterwards the cavity was restored with composite as in other groups.
2894586|NCT03286959|Active Comparator|PCR WITH DIRECT COMPOSITE|PCR WITH DIRECT COMPOSITE: After partial caries excavation , etching and bonding was done directly without using any liner and cavity was restored with composite as in other groups
2894587|NCT03286946|Experimental|Blunt-type block needle|block with Blunt-type block needle.
2894588|NCT03286946|Active Comparator|Sharp-type block needle|block with Sharp-type block needle.
2894589|NCT03286933|Experimental|Yoga therapy intervention|Participants will participate in weekly yoga therapy sessions and have the opportunity to use the home video online.
2894590|NCT03286920||Oral natural diet|As for patients in oral natural diet group, the the participants shall receive oral natural diet.
2894591|NCT03286920||Oral nutrition supplement group|As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
2894592|NCT03286920||Tube feeding nutrition supplement group|As for patients in tube feeding group, in addition to oral natural die, the participants shall receive tube feeding nutrition supplement providing 750-1500kcal/d.
2894593|NCT03286907|Experimental|Online videos|Participants will watch two online videos, complete a self-administered online tutorial, and receive reminders at Month 1, 2, 4, 6 & 8
2894594|NCT03286907|Experimental|Online videos and MI|Participants will watch two online videos, complete a self-administered online tutorial, received motivational interviewing (MI), and receive reminders at Month 1, 2, 4, 6 & 8
2894595|NCT03286907|Active Comparator|Control group|Participants will receive online messages about mental health problems and stress reduction exercises
2894596|NCT03286894||248 healthy schoolchildren|There is only one study group consisting of 248 children recruited at school.
2894597|NCT03286881|Experimental|Group 1|
2894598|NCT03286881|Experimental|Group 2|
2894599|NCT03286881|Experimental|Group 3|
2894600|NCT03286881|Experimental|Group 4|
2894601|NCT03286881|Active Comparator|Group 5|
2894602|NCT03286868|Placebo Comparator|Standard of Care TKA|Standard of Care Total Knee Arthroplasty (TKA): No data from the Verasense sensor will be used to influence the surgery
2894603|NCT03286868|Experimental|TKA with Verasense sensor|Total Knee Arthroplasty (TKA) with Verasense sensor for Intraoperative Balancing: Surgeon will attempt to optimize the intraoperative pressures using the data from the Verasense sensor
2894604|NCT03286855|Experimental|Vibrating Mesh Group|Patient's admitted with an acute exacerbation of COPD and prescribed nebulised combined salbutamol 2.5mg/ipratropium bromide 0.5mg (Combivent) are randomised to receive their treatment via the Aerogen Ultra (CE 0050) vibrating mesh Nebuliser.
2894605|NCT03286855|Active Comparator|Standard Hospital Care Group|Patient's admitted with an acute exacerbation of COPD and prescribed nebulised combined salbutamol 2.5mg/ipratropium bromide 0.5mg (Combivent) are randomised to receive their treatment via the Hudson micromist small volume nebuliser which is the standard of care at our institution.
2894606|NCT03286842|Experimental|Olaparib|Olaparib 150mg tablets administered orally twice daily continuously
2894607|NCT03286829|Experimental|Treatment A (Test 1)|"Treatment A (Test 1): A Tesomet FDC tablet (20 mg immediate release [IR] metoprolol, 1 mg tesofensine, 80 mg extended release [ER] metoprolol) in fasted condition (High dose)"
2894608|NCT03286829|Experimental|Treatment B (Test 2)|"Treatment B (Test 2): A Tesomet FDC tablet (5 mg immediate IR metoprolol, 0.2 mg tesofensine, 20 mg ER metoprolol) in fasted condition. (Low dose)"
2894609|NCT03286829|Active Comparator|Treatment C (Comparator)|Treatment C (Comparator): 1 mg tesofensine (2 tablets of 0.5 mg), 25 mg commercial IR metoprolol (1 tablet of 25 mg), 75 mg commercial ER metoprolol (1 tablet of 25 mg ER metoprolol and 1 tablet of 50 mg ER metoprolol), fasted condition
2894610|NCT03286829|Experimental|Treatment D (Test 3)|"Treatment D (Test 3): A Tesomet FDC tablet (20 mg immediate IR metoprolol, 1 mg tesofensine, 80 mg ER metoprolol in fed condition (High dose)"
2894611|NCT03286816|Experimental|Lactate infusion|Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels
2894612|NCT03286816|Placebo Comparator|NaCl infusion|As a control condition, subjects will receive intravenous NaCl infusion
2894613|NCT03286803|Experimental|Arm A|Inactivated Poliovirus vaccine
2894614|NCT03286803|Active Comparator|Arm B|fractional dose inactivated poliovirus vaccine
2894615|NCT03286803|Experimental|Arm C|inactivated poliovirus vaccine
2894616|NCT03286803|Active Comparator|Arm D|fractional dose inactivated poliovirus vaccine
2894617|NCT03286777|Placebo Comparator|Placebo|Mannitol and silicon dioxide
2894618|NCT03286777|Experimental|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide
2894619|NCT03286777|Experimental|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant
2894620|NCT03286764|Placebo Comparator|Placebo|Distilled water spray as a placebo during Colonoscopy
2894621|NCT03286764|Experimental|Peppermint Oil|Peppermint Oil spray during Colonoscopy
2894622|NCT03286751|Experimental|LY900014|Single dose of LY900014 administered subcutaneously (SC) in three of six periods
2894623|NCT03286751|Active Comparator|Insulin Lispro (Humalog)|Single dose of insulin lispro administered SC in three of six periods
2894624|NCT03286725|No Intervention|Control Group|The Control Group will be asked to continue with their normal PE lessons.
2894625|NCT03286725|Experimental|Intervention Group|'Physical Education (PE) Programme'
2894626|NCT03286712|Experimental|Incident Peritoneal Dialysis|After signing informed consent form, the patients will be started on Renogen® at 150 units/kg/week. Oral iron supplements will be started at 105 mg elemental iron per day. If the patients will not have an increase in Hb by 1-2 g/dl or an increase in the reticulocyte count after the first month of treatment, the dose of Renogen® will be increased to 200 units/kg/week. If there will still be no increase in the Hb or reticulocyte count in the second month, other causes of anemia will be ruled out. If the Hb/Hct will increase beyond the target, the Renogen® dose will be reduced by 50 units/kg/week. If the Hb/Hct will be below target, the Renogen® dose will be increased by 50 units/kg/week.
2894696|NCT03286205|Active Comparator|Weekly Dosage|weekly dose of 100mg
2894627|NCT03286699|Active Comparator|DIET|This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant.
2894628|NCT03286699|Active Comparator|DIET-PA|This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant. In addition, this group will be prescribed moderate-intensity Physical Activity Intervention that will progressively increase to the goal of 250 minutes/week.
2894629|NCT03286686|Experimental|Experience 1|
2894630|NCT03286686|Experimental|Experience 2|
2894631|NCT03286686|Experimental|Experience 3|
2894632|NCT03286686|Experimental|Experience 4|
2894633|NCT03286686|Experimental|Experience 5|
2894634|NCT03286686|Experimental|Experience 6|
2894635|NCT03286673|Experimental|calcium phosphate|Pentacalcium hydroxy-triphosphate (Ca5(PO4)3OH) was incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
2894636|NCT03286673|Experimental|Tricalcium Phosphate|β-tricalcium phosphate (Ca3(PO4)2) as incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
2894637|NCT03286673|Experimental|Calcium carbonate|Calcium carbonate (CaCO3) was incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
2894638|NCT03286673|Active Comparator|Placebo|Wholemeal and crispy wafer bread without additional calcium additive.
2894639|NCT03286660|Other|COPD patients|"All convenient COPD patients admitted in real life for a rehabilitation program were included.~Exercises consist on a Chair Rise Tests and short questionnaire were added to the usual tools for the evaluation."
2894640|NCT03286647|Experimental|NORMALGRIEF|Oral hygiene instruction
2894641|NCT03286647|Experimental|COMPLICATEDGRIEF|Oral hygiene instruction
2894642|NCT03286647|Active Comparator|CONTROLS|Oral hygiene instruction
2894643|NCT03286634|Experimental|SR|"Standard Risk (SR) :~CNS 3 or CNS 2 regardless of response OR Time-point #1 (Day 15 induction) Flow MRD ≥ 1% (treatment will not be de-escalated even MRD <0.01% by TP#2) OR Time-point #2 (Day 1 IDMTX/MP of Consolidation) ≥0.01%~SR strategy:~All SR patient will have to receive two doses of anthracycline and 12 L-asparaginase doses during induction except those who are escalated to SR at time point 2 when MRD ≥0.01%.~During the first year of maintenance phase (48 weeks; 4x12 weeks blocks), cyclophosphamide and cytarabine bolus will be administered at 4 weekly interval."
2894644|NCT03286634|Experimental|LR|"Low Risk (LR):~Time-point #1 (Day 15 induction) Flow MRD <1% AND Time-point #2 (Day 1 IDMTX/MP of Consolidation) <0.01% AND CNS 1 only~LR strategy:~For LR patients, one dose of anthracycline and 3 doses of L-asparaginase will be omitted during induction.~Following re-induction I, interim maintenance and additional block of re-induction ie. re-induction II prior to maintenance phase will be omitted for LR patients."
2894645|NCT03286621||Children with Autism Spectrum Disorder|Children with an Autism Spectrum Disorder according to DSM-5 criteria
2894646|NCT03286621||Typically Developing Children|Typically developing children
2894647|NCT03286621||Children with Delayed Development Disorders|Children with Delayed Developmental Disorders other than ASD
2894648|NCT03286595|Experimental|Early Psychosis (EP)|EP participants will be individuals who are either a) at clinical high risk (CHR) for developing psychosis and/or bipolar disorder, or b) First Episode Psychosis (FEP) participants meeting criteria for schizophreniform disorder, schizophrenia, schizoaffective disorder or another psychotic, non-schizophrenia diagnosis including those with bipolar disorder.
2894649|NCT03286595|Experimental|Clinicians|Clinicians/treatment team members who are providing treatment services to the EP participants at one of the three early psychosis clinics.
2894650|NCT03286582|Experimental|AC-203|
2894651|NCT03286582|Active Comparator|Clobetasol|
2894652|NCT03286569|Active Comparator|Active upper Wilson appliance|Active upper arch Wilson quadhelex appliance
2894653|NCT03286569|Placebo Comparator|Non active upper expansion appliance|Non-Active upper arch Wilson quadhelex appliance
2894654|NCT03286556|Experimental|Autoantibody Reductive Therapy|"Therapeutic Plasma Exchange (TPE) consisting of 1x estimated plasma volume exchanges for 3 successive days (1-3) and then, after a one day interval to enable equilibration of autoantibodies between intra- and extra-vascular spaces, again on days 5, 6, 9, 11, 13, and 15.~Rituximab: One gm i.v. will be administered on day 6 and day 15 after completion of the TPE on those days.~Intravenous immunoglobulin (IVIG): 0.5 gm/kg/day i.v. on days 16-19~All subjects in this trial, including patients in this arm, will receive identical empiric antibiotics and steroids. The steroid dose is: Prednisone 60 mg (p.o.) on day 1, followed by 20 mg/day on days 2-5, 7-14, and 16-19 (or the i.v. methylprednisolone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 6 and 15, as a premedication prior to the rituximab."
2894655|NCT03286556|Active Comparator|Treatment as Usual (TAU)|The same steroid regimen as described for the experimental arm, i.e., prednisone 60 mg (p.o.) on day 1, followed by 20 mg/day on days 2-5, 7-14, and 16-19 (or the i.v. methylprednisolone equivalent), and methylprednisolone 100 mg i.v. administered on days 6 and 15, as well as empiric antibiotics.
2894656|NCT03286543|Experimental|Treatment Group (SPRINT Beta System)|Subjects in the treatment group will have up to 2 leads placed in their leg that underwent total knee replacement, will use the SPRINT Beta System, and will receive electrical stimulation in addition to the standard of care.
2894657|NCT03286543|No Intervention|Control Group|Subjects in the control group will receive the standard of care.
2894658|NCT03286530|Experimental|Ruxolitinib|Following a standard of care allogeneic stem cell transplantation, participants will be started on Ruxolitinib. Ruxolitinib is administered orally 2 times per day at a fixed dose. Each study treatment cycle lasts 28 days. Up to 24 cycles.
2894659|NCT03286517|Experimental|Tanner Stage I|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 9.5 µg/BW.
2894660|NCT03286517|Experimental|Tanner Stage II|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 11.50 µg/BW.
2894697|NCT03286205|Active Comparator|3 week dosage|every 3 week dosage.
2894661|NCT03286517|Experimental|Tanner Stage III|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 12.67 µg/BW.
2894662|NCT03286517|Experimental|Tanner Stage IV|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 15.11 µg/BW.
2894663|NCT03286517|Experimental|Tanner stage V|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 20.5 µg/BW.
2894664|NCT03286517|Experimental|Adult Group|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 1 µg/kg.
2894665|NCT03286504|No Intervention|Standard-of-care|Adolescents randomized to the standard arm will receive monthly HIV care in the GHESKIO Adolescent Clinic. Clinical care is provided in an individual exam room by a nurse. The patient is sequentially referred to the laboratory, social worker, and pharmacy for medication refills. A typical visit, including wait time, lasts 3 hours.
2894666|NCT03286504|Experimental|FANMI - Cohort Care|Adolescents randomized to FANMI will receive all monthly HIV care in the community room of the Prince Albert School in Village of God. Adolescents will be grouped in cohorts of 5-8 peers. The entire visit will take ~ 2 hours.
2894667|NCT03286491||Patients presenting with acute coronary syndrome|Patients presenting to emergency department with acute coronary syndrome
2894668|NCT03286478|Experimental|Mindfulness|Mindfulness-based body image intervention
2894669|NCT03286478|Experimental|Dissonance|Cognitive dissonance-based body image intervention
2894670|NCT03286478|Experimental|Confident Me|Dove Confident Me body image intervention
2894671|NCT03286478|No Intervention|Control|Classes as usual, assessment-only control group.
2894672|NCT03286465|Experimental|Pediatric phlebotomy tubes|Use of pediatric size tubes for diagnostic blood collection.
2894673|NCT03286465|Active Comparator|Adult phlebotomy tubes|Use of adult size tubes for diagnostic blood collection.
2894674|NCT03286426|Experimental|Vision/Eye Screening|Image of back of each eye along with color vision and visual acuity assessment if able.
2894675|NCT03286413|Experimental|microwave ablation|Microwave ablation（MWA）refers to all electromagnetic methods of inducing tumor destruction by using devices with frequencies greater than or equal to 900MHz. The rotation of dipole molecules accounts for most of the heat generated during MWA. Water molecules as dipoles attempt to continuously reorient at the same rate in microwave's oscillating electric field. As a result of microwave transmission, the water molecules flip back and forth billions of times a second. The vigorous movement of water molecules produce friction and heat, thus inducing cellular death via coagulation necrosis. The microwave unit (KY-2000, Kangyou Medical, Nanjing, China) is capable of producing 100 Watts of power at 2450 MHz.The needle antenna has a diameter of 1.6 mm (16G) and a length of 10 cm. The active tip length is 3mm and 5mm.
2894676|NCT03286413|Active Comparator|cryoablation|Clinically, cryosurgery is accomplished by placing a cryoprobe(up to 3.5 mm) through a stab incision into the tumor under ultrasound guidance.Liquid nitrogen is utilized under low operating pressure as cryogen which is controlled by the computer modulated cryogen regulator. The cryoprobe achieves rapid freezing by means of an active freeze zone at its distal tip.
2894677|NCT03286400||CTAG Device with ACTIVE CONTROL|All consecutive patients meeting protocol selection criteria, consented, with an intention to be treated with CTAG Device with ACTIVE CONTROL.
2894678|NCT03286387|Experimental|Memory for naturalistic episodes|Encoding of episode in real life situations (using Smartphones) or in a virtual environment, followed by memory retrieval (either behavior only or with fMRI, in successive studies)
2894679|NCT03286374|Other|Occupational rehabilitation|The participants will receive the current occupational rehabilitation program at Muritunet.
2894680|NCT03286361|Experimental|BeGraft Peripheral + Stent Graft System|Patients treated with the BeGraft Peripheral Plus Stent Graft System
2894681|NCT03286335|Experimental|Proton Radiation|"Radiation therapy will be delivered typically five (5) days per week on weekdays~Proton Radiation dose be determine by histology"
2894682|NCT03286322|Experimental|manual therapy cervical spine|
2894683|NCT03286322|Sham Comparator|control group|
2894684|NCT03286309|Experimental|EMG-driven soft robot hand|subjects will receive EMG-driven soft robot hand system.
2894685|NCT03286309|Placebo Comparator|sham group|subjects will receive passive pre-programmed soft robot hand system.
2894686|NCT03286296|Experimental|LZM009|
2894687|NCT03286283|Experimental|J-Plasma|Each study subject will receive one procedure with J-Plasma at enrollment.
2894688|NCT03286257|Experimental|Exercise Intervention|Participants will complete a partially supervised 4 month exercise program consisting of 3-5 sessions/week at a moderate intensity (40-75% heart rate (HR) reserve) at Liverpool Lifestyles gyms. Participants will be given free access to the Wellness Key System© when using the Lifestyles exercise equipment which allows researchers to remotely track the exercise intensity of participants accurately.
2894689|NCT03286244|Experimental|CM082 plus paclitaxel|"In dose-escalation part, patients will be treated in dose levels at the following daily doses of CM082 and paclitaxel to establish the MTD and RP2D:~CM082 100mg qd + paclitaxel 80mg/m2/day; CM082 150mg qd + paclitaxel 80mg/m2/day; CM082 200mg qd + paclitaxel 80mg/m2/day; In dose-expansion part, patients will be treated at the RP2D established in dose escalation part."
2894690|NCT03286231||Healthy volunteers|Healthy volunteers who will undergo contrast-enhanced CT imaging of the gluteal venous vasculature in the prone and jackknife positions
2894691|NCT03286218|Placebo Comparator|Placebo|Placebo administered orally in one of five treatment periods
2894692|NCT03286218|Active Comparator|Alprazolam|Alprazolam administered orally in one of five treatment periods
2894693|NCT03286218|Experimental|Lasmiditan - Low Dose|Low dose of lasmiditan administered orally in one of five treatment periods
2894694|NCT03286218|Experimental|Lasmiditan - Medium Dose|Medium dose of lasmiditan administered orally in one of five treatment periods
2894695|NCT03286218|Experimental|Lasmiditan - High Dose|High dose of lasmiditan administered orally in one of five treatment periods
2894698|NCT03286192|Experimental|Single-Arm Intervention|All participants in this arm receive compassion cultivation training
2894699|NCT03286166||Study arm|"20 subjects will undergo one session of PRP in which 60 cc of blood is drawn and centrifuged into 3 months of autologous serum tears.~• Subjects will utilize autologous tears twice daily in the study eye."
2894700|NCT03286166||Control Arm|Subjects in the control arm will receive study vehicle to be used twice daily in the left eye.
2894701|NCT03286153|Experimental|Ideal Body Weight First|Randomized to receive factor product based on ideal body weight first
2894702|NCT03286153|Experimental|Actual Body Weight First|Randomized to receive factor product based on actual body weight first
2894703|NCT03286140|Active Comparator|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with deferred treatment of superficial reflux (usually once the ulcer has healed)
2894704|NCT03286140|Experimental|Early arm|Early endovenous treatment of superficial venous reflux(within 2 weeks) in addition to standard compression therapy
2894705|NCT03286127||PCU (unit)|Those patients who received specialised palliative care on a palliative care unit.(palliative care unit)
2894706|NCT03286127||IPCC (hospital)|"Those patients admitted to a regular hospital ward who received specialised palliative care from an inpatient palliative care consultation team.~(inpatient palliative care consultation team)"
2894707|NCT03286127||OPCC (outpatient)|Those patients who received specialised palliative care at home from an outpatient palliative care consultation team. (outpatient palliative care consultation team)
2894708|NCT03286114|Experimental|Pembrolizumab|
2894709|NCT03286101|Experimental|0.5% Ivermectin Lotion|
2894710|NCT03286101|Placebo Comparator|Vehicle control|
2894711|NCT03286088|Other|Group A|TransEsophageal Echocardiography + TransThoracic Echocardiography
2894712|NCT03286088|Other|Group B|TransEsophageal Echocardiography + TransThoracic Echocardiography + cardiac Magnetic Resonance
2894713|NCT03286088|Other|Group C|TransEsophageal Echocardiography + TransThoracic Echocardiography + MitraClip
2894714|NCT03286075|Experimental|Anode tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (anode on the left DLPF).~Subjects will receive a 30-minutes session of 2mA tDCS. Facial emotion recognition task and attentional and working memory tasks with measurement of eye-tracking, heart rate, respiratory frequency and skin conductance will be conducted before and after the session."
2894715|NCT03286075|Experimental|Cathode tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (cathode on the left DLPF).~Subjects will receive a 30-minutes session of 2mA tDCS. Facial emotion recognition task and attentional and working memory tasks with measurement of eye-tracking, heart rate, respiratory frequency and skin conductance will be conducted before and after the session."
2894716|NCT03286075|Placebo Comparator|Placebo tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (placebo).~Subjects will receive a 30-minutes SHAM session of tDCS."
2894717|NCT03286062|Experimental|VM110|Escalating dose of agent VM110 given to patients to visualize occult cancer with laproscopic infra red detect
2894718|NCT03286049||Healthy children (HC)|10 healthy children
2894719|NCT03286049||Children with non allergic rhinitis (NAR)|10 children with non allergic rhinitis
2894720|NCT03286049||Rhinitis children, perennial allergy (PAR)|10 rhinitis children, sensitized to perennial allergens
2894721|NCT03286049||Rhinitis children, seasonal allergy, outside season (OSR)|10 rhinitis children sensitized to seasonal allergens, observed outside the allergen season
2894722|NCT03286049||Rhinitis children, seasonal allergy, within season (WSR)|10 rhinitis children sensitized to seasonal allergens, observed during the allergen season
2894723|NCT03286036||Lung cancer patients|Patients with lung cancer who undergo surgical resection of the tumor
2894724|NCT03286023||Stereotactic radiation|Stereotactic radiation for brain metastases
2894725|NCT03286010|Experimental|Intervention|Participants in the W@H group will be assembled in small groups of 6-12 participants and attend 12-biweekly sessions over a 24-week intervention period. The sessions will be led by a trained peer leader and will be held in a variety of convenient locations in close geographic proximity to participants' home postal codes. Participants will receive a manual containing copies of learning exercises and educational material. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention).
2894726|NCT03286010|No Intervention|Wait List Control|Participants assigned to the WLC group will be offered the W@H program after a 26-week waiting period
2894727|NCT03285997|Experimental|GC3110A|One injection: Day 0 Two injection: Day 0 and Day 28
2894728|NCT03285997|Active Comparator|GCFLU Pre-filled syringe inj.|One injection: Day 0 Two injection: Day 0 and Day 28
2894729|NCT03285984|Experimental|Test product 1|Participants will brush once (1.5g ± 0.05g of Test product 1), under supervision of study staff for one timed minute
2894730|NCT03285984|Experimental|Test product 2|Participants will brush once (1.5g ± 0.05g of Test product 2), under supervision of study staff for one timed minute
2894731|NCT03285984|Experimental|Test product 3|Participants will brush once (1.5g ± 0.05g of Test product 3), under supervision of study staff for one timed minute
2894732|NCT03285984|Experimental|Test product 4|Participants will brush once (1.5g ± 0.05g of Test product 4), under supervision of study staff for one timed minute
2894733|NCT03285971|Experimental|CPP Alert Group|Device: Electronic CPP pager alert anesthesia providers will receive a pager alert when CPP decreases below 60 mmHg (median value over 5-minute epochs)
2894734|NCT03285971|No Intervention|Control|This arm will not receive the automated pager alerts.
2894735|NCT03285958|Experimental|STEPS Intervention Group|Participants will receive a wearable physical activity monitor and will be asked to report their daily step count in 3 different ways (2 weeks each of SMS text messages, Interactive Voice Response calls (IVR), automatic upload) during the 6-week study period.
2894736|NCT03285958|No Intervention|STEPS Control Group|Participants in this group will not receive a wearable physical activity monitor and will not be asked to report their step count.
2938200|NCT02984332|Experimental|Lower limb immobilisation|
2894739|NCT03285932|Experimental|Post-operative SRS of resection cavity|"High-resolution contrast-enhanced post-operative MRI imaging in preparation for Cyberknife SRS. Cyberknife SRS of the resection cavity and all potential additional metastases diagnosed in the treatment planning MRI (up to 10 lesions)~Resection cavity:~7 x 5 Gy @ 95%-isodose~Potential additional brain metastases:~20 Gy @ 70%-isodose (lesions < 2 cm max. diameter) 18 Gy @ 70%-isodose (lesions 2 - 3 cm max. diameter) 6 x 5 Gy @ 70%-isodose (lesions > 3 cm max. diameter)"
2894740|NCT03285932|Other|Post-operative WBRT|Post-operative WBRT will be performed according to the following dose regimen: 10 x 3 Gy
2894741|NCT03285919|Experimental|Case - stroke survivor|Stroke survivor, 6mon post stroke resulting in right-sided hemiparesis, 53yrs old, had completed a 2mon rehabilitation program prior to the study. He underwent 30 training sessions with the Balance Assessment Robot (BAR™) within a 10-week period, each consisting of 10-15min of unperturbed treadmill and 30-45min of perturbation training. Perturbations were delivered in the forward, backward, left and right direction, occurring every 6sec, at the left leg initial contact and the right leg initial contact. Two training sessions were spent to determine adequate treadmill speed (0.4m/s) and perturbation amplitude (60N), followed by the first assessment session. After the last training session, assessment was repeated using the same parameters plus 90N perturbation amplitude.
2894742|NCT03285919|Active Comparator|Control - matched healthy subject|Healthy male, height- and weight-matched to the Case. He was assessed according to the same protocol as the Case using the Balance Assessment Robot (BAR™) at perturbation amplitudes 60 and 90 N.
2894743|NCT03285906|Experimental|Treatment group|Apatinib：500 mg，po，qd
2894744|NCT03285893||Native Hawaiian cigarette smokers|oral cell DNA adducts
2894745|NCT03285893||White (European Americans) cigarette smokers|oral cell DNA adducts
2894746|NCT03285893||Japanese American cigarette smokers|oral cell DNA adducts
2894747|NCT03285880|Experimental|Declarative memory|Napping v. wake effect on a declarative memory task (storybook)
2894748|NCT03285880|Experimental|Procedural memory|Napping v. wake effect on a procedural memory task (motor sequence learning or mirror tracing)
2894749|NCT03285880|Experimental|Emotional memory|Napping v. wake effect on an emotional memory task (emotional faces or storybook)
2894750|NCT03285867||HCC received TACE|observational study set only one group with HCC received TACE
2894751|NCT03285854||Children with CKD stage 3-5 and dialysis|Children of all ages with an eGFR <60ml/min/1.73m2, including those on dialysis
2894752|NCT03285854||Healthy age and gender matched children|"All children <18 years~Normal renal function (eGFR 90-120ml/min/1.73m2 [calculated by Schwartz formula] in children >1 year and serum creatinine <35μMol/L in children <1 year)~Weight, height and BMI within 2 SD of normal using WHO growth charts In order to make this study as 'real-life' as possible, free-living UK children on their usual diet and dietary supplementation (including Ca and Vit D), if any, will be included, but analysis will account for medication doses and blood levels."
2894753|NCT03285841||Cervical Sites|Imaging complete cervix from endocervical canal to transformation zone to ectocervix.
2894754|NCT03285841||Vulvar sites|Imaging vulvar lesions
2894755|NCT03285828|Other|First group|Students received three four-hour sessions of a basic motivationnal interviewing training over a one week period. The students interviewed for 15 minutes a caregiver playing the role of a patient, six weeks before and three weeks after the training.
2894756|NCT03285828|Other|Second group|Students received three four-hour sessions of a basic motivationnal interviewing training over a one week period. The students interviewed for 15 minutes a caregiver playing the role of a patient, six weeks before and three weeks after the training.
2894757|NCT03285815|Experimental|Proton Therapy 60 CGE|60 CGE (3CGE X 20) for 4wks
2894758|NCT03285815|Experimental|Proton Therapy 47 CGE|47 CGE (4.7CGE X 10) for 2wks
2894759|NCT03285802|Experimental|Letrozole and Everolimus|Letrozole 2.5mg daily q 30 days Everolimus 10mg daily q 28 days
2894760|NCT03285789|Experimental|Dyslexics with reduced visual attention span|21 subjects diagnosed dyslexics with reduced visual attention span
2894761|NCT03285789|Experimental|Dyslexics with normal visual attention span|
2894762|NCT03285789|Active Comparator|controls|
2894763|NCT03285776||Study group|Children with coordination disorder between the ages of 5 to 7 years.
2894764|NCT03285776||control group|children with typical development between the ages of 5 to 7 years.
2894765|NCT03285763|Experimental|Atezolizumab|Participants with Stage IIIb or State IV NSCLC who have progressed after standard systemic chemotherapy will receive atezolizumab until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
2894766|NCT03285750||Diabetic group|Patients with recently diagnosed type 2 diabetes
2894767|NCT03285750||Controls|Age- and BMI-matched normoglycemic subjects
2894768|NCT03285737|Experimental|Whey protein supplement|Supplement will be delivered twice daily (30g per supplement) of whey protein isolate
2894769|NCT03285737|Active Comparator|Collagen peptide supplement|Supplement will be delivered twice daily (30g per supplement) of hydrolyzed collagen peptides.
2894770|NCT03285711|Experimental|Filgotinib|Filgotinib + GS-9876 placebo
2894771|NCT03285711|Experimental|GS-9876|GS-9876 + filgotinib placebo
2894772|NCT03285711|Experimental|Extended Blinded Treatment Phase|Based on reduction in urinary protein excretion, participants will continue to receive their assigned blinded study treatment for an additional 20 weeks or continue to either study treatment per the Investigator's discretion.
2894773|NCT03285698|Other|Integra®|Integra® is a bilayer wound matrix made out of bovine tissue.
2894774|NCT03285698|Experimental|DermACELL®|DermACELL® is a bilayer wound matrix made out of human tissue.
2894775|NCT03285685|Experimental|tDCS M1|active tDCS Participants will receive active transcranial direct current stimulation.
2894776|NCT03285685|Experimental|tDCS DLPF|active tDCS Participants will receive active transcranial direct current stimulation.
2894777|NCT03285685|Sham Comparator|tDCS sham|tDCS Sham Participants will receive sham transcranial direct current stimulation.
2894778|NCT03285672|Experimental|Arm 1|FP-101
2894779|NCT03285672|Placebo Comparator|Arm 2|Placebo Comparator
2894780|NCT03285659|Experimental|Intervention: INDI Implementation|Primary care centres which will implement the collaborative (INDI) care model for depression
2894781|NCT03285659|No Intervention|Control: no INDI implementation|Primary care centres in which the collaborative care strategy INDI will not be implemented, but will be compared in terms of their clinical practice towards depression
2894782|NCT03285646|Experimental|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
2894783|NCT03285646|Placebo Comparator|Placebo|SC every 4 weeks
2894784|NCT03285633|Other|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
2894785|NCT03285620|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive single oral dose of AL-034 (oral solution) (the starting dose in Cohort 1 of Part 1 will be 0.2 milligram [mg]) or matching placebo under fasted condition (Cohorts 1 to 5 or optional Cohort 7) on Day 1. Participants may receive AL-034 in a fed state (Cohort 6) to evaluate the effect of food on the pharmacokinetics (PK) of AL-034.
2894786|NCT03285620|Experimental|Part 2: Multiple-Dose Administration (MAD)|Participants will receive multiple oral doses of AL-034 or matching placebo for 4 consecutive weeks either once weekly (Qwk - for 4 doses) or every two weeks (Q2wk - for 3 doses) under fed or fasted conditions. The starting dose for Part 2 will be determined based on the initial PK and safety/tolerability data from Part 1.
2894787|NCT03285607|Experimental|Dose Level 1:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
2894788|NCT03285607|Experimental|Dose Level 2:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
2894789|NCT03285607|Experimental|Dose Expansion:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
2894790|NCT03285594|Experimental|Dose 1|Dose 1 of sotagliflozin (SAR439954) will be administered as two tablets, taken orally once daily, before first meal of the day. Background therapy with insulin glargine (Lantus) (with or without OADs) will continue throughout the study.
2894791|NCT03285594|Experimental|Dose 2|Dose 2 of sotagliflozin (SAR439954) will be administered as one tablet plus one placebo tablet, taken orally once daily, before first meal of the day. Background therapy with insulin glargine (Lantus) (with or without OADs) will continue throughout the study.
2894792|NCT03285594|Placebo Comparator|Placebo|Two placebo tablets, taken orally once daily, before first meal of the day. Background therapy with insulin glargine (Lantus) (with or without OADs) will continue throughout the study.
2894793|NCT03285581|Other|Arm-1|Device:Treatment Subject(s) will receive 2 RF treatments
2894794|NCT03285568||Palbociclib|women at least 18 years old, with ER+, HER2- advanced breast cancer, and were receiving palbociclib
2894795|NCT03285555|Active Comparator|STRATAFIX GROUP|For the active arm of the study, wound closure will be performed similarly in 3 layers with the use of barbed equivalents at every layer: STRATIFIX symmetric PDS Plus #1 will be used to close the deep fascia and muscles . The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson & Johnson) followed by the use of steri-strips and glue
2894796|NCT03285555|Placebo Comparator|CONTROL GROUP|For the control arm of the study, wound closure will be performed similarly in 3 layers with the use of vicryl to closure the deep fascia and muscles. The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson & Johnson) followed by the use of steri-strips and glue
2894797|NCT03285542|Active Comparator|DERMABOND GROUP|For the active arm of the study, the arthrotomy (deep layer) is repaired using number 1 Vicryl, the subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a STRATAFIX Spiral Knotless Tissue Control Device in addition to DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey) system for dermal closure.
2894798|NCT03285542|Placebo Comparator|CONTROL GROUP|For the control arm of the study, the arthrotomy (deep layer) is repaired using number 1 Vicryl, the subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by skin closure with staples
2894832|NCT03285256|Active Comparator|Comparator Memory Training 2|Alternative comparator memory training program
2894799|NCT03285529|Active Comparator|STRATAFIX GROUP|STRATIFIX symmetric PDS Plus #1 will be used to close the capsule following total knee arthroplasty. The subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl) followed by the use of steri-strips and adhesive
2894800|NCT03285529|Placebo Comparator|CONTROL GROUP|The arthrotomy (deep layer) is repaired using Vicryl #1 followed by closure of the intermediate layer with a 2-0 Vicryl and a subcutaneous layer with a 2-0 Monocryl followed by steri-strips and adhesive, following total knee arthroplasty.
2894801|NCT03285516|Experimental|START|The Safety Aid Reduction Treatment (START) protocol will consist of eight group sessions, delivered once weekly, lasting approximately one hour in duration. START will be delivered in-person by the PI and group co-leader.
2894802|NCT03285503|Experimental|400 mg group|Aripiprazole IM depot 400mg will be administered every four weeks for 20 weeks after drug switch / steady dose of oral aripiprazole tablets (each subject will receive 5 intramuscular injections totally).
2894803|NCT03285490|Experimental|KX2-391 Ointment 1%|KX2-391 Ointment will be applied once daily for X consecutive days on the face or scalp
2894804|NCT03285490|Placebo Comparator|Placebo|The Vehicle Ointment will be applied once daily for X consecutive days on the face or scalp
2894805|NCT03285477|Experimental|KX2-391 Ointment 1%|KX2-391 Ointment will be applied once daily for X consecutive days on the face or scalp
2894806|NCT03285477|Placebo Comparator|Placebo|The Vehicle Ointment will be applied once daily for X consecutive days on the face or scalp
2894807|NCT03285464|Active Comparator|Hip|This group will perform a known hip strengthening program
2894808|NCT03285464|Experimental|Trunk|This group will use the trunk as a lever to strengthen the hip
2894809|NCT03285438|Experimental|Reduced dose of DOAC|A reduced dose of DOAC (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) during a mean follow-up period of 24 months (12 to 48 months)
2894810|NCT03285438|Active Comparator|Full dose of DOAC|A full dose of DOAC (Apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily) during a mean follow-up period of 24 months (12 to 48 months).
2894811|NCT03285412|Experimental|Ribociclib Intermittent + Endocrine Rx|Ribociclib will be administered for 21 days on a 28 days cycle Endocrine therapy will be administered daily
2894812|NCT03285412|Experimental|Ribociclib Continuous + Endocrine Rx|Ribociclib will be administered daily on a 28 days cycle Endocrine therapy will be administered daily
2894813|NCT03285386|Experimental|Priming Exercise|Participants will perform constant power output tests at four separate, fixed intensities to exhaustion on a cycle ergometer on separate days. These exhaustive, constant power tests will be preceded by 3 minutes of light cycling, 6 minutes of high intensity cycling, 7 minutes of rest and 3 minutes of light cycling.
2894814|NCT03285386|Active Comparator|Control|Participants will perform constant power output tests at four separate, fixed intensities to exhaustion on a cycle ergometer on separate days. These exhaustive, constant power tests will be preceded by 3 minutes of light cycling only.
2894815|NCT03285373||patients with NVAF|patients with Non Valvular Atrial Fibrillation
2894816|NCT03285360|Experimental|sylc bioactive glass|"Sylc is a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment.~Steps:~Isolation: D.M. will make proper isolation for the teeth using cotton rolls.~Hand piece: NSK Prophymate Neo will be used to deliver the powder particles on the sensitive areas. Air stream adjusted at 40-46 psi.~Application: The hand piece will be held at constant distance (3-4mm) away from the tooth surface, with 60-80 degrees on the buccal surfaces. The powder will be applied for 5-10 seconds per tooth in a circular movement.~Suction: High volume suction will be used on lingual side of the teeth to suck any particles, and avoid patient from swallowing it."
2894817|NCT03285360|Active Comparator|fluoride varnish (Bifluorid 10)|"fluoride varnish Bifluorid 10(by VOCO) will be used. It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.~The single dose form will be used, to make sure the amount of fluoride varnish used is standardized.~Steps:~Preparation: The tooth will be properly cleaned, and the surface will be air-dried.~Dispensing: The foil will be pierced using a micro- tim, the opening will be enlarged, the brush will be wet in a circular movement.~Application: Thin coat will be applied on the tooth surface. The varnish will be left from 10-20 seconds then air dried.~Concerning the storage of the Bifluoride 10, it will be stored in refrigerator at the operative clinic to avoid exposure to high temperature or sunlight."
2894818|NCT03285347|Experimental|Brain+ Evolution|"Intervention: Training with computer-based programme Brain+ Evolution for 8 weeks, receiving follow-ups every second week.~Computer-based cognitive training."
2894819|NCT03285347|Experimental|Scientific Brain Training PRO|"Intervention: Training with computer-based programme Scientific Brain Training PRO for 8 weeks, receiving follow-ups every second week.~Computer-based cognitive training."
2894820|NCT03285347|No Intervention|Control group|This Group receives no intervention except for the same amount of follow-ups as the two training Groups. This is done to ensure that an effect of training is not aqtually due to the follow-up's with a professional.
2894821|NCT03285334|Experimental|XP-endo Shaper|The XP-endo Shaper is an innovative single instrument manufactured from Max wire. Its special ability to shift crystalline structure at body temperature in order to adapt to the root canal wall, has provided a unique instrument with the promise of anatomical shaping.
2894822|NCT03285334|Active Comparator|iRace|rotary files
2894823|NCT03285321|Experimental|Arm 1|Nivolumab 480mg IV every 4 weeks for up to 6 cycles
2894824|NCT03285321|Experimental|Arm 2|Nivolumab 3mg/kg IV every 2 weeks PLUS Ipilimumab 1mg/kg IV every 6 weeks for up to 4 cycles (12 doses Nivolumab and 4 doses of Ipilimumab)
2894825|NCT03285308|Experimental|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily for 12 weeks.
2894826|NCT03285308|Placebo Comparator|Placebo|Placebo injected twice daily for 12 weeks.
2894827|NCT03285282|Active Comparator|Intervention|Thoracolumber interfascial plane block
2894828|NCT03285282|No Intervention|Control|
2894829|NCT03285269||Shock Group|Patients presenting with signs and symptoms of shock will undergo the E-RUSH ultrasound protocol and bioreactance before and after a passive leg raise maneuver.
2894830|NCT03285256|Experimental|Experimental Memory Training|Experimental memory training program
2894831|NCT03285256|Active Comparator|Comparator Memory Training 1|Comparator memory training program
2894833|NCT03285243|Experimental|Monochromatic Blue Light|On arrival to the PACU, the Drager phototherapy lamp will be illuminated over the patients head and neck using the lamp setting connected to the monochromatic blue light as the intervention. The light will remain active and over the patient until the patient has been in the post anesthesia recovery unit (PACU) for 30 minutes. Two PACU nurses blinded to the patient group will be asked to complete the PAED scoring scale for evaluation of emergence delirium. They will complete the PAED scoring evaluation upon arrival to the PACU and at 10 minutes, 20 minutes and 30 minutes following arrival.
2894834|NCT03285243|Placebo Comparator|Placebo (Blue light from white bulb)|On arrival to the PACU, the Drager phototherapy lamp will be illuminated over the patients head and neck using the lamp setting for the Placebo (Blue light from white bulb) as the intervention.The light will remain active and over the patient until the patient has been in the post anesthesia recovery unit (PACU) for 30 minutes. Two PACU nurses blinded to the patient group will be asked to complete the PAED scoring scale for evaluation of emergence delirium. They will be asked to complete the scoring evaluation upon arrival to the PACU and at 10 minutes, 20 minutes and 30 minutes following arrival.
2894835|NCT03285217|Experimental|HMB|HMB Group (n=30) will receive received twice a day for 3 months a specialized, nutrient-dense ready-to-drink liquid (Abbott Nutrition) with 350 kcal, 20 g protein, 11 g fat, 44 g carbohydrate, 1.5 g calcium-HMB, 160 IU vitamin D and other essential micronutrients.
2894836|NCT03285217|Active Comparator|Control|Control Group (n=30) will receive twice a day for 3 months another supplement with similar composition in macro- and micro-nutrients but without HMB
2894837|NCT03285204||ALS patients|
2894838|NCT03285204||Friedreich Ataxia patients|
2894839|NCT03285204||Healthy control|
2894840|NCT03285191||Subjects participating in the CE interview|Thirty subjects (comprised of n=15 csDMARD-IR and n=15 bDMARD-IR) will participate in the CE interview.
2894841|NCT03285191||Subjects participating in interview and real-time data capture|Ten of the thirty CE interview participants will be offered the opportunity to participate in the real-time data capture App substudy.
2894842|NCT03285178|Experimental|IW-1701 Low Dose|
2894843|NCT03285178|Experimental|IW-1701 Medium Dose|
2894844|NCT03285178|Experimental|IW-1701 High Dose|
2894845|NCT03285178|Placebo Comparator|Placebo|
2894846|NCT03285165|Active Comparator|DEX I|Trauma Patients without TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
2894847|NCT03285165|Active Comparator|DEX II|Trauma Patients with TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
2894848|NCT03285165|Active Comparator|Propofol I|Trauma Patients without TBI received 10-70 mcg/kg/h propofol infusion.
2894849|NCT03285165|Active Comparator|Propofol II|Trauma Patients with TBI received 10-70 mcg/kg/h propofol infusion.
2894850|NCT03285152|Experimental|Ketogenic Diet (KD)|The KD cohort will receive a rotating 7 day meal plan prepared by the Clinical Translational Science Center (CTSC) at Weill Cornell Medical Center (WCMC) with weekly food pick-up. The meal plan will provide a 3:1 fat to net carbohydrate ratio and calories for weight maintenance (30kcals /kg for a BMI< 30kg/ m2 and 25 kcal/kg for a BMI.30 kg/ m2.
2894851|NCT03285152|Active Comparator|Standard Diet (SD)|Patients randomized to the SD group will consume their normal diet plan. They will meet with the dietitian from the CTSC at WCMC weekly and receive standard nutritional counseling from the CTSC. Average intake will be documented through analyzing a 3 day intake pre and post the 4 week period.
2894852|NCT03285139|Experimental|Immediate Intervention|Group CBT for PPD. Women in the treatment group will attend a 9-week group Cognitive Behavioural Therapy intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton and designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. The CBT intervention will be delivered by lay-peers.
2894853|NCT03285139|Experimental|Wait List Controls|Group CBT for PPD 9 weeks after enrollment. The women in this arm of the study will receive the same Cognitive Behavioural Therapy intervention as in the immediate intervention arm, however they will begin the CBT group 9 weeks after enrolling in the study.
2894854|NCT03285139|No Intervention|Healthy Controls|No treatment. The participants in this arm of the study will not be suffering from postpartum depression and will not receive the Cognitive Behavioural Therapy treatment. Healthy controls will complete study measures upon enrollment in the study, 9 weeks later as well as 6 months later.
2894855|NCT03285113|Experimental|Ultrahigh Frequency Stimulation|Patients with chronic lower limb pain will be treated with ultrahigh frequency stimulation via lead around DRG.
2894856|NCT03285087|Experimental|DEX 0.2 μg/kg/h|Patients will receive dexmedetomidine for sedation with initial maintenance dose rate of 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of −2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
2894857|NCT03285061|No Intervention|Standard Disposal Instructions|These patients will receive standard instructions on proper disposal of excess pain medication following orthopedic foot and ankle surgery. They will be asked complete a survey at their 6 post operative follow-up on excess medication disposal.
2894858|NCT03285061|Experimental|At Home Disposal|With patients' prescription for post operative pain medication, a Deterra portable drug deactivation system will be provided, along with instructions on proper use. They will be asked complete a survey at their 6 post operative follow-up on excess medication disposal.
2894859|NCT03285048|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Training is comprised of 8 weeks of active cognitive training using Brain HQ auditory and visual training tasks. Training is twice per week for up to 2 hours. Also included is a Bridging Group at each training session. The Bridging group provides information about cognitive training and compensatory strategies to generalize the benefits of training to daily life.
2894860|NCT03285035||Non-operable esophageal cancer|
2894861|NCT03285022|Experimental|Zinc modified glass ionomer|Zinc modified glass ionomer (chemfill rock) galss ionomer used as restoration for posterior teeth in case of partial caries removel
2894862|NCT03285022|Active Comparator|Conventionel glass ionomer|Conventional glass ionomer used as restoration for posterior teeth in case of partial caries removel
2894863|NCT03285009|Other|Training intervention|See information elsewhere
2894939|NCT03284463|Active Comparator|Glibenclamide|Glibenclamide Tablets
2894864|NCT03284983|Experimental|10 mm suture spacing|The investigators aim to determine how suture spacing affects cosmetic outcome of wound healing. One side (1/2 of the wound length) was sutured with 10 mm suture spacing
2894865|NCT03284970||Rebif (interferon beta 1a)|This study will retrospectively collect the data from the subjects who had been treated with Rebif subcutaneously (SC) at a dose of 44 micro-grams three times a week.
2894866|NCT03284970||Tecfidera (dimethyl fumarate)|This study will retrospectively collect the data from the subjects who had been treated with Tecfidera.
2894867|NCT03284957|Experimental|Part A Dose escalation: SAR439859 monotherapy|SAR439859 will be administered orally once a day. Treatment will begin with an identified starting dose. Administration of higher doses to subsequent patients is based on occurrence of DLTs and evaluation of target saturation and PK parameters at initial and subsequent doses, until maximum administered dose (MAD) is reached. Drug is administered in 28-day cycle.
2894868|NCT03284957|Experimental|Part B Dose expansion: SAR439859 monotherapy|Patients will be administered the determined monotherapy recommended dose (RD) of SAR439859. Drug is administered in 28-day cycle.
2894869|NCT03284957|Experimental|Part C Dose escalation: SAR439859/palbociclib combination|SAR439859 will be administered in combination with palbociclib: SAR439859 starting oral daily dose will be one dose level below monotherapy RD and palbociclib will be dosed at fixed standard dose. Administration of higher dose of SAR439859 (with standard palbociclib dose) to subsequent patients is based on occurrence of DLTs at initial and subsequent doses, until MAD of SAR439859 is reached. Drugs are administered in 28-day cycle (palbociclib is administered for 21 days of cycle).
2894870|NCT03284957|Experimental|Part D Dose expansion: SAR439859/palbociclib combination|Patients will be administered the determined SAR439859/palbociclib combination therapy RD of SAR439859, with standard dose of palbociclib. Drugs are administered in 28-day cycle (palbociclib is administered for 21 days of cycle).
2894871|NCT03284944||Control (Before) Period|Use of standard-volume blood collection tubes (6 weeks)
2894872|NCT03284944||Intervention (After) Period|"Use of small-volume (soft-draw) blood collection tubes (6 weeks following 2-week washout period)"
2894873|NCT03284931|Experimental|SAGE-217 high dose|SAGE-217
2894874|NCT03284931|Experimental|SAGE-217 low dose|SAGE-217
2894875|NCT03284931|Placebo Comparator|Placebo|Placebo
2894876|NCT03284918|Experimental|Plant stanol ester|Cereal based snack bar with added plant stanol ester (0.8 g plant stanols/bar). Two bars consumed daily as a snack, between meals, for 4 weeks (1.6 g plant stanols/d).
2894877|NCT03284918|Placebo Comparator|Placebo|Cereal based snack bar without plant stanol ester. Two bars consumed daily as a snack, between meals, for 4 weeks (0 g plant stanols/d).
2894878|NCT03284905|Active Comparator|Probiotics|
2894879|NCT03284905|Placebo Comparator|Placebo|
2894880|NCT03284892|Experimental|PED Care group|Received PED care addition to usual care
2894881|NCT03284892|Active Comparator|Control group|Received usual care only
2894882|NCT03284879||Patients with PsV and PsA treated with OTEZLA Tablets|Patients with psoriasis vulgaris and patients with psoriatic arthritis who are treated with OTEZLA Tablets
2894883|NCT03284866|Experimental|Arm I, recombinant HPV 9-valent vaccine|Patients receive Recombinant Human Papillomavirus Nonavalent Vaccine (Gardasil 9) IM at baseline, 4, and 26 weeks in the absence of disease progression or unacceptable toxicity, with sample collection for Laboratory Biomarker Analysis.
2894884|NCT03284866|Placebo Comparator|Arm II, saline|Patients receive saline placebo vaccine IM at baseline, 4, and 26 weeks, with sample collection for Laboratory Biomarker Analysis.
2894885|NCT03284853|Experimental|Netarsudil/Latanoprost 0.02%/0.005%|PG324 Ophthalmic Solution (netarsudil 0.02% / latanoprost 0.005%) one drop daily to each eye for 180 days.
2894886|NCT03284853|Active Comparator|GANFORT®|GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.
2894887|NCT03284840||Adults (18-65 years)|
2894888|NCT03284840||Elderly (65-74 years)|
2894889|NCT03284827|Experimental|NOAC|60 mg once daily
2894890|NCT03284827|Active Comparator|DAPT|clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD)
2894891|NCT03284814|Active Comparator|Standard product group|This group will be included in a single dose cross over study, and in multiple dose study with standard product (SP: CoQ10 hard capsules; 100 mg)
2894892|NCT03284814|Active Comparator|Comparative product group|This group will be included in a single dose cross over study, and in multiple dose study with comparative product (CP: CoQ10 soft-gel capsules; 100 mg)
2894893|NCT03284814|Experimental|Investigational product group|This group will be included in a single dose cross over study, and in multiple dose study with investigational product (IP: CoQ10 syrup; 100 mg)
2894894|NCT03284788|Experimental|In-Person ABT|Adolescent participants will attend sessions that include nutritional education and physical activity education. These sessions will also seek to build skills in the areas of goal-setting, problem solving, self-monitoring, and decision making.
2894895|NCT03284788|Experimental|Self-Guided At-Home ABT|Adolescent participants will receive mailed handouts covering the same information that was taught in each of the ABT sessions and will include nutritional education and physical activity education. The handouts will also provide information about building skills in the areas of goal-setting, problem solving, self-monitoring, and decision making.
2894896|NCT03284762||Treatment-naïve NVAF patients in Korea and Taiwan|Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions NVAF: Non-valvular atrial fibrillation
2894897|NCT03284749|Experimental|Copper impregnated wound dressing|Wound dressing impregnated with 3% copper oxide ions, to be applied for 7 days after caesarean section
2894898|NCT03284749|Placebo Comparator|Normal wound dressing|Wound dressing without copper, to be applied for 7 days after caesarean section
2894899|NCT03284749|Experimental|Copper impregnated maternity pads|Maternity pads impregnated with 3% copper oxide ions, to be used for 14 days after delivery
2894900|NCT03284749|Placebo Comparator|Normal maternity pads|Maternity pads without copper, to be used for 14 days after delivery
2894901|NCT03284736|Experimental|Periapical surgery with membrane|"After retrofilling of teeth with MTA , defect was covered with collagen resorbable membrane.~healiguide collagen type 1 resorbable membrane covering the defect by extending 2-3 mm in every direction."
2894902|NCT03284736|Active Comparator|Periapical surgery without membrane.|After retrofilling of teeth with MTA, flap was closed without application of collagen resorbable membrane.
2894903|NCT03284723|Experimental|PF-06804103|Study Treatment
2894904|NCT03284710|Active Comparator|Group 1: ALVAC-HIV + gp120/MF59|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120/MF59 in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
2894905|NCT03284710|Active Comparator|Group 2: ALVAC-HIV + gp120/Al(OH)3|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
2894906|NCT03284710|Active Comparator|Group 3: ALVAC-HIV + gp120/MF59|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid and Bivalent Subtype C gp120/MF59 in the right deltoid at months 0, 1, 6, and 12. All injections are via needle and syringe.
2894907|NCT03284710|Active Comparator|Group 4: ALVAC-HIV + gp120|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
2894908|NCT03284697|Active Comparator|DPC with Ca(OH)2|Direct pulp capping with Ca(OH)2.
2894909|NCT03284697|Active Comparator|DPC with MTA|Direct pulp capping with MTA
2894910|NCT03284684||circulating DNA plasma level test|
2894911|NCT03284671|Experimental|bifocal stimulation|Transcranial direct current Bifocal stimulation
2894912|NCT03284658||Observation|Patients with a Tyrosinemia type 1 or high-grade suspi-cion for Tyrosinemia type 1
2894913|NCT03284645||ART Before or Early in Pregnancy|HIV positive pregnant women who started antiretroviral therapy (ART) before or early in pregnancy for prevention of mother-to-child transmission of HIV and for their own health.
2894914|NCT03284645||ART Started Third Trimester|HIV positive pregnant women starting antiretroviral therapy (ART) during the third trimester of pregnancy for prevention of mother-to-child transmission of HIV and for their own health.
2894915|NCT03284645||ART Started Postpartum|HIV positive women starting antiretroviral therapy (ART) after delivery for prevention of mother-to-child transmission of HIV and for their own health.
2894916|NCT03284632||Smokers|
2894917|NCT03284632||E-cigarette users|
2894918|NCT03284632||Non-smokers|
2894919|NCT03284619|Experimental|treatment arm|Single arm study, 5 patient with bone metastasis will be enrolled for palliative treatment with the Magnetic resonance imager linear accelerator (MR-Linac).
2894920|NCT03284606|Experimental|TAPING|taping in conjunction with common rehabilitation for hemiplegic patients
2894921|NCT03284606|Placebo Comparator|NO TAPING|Common rehabilitation for hemiplegic patients without taping
2894922|NCT03284593||intensive chemotherapy group|patients treated with intensive chemotherapy
2894923|NCT03284593||Azacitidine group|patients treated with azacitidine
2894924|NCT03284580|Experimental|Ergonomic intervention group|Ergonomic intervention program at home for caregivers
2894925|NCT03284580|Experimental|Postural + kinesiotherapy intervention group|A postural + kinesiotherapy intervention program at home for caregivers
2894926|NCT03284580|Other|Control or conservative group|A conservative intervention by general information for caregivers
2894927|NCT03284567|Active Comparator|Football fitness|"Participants in the intervention group will practice soccer for 52 weeks two times weekly. A soccer instructor will be in charge of all training sessions. The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., < 5°C or heavy rain) training will be performed indoors. Participants will be told to avoid hard tackles and other actions that carry a risk of injury."
2894928|NCT03284567|No Intervention|Control group|Participants in the control group will receive verbal advice about the benefits of exercise and physical activity.
2894929|NCT03284554|Active Comparator|Encapsulated nutients|"Encapsulated nutrients known to be able to stimulate GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum).~The encapsulated nutrients will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
2894930|NCT03284554|Sham Comparator|Non-encapsulated nutrients|"Nutrients known to be able to stimulate GLP-1 and PYY release if they are encapsulated to provide release at pH ≈7.0 (in the distal part of the ileum). The same capsules in a non-coated form will be provided in order to study the effect of the coating.~The non-encapsulated nutrients will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
2894931|NCT03284554|Placebo Comparator|Placebo|"Nutrients known to have limited stimulation on GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum).~The placebo capsules will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
2894932|NCT03284541|Experimental|2GETHER|2GETHER is an HIV prevention and relationship education program designed for young male couples. 2GETHER consists of 4 sessions (2 group sessions, 2 individualized couple session) administered over the course of 1 month (1 session per week). Group sessions focus on developing skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
2894933|NCT03284541|Active Comparator|Existing Public Health Practice|The control condition consists of the single-session Couples-Based HIV Counseling and Testing protocol for HIV-negative couples, the single-session Life-Steps medication adherence protocol for HIV-positive couples, or both intervention delivered jointly to serodiscordant couples
2894934|NCT03284515||All women|Women who are between 16-32 weeks gestation and who have not previously received a pertussis vaccination in pregnancy.
2894935|NCT03284502|Experimental|Stage 1|Dose escalation
2894936|NCT03284502|Experimental|Stage 2|Expansion
2894937|NCT03284489||ICU patients|Patients with pancreatitis
2894938|NCT03284476||ICU patients|Collection of medical data of Patients with peritonitis (nosocomial or community-acquired) or Patients with post-operative peritonitis
2894943|NCT03284437|No Intervention|Usual Care|Usual medical care provided to patients in the ICU.
2894944|NCT03284437|Experimental|Early Cognitive Training|Usual medical care provided to patients in the ICU plus additional activities designed to engage the patient's attention and cognition. Activities are chosen by the family member from an activity cart according to the level designated by occupation therapy.
2894945|NCT03284424|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg via intravenous infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
2894946|NCT03284411|Experimental|Spinal Cord Stimulation|Each subject will be programmed to 4 different amplitude settings.
2894947|NCT03284398||Parenteral nutrition bag type|Groups with different parenteral nutrition bags (3CBs or HCBs)
2894948|NCT03284385|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2894949|NCT03284372|Experimental|Intervention 1|Text Message Only
2894950|NCT03284372|Experimental|Intervention 2, Incentive 1|Text message + Incentive 1
2894951|NCT03284372|Experimental|Intervention 2, Incentive 2|Text message + Incentive 2
2894952|NCT03284372|No Intervention|Cohort|For the cohort multiple randomized controlled trial (cmRCT), investigators will recruit 130 participants (the base cohort) ages 15-19. The base cohort allows investigators to measure normative food allergy self-management practices, while also serving as a control for experiments in Interventions 1 and 2.
2894953|NCT03284372|No Intervention|Control|The baseline cohort serves as the control group in this cmRCT. Participants will not receive text message reminders (during Intervention 1) or incentives (during Intervention 2). However, they will participate in all data collection points, including text message check-ins to assess epinephrine-carrying. Participants in the base cohort will receive usual care.
2894954|NCT03284372|No Intervention|Adolescent Allergy Advisors|We will pilot the text messages to be used in Interventions 1 and 2 through interviews and cognitive testing among 20 Adolescent Allergy Advisors, who will critique message content, framing, and language. These advisors will not be part of the cohort multiple randomized controlled trial.
2894955|NCT03284359|Experimental|Pre-Consent Nudge Bundle|Arm 1 will be administered a novel pre-consent nudge bundle which incorporates several behavioral economic interventions within a brief survey. Participants will subsequently be asked by the same research personnel to participate in a simulated randomized control trial (RCT) comparing two oxygen saturation targets among mechanically ventilated patients. Participants will receive the standard consent form followed by a risk assessment and demographic survey.
2894956|NCT03284359|Experimental|Enhanced Active Choice Consent|Participants in arm 2 will be approached by the research personnel to participate in a simulated RCT comparing two oxygen saturation targets among mechanically ventilated patients. Participants will receive a consent form which includes enhanced active choice. The enhanced active choice form includes a nudge whereby the available options for participating in the RCT, YES or NO, highlight the costs and benefits of participating versus not participating, Following the consent process participants will conduct the same risk assessment survey and demographic survey.
2894957|NCT03284359|No Intervention|Standard Consent|Arm 3 will serve as the control arm. Participants will be approached by the research personnel to participate in a simulated RCT comparing two oxygen saturation targets among mechanically ventilated patients. Participants will receive a standard consent form as detailed in the Study Instruments section. Following the consent process participants will conduct the same risk assessment survey and demographic survey.
2894958|NCT03284346|Experimental|Arm I (CARE)|Patients undergo supervised exercise sessions comprised of CARE over 50 minutes 3 days weekly for 16 weeks. Patients receive a Polar heart rate monitor to monitor heart rate during the CARE sessions.
2894959|NCT03284346|Active Comparator|Arm II (standard stretching)|Patients undergo a standard stretching program 3 days weekly for 16 weeks. After 16 weeks, patients may undergo supervised exercise sessions comprised of CARE as in Arm I.
2894960|NCT03284333|Experimental|other|no arm
2894961|NCT03284307|Experimental|Drug Administrated|Sedatives will be administered to participants while their brain activity is measured.
2894962|NCT03284294|Placebo Comparator|Placebo|Oral placebo daily for 8 weeks
2894963|NCT03284294|Active Comparator|Vitamin D|Vitamin D Cholecalciferol 2000 IU oral daily for 8 weeks
2894964|NCT03284281|Experimental|Interventional arm|Active TVNS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 8 hours daily (4 hours twice daily) for 1-week post discharge.
2894965|NCT03284281|Placebo Comparator|Control arm|No stimulation will be performed.
2894966|NCT03284268|Experimental|Dose escalation of VCN-01|Dose lower : 2E+9 viral particules/eye Dose medium: 2E+10 viral particules/eye Dose high: 2E+11 viral particules/eye
2894967|NCT03284255|Experimental|study group|in this group the subject will accept the treatment of BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System
2894968|NCT03284255|Active Comparator|control group|in this group the subject will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
2894969|NCT03284242|Experimental|Autologous Treg Infusion|This will be a single intravenous (IV) infusion. A participant's own expanded regulatory T cells will be added to Albumin, and administered to them. The amount of the solution will be approximately 300 ml and the infusion will take about 3 to 4 hours.
2894970|NCT03284229|Experimental|Excimer Laser Coronary Atherectomy|ELCA® in patients with single or multivessel CAD either as a stand-alone modality or in conjunction with Percutaneous Transluminal Coronary Balloon Angioplasty (PTCA). The entire procedure will be carried out as per the site routine practice and the device will be used as per the 'Instruction for Use'. Treating physicians/study investigators will be trained by the study Sponsor on the study protocol and procedures prior to clinical investigation procedure. Subject preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted.
2894971|NCT03284216|Other|Normal glycemia|Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered, but an exercise bout will be completed.
2894972|NCT03284216|Experimental|Steady-state hyperglycemia|Participants will be studied during experimental steady-state hyperglycemia induced via a variable-rate intravenous glucose infusion, and an exercise bout will be completed.
2938201|NCT02984319|Experimental|Dietary supplement|
2894973|NCT03284216|Experimental|Fluctuating hyperglycemia|Participants will be studied during experimental fluctuating hyperglycemia induced via repeated intravenous glucose injections, and an exercise bout will be completed.
2894974|NCT03284203|Experimental|SpiroPD|Participants in the intervention arm will be given a handheld spirometry device to take home and use daily for 30 consecutive days.
2894975|NCT03284190||ASDH Copenhagen, Denmark|
2894976|NCT03284190||ASDH Odense, Denmark|
2894977|NCT03284190||ASDH Århus, Denmark|
2894978|NCT03284190||ASDH Ålborg, Denmark|
2894979|NCT03284190||ASDH Lund, Sweden|
2894980|NCT03284190||ASDH Linköping, Sweden|
2894981|NCT03284190||ASDH Gothenburg, Sweden|
2894982|NCT03284190||ASDH Stockholm, Sweden|
2894983|NCT03284190||ASDH Uppsala, Sweden|
2894984|NCT03284190||ASDH Umeå, Sweden|
2894985|NCT03284177|Experimental|C13-CAC|
2894986|NCT03284164|Experimental|Healthy Subjects|Healthy Subjects matched to RI subjects Tenofovir Exalidex (TXL)
2894987|NCT03284164|Experimental|Severe RI|Severe Renal Impairment subjects Tenofovir Exalidex (TXL)
2894988|NCT03284138|Sham Comparator|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
2894989|NCT03284138|Placebo Comparator|Placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
2894990|NCT03284125||Facial paralysis|Patients affected by facial paralysis treated by LTM The aim is to evaluate the improvement of the swallowing disorders after surgery.
2894991|NCT03284112|Placebo Comparator|Control|School population without the Old SCHOOL Hip-Hop program, but with the My Pyramid in Egypt program.
2894992|NCT03284112|Experimental|Intervention|School population with the Old SCHOOL Hip-Hop program.
2894993|NCT03284099|Experimental|intervention|ACEIs or ARBs will be switch to be taken before bedtime
2894994|NCT03284099|Active Comparator|control|ACEIs or ARBs will be taken in the morning as usual
2894995|NCT03284086|Other|paraplegic|Well-trained participants with a spinal cord injury (<Th1) were included in this group.
2894996|NCT03284086|Other|able bodied|Upper-body trained, able-bodied participants were included in this group.
2894997|NCT03284073|Experimental|Uterus Transplantation|Patients undergo transplantation of the uterus from a live donor
2894998|NCT03284060|Experimental|Cognitive remediation program|
2894999|NCT03284047|Experimental|2.5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:~2.5 U~5 U~7.5 U"
2895000|NCT03284047|Experimental|5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:~2.5 U~5 U~7.5 U"
2895001|NCT03284047|Experimental|7.5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:~2.5 U~5 U~7.5 U"
2895002|NCT03284034|Active Comparator|Cyrolipolysis|
2895003|NCT03284034|Experimental|Deoxycholic Acid|
2895004|NCT03284021|Other|Fraxel laser|
2895005|NCT03284008|Experimental|Manual manoeuver + stretching|Patients will receive a manual manoeuver treatment and education to perform stretching exercises at home.
2895006|NCT03284008|Active Comparator|stretching exercise|Patients will receive education to perform stretching exercises at home.
2895007|NCT03283995||cardiogenic shock without SCA|
2895008|NCT03283995||cardiogenic shock with SCA|
2895009|NCT03283995||SCA,|
2895010|NCT03283995||acute left heart failure with severe alteration of LVEF|
2895011|NCT03283982|Active Comparator|Robotic IPOM|Robotic Ventral Hernia Repair with IPOM: The da Vinci® Surgical System robotic platform (Intuitive Surgical, Inc.) will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement.
2895012|NCT03283982|Active Comparator|Laparoscopic IPOM|Laparoscopic Ventral Hernia Repair with IPOM: The standard laparoscopic platform will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement.
2895013|NCT03283969|Placebo Comparator|Control Powder|Isocaloric powder
2895014|NCT03283969|Experimental|Freeze Dried Strawberry Powder|Contains freeze dried strawberries
2895015|NCT03283956||Patient records|Medical records of all patients who underwent DC bead TACE.
2895016|NCT03283943|Experimental|Durvalumab and focal radiotherapy|Durvalumab 1500 mg IV every 28 days, and 2 fractions of focal sensitizing radiation with cycles 1 and 2 of treatment.
2895017|NCT03283930|Experimental|Active ABMT|Active attention bias modification will be provided in addition to individual cognitive behavioral therapy
2895018|NCT03283930|Placebo Comparator|Placebo|Placebo attention bias modification will be provided in addition to individual cognitive behavioral therapy
2895019|NCT03283917|Experimental|Daratumumab + Ixazomib + Dexamethasone|"Daratumumab by vein on Days 1, 8, 15, and 22 of Cycles 1-2, then on Days 1 and 15 for Cycles 3-6, and on Day 1 of Cycles 7-12.~Ixazomib by mouth on Days 1, 8, and 15 of Cycles 1-12.~Dexamethasone by vein or by mouth on Days 1, 8, 15, and 22 of Cycle 1. Starting with Cycle 2 and beyond, Dexamethasone given as a premedication before each dose of Daratumumab and then again the next day. During weeks when no Daratumumab dose scheduled, Dexamethasone as a single dose 1 time a week."
2895020|NCT03283904|Experimental|Multicomponent PA intervention|Intervention schools will adopt a multicomponent intervention by integrating physical activities into different parts of the school day
2895021|NCT03283891|Experimental|educational intervention|Various pedagogical activities to mobilise Watson's ten Carative Factors
2895022|NCT03283891|No Intervention|control|No intervention during the different times of measurement. Educational intervention will be delivered after the last measure.
2895050|NCT03283631|Experimental|EGFRvIII-CARs|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
2895253|NCT03282227|Experimental|M207 Microneedle System 3.8 mg|M207 Microneedle System 3.8 mg (1.9 mg/patch x 2 patches)
2895023|NCT03283878|Experimental|Study Group 1|"Patients in Group #1 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within 30-60 minutes prior to skin incision in elective total knee arthroplasty. No further antibiotic administration will be given.~< 120 kg - patients will receive 2 grams of cefazolin~≥ 120 kg - patient will receive 3 grams of cefazolin~Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous monotherapy with vancomycin 15mg/kg monotherapy as an alternative or dual therapy with vancomycin 15 mg/kg and gentamicin 1.5 mg/kg."
2895024|NCT03283878|Experimental|Study Group 2|"Patients in Group #2 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 30-60 minutes prior to skin incision in elective total knee arthroplasty. In addition, two (every 8 hours) weight-based doses of cefazolin will be administered for 24 hours postoperatively.~< 120 kg - patients will receive 2 grams of cefazolin~≥ 120 kg - patient will receive 3 grams of cefazolin~Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin 15 mg/kg monotherapy or dual therapy with vancomycin 15 mg/kg and gentamicin 1.5 mg/kg as an alternative. If allergic, patients will also receive two weight-based doses of vancomycin but not gentamicin postoperatively. Vancomycin schedule: one dose preoperatively, one dose 12 h postoperatively, one dose 24 h postoperatively."
2895025|NCT03283865|Experimental|Ultrasound|"The attending anesthesiologist will perform or instruct the placement of a caudal block according to their standard of practice. At the time of administration of local anesthetic into the caudal space, the study collaborator (SC) will ultrasound the caudal space keeping the provider placing the block blinded to the imaging. The provider placing the block will inject 0.5mL of saline. The provider will then be asked to state if they are correctly in the caudal space or not. If the provider feels they are not in the caudal space, they will re-do the procedure. If the provider fails to identify incorrect location and this is noted by ultrasound, the SC will inform the provider to re-do the procedure.~All study participants will have ultrasound used for caudal block."
2895026|NCT03283839|Other|Temporomandibular disorder|
2895027|NCT03283839|Other|Without temporomandibular disorder|
2895028|NCT03283826|Experimental|Progressive or RRMS|Adult subjects with either progressive forms of MS (Population A) or with Relapsing Remitting Multiple Sclerosis (Population B) will be enrolled. Subjects will receive 2 cycles of treatment with each cycle consisting of a 15-day treatment period (with 3 infusions, each given approximately 7 days apart, on Days 1, 8 [±2 days], and 15 [±2 days]). Following the third dose of both treatment cycles, subjects will undergo a 20-day observation period. After completion of cycle 2, 20-day observation period, subjects will enter a follow-up period with 11 monthly (every 28 ±5 days) visits. Together, subjects will be observed for at least 1 year after the first dose of ATA188.
2895029|NCT03283813|Active Comparator|Active group - Zinc and Myo-inositol|This arm will receive a supplementation with Zinc and Myo-inositol once a day.
2895030|NCT03283813|Placebo Comparator|Placebo group|This arm will receive a supplementation with a same product equal to the active product but without Zinc and Myo-inositol inside.
2895031|NCT03283800|Experimental|Copper impregnated compression stocking|Copper compression stocking containing 2-3% copper ions to be worn on one leg, daily for 8 weeks.
2895032|NCT03283800|Placebo Comparator|Normal compression stocking|Similar compression stocking without copper to be worn on the other leg, daily for 8 weeks
2895033|NCT03283787|Active Comparator|Group 1|MicroMatrix® and Cytal™ Wound Matrix 2-Layer
2895034|NCT03283787|Active Comparator|Group 2|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
2895035|NCT03283787|Active Comparator|Group 3|Negative Pressure Wound Therapy
2895036|NCT03283761|Experimental|Treatment Arm|All patients in Stage I (N=12) and Stage II (N=25) will receive FOLFOX-A every 14 days of each cycle (1 cycle = 28 days). Nab-paclitaxel will be given at a dose of 150 mg/m^2 IV over 30 minutes, followed by oxaliplatin IV 85 mg/m^2 and leucovorin IV 400 mg/m^2 over 2 hours, and 5-FU as a continuous IV infusion over Day 1 and Day 2 (for a total dose of 2400mg/m^2 over 46-48 hours.). Radiographic assessment will be performed at baseline and every 8 weeks to evaluate response to treatment by RECIST Version 1.1 guidelines. Patients may continue to receive treatment until disease progression or unacceptable toxicity.
2895037|NCT03283748|Experimental|Measurement of Motor Movements|Wearable Accelerometer Sensors manufactured by leading manufacturers will be given to the participants to be worn around hands and legs. These sensors will be used to measure accelerations which will be impacted by the motor movements.
2895038|NCT03283735|Experimental|Elderly Enablement|The investigators will give enablement tools and talks with their GPs about how to issue the problem of polypharmacy.
2895039|NCT03283735|No Intervention|Control|This will be the control group.
2895040|NCT03283709|Experimental|Full-contour monolithic Zirconia crowns|If participants assigned to this arm are in need of surveyed crowns on RPD abutment teeth they will be fabricated from multi-layered monolithic zirconia
2895041|NCT03283709|Other|Conventional abutment crowns|If participants assigned to this arm are in need of surveyed crowns on RPD abutment teeth they will be fabricated from type III gold or high-noble metal veneered with feldspathic porcelain
2895042|NCT03283696|Experimental|Olaratumab + Doxorubicin + Ifosfamide + Mesna|Olaratumab, doxorubicin and ifosfamide plus mesna administered intravenously (IV).
2895043|NCT03283670|Experimental|Nitrous Oxide 25%|One hour inhalation of 25% nitrous oxide
2895044|NCT03283670|Experimental|Nitrous Oxide 50%|One hour inhalation of 50% nitrous oxide
2895045|NCT03283670|Placebo Comparator|Placebo Gas|One hour inhalation of placebo gas
2895046|NCT03283657|Experimental|DiRECT|DiRECT consists of the following components that will be delivered by medical assistants before patients' routinely scheduled office visits: 1) a prediabetes decision aid focused on type 2 diabetes (T2D) risk and treatment options for preventing T2D; 2) a 'think aloud' exercise; and 3) formulating a preliminary treatment plan for T2D prevention.
2895047|NCT03283657|Active Comparator|Usual Care (UC)|Participants randomized to standard care will receive routine medical care without the medical assistant delivered DiRECT intervention.
2895048|NCT03283644||Patients with a BMI over 40|Participants were aged between 27-65 years, BMI >40 , Co-Morbidities associated with obesity including sleep apnoea, hypertension, depression, hypercholesterolaemia and type 2 diabetes, Undergoing Gastric Band surgery
2895049|NCT03283644||Lean, healthy individuals|Participants were aged between 27-65 years, BMI<28 , Systemically healthy, taking no prescribed medication
2895051|NCT03283618|No Intervention|Control Group|The control group will receive the mHealth devices (scale, blood pressure cuff, and accelerometer watch) as well as caloric and step goals, but no health coaching. They will complete the same pre- and post-intervention measurements and consultations with the medical doctor and registered dietitian.
2895052|NCT03283618|Experimental|Video Conference-based Health Coaching|The video conference-based health coaching group will receive the mHealth devices (scale, blood pressure cuff, and accelerometer watch) meet the medical doctor at baseline and at 12 weeks via the Amwell® app using their smartphone. The participants will receive health coaching by meeting weekly (12 times) with the registered dietitian (RD) to discuss behavior modification, exercise, and nutrition goals.
2895053|NCT03283605|Experimental|Durvalumab + tremelimumab and SBRT|All subjects will receive durvalumab (1500 mg IV q4week) and tremelimumab (75mg q4week) for 4 doses, followed by durvalumab alone (1500 mg IV q4week) until disease progression, unacceptable toxicity or patient withdrawal. SBRT will be administered between cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
2895054|NCT03283592|Experimental|Rank-Heat Plot|The intervention group will receive an online survey to evaluate their interpretation of the results from the NMA with a rank-heat plot including results from 2 outcomes that were selected by our knowledge users (#injurious falls, #fractures).
2895055|NCT03283592|Active Comparator|SUCRA (surface under the cumulative ranking) Plot|The control group will receive an online survey to evaluate their interpretation of the results from the NMA with the SUCRA plots including results from the same 2 outcomes that will be presented to the intervention group (i.e., #injurious falls, #fractures).
2895056|NCT03283579||Pregnant women|
2895057|NCT03283566|Active Comparator|Hydroxychloroquine|Administered pre-transplant through 3 months after surgery.
2895058|NCT03283566|Placebo Comparator|Placebo|Placebo treatment following the same schedule as Arm 1 (i.e. Hydroxychloroquine).
2895059|NCT03283553|Experimental|Multicomponent Intervention|1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider, and to stimulate discussion about the role of the companion in the visit, 2.) facilitated registration for the patient portal (for patient and family member, as desired by the patient), and 3.) education (as relevant) on access to doctor's electronic visit notes.
2895060|NCT03283553|Placebo Comparator|Usual Care|Care as usual with the medical oncologist.
2895061|NCT03283540|Experimental|TaTME|Trans-anal Total Mesorectal Excision (TaTME) is the visualization and dissection of the rectum located deep in the pelvis. In it, a trans-anal port is inserted for the duration of the surgery. Multiple surgical tools are then introduced through the port and the rectum is resected from down-to-up under direct visualization.
2895062|NCT03283540|Active Comparator|abdominal TME|"Total Mesorectal Excision involves resecting the rectum along with its surrounding Mesorectal plane. If the anal sphincter is spared, this surgery is named Low Anterior resection (LAR) for rectal cancer. Traditionally, TME dissection in LAR is performed through open or laparoscopic incisions(s) made in the abdominal wall. Mobilization of the splenic flexure along with sigmoid dissection follows. Lastly, the rectum is dissected in accordance with TME principles from above. This up-to-down approach is known as abdominal TME."
2895063|NCT03283488|Experimental|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
2895064|NCT03283488|Active Comparator|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
2895065|NCT03283475|No Intervention|control group|"- Control group will include 60 adult individuals between 18 and 35 years old who have body mass index (BMI) between 19 and 25, not complaining of any thigh contour deformities or skin redundancy with no history of body weight fluctuations. This group will be divided into two subgroups, 30 males and 30 females.~The following measurements will be recorded :- Weight, height, thigh length, hip circumference, maximum buttocks circumference, upper thigh, middle thigh and lower thigh circumferences."
2895066|NCT03283475|Active Comparator|patient group|"- Patient group will include 30 patients suffering from thigh lipodystrophy and contour deformities who will undergo surgical intervention after their assessment.~After assessment, one of the following techniques will be selected:-~Liposuction only.~thigh lift.~Liposuction assisted thigh lift."
2895067|NCT03283462|Active Comparator|AMAZ-02|
2895068|NCT03283462|Placebo Comparator|Placebo|
2895069|NCT03283449|Experimental|AV-1451 Recipients|Participants in this arm of the study will all receive an injection of 10 Mci of AV-1451 and then be scanned in a PET scanner for brain imaging.
2895070|NCT03283436|Experimental|Superior hypogastric plexus block|Prior to the laparoscopic hysterectomy and any additional procedures, the SHPB will be performed on patients in the treatment arm. The block will contain 10 mL of 0.25% bupivacaine hydrochloride (Bupivacaine; 2.5 mg/mL = 25 mg). The anesthetic works by blocking nerve conduction and the steroid by reducing inflammation. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.
2895071|NCT03283436|No Intervention|No block|Patients in the control arm will undergo the hysterectomy with no intervention.
2895072|NCT03283410|Experimental|Single Study Arm|All patients will be sequentially allocated in the single study arm. All patients will receive some propofol dose.
2895073|NCT03283397|Experimental|EK-12|This arm will be treated with 12 mg EK-12 in 2 mL 0.9 % NaCl solution (SC, three times per week) for 144 weeks
2895074|NCT03283397|Active Comparator|INF Beta-1a|This arm will be treated with 44 mg INF Beta-1a in 0.5 mL solution (SC, three times per week) for 144 weeks
2895075|NCT03283384|Other|Advise letrozole, treatment choice free.|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of <1% in the biopsy taken after those two weeks of treatment are advised to stay on letrozole treatment until surgery. However, treatment choice is free.
2895144|NCT03282955|Active Comparator|Lipofundin MCT|i.v. lipid emulsion
2895354|NCT03281434|Active Comparator|Collagen peptide|Supplement will be delivered twice daily (30g per supplement) of hydrolyzed collagen peptides
2895076|NCT03283384|Active Comparator|Chemotherapy|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).
2895077|NCT03283384|Experimental|Ribociclib plus letrozole|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).
2895078|NCT03283371|Experimental|Natalizumab 300 mg|Participants will undergo a prospective baseline period of 6 weeks (Weeks -6 to 0) followed by placebo controlled phase to receive natalizumab 300 mg intravenous (IV) infusion every 4 weeks from Week 0 to Week 24. Participants will continue to receive natalizumab 300 mg IV infusion every 4 weeks for up to an additional 24 weeks in open label phase.
2895079|NCT03283371|Placebo Comparator|Placebo|Participants will undergo a prospective baseline period of 6 weeks (Weeks -6 to 0) followed by placebo controlled phase to receive natalizumab matching placebo intravenous (IV) infusion every 4 weeks from Week 0 to Week 24. Participants will then receive natalizumab 300 mg IV infusion every 4 weeks for 24 weeks in open label phase.
2895080|NCT03283358|Experimental|Person-centered follow up|The intervention program is a person-centered health promotion program led by a nurse and consists of two telephone calls (15 minutes each) at two weeks and nine months after surgical treatment for Intermittent Claudication and three visits (45 - 60 min) at six weeks, six months and one year after treatment. The program includes a baseline assessment, an individual plan for self-care and educational information about Intermittent Claudication, received treatment and secondary prevention (medication and modifiable risk factors). The purpose is to enhance self-care in terms of adherence to medication and to recommended changes of lifestyle.
2895081|NCT03283358|No Intervention|Standard follow up|Standard follow-up consist of two follow up appointments á 20 minutes at four-six weeks and one year after surgical treatment of Intermittent Claudication. The patients meet a vascular surgeon at the first follow up and a vascular nurse or a surgeon at the second follow up visit.
2895082|NCT03283345|Active Comparator|postmenopausal women|postmenopausal female breast cancer patients who underwent modified radical mastectomy
2895083|NCT03283345|Active Comparator|premenopausal women|premenopausal female breast cancer patients who underwent modified radical mastectomy
2895084|NCT03283319|Experimental|3.75 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 plus AS03
2895085|NCT03283319|Experimental|7.5 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with AS03
2895086|NCT03283319|Experimental|15 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with AS03
2895087|NCT03283319|Experimental|3.75 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 adjuvanted with MF59
2895088|NCT03283319|Experimental|7.5 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with MF59
2895089|NCT03283319|Experimental|15 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with MF59
2895090|NCT03283293|Experimental|Target volume delineation after NACT|
2895091|NCT03283280|Experimental|Short fiber RC|Short fiber reinforced resin composite restoration (Ever X Posterior, Gc Europe) that is used in high stress bearing areas as direct onlay restoration.
2895092|NCT03283280|Active Comparator|Nanohybrid RC|Nanohybrid resin composite (GrandioSO, VOCO GmbH Germany ) that can be used to make indirect restorations in posterior teeth.
2895093|NCT03283267|Experimental|ZS 5g, qd|Subjects randomized to this arm will receive ZS 5 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
2895094|NCT03283267|Experimental|ZS 10g, qd|Subjects randomized to this arm will receive ZS 10 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
2895095|NCT03283254|Experimental|Practical Resources for Effective Postpartum (PREPP)|A psychotherapeutic preventive intervention that involves psychoeducation and cognitive behavioral techniques.
2895096|NCT03283254|Active Comparator|Enhanced Treatment as Usual|Psychoeducation about Postpartum Depression, referral to treatment in the community and monitoring
2895097|NCT03283241|Active Comparator|Zolidd One ExHex|Coated titanium implant
2895098|NCT03283241|Sham Comparator|One ExHex|Uncoated titanium implant
2895099|NCT03283228||CD11b and CD56 markers|Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
2895100|NCT03283228||Haematological parameters in cases of adult AML|Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML
2895101|NCT03283202|Experimental|Avadomide (CC-122) plus R-CHOP-21|Avadomide (CC-122) by mouth (PO) at varying dose levels (Ph 1) on Days 1 through 5 and Days 8 through 12 plus Rituxan 375 mg/m2 by intravenous (IV) infusion, cyclophosphamide 750mg/m2 by IV infusion, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 (max is 2.0 mg) IV and 100 mg PO prednisone/prednisolone on Days 1 through 5 of each 21-day treatment cycles for up to 6 total treatment cycles (approximately 18 weeks or 4 months)
2895102|NCT03283189||Group 1|Pregnancy follow-up in the only maternity type III of the region (CHU) and in an urban area (around Clermont-Ferrand)
2895103|NCT03283189||Group 2|Pregnancy follow-up in the only maternity type III of the region (CHU) and in an urban area (around Clermont-Ferrand)
2895104|NCT03283189||Group 3|Pregnancy follow-up in the only private maternity (type II) of the region and in an urban area (around Clermont-Ferrand)
2895105|NCT03283189||Group 4|Pregnancy follow-up in the only private maternity (type II) of the region and in an urban area (around Clermont-Ferrand)
2895106|NCT03283189||Group 5|Pregnancy follow-up in a type I maternity and in a rural area (around Saint-Flour)
2895107|NCT03283189||Group 6|Liberal follow-up of pregnancy
2895108|NCT03283176||Sofo-Dacla with Ribavirin|Chronic Hepatitis C related Liver Cirrhosis patients who will take sofosbuveir, Daclatasvir with Ribavirin
2895109|NCT03283176||Sofo-Dacla without Ribavirin|Chronic Hepatitis C related Liver Cirrhosis patients who will take sofosbuveir, Daclatasvir without Ribavirin
2895110|NCT03283163|Experimental|Chronic Pain//PTSD group|This group will receive baseline and endpoint maximum load exercise testing which will inform their individualized exercise prescription (based on a progressive methodology) of aerobic exercise training aimed at meeting specific heart rate ranges over time (increasing up to 80% of maximum HRR between the midpoint and endpoint (6-12 weeks).
2895111|NCT03283163|Active Comparator|Trauma-exposed healthy control group|This group will receive baseline and endpoint maximum load exercise testing which will inform their individualized exercise prescription (based on a progressive methodology) of aerobic exercise training aimed at meeting specific heart rate ranges over time (increasing up to 80% of maximum HRR between the midpoint and endpoint (6-12 weeks).
2895112|NCT03283150|Active Comparator|Remifentanil|Remifentanil will be administered to subjects during microelectrode recordings (MER).
2895113|NCT03283150|Active Comparator|Propofol|Propofol will be administered to subjects during MER.
2895114|NCT03283150|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered to subjects during MER.
2895115|NCT03283137|Experimental|TGR-1202 and pembrolizumab|All patients will receive TGR-1202 and pembrolizumab. Patients will start receiving TGR-1202 daily for 6 weeks (2 cycles). Pembrolizumab will be given every 3 weeks for 8 cycles. If the daily dose of TGR-1202 (dose level 1) is tolerated in the first cohort the dose will be increased which is the only and final dose escalation. If TGR-1202 is not tolerated the dose will be decreased.
2895116|NCT03283124|Active Comparator|self-cut mesh procedure|This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.
2895117|NCT03283124|Active Comparator|mesh-kit procedure|This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.
2895118|NCT03283111|Experimental|autologous stem cell transplantation|Lymphoma patients received autologous stem cell transplantation for the first time
2895119|NCT03283098|Active Comparator|AMG 416|5mg IV Dose AMG 416 TIW (N=24)
2895120|NCT03283098|Placebo Comparator|Placebo|Placebo IV Dose TIW (N=8)
2895121|NCT03283085|Experimental|25 mg SHP647|Participants will be receiving 25 milligram (mg) of SHP647 subcutaneously every 4 weeks until the drug is commercially available, the participant withdraws from the study, or the investigator or sponsor decide to withdraw the participant, or the sponsor decides to close the study. Allocation will be decided based on how the participant entered into this study.
2895122|NCT03283085|Experimental|75 mg SHP647|Participants will be receiving 75 mg of SHP647 subcutaneously every 4 weeks until the drug is commercially available, the participant withdraws from the study, or the investigator or sponsor decide to withdraw the participant, or the sponsor decides to close the study. Allocation will be decided based on how the participant entered into this study.
2895123|NCT03283072|Sham Comparator|Sham|normoxia for 2 minutes, normoxia 1 minute x 8 using hypoxicator
2895124|NCT03283072|Experimental|Trubower|15 bouts of hypoxia for 1 minute, normoxic 1 minute using hypoxicator
2895125|NCT03283072|Experimental|Hayes|15 bouts of hypoxia for 2 minutes, normoxic 1 minute using hypoxicator
2895126|NCT03283072|Experimental|Tester|8 bouts of hypoxia for 2 minutes, normoxic 1 minute using hypoxicator
2895127|NCT03283059|Experimental|Octohydroaminoacridine Succinate Tablet|Octohydroaminoacridine Succinate Tablet 4mg P.O. tid
2895128|NCT03283059|Active Comparator|Aricept|Aricept 5mg/day P.O.
2895129|NCT03283059|Placebo Comparator|Placebo|Placebo P.O. tid
2895130|NCT03283046|Experimental|Nivolumab + Ipilimumab + Dexamethasone + Lenalidomide|"The first 4 study cycles are 21 days long, and all remaining cycles are 28 days long.~On Day 1 of Cycles 1-4, Nivolumab by vein over 60 minutes. Thirty (30)minutes after Nivolumab, Ipilimumab given by vein over 90 minutes. On Days 1 and 15 of Cycles 5 and beyond, Nivolumab given by vein over 60 minutes.~Lenalidomide tablets take by mouth on Days 1-14 of Cycles 1-4 and on Days 1-21 of Cycles 5 and beyond. Dexamethasone tablets taken by mouth on Days 1, 8, and 15 of Cycles 1-4, and on Days 1, 8, 15, and 22 of Cycles 5 and beyond.~For participants who are eligible for autologous stem cell transplant, those who achieve at least a partial response after at least 4 cycles of initial therapy will be eligible for:~EITHER Stem cell collection and storage OR Stem cell collection and autologous stem cell transplantation."
2895131|NCT03283033|Experimental|Experimental 3|Introduction of a new salad bar and marketing conditions during second semester of school year
2895132|NCT03283033|Experimental|Experimental 2|Introduction of marketing conditions during second semester of school year
2895133|NCT03283033|Experimental|Experimental 1|Introduction of a new salad bar during second semester of school year
2895134|NCT03283033|No Intervention|Control|No introduction of a new salad bar and no introduction of marketing conditions
2895135|NCT03283020|Active Comparator|RemifentanilMNTX|Volunteers are given an intravenous infusion with remifentanil, with an effect-site target concentration of 3 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
2895136|NCT03283020|Active Comparator|PlaceboMNTX|Volunteers are given an intravenous infusion with saline 0,9%. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
2895137|NCT03283007|Experimental|Nintedanib|Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months
2895138|NCT03283007|Placebo Comparator|Placebo|Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
2895139|NCT03282981|Experimental|Timolol|Timoptic-XE plus standard of care (SOC)
2895140|NCT03282981|Placebo Comparator|SOC plus non biologically active gel|SOC plus non biologically active gel (hydrogel as placebo medication)
2895141|NCT03282968|Experimental|Experimental|Regular neurophysiotherapy plus REWIRE exercises
2895142|NCT03282968|Active Comparator|Control|Regular neurophysiotherapy plus standing balance exercises
2895143|NCT03282955|Experimental|Lipidem|i.v. lipid emulsion containing fractionated fish oil (n-3 fatty acid triglycerides)
2895145|NCT03282942|Experimental|Exercise training protocols|Participants will be randomized in one of TWO groups: aerobic training group (AT) or strength training group (ST). Each training protocol will last 12 weeks, being the initial two weeks designed to participants' gradual adaptations to respective training protocol, with sessions performed three times per week in non-consecutive days.
2895146|NCT03282942|No Intervention|Control Group|The individuals who will be part of the control group will be instructed to follow their daily activities, avoiding any systematic exercise program and return to the end of the 12 weeks for reevaluation.
2895147|NCT03282929|Experimental|Part 1 Group 1|A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order.
2895148|NCT03282929|Experimental|Part 2 group 1|300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
2895149|NCT03282929|Experimental|Part 2 Group 2|500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
2895150|NCT03282929|Experimental|Part 2 Group 3|300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
2895151|NCT03282929|Experimental|Part 2 Group 4|300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
2895152|NCT03282916|Active Comparator|Valacyclovir|The oral valacyclovir will be distributed in 500mg caplets. Patients will take 4-8 caplets per day.
2895153|NCT03282916|Placebo Comparator|Placebo|The oral placebo sugar pill will be distributed in 500mg caplets. Patients will take 4-8 caplets per day.
2895154|NCT03282903||Crohn's disease patients|750 Crohn's disease patients who are symptomatically controlled.
2895155|NCT03282903||Ulceratice Colitis patients|750 Ulceratice Colitis patients who are symptomatically controlled.
2895156|NCT03282890|Experimental|CHRP-BB|Patients assigned to the CHRP-BB will receive a weekly HIV risk reduction and PrEP adherence group level intervention led by two facilitators trained and supervised by the PI, a licensed clinical psychologist. It is a substantially shortened version of the comprehensive Holistic Health Recovery Program (HHRP)-based interventions that have been identified as demonstrating evidence of effectiveness in two randomized clinical trials. The CHRP-BB, which includes four 50-minute groups (1 group per week), will contain only content that relates explicitly to drug- or sex-related HIV risk reduction and PrEP adherence. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
2895157|NCT03282890|No Intervention|Control Condition|The time-and-attention-matched control condition for the proposed research will be a time and contact-matched, non-contaminating support group for individuals in recovery modeled after similar groups offered in the community. There will be no overlap between the content of the comparison intervention and experimental intervention although the basic structure will be the same. Thus, each participant will be asked to attend four 50-minute weekly group sessions led by two trained facilitators. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
2895158|NCT03282877|Experimental|iCST web-application|A computerised cognitive stimulation programme consisting of 21 sessions.
2895159|NCT03282877|No Intervention|Treatment as usual (TAU)|The control group will consist of a treatment-as-usual group and will not receive any additional intervention.
2895160|NCT03282864|Active Comparator|Bedroom air filtered by an air filtration device|The air in the bedroom of study subjects in the active comparator arm was filtered by an air filtration device which processed air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter. The duration of being in the active comparator arm was 2 weeks.
2895161|NCT03282864|Placebo Comparator|Bedroom air filtered by a placebo air filtration device|The air in the bedroom of subjects in the placebo arm was filtered by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. The duration of being in the placebo arm was 2 weeks.
2895162|NCT03282851|Experimental|MSB11456|
2895163|NCT03282851|Active Comparator|US-licensed Actemra|
2895164|NCT03282851|Active Comparator|EU-approved RoActemra|
2895165|NCT03282838|Experimental|DFN-15 (fasted)|
2895166|NCT03282838|Experimental|DFN-15 (fed)|
2895167|NCT03282838|Experimental|Comparator (fed)|
2895168|NCT03282825|Experimental|Decitabine|"A standard 3+3 trial design will be used for Decitabine dose escalation cohorts.~The number of cohorts is three. The subjects will be administered Decitabine on every seven days in a 28day cycle and Decitabine is sequential administered with Paclitaxel.~Cohort 1: Decitabine 15mg/m2, Cohort 2: Decitabine 20mg/m2, Cohort 3: Decitabine 25mg/m2"
2895169|NCT03282812||cases|
2895170|NCT03282812||controls|
2895171|NCT03282799|Active Comparator|Standard Dose Etonogestrel Implant|Single 68 mg etonogestrel implant
2895172|NCT03282799|Experimental|Increased Dose Etonogestrel Implant|Two 68 mg (136 mg total) etonogestrel implants
2895173|NCT03282786|Active Comparator|CD patient with CO2 insufflation|The investigators aim to include 76 Crohn's disease (CD) patients undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.
2895174|NCT03282786|No Intervention|CD patient with air insufflation|The investigators aim to include 76 Crohn's disease patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.
2895175|NCT03282786|Active Comparator|UC patient with CO2 insufflation|The investigators aim to include 76 ulcerative colitis patients (UC) undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.
2895176|NCT03282786|No Intervention|UC patient with air insufflation|The investigators aim to include 76 ulcerative colitis patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.
2895177|NCT03282773|Experimental|Deferred stent implantation|Drug-eluting stents are implanted 4-10 days after primary angiography and restoration of blood flow in left main coroanry artery in a secondary PCI
2895178|NCT03282773|Active Comparator|Immediate stent implantation|Drug-eluting stents are implanted immediately after primary angiography and restoration of blood flow in left main coroanry artery
2895179|NCT03282760|Experimental|Human Neural Stem Cells Suspension|Intraventricular injections of Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10,16 or 24 millions)
2895180|NCT03282734|Experimental|The smart rehab group|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for 4 weeks
2895181|NCT03282734|Active Comparator|The control group|Conventional home rehabilitation exercise education for 4 weeks
2895182|NCT03282721||redesigned|the commissure constructions of the cleft side were precised located, include the upper and lower inherent vermilion border, the interior commissure, the outline of commissure, the exterior commissure, the upper skin-mucosa junction and the lower skin-mucosa junction.
2895183|NCT03282721||classical|follows the simple-symmetry rule, the commissure of the healthy side is measured, and then the affected side is located accordingly.
2895184|NCT03282708|Experimental|Microbiome|"Caretakers of captive great apes. One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).~Data collection with self-administered questionnaire"
2895185|NCT03282708|No Intervention|Anthropology|Caretakers of captive great apes. Two four-hour participant-observations of each caretaker's activities with captive great apes
2895186|NCT03282695||Surgery|"Patients on waiting list for surgery (by discectomy/microdiscectomy) who reject ozone infiltration during waiting time.~These patients will receive standard pain treatment until the planned surgery."
2895187|NCT03282695||Ozone|"Patients on waiting list for surgery (by discectomy/microdiscectomy) who accept treatment by ozone infiltration during waiting time.~These patients will be treated primarily by ozone therapy: Infiltration of intradiscal O3/O2 + foraminal infiltration of O3/O2 + corticoid + anesthetic.~These patients will receive standard pain treatment until the planned surgery."
2895188|NCT03282682|Experimental|hypogonadal males without TRT|Strength training
2895189|NCT03282682|Experimental|hypogonadal males with TRT|Strength training and regular prescribed testosterone therapy given by participant urologist.
2895190|NCT03282682|Active Comparator|healthy eugonadal males|Strength training
2895191|NCT03282669|Active Comparator|Intrathecal Morphine|Administration of 100µg intrathecal morphine to be given in the operative area.
2895192|NCT03282669|Active Comparator|Intravenous Hydromorphone|Administration of intravenous hydromorphone give IV pca in the post operative area.
2895193|NCT03282656|Experimental|Treatment arm|open-label, non-randomized, single center, pilot and feasibility, single arm cohort study of a single infusion of autologous bone marrow derived CD34+ HSC cells transduced with lentiviral vector containing a short-hairpin RNA targeting BC11A.
2895194|NCT03282643|Experimental|Rivaroxaban 10mg daily|orally, 10 mg once daily for day1 and day 2 after femoral venepuncture
2895195|NCT03282643|Experimental|Rivaroxaban 20mg daily|orally, 10 mg twice daily for day1 and day 2 after femoral venepuncture
2895196|NCT03282643|Active Comparator|Low-molecular-weight heparin|subcutaneously, 0.4 ml once daily, before femoral venepuncture (day1) and after the day of femoral venepuncture (day 2)
2895197|NCT03282630|Experimental|active acupuncture|"Procedure/Surgery: active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt de-qi sensations."
2895198|NCT03282630|Sham Comparator|sham acupuncture|Procedure/Surgery: Sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
2895199|NCT03282617|Experimental|locally recurrent or metastatic nasopharyngeal cancer|This cohort consists of patients with metastatic or locally recurrent NPC who have received systemic concurrent chemotherapy and have a favourable response of stable disease, partial or complete response. As up to 30% of these patients will suffer from relapse within 5 months of completion of chemotherapy, following definitive treatment, y, and treatment with CD137L-DC-EBV-VAX may activate T cell response against the tumor and prolong time to progression.
2895200|NCT03282617|Experimental|stage 4 locally advanced nasopharyngeal cancer|This cohort consists of patients with stage 4 locally advanced patients (N2 and N3 disease, and/or T4 disease) who are treated definitely with chemoradiation with curative intent, but who have a high risk of distant relapse. Treatment with CD137L-DC-EBV-VAX may activate antitumor T cell responses and prolong time to relapse.
2895201|NCT03282604||male|
2895202|NCT03282604||female|
2895203|NCT03282591|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
2895204|NCT03282591|Placebo Comparator|Matching Placebo Tablets|Placebo Tablets
2895205|NCT03282578|Active Comparator|Sternalock 360 sternal plating system|use of the SternaLock 360 system to close the sternum: 3 plates with 3 bands and measured screw length to engage but not penetrate the posterior sternal cortex, used to close the sternum
2895206|NCT03282578|Active Comparator|Sternal wires|"Stainless steel sternal wires applied in a figure of 8 configuration to close the sternum"
2895207|NCT03282565|Experimental|Functional Resistance Training|Participants will receive functional resistance training while walking on a treadmill 2-3 times a week for about 8 weeks.
2895208|NCT03282565|Sham Comparator|Control|Participants will while on a treadmill without an applied resistance 2-3 times a week for about 8 weeks.
2895209|NCT03282552|Active Comparator|Study Group 1|"The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 1, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment.~The first Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=60L/min."
2895210|NCT03282552|Active Comparator|Study Group 2|"The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 2, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment.~The second Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=40L/min."
2895211|NCT03282552|No Intervention|Control group|"In the third group (control group) all patients will receive oxygen treatment according to the standard practice of our cardiac ICU department, i.e., Venturi mask with FiO2=60% and flow of 15L/min.~In this group all patients will receive the usual standard of care, with no other interventions included"
2895212|NCT03282539||LAMS|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents.
2895213|NCT03282539||LAMS + pigtail|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
2895214|NCT03282526|Experimental|Whole body plethysmography|
2895215|NCT03282526|Active Comparator|spirometery|
2895216|NCT03282513|Experimental|Cohort 1A: Mild Hepatic Impairment|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with mild hepatic impairment(Child-Pugh Score A.)"
2895217|NCT03282513|Active Comparator|Cohort 1B: Healthy Volunteers|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with normal hepatic function."
2895218|NCT03282513|Experimental|Cohort 2A: Moderate Hepatic Impairment|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with moderate hepatic impairment (Child-Pugh Score B.)"
2895219|NCT03282513|Active Comparator|Cohort 2B: Healthy Volunteers|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with normal hepatic function."
2895220|NCT03282500|Experimental|Mindfulness Based Cognitive Therapy|In the experimental condition, participants will receive 12 sessions including the instruction of mindfulness skills and cognitive behavioral therapy.
2895221|NCT03282500|No Intervention|Psychoeducation on brain injury and treatment|In the control condition, participants will receive 12 sessions on the psychoeducation of brain injuries, outcomes, treatment, and support.
2895222|NCT03282487|No Intervention|Conventional immediate release hydrocortisone|
2895223|NCT03282487|Active Comparator|Modified release Hydrocortisone|12 weeks of modified release hydrocortisone (Plenadren)
2895224|NCT03282487|No Intervention|Healthy control group|Same research laboratory measurements performed in a healthy control group for comparison to patient group
2895225|NCT03282474|Experimental|Sofosbuvir|Sofosbuvir 400 MG film-coated tablet, oral administration of one tablet once daily for 24 weeks.
2895226|NCT03282461|Experimental|ABY-029|Between 3-9 patients will be administered ABY-029 as a single intravenous injection approximately 1-3 hours prior to surgery.
2895227|NCT03282448|Experimental|Family therapy|Adolescent mothers and their family members will receive a total of 10 weekly, 30-minute, video-based family therapy sessions.
2895228|NCT03282448|No Intervention|Historical comparison group|The Edinburgh Postnatal Depression Scale scores of adolescent mothers in the intervention group will be compared to those of adolescent mothers, who were previously enrolled in the home visiting programs, at the same time points.
2895229|NCT03282435|Experimental|CIK cells with PD-1 blocking|CIK cellular therapy with PD-1 blocking combined with standard lung cancer treatment
2895230|NCT03282435|Active Comparator|CIK cells without PD-1 blocking|CIK cellular therapy without PD-1 blocking combined with the same standard lung cancer treatment as the experimental group patients receive
2895231|NCT03282422|Experimental|Intervention group|Upper-limb splint and home-based protocol in specific tasks
2895232|NCT03282422|Active Comparator|Control group|Home-based protocol in specific tasks
2895233|NCT03282396|Experimental|Ibrutinib|"Participants receive Ibrutinib by mouth 1 time per day in a 28 day cycle.~Participants called by study staff every 2 months for the first 6 months after the End-of-Treatment visit, then every 2-4 months for 2 years, and then 4-6 months after 2 years."
2895234|NCT03282370|Experimental|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
2895235|NCT03282370|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
2895236|NCT03282357|Experimental|Radiesse®|Patients are randomized as to which of the two nasolabial folds is treated with Radiesse®.
2895237|NCT03282357|Active Comparator|Restylane®|Patients are randomized as to which of the two nasolabial folds is treated with Restylane®.
2895238|NCT03282344|Experimental|participants ≥18 years old NKTR-214 and Nivolumab|NKTR-214 0.006mg/kg will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks. Nivolumab (anti-PD-1) 360mg will be administered every 3 weeks as an IV infusion over 30 (±5) minutes for participants ≥18 years.
2895239|NCT03282344|Experimental|participants 12 - 17 years old NKTR-214 0.006mg/kg and Nivo|NKTR-214 0.006mg/kg will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks. Nivolumab (anti-PD-1) 4.5 mg/kg up to 360 mg will be administered every 3 weeks as an IV infusion over 30 (±5) minutes for participants 12 - 17 years.
2895240|NCT03282331|Experimental|standard oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
2895241|NCT03282331|Other|High flow nasal oxygen therapy|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
2895242|NCT03282331|Other|NonInvasive Ventilation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
2895243|NCT03282318|Experimental|ASP6294|Participants will receive subcutaneous (SC) administrations of ASP6294 at weeks 0, 4 and 8.
2895244|NCT03282318|Placebo Comparator|Placebo|Participants will receive SC administrations of Placebo at weeks 0, 4 and 8.
2895245|NCT03282292|Experimental|Jugular|CVC insertion in the left or right internal jugular vein
2895246|NCT03282292|Active Comparator|Femoral|CVC insertion in the right or left femoral vein
2895247|NCT03282279||TVOR population|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from all transvaginal oocyte retrieval procedures performed between 1996 and October 2016.
2895248|NCT03282266|Experimental|PADN + 5-phosphodiesterase|A total of 64 patients are assigned to PADN + 5-phosphodiesterase group after randomization schedule.
2895249|NCT03282266|Sham Comparator|Sham operation + 5-phosphodiesterase|A total of 64 patients are assigned to sham operation + 5-phosphodiesterase group after randomization schedule.
2895250|NCT03282240|Experimental|QIV-HD|Participants randomized to receive a single injection of the high dose quadrivalent influenza vaccine (QIV-HD) at Day 0.
2895251|NCT03282240|Active Comparator|TIV-HD1 (Licensed TIV-HD1)|Participants randomized to receive a single injection of the licensed high dose trivalent influenza vaccine (TIV-HD1) at Day 0.
2895252|NCT03282240|Active Comparator|TIV-HD2 (Investigational TIV-HD2)|Participants randomized to receive a single injection of the investigational high dose trivalent influenza vaccine with alternate B strain (TIV-HD2) at Day 0.
2895378|NCT03281304|Experimental|CP-690,550 5 mg|CP-690,550 5 mg tablet by mouth twice a day (BID)
2895254|NCT03282214|Experimental|Self-management energy conservation|Thai women with breast cancer randomized to the group will receive four sessions approximately every three weeks with the PI. The women will be instructed on how to do a self-management energy conservation program.
2895255|NCT03282214|No Intervention|Control|The participants will be given two pamphlets (general issues about breast cancer and self-care activities for patients receiving chemotherapy) provided by the health care team at the study sites. The participants in the control group will be encouraged to maintain their current daily activities during the 12-week period The participants will wear a pedometer to record the number of steps which is one of the activity outcomes.
2895256|NCT03282201||Transfused|Patients in whom blood transfusion is used
2895257|NCT03282201||Nontransfused|Patients in whom blood transfusion is not used
2895258|NCT03282188|Experimental|GROUP A (Reovirus only)|Group A patients will receive an initial low 'immunisation' dose of intravenous reovirus (1x108 TCID50), to ensure that neutralising antibody (NAB) levels have risen by the time a full cycle of reovirus is given. Group A patients will then receive only 1 cycle of treatment which will comprise of reovirus only at 1x1010 TCID50 as a 1-hour IV infusion on 2 consecutive days.
2895259|NCT03282188|Experimental|GROUP B (Reovirus plus GM-CSF)|Group B patients will receive an initial low 'immunisation' dose of intravenous reovirus (1x108 TCID50), to ensure that neutralising antibody (NAB) levels have risen by the time a full cycle of reovirus plus GM-CSF is given. Group B patients will be given a subcutaneous injection of GM-CSF (50mcg/day) for 3 days, followed by only 1 cycle of treatment which will comprise of reovirus at 1x1010 TCID50 as a 1-hour IV infusion on 2 consecutive days
2895260|NCT03282175|Experimental|Exercise|Participant in this group performed an acute resistance exercise protocol. The exercise protocol consisted of general warm-up of 10 min, followed by 8 exercises with 2 sets of 8 repetition and 1 min between sets.
2895261|NCT03282175|Experimental|Training|Participants allocated to intervention group initiated the progressive resistance training program of moderate intensity, with three weekly sessions throughout the 12-week treatment period.
2895262|NCT03282175|Active Comparator|Control group|Participants allocated to control group did not receive any placebo or treatment.
2895263|NCT03282162|Experimental|Oxytocin then placebo|Subjects will first receive oxytocin (24 IU).They then will receive placebo (24 IU) 2 weeks later.
2895264|NCT03282162|Experimental|Placebo then oxytocin|Subjects will first receive placebo (24 IU).They then will receive oxytocin (24 IU) 2 weeks later.
2895265|NCT03282149|Experimental|Dose 1|Lowest trial dose of XT-150
2895266|NCT03282149|Experimental|Dose 2|Second, escalating dose of XT-150
2895267|NCT03282149|Experimental|Dose 3|Third, escalating dose of XT-150
2895268|NCT03282149|Placebo Comparator|Saline placebo|2 of 8 participants in each cohort will randomly be assigned to placebo
2895269|NCT03282136|Active Comparator|incretin arm|T2DM with HF treated by CRTd participants will be assigned prospectively to an intervention (incretin therapy plus conventional hypoglycemic drug therapy) according to study protocol to evaluate the effect of the drug on cardiac deaths, all cause deaths, and hospital admission for heart failure.
2895270|NCT03282136|Placebo Comparator|conventional hypoglycemic drug arm|T2DM with HF treated by CRTd participants will be assigned prospectively to placebo comparator (placebo plus conventional hypoglycemic drug therapy) according to study protocol to evaluate the effect of the drug on cardiac deaths, all cause deaths, and hospital admission for heart failure.
2895271|NCT03282123|Experimental|MDMA-assisted psychotherapy|Three sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 80 to 120 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
2895272|NCT03282110|Experimental|ta-VNS & Electro-acupuncture|"Device:ta-VNS(transcutaneous vagus nerve stimulation):2 times per day,5 consecutive days per week for two months~Other:Electro-acupuncture:3 times per week, once every other day for two months"
2895273|NCT03282110|Active Comparator|Citalopram|citalopram for oral administration; 10mg for the first 1-3 days, 20mg for the following 4-7 days；40mg for the left days within two months
2895274|NCT03282097|Experimental|Mammogram decision aid|Will be mailed the DECAD decision aid before their next PCP visit in order to better inform their decision to continue or stop mammography.
2895275|NCT03282097|Active Comparator|Home safety guide|The home safety guide is a two-page paper pamphlet developed by the American Geriatrics Society Foundation for Health in Aging. It provides tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards. We selected the home safety guide to account for the attention given to the intervention group but not to provide information that would bias the control group away from talking about mammography with the patient's PCP.
2895276|NCT03282084||Unproven GERD|Subjects with no prior testing, normal prior EGD or prior LA Grade A esophagitis
2895277|NCT03282084||Proven GERD|LA Grade B-D esophagitis, long-segment Barrett's, prior positive pH study
2895278|NCT03282071|Experimental|Joyful Parenting Intervention|Subjects will participate in two-session interactive talks on joyful parenting (a core session intervention and booster intervention) and one family gathering activity; questionnaire evaluation will be conducted at baseline, post-session,1 month and 3 month after core session.
2895279|NCT03282071|No Intervention|Control|No intervention will be provided to control groups during study period.
2895280|NCT03282058|Experimental|Silastic Stent|"At the time of surgery, if the patient is identified in the silastic stent arm, dressing of the septal donor site with silastic stents will be performed after reconstruction has been achieved and the surgeon feels that the surgery proceeded routinely."
2895281|NCT03282058|No Intervention|No Stent|"At the time of surgery, if the patient is identified in the no silastic stent arm, dressing of the septal donor site without the stent will be performed after reconstruction has been achieved and the surgeon feels that the surgery proceeded routinely - this is currently the standard of care."
2895282|NCT03282045|Experimental|Lysobact Complete Sprey|"Lysobact Complete Sprey~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open~Dose regimen: Sprayed 3 to 6 doses a day. For a single dose, spraying pump should be pressed 5 times and one press of the spray pump release 0.20 mL of the solution containing 4 mg lysozyme, 0.3 mg cetylpyridine and 0.1 mg lidocaine hydrochloride."
2895355|NCT03281434|Experimental|Whey protein|Supplement will be delivered twice daily (30g per supplement) of whey protein isolate
2895283|NCT03282045|Active Comparator|Tantum Verde® Spray|"Tantum Verde® Spray~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open.~Dose regimen: Sprayed 4 to 8 doses, 2 to 6 times a day. One press means one dose."
2895284|NCT03282045|Active Comparator|Pharyngal® Oromucosal Spray|"Pharyngal® Oromucosal Spray~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open.~Dose regimen: Sprayed 2 to 4 doses, repeated 6 to 10 times per day. One press of the pump (one dose) releases 0.14 ml of the solution with 0.28 mg chlorhexidine digluconate and 0.07 mg of lidocaine hydrochloride."
2895285|NCT03282045|Placebo Comparator|Placebo|"Route of administration: Sprayed directly toward the affected area with the applicator while the mouth is wide open.~Dose regimen: Sprayed 3 to 6 doses a day. For a single dose, spraying pump should be pressed 5 times."
2895286|NCT03282032|Experimental|One-lung ventilation|Before surgical incision, 2-min of OLV followed by 2-min of TLV (1 cycle) is performed for 5 cycles.
2895287|NCT03282032|No Intervention|Two-lung ventilation|Maintain two-lung ventilation until surgical incision
2895288|NCT03282019|Experimental|Arm A(myAIRVO2® + HOT)|Subjects receive following protocol treatment; Home oxygen therapy (HOT) plus nocturnal high-flow nasal cannula therapy with the myAIRVO2 within 52weeks.
2895289|NCT03282019|Active Comparator|Arm B(HOT)|Subjects receive following protocol treatment; Home oxygen therapy (HOT) only within 52weeks.
2895290|NCT03282006|Experimental|Pivmecillinam|Patients treated with pivmecillinam
2895291|NCT03281993||CPAP-AT|After 2 hours from I-AT was performed the alternative AT by CPAP ventilation mode. Before CPAP-AT and 10 minutes after blood samples for arterial blood gases (ABG) were collected. If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%, CPAP-AT was aborterd.
2895292|NCT03281980|Experimental|Intervention (UCT+HE+PS)|The participants of this arm will receive UCT and HE along with psychosocial stimulation (PS)
2895293|NCT03281980|Sham Comparator|Government Intervention (UCT+HE)|The participants of this arm will receive only UCT and HE
2895294|NCT03281980|No Intervention|Comparison|
2895295|NCT03281967|Other|Minimally Invasive Ponto Surgery|Surgical method for installation of a bone anchored hearing system for hearing rehabilitation
2895296|NCT03281954|Placebo Comparator|Placebo|IV infusion once every 3 weeks for 4 doses (Cycle 1), once every 3 weeks for 4 doses (Cycle 2) and once every 3 weeks after surgery for 1 year after first dose
2895297|NCT03281954|Experimental|Atezolizumab|IV infusion, 1200mg, once every 3 weeks for 4 doses (Cycle 1), once every 3 weeks for 4 doses (Cycle 2) and once every 3 weeks after surgery for 1 year after first dose
2895298|NCT03281941|Other|Patients without BT|
2895299|NCT03281941|Other|Post BT|
2895300|NCT03281928|Experimental|Low Sodium plus Potassium Citrate|
2895301|NCT03281928|Placebo Comparator|Low Sodium plus placebo|
2895302|NCT03281928|Experimental|High Sodium plus Potassium Citrate|
2895303|NCT03281928|Placebo Comparator|High Sodium plus placebo|
2895304|NCT03281915||high inguinal approch|Patients undergoing high inguinal varicocelectomy with normal pre operative semen parameters, post operative semen analysis parameters will be recorded
2895305|NCT03281915||subinguinal approch|Patients undergoing subinguinal varicocelectomy with normal pre operative semen parameters, post operative semen analysis parameters will be recorded
2895306|NCT03281902||Ancillary-Correlative (genetic profile analysis)|Patients undergo collection of blood at baseline and on day 1 of each treatment cycle. Patients also undergo tumor biopsy at baseline and 2 months. Biopsy samples are analyzed for genetic profile via next generation sequencing and RNA sequencing. Biopsy samples are also used for the generation of xenograft mice model. Patients are followed up for 3 years.
2895307|NCT03281889|Experimental|Proton Radiotherapy|"Patients will be treated with Proton Beam once daily 5 days per week.~Doses will be prescribed such that maximum possible coverage is achieved"
2895308|NCT03281876|Experimental|GSK3277511A Group|Healthy males and females, 40 to 80 years of age, who received two doses of the adjuvanted GSK3277511A investigational vaccine containing surface protein D (PD), protein E- type IV pilus assembly protein (PE-PilA,) and ubiquitous surface protein A2 (UspA2) at Day 1 and Day 61.
2895309|NCT03281876|Placebo Comparator|CONTROL Group|Healthy males and females, 40 to 80 years of age, who received two doses of placebo vaccine at Day 1 and Day 61.
2895310|NCT03281837|Experimental|Group 1: Hymovis plus Physical Exercise Program (PEP)|Intra-articular (IA) Hyaluronan (HA) (Hymovis 24mg/3mL) combined with Physical Exercise program (PEP)
2895311|NCT03281837|Other|Group 2: Physical Exercise Program (PEP) alone alone|Specified designed Physical Exercise Program (PEP) not combined with any other intervention
2895312|NCT03281837|Other|Group 3: Cross-Over group|Patients who were randomized to receive only Physical Exercise Program (PEP) alone and do not respond after 3 months to this intervention will have the opportunity to cross-over to receive 2 intra-articular weekly injections, each injection given 1 week apart, of Hymovis.
2895313|NCT03281824|Experimental|ALT-P7|"7 groups: 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.8 mg/kg, 5.4 mg/kg~Administration: Day 1 of each 3-week cycle"
2895314|NCT03281811|Experimental|Treatment (aminolevulinic acid hydrochloride, PDT, RT)|Patients receive aminolevulinic acid hydrochloride topically and undergo photodynamic therapy on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning at week 24, patients undergo radiation therapy daily for 4 weeks.
2895315|NCT03281798|Experimental|Fetuses with LUTO|Performance of ultrasound-guided, percutaneous fetal cystoscopy with the Karl Storz Semi-Rigid TTTS Fetoscopy Instrument Set
2895316|NCT03281785|Active Comparator|Pressure controlled mandatory ventilation mode (P-CMV)|Patients will be ventilated using pressure controlled mandatory ventilation mode
2895317|NCT03281785|Active Comparator|Pressure synchronized intermittent mandatory ventilation|Patients will be ventilated using pressure synchronized intermittent mandatory ventilation mode (P-SIMV)
2895318|NCT03281785|Active Comparator|Pressure support mode (PS)|Patents will be ventilated with pressure support mode (PS)
2895352|NCT03281447|Experimental|Nurse navigation|Coherent navigation and support from a family-centred viewpoint throughout the cancer trajectory, despite the individual patient's affiliation to any department.
2895353|NCT03281447|Active Comparator|Current care coordination|Department-specific coordination and answers to questions from a patient-centred viewpoint.
2895319|NCT03281772||Provider|Consented providers with prescriptive privileges will use the clinical decision software - provider portal to manage study patients with uncontrolled hypertension for 6 months. Participants will conduct a baseline face-to-face visit with study patients, access the program daily to check for patient high blood pressure alerts and lab results, conduct virtual visits as needed every 7 - 10 days, track the time and number of patients managed using the program and complete two questionnaires.
2895320|NCT03281772||Patients|In a 6 month period, participants with uncontrolled hypertension will attend an initial face-to-face visit with a study provider, monitor their blood pressures 3x/week at home, enter their blood pressure readings manually or digitally into the clinical decision software - patient portal, get up to 4 blood draws, participate into up to 3 virtual visits monthly, and complete a questionnaire.
2895321|NCT03281759|Active Comparator|Active Coil Helmet|The patients will undergo 18 sessions (627 nm, 70 mW/cm2, 10 J/cm2) at four points of the frontal and parietal region for 30 s each, totaling 120 s three times per week for 6 weeks, lasting 30 minutes of transcranial LED stimulation.
2895322|NCT03281759|Placebo Comparator|Inactive Coil Helmet|The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions.
2895323|NCT03281746|Active Comparator|Group I (standard prevention education)|Patients undergo dental examination at baseline and then receive standard prevention education at diagnosis discussing the effects of prolonged neutropenia on oral hygiene, importance of a regular oral hygiene regimen, and the long term clinical outcomes of oncologic patients. Patients also receive fliers with pictograms describing proper brushing, use of mouth wash, and common oral complications during therapy, as well as a bottle and prescription for chlorhexidine gluconate 0.12% rinse.
2895324|NCT03281746|Experimental|Group II (standard and one-on-one education, consultation)|Patients undergo dental examination and receive standard prevention education as in Group I. Patients also receive one-on-one prevention education and counseling with the physician and pediatric dental resident.
2895325|NCT03281720|Experimental|Targeted Axillary Dissection|"After patients have completed their neoadjuvant systemic therapy, they will have a Savi Scout® electromagnetic reflector placed into the clipped axillary lymph nodes.~The surgeon will then use the Savi Scout detector intraoperatively to identify and remove your clipped lymph nodes prior to removing the remainder of the axillary lymph nodes in a surgery called an axillary dissection."
2895326|NCT03281694|Other|Nicotine - AVL-3288 Interaction Study|Over four different test days, all participants will be tested with Placebo, Nicotine, AVL-3288, and Nicotine + AVL-3288, in a counterbalanced sequence.
2895327|NCT03281681|Experimental|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
2895328|NCT03281668|Experimental|Intervention|Intervention consists of High Intensity Interval Training (HIIT) session which is af 3-5 minute warm up, followed by 10 repetitions of 1 minute bouts at individualized training intensity with 1 minute rest periods.
2895329|NCT03281655|Experimental|Vulvovaginal atrophy|Postmenopausal sexually active women affected by vulvovaginal atrophy undergoing treatment (15 days, 1 application per day) with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
2895330|NCT03281629|Active Comparator|Active TMS stimulation|Real active rTMS stimulation.
2895331|NCT03281629|Sham Comparator|Sham TMS stimulation|Sham repetitive TMS stimulation.
2895332|NCT03281616|Active Comparator|Diet and Physical Activity Recording|
2895333|NCT03281616|Active Comparator|Diet and No Physical Activity Recording|
2895334|NCT03281603|Experimental|CAD/CAM complete denture|"First intervention: Constructing complete denture by CAD/CAM technology utilizing milling technique.~Second intervention:Constructing complete denture CAD/CAM technology utilizing 3D printing technique"
2895335|NCT03281603|Active Comparator|Conventional complete denture|Constructing complete denture by conventional technique of denture processing
2895336|NCT03281590||Patients with stroke|Patients with the Acute Brain injury, Transient Ischemic Attack, Acute and Chronic Ischemic and Hemorrhagic Stroke, Subarachnoid hemorrhage, and cerebral venous thrombosis from pre-hospitalization, hospitalization (in-patient) and post hospitalization (clinic) data
2895337|NCT03281590||Patients without stroke|Control subject who have the risk factors but never had stroke.
2895338|NCT03281577|Experimental|TAK-954 0.1 mg|TAK-954 0.1 milligram (mg), 60-minute infusion, intravenous (IV), once daily for up to 3 days.
2895339|NCT03281577|Experimental|TAK-954 0.3 mg|TAK-954 0.3 mg, 60-minute infusion, IV, once daily for up to 3 days.
2895340|NCT03281577|Experimental|TAK-954 1 mg|TAK-954 1 mg, 60-minute infusion, IV, once daily for up to 3 days.
2895341|NCT03281577|Placebo Comparator|Placebo|TAK-954 placebo-matching, 60-minute infusion, IV, once daily for up to 3 days.
2895342|NCT03281564||Essure®|Patients with laparoscopic removal of Essure®
2895343|NCT03281551|Experimental|PZ01 CAR-T Cells|This is a phase I study. Patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma are eligible for enrollment.
2895344|NCT03281538|Experimental|CR845 0.5mcg/kg|CR845 0.5mcg/kg IV medication administered three times/week after dialysis
2895345|NCT03281499|Experimental|da Vinci Surgical System Model IS4000|Transoral robotic surgery, followed by tailored radiotherapy
2895346|NCT03281486|Experimental|HA formulation Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
2895347|NCT03281486|Placebo Comparator|Placebo Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
2895348|NCT03281473|Experimental|Arms A|Strategy 1 - Washout period - Strategy 2
2895349|NCT03281473|Experimental|Arms B|Strategy 2 - Washout period - Strategy 1
2895350|NCT03281460|Experimental|with in-bag morcellation|with More-cell-Safe AMI bag morcellation
2895351|NCT03281460|Active Comparator|without any morcellation bag|without any morcellation bag
2895356|NCT03281421|Experimental|Group from posterior to anterior (GPA)|Participants in group GPA will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense from posterior to anterior. The physiotherapist will be positioned in front the participant's ankle, and a belt will be posicioned above the participant's malleolus and around physiotherapist's pelvis. The therapist applies with belt a anterior slip sustained in the tibia of the participant, while the talus are secured with the space between the thumb and the second finger of the hand of both hands on the physiotherapist´s. The participant will be instructed to perform a slow dorsiflexion movement at its maximum amplitude and hold five seconds in that position, returning to the initial position at the end of the five seconds.
2895357|NCT03281421|Active Comparator|Group from anterior to posterior (GAP)|Participants in group GAP will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense from anterior to posterior. The physiotherapist will be positioned behind the participant's ankle. An belt will be posicioned above the participant's malleolus and around physiotherapist's trunk. The therapist applies with belt a posterior slip sustained in the tibia of the participant, while the heel and rearfoot are secured with the space between the thumb and the second finger of the hand of both hands on the physiotherapist´s. The participant will be instructed to perform a slow dorsiflexion movement at its maximum amplitude and hold five seconds in that position, returning to the initial position at the end of the five seconds.
2895358|NCT03281421|Active Comparator|Group GPA-AP|Participants in group GAP will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense both from posterior to anterior and anterior to posterior. In the group GPA-AP, will be apllied both the procedure described for the group GPA as for the group GAP. To standardized the sequence of mobilization, the first two sets will be performed with slip sense from posterior to anterior, and the last two sets will be performede with slip sense from anterior to posterior.
2895359|NCT03281408|No Intervention|Pre-Intervention Group|These 80 subjects will be cared for and monitored in hospital following current hospital protocol. No change or intervention is to be administered.
2895360|NCT03281408|Experimental|Intervention Group|These 80 subjects will be cared for and monitored in hospital following an updated hospital protocol.
2895361|NCT03281395||Cerebral aneurysm surgery with RVP|During surgery patients allocated to this group will undergo RVP. Subjects receive Magnetic Resonance Imaging or Computed Tomography as standard of care, pre-and postoperatively. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere(contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels are determinated preoperatively and 24 hours postoperatively by blood sample as standard of care. Maximum cTnl level and cTnl level 24 hours will be compared.
2895362|NCT03281395||Craniotomy without RVP|No rapid ventricular pacing is applied during surgery. Subjects receive Magnetic Resonance Imaging or Computed Tomography as standard of care, pre-and postoperatively. To screen for induced micro-infarcts, the contralateral hemisphere(contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels are determinated preoperatively and 24 hours postoperatively by blood sample as standard of care. Maximum cTnl level and cTnl level 24 hours will be compared.
2895363|NCT03281382|Experimental|Investigational Arm|Patients will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at one of three dose levels. Two days later, subjects will be administered (orally) 7 days of 5-fluorocytosine (5-FC) prodrug therapy. Fourteen days after completion of the 5-FC prodrug therapy course, subjects will be administered chemotherapy at the discretion of the treating physician. On an optional basis, subjects will be administered [18F]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify the intensity, persistence, and biodistribution of HSV-1 TK gene expression in the pancreas.
2895364|NCT03281369|Active Comparator|1L-Control: mFOLFOX6|Participants in the 1L Control arm will receive modified FOLFOX6 (mFOLFOX6) treatment consisting of 5-fluorouracil (5-FU), leucovorin (folinic acid), and oxaliplatin. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria.
2895365|NCT03281369|Experimental|1L-A: mFOLFOX6 + Atezo + Cobi|Participants in the 1L-A arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab plus cobimetinib.
2895366|NCT03281369|Experimental|1L-A2: Atezo + mFOLFOX6 followed by Atezo + Cobi|Participants in the 1L-A2 arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab during cycles 1 and 2 followed by atezolizumab plus cobimetinib during cycles 3 and beyond.
2895367|NCT03281369|Experimental|1L-B: mFOLFOX6 + Atezo|Participants in the 1L-B arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria.
2895368|NCT03281369|Active Comparator|2L-Control: Ramucirumab + Paclitaxel|Participants in the 2L Control arm will receive ramucirumab plus paclitaxel. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria.
2895369|NCT03281369|Experimental|2L-1: Atezo + Cobi|Participants in the 2L-1 arm will receive atezolizumab in combination with cobimetinib.
2895370|NCT03281369|Experimental|2L-2: Atezo + PEGPH20|Participants in the 2L-2 arm will receive atezolizumab in combination with PEGylated recombinant human hyaluronidase (PEGPH20). Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria.
2895371|NCT03281369|Experimental|2L-3: Atezo + BL-8040|Participants in the 2L-3 arm will receive atezolizumab in combination with BL-8040. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria.
2895372|NCT03281369|Experimental|2L-4: Atezo + Linagliptin|Participants in the 2L-4 arm will receive atezolizumab in combination with linagliptin. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria.
2895373|NCT03281356|Experimental|Intervention Group|
2895374|NCT03281343|Experimental|MI-NAV|A study therapist will deliver a motivational interviewing session with participants while they are incarcerated and serve as a role of patient navigator post-release.
2895375|NCT03281343|Active Comparator|Standard of Care (SOC)|Approximates care currently provided at the prison.
2895380|NCT03281291||R012-20 Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and Month 20 of study NCT03276962.
2895381|NCT03281291||R012-14-mD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 Month 14, Month 26, Month 38 of study NCT03276962.
2895382|NCT03281291||Fx012-14-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 2, Month 14, Month 26, Month 38 of study NCT03276962.
2895383|NCT03281291||Fx017-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 7, Month 20, Month 32 of study NCT03276962.
2895384|NCT03281291||Control Group|Subjects will receive rabies vaccine at Month 0, Month 1, Month 2 of study NCT03276962.
2895385|NCT03281239|Experimental|welder/airport agent|No drug and no placebo were used in this study.
2895386|NCT03281226|Active Comparator|RIPE (2m) and RI (4m)|The patients enrolled in this arm will receive a treatment regimen with an intensive phase lasting two months of rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (combined fixed dose tablet according to the weight) and a continuation with rifampicin 150mg and isoniazid 75mg (combined fixed dose tablet according to the weight) for 4 months.
2895387|NCT03281226|Experimental|RIPE+NAC (2m) and RI (4m)|The patients enrolled in this arm will receive a treatment regimen with an intensive phase lasting two months of rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (combined fixed dose tablet according to the weight) plus N-acetylcysteine (NAC) and a continuation with rifampicin 150mg and isoniazid 75mg (combined fixed dose tablet according to the weight) for 4 months. The NAC is administered by means of effervescent tablet 1200 mg (two sachets of 600 mg) to be diluted in 200ml of water and administered in a 12-hour interval.
2895388|NCT03281213||Female|
2895389|NCT03281213||Male|
2895390|NCT03281200||Anatomical main group:|
2895391|NCT03281200||Therapeutic subgroup|
2895392|NCT03281200||Pharmacological subgroup|
2895393|NCT03281200||Chemical subgroup|
2895394|NCT03281200||Chemical substance|
2895395|NCT03281187|Experimental|Nasotestt 5 mg|Participants randomized to this arm must administer one packet of Nasotestt 5 mg in each nostril (3 times a day - T.I.D) for 60 days.
2895396|NCT03281187|Active Comparator|Androgel 50 mg|Participants randomized to this arm must administer one packet of Androgel 50 mg applied once daily to skin of shoulder for 60 days.
2895397|NCT03281187|Placebo Comparator|Androgel Placebo|Participants must administer one packet of Androgel placebo applied once daily to skin of shoulder in addition to an experimental drug for 60 days.
2895398|NCT03281187|Placebo Comparator|Nasotestt Placebo|Participants must administer one packet of Nasotestt Placebo in each nostril (3 times a day - T.I.D) in addition to an experimental drug for 60 days.
2895399|NCT03281174||EV71 vaccine group|The group which received two doses EV71 vaccine (400U/0.5ml) on day 0,28 in phase III clinical trial.
2895400|NCT03281174||Placebo group|The group which received two doses placebo (0U/0.5ml) on day 0,28 in phase III clinical trial.
2895401|NCT03281161|Experimental|Sun Safe Workplaces Program|A follow up to the previous study that promoted the adoption of occupational sun protection policies by the local government organization comprised of personal visits with senior managers to promote policy adoption, promotional materials for sun safety, and in-person training of outdoor workers by research staff over two years. The follow up program consists of an analysis of sun safe practices by employees and an economic evaluation of the SSW intervention completed 2 years after the initial intervention.
2895402|NCT03281161|Active Comparator|Attention Control|A follow up to the previous study that promoted occupational sun protection practices by employees in local government organizations through two mailings containing educational materials and presentations at state professional meetings by project staff. The follow up program consists of an analysis of sun safe practices by employees and an economic evaluation of SSW completed 2 years after the initial program contact.
2895403|NCT03281148|Experimental|Computer guided implant insertion group|According to the allocation, the experimental group will receive implants immediately placed in extraction sockets using CAD/CAM surgical guides.
2895404|NCT03281148|Active Comparator|Free hand implant insertion group|According to the allocation, the control group will receive implants immediately placed in extraction sockets using traditional free hand technique.
2895405|NCT03281135|Other|HPV testing|This is an experimental arm for the primary outcome, 'adherence to the procedures'. In this group self sampling will be done using the Evalyn brush for HPV testing.
2895406|NCT03281135|No Intervention|Standard care: VIA screening|Control Arm, in which women's are invited to cervical cancer screening as per standard Ethiopian cervical cancer prevention and control guideline. Uptake of screening in this group will be compared with the HPV testing arm group to test for significant differences in adherence.
2895407|NCT03281122|Experimental|Arm A|Specified dose on specified days
2895408|NCT03281122|Placebo Comparator|Arm B|Specified dose on specified days
2895409|NCT03281096|Experimental|Berberine hydrochloride group|Berberine hydrochloride 300mg tablet by mouth, two times per day for 3 years
2895410|NCT03281096|Placebo Comparator|Placebo|identical-appearing placebo 300mg tablet by mouth, two times per day for 3 years
2895411|NCT03281083|Experimental|Levothyroxine (LT4)|Levothyroxine sodium (LT4) dose titrated at TSH 0.34 - 1.70mIU/L during maximum 12 weeks, followed by a maintenance phase of 16 weeks using the dose necessary for titration.
2895412|NCT03281057|Experimental|Individual CRAFT|Individual CRAFT is offered to 135 participants and each participants are going to get 6 sessions.
2895413|NCT03281057|Experimental|Group CRAFT|Open group CRAFT is offered to 135 participants in 6 sessions.
2895414|NCT03281057|Experimental|Self-help materials|Self-help materials (control group) are going to be offered a self-help book, because it is unethically not to offer any intervention, as the CRAFT intervention in early studies have shown to be very effectful
2895415|NCT03281044|Experimental|FMT group|Patient group receiving active FMT capsules
2895416|NCT03281044|Placebo Comparator|Placebo group|Patient group receiving placebo capsules
2895417|NCT03281031|Other|Additional MRI Examination|Single arm, all patient will undergo CT followed by additional MRI examination
2895603|NCT03279692|Experimental|Pembrolizumab|"Pembrolizumab will be administered every 3 weeks~Pembrolizumab will be administered through IV infusion"
2895418|NCT03281018|Experimental|Interventional arm|Caregiver Accompaniment Time (CAT) + preoperative hypnosis session (experimental arm): The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
2895419|NCT03281018|No Intervention|Control (CAT)|CAT is performed in routine care for all patients after the announcement of the illness by a trained nurse, if possible on the same day as the consultation or before the consultation of anesthesia. This is an interview of approximately 45 minutes to listen to the patient, to answer her questions and to re-explain the information delivered to her. The patient will tackle the history of the disease and then the treatment, this time dedicated evolves according to the desire of the patient and her ability to accept the disease. The patient can express her feelings, then the family circle is evoked talking about the resource persons and the future. The purpose of this interview is to obtain the autonomy of the patient by the setting up of supportive care
2895420|NCT03281005||Retinitis pigmentosa in Part 1A|Retinitis pigmentosa patients with severe visual impairment
2895421|NCT03281005||Retinitis pigmentosa in Part 1B|Retinitis pigmentosa patients with severe visual impairment
2895422|NCT03281005||Retinitis pigmentosa in Part 2|Retinitis pigmentosa patients with severe visual impairment
2895423|NCT03281005||Healthy volunteers in Part 3|Healthy volunteers
2895424|NCT03280979|Experimental|study group1|In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of MTX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
2895425|NCT03280979|Experimental|study group2|In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
2895426|NCT03280940||Dolutegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a dolutegravir containing regimen
2895427|NCT03280940||Raltegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a raltegravir containing regimen
2895428|NCT03280940||Elvitegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a elvitegravir containing regimen
2895429|NCT03280940||Protease inhibitors treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a protease inhibitors containing regimen
2895430|NCT03280927|Experimental|Jublia®|
2895431|NCT03280914||CPAP group|Automatic Continuous Positive Airway Pressure treatment and usual care
2895432|NCT03280914||Usual care group|Usual care without Continuous Positive Airway Pressure treatment
2895433|NCT03280901|Experimental|Standard HD|HD with constant temperature of 37°C, MRI scans of the heart, kidneys and brain during HD sessions
2895434|NCT03280901|Experimental|Thermocontrolled HD|HD applying the Blood Temperature Monitor (BTM), MRI scans of the heart, kidneys and brain during HD sessions
2895435|NCT03280875|Experimental|healthy volunteers|
2895436|NCT03280862|Active Comparator|Control|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator with the LV lead positioned preferentially in a posterolateral, non-apical position
2895437|NCT03280862|Experimental|Intervention|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator with the LV lead positioned according to the latest electrical activation in the CS
2895438|NCT03280849|Experimental|Patient with bilaminar chitosan implant|A 65 year old woman, right handed, started with progressive bilateral visual loss in her temporal field, over 10 months, she underwent an MRI and it was found a sellar lesion that compressed the optic chiasm, an endoscopic endonasal transsphenoidal surgery was done for the resection of the lesion, using a novel bilaminar chitosan scaffold to assist the closure of the sellar floor.
2895439|NCT03280836|No Intervention|Control|We ask that participants in the control arm do not start an exercise program.
2895440|NCT03280836|Experimental|Exercise|"Participants in the experimental arm will be asked to complete the exercise intervention with 80% or greater adherence.~Participants will work towards the goal of 75 or more minutes a week of moderate to vigorous exercise. Participants are provided an exercise toolkit and directed on exercise progression based on personal fitness level."
2895441|NCT03280810|Experimental|Movement group|patients with schizophrenia (experimental group) have psycho-corporal training once a week, during 1 hour and a half for a period of two months
2895442|NCT03280810|No Intervention|Control group|No intervervention : patients with schizophrenia (comparator group) who don't have psycho-corporal training
2895443|NCT03280797|Other|Control|
2895444|NCT03280797|Other|Rheumatoid arthritis patients|
2895445|NCT03280771|Experimental|Hope Soap group|Children in treatment households received a bi-monthly delivery of HOPE SOAP©, a colourful, translucent bar of soap with a toy embedded in its centre
2895446|NCT03280771|Active Comparator|Control group|Children in control households received a colourful, translucent bar or soap with the toy alongside it.
2895447|NCT03280758|Experimental|Muscle strengthening group|Participants will be required to perform muscle strengthening exercises 3 hours per week. Close kinetic chain exercises will be performed progressively according to the ACSM guidelines over the 4-month intervention period. The exercise intervention will be conducted by an experienced sports trainer.
2895448|NCT03280758|No Intervention|Control group|No exercise training.
2895449|NCT03280745|Active Comparator|7.3% NaCl (intervention)|At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl NaCl by infusion pump over 60 minutes.
2895450|NCT03280745|Active Comparator|0.9% NaCl (comparator)|At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
2895451|NCT03280732|Experimental|Lung Ultrasound|Bedside lung ultrasound will be performed by a paediatrician with specific LUS expertise and blinded to clinical and radiological data.
2895697|NCT03279107|No Intervention|Control beverage with glucose powder|Standard glucose beverage with 50 g of glucose powder
2895452|NCT03280719|Active Comparator|Supine Hypofractionated Radiotherapy|"Supine Radiotherapy and Hypofractionation:~Whole breast + regional nodal irradiation in supine position with a median dose of 15 x 2.67 Gy prescribed to the whole breast and nodal regions. Median dose of the simultaneously integrated boost is 3.12 Gy per fraction."
2895453|NCT03280719|Experimental|Prone Hypofractionated Radiotherapy|"Prone Radiotherapy and Hypofractionation:~Whole breast + regional nodal irradiation in prone position with a 15 x 2.67 Gy dose prescription to the whole breast and nodal regions. Median dose of the simultaneously integrated boost is 3.12 Gy per fraction."
2895454|NCT03280719|Experimental|Supine Accelerated Radiotherapy|"Supine Radiotherapy and Acceleration:~Whole breast + regional nodal irradiation in supine position with a median dose of 5 x 5.7 Gy to the whole breast. Lymph node regions receive a median dose of 5 x 5.4 Gy. Median dose of the simultaneously integrated boost is 6.2 Gy per fraction."
2895455|NCT03280719|Experimental|Prone Accelerated Radiotherapy|"Prone Radiotherapy and Acceleration:~Whole breast + regional nodal irradiation in prone position with a median dose of 5 x 5.7 Gy to the whole breast. Lymph node regions receive a median dose of 5 x 5.4 Gy. Median dose of the simultaneously integrated boost is 6.2 Gy per fraction."
2895456|NCT03280706|Experimental|Maltodextrin|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of maltodextrin 200kcal, no protein or fat, 49,5g of carbohydrate.
2895457|NCT03280706|Active Comparator|Orange Juice|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of orange juice, 200kcal, 2,82g of protein, 0,67g of fat, 47,08g of carbohydrate.
2895458|NCT03280706|Active Comparator|Coffee with milk|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of coffee with milk, 200kcal, 10,6g of protein, 10,73g of fat, 14,9g of carbohydrate.
2895459|NCT03280680|Experimental|Female+male group sessions|
2895460|NCT03280680|Experimental|Female group sessions|
2895461|NCT03280680|Other|No group sessions|
2895462|NCT03280667|Experimental|Pembrolizumab plus Denosumab|Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D, continued until disease progression or prohibitive toxicity
2895463|NCT03280654||Group 1:VAI levels <7,55|7,55 value was calculated as cut-off level for VAI by ROC analyse and area under curve was calculated as 0,487 Group 1 was defined as VAI levels <7,55
2895464|NCT03280654||group 2:VAI levels >=7,55|7,55 value was calculated as cut-off level for VAI by ROC analyse and area under curve was calculated as 0,487 group 2 was defined as VAI levels >=7,55
2895465|NCT03280641||Dabigatran Group|Patiets with atrial fibrillation received dabigatran (110mg, bid).
2895466|NCT03280641||Warfarin Group|Patiets with atrial fibrillation received warfarin (110mg, bid).The target international normalized ratio (INR):1.6-3.0
2895467|NCT03280628|Active Comparator|Absorbable Sutures|30 patients will have their laceration closed with sutures that absorb on their own and do not need to be removed.
2895468|NCT03280628|Experimental|Steri-Strips|"30 patients will have their laceration closed with a special medical tape called Steri-Strips."
2895469|NCT03280628|Experimental|Dermabond|"30 patients will have their laceration closed with a special skin glue called Steri-Strips."
2895470|NCT03280615|Experimental|Omega 3 fatty acids|Supplementation of 3.7 g of docosahexanoic and eicosapentanoic acids per day during 12 weeks
2895471|NCT03280615|Placebo Comparator|Corn oil|Supplementation of 3.7 g of corn oil per day during 12 weeks
2895472|NCT03280602|Active Comparator|Tension band wiring (TBW)|TBW following the AO principles with 2 x 1.6 mm K-wires and wire wire cerclage.
2895473|NCT03280602|Active Comparator|Plate fixation|Plate fixation with Syntes VA-LCP olecranon plates 2.7/3.5
2895474|NCT03280589|Active Comparator|Sitting Quietly|Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still, and allow the chair to support them. Instructions will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. The total duration of this session will be approximately 40 minutes.
2895475|NCT03280589|Experimental|Deep Breathing Self Paced|Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still, and allow the chair to support them. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. The total duration of this session will be approximately 40 minutes.
2895476|NCT03280589|Experimental|Deep Breathing Externally paced|Participants will have an instructional video with auditory queues prompting them to inhale and exhale at 6 bpm (approximately 4 seconds between inhale and exhale). Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still and allow the chair to support them. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. The total duration of this session will be approximately 40 minutes.
2895477|NCT03280589|Experimental|Sheetali/Sheetkali, self-paced:|Participant will follow on-screen instructions for Sheetali/Sheetkari with shaped lips/mouth as indicated (i.e., inhaling through the mouth held specific to each practice and exhaling through nostrils), fully filling and emptying the lungs with each breath. In Sheetali, the tongue is allowed to protrude from the mouth at a comfortable distance and rolled into a tube. Following 10 minutes of Sheetali practice, participants will have a one minute rest followed by Sheetkari. In Sheetkari, the tongue is not rolled into a tube; instead, it is rolled up to touch the upper palate. The teeth are then exposed and the lips are kept apart for inhalation and the mouth is closed, tongue is relaxed, and exhalation occurs through the nose. Study personnel will monitor their posture and breathing rate and pause the recording if additional coaching is necessary. The total duration of this session will be approximately 40 minutes.
2895478|NCT03280589|Experimental|Sheetali/Sheetkari, externally-paced|The participant will follow on screen instruction for Sheetali/Sheetkari with shaped lips/mouth as indicated, fully filling and emptying the lungs with each breath. The tongue is allowed to protrude from the mouth at a comfortable distance and rolled into a tube. Following 10 minutes of Sheetali practice, participants will have a one-minute rest before continuing. In Sheetkari the teeth are exposed and the lips are kept apart for inhalation and the mouth is closed, tongue is relaxed, and exhalation occurs through the nose. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. There will be an auditory queue to prompt the participant to breathe in and out. Study personnel will monitor their posture and breathing rate and pause the recording if additional coaching is necessary.The total duration of this session will be approximately 40 minutes.
2895479|NCT03280576||Sepsis|Patients with sepsis
2895480|NCT03280576||Cardiac Surgery|Patients undergoing cardiac surgery
2895481|NCT03280576||Healthy controls|Normal individuals
2895482|NCT03280563|Active Comparator|Stage 1: Fulvestrant|Participants will receive fulvestrant until unacceptable toxicity or disease progression according to RECIST v1.1.
2895483|NCT03280563|Experimental|Stage 1: Atezolizumab + Enitinostat|Participants will receive doublet combination treatment with atezolizumab plus enitinostat until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
2895484|NCT03280563|Experimental|Stage 1: Atezolizumab + Fulvestrant|Participants will receive doublet combination treatment with atezolizumab plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
2895485|NCT03280563|Experimental|Stage 1: Atezolizumab + Ipatasertib|Participants will receive doublet combination treatment with atezolizumab plus ipatasertib until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Prior to enrollment into this arm, the first 6 participants in the study will complete a safety run-in with atezolizumab plus ipatasertib.
2895486|NCT03280563|Experimental|Stage 1: Atezolizumab + Ipatasertib + Fulvestrant|Participants will receive triplet combination treatment with atezolizumab plus ipatasertib plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Prior to enrollment into this arm, the first 6 participants in the study will complete a safety run-in with atezolizumab plus ipatasertib.
2895487|NCT03280563|Experimental|Stage 2: Atezolizumab + Bevacizumab + Endocrine Therapy|Those who progress or experience unacceptable toxicity during treatment in Stage 1 may be eligible to enter Stage 2. Participants will receive triplet combination therapy with atezolizumab plus bevacizumab plus one of three endocrine therapies (fulvestrant, exemestane, or tamoxifen) selected by the physician. Treatment in Stage 2 will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
2895488|NCT03280563|Experimental|Stage 1: Mandatory On-Treatment Biopsy|For experimental combination arms that demonstrate clinical activity during the preliminary phase, the Sponsor may open enrollment into a separate mandatory on-treatment biopsy cohort for that combination.
2895489|NCT03280550|Experimental|Omalizumab|Participants will receive Omalizumab every 2 weeks or every 4 weeks.
2895490|NCT03280550|Placebo Comparator|Placebo|Participants will receive matching placebo every 2 weeks or every 4 weeks.
2895491|NCT03280537|Experimental|Omalizumab|Participants will receive Omalizumab every 2 weeks or every 4 weeks.
2895492|NCT03280537|Placebo Comparator|Placebo|Participants will receive matching placebo every 4 weeks or every 2 weeks.
2895493|NCT03280524|Placebo Comparator|Control Group|Control Group will receive self-care guidelines with feet
2895494|NCT03280524|Experimental|Treatment Group|Treatment will receive self-care guidelines with feet and 12 sessions of foot reflexology
2895495|NCT03280511|Experimental|Interventional|Eligible candidates will be enrolled according to in-/exclusion criteria. Two months after colon resection or immediately after adjuvant chemotherapy (if indicated), a standard laparoscopy including peritoneal lavage, peritoneal biopsies and PIPAC treatment with oxaliplatin 92 mg/m2 will be planned. This procedure will be repeated after another 5 weeks. Follow up CTs after 12, 24 and 36 months will be planned.
2895496|NCT03280498|Other|Intubation with Cole formula|ASA I-II pediatric patients in the age range of 2-10 years, planned to undergo elective surgeries under general anesthesia with endotracheal entubation,
2895497|NCT03280472|Experimental|Cognitive Bias Modification|Participants will complete three session of cognitive bias modification.
2895498|NCT03280472|Other|Symptom Tracking|Participants will track their symptoms.
2895499|NCT03280459||Ileal Conduit|Patient with ileal conduit as reconstruction of urinary diversion after robot-assisted cystectomy
2895500|NCT03280459||Neobladder|Patient with neobladder, (orthotopic, continent ileal pouch) as reconstruction of urinary diversion after robot-assisted cystectomy
2895501|NCT03280446|Experimental|30 pre-menopause and post-menopause women|Thirty healthy women with mild to moderate pelvic prolapse above the ages of 18 seeking treatment for vaginal laxity
2895502|NCT03280420|Active Comparator|early catheter removal|30 patients will receive Tamsulosin hydrochloride 0.4 mg once daily and the catheter will be removed after 3 days.
2895503|NCT03280420|Active Comparator|late catheter removal|30 patients will receive Tamsulosin hydrochloride 0.4 mg once daily and the catheter will be removed after 7 days.
2895504|NCT03280407|Active Comparator|A, capecitabine|Radiochemotherapy with 50.4 Gy in 28 fractions concomitantly with chemotherapy
2895505|NCT03280407|Experimental|B, FOLFOX or CAPOX|Neoadjuvant chemotherapy with CAPOX (oxaliplatin/capecitabine) or FOLFOX regimen (oxaliplatin/leucovorin/5FU), according to institutional practice
2895506|NCT03280381|Experimental|NIFTY Feeding Cup First|Each caregiver/infant pair will first use the Nifty Feeding Cup for two feeds and then the standardized generic cup for two feeds.
2895507|NCT03280381|Experimental|Generic Medicine Cup First|Each caregiver/infant pair will first use the standardized generic cup for two feeds and then the Nifty Feeding Cup for two feeds.
2895508|NCT03280368||A healthy volunteers|Pre-clinical study. Healthy volunteers. Plasma pooled and spiked with dabigatran. Measurement of plasma concentration of dabigatran with liquid chromatography tandem mass-spectrometry and the anticoagulant effect of dabigatran using coagulation assays.
2895509|NCT03280368||A patients|Pre-clinical study. Patients with atrial fibrillation treated with dabigatran etexilate.
2895698|NCT03279107|Experimental|Beverage with soluble corn fiber|Beverage with soluble corn fiber (50 gram of total carbohydrate)
2895510|NCT03280368||B|"Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation and intended for electrocardioversion.~Inclusion before initiation of anticoagulation."
2895511|NCT03280368||C|Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation. Inclusion before initiation of anticoagulation.
2895512|NCT03280355|Experimental|Singing Training|Singing Training as training activity in Pulmonary Rehabilitation: 10 weeks, twice a week for 1 1/2 hour, leading to a total of 20 sessions.
2895513|NCT03280355|Active Comparator|Physical Training|Physical Training as training activity in Pulmonary Rehabilitation: 10 weeks, twice a week for 1 1/2 hour, leading to a total of 20 sessions.
2895514|NCT03280342|Active Comparator|IR-TPM (Topamax)|IR-TPM (Topamax)
2895515|NCT03280342|Active Comparator|XR-TPM (Trokendi XR)|
2895516|NCT03280329|No Intervention|Control|the patients who belong to this group will not be assigned to a regulated music therapy treatment, thus they will listen to the background sounds (alerts, voices) right in the Intensive Care environment; radio use will be allowed according to medical/ nursing judgements
2895517|NCT03280329|Active Comparator|Personalised treatment|A music therapy advice will be performed with each patient (if possible from the neurological point of view) or their caregivers to assess their musical preferences and a list of songs will be generated which will be reproduced for 2 hours per day from admission to discharge with the use of earphones.
2895518|NCT03280329|Active Comparator|Generalized treatment|"Music will be broadcasted in each patient room after the creation of a 'weekly playlist' with the following considerations:~Daily sound reproduction from 7 am to 11 pm, with 10 minutes break about every 50 minutes of music;~Spread through the environment with specifically designated speakers, at a controlled volume (30-50 dB);~Choice of playlist of music both classic and modern, with very easy listening, selected according to the daily hours to restore circadian rhythm and following predictable activities of care provided to patients (hygienic care, retail food, administration other therapies, physiotherapy, visit by relatives, …);~Mixing tracks so that there is continuity and fluidity of listening"
2895519|NCT03280316|Experimental|patients with SVMs undergoing SNM|patients with SVMs are of consistent OAB (Overactive Bladder) after surgery and undergo sacral neuromodulation (SNM)
2895520|NCT03280316|Experimental|patients with SVMs receiving BTXA|patients with SVMs are of consistent OAB after surgery and accept botulinum toxin A (BTXA) injection
2895521|NCT03280316|Experimental|patients with SVMs receiving drug|patients with SVMs are of consistent OAB (Overactive Bladder) after surgery and accept M receptor antagonist
2895522|NCT03280303||non-interventional study|This prospective, observational study will be conducted according to each site's routine clinical practice.
2895523|NCT03280290|Experimental|receivers|"Eligible for allo-HSCs from peripheral blood stem cells from a compatible donor HLA family (Appendix 1, the pre-transplant assessment must be enabled)~In a complete remission rate of leucocytes with ≥ 2G / L~Affiliated to social security person or beneficiary of such a scheme."
2895524|NCT03280290|Experimental|Donors|"Member of the siblings and HLA-matched A, B, Cw, DR, DQ~Eligible to donate peripheral blood stem cells for allo-HSCs (Appendix 2, pre donation assessment must be enabled)~Having a rate of circulating lymphocytes ≥ 1 G / L~Having a proportion of CD4 + CCR7 + ≥ 80% of the total CD4 T population~The statutes CMV and EBV are known (positive or negative).~Affiliated to social security person or beneficiary"
2895525|NCT03280277|Experimental|Diagnostic (ferumoxytol-enhanced MRI)|Patients receive ferumoxytol IV over 15 minutes and then after 24-36 hours undergo ferumoxytol-enhanced MRI before start of chemoradiotherapy and before surgery at week 12.
2895526|NCT03280264|Experimental|KHK7580|oral administration
2895527|NCT03280251|Experimental|Methylphenidate and structured cognitive training|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
2895528|NCT03280251|Experimental|Placebo and structured cognitive training|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
2895529|NCT03280251|Experimental|Methylphenidate and pseudo cognitive training|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
2895530|NCT03280251|Experimental|Placebo and pseudo cognitive training|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
2895531|NCT03280238|Experimental|Experiment|"Individualized painful electrical stimuli, Surpass LT stimulator (EMS Biomedical, Korneuburg, Austria) with a bipolar felt pad electrode~Measurement of pupil diameter, Algiscan® (iDMed, Marseille, France)~Measurement of Analgesia Nociception Index, PhysioDoloris® (MetroDoloris, Lille, France)"
2895532|NCT03280225||VISNs requesting implementation support|VA has divided the country into regions of care and these are called Veteran Integrated Service Networks (VISNs). This group consists of VISNs with facilities that need additional implementation support to fully implement REACH VET and that agree to participate.
2895533|NCT03280212|Experimental|Tranexamic Acid Arm|"Tranexamic Acid 500 milligrams (MG)~Participants of the Tranexamic Acid (TXA) arm will receive the study drug, TXA. Participants of average body weight (60-100kg) will receive TXA according to a 500mg three times daily (TID) dose regimen. Weight deviations from this range will see dose adjustments as follows: participants <60kg will receive 500mg two times daily (BID), and participants >100kg will receive 1000mg BID."
2895534|NCT03280212|No Intervention|Control Arm|"No intervention~Participants in the control arm will not receive any additional intervention, medication, or placebo, and will serve as a comparative arm for the experimental arm."
2895535|NCT03280199|Other|Type of simulator - 1|"VR simulator with physical mannequin and probe.~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
2895536|NCT03280199|Other|Type of simulator - 2|"VR simulator with virtual mannequin / abdomen~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
2895537|NCT03280199|Other|Type of image acquisition - 3|"US images are acquired through real US volumes from patients~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
2895811|NCT03278444|Experimental|One-drug Regimes|Basic drugs therapy of HCC
2895538|NCT03280199|Other|Type of image acquisition - 4|"US images are acquired through computer-generated images.~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
2895539|NCT03280186|Experimental|Patients With SVMs|Patients with SVMs will be included in the group and undergo surgery.
2895540|NCT03280173|Experimental|61 mgA tafamidis free acid soft gelatin capsule fed|fasted
2895541|NCT03280173|Experimental|61 mgA tafamidis free acid soft gelatin capsule fasted|fed
2895542|NCT03280173|Experimental|4 × 20 mg tafamidis meglumine soft gelatin capsules fed|fed
2895543|NCT03280173|Experimental|4 × 20 mg tafamidis meglumine soft gelatin capsules fasted|fasted
2895544|NCT03280147|Experimental|7-day course of antibiotics|Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 7-day group will not receive any further antibiotics.
2895545|NCT03280147|Active Comparator|14-day course of antibiotics|Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 14-day group will receive 7 more days of the same antibiotics, to make it a total of 14 days.
2895546|NCT03280134|No Intervention|predictive nSLN-|No further axillary lymph node dissection (ALND)
2895547|NCT03280134|Active Comparator|predictive nSLN+|axillary lymph node dissection (ALND)
2895548|NCT03280121|Experimental|TIF using EsophyX ZR transoral device|Transoral incisionless fundoplication which is a minimally invasive treatment for gastroesophageal reflux disease (GERD) using EsophyX ZR transoral device
2895549|NCT03280095|Experimental|Treatment 1|One capsule of test product (co-codamol 15mg/500mg capsule) containing 15mg codeine phosphate hemihydrate and 500mg paracetamol.
2895550|NCT03280095|Experimental|Treatment 2|Two capsules of test product (co-codamol 15mg/500mg capsule), each containing 15mg codeine phosphate hemihydrate and 500mg paracetamol (i.e. a total dose of 30mg codeine phosphate hemihydrate and 1000mg paracetamol).
2895551|NCT03280095|Active Comparator|Treatment 3|One tablet of reference product (co-codamol 30mg/500mg tablet) containing 30mg codeine phosphate hemihydrate and 500mg paracetamol.
2895552|NCT03280082|Other|MUAC Program|"At the CRENAS, MUAC as unique anthropometric criteria for admission, monitoring, and care for the SAM output will be used.~The criteria for admission include:~MUAC <120 mm~Bilateral edema of grade + or ++~The criteria for release of care include:~MUAC ≥ 125 mm at 2 consecutive visits~Minimum stay 3 weeks in the program~Absence of acute medical complications~Absence of edema"
2895553|NCT03280082|Other|Standard Program|"Regular screenings in the communities on children between 6 and 59 months of age. Children with MUAC<125 mm will be referred to Nutrition Centers for admission.~The criteria for admission include:~MUAC<115 mm and/or~Z score <-3 and /or~Bilateral edema of grade + or ++~The criteria for release of care include:~MUAC ≥ 125 mm at 2 consecutive visits~Minimum stay 3 weeks in the program~Absence of acute medical complications~Absence of edema"
2895554|NCT03280069||Subjects between the ages of 40 - 70|Subjects who present with signs of skin laxity & evaporation dry eye will receive 3 treatments with the THERMIeyes® 20 RF System and monitored for improvements in the conditions for which they have presented.
2895555|NCT03280056|Active Comparator|NurOwn® (MSC-NTF cells)|Three Intrathecal administrations of NurOwn® (MSC-NTF cells) at bi-monthly intervals
2895556|NCT03280056|Placebo Comparator|Placebo|Three Intrathecal administrations of Placebo at bi-monthly intervals
2895557|NCT03280043||Cases|Women who underwent reduction mammoplasty and then developed a hematoma which required return to the operating room for evacuation.
2895558|NCT03280043||Controls|Women who had uncomplicated reduction mammoplasty.
2895559|NCT03280030|Experimental|Midostaurin|Patients will take study drug on day 8-21 during induction and consolidation phase; then continuously during continuation phase.
2895560|NCT03280030|Placebo Comparator|Placebo|Patients will take placebo on day 8-21 during induction and consolidation phase; then continuously during continuation phase.
2895561|NCT03280017|Experimental|Ketamine|Participant allocated to this arm will receive intravenous ketamine infusion starting after the induction of anesthesia until the end of the surgery at the beginning of skin closure Participant will receive an ultrasound-guide thoracic paravertebral block using 0.5% plain bupivacaine prior to the induction of anesthesia
2895562|NCT03280017|Placebo Comparator|Normal saline|Participant allocated to this arm will receive intravenous normal saline solution infusion starting after the induction of anesthesia until the end of the surgery at the beginning of skin closure Participant will receive an ultrasound-guide thoracic paravertebral block using 0.5% plain bupivacaine prior to the induction of anesthesia
2895563|NCT03280004||Moxifloxacin group|
2895564|NCT03280004||β-lactams group|
2895565|NCT03279978|Experimental|BI 730357|
2895566|NCT03279978|Placebo Comparator|Placebo|
2895567|NCT03279965||Cystic fibrosis|Patients with known cystic fibrosis
2895568|NCT03279965||Primary ciliary dyskinesia|Patients with known primary ciliary dyskinesia
2895569|NCT03279952|Other|medication arm|CNS Stimulant
2895570|NCT03279926|Experimental|PLAY|Preschoolers & their teachers will get activity trackers and the child care program/providers will get some basic information on the use of the trackers and how to integrate their use in the curriculum. A PLAY Champion will be identified to help support PLAY related activities.
2895571|NCT03279926|Experimental|PLAY Parents|Everything in Arm 1 plus one parent per child will receive an activity tracker and will get reports to help with physical activity goal setting for the family.
2895572|NCT03279926|Experimental|PLAY Teachers|Everything in Arm 1 plus an enhanced focus on teacher wellness, specifically with regard to active lifestyles for them.
2895573|NCT03279913|Experimental|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
2895601|NCT03279705|Experimental|Two-channel group|The colonoscopy was done with the new designed colonoscopy that integrated a separate water jet channel for infusing water. The dirty water was removed through other accessory channel.
2895602|NCT03279705|Active Comparator|One-channel group|The colonoscopy was done with the traditional colonoscopy. Water exchange was done by using the accessory channel for both infusing and suctioning of water.
2895699|NCT03279107|Experimental|Beverage with maltodextrin|Beverage with maltodextrin (50 gram of total carbohydrate)
2895574|NCT03279887||Post operative respiratory failure|"Patients with acute respiratory failure (ARF) less than 72 hours after a major cardiac surgery with cardiopulmonary bypass~ARF was defined as one of the following conditions:~If mechanical ventilation, a partial pressure of oxygen/ inspired oxygen fraction ratio (PaO2/FiO2) < 200, or failure of weaning (failure of spontaneous ventilation test, re-intubation in the first 24 hours), or need for non-invasive ventilation immediately after extubation,~If spontaneous ventilation: clinical signs of acute respiratory distress (dyspnea at least exertion, cyanosis, polypnea> 25/min, upper or intercostal swallowing, abdominal swing ...), pulse oximetry (SpO2) < 90% or PaO2 <60 mmHg despite oxygen therapy ≥ 3 L/min."
2895575|NCT03279874||German dentists|Dentists who are working in dental offices in Germany
2895576|NCT03279861|Active Comparator|Entresto|First-line anti-hypertensive: sacubitril-valsartan, starting at 24-26 mg twice daily, increasing to maximum dose of 97-103 mg twice daily
2895577|NCT03279861|Active Comparator|Usual meds|First-line anti-hypertensive: valsartan, starting at 40 mg twice daily, increasing to a maximum dose of 160 mg twice daily
2895578|NCT03279835||Absence of cognitive disorder|
2895579|NCT03279835||Asymptomatic cognitive disorder|
2895580|NCT03279835||Symptomatic cognitive impairment|
2895581|NCT03279835||HIV associated dementia|
2895582|NCT03279822||Group|
2895583|NCT03279809|Experimental|Intervention|Intervention : aspirin medication Case with aspirin medication for 6 months after stenting
2895584|NCT03279809|Placebo Comparator|Control|Control : placebo medication Case with placebo medication for 6 months after stenting
2895585|NCT03279796|Experimental|Autologous adipose-derived MSCs|The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
2895586|NCT03279796|Active Comparator|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
2895587|NCT03279783|No Intervention|WLI (White light Imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using standard white light.
2895588|NCT03279783|Active Comparator|LCI (Linked Color Imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked Color Imaging).
2895589|NCT03279757|Experimental|AHES 5 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 5 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
2895590|NCT03279757|Experimental|AHES 15 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 15 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
2895591|NCT03279757|Experimental|AHES 25 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 25 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
2895592|NCT03279757|Experimental|LTC 5 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 5 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
2895593|NCT03279757|Experimental|LTC 15 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 15 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
2895594|NCT03279757|Experimental|LTC 25 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 25 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
2895595|NCT03279757|Other|Unanesthetized skin|A pain stimulus will be given at unanesthetized skin with the fractional CO2 laser, 50 mJ, 5% density
2895596|NCT03279744|Experimental|Single-Arm|Radion™-pdt
2895597|NCT03279731|Active Comparator|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg via subcutaneous injection. Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
2895598|NCT03279731|Placebo Comparator|Placebo|Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg of placebo via subcutaneous injection. The placebo will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.The inactive ingredients include: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection.
2895599|NCT03279718|Experimental|periodontal treatment|
2895600|NCT03279718|No Intervention|only oral hygiene instruction, no treatment|
2895807|NCT03278470|Experimental|HL237 400mg|take oral tablet once
2895604|NCT03279679|Experimental|costoclavicular group|patients in this group are assigned to receive ultrasound-guided costoclavicular infraclavicular block with 0.5% ropivacaine for upper limb surgery at elbow joint and below
2895605|NCT03279679|Other|paracoracoid group|patients in this group are assigned to receive ultrasound-guided paracoracoid infraclavicular block with 0.5% ropivacaine for upper limb surgery at elbow joint and below
2895606|NCT03279666|Active Comparator|tenaculum with intracervical blockage|
2895607|NCT03279666|No Intervention|No tenaculum with intracercical blockage|
2895608|NCT03279666|Active Comparator|Tenaculum without intracervical blockage|
2895609|NCT03279666|No Intervention|No Tenaculum without intracervical blockage|
2895610|NCT03279653||SleeveGastrectomy|Sleeve Gastrectomy will be performed. Preoperative and Postoperative pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
2895611|NCT03279640|Experimental|Dual-mode stimulation|"rTMS on ipsilesional M1 + tDCS on contralesional M1~10 Hz of rTMS was applied over the ipsilesional M1 for 20 minutes with simultaneous application of cathodal tDCS on the contralesional M1.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
2895612|NCT03279640|Experimental|Single stimulation|"rTMS on ipsilesional M1~10 Hz of rTMS over the ipsilesional M1 was applied for 20 minutes.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
2895613|NCT03279627||Hypoglycemia|This group will be those who experience a BG < 70 mg/dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group. All participants in this group will be asked to complete the Diabetes Management Questionnaire.
2895614|NCT03279627||Hyperglycemia|This group will be those who experience a BG > 250 mg/dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group. All participants in this group will be asked to complete the Diabetes Management Questionnaire.
2895615|NCT03279627||Glycemic control|This group will be those who maintain BG of 70 to 250 mg /dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group, but study outcomes including comprehension of discharge instructions and 1 and 3 month readmissions will be analyzed according to group category.All participants in this group will be asked to complete the Diabetes Management Questionnaire.
2895616|NCT03279614|Experimental|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
2895617|NCT03279601|Experimental|A: Capecitabine Combined With Dacarbazine(CAPDTIC)|patients in arm A will receive chemotherapy of CAPDTIC regimen: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
2895618|NCT03279601|Experimental|B: Capecitabine Combined Temozolomide(CAPTEM)|patients in arm B will receive chemotherapy of CAPDTEM regimen: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o.d10-14 q4W
2895619|NCT03279575|Experimental|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
2895620|NCT03279575|Experimental|Graveyard Shift|Graveyard Shift is a puzzle video game with the transformational goal of helping physicians derive key triage decision principles for themselves. They complete a three-step game loop to obtain case information, compare cases to determine similarities and differences between cases, and then explicitly state the decision principle that should drive decision making.
2895621|NCT03279575|Active Comparator|Educational program|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then com
2895622|NCT03279575|Placebo Comparator|Control|Physicians in this arm will not be asked to complete any intervention.
2895623|NCT03279562|Experimental|Nalmefene and recovery coaching|Nalmefene prescribed for daily ingestion during the first 3 months of treatment; patients who maintain a successful recovery during the first 3 months of treatment will be offered an option to take Nalmefene on as needed basis, always before encountering situations or circumstances with heightened risk of alcohol or opioid use
2895624|NCT03279549|Active Comparator|dressing change group|Routine dressing change group
2895625|NCT03279549|Experimental|Dermal matrix dressing group|Limited debridement & Acellular dermal matrix dressing group.
2895626|NCT03279549|Experimental|Epidermal cell spraying group|Limited debridement & Epidermal cell spraying group
2895627|NCT03279549|Experimental|BFGF group|Limited debridement & Basic fibroblast growth factor group
2895628|NCT03279536|Experimental|Oral Lactoferrin|Group A is 120 mg of Oral lactoferrin for 4 weeks Intervention: The participants 66 will receive oral Lactoferrin 120mg for 4 weeks
2895629|NCT03279536|Active Comparator|Total dose infusion (TDI) iron dextran|Group B is a parenteral total dose infusion (TDI) of LMW iron dextran 20mg/kg body weight for 4 weeks Intervention: The participants 33 will receive parental iron 20mg/kg body weight for 4 weeks
2895630|NCT03279523|Experimental|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
2895631|NCT03279510|Experimental|Hearing aids|All study participants will be fit with hearing aids.
2895667|NCT03279276|Experimental|Primoris|Total hip arthroplasty surgery using a Primoris® femur component, Exceed ® acetabular cup + E-poly liner ®.
2895808|NCT03278470|Experimental|HL237 800mg|take oral tablet once
2895632|NCT03279497|Experimental|Health game|Health game intervention consists of 20 minutes guided training session with the mobile health game at school and 4 weeks free usage of the game via own smart phone during free time. Smart phones are tracking the actual physical activity (steps) of the participants via activity sensors and the tracked steps work as In-App Currency enabling the participants to play the game and proceed in it.
2895633|NCT03279497|Sham Comparator|Sport and fitness application|Sport and fitness application intervention consists of 20 minutes guided training session with the app at school and 4 weeks free usage of the app via own smart phone during free time. Sport and fitness application, when turned on, tracks the physical activity (running, cycling and every-day training) of the participant.
2895634|NCT03279484|Experimental|NAVIGO 4LV implant|All patients will be attempted to implant or implanted with NAVIGO 4LV lead
2895635|NCT03279471|Experimental|CBT/BIACA|These participants will receive CBT treatment using Behavioral Interventions for Anxiety in Children with Autism (BIACA). BIACA is an anxiety treatment package designed for children with ASD that includes elements of CBT and social skills training.
2895636|NCT03279471|Active Comparator|Sertraline|These participants will receive sertraline
2895637|NCT03279471|Placebo Comparator|Pill Placebo|These individuals will receive a pill placebo.
2895638|NCT03279458|Experimental|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted with the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform.
2895639|NCT03279458|Active Comparator|Ventilator|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted with the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air.The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
2895640|NCT03279445||African American|Patient of African American race
2895641|NCT03279445||Caucasian|Patient of Caucasian race
2895642|NCT03279419||Liver disease|"15 patients with acute or chronic liver disease of any aetiology. Serial static images to be taken at up to 3 time points using thermal imaging camera. Video images using thermal camera will be used to capture warming of one hand after cooling.~Patient may or may not be receiving terlipressin therapy."
2895643|NCT03279419||Normal|"15 patients without liver disease, and without any other disease or drug known to affect the peripheral circulation.~Serial static images to be taken at up to 3 time points using thermal imaging camera. Video images using thermal camera will be used to capture warming of one hand after cooling."
2895644|NCT03279393|Active Comparator|PTSD Subjects|
2895645|NCT03279393|Active Comparator|Trauma Control Subjects|
2895646|NCT03279393|Placebo Comparator|Healthy Control Subjects|
2895647|NCT03279380|Experimental|Single-nucleotide polymorphisms (SNPs)|In the first part the Case-control study design will be used to estimate the association between multiple single-nucleotide polymorphisms (SNPs) and the endurance/power athlete status.
2895648|NCT03279380|Active Comparator|High Intensity Interval Training (HIIT)|"High intensity interval exercise on the cycling ergometer (Velodyn, Racermate ™, USA).~Protocol: 8 x 5 min at 80% PPO (between intervals 1.5 min at 75 W). Baseline measurements will include the V̇O2peak test and peak power output. Monitoring of physiological responses with spirometry and analysis of expired air (oxygen and carbon dioxide output) (Quark, Cosmed, Rim, Italy)."
2895649|NCT03279380|Active Comparator|Low Intensity Continuous Training|"Low intensity continuous exercise on the cycling ergometer (Velodyn, Racermate ™, USA).~Protocol: continuous 60 min cycling at 50% PPO. Baseline measurements will include the V̇o2peak test and peak power output. Monitoring of physiological responses with spirometry and analysis of expired air (oxygen and carbon dioxide output) (Quark, Cosmed, Rim, Italy)."
2895650|NCT03279367||Hearing Impaired|Participants will be asked to wear an electro-encephalography (EEG) cap for measurement of brain activity whilst listening to speech stimuli. The speech stimuli will be presented through a loudspeaker positioned 1 meter in front of the participant. Participants will be asked to listen to the speech stimuli when using and without using their hearing aid. They will be asked to pay attention to the speech stimuli. This will be assured by asking them to answer questions related to the speech stimulus at random intervals. Subjects will also go through standard clinical procedures for assessing their hearing function and hearing aid setup.
2895651|NCT03279354|Experimental|Intervention group|Family Move app intervention
2895652|NCT03279354|Placebo Comparator|Control group|"HK FitNuts app intervention"
2895653|NCT03279341|Active Comparator|polyethylene glycol, osmotic laxitive|13.8g polyethylene glycol 3350 with sodium bicarbonate, sodium chloride, and potassium chloride, mixed with 125mL of water administered twice orally as a solution
2895654|NCT03279341|Active Comparator|bisacodyl, stimulant laxative|10 mg bisacodyl once daily oral administration with 125mL of water
2895655|NCT03279341|Active Comparator|prucalopride, prokinetic|2mg prucalopride, film-coated tablets (prucalopride succinate eq. 2mg), once daily oral administration with 125mL of water
2895656|NCT03279328|Active Comparator|Topical Steroid Ointment|One side of the face will receive a Topical Steroid ointment twice daily for seven days.
2895657|NCT03279328|Active Comparator|Vaseline|One side of the face will receive Vaseline twice daily for seven days.
2895658|NCT03279328|Active Comparator|Skin Barrier Moisturizer|One side of the face will receive Skin Barrier Moisturizer twice daily for seven days.
2895659|NCT03279315|Experimental|experimental period|the first period was with non-iodized salt, the second period was with iodized salt.
2895660|NCT03279302|Experimental|Group A|1 mg glepaglutide once daily, given as single SC injections on Days 1 to 7
2895661|NCT03279302|Experimental|Group B|5 mg glepaglutide once daily, given as single SC injections on Days 1 to 7
2895662|NCT03279302|Experimental|Group C|5 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36
2895663|NCT03279302|Experimental|Group D|10 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36
2895664|NCT03279302|Experimental|Group E|1 mg glepaglutide, given as an IV infusion at a rate of 4 mg/h for 15 minutes on Day 1
2895665|NCT03279289|Experimental|Group A|INDUCTION PHASE: 6 cycles of FOLFIRI + aflibercept MAINTENANCE PHASE: 5FU/LV + aflibercept
2895666|NCT03279289|Active Comparator|Group B|FOLFIRI + aflibercept
2895668|NCT03279276|Active Comparator|Echo|Total hip arthroplasty surgery using a standard uncemented Echo® femur component, Exceed ® acetabular cup + E-poly liner ®.
2895669|NCT03279263|Experimental|MLR-1023 25mg QD|MLR-1023 25mg QD Tablet
2895670|NCT03279263|Experimental|MLR-1023 50mg QD|MLR-1023 50mg QD Tablet
2895671|NCT03279263|Experimental|MLR-1023 100mg QD|MLR-1023 100mg QD Tablet
2895672|NCT03279263|Placebo Comparator|Placebo|Placebo QDTablet
2895673|NCT03279250|Experimental|LHRH Agonist + Apalutamide|"The type of LHRH agonist given depends on what the study doctor thinks is in participant's best interest and may be either Leuprolide, Goserelin, or Triptorelin.~Participants take 4 Apalutamide tablets by mouth 1 time each day.~Each study cycle is 28 days."
2895674|NCT03279250|Experimental|LHRH Agonist + Apalutamide + Abiraterone Acetate + Prednisone|"The type of LHRH agonist given depends on what the study doctor thinks is in participant's best interest and may be either Leuprolide, Goserelin, or Triptorelin.~Participants take 4 Apalutamide tablets by mouth 1 time each day.~Participants take 1 Prednisone tablet by mouth 2 times each day.~Participants take 4 Abiraterone Acetate tablets by mouth 1 time each day.~Each study cycle is 28 days."
2895675|NCT03279237|Experimental|FOLFIRINOX + pre-operative radiation|"FOLFIRINOX is a combination of 4 drugs that is administered twice per cycle~Oxaliplatin is administered intravenously~Leucovorin is administered intravenously~Irinotecan is administered intravenously~5-Fluorouracil is administered intravenously~Paclitaxel and Carboplatin will be given concurrently with radiation therapy every 7 days"
2895676|NCT03279224|Active Comparator|Allogenic FMT|Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) from a healthy, screened individual with no personal or family history of an Axis 1 disorder.
2895677|NCT03279224|Placebo Comparator|Autologous FMT|Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) by re-infusion of their own feces donated earlier in the study.
2895678|NCT03279211|Experimental|Zein protein|Zein protein included in the test-meal, 30 g of zein in 500 ml (water + flavour/sugar)
2895679|NCT03279211|Experimental|Whey protein isolate|Whey protein isolate included in the test-meal, 30 g of zein in 500 ml (water + flavour/sugar)
2895680|NCT03279211|Other|Protein-free|No protein added in the test-meal, only 500 ml of water + flavour/sugar In order to determine the endogenous loss of amino acid in the digesta samples.
2895681|NCT03279198|Placebo Comparator|Usual Care (UC)|The usual care group received usual care that varies dependent upon the practice setting.
2895682|NCT03279198|Active Comparator|TIWeb|TIWeb (Tailored Web Intervention) program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
2895683|NCT03279198|Active Comparator|Cancer Screening Call (CSC)|CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
2895684|NCT03279198|Active Comparator|TIWeb+CSC|TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
2895685|NCT03279185||Infected Cohort|Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment.
2895686|NCT03279172|Experimental|Group Direct Laryngoscope|direct laryngoscope (macintosh laryngoscope) is used in elective surgeries with maximal duration time for two hours. Standard anaesthesia was used on group and BIS monitorisation was applied. A record was made of IOP, hemodynamic changes and oxygen saturation at 3 and 10 minutes after intubation. Throat pain was evaluated by questioning the patient at 10 minutes and 24 hours after waking from general anaesthesia. The duration of intubation was recorded as the time from the laryngoscope entering the mouth to removal with end-tidal carbon dioxide on the monitor. Macintosh laryingoscope, BIS monitoring and tonometry would be used in Group Direct Laryngoscope.
2895687|NCT03279172|Experimental|Group videolaryngoscope|Videolaryngoscope is used in elective surgeries with maximal duration time for two hours. Standard anaesthesia was used on group and BIS monitorisation was applied. A record was made of IOP, hemodynamic changes and oxygen saturation at 3 and 10 minutes after intubation. Throat pain was evaluated by questioning the patient at 10 minutes and 24 hours after waking from general anaesthesia. The duration of intubation was recorded as the time from the laryngoscope entering the mouth to removal with end-tidal carbon dioxide on the monitor. Video laryingoscope, BIS monitoring and tonometry would be used in Group Video Laryngoscope.
2895688|NCT03279159|Experimental|Jaluronius CS cream (Difa Cooper S.p.a, Italy)|
2895689|NCT03279146|Active Comparator|Regimen A|Immediate release tablet Tenofovir exalidex (TXL)
2895690|NCT03279146|Experimental|Regimen B|New Formulation 1 Tenofovir exalidex (TXL)
2895691|NCT03279146|Experimental|Regimen C|New formulation 2 Tenofovir exalidex (TXL)
2895692|NCT03279133|Experimental|LDV/SOF for 12 weeks.|Ledipasvir 90mg/Sofosubvir 400mg fixed-dose combination (FDC) tablet for 12 weeks.
2895693|NCT03279120|Experimental|TFV/LNG IVR (8-10mg/20μg) (Continuous)|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (continuous).
2895694|NCT03279120|Experimental|TFV/LNG IVR (8-10mg/20μg) (Interrupted)|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (3x28 days interrupted).
2895695|NCT03279120|Placebo Comparator|Placebo (Continuous)|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (continuous).
2895696|NCT03279120|Placebo Comparator|Placebo (Interrupted)|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (3x28 days interrupted).
2895700|NCT03279107|Experimental|Snack with soluble corn fiber|snack with soluble corn fiber (50 gram of total carbohydrate)
2895701|NCT03279107|Experimental|Snack with maltodextrin|Snack with maltodextrin (50 gram of total carbohydrate)
2895702|NCT03279094|Experimental|Haploidentical stem cell transplantation|
2895703|NCT03279081|Experimental|Cx601|120 million cells administered by intralesional administration
2895704|NCT03279081|Placebo Comparator|Placebo|matching placebo administered by intralesional administration
2895705|NCT03279068||Without Pattern Interpretation|All women who are admitted for labor at Ayder Referral Hospital in Mekelle, Ethiopia will be asked to participate and a physician will obtain consent. If an indication arises and they are designated to receive EFM per previously established standard practice at Ayder Hospital, then their patient information will be collected. Patients who require EFM will be asked to provide basic health and demographic information, along with collection of information on labor and delivery course, post-partum outcome, and neonatal outcomes. The investigators estimate enrollment of up to 1800 patients which will result in at least 300 patients who will require EFM.
2895706|NCT03279068||With Pattern Interpretation|"All women who are admitted for labor at Ayder Referral Hospital in Mekelle, Ethiopia will be asked to participate and a physician will obtain consent. If an indication arises and they are designated to receive EFM per previously established standard practice at Ayder Hospital, then their patient information will be collected.~Their labor will be managed as in Phase 1 except that EFM will be interpreted and managed as per ACOG/FIGO guidelines using paper on which fetal heart tracings will be recorded. All other aspects of their care will proceed as per standard at Ayder Referral Hospital.~Patients who require EFM will be asked to provide basic health and demographic information, along with collection of information on labor and delivery course, post-partum outcome, and neonatal outcomes. The investigators estimate enrollment of up to 1800 patients which will result in at least 300 patients who will require EFM."
2895707|NCT03279055|Experimental|SHUTi|"Participants will be provided with an individual access code for SHUTi~SHUTi is delivered over 6 sessions, each taking 20-30 minutes~SHUTi is delivered by a virtual therapist~Participants will learn about the etiology and maintenance of their insomnia~Participants will learn how to maintain their sleep log~Participants will learn how to address lifestyle barriers that impact their sleep~Participants will be taught stimulus control techniques targeting non-sleep behaviors in the bedroom~Participants will learn a range of cognitive techniques that address the key cognitive factors that perpetuate poor sleep behavior~Participants will be taught how to gradually expand their restricted sleep"
2895708|NCT03279042|Experimental|Flapless corticotomy|Flapless corticotomy will be conducted in this group of patients.
2895709|NCT03279042|Active Comparator|Traditional corticotomy|Traditional corticotomy will be performed in this group.
2895710|NCT03279029|Experimental|patients with aortic valve disease (AVD).|
2895711|NCT03279029|Experimental|patients with left ventricular assist device (LVAD|
2895712|NCT03279003|Experimental|Light-emitting diode therapy|Exposure to LED light
2895713|NCT03278990|Experimental|Future Self - Value Affirmation|This is a behavioral intervention whereby participants write for 5 minutes about 1-2 values that are important to them, as well as about a time in their life when they were particularly important. Next, for five minutes, they write a letter to themselves in 20 years.
2895714|NCT03278990|Sham Comparator|Control|In this sham comparator, participants will also write--similar to the intervention above. However, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
2895715|NCT03278977|Other|ALTE group|Infants aged between 28 days and 12 months presenting severe(s) syncope(s) requiring hospitalization, for which a cause was identified during hospitalization.
2895716|NCT03278977|Other|iALTE group|Infant aged between 28 days and 12 months presenting a severe syncope(s) requiring hospitalization, for which no etiology was found during hospitalization.
2895717|NCT03278964|Active Comparator|Antro-ethmoidal technique|Patients in the inactive phase of Graves orbitopathy will be submitted to orbital decompression by antro-ethmoidal technique.
2895718|NCT03278964|Experimental|Lateral wall technique|Patients in the inactive phase of Graves orbitopathy will be submitted to orbital decompression by lateral wall technique.
2895719|NCT03278951|No Intervention|Control Group|The control group received the mHealth devices but no health coaching or feedback. Participants in this group completed the same pre- and post-intervention measurements.
2895720|NCT03278951|Experimental|Video Conferencing Health Coaching|The video conferencing group participants met via the eClinicalWorks® app using their smartphone, and met 12 times with the registered dietitian (RD) and 12 times with the exercise physiologist to discuss exercise and diet goals.
2895721|NCT03278951|Experimental|In Person Health Coaching|The in person group participants met 12 times with the registered dietitian (RD) and 12 times with the exercise physiologist over the course of the study to discuss both diet and exercise regimens.
2895722|NCT03278938|Active Comparator|bupropion added to citalopram|patients who did not remit with citalopram will continue at the same dose and have bupropion added
2895723|NCT03278938|Active Comparator|citalopram added to bupropion|Patients who did not remit with bupropion will have bupropion continued at the same dose and citalopram will be added
2895724|NCT03278925|Experimental|Prevention (defined green tea catechin extract)|Patients receive defined green tea catechin extract PO QD or BID for 24 weeks in the absence of disease progression or unacceptable toxicity.
2895725|NCT03278912||Healthy Volunteers|Healthy Volunteers
2895726|NCT03278912||Patients with CGD-IBD|Patients with chronic granulomatous disease(CGD)-IBD
2895727|NCT03278912||Patients with CGD without IBD|Patients with CGD without IBD
2895728|NCT03278912||Patients with IBD only (no PIDD)|Patients with inflammatory bowel disease (IBD) (without a primary immune dysregulation (PIDD))
2895729|NCT03278912||Patients with Hyper IgE Syndrome|Patients with Hyper IgE Syndrome
2895730|NCT03278912||Patients with LAD-I|Patients with Leukocyte adhesion deficiency type I (LAD-I)
2895731|NCT03278912||Patients with IPEX syndrome|Patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome
2895732|NCT03278912||Patients with CTLA4 Defects|Patients with cytotoxic T-lymphocyte-associated protein 4 (CTLA4) defects
2895733|NCT03278912||Patients with LRBA deficiency|Patients with lipopolysaccharide (LPS)-responsive-beige-likeanchor protein (LRBA) deficiency
2895734|NCT03278912||Patients with Hypomorphic RAG deficiency|Patients with hypomorphic recombination activating gene (RAG) deficiency
2895735|NCT03278886|Experimental|Low dose naltrexone|Participants randomized to this group will receive low dose naltrexone (4.5 mg) for 8 weeks.
2895736|NCT03278886|Experimental|Nalmefene|Participants randomized to this group will receive nalmefene (18 mg) for 8 weeks.
2895737|NCT03278873|Experimental|Biological-Low dose AAV - CNGB3|Subretinal administration of a single low dose of range AAV - CNGB3
2895738|NCT03278873|Experimental|Biological-medium dose AAV - CNGB3|Subretinal administration of a single medium dose of range AAV - CNGB3
2895739|NCT03278873|Experimental|Biological-high dose AAV - CNGB3|Subretinal administration of a single high dose of range AAV - CNGB3
2895740|NCT03278860|Experimental|Oxytocin then placebo|Participants first received oxytocin (24 IU). After a washout period of 2 weeks, they then received placebo (24 IU).
2895741|NCT03278860|Experimental|Placebo then oxytocin|Participants first received placebo (24 IU). After a washout period of 2 weeks, they then received oxytocin (24 IU).
2895742|NCT03278847||Enteral nutrition comparison|This comparison refers to differences in enteral nutrition during therapeutic hypothermia
2895743|NCT03278847||Parenteral nutrition comparison|This comparison refers to differences in parenteral nutrition during therapeutic hypothermia
2895744|NCT03278834|Experimental|Intervention Group|"Neuromuscular muscle stimulation machine - Muscle stimulation machine to be used on glutes and abductors on disuse atrophy setting.~Twice per day for 45 minutes.~Exercise - Home exercises programme once per day with 10 exercises."
2895745|NCT03278834|Placebo Comparator|Placebo Group|"Neuromuscular muscle stimulation- Muscle stimulation machine to be used on glutes and abductors on TENS setting. Twice per day for 45 minutes.~Exercise - Home exercises programme once per day with 10 exercises."
2895746|NCT03278821|Experimental|Self Match|The patient must choose between the five possible treatment options.
2895747|NCT03278821|Active Comparator|Expert Match|The Patient is referred to treatment by standard procedure which is Expert Match based on patient data.
2895748|NCT03278808|Experimental|Chloroquine-Azithromycin (CQ/AZ ) Group|Subjects will receive experimental intervention of 300mg of CQ orally (PO) and 2g of AZ PO weekly for 6 weeks
2895749|NCT03278808|Active Comparator|Chloroquine (CQ) Group|Subjects will only receive 300mg of CQ orally (PO) weekly for 6 weeks
2895750|NCT03278808|Other|CHMI Group - atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
2895751|NCT03278795|Active Comparator|PSV mode|PSV weaning group
2895752|NCT03278795|Experimental|VSV mode|VSV weaning group
2895753|NCT03278782|Experimental|Phase I: Pembrolizumab + Romidepsin|
2895754|NCT03278782|Experimental|Phase II: MTD Pembrolizumab + Romidepsin|
2895755|NCT03278769|Experimental|Ventilator setting|Positive end-expiratory pressure , Tidal volume
2895756|NCT03278756|Experimental|Cognitive Control Training|A cognitive control training, consisting of 10 sessions of 15 minutes each, will be administered. The task in this training is an adaptive paced auditory serial addition task, where participants need to click on the sum of the last two heard digits.
2895757|NCT03278756|Active Comparator|Active Control Training|An active control training, consisting of 10 sessions of 15 minutes each, will be administered. The task in this training is an adaptive low load cognitive task, where participants need to click on the last heard digit.
2895758|NCT03278743||low to moderate tea consumption|consumption of 0.4 to 4.6 cups of tea (200 ml) per day (n=463)
2895759|NCT03278743||High tea consumption|consumption of 4.6 to 11.9 cups of tea (200 ml) per day (n=213)
2895760|NCT03278730|Active Comparator|Para-Tyrosine intervention|"The patients will receive the study drug during their stay at the ICU but for a maximum of 7 days.~Study drug will be dispensed by a nominated member of the study team and administered to the patients by the ICU staff via nasogastric tube in form of oral suspension. The content of the hard capsules will be dissolved in 20 ml of tap water before the dosing.~Drug name: Tyrosine. Strength 500 mg. Oral dose form: hard capsule. Number of Dispensed at frequency of 3x2 g daily. Duration of administration: 4 to 7 days."
2895761|NCT03278730|Placebo Comparator|Placebo|"The patients will receive the study drug during their stay at the ICU but for a maximum of 7 days.~Study drug will be dispensed by a nominated member of the study team and administered to the patients by the ICU staff via nasogastric tube in form of oral suspension. The content of the hard capsules will be dissolved in 20 ml of tap water before the dosing.~Drug name: Placebo.. Strength N/A. Oral dose form: capsule matching to Tyrosine capsule. Number of Dispnsed an frequency 3x2 g daily. Duration of administration: 4 to 7 days."
2895762|NCT03278717|Experimental|Olaparib and Cediranib|"Patients will receive oral olaparib 300mg BD and oral cediranib 20mg OD.~Patients will attend hospital for a 2 weekly review for the first 8 weeks, then 4 weekly for year 1 and 8 weekly for year 2 onwards until discontinuation of all trial drugs. Treatment may continue beyond progression until the next line of treatment if the patient is deemed to still be deriving clinical benefit. QOL instruments will be collected at baseline, every clinic visit and continue to be completed after relapse."
2895763|NCT03278717|Active Comparator|Olaparib|"Patients will receive oral olaparib 300mg BD.~Patients will attend hospital for a 2 weekly review for the first 8 weeks, then 4 weekly for year 1 and 8 weekly for year 2 onwards until discontinuation of all trial drugs. Treatment may continue beyond progression until the next line of treatment if the patient is deemed to still be deriving clinical benefit. QOL instruments will be collected at baseline, every clinic visit and continue to be completed after relapse."
2895764|NCT03278704|Other|RE training only|RE only - Progressive resistance exercise training only (leg extension, leg step up, chest press and pull down).
2895765|NCT03278704|Experimental|Concurrent RE + HIIT|RE + HIIT - Progressive resistance exercise training (leg extension, leg step up, chest press and pull down) followed by HIIT (10 x 1 min at 90% heart rate maximum).
2895766|NCT03278691|Placebo Comparator|Placebo|Drug: Placebo Saline 1 ml IV Q6H
2895767|NCT03278691|Experimental|Intervention|Ketorolac 15 mg (15mg/ml) IV Q6H
2895768|NCT03278665|Experimental|4SC-202 + Pembrolizumab|Single arm study of 4SC-202 in combination with Pembrolizumab
2895769|NCT03278652||Patient with renal colic|
2895770|NCT03278639|Experimental|Rhythmic auditory stimulation|Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by music therapists board-certified in RAS.
2895771|NCT03278639|Active Comparator|Kinesiology|Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by board-certified kinesio therapists. The objectives of the training sessions will match those of RAS.
2895772|NCT03278626|Other|Nivolimumab+Carboplatin/paclitaxel+Radiation|240 mg IVPB every 2 weeks for 2 doses, nivolumab at 240 mg every 2 weeks will be added to paclitaxel and carboplatin, which will be dosed according to the standard of care: paclitaxel 50 mg/m2 weekly for 6 weeks and carboplatin AUC 2 weekly for 6 weeks and radiation
2895773|NCT03278613|Experimental|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS treatment entails insertion of a 34 gauge needle electrode at a 60 degree angle 3-4 cm deep towards the tibial nerve, approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. The PTNS grounding electrode, placed near the calcaneus and the needle electrode will be connected to the ES-130 device pulse generator.
2895774|NCT03278613|Sham Comparator|Validated Sham|Sham treatment will use the Streitberger acupuncture placebo needle in the same location as the needle electrode for PTNS. The sham uses an active gel surface electrode pad placed on the bottom of the foot just below the fifth (smallest) toe. This location is not part of the acupuncture nerve pathway connected to the bladder, pelvis or any major organs. Electrical current is delivered to this pad via a TENS unit resulting in sensory stimulation using the ES-130 device pulse generator.
2895775|NCT03278600|Experimental|site-specific therapy|standard treatments of sites of origin
2895776|NCT03278600|Active Comparator|standard empiric chemotherapy|standard empiric chemotherapy
2895777|NCT03278587|Active Comparator|Community-based screening|
2895778|NCT03278587|Active Comparator|Cataract camp program|
2895779|NCT03278587|Active Comparator|Community health worker program|
2895780|NCT03278587|No Intervention|No intervention|
2895781|NCT03278574|Experimental|Flexible band|Mitral valve repair with flexible posterior annuloplasty band
2895782|NCT03278574|Active Comparator|Complete ring|Mitral valve repair with complete rigid ring
2895783|NCT03278561||Early onset asthma|Sputum induction according to the European Respiratory Society (ERS) protocol. A blood sample of 100ml will be taken.
2895784|NCT03278561||Late onset asthma|Sputum induction according to the ERS protocol. A blood sample of 100ml will be taken.
2895785|NCT03278561||No pulmonary disease|Sputum induction according to the ERS protocol. A blood sample of 100ml will be taken.
2895786|NCT03278548|Experimental|Volulyte 6%|Volulyte 6% solution for infusion
2895787|NCT03278548|Active Comparator|Ionolyte|Ionolyte solution for infusion
2895788|NCT03278535||age group 18-29 years|CAREN-based gait analysis: 10 men and 10 women aged between 18-29 years
2895789|NCT03278535||age group 30-39years|CAREN-based gait analysis: 10 men and 10 women aged between 30-39years
2895790|NCT03278535||age group 40-49years|CAREN-based gait analysis: 10 men and 10 women aged between 40-49years
2895791|NCT03278535||age group 50-59years|CAREN-based gait analysis: 10 men and 10 women aged between 50-59years
2895792|NCT03278535||age group 60-69years|CAREN-based gait analysis: 10 men and 10 women aged between 60-69years
2895793|NCT03278535||age group 70-79years|CAREN-based gait analysis: 10 men and 10 women aged between 70-79years
2895794|NCT03278535||age group 80+|CAREN-based gait analysis: 10 men and 10 women aged 80 years and older
2895795|NCT03278522|Active Comparator|ramosetron iv at induction (I)|0.6mg of ramosetron is given to the patients intravenously at anesthesia induction
2895796|NCT03278522|Active Comparator|ramosetron iv at recovery (R)|0.6mg of ramosetron is given to the patients intravenously at end of surgery
2895797|NCT03278509|Experimental|Oral beta-blocker treatment|Patients randomized to beta-blockade will be prescribed oral beta-blocker (metoprolol succinate or bisoprolol) at a dose according to the treating physician. Metoprolol succinate will be strongly recommended as first choice. Bisoprolol will be allowed as an alternative. Atenolol (or any other beta-blocker therapy) will not be allowed. The treating physician will be encouraged to aim for a dose of ≥ 100 mg for metoprolol succinate and ≥ 5 mg for bisoprolol. Prescribed treatment and dosing will be registered. Initiation (whether the prescribed drug is dispensed) and adherence (defined as proportion of prescribed tablets that are dispensed), and persistence (time on treatment) will also be recorded via the Drug prescription registry.
2895798|NCT03278509|No Intervention|No beta-blocker treatment|Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Patients assigned to no beta-blockade also receive best evidence-based care, without beta-blockers. For blood pressure control, other drugs than beta-blockers will be recommended as first-line treatment. Regarding later use of beta-blockade, follow up is performed in the Drug prescription registry. Patients will be asked to provide future physicians with the written information about the study when beta-blockade treatment is discussed.
2895799|NCT03278496|Experimental|Recovery housing plus counseling|Intensive counseling in a 5-day per week program plus abstinence-contingent rent payment in a community recovery house. Intervention lasts 12 weeks with follow-up at 12 and 24 weeks post treatment entry.
2895800|NCT03278496|Experimental|Recovery Housing only|Abstinence-contingent payment for recovery housing rent in absence of any formal counseling. Intervention lasts 12 weeks with follow-up at 12 and 24 weeks post treatment entry.
2895801|NCT03278496|Active Comparator|Usual Care Referral|Participants receive referral resources for community substance abuse counseling and recovery housing but no formal treatment or help with rent payments. All participate in follow-up data collection.
2895802|NCT03278483|Active Comparator|Isoniazid|Diabetic patients with a positive TST of >10mm, will be randomly assigned to receive treatment with isoniazid 300mg Oral Tablet daily plus pyridoxine 50mg daily for six months
2895803|NCT03278483|Active Comparator|Rifampin|Diabetic patients with a positive TST of >10mm, who wil be randomly assigned to receive treatment with rifampin 600mg Oral Tablets daily for three months
2895804|NCT03278470|Experimental|HL237 50mg|take oral tablet once
2895805|NCT03278470|Experimental|HL237 100mg|take oral tablet once
2895806|NCT03278470|Experimental|HL237 200mg|take oral tablet once
2895812|NCT03278444|Experimental|Two-Drug Regimens|Basic drugs therapy of HCC; Arginine hydrochloride
2895813|NCT03278444|Experimental|Three-Drug Regimens|Basic drugs therapy of HCC; Arginine hydrochloride;Trimetazidine hydrochloride
2895814|NCT03278431|Active Comparator|Albendazole triple combi|Albendazole (400 mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
2895815|NCT03278431|Experimental|Pyrantel pamoate double combi|Pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
2895816|NCT03278431|Experimental|Albendazole double combi|Albendazole (400 mg) + oxantel pamoate (20 mg/kg)
2895817|NCT03278431|Experimental|Mebendazole triple combi|Mebendazole (500mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
2895818|NCT03278418|Experimental|Tricuspid Valve Repair|Concomitant tricuspid valve repair in patients undergoing left-sided valve surgery
2895819|NCT03278418|Active Comparator|left-sided valve surgery|No concomitant tricuspid valve repair in patients in pts undergoing left-sided valve surgery
2895820|NCT03278405|Experimental|Intervention Arm|Treatment with avelumab
2895821|NCT03278392|Experimental|Psychosocial challenge task|Participants will be assigned to complete the Trier Social Stress Test (TSST) immediately after consuming a standardized breakfast drink
2895822|NCT03278392|Sham Comparator|Placebo challenge task|Participants will be assigned to complete the placebo version of the TSST immediately after consuming a standardized breakfast drink
2895823|NCT03278379|Experimental|Intervention Arm|Treatment with Avelumab
2895824|NCT03278366|Experimental|Dancing students|Students will participate in dance activities from a video with their teacher in class.
2895825|NCT03278366|No Intervention|Non-Dancing Students|Students will continue with typical classroom activities in class and will not participate in dancing activities
2895826|NCT03278353|Experimental|Conservative care|Exercise and manual therapy
2895827|NCT03278340|Experimental|Sun Safe Workplaces - Technology (SSW-T)|Program promoting the adoption of sun protection policies by fire departments and state Departments of Transportation that is delivered via a range of technology systems including web-enabled visits with senior managers, online training of outdoor workers, and online access to collateral materials (e.g., brochures, posters, tip cards).
2895828|NCT03278340|Active Comparator|Sun Safe Workplaces - In Person (SSW-IP)|Program promoting the adoption of sun protection policies by fire departments and state Departments of Transportation that is delivered via personal visits with senior managers and in person training of outdoor workers by research staff over two years. Collateral materials (e.g., brochures, posters, tip cards) will be provided to worksites.
2895829|NCT03278327|Other|Endoscopic resection|
2895830|NCT03278288|Experimental|WellWe-Intervention group|WellWe-intervention includes the use of WellWe-app to assess the current situation of the wellbeing of the family at home and utilizing these results using WellWe-app during the health visit in Child health clinic.
2895831|NCT03278288|No Intervention|Usual care group|Usual care includes the filling of normal paper-based questionnaires to assess the current situation of the wellbeing of the family at home and utilizing these results during the normal health visit in Child health clinic.
2895832|NCT03278275|Experimental|uPAR PET/CT|One injection of the radioligand 68Ga-NOTA-AE105
2895833|NCT03278262||>= 70 letters|Baseline VA >= 70 letters
2895834|NCT03278262||36-69 letters|Baseline VA 36-69 letters
2895835|NCT03278262||<=35 letters|Baseline VA <=35 letters
2895836|NCT03278249|Experimental|Modified Atkins Ketogenic Diet|Modified Atkins Ketogenic Diet in combination with Temodar and Radiation
2895837|NCT03278236|Experimental|TRF|
2895838|NCT03278223|Active Comparator|Test solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.
2895839|NCT03278223|Active Comparator|Control solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.
2895840|NCT03278210||with EEG-fMRI data|EEG-fMRI was performed during the pre surgical evaluation, and its results were provided to the clinicians before surgery planification. The final surgery strategy was decided with EEG-fMRI results.
2895841|NCT03278210||without EEG-fMRI data|EEG-fMRI was performed during the pre surgical evaluation, but clinicians were blinded to the results. The final surgery strategy was decided without EEG-fMRI results.
2895842|NCT03278197|Experimental|1.Patients|"Patients diagnosed with prostate cancer and ex-prostate cancer patients:~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~Questionnaires"
2895843|NCT03278197|Other|2.Clinicians|"Radiotherapy-oncologists, Urologists, General practitioners, Nurses~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~Questionnaires"
2895844|NCT03278197|Other|3.Other involved organizations|Patient Organizations and insurance companies Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid
2895845|NCT03278184|Sham Comparator|tDCS sham motor cortex|20 participants will have sham stimulation for 20 minutes using transcranial direct current stimulation device.
2895846|NCT03278184|Active Comparator|Active motor cortex stimulation|20 participants will have active stimulation targeting the left motor cortex for 20 minutes using transcranial direct current stimulation device.
2895847|NCT03278184|Active Comparator|active prefrontal cortex stimulation|20 participants will have active stimulation targeting the left dorsolateral prefrontal cortex for 20 minutes using transcranial direct current stimulation device.
2895848|NCT03278171||Patients in intensive care unit|Cohort of patients leaving intensive care unit after a stay of more than 72 hours
2895849|NCT03278158|Placebo Comparator|Placebo|Subjects in the placebo arm will receive a single oral tablet containing no active drug.
2895850|NCT03278158|Experimental|XEN-D0501, 1 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet
2895851|NCT03278158|Experimental|XEN-D0501, 2 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet
2896068|NCT03276728|Active Comparator|AMG 986 Oral Dose Level F|or matching placebo - HV
2895852|NCT03278158|Experimental|XEN-D0501, 4 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
2895853|NCT03278145||Pediatric acute leukemia|Patients of the Institute of Hematology and Pediatric Oncology (IHOPe) with acute leukemia (LA) who came for initial diagnosis, relapse, or at the time of their remission .
2895854|NCT03278132|Experimental|EV71 vaccine & blood sampling (0, 10,60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 10, and 60 respectively for EV71 neutralizing antibody detection.
2895855|NCT03278132|Experimental|EV71 vaccine & blood sampling (0, 20,60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 20, and 60 respectively for EV71 neutralizing antibody detection.
2895856|NCT03278132|Experimental|EV71 vaccine& blood sampling (0, 30, 60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 30, and 60 respectively for EV71 neutralizing antibody detection.
2895857|NCT03278119||Sleep Apnea|"Overall 56~both male and female~age group 55 to 75 years, having mild to moderate obstructive sleep apnea (AHI4%5-30),~in good general health with no significant comorbidities~Located for the most part in boroughs of New York City"
2895858|NCT03278119||No Sleep Apnea|"Overall 56~both male and female~age group 55 to 75 years, without OSA (AHI4%<5),~in good general health with no significant comorbidities~Located for the most part in boroughs of New York City"
2895859|NCT03278106|Experimental|Treatment (TAS-102)|Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 orally PO BID on days 1-5 and 8-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2895860|NCT03278080|Other|driving test|
2895861|NCT03278067||Study cohort|Volunteered subjects who will receive influenza vaccination in approximately10 practices.
2895862|NCT03278054|Active Comparator|Manual group|Root Canal Treatment with hand instruments:Root canal treatment was done with instrumentation using manual K files.
2895863|NCT03278054|Active Comparator|ProTaper group|Root canal treatment with Protaper instruments:Root canal treatment was done using ProTaper rotary files S1, S2, F1, and F2.
2895864|NCT03278054|Active Comparator|Hybrid group|Root canal treatment with hybrid instrumentation:Root canal treatment was carried out using ProTaper and Hyflex CM files.
2895865|NCT03278041|Experimental|surgical reconstruction with submental flap|surgical reconstruction with submental flap
2895866|NCT03278041|Active Comparator|maxillary obturator|maxillary obturator
2895867|NCT03278028|Experimental|Active|A-101 Topical Solutions
2895868|NCT03278028|Placebo Comparator|Vehicle|Vehicle
2895869|NCT03278015|Experimental|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
2895870|NCT03278015|Experimental|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
2895871|NCT03278015|Experimental|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
2895872|NCT03278002||Group/Cohort Information|This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
2895873|NCT03277976||ThermoCool SmartTouch 1|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch Catheter and Ablation Index range: 380 for the posterior wall and 500 for the anterior wall
2895874|NCT03277976||ThermoCool SmartTouch 2|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch Catheter and Ablation Index range: 330 for the posterior wall and 450 for the anterior wall
2895875|NCT03277976||ThermoCool SmartTouch SF 1|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch SF Catheter and Ablation Index range: 330 for the posterior wall and 450 for the anterior wall
2895876|NCT03277976||ThermoCool SmartTouch SF 2|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch SF Catheter and Ablation Index range: 380 for the posterior wall and 500 for the anterior wall
2895877|NCT03277963|Active Comparator|Absence of sleep apnea syndrome|Pain perception tests
2895878|NCT03277963|Experimental|Presence of sleep apnea syndrome|Pain perception tests and for severe sleep apnea syndrome, treatment by positive airway pressure (PPC) ventilation
2895879|NCT03277950|Experimental|virtual reality with feedback|Participants received training via virtual reality game with feedback, 60 minutes/day, 3 days/week for 4 weeks, then follow up after 4 weeks.
2895880|NCT03277950|Active Comparator|virtual reality without feedback|Participants received training via virtual reality game without feedback, 60 minutes/day, 3 days/week for 4 weeks, then follow up after 4 weeks.
2895881|NCT03277950|Other|Healthy|Participants do not play virtual reality game.
2895882|NCT03277937|Experimental|Patients with gastric varices|Patients above 18 years old with gastric varices (GV) on the initial standard diagnostic upper endoscopy will be enrolled and treated using angiography in EUS-injection of coils + CYA. GV will be classified according to Sarin and Kumar classification. Only gastro-esophageal varices type II (GOV II) (fundal varices communicating with esophageal varices) and isolated gastric varices type I (IGV I) (fundal varices within a few centimeters of the gastric cardia) will be included. Gastro-esophageal varices type I (GOV I) will be excluded. Patients with active bleeding and history of previous bleeding due to GV (secondary prophylaxis) will be included as well as patients with high-risk GV suitable for primary prophylaxis according to Baveno VI consensus. T
2895883|NCT03277924|Experimental|Sunitinib+Nivolumab|"Single arm of sunitinib 37.5 mg/day (or recommended dose defined in phase I) orally continuously + nivolumab 3 mg/kg intravenous every 2 weeks infused over 1 hour.~Sunitinib (Sutent): Hard Capsule (12.5, 25 mg). Oral use. Nivolumab (Opdivo) 10 mg/mL concentrate for solution for infusion. Intravenous use"
2895915|NCT03277703|Active Comparator|Group 2 - Standard|Group 2 subjects will be receive the standard single dose of influenza vaccine in year 1 but will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 2.
2938202|NCT02984306|Experimental|Dietary supplement|
2895884|NCT03277898|Experimental|Aerobic Exercise|Participants will complete three supervised aerobic exercise sessions each week using the treadmill, stationary bicycle or elliptical training for the duration of their chemotherapy (12-16 weeks). Aerobic exercise will be performed for 20-40 minutes at 50-75% of heart rate reserve. Participants will wear heart rate monitors during all supervised sessions (Polar Electro Inc., Lake Success, NY) and will be provided with target heart rates that will be individualized using their baseline (i.e., week 0) assessment data. Home-based exercise will be introduced in week 3. For the home-based sessions, participants will be asked to complete at least 1 session per week of 30 minutes of aerobic exercise (an activity of their choosing; e.g., walking).
2895885|NCT03277898|Other|Usual Care (Wait-list Control)|Participants randomly assigned to UC group will be advised to continue with their regular activities of daily living. Following their chemotherapy, the UC group will receive the exercise intervention.
2895886|NCT03277872|Active Comparator|GlideScope (GVL) Blade|Patients in this arm will have the first laryngoscopy performed with the GlideScope (GVL) blade and the second one with the MacIntosh blade. The tool used for the third laryngoscopy, followed by intubation, (either GlideScope or MAC blade) will be decided according to a second randomization, necessary to one of our secondary objectives.
2895887|NCT03277872|Active Comparator|MacIntosh (MAC) Blade|Patients in this arm will have the first laryngoscopy performed with the MacIntosh (MAC) blade and the second one with the GlideScope blade. The tool used for the third laryngoscopy, followed by intubation, (either GlideScope or MAC blade) will be decided according to a second randomization, necessary to one of our secondary objectives.
2895888|NCT03277859|Experimental|YOGA-NOW|Participant will start the SAA-TBI (yoga) about 2 weeks (+/- 2 weeks) after Study Visit 3.
2895889|NCT03277859|Active Comparator|YOGA-WAIT|Participant will start SAA-TBI (yoga) about 10 weeks (+/- 2 weeks) after Study Visit 3.
2895890|NCT03277846|Experimental|Accept ECT - TES|Accept ECT where subject is randomized to TES
2895891|NCT03277846|Placebo Comparator|Accept ECT - SHAM|Accept ECT where subject is randomized to a SHAM condition
2895892|NCT03277846|Experimental|Reject ECT - TES|Reject ECT where subject is randomized to TES
2895893|NCT03277846|Placebo Comparator|Reject ECT - SHAM|Reject ECT where subject is randomized to SHAM
2895894|NCT03277833|Experimental|Gynostemma Pentaphyllum(Dungkulcha) Extract|Gynostemma Pentaphyllum(Dungkulcha) Extract (400mg/d)
2895895|NCT03277833|Placebo Comparator|Placebo|Placebo
2895896|NCT03277820|Experimental|Probiotic group|Intake of 1 portion (=6 droplets) Probactiol Mini during 4 weeks.
2895897|NCT03277820|No Intervention|Control group|No intake of Probactiol Mini
2895898|NCT03277807||Active|pregnant women who are physically active (spend a minimum of 150min/week with moderate to vigorous physical activity)
2895899|NCT03277807||Inactive|pregnant women who are physically inactive (spend less than 150min/week with moderate to vigorous physical activity)
2895900|NCT03277807||risk for hypertensive disorders|pregnant women with a history of preeclampsia or positive history for metabolic conditions increasing the risk of hypertensive disorders in pregnancy
2895901|NCT03277794|Active Comparator|Transitional Case Management Only|Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
2895902|NCT03277794|Experimental|Full HOP-C Service|Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
2895903|NCT03277781||Current smokers|
2895904|NCT03277781||Ex-smokers|
2895905|NCT03277781||Coronary heart disease|
2895906|NCT03277768||Control Group -Patent Ductus Arteriosus Absent|
2895907|NCT03277768||Study Group - Patent Ductus Arteriosus Present|
2895908|NCT03277755|Experimental|Cohort1:Participants With Moderately Impaired Hepatic Function|Participants With moderately impaired hepatic function will receive a single oral dose of AL-335 800 milligram (mg) (2 tablets of 400 mg AL-335) on Day 1 of Part 1 followed by a single oral dose of odalasvir (ODV) 25 mg (1 tablet of 25 mg ODV) on Day 8 of Part 1 and a combination of AL-335 800 mg (2 tablets of 400 mg AL-335) + ODV 25 mg (1 tablet of 25 mg ODV) + simeprevir (SMV) 75 mg (1 capsule of 75 mg SMV) once daily on Day 1 to 14 of Part 2. There will be a washout period between Part 1 and Part 2 of at least 14 days. Day 8 of Part 1 will be the start of the washout period. Prior to the start of study drug administration in Part 2, a safety review will be performed by the Sponsor.
2895909|NCT03277755|Experimental|Cohort 2: Participants With Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of AL-335 800 mg (2 tablets of 400 mg AL-335) on Day 1 of Part 1 followed by a single oral dose of ODV 25 mg (1 tablet of 25 mg ODV) on Day 8 of Part 1 and a combination of AL-335 800 mg (2 tablets of 400 mg AL-335) + ODV 25 mg (1 tablet of 25 mg ODV) + SMV 75 mg (1 capsule of 75 mg SMV) once daily on Day 1 to 14 of Part 2. There will be a washout period between Part 1 and Part 2 of at least 14 days. Day 8 of Part 1 will be the start of the washout period. Prior to the start of study drug administration in Part 2, a safety review will be performed by the Sponsor.
2895910|NCT03277742|Active Comparator|Control|This arm will receive the standard of care for patients with TB and DM2
2895911|NCT03277742|Experimental|Intervention|This arm will receive the community intervention
2895912|NCT03277729|Experimental|Treatment (CD20-specific CAR T cell, chemotherapy)|Patients undergo leukapheresis. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion.
2895913|NCT03277716|Experimental|TACE+MWA|Transcatheter arterial chemoembolization combined with microwave ablation: 2-3 times of TACE treatment, then followed by ablation treatment using MWA system.
2895914|NCT03277703|Experimental|Group 1 - Booster|Group 1 subjects will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 1 and year 2.
2895982|NCT03277248|Active Comparator|Teriflunomide + IV Placebo|Oral daily administration
2895916|NCT03277690|Experimental|Levoketoconazole|Double blind withdrawal phase: Levoketoconazole (up to a dose of 1200 mg); Double blind restoration phase: Levoketoconazole plus Placebo
2895917|NCT03277690|Placebo Comparator|Placebo|Double blind withdrawal phase: Placebo; Double blind restoration phase: Placebo plus Levoketoconazole
2895918|NCT03277677|Active Comparator|normal saline|
2895919|NCT03277677|Active Comparator|balanced solution|
2895920|NCT03277664|Experimental|intervention group|Outpatient or inpatient with doctor-diagnosed asthma aged 6 months-3 years attending Shanghai Children's Medical Center and 14 Community hospitals were screened for eligibility. Before randomization, all participants had the same chips attached to their regular nebulizers. Caregivers were told the devices monitored the date and time of all actuations. All caregivers were asked to fill the questionnaire about the patients. After randomisation, all caregivers had their nebulizer technique checked by a qualified asthma nurse, and received a brief asthma education session, emphasising the importance of taking inhaled steroids regularly. All participants were reviewed in their routine asthma clinics 3 monthly and all treatment decisions were made by the clinical team. A member of the study team downloaded data from the backend database weekly and calculate the adherence rate monthly.
2895921|NCT03277664|No Intervention|control group|"Caregivers of the recruited patients in the control group were not added to a Wechat group. All the decive-monitored adherence data were also downloaded and calculated weekly. However, the investigators did not give feedback to them. Monthly, Caregivers were also asked Have your child inhaled the medicine according to the doctor's instructions? and How about the frequency through telephone follow-up."
2895922|NCT03277651||liver fibrosis|liver biopsy proved
2895923|NCT03277651||portal hypertension|hepatic venous pressure gradient (HVPG) proved
2895924|NCT03277638|Experimental|Pembrolizumab injections 7 days before surgery|Patients will have intravenous pembrolizumab 7 days before surgery with Laser Interstitial Thermotherapy
2895925|NCT03277638|Experimental|Pembrolizumab injections 14 days after surgery|Patients will have intravenous pembrolizumab 14 days after surgery with Laser Interstitial Thermotherapy
2895926|NCT03277638|Experimental|Pembrolizumab injections 35 days after surgery|Patients will have intravenous pembrolizumab 35 days after surgery with Laser Interstitial Thermotherapy
2895927|NCT03277625||pancreaticoduodenectomy|patients undergoing pancreticoduodenectomy and having a soft, fragile and/or fatty pancreatic remnant, combined with small pancreatic duct having a Diameter <3 mm.
2895928|NCT03277612||C-Section|Infants delivered by C-section
2895929|NCT03277612||Vaginal Delivery|Infants delivered by spontaneous vaginal delivery after C-section.
2895930|NCT03277599|Active Comparator|Grup Y|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine+IV patient-controlled analgesia (PCA) tramadol
2895931|NCT03277599|Active Comparator|Grup B|ultrasound ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
2895932|NCT03277586|Experimental|Probio'Stick|
2895933|NCT03277586|Placebo Comparator|Placebo|
2895934|NCT03277573|Experimental|Salsalate|Drug: Salsalate 2 tablets twice daily (3,000 mg total daily) by mouth for 12 months
2895935|NCT03277573|Placebo Comparator|Placebo|Drug: Placebo 2 tablets twice daily by mouth for 12 months
2895936|NCT03277534|Experimental|Electrical stimulation|
2895937|NCT03277534|Sham Comparator|Control|
2895938|NCT03277521|Active Comparator|Neurologically Normal|Neurologically normal subjects (i.e., nonimpaired) will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
2895939|NCT03277521|Active Comparator|Quadriplegia|Individuals with quadriplegia will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
2895940|NCT03277521|Active Comparator|Quadriplegia with upper limb reconstruction|Individuals with quadriplegia and upper limb reconstruction will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
2895941|NCT03277508|Experimental|BCI robot assisted hand therapy|Brain-computer integration robot assisted hand therapy
2895942|NCT03277508|Active Comparator|CPM robot assisted hand therapy|Continue Passive Movement robot assisted hand therapy
2895943|NCT03277495|Active Comparator|nicotine SREC|The liquid in the e-cigarette refills contains nicotine
2895944|NCT03277495|Placebo Comparator|placebo SREC|The liquid in the e-cigarette refills does not contain nicotine
2895945|NCT03277482|Experimental|Phase I Safety Lead-In|"A modified 3+3 design will be used in this trial Lead-in phase with Durvalumab* and radiation therapy~*q4 weeks durvalumab for 13 cycles or until progression"
2895946|NCT03277482|Experimental|Phase I Radiation Dose Evaluation|"Durvalumab~Tremelimumab* -- Start radiation dose from safety lead-in (level 0 or level -1) *q4 weeks durvalumab / tremelimumab for 4 cycles and continue durvalumab for 13 cycles or until disease progression"
2895947|NCT03277469|Experimental|MRI Guided BRACHYTHERAPY with Tracker|"Standard pelvic MRI sequences will be obtained~MRI Tracker is used during catheter positioning with serial MR imaging during implant~All patients will undergo 3D-based image acquisition for brachytherapy treatment planning per standard clinical practice~The brachytherapy modality to be used is high-dose-rate brachytherapy using an iridum-192 stepping source"
2896067|NCT03276728|Active Comparator|AMG 986 Oral Dose Level E|or matching placebo - HV
2895948|NCT03277469|Experimental|MRI Guided BRACHYTHERAPY without Tracker|"Standard pelvic MRI sequences will be obtained~Standard process is used with serial MR imaging to evaluate catheter position during implant~All patients will undergo 3D-based image acquisition for brachytherapy treatment planning per standard clinical practice~The brachytherapy modality to be used is high-dose-rate brachytherapy using an iridum-192 stepping source"
2895949|NCT03277456|Experimental|Single intramuscular injection of MVA-NP+M1 vaccine|MVA-NP+M1, a novel vaccine will be administered intramuscular. The total volume given is 0.5ml and the dose given is 1.5E8 pfu. Each volunteer will receive one single injection only over a few seconds.
2895950|NCT03277443|Active Comparator|Conventional Model Surgery|"Lateral Cephalogram with analysis and tracing of facial profile.~Modified model surgical tecnique:~Obtain wax bite registration.~Record face-bow transfer.~Duplication of articulating model for surgical simulation.~Measure all casts and bases in standard model surgery fashion.~Fabricate intermediate splint & Final splint.~Condylar repositional splint."
2895951|NCT03277443|Experimental|Computer guided surgery|"Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.~Computer-aided planning for study group:~All planning will be done using specialized software (Anatomage Invivo 5.3) for preoperative surgical simulation and immediate postoperative evaluation.~Pre-operative Fabrication of computer aided surgical splint:~In the study group a stereo splint will be fabricated using rapid prototyping (RP) technique to guide the osteotomy and another one will be fabricated after virtual osteotomy to guide the surgical cuts. And stent for guided holes.~So that the osteotomy will be accomplished by the aid of computer guided templates that simulates the proper bite achieved preoperatively during surgical simulation and Planning."
2895952|NCT03277430|Experimental|Live donor uterus transplantation|Transplantation of uterus from a living donor. Immunosuppression with tacrolimus.
2895953|NCT03277430|Experimental|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor. Immunosuppression with tacrolimus.
2895954|NCT03277417||Isolated Oligohydramnios|Fetuses with amniotic fluid index (AFI) equal or less than 5 cm
2895955|NCT03277417||Isolated Polyhydramnios|Fetuses with amniotic fluid index (AFI) more than 25 cm
2895956|NCT03277417||Control Group|Fetuses with normal amount of amniotic fluid
2895957|NCT03277404|Experimental|Smear Layer Positive|Root canal treatment without smear layer removal: Root canal treatment and Irrigation with 1 ml of 2.5% sodium` hypochlorite for 1 min, followed by ultrasonic activation of 3 ml of 2.5% sodium hypochlorite for 1minute.
2895958|NCT03277404|Active Comparator|Smear layer negative|root canal treatment with smear layer removal:Root canal treatment and Irrigation with 1 mL of 17% EDTA solution and ultrasonic activation, followed by ultrasonic activation of 3 ml of 2.5% sodium hypochlorite for 1 minute.
2895959|NCT03277391|Active Comparator|Serratus anterior plane block|Deep serratus anterior plane block
2895960|NCT03277391|Active Comparator|patient-controlled analgesia|patient-controlled analgesia: pump containing morphine (1mg/ml) and dehydrobenzperidol (50 mcg/ml).
2895961|NCT03277378||Group 1 (AB)|Group 1 (AB): anatomic lead placement followed by BurstDR™ stimulation during an initial trial evaluation period
2895962|NCT03277378||Group 2 (TB)|Group 2 (TB): targeted lead placement followed by BurstDR™ stimulation during an initial trial evaluation period
2895963|NCT03277352|Experimental|INCAGN01876 + Pembrolizumab + Epacadostat|INCAGN01876 in combination with pembrolizumab and epacadostat
2895964|NCT03277339|Experimental|Paroxetine|Paroxetine (Deroxat®) Posology : 20 mg per day for 3 weeks. After 2 weeks of treatments, if indicated, physicians will prescribe until 50 mg.
2895965|NCT03277339|Other|Thermal cure|This study is controlled with a comparator which is the Thermal cure. Thermal cure is realized for 3 weeks.
2895966|NCT03277326|Active Comparator|ISB|Interscalene brachial plexus block
2895967|NCT03277326|Active Comparator|aSSB|Anterior Suprascapular Block
2895968|NCT03277326|Active Comparator|pSSB|Posterior Suprascapular Block
2895969|NCT03277313|Experimental|Epoch 1|Pediatric patients with primary immunodeficiency disease (PIDD) who are on intravenous (IV) or non-HYQVIA subcutaneous (SC) treatment with immunoglobulin (IV-pre-treated, SC-pre-treated) will be enrolled and treated with HYQVIA subcutaneously with a dose or interval ramp-up period of up to six weeks.
2895970|NCT03277313|Experimental|Epoch 2|"HYQVIA treatment at the following intervals:~For intravenous (IV)-pre-treated participants: every three or four weeks, depending on the participant's previous IV dosing schedule.~For subcutaneous (SC)-pre-treated participants: every three or four weeks, at the discretion of investigator and participant.~After one year in Epoch 2, the anti-rHuPH20 binding antibody assay results during that year will be used to decide the next steps in the study:~Participants with anti-rHuPH20 antibody titer < 160 at all time-points during the study will complete the study completion visit at the next possible occasion following the 12-months visit.~Participants with anti-rHuPH20 antibody titer ≥ 160 during the study and/or at the last measurement will continue in Epoch 2 for an additional two years of HYQVIA treatment and observation, and complete the study completion visits at the next possible occasion following the 36-months visit."
2895971|NCT03277313|Active Comparator|Epoch 3|Safety follow-up for participants whose anti-rHuPH20 antibody titer was ≥ 160 during Epoch 1 or Epoch 2 and who experience either related serious adverse event (SAE) or a related severe adverse event (AE)
2895972|NCT03277287|Experimental|Group A|Fractional CO2 laser will be applied on cleft lip scar 3 weeks post-surgical
2895973|NCT03277287|Experimental|Group B|Fractional CO2 laser will be applied on cleft lip scar 3 months post-surgical
2895974|NCT03277287|No Intervention|Group C|No intervention
2895975|NCT03277274|Experimental|Group 1 Mild Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, IV, administered as 60-minute infusion, once on Day 1.
2895976|NCT03277274|Experimental|Group 2 Moderate Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, IV, administered as 60-minute infusion, once on Day 1.
2895977|NCT03277274|Experimental|Group 3 Severe Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, IV, administered as 60-minute infusion, once on Day 1.
2895978|NCT03277274|Experimental|Group 4 Healthy Participants: TAK-954 0.2 mg|TAK-954 0.2 mg, IV, administered as 60-minute infusion, once on Day 1.
2895979|NCT03277261|Experimental|Ublituximab + Oral Placebo|IV Infusion
2895980|NCT03277261|Active Comparator|Teriflunomide + IV Placebo|Oral daily Administration
2895981|NCT03277248|Experimental|Ublituximab + Oral Placebo|IV infusion
2895983|NCT03277235|Experimental|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
2895984|NCT03277235|No Intervention|Control|Usual care
2895985|NCT03277222|Active Comparator|IN insulin 20 IU|Drug: IN insulin Dosage form: intranasal Dose: 20 IU Frequency: bid Duration: 16 weeks dose escalation over 4 weeks 10→20 IU twice daily
2895986|NCT03277222|Active Comparator|IN insulin 40 IU|Drug: IN insulin Dosage form: intranasal Dose: 40 IU Frequency: bid Duration: 16 weeks dose escalation over 4 weeks 10→20→30→40 IU twice daily
2895987|NCT03277222|Placebo Comparator|IN Lilly diluent|Drug: Lilly diluent Dosage form: intranasal Frequency: bid Duration: 16 weeks
2895988|NCT03277209|Experimental|All Subjects|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
2895989|NCT03277196|Experimental|Ivacaftor Arm|
2895990|NCT03277196|No Intervention|Observational Arm|
2895991|NCT03277183|Placebo Comparator|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
2895992|NCT03277183|Experimental|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
2895993|NCT03277170|Experimental|High-dose Montelukast Oral Granules|30 mg (high-dose) oral montelukast granules mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
2895994|NCT03277170|Placebo Comparator|Placebo|Identical placebo mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
2895995|NCT03277157|Experimental|Probiotic|Bifidobacterium animalis ssp. lactis B94 at 15 billion CFUs per capsule
2895996|NCT03277157|Placebo Comparator|Placebo|Placebo veggie capsule.
2895997|NCT03277144|Experimental|TST-TriStaple(3lines stapler)Technology|During gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with a TriStaple (three-lines linear stapler) Technology device.
2895998|NCT03277144|Active Comparator|OCT (other conventional techniques)|During gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with conventional techniques including manual sutures and devices with only two lines of staples.
2895999|NCT03277131|Experimental|1|Antimicrobial Dressing
2896000|NCT03277118||Cardiac Surgery Cohort|Patients aged 18 years or older who are scheduled to undergo elective cardiac surgery with cardiopulmonary bypass.
2896001|NCT03277105|Experimental|Dara SC|Participants will receive a fixed dose of daratumumab as 1800 milligram (mg) subcutaneously (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Unit per milliliter (U/mL), once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks.
2896002|NCT03277105|Active Comparator|Dara IV|Participants will receive daratumumab for intravenous infusion (Dara IV) 16 mg/kg by once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks at Day 1 in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
2896003|NCT03277092|Experimental|VeinViewer® group|Use of near infrared light to perform blood draw (VeinViewer®)
2896004|NCT03277092|Active Comparator|Usual care group|Blood drawing performed traditionally
2896005|NCT03277079|Active Comparator|statin + ezetimibe|Low dose statin associated with ezetimibe
2896006|NCT03277079|Active Comparator|statin + ezetimibe + Nutraceuticals|Low dose statin associated with ezetimibe and Nutraceuticals
2896007|NCT03277066|Experimental|Diclofenac Sodium Active Topical Patch 1|Diclofenac sodium 1 topical patches will be compared against placebo patches.
2896008|NCT03277066|Experimental|Diclofenac Sodium Active Topical Patch 2|Diclofenac sodium 2 topical patches will be compared against placebo patches.
2896009|NCT03277053|Sham Comparator|control|Patients receive an ipad with no app.
2896010|NCT03277053|Experimental|Mobile application no stoma|Patients who did not receive a stoma receive an ipad containing the app and are instructed how to use it.
2896011|NCT03277053|Experimental|Mobile application stoma|Patients who receive a stoma receive an ipad containing the app and are instructed how to use it.
2896012|NCT03277040|Experimental|Intervention (CSA membership)|Employees will gain CSA membership - they will receive bi-weekly deliveries of fresh fruits and vegetables to a central location near their place of employment.
2896013|NCT03277040|No Intervention|Control (no CSA membership)|Usual care, usual employee benefits. Employees do not gain CSA membership.
2896014|NCT03277001|Active Comparator|Enoxaparin|AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization Padua score > 4
2896015|NCT03277001|Experimental|Rivaroxaban|AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization Padua score > 4
2896016|NCT03276988|Experimental|Dose level 1 (GX-30 0.45mg)|Administration of GX-30 0.45mg, Intramuscular injection
2896017|NCT03276988|Experimental|Dose level 2 (GX-30 0.9mg)|Administration of GX-30 0.9mg, Intramuscular injection
2896018|NCT03276988|Experimental|Dose level 3 (GX-30 0.9mg x 2 times)|"Administration of GX-30 0.9mg, Intramuscular injection~Administration of GX-30 0.9mg, Intramuscular injection, 24h after the first injection"
2896019|NCT03276975|Experimental|Patching of CSF Leaks with Autologous Blood and Fibrin|
2896020|NCT03276975|No Intervention|Simulated Patching Procedure|
2896021|NCT03276962|Experimental|R012-20 Group|Subjects will receive full doses of RTS,S/AS01E at Month 0, Month 1, Month 2 and a full dose at Month 20.
2896022|NCT03276962|Experimental|R012-14-mD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and yearly full doses at Month 14, Month 26, Month 38.
2896023|NCT03276962|Experimental|Fx012-14-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 2, Month 14, Month 26, Month 38.
2896024|NCT03276962|Experimental|Fx017-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 andRTS,S/AS01E 1/5th dose at Month 7, Month 20, Month 32.
2896025|NCT03276962|Experimental|Control Group|Subjects will receive rabies vaccine at Month 0, Month 1, Month 2.
2896026|NCT03276949||Healthy volunteers|Non-diabetic healthy men/women in between age group 18-80 years (all races and ethnicity) will be included for blood glucose measurements
2896027|NCT03276936|Experimental|Minocycline Foam 1.5%|FMX-103
2896028|NCT03276923||Maternal Autoimmune Disease ReseArch (MADRA) Registry|Women with autoimmune diseases who are pregnant
2896029|NCT03276910|Experimental|Eprex 20 UI/kg|6 doses at 20 IU/kg in subcutaneous use
2896030|NCT03276910|Experimental|Eprex 50 UI/kg|6 doses at 50 IU/kg in subcutaneous use
2896031|NCT03276910|Placebo Comparator|Placebo|6 injections at 1ml in subcutaneous use of sodium chloride AGUETTANT 0.9%
2896032|NCT03276897|Experimental|Nutriage SPF 30 day cream and Nutriage night cream|Application of the study products (day cream at the morning and night cream at the evening), for an uninterrupted period of 3 months.
2896033|NCT03276884|Experimental|Experimental Infant Formula|Infant formula powder to be fed ad libitum
2896034|NCT03276884|Active Comparator|Control Infant Formula|Infant formula powder to be fed ad libitum
2896035|NCT03276871|Active Comparator|Balloon Dissection|Patients will undergo laparoscopic TEP inguinal hernia repair and creation of the extraperitoneal space will be performed with a balloon dissection technique using the Spacemaker Balloon Dissector.
2896036|NCT03276871|Experimental|Telescopic Dissection|Patients will undergo laparoscopic TEP inguinal hernia repair and creation of the extraperitoneal space will be performed with a telescopic dissection technique.
2896037|NCT03276858|Experimental|CRN00808 Oral Solution|CRN00808 oral solution, single-dose
2896038|NCT03276858|Experimental|CRN00808 Oral Capsule|CRN00808 oral capsule, single-dose and multiple-doses
2896039|NCT03276858|Placebo Comparator|Placebo Oral Solution|Placebo oral solution, single-dose
2896040|NCT03276858|Placebo Comparator|Placebo Oral Capsule|Placebo oral capsule, single-dose and multiple doses
2896041|NCT03276858|Other|Midazolam Oral Solution|Midazolam oral solution, two single-doses as part of the drug-drug interaction arm of the study
2896042|NCT03276845|Other|1|
2896043|NCT03276832|Experimental|Treatment (pembrolizumab, imiquimod)|Patients receive pembrolizumab IV on day 1 and apply imiquimod cutaneously on days 1-5 (Monday - Friday). Courses repeat every 21 days for up to 2 years (approximately 35 courses) in the absence of disease progression or unacceptable toxicity.
2896044|NCT03276819|Experimental|Cohort A|"Samples collection and Tobacco and alcohol status follow-up for patient with OPML:~Follow-up of the lesions (pictures, biopsies, brushes), malignant transformation oversight, smoking and alcohol status follow-up (questionnaires), blood and saliva samples"
2896045|NCT03276819|Experimental|Cohort B|"Samples collection; Psychological and Sociological evaluation; Intensive and sustained smoking cessation program; Tobacco and alcohol status follow-up for patient with resectable HNSCC requiring postoperative radiotherapy or chemoradiation and which are either current smokers motivated to quit or reformed smokers within 3 months before the diagnosis of a resectable HNSCC.~Randomization 1:1, arm 1 = minimal tobacco cessation intervention, arm 2 = intensive and sustained smoking cessation program.~Smoking and alcohol status follow-up, adhesion to the smoking cessation program, tumoral follow-up, second malignant lesion, tumoral collection, blood biomarkers research"
2896046|NCT03276819|Experimental|Cohort C|Samples collection and Tobacco and alcohol status follow-up for patients with resectable HNSCC wich are not eligible to cohort B Smoking and alcohol status follow-up (questionnaires), tumoral follow-up, second malignant lesion and OPML lesion appearance oversight, tumoral collection, blood biomarkers research
2896047|NCT03276806|Experimental|SDM + decision aid + tobacco counseling|Participants will receive tobacco dependence/smoking cessation counseling by a nurse, SDM and a decision aid.
2896048|NCT03276806|Active Comparator|LDCT brochure + tobacco counseling|Participants will receive tobacco dependence/smoking cessation counseling by a nurse and a LDCT informational brochure.
2896049|NCT03276793|Experimental|MRI and behavioral assessment|Subjects will undergo an hour-long MRI scanning session, a marking for the site of planned clinical TMS stimulation and a behavioral testing battery before and after their TMS treatment course.
2896050|NCT03276780|Experimental|In vivo|Will receive 4 types of short-acting NRT medication to use in combination with the nicotine patch in each counseling session for four sessions. At the fifth session, participants will select their short acting NRT to use with the patch to make a cessation attempt.
2896051|NCT03276780|Active Comparator|Standard of care|Will receive 4 sessions of behavioral counseling around their smoking. At the fifth session, participants will select their short-acting NRT to use with the nicotine patch based on a product description of each product to make a cessation attempt.
2896052|NCT03276767|Experimental|Online intervention with SMS reminder|"Reminders will be sendt by SMS-TEXTMESSAGE if users of Endre does not log on to an assigned online session by noon on the second day."
2896053|NCT03276767|Active Comparator|Online intervention with e-mail reminder|"Reminder will be sendt by E-MAIL if users of Endre does not log on to an assigned online session by noon on the second day."
2896054|NCT03276741|No Intervention|Control Group|Routine care during labor (authorized clear liquid diet).
2896055|NCT03276741|Active Comparator|Experimental Group|"Patients in the experimental group will have a gastric soft/bland diet available, which will include lean protein, fruits, vegetables, and low-fat dairy. This will be ordered in the EMR and is a standard non-select meal, referred to as a gastric/soft bland diet that is not based on patient's preferred menu selections."
2896056|NCT03276728|Active Comparator|AMG 986 IV Dose Level A|or matching placebo
2896057|NCT03276728|Active Comparator|AMG 986 IV Dose Level B|or matching placebo
2896058|NCT03276728|Active Comparator|AMG 986 IV Dose Level C|or matching placebo
2896059|NCT03276728|Active Comparator|AMG 986 IV Dose Level D|or matching placebo
2896060|NCT03276728|Active Comparator|AMG 986 IV Dose Level E|or matching placebo
2896061|NCT03276728|Active Comparator|AMG 986 IV Dose Level F|or matching placebo
2896062|NCT03276728|Active Comparator|AMG 986 IV Dose Level G|or matching placebo
2896063|NCT03276728|Active Comparator|AMG 986 Oral Dose Level A|or matching placebo - HV
2896064|NCT03276728|Active Comparator|AMG 986 Oral Dose Level B|or matching placebo - HV
2896065|NCT03276728|Active Comparator|AMG 986 Oral Dose Level C|or matching placebo - HV
2896066|NCT03276728|Active Comparator|AMG 986 Oral Dose Level D|or matching placebo - HV
2896069|NCT03276728|Active Comparator|AMG 986 Oral Dose Level A - MAD|or matching placebo - HV
2896070|NCT03276728|Active Comparator|AMG 986 Oral Dose Level B MAD|or matching placebo - HV
2896071|NCT03276728|Active Comparator|AMG 986 Oral Dose Level C MAD|or matching placebo - HV
2896072|NCT03276728|Active Comparator|AMG 986 Oral Dose Level D MAD|or matching placebo - HV
2896073|NCT03276728|Active Comparator|AMG 986 Oral Dose Level E MAD|or matching placebo - HV
2896074|NCT03276728|Active Comparator|AMG 986 Oral Dose Level F MAD|or matching placebo - HV
2896075|NCT03276728|Active Comparator|AMG 986 Oral dose regimen or placebo-HEF|Heart failure patients with reduced ejection fraction
2896076|NCT03276728|Active Comparator|AMG 986 Oral dose regimen or placebo-REF|Heart failure patients with preserved ejection fraction
2896077|NCT03276702||Participants|St. Jude Children's Research Hospital patients with relapsed or progressive solid tumor will be asked to complete a questionnaire on two occasions and optional re-biopsy of tumor tissue.
2896078|NCT03276689|Experimental|Duloxetine|The patients will take 2 tab/d of duloxetine 60mg for 8 weeks. In the first 7 days dose of duloxetine will be 30mg/day in order to lower side effects and improve compliance. For duloxetine, the morning dose will be a sham pill.
2896079|NCT03276689|Experimental|Pregabaline|The patients will take 2 tab/d of pregabaline 150mg x 2/day for 8 weeks.The initial 7-days dose of pregabaline will 75mg x 2.
2896080|NCT03276689|Experimental|Placebo|The patients will take 2 tab/d placebo for 8 weeks.
2896081|NCT03276676|Experimental|All Enrolled participants|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine
2896082|NCT03276663|Other|Formula fed group|Formula feeding regimen
2896083|NCT03276663|No Intervention|Human milk-fed group|
2896084|NCT03276650||critically ill AOSD patients|no intervention Data collection from hospitalisation reports (administrative, biological, clinical, outcome)
2896085|NCT03276637|Experimental|Healthy Active-Duty Airmen Cohort|Whole exome sequencing (WES) will be performed on 75 ostensibly healthy, active-duty Airmen (patient-participants) who receive medical care in military Primary Care, Internal Medicine and/or Family Practice settings who in their baseline survey expressed interest in receiving WES. Military healthcare providers who have received brief genomics training will return results to the patient-participants and the WES reports will be permanently integrated into their electronic medical record.
2896086|NCT03276624|Other|patients with low EF undergoing CABG|Chronic Unstable Angina patients with low ejection fraction and a viable myocardium will undergo surgical revascularization CABG
2896087|NCT03276598|Active Comparator|Amlodipine|One of the four monotherapy treatment periods.
2896088|NCT03276598|Active Comparator|Bisoprolol|One of the four monotherapy treatment periods.
2896089|NCT03276598|Active Comparator|Hydrochlorothiazide|One of the four monotherapy treatment periods.
2896090|NCT03276598|Active Comparator|Losartan|One of the four monotherapy treatment periods.
2896091|NCT03276598|Placebo Comparator|Placebo|Placebo treatment period.
2896092|NCT03276572|Experimental|All Subjects|A single dose of 225Ac−J591 will be given to subjects with documented progressive metastatic CRPC.
2896093|NCT03276559|Experimental|EMPOWER arm|"The EMPOWER arm includes 6 mini (approximately 15 minute each) sessions in a 1-on-1 format with a same interventionist, and 2 boosters (approximately 1 hour each) if needed, which will be conducted by phone. The mini sessions will last about 1.5 hours in total.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the EMPOWER intervention within 3 months conducted in person and by phone."
2896094|NCT03276559|Placebo Comparator|Usual care arm|The usual care arm indicates only regular ICU care. Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the usual care within 3 months conducted in person and by phone.
2896095|NCT03276546|Experimental|SHARE-D decision tool use|The intervention, a shared decision-making tool ('SHARE-D'), which is a paper-based questionnaire, will be used jointly by a health professional and patient to facilitate decision-making about initiating change in physical activity or diet behaviour
2896096|NCT03276533|Experimental|Intravenous saline, dexmedetomidine and lidocaine|
2896097|NCT03276533|Experimental|Intravenous saline, dexmedetomidine, lidocaine and combination|
2896098|NCT03276533|Experimental|Intravenous saline,dexmedetomidine plus lidocaine|
2896099|NCT03276533|Experimental|Intravenous saline, dexmedetomidine combined with lidocaine|
2896100|NCT03276520|Experimental|ethyl glucuronide|subjects being screened with ethyl glucuronide
2896101|NCT03276520|Active Comparator|ethanol|subjects being screened with ethanol
2896102|NCT03276494|Experimental|intraosseous hypertonic saline|administration of intraosseous hypertonic saline
2896103|NCT03276481||Multiple Myeloma|Participants with multiple myeloma undergoing autologous hematopoietic cell transplantation (HCT) after a high dose melphalan conditioning regimen
2896104|NCT03276468|Experimental|Experimental|Combination of venetoclax, atezolizumab and obinutuzumab
2896105|NCT03276455|Experimental|Experimental|Beta-thalassemia major subjects who are 8 years age or older are transplated by autologous CD34+ cells genetically modified(autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene).
2896106|NCT03276442|Experimental|Healthy diet|'Low-fat dietary intervention' to be administered to participants
2896107|NCT03276442|Experimental|Unhealthy diet|'High-fat dietary intervention' to be administered to participants
2896108|NCT03276429||Lung Cancer patients|All patients with lung cancer that referred to a tertiary Oncology Unit.
2896109|NCT03276416||130 children with concomitant asthma and rhinitis|Baseline and one-month administration of RAPP-children, RHINASTHMA-children, C-ACT, VAS, Kiddy KINDLE, GRS. Baseline and one-month spirometry.
2896110|NCT03276390|Active Comparator|Intervention study site|Exposure to the Northwestern Medicine (TM) Hispanic Kidney Transplant Program, a culturally targeted program for Hispanic potential recipients for transplant evaluation that is implemented into the 2 study sites.
2896111|NCT03276390|No Intervention|No intervention study site|Exposure to routine transplant evaluation at the two control sites.
2896112|NCT03276377||Exposed to VKA|VKA intake Patients who have been taking VKA for at least 3 months
2896113|NCT03276377||Non-exposed to VKA|DOAC intake Patients who have been taking DOAC for at least 3 months
2896114|NCT03276364||Shock|
2896115|NCT03276351|Active Comparator|Long-Stemmed with Hybrid Fixation|Participants will receive the Long-Stemmed revision implant with Hybrid Fixation during their surgery.
2896116|NCT03276351|Experimental|Long-Stemmed with Full Cement Fixation|Participants will receive the Long-Stemmed revision implant with Full Cement Fixation during their surgery.
2896117|NCT03276351|Experimental|Short-Stemmed with Augmented Fixation|Participants will receive the Short-Stemmed primary implant with Augmented Fixation during their surgery.
2896118|NCT03276338|Experimental|Intervention|Participation in the HOLA intervention designed to prevention HIV
2896119|NCT03276338|No Intervention|Delayed-intervention|Delayed intervention with participation in HOLA intervention after follow-up data have been collected
2896120|NCT03276325|Placebo Comparator|Placebo-nalbuphine|Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
2896121|NCT03276325|Active Comparator|Dexamethasone-nalbuphine|Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
2896122|NCT03276312|Experimental|Intervention|Lipogems - local injection of autologous micro-fragmented adipose tissue
2896123|NCT03276312|No Intervention|Control|Routine clinical practice
2896124|NCT03276299|Active Comparator|test 1|six minute walking test
2896125|NCT03276299|Experimental|test 2|six minute walking test
2896126|NCT03276299|Experimental|test with encouragement|six minute walking test
2896127|NCT03276299|Active Comparator|test without encouragement|six minute walking test
2896128|NCT03276286|Experimental|Nativis Voyager|Nativis Voyager combined with SOC Radiotherapy and temozolomide
2896129|NCT03276247||Asian American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Asian American and non-pregnant/non-breastfeeding.
2896130|NCT03276247||African American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as African American and non-pregnant/non-breastfeeding.
2896131|NCT03276247||Hispanic American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Hispanic American and non-pregnant/non-breastfeeding.
2896132|NCT03276247||White non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as white and non-pregnant/non-breastfeeding.
2896133|NCT03276247||Asian American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Asian American and pregnant or breastfeeding.
2896134|NCT03276247||African American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as African American and pregnant or breastfeeding.
2896135|NCT03276247||Hispanic American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Hispanic American and pregnant or breastfeeding.
2896136|NCT03276247||White pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as White and pregnant or breastfeeding.
2896137|NCT03276221|Active Comparator|Abstinent|This group of cannabis users are agree to remain abstinent from cannabis use for 30 days.
2896138|NCT03276221|No Intervention|Monitoring|This group of cannabis users are not asked to change their cannabis use behavior.
2896139|NCT03276221|No Intervention|Non-Users|This is a group of adolescents with little to no cannabis use history and is non-randomized.
2896140|NCT03276208|Experimental|Massage Therapy and Mindfulness|Participants in the intervention group will receive two prenatal massages a week for a three-week period. They will also be enrolled in the mindfulness-based Craving to Quit® tobacco cessation program during this 3-week period.
2896141|NCT03276208|Active Comparator|Mindfulness|Participants will enroll in the mindfulness-based Craving to Quit® tobacco cessation program during the same 3-week period. A massage will be provided upon completion of the study.
2896142|NCT03276195||Familial TSC and families|Individuals with familial TSC including those with a clinical diagnosis but no genetic confirmation and individuals with a genetic diagnosis
2896143|NCT03276195||Sporadic TSC and families|Individuals with sporadic TSC including those with a clinical diagnosis but no genetic confirmation and individuals with a genetic diagnosis
2896144|NCT03276182|Experimental|cataract patients|cataract patients undergoing phacoemulsification
2896145|NCT03276169|Experimental|Left atrial appendage closure group|
2896146|NCT03276169|Other|Radiofrequency ablation group|
2896147|NCT03276169|Experimental|LAAC combined with radiofrequency ablation group|
2896148|NCT03276156|Experimental|Apatinib plus S-1|Apatinib (425/500/675/750mg,qd,p.o.) concomitantly with S-1 (80mg to 120 mg, qd,days1-14, q3w, p.o.)
2896149|NCT03276143|Experimental|BAY1213790 pre and post surgery|Post-surgery administration part (A): Single infusion in the morning following the day of Total Knee Arthroplasty (TKA) Pre-surgery administration part (B): Single infusion in the second half of the day before Total Knee Arthroplasty (TKA)
2896150|NCT03276143|Active Comparator|Enoxaparin for at least 10 days|Started either in the evening before TKA or 6-8 hours after TKA (at investigator's discretion), followed by once daily subcutaneous injections for at least 10 days and until venography is performed
2896151|NCT03276143|Active Comparator|Apixaban for at least 10 days|For at least 10 days post-surgery and until venography is performed, starting within 12 to 24 hours after TKA surgery
2896152|NCT03276130||Part A: Retrospective register study|To describe the usage of prescribed pain, anti-depressive and anti-anxiety medication during a 10-year period based on retrospective data from patient and drug registries. Population: All People with Haemophilia A and B identified through national administrative register or from local register at each treatment centre. The People with Haemophilia group will be compared against an age and gender matched control group from the general population.
2896153|NCT03276130||Part B1: Survey to HTC|The survey will be sent out to the relevant physician at each Haemophilia Treatment Centers (HTC) with direct and frequent patient contacts.
2896154|NCT03276130||Part B2: Survey to PwH|All People with Haemophilia (PwH) listed at HTCs will be invited to participate in the patient survey.
2896155|NCT03276104|Active Comparator|IOL repositioning group|
2896156|NCT03276104|Active Comparator|IOL exchange group|
2896157|NCT03276091|Experimental|COLOFIT+ Study|Personnalized motivational phone call, done by a medical physician
2896158|NCT03276078|Experimental|Aclidinium Bromide/Formoterol Fumarate 400/12μg BID|Aclidinium bromide/Formoterol Fumarate 400/12μg inhalation powder twice-daily. Oral inhalation via Genuair® dry powder inhaler (DPI).
2896159|NCT03276065|Experimental|Laser plus Standard of Care Depilation|Laser depilation to the natal cleft (pilonidal region) every 4-6 weeks for 5 treatments with either an 810nm or Nd:YAG laser dependent on Fitzpatrick skin type and tolerability. Patients and families in the intervention group will also be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free between clinic treatments.
2896160|NCT03276065|Active Comparator|Standard of Care Depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
2896161|NCT03276052|Experimental|Aclidinium Bromide 200 μg|One inhalation from the 200 μg Aclidinium Bromide inhaler.
2896162|NCT03276052|Experimental|Aclidinium Bromide 400 μg|One inhalation from the 400 μg Aclidinium Bromide inhaler.
2896163|NCT03276052|Experimental|Aclidinium Bromide 800 μg|Two inhalations from the 400 μg Aclidinium Bromide inhaler.
2896164|NCT03276039||25 patients with non-alcoholic fatty liver disease|
2896165|NCT03276039||25 patients with NAFLD and chronic HCV|
2896166|NCT03276039||20 healthy controls|
2896167|NCT03276026|Active Comparator|Control Group/Neostigmine|The control group will be the 63 patients who receive Neostigmine in a dose of 5mg, along with the anti-cholinergic glycopyrrolate 0.6mg.
2896168|NCT03276026|Active Comparator|Study Group/Sugammadex|63 patients will be given Sugammadex in a dose of 2mg/kg if the train of four twitch count is 2 and 4mg/kg if the twitch response has reached 1-2 post-tetanic counts with no twitch response to train of four.
2896169|NCT03276013|Experimental|A|Doxorubicin 60 mg/kg IV over 30 minutes on day 1 every 3 weeks up to 9 cycles in combination with Pembrolizumab (MK-3475) 200 mg IV Q3W
2896170|NCT03276000|Active Comparator|Group A|50 patients receive 200 mg oral misoprostol (Misotac; Sigma Pharm) 3h before office hysteroscopy
2896171|NCT03276000|Active Comparator|group B|50 patients receive 200 mg misoprostol (Misotac; Sigma Pharm) 3h before office hysteroscopy moistened with saline solution will be inserted in posterior fornix of vagina.
2896172|NCT03275987|Experimental|Mammography treatment|Mammography direct mail coupled with a financial incentive
2896173|NCT03275987|Active Comparator|Mammography control/delayed intervention|Usual care (for 15 months); Mammography direct mail coupled with financial incentive (after 15 months)
2896174|NCT03275987|Experimental|Colonoscopy treatment|Colonoscopy direct mail coupled with a financial incentive
2896175|NCT03275987|Active Comparator|Colonoscopy control/delayed intervention|Usual care (for 15 months); Colonoscopy direct mail coupled with financial incentive (after 15 months)
2896176|NCT03275974|Experimental|Treatment|Patients receive 11C-glutamine IV and undergo PET imaging over 120 minutes. Beginning 2 hours to 7 days after 11C-glutamine PET, patients receive fluorine F 18 L-glutamate derivative BAY94-9392 IV and also undergo PET imaging over 120 minutes.
2896177|NCT03275961|Experimental|Depressed Subjects|Subjects will undergo an 8 week behavioral program with Stress Management and Resiliency Training.
2896178|NCT03275948|Experimental|whole grain|
2896179|NCT03275948|Other|refrence|white wheat based product
2896180|NCT03275935||Training Arm|Patients that were given training in regards to proper inhalation technique of Rotahalers
2896181|NCT03275922|Other|Run-in - ZNS - Placebo - OLE|After Run-in period, subjects will be randomized to ZNS followed by placebo ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).
2896182|NCT03275922|Other|Run-in - Placebo - ZNS - OLE|After Run-in period, subjects will be randomized to placebo ZNS followed by ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).
2896183|NCT03275909|Experimental|Study procedure|An experimental group the psychological treatment includes 50 sessions of integrated psychological therapy (IPT) (focused on attentional skills training, social perception skills training, verbal communication skills, social skills training, interpersonal problems solving skills) and 10 sessions of specific emotional management therapy (EMT), designed for this research and based on the contents developed by Hodel, Kern and Brenner.
2896184|NCT03275909|No Intervention|Treatment as usual|The treatment as usual is pharmacological treatment and activities in a Day Care Center.
2896185|NCT03275896|Experimental|Descemet Membrane Transplantation|Patients with severe, symptomatic Fuch's Endothelial Dystrophy (FED) will be offered Descemet Membrane Transplantation (DMT) for their condition.
2896186|NCT03275870|Experimental|Hydroxychloroquine treatment|Hydroxychloroquine 200mg BID for 6 months
2896187|NCT03275857|Other|Cisplatin|
2896188|NCT03275844||Group 1|Children with congenital heart disease
2896189|NCT03275844||Group 2|Control healthy subjects
2896190|NCT03275831|Active Comparator|Intrasite Gel|Intrasite Gel is an effective method for hydrating dry necrotic and sloughy wounds. It is an amorphous gel that contains 85% water, and gently increases the moisture level within the wound, encouraging moist wound healing through autolytic debridement.
2896191|NCT03275831|Experimental|PluroGel Burn and Wound Dressing|PluroGel contains a surfactant-based cleanser to assist wound debridement and cleansing
2896192|NCT03275818|Experimental|nab-paclitaxel|"nab-paclitaxel (ABRAXANE) will be administered as follows:~Age ≥ 21 and ≤ 80 years: 125 mg/m2 days 1, 8 and 15 in cycles of 28 days~Age ≥ 6 months and ≤ 20 years: 240 mg/m2 days 1, 8 and 15 in cycles of 28 days"
2896193|NCT03275805|Active Comparator|12 weeks Pavlik Treatment Arm|This arm will receive 12 weeks of full-time Pavlik Harness treatment. Patients will begin the 12-week regiment around 6 weeks of age.
2896194|NCT03275805|Experimental|6 weeks Pavlik Treatment Arm|This arm will receive 6 weeks of full-time Pavlik treatment. Patients will begin the 6-week regiment around 6 weeks of age. Patients will not be eligible for this arm, or study inclusion if they do not have acceptable findings at 6-week follow up.
2896230|NCT03275545||Anorexia Nervosa, Weight Restored|Individuals with a recent diagnosis of anorexia nervosa (within the past 6 months), who currently have their weight in a healthy range (BMI > or = 18.5 kg/m2)
2896231|NCT03275545||Non-eating disorder Control|Individuals without a history of an eating disorder and no current DSM-5 psychiatric diagnoses.
2896195|NCT03275792|Experimental|Admission/Intravascular Volume Expansion|"Infusion of 40 mL/kg of 0.9% normal saline (NS) IV over 60 minutes~0.9% NS with 5% dextrose at 150% of standard maintenance volume~If urine output is <0.5 ml/kg/hr over a 12-hour period (AKI Stage 2), repeat 20 mL/kg bolus or boluses of 0.9% NS will be infused as long as there are no signs of central volume overload~Oral fluids ad lib along with strict input/output documentation~Fluids will be restricted if: A) Anuria for 12 hours OR B) Evidence of fluid overload~Daily laboratory tests and in-person assessment until inpatient discharge criteria reached:~A) 2 - 4 days since symptom onset AND rising platelet count (>5% increase) documented over 48 hours in a clinically well child B) ≥5 days since symptom onset AND stable platelet count (<5% decrease) documented over 48 hours in a clinically well child~Repeat hematocrit, platelet, renal function 24 and 72-hours post-discharge."
2896196|NCT03275792|Active Comparator|Outpatient Observation|"Following standard emergency department (ED) care [volume status assessed; dehydration corrected employing oral rehydration in children with mild to moderate dehydration (most common); IV if severe (rarely)], children are discharged with saline lock IV (routine procedure across Canadian pediatric EDs).~Oral fluids (preferably electrolyte maintenance solutions) ad lib following ED discharge~Additional health assessments as required~Daily blood tests at a local laboratory with results conveyed daily to the site-investigator until outpatient discharge criteria achieved; no in-person assessment given logistics (i.e. distance), impact on family, and mirroring of standard practice A) 2 - 4 days since symptom onset AND rising platelet count (>5% increase) documented over 48 hours in a clinically well child B) ≥5 days since symptom onset AND stable platelet count (<5% decrease) documented over 48 hours in a clinically well child"
2896197|NCT03275779|Experimental|Low Frequency Condition|Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
2896198|NCT03275779|Experimental|High Frequency Condition|Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
2896199|NCT03275766|Active Comparator|DLPFC facilitatory|"repetitive transcranial magnetic stimulation (rTMS) of 15 Hz over left DLPFC~usually effective in depression treatment, probably no specific effect on psychomotor slowing"
2896200|NCT03275766|Experimental|preSMA/SMA inhibitory|"repetitive transcranial magnetic stimulation (rTMS) of 1 Hz over preSMA/SMA~should inhibit overactive premotor cortices"
2896201|NCT03275766|Experimental|preSMA/SMA facilitatory|"intermittend theta burst stimulation (iTBS) over preSMA/SMA~should facilitate neural activity within premotor cortices"
2896202|NCT03275766|Sham Comparator|sham TMS|"sham rTMS with a placebo coil over occipital cortex~should have no effect at all (no transcranial magnetic stimulation, only sound)"
2896203|NCT03275753||Normal Population|VA of 20/25 or better in the study eye with no prior diagnosis of any retinal or ocular diseases
2896204|NCT03275753||Early Dry AMD Population|VA of 20/40 or better in the study eye with clinical diagnosis of early dry AMD
2896205|NCT03275753||Intermediate Dry AMD Population|VA of 20/40 or better in the study eye with clinical diagnosis of intermediate dry AMD
2896206|NCT03275753||Advanced Dry AMD Population|Clinical diagnosis of advanced dry AMD in the study eye
2896207|NCT03275740|Experimental|PF-06755347|
2896208|NCT03275740|Placebo Comparator|Placebo|
2896209|NCT03275727|Experimental|A - iACT-BC experimental group|
2896210|NCT03275727|Other|B - Waiting list control group|
2896211|NCT03275714|Active Comparator|People With a Bipolar Affective Disorder|
2896212|NCT03275714|Active Comparator|Control subjects without a psychiatric disorder|
2896213|NCT03275701|Other|Triumeq|Single Arm, Open Label
2896214|NCT03275688||Stage 1 Lung Cancer (Case)|These are the participants with identified stage 1 lung cancer.
2896215|NCT03275688||Type 1 Control|These are participants who have similar clinical characteristics as our cases, but do not have any history of cancer.
2896216|NCT03275688||Type 2 Control|These are housemates of the participants with stage 1 lung cancer (cases).
2896217|NCT03275675||Patients with cancer chemotherapy|This study project is designed to evaluate the satisfaction of patients undergoing oral chemotherapy treated for a cancer and whose treatment is provided by their community pharmacies.
2896218|NCT03275662|Experimental|Fiber Group|Participants are asked to increase their usual dietary fiber intake by 20 grams/day.
2896219|NCT03275662|Experimental|Fermented Foods Group|Participants are asked to consume 6 servings of fermented foods per day.
2896220|NCT03275636|Experimental|Haploidentical donor|
2896221|NCT03275636|Experimental|partially matched unrelated donor|unrelated donor with a single allele or antigen mismatch at HLA-A, -B, -C, or -DRB1 and no concurrent DQB1 mismatch (9/10) shown by confirmatory typing
2896222|NCT03275623|Active Comparator|Antibiotic treatment|Standard prenatal care with treatment for any urine culture with growth of 1- 100,000 CFU of any organism.
2896223|NCT03275623|Active Comparator|No antibiotic treatment|Standard prenatal care without treatment for any urine culture with growth of 1- 100,000 CFU of any organism.
2896224|NCT03275597|Experimental|SBRT followed by Durvalumab+Tremelimumab|"Therapeutic Interventions Stereotactic Body Radiotherapy (SBRT) to all sites of disease between 30 and 50 Gy in five fractions administered over two weeks.~Investigational Product(s), Dose, and Mode of Administration: to begin 7 days (+/- 1 day) after radiation Durvalumab 1500 mg via infusion Q4W (equivalent to 20 mg/kg Q4W) until disease progression in patients > 30 kg Tremelimumab 75 mg via infusion Q4W (equivalent to 1 mg/kg Q4W) for up to 4 doses/cycles in patients >30 kg Weight-based dosing utilized for patients ≤30 kg; durvalumab 20 mg/kg Q4W and tremelimumab 1 mg/kg Q4W"
2896225|NCT03275584|Experimental|Main arm|N-13 ammonia intravenous injection; 2 injections, 3-7 MBq/kg per injection
2896226|NCT03275571|Experimental|cCBT intervention|Over the course of 9 weeks, 30 min online sessions, once per week, with a fictive therapist.
2896227|NCT03275558|Active Comparator|Axitinib|A single dose of Axitinib - 1 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
2896228|NCT03275558|Active Comparator|Sunitinib|A single dose of Sunitinib- 5 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
2896229|NCT03275558|Active Comparator|Pazopanib|A single dose of Pazopanib-5 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
2896232|NCT03275519|Active Comparator|Antibiotics prophylaxis cohort|Subjects were prescribed prophylactic antibiotics after the hypospadias surgery.
2896233|NCT03275519|Active Comparator|Antibiotic-sparing cohort|Subjects were not prescribed prophylactic antibiotics after the hypospadias surgery.
2896234|NCT03275506|Experimental|Pembrolizumab + Chemo|"Pembrolizumab (ketruda) 200 mg then carboplatin (AUC 5 or 6) and paclitaxel (175mg/m²), q3 weeks.~6 cyles 15 month total"
2896235|NCT03275506|Active Comparator|CHEMO alone|carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), q3 weeks. 6 cyles 15 month total
2896236|NCT03275493|Experimental|Experimental: Cohort 1|This cohort will determine the safety and efficacy of humanized CD19 CAR-T cells for CD19+ acute lymphoblastic leukemia
2896237|NCT03275493|Experimental|Experimental: Cohort 2|This cohort will determine the safety and efficacy of humanized CD19 CAR-T cells with CRS suppression technology for CD19+ acute lymphoblastic leukemia.
2896238|NCT03275467|Experimental|Faecal microbiota transfer (FMT)|Suspended stool from a healthy donor
2896239|NCT03275454|Experimental|BIVV009|Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009 and participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009 up to Day 133.
2896240|NCT03275441||Adult patients|Adult patients attending hospital for clinical visual electrophysiology.
2896241|NCT03275428||THRIVE group|Patients receiving non-intubated thoracic surgery for lung nodule resections using intravenous sedation and transnasal humidified rapid-insufflation ventilator exchange
2896242|NCT03275428||Double lumen group|Patients receiving non-intubated thoracic surgery for lung nodule resections using general anesthesia and double lumen endobronchial tube
2896243|NCT03275415|Active Comparator|Experimental|Curosurf + budesonide
2896244|NCT03275415|Placebo Comparator|Placebo|Curosurf + saline
2896245|NCT03275402|Experimental|131I-burtomab|"One treatment cycle of 131I-burtomab consists of 2 doses; 2mCi at week 1 and 50mCi at week 2). First cycle is initiated right after confirmation of eligibility at week 1. At week 6 the participant will be evaluated for safety and if eligible, receive a second cycle of 131I-burtomab.~Secondary efficacy endpoints will be evaluated at week 26 and primary efficacy endpoint will be evaluated at week 156."
2896246|NCT03275389|Experimental|D-SUIV Adjuvanted Group 1|Subjects will receive one dose of D-SUIV Formulation 1 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 2 at Month 14
2896247|NCT03275389|Experimental|D-SUIV Adjuvanted Group 2|Subjects will receive one dose of D-SUIV Formulation 2 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 1 at Month 14
2896248|NCT03275389|Experimental|D-SUIV Adjuvanted Group 3|Subjects will receive one dose of D-SUIV Formulation 1 at Day 1, one dose of D-SUIV Formulation 2 at Day 57 and one booster dose of D-SUIV Formulation 3 at Month 14
2896249|NCT03275389|Experimental|D-SUIV Adjuvanted Group 4|Subjects will receive one dose of D-SUIV Formulation 4 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 5 at Month 14
2896250|NCT03275389|Experimental|D-SUIV Adjuvanted Group 5|Subjects will receive one dose of D-SUIV Formulation 5 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 4 at Month 14
2896251|NCT03275389|Experimental|D-SUIV Adjuvanted Group 6|Subjects will receive one dose of D-SUIV Formulation 4 at Day 1, one dose D-SUIV Formulation 5 at Day 57 and one booster dose of D-SUIV Formulation 6 at Month 14
2896252|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 1|Subjects will receive one dose of D-SUIV Formulation 7 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 8 at Month 14
2896253|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 2|Subjects will receive one dose of D-SUIV Formulation 8 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 7 at Month 14
2896254|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 3|Subjects will receive one dose of D-SUIV Formulation 7 at Day 1, one dose D-SUIV Formulation 8 at Day 57 and one booster dose of D-SUIV Formulation 9 at Month 14
2896255|NCT03275389|Active Comparator|IIV4 Group|Subjects will receive one dose of Fluarix Quadrivalent at Day 1, one dose of Placebo at Day 57 and one dose of Fluarix Quadrivalent at Month 14
2896256|NCT03275376|Experimental|Statin treated group|
2896257|NCT03275376|Placebo Comparator|Control group|
2896258|NCT03275363||Cognitively normal controls (CNC)|No subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
2896259|NCT03275363||Subjective cognitive decline (SCD)|Subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
2896260|NCT03275363||Mild cognitive impairment (MCI)|Subjective memory complaints Low HK-MoCA Normal instrumental ADL All interventions as described
2896261|NCT03275363||Alzheimer's dementia|Subjective memory complaints Low HK-MoCA Poor instrumental ADL Probable Alzheimer's disease All interventions as described except EEG with ERP
2896262|NCT03275363||Vascular dementia|Subjective memory complaints Low HK-MoCA Poor instrumental ADL Related to stroke / cerebrovascular disease All interventions as described except EEG with ERP
2896263|NCT03275350|Active Comparator|XR-NTX|Extended-release naltrexone
2896264|NCT03275350|Active Comparator|TAU|Treatment as usual
2896265|NCT03275337|Experimental|Continuous Theta Burst-Cerebellar|Repetitive Transcranial Magnetic Stimulation (rTMS) Continuous theta burst stimulation, a form of repetitive transcranial magnetic stimulation, over the cerebellar target will be performed with stereotaxic neuronavigation. A standard protocol of 600 pulses will be employed.
2896266|NCT03275337|Experimental|Intermittent Theta Burst-Cerebellar|Repetitive Transcranial Magnetic Stimulation (rTMS) Intermittent theta burst stimulation, a form of repetitive transcranial magnetic stimulation, the cerebellar target will be performed with stereotaxic neuronavigation. A standard protocol of 600 pulses will be employed.
2896267|NCT03275337|Active Comparator|Continuous Theta Burst-Occipital|Repetitive Transcranial Magnetic Stimulation (rTMS) Continuous theta burst stimulation, a form of repetitive transcranial magnetic stimulation, an occipital cortex control site will be performed with stereotaxic neuronavigation. A standard protocol of 600 pulses will be employed.
2896268|NCT03275324||Enrolled patients|Surgical patients meeting enrollment criteria
2896362|NCT03274635|Experimental|Joint Immediate Contingent Reward, Money|Will receive daily performance-contingent monetary compensation with Amazon gift card, with additional compensation contingent on pedaling activity of co-worker participant.
2896269|NCT03275285|Experimental|Isatuximab + Carfilzomib + Dexamethasone (IKd)|Isatuximab (intravenous) on day 1, 8, 15 and 22 of 1st cycle, then on day 1 and 15 of subsequent cycles in combination with carfilzomib (intravenous) on day 1, 2, 8, 9, 15 and 16 + dexamethasone (intravenous or by mouth [po]) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
2896270|NCT03275285|Active Comparator|Carfilzomib + Dexamethasone (Kd)|Carfilzomib (intravenous) on day 1, 2, 8, 9, 15, 16 + dexamethasone (intravenous or po) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
2896271|NCT03275272|Other|level of IGF-1 in infant|Measurment of blood level of IGF-1 In infants
2896272|NCT03275259|Experimental|Extracorporeal shock waves|Composed of 30 female patients with glandular lipodystrophy in the buttocks and posterior thigh and fat located in abdomen and flanks that received the treatment of extracorporeal shock waves with energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
2896273|NCT03275246|Experimental|Total knee arthroplasty|Patients undergoing total knee arthroplasty
2896274|NCT03275207|Placebo Comparator|control group|an equal volume of saline
2896275|NCT03275207|Experimental|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
2896276|NCT03275194|No Intervention|Control group|After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm does not receive additional treatment and the procedure will be finished.
2896277|NCT03275194|Experimental|HIPEC group|After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm receive a HIPEC procedure with cisplatin and doxorubicin.
2896278|NCT03275181||Prostate cancer patient/survivor with ADT history|Prostate cancer patients or survivors who have a treatment history that includes androgen deprivation therapy. This includes 1) orchiectomy (surgical castration), 2) luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or Gonadotrophin-releasing hormone (GnRH) agonists), 3) LHRH antagonist, 4) CYP17 inhibitor, or 5) anti-androgen.
2896279|NCT03275181||Prostate cancer patient/survivor without ADT history|Prostate cancer patients or survivors who have never been treated with androgen deprivation therapy.
2896280|NCT03275181||Control|Individuals with no history of prostate caner androgen deprivation therapy. Free of known clinical cardiovascular disease
2896281|NCT03275168|Active Comparator|Control|Participants will receive individual evidence-based STI/HIV prevention intervention (Sister to Sister Teen for female participants and Focus on the Future for male participants) for STI prevention
2896282|NCT03275168|Experimental|Intervention|Participants will receive individual evidence-based STI/HIV prevention intervention (Sister to Sister Teen for female participants and Focus on the Future for male participants) for STI prevention plus dyadic counseling and negotiation practice with partner
2896283|NCT03275155||AFDAS|patients without history of atrial fibrillation before the qualifying stroke or transient ischemic attack who are diagnosed with atrial fibrillation during the 14 days of monitoring
2896284|NCT03275155||KAF|atrial fibrillation known before the stroke or transient ischemic attack
2896285|NCT03275155||NSR|patients without a history of atrial fibrillation who do not develop atrial fibrillation during the 14 days of cardiac monitoring
2896286|NCT03275142|Experimental|Icare Applanation|"Evaluation of corneal stability post-applanation with Icare tonometer via pre and post applanation keratometry readings with IOL Master, topography with Pentacam, fluorescein corneal staining. Patient's OD and OS are randomized into study or control, then undergo applanation with Icare. Investigator is masked as to which eye has undergone applanation."
2896287|NCT03275142|Active Comparator|No ICare Applanation|"Evaluation of corneal stability post-applanation with Icare tonometer via pre and post applanation keratometry readings with IOL Master, topography with Pentacam, fluorescein corneal staining. Patient's OD and OS are randomized into study or control, then undergo applanation with Icare. Investigator is masked as to which eye has undergone applanation."
2896288|NCT03275129|Experimental|Ultrasound assessment of heart and lungs|Patients (over the age of 18) who will be undergoing surgery for hip fracture repair. These patients will receive an ultrasound of the heart and lungs to determine whether or not information gained from this ultrasound assessment is significant enough to influence their anesthetic care plan.
2896289|NCT03275116|Active Comparator|Twice daily dual bronchodilation|Twice daily Aclidinium Bromide/Formoterol Fumarate 340/12 mcg during 4 days
2896290|NCT03275116|Active Comparator|Once daily single bronchodilation|Once daily Tiotropium 'Respimat' 5 mcg during 4 days
2896291|NCT03275103|Experimental|Dose Escalation for BFCR4350A|Study drug will be administered intravenously on a 21-day cycle. Initially, cohorts will consist of 1 participant each. Subsequently will consist of at least 3 participants, unless dose-limiting toxicities (DLTs) are observed in the first 2 prior to enrollment of a third participant. For each cohort, treatment with the first dose will be staggered such that the second participant enrolled in the cohort will receive study drug at least 72 hours after the first participant receives it to allow assessment of any severe and unexpected acute or subacute drug or infusion-related toxicities; dosing in subsequent participants in each cohort will be staggered by at least 24 hours.
2896292|NCT03275103|Experimental|Expansion Phase for BFCR4350A|Participants exhibiting acceptable safety and evidence of clinical benefit will be administered study drug every 21 days up to a maximum of 17 cycles until objective disease progression is documented or unacceptable toxicity, whichever occurs first.
2896293|NCT03275090|Active Comparator|Intralipid injectable product (MOFS)|20 preterm infants receive parenteral nutrition containing 20% MOFS lipid emulsion (Smoflipid ®)
2896294|NCT03275090|No Intervention|Pure Soybean oil lipid emulsion|20 preterm infants with sepsis receive the usual parenteral nutrition containing soybean oil based lipid emulsion (20% Intralipid ®) at daily increasing doses guided by serum triglycerides.
2896295|NCT03275077||Controls|Normal Healthy Volunteers
2896296|NCT03275077||ESRD patients|Patients with ESRD who have not received hemodialysis. Patients with known bleeding disorders, coexisting liver diseases, those who were on antiplatelet or anticoagulant therapy and patients who had received red blood cells, fresh frozen plasma or platelet transfusions in the past three months were excluded from the study.
2896297|NCT03275064|Experimental|LNA043|
2896298|NCT03275064|Placebo Comparator|Placebo|
2896299|NCT03275051|Experimental|All subjects|Subjects who have received treatment with GSK2696277 in and completed study TIGET-BTHAL will be included in this study. Subjects received GSK2696277 injection administered intraosseously in TIGET-BTHAL study. No study treatment will be administered in this study (207757).
2896300|NCT03275038|No Intervention|Control group|Maintain the original life style
2896301|NCT03275038|Experimental|Tai-Chi exercise group|Receive three one-hour Tai Chi exercise sessions weekly for 24 weeks, supervised for the first 12 weeks and unsupervised for the next 12 weeks
2896302|NCT03275038|Experimental|Aerobic exercise group|Receive three one-hour aerobic exercise sessions weekly for 24 weeks, supervised for the first 12 weeks and unsupervised for the next 12 weeks
2896303|NCT03275025|Experimental|YRA-1909 low dose|
2896304|NCT03275025|Experimental|YRA-1909 medium does|
2896305|NCT03275025|Experimental|YRA-1909 high dose|
2896306|NCT03275025|Placebo Comparator|YRA-1909 Placebo|
2896307|NCT03275012|Experimental|Group 1|Gabapentin + Morphine
2896308|NCT03275012|Placebo Comparator|Group 2|Placebo + Morphine
2896309|NCT03274999|Experimental|TrueTear Intranasal Application|Intranasal application of TrueTear device for approximately 3 minutes at Day 0 and Day 14 (±11 days)
2896310|NCT03274999|Active Comparator|TrueTear Extranasal Application|Extranasal application (control) of TrueTear device for approximately 3 minutes at Day 0 and Day 14 (±11 days)
2896311|NCT03274973||Zomacton|
2896312|NCT03274960|Experimental|Griess, Culture and antibiotic|Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
2896313|NCT03274960|No Intervention|No Griess, culture, treatment|No Griess reagents added in urine sample, no culture test with blood agar and no treatment with antibiotic for every positive results every trimester
2896314|NCT03274947|Active Comparator|Hypothesis 2 Protocol 2 Low dose TMS|Low level cerebellar TMS. Delivered once per day for 3 days.
2896315|NCT03274947|Active Comparator|Hypothesis 2 Protocol 2 High dose TMS|High level cerebellar TMS. Delivered twice per day for 5 days.
2896316|NCT03274947|Sham Comparator|Hypothesis 2 Protocol 2 Sham|Sham cerebellar TMS. Delivered twice a day for 5 days.
2896317|NCT03274947|Active Comparator|Hypothesis 2 Protocol 1 Cerebellar TMS|Cerebellar TMS at 10Hz, 250 pulses.
2896318|NCT03274947|Sham Comparator|Hypothesis 2 Protocol 1 Sham|Sham cerebellar TMS
2896319|NCT03274934|Experimental|Face-to-face and online support group|Behavioral: Structured web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is the five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach. In addition, they meet their coach twice in the face-to-face meetings. The aim of the meetings is to increase adolescents' internal motivation and thereby participation in the program.
2896320|NCT03274934|Experimental|Only online support group|Behavioral: web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is a five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach.
2896321|NCT03274934|Experimental|Control group|Behavioral: No intervention, school counseling as usual
2896322|NCT03274921||Cardiovascular complication|patients with history of CV complications in the past 4 years had biological determination
2896323|NCT03274921||No cardiovascular complication|patients free of any CV complications had biological determination
2896324|NCT03274908||Group|
2896325|NCT03274895|Experimental|PHMB 0.08% plus placebo|16 drops each in a day for 5 days,8 drops each in a day for 7 days,6 drops each in a day for 7 days and 4 drops each in a day up to clinical resolution
2896326|NCT03274895|Active Comparator|PPHMB 0.02% plus propamidine 0.1%|16 drops each in a day for 5 days,8 drops each in a day for 7 days,6 drops each in a day for 7 days and 4 drops each in a day up to clinical resolution
2896327|NCT03274882|Experimental|S95005|
2896328|NCT03274869||Scrub typhus without cardiovascular complications|Any patients with the scrub typhus infection without cardiovascular complication will be enrolled as a positive control group during admission and clinically followed by 1 year after discharge
2896329|NCT03274869||Scrub typhus with cardiovascular complication|Any patients with the scrub typhus infection with cardiovascular complication will be enrolled as a comparison group during admission and clinically followed by 1 year after discharge
2896330|NCT03274856|Other|Treatment Sequence 1|GLWL-01 (450mg) twice a day/ Placebo
2896331|NCT03274856|Other|Treatment Sequence 2|Placebo / GLWL-01 (450mg), twice a day
2896332|NCT03274843|Experimental|Patient with stroke|
2896333|NCT03274830||aneXys|cases with aneXys cup and Mathys hip stem
2896334|NCT03274817|Active Comparator|Escitalopram|Escitalopram (lexapro) is presently the most widely used selective serotonin reuptake inhibitor (SSRI) antidepressant.
2896335|NCT03274817|Active Comparator|Venlafaxine|Venlafaxine is a norepinephrine, serotonin and dopamine reuptake inhibitor antidepressant.The specific form of venlafaxine which will be employed is Effexor XR (venlafaxine hydrochloride extended release capsules)
2896336|NCT03274817|Placebo Comparator|Placebo|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
2896398|NCT03274414|Experimental|Unresectable paranasal sinus/nasal cavity malignancy|
2896723|NCT03272009|Experimental|Treatment G|oral EYP001a plus subcutaneous injection of Peg-INFα2a
2896337|NCT03274804|Experimental|Single arm, prospective, open-label trial|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22) together with maraviroc administered perorally on day 1 to 21 of each cycle (d1-21; qd22).
2896338|NCT03274791||Healthy subjects|"Healthy non-smoking subjects were never smokers with normal spirometry and did not have a history of lung disease or chronic respiratory symptoms.~Information about respiratory symptoms and comorbidities were collected. Healthy subjects underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
2896339|NCT03274791||COPD Never smokers|"Never smokers referred to subjects who had never smoked Airflow limitation in COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio <70% and FEV1 reversibility of <12% and 200 mL from baseline values after inhalation of 400 µg of Salbutamol.~Information about respiratory symptoms and comorbidities were collected. Never smoking subjects with COPD underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
2896340|NCT03274791||COPD Smokers|"Smokers were defined as persons who had smoked > 20 packs of cigarettes in a lifetime and who continue smoking every day.~Airflow limitation in COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio <70% and FEV1 reversibility of <12% and 200 mL from baseline values after inhalation of 400 µg of Salbutamol.~Information about respiratory symptoms and comorbidities were collected. Smoking subjects with COPD underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
2896341|NCT03274778|Experimental|Ruxolitinib|Oral administration of Ruxolitinib 20mg BID for 28 consecutive days
2896342|NCT03274765||Women with ovarian stimulation|Women followed in the MAP center of the Rennes University Hospital for ovarian stimulation monitoring Dosage of oestradiol
2896343|NCT03274752|Experimental|Paroxetine|Paroxetine 20mg QD per os for 12 weeks followed by 10mg for one additional week
2896344|NCT03274752|Placebo Comparator|Placebo|Placebo oral capsule QD per os for 13 weeks
2896345|NCT03274739||Pregnant women|
2896346|NCT03274713|Experimental|Electro-acupuncture group|After recruiting, patients are assigned to the electro-acupuncture group by randomization,and then receive electro-acupuncture treatment.Both treatments consist of 24 sessions of 30 minutes duration, administered over 8 weeks (usually three sessions per week). Participants in both groups will be evaluated at baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks.
2896347|NCT03274713|Experimental|Manual acupuncture group|After recruiting, patients are assigned to the manual acupuncture group by randomization,and then receive manual acupuncture treatment.Both treatments consist of 24 sessions of 30 minutes duration, administered over 8 weeks (usually three sessions per week). Participants in both groups will be evaluated at baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks.
2896348|NCT03274700|Active Comparator|Group 1: Patients receive tamsulosin|"Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.e foll The cases will be followed up as thowing:~In the first month: abdominal ultrasonography every week, KUB abdomen and pelvis for radiopaque stones.~At the end of the second month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones.~At the end of the third month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones, MSCT abdomen and pelvis for radiolucent stones."
2896349|NCT03274700|Placebo Comparator|Patients receive placebo.|"Patients who will receive placebo up to 8 weeks duration.The cases will be followed up as following:~In the first month: abdominal ultrasonography every week, KUB abdomen and pelvis for radiopaque stones.~At the end of the second month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones.~At the end of the third month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones, MSCT abdomen and pelvis for radiolucent stones."
2896350|NCT03274687|Experimental|Arm I (conventional radiation therapy)|Patients undergo conventional radiation therapy for 37 fractions over 7 weeks in the absence of disease progression or unacceptable toxicity. Patients may also receive androgen deprivation therapy for up to 6 months as per doctor recommendation.
2896351|NCT03274687|Experimental|Arm II (hypofractionated radiation therapy|Patients undergo hypofractionated radiation therapy for 25 fractions over 5 weeks in the absence of disease progression or unacceptable toxicity. Patients may also receive androgen deprivation therapy for up to 6 months as per doctor recommendation.
2896352|NCT03274674|Experimental|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Apply once a week and one month after the end of the injections, the patient will be called to the control.
2896353|NCT03274674|Active Comparator|I-PRF and Microneedling|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
2896354|NCT03274661|Experimental|Pembrolizumab 200 mg Q3W|Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
2896355|NCT03274648|Experimental|vegetarian diet|vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
2896356|NCT03274648|Experimental|Habitual diet + oral butyrate|habitual diet supplemented with 2.4g/day of oral butyrate
2896357|NCT03274648|Active Comparator|Habitual diet|habitual diet without supplementation
2896358|NCT03274635|Active Comparator|Usual Delayed Compensation, Money|Will receive delayed monetary compensation with Amazon gift card, non performance-contingent.
2896359|NCT03274635|Active Comparator|Usual Delayed Compensation, Food|Will receive delayed compensation with food-based gift card, non performance-contingent.
2896360|NCT03274635|Experimental|Individual Immediate Contingent Reward, Money|Will receive daily performance-contingent monetary compensation with Amazon gift card.
2896361|NCT03274635|Experimental|Individual Immediate Contingent Reward, Food|Will receive daily performance-contingent food-based gift card.
2896724|NCT03272009|Experimental|Treatment H|oral EYP001a plus subcutaneous injection of Peg-INFα2a
2896363|NCT03274635|Experimental|Joint Immediate Contingent Reward, Food|Will receive daily performance-contingent monetary compensation with food gift card, with additional compensation contingent on pedaling activity of co-worker participant.
2896364|NCT03274622|Experimental|Impact Parent Training|Parents receive 12 2-hour sessions with a Speech Language pathologist coaching them in the implementation of the Impact intervention
2896365|NCT03274622|Placebo Comparator|No Impact|No parent coaching is provided
2896366|NCT03274609||Suspected lung cancer|"Patients referred as part of a first diagnostic evaluation of newly detected pulmonary lesion(s) or when an indication for an invasive diagnostic procedure is found during follow-up of earlier detected pulmonary lesion.~Patients identified during per protocol CT imaging follow-up of known lesions when growth of the lesion is found and an indication for biopsy is determined by the treating physician and/or multidisciplinary board.~Patients identified when referred for surgical biopsy in case of nodule location inaccessible for CT-guided TTNA.~These will be subjected to a combined approach of modalities with the main intervention being augmented fluoroscopy guided virtual navigation.)"
2896367|NCT03274596|Active Comparator|Treatment A|Group A: received 12.5 IU of vitamin E orally every 12 hours, from 72 h of birth to 28 days old.
2896368|NCT03274596|Placebo Comparator|Treatment B|Group B: received 12.5 IU of placebo orally every 12 hours, from 72 hours of birth to 28 days old.
2896369|NCT03274583||Study Group|Patients being treated in the wards of Heart Center and Acute Internal Medicine of Turku University Hospital, Turku Finland between April and September 2017 with atrial fibrillation as the prevalent rhythm.
2896370|NCT03274583||Control group|Patients being treated in the wards of Heart Center and Acute Internal Medicine of Turku University Hospital, Turku Finland between April and September 2017 with sinus rhythm as the prevalent rhythm.
2896371|NCT03274557|Active Comparator|Radiofrequency microtenotomy|Treatment of Achilles tendinose with radio-frequency microtenotomy
2896372|NCT03274557|Active Comparator|Phusical therapy|Supervised eccentric training
2896373|NCT03274544|Experimental|PROLUNG|Herbal formula treatment PROLUNG in additional to current therapy
2896374|NCT03274531|Experimental|Interventional Arm|Immediate referral of hypertensive patients to the attending physician based on automated office blood pressure measurements
2896375|NCT03274531|No Intervention|Observational Arm|Repeated automated office blood pressure measurements and referral of hypertensive patients to the attending physician after completion of the trial
2896376|NCT03274518|Active Comparator|Online Hemodiafiltration|"The olHDF technique combines diffusion with high convection rates in which the dialysis fluid, free of toxins and pyrogens, is used to prepare the replacement fluid.~The online module of dialysis machine prepares the replacement fluid by a cold sterilization process. There is a cross-flow water preparation, in order to avoid the accumulation of possible contaminants. The addition of bicarbonate and acid solutions to water follows the process. Next, the ready-for-infusion dialysis solution is passed through another ultrafilter prior to being infused into patients."
2896377|NCT03274518|Experimental|Expanded Hemodialysis|More recently, membranes with high cutoff values, but with tight pore size distribution have been developed. The main concept is to keep both cutoff and retention onset values close to each other, but with a cutoff value lower than of albumin. This should allow removal of middle-to-high weight range uremic toxins, with very low albumin leak. Thus, these membranes, denominated high retention onset (HRO) membranes, allow performing both diffusive and convective processes in a conventional hemodialysis machine.
2896378|NCT03274505||Stroke patients|Patients seen by a rehabilitation physician at a routine 3 months' post-stroke examination
2896379|NCT03274505||TIA patients|"Patients seen by a stroke specialist at the SOS TIA examination"
2896380|NCT03274492|Experimental|R-CHP plus Vincristine Placebo plus Polatuzumab Vedotin|Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) intravenously (IV), placebo for vincristine IV, rituximab 375 milligrams per square meter (mg/m^2) IV, cyclophosphamide 750 mg/m^2 IV, and doxorubicin 50 mg/m^2 IV on Day 1 and prednisone 100 milligrams per day (mg/day) orally (PO) on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m^2 IV will be administered as monotherapy in Cycles 7 and 8.
2896381|NCT03274492|Placebo Comparator|R-CHOP plus Polatuzumab Vedotin Placebo|Participants will receive placebo for polatuzumab vedotin, rituximab 375 mg/m^2 IV, cyclophosphamide 750 mg/m^2 IV, doxorubicin 50 mg/m^2 IV, and vincristine 1.4 mg/m^2 IV (maximum 2 milligrams per dose [mg/dose]) on Day 1 and prednisone 100 mg/day PO on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m^2 IV will be administered as monotherapy in Cycles 7 and 8.
2896382|NCT03274479|Experimental|PBF-1129_40mg|
2896383|NCT03274479|Experimental|PBF-1129_80mg|
2896384|NCT03274479|Experimental|PBF-1129_160mg|
2896385|NCT03274479|Experimental|PBF-1129_320mg|
2896386|NCT03274466|Experimental|Closed Incision Negative Pressure Therapy (ciNPT)|Prevena Peel & Place or Prevena Plus Customizable Dressing and ActiVAC Therapy Unit or Prevena Plus Therapy Unit
2896387|NCT03274466|Active Comparator|Standard of Care Dressing|Silver impregnated dressing
2896388|NCT03274453|Active Comparator|Ketamine Naive|"After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.~Infusion will be maintained for 24 hours."
2896389|NCT03274453|Placebo Comparator|Naive Placebo|Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
2896390|NCT03274453|Placebo Comparator|Tolerant Placebo|Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
2896391|NCT03274453|Experimental|Tolerant Ketamine|"After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.~Infusion will be maintained for 24 hours."
2896392|NCT03274440|Experimental|High THC/Low CBD Marijuana|This condition involves the ingestion of marijuana with a high THC (5-10%) and low CBD (<1%) content.
2896393|NCT03274440|Experimental|Low THC/High CBD Marijuana|This condition involves the ingestion of marijuana with a low THC (<1%) and high CBD (>10%) content.
2896394|NCT03274440|Placebo Comparator|No THC/No CBD|This condition involves the ingestion of a placebo control with no THC and no CBD content.
2896395|NCT03274427|Experimental|One-drug Regimes|Basic drugs therapy of HCC by TACE.
2896396|NCT03274427|Experimental|Two-Drug Regimens|Basic drugs therapy of HCC by TACE; Arginine hydrochloride
2896397|NCT03274427|Experimental|Three-Drug Regimens|Basic drugs therapy of HCC by TACE; Arginine hydrochloride;Trimetazidine hydrochloride
2896399|NCT03274401|Active Comparator|Screening Arm|Screening for atrial fibrillation using a hand-held ECG device (Zenicor intermittent ECG) at least twice daily for two weeks. In patients where AF is detected prolonged OAC therapy will be administered.
2896400|NCT03274401|No Intervention|Control Arm|Standard of care
2896401|NCT03274388|Experimental|Control|Intervention of protein-rich nutritional therapy and counseling
2896402|NCT03274388|Experimental|Intervention|Intervention of protein-rich nutritional therapy and counseling combined with whole body electromyostimulation exercise training
2896403|NCT03274375|Experimental|IA session|"4 Rituximab injections~10 IA sessions"
2896404|NCT03274362|Experimental|Headspace Application Treatment Group|Participants in the treatment group will be given a free 3-month access code to Headspace. The app contains a series of sessions that guide the user through mindfulness training.
2896405|NCT03274362|No Intervention|Standard Care Control Group|Participants in the control group will be provided a list of resources that provides guidance on mindfulness and general health.
2896406|NCT03274349|Active Comparator|Control|Group of patients receiving individualized protein-rich nutritional therapy without exercise, 12 weeks intervention per patient
2896407|NCT03274349|Experimental|EMS-group|Group of patients receiving individualized protein-rich nutritional therapy with personalized whole body electromyostimulation exercise, 12 weeks intervention per patient
2896408|NCT03274336|Active Comparator|interview|questionnaire after face-to-face interview
2896409|NCT03274336|Placebo Comparator|brochure|questionnaire interview plus brochure
2896410|NCT03274336|Placebo Comparator|movie|questionnaire interview plus movie
2896411|NCT03274323|Experimental|2 iStent with travoprost or latanoprost|2 iStents will be injected into the trabecular meshwork and patients will be administered topical latanoprost or travoprost following surgery
2896412|NCT03274323|Active Comparator|trabeculectomy|Standard trabeculectomy
2896413|NCT03274310|Experimental|Surveillance + Education arm|Receipt of educational text message about ways to decrease household transmission of influenza and other respiratory infections in addition to surveillance messages
2896414|NCT03274310|No Intervention|Surveillance-only arm|No intervention solely surveillance messages
2896415|NCT03274297|Experimental|Group 1: Sequence AB (Right/Left)|A single patch of currently marketed EVRA patch (Treatment A) will be applied to the right buttock of participants on Day 1 of treatment period 1, followed by application of a single patch of transdermal contraceptive using the newly sourced adhesive component HMW PIB (Treatment B) to left buttock of participants on Day 1 of treatment period 2. The treatment periods will be separated by a washout period of 21 days.
2896416|NCT03274297|Experimental|Group 2: Sequence BA (Right/Left)|Treatment B will be applied to the right buttock of participants on Day 1 in Period 1 followed by Treatment A to the left buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
2896417|NCT03274297|Experimental|Group 3: Sequence AB (Left/Right)|Treatment A will be applied to the left buttock of participants on Day 1 in Period 1 followed by Treatment B to the right buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
2896418|NCT03274297|Experimental|Group 4: Sequence BA (Left/Right)|Treatment B will be applied to the left buttock of participants on Day 1 in Period 1 followed by Treatment A to the right buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
2896419|NCT03274284|Experimental|chemoradiotherapy|Chemoradiation in the form of cisplatin plus conformal radiotherapy 55GY/20 fractions which is biologically effective to 64GY/32 fractions fr
2896420|NCT03274271|Experimental|AP+CP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with all three behaviour change techniques of interest: action planning (AP), coping planning (CP) and self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
2896421|NCT03274271|Experimental|AP+CP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: action planning (AP) and coping planning (CP).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
2896422|NCT03274271|Experimental|AP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: action planning (AP) and self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
2896423|NCT03274271|Experimental|CP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: coping planning (CP) and self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
2896424|NCT03274271|Experimental|M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
2896425|NCT03274271|Experimental|CP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: coping planning (CP).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
2896426|NCT03274271|Experimental|AP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: action planning (AP).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
2896427|NCT03274271|Active Comparator|Control|Participants will receive the e- and mHealth intervention 'MyPlan 2.0' without the three behaviour change techniques of interest (action planning, coping planning, self-monitoring). They will receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support.
2896467|NCT03273972|Experimental|Alirocumab Treatment Arm|V2: Day 1 - Alirocumab 150mg (subcutaneous injection) V3: Day 15 +/- 3 days - Alirocumab 150mg (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
2896428|NCT03274258|Experimental|Nivolumab + Ipilimumab|"During Part A of this study, each study cycle is 21 days (3 weeks). During Part B of this study, each study cycle is 14 days (2 weeks).~During Part A, Nivolumab and Ipilimumab given by vein over about 30 minutes each on Day 1 of Cycles 1-4.~During Part B, Nivolumab given alone by vein over about 60 minutes on Day 1 of each cycle.~Study drugs given in combination for up to 4 cycles. After that, Nivolumab given alone for up to 2 years or until the disease gets worse, whichever comes first."
2896429|NCT03274245|Experimental|Latrine Use|Men and women in villages randomized to the latrine use arm will receive the intervention package that includes activities at the community and household levels, with additional activities and hardware for mothers of children under five.
2896430|NCT03274245|No Intervention|Control Group|Men and women in villages randomized to the control group will not receive an intervention.
2896431|NCT03274245|Experimental|Qualitative Research Group|Six villages unassociated with the randomized villages will engage in qualitative research. Three villages will receive the intervention. Three villages will not receive the intervention.
2896432|NCT03274232|Experimental|SUNEKOS ® 200|The 1st intradermal treatment (T1i) was performed during the basal visit (T0), after basal evaluations planned by the study procedure and repeated after 10 (T2i), 20 (T3i) and 30 (T4i) days.
2896433|NCT03274219|Experimental|bb21217 Experimental Arm|
2896434|NCT03274206|Experimental|BLS-ILB-E710c|"Drug: BLS-ILB-E710c 1,000mg~Dosage and duration: 4 capsules per day for 5 consecutive days at week 1,2,4, and 8)"
2896435|NCT03274206|Placebo Comparator|BLS-ILB-E710c-placebo|"Drug: BLS-ILB-E710c-placebo~Dosage and duration: 4 capsules per day for 5 consecutive days at week 1,2,4, and 8)"
2896436|NCT03274193|Experimental|Yoga|The yoga group will engage in the yoga training program which is 60 minutes per session, 2 times per week for 12 weeks.
2896437|NCT03274193|No Intervention|Control|The control group will be asked not to participate in any exercise program during the course of the study.
2896438|NCT03274180|Experimental|Nursing consultation|travel preventive consultation was performed by nurse
2896439|NCT03274180|No Intervention|Medical consultation|travel preventive consultation was performed by a doctor
2896440|NCT03274167|Experimental|Gabapentin|300 mg per day once daily before bedtime
2896441|NCT03274167|Placebo Comparator|Control|Capsule identical to the experimental arm, one tablet once daily before bedtime
2896442|NCT03274154|Experimental|Pre-Hyaluron 465 Innēov|43 caucasian female subjects have taken during a meal, for the first 4 months of trial,1 capsule and 1 tablet/die of the food supplement composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese) .
2896443|NCT03274154|No Intervention|Untreated group|23 caucasian female subjects untreated
2896444|NCT03274141||T2T Patients|RA patients managed with a treat-to-target (T2T) strategy
2896445|NCT03274141||RC Patients|RA patients managed with routine care(RC)
2896446|NCT03274128|Active Comparator|Study Group|The treatment included a comprehensive therapy: radon therapeutic baths and inhalations, kinesiotherapy. On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: MCGill scale and VAS scale and anxiety and depression levels - HADS scale.
2896447|NCT03274128|No Intervention|Control Group|On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: MCGill scale and VAS scale and anxiety and depression levels - HADS scale.
2896448|NCT03274115|No Intervention|White Light (WL)|White light will be used for histology prediction of colonic polyps (hyperplastic versus adenomatous).
2896449|NCT03274115|Active Comparator|Blue Light Imaging (BLI)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps.
2896450|NCT03274102|Experimental|Group I-EV71 vaccine and EPI vaccines|Concomitant administration of EV71 vaccine with EPI vaccines: EV71 Vaccine (intramuscular injection,0.5ml,first dose)/recombinant hepatitis B vaccine（intramuscular injection,0.5ml）on day 0 and EV71 Vaccine (injection, 0.5ml,second dose)/ Group A meningococcal polysaccharide vaccine(subcutaneous injection, 150ug) on day 30.
2896451|NCT03274102|Active Comparator|Group II-EPI vaccine only|Single injection of EPI vaccine: recombinant hepatitis B vaccine (intramuscular injection, 0.5ml) on day 0 and Group A meningococcal polysaccharide vaccine (subcutaneous injection,150ug) on day 30.
2896452|NCT03274102|Active Comparator|Group III-EV71 vaccine only|EV71 Vaccine only: the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 and day 30 respectively.
2896453|NCT03274089|Experimental|Kiosk intervention group|
2896454|NCT03274089|No Intervention|Nurse clinician control group|
2896455|NCT03274076|Active Comparator|Tofacitinib|5mg Tofacitinib twice a day
2896456|NCT03274076|Placebo Comparator|Placebo|5mg Placebo twice a day
2896457|NCT03274063|Active Comparator|Supported self-management|Escalation of urate lowering therapy will be supervised by clinical research team based on results of participant self-testing
2896458|NCT03274063|Sham Comparator|Usual care|Escalation of urate lowering therapy will remain the responsibility of the participants primary care physician.
2896459|NCT03274050||patient group|Surgery with robot - all patients operated in pediatric surgery department with indication of robot in the routine care (all specialities).
2896460|NCT03274050||control group|Open surgery or coelioscopy - patient operated for pyeloplasty
2896461|NCT03274037|Experimental|Examination of cerebral MRI elastography|The mechanical waves will be induced by pressure waves guided to the mouth of the elongated subject in the MRI
2896462|NCT03274024|Experimental|Tube implant|Ahmed Glaucoma Implant (AGI) surgery
2896463|NCT03274024|Active Comparator|Trabeculectomy|Trabeculectomy with mitomycin C surgery
2896464|NCT03274011|Experimental|Apatinib Treatment|Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
2896465|NCT03273985|Experimental|Dry needling|
2896466|NCT03273985|Experimental|Ischemic compression|
2896725|NCT03272009|Placebo Comparator|Treatment I|oral placebo plus subcutaneous injection of Peg-INFα2a
2896468|NCT03273972|Other|Comparator Treatment Arm|V2: Day 1 - Placebo (subcutaneous injection) V3: Day 15 +/- 3 days - Placebo (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
2896469|NCT03273959|No Intervention|Group control|Patients randomized to the control group will receive routine physiotherapeutic follow-up, performed by the physiotherapist of the hospital during the hospitalization period. Supervision includes inhalation therapy and respiratory physiotherapy. Respiratory exercises and thoracic maneuvers for bronchial hygiene will be performed, according to what the patient is accustomed to perform. Other techniques besides these can be added at the discretion of the physiotherapist according to the needs of the patient. In pediatric hospitalization patients also receive care from physical educators who associate recreational and recreational activities with the treatment.
2896470|NCT03273959|Experimental|Intervention group|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive a program of physical exercises, illustrated in the form of a booklet and guided by a health professional. The patient is instructed to perform physical exercises five times a week until a hospital discharge. The participant will receive with a booklet a diary to write down the days in which to carry out the proposed exercises, in case of fault he will write down the reason for not performing. The exercise protocol includes: Punching, climbing and descending steps, sit and stand, push-ups on the wall, stationary gait, abdominal, physiotherapy bridge, jumping on the floor ladder, cycling on the cycle ergometer and stretching.
2896471|NCT03273946||Subjects receiving fluticasone propionate|Eligible subjects will receive FP 50 µg twice daily inhaled via a pediatric pMDI with a face mask.
2896472|NCT03273933|Active Comparator|10 children with DragONE only|
2896473|NCT03273933|Experimental|10 children with DragONE and SmartOne|
2896474|NCT03273920|Experimental|Robotic gastrectomy|Robotic distal gastrectomy with D2 nodal dissection
2896475|NCT03273920|Active Comparator|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 nodal dissection
2896476|NCT03273907|Experimental|CyPass System|CyPass Micro-Stent implanted with CyPass 241-S applier in the angle of the eye during cataract surgery
2896477|NCT03273894||Paediatric patients undergoing surgery in general anesthesia|Paediatric patients undergoing surgery in general anesthesia with the expected duration over 30 minutes
2896478|NCT03273881|Active Comparator|glucose solution and insulin|Participants will receive intravenous saline solution boosted with 5% glucose + 8 units regular insulin in a rate of 125 mL/h.
2896479|NCT03273881|Active Comparator|glucose solution only|Participants will receive intravenous saline solution boosted with 5% glucose in a rate of 125 mL/h.
2896480|NCT03273868|Experimental|High velocity low amplitude manipulation|
2896481|NCT03273868|Sham Comparator|Sham manipulation|
2896482|NCT03273855|Active Comparator|Intervention|
2896483|NCT03273855|Placebo Comparator|Placebo|
2896484|NCT03273842|Experimental|PF-06881894|PF-06881894 6 mg SC
2896485|NCT03273842|Active Comparator|US-approved Neulasta|US-approved Neulasta 6 mg SC
2896486|NCT03273816|No Intervention|Patients without sessions of sophrology|The control group is also composed of Parkinsonian patients waiting for deep brain surgery but will not have any special preparation for the procedure. They will be subjected to the same assessments at the same time as the sophrology group.
2896487|NCT03273816|Experimental|Patients with sessions of sophrology|The experimental group is composed of patients with Parkinson's waiting for deep brain surgery. They will benefit from 10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
2896488|NCT03273790||NSCLC patients|Initiated Nivolumab treatment at least once from 01 Apr. 2016 through 31 Dec. 2016
2896489|NCT03273777|Experimental|Drawing of an incision line|An incision line of 14 cm will be drawn using a conventional surgical ruler and pen before skin incision.
2896490|NCT03273777|No Intervention|No drawing of an incision line|Skin incision will be carried out without previous drawing of an incision line.
2896491|NCT03273764||Preterm neonates with RDS|Singleton Preterm neonates with gestational age between 26 completed weeks to 34 completed weeks with clinical diagnosis of RDS without any major congenital anomalies.
2896492|NCT03273751|Experimental|Remote Ischemic Preconditioning (RIPC)|Four cycles of upper arm ischemia/reperfusion
2896493|NCT03273751|Sham Comparator|Sham control|Placement of a blood pressure cuff around upper arm without inflation.
2896494|NCT03273738||postmenopausal diabetic women|50 female patients with T2DM who visited Assiut University Hospital Diabetes Clinic in Assiut, Egypt in these patients folate level measurement, B12 level and homocysteine are measured
2896495|NCT03273738||postmenopausal without diabetes|Another 50 participants will be volunteered in the study as control.n these subjects folate level measurement', B12 level and homocysteine are measured
2896496|NCT03273712|Experimental|90Y-DOTA-tyr3-Octreotide|Patients will receive 3 doses of 90YDOTATOC followed by 90Y-DOTATOC PET scans, with 6 -8 weeks between doses. They will be followed for 6-9 months after the last treatment dose. CT or MRI scans will be given at the 3 month and 6-9 month followups plus a 68Ga-DOTATOC or DOTATATE PET scan at the 6-9 month followup. The exact dose of 90YDOTATOC therapy for each patient will be determined by dosimetry.
2896497|NCT03273699|Experimental|Mindfulness|"The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the GraphPad Quick Calcs online calculator which offers simple random allocation into equal-sized groups"
2896498|NCT03273699|No Intervention|Control|"The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the GraphPad Quick Calcs online calculator which offers simple random allocation into equal-sized groups"
2896583|NCT03273010|Active Comparator|Control group|Free gingival graft was harvested from palatal region and left to heal without applying periacryl.
2896499|NCT03273686|Experimental|group without NG tube after surgery|In this goup, patients will undergo preoperative gastrointestinal decompression and investigators will discharge the NG tube during the surgery.
2896500|NCT03273686|No Intervention|group with NG tube after surgery|In this goup, patients will undergo preoperative gastrointestinal decompression and investigators will discharge the NG tube 6-7 days after the surgery.
2896501|NCT03273673|Experimental|Biofeedback Intervention|The 6-week biofeedback training program is focused on altering loading and movement asymmetry during biweekly sessions on non-consecutive days (12 sessions). The biofeedback training program will provide sensory (visual and tactile) feedback to the subject to heighten awareness of asymmetrical movement strategies (e.g. load shift, movement asymmetry) during a squat. The two exercises that will be completed during the biofeedback training program will be a visual feedback squat and a resisted squat (tactile feedback). Each of these tasks will be completed 30 (3 sets of 10 repetitions) times per session. We will provide a 20 second rest between trials, and a 10 minute break between the visual and tactile feedback exercises to decrease the effect of fatigue.
2896502|NCT03273673|No Intervention|Control|The 6-week attention control group program will focus on providing educational information to the participants related to the clinical and sports expectations as they are released to return to sport. These participants will be asked to meet 6 times during the 6-week intervention time period. Three of these visits will be completed in person and three will be completed using an online educational module (6 sessions). The online sessions will be completed in week 1, week 3, and week 5 while the in person sessions will be completed during week 2, week 4, and week 6.
2896503|NCT03273660|Experimental|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|
2896504|NCT03273647|Experimental|surgery plus radiation|adjuvant radiotherapy is developed in this arm
2896505|NCT03273647|No Intervention|surgery alone|No adjuvant radiotherapy,that is surgery alone is developed in this arm
2896506|NCT03273634|Experimental|Active treatment|The treatment will consist of lanzoprazole 30 mg once daily at night time
2896507|NCT03273634|Placebo Comparator|Placebo|A Placebo pill to be given with similar looking to experimental drug but contains inactive ingredient
2896508|NCT03273621||Obese|Patients with a body mass index larger than 35 kg/m2
2896509|NCT03273595|Placebo Comparator|Control|
2896510|NCT03273595|Experimental|Experimental group|
2896511|NCT03273569|Experimental|Women with placenta accreta|PDI-UC protocol
2896512|NCT03273556|Experimental|Aliaxin® EV Essential Volume|Comparison within subjects of Aliaxin® EV Essential Volume with and without Lidocaine 0.3%
2896513|NCT03273543|Experimental|Nasal Tip Projection|
2896514|NCT03273543|Experimental|Upper Lip Position|
2896515|NCT03273530|Experimental|Integrated Supported Employment|Individual placement support intervention plus work-related social skills training
2896516|NCT03273530|No Intervention|Individualised Placement Support|Individual placement support intervention with pre-vocational training followed by placing individual participants to the job according to their preference and abilities
2896517|NCT03273530|No Intervention|Traditional Vocational Rehabilitation|general pre-vocational training and placement
2896518|NCT03273504|Experimental|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|"Comparison within subjects of Actapil Corpo Spray versus Placebo. The study product will be applied twice a dayon the right or left leg (tibialis area) according to a randomisation list.~The placebo product will be applied in the same way, on the controlateral leg."
2896519|NCT03273491|Experimental|Daily Self-Weighing Group|"Participants will be provided with a scale and instructions necessary to engage in daily self-weighing, first thing in the morning for the next three months.~Height and weight will be measured using standard procedures~Questionnaires will be administered at baseline and EOT: Sociodemographic questions (i.e. age, race/ethnicity, self-weighing frequency, weight goals will be collected at baseline. To assess factors that may modify reaction to intervention condition,a questionnaire will assess participant's eating attitudes, behaviors, and perception of their body.~Questionnaires (baseline, end of Week 1, 2, 3, 4 and EOT): In order to compare results with published studies assessing constructs over varying time frames, self-esteem, anxiety, and depression will be measured at baseline, weekly for the first month, and again at EOT."
2896520|NCT03273491|Active Comparator|Daily Temperature-Taking Group|"Participants will be provided with a thermometer and instructions necessary to engage in daily temperature-taking, first thing in the morning for the next three months.~Height and weight will be measured using standard procedures~Questionnaires will be administered at baseline and EOT: Sociodemographic questions (i.e. age, race/ethnicity, self-weighing frequency, weight goals will be collected at baseline. To assess factors that may modify reaction to intervention condition,a questionnaire will assess participant's eating attitudes, behaviors, and perception of their body.~Questionnaires (baseline, end of Week 1, 2, 3, 4 and EOT): In order to compare results with published studies assessing constructs over varying time frames, self-esteem, anxiety, and depression will be measured at baseline, weekly for the first month, and again at EOT."
2896521|NCT03273465|Experimental|Fecal transplantation|Fecal transplantation of feces from healthy donor via capsules. Oral application.
2896522|NCT03273465|Placebo Comparator|Placebo|Placebo capsules
2896523|NCT03273452|Experimental|treatment group|In this group, patients will be given prednisone 100mg,qd,d1-5; etoposide 100mg,qd,d1-5; thalidomide 100mg,qn,d1-14; Chidamide 30mg,biw;
2896524|NCT03273439|Experimental|repetitive TMS|Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
2896525|NCT03273439|Sham Comparator|Sham rTMS|all procedures were identical except they were the unmagnetized steel cylinders, instead of cylindrical magnets, that were rotated. Participants were, therefore, unable to distinguish between active and sham rTMS.
2896526|NCT03273426|Experimental|complete clinical response|Intervention (core needle biopsy or vacuum-assisted biopsy) for complete clinical response (cCR) or near-cCR predicted by MRI.
2896527|NCT03273413|Placebo Comparator|Placebo|Participants will receive inactive 40 mg tablets of placebo everyday for 6 weeks. If well tolerated, participants will continue taking inactive 40 mg dose of placebo everyday for 2 years.
2896851|NCT03271320||control|Healthy subjects
2896528|NCT03273413|Active Comparator|Pravastatin|Participants will receive 40 mg tablets of pravastatin everyday for 6 weeks. If well tolerated, participants will continue taking 40 mg dose of pravastatin everyday for 2 years.
2896529|NCT03273400|Experimental|Mobilisations|"The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The plinth will rest on force plates to allow the authors to analyse the force placed through the vertebrae. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.~Following the intervention all measure lumbar flexion, hamstring extensibility and sEMG activity will be recorded immediately, 5, 10, 15, 20, 30, 60 minutes post application as a single test."
2896530|NCT03273400|No Intervention|Control|All outcome measures (lumbar/hamstring range of motion; EMG activity of the Biceps Femoris and Erector Spinae) will be measured. The control group will then receive no intervention and be asked to lie supine on a plinth for the treatment duration before having the outcome measures reassessed.
2896531|NCT03273387|Placebo Comparator|Sugar pill|The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
2896532|NCT03273387|Experimental|trimetazidine|The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.
2896533|NCT03273374|Experimental|IORT group|Intraoperative radiation therapy of 10 Gy delivered during surgery followed by adjuvant gemcitabine chemotherapy
2896534|NCT03273361|Experimental|Seated|Participants completed work tasks while seated.
2896535|NCT03273361|Experimental|Low Intensity Pedaling|Participants completed work tasks while pedaling at a low intensity.
2896536|NCT03273361|Experimental|Low-Moderate Intensity Pedaling|Participants completed work tasks while pedaling at a low-moderate intensity.
2896537|NCT03273348|Other|oncoplastic breast surgery|This study aim to evaluate the outcome on oncological side and patient satisfaction on the aesthetic side with skin-sparing mastectomy and immediate breast reconstruction for patients with early breast cancer .
2896538|NCT03273335||Surgical patients|Surgical patients will undergo CSF biomarker assays, cognitive testing and fMRI scans.
2896539|NCT03273322|Experimental|1: Rivaroxaban 10 mg qd|Rivaroxaban 10 mg, 1 tablet a day, from randomization to Day 90 should be taken between 8 and 10 AM
2896540|NCT03273322|Experimental|2: Rivaroxaban 15 mg qd|"Rivaroxaban 15 mg, 1 tablet a day, from randomization to Day 90~should be taken between 8 and 10 AM"
2896541|NCT03273322|Active Comparator|3: DAPT|Aspirin 75 mg, 1 a day Clopidogrel 75 mg, 1 tablet a day from randomization to Day 90 should be taken between 8 and 10 AM
2896542|NCT03273309|Active Comparator|Vibratory Perineal Stimulus|It's thought that the vibratory perineal stimulation can produces afferent nerve impulses that goes to the sacral spinal cord (S2-S4) via the pudendal nerve and stimulates the sacral somatic response which will cause the pelvic muscle contraction.
2896543|NCT03273309|Active Comparator|Transvaginal Electrical Stimulation|Transvaginal electrical stimulation can produces direct and reflex responses of the pelvic floor muscles, being more effective in patients who can't voluntarily contract this musculature. In addition, it increases blood flow to the muscles, restores neuromuscular connections and improves muscle fiber function.
2896544|NCT03273296|Active Comparator|Amoxicillin|
2896545|NCT03273296|Active Comparator|Azithromycin|
2896546|NCT03273296|Active Comparator|Vancomycin|
2896547|NCT03273283|Experimental|Intervention|Patients received a brief intervention on alcohol use. This brief intervention was a little chat based on motivational techinques to enhance motivation to reduce alcohol use or to initate treatment. Patients were referred to specialized treatment when indicated.
2896548|NCT03273283|No Intervention|Control|Informative leaflets regarding alcohol use
2896549|NCT03273270|Experimental|Active TMS|1 Hz repetitive transcranial magnetic stimulation
2896550|NCT03273270|Placebo Comparator|Sham TMS|No active stimulation
2896551|NCT03273257|Active Comparator|Riociguat|Patients will receive riociguat for 3 months followed by pulmonary endarterectomy.
2896552|NCT03273257|Placebo Comparator|Placebo|Patients will receive placebo for 3 months followed by pulmonary endarterectomy.
2896553|NCT03273244||Device monitoring|NeuroSense monitoring and ANI monitoring
2896554|NCT03273231|Experimental|ketamine group|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
2896555|NCT03273231|Placebo Comparator|control group|0.9% saline solution
2896556|NCT03273218|Experimental|Tiger catheter|Tiger simple multipurpose catheter compared to Judkins catheters
2896557|NCT03273218|Active Comparator|Judkins catheter|Judkins right and judkins left catheter
2896558|NCT03273205|Experimental|Anodal tDCS|"The first group of patients has the real stimulation and the electrodes are placed in this position:~Anode: Left DLPFC [F3) Cathode: Right Supraorbital (FP2)"
2896559|NCT03273205|Sham Comparator|Sham tDCS|"The second group has the sham stimulation, but the electrodes are placed in the same position as in the first group:~Anode: Left DLPFC [F3) Cathode: Right Supraorbital (FP2)"
2896560|NCT03273192|Experimental|CinnaGen adalimumab|CinnoRA® (adalimumab auto-injector devices produced by CinnaGen Company) 40 mg/0.8 ml in auto-injector devices A single 40-mg dose of Adalimumab was subcutaneously administered to healthy subjects.
2896561|NCT03273192|Active Comparator|AbbVie adalimumab|Humira® (adalimumab auto-injector devices produced by AbbVie Company) 40 mg/0.8 ml in auto-injector devices A single 40-mg dose of Adalimumab was subcutaneously administered to healthy subjects.
2896562|NCT03273153|Experimental|Cobimetinib and Atezolizumab|Participants will receive 60 mg of cobimetinib orally from Days 1 to 21 along with 840 mg of atezolizumab by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first. There will be no cobimetinib administration for 7 days (Days 22-28) in each cycle.
2896584|NCT03272984|Experimental|ERAS group|Patients will undergo the ERAS programs.
2896585|NCT03272984|Other|SC group|Patients will undergo the SC group.
2939580|NCT02974504|Active Comparator|linagliptin|linagliptin 5mg qd
2896563|NCT03273153|Active Comparator|Pembrolizumab|Participants will receive 200 mg of pembrolizumab administered by IV infusion every 3 weeks (Q3W) until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first.
2896564|NCT03273140|Experimental|Gamification Diabetes Education Program (GDEP)|"The GDEP consists of two components, which are 1) gamification app on diabetes education, and 2) usual care group (face-to-face discussion with a DNE).~1) Gamification: The development of this gamification app, a mobile-based app of serious gaming, addresses the limitation and few recommendations from the current literature review. It aimed to enhance the user experience, and to facilitate diabetes education in an effective and efficient way, aligning with ADA (2014) guidelines, work instructions, and protocols in one tertiary organization. The learning modules are framed by socio-cognitive framework and self-efficacy. The gaming concept has been implemented into a mobile app, which can be accessed via iOS and Android platforms. It takes an average of 15 minutes to complete per stage. Hence, allowing flexibility for participants to access the games anywhere and anytime using i-pad or mobile devices."
2896565|NCT03273140|No Intervention|Standard group|The control group comprises of the standard care or usual care group, which is the face-to-face session with the DNE. The content during each session is dependent upon the individual's needs and concerns, including the reason for referral to DNE by the endocrinologist. For example, teaching the individual patient on self-management of blood glucose (SMBG) and emphasizing on diet modification and exercise if necessary. Educational pamphlets on diabetes management will be given to him/her if deemed necessary. Each session will usually requires an average of 45 minutes, which is considered as long consultation that costs 16 dollars. On the other hand, short consultation is categorised as less than 30 minutes that costs around eight dollars. The difference is that there is no GDEP in the control group. However, after the completion of data collection at six months time, the control group will also receive the intervention (GDEP). This is in order to give them equal opportunity.
2896566|NCT03273127|Experimental|Abediterol 5 μg|Out of 12 randomized patients, 9 will receive abediterol 5 μg as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive Abediterol 5.0 μg QD.
2896567|NCT03273127|Placebo Comparator|Placebo|Out of 12 randomized patients, 3 will receive placebo as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive placebo QD.
2896568|NCT03273114|Experimental|Cognitive Functional Therapy (CFT)|Cognitive Functional Therapy (CFT) is a behavioral intervention that addresses multiple aspects of low back pain. This approach focuses on changing the patient's beliefs, confronting their fears, educating them about pain mechanisms, increasing mental strength, and control of their body. This is done with functional tasks performed by individuals training them to reduce excessive muscle activity in the trunk and generate behavioral changes related to pain, from postures and provocative movements.
2896569|NCT03273114|Active Comparator|Core Training Exercise and Manual Therapy (CORE-MT)|The active comparator will be the combination of Core Training Exercise and Manual Therapy (CORE-MT).
2896570|NCT03273101|Experimental|Intervention group|The sit-to-stand training is assisted by mechanical device
2896571|NCT03273101|Active Comparator|Control group|The sit-to-stand training is assisted by manual device
2896572|NCT03273088|Experimental|AryoGen Pharmed etanercept|Altebrel (etanercept prefilled syringe produced by AryoGen Pharmed Company) 25mg/0.5ml in prefilled syringe.
2896573|NCT03273088|Active Comparator|Amgen etanercept|Enbrel® (etanercept prefilled syringe produced by Amgen Company) 25mg/0.5ml in prefilled syringe.
2896574|NCT03273075|Active Comparator|Prasugrel + Cangrelor|If eligible, assigned to this arm and without contraindications to prasugrel administration, patients will receive a loading dose of prasugrel (60 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
2896575|NCT03273075|Active Comparator|Ticagrelor + Cangrelor|If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age >75years, weight <60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
2896576|NCT03273075|Placebo Comparator|Prasugrel + Placebo|"If eligible, assigned to this arm and no contraindications to prasugrel, patients will receive a loading dose of prasugrel (60 mg) via nasogastric tube as soon as possible after arrival at the emergency department.~Afterwards a 30 micrograms (mcg)/kg iv bolus of placebo (0.9% NaCl) followed immediately by a 4 mcg/kg/min iv infusion of placebo (0.9% NaCl) (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered."
2896577|NCT03273075|Placebo Comparator|Ticagrelor + Placebo|"If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age >75years, weight <60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department.~Afterwards a 30 micrograms (mcg)/kg iv bolus of placebo (0.9% NaCl) followed immediately by a 4 mcg/kg/min iv infusion placebo (0.9% NaCl) (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered."
2896578|NCT03273062|Active Comparator|Study Period 1|"15 days of Tolcapone 200mg TID~OR~Placebo Comparator 15 days of Placebo pill TID"
2896579|NCT03273062|Placebo Comparator|Study Period 2|"15 days of Placebo pill TID~OR~Active Comparator 15 days of Tolcapone 200mg TID"
2896580|NCT03273036|Active Comparator|epidural steroid injection|40 mg triamcinolone acetate 1 cc
2896581|NCT03273036|Placebo Comparator|placebo injection|no injection agent
2896582|NCT03273010|Experimental|Periacryl group|Periacryl, a tissue adhesive, was applied on wound surfaces to achieve haemostasis
2896586|NCT03272971|Experimental|Radio-frequency Ablation|Single-arm study where subjects receive radio-frequency ablation prior to a scheduled, surgical resection.
2896587|NCT03272945|Experimental|LCI|Once the randomization assignment was announced, the whole colonoscopy from insertion to cecum to withdrawal of endoscope was carried out entirely by using Linked-color imaging (LCI).
2896588|NCT03272945|Placebo Comparator|WL|Once the randomization assignment was announced, the whole colonoscopy from insertion to cecum to withdrawal of endoscope was carried out entirely by using white light (WL).
2896589|NCT03272919|Experimental|Arm 1: Investigational INF|"Intraneural Facilitation (INF) treatment is an effective way to restore blood flow to damaged nerves as neuropathy is strongly impacted by reduced blood flow. INF utilizes three holds or positions, which widens tiny openings in arteries surrounding nerves and improves blood flow to targeted nerves. The improved blood flow in these nerves stimulates healing and reduces or even stops nerve pain.~INF treatment will be administered twice a week for six weeks under the supervision of treating physical therapist."
2896590|NCT03272919|Other|Arm 2: Standardized muscle stretching and strengthen|subjects will receive a standardized program of muscle stretching and strengthening exercise twice a week for six weeks under the supervision of treating physical therapist
2896591|NCT03272906|Experimental|A-tDCS & speech-language therapy|Anodal transcranial direct current stimulation (2 mA) plus speech-language therapy for 24 sessions (20-minutes per each 60-minute treatment session) over the course of 12 weeks. The electrical current will be administered over ventral inferior frontal gyrus. The stimulation will be delivered at an intensity of 2mA for a maximum of 20 minutes.
2896592|NCT03272906|Sham Comparator|Sham-tDCS & speech-language therapy|Sham transcranial direct current stimulation (2 mA) plus speech-language therapy for 24 sessions (20-minutes per each 60-minute treatment session) over the course of 12 weeks. Electrodes will be placed as in A-tDCS. Current will be ramped up for the first 30 seconds following which the intensity will drop to 0 mA.
2896593|NCT03272880|Experimental|arts-based programming for cancer survivors and caregivers|This is a 8-week, arts-based, health, resilience, and well-being program.
2896594|NCT03272867|Experimental|Intervention group|One group of volunteers will ingest a powder with dose of 6.1 g ProManna twice a day for a period of 2 weeks
2896595|NCT03272867|Placebo Comparator|Control group|Another group of volunteers will ingest a powder with the same amount of a placebo twice a day for a periode of 2 weeks
2896596|NCT03272854||Renal Transplant Recipients|A cohort or renal transplant recipients, all more than 1 year after transplantation at inclusion
2896597|NCT03272841||Transplant recipients|Renal, heart, lung, liver, small bowel, pancreas or combined transplant recipients
2896598|NCT03272828|Active Comparator|Parallel sided implant Group|A Parallel sided titanium dental implant will be placed in the edentulous mandible. Outcomes between the groups will be compared
2896599|NCT03272828|Active Comparator|Tapered shaped implant Group|A tapered shaped titanium dental implant will be placed in the edentulous mandible. Outcomes between the groups will be compared.
2896600|NCT03272815|Experimental|PD arm|Patients undergoing assessment of the chest with the percussion device (PD).
2896601|NCT03272815|Active Comparator|US arm|Patients undergoing assessment of the chest with the ultrasound (US).
2896602|NCT03272802|Experimental|Case group|"ALS patients who receive the usual treatment option (Riluzole) for this disease and Edaravone. Instructions:~Tab. Rilutek 50 mg PO q12hr on empty stomach.~Amp. Edaravone 60 mg per day IV infusion (in normal saline during 1 hour) for 14 days in the first 28 day cycle.~Amp. Edaravone 60 mg per day IV infusion (in normal saline during 1 hour) for 10 days in the following 28 day cycles after the first cycle (for 11 cycles)."
2896603|NCT03272802|Active Comparator|Control group|"ALS patients who receive the usual treatment option (Riluzole) for this disease.~Instructions:~1. Tab. Rilutek 50 mg PO q12hr on empty stomach."
2896604|NCT03272789|Other|interviews and questionnaires|Realization of interviews (at day 0, and at 1, 2, 3 6 and 12 months) and questionnaires delivery (at day 0, and at 3, 6 and 12 months)
2896605|NCT03272776||Protector Laryngeal Mask Airway|Patients undergoing anesthesia in which airway management includes a Protector Laryngeal Mask and fulfill the inclusion criteria of the study.
2896606|NCT03272750|Experimental|Bioscalin® new formulation with Galeopsis Segetum|2 placebo capsules + 1 Bioscalin with Galeopsis Segetum table
2896607|NCT03272750|Active Comparator|REFERENCE PRODUCT|2 reference product capsules + 1 placebo tablet
2896608|NCT03272750|Placebo Comparator|PLACEBO|2 placebo capsules + 1 placebo tablet
2896609|NCT03272737|Active Comparator|Traditional strength exercise|"This group will be carried out to knee extension exercise without blood flow restriction.~Interventions:~Laboratorial blood tests;~Plethysmography;~Protocols of isometric exercise;~Velocity of wave pulse (VWP);~Basal blood flow;~Vasodilatory capacity;~PA e FCC;~Quality of life (Euro Qol);~1RM test~Speed gait test"
2896610|NCT03272737|Active Comparator|Strength exercise with KAATSU|"This group will be carried out to knee extension exercise with partial blood flow restriction.~Interventions:~Laboratorial blood tests;~Plethysmography;~Protocols of isometric exercise;~Velocity of wave pulse (VWP);~Basal blood flow;~Vasodilatory capacity;~PA e FCC;~Quality of life (Euro Qol);~1RM test~Speed gait test"
2896611|NCT03272711|Experimental|Vortioxetine plus cognitive training|Vortioxetine (10 mg) plus cognitive training 5 times weekly for 30 minutes a day
2896612|NCT03272711|Placebo Comparator|Placebo plus cognitive training|Placebo plus cognitive training 5 times weekly for 30 minutes a day
2896613|NCT03272698|Experimental|Ketamine (HIKER)|Patients in the HIKER arm will receive a single dose of ketamine 0.75 mg/kg, which is enough to achieve a full anaesthetic effect (i.e., unconsciousness mimicking the GA regimen above), on 8 successive weekdays.
2896614|NCT03272698|Active Comparator|Ketamine-ECT (EAST)|Patients in the EAST arm will initially receive intravenous ketamine 0.75 mg/kg, remifentanil 1 mcg/kg (to reduce discomfort), and succinylcholine 0.75 mg/kg (for safety). Based on patients' anaesthetic response, the attending anaesthesiologist is given the freedom to vary the dose of remifentanil and succinylcholine as well as administer propofol to achieve safe and acceptable anaesthetic conditions. As per the Saskatoon Health Region's care standard, patients in the EAST arm will receive eight ECT sessions (on a bi/triweekly schedule) delivered by the attending psychiatrist with either unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method.
2896615|NCT03272685|Experimental|Very Low Nicotine Content Cigarettes|Very low nicotine content cigarettes (0.3 mg/cig nicotine yield; 9 mg of tar)
2896616|NCT03272685|Active Comparator|Normal Nicotine Content Cigarettes|Normal (Conventional) Nicotine Content (0.8 mg/cig nicotine yield; 9 mg of tar)
2896617|NCT03272672|Experimental|Braced|Össür Unloading Knee Brace used during walking protocol
2896618|NCT03272672|No Intervention|Unbraced|Walking protocol without the use of brace
2896619|NCT03272659|Experimental|Blue Light Cystoscopy with Cysview®|"The enema will be administered to participant. Fluorescence sigmoidoscopy will be performed with white light then blue excitation light after retention of the enema for 60 minutes, followed by a rest time of up to 30 minutes before rectoscopy.~Post-operative surgical specimens will be collected for further fluorescence microscopy studies and pathological correlation of fluoresce with malignant pathology/histology as the gold standard."
2896620|NCT03272646||Group 1 or NPS = 0|Patients undergoing surgery without alterations of the albumin and cholesterol levels, with normal NLR and LMR ratios.
2896621|NCT03272646||Group 2 or NPS >0 and < 3|Patients undergoing surgery with NPS between 1 or 2
2896622|NCT03272646||Group 3 or NPS > 2|Patients undergoing surgery with three or four alterations
2896623|NCT03272633|Experimental|Cohort I (initial IHC within 42 days)|Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.
2896624|NCT03272633|Experimental|Cohort II (initial IHC within 70 days or after relapse)|Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.
2896625|NCT03272607|No Intervention|Control|All participants in the control arm will receive medication reconciliation at admission and discharge, and identical follow up, but no prioritized deprescribing list will be generated.
2896626|NCT03272607|Experimental|Intervention|"Participants in the intervention arm will be electronically screened using an electronic software MedSafer which will generate output of PIMs that will be brought to the attention of the CTU team via the unit pharmacist as deprescribing opportunities. (Note that in the case of multiple recommendations, they will be limited and prioritized so as to avoid overwhelming the treating team.) Based on their own expert medical judgement, in collaboration with the patient/caregiver and other relevant clinicians, a decision will be made to deprescribe if appropriate by the patient's in-hospital doctors."
2896627|NCT03272594|Experimental|Breastfeeding|
2896628|NCT03272594|Active Comparator|24% oral sucrose|
2896629|NCT03272581|No Intervention|Control Group|Control group followed routine basketball training and traditional strength training.
2896630|NCT03272581|Experimental|Training Group|Functional exercises were applied to training group for 20 weeks (2 days/week) with routine basketball training.
2896631|NCT03272568|Experimental|Hemophilia A symptomatic female carriers|"Hemophilia A symptomatic female carriers with a baseline FVIII activity of ≤60% receive recombinant FVIII Fc fusion product Eloctate.~Some of participants will be taught to perform a hemoglobin check using a patient-operated diagnostic device for anemia AnemoCheck every other day during 2 consecutive menstrual cycles."
2896632|NCT03272568|Experimental|Hemophilia B symptomatic female carriers|"Hemophilia B symptomatic female carriers with a baseline FIX activity of ≤60% receive recombinant FIX Fc fusion product Alprolix.~Some of participants will be taught to perform a hemoglobin check using a patient-operated diagnostic device for anemia AnemoCheck every other day during 2 consecutive menstrual cycles."
2896633|NCT03272555|Other|Study Participants|The participants in this arm will engage in the WILD 5 Wellness activities combining five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition.
2896634|NCT03272542|Experimental|Prebiotic: soluble corn fiber|SCF (PromotorTM Soluble Corn Fiber 85, provided by manufacturer Tate & Lyle) will be dispensed to participants as a dry powder in sachets of 12 g SCF85 product (which is approximately 10 g fiber). Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be asked to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
2896635|NCT03272542|Placebo Comparator|Placebo|The placebo control will be maltodextrin powder in identical sachets. Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be requested to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
2896636|NCT03272529||Patient-specific simulated rehearsals|Participants recruited to this cohort will complete just-in-time simulation, i.e., practice a short time prior to the live event using hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. This is in addition to standard prerequisite simulation training.
2896637|NCT03272529||Idealized simulated rehearsals|Participants recruited to this cohort will complete just-in-time simulation, i.e., practice a short time prior to the live event using hydrogel models that incorporate the necessary anatomy, physiology, and pathology of an ideal training case. This is in addition to standard prerequisite simulation training.
2896638|NCT03272529||Standard simulation|Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in this group in addition to the standard.
2896639|NCT03272516|Active Comparator|Control group|This group receives treatment as usual (TAU) from his/hers physician. This treatment is different for each physician, but mainly consists of cognitive therapy, personal interviews or antidepressants or anxiolytics.
2896640|NCT03272516|Experimental|Intervention group|Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol..
2896712|NCT03272048|Experimental|Low-Fear/Temporary|
2896641|NCT03272503|Experimental|Group 1 (Pimozide 4 mg/day)|Pimozide will be initiated at 2 mg once daily for 7 days. On Day 8, subjects will begin taking 2 mg twice daily. The maximum dose will then be administered for a target period of 154 days.
2896642|NCT03272503|Placebo Comparator|Group 2 Placebo|Placebo tablets will be utilized and administered in an identical manner for subjects in Group 1
2896643|NCT03272490|Active Comparator|Medartis|Surgery using the Medartis Implant
2896644|NCT03272490|Active Comparator|Synthes|Surgery using the Synthes implant
2896645|NCT03272477|Active Comparator|Paclitaxel+Trastuzumab+Pertuzumab|"Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with standard Taxane chemotherapy.~Adjuvant Therapy: Standard of care"
2896646|NCT03272477|Experimental|Endocrine+Trastuzumab+Pertuzumab|"Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with endocrine therapy.~Adjuvant Therapy: Standard of care"
2896647|NCT03272464|Experimental|Trametinib + Dabrafenib + INCB039110|"Dabrafenib is administered orally every 12 hours~Trametinib is administered orally once a day~INCB039110 is administered orally once a day"
2896648|NCT03272451|Experimental|culprit vessel intervention|culprit vessel PCI prior to contralateral angiography using a single transradial guiding catheter
2896649|NCT03272451|Active Comparator|traditional approach|complete coronary angiography followed by guiding catheter selection for culprit vessel PCI
2896650|NCT03272438|Active Comparator|No schedule control|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will also monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions.
2896651|NCT03272438|Experimental|Consistent schedule condition|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions. In addition they will plan when, where, and how they will take steps in consistent contexts, i.e., that are very similar from day to day.
2896652|NCT03272438|Active Comparator|Inconsistent schedule condition|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions. In addition they will plan when, where, and how they will take steps in inconsistent contexts, i.e., that vary from day to day.
2896653|NCT03272425|Experimental|Sequence ABBA|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
2896654|NCT03272425|Experimental|Sequence BABA|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
2896655|NCT03272425|Experimental|Sequence ABAB|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
2896656|NCT03272425|Experimental|Sequence BAAB|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
2896657|NCT03272399|Experimental|H3-L6|High Omega-3, low Omega-6 diet
2896658|NCT03272399|Active Comparator|L3-H6|Control diet containing average US polyunsaturated fatty acid (PUFA) content with low omega-3 and high omega-6 content
2896659|NCT03272386||Observational study|Observational study with patients over 18 years old, consulting for lower urinary tract symptoms in a tertiary center are included.
2896660|NCT03272373|Other|Monoblock|Subjects that receive the NexGen TM Monoblock Tibia
2896661|NCT03272373|Other|Modular|Subjects that receive the NexGen TM Modular Tibia
2896662|NCT03272360||Chronic Pelvic Pain|
2896663|NCT03272360||Elective Tubal Ligation|
2896664|NCT03272347|Experimental|MK-8591 0.25 mg|Participants will be treated once daily (QD) with 0.25 mg MK-8591, 100 mg DOR, 300 mg 3TC, and placebo to MK- 1439A for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to MK-1439A may be discontinued. Around Week 60, participants may be switched to a selected open label dose of MK-8591 and DOR 100 mg QD and continue treatment until Week 120.
2896665|NCT03272347|Experimental|MK-8591 0.75 mg|Participants will be treated QD with 0.75 mg MK-8591, 100 mg DOR, 300 mg 3TC, and placebo to MK- 1439A for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to MK-1439A may be discontinued. Around Week 60, participants may be switched to a selected open label dose of MK-8591 and DOR 100 mg QD and will continue treatment until Week 120.
2896666|NCT03272347|Experimental|MK-8591 2.25 mg|Participants will be treated QD with 2.25 mg MK-8591, 100 mg DOR, 300 mg 3TC, and placebo to MK- 1439A for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to MK-1439A may be discontinued. Around Week 60, participants may be switched to a selected open label dose of MK-8591 and DOR 100 mg QD and will continue treatment until Week 120.
2896667|NCT03272347|Active Comparator|MK-1439A|Participants will be treated QD with placebo to MK-8591, placebo to DOR, placebo to 3TC, and MK-1439A consisting of 100 mg DOR + 300 mg 3TC + 300 mg tenofovir disoproxil fumarate (TDF) for a minimum of 24 weeks. Between week 24 through week 52 placebo treatments may be discontinued and participants will receive only MK-1439A QD open label up to Week 120.
2896668|NCT03272334|Experimental|Schedule #1|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 1 infusion of Pembrolizumab in week #7. No interventions within weeks #3 and 4.
2896669|NCT03272334|Experimental|Schedule #2|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 2 infusions of Pembrolizumab; the first given within weeks #3 - 4 and the second in week #7.
2896670|NCT03272334|Experimental|Schedule #3|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 3 infusions of pembrolizumab; the first given one week prior to first BATs infusion, the second is given within weeks #3 - 4, and the third at week #7.
2896671|NCT03272321|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
2896672|NCT03272321|Placebo Comparator|Placebo|saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
2896673|NCT03272295|Experimental|Arm A|Reference product (product 1) x 2, Single ingredients products 2, 3, 4, 5, 6 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
2896674|NCT03272295|Experimental|Arm B|Reference product (product 1), Single ingredients products 7, 8, 9, 10, 11 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
2896675|NCT03272269|Experimental|Cohort 1, low dose|4 SC injections of IMCY-0098 or Placebo
2896676|NCT03272269|Experimental|Cohort 2, medium dose|4 SC injections of IMCY-0098 or Placebo
2896677|NCT03272269|Experimental|Cohort 3, high dose|4 SC injections of IMCY-0098 or Placebo
2896678|NCT03272256|Experimental|IM156, Dose escalation|
2896679|NCT03272243|Active Comparator|Short Segment posterior spine fixation|Short segment transpedicular screw fixation with inclusion of the index level
2896680|NCT03272243|Active Comparator|Long Segment posterior spine fixation|Long segment transpedicular screw fixation with escape of the index level
2896681|NCT03272230|Experimental|bvFTD|"Initially especially patients diagnosed with behavioral variant frontotemporal dementia (bvFTD) according to the Rascovsky criteria (Rascovsky et al. 2011).~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
2896682|NCT03272230|Experimental|Healthy control|"Healthy age, sex and education matched controls~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
2896683|NCT03272230|Experimental|Parkinson|"Initially especially patients diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992).~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
2896684|NCT03272230|Experimental|Depression|"Initially especially patients diagnosed with depression (Major Depressive Disorder, DSM-IV)~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
2896685|NCT03272217|Experimental|Investigational Arm A|Patients will be randomized and stratified to receive atezolizumab 1200 mg (flat dose) IV plus bevacizumab 15 mg/kg IV every 21 days
2896686|NCT03272217|Experimental|Investigational Arm B|Patients will be randomized and stratified to receive atezolizumab 1200 mg (flat dose) IV monotherapy every 21 days
2896687|NCT03272204|Other|Natural Pubic Hair|Participant with natural hair crosses over to removed pubic hair
2896688|NCT03272204|Other|Removed Pubic Hair|Participant with no pubic hair crosses over to natural pubic hair
2896689|NCT03272178||Triathlon knee total knee arthroplasty|50 Patients who are assigned to Triathlon knee, half cemented/half cementless
2896690|NCT03272178||Depuy knee total knee arthroplasty|50 Patients who are assigned to Depuy knee, half cemented/half cementless
2896691|NCT03272165|Experimental|MEDI1341|
2896692|NCT03272165|Placebo Comparator|Placebo|
2896693|NCT03272152||Inflamed CD group|Inflamed ileal mucosa was obtained from inflammed lesions of active CD patients
2896694|NCT03272152||Non-inflamed CD group|Non-inflamed ileal mucosa was obtained from normal sites of active CD patients
2896695|NCT03272152||Control group|Control ileal mucosa was obtained from healthy patients
2896696|NCT03272139|Experimental|interscalene block (ISB)|The interscalene block will be done using an ultrasound-guided, in-plane approach. The anesthesiologists will target below the C5 nerve root. A 22 gauge 1.5-2 inch needle is advanced in-plane from lateral to medial through the middle scalene muscle until the needle tip is positioned in the interscalene groove between the C5 and C6 nerve roots. 15 20 ml of 0.5% bupivacaine will be injected.
2896697|NCT03272139|Experimental|superior trunk block (STB)|The superior trunk block will be performed at the point immediately distal to the roots when the c5-c6 form the superior trunk and lies anterior to the middle scalene muscle and below the deep cervical fascia, before the suprascapular nerve arises and goes into the omohyoid. A 22g 1.5-2inch needle will be advanced in-plane from lateral to medial. The needle tip will be placed lateral to the superior trunk and 15 20 ml of 0.5% bupivacaine will be injected just inferior to the deep cervical fasica. Local circumferential spread will be achieved both anterior and posterior to the superior trunk.
2896698|NCT03272126|Experimental|vitamin D bolus|vitamin D 160 000 IU given as bolus
2896699|NCT03272126|Experimental|vitamin D daily|vitamin D 4000 IU daily for 28 days
2896700|NCT03272126|Placebo Comparator|placebo|identical looking as vitamin d
2896701|NCT03272113|No Intervention|Control|"Usual care to provided by smoking cessation services in the two study sites. Site one: support from a specialist advisor using motivational interviewing, one to one, group and telephone support.~Site two: a smoking cessation incentive scheme administered through community pharmacies. Women who are verified by CO testing to have stopped smoking receive £12.50 per week."
2896702|NCT03272113|Experimental|Intervention|Women will receive usual care as described above plus the SKIP-IT intervention
2896703|NCT03272100||test side ( horizontal flap)|Horizontal incision was realised in alveolar mucosa, in order to obtain the exposure of the lateral wall of the maxillary sinus, thus accessing the sinus cavity
2896704|NCT03272100||control side ( standard flap)|Trapezoidal flap was realised, using a crestal incision and two deep vertical incisions extended in the fornix to expose the lateral wall of the maxillary sinus
2896705|NCT03272087|Active Comparator|Pleuroscopy|According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
2896706|NCT03272087|Active Comparator|VATS (thoracoscopy)|According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
2896707|NCT03272074|Experimental|Egg Group (Group A)|Participants will consume one large egg per day for 12 weeks
2896708|NCT03272074|Active Comparator|Egg White Group (Group B)|Participants will consume equivalent amounts of egg whites for 12 weeks
2896709|NCT03272061|Experimental|Aerobic-based exercise program|
2896710|NCT03272061|No Intervention|Control program|Maintenance of habitual physical activity levels
2896711|NCT03272048|Experimental|Low-Fear/Not-Temporary|
2896726|NCT03271996|Experimental|Primary closure|Excision of sinus and paramedian closure according to modified Karydakis technique
2896727|NCT03271996|Experimental|Fistulectomy|Removal / fistulectomy by scalpels or trephines of primary and drainage orifices and healing of the wound by second intention
2896728|NCT03271983|Other|metronidazole gel 1|RLD gel
2896729|NCT03271983|Other|metronidazole gel 2|generic gel
2896730|NCT03271983|Other|metronidazole cream|generic cream
2896731|NCT03271970||Patients with conductive hearing loss|
2896732|NCT03271944|Other|Single group 30 post menopause females.|
2896733|NCT03271931|No Intervention|Usual care|Cardiologists in this arm will receive no interventions and will act as usual care
2896734|NCT03271931|Experimental|Active choice|Cardiologists in this arm will be exposed to an active choice intervention through the electronic health record (EHR) using an alert to prompt recommendations for statin therapy for patients not on guideline-based therapy. Cardiologists will be have to make an active choice to prescribe a statin at the recommended dose or not.
2896735|NCT03271931|Experimental|Passive choice|Cardiologists in this arm will be exposed to a passive choice alert within the EHR, using the same evidence-based guidelines as in the active choice arm. The passive alert will not block clinician workflow and instead will be available in the background for the cardiologist to open and then use to make a prescribing decision.
2896736|NCT03271918|Experimental|Study Group|This group received cabergoline, in a total week dose of 3.5 mg, starting 6 months after transphenoidal surgical approach with evidence of tumoral rest in MRI and pituitary adenoma hystopathological confirmation.
2896737|NCT03271918|No Intervention|Control Group|This group was followed, with clinical visits in same frequency of study group, but without intervention.
2896738|NCT03271905|Experimental|Pressure-controled-ventilation (PCV)|Nebulization during mechanical ventilation on a pressure controled ventilation mode.
2896739|NCT03271905|Experimental|PCV and high PEEP|Nebulization during mechanical ventilation on a pressure controled ventilation mode and PEEP = 15 cmH2O.
2896740|NCT03271905|Experimental|Pressure suport ventilation (PSV)|Nebulization during mechanical ventilation on a pressure suport ventilation mode.
2896741|NCT03271892||Active surveillance|Patients under active surveillance choose to not have immediate thyroidectomy. Patients are closely monitored with respect to clinical status, ultrasound imaging, biochemical indices (thyroid function, thyroglobulin, and thyroglobulin antibodies) and any thyroid cancer-related treatments (if needed). Active surveillance is conducted at a participating study site. Criteria defining disease progression are established, and if such criteria are met, thyroid surgery is recommended to the patient. However, patients are free to choose to have thyroid surgery at any time, in the absence of disease progression. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
2896742|NCT03271892||Immediate Surgery|Patients who choose surgery, undergo thyroidectomy, as per current standards of care, by a surgeon of their choice in an institution of their choice. The treating surgeon, in discussion with the patient, will choose the extent of thyroid surgery that may be appropriate for the individual case. Post-surgical follow-up is per the discretion of the treating surgeon, endocrinologist, or other healthcare providers involved in the patient's thyroid cancer care. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
2896743|NCT03271879|Active Comparator|Empagliflozin at a dose of 10 mg/day|Patients will be treated with 10mg Empagliflozin once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
2896744|NCT03271879|Placebo Comparator|Placebo|Patients will be treated with Placebo once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
2896745|NCT03271866|Other|metformin treatment|
2896746|NCT03271866|No Intervention|non-metformin treatment|
2896747|NCT03271853||SBS II|
2896748|NCT03271827|Experimental|Apnoeic oxygenation group|Standard airway management + 3 L/min of oxygen by nasal cannula
2896749|NCT03271827|No Intervention|Standard care group|Standard airway management
2896750|NCT03271814|Experimental|LPS-Patient|Schizophrenia patients who are randomized to receive LPS injection.
2896751|NCT03271814|Active Comparator|LPS-Healthy|Healthy controls who are randomized to receive LPS injection.
2896752|NCT03271814|Placebo Comparator|Placebo-Patient|Schizophrenia patients who are randomized to receive placebo injection.
2896753|NCT03271801|Active Comparator|Child Health Education|The child health education condition will participate in a family-based obesity treatment program for the first 40 minutes of each session, followed by 20 minutes designated to education about a child health topic. Parents and children will be asked to self-monitor sugar-sweetened beverages, fruits, vegetables, and minutes of physical activity and screen time.
2896754|NCT03271801|Experimental|Skills Training|The skills training condition will participate in a family-based obesity treatment program for the first 40 minutes of each session followed by 20 minutes of experiential learning about meal stimulus control strategies. Parents and children will be asked to self-monitor sugar-sweetened beverages, fruits, vegetables, and minutes of physical activity and screen time. In addition they will self-monitor the use the following stimulus control strategies: portion control, energy density and variety.
2896755|NCT03271788|Experimental|stroke patients and caregivers|Stroke patients will conduct two phases ( A-Phase: regular occupational therapy; B-Phase occupational therapy with additional mindfulness) Caregivers of the patients will conduct the MBSR Course (Mindfulness) together with their relatives (Phase B). In Phase A they will not receive any treatment.
2896756|NCT03271775|No Intervention|control group|Patients in the control group will follow the doctor's instructions (medications and etc.) and will not participate in any physical therapy program.
2896757|NCT03271775|Experimental|PT treatment group for balance disorder|Patients in this research group will join to a 3 months' physical therapy treatment group designed to improve balance. The service for the group is provided by laboratory.
2896758|NCT03271775|Experimental|independant home computerized exercises|Patients in this group will be treated by 3 months' independent home computerized exercise program. Each patient will receive a personal access code for the exercise program. The duration of each practice is 5-10 minutes per day.
2896759|NCT03271762|Experimental|MITRACLIP NT Device|MitraClip NT System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
2897320|NCT03267719|Experimental|laser therapy|Erbium-laser therapy will be applied
2896760|NCT03271762|Active Comparator|cardiac surgery|mitral valve repair in first intervention, valve replacement if repair not feasible
2896761|NCT03271749|No Intervention|Conventional|The participants of this arm will receive the convencional pre operative, anesthesia and postoperative care for lung resections for treatment of lung neoplasms
2896762|NCT03271749|Experimental|PROSM interventional|The participants of this arm will receive the PROSM protocol pre operative, anesthesia and postoperative care for lung resections for treatment of lung neoplasms
2896763|NCT03271736|Experimental|Freezer|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
2896764|NCT03271736|Experimental|Non-freezer|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
2896765|NCT03271736|Active Comparator|Healthy control|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
2896766|NCT03271710|Experimental|Peripheral balloon angioplasty|Peripheral vascular percutaneous transluminal angioplasty (PTA) and capture and removal of embolic material during angioplasty for the femoral, iliac, popliteal and profunda arteries with the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection
2896767|NCT03271697|Experimental|AM group|Treatment group will accept Astragalus Membranaceus(AM) t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment.
2896768|NCT03271697|Placebo Comparator|Placebo group|Control group will accept placebo t.i.w treatment for 14 days from the second day of admission, in addition to standard ordinary treatment.
2896769|NCT03271684|Experimental|intervention group|Will receive one session of up to one-hour per week over a six-week period in self-management in addition to their usual rehabilitation and workbook.
2896770|NCT03271684|Other|control group|Will receive booklet consist of home exercises and education besides the usual care
2896771|NCT03271671|Active Comparator|PSV|Pressure support ventilation
2896772|NCT03271671|Experimental|NAVA|Neurally adjusted ventilator assist
2896773|NCT03271658|Experimental|Intervention|Patient/family are randomized to either the active intervention (web based life support patient decision aid - eLSDA and decision coaching) or Usual care comparison.
2896774|NCT03271658|No Intervention|Usual Care Comparison|Patients may also randomized to review current web based resources provided by the health region for seriously ill patients.
2896775|NCT03271645|Experimental|Space from depression|Space from depression is an 8 module CBT-based intervention.
2896776|NCT03271645|Experimental|Space from Anxiety|Space from anxiety CBT is an 8 module CBT-based intervention.
2896777|NCT03271645|Experimental|Space from stress|Space from stress CBT is an 8 module CBT-based intervention.
2896778|NCT03271645|Active Comparator|Face-to-face counselling|Face-to-face counselling
2896779|NCT03271632|Experimental|Single arm|CAR T cells to treat MM
2896780|NCT03271619||Transvenous ICD|Patients with a transvenous ICD undergoing defibrillation testing.
2896781|NCT03271619||Subcutaneous ICD|Patients with a subcutaneous ICD undergoing defibrillation testing.
2896782|NCT03271606|Experimental|ERAS group|The patients in this group receive enhanced measures perioperatively
2896783|NCT03271606|Active Comparator|Traditional group|The patients in this group receive traditional measures perioperatively
2896784|NCT03271593||All children admitted|All children admitted to hospital
2896785|NCT03271580||Diabetic patients infected ulcers|"Diabetic patients with HbA1c<9 with who have wound 4weeks or longer with infection with following interventions:~Finger prick test for HbA1c measurement~Punch biopsy~VAC sponge collection~Ankle brachial index"
2896786|NCT03271580||Diabetic patients non infected Ulcers|"Diabetic patients with HbA1c<9 who have wound 4 weeks or longer without infection with following interventions:~Finger prick test for HbA1c measurement~Punch biopsy~VAC sponge collection~Ankle brachial index"
2896787|NCT03271554||Alectinib|Participants with ALK-positive, locally advanced or metastatic non-small cell lung cancer, who are treated with alectinib in accordance with local clinical practice and local labeling, are observed in this study.
2896788|NCT03271541|Experimental|Bitopertin|"Part 1 - The main study - 16 weeks in total:~Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose of bitopertin.~Part 2 - Open Label Extension (OLE) - up to an additional 12 months:~Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed.~Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period."
2896789|NCT03271528|Experimental|lacosamide|
2896790|NCT03271528|Placebo Comparator|Placebo oral capsule|
2896791|NCT03271515|No Intervention|conventional therapy|patients accept conventional radioactive and chemical therapy.
2896792|NCT03271515|Experimental|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
2896793|NCT03271502|Experimental|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
2896794|NCT03271502|Active Comparator|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
2896795|NCT03271489|Experimental|Elagolix plus estradiol (E2)/norethindrone acetate (NETA)|Elagolix plus estradiol (E2)/norethindrone acetate (NETA)
2896796|NCT03271489|Placebo Comparator|Placebo|Placebo
2896797|NCT03271476|Experimental|Arms|Experimental: EMDR psychotherapy All the women will be in this arm and thus will receive the same intervention which is : 8 sessions (1 per week). The first session is an inclusion visit at Metz-Thionville Hospital, then 6 EMDR psychotherapy sessions and finally a last visit one month after for data recovery (questionnaire and semi-directive interview)
2896798|NCT03271463||Reliability/Validity of SCALE Assessment|Reliability + validity of the Selective Control Assessment of Lower Extremity (SCALE) in people with chronic stroke.
2896799|NCT03271450||Continuer at 90 Days: Dabigatran|
2896800|NCT03271450||Continuer at 180 Days: Dabigatran|
2896801|NCT03271450||Continuer at 270 Days: Dabigatran|
2896802|NCT03271450||Continuer at 90 Days: Apixaban|
2896803|NCT03271450||Continuer at 180 Days: Apixaban|
2896804|NCT03271450||Continuer at 270 Days: Apixaban|
2896805|NCT03271450||Continuer at 90 Days: Rivaroxaban|
2896806|NCT03271450||Continuer at 180 Days: Rivaroxaban|
2896807|NCT03271450||Continuer at 270 Days: Rivaroxaban|
2896808|NCT03271450||Continuer at 90 Days: Edoxaban|
2896809|NCT03271450||Continuer at 180 Days: Edoxaban|
2896810|NCT03271450||Continuer at 270 Days: Edoxaban|
2896811|NCT03271450||Continuer at 90 Days: Warfarin|
2896812|NCT03271450||Continuer at 180 Days: Warfarin|
2896813|NCT03271450||Continuer at 270 Days: Warfarin|
2896814|NCT03271450||Discontinuer at 90 Days: Dabigatran|
2896815|NCT03271450||Discontinuer at 180 Days: Dabigatran|
2896816|NCT03271450||Discontinuer at 270 Days: Dabigatran|
2896817|NCT03271450||Discontinuer at 90 Days: Apixaban|
2896818|NCT03271450||Discontinuer at 180 Days: Apixaban|
2896819|NCT03271450||Discontinuer at 270 Days: Apixaban|
2896820|NCT03271450||Discontinuer at 90 Days: Rivaroxaban|
2896821|NCT03271450||Discontinuer at 180 Days: Rivaroxaban|
2896822|NCT03271450||Discontinuer at 270 Days: Rivaroxaban|
2896823|NCT03271450||Discontinuer at 90 Days: Edoxaban|
2896824|NCT03271450||Discontinuer at 180 Days: Edoxaban|
2896825|NCT03271450||Discontinuer at 270 Days: Edoxaban|
2896826|NCT03271450||Discontinuer at 90 Days: Warfarin|
2896827|NCT03271450||Discontinuer at 180 Days: Warfarin|
2896828|NCT03271450||Discontinuer at 270 Days: Warfarin|
2896829|NCT03271437|Experimental|PC-trained therapists|
2896830|NCT03271437|Experimental|EMDR-trained therapists|
2896831|NCT03271424|No Intervention|Focus Group Discussions|Focus group discussions (FGD) with young women (n=2 FGDs) and young men (n=2 FGDs) in the study area to determine the best way to offer self-testing to study participants.
2896832|NCT03271424|Active Comparator|In Clinic Observation-Both|10 young women and 10 young men were assigned and conducted BOTH of the HIV self-tests. Participants tried two different self-testing kits, one that is oral fluid based (saliva), Oraquick HIV Self Test, and one that is blood based via a finger prick, Atomo HIV Self Test. Oraquick HIV Self Test and Atomo HIV Self Test - Both
2896833|NCT03271424|Active Comparator|In Clinic Observation-Subject Choice|20 young women and 20 young men were assigned and conducted EITHER of the HIV self-tests. Investigators asked them to choose which test they would prefer to use, one that is oral fluid based (saliva), Oraquick HIV Self Test, or one that requires the use blood via a finger prick, Atomo HIV Self Test. Oraquick HIV Self Test - Choice; Atomo HIV Self Test - choice
2896834|NCT03271411|Experimental|Eye movement desensitization and reprocessing (EMDR) arm|
2896835|NCT03271411|Experimental|Progressive counting (PC) arm|
2896836|NCT03271398||Adult victims of sexual assault|
2896837|NCT03271398||Children who have been exposed to domestic abuse|
2896838|NCT03271398||Women with perinatal emotional complications|
2896839|NCT03271398||Teens with behavior problems and histories of abuse|
2896840|NCT03271398||Veterans with military-related trauma|
2896841|NCT03271398||Survivors of intimate partner violence|
2896842|NCT03271385||hypertrophic cardiomyopathy group|The hypertrophic cardiomyopathy was diagnosed by left ventricular hypertrophy via echocardiography (wall thickness >15 mm) with either genetic determination of a pathogenic mutation or ) left ventricular hypertrophy (LVH) (end-diastolic wall thickness >15 mm) with resting left ventricular outflow tract obstruction or hypertrophy in a recognisable pattern, i.e., ventricular bulge in apical-variant HCM. And then patients with hypertrophic cardiomyopathy were evaluated by the predetermined differentiating formula.
2896843|NCT03271385||hypertensive heart disease group|The diagnosis of hypertensive heart disease was based on medical history and conventional echocardiography. Long durations of uncontrolled hypertension for at least 5 years with systolic blood pressure [BP] ≥150 mm Hg or diastolic BP ≥90 mm Hg or both in the absence of other cardiac or systemic diseases were used as criteria. And then patients with hypertensive heart disease were evaluated by the predetermined differentiating formula.
2896844|NCT03271385||control group|The healthy age-matched controls were generally volunteers with a normal electrocardiogram, normal echocardiographic examination, and overall normal CMR findings. And then patients with normal findings were were evaluated by the predetermined differentiating formula.
2896845|NCT03271372|Experimental|Arm I (avelumab)|Patients receive avelumab IV over 1 hour once every 15 days for the first 120 days (Induction Phase 1), once every 30 days for the next 120 days (Induction Phase 2), and then once every 120 days (Maintenance Phase) for a maximum of 720 days (approximately 24 months or 2 years total) in the absence of disease progression or unacceptable toxicity.
2896846|NCT03271372|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV over 1 hour once every 15 days for the first 120 days (Induction Phase 1), once every 30 days for the next 120 days (Induction Phase 2), and then once every 120 days (Maintenance Phase) for a maximum of 720 days (approximately 24 months or 2 years total) in the absence of disease progression or unacceptable toxicity.
2896847|NCT03271359|Experimental|Eye movement desensitization and reprocessing (EMDR) arm|
2896848|NCT03271359|Experimental|Progressive counting (PC) arm|
2896849|NCT03271333||patients with systemic sclerosis|
2896850|NCT03271320||systemic sclerosis|patients with systemic sclerosis
2896852|NCT03271307|No Intervention|Standard of care|Facilities assigned to the standard of care arm will not receive an intervention and will continue with Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for Aim 1 and partner referral mechanisms for Aim 2. PITC guidelines recommend OPD and STI providers to inform their patients about HIV testing and refer them to HIV testing services at the facility. Partner referral mechanism recommendations advise providers to offer partner referral slips to newly identified HIV-positive clients to monitor the number of partners presenting to the facility for HIV testing.
2896853|NCT03271307|Experimental|Optimized standard of care|Facilities assigned to the optimized standard of care arm will receive additional guidance and support from the study team to adopt the Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for Aim 1 and partner referral mechanisms for Aim 2.
2896854|NCT03271307|Experimental|HIV self-testing|Facilities assigned to the HIV self-testing arm will implement HIV self-testing procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (PITC and partner referral slips).
2896855|NCT03271294|Other|Exair transvaginal mesh surgery|This is a prospective study done in 80 consecutive subjects who underwent the Exair transvaginal mesh surgery from June 2013 to August 2015. The subjects were followed at 4 weeks, 6 months and 12 months post-operatively. All eligible subjects underwent a detailed urogynecologic history and examination including a Pelvic Organ Prolapse Quantification system assessment (POP-Q).
2896856|NCT03271281|Experimental|Experimental: Angiogenesis PET/CT|One injection of the radioligand 68Ga-NODAGA-E[c(RGDyK)]2 followed by PET/CT
2896857|NCT03271255|Experimental|Arm Apatinib|"Apatinib-FOLFIRI:~Apatinib Mesylate Tablets 500 mg po qd; Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1; Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1; 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion; Repeat every 2 weeks."
2896858|NCT03271255|Active Comparator|Arm Bevacizumab|"Bevacizumab-FOLFIRI:~Bevacizumab Injection 5 mg/kg IV over 30 minutes,day 1; Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1; Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1; 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion; Repeat every 2 weeks."
2896859|NCT03271242||Implementation support|Units and their patients where the unit according to pairwise randomization is offered systematic implementation support for 18 months for the specific practice.
2896860|NCT03271242||No implementation support|Units and their patients where the unit according to pairwise randomization is not offered systematic implementation support for 18 months for the specific practice.
2896861|NCT03271229|Active Comparator|Stem Cells|Participants will have Concentrated Bone Marrow Aspirate (BMAC) injections into symptomatic knee
2896862|NCT03271229|Active Comparator|Plasma|Participants will have Platelet-Rich Plasma (PRP) injections into symptomatic knee
2896863|NCT03271203||Subjects participating in the CE and CD interview|Thirty adult subjects from the US with erosive HOA will be asked to participate in CE and CD interviews.
2896864|NCT03271203||Subjects participating in interview and real time data capture|Ten adult subjects from the US (n=5 with erosive HOA, n=5 with non-erosive HOA) of the thirty subjects who are participating in the CE and CD interviews, will be asked to participate in the real-time data capture app task
2896865|NCT03271190|Experimental|ENGAGE SPANISH/MUSIC|Cognitive strategies to improve attention and memory skills and application in selected leisure activities (music or Spanish lessons, and videogames) over 4 months.
2896866|NCT03271190|Active Comparator|ENGAGE DISCOVERY|Educational program about brain and healthy aging complemented by learning of new information with videogames, documentaries and group discussions over 4 months.
2896867|NCT03271177|Experimental|7F Sheathless Guide Catheter|Patients in this arm will undergo their percutaneous coronary intervention using a 7F Sheathless guide catheter
2896868|NCT03271177|Placebo Comparator|6F Sheath/Guide Catheter Combination|Patients in this arm will undergo their percutaneous coronary intervention using a 6F Sheath/guide combination
2896869|NCT03271164|Experimental|Treatment with FBPM10 system|One breast will be randomized to be treated with FBPM10 System.
2896870|NCT03271164|Active Comparator|Treatment with standard of care|One breast will be selected to be treated with massages with vitamin E cream.
2896871|NCT03271151|Experimental|"Duloxetine (Cymbalta)"|"Epidural analgesia after knee arthroplasty is not as prevalent at HSS as formerly, in large part due to the rise of local infiltration analgesia. Studies using epidural analgesia may also lack generalizability given the infrequent use of epidural analgesia at other institutions. For these reasons, we plan to use adductor canal nerve blockade + local infiltration analgesia for management of immediate postoperative pain. Patients will receive spinal anesthesia as the primary anesthetic. It is particularly important to study duloxetine (Cymbalta) in the context of local infiltration analgesia, as patients receiving local infiltration analgesia receive increased doses of opioids, compared to patients receiving epidural analgesia."
2896872|NCT03271151|Placebo Comparator|Placebo|Placebo to compare pain scores and opioid use againts Duloxetine
2896873|NCT03271138|Active Comparator|Bifidobacterium Infantis NLS Super Strain|Participants in the probiotic period will take two capsules of Bifidobacterium infantis NLS super strain (Natren LIFE START®2) three times per day for three weeks. Each capsule contains 2 x 10^9 colony-forming units (CFU) of Bifidobacterium infantis NLS super strain, for a total daily dose of 12 X 10^9 CFU. The probiotic will be kept refrigerated during transportation and throughout the study period.
2896874|NCT03271138|Placebo Comparator|Placebo|Participants in the placebo period will take two capsules of placebo three times per day for three weeks. The placebo capsules contain rice flour, hydroxypropyl and methylcellulose. The placebo will be kept refrigerated during transportation and throughout the study period.
2896875|NCT03271125|Experimental|Treadmill group|Participants in the experimental group received supervised treadmill training
2896876|NCT03271125|Active Comparator|Resistance group|Participants in the control group were treated with Resistance exercises.
2896877|NCT03271112|Other|Exercise program|Participation to the 12-wks exercise program
2896878|NCT03271099|No Intervention|Usual Care|Usual care
2896879|NCT03271099|Experimental|Navigator|Patient navigator services provided as part of survivorship care plan
2896918|NCT03270839|Placebo Comparator|Non-responsive to Scopolamine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
2896880|NCT03271086|Experimental|Relaxation breathing training|Dyads of a parent and their child in this group will receive training on how to use breathing to relax with the StressEraser in the pediatric clinic and will then practice the breathing for about 4 weeks They will also complete a baseline questionnaire and two questionnaires one month after the training.
2896881|NCT03271086|Experimental|Technology-enhanced relaxation breathing|Dyads of a parent and their child in this group will receive technology-enhanced training on how to use breathing to relax with the StressEraser and the app Breathe2Relax in the pediatric clinic and will then practice the breathing for about 4 weeks and weekly receive weekly reminder text messages to practice their relaxation breathing. They will also complete a baseline questionnaire and two questionnaires one month after the training.
2896882|NCT03271073|Experimental|Apatinib plus S1|patients with advanced gastric cancer enrolled after failure of first-line systemic chemotherapy will be given Apatinib plus S1 till progressive disease,death or non-tolerable toxicity
2896883|NCT03271060|Active Comparator|Lumbar spondylolisthesis1|
2896884|NCT03271060|Active Comparator|Lumbar spondylolisthesis 2|
2896885|NCT03271047|Experimental|Phase 1b / Arm 1A|binimetinib + nivolumab
2896886|NCT03271047|Experimental|Phase 1b / Arm 1B|binimetinib + nivolumab + ipilimumab
2896887|NCT03271047|Experimental|Phase 2 / Arm 2A|binimetinib + nivolumab
2896888|NCT03271047|Experimental|Phase 2 / Arm 2B|binimetinib + nivolumab + ipilimumab
2896889|NCT03271034|Experimental|Baseline Lipedema characterization|Body composition and Fat distribution, adipose tissue biology, metabolic and immune function in women with Lipedema. Participants will receive a low-calorie diet therapy in the form of low calorie meals or shakes.
2896890|NCT03271021|Experimental|FMX101, 4% minocycline foam|FMX101, 4% minocycline foam applied topically once daily for 12 weeks
2896891|NCT03271021|Placebo Comparator|Vehicle foam|Vehicle foam applied topically once daily for 12 weeks
2896892|NCT03271008|Active Comparator|Macintosh laryngoscopy|In this group intubation attempt is carried out with a standard Macintosh (size 3 or 4) direct laryngoscopy blade.
2896893|NCT03271008|Active Comparator|KingVision videolaryngoscope|In this group intubation attempt is carried out with KingVision videolaryngoscope with a channeled, disposable single-use blade.
2896894|NCT03271008|Active Comparator|VividTrac videolaryngoscope|In this group intubation attempt is carried out with VividTrac Adult model using a smartphone or laptop running the VividVision proprietary software.
2896895|NCT03270995|Experimental|Group 1|Behavioral:Cognitive Existential Therapy Group 1- Weekly two-hour group sessions
2896896|NCT03270995|Active Comparator|Group 2|Behavioral: Supportive Therapy Group 2- Weekly two-hour group sessions
2896897|NCT03270982||Comprehensive SRS Replacement|
2896898|NCT03270969|Experimental|TDF/FTC|Tenofovir Disoproxil Fumarate/Emtricitabine group HIV-uninfected transgender women receiving feminizing hormone therapy plus tenofovir disoproxil fumarate/emtricitabine
2896899|NCT03270956|Experimental|Neo-Kidney Augment|Neo-Kidney Augment (NKA) Treatment - Patients will receive their first treatment of 2 injections of NKA as soon as NKA product is made available.
2896900|NCT03270943|Experimental|Mindful Self-Compassion (MFY)|An 8-week mindfulness self-compassion course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
2896901|NCT03270943|Active Comparator|Healthy Lifestyles (TCY)|An 8-week healthy lifestyles course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
2896902|NCT03270930||Survived|Pediatric patients in the age group of 5 to 10 years presenting with acute abdomen and undergoing emergency laparotomy who survived during their index 30-day hospital stay
2896903|NCT03270930||Expired|Pediatric patients in the age group of 5 to 10 years presenting with acute abdomen and undergoing emergency laparotomy who expired during their index 30-day hospital stay
2896904|NCT03270917|Other|Open|Open liver surgery
2896905|NCT03270917|Other|Laparoscopy|Laparoscopic liver surgery
2896906|NCT03270904|Experimental|Group 1 - Interventional Treatment|Participants in this group have been randomised to receive application of violet blue light administered by the hand held Microlight i:X device in addition to routine care of their foot ulcer. This intervention will be administered four times during the study.
2896907|NCT03270904|No Intervention|Group 2 - Usual care|This group receive routine care and no additional intervention.
2896908|NCT03270891|Active Comparator|Delayed intervention (control arm)|Patients in this arm will have PGx test results made available to physicians 3 months after study enrollment
2896909|NCT03270891|Experimental|PGx Test|Patients in this arm will have PGx test results made available to physicians as soon available after enrollment.
2896910|NCT03270878|Experimental|Glasdegib Oral tablet then IV|Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions in the first study period followed by washout. Then in the second period, a 50 mg IV solution will be infused over approximately 1.25 hours under fasted conditions.
2896911|NCT03270878|Experimental|Glasdegib IV solution followed by Oral tablet|Subjects will receive a 50 mg IV solution will be infused over approximately 1.25 hours in the fasted condition followed by washout in the first study period . Then in the second period, a single 100 mg oral tablet of glasdegib will be administered under fasted conditions
2896912|NCT03270865|Experimental|Usability and Ergonomic Evaluation of Self-Positioning System|
2896913|NCT03270852|Experimental|Enhanced reality|"Patients are provided with occupational therapy and physical therapy (task-oriented OT 30 min, FES 20 min) daily for 50 minutes.~ER therapy is provided 2 times a day for 10 minutes for 2 weeks (10 days of treatment week), except for time of installation, calibration, and 3 minute breaks."
2896914|NCT03270852|Active Comparator|No Enhanced reality|Patients are provided with occupational therapy and physical therapy (task-oriented OT 30 min, FES 20 min) daily for 50 minutes.
2896915|NCT03270839|Active Comparator|Responsive to Scopolamine (Active)|Scopolamine administration - subject will take 1 tablet per os (Kwells, Hyoscine Hydrobromide 0.3mg, 1*day )
2896916|NCT03270839|Placebo Comparator|Responsive to Scopolamine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
2896917|NCT03270839|Active Comparator|Non-responsive to Scopolamine (Active)|Scopolamine administration - subject will take 1 tablet per os (Kwells, Hyoscine Hydrobromide 0.3mg, 1*day )
2939581|NCT02974491|Experimental|Apple Juice|
2896919|NCT03270839|Active Comparator|Responsive to Meclizine (Active)|Meclizine administration - subject will take 1 tablet per os (Bonine 25Mg Chewable Tablet, Meclizine Hydrochloride 25mg, 1*day )
2896920|NCT03270839|Placebo Comparator|Responsive to Meclizine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
2896921|NCT03270839|Active Comparator|Non-responsive to Meclizine (Active)|Meclizine administration - subject will take 1 tablet per os (Bonine 25Mg Chewable Tablet, Meclizine Hydrochloride 25mg, 1*day )
2896922|NCT03270839|Placebo Comparator|Non-responsive to Meclizine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
2896923|NCT03270813|Experimental|RAGE-Control|There are 6 research intervention sessions, which will involve Relaxation training plus RAGE-Control. The first session includes a 30-minute lesson on the relationship between physiological arousal and anger, introduction to the RAGE-Control videogame and 15 minutes of videogame play. The next 5 sessions include a 10-minute check in about symptoms and functioning, a brief presentation of a relaxation skill, and 15 minutes of videogame play.
2896924|NCT03270813|Sham Comparator|Sham videogame|There are 6 research intervention sessions, which will involve Relaxation training plus Sham videogame. The first session includes a 30-minute lesson on the relationship between physiological arousal and anger, an introduction to the Sham videogame and 15 minutes of videogame play. The next 5 sessions include a 10-minute check in about symptoms and functioning, a brief presentation of a relaxation skill, and 15 minutes of videogame play.
2896925|NCT03270800|Experimental|IMX101 vaccine as intradermal and sublingual application|IMX101 vaccine will be administered intradermally and sublingually
2896926|NCT03270800|Experimental|CTA control as intradermal and sublingual application|CTA mucosal adjuvans will be administered intradermally and sublingually
2896927|NCT03270787|Placebo Comparator|Placebo Comparator|Placebo Comparator: controlled group Placebo,10pills,tid,po
2896928|NCT03270787|Experimental|Compound danshen dripping pills|Compound danshen dripping pills Compound danshen dripping pills ,10pills,tid,po
2896929|NCT03270748|Experimental|Experimental|Experimental: Experimental The experimental consists in the application of a therapeutic strategy: post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies Therapeutic intervention, namely conditioning regimen and GVHD prophylaxis, are based on standard current regimens: Busulfan 0,8 mg/kg 4 times per day during 2 h infusions for 4 consecutive days (from day −6 through day −3) Fludarabine 40 mg/m2 per day for 4 days (from day −6 through day −3); GvHD prophylaxis: Cyclosporine or Tacrolimus beginning day+5 up to at least 100 days. Micofenolate 15mg/kg twice a day from day +5 to +35.
2896930|NCT03270735|Experimental|Treatment|Snake venom thrombin
2896931|NCT03270735|Placebo Comparator|Placebo|Snake venom thrombin simulant
2896932|NCT03270722|Experimental|patients with scleroderma and trouble swallowing|
2896933|NCT03270722|Experimental|patients with scleroderma but no trouble swallowing|
2896934|NCT03270722|Active Comparator|patients without scleroderma undergoing endoscopy|
2896935|NCT03270709|Experimental|HIV+ smokers|Vitamin D3 500,000 IU orally
2896936|NCT03270709|Active Comparator|HIV- non-smokers|Vitamin D3 500,000 IU orally
2896937|NCT03270709|Active Comparator|HIV+ non-smokers|Vitamin D3 500,000 IU orally
2896938|NCT03270709|Active Comparator|HIV- smokers|Vitamin D3 500,000 IU orally
2896939|NCT03270696|Experimental|simultaneous administration of propofol and rocuronium|"In this group, the investigator will administrate propofol (2ml/kg) and rocuronium (0.6mg/kg) simultaneously, and start facemask ventilation after patient loss consciousness to induce general anesthesia.~The investigator will measure the mean tidal volume (TV) applied during facemask ventilation for 1 minute."
2896940|NCT03270696|Experimental|ordinal administration of propofol and rocuronium|"In this group, the investigator will administrate propofol (2ml/kg) first, and follow injection of rocuronium (0.6mg/kg) after patient loss consciousness and confirming facemask ventilation.~The investigator will measure the mean tidal volume (TV) applied during facemask ventilation for 1 minute."
2896941|NCT03270657|Other|IPG; RC+S|Subjects will be recruited and enrolled from individuals who have Parkinson's disease (PD) and who are scheduled to already undergo the planned deep brain electrode placement for treatment of their movement disorder.This intraoperative study will specifically compare our ability to record neural activity using circuitry developed at Duke for this purpose [Kent et al, 2015] to a new, implanted pulse generator (IPG; RC+S) developed by Medtronic. These intraoperative studies will specifically test a preliminary version of the RC+S (that is not designed for implantation), and will lead to a clinical trial assessing the efficacy of the implantable RC+S IPG in PD patients once this device is available and approved for this trial.
2896942|NCT03270644|Experimental|Lasmiditan|Single oral dose of lasmiditan on Day 1
2896943|NCT03270644|Active Comparator|Propranolol|Twice daily oral doses of propranolol on Days 4-10
2896944|NCT03270644|Experimental|Lasmiditan + Propranolol|Single oral dose of lasmiditan + two oral doses of propranolol on Day 9
2896945|NCT03270631|No Intervention|Control|Multidisciplinary rehabilitation, no interventions
2896946|NCT03270631|Experimental|FM and MCE|Subjects will have 4-5 times of fascial manipulation (FM) treatment and 4-6 times movement control exercises (MCE) at home to be done based on movement control testing (MCT). Both are given in 3 month period.
2896947|NCT03270631|Other|FM and sham-MCE|FM 4-5 times in 3 months and 4 general exercise prescription.
2896948|NCT03270631|Other|MCE and sham-FM|Sham-FM 4 times in 3 months including trigger point treatment in before decided points and 4-6 times MCE prescription and home exercises.
2896949|NCT03270631|Sham Comparator|Sham-MCE and sham-FM|4 general practice guiding and Sham-FM 4 times in 3 months including trigger point treatment in before decided points.
2896950|NCT03270605||Cesarean Myomectomy|patient with uterine fibroid during pregnancy and subjected to myomectomy during delivery by cesarean section
2896951|NCT03270605||Cesarean section|patient with uterine fibroid during pregnancy and delivered by cesarean section without myomectomy
2896952|NCT03270592|Other|Service dogs|Single arm study using a before after design where Before represent having a regular companion dog and after represent having a certified service dog
2897117|NCT03269214|No Intervention|control group|Patients underwent debridement of necrotic bone and the involved area closed primary
2896953|NCT03270579|Experimental|Part A: [18F]JNJ-64511070|Participants will receive an intravenous (IV) bolus injection of [18F]JNJ-64511070 at a dose of 185 megaBecquerel (MBq) on Day 1 of Part A to investigate the total body biodistribution and measure the radiation dosimetry of [18F]JNJ-64511070.
2896954|NCT03270579|Experimental|Part B: [18F]JNJ-64511070|Participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq on Day 1 of Part B to measure the uptake, binding, distribution, and washout of [18F]JNJ-64511070 and to model the tissue specific kinetics of [18F]JNJ‑64511070 in the human brain with the appropriate arterial IF.
2896955|NCT03270566|Experimental|Domestic ion-exchange water softener|The intervention group will have a domestic ion-exchange water softener installed prior to birth.
2896956|NCT03270566|No Intervention|Usual hard water supply|The control group will receive their usual domestic water supply.
2896957|NCT03270553|Experimental|Sequence 1|In Period 1, subjects receive metformin alone; in Period 2, subjects receive metformin + plazomicin
2896958|NCT03270553|Experimental|Sequence 2|In Period 1, subjects receive metformin + plazomicin; in Period 2, subjects receive metformin alone
2896959|NCT03270527|Experimental|High SFA diet to low SFA diet|Participants will undergo, sequentially, a high SFA diet (Diet 1) followed by a low SFA diet (Diet 2) for 4 weeks each. Study visits will occur before and after each dietary intervention period. To comply with current UK dietary recommendations, Diets 1 and 2 will both contain ~35% energy from total fat. These diets will be consumed within the homes of free-living participants, by the substitution of ~40g of habitual fat, with either SFA-rich or mono/poly-unsaturated fatty acid-rich (MUFA/PUFA) cooking oils, spreads and snack foods, while maintaining their habitual diet (consistent intake of protein and carbohydrates, including dietary fibre). This will be achieved using a dietary exchange model developed for the 'DIVAS' study (Vafeiadou K et al (2015) Am J Clin Nut 102, 40-8).
2896960|NCT03270514|Experimental|Exparel Injectable Product|Liposomal Bupivacaine Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the LB group (~59).
2896961|NCT03270514|Active Comparator|Bupivacaine Hydrochloride|Bupivacaine Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the bupivacaine group (~59).
2896962|NCT03270501|Experimental|Arm 1: Golimumab|
2896963|NCT03270488|Experimental|Laser Group|Laser application three times a week for 4 weeks.
2896964|NCT03270488|Placebo Comparator|Placebo group|The same equipment was used with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
2896965|NCT03270475|Experimental|Exercise|12-15 training sessions of 30 min over 4-5 weeks
2896966|NCT03270462|Other|Envarsus XR|A form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant.
2896967|NCT03270449|Experimental|Multidisciplinary intervention|The 10-week intervention will include twice weekly 1-2 hours sessions with multiple professional team members to undergo education and exercise sessions. The multidisciplinary team will consist of a rheumatologist, rheumatology nurse, dietitian, physiotherapist, a trained exercise therapist, a physiologist who specializes in pain management, a psychiatrist and a mental health clinician. All intervention team members have expertise in working with individuals with chronic pain conditions. General disease information, current best practices and techniques such as self-pain management, pacing, sleep hygiene, approach to a healthy lifestyle and weight loss will be discussed. The total number of hours for the 10 week intervention is 31 hours.
2896968|NCT03270449|No Intervention|Usual care|Usual care involves being referred to the local rheumatologist involved in the study. The rheumatologist and the rheumatology nurse will see the control group patients during a one hour one on one consultation appointment. During that time the patient's history will be taken, physical exam performed and investigations analyzed. If a diagnosis of fibromyalgia is confirmed, the rheumatologist and nurse will counsel the patient and provide resources for self directed management. Unless there is a concern of an alternative diagnosis, follow up will not be arranged.
2896969|NCT03270436|Active Comparator|Traditional Diabetes Prevention Education|
2896970|NCT03270436|Experimental|Pacific Diabetes Prevention Education|
2896971|NCT03270423|Active Comparator|Intervention SG|Therapy during 6 months with PathMate2 design. 6 therapy visits + PathMate2 over 6 months
2896972|NCT03270423|No Intervention|Control SG|Therapy during 6 months with usual care. 10 therapy visits over 6 months
2896973|NCT03270423|Active Comparator|Intervention VD|Adapted sport session 1h/week + PathMate-S during 6 months
2896974|NCT03270423|No Intervention|Control VD|Adapted sport session 1h/week during 6 months
2896975|NCT03270410||Neonates|Babies born in Rennes University Hospital
2896976|NCT03270397|Experimental|Active participants|"The first 20 students who signed up for the course: The group- theory and practice were included. No exclusion criteria were used. Full attendance in the course which includes 13 sessions was mandatory. In each session, students were assigned to different body image tasks that were discussed in the coming session. All students completed a self-report questionnaire at baseline and conclusion of the course."
2896977|NCT03270397|No Intervention|Controls|All the other students, that requested to sign up for the course but did not have a place, served as control group. All students completed a self-report questionnaire at baseline and conclusion of the course.
2896978|NCT03270384|Experimental|Treatment|Up to 15 subjects will be enrolled and treated with the Urotronic drug coated balloon (DCB)
2896979|NCT03270371|Experimental|MCO Dialysis|Theranova Dialyzer
2896980|NCT03270371|Active Comparator|Standard High Flux Dialysis|Standard High Flux Dialyzer
2896981|NCT03270358|Experimental|patient with stenosis|Patient coming to the vascular surgery unit to receive surgery regarding their fistula stenosis
2896982|NCT03270358|Other|patient without stenosis|Patient coming for their dialysis
2896983|NCT03270332|Experimental|albuterol first then placebo|For albuterol first then placebo, echocardiographic measurements will be made before and at 15, 30, 60, and 120 min after inhaled albuterol (270ug) at visit 2, and echocardiographic measurements before and at 15, 30, 60, and 120 min after inhaled placebo at visit 3
2896984|NCT03270332|Experimental|placebo first then albuterol|For placebo first then albuterol, echocardiographic measurements will be made before and at 15, 30, 60, and 120 min after inhaled placebo at visit 2 and inhaled albuterol (270ug) at visit 3
2898016|NCT03262428||Patients|Patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
2896985|NCT03270319||ICU patient|"Critically ill patients in our adult intensive care unit with the following characteristics:~advanced hemodynamic monitoring in place including pulmonary artery catheter and arterial catheter~intubated or tracheostomy in place~echocardiography requested by the treating physician~intervention of interest: hemodynamic assessment done by echocardiography and thermodilution (pulmonary artery catheter)"
2896986|NCT03270293|Experimental|Profhilo|"The intradermal procedure was performed bilaterally on the face, at level of the following five points:~zygomatic protuberance~nostril's angle~inferior margin of tragus~lip marionette lines~mandibular angle. The amount of product injected, was 0.2 ml for each injection-point."
2896987|NCT03270280|Placebo Comparator|Normal Saline|The group contains healthy individuals with chronic periodontitis who will receive Normal Saline as placebo
2896988|NCT03270280|Experimental|Nigella Sativa|The group contains healthy individuals with chronic periodontitis who will receive Nigella sativa Oil as intervention
2896989|NCT03270267||Patients with IBD|
2896990|NCT03270254|No Intervention|root surface debridement (RSD)|Standard care - root surface debridement (RSD)
2896991|NCT03270254|Active Comparator|light activated dye (PDT)|light activated dye photodynamic therapy (PDT)
2896992|NCT03270241|Experimental|Phototherapy (NB-UVB)|Phototherapy (NB-UVB) will be administered for all enrolled subjects. The starting dosage will be 250 mJ/cm2. The dose will be increased by 10% with each treatment, as long as there are no side effects with treatment.
2896993|NCT03270202|Experimental|PAI group|Participants randomized to the PAI-group will receive a wearable device (Mio Slice PAI wristband) that measure heart rate continuously and via an algorithm calculates a physical activity score called PAI. The weekly goal of 100 PAI can be reached by a combination of different intensities and durations and the participants will get continuous information about their current score and amount of activity needed to reach the goal. 100 PAI is expected to approximate current guidelines of 150 minutes of moderate intensity or 75 minutes of vigorous intensity for the average participant or somewhat less if the intensity of the chosen activity is high. Proper instruction in use of the device and App will be given both oral and written after baseline testing and randomization.
2896994|NCT03270202|Active Comparator|Usual care|Usual care: Participants in the control group will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.
2896995|NCT03270189|Experimental|orthoptic treatment|Patients with cervical dystonia occuring only during handwriting.
2896996|NCT03270189|No Intervention|Controls|Patients without cervical dystonia.
2896997|NCT03270176|Experimental|Debio 1143 and Avelumab|"Part A: Participants will receive Debio 1143 100 to 250 milligram (mg) capsule orally at an escalating dose levels for 10 days every 2 weeks along with avelumab 10 mg/kg as an intravenous (IV) infusion every 2 weeks.~Part B: Participants will receive Debio 1143 capsules orally at a recommended phase 2 dose (RP2D) established in Part A along with avelumab IV infusion at a RP2D dose established in Part A up to years unless disease progression or unacceptable toxicity occurs, as judged by investigators."
2896998|NCT03270163|Experimental|Experimental|Transcutaneous electrical stimulation of quadriceps
2896999|NCT03270150|Experimental|BTL-799 Therapy Arm|BTL-799 therapy, 4 therapies
2897000|NCT03270137|Active Comparator|Condition A: rTMS on L-DLPFC|"Repetitive transcranial magnetic stimulation- IDLPFC. The intervention will be rTMS delivered on left dorsolateral prefrontal cortex (L-DLPFC).~Every patient will receive 15 rTMS sessions (in weekdays) along three weeks at 5 Hz of frequency and at its 100% of motor threshold. Each session will consist of 30 trains separated by 10 seconds inter-train interval and 1500 total pulses per session.~Equipment to rTMS includes a Magpro R30 stimulator (Magventure, Denmark) with an 8-shape coil model MCF-B70."
2897001|NCT03270137|Active Comparator|Condition B: rTMS on six regions|"Repetitive transcranial magnetic stimulation - Six regions. Two sub-conditions will alternate each session, starting with day 1: rTMS on Broca and Wernicke area and lDLPFC and then day 2: rTMS on left and right parietal association cortex (lPAC; rPAC) and right dorsolateral prefrontal cortex (rDLPFC).~Patients will receive 15 intervention sessions (in weekdays) along three weeks at 5 Hz frequency and 100% of motor threshold. Each area will receive 10 trains (500 pulses) separated by 10 seconds of inter-train interval that correspond to 1500 total pulses per session.~Equipment to rTMS includes a Magpro stimulator (Dantec, Denmark) with an 8-shape coil model MC-B70."
2897002|NCT03270124|Active Comparator|No Resistance Exercise and No Activity Goal Arm|Blinded use of Fitbit with no daily activity goal and no resistance exercises
2897003|NCT03270124|Experimental|Resistance Exercise and Activity Goal Arm|Unblinded use of Fitbit with a daily activity goal (active minutes per day) and resistance exercises
2897004|NCT03270111|Experimental|A2: Breast Cancer Survivor|Participants will include breast cancer survivors who take part in a weight loss intervention program. The intervention is the same for all participants.
2897005|NCT03270111|Experimental|B: High Risk Women|Participants will include women at high risk of breast cancer who take part in a weight loss intervention program. The intervention is the same for all participants.
2897006|NCT03270098|Experimental|Aerobic Exercise|using traditional exercise equipment (i.e., treadmill, stationary bike) along with active-play video games (Xbox Kinect).
2897007|NCT03270098|Active Comparator|Stretching and Toning Exercise|
2897008|NCT03270085|Active Comparator|Colesevelam|"Once randomized, subjects will have baseline testing period, treatment period, and treatment testing period the study drug. This consists of nine visits and will be over a period of five to nine weeks.~Baseline testing period consists of: transit test, 4 day high fat diet with 48 hour stool collection, blood samples, rectosigmoid biopsies, one week stool diary, and medication pick up.~Treatment period will have subject take the study drug 1875 mg of medication orally twice daily with lunch and supper for 4-5 weeks.~The last period, is the treatment testing period. This consists of a full transit & urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused medication."
2897009|NCT03270085|Placebo Comparator|Placebo|"Once randomized, subjects will have a baseline testing period, treatment period and treatment testing period with the placebo. This consists of nine visits and will be over a period of five to nine weeks.~The last period, is the treatment testing period. This consists of a full transit & urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused placebo."
2898017|NCT03262428||Caregivers|Caregivers of patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
2897010|NCT03270072||Photon Therapy|The patients being treated on the Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) at Massachusetts General Hospital that were randomized to receive photon therapy.
2897011|NCT03270072||Proton Therapy|The patients being treated on the Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) at Massachusetts General Hospital that were randomized to receive proton therapy
2897012|NCT03270059|Experimental|Group I (gadolinium, ferumoxytol, MRI)|Patients receive gadolinium IV and then ferumoxytol IV and undergo MRI over 60 minutes on day 1.
2897013|NCT03270059|Experimental|Group II (ferumoxytol, gadolinium, MRI)|Patients receive ferumoxytol IV and then gadolinium IV and undergo MRI over 60 minutes on day 1.
2897014|NCT03270046|Placebo Comparator|No enema group|"Consecutive participants will be randomly assigned to take a preparation regimen of 3 liter of PEG 8-16 hr. before colonoscopy without water enema.~Before the procedure, investigators record baseline parameters. Colonoscopies underwent by experienced endoscopists and by GI fellows. During the colonoscopy, the investigators recorded video, cecal intubation and withdraw time, amount and position of polyps, rate of complete examination and complication. The video was sent to other 2 endoscopists who did not known which participant was enema to evaluate the quality of bowel cleansing by using Ottawa bowel preparation scale and Likert scale for evaluation of side effect, complication during PEG ingestion, enema and colonoscopy, and participant satisfactory."
2897015|NCT03270046|Active Comparator|Water enema group|"Consecutive participants will be randomly assigned to take a preparation regimen of 3 liter of PEG 8-16 hr. before colonoscopy and enema with sterile water until stool was clear or patient felt discomfort but not exceed 3 liter, before colonoscopy.~Before the procedure, investigators record baseline parameters. Colonoscopies underwent by experienced endoscopists and by GI fellows. During the colonoscopy, the investigators recorded video, cecal intubation and withdraw time, amount and position of polyps, rate of complete examination and complication.The video was sent to other 2 endoscopists who did not known which participant was enema to evaluate the quality of bowel cleansing by using Ottawa bowel preparation scale and Likert scale."
2897016|NCT03270033|Active Comparator|Dexamethasone|4 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
2897017|NCT03270033|Active Comparator|Dexmedetomidine|50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
2897018|NCT03270033|Active Comparator|Dexamethasone and Dexmedetomidine|4 milligrams dexamethasone and 50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
2897019|NCT03270020|Experimental|Treatment arm|This is a single arm study; the study arm include all patients participating in the study who will all receive Denosumab 70 MG/ML [Xgeva]
2897020|NCT03270007|Experimental|Chemotherapy|
2897021|NCT03270007|No Intervention|Control|
2897022|NCT03269994|Active Comparator|Cefoxitin|
2897023|NCT03269994|Experimental|Piperacillin-tazobactam|
2897024|NCT03269981|Experimental|Whole breast irradiation|Post-lumpectomy radiotherapy to the whole breast alone.
2897025|NCT03269981|Active Comparator|Whole breast and nodal irradiation|Post-lumpectomy radiotherapy to the whole breast and regional lymph node.
2897026|NCT03269968|Experimental|Negative pressure wound therapy (NPWT)|Women receiving NPWT will have a PREVENA Incision Management Therapy System applied directly onto their skin over the closed incision after delivery.
2897027|NCT03269968|Placebo Comparator|Standard dressing|Standard dressing
2897028|NCT03269955|Experimental|application of TachoSil®|Fibrinogen/thrombin-coated collagen patch (TachoSil®) and fibrin glue are applied to the pancreas anastomosis site in pancreatoduodenectomy
2897029|NCT03269955|No Intervention|control|Only fibrin glue alone is applied to the pancreas anastomosis site in pancreaticoduodenectomy.
2897030|NCT03269942|Active Comparator|Endovascular Flow-Diversion|Implantation of flow-diversion device
2897031|NCT03269942|Active Comparator|Cerebral Revascularization|Cerebral revascularization procedure with trapping of aneurysm
2897032|NCT03269929|Experimental|Music therapy|
2897033|NCT03269929|Active Comparator|Midazolam|
2897034|NCT03269916|Experimental|IBD patients|IBD patients, 17-40 years old, female
2897035|NCT03269916|Other|healthy control|17-40 years old , female, without any gynecological disease
2897036|NCT03269903|Experimental|Patients|Patients with malignant dysphagia treated with the HILZO stent
2897037|NCT03269890|Experimental|Capsule and cutaneous blocks|7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks per side. once before surgery
2897038|NCT03269890|Active Comparator|US-intermediate cervical plexus block|15 mL of 0.5% isobaric bupivacaine + Epinephrine 5 microgram/ ml. per side. once before surgery
2897039|NCT03269877||Liver cirrhosis and hypersplenism|Patients proven to have Liver Cirrhosis and Hypersplenism based on clinical examination, Laboratory findings, and abdominal ultrasound examinaton
2897040|NCT03269864|Active Comparator|pedicled perforator flaps|"Once the perforator is identified, the flap will be designed around the perforator or perforators according to the location and size of the defect.~A tourniquet is inflated without prior exsanguination. This maneuver facilitates identification of perforators as they remain filled with the blood.~An exploratory incision along the margin of flap is made keeping the position of marked perforator in mind. The incision is made through the skin, subcutaneous tissue, deep fascia (sub-fascial approach) and the perforator vessel is directly visualized. The incision is initially always made from one side of the flap only to properly identify the perforator.~Careful and meticulous dissection is done in a blunt way isolating the perforator.~After deflation of the tourniquet, hemostasis is performed."
2897041|NCT03269864|Active Comparator|free perforator flaps|"A two-team approach is used for microvascular free tissue transfer. The first team starts exploring the limb for the recipient vessel. The second team simultaneously begins elevating the perforator flap and its vascular pedicle.~Microvascular anastomosis will be carried out under operating microscope for one artery and one or two accompanying veins."
2897042|NCT03269812|Experimental|laparoscopic operated group|Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
2898377|NCT03259776||Visitors|Qualitative interviews and questionnaire survey
2897043|NCT03269812|Experimental|non laparoscopic operated group|Under general anesthesia ,abdominal exploration ,removal of a ganglionic part by soav ,duhamel procedures and trans-anal pull through procedures.
2897044|NCT03269799|Active Comparator|test group|vitamin C 500 mg oral capsule
2897045|NCT03269799|Placebo Comparator|control group|placebo
2897046|NCT03269786||cirrhotic patients with esophagel varisces|Endoscopic band ligation or injection scelerotheraby will be done for all patients
2897047|NCT03269773|Experimental|FURESTEM-AD Inj.|hUCB-MSC 5.0x10^7 cells
2897048|NCT03269773|Placebo Comparator|Placebo|
2897049|NCT03269760|No Intervention|Control|Current practice of postoperative care without sleep medicine measures
2897050|NCT03269760|Experimental|Interventional Sleep Medicine|Use of a multimodal sleep pathway including non-pharmacological sleep hygiene interventions and the use of zolpidem to improve patient sleep, pain control, and subsequent recovery after undergoing total shoulder arthroplasty.
2897051|NCT03269747|Active Comparator|Prednisone|Prednisone 40 mg daily for 7 days
2897052|NCT03269747|Placebo Comparator|Placebo|Placebo daily for 7 days
2897053|NCT03269721||Never Smoker|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
2897054|NCT03269721||Smoker/Past smoker-No Airflow Limitation|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
2897055|NCT03269721||Smoker/Past smoker-W/Airflow Limitation|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
2897056|NCT03269708|No Intervention|Control|Participants receive standard care in cardiac rehabilitation program
2897057|NCT03269708|Experimental|Knowledge transfer group|Participants receive standard care in cardiac rehabilitation program plus education regarding telomere length
2897058|NCT03269695|Experimental|PF-06687234|PF-06687234 subcutaneous (SC) weekly (QW) x 12 doses
2897059|NCT03269695|Placebo Comparator|Placebo|PF-06687234 Placebo SC QW x 12 doses
2897060|NCT03269669|Experimental|Arm I (obinutuzumab, umbralisib)|Patients receive obinutuzumab IV on day 1 and umbralisib PO daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2897061|NCT03269669|Experimental|Arm II (obinutuzumab, lenalidomide)|Patients receive obinutuzumab IV on day 1 and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2897062|NCT03269669|Active Comparator|Arm III (obinutuzumab, combination chemotherapy)|Patients receive obinutuzumab IV on day 1, cyclophosphamide IV over 15 minutes on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment with obinutuzumab repeats every 21 or 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Treatment with combination chemotherapy repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2897063|NCT03269656||AGES-Reykjavik participants|Exploring whether pre-diagnostic serum levels of 25(OH)D among older individuals living in Iceland were associated with survival after cancer diagnosis. We also assessed the risk of being diagnosed with cancer in association with 25(OH)D levels.
2897064|NCT03269630||Clinic patients (Comprehensive Pulmonary Hypertension Center)|"Pulmonary hypertension patients (WHO group 1-5)~Systemic sclerosis patients without pulmonary hypertension~Mixed connective tissue disease patients without pulmonary hypertension"
2897065|NCT03269630||Outpatient right heart catheterization patients|-Outpatients undergoing right heart catheterization for any indication
2897066|NCT03269630||Healthy controls|"Age>18~Not actively smoking~No chronic medical conditions"
2897067|NCT03269617|Placebo Comparator|Placebo Comparator|Placebo control: 1 capsule containing rice maltodextrin consumed 1x daily for 28 days.
2897068|NCT03269617|Experimental|Experimental|Bacteriophage mixture: 1 capsule containing rice maltodextrin and a mixture of 4 bacteriophages consumed 1x daily for 28 days.
2897069|NCT03269604|Active Comparator|Prophylactic antibiotic five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
2897070|NCT03269604|Active Comparator|Prophylactic antibiotic three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
2897071|NCT03269604|Experimental|Only a single dose of Prophylactic antibiotic|Only a single dose of Prophylactic antibiotic on the day of the procedure
2897072|NCT03269591|Active Comparator|Pulsed electromagnetic field|magnetic therapy device which generate frequency from 5-100 Hz and intensity from 1 to 60 Gauss. Group (A) received 20 min 3 times per week for three month with strength 60 gauss and frequency 50 Hz
2897073|NCT03269591|Experimental|diclofenac tablets|(50 mg) few hours at the onset of menstruation for 3 months
2897074|NCT03269591|Other|Visual analogue scale|was used to determine the pain intensity level. Pain assessed before and after treatment procedure (3 month)
2897075|NCT03269591|Other|Progesterone blood level|Sample of blood was taken to detect the level of progesterone.
2897076|NCT03269591|Other|Menstrual symptom questionnaire|to assess symptoms of dysmenorrhea.
2897077|NCT03269578||Patients|Adult patients who are being evaluated for and/or treated for cancer at the DTC.
2897078|NCT03269565|Experimental|Arm 1|BCD-100 1 mg/kg Q2W;
2897079|NCT03269565|Experimental|Arm 2|BCD-100 3 mg/kg Q3W.
2897080|NCT03269552|Experimental|Treatment (carfilzomib, rituximab)|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve at least 25% M-protein reduction for Waldenstrom's macroglobulinemia or partial response for marginal zone lymphoma after 2 courses of carfilzomib, receive rituximab IV weekly on days 1, 8, 15, and 22 of course 3 and then monthly on day 1 of courses 4-6 in the absence of disease progression or unacceptable toxicity.
2897081|NCT03269539||Headache Patients|Patients Referred for MRI with History of Headaches
2897082|NCT03269539||Motion prone patients|Patients without the ability to remain still for the entire protocol
2897083|NCT03269526|Experimental|EGFR BATs after standard of care chemo|Subjects will undergo apheresis to collect peripheral blood mononuclear cells. Cells will be cultured for up to 2 weeks before activated T-cells will be harvested, armed with EGFR Biarmed activated T-cells, washed to remove unbound EGFRBi, and cryopreserved. Subjects will then receive one dose of standard of care chemotherapy prior to receiving EGFR BATs (twice weekly for 4 weeks).
2897084|NCT03269513|Experimental|Intervention group|"Adolescent Obesity~The exercise program, nutritional counseling and oral health will last for five to three months and will be held in the gym and rooms of the University of Santa Cruz do Sul (UNISC).~The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week."
2897085|NCT03269513|No Intervention|Control group|
2897086|NCT03269500||malnourished older people|The hospitalized elderly with swallowing and/or Mastication problems.
2897087|NCT03269487||Healthcare professionals in partner sites|NHS employee or student nurse involved in the delivery of care to patients on partner wards in which the PERFECTED ERP is being implemented.
2897088|NCT03269474||Experimental Group|Blood and tissue specimen will be collected from subjects with an EBS diagnosis. Tissue specimen will be collected from blistered and nonblistered skin.
2897089|NCT03269474||Control Group|Blood and tissue specimen will be collected from healthy subjects with non-EBS. Tissue specimen will be collected from an inconspicuous skin area.
2897090|NCT03269461|Experimental|30 days evaluation|Angiography and Optical Coherence Tomography evaluations
2897091|NCT03269461|Experimental|2 months evaluation|Angiography and Optical Coherence Tomography evaluations
2897092|NCT03269461|Experimental|3 months evaluation|Angiography and Optical Coherence Tomography evaluations
2897093|NCT03269435|Experimental|Greater Occipital Nerve Block|"Bilateral greater occipital nerve block with bupivacaine 0.5%~+ Normal saline IV"
2897094|NCT03269435|Active Comparator|Metoclopramide|"Metoclopramide 10mg IV~+ Bilateral greater occipital nerve block with normal saline"
2897095|NCT03269422|Experimental|MR Image Guided, Intensity-Modulated Radiotherapy|Patients enrolled in this study will undergo MR-based, image-guided, intensity-modulated radiotherapy using similar equipment, techniques, and treatment-planning procedures as currently practiced at MSKCC.
2897096|NCT03269409|Sham Comparator|Hip Decompression with saline injection|Subjects will receive standard of care hip decompression along with an injection of 5 ccs of saline.
2897097|NCT03269409|Experimental|Hip Decompression with ADRC|Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution System (Cytori Therapeutics) before being transplanted into the femoral head after standard of care hip decompression.
2897098|NCT03269396|Experimental|Larynx Allograft Transplantation|Cadaveric laryngotracheal transplantation
2897099|NCT03269383|Sham Comparator|Saline|Patients will receive a stellate ganglion block but with 10ml of 0.9% saline.
2897100|NCT03269383|Experimental|Treatment|Patients will receive a stellate ganglion block with 10ml of 0.5% bupivacaine
2897101|NCT03269370|Experimental|1: Anchors Away|Family will receive access to the basic Anchors Away mobile app to test over 6 weeks.
2897102|NCT03269370|Experimental|2: Parent Enhanced Anchors Away|Family will receive access to the Parent Enhanced Anchors Away mobile app to test over 6 weeks.
2897103|NCT03269370|Active Comparator|3: Self-Help E-Book|"Group 3 will receive the Self Help e-Book as a comparative condition (families provided a kindle version copy of Helping Your Anxious Child: A Step-by-Step Guide ; Rapee, Wignall, Spence, Lyneham, & Cobham, 2008)."
2897104|NCT03269370|No Intervention|4: Waitlist Control|Group 4 will not receive any intervention, but will be randomized into an active study arm at 6 weeks.
2897105|NCT03269357|Other|Intervention|"Clinics randomized to intervention will provide structured LARC centered counselling"
2897106|NCT03269357|No Intervention|Routine counselling|Clinics randomized to routine counselling
2897107|NCT03269344|Placebo Comparator|Control Arm|Standard supportive care during definitive treatment plus placebo
2897108|NCT03269344|Experimental|Experimental Arm|Gabapentin plus standard supportive care
2897109|NCT03269331||ARCC EBP Model|CTEP EBP Immersion Course
2897110|NCT03269331||Control Group|No CTEP EBP Immersion Course
2897111|NCT03269318|Experimental|Personalised Medicine|Personalised Medicine who will be prescribed controller medication based on genetic test, Arg/Arg or Arg/Gly - montelukast (LTRA) or Gly/Gly -salmeterol (LABA).
2897112|NCT03269318|No Intervention|Standard Care|Standard of care (Standard Care will be prescribed controller medication based on guidelines)
2897113|NCT03269279|Experimental|Medical abortion arm|200mg of Mifepristone and repeat doses of 400mcg of misoprostol every 3 hours administered for medical abortion in 2nd trimester
2897114|NCT03269240|Experimental|LDHF plus m-Mentoring|"Participants will undergo pre-training assessment comprising multiple-choice questions and objective structured clinical examination (OSCE) using manikins. Training is divided into two 4-day low-dose sessions at the health facility or onsite training. Pre-training and immediate post-training assessments results will be compared. A score of ≥80% is acceptable competence (pass). During the one-month intervals between training sessions, participants practice using manikins to reinforce their competencies through simulation-based practices, facilitated by facility-based trained Peer Practice Coordinators (PPCs). The PPCs will also receive structured, monthly half-hour mentoring calls that will provide remote support, answering questions, providing guidance and reinforcing key messages. Acquisition of knowledge and clinical skills is measured."
2897115|NCT03269240|Active Comparator|Traditional training|The health providers will receive the same content of training in eight days, Off-site training, the way it's currently done in Nigeria. Both theoretical and practical through use of manikins - simulation. No reinforcement and further practice will take place once the participants are back in their work stations. Acquisition of knowledge and clinical skills is measured.
2897116|NCT03269227|Experimental|Accelerated hypofractionation with Tomotherapy|"Tomotherapy Treatment Planning System (TPS) will be used for treatment plannings.~Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for Gross Tumor Volume (GTV)."
2940281|NCT02969733|Experimental|Xylocaine|intravenous administration
2897118|NCT03269214|Experimental|treatment group|Patients received topical Phenytoin 5%+ Tetracycline after debridement before final closure.
2897119|NCT03269201||Parkinson;s Disease|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
2897120|NCT03269201||Essential tremor|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis.Additionally patients will be rated using mmse/ MoCA, Verbal Fluency, essential tremor rating assessment scale (TETRAS) clinical rating scale for tremor (CRST).SF-EMG and KinesiaOne and motion sensor assessment writing and drawing on digitizer, for tremor.
2897121|NCT03269201||Multiple system atrophy|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
2897122|NCT03269201||Normal Pressure Hydrocephalus|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - TIMED UP AND GO TASK (INSTRUMENTAL)
2897123|NCT03269201||DYSTONIA-focal, generalized and others|"Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.Fahn-Marsden Evaluation Scale for Dystonia~.SF-EMG and KinesiaOne and motion sensor assessment , writing and drawing on digitizer,for dystonia"
2897124|NCT03269201||Cerebellar ataxia|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency,Scale for the assessment and rating of ataxia (SARA), International Cooperative Ataxia Rating Scale . TIMED UP AND GO TASK (INSTRUMENTAL)
2897125|NCT03269201||Progressive supranuclear palsy|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
2897126|NCT03269201||Corticobasal degeneration|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
2897127|NCT03269201||Dementia with Lewy Bodies|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
2897128|NCT03269175|Other|Experimental arm 15 years ago|This long term study does not imply current study medication. It looks at the status 15 years after the clinicial trial (BENEFIT)
2897129|NCT03269175|Other|Placebo arm, offered treatment at MS diagnosis or at Month 24|This long term study does not imply current study medication. It looks at the status 15 years after the clinicial trial (BENEFIT)
2897130|NCT03269162|Experimental|Jinfukang + Chemotherapy Group|
2897131|NCT03269162|Placebo Comparator|Chemotherapy Group|
2897132|NCT03269149|Experimental|Adapted Tango Dance|20 improvisational, 90-minute adapted tango dance sessions over a 12-week period.
2897133|NCT03269149|Active Comparator|Educational Control|Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks.
2897134|NCT03269136|Experimental|PF-06863135|BCMA-CD3 bispecific antibody
2897135|NCT03269123|Other|A device to relieve Blepharospasm|The pressure device known as Pressop1 is the intervention which is attached to the spectacles and worn for 2 weeks prior to retreatment with Botulinum Toxin injections to assess its effectiveness in controlling eyelid spasms.
2897136|NCT03269110||Mother and child(ren)|FACT 4 Child is the post-delivery follow-up of the offspring born to FACT mothers once these children are between the age of 4 - 6 years.
2897137|NCT03269084||Children at HLA-conferred risk for T1D|
2897138|NCT03269071|Experimental|Treatment Cohort A|"See Study Description~TC-A: 0.7 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
2897139|NCT03269071|Experimental|Treatment Cohort B|"See Study Description~TC-B: 1.4 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
2897140|NCT03269071|Experimental|Treatment Cohort C|"See Study Description~TC-C: 2.8 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
2897141|NCT03269071|Experimental|Treatment Cohort D|"See Study Description~TC-D: 5.7 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
2897142|NCT03269058|Experimental|Patients not treated with statins|
2897143|NCT03269058|Experimental|Patients treated with statins|
2897144|NCT03269045|Other|Treatment with ORL-1B.|Pediatric patients with biotinidase deficiency.
2897145|NCT03269032|Experimental|Phase 1 Healthy Volunteers|Healthy volunteers will eat a typical American diet for 2 weeks and then eat a Mediterranean-style diet for 2 weeks.
2897146|NCT03269032|Experimental|Phase 2 IBS Patients|Participants with IBS will eat a typical American diet for 2 weeks and then eat a Mediterranean-style diet for 2 weeks
2897147|NCT03269019||HIT-group|The patients with heparin-induced thrombocytopenia.
2897148|NCT03269019||HITTs-group|The patients with heparin-induced thrombocytopenia with thrombosis.
2897149|NCT03269019||Control group|The patients without heparin-induced thrombocytopenia and heparin-induced thrombocytopenia with thrombosis.
2897150|NCT03269006|Experimental|Inesfly Paint|Inesfly 5AIGRNG TM containing Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%). The formulation is vinyl paint with an aqueous base, with the active ingredients residing within Ca CO3 and resin microcapsules, allowing a gradual release of active ingredients. Microcapsules range from one to several hundred micrometers in size.
2897151|NCT03269006|Experimental|IDWL (1m)|Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies.
2897152|NCT03269006|Experimental|ITN (KO-Tab 123)|impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin.
2897153|NCT03269006|Experimental|IRS (Delthamethrin)|indoor residual spraying with Delthamethrin in the living rooms
2897154|NCT03269006|No Intervention|Control|without any study interventions
2897155|NCT03268993|Other|Avmacol|You will be given a higher dose of Avmacol® each month, taking 2 Avmacol® tablets per day the first month (Cycle 1), 4 Avmacol® tablets per day the second month (Cycle 2), and 8 Avmacol® tablets per day the third month (Cycle 3). Investigators will study how Avmacol® affects your body by collecting three different tissues: 1) your cheek cells (buccal cells); 2) your urine; and 3) your blood. After you have finished three months of Avmacol®, you will return one month later for an end-of-study visit.
2897156|NCT03268980||Patients group|All patients (over 18y) admitted to the Hospices Civils de Lyon the day of the study, whatever the reason, able to fullfill the questionnaire by themselves.
2897157|NCT03268980||Hospital staff group|Anyone, whatever age and trade, paid directly by the Hospices Civils de Lyon on the day of the survey, regardless of the duration of the employment contract, and present on one of the sites of the Hospices Civils de Lyon the day of the investigation.
2897158|NCT03268980||Students group|Everyone who is regularly enrolled in one of the schools or institutes of the Hospices Civils de Lyon or in one of the two faculties of medicine of the Université Lyon I, in any initial training and present on one of the sites of the faculties the day of the investigation
2897159|NCT03268967|Active Comparator|Structured Admission procedure|After implementation of a structured admission procedure to all ICU patients inspired by principles of Crisis Resource Management, Closed loop communication, action cards, and staff simulation training
2897160|NCT03268967|No Intervention|Standard Care|Randomly admission procedure to all ICU patients based on the clinicians' evaluation prior implementation of the intervention.
2897161|NCT03268954|Experimental|Azacitidine + Pevonedistat|Azacitidine 75 mg/m^2, intravenous or subcutaneous, on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m^2, 60-minute (±10) infusion, intravenous, on Days 1, 3, and 5 in 28-day treatment cycles up to 12 cycles.
2897162|NCT03268954|Experimental|Azacitidine|Azacitidine 75 mg/m^2, intravenous or subcutaneous, on Days 1 to 5, Days 8 and 9 in 28-day treatment cycles up to 9 cycles.
2897163|NCT03268941|Experimental|Part 1: TAK 906 Maleate 5 mg|TAK-906 maleate 5 milligram (mg), capsule, orally, twice daily, under fasted condition for up to 9 days.
2897164|NCT03268941|Experimental|Part 1: TAK 906 Maleate 25 mg|TAK-906 maleate 25 mg, capsule, orally, twice daily, under fasted condition for up to 9 days.
2897165|NCT03268941|Experimental|Part 1: TAK 906 Maleate 100 mg|TAK-906 maleate 100 mg, capsule, orally, twice daily, under fasted condition for up to 9 days.
2897166|NCT03268941|Placebo Comparator|Part 1: Placebo|TAK-906 placebo-matching capsule, orally, twice daily, under fasted condition for up to 9 days.
2897167|NCT03268941|Experimental|Part 2: TAK-906 Maleate 25 mg Fed+TAK-906 Maleate 25 mg Fasted|TAK-906 maleate 25 mg, capsule, orally, once, in fed state, on Day 1 of Period 1, followed by a minimum of 7-day washout period, followed by TAK-906 maleate 25 mg, capsule, orally, once, in fasted state, on Day 1 of Period 2.
2897168|NCT03268941|Active Comparator|Part 2: Metoclopramide 10 mg|Metaclopramide 10 mg, tablet, orally, once, 1 hour prior to breakfast on Day 1.
2897169|NCT03268928|Experimental|Story Starters Intervention|"Children will receive the the Story Starters intervention for six months. Each child will be visited by a trained Story Starter volunteer twice a week while the child is in preschool. The sessions will last 20 minutes and in each session the Story Starter volunteer and child will read books and play with toys. The Story Starter volunteers will keep a record of the number of sessions each child attends.~Each child will receive one new book per month delivered to their home address by Dolly Parton's Imagination Library."
2897170|NCT03268928|Other|Wait-list Control|"Children in the wait-list control arm will continue to attend preschool as normal during the randomised controlled trial (RCT) and will receive the Story Starters intervention after the RCT has finished.~Each child will receive one new book per month delivered to their home address by Dolly Parton's Imagination Library."
2897171|NCT03268915|Experimental|patient with idiopathic pulmonary fibrosis|
2897172|NCT03268902|Experimental|Nicotinamide and Antimicrobials|Nicotinamide Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
2897173|NCT03268902|Experimental|Antimicrobials only|Placebo Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
2897174|NCT03268902|Experimental|Nicotinamide only|Nicotinamide Placebo Placebo
2897175|NCT03268902|Placebo Comparator|No active treatment|Placebo Placebo Placebo
2897176|NCT03268889|Experimental|treatment group|In this arm, patients would be given the regimen composed of Chidamide, Cyclophosphamide, epirubicin, Vincristine and Prednisone.
2897177|NCT03268876||Epithelial ovarial cancer|Patients primary treated with primary surgery for advanced epithelial ovarian cancer (> stage IIa) at the participating institutions will be asked to participate.
2897178|NCT03268863|Experimental|Virtual Reality|Google Cardboard Virtual Reality headset running an interactive game
2897179|NCT03268863|Sham Comparator|Control|Powered down Google Cardboard Virtual Reality headset
2897180|NCT03268850|Experimental|LW-A|The Lost Wages A (LW-A) arm will be composed of kidney transplant patients meeting the inclusion criteria. This arm allows for possible wage reimbursement of living donor lost wages up to a certain amount. This will also include standard of care.
2897181|NCT03268850|Experimental|LW-B|The Lost Wages B (LW-B) arm will be composed of kidney transplant patients meeting the inclusion criteria. This arm allows for possible wage reimbursement of living donor lost wages up to a different amount. This will also include standard of care.
2897182|NCT03268837|Experimental|Programmed Intermittent Bolus|
2897183|NCT03268837|Active Comparator|Continuous Infusion|
2897184|NCT03268824||Children / adolescents with drug-resistant focal epilepsy|
2897185|NCT03268824||Children / adolescents without drug-resistant focal epilepsy|
2897186|NCT03268811|Experimental|Teduglutide|Standard of care (SOC) treatment +/- teduglutide. Depending on teduglutide treatment eligibility, subjects may receive teduglutide 0.05 mg/kg subcutaneous once daily for 24-week intervals.
2897187|NCT03268798|Experimental|Wrist extension training|
2897188|NCT03268785|No Intervention|Control|Previous admitted patients who were given conventional thyroidectomy combined with central neck lymph node dissection, without intra-operative nodes identification were enrolled into control group.
2897189|NCT03268785|Experimental|Experimental group|Newly admitted patients,from august 2016 to august 2018, who were given thyroidectomy combined with central neck lymph node dissection, with intra-operative identification of suspicious lymph nodes or parathyroid glands were regarded as experimental group.Intraoperative identification method includes Diff-quik staining and PTH test assay. 200 participants were planed for enrollment.
2897190|NCT03268772|Experimental|PLD-IFO|pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO)
2897191|NCT03268759||PCE|Emerging adult individuals who were exposed to cocaine in-utero
2897192|NCT03268759||NCE|Emerging adult individuals who were not exposed to cocaine in-utero
2897193|NCT03268733|Experimental|Treatment group|45 PCOS patients will receive 5 mg folic acid
2897194|NCT03268733|No Intervention|control group|45 PCOS patients will receive no folic acid
2897195|NCT03268720|Other|healthy controls|FODMAP low diet gluten-free diet
2897196|NCT03268720|Other|NCGS patients|FODMAP low diet gluten-free diet
2897197|NCT03268707|Other|Conventional follow up|Conventional follow up at physician practice
2897198|NCT03268707|Experimental|Telemetric smartphone application|Structured follow up with a telemetric smartphone application
2897199|NCT03268694|Experimental|Cognitive and Emotion Processing Tasks|As a part of the clinical monitoring, intracranial EEG is continuously collected when the participant is at the Epilepsy Monitoring Unit at the UNC Neuroscience Hospital. We will use an FDA approved EEG amplifier/data acquisition system to collect the research data. Computer-based tasks will be presented through a laptop and task related timing information will be transmitted from the laptop to the data acquisition system. Computer-based tasks will include Working Memory task, Reward Learning Task and Facial Emotion Recognition Task
2897200|NCT03268655|Experimental|Ginger extract|Ginger extract, 2000 mg daily for 6 weeks, followed by 6 week washout.
2897201|NCT03268655|Experimental|Placebo|Placebo, daily for 6 weeks, followed by 6 week washout.
2897202|NCT03268642||Life-support Based Comprehensive Treatment Regimen group|"meet all the following conditions:~intravenous immune globulin;~large dose of glucocorticoids;~mechanical ventilation;~hemodynamic support: intra-aortic balloon pump (IABP) or/and extracorporeal membrane oxygenation (ECMO);~continuous renal replacement therapy."
2897203|NCT03268642||conventional therapy group|"meet one of the following conditions:~without/insufficient intravenous immune globulin;~without/with various doses of glucocorticoid ;~vasoactive drug;~without/delayed mechanical ventilation;~without/delayed hemodynamic support;~without/delayed continuous renal replacement therapy."
2897204|NCT03268629|Experimental|Mindfulness-Based Joyful Sleep|The proposed 'Joyful Sleep' program will be conducted weekly, 2 hours per session, 8 sessions, group-based in mindfulness. The content and skills are based upon MBSR, MAPs and Tai Chi. The proposed topics include: 1) mindfulness and insomnia, 2) mindful awareness of stress, 3) mindful working with thoughts, 4) mindful working with emotions, 5) mindful interactions, 6) moving mindfulness meditation: the first taste of Tai Chi, 7) moving mindfulness meditation: the second taste of Tai Chi, 8) dealing with obstacles of mindful practices and wrap-up. Mindfulness practices embedded in the program will include mindfulness breathing meditation, body scan meditation, sitting meditation, standing meditation, walking meditation, Taichi, and daily life meditation.
2897205|NCT03268629|Active Comparator|CBT-I|The CBT-I is a weekly, 2-hour, 8 session, group-based program. CBT-I includes 4 central components: stimulus control, sleep restriction, relaxation training and cognitive therapy. The aim of CBT-I is to reduce sleep-related physiologic and cognitive arousal so that restorative sleep function can be re-established.
2897206|NCT03268616|Experimental|Healthy Subjects|increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive.
2897207|NCT03268616|Experimental|Sever COPD Patients|increase the pressure support ventilation step by step, in order to decrease neural respiratory drive.
2897208|NCT03268603|Experimental|Mesenchymal Stromal Cells|Autologous Adipose-derived Mesenchymal Stromal Cells (aaMSCs) will be administered intrathecally at a single dose in a volume of 5-10 mL, all patients will receive 1 x 10^8 intrathecal aaMSCs at the first injection (Visit 4). Subsequent doses may be reduced to 5 x 10^7, based on Dose Modification Rules. One further dose reduction to 1 x 10^7 may occur in later injections.
2897209|NCT03268590|Sham Comparator|Room Air Breathing|Breathing 21% oxygen via non-rebreather face mask
2897210|NCT03268590|Active Comparator|Pure Oxygen Breathing|Breathing 100% oxygen via non-rebreather face mask
2897211|NCT03268577||Prevention (diet and activity tracking)|Patients complete the ASA24 about foods, cooking methods, and other aspects of diet every 2 months for up to 6 times, and complete ACT24 about activities and time reporting every 2 months for up to 6 times. Patients also complete DHQ-II questionnaires at the beginning and end of the study about the frequency and portion sizes of foods consumed over the past 12 months, provide a 7-day food checklist twice with the DHQ-II, and provide a 4-day food record twice, once every 6 months. Physical activity monitors are worn to measure movement at different intensity levels and sitting or standing periods, twice during the study with 6 months between each time they are worn.
2897212|NCT03268564|Experimental|HIVST-online promotion|"Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):~Viewing a promotion video and a demonstration video~Brief motivational interviewing through telephone~Visiting the HIVST-online webpage~Receiving a free self-testing kit and follow-up reminders~Health promotion for re-testers:~Viewing a promotion video and a demonstration video~Visiting the HIVST-online webpage~Receiving a free self-testing kit and follow-up reminders"
2897213|NCT03268525|Active Comparator|Study|Marcaine 0.5 % Injectable Solution will be injected before incision, and in a systematic fashion as a modified paracervical block. First, 2 ml will be injected through the vaginal fornices at 03.00, 06.00, 09.00, and 12.00 hours at 2 cm depth. Thus, 8 ml will be systematically injected around the cervical circumference before incision. In addition, 1 ml of the solution will be injected in each resection line (sacro-uterine and cardinal ligaments), adding up to a total of 10 ml. In case of performing additional anterior/ posterior colporrhaphy, additional solution of Marcaine 0.25%will be prepared: 5 ml of the solution will be injected to the cutting line of the anterior/ posterior vaginal wall, respectively, prior to incision.
2898167|NCT03261427|Active Comparator|Lyrica Capsule(Pregabalin 150mg)|Lyrica Capsule(Pregabalin 150mg), BID
2897214|NCT03268525|Placebo Comparator|Control|Sodium Chloride 0.9% will be injected before incision, and in a systematic fashion as a modified paracervical block. First, 2 ml will be injected through the vaginal fornices at 03.00, 06.00, 09.00, and 12.00 hours at 2 cm depth. Thus, 8 ml will be systematically injected around the cervical circumference before incision. In addition, 1 ml of the solution will be injected in each resection line (sacro-uterine and cardinal ligaments), adding up to a total of 10 ml. In case of performing additional anterior/ posterior colporrhaphy, additional solution of Sodium Chloride 0.9% will be prepared: 5 ml of the solution will be injected to the cutting line of the anterior/ posterior vaginal wall, respectively, prior to incision.
2897215|NCT03268512|Experimental|L-PRF|One socket will be filled with L-PRF membranes and covered with at least 2 L-PRF membranes. A modified horizontal mattress will be place as suture to keep the L-PRF in place.
2897216|NCT03268512|Experimental|A-PRF|One socket will be filled with A-PRF membranes and covered with at least 2 A-PRF membranes. A modified horizontal mattress will be place as suture to keep the A-PRF in place.
2897217|NCT03268512|No Intervention|Control|The socket will be filled with a natural blood clot. A modified horizontal mattress will be place as suture.
2897218|NCT03268499|Active Comparator|Lipiodol-cisplatin suspension|
2897219|NCT03268499|Active Comparator|Lipiodol-cisplatin emulsion|
2897220|NCT03268486||Triple monitoring|Pregnant women with singleton term pregnancies, spontaneous or induced/augmented labor, cephalic presentation, > 18 years of age, able to provide written informed consent, no contraindications to internal FHR monitoring and no known contraindication to vaginal delivery. After giving written informed consent, women will be simultaneously monitored with scalp electrode, Doppler, trans-abdominal ECG, abdominal EHG and TOCO, as soon as internal monitoring is possible.
2897221|NCT03268473|Experimental|Experimental: Non-surgical periodontal therapy|"Non-surgical periodontal therapy consisted of scaling and root planing and supportive periodontal therapy during 3 months~Intervention: Procedure: Non-surgical periodontal therapy"
2897222|NCT03268473|Active Comparator|Delayed non-surgical periodontal therapy|No periodontal treatment for 3 months
2897223|NCT03268447|Active Comparator|Lactobacillus plantarum P8|Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum P8, administered daily at a fixed dosage of 10 log CFU/sachet/day and continue for 12 weeks.
2897224|NCT03268447|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks.
2897225|NCT03268434|Experimental|D-MCT Group|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
2897226|NCT03268434|Active Comparator|Cognitive remediation|A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory.The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance.; 8 sessions (60min), once a week over a period of 8 weeks
2897227|NCT03268421|Experimental|Fibromyalgia Integrative Training for Teens|Fibromyalgia Integrative Training for Teens (FIT Teens) is a combined coping skills training and physical exercise program. Pain coping skills training, also called cognitive behavioral therapy (CBT) teaches a number of behavioral skills (e.g. breathing, relaxation, activity pacing, distraction, and calming statements). Participants also receive a specialized type of neuromuscular exercise training which focuses on core strength, gait and balance.
2897228|NCT03268421|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a psychological coping skills training using education on gate control theory of pain, behavioral strategies such as muscle relaxation and activity pacing, and cognitive strategies including distraction, problem-solving, and using calming self-statements.
2897229|NCT03268421|Active Comparator|Graded Aerobic Exercise|Graded aerobic exercise (GAE) utilizes a circuit-training approach with short intervals of exercise interspersed with brief rest breaks.
2897230|NCT03268408||Intervention|"Intervention aimed at improving self-efficacy parenting which consists in sending to new parents, during the first year of life of their son, eight newsletters with advices and recommendations on child care and development (project Baby Newsletter)."
2897231|NCT03268408||Control|Usual care
2897232|NCT03268395|Other|CO2 Measurement|Each subject will received simultaneous arterial blood gas CO2 and transcutaneous CO2 monitor assessments. The correlation of these two measurements will be compared.
2897233|NCT03268382|Experimental|APR-246 + PLD|
2897234|NCT03268369|Active Comparator|Control group|
2897235|NCT03268369|Experimental|Non lesional diurnal partial epilepsy|
2897236|NCT03268369|Experimental|Idiopathic generalized epilepsy|
2897237|NCT03268369|Experimental|Nocturnal frontal lobe epilepsy|
2897238|NCT03268369|Experimental|Epileptic patients with Vagus Nerve Stimulation (VNS)|
2897239|NCT03268343|Experimental|Schedule A|"Schedule A (12 subjects):~Period 1: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state).~Period 2: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)."
2897240|NCT03268343|Experimental|Schedule B|"Schedule B (12 subjects):~Period 1: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state).~Period 2: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)."
2897241|NCT03268317||Patients with chronic hepatitis C treated by DAAs|All subjects will be given the same treatment regimen which includes Sofosbuvir 400 mg orally/24 hours (pre-breakfast) and Daclatasvir 60 mg orally/24 hours after lunch with or without ribavirin for a total period of 12 weeks.
2897242|NCT03268291|Active Comparator|Standard outpatient observation|Outpatient management according to Ministry of health standards
2897286|NCT03267979|Other|Patients have a surgical operation|Patients have a surgical operation and have received analgesic treatment. One hour after the end of surgical patients will have electrocardiogram and video-pupillometer.
2897287|NCT03267966|Experimental|Group A|Standardized method of pathological evaluation
2897288|NCT03267966|No Intervention|Group B|Non standardized method of pathological evaluation
2897243|NCT03268291|Experimental|"Communicational program Trust"|"The developed program is based on the experience of international research studies and includes the following sections:~daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials;~service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators;~questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services."
2897244|NCT03268278|Active Comparator|buprenorphine and local anesthetic|buprenorphine added to local anesthetic
2897245|NCT03268278|Placebo Comparator|sterile saline and local anesthetic|sterile saline (placebo) added to local anesthetic
2897246|NCT03268252||2x/year MDA|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given twice per year
2897247|NCT03268252||1x/year MDA|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once per year
2897248|NCT03268239|Other|MRI sequences|"There will be only one arm of patients with central nervous system inflammatory disease.~Each patient will be its own control. The usual and additional MRI sequences will be performed in all patients and the number of lesions obtained in usual sequences and additional sequences will be compared in the same patient."
2897249|NCT03268226|Experimental|CHF5993|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI
2897250|NCT03268213|Experimental|Fecal microbial transplantation|Treated with fecal microbial transplantation
2897251|NCT03268200|Experimental|Case group|Each segment of colon (right colon, mid-colon, and left colon) was examined twice
2897252|NCT03268200|No Intervention|Control group|Withdrawal time in the each segment of colon (right colon, mid-colon, and left colon) was about 2 minutes.
2897253|NCT03268187|Experimental|Self-Alert Training|Biofeedback-based Self-Alert Training Vigilance Task Questionnaires accessing apathy, fatigue, depression, sleep quality, sleep behavior
2897254|NCT03268187|Active Comparator|Relaxation Training|Biofeedback-based Relaxation Training Vigilance Task Questionnaires accessing apathy, fatigue, depression, sleep quality, sleep behavior
2897255|NCT03268174|Active Comparator|AO+Mist|AO+Mist
2897256|NCT03268174|Placebo Comparator|Placebo|Placebo
2897257|NCT03268161||Patients with anti-MAG neuropathy|Mutational analysis of clonal B cells
2897258|NCT03268148|Experimental|low level laser group|LaserPen is applied to the local point for 20 seconds where heel-lancing will be performed in the low level laser group.
2897259|NCT03268148|No Intervention|breast milk group|Subjects in breast milk group are given 5ml expressed breast milk by mouth using a syringe tube inserted to the participant's oral cavity over a 2-minute period before heel-lancing.
2897260|NCT03268135||Non end-stage heart failure|Measurement of RNAs in non end-stage heart failure patients undergoing to left ventricle reconstruction
2897261|NCT03268135||End-stage heart failure|Measurement of RNAs in end-stage heart failure patients undergoing to left ventricular assisted device (LVAD)
2897262|NCT03268135||Aortic Stenosis|Measurement of RNAs in patients affected by cardiac hypertrophy leading to aortic stenosis and requiring cardiac myectomy
2897263|NCT03268135||Controls|Measurement of RNAs in individuals not affected by cardiovascular diseases
2897264|NCT03268122|Active Comparator|Standard Contact Isolation|Patients in the standard contact isolation arm will be under the standard contact isolation strategy during the entire time they are physically located in the Medical ICU.
2897265|NCT03268122|Active Comparator|Targeted Contact Isolation|Patients in the targeted contact isolation arm will be under the targeted contact isolation strategy during the entire time they are physically located in the Medical ICU.
2897266|NCT03268109||people living with HIV|subjects infected with HIV and with cognitive complaints
2897267|NCT03268109||control subjects|subjects not infected with HIV and with cognitive complaints
2897268|NCT03268083|Experimental|Group A1|3 to 6 years
2897269|NCT03268083|Experimental|Group A2|3 to 6 years
2897270|NCT03268083|Experimental|Group A3|3 to 6 years
2897271|NCT03268083|Experimental|Group B1|2 to 35 months
2897272|NCT03268083|Experimental|Group B2|2 to 35 months
2897273|NCT03268083|Experimental|Group B3|2 to 35 months
2897274|NCT03268070|Experimental|Repetitive TMS over contralateral premotor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): contralateral premotor cortex.
2897275|NCT03268070|Experimental|Repetitive TMS over ipsilateral premotor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): ipsilateral premotor cortex.
2897276|NCT03268070|Experimental|Repetitive TMS over contralateral primary motor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): contralateral primary motor cortex.
2897277|NCT03268070|Sham Comparator|Sham repetitive TMS over contralateral premotor cortex|Location of Sham repetitive Transcranial Magnetic Stimulation (rTMS): contralateral premotor cortex.
2897278|NCT03268070|Experimental|Single TMS over extensor carpi ulnaris spot of motor cortex|Location of single-pulse Transcranial Magnetic Stimulation (sTMS): extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1).
2897279|NCT03268057|Experimental|VX15/2503 + avelumab|VX15/2503 at a concentration of 5 mg/kg to 15 mg/kg with a fixed dose of avelumab at 10 mg/kg, administered intravenously on a bi-weekly dosing cycle.
2897280|NCT03268044||Weekend admission|Adults admitted to hospital at the weekend (Saturday or Sunday) and who underwent surgery
2897281|NCT03268044||Weekday admission|Adults admitted to hospital on a weekday (Tuesday to Thursday) and who underwent surgery
2897282|NCT03268031||Glaucoma patients|Glaucoma patients will take visual field test and OCT imaging of optic nerve area. All of these data will be collected as source of machine learning.
2897283|NCT03268031||Non-glaucoma participants|Non-glaucoma participants will take visual field test and OCT imaging of optic nerve area. All of these data will be collected as source of machine learning.
2897284|NCT03268005|Experimental|Faster aspart + insulin degludec with or without metformin|
2897285|NCT03268005|Active Comparator|NovoRapid/NovoLog + insulin degludec with or without metformin|
2897319|NCT03267732|Active Comparator|2|AM0010 (10 μg/kg) dosed on Day 1, and Days 4-9 SQ
2897289|NCT03267953|Experimental|First stage: Self-directed My Health CheckUp|Participants randomized to this group will be sent an e-mail invitation by the research team to register to the website. Once registered, participants will receive a second e-mail that will provide brief instructions on getting started and invite them to use the website for 12 weeks ad libitum. No additional contact will be provided thereafter by research team.
2897290|NCT03267953|Experimental|First stage: Minimally guided My Health CheckUp.|This group will also be invited to use the 12-week Internet-based stress management program, but they will additionally receive support via weekly telephone calls from a lay coach.
2897291|NCT03267953|Experimental|Second stage: High intensity Motivational Interviewing (MI)|After 6 weeks, response to the first stage programs will be assessed and only the non-responders will be randomized a second time to (a) continue with the first stage programs or (b) High-intensity MI. In addition to continued access to My Health CheckUp, participants in this group will also be supported with 6 weekly, telephone-based MI sessions.
2897292|NCT03267940|Experimental|Run-in Portion Arm 1: PEGCISGEM|Approximately 6 participants will receive 3.0 micrograms per kilogram (μg/kg) PEGylated Recombinant Human Hyaluronidase (PEGPH20) on Days 1, 8, and 15 in combination with 25 milligrams per meter squared (mg/m^2) of cisplatin (CIS) plus 1000 mg/m^2 of gemcitabine (GEM) administered on Days 2 and 9 of each 21-day cycle by intravenous (IV) infusion.
2897293|NCT03267940|Experimental|Run-in Portion Arm 2: PEGCISGEMATEZO|After the 6 participants in Arm 1 are treated for at least 1 cycle without significant toxicities, 6 additional participants will be enrolled into Arm 2 of the Run-in Portion of the study. Participants will receive 3.0 µg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg atezolizumab (ATEZO) (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. PEGPH20 dose reduction to a lower dose of 2.2 µg/kg or 1.6 µg/kg will be performed if necessary.
2897294|NCT03267940|Experimental|Expansion Portion Arm 1: PEGCISGEM|Participants will receive 3.0 µg/kg PEGPH20 on Days 1, 8, and 15 in combination with 25 mg/m^2 CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion.
2897295|NCT03267940|Experimental|Expansion Portion Arm 2: PEGCISGEMATEZO|Participants will receive 3.0 µg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion.
2897296|NCT03267940|Active Comparator|Expansion Portion Arm 3: CISGEM|Participants will receive 25 mg/m^2 CIS and 1000 mg/m^2 GEM on Days 1 and 8 of each 21-day cycle by IV infusion.
2897297|NCT03267927|Experimental|Patient with OSA|
2897298|NCT03267914|Experimental|Tray group|Control intervention Patients will use the custom-made tray to apply the fluoride locally to the teeth and wear for 5 minutes each day.
2897299|NCT03267914|Active Comparator|Brush group|Patients will brush with the fluoride for 2 minutes each day.
2897300|NCT03267901|Experimental|Walnut-Control|
2897301|NCT03267901|Experimental|Control-Walnut|
2897302|NCT03267888|Experimental|Radiation therapy, pembrolizumab|Patients undergo radiation therapy on day 1. Patients also receive pembrolizumab IV over 30 minutes on day 2 or 3. Courses with pembrolizumab repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
2897303|NCT03267875|Experimental|single arm|Patients after aneurysm in the aorta, Men and women aged 18-100 (not including special populations), who are able to read understand and sign a written consent to participate in the research
2897304|NCT03267849|Experimental|persons drinking water|all persons in the study will have images of the eye at baseline eye pressure, then the intervention will be to drink 2 bottles of water to increase eye pressure, then will have images taken a second time
2897305|NCT03267836|Experimental|Avelumab + Proton Therapy|"Avelumab will be started concurrently with proton therapy (up to 3 days before or after is permissible) and administered every 2 weeks for 3 months~Proton therapy 20 CGE (cobalt gray equivalent) will be given over 5 daily fractions of 4 CGE per day during weekdays~After 3 months of avelumab, patient will have a brain MRI evaluation, and radiological response will be assigned based on the iRANO criteria. Surgery will be performed as per routine clinical care~If the brain MRI after 3 months of avelumab shows complete response with no signs of residual tumor, no surgery will be indicated, and the patient may continue to take adjuvant avelumab for an additional 3 months.~After the patient has recovered from the surgery and if deemed medically eligible by the treating physician to receive additional immunotherapy, avelumab will be restarted and administered every 2 weeks for an additional 3 months"
2897306|NCT03267823||Heart surgery|Patients undergoing heart surgery will have blood samples tested for INR values
2897307|NCT03267810|Experimental|Active TENS|Participants are given 30 minutes of TENS therapy twice a week for 8 weeks.
2897308|NCT03267810|Sham Comparator|Sham TENS|Electrodes are placed on participants for 30 minutes twice a week for 8 weeks without TENS stimulation.
2897309|NCT03267797|Experimental|Treatment group|lymphocytes group
2897310|NCT03267797|No Intervention|control group|
2897311|NCT03267784|Experimental|Experimental: allo-APZ2-DFU|Application of IMP on patients wound
2897312|NCT03267771|Active Comparator|progesterone suppositories vaginal group|vaginal micronized progesterone suppositories (prontogest®) 400 mg, one vaginal suppository twice daily through 18 weeks of gestation.
2897313|NCT03267771|Experimental|Dydrogesterone oral tablets group|20 mg tablets (Duphaston ®), 2 tablets orally twice daily through 18 weeks of gestation.
2897314|NCT03267758|Experimental|Goodbelly First|Subjects in this arm will consume 1 serving of lactobacillus plantarum 299v daily for first 6 weeks.
2897315|NCT03267758|Experimental|Observation First|Subjects in this arm will be without lactobacillus plantarum 299v daily for first 6 weeks.
2897316|NCT03267745|Experimental|Amino Acid|Subjects in this arm will receive amino acid supplementation (5.97g) 3 times daily for 28 days. Amino acids will be provided in powder form to be dissolved in 8oz of water. Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
2897317|NCT03267745|Placebo Comparator|Placebo|Subjects in this arm will receive placebo 3 times daily for 28 days. Placebo will consist of 5.75g of maltodextrin (NF grade) dissolved in 8oz of water. Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
2897318|NCT03267732|Active Comparator|1|AM0010 (5 μg/kg) dosed on Day 1, and Days 4-9 SQ
2897321|NCT03267706|Active Comparator|Palliative Care Comprehensive Tool|Clinicians within the study will be randomly assigned and trained on the use of the Palliative Care Comprehensive Tool
2897322|NCT03267706|No Intervention|Usual Care|Clinicians within the study will be randomly assigned to usual palliative care (without the newly introduced tool)
2897323|NCT03267680|Experimental|Arm I (IRX-2)|Patients receive cyclophosphamide IV on day 1 and IRX-2 via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.
2897324|NCT03267680|Active Comparator|Arm II (placebo)|Patients receive cyclophosphamide IV on day 1 and placebo via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.
2897325|NCT03267667||obstructive sleep apnea patients|number of 90 patients will be investigated by 2D echocardiography and cardiac MRI to determine the right ventricle function
2897326|NCT03267667||healthy volunteers|number of 10 subjects will be investigated by 2D echocardiography and cardiac MRI to determine right ventricular function in healthy persons have risk factors other than cardiac or lung diseases
2897327|NCT03267654|Experimental|gefitinib combined with chemotherapy|gefitinib 250mg Qd combined with pemetrexed plus carboplatin: pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days.
2897328|NCT03267654|Experimental|gefitinib combined with apatinib|gefitinib 250mg Qd combined with apatinib 250mg per 21 days
2897329|NCT03267654|Active Comparator|gefitinib single agent|Advanced NSCLC patients with EGFR activating mutation (L858R, 19Del) received gefitinib 250mg Qd orally until progression, intolerable toxicity or death.
2897330|NCT03267628|Sham Comparator|Saline intrathecal as well as saline in Blocks|These 25 patients will receive 0.3ml saline added to the spinal anaesthetic and 25 ml saline both sides as a QLB2.
2897331|NCT03267628|Active Comparator|Saline intrathecal as well as local anaesthetic in Blocks|These 25 patients will receive 0.3ml saline added to the spinal anaesthetic and 25 ml local anaesthetic both sides as a QLB2.
2897332|NCT03267628|Active Comparator|Intrathecal morphine as well as local anaesthetic in Blocks|These 25 patients will receive 0.3ml (150mcg) morphine added to the spinal anaesthetic and 25 ml local anaesthetic both sides as a QLB2.
2897333|NCT03267628|Active Comparator|Intrathecal morphine as well as saline in Block|These 25 patients will receive 0.3ml (150mcg) morphine added to the spinal anaesthetic and 25 ml saline both sides as a QLB2.
2897334|NCT03267602|Experimental|Continuous Positive Airway Pressure (CPAP) Therapy|
2897335|NCT03267589|Experimental|Cohort A|Intervention: MEDI9447 (CD73) + durvalumab
2897336|NCT03267589|Experimental|Cohort B|Intervention: MEDI0562 (OX40) + durvalumab
2897337|NCT03267589|Experimental|Cohort C|Intervention: MEDI0562 (OX40) + tremelimumab combination
2897338|NCT03267576|Experimental|Treatment Sequence AB|Participants will receive metformin monotherapy at stable doses (greater than or equal to [>=] 1500 milligram per day [mg/day]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin >=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition. A washout period of at least 16 days (from Days 28 to 43) of metformin monotherapy will be maintained between each treatment period.
2897339|NCT03267576|Experimental|Treatment Sequence BA|Participants will receive treatment B from Day 0 to 27 (treatment Period 1), followed by treatment A from Day 44 to 71 (treatment period 2), under fasted condition. A washout period of at least 16 days (from days 28 to 43) of metformin monotherapy will be maintained between each treatment period.
2897340|NCT03267563|Experimental|Enhanced implementation as usual (EIAU)|All clinics will receive enhanced implementation as usual (EIAU) that is initial clinical and operational training + tools for sustainment. This occurs once at the beginning of the trial.
2897341|NCT03267563|Experimental|Low-intensity coaching and feedback|Clinics will receive enhanced implementation as usual (EIAU) plus low-intensity (every 3 months) implementation coaching and feedback (LICF). LICF consists of quarterly clinical and operational coaching and feedback calls, as well as quarterly participation in an implementation collaborative board.
2897342|NCT03267563|Experimental|High-intensity coaching and feedback|Clinics will receive enhanced implementation as usual (EIAU) plus high-intensity (every month) implementation coaching and feedback (HICF). HICF consists of monthly clinical and operational coaching and feedback calls, monthly participation in an implementation collaborative board, and on call technical assistance.
2897343|NCT03267550|Experimental|remote programming system|
2897344|NCT03267537|Active Comparator|Conventional office-based CBT-I|CBT-I will be delivered by a licensed clinical psychologist in weekly sessions lasting up to 1 hour. There will be 6 CBT-I sessions over the course of therapy with the option of an additional 2 treatments if deemed necessary by the clinical psychologist.
2897345|NCT03267537|Experimental|Telemedicine based CBT-I|The treatment will be the exact same as the active comparator group, with the same clinical psychologist doing the office-based CBT-I, but will be administered through a telemedicine modality
2897346|NCT03267524|Experimental|Supportive Care (Walking for Recovery from Surgery)|Patients and caregivers receive Walking for Recovery from Surgery prehabilitation intervention in 4 sessions 3-7 days before surgery, before discharge, and at 2 and 7 days post-discharge.
2897347|NCT03267511|Experimental|Test Product 1|Participants will be instructed to apply experimental dentifrice containing 5% potassium nitrate (KNO3) / 0.2542% sodium fluoride (NaF) dentifrice with 0.5% spherical silica.
2897348|NCT03267511|Experimental|Test Product 2|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP.
2897349|NCT03267511|Active Comparator|Reference Product 1|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica.
2897350|NCT03267511|Active Comparator|Reference Product 2|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP.
2897351|NCT03267498|Experimental|Nivolumab + chemoradiation|Patients receive nivolumab IV over 60 minutes on day 1 of courses 1-5 and 7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy QD 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
2897352|NCT03267446|Experimental|Interventional group|Patients confirmed having one or more of the signs of morbidly adherent placenta will be examined by 3D Ultrasound and 3D power Doppler. Patients will then be prepared for the operation.Cesarean hysterectomy will be done with removal of the uterus and the placenta as one mass.Cases with focal invasion of the uterus will be given a trial for conservative management. The whole specimen will be sent for histopathological examination, and the determination of length and depth of invasion.
2897353|NCT03267433|Experimental|Group I (auto-HCT, rituximab)|Patients receive standard of care preparative chemotherapy and undergo auto-HCT. Beginning 60-120 days after transplant, patients receive rituximab IV once every 8 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2897354|NCT03267433|Experimental|Group II (rituximab alone)|Patients receive standard of care induction chemotherapy. Beginning 40-120 days after completion of chemotherapy, patients receive rituximab as in Group I.
2897355|NCT03267420|Experimental|Group 1|A group of 30 randomly assigned study participants that will undergo the BpTRU First, Unattended Omron Second exposure.
2897356|NCT03267420|Active Comparator|Group 2|A group of 30 randomly assigned study participants that will undergo the Unattended Omron First, BpTRU Second exposure.
2897357|NCT03267420|Active Comparator|Group 3|A group of 30 randomly assigned study participants that will undergo the Partially Attended Omron First, Unattended Omron Second exposure.
2897358|NCT03267407||CrAg(+) and CM(-)|(1) Patients with CrAg positive without meningitis results will receive preemptive high-dose fluconazole to prevent developing meningitis.
2897359|NCT03267407||CrAg(+) and CM(+)|(2) Patients with CrAg positive and meningitis results will receive standard treatment for cryptococcal meningitis, following national guidelines.
2897360|NCT03267407||CrAg(-)|(3) Patients with CrAg negative results will be managed as other HIV infected patients with the standard of care, following national guidelines.
2897361|NCT03267381||Arm 1a|Stage III melanoma diagnosis (biopsy-proven lymph node positive (this is either clinically palpable or enlarged nodes detected by imaging, which are then biopsied and have macroscopic disease).
2897362|NCT03267381||Arm 1b|Stage III after sentinel node biopsy (microscopic disease diagnosed on sentinel node biopsy).
2897363|NCT03267381||Arm 2|Stage IV- will need to stratify by current treatment with immunotherapy, targeted therapy, none
2897364|NCT03267368|Experimental|Comprehensive Care Program|Pulmonary rehab and smoking cessation program/intervention/assessment
2897365|NCT03267355|Experimental|Gastrointestinal diseases|Endoscopic Ultrasound
2897366|NCT03267342|Experimental|All participants|low-income people with mental illness will be given one-on-one financial counseling, a weekly peer support group, supported access to mainstream banking services and access to a matched savings account for a 12-14 month period.
2897367|NCT03267329|Experimental|Duowell® Tab.|Once daily during 16 wks
2897368|NCT03267329|Active Comparator|Telmisartan|Once daily during 16 wks
2897369|NCT03267316|Experimental|Dose escalation|Cohorts of 3 subjects will receive once weekly (Q1W) treatment with CAN04. The Dose Limiting Toxicity (DLT) observation period for each dose level will be the first 21 days of treatment with CAN04.
2897370|NCT03267316|Experimental|Monotherapy|Subjects with either PDAC or NSCLC, will receive treatment with CAN04 monotherapy.
2897371|NCT03267316|Experimental|Combination|Subjects with PDAC or NSCLC, will receive once weekly treatment with CAN04 in combination with standard-of-care therapy (TBD).
2897372|NCT03267303|Experimental|TS-091 5mg|
2897373|NCT03267303|Experimental|TS-091 10mg|
2897374|NCT03267303|Placebo Comparator|Placebo|
2897375|NCT03267290|Experimental|Sonazoid- CEUS+CEMRI or CECT+CEMRI|
2897376|NCT03267277|Experimental|Treatment|Patient will be assessed for 10 weeks off treatment and then will receive 10 weeks of treatment. They will return at weeks 24 and 52 for safety and sustainability of efficacy assessments.
2897377|NCT03267264|Experimental|Group 1|
2897378|NCT03267264|Experimental|Group 2|
2897379|NCT03267264|Experimental|Group 3|
2897380|NCT03267264|Experimental|Group 4|
2897381|NCT03267251|Active Comparator|Usual Clinic communication - HPV Vaccine|Standard Usual and Customary HPV Information - CDC pamphlet
2897382|NCT03267251|Experimental|Usual Care and Web App on HPV Vaccine|Usual Care and Web app on HPV Vaccine: Vacteens Web app for mobile devices
2897383|NCT03267238|Experimental|Fecal Microbial transplantation|Fecal Microbial Transplantation will be offered to patients eligible to be part of the study.
2897384|NCT03267212|Active Comparator|Non-invasive Ventilation(NIV)|Subjects will perform FES-row testing while receiving bi-level positive airway pressure ventilation applied through a full face-mask.
2897385|NCT03267212|Sham Comparator|Sham Non-invasive ventilation(NIV)|Subjects will perform FES-row testing while receiving sham ventilation applied through a full face-mask.
2897386|NCT03267199||patients with high MPV,PDW,PFT|patients with high MPV,PDW,platelet function test
2897387|NCT03267199||patients with normal or low MPV,PDW, PFT|patients with normal or low MPV,PDW,platelet function test
2897388|NCT03267186|Experimental|Prevention (ibrutinib)|Beginning 60-90 days after allogeneic HCT, patients receive ibrutinib PO QD for up to 18 months post-transplant in the absence of disease progression or unacceptable toxicity.
2897389|NCT03267173|Experimental|CAR-T|A single dose of Chimeric antigen receptor T cells will be administered by vascular interventional mediated as one dose infusions. According to the patient's condition and weight, the intervention dose of aE7 CAR-T cells per kilogram of body weight was treated once.
2897390|NCT03267160||Sepsis with cardiopulmonary failure|Patient with sepsis and also respiratory and heart involvement, confirmed by Hemodynamic parameters
2897391|NCT03267160||Sepsis without cardiopulmonary failure|Patient with sepsis without respiratory and heart involvement
2897563|NCT03265691|Experimental|Early hyponatremia diagnosis and treatment|The early diagnosis of hiponatremia is not a stándar procedure. In the experimental arm, hyponatremia will be diagnosed and treated early.
2897392|NCT03267147||antiCCP positive|"Patients with a positive result in the anti-CCP quick test and positive in antiCCP ELISA will be examined by Rheumatologist for detection of RA symptoms and followed-up for 3 years or until RA diagnosis~no intervention is given"
2897393|NCT03267147||antiCCP negative|Patient with negative result in antiCCP quick test or negative antiCCP ELISA will be followed-up after one year (and 3 years for ELISA negative patients) with a short questionnaire if musculoskeletal symptoms are still present or if RA was diagnosed
2897394|NCT03267121|Experimental|Study Group|Apatinib Mesylate Tablets and Tegafur Gimeracil Oteracil Potassium Capsules administered as a daily oral treatment
2897395|NCT03267108|Placebo Comparator|Placebo|"Part 1: Placebo at a dose setting of 30 mcg/kg IBW/hr for up to 24 hours per day for 1 week run-in period and 8 week treatment period.~Part 2: iNO at a dose setting of 30 mcg/kg IBW/hr for up to 24 hours per day for open label treatment period."
2897396|NCT03267108|Experimental|Inhaled Nitric Oxide 30 mcg/kg IBW/hr|"Part 1: Placebo at a dose setting of 30 mcg/kg IBW/hr for up to 24 hours per day for 1 week run-in period followed by iNO at a dose setting of 30 mcg/kg IBW/hr for up to 24 hours per day for the 8 week treatment period.~Part 2: iNO at a dose setting of 30 mcg/kg IBW/hr for up to 24 hours per day for open label treatment period."
2897397|NCT03267095|Experimental|Study|.Patient in stduy Arm will receive music therapy sessions
2897398|NCT03267095|No Intervention|Control|Patient in control Arm will have cosuling for mother and follow up
2897399|NCT03267082|Experimental|Evaluation the role of Laparoscopic management of perforated a|
2897400|NCT03267069||alcohol liver disease|Patients with alcohol liver disease consenting to participate in the study will be administered an initial survey at inclusion and then follow-up surveys at 3, 6, 9, 12, 15, and 18 month intervals and then 2, 5, and 10 years. There is no intervention cohort, all enrolled will complete the same surveys. Recidivism will be measured by responses to survey questions, clinical interviews documented in the chart, and urine ethnyl glucuronide or blood ethanol testing.
2897401|NCT03267056||DCB arm|
2897402|NCT03267043|Active Comparator|Standard Care|Participants enrolled in Phase 1 will be receiving the current standard of care in the NICU at The Valley Hospital.
2897403|NCT03267043|Experimental|Family Nurture Intervention|Participants enrolled in Phase 2 will be receiving family nurture intervention (FNI) that focuses on supporting the parents and facilitating emotional connection between mother and infant during the infant's NICU stay.
2897404|NCT03267030|Experimental|GRASPA|GRASPA will replace remaining PEG-asparaginase doses in case of hypersensitivity.
2897405|NCT03267017||Patient scheduled for surgery under general anesthesia|
2897406|NCT03267004|Experimental|Meal Order 1|Meal A will be served to participant in meal session 1 and Meal B in meal session 2.
2897407|NCT03267004|Experimental|Meal Order 2|Meal B will be served to participant in meal session 1 and Meal A in meal session 2.
2897408|NCT03266991|Experimental|RPT-INH|Participants treated with weekly rifapentine and isoniazid for twelve weeks.
2897409|NCT03266991|Active Comparator|control|Participants treated with daily isoniazid for six months
2897410|NCT03266965|Experimental|Histidine Intervention Group|This is a single-arm study. A total of 15 subjects will be recruited in batches of 5. The first 5 subjects (3 MS and 2 normal) will be tested on a dose of L-Histidine 250 mg plus Carbidopa 50 mg twice a day (BID) for seven days. If there are no safety concerns, the next 5 patients will be recruited (3 MS and 2 normal) to test the dose of L-Histidine 500 mg with Carbidopa 50 mg BID for seven days. If there are no safety concerns then L-histidine 1,000 mg plus Carbidopa 50 mg BID will be tested in the next 5 subjects (3 MS patients and 2 normal subjects) for seven days.
2897411|NCT03266939|Placebo Comparator|Placebo|
2897412|NCT03266939|Active Comparator|Active Medication|
2897413|NCT03266926||Postoperative Patients with premarin|Patients who undergo vaginal surgery at Sunnybrook Health Sciences Centre (SHSC) who require vaginal packing postoperatively and receive premarin vaginal cream coated packing.
2897414|NCT03266926||Postoperative Patients with bupivacaine|Patients who undergo vaginal surgery at Patients who undergo vaginal surgery (SHSC) who require vaginal packing postoperatively and receive bupivacaine soaked packing.
2897415|NCT03266913|Active Comparator|Probiotic|Routine phototherapy plus probiotic oral drops at the dose of 10 drops daily
2897416|NCT03266913|No Intervention|No probiotic|Routine phototherapy
2897417|NCT03266900|Experimental|re-TURBT|Patients in this arm will receive a 2nd TURBT within 4-6 weeks of initial TURBT
2897418|NCT03266900|Active Comparator|6 BCG instillations|Patients in this arm will not receive a 2nd TURBT, but will receive 6 instillations of BCG.
2897419|NCT03266874||Patients who received the G7 BiSpherical Cup|Subject in need of a THA who met the inclusion/exclusion criteria and received the G7 BiSpherical cup.
2897420|NCT03266861||Patients undergoing exercise oximetry|Patients with PAD referred for treadmill testing and exercise oximetry
2897421|NCT03266835|Other|SoundBite™ Crossing System - Peripheral|This is a multinational, single-arm, pivotal trial assessing the efficacy and safety of the SoundBite™ Crossing System with subjects diagnosed with de novo infrainguinal arterial chronic total occlusion(s).
2897422|NCT03266822||Healthy control|
2897423|NCT03266822||RA patients on anti-TNF therapy|
2897424|NCT03266822||RA patients on anti-IL-6R therapy|
2897425|NCT03266809||Breast Cancer Patients|"Eligible participants will be women aged 18 years or over who have the following main characteristics:~Early invasive breast cancer (stage I-III)~Due to start SAT (adjuvant or neoadjuvant chemotherapy +/- trastuzumab +/- pertuzumab)~WHO performance status 0-2."
2897426|NCT03266796||Patients & Physical therapists|First consultations of peoples with musculoskeletal disorders and their physical therapists will be audiotaped. Audiotapes will be used to analyse the communication between the patients and their physicaltherapists to explore how much physical therapists involve their patients in the goal setting process, to see if there is a shared decision making existing.
2897427|NCT03266783|Active Comparator|Apixaban group|10 mg PO BID for 1 week, then 5 mg PO BID for 3 months of treatment
2897428|NCT03266783|Active Comparator|Rivaroxaban group|15 mg PO BID for 3 weeks, then 20 mg PO OD for 3 months of treatment
2897429|NCT03266770|Other|RELIEF stent placement|After meeting the inclusion criteria and being consented, patients will have the RELIEF stent inserted in the ureter during cystoscopy per standard of care for ureteral stent placement.
2897430|NCT03266744|Other|Main study group|"Patients will have repeat CT (Computerised Tomography) scans and WB-MRI (Whole Body Magnetic Resonance Imaging) every 12 weeks until disease progression. A baseline bone scan (99mTc-MDP) will be performed.~At the point of disease progression, a repeat bone scan will be obtained in addition to the CT and WB-MRI."
2897431|NCT03266744|Other|WB-MRI sub-study group|Patients will be given the opportunity to participate in a sub-study of WB-MRI reproducibility. This involves a repeat scan of the Whole Body Magnetic Resonance Imaging (WB-MRI) diffusion-weighted sequences. This will be shorter in duration than the full WB-MRI scan and will take place within one hour of completing the full WB-MRI scan.
2897432|NCT03266731|Experimental|use of aspirin and clopidogrel|
2897433|NCT03266718|Other|Physical Activity Intervention|Couples will receive four 60-minute intervention sessions via videoconference with Duke staff. Study staff will provide couples with instructions for use of the iPad computer and videoconference software which will be used to deliver the intervention sessions.The first 3 sessions will be conducted weekly, with a booster session occurring approximately one month later.
2897434|NCT03266718|Other|Waitlist control|Couples will have the option to receive the intervention after they complete the follow-up survey. This version of the intervention will not include the booster session, so will last approximately 1 month in total. If they choose to receive the intervention, they will be provided with a tablet computer if they do not have one.
2897435|NCT03266705|Experimental|61 mgA tafamidis free acid soft gelatin capsule|
2897436|NCT03266705|Experimental|4x20 mg tafamidis meglumine soft gelatin capsule|
2897437|NCT03266692|Experimental|ACTR087 in combination with SEA-BCMA|
2897438|NCT03266679|Other|Patients receiving metacognition-based intervention|Case-Series Design - all participants receive the intervention - metacognition-based therapy (adapted version of Metacognitive Reflection and Insight Therapy developed by Lysaker & Klion) - weekly for a period of 12 months. No control/comparison group.
2897439|NCT03266666|Other|Intervention Arm - WellnessRX|This is a longitudinal outcome study. All participants will receive the class and grocery credit intervention.
2897440|NCT03266653|Experimental|Refractory EBV|Patients with refractory EBV will get one dose of EBV specific CTLs. If they don't show a response based on EBV PCRs, patients may get up to another 4 doses of EBV-CTLs (5 doses maximum)
2897441|NCT03266640|Experimental|Refractory CMV|Patients with refractory CMV will be given one dose of CMV specific CTLs. HLA matched donors will get Dose 2.5 × 10(4) CD3/kg recipient weight; HLA mismatched will get 0.5x10(4) CD3/kg recipient weight. Additional doses may be given for a total of 5 doses if patients do not have a response to the first dose with a reduction in viral load to normal limits.
2897442|NCT03266627|Experimental|patients with adenoviral infection|patients will receive CTL dose x 1 with 2.5 × 10(4) CD3/kg for matched related donor and 0.5 × 104 CD3/kg for mis-matched related donor. Patients who don't respond to the first infusion may receive up to a total 5 CTL infusions.
2897443|NCT03266614|Experimental|Recovery 4 US|This group receives a smartphone with the Recovery 4 US application and access to the application website.
2897444|NCT03266614|No Intervention|Services as usual|This group receives a smartphone but no access to the Recovery 4 US application.
2897445|NCT03266601|Experimental|Recombinant Human Interferon α-2b Spray|
2897446|NCT03266601|Active Comparator|Ribavirin|
2897447|NCT03266588|Experimental|Rimegepant|
2897448|NCT03266575|Active Comparator|Pulmonary Rehabilitation|Participants will participate in formal Pulmonary Rehabilitation Exercise program
2897449|NCT03266575|Active Comparator|Home based program|Participants will participate in a Home based Exercise program
2897450|NCT03266562|Other|FES vs FDG|All patients will undergo two PEM studies, one with F-18 FDG and the second with F-18 FES. Co-registration of the PEM images from F-18 FDG and F-18 FES will be used to assess the heterogeneity of uptake of the F-18 FES relative to that of F-18 FDG. Heterogeneity of ER expression in the tumor will be determined by immunohistochemistry on the pathologic tissue
2897451|NCT03266549|Experimental|Botulinum toxin augmented surgery group|bilateral 7.0-mm medial rectus muscle recessions, with augmentation with 1.25units of botulinum toxin in 1 muscle for patients with deviations of 65 to 70 PD, and 2.5 units (either 1.25 units in both muscles or 2.5 units in 1 muscle) for patients with deviations greater than 70 PD
2897452|NCT03266549|Active Comparator|conventional surgery group|bilateral MR muscle recessions combined with unilateral or bilateral LR muscle resections (according to the standard correction tables)
2897453|NCT03266536|No Intervention|No western diet|Participants will undergo one-time testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will be finished with testing after the upper endoscopy is complete.
2897454|NCT03266536|Experimental|Western diet|Participants will undergo a first day of testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will then consume a Western diet for 7 days before a second day of identical testing (blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies).
2897455|NCT03266523||Control|The CONTROL (neutral) environment corresponds to the standard environment of the imaging waiting rooms
2897456|NCT03266523||Zen|The ZEN environment will represent a clean, minimalist nature
2897457|NCT03266523||Green|The GREEN environment will represent rural landscapes, undergrowth
2897458|NCT03266523||Sea|The SEA environment will represent lakes, ponds, seaside
2897459|NCT03266510|Experimental|Inspiratory muscle strength training|Using a handheld device, subjects were perform 30 breaths a day, six days a week. The device produces resistance that increases the effort of breathing in. The resistance to breathing will be strong.
2897460|NCT03266510|Sham Comparator|Sham training|Using a handheld device, subjects were perform 30 breaths a day, six days a week. The device produces resistance that increases the effort of breathing in. The resistance to breathing will be weak.
2897461|NCT03266484|Active Comparator|Probiotic Mixture|"Participants who are meeting the inclusion criteria will be randomized to either the probiotic mixture or an identical placebo.~The probiotics sachets will be taken twice a day for 12 weeks."
2897462|NCT03266484|Placebo Comparator|Placebo|"Participants who are meeting the inclusion criteria will be randomized to either the probiotic mixture or an identical placebo~The identical placebo sachets will be taken twice a day for 12 weeks."
2897564|NCT03265691|No Intervention|No intervention|Usual pattern of work will be performed in all patients who enter in Hospital. Duration: 6 months.
2897463|NCT03266471||Crohn's disease Patients|Patients that are seen in the Inflammatory Bowel Disease clinic with CD confirmed by endoscopy or radiology assessment who are initiating either an anti-tumor necrosis factor (TNF)-α agent (infliximab, adalimumab, certolizumab, or infliximab biosimilar), ustekinumab, or vedolizumab as part of their routine clinical care will be asked to provide blood samples and intestinal biopsies from standard of care colonoscopy at baseline and post therapy of at least 12 weeks duration but not more than 52 weeks.
2897464|NCT03266471||Controls|Healthy adults without IBD undergoing colonoscopy for colorectal cancer screening or other non-IBD related indication will be asked to provide blood samples and intestinal biopsies from standard of care colonoscopy.
2897465|NCT03266445|Active Comparator|+BUPRENORPHINE|Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone
2897466|NCT03266445|No Intervention|-BUPRENORPHINE (control)|Participants will be randomly assigned to have their daily dose of buprenorphine/naloxone held 3 days prior to surgery
2897467|NCT03266432|Other|60 pregnant women|60 pregnant women diagnosed with placenta previa will take from them 3 blood samples : one pre intervention and two samples postintervention
2897468|NCT03266419|Experimental|Deep NMB using rocuronium|The abdomen is insufflated to 12 mmHg pneumoperitoneum with deep NMB (post tetanic count 1-2) during operation
2897469|NCT03266419|Active Comparator|Moderate NMB using rocuronium|The abdomen is insufflated to 12 mmHg pneumoperitoneum with moderate NMB (train of four 1-2) during operation
2897470|NCT03266406|Experimental|Effect of hyaluronidase on IOP|
2897471|NCT03266393|Experimental|Arm A-Tacrolimus then Envarsus|Immediate release tacrolimus (twice a day oral formulation) 14 day run-in followed by 4 months of follow-up and then crossing over to Envarsus XR® with a 14 day run-in followed by 4 months of follow-up.
2897472|NCT03266393|Experimental|Arm B-Envarsus then Tacrolimus|Envarsus XR® 14 day run-in followed by 4 months of follow-up and then crossing over to immediate release tacrolimus (twice a day oral formulation) with a 14 day run-in followed by 4 months of follow-up.
2897473|NCT03266367||patients|NGAL and renal functions will be measured two hours after Percutaneous coronary intervention and two days later as a follow up
2897474|NCT03266367||Healthy Group|control group
2897475|NCT03266328||group 1|ST elevated myocardial infarction patient presented to assiut university hospital for Primary Percutaneous Coronary Intervention (PPCI) and their age is up to 40 years old
2897476|NCT03266328||group 2|ST elevated myocardial infarction patient presented to assiut university hospital for Primary Percutaneous Coronary Intervention (PPCI) and their age is more than 40 years old
2897477|NCT03266315|Experimental|Probiotics|subjects will be randomly assigned to receive FloraBaby
2897478|NCT03266315|Placebo Comparator|Placebo|subjects will be randomly assigned to receive placebo
2897479|NCT03266302|Experimental|Interventional group|Use of hemoadsorber for removal of cytokines. Participants undergoing cardiac surgery due to infective endocarditis will be treated using a hemoadsorption device (CytoSorb) within the cardiopulmonary Bypass circuit (=Intervention)
2897480|NCT03266302|No Intervention|Control group|Participants undergoing cardiac surgery due to infective endocarditis will be treated according to Standard of care (no hemoadsorption advice installed in the CPB circuit)
2897481|NCT03266276|No Intervention|Treatment as Usual Control Group|Treatment as usual.
2897482|NCT03266276|Experimental|Intervention Group|Use of a standardized PSOPC pathway approach, prompted follow up with patients and documentation.
2897483|NCT03266263|Experimental|automatic computer-led feedback|automated feedback for CPR quality provided by computers
2897484|NCT03266263|Active Comparator|instructor-led feedback|feedback for CPR quality provided by instructors
2897485|NCT03266250||spinal anesthesia Hypotensive patients|Transthoracic echocardiography of IVC before spinal anaesthesia
2897486|NCT03266250||spinal anesthesia Normotensive patients|Transthoracic echocardiography of IVC before spinal anaesthesia
2897487|NCT03266237|Experimental|Healthy Adult|Healthy adult participants aged 21-40 years will be vaccinated with Vaxigrip® influenza vaccine
2897488|NCT03266237|Experimental|Healthy Elderly|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
2897489|NCT03266237|Experimental|Healthy Elderly Pre-Frail|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
2897490|NCT03266237|Experimental|Healthy Elderly Frail|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
2897491|NCT03266224||Wryneck|those with a condition
2897492|NCT03266211||Patients|People older than 65 years in the Auvergne-Rhônes-Alpes region who are consulting their general practitioner.
2897493|NCT03266211||General practitioner|General practitioner of the Auvergne-Rhônes-Alpes region
2897494|NCT03266185|Experimental|45-minutes|45-minutes post-infusion cooling time
2897495|NCT03266185|Experimental|20-minutes|20-minutes post-infusion cooling time
2897496|NCT03266185|No Intervention|No scalp cooling|Patients who decline scalp cooling will be included as a control group to determine the incidence of paclitaxel-induced alopecia
2897497|NCT03266172|Experimental|Subjects in Part A|Subjects in Part A will receive GSK2982772 MR (Period 1, 2, 4, 5 and 6) and GSK2982772 IR (Period 3)
2897498|NCT03266172|Experimental|Subjects in Part B|Subjects in Part B will receive GSK2982772 MR
2897499|NCT03266159|Experimental|Part 1: Subjects receiving GSK525762 + trametinib|Eligible subjects will receive doses of GSK525762 with a starting dose of 40 milligrams (mg), or 60 mg in combination with trametinib with a starting dose of 1 mg or 1.5 mg or 2 mg, administered orally once daily. Dose escalation will continue until the maximally-tolerated dose combination (MTC) is reached. Once the MTC is reached, subjects will be enrolled in expansion cohort and will receive a fixed dose combination.
2897500|NCT03266159|Experimental|Part 2: Subjects with SCLC receiving GSK525762+ trametinib|Eligible subjects with small cell lung cancer (SCLC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
2897501|NCT03266159|Experimental|Part 2: Subjects with RMCRC receiving GSK525762+ trametini|Eligible subjects with Ras-mutated colorectal cancer (RMCRC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
2897677|NCT03264989|Experimental|crizanlizumab 5 mg/kg|SEG101 (crizanlizumab) drug at a dose of 5.0 mg/kg (or 7.5 mg/kg for exploratory group) by IV infusion.
2897502|NCT03266159|Experimental|Part 2: Subjects with RMNSCLC receiving GSK525762+ trametinib|Eligible subjects with Ras-mutated non small cell lung cancer (RMNSCLC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
2897503|NCT03266159|Experimental|Part 2: Subjects with RMPAC receiving GSK525762+ trametinib|Eligible subjects with Ras-mutated pancreatic adenocarcinoma (RMPAC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
2897504|NCT03266159|Experimental|Part 2: Subjects with RAST receiving GSK525762+ trametinib|Eligible subjects with Ras-pathway activated solid tumors (RAST) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
2897505|NCT03266146|Experimental|36 Weeks Methylprednisolone|Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA). Participants will then be followed for 24 weeks.
2897506|NCT03266146|Experimental|48 Weeks Methylprednisolone|Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in glucocorticoid 48 weeks of treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA). Participants will then be followed for 24 weeks.
2897507|NCT03266133|Experimental|Sleep Education Intervention|This is a two-session program designed to educate patients about healthy sleep in respect to timing, regularity, efficiency, and duration in order to promote sleep during pregnancy.
2897508|NCT03266133|No Intervention|Routine Care|Usual care
2897509|NCT03266120|Active Comparator|Art Intervention|Participants randomly assigned to this arm will receive a hands-on art intervention that will consist of twice weekly group sessions of approximately 60 minutes each in duration that will take place indoors over a period of four weeks for a total of eight art sessions. Participants will complete sets of self-report psychometric assessments and blood pressure and heart rate will be monitored before, during, and following the conclusion of the intervention.
2897510|NCT03266120|Experimental|Gardening Intervention|Participants randomly assigned to this arm will receive a hands-on gardening intervention that will consist of twice weekly group sessions of approximately 60 minutes each in duration that will take place in a greenhouse over a period of four weeks for a total of eight gardening sessions. Participants will complete sets of self-report psychometric assessments and blood pressure and heart rate will be monitored before, during, and following the conclusion of the intervention.
2897511|NCT03266107|Experimental|Treatment|Intracept System ablation
2897512|NCT03266094|Other|Bipolar instrument for tonsillectomies|BiZact™: A bipolar instrument for tonsillectomies
2897513|NCT03266081|Experimental|0.75% bupivacaine|
2897514|NCT03266068||Post Infectious IBS Case|Subjects who have suffered from acute bacterial gastroenteritis within last two years and have developed some symptoms that might be suggestive of post-infectious irritable bowel syndrome (IBS). Subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
2897515|NCT03266068||Post Infectious with no IBS Control|Subjects who have suffered from acute bacterial gastroenteritis within last two years and have not developed symptoms suggestive of post-infectious irritable bowel syndrome (IBS). Subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
2897516|NCT03266068||Healthy Control|Healthy volunteers; subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
2897517|NCT03266055|Experimental|Blueberry powder|
2897518|NCT03266055|Placebo Comparator|Blueberry placebo powder|
2897519|NCT03266016|Experimental|REDvent-acute|Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 > 90%), and undergoes a Spontaneous Breathing Trial (SBT). Patients will be managed with pressure control plus pressure support ventilation using a computerized decision support tool that will recommend changes to ventilator settings approximately every 4 hr (with or without a new blood gas). If the patient is spontaneously breathing, it will incorporate real-time measures of effort of breathing (esophageal manometry) to keep it in a target range.
2897520|NCT03266016|Placebo Comparator|Control-acute|Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 > 90%), and undergoes a Spontaneous Breathing Trial (SBT). Ventilator management will be per usual care until the patient meets weaning criteria and passes the oxygenation test.
2897521|NCT03266016|Experimental|REDvent-weaning|Weaning Phase: The weaning phase is defined as the time from the first Spontaneous Breathing Trial (SBT) until the patient successfully passes an SBT or is extubated (whichever comes first). Patients who pass the initial SBT at the end of the acute phase will not undergo weaning phase randomization. Patients will be managed in a pressure support/CPAP mode of ventilation with assessments or changes to the level of pressure support every 4 hours, targeting maintaining effort of breathing (esophageal manometry) in a normal range. An SBT will be conducted daily, and the weaning phase will continue until the patient passes the SBT.
2897522|NCT03266016|Placebo Comparator|Control-weaning|Weaning Phase: The weaning phase is defined as the time from the first Spontaneous Breathing Trial (SBT) until the patient successfully passes an SBT or is extubated (whichever comes first). Patients who pass the initial SBT at the end of the acute phase will not undergo weaning phase randomization. Ventilator management will be per usual care. An SBT will be conducted daily, and the weaning phase will continue until the patient passes the SBT.
2897523|NCT03266003|Other|Group 1: ipDOT followed by eDOT|Following 20 observable medication doses under an initial DOT study group assignment of in-person DOT (ipDOT), patients will be assigned (crossed-over) to electronic DOT (eDOT) to collect data on another 20 observable medication doses.
2897524|NCT03266003|Other|Group 2: eDOT followed by ipDOT|Following 20 observable medication doses under an initial DOT study group assignment of electronic DOT (eDOT), patients will be assigned (crossed-over) to in-person DOT (ipDOT) to collect data on another 20 observable medication doses.
2897525|NCT03265990|Experimental|Group A|Conventional haemrrhoidectomy,Ferguson technique
2897526|NCT03265990|Experimental|Group B|Ligasure haemorrhoidectomy
2897527|NCT03265977|Experimental|H56:IC31|5 ug H56/500 nmol IC31, 0.5 mL Intramuscular (IM), Days 0 and 56
2897528|NCT03265977|Placebo Comparator|Placebo|Normal saline, 0.5 mL IM, Days 0 and 56
2897529|NCT03265964|Active Comparator|Uridine|Subjects randomized to this study arm will receive uridine 2000 mg daily by mouth for 4 weeks
2897530|NCT03265964|Placebo Comparator|Placebo|Subjects randomized to this arm of the study will receive placebo 2000 mg daily by mouth for 4 weeks.
2897531|NCT03265951|Active Comparator|Ramelteon|Ramelteon 8 mg po at bedtime
2897532|NCT03265951|Placebo Comparator|Usual care|education brochure about sleep hygiene
2897533|NCT03265938||Indirect laryngoscopy|Head and neck pathology patients undergoing indirect laryngoscopy. Patients with a past medical history of active or previously treated head and neck pathology.
2897534|NCT03265925||Epilepsy patients Right Temporal Lobe|Epilepsy patients with seizures originating from the right temporal lobe
2897535|NCT03265925||Epilepsy patients Left Temporal Lobe|Epilepsy patients with seizures originating from the left temporal lobe
2897536|NCT03265925||Healthy|Healthy controls
2897537|NCT03265912||Mild Traumatic Brain Injury|Subjects enrolled in the GE healthcare study: Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase 2), mTBI (Mild Traumatic Brain Injury) patient group also called as Arm 1 in this study.
2897538|NCT03265912||Non Mild Traumatic Brain Injury|Subjects enrolled in the GE healthcare study, Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase 2), non-TBI (Non Mild Traumatic Brain Injury) patients also called as Arm 2 in this study.
2897539|NCT03265899|Experimental|Oxytocin|40 IU Oxytocin, intranasal application 30 min prior to the experiment
2897540|NCT03265899|Placebo Comparator|Placebo|sodium chloride solution, intranasal application 30 min prior to the experiment
2897541|NCT03265886|Experimental|Warm bupivacaine at (37°c)|Warmed bupivacaine at body temperature will be administered
2897542|NCT03265886|Active Comparator|Bupivacaine at operating room temperature (23°c)|Bupivacaine at temperature of 23°C will be administered
2897543|NCT03265847|Experimental|Culturally-tailored Safety Planning|Women in the intervention group receive the SDA intervention with the culturally-specific DA integrated as appropriate to the target group (i.e., immigrant, refugee or indigenous).
2897544|NCT03265847|No Intervention|Usual Care|The control group receive non-DA informed usual safety planning resources modeled on national and state domestic violence online resources, but not provided with immediate and visual feedback to their level of danger or a tailored safety planning.
2897545|NCT03265834|Experimental|Long course antibiotic therapy (28 days)|
2897546|NCT03265834|Experimental|Short course antibiotic therapy (≤10 days)|
2897547|NCT03265808|Experimental|allogeneic human mesenchymal stem cells (allo-hMSCs)|Forty (40) subjects will be treated with a single administration of allogeneic hMSCs: 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
2897548|NCT03265808|Placebo Comparator|Placebo|Forty (40) subjects will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
2897549|NCT03265795|Experimental|PEEK patient specific implant|this PEEK (poly ether ether ketone) Patient Specific Implant containing autogenous bone graft is used in reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
2897550|NCT03265782|Experimental|ibuprofen group|treatment of pda with oral ibuprofen with a loading dose 10 mg/kg/ds in the first day followed by 5 mg/kg/ds in the second ant third days then a follow up echo is done
2897551|NCT03265782|Experimental|paracetamol group|treatment of pda with oral paracetamol with dose of 15 mg/kg/ds every 6 hours for 3 days then a follow up echo is done
2897552|NCT03265769|Active Comparator|Transradial approach|target vessel revascularization via radial access site is labeled as transradial approach
2897553|NCT03265769|Active Comparator|Transfemoral approach|target vessel revascularization via femoral access site is labeled as transfemoral approach
2897554|NCT03265756||Healthy children|250 3D facial images of healthy children under 5yrs of age in the Democratic Republic of Congo (DRC).
2897555|NCT03265756||Suspected Pneumonia|50 young children (under 5 yrs) in hospital/clinics in Butembo DRC with suspected pneumonia
2897556|NCT03265743||Patients with Cystic Fibrosis|Patients with Cystic Fibrosis, followed in a pediatric or mixed Cystic Fibrosis center of the region Auvergne Rhône Alpes (AuRA), aged 11 years or older.
2897557|NCT03265717|Experimental|"Group 1: Untreated high risk watch and wait"|Newly diagnosed patients not eligible for any approved treatment (using NCI Working Group criteria), but having some poor prognosis characteristics (defined by MDACC nomogram criteria). Patients will be treated by INVAC-1 for 6 months and then MRD will be assessed. Patients will subsequently be managed as per usual care. For MRD negative patients after INVAC-1 who become MRD+ during follow-up, INVAC-1 can be resumed for one year.
2897558|NCT03265717|Experimental|Group 2: Ibrutinib treated patients|Patients who are receiving ibrutinib as 1st or 2nd line treatment. After at least 12 months of ibrutinib, patients will be assessed for MRD. MRD-positive patients will be treated with ibrutinib + INVAC-1 for 6 months and at the end of the combined treatment period, MRD will be assessed. MRD-negative patients (defined as <0.01% of CLL cells in total cells analyzed) will have the option to stop or continue ibrutinib. Then, they will be followed-up regularly for two years. Patients who become MRD-positive after being MRD-negative will resume ibrutinib single agent.
2897559|NCT03265704||AGA Neonates|AGA Control Group Appropriate for gestational age newborns of healthy mothers
2897560|NCT03265704||SGA Neonates|SGA - Control Group Small for gestational age newborns of healthy mothers
2897561|NCT03265704||AGA-PIH Neonates|AGA-PIH Study Group Appropriate for gestational age newborns of mothers with pregnancy induced hypertension
2897562|NCT03265704||SGA-PIH Neonates|SGA-PIH Study Group Small for gestational age newborns of mothers with pregnancy induced hypertension
2897565|NCT03265678||Arm|Registered participants will undergo a clinical assessment to determine whether they have high or low levels of skin ageing. The study will recruit 5 subjects with low levels of skin ageing and 5 subjects with high levels of skin ageing. Recruited patients will undergo skin punch biopsies, blood sampling and collection of lifestyle data.
2897566|NCT03265665|Experimental|ACTION Intervention|Women in the ACTION intervention will attend 1 asthma education/physical activity session and 5 group sessions in community location convenient to participants. Each session will last approximately 2 hours. Participants will be given Fitbit Charge HR to monitor their daily steps and will be sent motivational, educational and reminder text messages up to 3 times per week.
2897567|NCT03265665|Other|Enhanced usual care|Women in the Enhanced usual care arm will attend 1 asthma education/physical activity session and be given a Fitbit Charge HR to monitor their daily steps. They will be given a static step goal to achieve. Only reminder text messages for data collection visits will be sent.
2897568|NCT03265652|Experimental|Intense Pulsed Light (IPL) therapy|Subjects with receive 10-15 intense pulsed light (IPL) pulses on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and up to 3 mm from the lid margin of the lower eyelid. Following the administration of IPL pulses, subjects will undergo meibomian gland expression.
2897569|NCT03265652|Placebo Comparator|Sham therapy|Participants will undergo a sham treatment that will mimic the intense pulsed light (IPL) therapy. The tip of the IPL lightguide will be placed in 10-15 locations on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and up to 3 mm from the lid margin of the lower eyelid, but IPL pulses will not be actually delivered. Following this sham procedure, subjects will undergo meibomian gland expression.
2897570|NCT03265639|No Intervention|Pre-treatment|This arm is the 8-week observation period before the p-inulin treatment phase.
2897571|NCT03265639|Experimental|Intervention|This arm is the 8 week p-inulin treatment phase (8 grams twice daily, oral).
2897572|NCT03265639|No Intervention|Post-treatment|This arm is the 8-week observation period after the p-inulin treatment phase.
2897573|NCT03265626|Experimental|Comprehensive (Intervention 1)|A total of 586 study particpnats will be invloved on this comprehensive (main) experiment group.This arm will receive a comprehensive intervention package that include advocacy to local governors, community mobilization, awareness creation, training of community representatives and engagement partners. community mobilization through engaging husband as change agent to avert domestic violence in collaboration with community Health Extension Workers. The intervention will target married or cohabited women, partner, and community representatives (religious leaders, and elders). The intervention will be focused on physical, psychological and sexual violence, decision making, negotiation, communication on household matters, gender equality and equity norms, and their relationship with women's health. In addition, massive public information dissemination will be done in the intervention community.
2897574|NCT03265626|Active Comparator|Intervention 2|A total of 586 study particpnats will be invloved on this active comprator group. The intervention package such as advocacy to local governors, community mobilization, awareness creation and training of community representatives will be carried out for 12 months period.The main diffrence from the arm-1,here is no husband involvment in the interevntion targets. This intervention will be targeted married and cohabited women and community representatives (religious leaders, health care provider, police, politicians and associations). This group of participant will be selected from one urban and one rural Kebele in Banja District. Same tool and approach will be used to track the intervention progress.
2897575|NCT03265626|Other|Control/Comparator|"A total of 586 study partipants will be assigned to the control group that will receive the existing standard services from both urban and rural kebeles of the Guagussa Shikudad district. As comparator purpose, baseline and endline evaluation data will be taken.~-No intervention package but standard service will be maintained"
2897576|NCT03265613|Experimental|AD-MSCs group|AD-MSCs（adipose-derived multipotent mesenchymal stem cells ） intravenous injection at a dose of 0.5 million cells/kg at week 0,week 4，week 8 with a duration for treatment for 12 weeks.
2897577|NCT03265600|Active Comparator|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
2897578|NCT03265600|Other|Low-dose Comparator|Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group and allowed to receive behavioral and medical referrals and treatment as usual. All participants complete an action planning protocol during Week 7.
2897579|NCT03265587||Orientation 1|Nursing staff allocated to a bed space with orientation 1
2897580|NCT03265587||Orientation 2|Nursing staff allocated to a bed space with orientation 2
2897581|NCT03265587||Floater / Control group|Nursing staff not allocated to a bed space with an orientation.
2897582|NCT03265574|Experimental|Intervention|
2897583|NCT03265574|No Intervention|Standard care|
2897584|NCT03265561|Experimental|Bone allograft group|This participants will receive bone structural allograft management for vertebral reconstruction. All patients undergo surgical procedure to realize debridement of the lesion, and the application of allograft without autograft.
2897585|NCT03265561|Active Comparator|Bone auto and allograft group|This participants will receive bone structural allograft plus spongy autograft management for vertebral reconstruction. All patients undergo surgical procedure.
2897586|NCT03265548|No Intervention|Standard|Usual Direct view laryngoscopy
2897587|NCT03265548|Experimental|Intervention|Video laryngoscopy
2897588|NCT03265535||Healthy Volunteers|Subjects without history of coronary artery disease
2897589|NCT03265535||Subjects with coronary artery disease|Subjects with coronary artery disease and abnormal SPECT myocardial perfusion imaging within the last 12 months
2897590|NCT03265522|Experimental|"Group 1: ThinkMed resource at baseline"|"The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline (n=20)"
2897707|NCT03264794|Experimental|trial group|Gefitinib tablets (CTTQ），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）
2897591|NCT03265522|Experimental|"Group 2: ThinkMed resource (staged)"|"This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian (n=20)"
2897592|NCT03265522|Placebo Comparator|Group 3: Standard Care (control) group|"Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 6 month study visit (i.e. delayed intervention) (n=20)"
2897593|NCT03265509|Active Comparator|Glutamine|30 g/day Glutamine supplementation for three months
2897594|NCT03265509|Placebo Comparator|Fantomalt|30 g/day Fantomalt supplementation for three months
2897595|NCT03265496|Experimental|study procedure|Clinical exam. Liquid biopsy. Diagnostic exam (biopsy and imagery). 1st line treatment. tumor evaluation. Biopsy
2897596|NCT03265483|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
2897597|NCT03265483|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
2897598|NCT03265483|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
2897599|NCT03265483|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
2897600|NCT03265470|Experimental|Dexmedetomidine|Patients received intravenous infusion of dexmedetomidine
2897601|NCT03265470|Active Comparator|Fentanyl|Patients received intravenous infusion of fentanyl
2897602|NCT03265457||patient with pseudoexfoliation syndrome|The corneal Endothelial cell count will be measured by specular microscopy
2897603|NCT03265457||Normal people at same age|
2897604|NCT03265444|Experimental|CS10BR05|The single injection of CS10BR05 Inj. in the carotid artery
2897605|NCT03265431|Active Comparator|Control|Normal subjects without history of cardiac disease or arrhythmia
2897606|NCT03265431|Experimental|Arrhythmia|This cohort consist of patients with history of recurrent VT and scheduled for EAM-guided catheter ablation as part of their clinical treatment
2897607|NCT03265431|Experimental|Treatment Failure|A subset of the Arrhythmia cohort, this group will undergo a second imaging session. This subset corresponds to patients from the Arrhythmia cohort presenting with recurrent ventricular arrhythmia following initial EAM-guided catheter ablation and requiring repeated ablation. It is estimated that 30% of the Arrhythmia cohort patients will require repeat ablation based on rate of repeat ablation procedures at MGH. T
2897608|NCT03265418|Experimental|BioXmark liquid fiducial markers|Placement of 4 BioXmark liquid fiducial markers, standard treatment (chemo-radiotherapy followed by surgery or wait-and-see) with extra imaging to evaluate the behaviour of the markers before, during and after the radiotherapy
2897609|NCT03265405|Active Comparator|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be discontinued.
2897610|NCT03265405|Active Comparator|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be discontinued.
2897611|NCT03265405|No Intervention|Observation|The subjects with sarcoidosis who do not have any indication for immunosuppressive treatment will be observed and monitored. If any treatment requiring indication arises during the observed period, the subjects will be randomized to one of the above study groups
2897612|NCT03265392|Other|Part 1 - Bread + Water|Participants in this arm will randomly consume bread and 250 mL of water on 1 out of 3 visits of Part 1.
2897613|NCT03265392|Other|Part 1 - Bread + Lemon Juice|Participants in this arm will randomly consume bread and 250 mL of lemon juice on 1 out of 3 visits of Part 1.
2897614|NCT03265392|Other|Part 1 - Bread + Tea|Participants in this arm will randomly consume bread and 250 mL of tea on 1 out of 3 visits of Part 1.
2897615|NCT03265392|Other|Part 2 - Bread + water|Participants in this arm will randomly consume bread and 250 mL of water supplemented with 20 peas on 1 out of 3 visits of Part 2.
2897616|NCT03265392|Other|Part 2 - Bread+ Lemon Juice|Participants in this arm will randomly consume bread and 250 mL of lemon juice supplemented with 20 peas on 1 out of 3 visits of Part 2.
2897617|NCT03265392|Other|Part 2 - Bread+ tea|Participants in this arm will randomly consume bread and 250 mL of tea supplemented with 20 peas on 1 out of 3 visits of Part 2.
2897618|NCT03265379||patients with an isolated recurrence in the chest wall|
2897619|NCT03265379||distant metastatic disease is present but who undergo FTCWR|
2897620|NCT03265379||patient with primary tumor, no distant ds, failed conventional|
2897621|NCT03265379||patients refusing to undergo surgery|
2897622|NCT03265366|Experimental|ABPA|15 patients with ABPA
2897623|NCT03265366|Active Comparator|Severe asthma|12 patients with severe asthma
2897624|NCT03265353|Other|Moderate Potassium/Low Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the moderate potassium/low sodium diet.
2897625|NCT03265353|Other|Moderate Potassium/High Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the moderate potassium/high sodium diet.
2897626|NCT03265353|Other|High Potassium/High Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the high potassium/high sodium diet.
2897627|NCT03265340|Active Comparator|A|dTMS standard protocol 10 min session
2897628|NCT03265340|Active Comparator|B|dTMS standard protocol 20 min session
2897629|NCT03265340|Active Comparator|C|dTMS standard protocol 40 min session
2897630|NCT03265327|Experimental|Treatment|Subjects will receive an oral supplement containing fish oil, evening primrose oil and borage oil.
2897631|NCT03265327|Placebo Comparator|Placebo|Subjects will receive an oral supplement containing coconut oil and light olive oil.
2897632|NCT03265314|Experimental|LeadHer|The LeadHer curriculum is presented to the target population over a total of 30 hours. The program addresses the following adult preparation subjects: Healthy relationships, Adolescent development, Healthy life skills, Educational and career success. The LeadHer curriculum is also accompanied by a mobile application.
2897837|NCT03263767|Experimental|MYELOID HEMOPATHY|patients with myeloid hemopathy
2897633|NCT03265314|Placebo Comparator|Sassy Science|The Sassy Science curriculum is presented to the target population over a total of 30 hours. The program addresses the following subjects: States of Matter, Math, Engineering, Chemistry, Arts and Crafts, Sweet Treats and Celebrations. The curriculum does not have a mobile application.
2897634|NCT03265301|Other|Office hysteroscopy|
2897635|NCT03265301|Other|Conventional hysteroscopy|
2897636|NCT03265288|Experimental|Fenretinide|Active drug fenretinide (as LAU-7b capsules)
2897637|NCT03265288|Placebo Comparator|Placebo|Placebo oral capsule (as inactive capsules identical to active arm)
2897638|NCT03265262|Experimental|Children receiving OFC during a diagnost|paediatric patients attending food allergy
2897639|NCT03265249|Experimental|Group 1|BRIDGE device will be placed prior to start of the surgery with standard of care pain control analgesia
2897640|NCT03265249|No Intervention|Group 2|Subjects will receive the standard of care pain control analgesia
2897641|NCT03265236||Group1|Patients with early rheamatoid arthritis
2897642|NCT03265236||Group 2|patients with late rheamatoid arthritis
2897643|NCT03265236||Group 3|Healthy control
2897644|NCT03265223|No Intervention|Controls|Received 1 ml/cm normal saline (23 ml) both at intraperitoneal (=20 ml) as well as intraincisional (=3 ml) location.
2897645|NCT03265223|Active Comparator|Intraperitoneal group|Received 20 ml of 0.2% ropivacaine intraperitoneally (1 ml/cm; 16 ml along right hemi-dome, approximately equal to length of right hemi-dome of diaphragm in an average adult and 4 ml in gall bladder fossa) and 3 ml normal saline (1ml/cm of port site incision length)
2897646|NCT03265223|Active Comparator|Intraincisional group|Received 20 ml of normal saline intraperitoneally (1 ml/cm; 16 ml along right hemi-dome, approximately equal to length of right hemi-dome of diaphragm in an average adult and 4 ml in gall bladder fossa) and 3 ml 0.2% ropivacaine (1ml/cm of port site incision length)
2897647|NCT03265210|Experimental|Relief|Relief relies on a neurobiological model to simplify its behavioral targets and uses mobile technology to augment its interventions. Relief was co-developed with our primary care partners with the goal to be usable by non-physician clinicians of primary care offices eligible to provide billable services.
2897648|NCT03265210|No Intervention|Referral|Referral for mental health based on clinical indication.
2897649|NCT03265197|Experimental|Intratympanic injection of drugs;|intervention by Intratympanic injection of drugs in two studied groups; group A, injection of combined 2 drugs( lidocaine and dexamethasone) and group B, injection of one drug (dexamethasone only).
2897650|NCT03265197|Active Comparator|Data management of Intratympanic drugs|intervention by Manage data of two study group as blind statistical between group A, injection of combined 2 drugs( lidocaine and dexamethasone) and group B, injection of one drug (dexamethasone only).
2897651|NCT03265184|Experimental|intervention group|400 mg green coffee extract capsules twice per day for 8 weeks The Green coffee extract is standardised with 45% total chlorogenic acid by HPLC
2897652|NCT03265184|Placebo Comparator|placebo group|placebo capsules twice per day for 8 weeks have identical appearance to Green coffee extract capsules and contain starch
2897653|NCT03265145|Experimental|Stiolto Respimat|
2897654|NCT03265145|Active Comparator|ICS plus LABA plus LAMA (triple therapy)|ICS (Inhaled Corticosteroid) plus LABA (Long-Acting Beta Agonist) plus (Long-Acting Muscarinic Antagonist)
2897655|NCT03265132|Experimental|anakinra|2 mg/kg/day (max 100 mg/day) or 4 mg/kg/day (max 200 mg/day)
2897656|NCT03265132|Placebo Comparator|Placebo|Corresponding volume to anakinra 2 mg/kg/day or 4 mg/kg/day
2897657|NCT03265119|Experimental|AEVI-001|
2897658|NCT03265119|Placebo Comparator|Placebo|
2897659|NCT03265106|Experimental|BinD19|BinD19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity. Minimum/ maximum dose: 1x10^6/kg / 1x10^7/kg administered to childhood patients with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma.
2897660|NCT03265093|Active Comparator|experimental; Corticosteroid|Intralesional corticosteroid administration
2897661|NCT03265093|Experimental|Experimental; Injectable Platelet rich fibrin|Injectable Platelet rich fibrin
2897662|NCT03265080|Experimental|Dose Group 1|"Dose cohorts of 3 participants each will be treated. Initiation of dosing will be staggered by at least 4 weeks for participants in the first cohort, also known as intra-cohort staggering.~The first cohort will receive a dose of ADXS-NEO 1 x 10 to the 9th power colony forming unit (CFU) (DL1)."
2897663|NCT03265080|Experimental|Dose Group 2|The second cohort group will receive a dose of ADXS-NEO 2 x 10 to the 9th power CFU (DL2).
2897664|NCT03265080|Experimental|Dose Group 3|The third cohort group will receive a dose of ADXS-NEO 4 x 10 to the 9th power CFU (DL3).
2897665|NCT03265067|No Intervention|'Before' group|Patients who underwent primary PCI for STEMI prior to implementation of the RIC protol. These patients were not treated with the autoRIC device prior to PCI.
2897666|NCT03265067|Experimental|'After' group|Patients who underwent primary PCI for STEMI after implementation of the RIC protocol. These patients were treated with the autoRIC device prior to PCI.
2897667|NCT03265054||re-thrombosis|adult patients with a VTE history with at least 3 months of anticoagulant treatment, which suffered from a re-thrombosis within 5 years after stopping the anticoagulant treatment
2897668|NCT03265054||no thrombosis recurrence|adult patients with a VTE history with at least 3 months of anticoagulant treatment, without thrombosis recurrence
2897669|NCT03265028|Experimental|Intervention|Invited to take the TRACE e-learning.
2897670|NCT03265028|No Intervention|Control|Not (yet) invited to take the TRACE e-learning.
2897671|NCT03265015|Experimental|cTBS|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern.
2897672|NCT03265015|Active Comparator|iTBS|Transcranial Magnetic Stimulation delivered in an intermittent Theta Burst Stimulation (iTBS) pattern.
2897673|NCT03265002|Placebo Comparator|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
2897674|NCT03265002|Experimental|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
2897675|NCT03265002|Active Comparator|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
2897676|NCT03265002|Active Comparator|Inulin and Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
2897838|NCT03263754|Experimental|Intervention|
2897678|NCT03264976||Group 1|Patients without DR. Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years.
2897679|NCT03264976||Group 2|"Patients with mild non-proliferative DR (NPDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years."
2897680|NCT03264976||Group 3|"Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years."
2897681|NCT03264976||Group 4|"Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years."
2897682|NCT03264976||Group 5|"Proliferative DR (PDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years."
2897683|NCT03264963|Active Comparator|Control|
2897684|NCT03264963|Experimental|Intervention|
2897685|NCT03264950|Other|SIngle Arm|All patients undergo Elastography. This is a single arm study
2897686|NCT03264937||Wechat-based group|We set up a chat-group in wechat application, and pulled participatients' ID in this chat-group. We send anticoagulation knowledges, answer questions, remind them of monitoring INR et.al.
2897687|NCT03264937||Control group|We just observe without any additional contacts.
2897688|NCT03264924||Phase A, Study One|Semi-structured interviews to investigate staff and patients' experiences of participating and facilitating cardiac and pulmonary rehabilitation.
2897689|NCT03264924||Phase A, Study Two|Focus group with rehabilitation stakeholders to discuss perceived feasibility and acceptability of the intervention design.
2897690|NCT03264924||Phase A, Study Three|Pilot of the intervention, using a group of exercise physiologists external to the community rehabilitation services.
2897691|NCT03264924||Phase B|Community rehabilitation service staff will participate in the intervention. Patients will then participate in the rehabilitaiton programme. Physical activity levels of patients will be recorded throughout the rehabilitation programme and for six months post-discharge. Qualitative and quantitative follow-up sessions will patients will take place at discharge (8 weeks after start of rehabilitation), and three and six months post-discharge.
2897692|NCT03264911|Active Comparator|amoxicillin|Children will be randomized to receive, after consent to the study, an antibiotic (amoxicillin approximately 50 mg/kg/day) orally, twice a day for 6 days.
2897693|NCT03264911|Placebo Comparator|Placebo arm|Children will be randomized to receive, after consent to the study, a placebo orally, twice a day for 6 days.
2897694|NCT03264898||FIT Group|Fecal immunochemical tests will be completed.
2897695|NCT03264885|No Intervention|Usual Care|The usual stand of care (UC) after community eye screening was to provide a GP referral letter and advice to attend a tertiary eye care facility most accessible to them
2897696|NCT03264885|Other|Incentive Care|In addition to the UC, those assigned to the ICS also received social and financial support to incentivise and improve compliance. All ICS participants were assisted with scheduling their tertiary care appointments, given telephone reminders, provided once-off transportation allowance and subsidy for their first tertiary eye-care consultation - while participants with mobility issues were assisted by volunteers.
2897697|NCT03264872|Experimental|Peer-Enhanced Motivational Interviewing|Both dyad members, the target client and their peer support person, in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions with a trained counselor.
2897698|NCT03264872|Other|Waitlist Control|Delayed Treatment.
2897699|NCT03264846||Group 1|PCOS participants with periodontitis
2897700|NCT03264846||Group 2|PCOS participants with periodontally healthy
2897701|NCT03264846||Group 3|systemically healthy participants with periodontitis
2897702|NCT03264846||Group 4|systemically and periodontally healthy participants
2897703|NCT03264820|Experimental|Patients with scleroderma and potential arterial disease|"The patients (33) will undergo a medical examination in order to analyse their medical history, parameters and check inclusion and non-inclusion criterions.~Then will be performed :~Visit 1 :~Biology report * (* Biological evaluation carried out in all healthy subjects and in subjects whose biological check-up dates more than 2 years,+ urinary pregnancy test (if applicable))~Laser measurements at the forearm (with laser speckle)~Laser measurements at the level of each finger~Pain evaluation (EVA)~Measurement of blood pressure and heart rate~Environmental measures and skin temperature~Visit 2 :~Laser measurements at the level of each finger~Pain evaluation (EVA)~Measurement of blood pressure and heart rate~Environmental measures and skin temperature"
2897704|NCT03264820|Experimental|Healthy volunteers|"The healthy volunteers (11) will undergo :~Visit 1 :~Biology report (+ urinary pregnancy test (if applicable))~Laser measurements at the forearm (with laser speckle)~Laser measurements at the level of each finger~Pain evaluation (EVA)~Measurement of blood pressure and heart rate~Environmental measures and skin temperature~Visit 2 :~Laser measurements at the level of each finger~Pain evaluation (EVA)~Measurement of blood pressure and heart rate~Environmental measures and skin temperature"
2897705|NCT03264807|Active Comparator|D2 lymphadenectomy|Subtotal gastrectomy with D2 lymphadnectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) could be performed in this arm
2897706|NCT03264807|Experimental|D2 and #14v lymphadenectomy|Subtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and lymph node #14v lymphadnectomy could be performed in this arm
2897708|NCT03264794|Active Comparator|control group|Gefitinib tablets (Yi Ruisha），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）
2897709|NCT03264781|Experimental|Cyclofem group|Medroxyprogesterone Acetate 25 mg plus Estradiol Cypionate 5 mg (Cyclofem®) 0.5 ml IM injection single dose
2897710|NCT03264781|Placebo Comparator|Placebo group|normal saline 0.5 ml IM single dose
2897711|NCT03264768|No Intervention|control|standard care in case collateral ventilation is observed (by Chartis)
2897712|NCT03264768|Experimental|Endobronchial valves|Endobronchial valves in case collateral ventilation is absent (by Chartis)
2897713|NCT03264755|Active Comparator|cortical excitability in smokers|
2897714|NCT03264755|Active Comparator|cortical excitability in nonsmokers|
2897715|NCT03264729|Experimental|Isometric exercise|
2897716|NCT03264729|Active Comparator|Isotonic exercise|
2897717|NCT03264729|Active Comparator|Walking|
2897718|NCT03264716|Experimental|HepaSphere TACE (transarterial chemoembolization)|Using HepaSphere TACE (transarterial chemoembolization) for colorectal liver metastasis. TACE using HepaSphere load with doxorubicin.
2897719|NCT03264703||Participants with RA with cDMARD, but no anti-TNF experience|Male and female participants diagnosed with rheumatoid arthritis (RA), who have no experience with anti-tumor necrosis factor (anti-TNF) and who have experienced two or more Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) of a stable dose for at least 3 months.
2897720|NCT03264690||Microbial composition measured from IBD and non-IBD groups|Participants with inflammatory bowel disease (IBD) and non-IBD will be measured for microbial composition.
2897721|NCT03264677|Experimental|Group 1|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
2897722|NCT03264677|Experimental|Group 2|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
2897723|NCT03264677|Experimental|Group 3|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
2897724|NCT03264664|Experimental|E7386 BID|E7386 will be administered as a single agent orally, initially twice daily (BID) continuously in 28-day cycles at a starting dose of 5 milligrams (mg). The dose will be escalated in cohorts of participants subject to safety data and the absence of dose-limiting toxicities.
2897725|NCT03264651|Experimental|oral enobosarm and anastrozole|9 mg of oral enbosarm and 1 mg of anastrozole daily
2897726|NCT03264638|Experimental|Dingkundan|Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
2897727|NCT03264638|Experimental|Dingkundan & Diane-35|Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
2897728|NCT03264638|Active Comparator|Diane-35|Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
2897729|NCT03264625|Experimental|Treatment group|Patients will receive Cholecalciferol (2000IU qd) apart from routine therapy for PD
2897730|NCT03264625|Placebo Comparator|Control group|Patients randomized to the placebo group will receive routine therapy for PD.
2897731|NCT03264612|Active Comparator|Swimming group|"Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.~The exercise included three stages: warming up, swimming and cooling down."
2897732|NCT03264612|No Intervention|Non swimming group|no intervention
2897733|NCT03264599||occiput-spine angle > or = 126|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle > or = 126) will be performed to quantify the degree of fetal head flexion in respect to the trunk
2897734|NCT03264599||occiput-spine angle<126|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle < 126) will be performed to quantify the degree of fetal head flexion in respect to the trunk
2897735|NCT03264586|Active Comparator|Lidocaine-prilocaine cream|"Women who were assigned randomly to receive EMLA cream had a 5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate pemetration thrug stratum corneum~EMLA cream was applied, 1 hour before the expected time of birth.~With the assistance at birth, the residue of cream was removed to prevent contact with the fetus, because sodium hydroxide, which is a component of the cream, can cause fetal eye irritation.~No additional anesthetic was applied if episiotomy was necessary.~Before commancement of perineal repair any residual cream was wiped off."
2897736|NCT03264586|Active Comparator|mepivacaine infiltration group|"In the mepivacaine group, 10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.~In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.~The suture procedure was delayed 10 minutes after the injection of the aneathetic"
2897737|NCT03264573|Active Comparator|stem cell, PRP|Adipose derived MSCs, versus Platelet rich plasma
2897738|NCT03264573|Active Comparator|Stem cell, Stem cell and PRP|Adipose derived MSCs alone, other group is injected Adipose derived MSCs, and Platelet rich plasma
2897739|NCT03264560|Active Comparator|Synchronous Telepsychiatry (STP) group|
2897740|NCT03264560|Experimental|Asynchronous Telepsychiatry (ATP) group|
2897741|NCT03264547|Active Comparator|Arm A|"Trastuzumab + pertuzumab + Taxane*~*Taxane is chosen from the following; Docetaxel or Paclitaxel"
2897742|NCT03264547|Experimental|Arm B|Trastuzumab+ Pertuzumab + Eribulin
2897743|NCT03264534|Active Comparator|limbal relaxing incisions|Manually performed limbal relaxing incisions
2897744|NCT03264534|Active Comparator|astigmatic keratotomy|femtosecond laser-guided astigmatic keratotomy
2897745|NCT03264521||MTurk Participants|Participants who are registered users on Amazon Mechanical Turk (crowdsourcing platform) who volunteer to take survey.
2897746|NCT03264508|Experimental|Heat therapy|Hot water immersion 3-4x per week for 8-10 weeks
2897747|NCT03264508|Sham Comparator|Thermoneutral water immersion|Thermoneutral water immersion 3-4x per week for 8-10 weeks
2897748|NCT03264482|Active Comparator|THUVAP|thulium vaporization
2897749|NCT03264482|Active Comparator|M-TURP|monopolar transurethral resection
2897750|NCT03264456|Experimental|[18F] Fluciclovine PET/MRI|[18F] Fluciclovine PET/MRI for pretreatment staging of high-risk prostate cancer
2897751|NCT03264443|Active Comparator|Health education|Patients will receive weekly lectures on hypertension related topics during 12 weeks.
2897752|NCT03264443|Experimental|Combined training|Patients will complete 12 weeks of combined training (aerobic + strength exercise, 3x/week) in a pragmatic setup. In order to make the interventions more similar, contents of the health education arm will also be discussed with patients receiving this intervention.
2897753|NCT03264430|Active Comparator|The ketamine group|The ketamine group will receive intrathecal bupivacaine (7.5 mg) in 1.5 ml (Marcaine, Astra Zeneca, France, 0.5%) and ketamine (25mg) in 0.5 ml (Ketam, EIPICO, Egypt, 50 mg/mL),. Total volume is 2 ml will injected
2897754|NCT03264430|Placebo Comparator|The control group|group will receive only intrathecal bupivacaine (7.5 mg) in 1.5 ml plus 0.5ml normal saline to achieve total volume of 2 ml.
2897755|NCT03264404|Experimental|Pembrolizumab|Patients with advanced pancreatic cancer will receive pembrolizumab with the hypomethylating agent azacitidine.
2897756|NCT03264378|Experimental|PEI-GTO-ThAI|Physical exercise intervention (PEI) supported by the GTO-ThAI Implementation Model
2897757|NCT03264378|Active Comparator|PEI-Standard|Physical exercise intervention (PEI) supported by the standard governmental administrative procedures
2897758|NCT03264365|Experimental|Intervention|Relatives participated actively in the one out of three consultation conducted by trained study nurses at two months after intensive care superimposed on standard care.
2897759|NCT03264365|No Intervention|Standard care|Relatives to former ICU patients, who had received standard care (SC) completed a questionnaire package at 3 and 12 months after the patient was discharged from intensive care. After enrollment were all contract handled by primary investigator.
2897760|NCT03264352|Active Comparator|active-treatment group|Real antihypertensive agents will be provided for this arm, to decrease systolic BP both by at least 10 mm Hg and lower than 130 mm Hg. In the active-treatment group, the following study medications will be used: tablets with Allisartan Isoproxil 240 mg (first-line medication); tablets with Amlodipine 5 mg (second-line medication); scored tablets with hydrochlorothiazide 25 mg (third-line medication). Treatment will be started with Allisartan 240 mg. If necessary to reach the BP goal, Amlodipine (first 5 mg or then 10 mg daily) and afterwards hydrochlorothiazide (first 12.5 mg or then 25 mg daily) will be given in addition. If intolerable side effects occur, first-line medication may be replaced by second-line or similarly, second-line medication may be replaced by third-line medication.
2897761|NCT03264352|Placebo Comparator|placebo group|This arm receives identical agents to the active study drugs (Allisartan Isoproxil placebo, Amlodipine placebo and hydrochlorothiazide placebo) also to decrease systolic BP both by at least 10 mm Hg and lower than 130 mm Hg, with a similar schedule of administration to the parallel arm.
2897762|NCT03264339|Experimental|Smal step|Small Step Program, comprising 3 treatment focus areas (Hand use, Mobility, Communication)
2897763|NCT03264326|Experimental|BFR Group|Blood Flow Restriction Training with Eccentric Exercise Protocol
2897764|NCT03264326|Sham Comparator|Sham BFR Group|Sham Blood Flow Restriction Training with Eccentric Exercise Protocol
2897765|NCT03264313|Active Comparator|dTMS active|patients undergoing of dTMS real
2897766|NCT03264313|Sham Comparator|dTMS Sham|patients undergoing to placebo dTMS
2897767|NCT03264300|Active Comparator|Development of advanced MRI methods|Subjects with brain tumor. Subjects may be scanned using a single time-point to permit development and optimization of advanced MRI methods. Subjects may be scanned up to two times, with both visits occurring within one month, to permit analysis of test-retest reliability/repeatability.
2897768|NCT03264300|Active Comparator|Validation of rCBV accuracy|64 subjects with primary glioma and 96 subjects with recurrent glioma. Subjects will be scanned using a single time-point to validate rCBV accuracy.
2897769|NCT03264287|Experimental|3 times per week therapeutic frequency|"1.Acupuncture: GV20, LU5, LI11, LI4,GV14,BL13, ST2, BL2,ST7,ST6 and ashi point on the face.~Huatuo Brand needle (0.20*13mm) will be used for GV14, BL13, ST2, BL2, ST7, ST6 and ashi point on the face. Huatuo Brand needle (0.3*40mm) will be used for GV20, LU5, LI11 and LI4.~2.Moving capping: Du Meridian (from GV14 to GV3) as well as the first (from BL11 to BL28) and second (from BL41 to BL53) side lines of the Urinary Bladder Meridian of Foot-Taiyang.~Guoyiyan Brand cupping jar (size 4) will be used. 3.Ear point tapping: Lung (CO14), Heart (CO15), Stomach (CO4), Neifenmi (CO18), Pizhixia (AT4).~Huatuo Brand, made by the seed of Vaccaria segetalis ( Neck.)Garcke."
2897770|NCT03264287|Active Comparator|1 time per week therapeutic frequency|"The acupoints and treating procedures will be the same as the 3 times per week group. Only treating frequency is different. The treating frequency is 1 time per week.~Acupuncture: GV20, LU5, LI11, LI4,GV14,BL13, ST2, BL2,ST7,ST6 and ashi point on the face.~Moving capping: Du Meridian (from GV14 to GV3) as well as the first (from BL11 to BL28) and second (from BL41 to BL53) side lines of the Urinary Bladder Meridian of Foot-Taiyang.~Ear point tapping: Lung (CO14), Heart (CO15), Stomach (CO4), Neifenmi (CO18), Pizhixia (AT4).~Use the seed of Vaccaria segetalis ( Neck.)Garcke."
2897771|NCT03264274|Other|Aflibercept + DCE-US|Aflibercept: 4mg/kg IV every 2 weeks until discontinuation due to progression. DCE-US before treatment, and at 2 weeks and 8 weeks after the first Aflibercept administration.
2897772|NCT03264261|Experimental|robotic training|For the robotic training group, a controlled resistance load will be applied to the unaffected leg at the ankle and an assistance load will be applied to the pelvis.
2897773|NCT03264261|Active Comparator|treadmill training|For the treadmill training only group, a physical therapist will provide manual assistance to the affected leg at the knee and/or ankle joints as necessary during treadmill training.
2897774|NCT03264248|Experimental|E-Scale|E-scale daily bodyweight system coupled with a standardized behavioral treatment weight-loss intervention for overweight or obese wheelchair users
2897839|NCT03263754|Active Comparator|Control|
2940282|NCT02969733|Experimental|Ketamine|intravenous administration
2897775|NCT03264235|Experimental|Group 1 Exoskeleton|Both training groups will undergo inpatient physical therapy of the same duration and intensity. Group 1 will complete stair training wearing the Keeogo Exoskeleton in inpatient physical therapy.
2897776|NCT03264235|Active Comparator|Group 2 Traditional Therapy|Group 2 will complete traditional stair training in inpatient physical therapy.
2897777|NCT03264222|Other|Exposition to safety screening|One armed study with exposition to a new safety device (model QPS100) using radiofrequency technology
2897778|NCT03264209|Experimental|Intervention: Case management|Case management consists confirmation of hospital visit date, checking the efficacy of intervention, adverse effect and treatment compliance
2897779|NCT03264209|No Intervention|Control: usual care|Usual care is provided with life style intervention including exercise and nutrition by printed materials.
2897780|NCT03264196|Active Comparator|Operative|Open Reduction and Internal Fixation of Condylar Head Fracture
2897781|NCT03264196|No Intervention|Conservative|Non-operatively managed Condylar Head Fracture
2897782|NCT03264170|Active Comparator|Prediction of pregnancy outcome|Women will receive an individualised prediction score of the pregnancy being viable at the follow-up ultrasound generated from the prediction tool.
2897783|NCT03264170|No Intervention|Control|Women will not receive the prediction score
2897784|NCT03264157|Experimental|BPL HRIG + active rabies vaccine|20 IU/kg dose
2897785|NCT03264157|Active Comparator|Comparator HRIG + active rabies vaccine|20 IU/kg dose
2897786|NCT03264144|Experimental|Intervention|Students in the schools assigned to the intervention group will receive the intervention after the baseline survey. The intervention will be a social norms campaign involving posters, table tents, flyers and an online banner.
2897787|NCT03264144|No Intervention|Control|Students in the schools assigned to the control group will not receive anything during the randomised controlled trial. They will receive the intervention materials after the trial.
2897788|NCT03264131|Experimental|Open-label, Multicenter, Single-Arm|This is a single-arm intervention where patients will receive concurrent therapy with BV+CHEP [(brentuximab vedotin; 1.8 mg/kg IV, on D1 every 21 days) (cyclophosphamide 750 mg/m^2 on D1; doxorubicin 50 mg/m^2 on D1, etoposide 100 mg/m^2 IV infusion on D1-3; prednisone 100 mg orally once daily on D1-5; cycle length every 21 days)] for 4 to 6 cycles of induction therapy. After 6 cycles of BV + CHEP, responders (CR, PR or SD) who are not eligible for BMT and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV, every 21 days) until disease progression, withdrawal due to toxicity or death.
2897789|NCT03264118|Active Comparator|Control|Decontamination of furcation defect with scaling and root planing only.
2897790|NCT03264118|Experimental|Antimicrobial Photodynamic Therapy|Decontamination of furcation defect with scaling and root planing complemented by antimicrobial photodynamic therapy.
2897791|NCT03264105|Experimental|NovaPro™ Flow|NovaPro™ Flow Flowable Composite, Nanova Biomaterials company, USA
2897792|NCT03264105|Active Comparator|Conventional resin-based flowable composite|Filtek™Supreme Ultra Flowable Restorative, 3M ESPE company, USA
2897793|NCT03264092|Experimental|Wet suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the wet suction technique
2897794|NCT03264092|Experimental|Dry suction|This arm will include all the patients that will get and endoscopic ultrasound guided fine needle biopsy done with the dry suction technique
2897795|NCT03264092|Experimental|Slow pull|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the slow pull technique
2897796|NCT03264079|Experimental|Bardoxolone methyl 10 mg and Itraconazole 200 mg|Period 1: Bardoxolone methyl capsules 10 mg Period 2: two Itraconazole capsules 100 mg
2897797|NCT03264066|Experimental|Cohort 3 - RCC - treatment naive|In participants with metastatic RCC who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 milligrams (mg) once daily (QD) for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
2897798|NCT03264066|Experimental|Cohort 1 - SCCHN - treatment naive|In participants with recurrent or advanced / metastatic SSCHN who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
2897799|NCT03264066|Experimental|Cohort 2 - UC - treatment naive|In participants with advanced / metastatic UC who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
2897800|NCT03264066|Experimental|Cohort 4 - SCCHN - previous treatment exposure|In participants with SCCHN whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
2897801|NCT03264066|Experimental|Cohort 5 - UC - previous treatment exposure|In participants with UC whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
2897802|NCT03264066|Experimental|Cohort 6 - RCC - previous treatment exposure|In participants with RCC whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
2897803|NCT03264066|Experimental|Cohort 7 - biopsy cohort|In participants with solid non-melanoma, non- hematologic tumors who previously developed primary or secondary resistance to an anti-PD-1 or anti-PD-L1 agent, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle. The first dose of atezolizumab of 840 mg by IV infusions on Day 15 of Cycle 1. Thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles
2897909|NCT03263260||implanted patients|Patients with native coronary artery lesions with diameter between 2.5 and 4.0 and 34 mm of length treated only with the Inspiron Sirolimus eluting Stent
2897804|NCT03264053|Experimental|SOCKET SHIELD TECHNIQUE|Socket shield is the surgical removal of the frontal aspect of the badly broken root and retaining the lingual aspect so as to prevent crestal bone loss with insertion of the dental implant behind it
2897805|NCT03264053|Active Comparator|Conventional immediate implantation|Conventional immediate implantation is the surgical removal of the entire badly broken root
2897806|NCT03264040||Observation|Patients with Mannosidosis disease or high-grade suspicion for Mannosidosis disease
2897807|NCT03264027|Experimental|Carbon dioxide|Argon fulguration will be performed using CO2 for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
2897808|NCT03264027|Active Comparator|Ambient air|Argon fulguration will be performed using ambient air for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
2897809|NCT03264001|Experimental|Diet-induced negative energy balance|For the diet-induced negative energy balance arm, the three trials will include one control trial (isocaloric diet; zero energy balance) and two trials of progressively increasing negative energy balance induced by calorie restriction (20% and 40% reduction of daily energy needs for weight maintenance). With respect to physical activity, all diet trials will be performed under resting conditions.
2897810|NCT03264001|Experimental|Exercise-induced negative energy balance|For the exercise-induced negative energy balance arm, the three trials will include one control trial (rest; zero energy balance) and two trials of progressively increasing negative energy balance induced by aerobic exercise (20% and 40% reduction of daily energy needs for weight maintenance); with respect to caloric intake, all exercise trials will be performed under isocaloric conditions.
2897811|NCT03263988||PIEZO-Group|All patients in this study receive IBP by PICCO and piezocapacitative-interlayer-technology measurement.
2897812|NCT03263975|Experimental|Exercise heat STress (EHS)|EHS - dehydration produced by sweating and fluid restriction; primary loss of body water accompanied by small loss of electrolytes (hypertonicity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies.
2897813|NCT03263975|Experimental|Lasix (LAS)|LAS - dehydration produced by Lasix (diuretic, 80 mg oral dose) administration to produce losses of body water accompanied by large losses of electrolytes (isotoncity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies.
2897814|NCT03263962||With canrenone|Patients with canrenone
2897815|NCT03263962||Without canrenone|Patients without canrenone
2897816|NCT03263936|Other|Other|decitabine, vorinostat, fludarabine, high dose cytarabine, filgrastim (G-CSF)
2897817|NCT03263923|Experimental|Intervention group|Online intervention is cognitive behavioral skills' training and 4 weeks of online journaling. Participants receive cognitive behavioral skills training by online video, then participants must complete a 28 day online journal reflecting on the cognitive skills they have learned/used.
2897818|NCT03263923|Active Comparator|Comparison group|Comparator intervention is Reflective journaling training and 4 weeks of online journaling. Participants watch a reflective journaling video with specific instructions, and then the participants complete a 28 day journal using a different set of prompts to reflect on their days and describe how they handled various situations.
2897819|NCT03263910|Experimental|NPO-11|
2897820|NCT03263910|Placebo Comparator|Placebo|
2897821|NCT03263897|Experimental|Active|Receiving insufflation during an acute episode of migraine in both visits
2897822|NCT03263897|Sham Comparator|Sham|Receiving placebo insufflation during an acute episode of migraine in the first visit and receiving insufflation during an acute episode in the second visit
2897823|NCT03263884|Experimental|Real treatment group|"Transcranial magnetic stimulation (TMS) is used to stimulate small regions of the brain. During a TMS procedure, a magnetic field generator, or coil, is placed near the head of the person receiving the treatment. The coil produces small electric currents in the region of the brain just under the coil via electromagnetic induction.~The protocol used in this research includes 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses."
2897824|NCT03263884|Sham Comparator|Sham treatment group|Sham coil is used to mimic the clicking sound of the TMS coil and skin stimulation
2897825|NCT03263871|Experimental|Intervention|PTM202 and micro-nutrient sprinkles
2897826|NCT03263871|Other|Control|micro-nutrient sprinkles
2897827|NCT03263858|Experimental|Cohort 1 and 2|
2897828|NCT03263832||Exposed|"Patients with a monomicrobial S. aureus orhtopaedic device-related infection who have received antibiotherapy able to prevent biofilm formation following surgical intervention (from day 0 to day 7).~Upon inclusion, antibiograms were performed on the S. aureus isolated as part of routine procedure. S. aureus isolates was further analysed via an Antibiofilmogramme, which is an experimental element added by this research."
2897829|NCT03263832||Not Exposed|"Patients with a monomicrobial S. aureus orhtopaedic device-related infection who not have received antibiotherapy able to prevent biofilm formation following surgical intervention (from day 0 to day 7).~Upon inclusion, antibiograms were performed on the S. aureus isolated as part of routine procedure. S. aureus isolates was further analysed via an Antibiofilmogramme, which is an experimental element added by this research."
2897830|NCT03263819||POTS|patients with postural orthostatic tachycardia syndrome diagnosis.
2897831|NCT03263819||Healthy controls|Patients with Postural orthostatic tachycardia syndrome who has peripheral neuropathy
2897832|NCT03263806|Active Comparator|SOC Group Management|Attending physicians will dictate SOC management according to their own clinical judgment for medical management, stress test plus imaging or coronary artery catheterization with invasive fractional flow reserve.
2897833|NCT03263806|Experimental|CTFFR-Guided Group Management|Patients in this group will be triaged using CTFFR. CTFFR values will be provided to physicians with recommendations for medical management or coronary artery catheterization with invasive fractional flow reserve.
2897834|NCT03263793|Experimental|Behavioral vocal training|12-week vocal training program will use maximum vocal function exercises targeting vocal deficits specific to Parkinson Disease.
2897835|NCT03263780|Experimental|18F-Fluciclovine|10mCi +/-20% 18F-fluciclovine injection
2897836|NCT03263767|Experimental|LYMPHOID HEMOPATHY|patients with lymphoid hemopathy
2897840|NCT03263741|Experimental|Paclitaxel + S-1 + Oxaliplatin group|Paclitaxel: 175 mg/m2, iv, 3h, at D1 ; S-1: 60mg twice daily (after the breakfast and supper) for two weeks, and then suspend for one week; Oxaliplatin: 85 mg/m2, iv, 2h, at D1.
2897841|NCT03263728|Experimental|Stress Cardiac MR|
2897842|NCT03263715|Experimental|Tocilizumab|Tocilizumab-based regimen (Tocilizumab Prefilled Syringe [Actemra] 162 mg s.c. administered weekly) on top of rapidly tapered Glucocorticoid [Glucocorticoids]
2897843|NCT03263715|Placebo Comparator|Placebo|Placebo [Placebos] and rapidly tapered Glucocorticoid [Glucocorticoids] treatment
2897844|NCT03263702|Experimental|Computational Mapping Algorithm|AF mapping (utilizing CMA) will be performed and used to point the operator to regions within a heart chamber that should be interrogated further for suspicious electrogram activity, as measured by the St. Jude Ensite System, and ablated if the suspicious electrogram activity persists.
2897845|NCT03263689|Experimental|Intervention|"ITM group were given~Local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia~100 micrograms of preservative-free morphine."
2897846|NCT03263689|Active Comparator|Control|TAP group were given only local anaesthesia (plain hyperbaric bupivacaine 10 mgs) during the spinal anaesthesia.
2897847|NCT03263676|Experimental|Icon reusable underwear|
2897848|NCT03263676|Placebo Comparator|Disposable pad|
2897849|NCT03263663||Chemotherapy plus targeted treatment|Patients are treated in second-line with chemotherapy plus a targeted treatment according to the resistance mechanism to cetuximab pretreatment
2897850|NCT03263663||Chemotherapy according to physician choice standard|Patients are treated in second-line with chemotherapy according to physicians choice after cetuximab pretreatment
2897851|NCT03263650|Experimental|Cabazitaxel + Carboplatin|Cabazitaxel, Cabazitaxel and Carboplatin intravenously on day 1 of cycles 1-6. Prednisone by mouth twice daily on days 1-21 of cycles 1-6.
2897852|NCT03263650|Experimental|Olaparib Maintenance|Participants randomized to receive Olaparib by mouth twice daily on Day 1 of cycle 7.
2897853|NCT03263650|No Intervention|Observation Only|Participants randomized to observation only beginning cycle 7.
2897854|NCT03263637|Experimental|Arm A: (Cohort 1-6)|Dose level 1-6 in subjects with relapsed or refractory haematological malignancies
2897855|NCT03263637|Experimental|Arm B: (Cohort 1-6)|dose level 1-6 in subjects with relapsed or refractory AML, ALL, high-risk MDS, CMML, CLL and Richter's syndrome.
2897856|NCT03263624|Experimental|Group (A)|fractional carbon dioxide laser plus tazarotene 0.1% cream
2897857|NCT03263624|Active Comparator|Group (B)|Tazarotene Cream 0.1%
2897858|NCT03263611|Placebo Comparator|placebo|subject will receive single intradiscal injection of placebo
2897859|NCT03263611|Experimental|AMG0103 low dose|subject will receive single intradiscal injection of AMG0103 low dose
2897860|NCT03263611|Experimental|AMG0103 middle dose|subject will receive single intradiscal injection of AMG0103 middle dose
2897861|NCT03263611|Experimental|AMG0103 high dose|subject will receive single intradiscal injection of AMG0103 high dose
2897862|NCT03263585|Active Comparator|Spinal orthosis group|Women wearing the spinal orthosis Spinomed for 6 months at least 2 hours a day.
2897863|NCT03263585|Active Comparator|Equipment training group|Women training once a week in an equipment training group led by a physiotherapist for six months.
2897864|NCT03263585|No Intervention|Control|Women in the control group get no intervention for six months.
2897865|NCT03263572|Experimental|Newly Diagnosed Ph-Positive and/or BCR-ABL-Positive ALL|"First cycle is Induction Cycle, Cycles 2-5 are Consolidation Cycles, and Cycles 6 and beyond are Maintenance Cycles. Each cycle is 6 weeks.~Blinatumomab by vein non-stop on Days 1-28 of Cycles 1-5.~Dexamethasone by vein given within 1 hour before the start of each treatment cycle and at the time of any increase in dose to prevent side effects associated with Blinatumomab treatment. If side effects do occur, Dexamethasone given by mouth or orally or by vein for 3 to 7 days.~Methotrexate and Cytarabine given intrathecally on Days 1, 15, and 29 of Cycles 1-4.~Ponatinib by mouth each day during Weeks 1-4 of Cycle 1, followed by 2 weeks of no Ponatinib. Beginning with Cycle 2, Ponatinib given by mouth every day while on study."
2897866|NCT03263572|Experimental|Relapsed/Refractory ALL Disease|"First cycle is Induction Cycle, Cycles 2-5 are Consolidation Cycles, and Cycles 6 and beyond are Maintenance Cycles. Each cycle is 6 weeks.~Blinatumomab by vein non-stop on Days 1-28 of Cycles 1-5.~Dexamethasone by vein given within 1 hour before the start of each treatment cycle and at the time of any increase in dose to prevent side effects associated with Blinatumomab treatment. If side effects do occur, Dexamethasone given by mouth or orally or by vein for 3 to 7 days.~Ponatinib by mouth each day during Weeks 1-4 of Cycle 1, followed by 2 weeks of no Ponatinib. Beginning with Cycle 2, Ponatinib given by mouth every day while on study."
2897867|NCT03263559|Experimental|Haploidentical Transplantation|A conditioning regimen with Hydroxyurea, rabbit-ATG, Thiotepa, Fludarabine, Cyclophosphamide, Total Body Irradiation, and Mesna will be administered prior to Haploidentical Bone Marrow Transplantation.
2897868|NCT03263546|Experimental|Stepped care|Internet-delivered cognitive behavioral therapy (ICBT)
2897869|NCT03263546|Active Comparator|Gold standard treatment|Cognitive behavioral therapy (CBT)
2897870|NCT03263533|Experimental|Vorinostat Group 1 (P-V-P-P)|"This group will receive this sequence after the 1 initial week washout:~vorinstat (4 weeks) placebo (1 week) placebo (4 weeks)"
2897871|NCT03263533|Experimental|Vorinostat Group 2 (P-P-P-V)|"This group will receive this sequence after the 1 initial week washout:~placebo (4 weeks) placebo (1 week) vorinostat (4 weeks)"
2897872|NCT03263520|Experimental|Group 1: nandrolone and corticosteroid|the patient will receive an application of anabolic nandrolone decanoate at a dose of 50 mg (males) and 25 mg (females), intra-muscular form, in the first and fifteenth days. In addition to the anabolic steroid, the patient will use corticosteroids (dexamethasone) at home at a dose of 4 mg daily by mouth on the morning for both sexes for 30 days.
2897873|NCT03263520|Active Comparator|Group 2: corticosteroid|Patient will take corticosteroids ( 4 mg of dexamethasone) per oral, QD at morning for 30 days
2897874|NCT03263507|Experimental|IONIS PKK-LRx|Ascending single and multiple doses of IONIS PKK-LRx administered subcutaneously
2897875|NCT03263507|Placebo Comparator|Placebo (sterile saline 0.9%)|Calculated volume to match active comparator
2897876|NCT03263494|Active Comparator|CGM|
2897877|NCT03263494|No Intervention|BGM|
2941679|NCT02960321||CAG without PCI|Diagnostic coronary angiography only
2897878|NCT03263481|Experimental|ERCP with intraductal secretin test|Subjects undergoing ERCP for biliary indication in which inadvertent pancreatic cannulation occurs will receive intraductal secretin testing using a one-time intravenous injection of 16 mcg of human secretin for injection administered over one minute.
2897879|NCT03263468|Experimental|Same sitting complete revascularization|After treatment of the IRA, subjects will undergo PCI of all suitable significant non-IRA lesions (≥70% by visual assessment or FFR<0.80 in 50-70% lesions with vessel diameter >2mm).
2897880|NCT03263468|Active Comparator|Staged non-IRA PCI|Only the IRA will be intervened upon during the index primary PCI procedure. Staging of the non-IRA lesions will be performed 48 hours to 45 days after the primary PCI procedure. All suitable non-IRA lesions (≥70% by visual assessment or FFR<0.80 in 50-70% lesions with vessel diameter >2mm) will be treated with PCI irrespective of whether there are clinical symptoms or evidence of ischemia.
2897881|NCT03263455|Experimental|Kinesio Taping group|The tape in the KT group was applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension).
2897882|NCT03263455|Sham Comparator|Sham Taping group|"Patients in the ST group, smaller I-strips of KinesioTape were used and they were applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the Kinesio Taping group"
2897883|NCT03263442|Experimental|Intervention|Thiamine 200 mg IV
2897884|NCT03263442|Placebo Comparator|Control|Normal saline IV
2897885|NCT03263429|Experimental|Panitumumab/Irinotecan/CB-839|Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28, panitumumab IV over 60-90 minutes on days 1 and 15, and irinotecan hydrochloride IV over 90 minutes on day 1 and 15 (Phase I only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2897886|NCT03263416|Experimental|Arm A|
2897887|NCT03263416|Other|Arm B|Standard
2897888|NCT03263403|Experimental|Test Group|"44 participants will be randomly assigned to the test group for receiving the locally produced meningococcal vaccine Ingovax ACWY (Incepta)."
2897889|NCT03263403|Active Comparator|Comparator Group|44 participants will be randomly assigned to the comparator group for receiving 'Quadri Meningo' (BiO-MeD Private Limited).
2897890|NCT03263390||Bariatric Surgery|Subjects that have demonstrated extreme response to bariatric surgery.
2897891|NCT03263390||Anti Obesity Medications|Subjects that have demonstrated extreme response to anti obesity pharmacotherapy.
2897892|NCT03263377|Active Comparator|2|The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.
2897893|NCT03263377|Other|Non Intervention|A control group will be included in study design consisting of 7 schools selected randomly from 7 comparable yet adjacent Upazilas not slated for inclusion in the feeding programme. Use of a control group will enable later evaluations to attribute possible improvements in key impact/outcome variables to the intervention itself. An equal number of boys and girls will be selected from each class to enable gender analysis. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.No intervention had given in this group.
2897894|NCT03263351|Experimental|Cognitive-behavioral therapy group|Six-session cognitive-behavioral therapy group program designed as a prevention of depression intervention for adolescents at-risk for depression. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
2897895|NCT03263351|Active Comparator|Health education group|Six-session health education group program designed as a health education curriculum for teenagers. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
2897896|NCT03263338|Active Comparator|Group A|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target.
2897897|NCT03263338|Experimental|Group B|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group B.
2897898|NCT03263338|Experimental|Group C|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group C.
2897899|NCT03263325||AKI Group|Patients developing AKI after surgery
2897900|NCT03263325||No AKI Group|Patients who do not develop AKI after surgery
2897901|NCT03263312|Experimental|Fontan Patients|All Fontan patients included in this study will be part of an exercise intervention 2-6 times/week for 3-6 months.
2897902|NCT03263299|Active Comparator|cabergoline group|received cabergoline in addition to aspirin. Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer. Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
2897903|NCT03263299|Active Comparator|Aspirin group|Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
2897904|NCT03263299|Active Comparator|GnRH Group|Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.
2897905|NCT03263286|Experimental|HandSOME|The intervention is given to this group.
2897906|NCT03263273|Placebo Comparator|Topical Vehicle Gel|Topical administration of vehicle gel. Regimen: Apply once daily, at bedtime to the face
2897907|NCT03263273|Active Comparator|1% Topical Minocycline Gel|Topical administration of 1% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face
2897908|NCT03263273|Active Comparator|3% Topical Minocycline Gel|Topical administration of 3% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face
2897910|NCT03263247|Experimental|Visual Imaging Training|"Participants will receive visual imaging training to facilitate learning of written information.~Intervention: Visual Imaging Training in individual sessions"
2897911|NCT03263247|Active Comparator|Psychoeducation|"Participants will receive information about memory functioning and aging.~Intervention: behavioral: Psychoeducation in individual sessions"
2897912|NCT03263247|Experimental|Alphabet Search|"Participants will receive alphabet search training.~Intervention: Alphabet Search in individual sessions"
2897913|NCT03263234|Active Comparator|Group 1|Group 1 consists of elderly people with frailty and/or dementia living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are having CALED installed. Group 1 starts the 8 week control period and ends with the intervention consisting of 8 weeks of circadian adjusted LED-based lighting (CALED).
2897914|NCT03263234|Active Comparator|Group 2|Group 2 consists of elderly people with frailty and/or dementia living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are having CALED installed. Group 2 starts with the intervention consisting of 8 weeks of circadian adjusted LED-based lighting (CALED) and ends with the 8 week control period
2897915|NCT03263234|No Intervention|Group 3. Control group|"Group 3 consists of elderly people with frailty living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are not having CALED installed.~This group serves as a control for:~Physiological or mental decline in participants during the study period~Seasonal variation"
2897916|NCT03263208|Experimental|CD19 CAR-T|A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
2897917|NCT03263195||HIV-infected women|Pregnant women infected with HIV only and their infants.
2897918|NCT03263195||ZIKV-infected women|Pregnant women infected with ZIKV only and their infants.
2897919|NCT03263195||HIV- and ZIKV-infected women|Pregnant women infected with HIV and ZIKV and their infants.
2897920|NCT03263195||Not HIV- or ZIKV- infected women|Pregnant women not infected with either HIV or ZIKV and their infants.
2897921|NCT03263182||Nchelenge Facilities|Purposively selected health facilities based on criteria including: high demand for services, perceived need for support for quality improvement, and presence of a SBA to mentor.
2897922|NCT03263169||WE Health Tapestry|Completion of baseline measures then enrolled in a community-based personalized care intervention that consists of four core elements: volunteer support, interprofessional care, technology, social network linkage
2897923|NCT03263169||Usual Care|Completion of baseline measures with six-month delayed community-based personalized care intervention: volunteer support, interprofessional care, technology, social network linkage
2897924|NCT03263156|Experimental|Intervention group|The intervention will involve two face-to-face consultation sessions and one follow-up phone call with parents to help them learn sleep hygiene practices and specific behavioural strategies to improve their child's sleep and follow up on the progress.
2897925|NCT03263156|No Intervention|Waiting-list control|Children in the waiting-list control group will receive usual clinical care.
2897926|NCT03263143|No Intervention|Standard of Care|
2897927|NCT03263143|Other|Early Palliative Care Consultation|
2897928|NCT03263130||COPD, Emphysema, Asthma-COPD Overlap|Based on clinical, pathologic, laboratory, physiologic and radiologic differences, patient groups can be described.
2897929|NCT03263117|Active Comparator|Sedation|The protocol does not specify a particular combination of drugs that must be used for sedation. The choice of specific drugs and dosages for achieving sedation will be up to the anesthesiologist.
2897930|NCT03263117|Active Comparator|General Anesthesia|The protocol does not specify a particular combination of drugs that must be used for general anesthesia. The choice of specific drugs and dosages for achieving general anesthesia will be up to the anesthesiologist.
2897931|NCT03263104|Experimental|Lactobacillus plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402 equivalent to 2x10^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed twice daily, before breakfast and dinner with 250mL of water.
2897932|NCT03263104|Placebo Comparator|Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed twice daily, before breakfast and dinner with 250mL of water.
2897933|NCT03263091|Experimental|FG-4592 (Open Label, Double-blind, Three times a week)|Weight-based starting doses; dose adjustments to hemoglobin levels are allowed during the study.
2897934|NCT03263091|Placebo Comparator|Placebo (Double-blind, Three times a week)|Weight-based starting doses; dose adjustments to hemoglobin levels are allowed during the study.
2897935|NCT03263078|Experimental|TIVA with Propofol in major surgery|Total intravenous anesthesia(TIVA) with Propofol
2897936|NCT03263078|Active Comparator|Sevoflurane in major surgery|Inhalation anesthesia with Sevoflurane
2897937|NCT03263065|Experimental|Nopal added to test meal|test meal including nopal powder
2897938|NCT03263065|Experimental|Psyllium added to test meal|test meal including psyllium powder
2897939|NCT03263065|Experimental|Bran added to test meal|test meal including bran powder
2897940|NCT03263052||Tacrolimus XR|
2897941|NCT03263039|Other|Treatment with pembrolizumab|Pembrolizumab will be administered at a flat dose of 200 mg as a 30 minute (-5 min/+10 min) IV infusion every 3 weeks (Q3W)
2897942|NCT03263026|Active Comparator|R-CHOP + enzastaurin hydrochloride|Subjects in the R-CHOP + enzastaurin Arm will receive R-CHOP (Rituximab-375 mg/m2 i.v., Cyclophosphamide-750 mg/m2 i.v., Doxorubicin-50 mg/m2 i.v., Vincristine-1.4 mg/m2 i.v. (2 mg max), and Prednisone-100 mg p.o.), as directed, plus a 1125 mg loading dose of enzastaurin on Day 2 followed by 500 mg daily.
2897943|NCT03263026|Placebo Comparator|R-CHOP + placebo|Subjects in the R-CHOP + placebo Arm will receive R-CHOP (Rituximab-375 mg/m2 i.v., Cyclophosphamide-750 mg/m2 i.v., Doxorubicin-50 mg/m2 i.v., Vincristine-1.4 mg/m2 i.v. (2 mg max), and Prednisone-100 mg p.o.), as directed, plus an identical number of tablets as the subjects in the enzastaurin Arm.
2897944|NCT03263013||Patients|patients with functional movement disorders (FMD)
2897945|NCT03263000||Patients|24 patients with blepharospasm
2897946|NCT03263000||Healthy|24 healthy volunteers (HVs)
2897947|NCT03263000||Patients 2|24 patients with increased blinking alone.
2899230|NCT03253991|Experimental|MRgFUS treatment|MRgFUS device treatment, thalamotomy
2897948|NCT03262974||CML patients with MMR|CYP3A5*3 , CYP2C8*3 , ABCB1 2677G>T/A and SLC22A1 1222A > G SNPs on the plasma level by HPLC-UV and molecular response of imatinib by PCR
2897949|NCT03262974||CML patients without MMR|CYP3A5*3 , CYP2C8*3 , ABCB1 2677G>T/A and SLC22A1 1222A > G SNPs on the plasma level by HPLC-UV and molecular response of imatinib by PCR
2897950|NCT03262961|Active Comparator|Intervention Group|• The intervention group will be supplied with Sildenafil Citrate (Respatio® 20mg tablets manufactured by Pharma Right Group , Egypt) according to the patient's weight by the rate of (1.5 mg/kg/day) divided into three doses per day ( every 8 hours) till termination of pregnancy.
2897951|NCT03262961|Placebo Comparator|Control Group|- The control group will be supplied with a placebo drug that has the same shape, size and color but without the active ingredient and it would also be taken in a similar way. The placebo tablet will be manufactured at the faculty of pharmacy, Assiut University.
2897952|NCT03262948|Experimental|nab-paclitaxel plus carboplatin|nab-paclitaxel 260mg/m2,i.v., plus carboplatin AUC = 6,i.v., starting from randomization, once every 3 weeks, for 4-6 cycles, or progression, or intolerance,or death or start a new anti-tumor treatment, whichever occurs first.
2897953|NCT03262948|Active Comparator|Paclitaxel plus carboplatin|paclitaxel 175 mg/m2,i.v., plus carboplatin AUC = 6,i.v., starting from randomization, once every 3 weeks, for 4-6 cycles, or progression, or intolerance,or death or start a new anti-tumor treatment, whichever occurs first.
2897954|NCT03262935|Experimental|(vic-)trastuzumab duocarmazine|SYD985, every 3 weeks (Q3W)
2897955|NCT03262935|Active Comparator|Physician's choice|"Lap/Cap~T/Cap~T/Vino~T/Eri"
2897956|NCT03262909|Experimental|GelrinC prospective treatment arm|Patients will undergo GelrinC implantation.
2897957|NCT03262909|Other|Microfracture historical control arm|Microfracture historical control arm
2897958|NCT03262896||Patients with brain death|Ten patients with definite etiology, who were diagnosed with brain death because of Apnea test positive and / or cranial reflexes were not available and were male and female patients aged 18-72 years
2897959|NCT03262883||Chronic Critical Illness|"The patients who is over 18 years old and staying in the critical care unit at least 8 days. Additional criterias:~Prolonged mechanical ventilation (longer than 96 hours)~Tracheostomy~Sepsis~Serious injury (burn)~Stroke (hemorhagic or ischemic)~Traumatic brain injury~Postoperative (cardiac or non cardiac)~Acute coronary disease"
2897960|NCT03262857|Experimental|time of start of anesthesia|
2897961|NCT03262857|Experimental|intensity of anesthesia|
2897962|NCT03262844|Placebo Comparator|Conservative treatment|Conservative physiotherapy, intermittent catheterization, or drug treatment for bladder or bowel dysfunction
2897963|NCT03262844|Experimental|Capsule surgery|Nerve root axial decompression surgery (Capsule surgery)
2897964|NCT03262831|Experimental|Arm 1: Yoga|"Prior to start of treatment, a yoga therapist will work with each patient to develop a personalized yoga protocol using Gentle Hatha and Restorative Yoga~Each protocol will consist of 5-10 minutes of centering poses to invite focus and relaxation, then 15-20 minutes of seated and standing active poses, ending with 5-10 minutes of guided relaxation.~The personalized practice will be given to each participant and she will be asked to practice beginning at the start of neoadjuvant treatment at least 3 times a week (but preferably daily) at home for at least 30 minutes each time. Participants will continue their personalized yoga practice during the entirety of treatment. Each participant will be asked to journal when and for how long she practices at home and make any comments as to how the practice might have made her feel~During participation, weekly follow-up calls will be made by a member of the study team to each participant randomized to the yoga arm."
2897965|NCT03262831|Active Comparator|Arm 2: No Yoga|-Patients in this arm will not receive a personalized yoga plan
2897966|NCT03262818|Experimental|Transvaginal Ultrasound + Ultrasound/Photoacoustic imaging|"Transvaginal ultrasound (US) prior to surgery~Immediately after the transvaginal US, US/PAI imaging will be performed~Once the surgeon has removed the ovary(ies) they will be imaged ex vivo. The in vivo and ex vivo US/PAI images will be compared with the final pathologic diagnosis"
2897967|NCT03262805|Placebo Comparator|Placebo|Placebo
2897968|NCT03262805|Active Comparator|Active|Lanconone(R)
2897969|NCT03262792|Placebo Comparator|Placebo|Microcrystalline cellulose
2897970|NCT03262792|Active Comparator|ParActin 150|ParActin 150 mg
2897971|NCT03262792|Active Comparator|ParActin 300|ParActin 300 mg
2897972|NCT03262779|Experimental|combination nivolumab and ipilimumab|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, and ipilimumab 1 mg/kg administered IV every 6 weeks.
2897973|NCT03262766|Active Comparator|Acute intermittent hypoxia (AIH)|"Subjects will be exposed to acute intermittent hypoxia, daily for 5 days. Each session will consist of up to 90 seconds of 9-10% Oxygen (FiO2 0.09), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for up to 45 minutes, to maintain SpO2 at 80-90%. If the SpO2 drops below 75%, hypoxia exposure will be terminated immediately.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2)."
2897974|NCT03262766|Experimental|AIH+ Upper extremity training|"Subjects will be exposed to acute intermittent hypoxia, daily for 5 days. Each session will consist of up to 90 seconds of 9-10% Oxygen (FiO2 0.09), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for up to 45 minutes, to maintain SpO2 at 80-90%. If the SpO2 drops below 75%, hypoxia exposure will be terminated immediately.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2).~Following the AIH protocol, subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®."
2897975|NCT03262766|Active Comparator|Sham AIH + Upper extremity training|"Subjects will be exposed to sham hypoxia daily for 5 days. Each session will consist of up to 90 seconds of 21% Oxygen (FiO2 0.21), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery will be repeated up to 18 times per session each, for a total of up to 45 minutes.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2).~Following the sham AIH protocol, subjects will receive 45 minutes of task-specific, high repetition upper extremity training. Upper extremity training will be given using an upper-limb robotic rehabilitation device, the Armeo Spring®."
2897976|NCT03262766|Sham Comparator|Sham Acute intermittent hypoxia|"Subjects will be exposed to sham hypoxia daily for 5 days. Each session will consist of up to 90 seconds of 21% Oxygen (FiO2 0.21), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery will be repeated up to 18 times per session each, for a total of up to 45 minutes.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2)."
2897977|NCT03262753||surgery|Primary end-to-end surgical treatment of coarctation of the aorta
2897978|NCT03262753||balloon dilation|Primary balloon dilation treatment of coarctation of the aorta
2897979|NCT03262753||stent|Primary stent dilation treatment of coarctation of the aorta
2897980|NCT03262740|Experimental|BMS-986195 and Oral Contraceptive|Oral administration of contraceptive, then progress to combination
2897981|NCT03262727|Experimental|BMS-986165 and Oral Contraceptive|Oral administration of contraceptive, then progress to combination
2897982|NCT03262714|Experimental|Dancing|Elderly women randomized to the dance intervention programme.
2897983|NCT03262714|Experimental|Walking|Elderly women randomized to the walking intervention programme.
2897984|NCT03262714|Active Comparator|Stretching|Elderly women randomized to the stretching intervention programme.
2897985|NCT03262701|Experimental|HP13|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis and be given 1.7% hydrogen peroxide gel, oral, 0.75g, twice-daily for 15 minutes for 13 weeks.
2897986|NCT03262701|Experimental|HP26|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis and be given 1.7% hydrogen peroxide gel, oral, 0.75g, twice-daily for 15 minutes for 26 weeks.
2897987|NCT03262701|Other|Scaling and Root Planing|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis without any interventional hydrogen peroxide application in one or two visits.
2897988|NCT03262688|Experimental|INL-001|Bupivacaine HCl collagen-matrix implant
2897989|NCT03262688|Active Comparator|Infiltration|Bupivacaine HCl infiltration
2897990|NCT03262662|Experimental|Extended Run-In|"** 4 weeks of varenicline prior to the target quit date (TQD) **~+ 11 weeks of post-TQD varenicline~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.~Brief individual counseling at clinic visits"
2897991|NCT03262662|Active Comparator|Standard Run-In|"** 3 weeks of placebo followed by 1 week of varenicline prior to the target quit date (TQD) **~+ 11 weeks of post-TQD varenicline~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.~Brief individual counseling at clinic visits"
2897992|NCT03262649||Crohn's Disease Cohort|250 individuals in the Crohn's Disease Cohort
2897993|NCT03262649||ulcerative colitis cohort|108 individuals in the ulcerative colitis cohort
2897994|NCT03262636|Other|No Study MRI|"There will be two different patient population cohorts in this study. Both of them receive the study drug, indocyanine green, with intraoperative near-infrared (NIR) imaging. The two cohorts are as follows:~Cohort 1 (No Study MRI): Patients with extra-axial brain tumors such as meningioma, craniopharyngioma, schwannoma undergo standard-of-care MRI but no study sequences. They will undergo indocyanine green injection the day before surgery."
2897995|NCT03262636|Other|Study MRI|"Cohort 2 (Study MRI): Patients with intra-axial glial tumors such as glioblastoma multiforme, anaplastic astrocytoma will be in Cohort 2. This group of patients will undergo study MRI sequences before surgery. This group will also undergo ICG injection the day before surgery as described below.~Of note, sometimes it is difficult to determine the precise diagnosis of tumor based on preoperative imaging navigation MRI alone, and thus enrollment in Cohort 1 or 2 will be made at the discretion of the PI."
2897996|NCT03262623|Experimental|Radial nerve block|Patients will receive radial nerve block guided by a nerve stimulator.
2897997|NCT03262623|Placebo Comparator|Placebo|Patients will receive placebo through radial nerve block
2897998|NCT03262597|Experimental|Beverage Hydration Index of beverages|Subjects will consume 4 different beverages to obtain the beverage hydration index.
2897999|NCT03262571|Experimental|Group A|Group A includes patients undergoing lung ultrasound and physical examination.
2898000|NCT03262571|Placebo Comparator|Group B|Group B includes patients undergoing physical examination only.
2898001|NCT03262558||Patients with ECC|No intervention
2898002|NCT03262545|Experimental|experimental group|apatinib 500 mg p.o. once daily
2898003|NCT03262545|Placebo Comparator|control group|placebo p.o. once daily
2898004|NCT03262532||Experimental|Learning TEE manipulation with a Web-based TEE simulation module
2898005|NCT03262532||Control|Learning a TEE manipulation without the Web-based TEE simulation
2898006|NCT03262519||Patients at UCSD Sleep Medicine Clinic|Patients referred for sleep testing (either home sleep testing or in-lab full polysomnography) will be approached for participation.
2898007|NCT03262506|Experimental|Cognitive Training|
2898008|NCT03262493|Experimental|Interventional Group|It consists of the use of the feeding tube attachment device (FTAD) to fix the enteral probe.
2898009|NCT03262493|No Intervention|Conventional Group|It consists of the fixation of the enteral probe with adhesive tape of the micropore type and plaster.
2898010|NCT03262480|Active Comparator|Stroke volume optimization|Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4 (Voluven) will be administered within 10 minutes and stroke volume response will be recorded .If stroke volume increase by more than 10 % for 20 minutes, the aliquot will be repeated.
2898011|NCT03262480|Sham Comparator|Central venous pressure dynamic|Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4(Voluven) will be administered within 10 minutes and CVP response will be recorded. If CVP failed to rise sustainably for more than 2 mmHg for 20 minutes, the aliquot will be repeated.
2898012|NCT03262467|Active Comparator|Aneurysmorrhaphy with external porous prosthesis (Provena©)|
2898013|NCT03262467|Placebo Comparator|Aneurysmorrhaphy without external porous prosthesis|
2898014|NCT03262454|Experimental|Interventions|Atezolizumab
2898015|NCT03262441|Experimental|Mycophenolate mofetil|Mycophenolate Mofetil 500mg Tablets once per day for one week as a lead in to limit drug-related side effects. Provided they are tolerating the drug at lower dose, they will then initiate Mycophenolate Mofetil 500mg Tablets twice daily orally for 22 months
2898018|NCT03262428||Health care professionals|Health care professionals involved in the care of patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
2898019|NCT03262415||Study Cohort|30 adult subjects with type 1 or type 2 diabetes treated with insulin. The accuracy of the LabPatch Continuous Glucose Monitoring (CGM) will be evaluated during the study visit, comparing to YSI 2300 STAT Plus, OneTouch Verio and FreeStyle Lite.
2898020|NCT03262402|Experimental|HIV-infected group|Patients will be treated for their chronic periodontitis (basic periodontal treatment) and samples of gingival crevicular fluid and saliva will be collected at baseline, 30 days and 60 days after the periodontal treatment for the study analysis.
2898021|NCT03262402|Active Comparator|Non-HIV infected group|Patients will be treated for their chronic periodontitis (basic periodontal treatment) and samples of gingival crevicular fluid and saliva will be collected at baseline, 30 days and 60 days after the periodontal treatment for the study analysis.
2898022|NCT03262389|Experimental|Multiple Myeloma Patients|Participants will receive 4 different techniques of diagnosis: Fludeoxyglucose (F-18 FDG) PET/MRI, Sodium Acetate (C-11 acetate) PET/CT, C-11 PET/MRI, and F-18 FDG PET/CT. Each participant will receive both PET drugs by both diagnostic techniques and is therefore included in the analysis population for the four reporting groups.
2898023|NCT03262376|Experimental|Mineral + vits + botanical A|Mineral and vitamin complex combined with Botanical A
2898024|NCT03262376|Experimental|Mineral + vits + botanical B|Mineral and vitamin complex combined with Botanical B
2898025|NCT03262376|Experimental|Mineral+vits +botanical A+Botanical B|Mineral and vitamin complex combined with Botanical A and Botanical B
2898026|NCT03262376|Placebo Comparator|Placebo|Cellulose crystalline placebo
2898027|NCT03262363|Experimental|Curcumin/NFE2L2 A>G|Patients in Experimental group 1 and 2 will receive 800 mg/day of curcumin (for which a bioavailability of about 90% has been demonstrated and greater than other curcuminoids, administered in two doses of 400 mg each (the presentation will be in capsules containing 400 mg of THC).
2898028|NCT03262363|Placebo Comparator|Placebo/NFE2L2 A>G|Patients in control group 1 and 2, the placebo intervention will consist of administering sucralose capsules (a substance lacking pharmacological action, with no active principle and a lower intake of glucose compared to sucrose). Patients will receive 300 mg/day of sucralose distributed in two doses of 150 mg each.
2898029|NCT03262350|Experimental|Yoga Group|Participants are required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, body image, sleep habits, and loneliness and have their height and weight measured. Participants are also required to attend 50-minute yoga classes on Mondays, Wednesdays, and Fridays from 1:25-2:15pm for 10 weeks. The overall time commitment for Yoga Group participants is 3 hours of assessments and 50-minute yoga classes 3X week for 10 weeks.
2898030|NCT03262350|No Intervention|Control Group|Participants will be required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, health habits, body image, sleep habits and loneliness and have their height and weight measured. The overall time commitment for Control Group participants is 3 hours of assessments total.
2898031|NCT03262337||Elderly Travelers|approximately 135 travelers with an age >= 60 years will be enrolled
2898032|NCT03262337||Chronic diseased travelers|approximately 225 travelers with a chronic disease will be enrolled
2898033|NCT03262337||Healthy travelers|approximately 640 healthy travelers with be enrolled
2898034|NCT03262311|Experimental|Hypoxia marker|Administration of a single dose of the hypoxia marker Pimonidazole
2898035|NCT03262298|Experimental|anti-CD22 CAR-T|Patients will receive a full dose CART infusion at day 0.
2898036|NCT03262285||phacoemulsification|patients undergoing phacoemulsification surgery for senile cataract
2898037|NCT03262285||extracapsular cataract extraction|patients undergoing extracapsular cataract extraction surgery for senile cataract
2898038|NCT03262272|Experimental|Hemodialysis|patients treated by conventionnal hemodialysis
2898039|NCT03262272|Experimental|Hemodiafiltration post dilution|patients treated by HDF post-dilution
2898040|NCT03262259|Experimental|GSDG Intervention|Cities receiving a multi-component intervention, including screening and brief intervention, other evidence-based interventions (e.g., enforcement of drink-driving or underage drinking laws), and novel or partially tested interventions that warrant further evaluation.
2898041|NCT03262259|No Intervention|Comparison|Comparison cities receiving no evidence-based interventions.
2898042|NCT03262233|Experimental|Active|21 mg nicotine patches and 2 mg nicotine lozenges
2898043|NCT03262233|Placebo Comparator|Placebo|Placebo patches and placebo lozenges
2898044|NCT03262207||testicular tumours|
2898045|NCT03262207||fertile|
2898046|NCT03262207||infertile|
2898047|NCT03262181|Experimental|Isometric Exercise Condition|The participant will perform 5 sets of a 45-second isometric contractions at 70% of their maximum voluntary isometric contraction (MVIC). During the 45-second contraction, the participant will be provided with visual biofeedback on a computer screen (70% MVIC target line and +/- 5% error lines). The participant will be instructed to produce a level of isometric quadriceps contraction that maintains the isometric torque output line as close the target line as possible and always between the two error lines.
2898048|NCT03262181|Sham Comparator|Sham TENS Condition|"Two electrodes of the Select System TENS unit (Empi, Inc., St. Paul, MN) will be placed on either side of the patellar tendon on the test limb. The same instruction script will be used for each participant, stating, A surface electrode has been placed on either side of your patellar tendon. I will turn on the stimulation unit to emit a stimulus to your patellar tendon. This is a special sub-sensory stimulation treatment, so you will not feel anything during this period as the stimulus is set at a very low, non-detectable threshold. Please remain still during this 45-second period, letting your leg rest passively in the machine without contracting your leg muscles. After the 45-second period, the stimulation unit will be turned off and you will have a 2-minute rest period. We will repeat this same treatment/rest sequence 5 total times."
2898049|NCT03262168|Other|Study Group One|Six Minute Walk Test distance <450metres. Exercise programme including inspiratory muscle trainer for 12 weeks. Contact weekly (via phone or email).
2898050|NCT03262168|Other|Study Group Two|Six Minute Walk Test distance >450metres. Exercise programme including walking for 12 weeks. Contact every second week (via phone or email).
2898051|NCT03262168|Other|Study Group One - phase 2|Six Minute Walk Test distance <450metres. Exercise programme including inspiratory muscle trainer for 12 weeks. Contact weekly (via phone or email).
2898052|NCT03262168|Other|Study Group Two - phase 2|Six Minute Walk Test distance >450metres. Exercise programme including walking for 12 weeks. Contact every second week (via phone or email).
2898053|NCT03262155||ECMO / ECLS|Patients hospitalized for ARDS or Cardiogenic shock with ECMO / ECLS
2898054|NCT03262155||No ECMO / ECLS|Patients hospitalized for ARDS or Cardiogenic shock without ECMO / ECLS
2898055|NCT03262142|Active Comparator|Standard antibiotic treatment|Intravenous Piperacillin/tazobactam + oral Ciprofloxacin for 14 days
2898056|NCT03262142|No Intervention|Antibiotic-free treatment|
2898057|NCT03262116|Experimental|Bionic Pancreas - Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
2898058|NCT03262116|Experimental|Bionic Pancreas - Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
2898059|NCT03262116|Experimental|Bionic Pancreas - BioChaperone lispro|Subjects will participate in one week of wearing the insulin only bionic pancreas using biochaperone lispro as the rapid acting insulin.
2898060|NCT03262103|Experimental|Cohort 1|Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
2898061|NCT03262103|Experimental|Cohort 2|Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
2898062|NCT03262103|Experimental|Cohort 3|Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
2898063|NCT03262103|Experimental|Cohort 4|Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
2898064|NCT03262090|No Intervention|control group|Subjects were randomly assigned to receive saline before skin incision
2898065|NCT03262090|Active Comparator|0.2ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision
2898066|NCT03262090|Active Comparator|0.4ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision
2898067|NCT03262090|Active Comparator|0.6ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision
2898068|NCT03262090|Active Comparator|0.8ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision
2898069|NCT03262090|Active Comparator|1.0ug/kg dexmedetomidine|Subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
2898070|NCT03262077|Experimental|MB 1 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 1 min.
2898071|NCT03262077|Experimental|MB 3 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 3 min.
2898072|NCT03262077|Experimental|MB 5 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 5 min.
2898073|NCT03262077|Experimental|MBS 1 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 1 min.
2898074|NCT03262077|Experimental|MBS 3 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 3 min.
2898075|NCT03262077|Experimental|MBS 5 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 5 min.
2898076|NCT03262051||Patient with acute inflammation|patients undergoing hip surgery
2898077|NCT03262051||Patient with chronic inflammation|patients with rheumatoid arthritis
2898078|NCT03262038|Experimental|Ondansetron IV|Ondansetron IV X1 intraoperatively (0.1 mg/kg in 5 mLs) Ondansetron IV X 4 (Q 6 hrs for 24 hrs) (0.1 mg/kg in 5 mLs)
2898079|NCT03262038|Placebo Comparator|Placebo|Placebo Comparator: This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively X1 as well as IV every 6 hrs for 24 hours postoperatively. (X4)
2898080|NCT03262025||Operated patients who survived|Patients who were discharged in index hospital admission after operative intervention
2898081|NCT03262025||Operated patients who expired|Patients who expired in index hospital admission after operative intervention
2898082|NCT03262025||Non-operated patients who survived|Patients who were discharged in index hospital admission after being managed conservatively
2898083|NCT03262025||Non-operated patients who expired|Patients who expired in index hospital admission after being managed conservatively
2898084|NCT03262012|Experimental|BGF MDI (PT010)|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
2898085|NCT03262012|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
2898086|NCT03262012|Experimental|BFF MDI (PT009)|Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
2898087|NCT03262012|Active Comparator|Symbicort® Turbohaler® Inhalation Powder|Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
2898168|NCT03261414|Experimental|With preoperative hypnosis|standard care plus hypnosis followed by administration of propofol for anesthesia induction
2898088|NCT03261999|Experimental|Leuprolide Mesylate 25mg|"All subjects will be males with prostate cancer. They will be injected twice with a depot formulation containing 25 mg of Leuprolide Mesylate.~The first dose on day 0 and the second dose on day 84 (twelve weeks apart). Subjects will be followed until day 168."
2898089|NCT03261986|Other|Trident II acetabular cup|Subjects receive the Trident II acetabular cup and RSA beads and undergo a series of post-operative RSA exams.
2898090|NCT03261973|Other|DV8 esophageal deviation tool|This is a non-randomized one arm study.
2898091|NCT03261960|Experimental|Experimental Arm|BLI4700 Bowel Preparation
2898092|NCT03261960|Active Comparator|Control Arm|FDA Approved Bowel Preparation
2898093|NCT03261947|Experimental|TAK-931|TAK-931 50 milligram (mg), capsules, orally, once daily for 14 days, followed by 7-day washout period, in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 1 year).
2898094|NCT03261921|Active Comparator|Dexamethasone group|In this group the patients received 0.5 ml/kg of bupivacaine 0.25% + (0.1 mg/kg dexamethazone) caudally.
2898095|NCT03261921|Active Comparator|Dexmedetomidine group|In this group the Patients received 0.5 ml/kg of bupivacaine 0.25% + dexmedetomidine(1 mu/kg) caudally.
2898096|NCT03261921|Active Comparator|Combination group|In this group the patients received 0.5 ml/kg of bupivacaine 0.25% + dexamethasone(0.1mg/kg) and dexmedetomidine (1 mu/kg) caudally.
2898097|NCT03261908||wild genotype|Through next generation sequencing, distinguish wild genotype of simvastatin
2898098|NCT03261908||mutant genotype|Through next generation sequencing, distinguish mutant genotype of simvastatin
2898099|NCT03261895|Experimental|Intervention group|Nurse-led Integrative health and wellness programme
2898100|NCT03261895|No Intervention|control group|usual diabetes care
2898101|NCT03261882||Foreign-born Mexican-Americans|
2898102|NCT03261882||US-born Mexican-Americans|
2898103|NCT03261882||non-Hispanic Whites|
2898104|NCT03261869|Experimental|Cold application|Cold applied after extraction of third molar tooth.
2898105|NCT03261869|No Intervention|No Cold application|Cold application is not advised after extraction of third molar tooth
2898106|NCT03261843|Active Comparator|posterior lumbar interbody fusion + platelet rich plasma|the addition of autologous platelet rich plasma to the bone graft
2898107|NCT03261843|Active Comparator|posterior lumbar interbody fusion|bone graft alone
2898108|NCT03261830|Active Comparator|Pre-operative Antibiotics|Patients randomized to preoperative antibiotics will receive 25mg/kg cefazolin IV up to 1g or clindamycin 10mg/kg up to 600mg IV in cases of documented allergy to cefazolin.
2898109|NCT03261830|Placebo Comparator|Saline Placebo|Patients randomized to the no-antibiotic group will receive a saline placebo. This placebo will consist of a 10 mL pre-filled syringe of normal saline.
2898110|NCT03261817|Experimental|APA in patients|patients receiving physical activity (APA) by web during 16 weeks with 2 sessions a week
2898111|NCT03261817|Sham Comparator|HE in patients|patients receiving Health education program (HE) by web during 16 weeks with 2 sessions a week
2898112|NCT03261817|Active Comparator|APA in healthy volunteer controls|Healthy volunteers receiving physical activity (APA) by web during 16 weeks with 2 sessions a week
2898113|NCT03261817|Sham Comparator|HE in healthy volunteer controls|Healthy volunteers receiving Health education program (HE) by web during 16 weeks with 2 sessions a week
2898114|NCT03261804||Group I:internal vaginal douching users|
2898115|NCT03261804||Group II: none internal vaginal douching users|
2898116|NCT03261791|Experimental|Apatinib|Apatinib mesylate tablets 500 mg po qd.
2898117|NCT03261778|Experimental|Acromion 2.0 Brace|
2898118|NCT03261778|Active Comparator|Mitella Sling|
2898119|NCT03261765||Multiple repeat cesarean (four or more)|
2898120|NCT03261765||Fewer repeat cesarean (two-three)|
2898121|NCT03261752||patient with cancer|blood sample will be collected from patient before and after treatment (surgery or chemotherapy)
2898122|NCT03261752||healthy people|blood sample will be collected for comparison
2898123|NCT03261739|Experimental|RYI- 018|The doses of RYI-018 to be evaluated in sequential cohorts will be 0.6 mg/kg, 1.2 mg/kg, and 2.5 mg/kg.
2898124|NCT03261739|Placebo Comparator|Placebo|vehicle control
2898125|NCT03261726|Experimental|MedEl Test Electrode Placer|MedEl Test Electrode Placed at VIIIth nerve tumor resection
2898126|NCT03261713|Experimental|Virtual Reality|Virtual reality training designed to train standing balance, reaching, stepping, gentle strengthening and aerobic conditioning.
2898127|NCT03261713|Active Comparator|Control|iPad apps designed to train memory, cognition, visual tracking and fine motor skills.
2898128|NCT03261700|Experimental|RISE|This provider- administered brief- counseling intervention program will increase Women Veteran?s self- efficacy in addressing violence in their current or past relationships. The variable length (up to six- session) modular-based intervention aims at providing resources for WVs in the relevant domains of: 1) safety planning, 2) education on health effects of IPV, 3) improving coping and self- care, 4) enhancing social support, 5) making difficult decisions, and 5) connecting with resources.
2898129|NCT03261700|Active Comparator|Information and referral condition|Participants randomized to this arm will receive information about IPV and referrals to VA and community resources.
2898130|NCT03261687|Experimental|Water Exercise + advice|Each group undertook four, once weekly exercise sessions (including a warm up, cool down, relaxation, pelvic control and stability exercise). Both programmes focused on similar exercise and muscle groups, but due to the aquatic medium programmes were unable to be exactly matched.
2898131|NCT03261687|Experimental|Land Exercise + advice|Each group undertook four, once weekly exercise sessions (including a warm up, cool down, relaxation, pelvic control and stability exercise). Both programmes focused on similar exercise and muscle groups, but due to the aquatic medium programmes were unable to be exactly matched.
2898132|NCT03261674|Experimental|CBTI|Patients in this arm will receive Cognitive Behavioral Therapy for Insomnia (CBTI)
2898133|NCT03261674|Experimental|DTI|Desensitization Therapy for Insomnia (DTI)
2898134|NCT03261661|Experimental|Reading Plus Mindset|Multicomponent reading intervention providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency. Participants also complete mindset training and activities.
2942278|NCT02956499|Experimental|Cohort 9|multiple intravenous doses
2898135|NCT03261661|Experimental|Reading Embedded with Mindset|Multicomponent reading intervention (providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency) with mindset instruction specific to reading progress embedded in the intervention Participants also complete mindset training and activities.
2898136|NCT03261661|Active Comparator|Reading|Multicomponent reading intervention providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency.
2898137|NCT03261661|Active Comparator|Business as Usual|Participation in the typical reading instruction and intervention provided within participating schools.
2898138|NCT03261648||hospitalized patient|100 patients will completed the 'State-Trait-Anxiety Inventory (Forme Y) questionnaire Patients will evaluated here pain answering to a pain level scale
2898139|NCT03261648||partner of the hospitalized patient|100 partners will completed the State-Trait-Anxiety Inventory (Forme Y) questionnaire
2898140|NCT03261635|Active Comparator|Ranibizumab Monotherapy|All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
2898141|NCT03261635|Experimental|Ranibizumab + Indomethacin|All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients also self- administered one drop of indomethacin three times a day for 12 months. All patients were followed up for 12 months.
2898142|NCT03261622|Active Comparator|Control arm|Stimulation amplitude at 90% of sensory threshold during period 1 to 3. (each period 4 weeks)
2898143|NCT03261622|Sham Comparator|Intervention arm|"Alternation of stimulation amplitude~Period - Stimulation amplitude 0.05 Volts (lowest possible)~Period - Stimulation amplitude - 50% of sensory threshold.~Period - Stimulation amplitude - 90% of sensory threshold."
2898144|NCT03261609||Extremely preterm (EPT)|"All adults born at gestational age (GA) <29 wks at CHU Sainte-Justine (CHUSJ), the Royal Victoria Hospital (RVH), and the Jewish General Hospital (JGH), Montreal, in 1987-97.~Inclusion criteria: (a) Birth at GA<29 wks, (b) age 18-29 years at the time of assessment (age of peak human physiological function).~Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion. In case of twins (or +), if both fulfil inclusion criteria, only one will selected (random) to participate to the study."
2898145|NCT03261609||Term or controls|"Same-sex friends identified by EPT subject who have accepted to be contacted. Inclusion criteria: (a) Birth at GA ≥37 wks, (b) born in Quebec, to account for health care access during pregnancy and throughout infancy/childhood, (c) birth date within 2 years of index case, (d) age 18-29 years at the time of assessment, (e) same self-reported race as preterm participant.~Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion."
2898146|NCT03261596|Experimental|100 mg solid tablets 2x/day for 3 days|Assess the efficacy (Cure Rate/CR) and safety of 100 mg dose regimen of mebendazole in children aged 6 to 18 years, inclusive, infected with hookworm.
2898147|NCT03261596|Experimental|Single dose 500 mg solid tablets|Assess the efficacy (Cure Rate/CR) and safety of 500 mg dose regimen of mebendazole in children aged 6 to 18 years, inclusive, infected with hookworm.
2898148|NCT03261583||Thoracic Surgery|Observational study. It is only a matter of collecting clinical data.
2898149|NCT03261570|Active Comparator|Pyridostigmine and Placebo|Pyridostigmine 60mg by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
2898150|NCT03261570|Active Comparator|Digoxin and Placebo|Digoxin 0.5mg (500mcg) by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
2898151|NCT03261557|Experimental|CBT + SST|The treatment group will receive the intervention according to the CBSST protocol, adapted to adolescents.
2898152|NCT03261557|Active Comparator|Psychoeducation, habits and healthy lifestyle|The control group will receive 3 modules intervention: psychoeducation, habits and healthy lifestyle.
2898153|NCT03261544||Proximal Femur Replacement|The proximal femur is a common site for primary bone sarcomas and metastatic disease. The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
2898154|NCT03261531|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Healthy volunteers who are overweight or have class I obesity will receive T6 dermatomal electrical stimulation via Transcutaneous electrical nerve stimulation (TENS)
2898155|NCT03261505|Experimental|VGAIT|
2898156|NCT03261505|Sham Comparator|VGAIT Control|
2898157|NCT03261505|Active Comparator|Real Acupuncture|
2898158|NCT03261505|Placebo Comparator|Sham Acupuncture|
2898159|NCT03261492|Experimental|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program and presently includes 12 lessons that can be delivered once or twice a week. The SAGE garden-based curriculum includes active games and discussion as well as activities that include watering the ECEC garden.
2898160|NCT03261492|Active Comparator|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest. The curriculum will include concepts and lessons for educating young children on fire, pedestrian, water, household, neighborhood and playground safety. The curriculum includes handouts, coloring sheets, comic books, games, and songs that can be implemented with minimal training and preparation.
2898161|NCT03261479||Respiratory distress|Inclusion criteria are 1) subjects 28-days to 17-years of age, 2) who have respiratory distress, and 3) who receive a chest x-ray. We will exclude subjects with known chronic lung disease.
2898162|NCT03261466|Active Comparator|Active group Bifidobacterium breve BR03 and B632|This arm will receive a supplementation of probiotic containing Bifidobacterium breve B632 and Bifidobacterium breve BR03, 15 gtt/die (3x108 CFU/die) once a day.
2898163|NCT03261466|Placebo Comparator|Placebo group|This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
2898164|NCT03261453|Experimental|Treatment|Patients randomized to treatment will receive the Elipse device.
2898165|NCT03261453|Sham Comparator|Control|Patients randomized to the control arm will receive the sham device.
2898166|NCT03261427|Experimental|YNP-1807 Tablet(Pregabalin 330mg)|YNP-1807(Pregabalin 330mg), QD
2898169|NCT03261414|Active Comparator|Without preoperative hypnosis|standard care without preoperative hypnosis followed by administration of propofol for anesthesia induction
2898170|NCT03261401|Experimental|Part A: M5717|
2898171|NCT03261401|Placebo Comparator|Part A: Placebo|
2898172|NCT03261401|Experimental|Part B: M5717|
2898173|NCT03261401|Placebo Comparator|Part B: Placebo|
2898174|NCT03261401|Experimental|Part C: M5717|
2898175|NCT03261388||ABLE POWER Program|Participants on the Activity-Based Locomotor Exercise Program (ABLE) waitlist will be enrolled prior to beginning the ABLE program. This waiting period will allow outcomes to be compared (in the same participant) before receiving the intervention and after receiving the intervention.
2898176|NCT03261375|Experimental|Renal denervation (RDN) Group|
2898177|NCT03261375|Sham Comparator|Control Group|
2898178|NCT03261362|Placebo Comparator|Amino acid powder with all amino acids|amino acid powder 80 g oral Administration 1 week
2898179|NCT03261362|Active Comparator|Amino acid powder without BCAAs-reduced intake|Branched-chain amino acids reduced intake - amino acid powder lacking BCAAs 80 g oral Administration 1 week -
2898180|NCT03261349|Experimental|Anti-HCV (Ledipasvir and sofosbuvir)|Harvoni® (90 mg ledipasvir and 400 mg sofosbuvir) one tablet daily for 12 weeks
2898181|NCT03261336|Experimental|Calcitriol, Ketoconazole, Hydrocortisone|Patients receive calcitriol (10mcg QD X3 weekly) in addition to ketoconazole (400mg QD) and hydrocortisone (20mg AM, 10 mg PM).
2898182|NCT03261323|Active Comparator|Immediate breast reconstruction|The surgical schedule will follow unaltered standard protocol for immediate reconstruction right after the patient's mastectomy. Patients will complete a quality of life questionnaire (Breast-Q) both pre-operatively and at different time points during the follow up. The patient's chart will be followed from the mastectomy surgery onwards until 1 year post-final reconstructive surgery for determining complications and hospital costs.
2898183|NCT03261323|Experimental|Delayed breast reconstruction|Patients will start the reconstruction process after cancer therapy has been completed. Patients will be directed to smoking cessation and weight loss resources such as the Bariatric Institute to most directly facilitate risk reduction goals. Risk scores will be assessed at a plastic surgery appointment every 3 months. Reconstruction will proceed after the cancer treatment has been completed, according to individual patient evaluation. Patients will complete a quality of life questionnaire (Breast-Q) both pre-operatively and after the final reconstruction surgery. The patient's chart will be followed from the mastectomy surgery onwards until 1 year post-final reconstructive surgery for determining complications and hospital costs.
2898184|NCT03261310|Experimental|Acetaminophen & Craniotomy|Drug: Acetaminophen 1000mg administered intravenously during craniotomy
2898185|NCT03261310|Placebo Comparator|Placebo & Craniotomy|Placebo administered intravenously during craniotomy.
2898186|NCT03261310|Experimental|Acetaminophen & Laminectomy|Acetaminophen 1000mg administered intravenously during laminectomy.
2898187|NCT03261310|Placebo Comparator|Placebo & Laminectomy|Placebo administered during laminectomy.
2898188|NCT03261284|Experimental|DOAC group|Patients with elevated d-dimer levels was switched to DOAC (dabigatran 150mg, bid).
2898189|NCT03261284|Experimental|Higher-INR group|Patients' target INR was adjusted from 1.5-2.5 to 2.0-3.0 by adding warfarin dose.
2898190|NCT03261284|No Intervention|Control group|Patients continue previous strategy without change.
2898191|NCT03261271|Experimental|Weight Loss and Weight Maintenance|Participants will take part in a weight loss program for at least 4 weeks (and up to 16 weeks) before their prostatectomy, and a weight maintenance program for 6 months after their surgery.
2898192|NCT03261271|Active Comparator|Control|Participants will receive a standardized educational flyer about a healthy diet and exercise.
2898193|NCT03261258||Patients|Patients hospitalised in the ICU of Dijon CHU Burgundy
2898194|NCT03261258||Proches|Relatives/close friends of patients hospitalised in the ICU of Dijon CHU Burgundy
2898195|NCT03261245||Cas|Onset of a hypertension disorder during pregnancy
2898196|NCT03261245||Controls|No hypertension disorder during pregnancy
2898197|NCT03261219|Experimental|Intrapulmonary Percussive ventilation|
2898198|NCT03261219|Active Comparator|Chest Physiotherapy vest|
2898199|NCT03261206|No Intervention|5-ASA Continuation|Half of the subjects will continue on aminosalicylate therapy using the same dose and brand for the duration of the study
2898200|NCT03261206|Experimental|5-ASA Withdrawal|Half of the subjects will discontinue their aminosalicylate therapy
2898201|NCT03261193|Sham Comparator|ITM + Sham QLB|Standard spinal with intrathecal morphine for surgical anesthetic with sham saline block. Saline will be administered as a quadratus lumborum block prior to cesarean section.
2898202|NCT03261193|Experimental|ITM + Bupivacaine QLB|Standard spinal with intrathecal morphine for surgical anesthetic with ql block with bupivacaine local anesthetic. Interventional drug will be administered prior to cesarean section.
2898203|NCT03261180|Experimental|Group I (Nestle Impact AR)|Patients receive Nestle Impact AR for 5 days before and after surgery in addition to regular diet.
2898204|NCT03261180|Active Comparator|Group II (regular diet)|Patients receive regular diet.
2898205|NCT03261167|Experimental|Part 1: Subjects receiving 400 units of botulinum toxin A|Subjects will receive a total dose of 400 units of botulinum toxin A of which 240 units will be injected into the muscles that act on finger (including thumb flexors) and wrist flexors, and a total of 160 units will be injected into the muscles that act on the elbow flexors.
2898206|NCT03261167|Active Comparator|Part 1: Subjects receiving 240 units of botulinum toxin A|Subjects will receive 240 units of botulinum toxin A injected into the muscles that act on the finger (including thumb flexors) and wrist flexors. Placebo will be injected into the muscles that act on the elbow flexors.
2898207|NCT03261167|Experimental|Part 2,3,4: Subjects receiving 400 units of botulinum toxin A|Subjects will receive botulinum toxin A with a dose of 400 units injected in a divided doses.
2898227|NCT03260972|Active Comparator|Chloroprocaine arm|20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
2898228|NCT03260972|Placebo Comparator|Normal saline arm|20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
2898229|NCT03260959||Father|Male having been the father of at least one pregnancy whatever the outcome (pregnancy pursued, or abortion)
2898208|NCT03261141||study group sixty three children|"severity and character of dysphonia APA using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
2898209|NCT03261141||control group sixty three children|"severity and character of dysphonia (APA using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
2898210|NCT03261128||Group D-FOG|Filling of a self-questionnaire before each chemotherapy cure
2898211|NCT03261115|No Intervention|Control group|Topical Anesthesia
2898212|NCT03261115|Experimental|Study group|No topical anesthesia
2898213|NCT03261102|Active Comparator|Standard clinical care|"Adalimumab induction as per standard clinical care:~Week 0: 160 mg SC~Week 2: 80 mg SC~Followed by 40 mg SC every 2 weeks' maintenance therapy"
2898214|NCT03261102|Active Comparator|Active optimization|"Same as Standard clinical care Arm, except:~If ADAL trough ≤15 μg/ml, dose escalation with 80 mg SC at week 6 followed by 40 mg SC every week~If ADAL trough >15 μg/ml, no dose escalation and continued standard of care dosing"
2898215|NCT03261076|Experimental|SERIOUS Intervention|All youth will be juveniles in a residential facility for post-adjudicated youth. They will be recruited into the study as they are being placed in the facility post-adjudication, to ensure that they meet criteria and will be in the facility long enough to complete the program. All qualified youth will be invited to participate in the SERIOUS intervention; once a group of youth are recruited to complete the multiple baseline design and interventionists are free (from running interventions with other participants) to work with the youth, an intervention cycle will begin.
2898216|NCT03261063|Experimental|Evera Implanted Group|
2898217|NCT03261050||R61|In R61, participants are randomly assigned to either the treatment group or the wait-list condition. Participants assigned to the treatment group receive Counter Attitudinal Therapy (CAT). Participants in the treatment group are compared with participants in the wait-list condition. Participants will complete target and outcome measures at pretest and posttest, plus self-report intervention target and outcome measures at weeks 2, 4, and 6 during treatment for dosage analysis. Additionally, at pre-test and post-test participants will complete two MRI brain scans where they will be exposed to pictures of women and different types of foods. This will assess participants' thin-ideal and binge food valuation. Electrocardiography (ECG) data will be collected at pre and post.
2898218|NCT03261050||R33|In R33, participants from wait-list condition are assigned to receive either Counter Attitudinal Therapy. Participants will complete target and outcome measures at pretest and posttest, plus self-report intervention target and outcome measures at weeks 2, 4, and 6 during treatment for dosage analysis. At pre-test and post-test participants will complete two MRI brain scans where they will be exposed to pictures of women and different types of foods. This will assess participants' thin-ideal and binge food valuation. Additionally, thin-ideal valuation will be accessed outside the scanner at pre, post and follow-up. Similarly, binge food valuation will be accessed outside the scanner at pre, post, and follow-up and weeks 2, 4, and 6 during treatment for dose-response analysis. Electrocardiography (ECG) data will be collected at pre and post.
2898219|NCT03261037|Other|Participants With Suspicion of IPF/ILD|A participant will be eligible for inclusion if the Investigator has a suspicion that the participant may have IPF/ILD based on symptoms and radiological evidence.
2898220|NCT03261024|Active Comparator|Friction mechanics|"Upper and lower arches will be bonded, leveled and aligned until reaching 0.019 x 0.025 st st archwires.~Miniscrews will be inserted in the buccal alveolar bone between second premolars and first molars bilaterally.~Miniscrews will be connected to the molar bands by rigid wire. Extraction of upper first premolars. Upper anterior teeth will be ligated together. Hook between upper laterals and canines will be fixed on the main archwire.~Nickel Titanium coil spring ( friction mechanics of retraction)will be used for maxillary en-masse retraction by extending the spring from the hook to the molar bands.~Re-activation of the coil spring will be done in the follow up visits to maintain a constant force through the study."
2898221|NCT03261024|Active Comparator|Frictionless mechanics|"Upper and lower arches will be bonded, leveled and aligned until reaching 0.019 x 0.025 st st archwires.~Miniscrews will be inserted in the buccal alveolar bone between second premolars and first molars bilaterally.~Miniscrews will be connected to the molar bands by rigid wire. Extraction of upper first premolars. Upper anterior teeth will be ligated together. T-loops retraction arch ( frictionless mechanics of retraction)will be used for maxillary en-masse retraction. The wire will be cinched distal to the molar bands.~Re-activation of the retraction loops will be done in the follow up visits to maintain a constant force through the study"
2898222|NCT03261011|Experimental|AK-104|Single-arm
2898223|NCT03260998||diabetic patients type 1|electrocardiogram will be done for 60 children and adolescents with type 1 diabetes
2898224|NCT03260998||healthy persons|electrocardiogram will be done for 60 age and sex matched non diabetic children and adolescents
2898225|NCT03260985|Experimental|Feedback Group|All participants in the study will undergo a comprehensive neuroscience assessment including clinical questionnaires, a structured diagnostic interview, neuropsychological assessment, genetic testing, and structural and functional MRI. Participants randomized to the Feedback Group will have the results of this assessment shared with their psychiatric treatment team before they begin treatment. This data will be used at the full discretion of the treatment team to inform personalized treatment options. All treatment decisions remain up to the treatment providers and patient.
2898226|NCT03260985|No Intervention|Delayed Feedback Group|All participants in the study will undergo a comprehensive neuroscience assessment including clinical questionnaires, a structured diagnostic interview, neuropsychological assessment, genetic testing, and structural and functional MRI. However, participants randomized to the Delayed Feedback Group will not have the results of this assessment shared with their treatment team until the end of their participation in this study (12 weeks).
2898230|NCT03260946||Palliative/Supportive care|Individuals with cancer receiving palliative or supportive care
2898234|NCT03260907|Experimental|Electroacupuncture|The patients in this group received electroacupuncture using the same acupuncture points prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 1 years of clinical experience.
2898235|NCT03260907|Experimental|Acupuncture|The patients in this group received acupuncture without electric stimulation using the same acupuncture points prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 1 years of clinical experience.
2898236|NCT03260894|Experimental|Group 1|Pembrolizumab + epacadostat
2898237|NCT03260894|Active Comparator|Group 2|Sunitinib or pazopanib
2898238|NCT03260881|Active Comparator|L-group|• L-group will be started on liraglutide. Liraglutide will be started and administered for 12 weeks prior to CABG with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). The dose of 1.8 mg daily will be maintained until the end of the 12-week study. Other and current diabetes treatment will be continued
2898239|NCT03260881|Placebo Comparator|D-group|placebo will be administered in addition to current treatment prior to the CABG with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). D-group will be started on a supervised low calorie diet (LCD) to achieve approximately 5% of weight loss after 12 weeks.
2898240|NCT03260868|Experimental|Virtual|Patients in Virtual group will not visit the study sites during the study course. All study assessments, including vital signs, weight, laboratory variables, etc., will be completed via the electronic method. Video chat between the patients and investigators/designees occur at the planned study visits.
2898241|NCT03260868|Active Comparator|Traditional|Patients in Traditional group will follow the study visit schedules for all study assessments that will be performed via either in-person or phone visits.
2898242|NCT03260855|Other|Lymphoma survivorship|This present study is based on an interventional (with an analysis of human blood sample) and on the use of different Questionnaires/Scales.
2898243|NCT03260842||Pancreatic Cysts|Patients with pancreatic cyst undergoing endoscopic ultrasound and/or surgery who will have bio-specimens collected
2898244|NCT03260842||High Risk Individuals|Patients with established family history and/or genetic mutations for Pancreas cancer who will have bio-specimens collected
2898245|NCT03260829|Active Comparator|vitamin C injection|orthodontic traction with vitamin C injection
2898246|NCT03260829|Placebo Comparator|orthodontic traction|orthodontic traction without vitamin C injection
2898247|NCT03260816|Experimental|Internet-Delivered Parent Training|Families will receive weekly sessions of Internet-delivered Parent-Child Interaction Therapy (I-PCIT), a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
2898248|NCT03260816|Active Comparator|Referrals as Usual (RAU)|Families in the referrals as usual (RAU) group will be referred to services as usual in their Early Intervention exit interview, which includes a variety of clinic-based mental health services at local community agencies. At each assessment, the access and extent of participation in other services will be monitored.
2898249|NCT03260803|Experimental|postmenopausal osteopenic women receiveing Oligopin|postmenopausal osteopenic women receiving Oligopin ,150 mg ,once daily, 12 week
2898250|NCT03260803|Placebo Comparator|postmenopausal osteopenic women receiving placebo|postmenopausal osteopenic women receiving placebo, 150 mg,once daily,12 weeks
2898251|NCT03260790|Experimental|PCV13 and PPSV23|Participants randomized to receive PPSV23 primed with PCV13
2898252|NCT03260790|Active Comparator|PPSV23|Participants randomized to receive PPSV23 alone
2898253|NCT03260777||children with Alopecia Areata|
2898254|NCT03260777||children with tinea capitis|
2898255|NCT03260777||children with trichotillomania|
2898256|NCT03260777||children with tractional alopecia|
2898257|NCT03260764|Experimental|group A|
2898258|NCT03260764|Placebo Comparator|group B|
2898259|NCT03260764|Experimental|group C|
2898260|NCT03260764|Placebo Comparator|group D|
2898261|NCT03260751|Experimental|Zingiber officinale Roscoe extract 200 mg|2 cap/day, 800 mg/cap for 12 weeks
2898262|NCT03260751|Experimental|Zingiber officinale Roscoe extract 400 mg|2 cap/day, 800 mg/cap for 12 weeks
2898263|NCT03260751|Placebo Comparator|Placebo|Placebo for 12 weeks
2898264|NCT03260738|Experimental|"Robot Poppy group"|30 minutes of daily rehabilitation program (physical exercises dedicated to the mobility of the spine) supervised by Poppy robot during 4 weeks included in a 3hours daily (5 days a week) rehabilitation program.
2898265|NCT03260738|Active Comparator|Control group|Usual 3hours daily (5 days a week) rehabilitation program without robot during 4 weeks
2898266|NCT03260725|Experimental|Internet-delivered treatment|This treatment arm entails Internet-Delivered PCIT (I-PCIT) remotely delivered in real time using videoconferencing. Families stream live parent-child interactions from their own home to a remote therapist who provides live bug-in-the-ear parent coaching via a parent-worn Bluetooth earpiece.
2898267|NCT03260725|Active Comparator|Clinic-delivered treatment|This treatment arm entails Parent-Child Interaction Therapy (PCIT) delivered in the clinic. For much of the treatment, the therapist observes family interactions from behind a 1-way mirror and provides live bug-in-the-ear parent coaching via a parent-worn earpiece.
2898268|NCT03260712|Experimental|CisGem + pembrolizumab|Patients will be enrolled in the experimental arm and will receive CisGem [25mg/m2 cisplatin + 1000mg/m2 gemcitabine, on days 1 and 8 of a 21 day cycle] plus 200 mg pembrolizumab (fixed dose) on day 1 of a 21 day cycle.
2898269|NCT03260699|No Intervention|Control group|Subjects will receive two out-patient physical therapy (PT) visits per week for 2 weeks, followed by additional PT visits at clinician's discretion after TKA.
2898270|NCT03260699|Experimental|Bracing group|Subjects will be fitted with the Ongoing Care Solutions, Inc (OCSI) Rehabilitator brace prior to surgery. This brace will be worn for 6 weeks before surgery. The brace will be worn again after surgery ~10 days after surgery or when staples are removed until the end of the study. Participants will also have two PT visits per week for 2 weeks, followed by additional PT visits at clinician's discretion.
2942279|NCT02956499|Experimental|Cohort 10|multiple intravenous doses
2898271|NCT03260686|Experimental|Video Guided Group|Participants receive standard care physiotherapy for their upper limb rehabilitation, with exercises given either verbally or in writing as decided by the prescribing clinician. In addition the participants will receive a personalised video guide of their exercises, filmed during their therapy session to use for independent practice when back on the ward.
2898272|NCT03260686|No Intervention|Treatment as usual|Participants receive standard care physiotherapy for their upper limb rehabilitation, with exercises given either verbally or in writing as decided by the prescribing clinician
2898273|NCT03260673||the diabetic group|patients with type 2 diabetes scheduled to undergo cataract surgery
2898274|NCT03260673||the control group|patients without diabetes scheduled to undergo cataract surgery
2898275|NCT03260634||Voriconazole|"Patient was received voriconazole according to individual indication. The starting dose is 6 mg/kg iv twice daily for two dosages, followed by 4 mg/kg iv twice daily in intravenous form or a loading dose of 400 mg twice daily for two doses is used (for individuals >40 kg), followed by 200 mg twice daily, and in individuals <40 kg the maintenance dose is 100 mg twice daily in oral form.~The dosage was adjusted by drug level and toxicity. The duration of drug used was depended on indication of treatment."
2898276|NCT03260621|Other|echocardiographic increase in left atrial pressure|
2898277|NCT03260621|Other|echocardiographic no increase in left atrial pressure|
2898278|NCT03260608|Experimental|Intervention|Telesupport: eight weekly phone calls of psychoeducation and support on the illness of their relatives. Patients will also receive printed materials on problematic behaviors about dementia.
2898279|NCT03260608|No Intervention|Control|No active intervention. Patients will only receive printed materials on problematic behaviors about dementia and no contact by the research team.
2898280|NCT03260595|Experimental|Crisaborole ointment 2%|
2898281|NCT03260595|Placebo Comparator|Vehicle|
2898282|NCT03260582|No Intervention|Control arm (n=50)|Patients randomized to the control arm will receive usual cardiac rehabilitation care post-myocardial infarction.
2898283|NCT03260582|Experimental|Intervention arm: LifePod arm (n=100)|In addition to usual cardiac rehabilitation care, patients randomized to the LifePod arm will receive access to the LifePod® support software for six months.
2898284|NCT03260569|Active Comparator|Inhaled Nitric Oxide|Inhaled nitric oxide at 20 parts per million, administered once during first 36 hours following admission
2898285|NCT03260569|Placebo Comparator|Placebo|Nitrogen only, administered once during first 36 hours following admission
2898286|NCT03260556|Active Comparator|Pirfenidone|Pirfenidone titrated to three 267 mg tablets three times a day
2898287|NCT03260556|Placebo Comparator|Placebos|Placebo titrated to three tablets three times a day
2898288|NCT03260543|Experimental|fermented ginseng powder|tablets (2 tablets/day, 125 mg & 500 mg/day) for 12 weeks.
2898289|NCT03260543|Placebo Comparator|Placebo|Placebo for 12 weeks.
2898290|NCT03260517|Experimental|Treatment arm (Mdt Drug-Coated Balloon)|Medtronic Coronary Drug-Coated Balloon Catheter used for dilatation of the target lesion.
2898291|NCT03260504|Experimental|Treatment (pembrolizumab, aldesleukin)|Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive aldesleukin SC weekly on days 1-5 of courses 1 and 2 or aldesleukin IV on days 2-6 of courses 1 and 2. Treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2898292|NCT03260491|Experimental|U3-1402|Participants receive U3-1402 intravenously (IV) once every three weeks at planned doses (3.2, 6.4, 9.6, 12.8 mg/kg)
2898293|NCT03260478|Experimental|Liberal Transfusion Strategy|Patients will receive red blood cells transfusion if Hb ≤ 100 g/L.
2898294|NCT03260478|Experimental|Restrictive Transfusion Strategy|Patients will receive red blood cells transfusion if Hb ≤ 70 g/L.
2898295|NCT03260465|Experimental|seleXys PC|seleXys PC cup combined with the optimys stem
2898296|NCT03260465|Active Comparator|RM|RM Pressfit vitamys cup combined with the optimys stem
2898297|NCT03260452|Experimental|Patients|'Abdominal subcutaneous biopsies and Blood test'
2898298|NCT03260439|Other|G1 (group BT)|The children were randomized to 2 groups (n = 53 in each group) to receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Tramadol
2898299|NCT03260439|Other|G2 (group B or control)|The children were randomized to 2 groups (n = 53 in each group) to receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Placebo
2898300|NCT03260426|Experimental|Clear Liquid Diet|Clear liquids on postoperative day zero and intestinal rate measured by Abstats
2898301|NCT03260426|Experimental|Regular Solid Diet|Regular diet from postoperative day zero and intestinal rate measured by Abstats
2898302|NCT03260413||Pneumonia cases|Children between the ages of 1 month through 5 years of age who are admitted to Chenla Children's Healthcare between opening of the hospital (mid-2017) and early February 2018 for pneumonia and respiratory distress.
2898303|NCT03260400|Experimental|New Grafts|In this arm, participants will have an initial surgery to place partial muscle grafts on the amputated nerves. After a healing period, the participant will have a shorter surgical procedure to implant the electrodes onto the muscle grafts and in residual muscles. After another healing period, experiments with prosthetic control and sensory feedback will begin.
2898304|NCT03260400|Experimental|Existing Grafts|In this arm, participants have already had partial muscle grafts placed on the amputated nerves to control neuroma growth. The participant will have a short surgical procedure to implant the electrodes onto the muscle grafts and in residual muscles. After a healing period, experiments with prosthetic control and sensory feedback will begin.
2898305|NCT03260387||TPIAT|patients undergoing total pancreatectomy with islet autotransplant.
2898306|NCT03260374||children with cochlear implant|"30 subjects whose age ranges from 2-6 years old who are implanted with Medel multichannel cochlear implant male and female will be included and will undergo:-~Electric compound action potential~Electric stapedial reflex threshold~Electric auditory brain stem response"
2898307|NCT03260361|Experimental|Hypnosis Kinesitherapy and MEOPA|combined therapy of Hypnosis Kinesitherapy and MEOPA (HKM)
2898308|NCT03260361|Other|usual practice|physiopathology and treatments
2898309|NCT03260335|Experimental|Biofeedback intervention|Biofeedback prompt in text or graphic form to implement proactive anxiety management strategy, as per standard care plan
2898310|NCT03260322|Experimental|ASP8374|Participants will be enrolled in the escalation cohorts or expansion cohorts and receive ASP8374 (monotherapy) intravenously on Day 1 of every 3-week cycle (up to a maximum of 8 dose strengths).
2898311|NCT03260322|Experimental|ASP8374 and pembrolizumab|Participants will be enrolled in the escalation cohorts or expansion cohorts and receive ASP8374 and pembrolizumab (combination therapy) intravenously on Day 1 of every 3-week cycle (up to a maximum of 5 dose strengths of ASP8374 and one fixed dose strength of pembrolizumab).
2898312|NCT03260309|Experimental|semi-closed system group|"Semi-closed loop infusion system tactic. Programmed iv fluid and blood infusion system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion."
2898313|NCT03260309|Experimental|control group|Routine infusion therapy tactic
2898314|NCT03260296||University students|university students who use smartphones
2898315|NCT03260283|Experimental|Group I|0.4 mgkg-1 of pethidine hydrochloride
2898316|NCT03260283|Experimental|Group II|2ml of ropivacaine (0.75%) with 15 mcg of fentanyl
2898317|NCT03260257|Experimental|Schizophrenia patients|Thirty SCZ patients will receive neurofeedback to enhance gamma band response in an open-label, proof of concept study.
2898318|NCT03260231|Active Comparator|Intervention group|Dietary Supplement: Milled Seed Mix Intervention arm includes milled mix of flax, sesame and pumpkin seeds (18/6/6 g) in sour milk taken as dietary replacement meal during the day, and between lunch and dinner. Seeds are provided with the same producer at the Belgrade market.
2898319|NCT03260231|No Intervention|Control group|No supplement Control arm includes nutritional counseling with a similar dietary regime as for the intervention arm, but without milled seed mix. patients were instructed to avoid plant seeds during the study.
2898320|NCT03260205|Placebo Comparator|Placebo|Participant will receive placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
2898321|NCT03260205|Experimental|SPD489 (Lisdexamfetamine dimesylate)|Participants will be randomized to receive SPD489 capsule in a 5:5:5:5:6 ratio to SPD489 5, 10, 20, 30 milligram (mg) orally once daily for 6 weeks. Dosing will begin with the lowest strength of SPD489 (5 mg), and will be titrated until the randomly assigned fixed-dose is reached.
2898322|NCT03260179|Experimental|gastric carcinoma|20 gastric carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
2898323|NCT03260179|Experimental|hepatocellular carcinoma|20 hepatocellular carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
2898324|NCT03260179|Experimental|Nasopharyngeal carcinoma|20 Nasopharyngeal carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
2898325|NCT03260166|Experimental|nicotinamide|Patients will receive 10 nicotinamide tablets orally twice daily (nicotinamide 500 mg, p.o., Bid) for a period of 3 months. Each tablet contains 50 mg of nicotinamide.
2898326|NCT03260153|Experimental|Deproteinised Calf Blood Serum Injection|Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.
2898327|NCT03260153|Placebo Comparator|Sodium Chloride Physiological Solution|Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.
2898328|NCT03260140|Experimental|behavioral lifestyle intervention|The investigators will provide participants with the the behavioral lifestyle intervention
2898329|NCT03260140|No Intervention|usual care control|participant in this arm will continue with usual care
2898330|NCT03260127|Experimental|CEFT-CPT|Computerized executive function training plus Cognitive Processing Therapy for PTSD
2898331|NCT03260127|Active Comparator|WT-CPT|Word game training plus Cognitive Processing Therapy for PTSD
2898332|NCT03260114|No Intervention|Physical activity recommendations|Participants in this group will be advised to engage in physical activity recommendations from health authorities, i.e., 150 minutes per week of moderate intensity activity or 75 minutes per week of vigourous intensity activity or combination of both that results in same caloric expenditure.
2898333|NCT03260114|Active Comparator|PAI equal to or more than 100|Participants in this group will be advised to obtain a PAI score of 100 or more over a week.
2898334|NCT03260114|Active Comparator|PAI between 50 and 99|Participants in this group will be advised to obtain a PAI score between 50-99 over a week.
2898335|NCT03260101||one group, ApoGraft Follow up Study|Non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01
2898336|NCT03260088||patients with pleural effusion|In patients with pleural effusion that remains undiagnosed with common diagnostic algorithm, immunoglobulin G4 will be done in pleural fluid
2898337|NCT03260075||ward cat|Patients and staff at wards that have a cat present
2898338|NCT03260075||no ward cat|Patients and staff at wards that have no cat present
2898339|NCT03260062|Experimental|PEARLS|Parent-Child Early Approaches to Raising Language Skills
2898340|NCT03260062|Active Comparator|Control|Participants will receive standard care speech therapy.
2898341|NCT03260049||1|there was no retinal detachment (RD) at the first visit. The group 1 patients were treated with systemic antiviral medications, as well as with intravitreal antiviral injections
2898342|NCT03260049||2|there was no RD at the first visit. The group 2 patients were treated with systemic antiviral medications and PPV plus silicone oil tamponade and intravitreal injection.
2898343|NCT03260049||3|there was RD at the first visit. The group 3 patients were treated with systemic antiviral medications and PPV plus silicone oil tamponade and intravitreal injection
2898344|NCT03260023|Experimental|TG4001/Avelumab|
2898345|NCT03260010|Experimental|Fosfomycin Arm|Include intravenous fosfomycin in the treatment of PJI according to predetermined algorithm
2898346|NCT03259997|Active Comparator|Probiotic supplement|
2898347|NCT03259997|Placebo Comparator|Placebo|
2898378|NCT03259763|Active Comparator|EUS-guided gastroenterostomy (EUS-GE)|In this technique, the gastric wall and its adjacent small intestine are punctured by a needle to make a connection between the stomach and small intestine. Then a lumen-apposing metal stent is deployed at the puncture site to keep the stomach-small intestine connection open.
2898419|NCT03259477|Experimental|precise segmental clamping|These participants with clinical T1 renal cell carcinoma(RCC) undergo precise segmental renal arterial clamping during laparoscopic partial nephrectomy.
2898348|NCT03259984||Aim 1|This experiment will use the next generation sequencing reduced representation bisulfite sequencing to define patterns of DNA methylation in skeletal muscle and whole blood tissue of metabolically well-characterized lean healthy, obese nondiabetic, and type 2 diabetic volunteers. The investigators will test the hypotheses that: (a) There is an increased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation and altered methylation of promoters of genes coding for extracellular matrix and cytoskeletal proteins in insulin resistance, (b) The altered methylation patterns observed correspond to protein and mRNA expression changes, and (c) There are coordinated patterns of DNA methylation between the skeletal muscle and whole blood tissues in insulin resistance.
2898349|NCT03259984||Aim 2|This experiment will test the hypotheses in lean healthy, obese non-diabetic and type 2 diabetic volunteers that: (a) Increased methylation of the PGC-1α promoter predicts a decreased response of this gene to a single bout of exercise, and (b) Altered methylation of promoters of nuclear encoded mitochondrial genes predicts a decreased response of this gene to a single bout of exercise.
2898350|NCT03259984||Aim 3|This experiment will test the hypothesis in lean healthy, obese non-diabetic and type 2 diabetic volunteers that: (a) There is decreased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation, and the altered methylation corresponds to protein and mRNA (messenger ribonucleic acid) expression changes, (b) There is altered methylation of genes involved in inflammation and cytoskeletal structure.
2898351|NCT03259971|Placebo Comparator|Placebo (for tic disorder)|The placebo will be dispensed to equal the volume of 1 tablet of Probiotic PS128, which is taken orally in 2 divided doses, 12 hours apart during the study period of 2 months for Tic disorders.
2898352|NCT03259971|Active Comparator|PS128 (tic disorder)|The Probiotic group in tic disorder will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 2 months for Tic disorders.
2898353|NCT03259971|Placebo Comparator|Placebo (for Rett syndrome)|The placebo will be dispensed to equal the volume of 1 tablet of Probiotic PS128, which is taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett syndrome
2898354|NCT03259971|Active Comparator|PS128 (Rett syndrome)|The Probiotic group will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett Syndrome.
2898355|NCT03259958|Experimental|Donepezil TDS|Corplex Donepezil TDS 5 mg/day followed by Donepezil TDS 10mg/day applied weekly for 5 consecutive weeks
2898356|NCT03259958|Active Comparator|Aricept|Aricept 5 mg/day followed by Aricept 10 mg/day once daily for 5 consecutive weeks
2898357|NCT03259932|Other|usual management|
2898358|NCT03259932|Experimental|physical training|
2898359|NCT03259919|Experimental|Metformin|Metformin 850 mg x 2 daily
2898360|NCT03259919|Placebo Comparator|placebo|Placebo 1 tablet x 2 daily
2898361|NCT03259906|Active Comparator|Osteosynthesis using a posterior plate|
2898362|NCT03259906|Active Comparator|Osteosynthesis using an anterior plate|
2898363|NCT03259893|Active Comparator|Standard of care group 1|Participants randomized to the standard of care group will receive guideline-directed medical therapy according to clinical standard practice at Boston Medical Center. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
2898364|NCT03259893|Experimental|Intervention group 2|The intervention group will receive the AF program which include a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
2898365|NCT03259867|Experimental|Hepatocellular carcinoma|"PD-1 inhibitor (either Opdivo 240 mg Q2W IV or Keytruda 200 mg Q3W IV) starts at day 1, and continues until progression.~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
2898366|NCT03259867|Experimental|Colorectal cancer|"PD-1 inhibitor (Keytruda 200 mg Q3W IV) starts at day 1, and continues until progression.~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
2898367|NCT03259867|Experimental|Gastric cancer|"PD-1 inhibitor (Keytruda 200 mg Q3W IV) starts at day 1, and continues until progression.~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
2898368|NCT03259867|Experimental|NSCLC|"PD-1 inhibitor (Keytruda 200 mg Q3W IV) starts at day 1, and continues until progression.~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
2898369|NCT03259854|Active Comparator|oxygen mask control group|patients will receive oxygen by mask will be monitored regarding oxygen saturation, blood pressure, respiratory rate, heart rate, arterial blood gases
2898370|NCT03259854|Experimental|non invasive ventilation study group|patients will receive non invasive ventilation after successful weaning from invasive ventilation and will be monitored regarding oxygen saturation, blood pressure, respiratory rate, heart rate, arterial blood gases
2898371|NCT03259841||Fasted patients for cholecyctectomy|The fasted patients for cholecyctectomy except exclusion criteria are included
2898372|NCT03259828|Experimental|Adjuvant image-guided radiotherapy|Adjuvant radiotherapy with image guidance via cone beam computed tomography. Treatment is identical to the current standard of care.
2898373|NCT03259815|Experimental|PIOS Intervention Group|Operator-blinded pre and post-PCI coronary physiology measurements will be recorded. If FFR is < 0.90, the result will be disclosed to the operator and a hyperaemic pressure wire pullback during either a standard peripheral intravenous adenosine infusion (140mcg/kg/min) or an intracoronary adenosine infusion (360mcg/min) via a microcatheter will be performed. The operator will then follow the PIOS protocol to attempt to obtain the target optimal post-PCI FFR result.
2898374|NCT03259815|Active Comparator|Control Group|Operator-blinded pre and post-PCI coronary physiology measurements will be recorded and the angiographically defined result will be accepted.
2898379|NCT03259763|Active Comparator|Enteral Stenting (ES)|In this technique, under endoscopic visualization, a guidewire will be advanced through the obstructed part of the stomach. Then an enteral self-expandable metal stent will be deployed under direct endoscopic visualization and fluoroscopic guidance.
2898380|NCT03259750||professional athletes|athlete who volunteered in this study that should be a member of a professional sport team, All athletes must complete self reported outcome instrument (FAAM-T)
2898381|NCT03259698|Experimental|ARM 1 = NURSE-LED nPEP, TEXT MESSAGING SUPPORT|"PEP will be delivered by a sexual health clinic nurse operating under a medical directive, and participants will receive weekly text message check-ins via the WelTel system."
2898382|NCT03259698|Experimental|ARM 2 = ID PHYSICIAN-LED nPEP, TEXT MESSAGING SUPPORT|"PEP will be delivered according to the standard of care by an infectious diseases physician, and participants will receive weekly text message check-ins via the WelTel system."
2898383|NCT03259698|Experimental|ARM 3 = NURSE-LED nPEP, NO TEXT MESSAGING SUPPORT|PEP will be delivered by a sexual health clinic nurse operating under a medical directive, and participants will not receive any additional outreach beyond the usual standard of care.
2898384|NCT03259698|Active Comparator|ARM 4 = ID PHYSICIAN-LED nPEP, NO TEXT MESSAGING SUPPORT|PEP will be delivered according to the standard of care by an infectious diseases physician, and participants will not receive any additional outreach beyond the usual standard of care.
2898385|NCT03259685|Active Comparator|Regular beverages|Sugar sweetened soft drinks
2898386|NCT03259685|Experimental|Diet beverages|Soft drinks sweetened with artificial non-nutritive sweeteners (i.e. aspartame, acesulfame-K)
2898387|NCT03259685|Experimental|Stevia beverages|Soft drinks sweetened with natural non-nutritive sweeteners (i.e. steviol glycosides)
2898388|NCT03259672|Active Comparator|Sevoflurane|
2898389|NCT03259672|Experimental|Desflurane|
2898390|NCT03259659||irritable bowel disease patient|Patients with ulcerative proctitis and proctosigmoiditis who meet the inclusion criteria, they will have ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index.
2898391|NCT03259659||healthy control|Healthy participates who meet the inclusion criteria, they will have ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index.
2898392|NCT03259646|Experimental|Universal Education|Train providers to integrate screening, universal education, trauma informed counseling, and mobile health (mHealth) technology through the myPlan app safety decision aid in collaboration with local IPV programs as well as the integration of documentation and quality improvement templates and measures into clinical settings.
2898393|NCT03259646|No Intervention|Standard Practice|Standard clinical practice
2898394|NCT03259620|Experimental|CLS006|Furosemide Topical Gel, 0.125%
2898395|NCT03259620|Experimental|CLS006 Vehicle|Vehicle Topical Gel
2898396|NCT03259607|Experimental|Treatment A|Nicorette Extra Mint 2 mg Gum
2898397|NCT03259607|Active Comparator|Treatment B|Nicorette Mint 2 mg Gum
2898398|NCT03259607|Experimental|Treatment C|Nicorette Extra Mint 4 mg Gum
2898399|NCT03259607|Active Comparator|Treatment D|Nicorette Mint 4 mg Gum
2898400|NCT03259594|Experimental|endophytic group|participants are with endophytic renal cyst and undergo laparoscopic deroofing.2 day before laparoscopic deroofing, they were given intravenous 100 g of amino acids supplementation.
2898401|NCT03259594|Sham Comparator|exophytic group|participants are with exophytic renal cyst and undergo laparoscopic deroofing.2 day before laparoscopic deroofing, they were given intravenous 100 g of amino acids supplementation.
2898402|NCT03259581|Experimental|Transarterial chemoembolization|Transarterial chemoembolization
2898403|NCT03259568|Active Comparator|Active rTMS|
2898404|NCT03259568|Sham Comparator|Sham rTMS|
2898405|NCT03259555|Experimental|Brexpiprazole|Daily, oral, tablet
2898406|NCT03259555|Placebo Comparator|Placebo|Daily, oral, tablet
2898407|NCT03259542|Experimental|Arm 1|Mifepristone 300 MG alone or Mifepristone 300 MG with Itraconazole 100 MG will be administered.
2898408|NCT03259529|Experimental|Gemcitabine 500|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 500 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
2898409|NCT03259529|Experimental|Gemcitabine 700|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 700 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
2898410|NCT03259529|Experimental|Gemcitabine 1000|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 1000 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
2898411|NCT03259516|Experimental|Nivo + FC|Nivolumab 1 mg/kg days 1,15 iv q28days Fludarabine 25 mg/m2 days 1-3 iv q28days Cyclophosphamide 300 mg/m2 days 1-3 iv q28days
2898412|NCT03259516|Experimental|Nivo + LDAC + ATRA|Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days All-trans retinoic acid (ATRA) 45 mg/m2 po qd
2898413|NCT03259516|Experimental|Nivo + LDAC + Sildenafil|Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days Sildenafil 20 mg tid
2898414|NCT03259516|Experimental|Nivo + Melphalan|Nivolumab 1 mg/kg days 1,15 iv q28days Melphalan 2 mg qd days 1-10 q28days
2898415|NCT03259516|Experimental|Nivo + 5-aza|Nivolumab 1 mg/kg days 1,15 iv q28days 5-azacitidine 75 mg/m2 days 1-7 q28days
2898416|NCT03259503|Experimental|Olaparib + High Dose Chemo + Autologous Stem-Cell Transplant|"Palifermin by vein on Days -13 through -11, and on Days 0, +1, and +2. Olaparib and Vorinostat by mouth on Day -10 through Day -3. Dexamethasone by vein twice a day from day -10 PM to day -3 PM. Patients with CD20+ tumors receive Rituximab on Day -10 in the AM as an inpatient. Caphosol oral rinses four times a day used from Day -9 until end of clinical mucositis. Oral Glutamine 15 g four times a day, swished, gargled and swallowed, from Day -9 until end of mucositis. Gemcitabine by vein On Day -9 and -4. Busulfan by vein on Days -9, -8, -7, and -6. Melphalan by vein on Days -4 and -3. Pyridoxine three times a day by vein or by mouth from Day -1 until engraftment.~Stem cell infusion on Day 0.~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
2898417|NCT03259490|Experimental|Test Treatment|High dose empagliflozin/linagliptin/metformin XR fixed dose combination tablet
2898418|NCT03259490|Experimental|Reference Treatment|Single tablets of empagliflozin + linagliptin + metformin XR
2943128|NCT02951221|Experimental|Cohort 1|Treatment sub groups A and B
2898420|NCT03259477|Active Comparator|complete clamping|These participants with clinical T1 renal cell carcinoma(RCC) undergo complete renal arterial clamping during laparoscopic partial nephrectomy.
2898421|NCT03259464|Experimental|BI 685509|Chinese & Japanese subjects
2898422|NCT03259464|Placebo Comparator|Placebo|Chinese & Japanese subjects
2898423|NCT03259438|Experimental|Qigong|This course will meet twice weekly for 2 hours and 15 minutes per class for ten weeks. Topics will include guided instruction in the theory and background of qigong and healing. Practice will include gentle stretching and guided qigong movement as well as seated and lying down meditations. Participants will be asked to complete about 30 minutes a day of home assignments.
2898424|NCT03259438|Active Comparator|Healthy Living (CHIP + Pre-Train)|This course will meet twice weekly for 2 hours and 15 minutes per class for ten weeks. Topics will include plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) as well as core-stretching, strengthening, and light aerobic movements through a Pre-Train exercise program. Participants will be asked to complete about 30 minutes a day of home assignments.
2898425|NCT03259425|Experimental|Nivolumab and HF10, all patients|
2898426|NCT03259412|Experimental|Fish Oil|Fish oil 5.1g/ day - Premium Omega-3, Norwegian Pure-3, Oslo, Norway
2898427|NCT03259412|Placebo Comparator|Placebo|Olive Oil 6g/ day - Premium Omega-3, Norwegian Pure-3, Oslo, Norway
2898428|NCT03259399||wild genotype|Through next generation sequencing, distinguish wild genotype of enalapril
2898429|NCT03259399||mutant genotype|Through next generation sequencing, distinguish mutant genotype of enalapril
2898430|NCT03259386||Transradial or Transhumeral amputees|High-count microelectrode arrays are implanted into the upper limb peripheral nerves of transradial or transhumeral amputees.
2898431|NCT03259373|Experimental|Early Intervention|Educational mailing to (1) AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater) who appear to not have received OAC treatment at time of randomization and (2) their providers, where an individual provider may be identified
2898432|NCT03259373|Experimental|Delayed Intervention|Educational mailing to providers of AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater) who appear to not have received OAC treatment in the time following randomization. These patients will have received 'usual care' for the time between randomization and delayed educational mailing.
2898433|NCT03259360|Experimental|The Put It Out Project (POP):|a culturally tailored intervention developed for SGM young adults on Facebook
2898434|NCT03259360|Experimental|Tobacco Status Project (TSP):|the original TSP intervention (non-tailored) delivered to groups of only SGM participants on Facebook
2898435|NCT03259347|Experimental|Counter-attitudinal therapy|Counter-attitudinal therapy (CAT) is dissonance-based group intervention. CAT consists of behavioral, written, and verbal exercises in which participants discuss the costs of pursuing the thin ideal and behaviors that are used to pursue the thin ideal. The intervention is 8 sessions long (1-hr each) and is administered by a trained facilitator who uses an intervention script. Participants will be asked to complete weekly home exercises throughout the course of the intervention.
2898436|NCT03259347|Active Comparator|Educational-support group|The educational support group intervention that is representative of typical treatment groups offered at universities and community settings. For the current study, the educational support group was designed to match the dissonance group on treatment modality (group-based), duration (8 1-hr sessions), and use of an intervention script administered by a trained facilitator. In the intervention sessions, participants will be provided with a basic education about eating disorders, support for themselves and fellow group members, and learn mindfulness techniques.Participants will be asked to complete weekly homework assignments.
2898437|NCT03259334|Experimental|SHP647 25 mg|Participants will receive 25 milligram (mg) of SHP647 subcutaneous (SC) injection using a prefilled syringe (PFS) on Week 0, Week 4, and Week 8.
2898438|NCT03259334|Experimental|SHP647 75 mg|Participants will receive 75 mg of SHP647 SC injection using PFS on Week 0, Week 4, and Week 8.
2898439|NCT03259334|Placebo Comparator|Placebo|Participants will receive placebo matched to SHP647 SC injection using PFS on Week 0, Week 4, and Week 8.
2898440|NCT03259308|Experimental|SHP647 25 mg|Participants will receive 25 milligram (mg) of SHP647 subcutaneous (SC) injection using a prefilled syringe (PFS) on Week 0, Week 4, and Week 8.
2898441|NCT03259308|Experimental|SHP647 75 mg|Participants will receive 75 mg of SHP647 SC injection using PFS on Week 0, Week 4, and Week 8.
2898442|NCT03259308|Placebo Comparator|Placebo|Participants will receive placebo matched to SHP647 SC injection using PFS on Week 0, Week 4, and Week 8.
2898443|NCT03259295|Experimental|Skin tag removal initial|Removal of skin tags 1 cm or less using Digiclamp
2898444|NCT03259295|Experimental|Skin tag removal follow-up|Follow-up 2-3 months after skin tag removal.
2898445|NCT03259269||Bedaquiline and companion WHO Group 5 drugs|
2898446|NCT03259269||Delamanid and companion WHO Group 5 drugs|
2898447|NCT03259256|Experimental|Allogeneic transplantation of human islet|Each subject may receive 1-3 transplantations of allogeneic human islets we will inject the least dose of 3,000 IEQ/kg body weight of the recipient. Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml.
2898448|NCT03259243|Placebo Comparator|placebo group|0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and prior skin closure Drug: 0.9%Nacl Other Name: NSS
2898449|NCT03259243|Experimental|Preincision Bupivacaine|0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin closure Drug: 0.5% bupivacaine 10 ml (50 mg) Other Name: Marcaine 0.9%Nacl (Placebo) 10 ml Other Name: NSS
2898450|NCT03259243|Experimental|Preclosure bupivacaine|0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
2898451|NCT03259243|Experimental|Bupivacaine group|0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
2898452|NCT03259230||Malignancy-Associated Hemophagocytic Lymphohistiocytosis|
2898453|NCT03259230||Absence of HLH in patients diagnosed with malignancy|
2898454|NCT03259217|Experimental|stem cell product|stem cell transplant
2898979|NCT03255369||Child exposed Zika virus proved|child born to mothers with proved zika virus in pregnancy by RT-PCR
2898455|NCT03259204|No Intervention|Leg Immobilization|Routine care include that the lower limb will be immobilized in an orthosis or a below-knee plaster cast according to local routines.
2898456|NCT03259204|Experimental|Adjuvant IPC|Leg Immobilization with the addition of IPC. Patients will during lower limb immobilization receive bilateral calf IPC.
2898457|NCT03259191|Other|completely circumferential ARMS|
2898458|NCT03259191|Other|semi-circumferential ARMS|
2898459|NCT03259165|Experimental|Nitrate Intense Strategy|Patients randomized to the Nitrate intense strategy will be treated according to protocol with nitrates in combination with IV loop diuretics. This protocol only involves therapies used in everyday AHF clinical practice.
2898460|NCT03259165|Experimental|Diuretic Intense Strategy|Patients randomized to the Diuretic intense strategy will be treated according to protocol with IV loop diuretics in combination with nitrates. This protocol only involves therapies used in everyday AHF clinical practice.
2898461|NCT03259152|Experimental|Pre-Denosumab GctB|Specimens obtained during biopsy
2898462|NCT03259152|Experimental|Post-Denosumab GctB|Specimen after administration of Denosumab
2898463|NCT03259139|Experimental|Experimental: Violence with guns|Participants in this condition will play a video game with violent content which includes guns.
2898464|NCT03259139|Experimental|Experimental: Violence without guns|Participants in this condition will play a video game with violent content which does not include guns. Instead, the violence will include weapons such as swords.
2898465|NCT03259139|Other|Control: No violence|Participants in this condition will play a video game which contains no violent content or weapons.
2898466|NCT03259126|Experimental|SCUT|"Use of a Small Curtain under table (SCUT) placed under the cranial part of the angiographic table"
2898467|NCT03259126|No Intervention|Control|Control Group without the SCUT
2898468|NCT03259113|Other|Insertable cardiac monitor|All patients will undergo monitoring using an insertable cardiac monitor (single arm)
2898469|NCT03259087|Experimental|Part 1: Mild Renal Impairment (Panel A)|Participants receive a single IV dose of 200 mg MK-3866.
2898470|NCT03259087|Experimental|Part 1: Moderate Renal Impairment (Panel B)|Participants receive a single IV dose of 200 mg MK-3866.
2898471|NCT03259087|Experimental|Part 1: Severe Renal Impairment (Panel C)|Participants receive a single IV dose of 200 mg MK-3866.
2898472|NCT03259087|Experimental|Part 1: Healthy Matched Controls (Panel D)|Participants receive a single IV dose of 200 mg MK-3866.
2898473|NCT03259087|Experimental|Part 2: ESRD Requiring HD (Panel E)|In Period 1 participants receive a single IV dose of 200 mg MK-3866 immediately following completion of an HD session. Following a washout period of at least 6 days, participants receive a single IV dose of 200 mg MK-3866 approximately 30 minutes prior to commencing HD in Period 2.
2898474|NCT03259074|Experimental|Secukinumab 150 mg s.c.|Secukinumab 150 mg will be administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100
2898475|NCT03259074|Experimental|Secukinumab 300 mg s.c.|Secukinumab 300 mg will be administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100
2898476|NCT03259074|Experimental|GP2017 (adalimumab biosimilar) 40mg s.c.|GP2017 (adalimumab biosimilar) 40 mg will be administered at Baseline followed by dosing every 2 weeks until Week 102
2898477|NCT03259048||pediatric group|pediatric group from age of one day to eighteen years.
2898478|NCT03259035|Experimental|chemotherapy (FOLFOX or CAPOX) followed by tumour excision|
2898479|NCT03259009||Patients with metastatic colorectal cancer|Rechallenge with an anti-EGFR monoclonal antibody in patients with metastatic colorectal cancer
2898480|NCT03258996|Experimental|Modified vestibular incision subperiosteal tunnel access|Test group: Coverage of Class III multiples gingival recessions with the application of Modified vestibular incision subperiosteal tunnel access technique and a connective tissue graft from the palate.
2898481|NCT03258996|Active Comparator|Coronally advanced flap|Control group: Coverage of Class III multiples gingival recessions with the application of Coronally advanced flap and a connective tissue graft from the palate.
2898482|NCT03258983||The Diet, Cancer and Health cohort|
2898483|NCT03258957|Experimental|Fresh milk group|In the intervention group, mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day.Other time, feed frozen milk.
2898484|NCT03258944|Experimental|Breath-Stacking|Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session
2898485|NCT03258931|Experimental|Crenolanib|Crenolanib following salvage chemotherapy
2898486|NCT03258931|Active Comparator|Midostaurin|Midostaurin following salvage chemotherapy
2898487|NCT03258918|Experimental|Low-Carbohydrate Diabetes Prevention Program|At least 20 individuals with prediabetes will participate in a year-long , group-based program.
2898488|NCT03258905|Experimental|Grounding enhanced app|A mobile app that uses the Seeking Safety grounding chapter content, enhanced with features designed to create strong engagement and interactivity
2898489|NCT03258905|Active Comparator|Grounding text-only app|A mobile app that uses the Seeking Safety grounding chapter content in text format only
2898490|NCT03258892|Experimental|Arm A (STG pre-chemotherapy)|Patients receive the STG before completing 4 courses of standard of care chemotherapy.
2898491|NCT03258892|Experimental|Arm B (STG post-chemotherapy initiation)|Patients complete 2 courses of standard of care chemotherapy and then receive the STG before completing 2 additional courses of standard of care chemotherapy.
2898492|NCT03258879|Experimental|Modified CSE|MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally
2898493|NCT03258879|Active Comparator|Dural puncture epidural|Dural puncture performed with a spinal needle, but no medication will be injected intrathecally.
2898494|NCT03258866|Experimental|group A|In group A, Rituximab was given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22).
2898495|NCT03258866|Experimental|group B|In group B, Rituximab was given with a single dose of 375mg/m2
2899151|NCT03254485|Experimental|IW-1973 High Dose|
2898496|NCT03258853|Active Comparator|Usual Care|Usual Care diabetes management: Patients will manage their diabetes using standard of care for diabetes as per their typical regimen including use of an insulin pump or injectable insulin. Usual care arm for 7 days. Patients will wear a continuous glucose monitor (CGM) during this arm
2898497|NCT03258853|Experimental|Bi-hormonal bionic pancreas (insulin + glucagon)|Bi-hormonal Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 7 days.
2898498|NCT03258853|Experimental|Insulin only bionic pancreas|Insulin Only Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin only using a continuous glucose monitoring (CGM) device, for 7 days.
2898499|NCT03258840|Placebo Comparator|EPA placebo|EPA- placebo softgel (Containing 2 g edible paraffin oil), 2 times/day, for 8 weeks
2898500|NCT03258840|Active Comparator|EPA supplement|EPA supplement softgel (containing 2 g EPA per day), 2 times/day, for 8 weeks.
2898501|NCT03258827|Experimental|Exercise with a towel|There are 30 old adults in this group who receives exercise program with a towel.
2898502|NCT03258827|Placebo Comparator|Home-based exercise|There are 30 old adults in this group who is suggested a home-based program focuses on walking activity at fast speed.
2898503|NCT03258814||Participants receiving Humira® (adalimumab) and AST|This group includes participants receiving Humira® (adalimumab) and active supervised and standardized training.
2898504|NCT03258814||Participants receiving Humira® (adalimumab) and physiotherapy|This group includes participants receiving Humira® (adalimumab) and standard of care physiotherapy.
2898505|NCT03258801||Pirfenidone|Patients who are admitted to the lung transplantation department and fulfill the international criteria for idiopathic pulmonary fibrosis and are treated with Pirfenidone as bridging therapy.
2898506|NCT03258801||Control|Patients who are admitted to the lung transplantation department and fulfill the international criteria for idiopathic pulmonary fibrosis and are not treated with Pirfenidone.
2898507|NCT03258788||Non-Small Cell Lung Cancer|Participants with NSCLC not suitable for concurrent CTRT, being treated with standard radiotherapy (radical or palliative). All participants will be required to undergo a post radiotherapy course biopsy and will have blood samples taken.
2898508|NCT03258775|Active Comparator|250ml|
2898509|NCT03258775|Active Comparator|500ml|
2898510|NCT03258762|Experimental|Healthy Japanese male subjects|Healthy Japanese male subjects will receive a single oral dose of Pyrimethamine 50 mg in the fasted state co-administered with calcium folinate 15 mg on Day 1. Oral calcium folinate will be administered once daily until Day 8. Blood samples for PK analysis will be collected prior to administering first dose of Pyrimethamine and over 22 days post dose. Each subject will participate in the study for a duration of approximately 2 months from screening to follow-up.
2898511|NCT03258762|Experimental|Healthy Caucasian male subjects|Healthy Caucasian male subjects will receive a single oral dose of Pyrimethamine 50 mg in the fasted state co-administered with calcium folinate 15 mg on Day 1. Oral calcium folinate will be administered once daily until Day 8. Blood samples for PK analysis will be collected prior to administering first dose of Pyrimethamine and over 22 days post dose. Each subject will participate in the study for a duration of approximately 2 months from screening to follow-up.
2898512|NCT03258749|Active Comparator|Formoterol|inhaled formoterol(4.5μg, bid)
2898513|NCT03258749|Experimental|Tiotropium|inhaled Tiotropium(18μg, qd)
2898514|NCT03258736|Other|Caudal block|Caudal block Marcaine
2898515|NCT03258736|Other|ilionguinal/iliohypogastric block|ilionguinal/iliohypogastric block Marcaine
2898516|NCT03258723|Experimental|Intervention|Highest risk pre-diabetic patients
2898517|NCT03258723|No Intervention|Control|Control participants in existing ECHORN sites (Puerto Rico, Barbados and Trinidad) will be recruited. ECS does not have a recruitment site in New York; therefore, the New York LIME sites will need to recruit their own control participants, through random assignment of consented participants into the intervention and control groups.
2898518|NCT03258710|Experimental|All subjects treated with Tenofovir Disoproxil Fumarate|Subjects with on-going ETV treatment will be switched to Tenofovir Disoproxil Fumarate treatment. Subjects will start TDF on the day ETV is discontinued, without having overlapping treatment periods. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
2898519|NCT03258697|No Intervention|Patient-Controlled Analgesia|Patient had no local analgesic agent during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
2898520|NCT03258697|Active Comparator|Peri-articular LevoBupivacaine|Patient had periarticular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
2898521|NCT03258697|Experimental|Intra-articular LevoBupivacaine|Patient had intra-articular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
2898522|NCT03258684|Active Comparator|vitamin C、hydrocortisone、thiamine|Intravenous vitamin C (1.5 g every 6 h for 4 days or until ICU discharge), hydrocortisone (50 mg every 6 h for 7 days or until ICU discharge followed by a taper over 3 days), as well as intravenous thiamine (200 mg every 12 h for 4 days or until ICU discharge).
2898523|NCT03258684|Placebo Comparator|normal saline|Normal saline 500ml every day for 4 days，then 200ml every day for 3 days.
2898524|NCT03258671|Experimental|Mutation+ concurrent|IMRT concurrent with EGFR-TKI on paticipants with known sensitive EGFR mutations.
2898525|NCT03258671|Experimental|Mutation+ concomitant|IMRT concomitant with EGFR-TKI on paticipants with known sensitive EGFR mutations.
2898526|NCT03258658|Experimental|Autologous Engineered Urethral Construct|All subjects enrolled will undergo a full-thickness bladder biopsy as an out-patient surgical procedure. Urothelial and Smooth Muscle Cells recovered from the biopsy will be isolated and expanded over the next 4-6 weeks, and then seeded onto a tubular scaffold to create the autologous engineered urethral construct. Subjects will undergo a second surgical procedure to excise the urethral stricture and implant the urethral construct. All subjects will be followed for 3 years for safety and efficacy.
2898527|NCT03258645||Acute ischemic stroke|Non-valvular atrial fibrillation patients hospitalized with an acute ischemic stroke
2898555|NCT03258450|Experimental|Psycho-behavioural intervention arm (PBI)|Participants will receive 4 sessions(PBI) that lasts approximately 60 mins.
2943129|NCT02951221|Experimental|Cohort 2|Treatment sub groups C and D
2898528|NCT03258632|No Intervention|Usual Care|Under usual care, when a patient screens positive on the AUDIT-C administered at intake, a provider (social worker, nurse) provides Brief Intervention (BI), i.e., tells the patient that problems are associated with alcohol use, and about recommended drinking limits; notes the patient as ready to change drinking or not, and as agreeing to treatment or not. If the patient agrees to treatment, specialty addiction services are notified.
2898529|NCT03258632|Experimental|Intervention|Patients will attend one 50-minute individual session during their inpatient stay with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
2898530|NCT03258606||Chart review|ndividuals who came to the NIH Clinical Center for possible enrollment in research whose capacity to consent or assent was evaluated by the Bioethics Consultation Service (BCS), the Human Subjects Protection Unit (HSPU), or the Ability to Consent Assessment Team (ACAT), and all surrogate decision makers of individuals who were unable to consent and were allowed by protocol to give surrogate consent.
2898531|NCT03258593|Experimental|1-Run In|Durvalumab + Vicinium, escalating doses. Up to 2 dose levels will be evaluated in the first 6 L 12 subjects
2898532|NCT03258593|Experimental|2-Expansion|Durvalumab + Vicinium, at the MTD. Up to 24 subjects
2898533|NCT03258580||All substudies|Healthy Volunteers between the ages of 18-60 who were born in the United States
2898534|NCT03258580||Substudy 2|Healthy volunteers and Medical Providers (individuals with a terminal degree that allows them to see patients).
2898535|NCT03258567|Experimental|A|nivolumab 3mg/kg via IV infusion over approximately 60minutes every 2 weeks for up to 1 year in subjects without unacceptable toxicity who achieve complete remission; and up to 2 years in subjects with partial response (PR) or stable disease (SD) with clinical benefit if they are tolerating nivolumab
2898536|NCT03258554|Active Comparator|Arm I (cetuximab, radiation therapy)|Patients receive cetuximab IV weekly over 60-120 minutes. Treatment repeats every week for up to 8 courses in the absence of disease progression or unacceptable toxicity. Beginning 5-7 days after first cetuximab dose, patients undergo IMRT 5 fractions per week for up to 7 weeks.
2898537|NCT03258554|Experimental|Arm II (durvalumab, radiation therapy)|Patients receive durvalumab IV over 60 minutes every 4 weeks. Treatment repeats every 4 weeks for up to 7 courses in the absence of disease progression or unacceptable toxicity. Beginning week 2, patients undergo IMRT 5 fractions per week for up to 7 weeks.
2898538|NCT03258528|Active Comparator|right lateral position group|Neonates kept in the right lateral position for 6 hours with head tilted 30 degree upward with rolled towel supports the infant back at 90 degree angle on the bed.
2898539|NCT03258528|Active Comparator|supine position group|"Neonates kept in supine position for 6 hours with head tilted 30 degrees upward.~Infants were fed while in their positions via feeding tube."
2898540|NCT03258515|Experimental|Cohort 1|"Participants will receive orally single dose of study drugs in the sequence of ABC.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
2898541|NCT03258515|Experimental|Cohort 2|"Participants will receive orally single dose of study drugs in the sequence of ACB.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
2898542|NCT03258515|Experimental|Cohort 3|"Participants will receive orally single dose of study drugs in the sequence of BAC.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
2898543|NCT03258515|Experimental|Cohort 4|"Participants will receive orally single dose of study drugs in the sequence of BCA.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
2898544|NCT03258515|Experimental|Cohort 5|"Participants will receive orally single dose of study drugs in the sequence of CAB.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
2898545|NCT03258515|Experimental|Cohort 6|"Participants will receive orally single dose of study drugs in the sequence of CBA.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
2898546|NCT03258502|Experimental|RV521|RV521 drug substance in capsule for oral administration
2898547|NCT03258502|Placebo Comparator|Placebo|Micro-crystalline cellulose in capsule for oral administration
2898548|NCT03258489|Active Comparator|Transcutaneous nervous electric stimulation (TENS)|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after TENS. The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
2898549|NCT03258489|Active Comparator|Interferential electrical stimulation (IES)|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after Interferential electrical stimulation (IES). The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
2898550|NCT03258489|Placebo Comparator|TENS and IES Placebo|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after of the TENS and IES placebo. The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
2898551|NCT03258476|Experimental|GXR and Mindfulness Skills|Guanfacine Extended Release (GXR) will be started at 1 mg/day at Week 1 and tapered up by 1 mg per week to a maximum dose of 7 mg/day by week 7 (maximum of 6 weeks on drug). GXR dosing will be flexible for the first 5 weeks of the study based upon patient response and tolerability to drug. Optimal dose will be defined as that necessary to achieve ≥ 30% reduction in symptoms and a CGI-Improvement Score ≤ 2. Upon re-evaluation at (T1) and entry into the psychotherapy protocol dosing will become fixed for the remainder of the study. Mindfulness Skills Therapy will occur for the next 10 weeks.
2898552|NCT03258476|Active Comparator|Placebo and Mindfulness Skills|"Placebo will be started at 1 mg/day at Week 1 and tapered up by 1 mg per week to a maximum dose of 7 mg/day by week 7 (maximum of 6 weeks on drug). Placebo dosing will be flexible for the first 5 weeks of the study based upon patient response. Optimal dose will be defined as that necessary to achieve ≥ 30% reduction in symptoms and a CGI-Improvement Score ≤ 2. Upon re-evaluation at (T1) and entry into the psychotherapy protocol dosing will become fixed for the remainder of the study. Mindfulness Skills Therapy will occur for the next 10 weeks."
2898553|NCT03258463||Time Period 1|Women who obtained an abortion from January 1 2012-December 31 2012
2898554|NCT03258463||Time Period 2|Women who obtained an abortion from May 1 2014-April 30 2015.
2898556|NCT03258450|No Intervention|Waitlist Control Arm (WLC)|The WLC group receives standard usual care before being offered the same PBI protocol and assessment thereafter.
2898557|NCT03258437|Experimental|DA-9401|capsules (4cap/d, 2.16 g/d) for 12 weeks.
2898558|NCT03258437|Placebo Comparator|Placebo|Placebo for 12 weeks.
2898559|NCT03258424|Active Comparator|PTI-428|Subjects will receive once daily dosing of PTI-428 or placebo for 14 days.
2898560|NCT03258424|Placebo Comparator|Placebo|Subjects will receive once daily dosing of PTI-428 or placebo for 14 days.
2898561|NCT03258411|Active Comparator|Haas group (H)|Rapid Expansion of palatal suture device: tooth-tissue supported expander (Haas (H)).
2898562|NCT03258411|Active Comparator|Hyrax (Hx)|Rapid Expansion of palatal suture device: tooth anchored expander (Hyrax (Hx)).
2898563|NCT03258411|Active Comparator|Miniscrew-supported (MHx)|Rapid Expansion of palatal suture device: bone anchored expander (Temporary anchorage devices(miniscrew)-supported (MHx))
2898564|NCT03258398|Experimental|Part 1: eFT508 plus avelumab dose finding Arm|subjects will receive eFT508 in combination with a fixed dose of avelumab
2898565|NCT03258398|Experimental|Part 2: eFT508 plus avelumab|subjects will receive eFT508 in combination with a fixed dose of avelumab
2898566|NCT03258398|Experimental|Part 2: eFT508 alone|subjects will receive eFT508 alone
2898567|NCT03258385|Active Comparator|Vitamin B12-fortified UHT milk|Supplementation group (N=74) that will receive vitamin B12 fortified UHT milk daily
2898568|NCT03258385|Placebo Comparator|Plain UHT milk|Placebo group (N=74) that will receive plain UHT milk daily
2898569|NCT03258372|Experimental|Cohort 1|Mifepristone 300 MG, 1 tablet
2898570|NCT03258372|Experimental|Cohort 2|Mifepristone 1500 MG, 5 tablets
2898571|NCT03258359|Experimental|PACTN|Open label 3+3 dose escalation phase 1 trial; 200 to 1000 mL of immunized T cells infused at 0.3, 1, and 3 x 10e7 nucleated cells/kg body weight.
2898572|NCT03258346|Experimental|Exercise and Pomegranate Juice|Exercise training with daily consumption of pomegranate juice containing polyphenols
2898573|NCT03258346|Placebo Comparator|Exercise and Placebo|Exercise training with daily consumption of pomegranate juice with polyphenols removed
2898574|NCT03258333||Stented bioprosthesis|Standard aortic valve replacement with stented bioprosthesis. Surgery is performed through median sternotomy, aortic and right or bicaval venous cannulation, normothermic perfusion, antegrade cardioplegia with use cardioplegic solution Custodiol. A transverse aortotomy was performed 1 to 2 cm above the right coronary artery. The aortic annulus was thoroughly débrided of calcium. Valve sizing was performed with standard manufacturers' sizers, with selection of the size that would comfortably fit within the aortic annulus. A noneverting suture technique was used in all patients with interrupted horizontal mattress 2-0 braided sutures placed around the aortic annulus, with the pledgets on the ventricular aspect.
2898575|NCT03258333||Ozaki procedure|Aortic valve reconstruction using autologus pericardium (Ozaki procedure). The autologous pericardium is harvested after routine median sternotomy. Harvested pericardium is then treated with a 0.6% glutaraldehyde solution for 10 min and then rinsed 3 times with sterilized saline each time for 6 min. After resection of the diseased aortic valve cusps, the distance between each commissure is measured using a self-developed sizing instrument. Glutaraldehyde-treated autologous pericardium is trimmed with a self-developed template corresponding to the measured value. The annular margin of the pericardial leaflet is then running-sutured to each annulus with 3-0 monofilament sutures. Commissural coaptation is secured with additional 4-0 monofilament sutures. The coaptation of the 3 cusps is then checked with negative pressure on the left ventricular vent.
2898576|NCT03258320|Experimental|CDMS, Surgery|"Preoperative chemotherapy using Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.~Procedure: radical prostatectomy surgery."
2898577|NCT03258320|No Intervention|Control|No neoadjuvant chemotherapy using CDMS will be done for patients who are diagnosed with localized prostate cancer but subject to direct surgery to radically remove the primary tumor.
2898578|NCT03258307|Active Comparator|omentectomy|Preoperative
2898579|NCT03258307|Other|Omentectomy|Postoperative
2898580|NCT03258307|Other|No omentectomy|Preoperative post operative
2898581|NCT03258294|Experimental|Melatonin(Circadin®)|Melatonin(Circadin®) is taken orally, once daily before going to sleep for a period of 4 weeks.
2898582|NCT03258294|Placebo Comparator|Placebo|Placebo tablet is taken orally, once daily before going to sleep for a period of 4 weeks.
2898583|NCT03258281|Active Comparator|evolocumab 420mg|75 subjects on optimal statin therapy undergoing elective PCI will receive evolocumab 420mg.
2898584|NCT03258281|Placebo Comparator|placebo|75 subjects on optimal statin therapy undergoing elective PCI will receive placebo
2898585|NCT03258268|Experimental|Standard of Care with DSS|"Patients will receive standard of care with a board certified physician with EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
2898586|NCT03258268|Active Comparator|Standard of Care without DSS|"Patients will receive standard of care with a board certified physician without EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
2898587|NCT03258255|Active Comparator|Pudendal block group in circumcision|Nerve stimulated pudendal nerve block performed under general anesthesia
2898588|NCT03258255|Active Comparator|Penil block group in circumcision|Penil block performed by surgeon under general anesthesia
2898589|NCT03258242|Experimental|Experimental: Keluo Xin Capsule|
2898590|NCT03258242|Placebo Comparator|Placebo Comparator: Placebo|
2898591|NCT03258229|Experimental|Angelica gigas N. extract|capsules(2cap/d, 1,000mg/d) for 8 weeks.
2898592|NCT03258229|Placebo Comparator|Placebo|Placebo for 8 weeks
2898593|NCT03258216||peptic ulcer|patients who had upper GI symptoms and diagnosed as peptic ulcer by panendoscopy, followed tongue images by Automatic Tongue Diagnosis System
2898594|NCT03258216||healthy|patients who had no past history or systemic disease, diagnosed as UGI negative finding by panendoscopy, followed tongue images by Automatic Tongue Diagnosis System
2898595|NCT03258203|Experimental|diet 1|diet with moderate in fat (40% energy) and protein(15%)
2898596|NCT03258203|Experimental|diet 2|diet with moderate in fat (40% energy) and protein(25%)
2898597|NCT03258203|Experimental|diet 3|diet with low in fat (20% energy) and protein(15%)
2898598|NCT03258203|Experimental|diet 4|diet with low in fat (20% energy) and protein(25%)
2898599|NCT03258190|Experimental|Lime Powder Regimen|Participants were asked to take LPR twice a day for 6 months
2898600|NCT03258190|Placebo Comparator|Placebo|Participants were asked to take Placebo twice a day for 6 months
2898601|NCT03258177|Experimental|Virtual Visit Group|Participants assigned to the virtual visit group will receive a virtual visit as their postoperative follow-up visit.
2898602|NCT03258177|No Intervention|Standard In-person Group|Participants assigned to the standard in-person group will receive an in-person follow-up visit as their postoperative follow-up visit.
2898603|NCT03258164|Experimental|ASC|
2898604|NCT03258164|Active Comparator|Control|
2898605|NCT03258151||wild genotype|Through next generation sequencing, distinguish wild genotype of docetaxel
2898606|NCT03258151||mutant genotype|Through next generation sequencing, distinguish mutant genotype of docetaxel
2898607|NCT03258138|Experimental|More Intensive Program (MIP)|Participants will receive the more intensive program, which combines usual care with the full version of the healthy lifestyles program. Participants in this arm will meet weekly for group health and wellness learning sessions or brainstorming group sessions. In addition, they will meet monthly for individual sessions with a multidisciplinary health team, including a family physician, physical therapist and dietician to tailor their health goal development and action plans to their particular needs and situations. They will be asked to maintain physical activity and nutrition journals for a week each every three months.
2898608|NCT03258138|Experimental|Less Intensive Program (LIP)|Participants will receive the less intensive program, which combines usual care along with health goal development. Participants in this arm will meet at baseline to set health goals with the support of a research assistant trained in theories of health behaviour and goal setting. They will also meet every three months to measure progress in achieving their goals. They will be asked to maintain physical activity and nutrition journals for a week each every three months.
2898609|NCT03258125||severe EOPE|EOPE: PE starting before 34 weeks gestation Severe PE (Blood pressure more than 160/ 110 mm Hg on 2 occasions 2 hours to 2 weeks apart and proteinuria ( 24-hour urine protein >2000 mg/d).
2898610|NCT03258125||control|Healthy Pregnant women who come for termination of pregnancy by vaginal delivery or CS between 28-34 weeks gestational age.
2898611|NCT03258112|Other|catheter ablation|all patients indicated for catheter ablation of RVOT or LVOT ventricular arrhythmia are included in one arm for electrophysiological diagnosis of the origin of arrhythmia then for radiofrequency catheter ablation
2898612|NCT03258099||wild genotype|Through next generation sequencing, distinguish wild genotype of capecitabine
2898613|NCT03258099||mutant genotype|Through next generation sequencing, distinguish mutant genotype of capecitabine
2898614|NCT03258086|Experimental|Blood sample|2ml blood sample of of blood will be taken for assessment of vitamin D
2898615|NCT03258073|Experimental|Medical simulation using scenarion execution|Study participants will be exposed to medical simulation using scenario execution. In this exercise, participants will be exposed to a scenario that simulates a medical emergency. They will be required to respond. Following their response, the participants will have a chance to share with the investigators their experiences and what they have learnt from the exposure in a debriefing session. The investigator will then provide feedback on their performance.
2898616|NCT03258060|Active Comparator|Mechanical Dyssynchrony|Those with cardiac MRI evidence of mechanical dyssynchrony
2898617|NCT03258060|Active Comparator|No Mechanical Dyssynchrony|Those without mechanical dyssynchrony on cardiac MRI
2898618|NCT03258047|Experimental|CAR-T treatment|In this group, patients will be treated with autologous CAR-T, and the safety and efficacy will be evaluated
2898619|NCT03258034|Experimental|Conversion treatment|after 3-4 cycles S1/Paclitaxel chemotherapy plus Apatinib,subsequent surgery will be conducted with curative intent.
2898620|NCT03258021||GBM with indication for TTFields|newly diagnosed GBM with clinical indication for TTFields
2898621|NCT03258008|Experimental|Utomilumab + ISA101b|"Utomilumab by vein every 4 weeks for up to 12 doses beginning on Cycle 1 Day 1.~ISA101b as an injection under the skin every 4 weeks for 3 doses. Participants receive 2 injections each time."
2898622|NCT03257995|Experimental|Sequence 1|A-B-C
2898623|NCT03257995|Experimental|Sequence 2|B-C-A
2898624|NCT03257995|Experimental|Sequence 3|C-A-B
2898625|NCT03257995|Experimental|Sequence 4|A-C-B
2898626|NCT03257995|Experimental|Sequence 5|B-A-C
2898627|NCT03257995|Experimental|Sequence 6|C-B-A
2898628|NCT03257982|Experimental|BCI-FES hand therapy|BCI-FES hand therapy sessions (set up and use of system)
2898629|NCT03257969|Experimental|The DROP program|
2898630|NCT03257969|Other|Standard of care|
2898631|NCT03257943|Experimental|Ivermectin Lotion, 0.5%|One 10 minute application, under at-home use conditions
2898632|NCT03257943|Active Comparator|SKLICE (ivermectin) Lotion, 0.5%|One 10 minute application, under at-home use conditions
2898633|NCT03257943|Placebo Comparator|Vehicle of the Test product|One 10 minute application, under at-home use conditions
2898634|NCT03257930|Experimental|injection of ethanol|use of ethanol injection in the treatment of cystic thyroid nodule
2898635|NCT03257891|Experimental|Arm 1|patients with advanced Adrenocortical- Carcinoma progressing after previous chemotherapy lines will be treated with Cabazitaxel
2898636|NCT03257878||Systemic sclerosis (SSc)|validated Korean version of the SF36 and EQ-5D
2898637|NCT03257878||Rheumatoid arthritis (RA)|validated Korean version of the SF36 and EQ-5D
2898638|NCT03257878||Systemic lupus erythematosus (SLE)|validated Korean version of the SF36 and EQ-5D
2898639|NCT03257878||Sjogren's syndrome|validated Korean version of the SF36 and EQ-5D
2898640|NCT03257878||Control|validated Korean version of the SF36 and EQ-5D
2898641|NCT03257865|Experimental|Brexpiprazole|Daily, oral, tablet
2898643|NCT03257852|Experimental|ASP5094 Group|To be intravenously administered ASP5094 in patients with rheumatoid arthritis (RA) treated with methotrexate.
2898644|NCT03257852|Placebo Comparator|Placebo Group|To be intravenously administered ASP5094 in patients with rheumatoid arthritis (RA) treated with methotrexate.
2898645|NCT03257839||Asymptomatic women with dense breast tissue|Healthy women presenting to enrollment sites for routine annual mammographic examinations, confirmed to have BI-RADS category c or d breast composition (density).
2898646|NCT03257826|Experimental|surgery|Percutaneous Kirschner wire
2898647|NCT03257813|Other|Group A|In group A, therapy with Krytantek Ofteno® will be continued for 30 days, in which the subject will be retested and switched to a PRO-122 solution which will be used for 30 days until the 60th day, The final visit.
2898648|NCT03257813|Other|Group B|In group B, therapy with Krytantek Ofteno® will be suspended and changes for PRO-122 for 30 days, in which the subject will be retested and later switched to Krytantek Ofteno® solution which will be used for 30 days until the 60th day, The final visit.
2898649|NCT03257800|Active Comparator|ketamine-propofol group|"Ketamine (50mg/ml) at 0.5 mg.kg-1 was injected intravenously 1min prior 3 mgkg-1 of propofol and 1 min before LMA insertion in Ketamine-propofol group.~sevoflurane 6-7% was used on vaporizer setting with 50% nitrous oxide in oxgen prior intravenous anesthesia. The loss of eyelash reflex was considered as the desired end point for induction."
2898650|NCT03257800|Placebo Comparator|propofol group|"0,9% saline solution ( Placebo ) at the same volume as ketamine (50mg/ml) was injected intravenously 1min prior propofol 3 mg.kg-1 and 1 min before LMA insertion in propofol group.~sevoflurane 6-7% was used on vaporizer setting with 50% nitrous oxide in oxgen prior intravenous anesthesia. The loss of eyelash reflex was considered as the desired end point for induction."
2898651|NCT03257787|Experimental|Test of a new adhesive strip|A new adhesive strip has been developed and will be tested in this investigation.
2898652|NCT03257774|Experimental|Test of three new adhesive strips|"The subjects test three new adhesive strips~adhesive strip A~adhesive strip B~adhesive strip C"
2898653|NCT03257761|Experimental|Treatment (guadecitabine, durvalumab)|Patients receive guadecitabine SC QD on days 1-5 and durvalumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2898654|NCT03257748|Experimental|LED group|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
2898655|NCT03257748|Experimental|Laser group|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
2898656|NCT03257722|Experimental|Phase 1 Dose Escalation|Sequential cohorts of 3 patients will receive pembrolizumab 200 mg intravenously every 3 weeks, in addition to the oral drug, idelalisib, every day for 21 days. The first group of 3 will receive idelalisib 50 mg twice daily; the next cohort will receive idelalisib 100 mg twice daily; the last cohort will receive idelalisib 150 mg twice daily.
2898657|NCT03257722|Experimental|Phase 2 Efficacy|All patients in the efficacy assessment phase will be treated with pembrolizumab (200 mg intravenously every 3 weeks) in combination with oral idelalisib (dose not exceeding 150 mg twice daily, per the phase 1 assessment) for 18 weeks before maintenance with pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years, until disease progression or unacceptable toxicity.
2898658|NCT03257709|Active Comparator|Arthroscopic acetabular labral repair|Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).
2898659|NCT03257709|Active Comparator|Arthroscopic acetabular labral resection|The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
2898660|NCT03257683||Selected group with cardiac ischemia|This selected study group will have a specific echocardiographic imaging protocol performed, which includes the known ischemic regions. All segments will be collected and analyzed as a pre-therapeutic baseline using specialized STE software to derive strain values. Following eight (8) weeks of ranolazine therapy, each subject will be re-interrogated with the same echocardiographic imaging protocol and have identical measurements of regional strain performed. Ranolazine will be added to the patients' usual medical therapy. Each patient will serve as their own control, from baseline to post therapeutic state.
2898661|NCT03257670|Active Comparator|CO2RE Laser|This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
2898662|NCT03257670|Active Comparator|4% Topical Lidocaine Gel|This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
2898663|NCT03257657|Experimental|Observational Group|Intervention: Participants will receive usual WIC care plus they will be given a packet of written WIC materials on lifestyle recommendations at the baseline visit, and offered an appointment with a WIC RD at the 12 week visit.
2898664|NCT03257657|Experimental|Lifestyle Group|"Intervention: Visits with WIC staff at Baseline, 4 weeks, 8 weeks: Meet with WIC staff who will use motivational interviewing during visits. Participants will complete an iPad app that asks lifestyle questions. Responses are provided to WIC staff in an easy to read format to guide lifestyle counseling and informational handouts are provided to participants.~In-between visits: Participants receive text messages with informational and motivational content. They are invited to a Facebook private group providing informational and motivational content and encouraging cross-support amongst participants. They are asked to self-monitor activity and weekly weights and will be offered weekly phone coaching appointments with WIC staff."
2898665|NCT03257644|Experimental|Cohort 1|INCB018424 phosphate cream 0.5%.
2898666|NCT03257644|Experimental|Cohort 2|INCB018424 phosphate cream 1.5%.
2898728|NCT03257137|Experimental|Simulated Fast Food (SFF)|This dietary pattern will represent the typical American diet for fiber, added sugar, and saturated fat intake.
2898667|NCT03257631|Experimental|Pomalidomide|Pomalidomide will administered at a starting dose of 2.6 m2/day. Pomalidomide will be provided as either a capsule (0.5 mg, 1 mg, 2 mg, 3 mg or 4 mg) or as an oral suspension (2 mg/mL).
2898668|NCT03257618|Experimental|Temozolomide|"Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.~Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression."
2898669|NCT03257605||Study group|Participants enrolled in PACE who underwent pharmacogenomics testing as part of their medical care and also consented to the use of their de-identified data for research purposes.
2898670|NCT03257592|Experimental|Patients with Schizophrenia Disorder|Patients with Schizophrenia Disorder will be imaged with [11C] DPA-713
2898671|NCT03257592|Experimental|Patients with Bipolar Disorder|Patients with Bipolar Disorder will be imaged with [11C] DPA-713
2898672|NCT03257592|Experimental|Control|Normal volunteers will be imaged with [11C] DPA-713
2898673|NCT03257579|Experimental|90 Day Supply|Intervention: At Hamilton Health Sciences a policy change implementing a standardized discharge prescription form of a 90-day supply with 3 repeats for all cardiac medications available on all wards where MI patients are managed.
2898674|NCT03257579|Experimental|Education Alone|At St. Joseph's Hospital education regarding the benefits of lengthening prescriptions to a 90 day supply with 3 repeats for all cardiac medications will be implemented.
2898675|NCT03257579|Experimental|Education Plus Point of Care reminders|The intervention at Niagara Health System will consist of point of care reminders at the time of discharge for internal medicine on all wards where MI patients are managed advising a 90 day supply with 3 repeats for all cardiac medications, plus education on benefits of this practice.
2898676|NCT03257579|No Intervention|Control|Remaining Ontario cardiac sites will receive usual care and act as concurrent control group.
2898677|NCT03257553|Experimental|intervention arm|do fecal calprotectin, doppler and ultrasound for each patient
2898678|NCT03257540||Small Bone Intramedullary Nail|All study participants
2898679|NCT03257527|Experimental|ENHANCE group|The ENHANCE group is comprised of 12 weekly session to be completed in-person and delivered by trained group facilitators.
2898680|NCT03257527|Active Comparator|MBSR group|"The MBSR group will complete a self-help workbook entitled, A Mindfulness-Based Stress Reduction Workbook over a 12 week period."
2898681|NCT03257514|Active Comparator|alpha lipoic acid|51 women will receive alpha lipoic acid drug (thiotacid film coated tablets 600 mg) for 6 weeks after cesarean section then uterine scar healing will be assessed by saline sonohysterography (by placing catheter in the cervical os helping to administering saline into uterine cavity then using the transvaginal ultrasound to view the uterus in the longitudinal view)
2898682|NCT03257514|Placebo Comparator|placebo|51 women will receive a placebo drug for 6 weeks after cesarean section then uterine scar healing will be assessed by saline sonohysterography(by placing catheter in the cervical os helping to administering saline into uterine cavity then using the transvaginal ultrasound to view the uterus in the longitudinal view)
2898683|NCT03257488|Active Comparator|Screening device-Traditional device|The patients included in the A Group will be studied during the first night with the screening device (type IV portable monitoring Somnocheck micro Weinmann) and with the traditional one during the following night.
2898684|NCT03257488|Active Comparator|Traditional device-Screening device|The patients included in the B Group will be studied during the first night with the traditional device and with the screening one (type IV portable monitoring Somnocheck micro Weinmann) during the following night.
2898685|NCT03257462|Experimental|Cohort A|The first cohort of 9 patients will be administered SPR001 at dose strength of Dose A daily for 2 weeks, and escalating through Dose B per day for 2 weeks and Dose C per day for 2 weeks.
2898686|NCT03257462|Experimental|Cohort B|Cohort B will begin enrollment after Cohort A has been fully enrolled. Starting dose selection and the stepwise dosing paradigm for Cohort B will be determined by an interim review of safety and PK/PD data from from Cohort A.
2898687|NCT03257436|Other|Single Arm|General population who receive a Boston Scientific Resonate family of CRT-D device in accordance with its labeled indication for use.
2898688|NCT03257423|Active Comparator|I.v. + p.o. antibiotics (APPAC II)|Patients in this group recruited also in APPAC II trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 2 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 5 days, for a total treatment duration of 7 days. From these patients, rectal swab samples will be collected at day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
2898689|NCT03257423|Active Comparator|P.o. moxifloxacin (APPAC II)|Patients in this group recruited also in APPAC II trial will receive p.o. antibiotics for a total of 7 days, moxifloxacin 400 mg once per day. From these patients, rectal swab samples of faces will be collected at two time points, day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
2898690|NCT03257423|Placebo Comparator|Placebo treatment (APPAC III)|Patients in this group recruited also in APPAC III trial will receive i.v. placebo 3 times per day for 3 days followed by p.o. placebo 3 times per day for 4 additional days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
2898691|NCT03257423|Other|Surgery (complicated appendicitis)|Patients in this group will undergo appendectomy and are recruited only in the MAPPAC trial. Rectal swab samples and biopsies from the removed appendix will be collected from these patients.
2898692|NCT03257423|Other|Surgery (uncomplicated appendicitis)|Patients in this group will undergo appendectomy either after refusing to participate in the APPAC II or APPAC III trials or after presenting with recurrent appendicitis after antibiotic or placebo therapy. Rectal swab samples of faces and biopsies from the removed appendix will be collected from these patients.
2898729|NCT03257124|Experimental|AZD9291 in BM or LM cohort in T790M positive|"Brain metastasis cohort (BM cohort)~Leptomeningeal metastasis cohort (LM cohort)"
2898730|NCT03257098|Experimental|allo-APZ2-CVU|Application of IMP on patients wound
2898731|NCT03257085|Experimental|Low-carbohydrate, high-fat|Participants adhering to low-carbohydrate, high-fat diet for 8 weeks.
2898693|NCT03257423|Active Comparator|I.v. + p.o. antibiotics (APPAC III)|Patients in this group recruited also in APPAC III trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 3 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 4 days, for a total treatment duration of 7 days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
2898694|NCT03257397|Experimental|left iTBS and right cTBS|40 patients will receive intermittent theta-burst stimulation (iTBS) over the left dorsolateral prefrontal cortex (DLPFC) and continuous TBS (cTBS) over the right DLPFC
2898695|NCT03257397|Active Comparator|left and right iTBS|40 patients will receive intermittent theta-burst stimulation (iTBS) over the left and right dorsolateral prefrontal cortex (DLPFC)
2898696|NCT03257371||Post-traumatic knee OA|post-traumatic knee OA and requiring a tibial plateau and meniscus arthroplasty plus a femoral condyle arthroplasty
2898697|NCT03257358|Other|Cohort 1|RMS patients who are newly prescribed commercially available fingolimod 0.5mg per day
2898698|NCT03257358|Other|Cohort 2|RMS patients who have been on commercially available fingolimod 0.5mg per day continuously for ≥ 2 years
2898699|NCT03257332||Slagelse|Subjects should have received curative surgery for rectal cancer (low anterior resection) and scheduled for stoma closure within the next 6 months.
2898700|NCT03257319|Experimental|inhaled morphine + IV placebo|Arm A: inhaled titration of morphine chlorhydrate+ IV placebo
2898701|NCT03257319|Placebo Comparator|IV morphine +inhaled placebo|Arm B:IV titration of morphine chlorhydrate + inhaled placebo
2898702|NCT03257306|Active Comparator|Magnetic double-J ureteric stent|Double-J ureteric stent removed using magnet
2898703|NCT03257306|Active Comparator|Standard double-J ureteric stent|Double-J stent removed using cystoscopy
2898704|NCT03257293|Active Comparator|Routine Cystoscopy|
2898705|NCT03257293|Experimental|Modified Cystoscopy|
2898706|NCT03257280|Experimental|Early oral nutrition|An early oral nutrition with supplements and increased progressively according to an established schedule, start 48 hours after total gastrectomy.
2898707|NCT03257280|No Intervention|control group|In our center, the classical postoperative management consisted in one week period of non oral intake and total parenteral nutrition. At the 7 day, an oral contrast image is performed to prove the correct function of the anastomosis, in witch case, a three days progressive oral diet is begin.
2898708|NCT03257267|Experimental|Experimental Therapy|REGN2810
2898709|NCT03257267|Active Comparator|Control Therapy|Investigator choice (IC) chemotherapy
2898710|NCT03257241|Active Comparator|A arm (DA-90)|"Induction I:~DNR 90 mg/m2 D 1-3 in 30-60 min i.v. infusion~Ara-C 100 mg/m2 D 1-7 in 24 h i.v. infusion"
2898711|NCT03257241|Active Comparator|B arm (DAC)|"Induction I:~DNR 60 mg/m2 D 1-3 in 30-60 min i.v. infusion~cladribine 5 mg/m2 D 1-5 in 2 h i.v. infusion prior to Ara-C~Ara-C 200 mg/m2 D 1-7 in 22 h i.v. infusion."
2898712|NCT03257241|Active Comparator|A arm (CLAG-M)|Cladribine 5mg/m2 in 2 h i.v. infusion on days (1-5) Ara-C 2 g/m2 in 4 h i.v. infusion, 2 h after cladribine infusion on days (1-5) Mitoxantrone 10 mg/m2 i.v. 1xd on days (1-3) G-CSF 30MU s.c. 1xd from day 0 to 5 of the treatment (6 doses).
2898713|NCT03257241|Active Comparator|B arm (FLAG-IDA)|Fludarabine 30 mg/m2 in 30-min i.v. infusion on days (1-5) Ara-C 2 g/m2 in 4 h i.v. infusion, 2 h after fludarabine infusion on days (1-5). Idarubicin 8 mg/m2 i.v. 1xd on days (1-3) G-CSF 30MU s.c. 1xd from day 0 to 5 of the treatment (6 doses).
2898714|NCT03257228||oral lichen planus and diabetes mellitus|Histopathologically confirmed samples of oral lichen planus underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking biopsy.
2898715|NCT03257228||oral lichen planus|Histopathologically confirmed samples of oral lichen planus underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking biopsy.
2898716|NCT03257228||healthy mucosa|Samples of healthy mucosa underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking mucosa samples.
2898717|NCT03257215|Active Comparator|Stoss vitamin D|Stoss vitamin D at Day 1 and daily placebo for 90 days (Day 1 to 90)
2898718|NCT03257215|Active Comparator|Daily vitamin D|Stoss placebo at Day 1 and daily vitamin D for 90 days (Day 1 to 90)
2898719|NCT03257215|Placebo Comparator|Placebo|Stoss placebo at Day 1 and daily placebo for 90 days (Day 1 to 90)
2898720|NCT03257202|No Intervention|Control|No topical treatment
2898721|NCT03257202|Experimental|Clindamycin alone|topical clindamycin alone using Clindamycin 1% Gel
2898722|NCT03257202|Experimental|Benzoyl peroxide alone|topical benzoyl peroxide alone using Benzoyl Peroxide 5% Gel
2898723|NCT03257202|Experimental|Clindamycin and benzoyl peroxide|Topical clindamycin and topical benzoyl peroxide together using BenzaClin 5%-1% Topical Gel
2898724|NCT03257176|Experimental|Stepping Stones and Creating Futures|Receive the 21 session intervention
2898725|NCT03257163|Experimental|Treatment (pembrolizumab, capecitabine, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks, patients undergo surgery. Beginning up to 56 days after surgery, patients receive pembrolizumab IV over 30 minutes on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks of resting, patients continue to receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 11 courses in the absence of disease progression or unacceptable toxicity. Beginning course 4, patients undergo radiation therapy over 15-30 minutes on days 1-5 for up to 5 weeks.
2898726|NCT03257150|Experimental|Study Treatment|"For the patients with locally advanced pancreatic ductal adenocarcinoma:~Irreversible electroporation using the NanoKnife system to treat cancer tumor.~Positron emission tomography (PET) scan using 18F-Fluoroazomycin arabinoside contrast to assess tumor hypoxia."
2898727|NCT03257137|Experimental|Healthy Diet|This dietary pattern will represent recommendations for fiber and added sugar set forth in the 2015 Dietary Guidelines for Americans and saturated fat guidelines from the American Heart Association
2898732|NCT03257085|Experimental|High-carbohydrate, moderate fat|Participants following high-carbohydrate, moderate-fat diet for 8 weeks.
2898733|NCT03257072|Experimental|A: 50 Necator americanus L3 larvae|Mock infections with water at week 0 and 2, infection with 50 Necator americanus L3 larvae at week 4
2898734|NCT03257072|Experimental|B: 100 Necator americanus L3 larvae|Mock infections with water at week 0, infection with 50 Necator americanus L3 larvae at week 2 and 4
2898735|NCT03257072|Experimental|C: 150 Necator americanus L3 larvae|Infection with 50 Necator americanus L3 larvae at week 0, 2 and 4
2898736|NCT03257059|Experimental|Breakfast|Subject given standardized breakfast (glutinous rice) to test blood glucose response
2898737|NCT03257059|Experimental|No breakfast|Subject not given breakfast to test blood glucose response
2898738|NCT03257046|Experimental|1 mg ITI-214|Administered once daily for 7 days
2898739|NCT03257046|Experimental|3 mg ITI-214|Administered once daily for 7 days
2898740|NCT03257046|Experimental|10 mg ITI-214|Administered once daily for 7 days
2898741|NCT03257046|Experimental|30 mg ITI-214|Administered once daily for 7 days
2898742|NCT03257046|Experimental|90 mg ITI-214|Administered once daily for 7 days
2898743|NCT03257046|Placebo Comparator|Placebo|Administered once daily for 7 days
2898744|NCT03257033|Experimental|IA Therapy|IA Treatments with 1,000 mg/m2 gemcitabine administered through RenovoCath every other week for a maximum of 8 treatments for approximately 16 weeks.
2898745|NCT03257033|Active Comparator|IV Therapy|IV gemcitabine and nab-paclitaxel will be administered for 16 weeks on days 1, 8, and 15 of a 28 day cycle. Nab-paclitaxel will be administered intravenously following pre-medication at a dose of 125 mg/m2 over 30 minutes followed by an infusion of gemcitabine at a dose of 1000 mg/m2 over 30 minutes.
2898746|NCT03257020||Normal subject|Measure BMO-MRW and RNFL with SD-OCT. If the BMO-MRW and RNFL is within the normal range and those with no history of ocular disease, an intraocular pressure < 21 mmHg, an absence of glaucomatous optic disc appearance, and a normal visual field, they will be classified into normal group.
2898747|NCT03257020||Glaucoma patients|Measure BMO-MRW and RNFL with SD-OCT. If the BMO-MRW and RNFL is below the normal range and those with glaucomatous optic disc and two consecutive abnormal visual field test results with open angles on gonioscopy, glaucomatous optic neuropathy, RNFL defects congruent with visual field defects, they will be classified into glaucoma patients.
2898748|NCT03257007|No Intervention|Usual Care|Participants assigned to Usual Care will continue to receive standard care from their oncology team, including access to supportive care from oncology social workers. At the end of the study, usual care dyads will receive a packet of informational materials on mindfulness meditation, receive a CD with 5 mindfulness meditation practices, and meet with the study interventionist for guidance on how to use the materials and mindfulness recordings to their advantage in coping with cancer-related challenges.
2898749|NCT03257007|Active Comparator|Mindfulness|The Mindfulness intervention will consist of six 2-hour sessions that will include guided mindfulness practices, didactics, and group discussion. The course curriculum is modeled on the Mindfulness-Based Stress Reduction program which involves intensive experiential training of participants in secular mindfulness meditation practices (i.e., body scan, sitting meditation, gentle hatha yoga with chair adaptations, compassion meditation), with an emphasis on embodying interpersonal mindfulness in dialogue.
2898750|NCT03256981|Experimental|SBRT and continued TKI therapy|"Patients will continue to receive background TKI treatment as prior to trial entry.~Simultaneous administration (SBRT & TKI) or break in TKI during SBRT will be by centre preference and determined prior to commencing recruitment.~Repeat SBRT will be permissible upon development of subsequent OPD lesions dependent on SBRT suitability and total progression lesion number at any one point remaining ≤ 3."
2898751|NCT03256981|Active Comparator|Continued TKI therapy alone|Continuation on the same background TKI treatment as prior to trial entry
2898752|NCT03256968|Experimental|ataluren administration|dose of the drug administered (mg/kg body weight)
2898753|NCT03256955|Other|Tof Watch SX and Tof Cuff|Patients undergoing surgery with intubation and receiving a single intubation dose of rocuronium (0.6 mg/kg) under propofol anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
2898754|NCT03256942|Experimental|Etermis 4® Treatment|"Etermis 4® will be applied according to the method of administration described in the current version of the Instructions for Use (IFU) until optimal cosmetic result is obtained at the discretion of the treating investigator.~Single injection session, injections into the lips."
2898755|NCT03256942|No Intervention|No Treatment|
2898756|NCT03256929|Experimental|personalized diet-driven microbiota|personalized diet intervention based on microbiota analysis and health status
2898757|NCT03256929|Experimental|control|General information on nutrition and health
2898758|NCT03256916|Experimental|Nelfinavir Arm|"If patient is randomized to nelfinavir arm then nelfinavir will be given orally with food at the dose of 1250 mg bid 5-7 days prior to start of chemoradiation.~Then Pelvic EBRT (46Gy /23#/4.5weeks) + Weekly cisplatin 40mg/m2 & ICRT 7Gy X4 # will be given."
2898759|NCT03256916|Other|Standard Arm|"If patient is randomized to standard arm (Cisplatin +Pelvic EBRT and Brachytherapy).~In this patient will receive Pelvic EBRT (46Gy /23#/4.5weeks) + Weekly cisplatin 40mg/m2 & ICRT 7Gy X4 #"
2898760|NCT03256903|Experimental|Methoxyflurane|Patients will be supplied with up to two inhalers containing 3 mL methoxyflurane. A member of the research team will train the patient to self-administer methoxyflurane
2898761|NCT03256903|Active Comparator|Standard of Care (SoC)|Patients will be treated following standard of care (SoC) of the hospital, for emergency relief of trauma and associated pain. Any kind of analgesia administered by any route will be valid. Only administration of one analgesic (or fixed combinations) at baseline will considered SoC. Other required analgesics will be considered rescue medication.
2898762|NCT03256890|Experimental|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, we work to provide access within health insurance constraints.
2899152|NCT03254485|Placebo Comparator|Placebo|Placebo to match experimental drug
2898763|NCT03256890|Active Comparator|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
2898764|NCT03256877||All participants|Patients with haematuria.
2898765|NCT03256864|Experimental|Tacrolimus and Everolimus BID|"TAC BID (C0 2.5-5 ng/mL) EVR BID (1.0 mg BID targeted to C0 3-8 ng/mL)~Other Names:~Prograf~Advagraf~Zortress~Certican"
2898766|NCT03256864|Experimental|Tacrolimus and Everolimus QD|"TAC QD (C0 2.5-5 ng/mL) EVR QD (2.0 mg QD targeted to C0 3-8 ng/mL)~Other Names:~Prograf~Advagraf~Zortress~Certican"
2898767|NCT03256851|Active Comparator|In-Person Delivered Exercise|"Participants in the in-person training group will:~participate in a home exercise program including aerobic training 2x/week and strength training 3x/week.~complete one of their prescribed training sessions (lasting 1 hour total) each week with a physical therapist or trained member of the research team. Training sessions will focus on progression of aerobic and strength training exercises."
2898768|NCT03256851|Experimental|Telephone-Delivered Exercise|"Participants in the telephone-delivered training group will:~participate in a home exercise program including aerobic training 2x/week and strength training 3x/week.~receive a 60-minute, 1x/week telephone call from a trained research team member. Participants will report their progress from the prior week, discuss/troubleshoot any issues or problems, and receive progressions of both aerobic and strength training exercises for the upcoming week."
2898769|NCT03256838|Experimental|Ferric citrate|Ferric Citrate (Nephoxil® Capsules) will be dosed three times a day (with meals).
2898770|NCT03256825|Other|Rapid diagnostics|patients admitted to medical and surgical wards with urinary tract infections at Ålesund Hospital, Moere and Romsdal, Norway. Here, rapid diagnostics alone will be implemented.
2898771|NCT03256825|Other|Rapid diagnostics and RADS|patients admitted to medical and surgical wards with urinary tract infections at Molde Hospital, Moere and Romsdal, Norway. Here, rapid diagnostics will be implemented in conjunction with Real-time antimicrobial stewardship decision support : rapid diagnostics and RADS.
2898772|NCT03256812|Experimental|ICT-based ECG monitoring group|Continuous monitoring with ICT-based ECG monitoring will begin from the time of participation in the trial in the ICT-based monitoring group. Depending on the lifestyle pattern of the patient, the specific time will be set to allow 30 min of monitoring per day, even if there are no symptoms. If symptoms do appear, additional monitoring will be performed for at least 10 more minutes. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group.
2898773|NCT03256812|Active Comparator|Holter monitoring group|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in the Holter monitoring group
2898774|NCT03256786||Active warming|preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid
2898775|NCT03256786||Control|no preoperative warming and room temperature intravenous fluid
2898776|NCT03256773||Notmal|No lung Disease
2898777|NCT03256773||Cystic Fibrosis|cystic fibrosis Lung Disease
2898778|NCT03256773||PCD|Primary Ciliary Dyskinesia
2898779|NCT03256773||COPD|Chronic Obstructive Lung Disease
2898780|NCT03256760|Experimental|Endotoxin|Endotoxin 0.8 ng/kg body weight
2898781|NCT03256760|Placebo Comparator|Placebo|Placebo
2898782|NCT03256747|Experimental|NMES group|NMES will be placed at the knee extensors, with maximal intensity tolerance evaluated by to induce visible contractions.
2898783|NCT03256747|Placebo Comparator|NMES-placebo group|NMES-placebo will be placed at the knee extensors, with minimal intensity to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
2898784|NCT03256721|Experimental|Apatinib+docetaxel/pemetrexed|Apatinib 500mg QD PO d1-21+docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d
2898785|NCT03256721|Active Comparator|docetaxel/pemetrexed|docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d
2898786|NCT03256708|Experimental|Prolardii|Prolardii GR Caps includes 4 strains of living lyophilized lactic bacteria (Lactobacillus rhamnosus GG, Bifidobacterium lactis B94, Lactobacillus casei 5773 and Lactobacillus acidophilus LA3), a yeast (Saccharomyces boulardii), a fructo-oligosaccharide (Actilight) and a dry extract of Inula helenium.
2898787|NCT03256708|Placebo Comparator|Placebo|Inactive ingredients
2898788|NCT03256695|Experimental|ABS eMDPI|
2898789|NCT03256682|Experimental|Mobile Video Counseling|Utilize mobile imaging equipment, receive a total of 4 stress management consultations every 50 minutes at a time, once a week.
2898790|NCT03256682|Active Comparator|Offline Counseling|Receive a total of 4 stress management counseling, once a week for 50 minutes each session.
2898791|NCT03256682|No Intervention|Selfcare|Use stress management materials to manage yourself.
2898792|NCT03256669|Experimental|umbilical incision|neonates undergone surgery by umbilical incision
2898793|NCT03256656|Experimental|Healthy subjects|
2898794|NCT03256656|Active Comparator|Patients with SCI|
2898795|NCT03256643|Experimental|Exercise|Exercise is the intervention. People be tested before the start of, and after the end of the eight (8) week exercise program.
2898796|NCT03256643|Experimental|Delayed Exercise|Delayed Exercise Group will have exercise as intervention. People be tested before the start of, and after the end of the eight (8) weeks then after exercise intervention.
2898797|NCT03256643|Experimental|Exercise and Enrichment|Exercise and Enrichment Group is the intervention. The group will be tested at the beginning and end of their exercise/enrichment program.
2898798|NCT03256617|Experimental|Provider training|
2898799|NCT03256604||Fresh left-over sputum|All fresh sputum samples that were sent to the Department of Microbiology between November 1 2015 and January 30 2016 under the standard requirements for sputum cultures at the accredited (ISO 17025 and 15189 beginning in 1993) laboratory were kept cold (4-8 ͦC) after analysis by microscope and cultures until it was collected and coded by the study nurse in the evening (left-over samples).
2898800|NCT03256591|Experimental|HBB plus simulation training|Participants receive training from facilitators for HBB training with simulation skills
2898801|NCT03256591|No Intervention|Control|Participants receive training from facilitators for HBB training without simulation skills
2898802|NCT03256578|Experimental|RFM visible|During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants can see the information displayed on the New Life Box Respiratory Function Monitor screen.
2898803|NCT03256578|No Intervention|RFM masked|During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants cannot see the information displayed on the New Life Box Respiratory Function Monitor screen. Though the display is masked, data is collected in the background.
2898804|NCT03256552|Active Comparator|GP MDI 28.8 micrograms|Glycopyrronium Metered Dose Inhaler 28.8 micrograms
2898805|NCT03256552|Active Comparator|GP MDI 14.4 micrograms|Glycopyrronium Metered Dose Inhaler 14.4 micrograms
2898806|NCT03256552|Active Comparator|GP MDI 7.2 micrograms|Glycopyrronium Metered Dose Inhaler 7.2 micrograms
2898807|NCT03256552|Placebo Comparator|Placebo MDI|Placebo Inhalation Aerosol
2898808|NCT03256539|Experimental|Sleep Intervention|Sleep treatment program (to be developed) that incorporates modified cognitive behavioral therapy for insomnia (CBT-I) and bright light therapy (BLT)
2898809|NCT03256539|Placebo Comparator|Placebo intervention|Placebo (quasi-desensitization) intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration).
2898810|NCT03256526|Placebo Comparator|Placebo|
2898811|NCT03256526|Experimental|PF-06835919 Low Dose|75 mg once daily
2898812|NCT03256526|Experimental|PF-06835919 High Dose|300 mg once daily
2898813|NCT03256513|Experimental|model controlling|an statistical model for periprocedural blood pressure control
2898814|NCT03256513|Active Comparator|conventional controlling|an conventional strategy for periprocedural blood pressure control
2898815|NCT03256500|Experimental|tDCS administered|Subjects will receive stimulation via tDCS (Transcranial Direct Current Stimulation) for 20 minutes per day, 5 days per week, for 1 week.
2898816|NCT03256500|Sham Comparator|Sham tDCS administered|Subjects will receive sham tDCS (Transcranial Direct Current Stimulation) for 20 minutes per day, 5 days per week, for 1 week.
2898817|NCT03256487|Experimental|Buprenorphine|"Patients will receive IV buprenorphine 0.3mg diluted to a volume of 10mL with NS in a plastic syringe administered over 3-5 minutes. At 20 minutes, the patient will be asked would you like more pain medication? If he/she answers yes, then he/she will receive a second dose of IV buprenorphine 0.3mg."
2898818|NCT03256487|Active Comparator|Morphine|"Patients will receive IV morphine 0.1mg/kg (max dose 8mg) diluted to a volume of 10mL with NS in a plastic syringe administered over 3-5 minutes. At 20 minutes, the patient will be asked would you like more pain medication? If he/she answers yes, then he/she will receive a second dose of IV morphine 0.1mg/kg (max dose 8mg)."
2898819|NCT03256461|Experimental|Lactate clearance 10% target group|Lactate clearance falls by 10-percent every two hours.
2898820|NCT03256461|Experimental|Lactate clearance 20% target group|Lactate clearance falls by 20-percent every two hours.
2898821|NCT03256461|Placebo Comparator|Standard EGDT group|Refer to the Surviving Sepsis Campaign(SSC) 2012 sepsis guidelines within 6 h liquid resuscitation.
2898822|NCT03256435|Experimental|Treatment Arm|RAMP PrEP initiation, adherence, and retention intervention package as well as standard of care (access to a financial advocate and clinical staff to support, facilitate, and assist in linkage to the established PrEP clinic at Open Arms and to facilitate initiation of, and obtaining, PrEP medications)
2898823|NCT03256435|No Intervention|Control Arm|Standard of care (access to a financial advocate and clinical staff to support, facilitate, and assist in linkage to the established PrEP clinic at Open Arms and to facilitate initiation of, and obtaining, PrEP medications)
2898824|NCT03256422|Experimental|4 days / 7|Patients included in this arm will take their ARV treatment 4 consecutive days per week during 98 weeks
2898825|NCT03256422|Active Comparator|7 days / 7|Patients included in this arm will continue their ARV therapy 7 days per weeks during 48 weeks and after W48, they will take their ARV treatment 4 days per week until W98
2898826|NCT03256409|Experimental|Five Bar overdenture: BOD|Five systems titanium bar CARES® and synOcta® Straumann® Dental Implant System, Holding AG Inc., Basel, Switzerland (Bar overdenture: Group 1) For the manufacture of the overdentures it was used as material of choice Lucitone 199® (Dentsply International Inc. York, PA) and for the adaptation of the retention systems it was used Softreliner Tough Soft® Tocuyama Dental Corporation Inc., Japan. The working protocol for determining the BOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator. Patients were randomly assigned to group 1. The BOD were removed at 30 - 180 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml).
2898827|NCT03256409|Experimental|Five Ball Joint Overdenture: BJOD|Five systems ball joint Klockner® Implant System; Soadco Inc., Escaldes-Engordany, Andorra (Ball Joint Overdenture: Group 2) For the manufacture of the overdentures it was used as material of choice Lucitone 199® (Dentsply International Inc. York, PA) and for the adaptation of the retention systems it was used Softreliner Tough Soft® Tocuyama Dental Corporation Inc., Japan. The working protocol for determining the BJOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator. Patients were randomly assigned to group 2. The s BJOD were removed at 30 - 180 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml).
2898828|NCT03256396|Experimental|Group E|PEEP set according to esophageal pressure measured
2898829|NCT03256396|No Intervention|Group C|PEEP set at 5 cm H2O
2898830|NCT03256383||Adult|Patients aged 18+ years
2898831|NCT03256383||Children 7 - 17|Patients aged 7 - 17 years
2898832|NCT03256383||Children <7|Patients aged under 7 years
2898833|NCT03256370||Infants with allergic diseases|allergic disease : atopic dermatitis or food allergy
2898834|NCT03256370||Healthy infants with atopic mothers|atopic mothers : mothers with asthma or allergic rhinitis or allergic dermatitis (diagnosed by doctors)
2898835|NCT03256370||Healthy infants with non-atopic mothers.|non-atopic mothers : mothers without history of asthma or allergic rhinitis or allergic dermatitis
2944356|NCT02942719||Changsha Hospital for Maternal and Child Health Care|
2898836|NCT03256357|Active Comparator|CIMT + AOT|"In a 2-week day camp model children receive constraint-induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.~Action observation training consists of 15 sessions of 1 hour. Children watch video sequences showing goal-directed actions and subsequently execute the observed actions with the affected upper limb."
2898837|NCT03256357|Placebo Comparator|CIMT + POT|"In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.~Placebo observation training consists of 15 sessions of 1 hour.This group performs the same actions after watching computer games without biological movements."
2898838|NCT03256344|Experimental|Talimogene Laherparepvec with Atezolizumab|Talimogene laherparepvec given by intralesional injection on Day one and every 21 days per protocol for a maximum on 12 cycles. Atezolizumab given by intravenous injection on Day one and every 21 days per protocol
2898839|NCT03256331|Experimental|BEL-X-HG|3+3 dose escalation
2898840|NCT03256318||Children in CKRI Sports and Rec|Children who enter the study between ages 5 and 8 who are participating in CKRI Sports and Recreation Program. They will receive no intervention, only surveys.
2898841|NCT03256318||Comparison Children|Children who enter the study between ages 5 and 8 and end participation in CKRI Sports and Recreation Program at a later date. They will receive no intervention, only surveys.
2898842|NCT03256305|Experimental|"personalized rTMS+drug treatment"|"Received personalized rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks"
2898843|NCT03256305|Active Comparator|Traditional rTMS +drug treatment|Received traditional rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks
2898844|NCT03256292||testosterone, diet, and increased physical activity|Group receiving standard of care consisting of diet and regular exercise counseling + testosterone replacement therapy
2898845|NCT03256279|Experimental|Heat-activated archwire|".014 NiTi heat-activated archwire in the lower arch during the first three months of the orthodonci treatment"
2898846|NCT03256279|Active Comparator|superelasticwire|"This arm are going to receive .014 NiTi Superelastic archwire in the lower arch during the first three months of the orthodonci treatment"
2898847|NCT03256266||healthy controls|healthy controls
2898848|NCT03256266||patients with allergy|patients with Food intolerances or Food allergy
2898849|NCT03256266||gastrointestinal disorders|patients with inflammatory bowel disease, irritable bowel disease, gluten sensitivity, short bowel syndrome
2898850|NCT03256253|Experimental|pregabalin|pregabalin up to daily dose of 600 mg
2898851|NCT03256240|Active Comparator|side-to-side functional end anastomosis|side-to-side functional end anastomosis creation
2898852|NCT03256240|Active Comparator|Kono-S|antimesenteric functional side-to-side handsewn anastomosis, known as the Kono-S anastomosis
2898853|NCT03256227|Experimental|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
2898854|NCT03256227|Active Comparator|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
2898855|NCT03256214|Experimental|Closed suction system|Patients in mechanical ventilation were aspirated with closed suction system.
2898856|NCT03256214|Active Comparator|Open suction system|Patients in mechanical ventilation were aspirated with open suction system.
2898857|NCT03256201|Experimental|Standard Exercise Group|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
2898858|NCT03256201|Experimental|Enhanced Exercise Group|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
2898859|NCT03256188|Experimental|Active classroom|Twenty elementary school teachers implemented 10, 3-minute moderate-to-vigorous physical activity breaks (50-75% of heart rate maximum), 5 days per week in their classrooms over a 16-week period.
2898860|NCT03256175|Experimental|Oxygen|Patient was give 15L/min of Oxygen via HFM 30 mins before and continue through out the procedure. 6 weeks post procedure, EST was arranged
2898861|NCT03256175|Placebo Comparator|Air|Patient was given Facemask without oxygen through out the procedure. 6 weeks post procedure, EST was arranged
2898862|NCT03256162|Experimental|Ketamine|Participants will receive four once-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
2898863|NCT03256162|Active Comparator|Midazolam|Participants will receive four once-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
2898864|NCT03256149|Experimental|Treatment group|Dexamethasone, 4 mg IV given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total
2898865|NCT03256149|Placebo Comparator|Placebo group|Saline given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total
2898866|NCT03256136|Experimental|Nivolumab Plus Ipilimumab EGFR|Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
2898867|NCT03256136|Experimental|Nivolumab Plus Ipilimumab ALK|Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
2898868|NCT03256136|Experimental|Nivolumab + Carboplatin + Pemetrexed with EGFR Chemo naive|Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
2898943|NCT03255603|Experimental|Modified potato starch|Modified potato starch is a resistant starch type IV and will be used as an experimental arm.
2898869|NCT03256136|Experimental|Nivolumab + Carboplatin + Pemetrexed ALK Chemo naive|Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
2898870|NCT03256123|Experimental|red palm shortening group|A group receiving the supplementation of red palm shortening biscuits. The subjects are expected to receive 630 µg RE of vitamin A/day by consuming the biscuits four days a week.
2898871|NCT03256123|Placebo Comparator|palm shortening group|A group receiving supplementation of palm shortening biscuits with corresponding fatty acids as red palm shortening group.
2898872|NCT03256110|Experimental|Intervention|Patients and providers in this arm receive the culturally-tailored Improving Communication about Serious Illness (ICSI) Intervention. The ICSI involves providing the provider and the patient with an individualized, one-page summary of patient-specific preferences for advance care planning communication that prompts the patient and the provider to have a conversation about advance care planning at the next clinical visit.
2898873|NCT03256110|No Intervention|Control|Patients and providers in this arm receive usual care.
2898874|NCT03256097|Experimental|XDP sound processing strategy|XDP sound processing strategy is cochlear implant sound processing strategy. It is non adaptive and does not alter its functioning according to the listening environment.
2898875|NCT03256097|Experimental|Voice Guard sound processing strategy|Voice Guard sound processing strategy is cochlear implant sound processing strategy. It is adaptive and alters its functioning according to the listening environment.
2898876|NCT03256097|Experimental|Voice Track noise cancellation|Voice Track in a cochlear implant noise cancellation technique
2898877|NCT03256084|Experimental|Colorectal Cancer|"Localized stage II/III (group 1), metastatic non resectable (group 2), metastatic potentially resectable (group 3).~Additional blood samples specific for the research will be collected. Tissue samples will be taken on surgical specimens from surgery."
2898878|NCT03256071|Experimental|Decitabine plus Modified BUCY|For high-risk patients with Acute Myeloid Leukemia (AML) undergoing allo-HSCT, The Decitabine plus Modified BuCy regimen consisted of decitabine,semustine,cytarabine, busulfan and cyclophosphamide.
2898879|NCT03256071|Active Comparator|Modified BUCY|For high-risk patients with Acute Myeloid Leukemia (AML) undergoing allo-HSCT, The Modified BuCy regimen consisted of semustine,cytarabine, busulfan and cyclophosphamide.
2898880|NCT03256058|Active Comparator|Reinflation after early deflation|The tourniquet would be inflated immediately before incision and deflated after the use of the cement, and 10 minutes later (after the hardening of the cement) , reinflate the tourniquet and deflate at the end of the operation.The total time of tourniquet inflation is controlled within 90 minutes.
2898881|NCT03256058|Placebo Comparator|Control|The tourniquet would be inflated immediately before incision and deflated at the end of the operation. The inflation of tourniquet should not last more than 90 minutes.
2898882|NCT03256045|Experimental|Treatment (panobinostat, carfilzomib, dexameth, chemo assay)|Patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19. Patients also receive carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay.
2898883|NCT03256019|Active Comparator|DL user|Experienced emergency physicians who primarily used the direct laryngoscopy (DL) for endotracheal intubation during cardiopulmonary resuscitation.
2898884|NCT03256019|Active Comparator|VL user|Experienced emergency physicians who primarily used the videolaryngoscopy (VL) for endotracheal intubation during cardiopulmonary resuscitation.
2898885|NCT03255993|Experimental|SPH3127 100mg|A single dose of SPH3127 50 mg*2 qd *7 days
2898886|NCT03255993|Placebo Comparator|Placebo to SPH3127 100mg|A single dose of placebo matching to SPH3127 50mg*2 qd *7 days
2898887|NCT03255993|Experimental|SPH3127 200mg|A single dose of SPH3127 100 mg*2 qd *7 days
2898888|NCT03255993|Placebo Comparator|Placebo to SPH3127 200mg|A single dose of placebo matching to SPH3127 100mg*2 qd *7 days
2898889|NCT03255993|Experimental|SPH3127 400mg|A single dose of SPH3127 100 mg*4 qd *7 days
2898890|NCT03255993|Placebo Comparator|Placebo to SPH3127 400mg|A single dose of placebo matching to SPH3127 100mg*4 qd *7 days
2898891|NCT03255980|Experimental|Xonrid®|Xonrid® is a medical device for radiation dermatitis
2898892|NCT03255980|Active Comparator|Standard of Care|Standard of care suggested by MASCC guidelines
2898893|NCT03255967|Experimental|QI program care|DSM-H performance improvement program Patients in the performance improvement group will receive care from a care team who has received the DSM-H performance improvement program
2898894|NCT03255967|Active Comparator|Control|provide usual carereceive usual care from a care team who has not received the performance improvement program
2898895|NCT03255954|Experimental|Interpersonal Counseling-C|Interpersonal Counseling for University Counseling Centers is a psychotherapeutic intervention
2898896|NCT03255941|Active Comparator|Lay provider & DMPA|Lay provider providing DMPA
2898897|NCT03255941|Active Comparator|Lay provider & Sayana Press|Lay Provider providing Sayana Press
2898898|NCT03255941|Active Comparator|Clinic provider & DMPA|Clinic provider providing DMPA
2898899|NCT03255941|Active Comparator|Clinic provider and Sayana Press|Clinic provider providing Sayana Press
2898900|NCT03255928||VAD-implanted patients|All patients receiving a VAD implant
2898901|NCT03255928||VAD-patients suffering adverse events (AE)|VAD-patients sustaining a thromboembolic/bleeding complication over the course of support
2898902|NCT03255915|Experimental|Arm 1|Arm 1 will receive the Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) pod-IVR for Stage 2 followed by the placebo pod-IVR during Stage 3.
2898903|NCT03255915|Experimental|Arm 2|Arm 2 will receive the placebo pod-IVR for Stage 2 followed by the Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) pod-IVR during Stage 3.
2898904|NCT03255902|Experimental|Families attending parenting classes|Families attended 6 parenting sessions, filled out daily glucose screens, & questionnaires
2898905|NCT03255889|Active Comparator|Active|Glyceryl Tridecanoate emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts
2898906|NCT03255889|Placebo Comparator|Placebo|Sunflower oil emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts
2898944|NCT03255603|Experimental|Modified corn starch|Modified corn starch is a resistant starch type IV and will be used as an experimental arm.
2898907|NCT03255876|Experimental|Enriched pomegranate juice|Participants will consume 200 ml of pure pomegranate juice enriched with grape seed and apple peel extracts concomitantly with 109 g of white bread
2898908|NCT03255876|Placebo Comparator|Placebo beverage|Participants will consume 200 ml of placebo drink concomitantly with 109 g of white bread
2898909|NCT03255863|Other|Questionnaire|Auto and hetero questionnaire
2898910|NCT03255850||Adolescents with CHD|Adolescents with CHD are required to complete the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES)
2898911|NCT03255850||Healthy control|Data of healthy control who completed the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES) are retrieved from previous studies.
2898912|NCT03255850||Childhood cancer survivors|Data of childhood cancer survivors who completed the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES) are retrieved from previous studies.
2898913|NCT03255837|Experimental|Transcranial direct current stimulation (tDCS) - anodal|Transcranial direct current stimulation - anodal (positive) 1.5 millamps for 15 minutes
2898914|NCT03255837|Experimental|Transcranial direct current stimulation (tDCS) - cathodal|Transcranial direct current stimulation - cathodal (negative) 1.5 millamps for 15 minutes
2898915|NCT03255837|Sham Comparator|Transcranial direct current stimulation (tDCS) - sham|Transcranial direct current stimulation - sham session 15 minutes
2898916|NCT03255824|Active Comparator|Propofol Group|Group of patients to be administered a standard Propofol, Midazolam, Fentanyl anesthesia combination.
2898917|NCT03255824|Experimental|Dexmedetomidine Group|Group of patients to be administered the Dexmedetomidine and Midazolam anesthesia combination.
2898918|NCT03255811|Experimental|The dosage regimen|The chemotherapy response rate reached the maximum after 14-28 days, apatinib, 750 mg (QD), once a day, half an hour after meal (daily dosing time should be as same as possible), with warm boiling water delivery service. 28 days for a dosing cycle.
2898919|NCT03255798|Other|G2 and G3 implantation|Two iStent inject stents and one iStent Supra stent
2898920|NCT03255785|Experimental|G1 plus G3 with phaco|Cataract surgery via phacoemulsification followed by implantation of one iStent and one iStent Supra
2898921|NCT03255772||Acute Chest pain|All patients admitted to the Clinical Decision Unit presenting to the Emergency Department (ED) with chest pain with risk factors suggesting a possible cardiac etiology.
2898922|NCT03255759|Active Comparator|Molecular dx arm|Positive blood cultures are tested using a molecular ID system in addition to the standard of care (biochemical identification)
2898923|NCT03255759|No Intervention|Standard of care arm|Positive blood cultures are treated as per normal lab protocol (biochemical identification)
2898924|NCT03255746|Experimental|Sleep Enhancement|
2898925|NCT03255746|Placebo Comparator|Health Education|
2898926|NCT03255733|Experimental|Intense Therapeutic Ultrasound Treatment|Intense Therapeutic Ultrasound applied along and length and width of the Common Extensor Tendon. 80, 1 Joule pulses were applied twice, four weeks apart.
2898927|NCT03255720||20 patients with Alzheimer disease|"The study will be performed at the Radiodiagnosis department of assiut university hospital.~Selection of 20 patients clinically and laboratory diagnosed as Alzheimer disease and another 20 people matched healthy controls who have no complaints of cognitive problems."
2898928|NCT03255720||20 people matched healthy controls|health control people who have no complaints of cognitive problems.
2898929|NCT03255707|Experimental|Group A|50 patients will receive the gold standard occlusion therapy
2898930|NCT03255707|Experimental|Group B|50 patients will receive dichoptic treatment in the form of playing a video game (Lazy Eye Blocks ®) while wearing a red/green goggle.
2898931|NCT03255694|Experimental|PEG-somatropin|After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for the high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
2898932|NCT03255681|Experimental|Split face study|Split face study with the left side of the face receiving PRP injections and the right side of the face receiving PRP with 0.1cc of 10% calcium chloride per 1mL of PRP. The volume of PRP will be used upon the discretion of the provider for treatment of the cosmetic facial deformity but will be in equal amounts for each side on every patient participating in the study.
2898933|NCT03255655|Experimental|ITU Treatment|Intense Therapeutic Ultrasound (ITU) treatment applied along the length and width of the Plantar Fascia: 350 - 5 Joule pulses were applied twice, two weeks apart.
2898934|NCT03255655|Placebo Comparator|Sham ITU Treatment|Sham / Placebo Intense Therapeutic Ultrasound treatment (ITU) applied along the length and width of the Plantar Fascia: 350 - 0 Joule pulses were applied twice, two weeks apart.
2898935|NCT03255642|Active Comparator|Melatonin 2mg|Two weeks of 2mg of prolonged release Melatonin
2898936|NCT03255642|Placebo Comparator|ClonazePAM 0.5 MG|Two weeks of 0.5mg of rivotril
2898937|NCT03255629|Experimental|Treatment Arm|Each subject will have two mixed meal tolerance tests performed. Each will be randomized to receive either glucagon or matched placebo during the first testing session. The opposite treatment will be given during the second testing session. Both participants and the study team will be blinded to the intervention being used during each session.
2898938|NCT03255629|Placebo Comparator|Control Arm|Each subject will have two mixed meal tolerance tests performed. Each will be randomized to receive either glucagon or matched placebo during the first testing session. The opposite treatment will be given during the second testing session. Both participants and the study team will be blinded to the intervention being used during each session.
2898939|NCT03255616|Experimental|Healthy subjects, topical anesthetic|Applicaton of topical anesthetic and mechanical stimulation
2898940|NCT03255616|Experimental|Healthy subjects, hydrating cream|Applicaton of hydrating cream and mechanical stimulation
2898941|NCT03255616|Experimental|patients, topical anesthetic|Applicaton of topical anesthetic and mechanical stimulation
2898942|NCT03255616|Experimental|patients, hydrating cream|Applicaton of hydrating cream and mechanical stimulation
2898945|NCT03255603|Experimental|Modified tapioca starch|Modified tapioca starch is a resistant starch type IV and will be used as an experimental arm.
2898946|NCT03255603|Placebo Comparator|Corn starch|Corn starch is digestible and will therefore will be used as a placebo control for the study.
2898947|NCT03255590|Experimental|Real tDCS & Configuration task|Real-stimulation: Chronic stroke patients (i.e. great than 6 months) with ischemic stroke confirmed by CT or MRI, residual unilateral upper extremity weakness, able to give informed consent, and able to understand the tasks involved. Participants will receive REAL anodal tDCS stimulation during the training.
2898948|NCT03255590|Sham Comparator|Sham tDCS & Configuration task|Sham-stimulation: Chronic stroke patients (i.e. great than 6 months) with ischemic stroke confirmed by CT or MRI, residual unilateral upper extremity weakness, able to give informed consent, and able to understand the tasks involved. Participants will receive sham SHAM tDCS stimulation during the training.
2898949|NCT03255577|Experimental|Sentinel Lymph Node Biopsy (SLNB)|The patients will undergo SLNB with dual tracer mapping using technetium-99m sulfur colloid and isosulfan blue dye, as is standard practice at our institution for cN1 patients. Than the SLNB procedure will be performed
2898950|NCT03255538|Experimental|DFM: Mean pressure|In this group, deep friction massage will be applied with the mean pressure, previously obtained in a baseline assessment.
2898951|NCT03255538|Experimental|DFM: Mean pressure - 25%|In this group, deep friction massage will be applied will less 25% of the pressure previously obtained in a baseline assessment.
2898952|NCT03255538|Experimental|DFM: Mean pressure +25%|In this group, deep friction massage will be applied will an increment of 25% of the pressure previously obtained in a baseline assessment.
2898953|NCT03255538|No Intervention|Control session|In this group, the participants will rest for 15 minutes
2898954|NCT03255525|Active Comparator|Deep friction massage P50|In this group it was applied a pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
2898955|NCT03255525|Experimental|Deep friction massage P25|In this group it was applied the percentile 25, of the pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
2898956|NCT03255525|Experimental|Deep friction massage P75|In this group it was applied the percentile 75, of the pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
2898957|NCT03255512|Experimental|Vericiguat + isosorbite mononitrate|Co-administration of vericiguat and isosorbite mononitrate.
2898958|NCT03255512|Placebo Comparator|Placebo + isosorbite mononitrate|Administration of (vericiguat) matching placebo and isosorbite mononitrate.
2898959|NCT03255499|Experimental|Exercise and cognitive training|This intervention includes a combination of high-intensity exercise (10min/day) and computerized cognitive training (20min/day). The software for the latter has been developed by our group, and includes 8 mini-games targeting different cognitive abilities. Both are developed for the MovinCog intervention. The intervention is personalized, based on individual performance.
2898960|NCT03255499|Experimental|Exercise|High-intensity training regimen, 10min/day. Developed for the MovinCog intervention.
2898961|NCT03255499|Experimental|Cognitive training|Computerized cognitive training, 20min/day. Developed for the MovinCog intervention.
2898962|NCT03255499|Active Comparator|Games|The active control is composed of a blend of board games, computer games, and trivia quizzes. Specific content is personalized based on individual preferences, so as to reflect the flexibility of the experimental arms.
2898963|NCT03255486|Experimental|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
2898964|NCT03255473|Active Comparator|Dexamethasone|All subject identification (ID) numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
2898965|NCT03255473|Active Comparator|Prednisone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
2898966|NCT03255460||Multiple Sclerosis individuals|Multiple sclerosis patients included in this study. Inclusion and exclusion criteria were considered.
2898967|NCT03255460||Healthy individuals|Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
2898968|NCT03255447|Experimental|Immunoadsorption therapy|Peptide GAM immunoadsorption therapy
2898969|NCT03255434|Active Comparator|Folfox 4|Standard FOLFOX4: Oxaliplatin and simplified LV5FU2 Dose of oxaliplatin 85mg/m²
2898970|NCT03255434|Experimental|Folfox 4 LBM|Adapted FOLFOX4: Oxaliplatin and simplified LV5FU2 Dose of oxaliplatin allocated according to lean body mass (LBM)
2898971|NCT03255421||Patients enrolled|"Patients over 18 years old, consulting for lower urinary tract symptoms and performing an urodynamic examination with a cystometry in a tertiary center are included.~First pressure measurement in the bladder during the classic cystometry. Second measurement of bladder pressures during the bladder emptying."
2898972|NCT03255408|Active Comparator|CBF Lowering and Normoxia Sleep|Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
2898973|NCT03255408|Experimental|CBF Lowering and IH Sleep|Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
2898974|NCT03255408|Sham Comparator|Placebo and Normoxia Sleep|Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
2898975|NCT03255408|Placebo Comparator|Placebo and IH Sleep|Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
2898976|NCT03255395|Experimental|Magnetic resonance-guided focused ultrasound (MRgFUS)|Ten amputees will recieve magnetic resonance-guided focused ultrasound (MRgFUS) treatment aimed to ablate neromas, which are beleived to cuase phantom / residual limb pain
2898977|NCT03255382|Experimental|Risankizumab|Participants randomized to receive risankizumab for16 weeks.
2898978|NCT03255382|Active Comparator|Fumaderm|Participants to received Fumaderm for 24 weeks.
2898980|NCT03255369||Child exposed to zika virus suspected|Child born with symptoms similar to babies proved exposed to zika virus but mothers without symptoms or positive RT-PCR
2898981|NCT03255369||Normal Child|Normal child from mothers without Zika (IgG and IgM negative)
2898982|NCT03255356||Cohort|An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
2898983|NCT03255343|Experimental|IMDENDRIM|
2898984|NCT03255330|Experimental|Arm G1800|administration of gabapentin with a gradual increasing dose of up to 1800 mg / day
2898985|NCT03255330|Active Comparator|G0|Standardized medical treatment of central neuropathic pain: metamizole, tramadol
2898986|NCT03255317|Experimental|Within-participant micro-randomization|Intervention includes Reinforcers and Notifications through the app. At each available decision time, each participant is randomly assigned to either receive an engagement strategy or to not receive an engagement strategy.
2898987|NCT03255304|Experimental|health prime|
2898988|NCT03255304|Experimental|palatability prime|
2898989|NCT03255291|Experimental|1st randomization: Receive results via risk ladder|"Participants will complete all baseline activities in person with a research assistant. Participants will complete the Risk Display App and Initial Audio Recording. The Risk Display App walks the participant through background and health questions. They are then randomized on how they will receive personalized risk results for their current activity level and how it would change if they began exercising regularly.~Complete baseline survey"
2898990|NCT03255291|Active Comparator|1st randomization: Receive results as a table|"Participants will complete all baseline activities in person with a research assistant. Participants will complete the Risk Display App and Initial Audio Recording. The Risk Display App walks the participant through background and health questions. They are then randomized on how they will receive personalized risk results for their current activity level and how it would change if they began exercising regularly.~Complete baseline survey"
2898991|NCT03255291|Active Comparator|1st randomization: Receive results as alphanumeric text|"Participants will complete all baseline activities in person with a research assistant. Participants will complete the Risk Display App and Initial Audio Recording. The Risk Display App walks the participant through background and health questions. They are then randomized on how they will receive personalized risk results for their current activity level and how it would change if they began exercising regularly.~Complete baseline survey"
2898992|NCT03255291|Experimental|2nd randomization: Mental imagery (Exercise)|"Participants are randomized to two types of Mental Imagery Audio Recording and goal setting activity (exercise or sleep).~The recording walks the participant through a set of mental imagery instructions. They will be asked to practice the mental imagery twice a day over 3 weeks. The participant also writes down a exercise goal. After the mental imagery ends, the participant will take a second survey.~Text messages will then be sent to participant as a reminder to practice the imagery twice daily for 5 minutes each time (3 text messages per week for 3 weeks). Participants will receive a survey via text message at the end of each week for four weeks.~90 days after 1st session, the participants will receive another survey in mail to complete~1 year later, 20 participants may be contacted by phone for an additional survey"
2898993|NCT03255291|Active Comparator|2nd randomization: Mental imagery (Sleep)|"Participants are randomized to two types of Mental Imagery Audio Recording and goal setting activity (exercise or sleep).~The recording walks the participant through a set of mental imagery instructions. They will be asked to practice the mental imagery twice a day over 3 weeks. The participant also writes down a sleep goal. After the mental imagery ends, the participant will take a second survey.~Text messages will then be sent to participant as a reminder to practice the imagery twice daily for 5 minutes each time (3 text messages per week for 3 weeks). Participants will receive a survey via text message at the end of each week for four weeks.~90 days after 1st session, the participants will receive another survey in mail to complete~1 year later, 20 participants may be contacted by phone for an additional survey"
2898994|NCT03255278|Experimental|Safety and portable study group|"12 persons who have got a single decreased dose (0.25 of the planned dose for regular administration) of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: single GamTBvac vaccination (0.25 dose)."
2898995|NCT03255278|Placebo Comparator|Placebo safety study group|12 persons who have got a single dose of placebo (0.5 ml). The intervention for the Arm: Placebo administration (0.5 ml)
2898996|NCT03255278|Experimental|Immunogenicity study group #1|"12 persons who will get a double sequential administration of the decreased dose (0.25 of the planned dose for regular applying) of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: double GamTBvac vaccination (0.25 dose)."
2898997|NCT03255278|Experimental|Immunogenicity study group #2|"12 persons who will get a double sequential administration of the mean dose (0.5 of the planned dose for regular applying) of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: double GamTBvac vaccination (0.5 dose)."
2898998|NCT03255278|Experimental|Immunogenicity study group #3|"12 persons who will get a double sequential administration of the maximum (regular) dose of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: double GamTBvac vaccination (1.0 dose)."
2898999|NCT03255265||Acute rejection|
2899000|NCT03255265||No acute rejection|
2899001|NCT03255252|Experimental|Cisplatin|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
2899002|NCT03255239|Experimental|Preperitoneal mesh repair|Ventral hernia repair using polyester preperitoneal mesh repair
2899003|NCT03255239|Experimental|Retromuscular mesh repair|Ventral hernia repair using polyester retromuscular mesh repair
2899004|NCT03255239|Experimental|Suture repair|Ventral hernia repair using suture repair
2899005|NCT03255226|Experimental|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
2899006|NCT03255213|Experimental|Late Onset Pompe Disease who have tongue weakness|
2899007|NCT03255187|Experimental|Fish oil supplementation|This group receive 2.5 g/day (two 1.25-g capsules daily) of fish oil (marine-derived n-3 PUFA) for 4 consecutive months.
2899008|NCT03255187|Placebo Comparator|Sunflower seed oil supplementation|This group receive 2.5 g/day (two 1.25-g capsules daily) of placebo (sunflower seed oil) for 4 consecutive months.
2899153|NCT03254459|Experimental|Buprenorphine Sublingual Spray 0.5 mg|Buprenorphine Sublingual Spray 0.5 milligrams (mg) three times a day (TID) for 7 days.
2899009|NCT03255174|Experimental|EVARREST® Fibrin Sealant Patch|EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of biological components (human plasma‐derived fibrinogen and thrombin) embedded in a flexible composite patch component.
2899010|NCT03255161|Experimental|Immediate communication education and support group|
2899011|NCT03255161|No Intervention|Waitlist|
2899012|NCT03255148|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
2899013|NCT03255148|Placebo Comparator|Placebo|saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
2899014|NCT03255135|Experimental|HIFU|Patients with untreated recent diagnosed localized prostate cancer candidates of focal therapy.
2899015|NCT03255122|Experimental|Immediate treatment|Individuals in this condition will immediately receive I-CALM treatment, which draws on videoconferencing to remotely deliver real time cognitive-behavioral therapy for early child anxiety to families in their home.
2899016|NCT03255122|Other|Waitlist|Individuals in Waitlist will participate in an initial waitlist condition, and then after post-waitlist assessment will be offered the I-CALM intervention. Accordingly families in this condition receive Delayed I-CALM.
2899017|NCT03255096|Experimental|Dose Escalation Phase (Part 1)|Participants will receive either RO6870810 and venetoclax or RO6870810 and venetoclax along with rituximab until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.
2899018|NCT03255096|Experimental|Expansion Phase (Part 2)|Participants will receive RO6870810 and venetoclax along with rituximab (or RO6870810 and venetoclax, if the combination of the 3 drugs is not tolerable) at a recommended dose established in dose escalation phase until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.
2899019|NCT03255083|Experimental|DS-1205c with osimertinib|Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 600 mg, 800 mg) in combination with daily 80 mg oral dose of osimertinib
2899020|NCT03255070|Experimental|Phase 1a: Cohort 1|Cohort 1 will administer Dose Level 1 of ARX788 every 4 weeks (Q4W) via intravenous infusion.
2899021|NCT03255070|Experimental|Phase 1a: Cohort 2|Cohort 1 will administer Dose Level 1 of ARX788 every 3 weeks (Q3W) via intravenous infusion.
2899022|NCT03255070|Experimental|Phase 1a: Cohort 3|Cohort 3 will administer Dose Level 2 of ARX788 every 4 weeks (Q4W) via intravenous infusion.
2899023|NCT03255070|Experimental|Phase 1a: Cohort 4|Cohort 4 will administer Dose Level 2 of ARX788 every 3 weeks (Q3W) via intravenous infusion.
2899024|NCT03255070|Experimental|Phase 1a: Optional Cohort 5 Q3W|Cohort 5 may administer Dose Level 3 of ARX788 every 3 weeks (Q3W) via intravenous infusion.
2899025|NCT03255057|Experimental|Hemolung plus SOC IMV|Low-flow ECCO2R with the Hemolung Respiratory Assist System as an alternative or adjunct to standard-of-care (SOC) invasive mechanical ventilation (IMV)
2899026|NCT03255057|Active Comparator|SOC IMV|Standard-of-care (SOC) invasive mechanical ventilation (IMV) alone
2899027|NCT03255044|Active Comparator|Lipophilic statin|Atorvastatin 40 mg administered daily in addition to guideline directed therapy for heart failure.
2899028|NCT03255044|Active Comparator|Hydrophilic statin|Rosuvastatin 20 mg administered daily in addition to guideline directed therapy for heart failure.
2899029|NCT03255031|Experimental|KD Diet meals and shakes|3 week KD diet
2899030|NCT03255031|Experimental|SA Diet meals and shakes|3 week SA diet
2899031|NCT03255018|Experimental|1|Subjects with gray-zone lymphoma (GZL) or extranodal DLBCL relapsed from or refractory to prior therapy with an anthracycline-based regimen
2899032|NCT03255005|Active Comparator|Treatment group|Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
2899033|NCT03255005|Active Comparator|Controled group|Diet for 6 months then Endoscopic sleeve gastroplasty (Endomina) with multidisciplinary follow-up for 1 year
2899034|NCT03254992|Experimental|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
2899035|NCT03254992|Experimental|ASD - Tangible task|Experimental group using Keyboard with more real activity.
2899036|NCT03254992|Active Comparator|TD - Abstract task|Control group using Kinect with more virtual activity.
2899037|NCT03254992|Active Comparator|TD - Tangible task|Control group using Keyboard with more real activity.
2899038|NCT03254979|Experimental|Sequential engagement|Inter-professional collaborative practice directed by a local leader and an external facilitator to optimize the integration of a T2D primary prevention recommended clinical intervention. In this group, a sequential engagement of professional categories, initiated in nursing, which finally involves the whole professional groups of the center (eg. physicians, etc), will be followed
2899039|NCT03254979|Active Comparator|Global engagement|Inter-professional collaborative practice directed by a local leader and an external facilitator to optimize the integration of a T2D primary prevention recommended clinical intervention. In this group, a global strategy of engagement with the participation of all professionals from the beginning, will be followed
2899040|NCT03254966|Experimental|SHR0302 dose level 1|
2899041|NCT03254966|Experimental|SHR0302 dose level 2|
2899042|NCT03254966|Experimental|SHR0302 dose level 3|
2899043|NCT03254966|Experimental|SHR0302 dose level 4|
2899044|NCT03254966|Placebo Comparator|Placebo|
2899045|NCT03254953|Experimental|Sequential Intervention|"in this Sequential eHealth intervention, participants are asked to self-monitor only their body weight for the first month, then for months 2 and 3 they will be asked to also self-monitor their diet~participants are asked to use the MyFitnessPal app for self-monitoring~given goal to lose 5% weight by end of intervention (3 months)~weekly personalized feedback via email~weekly skills training materials (behavioral modification lessons; tips on using different features of the app) via email~weekly action plans via email"
2899046|NCT03254953|Experimental|Simultaneous Intervention|"in this Simultaneous eHealth intervention, participants are asked to self-monitor both their body weight and diet for 3 months~participants are asked to use the MyFitnessPal app for self-monitoring~given goal to lose 5% weight by end of intervention (3 months)~weekly personalized feedback via email~weekly skills training materials (behavioral modification lessons; tips on using different features of the app) via email~weekly action plans via email"
2944357|NCT02942719||Xinxiang Maternity and Child Health Hospital|
2899047|NCT03254953|Experimental|Control (diet-tracking only)|"participants are asked to self-monitor their diet for 3 months~participants are asked to use the MyFitnessPal app for self-monitoring~given goal to lose 5% weight by end of intervention (3 months)"
2899048|NCT03254940|Experimental|Arm 1: WT-SM-OR-SS-CS|Charge: weekly tracking, self-generated motivational messages, one reminder, summary score, compare to self
2899049|NCT03254940|Experimental|Arm 2: WT-SM-OR-SS-CG|Charge: weekly tracking, self-generated motivational messages, one reminder, summary score, compare to group
2899050|NCT03254940|Experimental|Arm 3: WT-SM-OR-SF-CS|Charge: weekly tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to self
2899051|NCT03254940|Experimental|Arm 4: WT-SM-OR-SF-CG|Charge: weekly tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to group
2899052|NCT03254940|Experimental|Arm 5: WT-SM-MR-SS-CS|Charge: weekly tracking, self-generated motivational messages, multiple reminders, summary score, compare to self.
2899053|NCT03254940|Experimental|Arm 6: WT-SM-MR-SS-CG|Charge: weekly tracking, self-generated motivational messages, multiple reminders, summary score, compare to group.
2899054|NCT03254940|Experimental|Arm 7: WT-SM-MR-SF-CS|Charge: weekly tracking, self-generated motivational messages, multiple reminders, specific feedback, compare to self
2899055|NCT03254940|Experimental|Arm 8: WT-SM-MR-SF-CG|Charge: weekly tracking, self-generated motivational messages, multiple reminders, specific feedback, compare to group
2899056|NCT03254940|Experimental|Arm 9: WT-EM-OR-SS-CS|Charge: weekly tracking, expert-generated motivational messages, one reminder, summary score, compare to self
2899057|NCT03254940|Experimental|Arm 10: WT-EM-OR-SS-CG|Charge: weekly tracking, expert-generated motivational messages, one reminder, summary score, compare to group
2899058|NCT03254940|Experimental|Arm 11: WT-EM-OR-SF-CS|Charge: weekly tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to self
2899059|NCT03254940|Experimental|Arm 12: WT-EM-OR-SF-CG|Charge: weekly tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to group.
2899060|NCT03254940|Experimental|Arm 13: WT-EM-MR-SS-CS|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, summary score, compare to self
2899061|NCT03254940|Experimental|Arm 14: WT-EM-MR-SS-CG|Charge: weekly tracking, expert-generated motivational messages, multiple reminders,summary score, compare to group
2899062|NCT03254940|Experimental|Arm 15: WT-EM-MR-SF-CS|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to self
2899063|NCT03254940|Experimental|Arm 16: WT-EM-MR-SF-CG|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to group
2899064|NCT03254940|Experimental|Arm 17: DT-SM-OR-SS-CS|Charge: daily tracking, self-generated motivational messages, one reminder, summary score, compare to self.
2899065|NCT03254940|Experimental|Arm 18: DT-SM-OR-SS-CG|Charge: daily tracking, self-generated motivational messages, one reminder, summary score, compare to group
2899066|NCT03254940|Experimental|Arm 19: DT-SM-OR-SF-CS|Charge: daily tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to self.
2899067|NCT03254940|Experimental|Arm 20: DT-SM-OR-SF-CG|Charge: daily tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to group
2899068|NCT03254940|Experimental|Arm 21: DT-SM-MR-SS-CS|Charge: daily tracking, self-generated motivational messages, multiple reminders, summary score, compare to self
2899069|NCT03254940|Experimental|Arm 22: DT-SM-MR-SS-CG|Charge: daily tracking, self-generated motivational messages, multiple reminders, summary score, compare to group.
2899070|NCT03254940|Experimental|Arm 23: DT-SM-MR-SF-CS|Charge: daily tracking, self-generated motivational messages, multiple reminders, specific goal feedback, compare to self.
2899071|NCT03254940|Experimental|Arm 24: DT-SM-MR-SF-CG|Charge: daily tracking, self-generated motivational messages, multiple reminders, specific goal feedback, compare to group
2899072|NCT03254940|Experimental|Arm 25: DT-EM-OR-SS-CS|Charge: daily tracking, expert-generated motivational messages, one reminder, summary score, compare to self
2899073|NCT03254940|Experimental|Arm 26: DT-EM-OR-SS-CG|Charge: daily tracking, expert-generated motivational messages, one reminder, summary score, compare to group
2899074|NCT03254940|Experimental|Arm 27: DT-EM-OR-SF-CS|Charge: daily tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to self
2899075|NCT03254940|Experimental|Arm 28: DT-EM-OR-SF-CG|Charge: daily tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to group
2899076|NCT03254940|Experimental|Arm 29: DT-EM-MR-SS-CS|Charge: daily tracking, expert-generated motivational messages, multiple reminders, summary score, compare to self
2899077|NCT03254940|Experimental|Arm 30: DT-EM-MR-SS-CG|Charge: daily tracking, expert-generated motivational messages, multiple reminders, summary score, compare to group
2899078|NCT03254940|Experimental|Arm 31: DT-EM-MR-GF-CS|Charge: daily tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to self
2899079|NCT03254940|Experimental|Arm 32: DT-EM-MR-GF-CG|Charge: daily tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to group.
2899080|NCT03254927|Experimental|CDX-3379 and cetuximab|During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.
2899081|NCT03254914||Control Site|Measure Clinic Blood Pressure
2899082|NCT03254914||Test Site|Measure Clinic Blood Pressure and Home Blood Pressure
2899083|NCT03254901||health care workers|health care workers in Assiut health directorate, Abutig central hospital, El-Quseya central hospital and Sahil selim central hospital in Assiut governorate .All of them will be screened for hepatitis C infection and interviewed about mode of transmission of infection
2899084|NCT03254888||Low Grade group|"• 50 tumor tissue samples from patients with Low Grade Bladder Cancer undergoing either trans urethral resection of bladder tumor or Radical Cystectomy ,~The followings markers must be estimated :~Autophagy markers:~( Atg7) level using (quantitative real time polymerase chain reaction).~(LC3A)level using immunohistochemistry .~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~Oxidative stress Marker:(MDA)using chemical method~Apoptotic marker:(caspase 3) using(quantitative real time polymerase chain reaction) ."
2944358|NCT02942719||Yanshi People's Hospital|
2899085|NCT03254888||High Grade group|"• 50 tumor tissue samples from patients with High Grade Bladder Cancer undergoing either trans urethral resection of bladder tumor or Radical Cystectomy,~The followings markers must be estimated :~Autophagy markers:~( Atg7) level using (quantitative real time polymerase chain reaction).~(LC3A)level using immunohistochemistry .~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~Oxidative stress Marker:(MDA)using chemical method~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction) ."
2899086|NCT03254888||Safety margin group|"• 50 normal bladder urothelial tissue samples from the safety margin around the tumor(0.5cm to the tumor),~The followings markers must be estimated :~Autophagy markers:~( Atg7) level using (quantitative real time polymerase chain reaction).~(LC3A)level using immunohistochemistry .~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~Oxidative stress Marker:(MDA)using chemical method~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction)."
2899087|NCT03254888||Control group|"• 50 (age and sex matched )control~The followings markers must be estimated :~Autophagy markers:~( Atg7) level using (quantitative real time polymerase chain reaction).~(LC3A)level using immunohistochemistry .~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~Oxidative stress Marker:(MDA)using chemical method~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction).."
2899088|NCT03254875|Experimental|Intervention|Individually tailored nurse navigation
2899089|NCT03254875|No Intervention|Control|Usual care
2899090|NCT03254862|Experimental|Group A: CSS & AsynS|"Electrical stimulation training on both legs:~Conventional synchronous stimulation (CSS) and Asynchronous Sequential Stimulation (ASynS) - CSS/ASynS"
2899091|NCT03254862|Experimental|Group B: CSS & AsynR|"Electrical stimulation training on both legs:~Conventional synchronous stimulation (CSS) and Asynchronous Random Stimulation (ASynR) - CSS/ASynR"
2899092|NCT03254849|Experimental|empagliflozin 25 mg|Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 1: 25 mg/d empagliflozin + hydrochlorothiazide placebo
2899093|NCT03254849|Experimental|hydrochlorothiazide 25 mg|Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 2: 25 mg/d hydrochlorothiazide + empagliflozin placebo
2899094|NCT03254836||Colorectal cancer undergoing elective surgery|"All patients eligible for elective curative intended surgery for colonic adenocarcinoma at Zealand University Hospital.~Patients will recieve treatment as per standard of care."
2899095|NCT03254823||Severe ME/CFS patients|patients with a clinical diagnosis of ME/CFS and are house or bed bound.
2899096|NCT03254823||Household controls|Healthy human participants who are either related/non-related to, living in the same household or in close proximity to, or providing care to the severe ME/CFS patient they are paired with. They are used as an environmental control.
2899097|NCT03254810|Experimental|SYN060|a single 0.57 mg/kg dose of SYN060
2899098|NCT03254810|Active Comparator|Adalimumab North American source|a single 0.57 mg/kg dose of adalimumab from North American source
2899099|NCT03254810|Active Comparator|Adalimumab European source|a single 0.57 mg/kg dose of adalimumab from European source
2899100|NCT03254797|Experimental|Stepping training with feedback|"Subjects will be instructed to perform the stepping task with external feedback continuously until 20 minutes (excluding resting periods) but without fatigue. Then they continue a training program of overground walking for 10 minutes.~They have to be involved in a training program of their groups 5 times/week, for 4 weeks in total."
2899101|NCT03254797|Active Comparator|Stepping training without feedback|"Subjects will be instructed to perform the stepping task without external feedback continuously until 20 minutes (excluding resting periods) but without fatigue. Then they continue a training program of overground walking for 10 minutes.~They have to be involved in a training program of their groups 5 times/week, for 4 weeks in total."
2899102|NCT03254784|Experimental|Tablet-Capsule Crossover 1|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
2899103|NCT03254784|Experimental|Tablet-Capsule Crossover 2|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
2899104|NCT03254784|Experimental|Tablet-Capsule Crossover 3|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
2899105|NCT03254784|Experimental|Tablet-Capsule Crossover 4|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
2899106|NCT03254784|Experimental|Tablet-Capsule Crossover 5|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
2899107|NCT03254784|Experimental|Tablet-Capsule Crossover 6|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
2899108|NCT03254771|No Intervention|Control group|In the control group, the usual explanation about the disease and the possibilities of treatment will be followed
2899109|NCT03254771|Experimental|Intervention group|In the Intervention group, the Decision Aid (DA) will be presented and explained to the patient by research personnel at a schedule previously agreed with the patient. The patient will be given a paper copy of the (DA) to take home, as well as a web link to the computer application, and oral and written instructions to review the material again and perform value clarification exercises.
2899110|NCT03254758|Experimental|Mesenchymal stem cell|Single dose of ADR-001 (Mesenchymal stem cell)
2899111|NCT03254745|Experimental|Pharmacist intervention|"Disease education (General education about rheumatoid arthritis in a verbal and written manner)~Dietary and lifestyle modifications (General recommendations as well as specific ones based on patients' baseline health status)~Counseling regarding adherence (General lecture on adherence to medications and physical rehabilitation in rheumatoid arthritis as well as specific advice based on patients health status)~Advice on medication use (General counseling on medication use as well as patient centered counseling)."
2899112|NCT03254745|No Intervention|Usual care|Patients will not be counseled by pharmacist and will be allowed to take usual care.
2899113|NCT03254732|Experimental|ADI-PEG 20|This is a phase 1b, open label trial of ADI-PEG 20 (36 mg/m2) weekly in combination with pembrolizumab (1 and 2 mg/kg or 200 mg) every three weeks.
2899186|NCT03254277|Experimental|Group 1B|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 10 mg/kg.
2899114|NCT03254719|Other|Treatment Arm|All participants enrolled in the study will receive chiropractic care consistent with the usual chiropractic procedures for the management of chronic low back pain at the Iowa City VA Health Care System. Participants will also complete study assessments as described in outcomes.
2899115|NCT03254706|Active Comparator|Peak etch-and-rinse (P1)|Application Mode - According to the manufacturer's instructions.
2899116|NCT03254706|Experimental|Peak applied for double time(P2X)|Application Mode - According to the manufacturer's instructions, but for the double time.
2899117|NCT03254706|Active Comparator|Single Link etch-and-rinse (SL1)|Application Mode - According to the manufacturer's instructions.
2899118|NCT03254706|Experimental|Single Link double time (SL2X)|Application Mode - According to the manufacturer's instructions, but for the double time.
2899119|NCT03254693|Active Comparator|1-step self-etch approach (SE)|According to the manufacturer's instructions.
2899120|NCT03254693|Active Comparator|selective enamel etching (SEE)|According to the manufacturer's instructions.
2899121|NCT03254693|Experimental|1-step self-etch for double time (SE2X)|According to the manufacturer's instructions, but for the double time (20 s) in the each application.
2899122|NCT03254693|Experimental|1-step self-etch additional layer (SE1+)|According to the manufacturer's instructions, but apply tree times.
2899123|NCT03254680|Experimental|Turmeric Oil|stable dose of orally administered turmeric oil
2899124|NCT03254667||Brodalumad exposed|1500 subjects exposes to brodalumab
2899125|NCT03254667||Comparator Subjects|2000 comparator subjects
2899126|NCT03254654|Experimental|Vinorelbine Plus Apatinib|"Vinorelbine: 20 mg/m2, D6, D13, D20~Apatinib: 250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2."
2899127|NCT03254654|Active Comparator|Vinorelbine|Vinorelbine: 25 mg/m2, D1, D8, D15
2899128|NCT03254641||hypogondal men|men referred for hCG stimulation test
2899129|NCT03254628|Experimental|Full - Train/oxy&miso/ B&M/Mentor/Phone|Helping Mothers Survive- Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask, designation of Clinical Mentor in each facility to support deliberate practice, phone-based support from district trainer for Clinical Mentor.
2899130|NCT03254628|Experimental|Partial - Train/oxy & miso/ B&M/Mentor|Helping Mothers Survive - Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask, designation of clinical mentor in each facility to support deliberate practice.
2899131|NCT03254628|Active Comparator|Comparison - Train/oxy & miso/ B&M|Helping Mothers Survive - Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask,.
2899132|NCT03254615|Experimental|Group 1|"Group I will receive I Prefer Plain Water only during the first grade"
2899133|NCT03254615|Experimental|Group 2|"Group II will receive I Prefer Plain Water during first and second grades"
2899134|NCT03254615|Experimental|Group 3|"Group III will receive I Prefer Plain Water during first, second, and third grades"
2899135|NCT03254602|Experimental|Intense Therapeutic Ultrasound Treatment|Intense Therapeutic Ultrasound treatment applied along the length and width of the proximal Plantar Fascia. 1000 - 5 Joule pulses were applied twice, four weeks apart.
2899136|NCT03254589|Experimental|Group 1|Newly diagnosed RA patients started on subcutaneous MTX - open randomisation vs. sulfasalazine. In this group, use of NSAIDs, steroids, and/or other DMARDs, is allowed, if indicated, for symptom control. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice .
2899137|NCT03254589|Active Comparator|Group 2|Newly diagnosed RA patients started on sulfasalazine - open randomisation vs. subcutaneous MTX. In this group, use of NSAIDs, steroids, and/or other DMARDs (except MTX), is allowed, if indicated, for symptom control. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
2899138|NCT03254589|Experimental|Group 3|RA patients on long-term treatment (> 1 year) with oral MTX, with or without other DMARDs, NSAIDs and/or steroids, switched to subcutaneous MTX (same dose). In these patients, treatment with other DMARDs, NSAIDs and/or steroids will continue. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
2899139|NCT03254589|Active Comparator|Group 4|RA patients on stable treatment (> 1 year) with other (non-MTX) DMARDs, with or without NSAIDs and/or steroids, and continued on the same treatment. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
2899140|NCT03254576||Children at high-risk for obesity|Healthy-weight children (30th-75thBMI%) with two overweight/obese parents (BMI>25)
2899141|NCT03254576||Children at low-risk for obesity|Healthy-weight children (30th-75thBMI%) with two healthy-weight parents (BMI = 18-24.9)
2899142|NCT03254563||Obese with NAFLD|Patients who have NAFLD based upon ultrasound
2899143|NCT03254563||Obese without NAFLD|Patients who do not have NAFLD based upon ultrasound
2899144|NCT03254537|Experimental|Mediterranean Organic|
2899145|NCT03254537|Experimental|Mediterranean conventional|
2899146|NCT03254524||Patients visiting an emergency department in New York State|
2899147|NCT03254511|Experimental|enoxaparin|In the enoxaparin group, patients are going to receive radiotherapy (median treatment dose will be 50.40 Gy in 25 to 32 fractions) with weekly concurrent chemotherapeutic combinations (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]) with Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable (40 mg daily).
2899148|NCT03254511|Active Comparator|control|In the control group, patients are going to receive radiotherapy (median treatment dose will be 50.40 Gy in 25 to 32 fractions) with weekly concurrent chemotherapeutic combinations (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]) alone.
2899149|NCT03254498|Active Comparator|Endocuff assisted colonoscopy|Participants are randomised to undergo first either with Endocuff or cap assisted colonoscopy during colonoscopy.
2899150|NCT03254498|Placebo Comparator|Cap assisted colonoscopy|Participants are randomised to undergo first either with Endocuff or cap assisted colonoscopy during colonoscopy.
2899154|NCT03254459|Active Comparator|Standard of Care Narcotic Therapy|Morphine intravenous (IV), 4 mg TID for 24 hours, followed by oxycodone hydrochloride tablet, 10 mg TID for 6 days.
2899155|NCT03254446|Experimental|TRC150094 45 mg|TRC150094 45 mg Tablet to be administered orally once a day for 50 weeks
2899156|NCT03254446|Placebo Comparator|Placebo|Matching Placebo Tablet to be administered orally once a day for 50 weeks
2899157|NCT03254433|Experimental|BAS+|As part of the main study, participants will attend 8 counseling sessions and receive a behavioral activation intervention to smoking cessation and to post-cessation weight gain (BAS+).
2899158|NCT03254433|Placebo Comparator|SC|As part of the main study, participants will attend 8 counseling sessions and receive standard smoking cessation counseling (SC).
2899159|NCT03254420|Active Comparator|Image-guided radiation therapy (IGRT) with standard margins|Standard IMRT during 8 weeks
2899160|NCT03254420|Experimental|Calypso tracking system with margin reduction|Standard IMRT during 8 weeks after calypso beacon implant 10 days before
2899161|NCT03254407|Other|Screening medical record|Screening medical record for possible IV-PO switch Possbile IV/PO switch communicated to prescriber by phone or e-note
2899162|NCT03254394|Placebo Comparator|Placebo + FOLFOX|"Intravenous infusion of D5W solution over a 130 minute period.~FOLFOX:~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
2899163|NCT03254394|Active Comparator|Lidocaine + FOLFOX|"Intravenous infusion of lidocaine hydrochloride solution in D5W over a 130 minute period.~FOLFOX:~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
2899164|NCT03254381|Experimental|Aerobic Training|"An outdoor and/or indoor walking program (weather dependent) will be used for this group. Both programs will use a track on campus. Exercise intensity will begin at 40% of one's age specific target heart rate (i.e., heart rate reserve, HRR) and will progress to 60% of HRR over a 5 month period. Once the target of 60% of HRR is achieved, it will be sustained by the participant for the remainder of the intervention period. investigators will monitor heart rate during the exercise, but also subjectively monitor the intensity of workouts using Borg's Rating of Perceived Exertion and the talk test - participants will be asked to initially walk at a pace where they converse comfortably without effort and progress to a walking pace where conversation requires effort."
2899165|NCT03254381|Experimental|Resistance Training|Participants will use programmable weight machines along with free weights to target primary muscle groups. In addition, they will complete mini-squats, mini-lunges, and lunge walks. Participants will complete two sets of 6-8 reps. Training stimulus will be increased using the 7RM method - when 2 sets of 6-8 reps are completed with proper form and without discomfort. Investigators will record the number of sets completed and the load lifted for each exercise for each participant at every class.
2899166|NCT03254381|Experimental|Balance and Tone Training (Control)|Exercises will include stretching exercises, range of motion exercises, basic core-strength exercises, balance exercises, and relaxation techniques. Only bodyweight will be applied (i.e., no additional loading). This group controls for confounding variables such as physical training received by traveling to the training centres, social interaction, and changes in lifestyle secondary to study participation.
2899167|NCT03254368|Experimental|0.05 mg ZGN-1061 (A)|0.05 mg ZGN-1061 subcutaneous injection once every 3 days
2899168|NCT03254368|Experimental|0.3 mg ZGN-1061 (B)|0.3 mg ZGN-1061 subcutaneous injection once every 3 days
2899169|NCT03254368|Experimental|0.9 mg ZGN-1061 (C)|0.9 mg ZGN-1061 subcutaneous injection once every 3 days
2899170|NCT03254368|Experimental|1.8 mg ZGN-1061 (CC)|1.8 mg ZGN-1061 subcutaneous injection once every 3 days
2899171|NCT03254368|Placebo Comparator|Placebo (D)|Placebo subcutaneous injection once every 3 days
2899172|NCT03254355|Experimental|Multimodal physiotherapy|12 weeks of weekly multimodal physiotherapy treatments
2899173|NCT03254355|No Intervention|Waiting-list control group|12 weeks of weekly full-body relaxation massage
2899174|NCT03254342||Major depressive disorder|There is no intervention/treatment in this study.
2899175|NCT03254342||Non-depressed individuals|There is no intervention/treatment in this study.
2899176|NCT03254329||Bangladesh|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
2899177|NCT03254329||Brazil|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
2899178|NCT03254329||Denmark|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
2899179|NCT03254329||The Gambia|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
2899180|NCT03254303|Other|60s (group E)|The Time of catheterization at 60s (group E) was applied in this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 60 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 60 s
2899181|NCT03254303|Other|90s (groupe L)|In this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 90 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 90 s
2899182|NCT03254303|Other|120s (groupe L)|In this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 120 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 120 s
2899183|NCT03254290|Experimental|Experimental NeoMTA|The new formulation of MTA (does not contain bismuth oxide) will be used in one tooth receiving a pulpotomy to determine if the color of the tooth changes over time.The new formulation has received the FDAs 510(k) substantial equivalence clearance for Class II dental materials and is equivalent to its MTA predicate (ProRoot, Dentsply Tulsa Dental, Tulsa, OK, USA).
2899184|NCT03254290|Active Comparator|Formocresol|"Control group. This group will receive the gold standard formulation of a formocresol pulpotomy."
2899185|NCT03254277|Experimental|Group 1A|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 3 mg/kg.
2944359|NCT02942719||The Maternal and Child Health Hospital of Guangxi|
2899187|NCT03254277|Experimental|Group 1C|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
2899188|NCT03254277|Experimental|Group 2B|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml or off ART for at least 8 weeks with HIV-1 plasma RNA levels < 100,000 copies/ml, will be administered one infusion of 3BNC117-LS dosed at 10 mg/kg.
2899189|NCT03254277|Experimental|Group 2C|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml, or off ART for at least 8 weeks with HIV-1 plasma RNA levels < 100,000 copies/ml, will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
2899190|NCT03254264|Experimental|ESDM-12|an experimental group of 60 children receiving 12 hours a week of Early Start Denver Model (ESDM) intervention delivered by trained therapists during 2 years ESDM is a comprehensive relational, developmental and behavioral intervention.It's described in a manual for Professional and parents.
2899191|NCT03254264|Active Comparator|Control group|a control group of 120 children receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
2899192|NCT03254251|Experimental|Stair Climbing (SC)|N=20, 12 weeks of stair climbing exercise training.
2899193|NCT03254251|No Intervention|No Exercise (CON)|N=21, No exercise for 12 weeks
2899194|NCT03254225|Experimental|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
2899195|NCT03254225|No Intervention|Control|
2899196|NCT03254212|Experimental|Oxygen therapy|Fixed nightime oxygen therapy throughout the protocol duration
2899197|NCT03254199|Experimental|Experimental|
2899198|NCT03254199|Placebo Comparator|Placebo Comparator|
2899199|NCT03254186|Experimental|Propranolol Hydrochloride|Two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks then will remain on a stable dose for six weeks. The patients will be treated for eight weeks, complete a one week washout and then crossed over to another arm for eight weeks.
2899200|NCT03254186|Placebo Comparator|Placebo Oral Tablet|Identical placebo. The patients will be treated for eight weeks, complete a one week washout and then crossed over to another arm for eight weeks.
2899201|NCT03254173|Active Comparator|Arm A|Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets ) , as half tablet daily , i.e , 15mg daily , before sleep for a duration of 8 weeks
2899202|NCT03254173|Placebo Comparator|Arm B|Placebo oral tablets , as half tablet daily before sleep for a duration of 8 weeks
2899203|NCT03254160|Experimental|DNS-3379 (0.5mg)|
2899204|NCT03254160|Experimental|DNS-3379 (2.5mg)|
2899205|NCT03254160|Placebo Comparator|Placebo|
2899206|NCT03254147||patients prescribed with Oral Anti-Coagulants|warfarin and non-vitamin K dependent oral anti-coagulants
2899207|NCT03254134||Atrial Fibrillation|patients with atrial fibrillation
2899208|NCT03254121||Patients with SVR and developed HCC|HCV patients with SVR and developed HCC plus available tissue from HCC
2899209|NCT03254108|Experimental|OPC-61815 injection 2mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
2899210|NCT03254108|Experimental|OPC-61815 injection 4mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
2899211|NCT03254108|Experimental|OPC-61815 injection 8mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
2899212|NCT03254108|Experimental|OPC-61815 injection 16mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
2899213|NCT03254108|Active Comparator|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
2899214|NCT03254082|Experimental|F-1000 (fontanelle flour)|Fontenel sorghum flour
2899215|NCT03254082|Experimental|Sumac|Sumac sorghum flour
2899216|NCT03254082|Experimental|Wheat|Wheat flour
2899217|NCT03254082|Experimental|MMR|MMR cultivar of sorghum flour -- from MMR Genetics, a company that produces sorghum seed.
2899218|NCT03254082|Active Comparator|Sucrose|Table sugar
2899219|NCT03254069|Experimental|Stainless Steel Crown Arm|Children with SSCs placed and followed longitudinal. Consent was obtained from all parents and verbal assent was obtained. The following data was collected: Demographic Data of the Children, clinical examination, radiographs, treatment planning, details of stainless steel crowns placement, OBF measurements were made before the SSC placement and periodically post placement
2899220|NCT03254069|No Intervention|Control Arm|A second group consisted of twenty-two children (11 females and 11 males; a mean age of 5.20 ± 0.36 years) were selected to act as a control sample and received no dental treatment. MOBF was recorded in these subjects at T0 and T5 (6 months after).
2899221|NCT03254056|Active Comparator|Conventional Technique|The edges of the fascia will be hold by the surgical instruments. The fascial defect will be repaired by using devices which are generated for laparotomy operations.
2899222|NCT03254056|Active Comparator|Berci Technique|This instrument facilitates full thickness abdominal wall closure under the view of laparoscopic optic.
2899223|NCT03254043|Active Comparator|Treatment-as-Usual|Participants will routine methadone clinic care.
2899224|NCT03254043|Experimental|"Take-home Dosing using MedMinder Jon Electronic Pill Box"|Participants will receive 50% of their methadone dose in the morning in the clinic and 50% of their dose will be dispensed in an electronic pill box for participants to take at home later that day.
2899225|NCT03254043|Other|Choice Phase|"Participants will be allowed to select one final Treatment-As-Usual or the MedMinder Jon Electronic Pill Box for the final phase of the study."
2899226|NCT03254030|Placebo Comparator|Inspection on withdrawal|Participants colonic mucosa will be examined only during withdrawal phase of the examination.
2899227|NCT03254030|Active Comparator|Inspection on insertion and withdrawal|Participants colonic mucosa will be examined during insertion and withdrawal phase of the examination
2899228|NCT03254017|Experimental|Experimental Deep Brain Stimulation|Device：Suzhou Sceneray® DBS system
2899229|NCT03254004|Experimental|single arm: pembrolizumab|pembrolizumab 200 mg every 3 weeks
2899231|NCT03253978|Experimental|SABR to prostate / seminal vesicles with pelvic ENI|36.25Gy / 5 fractions to prostate and seminal vesicles with additional SABR (25Gy /5 fractions) delivered to the pelvic nodes.
2899232|NCT03253978|Active Comparator|SABR to prostate and seminal vesicles only|36.25Gy / 5 fractions to prostate and seminal vesicles.
2899233|NCT03253965|Experimental|Walking: Treadmill then Overground|Walking while receiving auditory cueing intervals from a metronome and music. Testing performed using metronome normal, metronome slow, and metronome fast speed settings as well as music normal, music slow, and music fast tempos. Subjects will also walk with no auditory cueing.
2899234|NCT03253965|Experimental|Walking: Overground, then Treadmill|Walking while receiving auditory cueing intervals from a metronome and music. Testing performed using metronome normal, metronome slow, and metronome fast speed settings as well as music normal, music slow, and music fast tempos. Subjects will also walk with no auditory cueing.
2899235|NCT03253952||Traumatic Spinal Cord Injury|Observational study - monitoring immune response and heart rate variability
2899236|NCT03253952||Traumatic Spine Fracture, Control Group|Observational study - monitoring immune response and heart rate variability acting as a control group.
2899237|NCT03253939||Case group|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
2899238|NCT03253939||Control group|Cytoreductive surgery alone
2899239|NCT03253926|Experimental|Lorcaserin + Marijuana|
2899240|NCT03253926|Placebo Comparator|Placebo + Marijuana|
2899241|NCT03253913|Experimental|Treatment Arm|"Resveratrol 250mg daily for the first 8 weeks, followed by 250mg twice daily for the next 8 weeks, and then 500mg twice daily for the last 8 weeks.~Patients will be on a stable background therapy of sirolimus prior to enrolling and will continue on that regimen throughout the study."
2899242|NCT03253900|Experimental|Experimental group|A group of rowers to be administered to intervention on a Stable rowing simulator, a Slides based rowing simulator or a Tilt board based rowing simulator.
2899243|NCT03253887|Experimental|Ethanol-lock|This group received daily alcohol 70% (ethanol-lock) with intraluminal alcoholization of both lumens of the central venous catheters
2899244|NCT03253887|No Intervention|Comparative|This group did not receive the ethanol-lock, being only followed daily.
2899245|NCT03253874|Experimental|Intervention Site-LAC+USC Medical Center|In this arm or study site,new guidelines are disseminated to all residents attending and faculty physicians within the department of Ophthalmology and Anesthesiology. New guidelines call for the across the board elimination of pre-operative testing and visits for patients undergoing cataract surgery.
2899246|NCT03253874|No Intervention|Control Site--Harbor-UCLA Medical Center|In this arm or study site, patients will undergo standard of care for cataract surgery without any new guidelines.
2899247|NCT03253861||control patients|patients without an infected pancreatic necrosis
2899248|NCT03253861||Case patients|patients with an infected pancreatic necrosis
2899249|NCT03253848||Observational (simplified guidelines and support)|Patients receive standard of care treatment for APL. Patients? doctors regularly discuss with an APL expert to identify and mange treatment.
2899250|NCT03253835||Myocardial Injury|patients with myocardial injuries due to ischemic heart disease, patients with myocardial injuries due to non-ischemic heart disease.
2899251|NCT03253835||No Myocardial Injury|subjects without myocardial injuries with normal cardiac function subjects without myocardial injuries with altered cardiac function
2899252|NCT03253822|Experimental|Intervention group|"This group receives a baseline questionnaire before their screening invitation. Respondents are included, and those receiving a screening reminder receive the decision aid.~At least three months after their screening invitation the included citizens (baseline questionnaire respondents) will receive a follow-up questionnaire."
2899253|NCT03253822|No Intervention|Control group|This group receives a baseline questionnaire before their screening invitation. Respondents are included. At least three months after their screening invitation, baseline questionnaire respondents will receive a follow-up questionnaire.
2899254|NCT03253822|No Intervention|Historic cohort|A group of people already invited for colorectal cancer screening. This group receives a questionnaire at least three months after their screening invitation. Respondents are included in the study.
2899255|NCT03253809|Experimental|Coronary Sinus Branch Pacing|"After cannulation, pacing impulses will be delivered via a Biotronik Vision Guidewire to 3 sites (apical, mid ventricular, and basal) within each coronary sinus branch receiving venous blood from the anterior, lateral and posterior regions of the ventricle.~ECG signals will be saved digitally for analysis"
2899256|NCT03253796|Experimental|Open-label (OL) GLM SC QM ---> PBO SC QM|In Period 1 participants are treated with OL GLM SC QM; followed by Period 2 where participants are treated with placebo (PBO) SC QM
2899257|NCT03253796|Experimental|OL GLM SC QM ---> DB GLM SC QM|In Period 1 participants are treated with OL GLM SC QM; followed by Period 2 where participants are treated with double-blinded (DB) GLM SC QM
2899258|NCT03253796|Experimental|OL GLM SC QM ---> DB GLM SC Q2M|In Period 1 participants are treated with OL GLM SC QM; followed by Period 2 where participants are treated with DB GLM SC Q2M
2899259|NCT03253770|Experimental|Digital Cognitive Aid|The digital cognitive aid is designed as a smartphone app. Intervention : cognitive aid in the hand of the leader during crises management.
2899260|NCT03253770|Experimental|No digital aid|No cognitive aid in the hand of the leader during crises management. Intervention : no cognitive aid in the hand of the leader during crises management.
2899261|NCT03253770|Experimental|Paper Cognitive Aid|"The paper cognitive aid is the document officially recommended to be used in case of crises by the French Society of Anaesthesia and Intensive Care.~Intervention : paper cognitive aid in the hand of the leader during crises management."
2899262|NCT03253744|Experimental|1/Tumor Irradiation|SBRT will be delivered to areas of recurrent prostatecancer identified on imaging and biopsy
2899263|NCT03253744|Experimental|2/Prostate and Tumor Irradiation|SBRT will be delivered to areas of recurrent prostatecancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate
2899264|NCT03253731||Healthy Volunteers|15 healthy volunteers
2899265|NCT03253718||Healthy Volunteers|STDT: 50 HV sASR: 50 HV s
2899266|NCT03253705||Healthy Volunteers|Healthy Volunteers who donate samples of assay development
2899267|NCT03253705||Researach Subjects|Research Subjects who donate samples of assay development
2899268|NCT03253692||Patients|People ages 18 years and older who need a computed tomography (CT) scan of the heart.
2899269|NCT03253679|Experimental|Treatment (WEE1 inhibitor AZD1775)|Patients receive WEE1 inhibitor AZD1775 PO QD on days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2899270|NCT03253666||Nurses' Health Study|"See Detailed Description"
2899271|NCT03253666||Health Professionals Follow-Up Study|"See Detailed Description"
2899272|NCT03253653|Experimental|Waterpipe smoking|In a repeated measures design, 50 adult male and female exclusive WP smokers will smoke WP tobacco weekly over a 3-week study period with 3 WP smoking practices.
2899273|NCT03253653|No Intervention|Control|A total of 25 adult make and female nonsmokers will be recruited as a control.
2899274|NCT03253640||Patients with HAI during hospital stay|Patients who meet the European Centre for Disease Control (ECDC) Healthcare Associated Infection (HAI) case definitions. Case note review will be undertaken during hospital stay. Questionnaire will be administered at recruitment, pre-discharge, one, three, six and twelve months post discharge.
2899275|NCT03253640||Patients without HAI during hospital stay|Patients who do not meet the European Centre for Disease Control (ECDC) Healthcare Associated Infection (HAI) case definitions. Case note review will be undertaken during hospital stay. Questionnaire will be administered at recruitment, pre-discharge, one, three, six and twelve months post discharge.
2899276|NCT03253627|Experimental|MBSR|Mindfulness-Based Stress Reduction
2899277|NCT03253627|Active Comparator|HEP|Health Enhancement Program
2899278|NCT03253614||Exposed group|250 children aged 6-15 years exposed to gentamicin in the neonatal period
2899279|NCT03253614||Control group|25 healthy children aged 6-15 years NOT exposed to gentamicin in the neonatal period
2899280|NCT03253601|Experimental|Strategy Training: iADAPTS Application|Participants will use the iADAPTS mobile health application to supplement to in-person and remote intervention sessions.
2899281|NCT03253601|Active Comparator|Strategy Training: Workbook|Participants will use a printed workbook to supplement to in-person and remote (by telephone) intervention sessions.
2899282|NCT03253575||Squamous Carcinoma of the Head and Neck (HNSCC)|"1st line metastatic/locally advanced~2nd line metastatic/locally advanced"
2899283|NCT03253575||Triple Negative Breast Cancer (TNBC)|1. Triple Negative Breast Cancer (TNBC) A 1st line metastatic/locally advanced B ≥2nd line metastatic/locally advanced
2899284|NCT03253575||Non-small Cell Lung Cancer (NSCLC)|1. Non-small Cell Lung Cancer (NSCLC) A ≥2nd line Stage 3B or 4
2899285|NCT03253575||Epithelial Ovarian Cancer (EOC)|1. Epithelial Ovarian Cancer (EOC) A 2nd line platinum-resistant Stage 3 or 4 B 2nd line platinum-sensitive Stage 3 or 4 C ≥3rd line platinum-sensitive Stage 3 or 4
2899286|NCT03253575||Colorectal Cancer (CRC)|1. Colorectal Cancer (CRC) A 1st line Stage 4 B Recurrent or progressive disease following treatment with both oxaliplatin- and irinotecan-containing regimens
2899287|NCT03253562|No Intervention|Healthy control|healthy volunteers not suffering from diabetes or hypertension
2899288|NCT03253562|No Intervention|diabetic hypertensive recently diagnosed patients|recently diagnosed patients suffers from diabetes type 2 and hypertension but didnot receive their proper treatment yet
2899289|NCT03253562|Other|Metformin treated group|diabetic hypertensive patients which were treated with captopril for their hypertension and metformin for their diabetes
2899290|NCT03253562|Other|Vildagliptin treated group|diabetic hypertensive patients which were treated with captopril for their hypertension and vildagliptin for their diabetes
2899291|NCT03253549|Experimental|SMArTVIEW|
2899292|NCT03253549|No Intervention|Standard Care|
2899293|NCT03253536||entire cohort|none (observational study)
2899294|NCT03253523|No Intervention|Continued maximal medical management|
2899295|NCT03253523|Experimental|Surgical occipital nerve neurolysis|
2899296|NCT03253510|Experimental|Poly-amide|new thermoplastic material used as a denture base, that has excellent ethetics and flexibility
2899297|NCT03253510|Active Comparator|poly-methyl methacrylate|Polymethylmethacrylate is one of the most widely used denture base material, because of its good biocompatibility, reliability and dimensional stability
2899298|NCT03253497|Active Comparator|Chlorhexidine- benzidamine|before 15 minute anesthesia induction Chlorhexidine-benzidamine spray will be administrated to oropharynx
2899299|NCT03253497|No Intervention|Control|before 15 minute normal salin will be administrated to oropharynx
2899300|NCT03253484|Experimental|NAFL-treated wounds|NAFL treated wounds
2899301|NCT03253484|No Intervention|Control|untreated control wound
2899302|NCT03253471|Experimental|AL-611|
2899303|NCT03253471|Placebo Comparator|Placebo to Match AL-611|
2899304|NCT03253458|Experimental|Optical imaging|All consenting patients will undergo Confocal Laser Endomicroscopy or Optical Coherence Tomography imaging prior to biopsy or surgery.
2899305|NCT03253445|Experimental|Acceptance and commitment therapy|All participants are given a brief educational talk on encouraging quitting smoking, a self-help leaflet on smoking cessation and an additional 10-session face-to-face ACT on a weekly basis.
2899306|NCT03253445|Placebo Comparator|Control|All participants are given a brief educational talk on encouraging quitting smoking , a self-help leaflet on smoking cessation and 10-sessions of face-to-face social support on a weekly basis.
2899307|NCT03253432||Strata 0-0.05|Lowest probability of having familial hypercholesterolemia
2899308|NCT03253432||Strata 0.06-0.15|Second lowest probability of having familial hypercholesterolemia
2899309|NCT03253432||Strata 0.16-0.19|Moderate probability of having familial hypercholesterolemia
2899310|NCT03253432||Strata 0.20-0.34|Second highest probability of having familial hypercholesterolemia
2899311|NCT03253432||Strata greater than or equal to 35|Highest probability of having familial hypercholesterolemia
2899312|NCT03253419|Other|Home Safety Application|Use of Home Safety application as part of assessment for home safety. The only intervention is the use of the home safety application and identification of home safety issues by the patient using this application.
2899313|NCT03253406|Experimental|Polar M400 + Facebook Group (PM400+FG)|Will be provided a Polar M400 to track physical activity and energy expenditure while also being included in a Facebook group wherein Social Cognitive Theory-based physical activity and nutritious eating tips will be provided twice weekly for 12 weeks.
2899314|NCT03253406|Active Comparator|Facebook Only Group (FG)|Included exclusively in a separate, but content-identical, Facebook group for 12 weeks.
2899315|NCT03253393|Experimental|Smart Touch Technology Contact Lens|
2899316|NCT03253393|Active Comparator|Contact Lens in Conventional Packaging|
2899317|NCT03253380|Experimental|early rehabilitation program on mechanical ventilated COPD pat|compare the effect of early rehabilitation program on mechanical ventilated COPD patient in RICU to those using current standard care as regarding (morbidity and thirty day mortality ,diaphragm function and weaning outcomes, disease exacerbation , Duration spent on machin , Length of ICU stay.
2899318|NCT03253367||Current/former clozapine users|This group has only one visit.
2899319|NCT03253367||New clozapine users|This group will be followed for 6 months prospectively.
2899320|NCT03253354|Active Comparator|Pharyngeal stimulation|Pharyngeal stimulation given at 5Hz for 10 minutes
2899321|NCT03253354|Active Comparator|repetitive magnetic stimulation (1Hz)|repetitive transcranial magnetic stimulation at 1Hz applied for 600 pulses
2899322|NCT03253354|Active Comparator|repetitive magnetic stimulation (5Hz)|repetitive transcranial magnetic stimulation at 5Hz applied for 600 pulses
2899323|NCT03253354|Sham Comparator|Sham treatment|Sham repetitive transcranial magnetic stimulation using the coil tilt technique
2899324|NCT03253341|Experimental|Smart Aging Program|Participants will be enrolled into the Smart Aging Program.
2899325|NCT03253341|Active Comparator|Control Group|Participants will be enrolled into group that receives educational materials that reflect the current standard of care.
2899326|NCT03253328|Active Comparator|Active Arm N-acetyl cysteine (NAC)|Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to a standard adult intravenous dose of NAC (1200mg twice a day) for 6 days post-amputation.
2899327|NCT03253328|Placebo Comparator|Placebo Arm|Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to placebo ½ normal saline infusion (twice a day) for 6 days post-amputation.
2899328|NCT03253289|Experimental|Meclizine 100 mg|
2899329|NCT03253276|Active Comparator|Obeticholic Acid|Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.
2899330|NCT03253276|Placebo Comparator|placebos|Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.
2899331|NCT03253263|Experimental|SHP607 250 mcg/kg/24 hours|Participants will receive SHP607 at a dose of 250 microgram (mcg)/kg/24 hours through continuous intravenous (IV) infusion from birth up to postmenstrual age (PMA) 29 weeks +6 days.
2899332|NCT03253263|Experimental|SHP607 400 mcg/kg/24 hours|Participants will receive SHP607 at a dose of 400 mcg/kg/24 hours through continuous IV infusion from birth up to PMA 29 weeks +6 days.
2899333|NCT03253263|No Intervention|Standard Neonatal Care|Neonatal care alone will be provided.
2899334|NCT03253250|Active Comparator|Group A|The subjects will be treated by NAs (ETV, 0.5mg，qd；TDF，300mg，qd；ADV，10mg，qd）for 96 weeks
2899335|NCT03253250|Experimental|Group B|The subjects will be treated by peginterferon alfa-2a （135μg/week）combination with NAs(ETV\TDF\ADV) for 96 weeks.
2899336|NCT03253224|Placebo Comparator|Saline|Patient who received normal saline during the operation
2899337|NCT03253224|Experimental|Magnesium|Patient who received magnesium sulfate during the operation
2899338|NCT03253211||State|North Carolina and South Carolina
2899339|NCT03253211||SCD Patients|
2899340|NCT03253211||Providers|Primary care and emergency department clinicians
2899341|NCT03253211||Year|Baseline, year 2, year 3
2899342|NCT03253198|Active Comparator|Preoperative block plus saline|Preoperative interscalene brachial plexus single-shot block using 25ml of 0.5% Ropivicaine plus postoperative 40cc local infiltration of saline
2899343|NCT03253198|Active Comparator|Preoperative block plus Bupivacaine extended-release liposome|Interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
2899344|NCT03253185|Experimental|SC-007|SC-007 intravenous (IV) (various doses and dose regimens)
2899345|NCT03253172|Placebo Comparator|Placebo|Placebo
2899346|NCT03253172|Experimental|Potassium Chloride|Experimental Arm 1 - Rationale is that most evidence for a positive effect of potassium comes from studies using potassium chloride
2899347|NCT03253172|Experimental|Potassium Citrate|Experimental Arm 2 - Rationale for citrate is that recent evidence indicates that alkali treatment may also be renoprotective.
2899348|NCT03253159|Experimental|Hypnosis group|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room
2899349|NCT03253159|No Intervention|Control group|No special preparation before intravenous general anesthesia induction in the operative room
2899350|NCT03253146||sepsis|"Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.~Organ dysfunction can be identified as an acute change in total SOFA score ≥2 points consequent to the infection.~The baseline SOFA score can be assumed to be zero in patients not known to have preexisting organ dysfunction.~ASOFA score ≥2 reflects an overall mortality risk of approximately 10% in a general hospital population with suspected infection. Even patients presenting with modest dysfunction can deteriorate further, emphasizing the seriousness of this condition and the need for prompt and appropriate intervention, if not already being instituted.~In lay terms, sepsis is a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs."
2899351|NCT03253146||septic shock|Patients with septic shock can be identified with a clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain MAP ≥65 mm Hg and having a serum lactate level >2 mmol/L (18mg/dL) despite adequate volume resuscitation.
2899379|NCT03252977|Sham Comparator|control group|Regimen of IV PCA without considering pain sensitivity The regimen of IV PCA will be determined according to experimental group patient assignments. Pressure pain threshold will not be measured in these patients. Patients will use IV PCA with fentanyl 1000mcg or fentanyl 1500mcg. The determination will be paired to assignment of experimental group.
2900319|NCT03246451|Placebo Comparator|Placebo|Placebo, oral tablet in 14 days and in liquid meal.
2899352|NCT03253133|Experimental|Oxaliplatin|"IP neoadjuvant chemotherapy protocol:~Oxaliplatine will be administered in IP in a total solution of 2L of serum G5%. A continuous infusion pump of Oxycodone would be administered for the entire duration of the intraperitoneal chemotherapy. Perfusion time for the intraperitoneal chemotherapy is estimated but not limited to one and a half hour.~Intravenous chemotherapy protocol:~Associated Intravenous (systemic) chemotherapy is administered during IP chemotherapy including at least LVFU2 (5FU-Leucovorin) or FOLFIRI (5FU-Irinotecan) regimens and targeted therapy if needed."
2899353|NCT03253120|Other|Patient|Patients will drink 5dl of water.
2899354|NCT03253120|Other|Healthy volunteer|Healthy volunteers will drink 5dl of water.
2899355|NCT03253107||responder in palliative chemotherapy|After initial chemotherapy, responder (complete remission, partial remission)
2899356|NCT03253107||non-responder in palliative chemotherapy|After initial chemotherapy, disease progression
2899357|NCT03253107||responder in adjuvant chemotherapy|complete cure and no recurrence at least 1 year after treatment
2899358|NCT03253107||non-responder in adjuvant chemotherapy|non-complete cure or recurrence within 1 year after treatment
2899359|NCT03253094|Active Comparator|Fluconazole|150 mg/day for 1 day
2899360|NCT03253094|Experimental|SCY-078|5 different active dosing groups with 2 different treatment regiments of either 1 or 3 days
2899361|NCT03253081|Active Comparator|PARENT focused intervention|The PF condition will consist of a 90-minute parent group session twice per week. The group will comprise 3 to 4 parents and will focus on psychoeducation and support/well-being for the parent.
2899362|NCT03253081|Active Comparator|CHILD focused intervention|In the CF condition both parent and child will attend the 90-minute session twice weekly. The session will be divided into 30-minute segments and include two 30-minute individualized 1-on-1 sessions with a trained interventionist.
2899363|NCT03253068|Experimental|Pembrolizumab plus amurubicin|Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
2899364|NCT03253055||Male Athletes|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
2899365|NCT03253055||Female Athletes|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
2899366|NCT03253055||Controls|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
2899367|NCT03253042|Experimental|WBV exercise program|8-week exercise program associated with the vibratory platform. Each exercise session will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will be connected at the beginning of each series, set at a vibration frequency of 40 Hertz (Hz) and peak-to-peak amplitude of 4 millimeters (mm) resulting in a peak acceleration of 128 ms2 (12.8 g). This should provide the equivalent of 3600 vertical vibrations, totaling 14400 vibrations per training session.
2899368|NCT03253042|Sham Comparator|Sham WBV exercise program|8-week exercise program in which each session will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
2899369|NCT03253029|Experimental|Treatment|(arm 1) consume five scoops total per day of Pure Encapsulations Branched Chain Amino Acid powder on an outpatient basis (take 2 scoops both in the morning and afternoon and 1 scoop in the evening)
2899370|NCT03253029|Placebo Comparator|Control|(arm 2): control group (no BCAAs provided)
2899371|NCT03253016|Experimental|cervicall cerclage|to test vaginal microbiome distribution in women with cervical cerclage due to cervical incompetence in weeks: 12 14 18 26 32
2899372|NCT03253016|Experimental|vaginal progesterone|to test vaginal microbiome distribution in women treated with vaginal progesterone due to cervical shortening in weeks: 12 14 18 26 32
2899373|NCT03253016|No Intervention|contol|to test vaginal microbiome during pregnancies without cerclage or progesterone
2899374|NCT03253003|Experimental|Audéo B hearing aid line extension|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
2899375|NCT03252990||Optimization subjects|Before the enrollment of the actual study subjects, 5 stable angina pectoris patients that are scheduled for a PCI procedure at the MUMC+ will be included at the MUMC+ for a single PET-MRI scan to optimize the parameters of the coronary PET-MRI scan. All patients will receive standard, guideline-based clinical care, while PET-MRI will be performed as an additional measurement.
2899376|NCT03252990||Patients from the VieCuri hospital|15 NSTEMI or STEMI patients who underwent urgent percutaneous coronary intervention (PCI) of the culprit vessel, who are diagnosed with multivessel coronary disease and are currently scheduled for a second PCI at the VieCuri hospital will be included. These patients will be subjected to an additional 18F-choline PET-MRI examination at the MUMC+ and an additional optical coherence tomography (OCT) examination (during the PCI procedure) at the Viecuri hospital. OCT will be performed as a reference standard to validate 18F-choline PET-MRI for detection of vulnerable plaques in the coronary arteries. All patients will receive standard, guideline-based clinical care, while PET-MRI and OCT will be performed as additional measurements.
2899377|NCT03252990||Patients from the MUMC+|15 NSTEMI patients, who are scheduled for PCI of the culprit lesion at the MUMC+, will be subjected to an additional 18F-choline PET-MRI examination at the MUMC+. Hereby, the culprit coronary vessel and thereby the culprit plaque can be identified by the location of the myocardial infarct, as identified by late enhanced MRI. The investigators will study whether the culprit plaque shows an increased 18F-choline uptake on 18F-choline PET-MRI compared to non-culprit plaques in the other coronary arteries. All patients will receive standard, guideline-based clinical care, while PET-MRI will be performed as an additional measurement.
2899378|NCT03252977|Experimental|Tailored group|Tailored regimen of IV PCA according to pain sensitivity The regimen of IV PCA will be determined according to preoperative pain sensitivity of patients. Pressure pain threshold will be measured preoperatively in these patients using pressure algometer. Patients with low pain threshold will use high dose IV PCA containing fentanyl 1500mcg, while patients with high pain threshold will use low dose IV PCA containing fentanyl 1000mcg.
2899380|NCT03252964|Experimental|Diabetes Management Educational Program|Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.
2899381|NCT03252951|Experimental|Eccentric Training|
2899385|NCT03252938|Experimental|Solid tumors|Biweekly intra-tumoral injections of escalating doses (6 mg, 12 mg, 24 mg and 30 mg) of IMP321 as a monotherapy
2899386|NCT03252938|Experimental|Solid tumors + peritoneal carcinomatosis|Biweekly intra-peritoneal, escalating doses of IMP321 (1 mg, 3 mg, 6 mg, 12 mg and 30 mg)
2899387|NCT03252938|Experimental|solid tumors +chemotherapy|Subcutaneous (s.c.) injections with the optimal dose of IMP321 defined in the AIPAC trial for a maximum of 24 weeks
2899388|NCT03252925|Experimental|Experimental Group|N-Acetylcysteine
2899389|NCT03252925|Placebo Comparator|Control Group|Placebo Oral Tablet
2899390|NCT03252912|Experimental|Biological samples|The CSF samples will be taken at the occasion of the first lumbar puncture performed for clinical purposes (suspected LM). If necessary for the routine diagnosis, a second and a third lumbar puncture will be performed according to the gold standard Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar puncture and transferred at ambient temperature to the Biological Resource Center of the ICM (Jean-Pierre Bleuse, Biobank number BB-0033-00059) to be processed within 1 hour Blood samples will be centrifuged at 3,000 g for 10 minutes at ambient temperature and will be aliquoted in 4 plasma and 4 serum aliquots and then stored at -80°C. Aliquots must be anonymized.
2899391|NCT03252899||Therapists|Physiotherapists/occupational therapists experienced in working with stroke patients.
2899392|NCT03252899||Subacute stroke patients|Stroke patients less than 6 months after their stroke suffering from upper limb paresis.
2899393|NCT03252899||Chronic stroke patients|Stroke patients more than 6 months after their stroke suffering from upper limb paresis.
2899394|NCT03252886|Active Comparator|DL user|Experienced emergency physicians who primarily use the direct laryngoscopy (DL) for endotracheal intubation during cardio-pulmonary resuscitation.
2899395|NCT03252886|Active Comparator|VL user|Experienced emergency physicians who primarily use the videolaryngoscopy (VL) for endotracheal intubation during cardio-pulmonary resuscitation.
2899396|NCT03252847|Experimental|Low dose AAV-RPGR|Single, subretinal administration of low dose AAV-RPGR
2899397|NCT03252847|Experimental|Intermediate dose AAV-RPGR|Single, subretinal administration of intermediate dose AAV-RPGR
2899398|NCT03252847|Experimental|High dose AAV-RPGR|Single, subretinal administration of high dose AAV-RPGR
2899399|NCT03252834||Patients with endometrial or ovarian cancer|
2899400|NCT03252834||Patients with colorectal cancer|
2899401|NCT03252821|Experimental|High-intensity aerobic training group|High intensity interval training
2899402|NCT03252821|Active Comparator|Resistance training group|Muscle strengthening
2899403|NCT03252821|No Intervention|Control group|Usual care
2899404|NCT03252808|Experimental|TBI-1401(HF10) + Gem/nab-PTX|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and 1000 mg/m^2 Gemcitabine and 125 mg/m^2 Nab-paclitaxel injected by intravenous infusions.
2899405|NCT03252808|Experimental|TBI-1401(HF10) + TS-1 (primary)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and TS-1 administered by oral.
2899406|NCT03252808|Experimental|TBI-1401(HF10) + TS-1 (primary and meta)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and hepatic metastasis in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection or percutaneous injection and TS-1 administered by oral.
2899407|NCT03252795|Experimental|Uterus transplantation|
2899408|NCT03252782|Active Comparator|Functional Treatment|Acrylic Splint Herbst Appliance
2899409|NCT03252782|Active Comparator|Distalization Treatment|Mini-implant-borne Distal Jet Appliance
2899410|NCT03252769|Other|Self-sampling|Invitation to self-sample
2899411|NCT03252756|Placebo Comparator|Placebo|600mg Saline (PO) for 4 weeks, immediately followed by 1200mg Saline/ day (PO) for an additional 4 weeks (8 total weeks).
2899412|NCT03252756|Experimental|Phytocannabinoid cannabidiol (CBD)|600mg CBD/day (PO) for 4 weeks, immediately followed by 1200mg CBD/day (PO) for an additional 4 weeks (8 total weeks).
2899413|NCT03252743|Experimental|Internet-delivered CBT|Exposure-based internet-delivered CBT with ten weekly modules distributed over the internet during ten weeks, and weekly therapist support over the internet.
2899414|NCT03252730|Experimental|WO 4260 Cosmetic Product for Topical Use|WO 4260 is used to treat dry and itchy scalp
2899415|NCT03252717|Experimental|blood sample|Pre-treatment blood samples will be collected: 8 samples
2899416|NCT03252704|Experimental|High fiber - low fiber|Treatment order described in arm title, resistant starch (high fiber muffin top) - conventional flour (low fiber muffin top)
2899417|NCT03252704|Experimental|low fiber - high fiber|Treatment order described in arm title, conventional flour (low fiber muffin top)- resistant starch (high fiber muffin top)
2899418|NCT03252678|Experimental|A Book and Videos about ACP|Subjects in experimental group get a book of 45 pages and three videos about advanced care planning based on Smart Management Strategy for Health (SMASH). After they finish reading and watching the materials, they fill out the questionnaire.
2899419|NCT03252678|Active Comparator|A Book and Videos about Pain Control|Subjects in the group get a book and two videos about pain control for cancer patients. After they finish reading and watching the materials, they fill out the questionnaire.
2899420|NCT03252665|Experimental|alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
2899421|NCT03252665|Experimental|nicorandil|nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
2899422|NCT03252665|Placebo Comparator|nitroglycerin|nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
2899423|NCT03252639||Patients with Renal Artery Stenosis|Patients with renal artery stenosis which may benefit from endovascular treatment will be recruited. Those patients who cannot benefit from this procedure will be excluded.
2899424|NCT03252626|Active Comparator|Alprostadil|Based on the standard medical care, 2ml of Alprostadil
2899425|NCT03252626|Placebo Comparator|Normal saline|Based on the standard medical care, 2ml of 0.9% saline as the placebo
2899426|NCT03252600|Experimental|Arm I (lenalidomide, dexamethasone, elotuzumab)|"Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on days 1, 8, 15, and 22 of courses 1 and 2 and days 1 and 15 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
2899427|NCT03252600|Experimental|Arm II(lenalidomide,dexamethasone,elotuzumab,cyclophosphamide)|"Patients receive lenalidomide, dexamethasone, and elotuzumab as in Arm I. Patients also receive cyclophosphamide IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
2899428|NCT03252587|Experimental|BMS-986165 Dose 1 oral administration|
2899429|NCT03252587|Experimental|BMS-986165 Dose 2 oral administration|
2899430|NCT03252587|Experimental|BMS-986165 Dose 3 oral administration|
2899431|NCT03252587|Placebo Comparator|Placebo oral administration|
2899432|NCT03252574|Other|Sequence AB|No mask, followed by AIR+ Smart Mask only (A), then AIR+ Smart Mask with micro-ventilator (B)
2899433|NCT03252574|Other|Sequence BA|No mask, followed by AIR+ Smart Mask with micro-ventilator (B), then AIR+ Smart Mask only (A).
2899434|NCT03252561|Experimental|TAP block|Patients in this arm will receive ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
2899435|NCT03252561|Active Comparator|Local anaesthetic infiltration|Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
2899436|NCT03252535|Experimental|Cellavita HD Lower Dose|The participants randomized to this group will receive a total of 9 intravenous administrations of 1x10^6 cells/kg body weight divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
2899437|NCT03252535|Experimental|Cellavita HD Higher Dose|The participants randomized to this group will receive a total of 9 intravenous administrations of 2x10^6 cells/kg body weight divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
2899438|NCT03252535|Placebo Comparator|Placebo Group|The participants randomized to this group will receive a total of 9 intravenous administrations divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
2899439|NCT03252522|Experimental|Intervention|Will receive capsules with blend of vitamins, minerals, amino acids and antioxidants
2899440|NCT03252522|Placebo Comparator|Placebo|Will receive placebo capsules
2899441|NCT03252509|Experimental|Percutaneous radiologic gastrostomy.|Outpatient percutaneous radiologic gastrostomy in patients with head and neck tumors before, during or after the oncologic treatment.
2899442|NCT03252496|Experimental|Combination|250 mL colloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL colloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.
2899443|NCT03252496|Active Comparator|Crystalloid|250 mL crystalloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL crystalloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.
2899444|NCT03252483|Active Comparator|HIV Only|Those randomized to the control group were offered only an HIV test.
2899445|NCT03252483|Experimental|Bundled HCV/HIV|Those randomized to the intervention group were offered both HCV and HIV test.s
2899446|NCT03252470||2D laparoscopic surgeries|Two-Dimensional Laparascopic Surgical Video System
2899447|NCT03252470||3D laparoscopic surgeries|Three-Dimensional Laparascopic Surgical Video System
2899448|NCT03252457|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take decitabine in combination with dexamethasone at the indicated dose
2899449|NCT03252457|Active Comparator|single treatment group|100 enrolled patients are randomly picked up to take dexamethasone at the indicated dose
2899450|NCT03252444|Experimental|Biofeedback group|After 1 minute of rest, participants will perform 6 trials of bilateral, active, weighted arm elevation in the scapular plane and a therapist classifies the scapular motion into specific patterns of scapular dyskinesis. After the evaluation of scapular dyskinesis, the kinematics and surface EMG (sEMG) data will be collected during 5 trials of the same arm movements and 3 selected exercises.
2899451|NCT03252444|Active Comparator|Conscious control group|Conscious correction of scapular orientation will be taught to the subjects in the manner described in previous studies. The starting position is determined in each individual by actively positioning the scapula between maximal upward and downward rotation, external and internal rotation, and posterior and anterior tilt. Scapular assistance test (SAT) is also conducted by passively assisting patients' scapula into appropriate position to correct scapula dyskinesis
2899452|NCT03252431|Experimental|F-627|F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.
2899453|NCT03252431|Active Comparator|Neulasta|6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles
2899454|NCT03252418|Experimental|ascorbic acid|injection of 1 ml intamucosal ascorbic acid 3 times with 1 week interval
2899455|NCT03252418|Experimental|diode laser|photothermolysis by diode laser in one session
2899456|NCT03252405|Active Comparator|mask ventilation|induction is made with mask ventilation
2899457|NCT03252405|Experimental|intravenous induction|induction is made with intravenous cannulation
2899848|NCT03249714|Placebo Comparator|Placebo arm|Placebo subcutaneous injection matching to ofatumumab every 4 weeks for 24 weeks
2899458|NCT03252392||children with autism spectrum disorder|Children aged 3-12 years diagnosed to have mild to moderate autism spectrum disorder diagnosed by childhood autism spectrum disorder(CARS 35% or less)
2899459|NCT03252392||healthy non autistic age matched volunteers|children aged 3-12 years old never diagnosed to have autism spectrum disorder
2899460|NCT03252379|Experimental|Group A|Patients undergoing modified hepaticojejunostomy with gastric access loop
2899461|NCT03252379|Experimental|Group B:|Patients undergoing modified hepaticojejunostomy with subcutaneous access loop
2899462|NCT03252379|Experimental|Group C:|Group C: Patients undergoing standard hepaticojejunostomy with no endoscopic access loop
2899463|NCT03252366|Active Comparator|GELFOAM (ABSORBABLE GELATIN)|"Sterile Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic.~it act as a space maintainer and alternative to bone filler for new bone formation in the maxillary sinus. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids its effect appears to be more physical than the result of altering the blood clotting mechanism. When placed in soft tissues, GELFOAM is usually absorbed completely within four to six weeks, without inducing excessive scar tissue"
2899464|NCT03252366|Active Comparator|XENOGRAFT (TUTOGEN)|xenografts as a sinus bone replacement graft ,The osteoconductive properties of xenografts in human sinus grafting have been well documented. They are due to both their chemical composition and their macro and micro morphology.The efficacy of xenografts as a sinus bone replacement graft may be due to combination of factors. Foremost would be the osteoconductive capacity of xenografts. In addition, they supply minerals that are necessary for bone formation, their density provides stability to the graft and the implants placed in them, and this density persists long term due to the fact that these grafts do not completely resorb.
2899465|NCT03252353|Active Comparator|Octreotide capsules|Octreotide capsules
2899466|NCT03252353|Placebo Comparator|Matching Placebo|Matching placebo capsules
2899467|NCT03252340||Drug: ADSTEM Inj.|Participants in Phase I clinical trials treated with ADSTEM Inj.
2899468|NCT03252327|No Intervention|routine care|Preterm infants in the control condition will receive only usual neonatal intensive care units (NICU) care
2899469|NCT03252327|Experimental|Multiple Sensory Integrations(1)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
2899470|NCT03252327|Experimental|Multiple Sensory Integrations(2)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
2899471|NCT03252327|Experimental|Multiple Sensory Integrations(3)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
2899472|NCT03252314||Subjects with ruptured aneurysms|
2899473|NCT03252288|No Intervention|No intervention|No intervention
2899474|NCT03252288|Experimental|Reminders only|Reminders are sent 1 week and 1 day before each scheduled vaccination date
2899475|NCT03252288|Experimental|Reminders + Conditional financial transfer|Reminders are sent 1 week and 1 day before each scheduled vaccination date; and conditional financial transfers are made for each on-time vaccination visit
2899476|NCT03252275|Experimental|Intervention|Standard HBB and ECEB training with peer learning
2899477|NCT03252275|No Intervention|Control|Standard HBB and ECEB training only
2899478|NCT03252262|Active Comparator|Jack Satter House|Residents of Jack Satter House who participated in the Vitalize 360 Program.
2899479|NCT03252262|Active Comparator|Center Communities of Brookline|Residents of Center Communities of Brookline who participated in the Vitalize 360 Program.
2899480|NCT03252262|Active Comparator|Simon C. Fireman|Residents of Simon C. Fireman who participated in the Vitalize 360 Program
2899481|NCT03252249|Active Comparator|3 months dual anti-platelet therapy|3 months dual anti-platelet therapy is the intervention.
2899482|NCT03252249|Active Comparator|12 months dual anti-platelet therapy|12 months dual anti-platelet therapy is the intervention.
2899483|NCT03252236|Experimental|Tai Chi|Subjects in this group were trained with Tai Chi exercise. The training lasted for 12 weeks, one hour per session and twice a week. Subjects were asked to practice outside of the class 30 minutes at least once a week.
2899484|NCT03252236|Active Comparator|Conventional exercise|Subjects in this group were trained with conventional exercises. Subjects were also asked to practice the exercises outside of the class 30 minutes at least once a week
2899485|NCT03252236|No Intervention|Control|No training was given to the subjects in this group
2899486|NCT03252223|Active Comparator|Women with normal menses|
2899487|NCT03252223|Active Comparator|Women with Polycystic Ovary Syndrome|
2899488|NCT03252210|Experimental|Stereoscopic Versus Methylene Blue|"In the same participant,we perform both Stereoscopic and Methylene Blue localization。Then，compare the distance between the methylene blue's anchor point and the location of lesion,stereoscopic Localization's anchor point and the location of lesion,methylene blue's anchor point and stereoscopic Localization's anchor point.~Post Hoc Multiple Comparisons"
2899489|NCT03252197|Experimental|New device group|participants who are tested performance for ultrasound guided cannulation using device
2899490|NCT03252197|Active Comparator|Conventional group|participants who are tested performance for ultrasound guided cannulation using conventional method
2899491|NCT03252184|Experimental|Low level laser therapy (G1)|Low level laser therapy with energy dose of 2J will be applied on left brachial artery of the subject.
2899492|NCT03252184|Experimental|Low level laser therapy (G2)|Low level laser therapy with energy dose of 4J will be applied on left brachial artery of the subject.
2899493|NCT03252184|Experimental|Low level laser therapy (G3)|Low level laser therapy with energy dose of 6J will be applied on left brachial artery of the subject.
2899494|NCT03252184|Placebo Comparator|Placebo low level laser therapy (G4)|Low level laser therapy with equipment turn off (placebo) be applied on left brachial artery of the subject.
2899495|NCT03252171|Experimental|Experimental: CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen by infusion.
2899496|NCT03252171|No Intervention|No Intervention|
2899651|NCT03251092|Active Comparator|MAD PTI-808 Active|Three cohorts of MAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
2899497|NCT03252158|Experimental|Decrease less healthy item availability|"Intervention: Availability of healthier vs. less healthy foods~Remove less healthy items in 20% of slots, then fill the empty slots with healthier items."
2899498|NCT03252158|Experimental|Decrease healthier item availability|"Intervention: Availability of healthier vs. less healthy foods~Remove healthier items in 20% of slots, then fill the empty slots with less healthy items."
2899499|NCT03252145|Experimental|Negative Pressure|PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb
2899500|NCT03252145|Active Comparator|Manual Lymph Drainage|Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb
2899501|NCT03252132|Active Comparator|12-week resistance training|
2899502|NCT03252132|No Intervention|No training|
2899503|NCT03252119|No Intervention|standard therapy group|standard treatment of viral bronchiolitis with low flow oxygen.
2899504|NCT03252119|Experimental|high flow humidified oxygen group|treatment of viral bronchiolitis with high flow humidified oxygen therapy.
2899505|NCT03252106|Experimental|Contour augmentation|
2899506|NCT03252093|Experimental|Angiotensin-(1-7)|Intervention: Drug: 200 mcg/kg/day injected subcutaneously once daily for 21 days
2899507|NCT03252093|Placebo Comparator|Placebo for Angiotensin-(1-7)|Intervention: Placebo for Angiotensin-(1-7) injected subcutaneously once daily for 21 days
2899508|NCT03252080|Active Comparator|Education (Group A)|short-intensive education for one month
2899509|NCT03252080|Experimental|Education & holistic management(Group B)|short-intensive education for one month followed with holistic management for 6 months
2899510|NCT03252067|Experimental|azithromycin eyedrop|Each of the subjects' eyes will receive single dose of azithromycin eyedrops and then attribute the time for tear sampling at seven time points up to 24 hours.
2899511|NCT03252054||Patients aged 70 or over|Patients eligible for the study will undergo screening for memory disorders, attention disorders, and malnutrition
2899512|NCT03252015|Experimental|Probe Drug Cocktail (Cohort 1)|Probe Drug Cocktail administered orally on Day -3.
2899513|NCT03252015|Experimental|Lasmiditan+Probe Drug Cocktail (Cohort 1)|Lasmiditan administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7.
2899514|NCT03252015|Placebo Comparator|Placebo+Probe Drug Cocktail (Cohort 1)|Placebo administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7.
2899515|NCT03252015|Experimental|Lasmiditan (Cohort 2)|Lasmiditan administered orally for 7 days.
2899516|NCT03252015|Experimental|Placebo (Cohort 2)|Placebo administered orally for 7 days.
2899517|NCT03252002|Experimental|Single/multiple doses of 10 mg BAY1101042 or placebo|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
2899518|NCT03252002|Experimental|Single/ multiple doses of 20 mg BAY1101042 or placebo|Single oral dose of 20 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
2899519|NCT03252002|Experimental|Single/ multiple doses of 30 mg BAY1101042 or placebo|Single oral dose of 30 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
2899520|NCT03252002|Experimental|Single/ multiple doses of 40 mg BAY1101042 or placebo|Single oral dose of 40 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
2899521|NCT03252002|Experimental|Single/ multiple doses of 50 mg BAY1101042 or placebo|Single oral dose of 50 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
2899522|NCT03252002|Experimental|Optional: Single/multiple doses of 5 mg BAY 1101042 or placebo|Single oral dose of 5 mg BAY1101042 MR tablets or corresponding placebo followed by once daily dosing for 7 days
2899523|NCT03251989||Participants|participants greater than or equal to 18 years of age who self-identify as being diagnosed with an ependymoma.
2899524|NCT03251976|Experimental|Intervention|video decision aid
2899525|NCT03251976|Active Comparator|Usual care|
2899526|NCT03251963|Experimental|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose.
2899527|NCT03251963|Experimental|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose.
2899528|NCT03251950|Experimental|Intervention group|15 week healthy eating and gardening curriculum to be implemented in Osage Nation Early Childhood Programs; 15 week healthy eating parenting curriculum to be implemented online to parents of enrolled children
2899529|NCT03251950|Other|Control group|Wait list control -- to receive intervention after serving as wait list group
2899530|NCT03251937|Experimental|Spinal Cord Stimulation|Spectra WaveWriter SCS System
2899531|NCT03251924|Experimental|BMS-986226|administered intravenously
2899532|NCT03251924|Experimental|BMS-986226 and Nivolumab|administered intravenously
2899533|NCT03251924|Experimental|BMS-986226 and Ipilimumab|administered intravenously
2899534|NCT03251911|Experimental|Ivacaftor (VX770)|Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
2899535|NCT03251898||study group|pregnant women who are diagnosed as PROM or chorioamnionitis and whose gestational age is ≥ 24 weeks
2899536|NCT03251898||control group|pregnant women without PROM and chorioamnionitis
2899537|NCT03251872|Experimental|Drug: Olaparib|Olaparib up to 400 mg BID (100 to 400 mg) for 16 weeks
2899538|NCT03251859|Active Comparator|Standard ticagrelor maintenance dose|Ticagrelor 90 mg twice daily for the first 45 days after myocardial infarction treated with percutaneous coronary intervention.
2899539|NCT03251859|Experimental|Reduced ticagrelor maintenance dose|Ticagrelor 90 mg twice daily for the first 30 days after myocardial infarction treated with percutaneous coronary intervention, then reduction of the maintenance dose to ticagrelor 60 mg twice daily for the next 15 days.
2899540|NCT03251833||obese|Body mass index >30 Kilogram/m2
2899541|NCT03251833||non-obese|Body mass index <30 Kilogram/m2
2899542|NCT03251807|Experimental|Twin-block|The patients in this control group will be treated using the Twin-block appliance.
2899988|NCT03248778|Experimental|disclosure-support counseling|
2899543|NCT03251807|Experimental|Twin-block combined with LIPUS|The patients in this experimental group will be treated using the Twin-block combined with LIPUS (Low-intensity pulsed ultrasound).
2899544|NCT03251794||threatened preterm labor|women presented to the reception unit from 28-37 weeks by regular contractions and opened cervix
2899545|NCT03251781|Experimental|Pulmonary Rehabilitation|Pulmonary Rehabilitation
2899546|NCT03251768|Experimental|Test group|"intervention: rHSA-GCSF 2.4 mg Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2)and Epirubicin(75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（2.4mg）will be injected subcutaneously at at 10 am (±90 min) on the 3th and 7th day of each chemotherapy cycle.After injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 5.0×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration."
2899547|NCT03251768|Active Comparator|Positive control group|"intervention: GCSF Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2)and Epirubicin(75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Granulocyte Colony-Stimulating Factor Injection (5μg/kg/day) will be injected subcutaneously at 10 am (±90 min) from the 3rd of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 5.0×109/L at two contiguous times at least. (The minimum of usage was continuous 7 days ,The maximum of usage was continuous 14 days)"
2899548|NCT03251755|Experimental|Exercise|Exercise promotion using Dao-in (Chinese Yoga)
2899549|NCT03251755|No Intervention|Control|Usually clinical practice
2899550|NCT03251742|Active Comparator|Fontan patient population|
2899551|NCT03251742|Sham Comparator|Healthy volunteers|
2899552|NCT03251729|Experimental|Cerclage|Cervical cerclage placement along with vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.
2899553|NCT03251729|Other|Control|Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.
2899554|NCT03251716|Experimental|berberine adjunctive group|Only one treatment group in this study, without a preset control group,subjects who meet the criteria will entere the berberine adjunctive group
2899555|NCT03251690|Experimental|Switching TDF/FTC/EFV to TDF/FTC/RPV|Switching from Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Efavirenz 600 mg/day (once daily) to Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Rilpivirine 25 mg/day (once daily) Intervention: Tenofovir/Emtricitabine/Rilpivirine
2899556|NCT03251690|Active Comparator|Continuing TDF/FTC/EFV|Continuing Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Efavirenz 600 mg/day Intervention: Tenofovir/Emtricitabine/Efavirenz
2899557|NCT03251677|Active Comparator|Total laparo hysterectomy|Surgical procedure, Hysterectomy (removal of the uterus by laparoscopy)
2899558|NCT03251677|Active Comparator|Mini-lap hysterectomy|Surgical procedure, Hysterectomy (removal of the uterus by mini-laparotomy)
2899559|NCT03251664||Anemic|Hemoglobin <11 g/l
2899560|NCT03251664||Non-anemic|Hemoglobin 11 g/l (and above)
2899561|NCT03251651|Experimental|PPF|Patient who received propofol during the operation
2899562|NCT03251651|Experimental|DEX|Patient who received dexmedetomidine during the operation
2899563|NCT03251625|Placebo Comparator|To assess the effect of multistrain probiotics on abdominal|To assess the effect of multistrain probiotics on abdominal pain using a validated symptom severity score in IBS patients.
2899564|NCT03251625|Placebo Comparator|To assess the efficacy of a multistrain probiotic supplement|To assess the efficacy of a multistrain probiotic supplement as a treatment option for IBS in a tertiary referral centre
2899565|NCT03251612|Other|Treatment|1 drug or a combination of drugs considered standard anticancer treatment is given according to the result of the sensitivity analysis.
2899566|NCT03251599|Sham Comparator|Glyceryl trinitrate 0.2|Drug Intervention Generic name: Glyceryl trinitrate Dosage form: Ampoule for intravenous infusion Dosage: 0.2 mcg/kg/minute Frequency and duration: The infusion will start as soon as the rewarming period starts, will continue throughout the operation and throughout the first 24 hours of the postoperative period.
2899567|NCT03251599|Active Comparator|Glyceryl trinitrate 0.5|Drug Intervention Generic name: Glyceryl trinitrate Dosage form: Ampoule for intravenous infusion Dosage: 0.5 mcg/kg/minute Frequency and duration: The infusion will start as soon as the rewarming period starts, will continue throughout the operation and throughout the first 24 hours of the postoperative period.
2899568|NCT03251586|Experimental|20-29|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
2899569|NCT03251586|Experimental|30-39|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
2899570|NCT03251586|Experimental|40-49|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
2899571|NCT03251586|Experimental|50-59|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
2899572|NCT03251586|Experimental|60-69|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
2899573|NCT03251586|Experimental|70-79|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
2899574|NCT03251586|Experimental|80-89|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
2899575|NCT03251586|Experimental|90-99|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
2899576|NCT03251560|Experimental|Fuke Qianjin capsule|Fuke Qianjin capsule, 2 pills each time,three times a day, orally (0.4g/pill）,for 2months,
2899577|NCT03251560|Placebo Comparator|Placebo oral capsule|placebo pills, 2 pills each time,three times a day, orally, for 2months
2899578|NCT03251547||NovoSeven|Non-hemophiliac patients experienced massive haemorrhage who was treated with recombinant activated factor VII
2899579|NCT03251521||spasticity post-stroke|pain rating during injection with botulinum toxin The pain intensity was rated verbally on a numeric scale
2899580|NCT03251508|Experimental|Peanut OIT/food equivalent|Single arm study with all subjects receiving peanut OIT study drug for the initial 6 months followed by an equivalent amount of peanut food for an additional 6 months.
2899581|NCT03251495|Experimental|Vaxchora Vaccination|Healthy subjects will receive a single dose of oral live cholera vaccine.
2899582|NCT03251482|Experimental|Part 1: Cohort 1 (0.3 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenously (IV) or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
2899583|NCT03251482|Experimental|Part 1: Cohort 2 (0.6 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 0.6 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
2899584|NCT03251482|Experimental|Part 1: Cohort 3 (1.2 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 1.2 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
2899585|NCT03251482|Experimental|Part 1: Optional Cohort 4 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose to be determined (TBD) based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
2899586|NCT03251482|Experimental|Part 1: Optional Cohort 5 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
2899587|NCT03251482|Experimental|Part 1: Optional Cohort 6 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
2899588|NCT03251482|Experimental|Part 2: Group A: JNJ-64179375 A mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose A mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
2899589|NCT03251482|Experimental|Part 2: Group B: JNJ-64179375 B mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose B mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
2899590|NCT03251482|Experimental|Part 2: Group C: JNJ-64179375 C mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose C mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
2899591|NCT03251482|Experimental|Part 2: Group D: JNJ-64179375 D mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose D mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
2899592|NCT03251482|Experimental|Part 2: Group E: JNJ-64179375 placebo IV and apixaban 2.5 mg|Participants will receive JNJ-64179375 placebo (saline) IV as a single dose on Day 1 and apixaban 2.5 mg orally twice a day for 10 to 14 days.
2899593|NCT03251469|Active Comparator|Group 1|intravenous tranexamic acid, 15mg/kg, preoperatively, single dose
2899594|NCT03251469|Placebo Comparator|Group 2|Intravenous normal saline, 100mg, preoperatively, single dose
2899595|NCT03251456|Experimental|Tertiary care|
2899596|NCT03251456|Active Comparator|Usual care|
2899597|NCT03251443|Experimental|Apatinib|A molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
2899598|NCT03251430||Control group|38 patients without gastrectomy , who are similar background in other group, are collected from date Pathologic analysis of primary osteoporosis: investigating age and osteoporosis related changes of bone microstructure by using HR-pQCT (UMIN000023535)
2899599|NCT03251430||Distal Gastrectomy (DG) group|38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
2899600|NCT03251430||Total Gastrectomy (TG) group|38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
2899601|NCT03251417|Experimental|Combination treatment|Combination treatment of irinotecan and apatinib.
2899602|NCT03251404|Active Comparator|Knee Control original|The Knee Control program exercise program will be performed during the warm-up to each football practice (at least twice per week) during the 12 week intervention period.
2899603|NCT03251404|Experimental|Knee Control+|The Knee Control+ is an extension of the original Knee Control exercise program offering a wider selection of exercises (to increase adherence) and more physically challenging exercises (adapted for athletes in the late teens and provide further stimuli to increase player performance and neuromuscular function). The program will be performed during the warm-up to each football practice (at least twice per week) during the 12 week intervention period.
2899604|NCT03251391|Experimental|Cardiac Rehabilitation Group|Participants randomized to this group will undergo cardiac rehabilitation program.
2899605|NCT03251391|Active Comparator|Control Group|Participants randomized to this group will receive care for their condition, conventional therapy, that they would normally receive.
2899606|NCT03251378|Experimental|3 mg Safety Run-In|3 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off
2899607|NCT03251378|Experimental|5 mg Safety Run-In|5 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off
2899608|NCT03251378|Experimental|Fruquintinib Expansion Phase|The fruquintinib dose as the recommended tolerated dose from the safety run-in arms. Dose: Fruquintinib (HMPL-013), (dose to be determined) mg, tablet taken daily, 3 weeks on, 1 week off.
2899609|NCT03251365|No Intervention|Group I, Normal|Group I. After cytoreductive surgery, R0, and intestinal reconstruction, the patient after multidisciplinary study will receive adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
2899610|NCT03251365|Experimental|Group II,experimental.HIPEC-Gemcitabine|• Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
2899652|NCT03251092|Placebo Comparator|MAD PTI-808 Placebo|Three cohorts of MAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
2899611|NCT03251352||TKI Discontinuation Group|The enrolled patients will be undertaking TKI discontinuation under the conditions of informed consent and frequent monitoring according to the clinical guideline.
2899612|NCT03251339|Experimental|MSB11455|
2899613|NCT03251339|Experimental|Neulasta|
2899614|NCT03251326|Experimental|Nabilone|Nabilone capsules (4 mg)
2899615|NCT03251326|Active Comparator|Propranolol|Propranolol capsules (40mg)
2899616|NCT03251326|Experimental|Smoked cannabis|(0.0 and 5.6% THC)
2899617|NCT03251326|Placebo Comparator|Placebo|Placebo capsules
2899618|NCT03251313|Experimental|JS001 120mg+GP|Level 1: JS001 120mg +GP q3w,*6 cycles, then JS001 120mg q3w for maintenance therapy for up to approximately 2 years.
2899619|NCT03251313|Experimental|JS001 240mg+GP|Level 2: JS001 240mg +GP q3w,*6 cycles, then JS001 240mg q3w for maintenance therapy for up to approximately 2 years.
2899620|NCT03251313|Experimental|JS001 480mg +GP|Level 3: JS001 480mg+GP q3w,*6 cycles, then JS001 480mg q3w for maintenance therapy for up to approximately 2 years.
2899621|NCT03251313|Experimental|GP followed by JS001|sequential treatment: Patients receive 6 cycles of GP without JS001 and then receive JS001 maintenance therapy for up to approximately 2 years. JS001 will be given at RP2D.
2899622|NCT03251300|Experimental|group A|daytime dosing of mirabegron
2899623|NCT03251300|Active Comparator|group B|nighttime dosing of mirabegron
2899624|NCT03251287|Active Comparator|Sodium Nitrate|Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
2899625|NCT03251287|Placebo Comparator|Placebo|Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
2899626|NCT03251274|Experimental|machine bathing group|structured machine bathing for 20-min duration at evening.
2899627|NCT03251274|Active Comparator|traditional bathing group|traditional bathing at evening.
2899628|NCT03251261||Specimen collection|
2899629|NCT03251248|Experimental|First MSB11455 Then Neulasta|
2899630|NCT03251248|Experimental|First Neulasta Then MSB11455|
2899631|NCT03251235|Experimental|Treatment Group|Group receives four weekly sessions of CBT prior to experimental testing/ fMRI
2899632|NCT03251235|No Intervention|Waiting Group|Group receives four weekly sessions of CBT after experimental testing/ fMRI
2899633|NCT03251222|Experimental|Dexmedetomidine group|Patients who will receive Dexmedetomidine intranasal prior the sedation with remifentanil
2899634|NCT03251222|Placebo Comparator|Placebo Concentrate|Patients will recive 0.9% NaCl
2899635|NCT03251209|Experimental|Group 1|Post-stroke participants receive the mental practice before the physical practice. The activities will be presented in a videotherapy way.
2899636|NCT03251209|Experimental|Group 2|Post-stroke participants receive the mental practice after the physical practice. The activities will be presented in a videotherapy way.
2899637|NCT03251209|Active Comparator|Group 3|Post-stroke participants receive only physical practice. The activities will be presented in a videotherapy way.
2899638|NCT03251183||Main group|Blood sampling Comprehensive Cardiovascular magnetic resonance (CMR) Transthoracic echocardiography (TTE) (EchoErgo) Invasive pressure-volume (PV) Loops Left ventricular (LV) biopsy
2899639|NCT03251183||Reproducibility group|Stress-perfusion Cardiovascular magnetic resonance (CMR)
2899640|NCT03251183||Age/gender matched control group|Blood sampling Stress-perfusion Cardiovascular magnetic resonance (CMR) TTE (EchoErgo)
2899641|NCT03251183||Healthy volunteers|Blood sampling Stress-perfusion Cardiovascular magnetic resonance (CMR) TTE (EchoErgo)
2899642|NCT03251170|Experimental|Ketamine group|This group of patients will receive: 1 mg/Kg ketamine + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
2899643|NCT03251170|Active Comparator|Fentanyl|2.5 mg/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
2899644|NCT03251144|Experimental|Switch to E/C/FTC/TAF daily|"Intervention: Participants will be asked to switch antiretrovirals (ART) for a period up to 12 months and mitochondrial physiology will be assessed using a variety of assays. The new ART will be~If the participant is on an ART other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to E/C/FTC/ tenofovir alafenamide (TAF) 1 tablet once daily for a period of 12 months.~If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months."
2899645|NCT03251131|Experimental|Restrictive fluid management|Restrictive fluid management Targeting a negative or maximum 300ml positive daily fluid balance.
2899646|NCT03251131|No Intervention|Standard therapy|Randomized allocation of standard care at the clinician's discretion in accordance with current best practice.
2899647|NCT03251105|Active Comparator|ProSeal group|This group received the ProSeal LMA for supraglottic airway intubation and ventilation during anaesthesia.
2899648|NCT03251105|Active Comparator|Supreme group|This group received the Supreme LMA for supraglottic airway intubation and ventilation during anaesthesia.
2899649|NCT03251092|Active Comparator|SAD PTI-808 Active|Three cohorts of SAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
2899650|NCT03251092|Placebo Comparator|SAD PTI-808 Placebo|Three cohorts of SAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
2899653|NCT03251092|Active Comparator|FE PTI-808 Active|Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
2899654|NCT03251092|Placebo Comparator|FE PTI-808 Placebo|Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
2899655|NCT03251092|Experimental|Part 2 PTI-808 + PTI-801 + PTI-428 Active|One cohort is planned where subjects will be randomized to either the triple active arm (dosed with PTI 808+PTI 801+PTI 428) OR placebo arm.
2899656|NCT03251092|Placebo Comparator|Part 2 matching Placebos|In all three cohorts in part 2, subjects will be randomized to active drug or placebo. The placebo arm for all cohorts consists of placebo capsules matching PTI-808+PTI-801+PTI-428.
2899657|NCT03251092|Experimental|Part 2 dual active arm PTI-801+PTI-428+ PTI-808 placebo|One cohort is planned where subjects are randomized to either 808 placebo + dual active arm (dosed with placebo matching PTI 808 plus PTI 801 + PTI 428) OR placebo arm.
2899658|NCT03251092|Active Comparator|Part 2 dual active arm PTI-801+PTI-808+PTI-428 placebo|One cohort is planned where subjects are randomized to either 428 placebo + dual active arm (dosed with placebo matching PTI 428 plus PTI 808 and PTI 801) OR placebo arm.
2899659|NCT03251092|Active Comparator|Part 3 CF MAD PTI-808 + PTI-801 + PTI-428|In all three cohorts in Part 3, subjects will be will be randomized to receive 7 days of PTI-808 or placebo followed by 14 days of co-administration of PTI-808+PTI-801+PTI-428 or matching placebos. A follow-up will occur on Day 28.
2899660|NCT03251092|Placebo Comparator|Part 3 CF MAD PTI-808 placebo+PTI-801 placebo+PTI-428 placebo|In all three cohorts in Part 3, subjects will be randomized to receive 7 days of PTI-808 or placebo followed by 14 days of co-administration of PTI-808+PTI-801+PTI-428 or matching placebos. A follow-up will occur on Day 28.
2899661|NCT03251066|Other|Test group|Proponent Nasal Spray Medical device
2899662|NCT03251053|Experimental|Electronic cigarette use|Subjects who try to switch to electronic cigarettes (EC) and subjects who successfully switch to EC.
2899663|NCT03251053|Other|Control regular cigarette smokers|Habitual smokers without EC use
2899664|NCT03251040|Other|Fibrin sealant|Single arm pilot study
2899665|NCT03251027|Experimental|Intensity-Modulated Radiation Therapy|Patients undergo intensity-modulated (IM)-stereotactic radiotherapy (SRT) daily over 6 weeks.
2899666|NCT03251014|Experimental|YSS/salmon group|YSS followed by salmon
2899667|NCT03251014|Experimental|Salmon/YSS group|Salmon followed by YSS
2899668|NCT03251001|Active Comparator|Control|Sites receiving a free gingival graft
2899669|NCT03251001|Experimental|Device - Acellular dermal matrix|Sites receiving acellular dermal matrix
2899670|NCT03250975|Other|Cohort|Post-extubation endoscopic examination group
2899671|NCT03250962|Experimental|SHR-1210-plus-Decitabine|
2899672|NCT03250962|Experimental|SHR-1210|
2899673|NCT03250949|No Intervention|Conventional-Drilling Tight Fit (Control) group|osteotomy will be achieved with no. 6 round , then widened , using a drill 1 mm larger than the final drill provided by the manufacturer. the final size of the control osteotomies were same diameter of the implant.
2899674|NCT03250949|Experimental|Over-drilling Loose Fit (Test) group|Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.
2899675|NCT03250936||Trampoline group|Child patients with trauma due to trampoline from june 2016 to december 2016 consulting in emergencies unit of Rennes' hospital
2899676|NCT03250936||Control group|Child patients with trauma related to sport from june 2016 to december 2016 consulting in emergencies unit of Rennes' hospital
2899677|NCT03250923|Experimental|silver citrate complex and acemannan|This is a single arm open pilot trial. All participants will receive study drug.
2899678|NCT03250910|Experimental|HIV/HCV compensated liver disease|Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) received a generic version of Sofosbuvir and Velpatasvir fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
2899679|NCT03250910|Experimental|HIV/HCV decompensated liver disease|Patients with decompensated cirrhosis (Child-Pugh B or C) received Sofosvel® 1 tablet per day in combination with weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight < 75 mg) for 12 weeks.
2899680|NCT03250910|Active Comparator|HCV compensated liver disease|Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) received a generic version of Sofosbuvir and Velpatasvir fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
2899681|NCT03250910|Active Comparator|HCV decompensated liver disease|Patients with decompensated cirrhosis (Child-Pugh B or C) received Sofosvel® 1 tablet per day in combination with weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight < 75 mg) for 12 weeks.
2899682|NCT03250871|Placebo Comparator|Placebo|"Placebo will be the suggestion of self-relaxation methods (for example, try to relax ,try to think of pleasant moment ) and the diffusion of white noise during surgery."
2899683|NCT03250871|Experimental|Hypnosis|"Hypnosis will be associated with the usual anesthesia. Hypnosis is a temporary modification of consciousness technique based on suggestion.~It is divided into three phases:~induction: attention of the patient fixed on an object or a part of the body,~the dissociation where the patient cuts off auditory, visual and tactile perceptions,~and finally the opening towards a hypnotic experience thanks to the imaginary."
2899684|NCT03250858|Placebo Comparator|Non-personalised advice|"Control group. Online (web-based) delivery of non-personalised dietary, weight and physical activity advice based on the UK general health guidelines.~This is an online trial and this arm will be using the e-Nutri web application. Participants in this group will receive online general recommendations (non-personalised)."
2899685|NCT03250858|Experimental|Personalised advice|Online (web-based) delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive online personalised reports.
2899686|NCT03250832|Experimental|Experimental: Part 1 - Dose Escalation|Part 1 will be a dose escalation to determine the RP2D of TSR-033 as a single agent and in combination with an anti-PD-1.
2899687|NCT03250832|Experimental|Experimental: Part 2 - Expansion Cohorts|Part 2 of the study will further explore the safety and clinical activity of TSR-033 in combination with anti-PD-1 in patients with select tumor types
2899688|NCT03250819||Corticosteroid responders|Patients who develop an increase in eye pressure after the use of corticosteroids
2899689|NCT03250819||Non-corticosteroid responders|Patients who use/used corticosteroids but didn't develop an increase in eye pressure
2899690|NCT03250806||newly identified aortic stenosis|Patients identified on auscultation or target echocardiography with aortic stenosis. Consecutive patients per centre with no limit to numbers.
2899691|NCT03250793|Experimental|Neonate with congenital diaphragmatic hernia|Neonates with congenital diaphragmatic hernia in post-surgical period under mechanical ventilation during weaning of mechanical ventilation
2899692|NCT03250780|Experimental|Patients with extensive colitis|Patients with extensive colitis, for at least 8-10 years, already on the surveillance programme or newly referred whilst attending their outpatients IBD clinic at Leeds Teaching Hospitals NHS Trust will be screened by one of the research doctors who will be performing the surveillance colonoscopy.
2899693|NCT03250767||Integra Titan Modular Shoulder System 2.5|
2899694|NCT03250754||Pharmacological treatment group|Treatment decision making is based on physician's choice and patient preferences. Patients were referred to the Pain Service Unit. Patients continued with a prophylactic treatment alone
2899695|NCT03250754||Electroacupuncture group|Treatment decision making is based on physician's choice and patient preferences. Patients were referred to the Pain Service Unit. Patients continued with a new prophylactic treatment and additionally, received 12 sessions of acupuncture. The treatments, which included electro-stimulation.
2899696|NCT03250741|Active Comparator|Rotigotine 4 mg|Rotigotine transdermal patches 4 mg
2899697|NCT03250741|Placebo Comparator|Placebo|Placebo transdermal patches
2899698|NCT03250728|Other|CDG with stroke-like history|
2899699|NCT03250728|Other|CDG without stroke-like history|
2899700|NCT03250715|Experimental|Low Level Laser Therapy group|Six points of application will be defined in the quadriceps and two points of application in the gastrocnemius. The parameters adopted for the irradiation will be: 30 Joules per application point, wavelength of 660 and 850 nm and output power of 200 mW. Each point will be radiated for 30 seconds.
2899701|NCT03250715|No Intervention|Control group|This group will receive no intervention. This group will be evaluated before the intervention, after four and eight weeks of follow up.
2899702|NCT03250689|Experimental|Danirixin 35 mg|Eligible subjects will receive danirixin 35 mg tablet with food twice daily for 14 Days.
2899703|NCT03250689|Experimental|Placebo Comparator|Eligible subjects will receive placebo tablet with food twice daily for 14 Days.
2899704|NCT03250676|Experimental|H3B-6545 Arm 1: Dose escalation|
2899705|NCT03250676|Experimental|H3B-6545 Arm 2: Phase 2|
2899706|NCT03250663|Active Comparator|Arm 1 - Standard of Care|Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and follow standard of care
2899707|NCT03250663|Experimental|Arm 2 - Online Treatment Response|Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and electronic treatment response emails
2899708|NCT03250650|Active Comparator|Group 1: TTNS|Intervention for Group 1: transcutaneous tibial nerve electric stimulation (TTNS), using a Device Dualpex 961(Quark medical), with 2 silicone electrode in the tibial nerve path, being one on the lower border of the medial malleolus and another one, 10cm above. Once a week for 12 weeks. The parameters used on device were, 200 microseconds for pulse time and 10Hz for Frequency, during 30 minutes.
2899709|NCT03250650|Experimental|Group 2: ES + TTNS|Intervention for Group 2: transvaginal electric stimulation plus transcutaneous tibial nerve electric stimulation (ES + TTNS), using a Device Dualpex 961(Quark medical), with transvaginal electrode, located inside the vagina. Once a week for 12 weeks. The parameters used on device were 1milisecond for pulse time and 10Hz for Frequency, during 20 minutes. After transvaginal stimulation, the tibial stimulation will be applied like described on Group 1.
2899710|NCT03250637||Colorectal cancer cases|1038 participants diagnosed with colorectal cancer from the Diet, Cancer and Health cohort.
2899711|NCT03250637||Sub-cohort members|1857 persons randomly selected within the full cohort at time of entry into the Diet, Cancer and Health cohort. These participants serve as controls for the colorectal cancer cases.
2899712|NCT03250624|Experimental|CD5024 0.3% cream|Active drug
2899713|NCT03250624|Experimental|CD5024 cream placebo|Placebo of active drug
2899714|NCT03250611|Experimental|Occipito-Cervical Instability|Stabilization of the occipito-cervical junction by Occipital Condyle Screw (OCS) as a sole cranial anchor, with posterior bone graft.
2899715|NCT03250598|Experimental|Cohort A|
2899716|NCT03250598|Experimental|Cohort B|
2899717|NCT03250598|Experimental|Cohort C|
2899718|NCT03250585||Sickle Cell Patients with Acute Chest Syndrome|Sickle cell patients with active acute chest syndrome (ACS) from which samples of EBC and plasma will be collected during acute illness within 48 hours of admission with or diagnosis of ACS (Time point 1) in 3 sessions each 1 hour apart (Time point 1a, 1b, and 1c), and 2 weeks after discharge when have returned to steady-state (Time point 2). Time point 2 samples will serve as control (baseline) samples.
2899719|NCT03250572||control group|
2899720|NCT03250572||NAFLD patients without hepatic fibrosis|
2899721|NCT03250572||NAFLD patients with hepatic fibrosis|
2899722|NCT03250559|Active Comparator|ultrasound guided group|"The group of renal stones that would have percutaneous nephrolithotomy under ultrasound guidance.~Intervention: percutaneous nephrolithotomy."
2899723|NCT03250559|Active Comparator|fluoroscopy guided group|"The group of renal stones that would have percutaneous nephrolithotomy under fluoroscopy guidance.~Intervention: percutaneous nephrolithotomy."
2899724|NCT03250546|Experimental|Haplo-identical group|
2899725|NCT03250546|Active Comparator|HLA-9/10 MMUD group|
2899726|NCT03250533|Experimental|LED 620 nm group (G-LED 620)|The LED device in the red light spectrum, with a wavelength of 620 nm, will be applied over the full extent of the wound.
2899727|NCT03250533|Experimental|LED 940 nm group (G-LED 940)|The LED device in the infrared light spectrum, with a wavelength of 940 nm, will be applied over the full extent of the wound.
2899846|NCT03249740|Active Comparator|Active Comparator: Phase 2 - Aflibercept|Aflibercept 2 mg injected every 2 months
2899728|NCT03250533|Experimental|Fixed diphasic current group (G-DF)|The electrical stimulation will be carried out with the fixed diphasic current of the Dualpex 071 equipment, being applied throughout the extension of the wound.
2899729|NCT03250533|No Intervention|Control group (G-C)|Volunteers from this group will not be submitted to treatment and will only be evaluated before, every 30 days, after the 12 week period and 30 days after the last evaluation. It is worth mentioning that, after the end of its participation, if the wound is not fully healed, the treatment will be offered with LED or diphasic current.
2899730|NCT03250520|Experimental|glioma brain stem|
2899731|NCT03250520|Experimental|high grade recurrent brain tumor in the central nervous system|
2899732|NCT03250507|Active Comparator|Bupivacaine|Patients will receive a TAP block with 60 mL 0.25% bupivacaine. this group will not receive Liposomal bupivacaine
2899733|NCT03250507|Active Comparator|Liposomal bupivacaine|"Patients will receive a TAP block with 20 mL liposomal bupivacaine and 40 mL saline.~this group will not receive bupivacaine. they receive only liposomal bupivacaine."
2899734|NCT03250507|Experimental|Liposomal bupivacaine and bupivacaine|"Patients will receive a TAP block with 20 mL liposomal bupivacaine and 40 mL 0.25% bupivacaine.~this group will receive the mixture of Liposomal bupivacaine and bupivacaine."
2899735|NCT03250494|Active Comparator|group (I) (GI) (n=25)|
2899736|NCT03250494|Active Comparator|group (II) (GII) (n=25)|
2899737|NCT03250494|Placebo Comparator|group (III) (GIII) (control group) (n=25)|
2899738|NCT03250481|Active Comparator|'Sedation guidance with RASS-group|Sedation is guided with RASS. Targeted sedation level is RASS -3 - 0. Propofol: an initial rate of 2.4 mg/kg/h for one hour. Thereafter, the infusion rate of propofol is 0.8-4 mg/kg/h to reach or maintain the target RASS score. Propofol bolus of 20-40 mg is allowed. Oxycodone as 3-6 mg boluses for pain management. Other opiates are not allowed. Midazolam may given if the maximum dose of propofol is reached and pain management by oxycodone restricted achievement of the target sedation level. Midazolam will supply intravenously in boluses of 1-2 mg (based on the weight of the patient), starting at 3 boluses/h for the first hour. Dexmedetomidine and other sedatives are not allowed.
2899739|NCT03250481|Experimental|'Sedation guidance with RI|Sedation is guided with RI. Targeted sedation level is RI 40-80. Propofol: an initial rate of 2.4 mg/kg/h for one hour. Thereafter, the infusion rate of propofol is 0.8-4 mg/kg/h to reach or maintain the target RI score. Propofol bolus of 20-40 mg is allowed. Oxycodone as 3-6 mg boluses for pain management. Other opiates are not allowed. Midazolam may given if the maximum dose of propofol is reached and pain management by oxycodone restricted achievement of the target sedation level. Midazolam will supply intravenously in boluses of 1-2 mg (based on the weight of the patient), starting at 3 boluses/h for the first hour. Dexmedetomidine and other sedatives are not allowed.
2899740|NCT03250468|Experimental|CBT-I|Participants randomized to receive the intervention will attend 6 weekly group-based CBT-I sessions. Each 90-minute group will include 6-12 participants.
2899741|NCT03250468|No Intervention|Wait-list control|The wait-list control group will receive treatment as per our standard cardiac rehabilitation program. After completion of the 3-month follow-up questionnaire, wait-list control participants may take part in the intervention.
2899742|NCT03250455||CTA+CTP|
2899743|NCT03250455||CTA only|
2899744|NCT03250442|Other|Group A: Standard Dry Dressing|The standard dry dressing is comprised of nonadherent dressing, dry gauze, cotton undercast padding, compression, and immobilization.
2899745|NCT03250442|Active Comparator|Group B: Foam, Drape, and PrevenaTM|This arm is comprised of foam, drape, the PrevenaTM Device, compression, and immobilization.
2899746|NCT03250429||CRS subjects|CRS subjects who have sinus surgery
2899747|NCT03250403|Experimental|PRP injection|
2899748|NCT03250403|Active Comparator|medical treatment|
2899749|NCT03250390|Experimental|patients|Patients with bronchopulmonary cancer who have not yet received therapeutic treatment.
2899750|NCT03250390|Active Comparator|controls|The controls consisted of 2 groups: smokers and non-smokers.
2899751|NCT03250377|Experimental|Brivaracetam|Subjects randomized to this arm will receive open-label Brivaracetam
2899752|NCT03250364|Experimental|Multilayer bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + multilayer bandage consisting of three layers. The first was a 100% cotton tubular bandage which will be directly placed on the skin to prevent any injury (Tubinylex TM). The second layer is a paddle with the purpose of unify and increase pressure; and a final layer of short-stretch bandage of different sizes depending on the place of the upper limb (UL): 8 cm width for the forearm and 10 cm for the arm (ComprilanTM). All the bandage layers will be placed from caudal to cranial in a circular disposition, overlapping in one third the previous layer for a correctly cover of the limb and not to leave open spaces. The cotton tubular bandage and the short-stretch bandage could be cleaned without losing their material properties."
2899753|NCT03250364|Experimental|Double compression bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + double compression bandage consisting of two layers, made up of a first rigid cotton bandage (11 cm X 4m MedicaTM 315 anti oedema; Thuasne, France) and a second elastic bandage (BiflexTM 16 light; Thuasne, France). The two layers will be placed caudal to cranial in a circular manner, overlapping in one third the previous layer. The elastic bandage have squares drawn to help to the physiotherapist to control the stretch they given to the bandage. The two bandages could be cleaning without losing their properties. If there was any oedema concentration or a fibrous place, a paddle pad will be put in these places (Mobiderm TM, Thuasne, France)."
2899754|NCT03250364|Experimental|Cohesive bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + cohesive bandage consisting of a single short-stretched layer that will be put directly on the subject skin and stick on itself (Medi-Rip TM LF Hartmann, Germany. Measures: 7,5 cm x 4,5 m). It will be placed in a circular manner distal to cranial with a paddle pad in the elbow fold not to damage this moving part. This bandage will be reused twice in the same subject."
2899755|NCT03250364|Experimental|Adhesive compression bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + adhesive compression bandage consisting of an elastic bandage (BiplastTM Thuasne, France. Measures: 10cm x 2,5 m) which will put over a pre-tape bandage not to damage the skin. It will be placed in a circular disposition from distal to cranial. In each physiotherapy session, the bandage has to be replaced with a new one."
2899989|NCT03248778|No Intervention|Treatment as Usual|
2899756|NCT03250364|Experimental|Kinesiotaping bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + kinesiotaping bandage consisting of K-Active Tape. The k-tape will be pasted directly on the skin and put longitudinally in thin bands in a cranio-caudal disposition. The width of the bandage will be of 5cm, and will be cut in four bands that will cover all the upper limb cranial to caudal in a spiral way surrounded it. The bandage will be placed moving the limb into internal and external rotation for putting the skin in a little stretch without lengthen the tape."
2899757|NCT03250351|Experimental|Neurodynamic group|3 to 5 days after surgery, the participants assigned to this group will receive 9 sessions of early physical therapy plus educational program plus neurodynamic techniques consisting of neural tissue longitudinal glide using the Upper Limb Neurodynamic Test 1 (ULNT1), the neurodynamic test sequence for the median nerve, described by Butler. With participants in the supine position, the shoulder was abducted and externally rotated, the scapula depressed, the forearm supinated, and the wrist and fingers extended. Mobilization was applied by depressing the scapula, flexing the elbow, and elevating the scapula, extending the elbow, within a pain-free range. The mobilization was applied for 2 minutes. Each session will be of 40 minutes approximately and will be held 3 sessions a week for 3 weeks.
2899758|NCT03250351|Active Comparator|Control group|3 to 5 days after surgery, the participants assigned to this group will receive 9 sessions of early physical therapy plus educational program consisting of physical therapy aimed at reducing postoperative edema, treatment of the scar, the muscle pain and / or joint and recovery and integration of the upper limb functional motor patterns plus instructions with printed material about lymphatic system, lymphedema, pain, movement & pain; etc…. (educational strategy). Each session will be of 40 minutes approximately and will be held 3 sessions a week for 3 weeks.
2899759|NCT03250338|Experimental|Crenolanib|Crenolanib following salvage chemotherapy
2899760|NCT03250338|Placebo Comparator|Placebo|Placebo following salvage chemotherapy
2899761|NCT03250325|Experimental|Split dose of 5x10^9 TBI-1301|Split dose of 5x10^9 TBI-1301 will be administered intravenously for 2 days following cyclophosphamide pre-treatment 750 mg/m2/d for 2 days.
2899762|NCT03250312|Active Comparator|The OMT group|This group will be treated by the osteopathic manipulation techniques (OMT). The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping. The total treatment time will not to exceed 20 minutes.
2899763|NCT03250312|No Intervention|The control group|"The control group will wait in another room for approximately 30 minutes.~To encourage participation in the proposed study, participants who are assigned to the control group will have an opportunity to receive OMT after the second blood draw"
2899764|NCT03250299|Experimental|Dose Level 1 8mg - BAL101553|"8mg BAL101553 PO (7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest. Off treatment after 4 week rest.~Microtubule-targeted Agent BAL101553 Radiation Therapy Laboratory Biomarker Analysis Pharmacological Study"
2899765|NCT03250299|Experimental|Dose Level 2 15mg - BAL10553|"15mg BAL101553 PO(7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest. Off treatment after 4 week rest.~Microtubule-targeted Agent BAL101553 Radiation Therapy Laboratory Biomarker Analysis Pharmacological Study"
2899766|NCT03250299|Experimental|Dose Level 3 20mg - BAL10553|"20mg BAL101553 PO(7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest. Off treatment after 4 week rest.~Microtubule-targeted Agent BAL101553 Radiation Therapy Laboratory Biomarker Analysis Pharmacological Study"
2899767|NCT03250299|Experimental|Dose Level 4 25mg - BAL10553|"25mg BAL101553 (7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest. Off treatment after 4 week rest.~Microtubule-targeted Agent BAL101553 Radiation Therapy Laboratory Biomarker Analysis Pharmacological Study"
2899768|NCT03250286|Experimental|EUS-ERCP group|EUS is performed first, and when the examiner finds bile duct stone in the EUS examination, ERCP is performed to remove the stone.
2899769|NCT03250286|Active Comparator|ERCP group|ERCP without EUS is performed in all patients.
2899770|NCT03250273|Experimental|Arm A - Chloangiocarcinoma|
2899771|NCT03250273|Experimental|ARM B - Pancreatic Cancer|
2899772|NCT03250260|No Intervention|Standard Care|Patient receives standard pre-operative preparation which involves a discussion in to the likely aesthetic outcome with their surgeon or specialist nurse
2899773|NCT03250260|Experimental|2-dimensional Portfolio|Patient views photographs of women matched for BMI, age, and breast volume who are 1-5 years post BCT pre-operatively.
2899774|NCT03250260|Experimental|3-dimensional simulation|Patient pre-operatively views a simulation of their own breast of their likely outcome after BCT.
2899775|NCT03250247|Experimental|Endovascular Therapy - Intervention|"All subjects (EVT and No-EVT Arms) will receive optimal PTS care. At each Clinical Center, this will be supervised by a physician experienced in managing PTS.~Subjects randomized to EVT will receive the following:~imaging-guided iliac vein stent placement, and~endovenous ablation of refluxing saphenous vein(s), if the patient has truncal reflux and is still symptomatic.~optimal PTS therapy: medical and compression, lifestyle interventions and venous ulcer care"
2899776|NCT03250247|No Intervention|Non-Endovascular Therapy - Control|All subjects will receive optimal PTS care as noted above.
2899777|NCT03250234|Other|Adequate Carbohydrate|Carbohydrate beverage (1 g/kg/hr) Adequate carbohydrate diet 6.0 g/kg/d
2899778|NCT03250234|Other|Low Carbohydrate|Non-nutritive control beverage. Low carbohydrate diet 1.2 g/kg/d
2899779|NCT03250221||Robotic or laparoscopic myomectomy|Women who received robotic or laparoscopic myomectomy
2899780|NCT03250208|Placebo Comparator|Control Group|Participants randomized to this group will take two placebo capsules daily during days 21-60.
2899781|NCT03250208|Experimental|Intervention group|The intervention in this study is a probiotic. Participants randomized to this group will take two capsules of a probiotic daily during days 21-60
2899782|NCT03250195|Other|PET/MRI|All participants will have a PET/MRI performed
2899783|NCT03250182|Experimental|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol per protocol. Administered as 2 inhalations per use as instructed in the protocol.
2899990|NCT03248765||Chronic pain group|post-surgical opioid use measured at 1 day and 1 week.
2899784|NCT03250156|Experimental|MBAT with proctored practice|Participants will engage in Mindfulness Based Attention Training (MBAT) in 4, 2-hour training classes with 1 class per week. Participants in the proctored practice group will complete assigned, out of class mindfulness exercises during the duty day - for example, as part of their daily physical training (e.g., mindful cooldown, final 15 minutes of PT is spent engaging in a mindfulness exercise using a guided recording).
2899785|NCT03250156|Active Comparator|MBAT with non-proctored practice|Participants will engage in Mindfulness Based Attention Training (MBAT) in 4, 2-hour training classes with 1 class per week. Participants in the non-proctored practice group will complete assigned, out of class mindfulness exercises on their own time with no structured duty day support.
2899786|NCT03250156|No Intervention|No Training Control|This group will receive no intervention.
2899787|NCT03250143|Active Comparator|group A|Oral cyclosporine 3mg/kg/day (200mg/day) will be started.If there is no improvement in 1 week then escalating the dose maximum upto 5mg/kg/day.
2899788|NCT03250143|Active Comparator|group B|Oral azathioprine will be started at 1mg/kg/day.If there is no improvement in 1 week then escalating the dose maximum upto 100mg/day
2899789|NCT03250130|Experimental|Hypnosis|The patient achieve self-hypnosis sessions in these chemotherapy treatments
2899790|NCT03250117|Experimental|Cohort 1|Requip; One Ropinirole Implant
2899791|NCT03250117|Experimental|Cohort 2|Requip; Two Ropinirole Implants
2899792|NCT03250117|Experimental|Cohort 3|Requip; Three Ropinirole Implants
2899793|NCT03250117|Experimental|Cohort 4|Requip; Four Ropinirole Implants
2899794|NCT03250091||Gastric cancer|Gastric adenocarcinoma and other gastric malignancies
2899795|NCT03250091||Gastric mucosal dysplasia|Includes: a. High-grade dysplasia; b. Low-grade dysplasia; c. Indefinite for dysplasia
2899796|NCT03250091||High-risk IM gastritis stages|High-risk stages according to OLGIM classification: OLGIM Stage IV and OLGIM Stage III.
2899797|NCT03250091||High-risk atrophic gastritis stages|High-risk stages according to OLGA classification: OLGA Stage IV and OLGA Stage III.
2899798|NCT03250091||Extensive gastric intestinal metaplasia|Intestinal metaplasia of any grade both in gastric corpus and antrum/incisura (other than OLGIM III-IV).
2899799|NCT03250091||Extensive atrophy|Moderate to severe (++ or +++) atrophy both in corpus and antrum/incisura, other than OLGA III-IV.
2899800|NCT03250091||Isolated corpus atrophy|Isolated moderate-to-severe atrophy or IM in the corpus.
2899801|NCT03250078||NEW-ONSET DIABETES MELLITUS|Diabetes Mellitus diagnosed within the past 12 months.
2899802|NCT03250078||FAMILIAL PANCREATIC CANCER and/or GENE MUTATION|An inherited genetic syndrome associated with Pancreatic Cancer and/or with a strong family history of Pancreatic Cancer.
2899803|NCT03250065|Experimental|ETT Study Group|The Sensing ET Tube study Group
2899804|NCT03250052|Experimental|Part A|Period 1(fimasartan) x 7days - Period 2(fimasartan + linagliptin) x 7days
2899805|NCT03250052|Experimental|Part B|Period 1(linagliptin) x 7days - Period 2(fimasartan + linagliptin) x 7days
2899806|NCT03250039|Experimental|Mass Balance|Cumulative recovery of radioactivity in urine and feces
2899807|NCT03250039|Experimental|Absolute Bioavailability|Oral absolute bioavailability
2899808|NCT03250026|Experimental|Intervention (Workplace dialogue)|Intervention: Work place convergence dialogue contact
2899809|NCT03250026|Active Comparator|Care Manager|Intervention: Care Manager contact 12 weeks (Care as usual)
2899810|NCT03250013||Children and adolescents with ADHD|Children and adolescents medicating for ADHD of any subtype (presentation) with comorbidities
2899811|NCT03250000||COPD-stable|Stable COPD patients at pulmonology consultation in Ziekenhuis Oost-Limburg (ZOL) Genk
2899812|NCT03250000||COPD-Ex|Patients admitted to the respiratory ward of ZOL Genk with a diagnosis of acute exacerbation, based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
2899813|NCT03249987|Other|Electronic bladder diary|Participants will be asked to complete the electronic diary for three days before crossing over to the paper diary. Patients will be asked to record the time and volume of voids, any incontinence or urgency episodes and sleep-wake times. Patients will be asked to complete a short questionnaire regarding their opinions
2899814|NCT03249987|Other|Paper bladder diary|Participants will be asked to complete the paper diary for three days before crossing over to the electronic diary. Patients will be asked to record the time and volume of voids, any incontinence or urgency episodes and sleep-wake times. Patients will be asked to complete a short questionnaire regarding their opinions
2899815|NCT03249974||Target group|Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
2899816|NCT03249961|Experimental|Placebo Brain stimulation|Participants will receive Sham TDCS, and Transcranial Magnetic Stimulation (TMS)
2899817|NCT03249961|Experimental|Excitatory Brain Stimulation|Participants will receive Anodal TDCS, and Transcranial Magnetic Stimulation (TMS)
2899818|NCT03249948|No Intervention|Standard defibrillation|All defibrillation attempts will occur using the standard defibrillation method, i.e. defibrillation pads will be placed in the anterior-anterior configuration. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
2899819|NCT03249948|Other|Vector change defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. All further shocks will occur with the pads placed in the anterior-posterior position. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
2899820|NCT03249948|Other|Double-sequential defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. For all further shocks, a second set of defibrillation pads (via a second on scene EMS or fire defibrillator) will be applied in the anterior-posterior position, and defibrillation will be carried out by sequential defibrillation shocks provided by the two defibrillators (i.e. with a short delay between the two defibrillators). The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
2899821|NCT03249935|Active Comparator|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
2899847|NCT03249714|Experimental|Ofatumumab arm|Ofatumumab 20 mg subcutaneous injections every 4 weeks for 24 weeks
2899991|NCT03248765||No chronic pain|post-surgical opioid use measured at 1 day and 1 week.
2899822|NCT03249922||Treatment Group|"All patients who are considered candidates for spinal cord stimulator implant will be assigned to the Treatment Group. Participiants will be clinically evaluated and given the Owenstry low back disability index, WHODAS 12, Beck depression index and SF-36."
2899823|NCT03249909|Experimental|Dressings|
2899824|NCT03249896|Experimental|Intervention|Patients in the intervention arm will receive standard medical care and in addition to that, be given the Aina or Aina Mini device for self-monitoring of blood glucose (SMBG), the Habits-GDM mobile app, and a weighing scale.
2899825|NCT03249896|No Intervention|Control|"Patients in the control arm will receive standard medical care and only be given the Aina or Aina Mini device for SMBG.~Standard medical care involves one session of face-to-face education by a diabetes nurse educator and a dietician. Patients are initiated on capillary glucose monitoring. Subsequently, standard clinical care is provided by their obstetrician. Participation in this study will not increase the frequency of clinic visits. The frequency of SMBG will be as clinically indicated and not increased as a result of participation in this study. Should the obstetrician feels that insulin is required, it will be initiated and if necessary the patient will be referred to the endocrinology service for management of insulin therapy. In some patients, the clinician may decide to prescribe metformin."
2899826|NCT03249883|Active Comparator|SACH first|Will use a SACH foot for the first three weeks of prosthetic gait training , and a 1M10 foot for the second three weeks of prosthetic gait training
2899827|NCT03249883|Active Comparator|1M10 first|Will use a 1M10 foot for the first three weeks of prosthetic gait training , and a SACH foot for the second three weeks of prosthetic gait training
2899828|NCT03249870|Experimental|Inotuzumab ozogamicin (INO)|
2899829|NCT03249857|Experimental|patients|Patients suffering bipolar affective disorders and who will perform cognitive tasks + IQ + MINI + experimental task
2899830|NCT03249857|Active Comparator|control group|Healthy volunteers (Control group) who will perform cognitive tasks + experimental task
2899831|NCT03249844|Experimental|experimental group|Children will be treated by methylprednisolone + prednisolone and standard of care
2899832|NCT03249844|No Intervention|control group|Children will be treated by standard of care alone
2899833|NCT03249831|Experimental|COH-MC-17 and immunosuppressants|"Participants receive COH-MC-17: a 21-day nonmyeloablative conditioning regimen (cyclophosphamide, pentostatin and rabbit anti-thymocyte globulin), followed by CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant on Day 0.~Immunosuppressants (tacrolimus and mycophenolate mofetil) given on Day -1 onwards until discontinuation post-transplant.~The minimally manipulated transplant product is manufactured using the CliniMACS device."
2899834|NCT03249818|Other|HITT Device|HITT device to scan eyes of participants 3 times (30 seconds each) at time of admittance to hospital for diagnosed traumatic brain injury. If patient is still in hospital 2 weeks post-enrollment, a second set of 3 tests will be performed
2899835|NCT03249805|Experimental|Steenbeek Foot Abduction Brace (SFAB)|The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The Steenbeek Foot Abduction Brace (SFAB) is a fixed metal bar attached to two leather shoes with laces. The shoes have laces and a strap. The FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
2899836|NCT03249805|Experimental|MiracleFeet Foot Abduction Brace (mFAB)|The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The MiracleFeet Foot Abduction Brace (mFAB) is an injected plastic molded bar with fabric shoes that clip off and on. The shoes have laces and a strap. Both FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
2899837|NCT03249792|Experimental|Arm 1: MK-2118 IT Monotherapy|Participants receive MK-2118 via IT injection once weekly (Q1W) on Days 1, 8 and 15 of Cycles 1-3 followed by MK-2118 via IT injection once every 3 weeks (Q3W) on Day 1 of Cycle 4 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
2899838|NCT03249792|Experimental|Arm 2: MK-2118 IT+Pembro Combo Therapy|Participants receive pembrolizumab (pembro) 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 4 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
2899839|NCT03249792|Experimental|Arm 3: MK-2118 Visceral IT+Pembro Combo Therapy|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-2 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 3 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
2899840|NCT03249792|Experimental|Arm 4: MK-2118 SC+Pembro Combo Therapy|Participants receive MK-2118 monotherapy via SC injection Q1W on Cycle 1 Days 1 and 8 followed by MK-2118 SC injection Q1W on Cycles 2-4 Days 1, 8 and 15, for a total of up to 35 cycles (approximately 2 years) plus pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for up to 35 cycles (approximately 2 years). Cycle 1 is 2 weeks long and Cycles 2 and beyond are 3 weeks long.
2899841|NCT03249779|Experimental|Open|All participants will receive electrical stimulation applied to the lower extremities using the Scrambler.
2899842|NCT03249753|Experimental|SPH3127 200mg Panel A|Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.
2899843|NCT03249753|Experimental|SPH3127 200mg Panel B|Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
2899844|NCT03249740|Experimental|Experimental: Phase 1 - GB-102|Subjects will be assigned to 1 of 4 cohorts to receive a single intravitreal injection of up to 2.0 mg (50 μL) GB-102.
2899845|NCT03249740|Experimental|Experimental: Phase 2 - GB-102|Low dose or high dose injected every 6 months
2899849|NCT03249701|Experimental|TEAS group|Transcutaneous Electrical Acupoint Stimulation on Neiguan, Quchi, Zusanli, Sanyinjiao. Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
2899850|NCT03249701|Placebo Comparator|Electroacupuncture group|Hand-needle on Neiguan, Quchi, Zusanli, Sanyinjiao.Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
2899851|NCT03249701|Sham Comparator|sham TEAS group|Sham transcutaneous electrical acupoint stimulation on Neiguan, Quchi, Zusanli, Sanyinjiao; Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
2899852|NCT03249688|Other|Control|Regular health advice
2899853|NCT03249688|Experimental|Multidomain 1|Multidomain lifestyle
2899854|NCT03249688|Experimental|Multidomain 2|Multidomain lifestyle + medical food
2899855|NCT03249675||ARM 1|ARM 1: Retrospective Arm: Subjects tested with BNA in the past and have been diagnosed by their physician as having Post Concussive Syndrome. Study staff will contact the subjects and obtain Informed Consent. Study physicians will then review both BNA data and Clinical data. All relevant clinical data and all available BNA data will be shared with ElMindA. Subjects may be invited for an additional BNA follow up as part of the study.
2899856|NCT03249675||ARM 2|"ARM 2: Subjects will be prospectively enrolled in the study at the following time points when available:~Acute: within 2 weeks of injury~PCS: Subjects which sustained a concussion in the past 3 months or more, and are still experiencing symptoms related to the injury"
2899857|NCT03249662|Experimental|bupivacaine 100 mg|bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add Normal saline solution(NSS) to 80 ml divided to two syringes for bilateral periarticular infiltration
2899858|NCT03249662|Active Comparator|bupivacaine 200 mg|bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
2899859|NCT03249649||Phoenix Cohort|Somali Refugee women ages 15 and older
2899860|NCT03249649||Tucson Cohort|Somali Refugee women ages 15 and older
2899861|NCT03249636||ALL patients|New cases of patients with acute lymphocytic leukemia. Evaluation of markers 15 days after induction.
2899862|NCT03249623|Experimental|Beacon Caresystem|On randomisation to the Beacon group, a Beacon Caresystem will be connected to the patient. This involves connecting a pulse oximeter to the patient's finger (toe or ear) to measure pulse oximetry oxygen saturation and pulse, and placing a standard clinical respiratory gas analysis and flow sensor in the respiratory tubing connecting the ventilator to the patient. This sensor allows measurement of respiratory pressure, flow and volume; plus respiratory gas CO2 and O2.
2899863|NCT03249623|No Intervention|Standard Care|For this group mechanical ventilation is managed according to standard care. A Beacon CareSystem will be connected to the patient, as for the Beacon Randomisation group, but the system will be used solely for data collection, and advice will be disabled. Physiological variables captured in this arm of the study will mirror the intervention arm. Decision relating to weaning, extubation, reintubation and sedation including level of seniority of personnel involved in the decision tree process will be documented accordingly.
2899864|NCT03249610|Experimental|Jindal Steel Pvt Ltd|Lifestyle intervention given
2899865|NCT03249610|Experimental|Maruti Udyog Ltd|Lifestyle intervention given
2899866|NCT03249610|No Intervention|Tata Capital|Control arm so no intervention given
2899867|NCT03249610|No Intervention|Powergrid Corporation|Control arm so no intervention given
2899868|NCT03249597||1. Suspected Infection.|Adult (≥18 years), non-trauma patient transported by the ambulance, who according to the EMS suffer from an infection.
2899869|NCT03249597||2. Control|Adult (>18 years of age), non-trauma patient immediately following the included patient with suspected infection, transported in the same ambulance but without infection.
2899870|NCT03249584|Other|OsteoCool™ RF Ablation|Subjects will undergo a single OsteoCool™ RF Ablation procedure.
2899871|NCT03249571|Experimental|Flavonoid|Flavonoid supplement
2899872|NCT03249571|Placebo Comparator|Placebo|Placebo
2899873|NCT03249558|Active Comparator|Morphine, Duloxetine|Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and 60 mg of duloxetine capsules.
2899874|NCT03249558|Placebo Comparator|Morphine, Placebo Duloxetine|Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and placebo duloxetine capsules.
2899875|NCT03249558|Placebo Comparator|Placebo Morphine, Duloxetine|Subjects will take placebo morphine capsules and 60 mg of duloxetine capsules.
2899876|NCT03249532|Active Comparator|standard hemodialysis|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 0 Liters (L)
2899877|NCT03249532|Active Comparator|cool hemodialysis|prescription of dialysate temperature: 35.5 degrees celsius prescription of convection volume: 0 L
2899878|NCT03249532|Active Comparator|low volume hemodiafiltration|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
2899879|NCT03249532|Active Comparator|high volume hemodiafiltration|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
2899880|NCT03249519|Experimental|Standard Arm|Radiation therapy: 50.4 Gy Brachytherapy: 35-40 Gy Chemotherapy: Cisplatin weekly 40mg/m^2 (6 cycles) Hyperthermia: 10 times
2899881|NCT03249506||Cohort 1: Non-SGLT2i new Users|This is a retrospective cohort study identifying participants with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease using the Military Health System (MHS) over a 3-year period. Cohort 1 included participants with incident exposure of one or more non-sodium glucose co-transporter 2 inhibitor (SGLT2i) anti-hyperglycemic agent (AHA) therapy during the study period with no prior or subsequent SGLT2i exposure throughout the study period. New users are defined as participants whose first exposure to any non-metformin AHA medication occurs greater than or equal to (>=) 365 days after their start of observation in the database with no prior exposure to any medication within the same AHA medication class in the prior 365 days.
2899882|NCT03249506||Cohort 2: SGLT2i new Users|Cohort 2 included participants with incident SGLT2i exposure during the study period regardless of prior or concurrent exposure to one or more additional AHA therapy. New users are defined as participants whose first exposure to SGLT2i medication occurs >= 365 days after their start of observation in the database with no prior exposure to the same AHA medication class in the prior 365 days.
2944360|NCT02942719||Northwest Women and Children's Hospital|
2899883|NCT03249493||HIV Injection drug users|Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
2899884|NCT03249493||HIV Non injection drug users|Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
2899885|NCT03249480|Experimental|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
2899886|NCT03249454|Active Comparator|Cathodal tsDCS|Each subject will be assigned to receive two cathodal tsDCS interventions randomly. There will be at least 1 week washout period between any 2 sessions.
2899887|NCT03249454|Active Comparator|Anodal tsDCS|Each subject will be assigned to receive two anodal tsDCS interventions randomly. There will be at least 1 week washout period between any 2 sessions.
2899888|NCT03249454|Sham Comparator|Sham tsDCS|Each subject will be assigned to receive one sham tsDCS interventions randomly. There will be at least 1 week washout period between any 2 sessions.
2899889|NCT03249441|Experimental|Compassion-focused therapy|Compassion-Focused Therapy (CFT) Participants were taught the main compassion-focused exercises as outlined in 'The Compassion-Mind Guide to Ending Overeating: Using Compassion-Focused Therapy to overcome Bingeing and Disordered Eating' manual (Goss, 2011) over a ten session period (weekly for 2 hours), offered over a 3 month period. Self-criticism and shame were key foci across sessions. Participants in the CFT arm also received Treatment as Usual.
2899890|NCT03249441|No Intervention|Treatment as Usual|Treatment As Usual Treatment as usual was based in the Diabetes, Endocrinology and Metabolism Clinic in Galway University Hospital. The Weight Management Service provides assessment by a multi-disciplinary team of endocrinologists, dieticians, nurse specialists and clinical psychologists. Dietary advice is given by a specialist dietician regarding weight management, assessment by the Consultant Endocrinologist with possible medication for management of diabetes and weight, and participation in a healthy lifestyle education program.
2899891|NCT03249428|Active Comparator|Nicotine Replacement Therapy & One-on-One Counseling|Standard NRT such as the nicotine patch, gum, inhaler, and/or lozenge as per participant liking and clinical indication deemed necessary by the expert smoking cessation nurse. Counseling will include a number of approaches such as reviewing smoking history, development and revision of a reduced or quit plan, encouragement of self-monitoring, review of triggers and challenges, and coping skills.
2899892|NCT03249428|Active Comparator|Electronic Nicotine Delivery Systems & One-on-One Counseling|Electronic Nicotine Delivery Systems with nicotine. Counseling will include a number of approaches such as reviewing smoking history, development and revision of a reduced or quit plan, encouragement of self-monitoring, review of triggers and challenges, and coping skills.
2899893|NCT03249402|Experimental|Oral Contraceptive Tablet + JNJ‑42847922|All participants will receive one oral contraceptive (OC) tablet containing ethinyl estradiol (EE) 0.03 milligram (mg) and levonorgestrel (LN) 0.15 mg once daily on Days 1 to 21 for both cycle 1 and cycle 2. In addition, in cycle 2, participants will receive 40 mg of JNJ‑42847922 once daily on Days 14 to 21. Participants will not be given OC tablet on Days 22 to 28 during cycle 1 and cycle 2 (tablet-free period).
2899894|NCT03249389|Experimental|Blood sample|patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
2899895|NCT03249376|Experimental|Lumateperone|Lumateperone (ITI-007 60 mg) administered once daily every evening for 6 weeks
2899896|NCT03249376|Placebo Comparator|Placebo|Placebo administered once daily every evening for 6 weeks
2899897|NCT03249363|Experimental|Group A - Pulsed PVP-I Irrigation|Group in wich the patients who underwent spinal surgery were treated with 5-10 minutes of low-pressure irrigation with Povidone-Iodine (PVP-I) diluted to a 3% concentration (30g/l) in 2 l of saline performed before applying the bone graft
2899898|NCT03249363|Active Comparator|Group B - Pulsed Saline Irrigation|Group in wich the patients who underwent spinal surgery were treated with 5-10 minutes of low-pressure irrigation with only 2 litres of saline solution (without povidone Iodine) performed before applying the bone graft
2899899|NCT03249350|Active Comparator|Standard Contingency Management (CM)|This group will receive standard CM for adolescent substance abuse.
2899900|NCT03249350|Experimental|Enhanced Contingency Management (CM+)|This group will receive an enhanced CM protocol for adolescent substance abuse that targets parenting more intensely.
2899901|NCT03249337|Active Comparator|Glanatec(R) 3 times a day|
2899902|NCT03249337|Active Comparator|Glanatec (R) 6 times a day|
2899903|NCT03249324|Experimental|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will discuss potential costs of unhealthy behaviors and the benefits of healthier lifestyle choices, and how they apply not only to adults, but also to developing children. Theoretically, discussing these perspectives will make the mothers more likely to make healthier lifestyle choices in the future.
2899904|NCT03249324|Active Comparator|Usual Care (UC)|UC includes regular clinic visits, routine blood and urine screening tests, and anticipatory guidance from a primary care provider in accordance with the VA/DoD Guideline for the Management of Pregnancy. After delivery, participants receive routine well-child care in accordance with established guidelines from the American Academy of Pediatrics and the American Academy of Family Physicians.
2899905|NCT03249311|Experimental|Levomilnacipran|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
2899906|NCT03249311|Active Comparator|Duloxetine (Cymbalta)|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
2899907|NCT03249311|Placebo Comparator|Levomilnacipran Placebo-matched capsules|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
2899908|NCT03249298|Active Comparator|Crystalloids|"Bolus of crystalloids~Bolus of 250 ml crystaloids will be infused regarding the measures"
2899909|NCT03249298|Active Comparator|Colloids|"Bolus of colloids~Bolus of 250 ml colloids will be infused regarding the measures"
2899910|NCT03249285|Experimental|Peri profile yes|patient with genetic Perindopril profile, receiving Perindopril treatment with 4-8 mg/day oral for 4-8 weeks
2899911|NCT03249285|Experimental|HCTZ profile yes|patient with genetic HCTZ profile, receiving HCTZ treatment with 12,5-25 mg/day oral for 4-8 weeks
2900027|NCT03248531|Placebo Comparator|Placebo|Subjects will receive several placebo applications to keep the blinding.
2899912|NCT03249285|Active Comparator|Peri no profile|patient with no genetic profile, receiving after randomisation Perindopril treatment with 4-8 mg/day oral for 4-8 weeks
2899913|NCT03249285|Active Comparator|HCTZ no profile|patient with no genetic profile, receiving after randomisation HCTZ treatment with 12,5-25 mg/day oral for 4-8 weeks
2899914|NCT03249272|Active Comparator|Hypertrophic cardiomyopathy|
2899915|NCT03249272|Active Comparator|Non-ischemic dilated cardiomyopathy|
2899916|NCT03249272|Active Comparator|Atypical chest pain|
2899917|NCT03249259|Experimental|Choline alfoscerate|choline alfoscerate 400mg (2 caps - 1 cap bid)
2899918|NCT03249259|Placebo Comparator|Control|Placebo (2 caps - 1 cap bid)
2899919|NCT03249246||Infection only|The patients have only infection
2899920|NCT03249246||Infection + SIRS|Patients have infection plus systemic inflammatory response syndrome (SIRS)
2899921|NCT03249246||Severe sepsis|Septic patients with newly developed organ dysfunctions
2899922|NCT03249246||Septic shock|Sepsis plus sepsis related hypotension
2899923|NCT03249233|Experimental|Keratoconics wearing ZenLens with high central clearance|Scleral contact lenses designed to provide approximately 450 microns of central clearance.
2899924|NCT03249233|Experimental|Keratoconics wearing ZenLens with low central clearance|Scleral contact lenses designed to provide approximately 350 microns of central clearance.
2899925|NCT03249233|Active Comparator|Healthy controls wearing ZenLens with high central clearance|Scleral contact lenses designed to provide approximately 450 microns of central clearance.
2899926|NCT03249233|Active Comparator|Healthy controls wearing ZenLens with low central clearance|Scleral contact lenses designed to provide approximately 350 microns of central clearance.
2899927|NCT03249220|Experimental|CBMS|
2899928|NCT03249207|Active Comparator|IL-1Ra twice daily|
2899929|NCT03249207|Placebo Comparator|Placebo twice daily|
2899930|NCT03249194|Experimental|HCV+ Donor Kidney Recipient|"All HCV- participants who receive an HCV+ donor kidney transplant will receive a first 'on-call' dose of Epclusa (sofosbuvir/velpatasvir; Gilead) and then three more doses on post-operative Day 1, 2 and 3. Donor HCV Genotype data will be available by Day 7 of transplant.~Patients will then be followed by serial HCV PCRs. Patients who are HCV PCR positive by Day 14 will be treated with Epclusa once daily x 12 weeks."
2899931|NCT03249181|Experimental|Dolutegravir|"Dolutegravir group (DTG+2 NRTIs) - to make best comparison with standard of care, these NRTIs should be those recommended by national policy.~Participants randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs"
2899932|NCT03249181|Active Comparator|Standard of Care (EFV + 2 NRTI backbone)|Participants randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy (EFV + 2NRTIs at both study sites).
2899933|NCT03249168|Experimental|case group|Duloxetine 60mg orally 12 hours before surgery
2899934|NCT03249168|Active Comparator|Control group|Placebo (glucose powder in a tablet) orally 12 hours before surgery
2899935|NCT03249155|Experimental|AO - plus sonification|patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture.
2899936|NCT03249155|Active Comparator|CUE - visual and auditory|patients re-learn 8 motor gestures practicing a traditional protocol combining visual and auditory cues.
2899937|NCT03249142|Experimental|ARM A Durvalumab/chemotherapy association|
2899938|NCT03249142|Experimental|ARM B Durvalumab/Tremelimumab/chemotherapy association|
2899939|NCT03249116|Active Comparator|Control|Active control - interaction with a therapy dog
2899940|NCT03249116|Experimental|Therapy dog - social|animal-assisted intervention - social interaction only with therapy dog during TSST.
2899941|NCT03249116|Experimental|Therapy dog - Social + physical|animal-assisted intervention - Social interaction and physical interaction with therapy dog during TSST.
2899942|NCT03249103|Placebo Comparator|Placebo|Up to 24 subjects will receive Placebo
2899943|NCT03249103|Experimental|NYX-2925 High Dose|Up to 24 subjects will receive High Dose of NYX-2925
2899944|NCT03249103|Experimental|Low Dose|Up to 24 subjects will receive Low Dose of NYX-2925
2899945|NCT03249090|Experimental|patient reporting symptoms + symptom guidelines|Patients report symptoms weekly via web or automated telephone system. Email alerts to nurses for severe/worsening symptoms; printouts for clinicians at visits. Evidence based symptom management pathways provided to patients and clinicians.
2899946|NCT03249090|Active Comparator|Usual care delivery + symptom guidelines|Evidence-based symptom management pathways provided to patients and clinicians
2899947|NCT03249077|Active Comparator|DPP enrolled|In the DPP enrolled arm, patients will be offered the opportunity to enroll in DPP online or DPP in-person. Once patients receive the recruitment letter via the electronic health record patient portal, they will be able to sign-up for the DPP online program using a web link or sign-up for the DPP in-person by contacting a staff member in KPNW Health Engagement and Wellness Services who will assist the patient in enrolling. The DPP online program is a CDC-certified translation of the DPP lifestyle intervention delivered in an online small group format of 10-15 participants. DPP in-person participants will attend group sessions of ~20 participants in size at KPNW clinics. The group facilitator will use the CDC National DPP curriculum.
2899948|NCT03249077|No Intervention|DPP not enrolled (usual care)|KPNW offers services to members with prediabetes to reduce their risk of progression to diabetes. Services include a one-time diabetes prevention class, group weight loss classes, and individual nutrition counseling. The Health Engagement and Wellness Services department offers individual phone and in-person counseling (generally one contact), small group programs, and virtual small group webinars. Thus, the not enrolled (usual care) arm is an ideal comparator to determine the effectiveness of DPP beyond services already provided.
2899949|NCT03249064||Vitiligo untreated patients|
2899950|NCT03249064||Control. Patients without vitiligo|
2899951|NCT03249051|Experimental|Indirect Calorimetry|The energy need is being determined by using indirect calorimetry and if necessary, optimized by parenteral, enteral and additive parenteral nutrition.
2899952|NCT03249051|No Intervention|Standard Care|"This group receives nutrition supply according to the hospital routine (standard care)"
2900028|NCT03248518|Active Comparator|Usual Care alone|Participants receive written information about fatigue which is designed as self-management guide.
2899953|NCT03249025|Experimental|Lidocaine-Ketamine Infusion|Lidocaine-Ketamine Infusions 1 time per month for 6 months. Pretreatment with Midazolam 1-3 mg IV Push or Subcutaneously and Clonidine 0.1 mg PO prior to infusion.
2899954|NCT03249012|Experimental|Empiric calcium and calcitriol repletion group|All patients in this group will receive post-operative calcium carbonate and calcitriol.
2899955|NCT03249012|Experimental|PTH based repletion group|Patients in this group will be prescribed calcium carbonate and calcitriol based on their post-operative PTH.
2899956|NCT03248999|Experimental|Experimental|realization of a rectal swab or stool sample for all the résidents included in the study.
2899957|NCT03248960|Experimental|iTreat Flu A+B Test and ellume.lab Flu A+B Test|"Upper respiratory tract samples from participants will be tested with:~iTreat Flu A+B Test; ellume.lab Flu A+B Test; Reverse Transcriptase Polymerase Chain Reaction (RT-PCR); and viral culture."
2899958|NCT03248947|Other|Pharmacy opioid use disorder care|A single-arm study to evaluate the feasibility and acceptability of transitioning office-based buprenorphine treatment of adult patients with opioid use disorder from physicians to pharmacists.
2899959|NCT03248934|Experimental|Patient Self-Administered Exam Group|Participants with hip pain presenting in the hip preservation clinics will be asked to complete two diagnostic exams. Participants with hip pain will first complete a patient self-administered diagnostic exam.
2899960|NCT03248934|Active Comparator|Clinician-Performed Exam Group|Participants with hip pain presenting in the hip preservation clinics will be asked to complete two diagnostic exams. Participants with hip pain will next complete a clinician-performed diagnostic exam.
2899961|NCT03248921||High-Fit obese|Cardiac surgery patients will be segregated into the high-fit group based on 6 minute walk test distance and other measures of functional capacity
2899962|NCT03248921||Low-Fit obese|Cardiac surgery patients will be segregated into the low-fit group based on 6 minute walk test distance and other measures of functional capacity
2899963|NCT03248908|Experimental|Intervention 1|Pupillary dilation reflex based perioperative intravenous remifentanil administration. Starting dose 5 ng/ml by continous infusion, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, the dosage is decreased with 0.2 ng/ml. When PPI score is greater than 1, the dosage is increased with 0.2 ng/ml.
2899964|NCT03248908|Active Comparator|Intervention 2|Anesthesiologist based perioperative intravenous remifentanil administration (daily practice, standard of care). Starting dose 5 ng/ml, dosage adjustments are made when deemed necessary by attending anesthesiologist.
2899965|NCT03248908|Experimental|Intervention 3|Pupillary dilation reflex based perioperative intravenous sufentanil administration. Starting dose 0.1 mcg/kg bolus, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, no supplementary administration is executed. When PPI score is greater than 1, a supplementary bolus of 0.1 mcg/kg is given.
2899966|NCT03248908|Active Comparator|Intervention 4|Anesthesiologist based perioperative intravenous sufentanil administration (daily practice, standard of care). Starting dose 0.1 mcg/kg bolus, dosage adjustments are made when deemed necessary by attending anesthesiologist.
2899967|NCT03248895|Active Comparator|Immediate (I-med)|Participants allocated to the I-med group will take part in the mobile DOT intervention for the first 6 weeks. Outcomes will be evaluated at the start (week 0) and end of the 6 week intervention period and during clinic visits at weeks 12 and 18 for follow-up
2899968|NCT03248895|Active Comparator|Delayed (D-med)|"Those participants allocated to the D-med group will have the DOT intervention started after a 6 week intervention-free interval with usual Asthma Clinic care. Outcomes in the D-med group will be assessed at baseline (week 0), week 6 (intervention start), week 12 (end of intervention), and at weeks 18 and 24 for follow-up."
2899969|NCT03248882|Placebo Comparator|Placebo|Double-Blind, PF-05221304-matching Placebo
2899970|NCT03248882|Active Comparator|PF-05221304 - 2 mg|PF-05221304 - 2 mg, once-daily
2899971|NCT03248882|Active Comparator|PF-05221304 - 10 mg|PF-05221304 - 10 mg, once-daily
2899972|NCT03248882|Active Comparator|PF-05221304 - 25 mg|PF-05221304 - 25 mg, once-daily
2899973|NCT03248882|Active Comparator|PF-05221304 - 50 mg|PF-05221304 - 50 mg, once-daily
2899974|NCT03248869|Active Comparator|Current Daily Survey|need description
2899975|NCT03248869|Experimental|Mobile Health App (MHA)|Participants download the mobile health app via the Apple App Store
2899976|NCT03248856|Other|Group 1|Group 1 will receive triamcinolone acetonide 10mg 20 to 24hours before sampling.
2899977|NCT03248856|Other|Group 2|Group 2 will receive triamcinolone acetonide 40mg 20 to 24hours before sampling.
2899978|NCT03248856|Other|Group 3|Group 3 will receive triamcinolone acetonide 10mg 1 to 2 hours before sampling.
2899979|NCT03248856|Other|Group 4|Group 3 will receive triamcinolone acetonide 40mg 1 to 2 hours before sampling.
2899980|NCT03248843|Experimental|KN035|Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1.0, 2.5, 5.0 and 10 mg/kg weekly. Dose escalation will continue until identification of MTD up to a maximum dose of 10 mg/kg.
2899981|NCT03248817|Experimental|single shot|spinal anesthesia will be performed using intrathecal bupivacaine. Then, a single shot phenylephrine (1.5 ug/Kg) will be administered
2899982|NCT03248817|Active Comparator|fixed infusion|spinal anesthesia will be performed using intrathecal bupivacaine. Then, fixed infusion phenylephrine will be administered at a dose of (0.75 mcg/Kg/min). the infusion will stop if reactive hypertension occurred
2899983|NCT03248817|Active Comparator|variable infusion|spinal anesthesia will be performed using intrathecal bupivacaine. Then, variable infusion phenylephrine will be administered at a starting dose of (0.75 mcg/Kg/min). the infusion will be titrated according to blood pressure
2899984|NCT03248804|Experimental|Soy Group|Subjects in the soy group were asked to participate in the Colorado Diet program and to consume 3 soy food items per day.
2899985|NCT03248804|Other|Non-soy Group|Subjects in the non-soy group were asked to participate in the Colorado Diet program and to avoid soy food products.
2899986|NCT03248791|Active Comparator|Phenylephrine|Will receive spinal anesthesia using Bupivacaine. Then, phenylephrine infusion by a starting rate of 0.75 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure
2899987|NCT03248791|Experimental|Norepinephrine|Will receive spinal anesthesia using Bupivacaine. Then, norepinephrine infusion by a starting rate of 0.1 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure
2899992|NCT03248752|Experimental|Group 1 - Physician monitored|Fitbit use and reports details: Participant will receive a Fitbit device to wear for 3 months. Weekly Fitbit reports will be sent to the participant's physician.
2899993|NCT03248752|Experimental|Group 2 - Family monitored|Fitbit use and reports details: Participant will receive a Fitbit device to wear for 3 months. Weekly Fitbit reports will be sent to the participant's spouse/partner.
2899994|NCT03248752|Experimental|Group 3 - Self monitored|Fitbit use and reports details: Participant will receive a Fitbit device to wear for 3 months. Weekly Fitbit reports will be seen only by the participant.
2899995|NCT03248752|Other|Group 4 - Control|Fitbit use and reports details: Participants will not receive a Fitbit device to wear.
2899996|NCT03248739|Active Comparator|Clear Bactiseal 'large' catheter (EVD)|All EVDs will be placed by neurological surgeons in either the major operating suite or in an ICU setting using a previously published protocol. This protocol includes using a burr hole entry point 1 cm anterior to the coronal suture in the mid-pupillary line, prep and sterile drape, pre-procedural antibiotic administration, and tunneling the catheter to an exit site at least 5 cm from the incision. In general, physicians are instructed to first attempt distal irrigation of the drainage chamber using sterile techniques (rarely effective), followed by gentle aspiration of the proximal system and catheter if distal flushing is not effective. If these do not restore patency, a small volume of sterile saline, 3 ml or less, is flushed proximally into the catheter. Patency is checked by lowering the EVD drainage system and evaluating for spontaneous flow through the EVD.
2899997|NCT03248739|Active Comparator|Orange Bactiseal 'small' catheter (EVD)|All EVDs will be placed by neurological surgeons in either the major operating suite or in an ICU setting using a previously published protocol. This protocol includes using a burr hole entry point 1 cm anterior to the coronal suture in the mid-pupillary line, prep and sterile drape, pre-procedural antibiotic administration, and tunneling the catheter to an exit site at least 5 cm from the incision. In general, physicians are instructed to first attempt distal irrigation of the drainage chamber using sterile techniques (rarely effective), followed by gentle aspiration of the proximal system and catheter if distal flushing is not effective. If these do not restore patency, a small volume of sterile saline, 3 ml or less, is flushed proximally into the catheter. Patency is checked by lowering the EVD drainage system and evaluating for spontaneous flow through the EVD.
2899998|NCT03248726|Experimental|Polyethylene glycol and bisacodyl|In order to decrease the dose and frequency of polyethylene glycol, we added bisacodyl at the night before examination to facilitate the action of polyethylene glycol given solely in the morning of examination.
2899999|NCT03248726|Active Comparator|Split-dose polyethylene glycol|The standard regimen of polyethylene glycol was used in this group. The participant of this arm receives polyethylene glycol in the evening before examination and the morning of examination .
2900000|NCT03248713|Active Comparator|Mifepristone|Mifepristone 600 mg/day in 2 tablets
2900001|NCT03248713|Placebo Comparator|Placebo|matching placebo in 2 tablets
2900002|NCT03248700|Experimental|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
2900003|NCT03248687|Experimental|Home follow up|Patients with a distal radius buckle fracture treated in a removable splint will be provided with discharge instructions and anticipatory guidance without any scheduled physician follow up.
2900004|NCT03248687|Active Comparator|Primary Care Physician Follow up|Patients with a distal radius buckle fracture treated in a removable splint will be provided with discharge instructions and anticipatory guidance with scheduled primary care physician follow up at 1-2 weeks post visit to the emergency department.
2900005|NCT03248661|Experimental|Intervention media condition|monthly social media contact will be used to keep people connected to the idea of completing a second screening test 12 months after their last one.
2900006|NCT03248661|No Intervention|control condition|this group will receive only a standard reminder for the annual repeat test, one month before the test due date
2900007|NCT03248648|Active Comparator|Neostigmine group|At the end of the surgery patients receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
2900008|NCT03248648|Active Comparator|ketamine group|At the end of the surgery patients receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
2900009|NCT03248635||Focus group|Male and female adults age 40-75
2900010|NCT03248622||Anti-HBc positive|Anti-HBc positive
2900011|NCT03248622||HCV positive Cohort|HCV positive Cohort
2900012|NCT03248609|Experimental|Milano grapes|Unique grape varietal to test glycemic response.
2900013|NCT03248609|Active Comparator|Table grapes|Common grape varietal to test glycemic response and compare to the glycemic response elicited by the Milano grape varietal.
2900014|NCT03248609|Active Comparator|Grape juice|Used to test the glycemic response without a complex food matrix and compare to the glycemic response elicited by the Milano grape varietal.
2900015|NCT03248609|Placebo Comparator|Glucose beverage|Used to test the glycemic response with a standardized glucose beverage and compare to the glycemic response elicited by the Milano grape varietal.
2900016|NCT03248583|Experimental|Default|
2900017|NCT03248583|Active Comparator|Psychoeducation|
2900018|NCT03248583|Active Comparator|Incentive|
2900019|NCT03248570|Experimental|DNA damage repair proficient group|Twenty-five subjects with mismatch repair (MMR) intact
2900020|NCT03248570|Experimental|DNA damage repair defective group|Twenty-five subjects with defective DNA repair
2900021|NCT03248557||Study|Comatose survivors (GCS ≤8) after RoSC, in whom neurological prognosis is unknown at the time of admission. Neurological performance of patients from the study group (prospective and retrospective) will be categorized according to a risk score obtained from the multivariate spectral-based model.
2900022|NCT03248557||Control|Patients who are conscious (GCS=15) and whose neurological status is known and good at admission.
2900023|NCT03248544|Experimental|vitamin D|Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection
2900024|NCT03248544|Other|control|Control patients will not be received any intervention
2900025|NCT03248531|Experimental|Bimekizumab|Subjects will receive one Bimekizumab loading dose 1 and several Bimekizumab dose 2 applications.
2900026|NCT03248531|Active Comparator|Adalimumab|Subjects will receive one Adalimumab loading (dose 1) and several Adalimumab dose 2 and dose 3 applications.
2900176|NCT03247517|Placebo Comparator|Placebo|Placebo qd
2900029|NCT03248518|Active Comparator|CBA + usual care|In addition to usual care, participants receive a talking therapy using a cognitive behavioural approach. The talking therapy will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 8 sessions over a period of 6 months.
2900030|NCT03248518|Active Comparator|PEP + usual care|In addition to usual care, participants receive a personalised exercise programme. After an initial face-to-face assessment, the remaining programme will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 7 sessions over a period of 6 months.
2900031|NCT03248505|Placebo Comparator|Placebo TENS|TENS unit turned on, but with zero amplitude.
2900032|NCT03248505|Experimental|Conventional TENS|Symmetrical biphasic pulsed current, with frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude.
2900033|NCT03248505|Experimental|Burst TENS|Carrier frequency of 100 Hz burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.
2900034|NCT03248505|Experimental|Cryotherapy|1,5 Kg crushed ice pack
2900035|NCT03248505|Experimental|Burst TENS + Cryotherapy|Carrier frequency of 100 Hz burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus an ice pack of 1,5 Kg.
2900036|NCT03248505|Experimental|Conventional TENS + Cryotherapy|Symmetrical biphasic pulsed current, with frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude plus an ice pack of 1,5 Kg.
2900037|NCT03248492|Experimental|DS-8201a Low Dose|T-DM1 resistant/refractory (R/R) patients in the low dose treatment group
2900038|NCT03248492|Experimental|DS-8201a Medium Dose|T-DM1 resistant/refractory (R/R) patients in the medium dose treatment group
2900039|NCT03248492|Experimental|DS-8201a High Dose|T-DM1 resistant/refractory (R/R) patients in the high dose treatment group
2900040|NCT03248492|Other|Exploratory Arm|In Part 2b- Continuation Stage, about 10 T-DM1 Intolerant patients will receive the DS-8201a recommended dose (RD) as an exploratory arm
2900041|NCT03248479|Experimental|Relapsed/Refractory AML or MDS|Patients with relapsed or refractory AML or intermediate/high risk MDS will receive Hu5F9-G4 monotherapy
2900042|NCT03248479|Experimental|Treatment-naive Unfit AML or MDS|Patients with previously untreated AML who are ineligible for standard induction chemotherapy, or previously untreated intermediate/high risk MDS, will receive Hu5F9-G4 in combination with azacitidine
2900043|NCT03248479|Experimental|Rollover|Patients on a previous AML Phase 1 trial (SCI-CD47-002) with clinical benefit on Hu5F9-G4 treatment will receive Hu5F9-G4 monotherapy
2900044|NCT03248466|Placebo Comparator|Traditional treatment|Traditional treatment such as insulin,antidiabetes,dressing
2900045|NCT03248466|Experimental|PRG combined with BMMSCs transplantation|Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG combined with BMMSCs
2900046|NCT03248466|No Intervention|PRG treatment|Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG
2900047|NCT03248453|Experimental|CoPS feedback|Each participant will as feedback be given the actual CoPS after reaching the cecum on the standardized Kagaku Training Model. A leaderboard with experts performances will be present for comparison.
2900048|NCT03248453|No Intervention|No CoPS feedback|No feedback is given and the participants are not aware of the CoPS
2900049|NCT03248440|Experimental|SUN-131 1.5% TDS|
2900050|NCT03248440|Placebo Comparator|Placebo TDS|
2900051|NCT03248427|Experimental|Ribociclib + Letrozol|Ribociclib: 600mg, 3-weeks-on/-week-off treatment Letrozole: 2.5mg daily; Six 28 days cycles
2900052|NCT03248427|Other|Chemotherapy|Chemotherapy treatment will consist of four cycles of AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days) followed by weekly paclitaxel during 12 weeks.
2900053|NCT03248414|Experimental|Lactobacillus sakei|2 packs per day
2900054|NCT03248414|Placebo Comparator|Control|2 packs per day
2900055|NCT03248401|Experimental|Cilostazol group|Cilostazol 200 mg or maximal tolerate dose
2900056|NCT03248401|Active Comparator|Aspirin group|Aspirin 100 mg
2900057|NCT03248388|Experimental|Adults with Retinitis Pigmentosa using ARGUS II|Subjects will use the ORCAM system mounted onto the Argus II eyeglasses.
2900058|NCT03248375|Other|Radiation Segmentectomy|Radiation Segmentectomy on Resectable HCC
2900059|NCT03248362|Experimental|TPTNS Intervention|Transcutaneous posterior tibial nerve stimulation (TPTNS) delivered in 30 minute sessions twice weekly over a 6 week period. The tibial nerve, which lies immediately posterior to the medial malleolus will be stimulated electrically using a portable TENS machine and two surface electrodes. The cathode electrode will be positioned behind the medial malleolus and the anode 10cm cephalad to it. Standardised stimulation parameters will be applied at 10 Hz frequency, 200µs-1 pulse width in continuous mode and stimulation intensity (mA-1) will be adjusted on a session-by-session basis according to individual resident comfort levels.
2900060|NCT03248362|Sham Comparator|Sham stimulation|Sham stimulation comprises low intensity, sub-clinical stimulation of the lateral sub-malleolar area, positioned specifically on the lateral aspect to avoid the tibial nerve, which runs close to the skin surface behind the medial malleolus. The stimulation parameters are identical to the TPTNS stimulation other than the intensity of the current which will be set at 4mA, rather than adjusted individually as it is in the TPTNS intervention group. The current will be initially increased until the resident reports feeling some sensation following which the current will be reduced down to 4mA. All residents will be informed that they may not feel anything with this intervention and that this is quite normal.
2900061|NCT03248349||1|Pharmacokinetics
2900062|NCT03248336|Experimental|Vision therapy group|Twelve, 60-minute, weekly visits of office-based vergence/accommodation therapy will be administered by a trained therapist combined with procedures to practice at home (15 minutes, 5 times per week). This treatment sequence is a well-accepted approach for treatment of CI and has been successfully implemented in previous studies. Fifteen minutes of home-based therapy was prescribed to be performed 5 days per week, and compliance with home-based therapy was monitored at each visit by the therapist
2900063|NCT03248323||pre-con|
2900064|NCT03248310||vascularized lymph node transfer (VLNT)|This is an observational study to assess QOL in patients who have elected to undergo or considered undergoing VLNT. There is no therapeutic intervention involved during the follow-up study period.
2900177|NCT03247517|Experimental|200mg SPN-812 ER|200mg SPN-812 ER qd
2900065|NCT03248310||non-surgical treatment|This is an observational study to assess QOL in patients who have elected to undergo or considered undergoing VLNT. There is no therapeutic intervention involved during the follow-up study period.
2900066|NCT03248297|Experimental|Azithromycin and amoxicillin placebo|Patients in this arm will receive 1 gram oral azithromycin as a single dose and amoxicillin placebo.
2900067|NCT03248297|Experimental|Azithromycin + amoxicillin|Patients in this arm will receive 1 gram oral azithromycin and 2 grams oral amoxicillin in a single dose.
2900068|NCT03248297|Placebo Comparator|Usual Care|This arm will consist of routine care at the clinical sites (which is usually no antibiotic). They will receive placebo (for azithromycin) and placebo (for amoxicillin)
2900069|NCT03248271||Type 2 Diabetes, Insulin Naive|Study participants will be tested prior to and 3 and 6 months after starting insulin to manage their diabetes
2900070|NCT03248245|Experimental|LOG-model schools|Experimental schools implement the LOG-model
2900071|NCT03248245|Active Comparator|Treatment as usual schools - TAU|Control schools performing interprofessional team collaboration as usual
2900072|NCT03248206|Active Comparator|PNF exercise program group|The PNF home-program exercise group: perform grade 1&2 two times a day, at least 3 times per week, for 3 sets of 12 repetitions to increase neuromuscular and musculoskeletal endurance. (Grade 1: The participants performs the diagonal- spiral pattern that will enhance the strength or movement of a targeted muscle or muscle group.; Grade 2:The participants performs PNF exercise with elastic bands . )
2900073|NCT03248206|Experimental|PNF in conjunction with tendon gliding exercise group|Patients in PNF in conjunction with TGE group will perform PNF grade 1&2 as well as tendon gliding exercise two times a day, at least 3 times per week, for 3 sets of 10 repetitions. Training duration for both the two groups is twelve weeks.
2900074|NCT03248193|Experimental|Healthy subjects|To assess safety and tolerability of scalp and limb hypothermia, as well as to determine the optimal temperature and pressure to be used. Establishing the occurrence or lack of core hypothermia will be studied.
2900075|NCT03248193|Experimental|Cancer subjects|Once the optimal temperature and pressure of scalp and limb hypothermia is established in healthy patients, a group of cancer patients will undergo concomitant scalp and limb hypothermia over multiple cycles of chemotherapy to establish safety and tolerability of repeated therapy.
2900076|NCT03248180||Guided dose reduction (GDR)|Patients in the GDR group will be advised to reduce < 25% of their current dose of antipsychotic agents estimated on a weekly base and follow-up every 4 weeks for at least 12 weeks.
2900077|NCT03248180||Maintenance treatment group (MTG)|Patients in the MTG will be advised to stay on their current dose of antipsychotics throughout the observational period, follow-up every 12 weeks.
2900078|NCT03248167|Experimental|Cannabidiol (CBD 400 mg daily)|6 weeks, such that both participants and study staff are blind to treatment condition.
2900079|NCT03248167|Placebo Comparator|Placebo|6 weeks, such that both participants and study staff are blind to treatment condition.
2900080|NCT03248154|No Intervention|Immunocompetent with 2-14% TBSA|Immunocompetent with 2-14% TBSA thermal burn subjects. Does biofilm infection result in conversion of partial-thickness burn wounds to full-thickness?
2900081|NCT03248154|Experimental|Immunocompromised with >=20% TBSA|Immunocompromised patients with large thermal burn >=20% TBSA. Higher bacterial burden with biofilm infection will result in higher rates of graft loss. Does application of a wireless electroceutical dressing (Procellera) lower biofilm burden compared to burn subjects receiving standard of care therapy?
2900082|NCT03248154|No Intervention|Peripheral blood - all subjects|All subjects enrolled in arms 1 and 2. Do children have a more robust innate immune response to prevent biofilm infection?
2900083|NCT03248141||Hemophilia B|real world administration patterns and resource utilization implications
2900084|NCT03248141||Hemophilia A|real world administration patterns and resource utilization implications
2900085|NCT03248128|Experimental|Subjects receiving FF/VI in cohort A|Subjects will be randomized in 1:1 ratio to receive a FDC of FF/VI with a dose of 50/25 mcg administered once daily in the morning via ELLIPTA DPI.
2900086|NCT03248128|Active Comparator|Subjects receiving FF in cohort A|Subjects will be randomized in 1:1 ratio to receive FF with a dose of 50 mcg administered once daily in the morning via ELLIPTA DPI.
2900087|NCT03248128|Experimental|Subjects receiving FF/VI in cohort B|Subjects will be randomized in 1:1 ratio to receive a FDC of FF/VI with a dose of 100/25 mcg administered once daily in the morning via ELLIPTA DPI.
2900088|NCT03248128|Active Comparator|Subjects receiving FF in cohort B|Subjects will be randomized in 1:1 ratio to receive FF with a dose of 100 mcg administered once daily in the morning via ELLIPTA DPI.
2900089|NCT03248102|Experimental|Patients with suspected appendicitis|Patients with suspected appendicitis Aged 5 and up to their 16th birthday on arrival to A&E
2900090|NCT03248076||Fentanyl citrate|Baseline blood sample and oocyte fluid will be collected under propofol anesthesia. Fifteen minutes after administration of 1γ/kgfentanyl, it will be collected again blood sample and oocyte fluid. Cortisone and fentanyl level will be measured in all samples.
2900091|NCT03248063|Active Comparator|Cloxacillin|Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 6 hours (without exceeding the maximum daily dose of 12 g/day), administered as a 30-minutes infusion.
2900092|NCT03248063|Experimental|Cefazolin|Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion.
2900093|NCT03248050|Experimental|Intervention pharmacy|Pharmacies in the intervention group will receive training, materials, and monitoring visits to encourage them to inform women who buy mifepristone + misoprostol or misoprostol alone to call the MSZ call centre for advice on how to use the pills before they take them.
2900094|NCT03248050|No Intervention|Control pharmacy|
2900095|NCT03248037|Experimental|Netarsudil|Netarsudil ophthalmic solution 0.02%, dosed topically once a day for 9 months
2900096|NCT03248037|Placebo Comparator|Placebo|Placebo eye drop, dosed topically once a day for 9 months
2900097|NCT03248011|Experimental|Flexibility|Stretching exercise
2900098|NCT03248011|Experimental|Strength|Eccentric hamstring strengthening exercise
2900099|NCT03248011|Experimental|Neuromuscular|Balance exercise
2900100|NCT03248011|No Intervention|Control|No exercise
2900178|NCT03247517|Experimental|400mg SPN-812 ER|400mg SPN-812 ER qd
2944361|NCT02942719||Suining Central Hospital|
2900101|NCT03247998|Experimental|General Anesthesia|"Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). General Anesthesia Protocol: (Melinda J. Davis, Cynthia R. Campos-Herrera, & David P. Archer, 2012; Powers et al., 2015; Talke et al., 2014). Patient will be monitored in accordance with standard monitoring guidelines and the rest of the procedure will proceed in accordance with standard of care.~See Detailed Description for additional details and description of follow-up procedures."
2900102|NCT03247998|Experimental|Conscious Sedation with Remifentanil|"Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Patient will be monitored in accordance with standard monitoring guidelines and the rest of the procedure will proceed in accordance with standard of care.~See Detailed Description for additional details and description of follow-up procedures."
2900103|NCT03247985|Active Comparator|PROLENE Polypropylene Tacking Mesh|Participants will be randomized to Tacking Mesh for their inguinal hernia surgery.
2900104|NCT03247985|Active Comparator|ProGrip Self-fixating Mesh|Participants will be randomized to Self-fixing mesh for their inguinal hernia surgery
2900105|NCT03247972||Patients with PAD|
2900106|NCT03247959|Experimental|Group A|Group A: Videogame distraction during extraction procedure
2900107|NCT03247959|Experimental|Group B|Group B: Video distraction during extraction procedure
2900108|NCT03247959|Active Comparator|Group C|group C: Verbatim during extraction procedure
2900109|NCT03247946|Active Comparator|Intervention group|intervention: upright head position
2900110|NCT03247946|No Intervention|Control group|no feeding position instructions
2900111|NCT03247933|Experimental|Telemedicine (TeleRR)|"The intervention: Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance Respiratory Rehabilitation supported by telemedicine (TeleRR).~A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.~The exercises dates must be sent after doing the training each day by the PDA . The dates will be monitoring by the physician ."
2900112|NCT03247933|No Intervention|Clinical Practice (Recommendation)|"No intervention. A recommendation from standard maintenance respiratory rehabilitation program with a minimum monitoring.~Clinical practice."
2900113|NCT03247920|Active Comparator|Oral group|"After 48 hours of intravenous antibiotics eligible neonates will switch to amoxicillin/clavulanic acid suspension for the remaining 5 days. When the oral suspension is well tolerated neonates can be discharged from hospital.~In order to investigate the pharmacokinetic profile of oral amoxicillin/clavulanic acid serum levels will be measured."
2900114|NCT03247920|Active Comparator|Intravenous group|Neonates will complete the full course of antibiotics of 7 days intravenously in hospital following local protocol.
2900115|NCT03247907|Active Comparator|Condition A: CPAP with No Humidification|CPAP with No Humidification with no mouth leak
2900116|NCT03247907|Active Comparator|Condition B: CPAP with No Humidification|CPAP with No Humidification with mouth leak
2900117|NCT03247907|Active Comparator|Condition C: CPAP with Cold Passover humidifier|CPAP with Cold Passover humidifier with mouth leak
2900118|NCT03247907|Active Comparator|Condition D: CPAP with Modified Humidifier|CPAP with Modified Humidifier with mouth leak
2900119|NCT03247907|Active Comparator|Condition E: CPAP with Ambient Tracking|CPAP with Ambient Tracking with mouth leak
2900120|NCT03247907|Active Comparator|Condition F: CPAP with Heated Humidification|CPAP with Heated Humidification at default setting with mouth leak
2900121|NCT03247907|Active Comparator|Condition G: CPAP with Heated Humidification|CPAP with Heated Humidification at max setting with mouth leak
2900122|NCT03247907|Active Comparator|Condition H: CPAP with New level humidification|CPAP with New level humidification with mouth leak
2900123|NCT03247894||MS patients who after labour|Patients with multiple sclerosis after labour in tertiary center was screened for progression of MS in 10 months period after labour
2900124|NCT03247881|Other|Nut Free Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet with 0 g/d of mixed nuts.
2900125|NCT03247881|Active Comparator|Added Mixed Nuts Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet which will include 2 servings (2 ounces) of mixed nuts per day (1 serving just prior to breakfast and 1 serving as an afternoon snack).
2900126|NCT03247868|Experimental|Botulinum toxin+SPRInt protocol|patients affected by cervical dystonia receive botulinum toxin treatment (EMG-US guided injections in dystonic muscles) for two times at T0 and T2; after T2 patients are treated also with SPRInt rehabilitation protocol based on motor learning techniques.
2900127|NCT03247855|Other|Minimal invasive coronary artery bypass graft|
2900128|NCT03247842|Active Comparator|suprascapular nerve block|
2900129|NCT03247842|No Intervention|non interventional group|
2900130|NCT03247829||Patients with CardioMEMS and LVAD|Patients with CardioMEMS and LVAD, previously implanted, will receive hemodynamic management using CardioMEMS
2900131|NCT03247803|Experimental|Air-Q SP|air-Q Self-Pressurizing intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mecury Medical, Clearwater, FL, USA)
2900132|NCT03247803|Experimental|Williams Intubating Airway|Airway Intubator, Williams, Adult Female, Single Use, Molded Surlyn Plastic, 9 cm or Airway Intubator, Williams, Adult Male, Single Use, Molded Surlyn Plastic, 10 cm
2900133|NCT03247790|Experimental|Lasmiditan (Period 1)|Lasmiditan given once orally during migraine attack.
2900134|NCT03247790|Experimental|Lasmiditan (Period 2)|Lasmiditan given once orally during inter-ictal period.
2900135|NCT03247777|Active Comparator|Traditional strengthening|These subjects performed traditional strengthening exercises of targeted muscle groups (For example, bench press, lat pulldowns, dead lifts and wrist curls)
2900136|NCT03247777|Active Comparator|Functional Strengthening|These subjects performed exercises that either mimicked golf (diagonal chop) or that required balance and stability (single leg dead lift)
2900137|NCT03247764||patients with epilepsy and depression|Patients with comorbidity of epilepsy and depression will be asked to use antidepressants such as selective serotonin reuptake inhibitor(SSRIs) or xylaria nigripes and followed up
2900138|NCT03247751|Experimental|one group|one group receiving NIDEK intraocular lens
2900139|NCT03247738|Experimental|Cangrelor|Cangrelor will be administered as 30 μg/kg bolus followed by 4 μg/kg/min infusion for 2 hours
2900140|NCT03247738|Placebo Comparator|Placebo|Normal saline bolus and infusion for 2 hours
2900141|NCT03247725|Active Comparator|Treatment as usual (waiting list)|Patients at this condition will receive the usual medical treatment at the pain unit, but they will not be monitored daily using the app.
2900142|NCT03247725|Experimental|Treatment as usual + app (without alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Because alarms will not be generated, physicians will not know if an undesired event is occuring despite the app is actually collecting data.
2900143|NCT03247725|Experimental|Treatment as usual + app (with alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
2900144|NCT03247712|Experimental|Treatment Cohort 1|Nivolumab administration (3 doses) and 5 days radiation therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
2900145|NCT03247712|Experimental|Treatment Cohort 2|Nivolumab administration (3 doses) and 3 days radiation therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
2900146|NCT03247699|Other|"Basel phenotyping cocktail capsule"|
2900147|NCT03247699|Other|"Basel phenotyping cocktail individual components"|
2900148|NCT03247686|Placebo Comparator|Placebo|Placebo
2900149|NCT03247686|Active Comparator|RSLV-132|Experimental drug
2900150|NCT03247673|Experimental|CT-P16|CT-P16 will be administrated once in IV infusion of 5mg/KG to healthy male subjects
2900151|NCT03247673|Active Comparator|EU-approved Avastin|EU-approved Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
2900152|NCT03247673|Active Comparator|US-licensed Avastin|US-licensed Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
2900153|NCT03247660|Experimental|PFMT&HE group|A directly pelvic floor muscle (PFM) training protocol will be applied. Participants will performed PFM exercises in the way proposed by the PERFECT scheme. Biofeedback exercises will be also performed in lithotomy position. If the evolution of the women will allow it, the last two treatment biofeedback sessions will be conducted in standing position, to train PFM in more challenging and functional situation. In this group participants will be also trained hypopressive breathing and will perform five hypopressive exercises: two postures in supine, one on four-kneeling, and two in standing position. Educational strategy will also be applied. The intervention will last 8 weeks, 2 sessions per week. Each session will last 40/50 minutes.
2900154|NCT03247660|Experimental|HE group|"Women will be instructed in thirty-three Hypopressives exercises (HE) described by the developer of the Hypopressive Abdominal Gymnastics, Dr. Caufriez plus Educational strategy.~The intervention will last 8 weeks, 2 sessions per week. Each session will last 40/50 minutes."
2900155|NCT03247660|Active Comparator|Control group|The educational strategy will consist of instruction of printed materials and dimensional anatomical models about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, weight lifting, high impact sports, constipation, smoking, or drinking too much caffeine. They will also instruct in toilet habits, and will be taught to use the knack maneuver before and during increases of intra-abdominal pressure. The intervention will last 8 weeks, 1 session per week. Each session will last 40/50 minutes.
2900156|NCT03247647|Experimental|Enhanced Intervention|Participants assigned to this arm will complete a personal values task before reviewing their personalized feedback (eCheckUpToGo).
2900157|NCT03247647|Placebo Comparator|Standard Intervention|Participants assigned to this arm will complete a writing task about the food they have eaten in the past 48 hours immediately before reviewing their personalized feedback (eCheckUpToGo).
2900158|NCT03247634|Experimental|Getting Ahead Program|12 staggered cohorts will be given the Getting Ahead program, using the established Getting Ahead in a Just-Gettin'-By World program. Six practices will be used. Each participant will come in for 16 session over an eight week period and will be followed up six months post intervention
2900159|NCT03247621|Experimental|Whatsapp|Participants will engage in Whatsapp chats on their smartphones during the taste test
2900160|NCT03247621|Placebo Comparator|Article|Participants will read a neutral article on their smartphones during the taste test
2900161|NCT03247621|Active Comparator|No Phone|Participants will not use their phones during the taste test
2900162|NCT03247608|Experimental|Ambio Health Remote Monitoring|Ambio Health is an end-to-end remote patient monitoring system which includes a weight scale, blood pressure meter and blood glucose meter with wireless transmission of biometric readings through a home gateway to a web-based care management application that provides population health remote patient monitoring and engagement with automated delivery of the CarePlans.
2900163|NCT03247595|Active Comparator|Polyethylene Glycol|Polyethylene Glycol 3350: 4 Liters
2900164|NCT03247595|Experimental|Magnesium Citrate Capsules|36 Magnesium citrate capsules
2900165|NCT03247582||Edoxaban|NVAF Patients treated with Edoxaban
2900166|NCT03247569||Edoxaban|Patients treated with Edoxaban
2900167|NCT03247556|Experimental|Placebo|
2900168|NCT03247556|Active Comparator|SPN-812 ER High Dose A|
2900169|NCT03247556|Active Comparator|SPN-812 ER High Dose B|
2900170|NCT03247543|Placebo Comparator|Placebo|Placebo will be administered once daily
2900171|NCT03247543|Active Comparator|High Dose A|SPN-812 ER high dose A will be administered once daily and compared to placebo
2900172|NCT03247543|Active Comparator|High Dose B|SPN-812 ER high dose B will be administered once daily and compared to placebo
2900173|NCT03247530|Placebo Comparator|Placebo|Placebo qd, oral capsule
2900174|NCT03247530|Experimental|100mg SPN-812 ER|SPN-812 ER Low Dose A, oral capsule
2900175|NCT03247530|Experimental|200mg SPN-812 ER|SPN-812 ER Low Dose B, oral capsule
2900179|NCT03247491|Experimental|Experimental|TAU + mindfulness applied face to face 8 sessions of 120 minutes/session Mindfulness and Compassion based intervention applied in groups of 12-15 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
2900180|NCT03247491|No Intervention|No intervention|Usual medical treatment (TAU) In this group the midwife will apply the usual treatment (childbirth education class in the third trimester of pregnancy).
2900181|NCT03247478||invasive breast cancer|Patients with invasive breast cancer who underwent computed tomography (CT) reconstruction of axillary lymph node for assessment of lymph node response after NAC are eligible for this study. Axillary lymph node metastasis is confirmed by fine needle aspiration (FNA) or core needle biopsy (CNB) at initial diagnosis.
2900182|NCT03247465|Experimental|"Group Fusion"|Trans aortic valve replacement with usual procedure with the addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
2900183|NCT03247465|No Intervention|"Group Control"|Trans aortic valve replacement with usual procedure
2900184|NCT03247452|Active Comparator|One-day low fiber diet|"Patients assigned to the active comparator will receive oral and written instructions about the same structured low fiber diet designed by an Endocrinologist but they will follow this diet only the day before colonoscopy.~2 liters of polyethylene glycol plus ascorbic acid will be administered"
2900185|NCT03247452|Experimental|Three-day low fiber diet|"Patients assigned to the experimental group will receive oral and written instructions about a structured low fiber diet designed by an Endocrinologist. They must follow this diet three days before colonoscopy.~2 liters of polyethylene glycol plus ascorbic acid will be administered"
2900186|NCT03247439|Experimental|Cartiva|Synthetic Cartilage Implant
2900187|NCT03247426||Evaluation individuals with exercise|Individuals who work in sitting position and do regular exercises will be recruited.
2900188|NCT03247426||Evaluation individuals without exercise|Individuals who work in sitting position and do not perform regular exercises will be recruited.
2900189|NCT03247413|Experimental|Dexamethasone|Lesions where dexamethasone 4 milligram is administered post-radiofrequency ablation
2900190|NCT03247413|Placebo Comparator|Placebo|Lesions where 1 milliliter of normal saline is administered post-radiofrequency ablation
2900191|NCT03247400|Active Comparator|1% simvastatin-acid sodium salt ointment|1% simvastatin-acid sodium salt ointment applied onto a predefined limb compared with placebo ointment applied onto an opposite limb
2900192|NCT03247400|Active Comparator|1% atorvastatin calcium salt ointment|1% atorvastatin calcium salt ointment applied onto a predefined limb compared with placebo ointment applied onto an opposite limb
2900193|NCT03247400|Placebo Comparator|Vehicle ointment|Placebo ointment applied onto limbs opposite to treated with active substances
2900194|NCT03247374|Experimental|"ProComp5 Infiniti Biofeedback"|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, a surface electrode will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and Masako maneuver, the first two with bolus administration, if possible. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist."
2900195|NCT03247374|Active Comparator|Standard Speech and Language Therapy|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and Masako maneuver, the first two with bolus administration, if possible. The control group will attend this training for 45 minutes, receiving verbal feedback from the speech and language therapist."
2900196|NCT03247361|Experimental|High-intensity IMT|"High-intensity IMT + Aerobic/resistance exercise~IMT: Training loads will be adjusted weekly to the maximal inspiratory pressure (MIP). In the first 2 weeks as adaptation, the protocol will be of 2 minutes warm-up with intensity 20% of MIP. The training will have 7 peaks of intensity with 70% of MIP for 30 sec, with 30-sec of passive rest between the peaks, finishing the training with 20% of MIP for 2 min, totaling 10 min and 30 sec. From the third week the protocol will be of 2 min warm-up with intensity 30% of MIP. The training will have 7 peaks of intensity with 70% of MIP for 60 sec, with 60-second of passive rest between the peaks, finishing the training with 20% of MIP for 2 min, totaling 17 min.~Exercise: see group Combined aerobic/resistance exercise"
2900197|NCT03247361|Active Comparator|Low-intensity IMT|"Low-intensity IMT + Aerobic/resistance exercise~IMT:Training loads will be also adjusted weekly to the maximal inspiratory pressure (MIP). In the first two weeks as adaptation, the protocol will be of 2 minutes warm-up with intensity 20% of MIP. The training will be held with 3 sets of 15 repetitions, with 40% of MIP, finishing the training with 20% of MIP for 2 minutes. From the third week the protocol will be of 2 minutes warm-up with intensity 30% of MIP. The training will be held with 3 sets of 15 repetitions, with 60% of MIP, finishing the training with 30% of MIP for 2 minutes.~Exercise: see group Combined aerobic/resistance exercise"
2900198|NCT03247361|Sham Comparator|Aerobic/resistance exercise|"Sham IMT + Aerobic/resistance exercise~Aerobic session will consist of a 4-min of warm-up, 20 minutes of exercise, and 4 min of cool-down. Intensity will set by the formula: Training HR = (maximum HR - resting HR) × intensity % + resting HR. Patients will exercise using 30 seconds, high-intensity work phases 0.7% followed by 1-minute recovery bouts 0.5%. Resistance exercise will consist of dynamic lower and upper limb exercise. Upper limb exercises will include 3 sets of exercises for each muscle group performed with 10 repetitions each. Lower limb exercises will include 3 sets of exercises for each muscle group performed with 12 repetitions each. Resistance exercises will be performed at 12-MR."
2900199|NCT03247322|Experimental|Intervention Group|Patients in the intervention cohort will have enhanced medication safety monitoring utilizing a Pharmacist-led medication therapy using mHealth application. The application will provide patients a useful tool to conduct self-care monitoring and management, including timely reminders to take medications, automated messages when patients miss multiple medication doses, tracking of medication side effects and reporting trends in blood pressures and glucoses (when applicable).
2900200|NCT03247322|No Intervention|Control Group|Subjects in the control group will receive the usual standard of follow up care for kidney transplant patients.
2900201|NCT03247309|Experimental|IMA201 Product|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~One dose of IMA201 product will be infused intravenously. Four dose levels will be evaluated. At least two patients per cohort will be treated.~Post-infusion of IMA201 product, administration of low-dose recombinant human interleukin-2"
2900202|NCT03247296||Group A|Patients taking Sofosbuvir and Daclatasvir
2900203|NCT03247296||Group B|Patients taking Sofosbuvir,Daclatasvir, and Ribavirin
2900204|NCT03247283|Experimental|Single Oral Dose of BMS-986205|
2900205|NCT03247270|Experimental|Intervention I|Physical exercise intervention: 12 week exercise program with low-intensity fitness training 3 times per week.
2900206|NCT03247270|Experimental|Intervention II|Physical exercise intervention:12 week exercise program with moderate to high-intensity fitness training 3 times per week
2900207|NCT03247270|No Intervention|Control group|Control group, who will have a physiotherapy session once and will be given general advice about physical activity.
2900208|NCT03247257|Active Comparator|Group A: General Anesthesia|35 patients will be randomized to receive general anesthesia during their laparoendoscopic single site incision cholecystectomy.
2900209|NCT03247257|Active Comparator|Group B: Epidural Anesthesia|35 patients will be randomized to receive epidural anesthesia during their laparoendoscopic single site incision cholecystectomy.
2900210|NCT03247244|Other|1|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: A (THC 10%, CBD <0.5%), B (THC 8.6%, CBD 8.6%), C (THC 0.6%, CBD 14%) and placebo D (THC <0.3%, CBD <0.3%).
2900211|NCT03247244|Other|2|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: B (THC 8.6%, CBD 8.6%), placebo D (THC <0.3%, CBD <0.3%), A (THC 10%, CBD <0.5%), C (THC 0.6%, CBD 14%).
2900212|NCT03247244|Other|3|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: C (THC 0.6%, CBD 14%), A (THC 10%, CBD <0.5%), placebo D (THC <0.3%, CBD <0.3%), B (THC 8.6%, CBD 8.6%).
2900213|NCT03247244|Other|4|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: placebo D (THC <0.3%, CBD <0.3%), C (THC 0.6%, CBD 14%), B (THC 8.6%, CBD 8.6%), A (THC 10%, CBD <0.5%).
2900214|NCT03247218|Experimental|Single group of patients|"In this study 40 patients with SCD will be included. Twenty patients aged 18 years or older (cohort 1) and twenty patients 10 - 17 years old (cohort 2).~All the patients will receive Memantine Teva® film-coated tablets (Memantine hydrochloride) produced by Teva Pharma AG and will be provided as 5 mg, 10 mg, and 20 mg tablets packed in blister.~The study drug will be taken once a day per os, during one year."
2900215|NCT03247205|Experimental|HipERS|A trained physical therapist will visit each participant for a 1-hour session 3 times a week for the initial 2 weeks, and then 2 times a week for 4 weeks (total 14 hours over 6 weeks).
2900216|NCT03247192|Experimental|Whey protein-placebo|"Participants received a dose of 35 grams of whey protein before resistance training (RT) and a dose of 35 grams of maltodextrin (placebo) after RT.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
2900217|NCT03247192|Experimental|Placebo-whey protein|"Participants received a dose of 35 grams of maltodextrin (placebo) before resistance training (RT) and a dose of 35 grams of whey protein after RT.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
2900218|NCT03247192|Placebo Comparator|Placebo-placebo|"Participants received a dose of 35 grams of maltodextrin (placebo) before and after resistance training.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
2900219|NCT03247179|Experimental|PTSD Coach Condition|PTSD Coach App
2900220|NCT03247179|No Intervention|Treatment as Usual Condition|Treatment as Usual
2900221|NCT03247166|Experimental|Lower Back and Leg Pain Patients|Patients suffering from lower back and leg pain resulting in degenerative spondylolisthesis and/or spinal stenosis will undergo treatment using the TOPS™ System
2900222|NCT03247153|Experimental|Corticosteroid Therapy Patients|Corticosteroid therapy patients will be examined by echocardiography before, during and after receiving treatment
2900223|NCT03247140|Experimental|Group I (JLP-1401)|JLP-1401(Telmisartan 80 mg, amlodipine 10 mg, rosuvastatin 20 mg)
2900224|NCT03247140|Experimental|Group II(Telmisartan/Amlodipine, Rosuvastatin)|Twinsta(Telmisartan 40 mg, amlodipine 5 mg) 2 tab and Crestor(rosuvastatin 20 mg)
2900225|NCT03247127|Other|HA-WBRT|Patients with brain metastases outside a 5-mm margin around either hippocampus and are eligible to this study will receive hippocampal avoidance whole brain radiotherapy 30 gray (Gy) in 10 fractions. The primary endpoint is Wechsler Memory Scale (Chinese) and cognitive abilities screening instrument (CASI) at 4 months.
2900226|NCT03247114|Experimental|Water-glucose-sucralose-fructose-sucrose|First plain water, then glucose, then sucralose, then fructose and then sucrose
2900227|NCT03247114|Experimental|water-sucralose-glucose-sucrose-fructose|First plain water, then sucralose, then glucose, then sucrose and then fructose
2900911|NCT03242213|Active Comparator|Mobile App|Standard of Care and Mobile App
2900228|NCT03247114|Experimental|Glucose-water-fructose-sucralose-sucrose|First glucose, then plain water, then fructose, then sucralose and then sucrose
2900229|NCT03247114|Experimental|Glucose-fructose-water-sucrose-sucralose|First glucose, then fructose, then plain water, then sucrose and then sucralose
2900230|NCT03247114|Experimental|Fructose-glucose-sucrose-water-sucralose|First fructose, then glucose, then sucrose, then plain water and then sucralose
2900231|NCT03247114|Experimental|Fructose-sucrose-glucose-sucralose-water|First fructose, then sucrose, then glucose, then sucralose and then plain water
2900232|NCT03247114|Experimental|Sucrose-fructose-sucralose-glucose-water|First sucrose, then fructose, then sucralose, then glucose and then plain water
2900233|NCT03247114|Experimental|Sucrose-sucralose-fructose-water-glucose|First sucrose, then sucralose, then fructose, then plain water and then glucose
2900234|NCT03247114|Experimental|Sucralose-water-sucrose-glucose-fructose|First sucralose, then plain water, then sucrose, then glucose and then fructose
2900235|NCT03247114|Experimental|Sucralose-sucrose-water-fructose-glucose|First sucralose, then sucrose, then plain water, then fructose and then glucose
2900236|NCT03247101|Experimental|Probiotics group|Miyarisan-BM (Clostridium Butyricum Miyairi) 40 mg po tid x 6 months
2900237|NCT03247101|Active Comparator|Urso group|ursodoxycholic acid, 200mg po tid x 6 months
2900238|NCT03247101|Active Comparator|Biotase group|Biotase 1# [Biodiastase 30mg + lipase 65mg + newlase 10mg]/tab po tid x 6 months
2900239|NCT03247088|Experimental|Matched Related Donors|"On Days -24 through -5, Sorafenib as a tablet by mouth once or twice a day.~Busulfan by vein over on 2 separate days as either an outpatient in the clinic or as an inpatient in the hospital. Then Busulfan given on Days -6 through -3.~Fludarabine by vein given on Days -6 through -3.~Stem cell transplant by vein on Day 0.~Cyclophosphamide by vein on Days +3 and +4.~Mesna by vein every 4 hours for a total of 10 doses on Days +3 and +4.~Starting on Day +5, Tacrolimus nonstop by vein until able to take it by mouth to help lower the risk of GVHD. Then Tacrolimus by mouth 2 times a day for about 50 days.~Starting on Day +7, Filgrastim as an injection under the skin 1 time a day, until blood cell levels are high enough.~Starting between Day +30 and Day +120, Sorafenib as a tablet by mouth twice a day for up to 1 year."
2900240|NCT03247088|Experimental|Matched Unrelated Donors|"On Days -24 through -5, Sorafenib as a tablet by mouth once or twice a day.~Busulfan by vein over on 2 separate days as either an outpatient in the clinic or as an inpatient in the hospital. Then Busulfan given on Days -6 through -3.~Fludarabine by vein given on Days -6 through -3.~Stem cell transplant by vein on Day 0.~Cyclophosphamide by vein on Days +3 and +4.~Mesna by vein every 4 hours for a total of 10 doses on Days +3 and +4.~Starting on Day +5, Tacrolimus nonstop by vein until able to take it by mouth to help lower the risk of GVHD. Then Tacrolimus by mouth 2 times a day for about 50 days.~Starting on Day +5, MMF as a tablet by mouth 3 times a day for 90 days or longer, if participant has a matched unrelated donor.~Starting on Day +7, Filgrastim as an injection under the skin 1 time a day, until blood cell levels are high enough.~Starting between Day +30 and Day +120, Sorafenib as a tablet by mouth twice a day for up to 1 year."
2900241|NCT03247075|Experimental|Internet-delivered Cognitive Behavior Therapy|10 weeks of guided Internet-delivered Cognitive Behavior Therapy
2900242|NCT03247075|Active Comparator|Internet-delivered Support and Counseling|10 weeks of guided Internet-delivered support and counseling
2900243|NCT03247062|Other|Cohort study (Before-after desgin)|"Quality improvement - sleep bundle Intervention consists in a sleep bundle, an aggregate of several propositions to improve the sleep of patients.: implementation of a sleep bundle.~The entire ICU population will be observed before and after intervention."
2900244|NCT03247023||Integra Cadence Total Ankle System|
2900245|NCT03246997|Other|Autumn Group|Intervention Group
2900246|NCT03246997|Other|Spring Group|Delayed Intervention
2900247|NCT03246984|Experimental|VasQ device implantation|
2900248|NCT03246971|Experimental|Wafermine™|
2900249|NCT03246971|Placebo Comparator|Placebo|
2900250|NCT03246958|Experimental|Nivolumab alone for two weeks|Ipilimumab will be administered via IV infusion, starting two weeks after Nivolumab
2900251|NCT03246958|Experimental|Ipilimumab alone for two weeks|Nivolumab will be administered via IV infusion, starting two weeks after Ipilimumab
2900252|NCT03246945|Experimental|Study Arm|Patient-Parent Dyad receiving photography instructions prior to taking photographs of skin conditions
2900253|NCT03246945|No Intervention|Control Arm|Patient-Parent Dyad not receiving photography instructions prior to taking photographs of skin conditions
2900254|NCT03246932|Experimental|Peer-led psycho-education group|A structured, researcher-designed peer expert-led psycho-education program (6 months), comprised of 12 bi-weekly, 2-hour group sessions (10-12 patients per group). The program was based on the psycho-education and self-help, problem-solving programs by Chien et al. (2010) and Lehman et al. (2004).
2900255|NCT03246932|Other|Routine psychiatric care|Routine psychiatric outpatient care, including medication, psychiatric consultation in outpatient clinic, brief education by psychiatric nurses, financial and social welfare advices by social workers, and individual counseling by clinical psychologist.
2900256|NCT03246932|Active Comparator|Profession-led psycho-education group|A psycho-education group program (12 sessions, bi-weekly) based on Dr. Macpherson's Family Psychoeducation Program in 1996 and Chien and Bressington's one in 2014/15 will be used.
2900257|NCT03246919|Placebo Comparator|Control (Group A)|One bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia. This amount of fluid is part of standard of care.
2900258|NCT03246919|Active Comparator|Intervention (Group B)|One bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia. This amount of fluid is part of standard of care.
2900259|NCT03246906|Experimental|Arm I (mycophenolate mofetil, cyclosporine, sirolimus)|Patients undergo allogeneic HCT at day 0. Patients with an HLA-matched unrelated donor receive mycophenolate mofetil PO on days 0 to 40, cyclosporine PO every 12 hours BID on days -3 to 96 then tapered to day 150, and sirolimus PO QD on days -3 to day 150 then tapered to day 180. Patients with an HLA-mismatched donor receive mycophenolate mofetil PO on days 0-100 then tapered to day 150, cyclosporine PO BID on days -3 to 150 then tapered to day 180, and sirolimus PO QD on days -3 to 180 then tapered to day 365.
2900260|NCT03246906|Experimental|Arm II (cyclosporine, sirolimus, cyclophosphamide)|Patients undergo HCT at day 0. Patients with an HLA-matched unrelated donor receive cyclosporine PO BID on days 5-96 then tapered to day 150, sirolimus PO QD on days 5-150 then tapered to day 180, and cyclophosphamide IV on days 3 and 4. Patients with an HLA-mismatched donor receive cyclosporine PO BID on days 5-150 then tapered to day 180, sirolimus PO QD on days 5-180 then tapered to day 365, and cyclophosphamide IV on days 3 and 4.
2900261|NCT03246893|Placebo Comparator|Noninvasive positive pressure ventilation|After extubation, patient will receive non invasive positive pressure ventilation (NIV) for prevent respiratory and reintubation
2900262|NCT03246893|Experimental|High flow oxygen nasal cannula|After extubation, patient will receive high flow oxygen cannula for prevent respiratory and reintubation
2900263|NCT03246880|Experimental|Tamsulosin 0.2mg+Tadalafil 5mg|Tamsulosin 0.2mg+Tadalafil 5mg, po, q.d.
2900264|NCT03246880|Active Comparator|Tamsulosin 0.2mg|Tamsulosin 0.2mg, po, q.d.
2900265|NCT03246880|Active Comparator|Tadalafil 5mg|Tadalafil 5mg, po, q.d.
2900266|NCT03246867|Experimental|Isolytic stretching group|The participants in this group will receive isolytic stretching in modified cross body position.
2900267|NCT03246867|Experimental|Static stretching group|The participants in this group will receive static stretching in modified cross body position.
2900268|NCT03246867|Active Comparator|Control group|The participants in this group will receive no stretching. They will only be evaluated.
2900269|NCT03246854|Experimental|DBPR112|
2900270|NCT03246841|Other|Analysis of the gene panel|The laboratory will carry out the TUMOSPEC gene panel analysis at the same time as the BRCA1 and BRCA2 analysis and will return a negative (no mutation) or positive (presence of a mutation allowing enrolment of family members) result.
2900271|NCT03246828|Experimental|Omission of gliclazide|
2900272|NCT03246815||universal opt-out screening for STDs|Patients who present to primary care practices who employee a universal opt-out strategy to medical assistants or nurses
2900273|NCT03246815||without universal opt-out screening for STDs|Patients who present to primary care practices who do not employee a universal opt-out strategy to medical assistants or nurses
2900274|NCT03246802|Experimental|HDR partial prostate brachytherapy|2 fractions of high dose rate prostate brachytherapy will be delivered to the site of recurrent disease as determined by mp-MRI
2900275|NCT03246789|Experimental|Engage-M|Participants will meet individually with a therapist once before beginning weekly group sessions for eight weeks. Each weekly session will last approximately 50 minutes. Study investigators have trained Engage-M therapists to provide participants with a group therapy approach called Engage-M. During the weekly therapy sessions, therapists will encourage participants to engage in physical and social activities that you find pleasurable or rewarding.
2900276|NCT03246789|Active Comparator|Wellness in Mind and Body (W-MH)|Participants will meet with a therapist for group therapy once a week for eight weeks. Each weekly session will last approximately 50 minutes. During these weekly sessions, the therapist will educate participants about health and mental health.
2900277|NCT03246776|Experimental|Halometasone Triclosan Cream|All subjects receive external Use of Halometasone Triclosan Cream
2900278|NCT03246763|Experimental|Durham County|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
2900279|NCT03246763|Experimental|Richmond/Montgomery Counties|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
2900280|NCT03246763|Experimental|TBD|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
2900313|NCT03246529|Experimental|BL-8040 1.25mg/kg + G-CSF|double-blind placebo-controlled setting designed to assess the safety, tolerability and efficacy of G-CSF + BL-8040 as compared to G-CSF + Placebo, for stem cell mobilization in MM.
2900314|NCT03246529|Active Comparator|Placebo + G-CSF|double-blind placebo-controlled setting designed to assess the safety, tolerability and efficacy of G-CSF + BL-8040 as compared to G-CSF + Placebo, for stem cell mobilization in MM.
2900315|NCT03246516|Experimental|Questionnaire|Auto and hetero questionnaire
2900316|NCT03246490|Other|All Participants|All participants complete the same study procedures, which involve drinking alcohol to a .08 blood alcohol level and walking short distances while their blood alcohol level is increasing to .08 and decreasing down to .00.
2900281|NCT03246763|Experimental|To be determined|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
2900282|NCT03246750|Experimental|B-MAD chemotherapy|Brentuximab Vedotin, Methotrexate, L-Asparaginase, and Dexamethasone
2900283|NCT03246737||pregnant women|
2900284|NCT03246724|Experimental|Cataract Procedures|"The following ocular procedures will fall under this arm of the study:~• Cataracts~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
2900285|NCT03246724|Experimental|Retina Procedures|"The following ocular procedures will fall under this arm of the study:~Pars plana vitrectomy~Pars plana vitrectomy with cataracts, epiretinal membrane peel, pars plana lensectomy, and/or endolaser, silicone oil removal~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
2900286|NCT03246724|Experimental|Cornea Procedures|"The following ocular procedures will fall under this arm of the study:~Descemet Stripping Endothelial Keratoplasty (DSEK)~Cataracts with Descemet Stripping Endothelial Keratoplasty (DSEK)~Descemet Membrane Endothelial Keratoplasty (DMEK)~Cataracts with Descemet Membrane Endothelial Keratoplasty (DMEK)~Conjunctival and/or corneal lesion excisions~Pterygium~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
2900287|NCT03246724|Experimental|Glaucoma Procedures|"The following ocular procedures will fall under this arm of the study:~Ahmed valve~Ahmed valve with cataracts~Trabeculectomy~Trabeculectomy with cataracts~Baerveldt~Baerveldt with cataracts~Endocyclophotocoagulation~Endocyclophotocoagulation with cataracts~Istent~Cataracts with istent~Kahook~Cataracts with kahook~Cypass~Cypass with cataracts~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
2900288|NCT03246711||Totally fasting|Fasting each day from sunrise to sunset the whole month
2900289|NCT03246711||Partially fasting|means fasting from sunrise to sunset part of the month
2900290|NCT03246711||Non fasting|women who did not fast at all
2900291|NCT03246698|Experimental|Isolytic stretching group|The participants in this group will receive isolytic stretching in modified cross body position. Additionally they will receive standard physiotherapy.
2900292|NCT03246698|Experimental|Static stretching group|"The participants in this group will receive static stretching in modified cross body position.~Additionally they will receive standard physiotherapy."
2900293|NCT03246698|Active Comparator|Control group|The participants in this group will receive only standard physiotherapy.
2900294|NCT03246685|Experimental|Pembrolizumab Failures|Imprime PGG + Pembrolizumab
2900295|NCT03246685|Experimental|Active Stable Disease on Pembrolizumab|Imprime PGG + Pembrolizumab
2900296|NCT03246672|Experimental|maintenance|behavioral intervention to increase adherence to lifestyle recommendations
2900297|NCT03246659|Experimental|arm 1|111In-CP04
2900298|NCT03246659|Experimental|arm 2|111In-CP04 with co-administration of gelofusine/gelaspan
2900299|NCT03246646|Experimental|Coaching|Telephone coaching along with web-based CRAFT course
2900300|NCT03246633|Other|Perceptual Training|Single-Arm study, all participants will receive educational training via online modules and will be assessed after completion of the training.
2900301|NCT03246620|Experimental|Olanzapine|oro-dispersible tablet (wafer)(Zyprexa), 5 mg, single dose
2900302|NCT03246620|Active Comparator|Haloperidol|Haloperidol encapsulated tablet, 2 mg tablet, single dose
2900303|NCT03246620|Active Comparator|Diazepam|Diazepam encapsulated tablet, 2mg tablet, single dose
2900304|NCT03246607||Monitoring with MicroEye & ContinuMon|72 hour study interval with monitoring using intravascular glucose monitoring system alongside routine clinical care.
2900305|NCT03246594|Experimental|Esophageal Probe|"Participants in this group will receive ablation for atrial fibrillation with a oesophageal probe placed for temperature monitoring.~Placement of oesophageal probe for temperature measurement"
2900306|NCT03246594|Experimental|No Esophageal Probe|"Participants in this group will receive ablation for atrial fibrillation without a oesophageal probe placed for temperature monitoring.~Intervention: Power limitation of RF generator"
2900307|NCT03246581|Experimental|Test Product|tiotropium pMDI 2 inhalations
2900308|NCT03246581|Active Comparator|Commercial Product|tiotropium pMDI 2 inhalations
2900309|NCT03246568|Active Comparator|Pulmonary vein isolation alone|PVI by cryo-balloon ablation without linear ablation
2900310|NCT03246568|Experimental|Renal nerve denervation|PVI by cryo-balloon ablation without linear ablation plus bilateral RND using a multi-electrode renal denervation catheter.
2900311|NCT03246555|Experimental|Fimasartan or Fimasartan/Hydrochlorothiazide|
2900312|NCT03246555|Active Comparator|Perindopril or Perindopril/Indapamide|
2900317|NCT03246464|Placebo Comparator|Single-vision spectacles|
2900318|NCT03246464|Active Comparator|Orthokeratology lenses|
2900320|NCT03246451|Experimental|Metformin|Metformin, oral tablet 2-4 x 500 mg in 14 days and in liquid meal.
2900321|NCT03246451|Experimental|Saline|Saline infusion (9mg/mL) on experimental days
2900322|NCT03246451|Experimental|Exendin(9-39)|Exendin(9-39) infusion. GLP-1 receptor antagonist used as a study tool on experimental days.
2900323|NCT03246438|Experimental|Control|Colonoscopy only outreach and follow-up
2900324|NCT03246438|Experimental|Sequential Choice|Colonoscopy outreach + mailed FIT follow-up
2900325|NCT03246438|Experimental|Active Choice|Colonoscopy + mailed FIT outreach and follow-up
2900326|NCT03246425|Active Comparator|1. Volume control- Pressure control- APRV- VPA group|
2900327|NCT03246425|Active Comparator|2. Pressure control- APRV- Volume control- PAV group|
2900328|NCT03246425|Active Comparator|3. APRV- Volume control- pressure control- AVP group|
2900329|NCT03246412|Experimental|Nevus doctor clinical decision support|"The GPs have access to the clinical decision support tool Nevus doctor."
2900330|NCT03246412|No Intervention|Control|"The GPs have no access to the clinical decision support tool Nevus Doctor."
2900331|NCT03246399|Experimental|0.03mg SM04690|0.03mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
2900332|NCT03246399|Experimental|0.07mg SM04690|0.07mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
2900333|NCT03246399|Experimental|0.15mg SM04690|0.15mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
2900334|NCT03246386|Experimental|Obese subjects|Subjects with a BMI>35 kg/m2
2900335|NCT03246386|Active Comparator|Non-obese subjects|Subjects with a BMI>18.5 and <25 kg/m2
2900336|NCT03246360|Active Comparator|Intermittent administration of cloxacillin|
2900337|NCT03246360|Experimental|continuous administration of cloxacillin|
2900338|NCT03246347|Experimental|Single Arm|Docetaxel + Enzalutamide + Androgen Deprivation Therapy
2900339|NCT03246334||Cohort|Case group: critically ill patients admitted >12 hours to the ICU. Control group: critically ill patients to the ICU <12 hrs, or to Post Anaesthesia Care Unit (PACU), or Medium Care or High Dependency Unit.
2900340|NCT03246321|Experimental|PIPAC|Instead of standard palliative systemic therapy, patients receive upfront laparoscopic PIPAC with oxaliplatin (92 mg/m2) and simultaneous intravenous bolus 5-fluorouracil/leucovorin (400/20 mg/m2), intentionally repeated with an interval of six weeks until intraperitoneal disease progression, unfitness for laparoscopy, or laparoscopic non-access. In case of intraperitoneal disease progression, unfitness for laparoscopy, or laparoscopic non-access, patients intentionally receive standard palliative systemic therapy, while further PIPAC-procedures are cancelled. In case of systemic disease progression with intraperitoneal disease response or stable disease, patients intentionally receive standard palliative systemic therapy, while further PIPAC-procedures are intentionally continued until intraperitoneal disease progression, unfitness for laparoscopy, or laparoscopic non-access.
2900341|NCT03246295||Gestational diabetes mellitus|Those women were diagnosed as gestational diabetes mellitus
2900342|NCT03246295||Control|Those women were diagnosed without gestational diabetes mellitus
2900343|NCT03246282|Experimental|Treatment Group|"Polychromatic light emitting diode system is a non-significant risk device that administers low-dose light generated by light emitting diode(s). A small adapter attaches directly to a standard 20-guage catheter that threads a small fiber optic through the distal end of the catheter. The optic terminates at the proximal end of the catheter. Polychromatic light is emitted to illuminate the catheter near the site of catheter entrance. Concurrently, normal saline flows through the optic adapter, into and through the 20-gauge catheter.~Device: UVL1000 Treatment Station Drug: Normal Saline 0.9% Infusion Solution Bag Device: Peripheral Catheterization"
2900344|NCT03246269||MoCA cohort|The German MoCA is administered once to all study participants.
2900345|NCT03246256||Group 1|Patients with acute ischaemic stroke who were administered intavenous thrombolysis or patients with acute ischaemic stroke refusing intravenous thrombolysis; recall in both cases 60 to 90 minutes after the informed consent procedure
2900346|NCT03246256||Group 2|1st of 2nd degree relatives of patients with acute ischaemic stroke, who witnessed the informed consent procedure
2900347|NCT03246256||Group 3|Stroke patients with acute or subacute ischaemic stroke with a contraindication for intravenous thrombolysis
2900348|NCT03246256||Group 4|Patients without an ischaemic stroke but similiar risk factors (admitted to the Departement of Cardiology and Pneumology, Charité, Campus Benjamin Franklin, Berlin, Germany)
2900349|NCT03246256||Group 5|Patients with acute ischaemic stroke who were administered intavenous thrombolysis - recall 24 hours after the informed consent procedure
2900350|NCT03246243||Preterm infants with and without HIE|Group A will consist of preterm infants born < 37 weeks gestational age. Subjects will be further classified as not having or having a brain lesion on MRI scan. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. In addition, EEG and EMG data will be collected while the infant is at rest during one of the first and one of the last sucking sessions using the WaveGuard (TM) EEG cap. An anatomical and resting-state fMRI/DTI scan will also be conducted to estimate structural connectivity during sleep following a sucking session and simultaneous resting-state MEG/EEG data will be recorded from the infant during sleep with the BabyMEG.
2900351|NCT03246243||Term infants with HIE|Group B will consist of term infants admitted to the NICU for therapeutic hypothermia at risk of developing HIE, have concerns for neonatal stroke, and have seizures of unknown etiology. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. In addition, EEG and EMG data will be collected while the infant is at rest during one of the first and one of the last sucking sessions using the WaveGuard (TM) EEG cap. An anatomical and resting-state fMRI/DTI scan will also be conducted to estimate structural connectivity during sleep following a sucking session and simultaneous resting-state MEG/EEG data will be recorded from the infant during sleep with the BabyMEG.
2900416|NCT03245762|Placebo Comparator|IN-placebo|Intervention: 4 IU/day of placebo via nasal spray device each morning.
2900417|NCT03245736|Experimental|Tisotumab Vedotin|All patients will be administered tisotumab vedotin (HuMax-TF-ADC) in 21 day treatment cycles.
2900418|NCT03245723||National Lung Project Cohort|Individuals born premature that are registered on the National Lung Project. Individuals are in their late twenties. Subjects will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging.
2900352|NCT03246243||Term infants healthy at birth|Term infants recruited from the community will be observed during a single visit to BCH. If inpatient, recordings will be taken for the duration of the hospital stay. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. In addition, EEG and EMG data will be collected while the infant is at rest during one of the first and one of the last sucking sessions using the WaveGuard (TM) EEG cap. An anatomical and resting-state fMRI/DTI scan will also be conducted to estimate structural connectivity during sleep following a sucking session and simultaneous resting-state MEG/EEG data will be recorded from the infant during sleep with the BabyMEG.
2900353|NCT03246230|No Intervention|NO VACCINES AT BIRTH|These will be newborns who will not receive any vaccines at birth and will have delayed immunization with catch-up (i.e., HBV, BCG and polio vaccine) by Day of Life 7.
2900354|NCT03246230|Other|HBV VACCINE AT BIRTH|Participants in this arm will receive licensed hepatitis B vaccine (HBV) at birth (Day of Life (DOL)-0) with catch up immunization (i.e., BCG and polio vaccine) at DOL-1, -3, or -7.
2900355|NCT03246230|Other|BCG VACCINE AT BIRTH|Participants in this arm will receive licensed Bacillus Calmette-Guérin (BCG) vaccine at birth (Day of Life(DOL)-0) with catch up immunization (i.e., HBV and polio vaccine) at DOL-1, -3 or- 7.
2900356|NCT03246230|Other|(HBV + BCG) VACCINES AT BIRTH|Participants in this arm will receive licensed hepatitis B vaccine (HBV) and licensed Bacillus Calmette-Guérin (BCG) vaccine at birth (Day of Life (DOL- 0) with catch up immunization (i.e., polio vaccine) at DOL-1, -3, or -7.
2900357|NCT03246217|Experimental|Therapeutic Instrumental Music Performance|Therapeutic Instrumental Music Performance is a Neurologic Music Therapy technique in which selection of instruments, spatial configurations and sequences for playing are designed to facilitate retraining of movement patterns used in everyday life. Participants will receive nine individual forty-five minute sessions of Therapeutic Instrumental Music Performance, three sessions per week.
2900358|NCT03246217|Experimental|Therapeutic Performance with Sensory-Enhanced Motor Imagery|Participants will receive nine individual sessions, three times per week: thirty minutes of Therapeutic Instrumental Music Performance, followed by fifteen minutes of sensory-enhanced motor imagery. During sensory-enhanced motor imagery, participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
2900359|NCT03246217|Experimental|Therapeutic Performance with Motor Imagery|Participants will receive nine individual sessions, three times per week: thirty minutes of Therapeutic Instrumental Music Performance, followed by fifteen minutes of motor imagery. Motor imagery will involve mental practice of previous movement exercises.
2900360|NCT03246178|Other|MSD-HSCT|This group received treatment of matched sibling donor - hematopoietic stem cell transplantation (MSD-HSCT).
2900361|NCT03246178|Experimental|HFD-HSCT|This group received treatment of haploid family donor - hematopoietic stem cell transplantation (HFD-HSCT).
2900362|NCT03246152|Experimental|Bevacizumab group|Monthly intravitreal injection of 2.5 mg of Bevacizumab for at least 3 consecutive months. This is followed by treat and extend regimen after resolution of macular edema.
2900363|NCT03246139|Experimental|Action observation, imagery & execution|
2900364|NCT03246139|Active Comparator|Action observation|
2900365|NCT03246139|Active Comparator|Customary upper-extremity rehabilitation|
2900366|NCT03246126|Experimental|Valiant™Thoracoabdominal Stent Graft System|The implantation of the Valiant™ Thoracoabdominal Stent Graft System is conducted under fluoroscopic/angiographic guidance
2900367|NCT03246113|Experimental|Cannabis + Chemoradiation|Patients will receive a cannabis strain with high cannabidiol (4.8%) and low Delta-9-THC (3.23%). Patients will smoke the cannabis over a 2 hour session (from 0.5 - 2.0 cannabis cigarettes) before receiving chemoradiation therapy with radiation and concurrent temozolomide.
2900368|NCT03246100|No Intervention|Control|These patients will receive no reminders from the health department and will receive usual care.
2900369|NCT03246100|Experimental|Autodialer R/R|Autodialer calls (up to 3 reminders)- with brief education message + practice name + practice phone #
2900370|NCT03246100|Experimental|Mail R/R|Mailed reminder (up to 3 reminders)-- with brief education message + practice name + practice phone #
2900371|NCT03246087|Active Comparator|Acupuncture|Patients will receive acupuncture for plantar fasciosis. The standard of care home exercise program will be reviewed along with the stretching and strengthening exercises.
2900372|NCT03246087|Experimental|Standard of Care|The standard of care home exercise program will be reviewed along with the stretching and strengthening exercises.
2900373|NCT03246087|Experimental|Crossover|At the end of the study, patients in the Standard of Care group whom are still experiencing pain and symptoms will be rolled into the acupuncture treatment arm of the study.
2900374|NCT03246074|Experimental|Fostamatinib and Paclitaxel|Participants will receive paclitaxel on Days 1, 8 and 15 of each cycle and fostamatinib at a fixed oral dose twice daily throughout each 28-day cycle. The dose of fostamatinib will be determined by the enrollment dose level. Given the mTPI design, dose-escalation decisions will be made based on the three dosing intervals, where the underdosing interval corresponds to dose escalation (E), overdosing interval corresponds to dose de-escalation (D), and proper dosing corresponds to staying at the current dose (S). The initial dose level will be Level 1 of Table 1. Participants will be individually continually assessed for DLT. The associated dose-escalation decisions are presented in Table 2. For illustration, suppose a cohort of 3 patients is at the current dose.
2900375|NCT03246061|Experimental|RF Ablation|RF ablation
2900376|NCT03246061|Active Comparator|Control|Continue with non-surgical management therapies
2900377|NCT03246035|Active Comparator|Control Group (Standard Care)|The control group will receive outpatient follow-up, medication advice and lifestyle guidance as prescribed at discharge from the ED or hospital.
2900378|NCT03246035|Experimental|Intervention Group|The intervention will consist of contacting the patient 5 days post-discharge and arranging definitive outpatient follow-up and providing targeted medical and lifestyle advice based on deficient domains identified at baseline.
2900419|NCT03245723||Healthy Controls|Healthy individuals that were not born premature. Individuals are ages 18-35. Subjects will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging.
2900457|NCT03245476|Active Comparator|manual therapy and home-exercises|corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
2900379|NCT03246022|Experimental|OSA with hypertension|One hundred and fifty subjects with severe OSA were recruited and categorized into three groups: Group l: SBP index was less than 30% of AHI; Group 2: SBP index was less than 60% but more than 30%; Group 3: SBP index is more than 60% of AHI. Nocturnal dynamic BP changes was monitored continuously during polysomnographic examination via pulse transfer time(PTT) based method. The investigator would compare the effect of continuous positive airway pressure (CPAP)treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups. Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated.
2900380|NCT03246009|Experimental|single injection-1.8mg|rHSA/GCSF,injection,1.8mg,Single subcutaneous injection,Duration 1 day
2900381|NCT03246009|Experimental|single injection-2.1mg|rHSA/GCSF,injection,2.1mg,Single subcutaneous injection,Duration 1 day
2900382|NCT03246009|Experimental|single injection-2.4mg|rHSA/GCSF,injection,2.4mg,Single subcutaneous injection,Duration 1 day
2900383|NCT03246009|Experimental|multiple injection-1.8mg|rHSA/GCSF,injection,1.8mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
2900384|NCT03246009|Experimental|multiple injection-2.1mg|rHSA/GCSF,injection,2.1mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
2900385|NCT03246009|Experimental|multiple injection-2.4mg|rHSA/GCSF,injection,2.4mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
2900386|NCT03245996|Experimental|Subjects|Subjects with a cardiac pacemaker
2900387|NCT03245983|Experimental|Patient willing to participate|
2900388|NCT03245970|Active Comparator|Treatment Arm|"Treatment arm patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.~Intervention: Labetalol Hydrocholoride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily"
2900389|NCT03245970|No Intervention|Non Treatment|Non treatment Arm patients who are randomized to the non-treatment arm will not receive antihypertensive medications.
2900390|NCT03245957||Ischemic stroke|Patients with ischemic stroke diagnosed by MRI or CT scan
2900391|NCT03245957||Haemorrhagic stroke|Patients without haemorrhagic stroke diagnosed by MRI or CT scan
2900392|NCT03245957||Mimick stroke|Patients without haemorrhagic or ischemic stroke diagnosed by MRI or CT scan
2900393|NCT03245944|Active Comparator|early angioplasty|Patients who initiated hemodialysis with a CVC, then had a new AVF created after commencing dialysis, and then had a 6-week postoperative ultrasound that revealed an immature AVF (diameter < 4 mm diameter or blood flow < 500 ml/min). These patients who an early angioplasty intervention group that will undergo a routine Angioplasty at 6 weeks after AVF creation
2900394|NCT03245944|Experimental|late Angioplasty|Patients who initiated hemodialysis with a CVC, then had a new AVF created after commencing dialysis, and then had a 6-week postoperative ultrasound that revealed an immature AVF (diameter < 4 mm diameter or blood flow < 500 ml/min). These patients who a late angioplasty intervention group in which early Angioplasty will be avoided and subsequently be performed only if the 3-month ultrasound indicates persistent AVF immaturity
2900395|NCT03245918|Other|Aprepitant Capsule Study Period #1|
2900396|NCT03245918|Other|Aprepitant Oral Suspension Study Period#1|
2900397|NCT03245905|Experimental|Chidamide|
2900398|NCT03245892|Experimental|Carboplatin and Paclitaxel Chemotherapy With Nivolumab|Enrolled patients will receive paclitaxel, carboplatin and nivolumab as per the study schedule during Cycles 1-3 prior to surgery, and Cycles 4-6 following surgery; at the investigator's discretion, up to 6 cycles are permitted prior to surgery. Each cycle will be 21 days in duration. Patients will receive study treatment for a total of 6 to 8 cycles at the investigator's discretion, followed by maintenance nivolumab every 4 weeks (12, 28-day cycles) or until radiologic disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination.
2900399|NCT03245879|Active Comparator|Program 1|Implementation of a basic antibiotic stewardship program focusing on education, access to Infectious Diseases physicians, and availability of antibiotic use data.
2900400|NCT03245879|Active Comparator|Program 2|This arm increases antibiotic stewardship education and interventions. Program 2 hospitals performed audit and feedback of pre-specified antibiotics and implemented locally controlled restrictions.
2900401|NCT03245879|Active Comparator|Program 3|This arm was the most intensive antibiotic stewardship intervention. It included signficant audit and feedback, ID controlled restrictions, and ID review of designated culture/lab results.
2900402|NCT03245866||Aneurysmal Subarachnoid hemorrhage|Patients suffering from a ruptured cerebral aneurysm are included in the study.
2900403|NCT03245853|Other|Treatment|Treatment as per protocol, there is no placebo arm.
2900404|NCT03245840|Experimental|Budesonide Oral Suspension|Participants will be initiated on 10 milliliter (mL) of Budesonide oral suspension (0.2 milligram/mL) twice daily up to 48 months (Visit 8) or early termination (ET).
2900405|NCT03245827|Active Comparator|Obese males with hypogonadism-active|Subjects will be randomized to receive clomiphene capsules
2900406|NCT03245827|Placebo Comparator|Obese males with hypogonadism-placebo|Subjects will be randomized to receive placebo capsules
2900407|NCT03245827|No Intervention|Obese males with normal testosterone|comparison group
2900408|NCT03245827|No Intervention|lean males with normal testosterone|comparison group
2900409|NCT03245814|Experimental|Service Dog|Participants in the service dog arm will receive unrestricted, non-study usual care, in addition to a trained service dog.
2900410|NCT03245814|No Intervention|Waitlist Control|Participants in the control arm will receive unrestricted, non-study usual care, while on the waitlist for a service dog.
2900411|NCT03245788|Experimental|Lay Navigation|Patients with even MRN.
2900412|NCT03245788|No Intervention|Usual Care|Patients with odd MRN.
2900413|NCT03245775|Experimental|iChoose|12 bi-weekly sessions & 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only
2900414|NCT03245775|Experimental|Family Connections|2 in-person sessions spaced one week apart & 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
2900415|NCT03245762|Active Comparator|Intranasal oxytocin|Intervention: 4 IU/day of intranasal oxytocin via a nasal spray device each morning.
2900420|NCT03245723||Non-National Lung Project Preterm Adults|Individuals that were born premature, but are not a part of the National Lung Project Cohort. Individuals are ages 18-35. Subjects will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging.
2900421|NCT03245710|Experimental|Zhibai Dihuang powder|Arm: Experimental: Zhibai Dihuang Formula powder Zhibai Dihuang Formula powder: Traditional Chinese medicine formula powder product 5g by mouth, after meal, 3 times in one day for 12 weeks
2900422|NCT03245710|Placebo Comparator|placebos|Arm: placebo Comparator placebos 5g by mouth after meal, 3 times in one day for 12 weeks
2900423|NCT03245697||Lactating mothers|Lactating mothers recruited in Galicia (NW Spain)
2900424|NCT03245684|Experimental|Pressure Support Ventilation|"after 48h of controlled ventilation the patient randomised in this arm will desedated and switched on Pressure Support Ventilation (PSV): patient's spontaneous activity will maintained and sedation will be maintained at a level of Richmond Assessment Sedation Scale (RASS) between -2 and -3. The level of pressure support (including PEEP) will be limited to ≤ 30 cmH2O; the pressure support level will ensure a tidal volume of 6 ml / Kg ideal body weight. PEEP, FiO2 and respiratory rate will be regulated according the ARDSnet protocol.~assessment of inflammatory response during PSV"
2900425|NCT03245684|Active Comparator|Controlled Mechanical Ventilation|patient's spontaneous activity will be shut done by sedation and/or respiratory muscles paralysis. Volume (during volume control) or pressure (during pressure control), PEEP, FiO2 and respiratory rate will be regulated according the ARDSnet protocol
2900426|NCT03245671|Active Comparator|Decadron|Patients in the Decadron group will receive epidural injections containing a total of 15 mg Decadron.
2900427|NCT03245671|Active Comparator|Kenalog|Patients in the Kenalog group will receive epidural injections containing a total of 80 mg Kenalog.
2900428|NCT03245658|Experimental|THC and CBD Mixture|32 patients with palliative pancreatic cancer, intervention with oral drops of THC, 25mg/ml and CBD 50mg/ml, daily administered for 4 weeks
2900429|NCT03245658|No Intervention|Control|32 patients with palliative pancreatic cancer, no experimental treatment,
2900430|NCT03245645|Experimental|100% Fructose|The fructose group will help to determine whether an absolute amount of fructose will lead to IBS symptoms.
2900431|NCT03245645|Placebo Comparator|100% Glucose|The glucose group will serve as a control since glucose is not a FODMAP and as a result is not expected to lead to recurrent symptoms.
2900432|NCT03245645|Active Comparator|Fructose and Glucose|The glucose/fructose mixture group is a cross comparison group that will determine whether the relative excess fructose concentration is an important cause of IBS symptoms.
2900433|NCT03245632||Carbapenem-Resistant K. pneumoniae|Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
2900434|NCT03245632||Carbapenem-Sensitive K. pneumoniae|Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.
2900435|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 1 and 2) in Part A|Male subjects will be assigned to Cohort 1 and 2. In each cohort, six subjects will be randomized to receive alternating and escalated doses of GSK3335065. Each subject in cohort 1 and 2 will receive up to three active dose strengths in a 4 period crossover design.
2900436|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 1 and 2) in Part A|Male subjects will be assigned to Cohort 1 and 2. In each cohort, two subjects will be randomized to receive placebo.
2900437|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 3-6) in Part B|Male subjects will be assigned to one of four cohorts (3, 4, 5 or 6). In each cohort, six subjects will be randomized to receive GSK3335065. In all cohorts each dose level will consist of an IV bolus on Day 1 subsequently followed by a continuous IV infusion for seven days.
2900438|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 3-6) in Part B|Male subjects will be assigned to one of four cohorts (3, 4, 5 or 6). In each cohort, two subjects will be randomized to receive placebo.
2900439|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 7) in Part C|WONCBP will be assigned to cohort 7. Six subjects will be randomized to receive a single IV dose of GSK3335065.
2900440|NCT03245619|Experimental|Subjects receiving Placebo(Cohort 7) in Part C|WONCBP will be assigned to cohort 7. Two subjects will be randomized to receive placebo
2900441|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 8) in Part C|WONCBP will be assigned to cohort 8. Six subjects will be randomized to receive a continuous IV infusion over 7 days of GSK3335065.
2900442|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 8) in Part C|WONCBP will be assigned to cohort 8. Two subjects will be randomized to receive placebo.
2900443|NCT03245606||Patients with Non Alcoholic Fatty Liver Disease|"Patients (240) will undergo a medical examination in order to analyse their medical history and check inclusion and non-inclusion criterions.~Then will be performed:~a liver biopsy~an abdominal MRI~a transient elastography"
2900444|NCT03245593||Shared Decision making for care|
2900445|NCT03245593||Standard decision making for care|
2900446|NCT03245580|Other|Arm 1 -modified wet suction|Intervention:Procedure Core Liver Biopsy Technique: Modified Wet Suction
2900447|NCT03245580|Other|Arm 2- Slow Pull|Intervention: Procedure Core Liver Biopsy Technique: Slow Pull
2900448|NCT03245567|Experimental|Pre, post, delayed test|Participants will not do the PLM, but will perform a pretest, a posttest and a delayed test at 6 months
2900449|NCT03245567|Experimental|PLM group (pre, post, delayed test, PLM)|Participants will do a pretest, the PLM, a posttest and a delayed test at 6 months
2900450|NCT03245554|Experimental|placebo and propranolol|We used propranolol and placebo as an control drug to treat with patients.
2900451|NCT03245541|Experimental|Durvalumab + SABR|Durvalumab + Stereotactive Ablative Body Radiotherapy
2900452|NCT03245515|Experimental|BMS-986195|A single oral solution dose of BMS-986195
2900453|NCT03245502||Transfused|Patients who have blood transfusion during cardiac surgery
2900454|NCT03245502||Not-Transfused|Patients who don't have blood transfusion during cardiac surgery
2900455|NCT03245489|Experimental|Group 1|Group 1 will be treated with Regimen A, followed by Regimen B. Regimen A is pembrolizumab, ASA and clopidogrel daily for 6 weeks. Regimen B is pembrolizumab alone for 6 weeks.
2900456|NCT03245489|Experimental|Group 2|Group 2 will be treated with Regimen B, followed by Regimen A. Regimen B is pembrolizumab alone for 6 weeks. Regimen A is pembrolizumab, ASA and clopidogrel daily for 6 weeks.
2900458|NCT03245476|Active Comparator|education and supported home exercises|corticosteroid injection + physiotherapy with focus on education and supported home exercises
2900459|NCT03245463|Active Comparator|Teaching Method A|Patient will receive an educational handout on self-management strategies. Patient will be asked to take the handout home to read and to call the office if he/she has any questions.
2900460|NCT03245463|Active Comparator|Teaching Method B|Patient will receive an educational handout on self-management strategies. A provider will review the handout with the patient (approximately 5 minutes including a question-and-answer session).
2900461|NCT03245450|Experimental|Eribulin mesilate plus irinotecan hydrochloride|In Schedules A and B, eribulin mesilate at the dose of 1.4 milligrams per meters squared (mg/m^2) will be administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle. In Schedule A, irinotecan hydrochloride at the doses of 20 mg/m^2 or 40 mg/m^2 will be administered as an IV infusion on Days 1 to 5 of a 21-day cycle. In Schedule B, irinotecan hydrochloride at the doses of 100 mg/m^2 or 125 mg/m^2 will be administered as an IV infusion on Days 1 and 8 of a 21-day cycle.
2900462|NCT03245437|Experimental|Oxytocin with SCST|Oxytocin with SCST (active condition)
2900463|NCT03245437|Sham Comparator|Oxytocin with Health Management|Administration of OT with control psychosocial treatment
2900464|NCT03245437|Placebo Comparator|Placebo with SCST|Administration of Placebo with active psychosocial treatment
2900465|NCT03245437|Placebo Comparator|Placebo with HM|Administration of Placebo with control psychosocial treatment
2900466|NCT03245411|No Intervention|Standard of Care (Control Group)|All participants in this group will receive the standard of care intervention provided by the RN.
2900467|NCT03245411|Experimental|Intervention Group|"In addition to the standard of care, the participants randomized to Intervention Group will be invited to a separate room. The following activities will be undertaken, in order to address patients' questions and concerns, and discuss potential solutions to their barriers to care~The patient will be asked to watch brief educational videos on Life with oral cancer treatment. The information contained in the videos will be reinforced with materials written at a 4th grade level, that correspond to each of the brief videos.The patient will receive a brief phone call (from the study coordinator) on the first business day following the baseline interview, and thereafter, two weeks following each visit to the oncology clinic."
2900468|NCT03245398|Active Comparator|Single dose of mebendazole|In day 1 each child in this treatment arm will receive a 500 mg tablet of mebendazole plus one 100 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the placebo. In day 2 and 3 each child will receive one placebo twice a day (in the morning and in the evening)
2900469|NCT03245398|Active Comparator|Multiple dose of mebendazole|In day 1 each child in this treatment arm will receive a 100 mg tablet of mebendazole plus one 500 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the 100 mg tablet of mebendazole. In day 2 and 3 each child will receive one 100 mg tablet of mebendazole twice a day (in the morning and in the evening).
2900470|NCT03245385|Experimental|Treatment with topical halobetasol spray 0.05%|Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.
2900471|NCT03245372|Active Comparator|Standard care|Basic intraoperative hemodynamic objectives
2900472|NCT03245372|Experimental|Goal directed therapy|Target value is a cardiac index equal or superior to 2.2 l/min/m2.
2900473|NCT03245359|Active Comparator|Short-term ON-Q|Single port, select-a-flow pump and ON-Q 750mL ball filled with bupivacaine 0.125% saphenous (adductor canal) nerve block and single port, fixed flow pump and 400mL ON-Q ball with bupivacaine 0.125% wide field posterior knee block to provide analgesia from surgery until medication has been depleted (typically 2-4 days)
2900474|NCT03245359|Experimental|Long-term ON-Q|Single port, select-a-flow pump and two 750mL ON-Q balls filled with bupivacaine 0.125% saphenous (adductor canal) nerve block and single port, fixed flow pump and two 400mL ON-Q ball with bupivacaine 0.125% wide field posterior knee block to provide analgesia from surgery up to 7 days post-operative. The second ball for each location will be provided pre-operatively, along with patient education for connection.
2900475|NCT03245346|Experimental|GEA+PCEA|General anesthesia combined with epidural anesthesia will be performed during surgery and patient-controlled epidural analgesia (PCEA) will be provided after surgery.
2900476|NCT03245346|Other|GA+PCIA|General anesthesia will be performed during surgery and patient-controlled intravenous analgesia (PCIA) will be provided after surgery.
2900477|NCT03245333|Experimental|Stage 1-experimental group|JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）, for 52 weeks.
2900478|NCT03245333|Other|Stage 1-negative control|observed only for 52 weeks.
2900479|NCT03245333|Experimental|Stage 2-experimental group|After completing the stage 1, experimental groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.
2900480|NCT03245333|Other|Stage 2-negative control|After completing the stage 1, negative control groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.
2900481|NCT03245320||TITAN™ Total Shoulder System Generation 1.0|Integra TITAN™ Total Shoulder System Generation 1.0
2900482|NCT03245307|Experimental|Treament|In phase A, subjects receiving a single 30 mg oral dose of Nifedipine controlled-release tablets and wash-out for 2 days,a single 3 mg oral dose of warfarin tablets and wash-out for 12 days, then apatinib 750 mg once daily with a single 30 mg oral dose of Nifedipine controlled-release tablets co-administered on day 6 ,a a single 3 mg oral dose of warfarin tablets co-administered on day 9.
2900483|NCT03245294|Active Comparator|Lumbar ESI with paramedian approach|Lumbar ESI with paramedian approach
2900484|NCT03245294|Active Comparator|Lumbar ESI with midline approach|Lumbar ESI with midline approach
2900485|NCT03245281|Experimental|Diuretic Suspension (DS)|
2900486|NCT03245281|Experimental|Diuretic Increase (DI)|
2900487|NCT03245281|Experimental|Diuretic and Medication Suspension (DMS)|
2900488|NCT03245255|Experimental|Sonazoid for pressure measurements|48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% sodium chloride solution infused at a rate of at least 2 ml/min.
2900489|NCT03245242||Enhanced Recovery After Surgery|Prospectively enrolled group to receive standardized care under a set ERAS protocol/pathway.
2900490|NCT03245242||Historical usual surgical care|Recent historical patients (5 years prior to start of ERAS) that will be propensity-matched to ERAS patients to be used as controls for comparison of outcomes.
2900491|NCT03245229|Experimental|Treatment A|In the morning of Day 1, a single dose of 10 mg rosuvastatin will be administered in the fasted state followed by an observation period of 96 h
2900492|NCT03245229|Experimental|Treatment B1|25 mg ACT-132577 will be administered o.d. from Day 5 to Day 12
2900493|NCT03245229|Experimental|Treatment B2|"In the morning of Day 13, a single dose of 10 mg rosuvastatin will be administered in the fasted state, concomitantly with 25 mg ACT-132577, followed by an observation period of 120 h.~Doses of 25 mg ACT-132577 will be administered o.d. from Day 14 to Day 17."
2900494|NCT03245216|Experimental|aerobic exercise + motor skill practice|acute bout of aerobic exercise before motor learning
2900495|NCT03245216|Active Comparator|rest + motor skill practice|seated rest before motor learning
2900496|NCT03245203|Experimental|Experimental group|beacizumab+ neoadjuvant chemotherapy (FOLFIRI+beacizumab)
2900497|NCT03245203|Active Comparator|Control group|neoadjuvant CRT for consecutive 5 weeks
2900498|NCT03245190|Experimental|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
2900499|NCT03245177|Experimental|Pembrolizumab plus radiotherapy|Pembrolizumab is given by intravenous infusion over 30 minutes at a maximum dose of 200mg. The first dose of pembrolizumab is administered 14 days prior to the initiation of radiotherapy and every 3 weeks thereafter. Radiotherapy is given as a standard dose (60-66 Gy in 2 Gy/fraction) over 40-45 days (daily on Mon-Fri) Following completion of radiotherapy, participants will continue to receive pembrolizumab every 3 weeks for up to 12 months of maintenance treatment.
2900500|NCT03245164|Experimental|Physiotherapy group exercises|This group continued physiotherapy group exercises for 12 weeks.
2900501|NCT03245164|Experimental|Basketball program|Basketball educaiton was presented for 12 weeks.
2900502|NCT03245164|No Intervention|Control group|This group did not continue any physical activity regularly.
2900503|NCT03245151|Experimental|Phase 1: Phase 1; Recurrent or refractory solid tumors|During Phase 1 (Treatment Phase: 1 cycle; 28 days of treatment), utilizing a rolling 6 design, participants with recurrent or refractory solid tumors will receive escalating doses of lenvatinib in combination with everolimus for determination of the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Participants who complete 1 cycle of treatment will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
2900504|NCT03245151|Experimental|Phase 2: Cohort 1, Ewing sarcoma/pPNET|During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory Ewing sarcoma/peripheral primitive neuroectodermal tumor (pPNET) (Cohort 1) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1. Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
2900505|NCT03245151|Experimental|Phase 2: Cohort 2, Rhabdomyosarcoma|During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory rhabdomyosarcoma (Cohort 2) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks of treatment). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
2900506|NCT03245151|Experimental|Phase 2: Cohort 3, High Grade Glioma (HGG)|During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory HGG (Cohort 3) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
2900507|NCT03245138|Experimental|endoscopic third ventriculostomy|endoscopic third ventriculostomy for the treatment of iNPH
2900508|NCT03245138|Active Comparator|ventricular peritoneal shunt|Insertion of a ventriculo-peritoneal Shunt for the treatment of iNPH
2900509|NCT03245125||HIIT subjects in HFrEF patients|heart failure patients with reduced ejection fraction (HFrEF) received at least 36 times of high-intensity interval training (HIIT)
2900510|NCT03245125||MDP subjects in HFrEF patients|heart failure patients with reduced ejection fraction (HFrEF) received only multidisciplinary disease management program (MDP) and underwent less than 36 times of high-intensity interval training (HIIT) or no exercise training
2900511|NCT03245125||HIIT subjects in HFpEF patients|heart failure patients with preserved ejection fraction (HFpEF) received at least 36 times of high-intensity interval training (HIIT)
2900512|NCT03245125||MDP subjects in HFpEF patients|heart failure patients with preserved ejection fraction (HFpEF) received only multidisciplinary disease management program (MDP) and underwent less than 36 times of high-intensity interval training (HIIT) or no exercise training
2900513|NCT03245086||Transanal hemorrhoid dearterialization (THD)|Patients with prolapsed, non-incarcerated, reducible hemorrhoids in at least 3 columns undergoing transanal hemorrhoid dearterialization (THD).
2900514|NCT03245086||Ferguson hemorrhoidectomy|Patients with prolapsed, non-incarcerated, reducible hemorrhoids in at least 3 columns undergoing Ferguson hemorrhoidectomy.
2900515|NCT03245073|Active Comparator|Exercise|Strengthening and stretching exercises for hip and knee muscles, balance and proprioceptive exercises
2900516|NCT03245073|Experimental|Action observation therapy and exercise|Video of normal human movement and Strengthening and stretching exercises for hip and knee muscles
2900517|NCT03245060|Experimental|Intervention: immediate SFBT|The Intervention arm will receive up to six Adapted Solution Focused Brief Therapy (SFBT) sessions immediately post randomisation. The sessions will be spaced over 3 months. Participants will also receive all usual care.
2900518|NCT03245060|Other|Intervention: delayed SFBT|The wait-list control arm will receive the same intervention (Adapted Solution Focused Brief Therapy, SFBT) as the intervention arm, but after a delay of six months. Participants will also receive all usual care.
2944362|NCT02942719||Inner Mongolia Maternity and Child Health Hospital|
2900519|NCT03245047|Experimental|Intervention group|Dietary Supplement: Oral Nutritional Supplement with AN777 Participants in the intervention group will be asked to consume two servings of oral nutritional supplement per day for 180 days. (Oral Consumption)
2900520|NCT03245047|Placebo Comparator|Control group|Participants in the control group will be asked to consume two servings of Oral nutritional supplement per day for 180 days.(Oral Consumption)
2900521|NCT03245034|Experimental|fourth-year Obstetrics and Gynecology residents|The intervention will be three sessions of auricular acupuncture therapy; there will be no control intervention.
2900522|NCT03245021|Other|Open-Label|Opdivo - Single-arm open label study
2900523|NCT03245008|Experimental|MT-5547 dosing regimen 1|MT-5547 Subcutaneous (SC) dosing regimen 1. Naproxen-matching placebo oral after Week 16.
2900524|NCT03245008|Experimental|MT-5547 dosing regimen 2|MT-5547 SC dosing regimen 2. Naproxen-matching placebo oral after Week 16.
2900525|NCT03245008|Experimental|MT-5547 dosing regimen 3|MT-5547 SC dosing regimen 3. Naproxen-matching placebo oral after Week 16.
2900526|NCT03245008|Placebo Comparator|MT-5547-matching placebo|MT-5547-matching placebo SC dosing. Naproxen oral after Week 16.
2900527|NCT03244995|Experimental|Couple-Based Mind-Body (CBMB) Group|"Couples complete baseline measures (T1) prior to group assignment. CBMB group complete follow-up assessments at the end of treatment (T2) and again 3 months later.~Participants and their partners take part in up to 4 sessions over the course of 6 weeks. First session of CBMB is face-to-face or via videoconferencing depending on availability of the participants. All remaining sessions delivered via videoconferencing.~Couples receive compact discs (CD's) and printed materials with instructions regarding home-practice.~Couples in CBMB group receive up to two weekly booster phone calls to ascertain participants complete the homework and answer questions regarding the exercises."
2900528|NCT03244995|Active Comparator|Waitlist Control Group|"Couples complete baseline measures (T1) prior to group assignment.~Participants receive standard of care. Participants and their partners complete follow-up assessments at the end of treatment (T2) and again 3 months later.~After completing last assessment at the 3-month follow-up, participants and their partners offered the intervention."
2900529|NCT03244982|Active Comparator|Full-Dose|Participants in this arm will receive Fluorescein Na 10% Inj 500mg pushed over several seconds one time, prior to their fluorescein angiogram. If they return for a second (clinically indicated) angiogram, they will receive Fluorescein Na 10% Inj 250mg pushed over several seconds one time.
2900530|NCT03244982|Experimental|Half-Dose|Participants in this arm will receive Fluorescein Na 10% Inj 250mg pushed over several seconds one time, prior to their fluorescein angiogram. If they return for a second (clinically indicated) angiogram, they will receive Fluorescein Na 10% Inj 500mg pushed over several seconds one time.
2900531|NCT03244956|Experimental|patients with RAS mutation|
2900532|NCT03244956|Experimental|patients with BRAFV600E mutation|
2900533|NCT03244943|Other|Non surgical periodontal treatment|The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia.
2900534|NCT03244930|Experimental|Arm 1|Plerixafor 0.12 mg/kg SC will be administered in the evening, 11 hours prior to initiation of apheresis. G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
2900535|NCT03244917|Experimental|TRAIN-AD|The study intervention is a multi-component training and education program targeting direct care providers and healthcare proxies for advanced dementia NH residents, intended to improve the management of urinary and lower respiratory tract infections in advanced dementia patients. There are two components to this practice intervention: 1. Provider Training, and 2. Proxy Education.
2900536|NCT03244917|No Intervention|CONTROL|Facility randomized to the control arm will employ usual care for the management for suspected infections in advanced dementia,
2900537|NCT03244891|Experimental|Studied subjects|"Each subject will be studied during two sequential phases:~before fluid challenge~after fluid challenge~During each phase, the subjects will be studied at:~baseline - spontaneously breathing~head down position - spontaneously breathing~baseline - positive pressure ventilation~head down position - positive pressure ventilation The sequence a-b-c-d will be randomized for each subject and for each phase"
2900538|NCT03244878|Experimental|Intervention - Thrive program|Participants will receive access to the Thrive program for 8 weeks
2900539|NCT03244878|No Intervention|Wait-list Control|Participants will have no access to the Thrive program for 8 weeks upon enrollment. They will receive a link to the NIMH website to read about information on depression.
2900540|NCT03244865||Pregnant Females|"All patients admitted to the Labor & Delivery Suite at UF Health, will be eligible for inclusion in the study except minors and those unable to consent for themselves.~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus. No longitudinal follow-up is planned or indicated."
2900541|NCT03244852||OCD Patients with Deep Brain Stimulators|Patients with deep brain stimulation for intractable obsessive compulsive disorder (OCD)
2900542|NCT03244826|Experimental|Shared Care|"For the first 90 days, patients alternate between local oncologist and DFCI for weekly visits.~From 90 to 180 days, patients alternate between local and DFCI every 2-3 weeks.~Shared Care include the following~Formal Care Coordination Plan~Patient Engagement and Education~Local Oncologist Engagement and Education~Patient/Local Oncologist/Transplant Oncologist Web Portal"
2900543|NCT03244826|Other|Usual Care|"Patients receive all follow-up care at DFCI only, which is currently the Standard Care.~Majority of routine visits in first 180 days will be at DFCI."
2900544|NCT03244826|Other|Non-Randomized|Patients receive all follow-up care at DFCI only (Standard Care).
2900545|NCT03244813|Experimental|Adapted physical activity|
2900546|NCT03244813|No Intervention|Standard care|
2900547|NCT03244800|Experimental|MEDI0382|MEDI0382 administered subcutaneously
2900548|NCT03244800|Placebo Comparator|Placebo|Placebo administered subcutaneously
2900604|NCT03244397|Experimental|PT group|"The participants assigned to this group will receive 16 sessions of physical therapy. Each session will last 45/50 minutes, 2 sessions a week for 8 weeks.~A directly pelvic floor muscle(PFM) training protocol will be applied. Throw vaginal palpation and in lithotomy position, participants will perform PFM exercises per the treatment proposed by the PERFECT scheme. Biofeedback exercises will be also performed in lithotomy position. Hypopressive exercises which are also home daily from the eighth session. Plus educational strategy."
2900549|NCT03244787|Experimental|patient navigation|PN will contact patients during their visits to health cancer or over the phone. During this initial contact, the PN will educate patients about CRC, screening and explore their barriers to screening. The PN will coordinate scheduling of CRC screening and remind patients about the tests. PN will explain preparation for colonoscopy and whenever feasible, accompany patient to obtain the test. Further interventions may include: reminding the patient about the test, helping with translation, insurance issues, transportation, and overcoming any other system barriers as needed.
2900550|NCT03244787|No Intervention|usual care|patients randomly assigned to the control will receive usual care and be eligible for navigation after the study period.
2900551|NCT03244774|Experimental|Apatinib plus POF|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: apatinib 250 mg per day and POF. Cohort 2: apatinib 375 mg per day and POF. Cohort 3: apatinib 500 mg per day and POF. Cohort 4: apatinib 625 mg per day and POF. Cohort 5: apatinib 750 mg per day and POF.~A dose limiting toxicity (DLT) event is defined as any of the following events in the first 4-week period:~CTCAE Grade 4 event (except for neutropenia lasting for ≤ 5 days);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase)~If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
2900552|NCT03244761||The standard HFT|The high-flow oxygen was delivered via tracheostomy using a standard HFT.
2900553|NCT03244761||The modified HFT|The high-flow oxygen was delivered via tracheostomy using a modified HFT.
2900554|NCT03244748||Group 1|Patients underwent ablation and continued having amiodarone after the procedure
2900555|NCT03244748||Group 2|Patients underwent ablation and not having amiodarone after the procedure
2900556|NCT03244735|Experimental|Modified Atkins Diet (MAD)|CCH patients that follows at least 3 months of MAD
2900557|NCT03244722|Other|Obese - Very low calorie diet (VLCD)|Participants will adopt a very-low calorie diet
2900558|NCT03244722|Other|Obese - Standard of care (SOC)|Participants will receive the standard of care for obese women looking to become pregnant.
2900559|NCT03244722|Other|Lean - Standard of care (SOC)|Participants will receive the standard of care for lean women looking to become pregnant.
2900560|NCT03244709|Experimental|Patients with GCA (ACR 1990 criteria)|"At diagnosis, all GCA patients with or without involvement of aorta and its thoracic branches will receive PDN 50 mg/day and TCZ 8 mg/Kg/iv monthly. In all patients PDN dose will be reduced of 10 mg every 2 weeks until interruption at week 12.~Week 12. Subcutaneous TCZ 162 mg/weekly will be administered for additional 12 weeks.~Week 24. TCZ tapering every 8 weeks as follows:~1 injection every 2 weeks~1 injection every 3 weeks~1 injection every 4 weeks Week 48. TCZ withdrawal. Week 72. Remission evaluation."
2900561|NCT03244696|Experimental|Step Tracking|Participants will track their physical activity in steps using an accelerometer for a period of 6 months. Participants will monitor their overall step-count using the accelerometer, and daily and weekly summaries of their progress provided by the experimenters.
2900562|NCT03244696|Active Comparator|Water Tracking|Participants will track their water-intake using a smart water bottle for a period of 6 months. Participants will monitor their overall water consumption using a smart water bottle, and daily and weekly summaries of their progress provided by the experimenters.
2900563|NCT03244683|Other|Intervention|Subjects randomized to this arm will receive: An Oral Nutritional Supplementation (Ensure Surgical), home-based resistance training, and dietary counseling
2900564|NCT03244683|Other|Nutrition Counseling alone|Subjects randomized to this arm will receive: Dietary counseling along with standard of care procedures.
2900565|NCT03244657|Experimental|Q12W group|
2900566|NCT03244657|Experimental|TAE group|
2900567|NCT03244644|Placebo Comparator|Group A|Placebo is an enema of normal saline. Packaging and labeling are identical to the packaging and labeling for RBX2660 to support the study blinding
2900568|NCT03244644|Experimental|Group B|RBX2660 is an enema of a microbiota suspension in a 0.9% sodium chloride irrigation USP solution and cryoprotectant
2900569|NCT03244631|Active Comparator|Lumbar Plexus Block|"A lumbar plexus 'nerve block' is a procedure in which local anesthetic (numbing medicine) is injected around a specific group of nerves to provide pain relief directly to the nerves supplying the area of the body undergoing surgery."
2900570|NCT03244631|Active Comparator|Pericapsular Injection|"The pericapsular injection is a procedure in which local anesthetic (numbing medicine) is injected around the hip joint to provide direct pain relief to the area undergoing surgery."
2900571|NCT03244618|Experimental|CSSP Toothpaste|Toothpaste containing Calcium Silicate and Sodium Phosphate
2900572|NCT03244618|Placebo Comparator|Fluoride Toothpaste|Toothpaste containing Sodium monofluorphosphate
2900573|NCT03244605|Experimental|Rehabilitation training plus TCM|"Rehabilitation training include aerobic exercise training and Liu Zi Jue lung exercises, which will be started in one month after operation.~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.The patient will take TCM granules for 3 months."
2900574|NCT03244605|Placebo Comparator|Rehabilitation education plus placebo|"Patients who received rehabilitation education will not accept rehabilitation training.~We compromise the raw materials for the placebo including food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages.~The patient will take placebo granules for 3 months."
2900575|NCT03244592|Active Comparator|Minocycline|200 mg/day
2900576|NCT03244592|Placebo Comparator|Sugar Pill|Matched placebo
2900636|NCT03244163|Active Comparator|CONVENTIONAL ARM|Stone removal by conventional techniques, for example BML, without laser lithotripsy
2900637|NCT03244150||School sample|Conducted in 1983 and included 1260 students in high school or trade school.
2900638|NCT03244150||Nationwide sample|Conducted in 1985 and included a representative sample of 2498 teenagers drawn from the Danish Civil Registration (CPR)
2900577|NCT03244579|Experimental|Dietary intervention CHO counting|Carbohydrate counting diet will be prepared according to Kulkarni, (2005). Tailored diet plans according to patient's food preference, physical activity level and appropriate insulin: Carbohydrates ratio will be prescribed for each participants. Diets were based on each participants's recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) (Thomas and Gutierrez, 2005; Kleinwechter et al., 2014). Energy requirement will be determined in the participants' pre-pregnancy weight with adding the extra requirement (450 kcal) due to pregnancy. The carbohydrate counts will be distributed into three main meals and 3 snacks.
2900578|NCT03244579|Experimental|Dietary intervention CHO Counting & DASH|The recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) will be similar to that in carbohydrate counting diet which mentioned above. DASH diet food choices will be inserted in the diet of the participants assigned for the combined diet of DASH and carbohydrate counting. The emphasis will be more on the fruits and vegetables group (>8 servings/day), whole grains (at least half of the amount of the total servings of cereals; 6-8 servings/day), fat free dairy products (2-3 servings/day), lean meat and plant proteins (0-2 servings/day) and nuts (5-7 servings/week). From the fat group olive oil will represent the main type of fat (20-25% of total fat %). Adequate intake of sodium (2000mg) will be applied into participants' diet.
2900579|NCT03244579|No Intervention|General Dietary guidlines|the general dietary advice and diet that will be prescribed by hospital for participants
2900580|NCT03244553|Experimental|Active intervention|Prucalopride for 5 days. Dosage: day 1 2mg, days 3-5 4mg
2900581|NCT03244540|Experimental|PCA|Subarchnoid anesthesia with bupivacaine PCA with morphine in the PACU
2900582|NCT03244540|Experimental|TAP|"Subarchnoid anesthesia with bupivacaine TAP (transversus abdominis plane block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.~PCA with morphine in the PACU"
2900583|NCT03244540|Experimental|QLB|"Subarchnoid anesthesia with bupivacaine QLB (quadratus lumborum block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.~PCA with morphine in the PACU"
2900584|NCT03244527|Experimental|BCAA group|Participants in the BCAA group take 40g of BCAA supplement before each aerobic exercise session. The interventions include 24 aerobic training sessions. Accordingly, the participants intake 960g of BCAA during a 8-week intervention period.
2900585|NCT03244527|Placebo Comparator|Control group|Participants in the control group take 40g of placebo before each aerobic training session. The placebo has the same caloric as the BCAA supplement but with different constitution (eg, different percentage of protein, fat and carbohydrate)
2900586|NCT03244514|Experimental|Intervention group|"Implementation of the cardiovascular surgery AKI bundle~discontinuation of all nephrotoxic agents when possible~optimization of volume status and hemodynamic parameters~close monitoring of serum creatinine, fluid balance and urinary output~avoidance of hyperglycemia~considerations of alternatives to radiocontrast agents~discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period~avoidance of HES, gelatin, and chlorid-rich solutions"
2900587|NCT03244514|No Intervention|Control group|The patients will receive standard of care (according to each center)
2900588|NCT03244501|Experimental|Left Frontal|An active magnet (active tSMS) will be placed over the left frontal cortex, while a sham magnet (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the right frontal cortex.
2900589|NCT03244501|Experimental|Right Frontal|An active magnet (active tSMS) will be placed over the right frontal cortex, while a sham magnet (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the left frontal cortex.
2900590|NCT03244501|Sham Comparator|Sham Frontal|Sham magnets (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the left and right frontal cortex.
2900591|NCT03244488||HIV-Positive|Patients will be administered each of 4 possible treatments: high dose (5 mcg/kg) scopolamine, high dose (20 mg) mecamylamine, a low dose combination (2.5mcg/kg and 10 mg) of scopolamine and mecamylamine, or placebo.
2900592|NCT03244488||HIV-Negative|Patients will be administered each of 4 possible treatments: high dose (5 mcg/kg) scopolamine, high dose (20 mg) mecamylamine, a low dose combination (2.5mcg/kg and 10 mg) of scopolamine and mecamylamine, or placebo.
2900593|NCT03244475|Experimental|Neurofeedback|mTBI Veterans blindly assigned to a 6 week IASIS neurofeedback treatment with two sessions per week.
2900594|NCT03244475|Placebo Comparator|Sham Treatment|mTBI Veterans blindly assigned to a sham treatment for 6 weeks with two sessions per week.
2900595|NCT03244475|No Intervention|Control|Veterans who are age-, gender-, education-, combat exposure-, and socioeconomically-matched. They will not undergo a treatment.
2900596|NCT03244462|Experimental|Oral BAY1834845|"Study Part A, cross over sequence:~single oral dose of BAY1834845~single oral dose of BAY1834845 + i.v. BAY1834845~single oral dose of BAY1834845 under fed conditions"
2900597|NCT03244462|Experimental|Oral BAY1834845 + i.v. BAY1834845|"Study Part A, cross over sequence:~single oral dose of BAY1834845+ i.v. BAY1834845~single oral dose of BAY1834845~single oral dose of BAY1834845 under fed conditions"
2900598|NCT03244462|Experimental|Oral Methotrexate|"Study part B, cross over sequence:~single oral dose of methotrexate (MTX)~single oral dose of MTX + single oral dose of BAY1834845"
2900599|NCT03244462|Experimental|Oral Methotrexate + oral BAY1834845|"Study part B, cross over sequence:~single oral dose of methotrexate (MTX) + single oral dose of BAY1834845~single oral dose of MTX"
2900600|NCT03244423|Placebo Comparator|Group 1|In control group will receive normal saline,
2900601|NCT03244423|Active Comparator|Group 2|Intravenous Tranexamic acid group will received Intravenous 50 mg / kg followed by infusion of 1 mg/kg/hr for six hours
2900602|NCT03244423|Active Comparator|Group 3|the topical Tranexamic acid group will receive 50 mg / kg poured before sternal closure.
2900603|NCT03244410||immune thrombocytopenic purpura|immune thrombocytopenic purpura an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number we used complete blood picture
2900701|NCT03243760|Experimental|Cohort E: Single dose CCI15106 45 mg /Placebo|Healthy subjects will receive single dose of either 45 mg CCI15106 (6 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
2900605|NCT03244397|Active Comparator|Control group|Only educational strategy 1 session per week for 6 weeks (every session will last 40/45 minutes). The educational strategy will consist of instruction of printed materials and dimensional anatomical models about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, weight lifting, high impact sports, constipation, smoking, or drinking too much caffeine. They will be also instructed in toilet habits, and will be taught to use the knack maneuver before and during increases of intra-abdominal pressure.
2900606|NCT03244384|Active Comparator|Treatment (observation)|Patients undergo observation.
2900607|NCT03244384|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
2900608|NCT03244371|Experimental|Co infected HIV and HCV patients|
2900609|NCT03244358|Experimental|Epalrestat|Epalrestat added to standard treatment
2900610|NCT03244345|Experimental|Epileptic patient|
2900611|NCT03244332|Experimental|Decompensated cirrhosis|Children suffering from decompensated cirrhosis and needing an orthotopic liver transplantation.
2900612|NCT03244332|Experimental|Compensated cirrhosis|Children suffering from a compensated cirrhosis (compensated cirrhosis with kasai surgery in biliary atresia patients e.g) or from portal hypertension without cirrhosis (portal vein thrombosis e.g)
2900613|NCT03244319|Experimental|Edoxaban|
2900614|NCT03244319|Active Comparator|Warfarin|
2900615|NCT03244306|Experimental|Autologous CD22-specific CAR T-cells expressing EGFRt|
2900616|NCT03244280|Other|MOB015B|
2900617|NCT03244267|Active Comparator|Standard Education|Participants randomized to this arm will receive the standard education provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery.
2900618|NCT03244267|Experimental|Medication Reminder App + Standard Education|Participants randomized to this arm will use a smartphone app with preset reminders to take aspirin to prevent thromboembolic events after orthopedic surgery in addition to usual postoperative discharge teaching.
2900619|NCT03244254||Test Group|Children up to 17 years of age at recruitment undergoing endoscopy in order to diagnose or rule out Celiac disease, whose Marsh score at endoscopy is 2 or higher.
2900620|NCT03244254||Control Group|Children up to 17 years of age undergoing endoscopy as part of abdominal pain workup, whose Celiac serology is negative, and the Marsh score found at endoscopy is 0.
2900621|NCT03244241|Active Comparator|Intervention|Basal-bolus insulin regime with Insulin Degludec and insulin aspart
2900622|NCT03244241|No Intervention|Standard|Standard treatment according to hospital guidelines with sliding scale insulin
2900623|NCT03244228|Experimental|Part 1a SAD HTL0016878/Placebo|In Part 1a, single ascending doses of HLT0016878 or matching placebo will be administered to groups of 12 subject each (9 active, 3 placebo). Each subject will have up to four treatment sessions separated by an appropriate wash-out. Healthy, young, male subjects.
2900624|NCT03244228|Experimental|Part 1b single dose HTL0016878|In Part 1b, a single dose of HTL0016878 will be administered to 6 subjects on two occasions: once in the fasted and once the fed state. This will be open-label. Healthy, young, male or female subjects.
2900625|NCT03244228|Experimental|Part 1c single dose HTL0016878|In Part 1c, a single dose of HTL0016878 will be administered to up to 6 (optional up to 12) healthy elderly subjects This will be open-label. Healthy, elderly, male subjects.
2900626|NCT03244228|Experimental|Part 2a MAD HTL0016878/Placebo|In Part 2a, multiple doses of HTL0016878 will be administered to up to 5 cohorts (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
2900627|NCT03244228|Experimental|Part 2b MAD HTL0016878/Placebo|In Part 2b, multiple doses of HTL0016878 will be administered to up to 3 cohorts of healthy, elderly subjects (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
2900628|NCT03244215|Experimental|The study group|"The intervention to be evaluated is the patient response and compliance to best medical treatment and prevention of recognized stroke risk factors and the recurrence of stroke and TIA in the study group and its relation to the incidence of blood biomarkers.~The Nurse practitioners at the stroke ward will withdraw blood and collect urine samples from all the subjects. All the subjects from the study group will have 2 follow up visits (1 month and at 1 year) at HGH and one telephonic follow up at 3 months. The blood samples will be used to monitor blood inflammatory biomarker levels. At the beginning of the study, all subjects will have an MRI scan to assess plaque volume (this MRI scan will be ordered as part of the standard of care as per the policies applied to all stroke patients). MRI scans will be repeated at one year to assess any progression or regression in the plaque volume of the subjects.~No drugs will be administered to the patients for the purpose of our study."
2900629|NCT03244215|Other|Control|The control group will have blood work done to assess their blood inflammatory biomarkers but not the corneal confocal imaging.
2900630|NCT03244202|Experimental|Decision Aid Plus Counselling|Participants will use a decision aid to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing. After using the decision aid the participants will speak with a genetic counsellor over the phone about their choice.
2900631|NCT03244202|Active Comparator|Genetic Counselling Only|Participants will a genetic counsellor over the phone to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing.
2900632|NCT03244189|Experimental|Intervention|"Participants in the intervention arm will receive an individualized fluid prescription, which will be the additional volume of fluid intake needed to maintain a study-specified urine output. This fluid will be consumed from and measured by a smart water bottle. The intervention arm also includes a behavioral program that consists of financial incentives and structured problem solving (SPS) to maintain the recommended fluid intake."
2900633|NCT03244189|No Intervention|Control|"Participants in the control arm will receive standard care instructions according to American Urological Association (AUA) guidelines to increase overall fluid consumption to achieve study-specified urine output. They will also receive a smart water bottle with capability to self-monitor their fluid intake."
2900634|NCT03244176|Other|Open-label|Avelumab - Single-arm open label study
2900635|NCT03244163|Experimental|LASER ARM|Spyglass DS cholangioscope guided laser or electrohydraulic lithotripsy
2944363|NCT02942719||Fujian Province Maternity and Child Health Hospital|
2900639|NCT03244137||Pulmonary rehabilitation|The whole population will benefit from a comprehensive pulmonary rehabilitation program, including aerobic training, superior and inferior limb strength training, self-management and add-on to pulmonary rehabilitation as needed (i.e : electrical muscle stimulation, inspiratory muscle training, non-invasive ventilation, high flow nasal canula).
2900640|NCT03244124|Active Comparator|SET (Self-Etching)|50 teeth will receive restorations using Self-Etching Application Strategy
2900641|NCT03244124|Experimental|SEE (Selective Enamel Etching)|50 teeth will receive restorations using Enamel Etching Application Strategy
2900642|NCT03244124|Experimental|ERDry (Etch&Rinse Dry)|50 teeth will receive restorations using Etch&Rinse Dry Application Strategy, leaving dentin dry (but not overdry)
2900643|NCT03244124|Experimental|ERWet (Etch&Rinse Wet)|50 teeth will receive restorations using Etch&Rinse Wet Application Strategy, leaving dentin wet
2900644|NCT03244111|Active Comparator|Healthy Cognition|The intervention will be carried out as described in the study details using the simple memory tool. The group with healthy cognition may perform better on tasks since they have a higher level of cognition.
2900645|NCT03244111|Active Comparator|MCI|The intervention will be carried out as described in the study details using the simple memory tool. The group with MCI may have a lower level of performance on tasks since they have a lower level of cognition. Some tasks may take longer for the participant or need more explanation from the researcher (e.g., explanation of a question).
2900646|NCT03244098|Experimental|Transition Assistance Program (TAP)|
2900647|NCT03244098|No Intervention|Standard of Care|
2900648|NCT03244085|Experimental|100 mg BID|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (100 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
2900649|NCT03244085|Experimental|200 mg BID|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (200 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
2900650|NCT03244085|Experimental|600 mg QD|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (600 mg once a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
2900651|NCT03244072|Active Comparator|Treatment group|Intracameral injection of moxifloxacin solution after cataract surgery
2900652|NCT03244072|Placebo Comparator|Placebo group|Intracameral injection of placebo after cataract surgery
2900653|NCT03244059|Experimental|Belimumab|"Subjects randomized to the experimental treatment arm will receive i.v. administrations of belimumab (10 mg/kg), consisting of three loading doses, two weeks apart, followed by five (5) more monthly infusions. The final assessment will be performed at month 8."
2900654|NCT03244059|Placebo Comparator|Placebo|"These subjects will be treated with identically appearing placebo i.v. on the same schedule as the experimental arm subjects (i.e., three loading doses, two weeks apart, followed by five more monthly infusions. Again, the final assessment will be performed at month 7 (210+10 days after treatment start)."
2900655|NCT03244046|Active Comparator|Physiotherapy (Phys)|12 sessions of guided physiotherapy for low back pain. Cognitive Behavioral Therapeutic elements included targeting Fear Avoidance Beliefs.
2900656|NCT03244046|Experimental|Somatic Experiencing + phys|12 sessions of psychotherapy (somatic experiencing) and 12 sessions of guided physiotherapy for low back pain. Cognitive Behavioral Therapeutic elements included targeting Fear Avoidance Beliefs.
2900657|NCT03244033|Experimental|Contextual Survey + Contextual CDS|Contextual factors obtained from patients in the Contextual Survey along with contextual red flags already stored in the EHR will produce a variety of Contextual Clinical Decision Support, both passive and interruptive alerts.
2900658|NCT03244033|Active Comparator|Contextual Survey Only|Contextual factors obtained from patients in the Contextual Survey along with contextual red flags already stored in the EHR will not be used for CDS or to produce alerts.
2900659|NCT03244020|Experimental|LMWH for Soft Tissue Sarcoma|Patients undergoing surgery for pelvic/lower extremity soft tissue sarcomas and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
2900660|NCT03244020|Experimental|ASA for Soft Tissue Sarcoma|Patients undergoing surgery for pelvic/lower extremity soft tissue sarcomas and are randomized to aspirin 325 mg po daily for VTE prophylaxis
2900661|NCT03244020|Experimental|LMWH for Primary Bone Tumor|Patients undergoing surgery for pelvic/lower extremity primary bone tumor and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
2900662|NCT03244020|Experimental|ASA for Primary Bone Tumor|Patients undergoing surgery for pelvic/lower extremity primary bone tumor and are randomized to aspirin 325 mg po daily for VTE prophylaxis
2900663|NCT03244020|Experimental|LMWH for Metastatic Disease|Patients undergoing surgery for pelvic/lower extremity metastatic bone disease and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
2900664|NCT03244020|Experimental|ASA for Metastatic Disease|Patients undergoing surgery for pelvic/lower extremity metastatic bone disease and are randomized to aspirin 325 mg po daily for VTE prophylaxis
2900665|NCT03244007||Eyes with residual fragment|The eyes with residual fragments detected with intraoperative optical coherence tomography
2900666|NCT03244007||Eyes without residual fragment|The eyes without residual fragments detected with intraoperative optical coherence tomography
2900667|NCT03243994|Experimental|COPD|Patients with COPD without Cor Pulmonale
2900668|NCT03243994|Experimental|COPD + Cor Pulmonale|Patients with Cor Pulmonale in addition
2900669|NCT03243981|Experimental|Open label study-- single arm|all patients will receive Skintyte treatment as well as Skintyte plus broadbandlight
2900670|NCT03243968||Ischemic patient - IP|25 participants with myocardial ischemia detected by scintigraphy and normal coronarography
2900671|NCT03243968||Control group - CG|25 healthy non-ischemic individuals
2900672|NCT03243955|Active Comparator|TEAS|True acupoint locations for placement of TENS unit pads
2900673|NCT03243955|Sham Comparator|Placebo|non-acupoint locations for placement of TENS unit pads
2900674|NCT03243942|Experimental|Definity for pressure measurements|2 vials of activated Definity mixed with 50 ml saline. As per manufacturer's recommendation the infusion rate may vary between 4-10 ml/min (to provide diagnostic intracardiac contrast visibility).
2900675|NCT03243929|Experimental|Intervention|All participants in the Translation of District Sun Safe Policies to Schools arm received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices.
2900676|NCT03243929|Other|Attention Control|All participants in the attention control arm received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
2900677|NCT03243916|Experimental|combination|TACE plus cyber knife
2900678|NCT03243903|Experimental|QS-M insulin-free injector|Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
2900679|NCT03243903|Active Comparator|needle-insulin pen|Using needle-insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
2900680|NCT03243890|Experimental|Intervention|Study drug. Supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day)
2900681|NCT03243890|Placebo Comparator|Placebo|Placebo tablet (no active treatment). The placebo tablet is matched to the study drug for taste, color, and size.
2900682|NCT03243877||Breast Cancer Positive|"A 5cc blood sample will be collected from subjects who were screened for breast cancer at the treating facility and results were positive.~MammoAlert Screening Test will be performed on plasma obtained from the blood sample."
2900683|NCT03243877||Breast Cancer Negative|"A 5cc blood sample will be collected from subjects who were screened for breast cancer at the treating facility and results were negative.~MammoAlert Screening Test will be performed on plasma obtained from the blood sample."
2900684|NCT03243864||Ceftazidime and Avibactam|Ceftazidime-avibactam pharmacokinetic monitoring
2900685|NCT03243851|Experimental|Temozolomide+metformin|"Temozolomide :~1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks~Metformin :~1st cycle (4 weeks)~1 week(1st~7th day) = 1,000mg/day~1 week(8th~14th day) = 1,500mg/day~2 weeks(15th ~28th day) = 2,000mg/day~2nd to 6th cycle (20 weeks) = 2,000mg/day"
2900686|NCT03243851|Placebo Comparator|Temozolomide+placebo|"Temozolomide :~1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks~Placebo:~1st cycle (4 weeks)~1 week(1st~7th day) = 1,000mg/day~1 week(8th~14th day) = 1,500mg/day~2 weeks(15th~28th day) = 2,000mg/day~2nd to 6th cycle (20 weeks) = 2,000mg/day"
2900687|NCT03243838|Experimental|Experimental Group|Four cycles of docetaxel combined with apatinib followed by four cycles of epirubicin and cyclophosphamide as Neoadjuvant Treatment for Triple-Negative Breast Cancer
2900688|NCT03243825|Experimental|chemo/brachytherapy|Patients in this arm will receive neoadjuvant chemotherapy (paclitaxel/cisplatinum) and brachytherapy before radical hysterectomy.
2900689|NCT03243825|Active Comparator|chemotherapy|Patients in this arm will receive neoadjuvant chemotherapy (paclitaxel/cisplatinum) before radical hysterectomy.
2900690|NCT03243812|Active Comparator|SS genotype group|"Sickle cell patients with SS genotype. Each subject will undergo the following :~Blood sample~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
2900691|NCT03243812|Active Comparator|SC genotype group|"Sickle cell patients with SC genotype. Each subject will undergo the following :~Blood sample~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
2900692|NCT03243812|Active Comparator|control group|"Healthy subjects. Each subject will undergo the following :~Blood sample~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
2900693|NCT03243799|Experimental|Intervention Group|"The intervention group will participate in psychoeducational groups: 12 weekly 90-minute sessions led by two nurses from Primary Care, consisting of health education on chronic physical illness and depressive symptoms.~Group psychoeducation."
2900694|NCT03243799|No Intervention|Control Group|Usual clinical care
2900695|NCT03243786|Active Comparator|"12-week Stay on Track intervention"|The study intervention includes three personal exercise training sessions, three dietary counseling sessions, use of a physical activity tracking device, and approximately three weekly text messaging
2900696|NCT03243786|Active Comparator|12-week self-guided control|The self guided group does not receive the study intervention, but is offered a Nutrition and wellness guide at the end of 6 months
2900697|NCT03243760|Experimental|Cohort A: Single dose CCI15106 7.5 mg /Placebo|Healthy subjects will receive single dose of either 1 capsule CCI15106 7.5 milligram (mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
2900698|NCT03243760|Experimental|Cohort B: Single dose CCI15106 15 mg /Placebo|Healthy subjects will receive single dose of either 15 mg CCI15106 (2 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
2900699|NCT03243760|Experimental|Cohort C: Single dose CCI15106 30 mg /Placebo|Healthy subjects will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
2900700|NCT03243760|Experimental|Cohort D: Single dose CCI15106 30 mg /Placebo-BAL|Healthy subjects will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. BAL procedures will be performed in this cohort additionally.
2900702|NCT03243760|Experimental|Cohort F: Single dose CCI15106 60 mg /Placebo|Healthy subjects will receive single dose of either 60 mg CCI15106 (8 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
2900703|NCT03243760|Experimental|Cohort G: CCI15106 7.5 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either 7.5 mg CCI15106 (1 capsule) or matching placebo twice daily (BID) for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
2900704|NCT03243760|Experimental|Cohort H: CCI15106 15 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either 15 mg CCI15106 (2 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
2900705|NCT03243760|Experimental|Cohort I: CCI15106 30 mg /Placebo BID 14 Days-BAL|Healthy subjects will receive repeat dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. BAL procedures will be performed in this cohort additionally.
2900706|NCT03243760|Experimental|Cohort J: CCI15106 =<30 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either =< 30 mg CCI15106 (less than or equal to 4 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. The dose for cohort J is unknown at this time and will depend on results seen in the previous cohorts.
2900707|NCT03243760|Experimental|Cohort K: Single dose CCI15106 30 mg /Placebo-COPD|COPD patients will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
2900708|NCT03243734|Experimental|trūFreeze® System spray cryotherapy|trūFreeze® System spray cryotherapy as clinically indicated for symptom relief
2900709|NCT03243721|Experimental|Gilenya treated MS patients|Multiple sclerosis patients treated with Gilenya for at least six months. This group will receive diagnostic tests: 7T MRI and Neurocognitive testing.
2900710|NCT03243721|Experimental|Healthy controls|Subjects without multiple sclerosis or other diseases of the central nervous system. This group will receive diagnostic tests: 7T MRI and Neurocognitive testing.
2900711|NCT03243708|No Intervention|Usual Care|Control: Standard order set without risk calculator (usual care)
2900712|NCT03243708|Active Comparator|Risk calculator|Intervention: VTE risk calculator embedded in the smart order set incorporated into the EHR and activated for all medical patients
2900713|NCT03243695|Experimental|Angled abutment|According to the allocation, the experimental group will receive an angled abutment on the immediately placed implant. A vaccum stent will be used to fabricate a temporary crown using tooth colored auto-polymerizing resin(structur 2 SC/ QM , VOCO GmbH, Germany)
2900714|NCT03243695|Active Comparator|Straight abutment|According to the allocation, the control group will receive on the immediately placed implant a Straight zero degree abutment . A vaccum stent will be used to fabricate a temporary crown using tooth colored auto-polymerizing resin(structur 2 SC/ QM , VOCO GmbH, Germany)
2900715|NCT03243682|Active Comparator|Bidirectional Shock Wave Lithotripsy|alternating bidirectional (under and over table) approach
2900716|NCT03243682|Active Comparator|Standard Shock Wave Lithotripsy|standard unidirectional approach
2900717|NCT03243669|Active Comparator|Fujinon standard|
2900718|NCT03243669|Active Comparator|Fujinon HD|Fujinon high-definition
2900719|NCT03243669|Active Comparator|Fujinon HD + VC|Fujinon high-definition + virtual chromoendoscopy
2900720|NCT03243669|Active Comparator|Olympus standard|
2900721|NCT03243669|Active Comparator|Olympus HD|Olympus high-definition
2900722|NCT03243669|Active Comparator|Olympus VC|Olympus virtual chromoendoscopy
2900723|NCT03243669|Active Comparator|Olympus HD + VC|Olympus high-definition + virtual chromoendoscopy
2900724|NCT03243669|Active Comparator|Pentax standard|
2900725|NCT03243669|Active Comparator|Pentax HD|Pentax high-definition
2900726|NCT03243669|Active Comparator|Pentax VC|Pentax virtual chromoendoscopy
2900727|NCT03243669|Active Comparator|Pentax HD + VC|Pentax high-definition + virtual chromoendoscopy
2900728|NCT03243656|No Intervention|control arm|standard immunosuppressive therapy (antilymphocyte globulin and cyclosporine),
2900729|NCT03243656|Active Comparator|case arm|standard immunosuppressive therapy plus an oral dose of Eltrombopag
2900730|NCT03243643|Experimental|HS-1024+apatinib|"For part 1 (PK study) subjects will be given single dose of HS-10241 and then multiple dose of HS-10241 (1 cycle, each cycle 14days) and then HS-10241+aptatinib (each cycle 21 days) until PD.~For part 2 (expansion study) subjects will be given HS-10241+aptatinib (each cycle 21 days) until PD (Progression of disease)."
2900731|NCT03243630|Placebo Comparator|Menthol e-liquid|Menthol Flavor + IV saline Menthol Flavor + IV nicotine (0.25mg/70kg) Menthol Flavor + IV nicotine (0.5mg/70kg)
2900732|NCT03243630|Active Comparator|green apple e-liquid|Green apple + IV saline Green apple + IV nicotine (0.25mg/70kg) Green apple + IV nicotine (0.5mg/70kg)
2900733|NCT03243630|Active Comparator|green apple and menthol e-liquid|Green apple and menthol + IV saline Green apple and menthol + IV nicotine (0.25mg/70kg) Green apple and menthol + IV nicotine (0.5mg/70kg)
2900734|NCT03243617|Active Comparator|AO+Mist|Cosmetic Product AO+Mist
2900735|NCT03243617|Placebo Comparator|Placebo|Placebo
2900736|NCT03243591|Active Comparator|Livionex gel|Brushing area of mucositis with Livionex gel for 30 days
2900737|NCT03243591|Active Comparator|Aquafresh gel|Brushing area of mucositis with Aquafresh gel for 30 days
2900738|NCT03243565|Active Comparator|OM-85|OM-85 by mouth (3.5 mg once per day, first 10 days, consecutive 3 months; 10-10-10 days, standard treatment regimen) A second cure of treatment will be given 6 months after inclusion.
2900739|NCT03243565|Placebo Comparator|Placebo|Placebo by mouth (Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate) the same posology (3.5 mg once per day, first 10 days for consecutive 3 months) A second cure of treatment will be given 6 months after inclusion.
2900740|NCT03243552|Active Comparator|L-DOPA versus Placebo|L-DOPA or placebo (1:1 randomization). Dosing will begin at 25mg carbidopa/100mg L-DOPA in 3 divided doses, with a fixed-flexible titration schedule, allowing dose increases once per week of 100mg L-DOPA. Maximum dose is 600mg/d.
2900741|NCT03243552|Experimental|Social Skills|All participants will receive 16-week manualized social skills training.
2900742|NCT03243539|Experimental|Lung Protective Ventilation|Subjects with acute brain injury (traumatic brain injury and non-traumatic brain injury) will receive neuro lung protective ventilation which targets a normal arterial partial pressure of carbon dioxide with the lowest tidal volume possible (6 to 8 ml/kg predicted body weight). Protocols for oxygenation and weaning from the ventilator will also be followed.
2900743|NCT03243526|Placebo Comparator|Central venous pressure group|fluid therapy to maintain CVP not 5 cmH2o
2900744|NCT03243526|Experimental|Pulse pressure variation|fluid therapy will be guided by PPV to be less than 14%
2900745|NCT03243500|Sham Comparator|Group C|"2.5 ml of lidocaine 2% 2.5 ml of bupivacaine 0.5% hyaluronidase powder 15 IU/ml~1 ml normal saline to make a total volume of 6 ml from which the patient received 5-6 ml through percaruncular peribulbar injection."
2900746|NCT03243500|Active Comparator|Group A|"5 mg atracurium 2.5 ml of lidocaine 2% 2.5 ml of bupivacaine 0.5% hyaluronidase 15 IU/ml~1 ml normal saline to make a total volume of 6 ml from which the patient received 5-6 ml through percaruncular peribulbar injection."
2900747|NCT03243487|Experimental|PAMS service|"Study participants will be randomly assigned to have their Continuous positive airway pressure therapy (CPAP) or Bilevel Positive Airway Pressure (BiPAP) therapy followed by a structured patient adherence management service (PAMS).~Interventions: Call to patient by sleep coach on days 3,7,14,32,45, 60, and 75 after participants begin PAP treatment. At each time frame sleep coach reviews CPAP adherence data on EncoreAnywhere (EA) a cloud based program collecting adherence data via wireless modem on CPAP units. Calls will not be made at days 7 and 14 if adherence is good. If problems are identified and cannot be handled over the telephone the problems will be escalated to VA MD or CPAP respiratory therapy (RT) providers for direct intervention. All patients are seen in sleep clinic by a VA MD sleep provider 3 months after starting treatment."
2900748|NCT03243487|Active Comparator|Standard Care (SCP)|Study participants will be randomly assigned to have their CPAP or BiPAP therapy followed by the current Sleep Center standard care process. This includes a telephone number that patients can call or problems and review of adherence data on EncoreAnywhere (EA) at 4 to 6 weeks after starting treatment. Patients are seen in sleep clinic by a VA MD sleep provider 3 months after starting treatment.
2900749|NCT03243474||65 - 69 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 65 - 69 years.
2900750|NCT03243474||70 - 74 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 70 - 74 years
2900751|NCT03243474||75- 79 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 75 - 79 years
2900752|NCT03243474||80 - 84 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 80 - 84 years
2900753|NCT03243474||85 - 89 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 85- 89 years
2900754|NCT03243474||≥90 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged ≥90 years
2900755|NCT03243461|Experimental|Temozolomide + Valproic acid|Valproat-neuraxpharm®, Valproat-neuraxpharm® Lösung, Ergenyl®, Ergenyl®-Lösung oder Orfiril® Saft (Valproic acid), [10 mg/kg/d] tablet oder juice, p.o., every day in parallel to simultaneous radiochemotherapy with cytostatic drug Temodal (Temozolomid): [75 mg/m2/d] during simultaneous radiochemotherapy (7 days a week, max. 49 days); [150-200 mg/m2/d] during consolidation therapy (for 5 days every 28 days, 12 cycles), tablets, p.o. (or powder for preparation of an intravenously applicable solution).
2900756|NCT03243461|Experimental|Temozolomide + Chloroquine|Resochin junior® (Chloroquine), depending on patient weight and treatment scedule 1/2 to 3 tablets [25-150 mg] every day, p.o., in parallel to simultaneous radiochemotherapy with cytostatic drug Temodal (Temozolomid): [75 mg/m2/d] during simultaneous radiochemotherapy (7 days a week, max. 49 days); [150-200 mg/m2/d] during consolidation therapy (for 5 days every 28 days, 12 cycles), tablets, p.o. (or powder for preparation of an intravenously applicable solution).
2900757|NCT03243448||The general public|people between 20-85 years old, without sympathetic hyperactivity disease
2900758|NCT03243448||Sympathetic hyperactivity diseases|Sympathetic hyperactivity diseases included: hypertension, heart failure atherosclerotic diseases, arrhythmias, cardiomyopathy, pulmonary hypertension, chronic obstructive pulmonary disease, sleep apnea, pulmonary embolism, hepatitis, liver cirrhosis, hepatopulmonary syndrome, hepatorenal syndrome, renal failure, nephritis, irritable bowel syndrome.
2900759|NCT03243435||Native 1,5 Tesla breast MRI group|From all patients a 1,5 Tesla MRI of the breast will be obtained
2900760|NCT03243422|Active Comparator|Successful aging education intervention|Individual sessions on healthy aging topics
2900761|NCT03243422|Active Comparator|Hearing intervention|Best practices hearing rehabilitative treatment
2900762|NCT03243396|Experimental|Community-Based CBT|These participants will receive Trauma-Focused Cognitive Behavioral Therapy in a community setting from community health volunteers
2900763|NCT03243396|Experimental|School-Based CBT|These participants will receive Trauma-Focused Cognitive Behavioral Therapy in a school setting from specified teachers
2900764|NCT03243383|No Intervention|Low-risk Group|Low-risk as determined by the predicted risk of readmission by the DERRI. The low-risk group will be followed in a prospective, observational arm of the study.
2900765|NCT03243383|Experimental|High-risk Group - Intervention|High-risk as determined by the predicted risk of readmission by the DERRI. Subjects in the high-risk group will be randomly assigned to receive either the intervention (DiaTOHC Program) or usual care (control).
2900766|NCT03243383|No Intervention|High-risk Group - Usual Care|Patients in the high-risk usual care group will receive the standard hospital discharge process and post-discharge followup.
2900797|NCT03243149|Experimental|Free Regulate|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. Free regulate shows a thermometer that indicates true activation of ventromedial PFC minus amygdala while the participant attempts neuroregulation.
2900798|NCT03243123|Experimental|Passive mobilization|Upper limb passive mobilization assisted with robotic device
2900903|NCT03242252|Experimental|Dose 1|2 tablets: 1 sotagliflozin tablet and 1 placebo tablet (identical to sotagliflozin dose 2 in appearance), once daily before the first meal of the day
2900767|NCT03243357|Experimental|TF Adaptive (First Apical Binding File)|Endodontic treatment(teeth with periapical periodontitis&radiolucence).Local anesthesia (4%Articaine with1:100,000 epinephrine),isolation with rubber dam&standard access cavity preparation.Using 2.5 %sodium hypochlorite,canal negotiation,glide path,coronal flaring with Sx(ProTaper),determining working length&first apical binding file.Intervention: Root canal instrumentation:TF Adaptive system with enlargement of the root canal performed with up to 3 files larger than the diameter of the initial apical file. Irrigation2.5%NaOCl&EDTA (Ethylenediaminetetraacetic acid)under activation with ultrasound. Irrigation with saline solution and placement of medication based on calcium hydroxide. After 14 days, obturation: gutta-percha&epoxy resin sealer.
2900768|NCT03243357|Experimental|XP Endo Finisher|Endodontic treatment (teeth with periapical periodontitis&radiolucence). Local anesthesia(4% Articaine with 1:100,000 epinephrine), isolation with rubber dam&standard access cavity preparation. Using 2.5 % sodium hypochlorite, canal negotiation, determining working length&glide path. Root canal instrumentation (TF Adaptive system according to the protocol recommended by the manufacturer and complemented with XP Endo Finisher). Irrigation 2.5% NaOCl & EDTA(Ethylenediaminetetraacetic acid) under activation with ultrasound. Irrigation with saline solution and placement of medication based on calcium hydroxide. After 14 days, the canals will be obturated with gutta-percha and epoxy resin sealer.
2900769|NCT03243357|Other|TF Adaptive (Control)|In the control group,endodontic treatment (teeth with periapical periodontitis&radiolucence). Local anesthesia(4% Articaine with 1:100,000 epinephrine), isolation with rubber dam&standard access cavity preparation. Using 2.5 % sodium hypochlorite, canal negotiation, determining working length&glide path. Root canal instrumentation:TF Adaptive system according to the protocol recommended by the manufacturer.Irrigation 2.5% NaOCl & EDTA(Ethylenediaminetetraacetic acid)under activation with ultrasound. Irrigation with saline solution and placement of medication based on calcium hydroxide. After 14 days, the canals will be obturated with gutta-percha and epoxy resin sealer.
2900770|NCT03243344|Experimental|Surgiflo|Using Surgiflo® (Absorbable Gelatin Hemostatic) for the post-operative haemostasis in endonasal surgery.
2900771|NCT03243344|Experimental|Floseal|Using Floseal® (Absorbable Gelatin Hemostatic) containing human thrombin for the post-operative haemostasis in endonasal surgery
2900772|NCT03243344|Experimental|Algosteril|Using Algosteril® (Hemostatic Sterile Wick) for the post-operative haemostasis in endonasal surgery
2900773|NCT03243344|No Intervention|Abstention|Not using device for the post-operative haemostasis in endonasal surgery
2900774|NCT03243331|Experimental|Gedatolisb + PTK7-ADC|
2900775|NCT03243318||Presence of motor evoked potentials|Those patients with Shoulder Abduction and Finger Extension (SAFE) score <8/10 with the presence of motor evoked potentials elicited by TMS over the ipsilesional motor cortex
2900776|NCT03243318||absence of motor evoked potentials|Those patients with Shoulder Abduction and Finger Extension (SAFE) score <8/10 with the absence of motor evoked potentials elicited by TMS over the ipsilesional motor cortex
2900777|NCT03243305|Experimental|Interventional|This is a single-arm, open-label, Phase III study of AMPHORA , a non hormonal contraceptive, at approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy.
2900778|NCT03243292||Treated|Subjects that received Bronchial Thermoplasty in a prior study (AIR, RISA, or AIR2)
2900779|NCT03243292||Control|Subjects that participated in prior study (AIR) or (RISA) but did not receive Bronchial Thermoplasty Treatment
2900780|NCT03243292||Sham|Subjects that participated in the AIR2 study, were blinded and did not receive the treatment
2900781|NCT03243279||Surgical|No interventions. Patients undergoing cardiothoracic surgery will be assessed for baroreflex sensitivity and the outcomes of interest.
2900782|NCT03243266||CBC/Diff Reference Interval|Hematology routine diagnostic test
2900783|NCT03243227|Experimental|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by an experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
2900784|NCT03243227|Active Comparator|Exercise|Exercise therapy 4 sessions of exercise treatment will be provided by an experienced physiotherapist. It will include active range of motion, stretching, and strengthening exercise. patients will be given a brochure to continue the exercises as home exercise program during and after the treatment period.
2900785|NCT03243214|Active Comparator|PD-MCI, TMS|The patient is treated with TMS stimulation according to protocol with an active coil.
2900786|NCT03243214|Sham Comparator|PD-MCI, Sham-TMS|The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil.
2900787|NCT03243201|Experimental|Colloidal Silver|The colloidal silver arm will administer intranasal colloidal silver, 2 sprays each nostril twice daily, for a total volume of 0.8ml per day (8 mcg of silver per day), for 28 days.
2900788|NCT03243201|Placebo Comparator|Purified Water|The placebo arm will administer intranasal purified water, 2 sprays each nostril twice daily, for a total volume of 0.8ml per day, for 28 days.
2900789|NCT03243188||Participants|Cancer patients with palliative care needs (+/- their carers)
2900790|NCT03243175|Experimental|Direct Oral Anticoagulant (DOAC)|Apixaban 5MG twice daily
2900791|NCT03243175|Experimental|Left Atrial Appendage Closure (LAAC)|Devices will be chosen by local teams.
2900792|NCT03243175|No Intervention|Control|avoiding anticoagulation and LAAC during the entire study period The standard clinical practice without OAC may include: antiplatelet drug (in case of comorbidities such as coronary heart disease) or no antithrombotic drug
2900793|NCT03243162|Experimental|CBPT-ACLR|CBPT-ACLR program consisting of weekly phone calls.
2900794|NCT03243162|Active Comparator|Education|Education program consisting of weekly phone calls.
2900795|NCT03243149|Sham Comparator|False Feedback|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. False feedback (sham) shows a thermometer that indicates false feedback consisting of noise.
2900796|NCT03243149|Active Comparator|View Condition|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. View condition shows a thermometer that indicates true activation of ventromedial PFC minus amygdala but the participant is asked not to attempt neuroregulation.
2900902|NCT03242252|Placebo Comparator|Placebo|2 placebo tablets (identical to sotagliflozin dose 2 in appearance), once daily before the first meal of the day - Type: Placebo Comparator
2900799|NCT03243110||Asthmatics requiring breathing test|"Participants must have had a diagnosis of asthma by a physician. The participant must have had a self-reported health care interaction related to asthma (physician visit, ED visit, hospitalization) in the past 5 years.~Participants must be 1 to 85 years old."
2900800|NCT03243097|Experimental|Study Subjects|All subjects enrolled in the study are required to complete Phase I before entering Phase II, and Phase II before entering Phase III.
2900801|NCT03243084|Sham Comparator|Sham Stimulation|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.
2900802|NCT03243084|Active Comparator|Alpha Stimulation|Participants will receive 2mA of alternating current stimulation at a frequency of 10Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
2900803|NCT03243071|Experimental|Intervention Group|The intervention group (n=50) will have access to culturally tailored website.
2900804|NCT03243071|Active Comparator|Control Group|Participants in the control group (n=50) will have access to NYU 's standard trial participation website.
2900805|NCT03243058|Active Comparator|Treatment Arm|Proleukin® (Aldesleukin; IL-2), 0.5 million IU/m2 (up to a maximum of 1 million IU), or placebo, will be given for 5 consecutive days (days 1-5), and then on day 15 and every 15 days thereafter, for one year; at the one year endpoint, subjects in the treatment arm will be randomized 1:1 to continued therapy or switched to placebo, for 1 more year.
2900806|NCT03243058|Placebo Comparator|Control Arm|18 patients will be randomized to the control arm and will receive placebo for two years.
2900807|NCT03243032|Experimental|Local Anesthetic Group 1|Group 1 (Pre-emptive analgesia with long acting local anesthesia - experimental group): Ibuprofen 600mg given 30 minutes prior to beginning of surgery. Surgery will be performed only using 0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg four times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
2900808|NCT03243032|Placebo Comparator|Local Anesthetic Control|Group 2 (Control / standard of care group): Placebo oral capsule (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery. Surgery will be performed using 2% lidocaine with 1:100,000 epinephrine as the local anesthesia. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg 4 times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
2900809|NCT03243019|Experimental|SIROLIMUS|
2900810|NCT03243006|Placebo Comparator|group Placebo|Patients in this group (Placebo Oral Tablet) received two placebo tablets
2900811|NCT03243006|Active Comparator|group Paracetamol|Patients in this group received two 500 mg paracetamol tablets
2900812|NCT03243006|Active Comparator|group Tramadol/Paracetamol combination|Patients in this group (Tramadol/Paracetamol combination ) received 2 tablets of Tramadol/Paracetamol combination (37.5mg/325mg)
2900813|NCT03242993|Experimental|treatment group|"all patients successfully enrolled will be assigned to the treatment group:~1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to [18F]-AzaFol"
2900814|NCT03242980|No Intervention|Enhanced adherence counseling|Individuals with elevated VL are required to attend a minimum of 2 session of enhanced adherence counselling performed at monthly intervals. A follow-up VL is done at 8 to 12 weeks after the first counselling session.
2900815|NCT03242980|Experimental|Structured EAC plus SMS|The behavioral intervention will consist of structured adherence counseling and a short text message (SMS). A culturally adapted graphical brochure was specifically developed to guide adherence-counselling for individuals with unsuppressed VL.
2900816|NCT03242967|Experimental|Vadadustat|Oral tablet
2900817|NCT03242967|Active Comparator|Darbepoetin alfa|subcutaneous or intravenous
2900818|NCT03242954|Active Comparator|Adolescents: Consent Condition 1|Parental permission required
2900819|NCT03242954|Active Comparator|Adolescents: Consent Condition 2|Adult permission required
2900820|NCT03242954|Active Comparator|Adolescents: Consent Condition 3|Autonomous consent
2900821|NCT03242954|Active Comparator|Parents: Consent Conditions 1-3|Parental permission required and Adult permission required and Autonomous consent
2900822|NCT03242928|Placebo Comparator|Placebo|
2900823|NCT03242928|Experimental|AFQ056|
2900824|NCT03242915|Experimental|Pembrolizumab/Carboplatin/Pemetrexed|Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks
2900825|NCT03242902|Experimental|Light intensity 1|The light intervention includes exposure to white light (10.000 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
2900826|NCT03242902|Experimental|Light intensity 2|The light intervention includes exposure to white light (10-20 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
2900827|NCT03242889|Experimental|DARA SC|Participants will receive DARA SC (daratumumab 1800 milligram [mg] with Recombinant Human Hyaluronidase [rHuPH20] 30,000 units [U] that is 2000 U/milliliter [U/mL]) subcutaneous (SC) injection once weekly for the first 8 weeks in Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks in Cycles 3 to 6 (Days 1 and 15) for the following 16 weeks and then every 4 weeks (from Cycle 7 [Day 1]) in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation. Each cycle is 28 days in duration.
2900828|NCT03242876|Placebo Comparator|Control meal|Control will be 109 g white bread and 200 mL water. The glycaemic response to the test meal will be compared to the response of the control meal.
2900904|NCT03242252|Experimental|Dose 2|2 sotagliflozin tablets, once daily before the first meal of the day
2900829|NCT03242876|Experimental|Test meal|Test will be 109 g white bread and 200 mL water containing 3.819 g citric acid and 119 mg malic acid adjusted to pH 3.2. The glycaemic response to this meal will be compared to that of the control meal.
2900830|NCT03242863|Experimental|Control|Baseline proportions of high and low energy dense foods.
2900831|NCT03242863|Experimental|Addition|Increased portion of low energy dense foods.
2900832|NCT03242863|Experimental|Substitution|Increased portion of low energy dense foods substituted for equal portion of foods higher in energy density.
2900833|NCT03242850|No Intervention|Regular care group|This group will receive regular care including standard guidance on shared reading. Participants in this arm will not view the video at the time of enrollment nor will they receive the text messages throughout the 6 months of the randomized controlled trial.
2900834|NCT03242850|Experimental|Intervention group|
2900835|NCT03242837|Experimental|Army Resilience Training|Resilience training: four training sessions of 90 minutes each (in week 3, 5, 6 and 7 of military training), in classroom, psychoeducational inputs on stress management and resilience related topics, cognitive behavioral interventions and moderated exercises
2900836|NCT03242837|Active Comparator|Diversity Management Training|Diversity Management: four training sessions of 90 minutes each (in week 3, 5, 6 and 7 of military training), classroom, psychoeducational inputs on social awareness and exercises
2900837|NCT03242824|Experimental|18F-DOPA PET|Patients will receive 18FDOPA-PET for radiation treatment planning
2900838|NCT03242811|Experimental|Examination by MRI|MRI scan of knee, ankle and wrist
2900839|NCT03242785|Experimental|Self-monitoring/Self-titration|The intervention consists of self-monitoring blood pressure at home, and subsequent medication self-titration, based on a medication adjustment plan pre-established by the family physician, in patients with uncontrolled hypertension.
2900840|NCT03242785|No Intervention|Routine care|Patients in this arm will receive routine care for high blood pressure in the primary health care center.
2900841|NCT03242772|Active Comparator|P-ESDM + Amphetamine|"Amphetamine regimen (24 weeks total duration) will begin 10 weeks prior to initiation of Parent-Delivered Early Start Denver model (P-ESDM), continue throughout 12 weeks of P-ESDM, and 2 weeks after P-ESDM. The drug is an orally dissolvable, extended-release form of d- and l-amphetamine.~Both arms will receive 12 consecutive weekly P-ESDM sessions (1 hr each)"
2900842|NCT03242772|Placebo Comparator|P-ESDM + Placebo|"Placebo regimen (24 weeks total duration) will begin 10 weeks prior to initiation of Parent-Delivered Early Start Denver model (P-ESDM) and continue throughout 12 weeks of P-ESDM. The placebo contains no active drug and appears identical to the amphetamine (active drug).~Both arms will receive 12 consecutive weekly P-ESDM sessions (1 hr each)"
2900843|NCT03242759||patients with idiopathic pulmonary fibrosis (IPF)|
2900844|NCT03242746||Control group|"The study will include 150 women of reproductive age (21-45 years) who wished to have future pregnancies and had cervical biopsy or Pap test, without any other cervical procedure, in the same calendar year.~a 3-years follow-up for pregnancy outcome~Transvaginal ultrasound for pretreatment cervical dimensions/volume"
2900845|NCT03242746||LEEP group|"The study will include 150 women of reproductive age (21-45 years) planning for excisional treatment for CIN who wished to have future pregnancies. Women are included irrespective of their parity, previous obstetric history, and CIN grade.~a 3-years follow-up for pregnancy outcome~Transvaginal ultrasound for pretreatment cervical dimensions/volume~Transvaginal ultrasound for posttreatment cervical dimensions/volume in the follow-up visit~Estimation of cone dimensions/volume~Calculation of the proportion of volume/length excised"
2900846|NCT03242733||Hip fracture patients|Fasted elderly patients scheduled for hip fracture surgery except exclusion criteria are enrolled.
2900847|NCT03242720|Active Comparator|Active Positive Airway Pressure|Active positive airway pressure for treatment of Obstructive Sleep Apnea
2900848|NCT03242720|Sham Comparator|Sham Positive Airway Pressure|Sham positive airway pressure for treatment of Obstructive Sleep Apnea
2900849|NCT03242707|Experimental|Autologous adipose tissue knee injection|Fat will be removed from the abdomen and processed using the Lipogems device. Approximately 5ml of the microfragmented fat product will be injected into the knee joint.
2900850|NCT03242707|Active Comparator|Hyaluronic Acid knee injection|Hyaluronic Acid - Synvisc-One®: A high molecular weight sodium hyaluronate (HA). HA is an FDA approved, standard of care treatment.
2900851|NCT03242694||persistent atrial fibrillation|invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
2900852|NCT03242681|Experimental|Endoscopy Assisted Probing|Endoscopy Assisted Probing
2900853|NCT03242681|Active Comparator|Simple Probing|Simple Probing
2900854|NCT03242668|Experimental|PVB using PVC for PCA in VATS|The VATS was performed.Paravertebral space was identified by loss of resistance technique combined with video-assisted inside thoracic space before chest close.PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA with background rate 3ml/h, bolus dose 2ml was infused through PVC.
2900855|NCT03242655|Experimental|HCV GET-UP (Group Intervention)|HCV GET-Up (Group Evaluation and Treatment Uptake)
2900856|NCT03242655|No Intervention|Control|Individual onsite HCV treatment at a primary care center
2900857|NCT03242642|Experimental|Surgical Candidate - TMVR|Treatment of mitral regurgitation with the Medtronic Transcatheter Mitral Valve Replacement System (TMVR)
2900858|NCT03242642|Active Comparator|Surgical Candidate - SMVR|Treatment of mitral regurgitation with conventional Surgical Mitral Valve Replacement (SMVR)
2900859|NCT03242642|Experimental|Non-Surgical Candidate - TMVR|Treatment of mitral regurgitation with the Medtronic Transcatheter Mitral Valve Replacement System (TMVR)
2900860|NCT03242629|Active Comparator|oral group|
2900861|NCT03242629|Experimental|enema group|
2900862|NCT03242616|Experimental|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 & 8)~Pemetrexed (500 mg/m2, day 1)~Actinamide 1mg IM: 1 week before 1st dose, q 9 weeks (1wk before 1st cycle, 4th,7th,10th…. cycle after then.)~Folic acid 1mg daily: 1 week before 1st dose until 3 weeks after last dose~Dexa 4mg po bid on D0-2"
2900863|NCT03242616|Active Comparator|Vinorelbine|Vinorelbine (25 mg/m2, day 1 & 8)
2900905|NCT03242239|Experimental|ALT02|
2900906|NCT03242239|Active Comparator|EU-licensed Herceptin|
2900864|NCT03242603|Experimental|Anti-GD2 in combination with NK cells|This is a single arm study. Patients with high risk neuroblastoma who have residual measurable disease will receive a combination of 5 days of anti-GD2 with expanded activated NK cells.
2900865|NCT03242590|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate, LPCN 1021 225 mg TU two times a day.
2900866|NCT03242564|Experimental|Active Device|"Active Device: Vevazz LED red light therapy system~Vevazz LED red light therapy system is a treatment regimen using the Vevazz LED device for fat removal using LED red light therapy."
2900867|NCT03242551|Experimental|Neoadjuvant chemotherapy|Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days.
2900868|NCT03242538|Experimental|Pelvic Exercise Intervention|Patients will perform two pelvic exercises prior to each external beam radiation treatment.
2900869|NCT03242525||Emergency room|Twelve bleeding patients who are assigned to the emergency department receive a simultaneous blood analysis with POCT and central laboratory.
2900870|NCT03242525||Delivery room|Twelve bleeding patients who are assigned to the delivery room receive a simultaneous blood analysis with POCT and central laboratory.
2900871|NCT03242512|Experimental|30 mg single dose cohort|Subjects would receive a 30 mg single dose of TK006.
2900872|NCT03242512|Experimental|60 mg single dose cohort|Subjects would receive a 60 mg single dose of TK006.
2900873|NCT03242512|Experimental|120 mg single dose cohort|Subjects would receive a 120 mg single dose of TK006.
2900874|NCT03242499|Experimental|Active|Lovastatin 80mg per day for 48 weeks.
2900875|NCT03242499|Placebo Comparator|Placebo|Placebo 80mg per day for 48 weeks.
2900876|NCT03242486|Experimental|toric intraocular lens|toric intraocular lens is implanted to all subjects
2900877|NCT03242473|Experimental|Lactated Ringers (LR)|The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.
2900878|NCT03242473|Experimental|Normal Saline (NS)|The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.
2900879|NCT03242460|Experimental|Pomalidomide, Dexamethasone, Cyclophosphamide|Pomalidomide 4mg Days 1-21 Dexamethasone 20mg Days 1, 8, 15, 22 Cyclophosphamide 400mg Days 1, 8, 15
2900880|NCT03242447|Experimental|e-Practice Self-Regulation (e-PS-R)|e-Practice Self-Regulation (e-PSR) is the treatment condition. e-PS-R is a 'blended learning' intervention, combining online and face-to-face instruction. e-PS-R aims to increase knowledge of sexual health and the impact of trauma on sexual decision-making.
2900881|NCT03242447|Active Comparator|Video Health Group|The Video Health Group is the control counterfactual condition. Youth assigned to the control group will view a video on a non-sexual health topic (the hazards of smoking).The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes. The informational video uses both narration and interviews to educate viewers on the dangers that cigarettes pose.
2900882|NCT03242434|Other|Healthy controls|Approximately 15 healthy participants of age 18 years or above will be included in the study and will receive STM intermittently via oral route. The total duration of study for healthy participants will be approximately 2 weeks.
2900883|NCT03242434|Other|Thermal injury participants|Approximately 25 thermally injured participants having TBSA more than or equal to 15 percent and who are co-consented to the SIFTI-2 and HESTIA studies will be included in the study and will receive STM intermittently via oral route. The total duration of study for thermal injury participants will be approximately 6 months.
2900884|NCT03242408|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate, LPCN 1021 150 mg TU three times a day
2900885|NCT03242395||Burn patients|Adult survivors of severe burns who have been admitted to Burns ITU for invasive ventilation within 10 years of neurocognitive assessment
2900886|NCT03242395||Controls|Healthy volunteers, controlled for age/sex/IQ
2900887|NCT03242382|Experimental|Palbocilib|Palbociclib will be administered orally at a dose of 125 mg once a day for 21 consecutive days followed by 7 rest days to comprise a complete cycle of 28 days.
2900888|NCT03242369|Experimental|PEG group|100 patients undergoing colonoscopy.
2900889|NCT03242369|Experimental|SBS group|100 patients undergoing colonoscopy
2900890|NCT03242369|Experimental|PEG 2L + ascorbic acid group|100 patients undergoing colonoscopy.
2900891|NCT03242369|Experimental|PICO group|100 patients undergoing colonoscopy.
2900892|NCT03242343|Experimental|VasQ device implantation|
2900893|NCT03242330|Experimental|Two-piece subperiosteal implant|The two-piece subperiosteal implant will be designed with an internal connection that will receive its prosthetic counterpart later in the second stage surgery, which will retain the final prosthesis in place. Two-piece constructions allow for undisturbed submerged healing, without being exposed to the oral environment, achieved by attaining primary closure over the inserted implant body.
2900894|NCT03242330|Active Comparator|Single-piece subperiosteal implant|The single-piece subperiosteal implant will be designed in the from of a framework with protruding posts that will appear penetrating through the mucosa, and will later carry the overlying superstructure (prosthesis). Single-piece subperiosteal implants do not require a second stage surgery.
2900895|NCT03242317|Experimental|Mitomycin C + Raindrop Near Vision Inlay|The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the Raindrop Near Vision Inlay in Presbyopes.
2900896|NCT03242304||Control group|A control group composed of subjects without physical or psychiatric disease.
2900897|NCT03242304||Acute Ischemic Stroke group|An AIS group composed of subjects within the first 24 hours of the neurovascular event.
2900898|NCT03242291|Active Comparator|conventional resin-based flowable composite|
2900899|NCT03242291|Other|Hydroxyapatite Nanofiber reinforced flowable composite|
2900900|NCT03242278||NVAF patients receiving 20 mg rivaroxaban|NVAF patients who receive a standard dose of rivaroxaban (20 mg daily)
2900901|NCT03242278||NVAF patients receiving 15 mg rivaroxaban|NVAF patients who receive a reduced dose of rivaroxaban (15 mg daily)
2900912|NCT03242200|Other|Mobile Health App|Participants will be prompted to complete questionnaires.
2900913|NCT03242187|Experimental|Trans-anal TME (TaTME)|Trans-anal total mesorectal excision(TaTME) will be offered to patients in this group (assisted by minilaparoscopy to control the IMA and splenic flexure mobilisation)
2900914|NCT03242187|Active Comparator|Lap. TME|Laparoscopic total mesorectal excision(Lap.TME) starting by IMA ligation then splenic flexure mobilisation and pelvic dissection
2900915|NCT03242174||Traditional Obstetrical Prenatal Care|Pregnant women receiving traditional obstetrical prenatal care and delivering in a hospital will be offered the Health Behavior questionnaire packet at third trimester prenatal appointment
2900916|NCT03242174||Prenatal Care from Midwife|Pregnant women receiving prenatal care from a midwife and delivering at the birth center will be offered the Health Behavior questionnaire packet at third trimester prenatal appointment
2900917|NCT03242161|Experimental|LabPatch-alcohol|All subjects will be administered alcohol and then monitored by a non-invasive alcohol sensor
2900918|NCT03242122|Active Comparator|CHO Control 1 Glucose|25 g glucose
2900919|NCT03242122|Experimental|CHO Experimental 1 Slowly Digested|25 g slowly-digested carbohydrate blend
2900920|NCT03242122|Experimental|CHO Experimental 2 Digestion Resistant|25 g digestion-resistant carbohydrate blend
2900921|NCT03242122|Experimental|CHO Experimental 3 Low Sugar|25 g low sugar carbohydrate blend
2900922|NCT03242122|Experimental|CHO Experimental 4 Maltodextrin|25 g maltodextrin
2900923|NCT03242122|Active Comparator|CHO Control 2 Glucose|25 g glucose
2900924|NCT03242096|Experimental|Sirolimus coated balloon|Treatment of in-stent restenosis with a sirolimus coated balloon
2900925|NCT03242096|Active Comparator|Paclitaxel coated balloon|Treatment of in-stent restenosis with a paclitaxel coated balloon
2900926|NCT03242083||Primary atrophic AMD|
2900927|NCT03242083||Secondary atrophic AMD|
2900928|NCT03242070|Experimental|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
2900929|NCT03242070|No Intervention|Control Group|No specific intervention will be provided to the control group participants
2900930|NCT03242057|Experimental|NI-NAVA|"Wait to meet extubation criteria within 14 days postnatal age~Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) Pi to determine eligibility or exclusion~Randomize to either NIPPV or NI-NAVA, 1:1 randomization~PI will not be blinded to the intervention (not feasible)~If extubating to NAVA then place the catheter to optimize position and Edi 1 hr. prior to planned extubation.~ABG or CBG to be obtained at 4 hrs. post extubation~NI-NAVA settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
2900931|NCT03242057|Active Comparator|NIPPV|"Wait to meet extubation criteria within 14 days postnatal age~Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) PI to determine eligibility or exclusion~Randomize to either NIPPV or NI-NAVA, 1:1 randomization~PI will not be blinded to the intervention (not feasible)~ABG or CBG to be obtained at 4 hrs. post extubation~NIPPV settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
2900932|NCT03242044|Experimental|Resuscitation with intact umbilical cord|This is a one arm study. Pregnant women greater than 18 years of age with a fetus with left or right sided congenital diaphragmatic hernia of age that consent to the protocol will be enrolled in the study. This is a pilot feasibility study that will assess maternal and infant tolerance to resuscitation with an intact umbilical cord as well as the optimal method for performing an advanced resuscitation with the umbilical cord intact. For this reason patients will not be randomized.
2900933|NCT03242031|Experimental|1 session|
2900934|NCT03242031|Active Comparator|4 sessions|
2900935|NCT03242018|Placebo Comparator|Placebo|Given as two placebo tablets (identical to sotagliflozin dose 2 in appearance) orally once daily
2900936|NCT03242018|Experimental|Dose 1|Given as two sotagliflozin dose 2 tablets orally once daily
2900937|NCT03242018|Experimental|Dose 2|Given as two tablets: one sotagliflozin dose 2 tablet and one placebo tablet (identical to sotagliflozin dose 2 in appearance) orally once daily
2900938|NCT03242005|Experimental|Pro-set® vs. Quick-set®|Subjects will be randomized to start with one of the study subcutaneous insulin administration sets (MiniMed® Pro-set® or MiniMed® Quick-set®). After completing the first study period,subjects will be placed in the alternative group according to the cross-over study design.
2900939|NCT03241992|Experimental|MyChart Intervention|Subjects in the control arm will be enrolled in MyChart during the consent process and receive MyChart Disease Specific targeted IBD information and reminders as well as mood questionnaires. At week 2 subjects will receive reminders to get vaccinated with another reminder sent at 3 months. At month 1, subjects will receive the Promis Adult Short Form questionnaires for depression and anxiety through MyChart. If a subject is identified as having mild, moderate or a severe mood disorder a message will be sent to their gastroenterologist with a recommendation to discuss the results with the patient and to consider a referral to mental health services. Subjects will also receive educational information about IBD every 6 weeks along with reminders to take their medications.
2900940|NCT03241992|No Intervention|Usual Care|Subjects in the control arm will be enrolled in MyChart during the consent process if they are not previously enrolled. Enrollment in MyChart will provide them with access to their medical record and the ability to send or receive messages with their gastroenterologist or any other providers they see at our institution. For patients with IBD it is standard practice to discuss medication adherence, vaccinations, and their mood at each appointment. Subjects will receive generic, non-IBD related messages through MyChart.
2900941|NCT03241979||laryngeal microsurgery|
2900942|NCT03241966||People with Parkinson's Disease|Individuals diagnosed with idiopathic Parkinson's disease without dementia.
2900943|NCT03241966||Informant|Family member, spouse, significant other, caregiver, or other close associate of someone with Parkinson's disease.
2901034|NCT03241381||Group B: Non Melasma|Patients without any facial pigmentation or melasma
2900944|NCT03241953|Experimental|debridement made by ultrasonic tips|mechanical debridement made by ultrasonic polyetheretherketone coated tips developed for implant surface and combined air-flow debridement
2900945|NCT03241953|Active Comparator|implants were debrided with standard plastic curettes|dental implants were debrided with standard plastic curettes, debridement made by combined klorhegsidin rinse
2900946|NCT03241940|Experimental|Treatment (CD19/CD22-CAR T cells, chemotherapy)|Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and cyclophosphamide IV over 60 minutes on day -2. Patients then receive CD19/CD22-CAR T cells IV over 10-20 minutes on day 0. Patients that benefited from the first dose of CD19/CD22-CAR T cells, had no unacceptable side effects, and have enough cells left over may receive 2 or 3 additional doses of CD19/CD22-CAR T cells.
2900947|NCT03241927|Experimental|Pembrolizumab|200 mg IV infusion every 3 weeks
2900948|NCT03241927|No Intervention|Healthy Donors|
2900949|NCT03241914|Active Comparator|MA|Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
2900950|NCT03241914|Experimental|MA+LNG-IUS|Patients will receive MA (160mg po qd) plus LNG- IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
2900951|NCT03241901|Active Comparator|3 Days Artemether-Lumefantrine + Placebo|"Oral tablets of artemether-lumefantrine (20-120mg):~tablet for 5-14kg;~tablets for 15-24 kg;~tables for 25 - 34kg and~tablets for above 35 Kg. The full course of treatment is 6-doses for 3 days given twice daily, at 0, 8, 24, 36, 48, 60 with the dose being given as directly observed therapy.~Oral placebo after completion of the standard 3 days-six dose regimen. A fatty snack (biscuits) will be administered together with all artemether-lumefantrine doses to optimize absorption."
2900952|NCT03241901|Experimental|6Days Artemether/Lumefantrine+Primaquine|"Artemether-lumefantrine (20-120mg) twice daily for 6 days according to body weight as in the active comparator arm.~And in addition to that, , a single 0.25 mg/kg primaquine dose (Primaquine phosphate) will be administered concomitantly with the last (i.e. twelfth) artemether-lumefantrine dose. Primaquine will be prepared and administered in an aqueous solution."
2900953|NCT03241888|Active Comparator|MA|Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
2900954|NCT03241888|Active Comparator|LNG-IUS|Patients will receive LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
2900955|NCT03241888|Experimental|MA+LNG-IUS|Patients will receive MA (160mg po qd) plus LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
2900956|NCT03241875|Placebo Comparator|placebo|Patients receive 2 capsules as placebo 2 hours before anesthesia. The capsules are delivered by the hospital pharmacy.
2900957|NCT03241875|Experimental|pregabalin|patients receive 2 capsules of pregabalin (pregabalin 75), two hours before anesthesia.
2900958|NCT03241875|Experimental|gabapentin|patients receive 2 capsules of gabapentin (gabapentin 300), two hours before anesthesia.
2900959|NCT03241862|Experimental|Restylane® Silk|All subjects enrolled in the study will undergo lip rejuvenation treatment with Restylane® Silk.
2900960|NCT03241849|Other|Modified surgical technique for placenta accreta|
2900961|NCT03241823||Patients with hepatitis c virus related liver cirrhosis|"Patients with chronic hepatitis C virus whose ultrasound shows liver cirrhosis, fibroscan F3 and F4, Child score A and B, of any MELD score, who achieved Sustained Virological Response after direct acting antiviral drugs (Sofosbuvir, Daclatasvir ± Ribavirin)."
2900962|NCT03241810|Experimental|Arm A|"Seribantumab~Fulvestrant"
2900963|NCT03241810|Active Comparator|Arm B|"Placebo~Fulvestrant"
2900964|NCT03241797|Experimental|Patients who suggested having AIP|Patients who suggested having AIP and underwent EUS-FNA biopsy by using a standard 22-gauge aspiration needle were enrolled between January 2013 and May 2017.
2900965|NCT03241784|Experimental|Treatment arm|All subjects are enrolled in the one arm consisting of infusions of autologous T-regulatory lymphocytes at a dose of 1x10 to the sixth/kg and subcutaneous injections of Interleukin-2 at a dose of 2x10 to the fifth IU/m2 three times a week.
2900966|NCT03241771|Experimental|Naloxone Navigator 1.0|Participants randomized to the Naloxone Navigator 1.0 arm will receive a link to the web-based resource. They will also receive usual care from their health plan, pharmacy and physicians. As part of usual care, participants will have access to naloxone through standing orders (i.e., they can request it without a prescription under their usual pharmacy benefit).
2900967|NCT03241771|No Intervention|Usual Care|Participants in the usual care arm will receive usual care from their health plan, pharmacy and physicians. As part of usual care, participants will have access to naloxone through standing orders (i.e., they can request it without a prescription under their usual pharmacy benefit).
2900968|NCT03241758||Group #1|Patients with prostate cancer who will undergo radical prostatectomy
2900969|NCT03241745|Experimental|Nivolumab|Nivolumab treatment: Nivolumab 240 mg IV once every 2 weeks. Treatment will continue until time of disease progression or until development of unacceptable toxicity, whichever comes first.
2900970|NCT03241732|Active Comparator|Dietary (AID) Cohort|Anti-inflammatory Diet: This arm will focus on adjusting dietary practices to eat foods that have lower amounts of inflammatory foods that might help reduce overall inflammation in the brain and body. This arm will introduce patients to an integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.
2900971|NCT03241732|Active Comparator|Intravenous/Oral NAC Cohort|N-acetyl Cysteine: This arm provide patients with a natural supplement, n-acetyl cysteine (NAC) which is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine, that supports antioxidants to reduce oxidative damage in the body. NAC is a common over-the-counter supplement. It is used as an injectable pharmaceutical to protect the liver in cases of acetaminophen overdose. Laboratory studies have suggested that NAC might have a beneficial effect in neurodegenerative disorders such as TBI. Patients in this arm will receive IV NAC once a week plus oral NAC supplement 500 mg twice per day for approximately 3 months until the follow up evaluation.
2901321|NCT03239535|Placebo Comparator|Normal saline|Normal saline, Intramuscular injection
2900972|NCT03241732|No Intervention|Control Cohort|Control Group: Standard of Care Treatment for at least 3 months. After the first 3 month, participants in this arm may crossover to the NAC study arm.
2900973|NCT03241719|Experimental|Treatment|Subjects who receive transplantation and undergo IL-2 treatment
2900974|NCT03241706|Experimental|Aim 1: Healthy Controls|Each healthy control (CON) subject (i.e., they will not have type 1 diabetes) will undergo two metabolic studies in random order; one in which their liver glycogen content will be increased by a peripheral infusion of fructose (CON-Gly++; 1.3 mg/kg/min for 4h) and one in which they will receive saline (CON-Gly; i.e., their liver glycogen content will not be experimentally increased).
2900975|NCT03241706|Experimental|Aim 1: Type 1 Diabetics|Each T1D subject will undergo two metabolic studies in random order; one in which their liver glycogen content will be increased by a peripheral infusion of fructose (T1D-Gly++; 1.3 mg/kg/min for 4h) and one in which they will receive saline (T1D-Gly; i.e., their liver glycogen content will not be experimentally increased).
2900976|NCT03241706|Active Comparator|Aim 2: Type 1 Diabetics Receiving Saline|Each T1D subject will undergo a procedure to induce hypoglycemia-associated autonomic failure (HAAF) on day 1. Then, the next day, each subject will undergo metabolic testing where their liver glycogen content is normal (i.e., the saline infusion).
2900977|NCT03241706|Experimental|Aim 2: Type 1 Diabetics Receiving Fructose|Each T1D subject will undergo a procedure to induce hypoglycemia-associated autonomic failure (HAAF) on day 1. Then, the next day, each subject will undergo metabolic testing where their liver glycogen content is increased (i.e., the fructose infusion).
2900978|NCT03241693|Other|control group|Physiotherapy students
2900979|NCT03241693|Experimental|experimental group|Physiotherapy students
2900980|NCT03241680|No Intervention|Control Group with conventional citology|Patients who do not have high grade cervical intraepithelial neoplasia and will have anal cytology performed by conventional method
2900981|NCT03241680|No Intervention|Control Group with liquid based citology|Patients who do not have cervical intraepithelial neoplasia of high grade and will have anal cytology performed by liquid based method
2900982|NCT03241680|No Intervention|CIN 2-3/Conventional Citology|Patients with high grade cervical intraepithelial neoplasia and will have anal citology performed by conventional method
2900983|NCT03241680|Active Comparator|CIN 2-3/Liquid Based|Patients with high grade cervical intraepithelial neoplasia and will have anal citology performed by liquid based method
2900984|NCT03241654||the lowest trigger sensitivity|The flow trigger of ventilator was set as the lowest level of sensitivity.
2900985|NCT03241654||the highest trigger sensitivity|The flow trigger of ventilator was set as the highest level of sensitivity.
2900986|NCT03241641|Experimental|Maintaining TAF monotherapy|- Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 96 weeks
2900987|NCT03241641|Active Comparator|Switching from TDF to TAF|"Tenofovir Disoproxil Fumarate (Viread) Tablet, 300mg, Daily Oral, 48 weeks~Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 48 weeks"
2900988|NCT03241628||Dressing Glove|"Fitting bespoke dressing gloves (viscose Class 1 medical device) and evaluating dressing glove performance in the management of blisters using patient recorded outcome measures. The aim is to obtain proof of concept data for the dressing glove as an acceptable alternative to patch work dressings held in place with bandages.~The study protocol recommends a daily change of the dressing glove but the patients also contribute their preference for frequency of dressing changes."
2900989|NCT03241615||Neurogenic dysphagia|Patients with neurogenic dysphagia who will willing to participate in the study, being over the age of 18, normal cognitive function ([24 points according to the Mini Mental State Examination), suffering from dysphagia at least one month, and having clinically stable neurological disease will be included. Dysphagia evaluation will be performed.
2900990|NCT03241602|Active Comparator|group of Pulmonary recruitment & Intraperitoneal libocai|
2900991|NCT03241602|Active Comparator|Group of Intraperitoneal lidocaine|
2900992|NCT03241602|Active Comparator|Group of pulmonary recruitment|
2900993|NCT03241602|No Intervention|group receive passive exsufflation through port|
2900994|NCT03241589|Experimental|VA Telederm Use|VA sites who have received the VA Telederm from OCC
2900995|NCT03241589|Experimental|Control VA Telederm|VA sites to eventually receive VA Telederm but at present have not
2900996|NCT03241589|Experimental|My Telederm Use|VA sites who have received the My Telederm app from OCC
2900997|NCT03241589|Experimental|Control My Telederm|VA sites to eventually receive My Telederm but at present have not
2900998|NCT03241576|Experimental|Small portion size provision|Participants in this arm are served a small serving of a lunchtime food to eat (session 1).
2900999|NCT03241576|Active Comparator|Large portion size provision|Participants in this arm are served a large serving of a lunchtime food to eat (session 1).
2901000|NCT03241563|Active Comparator|without triamcinolone|sodium Deoxycholate without triamcinolone
2901001|NCT03241563|Active Comparator|with triamcinolone|sodium Deoxycholate with triamcinolone
2901002|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 1: 1 to < 6 years of age|Patients will receive an intravenous (IV) loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
2901003|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 2: 6 to < 12 years of age|Patients will receive an IV loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
2901004|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 3: 12 to < 18 years of age|Patients will receive an IV loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
2901005|NCT03241550|Experimental|isavuconazonium sulfate oral cohort 4: 6 to < 12 years of age|Patients will receive a loading regimen of isavuconazonium sulfate by oral administration, comprising one dose every 8 hours (+/- 2 hours) on days 1 and 2 (a total of six doses), followed by once daily oral maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
2901035|NCT03241368|Other|Capsule Endoscopy|This group will receive the Capsule Endoscopy procedure at 6 and 12 month follow up visits.
2901006|NCT03241550|Experimental|isavuconazonium sulfate oral cohort 5: 12 to < 18 years of age|Patients will receive a loading regimen of isavuconazonium sulfate by oral administration, comprising one dose every 8 hours (+/- 2 hours) on days 1 and 2 (a total of six doses), followed by once daily oral maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
2901007|NCT03241537|No Intervention|Hormonal therapy alone|total androgen ablation or antiandrogen therapy alone for 2-3 years
2901008|NCT03241537|Active Comparator|Hormonal therapy with radiotherapy|total androgen ablation or antiandrogen therapy for 2-3 years combined with radiotherapy on whole pelvis
2901009|NCT03241524|Experimental|Exercise program for pelvic muscle floor|Training program for pelvic muscles and application of 3 questionnaires for sexual function evaluation and the use of PERFECT and Perina methods to evaluate perineal musculature.
2901010|NCT03241511|Experimental|Test|Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic and repeated supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene). Outcomes will be assessed at 2-, 4-, and 6-months. Throughout the course of the study, additional dental needs will be addressed with immediate referral to the subject's general dentist or clinics at the University of Connecticut.
2901011|NCT03241511|No Intervention|Control|The Control arm will receive only a single treatment session without maintenance sessions (see visit Table in Human Subject Protection section). Outcomes will be assessed at 2-, 4-, and 6-months.
2901012|NCT03241498|No Intervention|Control arm|All patients allocated to the control group, who on checking meet the study entry criteria and who consent (written informed consent) to participate in the research, will be asked to complete the three study questionnaires (see below) and will be advised that repeat questionnaires will be distributed by post at the end of the study (6 months) for completion at home and return by post. The patients will continue to receive all services provided by the GP practice (normal care) but will not receive the bespoke clinical pharmacist intervention which is being evaluated in this research study.
2901013|NCT03241498|Experimental|Intervention arm|Participants meeting all study entry criteria who are allocated to the intervention group will also be asked to complete the three study questionnaires. Having completed the questionnaires they will receive the medicines optimisation intervention by the clinical pharmacist. They will be asked to return for repeat appointments with the clinical pharmacist at 2 and 4 months and will be advised that they will be asked to complete the study questionnaires again at the end of the study (at home, via post at 6 months).
2901014|NCT03241485|Placebo Comparator|Placebo|60 patients will be randomly assigned to this arm. The patients in this arm will receive intrathecal saline.
2901015|NCT03241485|Active Comparator|Intrathecal morphine|60 patients will be randomly assigned to this arm. The patients in this arm will receive intrathecal morphine.
2901016|NCT03241472|Experimental|Lertozole|oral tablets 5 mg start from third day cycle for 5 days
2901017|NCT03241472|Active Comparator|clomiphene plus N- acetyl cystiene|clomiphene 100 mg plus N-acetyl cystiene 600 mg start from third day cycle for 5 days
2901018|NCT03241459|Experimental|Surmodics SurVeil DCB|Surmodics SurVeil Drug-Coated Balloon is an investigational device coated with paclitaxel.
2901019|NCT03241459|Active Comparator|Medtronic IN.PACT Admiral DCB|
2901020|NCT03241446|Experimental|50 ug Tilmanocept|Single dose of 50 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
2901021|NCT03241446|Experimental|200 ug Tilmanocept|Single dose of 200 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
2901022|NCT03241446|Experimental|400 ug Tilmanocept|Single dose of 400 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
2901023|NCT03241433|Active Comparator|High intensity interval training|Exercise training will be conducted 3 times per week using cycle ergometers at commercial fitness facilities for 12 weeks 2 minute warmup/3 minute cooldown- at 50W Intensity- 3 X 20-second sprint interval cycling -as fast as possible at 90-95% peak power low intensity- 2 X 2 minute cycling at slow pace 50W
2901024|NCT03241433|Active Comparator|Moderate intensity continuous training|Exercise training will be conducted 3 times per week using cycle ergometers at commercial fitness facilities for 12 weeks 2 minute warmup/3 minute cooldown- at 50W Intensity- 45 minutes of continuous cycling at 45-60% peak power
2901025|NCT03241433|Active Comparator|No exercise|No excercise training will be done
2901026|NCT03241420|Active Comparator|Chronic Lung conditions|Study participation will consist of one visit: Informed consent, complete both Lung Clearance Index (LCI) testing and spirometry.
2901027|NCT03241420|Active Comparator|Healthy control group|Study participation will consist of one visit: Informed consent, brief questionnaire, LCI testing and spirometry.
2901028|NCT03241407|Placebo Comparator|Placebo toothpaste|Fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.
2901029|NCT03241407|Experimental|triclosan/copolymer/fluoride toothpaste|triclosan/copolymer/fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min. During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
2901030|NCT03241394||Lean|Individuals with Body Mass Index (BMI) = 18.5 - 25.0 Kg/m2
2901031|NCT03241394||Obese with MS|Individuals with BMI ≥ 30.0 Kg/m2 and metabolic syndrome (MS) MS was defined as the presence of three or more of the following criteria: 1) waist circumference ≥ 102 cm in men and ≥ 88 cm in women, 2) serum triglycerides ≥ 150 mg/dL, 3) high density lipoprotein-cholesterol (HDL-C) < 40 mg/dl in men and < 50 mg/dl in women, 4) systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg or antihypertensive drug treatment, 5) fasting glucose ≥ 100 mg/dL
2901032|NCT03241394||Obese without MS|Individuals with BMI ≥ 30.0 Kg/m2 but not MS
2901033|NCT03241381||Group A : Melasma|patients with facial pigmentation in the form of melasma
2901036|NCT03241368|Other|Comparator Group (IC plus MRE or IC alone)|This group will receive ileocolonoscopy (IC) plus MRE or IC alone at 6 and 12 month follow up visits.
2901037|NCT03241355|Active Comparator|prebiotic inulin-type fructan|
2901038|NCT03241355|Placebo Comparator|placebo maltodextrin|
2901039|NCT03241342|Active Comparator|1 mg GTx-024|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
2901040|NCT03241342|Active Comparator|3 mg GTx-024|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
2901041|NCT03241342|Placebo Comparator|matching placebo|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
2901042|NCT03241329||Case : endometriosis|Infertile patients with endometriosis that is the only cause of their infertility
2901043|NCT03241329||Control : tubal factor|infertile patients with tubal factor that is the only cause of their infertility
2901044|NCT03241316||district-level representative rural survey|Approximately 4,800 adults in 60 villages across Thailand and Lao PDR to study health and antimicrobial resistance (AMR)-related behaviour in breadth.
2901045|NCT03241316||village-level social network census|Approximately 4,800 adults across 6 villages in rural Thailand and Lao PDR that are exposed to AMR awareness activities to study health behaviour within social networks.
2901046|NCT03241303|Experimental|Acarbose|50 mg and 100 mg glucobay tablets. 2 weeks. Other name: Precose
2901047|NCT03241303|Placebo Comparator|Placebo Oral tablets|180 mg. 2 weeks.
2901048|NCT03241303|Experimental|Exendin (9-39)|Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.
2901049|NCT03241303|Placebo Comparator|Placbo Saline|9 mg/ml placebo saline infusion on experimental day.
2901050|NCT03241290||Use of C-ARM ARCO FP-Rk521S|C-ARM ARCO FP-Rk521S is mobile X-ray device that combines a X-Ray sensor and a sensor management software used during surgeries for real-time imaging.
2901051|NCT03241277|Experimental|Social phobia|Patients with social phobia with no psychiatric treatment Intervention- non surgical periodontal treatment
2901052|NCT03241277|Experimental|Social phobia under Psych T|Patients with social phobia under psychiatric treatment (Psych T) Intervention- non surgical periodontal treatment
2901053|NCT03241277|Active Comparator|Controls|Patients without social phobia Intervention- non surgical periodontal treatment
2901054|NCT03241264|Experimental|Module A|Lyophilized Formulation
2901055|NCT03241264|Experimental|Module B|Frozen Formulation
2901056|NCT03241251||parents children pediatric cancer|Screening questionnaire psychosocial risk factors
2901057|NCT03241238|Other|Regular Brownie|Regular Brownie For the regular brownie condition (RB), participants will consume the brownie preload and then consume a meal 20 minutes later.
2901058|NCT03241238|Other|Psyllium Brownie|For the psyllium brownie (PG), participants will consume a psyllium brownie and then consume a meal 20 minutes later.
2901059|NCT03241238|Other|β-glucan Brownie|For the β-glucan Brownie (BG), participants will consume a β-glucan Brownie preload and then consume a meal 20 minutes later
2901060|NCT03241225|Experimental|EM/PROTECT|This group of participants will receive the EM/PROTECT intervention, a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services.
2901061|NCT03241225|Active Comparator|EM/MH|This group of participants experiencing elder mistreatment will receive support services from staff trained in linking elder mistreatment victims to community mental health services.
2901062|NCT03241212|No Intervention|Control|"At baseline enrollment: participants will be asked to fill out a demographic survey, the MWIKAD survey and the SMOD-A survey. HbA1c, frequency of Blood Glucose (BG) checks and percent of glucose values above, within and below the target range will be extracted from chart review.~Surveys (with the exception of demographics) and chart extraction will be repeated at 3 months and 6 months post enrollment."
2901063|NCT03241212|Experimental|Texting|"Participants will be asked to complete the same surveys on the same timeline as above. The texting group will be asked to provide their cell phone number to the texting software.~From baseline appointment to 26 weeks post enrollment, participants will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen."
2901064|NCT03241199|Experimental|Imatinib Mesylate|imatinib 400mg daily
2901065|NCT03241186|Experimental|Ipilimumab (1 mg/kg) + Nivolumab (3 mg/kg) IV|"Cycles 1-4: Ipilimumab (1 mg/kg) + Nivolumab (3 mg/kg) IV Day 1 of each Cycle Each Cycle = 21 days~Cycles 5-15: Nivolumab IV 480 mg Day 1 of each Cycle Each Cycle = 28 days"
2901066|NCT03241173|Experimental|INCAGN01949 + Nivolumab|INCAGN01949 combined with nivolumab.
2901067|NCT03241173|Experimental|INCAGN01949 + Ipilimumab|INCAGN01949 combined with ipilimumab.
2901068|NCT03241173|Experimental|INCAGN01949 + Nivolumab + Ipilimumab|INCAGN01949 combined with nivolumab and ipilimumab.
2901069|NCT03241160||Children with cerebral palsy|Children with a diagnosis of spastic cerebral palsy aged between 2 to 12 years who will be referred by pediatric neurologists will be included. Children under the age of 24 months, and used any medicine and/or oral appliances that could affect the chewing performance, will be excluded. Chewing evaluation will be performed.
2901070|NCT03241147|Experimental|Subjects with severe renal impairment (Group A)|
2901071|NCT03241147|Experimental|Healthy subjects (Group B)|
2901072|NCT03241147|Experimental|Subjects with moderate renal impairment (Group C)|
2901073|NCT03241147|Experimental|Subjects with mild renal impairment (Group D)|
2901074|NCT03241134|Experimental|Dry needling|A single dry needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into skin surface, fascia, into the muscle tissue at the MTrP location, and will move the needle up and down in multiple directions. In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct.
2901146|NCT03240640|Experimental|Inspiratory Muscle Strength Training|High intensity inspiratory muscle training
2901075|NCT03241134|Sham Comparator|Sham needling|A single sham needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated.
2901076|NCT03241121|Experimental|Time restricted feeding|For those in the intervention phase (Part 2)
2901077|NCT03241121|Active Comparator|Regular dietary advices|For those in the intervention phase (Part 2)
2901078|NCT03241108|Experimental|NI-0101|A therapeutic humanized monoclonal antibody, administered by intravenous infusion every 2 weeks.
2901079|NCT03241108|Placebo Comparator|Placebo|The placebo matches NI-0101 without active ingredient, administered by intravenous infusion every 2 weeks.
2901080|NCT03241095|No Intervention|Control|
2901081|NCT03241095|Sham Comparator|Sham OMT|
2901082|NCT03241095|Active Comparator|OMT|
2901083|NCT03241069|Experimental|patients with acute dyspnea|"patients presenting to the emergency department with acute onset dyspnea are assessed for acute heart failure using the bio impedance technology (BIOPAC system) to measure the cardiac output in different clinical situations.~FIRST: the cardiac output (CO) is measured at the reference position. Inbetween each step the patient was put in the reference position during 5 minutes."
2901084|NCT03241069|Experimental|the sitting position|the patient is put at the sitting position and we measure the cardiac output by BIOPAC system (patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured)
2901085|NCT03241069|Experimental|a passive leg rising maneuver|we make a passive leg rising and we measure the cardiac output by BIOPAC system (45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver.)
2901086|NCT03241069|Experimental|Valsalva maneuver|the patient was asked to perform the Valsalva maneuver and we measure the cardiac output by BIOPAC system(patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.)
2901087|NCT03241069|Experimental|TRINITRINE|0.6 mg of nitroglycerin was given to the patient sublingual and we measure the cardiac output by BIOPAC system(0.6 mg of Nitroglycerin was administered by sublingual root and CO was evaluated.)
2901088|NCT03241056|Experimental|CBT for Maladaptive Beliefs about Memory|Using cognitive-behavioural therapy principles, this therapy is intended to examine and change maladaptive beliefs about memory as they pertain to compulsive checking.
2901089|NCT03241056|Active Comparator|Treatment as Usual|This is a control treatment, Treatment as Usual (TAU), which is what patients or community members would otherwise normally receive.
2901090|NCT03241043|Experimental|Envarsus - Advagraf|
2901091|NCT03241043|Active Comparator|Advagraf - Envarsus|
2901092|NCT03241030|Experimental|Experimental Group|Subjects will receive sucralfate
2901093|NCT03241030|Placebo Comparator|Placebo Group|Subjects will receive a placebo
2901094|NCT03241017|Experimental|Durvalumab|Durvalumab 1500 mg (day 1) given every 4 weeks for a total of 12 applications (1 year).
2901095|NCT03241004|Experimental|Intensive Care Unit|"Patients will be induced in a standard fashion using intravenous (IV) anesthetics. A continuous administration of propofol will be used for maintenance of anesthesia.~Baseline EEG readings will be established for 30 minutes, then EEG data will be recorded and a sleep mask applied to the patient for one hour. After one hour, eye masks will be removed for an hour and reapplied after another hour. During the hour that the mask is off, 2 hours into sedation, EEG data will again be recorded."
2901096|NCT03241004|Experimental|Operating Room|"Patients will be induced in a standard fashion using intravenous (IV) anesthetics. A continuous administration of propofol and inhalational anesthetics will be used for maintenance of anesthesia.~Baseline EEG readings will be established for 30 minutes, then EEG data will be recorded and a sleep mask applied to the patient for one hour. After one hour, eye masks will be removed for an hour and reapplied after another hour. During the hour that the mask is off, 2 hours into sedation, EEG data will again be recorded."
2901097|NCT03240991||Quality of life questionnaires|Data will be collected retrospectively and prospectively.
2901098|NCT03240978|Experimental|High intensity intervention|Exercise intervention at 70 to 80% of estimated heart reate maximum for 12 weeks.
2901099|NCT03240978|Experimental|Moderate intensity intervention|exercise intervention at 50 to 70% of estimated heart rate maximum for 12 weeks.
2901100|NCT03240978|No Intervention|non-exercise group|Participants will not receive any type of exercise training.
2901101|NCT03240965||Volunteers <60 years|Volunteers, who are able to consent to participation in the study, as control.
2901102|NCT03240965||Volunteers >60 years|Volunteers, who are able to consent to participation in the study, as control.
2901103|NCT03240965||Stroke patients|Stroke patients with supratentorial stroke, who are able to consent to participation in the study.
2901104|NCT03240939|Active Comparator|Dutasteride&Tadalafil|Dutasteride 0.5 mg capsule and Tadalafil 5 mg Tablet, single dose
2901105|NCT03240939|Experimental|YY-201|YY-201 capsule, singe dose
2901106|NCT03240926|Experimental|Loop Band|Measure accuracy of vital sign measurements
2901107|NCT03240913|Experimental|Treatment Group|
2901108|NCT03240913|Placebo Comparator|Non Treatment Group|Conventional information
2901109|NCT03240900|Experimental|Electrical Stimulation Breast|Breast that will receive 1 hour of intraoperative electrical stimulation
2901110|NCT03240900|Placebo Comparator|No Electrical Stimulation Breast|The contralateral breast of the patient will receive no electrical stimulation
2901111|NCT03240887|Experimental|Peer Group Connection (PGC)|Ninth-grade participants are assigned to small groups of 10-14 students that attend weekly peer group outreach sessions led by older peer leaders.
2901112|NCT03240887|No Intervention|Business as usual|Ninth grade students remain in their regularly scheduled school classes or activities during PGC outreach times.
2901113|NCT03240874|Experimental|Focus Group|"Mobile Application Usability Testing (phase 1): SweetMama Focus Groups~Focus groups: Women with a confirmed intrauterine pregnancy or postpartum until 12 weeks after delivery with gestational diabetes mellitus or type 2 diabetes mellitus will be recruited to undergo a single 1-hour focus group."
2901147|NCT03240640|Sham Comparator|Inspiratory Muscle Endurance Training|Sham inspiratory muscle training at low intensity
2901386|NCT03239145|Experimental|Pembrolizumab + Trebananib|Part 1 Standard 3+3 Dose Escalation
2901114|NCT03240874|Experimental|Individual Testing|"Mobile Application Usability Testing (phase 2): SweetMama Individual Testing~Individual testing: Women with a confirmed intrauterine pregnancy prior to 30 weeks' gestational age with gestational diabetes mellitus or type 2 diabetes mellitus will be recruited to use SweetMama for 4 weeks and provide feedback."
2901115|NCT03240861|Experimental|Treatment (Genetically engineered PBMC and PBSC)|"G-CSF AND PLERIXAFOR MOBILIZED LEUKAPHERESIS: Between 6 months and 3 weeks before infusion of cells, patients undergo G-CSF and plerixafor mobilization of CD34+ peripheral blood stem cells. Patients receive G-CSF SC on mobilization days 1-8 and plerixafor SC on mobilization days 4-7. Patients also undergo an unmobilized leukapheresis on day -5 before infusion of cells.~CHEMOTHERAPY CONDITIONING REGIMEN: Patients receive busulfan IV on days -4 to -2 and fludarabine IV over 30 minutes on days -3 to -2.~Patients receive LV-NYESO TCR/sr39TK PBSC IV on day 0, and after approximately 24 hours, patients receive RV-NYESO TCR PBMC IV on day 1. Beginning on day 2, patients receive aldesleukin SC BID for up to 7 days. Patients undergo blood collection for safety and immune monitoring on days 0, 1, 3, 5, 7, 14, 30, 60, 90, and 120. Patients receive 18F-FHBG IV, and after 1 hour, undergo PET/CT on days 25 and 120."
2901116|NCT03240848|Experimental|artificial intelligent clinic|"Procedure: the initial diagnosis from artificial intelligent clinic Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.~Procedure: the final definite diagnosis from experts After making the initial diagnosis in artificial intelligent clinic, participants in group A went to get the final definite diagnosis from experts with more than 10 years of clinical experience."
2901117|NCT03240848|Active Comparator|normal clinic|"Procedure: the initial diagnosis from normal clinic Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.~Procedure: the final definite diagnosis from experts After making the initial diagnosis in normal clinic, participants in group B went to get the final definite diagnosis from experts with more than 10 years of clinical experience."
2901118|NCT03240835||CCRT±NACT|Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin) , or treated with CCRT only
2901119|NCT03240822|Experimental|Penile Allotransplant and Immunosuppression Treatment|Penile transplantation with monoclonal antibody induction therapy of humanized anti CD52 followed by donor bone marrow infusion and tacrolimus monotherapy.
2901120|NCT03240809|Experimental|Cohort 1|(ages 12 to <18 years): 140 mg SC dose of brodalumab
2901121|NCT03240809|Experimental|Cohort 2|(ages 6 to <12 years): 70 mg SC dose of brodalumab
2901122|NCT03240796|Active Comparator|traditional cataract surgery|
2901123|NCT03240796|Experimental|intraocular lens implantation surgery|
2901124|NCT03240783|Experimental|Arm 1|Betamethasone OR Dexamethasone Injectable CT - fluoroscopic guided transforaminal lumbar epidural steroid
2901125|NCT03240783|Experimental|Arm 2|Normal Saline Flush, 0.9% Injectable Solution CT - fluoroscopic guided transforaminal lumbar epidural normal saline
2901126|NCT03240783|Experimental|Arm 3|"Dexamethasone Oral Tablet:~Oral dexamethasone 15 day tapered dosing is as follows: (i) days 1-5, 4 mg morning and evening, (ii) days 6-10, 2 mg morning and evening, and (iii) days 11-15, 1mg morning and evening."
2901127|NCT03240783|Other|Arm 4|Sham Injection and/or oral placebo: CT/fluoroscopic guided (parameters set to zero) transforaminal lumbar sham (needle placement down to muscle and no injection of any fluid) AND placebo oral tablets taper.
2901128|NCT03240770|No Intervention|14 Day Tray + Sham|Trays worn at 14 day intervals + Sham
2901129|NCT03240770|Experimental|7 Day Tray + Sham|"Trays worn at 7 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ Sham"
2901130|NCT03240770|Experimental|5 Day Tray + Sham|"Trays worn at 5 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ Sham"
2901131|NCT03240770|Experimental|7 Day Tray + VPro5|"Trays worn at 7 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ HFV with the VPro5 device at 5 min/day"
2901132|NCT03240770|Experimental|5 Day Tray + VPro5|"Trays worn at 5 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ HFV with the VPro5 device at 5 min/day"
2901133|NCT03240757|Active Comparator|Breakfast without exercise|Each subject of the same arm underwent 2 interventions: breakfast with/without exercise
2901134|NCT03240757|Experimental|Breakfast with exercise|Each subject of the same arm underwent 2 interventions: breakfast with/without exercise
2901135|NCT03240744|Experimental|vaccine (3.0EU)|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
2901136|NCT03240731|Experimental|bone marrow transplant|"All the included patient will receive an haploidentical bone marrow transplant with the following protocol concerning the conditioning and GvHD prevention~Conditioning~THYMOGLOBULINE : 0.5mg/kg at D-9 and 2 mg/kg at D-8 and D-7~THIOTEPA: 10mg/kg/j at D-7~CYCLOPHOSPHAMIDE (Endoxan®):14.5mg/kg/j at D−6 and D−5~FLUDARABINE (Fludara®): 30mg/m2 per Day from D−6 to D-2~TBI : 2GY : D −1 Graft : Injection at D0 of G-CSF-stimulated bone marrow transplant.~Prophylaxis of GvHD~CYCLOPHOSPHAMIDE (Endoxan®): 50mg/Kg per Day from D+3 to D+4~Sirolimus and MycophénolateMofétil (MMP) from D+5. In the absence of acute GvHD (aGvHD), stop of MMP to D35 and pursuit of sirolimus 1 year after the graft."
2901137|NCT03240718|Experimental|Laser treated HSc scar|Co2 laser treatment
2901138|NCT03240718|No Intervention|Control scar|Standard care
2901139|NCT03240705|Experimental|Gratitude journaling|Students perform gratitude journaling 3 times per week on a form. This activity consists of writing elements of their day that brought happiness to them. Can be in keyword form or in sentences.
2901140|NCT03240705|No Intervention|No intervention|Students proceed with their surgical clerkship as is standard in our institution.
2901141|NCT03240692|Experimental|Accelerated theta burst treatment|All participants will receive theta-burst TMS.
2901142|NCT03240679|Active Comparator|EMR with Extracelluar Matrix|Patients with lesions that lift and are amenable to cap-assisted EMR will be randomized to receive Extracellular Matrix to the defect site
2901143|NCT03240679|No Intervention|EMR|assess baseline dysphagia (Mellow-Pinkas scale and Mayo Dysphagia Questionnaire). Patients with lesions that lift and are amenable to cap-assisted EMR will be randomized to receive standard of care.
2901144|NCT03240653||Patients Type III|Stratified response to EnzymeTherapy
2901145|NCT03240653||Patients Type I|Stratified response to Enzyme Therapy and Substrate Reduction Therapy
2901148|NCT03240627|Experimental|LH-8 cutaneous solution|LH-8 cutaneous solution (0.126 mL per spray) applied to the whole scalp:
2901149|NCT03240627|Placebo Comparator|Placebo cutaneous solution|Placebo cutaneous solution (0.126 mL per spray) applied to the whole scalp:
2901150|NCT03240614|Active Comparator|BMI <30 no lung disease|Patients with a BMI <30 with no lung disease
2901151|NCT03240614|Active Comparator|BMI <30 with lung disease|Patients with a BMI <30 with lung disease
2901152|NCT03240614|Active Comparator|BMI 30-35 with no lung disease|Patients with a BMI between 30 and 35 with no lung disease
2901153|NCT03240614|Active Comparator|BMI 30-35 with lung disease|Patients with a BMI between 30 and 35 with lung disease
2901154|NCT03240614|Active Comparator|BMI >35 with no lung disease|Patients with a BMI> 35 with no lung disease
2901155|NCT03240614|Active Comparator|BMI >35 with lung disease|Patients with a BMI> 35 with lung disease
2901156|NCT03240601|Sham Comparator|Subthreshold|Individuals will undergo their standard physical therapist directed locomotor training while receiving transcutaneous spinal cord stimulation. The stimulation intensity will briefly ramp up to the lowest intensity that is first detected by the participant and then ramped down to a level no longer detected by the participant. Participants will continue their locomotor training.
2901157|NCT03240601|Experimental|Active|Individuals will undergo their standard physical therapist directed locomotor training while receiving transcutaneous spinal cord stimulation. The stimulation intensity will ramp up slowly to a level that produces parasthesia (tingling) throughout the lower extremity. This intensity will be applied for 30 minutes while participants continue their locomotor training.
2901158|NCT03240588|Active Comparator|De Novo Cohort|Newly enrolled RELIEF and NAVITAS Study subjects who have not previously attempted a Neurostimulator trial will be followed up to 36 months post-Neurostimulation trial procedure on the use of their Neurostimulation system.
2901159|NCT03240588|Active Comparator|Existing Cohort|Enrolled (existing) RELIEF Study subjects which have completed permanent neurostimulator IPG implant and are in various stages of follow-up prior to 24-month RELIEF study Post Neurostimulation Trial Procedure Visit at time of NAVITAS study enrollment will be followed up to 36 months post-Neurostimulation trial procedure on the use of their Neurostimulation system.
2901160|NCT03240575|Experimental|Tiotropium + Olodaterol fixed dose combination|
2901161|NCT03240575|Active Comparator|Fluticasone propionate + Salmeterol fixed dose combination|
2901162|NCT03240562|Sham Comparator|IV-PCA group|no block performing, only use intravenous patient controled analgesia(IV-PCA)
2901163|NCT03240562|Experimental|SAPB group|serratus anterior plane block(SAPB) and intravenous patient controled analgesia(IV-PCA)
2901164|NCT03240549|No Intervention|conventional therapy group|Treatment with previous regimen of combined chemotherapy
2901165|NCT03240549|Experimental|bevacizumab group|Adding bevacizumab to the previous regimen of combined chemotherapy
2901166|NCT03240536|Experimental|Intervention Group|Ordering physicians who have referred to a rheumatologist in the St. Joseph's rheumatology clinic randomized to the intervention group will receive a brief Choosing Wisely form (for education of guidelines) faxed with the referral notice. At one and two years all ordering physicians will receive by fax a three question survey.
2901167|NCT03240536|No Intervention|Control Group|Ordering physicians who have referred to rheumatologists in the control group will not receive the Choosing Wisely form. At one and two years all ordering physicians will receive by fax a three question survey.
2901168|NCT03240523|Experimental|Group A1: Vilaprisan (3/1 regimen)|Orally, 2 mg, once daily, 3 months treatment followed by 1 menstrual bleeding episode
2901169|NCT03240523|Experimental|Group A2: Vilaprisan (6/2 regimen)|Orally, 2 mg, once daily, 6 months treatment followed by 2 menstrual bleeding episodes
2901170|NCT03240523|Experimental|Group A3/B (3/2 regimen)|"Orally, 2 mg, once daily, 3 months treatment followed by 2 menstrual bleeding episodes~No new subjects will be randomized to previous group A3 and group B after implementation of Protocol version 5.0. All subjects originally assigned to those groups will receive open-label treatment with Vilaprisan only. New treatment group is called A3/B."
2901171|NCT03240497|Experimental|Cold Exposure|A group of subjects (n=12) that will receive an extensive course in cold exposure similar in length to our previous study (total of 10 days) before the endotoxemia experiment.
2901172|NCT03240497|Experimental|Strength Ventilation|A group of subjects (n=12) that will be trained in the strength ventilation breathing technique before the endotoxemia experiment.
2901173|NCT03240497|Experimental|Cold Exposure and Strength Ventilation|A group of subjects (n=12) that will receive both the cold exposure course (same as the STV group) as well as the training in the strength ventilation breathing technique (same as the CEX group) before the endotoxemia experiment.
2901174|NCT03240497|No Intervention|Control group|A group of subjects (n=12) that will receive no training and will not be exposed to cold before the endotoxemia experiment.
2901175|NCT03240484||Spine Fusion and Total Hip Replacement|Any patient who has had lumbar spine fusion (LSF) and total hip arthroplasty (THA). Patients will undergo x-ray imaging and complete functional assessment questionnaires.
2901176|NCT03240484||Total Hip Replacement Group|Any patient who has had THA only (no spine fusion surgery). Patients will undergo x-ray imaging and complete functional assessment questionnaires.
2901177|NCT03240471|Experimental|One week of plaster cast|One week of plaster cast after a non-reduced distal radius fracture.
2901178|NCT03240471|Other|Control; four-five weeks of plaster cast|Four-five weeks of plaster cast after a non-reduced distal radius fracture, usual care.
2901179|NCT03240445|Experimental|Period 1|ODM-203 dosed after food
2901180|NCT03240445|Experimental|Period 2|ODM-203 dosed before food
2901181|NCT03240445|Experimental|Periods 3-6|ODM-203 dosed as a tablet or dispersion
2901182|NCT03240432|Active Comparator|Continuous Glucose Monitor group|CGM group participants will be asked to use a Dexcom CGM sensor on a daily basis, inserting a new sensor as needed. Participants will be instructed to use the sensor according to FDA labeling. In addition, participants will be advised to check the blood glucose when symptoms or expectations do not match the CGM reading. Participants will have clinic visits at 10 days, 4 weeks, 8 weeks, 16 weeks, and 26 weeks.
2901220|NCT03240185||Hemroidectomy patients|Patients undergoing hemorrhoid surgery who receive education regarding deep breathing exercises for pain control as part of their preoperative appointment
2944364|NCT02942719||Qinghai Red Cross Hospital|
2901183|NCT03240432|No Intervention|Blood Glucose Meter group|BGM group participants will be asked to use a study blood glucose meter with test strips for a fingerstick blood glucose check with a recommendation of 4 times a day. Participants will be permitted to check a fingerstick glucose as many times a day as they choose. Participants will have a phone visits at 10 days and clinic visits at 4 weeks, 8 weeks, 16 weeks, and 26 weeks. In addition to the in-clinic study visits, the BGM group will have blinded sensor placement visits one week prior to each of the 8, 16, and 26 week visits.
2901184|NCT03240419|Experimental|Probiotics|Each probiotic capsule contains 180 mg of a standardized white to light beige fine powder consisting of freeze-dried cultures. Specifically, Bifidobacterium BB-12® and Lactobacillus rhamnosus LGG® (50%:50%). This product has a minimum potency of 6.5 billion (6.5E+9) CFU (ColonyForming Units) per capsule. Other ingredients in the powder are: microcrystalline cellulose, maltodextrin, silicon dioxide and magnesium stearate. Participants in this group will take one daily capsule orally starting at the time of recruitment (gestation week 12) and until delivery.
2901185|NCT03240419|Placebo Comparator|Placebo|Participants in this group will take one capsule containing microcrystalline cellulose, maltodextrin, silicon dioxide and magnesium stearate (all ingredients listed in the probiotic capsules except the culture) . Participants in this group will take one daily capsule orally starting at the time of recruitment (gestation week 12) and until delivery.
2901186|NCT03240406|Active Comparator|Anti-inflammatory dietary intervention|18 month intervention of dietary counseling to adhere to the Multicultural Healthy Diet or the anti-inflammatory diet,
2901187|NCT03240406|Placebo Comparator|Usual Diet plus Self-Care|18 month intervention of usual diet plus self-care modules
2901188|NCT03240393|Experimental|cMET GCN ≥ 6|Pre-treated patients with cMET GCN ≥ 6 treated with INC280 at 400mg BID
2901189|NCT03240393|Experimental|cMET GCN ≥ 4 and < 6|Pre-treated patients with cMET GCN ≥ 4 and < 6 treated with INC280 at 400 mgBID
2901190|NCT03240393|Experimental|cMET mutations|Pre-treated patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID
2901191|NCT03240380|Experimental|joint crisis plan|Subjects benefit from a joint crisis plan and the process of its negotiation in addition to the usual in-patient or out-patient care.
2901192|NCT03240380|Active Comparator|crisis card|Subjects benefit from a crisis card in addition to the usual in-patient or out-patient care.
2901193|NCT03240367|Experimental|coutery|Stapler bloom will be stopped with cautery
2901194|NCT03240367|No Intervention|clips|Stapler bloom will be stopped with clipping
2901195|NCT03240354|Experimental|Saline|Use of saline to inflate cuff of endotracheal tube
2901196|NCT03240354|Active Comparator|Control|Use of air to inflate cuff of endotracheal tube
2901197|NCT03240341|Experimental|Patient Activation Measure (PAM)|completion of the PAM questionnaire
2901198|NCT03240328|Experimental|CAR-T therapy|Transfuse CAR-T cells 1 million clone every time (totally twice) based on cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ml) over 1 year by cART
2901199|NCT03240328|No Intervention|Without CAR-T therapy|Without CAR-T cells transfusion but continue cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ml) over 1 year by cART.
2901200|NCT03240315||COPD subjects|Subjects with GOLD stage I-IV COPD
2901201|NCT03240302|Active Comparator|ICSI Procedure|The ICSI procedure is the standard procedure of selection and injection of sperm into the oocyte using a standard ICSI petri dish.
2901202|NCT03240302|Active Comparator|PICSI Procedure|The PICSI procedure is based on a selection of mature spermatozoa with CD44 receptors and their injection into the oocyte using the PICSI petri dish that has been coated with hyaluronic acid on its bottom.
2901203|NCT03240289|Other|Texting|Texting group
2901204|NCT03240276|Active Comparator|ICSI Procedure|The ICSI procedure is the standard procedure of selection and injection of sperm into the oocyte
2901205|NCT03240276|Active Comparator|IMSI Procedure|The IMSI procedure is the injection of normal ultramorphological spermatozoa that have been selected using an inverted microscope with magnification of 6300x (MSOME)
2901206|NCT03240263|Experimental|Inspiratory muscle training|High intensity inspiratory muscle training
2901207|NCT03240263|Sham Comparator|Sham endurance training|Sham inspiratory muscle training at low intensity
2901208|NCT03240250||Uni-portal VATS|VATS uni-portal lobectomy and lymphoadenectomy
2901209|NCT03240250||Three-portal VATS|VATS three-portal lobectomy and lymphoadenectomy
2901210|NCT03240237|Experimental|CCM therapy|Optimizer SMART
2901211|NCT03240224|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2901212|NCT03240224|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2901213|NCT03240224|Experimental|Combination therapy|"In this group, the patients will receive combination therapy, including ablation and life information rehabilitation therapy. They will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm), then drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2901214|NCT03240224|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2901215|NCT03240211|Experimental|Pembrolizumab plus Pralatrexate|Subjects will receive pembrolizumab 200 mg IV day 1 with pralatrexate 30 mg/m2 IV day 1, 8, and 15.
2901216|NCT03240211|Experimental|Pembrolizumab plus Pralatrexate plus Decitabine|Subjects will receive pembrolizumab 200 mg IV day 8 with pralatrexate 20 mg/m2 IV day 1, 8, and 15 and decitabine 10 mg/m2 from day 1 to 5.
2901217|NCT03240211|Experimental|Pembrolizumab plus Decitabine|Subjects will receive pembrolizumab 200 mg IV and decitabine 20 mg/m2 from day 1 to 5.
2901218|NCT03240198||COPD|
2901219|NCT03240198||Controls|
2901362|NCT03239262|Experimental|Group LA|Sixty five patients (65%) in whom no intervention related to ganglionated plexi was performed (Group LA).
2901221|NCT03240159|Active Comparator|Deg-24mg|"Single dose of Degarelix 24mg, on day 24th of previous luteal face cycle. On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
2901222|NCT03240159|Active Comparator|Deg-16mg|"Single dose of Degarelix 16mg, on day 24th of previous luteal face cycle. On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
2901223|NCT03240159|Active Comparator|Deg-12mg|"Single dose of Degarelix 12mg, on day 24th of previous luteal face cycle.On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
2901224|NCT03240146|Active Comparator|Study Group|Subjects in this group will receive an active pulsed shortwave therapy device.
2901225|NCT03240146|Placebo Comparator|Control Group|Subjects in this group will receive a placebo pulsed shortwave device that it does not emit energy.
2901226|NCT03240133|Experimental|Part1: BCX7353 750 mg|
2901227|NCT03240133|Experimental|Part 2: BCX7353 500 mg|
2901228|NCT03240133|Experimental|Part 3: BCX7353 250 mg|
2901229|NCT03240133|Placebo Comparator|Parts 1, 2 and 3: placebo|
2901230|NCT03240120|Experimental|Dabigatran etexilate & Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed dabigatran 150mg twice daily from Day 6 onward till 6 months after underlying disease remission.
2901231|NCT03240107|Active Comparator|levator resection|20 patients who will undergo levator aponeurosis resection technique
2901232|NCT03240107|Active Comparator|levator tucking|20 patients who will undergo two point fixation levator tucking technique
2901233|NCT03240094|Experimental|Nutritional telemonitoring|Participants in the intervention group receive a telemonitoring intervention, including self-measurements of body weight, nutritional status, appetite, diet quality, and physical activity. Additionally, participants receive guidance on nutrition and physical activity by means of customized and general television messages and/or if necessary personal guidance by a nurse.
2901234|NCT03240094|No Intervention|Usual care|Participants in the control group receive usual care.
2901235|NCT03240081|Active Comparator|50mcg estradiol cream|Subjects randomized to 50mcg of study medication will be issued a pump that will dispense 0.5gm of cream with each pump
2901236|NCT03240081|Active Comparator|100mcg estradiol cream|Subjects randomized to 100mcg of study medication will be issued a pump that will dispense 0.5gm of cream with each pump
2901237|NCT03240068|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of five ascending doses of angiotensin-(1-7). The doses are: 1, 2, 4, 8, and 12 ng/kg/min. Each dose will be maintained for 10 minutes, for a total infusion period of 50 minutes.
2901238|NCT03240068|Placebo Comparator|Saline|Subjects will receive intravenous infusion of saline that is matched in volume to the angiotensin-(1-7) arm. Saline infusion will be maintained for a total infusion period of 50 minutes.
2901239|NCT03240055|Experimental|Group SE|21 patients received spinal anesthesia first. After confirmation of the level (T4-T6) of the sensory anesthesia, the sequential administration of etomidate was conducted
2901240|NCT03240055|Placebo Comparator|Group E|27 patients without spinal anesthesia in this group received sequential administration of etomidate
2901241|NCT03240042|Experimental|Nasoendo group|Participants received nasotracheal intubation under general anesthesia for the anterior cervical spine surgery.
2901242|NCT03240042|Other|Oroendo group|Participants received orotracheal intubation under general anesthesia for the anterior cervical spine surgery.
2901243|NCT03240029|Experimental|Children in cancer remission|Children in cancer remission sent to ordinary schools: primary (3rd, 4th, 5th grade) and middle (6th, 7th grade) schools.
2901244|NCT03240029|Other|Control children|Children (not in cancer remission) sent to ordinary schools (age and sex matched): primary (3rd, 4th, 5th grade) and middle (6th, 7th grade) schools.
2901245|NCT03240016|Experimental|Pembrolizumab and Abraxane|Pembrolizumab 200mg IV D1 Abraxane 125mg/m^2 IV D1 and D8 21 Day Cycles
2901246|NCT03240003|Experimental|GC-MRT|Group 1 will receive a 4-week (8-sessions) course of standard GC-MRT
2901247|NCT03240003|Active Comparator|non-GC-MRT|Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
2901248|NCT03240003|Experimental|GC-MRT-modified|Group 3 will receive a 4-week (8-sessions) course of modified GC-MRT.
2901249|NCT03239990|Experimental|Incredible Years, Parent support|Incredible Years, Parent group supported by home visiting includes the Incredible Years Parent Training Program, Preschool Basic version, with 18-20 group meetings. Four home visits are added to the program to support parents in practicing new skills and to provide individual practical consultation.
2901250|NCT03239990|No Intervention|Treatment as usual|The control group will receive treatment as usual
2901251|NCT03239977|Experimental|Online Social Intelligence Training|The Social Intelligence Intervention (SII) is delivered online to both custodial grandmothers and their adolescent grandchild separately. This is the sole active treatment condition within this RCT.
2901252|NCT03239977|Placebo Comparator|Attention Control (AC)|The attention control (AC) condition, known as The Healthy Living program provides information about different aspects of health.
2901319|NCT03239548||Key informants|It refers to the general public including patients admitted and attending O.P.D and their attendants with minimum qualification as graduation.
2901253|NCT03239964|Active Comparator|excision only group|"Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of keloid is performed and minimal undermining followed by usual steps of caesarean section. Primary closure of wound in layers is achieved in all cases. A running subcuticular prolene 2/0 stitch is used to suture the skin. Group A of 73 patients will not receive further injection. The wound is painted with betadine and sealed until postoperative day 14, at which time the subcuticular stitch is removed.~Routine postoperative medications are given to all patients. They are advised to avoid direct sun exposure for the following month. No postoperative applications (eg, compression, steroid injections, etc) are used in any of the patients. All patients are reviewed once per month for 6 months."
2901254|NCT03239964|Active Comparator|excision and injection group|"Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of keloid is performed and minimal undermining followed by usual steps of caesarean section and primary closure of the wound in layers. A running subcuticular prolene 2/0 stitch is used to suture skin.In 73 patients (group B), wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue. The wound is painted with betadine and sealed until postoperative day 14 to remove the subcuticular stitch.~Routine postoperative medications are given, avoidance of direct sun exposure for one month,No postoperative applications as compression, steroid injections, etc. All patients are reviewed once per month for 6 months."
2901255|NCT03239951|Experimental|Device|temporary implant
2901256|NCT03239951|Active Comparator|Control|Standard of Care
2901257|NCT03239938|Experimental|Modern pain neuroscience approach|Modern pain neuroscience approach
2901258|NCT03239938|Active Comparator|Usual care evidence-based physiotherapy|Usual care physiotherapy
2901259|NCT03239925|Experimental|Experimental group|all participants in this group would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.
2901260|NCT03239925|Placebo Comparator|Control group|these would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode
2901261|NCT03239912|Experimental|Twin-block group|Functional treatment will be applied using the Twin-block appliance.
2901262|NCT03239912|Experimental|Twin-block combined with low level laser|Functional treatment will be applied using the Twin-block appliance combined with low level laser.
2901263|NCT03239899|Experimental|Pembrolizuma|
2901264|NCT03239886|Experimental|Discontinuation|All subjects will discontinue imatinib
2901265|NCT03239873|Experimental|VARIVAX™ PE34 Process + M-M-R II™|VARIVAX™ Passage Extension (PE34) Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II™ vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
2901266|NCT03239873|Active Comparator|VARIVAX™ 2016 Commercial Process + M-M-R II™|VARIVAX™ 2016 Commercial Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II™ vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
2901267|NCT03239860|Experimental|Dose 1 GNbAC1|Monthly IV
2901268|NCT03239860|Experimental|Dose 2 GNbAC1|Monthly IV
2901269|NCT03239860|Experimental|Dose 3 GNbAC1|Monthly IV
2901270|NCT03239847|Experimental|EndoPhys Sheath and Radial Arterial Line|This group of patients will have both the EndoPhys sheath and the radial arterial line placed during surgery.
2901271|NCT03239847|Experimental|EndoPhys Sheath|This group of patients will only receive the EndoPhys sheath during surgery.
2901272|NCT03239834||OncAlert RAPID test in oral cavity biopsy patients.|Patients at an intermediate and high level of clinical risk for HNSCC and scheduled for initial and immediate incisional diagnostic biopsy of their Oral Cavity.
2901273|NCT03239834||OncAlert RAPID test in oropharyngeal biopsy patients.|Patients at an intermediate to high level of clinical risk for HNSCC and scheduled for initial and immediate incisional diagnostic biopsy of their Oropharnyx
2901274|NCT03239834||OncAlert RAPID test in clinical decision to biopsy.|Patients at a lower level of clinical risk for HNSCC and not scheduled for an immediate biopsy. Patients will be offered medical management and have an initial RAPID test. All patients will return within 1-3 months for follow-up test and a possible biopsy if clinically indicated.
2901275|NCT03239821|Sham Comparator|Placebo - deflated balloon|
2901276|NCT03239821|Placebo Comparator|Placebo - inflated balloon|
2901277|NCT03239821|Active Comparator|Codeine - delfated balloon|
2901278|NCT03239821|Active Comparator|Codeine - inflated balloon|
2901279|NCT03239808|Experimental|Experimental group|76 patients who start RRT with the incremental HD regimen.
2901280|NCT03239808|Active Comparator|Control group|76 patients who start RRT with the conventional HD (3 sessions per week)
2901281|NCT03239795|Experimental|Intervention group|Family physicians' patients exposed to advertisement in waiting rooms consisting in a poster and pamphlets promoting seasonal influenza vaccination (+ usual mandatory information)
2901282|NCT03239795|No Intervention|Control group|Family physicians' patients exposed to usual laying out of waiting rooms
2901283|NCT03239782|Experimental|Metabolically unhealthy|"Subjects classified as metabolically unhealthy (MONW) go on to participate in a calorie restriction intervention.~MONW subjects will participate in a supervised weight loss program to help ensure they are under a similar weekly energy deficit and achieve a 5 % weight loss at approximately the same time. Participants will be prescribed a reduced-calorie diet (~500 kcal/d below their needs for weight maintenance), and will be instructed not to change their physical activity habits, in order to achieve a weekly weight loss of ~0.5 kg.~The macronutrient composition of the diet will be the same for all groups (55-60 % of energy from carbohydrate, 15-20 % from protein, and 20-30 % from fat); no vitamins or other nutritional supplements will be given."
2901284|NCT03239769|Active Comparator|conventional access group (CA)|A 4- to 5-cm incision was created, subplatysmal flaps were raised, and the strap muscles were mobilized. Then, the superior pole of the thyroid gland was exposed and the gland was delivered through the surgical incision, and the thyroid isthmus was divided. Finally, CLND was performed. The strap muscles were re-approximated with No.1 silk suture. The full-thickness skin was closed with interrupted monofilament.
2901320|NCT03239535|Experimental|Mesenchymal stem cells|Mesenchymal stem cells, Intramuscular injection
2901285|NCT03239769|Experimental|aesthetic principles access group (APA)|The key difference focused on the disposal incision using aesthetic principles, which are depicted below. The incision was protected by Vaseline ointment. Excessive skin traction was avoided to prevent the injury on the skin edge. Bleeding was stanched with a low-power bipolar coagulation device. The surgical field does not have to be pulled in every direction to show the full operation field. The cervical linea alba was closed by continuous sutures with 3-0 absorbable Vicryl sutures. Interrupted sutures of 4-0 Vicryl were used to re-approximate the subcutaneous tissues. The epidermis was fixed with 3M steri-strip elastic skin closures rather than skin sutures.
2901286|NCT03239769|Experimental|minimally invasive access group (MIA)|With the MIA approach, a shorter incision of between 3 and 4 cm was created. The procedure used the Harmonic scalpel as an auxiliary device. First, the isthmus was divided. Second, the lower pole of the thyroid was dissected from the adipose tissue, and the inferior thyroid vessels were divided close to the thyroid gland for mobilization. The RLN and parathyroid glands were carefully dissected. Third, the superior pole of the thyroid gland was disconnected. Finally, CLND was performed. The closure procedure for the incision was similar to that for APA.
2901287|NCT03239756|Experimental|60 mg single dose cohort|patients would receive a 60 mg single dose of TK006.
2901288|NCT03239756|Experimental|120 mg single dose cohort|patients would receive a 120 mg single dose of TK006.
2901289|NCT03239756|Experimental|180 mg single dose cohort|patients would receive a 180 mg single dose of TK006.
2901290|NCT03239756|Experimental|120 mg Q4W cohort|patients would receive 120 mg TK006 every 4 weeks, for a total of 3 doses.
2901291|NCT03239743|Experimental|Virtual Reality Group|Subjects will be given the virtual reality device to interact with prior to surgery without the use of a pre-medication.
2901292|NCT03239743|Active Comparator|Midazolam Group|Subjects will be given the drug Midazolam to help alleviate the pre-operative anxiety.
2901293|NCT03239717|Placebo Comparator|Whey protein powder|Subjects in the Placebo Arm will replace two-thirds of participants dietary protein intake with meal replacement beverages utilizing a complete protein powder.
2901294|NCT03239717|Experimental|Experimental|Subjects in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
2901295|NCT03239704|Experimental|Telemedicine Follow-Up and Telemedicine Monitoring|
2901296|NCT03239704|Active Comparator|Minimal Intervention|
2901297|NCT03239691|Experimental|ACT-709478 - Single dose administration|Up to 16 subjects with photosensitive epilepsy will be studied across a maximum of 4 dose levels. Each dose level will initially be investigated in cohorts of 4 subjects undergoing a fixed sequence of study treatment administration in fed condition
2901298|NCT03239691|Placebo Comparator|Placebo|Placebo will be administered on two study days
2901299|NCT03239678|Active Comparator|group A|100% Oxygen
2901300|NCT03239678|Experimental|group B|30% Oxygen.
2901301|NCT03239678|Experimental|group C|21% Oxygen
2901302|NCT03239678|Experimental|group D|40% Oxygen
2901303|NCT03239678|Experimental|group E|60% Oxygen
2901304|NCT03239678|Experimental|group F|80% Oxygen
2901305|NCT03239665|Active Comparator|Pharmacist-led Intervention (PHARM)|In the PHARM intervention group, participants will be given a 60-minute formal presentation on vaccine-preventable diseases to address knowledge and beliefs related to zoster, pneumonia, and influenza and to address barriers to receiving vaccination. In several studies, it has been demonstrated that those who believe it is wise to receive vaccinations and those that have discussed vaccination with their healthcare provider are more likely to receive a vaccine.
2901306|NCT03239665|Experimental|Peer-led Intervention (PEER)|A pharmacist will train the peer educators about vaccine-preventable diseases over the course of two didactic sessions. Following this training, a third session will be held to train the peer educators on the script that they will deliver to participants. The script will include the key learning points to be taught by the peer educators to participants about vaccine preventable diseases and vaccination. The script will also include role-play exercises. In the role-play exercises, 3 vaccination-related scenarios (one for each disease- zoster, pneumonia, and influenza) will be delivered to illustrate situations participants might encounter when interacting with healthcare providers or friends/family.
2901307|NCT03239652|Experimental|Taiwan ACE Beads microspheres|The maximum use of dosage will not exceed 100 milligrams. The embolization procedure usually lasts less than an hour.
2901308|NCT03239639|Experimental|Advance care planning education session|Delivery of an advance care planning education session at the family doctor's office
2901309|NCT03239639|Sham Comparator|Wait list control|The intervention is not provided.
2901310|NCT03239626|Experimental|POHIM-RT|adjuvant hypofractionated IMRT for cervical cancer patients
2901311|NCT03239613|Other|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
2901312|NCT03239600|Experimental|Part I & II: GSK2618960 2 milligram per kilogram (mg/kg)|GSK2618960 2mg/kg will be administered intravenously (IV) with Methotrexate (MTX)
2901313|NCT03239600|Placebo Comparator|Part II: Placebo|Placebo will be administered IV with MTX
2901314|NCT03239587||No Musical Intervention - Control Group|"Participants wait for 30 minutes in a standard pre-surgery waiting area without music.~Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.~Participants complete 2 questionnaires about anxiety and stress levels."
2901315|NCT03239587||Musical Intervention Group|"Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.~Blood drawn before, and about 30 minutes after participant in the waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.~Participants complete 2 questionnaires about anxiety and stress levels."
2901316|NCT03239561|Experimental|[18F]MNI-1020|Participants will receive a single intravenous bolus injection of [18F]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
2901317|NCT03239548||Doctor|It refers to the doctors with minimum qualification as M.B.B.S and B.A.M.S; working on various posts in the clinical areas of all the departments of selected hospitals.
2901318|NCT03239548||Nurses|It refers to the Registered Nurses working on various posts in the clinical areas of all the departments of selected hospitals and Principals, Vice Principals of selected colleges.
2901322|NCT03239522|Experimental|All participants receiving treatment|Each participant will receive a single 6 milligram (mg) oral dose of daprodustat on Day 1 of period 1. After approximately 1 hour, participants will receive 50 microgram (µg) of [14C]-GSK1278863 by IV infusion over 1 hour. On Day 1 of period 2, each participant will receive 25 mg [14C]-GSK1278863 as an oral solution.
2901323|NCT03239509||Bioprosthesis|All patients operated on of isolated AVR with a bioprosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
2901324|NCT03239509||Mechanical prosthesis|All patients operated on of isolated AVR with a Mechanical prosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
2901325|NCT03239496|Experimental|Group A|3 doses IPV IM at 10, 14 & 36 weeks of age incl. blood sampling at 10, 14, 18 & 40 weeks.
2901326|NCT03239496|Experimental|Group B|2 doses IPV IM at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
2901327|NCT03239496|Experimental|Group C|3 doses f-IPV ID at 10, 14 & 36 weeks of age incl. blood sampling at 10, 14, 18 & 40 weeks.
2901328|NCT03239496|Experimental|Group D|2 doses f-IPV ID at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
2901329|NCT03239483|Experimental|Dapivirine gel|Participants will receive a single dose of dapivirine gel rectally, followed by 7 daily doses of dapivirine gel to be administered under direct observation in the clinic.
2901330|NCT03239483|Placebo Comparator|Placebo gel|Participants will receive a single dose of placebo gel rectally, followed by 7 daily doses of placebo gel to be administered under direct observation in the clinic.
2901331|NCT03239470|Experimental|Cohort 1: 2.5 x 10^8 PolyTregs|A single intravenous infusion of 2.5 x 10^8 PolyTregs will be administered.
2901332|NCT03239470|Experimental|Cohort 2: 10x10^8 PolyTregs|A single intravenous infusion of 10x10^8 PolyTregs will be administered.
2901333|NCT03239457||Heberprot P treatment|Patients with diabetic foot ulcers treated with Heberprot P
2901334|NCT03239444|Other|Assigned Intervention|Device: Foresight ICE System The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird console. The Foresight ICE system will be used in guiding the physician during the trans-septal puncture and provide physiological information during the course of the procedure.
2901335|NCT03239431||Asthma group|Patients with asthma
2901336|NCT03239418|Experimental|EyeStim Group|Receive an active NMES treatment to the targeted muscles controlling eyelid function.
2901337|NCT03239418|Sham Comparator|Control Group|Undergo all the same procedures as the EyeStim group except receive a sham NMES treatment.
2901338|NCT03239405||SCS|Treated via suction callibrated system
2901339|NCT03239405||Bougie|Treated with multiple tubes & bougie
2901340|NCT03239392|Experimental|BNZ-1|IV PEGylated BNZ132-1-40
2901341|NCT03239379|Placebo Comparator|Placebo|Normal saline
2901342|NCT03239379|Experimental|BNZ132-1-40|PEGylated BNZ-1 for Injection
2901343|NCT03239366|Active Comparator|Active arm|Active product 'BioK+ 100% probiotic: Bio-K+50B® probiotic will be administered orally for a period of 12 weeks. Dose: two (2) capsules of 50 billion (B) colony forming units (CFU) providing a dosage of 100 billion CFU per day
2901344|NCT03239366|Placebo Comparator|Placebo arm|Placebo product (without the 3 strains of bacterias) will be administered orally for a period of 12 weeks. Dose: Two (2) capsules of Placebo per day
2901345|NCT03239353|Active Comparator|1.5 mg ETV XR tablet|
2901346|NCT03239353|Active Comparator|3 mg ETV XR tablet|
2901347|NCT03239353|Active Comparator|6 mg ETV XR tablet|
2901348|NCT03239353|Placebo Comparator|Placebo-to-match 1.5 mg ETV XR tablet|
2901349|NCT03239353|Other|0.5 mg ETV IR tablet|
2901350|NCT03239340|Experimental|Osimertinib|An oral, potent, selective, irreversible inhibitor of both EGFR tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer
2901351|NCT03239327|Experimental|study group|For the study group the enrolled women will receive 50 microgram misoprostol vaginally 60 minutes before CS
2901352|NCT03239327|No Intervention|control group|For the control group mothers enrolled will receive nothing.
2901353|NCT03239314|Active Comparator|group I|Group I (MS): received single shot 20 ml 0.5% isobaric bupivacaine + 2.0 ml normal saline solution injected into the adductor canal preoperatively.
2901354|NCT03239314|Active Comparator|group II|Group II (MD): received 20 ml 0.5% isobaric bupivacaine + 8.0 mg dexamethasone (2.0 ml) injected into adductor canal preoperatively.
2901355|NCT03239301|Active Comparator|Conventional Rehabilitation|Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.
2901356|NCT03239301|Active Comparator|Robotic Rehabilitation + Conventional Rehab|The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. A
2901357|NCT03239288|Placebo Comparator|Control digestible carbohydrate|Control baked breakfast bar
2901358|NCT03239288|Experimental|Test resistant starch type 4|Test baked breakfast bar
2901359|NCT03239275|Experimental|Labial biocreative therapy group|"Upper six anterior teeth will be bonded (0.018-inch slot brackets), leveled and aligned until reaching 0.017*0.025 stainless steel archwire.~Right and left bracket head mini-screw (1.6*8 mm) will be inserted under local anaesthetic into the inter-radicular space between upper second premolar and first molar at the level of mucogingival junction. Crimpable hooks (10 mm) will be crimped onto the archwire between the upper lateral incisor and canine. 200 grams retraction force will be applied using NiTi coil springs from the hooks to the minscrew on both sides. Overlay reverse curve 0.016*0.022 NiTi will be inserted posteriorly into the mini-screw and ligated anteriorly to the archwire in the midline."
2901360|NCT03239275|Active Comparator|Lingual biocreative therapy group|En masse retraction of the six anterior teeth was accomplished using a lingual retractor bonded on to the lingual surface of the 6 anterior teeth, C-palatal plate fixed near the median palatal suture with 3 micro-screws, and Nickel Titanium (Ni-Ti) closing coil springs to apply a force of 200 g per side (total 400 g) directly from the C-plate to the lingual retractor.
2901361|NCT03239262|Experimental|Group GP|Thirty-five patients (35%) from our population underwent concomitant mapping and radiofrequency ablation of ganglionated plexi (Group GP).
2901363|NCT03239249|Experimental|Intervention group: IKO-model (20 schools)|Schools randomized to experimental group will implement the IKO-drop-out prevention intervention. Each county have a project leader responsible for following up the implementation. The model is described in a manual, that schools should follow.
2901364|NCT03239249|Active Comparator|Treatment as usual (22 schools)|Schools randomized to control group will work as previously with their drop-out prevention. This include various activities, but they are not systematic as in the IKO-model.
2901365|NCT03239236|Experimental|t-RSI|"Rapid sequence induction t-RSI. Traditional rapid sequence induction with Anesthetics. Preoxygenation via face mask, no ventilation with no PEEP until intubation. Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
2901366|NCT03239236|Experimental|m-RSI-PEEP|"Rapid sequence induction m-RSI-PEEP. Modified rapid sequence induction with Anesthetics and PEEP. Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
2901367|NCT03239236|Experimental|m-RSI-vent|"Rapid sequence induction m-RSI-vent. Modified rapid sequence induction with Anesthetics and intermittent ventilation. Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
2901368|NCT03239236|Experimental|m-RSI-vent-cric|"Rapid sequence induction m-RSI-vent-cric. Modified rapid sequence induction with Anesthetics and intermittent ventilation and cricoid pressure. Same as modified rapid sequence induction with intermittent ventilation arm with additional cricoid pressure.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
2901369|NCT03239223|Experimental|Dose 1 - Multiple Ascending Dose (MAD)|ABI-1968 or Placebo topical cream applied at Day 1, Day 8, Day 15 and Day 22
2901370|NCT03239223|Experimental|Dose 2 - Multiple Ascending Dose (MAD)|ABI-1968 or Placebo topical cream applied at Day 1, Day 8, Day 15 and Day 22
2901371|NCT03239210|Active Comparator|Ondansetron (OND)|24 mg/day for 4 weeks
2901372|NCT03239210|Placebo Comparator|Placebo (PL)|Placebo pill
2901373|NCT03239197||mother infant pair|mother infant pair, singleton infant, vaginal birth
2901374|NCT03239184|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2901375|NCT03239184|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2901376|NCT03239184|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2901377|NCT03239184|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2901378|NCT03239171|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2901379|NCT03239171|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2901380|NCT03239171|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2901381|NCT03239171|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2901382|NCT03239158|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2901383|NCT03239158|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2901384|NCT03239158|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2901385|NCT03239158|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2901387|NCT03239145|Experimental|Pembrolizumab + Trebananib (Melanoma)|Part 2 Dose Expansion
2901388|NCT03239145|Experimental|Pembrolizumab + Trebananib (Ovarian)|Part 2 Dose Expansion
2901389|NCT03239145|Experimental|Pembrolizumab + Trebananib (Colorectal)|Part 2 Dose Expansion
2901390|NCT03239145|Experimental|Pembrolizumab + Trebananib (Renal Cell Carcinoma)|Part 2 Dose Expansion
2901391|NCT03239132|Experimental|Breath-based meditation|The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks, as well as meditation educational materials.
2901392|NCT03239132|Active Comparator|Control|The control will receive meditation educational materials.
2901393|NCT03239119|Experimental|rE-4 5 mcg|Placebo, then rE-4 5 mcg, then rE-4 5 mcg
2901394|NCT03239119|Experimental|rE-4 10 mcg|Placebo, then rE-4 5 mcg, then rE-4 10 mcg
2901395|NCT03239119|Placebo Comparator|Placebo 5 mcg|Placebo 5 mcg, then Placebo 5 mcg, then Placebo 5 mcg
2901396|NCT03239119|Placebo Comparator|Placebo 10 mcg|Placebo 5 mcg, then Placebo 5 mcg, then Placebo 10 mcg
2901397|NCT03239106|Experimental|open label|All participants will receive Apremilast 30 mg BID.
2901398|NCT03239080|Active Comparator|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
2901399|NCT03239080|Placebo Comparator|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
2901400|NCT03239067||ticagrelor group|patients prescribed with ticagrelor
2901401|NCT03239067||clopidogrel group|patients prescribed with clopidogrel
2901402|NCT03239054|Experimental|Study Group|Participants in the study group will complete the Parmed-X Pregnancy form and be provided with a prescription for exercise.
2901403|NCT03239054|Other|Control Group|"The control group will be provided with the ACOG Pamphlet entitled Exercise during pregnancy and will be encouraged to become physically active during their pregnancy. They will receive routine care as scheduled."
2901404|NCT03239041|Active Comparator|Intervention Arm|"The intervention group will have access to the services of a social navigation team. The social navigation team will consist of trained community health liaisons, a clinician and a social worker.~The social navigation team will function as follows:~The research assistant will then instruct the community health intern to review the results of the completed computerized survey. The community health intern will review the results, create a plan of action, i.e. specific referrals to community agencies and next steps needed by the caregiver and or adolescent (e.g., documents to gather, appointments to make, etc.), following pre-developed protocols for each risk area. Each plan will be reviewed with the social worker prior to presentation to the family. Each family will also receive a packet of community resources relevant to each social domain covered in the screening survey, similar to that provided to the enhanced usual care group."
2901405|NCT03239041|No Intervention|Enhanced Usual Care Arm|The enhanced usual care arm will only receive printed information regarding community resources.
2901406|NCT03239028||Danish National Birth Cohort|
2901407|NCT03239015|Experimental|Targeted Drug Therapy Group|All recruited patients with druggable molecular event will be treated with corresponding targeted drug including Gefitinib/Erlotinib/Afatinib, Trastuzumab, Oxazolidine, Olaparib, Everolimus, Cabozantinib, Vemurafenib/Dabrafenib, and Palbociclib.
2901408|NCT03238976|Experimental|Nature sounds exposure|"Patients will be randomly assigned to either the nature sounds group or the standard care group.~Patients in the nature sounds group will be exposed to continuous nature sounds during the core needle biopsy (CNB) procedure.~The CNB procedure will continue as planned with nature sounds playing instead of the supportive dialogue. All sounds will be played out of a speaker situated in the corner of the room."
2901409|NCT03238976|No Intervention|Standard care (supportive dialogue)|"Patients will be randomly assigned to either the nature sounds group or the standard care group.~The CNB procedure will continue as planned with supportive dialogue which will be played out of a speaker situated in the corner of the room. This group follows the current standard of care."
2901410|NCT03238963|Experimental|BI 1467335|
2901411|NCT03238963|Placebo Comparator|Placebo|
2901412|NCT03238950|Other|Porcine Group|Training conducted on Porcine model
2901413|NCT03238950|Other|Synthetic|Training conducted on synthetic model
2901414|NCT03238937|Other|Phrenic Nerve Stimulator|Phrenic Nerve Stimlator
2901415|NCT03238937|No Intervention|no intervention|Patients without phrenic nerve stimulation
2901416|NCT03238924|Experimental|Oxytocin|40 IU intranasal oxytocin spray
2901417|NCT03238924|Placebo Comparator|Placebo|Placebo is matching saline nasal spray
2901418|NCT03238911|Experimental|Iron Isomaltoside|Iron Isomaltoside (Monofer) administered IV
2901419|NCT03238911|Active Comparator|Ferric Carboxymaltose|Ferric Carboxymaltose (Injectafer) administered IV
2901420|NCT03238898|Active Comparator|botulinum toxin type A|Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
2901421|NCT03238898|Placebo Comparator|Normal saline|The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
2901422|NCT03238885||LARC-CRT|LARC patients who will receive neoadjuvant CRT before surgical resection.
2901423|NCT03238872|Experimental|Prompt Mental Health Care|Clients in the experimental group receive short-term cognitive behavioural therapy in the form of a psycho-educational group course, guided self-help, or individual face-to-face therapy.
2901424|NCT03238872|Active Comparator|Treatment as usual|Clients in the comparison group are offered treatment as usual from their general practitioner.
2901425|NCT03238859|Experimental|Real cTBS|10 days of real cTBS treatment will be given (3600 pulses to the left frontal pole as defined by EEG coordinate: FP1; 60 second pause after 1800 pulses; 110% RMT including a 30 second initial ramp period 80%-110% RMT; Magventure MagPro X100 Cool Coil).
2901426|NCT03238859|Sham Comparator|Sham cTBS|10 days of sham cTBS treatment will be given (3600 pulses to the left frontal pole as defined by EEG coordinate: FP1; 60 second pause after 1800 pulses; 110% RMT including a 30 second initial ramp period 80%-110% RMT; Magventure MagPro X100 Cool Coil).
2901829|NCT03236051|Experimental|multimodal analgesia|Patients received multimodal analgesia after laparoscopic gastrectomy .
2901427|NCT03238846|No Intervention|3MF: 3-month ART dispensing at facilities|Ten sites at which patients will receive standard of care where ART is dispensed three monthly from the facility based on usual practice at the clinic. The approach will be consistent with applicable country guidelines at the time of study.
2901428|NCT03238846|Experimental|3MC: 3-month ART dispensing in CARGs|Ten sites at which patients will receive ART dispensed three monthly in CARGs. Providers at facilities will assist in the formation of CARGs and will provide all enrolled patients with a 3 month supply of ART and associated HIV medications. All other aspects of care will be as per standard of care for the enrolling clinic.
2901429|NCT03238846|Experimental|6MC: 6-month ART dispensing in CARGs|Ten sites at which patients will receive ART dispensed six monthly in CARGs. Providers at facilities will assist in the formation of CARGs and will provide all enrolled patients with a 6 month supply of ART and associated HIV medications. All other aspects of care will be as per standard of care for the enrolling clinic.
2901430|NCT03238833|Experimental|luteal ovarian stimulation|The controlled ovarian stimulation in in vitro fertilization cycle was started since luteal phase.
2901431|NCT03238833|Active Comparator|follicular ovarian stimulation|The controlled ovarian stimulation in in vitro fertilization cycle was started since early follicular phase phase.
2901432|NCT03238820|Experimental|The robot group|Patients undergo robotic gastric gastrointestinal stromal tumors resection.
2901433|NCT03238807|Experimental|Intervention Group|Group that will receive intrauterine injection of human Chorionic Gonadotropin before ET
2901434|NCT03238807|No Intervention|Control Group|Control Group
2901435|NCT03238794|Active Comparator|Roux-En-Y Gastric Bypass (RYGB)|Participants will have elected to have RYGB surgery per standard of care.
2901436|NCT03238794|Active Comparator|Low-calorie Diet|Participants will have a low-calorie diet prescribed by a registered dietitian.
2901437|NCT03238781|Placebo Comparator|Placebo|AMG 301 Placebo Comparator
2901438|NCT03238781|Experimental|AMG 301 High|High dose of AMG 301 Investigational Product
2901439|NCT03238781|Experimental|AMG 301 Low|Low dose of AMG 301 Investigational Product
2901440|NCT03238768|Experimental|Enhanced Nutrition|Infants randomized to the study protocol will start on higher initial amounts of calories, proteins and fats. They will also undergo faster increases of these nutrients during their first week of life.
2901441|NCT03238768|Active Comparator|Standard Nutrition|Infants randomized to the standard nutrition protocol will start on standard amounts of calories, proteins and fats per the usual NICU routine. They will also undergo standard increases of these nutrients during their first week of life.
2901442|NCT03238755||Statin group|HIV-infected individuals receiving statin therapy for the duration of the study
2901443|NCT03238755||Placebo group|HIV-infected individuals receiving placebo therapy for the duration of the study
2901444|NCT03238742|Experimental|Intervention Group|100ml Xuebijing Injection will be dissolved in 100 mL of 0.9% normal saline every 12 hours for 5 days in a single-blind fashion.
2901445|NCT03238742|Placebo Comparator|Placebo group|0.9% normal saline 200 mL every 12 hours for 5 days
2901446|NCT03238729|Experimental|CHF App|Patients will be provided with a mobile app on a smartphone for education and management of heart failure.
2901447|NCT03238729|Active Comparator|Standard of Care|Patients will be provided standard literature on heart failure management.
2901448|NCT03238716|Experimental|Electric DN, NM Re-ed, Exercise|
2901449|NCT03238716|Active Comparator|NM Re-ed and Exercise|
2901450|NCT03238703|Experimental|Treatment (AI, SERM)|Patients receive exemestane PO QD, anastrozole PO QD, letrozole PO QD, tamoxifen citrate PO QD, or toremifene citrate PO QD at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity.
2901451|NCT03238690|Experimental|Controlled Cardiac Reloading|Heart failure patients with recent LVAD implantation after an optimum unloading phase, will undergo controlled cardiac reloading through LVAD speed adjustment reductions in a controlled reloading phase
2901452|NCT03238677|Experimental|Biofeedback, Massed->Distributed|Sequenced biofeedback Mass Practice--> Distributed Scheduling
2901453|NCT03238677|Active Comparator|No Biofeedback, Distributed|Speech Motor Chaining with no biofeedback. 2 sessions/wk for 10 weeks
2901454|NCT03238677|Experimental|Biofeedback, Distributed|Sequenced biofeedback, 2 sessions/wk for 10 weeks
2901455|NCT03238677|Experimental|No Biofeedback, Massed-> Distributed|Speech Motor Chaining with no biofeedback. Mass Practice--> Distributed Scheduling
2901456|NCT03238664|Experimental|Arm A (laparoscopic HIFU, RARC)|Patients undergo pre-HIFU CEUS, standard of care biopsy of the bladder tumor, laparoscopic HIFU, and post-HIFU CEUS. Patients then undergo standard of care RARC.
2901457|NCT03238664|Active Comparator|Arm B (RARC)|Patients undergo standard of care RARC.
2901458|NCT03238651|Experimental|Dose Escalation Part: TAK-659 60 mg in Cohort 1|TAK-659, tablet, orally, once daily, in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 60 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema . If 60 mg, once daily is safe and tolerable, then the dose will be escalated to 100 mg, once daily and subsequently in 20 mg increments until MTD and/or RP2D is determined.
2901459|NCT03238651|Experimental|DLBCL Expansion Part: TAK-659 RP2D|TAK-659, tablet, orally, once daily, in a 28-day treatment cycle until disease progression or unacceptable toxicity. Dose for this part will be MTD/RP2D determined from results of dose escalation part.
2901460|NCT03238638|Experimental|Acquired Resistance Cohort and Suboptimal Benefit Cohort|"Patients will be divided into two cohorts. Investigators anticipate 15 patients per cohort.~Cohort 1: Acquired Resistance Cohort~Treat upon emergence of acquire resistance~Prior benefit from an9-PD-1/PD-L1 therapy defined as a. preior response, and/or b. greater than or equal to 5 months of stable disease~Progressive disease on recent scans~Intercurrent therapy is allowed~Cohort 2: Suboptimal Benefit Cohort~Treat subop. mal response/benefit, BEFORE emergence of acquired resistance~Prolonged stable disease greater than or equal to 5 months OR Subop9mal response (greater than 10% and less than 50%)~Ongoing stable disease on recent scans~Both cohorts will receive pembrolizumab and epacadostat."
2901515|NCT03238222|Experimental|MOSAIC Treatment|MOSAIC treatment plus Usual NHS Care. MOSAIC treatment comprises 2 x 60-minute individual face-to-face consultations (weeks 1 & 2) and 2 x 20-minute follow-up telephone calls (weeks 6 & 12) with a trained physiotherapist.
2944365|NCT02942719||Xinjiang Maternity and Child Health Hospital|
2901461|NCT03238625|Active Comparator|Group 1|"Consisting of 24 individuals between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.~Intervention: Every individual receives four injections IMP1: Lidocaine and sodium bicarbonate ratio 3:1, IMP 2: Lidocaine and sodium bicarbonate ratio 9:1, IMP 3: Lidocaine, and IMP 4: Sodium cloride 0.9% (=placebo), namely two in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the four areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes."
2901462|NCT03238625|Placebo Comparator|Group 2|"Consisting of 24 different individuals than those belonging to Group 1. Between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.~Intervention: Every individual receives two injections:~IMP 3 Lidocaine, and IMP 4 Sodium cloride 0.9% (=placebo), namely one in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the two areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes."
2901463|NCT03238612|Experimental|FFA, clarithromycin, oseltamivir|oseltamivir 75mg + clarithromycin 500mg + FFA 200mg all twice daily for 2 days, followed by oseltamivir 75mg twice daily for 3 days
2901464|NCT03238612|Placebo Comparator|Oseltamivir alone|oseltamivir 75mg + two placebo capsules (identical in appearance to clarithromycin and FFA capsules respectively) twice daily for 2 days, followed by oseltamivir 75mg twice daily for 3 days
2901465|NCT03238599|Experimental|Pedometer-based activity monitoring|The physical activity of patients after autologous transplantation for lymphoma and myeloma is measured with the pedometer
2901466|NCT03238586|Experimental|WELL Program|Five-week treatment program that aims to improve knowledge, motivation, and skills. It is designed to motivate participants to take their medications routinely, improve the quality of life for those living with HIV, and decrease risky behaviors that may lead to HIV transmission.
2901467|NCT03238586|No Intervention|Standard of Care|Five-week standard of care program.
2901468|NCT03238573||optical enhancment endoscopy|
2901469|NCT03238547||diabetes|Diabetes patients with normal renal function and normal urinalysis
2901470|NCT03238534|Active Comparator|Omeprazole 20mg|"Patients will be provided with enough amount of 20 mg omeprazole [30' before meal] and Neobianacid® placebo [30' after meal] (both per os) to complete the first phase of the treatment (day 1-27). Then, at day 28, the patients will be provided with Neobianacid® that can be administered on demand until the study end (day 56). Malgradate will be also provided as rescue medication.~Treatment regimen:~Day 0-13 Breakfast: Omeprazole + Neobianacid® placebo Lunch: Neobianacid® placebo Midafternoon: Neobianacid® placebo Dinner: Neobianacid® placebo Before going to bed: Neobianacid® placebo~Day14-27 Breakfast: Omeprazole+ Neobianacid® placebo (both on demand) Lunch: Neobianacid® placebo on demand Dinner: Neobianacid® placebo on demand Any other time: Neobianacid® placebo on demand, if needed~Day28-55 Breakfast: Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed"
2901471|NCT03238534|Experimental|Neobianacid®|"Patients will be provided with enough amount of Omeprazole placebo [30' before meal] and Neobianacid® [30' after meal] (both per os) to complete the first phase of the treatment (day 1-27). Then, at day 28, the patients will be provided with Neobianacid® that can be administered on demand until the study end (day 56). Malgradate will be also provided as rescue medication.~Treatment regimen:~Day 0-13 Breakfast: Omeprazole placebo + Neobianacid® Lunch: Neobianacid® Midafternoon: Neobianacid® Dinner: Neobianacid® Before going to bed: Neobianacid®~Day14-27 Breakfast: Omeprazole placebo + Neobianacid® (both on demand) Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed~Day28-55 Breakfast: Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed"
2901472|NCT03238521|Active Comparator|classical pedicle finder|Spinal osteosynthesis with classical pedicle finder
2901473|NCT03238521|Experimental|pedicle finder with impedancemetry|Spinal osteosynthesis with pedicle finder with impedancemetry
2901474|NCT03238508||Immediate stenting group|Conventional stenting immediate after the re-opening of infarct-related artery during primary PCI
2901475|NCT03238508||Deferred stenting group|Elective stenting following cooling down of infarct- related artery for several days after restoration of epicardial coronary blood flow during primary PCI
2901476|NCT03238495|Active Comparator|Chemotherapy Only|Taxotere, Carboplatin, Herceptin + Pertuzumab (TCH+P)
2901477|NCT03238495|Experimental|Chemotherapy plus Metformin|TCH+P plus metformin
2901478|NCT03238482|Active Comparator|Seretide Diskus|salmeterol-fluticasone 2 inhalations as a single dose
2901479|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, E|salmeterol-fluticasone 2 inhalations as a single dose
2901480|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, F|salmeterol-fluticasone 2 inhalations as a single dose
2901481|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, G|salmeterol-fluticasone 2 inhalations as a single dose
2901482|NCT03238469|Experimental|Microwave ablation|One-sided single microwave ablation (MWA) treatment in one axillary region with a miraDry device.
2901483|NCT03238469|No Intervention|No microwave ablation|Lesion intervention in the non-MWA treated contralateral axilla consists of once daily topical clindamycin 1% lotion.
2901484|NCT03238456|Experimental|Intervention|The intervention entitled Motivating Pacifika Against Cigarettes and Tobacco (MPACT) was implemented for eight weeks starting on the quit date that the participant chose with their assigned coach during the baseline assessment. At the baseline assessment, each participant watched an introductory video that described the online smoking cessation program. The online program was accessed through the participant's Facebook account. The program included eight education modules and a forum. Participants also received automated daily text messages to provide support and encouragement during the quitting process.
2901516|NCT03238222|No Intervention|Usual Care Comparison|Usual NHS care for people with intermittent claudication typically consists of an initial assessment, drug therapy and simple advice to walk provided by a vascular specialist and delivered in the vascular outpatient clinic.
2901830|NCT03236051|Active Comparator|PCIA analgesia|Patients received PCIA analgesia after laparoscopic gastrectomy.
2944366|NCT02942719||Jiangmen Maternity and Child Health Care Hospital|
2901485|NCT03238456|No Intervention|Control|Participants in the control group set a quit date within two weeks of their baseline assessment and watched an introductory video that described the smoking cessation program. They received one text message every other week over a period of eight weeks following the quit date. The messages were delivered by a web-based system not connected to the online intervention program. Participants were also given a handout listing local tobacco cessation and education resources, a link to a generic online smoking cessation program, a fact sheet on smoking and tobacco use among PI young adults, and a quit kit containing chewing gum and a stress ball.
2901486|NCT03238430|Experimental|Ropivacaine infiltration|Continuous infiltration of local anesthetics + PCA morphine.
2901487|NCT03238430|Experimental|intrathecal morphine|Rachianalgesia + PCA morphine
2901488|NCT03238430|Active Comparator|morphine PCA|PCA morphine alone
2901489|NCT03238417|Experimental|Evidence-Based Quality Improvement (EBQI)|EBQI represents a multilevel stakeholder engaged top-down/bottom-up research-clinical partnership approach to systematically improving the design and implementation of local innovations adapted to local contexts. The EBQI contractor will (1) convene facility-level stakeholder meetings, (2) facilitate local facility-level QI team design meetings, (3) provide external practice facilitation through within and across facility QI collaboration calls, (4) provide formative QI data feedback and (5) provide QI training/education to local teams.
2901490|NCT03238417|No Intervention|Waitlist Controls|Waitlist controls will continue naturalistic routine care implementation of VHA directives and other guidance related to comprehensive women's health care.
2901491|NCT03238404|Experimental|NAC group|Patients will receive neoadjuvant chemotherapy (NAC) before the gastrectomy and ERAS.
2901492|NCT03238404|Active Comparator|Surgery alone group|Patients will not receive NAC before the gastrectomy and ERAS.
2901493|NCT03238391|Experimental|Study group|Patients will receive ischemia and reperfusion of the arm by inflating a blood pressure cuff around the arm at 50 mmHg above the systolic blood pressure for 5 minutes, followed by 5 minutes of reperfusion and this cycle will be repeated three times
2901494|NCT03238391|Sham Comparator|Sham group|Patients will receive ischemia and reperfusion of the arm by inflating a blood pressure cuff around the arm at 10 mmHg below the diastolic blood pressure for 5 minutes, followed by 5 minutes of reperfusion and this cycle will be repeated three times
2901495|NCT03238378|Experimental|Therapy|Brachytherapy d1-5(6) Hyperthermia d2 + 5
2901496|NCT03238365|Active Comparator|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes on days 3 and 17 and undergo surgery on day 31.
2901497|NCT03238365|Experimental|Arm II (nivolumab, tadalafil)|Patients receive nivolumab IV over 60 minutes on days 3 and 17 and tadalafil PO QD on days 3-31. Patients then undergo surgery on day 31.
2901498|NCT03238339||The Portable Home Noninvasive Ventilator treatment group|The patients maintain a stable COPD regimen, and on the basis of conventional home oxygen therapy, a portable, wearable, non-invasive ventilator will be used.
2901499|NCT03238339||Routine home oxygen therapy group|The patient maintained a stable COPD regimen and conventional home oxygen therapy.
2901500|NCT03238326|Experimental|Rollover & De-Novo|1-4 mg/day; Start at 0.5 mg/day, titrate and maintain between 1mg/day to max of 4 mg/day
2901501|NCT03238313|Experimental|Plan A|Plan A is the treatment condition. It is a 23 minute video that is designed to teach youth about LARC.
2901502|NCT03238313|Active Comparator|Toxic Life Cycle of a Cigarette|The Toxic Life Cycle of a Cigarette is the counterfactual condition. It is a video of similar length to the treatment video but contains no information about reproductive health. Instead, the video teaches on the harms of cigarettes.
2901503|NCT03238300|Experimental|N-Acetylcysteine|N-Acetylcysteine 600mg capsules by mouth, two pills twice daily for 10 days.
2901504|NCT03238300|Placebo Comparator|Placebo Oral Capsule|Placebo capsules by mouth, two pills twice daily for 10 days.
2901505|NCT03238287|Active Comparator|Manuel chest compression|In the application of advanced cardiac life support, chest compression is done with hands. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
2901506|NCT03238287|Active Comparator|Mechanical chest compression|In the application of advanced cardiac life support, chest compression is done with mechanical chest compression device. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
2901507|NCT03238274||Arm 1|Arm 1 is a multi-site, single visit, prospective clinical study where subjects will be enrolled based on a physician's assessment of current Lyme specific symptoms from recent contact with a tick.
2901508|NCT03238274||Arm 2|Arm 2 will consist of subjects selected from a pool of patients that were previously determined to have Lyme disease either by the presence of the diagnostic rash (erythema migrans) or through laboratory findings and physician diagnosis based on patient symptoms. In this Arm the site may recruit by contacting subjects previously diagnosed with Lyme disease no longer than 16 months post diagnosis and no earlier than 1 week post diagnosis.
2901509|NCT03238274||Arm 3|Arm 3 will consist of subjects selected from a pool of patients that were previously determined to have Lyme disease either by the presence of the diagnostic rash (erythema migrans) or through laboratory findings and physician diagnosis based on patient symptoms. In this Arm the site may recruit by contacting subjects previously diagnosed with Lyme disease between 17 months and 50 months post diagnosis. For the subject to be enrolled, a physician must have diagnosed the subject to have Lyme disease based on clinical symptoms.
2901510|NCT03238261|Experimental|Chemotherapy and concomitant radiotherapy|
2901511|NCT03238261|Active Comparator|Radiotherapy|
2901512|NCT03238248|Experimental|Pevonedistat and Azacitidine|"Participants will receive Azacitidine (via an injection under the skin, or via an intravenous infusion (IV bag) on days 1, 2, 3, 4 and 5 of each 28-day cycle.~Participants will receive Pevonedistat (through a vein in the arm) on Days 1, 3 and 5 of each 28-day cycle."
2901513|NCT03238235|Active Comparator|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
2901514|NCT03238235|Placebo Comparator|placebo|Placebo oral suspension (10 mg/mL) twice daily in a fed state
2901590|NCT03237767|Experimental|High-intensity vs. Moderate intensity exercise (randomised)|Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (HIIE completed first)
2901517|NCT03238209|Experimental|Exercise testing|The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
2901518|NCT03238196|Experimental|Escalation|"Fulvestrant - injection into muscle 1 time per month~Palbociclib capsule taken by mouth 1 time per day every 21 days followed by 1 week of rest (no drug taken)~Erdafitinib tablet taken by mouth 1 time per day"
2901519|NCT03238196|Experimental|Expansion|"Fulvestrant - injection into muscle 1 time per month~Palbociclib capsule taken by mouth 1 time per day every 21 days followed by 1 week of rest (no drug taken)~Erdafitinib tablet taken by mouth 1 time per day"
2901520|NCT03238183|Active Comparator|hyaluronic acid combined dextrose group|Hyaluronic acid (2 cc) combined 25% dextrose (3.5 cc 50% dextrose plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
2901521|NCT03238183|Placebo Comparator|hyaluronic acid group|Hyaluronic acid (2 cc) combined normal saline (3.5 cc normal saline plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
2901522|NCT03238170|Experimental|MR-Simulation|Patients will have 1 MRI scan appointment, using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan. The MR scan will be performed in the radiotherapy treatment position.
2901523|NCT03238157|No Intervention|Observation|"The study will only include those patients that are ascertained be at more than 50% risk for vision loss (20/200 or worse at 3 years) because of total radiation dose of >40 Gy to the center of the macula. These at risk patients included in the study will receive intravitreal triamcinolone (4 mg in 0.1 ml) injected at the time of plaque removal. If lack of IOP rise (30 mm Hg or more) at 3 months, then randomized to either observation (2:1) (standard of care)."
2901524|NCT03238157|Active Comparator|Intervention|"The study will only include those patients that are ascertained be at more than 50% risk for vision loss (20/200 or worse at 3 years) because of total radiation dose of >40 Gy to the center of the macula.1 These at risk patients included in the study will receive intravitreal triamcinolone (4 mg in 0.1 ml) injected at the time of plaque removal. If lack of IOP rise (30 mm Hg or more) at 3 months, then randomized to intravitreal Fluocinolone Acetonide (FA) implant."
2901525|NCT03238144|Other|MRF +/-contrast enhanced MRI|MRF with or without contrast enhanced MRI
2901526|NCT03238131|Active Comparator|IVM annually (standard treatment)|The comparator (standard treatment) IVM 200 µg/kg body weight given at 0, 12 and 24 months plus vitamin pills at 6 and 18 months.
2901527|NCT03238131|Experimental|IVM plus ALB twice annually|IVM 200 µg/kg plus ALB 800 mg (regardless of weight) given at 0, 6, 12, 18, 24 months
2901528|NCT03238131|Active Comparator|IVM plus ALB once annually|IVM 200 µg/kg plus ALB 800 mg given at 0, 12, 24 months plus vitamin pills at 6 and 18 months.
2901529|NCT03238131|Active Comparator|IVM twice annually|IVM 200 µg/kg given 0, 6, 12, 18, and 24 months
2901530|NCT03238118|Experimental|Attention bias modification training|For attention-toward-positive, stimuli are colour-pictures of 16 angry and 16 happy faces (half female). Each happy face is presented 10 times, and each angry face presented 80 times across trials, balanced across the different positions in the 3 × 3 matrix. This yielded 160 training trials (two blocks of 80 trials). Children had to mouse-click on the happy face within the 3 × 3 matrix of angry faces as quickly and as accurately as possible. The matrix disappeared after the child mouse-clicked on the correct face and the next trial began.
2901531|NCT03238118|Placebo Comparator|Attention Control Training|For attention-training-control, stimuli are 20 colour-pictures of individual birds and flowers used in prior visual-search tasks with children. Children mouse-clicked on the bird presented amongst flowers as quickly and accurately as possible. Other task parameters were similar to the attention-toward-positive task (160 training trials). No performance feedback is given in either condition.
2901532|NCT03238118|Placebo Comparator|Psychoeducation|Psychoeducation is an intervention that is characterized by informing the participant of their irritability symptoms. The goal is to teach participants how to understand their symptoms, explain their treatment modalities, recognize signs that may lead to a possible crisis, and provide tips and strategies on how to deal with irritability.
2901533|NCT03238105|Experimental|Intense pulsed light|The application model will be 3 months of treatment with monthly interval between sessions, totaling 3 sessions. The parameters are as follows: frequency 15 J / cm2, pulse duration 15 ms, 1-2 passed as erythema. Eye protection for IPL will be used during all sessions.
2901534|NCT03238105|Experimental|Peeling of 10% thioglycolic acid|In the first session the acid will be applied for three minutes, and with each new session the duration time with the product will increase in three minutes, so that in the last session the duration of the application will be 9 minutes. For the application of the product will be used flexible cotton rod, sparing the region just below the eyelids of the lower eyelid 0.5cm, therefore, no other measure is necessary for eye protection. After the given time, the substance will be removed with lint with 0.9% saline solution.
2901535|NCT03238092|Active Comparator|Estradiol group|In the late luteal phase, the participant will receive estradiol 2mg and will take orally a total of 4mg per day (2mg in the morning and 2 mg in the night) until the next menstrual bleeding. After that, the patient will descontinue the medication and proceed to the regular in vitro fertilization protocol.
2901536|NCT03238092|No Intervention|Control group|No pre-treatment will be administrated. The regular in vitro fertilization protocol will be performed.
2901537|NCT03238092|Experimental|Testosterone group|Testosterone 25mg (10mg/g) transdermal during the late luteal phase, until the next menstrual bleeding.
2901538|NCT03238079|Experimental|Open-Label 10% IGIV|"IMP will be administered every 21 or 28 days in accordance with the subject's weekly regimen at screening for a period of 12 months. Subjects on a 21-day regimen will receive approximately 17 infusions, and subjects on a 28-day regimen will receive approximately 13 infusions.~The starting dose will be the previous IGIV dose or a dose calculated from the previous SCIG dose up to a maximum of 900 mg/kg/mo."
2901591|NCT03237754|Experimental|Real Neurostimulation|4 weeks of neurostimulation (using tDCS)
2901592|NCT03237754|Sham Comparator|Sham Neurostimulation|4 weeks of sham Treatment with the same device used for real neurostimulation
2901539|NCT03238066|Experimental|Treatment Arm|"The physician can choose either HDR or PDR brachytherapy.~If HDR BT is chosen:~d1: hyperthermia (IHT) 60 minutes + 10Gy HDR brachytherapy (HDRBT) d22: IHT 60 minutes + 10 Gy HDRBT d43: IHT 60 minutes + 10 Gy HDRBT~If PDR BT is chosen:~d1-3: IHT 60 minutes + 30Gy PDRBT d29-31: IHT 60 minutes + 30Gy PDRBT"
2901540|NCT03238053|Active Comparator|Menopausal Laser|20 women with vaginal laser treatment
2901541|NCT03238053|Sham Comparator|Menopausal sham|20 women with probe, no active laser ray
2901542|NCT03238053|Active Comparator|breast cancer laser|20 women with breast cancer with vaginal laser treatment
2901543|NCT03238053|Sham Comparator|breast cancer sham|20 women with breast cancer with vaginal probe, no active laser rays
2901544|NCT03238053|Active Comparator|endometrial cancer laser|20 women with endometrial cancer with vaginal laser treatment
2901545|NCT03238053|Sham Comparator|endometrial cancer sham|20 women with endometrial cancer with vaginal probe, no active laser rays
2901546|NCT03238027|Experimental|Ph1a D1: 1 mg/kg SNDX-6352|Three (3) patients receive starting dose of 1 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
2901547|NCT03238027|Experimental|Ph1a D2: 3 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 3 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
2901548|NCT03238027|Experimental|Ph1a D3: 6 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 6 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
2901549|NCT03238027|Experimental|Ph1a D4: 10 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 10 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
2901550|NCT03238027|Experimental|Ph1b D1: 1 mg/kg SNDX-6352+1500mg durva|Three (3) patients receive starting dose of 1 mg/kg of SNDX-6352 every two weeks and 1500mg durvalumab every four weeks and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee. If 1 DLT is observed in 1 of 3 patients, then 3 additional patients will be treated at the 1 mg/kg SNDX-6352 dose level; if none of the 3 additional patients experience a DLT (i.e. 1 of 6), the dose will be escalated to an intermediate dose of 2 mg/kg. Escalation from 2 mg/kg to 3 mg/kg will follow the general dose escalation rules described above for both study phases.
2901551|NCT03238027|Experimental|Ph1b D2: 3 mg/kg SNDX-6352+1500mg durva|Three (3) patients receive next higher dose of 3 mg/kg of SNDX-6352 every two weeks and 1500mg durvalumab every four weeks and are followed for possible DLTs. For cohorts with doses ≥3 mg/kg, a sentinel recruitment approach will be utilized. Initially 1 patient in each cohort will be treated with the combination therapy and safety will be evaluated by SRC at Cycle 1, Day 8; if no safety concerns are identified, the next 2 patients can be treated in that cohort. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
2901552|NCT03238027|Experimental|Ph1b D3: 3 mg/kg SNDX-6352+1500mg durva|Three (3) patients receive next higher dose of 6 mg/kg of SNDX-6352 every two weeks and 1500mg durvalumab every four weeks and are followed for possible DLTs. For cohorts with doses ≥3 mg/kg, a sentinel recruitment approach will be utilized. Initially 1 patient in each cohort will be treated with the combination therapy and safety will be evaluated by SRC at Cycle 1, Day 8; if no safety concerns are identified, the next 2 patients can be treated in that cohort. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
2901553|NCT03238014|Experimental|High-intensity noninvasive ventilation|High-intensity noninvasive positive pressure ventilation aims at maximally improving PaCO2.
2901554|NCT03238014|Active Comparator|Low-intensity noninvasive ventilation|Low-intensity noninvasive positive pressure ventilation is a classic setting of noninvasive ventilation.
2901555|NCT03238001|Experimental|All qualified participants|Participants received DCTclock, Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and a battery of other traditional pen and paper neuropsychological assessments.
2901556|NCT03237988|Active Comparator|Sequence ABC|100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed).
2901557|NCT03237988|Active Comparator|Sequence BCA|100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted).
2901558|NCT03237988|Active Comparator|Sequence CAB|100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted).
2901559|NCT03237975|Experimental|Be the Expert for Your Own (BEYO)|BEYO is a group-based consultation project. Each group contains 1 facilitator, 1 assistant and 8 elderly patients. 5 weekly sessions are provided to let patients receive health knowledge, discuss problems and experiences, explore available resources and build up goals and solutions. Each session lasts for 40 minutes. Session 1 aims to build social network among group members and introduce group goals and tasks. Session 2-4 covers six topics: (i) healthy dietary, (ii) exercise and activity, (iii) taking medication, (iv) blood glucose monitoring, (v) reducing risks for complication, (vi) healthy coping with mental stress. Session 5 aims to review the process, summarize effective solutions, and set up plans for the future.
2901560|NCT03237975|Active Comparator|Routine health education|To neutralize the effect of extra attention from the facilitator, participants in control group will receive routine health education on topics related to type 2 diabetes. Contents for the routine education will be based on the national guideline of basic public health service for diabetes and specific implementation protocols in each community. Participants in control group will receive 5-weekly education packet at the same time with participants in intervention group. The patients will not be given any strengths-based information, but they are free to discuss their disease status with nurses or physicians at their regular follow-up appointments.
2901561|NCT03237962|Experimental|High Flow Nasal Cannula|Patients are randomly assigned into High flow nasal cannula group for the exercise training
2901562|NCT03237962|Experimental|Nasal Cannula|Patients are randomly assigned into nasal cannula group for the exercise training.
2901563|NCT03237949|Active Comparator|Phone counseling|The patient will receive standard care inside the hospital. After discharge the active comparator group will receive four phone counseling sessions. The sessions will provide basic information about smoking and successful quitting. The counselor will use motivational interview techniques to build coping skills with the goal of helping the participant build and implement a quit plan. The counseling timing, duration, and content will be consistent with guideline-based recommendations.
2901564|NCT03237949|Experimental|Text message|The patient will receive standard care inside the hospital. After discharge the experimental group will receive extended care including text messages. Participants in this arm will be offered up to 30 text messages to help implement the quit plan discussed during the hospitalization. Patients motivated to quit in the next 30 days or that had already quit will receive 30 messages and patients unwilling to quit will receive 16 messages. The messages content follows the self efficacy theory.
2901565|NCT03237936|Experimental|IKERVIS® (1mg/mL ciclosporin) eye drops|one drop of study medication (IKERVIS®1mg/mL) once daily in each eye at bedtime during 3 months.
2901566|NCT03237910|Experimental|AMSA-CPR|The professional rescuer decides to deliver the defibrillation attempt based on the AMSA value displayed in the defibrillator
2901567|NCT03237910|Active Comparator|Standard-CPR|The defibrillation is delivered based on the 2015 European Resuscitation Council CPR guidelines
2901568|NCT03237897||Class attendees|A cohort of patients who are scheduled to undergo colorectal surgical procedures and attend the preoperative education class. Patients will be affixed with a pedometer in the postoperative period until discharge.
2901569|NCT03237897||Class non-attendees|A cohort of patients who are scheduled to undergo colorectal surgical procedures and do not attend the scheduled preoperative education class. Patients will be affixed with a pedometer in the postoperative period until discharge.
2901570|NCT03237871|Experimental|Survey and informational text messages|Text-message survey and informational text messages
2901571|NCT03237858|Active Comparator|HeartLogic ON|ICD and CRT-D devices with HeartLogic alerts turned ON
2901572|NCT03237858|Placebo Comparator|HeartLogic OFF|ICD and CRT-D devices with HeartLogic alerts turned OFF
2901573|NCT03237845|Experimental|BHV-3000|rimegepant 75 mg tablet QD
2901574|NCT03237845|Placebo Comparator|Placebo|Matching 75mg placebo tablet QD
2901575|NCT03237832|Placebo Comparator|Cohort 1|Cohort 1 (sentinel group): 1 subject received 50 mg ARN-6039 and 1 subject placebo Cohort 1: 7 subjects received 50 mg ARN-6039 and 1 subject placebo
2901576|NCT03237832|Placebo Comparator|Cohort 2|Cohort 2 (sentinel group): 1 subject received 100 mg ARN-6039 and 1 subject placebo Cohort 2: 7 subjects received 100 mg ARN-6039 and 1 subject placebo
2901577|NCT03237832|Placebo Comparator|Cohort 3|Cohort 3 (sentinel group): 1 subject received 150 mg ARN-6039 and 1 subject placebo Cohort 3: 7 subjects received 150 mg ARN-6039 and 1 subject placebo
2901578|NCT03237832|Placebo Comparator|Cohort 4|Cohort 4 (sentinel group): 1 subject received 200 mg ARN-6039 and 1 subject placebo Cohort : 7 subjects received 200 mg ARN-6039 and 1 subject placebo
2901579|NCT03237832|Placebo Comparator|Cohort 5|Cohort 5 Period 1, fasted (sentinel group): 1 subject received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 1, fasted: 7 subjects received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 2, fed (sentinel group): 1 subject received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 2, fed: 7 subjects received 300 mg ARN-6039 and 1 subject placebo
2901580|NCT03237819|Placebo Comparator|Placebo|Glucose serum (3 ampoules)
2901581|NCT03237819|Experimental|Magnesium Sulfate|20/5000 magnesium sulfate (4 ampoules, 1,5g each)
2901582|NCT03237806|No Intervention|Baseline|In this phase, patients were sedated to the level of Ramsay 6 before Deep sedated or Light sedated
2901583|NCT03237806|Experimental|Deep sedation|In this Arm, patients were sedated to the level of Ramsay 5(Deep sedated) by Midazolam IV continuously
2901584|NCT03237806|Experimental|Light sedation|In this Arm, patients were sedated to the level of Ramsay 3(Light sedated)by Midazolam IV continuously
2901585|NCT03237793|Active Comparator|Fluorosed Group|45 patients for the fluorosis groupGROUP 1A: Patients with healthy fluorosed teeth receiving desensitising agent (potassium nitrate- RA Themoseal**) treatment. (n=15) GROUP 1B: Patients with healthy fluorosed teeth receiving diode laser treatment$. (n=15) GROUP 1C: Patients with healthy fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA Thermoseal**) treatment. (n=15)
2901586|NCT03237793|Placebo Comparator|Non Flourosed Group|45 patients for the non-fluorosis groupGROUP 2- Non Flourosed Group (n=45) GROUP 2A: Patients with healthy non fluorosed teeth receiving desensitising agent (potassium nitrate- RA Thermoseal**) treatment. (n=15) GROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal**) treatment. (n=15
2901587|NCT03237780|Experimental|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2901588|NCT03237780|Experimental|Arm II (atezolizumab, eribulin mesylate)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and eribulin mesylate IV over 2-3 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2901589|NCT03237767|Experimental|Moderate vs. High-intensity exercise (randomised)|Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (MIE completed first)
2902281|NCT03232983|Experimental|LY900014 (SC Arm)|Single dose of LY900014 administered SC into the arm in one period
2901593|NCT03237741|Experimental|Treatment Sequence 1: ABC1D1|Single dose of reference capsule GDC-0134 (Treatment A) during Period 1. Single dose of prototype capsule GDC-0134 (Treatment B) during Period 2. Single dose of GDC-0134 prototype capsule administered as GDC-0134-in-applesauce preparation under fasting conditions (Treatment C1) during Period 3. Single dose of GDC-0134 prototype capsule administered under fasting conditions in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D1) during Period 4. The washout period between doses will be a minimum of 21 days.
2901594|NCT03237741|Experimental|Treatment Sequence 2: ABC2D2|Single dose of reference capsule GDC-0134 (Treatment A) during Period 1. Single dose of prototype capsule GDC-0134 (Treatment B) during Period 2. Single dose of GDC-0134 prototype capsule administered after a high-fat meal (Treatment C2) during Period 3. Single dose of GDC-0134 prototype capsule administered after a high-fat meal in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D2) during Period 4. The washout period between doses will be a minimum of 21 days.
2901595|NCT03237741|Experimental|Treatment Sequence 3: BAC1D1|Single dose of prototype capsule GDC-0134 (Treatment B) during Period 1. Single dose of reference capsule GDC-0134 (Treatment A) during Period 2. Single dose of GDC-0134 prototype capsule administered as GDC-0134-in-applesauce preparation under fasting conditions (Treatment C1) during Period 3. Single dose of GDC-0134 prototype capsule administered under fasting conditions in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D1) during Period 4. The washout period between doses will be a minimum of 21 days.
2901596|NCT03237741|Experimental|Treatment Sequence 4: BAC2D2|Single dose of prototype capsule GDC-0134 (Treatment B) during Period 1. Single dose of reference capsule GDC-0134 (Treatment A) during Period 2. Single dose of GDC-0134 prototype capsule administered after a high-fat meal (Treatment C2) during Period 3. Single dose of GDC-0134 prototype capsule administered after a high-fat meal in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D2) during Period 4. The washout period between doses will be a minimum of 21 days.
2901597|NCT03237728|Experimental|0.06mg/kg,KB and Placebo|Group A:0.06mg/kg,Q8h,Day1-Day7
2901598|NCT03237728|Experimental|0.12mg/kg,KB|Group B:0.12mg/kg,Q8h,Day1-Day7
2901599|NCT03237728|Experimental|0.24mg/kg,KB|Group C:0.24mg/kg,Q8h,Day1-Day7
2901600|NCT03237728|Experimental|Placebos|Group D:Placebos,Q8h,Day1-Day7
2901601|NCT03237715||Breast fed cohort|
2901602|NCT03237715||Formula fed cohort|
2901603|NCT03237702|Experimental|MCS arm|The participants who will have Multi-Carotenoids for 8 weeks The intervention is Multi-Carotenoids 30 mg for 8 weeks.
2901604|NCT03237689|Experimental|Hydrocortisone|Low dose hydrocortisone (10mg orally)
2901605|NCT03237689|Placebo Comparator|Placebo|Placebo tablets, made of starch 1500 powder
2901606|NCT03237676|Experimental|Individualised structured cognitive rehabilitation therapy|Participants of interventional arm will receive individualised structured cognitive rehabilitation therapy at the proposed health centre (University Malaya Medical Centre, Malaysia).
2901607|NCT03237676|Active Comparator|Patient-centred cognitive therapy|Participants of conventional arm will receive an existing cognitive rehabilitation treatment available at the proposed health centre (University Malaya Medical Centre, Malaysia).
2901608|NCT03237663|Experimental|One enteric capsule|
2901609|NCT03237663|Experimental|Two enteric capsule|
2901610|NCT03237637|Active Comparator|Group A- Propranolol|Oral propranolol 1mg/kg/day as crushed tablets, in two divided doses, increased to 2mg/kg/day in two divided doses after 24 hours if tolerated well. Treatment will be stopped at complete clinical clearance of lesion (defined arbitrarily as >90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier.
2901611|NCT03237637|Experimental|Group B- Atenolol|Oral atenolol 0.5mg/kg as a single dose, increased to 1mg/kg as a single dose after 24 hours if tolerated well. Treatment will be stopped at complete clinical clearance of lesion (defined arbitrarily as >90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier.
2901612|NCT03237624|Experimental|Functional chewing gum|Subjects given as intervention functional chewing gum device to supplement oral hygiene practices. Functional gum contains chitosan which is a food additive or generally recognized as safe food product. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
2901613|NCT03237624|Placebo Comparator|Control chewing gum|Subjects given control gum to supplement oral hygiene practices. Placebo gum does not contain any active ingredients. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
2901614|NCT03237611|Experimental|low dose aprepitant or fosaprepitant|In addition to standard prophylactic antiemetics (Ondansetron 16mg and Dexamethasone 20mg) patients will be given aprepitant 125mg orally or 115mg fosaprepitant intravenously prior to the first cycle of carboplatin-based chemotherapy. The only medication that will be given then on day 3 is oral 12mg dexamethasone
2901615|NCT03237598||male|young (≥18 and ≤45), adult (45~60), and old (>60) , n=1960
2901616|NCT03237598||female|young (≥18 and ≤45), adult (45~60), and old (>60) , n=2348
2901617|NCT03237585|Experimental|i) Intervention arm- Receive Gender Centre's RRS package|
2901618|NCT03237585|No Intervention|No intervention|
2901619|NCT03237572|Experimental|Arm A: 1st dose of pembrolizumab after HIFU|Pembrolizumab (200 mg) administered intravenously, days 22, 43, 64, followed by day 1 of each ensuing 3 -week cycle. Focused ultrasound tumor ablation day 15. High-intensity focused ultrasound ablation will target 50% of the tumor, up to 3 cubic centimeters.
2901620|NCT03237572|Experimental|Arm B: 1st dose of pembrolizumab before HIFU|Pembrolizumab (200 mg) intravenously, days 1, 22, 43, 64, followed by day 1 of each ensuing 3 -week cycle. Focused ultrasound tumor ablation day 15. High-intensity focused ultrasound ablation will target 50% of the tumor, up to 3 cubic centimeters.
2901621|NCT03237559||eligible couples|Eligible couples refers to methods that are adopted by eligible couples for having physically and psychologically healthy conception and pregnancy
2901669|NCT03237208|Sham Comparator|placebo group|Patients receiving the application of transcutaneous electrical nerve stimulation, but transcutaneous electrical nerve stimulation will not be activated.
2901622|NCT03237546|Active Comparator|Serratus blocks|The serratus plane is interstitial tissue, below the serratus muscle. The injection of bupivacaine numbs the anterior branch of the thoracodorsal nerve. This technique allows for the medication to diffuse along the area of the serratus plane to provide numbing of that area. Upon completion of the block, the patient will be evaluated for extubation and emerged from general anesthesia if appropriate.
2901623|NCT03237546|Active Comparator|PCA-alone (no block)|All subjects will receive fentanyl intravenous patient controlled anesthesia pumps as part of standard care. The amount of fentanyl self-administered by the patient or given by a clinician during 24 hours following surgery will be compared amongst the two groups.
2901624|NCT03237533|Active Comparator|Study Group|in this group patients will be treated with Dexamethasone local application
2901625|NCT03237533|Active Comparator|Control Group|in this group patients will be treated with dexamethasone, doxycycline and nystattin
2901626|NCT03237520|Experimental|Virtual Reality Therapy|Intervention: Virtual Reality therapy(VRT) reinforcing modified Constraint Induced Movement therapy(mCIMT) VRT will be administered using computer based program. mCIMT will be administered using the physical rehabilitation protocol.
2901627|NCT03237520|Active Comparator|mCIMT|Intervention: Modified Constraint Induced Movement Therapy Only mCIMT will be administered using the physical rehabilitation protocol.
2901628|NCT03237507||Chemotherapy Group|chemotherapy treatment（S-1 and Oxaliplatin） for patients until disease progress
2901629|NCT03237507||Chemotherapy plus HIPEC Group|Hyperthermic Intraperitoneal chemoperfusion（HIPEC）with Paclitaxel more than 2 cycles and plus chemotherapy
2901630|NCT03237494||Observation|Patients with polyneuropathy or cardiomyopathy of undetermined etiology
2901631|NCT03237481|Experimental|Treatment Group 1|HTX 011
2901632|NCT03237481|Active Comparator|Treatment Group 2|Bupivacaine HCl
2901633|NCT03237481|Placebo Comparator|Treatment Group 3|Saline placebo
2901634|NCT03237468|Experimental|Exercise arm|This arm will perform twice weekly neck strengthening exercises.
2901635|NCT03237455|Experimental|study group|Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
2901636|NCT03237455|Active Comparator|control group|Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
2901637|NCT03237442|Experimental|group 1|
2901638|NCT03237442|Active Comparator|group 2|
2901639|NCT03237429||cancer patients|The first study population will represent patients scheduled for surgery for a new diagnosed cancer pathology
2901640|NCT03237429||non-cancer patients|The second study population will represent patients scheduled for surgery not for cancer disease
2901641|NCT03237416|Experimental|BAY1841788/Healthy subjects|Period 1: intake of Midazolam and Dabigatran etexilate at day 1 followed by Period 2: intake of Darolutamide at days 1-11 (twice daily), intake of dabigatran etexilate at days 3 and 9, intake of Midazolam at day 9
2901642|NCT03237390|Experimental|Treatment (gemcitabine hydrochloride, ribociclib)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and ribociclib PO QD on days 8-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2901643|NCT03237377|Experimental|Durvalumab with Radiation|
2901644|NCT03237377|Experimental|Durvalumab and Trememlimumab with Radiation|
2901645|NCT03237351|Active Comparator|Conventional therapy group|Patients in Conventional therapy group were received fluid therapy: intraoperative transfusion volume=maintenance fluids+deficit replacement+restoration of losses and with heart rate, mean arterial pressure, urine measurement ect.
2901646|NCT03237351|Experimental|Low value of PPV group|Patients in low value of PPV group were received fluid therapy according to PPV (3% ≤PPV < 5%) .
2901647|NCT03237351|Experimental|High value of PPV group|Patients in high value of PPV group were received fluid therapy according to PPV (5% ≤PPV < 8%) .
2901648|NCT03237338|Experimental|Insomnia-ture acupuncture|"True acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints will be administered on CID patients Intervention: Procedure: true acupuncture"
2901649|NCT03237338|Sham Comparator|Insomnia-sham acupuncture|"Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints will be administered on CID patients Intervention: Procedure: true acupuncture"
2901650|NCT03237325|Experimental|SGX942|Patients are randomized 1:1 active/placebo.
2901651|NCT03237325|Placebo Comparator|Placebo|Patients are randomized 1:1 active/placebo.
2901652|NCT03237312|Other|The control group|Four punctures in each ovary were done regardless of the level of antimullerian hormone
2901653|NCT03237312|Other|The study group|The number of ovarian drills was adjusted according to antimullerian hormone level
2901654|NCT03237299||Cases|Cases: children with loco-regional complications of pharyngitis
2901655|NCT03237299||Controls|Controls: children with pharyngitis but without infectious complications
2901656|NCT03237286|Experimental|Ketamine + Cognitive Training|
2901657|NCT03237286|Sham Comparator|Ketamine + Sham Training|
2901658|NCT03237286|Placebo Comparator|Saline + Cognitive Training|
2901659|NCT03237273|Experimental|Single|All patients will undergo ultrasound scan using the HEAD-US Scoring System by a non-imaging specialist
2901660|NCT03237260|Experimental|Vedolizumab 300mg|
2901661|NCT03237247||Benign|cases with benign biliary stricture
2901662|NCT03237247||Calcular OJ|cases with calcular extrahepatic cholestasis
2901663|NCT03237247||Malignant Distal|cases with malignant distal extrahepatic cholestasis
2901664|NCT03237247||Malignant Proximal|cases with malignant proximal extrahepatic cholestasis
2901665|NCT03237247||Intrahepatic|cases with intrahepatic cholestasis
2901666|NCT03237234|Sham Comparator|Motor Training + Sham tDCS|Individuals will participate in 3 consecutive sessions of lower extremity motor skill training while receiving sham transcranial direct current stimulation (tDCS).
2901667|NCT03237234|Experimental|Motor Training + tDCS|Individuals will participate in 3 consecutive sessions of lower extremity motor skill training combined with transcranial direct current stimulation (tDCS) delivered at 2mA to the motor cortex.
2901668|NCT03237208|Active Comparator|TENS|Patients receiving the real transcutaneous electrical nerve stimulation (TENS) with 100 hertz, pulse width 200 microseconds, voltage 2 milliampere
2901670|NCT03237182|Experimental|Individualized treatment for drug resistant tuberculosis|Patients with drug resistance will have whole genome sequencing performed on the respective positive MGIT sample. An individualized TB treatment regimen will be provided to patients based on the whole genome sequencing results
2901671|NCT03237182|Active Comparator|Standard treatment regimen for drug resistant tuberculosis|As per South African Department of Health Standard of Care for the treatment of drug resistant tuberculosis
2901672|NCT03237169||Prospective cohort|Prospective cohort of patients with stable or stabilized coronary artery disease and de novo coronary lesions, in whom functional evaluation is performed, according do standard clinical indications.
2901673|NCT03237156|Experimental|TAK-906 50 mg; Cohort 1|TAK-906 50 milligrams (mg) capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 50 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
2901674|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 1|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
2901675|NCT03237156|Experimental|TAK-906 100 mg; Cohort 2|TAK-906 100 mg capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 100 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period. Cohort 2 will be conducted after Cohort 1.
2901676|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 2|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period. Cohort 2 will be conducted after Cohort 1.
2901677|NCT03237156|Experimental|TAK-906 10 mg; Cohort 3|TAK-906 10 mg capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 10 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
2901678|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 3|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
2901679|NCT03237130||preoperative enhanced chest CT|The cohort contains patients with preoperative therapies and patients without preoperative therapies. Each patient receives regular preoperative enhanced chest CT; for patients with preoperative therapies, they usually undergo twice enhanced chest CT examination at before and after preoperative therapies, the CT images after preoperative therapies will be used for analysis
2901680|NCT03237117|Experimental|GH group|35 women with a history of RIF with donated oocytes. For receiving donated oocytes, the women are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. Additionally, these patients are co-treated with growth hormone (GH).
2901681|NCT03237117|Active Comparator|non-GH group|35 women with a history of RIF with donated oocytes. For receiving donated oocytes, the women are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. The treatment protocol is identical to the GH group, only that no GH is added.
2901682|NCT03237117|No Intervention|positive control group|35 infertile women undergoing their first oocyte donation attempt are included as a positive control group. Women receiving donated oocytes are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. The treatment protocol is identical to the non-GH group, with no GH added.
2901683|NCT03237104||acute spondylolysis|Athletes who meet the inclusion criteria and consent to participate in the pilot study will be referred directly to PT care for 2 times per week until cleared to return to sport.
2901684|NCT03237091|Experimental|bihemispheric transcranial pulsed current stimulation (tPCS)|
2901685|NCT03237091|Experimental|unihemispheric transcranial pulsed current stimulation (tPCS)|
2901686|NCT03237091|Experimental|bihemispheric transcranial direct current stimulation (tDCS)|
2901687|NCT03237091|Experimental|unihemispheric transcranial direct current stimulation (tDCS)|
2901688|NCT03237091|Active Comparator|sham-control|
2901689|NCT03237078|Experimental|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
2901690|NCT03237065|Experimental|Iron isomaltoside (Monofer)|Administered iv
2901691|NCT03237065|Active Comparator|ferric carboxymaltose (Injectafer)|Administered iv
2901692|NCT03237052|Experimental|model|model aided decision
2901693|NCT03237052|Active Comparator|non-model|real-world psychiatrist decision
2901694|NCT03237039|Other|X-ray examination, fall-risk and gait|simultaneous acquisition in upright position of two full-body radiographic images, one in the coronal plane and one in the sagittal plane. In addition, 40 out of 160 subjects will undergo fall-risk assessment and gait cycle analysis evaluation.
2901695|NCT03237026||Cohort A|Cohort A will be recruited in the first 12 months of the study period to generate the first batch of urine metabolite profiles as predictive and prognostic markers.
2901696|NCT03237026||Cohort B|Cohort B will be recruited in the next 12 months of the study period to validate the first batch of newly developed urine metabolite profiles.
2901697|NCT03237013|No Intervention|Control (Treatment as Usual only)|"Following baseline assessment, all participants were given health literature on tanning behavior from the U.S. Centers for Disease Control and Prevention (CDC). These materials included informational pamphlets addressing common myths regarding tanning behaviors, including Tanned skin is not healthy skin, and A base tan is not a safe tan. These misconceptions were accompanied by burning truth, scientific data debunking these myths. Additionally, all participants received a packet on sun protective practices for oneself and family, which include skin cancer statistics and information on UV rays."
2901698|NCT03237013|Experimental|Treatment as Usual + Facial Morphing|"In addition to the health literature, participants completed the Facial Morphing Intervention. Participants had a digital photograph taken and uploaded to the APRIL® software, accompanied by information about their current age and self-identified race. Participants were presented with two, side-by-side identical 2D images of their face. Participants first viewed an image of their face from their current age, in two-year intervals, to age 72, the maximum age, with the UV exposure setting turned on. This process was repeated. Next, participants viewed the projected aging process, toggling the UV exposure setting (on and off), every ten year interval. The process was repeated using 3D images to view projected changes to their facial profiles."
2901699|NCT03237013|Placebo Comparator|Treatment as Usual + Mindfulness|In addition to the health literature, participants completed the Mindfulness Intervention. Participants listened to a 10-minute self-guided mindfulness audio exercise. The audio file is a scripted reading of an established, brief mindfulness exercise (Erisman & Roemer, 2010). During this guided session, participants learned what mindfulness was, when it can be used, and benefits from practice. Listeners were led through steps, focusing on the physical sensations, breathing, and thoughts. After the exercise, participants were provided a handout highlighting key points about mindfulness and how to incorporate informal mindfulness practice into their daily life.
2901700|NCT03237000|Experimental|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
2901701|NCT03236987|Active Comparator|Clarithromycin 1000 MG|"The patient will received a combination of 3 antibiotics :~Rifampicin (10mg/kg once daily)~Ethambutol (15 to 20 mg/kg once daily)~Clarithromycin (500 mg twice daily)"
2901702|NCT03236987|Experimental|Azithromycin 250 MG|"The patient will received a combination of 3 antibiotics :~Rifampicin (10mg/kg once daily)~Ethambutol (15 to 20 mg/kg once daily)~Azithromycin (250 mg once daily)"
2901703|NCT03236974|Active Comparator|Standard arm|Fulvestrant, 500 mg
2901704|NCT03236974|Experimental|AZD9496|250 mg bd taken orally for 5-14 days
2901705|NCT03236961|Active Comparator|Intravenous & per oral antibiotics|Ertapenem 1 g x 1 for two days i.v. followed by p.o. levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 5 days, duration of treatment one week.
2901706|NCT03236961|Active Comparator|Per oral antibiotics|Moxifloxacin 400 mg x 1 foe seven days, duration of treatment one week.
2901707|NCT03236948|Experimental|WfWI Intervention|Women receive the WfWI intervention. This comprises of three main components. First, a social empowerment and health intervention. Second a livelihood strengthening intervention, including numeracy training, and vocational training. Third, a cash transfer conditional on attendance at the intervention to cover costs of attendance and provide start-up capital. The intervention is delivered over 12 months.
2901708|NCT03236948|No Intervention|Control|
2901709|NCT03236935|Experimental|L-NMMA Plus Pembrolizumab|L-NMMA and pembrolizumab will be administered for 6 cycles. Cycle length will be 21 days. L-NMMA will be administered as a 2-hour intravenous (IV) infusion on Days 1−5 at each cycle. The dose levels of L-NMMA are as follows: Dose Level -1, 12.5 mg/kg; Dose Level 0 (starting dose), 15.0 mg/kg; and Dose Level 1, 17.5 mg/kg. L-NMMA dose will escalate/de-escalate based on the occurrence of dose-limiting toxicities. Pembrolizumab at a fixed dose of 200 mg will be IV infused over 30 minutes on Day 5 at each cycle. Pembrolizumab will be administered 1 hour after L-NMMA infusion on Day 5 at each cycle. Subjects without disease progression after 6 cycles of L-NMMA and pembrolizumab will continue pembrolizumab until disease progression or unacceptable AEs.
2901710|NCT03236922|Active Comparator|Pubococcygeus Sling|This is one anti-incontinence technique commonly used at the time of fistula surgery.
2901711|NCT03236922|Active Comparator|Rectus Fascia Sling|This is another anti-incontinence technique used at the time of fistula surgery, however, less commonly than the pubococcygeus.
2901712|NCT03236896|Active Comparator|Exercise Intervention|This group will participate in a weekly exercise regimen and actively log the physical activity in a diary. They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
2901713|NCT03236896|Active Comparator|No Exercise|They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
2901714|NCT03236883|Experimental|GEM plus GPBSC|Gemcitabine chemotherapy with mobilized GPBSC infusion:Gemcitabine 1000mg/m2 +GPBSC(2-3)*10^8/kg
2901715|NCT03236883|Other|Gemcitabine|
2901716|NCT03236883|Other|GPBSC|
2901717|NCT03236870||Participants with moderate to severe plaque psoriasis in China|Participants with moderate to severe plaque psoriasis in China receiving adalimumab in daily clinical practice.
2901718|NCT03236857|Experimental|Venetoclax with or without chemotherapy|Venetoclax administered orally once daily (QD) with various doses and dosing regimens with or without chemotherapy at the discretion of the investigator. Allowed chemotherapy regimens as outlined in the study protocol.
2901719|NCT03236844|Experimental|Gantenerumab G4|Participants will receive single dose of gantenerumab HCLF manufactured by G4 process on Day 1.
2901720|NCT03236844|Experimental|Gantenerumab G3|Participants will receive single dose of gantenerumab HCLF manufactured by G3 process on Day 1.
2901721|NCT03236831|Other|Subjects Undergoing Prospective VAD|Patients undergoing VAD placement. The investigators will provide clinical recommendations to the subject's primary care provider.
2901722|NCT03236818|Other|Upfront combination therapy|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
2901723|NCT03236805|Experimental|Ketamine IV|
2901724|NCT03236805|Active Comparator|Morphine IV|
2901725|NCT03236792|Experimental|Newly Diagnosed AL Amyloidosis|Ixazomib/Cyclophosphamide/Dexamethasone. Treatment cycles will be repeated up to 6 cycles or until disease progression or until development of significant treatment-related toxicities.
2901726|NCT03236779|Experimental|Dry needling (DN) arm|Once the clinician locates the MTrP, he will insert the needle over it and he will do a quick entry of the needle. The chosen technique to manipulate the needle will be Hong technique, which consist of quick entry and exit of the needle (fast in/fast out) to get local twitch response (LTR), it will be repeated 5 times with a rhythmic movement of 1Hz/sec. LTRs will be counted and registered.
2901756|NCT03236532|Experimental|Glutamine and exercise|Glutamine dipeptide (20g/day) in 300 ml of water and ingest it after lunch during 7 days. In case of forgetfulness, they were suggested to ingest it soon after dinner. All participants were instructed to maintain their routine eating habits throughout the duration of the study. On the seventh and last day of supplementation, they were submitted to the resistance training session.
2901727|NCT03236779|Active Comparator|Percutaneous needle electrolysis (PNE) arm|The electrotherapy equipment used (Enraf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3, 1.5 mA for 5 seconds conveyed to the muscle will be applied. It will be done exactly the same way as in the DN group with the only difference that the needle will be transmitting the electrical current.
2901728|NCT03236753|Experimental|Thread-Embedding Acupuncture (TEA)|The TEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm TEA on predefined 23 acupoints selected by expert group according to STRICTA. All other treatment affecting the outcomes will be prohibited during the trial period. All therapeutic procedure will be performed by acupuncture specialists who have received training for the consensus of multicenter.
2901729|NCT03236753|Sham Comparator|Sham Thread-Embedding Acupuncture (STEA)|The STEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm sham TEA on predefined 23 acupoints selected by expert group according to STRICTA.
2901730|NCT03236740|Active Comparator|Metformin|Metformin 500mg bid in morning and evening after meals to be taken for 6 months.
2901731|NCT03236740|Active Comparator|OCP|OCP containing 35 microgram ethinylestradiol and 2-milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill. OCP to be taken for 6 months.
2901732|NCT03236727|No Intervention|Control|Data of SSEPs (amplitude and latency) before dexmedetomidine infusion.
2901733|NCT03236727|Active Comparator|Dexmedetomidine|Data of SSEPs (amplitude and latency) after dexmedetomidine infusion.
2901734|NCT03236701|No Intervention|Control|usual diet
2901735|NCT03236701|Experimental|Intervention|egg white instead of meat or fish in two meals twice a week for three months
2901736|NCT03236688||MCRPC|Metastatic Castrate Resistant Prostate Cancer (MCRPC) Patients
2901737|NCT03236675||EML4-ALK|ALK positive patients
2901738|NCT03236675||T790M EGFR|T790M positive patients
2901739|NCT03236662|Experimental|Treatment|(-)-epicatechin 50mg twice per day (100mg per day total dose)
2901740|NCT03236649|Experimental|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
2901741|NCT03236649|Active Comparator|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
2901742|NCT03236636|Experimental|Icaritin|Icaritin:600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
2901743|NCT03236636|Active Comparator|HUACHANSU PIAN|HUANCHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
2901744|NCT03236623|Experimental|Menthol Popsicle|The patient will be questioned when the intensity and discomfort of thirst. After randomization, the patient assigned to the experimental group will experience a menthol popsicle. After 20 minutes of the end of the popsicle, will again be questioned as to the intensity and discomfort of thirst. The popsicle will have a support that will assist the patient in the administration of the intervention, giving him autonomy and safety in the application of the intervention.
2901745|NCT03236623|No Intervention|Usual care|The patient will be questioned when the intensity and discomfort of thirst. After randomization, the patient assigned to the control group should receive the usual care consisting of absolute fasting the food and drinks.
2901746|NCT03236610|Experimental|tenofovir|
2901747|NCT03236610|Active Comparator|tenofovir plus entecavir|
2901748|NCT03236597|Experimental|Sit-Stand Desk|a sit/stand workstation will be installed at participants' desk for four weeks.
2901749|NCT03236597|Experimental|Treadmill desk|Participants will be asked to use a treadmill desk for a minimum of one hour per day for four weeks (Participants will be assigned to a 30 minute slot in the morning and a 30 minute slot in the afternoon; slots will be designated with participant input). Additional time may be spent on the treadmill, time permitting (two treadmills will be available to 10 people over the four week period).
2901750|NCT03236584|Active Comparator|lamivudine adefovir|
2901751|NCT03236584|Experimental|tenofovir|
2901752|NCT03236571|Experimental|Rehabilitation Program|It will consist of 2 sessions of 40 minutes per week, for 12 weeks on ergometric bicycle. Each session of 40 min will include 5 minutes of warm-up, 5 minutes of recovery and 6 sequences of 5 min. Each 5-minute sequence will alternate between 4 minutes of pedaling at a load corresponding to the 1st ventilatory threshold (determined in the initial maximum cardiorespiratory effort test) and 1 minute of pedaling at a load corresponding to 2nd ventilatory threshold (determined in the initial maximum cardiopulmonary stress test).
2901753|NCT03236558|Experimental|Patients with diabetes|T1D patients with blood collection
2901754|NCT03236545|Experimental|No to Low Endogenous Estrogen|PMW and young women (YW) will receive medical study clearance after a detailed physical examination. YW will self-administer subcutaneous injections of the gonadotropin-releasing hormone (GnRH) antagonist, ganirelix acetate (Antagon, 0.25 mg/day in 0.5 ml of normal saline, Organon, Inc., West Orange, New Jersey,) daily to suppress endogenous ovarian hormone production (16, 17, 18). This will begin following a separate medical screening at Reproductive Associates of Delaware 48 hours prior to initiating the hormone intervention to rule out other contraindications prior to beginning the treatment. YW will begin using the antagonist on days 26-28 of their menstrual cycle, and continue daily for 10-12 days. The experimental protocol will be conducted in YW after 3-4 days of using the GnRH antagonist. PMW will complete the experimental protocol prior to use of the 17β-estradiol (E2, 0.1 mg/day patch, Vivelle dot; estradiol patch).
2901755|NCT03236545|Experimental|Estrogen Add-Back|Estradiol (E2, 0.1 mg/day patch, Vivelle dot; estradiol patch) will be administered for 7 days to both young and PMW. Young women will use the E2 over the last 7 days of Antagon administration.
2901783|NCT03236350|Experimental|CRIC Treatment|An autoRIC® Device will be placed on the upper arm daily to complete the preset protocol and will be repeated daily for 28 days.
2902282|NCT03232983|Active Comparator|LY900014 (IV)|Single dose of LY900014 administered intravenously (IV) in one period
2901757|NCT03236532|Placebo Comparator|Maltodextrin and exercise|Maltodextrin (20g/day) in 300 ml of water and ingest it after lunch during 7 days. In case of forgetfulness, they were suggested to ingest it soon after dinner. All participants were instructed to maintain their routine eating habits throughout the duration of the study. On the seventh and last day of supplementation, they were submitted to the resistance training session.
2901758|NCT03236506|Experimental|Daily observed therapy|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a daily, observed basis by either the nurse or a community pharmacist.
2901759|NCT03236506|Active Comparator|Fortnightly pick-up|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse.
2901760|NCT03236506|Active Comparator|Fortnightly pick-up +psych intervention|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse. In addition, this group will receive a one-off interview with the researcher to complete a psychological intervention designed to improve adherence to the medication regimen.
2901761|NCT03236493|Experimental|PF-06700841|Multiple ascending doses of PF-06700841
2901762|NCT03236493|Placebo Comparator|Placebo|Multiple ascending doses of Placebo
2901763|NCT03236480||COPD|Patients who admitted to Peking Universtiy People's Hospital and Ningde City Hospital between January 2017 and January 2019 with AECOPD will be enrolled
2901764|NCT03236480||healthy control|People aged over 40, without any chronic respiratory disease or acute respiratory infections in the last 2 weeks, and be willing to participate in the study
2901765|NCT03236467|Experimental|FM + PTSD|Individuals suffering from Fibromyalgia and PTSD
2901766|NCT03236454|Active Comparator|anodal tDCS|DC-Stimulator MC, NeuroConn: 20 minutes of 2 mA anodal stimulation
2901767|NCT03236454|Sham Comparator|sham tDCS|DC-Stimulator MC, NeuroConn: 20 minutes of sham stimulation; Ramping up over 50 seconds at the beginning and an equal amount of time for tapering off at the end;
2901768|NCT03236441|Active Comparator|RIPC Group|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
2901769|NCT03236441|Sham Comparator|Sham-RIPC Group|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 10 mmHg for 5 minutes and deflation for 5 minutes (Control)
2901770|NCT03236428|Experimental|Daratumumab|Daratumumab will be administered by IV infusion weekly during cycles 1 and 2 Daratumumab will be administered by IV infusion every other week during cycles 3 through 6 Daratumumab will be administered by IV infusion monthly during cycles 7 through 20
2901771|NCT03236415|Active Comparator|Xience Drug Eluting Stent|Patients with diabetes mellitus will be randomized to receive either a Xience drug eluting stent or an ABSORB bioresorbable vascular scaffold for treatment of obstructive coronary artery disease
2901772|NCT03236415|Active Comparator|ABSORB Bioresorbable Vascular Scaffold|Patients with diabetes mellitus will be randomized to receive either a Xience drug eluting stent or an ABSORB bioresorbable vascular scaffold for treatment of obstructive coronary artery diseasee
2901773|NCT03236402||Early young adult (20 years - 30 years)|Adults who were in the age group of 20 - 30 years was the first group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 20-30 years.
2901774|NCT03236402||Middle age adult (31 -50 years)|Adults who were in the age group of 31-50 years were in second group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 31-50 years.
2901775|NCT03236402||Late adult (51 years - 65 years)|Adults who were in the age group of 51-65 years were in third group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 51-65 years.
2901776|NCT03236402||>65 years|Adults who were in the age group of >65 years were in fourth group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of >65 years.
2901777|NCT03236389|Experimental|Collar Wearing|subjects will wear collar during MRI testing
2901778|NCT03236376|Experimental|sensorimotor therapy|sensorimotor therapy will consist of 30minutes of sensory discrimination training and 30 minutes of sensorimotor training per session. The sensory discrimination training is based on on the SENSe training of Carey et all. The sensorimotor training is the same individually tailored motor therapy as described below, but with integration of sensory discrimination training aspects.
2901779|NCT03236376|Active Comparator|motor therapy|The motor therapy consists of 30 minutes of cognitive and attention-based table top games and 30 minutes of motor training per session. The cognitive-attention-based therapy consists of table top games such as chess, rush hour, or other smart games. Individually tailored motor therapy consists of a unilateral motor exercise program for the upper limb, while seated at a table, under supervision of a therapist to match the therapy and intensity provided in the other sensorimotor therapy group. This 30 minutes of motor arm training is based on a set of standardized exercises which comprise task-related practice for gross movements and dexterity including different grips and selective finger movements, and training in daily life activities, however without any attention to sensory discrimination training.
2901780|NCT03236363|Experimental|MOVI-da 10! active breaks|It is a physical activity intervention that consists on two daily physical activity active breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
2901781|NCT03236363|No Intervention|Control|No intervention
2901782|NCT03236363|Experimental|MOVI-da10! integrated physical activity|It is an integrated physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate <150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
2944367|NCT02942719||Gansu Provincial Maternity and Child-care Hospital|
2901784|NCT03236350|Sham Comparator|Sham Control|An autoRIC® Device visually identical to that used in the CRIC protocol will be placed on the upper arm daily to complete the preset protocol and will be repeated daily for 28 days.
2901785|NCT03236337|No Intervention|Control|No intervention
2901786|NCT03236337|Experimental|MOVI intervention|- MOVI-da Fit! is a high intensity interval training intervention that consists on: a) 4 h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
2901787|NCT03236324|Placebo Comparator|TFP block with saline|Placebo bilateral ultrasound-guided nerve block [transversalis fascia plane (TFP) block] with 40 mL saline, single shot
2901788|NCT03236324|Experimental|TFP block with local anesthetic|Experimental bilateral ultrasound-guided nerve block [transversalis fascia plane (TFP) block] with local anesthesic of Bupivacaine-epinephrine [0.25% bupivacaine with 2.5 mcg/mL epinephrine 40 mL (maximum 2.5 mg/kg)], single shot
2901789|NCT03236311|Experimental|SAR407899|SAR407899 with dose titration over 4 weeks administration
2901790|NCT03236311|Placebo Comparator|Placebo|Matching placebo for 4 weeks
2901791|NCT03236298|Active Comparator|PIEB speed of infusion 250 ml/hr|The programmed intermittent bolus of 10ml will be administered every 40 minutes, at a speed of 250 ml/hr by the CADD-Solis Ambulatory Infusion System.
2901792|NCT03236298|Active Comparator|PIEB speed of infusion 125 ml/hr|The programmed intermittent bolus of 10ml will be administered every 40 minutes, at a speed of 125 ml/hr by the CADD-Solis Ambulatory Infusion System.
2901793|NCT03236285|Experimental|HIIT only|Volunteers will be submitted to high-intensity interval training (HIIT) performed in fed state
2901794|NCT03236285|Experimental|CT+FAST|Volunteers will be submitted to continous training (CT) performed in the fasting state
2901795|NCT03236285|Experimental|CT only|Volunteers will be submitted to continous training (CT) performed in fed state.
2901796|NCT03236285|Experimental|HIIT+FAST|Volunteers will be submitted to high-intensity interval training (HIIT) performed in the fasting state.
2901797|NCT03236272||case group|patients with ARDS
2901798|NCT03236272||control group|patients Without ARDS
2901799|NCT03236259|Active Comparator|Brainport high dose|
2901800|NCT03236259|Active Comparator|Brainport low dose|
2901801|NCT03236259|Placebo Comparator|Placebo|Maltodextrin
2901802|NCT03236246|Experimental|Group 1|KRX-0502 1 tablet thrice daily (TID) with meals
2901803|NCT03236246|Experimental|Group 2|KRX-0502 2 tablets twice daily (BID) with the largest 2 daily meals
2901804|NCT03236233|Experimental|Single dose - healthy subjects|
2901805|NCT03236233|Experimental|Repeat dose - healthy subjects|
2901806|NCT03236233|Experimental|Single dose - subjects with asthma|
2901807|NCT03236220|Experimental|N-acetyl-L-cysteine group|Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine.
2901808|NCT03236207|Experimental|Test infant formula|Test non-commercial extensively hydrolyzed infant formula with HMOs
2901809|NCT03236207|Active Comparator|Control infant formula|Control non-commercial extensively hydrolyzed infant formula without HMOs
2901810|NCT03236181|Other|Saturated Fat/SFA|30 grams saturated fat (SFA) in the form of heavy whipping cream will be provided to subject in a mixed meal shake
2901811|NCT03236181|Other|Monounsaturated Fat/MUFA|30 grams monounsaturated fat (MUFA) in the form of olive oil will be provided to subject in a mixed meal shake
2901812|NCT03236181|Other|Polyunsaturated Fat Linoleic/PUFA|30 grams high linoleic polyunsaturated fat (PUFA) in the form of high linoleic sunflower oil will be provided to subject in a mixed meal shake
2901813|NCT03236181|Other|Polyunsaturated Fat Omega-3/LCn3|30 grams high omega-3 polyunsaturated fat (LCn3) in the form of fish oil will be provided to subject in a mixed meal shake
2901814|NCT03236168|Other|Intervention Arm|This study consists of a single treatment arm. Patients will receive Ivermectin or where contraindicated (Pregnancy, Breastfeeding, Weight <15kg) Permethrin Cream and Malathion shampoo
2901815|NCT03236155|Active Comparator|1 prescription|Receives 90 pills in single prescription at discharge from hospital
2901816|NCT03236155|Active Comparator|3 prescriptions|Receives 30 pill prescription at discharge from hospital. Two refills available if requested.
2901817|NCT03236142|Active Comparator|Standard Duodenal Switch (DS)|
2901818|NCT03236142|Experimental|Single Anastomosis, 300 cm Loop, Duodenal Switch (SIPS)|
2901819|NCT03236129|Experimental|Treg depleted DLI|Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by Treg depleted (Donor Lymphocytes Infusion (DLI)
2901820|NCT03236129|Active Comparator|Unmanipulated DLI|Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by a standard DLI (unmanipulated)
2901821|NCT03236116|Experimental|Almond Group|Participants will consumed almonds every day for 6 months.
2901822|NCT03236116|Experimental|Control Group|Participants will continue with their normal eating routine for 6 months, but will not be allowed to consume any nut products.
2901823|NCT03236103|Other|Subjects with VAD in place|Adult patients with VAD in place who are admitted to the hospital for acute medical illness. The investigators will provide clinical recommendations to the subject's primary care provider.
2901824|NCT03236090|Active Comparator|Outpatients with refractory ascites|20 consecutive outpatients with cirrhosis and refractory ascites Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
2901825|NCT03236090|Active Comparator|Patients hospitalized because bacterial infection|30 consecutive patients with cirrhosis and bacterial infections. All patients will receive endovenous antibiotics and, only in the case of patients with SBP, also intravenous albumin Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
2901826|NCT03236077|No Intervention|Control|
2901827|NCT03236077|Experimental|Intervention|
2901828|NCT03236064|Experimental|Nerve injury to palm and fingers|Adult patients with acute clean nerve transections of the higher arm injuries in the forearm, wrist, palm and digits of the hand will be recruited
2946277|NCT02929732|Experimental|Healthy volunteers (CONTROL)|
2901831|NCT03236025|Experimental|Experimental group|Video+telephone counselling+pamphlet will be allocated to the participants in the experimental group. The videos which presented the health effects of smoking, especially emphasizing the importance of smoking cessation on the fetal and pregnancy, will be sent in sequence through the smart phone to the participants in the experimental group. Also the participants will receive a short telephone counselling during the first assessment. In addition, pamphlet material related to the smoking cessation will be allocated to the participants at the same time.
2901832|NCT03236025|Active Comparator|Conditional control group|A telephone counselling will be implemented to the participants in the conditional control group after the first assessment. Pamphlet materials showed the information related to the smoking cessation will be allocated to them at the same time.
2901833|NCT03236025|Placebo Comparator|Placebo control group|Participants in the control group will be given a very brief, minimal and general smoking cessation advice during the first assessment. A pamphlet showed the information related to the smoking cessation will be allocated to them at the same time.
2901834|NCT03236012|Other|Iodine Skin Test|The iodine-starch test can be useful in diagnosing hyperhidrosis and grading its severity if it can demonstrate discriminate validity -- to accurately test positive in patients with the condition, and test negative in patients without the condition.
2901835|NCT03236012|Active Comparator|Aluminum Chloride Topical|Test the effectiveness of a prescription strength topical antiperspirant Aluminum Chloride 20 percent on hyperhidrosis of the residual limb.
2901836|NCT03236012|Experimental|Botulinum Toxin Therapy|Test the effectiveness of Botulinum Toxin therapy in subjects who fail or do not tolerate Aluminum Chloride.
2901837|NCT03235999||Talc pleurodesis|Up to 10 patients who have had talc pleurodesis
2901838|NCT03235999||IPC|Up to 10 patients who have had indwelling pleural catheters (IPC)
2901839|NCT03235986|Experimental|nCPAP+ Nebulised Curosurf®|Curosurf® administered through nebulization
2901840|NCT03235986|Other|nCPAP alone (control)|Standard of care, respiratory support used also during experimental arms
2901841|NCT03235973|Experimental|Fludarabine-Cladribine-Busulfan conditioning regimen|
2901842|NCT03235947|Experimental|Fosfomycin disodium|"Fosfomycin disodium 4 g intravenously: 3 hours before kidney transplant surgery, 3 hours before urinary catheter removal and 3 hours prior to ureteral catheter removal.~Trimethoprim / Sulfamethoxazole (160/800 mg) 1 tablet orally every 24 hours."
2901843|NCT03235947|Active Comparator|Trimethoprim / Sulfamethoxazole|"Trimethoprim / Sulfamethoxazole (160/800 mg) 1 tablet orally every 24 hours.~Intravenous placebo solution at the same time of application of fosfomycin disodium in the experimental arm."
2901844|NCT03235921|Other|nitroglycerin|nitroglycerin patch 5 mg applied to front of chest in each patient at time of admission once.
2901845|NCT03235921|Other|control group|no drug given to the patients in control group
2901846|NCT03235908||Patients with an acute psychosis|Acute psychosis in schizophrenia spectrum disorder, affective disorder and bipolar disorder; Observation only
2901847|NCT03235895|Experimental|Internet based|"Six days of Instructional online CME educational material using Test-Enhanced E-Learning strategy.~Followed by one day face to face CME activity"
2901848|NCT03235895|Active Comparator|Face to Face|Three days face to face Conventional CME educational materials
2901849|NCT03235895|No Intervention|Wait listed|No CME activity will be given
2901850|NCT03235882||observational group|"Infants born 24-32 weeks.~Inclusion criteria:~Have gastric aspirate and oral secretions obtained within 45 minutes from birth via:~a naso- or orogastric tube inserted in the delivery room if clinically indicated as part of resuscitation or~a nasogastric tube inserted as part of routine management of preterm infants.~Written informed consent has been obtained"
2901851|NCT03235869|Experimental|Radiation Therapy + Durvalumab|Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions) Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
2901852|NCT03235856||Keratoconus patients|This study involves a retrospective analysis of data recorded during routine clinical follow-up of keratoconus patients. As such, the impact for the patient is minimal as no additional tests need to be performed
2901853|NCT03235843|Active Comparator|Rate Adaptive Pacing ON|AAIR pacing using a MV sensor
2901854|NCT03235843|Placebo Comparator|Rate Adaptive Pacing OFF|DDI-pacing
2901855|NCT03235830|Active Comparator|Enhanced Standard of Care (ESoC)|Subjects received a condensed version of the American Academy of Pediatrics Bright Futures content at their scheduled well-child visits though 6 months of age. The enhanced standard of care (ESoC) materials were added, by members of the research team, to registration packets and were given to caregivers by clinic staff, who were all trained to give the ESoC. For any patients who did not receive ESoC materials at their visit, an age-appropriate ESoC was mailed to the caregiver.
2901856|NCT03235830|Experimental|Enhanced Standard of Care (ESoC) + Text|Subjects assigned to the text messaging intervention group received four educational messages per week until their child was 6 months of age in addition to the ESoC documents. The text messages directly reflected Bright Futures and ESoC content, addressing infant development, safety, care, and the most common causes of nonurgent visits in the first year. Bright Futures content was adapted both for language and length to accommodate character limits and the patient population.
2901857|NCT03235817|Experimental|Spontaneous ventilation|
2901858|NCT03235817|Experimental|Pressure support ventilation|
2901859|NCT03235817|Active Comparator|Pressure control ventilation|
2901860|NCT03235804|No Intervention|Control Group|Those assigned to the Control group will be asked to maintain their usual dietary intake over 12 weeks. Participants' usual dietary intake is expected to reflect the North American dietary pattern (i.e. ~15% of total energy intake coming from protein, ~50% from carbohydrate and ~35% from fat).
2901861|NCT03235804|Experimental|High-Protein Group|Those assigned to the High-Protein group will be asked to maintain their usual dietary intake and consume a nutritional supplement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
2946364|NCT02929160|Experimental|PCN|Percutaneous nephrostomy
2901862|NCT03235778|Experimental|group1|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:11.78mg Volume:0.50ml Frequency:Once Duration:30min A total of 10 subjects, 2 subjects served as pre-test groups, given to the test drug；the remaining 8 subjects,6 received the test drug and 2 received the placebo.
2901863|NCT03235778|Experimental|group2|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:23.56mg Volume:1.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
2901864|NCT03235778|Experimental|group3|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:47.13mg Volume:2.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
2901865|NCT03235778|Experimental|group4|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:94.25mg Volume:4.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
2901866|NCT03235778|Experimental|group5|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:164.92mg Volume:7.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
2901867|NCT03235778|Experimental|group6|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:259.16mg Volume:11.00ml Frequency:Once A total of 8 subjects,6 received the test drug and 2 received the placebo. Duration:30min
2901868|NCT03235778|Experimental|group7|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:377.00mg Volume:16.00ml Frequency:Once A total of 8 subjects,6 received the test drug and 2 received the placebo. Duration:30min
2901869|NCT03235765||Cohort A|Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy
2901870|NCT03235765||Cohort B|Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.
2901871|NCT03235752|Experimental|TJ301 300mg|TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
2901872|NCT03235752|Experimental|TJ301 600mg|TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
2901873|NCT03235752|Placebo Comparator|Placebo|Placebo administrations will occur on Days 0, 14, 28, 42, 56, and 70.
2901874|NCT03235739|Experimental|Treatment Arm|Naloxegol 25 mg given once in the morning every day until Post-operative Day 3 or day of discharge whichever occurs first
2901875|NCT03235739|Placebo Comparator|Placebo Arm|Matching placebo given once in the morning every day until Post-operative Day 3 or day of discharge whichever occurs first
2901876|NCT03235726|Experimental|Cohort A, Part 1: Active|60 milligrams (mg) single dose of CCI15106 will be administered by inhalation route on Day 1; 120 mg single dose will be administered on Day 3; and then 30 mg dose will be administered twice daily (BID) on Days 6-19 to healthy subjects.
2901877|NCT03235726|Placebo Comparator|Cohort A, Part 1: Placebo|60 mg single dose of placebo will be administered by inhalation route on Day 1; 120 mg single dose will be administered on Day 3; and then 30 mg dose will be administered BID on Days 6-19 to healthy subjects.
2901878|NCT03235726|Experimental|Cohort B, Part 1: Active|60 mg of CCI15106 BID will be administered by inhalation route for 14 days to healthy subjects.
2901879|NCT03235726|Placebo Comparator|Cohort B, Part 1: Placebo|60 mg of placebo BID will be administered by inhalation route for 14 days to healthy subjects.
2901880|NCT03235726|No Intervention|Cohort C, Part 1: bystanders|Healthy subjects will be enrolled to follow bystander exposure and will be studied concomitantly with Cohort B.
2901881|NCT03235726|Experimental|Cohort A, Part 2: Active|60 mg single dose of CCI15106 will be administered by inhalation route to subjects with COPD.
2901882|NCT03235726|Placebo Comparator|Cohort A, Part 2: Placebo|60 mg single dose of placebo will be administered by inhalation route to subjects with COPD.
2901883|NCT03235726|Experimental|Cohort B, Part 2: Active|60 mg BID dose of CCI15106 will be administered by inhalation route for 14 days to subjects with COPD.
2901884|NCT03235726|Placebo Comparator|Cohort B, Part 2: Placebo|60 mg BID dose of placebo will be administered by inhalation route for 14 days to subjects with COPD.
2901885|NCT03235700|Experimental|Adenosine followed by nicorandil|
2901886|NCT03235700|Experimental|Nicorandil followed by adenosine|
2901887|NCT03235687|Experimental|Cohort A|Patients randomized to Cohort A will receive ExoDx Prostate (IntelliScore) test results along with a post-ExoDx Prostate (IntelliScore) test result questionnaire to evaluate impact of test results in the biopsy decision process, utility, ease of understanding and work-flow implementation.
2901888|NCT03235687|No Intervention|Cohort B|Patients randomized to Cohort B will proceed with conventional standard of care.
2901889|NCT03235674|Experimental|High-intensity stair climbing exercise|3 x 60 seconds of stair climbing, at a vigorous pace as described by rating of perceived exertion, separated by 60 seconds of rest. Subjects will complete supervised sessions 3 times/week for 2 weeks, and then continue unsupervised for the following 10 weeks.
2901890|NCT03235674|No Intervention|standard cardiac rehabilitation exercise|Subjects will complete the traditional cardiac rehabilitation program, combination of aerobic and resistance exercise 2 times/week for 2 weeks, and then continue unsupervised for the following 10 weeks.
2901891|NCT03235661|Experimental|BiPAP|BiPAP as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
2901892|NCT03235661|Active Comparator|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
2901893|NCT03235648|Experimental|cardiophrenic nodes excision in ovarian cancer|We are going to evaluate the comorbidites and impact of cardiophrenic lymph nodes excision in cases of advanced ovarian cancer with positive cardiophrenic lymph nodes
2901894|NCT03235635||Preterm|newborn infants were born with a gestational age of less than 32 weeks
2901895|NCT03235635||Late preterm|newborn infants were born with a gestational age of greater than 32 weeks and less than 36 weeks
2901896|NCT03235635||full-term|newborn infants were born with a gestational age of greater than or equal to 37 weeks
2901897|NCT03235609|Active Comparator|Fentanyl|Group I (FP): will receive 0.5 µg/ kg fentanyl + 2 mg/ kg propofol IV.
2901898|NCT03235609|Active Comparator|Ketamine|Group II (KP): will receive 0.5 mg/kg ketamine + 2 mg/kg propofol IV.
2901899|NCT03235596|Experimental|treated arm|Patients received cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2 mA during 15 minutes. They have 10 sessions in 5 consecutive days, 2 sessions per day.
2901900|NCT03235583|Other|MotionPod Validation|Medical device validation
2901901|NCT03235570|Experimental|INCB054828|Part 1 is an open-label dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.
2901902|NCT03235544|Experimental|Cohort 1- INCB050465|Participants who have previously received ibrutinib.
2901903|NCT03235544|Experimental|Cohort 2 - INCB050465|Participants who have not previously received a BTK inhibitor.
2901904|NCT03235531|Experimental|CIWA Protocol/BZD and Valproate|"Interventions to decrease symptoms of AWS will be made based on the CIWA tool.~CIWA Score 9-14: 1 mg IV push lorazepam~CIWA Score >15: 2 mg IV push lorazepam~Patients who have a known history of alcohol withdrawal seizures or who have received greater than 4 mg IV lorazepam per CIWA protocol will be placed on a scheduled lorazepam regimen, 1 mg every 6 hours. The primary managing service may increase the scheduled lorazepam regimen above 1mg every 6 hours if needed to control withdrawal symptoms. Scheduled lorazepam will be discontinued or de-escalated following a 24-hour period in which no additional lorazepam was received per CIWA protocol.~The treatment group will also receive scheduled valproate (VPA), 15 mg/kg divided over 4 doses, rounded up to the nearest increment of 50mg (i.e. a 70 kg person would be administered 300 mg IV VPA every 6 hours) for 96 hours."
2901905|NCT03235531|Active Comparator|CIWA Protocol Only|"Interventions to decrease symptoms of AWS will be made based on the CIWA tool~CIWA Score 9-14: 1 mg IV push lorazepam~CIWA Score >15: 2 mg IV push lorazepam~Patients who have a known history of alcohol withdrawal seizures or who have received greater than 4 mg IV lorazepam per CIWA protocol will be placed on a scheduled lorazepam regimen, 1 mg every 6 hours. The primary managing service may increase the scheduled lorazepam regimen above 1mg every 6 hours if needed to control withdrawal symptoms. Scheduled lorazepam will be discontinued or de-escalated following a 24-hour period in which no additional lorazepam was received per CIWA protocol."
2901906|NCT03235518||Structure Interviews with FSW|Structured interviews with 200 purposively sampled FSW will be conducted. These interviews will be conducted prior to focus group discussion (FGD) and in-depth qualitative interview (IDI) with FSW. Structured interviews will take approximately 45-60 minutes to complete and will be administered privately in Kiswahili, Dholuo or English by trained female research staff. Quantitative interviews will be administered to conduct an assessment of FSW sociodemographics, sexual behaviour patterns and HIV-related knowledge, attitudes and practices regarding HIV prevention and other factors that might affect initiation and adherence to PrEP use, ability to use PrEP covertly, HIV testing history, mobility patterns, social networks, pregnancy intentions, ability to use condoms consistently with clients, and regular partners, and interpersonal violence from clients, regular partners and the police.
2901907|NCT03235518||Focus Group Discussions with FSW|Three to five FGDs of up to 10 FSW per group will be conducted. These FGD will take place prior to FSW IDI. FSW who participated in FGDs will be ineligible for participation in the IDI. All group discussions will last approximately 1.5 to 2 hours and be conducted in Kiswahili, Dholuo or English. Each group discussion will be facilitated by trained female research staff and held in a private space at a pre-specified location. The themes that will be explored in the FGDs include: FSW social networks, participation in PrEP studies, barriers and facilitators to PrEP use and use of resource transfers for PrEP adherence. In addition, participants will complete a brief demographic survey.
2901908|NCT03235518||In-Depth Qualitative Interviews with FSW|30 IDI will be conducted with FSW. FSW who participated in FGDs will be ineligible for participation in the IDI. All in-depth interviews will be conducted by trained female research staff using a semi-structured interview guide. All interviews will be held in a private space at a pre-specified location within the community. The topics that will be discussed in the IDI with FSW include demographics, social support, dynamics of sex work, HIV prevention methods (including condom use), perception of HIV risk and development of PrEP intervention.
2901909|NCT03235518||In-Depth Qualitative Interviews with MC|30 IDI will be conducted with MC. All IDI will last approximately 60-90 minutes and be conducted in Kiswahili, Dholuo, or English. Each interview will be conducted by a trained male research staff using semi-structured interview guide. All interviews will be held in a private space at a pre-specified location. Topics include demographics, relationships with FSW, HIV prevention methods (including use of condoms), perception of HIV risk and development of PrEP intervention.
2901910|NCT03235518||In-Depth Qualitative Interviews with HCPs|30 IDI will be conducted with health care provider (HCP). All IDI will last approximately 60-90 minutes and be conducted in English. Each interview will be conducted by trained research staff using a semi-structured interview guide. Interviews will be held in a private space at the health facility where they work or another venue preferred by the HCP. Topics include demographics, health care needs of FSW and sources of care, HIV prevention needs of FSW, PrEP for FSW and training needs for HCP.
2901911|NCT03235505|Experimental|Nicotine containing e-cigarettes|Nicotine containing e-cigarettes + placebo-varenicline + Motivational Interview (MI)
2901912|NCT03235505|Active Comparator|Nicotine-free e-cigarettes|Nicotine-free e-cigarettes + varenicline tartrate+ MI
2901913|NCT03235505|Placebo Comparator|Motivational Interview (MI)|Placebo-varenicline + nicotine -free e-cigarettes + Motivational Interview
2901914|NCT03235492|Experimental|SmartAlbu|If a participant agrees, after obtaining informed consent, the investigator will measure and record temperature, blood pressure, heart rate, height and weight. The participant will be given detailed instruction on how to hold the container and will be asked to spit (or deposit) their saliva up to the indicated line. The procedure will be performed twice to study the reproducibility of the test. The participant will then be asked to have a standard blood draw of 2-3 mls of blood into a vacutainer tube for analysis of HbA1c at the central lab and 1-2 mls of blood for glycated albumin for assay analysis, and a finger stick for point of care HbA1c measurement.
2901915|NCT03235479|Experimental|BHV-3000|
2901916|NCT03235479|Placebo Comparator|Placebo|
2901959|NCT03235180|Experimental|Crohn's Disease Subjects|"Subjects will receive ultrasound exams of the bowel with 2 different machines (Ultrasound Elastography and Ultrasound Vascularity) at three time points: baseline, 4 weeks, and 6 months. The ultrasound exams will be performed at first with no contrast agent, and then ultrasound measurements will be repeated with 1-2 ml of Sulfur Hexafluoride, a contract agent.~Subjects also will receive Magnetic Resonance Enterography (MRE) exams at baseline and 6 months as part of their clinical care."
2901917|NCT03235466|Active Comparator|Voice Therapy|(Group 1) will undergo active training in behavioral cough suppression and laryngeal relaxation exercises, but will not receive HRVB. Traditional cough suppression and laryngeal relaxation exercises include pursed lip breathing, swallowing (water, lozenge, gum, ice chips), sustained semi-occluded voicing, discussion and mitigation of triggers, maintaining a cough journal, addressing muscle tension dysphonia if indicated, and developing prophylaxis suppression and laryngeal relaxation based on stimulability. Participants in Group 1 will receive handwritten guidance indicating exercises to practice at home.
2901918|NCT03235466|Active Comparator|Voice Therapy and Heart Rate Variability Biofeedback|Voice therapy as described in Arm 1. HRVB involves measure respiratory rate, heart rate, body temperature and skin conductance. Participants are guided through reduced breathing rate until a resonant frequency is attained. HRVB breathing simulates resonance between the baroreflex rhythm and respiration based rhythm, increasing heart rate variability and baroreceptor sensitivity. Evidence suggests HRVB improves autonomic regularity. We propose this novel modality to address centrally regulated hypersensitivity that perpetuates coughing.
2901919|NCT03235466|Active Comparator|Heart Rate Variability Biofeedback|HRVB as indicated in Arm 2. No instruction will be provided for cough suppression, laryngeal desensitization, voice tasks or hygiene that traditionally reduces cough frequency and severity. This is the experimental arm.
2901920|NCT03235453|Experimental|Binary rhythm|Experimental: binary rhythm The randomized group for binary-rhythm intervention will receive a 12-week intervention with dance lessons. Classes will be divided into: Heating and stretching (5 minutes), main part (binary) (35 minutes) and relaxation (5 minutes).
2901921|NCT03235453|Experimental|Quaternary rhythm|The randomized group for the quaternary rhythm intervention will receive a 12-week intervention with dance classes. Classes will be divided into: Heating and stretching (5 minutes), main part (quaternary rhythm) (35 minutes) and relaxation (5 minutes).
2901922|NCT03235440|Experimental|Kids N Fitness|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
2901923|NCT03235427||Received Radiation Therapy(RT)|Patients who had received radiotherapy will be sub-stratified into those who received treatment to the left or right breast.
2901924|NCT03235427||Did not receive Radiation Therapy (RT)|Patients who did not receive radiation treatment, but received chemotherapy, hormonal therapy, and/or surgery will be used as study controls to compare the prevalence and burden of cardiac disease as compared to radiation patients.
2901925|NCT03235414|Experimental|Normals|Will receive an MRI and a blood draw
2901926|NCT03235401||Pulmonary Arterial Hypertension patients|
2901927|NCT03235388|Experimental|Intervention|Audit filter implementation in hospital
2901928|NCT03235388|No Intervention|Control|Routine care
2901929|NCT03235375|Experimental|Group 1: End Stage Renal Disease (ESRD)|Subjects with CrCl <20ml/min will receive MEDI0382 administered subcutaneously
2901930|NCT03235375|Experimental|Group 2: Severe and ESRD Subjects|Subjects with CrCl >20 and < 30 ml/min will receive MEDI0382 administered subcutaneously
2901931|NCT03235375|Active Comparator|Group 3: Healthy Subjects|Subjects with CrCl >90 ml/min will receive MEDI0382 administered subcutaneously
2901932|NCT03235375|Experimental|Group 4: Moderate Renal Disease|Subjects with CrCl > or equal to 30 and < 60 mL/min will receive MEDI0382 administered subcutaneously
2901933|NCT03235362|Experimental|1|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 3."
2901934|NCT03235362|Experimental|2|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 3."
2901935|NCT03235362|Experimental|3|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1706 QD for 6 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 3."
2901936|NCT03235362|Experimental|4|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1706 QD for 6 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 3.~There will be a washout of at least 10 days between the last dose in one period and the first dose in the subsequent period."
2901937|NCT03235362|Experimental|5|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 3."
2901938|NCT03235362|Experimental|6|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 3."
2901939|NCT03235349|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 or 16 weeks.
2901960|NCT03235167|Experimental|CpG DNA|CpG DNA concentrate
2901961|NCT03235167|Placebo Comparator|placebo|placebo concentrate
2901962|NCT03235154|Other|Treatment Arm|In this open label, single arm study, all subjects will receive the intervention as prescribed by psychiatrists in the office based opiate addition treatment program.
2902283|NCT03232970|Experimental|FPD group|This group will undergo three months of weekly lectures to incorporate more fiber in their diet.
2901940|NCT03235323|Experimental|ECP group|Patients of ECP group are subjected to a standard ECP protocol one week postoperatively. A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
2901941|NCT03235323|No Intervention|Control group|Patients of Control group received routine medicine treatment postoperatively
2901942|NCT03235297||Healthy subjects|Healthy subjects
2901943|NCT03235297||Subjects with COPD|Subjects with a diagnosis of COPD
2901944|NCT03235284|Active Comparator|kinesiotherapy|A program of therapeutic exercises (GC) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The GC treatment program consists of the following protocols: a) protocol 1: 20 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation),10 minutes diagonal exercise scapula (anterior and posterior elevation) and 10 minutes of exercise for trunk extension; b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training;
2901945|NCT03235284|Experimental|Nintendo Wii|"Nintendo Wii program (GW) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The GW treatment program consists of the following protocols: a) protocol 1 games (Boxing and Soccer); b) protocol 2 games (Golf and running). 20 minutes for each game"
2901946|NCT03235284|Experimental|kinesiotherapy and Nintendo Wii|In GCW program will be performed 20 minutes GC protocol (1 or 2, used alternately between sessions a week) and 20 minutes GW protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols.
2901947|NCT03235271||Group A: Large-Vessel Ischemic Stroked|Group A will include subjects that present with focal neurological deficits and clinical features consistent with ischemic stroke with a large vessel occlusion (see Key Terms for definition). Subjects in this group will have a clinical presentation consistent with ischemic stroke and a large vessel occlusion confirmed through angiography. It is common practice to have the CTA completed immediately after CT imaging. Clinical presentation will include classic features of stroke syndromes that occur based on the localization of the infarct, which includes cortical symptoms that can be lateralized to the left side or right side of the brain.
2901948|NCT03235271||Group B: Hemorrhagic Stroke|Subjects in this group will present with symptoms similar to Group A. In addition, they will present with clinical symptoms consistent of increased intracranial pressure such as nausea, vomiting, loss of consciousness and severe headache. In order for a subject to be eligible, the hemorrhage will be limited to primarily intracerebral hemorrhage with a minimum volume of 10mL. Subarachnoid hemorrhage and intraventricular hemorrhage may also be present as incidental findings. Since it is unlikely that these subjects proceed for neuro-intervention, they will not have a follow-up BrainPulse recording and they will be exited after completing study procedures.
2901949|NCT03235271||Group C: Transient Ischemic Attack|Subjects in this group will present with focal neurological symptoms consistent with stroke. In order for subjects to be eligible for this group, enrollment will need to be within 6 hours of resolution of symptoms along with a confirmation of TIA by treating team. In addition, initial and follow-up radiological imaging needs to show that there are no signs of ischemic stroke or hemorrhage.
2901950|NCT03235271||Group D: Non-Stroke Subjects|Subjects in this group will present with stroke-like symptoms but do not have a diagnosis of stroke nor TIA. In order to qualify for this group, subjects will also need to show evidence of no stroke on radiological imaging (CT and/or MRI). Diagnoses in this group may include seizure, systemic infection, brain tumor, metabolic disorder, positional vertigo, hemiplegic migraine, encephalopathy, cranial nerve injury, spinal cord injury, brachial/sacral plexus injury, peripheral nerve injury, etc.
2901951|NCT03235245|Active Comparator|ARM A: Nivolumab + Ipilimumab|nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression. Then treatment will be left at the investigator choice and continued until the 2nd progression.
2901952|NCT03235245|Experimental|ARM B: Encorafenib + Binimetinib + Nivolumab + Ipilimumab|encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks followed, after a week of pause, by nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections, followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression. Then patients will be rechallenged with encorafenib 450 mg QD + binimetinib 45 mg BID orally continuously until the 2nd progression.
2901953|NCT03235232|Experimental|BREMEN eye drops|1 drop in affected eye(s), each 12 hours for 8 weeks.
2901954|NCT03235232|Active Comparator|Combigan® and Azopt® concomitantly|"1 drop of Combigan® in affected eye(s), each 12 hours for 8 weeks.~1 drop of Azopt® in affected eye(s), each 8 hours for 8 weeks."
2901955|NCT03235219|Experimental|Cohort 1 to 4: JNJ-64565111 or Placebo|Participants in cohort 1 to 4 in a ratio of 4:1 will receive a dose of JNJ-64565111 or placebo subcutaneously on Days 1, 8, 15 and 22. Cohort 1, 2 and 3 will be dosed in parallel. Dosing for subsequent cohort 4 will be escalated based on review by the Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29, but will not exceed from well-tolerated dose.
2901956|NCT03235219|Experimental|Cohort 5: JNJ-64565111 (Repeat or Lower Dose) or Placebo|Participants in ratio of 4:1 will receive a dose of JNJ-64565111 or placebo subcutaneously on Days 1, 8, 15 and 22, and may be modified. The dose can be repeated or lower than a dose previously assessed as well tolerated.
2901957|NCT03235193|Experimental|With InSight|Healthcare provider receives an alert from InSight for patients trending towards severe sepsis. Healthcare provider also receives information from the severe sepsis detector in the CHH electronic health record.
2901958|NCT03235193|Active Comparator|Without Insight|Healthcare provider does not receive any alerts from InSight. Healthcare provider receives information from the severe sepsis detector in the CHH electronic health record.
2902794|NCT03229395||patients with Cushing's syndrome|Patients were selected by the PI at the diagnosis.
2901963|NCT03235141|Experimental|azithromycin eye drops by essex|In one cycle, give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the AzaSite eye drops,2.5ml/25mg，1 drop，once.
2901964|NCT03235141|Active Comparator|AzaSite|In one cycle, give the AzaSite eye drops,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once.
2901965|NCT03235128||Group1|Steroid sensitive nephrotic syndrome(10 cases).
2901966|NCT03235128||Group2|Steroid resistant nephrotic syndrome(10 cases).
2901967|NCT03235128||Group3|immunosuppressive resistant nephrotic syndrome(10 cases).
2901968|NCT03235128||Group4|Refractory nephrotic syndrome(10 cases).
2901969|NCT03235128||Group5|Normal children as a healthy control group(5 cases).
2901970|NCT03235115|Active Comparator|Methafilcon A IV|Subjects are randomized to wear Methafilcon A IV for 1 hour during the cross over study.
2901971|NCT03235115|Active Comparator|Ocufilcon B|Subjects are randomized to wear Ocufilcon B for 1 hour during the cross over study.
2901972|NCT03235115|Active Comparator|Omafilcon A|Subjects are randomized to wear Omafilcon A for 1 hour during the cross over study.
2901973|NCT03235102||People with Obesity|People with obesity, or weight loss patients. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
2901974|NCT03235102||Healthcare Providers|PCPs will include family practitioners; general practitioners; internal medicine; nurse practitioners; and dietitians. Specialists will include endocrinologists and bariatric surgeons, and any of the above if they focus on obesity treatment. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
2901975|NCT03235102||Employers|Employers in Canada. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
2901976|NCT03235076|Experimental|Subjects with mild renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
2901977|NCT03235076|Experimental|Subjects with moderate renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
2901978|NCT03235076|Experimental|Subjects with severe renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
2901979|NCT03235076|Experimental|Matched healthy subject group|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
2901980|NCT03235050|Experimental|MEDI0382 low dose + Metformin|Drug: MEDI0382 low dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
2901981|NCT03235050|Experimental|MEDI0382 mid dose + Metformin|Drug: MEDI0382 mid dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
2901982|NCT03235050|Experimental|MEDI0382 high dose + Metformin|Drug: MEDI0382 high dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
2901983|NCT03235050|Placebo Comparator|Placebo + Metformin|Drug: Placebo Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
2901984|NCT03235050|Active Comparator|Liraglutide + Metformin|Drug: Liraglutide Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
2901985|NCT03235037|Other|Sinemet|The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
2901986|NCT03235024|Active Comparator|B244|"B244 suspension in 30ml/bottle~Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day"
2901987|NCT03235024|Placebo Comparator|Vehicle|"Vehicle, 30ml/bottle~Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day"
2901988|NCT03234998|Experimental|motor-cognitive dual-task training|Participants in the motor-cognitive dual-task training group will participate in 12-session programs administered for 60 minutes each session, 3 times per week for 4 weeks.
2901989|NCT03234998|Active Comparator|cognitive dual-task training|Participants in the cognitive dual-task training group will also participate in a 12-session program conducted 60 minutes per session, 3 days a week, for a total of 4 weeks.
2901990|NCT03234985||acute myeloid leukemia patients|Patients over 18 years with acute myeloid leukemia
2901991|NCT03234972|Experimental|Arm A: Daratumumab, Velcade, and Dexamethasone (DVd)|Participants will receive daratumumab as an intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, every 3 weeks (q3w) on Day 1 of Cycles 4-9, and then every 4 weeks (q4w) thereafter, Velcade at a dose of 1.3 milligram per square meter (mg/m^2) subcutaneous (SC) on Days 1, 4, 8 and 11 of each 21-day cycle (up to 8 treatment cycles) and dexamethasone (Dex) orally (PO) at 20 milligram (mg) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the 8 Velcade treatment cycles.
2901992|NCT03234972|Experimental|Arm B: Velcade and Dexamethasone (Vd)|Participants will receive Velcade SC at a dose of 1.3 mg/m^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle and Dex 20 mg PO on Days 1, 2, 4, 5, 8, 9, 11, 12 (up to 8 cycles).
2901993|NCT03234959|Experimental|CareToy Intervention|Infants will perform individualized goal-directed activities for 30-45 minutes per day with CT system, while continuing SC. The CT training will be monitored and modified remotely by clinical staff, according to infants' developmental needs, abilities and progresses. It will last 8 wks.
2901994|NCT03234959|Active Comparator|Infant Massage|Infants and their caregivers will perform 4-5 sessions (around 1 hour every 2 weeks) of Infant massage conducted by an expert child therapist. The therapist will instruct the parent in the baby's massage and provide advises on promoting development. Parents will be invited to perform infant massage five days a week, for 8 weeks. Parent will take a diary in which will record the frequency of the IM.
2901995|NCT03234946|No Intervention|Group A|Relatives of patients with diabetes who will only attend sessions at the center along with the patients on all the interventions of the center (except psychology and psychiatry), receiving instructions from each area on the first and fourth visit. When the patient with diabetes is in the psychology or psychiatry consultation, the relative will also be evaluated in these areas in an analogue form.
2902024|NCT03234751|Active Comparator|Obese nondiabetic insulin resistant subjects- Panel B|IV nesiritide 2 pmol/kg/min or placebo for nesiritide
2902795|NCT03229395||control patients|Selected patients are matched for age and sex.
2901996|NCT03234946|Experimental|Group B|Relatives who will receive multidisciplinary care at the center The subjects from group B will be asked to be accompanied by another relative. If they accept, they will be included as a patient of the CAIPaDi program to receive all the interventions of the second, third and fourth visits in an individual form, without following the patient with diabetes.
2901997|NCT03234933|Experimental|Mobility Tracker|"Each patient will be provided by the research team staff with a new mobility tracker~The standard pre-operative assessment, surgical procedure and post-operative care will still be done~Measurements of each patient (steps, distance and calories) will be obtained by the research staff"
2901998|NCT03234920|Placebo Comparator|Group 1- Control Group|Placebo The placebo will be 200 ml of fruit juice twice a day. Placebo will be provided for 12 weeks
2901999|NCT03234920|Experimental|Group 2 - Treatment group|HMB Supplementation with 1.5 g of HMB dissolved in 200 ml of fruit juice and taken twice daily. Supplementation will be provided for 12 weeks
2902000|NCT03234907|Experimental|Induction Phase: Vedolizumab 300 mg|Vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, and 6 in the induction phase.
2902001|NCT03234907|Placebo Comparator|Induction Phase: Placebo|Vedolizumab placebo-matching IV, infusion, at Weeks 0, 2, and 6 in the induction phase.
2902002|NCT03234907|Experimental|Maintenance Phase: Vedolizumab 300 mg Q8W + Placebo Q8W|Vedolizumab 300 mg, IV, infusion, every 8 Weeks (Q8W), at Weeks 14, 22, 30, 38, 46 and 54 and vedolizumab placebo-matching IV, infusion Q8W at Weeks 18, 26, 34, 42, 50 and 58 in the maintenance phase in participants who receive vedolizumab in the induction phase and achieve clinical response at Week 10.
2902003|NCT03234907|Experimental|Maintenance Phase: Vedolizumab 300 mg Q4W|Vedolizumab 300 mg, IV, infusion, every 4 weeks (Q4W), from Week 14 to Week 58 in the maintenance phase in participants who receive vedolizumab or placebo in the induction phase and do not achieve clinical response at Week 10.
2902004|NCT03234907|Placebo Comparator|Maintenance Phase: Placebo|Vedolizumab placebo-matching IV, infusion, every 4 weeks, Week 14 to Week 58 in the maintenance phase in participants who receive placebo in the induction phase and achieve clinical response at Week 10.
2902005|NCT03234881|Active Comparator|MOVE!|Weight management delivered as Treatment-as-Usual
2902006|NCT03234881|Experimental|MOVE!+gshCBT|Weight management delivered as Treatment-as-Usual plus use of a short duration, low-intensity CBT for recurrent binge eating.
2902007|NCT03234868|Experimental|Optical impression|The optical impression system used for the study is TRIOS (3 shape). First of all, the operators in charge of taking the digital impressions are going to get trained prior the study and will calibrate (learning curve). MIS Scan bodies will be placed on the multi-unit plaforms, an x-ray will be taken in order to check the fit) and the impression will be realised following the instruction given by the system (first the maxillary and mandibular impressions followed by the bite registration). Shade will be chosen using VITA toothguide 3D master (to pick the right zirconia shade).
2902008|NCT03234868|Active Comparator|Conventional impression|Once the impression coping is placed on the multi-unit plaform, the fit will be checked with an intra-oral X-ray. The impressions will be made with medium viscosity silicon. As a second step, alginate antagonist impression will be done. Bite will not be recorded (single tooth missing). The two impressions will be placed in a hermetic plastic bag and send to lab. Shade will be chosen using VITA toothguide 3D master.
2902009|NCT03234868|Experimental|Digital workflow|The implant crowns issued from digital impressions will be done according a cast less / full digital workflow. The STL files collected from the TRIOS will be sent directly to the lab. The designing of the full zirconia crowns will be performed in the TRIOS 3SHAPE program. The resulting files will be sent to the CAM unit production (Amman Girrbach milling machine & MAZAK CNC machine: Mcenter to be specify (Berlin or Israel) to be milled (milled & sintered only) considering the direct adaption for a Multi-Unit connection. A superficial make-up will be done on the monolithic crown in the lab. And finally, the products will be delivered to the dentist.
2902010|NCT03234868|Active Comparator|Conventional workflow|"The implant crowns issued from conventional impressions will be realised by sending the impressions to the lab (Mirko Picone). The lab will pour the impressions in dental stone (class 4 scannable without powdering: extra hard and scanning powder included). Then, the technician will realize a mock-up of the crown's framework on a temporary abutment in DuraLay Resin.~The mock up will be scanned with ZIRKONZAHN scanner (or equivalent) and send this information to a central fabrication facility for milling (Amman Girrbach milling machine & MAZAK CNC machine:~Mcenter: to be specify (Berlin or Israel). The lab technician will get the Zi framework back and will apply veneer ceramic."
2902011|NCT03234855||LMD|Physician uses LMD during procedure.
2902012|NCT03234842|Experimental|Proton|Proton beam therapy of 59.4 Gy in 1.8 Gy fractions (50.4 Gy if unable to meet cardiac/lung- organs at risk (OAR) constraints) plus concurrent standard chemotherapy
2902013|NCT03234842|Active Comparator|Photon|Photon Radiation therapy of 59.4 Gy in 1.8Gy fractions ( 50.4 Gy if unable to meet cardiac/lung- organs at risk (OAR) constraints) plus concurrent standard chemotherapy
2902014|NCT03234816|Experimental|- 0.05 mcg /Kg/min group|will receive norepinephrine 0.05 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
2902015|NCT03234816|Experimental|- 0.1 mcg /Kg/min group|will receive norepinephrine 0.1 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
2902016|NCT03234816|Experimental|- 0.15 mcg /Kg/min group|will receive norepinephrine 0.15 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
2902017|NCT03234803|Experimental|poly-amide|poly-amide is a thermoplastic material recently introduced to be used as a complete denture material, that provide excellent aesthetics and flexibility.
2902018|NCT03234803|Active Comparator|poly-methyl methacrylate|poly-methyl methacrylate has been commonly used as a material for constructing complete dentures and proved to have high success rate and considered to be gold standard.
2902019|NCT03234790|Active Comparator|Filtered Air Exposure|Exposure for 4 hours to filtered air
2902020|NCT03234790|Experimental|Diesel Exhaust Exposure|Volunteers exposed to different concentrations of diesel exhaust
2902021|NCT03234777|Experimental|Whiteboard animation video|3 minute video on treatment, management of pediatric acute gastroenteritis
2902022|NCT03234777|Sham Comparator|Regular video|3 minute video on hand washing for infection control
2902023|NCT03234751|Active Comparator|Obese nondiabetic insulin resistant subjects- Panel A|IV nesiritide 3 pmol/kg/min or placebo for nesiritide
2902025|NCT03234738|Active Comparator|Cohort A|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.5 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
2902026|NCT03234738|Active Comparator|Cohort B|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 1.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
2902027|NCT03234738|Active Comparator|Cohort C|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
2902028|NCT03234738|Active Comparator|Cohort D|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.5 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
2902029|NCT03234738|Active Comparator|Cohort E|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 3.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
2902030|NCT03234725||LCI out group|
2902031|NCT03234725||WL (white light) out group|
2902032|NCT03234712|Experimental|ABBV-321|ABBV-321 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
2902033|NCT03234699|Experimental|Single Group|
2902034|NCT03234686|Experimental|Deferiprone|Patients will orally receive the equivalent 15 mg/kg of 600mg delayed release Deferiprone tablets twice daily.
2902035|NCT03234686|Placebo Comparator|Placebo|Patients will receive matching placebo tablets designed to mimic the experimental treatment, twice daily
2902036|NCT03234673|Experimental|Group A (Tacrolimus group):|fractional CO2 laser therapy and Tacrolimus ointment 1
2902037|NCT03234673|Experimental|Group B (Calcipotriol group):|fractional CO2 laser therapy and Calcipotriol ointment
2902038|NCT03234673|Experimental|Group C (NB-UVB group):|fractional CO2 laser therapy and NB-UVB twice weekly
2902039|NCT03234660|Experimental|Dexmedetomidine|
2902040|NCT03234660|Placebo Comparator|control|
2902041|NCT03234647|Experimental|AHF patients|AHF patient treatment with the Doraya catheter
2902042|NCT03234634|No Intervention|Group 1: patients with good collateral|
2902043|NCT03234634|Experimental|Group 2a, patient with poor collaterals|Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
2902044|NCT03234634|No Intervention|Group 2b, patients with poor collaterals|Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
2902045|NCT03234621|Experimental|conventional tidal group|provide tidal volume of 6ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
2902046|NCT03234621|Experimental|low tidal group|provide tidal volume of 4ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
2902047|NCT03234621|Experimental|high tidal group|provide tidal volume of 8ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
2902048|NCT03234608|Experimental|Intervention|Patients will use the AASPIRE Healthcare Toolkit and will share a copy of their Autism Healthcare Accommodations Report with their primary care provider.
2902049|NCT03234608|No Intervention|Control|Patients will receive usual care.
2902050|NCT03234595|Experimental|single arm|There is 1 treatment arm with 4 dose cohorts in Phase I and 1 treatment arm in Phase IIa.
2902051|NCT03234569|Experimental|sonoHSG|This is the research procedure and it will be added onto the standard of care procedure for all subjects.
2902052|NCT03234556|Active Comparator|Arm I (SR-Bx)|Patients undergo SR-Bx. If SR-Bx doesn't reveal clinically significant cancer, then MRI will be done in 3 months, and if lesion is present (PIRADS ≥ 3) schedule for MRUS-Bx. If there is no lesion, then no biopsy. Schedule MRI in 12 months after the initial MRI.
2902053|NCT03234556|Experimental|Arm II (MRI, MRUS-Bx, SR-Bx)|"Patients undergo MRI. Must be scheduled at least one day before MRUS biopsy.~If MRI shows no lesion present (PIRADS 1-2), then no MRUS-Bx. Schedule for SR-Bx only.~If MRI shows lesion present (PIRADS ≥ 3), perform MRUS-Bx, which will be done first and followed immediately by SR-Bx."
2902054|NCT03234543|Experimental|Remote Ischemic Conditioning|The RIC intervention consists of 5 minutes of inflation of a pneumatic tourniquet placed mid-thigh followed by 5 minutes of deflation, repeated for 3 cycles. The pressure used will be 250 mmHg for the pre-operative intervention. Subsequent tourniquet pressures will be 50 mmHg above the patient's systolic blood pressure.
2902055|NCT03234543|Sham Comparator|No Remote Ischemic Conditioning|The No RIC group will receive a sham intervention at all the same time points. The thigh tourniquet will be inflated to only 20 mmHg (to mask the intervention from the subject).
2902056|NCT03234530||WTC responders|WTC Health Program participants
2902057|NCT03234530||Urban workers|Control group of urban workers in NYC not exposed to the dust from the WTC
2902058|NCT03234517|Experimental|Vaginal Clindamycin Cream Plus continuous Vaginal Probiotic|Vaginal Clindamycin Cream followed by continuous Vaginal Probiotic use for 60 days
2902059|NCT03234517|Active Comparator|Vaginal Clindamycin Cream Plus interrupted Vaginal Probiotic|Vaginal Clindamycin Cream followed by interrupted Vaginal Probiotic use
2902060|NCT03234504||Normal healthy volunteers|
2902061|NCT03234491|Active Comparator|A-HCL low|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
2902062|NCT03234491|Active Comparator|A-HCL high|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
2902121|NCT03234062|Experimental|50% Cho, 100% Cho, 25% Cho|Diets containing 275mg (50% Cho diet), 550mg (100% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
2902063|NCT03234491|Active Comparator|R-HCL|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
2902064|NCT03234478||GBA mutation carriers without DBS|Parkinson's disease patients who have moderate to advanced disease but have not undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
2902065|NCT03234478||non-mutation carriers without DBS|Parkinson's disease patients who have moderate to advanced disease but have not undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
2902066|NCT03234478||GBA mutation carriers with DBS|Parkinson's disease patients who have moderate to advanced disease and have undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
2902067|NCT03234478||non-mutation carriers with DBS|Parkinson's disease patients who have moderate to advanced disease and have undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
2902068|NCT03234465|Experimental|AG013: three mouth rinses/day|Subjects will rinse three times per day with AG013 mouth rinse beginning from the start of radiotherapy until 2 weeks following its completion. The active treatment phase lasts for 7 to 9 weeks, depending on the duration of radiotherapy.
2902069|NCT03234465|Placebo Comparator|Placebo: three mouth rinses/day|Subjects will rinse three times per day with placebo mouth rinse beginning from the start of radiotherapy until 2 weeks following its completion. The active treatment phase lasts for 7 to 9 weeks, depending on the duration of radiotherapy.
2902070|NCT03234452|Experimental|Lactoflorene plus|10 ml mixture of Lactobacillus acidophilus LA-5®, Bifidobacterium animalis subsp. lactis, BB-12®, Lactobacillus paracasei subsp. paracasei, L. CASEI 431® , Bacillus coagulans BC513, zinc and B-vitamins (niacin, B1, B2, B5, B6, B12 and folic acid) twice a day
2902071|NCT03234452|Placebo Comparator|Placebo Lactoflorene plus|Identical placebo mixture without probiotics, B-vitamins and zinc. The active and placebo products had similar appearance, taste and smell and were provided in identical bottles of 10 ml with identical labelling.
2902072|NCT03234439|Experimental|myStrength Intervention|The myStrength intervention arm will be encouraged to utilize the chronic pain offering consisting of 6 modules. Each module has 5 activities and can take on average 5-15 minutes to complete. Study participants assigned to the myStrength intervention will have one week to complete each module. In addition to completing the required chronic pain modules, study participants in the myStrength intervention arm will have the option to also select other areas of interest and complete corresponding activities at their own pace. myStrength utilization will be recorded and analyzed.
2902073|NCT03234439|No Intervention|Waitlist Control|The waitlist control group will gain access to the myStrength platform 180 days following the start of the study.
2902074|NCT03234426|Experimental|Experimental Group|manual perturbations were given in forward, Backward,right and left sideways, 10 perturbations were given,6 days in week,in fallowing positions- sitting,kneeling, standing positions
2902075|NCT03234426|Placebo Comparator|Control group|Conventional Physiotherapy were given 6 days in a week, for 30 mins for 4 weeks, includes stretching, strengthening of contralateral limbs
2902076|NCT03234400|Experimental|25 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 25 mg to be replaced every 4 weeks for 8 weeks, then worn for an additional 5 weeks for a total of 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
2902077|NCT03234400|Experimental|100 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 100 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
2902078|NCT03234400|Experimental|200 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 200 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
2902079|NCT03234387||Cystic fibrosis (CF) with established CF-related diabetes|"Cystic fibrosis (CF) with established CF-related diabetes~Inclusion criteria:~Males and females ≥ 12 years of age~CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride > 60 mmol·L-1 > 100 mg sweat) and, where possible, diagnostic genotyping~Established CFRD in accordance with the most recent American Diabetes Association positional statement]. This statement recommends CFRD is diagnosed using a 2 hour OGTT. However, the present study will also include those based on fasting plasma glucose and glycated hemoglobin levels, when symptoms of diabetes are also present:~2 hour OGTT plasma glucose ≥ 200 mg.dL-1 (11.1 mmol.L-1)~Fasting plasma glucose ≥ 126 mg.dL-1 (7.0 mmol.L-1)~Glycated hemoglobin ≥ 48 mmol/mol~No contraindications to performing exhaustive exercise~Can understand and cooperate with the study protocol~No increase in symptoms or weight loss in the preceding 2 weeks"
2902080|NCT03234387||Cystic fibrosis (CF) without established CF-related diabetes|"Cystic fibrosis (CF) without established CF-related diabetes~Inclusion criteria:~Males and females ≥ 12 years of age~CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride > 60 mmol·L-1 > 100 mg sweat), where possible, diagnostic genotyping would also be desired~No evidence of established, gestational or exacerbation induced CFRD in accordance with the American Diabetes Association criteria (stated above; [110]).~No contraindications to performing exhaustive exercise~Can understand and cooperate with the study protocol~No increase in symptoms or weight loss in the preceding 2 weeks"
2902081|NCT03234387||Healthy controls|Age- and gender-matched healthy control participants.
2902082|NCT03234374|Experimental|INL-001|3 x 100 mg INL-001 (bupivacaine HCl collagen implants). Total bupivacaine HCl dose 300 mg.
2902083|NCT03234374|Active Comparator|Marcaine 0.25% infiltration|Marcaine 0.25% infiltration (bupivacaine HCl 175 mg).
2902084|NCT03234361|Experimental|High Phosphate Phase|All subjects will be on a low Pi diet containing 700mg/day of phosphate and 2 capsules of sodium phosphate with 500mg/day of phosphate for 4 weeks.
2902085|NCT03234361|Placebo Comparator|Low Phosphate Phase|All subjects will be on a low Pi diet containing 700mg/day of phosphate and 2 capsules of sodium chloride for 4 weeks.
2902086|NCT03234348|Experimental|Magmaris|Percutaneous coronary intervention by means of Magnesium-based sirolimus-eluting bioresorbable scaffold implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.
2902602|NCT03230578||Women|Reproductive age, 18-45 years old from rural counties in New Mexico and who are fluent in English.
2902087|NCT03234348|Placebo Comparator|Orsiro|Percutaneous coronary intervention by means of Biodegradable polymer sirolimus-eluting stent implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.
2902088|NCT03234335||Myeloma patients with severe renal impairment|Myeloma patients with severe renal impairment. Data collection will concern myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation.
2902089|NCT03234322|Experimental|Intervention group|In the intervention group the routine health check is expanded by usage of a non-invasive diabetes risk score.
2902090|NCT03234322|No Intervention|Control group|In the control group the routine health check is conducted.
2902091|NCT03234309|Experimental|Diagnostic (ferumoxytol, MRI)|Patients undergo MRI with GBCA per standard of care over 45-60 minutes and then receive ferumoxytol IV followed by MRI over 10 minutes on day 1. Patients may optionally undergo MRI over 30 minutes without any contrast agent on day 2. Each study visit consisting of 2 days may repeat no more frequently than 4 weeks for up to 5 study visits at different stages of the disease as determined by the investigator.
2902092|NCT03234296|Active Comparator|Antibiotic treatment|Ertapenem 1 g x 1 intravenously for 3 days, followed by per oral levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 4 days, duration of treatment 7 days.
2902093|NCT03234296|Active Comparator|Placebo|Intravenous placebo once a day for 3 days, followed by per oral placebo for 4 days with similar p.o. tablets as in the antibiotic group.
2902094|NCT03234283|Experimental|Study intervention group|All participants will be intubated with a video-laryngiscope by guiding the tracheal tube according to the highlighted Larynx on the Video Screen.
2902095|NCT03234270|Experimental|F35 pilots|
2902096|NCT03234270|Active Comparator|F15 pilots|
2902097|NCT03234257|Other|patients with carotid stenosis.|asymptomatic patients with carotid stenosis.
2902098|NCT03234244|Active Comparator|Bazedoxifene 20mg|Subjects will take bazedoxifene 1 Tablet.
2902099|NCT03234244|Active Comparator|Cholecalciferol|Subjects will take Cholecalciferol 2 Tablets.
2902100|NCT03234244|Experimental|Bazedoxifene 20mg and Cholecalciferol|Subjects will take bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
2902101|NCT03234231|No Intervention|Control Group|This group receive nothing during the study period.
2902102|NCT03234231|Experimental|Intervention Group|A 3-month supervised tooth brushing programme will be provided to the students. An oral health education talk with written material delivered to the carers and the students
2902103|NCT03234205|Experimental|MRI scan during free respiration|
2902104|NCT03234192|Active Comparator|Therapeutic ultra sound|
2902105|NCT03234192|Active Comparator|Astym Treatment Technique|
2902106|NCT03234192|Active Comparator|Graston Treatment Technique|
2902107|NCT03234153|Experimental|Durvalumab and Tremelimumab|Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
2902108|NCT03234140||"Group Genome Wide Association Studies"|"Patients are adults, male or female, with a follicular lymphoma, homogeneously treated by immunochemotherapy included in one of the following cohorte :~PRIMA Cohort : phase III (Sponsor LYSARC, France; NCT00140582): N=396~RELEVANCE Cohort : phase III (Sponsor LYSARC, France; NCT01476787 ): N=441~FOLL05 Cohort: phase III (Sponsor Italian lymphoma Foundation, Italy; NCT00774826): N=229~MER1 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987): N=178~MER2 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987):N=321~Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data."
2902109|NCT03234140||"Group EPIC"|"Patients are adults, male or female, included in the EPIC Cohort (European Prospective Investigation Into Cancer and Nutrition study between 1992 and 2000. (Sponsor IARC, Lyon, France).~The investigators plan to analyze the influence of single-nucleotide polymorphisms on circulating t(14;18) levels in these 318 healthy individuals including 100 who will develop follicular lymphoma later on, and assess if these biomarkers are helpful to refine the identification of high-risk follicular lymphoma individuals."
2902110|NCT03234127|Other|Atherosclerosis- resistance|FH Patient without atherosclerosis
2902111|NCT03234127|Other|Control|FH patient with atheroclerosis
2902112|NCT03234114|Experimental|4 weeks TT|Randomized control group; Triple antithrombotic therapy (warfarin with targeted INR 2.0-2.5, clopidogrel 75 mg per day and aspirin 100 mg per day) for 4 weeks then warfarin (targeted INR 2.0-2.5) plus clopidogrel 75 mg per day till 12 months after PCI
2902113|NCT03234114|Experimental|6 months TT|Randomized control group; Triple antithrombotic therapy (warfarin with targeted INR 2.0-2.5, clopidogrel 75 mg per day and aspirin 100 mg per day) for 6 months then warfarin (targeted INR 2.0-2.5) plus clopidogrel 75 mg per day till 12 months after PCI
2902114|NCT03234114|Experimental|12 months DT|A prospective cohort group; Dual antithrombotic therapy (dabigatran 110 mg b.i.d. plus ticargrelor 90 mg b.i.d.or clopidogrel 75 mg qd) for 12 months after PCI
2902115|NCT03234088|Other|Home HF monitoring|Digital scale readings are transmitted wirelessly to the handheld device. Patients will remotely log on to a secure server to answer daily symptom questions. Patients will complete surveys after voluntarily completing the informed consent process and at study closeout.
2902116|NCT03234075||Control group|Patients supported without regional organization for promotion of renal transplantation Setting : French Auvergne Rhone Alpes region and French Center region
2902117|NCT03234075||Intervention group|Patients supported with the regional organization for promotion of renal transplantation Setting : French Auvergne Rhone Alpes region
2902118|NCT03234062|Experimental|25%Cho, 50%Cho, 100%Cho|Diets containing 137.5mg (25% Cho diet), 275mg (50% Cho diet), and 550mg (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
2902119|NCT03234062|Experimental|25% Cho, 100% Cho, 50% Cho|Diets containing 137.5mg (25% Cho diet) , 550mg (100% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
2902120|NCT03234062|Experimental|50% Cho, 25% Cho, 100% Cho|Diets containing 275mg (50% Cho diet), 137.5mg (25% Cho diet), and 550mg Cho (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
2902603|NCT03230565|Active Comparator|Continuous Infusion|Local anesthetic medication (Ropivacaine 0.2%) is provided at a continuous basal rate.
2902122|NCT03234062|Experimental|100% Cho, 25% Cho, 50% Cho|Diets containing 550mg (100% Cho diet), 137.5mg (25% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
2902123|NCT03234062|Experimental|100% Cho, 50% Cho, 25% Cho|Diets containing 550mg (100% Cho diet), 275mg (50% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
2902124|NCT03234049|No Intervention|Control Arm|In the control arm, teams will not receive a copy of the checklist for use.
2902125|NCT03234049|Experimental|Checklist Arm|In the intervention arm, the participants will watch a 10 minute recorded educational video demonstrating the use of the trauma checklist prior to their simulation scenario. These teams will subsequently receive a copy of the checklist for use during their simulation scenario.
2902126|NCT03234036|Experimental|Treatment sequence ABC: Part 1|"A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 1 in Part 1A.~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 2 in Part 1A.~Both these treatments in Part 1A will be administered with RTV in fed state with a washout of 10 days.~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.~There will be a wash out of 15 days between Part 1A and Part 1B."
2902127|NCT03234036|Experimental|Treatment sequence BAC: Part 1|"A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 1 in Part 1A.~A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 2 in Part 1A.~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.~There will be a wash out of 15 days between Part 1A and Part 1B."
2902128|NCT03234036|Experimental|GSK2838232 tablet without RTV: Part 2|In Part 2, subjects will receive non-RTV boosted GSK2838232 500 mg, given as single daily doses for 11 days. The dose will not exceed 500 mg (as 5 x 100 mg tablets) once daily (QD).
2902129|NCT03234036|Placebo Comparator|Placebo without RTV: Part 2|In Part 2, subjects will receive a Placebo given as single daily doses for 11 days.
2902130|NCT03234023|Active Comparator|INTERVENTION GROUP|The participants of this group will follow recommendations of food, physical exercise, control of consumption of drugs and consumption of alcohol and tobacco.
2902131|NCT03234023|No Intervention|CONTROL GROUP|The participants of this group are submitted to the standard intervention.
2902132|NCT03234010|Experimental|FT21092 Group|7 day at-home use of electronic cigarette FT21092 followed by a 2 day in-clinic period.
2902133|NCT03234010|Experimental|FT21093 Group|7 day at-home use of electronic cigarette FT21093 followed by a 2 day in-clinic period.
2902134|NCT03234010|Experimental|FT21096 Group|7 day at-home use of electronic cigarette FT21096 followed by a 2 day in-clinic period.
2902135|NCT03234010|Experimental|FT21097 Group|7 day at-home use of electronic cigarette FT21097 followed by a 2 day in-clinic period.
2902136|NCT03233997|Experimental|FT21018 Group|7 day at-home use of electronic cigarette FT21018 followed by a 2 day in-clinic period.
2902137|NCT03233997|Experimental|FT21033 Group|7 day at-home use of electronic cigarette FT21033 followed by a 2 day in-clinic period.
2902138|NCT03233997|Experimental|FT21034 Group|7 day at-home use of electronic cigarette FT21034 followed by a 2 day in-clinic period.
2902139|NCT03233997|Experimental|FT21035 Group|7 day at-home use of electronic cigarette FT21035 followed by a 2 day in-clinic period.
2902140|NCT03233984|No Intervention|Leaflet only|Women will only receive a leaflet about endocrine disruptor at home.
2902141|NCT03233984|Active Comparator|non immersive program|In addition of the leaflet, women will sit in the sensibilisation program that will take place in a neutral environment
2902142|NCT03233984|Experimental|immersive program|In addition of the leaflet, women will si in the sensibilisation program that will take place in an immersive environment
2902143|NCT03233971||Older adults|
2902144|NCT03233971||Caregivers|
2902145|NCT03233958||Workshop participants|Participants of systemic / family constellation workshops
2902146|NCT03233932|Active Comparator|LeuplinⓡInj|LeuplinⓡInj(=leuprorelin acetate 3.75mg)
2902147|NCT03233932|Experimental|CKD-841|CKD-841(=leuprorelin acetate 3.75mg)
2902148|NCT03233919|Experimental|CORIC|"Comprehensive remote ischaemic conditioning (CORIC) will be induced using an automated RIC device:~Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.~Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.~Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI."
2902149|NCT03233919|No Intervention|Non-CORIC|Controls did not undergo comprehensive remote ischaemic conditioning.
2902150|NCT03233906|Active Comparator|Chia Seeds|10% of a participants total kcal estimated needs given in chia seeds everyday for 8 weeks.
2902151|NCT03233906|No Intervention|Control|Habitual diet with avoidance of high fiber and high omega-3 fatty acid foods.
2902152|NCT03233893|Experimental|light activated calcium silicate|Apply light activated calcium silicate in deep occlusal caries lesions and taking the base line image for the first group after restoring the cavity with composite restoration and taking the follow up x-ray image after one year to measure the calcific bridge formation.
2902153|NCT03233893|Active Comparator|light activated calcium hydroxide|Apply the light activated calcium hydroxide in deep occlusal carious lesions and taking the base line image for the second group after restoring with composite restoration and taking the follow up x-ray image after one year to measure the calcific bridge formation.
2902154|NCT03233880|Active Comparator|Azithromycin group|Azithromycin 1Gm orally, single dose (Xithrone 500 mg two tablets, Amoun, Inc, Cairo, Egypt) will be given to pregnant women at 16/20 weeks of pregnancy
2902155|NCT03233880|Placebo Comparator|placebo group|- Matching placebo orally, single dose
2902212|NCT03233438|Active Comparator|Usual Care|Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
2902156|NCT03233854|Experimental|Treatment (CD19/CD22 CAR T cells, chemotherapy)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine phosphate IV over 30 minutes on days -5 to -3. Patients then receive CD19/CD22 CAR T cells IV over 10-20 minutes on day 0. Patients that benefited from the first dose of CD19/CD22 CAR T cells, had no unacceptable side effects, and have enough cells left over may receive 2 or 3 additional doses of CD19/CD22 CAR T cells.
2902157|NCT03233841||Living non-HSCT Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are currently alive and have not undergone hematopoietic stem cell transplantation (HSCT).
2902158|NCT03233841||Living HSCT Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are currently alive and have undergone hematopoietic stem cell transplantation (HSCT).
2902159|NCT03233841||Deceased Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are deceased (including patients who may or may not have undergone hematopoietic stem cell transplantation).
2902160|NCT03233828|Experimental|Intralesional IL-2 Injection|Two subcutaneous intralesional injections of Aldesleukin, prepared by the pharmacy such that the contents will be masked, will be administered by the care provider in a clinic seven days apart.
2902161|NCT03233828|Placebo Comparator|Saline Injection|Two subcutaneous intralesional injections of Saline, prepared by the pharmacy such that the contents will be masked, will be administered by the care provider in a clinic seven days apart.
2902162|NCT03233815||Inhaled anesthesia (Sevoflurane)|Patients undergoing cardiovascular surgery with inhaled anesthesia with sevoflurane.
2902163|NCT03233815||Total Intravenous Anesthesia (Propofol)|Patients undergoing cardiovascular surgery with total intravenous anesthesia with propofol.
2902164|NCT03233802|Experimental|Individualized Assess & Treatment (IATP)|Intervention: Cognitive-Behavioral IATP consists of 12 weekly visits of individual treatment. IATP employs cellphone-based experience sampling via interactive voice response (IVR) to assess drinking, plus craving, thoughts, feelings, and coping behaviors to develop near a real-time picture of patients' high-risk situations and the ways they use to deal with them. This information will be used by the therapist and client together to problem-solve and devise adaptive coping responses to these specific high-risk situations, and develop generalized solutions to deal with other situations in the future.
2902165|NCT03233802|Active Comparator|Packaged Cognitive-Behavioral (PCBT)|Intervention: Cognitive-Behavioral PCBT consists of 12 weekly visits of individual treatment. PCBT is designed to remediate deficits in skills for coping with interpersonal (e.g., social pressure, conflict with others) and intrapersonal (e.g., craving, anger) antecedents to drinking. The treatment consists of 6 mandatory modules (e.g., managing cravings) plus 6 electives from a list of 10 (e.g., receiving criticism; scheduling pleasant activities).The treatment, based on manuals developed for our previous clinical research provides a structured experience using didactic presentations, behavioral rehearsal, and homework practice exercises.
2902166|NCT03233802|Active Comparator|Case Management (CaseM)|Intervention: Social and Instrumental Support CaseM is included to control for cohort and other common factors in treatment. During the 12 individual CaseM sessions the therapist and participant will identify problems in daily living that may be of concern, and consider community resources that might help in dealing with them (e.g., contacting a psychiatrist for depression, or finding a better place to live). The therapist's role is to explore the patient's concerns, help to identify goals and resources, provide verbal support, and troubleshoot difficulties that may arise in obtaining or following through with services. The support and attention to ancillary services has proven effective in reducing drinking in previous studies.
2902167|NCT03233776|Experimental|Anakinra|Dosage form: intravenous. Dosage: either 100 mg, 200 mg or 300 mg. Frequency: once daily. Duration: 15 days (day -2 until day +12).
2902168|NCT03233750|Experimental|Stress Inoculation Training|"Phase 1: Conceptualization / Educational Phase (60 minutes) Provision of preparatory information, to allow the participants to form accurate expectations regarding the stress environment and stress reactions.~Phase 2: Skill Acquisition and Rehearsal (60 minutes) Development and practice of cognitive restructuring techniques and relaxing training to reduce anxiety and enhance the individual's capacity to respond effectively to stressful situations, in low stress conditions.~Phase 3: Application of Coping Skills (180 minutes) Coping skills are applied in increasingly stressful conditions that approximate the real-world stressor environment."
2902169|NCT03233750|Active Comparator|Crisis Resource Management Training|The CRM training targets the non-technical skills (e.g. behavioural and cognitive skills) required for effective teamwork during crisis situations. It focuses on communication, teamwork, situational awareness and leadership
2902170|NCT03233737|Experimental|CTY-5339-A Anesthetic Spray - 1 Spray|Benzocaine 14% + Tetracaine 2% in 200 uL per spray
2902171|NCT03233737|Active Comparator|CTY-5339-CB Anesthetic Spray - 1 Spray|Benzocaine 14% in 200 uL per spray
2902172|NCT03233724|Experimental|2/Dose Expansion|DAC-THU + pembrolizumab at the dose established in Arm 1
2902173|NCT03233724|Experimental|1/Dose Escalation|DAC-THU + pembrolizumab at escalating doses
2902174|NCT03233711|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 14 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2902175|NCT03233711|No Intervention|Arm B (clinical observation)|Patients undergo observation.
2902176|NCT03233685|Experimental|Experimental Group|Subjects will perform a visual training for 12 weeks
2902177|NCT03233685|Active Comparator|Control Group|Subjects will perform the normal training routine for 12 weeks
2902178|NCT03233672|Other|Hypo-fractionated postoperative IMRT-SIB|All patients underwent combined, intensified and modulated radiotherapy for five days a week with the following doses: 62.5 Gy to the prostate bed and 45 Gy to pelvis nodes in 25 fractions.
2902179|NCT03233659||BMT patients|All patients undergoing Allogeneic Stem Cell Transplantation are enrolled in the study.
2902180|NCT03233646|Experimental|Case|100 patients with MCI and/or AD
2902181|NCT03233646|Active Comparator|Controls|Controls will be recruited from the relatives/attendants of the patients , or will be patients themselves, and will not have a diagnosis of MCI/AD.
2902182|NCT03233633|Other|Single treatment arm|marijuana adjuvant treatment group utilizing scheduled opioid therapy in inpatient hospice hospital setting
2902183|NCT03233620|Other|working age patients|Prospective cohort of 250 patients.
2902279|NCT03232983|Experimental|LY900014 (SC Abdomen)|Single dose of LY900014 administered subcutaneously (SC) into the abdomen in one period
2902184|NCT03233607||Antepartum Patients|Includes antepartum patients receiving prenatal care at the Broadway Practice who plan to deliver at Allen Hospital in New York City (NYC). On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation.
2902185|NCT03233594||Chiropractic Group|Participants receiving chiropractic care will complete initial pain evaluations and questionnaires for chronic pain symptoms. After approximately 8 weeks participants will receive follow evaluation for pain. Pre and Post PET-MRI scan will be conducted to evaluate changes.
2902186|NCT03233594||Healthy Control Group|Participants will receive initial evaluations and questionnaires followed by a PET-MRI scan.
2902187|NCT03233581|Experimental|Fitbit + Facebook + Health Coaching|Participants will use the Fitbit device and join the Facebook group. They will also receive brief weekly health coaching from a research staff. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide them with support.
2902188|NCT03233581|Active Comparator|Usual care control with Fitbit only|Participants will be loaned a Fitbit device only. They will not join the Facebook group nor receive health coaching. They will not select an adult family member or friend to receive a Fitbit device to provide them with support.
2902189|NCT03233568||Indirect Calorimetry group (IC group)|Group who performed indirect calorimetry. REE measured by indirect calorimetry.
2902190|NCT03233568||NO Indirect Calorimetry group (NO-IC group)|Group who did not perform indirect calorimetry. Resting Energy Expenditure calculated by Harris-Benedict formula
2902191|NCT03233555|Active Comparator|Arm I (brochure)|Participants receive National Cancer Institute's Facing Forward brochure.
2902192|NCT03233555|Experimental|Arm II (EXCELS website)|Participants have untimed access to the EXCELS mobile web application.
2902193|NCT03233555|Experimental|Arm III (Healthcare coaching call)|Participants also receive 4 quarterly calls of 15-20 minutes each over 3 months. These calls focus on checking if patients have received preventive and cancer related follow-up care.
2902194|NCT03233555|Experimental|Arm IV (EXCELS website, health coaching calls)|Participants have access to EXCELS as in Arm II. Participants also receive 4 calls as in Arm III.
2902195|NCT03233542|Experimental|Panic Disorder: CBT|Participants with Panic Disorder randomized to this arm will receive a manualised Cognitive Behaviour Therapy (CBT) treatment for Panic Disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
2902196|NCT03233542|No Intervention|Panic Disorder: Waiting list|After the pre-treatment testing session, participants with Panic Disorder randomized to this arm will wait a length of time equivalent to that for the pre/post-treatment duration for the Panic Disorder: Cognitive Behaviour Therapy arm (approx. 3 months), before returning to the post-treatment assessment. After completing all the study procedures, participants in this arm receive also the manualised Cognitive Behaviour Therapy treatment for Panic Disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
2902197|NCT03233542|Other|Anxious Control Group: CBT|All participants in the Anxious Control Group will receive a manualised Cognitive Behaviour Therapy (CBT) treatment for their diagnosed anxiety disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
2902198|NCT03233529|Experimental|Crisaborole ointment|
2902199|NCT03233529|Placebo Comparator|Placebo ointment (vehicle)|
2902200|NCT03233516||Cases with clinical CAP|Children 1-59 months at Sachs' Children and Youth Hospital with clinical CAP (both severe and non-severe) according to WHO-criteria.
2902201|NCT03233516||Control subjects|Children 1-59 months at Sachs' Children and Youth Hospital treated for a minor orthopedic (elective (e.g. hand surgery) or acute) or minor surgical disease, e.g. minor trauma (excluding e.g. appendicitis, major burns, major trauma).
2902202|NCT03233503||Dutch trained taste panel|The study population consists of a sample of 15 healthy Dutch males and females, recruited in the Wageningen area.
2902203|NCT03233503||Malaysian trained taste panel|The study population consists of a sample of 20 healthy Malaysian males and females, recruited in the Subang Jaya, Selangor area.
2902204|NCT03233490|Experimental|CPR training and web corse intervention|The students performed a web course (Help Brain Heart) prior training
2902205|NCT03233490|Experimental|CPR training intervention|CPR training without web course
2902206|NCT03233477||Posner-Schlossman Syndrome|"Inclusion criteria：~Clinical diagnosis of Posner-Schlossman Syndrome~Able to communicate with doctor and understand this study~Exclusion criteria:~Not be able to communicate with doctor and understand this study~One or more authorized investigators think he or she will suffer from any severe risks from the study"
2902207|NCT03233477||cataract|"Inclusion criteria：~Clinical diagnosis of age-related cataract~Prepare for cataract operation~Open angle and intraocular pressure is normally at anytime~No family history of glaucoma~Exclusion criteria:~Patients above 65 years old~With Secondary ocular hypertension~Have the history of receiving any ophthalmologic operation or anti-viral therapy~With diabetes mellitus~With autoimmune disease~Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month"
2902208|NCT03233477||primary open-angle glaucoma|"Inclusion criteria：~Both eyes involved~Open angle~Progressive glaucomatous optic neuropathy~Specific visual field loss of glaucoma~Intraocular pressure above the up limit of normal people~Exclusion criteria:~Patients above 65 years old~With Secondary ocular hypertension~Have the history of receiving any ophthalmologic operation or anti-viral therapy~With diabetes mellitus~With autoimmune disease~Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month"
2902209|NCT03233451|Experimental|Interventional group|Subjects receive guided psycho-behavioral intervention once a week for 8 weeks. After 8 weeks, the subjects will receive monthly psychological counseling for 7 months.
2902210|NCT03233451|No Intervention|control group|Subjects will receive usual care and be contacted as same frequent as the intervention group.
2902211|NCT03233438|Active Comparator|New Critical Pathway|The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
2902796|NCT03229382|Experimental|Obinutuzumab 1000 mg IV infusion, day: 1, 8, 15, 22|
2902213|NCT03233412|Other|Control|Will be offered the standard treatment, which is the conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).
2902214|NCT03233412|Experimental|Imiquimod|Will receive topical uterine cervix (Imiquimod) treatment for a period of 12 weeks with weekly applications (1x / week). 30-60 days afterwards they will be submitted to standard treatment with conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).
2902215|NCT03233399|Active Comparator|Healthy Patients|All healthy volunteers will complete the healthy volunteer form, MRI safety screening form, and the Montreal Cognitive Assessment (MOCA).
2902216|NCT03233399|Active Comparator|PMD/PNES patients|PMD and PNES subjects will be referred by the treating
2902217|NCT03233386||Condition 1|Mexico City Cohort
2902218|NCT03233386||Condition 2|Monterrey Cohort
2902219|NCT03233386||Condition 3|Guadalajara Cohort
2902220|NCT03233373||Otolaryngology Clinic Patients|Healthy subjects with no present complaints of nasal obstructions. Patients visiting the clinic, once consented, will be asked which nostril they breathe better from. They will then be asked to perform 3-4 normal respiration cycles through their nose which will be recorded using our thermal imaging device, the Seek CompactPro thermal imager
2902221|NCT03233347|Experimental|Treatment (combination chemotherapy, nivolumab)|Patients receive doxorubicin hydrochloride IV over 3-5 minutes, vinblastine IV over 3-5 minutes, and darcarbazine IV over >= 30 minutes, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients with PET-positive then receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. PET-positive patients then receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or unacceptable toxicity. PET-negative patients receive nivolumab IV over 60 minutes on day 1 starting after AVD and BV treatment. Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
2902222|NCT03233334|Experimental|Purpose Project Group|Group receiving Purpose Project intervention.
2902223|NCT03233321|Experimental|Experimental group|30 patients were selected in experimental group. Dry cold was applied to the subcutaneous injection site using ice bag filled with crushed ice with half table spoon of salt for 20 minutes after the administration of injection.Pain intensity was measured using numeric pain rating scale immediately after dry cold application and bruise size was assessed using bruise assessment scale after 12, 48 and 72 hrs of injection administration.
2902224|NCT03233321|No Intervention|Comparison group|No intervention was given. Pain intensity was measured using numeric pain rating after 20 minutes of subcutaneous injection and bruise size was assessed using bruise assessment scale after 12, 48 and 72 hrs of injection administration.
2902225|NCT03233308|Experimental|Netarsudil Ophthalmic Solution 0.02%|Netarsudil ophthalmic solution 0.02%; 1 drop daily, in the morning (QD AM), topical ocular; one eye for 7 days
2902226|NCT03233308|Placebo Comparator|Placebo Comparator|Netarsudil ophthalmic solution placebo; 1 drop in the morning (QD AM) on contralateral eye for 7 days
2902227|NCT03233295|Experimental|Vitamin D deficiency|
2902228|NCT03233282|Other|Cognitive Fatigability|
2902229|NCT03233282|Other|Physical Fatigability|
2902230|NCT03233269|Experimental|Music Therapy Group|Music therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Music therapy is an established health profession in which music is used within a therapeutic relationship to address physical, emotional, cognitive, and social needs of individuals (American Music Therapy Association [AMTA], 2013, para 1 and 2).
2902231|NCT03233256|Experimental|Healthy adults (18-45 yrs.)|Healthy adults (18-45 yrs.) will be recruited from the local Denver area. The investigators have elected to study a relatively homogenous sample to limit the impact of age, weight, and chronic disease on isotope fractionation in breath.
2902232|NCT03233243|Experimental|Patients with positive 18F-NaF plaques|Patients with 18F-NaF-positive plaques (coronary, aortic or carotid) with TBR > 1.5
2902233|NCT03233243|No Intervention|Patients without 18F-NaF-positive plaques|Subjects without 18F-NaF- positive plaques will be excluded from the pharmacological intervention study
2902234|NCT03233230|Experimental|Evobrutinib Low Dose|
2902235|NCT03233230|Experimental|Evobrutinib Mid Dose|
2902236|NCT03233230|Experimental|Evobrutinib High Dose|
2902237|NCT03233230|Placebo Comparator|Placebo|
2902238|NCT03233217|Experimental|Cohort 1: QIV-HD by IM|Participants in Cohort 1 will be randomized to receive a single injection of QIV-HD by IM route on Day 0.
2902239|NCT03233217|Experimental|Cohort 1: QIV-HD by SC|Participants in Cohort 1 will be randomized to receive a single injection of QIV-HD by SC route on Day 0.
2902240|NCT03233217|Experimental|Cohort 2: QIV-HD by IM|Participants in Cohort 2 will be randomized to receive a single injection of QIV-HD by IM route on Day 0.
2902241|NCT03233217|Experimental|Cohort 2: QIV-HD by SC|Participants in Cohort 2 will be randomized to receive a single injection of QIV-HD by SC route on Day 0.
2902242|NCT03233217|Active Comparator|Cohort 2: QIV-SD by SC|Participants in Cohort 2 will be randomized to receive a single injection of QIV-SD by SC route on Day 0.
2902243|NCT03233204|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
2902244|NCT03233191|Experimental|Arm A (digital mammography)|Patients undergo bilateral screening DM with standard CC and MLO views at baseline, 12, 24, 36, and 48 months if pre-menopausal or at baseline, 24, and 48 months if post-menopausal.
2902245|NCT03233191|Experimental|Arm B (digital tomosynthesis mammography)|Patients undergo manufacturer-defined screening TM at baseline, 12, 24, 36, and 48 months if pre-menopausal or at baseline, 24, and 48 months if post-menopausal.
2902246|NCT03233178||SGLT2|Patients initiating SGLT2 inhibitors
2902247|NCT03233178||Liraglutide|Patients initiation liraglutide
2902248|NCT03233178||Sitagliptin|Patients initiating sitagliptin
2902249|NCT03233178||Control Group|Patients who did not initiate any new anti-hyperglycemic treatment
2902280|NCT03232983|Experimental|LY900014 (SC Thigh)|Single dose of LY900014 administered SC into the thigh in one period
2902250|NCT03233165|Experimental|Patients with diagnosed leukoplakia 1|"Patients who meet the conditions of pathohistological diagnosis of leukoplakia and clinical criteria for diagnosis of non-homogeneous leukoplakia.~Intervention using Er:YAG laser"
2902251|NCT03233165|Experimental|Patients with diagnosed leukoplakia 2|"Patients who meet the conditions of pathohistological diagnosis of leukoplakia and clinical criteria for diagnosis of non-homogeneous leukoplakia.~Intervention using Er,Cr:YSGG laser"
2902252|NCT03233152|Experimental|ipilimumab + nivolumab|"Only one study cohort will be predefined in this phase I clinical trial; a classical phase I 3+3 patient recruitment design will be used to guide patient recruitment.~Ipilimumab (YervoyTM, 50 mg/10 mL) will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (2 ml of YervoyTM, 50 mg/10mL vial).~First administration of 10 mg Nivolumab (OpdivoTM, 40 mg/4mL solution) by the intravenous route will be administered within 24 hours prior to the planned neurosurgical resection. The following administrations of 10 mg nivolumab will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary)."
2902253|NCT03233139|Experimental|REGN2810|
2902254|NCT03233126|Experimental|KRN23|
2902255|NCT03233113|Active Comparator|Exposure and response prevention|Exposure therapy with response prevention involves four hour-long individual sessions with a trained exposure therapist. Session 1 involves functional assessment, psychoeducation, presentation of the treatment rationale, and treatment planning. Sessions 2-4 involve a review of the model/treatment rationale, condition-specific reminders about how to prevent engaging in any safety behaviors during exposure, a 30-minute in-vivo exposure trial involving a live tarantula, and post-exposure processing. Session 4 also involves a discussion of relapse prevention strategies.
2902256|NCT03233113|Experimental|Exposure with judicious safety behaviors|Exposure therapy with judiciously used safety behaviors for spider phobia involves four hour-long individual sessions with a trained exposure therapist. Session 1 involves functional assessment, psychoeducation, presentation of the treatment rationale, and treatment planning. Sessions 2-4 involve a review of the model/treatment rationale, condition-specific reminders about how to strategically incorporate safety behaviors during exposure, a 30-minute in-vivo exposure trial involving a live tarantula, and post-exposure processing. Session 4 also involves a discussion of relapse prevention strategies.
2902257|NCT03233100|Experimental|FMT group|
2902258|NCT03233087||Top third of subjects based levels of selected biomarker.|
2902259|NCT03233087||Middle third of subjects based levels of selected biomarker.|
2902260|NCT03233087||Bottom third ofsubjects based levels of selected biomarker.|
2902261|NCT03233074||Acute Myeloid Leukemia patients|For diagnosis purpose, bone marrow sampling is performed for acute myeloid leukemia patients. 2 milliliters of this sample will be collected and analysed for the COSMOS study.
2902262|NCT03233074||Healthy donors|Healthy donors are patients undergoing cardio-vascular surgery for their usual support. During this surgery, 2 milliliters of the bone marrow will be collected, and analysed for the COSMOS study.
2902263|NCT03233061|Active Comparator|NO|NON OBESE WOMEN GROUP ( same age and same physical activities ) cardiorespiratory exercise testing with evaluation of peak oxygen uptake, heart rate and maximal cycling power output. Cardiorespiratory functioning is assessed during household activities such as ironing,cleaning floor,walking and climbing stairs.
2902264|NCT03233061|Experimental|OB|OBESE GROUP cardiorespiratory exercise testing with evaluation of peak oxygen uptake,heart rate and maximal cycling power output.Cardiorespiratory functioning is assessed during household activities such as ironing, cleaning floor, walking and climbing stairs
2902265|NCT03233048|Experimental|ORBERA™ Intragastric Balloon|Participants will have the ORBERA™ Intragastric Balloon inserted for 6 months. In addition, participants will have ongoing visits with a physician, dietitian, and psychologist before the balloon is inserted, while its in place, and for 6 months after the balloon is removed, for a total of approximately 1 year.
2902266|NCT03233035|Placebo Comparator|placebo group|Intranasal placebo pulverisation
2902267|NCT03233035|Active Comparator|Ketamine group|Intranasal ketamine pulverisation
2902268|NCT03233022|Active Comparator|Unchanged Happify|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
2902269|NCT03233022|Active Comparator|Negatively-focused tracks|"Participants use two pre-selected Happify tracks that focus on remediating negatives (e.g. conquering negative thoughts and managing stress). Several engagement elements are missing, including social forums, regular informational emails, and the ability to play games. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period."
2902270|NCT03233022|Active Comparator|Positively-focused tracks|Participants use two pre-selected Happify tracks that focus on improving positives (e.g. building well-being, using one's strengths). Several engagement elements are missing, including social forums, regular informational emails, and the ability to play games. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
2902271|NCT03233022|Placebo Comparator|Placebo condition|Participants complete a Happify program that is designed to engage with specific activities, but that does not aim to promote positive emotion or reduce negative emotion. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
2902272|NCT03233022|Sham Comparator|Distraction condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
2902273|NCT03233009|Experimental|Test Product 1|Participants will topically apply test product 1 via semi occlusive patch.
2902274|NCT03233009|Experimental|Test Product 2|Participants will topically apply test product 2 via semi occlusive patch.
2902275|NCT03233009|Experimental|Test Product 3|Participants will topically apply test product 3 via semi occlusive patch.
2902276|NCT03233009|Experimental|Test Product 4|Participants will topically apply test product 4 via semi occlusive patch.
2902277|NCT03233009|Sham Comparator|Reference Product|Participants will topically apply Reference product via semi occlusive patch.
2902278|NCT03232996|Experimental|Experimental Group|Computer Game based balance and walk rehabilitation
2902284|NCT03232970|No Intervention|FPD Control group|This group will receive all the assessments before, during and after the three months program period but will not attend the weekly lectures.
2902285|NCT03232957|Experimental|No IT morphine|Spinal block with 0.5% isobaric with no intrathecal morphine
2902286|NCT03232957|Experimental|50 ug IT morphine|Spinal block with 0.5% isobaric with 50 ug intrathecal morphine
2902287|NCT03232957|Experimental|100 ug IT morphine|Spinal block with 0.5% isobaric with 100 ug intrathecal morphine
2902288|NCT03232944||CRT non-responders with MPP enabled|Patients enrolled and implanted with a CRT Quad system, who are identified as CRT non-responder, for which MPP is enabled.
2902289|NCT03232931|Experimental|Intervention|The Multisensory intervention will be carried out in addition to standard care and will include 2 components: (1) holding and light pressure containment of the infant against the hospital-gown covered chest of the therapist for tactile and non-specific auditory stimulation simultaneous with (2) playing of mother's voice contingent on infant pacifier sucking for the first 20 minutes of holding. Additionally, a gauze square scented with parent's skin will be used to provide olfactory stimulation.
2902290|NCT03232931|Other|Control (standard of care)|The standard care of infant currently follows 2 medical protocols, one for parental Skin-to-Skin holding and one for exposure to parent's voice.
2902291|NCT03232918|No Intervention|Standard Dose Oxytocin|Patients randomized to the standard dose oxytocin will have their oxytocin infusion maintained at the standard of care protocol prior to placement of a combined spinal epidural for labor analgesia
2902292|NCT03232918|Experimental|Half Dose Oxytocin|Patients randomized to the half dose oxytocin will have their oxytocin infusion reduced by 50 % prior to placement of a combined spinal epidural for labor analgesia.
2902293|NCT03232905|Experimental|PF-06651600|Multiple ascending doses of PF-06651600
2902294|NCT03232905|Placebo Comparator|Placebo|Multiple ascending doses of Placebo
2902295|NCT03232892|Experimental|Trametinib 2.0mg PO daily|Trametinib 2.0mg PO daily in 28-day cycles. A maximum of two trametinib dose level reductions are allowed (1.5mg and 1mg) in the case of adverse reactions.
2902296|NCT03232879|Experimental|Experimental 1|Motor Imagery
2902297|NCT03232879|Experimental|Experimental 2|Action Observation
2902298|NCT03232879|No Intervention|Control Group|No intervention
2902299|NCT03232866|Experimental|Experimental group|(n = 20) will practice Pilates exercises
2902300|NCT03232866|No Intervention|Control group|(n = 20) will not carry out the intervention
2902301|NCT03232827|Active Comparator|Flavored-sweetened|Flavored-sweetened WP tobacco will be associated with longer and more frequent puffing resulting in the greatest overall levels of smoke inhalation (mL of smoke inhaled), highest abuse potential, and greatest levels of exposure to nicotine and carbon monoxide (CO). , followed by unflavored-sweetened WP, and lastly unflavored-very low sweetened WP. (H1d) A majority of WP smokers will report having initiated WP smoking with flavored-sweetened tobacco and report flavoring as an important reason for trying WP.
2902302|NCT03232827|Active Comparator|Unflavored-sweetened|Unflavored-sweetened WP will be associated with the second longest and more frequent puffing resulting in the second greatest overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
2902303|NCT03232827|Active Comparator|Unflavored very low sweetened|Unflavored-very low sweetened WP will be associated with the shortest and the least frequent puffing resulting in the least overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
2902304|NCT03232814|Experimental|Group-based walking|Participants will engage in one supervised outdoor group-based walking session per week for the 8 week program.
2902305|NCT03232801|Experimental|mindfulness group|a multicomponent group-based intervention rooted in mindfulness, administered in 3 sessions over 6 weeks
2902306|NCT03232801|Active Comparator|educational group|a general midlife health and aging educational group, administered in 3 sessions over 6 weeks
2902307|NCT03232788|Experimental|Test group|Bone regeneration with autogenous bone + scaffold.
2902308|NCT03232788|Active Comparator|Control group|Bone regeneration with autogenous bone + collagen membrane.
2902309|NCT03232775|Other|Treatment|Treatment: Physical Exam with Visual Pedagogy and Structure
2902310|NCT03232775|Other|Control|Control: Physical Exam without Visual Pedagogy and Structure
2902311|NCT03232762|Active Comparator|Diet A|high proportion of calories from refined grains as a carbohydrate source
2902312|NCT03232762|Active Comparator|Diet B|a high proportion of calories from whole grains
2902313|NCT03232749|Other|symptomatic primary osteoarthritis of the shoulder|Subjects enrolled into the study will be those who have failed previous treatment including over-the-counter analgesics and activity modification, and have elected to receive a medically-indicated, ultrasound-guided IACSI in the shoulder
2902314|NCT03232736|No Intervention|Healthy Control|
2902315|NCT03232736|Experimental|LVAD Group w/Pacemaker|Pacemaker adjustments will be made to this group in blinded manner.
2902316|NCT03232723|Other|MEG Recording|Magnetic fields will be recorded using a 275-channel whole-head MEG system
2902317|NCT03232710|Experimental|pilot study group|
2902318|NCT03232710|Experimental|group 1 (under fasting condition)|
2902319|NCT03232710|Experimental|group 2 (under fasting condition)|
2902320|NCT03232710|Experimental|group 3 (under fed condition)|
2902321|NCT03232710|Experimental|group 4 (under fed condition)|
2902322|NCT03232697|Other|Healthy subjects|Subjects will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
2902323|NCT03232697|Other|Alzheimer patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
2902324|NCT03232697|Other|Parkinson and Huntington patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
2902325|NCT03232697|Other|Diabetic patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
2902604|NCT03230565|Active Comparator|Intermittent Bolus Infusion|Local anesthetic medication (Ropivacaine 0.2%) is provided in scheduled, intermittent boluses.
2902326|NCT03232645|Other|Rhythmia HDx and DirectSense technology|"Subjects will undergo ablation treatment of the pulmonary veins with the Rhythmia HDx mapping system with DirectSense technology. Subjects indicated for ablation treatment of de-novo PAF will be selected based on the inclusion/exclusion criteria and if deemed to be eligible for participation, will be asked to sign the Informed Consent Form.~For all enrolled subjects who undergo the ablation procedure, the subjects will be treated with the commercial Rhythmia HDx System with commercially available Software Version 2.0 with DirectSense technology (or any commercially available updates that are released during the course of the study); the IntellaMap Orion mapping catheter and the IntellaNav MiFi OI ablation catheter."
2902327|NCT03232632|Experimental|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl®) = product under Alzheimer's disease indication
2902328|NCT03232619|Experimental|CD19-CART with a murine scFv|All enrolled patients in this arm will receive CD19-CART with a murine scFv.
2902329|NCT03232619|Experimental|humanized CD19-CART|All enrolled patients in this arm will receive humanized CD19-CART.
2902330|NCT03232606||Asthmatic children|Asthmatic children aged 6 to 17 year old coming to follow-up at asthma clinic
2902331|NCT03232593||Participants who Receive Atezolizumab|Participants who are administered with atezolizumab as per the local label and standard of care at physician's discretion will be observed for approximately 6 years.
2902332|NCT03232580|Experimental|Patients|All patients will receive a single administration of 99mTc-rhAnnexin V-128 at Day 0.
2902333|NCT03232567|Experimental|NasoVAX low dose|NasoVAX administered by intranasal spray at a single dose of 1×10(9th) viral particles (vp) versus placebo
2902334|NCT03232567|Experimental|NasoVAX medium dose|NasoVAX administered by intranasal spray at a single dose of 1×10(10th) viral particles (vp) versus placebo
2902335|NCT03232567|Experimental|NasoVAX high dose|NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
2902336|NCT03232554|Experimental|Buxue Yimu Pills|Buxue Yimu Pill 12g pill by mouth, twice daily
2902337|NCT03232554|Experimental|Buxue Yimu Pills &Ferrous Sulfate|Buxue Yimu Pill 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
2902338|NCT03232554|Active Comparator|Ferrous Sulfate|Ferrous Sulfate 0.3g tablet by mouth, three times daily
2902339|NCT03232541|Other|Standard care (A)|Standard care (A) with neutral communication (A1) or positive communication (A2)
2902340|NCT03232541|Placebo Comparator|Sham acupuncture (B)|Standard nausea treatment plus Sham acupuncture (B) with neutral communication (B1) or positive communication (B2)
2902341|NCT03232541|Experimental|Genuine acupuncture (C)|Standard nausea treatment plus Genuine acupuncture (C) with neutral communication (C1) or positive communication (C2)
2902342|NCT03232528|Experimental|Herb-partitioned moxibustion|Drug: Herbal cake, Device: Moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Herbal cakes with moxa cones will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
2902343|NCT03232528|Sham Comparator|Sham herb-partitioned moxibustion|Drug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
2902344|NCT03232515|Experimental|Intervention group|Evaluation,estimation and modification of the dry weight by BIVA.
2902345|NCT03232502|No Intervention|Control|
2902346|NCT03232502|Experimental|Intervention|
2902347|NCT03232476|Other|Loaded upper extremity|This is a one-arm study. In postmenopausal women prescribed teriparatide for osteoporosis treatment, enrolled subjects will perform voluntary loading exercises on one upper extremity. A data logger device will assist in recording exercises and determining goal force during the exercises. Each subject's non-loaded upper extremity will serve as a control.
2902348|NCT03232450|Active Comparator|PFO Closure|Subjects randomized to this arm will receive 81 mg enteric coated aspirin, a Cardiovascular Implantable Device (CIED), Gore Cardioform Septal Occluder.
2902349|NCT03232450|Other|Control|Subjects randomized to this arm will receive 81 mg enteric coated aspirin, a Cardiovascular Implantable Device (CIED)
2902350|NCT03232424|Experimental|NovoTTF-200A + Temozolomide Chemoradiation|NovoTTF-200A, concomitant with radiotherapy and temozolomide, as front-line therapy for glioblastoma
2902351|NCT03232398|Active Comparator|Apixaban|Apixaban Oral Tablet [Eliquis]
2902352|NCT03232398|Active Comparator|Warfarin|Warfarin - Vitamin K antagonist
2902353|NCT03232385|Experimental|MR-US Fusion Arm|Clear Guide SCENERGY, MR-US
2902354|NCT03232385|Active Comparator|EM Fusion or No Fusion Arm|
2902355|NCT03232372|Experimental|External-Connection non-submerged Imp|We will place implants with external connection and non- submerged to assess the bone loss around
2902356|NCT03232372|Experimental|Internal Connection Submerged implants|We will place implants with internal connection and submerged to assess the bone loss around
2902357|NCT03232372|Experimental|Internal Connection non-Submerged Impl|We will place Internal connection implant and non-Submerged Implants to assess the bone loss around
2902358|NCT03232359||SPE/HELLP group|This group included 24 pregnant women (gestational age of >20 weeks) who were diagnosed as having TMA with provisional diagnosis of pre-eclampsia, HELLP syndrome. immature platelets fraction assessment within 12 hours of diagnosis
2902359|NCT03232359||TTP/HUS group|This group included 13 pregnant women (gestational age of >20 weeks) who were diagnosed as having TMA with provisional diagnosis of TTP/HUS. HELLP syndrome. immature platelets fraction assessment within 12 hours of diagnosis
2946365|NCT02929160|Experimental|JJ Stent|Retrograde ureteric JJ stent
2902360|NCT03232359||Control group|This group included 20 pregnant women (gestational age of >20 weeks) having normal pregnancy with normal blood pressure and platelet count.
2902361|NCT03232346|Experimental|Regimen 1|Rapid Monday to Friday oral naltrexone-induction procedure
2902362|NCT03232346|Experimental|Regimen 2|5-week buprenorphine taper from maintenance dose of 8, 6, or 4mg
2902363|NCT03232333||MIRODERM|Biologic wound graft
2902364|NCT03232320|Experimental|MEDITOXIN|
2902365|NCT03232320|Placebo Comparator|Placebo|
2902366|NCT03232307|Experimental|Ibrutinib + Rituximab + Lenalidomide|Ibrutinib by mouth each day. Lenalidomide by mouth on Days 1-21. Rituximab by vein on Days 1, 8, 15, and 22 of Cycles 1 and 2. After that, Rituximab by vein on Day 1 of Cycles 3-8 and then every other cycle after that (Cycles 10, 12, 14, and so on). Study cycles are 28 days.
2902367|NCT03232294||the study group|A total of 96 women with low risk pregnancy coming to the clinic for a routine antenatal examination in 26-28th gestational weeks were included to this study
2902368|NCT03232281|Experimental|triptorelin pamoate PR 3-month|
2902369|NCT03232281|Active Comparator|triptorelin acetate PR 1-month|
2902370|NCT03232268|Experimental|HLA-mismatched microtransplantation|HLA-mismatched microtransplantation without immunosuppressive treatment
2902371|NCT03232255|Experimental|Treatment Group|
2902372|NCT03232229||Tennis players|
2902373|NCT03232216|Experimental|Vitamin D3 supplementation. Deficiency.|Vitamin D3 50.000 UI in each packet of powder for solution. Two packets every week for 5 weeks.
2902374|NCT03232216|Placebo Comparator|Placebo. Deficiency.|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 5 weeks.
2902375|NCT03232216|Experimental|Vitamin D3 supplementation.Insufficiency|Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 3 weeks.
2902376|NCT03232216|Placebo Comparator|Placebo. Insufficiency.|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 3 weeks.
2902377|NCT03232203||Health care providers|A HCP survey instrument of approximately 20 questions will be provided. Survey questions will be based on the STRIMVELIS summary of product characteristics and educational materials
2902378|NCT03232203||Parent/carer|A parent/carer survey instrument of approximately 20 questions will be provided. Survey questions will be based on the STRIMVELIS Patient Information Leaflet and educational materials
2902379|NCT03232190|Experimental|INTNIC|NICU Intervention Group Web Application Infants < 32 weeks
2902380|NCT03232190|No Intervention|CNIC|NICU Control Group No Web Application Infants < 32 weeks
2902381|NCT03232190|No Intervention|CMAT|Maternity Unit Control Group No Web Application Infants > 37 weeks
2902382|NCT03232177|Experimental|Anagre Cap.|twice a day
2902383|NCT03232164|Experimental|18F-DCFPyL PET|We will have three separate sub-studies evaluating 18F-DCFPyL PET imaging of prostate cancer in three prostate cancer clinical scenarios under the following subheadings: (1) primary prostate cancer, (2) biochemical recurrence post-prostatectomy prior to radiation therapy, and (3) androgen-resistant metastatic disease.
2902384|NCT03232151|Experimental|C-ARM CBCT|A C-arm CBCT evaluation with SMART RECON novel software for the rapid assessment of time-resolved CT angiogram and CT perfusion.
2902385|NCT03232138|Experimental|Sulforaphane (Study Drug)|Sulforaphane four tablets 2 times per day with breakfast and dinner each dose contains approximately 120 micromole of Sulforaphane
2902386|NCT03232138|Placebo Comparator|Placebo|Placebo (containing no active drug) four tablets 2 times per day with breakfast and dinner
2902387|NCT03232125|Experimental|Ramosetron group|Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.
2902388|NCT03232125|Placebo Comparator|Placebo group|In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
2902389|NCT03232112|Active Comparator|Exenatide 2 MG Injection|Bydureon® (exenatide) is supplied as powder and solvent for prolonged release injection (once-weekly). Bydureon® is delivered in a carton containing four pens. Each single-dose, dual-chamber pen contains 0.65 ml of diluent and 2 mg of exenatide, which are isolated until mixed by the person administering the drug. Needles are supplied with the pen.
2902390|NCT03232112|Placebo Comparator|BD PosiFlush (saline)|The placebo will be supplied for as pre-filled saline syringes (BD PosiFlush™, BD Worldwide) containing 3 ml each. Needles are bought separately.
2902391|NCT03232099|Experimental|Red Wine group (RW)|After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
2902392|NCT03232099|Active Comparator|Abstemious|After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
2902393|NCT03232086|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
2902394|NCT03232086|Active Comparator|Concentrated PM2.5|Exposure to PM2.5 will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
2902395|NCT03232073|Experimental|Ponesimod|20 mg administered orally once daily
2902396|NCT03232047|Experimental|Adaptive Working Memory Training|The training is considered 'adaptive', which means that the difficulty level of the tasks increases during the sessions according to the individual level of mastering for each participant, making the patient work at their maximum capacity at all times.
2902397|NCT03232047|No Intervention|Waiting-list control group|Participants in the control condition will conduct the same training as the intervention group after a 24-week waiting period. During the 24-week waiting period, the participants will receive assessment with the same protocol as the interventional group.
2902398|NCT03232034|Placebo Comparator|Calcium Citrate|Calcium citrate (1000 mg calcium) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
2902399|NCT03232034|Active Comparator|Milk Mineral Supplement|Milk mineral supplement (equating to 1000 mg calcium) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
2902797|NCT03229369|Active Comparator|Isolated ACL|Standard Anterior Cruciate Ligament Reconstruction only
2902400|NCT03232034|Experimental|Milk mineral supplement plus Whey Protein Hydrolysate|Milk mineral supplement (equating to 1000 mg calcium) plus whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
2902401|NCT03232021|Placebo Comparator|Group I|Administration of a placebo capsule 1 hour prior to the surgical operation
2902402|NCT03232021|Experimental|Group II|Administration of 75mg of pregabalin 1 hour prior to the surgical operation
2902403|NCT03232021|Experimental|Group III|Administration of 150mg of pregabalin 1 hour prior to the surgical operation
2902404|NCT03232008|Experimental|Canderel|Canderel drink (3g in 250ml water)
2902405|NCT03232008|No Intervention|Control|3g of maltodextrin in 250 ml of water
2902406|NCT03231995|Experimental|Respiratory microbiome biomarkers|
2902407|NCT03231982|Experimental|Group I|Fixed-Dose combination of Candesartan cilexetil 8mg and Amlodipine 5mg(or Fixed-Dose combination of Candesartan cilexetil 16mg and Amlodipine 5mg), once a day for 8 weeks
2902408|NCT03231982|Active Comparator|Group II|Candesartan cilexetil 8mg and Amlodipine 5mg(or Candesartan cilexetil 16mg and Amlodipine 5mg), once a day for 8 weeks
2902409|NCT03231969|Experimental|Bilastine 0.2%|
2902410|NCT03231969|Experimental|Bilastine 0.4%|
2902411|NCT03231969|Experimental|Bilastine 0.6%|
2902412|NCT03231969|Placebo Comparator|Bilastine 0%|
2902413|NCT03231956||Group 0|Control Sepsis Mimic Group (minor infections or asthma/COPD exacerbations) venous blood lactate levels are not required for this subgroup.
2902414|NCT03231956||Group 1|Suspected infection plus Initial Venous Blood Lactate ≥ 0 - 1.9 mmol/dL
2902415|NCT03231956||Group 2|Suspected infection plus Initial Venous Blood Lactate ≥ 2.0 - 3.9 mmol/dL
2902416|NCT03231956||Group 3|Suspected infection plus Initial Venous Blood Lactate ≥ 4.0 mmol/dL
2902417|NCT03231943|Experimental|Subjects in cohort 1-2: Part 1|Eligible subjects will participate in cohort 1 or 2 and each of these two cohorts will contain up to four escalating doses of GSK3640254. In each cohort, 6 subjects will be randomized to receive single oral dose of GSK3640254 and 2 subjects will be randomized to receive placebo. Hence, each subject in cohort 1 and 2 will receive up to 3 escalating doses of GSK3640254 and one placebo in crossover manner.
2902418|NCT03231943|Experimental|GSK3640254 receivers (cohort 3-6 and expansion): Part 2|Eligible subjects will participate in one of the 4 cohorts (3,4,5,6). In each cohort, 6 subjects will be randomized to receive a once-daily oral dose of GSK3640254 for 14 days. After the safety data of cohort 3-6 is available, 18 eligible subjects will be randomized to receive once daily oral dose of GSK3640254 for 14 days in expansion cohort.
2902419|NCT03231943|Placebo Comparator|Subjects receiving placebo (cohort 3-6): Part 2|Eligible subjects will participate in one of the 4 cohorts (3,4,5,6). In each cohort, 2 subjects will be randomized to receive a once-daily oral dose of placebo for 14 days. After the safety data of cohort 3-6 is available, 6 eligible subjects will be randomized to receive once daily oral dose of placebo for 14 days in expansion cohort.
2902420|NCT03231930|Experimental|Intervention group|Rapid point of care testing will be done using the OraQuick HCV Ab test and the Xpert HCV RNA viral load test. All participants will undergo rapid point of care testing for hepatitis C antibodies using the OraQuick test with oral fluid, followed by point of care testing for the detection of hepatitis C virus RNA using the Cepheid Xpert HCV viral load test on the GeneXpert system. Participants who are found to have current HCV infection will be worked up for treatment at the clinic and referred to appropriate practitioners for HCV treatment. As these tests are not yet licensed for diagnostic use in Australia, confirmatory testing using standard laboratory tests will be performed for all participants.
2902421|NCT03231917|Experimental|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
2902422|NCT03231917|Experimental|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion.
2902423|NCT03231878|Active Comparator|Active|
2902424|NCT03231878|Placebo Comparator|Placebo|
2902425|NCT03231865||Preoperative patients|Patients present themselves before an operation to the Anesthesiologist. They are screened for study eligibility.
2902426|NCT03231852||Study Population|Women with a gynecologic malignancy will complete several surveys to assess their willingness to participate in clinical trials.
2902427|NCT03231839|Placebo Comparator|Caloric restriction (control)|daily reduction of caloric intake aimed at 400 kcal/day
2902428|NCT03231839|Active Comparator|No red meat|daily reduction of caloric intake aimed at 400 kcal/day plus no red meat intake
2902429|NCT03231839|Active Comparator|Increased fiber intake|daily reduction of caloric intake aimed at 400 kcal/day plus increased fiber intake (aim: 40gr/day)
2902430|NCT03231813|Experimental|SLS irritation model and Treatment|SLS induced irritation on two sites each on forearms and back Emollient cream treatment
2902431|NCT03231813|Placebo Comparator|SLS irritation model and No Treatment|SLS induced irritation on two sites each on forearms and back No treatment
2902432|NCT03231813|Sham Comparator|Sham irritation and Treatment|Sham irritation (water) on two sites each on forearms and back Emollient cream treatment
2902433|NCT03231813|No Intervention|Sham irritation and No Treatment|Sham irritation (water) on two sites each on forearms and back No treatment
2902434|NCT03231800|Experimental|Dasotraline|Dasotraline capsule 2mg/day
2902435|NCT03231800|Placebo Comparator|Placebo|Placebo capsule
2902436|NCT03231787|Experimental|Experimental group|"In this group the platelet aggregability will be evaluated and if it is normal, the surgery will be performed within 24-48 hours.~If it is not normal, the evaluation of platelet aggregability will be repeated daily until the third day or until it is normalized if it is earlier.~If at the third day is not normalized, it will proceed as with the control group, which will take into account the safety time of the drug."
2902437|NCT03231787|No Intervention|Control group|The control group will wait for the safety time of the drug according to the usual practice of the center.
2902438|NCT03231761|Experimental|Service user testimonial videos|Videos with service user testimonials about depression and psychosis
2902605|NCT03230552|Experimental|Video group|Residents assigned to this group will watch an instructional surgical video prior to LSO surgery.
2902439|NCT03231761|Active Comparator|mhGAP didactic video|The intervention in the active comparator arm includes two didactic videos with instruction about depression and psychosis based on the World Health Organization mental health Gap Action Programme (mhGAP) modules for those conditions
2902440|NCT03231761|No Intervention|No video|Participants do not observe any videos prior to the assessment
2902441|NCT03231735|Other|Mid frequency ventilation|Mid frequency ventilation delivered at rates > 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.
2902442|NCT03231735|Other|Standard frequency ventilation|Standard frequency ventilation delivered at rates < 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.
2902443|NCT03231722|Active Comparator|mFOLFOX6 + Panitumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1 (if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes) followed by~Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 in two-way with~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by~5-fluorouracil 400 mg/sqm iv bolus, day 1 followed by~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance with 5FU/LV plus pan at the same dose used at the last cycle of the induction treatment. 5FU/LV plus pan will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. The prosecution of pan until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
2902444|NCT03231722|Experimental|mFOLFOXIRI + Panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1 (if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes) followed by~Irinotecan 150 mg/sqm iv over 60 minutes day 1, followed by~Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance with 5FU/LV plus pan at the same dose used at the last cycle of the induction treatment. 5FU/LV plus pan will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. The prosecution of pan until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
2902445|NCT03231709|Experimental|Trelagliptin 100 mg + Alogliptin 25 mg|Trelagliptin preceding group (T-A group): 100 mg of trelagliptin tablets, orally, once a week for 8 weeks, followed by 25 mg of alogliptin, orally, once a day for 8 weeks.
2902446|NCT03231709|Experimental|Alogliptin 25 mg + Trelagliptin 100 mg|Alogliptin preceding group (A-T group): 25 mg of alogliptin, orally, once a day for 8 weeks, followed by 100 mg of trelagliptin, orally, once a week for 8 weeks.
2902447|NCT03231696||Patients receiving Regional Anesthesia|All patients 18 years or older with a peripheral nerve block at Charité - Universitätsmedizin Berlin Campus Charite Mitte from 2012 to 2016.
2902448|NCT03231683|Active Comparator|Esketamine|Esketamine and remifentanil to be given alongside with propofol through target control infusion pump.
2902449|NCT03231683|Placebo Comparator|Control|Saline and remifentanil to be given alongside with propofol through target control infusion pump.
2902450|NCT03231670||lobar pneumonia|Inpatient with lobar pneumonia will undergo a blood sampling during their hospitalization and after resolution of the infection (2 Months)
2902451|NCT03231657|Experimental|Incorporation of the sFlt1/P1GF ratio|"Incorporation of the ratio in the diagnosis and classification of pre-eclampsia:~sFlt1/PlGF ratio >38: pre-eclampsia risk~sFlt1/PlGF ratio >85: pre-eclampsia~ISSHP pre-eclampsia definition + ratio >210: severe PE~ISSHP pre-eclampsia definition + ratio sFlt1/PlGF ratio >600: consider deliver"
2902452|NCT03231657|No Intervention|Routine clinical practice|Criteria for the definition of PE were those of the International Society for the Study of Hypertension in Pregnancy
2902453|NCT03231644||FD/MAS Patients|Patients with fibrous dysplasia and/or McCune-Albright syndrome and related disorders.
2902454|NCT03231631|Experimental|Education plan and adherence to exercise|"Educational talk about the importance of nutrition and exercise as an important strategy to change cardiovascular risk factors at the start of the study.~It will be sent via text, whatsapp, and / or e-mail on a weekly basis three text messages that remind them of the importance of doing the exercise and how often they should do it, it will be a predetermined text."
2902455|NCT03231631|No Intervention|Control|"The blood sample will be taken for the collection of serum HDL and the aerobic capacity test measured in MET will be recorded at the beginning of the study.~A survey will be conducted at week 12 of monitoring where adherence to exercise is measured during the 12-week study."
2902456|NCT03231618|Experimental|Normal weight group|20 normal-weight males taking 3 types of assigned diets in random orders
2902457|NCT03231618|Experimental|Overweight/ obesity group|20 overweight/ obesity males taking 3 types of assigned diets in random orders
2902458|NCT03231605|Experimental|Group 1|Group 1 is experimental group which used the Hepatitis A Vaccine product by Changchun Institute of Biological Co.,Ltd
2902459|NCT03231605|Active Comparator|Group 2|Group 2 is control group which used the Hepatitis A Vaccine product by Changchun Changsheng Life Sciences Limited
2902460|NCT03231592|Experimental|CSA Group|This group will receive CSA Shares (a selection of fresh fruits and vegetables from a local farm) each week for 24 weeks over the summer of 2017 and 2018. The CSA does not operate over the winter.
2902461|NCT03231592|Active Comparator|Enhanced Usual Care Group|This group will receive a handout about healthy eating, in addition to routine care in their primary care practice.
2902462|NCT03231566|Active Comparator|Usual education control group (CG)|The CG received the traditional hospital preoperative program, which was consistent with current preoperative TKA protocols. The CG received education covering anatomy of the knee joint, information about the joint replacement surgery, what to expect when they were admitted for surgery, what to expect immediately after surgery, pain medications, postoperative rehabilitation/physical therapy, etc. The CG received a hospital-based booklet with this information.
2902463|NCT03231566|Experimental|Experimental group (EG)|The EG underwent an additional 30-minute group PNE program, followed by the usual preoperative education program from the hospital. The PNE program used in this TKA study was an adaptation of the PNE program developed for LS. The educational program was designed to be delivered by a physical therapist in a group session to patients prior to their TKA.
2902927|NCT03228498|Placebo Comparator|Placebo|"Placebo and Drug: Nimodipine 90 mg per day only~concomitant administration"
2902464|NCT03231553|Experimental|Intervention|"Receive usual NHS antenatal care and any NHS smoking cessation support which they choose to access plus an NHS leaflet giving advice on stopping smoking.~Receive MiQuit text message cessation programme."
2902465|NCT03231553|No Intervention|Control|Receive usual NHS antenatal care and any NHS smoking cessation support which they choose to access plus an NHS leaflet giving advice on stopping smoking.
2902466|NCT03231540|Experimental|intervention group|whey protein supplement enriched enteral nutrition, with protein intake of 1.5g/kg/day; in addition to standardized exercise training
2902467|NCT03231540|No Intervention|control group|standard enteral nutrition, with protein intake of 1g/kg/day; in addition to standardized exercise training
2902468|NCT03231527||Total Arterial coronary CABG|Total Arterial revascularization
2902469|NCT03231527||Saphenous vein based CABG|Saphenous vein based revascularization
2902470|NCT03231514|Placebo Comparator|Carbohydrate Diet & Placebo & Exercise|This group receives the carbohydrate-based diet and flavored placebo pre-workout drink. All participate in the exercise intervention.
2902471|NCT03231514|Active Comparator|Carbohydrate Diet & Carbohydrate Supplement(Carb10) & Exercise|This group receives the carbohydrate-based diet and supplemental carbohydrate. Will be compared to Carbohydrate & Placebo for effects of supplement. All participate in the exercise intervention.
2902472|NCT03231514|Experimental|Ketogenic Diet & Placebo & Exercise|This group receives the ketogenic diet and flavored placebo. It is both an experimental (vs. carbohydrate diet & placebo) and placebo control group (vs. ketogenic & supplement). All participate in the exercise intervention.
2902473|NCT03231514|Experimental|Ketogenic Diet & Carbohydrate Supplement (Carb10) & Exercise|This group receives the ketogenic diet and supplemental carbohydrate. All participate in the exercise intervention.
2902474|NCT03231501|Experimental|single arm|This is a single arm study. It is an open-label study. The intervention is eptinib succinate.
2902475|NCT03231488|Experimental|Mindfulness intervention|
2902476|NCT03231488|Active Comparator|Control intervention (unfocused attention)|
2902477|NCT03231475|Experimental|SPH1188-11|SPH1188-11 dose escalation, 50mg/100mg/200mg/300mg/450mg/600mg
2902478|NCT03231436|Experimental|Fixed dose of 12.5mg bupivacaine|Participants that receive the same dose of intrathecal bupivacaine and 25mcg of fentanyl, regardless of their height.
2902479|NCT03231436|Active Comparator|Height-adjusted dose of bupivacaine|Participants that receive the dose of intrathecal bupivacaine adjusted to their height and 25mcg of fentanyl
2902480|NCT03231423|Experimental|DRAIN PLACEMENT|Effects of drainage
2902481|NCT03231423|No Intervention|DRAIN NOT PLACED|Effects of not using drain
2902482|NCT03231397|Other|Control Group|"Six control subjects (three males and three females) with known atherosclerosis by standard clinical criteria without aneurysmal disease.~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
2902483|NCT03231397|Other|Small AAA's|"Six subjects (three males and three females) with small AAAs (diameter 3.0-4.5cm).~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
2902484|NCT03231397|Other|Rapidly expanding AAA's|"Six subjects (three males and three females) with rapidly expanding AAAs (>0.5cm over 6 months and/or >1.0cm over 12 months).~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
2902485|NCT03231384|Experimental|RIC group|The upper limb ischemic conditioning is composed of five cycles of upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 2 hours after r-tPA thrombolytic therapy. In addition, all participants receive a standard clinical therapy.
2902486|NCT03231384|No Intervention|Control group|The participants received r-tPA thrombolytic therapy after diagnosed ischemic stroke. In addition, all participants receive a standard clinical therapy.
2902487|NCT03231371|Experimental|Study Arm|
2902488|NCT03231358|Experimental|Intervention|"Participants randomized to the behavioral intervention called Our Family Our Future. These participants will receive an intervention to prevent sexually transmitted infections (STIs) including HIV, Chlamydia trachomatis and Neisseria gonorrhoeae; sexual risk behavior; and depression onset. This is a behavioral intervention involving adolescent-parent dyads, delivered in a group setting over 3-4 consecutive weeks."
2902489|NCT03231358|No Intervention|Control|The control arm will receive usual care (consisting of a packet of existing available brochures on HIV, STIs, mental health including places to access care).
2902490|NCT03231345|Experimental|US guided IJ|A physician placed ultrasound-guided IV in the internal jugular vein
2902491|NCT03231332|Experimental|H.pylori Eradication index|Microbiome diversity detection in Participants Positive for H.pylori and undergoing Eradication therapy with Clarythromycin-containing eradication therapy
2902492|NCT03231332|No Intervention|Control|Microbiome diversity detection in Participants Without H.pylori Eradication therapy
2902493|NCT03231332|Active Comparator|H.pylori Eradication comparative|Microbiome diversity detection in Participants Positive for H.pylori and undergoing Eradication therapy with high dose Amoxicillin and bismuth containing eradication therapy
2902494|NCT03231319|Active Comparator|fascia iliaca compartment block+ IV-PCA|
2902495|NCT03231319|Active Comparator|femoral nerve and lateral femoral cutaneous nerve block+IV PCA|
2902496|NCT03231319|Placebo Comparator|IV PCA only|
2902529|NCT03231085|Experimental|Ferinject|The single intravenous treatment the day of the inclusion. Dosage according to: 15mg / kg iron (to dilute in 3 ml / kg of Nacl 0.9% (SSI), to pass in 15 minutes.
2902530|NCT03231059||Experimental treatment strategy|All patients in the treatment group received acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy
2902606|NCT03230552|No Intervention|No video group|Residents assigned to this group will not watch an instructional surgical video prior to LSO surgery.
2902928|NCT03228485||My BPH tracker cohort|All patients enrolled in this study.
2902497|NCT03231306|Experimental|Open label study of Binimetinib (MEK162)|"Subjects (≥ 18 years) (Stratum A) will receive a course of binimetinib by mouth twice a day (12 hours apart) of 45 mg/dose. Duration of each course is 4 weeks. After 8 courses, subjects will receive additional courses if MRI results showed at least 15% reduction in volume of the target tumor. Subjects can continue on therapy and will be evaluated at the end of 12 courses. Subjects who have ≥ 20% reduction in volume of the target tumor according to the MRI results can continue therapy up to an additional year (maximum of 24 total courses). Subjects who have not met the tumor reduction at the specified times will be removed from the study therapy. Subjects will be carefully monitored for toxicities associated with binimetinib.~Recruitment of subjects 1 - 17 years of age (Stratum B) is not currently available. The pediatric maximum tolerated dose (MTD) of binimetinib the pediatric patients (Statum B) is currently being established in an ongoing phase 1 study (NCT022)."
2902498|NCT03231280|Experimental|SB-061|SB-061
2902499|NCT03231280|Placebo Comparator|Placebo|Placebo
2902500|NCT03231267||"Carrierof Ec-BLSE/EPC or Kp-BLSE/EPC"|During resuscitation, evaluation of the acquisition or not of phages able to lyse Ec-BLSE / EPC or Kp-BLSE / EPC
2902501|NCT03231267||Non-Carrier of Ec-BLSE/EPC orKp-BLSE/EPC|During resuscitation, evaluation of the acquisition or not of phages able to lyse Ec-BLSE / EPC or Kp-BLSE / EPC
2902502|NCT03231254||Chinese patients with OSA|
2902503|NCT03231254||Canada patients with OSA|
2902504|NCT03231241||Episodic Headache|Participants experiencing headache of any type more than twice per year but less than 15 days per month. No interventions
2902505|NCT03231241||Chronic Headache|Participants experiencing headache more than 15 days per month for at least three consecutive months. No interventions
2902506|NCT03231241||Control|Participants reporting fewer than two headaches per year. No interventions
2902507|NCT03231228|Active Comparator|Cefazolin 1 g Infusion|Pediatric surgical subjects weighing at least 25 kg to less than 60 kg will receive a single 30-minute infusion of 1 g cefazolin.
2902508|NCT03231228|Active Comparator|Cefazolin 2 g Infusion|Pediatric surgical subjects weighing at least 60 kg will receive a single 30-minute infusion of 2 g cefazolin.
2902509|NCT03231215|Placebo Comparator|controlled group|Group І (control group): the patients received 15 ml epidural plain bupivacaine (0.5%) +2 ml normal saline Group (BS).
2902510|NCT03231215|Active Comparator|dexamethasone group|Group II (dexamethasone group):- the patients received 15 ml epidural plain bupivacaine (0.5%) + 8mg dexamethasone (2ml) Group (BD)
2902511|NCT03231202|Experimental|Embolization|"The intervention arm will perform SAE as a central embolization of the splenic artery.~Additional peripheral embolization is left to the discretion of the interventional radiologist.~The study does not interfere with local diagnostic work-up and treatment protocols."
2902512|NCT03231202|No Intervention|Observation|The control arm in this randomized controlled trial will include only NOM patients diagnosed with splenic injuries OIS grade 4 or 5 and suitable for observation alone, and will comprise clinical observation according to local routines and protocols.
2902513|NCT03231176|Experimental|Varlitinib and Capecitabine|
2902514|NCT03231163|Placebo Comparator|No Music|
2902515|NCT03231163|Experimental|Relaxing Classical Music|
2902516|NCT03231163|Experimental|Self-Selected Relaxing Music|
2902517|NCT03231150|Active Comparator|Anatomical injection|"Once patient has been randomized, if placed in the anatomically-guided injection group, the medial band of the plantar fascia origin on the calcaneus will be palpated and marked approximately. In the clinical setting, a sham ultrasound machine will be utilized to locate the plantar fascia keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage."
2902518|NCT03231150|Experimental|Ultrasound Guided Injection|Once patient has been randomized, if placed in the USGI group, the patient will be scheduled for an ultrasound therapy in the radiology department at Penn Presbyterian Medical Center. In this setting, the patient will be informed that in order to keep them blinded, that all patients must have either injection performed in the radiology department and that the ultrasound machine utilized will either be on or off during the injection keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage.
2902519|NCT03231137|Experimental|PRGF/ATV|Included 10 patients undergoing single tooth extraction and platelet rich in growth factors fibrin scaffold loaded with Atorvastatin powder (PRGF/ATV) were placed to fill the extraction socket.
2902520|NCT03231137|Experimental|ATV gel|Included 10 patients undergoing single tooth extraction and Atorvastatin gel were placed to fill the extraction socket.
2902521|NCT03231137|Experimental|PRF|Included 10 patients undergoing single tooth extraction and platelet rich fibrin (PRF) were placed to fill the extraction socket.
2902522|NCT03231137|Experimental|PRGF|Included 10 patients undergoing single tooth extraction and plasma rich in growth factors (PRGF) were placed to fill the extraction socket.
2902523|NCT03231137|No Intervention|Control|Spontaneously healed socket
2902524|NCT03231124|Experimental|LEO 32731|"Incremental dosing of LEO 32731 progressing to a maximum of 30 mg.~Days 1 - 3: 10 mg dose twice a day for three days~Days 4 - 6: 20 mg dose twice a day for three days~Days 7 - 11: 30 mg dose twice a day for five days~Days 12: 30 mg dose once in the morning"
2902525|NCT03231124|Placebo Comparator|Placebo|"Incremental dosing of placebo progressing to a maximum of 30 mg.~Days 1 - 3: 10 mg dose twice a day for three days~Days 4 - 6: 20 mg dose twice a day for three days~Days 7 - 11: 30 mg dose twice a day for five days~Days 12: 30 mg dose once in the morning"
2902526|NCT03231111|No Intervention|traditional group|
2902527|NCT03231111|Experimental|Multimedia group|
2902528|NCT03231085|Active Comparator|Fumafer|"The oral treatment should begin 21 days before surgery.~Recommended Dosage according to the SPC in force:~5 to 8 kg: 2 cd rases / d or 200mg of ferrous fumarate~8 to 10 kg: 3 cd rases / d or 300mg of ferrous fumarate~10 to 12kg: 4 cd rases / d or 400mg of ferrous fumarate"
2946845|NCT02926118|Experimental|High glycemic load|High glycemic load
2902531|NCT03231059||Reference treatment strategy|"Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and ticagrelor for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy."
2902532|NCT03231046|Experimental|CBCT-US Fusion Arm|Clear Guide SCENERGY, CBCT-US
2902533|NCT03231046|Active Comparator|EM Fusion or No Fusion Arm|
2902534|NCT03231033|Experimental|Pioglitazone|Oral administration of Actos at 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
2902535|NCT03231020||Adherent Group|Parent(s) that submitted a high rate of data transfer (top 25th percentile) with rate of data days of mHealth technology for data transfer
2902536|NCT03231020||Non-Adherent Group|Parent(s) that chose to return mHealth technology before the end of the interstage period and/or low rate of data transfer (bottom 25th percentile) with rate of data days
2902537|NCT03231007||Innovators|Maternity units that implemented the Care Bundle to the highest level (according to an NHS survey in 2015) are categorised as 'Innovators'.
2902538|NCT03231007||Early Adopters|Maternity units that implemented the Care Bundle to the second-highest level (according to an NHS survey in 2015) are categorised as 'Early Adopters'.
2902539|NCT03231007||Late Adopters|Maternity units that implemented the Care Bundle to the third-highest level (according to an NHS survey in 2015) are categorised as 'Late Adopters'.
2902540|NCT03231007||Low Adopters|Maternity units that implemented the Care Bundle to the fourth-highest level (according to an NHS survey in 2015) are categorised as 'Low Adopters'.
2902541|NCT03230994||Different Treatment Groups|Women would receive different pharmacotherapy from the standard approach，such as levonorgestrel-releasing intrauterine system(LNG-IUS)，Gonadotrophin releasing hormone agonist(GnRH-a),surgery,etc.
2902542|NCT03230981|Experimental|Healthy subjects|Optical imaging of the cornea in healthy subjects
2902543|NCT03230968|No Intervention|Phase 1 without intervention|In selected heath centers we interviewed all consenting patients older than 15 years. Before the physician consultation, we investigated sociodemographic, epidemiologic, clinical characteristics and reason for seeking health services. Immediately after consultation, we asked the patient his/her diagnoses. We confirmed all diagnoses with treating physicians. If the patient had been diagnosed with respiratory disease, we collected information on prescribed treatment, and classified the type of respiratory disease and comorbidities based on the 10th International Classification of Diseases (ICD-10). Patients were given follow up one month later.
2902544|NCT03230968|Active Comparator|Phase 2 with intervention|"We trained health personnel from the participating health centers on implementation of the proposed model based on the AIRE guidelines previously approved by the AIRE committee of the National Institute for Respiratory Diseases. The AIRE guidelines have been adapted from WHO Practical Approach to Lung Health. Once the model was in action we interviewed all consenting patients older than 15 years as in phase 1."
2902545|NCT03230955|Experimental|Psychological and psycho-educational support|The intervention group (IG) [that will receive telephone-based assistance to quit (including psychological and psycho-educational support and pharmacological treatment advice, if required) provided by trained nurses who will proactively call at one week, 15 day, a month, 3, 6 and 12 months after discharge, plus the calls made by the patients during the process]
2902546|NCT03230955|Active Comparator|Control Group|The control group (CG) [that will receive only a brief counselling session after discharge]
2902547|NCT03230942|Experimental|Patient education program|Pre-operative education and pos-operative rehabilitation in individuals will be undergo knee arthroplasty.
2902548|NCT03230942|Active Comparator|Control - only pos-op rehabilitation|Pos-operative rehabilitation in individuals will be undergo knee arthroplasty.
2902549|NCT03230929|Experimental|BIS-PLE|Anesthesiologist attaches the sensors of BIS and PLEM 100 on the forehead of the patient, and monitor the monitor and record the values of BIS, PLEM 100, and neuromuscular monitoring.
2902550|NCT03230916|Experimental|IMI/REL FDC|Imipenem/Cilastatin/Relebactam (IMI/REL) administered as a single fixed 2:1 ratio of imipenem/cilastatin to relebactam, with a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
2902551|NCT03230903|Experimental|Home Telerehabilitation|The physical telerehabilitation group will receive an exercise plan, exercise equipment, a computer, and access to a daily individualized exercise plan. Participants in this group will follow the exercise plan that is sent to their computer via the telerehabilitation software. Participants will have interactions with a physical therapist and an exercise physiologist throughout training intervention.
2902552|NCT03230903|Sham Comparator|Usual Care|The usual care group will receive an individualized exercise program at baseline however participants will not receive the home telerehabilitation system or exercise equipment. Participants assigned to the usual care group will also not have access to the study physical therapist or exercise physiologist during the intervention.
2902553|NCT03230890|Experimental|HIRREM|This is the intervention, treatment arm that all participants receive in this open label, single arm trial. The intervention is High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM).
2902554|NCT03230864|Experimental|Lu AF35700 10 mg|10 mg encapsulated tablets administered orally, once daily.
2902555|NCT03230864|Experimental|Continued treatment from Period A|4-6 mg risperidone or 15-20 mg olanzapine encapsulated tablets administered orally, once daily.
2902556|NCT03230851|Experimental|aspirin 100mg/d therapy|Group1: aspirin 100 mg/d;
2902557|NCT03230851|Experimental|aspirin 100mg/2d therapy|Group2: aspirin ;
2902558|NCT03230851|Experimental|aspirin 100mg/3d therapy|Groups3: aspirin ;
2902559|NCT03230851|Experimental|aspirin 50mg bid therapy|Groups4: morning 50mg evening 50mg;
2902560|NCT03230851|Experimental|aspirin 75mg/d therapy|Group5: aspirin 75mg / d;
2902561|NCT03230851|Experimental|aspirin 50mg/d therapy|Group6: aspirin 50mg / d;
2902562|NCT03230851|Experimental|indobufen 100mg bid therapy|Group7: 100mg bid
2902563|NCT03230838|Experimental|Ceftolozane/Tazobactam|Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum ceftolozane 1 g/dose and tazobactam 0.5 g/dose) administered intravenously (IV) every 8 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 7 days and a maximum of 14 days.
2902564|NCT03230838|Active Comparator|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 7 days and a maximum of 14 days.
2902565|NCT03230825|Experimental|Oral contraceptives|Oral contraceptive agent, given for free, for 3 weeks and a follow up visit a week after treatment withdrawal.
2902566|NCT03230825|Sham Comparator|Expectant management|Expectant management for 3 weeks and a follow up visit a week later.
2902567|NCT03230812|Experimental|Low carnitine status|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
2902568|NCT03230812|Experimental|High carnitine status|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
2902569|NCT03230799|Active Comparator|traditional cataract surgery|
2902570|NCT03230799|Experimental|minimal invasive lens surgery|
2902571|NCT03230786|Placebo Comparator|Placebo|Placebo QD for 12 weeks as add-on to metformin
2902572|NCT03230786|Experimental|15µg KBP-042 QD|Up to 15µg KBP-042 QD for 12 weeks as add-on to metformin
2902573|NCT03230786|Experimental|30µg KBP-042 QD|Up to 30µg KBP-042 QD for 12 weeks as add-on to metformin
2902574|NCT03230786|Experimental|50µg KBP-042 QD|Up to 50µg KBP-042 QD for 12 weeks as add-on to metformin
2902575|NCT03230773|Experimental|Defibrillator - Model 1|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
2902576|NCT03230773|Experimental|Defibrillator - Model 2|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
2902577|NCT03230773|Experimental|Defibrillator - Model 3|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
2902578|NCT03230773|Experimental|Defibrillator - Model 4|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
2902579|NCT03230773|Experimental|Defibrillator - Model 5|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
2902580|NCT03230773|Experimental|Defibrillator - Model 6|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
2902581|NCT03230760|Experimental|treatment|
2902582|NCT03230734|Experimental|Treatment Arm A|radium-223 initially followed by docetaxel plus prednisone at the time of progression (PD)
2902583|NCT03230734|Experimental|Treatment Arm B|docetaxel plus prednisone initially followed by radium-223 at the time of progression (PD)
2902584|NCT03230721|Active Comparator|ThuLEP group|Patients who underwent thulium-fiber laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
2902585|NCT03230721|Active Comparator|Monopolar enucleation group|Patients who underwent monopolar enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
2902586|NCT03230721|Active Comparator|HoLEP group|Patients who underwent Ho:YAG laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
2902587|NCT03230708|Experimental|Erythrocytes derived MPs containing MTX|Suspension of erythrocytes derived MPs containing MTX, qd×6, 6 units MPs a time , Two courses.
2902588|NCT03230708|Active Comparator|convention drugs|Chemotherapeutic drugs, biologicals or traditional Chinese medicine.Dosage form, dosage, frequency and duration according to respective medicine instructions.
2902589|NCT03230695|Active Comparator|Active stimulation + robotic therapy|"Active transcranial direct current stimulation will be applied during 20 minutes prior to robotic training.~Number of interventions sessions: 1"
2902590|NCT03230695|Sham Comparator|Sham stimulation + robotic therapy|"Sham transcranial direct current stimulation will be applied during 20 minutes prior to robotic training.~Number of interventions sessions: 1"
2902591|NCT03230682||major depressive disorder|
2902592|NCT03230669|No Intervention|Control|this arm receives treatment as usual and no intervention.
2902593|NCT03230669|Experimental|CBT4CBT|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
2902594|NCT03230656|Experimental|Early therapy 1 month post-injury|"Early cognitive-communication therapy 1 month post-injury:~working memory strategies~executive function program~divided attention program~environmental changes~identification of problematic cognitive-communication situations"
2902595|NCT03230656|Active Comparator|Waitlist therapy 2 months post-injury|"Waitlist early cognitive-communication therapy 2 months post injury:~- Same cognitive-communication therapy is administered"
2902596|NCT03230617||Intrinsic positive end expiratory pressure > 5|chronic obstructive pulmonary disease patient with intrinsic positive end expiratory pressure more than5
2902597|NCT03230617||Auto positive end expiratory pressure < 5|chronic obstructive pulmonary disease patient with intrinsic positive end expiratory pressure less than5
2902598|NCT03230604|Active Comparator|Bulk-Fill composite Class I, II and V cavities|Restorative with Filtek Bulkfill composite in class I, II and V Restorative with Tetric N Ceram composite in class I, II and V
2902599|NCT03230604|Active Comparator|Z 350 xt Composite|Restorative with Z 350 xt composite in class I, II and V
2902600|NCT03230591||Fabry's disease|Fabry's disease patients who were confirmed by enzyme assay and gene study
2902601|NCT03230578||Pharmacists|Actively employed and currently licensed and working in rural counties in New Mexico.
2904411|NCT03218254|Other|Placebo - Methylphenidate|Methylphenidate after placebo
2902607|NCT03230539|Experimental|UPA IUS 20 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
2902608|NCT03230539|Experimental|UPA IUS 5 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks
2902609|NCT03230539|Experimental|UPA IUS 40 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks
2902610|NCT03230513|Active Comparator|Self Epley Manoeuvre|Self Epley Manoeuvre.
2902611|NCT03230513|Active Comparator|Brandt-Daroff Exercise|Brandt-Daroff Exercise.
2902612|NCT03230500|Experimental|computer guided immediate implant placement|For the test group, the computer aided surgical guide will be used for implant drilling and placement.
2902613|NCT03230500|Active Comparator|free hand immediate implant placement|For the control group, free hand implant drilling and placement will be performed guided by the extraction socket walls.
2902614|NCT03230487|Experimental|BI 1015550|
2902615|NCT03230487|Placebo Comparator|Placebo|
2902616|NCT03230474|Active Comparator|group 1|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
2902617|NCT03230474|Active Comparator|group 2|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\ kg naloxone in 0.5 ml volume (total volume 2mL).
2902618|NCT03230461|Experimental|Target compression depth 4.0-5.0 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
2902619|NCT03230461|Experimental|Target compression depth 4.5-5.5 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
2902620|NCT03230461|Experimental|Target compression depth 5.0-6.0 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
2902621|NCT03230448||positive alcoholism|positive acute alcoholism had questionnaire about suicidal intentionality
2902622|NCT03230448||negative alcoholism|negative acute alcoholism had questionnaire about suicidal intentionality
2902623|NCT03230435||Anorexia nervosa|Treatment settings as usual.
2902624|NCT03230435||Healthy controls|No interventions.
2902625|NCT03230422|Experimental|normal airway|Time (normal airway) using the novel King Vision™ Pediatric aBlade (KV) video laryngoscope, C-MAC™ D-blade Ped (DP), C-MAC™ Miller Blade (MB), shortened as VL, compared with conventional direct laryngoscopy (DL)
2902626|NCT03230422|Experimental|difficult airway|Time (difficult airway) using the novel King Vision™ Pediatric aBlade (KV) video laryngoscope, C-MAC™ D-blade Ped (DP), C-MAC™ Miller Blade (MB), shortened as VL, compared with conventional direct laryngoscopy (DL)
2902627|NCT03230409|No Intervention|Phase 1, Retrospective|Routine outpatient follow-up visits were scheduled as follows: (a) in patients receiving primary chemoprophylaxis or Latent Tuberculosis Infection (LTBI) treatment: baseline visit, and 2 weeks and 3 months later (end of treatment in most cases); (b) in patients treated for Tuberculosis disease: baseline visit, 2 weeks later and on a monthly basis thereafter.
2902628|NCT03230409|Experimental|Phase 2, Prospective|"Four nurse-led interventions were implemented after Phase 1:~Intervention 1: at baseline visit, the parents or carers of the children, were given a leaflet in the mother tongue. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.~Intervention 2: a follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits.~Intervention 3: the Eidus-Hamilton test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test.~Intervention 4: a written questionnaire about adherence to anti-TB treatment on all the follow-up visits."
2902629|NCT03230396|Placebo Comparator|Placebo|"Commercially-available chewing gum not supplemented with vitamins. Contains: Sugar; Dextrose; Gum Base; Corn Syrup; Natural and artificial flavors; artificial colors; carnauba wax; resinous glaze; neotame; butylated hydroxytoluene.~For saliva collection phase: No placebo is used. For blood collection phase: Subjects will chew two pieces at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
2902630|NCT03230396|Experimental|Vitamingum Sport|"Same gum base as placebo but supplemented with vitamins (per piece): retinyl palmitate (1250 IU); ascorbic acid (15 mg); cholecalciferol (100 IU); dl-tocopherol acetate (7.5 IU); thiamine mononitrate (375 microg); riboflavin (425 microg); niacinamide (5 mg); calcium d-panothenate (2.5 mg); pyroxidine HCl (500 microg); cyanocobalamin (1.5 microg); folic acid (100 microg); biotin (11.25 microg).~For saliva collection phase: Subjects will chew 2 pieces for 30 min. For blood collection phase: Subjects will chew two pieces at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
2902631|NCT03230396|Experimental|Vitamingum Immunity|"Same gum base as placebo but supplemented with vitamins (per piece): retinyl palmitate (2000 IU); ascorbic acid (62.5 mg); cholecalciferol (200 IU); dl-tocopherol acetate (20 IU); niacinamide (10 mg); calcium d-panothenate (10 mg); pyroxidine HCl (1 mg); cyanocobalamin (5 microg); folic acid (200 microg); biotin (75 microg); zinc sulfate (2.5 mg); sodium selenite (17.5 microg); chromium picolinate (60 microg); and potassium iodide (40 microg).~For saliva collection phase: Subjects will chew 1 pieces for 30 min. For blood collection phase: Subjects will chew 1 piece at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
2902632|NCT03230383|Experimental|Cohort 1_90mg and Matching Placebo|
2902633|NCT03230383|Experimental|Cohort 2_300mg and Matching Placebo|
2902634|NCT03230383|Experimental|Cohort 3_900mg and Matching Placebo|
2902635|NCT03230383|Experimental|Cohort 4_1800mg and Matching Placebo|
2902636|NCT03230383|Experimental|Cohort 5_3000mg and Matching Placebo|
2902637|NCT03230383|Experimental|Optional Cohort 6_TBD mg and Matching Placebo|
2902638|NCT03230383|Experimental|Optional Cohort 7_TBD mg and Matching Placebo|
2902671|NCT03230110||Chronic Hypretension in Pregnancy|Pregnant subjects between 10-20 weeks gestation with chronic hypertension (on medication or hypertensive blood pressures documented at 2 clinic visits)
2902639|NCT03230370|Experimental|enhanced upper-extremity program, EUEP|"Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.~The EUP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity.~The participants receive 20-day training over a 4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity.~Accordingly, one group can be used as the control group of the other one."
2902640|NCT03230370|Experimental|enhanced lower-extremity program,ELLP)|"Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.~The ELP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.~The participants receive 20-day training over a4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity.~Accordingly,one group can be used as the control group of the other one."
2902641|NCT03230357|Experimental|PICC guided by EDUG|PICC(Peripherally Inserted Central Catheter)guided by ECG Doppler ultrasonic Guidance（EDUG),EDUG is a combination device which can be used for selecting the right vein and precise positioning for the catheter tip during the PICC cathetering.
2902642|NCT03230344|Active Comparator|Group 1|Periodontal treatment initiated with scaling and root planing along with root canal treatment and followed by open flap debridement after 6 weeks.(Open flap debridement simultaneously with root canal treatment )
2902643|NCT03230344|Experimental|Group 2|Periodontal treatment initiated with scaling and root planing followed by open flap debridement after 6 weeks. Endodontic treatment will be initiated after 3 months of periodontal surgery.(open flap debridement and delayed root canal treatment )
2902644|NCT03230331||STN DBS|Parkinson's disease (PD) patients who underwent deep brain stimulation (DBS) of the subthalamic nucleus (STN)
2902645|NCT03230331||CONTROL|Parkinson's disease (PD) patients received optimized medical treatment according to published evidence based guidelines
2902646|NCT03230318|Experimental|ARQ 087|
2902647|NCT03230305||Elderly cancer patient cohort|"Aged 70 years or over~With solid cancer irrespective of the stage~Pre-screened or screened for at least one ongoing clinical trial in the center~Informed oral consent (patient, his/her legal representant, trustworthy person or family member)~Social security affiliation"
2902648|NCT03230292|Experimental|Cohort 1|Subjects in this cohort will receive dose 1 every four weeks (Q4W) subcutaneously (sc) during the 48-week open-label Treatment Period. There will be an option to increase the dose to dose 2 Q4W at the discretion of the Investigator if the subject's Psoriasis Area and Severity Index (PASI) response is >=50% to <75% reduction from the Baseline of PS0016 at Week 12 or later. If the subject's disease is adequately controlled on dose 2 Q4W, they may return to dose 1 Q4W at the discretion of the Investigator.
2902649|NCT03230279|Active Comparator|Sacroiliac joint fusion|The subject will receive a sacroiliac joint fusion
2902650|NCT03230279|Active Comparator|Sacroiliac radio frequency ablation|The subject will receive a sacroiliac joint radiofrequency ablation
2902651|NCT03230266|Other|collection|collection of biological and device samples
2902652|NCT03230253|Experimental|Sequential training group|Exercise training for 30 minutes followed by 30 minutes of cognitive-based intervention
2902653|NCT03230253|Experimental|Dual training group|Exercise training simultaneously combined cognitive-based intervention for 60 minutes
2902654|NCT03230253|Active Comparator|Control training group|non-aerobic exercise (e.g., stretch, range of motion exercise...) and unstructured cognitive rehabilitation programs (e.g., reading newspapers, playing board games...) for 60 minutes
2902655|NCT03230240||HIPEC|Patients with carcinomatosis or other peritoneal surface malignancy
2902656|NCT03230227|Active Comparator|Bupivacaine magnesium|( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
2902657|NCT03230227|Active Comparator|bupivacain only|bupivacaine 0.125% infusion in the presternum , for 48 hours
2902658|NCT03230214||DNA positive patients|patients who have bacterial DNA in their samples
2902659|NCT03230214||DNA negative patients|patients who do not have bacterial DNA in their samples
2902660|NCT03230201|No Intervention|Blank control|do not receive Lymph node dissection during surgery.
2902661|NCT03230201|Experimental|Lymph node dissection|will receive Lymph node dissection during radical nephroureterectomy.
2902662|NCT03230188||Severe Asthmatics|Individuals with severe asthma that are already enrolled in the University of Wisconsin Severe Asthma Research Program III study will fill out asthma and psychological questionnaires (non-diagnostic), will undergo Cognitive Function Testing (non-diagnostic), and will undergo a simulated and actual functional Magnetic Resonance Imaging (research grade) scan.
2902663|NCT03230175|Experimental|TTAX01|TTAX01 will be applied directly to the wound surface and retained with non-absorbable sutures. A single layer of the test article should cover the entire open surface of the wound. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case dosing is suspended; or, if the test article has been accidentally dislodged, it may be replaced at any time.
2902664|NCT03230162|Experimental|sildenafil citrate|50 pregnant female will be treated with sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery.
2902665|NCT03230162|Experimental|low molecular weight heparin|50 pregnant female will be treated with a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery according to body weight as follow < 50 kg 3500 units daily 50-90 kg 4500 units daily 91-130 kg 7000 units daily 131-170 kg 9000 units daily > 170 kg 75 u/kg/day
2902666|NCT03230149||Molecular and genetic tests|Measurements of the alpha-GAL enzyme activity will be performed knowing that for male patients with alpha-GAL activities below the cut-off value and all female patients, a blood sampling for full genetic sequencing of all seven exons including promotors of the a-GAL gene will be done
2902667|NCT03230136|Experimental|Multimodal cardioprotection therapeutic strategy|
2902668|NCT03230136|Active Comparator|Traditional anesthetic and therapeutic|standard anesthetic procedure No intervention (Control).
2902669|NCT03230123|Experimental|Green banana biomass|The intervention group is constituted diet counseling plus 4.5 g of resistant starch from green banana biomass, per day, during six months.
2902670|NCT03230123|Placebo Comparator|Diet alone|The control group will receive diet counseling during six months.
2902763|NCT03229590||Surgical dislocation|Reduction of slipped epiphysis via surgical dislocation technique
2902672|NCT03230110||Normotensive in Pregnancy|Pregnant subjects between 10-20 weeks gestation with normal blood pressure, and not on any treatment for chronic hypertension and no history of chronic hypertension, and matched for body mass index (+/- 3 kg/m2) with the chronic hypertension group.
2902673|NCT03230097|Experimental|BI 409306|
2902674|NCT03230097|Placebo Comparator|Placebo|
2902675|NCT03230084|Experimental|Urine PDG test|Urine pregnanediol 3-glucuronide (PDG) test strip
2902676|NCT03230071|Placebo Comparator|Placebo|placebo identified to TMBCZG,0.1g per pill which contains 0mg TMBCZG，3 pills per time, 2 times per day for 24 weeks.
2902677|NCT03230071|Experimental|TMBCZG-high dose|TMBCZG, 0.1g per pill which contains 14mg TMBCZG, 3 pills per time, 2 times per day for 24 weeks.
2902678|NCT03230071|Experimental|TMBCZG-medium dose|TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 2 TMBCZG pills and 1 placebo pill per time, 2 times per day for 24 weeks.
2902679|NCT03230071|Experimental|TMBCZG-low dose|TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 1 TMBCZG pills and 2 placebo pill per time, 2 times per day for 24 weeks.
2902680|NCT03230058|Experimental|group 1|"Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The experimental group (Group 1) will receive 1% voriconazole eye drop (Aurolab, Madurai, India) + 5% Natamycin ophthalmic suspension eye drop hourly (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).~The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.~Patients will be followed up every week after being discharged until complete resolution is noted."
2902681|NCT03230058|Placebo Comparator|group 2|"Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The placebo group (Group 2) will receive Vehicle eye drops + 5% Natamycin ophthalmic suspension every hour (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).~The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.~Patients will be followed up every week after being discharged until complete resolution is noted."
2902682|NCT03230045|Experimental|Acupoint stimulation|Acupoint Zhongfu and Zusanli are stimulated by transcutaneous electrical stimulation
2902683|NCT03230045|Sham Comparator|no treatment|Electrodes are attached to Acupoint Zhongfu and Zusanli, but no stimulation is given
2902684|NCT03230032|Experimental|Intervention Group|Sessions will use a pacifier-activated device (PAL) system. The device sensor attaches to a routinely-used pacifier and measures timing and pressure of the sucks. If the infant reaches the preset suck pressure, he receives 10 seconds of mother's voice. The receiver/speaker box controls the volume to < 65dB on scale C. PAM will be set to the lowest settings for the first session. Using sensor measurements, the therapist will increase the threshold for number of sucks and strength once the infant produces three consecutive sucks above current level and continue per protocol.
2902685|NCT03230032|No Intervention|Control Group|Infants will receive 2 daily 15-min listening sessions of mother's voice recording, contiguous but not simultaneous with PAM NNS sessions without suck-contingent reinforcement (no voice).
2902686|NCT03230019|Active Comparator|chest tube|VATS with chest tube placement
2902687|NCT03230019|Experimental|two-lumen catheter|VATS with two-lumen catheterization
2902688|NCT03230006|Active Comparator|Unified Protocol|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) consists of 5 core skills modules based on cognitive behavioral treatment elements of proven effectiveness. As noted above, these core skills modules were designed to target (and have been shown to address) negative emotionality and aversive reactivity to emotional experiences when they occur (Boswell et al., 2013; Carl et al., 2014; Sauer-Zavala et al., 2012). These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. A final module consists of relapse prevention. As the treatment proceeds, the domains of thoughts, feelings, and behaviors are each explored in detail, focusing specifically on elucidating dysfunctional emotion regulation strategies that the patient has developed over time within each of these domains, and teaching patients more adaptive emotion regulation skills.
2902689|NCT03230006|Placebo Comparator|Take Control|TC is a psychotherapy platform derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA) self-help approach, Rethinking Drinking. In this study, TC, originally designed as a computerized treatment has been modified to be administered by the therapist to control for effects that may be related to patient-therapist interaction (as opposed to elements of the treatment itself). Specifically, on a weekly basis, therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
2902690|NCT03229993|Experimental|OCT guided PCI|
2902691|NCT03229993|Experimental|OCT guided medicine|
2902692|NCT03229993|No Intervention|SPECT guided PCI|
2902693|NCT03229993|No Intervention|SPECT guided medicine|
2902694|NCT03229980|Active Comparator|Group L|Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg The content of cardioplegic solution will be (K+, 10mmol/L) lidocaine 50 mg/L, magnesium sulphate 1 gm/L,dextrose 25% 25 mL/L and sodium bicarbonate 8.4% 25 mL/L during cardiac surgery. Cardioplegic infusion duration will be infused over 300s.
2902695|NCT03229980|Active Comparator|Group S|Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg The content of cardioplegic solution will be (K+, 30mmol/L) lidocaine 150 mg/L, magnesium sulphate 3 gm/L, dextrose 25% 25 mL/L and sodium bicarbonate 8.4% 25 mL/L during cardiac surgery.
2902696|NCT03229967||Exploration Cohort|Approximately 150 VLBW (very low birthweight) infants enrolled from the Regional One Health NICU (neonatal intensive care unit). Weekly stool samples will be obtained. After 36 weeks infants diagnosed with BPD per NIH guidelines will be matched with infants without BPD. Stool samples from these infants will be sent for 16s rRNA (ribosomal ribonucleic acid) sequencing after conclusion of initial enrollment period.
2902764|NCT03229577|Experimental|YESplus|YESplus is a nationally-recognized program developed for university students that focuses on teaching yoga-based breathing techniques.
2902697|NCT03229967||Validation Cohort|Approximately 50 VLBW infants enrolled from the Le Bonheur Children's Hospital NICU. Weekly stool samples will be obtained. After 36 weeks infants diagnosed with BPD per NIH guidelines willl be matched with infants without BPD. Stool samples from these infants will be sent for 16s rRNA sequencing after conclusion of initial enrollment period.
2902698|NCT03229967||Well Baby Cohort|10 Well Baby Infants may be enrolled pending funding as a well infant cohort.
2902699|NCT03229954|Experimental|IV iron (Monofer) group|Iron isomaltoside(Monofer) will be injected intravenously and injection dose will be calculated using Ganzoni formula.
2902700|NCT03229954|Active Comparator|Oral iron group|Ferrous sulfate(Feroba-YOU) 160mg/day for 12 weeks will be taken per oral.
2902701|NCT03229941|Experimental|Restrictive|Transfusion trigger: Hb<10gm/dl
2902702|NCT03229941|Experimental|Liberal|Transfusion trigger: Hb<7gm/dl
2902703|NCT03229928||Stakeholder Advisory Panel|The investigators will recruit 2 parents of children with IDD, 2 special education teachers, and 2 behavior health professionals to assist with the development and initial testing of the upgraded MOCHA application features to test usability.
2902704|NCT03229928||Primary Participants|The study primarily involves recruitment of clinically referred minor patients with IDD and their parents and teachers. Parents and teachers of 10 patients with IDD and co-morbid behavior problems will be asked to collect data via the MOCHA application on the frequency, antecedents,consequences, and other correlates of specific behavioral concerns.
2902705|NCT03229928||Sensor Wearing Participants|These will be the same participants from aim 2. All participants will be offered the opportunity to wear the sensors and provide and chose which ones they would prefer to wear. Two participants will be asked to wear the sensor for 48 hours in order to pilot test the feasibility of syncing sensor and MOCHA application data collection.
2902706|NCT03229915|Active Comparator|PTSD|Will receive Cognitive Processing Therapy
2902707|NCT03229915|Active Comparator|Trauma-exponsed control|Will receive Cognitive Processing Therapy
2902708|NCT03229915|No Intervention|no trauma healthy control|Scanned twice (13 weeks apart) without any intervention
2902709|NCT03229902|Experimental|mantra meditation|Each session of mantra meditation lasts for 30 minutes. The participants in each session comprise 1 subject and the PI. In each session, the subject and the PI co-participate in repetitive intonation of a pre-specified mantra. Intervention is comprised of 9 sessions, each of which occurs on a separate weekday at approximately equal intervals over a total intervention period of 3 weeks.
2902710|NCT03229889|Active Comparator|Flomax + Placebo|Patients will be prescribed Flomax 0.4Mg Capsule and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
2902711|NCT03229889|Active Comparator|Cialis + Placebo|Patients will be prescribed Cialis 5Mg tablet and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
2902712|NCT03229889|Active Comparator|Cialis + Flomax|Patients will be prescribed .4mg of Flomax and 5mg of Cialis. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
2902713|NCT03229889|Placebo Comparator|Placebo + Placebo|Given 2 bottles of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
2902714|NCT03229876|Experimental|universal CD19-CART|Patients will receive a conditioning therapy with cyclophosphamide and fludarabine before CART therapy. CD19-UCART cells will be injected intravenously (IV) on day 0
2902715|NCT03229863|Experimental|Sweet Potatos|Infants will consume commercially available baby food sweet potato (SP) (Plum Organics, Just Sweet Potato) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of sweet potato to their infant at least three times per day for seven days in a row.
2902716|NCT03229863|Experimental|Pears|Infants will consume commercially available baby food pear (P) (Earth's Best, First Pears) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of pears to their infant at least three times per day for seven days in a row.
2902717|NCT03229850|Other|Subclinical Lipohypertrophy|Insulin lispro will be injected in the abdomen into an area of subclinical lipohypertrophy.
2902718|NCT03229850|Other|No Subclinical Lipohypertrophy|Insulin lispro will be injected in the abdomen into an area where there is no subclinical lipohypertrophy.
2902719|NCT03229824|Experimental|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
2902720|NCT03229824|No Intervention|Standard care|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site and the tubing with a cotton swab dipped in rubbing alcohol.
2902721|NCT03229811|No Intervention|Standard pre-dialysis education|Standard pre-dialysis options education including hemodialysis, peritoneal dialysis, and kidney transplantation
2902722|NCT03229811|Active Comparator|ESRD education + ACP|Standard ESRD education + advance care planning
2902723|NCT03229798|Active Comparator|Sumatriptan Succinate Oral Tablet|100 mg oral tablet commercial Imitrex sumatriptan succinate tablet
2902724|NCT03229798|Experimental|Sofusa Profile #1|Combination device for transdermal delivery of sumatriptan succinate Current approved dose (SC)
2902725|NCT03229798|Experimental|Sofusa Dose Profile #2|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #1
2902726|NCT03229798|Experimental|Sofusa Dose Profile #3|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #2
2902727|NCT03229798|Experimental|Sofusa Dose Profile #4|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #3
2902728|NCT03229798|Experimental|Sofusa Dose Profile #5|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from prior Sofusa Dose Profile #2-4
2902729|NCT03229785|Experimental|Human Umbilical Cord Blood Plasma|Six intravenous infusions of human umbilical cord blood plasma (HUCBP) during a twelve month study period. The amount of HUCBP being infused on each occasion is 50 mL.
2902730|NCT03229772|Other|Subjects indicated for dynamic nuclear medicine scanning|The trial will consist of a single arm composed of subjects with preexisting indications for dynamic nuclear medicine scanning at the site. All patients will undergo nuclear medicine scintigraphy using the GE Discovery 670 NM/CT device with and without CZT enabled during a single visit.
2902731|NCT03229759|Experimental|Investigational Product|Polyester cloth impregnated with investigational product
2902732|NCT03229759|Placebo Comparator|Vehicle Control (VC)|Polyester cloth impregnated with the vehicle control
2902733|NCT03229759|Placebo Comparator|Saline Control (SC)|Saline applied wtih polyester cloth
2902734|NCT03229746|Experimental|hydroxychloroquine group|hydroxychloroquine tablets 200mg ,two times/day for at least 6 month
2902735|NCT03229746|Active Comparator|vincristine group|vincristine ampoule , 1mg/ week, I.v drep over 2 hours for 4 weeks
2902736|NCT03229746|Active Comparator|azathioprine group|azathioprine tablet 50mg, dose 100-150 mg daily for 6 month
2902737|NCT03229733|Experimental|Experimental group|Patients randomized to the experimental group participate in exergames training with Kinect. The supervised OT chooses different games according to the patient's needs and abilities. During therapy patients are at sitting position. The game program will be adjusted when patients got improvement. After 30 minutes of exergames training, participants will receive a 30-minutes of traditional occupational therapy.
2902738|NCT03229733|Active Comparator|Control group|Patients in the control group will receive individually tailored traditional occupational therapy consisting of the similar movement and dose as the experimental group doing by using the traditional equipment, such as climbing bar.
2902739|NCT03229720|Active Comparator|Audio-Visual Distraction Group|In this arm, the patient will be introduced to the audio-visual distraction device and given some instruction on how to use it and rules while using it. other than that, the dental procedure is as same as the other arm group.
2902740|NCT03229720|No Intervention|Normal Dental Environment Group|Normal Dental Environment without any distractions.
2902741|NCT03229707|Active Comparator|group 1 Color matching using Vita 3D master|"Outcome Name: Color Matching measured by :~Modified (USPHS) criteria"
2902742|NCT03229707|Experimental|group 2 Color matching using digital photography|"Outcome Name: Color Matching measured by Digital Photography using (Photoshop)~Software:~0 to 1: no difference in perception~1 to 2: only perceptible to a trained observer~2 to 3.5: perceptible difference~3.5 to 5: marked difference"
2902743|NCT03229694|Experimental|Tracleer (or Bosentan)|Tracleer (Tracleer 125Mg Tablet) was administered orally at two hours before surgery and six hours after surgery
2902744|NCT03229694|Placebo Comparator|Placebo|Placebo was administered orally at two hours before surgery and six hours after surgery
2902745|NCT03229681|Experimental|Baduanjin exercise group|Participants in this group received routine rehabilitation training and Baduanjin exercise
2902746|NCT03229681|Active Comparator|Routine rehabilitation group|Participants in this group only received routine rehabilitation training
2902747|NCT03229668|Placebo Comparator|Group I|Administration of a placebo capsule 1 hour prior to the surgical operation
2902748|NCT03229668|Experimental|Group II|Administration of 75mg of pregabalin 1 hour prior to the surgical operation
2902749|NCT03229668|Experimental|Group III|Administration of 150mg of pregabalin 1 hour prior to the surgical operation
2902750|NCT03229655|Experimental|Sequential stent addition|ERCP with sphincterotomy and stent placement is initially performed, then additional stents are placed across the stricture during sequential ERCPs, without stent removal/exchange or stricture dilation.
2902751|NCT03229655|Active Comparator|Incremental Dilation & Stent Exchange|ERCP with sphincterotomy and stent placement is initially performed, with subsequent ERCPs involving removal of previously placed stents, stricture dilation and balloon sweeps to extract stone debris/sludge.
2902752|NCT03229642|Experimental|Active rTMS treatment|The rTMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions.
2902753|NCT03229642|Sham Comparator|Sham rTMS treatment|The rTMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min, with a figure-of-eight sham coil. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions.
2902754|NCT03229629|Experimental|Maternal BCC only|Mothers with child under 20 months or pregnant will receive Behavior Change Communication (BCC)
2902755|NCT03229629|Experimental|Maternal BCC & Paternal BCC|"Mothers with child under 20 months or pregnant will receive BCC~Husband/partner of the enrolled mother will receive BCC *BCC: Behavior Change Communication"
2902756|NCT03229629|Experimental|Food voucher|"Mothers or fathers with child under 20 months or pregnant will receive monthly food voucher worth 200 birr(~$10)~Within household, recipient of voucher (mother or father) will be randomly selected.~Food voucher"
2902757|NCT03229629|Experimental|Maternal BCC & Food Voucher|"Mothers with child under 20 months or pregnant will receive BCC~Mothers or fathers with child under 20 months or pregnant will receive monthly food voucher worth 200 birr(~$10)~Within household, recipient of voucher (mother or father) will be randomly selected.~BCC: Behavior Change Communication"
2902758|NCT03229629|Experimental|Maternal BCC&Paternal BCC &Food Voucher|"Mothers with child under 20 months or pregnant will receive BCC~Husband/partner of the enrolled mother will receive BCC~Enrolled participants will receive monthly voucher worth 200 birr(~$10)~Within household, recipient of voucher (mother or father) will be randomly selected.~BCC: Behavior Change Communication"
2902759|NCT03229629|No Intervention|Control|Control group
2902760|NCT03229616|Experimental|BUCY+VP-16|For DLBCL patients undergoing auto-HSCT，BUCY+VP-16 conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2; VP-16 15mg/kg/day on days -3 and -2.
2902761|NCT03229616|Active Comparator|BUCY|For DLBCL patients undergoing auto-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
2902762|NCT03229603|Other|Cluster of 3000 women|Cluster will be selected from an existing cervical, breast, and oral cancer screening program in Mumbai, India and its surrounding semi-urban and rural areas.
2902765|NCT03229577|Experimental|KORU|KORU is a nationally-recognized program developed for university students that focused on teaching mindfulness techniques.
2902766|NCT03229577|Experimental|Emotional Intelligence|Emotional Intelligence is a program developed for university students that focuses on teaching the skills of emotional intelligence such as labeling, understanding, and regulating emotions.
2902767|NCT03229577|No Intervention|Control|The control group will receive no intervention.
2902768|NCT03229564|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
2902769|NCT03229551|Experimental|Xylitol|This arm will evaluate the effect of topical xylitol therapy on biofilm production with the use of PCR bacterial sequencing before and after medical intervention.
2902770|NCT03229551|Active Comparator|Control|This arm is the standard of care saline irrigation solution.
2902771|NCT03229538|Experimental|Methylprednisolone Arm|IV Methylprednisolone
2902772|NCT03229538|Placebo Comparator|Placebo Arm|IV Isotonic Saline
2902773|NCT03229525|Active Comparator|Trauma Related Expressive Writing|Participants randomized to this condition will complete six sessions during which they will write about their trauma for 20 minutes. The participant will receive instructions to write about the traumatic event that they feel affects them the most. For each session they will be instructed to write about the same event. For the first session, participants will complete psychoeducation and treatment rationale modules. The instructions for writing about the traumatic event will emphasize the importance of exploring their deepest emotions and thoughts at the time of the event, as well as providing detailed information about the event itself. For the remaining five writing sessions participants will be instructed to write about the same event and to focus on providing a detailed description of the part of the event that was most distressing to them, as well as how the event had affected their lives. A researcher will review the writing independently to ensure treatment compliance.
2902774|NCT03229525|Active Comparator|Trauma Related Expressive Speaking|Participants randomized to this condition will complete six sessions during which they will speak about their trauma for 20 minutes. The participant will receive instructions to speak about the traumatic event that they feel affects them the most. For each session they will be instructed to speak about the same event. For the first session, participants will complete psychoeducation and treatment rationale modules. The instructions for speaking about the traumatic event will emphasize the importance of exploring their deepest emotions and thoughts at the time of the event, as well as providing detailed information about the event itself. For the remaining five sessions participants will be instructed to speak about the same event and to focus on providing a detailed description of the part of the event that was most distressing to them, as well as how the event had affected their lives. A researcher will review the recording independently to ensure treatment compliance.
2902775|NCT03229525|Sham Comparator|Neutral Expressive Writing|Participants randomized to this condition will complete six sessions during which they will write about their day, without describing emotions or opinions. Previous research has shown a significant reduction of symptoms with this type of control writing condition in participants with PTSD (Sloan et al., 2011). A researcher will review the writing to ensure compliance.
2902776|NCT03229512|Experimental|Intervention|Topical 1% Sildenafil Cream
2902777|NCT03229499|Experimental|Anastrozole|1mg (1 tablet)taken by mouth once a day for one year
2902778|NCT03229499|Placebo Comparator|Placebo|1 tablet taken by mouth once a day for one year
2902779|NCT03229486|Experimental|Sugammadex Injection [Bridion]|reversal of neuromuscular blockade with sugammadex
2902780|NCT03229486|Active Comparator|Neostigmine+Glycopyrronium|reversal of neuromuscular blockade with neostigmine & glycopyrrolate
2902781|NCT03229460|Active Comparator|standard low flow therapy|In the standard low flow therapy is applied continuously through a nonrebreather face mask at a flow rate of 10 liters per minute or more. The rate was adjusted to maintain an oxygen saturation level of 92% or more.
2902782|NCT03229460|Experimental|high flow nasal oxygen therapy|In the high-flow-oxygen group is passed through a heated humidifier and applied continuously through large-bore binasal prongs, with a gas flow rate of 30-60 liters per minute . The fraction of oxygen in the gas flowing in the system was subsequently adjusted to maintain an Spo2 of 92% or more.
2902783|NCT03229460|Placebo Comparator|Noninvasive ventilation|In the noninvasive-ventilation group is delivered to the patient through a face mask that was connected to an ICU ventilator,with pressure support applied in a noninvasive ventilation mode. The Fio2 or PEEP level (or both) were then adjusted to maintain an Spo2 of 92% or more.
2902784|NCT03229447|Active Comparator|E-learning intervention|The E-learning intervention consists of two 20-minute e-learning modules that combine a didactic component with testimonials from respected professionals in the fields of addiction treatment and criminal justice. Module 1 describes the nature of opioid addiction and treatment modalities. Module 2 addresses specific criminal justice concerns of cost, acceptance, usefulness, and diversion, perceived obstacles to providing MAT access as described to us by Ohio criminal justice professionals in formative phase. All courts recruited for the study are exposed to E-Learning.
2902785|NCT03229447|Experimental|Change Team Intervention|Half of the courts exposed to e-learning will be randomly assigned to a change team intervention. The change team will reinforce the information in the modules and provide instrumental assistance in linking courts to MAT providers and financial resources.
2902786|NCT03229434|Experimental|Widely pristine area|Outdoor mountain hiking (approximately 6 hours, 8km, 800 altitude meters, estimated speed: 4km/h [uphill], 5.2km/h [downhill]) in a widely pristine area with moderate intensity (Rating of perceived exertion: ~ 11-15).
2902787|NCT03229434|Active Comparator|Anthropogenically influenced area|"Outdoor mountain hiking (approximately 6 hours, 8km, 800 altitude meters, estimated speed: 4km/h [uphill], 5.2km/h [downhill]) in an anthropogenically influenced area with moderate intensity (Rating of perceived exertion: ~ 11-15).~All characteristics of the hiking (duration, time, difference in altitude, ...) are planned to be comparable to the experimental condition except the area."
2902788|NCT03229408|Experimental|Salsalate-Treated Lean PCOS without IR|n=15
2902789|NCT03229408|Placebo Comparator|Placebo-Treated Lean PCOS without IR|n=15
2902790|NCT03229408|Experimental|Salsalate-Treated Lean PCOS with IR|n=15
2902791|NCT03229408|Placebo Comparator|Placebo-Treated Lean PCOS with IR|n=15
2902792|NCT03229408|Experimental|Salsalate-Treated Obese PCOS|n=15
2902798|NCT03229369|Experimental|Combined ACL and ALL|Anterior Cruciate Ligament Reconstruction associated with Anterolateral Ligament Reconstruction
2902799|NCT03229356|No Intervention|Waitlist Control|BPA will be rolled out to waitlist control sites after 6 months
2902800|NCT03229356|Active Comparator|Best Practices Advisory (BPA)|Clinicians will receive an email describing the BPA and order set, along with internet links to MD Quit Line without additional supplemental education.
2902801|NCT03229356|Active Comparator|BPA+ Enhanced Education|Clinicians will receive an email describing the new smoking BPA, educational materials offered, and a small tutorial on using the BPA and a new smoking cessation smart set in Epic. Education materials will include the educational hand out and academic detailing from Maryland Quit Line counselors.
2902802|NCT03229343|Experimental|Experimental|Supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
2902803|NCT03229343|No Intervention|standard|pneumological consultation performed at M0, M3 and M6
2902804|NCT03229330|Experimental|Intervention|Low-level Light Therapy: Wavelength of 660 nm (red laser) and Conventional treatment: Topical treatment with compressive therapy, exercises of lower extremities, resting; once a week for 16 weeks.
2902805|NCT03229330|Active Comparator|Controls|Conventional treatment: Topical treatment with compressive therapy, exercises of lower extremities, resting; once a week for 16 weeks.
2902806|NCT03229291|Experimental|Low Dose|Topical SM04755 solution (15 mg/mL) applied once per day for 14 days
2902807|NCT03229291|Experimental|Mid Dose|Topical SM04755 solution (45 mg/mL) applied once per day for 14 days
2902808|NCT03229291|Experimental|High Dose|Topical SM04755 solution (90 mg/mL) applied once per day for 14 days
2902809|NCT03229291|Placebo Comparator|Vehicle|Vehicle solution applied once per day for 14 days
2902810|NCT03229278|Experimental|Treatment (trigriluzole, nivolumab, pembrolizumab)|Patients receive trigriluzole PO QOD, BID, QAM or QHS on days -14 to -1. Patients then receive nivolumab IV over 60 minutes every 2 weeks beginning week 1 and trigriluzole PO QOD, BID, QAM or QHS. Once the MTD of trigriluzole with nivolumab is identified, patients receive pembrolizumab IV over 30 minutes every 3 weeks beginning week 1 and trigriluzole PO. Treatment repeats for up to 1 year in the absence of disease progression or unacceptable toxicity.
2902811|NCT03229265|Experimental|Patiromer|
2902812|NCT03229252|Placebo Comparator|Placebo|Placebo Inhalation solution twice daily for 28 days.
2902813|NCT03229252|Experimental|SPX-101 Low Dose|Inhalation solution twice daily for 28 days.
2902814|NCT03229252|Experimental|SPX-101 High Dose|Inhalation solution twice daily for 28 days.
2902815|NCT03229239|Experimental|corneal stroma implantation|implant the corneal stroma to the diseased cornea of keratoconus patients
2902816|NCT03229226||2016 OPPE|All faculty participating in yearly ongoing professional Practice evaluation were eligible for enrollment
2902817|NCT03229213||Cystic Fibrosis|Cystic fibrosis patients will be invited to participate in the study. All participants will complete a questionnaire to assess the level of physical activity prior to evaluation. On the first visit they will perform the cardiopulmonary exercise test (CPET) to evaluate cardiorespiratory responses during exercise. On the second visit an evaluation of the cardiorespiratory responses during the use of interactive video games (Nintendo Wii or Xbox One) will be performed. During interactive games, participants will use an accelerometer to assess the level of physical activity.
2902818|NCT03229213||Healthy|Healthy subjects will be invited to participate in the study. All participants will complete a questionnaire to assess the level of physical activity prior to evaluation. On the first visit they will perform the cardiopulmonary exercise test (CPET) to evaluate cardiorespiratory responses during exercise. On the second visit an evaluation of the cardiorespiratory responses during the use of interactive video games (Nintendo Wii or Xbox One) will be performed. During interactive games, participants will use an accelerometer to assess the level of physical activity.
2902819|NCT03229200|Experimental|Ibrutinib|Treatment with Ibrutinib, once daily until disease progression or unacceptable toxicity.
2902820|NCT03229187||neoadjuvant chemotherapy|
2902821|NCT03229174|Experimental|Intervention phase|Droxidopa unforced titration dose (starting at 100mg by mouth TID) or matching placebo and titrated over 2 weeks up to maximum of 600 TID. Efficacy evaluation of given dose at week 4
2902822|NCT03229174|Other|Open label extension phase|All subjects allowed into a 4 week open label extension. Similar titration will start at 100mg Droxidopa three times a day (TID), but can be titrated up daily using the same dose escalation scale.
2902823|NCT03229161|Experimental|IWT-group|The IWT-group follows the standardized GDM care program for GDM patients at OUH and is prescribed to a 6-week non-supervised IWT-program consisting of 3 IWT sessions per week of 40-50 minutes each.
2902824|NCT03229161|No Intervention|Con-group|The con-group follows the standardized GDM care program for GDM patients at OUH
2902825|NCT03229148|Active Comparator|General anaesthesia|In the general anesthesia group, rapid sequence induction is used. Conduction of general anesthesia and drugs used are left to the expertise of each investigating center. Systolic blood pressure has to be maintained between 140 and 180 mmHg with an intravenous norepinephrine infusion if necessary, tele-expiratory carbon dioxyde concentration (EtCO2) has to be maintained between 30 and 35 mmHg and SpO2 has to be maintained between 94 and 98 %.
2902826|NCT03229148|Active Comparator|Conscious Sedation|In the conscious sedation group, drugs choice as well as pharmacological modulation will be left to the expertise of each investigating center. A sedation level between 0 and -3 with spontaneous breathing will be targeted, using the Richmond Agitation Sedation Scale (RASS) score validated in French. The lightest sedation level will be targeted, i.e. minimal to moderate sedation according to the US recommendations for sedation / analgesia. Systolic blood pressure will be maintained between 140 and 180 mmHg with an intravenous norepinephrine infusion if necessary and SpO2 will be maintained between 94 and 98%.
2902827|NCT03229135||Group A|Group A (CLcr≥60mL/min) : Teicoplanin was intravenously administered 3 times for moderate infections (skin, soft tissue and respiratory infections) or 6 times for severe infections(endocarditis caused by MRSA or severe pneumonia) at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d.
2902828|NCT03229135||Group B|Group B (40 mL/min≤CLcr<60mL/min) : Teicoplanin was intravenously administered 3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d.
2904412|NCT03218241|Experimental|PRT0064445 Dose 1|Dose 1 versus Placebo
2902829|NCT03229135||Group C|Group C (CLcr<40mL/min) : Teicoplanin was intravenously administered 2 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d.
2902830|NCT03229135||Group D|Group D (standard regimen) : Teicoplanin was intravenously administered 1-3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d.
2902831|NCT03229109||Analysis of sweat secretions Males|age 18-25 - 25 subjects, age 26-35 - 25 subjects age 36-45 - 25 subjects, age 46-50 - 25 subjects
2902832|NCT03229109||Analysis of sweat secretions Females|age 18-25 - 25 subjects, age 26-35 - 25 subjects age 36-45 - 25 subjects, age 46-50 - 25 subjects
2902833|NCT03229096|Experimental|Apatinib plus XELOX|Patients will be given the perioperative chemotherapy of Apatinib plus XELOX once recruited
2902834|NCT03229083|Experimental|Use of Carevive software|Reporting and management of side effects from oral targeted therapy or immunotherapy, through Carevive software, in patients who have advanced Renal Cell Carcinoma (RCC).
2902835|NCT03229070|No Intervention|Control Group|Control Group: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) and assessments at discharge
2902836|NCT03229070|Experimental|Interval effort group|Interval effort group: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Active phase (high load) lasting 60 seconds, followed by an active recovery phase with light / moderate load (60% of the maximum load) lasting 4 minutes. The pedaling speed should be maintained between 30-60rpm. There will be 5 cycles that will total 20 minutes of physical effort, and assessments at discharge.
2902837|NCT03229070|Experimental|Continuous effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Intensity used will be mild / moderate, ie 60% of the maximum load reached in the incremental test. The pedaling speed should be maintained between 30-60rpm. The execution time, from this exercise regime will be 20 minutes, and assessments at discharge.
2902838|NCT03229057|Active Comparator|OCP + Placebo|The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Placebo pills will be administered to individuals randomized to OCP only in order to maintain study blinding.
2902839|NCT03229057|Active Comparator|Metformin + Placebo|Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side effects. Subjects will begin with one tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg. Placebo pills will be administered to individuals randomized to metformin only in order to maintain study blinding.
2902840|NCT03229057|Experimental|OCP + Metformin|The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side effects. Subjects will begin with one tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg.
2902841|NCT03229044||BMI 18-21|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 18-21 kg/m2
2902842|NCT03229044||BMI 33-39|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 33-39 kg/m2
2902843|NCT03229044||BMI 25-30|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 25-30 kg/m2
2902844|NCT03229031|Experimental|ES135|
2902845|NCT03229031|Placebo Comparator|Placebo|
2902846|NCT03229018|Other|voxel size|200 μm and 300 μm Voxel Sizes
2902847|NCT03229005||A1 thick-high|group with thick tissue and high prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
2902848|NCT03229005||A2 thick-low|group with thick tissue and low prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
2902849|NCT03229005||B1 thin-high|group with thin tissue and high prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
2902850|NCT03229005||B2 thin-low|group with thin tissue and low prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
2902851|NCT03228992|Active Comparator|Ibuprofen|Subjects will receive a total of 4 doses of oral ibuprofen 400 mg over a 24 hour period.
2902852|NCT03228992|Placebo Comparator|Placebo|Subjects will receive a total of 4 doses of oral placebo over a 24 hour period.
2902853|NCT03228979|Active Comparator|Structured Semi-Interactive Prevention|The intervention arm will receive a Structured Semi-Interactive Stroke Prevention Package including patient workbook, short messaging services and health education videos for a period of one-year in addition to standard of care as per current guidelines
2902854|NCT03228979|No Intervention|Control group|Patients will receive standard post stroke care for 1 year
2902855|NCT03228953|Experimental|Pharmacogenomic-guided therapy group|In this group, results of pharmacogenomic testing will be provided to the treating physician within 2-5 working days. Thus, the patient's treatment provider will be able begin antidepressant adjustments based on pharmacogenomic testing report within a week of the baseline visit.
2902856|NCT03228953|No Intervention|Treatment as usual (TAU) group|For patients randomized to this group, medication treatment decisions by the treating clinicians will be made without the availability of the pharmacogenomic report; however, the test results will be provided after the study completion to the patient treating physician.
2902857|NCT03228940|Experimental|treatment|RVX000222 (apabetalone) 100 mg to be administered orally BID 12 hours apart.
2902858|NCT03228927||twin A|Sampling of the facial and fecal microbiome
2902859|NCT03228927||twin B|Sampling of the facial and fecal microbiome
2902860|NCT03228914|Active Comparator|Oxymetazoline|Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
2904007|NCT03221062|Experimental|Laser en Bloc Resection|Laser en Bloc Resection of bladder tumor(laser ERBT)
2902861|NCT03228914|Active Comparator|Epinephrine|Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
2902862|NCT03228901|Experimental|Oxytocin|24IU Syntocinon, delivered in a single nose via a nasal spray
2902863|NCT03228901|Placebo Comparator|Placebo|Matched nasal spray
2902864|NCT03228888|Experimental|Artificial Sounds|"Participants were provided headphones and a portable MP3 device which played a metronome tick at specified rhythm calculated as follows: a) if a patient's cadence was below the normality, the BPM of the stimulus was set at a value of 10% higher than one's own cadence; b) if a patient's cadence was below, but close to normality (less than 10% difference), the BPM of the stimulus was set at normality values; c) if a patient's cadence was above the normality, the BPM of the stimulus was set at a value equal to one's own cadence.~Participants performed daily 30 minutes of walking assisted by the rhythmic acoustic stimuli."
2902865|NCT03228888|Experimental|Ecological Sounds|"Participants were provided headphones and a portable MP3 device which played an ecological rhythmic sound obtained by actual footsteps of human at specified rhythm calculated as follows: a) if a patient's cadence was below the normality, the BPM of the stimulus was set at a value of 10% higher than one's own cadence; b) if a patient's cadence was below, but close to normality (less than 10% difference), the BPM of the stimulus was set at normality values; c) if a patient's cadence was above the normality, the BPM of the stimulus was set at a value equal to one's own cadence.~Participants performed daily 30 minutes of walking assisted by the rhythmic acoustic stimuli."
2902866|NCT03228862|Experimental|D40000|Patients are randomly assigned to receive Ergocalciferol 40000 IU once weekly
2902867|NCT03228862|Experimental|D60000|Patients are randomly assigned to receive Ergocalciferol 60000 IU once weekly
2902868|NCT03228862|Experimental|D80000|Patients are randomly assigned to receive Ergocalciferol 80000 IU once weekly
2902869|NCT03228849|Active Comparator|Conservative Treatment|Patients were treated with 6 weeks with splinting and were then started on physical therapy for 2 weeks.
2902870|NCT03228849|Active Comparator|Surgical Treatment|Patients were treated with the new suture anchor technique and after 6 weeks were started on physical therapy for 2 weeks.
2902871|NCT03228836|Experimental|IBI308|
2902872|NCT03228823|Active Comparator|Radiofrequency Ablation|Radiofrequency ablation (RFA) will be performed after 3-month observation period. EPS and RFA will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study. In the event of polymorphic PVCs, all morphologies are to be targeted for ablation
2902873|NCT03228823|Active Comparator|Antiarrhythmic Drug|Antiarrhythmic drugs (AADs) will be only initiated after 3-month observation period. AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Investigators define successful PVC suppression only if ≥ 80% absolute reduction in PVC burden is achieved after a drug or intervention. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
2902874|NCT03228810||Men >18 years old with metastatic prostate cancer|
2902875|NCT03228797|Active Comparator|Group I|( 20 patients) will receive an ultrasound guided rectus sheath block by the end of the surgery using 15 ml ropivacaine 0.5% on either side.
2902876|NCT03228797|Active Comparator|Group II|( 20 patients) multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer, a10 ml bolus of ropivacaine 0.2% will be administered through the catheter and then connected to an elastomeric pump delivering a continuous fixed -rate of ropivacaine 5ml/h.
2902877|NCT03228797|Active Comparator|Group III|( 20 patients) a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
2902878|NCT03228771|Active Comparator|PRGF/ATV|"Group I (PRGF/ATV) : It was included 10 patients undergoing single tooth extraction followed by socket fill with 1.2% Atorvastatin loaded in PRGF derived fibrin scaffold then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.~Intervention: Atorvastatin drug loaded in platelets rich in growth factors (PRGF)."
2902879|NCT03228771|Active Comparator|ATV gel|Group II (ATV gel) : Will include 10 patients undergoing single tooth extraction followed by socket fill with 1.2% Atorvastatin in methyl cellulose gel then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.
2902880|NCT03228771|No Intervention|Empty socket|Group III Empty socket( control) : Will include 10 patients undergoing single tooth extraction then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.
2902881|NCT03228758|Active Comparator|Anterior Orientation|"The anterior endoscopic myotomy of the lower esophageal sphincter will be performed between the 11 o'clock to 3 o'clock position in the esophagus determined by the usual endoscopic convention of 12 o'clock representing the most anterior aspect of the esophagus on endoluminal view.~Intervention is the endoscopic myotomy of the lower esophageal sphincter."
2902882|NCT03228758|Active Comparator|Posterior Orientation|"The posterior endoscopic myotomy of the lower esophageal sphincter will be performed between the 5 o'clock to 6 o'clock position in the esophagus determined by the usual endoscopic convention of 12 o'clock representing the most anterior aspect of the esophagus on endoluminal view.~Intervention is the endoscopic myotomy of the lower esophageal sphincter."
2902883|NCT03228745|Experimental|pre-operative MBSR|Pre-operative MBSR is a condition where individuals will receive a pre-operative 8-week community-based MBSR course, which includes group classes lasting 2.5 hours a week, 45-minutes of home practice 6 days per week, a 1-hour orientation session at the beginning, and a full-day silent retreat at the end. During the orientation, participants will complete the study measures for this study.
2902884|NCT03228745|No Intervention|treatment-as-usual (TAU)|The individuals in the TAU group will receive their treatment as usual.
2902885|NCT03228732|Placebo Comparator|Placebo 1|"Visit 1:~Study Day 1: Hyperinsulinemia/ euglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with placebo~Visit 2:~same as visit 1"
2902929|NCT03228472|Experimental|real stimulation|Cranial - electrical or magnetic stimulation. Stimulation will be different according to clinical conditions, as specified elsewhere.
2902886|NCT03228732|Placebo Comparator|Placebo 2|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with placebo~Visit 2:~same as visit 1"
2902887|NCT03228732|Active Comparator|Fluoxetine|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with fluoxetine~Visit 2:~same as visit 1"
2902888|NCT03228732|Active Comparator|DHEA|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with DHEA~Visit 2:~same as visit 1"
2902889|NCT03228732|Active Comparator|Fluoxetine and DHEA|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with fluoxetine and DHEA~Visit 2:~same as visit 1"
2902890|NCT03228719|Active Comparator|Control Group|Standardized Outpatient Physical Therapy after TKR
2902891|NCT03228719|Experimental|Intervention Group|Standardized Outpatient Physical Therapy after TKR with a Physical Activity Intervention
2902892|NCT03228706|Experimental|Intervention Group|All the participants who are randomly assigned to the intervention group will be undergoing the Know Your Medicine-Take it for Health (KYM-TIFH) program, which is a one-off structured group-based intervention (SGBI).
2902893|NCT03228706|No Intervention|Control Group|All the participants who are randomly assigned to the control group will not be given any information related to KYM-TIFH. However, they will be assigned to the venue for the control group and will be asked to fill in questionnaires with the assistance of four facilitators. A briefing on how to answer the questionnaire will be given by the main facilitator and all facilitators are allowed to answer any questions raised by respondents related to the questionnaire. However, they are not allowed to answer on behalf of the respondents. After the completion of the questionnaire, they will be informed about the subsequent follow-up measurement after three, six and twelve months. After that, they will be dismissed and having usual care provided by the health clinic as before without any changes.
2902894|NCT03228693|Active Comparator|Group 1|Baseline lesional and non-lesional biopsies and re-biopsy 6-8 weeks later with intralesional triamcinolone injections at 9-10, 12-16, and 24-32 weeks.
2902895|NCT03228693|Active Comparator|Group 2|Baseline lesional biopsy and re-biopsy at 6-8 weeks with intralesional triamcinolone injections at 3-4, 9-10, 12-16, and 24-32 weeks
2902896|NCT03228693|Active Comparator|Group 3|Baseline lesional and non-lesional biopsy and re-biopsy 3-4 months later with intralesional triamcinolone injections at 18-20 and 24-32 weeks.
2902897|NCT03228693|Active Comparator|Group 4|Baseline lesional biopsy and re-biopsy at 3-4 months with intralesional triamcinolone injections at 3-4, 6-8, 18-20 and 24-32 weeks.
2902898|NCT03228693|Active Comparator|Group 5|Normal patient skin (surgical or adjacent to other biopsy) from subjects with no self-reported history of keloids.
2902899|NCT03228693|Other|Earlobe Keloid|Complete excision of an earlobe keloid measuring > 10mm will be taken.
2902900|NCT03228680|Experimental|FE 999049|
2902901|NCT03228680|Active Comparator|Follistim|
2902902|NCT03228667|Experimental|Group A|Patients who are currently receiving PD-1 checkpoint inhibitor therapy and have disease progression after experiencing an initial response (defined as either a complete response (CR) or partial response (PR)) to PD-1 checkpoint inhibitor therapy.
2902903|NCT03228667|Experimental|Group B|Patients who are currently receiving PD-1 checkpoint inhibitor therapy and have disease progression after experiencing stable disease for at least six months following previous treatment with PD-1 checkpoint inhibitor therapy.
2902904|NCT03228654|Experimental|Unipolar electrocautery|vaginal hysterectomy using Unipolar electrocautery
2902905|NCT03228654|Active Comparator|Purohit's technique|Vaginal hysterectomy using Purohit's technique
2902906|NCT03228641|Experimental|micro-excisional skin removal|Facial and neck wrinkles will be treated with micro-excisional skin removal
2902907|NCT03228628|Experimental|Nitrous oxide|will inhale experimental treatment (50% N2O - 50% O2)
2902908|NCT03228628|Placebo Comparator|Placebo|will inhale medical air (22% O2 - 78% N2)
2902909|NCT03228615|Experimental|Shared Decision Making Intervention|
2902910|NCT03228615|No Intervention|Usual Care Group|
2902911|NCT03228602|Active Comparator|healthy subjects|
2902912|NCT03228602|Experimental|obese|
2902913|NCT03228602|Experimental|obese diabetic|
2902914|NCT03228589|Experimental|probiotic strain|Active arm treated with the probiotic strain for 8 weeks.
2902915|NCT03228589|Placebo Comparator|Placebo|Placebo arm treated with placebo capsules (identical to active product capsule besides the bacteria) for 8 weeks.
2902916|NCT03228576||TREVISE|
2902917|NCT03228563|Experimental|probiotics|taking 1 probiotic capsule qd and H.S for three months
2902918|NCT03228550|Experimental|Efamol Active 50+ and exercise|Efamol Active 50+ Multinutrient supplement and aerobic exercise
2902919|NCT03228550|Experimental|Efamol Active 50+ and non-exercise|Efamol Active 50+ Multinutrient supplement and non-aerobic exercise
2902920|NCT03228550|Experimental|Placebo and exercise|Placebo supplement and aerobic exercise
2902921|NCT03228550|Experimental|Placebo and non-exercise|Placebo supplement and non- exercise
2902922|NCT03228537|Experimental|Treatment (chemotherapy, surgery, RT)|"NEOADJUVANT: Patients receive atezolizumab IV over 60-90 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unexpected toxicity.~SURGERY: Patients undergo EPP or PD. After 4-8 weeks after EPP, patients may receive radiation therapy.~MAINTENANCE: Beginning 6-8 weeks after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity."
2902923|NCT03228524|Experimental|D-aspartato+ET|Patients will be administered oral D-aspartate (2660 mg once daily) for 6 weks. Moreover, patients will receive therapeutic exercise.
2902924|NCT03228524|Placebo Comparator|Placebo+ET|Patients will be administered oral placebo for 6 weks. Moreover, patients will receive therapeutic exercise.
2902925|NCT03228511|Experimental|Formerly Arm Label|
2902926|NCT03228498|Experimental|Choline alphoscerate|"Drug: Choline alphoscerate 1200 mg per day and Nimodipine 90 mg per day~concomitant administration"
2902930|NCT03228472|Placebo Comparator|sham stimulation|"Patients will be treated as in the Real stimulation arm, but no electrical or magnetic stimulation will be induced."
2902931|NCT03228459|Experimental|Intervention group|In the MU, besides clinical data collection, dried blood spot and urine spot tests, patients will be evaluated with artery ultrasound (carotid, femoral, transcranial and abdominal aorta), ankle-brachial index, spirometry, determination of advanced glycation end products and atrial fibrillation screening. Additionally, blood and urine samples will be collected and stored in the biobank to identify new biomarkers using omic studies. Finally, a report with the exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
2902932|NCT03228459|No Intervention|Control group|Patients will be evaluated in primary care units only according to their cardiovascular risk scores.
2902933|NCT03228446|Experimental|Young subjects|Working memory training & attentional filter training for participants (18-30 years)
2902934|NCT03228446|Experimental|Old subjects|Working memory training, attentional filter training and no training (control) for participants (60-80 years)
2902935|NCT03228433|Experimental|Cohort 1: TAK-418 5 mg|TAK-418 5 milligram (mg), capsule, orally, once on Day 1.
2902936|NCT03228433|Experimental|Cohort 2: TAK-418 15 mg|TAK-418 15 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
2902937|NCT03228433|Experimental|Cohort 3: TAK-418 45 mg Fasted + TAK-418 45 mg Fed|TAK-418 45 mg, capsule, in fasted state, orally, once on Day 1, followed by at least 7-day washout period, further followed by TAK-418 45 mg, capsule, in fed state, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
2902938|NCT03228433|Experimental|Cohort 4: TAK-418 90 mg|TAK-418 90 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
2902939|NCT03228433|Experimental|Cohort 5: TAK-418 180 mg|TAK-418 180 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
2902940|NCT03228433|Placebo Comparator|Cohorts 1-5: Placebo|TAK-418 placebo-matching, capsule, orally, once on Day 1.
2902941|NCT03228420|Active Comparator|HF10 therapy plus CMM|The addition of HF10 (10kHz SCS) therapy to Conventional Medical Management
2902942|NCT03228420|Other|CMM Alone|Conventional Medical Management
2902943|NCT03228407|Active Comparator|Non-erosive reflux disease (NERD)|Patient's with GERD refractory to PPI with no evidence of erosive esophagitis on endoscopy. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
2902944|NCT03228407|Active Comparator|Barrett's esophagus/erosive esophagitis|Patient's with Barrett's esophagus or with erosive esophagitis on endoscopy. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
2902945|NCT03228407|Placebo Comparator|Control|Patient's with no h/o GERD or Barrett's esophagus who are undergoing endoscopy for non-GERD related indication. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
2902946|NCT03228394|Experimental|Ganaxolone|Intravenous
2902947|NCT03228394|Placebo Comparator|Placebo|Intravenous
2902948|NCT03228381|Experimental|BOSS Device|Patients who are undergoing open chest cardiac surgery via sternotomy will receive the BOSS device to assess acute anatomical and geometric annular and ventricular changes that occur when strategically positioned an external inflatable chambers are applied to the outside of the heart.
2902949|NCT03228368||Atezolizumab (MPDL3280)|Atezolizumab 1200 milligrams (mg) will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
2902950|NCT03228355|Active Comparator|Levcromakalim|
2902951|NCT03228355|Placebo Comparator|Saline|
2902952|NCT03228342|Experimental|Ultrasound shared|Patient will be assessed with ultrasound (GUS-7 score)
2902953|NCT03228342|Experimental|Ultrasound not shared|Patient will be assessed with ultrasound (GUS-7 score)
2902954|NCT03228329|Other|cardiometry|fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
2902955|NCT03228316|Experimental|the study group one|20 patients with superior hypogastric plexus block
2902956|NCT03228316|Experimental|the study group two|20 patients with superior hypogastric plexus block combined to pulsed radiofrequency on sacral nerve roots 2,3 and 4
2902957|NCT03228303|Active Comparator|Chronic phase CML treated by nilotinib|Newly diagnosed
2902958|NCT03228303|Active Comparator|Chronic phase CML treated by imatinib|Newly diagnosed
2902959|NCT03228277|Experimental|Olmutinib|Single arm of Olmutinib, staring dose of 800 mg
2902960|NCT03228264|Experimental|High teleSLT frequency|During four weeks all patients will do a daily two-hour training session with a tablet computer (consisting of teleSLT and teleCT) at their home. In the experimental group 80% of the training time will be devoted to teleSLT and 20% to teleCT. Both groups receive the same amount of ucSLT.
2902961|NCT03228264|Active Comparator|Low teleSLT frequency|During four weeks all patients will do a daily two-hour training session with a tablet computer (consisting of teleSLT and teleCT) at their home. In the control group 20% of the training time will be devoted to teleSLT and 80% to teleCT. Both groups receive the same amount of ucSLT.
2902962|NCT03228251||Observation Group 1|all stroke patients receiving thrombolysis and/or thrombectomy in a time period of three months before stroke team simulation training
2902963|NCT03228251||Observation Group 2|all stroke patients receiving thrombolysis and/or thrombectomy in a time period of three months after stroke team simulation training
2902964|NCT03228238|Experimental|Dual subgroup|Standard medication for variant angina plus Vitamin C+E plus Statin Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU Statin : Atorvastatin calcium 10mg
2902965|NCT03228238|Experimental|Statin subgroup|Standard medication for variant angina plus Statin Statin : Atorvastatin calcium 10mg
2902966|NCT03228238|Experimental|Vitamin subgroup|Standard medication for variant angina plus Vitamin C+E Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU
2902967|NCT03228238|Active Comparator|Control group|Control subgroup : Standard medication for Variant angina only
2903054|NCT03227796|Placebo Comparator|Cohort 7 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
2902968|NCT03228225|Experimental|Tele cardiac rehabilitation|Following a standard intake process, patients will begin exercise in the institute and will gradually over a period of 6 months reduce the number of institution visits and will concomitantly increase the number of home \ community exercise sessions. During the entire period we will monitor program, coach and fine-tune the exercise program. Weekly exercise data will be securely transmitted to the rehabilitation team (heart rate zones, duration of exercise and type, step count, caloric expenditure, blood pressure and patients reported impressions)
2902969|NCT03228212|Experimental|TEST/CONTROL/CONTROL|Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old. Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis. Subjects will be randomly assigned to one of the two lens wear sequences, (TEST/CONTROL/CONTROL)
2902970|NCT03228212|Experimental|CONTROL/TEST/TEST|Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old. Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis. Subjects will be randomly assigned to one of the two lens wear sequences, (CONTROL/TEST/TEST)
2902971|NCT03228199|Other|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance as measured using a chart placed at the top of a typical tea bush.
2902972|NCT03228199|Other|Control Group|Will be deferred to receive spectacles as above, after the 12 weeks evaluation period.
2902973|NCT03228186|Experimental|Pevonedistat plus Docetaxel|Pevonedistat 25mg/m2 days 1, 3, 5 Docetaxel 75mg/m2 day 1 21 day cycle
2902974|NCT03228160|Experimental|SGI irradiation|Experimental group with active Linearly Polarized Near-Infrared light irradiation to stellate ganglion.
2902975|NCT03228160|Sham Comparator|Shame irradiation|Control group with shame Linearly Polarized Near-Infrared light irradiation to stellate ganglion.
2902976|NCT03228147|Experimental|Supportive Care (nutrition supplement)|Patients receive 10 different nutrition supplements PO and complete questionnaires based on each sample in a single session over 60-90 minutes.
2902977|NCT03228134|Experimental|Hanxiao treatment group|80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.
2902978|NCT03228134|Sham Comparator|Hanxiao control group|80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule placebo oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.
2902979|NCT03228134|Experimental|Xuxiao treatment group|80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.
2902980|NCT03228134|Sham Comparator|Xuxiao control group|80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule placebo oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.
2902981|NCT03228121|Experimental|Cohort A|Cohort A (Treatment Then Placebo group) will receive three days of cell therapy using the venous procedure (three consecutive days of blood harvest, cell separation and cell application). Cohort A will return in three months and receive three consecutive days of placebo.
2902982|NCT03228121|Experimental|Cohort B|Cohort B (Placebo Then Treatment group) will receive three consecutive days of placebo. Cohort B will return in three months and receive three consecutive days of cell therapy using the venous procedure.
2902983|NCT03228108|Experimental|Targeted antimicrobial prophylaxis|"Men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prior to biopsy (equal to the active comparator arm), and men whose swabs do show ciprofloxacin-resistant bacteria will receive alternative oral antibiotics, based on culture results, in the following order:~trimethoprim/sulfamethoxazole (SXT) 960 mg orally 2 hours before and 12 hours after prostate biopsy, or~fosfomycin 3 g orally 2 hours before prostate biopsy, or~pivmecillinam/augmentin respectively 400 mg and 500/125 mg 2 hours before prostate biopsy followed by 2 days with three divided doses each day after prostate biopsy."
2902984|NCT03228108|Active Comparator|Routine empirical prophylaxis|Ciprofloxacin 500 mg orally 2 hours before and 12 hours after transrectal prostate biopsy.
2902985|NCT03228095||Active Tuberculosis|Participants with Active Tuberculosis Disease Intervention: Diagnostic Test: VOC detection in breath and in skin headspace Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Breath sampling Intervention: Headspace analysis for biological material
2902986|NCT03228095||Group of Control (Tuberculosis)|Participants Without Active Tuberculosis Disease Intervention: Diagnostic Test: VOC detection in breath and in skin headspace Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Breath sampling Intervention: Headspace analysis for biological material
2902987|NCT03228095||Gastric cancer|Patients with histologically confirmed gastric cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Feacal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical speciment
2902988|NCT03228095||Gastric dysplasia|Patients without gastric adenocarcinoma but with histologically confirmed dysplasia (either high- or low-grade) of the stomach Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen
2902989|NCT03228095||High-risk gastric lesions|Patients graded Stage III-IV according to OLGIM (Operative Link of Gastric Intestinal Metaplasia Assessment) staging system, Stage III-IV according to OLGA (Operative Link for Gastric Atrophy Assessment), and those with incomplete type of intestinal metaplasia, but excluding those with dysplasia Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen Intervention: Headspace analysis for biological material
2903009|NCT03228043|Experimental|Apatinib group|Apatinib combined with CAPEOX program. Apatinib tablets: 500 mg po qd from the second cycle of chemotherapy. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
2902990|NCT03228095||Normal and low-risk gastric lesions|Staged 0-III according to OLGIM. Dysplasia should be excluded Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
2902991|NCT03228095||Colorectal cancer|Patients with histologically confirmed colorectal cancer (adenocarcinoma) Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical specimen
2902992|NCT03228095||Colorectal high-risk lesions|Patients without colorectal adenocarcinoma, but carrying high-risk adenomatous polyps being described by one of the following: 1) size≥1 cm; 2) high-grade dysplasia; 3) villous component. Prior to removal of the lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen
2902993|NCT03228095||Colorectal low-risk adenoma|Patients without colorectal adenocarcinoma and without colorectal high-risk lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
2902994|NCT03228095||Group of control (colorectal)|Patients having undergone colonoscopy without an evidence for colorectal lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical specimen
2902995|NCT03228095||Average risk general population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
2902996|NCT03228095||Pancreatic cancer|Patients with histologically confirmed pancreatic cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
2902997|NCT03228095||Chronic pancreatitis|Patients with clinically and/or histologically and/or radiologically confirmed chronic pancreatitis Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
2902998|NCT03228095||Liver cancer|Patients with histologically confirmed primary liver cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
2902999|NCT03228095||Chronic liver disease|Patients with histologically confirmed liver cirrhosis of viral or other ethiology Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
2903000|NCT03228095||Upper respiratory tract acute infections|Patients with serologically confirmed infectious disease or individuals of high risk (e.g. population in season of flu epidemy). This group does not include tuberculosis Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
2903001|NCT03228095||Oncological diseases of other locations|Patients with histologically confirmed oncological diseases, excluding gastric, colorectal, pancreatic and primary liver cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
2903002|NCT03228082|Experimental|Home Blood Pressure Monitoring (HBPM)|"Home monitoring of blood pressure will be performed. Blood pressure measurements will be entered automatically through a smartphone application into a patient-controlled medical record ('Patients Know Best'). The data will be available to the study coordinator, who will provide patients within 1 week with feedback on the measurements. If necessary lifestyle advice will be given, in case of hypertension patients will be referred to their GP.~Once monthly a questionnaire on well-being (SF-12) and symptoms will be completed. After 6 months and 1 year patients will also receive a questionnaire on feasibility and usability of the blood pressure device."
2903003|NCT03228082|No Intervention|Control group|Patients in the control group will be asked to register their blood pressure if measured during a doctor's visit, and to note medication use if applicable. They will also be asked to complete a short questionnaire on well-being (SF-12) once per month, which will be evaluated at the end of the study. No interim contact with the study coordinator is scheduled.
2903004|NCT03228069|Experimental|single visit 4-site ID vaccination|Blood would be drawn from those who received a single visit 4-site ID rabies booster vaccination in the previous trial.
2903005|NCT03228069|Active Comparator|Conventional IM vaccination|Blood would be drawn from those who received a conventional intramuscular rabies booster vaccination in the previous trial.
2903006|NCT03228056|Experimental|uniportal VATS lobectomy|"uniportal VATS lobectomy~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)~ketoprofene 100 mg i.v every 12 hours~paracetamol 1000 mg i.v every 8 hours~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)~pain intensity measured in VAS scale"
2903007|NCT03228056|Active Comparator|two-ports VATS lobectomy|"two-ports VATS lobectomy~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)~ketoprofene 100 mg i.v every 12 hours~paracetamol 1000 mg i.v every 8 hours~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)~pain intensity measured in VAS scale"
2903008|NCT03228056|Active Comparator|three-ports VATS lobectomy|"three-ports VATS lobectomy~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)~ketoprofene 100 mg i.v every 12 hours~paracetamol 1000 mg i.v every 8 hours~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)~pain intensity measured in VAS scale"
2903053|NCT03227796|Placebo Comparator|Cohort 6 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
2903010|NCT03228043|Placebo Comparator|Control group|CAPEOX program. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
2903011|NCT03228030|Experimental|Thiamine mononitrate 500mg po daily|3 months on thiamine, followed by 6 week washout period, and then 3 months on placebo arm
2903012|NCT03228030|Placebo Comparator|Placebo|3 months on placebo, followed by 6 week washout period, and then 3 months on thiamine
2903013|NCT03228017|Other|Psoriatic Disease Patients|Moderate to severe psoriatic disease
2903014|NCT03228017|No Intervention|Healthy Control|
2903015|NCT03228004|Experimental|Intervention Group|Participants will be provided with training on how to upload glucose data via GLOOKO and will receive reminders to upload glucose data on a biweekly basis between clinic visits.
2903016|NCT03227991|Active Comparator|Safety Planning Intervention|SPI is a personalized approach that focuses on early identification of warning signs and execution of systematic steps to manage suicidal thoughts, created collaboratively by the patient and clinician.
2903017|NCT03227991|Active Comparator|Risk factors and Warning signs|Patients will receive a generic suicide risk factors and warning signs information handout.
2903018|NCT03227978|Experimental|PCL mesh group|Intervention: The participants will be received thoracoscopic bullectomy and abrasion of pleura, then PCL mesh will be applied over the lung.
2903019|NCT03227965|Other|ELITE|
2903020|NCT03227952|Active Comparator|Active treatment|Vibrotactile sensory stimulation
2903021|NCT03227952|Sham Comparator|Sham|Identical device. No vibration
2903022|NCT03227939|Experimental|Combined Surgery Group|LSG + UPPP＆Adenoidectomy/Tonsillectomy
2903023|NCT03227939|Active Comparator|LSG Group|LSG only
2903024|NCT03227926|No Intervention|Molecular Screening|"Molecular Screening Phase will determine the molecular eligibility of the patients for 3rd line panitumumab re-challenge. Patients will be liquid biopsied (LB) at different check-points and their ctDNA tested by ddPCR to monitor the emergency, and subsequent decay, of RAS altered clones. The RAS Baseline Mutational Load (BML) will be defined within 15 days from last anti-EGFR dose prior documented 1st line PD. Only patients with a > 3% RAS fractional mutational abundance (RAS+) will move to the next step of the screening. RAS+ patients will receive a 2nd line anti-EGFR-free chemotherapy according to physician choice. RAS+ patients progressing during or after 2nd line therapy will be retested at the Rechallenge Mutational Load (RML) checkpoint. Patients showing a >50% drop in RAS mutational load at RML compared to BML will be declared molecularly eligible for the Trial Phase."
2903025|NCT03227926|Experimental|Trial Phase|"Patients resulting molecularly eligible at the RML (Rechallenge Mutational Load) checkpoint, upon Informed Consent signature and having satisfied all other eligibility criteria, will be treated with panitumumab monotherapy at standard dose until documented radiological progression or unacceptable toxicity or any other reason whichever comes first."
2903026|NCT03227913|Active Comparator|Good chewing ability|
2903027|NCT03227913|Experimental|Impaired chewing ability|
2903028|NCT03227900|Active Comparator|Lidocaine|LIdocaine dissolved in water for injections
2903029|NCT03227900|Placebo Comparator|Placebo|Water for injections
2903030|NCT03227887|Active Comparator|Good chewing ability|
2903031|NCT03227887|Experimental|Impaired chewing ability|
2903032|NCT03227874|Experimental|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
2903033|NCT03227874|Experimental|Muffin|two muffins, each with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
2903034|NCT03227861|Experimental|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.
2903035|NCT03227822|Experimental|Short spot stenting|Short spot stenting
2903036|NCT03227822|Experimental|Long lesion stenting|Long lesion stenting
2903037|NCT03227809|Experimental|Handbook condition|Parents in this condition receive a handbook designed for parents of first-year college-going students the summer before school starts
2903038|NCT03227809|Experimental|Handbook plus condition|Parents in this condition receive a handbook designed for parents of first-year college-going students the summer before school starts plus a series of text messages during students' first year of college
2903039|NCT03227809|No Intervention|Control|Parents receive treatment as usual of incoming university student parents
2903040|NCT03227796|Experimental|Cohort 1 Healthy Volunteers Active|LEVI-04 0.003 mg/kg single intravenous dose Healthy Volunteers
2903041|NCT03227796|Experimental|Cohort 2 Healthy Volunteers Active|LEVI-04 Dose Level 2 (planned 0.01 mg/kg) single intravenous dose Healthy Volunteers
2903042|NCT03227796|Experimental|Cohort 3 Healthy Volunteers Active|LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Healthy Volunteers
2903043|NCT03227796|Experimental|Cohort 4 Osteoarthritis Patients Active|LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Osteoarthritis Patients
2903044|NCT03227796|Experimental|Cohort 5 Osteoarthritis Patients Active|LEVI-04 Dose Level 4 (planned 0.1 mg/kg) single intravenous dose Osteoarthritis Patients
2903045|NCT03227796|Experimental|Cohort 6 Osteoarthritis Patients Active|LEVI-04 Dose Level 5 (planned 0.3 mg/kg) single intravenous dose Osteoarthritis Patients
2903046|NCT03227796|Experimental|Cohort 7 Osteoarthritis Patients Active|LEVI-04 Dose Level 6 (planned 1.0 mg/kg) single intravenous dose Osteoarthritis Patients
2903047|NCT03227796|Experimental|Cohort 8 Osteoarthritis Patients Active|LEVI-04 Dose Level 7 (planned 3.0 mg/kg) single intravenous dose Osteoarthritis Patients
2903048|NCT03227796|Placebo Comparator|Cohort 1 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
2903049|NCT03227796|Placebo Comparator|Cohort 2 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
2903050|NCT03227796|Placebo Comparator|Cohort 3 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
2903051|NCT03227796|Placebo Comparator|Cohort 4 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
2903052|NCT03227796|Placebo Comparator|Cohort 5 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
2903055|NCT03227796|Placebo Comparator|Cohort 8 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
2903056|NCT03227783|Active Comparator|Real tDCS|"Constant weak electric currents through scalp via two electrodes will be delivered.~Current intensity: 2mA, 20min/day"
2903057|NCT03227783|Sham Comparator|Sham tDCS|"a 1 mA current, for 30 s giving an initial sensation of tDCS while minimizing stimulatory effects~Ramp up and ramp down was over 10 s. (Ref. Loo CK et al., Br J Psychiatry 2012;200:52-9)"
2903058|NCT03227770|Active Comparator|regular hemodialysis|Low-flux hemodialysis treatment at a frequency of 2 times a week and online-hemodiafiltration treatment at a frequency of once a week, with each treatment session lasting 4 hours.
2903059|NCT03227770|Experimental|hemoperfusion combined with hemodialysis|Combination of hemodialysis and hemoperfusion treatment once every two week
2903060|NCT03227757|Experimental|Tricuspid Valve Repair System|Subjects who received TVRS will be included in this arm.
2903061|NCT03227744|Active Comparator|Enrolled in group therapy|Patients in the group therapy arm will be enrolled in group therapy and be issued surveys.
2903062|NCT03227744|Placebo Comparator|Not enrolled in group therapy|Patients in control arm will be issued surveys
2903063|NCT03227731|Active Comparator|Arm A (Intervention - Truvada)|Standard HIV Prevention strategy PLUS a once daily dose of Truvada (FTC 200mg/TDF 300mg tablet) initiated in pregnancy and continuing until cessation of breastfeeding or 18 months postdelivery whichever is earliest and thereafter the option to continue PrEP post breastfeeding cessation.
2903064|NCT03227731|No Intervention|Arm B (Control - Standard of Care)|Standard HIV Prevention strategy throughout pregnancy until 18 months postdelivery PLUS the offer to initiate PrEP post breastfeeding cessation
2903065|NCT03227718||athletic background|ex-gymnasts
2903066|NCT03227718||control|age-matched non-gymnastics background
2903067|NCT03227705|Active Comparator|Intravaginal progesterone|Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime up to 36 6/7 weeks of gestation, Merck Canada Inc.)
2903068|NCT03227705|Experimental|Intravaginal progesterone and pessary|Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime, Merck Canada Inc.). Also, a perforated pessary (Dr. Arabin, cerclage pessary perforated) will be inserted. The pessary will be removed and the progesterone treatment will be stopped at 36 6/7 weeks of gestation.
2903069|NCT03227692|Experimental|Persona with iASSIST Knee|Having total knee arthroplasty (Persona Knee System) surgery with the use of a navigation system iASSIST Knee.
2903070|NCT03227692|Active Comparator|Persona without iASSIST Knee|Having total knee arthroplasty surgery (Persona Knee System) with the use of conventional surgical instruments, and without a navigation system iASSIST Knee.
2903071|NCT03227679|Active Comparator|Metabolism-Informed Care (MIC)|Smoking Cessation Pharmacotherapy (varenicline, bupropion, and nicotine patch) recommendations were guided by Nicotine Metabolism as measured by the Nicotine Metabolite Ratio. Ultimately, after being educated about smoking cessation medication efficacy and side-effects, the participant could decide to take any medication for which they were medically cleared, but the recommendation was made based on rate of Nicotine Metabolism.
2903072|NCT03227679|Active Comparator|Guideline-Based Care (GBC)|Smoking Cessation Pharmacotherapy (varenicline, bupropion, and nicotine patch) was co-selected from those they were medically able to receive after educating participants about smoking cessation medication efficacy and side-effects.
2903073|NCT03227666|Experimental|Intervention Group|The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
2903074|NCT03227666|No Intervention|Control group|The control group recieves a health consultation that highlights the importance of physical activity and balance exercise according to standard practice within the HAI project. They are asked to return after 4 weeks for follow up.
2903075|NCT03227653||Efavirenz|Children using efavirenz-based cART for at least 6 months
2903076|NCT03227653||Non-efavirenz|Children using non-efavirenz-based cART (nevirapine or Lopinavir-Ritonavir Drug Combination) for at least 6 months.
2903077|NCT03227640|Active Comparator|stripping|standardized laparoscopic stripping technique
2903078|NCT03227640|Experimental|CO2 laser vaporization|drainage of the cyst content and vaporization of the internal wall with CO2 laser
2903079|NCT03227627|Experimental|VitalStim|"One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®. VitalStim® therapy involves the placement of electrodes to the muscles of the throat that is attached to a device that provides electrical stimulation. The intensity will be increased according to the subject's tolerance and when a therapeutic level is reached. Signs of reaching therapeutic level include changes in audible quality of swallows, triggers of swallows, and changes in quality of voice. This therapy is to be performed by a VitalStim® certified practitioner."
2903080|NCT03227627|Active Comparator|Traditional therapy|The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
2903081|NCT03227614|No Intervention|Control|This arm of participants will not experience the intervention of having a support person of the patient's choice support the patient during their abortion.
2903082|NCT03227614|Experimental|Support Person Intervention|This arm of participants will experience the intervention of having a support person of the patient's choice support them during their abortion procedure.
2903083|NCT03227575|Experimental|Post-Meal Walking Group|"Following a 30-minute digestion period, the Post-Meal Walking Group will be instructed to walk following breakfast, lunch, and dinner at least 4 times per week (180 minutes of moderate intensity exercise/week). Participants will walk at a brisk pace for 15 minutes, as demonstrated in a previous study. A Garmin VivoFit activity monitor will measure their physical activity across the four-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
2903183|NCT03226899|Placebo Comparator|Placebo + XOI|lesinurad placebo matching tablet plus a stable, medically appropriate dose of an XOI
2903186|NCT03226860|Experimental|Gait Myoelectric Stimulator|The Gait Myoelectric Stimulator device stimulates the dorsiflexor and plantarflexor muscles at the correct time for typical walking.
2903084|NCT03227575|Experimental|Traditional Exercise Group|"The Traditional Exercise Group will perform aerobic and light resistance training exercise over the 4-week intervention. A group of trained Exercise and Sports Physiology students will conduct the aerobic exercise and light resistance training program three times per week (180 minutes of moderate to high intensity exercise/week). Garmin VivoFit activity monitors will measure their physical activity across the four-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
2903085|NCT03227575|No Intervention|Case Control Group|"The participant will be instructed to maintain their current diet and levels of physical activity for four weeks. Participants in this group will wear an ambulatory blood pressure monitor at baseline and at follow-up. Any change in diet and physical activity level might significantly affect the study results. The Control Group will maintain their current lifestyle for four weeks. Garmin VivoFit activity monitors will measure their physical activity throughout the 4-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
2903086|NCT03227562|Other|Responder|The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
2903087|NCT03227562|Other|Non responder|The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
2903088|NCT03227549|Experimental|Direct Superior Approach|The intervention being tested is the surgical approach.
2903089|NCT03227549|Active Comparator|Posterior Approach|
2903090|NCT03227523||subjects with copd|
2903091|NCT03227523||subjects without pulmonary disease|
2903092|NCT03227510||HCC Cases (Group 1)|This group will include 63 subjects and the diagnoses will be based on clinical examination, laboratory tests such as (Liver Function tests, Alpha-fetoprotein , Ultrasound, and biopsy in some cases if possible (Depends on the patients and their financial issues).
2903093|NCT03227510||Chronic Liver Diseases (group 2)|This group will be including 31 patients, and the diagnoses will be based on laboratory such as (liver function tests, viral markers, AFP,) and by ultrasound findings (shrunken liver, coarse echo-pattern, attenuated hepatic vein and finding nodular surface)
2903094|NCT03227510||Healthy Volunteer (group 3)|"It will include 32 subjects that serve as control group.~These all patients and control groups will be subject the following parameters: Biochemical tests such as (Liver function tests, viral markers, serum AFP, CBC, Kidney functions and others) and circulating MicroRNAs levels of all these subjects."
2903095|NCT03227497|Active Comparator|Walnut|"At the beginning of the study, subjects are randomly assigned to receive either intervention treatment (whole walnuts) or no treatment (control arm).~Treatment arm includes 56 g of whole walnuts daily."
2903096|NCT03227497|No Intervention|Control|At the beginning of the study, subjects are randomly assigned to receive either intervention treatment (whole walnuts) or no treatment (control arm).
2903097|NCT03227484|Active Comparator|Empagliflozin|25mg Empagliflozin once daily over 8 weeks
2903098|NCT03227484|Placebo Comparator|Placebo|Matching placebo tablet once daily over 8 weeks
2903099|NCT03227471|Experimental|Part A: VX-445 in Healthy Subjects (HS)|Part A includes single dose escalation.
2903100|NCT03227471|Placebo Comparator|Part A: Placebo|
2903101|NCT03227471|Experimental|Part B: VX-445 in HS|Part B includes multiple-dose escalation.
2903102|NCT03227471|Placebo Comparator|Part B: Placebo|
2903103|NCT03227471|Experimental|Part C: VX-445 in Triple Combination (TC) with TEZ/IVA in HS|Multiple-dose escalation of VX-445 in TC with TEZ/IVA
2903104|NCT03227471|Placebo Comparator|Part C: Placebo|
2903105|NCT03227471|Experimental|Part D1: F/MF genotypes TC|Subjects will receive 100 mg VX-445 qd in TC with TEZ and IVA for 4 weeks.
2903106|NCT03227471|Placebo Comparator|Part D1: Placebo|Subjects will receive placebo for 4 weeks.
2903107|NCT03227471|Experimental|Part D2: F/MF genotypes TC-High|Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks.
2903108|NCT03227471|Experimental|Part D2: F/MF genotypes TC-Mid|Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks.
2903109|NCT03227471|Experimental|Part D2: F/MF genotypes TC-Low|Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks.
2903110|NCT03227471|Placebo Comparator|Part D2: Placebo|
2903111|NCT03227471|Experimental|Part E: F/F genotype - TC|Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks
2903112|NCT03227471|Active Comparator|Part E: TEZ/IVA|Subjects will receive TEZ and IVA for 4 weeks.
2903113|NCT03227471|Experimental|Part F: F/MF genotypes - TC|Subjects will receive VX-445 in TC with TEZ and VX-561 for 4 weeks.
2903114|NCT03227471|Experimental|Part F: Placebo|
2903115|NCT03227458|Active Comparator|Exercise and DHEA|1 study pill containing 50 mg of DHEA daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
2903116|NCT03227458|Active Comparator|Exercise and Placebo|1 study pill containing placebo daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
2903117|NCT03227458|Active Comparator|DHEA only|1 study pill containing 50 mg of DHEA daily for 36 weeks
2903118|NCT03227445|Experimental|Treatment sequence A|Eligible subjects will use ELLIPTA DPI QD for 28 days in Period 1 followed by DISKUS BID with HandiHaler QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 1 at Visit 3 (Day 56).
2903119|NCT03227445|Experimental|Treatment sequence B|Eligible subjects will use ELLIPTA DPI QD for 28 days in Period 1 followed by DISKUS BID with HandiHaler QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 2 at Visit 3 (Day 56).
2903120|NCT03227445|Experimental|Treatment sequence C|Eligible subjects will use DISKUS BID with HandiHaler QD for 28 days in Period 1 followed by ELLIPTA DPI QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 1 at Visit 3 (Day 56).
2903121|NCT03227445|Experimental|Treatment sequence D|Eligible subjects will use DISKUS BID with HandiHaler QD for 28 days in Period 1 followed by ELLIPTA DPI QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 2 at Visit 3 (Day 56).
2903185|NCT03226873|Experimental|Peer Navigation|PrEP-UP involves a Peer delivering PrEP education and counseling during street-based outreach followed by offer of a PrEP care appointment along with peer navigation (e.g., appointment accompaniment and reminders, etc.) for the first several PrEP visits.
2904413|NCT03218241|Experimental|PRT064445 Dose 2|Dose 2 versus Placebo
2903122|NCT03227432|Experimental|Nivolumab + Elotuzumab|"22 patients will be entered, If > 4 patients achieve at least a partial response (PR) within 4 cycles an additional 18 patients will be treated.~Nivolumab will be administered intravenously twice per cycle for cycle 1-4~Nivolumab will be administered intravenously once per cycle for cycle 5~Elotuzumab will be administered intravenously 4 times per cycle for cycle 1-2~Elotuzumab will be administered intravenously twice per cycle for cycle 3-4~Elotuzumab will be administered intravenously once per cycle for cycle 5"
2903123|NCT03227432|Experimental|Nivolumab+Elotuzumab+Pomalidomide+Dexamethasone|"Nivolumab will be administered intravenously twice per cycle for cycle 1-4~Nivolumab will be administered intravenously once per cycle for cycle 5~Elotuzumab will be administered intravenously 4 times per cycle for cycle 1-2~Elotuzumab will be administered intravenously twice per cycle for cycle 3-4~Elotuzumab will be administered intravenously once per cycle for cycle 5~Pomalidomide will be administered for 21 days per cycle~Dexamethasone will be administered weekly"
2903124|NCT03227419|Experimental|Tocilizumab Prefilled Syringe|"Market approval recommendations will be respected. Treatment should be started within 7 days of randomization.~The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below."
2903125|NCT03227419|Experimental|Abatacept Prefilled Syringe|"Market approval recommendations will be respected. Treatment should be started within 7 days of randomization.~The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below."
2903126|NCT03227406|No Intervention|Daytime Wake|Subjects are trained and retested during a single period of daytime wake
2903127|NCT03227406|No Intervention|Overnight sleep|Subjects are trained on one day and tested the next day, after a night of normal sleep
2903128|NCT03227406|Experimental|Sleep deprivation|Subjects are trained on one day and tested the next day, after a night of sleep deprivation
2903129|NCT03227406|Experimental|Daytime Nap|Subjects are trained and then retested after a daytime nap
2903130|NCT03227393|No Intervention|No yoga training|This will be the control arm. The patients in this arm will not receive any yoga training. They will be continued on all their home, guideline-directed heart failure medications. They will undergo the same baseline and study completion evaluation as the treatment arm, including an I-123 MIBG scan, 24-hour holter monitoring and device interrogation.
2903131|NCT03227393|Experimental|Yoga training|The patients in this arm will receive yoga training. This includes weekly group yoga sessions consisting of breathing exercises, yoga poses, and relaxation and meditation lasting for about 80-90 minutes total. Patients will be asked to do home yoga practices at least twice a week and to document the date and time. Patients in this arm will have the same baseline and study completion evaluation as the control arm, including an I-123 MIBG scan, 24-hour holter monitoring and device interrogation.
2903132|NCT03227380|Other|radiological evaluation|to explore by thoracic densitometry with contrast the spared segments after stapling of the intersegmental plan following a thoracoscopic segmentectomy
2903133|NCT03227367|Experimental|Test group|Mononuclear cells isolated from the peripheral blood of 25 chronic periodontitis patients were interveened with 1ml/well preparation of Platelet rich fibrin(PRF), Biphasic calcium phosphate (BCP) and PRF and BCP combination in-vitro.
2903134|NCT03227367|Other|control group|Mononuclear cells isolated from the peripheral blood of healthy individuals in-vitro.
2903135|NCT03227341|Other|patients with uncontrolled asthma.|8 week pulmonary rehabilitation program
2903136|NCT03227341|Other|patients with partially controlled asthma|8 week pulmonary rehabilitation program
2903137|NCT03227328|Experimental|Treatment Arm A|concomitant chemotherapy plus an aromatase inhibitor (AI); the AI must continue until disease progression or toxicity or patient refusal; chemotherapy may be stopped after achievement of maximum response (generally after at least about 3-6 months of treatment) or in case of toxicity or patient refusal.
2903138|NCT03227328|Active Comparator|Treatment Arm B|chemotherapy followed by an aromatase inhibitor (AI); at the time of progression to chemotherapy (if an endocrine therapy is deemed indicated by the treating physician) or as maintenance therapy after achieving maximum response to chemotherapy (generally after at least about 3-6 months of treatment) or after stopping chemotherapy for toxicity or patient refusal.
2903139|NCT03227302||attending obstetrician|the low grade doctor who can do caesarean operation with no pregnant complications.
2903140|NCT03227302||associate chief obstetrician|The middle grade doctor who can do caesarean operation with no or mild or middle pregnant complications.
2903141|NCT03227302||chief obstetrician|the high doctor who can do all caesarean operation without limitations
2903142|NCT03227289||Stayed in NRDS|The neonates with NRDS are stayed in NRDS
2903143|NCT03227289||Converted to ARDS|The neonates with NRDS are converted to ARDS
2903144|NCT03227276|Placebo Comparator|Placebo|
2903145|NCT03227276|Experimental|Litramine|
2903146|NCT03227263|Experimental|Bevacizumab|Intravenous infusion of Bevacizumab at a dose of 5 mg/kg
2903147|NCT03227263|Placebo Comparator|Placebo|0.9% of sodium chloride is infused every 14 days for 6 consecutive administrations
2903148|NCT03227250||GPI DBS|patients who had freezing of gait and underwent deep brain stimulation (DBS) of the globus pallidus interna (GPi)
2903149|NCT03227237||Case group|Introduction was given about research and researcher to participants. Got the assent from participants, consent from parents and collected baseline data (demographic variable, specific IPR variable) from the participants. Collected data about IPR on the basis of Modified Washington State Juvenile Court Assessment Scale from the participants.Participants were asked to fill out IPR related information of pre delinquent period with paper & pencil mode of technique. It took for each group of participants about 40 minutes. Collected data regarding conduct variables from parents with interview technique. On each day 8-16 participants were covered.
2903184|NCT03226886||All patients|In London renal cell carcinoma patients undergo nephrectomy at centres for urological oncology, including the Royal Marsden, Guy's and St Thomas', St Georges, Charing Cross and Kings Hospitals. It is not uncommon for the same patients to undergo palliative resection for metastatic sites of disease. The majority of tissue from these resections does not undergo routine histopathological examination. As such, it is ethically feasible to use these specimens for laboratory research in the presence of patient consent. Practically, these specimens are often large, thereby offering considerable scope for a range of molecular analyses.
2903150|NCT03227237||Control group|Introduction was given about research and researcher to participants. Confirmed telephonic consent from Parents.Collected baseline data (demographic variable, specific IPR variable) from the participants.Collected data about IPR on the basis of Modified Washington State Juvenile Court Assessment Scale from the participants. Participants were asked to fill out IPR related information of their past life from before 2 years with paper & pencil mode of technique. It took for each group of participants about 40 minutes. On each day 8-20 participants were covered Got the written consent form parents and collected data regarding conduct variables from parents with interview technique.
2903151|NCT03227224|Placebo Comparator|Placebo|Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
2903152|NCT03227224|Experimental|JNJ-42847922|Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
2903153|NCT03227211||COPD exacerbated patients admitted|No specific intervention
2903154|NCT03227198|Experimental|Intramyocardial injection of stem cell|Intramyocardial injection of autologous bone marrow mononuclear cells in patients with Heart Failure
2903155|NCT03227198|Placebo Comparator|Placebo|Placebo intramyocardial injection in patients with Heart Failure
2903156|NCT03227185|Experimental|Real - sham anodal tDCS|"Session 1: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.~Session 2: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase."
2903157|NCT03227185|Experimental|Sham - real anodal tDCS|"Session 1: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.~Session 2: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase."
2903158|NCT03227146|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
2903159|NCT03227133|Experimental|Single arm|Psychiatric interview, Neuropsychological evaluations, cardiovascular risk assessment
2903160|NCT03227120|Experimental|Prehabilitation Exercise|Receives Prehabilitation exercise program for three times a week for eight weeks of direct outpatient exercise instruction.
2903161|NCT03227120|No Intervention|Control|Receives the usual standard of care which is a one time Strength and Flexibility written home exercise program provided during total joint education pre-surgery class.
2903162|NCT03227094|Other|Standard OGTT|OGTT standard test at hospital (75g glucose beverage; 2-h test with plasma glucose collection)
2903163|NCT03227094|Experimental|Home-based OGTT (Beverage)|Home-based OGTT with CGM device, without glucose collection (75g glucose beverage; 2-h test: glycemia measured by CGM)
2903164|NCT03227094|Experimental|Home-based OGTT (Candy)|Home-based OGTT with CGM device, without glucose collection (75g of glucose (Jelly Beans); 2-h test: glycemia measured by CGM)
2903165|NCT03227081|No Intervention|Sleep|Sleep
2903166|NCT03227081|Experimental|Sleep Deprivation|Sleep Deprivation
2903167|NCT03227068|Experimental|PEDSS - symptom management|Content for the PEDSS - symptom management includes the most commonly experienced treatment-related physical symptoms, descriptions of each symptom, strategies to reduce symptom distress, and when and how to contact the cancer care team.
2903168|NCT03227068|Experimental|PEDSS - support for the caregiver|Content for the PEDSS - support for the caregiver includes five topics and suggestions on how caregivers can care for themselves during this time.
2903169|NCT03227055||CKD|Children and adolescents with stage G1-G4 CKD, age 3 to 18 yr
2903170|NCT03227029|Experimental|RSV ΔNS2/Δ1313/I1314L vaccine|Participants will receive a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
2903171|NCT03227029|Experimental|RSV 276 vaccine|Participants will receive a single dose of the RSV 276 vaccine at study entry (Day 0).
2903172|NCT03227029|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
2903173|NCT03227016|Experimental|Combination Topo/Veli|Topotecan and Veliparib in increasing doses
2903174|NCT03226977|Experimental|NIPPV|NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
2903175|NCT03226977|Active Comparator|NCPAP|NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
2903176|NCT03226964|Experimental|High flow nasal oxygen|(Optiflow; Fisher & Paykel, Auckland, New Zealand)
2903177|NCT03226964|Active Comparator|Nasal prongs|
2903178|NCT03226951|Experimental|Subtherhold 532 nm laser|Applying 532nm subtherhold laser with 5% duty cycle using high density low intensity protocol at the area of non central clinical significant macular edema
2903179|NCT03226925|Experimental|Healthy volunteers on ventilation|Dynamic MRI acquisition will be performed at two different time points with 10 healthy volunteers under non-invasive mechanically-assisted ventilation with a respirator. Different modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
2903180|NCT03226925|Experimental|Cancer patients on ventilation|Dynamic MRI acquisition will be performed at two different time points with 10 patients (intended for a radiation treatment of their thoracic or upper abdominal tumours) under non-invasive mechanically-assisted ventilation with a respirator. Different modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
2903181|NCT03226925|Experimental|Planning with patients on ventilation|Planning 4D-CT will be performed with 10 patients (intended for a radiation treatment of their thoracic or upper abdominal tumours) under non-invasive mechanically-assisted ventilation with a respirator. Different ventilation modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
2903182|NCT03226899|Active Comparator|Lesinurad + XOI|lesinurad 200 mg oral tablet once daily (QD) plus a stable, medically appropriate dose of an XOI
2903187|NCT03226860|Active Comparator|Ready, Set, Go! 5210 program|Nationwide Initiative which recommends eating 5 servings a day of fruits and vegetables, 2 hours a day or less of screen time, 1 hour/day or more of physical activity, and 0 sugary drinks/day. This program supports the current focus in pediatric physical therapy on life-long fitness in youth with disabilities.
2903188|NCT03226847|Experimental|Pulmonary Vein Isolation|
2903189|NCT03226834|Active Comparator|MUSIC CARE|Listening for 20 min of one of the music style U sequences proposed by the medical device MUSIC CARE
2903190|NCT03226834|Experimental|PERSONAL PLAY-LIST|Listening for 20 min of patient's play-list
2903191|NCT03226821|Experimental|Tesamorelin|Subjects will be treated with tesamorelin 2 mg by subcutaneous injection daily. Enrolled subjects will have 6 visits - a baseline visit before starting tesamorelin, a visit at 1 month, 3 months, 6 months, 9 months and at 1 year of tesamorelin (GHRH analogue) therapy. Blood sampling for safety labs and clinical examinations will be performed at each visit.
2903192|NCT03226808|Other|Vivacit-E Liner|All subjects enrolled receive the study implant.
2903193|NCT03226795|Experimental|interventional arm|
2903194|NCT03226782|Active Comparator|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
2903195|NCT03226782|Active Comparator|Long Intervention protocol|"Consisting of 29 exercises to be performed at home. The guideline is to perform each exercise 6 to 8 times in a gentle manner keeping your attention on movement.~This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect."
2903196|NCT03226769|Experimental|TrueTear|Intranasal application of TrueTear device for approximately 8 minutes at Day 0, for approximately 3 minutes at Day 7 and then daily use of TrueTear per Patient Guide with assessments at Day 7, Day 14 and Day 30.
2903197|NCT03226769|Active Comparator|Thermalon Dry Eye Compress|Application of Thermalon Dry Eye Compress at Day 0, Day 7 and daily use as per label instructions with assessments at Day 7, Day 14 and Day 30.
2903198|NCT03226756|Experimental|Nivolumab|All patients enrolled in the study will received Nivolumab injections, 3mg/kg IV, every 2 weeks, up to 12 cycles (1 cycle = 28 days).
2903199|NCT03226743|Experimental|Intervention Group|collaborative and stepped care model for depressive, anxiety, somatoform and/or alcohol abuse disorders within a multiprofessional network
2903200|NCT03226743|No Intervention|Control Group|treatment as usual in German health care system
2903201|NCT03226730|Experimental|Arm 1: Household Visits|Arm 1 will receive gender synchronized household visits (i.e., visits by a female community health worker to the participating married adolescent female and visits by a male community health worker to the participating husband of the married adolescent female). Approximately 10-12 visits with wives and 4-6 visits with husbands are expected to take place over the course of the project. Study Arms 1-3 will additionally receive community enabling environment activities and adolescent-specific service delivery activities to support adolescent contraception use. Community enabling environment activities will include engaging religious leaders, community leaders, and familial gatekeepers of the married adolescent wives, such as in-laws, in community dialogues on a monthly basis.
2903202|NCT03226730|Experimental|Arm 2: Small Groups|This arm will receive, in addition to the community-level components, gender synchronized group-based interventions (i.e., separate group-based interventions for husbands of adolescent wives and adolescent wives, themselves). Male-only and female-only small groups for participating husbands and wives will be held separately on bimonthly and monthly intervals, respectively. In this project, each small group will consist of 10-15 participants and will be held in places participants have deemed safe spaces (e.g., a place that has auditory and visual privacy, is safe for girls to walk to, has been designated by community leaders as a protected place for girls to meet). Approximately 8-10 female small groups and 4-6 male groups are expected to take place over the course of the project.
2903203|NCT03226730|Experimental|Arm 3: Household Visits + Small Groups|In addition to the community enabling environment components, this arm will receive a combination of household visit and small groups intervention components, as described above for Arms 1 and 2, in order to understand the combined effect of these two interventions on the outcomes of interest.
2903204|NCT03226730|No Intervention|Arm 4: Control|The fourth arm will serve as the control condition. Individuals in these villages will not receive the household, small group, or community-enabling environment intervention components.
2903205|NCT03226717||Hepatitis C patients|Antiviral agents (sofosbuvir,daclatasvir,ribavirin) will be given to hepatitis C patients with arthropathy.
2903206|NCT03226704||1|Patients 4-30 years of age, at least 15 kg, with relapsed/refractory leukemia or lymphoma; ORpreviously treated patients without detectable disease at the time of leukapheresis but at high-relapse risk.
2903207|NCT03226691|Experimental|Single Cohort|Plerixafor at a single dose of 240 microgram/kg
2903208|NCT03226678|Experimental|Cohort 1 wAIHA (n=6)|
2903209|NCT03226678|Experimental|Cohort 2 CAD (n=6)|
2903210|NCT03226652||Sleep Disordered Breathing assessment|Patients referred for Sleep disordered breathing assessment.
2903211|NCT03226626|Active Comparator|IVAD|IV antibiotic delivery (IVAD) alone as surgical site infection prevention. The intervention is IV antibiotics alone.
2903212|NCT03226626|Experimental|TAAD + IVAD|Both subcutaneous tumescent anesthesia & antibiotic delivery (TAAD) and IVADThe The intervention is subcutanious and IV antibiotics
2903213|NCT03226613|Experimental|Patients with suspected or known oropharyngeal cancer|Patients with either known or suspected oropharyngeal cancer will be asked to undergo a transcervical ultrasound and to provide a blood and oral rinse specimen.
2903214|NCT03226600|Active Comparator|Connective Tissue Graft|Connective Tissue is harvested from the palate of the subject then placed over the recession defect on the facial of the designated tooth. A coronally advanced flap is raised to cover the connective tissue graft and the recession.
2903215|NCT03226600|Experimental|OrACELL|Allograft Tissue (human dermis) is removed from packing and placed over the recession defect on the facial of the designated tooth. A coronally advanced flap is raised to cover the OrACELL graft and the recession.
2903216|NCT03226587|Experimental|Blue light|Each subject will be undergo a whole body exposure to blue light (453 nm wavelength) for 30 minutes.
2903217|NCT03226587|Placebo Comparator|Control exposure|Each participant will also undergo a control examination, where the body will be covered with a light tight foil during blue light exposure for 30 minutes.
2903218|NCT03226574|Experimental|RTX|
2903219|NCT03226561|Active Comparator|Panoptix Group|Patients will receive bilateral phacoemulsification with diffractive trifocal lenses implantation (Phaco / Panoptix)
2903220|NCT03226561|No Intervention|Control Group|Control, age-matched presbyopic group corrected with presbyopic glasses
2903221|NCT03226548|Experimental|Experimental|Paycheck Plus: Participants will receive four times the standard Earned Income Tax Credit after filing their annual taxes
2903222|NCT03226548|No Intervention|Control|Control participants will receive the standard Earned Income Tax Credit after filing their annual taxes
2903223|NCT03226535|Experimental|Ultrasound-CT Fusion Guidance|The participants in this group (test group) will utilize the ultrasound-CT fusion system for guiding needle placement.
2903224|NCT03226535|No Intervention|CT Guidance|The participants in this group (control group) will receive the procedure with traditional CT methods and equipment, for guiding needle placement.
2903225|NCT03226522|Experimental|AXS-05|AXS-05 tablets taken by mouth for 5 weeks.
2903226|NCT03226522|Active Comparator|Bupropion|Bupropion tablets taken by mouth for 5 weeks.
2903227|NCT03226522|Placebo Comparator|Placebo|Placebo tablets taken by mouth for 5 weeks.
2903228|NCT03226496|Experimental|Intervention Group|This group receives a brief motivational interviewing session about PrEP
2903229|NCT03226496|No Intervention|Control Group|This group receives standard of care clinic based counseling about PrEP
2903230|NCT03226483|Experimental|Intraoperative radiotherapy|"After neurosurgical resection and proven metastasis (frozen section) a local intraoperative radiotherapy with soft energy x-rays is applied to the resection cavity.~To perform this an applicator is inserted into the situs in the tightest fit rule. The highest possible dose between 30-20 Gy is chosen depending on nearby risk structures (Optic nerve, brainstem) is prescribed. After radiotherapy the applicator is removed and the surgery will be finished in standard way."
2903231|NCT03226470|Experimental|T27 group|Subjects will receive suppository with T27 at 2 intervals for one month.
2903232|NCT03226470|Experimental|T512 group|Subjects will receive suppository with T512 at 2 intervals for one month.
2903233|NCT03226470|No Intervention|Control group|Observation
2903234|NCT03226457|Active Comparator|Empagliflozin|Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks
2903235|NCT03226457|Placebo Comparator|Placebo|Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator
2903236|NCT03226444|Experimental|0.005% Lacripep|0.005% Lacripep ophthalmic solution
2903237|NCT03226444|Experimental|0.01% Lacripep|0.01% Lacripep ophthalmic solution
2903238|NCT03226444|Placebo Comparator|placebo|placebo solution
2903239|NCT03226431|Experimental|ARINA-1|Glutathione (ARINA-1) (inhaled L-glutathione 150 mg/ml, 4 ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
2903240|NCT03226418|Experimental|Group I (lower-risk)|"INTENSIVE INDUCTION THERAPY: Patients receive cytarabine IV on days 1-7 and idarubicin over 10-15 minutes on days 1-3, or liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3 and 5. Treatment continues for 1 course in the absence of disease progression or unacceptable toxicity.~INTENSIVE CONSOLIDATION THERAPY: Patients who go into remission, receive cytarabine IV over 1-3 hours BID on days 1, 3, and 5. Treatment repeats every 4 weeks for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients treated with liposome-encapsulated daunorubicin-cytarabine receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 5-8 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
2903241|NCT03226418|Experimental|Group II (higher-risk)|"LOW-INTENSITY INDUCTION: Patients receive decitabine IV over 1-3 hours on days 1-10. Treatment repeats every 4 weeks for 1-4 courses in the absence of disease progression or unacceptable toxicity.~LOW-INTENSITY CONSOLIDATION: Patients who receive complete remission, receive decitabine IV over 1-3 hours on days 1-5. Treatment repeats every 4 weeks for 6 or more courses in the absence of disease progression or unacceptable toxicity."
2903242|NCT03226405|Experimental|Patient Navigation Program|"The study team will identify, track, and provide navigation for all adult patients referred to Cancer Center from the CHC and community partners for cancer treatment.~The Patient Navigation Program include~Education,~Appointment reminders,~Help with insurance,~Transportation,~Navigating the Cancer Center,~Assisting in finding appropriate child care,~Interpreting,~Connecting the patient to psychosocial and/or palliative care teams,~Physically escorting the patient to appointments"
2903243|NCT03226405|Active Comparator|Standard of Care|"The patients will receive enhanced usual care,~This consist of personal phone call reminders about upcoming appointments at the MGH Cancer Center"
2903244|NCT03226392|Active Comparator|QAW039|QAW039 once daily
2903245|NCT03226392|Placebo Comparator|Placebo|Placebo once daily
2903246|NCT03226366||Pre-implementation (intervention site)|Adult patients age ≥18 years who received usual care after presenting to the ED of the intervention hospital with sepsis or septic shock between May 16, 2015 and April 15, 2016
2903247|NCT03226366||Post-implementation (intervention site)|"Adult patients age ≥18 years eligible to receive immediate evaluation by multidisciplinary team (swarming) after presenting to the ED of the intervention hospital with sepsis or septic shock between May 16, 2016 and February 15, 2017"
2903248|NCT03226366||Pre-implementation (control site)|Adult patients age ≥18 years who received usual care after presenting to the ED of a non-intervention study hospital with sepsis or septic shock between May 16, 2015 and April 15, 2016
2904414|NCT03218241|Experimental|PRT064445 Dose 3|Dose 3 versus Placebo
2903249|NCT03226366||Post-implementation (control site)|Adult patients age ≥18 years who received usual care after presenting to the ED of a non-intervention study hospital with sepsis or septic shock between May 16, 2016 and February 15, 2017
2903250|NCT03226353|Other|omafilcon A 1-day soft contact lenses|
2903251|NCT03226340|Experimental|S-amlodipine + Chlorthalidone|patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
2903252|NCT03226340|Active Comparator|S-amlodipine + Telmisartan|patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
2903253|NCT03226327|Experimental|hypertension patients|
2903254|NCT03226314||stool sampled community patients|community patients entering emergency ward or intensive care unit in Reunion Island university hospital and having the stools sampled for bacterial analysis.
2903255|NCT03226301|Experimental|Ibrutinib until progression/relapse|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRDpositive patients (PB and BM) will continue on Ibrutinib maintenance (non-randomized group) until progression/relapse"
2903256|NCT03226301|Experimental|Arm A|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRD negative patients (PB and BM) will be randomized to Arm A or Arm B. Arm A: Ibrutinib until progression/relapse (Continuous ibrutinib treatment until toxicity or progression)"
2903257|NCT03226301|Experimental|Arm B|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRD negative patients (PB and BM) will be randomized to Arm A or Arm B. Arm B: Observation until event.~Patients randomized to Arm B will get reinitiation of therapy during the observation period in case of:~progression according to IWCLL criteria or~MRD≥10-3 (PB) and at least one month later MRD ≥10-2 (PB).~Treatment reinitiation will consist of ibrutinib and venetoclax (with ramp up of venetoclax from cycle 1) for 12 cycles"
2903258|NCT03226275|Experimental|First Bisoprolol-Amlodipine FDC, Then Both Separately|Subjects will receive single oral dose of bisoprolol-amlodipine FDC tablet on Day 1. After a washout period of 14 days, subjects will receive single oral dose of bisoprolol tablet and single dose of amlodipine tablet given concomitantly on Day 15.
2903259|NCT03226275|Experimental|First Bisoprolol + Amlodipine Separately, Then FDC|Subjects will receive single oral dose of bisoprolol tablet and single dose of amlodipine tablet given concomitantly on Day 1. After a washout period of 14 days, subjects will receive a single oral dose of mg bisoprolol-amlodipine FDC tablet on Day 15.
2903260|NCT03226249|Experimental|Treatment (FDG-PET/CT, pembrolizumab, chemotherapy)|See Detailed Description
2903261|NCT03226236|Experimental|study treatment|boost radiotherapy (XRT) plus intradermal autologous dendritic cell vaccine loaded with autologous tumor homogenate (Autologous DC vaccine) plus High-Dose IL-2
2903262|NCT03226223|Placebo Comparator|Naltrexone 0 mg|This aim assess the effects of pretreatment with 0 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
2903263|NCT03226223|Experimental|Naltrexone 50 mg|This aim assess the effects of pretreatment with 50 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
2903264|NCT03226210|Experimental|NovoRapid group (group Asp)|
2903265|NCT03226210|Experimental|Prandilin group (group Lis)|
2903266|NCT03226197|Experimental|Study group|Ketone ester drink to be administered by nasogastric tube. Initial bolus dose of 25 ml on enrollment. After 1 hour, begin 47 hr infusion at 6 ml per hour.
2903267|NCT03226171|Experimental|Dose-adjusted SK-1403|
2903268|NCT03226145|Active Comparator|Patients|"80 Patients : 40 FC 40 IBS-C~Will have MRI Motility and High Resolution Manometry~Then will have:~Bisacodyl 10mg once daily for 10 days, and matched placebo hyoscine butylbromide Buscopan 20mg three times daily for 10 days, and matched placebo~Both agents will have their matched placebo dispensed alongside the active product of the other agent.~All agents to be used in this study as tools for their known mechanisms of action, rather than to assess their effects."
2903269|NCT03226145|Active Comparator|Healthy Volunteers|40 HVs Will have MRI Motility and High Resolution Manometry No other interventions
2903270|NCT03226132|Experimental|Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia
2903271|NCT03226132|Active Comparator|Repeated Contact|Repeated Contact
2903272|NCT03226119|Experimental|HTLV Infected (n=50)|Serum/plasma specimens which are HTLV I, HTLV II or HTLV I/II known positive (KP)
2903273|NCT03226119|Experimental|Neurological Disorders (n=100)|Serum/plasma specimens with symptoms or any of the following neurological disorders: Acute Disseminated Encephalitis, Amyotrophic Lateral Sclerosis, Autonomic Dysfunction, Conus Medularis Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Dermatomyositis, HAM-TSP, Meningitis, Mild Cognitive Impairment, Multiple Sclerosis, Polymyositis, Spastic Paraparesis, Sciatica
2903274|NCT03226106|Experimental|Physical Activity Behavior Intervention|A 12-week behavior change intervention that supplements conventional rehabilitation including: 10 telerehabilitation sessions, daily activity sensor use, education, self-monitoring, tailored feedback, barrier/facilitator identification, promotion of problem solving, action planning, and encouragement.
2903275|NCT03226106|Active Comparator|Attention Control|Conventional rehabilitation with 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
2903276|NCT03226093|Experimental|Stromal Vascular Fraction|Isolation of SVF from fat tissue for re-administration into the same patient
2903277|NCT03226080|Placebo Comparator|Placebo|Patients will be monitored and then sedated with midazolam, fentanyl, and ketamine as necessary per standard practice to facilitate lateral positioning. Patients will be positioned with the operative side down for the spinal blockade. Under sterile conditions, spinal anesthesia will be induced with 9mg (1.2mL) of hyperbaric 0.75% bupivacaine as per standard practice. The patient will then be given a standard general anesthetic induction consisting of propofol, succinylcholine, fentanyl, and lidocaine. At the time of incision, this group will be given 10cc normal saline. Once skin closure has been initiated, 2mL normal saline will be administered.
2903341|NCT03225625|Experimental|Paraspinal|Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.
2904415|NCT03218241|Experimental|PRT064445 Dose 4|Dose 4 versus Placebo
2903278|NCT03226080|Active Comparator|Neuromuscular Blockade|Patients will be monitored and then sedated with midazolam, fentanyl, and ketamine as necessary per standard practice to facilitate lateral positioning. Patients will be positioned with the operative side down for the spinal blockade. Under sterile conditions, spinal anesthesia will be induced with 9mg (1.2mL) of hyperbaric 0.75% bupivacaine as per standard practice. The patient will then be given a standard general anesthetic induction consisting of propofol, succinylcholine, fentanyl, and lidocaine. At the time of incision, this group will be given IV rocuronium 0.6mg/kg in a volume of 10cc. Once skin closure has been initiated, sugammadex 200mg in 2ml will be administered.
2903279|NCT03226067|Experimental|GKT137831 400mg twice daily|"GKT137831 400mg twice daily~Patients will self-administer 4 capsules in the morning and 4 capsules in the evening."
2903280|NCT03226067|Experimental|GKT137831 400mg once daily|"GKT137831 400mg once daily~Patients will self-administer 4 capsules in the morning and 4 capsules in the evening. The capsules in the evening will be placebos."
2903281|NCT03226067|Placebo Comparator|Placebo Arm|Patients will self-administer 4 capsules in the morning and 4 capsules in the evening. All capsules will be placebos.
2903282|NCT03226054|Other|PPI Taper|PPI Taper using Lifestyle Modifications, per study protocol
2903283|NCT03226041|Experimental|retroperitoneoscopic urologic surgery|All included patients will undergo retroperitoneoscopic renal or adrenal surgery with the transcutaneous carbon dioxide monitor.
2903284|NCT03226028|Experimental|Music|"The recruiter will give the patient an ipod with earphone, in which the ipod is equipped with saved playlists of different music genres. Patient will choose the desired playlists and listen to the music for about 30 minutes, seated in a quiet environment in pre-operative waiting area before her turn for the scheduled surgery. Hospital Anxiety and Depression Scale (HADS) and EQ-5D-3L questionnaire will be conducted during this period.~Patient will be sent to the recovery room after the surgery, and will start the music listening again for 30 minutes once she is ready and feel comfortable to start the session. Pain score, HADS and EQ-5D-3L will be collected from the patient, as well as interview on her satisfaction and experience on the music listening."
2903285|NCT03226002|Active Comparator|Airtraq NT right nostril|nasotracheal intubation with Airtraq NT through the right nostril
2903286|NCT03226002|Active Comparator|Airtraq NT left nostril|nasotracheal intubation with Airtraq NT through the left nostril
2903287|NCT03225989|Experimental|LOAd703|LOAd703 oncolytic adenovirus administered add-on to standard of care chemotherapy or gemcitabine immune-conditioning if standard of care is no longer an option (e.g. after last line)
2903288|NCT03225976|Experimental|Infrared LED group (G-I)|The Light-Emitting Diode Device with wavelength of 904nm will be applied throughout the quadriceps femoralis extension bilaterally.
2903289|NCT03225976|Experimental|Red LED group (G-V)|The Light-Emitting Diode Device with a wavelength of 620nm will be applied throughout the quadriceps femoralis extension bilaterally.
2903290|NCT03225976|Sham Comparator|Sham Group (G-S)|The Sham Light-Emitting Diode Device will be positioned throughout the quadriceps femoral muscle extension, however, there will be no light emission.
2903291|NCT03225976|Experimental|Infrared plus Red LED group (G-IV)|The Light-Emitting Diode Device with a wavelength of 620nm plus 904nm will be applied throughout the quadriceps femoralis extension bilaterally.
2903292|NCT03225950||Chronic periodontitis donors|"Donors are medically healthy.~Slow to moderate attachment loss and bone destruction.~Good correlation between etiological factors and serverity of attachment loss."
2903293|NCT03225950||Aggressive periodontitis donors|"Donors are medically healthy.~Rapid attachment loss and bone destruction.~Familial aggregation.~No correlation between etiological factors and serverity of attachment loss."
2903294|NCT03225950||Control donors|"Donors are medically healthy.~No sign of inflammatory conditions."
2903295|NCT03225937|Experimental|Cohort A|Trastuzumab and lapatinib
2903296|NCT03225937|Experimental|Cohort B|Pertuzumab and Trastuzumab-emtansine
2903297|NCT03225924|Experimental|Experimental|Entospletinib + Rituximab + Cyclophosphamide + Doxorubicine + Vincristine + Prednisone
2903298|NCT03225911|Experimental|Insole group|This group will be treated via using lateral wedge insole. lateral wedge insole is an insole with higher lateral side than medial side. This insole is inserted in the participant shoes.
2903299|NCT03225911|Experimental|Sleeve group|This group will be treated via using simple knee sleeve. Simple knee sleeve is a knee support which has no metal support. This sleeve is wrapped around each participant knee.
2903300|NCT03225911|Experimental|insole + sleeve group|this group will have treated via using the later wedge insole and the sleeve together as combined treatment. lateral wedge insole is an insole with higher lateral side than medial side. This insole is inserted in the participant shoes. Simple knee sleeve is a knee support which has no metal support. This sleeve is wrapped around each participant knee.
2903301|NCT03225898|Experimental|Resistance Exercise with Blood flow restriction|Subjects will perform 4 sets with 30, 15, 15, 15 repetitions at 30% 1RM.
2903302|NCT03225898|Active Comparator|High-intensity resistance exercise|Subjects will perform 4 sets of 8 repetitions at 70% 1RM.
2903303|NCT03225885|Active Comparator|Printed Handout|Participants in this arm will receive verbal prematurity counseling from a Neonatologist or Neonatal fellow as well as a printed gestational age specific handout about prematurity.
2903304|NCT03225885|Experimental|Multimedia Information|Participants in this arm will receive verbal prematurity counseling from a Neonatologist or Neonatal fellow as well as have bedside access to iPad multimedia information regarding prematurity.
2903305|NCT03225872||Osteosarcoma patients and family members|Osteosarcoma patients and family members
2903306|NCT03225859|Experimental|Self-Management Program|Patients in this arm will receive the therapist assisted self-management intervention following completion of trauma-focused therapy for PTSD.
2903307|NCT03225846|Experimental|WVE-120102 (Dose A) or placebo|
2903308|NCT03225846|Experimental|WVE-120102 (Dose B) or placebo|
2903309|NCT03225846|Experimental|WVE-120102 (Dose C) or placebo|
2903310|NCT03225846|Experimental|WVE-120102 (Dose D) or placebo|
2903311|NCT03225833|Experimental|WVE-120101 (Dose A) or placebo|
2903312|NCT03225833|Experimental|WVE-120101 (Dose B) or placebo|
2903313|NCT03225833|Experimental|WVE-120101 (Dose C) or placebo|
2903314|NCT03225833|Experimental|WVE-120101 (Dose D) or placebo|
2903429|NCT03224949||Healthy controls|
2903315|NCT03225820||Overall Pharmacogenomics|"All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the usual care arm (no study-specific PGx information available to providers for these patients). Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance.~NOTE: The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits."
2903316|NCT03225820||Warfarin Sub-Study|"All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the warfarin sub-study, in which patients will be randomized in 1:1 fashion to the pharmacogenomics arm of the study. Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance.~NOTE: Warfarin is prescribed as a standard of care drug. The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits."
2903317|NCT03225794||Controls|Adults living in rural area of Cameroon, not infected with simian foamy viruses
2903318|NCT03225794||Simian Foamy virus infection|Adults living in rural area of Cameroon, infected with simian foamy viruses
2903319|NCT03225768|Experimental|Guided Training|
2903320|NCT03225755||Adults with growth hormone deficiency|12 subjects with GH deficiency, adult or childhood onset, and not currently on GH therapy will be studied. Subjects enrolled will be those planning GH therapy and beginning this therapy as part of their routine clinical care. Subjects will be 50% female and all subjects will be on 3 months of stable hormone replacements prior to testing.
2903321|NCT03225742||urinary catheterization time; one day|the patient urinary catheterization after surgery; one day
2903322|NCT03225742||urinary catheterization time; two day|the patient urinary catheterization after surgery; two day
2903323|NCT03225729|Experimental|CRYOBEAUTY MAINS ET DECOLLETE|"CRYOBEAUTY MAINS ET DECOLLETE is a new technology conceived to treat solar lentigo.~One side left, or right of neckline and/or hands is attributed to this device according to randomization protocol."
2903324|NCT03225729|Active Comparator|Liquid nitrogen|Liquid nitrogen is a classic cryotherapy device. One side, either left or right of neckline and/or hands are attributed to this device according to randomization protocol.
2903325|NCT03225716|Experimental|Ibrutinib + Ulocuplumab|"Ibrutinib administered orally once daily~Ulocuplumab administered intravenously 2-4 times per cycle for Cycles 1-6"
2903326|NCT03225703|Active Comparator|Exercise Leg|Left or right leg randomly assigned as exercise leg in a unilateral, exercise intervention. This will be a progressive exercise programme with the aim being to complete 50 multidirectional hops completed daily. (Hopping)
2903327|NCT03225703|No Intervention|Non exercise Leg|Randomly assigned non-exercise, control leg.
2903328|NCT03225690|Placebo Comparator|serum physiologic|2 ml serum physiologic will apply via epidural catheter before surgical incision.
2903329|NCT03225690|Active Comparator|Preemptive Morphine|1 mg morphine will apply via epidural catheter before surgical incision.
2903330|NCT03225690|Active Comparator|Morphine|1 mg morphine will apply via epidural catheter before at the time point of the peritoneum closed.
2903331|NCT03225677||Patients with Cirrhosis|Patients with a diagnosis of cirrhosis will have a blood draw and muscle biopsy will be performed.
2903332|NCT03225677||controls|control group should have serum ALT and AST within normal range and a blood draw and muscle biopsy will be performed
2903333|NCT03225664|Experimental|Phase Ib: Trametinib + Pembrolizumab|"Phase Ib: The phase Ib part of the study includes participants with refractory to frontline chemotherapy KRAS mutation positive (mut+) and KRAS wild‐type advanced NSCLC.~The first cycle is 35 days in duration and consists of a 14 day Trametinib run‐in followed by a 21‐day cycle. Participants receive Trametinib by mouth daily and Pembrolizumab by vein every 3 weeks with the following schedule: Trametinib 2 weeks lead‐in, followed by Trametinib 10 days on, 11 days off. Throughout dose escalation Pembrolizumab administered at the fixed dose of 200 mg by vein every 3 weeks.~Dose level 1: Trametinib 1.5 mg by mouth daily for 2 weeks lead‐in followed by Trametinib 10 days on, 11 days off. Dose level 2 : Trametinib 2 mg by mouth daily for 10 days on, 11 days off."
2903334|NCT03225664|Experimental|Phase II Group 1: Pembrolizumab|"Participants in this group have not previously received immunotherapy.~Pembrolizumab 200 mg given by vein every 3 weeks."
2903335|NCT03225664|Experimental|Phase II Group 2: Trametinib + Pembrolizumab|"Participants in this group have not previously received immunotherapy.~Starting dose of Trametinib is MTD from Phase Ib. Trametinib given with 2 weeks lead‐in followed by Trametinib 10 days on, 11 days off.~Pembrolizumab 200 mg by vein on Day 22 and every 3 weeks."
2903336|NCT03225664|Experimental|Phase II Group 3: Trametinib + Pembrolizumab|"Participants in this group have previously received immunotherapy.~Starting dose of Trametinib is MTD from Phase Ib. Trametinib given with 2 weeks lead‐in followed by Trametinib 10 days on, 11 days off.~Pembrolizumab 200 mg by vein on Day 22 and every 3 weeks.~Starting dose of Trametinib is MTD from Phase Ib. Trametinib 2 weeks lead‐in followed by Trametinib 10 days on 11 days off. and Pembrolizumab on Day 22 and every 3 weeks."
2903337|NCT03225651|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
2903338|NCT03225651|Experimental|Psychological therapy and rehabilitation|Psychological therapy Rehabilitation in 3 months
2903339|NCT03225638|Other|Group 1|Nominal strength thigh injection of 0.65ml of saline solution (0.9%) Low threshold (upper limit) strength thigh injection of 0.65ml of saline solution (0.9%)
2903340|NCT03225638|Other|Group 2|Nominal strength thigh injection of 0.65ml of saline solution (0.9%) Low threshold (lower limit) strength thigh injection of 0.65ml of saline solution (0.9%)
2903430|NCT03224949||Alcoholic hepatitis|
2903431|NCT03224949||Alcoholic steatosis|
2903342|NCT03225625|Experimental|Paraspinal EX|"Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.~Exoskeleton or equivalent stimulation following this treatment."
2903343|NCT03225625|Experimental|Paraspinal VR|"Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.~Virtual Reality or equivalent visualization following this treatment."
2903344|NCT03225612|Experimental|Open Label|Non-randomized, open label clinical study that intends to treat up to 60 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.
2903345|NCT03225586||Adults|Between 35 to 70 years of age at time of enrollment
2903346|NCT03225560|Experimental|Smart Phone Application|A novel smart phone application available for both Apple iOS and Google Android platforms with capabilities to populate the phone calendar with automated reminders/notifications at the appropriate times prior to the colonoscopy.
2903347|NCT03225560|Active Comparator|Traditional Paper Instructions|Traditional paper instructions for bowel preparation
2903348|NCT03225547|Experimental|Cohort 1|Enrollment will be paused after the first 10 patients are enrolled in the study for a safety evaluation. Once safety is confirmed, patients with hormone receptor positive, hormone refractory advanced breast cancer will be enrolled in cohort 1. Regardless of cohort, all eligible patients will be treated with pembrolizumab (on day 1 of every 21 day cycle), and mifepristone (administered daily starting the week prior to pembrolizumab).
2903349|NCT03225547|Experimental|Cohort 2|Enrollment will be paused after the first 10 patients are enrolled in the study for a safety evaluation. Once safety is confirmed, patients with triple-negative advanced breast cancer will be enrolled in cohort 2. Regardless of cohort, all eligible patients will be treated with pembrolizumab (on day 1 of every 21 day cycle), and mifepristone (administered daily starting the week prior to pembrolizumab).
2903350|NCT03225521|Experimental|HeartSteps intervention|"For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not. The randomization probability is 0.6 for receiving a message and 0.4 for not receiving a message.~For activity planning, at each decision point, the participant is randomized to either receive evening planning or not at that decision time. The randomization probability for receiving planning is 0.5, and 0.5 for not receiving planning."
2903351|NCT03225508||Phase 1|"The first phase will be to evaluate a new lung ultrasound technique to measure diaphragmatic excursion using a linear probe in the mid-axillary line. This will involve scanning 75 healthy patients undergoing elective surgery to determine normal reference values in men and women.~The following interventions will be carried out:~(i) Measurement of diaphragmatic movement with a linear ultrasound probe on both sides of the chest (ii) Measurement of diaphragmatic movement with a curved ultrasound probe on both sides of the chest"
2903352|NCT03225508||Phase 2|"This will involve patients undergoing an interscalene / supraclavicular brachial plexus block for their routine care, it will examine the reduction in diaphragmatic motion due to phrenic nerve palsy.~Interventions:~(i) Measurement of diaphragmatic movement with a linear ultrasound probe bilaterally.~(ii) Measurement of diaphragmatic movement with a curved ultrasound probe bilaterally.~(iii) Pulmonary function tests prior to the brachial plexus block (iv) Planned supraclavicular / interscalene block by the clinical team. (v) Repeat measurement of diaphragmatic movement with linear ultrasound, only on the side of the brachial plexus block.~(vi) Repeat measurement of diaphragmatic movement with curved ultrasound, only on the side of the brachial plexus block."
2903353|NCT03225495|Active Comparator|Standard Implant|
2903354|NCT03225495|Experimental|Ultra-narrow Implant|
2903355|NCT03225482|Experimental|ME-CCT|8-week Motivationally Enhanced Compensatory Cognitive Training group
2903356|NCT03225482|Active Comparator|SC|8-week Goal-focused Supportive Contact group
2903357|NCT03225469|Experimental|reinforced family member education group|Regular instructions will be given to all patients during the colonoscopy appointment. At least one family member who lives with the patient together will be given instruction at the basis of patent education.
2903358|NCT03225469|No Intervention|regular education group|Regular instructions will be given to the patients during the colonoscopy appointment. There will be nothing specially for family members.
2903359|NCT03225456|Experimental|Oxytocin|Participants will receive two doses of 24 IU intra-nasal oxytocin (Syntocinon) in a single session
2903360|NCT03225456|Placebo Comparator|Placebo|Participants will received match placebo, again in two doses in a single session
2903361|NCT03225443||Particle Radiotherapy|The patients will receive particle radiotherapy before operation,and then radical hysterectomy, removal of pelvic lymph nodes and abdominal aorta lymph nodes would be conducted. Besides ovary reservation would be made according to the individual situation. Concurrent radiation and chemotherapy would be performed according to the clinical situation.
2903362|NCT03225443||Neoadjuvant Chemotherapy|The patients will receive NACT before operation,and then radical hysterectomy, removal of pelvic lymph nodes and abdominal aorta lymph nodes would be conducted. Besides ovary reservation would be made according to the individual situation. Concurrent radiation and chemotherapy would be performed according to the clinical situation.
2903363|NCT03225430|Active Comparator|Comprehensive Behavioural Intervention|"Participant will received psychoeducation about tic disorders, creating a tic hierarchy that will be revised during future sessions, introduce concept of function-based intervention, behavioral reward program, self-monitoring training, habit reversal training for their tics. They will received an introduction of relaxation techniques and diaphragmatic breathing exercise and an introduction of progressive muscle relaxation (PMR) exercise.~They will received booster sessions for three months and he will do hierarchy review, inconvenience review, function-based intervention and competing response review, review of relaxation techniques and relapse prevention review."
2903432|NCT03224949||Alcoholic cirrhosis without HCC|
2903433|NCT03224949||Nonalcoholic steatohepatitis (NASH)|
2903434|NCT03224949||Alcoholic cirrhosis with HCC|
2903435|NCT03224936||DISE group|All patients in this study group will receive a propofol PSI controlled DISE (drug induced sleep endoscopy).
2904008|NCT03221062|Experimental|Hydroknife en Bloc Resection|Hydroknife en Bloc Resection of bladder tumor (Hydroknife ERBT)
2903364|NCT03225430|Experimental|Cognitive psychophysiological (CoPs)|The participant will received a rational about the treatment and awareness training about tics and creating list of tics. He will identifying high and low risk situations provoking tics, do video record and make a list of inconveniences of tic. He will do a screening session of the video and muscle discrimination exercises. Worked on a situational profile with a Kelly's grill and beginning relaxation and breathing exercises. He will identifying style of planning and work on it to do an advantages and inconveniences list to adopt this style. Some behavioral and cognitive re structuration about style of planning and how to modifying. At the end, he will received a relapse prevention informations and how to generalize the learnings and a record of the therapy. Finally, he will have to practice all this techniques at home for four week and do a last session to discuss home practice and received strategies for the future.
2903365|NCT03225417|Experimental|Experimental group|"Ixazomib + Tacrolimus + Sirolimus Phase I: Ixazomib doses in this study is 3 to 4 mg of ixazomib on day +1, +8 and +15.~Tacrolimus at a dose of 0.02 mg/kg/day and then 0.06 mg/kg/day. Sirolimus at a dose of 6 mg on day -5 and then 4 mg per day.~Phase II: Starting Dose of Ixazomib according to phase I. Tacrolimus at a dose of 0.02 mg/kg/day and then 0.06 mg/kg/day. Sirolimus at a dose of 6 mg on day -5 and then 4 mg per day."
2903366|NCT03225417|Other|Control group|Tacrolimus + Sirolimus Tacrolimus at a dose of 0.02 mg/kg/day and then 0.06 mg/kg/day. Sirolimus at a dose of 6 mg on day -5 and then 4 mg per day.
2903367|NCT03225404|Experimental|Experimental group|EPTE + EXER Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
2903368|NCT03225404|Experimental|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises device at home. Patient received 3 sessions of dry needling a week for four weeks.
2903369|NCT03225391|Experimental|Nap 1|Subjects who take, during a night shift, first a nap from 0:00 to 3:00 hours and, after 6 weeks of lavage, another nap from 3:00 to 6:00 hours.
2903370|NCT03225391|Experimental|Nap 2|Subjects who take, during a night shift, first a nap from 3:00 to 6:00 hours and, after 6 weeks of lavage, another nap from 0:00 to 3:00 hours.
2903371|NCT03225378||Acute circulatory failure|Mechanically ventilated patients displaying acute circulatory failure in whom the physician decides to perform a fluid challenge (fluid loading of 500 mL of crystalloid solution) and a passive leg raising test to predict fluid responsiveness.
2903372|NCT03225365|Other|Nivolumab|"Previous untreated patient with metastatic melanoma eligible for a Nivolumab treatment.~30 patients will be included in the arm."
2903373|NCT03225365|Other|Nivolumab + Ipilimumab|"Previous untreated patient with metastatic melanoma eligible for a Nivolumab + Ipilimumab treatment.~30 patients will be included in the arm."
2903374|NCT03225352|Experimental|Sequence 1: starting with BAYE4465 500 mg|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
2903375|NCT03225352|Experimental|Sequence 2: starting with BAYE4465 1000 mg|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
2903376|NCT03225352|Experimental|Sequence 3: starting with Nurofen|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
2903377|NCT03225352|Experimental|Sequence 4: starting with Dolormin Extra|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
2903378|NCT03225339|Experimental|Lifestyle Intervention|The intervention includes the use of Low Energy Diet replacement products in combination with physical activity, followed by gradual introduction of food, and increasing physical activity. Behavioural support for the lifestyle intervention will also be provided.
2903379|NCT03225339|No Intervention|Usual Care|This will be based on current clinical practice aiming to reduce diabetes symptoms and complications, and general recommendations on diet and physical activity.
2903380|NCT03225326|Experimental|Computer controlled 4% articaine delivery by Anaeject|
2903381|NCT03225326|Active Comparator|Conventional 4% articaine delivery by carpule syringe|
2903382|NCT03225313|Placebo Comparator|control group|normal saline will be injected in the rectus sheath
2903383|NCT03225313|Active Comparator|Rectus block group|bupivicaine will be injected in the rectus sheath
2903384|NCT03225313|Experimental|Local group|bupivicaine will be injected locally
2903385|NCT03225300|Experimental|Simultaneous integrated boost|In this protocol, the newly diagnosed, primary glioblastoma patients receive SIB 69 Gy/30 fractions to preoperative tumor bed and surgical cavity, while 60 Gy/30 fractions were covering preoperatively edematous area. PTV is 5 mm.
2903386|NCT03225287|Experimental|RA101495|Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study
2903387|NCT03225274|Experimental|Experimental Group|Experimental Group consist of 30 subjects. Pre-assessment of respiratory status among children was assessed. Then after 5 minutes of administration of Nebulization, breathing exercises as therapeutic play (balloon inflation, candle blowing, blow air into water with a straw was administered for 15 minutes once in a day for 3 days consecutively and then post-assessment was taken daily 5 minutes after the administration of breathing exercises as therapeutic play.
2903388|NCT03225274|No Intervention|Comparison Group|Comparison Group consist of 30 subjects. Pre-assessment of respiratory status among children was assessed. Then only nebulization therapy was administered and then post-assessment was taken daily after 25 minutes of administered.
2903389|NCT03225261|Experimental|Citrus extract UC|Citrus extract, patients with ulcerative colitis
2903390|NCT03225261|Placebo Comparator|Placebo UC|Maltodextrin, patients with ulcerative colitis
2903391|NCT03225261|Experimental|Citrus extract IBS|Citrus extract, patients with irritable bowel syndrome
2903392|NCT03225261|Placebo Comparator|Placebo IBS|Maltodextrin, patients with irritable bowel syndrome
2903393|NCT03225248|Experimental|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
2903394|NCT03225248|Active Comparator|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
2903481|NCT03224598|Experimental|Open-Label|A-101 Topical Solution 40%
2903482|NCT03224585|Experimental|Anakinra|100 mg subcutaneous injection
2903483|NCT03224585|Placebo Comparator|Placebo|100 mg NaCl 0.9% subcutaneous injection
2904009|NCT03221062|Experimental|conventional transurethral resection|conventional transurethral resection of bladder tumor(cTURBT)
2903395|NCT03225235|Experimental|Hypofractionated Stereotactic SBRT|"By assuming a hypofractionated irradiation scheme, it is assumed that between the fractions sublethal radiation damage is being treated and the time factor does not significantly affect RT result. The SBRT fractional dose was determined on the basis of a Biologically Effective Dose (BED) calculation using a linear-square model, which assumes that α / β takes the following values for:~tumor (RS) = 1.5~Late rectal and bladder complications = 3.0~early rectal and bladder complications = 10.0."
2903396|NCT03225222||Low-risk PCa|No TRUS-guided biopsy
2903397|NCT03225222||Intermediate/high-risk PCa (Control)|TRUS-guided biopsy 'only' (current standard practice).
2903398|NCT03225222||Intermediate/high-risk PCa (Intervention 1)|TRUS-guided biopsy 'first'; if indicated followed by MRI and targeted biopsies.
2903399|NCT03225222||Intermediate/high-risk PCa (Intervention 2)|MRI-'first', followed by TRUS-guided and targeted biopsies.
2903400|NCT03225209|Experimental|OPTIFAST|"Subjects meeting inclusion criteria will be receive OPTIFAST meal replacement (MR) in the following manner:~WK1-WK12 (5 MR/DAY)~WK13-14 (4 MR/DAY)~WK 15 (3 MR/DAY)~WK 16 (2 MR/DAY)~WK 17-18 (1 MR/DAY)~WK 19-24 (No MR)"
2903401|NCT03225196||Samples|We seek to measure a 665 exRNAs spanning a variety of classes in plasma from 4095 young to middle-aged adult participants in the Third Generation cohort of the FHS
2903402|NCT03225183||Cohort Exam 2 Participants|We propose to extend the investigation of transcriptomics in FHS Third Generation cohort exam 2 participants.
2903403|NCT03225170|Experimental|Intervetion|Arm Description: Participants will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. They will then be asked to write about the item that is most important to them and why it may be important to them.
2903404|NCT03225170|Sham Comparator|Control|The control group will rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. They will then be asked to write about the 9th ranked item and why it might be important to someone else. The control condition is consistent with the control used in other SA intervention studies. The 9th ranked item is chosen to inhibit a reverse effect, where participants feel affirmed because they do not value something that is averse to them.
2903405|NCT03225157||Patients|Subjects will be adult patients with head and neck squamous cell carcinoma of the upper aerodigestive tract
2903406|NCT03225144||Patients|patients who are referred with a diagnosis of frontotemporal dementia, motor neuron disorder, or related adult-onset neurodegenerative disorder to assess patient eligibility for ongoing protocols
2903407|NCT03225131||Group 3|Group 3 (N=40) is defined as participants with large drusen (greater than or equal to 125 microns) in the study eye and advanced AMD (CNV or GA) in the fellow eye.
2903408|NCT03225131||Group 4|Group 4 (N=40) is defined as participants with findings of reticular pseudodrusen (RPD) in the study eye, without advanced AMD in the study eye, and any level of AMD in the fellow eye.
2903409|NCT03225131||Group 2|Group 2 (N=40) is defined as participants with bilateral large drusen (greater than or equal to 125 microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes.
2903410|NCT03225131||Group 0|Group 0 (N=40) is defined as participants without AMD meaning no large drusen (greater than or equal to 125 microns) or advanced AMD in either eye.
2903411|NCT03225131||Group 1|Group 1 (N=40) is defined as participants with large drusen (greater than or equal to 125 microns) in the study eye and no large drusen or advanced AMD (choroidal neovascularization (CNV) or geographic atrophy (GA)) in the fellow eye.
2903412|NCT03225118||HIV/ATI|HIV-infected Adults (age 18-65 years) on ART with suppressed viremia willing to interrupt treatment and then restart once criteria is met.
2903413|NCT03225105|Experimental|M3541 + Palliative Radiotherapy (RT)|
2903414|NCT03225092|Experimental|PRP Injection|Ultrasound-guided platelet rich plasma injection
2903415|NCT03225066|Experimental|Poly-L-Lactic Acid - Sculptra|Each area will be treated with a dose contained in a vial of Sculptra®. For conducting the study, six vials of the product will be available per subject, and one vial will be used in each session with up to maximum a total volume of 16mL per treated area. It will be 3 session with interval of 1 month in total.
2903416|NCT03225053|Experimental|MEP® technique|G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
2903417|NCT03225040||Acromegaly patients on pegvisomant|25 subjects with acromegaly on pegvisomant therapy with a normal IGF-1 level for at least 1 year.
2903418|NCT03225027|Experimental|Patients with schizophrenia|Emotional judgment task, post-experimental questionnaire, recognition task, detection task, questionnaire CAPE-42, trait emotional intelligence questionnaire and positive and negative syndrome scale.
2903419|NCT03225027|Experimental|Few psychotic experiences|Healthy participants with few psychotic experience. Participants with the lowest score to the CAPE-42 test. Mini International Neuropsychiatric Interview
2903420|NCT03225027|Experimental|Several psychotic experiences|Healthy participants with several psychotic experiences. Participants with the highest score to the CAPE-42 test. Mini International Neuropsychiatric Interview
2903421|NCT03225014|Active Comparator|Physical Therapy|
2903422|NCT03225014|Active Comparator|ARP Wave Therapy|
2903423|NCT03225001|Experimental|Failing surgical valve|Patients with a failing surgical bioprosthetic valve in the aortic position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN XT transcatheter valve.
2903424|NCT03224988||Normal Adults|
2903425|NCT03224988||MCI Adults|
2903426|NCT03224975|Experimental|patients|Patient who was burned will have fMRI.
2903427|NCT03224975|Active Comparator|control group|Healthy volunteers (control group) will have fMRI.
2903428|NCT03224962||diagnostic tool|Light induced fluorescence camera Caries detection dye. visual assessment method (ICDAS criteria)
2903436|NCT03224923|Experimental|Personalized Treatment Algorithm|"A DAPT score using various patient demographics will be calculated:~If score under 2, patients will receive only aspirin 81 mg once daily~If DAPT score is ≥ 2~A point-of-care bedside genetic test using a buccal swab will be conducted in order to determine medication regimen~Those with a positive genetic test (presence of CYP2C19*2 or CYP2C19*3), will receive 60mg Ticagrelor twice daily~Those with a negative genetic test (absence of CYP2C19*2/*3) will receive 75mg clopidogrel once daily"
2903437|NCT03224923|Active Comparator|Long-Term Ticagrelor|Patients will be given 60mg Ticagrelor twice daily with no aspirin
2903438|NCT03224897|Active Comparator|Cathodal tDCS|
2903439|NCT03224897|Active Comparator|Anodal tDCS|
2903440|NCT03224897|Sham Comparator|Sham tDCS|
2903441|NCT03224884|Active Comparator|Interscalene block|Patients randomized to receive an interscalene block .
2903442|NCT03224884|Experimental|Supraclavicular block|Patients randomized to receive a supraclavicular block.
2903443|NCT03224871|Experimental|Nivolumab|Intralesional IL-2, Radiotherapy will be given to all patients. Immune checkpoint blockade with Nivolumab will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks.
2903444|NCT03224871|Experimental|Pembrolizumab|Intralesional IL-2, Radiotherapy will be given to all patients. Immune checkpoint blockade with Pembrolizumab will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks.
2903445|NCT03224858|Experimental|SUMMIT intervention group|This group will transfer primary care to the SUMMIT team, which consists of: 1 primary care provider, 1 clinical nurse, 1 team manager, 2 care-coordinators, 2 behavioralists, 1 clinical pharmacist. This interdisciplinary team will have reduced patient panel load and increased flexibility in time and scheduling in order to foster trust and continuity with the patient with a goal of decreasing treatment burden and increasing patient capacity. Specific activities that participants will receive include: 1) comprehensive initial intake and care plan development that incorporates patient goal setting; 2) flexible scheduling of appointments with outreach; 3) transitional care coordination; 4) built-in behavioural counselling and case management; 5) regular review of care plan by team members.
2903446|NCT03224858|Active Comparator|enhanced usual care group|This group will continue to receive primary care as usual for 6 months. This includes care provided by the patient's existing primary care provider, access to a clinic's Health Resilience outreach worker, mental health consultation, and other services provided by usual care. After 6 months, the baseline survey is administered and the participant will transfer care to the intervention as described above in the SUMMIT intervention group.
2903447|NCT03224845|Experimental|Cognitive behavioural skills training|
2903448|NCT03224845|No Intervention|No intervention|Participants in the control group will receive their usual clinical care and will not be discouraged from seeking any intervention.
2903449|NCT03224832|Experimental|group 1|group 1 will be Pancreatoduodenectomy With Mesopancreas. Artery-first Approach
2903450|NCT03224832|Experimental|group2|group2 will be Pancreatoduodenectomy With Mesopancreas Dissection. Standard Approach
2903451|NCT03224819|Experimental|Exploration Phase|Dose finding phase of the study
2903452|NCT03224819|Experimental|Expansion Phase|Maximum Tolerated Dose identified by Exploration Phase administered to subjects
2903453|NCT03224806|Other|Wholegrain bread|
2903454|NCT03224806|Other|White bread|
2903455|NCT03224806|Other|15% fiber-rich bread|
2903456|NCT03224806|Other|30% fiber-rich bread|
2903457|NCT03224793|Experimental|BIIB059 20 mg|Participants will receive single subcutaneous (SC) dose of 20 milligram (mg) BIIB059 or matching placebo on Day 1.
2903458|NCT03224793|Experimental|BIIB059 50mg|Participants will receive single SC dose of 50 mg BIIB059 or matching placebo on Day 1.
2903459|NCT03224793|Experimental|BIIB059 150mg|Participants will receive single SC dose of 150 mg BIIB059 or matching placebo on Day 1.
2903460|NCT03224793|Experimental|BIIB059 450mg|Participants will receive single SC dose of 450 mg BIIB059 or matching placebo on Day 1.
2903461|NCT03224767|Experimental|Treatment (vemurafenib, cobimetinib)|Patients receive vemurafenib PO BID on day 1-28 and cobimetinib PO QD on days 1-21. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive radiation therapy, surgery, or continued treatment with vemurafenib and cobimetinib at the discretion of the treating physician.
2903462|NCT03224741|Placebo Comparator|Information|
2903463|NCT03224741|Active Comparator|Active Choice|
2903464|NCT03224741|Experimental|Monetary incentive|
2903465|NCT03224728||2 different Intraocular lenses|2 different intraocular lenses were compared
2903466|NCT03224715|Experimental|Actinic Cheilitis patients|
2903467|NCT03224702|Experimental|M6495|
2903468|NCT03224702|Placebo Comparator|Placebo|
2903469|NCT03224689|Experimental|PEEK Femoral|
2903470|NCT03224663|Experimental|Module based learning|Module based learning is self-reading method using learner's guide module on FBNC provided by Department of Pediatrics
2903471|NCT03224663|Experimental|Mobile application based learning|"Mobile application based learning is learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters, videos, Modules."
2903472|NCT03224650||Surgical|Patients treated surgically for spinal metastases
2903473|NCT03224650||Non-operative|Patients treated non-operatively for spinal metastases
2903474|NCT03224650||Expectant|Patients receiving no treatment for spinal metastases
2903475|NCT03224637|Active Comparator|radiofrequency group|radiofrequency was done in the three genicular nerves upper medial and upper lateral and lower medial
2903476|NCT03224637|Active Comparator|conventional group|the patients received conventional paracetamol and non steroidal antiinflammatory
2903477|NCT03224624|Experimental|self-management|Participants will be taught to monitor blood pressure and make limited adjustments to their medications
2903478|NCT03224624|No Intervention|usual care|Participants will be enrolled in the study and undergo a baseline, 6 month, and 1 year visit but their hypertension care will be per usual care.
2903479|NCT03224611|No Intervention|Control group|"The flexible LMA is inserted using index finger technique"
2903480|NCT03224611|Active Comparator|Light wand group|The flexible LMA is inserted using light wand as a stylet
2903484|NCT03224572|Experimental|The study group|The study group will receive intravenous high-dose vitamin C 30 gm in 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
2903485|NCT03224572|Placebo Comparator|The control group|The control group will receive 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
2903486|NCT03224559||Sham Stimulation|subject receives minimal transcranial electrical stimulation
2903487|NCT03224559||Left Side Stimulation|transcranial electrical stimulation on the left side of the head.
2903488|NCT03224559||Right Side Stimulation|transcranial electrical stimulation on the right side of the head.
2903489|NCT03224546|No Intervention|Control Group|This group will receive payment for providing urine samples throughout the trial.
2903490|NCT03224546|Experimental|Low Value Alternative Reinforcer Group|This group will receive payment for providing cocaine negative urine samples throughout the trial.
2903491|NCT03224546|Experimental|High Value Alternative Reinforcer Group|This group will receive payment for providing cocaine negative urine samples throughout the trial.
2903492|NCT03224533||No Nuts|"All other foods that did not include walnuts or other nuts were classified as no nuts (NN)."
2903493|NCT03224533||Other Nuts|"Foods codes describing nuts that are not walnuts (i.e. cashew nuts, pistachios, etc.) or nut-containing foods that do not commonly contain walnuts (e.g. granola) were classified as other nuts (ON)."
2903494|NCT03224533||Walnuts with other nuts|"food codes describing nut mixes and foods that commonly include walnuts were classified as walnuts with other nuts (WwON)"
2903495|NCT03224533||Walnuts with high certainty|"Foods consisting entirely or mostly of walnuts were classified as walnuts with high certainty (WwHC)"
2903496|NCT03224520|Experimental|Fully enhanced|Peer recruitment and recommender CTHC
2903497|NCT03224520|Experimental|Recommender CTHC only|Recommender CTHC and standard online recruitment
2903498|NCT03224520|Experimental|Peer recruitment only|Peer recruitment and standard CTHC
2903499|NCT03224520|Experimental|Standard|Standard online recruitment and standard CTHC
2903500|NCT03224507|Experimental|KRdD followed by auto-HCT|Cycle 1-Dexamethasone 40mg orally days 1/8/15/22; Lenalidomide 25mg orally days 1-21; Carfilzomib 20mg/m2 days 8/9 then 36mg/m2 venous days 15/16; Daratumumab 16mg/kg venous days 1/8/15/22 (KRd-Dara). Cycle 2 the same except Carfilzomib 36mg/m2 venous days 1/2/8/9/15/16. Cycles 3,4 the same but no Daratumumab Days 8 and 22. Dosage adjusted for last tolerated dose (LTD). Following induction therapy, auto-HCT is done (consolidation 1), then up to two 4-cycle blocks of KRd-Dara consolidation (consolidations 2 and 3). Minimum residual disease (MRD) checked after each phase. Patients with confirmed MRD(-) at or after consolidation 1 will not undergo maintenance and will be actively monitored for resurgence of MRD or clinical relapse. After consolidation if MRD+ patients will undergo standard of care lenalidomide maintenance.
2903501|NCT03224507|Experimental|KRdD only|Cycle 1-Dexamethasone 40mg orally days 1/8/15/22; Lenalidomide 25mg orally days 1-21; Carfilzomib 20mg/m2 days 8/9 then @ 36mg/m2 venous days 15/16; Daratumumab 16mg/kg venous days 1/8/15/22. Cycle 2 the same except Carfilzomib 36mg/m2 venous days 1/2/8/9/15/16. Cycles 3,4 the same but no Daratumumab Day 22. Dosage adjusted for last tolerated dose (LTD). Following induction therapy, Following induction therapy, patients will receive up to three 4-cycle blocks of KRd-Dara consolidation (consolidations 1, 2 and 3). Minimum residual disease (MRD) checked after each phase. Patients with confirmed MRD(-) at or after consolidation 1 will not undergo maintenance and will be actively monitored for resurgence of MRD or clinical relapse. After consolidation if MRD+ patients will undergo standard of care lenalidomide maintenance.
2903502|NCT03224494|Other|IBS Patients|"Patients 18 years or older with a diagnosis of irritable bowel symptom, as per Rome IV criteria. The diagnosis is established by the patient's gastroenterologist. Please see inclusion and exclusion section for more details.~They will undergo Rapid Barostat Bag testing, and they will answer the IBS severity scoring system questionnaire (IBS-SSS) and HAD scale questionnaire."
2903503|NCT03224494|Other|Healthy Controls|"Patients 18 years of age without IBS or other colo-rectal symptoms or pathology seen for other issues in the general GI clinic.~They will undergo Rapid Barostat Bag testing, and they will answer the IBS severity scoring system questionnaire (IBS-SSS) and HAD scale questionnaire."
2903504|NCT03224481|Experimental|Receive electronic reminder|Participants in the intervention group will receive tailored electronic reminders. The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
2903505|NCT03224481|No Intervention|Control group|Participants in the control group will not receive additional reminders.
2903506|NCT03224468|Active Comparator|Medical Marijuana Arm|This group can begin using medical marijuana immediately.
2903507|NCT03224468|No Intervention|Waitlist Control Arm|This group agrees to wait 3 months before using medical marijuana.
2903508|NCT03224442|Experimental|PRF with immediate implants|Immediate implants placed and covered with two prf layers
2903509|NCT03224442|Active Comparator|palatal pedicle graft|immediate implant placement followed by soft tissue augmentation by oalatal pedicle graft
2903510|NCT03224429|Other|Decisional Needs Assessment|Caregivers and patients with sickle cell disease will participate in a semi-structured open ended interview regarding treatment decision making.
2903511|NCT03224429|Other|Beta Testing|Caregivers and patients with sickle cell disease will review the web-based Sickle Cell Decision Aid.
2903512|NCT03224416|Experimental|Alcohol|In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
2903513|NCT03224416|Placebo Comparator|Placebo|"In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims."
2904010|NCT03221049||chronic hepatitis B patients|ultrasound and radiomics
2903514|NCT03224416|Sham Comparator|True Control|In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
2903515|NCT03224403|Experimental|Test acetaminophen|Test acetaminophen 1000 mg dose
2903516|NCT03224403|Active Comparator|Commercial acetaminophen|Commercial acetaminophen 1000 mg dose
2903517|NCT03224403|Active Comparator|Commercial ibuprofen|Commercial ibuprofen, 400 mg dose
2903518|NCT03224403|Placebo Comparator|Placebo|Placebo
2903519|NCT03224390|Experimental|Encouragement Arm|Women randomized to the encouragement arm will receive an invitation via SMS to try the new digital family planning screening and referral service.
2903520|NCT03224390|No Intervention|Control Arm|Women randomized to the control arm will receive a different set of SMS messages that do NOT include a special encouragement try the new digital family planning screening and referral service.
2903521|NCT03224377||rheumatoid arthritis patients|Complete blood count Esr Crp Liver function test Kidney function test Hepatitis markers Rheumatoid factor Urine analysis Anti cyclic citrullinated peptide antibodies Anti mutated citrullinated vimentin antibodies
2903522|NCT03224377||healthy control|Complete blood count Esr Crp Liver function test Kidney function test Hepatitis markers Rheumatoid factor Urine analysis Anti cyclic citrullinated peptide antibodies Anti mutated citrullinated vimentin antibodies
2903523|NCT03224364|Placebo Comparator|LC & nonsolo approach|The surgical intervention is nonsolo LC
2903524|NCT03224364|Active Comparator|LC & solo approach|The surgical intervention is solo LC.
2903525|NCT03224351|Experimental|Part 1: F/MF genotype -TC Low|Subjects will receive 80 mg of VX-659 qd in TC with TEZ and IVA for 4 weeks.
2903526|NCT03224351|Experimental|Part 1: F/MF genotype - TC Mid|Subjects will receive 240 mg of VX-659 qd in TC with TEZ and IVA for 4 weeks.
2903527|NCT03224351|Experimental|Part 1: F/MF genotype - TC High|Subjects will receive 400 mg VX-659 qd in TC with TEZ and IVA for 4 weeks.
2903528|NCT03224351|Placebo Comparator|Part 1: F/MF genotype - Placebo|Subjects will receive placebo for 4 weeks.
2903529|NCT03224351|Experimental|Part 2: F/F genotype - TC|Subjects will receive 400 mg of VX-659 qd in TC with TEZ and IVA for 4 weeks.
2903530|NCT03224351|Active Comparator|Part 2: F/F genotype - TEZ/IVA|Subjects will receive TEZ and IVA for 4 weeks.
2903531|NCT03224351|Experimental|Part 3: F/MF genotype - TC|Subjects will receive 400 mg of VX-659 qd in TC with TEZ and VX-561 for 4 weeks.
2903532|NCT03224351|Placebo Comparator|Part 3: F/MF genotype - Placebo|Subjects will receive placebo for 4 weeks.
2903533|NCT03224338|Experimental|: Dolutegravir (DTG)|
2903534|NCT03224325|Experimental|Cohort 1, TAK-831 Low Dose|TAK-831, low dose tablets, orally, once daily or TAK-831 placebo-matching, orally, once daily on Day 1 and Days 3 through 16.
2903535|NCT03224325|Experimental|Cohort 2, TAK-831 High Dose|TAK-831, high dose, suspension, orally, once daily or TAK-831 placebo-matching, orally, once daily on Day 1 and Days 3 through 16.
2903536|NCT03224325|Experimental|Cohort 3, TAK-831 Dose 3|TAK-831, suspension, orally, once daily or TAK-831 placebo-matching, orally, once daily on Day 1 and Days 3 through 16. Dose of TAK-831 will be based on safety and tolerability in above cohorts.
2903537|NCT03224325|Experimental|Cohort 4, TAK-831 Dose 4|TAK-831, tablets or suspension, orally, once daily or TAK-831 placebo-matching, orally, once daily on Day 1 and Days 3 through 16. Dose of TAK-831 will be based on safety and tolerability in above cohorts.
2903538|NCT03224325|Experimental|Cohort 5: TAK-831 Dose 5|TAK-831 tablets or suspension, orally, once daily or TAK-831 placebo-matching, orally, once daily on Day 1 and Days 3 through 16. Dose of TAK-831 will be based on safety and tolerability in above cohorts.
2903539|NCT03224325|Experimental|Cohort 6: TAK-831 Dose 6|TAK-831 tablets or suspension, orally, once daily or TAK-831 placebo-matching, orally, once daily on Day 1 and Days 3 through 16. Dose of TAK-831 will be based on safety and tolerability in above cohorts.
2903540|NCT03224312||Primary aldosteronism|
2903541|NCT03224312||Essential hypertension|
2903542|NCT03224299|Experimental|Investigational Product #1 (IP1)|Antimicrobial agent in a single use applicator
2903543|NCT03224299|Experimental|Investigational Product #2 (IP2)|Antimicrobial agent in a single use applicator
2903544|NCT03224299|Active Comparator|Active Control|Active control
2903545|NCT03224286||Incubator + <1500 g|Infants currently in an incubator with a weight of less than 1500 grams will be monitored while lying on a pressure sensitive mat.
2903546|NCT03224286||Incubator + 1500 - 2500 g|Infants currently in an incubator with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
2903547|NCT03224286||Overhead warmer + <1500 g|Infants currently in an overhead warmer with a weight less than 1500 grams will be monitored while lying on a pressure sensitive mat.
2903548|NCT03224286||Overhead warmer + 1500 - 2500 g|Infants currently in an overhead warmer with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
2903549|NCT03224286||Overhead warmer + >2500 g|Infants currently in an overhead warmer with a weight over 2500 grams will be monitored while lying on a pressure sensitive mat.
2903550|NCT03224286||Crib + 1500 - 2500 g|Infants currently in a crib with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
2903551|NCT03224286||Crib + >2500 g|Infants currently in a crib with a weight over 2500 grams will be monitored while lying on a pressure sensitive mat.
2903552|NCT03224273|Experimental|( proximal box design)|The proximal box at least ( 1mm wide and has 6◦ divergences, and extend 2 mm apical to the isthmus ﬂoor.
2903553|NCT03224273|Active Comparator|( inlay shaped design)|The occlusal inlay has a preparation depth of 2.0 mm for the ceramic. The occlusal preparation ( 4 mm wide and extend 4mm for premolar and 6 mm for molar mesiodistally
2903554|NCT03224260|Experimental|Treatment A|Receive 50 mg BMS-986177 once daily or placebo
2903555|NCT03224260|Experimental|Treatment B|Receive 200 mg BMS-986177 once daily or placebo
2903556|NCT03224260|Experimental|Treatment C|Receive 500 mg BMS-986177 once daily or placebo
2903557|NCT03224247|Active Comparator|Transverse splitting|transverse cutting and/or pulling of lower uterine segment during lower segment cesarean section.
2903558|NCT03224247|Active Comparator|Vertical splitting|vertical splitting,of lower uterine segment during lower segment cesarean section.
2903559|NCT03224234|Experimental|Insulclock with feedback (Group A)|Participants will use the Insulclock and receive daily information on their smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses. At midpoint (week 12), patients will be converted to the alternate arm.
2903560|NCT03224234|Active Comparator|Insulclock without feedback (Group B)|Participants will use the Insulclock, but will not receive feedback on insulin administration. At midpoint (week 12), patients will be converted to the alternate arm.
2903561|NCT03224221|Experimental|Apatinib with Chemotherapy|Apatinib with Chemotherapy(Fluorouracil and platinum)，patients will receive Apatinib at 500mg/times,oral one times daily for 28 days.the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
2903562|NCT03224221|Active Comparator|Chemotherapy|Chemotherapy (Fluorouracil and platinum)，the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients.
2903563|NCT03224208|Experimental|Single arm|"Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28. Cobimetinib will be given orally at 60 mg qd on Days 1−21 of each 28-day treatment cycle until disease progression.~Treatments will be continued until the development of progressive disease (as per Investigator assessment), unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination by the Sponsor."
2903564|NCT03224182|Experimental|Qapzola|One dose of 8mg Qapzola on Day 1
2903565|NCT03224182|Placebo Comparator|Placebo|One dose of placebo on Day 1
2903566|NCT03224169|Experimental|Intervention|Directly observed hand hygiene
2903567|NCT03224169|No Intervention|Control|No directly observed hand hygiene
2903568|NCT03224156||Dilated Cardiomyopathy|
2903569|NCT03224143|Experimental|Doll Therapy Intervention (DTI)|"The DTI involves the presentation of a doll produced by a Swedish brand and conceived for Doll Therapy use. It is designed to recreate the sensation of touching, looking and holding a child in the arms. The doll presentation involves five standard steps:~A nurse (whom the patient knows) accompanies the patient in the room and invites her to sit on the chair.~The nurse presents the object (doll or cube) to the patient.~The nurse leaves the patient alone with the object.~Interaction with the object: it lasts 3 minutes starting from the moment when the nurse leaves the room. This phase is interrupted if the patient drops the object before the time limit.~The nurse returns into the room and takes back the object."
2903570|NCT03224143|Active Comparator|Active control group (SI)|"The SI involves the presentation of a non-anthropomorphic object, a soft foam rubber cube covered with a coloured and velvety textile. The procedure is the following:~A nurse (whom the patient knows) accompanies the patient in the room and invites her to sit on the chair.~The nurse presents the cube to the patient.~The nurse leaves the patient alone with the cube.~Interaction with the cube: it lasts 3 minutes starting from the moment when the nurse leaves the room. This phase is interrupted if the patient drops the object before the time limit.~The nurse returns into the room and takes back the cube."
2903571|NCT03224130|Experimental|Nurse Phone Call|Families in this arm will receive a phone call within 96 hours of discharge
2903572|NCT03224130|Active Comparator|Standard of Care|This arm will receive standard of care.
2903573|NCT03224117|Placebo Comparator|Placebo|SQ injection
2903574|NCT03224117|Experimental|DWJ211_0.5%|SQ injection with DWJ211 0.5%
2903575|NCT03224117|Experimental|DWJ211_1%|SQ injection with DWJ211 1.0%
2903576|NCT03224117|Experimental|DWJ211_2%|SQ injection with DWJ211 2.0%
2903577|NCT03224104|Experimental|Group A - TG02 + RT|Elderly patients with IDH1R132H-non mutant and MGMT promoter-unmethylated anaplastic astrocytoma or glioblastoma who will receive TG02 and radiation therapy.
2903578|NCT03224104|Experimental|Group B - TG02 + TMZ|Elderly patients with IDH1R132H-non mutant and MGMT promoter-methylated anaplastic astrocytoma or glioblastoma who will receive TG02 and temozolomide.
2903579|NCT03224104|Experimental|Group C - TG02|Patients initially diagnosed with anaplastic astrocytoma or glioblastoma at first relapse post TMZ/RT --> TMZ therapy who will receive TG02.
2903580|NCT03224078||adult Emergency Department Patients|adult patients that were treated with any condition in one of the participating emergency departments in 2016 (n≈680.000 cases)
2903581|NCT03224065|No Intervention|Recommended therapy group|Guideline recommended regimen for treatment, regardless of antibiotic resistant genotype test results
2903582|NCT03224065|Experimental|Optimized therapy group|Optimized therapy based on antibiotic resistant genotype test results
2903583|NCT03224052||Patients with falciparum malaria|"Empirical antibiotic therapy with levofloxacin 750mg daily for 48 hours. This will be ceased if there is no laboratory or radiological evidence of infection at 48 hours.Therapy will be modified based on culture results or clinical judgment if cultures are not available.~If patients deteriorate in the first 48 hours on levofloxacin, antibacterial therapy comprising vancomycin (1.5g bd) and meropenem (1g tds) will be substituted for levofloxacin in addition to increasing supportive care as appropriate.~The dosing of all antibiotics will be adjusted according to creatinine clearance."
2903584|NCT03224052||Patients with vivax malaria|No empirical therapy will be commenced in these patients. If there is laboratory or radiological evidence of infection antibacterial therapy will be administered based on culture results or clinical judgment if cultures are not available.
2903585|NCT03224039|Experimental|Intranasal sufentanil|"Treatment arm to include~Sufentanil 0.7 mcg/kg intranasal (IN) x 1 dose~Normal saline 1ml intravenous (IV) push x 1 dose"
2903586|NCT03224039|Active Comparator|Intravenous morphine|"b. Treatment B:~Normal saline 0.3 mL IN x 1 dose~Morphine 0.1 mg/kg IV push x 1 dose"
2903587|NCT03224026||Fever Without Source|Clinical diagnosis of FWS (fever of less than 7 days with no cause determined by the history and the physical exam).
2903588|NCT03224026||Healthy control|Children visiting the hospital due to a non-infectious, non inflammatory etiology
2903589|NCT03224013|Active Comparator|Hyperopic LASIK with crosslinking|group 1:hyperopic customized LASIK with concurrent prophylactic high-fluence cross-linking
2903590|NCT03224013|Active Comparator|Hyperopic LASIK only|group 2: hyperopic customized LASIK only
2903660|NCT03223532|Experimental|PrePex Day 0 FRP|On the day of device placement the foreskin is removed, the device is removed 1 week later.
2903661|NCT03223519|Experimental|Comboprofen|Triple combination of Ibuprofen, Magnesium and Vitamin C.
2903662|NCT03223519|Placebo Comparator|Placebo|
2903663|NCT03223519|Active Comparator|Ibuprofen|
2903591|NCT03224000|Experimental|MRI Guided Intensity Modulated Radiotherapy (IMRT)|"Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Video-strobe procedure performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~IMRT planned with MRI guidance. Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days."
2903592|NCT03224000|Active Comparator|Standard-of-Care Intensity Modulated Radiotherapy (IMRT)|"Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Video-strobe procedure performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~IMRT planned by standard-of-care. Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days."
2903593|NCT03223974|Experimental|Paclitaxel DCB for MB and SB|Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM(atmosphere), lasting for >30 seconds
2903594|NCT03223974|Active Comparator|DES in MB|with regular techniques
2903595|NCT03223961|Experimental|Early onset arm|Intervention: early onset of Eprex60000 IU/week , at patient inclusion
2903596|NCT03223961|Experimental|Delayed onset arm|Intervention: late introduction of Eprex60000 IU/week, whenever the patient reaches the level chosen RBC transfusions (based on age, comorbidities, anticipated tolerance of anemia).
2903597|NCT03223948|Active Comparator|30 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
2903598|NCT03223948|Active Comparator|45 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
2903599|NCT03223948|Active Comparator|60 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
2903600|NCT03223935|Active Comparator|Roasted snacks|Corn nuts
2903601|NCT03223935|Experimental|Roasted chickpeas|Chickpeas
2903602|NCT03223935|Experimental|Roasted yellow peas|Yellow peas
2903603|NCT03223935|Experimental|Roasted pinto beans|Pinto beans
2903604|NCT03223935|Experimental|Roasted soybeans|Soybeans
2903605|NCT03223935|Experimental|Roasted almonds|Almonds
2903606|NCT03223922|Experimental|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy|Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
2903607|NCT03223909|Experimental|PRO-087 PF|Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
2903608|NCT03223909|Active Comparator|Systane Ultra|"Systane Ultra ophthalmic solution, Dropper bottle, Multidose.~1 drop every 4 hours for 90 days."
2903609|NCT03223909|Active Comparator|Systane Ultra PF|"Systane Ultra, preservative free ophthalmic solution, single-use vials.~1 drop every 4 hours for 90 days."
2903610|NCT03223896|Active Comparator|Group A|max 8 mg/per day naloxone nasal spray
2903611|NCT03223896|Active Comparator|Group B|max 16 mg/per day naloxone nasal spray
2903612|NCT03223883|Experimental|Curcumin|Patients will receive curcumin (Lonvida) 2000 mg PO once a day
2903613|NCT03223883|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
2903614|NCT03223870||Oximeters|Comparison of respiratory rates with other devices in normal subjects as observational with other pulse oximeters. No treatment of interventions will be performed.
2903615|NCT03223844|Experimental|Healthy subjects|Measurement of Dextroamphetamine Sulfate-induced dopamine release and synthesis before and after amphetamine sensitization.
2903616|NCT03223831|Active Comparator|Partially covered duodenal stent (PCDS)|The PCDS used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions. The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh.
2903617|NCT03223831|Active Comparator|Uncovered duodenal stent (UDS)|The UCDS used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
2903618|NCT03223818|Experimental|Fast-track Arm|Patients recruited will undergo ERAS perioperative program.
2903619|NCT03223818|No Intervention|Conventional Group|Patients recruited to conventional group will undergo conventional perioperative program
2903620|NCT03223805|Other|Control Arm|Usual Care
2903621|NCT03223805|Experimental|Intervention Arm|Respiratory Distress Symptom Intervention plus Usual Care
2903622|NCT03223792|Active Comparator|Control|
2903623|NCT03223792|Experimental|Investigational|
2903624|NCT03223779|Experimental|TAS-102|"Photon treatments will be performed on a linear accelerator~Photon SBRT will be given during TAS-102 dosing~TAS-102 dosing occurs on days 1 through 5 and 8 through 12~TAS-102 tablets should be taken twice a day orally"
2903625|NCT03223766||Participants|Participants will be those enrolled to receive proton therapy on other protocols at SJCRH on or after November 18, 2015.
2903626|NCT03223753|Active Comparator|Arm I (Sqord monitor, limited version of Sqord website|Patients receive educational handouts about physical activity and are encouraged to increase physical activity to at least 420 minutes per week. Patients wear Sqord activity monitor daily and upload data at least once a week to the Sqord website. Patients also access the limited version of Sqord website to get basic information related to their physical activity for 6 months.
2903664|NCT03223519|Active Comparator|Magnesium|
2903665|NCT03223519|Active Comparator|Vitamin C|
2903666|NCT03223506|Experimental|Paracetamol arm|Administration of 10 mg/ml of paracetamol
2903667|NCT03223493||People with Obesity|General population, respondents are recruited via email and/or phone through an online panel company with which respondents have provided permission to be contacted for research
2903627|NCT03223753|Experimental|Arm II (Sqord monitor, interactive-reward based Sqord website)|Patients receive educational handouts about physical activity and are encouraged to increase physical activity to at least 420 minutes per week. Patients wear Sqord activity monitor daily and upload data at least once a week to the Sqord website. Patients also access the full version of the interactive-reward based Sqord website to see their activity, earn activity points, see other Sqord player's activity, and interact with other Sqord members for 6 months.
2903628|NCT03223740|Experimental|Arm 1 pre-operative chemoradiation|Chemo1 x 2 followed by ChemRT followed by Surgery followed by Chemo2 x 2
2903629|NCT03223740|Active Comparator|Arm 2 post operative chemoradiation|Surgery followed by Chemo1 x 2 followed by ChemRT followed by Chemo2 x 2
2903630|NCT03223714|Experimental|Conbercept|"Subjuct receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5).~If subjucts meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)."
2903631|NCT03223714|Sham Comparator|Conbercept or sham|"Subjects receive sham injection into their study eyes every month (Day 0 - Month 5).~Subjects receive a single intravitreal injection of 0.5 mg Conbercept ophthalmic injection in month 6, followed monthly review, if he/she meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)."
2903632|NCT03223701|Other|Treatment group|The group will consist of 10 patients who would be examined for fusion rates of Transforaminal Lumbar Interbody Fusion with a standalone lumbar implant device and Solum IV and the patient's bone marrow concentrate and general fluid concentrate.
2903633|NCT03223688|Experimental|Day-Care early intervention program|The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training. Said therapists assisted the caregivers in improving their nurturing and parenting skills with their children, as well as their techniques with regards to influencing them.
2903634|NCT03223688|Experimental|OPD+SI intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
2903635|NCT03223688|Active Comparator|OPD intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
2903636|NCT03223675|Experimental|Hippocampus-sparing WBRT plus SIB|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25‐mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of whole brain radiation (WBRT) and simultaneous integrated boost(s) (SIB), the technique of volumetric modulated arc therapy (VMAT) via Linac‐based RapidArc®.In terms of dose prescription, a dose of 30 Gy in 12 fractions was prescribed to whole-brain planning target volume (PTV) containing the normal brain parenchyma; an simultaneous integrated boost up to 120 - 150% is attempted to irradiate the gross metastatic foci.
2903637|NCT03223662|Other|1/Arm 1|Standard of care nCRT and esophagectomy
2903638|NCT03223649|Experimental|Sedentary|(Control intervention) Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
2903639|NCT03223649|Experimental|Walking bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory thresholdas determined during a V02max test.
2903640|NCT03223636||Healthy Volunteers|Right handed individuals
2903641|NCT03223623||Focal Hand Dystonia (FHD)|Focal Hand Dystonia (FHD)
2903642|NCT03223623||CRPS dystonia|CRPS dystonia
2903643|NCT03223623||CRPS without dystoni|CRPS without dystonia
2903644|NCT03223623||Healthy Volunteer|Healthy Volunteers
2903645|NCT03223610|Experimental|Arm 1 Dose Escalation|iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPO (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6
2903646|NCT03223610|Experimental|Arm 2 Dose Escalation/Expansion|ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
2903647|NCT03223584||Pharmacists-Leuven|Individual interviews with approximately 5 pharmacists
2903648|NCT03223584||Pharmacists-Bruges|Individual interviews with approximately 5 pharmacists
2903649|NCT03223584||Pharmacists-Mortsel|A focus group with pharmacists and general practitioners
2903650|NCT03223584||General Practitioners-Leuven|Individual interviews with approximately 5 general practitioners
2903651|NCT03223584||General Practitioners-Bruges|Individual interviews with approximately 5 general practitioners
2903652|NCT03223584||General Practitioners-Mortsel|A focus group with pharmacists and general practitioners
2903653|NCT03223571||Early post-stroke (<2 months)|Participants within 2 months of a first supra-tentorial ischeamic stroke, that show a motor deficit of the upper-limb (Fugl Meyer upper limb score < 30/66), older than 18yrs, without aphasie, cognitive troubles or hemineglect Post-stroke participants receive 6 week of motor rehabilitation training of the paretic upper-limb.
2903654|NCT03223571||Controls|Healthy people with no history of neurological pathologies
2903655|NCT03223558|Experimental|early rehab group|start of 8 weeks cardiac rehabilitation 2 weeks following surgery
2903656|NCT03223558|Active Comparator|usual care group|start 8 weeks of cardiac rehabilitation 6 weeks post surgery
2903657|NCT03223545|Experimental|Mindfulness-based cognitive therapy delivered by telephone|
2903658|NCT03223545|Placebo Comparator|Usual Care (UC)|
2903659|NCT03223532|Active Comparator|PrePex Day 7 FRP|"Standard PrePex procedure, 1 week after device placement foreskin and device are removed.~*Subjects must be adequately vaccinated, or willing to be vaccinated, against Tetanus based on appropriate national guidance for male circumcision"
2903668|NCT03223493||Healthcare Providers|Health care professionals, respondents will be recruited via email, USPS mail, and/or phone through an online panel company with which respondents have provided permission to be contacted for research purposes or through the AMA Masterfile
2903669|NCT03223493||Employer representatives|Employers, respondents will be recruited via email, USPS mail, and/or phone through an online panel company with which respondents have provided permission to be contacted for research purposes
2903670|NCT03223480|Experimental|EUS-guided gastrojejunostomy|"The procedures would be performed under conscious sedation or monitored anesthesia by a therapeutic gastroscope. The endoscope would be used to reach the site of obstruction. The stricture would be cannulated with a 0.025 or 0.035 guide-wire. The double balloon occluder would then be inserted on guidewire beyond the duodenal-jejunal flexure and the two balloons of the occluder would be inflated. A segment of duodenum/jejunum would then be occluded and saline would be injected. A linear echoendoscope would then be inserted into the stomach to guide insertion of the gastrojejunostomy stent."
2903671|NCT03223467|Active Comparator|Biliopancreatic diversion|Study participants will undergo biliopancreatic diversion which is a type of bariatric surgery where a part of the stomach are removed and the remaining stomach is attached to a distal segment of the small intestine.
2903672|NCT03223467|Active Comparator|Gastric sleeve|Study participants will undergo sleeve gastrectomy which is a restrictive form av bariatric surgery where the size of the stomach is reduced.
2903673|NCT03223467|Active Comparator|Gastric bypass|Study participants will undergo gastric bypass which is a type of bariatric surgery where a small pouch of the stomach is created and attached to a segment of the small intestine.
2903674|NCT03223467|No Intervention|No intervention|Study participants that do not want to undergo surgical treatment.
2903675|NCT03223454|Experimental|biological amnion loaded with hAECs|Biological amnion loaded with 100 million hAECs is placed into uterine cavity immediately after TCRA.
2903676|NCT03223454|Placebo Comparator|biological amnion|Biological amnion is placed into uterine cavity immediately after TCRA.
2903677|NCT03223454|Experimental|intravenous infusion of hAECs|intravenous infusion of 100 million hAECs immediately after TCRA
2903678|NCT03223454|Experimental|intrauterine infusion of hAECs|100 million hAECs is infused into uterine cavity immediately after TCRA.
2903679|NCT03223454|Experimental|hydrogel loaded with hAECs|Hydrogel loaded with 100 million hAECs is infused into uterine cavity immediately after TCRA.
2903680|NCT03223428||Carcinoid Syndrome patients initiating Xermelo|Patients with Carcinoid Syndrome who are initiating treatment with XERMELO.
2903681|NCT03223415|Experimental|Experimental arm|Detection and isolation of C. difficile carriers
2903682|NCT03223415|No Intervention|Control arm|No detection of C. difficile carriers upon admission and no implementation of contact isolation precautions for C. difficile carriers
2903683|NCT03223402|Experimental|nevirapine plus lamivudine|patients from one Center switching from a Nevirapine based Regimen on Nevirapine + 3TC
2903684|NCT03223389|Experimental|10 gastric bypass operated patients|3 different oils ingested at separate study days will be tested against each others ability to induce gut hormone secretion.
2903685|NCT03223389|Experimental|10 healthy control subjects|3 different oils ingested at separate study days will be tested against each others ability to induce gut hormone secretion.
2903686|NCT03223376|Active Comparator|fruquintinib+paclitaxel|treatment arm (fruquintinib+paclitaxel) : Fruquintinib 4mg once daily, 3 weeks on/1week off combined with Paclitaxel 80mg/m2 day1, 8, 15 of 4 weeks cycle.
2903687|NCT03223376|Placebo Comparator|placebo+paclitaxel|control arm (placebo+paclitaxel): Fruquintinib placebo 4mg once daily, 3 weeks on/1week off combined with Paclitaxel 80mg/m2 day1, 8, 15 of 4 weeks cycle.
2903688|NCT03223363|Experimental|Development Group|Development Group is used to establish the prediction model.2D and 3D ultrasonography are performed in this group. Through statistical analysis we obtain a new model.
2903689|NCT03223363|Other|Validation group|Validation Group is used to confirm the efficacy of the prediction model.2D and 3D ultrasonography are performed in this group.Absolute and percentage error are calculated and compared with a common formula to confirm the accuracy of this new model.
2903690|NCT03223350|Experimental|Capsaicin|0.075% capsaicin cream, one application
2903691|NCT03223350|Placebo Comparator|Placebo|Topical cream with no active drug
2903692|NCT03223337|Experimental|Subjects with moderate hepatic impairment: Part 1|Approximately 8 subjects with moderate hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 7, one with a score of 8 and one with a score of 9. The group will also include at least one female and at least one male subject.
2903693|NCT03223337|Active Comparator|Matched Healthy controls: Part 1|Approximately 8 healthy controls, matched in gender, age and BMI to subjects with moderate hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
2903694|NCT03223337|Experimental|Subjects with either mild or severe hepatic impairment: Part 2|Approximately 8 subjects with mild or severe hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 5 and one with a score of 6 for mild hepatic impairment and at least one subject with a Child-Pugh score of 10 or 11 and one with a score of 12 or 13 for severe hepatic impairment. The group will also include at least one female and at least one male subject.
2903695|NCT03223337|Active Comparator|Matched healthy controls: Part 2|Approximately 8 healthy controls, matched in gender, age and BMI to subjects with mild or severe hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
2903696|NCT03223324||Pre Term and Threatened Pre-Term Labor|abdominal fetal/maternal monitoring
2903729|NCT03223051|Experimental|Evaluation|"Included patients will be invited to participate in 1 session, to be evaluated with the Motor Function Measure and the new test of space exploration, during 2 hours maximum, to compare scores with these 2 tests.~An occupational therapist will be required to install the patient in front of the table and to give the instructions."
2903730|NCT03223025|Experimental|CinnaTropin®, Then Nordilet®|CinnaTropin® was administered with 0.03 mg/kg daily subcutaneous injections for three months. After that, the participants received 0.03 mg/kg daily subcutaneous injections of Nordilet® for three months.
2903697|NCT03223298|Experimental|Botulinum Toxin Type A|The intramuscular injections will be performed with the patient awake in the oral and maxillofacial surgery clinic. Three injection sites into bilateral masseter muscles and two injection sites into bilateral temporalis muscles will be identified by having the patient clench. The sites will be marked with a surgical pen prior to injections. The skin at the injection sites will be cleaned with an alcohol swab. Via a 1cc TB syringe and a 30-gauge needle, the subject will then receive 100 units of reconstituted botulinum toxin A. 37.5 units will be injected into each masseter muscle and 12.5 units into each temporalis muscle. A written post-operative instruction sheet will be provided to all patients.
2903698|NCT03223298|Placebo Comparator|0.9% Sodium Chloride Injection|The intramuscular injections will be performed with the patient awake in the oral and maxillofacial surgery clinic. Three injection sites into bilateral masseter muscles and two injection sites into bilateral temporalis muscles will be identified by having the patient clench. The sites will be marked with a surgical pen prior to injections. The skin at the injection sites will be cleaned with an alcohol swab. Via a 1cc TB syringe and a 30-gauge needle, the subject will then receive unpreserved 0.9% sodium chloride. A written post-operative instruction sheet will be provided to all patients.
2903699|NCT03223285|Experimental|Real Treatment Group|Patients included in this group will receive 3 multifaced physiotherapy/osteopathic treatments + experimental manoeuvres, 1 treatment/week. Each session will last about 30 minutes.
2903700|NCT03223285|Sham Comparator|Sham Treatment Group|Patients included in this group will receive 3 multifaced physiotherapy/osteopathic treatments + sham manoeuvres, 1 treatment/week. Each session will last about 30 minutes.
2903701|NCT03223272|Experimental|Reserpine|Subjects will receive open-label reserpine 0.1 mg daily for - weeks; titrating to 0.25 mg daily for additional 4-weeks
2903702|NCT03223259|Other|Injury Prevention Workshops|Subjects will attend two Injury Prevention Workshops
2903703|NCT03223246|No Intervention|Usual care|
2903704|NCT03223246|Experimental|Additional teaching|
2903705|NCT03223233||No secondary suture|The participants who developed post-cesarean surgical site infection and follow-up only antibiotic treatment for their wound care.
2903706|NCT03223233||Secondary suture|The participants who developed post-cesarean surgical site infection and need a secondary suture for their wound care
2903707|NCT03223220|Experimental|Study Drug|Will receive Ketamine infusion, and Midazolam (Versed).
2903708|NCT03223220|Placebo Comparator|Placebo|Will receive Normal saline infusion and Midazolam (Versed).
2903709|NCT03223207||Control Group|The control group will include CIED patients who have been evaluated in the ED at The Heart Hospital Baylor Plano and Baylor Regional Medical Center at Plano. A minimum of 50 devices not compatible with the CareLink Express® system will be prospectively interrogated in the traditional evaluation method using the device manufacturer representative.
2903710|NCT03223207||CareLink Express|The study group will include CIED patients who present to the ED and receive a device evaluation using the CareLink Express® system. A minimum of 50 devices will be prospectively evaluated using CareLink Express®.
2903711|NCT03223194|Experimental|Cohort 1|1.5 x 10^12 vg/kg of AT342 delivered intravenously one time
2903712|NCT03223194|Experimental|Cohort 2|6.0 x 10^12 vg/kg of AT342 delivered intravenously one time
2903713|NCT03223194|Experimental|Cohort 3|1.5 x 10^13 vg/kg of AT342 delivered intravenously one time
2903714|NCT03223194|No Intervention|Delayed-Treatment Control|Control subjects will generally have the same assessments as treated subjects. Once the optimal dose is selected, control subjects will undergo pre-treatment baseline procedures to confirm that they are eligible to receive treatment with AT342. Once eligible control subjects are dosed with AT342, they will initiate the same post-dose procedures as subjects who received AT342.
2903715|NCT03223181||COMİSS|Measure of CoMiSS followed by two to four weeks eviction Cow's milk protein diet and second CoMiSS measurement
2903716|NCT03223168|Experimental|Hayek RTX ventilator|Participants will receive noninvasive negative pressure ventilation.
2903717|NCT03223155|Experimental|Sequential Arm|Patients will be randomized to either the Sequential Arm or the Concurrent Arm. Patients in the Sequential Arm will complete SBRT to 2-4 sites and then begin treatment with nivolumab/ipilimumab between 1-7 days after completion of SBRT.
2903718|NCT03223155|Experimental|Concurrent Arm|Patients will be randomized to either the Sequential Arm or the Concurrent Arm. Patients in the Concurrent Arm will begin treatment with nivolumab/ipilimumab first and must complete planned SBRT to 2-4 sites within 2 weeks (prior to second dose of nivolumab).
2903719|NCT03223142|Experimental|Multi-modal Precision Ablation|In Multi-modal Precision Ablation group, patients received cryoablation immediately followed by radiofrequency ablation
2903720|NCT03223129|Other|Patients with normal glucose tolerance|"Patients included in this arm will have a plasma glucose below 140 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
2903721|NCT03223129|Other|Patients with impaired glucose tolerance|"Patients included in this arm will have a plasma glucose between 140 mg/dl to 199 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
2903722|NCT03223129|Other|Patients with type 2 diabetes mellitus|"Patients included in this arm will have a plasma glucose above 200 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
2903723|NCT03223116|Experimental|Radiofrequency|Radiofrequency delivery to the gastroesophageal junction
2903724|NCT03223103|Experimental|Mutation-derived tumor vaccine|MTA-based Personalized Vaccine (peptides + Poly-ICLC with Tumor Treating Fields
2903725|NCT03223090|Experimental|Tool training group|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
2903726|NCT03223090|Active Comparator|Hand training group|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
2903727|NCT03223077||Acute Campylobacter|
2903728|NCT03223064|Experimental|PSMA PET-CT and USPIO MRI|
2903731|NCT03223025|Active Comparator|Nordilet®, Then CinnaTropin®|Nordilet® was administered with 0.03 mg/kg daily subcutaneous injections for three months. After that, the participants received 0.03 mg/kg daily subcutaneous injections of CinnaTropin® for three months.
2903732|NCT03223012||Participants not included in the AbbVie care program|Participants receiving adalimumab not included in the AbbVie care patient support program.
2903733|NCT03223012||Participants included in the AbbVie care|Participants receiving adalimumab included in the AbbVie care patient support program.
2903734|NCT03222986||Sepsis with organ failure|Patients have organ failure
2903735|NCT03222986||Sepsis without organ failure|Patients have no organ failure
2903736|NCT03222973|Experimental|BIIB033 (opicinumab) 750 mg|Participants with relapsing multiple sclerosis (RMS) will receive BIIB033 750 milligram (mg) intravenously (IV) as an add-on therapy to a background disease-modifying therapy (DMT) once every 4 weeks over 72 weeks.
2903737|NCT03222973|Placebo Comparator|Placebo|Participants with RMS will receive placebo IV as an add-on therapy to a background DMT once every 4 weeks over 72 weeks. The placebo looks like BIIB033 but does not contain the active ingredient that is thought to have an effect on MS disease. The placebo used in this study is sterile normal saline (water with a small amount of sodium chloride [salt]).
2903738|NCT03222960|Experimental|Propolis-containing toothpaste|Assessment of caries risk for participants using Propolis-containing toothpaste before the treatment , after 3 months and 6 months follow up.
2903739|NCT03222960|Experimental|Fluoride-containing toothpaste|Assessment of caries risk for participants using Fluoride-containing toothpaste before the treatment , after 3 months and 6 months follow up.
2903740|NCT03222947||Taybi-Linder index cases|Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
2903741|NCT03222947||Blood relatives of Taybi-Linder index cases|Blood relatives of Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
2903742|NCT03222934||Nasal disorders|patients with nasal disorders with free sphenoid sinus
2903743|NCT03222908|No Intervention|Control: Prescriptive Advice|Amenable patients will be enrolled into the study, their intervention will be current standard of care smoking cessation counseling by their surgeon, they will undergo 3 urine tests and a chart review for outcomes.
2903744|NCT03222908|Experimental|Intervention1: Contract Agreement|Amenable patients will be enrolled into the study, their intervention will be a smoking cessation contract with their surgeon, they will undergo 3 urine tests and a chart review for outcomes.
2903745|NCT03222908|Experimental|Intervention2: Implementation Intentions|Amenable patients will be enrolled into the study, their intervention will be a worksheet to fill out with their smoking cessation implementation intentions that will be signed by patient and surgeon, they will undergo 3 urine tests and a chart review for outcomes.
2903746|NCT03222895||TIGER study cohort|This is the entire patient cohort. Alle patients with resectable esophageal cancer undergoing a transthoracic esophagectomy with at least a 2-field lymphadenectomy
2903747|NCT03222882|Experimental|RIF group|According to the histological dating and transcriptomic profile of endometrium of hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer . The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on day P＋7 in an HRT cycle. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy outcome of the FET cycle .
2903748|NCT03222869||Laryngotracheal Stenosis|Patients with laryngotracheal stenosis will have pressure sensors placed proximal and distal to the stenosis. Pressure and air flow will be measured
2903749|NCT03222856|Experimental|Pembrolizumab + eribulin|All eligible patients will be treated with MK3475 (pembrolizumab) 200 mg on day 1 of each 21-day cycle and eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) on days 1 and 8 of every 21-day cycle. Treatment with MK3475 (pembrolizumab) and eribulin will continue based on physician criteria. No maximum duration of treatment is specified. Study follow-up will be performed 12 months after last study dose.
2903750|NCT03222843|Experimental|Arm 1|oral hetrombopag at an initial dose of 2.5 mg once daily
2903751|NCT03222843|Experimental|Arm 2|oral hetrombopag at an initial dose of 5 mg once daily
2903752|NCT03222843|Placebo Comparator|Arm 3|oral placebo at an initial dose of 2.5 mg once daily
2903753|NCT03222843|Placebo Comparator|Arm 4|oral placebo at an initial dose of 5 mg once daily
2903754|NCT03222830|Experimental|RIF group|"According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle ."
2903755|NCT03222817|Experimental|HPV Self-sampling|All participants will receive HPV self-sampling. HPV self-sampling allows an individual to screen themselves for cervical cancer in private, using a device that is similar to a tampon.
2903756|NCT03222804|Active Comparator|Exclusively breastfed|Exclusive breastfeeding will be defined at screening as infants who have not consumed any infant formula after 7 days postnatal and have been exclusively breastfed without formula between day 7 of life through the end on the Lead-in period. ). Infants will consume B. infantis for twenty-one consecutive days.
2903757|NCT03222804|Active Comparator|Exclusively formula fed|Exclusive formula feeding is defined at screening as infants who consume only infant formula between day 7 of life through the end on the Lead-in period. Infants will consume B. infantis for twenty-one consecutive days.
2903758|NCT03222804|Active Comparator|Mixed fed|Mixed feeding is defined at screening as infants who consume a combination of infant formula and breast milk between day 7 of life through the end on the Lead-in period. Infants will consume B. infantis for twenty-one consecutive days.
2903759|NCT03222791|Experimental|Algorithm-based diet|Subjects randomized to this arm will receive personally tailored dietary recommendations based on their predicted glycemic responses according to the study algorithm.
2903760|NCT03222791|Other|Mediterranean-style low-fat diet|Subjects randomized to this arm will receive nutritional recommendations according to the standard Israeli dietary approach for treating pre-diabetes: Mediterranean-style low-fat diet.
2903761|NCT03222778||hypovolemia (fluid responsiveness)|The patients with fluid responsiveness (an increase in stroke volume index of ≥12%) after fluid challenge using 6 ml/kg of balanced 6% hydroxyethyl starch 130/0.4 (Volulyte; Fresenius Kabi, Bad Homburg, Germany)
2903762|NCT03222778||NO hypovolemia (NO fluid responsiveness)|The patients without fluid responsiveness after fluid challenge using 6 ml/kg of balanced 6% hydroxyethyl starch 130/0.4 (Volulyte; Fresenius Kabi, Bad Homburg, Germany)
2903763|NCT03222765|Placebo Comparator|Placebo|"Placebo~Lifestyle modification (diet and physical activity recommendations)"
2903764|NCT03222765|Experimental|Metformin|"Metformin~Lifestyle modification (diet and physical activity recommendations)"
2903765|NCT03222765|Experimental|Linagliptin|"Linagliptin~Lifestyle modification (diet and physical activity recommendations)"
2903766|NCT03222765|Experimental|Linagliptin and Metformin|"Fixed dose combination of Linagliptin and metformin~Lifestyle modification (diet and physical activity recommendations)"
2903767|NCT03222752|Active Comparator|Treatment Group|Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.
2903768|NCT03222752|Sham Comparator|Sham Treatment Group|Groups receives treatment using sham cranial electrotherapy stimulation devices for 6 weeks. No actual treatment will be received. This group will not receive any treatment interventions. The same outcome measures will be used as the treatment group.
2903769|NCT03222739|Other|Device Arm|This is a single arm study comparing an ultrasound with the industry standard of x-ray to detect and monitor scoliosis curvature.
2903770|NCT03222726|Active Comparator|exercise group|6000 steps/day or 40,000 steps/week
2903771|NCT03222726|Other|less-exercise group|less than 6000 steps/day or 40,000 steps/week
2903772|NCT03222700||robotic thyroidectomy group|
2903773|NCT03222700||open thyroidectomy group|
2903774|NCT03222687|Experimental|therapy group|Immunosuppressive therapy included tacrolimus and prednisone.
2903775|NCT03222674|Experimental|Single arm|CAR T cells to treat AML
2903776|NCT03222648|Experimental|Structured Responsive Exercise Training|8 week twice weekly supervised structured responsive static-cycle based exercise training. Training protocol used the same as Loughney et al. 2016
2903777|NCT03222635|Experimental|Endoscopic follow-up|Patients treated with endoscopic resection (ER) for a submucosal esophageal adenocarcinoma without lymphnode- or distant metastases (T1bN0M0 EAC) will undergo endoscopic follow-up.
2903778|NCT03222622|Experimental|Cohort 1|65 patients with mild to moderate psoriasis will be randomized to receive 1% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
2903779|NCT03222622|Experimental|Cohort 2|65 patients with mild to moderate psoriasis will be randomized to receive 2% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
2903780|NCT03222622|Experimental|Cohort 3|65 patients with mild to moderate psoriasis will be randomized to receive 4% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
2903781|NCT03222622|Placebo Comparator|Cohort 4|65 patients with mild to moderate psoriasis will be randomized to receive placebo cream (blank cream containing no icotinib hydrochloride), applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
2903782|NCT03222609|Experimental|Navitoclax + ruxolitinib|Navitoclax once daily (QD) at various doses added to current stable dose of ruxolitinib twice daily (BID).
2903783|NCT03222596|Experimental|Multiple Sclerosis Exercise|Ambulatory and non-ambulatory MS individuals that will exercise-group (MSE). Intervention is exercise training.
2903784|NCT03222596|No Intervention|Multiple Sclerosis Control (no-Exercise)|Ambulatory and non-ambulatory MS individuals that will not exercise-group (MSC).
2903785|NCT03222583|Experimental|Arm A DB Active Drug|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 or 16 weeks (double-blind [DB] treatment period)
2903786|NCT03222583|Experimental|Arm B DB Placebo then OL Active Drug|Placebo for ABT-493/ABT-530 QD for 8 or 16 weeks (DB treatment period) followed by ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 or 16 weeks (open-label [OL] treatment period)
2903787|NCT03222570|Experimental|IPT-A - possible augment with addl IPT-A|Adolescents begin with an initial treatment plan of 12 weekly sessions of interpersonal psychotherapy for depressed adolescents (IPT-A). Depressive symptoms will be assessed systematically over the course of therapy. If an adolescent demonstrates an insufficient response to IPT-A at one of these assessments, the dose of IPT-A will be increased by scheduling sessions twice per week for 4 weeks (16 sessions total).
2903788|NCT03222570|Experimental|IPT-A - possible augment with SSRI|Adolescents begin with an initial treatment plan of 12 weekly sessions of interpersonal psychotherapy for depressed adolescents (IPT-A). Depressive symptoms will be assessed systematically over the course of therapy. If an adolescent demonstrates an insufficient response to IPT-A at one of these assessments, treatment will be augmented by adding a selective serotonin reuptake inhibitor (SSRI).
2903789|NCT03222570|Active Comparator|Usual Care|Therapists will implement therapy procedures that they usually use and believe to be effective in clinical practice. Therapists will use whatever methods they usually use to make decisions regarding the frequency of therapy sessions and whether to refer the adolescent to start an SSRI.
2903790|NCT03222557|Experimental|Electroacupuncture (EA)|Bilateral acupoints relevant to the treatment of abdominal pain, abdominal distension, and constipation, including Zusanli (stomach meridian ST-36), Sanyinjiao (spleen meridian SP-6), Hegu (large intestine meridian LI-4), and Zhigou (triple energizer meridian TE-6), will be used. Electric stimulation at a frequency of 50 Hz will be employed to the needles
2903791|NCT03222557|Sham Comparator|Sham Acupuncture (SA)|Sterile blunt-tip needles will be placed (without skin penetration) 20 mm away from the acupoints. The needle will be first inserted through a sterile plastic tube mounted on a foam block, and then pressed on the skin. The foam block compresses to give the impression that the needle is penetrating the skin, thus providing a SA effect. 'Pseudostimulation' will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current.
2903792|NCT03222544|Experimental|Photodynamic Therapy|The photosensitizer, indocyanine green, is applied topically to the ulcer surface and the ulcer was shielded from light for 10 min. Then the ulcer area is illuminated using a photon therapy instrument for 20 minutes. Photodynamic therapy is applied once a day for a total of ten times.
2903793|NCT03222544|Active Comparator|Photon therapy|The placebo is applied topically to the ulcer surface and the ulcer was shielded from light for 10 min. Then the ulcer area is illuminated using a photon therapy instrument for 20 minutes. Photon therapy is applied once a day for a total of ten times.
2903794|NCT03222531||Heart Transplant|Patients will be transplanted with HCV positive heart. Recipients whom test positive for HCV viremia for 2 consecutive tests at any point will complete 12 weeks of Epclusa (Sofosbuvir/velpatasvir).
2903795|NCT03222518|Active Comparator|Parcetamol + Placebo Group|The patient receives an envelope containing Paracetamol 1000 mg + a placebo at the dose of 3 times / day + follow-up sheet + appointment card.
2903796|NCT03222518|Active Comparator|NSAID + Placebo Group|The patient receives an envelope containing NSAID 50 mg + a placebo in a dose of 3 times / day + follow-up sheet + appointment card.
2903797|NCT03222518|Active Comparator|NSAID + Paracetamol Group|The patient receives an envelope containing NSAID 50 mg + Paracetamol 1000 mg at a dose of 3 times / day + follow-up sheet + appointment card.
2903798|NCT03222505|Experimental|Treadmill|
2903799|NCT03222505|Experimental|Overground Walking|
2903800|NCT03222492|Experimental|Cohort 1: 0.6 mg/kg brentuximab vedotin|"This is the first of three ascending dose cohorts. Participants in this cohort will receive 0.6 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.~Cohort 1 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
2903801|NCT03222492|Placebo Comparator|Cohort 1: placebo|"0.6 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 0.6 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.~Cohort 1 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
2903802|NCT03222492|Experimental|Cohort 2: 1.2 mg/kg brentuximab vedotin|"This is the second of three ascending dose cohorts. Participants in this cohort will receive 1.2 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.~Cohort 2 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
2903803|NCT03222492|Placebo Comparator|Cohort 2: placebo|"1.2 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 1.2 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.~Cohort 2 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
2903804|NCT03222492|Experimental|Cohort 3: 1.8 mg/kg brentuximab vedotin|"This is the third/last of three ascending dose cohorts. Participants in this cohort will receive 1.8 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.~Cohort 3 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
2903805|NCT03222492|Placebo Comparator|Cohort 3: placebo|"1.8 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 1.8 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.~Cohort 3 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
2903806|NCT03222479|Experimental|treatment arm|All individual is instructed to use the application we developed for 4 weeks
2903807|NCT03222466|Experimental|Co-created PEM|A co-created PEM has been designed in collaboration with patients. Participants receiving the intervention will be asked to read and answer questions before and after viewing the co-created PEM.
2903808|NCT03222466|No Intervention|Traditional PEM|Participants will be asked to read and answer questions before and after viewing the traditional PEM created by clinicians and researchers.
2903809|NCT03222453|Experimental|Intervention Patient|Hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells.
2903810|NCT03222453|No Intervention|non-intervention Patient|No treatment
2903811|NCT03222440|Experimental|SHR-1210+ Radiotherapy|Radiotherapy,intensity modulated radiation therapy (IMRT), 54-60 Gy, 1.8-2.0 Gy per fraction ,5 fractions per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks for 9 cycles,one cycle is two weeks ) will be administered as an intravenous infusion over 30 minutes.
2903812|NCT03222427|Experimental|LY3314814|Single oral dose of LY3314814
2903813|NCT03222427|Experimental|[13C415N3] LY3314814|Single IV infusion of [13C415N3] LY3314814
2903814|NCT03222414|Experimental|conical Ultra Curve BP cuff|Non-invasive BP recording with conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring
2903815|NCT03222414|Active Comparator|traditional cylindrical BP cuff|Non-invasive BP recording with traditional cylindrical BP cuff and direct invasive arterial pressure monitoring
2903816|NCT03222401|No Intervention|Control Group|Control subjects will not receive an infusion or placebo
2903817|NCT03222401|Experimental|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
2903818|NCT03222401|Experimental|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
2903819|NCT03222401|Experimental|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
2903820|NCT03222388||IIEF5 paper-electronic|
2903821|NCT03222388||IIEF5 electronic-paper|
2903822|NCT03222388||IIEF15 paper-electronic|
2903823|NCT03222388||IIEF15 electronic-paper|
2903824|NCT03222388||IIEF5 electronic-electronic|
2903825|NCT03222388||IIEF15 electronic-electronic|
2903826|NCT03222375||Autism|Individuals with autism will have either Image converter (iSQUED™) for Hysteresis of Spiral Autowaves, Sound converter (sSQUED™) for Drift of Spiral Autowaves or Electromagnetic converter (eSQUED™) for Annihilation Autowave reverberator.
2903924|NCT03221647||GFD CD (Gluten Free Diet CD)|Intestinal biopsies from GCD-CD patients with villous atrophy (Marsh T3a-c) had positive serology (anti-tTg antibodies >30 U/ml and EMA positive) ).
2903827|NCT03222362||patients 85 years and above|120 consecutive patients (male and female), aged 85 years and above, who underwent pars plana vitrecromy in the Tel Aviv Medical Center during the years 01/01/2006 - 31/12/2013, and were followed by physicians in the ophthalmology department in the center until December 2015.
2903828|NCT03222349|Other|Interictal State (Period A) of Epilepsy|Diazepam Buccal Soluble Film will be administered to epileptic patients during the icterictal state (Period A)
2903829|NCT03222349|Other|ictal/peri-ictal state (Period B)|Diazepam Buccal Soluble Film will be administered to epileptic patients during the ictal/peri-ictal state (Period B)
2903830|NCT03222323|Experimental|Perineural dexmedetomidine|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml 100ug/ml dexmedetomidine perineurally
2903831|NCT03222323|Active Comparator|Systemic dexmedetomidine|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml isotonic saline (placebo) perineurally + 100ug dexmedetomidine systemically (absorbed and redistributed from the opposite ulnar nerve block)
2903832|NCT03222323|Placebo Comparator|Placebo|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml isotonic saline (placebo) perineurally
2903833|NCT03222323|Active Comparator|High dose Ropivacaine|Ulnar nerve block 4ml ropivacaine 7.5mg/ml + 1ml isotonic saline (placebo) perineurally
2903834|NCT03222310|Experimental|Ipatasertib|Participants will receive one 100 milligram (mg) ipatasertib tablet orally on Day 1 of treatment in treatment period 1 followed by two 100 mg itraconazole capsules orally on Days 15 to 23 along with one 100 mg of ipatasertib on Day 19 in treatment period 2. Both the treatment period will be separated by a washout period of 14 days.
2903835|NCT03222297||test group|Patients with craniocerebral injury were randomized into test group (n = 40) with early skull repair using titanium mesh within 1-3 months after decompression.
2903836|NCT03222297||control group|Patients with craniocerebral injury were randomized into control group (n = 46) with late-stage skull repair using titanium mesh within 6-12 months after decompression.
2903837|NCT03222284|Experimental|Group 1|"N=10 Device intervention~1. Cornerstones4Care Powered by Glooko App Visits Day 1 Day 7 Day 28"
2903838|NCT03222284|Experimental|Group 2|"N=20 Device intervention~1. Cornerstones4Care Powered by Glooko App Visits Day 1 Day 28"
2903839|NCT03222271|Active Comparator|I) Extubation to NIV (S/T mode)|"The patients will receive NIV using S/T mode after extubation with the following parameters:~Expiratory Positive Airway Pressure (EPAP): 4-8 centimeter water (cmH2O).~Inspiratory Positive Airway Pressure (IPAP): 12-20 cmH2O.~Respiratory rate (RR): 10-12 breath/minute."
2903840|NCT03222271|Experimental|II) Extubation to NIV (iVAPS) mode|"The patients will receive NIV using iVAPS mode after extubation with the following parameters:~Patient's height in cm..~Target alveolar ventilation (Va): adjusted provided that tidal volume is 8 ml/kg of ideal body weight (IBW).~Expiratory Positive Airway Pressure (EPAP) :4-8 cmH2O~Minimum and maximum Pressure Support (PS) :8-16~Respiratory rate :10-12 breath/min."
2903841|NCT03222258||Early palliative care for adult|Being referred to palliative care team before totally terminating their chemotherapy among adult participants.
2903842|NCT03222258||Routine hospice care for adult|Being referred to palliative care team when their last chemotherapy is ended among adult participants.
2903843|NCT03222258||Unused palliative care for adult|haven't been under the palliative care among adult participants
2903844|NCT03222258||Palliative care for pediatrics|receiving the palliative care among pediatric participants
2903845|NCT03222258||Unused palliative care for pediatrics|haven't received the palliative care among pediatric participants
2903846|NCT03222245||Exposed group|This group consists of participants identified as needing to start injectable therapy within 1 month from the recruitment date (50% insulin and 50% GLP-1 analogues)
2903847|NCT03222245||Non-exposed group|This group consists of participants treated with oral anti- hyperglycaemic agents (OAHAs) and their combinations
2903848|NCT03222232||chronic intestinal failure patients|Patients with chronic intestinal failure on home parenteral support and enrolled in the Copenhagen Intestinal failure database between January 1, 2002 and December 31, 2015.
2903849|NCT03222219||low implant stability quotient|dental implant insertion with low torque values
2903850|NCT03222219||medium implant stability quotient|dental implant insertion with medium torque values
2903851|NCT03222219||high implant stability quotient|dental implant insertion with high torque values
2903852|NCT03222206|Experimental|Salsalate|17 patients received continuous medication with salsalate 2g/day after run-in period
2903853|NCT03222206|Placebo Comparator|Placebo|17 patients received continuous medication with Placebo 2g/day after run-in period
2903854|NCT03222193|Experimental|TRP group|Snoring subjects treated with the Tongue Right Positioner (TRP) medical device
2903855|NCT03222180|Experimental|Website|Participants will be provided with password-protected access to use of the online resource created during the first phase of the project during the one year randomized controlled trial. Participants' children with T1D will receive Usual Care for T1D as described below.
2903856|NCT03222180|No Intervention|Usual Care|Participants' children with T1D will receive care for T1D at their respective institutions equivalent to that received by comparable patients who do not enroll in the trial. At all sites, Usual Care is designed to be consistent with the current American Diabetes Association Standards of Care for T1D in this clinical population.
2903857|NCT03222167|Experimental|Elbasvir/ Grazoprevir|Elbasvir/ Grazoprevir 50/100 mg fixed dose combination for 12 weeks treatment aimed to evaluate SVR12 in treatment naïve patients with chronic hepatitis C (genotype 1b) infection, associated with metabolic syndrome, with or without severe fibrosis / compensated cirrhosis.
2903858|NCT03222154|No Intervention|Control|20 volunteers without intervention. At the end of the study they received an application of shock wave therapy.
2903859|NCT03222154|Placebo Comparator|Placebo|20 volunteers who received simulation of the application of shock wave therapy
2903860|NCT03222154|Experimental|Experimental|20 volunteers who received shock wave therapy
2903861|NCT03222141|Experimental|SAPIEN 3™ valve|
2903862|NCT03222128|Experimental|PIIS3i - SAPIEN 3|PIIS3i - SAPIEN 3 is Operable Group
2903863|NCT03222102|Experimental|Phasix mesh|Phasix mesh will be affixed to the exposed fascia after closure of the Abdomen in the course of liver transplantation.
2903864|NCT03222102|No Intervention|Standard surgery|Surgery will be performed according to routine, without the use of Phasix mesh.
2904011|NCT03221049||patients with liver space occupying lesions|ultrasound and radiomics
2903865|NCT03222089|Experimental|FOLFOXIGIL|"The FOLFOXIGIL chemoimmunotherapy regimen is composed by FOLFOXIRI chemotherapy and the immunotherapy of GM-CSF and IL-2.~FOLFOXIRI: Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, repeated every 2 weeks.~GM-CSF 150ug s.c. d3-7; Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity."
2903866|NCT03222089|Active Comparator|FOLFOXIRI|"Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, Repeated every 2 weeks.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity."
2903867|NCT03222076|Experimental|Arm A (Resectable Cohort): Nivolumab|Participants receive Nivolumab at 240 mg by vein every 2 weeks for 3 doses followed by liver imaging and hepatic resection on day 1 of week 7, followed (after 4 weeks from surgery) by Nivolumab 240 mg by vein every 2 weeks in the adjuvant setting until disease progression or for 2 years, whichever is sooner.
2903868|NCT03222076|Experimental|Arm B (Resectable Cohort): Nivolumab + Ipilimumab|Participants receive Nivolumab 240 mg by vein every 2 weeks for 3 doses plus Ipilimumab 1 mg/kg by vein on day 1 of therapy (3 doses of nivolumab, 1 dose of ipilimumab) followed by hepatic resection followed (after 4 weeks from surgery) by Nivolumab 240 mg by vein every 2 weeks plus Ipilimumab 1 mg/kg by vein every 6 weeks in the adjuvant setting until disease progression or for 2 years, whichever is sooner.
2903869|NCT03222076|Experimental|Arm C (Potentially Resectable Cohort): Nivolumab + Ipilimumab|Participants receive Nivolumab 240 mg by vein every 2 weeks for 3 doses plus Ipilimumab 1 mg/kg by vein on day 1 of therapy (3 doses of Nivolumab, 1 dose of Ipilimumab) followed by post-treatment biopsy and liver imaging on Day 1 of week 7. Thereafter, participants continue to receive Nivolumab 240 mg by vein every 2 weeks plus Ipilimumab 1 mg /kg by vein every 6 weeks with re-staging every 12 weeks until deemed surgically resectable or up to 2 years, whichever is sooner.
2903870|NCT03222063|Experimental|Experimental group|"Experimental Group:~Experimental group consists of 30 hospitalized children.In Experimental group after taking pretest on 1st day play interventions were introduced to the children and instructions regarding the way to play with all the interventions were provided to the children. Though all the children were free to choose the play yet the younger children were given simple and easy play interventions such as drawing, coloring etc. to obtain more sensory experience whereas the older children were offered play interventions such as puzzle, building blocks, ludo etc. with high cognitive demand. The play interventions were administered for 1 hour daily for continuous 5 days.Post test assessment of anxiety was done on 5th day."
2903871|NCT03222063|No Intervention|Comparison group|Comparison Group: 30 hospitalized children were selected by purposive sampling in comparison group. Pretest anxiety was measured on 1st day . No intervention was administered. only usual medical and nursing care was administered to the hospitalized children. Post test assessment of anxiety was done on 5th day.
2903872|NCT03222050|Experimental|electronic toy group|Distraction technique was given by electronic toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
2903873|NCT03222050|Experimental|key toy group|Distraction technique was given by key toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
2903874|NCT03222050|Experimental|Simple toy group|Distraction technique was given by simple toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
2903875|NCT03222050|No Intervention|control group|Routine care was given during immunization and no intervention was given
2903876|NCT03222037|Experimental|TEST/SCR|Subjects who are current soft contact lens wearers between the ages of 18 and 35 will be randomized to the two different treatments (TEST/SCR) sequentially
2903877|NCT03222037|Experimental|SCR/TEST|Subjects who are current soft contact lens wearers between the ages of 18 and 35 will be randomized to the two different treatments (SCR/TEST) sequentially
2903878|NCT03222024||Severe ischaemic stroke|patients with severe stroke on admission
2903879|NCT03222024||Malignant ischaemic stroke|patients without severe stroke on admission but developing it in hospital
2903880|NCT03222024||Mild to moderate ischaemic stroke|patients without severe stroke from onset to discharge
2903881|NCT03222011|Active Comparator|Standard endoscopic therapy|Single endoscopic dilatation
2903882|NCT03222011|Experimental|Intensive endoscopic therapy|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
2903883|NCT03221998|Experimental|IV paracetamol|Patients in the first group will receive in the operating room before surgery 1 gram (100 ml) of intravenous paracetamol ( IV paracetamol) for 15 minutes intraoperative
2903884|NCT03221998|Placebo Comparator|IV saline (NaCl 0.9 %)|Patients in the second group will receive 100 mL NACL 0.9% (IV NaCl 0.9 %)intraoperative
2903885|NCT03221985|Other|Questionnaires|
2903886|NCT03221946|Active Comparator|Diclofenac sodium oral|Group A which included 30 patients of either gender. Dosage drug: Diclofenac sodium Dosage form: Oral medication Frequency: twice daily Dose: 50mg Duration: 2 days
2903887|NCT03221946|Experimental|diclofenac sodium patch|Group B which included 30 patients who were prescribed Drug: Diclofenac sodium Dose: 100mg Drug form: transdermal patch to equate the oral dosage of 50mg Duration: for 2 days Frequency: Once daily
2903888|NCT03221946|Other|Diclofenac sodium injection|Group C which included 30 patients of either gender Drug: diclofenac sodium intra muscular injections Dose: 75mg which was the nearest available dosage to 100 mg availability in India Frequency: once daily Duration: for 2 days
2903889|NCT03221933|Experimental|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses.
2903890|NCT03221933|Experimental|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided doses.
2903891|NCT03221920|Experimental|Very Low Carbohydrate Diet|The patient will be evaluated for baseline clinical and laboratory values, and counselled on very low carbohydrate diet.
2903892|NCT03221920|No Intervention|Control|The patient will be evaluated for baseline clinical and laboratory values, and counselled on normal healthy .
2903893|NCT03221907|Experimental|GLA5PR GLARS-NF1 & Pregabalin placebo|GLA5PR GLARS-NF1 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin placebo 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months
2904012|NCT03221049||patients undergo ablation|ablation, ultrasound and radiomics
2904416|NCT03218241|Experimental|PRT064445 Dose 5|Dose 5 versus Placebo
2903894|NCT03221907|Active Comparator|GLA5PR GLARS-NF1 placebo & Pregabalin|GLA5PR GLARS-NF1 placebo 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months
2903895|NCT03221894||Conventional therapy with herbs|Patients were treated with conventional therapy with Chinese herbal medicine (GRAPE granules).
2903896|NCT03221894||Conventional therapy alone|In conventional therapy group, donepezil was the commonly used ChEI(cholinesterase inhibitor) to treat mild to severe AD patients. Memantine, a NMDA(N-methyl-D-aspartate ) antagonist, was given to moderate and severe AD patients. The dose of donepezil ranged from 5 to 10 mg once a day according to patients.
2903897|NCT03221881|Experimental|Pegylated Liposomal Doxorubicin and docetaxel|Pegylated Liposomal Doxorubicin 30-35 mg/m (2) and docetaxel 75-80 mg/m(2) were both administered on day 1,intravenous, Cycles were repeated in 3-week intervals,for 6 cycles.
2903898|NCT03221868|Experimental|Physical exercise intervention|Exercise group. Physical exercise intervention with sessions carried out as circuit-training, three times a week for 12 weeks to improve physical fitness and metabolic control. The sessions will last between 10 and 45 minutes.
2903899|NCT03221868|Active Comparator|Control|Control group consisting of women who underwent the same measurements for future comparisons and were assigned to receive information about health and counseling to practice of physical activity.
2903900|NCT03221855|Active Comparator|Domperidone|Domperidone 10mg every 8 hours for 7 days.
2903901|NCT03221855|Placebo Comparator|Placebo|Placebo 10mg every 8 hours for 7 days.
2903902|NCT03221842|Experimental|C1-INH|C1-esterase inhibitor
2903903|NCT03221842|Placebo Comparator|Placebo|Excipients of C1-INH plus albumin
2903904|NCT03221816|Placebo Comparator|Placebo Oral Tablet|"Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study.~The women were randomly allocated to control or experimental group (30 in each group) in a double-blind controlled clinical trial.~The control group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months."
2903905|NCT03221816|Experimental|Experimental group (Tenavit®)|"Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study.~The experimental group received one tablet of Tenavit® (pyridoxine hydrochloride 4.00mg + folic acid 0.80mg + cyanocobalamin 0.40 mg) daily and the placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months."
2903906|NCT03221803|Experimental|OT Vertical attachment|The attachment consists of a male part that is in the form of a steady with a central hole. This part is attached to the abutments .the female component is a white standard retentive clip engaging the outer walls of a steady male. It is incorporated in the partial denture together with a castable balancing pin that fits into the central hole of the steady male and aids in centering the prosthesis during the final stage of insertion; thereby ensuring a longer life to the retentive clips.
2903907|NCT03221803|Active Comparator|OT Cap attachment|Beveled castable bar with micro-size sphere located in first molar region, and attached to the distal surface of the waxed crowns to be cast as one piece, Nylone caps of standard retention for micro size sphere this nylon caps fit onto their spheres and located in metal housing at fitting surface on the denture and Positioning rings to maintain the space for nylon cap during construction of the partial denture metal framework.
2903908|NCT03221790|Experimental|Low and High FODMAP Diets in IBS|"This study will be comprised of the following four time periods: baseline, run-in, low FODMAP diet, and high FODMAP diet. Participants will undergo baseline assessment with questionnaires on demographics, IBS symptoms (IBS symptom severity scoring questionnaire), diet, and psychological parameters. Baseline mucosal colonic biopsies will be obtained, and metabolome analysis from urine samples. These will be repeated 3 other times during each of the above time periods. Low FODMAP Diet followed by a High FODMAP Diet"
2903909|NCT03221777||AFOTS - Medical Illness Cases|"Patients who have AF detected for the first time in the setting of an acute non-cardiovascular medical (i.e. non-surgical ).~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
2903910|NCT03221777||Medical Illness Controls|"Patients without a history of AF who are hospitalized for an acute non-cardiovascular medical (i.e. non-surgical) and do not have AF detected.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
2903911|NCT03221777||AFOTS - Non-cardiac surgery Cases|"Patients who have AF detected for the first time following non-cardiac surgery.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
2903912|NCT03221777||Non-cardiac Surgery Controls|"Patients without a history of AF who are hospitalized after non-cardiac surgery and do not have AF detected.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
2903913|NCT03221764|Experimental|Amiodarone with CoSeal administered with CO2 driver|Lung Transplant Recipients who receive Intraoperative application of an Amiodarone containing hydrogel at the time of transplant.
2903914|NCT03221751|Experimental|Prazosin|Subjects will be titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose is 5 mg in the morning, 5 mg in the afternoon and 15 mg at bedtime.
2903915|NCT03221751|Placebo Comparator|Placebo|Subjects will be titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose is 5 mg in the morning, 5 mg in the afternoon and 15 mg at bedtime.
2903916|NCT03221738|Experimental|App-Based Cognitive Behavioral Therapy|12-week Smartphone-delivered CBT for BDD.
2903917|NCT03221699|Placebo Comparator|control|Formula without ZnO
2903918|NCT03221699|Active Comparator|intervention|Formula with ZnO
2903919|NCT03221686|Placebo Comparator|Control|Total daily protein intake: 1.5 g protein/kg body weight
2903920|NCT03221686|Active Comparator|Intervention|55 mg zinc/day, 1251 mg vitamin C/day, and 15 g arginine/day. Total daily protein intake: 1.5 g protein/kg body weight
2903921|NCT03221660|Experimental|F-Composite 2 system|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the F-Composite 2 system.
2903922|NCT03221647||Controls|Intestinal biopsies from controls, affected by gastroesophageal reflux,
2903923|NCT03221647||GCD CD (Gluten Containing Diet CD)|Intestinal biopsies from GFD patients had with negative serology (anti-tTg antibodies between 0 and 1.5 U/ml and EMA negative) and normal biopsy (Marsh T0-1).
2903925|NCT03221634|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 administrations (up to approximately 2 years) and receive daratumumab 16 mg/kg by IV infusion on Days 1, 8, 15, and 22 of Cycles 1-2; on Days 1 and 15 of Cycles 3-6, and on Day 1 of Cycle 7 and beyond, for up to 2 years. Each cycle is 28 days long.
2903926|NCT03221621|Active Comparator|Adalimumab Monotherapy|Adalimumab injections will be administered through subcutaneously in a weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2, continued for 2 years in total.
2903927|NCT03221621|Experimental|Adalimumab + Surgery|Patients will be treated with a combination of adalimumab and wide excision, with a maximum of three surgical interventions within the first year. Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2, continued until the last surgery.
2903928|NCT03221608|Active Comparator|surgery alone(open/laparoscopic)|The patients with colorectal cancer (T4N0-2M0) who have a high risk of developing colorectal Peritoneal Carcinomatosis (PC) undergo curative surgery(open/laparoscopic).
2903929|NCT03221608|Experimental|surgery and HIPEC|Standard surgical treatment and HIPEC with Lobaplatin.
2903930|NCT03221595|Experimental|Operative|Patients in the operative arm will undergo best medical management, in addition to surgical stabilization of their displaced rib fractures within 72 hours of admission to the hospital.
2903931|NCT03221595|No Intervention|Non-operative|Patients in the non operative arm will undergo best medical management of their displaced rib fractures.
2903932|NCT03221582|Experimental|EBR/GZR (Zepatier) - HCV/HIV co-infected|Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.
2903933|NCT03221582|Experimental|EBR/GZR (Zepatier) - HCV monoinfected|Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.
2903934|NCT03221569|Experimental|Intravenous ketamine|Arm will include 0.3 mg/kg intravenous piggyback ketamine over 10 minutes for 1 dose and a 1ml normal saline placebo via intravenous push
2903935|NCT03221569|Active Comparator|ketorolac|Arm will include 30mg ketorolac intravenous push and 50ml normal saline over 10 minutes
2903936|NCT03221556|Active Comparator|Engagement-Focused Care Coordination|The brief intervention in Engagement-Focused Care Coordination is the Engagement Interview. In this model, providers meet one to two times with mothers who screen positive for depression, and use techniques of shared decision-making to help mothers process the results of the screen; explore treatment options; and connect with formal mental health services. Engagement-Focused Care Coordination emphasizes referral to formal mental health services.
2903937|NCT03221556|Active Comparator|Problem Solving Education (PSE)|The brief Problem Solving Education (PSE) is a six-session cognitive-behavioral program. PSE offers immediate intervention in the PCMH, followed by referral to further treatment if symptoms persist.
2903938|NCT03221543|Experimental|Resting Metabolic Rate Testing|All subjects will have the resting metabolic rate test. The ReeVue Indirect Calorimeter from Korr Medical will be used to obtain the resting metabolic rate.
2903939|NCT03221530|Experimental|EISR-I|Participants in the Early Intervention for Suicide Risk Among Immigrant Youth (EISR-I) family-based intervention will attend 8 in-person sessions with at least one parent/guardian.
2903940|NCT03221530|Active Comparator|Enhanced usual care|Participants in the usual care arm will receive a safety planning and assessment feedback session from the research team and will receive usual care in the behavioral health clinic where the study takes place.
2903941|NCT03221517|Experimental|Cohort 1|Shift workers receive a standardized meal with a glucose challenge test
2903942|NCT03221517|Experimental|Cohort 2|Matched healthy controls receive a standardized meal with a glucose challenge test
2903943|NCT03221504|Active Comparator|Antibiotic therapy for 10 days|After 7 days of cefuroxime treatment (oral, intravenous or sequential), patients from day 8 to day 10 will continue to receive the antibiotic (in blinded bottle).
2903944|NCT03221504|Experimental|Antibiotic therapy for 7 days|After 7 days of cefuroxime therapy (oral, intravenous or sequential), children from day 8 to day 10 will receive placebo (in blinded bottle).
2903945|NCT03221491|Experimental|No Background Infusion Group(Group B0)|Patients in Group B0 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 0ml/h.
2903946|NCT03221491|Experimental|Low Background Infusion Group(Group B1)|Patients in Group B1 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 1ml/h.
2903947|NCT03221491|Experimental|High Background Infusion Group(Group B2)|Patients in Group B2 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 2ml/h.
2903948|NCT03221478|Active Comparator|Kinesio Taping placebo and exercises|kinesio placebo and exercises
2903949|NCT03221478|Experimental|Kinesio Taping and exercises|kinesio with tension and exercises
2903950|NCT03221478|Experimental|Kinesio Taping with tension|Kinesio Taping with tension
2903951|NCT03221465|No Intervention|Usual Care|Usual care: dietary and exercise counseling only at baseline, no other intervention.
2903952|NCT03221465|Active Comparator|Usual Care + self-monitoring of physical activity|Tracking Device control: The intervention applied is usual care and self-monitoring of physical activity. Patients will receive a pedometer (e.g. Misfit brand wrist pedometer) to allow for self-monitoring of physical activity. They will be able to obtain daily feedback on step counts via the wearable device and their smartphones. They will also have a 2-week run-in period like the incentive arm.
2903953|NCT03221465|Experimental|Self-monitoring + incentives of physical activity|The intervention applied is self-monitoring of physical activity with incentives. Patients will receive a a pedometer (e.g. Misfit brand wrist pedometer) to allow for self-monitoring of physical activity. Participants will monitor daily step counts with automated feedback on goal attainment via text message. We will establish a baseline step count for each participant (during a 2-week run-in period) and then recommend a 15 percentage point increase in daily step goal every 2 weeks during the 12-week intervention period (weeks 3-14) with a maximum goal of 7,000 steps. Two health engagement questions will be sent per week to participants as well for the 12-week intervention period.
2904002|NCT03221101|Active Comparator|Non invasive ventilation|"Home non invasive ventilation is prescribed with the following settings~PS mode~IPAP according to clinical and hemodynamic tolerance~EPAP according to air trapping~RR around 12/ min.~LOT for SaO2 > 90%~Monitoring with capnometry for settings validation"
2903954|NCT03221452|Other|Intervention|The intervention includes 4 every other week, 2-hour educational sessions to teach compensatory strategies along with skill development and training. Educational sessions will include content on common cognitive problems experienced by people with T2DM and discussion of compensatory strategies to improve cognitive skills as well as content on behaviors and lifestyle strategies to maintain cognitive functioning. Each participant will use the online training program (BrainHQ/Posit Science) for a minimum of 45 minutes 3 times a week and to record practice times and dates. Tasks in the computer training are arranged so that as the user moves forward, the tasks become more challenging. Each task is in a game-like format.
2903955|NCT03221439|Experimental|Cognitive Functional Therapy|Cognitive Functional Therapy (CFT) is a behavioral intervention that addresses multiple aspects of low back pain. This approach focuses on changing the patient's beliefs, confronting their fears, educating them about pain mechanisms, increasing mental strength, and control of their body. This is done with functional tasks performed by individuals training them to reduce excessive muscle activity in the trunk and generate behavioral changes related to pain, from postures and provocative movements.
2903956|NCT03221439|Active Comparator|Manual Therapy and Exercise|The active comparator will be the combination of manual therapy and motor control exercises.
2903957|NCT03221426|Experimental|Pembrolizumab+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets twice each day (BID) on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5-fluorouracil (5FU) via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle for up to 14 cycles."
2903958|NCT03221426|Placebo Comparator|Placebo+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive placebo via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle for up to 14 cycles."
2903959|NCT03221426|Experimental|Pembrolizumab+FLOT Safety Cohort|"FLOT=docetaxel+oxaliplatin+5FU+leucovorin (calcium folinate). Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin (calcium folinate) 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.~Adjuvant: 4 to 10 weeks postsurgery, participants receive pembrolizumab 200 mg via IV infusion Day 1 Q3W for up to 11 cycles PLUS docetaxel 50 mg/m^2, oxaliplatin 85 mg/m^2, 5FU 2600 mg/m^2, and leucovorin 200 mg/m^2 Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations."
2903960|NCT03221426|Placebo Comparator|Placebo+FLOT Safety Cohort|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.~Adjuvant: 4 to 10 weeks postsurgery, participants receive placebo via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations."
2903961|NCT03221413|Experimental|PD tACS|Persons with Parkinson disease who will be treated with tACS: Intervention: tACS (transcranial alternating current stimulation)
2903962|NCT03221413|Experimental|Pain tACS|Persons with neuropathic pain who will treated with tCAS. Intervention: tACS (transcranial alternating current stimulation)
2903963|NCT03221400|Experimental|PEN-866|Intravenous administration of PEN-866
2903964|NCT03221387|Other|Nasal high flow with oxygen|While in the clinic High Flow Nasal Cannula oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep arterial oxygen saturation (SaO2) > 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience. The subject will be discharged to home and instructed to use the high flow nasal cannula system at night and during the daytime while at home and resting.
2903965|NCT03221374|Experimental|Mindfulness Based Stress Reduction|Participants will attend an 8-week Mindfulness Based Stress Reduction (MBSR) course between pre- and post-testing.
2903966|NCT03221374|No Intervention|Waitlist|Participants will be added to a waitlist intervention group for 8-weeks between pre-and post-testing.
2903967|NCT03221361|Active Comparator|Thermoplastic resin group|Thermoplastic complete denture placement is done
2903968|NCT03221361|Placebo Comparator|conventional acrylic resin group|conventional acrylic resin complete denture placement is done
2903969|NCT03221348|Experimental|Open label treatment|Study drug (CHO-H01) administered on Day 1 of 28 day cycles up to 6 cycles total.
2903970|NCT03221335|Experimental|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea).
2903971|NCT03221322||Control|20 kg/m2 ≤ BMI ≤ 25 kg/m2, healthy, with no eating disorder, 150 subjects, 20 - 40 years old
2903972|NCT03221322||Superlean|15 kg/m2 ≤ BMI ≤ 18 kg/m2, healthy, with no eating disorder, 150 subjects, 25 - 35 years old in particular
2903973|NCT03221309||Adults infected with HCV|HCV-infected adults with on-going injection drug use with opioids
2904003|NCT03221088|Experimental|Jintrolong® low dose group|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
2904598|NCT03216954|Experimental|High Dose n-Acetylcysteine|Subjects will receive 1.2 g oral n-acetylcysteine two times daily.
2903974|NCT03221296|Experimental|Vestibular Training (Intervention Group)|"For the actual intervention, participants will be asked to commit a total of approximately 20 minutes a day of vestibular exercise, divided into three separate sessions (i.e. three 7 minute sessions).~These will include eye movement exercises, walking and balancing. Every 2 weeks, there will be a slight change to the exercises to increase difficulty. (i.e. balancing on one leg or walking with head turns)"
2903975|NCT03221296|No Intervention|Usual Care (Control group)|Patients that are randomized to standard of care Control group will undergo Baseline and 12-week assessments including vestibular testing and questionnaires.
2903976|NCT03221283|No Intervention|control group|Participants only accept the regular scheduled in the compulsory isolated detoxification center.
2903977|NCT03221283|Experimental|Music therapy group|Use randomized controlled clinical trial design.The main content of music therapy is emotional experience , emotion regulation, emotional control and emotional expression. The experimental group received 13 group music sessions over a three-month period.
2903978|NCT03221270|Experimental|tACS (alpha)|20 participants: 10 Hz tACS with a peak-to-peak amplitude of 2mA for 20 minutes twice daily during 5 consecutive days of stimulation, then 40 minutes once weekly for 8 weeks of maintenance stimulation.
2903979|NCT03221270|Sham Comparator|Sham tACS (alpha)|20 participants: Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation twice daily during 5 consecutive days of stimulation, then once weekly for 8 weeks of maintenance stimulation.
2903980|NCT03221257|Placebo Comparator|Placebo (Plac) + Mycophenolate (MMF)|Participants will receive Placebo (Plac) as add-on to a background therapy of Mycophenolate Mofetil (MMF).
2903981|NCT03221257|Experimental|Pirfenidone (PFD) + Mycophenolate (MMF)|Participants will receive Pirfenidone (PFD) as add-on to a background therapy of Mycophenolate Mofetil (MMF).
2903982|NCT03221244|Experimental|VR Treatment|"The VR distractor condition is an adaptive training, experimental treatment. Participants will wear a headset VR system programmed to simulate a virtual classroom. They will be asked to perform computer tests of math, attention, or working memory in the virtual reality context. Distractors will be presented intermittently throughout the test session. During training sessions, distractor saliency and frequency will increase or decrease based on performance on the tests.~25 sessions should be completed in approximately 5-7 weeks. In-home VR training sessions will each be about 20-30 minutes in length.~The investigators expect a decrease in distraction after adaptive distractor exposure in the VR classroom."
2903983|NCT03221244|Active Comparator|VR Active Control|"The VR classroom with no distractors presented is an active control group. This group will undergo the same training regimen, only their virtual classroom environment will not contain adaptive distractors. Participants will wear a headset VR system programmed to simulate a virtual classroom. They will be asked to perform computer tests of math, attention, or working memory in the virtual reality context.~25 sessions should be completed in approximately 5-7 weeks. In-home VR training sessions will each be about 20-30 minutes in length.~The investigators expect no change in response to distraction in the ADHD group after control exposure to the VR classroom."
2903984|NCT03221231|Experimental|N-acetylcysteine|
2903985|NCT03221231|Placebo Comparator|Placebo|
2903986|NCT03221231|Active Comparator|Healthy controls|
2903987|NCT03221218|Experimental|Enhanced screening-informed letter|Family physicians will receive a letter that includes their patient's screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines for MTBI (2013).
2903988|NCT03221218|No Intervention|Standard letter|Family physicians will receive a letter that includes generic recommendations for managing MTBI based on the Ontario Neurotrauma Foundation clinical practice guidelines (2013). Screening test results will not be provided.
2903989|NCT03221205|Sham Comparator|Sham CPAP|Patientes randomized to use sham CPAP via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.
2903990|NCT03221205|Experimental|Therapeutic CPAP|Patients randomized to use CPAP programmed to administer automatically pressure from 4 to 20 cm H2O via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.
2903991|NCT03221192||Subjects participating in CE and CD interviews|Twenty adult subjects from the US and 10 adult subjects from Germany with severe recurrent nasal polyps who have received nasal polyp surgery in the past 10 years prior to screening will be asked to participate in CE and CD interviews
2903992|NCT03221192||Subjects participating in interview and real-time data capture|Ten subjects from the US with severe recurrent nasal polyps who are participating in CE and CD interviews will be asked to complete the real-time data capture app task.
2903993|NCT03221179|Experimental|RO7049665|Participants will be administered a single SC dose of RO7049665 administered in up to 4 SC injection.
2903994|NCT03221179|Placebo Comparator|Placebo|Participants will be administered a single SC dose of matching placebo formulation administered in up to 4 SC injections.
2903995|NCT03221166|Experimental|Thalidomide|Thalidomide is a immunomodulatory and antiangiogenetic drug with anti tumor necrosis factor (TNF) alpha properties
2903996|NCT03221166|Active Comparator|Infliximab|Infliximab is a chimeric monoclonal antibody against TNF alpha
2903997|NCT03221153|No Intervention|No Intervention|This is the control group. Participants in this group will take the usual course without simulation techniques.
2903998|NCT03221153|Experimental|Simulation|This is the intervention group. Participants in this group will to take the course with simulation techniques.
2903999|NCT03221114|Experimental|Positive Psychological Intervention|Our culturally-tailored Positive Psychology (PP) Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
2904000|NCT03221114|No Intervention|Wait list control|Receipt after the active treatment group has completed the positive psychological intervention.
2904001|NCT03221101|No Intervention|Long Term Oxygen Therapy alone|Long Term oxygen therapy is prescribed according to the guidelines
2904004|NCT03221088|Experimental|Jintrolong® high dose group|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
2904005|NCT03221088|No Intervention|Negative control group|Untreated Control Group
2904013|NCT03221036|Experimental|Induction Phase: Vedolizumab 300 mg|Vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, and 6 during induction phase.
2904014|NCT03221036|Placebo Comparator|Induction Phase: Placebo|Matching placebo IV infusion at Weeks 0, 2, and 6 during induction phase.
2904015|NCT03221036|Experimental|Maintenance Phase: Vedolizumab 300 mg|Participants who received vedolizumab IV 300 mg in induction phase and achieved clinical response at Week 10 will be randomized to receive vedolizumab 300 mg IV infusion at Weeks 14, 22, 30, 38, 46 and 54. Participants who did not achieve clinical response at Week 10 will receive vedolizumab 300 mg IV infusion every 4 weeks from Week 14 up to Week 58.
2904016|NCT03221036|Placebo Comparator|Maintenance Phase: Placebo|Participants who received vedolizumab IV 300 mg in induction phase and achieved clinical response at Week 10 will be randomized to receive placebo, IV infusion at Weeks 14, 22, 30, 38, 46 and 54. Participants who received matching placebo in the induction phase and achieved clinical response at Week 10 will continue to receive placebo at Week 14, 22, 30, 38, 46, and 54.
2904017|NCT03221023|Experimental|Vancomycin|These patients will receive intrawound Vancomycin-saline and IV antibiotics
2904018|NCT03221023|Placebo Comparator|Saline|These patients will receive intrawound saline + IV antibiotics alone
2904019|NCT03221010|Experimental|Motivational Interviewing|Intervention Group: in this group, composed of 6 randomized Basic Health Units, the professionals who coordinate the smoking groups will receive the training for the use of the Motivational Interviewing as an additional resource to the work of motivation and cognitive-behavioral approach usually performed in the groups, however , With an approach based on Motivational Interviewing.
2904020|NCT03221010|Active Comparator|Traditional cognitive-behavioral approach|Control Group: in this group composed of the remaining 6 Randomized Basic Health Units, professionals will use only the traditional cognitive-behavioral approach advocated by the Brazilian Ministry of Health's smoking program.
2904021|NCT03220997|Experimental|Interventional|Mothers will be given six sachets of carbohydrate powder to be mixed in water . Instructions will be given to have two sachets in 800ml water at 10pm the night before and one sachet in 400ml water at 6 am on the morning of surgery. The order of the list will be decided at 8.45am on the morning of surgery by the surgical team. Mothers scheduled to have surgery later than 11am will be given a further sachet at 9.30am. Mothers scheduled for surgery after 1pm will be given a sachet at 9am and 11am.
2904022|NCT03220997|No Intervention|Standard Care|"Standard fasting instructions will given to mother:~Food until midnight before surgery 800ml water at 10pm night before surgery 400ml water at 6 am morning of surgery The order of the list will be decided at 8.45am on the morning of surgery by the surgical team.~Mothers scheduled to have surgery later than 11am will be given a further 400ml water at 9.30am. Mothers scheduled for surgery after 1pm will be given 400ml water at 9am and 11am."
2904023|NCT03220984|Experimental|Immunotherapy group|All enrolled patients receive a total of 12 times of Immuncell-LC therapy
2904024|NCT03220971||proposed cross-section study|"100 subjects with NAFLD/NASH and negative anti-HCV Ab~50 subjects with HCC and negative anti-HCV Ab~50 subjects with HCC and positive for genotype-1 HCV~50 controls with all negative for NAFLD/NASH but positive for genotype-1 HCV~50 controls with all negative for NAFL, NASH and HCV"
2904025|NCT03220971||proposed longitudinal study|"50 NAFLD/NASH patients and positive for genotype-1 HCV with SVR~10 NAFLD/NASH patients and positive for genotype-1 HCV without SVR~10 HCC patients and positive for genotype-1 HCV with SVR~10 HCC patients and positive for genotype-1 HCV without SVR~50 chronic hepatitis C but not NAFLD patients with SVR~10 chronic hepatitis C but not NAFLD patients without SVR"
2904026|NCT03220958|Experimental|Metoclopramide|Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip
2904027|NCT03220958|Placebo Comparator|Placebo|Normal saline, administered as an intravenous drip
2904028|NCT03220945|No Intervention|Arm I (Control group)|Patients may receive yoga instruction for 1 week after post-test 2.
2904029|NCT03220945|Experimental|Arm II (Yoga group)|Patients receive yoga instruction over approximately 3 hours daily for 5 days of week 1 and over 2 hours once a week of weeks 2-13.
2904030|NCT03220932|Experimental|Cytoreductive surgery combined with HIPEC|All patients will start with three cycles of CT-BEV 15 mg/kg, and will then be randomly. Then one cycle of monochemotherapy without bevacizumab is administered and followed by an interval CRS and HIPEC with postoperative chemotherapy and bevacizumab (CT-BEV - 15 mg/kg once every 3 weeks) until disease progression
2904031|NCT03220932|Active Comparator|Aurelia arm|Chemotherapy and bevacizumab (CT-BEV) once every 3 weeks from enrollment until disease progression
2904032|NCT03220919|Experimental|Weight-based|Weight-based insulin insulin titration regimen
2904033|NCT03220919|Placebo Comparator|Glucose level-based|Glucose level-based insulin titration regimen
2904034|NCT03220906||Arterial line|Children undergoing surgical procedure with planned arterial cannula placement.
2904035|NCT03220893||Women with Dense Breast Tissue|"Subjects will have had heterogeneously dense or extremely dense breasts on most recent prior mammographic examination (Breast Imaging Reporting and Data System (BI-RADS) c or d) and be asymptomatic for breast disease.~Subjects will receive Molecular Breast Imaging (MBI) and Digital Breast Tomosynthesis (DBT) at Year 0 screening within a 24-hour period. All patients who did not receive a diagnosis of breast cancer during the Year 0 screening will undergo DBT and MBI at approximately one year (Year 1 screening), again within a 24-hour period."
2904036|NCT03220880||Intranasal dexmedetomidine|Intranasal dexmedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
2904037|NCT03220867|Experimental|Treatment Sequence: AB|Participants in cohort 1 (fasting) and cohort 2 (fed) will receive 1 milligram (mg) risperidone administered as Xian Risperdal (test) 1*1 mg oral tablet (Treatment A) on Day 1 in Period 1 followed by 1 mg risperidone administered as Gurabo Risperdal (reference) 1*1 mg oral tablet (Treatment B) on Day 1 in period 2. There will be a washout period of at least 10 days between treatments.
2904038|NCT03220867|Experimental|Treatment Sequence: BA|Participants in cohort 1 (fasting) and cohort 2 (fed) will receive Treatment B on Day 1 in period 1 followed by Treatment A on Day 1 in period 2. There will be a washout period of at least 10 days between treatments.
2904039|NCT03220854|Experimental|SRT + PD-1 or PD-L1 inhibitor|Stereotactic radiotherapy (SRT), 3-5 fractions over 1-2 weeks plus programmed death receptor-1 (PD-1) or programmed death-ligand1 (PD-L1) inhibitor after last SRT fraction (on same day) and continuing per standard treatment schedule for 12 months
2904703|NCT03216226|Experimental|dasiglucagon (ZP4207)|Repeated single fixed doses (s.c.injection) of dasiglucagon
2904040|NCT03220841|Active Comparator|Standard drug therapy|Adalimumab monotherapy, Standard Dose induction (160mg at week 0, 80mg week 2 and 40mg fortnightly thereafter)
2904041|NCT03220841|Experimental|Intensive drug therapy|Adalimumab in combination with dose optimized thiopurine, Intensive induction (160mg weekly for 4 weeks then 40mg fortnightly). Anti-TNF dose may be increased if ongoing inflammation every 4 months until study endpoint.
2904042|NCT03220828|No Intervention|Control|The control group will be provided standard of care, which is no use of technologies. Midazolam may be used as a part of standard of care to provide ease of anxiety in children undergoing vascular access procedures.
2904043|NCT03220828|Experimental|Intervention Group with Passive Content|Interventional arm will use technology based distractions (VR headsets, AR headset, tablets, or BERT projector) to prevent high anxiety before vascular access.
2904044|NCT03220828|Experimental|Intervention Group with Active Content|Interventional arm will use technology based distractions (VR headsets, AR headset, tablets, or BERT projector) to prevent high anxiety before vascular access.
2904045|NCT03220815|Experimental|Biologic drilling drilling at low speed|
2904046|NCT03220815|Active Comparator|conventional drilling drilling at high speed|
2904047|NCT03220802|Experimental|Test group|participants receive a daily dose of OMNI-BiOTiC PPI for three months
2904048|NCT03220789|Experimental|Biologic drilling drilling at low speed|Procedure/Surgery: Drilling at low speed
2904049|NCT03220789|Active Comparator|conventional drilling drilling at convention|Procedure/Surgery: Drilling at conventional or high speed
2904050|NCT03220776|Experimental|N-Acetylcysteine|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
2904051|NCT03220776|Experimental|Gabapentin|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
2904052|NCT03220776|Placebo Comparator|Placebo Oral Tablet|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
2904053|NCT03220763||Thirds of number of restaurant meals|Respondent self-reports of # of times/week restaurant prepared meals were consumed. The respondents will be categorized into approximate thirds.
2904054|NCT03220737|Experimental|VAXCHORA (Cholera Vaccine, Live, Oral)|Vaxchora will be administered in 3 age groups. 100ml will be administered to age groups 12 to <18 years and 6 to <12 years. 50ml will be administered to age group 2 to <6 years.
2904055|NCT03220737|Placebo Comparator|Placebo group|0.9% saline will be administered in 3 age groups. 100ml will be administered to age groups 12 to <18 years and 6 to <12 years. 50ml will be administered to age group 2 to <6 years.
2904056|NCT03220724|Experimental|Part A: Group 1|Participants will receive 20 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
2904057|NCT03220724|Experimental|Part A: Group 2|Participants will receive 100 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
2904058|NCT03220724|Experimental|Part A: Group 3|Participants will receive 400 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
2904059|NCT03220724|Placebo Comparator|Part A: Group 4|Participants will receive placebo at Months 0, 2, 4, 8, and 12.
2904060|NCT03220724|Experimental|Part B: Group 5|Participants will receive CH505TF (admixed with GLA-SE) and placebo at Month 0; CH505w53 (admixed with GLA-SE) and placebo at Month 2; CH505w78 (admixed with GLA-SE) and placebo at Month 4; and CH505w100 (admixed with GLA-SE) and placebo at Months 8, 12, and 16.
2904061|NCT03220724|Experimental|Part B: Group 6|Participants will receive CH505TF (admixed with GLA-SE) and 4 mg of DNA Mosaic-Tre at Month 0; CH505w53 (admixed with GLA-SE) and 4 mg of DNA Mosaic-Tre at Month 2; CH505w78 (admixed with GLA-SE) and 4 mg of DNA Mosaic-Tre at Month 4; CH505w100 (admixed with GLA-SE) and 4 mg of DNA Mosaic-Tre at Months 8, 12, and 16.
2904062|NCT03220724|Experimental|Part B: Group 7|Participants will receive CH505TF (admixed with GLA-SE) and placebo at Month 0; CH505TF + CH505w53 (admixed with GLA-SE) and placebo at Month 2; CH505TF + CH505w53 + CH505w78 (admixed with GLA-SE) and placebo at Month 4; CH505w53 + CH505w78 + CH505w100 (admixed with GLA-SE) and placebo at Month 8; CH505w78 + CH505w100 (admixed with GLA-SE) and placebo at Month 12; and CH505w100 (admixed with GLA-SE) and placebo at Month 16.
2904063|NCT03220724|Experimental|Part B: Group 8|Participants will receive CH505TF (admixed with GLA-SE) and 4 mg of DNA Mosaic-Tre at Month 0; CH505TF + CH505w53 (admixed with GLA-SE) and 4 mg of DNA Mosaic-Tre at Month 2; CH505TF + CH505w53 + CH505w78 (admixed with GLA-SE) and 4 mg of DNA Mosaic-Tre at Month 4; CH505w53 + CH505w78 + CH505w100 (admixed with GLA-SE) and 4 mg of DNA Mosaic-Tre at Month 8; CH505w78 + CH505w100 (admixed with GLA-SE) and 4 mg of DNA Mosaic-Tre at Month 12; and CH505w100 (admixed with GLA-SE) and 4 mg of DNA Mosaic-Tre at Month 16.
2904064|NCT03220724|Placebo Comparator|Part B: Group 9|Participants will receive two injections of placebo at Months 0, 2, 4, 8, 12, and 16.
2904065|NCT03220711|Experimental|Subjects with abnormal colon tissue|The study subjects will be high-risk for colonic adenomas (i.e. strong family history of adenomas/adenocarcinoma or personal history of adenomas/adenocarcinoma), known adenoma scheduled for endoscopic resection, or in subjects with suspected dysplasia in inflammatory bowel disease (IBD). Fluorescein will be sprayed on the area of interest to provide imaging contrast for the images taken with the confocal endomicroscope.
2904066|NCT03220685||1.controlled|normal persons as a control
2904067|NCT03220685||2.CKD pt without ttt for anemia|first group includes 30 newly diagnosed CKD patients without treatment of anemia.
2904068|NCT03220685||3.CKD pt with ttt for anemia|group 30 CKD patients on erythropoietin and iron therapy
2904069|NCT03220672|Experimental|Expertimental|The sample will receive a tailored assessment and educational intervention on Motor Control of the Pelvic Floor Muscle
2904070|NCT03220659|Placebo Comparator|Standard settings|Usual pacing programming
2904071|NCT03220659|Experimental|Multi-point pacing|MPP programming
2904072|NCT03220646|Experimental|A:recurrent IDH wildtype RB1 intact grade II and III gliomas|The main study cohort will consist of patients with recurrent IDH wildtype, RB1 wildtype, WHO grade II and III gliomas that have failed previous therapy.
2904630|NCT03216720|Active Comparator|CABG with miniaturized ECC|Elective (CABG) with conventional miniaturized extracorporeal circulation (miECC)
2904073|NCT03220646|Experimental|B:Recurrent glioma any grade|Ten patients who require standard of care cytoreductive surgery for recurrent astrocytoma, oligodendroglioma, or glioblastoma, will be offered pre-surgical abemaciclib and then resume the drug following recovery from surgery, continuing until disease progression or unacceptable toxicity analogous to the non-surgical patients in cohort A and C.
2904074|NCT03220646|Experimental|C:All other recurrent brain tumors|This is an exploratory cohort including patients with recurrent IDH mutant glioma, meningioma, recurrent ependymoma, and recurrent PCNSL.
2904075|NCT03220633|Experimental|ATB-346|Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of ATB-346.
2904076|NCT03220633|Placebo Comparator|Placebo|Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of placebo.
2904077|NCT03220620||GDT Group|receives goal-directed therapy
2904078|NCT03220620||Not GDT Group|receives no individualized goal-directed therapy
2904079|NCT03220607||Medical induced abortion|120 singleton nulliparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were nulliparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
2904080|NCT03220594||Hypogastric artery ligation (HAL)|Patients who underwent only hypogastric artery ligation performed during the delivery of their babies. Six months after the operation they will evaluated for their ovarian reserve via hormones and astral follicle count (AFC)
2904081|NCT03220594||HAL and hysterectomy|Patients who underwent both hypogastric artery ligation and hysterectomy performed during the delivery of their babies. Six months after the operation they will evaluated for their ovarian reserve via hormones and astral follicle count (AFC)
2904082|NCT03220594||Postpartum|Postpartum control group constituted of patients delivered baby without any complication and evaluated 6 months later.
2904083|NCT03220581|Active Comparator|Referral for care|Referral for mental health issues and family support services
2904084|NCT03220581|Experimental|Behavioral therapy|8-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors
2904085|NCT03220555|Experimental|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
2904086|NCT03220555|Active Comparator|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
2904087|NCT03220542|Experimental|Probiotics|Saccharomyces boulardii + Esomeprazole + Amoxicillin + Clarithromycin
2904088|NCT03220542|Experimental|Broccoli|Broccoli Sprouts Extract + Esomeprazole + Amoxicillin + Clarithromycin
2904089|NCT03220542|Active Comparator|Triple Therapy|Esomeprazole + Amoxicillin + Clarithromycin
2904090|NCT03220529|Active Comparator|Normal healthy subjects|Healthy subjects with normal appearing corneas respecting all the general inclusion/exclusion criteria. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
2904091|NCT03220529|Active Comparator|Keratoconus subjects|Subjects classified as patients with mild, moderate, or advanced keratoconus. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
2904092|NCT03220529|Active Comparator|Subjects diagnosed with PMD|Subjects with Pellucid marginal corneal degeneration (PMD). Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
2904093|NCT03220529|Active Comparator|Patients before and after LASK surgery|Healthy subjects who are scheduled to undergo LASIK surgery. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
2904094|NCT03220529|Active Comparator|Patients with keratoconus before and after CXL|Subjects who are scheduled to undergo collagen crosslinking treatment. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
2904095|NCT03220516|Experimental|single-use digital ureteroscope|Participants under this arm will undergo retrograde intrarenal surgery (RIRS) procedure under the single use digital ureteroscope.
2904096|NCT03220516|Experimental|reusable fiberoptic ureteroscopes|Participants under this arm will undergo the RIRS procedure under the reusable fiberoptic ureteroscope
2904097|NCT03220516|Experimental|reusable digital flexible ureteroscopes|Participants under this arm will undergo the RIRS procedure under the reusable digital flexible ureteroscope.
2904098|NCT03220503|Experimental|Group (A)|consists of 25 patients will receive frozen embryo with endometrial scratching on day 7 of transfer cycle.
2904099|NCT03220503|No Intervention|Group (B)|consists of 25 patients will receive frozen embryo without endometrial scratching as control group.
2904100|NCT03220490|Experimental|Short term: interval no-interval eye|"On the first day of the study, in the selected eye the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval.~One drop of two types of IOP reduction drugs (Brimonidine and Timolol) will be given with a 5 minutes interval between the first (Brimonidine) and the second (Timolol) drop. IOP measurements will be taken every hour up to 6 hours after treatment.~On the second day of the study (two weeks after the first day) the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol no time interval. Again one drop of the same two types of drugs will be given at the same order but with no time interval between them. IOP measurements will be taken in the same manner as on the first day."
2904101|NCT03220490|Experimental|Short term: No-interval interval eye|"On the first day of the study, in the selected eye the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval.~One drop of two types of IOP reduction drugs (Brimonidine and Timolol) will be given with no waiting period between the first (Brimonidine) and the second (Timolol) drop. IOP measurements will be taken every hour up to 6 hours after treatment.~On the second day of the study (two weeks after the first day) the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval. Again one drop of the same two drugs will be given at the same order but with a five minute time interval between the first and second drop. IOP measurements will be taken in the same manner."
2904631|NCT03216720|Active Comparator|CABG with conventional ECC|Elective CABG with conventional extracorporeal circulation (cECC)
2904102|NCT03220490|Experimental|Long term: interval no-interval eye|"In the first phase the effect of 5 minute interval between regular glaucoma drops - long term will be examined. The patients will be asked in this eye to wait 5 minutes after taking one of their IOP reduction drugs, before instilling the second type for a total duration of 1 month.~After the one month has passed IOP measurement will be taken and the patients will be asked to switch to the no interval between regular glaucoma drops - long term phase in which they will be asked to take the drops for this eye at the same order but with no waiting period for a duration of 1 month. After the second month has passed IOP measurements will be repeated."
2904103|NCT03220490|Experimental|Long term: No-interval interval eye|"In the first phase no interval between regular glaucoma drops - Long term will be examined. The patients will be asked in this eye to take both IOP reduction drugs, with no waiting period between them for a total duration of 1 month.~After the one month has passed IOP measurement will be taken and the patient will be asked to switch to the to 5 minute interval between regular glaucoma drops - Long term phase and take the drops for the same eye at the same order but with a five minute waiting period for a duration of 1 month. After the second month has passed IOP measurements will be repeated."
2904104|NCT03220477|Experimental|pembrolizumab plus guadecitabine and mocetinostat|Pembrolizumab given IV; guadecitabine given SQ, mocetinostat given PO.
2904105|NCT03220464|Experimental|Close contacts of active pulmonary tuberculosis patients|One arm study of conducting ULDCT, chest x-ray, and IGRA
2904106|NCT03220451|Experimental|Adhesive elastic taping|After a 4-week observation of the pressure ulcer under investigation, adhesive elastic tape is applied around it for a 4-week period (the tape is changed twice a week), according to a planned application protocol. The ulcer is then observed for a subsequent follow-up period of 4 weeks.
2904107|NCT03220438|Active Comparator|TMS|rTMS
2904108|NCT03220438|Sham Comparator|Sham TMS|A sham coil will be used. This condition controls for the auditory artifacts induced by rTMS.
2904109|NCT03220425|Experimental|Insulin detemir|
2904110|NCT03220425|Active Comparator|NPH insulin|
2904111|NCT03220412|Experimental|Experimental Condition|Participants in this condition viewed a movie without guns. The movie (National Treasure or The Rocketeer) was edited to remove guns from scenes.
2904112|NCT03220412|No Intervention|Control Condition|Participants in this condition viewed a movie with guns, as it was filmed and distributed. The actual scenes in the movie (National Treasure or The Rocketeer) was not edited, but the same scenes were used as the Experimental Condition
2904113|NCT03220399|Experimental|NVP-1603-1 (P)|"Drug: NVP-1603-1~1capsule, oral dosing"
2904114|NCT03220399|Experimental|NVP-1603-2(T)|"Drug: NVP-1603-2~1Tablet, oral dosing"
2904115|NCT03220399|Experimental|NVP-1603-1and NVP-1603-2 (P+T)|Drug: NVP-1603-1, 1capsule and NVP-1603-2, 1Tablet co-adminstration (oral dosing)
2904116|NCT03220386|Other|Emergency Department patients|All patients will be tested for nasal MSSA/MRSA-colonization. Patients tested positive for nasal MSSA/MRSA-colonization receive a decolonization treatment. This treatment includes octinidin nasal treatment and skin washings.
2904117|NCT03220360|Experimental|indirect pulp capping group|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
2904118|NCT03220360|Experimental|direct pulp capping group|Sixty children with deep caries of deciduous teeth underwent direct pulp capping, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
2904119|NCT03220360|Experimental|vital pulpotomy group|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
2904120|NCT03220347|Experimental|CC-90010 in patients with solid tumors and NHL|Subjects will administer CC-90010 starting on Day 1 for 3 consecutive days followed by 4 consecutive days off drug every week (3/7-days schedule) in each 28 day cycle.
2904121|NCT03220334|Experimental|Apply platelet rich plasma to the artificial gastric ulcer|
2904122|NCT03220334|Placebo Comparator|Apply normal saline to the artificial gastric ulcer|
2904123|NCT03220321|Active Comparator|IPS e.max hybrid abutment crown|
2904124|NCT03220321|Experimental|VITA Enamic hybrid abutment crown|
2904125|NCT03220308|Other|Care-as-usual (CAU) only|Care-as-usual for children (8-16 years old) with ADHD
2904126|NCT03220308|Experimental|Mindfulness for child and parent + CAU|MYmind mindfulness training in addition to care-as-usual for children aged 8-16 years with ADHD
2904127|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 1|Dose Escalation of VU319
2904128|NCT03220295|Placebo Comparator|Placebo - Dose 1|Dose Escalation of Placebo
2904129|NCT03220295|Experimental|Single Dose of VU319 under Fed State|Single dose of VU319 (50% of the maximum tolerated dose) 30 minutes after a High Fat Standard Breakfast
2904130|NCT03220295|Placebo Comparator|Single Dose of Placebo under Fed State|Single dose of Placebo 30 minutes after a High Fat Standard Breakfast
2904131|NCT03220295|Experimental|Single Dose of VU319 under Fasted State|Single dose of VU319 (50% of the maximum tolerated dose) after overnight fast
2904132|NCT03220295|Placebo Comparator|Single Dose of Placebo under Fasted State|Single dose of placebo after overnight fast
2904133|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 2|Dose Escalation of VU319
2904134|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 3|Dose Escalation of VU319
2904135|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 4|Dose Escalation of VU319
2904136|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 5|Dose Escalation of VU319
2904137|NCT03220295|Placebo Comparator|Placebo - Dose 2|Dose Escalation of Placebo
2904138|NCT03220295|Placebo Comparator|Placebo - Dose 3|Dose Escalation of Placebo
2904139|NCT03220295|Placebo Comparator|Placebo - Dose 4|Dose Escalation of Placebo
2904140|NCT03220295|Placebo Comparator|Placebo - Dose 5|Dose Escalation of Placebo
2904141|NCT03220282|Active Comparator|Donor milk|Pasteurized donor breast milk
2904142|NCT03220282|Placebo Comparator|Preterm infant formula|Preterm formula determined by clinical practice
2904704|NCT03216226|Experimental|GlucaGen|Repeated single fixed doses (s.c.injection) of GlucaGen
2904143|NCT03220269||Out-of-hospital cardiac arrest (OHCA)|An OHCA is defined as cessation of cardiac mechanical activity that occurs outside of the hospital setting and is confirmed by the absence of signs of circulation.
2904144|NCT03220269||In-hospital cardiac arrest (IHCA)|An IHCA is defined as cessation of cardiac mechanical activity that occurs inside of the hospital setting and is confirmed by the absence of signs of circulation.
2904145|NCT03220256|Experimental|Lamotrigine tolerance|The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks.
2904146|NCT03220243|Experimental|MSC-AFP Single Treatment Group|Eligible patients will be treated, single treatment group, no placebo arm.
2904147|NCT03220217|Experimental|5-20μg/40-80 MBq, 30-45μg/100-140 MBq|Subjects will receive a first intravenous (i.v.) injection of 68Ga-OPS202 with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 40 to 80 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of 68Ga-OPS202 with a peptide mass dose range of 30-45 μg and a radioactivity dose range 100 to 140 MBq.
2904148|NCT03220217|Experimental|5-20μg/100-140 MBq, 30-45μg/160-200 MBq|Subjects will receive a first i.v. injection of 68Ga-OPS202 with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 100 to 140 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of 68Ga-OPS202 with a peptide mass dose range of 30-45 μg and a radioactivity dose range 160 to 200 MBq.
2904149|NCT03220217|Experimental|5-20μg/160-200 MBq, 30-45μg/40-80 MBq|Subjects will receive a first i.v. injection of 68Ga-OPS202 with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 160 to 200 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of 68Ga-OPS202 with a peptide mass dose range of 30-45 μg and a radioactivity dose range 40 to 80 MBq.
2904150|NCT03220204|Experimental|PP-based health behavior intervention|Participants will undergo a 12-week, PP-based health behavior intervention. Each weekly session will include (a) a review of the week's PP exercise, (b) a discussion of the rationale of the next week's PP exercise through a guided review of the PP manual, and (c) assignment of the next week's PP exercise. Additionally for the goal-setting portion, participants will (a) review their goals and behaviors from the prior week, (b) discuss techniques for improving health behavior adherence (e.g., monitoring physical activity, reading nutrition labels), and (c) set goals for the next week.
2904151|NCT03220204|Experimental|MI-based educational control condition|Participants will undergo 12 weekly phone sessions to learn about a different health behavior topic related to cardiac health. They will also be introduced to motivational interviewing topics in concert with the health behavior education topics.
2904152|NCT03220204|No Intervention|Treatment as Usual (TAU)|Participants in the TAU group will not receive any interventions between the baseline visit and follow-up visits.
2904153|NCT03220191|Experimental|palbociclib tablet with/without PPI|palbociclib tablet formulation alone in period 1 + palbociclib tablet formulation plus rabeprazole in period 2
2904154|NCT03220178|Experimental|CANKADO active|CANKADO active is the fully functional CANKADO-based eHealth treatment support service, including a high density observation of patient reported outcome.
2904155|NCT03220178|Other|CANKADO inform|CANKADO inform stands for a CANKADO-based eHealth service with a personal login. For the patient , on-site surveys without feedback functions and a dosing tracker to document daily drug intake will be available. CANKADO inform will be used for the initial ePRO and further on-site ePROs. Patients can login from home, but they will only get text information about their disease and treatment. Further features will be unavailable.
2904156|NCT03220165|Experimental|Treatment|MGL-3196
2904157|NCT03220152|Experimental|emtricitabine / tenofovir 200/300 mg|emtricitabine / tenofovir 200/300 mg Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year.
2904158|NCT03220126|Experimental|LY3074828 - Treatment 1|Single intravenous (IV) dose of LY3074828
2904159|NCT03220126|Experimental|LY900021 - Treatment 2|Single subcutaneous (SC) dose of LY900021 (LY3074828 coadministered with LY9999QS)
2904160|NCT03220126|Experimental|LY900021 - Treatment 3|Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)
2904161|NCT03220126|Experimental|LY900021 - Treatment 4|Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)
2904162|NCT03220113|Experimental|Dexamethasone,Lidocaine,Thiamine cohort|"Simultaneous administration of a combination of sterile dexamethasone phosphate total dose (bilaterally) of 20 mg, 4 mg/ml, Lidocaine Hydrochloride 1% 40 mg, 10 mg/ml, and Thiamine Hydrochloride 100 mg, 100 mg/ml in a single session into the accessible branches of the trigeminal nerve of the first, second, and third divisions, as well as into the greater and lesser occipital nerve. In first,patient placed in supine position then in prone position for comfortable access to injection site.~De-Novo Treatment medication 'Dexamethasone, Lidocaine, Thiamine Cohort' prepared in single 1 milliliter volume sterile syringes, using 27 Gauge-30 Gauge needles."
2904163|NCT03220100|Experimental|Stepped Palliative Care|All participants will receive palliative care Participants will complete the Functional Assessment of Cancer Therapy-Lung (FACT-L) every six weeks FACT-L scores will be used to determine which patients need to step up to every 6 week palliative care visits Patients on step 1 of the intervention will have a palliative care visit every 9 weeks Patients on step 2 of the intervention will have a palliative care visit every 6 weeks
2904164|NCT03220087||Group A - Uncontrolled CS|Patients who have had at least one episode of uncontrolled CS, according to medical criteria, since the start of their treatment for NET.
2904165|NCT03220087||Group B - Controlled CS|Patients who have not had any episode of uncontrolled CS, according to medical criteria, in the last 12 months.
2904166|NCT03220074|Other|treatment|oral linezolid tablet 600 mg /day combine with either oral quinolone (ciprofloxacin or levofloxacin) or oral macrolide (azithromycin or clarithromycin)
2904167|NCT03220061|Experimental|experimental|music therapy was used in the study for 30 minutes
2904168|NCT03220061|No Intervention|control|usual care was given to participant in control group
2904169|NCT03220048|Experimental|PrEP-001|6400μg dose administered equally over both nostrils and on 2 consecutive days, using a single dose nasal powder device.
2904170|NCT03220048|Placebo Comparator|G-004|Nasal dose of placebo equally divided over both nostrils and on 2 consecutive days, using a single dose nasal powder device.
2904699|NCT03216265|Other|Positive control /no treatment|Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.
2904171|NCT03220035|Experimental|Treatment (vemurafenib)|Patients receive vemurafenib PO BID on day 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2904172|NCT03220022|Experimental|Treatment (R-da-EPOCH)|Patients receive rituximab IV on day 1 (for CD20 positive patients only), etoposide IV over 96 hours on days 1-4, doxorubicin hydrochloride IV over 96 hours on days 1-4, vincristine sulfate IV over 96 hours on days 1-4, prednisone PO daily on days 1-5, cyclophosphamide IV over 1 hour on day 5, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim SC from 1 calendar day up to 48 hours or filgrastim SC beginning on day 6 for up to 10 days until ANC is satisfactory.
2904173|NCT03220009|Active Comparator|Arm I (nivolumab, ipilimumab, surgery, active surveillance)|"PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.~PART II: Patients undergo active surveillance for 1 year."
2904174|NCT03220009|Experimental|Arm II (nivolumab, ipilimumab, surgery, nivolumab)|"PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.~PART II: Patients receive nivolumab IV over 30 minutes once every 2 weeks for 4 doses. Patients then continue to receive nivolumab IV over 30 minutes once every 4 weeks for up to 11 doses in the absence of disease progression or unacceptable toxicity."
2904175|NCT03219996||non-survivor group|
2904176|NCT03219996||survivor group|
2904177|NCT03219983|Active Comparator|Interscalene Block|Ultrasound guided interscalene catheter will be placed and a 30 ml .5% ropivacaine will be given pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score > 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
2904178|NCT03219983|Active Comparator|Deep soft tissue/surgical site injection|A total volume of 100ml will be comprised of 60ml of 0.9% normal saline + 20ml 0.5% bupivacaine + 20ml liposomal bupivacaine will be injected into the deep soft tissue using an 18 or 20 gauge needle prior to or after prosthesis insertion
2904179|NCT03219970||EGFR T790M positive NSCLC patients|Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI treatment.
2904180|NCT03219957|Experimental|AT-527|
2904181|NCT03219957|Placebo Comparator|Placebo|
2904182|NCT03219944|Experimental|Platelet Rich Fibrin for soft tissue augmentation|blood will be drawn from the patient vein for PRF. The blood sample will be centrifuged for 10-12 min. PRF membrane is obtained
2904183|NCT03219944|Active Comparator|sub epithelial connective tissue graft|The connective tissue graft will be harvested from the palate. Then the SCTG will be placed over the recipient site extending palataly and sutured.
2904184|NCT03219931|Active Comparator|Active group - Breastfeeding infants|In this Group will be enrolled only infants who are breastfed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
2904185|NCT03219931|Active Comparator|Active Group - Bottlefeeding infant|In this active Group will be enrolled only infant who are bottle-fed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
2904186|NCT03219931|Placebo Comparator|Placebo group - Breastfeeding infants|In this placebo Group will be enrolled only infants who are breastfed. This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
2904187|NCT03219931|Placebo Comparator|Placebo group - Bottlefeeding infants|In this placebo Group will be enrolled only infants who are bottlefed. This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
2904188|NCT03219918|Active Comparator|With EndoRings|Colonoscopy is performed with the use of the cap-device EndoRings II Distal Attachment to be attached to the tip of the colonoscope
2904189|NCT03219918|No Intervention|NO EndoRings|Colonoscopy is performed conventionally without any caps
2904190|NCT03219905|Experimental|Kinesio-taping Group|Therapeutic Kinesio-taping
2904191|NCT03219905|Sham Comparator|Control Group|Sham Kinesio-taping
2904192|NCT03219892|Experimental|High-frequency rTMS|Patients randomized to this group will receive rTMS delivering over the supplementary motor area (SMA). Each treatment consists 1000 pulses (5-second burst of 10Hz rTMS, repeated 20 times at every minute ).Stimulus intensity is 90% of resting motor threshold. A figure-of-8 coil is connected to a biphasic magnetic stimulator, and the induced current is perpendicular to the midline.
2904193|NCT03219892|Sham Comparator|Sham rTMS|Patients randomized to this group will receive the sham rTMS. The procedure is same as used in patients receiving experimental rTMS, except that the coil is angled 90° away.
2904194|NCT03219879|Experimental|Telephone-administered continuation therapy|Cognitive-behavioral continuation therapy (T-CT) delivered over the telephone by trained psychotherapist
2904195|NCT03219879|Active Comparator|Usual care|Treatment as usual
2904196|NCT03219866|Experimental|Nebulizers|Subjects will receive a long-acting B2-agonist (LABA; Brovana, twice daily), corticosteroid (ICS; Pulmicort, twice daily), and a short-acting anti-cholinergic (SAMA; Atrovent, three times a day).
2904197|NCT03219866|Experimental|Dry Powder Inhaler|Subjects will receive a LABA/ICS (Advair Diskus, twice daily) plus a long-acting anticholinergic (LAMA; Spiriva Handihaler, once daily).
2904198|NCT03219853|Experimental|Lower selenium-status|
2904199|NCT03219853|Experimental|higher selenium|
2904200|NCT03219840|Experimental|CPC-Xylitol complex|Cetylpyridium Chloride (CPC) 0.09% + Xylitol chewing gum A All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
2904201|NCT03219840|Placebo Comparator|Placebo|Xylitol chewing gum B All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
2904290|NCT03219086|Active Comparator|Group P|A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)
2904202|NCT03219827|Experimental|Patients allergic to wasp venom|"Patient with major allergic reaction to wasp venom.~Blood samples collection at visit 1, at visit 2 (4 weeks after visit 1), at visit 3 (one year after treatment onset)~After visit 1, an allergen-specific immunotherapy will be conducted as part of the classical patient care program."
2904203|NCT03219827|Experimental|Patients allergic to penicillin|"Patient with major allergic reaction to penicillin.~- Blood samples collection at visit 1 and at visit 2 (4 weeks after visit 1= end of study, none treatment will be evaluated in this arm)"
2904204|NCT03219814|Experimental|Cognitive Dissonance Intervention|"Participants in the Cognitive Dissonance condition will complete tasks from Becker et al.'s (2005) 2-session adaptation of the Body Project. In the intervention groups, participants will be asked to consider the costs of pursuing the thin ideal in verbal, written, and behavioural exercises. Participants will be asked to assume the role as a body activist, and will be given several opportunities to vocalize opposition to the social forces that drive the thin ideal throughout the sessions.~The first session will involve exercises and discussions about the thin ideal and the costs associated with pursuing it. They will be given a homework assignment to complete at home over the next week. In the following week's session the participants will engage in a role-play exercise, as well as continuing the discussion on the costs of pursuing the thin ideal."
2904205|NCT03219814|Active Comparator|Mediapsychoeducation Intervention|"Participants in the Mediapsychoeducation condition will complete two sessions of tasks as outlined for Becker et al.'s (2005) media psychoeducation group, which includes no cognitive dissonance tasks. The first session will have the participants discuss the thin ideal and the media's influence on it. They will then watch a 35-minute psychoeducational video on the influence that advertisements have on body image and perpetuating the thin ideal. They will be assigned homework to complete at home during the week between the sessions. The second session will include a discussion surrounding the attainability to the thin ideal, and this discussion will also be expanded to include all forms of media. Participants will then be asked to consider and discuss differences between media images and themselves, as well as whether achieving this ideal is realistic, and the costs in trying to achieve this thin ideal. They will then watch a 20-minute video on eating disorders."
2904206|NCT03219814|No Intervention|Waitlist Control|The participants in the Waitlist condition will be given the Cognitive Dissonance intervention between 5 and 6 weeks after their second assessment-only session (the cognitive dissonance intervention will be offered and scheduled 1 week after their 1-month online follow-up questionnaire).
2904207|NCT03219814|No Intervention|Body-Satisfied Assessment Only Condition|Body-satisfied women will be recruited to engage in the assessment portion of the study only (i.e. they will be given NO intervention but are serving as a control in terms of eye-tracking assessment). Body-satisfied women will be assessed to compare their attention to weight words with body-dissatisfied women's attention to weight words. This comparison will be done with an aim of replicating the findings of Tobin (2015), to ensure that for this particular sample, body-dissatisfied women exhibit stronger attentional biases for weight words than body-satisfied women. Attention to weight words in body-satisfied women will be assessed at two time points, one week apart, to ensure there are no spurious changes in attention in body satisfied women.
2904208|NCT03219801|Experimental|mesenchymal stem cells|Selected SLE patients were randomly divided into treated group and control group. In the treated group, 100-300 million allogeneic human umbilical cord derived mesenchymal stem cells were infused intravenously for one SLE patient. The possible adverse events, including immediately after mesenchymal stem cells infusions, as well as the long-term safety profiles were observed.
2904209|NCT03219788|Placebo Comparator|Group 1(Normal saline)|Patients who will receive placebo (one ml normal saline). The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
2904210|NCT03219788|Active Comparator|Group 2 (Remifentanil 0.1 ug/kg)|Patients who will receive remifentanil at a dose of 0.1 ug/kg. The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
2904211|NCT03219788|Active Comparator|Group 3 ((Remifentanil 0.2 ug/kg))|Patients who will receive remifentanil at a dose of 0.2 ug/kg. The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
2904212|NCT03219775|Experimental|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab~If CR/PR: Nivolumab Maintenance Mono-Therapy~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy~If CR/PR: Nivolumab Maintenance Mono-Therapy~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy"
2904213|NCT03219762|Experimental|Nab-paclitaxel|Nab-paclitaxel (30-min infusion) 100 mg/sqm weekly on days 1, 8, 15 q 28 days.
2904214|NCT03219749|Experimental|Exercise Intervention|Exercise training will take place three times per week for six weeks and involve both aerobic and resistance exercise.
2904215|NCT03219736|Active Comparator|Control|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. To summarize, all moderate and severe acute asthma exacerbations receive albuterol and atrovent continuous aerosols, oral or intravenous steroids and intravenous magnesium sulfate. At the discretion of the treating physician, the patient may also receive subcutaneous terbutaline or epinephrine
2904216|NCT03219736|Active Comparator|NiPPV|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine (EnVe Ventilator). Optimal settings for each participant should be achieved within 20 minutes of initiation of NiPPV. Pediatric asthma scores will continue to be recorded at least every hour or with every physician suggested NIPPV ventilator setting change for an 8 hour period. Furthermore, the NIPPV machine in conjunction with NM3 volumetric end tidal CO2 monitoring will record ventilatory data in this NIPPV/BiPAP group and will be compared to other study groups. The subjects will remain in the study for minimum of 4 hrs NIPPV therapy and total of 8 hours.
2904217|NCT03219723||Vonoprazan 20 mg|For adults, the following three-drug regimen will be administered orally at the same time twice daily for 7 days: 20 mg dose of vonoprazan, 750 mg (potency) dose of amoxicillin hydrate, and 200 mg (potency) dose of clarithromycin. The dose of clarithromycin may be increased as clinically warranted. However, dosage should not exceed 400 mg (potency)/dose twice daily. If H. pylori eradication with a three-drug regimen comprising vonoprazan or proton pump inhibitor + amoxicillin hydrate + clarithromycin has been unsuccessful, as an alternative treatment, the following three drugs will be administered orally twice daily for 7 days to adults: 20 mg dose of vonoprazan, 750 mg (potency) dose of amoxicillin hydrate, and 250 mg dose of metronidazole. Participants will receive interventions as part of routine medical care.
2947799|NCT02919774|Placebo Comparator|Placebo|Placebo BID for 10 days
2904218|NCT03219710|Active Comparator|Arm A|"Patient on control group with weight category of 15-40 kg will receive:~Day1, Day2 & Day3 - Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg), Aprepitant 80 mg;~The patient on control group with weight category of >40kg will receive:~Day1- Dexamethasone 3mg/m2, ondansetron(0.15 mg/kg), Aprepitant 125 mg; Day2 & Day3 - Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg), Aprepitant 80 mg Note: Aprepitant will be administered as single daily dose (PO). Dexamethasone and Ondansetron will be administered q8h(PO/IV)"
2904219|NCT03219710|Experimental|Arm B|"Experimental group:~weight category of 15-40 kg will receive: Day1,Day2 &Day3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg), Aprepitant 80 mg and olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) Day 4- olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg)~Weight category of >40 kg in study group will receive:~Day1- Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg), Aprepitant 125 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) Day2 & Day3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg), Aprepitant 80 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) Day4- olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) Note: Aprepitant and Olanzapine will be administered as single daily dose (PO). Dexamethasone and Ondansetron will be administered q8h(PO/IV)."
2904220|NCT03219697|Experimental|Parenting education program|Receive 10 weeks of group parenting education sessions with 2-4 public health nurse home visits
2904221|NCT03219697|No Intervention|Control|Receive regular health care
2904222|NCT03219671|Experimental|nivolumab plus ipilimumab|nivolumab 240mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks
2904223|NCT03219658|Experimental|Parenting education sessions|Receive 10 weeks of group parenting education sessions with 2-4 public health nurse home visits.
2904224|NCT03219658|No Intervention|Control|Attend one-on-one check-ins with the interdisciplinary team at STOMP; wait-listed control group.
2904225|NCT03219645|Active Comparator|Ginkgo and aspirin|Ginkgo Diterpene Lactone Meglumine Injection 25mg/5ml,once/day from Day 1 to Day 14. The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours;combined with Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
2904226|NCT03219645|Placebo Comparator|aspirin|Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
2904227|NCT03219619|Experimental|Cap group: Cap-EGD|Undergoing cap-assisted esophagogastroduodenoscopy
2904228|NCT03219619|Active Comparator|Duo group: Duo|Undergoing side-viewing duodenoscope
2904229|NCT03219606|Experimental|education arm|Participants in education arm will have an organized education course of modified Rodnan Skin Scoring.
2904230|NCT03219593|Experimental|Apatinib Group|take apatinib orally (500mg/d, once a day, continuously)
2904231|NCT03219580|Active Comparator|5-Fluorouracil Active Treatment Arm|A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The active treatment arm brow will be injected with 0.05ml of 5-Fluorouracil 50mg/ml in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
2904232|NCT03219580|Placebo Comparator|Placebo Arm|A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The placebo arm brow will be injected with 0.05ml of 0.9% Normal Saline in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
2904233|NCT03219554|Experimental|palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
2904234|NCT03219541|Active Comparator|Interventional Automated mobile phone text|"Subjects will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention. During the intervention, participants will receive a text question at the end of every day asking you How many cigarettes have you smoked today?"
2904235|NCT03219541|Placebo Comparator|Control Texts|The intervention will consist of a 3-day pre-quit period and then a 4-week post-quit period. Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
2904236|NCT03219528|Active Comparator|Rifaximin|Rifaximin 550 mg three times daily for 14 days
2904237|NCT03219528|Active Comparator|Low FODMAP Group|Low FODMAP diet for 4 weeks
2904238|NCT03219515|Experimental|Gongjin-dan|Participants will be orally administered Gongjin-dan pills of 3.75g, 1 pill/day, 8 weeks (56 days).
2904239|NCT03219515|Placebo Comparator|placebo|Participants will be orally administered placebo pills of 3.75g, 1 pill/day, 8 weeks (56 days).
2904240|NCT03219502|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS) Group|"Questionnaires completed at baseline, 1 week after last rTMS session, again 1 month later.~EEG performed at baseline and at 1 month follow up visit.~Ten rTMS sessions given over a 10 business day period.~Pain questionnaire completed before the session, and again after the session is complete."
2904241|NCT03219502|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation (rTMS) Group|"Questionnaires completed at baseline, 1 week after last rTMS session, again 1 month later.~EEG performed at baseline and at 1 month follow up visit.~Ten sham rTMS sessions given over a 10 business day period.~Pain questionnaire completed before the session, and again after the session is complete."
2904242|NCT03219502|Other|Wait List Control Group (WLC)|"WLC Group receives standard of care.~Questionnaires completed at baseline and at 1 month follow up visit.~EEG performed at baseline and at 1 month follow up visit."
2904243|NCT03219489|Experimental|Intervention|Clinics randomized to intervention will use the electronic medical record alert for progesterone, informed by guidelines and the foundational meta-analyses demonstrating its efficacy.
2904244|NCT03219489|No Intervention|Control|Clinics randomized to control will not use the electronic medical record alert for progesterone. The control group will receive the usual prenatal care.
2904291|NCT03219073|Sham Comparator|SHAM tDCS|SHAM tDCS using tDCS device will be used for sham stimulation where the electrodes will be placed in the same positions as for anodal M1 stimulation, but the stimulator will be turned off after 90 seconds. Therefore, the patients feel the initial itching sensation but receive no current for the rest of the stimulation period.
2904245|NCT03219476|Experimental|Neoadjuvant endocrine therapy treatment (physician's choice)|Once enrolled, patients would be treated with the current standard-of-care endocrine therapy. Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status. The patient would be treated with endocrine therapy in a neoadjuvant setting for four weeks, with dosing continuing until surgery.
2904246|NCT03219463|Experimental|Regular Exercise Group|at least 30 minutes of moderate to vigorous activity at least 3 times per week. Will recieve 3 grams of ginger for 8 weeks.
2904247|NCT03219463|Active Comparator|Non Regular Exercise Group|at least 30 minutes of moderate to vigorous activity 1-2 times per week. Will recieve 3 grams of ginger for 8 weeks.
2904248|NCT03219450|Experimental|NeoVax|"NeoVax will be administered in a priming and booster phase.~The priming shots will comprise days 1, 4, 8, 15, and 22.~Booster shots will be given on days 78 and 134."
2904249|NCT03219450|Experimental|Neovax + Low-dose cyclophosphamide|"NeoVax will be administered in a priming and booster phase.~The priming shots will comprise days 1, 4, 8, 15, and 22.~Booster shots will be given on days 78 and 134.~Low dose cyclophosphamide is administered twice daily on weeks -2, 1, 3, 5"
2904250|NCT03219437|Active Comparator|Methotrexate|Participants to receive double-blind methotrexate.
2904251|NCT03219437|Experimental|Risankizumab|Participants to receive double-blind risankizumab.
2904252|NCT03219411|Active Comparator|Cinnamon|Cinnamon burmannii administered orally as 500-mg capsules three times daily over 12 weeks
2904253|NCT03219411|Placebo Comparator|Placebo|Placebo administered orally as capsules three times daily over 12 weeks
2904254|NCT03219398|Active Comparator|8-10 mmHg|Patients receive lower pneumoperitoneum pressure
2904255|NCT03219398|Active Comparator|10-14 mmHg|Patients receive higher pneumoperitoneum pressure
2904256|NCT03219385|Experimental|Treatment with the Mirabilis System|
2904257|NCT03219372|Experimental|Pravastatin Pill|Daily pravastatin (40mg)
2904258|NCT03219372|Placebo Comparator|Placebo Oral Tablet|Placebo
2904259|NCT03219359|Experimental|Experimental|Hematopoietic Stem Cell Transplant followed by maintenance Vedolizumab
2904260|NCT03219346|Experimental|Oral hygiene|
2904261|NCT03219333|Experimental|Enfortumab vedotin|Enfortumab vedotin on days 1, 8 and 15 every 28 days
2904262|NCT03219320|Placebo Comparator|Placebo Oral Capsule|Up to 300 subjects: Placebo
2904263|NCT03219320|Experimental|NYX-2925|Up to 300 subjects: Multiple dose levels of NYX-2925 daily for 28 days
2904264|NCT03219307|Experimental|NOVOCART 3D|Matrix associated autologous chondrocyte implant
2904265|NCT03219294|Active Comparator|Moderate NMB|Intubating dose of Vecuronium 0.1 mg/kg (IBW) and re-dosing with 0.0125 to 0.05 mg/kg as needed to achieve and maintain 1 to 2 TOF contractions. Redosing in this manner is a current clinical practice.
2904266|NCT03219294|Active Comparator|Deep NMB|Deep NMB: Intubating dose of Vecuronium 0.2 mg/kg (IBW) and re-dosing with 0.025 to 0.1 mg/kg to achieve and maintain zero twitches in the TOF, and post tetanic count (PTC) of 1 to 2 contractions. This level of blockade is new to the practice since approval of the drug for use at MMC but is in common use since the advent of Sugammadex.
2904267|NCT03219268|Experimental|MGD013|MGD013 administered IV once every 2 weeks for up to 12 8-week cycles
2904268|NCT03219255||Subjects receiving RELVAR 100 ELLIPTA|Subjects with a diagnosis of COPD, for which RELVAR is indicated, who are naive to RELVAR will be included.
2904269|NCT03219242|Experimental|Caiman device|Time sparing and post-operative outcome in ovarian cancer including bowel resection for cytoreductive surgery with Caiman device
2904270|NCT03219229||Prepubertal children|Healthy 7-11 year old girls and boys.
2904271|NCT03219216|Experimental|Arm B Compensated Cirrhosis (F4)|Arm B: HCV GT 1 - 6 participants with compensated cirrhosis (F4) administered GLE/PIB 300 mg/120 mg once daily (QD) for 12 weeks.
2904272|NCT03219216|Experimental|Arm A without Cirrhosis (F2 - F3)|Arm A: Hepatitis C virus (HCV) genotype (GT) 1 - 6 participants without cirrhosis (F2 - F3) administer Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
2904273|NCT03219203|Experimental|Arm A: Single dose hepatitis B vaccine|Single dose of hepatitis B vaccine group will receive a 20 µg recombinant HBV vaccine intramuscular at entry
2904274|NCT03219203|Active Comparator|Arm B: 3-dose series of hepatitis B vaccine|3-dose series of hepatitis B vaccine group will receive a 20 µg recombinant HBV vaccine intramuscular at month 0, 1, and 6
2904275|NCT03219190|Experimental|LST High School Online|
2904276|NCT03219190|No Intervention|Treatment as Usual (Control)|
2904277|NCT03219177|Experimental|Patient education group|
2904278|NCT03219177|Active Comparator|Control- Standard of care counseling|
2904279|NCT03219164|Experimental|AZLI|AZLI for 28 days
2904280|NCT03219164|Experimental|AZLI + Placebo|AZLI for 14 days followed by placebo for 14 days
2904281|NCT03219151|Experimental|eMAR game|Participants provided access to eMAR simulator game in advance of simulated return-demonstration; also receive normal education pre-work related to eMAR administration
2904282|NCT03219151|Active Comparator|Normal pre-work|Participants receive normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
2904283|NCT03219138|No Intervention|Electromyography|Neuromuscular function was monitored, using evoked electromyography of the adductor pollicis muscle with a neuromuscular transmission module by a non-blinded investigator.
2904284|NCT03219138|Experimental|Acceleromyography|Immediately after extubation the blinded anaesthesiologist tested with an uncalibrated acceleromyography on the contralateral arm.
2904285|NCT03219125||Group 1 (cases)|occurence of incident major osteoporotic fracture less than 12 weeks
2904286|NCT03219125||Group 2 (controls)|no history of fragility fracture
2904287|NCT03219112|Experimental|Intervention|15 cp children + 10 typically developing children (anticipated) Will have 8 weeks VR training Will have 1 VR training session
2904288|NCT03219112|No Intervention|Control|15 cp children (anticipated) Will not have 8 weeks of VR training Will not have 1 VR training session
2904289|NCT03219086|Active Comparator|Group M|combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%
2904700|NCT03216252|Other|biological samples|biological samples on patients with MITOCHONDRIAL DISEASES
2904292|NCT03219073|Active Comparator|Active tDCS with a tDCS device|Active tDCS using tDCS device (Neuroelectrics Inc., Simi Valley, CA, USA) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The anodal electrode will be placed over the M1 contralateral to the worst somatic pain area (C3, EEG 10/20 system) and the cathode over the supraorbital area contralateral to the anodal electrode. A constant current of 2 mA intensity will be applied for 20 minutes once a day for 5 consecutive days.
2904293|NCT03219060|Experimental|Intervention group|MI based four individual sessions
2904294|NCT03219060|Active Comparator|Control group|Brief advice following 5As
2904295|NCT03219047|Experimental|Ibrutinib Exposed Group|"Participants treated with investigator's choice therapy or standard of care.~Xenograft developed and a suitable drug/regimen tested in the xenograft model.~If participant relapses on investigator's choice treatment, participant treated with therapy proven to be effective in participant's xenograft ."
2904296|NCT03219047|Experimental|Ibrutinib Naive Group|"Participants treated with Ibrutinib at standard dose and schedule.~Participant's xenograft simultaneously treated with Ibrutinib.~Participants who respond but relapse/progress during Ibrutinib therapy, and have xenograft data available, directed to the salvage therapy proven effective in their simultaneous xenograft model."
2904297|NCT03219034|Experimental|Oral appliance - A|"Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.~Trade Name: TAP1 Oral Appliance, Airway Management Inc. Dallas, TX"
2904298|NCT03219034|Experimental|Oral appliance - B|"Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.~Trade name: SomnoDent Flex Oral Appliance, SomnoMed Inc., Plano TX"
2904299|NCT03219008|Experimental|Depression/underload 1|This group would be treated with fluoxetine from the minimum dosage.
2904300|NCT03219008|Experimental|Depression/underload 2|This group would be treated with fluoxetine combined with cognitive behavior treatment
2904301|NCT03219008|Experimental|Depression/underload 3|This group would be treated with fluoxetine and amfebutamone from the minimum dosage.
2904302|NCT03219008|Experimental|Depression/underload 4|This group would be treated with fluoxetine + physical treatment to help to cure depressive disorder.
2904303|NCT03219008|Experimental|Atypical 1|This group would be treated with fluvoxamine from the minimum dosage.
2904304|NCT03219008|Experimental|Atypical 2|This group would be treated with fluoxetine + cognitive behavior treatment
2904305|NCT03219008|Experimental|Atypical 3|This group would be treated with fluvoxamine + lithium from the minimum dosage.
2904306|NCT03219008|Experimental|Atypical 4|This group would be treated with fluvoxamine + lithium + physical treatment
2904307|NCT03219008|Experimental|Anxiety/somatization 1|This group would be treated with mirtazapine/selective serotonin-norepinephrine reuptake inhibitors（SNRIs） from the minimum dosage.
2904308|NCT03219008|Experimental|Anxiety/somatization 2|This group would be treated with mirtazapine/SNRIs + cognitive behavior treatment.
2904309|NCT03219008|Experimental|Anxiety/somatization 3|This group would be treated with mirtazapine + SNRIs from the minimum dosage.
2904310|NCT03219008|Experimental|Anxiety/somatization 4|This group would be treated with mirtazapine + SNRIs + physical treatment.
2904311|NCT03219008|Experimental|treatment as usual(TAU)|The investigators recommend therapy strategies according to accessible methods.
2904312|NCT03218995|Experimental|Experimental: Treated Group|
2904313|NCT03218982|Experimental|Active Intervention|Six weekly intervention sessions (2 hours, each) that include enhanced psycho-education and discussion of AD and cultural impacts on beliefs about dementia and caregiving, management of problem behaviors, facilitation of support seeking, and mindful Tai Chi.
2904314|NCT03218982|No Intervention|Control|Participants will receive educational materials/pamphlets on dementia and occasional phone-calls by research assistants to maintain contact, as is the standard of care in most caregiver intervention studies.
2904315|NCT03218969|Experimental|Study period 1|"Ecopipam or matching placebo 25 mg by mouth for 7 days (week 1), followed by~Ecopipam or matching placebo 50 mg by mouth for 7 days (week 2), followed by~Ecopipam or matching placebo 100 mg by mouth for 23 days (weeks 3)."
2904316|NCT03218969|Experimental|Study period 2|"Matching placebo or ecopipam 25 mg by mouth for 7 days (week 7), followed by~Matching placebo or ecopipam 50 mg by mouth for 7 days (week 8), followed by~Matching placebo or ecopipam 100 mg by mouth for 23 days (week 9)."
2904317|NCT03218956|Experimental|Protein intake|Dietary supplement: Protein intake
2904318|NCT03218943|Active Comparator|APRV ventilation|They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours Then, they will return to the initial settings ( PCV ) for 2 hours . then, they will be switched into BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours. Then left for ventilation according to the preference of the physician in charge.
2904319|NCT03218943|Active Comparator|BiPAP ventilation|They will start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours. Then, they will return to the initial settings ( PCV ) for 2 hours . then, they will be switched into APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours. Then left for ventilation according to the preference of the physician in charge.
2904320|NCT03218930|Other|Social marketing intervention|Participants will receive a total combination of four interventions.
2904321|NCT03218917|Experimental|INS1007 10 mg Oral Tablet|Once per day for 24 weeks.
2904322|NCT03218917|Experimental|INS1007 25 mg Oral Tablet|Once per day for 24 weeks.
2904323|NCT03218917|Placebo Comparator|Placebo Oral Tablet|Once per day for 24 weeks.
2904324|NCT03218904|Experimental|Glucose intake|Experiment 1: study day 1- single oral dose of glucose study day 2- single oral dose of glucose with U-13C-glucose
2904365|NCT03218644|Experimental|Experimental group|The same procedure is followed by substituting proprioceptive exercises for craniocervical sensorimotor control with a laser instrument located on the patient's head and a target.
2904325|NCT03218904|Experimental|Carbohydrates intake|Experiment 2: study day 1-single oral dose of uncooked cornstarch study day 2-single oral dose of uncooked cornstarch with U-13C-glucose study day 3-single oral dose of Glycosade® study day 4-single oral dose of Glycosade® with U-13C-glucose
2904326|NCT03218891|Experimental|Clinical treatment physical training|"Patients with optimized clinical treatment group that will do physical training for 12 weeks. They will do the tests in moment 1 and after 3 mounths.~The intervention is the Cardiac Rehabilitation."
2904327|NCT03218891|No Intervention|Optimized clinical treatment|Patients with optimized clinical treatment group that will not do physical training.They will do the tests in moment 1 and after 3 mounths.
2904328|NCT03218891|No Intervention|Coronary insufficiency without angina|Group with coronary insufficiency without angina and will not do physical training. They will do the tests only one moment.
2904329|NCT03218891|No Intervention|Normal healthy subjects|Group normal healthy subjects, without coronary injuries, diabetes, hypertension and another chronic disease. These group have be sedentary and will not do physical training. They will do the tests only one moment.
2904330|NCT03218865|Experimental|ViE High flux dialyzer|vitamin E coated polysulfone membrane manufactured by Asahi Kasei Medical, with CE mark and intended for use in hemodialysis for the patient suffering from acute or chronic renal failure
2904331|NCT03218865|Active Comparator|Leoceed H high flux dialyzer|polysulfone membrane manufactured by Asahi Kasei Medical, with CE mark and intended for use in hemodialysis for patient suffering from acute or chronic renal failure
2904332|NCT03218852|Experimental|prednisone and cyclophosphamide|"prednisone(0.5mg/kg/day*6 months)~cyclophosphamide(1g intravenous use,per 1 month*6months);~supportive care,including ACE-I or ARBs and blood pressure control"
2904333|NCT03218852|Experimental|prednisone alone|"prednisone(0.5mg/kg/day*6months);~supportive care,including ACE-I or ARBs and blood pressure control"
2904334|NCT03218839|Experimental|HIV+ PrePex|PrePex male circumcision device
2904335|NCT03218826|Experimental|Treatment (docetaxel, PI3Kbeta inhibitor AZD8186)|Patients receive docetaxel IV over 1 hour on day 1 and PI3Kbeta inhibitor AZD8186 PO BID for 5 days each week. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2904336|NCT03218813|No Intervention|Control cohort ('before' group)|Control cohort ('before' group): eligible patients will receive treatment as usual (TAU) and will complete all outcome measures.
2904337|NCT03218813|Experimental|Intervention cohort ('after' group)|Eligible patients will receive the pharmacist-led intervention and will complete all outcome measures.
2904338|NCT03218800|Active Comparator|Intravenous Ertapenem|Patients with urinary tract infection will be treated with ertapenem by the intravenous route.
2904339|NCT03218800|Experimental|Subcutaneous Ertapenem|Patients with urinary tract infection will be treated with ertapenem by the subcutaneous route.
2904340|NCT03218787|Experimental|XIENCE + 3-month DAPT|
2904341|NCT03218774|Other|Home Group|
2904342|NCT03218774|Experimental|Center Group|
2904343|NCT03218761||POTS Patients|"Patients who self-identify as having Postural Tachycardia Syndrome.~They will have assessment of NET mRNA levels, supine plasma catechols, standing plasma catechols, and urine catechols."
2904344|NCT03218761||Control Subjects|"Subjects who do not have Postural Tachycardia Syndrome.~They will have assessment of NET mRNA levels, supine plasma catechols, standing plasma catechols, and urine catechols."
2904345|NCT03218748|Experimental|Honest, Open, Proud|"The group program is about disclosure versus secrecy of one's mental illness. The groups are facilitated by two peers (soldiers with lived experience of mental illness). Each group runs for three weeks, one meeting per week, and two hours per meeting. There is one 2-hour booster session in week 6.~Fidelity to manual: rated by a research assistant who is present during the group session"
2904346|NCT03218748|No Intervention|Control group|Treatment as usual (TAU)
2904347|NCT03218735|Experimental|Labor induction at 37.0 weeks to 37.6 weeks of gestation|Diagnosis of LGA with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
2904348|NCT03218735|Active Comparator|Expectant monitoring and delivery|Diagnosis of LGA with expectant monitoring and delivery as indicated by standard obstetric practices
2904349|NCT03218722|Experimental|PCC treatment|Conventional strategy for ATC management in addition to of intravenous Pro-Thrombin Concentrate Complex (25IU/kg factor IX)
2904350|NCT03218722|Placebo Comparator|Placebo treatment|Conventional strategy for ATC management without PCC (NaCl 0.9%)
2904351|NCT03218709|Experimental|High-dose multi-vitamins with minerals|Generic name: High-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months
2904352|NCT03218709|Experimental|Low-dose multi-vitamins with minerals|Generic name: Low-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months
2904353|NCT03218709|Active Comparator|Hypouricemic tablets|Generic name: Hypouricemic tablets Dosage form: Capsule Frequency: Six pills daily for 3 months
2904354|NCT03218709|Placebo Comparator|Placebo|Generic name: Placebo Dosage form: Capsule Frequency: Two pills daily for 6 months
2904355|NCT03218696|Experimental|Cough Syrup for adults and children|CE Marked (authorized) medical device acting by protecting the oropharynx, in a non-pharmacological way, to reduce cough. It contains honey, plantago lanceolata, thymus vulgaris. Dosage form: syrup Dosage: 5 ml. Duration: one night
2904356|NCT03218696|Placebo Comparator|Placebo|The placebo intervention is a similar syrup of taste and colour, with general protective components and other necessary synthetic components which may have an influence on cough, without the specific natural protective components. Dosage form: syrup. Dosage: 5 ml. Duration: one night
2904357|NCT03218683|Experimental|Cohort 1|Dose level 1
2904358|NCT03218683|Experimental|cohort 2|Dose level 2
2904359|NCT03218683|Experimental|cohort 3|Dose level 3
2904360|NCT03218683|Experimental|cohort 4|Dose level 4
2904361|NCT03218683|Experimental|cohort 5|Dose level 5
2904362|NCT03218657|Experimental|experimental group|the patients treated with levamisole hydrochloride 150mg qod +androgens 80mg qd+cyclosporins 3-5mg/kg*d at least for one year
2904363|NCT03218657|Other|control group|the patients treated without levamisole hydrochloride，but androgens 80mg qd+cyclosporins 3-5mg/kg*d at least for one year
2904364|NCT03218644|Active Comparator|Control group|Follow the usual treatment and perform the exercises of cervical mobility before a mirror.
2904366|NCT03218631|Other|Oxandrin|Administration of a single dose of approximately 0.1 mg/kg of a medium chain triglyceride (MCT) oil Oxandrin (oxandrolone) solution vs. 01.mg/kg tablets in a small cohort of healthy adults. Participants will be dosed at two time points one week apart.
2904367|NCT03218605|Experimental|healthy active participants|
2904368|NCT03218592|Experimental|Maraviroc|12 Healthy subjects will dose with Maraviroc Pill and we will collect blood and hair over all three phases
2904369|NCT03218592|Experimental|Dolutegravir|12 Healthy volunteers will dose with Dolutegravir Pill and we will collect blood and hair over all three phases
2904370|NCT03218592|Experimental|Truvada|12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases
2904371|NCT03218579|No Intervention|No intervention|No intervention after antibiotic treatment.
2904372|NCT03218579|Active Comparator|Probiotic microbiome rehabilitation|Probiotic treatment after antibiotic treatment.
2904373|NCT03218579|Active Comparator|Bacteriotherapy microbiome rehabilitation|Bacteriotherapy after antibiotic treatment.
2904374|NCT03218566|Other|Single Arm|Single Arm - Use of Indigo Aspiration System (mechanical thrombectomy) to treat pulmonary embolism
2904375|NCT03218553|Experimental|Dexamethasone|Standard cares plus postoperative administrations of glucocorticoid
2904376|NCT03218553|Placebo Comparator|placebo|Standard cares plus postoperative administrations of placebo
2904377|NCT03218540|Experimental|SVV group|Fluid management protocol
2904378|NCT03218540|Active Comparator|CVP group|Fluid management protocol
2904379|NCT03218501|Active Comparator|SK-1405 high dose|SK-1405 high dose is to be administered orally once daily for 2 weeks
2904380|NCT03218501|Active Comparator|SK-1405 low dose|SK-1405 low dose is to be administered orally once daily for 2 weeks
2904381|NCT03218501|Placebo Comparator|Placebo|Placebo is to be administered orally once daily for 2 weeks
2904382|NCT03218488||Participants With Moderate to Severe Plaque Psoriasis|All Participants diagnosed with moderate to severe plaque psoriasis who will either start therapy with ustekinumab within 30 days of baseline or have started therapy with ustekinumab in the 12-week period before enrollment as per routine clinical practice, will be monitored for the long-term safety of ustekinumab and long-term effects of ustekinumab on growth and development of pediatric participants. The primary data source for the study will be the medical records of participants and standardized questionnaires (completed by the physician and by the participant/parent).
2904383|NCT03218475|Experimental|MR Guided HIFU|
2904384|NCT03218462|Experimental|Group 1|Sensory adapted dental environment (SADE) at first exam (visit 1)
2904385|NCT03218462|Experimental|Group 2|Sensory adapted dental environment (SADE) at recall exam (visit 2)
2904386|NCT03218449||1/NC|noninfective complication
2904387|NCT03218449||2/IC|infective complication
2904388|NCT03218436|Active Comparator|CAP cohort|Cold Atmospheric plasma intervention
2904389|NCT03218436|No Intervention|Control cohort|no intervention
2904390|NCT03218410|Active Comparator|surgical pulmonary embolectomy|
2904391|NCT03218410|Active Comparator|catheter-directed thrombolysis|
2904392|NCT03218397|Active Comparator|Standard blood culture and AST|Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.
2904393|NCT03218397|Active Comparator|Rapid organism identification and AST|Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.
2904394|NCT03218384|Experimental|ferric carboxymaltose|32 eligible subjects will be randomly assigned (1:1) to ferric carboxymaltose 750 mg or placebo (normal saline)
2904395|NCT03218384|Active Comparator|Placebo|32 eligible subjects will be randomly assigned (1:1) to ferric carboxymaltose 750 mg or placebo (normal saline)
2904396|NCT03218371||study group (Indentation)|Eyes (participants) for whom chandelier-assisted peripheral vitrectomy under air had been performed with scleral indentation. (Exposure)
2904397|NCT03218371||control group (Non-indentation)|eyes (participants) for whom chandelier-assisted peripheral vitrectomy under air had been performed without scleral indentation.
2904398|NCT03218345|Experimental|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea)
2904399|NCT03218332||Former concussed pro-athletes|Biomarkers for detecting possible CTE invivo in former pro-athletes with multiple concussions: Imaging/blood/cerebrospinal fluid (CSF)/Positron emission tomography (PET-)tau/magnetic resonance imaging (MRI)/neuropsychological assessment.
2904400|NCT03218332||Healthy controls|Active Comparator
2904401|NCT03218319|Experimental|All patients|
2904402|NCT03218306|Experimental|SPI guided analgesia|SPI ≤ 10 percentual points over the post-induction/pre-surgical incision value
2904403|NCT03218306|Active Comparator|Clinical Guided Analgesia|No SPI guidance
2904404|NCT03218293|Experimental|RIPC|Remote ischemic postconditioning（RIPC）：Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5‑min cuff inflation followed by 3‑min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after thrombolysis while in-hospital.
2904405|NCT03218293|No Intervention|Blank control group(BC)|Blank control group:Patients in the BC group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin, 100-300 mg/d) and lipid-lowering (atorvastatin, 20 mg/d) drugs,throughout the 14 days in-hospital period without remote ischemic postconditioning after thrombolysis.
2904406|NCT03218280|Active Comparator|Antioxidant Therapy|
2904407|NCT03218280|No Intervention|Antioxidant Free|
2904408|NCT03218267|Experimental|Individuals after total hip replacement|Individuals after total hip replacement. Patients treated at the Out-Patient Ward of W. Dega Orthopaedic-Rehabilitation Clinical Hospital of Karol Marcinkowski University of Medical Sciences in Poznań. The examination of participants included the static posturography and one-leg standing test.
2904409|NCT03218267|Active Comparator|control group|The group with healthy individuals; without total hip replacement. The examination of participants included the static posturography and one-leg standing test.
2904410|NCT03218254|Other|Methylphenidate - Placebo|Methylphenidate before placebo
2904417|NCT03218228|Placebo Comparator|implants in healthy individuals|immediate placement of dental implants in individuals with healthy periodontium. the device is dental implants, radiographs, william's periodontal probe
2904418|NCT03218228|Experimental|implants in periodontitis patients|immediate implantation in patients suffering from aggressive periodontitis. the device is the dental implants, radiographs, william's periodontal probe
2904419|NCT03218176|Active Comparator|Proximal single upper limb|Laying a single tourniquet on the root of the upper limb
2904420|NCT03218176|Experimental|Proximal staggered upper limb|Laying two staggered tourniquets : one on the root of the upper limb and a second 5 cm below the previous one
2904421|NCT03218176|Experimental|Distal single upper limb|Laying a single tourniquet on the forearm
2904422|NCT03218176|Experimental|Distal staggered upper limb|Laying two staggered tourniquets : one on the forearm and a second 5 cm below the previous one
2904423|NCT03218176|Active Comparator|Proximal single lower limb|Laying a single tourniquet on the root of the lower limb
2904424|NCT03218176|Experimental|Proximal staggered lower limb|Laying two staggered tourniquets : one on the root of the lower limb and a second 5 cm below the previous one
2904425|NCT03218176|Experimental|Distal single lower limb|Laying a single tourniquet on the calf
2904426|NCT03218176|Experimental|Distal staggered lower limb|Laying two staggered tourniquets : one on the calf and a second 5 cm below the previous one
2904427|NCT03218163|Experimental|MEDI-551 Treatment Arm|Medi-551 maintenance therapy will be initiated on Day 60, Day 90, or Day 120 of NM-AlloSCT based on the eligibility criteria for the initiation of maintenance therapy as described in Section 3.1. MEDI-551 will be administered on 28-day cycles at a dose of 4mg/kg, as an IV infusion over 60 ±15 minutes. Infusion sets must contain a 0.2 micron in-line filter. MEDI-551 will be administered on days 1, 8, 15, and 22 of cycle 1, then 4mg/kg IV on day1 of cycles 2 through 12. Treatment may be stopped earlier if there is unacceptable toxicity, development of Grade 3 or 4 graft-versus-host disease (GVHD), documentation of disease progression, or patient withdrawal for other reasons.
2904428|NCT03218150||bone cement group|patient underwent to cranioplasty reconstruction with customized hydroxyapatite prosthesis
2904429|NCT03218150||titanium mesh group|patient underwent to cranioplasty reconstruction with titanium mesh
2904430|NCT03218150||autologous bone group|patient underwent to cranioplasty reconstruction with autologous bone graft
2904431|NCT03218137|Other|Adenosine Arm|"Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes)~All subjects will receive same dosing as this is a single arm study"
2904432|NCT03218124|Experimental|remifentanil|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
2904433|NCT03218111|Other|Healthy Normal Subjects|Healthy normal subjects 20-80 years old. All subjects will undergo the same procedures: intrathecal injection, using CT-guidance, with an MRI contrast. After injection subjects will undergo six sessions of MR imaging over a 10-12 hour period
2904434|NCT03218098|Experimental|Smaller Incision|UVATS access for lobectomy with small skin access 4 cm
2904435|NCT03218098|Active Comparator|Traditional Incision|UVATS access for lobectomy with longer skin access 8 cm
2904436|NCT03218072|Experimental|HLX01 250 mg/m2|HLX01 250 mg/m2 administrated intravenously
2904437|NCT03218072|Experimental|HLX01 375 mg/m2|HLX01 375 mg/m2 administrated intravenously
2904438|NCT03218072|Experimental|HLX01 500 mg/m2|HLX01 500 mg/m2 administrated intravenously
2904439|NCT03218046|Experimental|EMDR group|This is the treatment arm that will receive EMDR therapy
2904440|NCT03218033|No Intervention|Control|Participants visited the Facinglupustogether.com website and participated in consecutive weekly modules for 8 weeks. At the end of each module there were questions pertaining to the subject of each module. The control group answered the questions in provided journals and these were sent back to the investigator. All subjects completed surveys in REDCap prior to the study intervention and again 6 weeks after study completion to assess secondary outcome measures. Medication adherence was assessed by calculating a medication possession ratio by acquiring information on fill dates at the subjects' pharmacies.
2904441|NCT03218033|Active Comparator|Social Media (SM)|"The intervention phase was 8 weeks in duration. Participants visited the Facinglupustogether.com website and participated in consecutive weekly modules. 8 The SM group answered the questions at the end of each module on a blogging site with other SM participants. SM participants were encouraged to provide feedback or questions about the material or personal questions that arose in response to each module.~All subjects completed surveys in REDCap prior to the study intervention and again 6 weeks after study completion to assess secondary outcome measures. Medication adherence was assessed by calculating a medication possession ratio by acquiring information on fill dates at the subjects' pharmacies."
2904442|NCT03218020||Random Subcohort|Random subcohort (~10 % of the initial cohort, study has a case-cohort design; details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).
2904443|NCT03218020||Incident CVD Cases|Validated incident cases of myocardial infarction, stroke and CVD death that occured until Dec-31-2009 (details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).
2904444|NCT03218007|Experimental|acute coronary syndrome|
2904445|NCT03217994|Active Comparator|37.5% gel|37.5% gel to bleach teeth
2904446|NCT03217994|Experimental|6% gel|6% gel to bleach teeth
2904447|NCT03217981||2015|2015 - Individuals with a diagnosis of sepsis from June 2014 to May 2015
2904448|NCT03217981||2016|2016 -Individuals with a diagnosis of sepsis from June 2015 to May 2016
2904449|NCT03217968|Experimental|Active|120 minutes of Cefaly® Abortive Program device stimulation as abortive treatment of an early stage migraine attack
2904450|NCT03217955|Experimental|CBT-SA|"Group sessions for 4 weeks, two sessions per week, 60 minutes per session, two trainers (a CBT therapist and a CBT assistant); eight participants, and;~Individual sessions (crystallizing learned skills, focus on individual needs) during 6-8 weeks, one session per week, 45 minutes per session"
2904705|NCT03216213|No Intervention|Control|Vignette contains no extra information
2904706|NCT03216213|Experimental|Frame|Vignette is framed in a particular manner
2904451|NCT03217955|Active Comparator|Standard Treatment|Participants in both study conditions will receive ST. Participants are hospitalized or attending day-treatment at the Department of Early Psychosis, Amsterdam, the psychosis department of the ABC team, Utrecht, Parnassia Den Haag and collaborating (local community) mental health centers.
2904452|NCT03217942|Experimental|Low dose|All participants will receive 5 i.m injections of NGF (1 ug/0.5ml) into the tibialis anterior muscle (either left or right leg)
2904453|NCT03217942|Experimental|High dose|All participants will receive 1 high dose i.m bolus injection of NGF (5 ug/0.5ml) and 4 injections of saline (control/same volume) into the tibialis anterior muscle (either left or right leg)
2904454|NCT03217929|Active Comparator|Active-taVNS|
2904455|NCT03217929|Sham Comparator|Sham-taVNS|
2904456|NCT03217916||normotensive groups|pregnant women with normal blood pressure
2904457|NCT03217916||hypertensive groups|pregnant women with severe preclampsia
2904458|NCT03217903|Experimental|Patients with High-risk MDS With Excess Blasts|
2904459|NCT03217877|Active Comparator|No Routine stress testing after PCI|
2904460|NCT03217877|Experimental|Routine stress testing at 9~15 months after PCI|
2904461|NCT03217851||Patients Presenting P. falciparum Malaria|
2904462|NCT03217838|Experimental|Part A|AZD2811 single agent dose escalation cohorts
2904463|NCT03217838|Experimental|Part B|Following the single agent dose escalation (Part A), additional evaluable patients will be enrolled at the maximum tolerated dose and/or below, in order to further explore the tolerability, PK and clinical activity at this dose (Part B).
2904464|NCT03217825|Experimental|Rostafuroxin 6 micrograms capsules|1 capsule of ROSTAFUROXIN (6 micrograms) once a day before breakfast.
2904465|NCT03217825|Experimental|Rostafuroxin 50 micrograms capsules|1 capsule of ROSTAFUROXIN (50 micrograms) once a day before breakfast.
2904466|NCT03217825|Experimental|Rostafuroxin 500 micrograms|1 capsule of ROSTAFUROXIN (500 micrograms) once a day before breakfast.
2904467|NCT03217825|Active Comparator|Losartan 50 mg encapsulated|1 capsule containing one cpr of Losartan 50 mg once a day before breakfast.
2904468|NCT03217812|Active Comparator|Treatment A: VMP Alone|Participants will receive Velcade (bortezomib) 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 orally, once daily (on Days 1 to 4) and prednisone 60 mg/m^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
2904469|NCT03217812|Experimental|Treatment B: D-VMP|Participants will receive Velcade 1.3 mg/m^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2, orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 milligram per kilogram (mg/kg) as intravenous (IV) infusion, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycles 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study. Participants will receive pre-infusion medications before each daratumumab infusion.
2904470|NCT03217773|Experimental|ESD|ESD is an endoscopic procedure that enables en bloc resection of large tumors in the gastrointestinal tract, irrespective of the size of the lesion. ESD uses an electrosurgical cutting device to purposely dissect the deeper layers of the submucosa to remove neoplastic mucosal lesions in a single piece.
2904471|NCT03217773|Active Comparator|TAMIS|TAMIS is a minimally invasive means of removing large rectal neoplastic lesions not accessible by conventional transanal excision. It is performed using the GelPOINT path transanal access platform and laparoscopic instruments.
2904472|NCT03217760||Patients|The main aim of the study is to examine the patient's induced stress during endodontic treatment in order to offer customised solutions to lessen stress. The other aims is also to evaluate the patient's pain and discomfort during endodontic treatment.
2904473|NCT03217760||Young dentists practitioners.|The other aims are to evaluate the young dentist's induced stress and to examine and compare the patient's induced stress and the young dentist's induced stress.
2904474|NCT03217747|Experimental|Arm A: Avelumab and Utomilumab|"Utomilumab 100 mg by vein every 4 weeks starting Cycle 1 Day 1.~Avelumab 10 mg/kg by vein every 2 weeks starting Cycle 1 Day 15.~Treatment cycles are 28 days."
2904475|NCT03217747|Experimental|Arm B: Avelumab and PF-04518600|"PF-04518600 0.3 mg/kg by vein every 2 weeks starting Cycle 1 Day 1.~Avelumab 10 mg/kg by vein every 2 weeks starting Cycle 1 Day 15.~Treatment cycles are 28 days."
2904476|NCT03217747|Experimental|Arm C: Avelumab, Utomilumab and PF-04518600|"Phase I Starting Dose of PF-04518600: 0.1 mg/kg by vein every 2 weeks starting Cycle 1 Day 1.~Phase II Starting Dose of PF-04518600: Maximum tolerated dose (MTD) from Phase I.~Phase I and II Starting Dose of Utomilumab: 100 mg by vein every 4 weeks starting Cycle 1 Day 1.~Phase I and II Starting Dose of Avelumab: 10 mg/kg by vein every 2 weeks starting Cycle 1 Day 15.~Treatment cycles are 28 days."
2904477|NCT03217747|Experimental|Arm D: Avelumab, Utomilumab, and Radiation|"Phase I Starting Dose of Radiation: 60 Gy in 6 Gy / fraction for 10 fractions on days 2-11 of Cycle 1.~Phase II Starting Dose of Radiation: MTD from Phase I.~Phase I and II Starting Dose of Utomilumab: 100 mg by vein every 4 weeks starting Cycle 1 Day 1.~Phase I and II Starting Dose of Avelumab: 10 mg/kg by vein every 2 weeks starting Cycle 1 Day 1.~Treatment cycles are 28 days."
2904478|NCT03217747|Experimental|Arm E: Avelumab, PF-04518600, and Radiation|"Phase I Starting Dose of Radiation: 60 Gy in 6 Gy / fraction for 10 fractions~Phase II Starting Dose of Radiation: MTD from Phase I.~Phase I and II Starting Dose of PF-04518600 to be determined, given by vein every 2 weeks starting Cycle 1 Day 1.~Phase I and II Starting Dose of Avelumab: 10 mg/kg by vein every 2 weeks starting Cycle 1 Day 1."
2904479|NCT03217747|Experimental|Arm F: Avelumab, Utomilumab, PF-04518600, and Radiation|"Phase I Starting Dose of Radiation: 60 Gy in 6 Gy / fraction for 10 fractions on Days 2-11 of Cycle 1.~Phase II Starting Dose of Radiation: MTD from Phase I.~Phase I and II Starting Dose of PF-04518600: MTD from Arm C by vein every 2 weeks starting Cycle 1 Day 1.~Phase I and II Starting Dose of Utomilumab: 100 mg by vein every 4 weeks starting Cycle 1 Day 1.~Phase I and II Starting Dose of Avelumab: 10 mg/kg by vein every 2 weeks starting Cycle 1 Day 1."
2904506|NCT03217539|No Intervention|Passive Study Population|In the no intervention arm, women aged 40-74 who were randomly selected to not receive an invitation to undergo periodic single view mammography screening received usual care. This arm is referred to as the Passive Study Population (PSP)
2904480|NCT03217747|Experimental|Arm G: Avelumab, Cisplatin, and Radiation|"Phase I and II Starting Dose of Radiation: 45 Gy in 1.8 Gy / fraction for 25 fractions on Days 1-5 for the first 5 weeks starting Cycle 1 Day 1.~Phase I and II Starting Dose of Cisplatin: 40 mg/m2 by vein weekly for 6 weeks only.~Phase I Starting Dose of Avelumab: 10 mg/kg by vein every 2 weeks starting Cycle 1 Day 1.~Phase II Starting Dose of Avelumab: MTD from Phase I."
2904481|NCT03217734|Placebo Comparator|ADA and Placebo|Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Placebo, Tablet, Oral, Weekly, 16 Weeks
2904482|NCT03217734|Active Comparator|ADA and MTX|Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Methotrexate, 2.5 mg Tablet, 10 mg Weekly, Oral, 16 Weeks
2904483|NCT03217708||Children without OSA|Children for AT due to chronic tonsillitis without OSA.
2904484|NCT03217708||Children with OSA|Children with OSA for AT as determined by PSG
2904485|NCT03217695|Experimental|Mindfulness-based Yoga Arm|"8-week period, 1x/week for 45-60 minutes/session. Sessions 1-2: Participants instructed to focus their attention on their breath, and the physical sensations in their bodies while holding the yoga postures, to develop sustained and focused attention. Sessions 3-4: exploring the sensorial qualities of physical sensation in the body whether pleasant or unpleasant and to notice thoughts and label them (e.g., planning, remembering), and to the same with emotions (e.g., worry, frustration, fear) to practice disengaging from automatic associative thinking. Session 6-8: Instructor will guide participants to allow sensations of discomfort or effort to be as they are and to bring awareness to automatic patterns of reactivity. The goal is to foster distress tolerance, provide opportunities for participants to practice self-care, and allow an opportunity to observe and respond skillfully, instead of react automatically, to unpleasant stimuli (sensations, emotions)."
2904486|NCT03217682|Experimental|Music Therapy|Music therapy twice a week for two weeks, each session lasting approximately 45 min-1 hr
2904487|NCT03217682|Experimental|Massage Therapy|Massage therapy twice a week for two weeks, each session lasting approximately 45 min-1 hr
2904488|NCT03217669|Experimental|Sirolimus/Epacadostat Dose Escalation|"Traditional 3 + 3 dose escalation design.~Starting doses: sirolimus 3milligrams (mg) loading/1mg maintenance and epacadostat 300mg twice daily (BID). If 0 in 3 subjects develops dose limiting toxicity (DLT), next 3 subjects will be treated at dose level 2 (DL2): sirolimus 6mg loading/2mg maintenance and epacadostat 300mg BID. If 1 subject in dose level 1 (DL1) develops DLT, 3 additional subjects will be enrolled in DL1. If 2 or more subjects in a total of 6 subjects, or 2 or more subjects in the initial 3 subjects develop DLT, the next 3 subjects will be treated at dose level -1 (DL-1): 3mg loading/1mg sirolimus + epacadostat 100mg BID. If only 1 subject in a total of 6 develops DLT, dose escalation to DL2 will be made for the next 3 subjects. Same algorithm will apply to DL2 except no further dose escalation/de-escalation will be made.~Sirolimus lead-in phase: loading dose on day -7 and maintenance dose starting day -6. On Cycle 1 Day 1, epacadostat 300mg BID will be added."
2904489|NCT03217669|Experimental|Sirolimus/Epacadostat Dose Expansion|"Once recommended phase 2 dose (RP2D) is defined, a total of 10 non-small cell lung cancer (NSCLC) patients who meet eligibility will be enrolled in the dose expansion cohort. Treatment will be sirolimus RP2D once daily and epacadostat RP2D twice daily (BID).~Sirolimus lead-in phase: loading dose on day -7 and maintenance dose starting day -6. On Cycle 1 Day 1, epacadostat 300mg BID will be added."
2904490|NCT03217656||Mother-child birth cohort|
2904491|NCT03217643|Experimental|Brentuximab Vedotin|The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.
2904492|NCT03217630||Diabetic patients|
2904493|NCT03217630||Non-diabetic patients|
2904494|NCT03217617|Experimental|Single arm|Gene transfer to treat SCID-X1
2904495|NCT03217604|Placebo Comparator|Placebo|Placebo
2904496|NCT03217604|Experimental|PF-06852231|Single ascending doses of PF-06852231
2904497|NCT03217591|Experimental|IW-1973 Low Dose|Administered daily for 12 weeks
2904498|NCT03217591|Experimental|IW-1973 High Dose|Administered daily for 12 weeks
2904499|NCT03217591|Placebo Comparator|Placebo|Placebo to match experimental drug administered daily for 12 weeks
2904500|NCT03217565|Experimental|IV Tedizolid Phosphate|A single dose of 5 mg tedizolid phosphate/kg body weight administered intravenously (IV) as a 0.8 up to 1.6 mg/mL solution
2904501|NCT03217565|Experimental|Oral Suspension Tedizolid Phosphate|A single dose of 5 mg tedizolid phosphate/kg body weight administered as an oral suspension
2904502|NCT03217552||The Emergency Department|"The study aims to evaluate the test in this environment as a potential diagnostic. All patients will be screened using the electronic patient management system within the ED.~A single sample of approximately 20ml of blood, will be obtained at the same time as a clinically indicated blood culture (triggered by clinician concern for infection). The sample will be processed as described in the laboratory manual, aliquoted and frozen for future batch analysis. This analysis will include:~The Mologic Biomarker Panel~PCT~CRP~Other inflammatory markers or pathogen detection that may augment the panels accuracy~All conventional standard of care testing will be done at the study site as part of the enrolled subject's routine clinical care."
2904503|NCT03217552||Critical Care Unit|"Two patient populations admitted to the CCU will be approached for inclusion into the study:~Patients being managed for potential infection~Patients having undergone elective major surgery and admitted to the CCU as part of their care pathway. These patients will act as controls as the majority show signs and symptoms of inflammation but rarely develop an infection.~Patients with potential infection: UCLH Critical Care Unit has approximately 1000 emergency admissions per year. Complicated infection (sepsis or septic shock) being the commonest underlying reason for admission."
2904504|NCT03217552||Patients undergoing major surgery|UCLH Critical Care admits approximately 1000 patients per year following major elective surgery. These patients frequently exhibit the features of SIRS but the incidence of infection/sepsis is low (approximately 5%) and very rare in the first 3 days' post-surgery. This group is to be studied as a negative control group to ensure the Mologic Biomarker Panel is able to detect the difference between the similar inflammatory phenotypes developed through infection and surgical trauma.
2904505|NCT03217539|Experimental|Active Study Population|In the experimental arm, women aged 40-74 who were randomly selected to receive an invitation to undergo imaging with periodic single view mammography screening. This arm is referred to as the Active Study Population (ASP)
2904507|NCT03217526|Active Comparator|Ex Group|"EX: Standard exercise program (EX) (active range-of otion exercises, balance and mobility exercises) and walking training on the overground.~This rehabilitation program physiotherapist will be applied to participants for five days a week. Walking training will be applied according to the gait speed determined by GAITRite computerized gait analysis system at initial assessment. Individuals will be instructed to walk with verbal commands and encourage them to continue their walk at constant speed.The duration of walking training will be recorded every day. The walking time will be determined according to the fatigue level of the individual. The level of fatigue of the individual will be questioned according to the modified borg scale."
2904508|NCT03217526|Experimental|Ex +WT Group|Ex: A standard exercise (SE) (active range-of otion exercises, balance and mobility exercises) WT: walking training on the treadmill (WT). This rehabilitation program physiotherapist will be applied to participants for five days a week.Walking training will be applied according to the gait speed determined by GAITRite computerized gait analysis system at initial assessment. Individuals will be trained on the treadmill.The duration of walking training and the speed of walking training will be recorded every day. The walking time will be determined according to the fatigue level of the individual. The level of fatigue of the individual will be questioned according to the modified borg scale.
2904509|NCT03217513||Forteo|teriparatide 20-microgram once daily available in a 2.4-mL delivery device for subcutaneous injection by the patient
2904510|NCT03217513||Prolia|denosumab 60 mg administered as a single subcutaneous injection every 6 months by the health care provider
2904511|NCT03217500|Experimental|Corneal epithelial autograft|pterygium resection combined with femtosecond laser assisted corneal epithelial autograft
2904512|NCT03217500|Active Comparator|Limbal conjunctival autograft|pterygium resection combined with diamond knife assisted limbal conjunctival autograft
2904513|NCT03217500|Active Comparator|Simple removal|Simple removal of pterygium
2904514|NCT03217487|Experimental|Corneal epithelial autograft|Femtosecond laser assisted corneal epithelial autograft from the other eye in the treatment of LSCD
2904515|NCT03217487|Active Comparator|Limbal conjunctival autograft|Diamond knife assisted limbal conjunctival autograft from the other eye in the treatment of LSCD
2904516|NCT03217474|Experimental|FLDEB combined with GCV orally|Femtosecond laser-assisted cornea debridement (FLDEB) combined with ganciclovir (GCV) orally.
2904517|NCT03217474|Active Comparator|GCV orally|Ganciclovir (GCV) orally only
2904518|NCT03217461|Experimental|Corneal epithelial autograft|Corneal dermoid tumor resection combined with femtosecond laser assisted corneal epithelial autograft
2904519|NCT03217461|Active Comparator|Limbal autograft|Corneal dermoid tumor resection combined with femtosecond laser assisted limbal autograft
2904520|NCT03217448|Experimental|Dabigatran etexilate group|Subjects in this group will take Dabigatran etexilate for 6 months after randomization
2904521|NCT03217448|Active Comparator|Warfarin group|Subjects in this group will take Warfarin for 6 months after randomization
2904522|NCT03217435|Experimental|Cornea epithelial allograft|Femtosecond laser assisted corneal epithelial allograft from live relatives in the treatment of limbal stem cell deficiency (LSCD)
2904523|NCT03217435|Active Comparator|Limbal conjunctival allograft|Diamond knife assisted limbus conjunctival allograft from live relatives in the treatment of limbal stem cell deficiency (LSCD)
2904524|NCT03217422|Experimental|Arm 1|VAY736 Dose 1
2904525|NCT03217422|Experimental|Arm 2|VAY736 Dose 2
2904526|NCT03217422|Experimental|Arm 3|VAY736 Dose 3
2904527|NCT03217422|Placebo Comparator|Arm 4|Placebo
2904528|NCT03217409|Experimental|Rosuvastatin+Ezetimibe|Rosuvastatin 5mg+Ezetimibe 10mg Rosuvamibe ® Tablet, 1T, Once a day/8week
2904529|NCT03217409|Active Comparator|Rosuvastatin|Rosuvastatin 5mg Monorova ® Tablet, 1T, Once a day/8week
2904530|NCT03217396||multiple sclerosis patients|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
2904531|NCT03217396||neurodegenerative disease patients|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
2904532|NCT03217396||control subjects|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
2904533|NCT03217383|Experimental|MATRx plus test|All study participants will receive the same test protocol. All participants will complete the MATRx plus theragnostic test and receive a prediction of oral appliance outcome. All participants will then receive a custom oral appliance set to the predicted protrusive position or a sham position, and outcome home sleep tests will be performed with the custom oral appliance in place to determine if the test prediction was correct.
2904534|NCT03217370|Other|all haematologists|There will be only one arm: the haematologists will all be included in the interventional phase
2904535|NCT03217357|Active Comparator|Transcranial stimulation in direct current(tDCS)active|30 minutes of active Transcranial stimulation in direct current
2904536|NCT03217357|Placebo Comparator|Transcranial stimulation in direct current(tDCS) placebo|30 minutes of placebo stimulation
2904537|NCT03217344|Experimental|1-week|patients undergoing 1-week immobilization period
2904538|NCT03217344|Experimental|3-week|patients undergoing 3-week immobilization period
2904539|NCT03217331|Experimental|CRD-102 Treatment|CRD102 Treatment
2904540|NCT03217318|Active Comparator|ureteral stenting with standard ureteral stent|Group 1 will receive a standard ureteral stent. Diameter: 6F, length according to surgeons' estimation and patient's height.
2904541|NCT03217318|Active Comparator|ureteral stenting with suture-stent|In Group 2, a modification of the standard ureteral stent will be inserted. The stent will be cut through obliquely according to the position of the ureteral calculus. The extend to be removed can be easily measured by the retrograde probing catheter and is replaced by a monofilament, non-absorbable suture as described previously by Vogt et al. (W J Urol, 2015). This suture can be easily attached by puncturing the bevelled stent end.
2904542|NCT03217305|Other|NAVA vs Pressure Support|Control (pressure support) - NAVA - Control (Pressure Support) Intervention is NAVA
2904570|NCT03217097|Experimental|Unmethylated MGMT NET - OX|"Patients with unmethylated MGMT NET will be randomly assigned (1:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
2904543|NCT03217292|Experimental|Group S|"IV patient-controlled analgesia (PCA) tramadol+Serratus Anterior Plane Block(SAPB) Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.~20 mL of bupivacaine at a concentration of 0.25% to between serratus anterior and intercostal muscle using the in-line technique for SAPB."
2904544|NCT03217292|Active Comparator|Group T|IV patient-controlled analgesia (PCA) tramadol Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
2904545|NCT03217266|Experimental|Treatment (MDM2 inhibitor AMG-232, radiation therapy)|Patients receive MDM2 inhibitor AMG-232 PO on day 2, days 2 and 4, days 2-4, days 2-5, or days 1-5 of weeks -1 to 5. Patients also undergo radiation therapy daily on weeks 1-5. Treatment continues in the absence of disease progression or unacceptable toxicity.
2904546|NCT03217253|Experimental|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2904547|NCT03217240||Congenital Heart Disease|Tetralogy of Fallot Repair/Pulmonary Hypertension Cardiac Magnetic Resonance - MRI Cardiopulmonary Exercise Test Blood Sampling for all participants
2904548|NCT03217240||Healthy Volunteer|Cardiac Magnetic Resonance - MRI Cardiopulmonary Exercise Test Blood Sampling for all participants
2904549|NCT03217227||Healthy Volunteer|"Healthy Volunteers will undergo the following study procedures:~Cardiovascular Magnetic Resonance Imaging with Exercise Bike~Blood Sampling~Activity and Lifestyle Questionnaires"
2904550|NCT03217227||Patients with Chest Pain|"Patients will undergo the following study procedures:~Cardiovascular Magnetic Resonance Imaging with Exercise Bike~Blood Sampling~Cardiac Catherization~Activity, Lifestyle and Medication Compliance Questionnaires~Retinal Photography (Optional)"
2904551|NCT03217214||EP-PT|"Existing Procedure EP- Passive Thermography PT (40 patients)~Passive Thermography (PT): 2 thermoscans of the following parts:~Both carotid artery on left and right of the neck.~Both superficial temporal artery on the left and right of forehead.~Left forearm. No relaxation time will be given between the two tests. Each thermoscanning of region will take 60 seconds. The complete procedure will take 10-15 minutes of time."
2904552|NCT03217214||EP-ATLIC/ATPC|"Existing Procedure EP- Active Thermography ATLIC/ATPC (60 patients)~Active Thermography (AT): Temperature mapping over both carotid arteries will be done with the application of maximum cooling for 45-60 seconds in pulsed or lock-in manner. Pulsed mode is continuous, lock-in cooling will be intermittent. Maximum cooling time is 45-60 seconds, using a cooling pad/ cold air blower. Continuous thermoscanning will be done from the instance of application of cooling to reaching of a fixed temperature during rewarming. Procedure will be done 2 times per subject on both carotid arteries. Relaxation time between procedures is 10 minutes. A warming pad/ hot air blower will be used after the test to bring the skin temperature to normal. The complete procedure will take 60 min."
2904553|NCT03217201|Experimental|Adjuvant, Experimental Light|30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
2904554|NCT03217201|Active Comparator|Adjuvant, Comparison Light|30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
2904555|NCT03217201|Experimental|Neo-Adjuvant, Experimental Light|30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
2904556|NCT03217201|Active Comparator|Neo-Adjuvant, Comparison Light|30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
2904557|NCT03217188|Experimental|fractionated full dose re-irradiation|
2904558|NCT03217188|Experimental|hypofractionated palliative re-irradiation|
2904559|NCT03217175|Active Comparator|Bihormonal Bionic Pancreas|Bihormonal bionic pancreas exercise visit - subjects will participate in the outpatient bihormonal bionic pancreas run in period, and will use the bihormonal bionic pancreas for their exercise visit at the end of the run in. The glucagon pump of the bionic pancreas will be filled with glucagon.
2904560|NCT03217175|Placebo Comparator|Insulin Only Bionic Pancreas|Insulin-only bionic pancreas exercise visit - Bihormonal bionic pancreas exercise visit - subjects will participate in the outpatient bihormonal bionic pancreas run in period, and will use the insulin-only bionic pancreas for their exercise visit at the end of the run in. The glucagon pump of the bionic pancreas will be filled with placebo (normal saline).
2904561|NCT03217162|Experimental|surfactant combined with mechanical ventilation|surfactant is given to the infant with ARDS.
2904562|NCT03217162|Active Comparator|mechanical ventilation|mechanical ventilation is given to the infant with ARDS.
2904563|NCT03217149|Experimental|heliox combined with mechanical ventilation (MV)|heliox combined with mechanical ventilation (MV) is given to infant with ARDS
2904564|NCT03217149|Active Comparator|mechanical ventilation|mechanical ventilation (MV) is given to infant with ARDS
2904565|NCT03217136|Experimental|Ceftolozane/Tazobactam + Metronidazole|Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum ceftolozane 1 g/dose and tazobactam 0.5 g/dose); plus Metronidazole 10 mg/kg (maximum 1.5 g/day) administered intravenously (IV) every 8 to 12 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 5 days and a maximum of 14 days.
2904566|NCT03217136|Active Comparator|Meropenem + Placebo for Metronidazole|Meropenem 20 mg/kg (maximum 1 g/dose) plus placebo for Metronidazole administered IV every 8 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 5 days and a maximum of 14 days.
2904567|NCT03217123|Experimental|Deep Brain stimulation|After the surgery, a random sequence of contact activations (0 [Nacc],1,2 and 3), including sham (-), was generated for each patient. Each contact was activated using 130 Hz, 60 ms, and 4.5 V for three months (the sham activation was 0 V) following the patient's individual sequence, separated by one month of washout with the generator turned off
2904568|NCT03217110|Experimental|rTMS|Subjects will receive 5 days of 2x daily rTMS targeted over the cerebellum.
2904569|NCT03217110|Sham Comparator|Sham rTMS|Subjects will receive 5 days of 2x daily sham stimulation of the cerebellum.
2904571|NCT03217097|Active Comparator|Unmethylated MGMT NET - ALKY|"Patients with unmethylated MGMT NET will be randomly assigned (1:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
2904572|NCT03217097|Experimental|Methylated MGMT NET - OX|"Patients with methylated MGMT NET will be randomly assigned (2:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
2904573|NCT03217097|Active Comparator|Methylated MGMT NET - ALKY|"Patients with methylated MGMT NET will be randomly assigned (2:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
2904574|NCT03217084|Active Comparator|MI varnish GC|MI Varnish is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDEN Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish . Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue.
2904575|NCT03217084|Active Comparator|White Varnish 3M|"White Varnish is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. White Varnish an innovative tri-calcium phosphate.~Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish . Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue."
2904576|NCT03217071|Experimental|Pembrolizumab|Patients will receive 200mg pembrolizumab on Day 1 of each 3 week cycle, for 2 cycles, prior to surgery. Pembrolizumab will be administered via IV infusion for 30 minutes. Surgery will occur no later than 6 weeks following the last dose of pembrolizumab.
2904577|NCT03217071|Experimental|Pembrolizumab + Radiation|Patients will receive 200mg pembrolizumab on Day 1 of each 3 week cycle, for 2 cycles. Pembrolizumab will be administered via IV infusion for 30 minutes.Within the week (7 days +/- 3 days) following administration of the second cycle, a single 12 Gy dose of stereotactic radiation therapy (SRT) will be delivered to 50% of the primary tumor only. Definitive surgical resection will occur no later than 6 weeks following the last dose of pembrolizumab.
2904578|NCT03217058||Pre-implementation|The pre-implementation cohort includes data from 4600 HIV primary care clinic patients in Kaiser Permanente Northern California, who receive services prior to implementation of computerized screening and behavioral intervention in the clinics.
2904579|NCT03217058||Post-implementation|The post-implementation cohort includes data from 4600 HIV primary care clinic patients in Kaiser Permanente Northern California, who receive services after computerized screening and behavioral intervention have been implemented in the clinics.
2904580|NCT03217045||Before Protocol|72 premature infants born between 26 and 32 weeks gestation, over 6 months period, and involved before the introduction of a strict nutrition protocol
2904581|NCT03217045||After Protocol|86 premature infants born between 26 and 32 weeks gestation, over 6 months period, and involved after the introduction of a strict nutrition protocol and a washout period of 6 months
2904582|NCT03217032|Experimental|YUVA-GT-F801|Gene transfer to treat Hemophilia A
2904583|NCT03217032|Experimental|YUVA-GT-F901|Gene transfer to treat Hemophilia B
2904584|NCT03217019|Experimental|Guidewire|"Radial artery puncture with direct radial pulse palpation.~24G angiocatheter insertion with guidewire-assist. (Catheter over guidewire)"
2904585|NCT03217019|Active Comparator|Direct|"Radial artery puncture with direct radial pulse palpation.~24G angiocatheter insertion without guidewire-assist. (Catheter over needle)"
2904586|NCT03217006|Experimental|Single Arterial Group|Patients in this group will receive a single arterial graft which will be the left internal thoracic artery. Additional grafts used in this group will all be venous grafts.
2904587|NCT03217006|Experimental|Multiple Arterial Group|Patients in the group will receive multiple arterial grafts. All patients will receive at least two arterial grafts, the left internal thoracic artery with the addition of either the right internal thoracic artery or the radial artery as the second conduit. Some patients may receive additional arterial grafts consisting of the radial artery, the right internal thoracic artery, or the right gastroepiploic artery.
2904588|NCT03216993|Other|Standard care|Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units
2904589|NCT03216993|Experimental|Protocol care|Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
2904590|NCT03216980|Experimental|PTSD Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
2904591|NCT03216980|Placebo Comparator|PTSD Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
2904592|NCT03216980|Experimental|Healthy Control Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
2904593|NCT03216980|Placebo Comparator|Healthy Control Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
2904594|NCT03216967|Active Comparator|IS lowering alone|50% decrease of the dose of mycophenolic acid at M1 (target AUC 20 mg.h/L)
2904595|NCT03216967|Experimental|Everolimus + IS lowering|Stop mycophenolate acid (Cellcept or myfortic) Introduction of everolimus : 2 x 0.75 mg/d per os in patiens treated by ciclosporine
2904596|NCT03216954|Placebo Comparator|Placebo|Subjects will receive oral placebo capsules two times daily.
2904597|NCT03216954|Experimental|Low Dose n-Acetylcysteine|Subjects will receive 0.6 g oral n-acetylcysteine two times daily.
2904707|NCT03216213|Experimental|Prime|Priming question is placed
2904599|NCT03216941|Active Comparator|ketamine|assessment of agitation status with Ramsay Sedation Scale administration of ketamine 10 mg / ml IM one dose supervision of vital signs registration of time of ketamine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of ketamine administration) withdrawal of patient from the study if other medication was needed (aside of ketamine)
2904600|NCT03216941|Active Comparator|olanzapine|assessment of agitation status with Ramsay Sedation Scale administration of olanzapine 10 mg / ml IM one dose supervision of vital signs registration of time of olanzapine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of olanzapine administration) withdrawal of patient from the study if other medication was needed (aside of olanzapine)
2904601|NCT03216928|Experimental|Group 1|patients with good response to anti-TNF had a blood test
2904602|NCT03216928|Experimental|Group 2|patients with moderate or non-response to anti-TNF had a blood test
2904603|NCT03216902|Placebo Comparator|Placebo (Vehicle of DE-126) followed by high dose of DE-126|
2904604|NCT03216902|Experimental|Ultra-low dose DE-126|
2904605|NCT03216902|Experimental|Low dose DE-126|
2904606|NCT03216902|Experimental|Medium dose DE-126|
2904607|NCT03216902|Experimental|High dose of DE-126|
2904608|NCT03216902|Active Comparator|0.005% Latanoprost|
2904609|NCT03216889|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|6 weeks of CBT-I.
2904610|NCT03216889|Active Comparator|Control|6 weeks of stretching and thinking games.
2904611|NCT03216876|Experimental|Healthy Controls|Healthy subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg
2904612|NCT03216876|Experimental|PSC Single Dose|PSC subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg
2904613|NCT03216876|Experimental|PSC Multiple Dose|PSC subjects assigned to treatment with daily oral ursolic acid at the dose determined to be optimal in the first phase of the study. The treatment will last for 24 weeks with an off-treatment follow up of 28 weeks
2904614|NCT03216863|Experimental|8 weeks Respiratory rehabilitation|
2904615|NCT03216850||Patients in ICU requiring parenteral nutrition|
2904616|NCT03216837|Experimental|Cathodal Transcranial direct current stimulation|Cathodal tDCS
2904617|NCT03216837|Sham Comparator|Sham Transcranial direct current stimulation|Sham
2904618|NCT03216824|Active Comparator|Dressing|A dressing is maintained on the CVAD exit site.
2904619|NCT03216824|Experimental|No-Dressing|The CVAD exit site is not covered with a dressing.
2904620|NCT03216811|Experimental|nutraceutical|after 4 weeks of lifestyle advice and changes, all subjects will receive for 8 weeks the administration of CARDIOVIS COLESTEROLO 3 mg, a nutraceutical compound containing containing red rice fermented with Monascus purpureus titrated with 3% monacolin K, hydrol mixture of olive fruit titrated with vitamin E, Coenzyme Q10 and polymethoxyflavones
2904621|NCT03216772|Experimental|Olympus PK Morcellator in PneumoLiner|Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using the Olympus PK Morcellator in PneumoLiner containment device
2904622|NCT03216759|No Intervention|control group|Tourniquet would be tied to left upper limb of Patients who undergoing laparotomy for 30 minutes after the induction of anesthesia,but put no press on it. Other processes are consistent with conventional methods.
2904623|NCT03216759|Experimental|intervention|"After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning.~At the beginning of anesthesia induction, 3 μg / kg / h of dexmedetomidine was infused and adjusted to 0.3 ug / kg / h after 10 min of infusion until 30 minutes before the end of the procedure.~Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap."
2904624|NCT03216746|Experimental|Oral orientation with App|The oral health educational method of this group comprised a total of 66 adolescents aged between 14 and 19 years who received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. This intervention was carried out in a classroom, in a group with approximately 20 participants, providing an environment of discussions about the subjects covered. The duration was approximately 15 minutes. The participants also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
2904625|NCT03216746|Active Comparator|Oral orientation without App|The oral health educational method of this group comprised a total of 71 adolescents aged between 14 and 19 years who received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. This intervention was carried out in a classroom, in a group with approximately 20 participants, providing an environment of discussions about the subjects covered. The duration was approximately 15 minutes. In this group, participants did not receive the App for smartphone.
2904626|NCT03216746|Experimental|Video with App|The oral health educational method of this group comprised a total of 63 adolescentes aged between 14 and 19 years who received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The elaboration counted with the participation of three actors, two acting as adolescents and the third as a dental surgeon. The video had a total duration of 14 minutes. The participants also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
2904627|NCT03216746|Active Comparator|Video without App|The oral health educational method of this group comprised a total of 63 adolescentes aged between 14 and 19 years who received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The elaboration counted with the participation of three actors, two acting as adolescents and the third as a dental surgeon. The video had a total duration of 14 minutes. In this group, participants did not receive the App for smartphone.
2904628|NCT03216733|Experimental|COMBO|PCI with COMBO stent
2904629|NCT03216733|Active Comparator|ORSIRO|PCI with ORSIRO stent
2947800|NCT02919761|Experimental|Open Label|Acthar 1 mL (80 U) 2x/week
2904632|NCT03216707|Sham Comparator|HD tDCS sham motor cortex|the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min
2904633|NCT03216707|Active Comparator|HD tDCS active motor cortex|the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min
2904634|NCT03216707|Active Comparator|HD tDCS active insula cortex|the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min
2904635|NCT03216681||Hoat Huyet Nhat Nhat|Administered orally twice a day, 2 tablets each time, for 45 days.
2904636|NCT03216681||Tanakan 40mg|Administered orally three times a day, one tablet each time, for 45 days.
2904637|NCT03216668|Experimental|TONKA|Administered orally twice a day, 2 tablets each time, for 6 weeks
2904638|NCT03216668|Active Comparator|LEGALON|Administered orally three times a day, two tablets each time, for 6 weeks
2904639|NCT03216655|Experimental|traditional group|phone call
2904640|NCT03216655|Experimental|new device group|wechat group
2904641|NCT03216629|Experimental|Sorry|A small strip of self-adhesive dressing (3cm by 4cm) will be applied to the back of the patients' participants' hand and side of neck. After one minute of acclimatization, the dressing will be removed by the examiner. During the removal, the examiner will say sorry repeatedly. Following the dressing removal, participant will rate their pain with a 10 point visual analog scale.
2904642|NCT03216629|No Intervention|Not Sorry|A small strip of self-adhesive dressing (3cm by 4cm) will be applied to the back of the patients' participants' hand and side of neck. After one minute of acclimatization, the dressing will be removed by the examiner. During the removal, the examiner will remain silent. Following the dressing removal, participant will rate their pain with a 10 point visual analog scale.
2904643|NCT03216616|Experimental|Patients with inflammatory rheumatic diseases|The patients will participate in a cognitive behavioural therapy intervention
2904644|NCT03216603|Experimental|Health literacy intervention group|Health literacy intervention group will receive self-management help using a motivating interviewing technique delivered by nurses trained on motivating interviewing technique and COPD.
2904645|NCT03216603|No Intervention|Usual care group|Usual care group will receive usual follow up
2904646|NCT03216590|No Intervention|Standard draping|Shoulder arthroscopy will be performed using standard draping with the shoulder exposed.
2904647|NCT03216590|Experimental|Compressive draping|After standard preparation similar to the no-intervention group, the shoulder will be draped with compressive draping using adhesive incise drape (Ioban™2 Antimicrobial Incise Drape, 3M Inc.,USA)
2904648|NCT03216577||Exposed to purpura fulminans|Patients who were admitted in the intensive care unit and survived a purpura fulminans episode
2904649|NCT03216577||Non-exposed to purpura fulminans|Patients admitted in the intensive care unit for a septic shock unrelated to a purpura fulminans, and matched to exposed patients for age, gender, and severity of illness.
2904650|NCT03216564|Experimental|Intervention Group|Participants are treated with angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) AND active vitamin D (Calcitriol) 0.25 micrograms orally per day for 26 weeks.
2904651|NCT03216564|No Intervention|Usual Care|Participants are treated with ACEI/ARB alone for 26 weeks.
2904652|NCT03216551||Selective lymphadenectomy group|Patients with frozen section diagnosis of adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma will be considered as negative mediastinal involvement, and patients with apical tumors will be considered as negative inferior mediastinal involvement. Mediastinal nodal status of the rest of patients will be determined by the final pathology by complete lymphadenectomy.
2904653|NCT03216538|Active Comparator|AS101 1% oral solution|Daily dose 0.4 ml administered orally
2904654|NCT03216538|Placebo Comparator|Placebo|Daily dose of 0.4 ml administered orally
2904655|NCT03216525|Active Comparator|Oral Alvimopan|Oral Alvimopan (Entereg, Merck) 12 mg between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
2904656|NCT03216525|Placebo Comparator|Matching Placebo|Matching placebo between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
2904657|NCT03216512|Experimental|Noise cancelling headphone first, then sham control headphone|This group will use the noise cancelling headphone during the first experimental session as they complete study assessments. They will then return within a week, for experimental session day 2, to complete the same assessments this time using a sham control headphone.
2904658|NCT03216512|Experimental|Sham control headphone first, then noise cancelling headphone|This group will use the sham control headphone during the first experimental session as they complete study assessments. They will then return within a week for experimental session day 2, to redo the same assessments this time using a noise cancelling headphone.
2904659|NCT03216499|Experimental|Treatment (HIF-2 alpha inhibitor PT2385)|"Patients receive HIF-2 alpha inhibitor PT2385 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pharmacological Study~Laboratory Biomarker Analysis~Pharmacogenomic Study"
2904660|NCT03216486|Experimental|BPS804 Dose 1|BPS804 IV Infusion
2904661|NCT03216473|Experimental|Neuronox|Botulinum Toxin Type A for injection
2904662|NCT03216473|Active Comparator|Botox|Botulinum Toxin Type A for injection
2904701|NCT03216239||Colectomy Group|Mean age 52.3 years (range:20-85), 82% females, and a mean duration of symptoms of 79.9 months in the colectomy group. The indication for colectomy was constipation (36%), diverticular disease (8%), bowel obstruction (8%), colorectal carcinoma (8%), colon polyps (6%), and other (34%).
2904702|NCT03216239||Control Group|Mean age of 49.9 years (range 18-88), 76% females, and mean duration of symptoms 77.6 months,
2904663|NCT03216460|Other|Supervised Free-Living|Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study CGM and remain on current MDI or pump therapy. This will be followed by a 5-day/4-night or from approximately 48 to 72 hours for children ages 2.0-5.9 years, hybrid closed-loop phase conducted in a supervised hotel/rental house setting, where subjects will be encouraged to eat regular meals and to perform exercise each day.
2904664|NCT03216447|Experimental|Experimental Arm|Switch from Prograf to Advagraf on POD 15
2904665|NCT03216447|Active Comparator|Control Arm|Continue Prograf treatment
2904666|NCT03216434|Experimental|PTSD Diagnosed|Veterans exposed to combat and diagnosed with PTSD. MRI using DaTscan.
2904667|NCT03216434|Experimental|Designated Combat-Experienced Controls|Veterans exposed to combat, but never diagnosed with PTSD. MRI using DaTscan.
2904668|NCT03216421|Other|Low/Intermediate Grade DCIS|Subjects with Low/Intermediate Grade DCIS will complete quality of life questionnaires before and after the IORT.
2904669|NCT03216421|Other|High Grade DCIS|Subjects with High Grade DCIS will complete quality of life questionnaires before and after the IORT.
2904670|NCT03216408|Experimental|Neuronox|Botulinum toxin type A for Injection
2904671|NCT03216408|Active Comparator|Botox|Botulinum toxin type A for Injection
2904672|NCT03216395|Experimental|Over-the-scope Clips|Endoscopic Application of Over-the-scope Clips
2904673|NCT03216395|Active Comparator|standard treatment|standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine <=20 clips or pulse
2904674|NCT03216382|Experimental|Attention Training Technique|Participants in this arm will listen to the Attention Training Technique. Participants will listen to the recording once in the lab, followed by a week of once/day listening at home for a week. For a week before the intervention, and for the week during the intervention, participants will respond to questions every evening, about their worry and attention that day.
2904675|NCT03216382|Placebo Comparator|Control Condition|Participants in this arm will listen to the control condition recording. Participants will listen to the recording once in the lab, followed by a week of once/day listening at home for a week. For a week before the intervention, and for the week during the intervention, participants will respond to questions every evening, about their worry and attention that day.
2904676|NCT03216369||carotid artery stenting and carotid endarterectomy|Symptomatic patients with unilateral ICA severe stenosis by magnetic resonance angiography were performed 3D pseudo-Continuous Arterial Spin Labeling MRI before and after CAS and CEA.
2904677|NCT03216356|Experimental|CBT + ImRs + DCS pill|The experimental arm involves cognitive-behavioral therapy, imagery rescripting techniques and d-cycloserine medication (pill).
2904678|NCT03216356|Active Comparator|CBT + ImRs + placebo|The active comparator arm involves cognitive behavioral therapy, imagery rescripting techniques and placebo medication (pill).
2904679|NCT03216356|Active Comparator|CBT + I.E. + placebo|The placebo comparator involves cognitive behavioral therapy, imaginal exposure and placebo medication (pill).
2904680|NCT03216343|Experimental|Study Arm|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle until objective disease progression
2904681|NCT03216330||Case|"Consented to participate in the Data Registry (H16-00264) prior to their physician appointment at the BC Women's Health Centre.~New or re-referred to the BC Women's Health Centre for Pelvic Pain and Endometriosis.~Endometriosis (previously surgically diagnosed, or current endometrioma, or current nodule)~Willing and committed to indicating pain scores and menstrual data on a REDCap survey every day for 6 weeks after the test date.~At least 18 years old"
2904682|NCT03216330||Control|"Reproductive aged female with no suspected or diagnosed endometriosis.~Have not experienced any sexual pain scores over 4/10 on a 11-point numeric rating scale, as determined on an online questionnaire prior to test day.~At least 18 years old"
2904683|NCT03216317|Active Comparator|Intervention Group|Subjects will perform three weekly sessions of isometric handgrip training consisting of four series (two in each arm) with two minutes of isometric contraction with intensity of 30% of maximum voluntary contraction with interval between the two-minute series under the guidance of the trained researcher.
2904684|NCT03216317|No Intervention|Control Group|Individuals randomized to Control Group will be encouraged to increase their level of general physical activity, but without specific recommendations on physical activity.
2904685|NCT03216304|Experimental|rosuvastatin|Film-coated tablets Rosuvastatin will be administered at the dose of 20 mg (single dose at day 1)
2904686|NCT03216304|Experimental|safinamide + rosuvastatin|Film-coated tablets Safinamide will be administered at the dose 100 mg (once a day for 11 days) Film-coated tablets Rosuvastatin will be administered at the dose of 20 mg (single dose at 12)
2904687|NCT03216291|Active Comparator|Home Biofeedback|Patients will be given home biofeedback device (InTone) to take home and practice biofeedback exercises at least twice a day for six weeks of therapy. Intervention: Home device biofeedback training.
2904688|NCT03216291|Active Comparator|Office biofeedback|Patients with fecal incontinence will receive traditional office biofeedback, once weekly, over six weeks. Intervention: Regular office biofeedback training with assistance of biofeedback person..
2904689|NCT03216278|Experimental|Treatment A|Dapagliflozin/metformin XR 5/500 Mount Vernon Test Product Fed
2904690|NCT03216278|Active Comparator|Treatment B|Dapagliflozin/metformin XR 5/500 Humacao Reference Product Fed
2904691|NCT03216278|Experimental|Treatment C|Dapagliflozin/metformin XR 5/500 Mount Vernon Test Product Fasted
2904692|NCT03216278|Active Comparator|Treatment D|Dapagliflozin/metformin XR 5/500 Humacao Reference Product Fasted
2904693|NCT03216278|Experimental|Treatment E|Dapagliflozin/metformin XR 10/1000 Mount Vernon Test Product Fed
2904694|NCT03216278|Active Comparator|Treatment F|Dapagliflozin/metformin XR 10/1000 Humacao Reference Product Fed
2904695|NCT03216278|Experimental|Treatment G|Dapagliflozin/metformin XR 10/1000 Mount Vernon Test Product Fasted
2904696|NCT03216278|Active Comparator|Treatment H|Dapagliflozin/metformin XR 10/1000 Humacao Reference Product Fasted
2904697|NCT03216265|Other|Test product/ No treatment|Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.
2904698|NCT03216265|Other|Test product/positive control|Participants randomized to this arm will apply Test and positive product at allocated sites.
2904708|NCT03216213|Experimental|Norms|Vignette contains extra information about norms
2904709|NCT03216213|Experimental|All|Vignette contains extra information about norms and is framed in a particular manner. Priming question is placed
2904710|NCT03216200|Experimental|Experimental|5 Subjects with 20-75% Distal Subungual Onychomycosis (mild to moderate DSO) infection of their big toe (hallux) nail infected by the dermatophytes Trichophyton (T.) rubrum or T. mentagrophytes will be enrolled. All Subjects will receive three 45-minute plasma treatments performed over a week.
2904711|NCT03216187|Experimental|Pregabalin|Pregabalin 150 mg twice daily, starting from the evening before surgery, continuing with two times 150mg per day for 12 days, and ending with one 150mg capsule every evening for the final 3 days.
2904712|NCT03216187|Placebo Comparator|Placebo|Identical placebo capsules twice daily, starting from the evening before surgery, continuing with two capsules per day for 12 days, and ending with one capsule every evening for the final 3 days.
2904713|NCT03216174|Experimental|NESS-EFTR|This arm will be received non-exposure simple suturing endoscopic full-thickness resection after sentinel lymph node navigation
2904714|NCT03216148|Experimental|FET-PET|All participating patients will receive a FET PET-scan with intravenous O-(2-[18F]Fluoroethyl)-L-Tyrosine parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
2904715|NCT03216135||(GERD) with no Barrett's Esophagus|Squamous epithelium from patient with gastroesophageal reflux disease (GERD) with no BE or EAC diagnosed will be collected and a control sample (area with no disease).
2904716|NCT03216135||Barrett's Esophagus|BE/columnar epithelium from patient diagnosed with BE and a control sample (area with no disease).
2904717|NCT03216135||Cancer Tissue|Cancer tissue, and a control squamous epithelium from the same patient.
2904718|NCT03216122|Active Comparator|Control group (CG)|The implant will be loaded after 3-4 months of placement (Conventional/Delayed Loading)
2904719|NCT03216122|Active Comparator|Test group (TG)|The implant will be loaded non-occlusally within 3-4 days of placement (Immediate Loading)
2904720|NCT03216109|Experimental|Weekly telephone symptom assessment|"Each patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Symptom assessments will be documented into an encrypted, HIPAA compliant digital platform which provides longitudinal symptom data management and also provides symptom assessment tools for the clinical team in their intervention strategies.~In addition, patients will complete symptom and quality of life surveys at 0, 3, 6 and 9 months."
2904721|NCT03216109|No Intervention|Control Arm|Patients randomized to usual clinical care will receive standard of care for thoracic malignancies as provided by the VA Palo Alto Health Care System. Patients will complete outcome surveys at 0, 3, 6, and 9 months.
2904722|NCT03216096|Experimental|3% DE-089 ophthalmic solution|
2904723|NCT03216083|Experimental|Tranexamic Acid|Tranexamic Acid Injectable Solution (1g intravenous) Single dose prior to the start of surgery, after the induction of anesthesia
2904724|NCT03216083|Placebo Comparator|Placebo|67mL intravenous normal saline (0.9% sodium chloride) Single dose prior to the start of surgery, after the induction of anesthesia
2904725|NCT03216070|Experimental|Arm1 Low Dose Dasatinib|We will give 50mg of dasatinib orally daily for 6 months
2904726|NCT03216057|Experimental|Omega-3 fatty acid 3 grams per day|Each capsule contains 400 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 2000 mg of eicosapentaenoic acid and 1000 mg of docosahexaenoic acid per day (3 grams of Omega 3 per day) by mouth for 12 weeks. The trademark is Omega Rx Dr.Sears Zone labs Inc.
2904727|NCT03216057|Placebo Comparator|Placebo|Each capsule contains 600 mg of soybean oil. We allocated five capusles per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 3000 mg of soybean oil per day (3 gr soya oil per day) by mouth for 12 weeks.
2904728|NCT03216018|Experimental|"Experimental: Prevention Program In Favor of Resilient Self"|"The program In Favor of Resilient Self delivered to adolescence aged 15-17, over 3 months. The program contained nine weekly 90-min sessions that focus on enhancing self- resilience, self-esteem, self-image, body image. All participants will complete a self-report questionnaire at baseline, conclusion and 3 months after program conclusion."
2904729|NCT03216018|No Intervention|No Intervention: control group|The control group didn't receive the intervention program, instead they received a lesson on healthy nutrition. The control group will complete the same self-report questionnaire as the intervention group at baseline, conclusion and 3 months after program conclusion.
2904730|NCT03216005|Experimental|BlueLeaf System|The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.
2904731|NCT03215992|Other|Men diagnosed with prostate cancer|This group will include men over the age of 18 suspected of having prostate cancer who will undergo an ultrasound guided transrectal prostate biopsy. Each study participant will undergo a standard prostate biopsy and DOT imaging using the Diffuse Optical Tomography (DOT) System will be performed at the same time.
2904732|NCT03215992|Other|Men without prostate cancer|This group will include men who do not have prostate cancer. Each study participant will undergo a standard prostate biopsy and DOT imaging using the Diffuse Optical Tomography (DOT) System will be performed at the same time.
2904733|NCT03215979|Experimental|PEP-Arm|In this arm, surgeon will be applying platelet enriched plasma(PEP) (5 ml) during the second stage procedure of auricular reconstruction. PEP will be infected in the temporal fascia used to cover the cartilage frame.
2904734|NCT03215979|Placebo Comparator|Placebo-Arm|This arm will be used as control. The surgeon will inject 0.9% saline solution (5ml) in a blinded basis.
2904735|NCT03215966|Experimental|Sequence A/B|Subjects receive one tablet of macitentan / tadalafil FDC (fixed dose combination) during Period 1, then after a washout period of at least 7 days they receive one tablet of macitentan (Opsumit®) and two tablets of tadalafil (Adcirca®) during Period 2
2904803|NCT03215511|Experimental|LOXO-195|Phase 1- Dose Escalation and determination of MTD; Multiple dose levels of LOXO-195 to be evaluated Phase 2 - Treatment with LOXO-195 at the recommended dose from Phase 1 identified for further study
2904736|NCT03215966|Experimental|Sequence B/A|Subjects receive one tablet of macitentan (Opsumit®) and two tablets of tadalafil (Adcirca®) during Period 1, then after a washout period of at least 7 days, they receive one tablet of macitentan / tadalafil FDC (fixed dose combination) during Period 2
2904737|NCT03215953|Active Comparator|Group A|cast shoe plus standard wound care
2904738|NCT03215953|Active Comparator|Group B|forefoot offloading shoe plus standard wound care
2904739|NCT03215940|Active Comparator|Delta-9-Tetrahydrocannabinol's (Delta-9-THC) effects on pain|This arm will be testing the analgesic effects of orally dosed Delta-9-Tetrahydrocannabinol on subjects with chronic non-cancer pain.
2904740|NCT03215940|Active Comparator|Cannabidiol's (CBD) effects on pain|This arm will be testing the analgesic effects of orally dosed Cannabidiol on subjects with chronic non-cancer pain.
2904741|NCT03215940|Placebo Comparator|Placebo|This Placebo arm will act as the control as standard of care medications will be continued through the study. This arm will allow us to compare the analgesic effects of the other two arms with the standard of care treatments for chronic non-cancer pain.
2904742|NCT03215927|Placebo Comparator|Placebo|Subcutaneous placebo injection weekly for 24 weeks.
2904743|NCT03215927|Experimental|Abatacept|Subcutaneous injection of abatacept 125 mg weekly for 24 weeks. 24 week optional follow up phase all subjects receive abatacept 125 mg weekly.
2904744|NCT03215914|Experimental|Subjects with type 1 diabetes using MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels < 70 mg/dl.
2904745|NCT03215901|Experimental|A Beautiful Future Video|Participants randomized to intervention will view intervention video.
2904746|NCT03215901|Sham Comparator|Active Control Video|Participants randomized to control will watch a video of similar length as the intervention video on a different topic.
2904747|NCT03215901|No Intervention|Pure Control|Participants view no video.
2904748|NCT03215888||Obese|Obese individuals undergoing bariatric surgery
2904749|NCT03215888||controls|matched non-obese controls
2904750|NCT03215875|Experimental|Fed- 60mg ER Torsemide|Adult healthy subjects will be given standardized high-fat, high-calorie meal prior to dosing
2904751|NCT03215875|Experimental|Fasting- 60mg ER Torsemide|Adult healthy subjects will fast overnight (at least 10h) prior to dosing
2904752|NCT03215862|Active Comparator|Control|
2904753|NCT03215862|Experimental|Experimental|
2904754|NCT03215849|Sham Comparator|Routine Medical Therapy|Routine Medical Therapy
2904755|NCT03215849|Experimental|Routine Medical Therapy + LVP|Routine Medical Therapy + LVP
2904756|NCT03215849|Experimental|Routine Medical Therapy + BiVP|Routine Medical Therapy + BiVP
2904757|NCT03215836|Other|Obese (BMI ≥ 30) asthmatics without metabolic syndrome|
2904758|NCT03215836|Other|Obese asthmatics with metabolic syndrome|
2904759|NCT03215836|Other|Obese non-asthmatics|
2904760|NCT03215836|Other|d) Non - obese (lean > 18 <= 25, OW > 25 - <30) asthmatics|
2904761|NCT03215823||1. Easy endotracheal intubation|Easy endotracheal intubation
2904762|NCT03215823||2. Difficult endotracheal intubation|Difficult endotracheal intubation
2904763|NCT03215810|Experimental|TIL+ Nivolumab|Tumor-infiltrating Lymphocyte Therapy (TIL) + Nivolumab Treatment Plan: Tumor harvest, Tumor-infiltrating Lymphocytes growth, 4 cycles of nivolumab, cytoreductive chemotherapy with cyclophosphamide and fludarabine, TIL infusion, Interleukin-2 treatment.
2904764|NCT03215797|Active Comparator|phenylephrine and norepinephrine|Phenylephrine 100ug/ml and Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of perioperative hypotension.
2904765|NCT03215797|Other|Norepinephrine and phenylephrine|Phenylephrine 100ug/ml and Norepinephrine 5ug/ml IV infusion in postoperative time in case of hypotension
2904766|NCT03215784|Placebo Comparator|Eutrophy Control|Gelatin capsules a day, from 28ª week to 36ª week gestation.
2904767|NCT03215784|Experimental|Eutrophy+ Probiotic|Capsules gastro resistant containing 2.5 billions colony forming unit (UFC) Lactobacillus rhamnosus GG + 2.5 billions colony forming unit (UFC) Bifidobacterium bifidum a day, from 28ª week to 36ª week gestation
2904768|NCT03215784|Experimental|Obesity + Fish oil|DHA (100 mg) + EPA (137 mg) a day, from 13ª week gestation to 36ª week gestation
2904769|NCT03215784|Experimental|Obesity + Probiotic|2.5 billions colony forming unit (UFC) Lactobacillus rhamnosus GG + 2.5 billions colony forming unit (UFC) Bifidobacterium bifidum a day, from 28ª week to 36ª week gestation
2904770|NCT03215758|Active Comparator|QAW039|QAW039 once daily
2904771|NCT03215758|Placebo Comparator|Placebo|Placebo once daily
2904772|NCT03215745|Experimental|Delirium prevention program|Delirium prevention program involved a non-pharmacologic preventive interventions that will be focused in: Delirium prevention program includes individualized non-pharmacological interventions such as multisensory stimulation, cognitive stimulation, activate the functional and family involvement.
2904773|NCT03215745|No Intervention|Control group|Usual care
2904774|NCT03215719|Experimental|HPV-Positive Oropharyngeal Carcinoma (OPSCC)|Standard radiation therapy + cisplatinum
2904775|NCT03215706|Experimental|Module A|Chemotherapy/Biologics combined
2904776|NCT03215706|Active Comparator|Module B|Chemotherapy Combination
2904777|NCT03215693|Experimental|X-396 capsule|225mg once daily
2904778|NCT03215680||Tanzanian Women of Reproductive Age|Healthy women of reproductive age living in Tanzania in an area with hot and temperate climate
2904779|NCT03215680||South African Women of Reproductive Age|Healthy women of reproductive age living in South Africa in an area with hot and temperate climate
2904780|NCT03215667|Experimental|Device treatment|easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane
2904781|NCT03215654|Experimental|Sensitization Program (SP)|Include the concepts of mental health and mental disorder, healthy and risky behaviors of mental health, and use of health services. Duration 1 hour.
2904804|NCT03215498|Experimental|Faster aspart followed by insulin aspart|Each participant will have 2 dosing visits (faster aspart and insulin aspart), the order decided by lottery
2904782|NCT03215654|Experimental|Mental Health Literacy Program (MHL)|MHL module contents are: 1) Our emotions. Definitions of mental health and mental disorders. Mental health multidisciplinary team network; 2) Healthy and risky behaviors of mental health; 3) Social skills and antisocial behavior, bullying and cyberbullying; 4) Anxiety, depression, self-harm, and suicidal behaviors; 5) Eating and behavioral disorders; 6) Substance abuse (alcohol and cannabis), an psychotic disorder. Duration 6 hours.
2904783|NCT03215654|Experimental|MHL more Stigma Reduction (ER)|Includes the six teaching units of MHL and a first contact presentation with lived experience of any mental disorder, who will be delivered by a voluntary member of Activament Catalunya Associació (http://www.activament.org/es), a non-profit group specialized in reducing stigma. Duration 7 hours.
2904784|NCT03215654|No Intervention|Control group|Control group will be a waiting list condition and they will receive the full program of 7h at the next year of academic course
2904785|NCT03215641|No Intervention|Control|The control group families will participate in the standard Body Works weight loss program. They will fill out brief surveys regarding their physical activity on a weekly basis, but otherwise will receive the standard curriculum. they will receive weekly feedback based on their physical activity surveys.
2904786|NCT03215641|Experimental|Intervention|The intervention group families will be given fitbits on the first day of the Body Works program. They will otherwise receive the same curriculum as the control families. the will fill out the same physical activity surveys as the control families. they will receive weekly feedback based on the objectively measured physical activity.
2904787|NCT03215628|Active Comparator|Group A - TCEUS with HLM|General neonatal cardiac surgery with HLM (art. switch, aortopulmonary shunts)
2904788|NCT03215628|Experimental|Group B - TCEUS with HLM|Surgery of the aortic arc
2904789|NCT03215628|Active Comparator|Group C - TCEUS without HLM|Neonatal cardiac surgery without HLM
2904790|NCT03215615|Active Comparator|Group NF + TE|Nanofilled Composite - Filtek Z350 XT® - 3M ESPE (NF) + Total Etch adhesive - Adper Single Bond 2® - 3M ESPE (TE) adhesive: combined lesions will be treated with partial restoration with nanofilled resin composite and total-etch adhesive system (two step). Subsequently, periodontal surgery will be performed for root coverage.
2904791|NCT03215615|Active Comparator|Group NF + UA|Nanofilled Composite - Filtek Z350 XT® - 3M ESPE (NF) + Universal Adhesive - Single Bond Universal® - 3M ESPE (UA): combined lesions will be treated with partial restoration with nanofilled resin composite and one-step self-etching adhesive system. Subsequently, periodontal surgery will be performed for root coverage.
2904792|NCT03215615|Active Comparator|Group MH + TE|Micro-Hybrid Composite - Charisma Classic® - Heraeus Kulzer (MH) + Total Etch adhesive - Adper Single Bond 2® - 3M ESPE (TE) adhesive: combined lesions will be treated with partial restoration with micro-hybrid resin composite and total-etch adhesive system (two step). Subsequently, periodontal surgery will be performed for root coverage.
2904793|NCT03215615|Active Comparator|Group MH + UA|Micro-Hybrid Composite - Charisma Classic® - Heraeus Kulzer (MH) + Universal Adhesive - Single Bond Universal® - 3M ESPE (UA): combined lesions will be treated with partial restoration with micro-hybrid resin composite and one-step self-etching adhesive system. Subsequently, periodontal surgery will be performed for root coverage.
2904794|NCT03215602|Experimental|NEMEX and education + strength training|"Participants will undergo 12 weeks of twice weekly exercise. Each exercise session will last for 70-90 min. and will consist of 1 hour of specific exercises to optimize sensorimotor control and achieve compensatory functional stability performed in a multiple-joint weight-bearing specific manner. The final part of the session will consist of focused knee extensor strength training performed in gym machines (knee extension & leg-press) in a combination of low-load fatiguing exercises (knee-extension) followed by high-load exercises (leg-press).~Additionally, participants will receive 2 educational sessions, which include disease- and exercise specific counseling."
2904795|NCT03215602|Active Comparator|NEMEX and education|"Participants will undergo 12 weeks of twice weekly exercise. Each exercise session will last for approximately 60 min. and will consist of 1 hour of specific exercises to optimize sensorimotor control and achieve compensatory functional stability performed in a multiple-joint weight-bearing specific manner.~Additionally, participants will receive 2 educational sessions, which include disease- and exercise specific counseling."
2904796|NCT03215563||Carotid|Patients with carotid artery stenosis who either do not meet surgical criteria (< 50% by NASCET criteria for men, <70% for women), or meet criteria but do not undergo surgery (surgery declined or not offered) and are currently treated with OMT. This cohort will be recruited from the acute TIA clinics and Vascular Laboratory logbooks at Edinburgh Royal Infirmary and Western General Hospital.
2904797|NCT03215563||Non Carotid|Patients with an atherosclerotic disease in the aortic arch including origins of its major branches other than the internal carotid artery treated with OMT. Patients with a cardiac source of embolism will be excluded from the study. This group will be recruited from the acute TIA clinics and inpatients at Edinburgh Royal Infirmary and Western General Hospital.
2904798|NCT03215550||Carotid Endarterectomy|Patients who are scheduled to undergo carotid endarterectomy for symptomatic carotid artery stenosis (≥50% by NASCET criteria for men, ≥70% for women) who are above 40 years of age.
2904799|NCT03215537|No Intervention|observation|No Intervention
2904800|NCT03215537|Active Comparator|comprehensive intervention|preoperative: exercise counseling postoperative : symptoms counseling and pulmonary rehabilitation
2904801|NCT03215524|Experimental|ARM A|"Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide~Daratumumab, IV, at 16 mg/kg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle.~Cyclophosphamide, orally, at 400 mg on Days 1, 8, 15 of each 28-day cycle for 24 cycles.~Dexamethasone, orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration, 40 mg dexamethasone weekly.~Pomalidomide, orally, at 4 mg on Days 1- 21 of each 28-day cycle."
2904802|NCT03215524|Experimental|ARM B|"Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide~Daratumumab, IV, at 16 mg/kg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle.~Cyclophosphamide, orally, at 400 mg on Days 1, 8 and 15 of each 28-day cycle for 24 cycles.~Dexamethasone,orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration,40mg dexamethasone weekly.~Pomalidomide, orally, added at first progression at 4 mg on Days 1- 21 of each 28-day cycle."
2947801|NCT02919761|Experimental|Acthar|Acthar 1 mL (80 U) 2x/week
2904805|NCT03215498|Experimental|Insulin aspart followed by faster aspart|Each participant will have 2 dosing visits (faster aspart and insulin aspart), the order decided by lottery
2904806|NCT03215485|Experimental|Intervention Group|"All intervention youth participants will receive three components:~Nutrition lessons~Virtual World learning environment~Newsletters"
2904807|NCT03215485|Active Comparator|Comparison|"All comparison youth participants will only receive one component:~1) Newsletters"
2904808|NCT03215472|Experimental|DASH Cloud intervention|In group 1, participants will be instructed to input their dietary intake daily for three months using the Nutritionix app. A participant's data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send daily or weekly feedback text messages reflecting DASH adherence. The intervention components include tailored feedback texts, and behavioral skills training videos.
2904809|NCT03215472|Experimental|Dash Light|Group 2 participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
2904810|NCT03215459||Cardiopulmonary Exercise Test|A cardiopulmonary exercise bike test will be administered prior to palliative chemotherapy treatment.
2904811|NCT03215446|Active Comparator|propofol|
2904812|NCT03215446|Experimental|sevoflurane|
2904813|NCT03215420|Experimental|Certain or probable Meniere's disease|
2904814|NCT03215407|Experimental|Intra-articular Tocilizumab|Tocilizumab, solution, 80mg intra-articular.
2904815|NCT03215407|Active Comparator|Intra-articular Compound Betamethasone|Compound betamethasone, solution, 14mg intra-articular
2904816|NCT03215394|Experimental|Enhanced Social ABCs|Receive 4-week attention training program, followed by 12-week Social ABCs intervention. The stimuli include four gaze-contingent training tasks that will be presented on a laptop screen using custom MATLAB scripts. Each task will be presented until the infant becomes inattentive, at which point they will go to the next task or take a break. Training stimuli will be presented until toddlers become fidgety or distressed.
2904817|NCT03215394|Sham Comparator|Standard Social ABCs|Receive 4-week sham attention program, followed by 12-week Social ABCs intervention. Sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training intervention. Infants are exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (infant appropriate television clips and animations). Sham attention stimuli will be presented until toddlers become fidgety or distressed.
2904818|NCT03215394|Other|Treatment As Usual|A convenience sample of age-equivalent toddlers who meet clinical eligibility criteria but are otherwise unable or unwilling to participate in the interventions, will be used as a Treatment as Usual comparison group. The same assessments will be administered at parallel time points through an existing research study. Receive no attention training program and no Social ABCs.
2904819|NCT03215381|Other|[11C]AZD1390 Microdose|[11C]AZD1390 single dose not exceeding 10 ug by IV bolus
2904820|NCT03215355|Experimental|Participants receiving Primovist|Because this is a proof of concept study, only one arm will be considered which is the patients that receive the one time contrast injection prior to their first treatment. The intervention is that although this drug is approved, an off label dosing regiment is being used to improve a separate imaging modality than what it was approved for. Based on preliminary phantom experiments and toxicity results in the literature, four times the dose was deemed safe and required to use for CBCT.
2904821|NCT03215342|Experimental|pGMT|Pediatric Goal Management Training
2904822|NCT03215342|Experimental|pBHW|Pediatric Brain Health Workshop
2904823|NCT03215329||CPAP30|Alveolar recruitment maneuver with a continuous positive airway pressure (CPAP) at 30 cmH2O during 30 seconds
2904824|NCT03215329||PEEPsteps|Alveolar recruitment maneuver with a stepwise increase and decrease in positive end expiratory pressure from 5 to 20 cmH2O.
2904825|NCT03215303|Experimental|Continuous Positive Airway Pressure (CPAP)|Participants in the intervention group will use CPAP device, for a period of 40 minutes, with the following parameters: PEEP of 10cmH2O and FiO2 0.21.
2904826|NCT03215303|Placebo Comparator|CONTROL|Participants in the control group will use CPAP device, for a period of 40 minutes, with the following parameters: PEEP of 1cmH2O and FiO2 0.21.
2904827|NCT03215290|Experimental|Trans-parenchymal compressing suture|"TCS: After liver transection, check for active hemorrhage and visible sites of bile leakage of cutting surface by stainless gauze which covered up on the raw cutting surface for 5 minutes. For patients with any positive findings including bloodstain and (or) bile staining, the cutting surface was recognized as not good cutting surface and further trans-parenchymal compressing sutured, if possible, using a hepatic needle."
2904828|NCT03215290|No Intervention|Exposed surface (ES)|147 Patients with exposed surface (ES) were matched as control group. No TCS.
2904829|NCT03215277|Experimental|Bimekizumab Arm|Subjects will receive several Bimekizumab applications on pre-defined time points. Placebo will be provided in this arm to mask the Certolizumab Pegol loading dose.
2904830|NCT03215277|Experimental|Certolizumab Pegol Arm|Subjects will receive several Certolizumab Pegol applications on pre-defined time points.
2904831|NCT03215264|Experimental|Single Arm|
2904832|NCT03215251|Experimental|EXPERIMENTAL GROUP|Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
2904833|NCT03215251|No Intervention|CONTROL GROUP|No Intervention administered. Thirst and Dry mouth scores were assessed only. Usual care was continued.
2904834|NCT03215238||neurosurgical patients|Neurosurgical patients undergoing craniotomies for tumor. 25 subjects
2904835|NCT03215238||Neurointerventional patients|Patients undergoing neurointerventional procedures under general anesthesia. 25 subjects
2904836|NCT03215225||Root canal treatment|
2904837|NCT03215212|Experimental|earplug|Ear plug made from polyurethane with (NRR= 29 db and SNR= 37 db) administered from 10 pm to 7 am.
2905133|NCT03212859|Experimental|Coach2Move Intervention Group|Coach2Move Intervention Group
2904838|NCT03215212|Experimental|eye mask|eye mask (18.5 cm, width 8.5cm, height -30mm )dark coloured cloth with 2 elasticised strap, covering both eyes administered from 10 pm to 7 am.
2904839|NCT03215212|Experimental|ocean sound|Ocean sound a type of white noise administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
2904840|NCT03215199|No Intervention|Usual Care Group|The Usual Care Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Supportive care will be offered or provided according to patients' wishes.
2904841|NCT03215199|Active Comparator|NAPT Group|The NAPT Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Patients will be given access to a web-based application that monitors depression, distress, and functional outcomes scores at regular intervals for 12 months. Patients will be able to alert the treatment team of decreased mood, increased distress, and functional issues impacting both. Patients will also be able to track their mood and distress levels throughout the 12 months and involve care-givers in monitoring as well.
2904842|NCT03215186||Cataract children|All children in this group were diagnosed as congenital cataracts. The four respects of following information of CC patients were collected and confirmed: 1) demography: including age, sex, and laterality; 2) family and pregnancy-labor histories: including family history, mothers' disease and medication histories during pregnancy, premature or term infant, cesarean or eutocia, and history of oxygen inspiration/infant incubator; 3) complicated systemic diseases; 4) living environment: including radiation/pollution exposure, parental smoking, parental education level, and family income.
2904843|NCT03215186||Healthy children|All children in this group were healthy and without cataracts. The four respects of following information of CC patients were collected and confirmed: 1) demography: including age, sex, and laterality; 2) family and pregnancy-labor histories: including family history, mothers' disease and medication histories during pregnancy, premature or term infant, cesarean or eutocia, and history of oxygen inspiration/infant incubator; 3) complicated systemic diseases; 4) living environment: including radiation/pollution exposure, parental smoking, parental education level, and family income.
2904844|NCT03215173|Experimental|Fit After Baby Group|Fit After Baby mobile health lifestyle intervention to increase postpartum weight loss, increase postpartum physical activity, and improve postpartum diet.
2904845|NCT03215173|Active Comparator|Text4Baby Control Group|Receive text messages from the free Text4Baby program.
2904846|NCT03215160|Experimental|Mobilization Exercise Group|Mobilization exercises in addition to classical exercises performed in the early post-op period
2904847|NCT03215160|Active Comparator|Classical Exercise Group|only classical exercises performed in the early post-op period
2904848|NCT03215134|Experimental|Self-criticism intervention|6 weekly face to face therapy sessions (1st assessment an intervention session of 60 to 90 minutes; sessions 2-5 are 60 minutes each) and a 2 month follow-up telephone call of upto 30 minutes.
2904849|NCT03215121|Active Comparator|One handed mask airway, switch to two hands|Induction of anesthesia started as follows while children are breathing spontaneously: One handed mask airway + chin lift - 20 sec and then switch to two hands + jaw thrust - 20 sec
2904850|NCT03215121|Active Comparator|Two handed mask airway + jaw thrust|Induction of anesthesia started as follows while children are breathing spontaneously: Two handed mask airway + jaw thrust - 40 sec
2904851|NCT03215121|Active Comparator|Two handed mask airway, switch to one hand|Induction of anesthesia started as follows while children are breathing spontaneously: Two handed mask airway + jaw thrust - 20 sec and then switch to one hand + chin lift - 20 sec
2904852|NCT03215108|Experimental|Flower-CSEMS|EGIS Flower Biliary Full Covered Stent(Flower-CSEMS), Bile Duct Stent, (S & G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
2904853|NCT03215108|Experimental|Conventional-CSEMS|Conventional-CSEMS (S & G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
2904854|NCT03215095|Experimental|Radioiodine (RAI) in Combination with Durvalumab (Medi4736)|Enrolled patients will be treated with durvalumab 1500 mg IV every 4 weeks. In Cycle 1/Week 3, Thyrogen 0.9 mg IM will be administered on two consecutive calendar days followed by 100 mCi (+/- 10 mCi) of RAI the next calendar day. Durvalumab will be continued every 4 weeks.
2904855|NCT03215082|Experimental|Experimental|The intervention will be an individualized impairment-based program based on a pre-determined sequence. A minimal intervention for all participants randomized to the intervention group at all sites will include general oculomotor and gaze stabilization retraining as tolerated. Intervention activities will be recorded and described in detail in a treatment log.
2904856|NCT03215082|Active Comparator|Control|Standard care for mild TBI consists mainly of general education, energy conservation, academic adaptations, and restricting children and adolescents from participation in vigorous physical activities as well as complex cognitive activities until complete symptom resolution. It is the usual approach promoted by various associations and consensus groups. In addition, in all participating centers, children and teens requiring musculoskeletal approaches to address neck pain/dysfunction will receive it as indicated, based on the clinical judgment of the local team. Participants with moderate and severe TBI will also receive rehabilitation activities as planned in their respective centers. The standard care intervention will be recorded and described in detail in a treatment log.
2904857|NCT03215069|Experimental|Empagliflozin|Empagliflozin 10 mg PO daily
2904858|NCT03215069|Placebo Comparator|Placebo|Matched placebo PO daily
2904859|NCT03215056|Experimental|PENTHROX® (methoxyflurane)|"PENTHROX® (methoxyflurane) administered as a liquid for inhalation and should be self-administered under supervision of research nurse trained in its administration, using the hand held PENTHROX® inhaler.~One vial of 3 mL PENTHROX® is to be vaporised in a PENTHROX® inhaler. On finishing the 3 mL dose, another 3 mL may be used.~Dose of PENTHROX® should not exceed 6 mL in a single administration.~The patient is instructed to inhale ten successive inhalations of PENTHROX® (methoxyflurane) followed by additional intermittent inhalations as required.~The maximum dose administered will not exceed 6 mL of methoxyflurane."
2904893|NCT03214783||No CAD group|Patients enrolled without coronary lesion stenosis ≥50% according to coronary computer tomography or coronary angiography will be assigned to CAD group.
2904894|NCT03214770|Experimental|Light-cured calcium silicate|This biomaterial calcium silicate is manufactured to have an anti-bacterial effect on micro-organisms within the dentin, thus allowing the inhibition of bacterial growth therefore no caries will progress. Material is injected and light-cured within the dentin and sealed with a restoration.
2904860|NCT03215056|Placebo Comparator|Normal saline|"Normal saline will be administered as a liquid for inhalation and should be self-administered under supervision of research nurse trained in its administration, using the hand held PENTHROX® inhaler.~One vial of 5 mL of normal saline is to be vaporised in a PENTHROX® inhaler. On finishing the 5 mL dose, another 5 mL may be used.~Dose of normal saline should not exceed 10 mL in a single administration.~In this study, the patient is instructed to inhale ten successive inhalations of placebo followed by additional intermittent inhalations as required.~The maximum dose administered will not exceed 10 mL of placebo (2 × 5 mL)"
2904861|NCT03215043|Experimental|Group A|Individuals will receive a dose of 140 mg / d eriocitrin for 12 weeks
2904862|NCT03215043|Experimental|Group B|Individuals will receive a dose of 280 mg / d eriocitrin for 12 weeks
2904863|NCT03215043|Experimental|Group C|Individuals will receive a dose of 560 mg / d eriocitrin for 12 weeks
2904864|NCT03215043|Placebo Comparator|Group D|Individuals will receive the placebo with corn starch excipient for 12 weeks
2904865|NCT03215030|Experimental|Phase 1: TAK-573 0.001 to 14 mg/kg|TAK-573 0.001 to 14 milligram per kilogram (mg/kg), infusion, intravenously, once on Days 1, 8, 15 and 22 of each 28-day treatment cycle up to 2 cycles, followed by once on Days 1 and 15 of each 28-day treatment cycle up to 4 cycles, followed by once on Day 1 of each 28-day treatment cycle up to 7 cycles or maximum of 14 cycles or until disease progression or unacceptable toxicity.
2904866|NCT03215030|Experimental|Phase 2: TAK-573 TBD|Dose for Phase 2 will be based on safety and tolerability results from the preceding Phase 1 dose escalation cohorts.
2904867|NCT03215017|Experimental|Transanal irrigation|Manual transanal irrigation to control bowel function.
2904868|NCT03215017|Active Comparator|Medication|Medication to control bowel function.
2904869|NCT03214965|Active Comparator|Facebook group|Patients of the kidney transplantation group randomly assigned to be part of a closed facebook group.
2904870|NCT03214965|No Intervention|Control group|Patients of the kidney transplantation group that do not receive specific educational interventions.
2904871|NCT03214952||Vonoprazan 20 mg|The usual adult dosage for oral use is 20 mg of Vonoprazan administered once daily. An 8-week treatment for gastric ulcer and a 6-week treatment for duodenal ulcer. For reflux esophagitis, the usual adult dosage for oral use is administered for a total of 4 weeks of treatment, and if that dosing proves insufficient, the administration may be extended, but for no longer than 8 weeks of treatment. Participants will receive interventions as part of routine medical care.
2904872|NCT03214939|Experimental|Immunotherapy based on dendritic cells|Intravenous administration dendritic cell and activated mononuclear cells at least 3 times 20-30 million cells / injection
2904873|NCT03214926|Experimental|Moving Through Glass intervention|Participants were asked to use Moving Through Glass (MTG) intervention on Google Glass for at least once a day for 3 weeks. MTG intervention includes 4 difference guided-dance/movement modules for the participants.
2904874|NCT03214913|Other|EGDT Group|Early Goal Directed Therapy ：30ml/kg in the first bolus to have a CVP（central venous pressure） 8-12 mmHg and MAP（mean artery pressure ） 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenaline，red blood cell transfusion if necessary.
2904875|NCT03214913|Other|Ruijin Group|"Ruijin Strategy therapy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.~target： fulfillment of two or more of four criteria:1. HR（heart rate） <120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT（hematocrit） 25%~35%."
2904876|NCT03214887|Experimental|RV-P1501-4|Gel-like product with 10 thousand BMMNCs in each ml of 1% hyaluronan (HA) solution
2904877|NCT03214887|Experimental|RV-P1501-5|Gel-like product with 100 thousand BMMNCs in each ml of 1% hyaluronan (HA) solution
2904878|NCT03214887|Experimental|RV-P1501-6|Gel-like product with 1 million BMMNCs in each ml of 1% hyaluronan (HA) solution
2904879|NCT03214874|Active Comparator|Demadex 20mg Tablet|Demadex (IR Torsemide) 20mg tablet once daily is the reference listed drug (RLD) and is marketed for decades to treat edema in Chronic Congestive Heart Failure (CHF) and Chronic Kidney Disease (CKD) patients
2904880|NCT03214874|Experimental|ER Torsemide 20mg Tablet|ER Torsemide 20mg tablet once daily is is the new formulation that will release the active ingredient over an extended period
2904881|NCT03214861||Nurses Health Study|The Nurses' Health Study (NHS) was initiated in 1976 as a prospective cohort study, where 121,701 female registered nurses between the ages of 30 and 55 years were recruited from 11 US states.
2904882|NCT03214861||Health Professionals Follow-Up Study|The Health Professionals Follow-up Study (HPFS) was initiated in 1986 and recruited 51,529 US men between the ages of 40-75.
2904883|NCT03214848|No Intervention|Standart of Care|Standard of care at the clinic is to discuss the abortion procedure without specific contraceptive counseling given prior to the day of abortion procedure.
2904884|NCT03214848|Experimental|Contraceptive education prior to abortion|Addition (to the standard or care) of a brief phone contraceptive education with optional financial counseling referral prior to abortion visit.
2904885|NCT03214835|Experimental|Brush biopsy for laryngeal lesion|Brush biopsy of the larynx - in addition to the standard biopsy
2904886|NCT03214835|Experimental|Brush biopsy for LPR|Brush biopsy of the larynx at the post cricoid region - in addition to the standard examination for LPR (PH monitoring double probe)
2904887|NCT03214822|No Intervention|HMF (standard of care)|"The HMF Control Group will receive the current standard feeding protocol of human milk fortified with bovine (cow) human milk fortifier (HMF)"
2904888|NCT03214822|Experimental|H2MF|"The H2MF Intervention Group will receive identical treatment with human-derived human milk fortifier (H2MF) replacing standard bovine HMF until the baby reaches an adjusted gestation age of 33 weeks; followed by a 5 day ween to standard HMF according to the manufacturer's recommendation."
2904889|NCT03214809|Experimental|Thoracic ultrasound protocol|ABCDE algorithm with Thoracic ultrasound protocol
2904890|NCT03214809|No Intervention|No Thoracic ultrasound protocol|ABCDE algorithm without Thoracic ultrasound protocol
2904891|NCT03214796||Albumin infusion|Patients with decompensated cirrhosis and an indication for routine human albumin infusion
2904892|NCT03214783||Coronary artery disease (CAD) group|Patients enrolled with at least one coronary lesion stenosis ≥50% according to coronary computer tomography or coronary angiography will be assigned to CAD group.
2904969|NCT03214250|Experimental|Gem/NP/nivolumab/APX005M|Gemcitabine+Nab-Paclitaxel+nivolumab+APX005M
2904895|NCT03214770|Active Comparator|Light-cured calcium hydroxide|This biomaterial calcium hydroxide is manufactured to have an anti-bacterial effect on micro-organisms within the dentin, thus allowing the inhibition of bacterial growth therefore no caries will progress. Material is injected and light-cured within the dentin and sealed with a restoration.
2904896|NCT03214757||group with dilated cardiomyopathy without anemia|
2904897|NCT03214757||group with dilated cardiomyopathy with anemia|
2904898|NCT03214731|Experimental|low dose Art|25mg bid Artesunate and standard of care was given to patients
2904899|NCT03214731|Experimental|high dose Art|50mg bid Artesunate and standard of care was given to patients
2904900|NCT03214731|Placebo Comparator|placebo|Placebo and standard of care was given to patients
2904901|NCT03214718|Experimental|CML patients treated with imatinib 400 mg/day|Measurement of the level of myeloid derived suppressor cells (MDSCs) by flowctytometry for each newly diagnosed chronic phase chronic myeloid leukemia (CML) patients treated with imatinib 400 mg/day before starting treatment and every 3 months till one year and correlate between it and level of BCR-ABL gene level and the sokal score of the patients and deep molecular response of the patients after one year .
2904902|NCT03214718|Active Comparator|CML patients treated with nilotinib 600 mg/day|Measurement of the level of myeloid derived suppressor cells (MDSCs) for each newly diagnosed chronic phase chronic myeloid leukemia ( CML) patients treated with nilotinib 600 mg/day before starting treatment and every 3 months till one year and correlate between it and level of BCR-ABL gene, the sokal score and deep molecular response of the patients after one year .
2904903|NCT03214705||Patients with poor outcome|Follow up of patients is done for 21 days by combined clinical and radiological examination. Poor clinical outcome is associated with vasospasm leading to permanent neurological deficit, stroke or death.
2904904|NCT03214705||Patients without poor outcome|Patients who do not develop delayed cerebral ischemia or stroke, confirmed by combined clinical and radiological examination.
2904905|NCT03214692|Experimental|Gum Arabic|The patients will receive 30 grams of Gum Arabic dissolved in 200 ml of water to ingest orally
2904906|NCT03214679|Experimental|Accessible Care|"Accessible Care for PWID is low-threshold care provided in the needle exchange programs, where they can comfortably access services without fear of the shame or stigma that often attends them in mainstream institutions.It includes features such as an informal, nonjudgmental atmosphere, availability of walk-in appointments, and a harm reduction framework to help them identify and pursue their own personal health goals. Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program."
2904907|NCT03214679|Active Comparator|Usual Care|Usual care represents the current procedure after someone tests positive for HCV antibody on site at the syringe exchange program. An on site care coordinator (not provided by study) assists with insurance and linkage to HCV medical provider at sites throughout NYC through the NYC Dept of Health Check Hep C program.
2904908|NCT03214666|Experimental|161533 TriKE (Phase I: Dose Finding Component)|Patients receive a single course of 161533 TriKE at their assigned dose as 3 weekly treatment blocks. Each block consists of four consecutive 24 hour continuous infusions (over approximately 96 hours) of 161533 TriKE followed by a 72 hour break after Block #1 and #2. All treatment is given as an inpatient. The assigned dose will be calculated on a weight obtained within 5 days prior to or on day of the 1st dose. The dose is not be recalculated for subsequent treatment blocks.
2904909|NCT03214666|Experimental|161533 TriKE Only (Phase II: Extended Component)|The treatment schedule is identical to the dose finding component. The extended component uses a Simon's MiniMax two-stage design for continued enrollment using the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
2904910|NCT03214653|Active Comparator|Propofol|Those who received target-controlled infusion of propofol using Schinder technique effect mode with the administration of maintenance agent was adjusted by the depth of sedation using bispectral index monitor with target of 45-50.
2904911|NCT03214653|Active Comparator|Sevoflurane|Those who received sevoflurane 1,5-2% as maintenance agent of anesthesia.
2904912|NCT03214640|Active Comparator|Palpation|When the subject is ready for neuraxial procedure, the location for the epidural or spinal needle insertion will be identified by palpation using conventional landmarks (spinous process and iliac crest). Those in group P, the neuraxial block will be performed as in the usual method using the needle insertion site identified with palpation. After placement of neuraxial labor analgesia the usual standard dose of medication will be administered as in usual manner for patients regardless in this study or not.
2904913|NCT03214640|Experimental|Rivanna Accuro Ultrasound Device|When the subject is ready for neuraxial procedure, the location for the epidural or spinal needle insertion will be identified with Rivanna Accuro U/S device. For subjects in group R, the needle insertion site will be the site identified by the Rivanna Accuro U/S device. After placement of spinal anesthesia, the usual standard dose of medication will be administered as in usual manner for patients regardless in this study or not.
2904914|NCT03214627|Experimental|Anemia Control Model IV iron and ESA|"Anemia Control Model (ACM) algorithm to recommend monthly IV and ESA dose over a 6 month period~IV iron: given monthly as required - dosing recommendation by ACM over 6 a month period~Erythropoiesis-Stimulating Agent (ESA): given monthly as required - dosing recommendation by ACM over 6 a month period"
2904915|NCT03214614|Experimental|GLPG2451 multiple dose|Multiple doses of GLPG2451 oral suspension at up to 3 dose levels in ascending order
2904916|NCT03214614|Placebo Comparator|Placebo multiple dose|Multiple doses of Placebo oral suspension
2904917|NCT03214614|Experimental|GLPG2451/GLPG2222|Multiple doses of GLPG2451 oral suspension combined GLPG2222 oral suspension at up to 2 dose levels
2904918|NCT03214614|Placebo Comparator|Combined Placebo multiple dose|Multiple doses of Combined Placebo oral suspension
2904919|NCT03214601|Experimental|Relay Branch System|Subjects who receive the Relay Branch System for repair which includes those with aneurysmal disease, penetrating atherosclerotic ulcer (PAU), and chronic uncomplicated Type B aortic dissection.
2904920|NCT03214588|Experimental|TAK-831 High Dose|TAK-831 300 mg, tablets, orally, twice daily for up to 12 weeks.
2904921|NCT03214588|Experimental|TAK-831 Low Dose|TAK-831 75 mg, tablets, orally, twice daily for up to 12 weeks.
2904922|NCT03214588|Placebo Comparator|Placebo|TAK-831 placebo-matching tablets, orally, twice daily for up to 12 weeks.
2947802|NCT02919761|Placebo Comparator|Placebo|Placebo 1 mL
2904923|NCT03214575|Active Comparator|Conventional method|For the Conventional method of ultrasound guided central venous catheter insertion,we use the ultrasound machine, eZono 4000 and linear array transducer L3-12NGS (3-12 MHz)
2904924|NCT03214575|Experimental|GPS method|For the GPS method, we use the ultrasound machine, eZono 4000 with built-in adaptive needle recognition software called eZGuide (eZono, Jena, Germany) and linear array transducer L3-12NGS (3-12 MHz).
2904925|NCT03214562|Experimental|Venetoclax + FLAG-IDA (Induction)|"Fludarabine by vein daily on days 2, 3, 4, 5, 6. Cytarabine by vein on days 2, 3, 4, 5, 6. Idarubicin by vein on days 4 and 5. Filgrastim given subcutaneously daily on days 1, 2, 3, 4, 5, 6, 7. Alternatively, a single injection of Pegylated Filgrastim can be administered subcutaneously after day 5 to replace remaining injections of Filgrastim.~For patients not in remission after the first induction therapy cycle, a second re-induction can be administered using the same dosing as induction.~Venetoclax starting dose of 100 mg by mouth on day 1, 200 mg on day 2, and 400 mg on day 3-14 of the first day cycle. At dose level -1, venetoclax administered at a dose of 100 mg on day 1, and 200 mg on day 2-14 of the first cycle.~Phase Ib: The dose escalation portion (Part 1) includes a 3+3 design starting at dose level -1, with standard FLAG-IDA and Venetoclax at 200 mg orally daily.~Study cycles are 28 days."
2904926|NCT03214562|Experimental|Venetoclax + FLAG-IDA (Expansion) - Naive AML|"Fludarabine by vein daily on days 2, 3, 4, 5, 6. Cytarabine by vein over about 4 hours on Days 2-4 of each cycle. Idarubicin by vein on days 4 and 5. Filgrastim given subcutaneously daily on days 1, 2, 3, 4, 5, 6, 7. Alternatively, a single injection of Pegylated Filgrastim can be administered subcutaneously after day 5 to replace remaining injections of Filgrastim.~Venetoclax starting dose is MTD from Induction Phase taken by mouth Days 1-14 of each cycle during the consolidation phase."
2904927|NCT03214562|Experimental|Venetoclax + FLAG-IDA (Expansion) - Relapsed/Refractory AML|"Fludarabine by vein daily on days 2, 3, 4, 5, 6. Cytarabine by vein over about 4 hours on Days 2-4 of each cycle. Idarubicin by vein on days 4 and 5. Filgrastim given subcutaneously daily on days 1, 2, 3, 4, 5, 6, 7. Alternatively, a single injection of Pegylated Filgrastim can be administered subcutaneously after day 5 to replace remaining injections of Filgrastim.~Venetoclax starting dose is MTD from Induction Phase taken by mouth Days 1-14 of each cycle during the consolidation phase."
2904928|NCT03214562|Experimental|Venetoclax + FLAG-IDA (Maintenance)|Venetoclax monotherapy maintenance at MTD continues for a period of one year after completion of induction/consolidation therapy, for those patients who do not proceed to stem cell transplantation.
2904929|NCT03214549|Active Comparator|gull wing preparation veneers|intervention: gull wing preparation in laminates veneers proximal margin of the preparation is placed toward the lingual .The area of the proximal margin between the contact area and the gingival papilla is placed even further to the lingual. This preparation design helps to hide the margin when the restorations are viewed from an angle.
2904930|NCT03214549|Active Comparator|conventional preparation veneers|intervention: conventional preparation in laminates veneers preparation of veneers without lingual extension of preparation in mesial and distal areas
2904931|NCT03214536|Experimental|erector spinae block|bilateral erector spine block with 20 ml 0,375% ropivacaine
2904932|NCT03214523|Experimental|Sleep Education|The intervention will be a brief education of the importance of sleep and healthy sleep habits. Subjects will also receive a standard sleep brochure on healthy sleep (which will also be given to the other arm).
2904933|NCT03214523|No Intervention|Sleep Brochure|Subjects will receive a one page hand out on healthy sleep habits.
2904934|NCT03214510|Experimental|Transversus Abdominus Plane Block|"Participants have a post-induction, pre-incision ultrasound-guided, four-quadrant plain bupivacaine and liposomal bupivacaine TAP block placed by the anesthesia team.~Participants asked to rate level of pain every hour when first out of surgery. When participant moved room (overnight recovery or surgical floor), it will happen about every 4 hours.~Questionnaires completed before surgery, every other day after surgery (Day 1 through Day 6), every other week for 6 weeks, monthly for 4 months, at then at Month 6."
2904935|NCT03214510|Experimental|Epidural Pain Management|"After induction of anesthesia, participant's epidural initially dosed according to current practices with hydromorphone (10 mcg/kg for patients 65 yrs or younger and 5 mcg/kg for patients > 65yrs). Bupivacaine (0.075%) at 10 ml/hr continuous infusion and a 3 ml every 10 minutes demand dosing, and a 5 ml every 3 hours clinician bolus as needed for additional pain control.~Participants asked to rate level of pain every hour when first out of surgery. When participant moved room (overnight recovery or surgical floor), it will happen about every 4 hours.~Questionnaires completed before surgery, every other day after surgery (Day 1 through Day 6), every other week for 6 weeks, monthly for 4 months, at then at Month 6."
2904936|NCT03214497|Active Comparator|Protector group|All patients collocated randomly to the Protector Group Primary and secondary outcome Parameters are studied
2904937|NCT03214497|Placebo Comparator|Supreme group|All patients collocated randomly to the Supreme Group, Primary and secondary outcome Parameters are studied
2904938|NCT03214484|Active Comparator|electronc tablet|"On ET or Computer, the AV is measured at a closer distance (40 cm and 80 cm, respectively). At this closer distance (ie near and near vision), the eccentric fixation is much more Difficult to perform, unnatural, often requiring learning in the context of low vision rehabilitation.~Our aim is to compare the evolution curves of the Visual Acuity (AV) measured in each patient on Electronic Tablet (TE)/ computer(O) and on the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, in order to check the reliability of the measurements performed by TE / O by comparing them with a well-known reference measure And is routinely practiced routinely in ophthalmology centers."
2904939|NCT03214484|Active Comparator|computer|"On ET or Computer, the AV is measured at a closer distance (40 cm and 80 cm, respectively). At this closer distance (ie near and near vision), the eccentric fixation is much more Difficult to perform, unnatural, often requiring learning in the context of low vision rehabilitation.~Our aim is to compare the evolution curves of the Visual Acuity (AV) measured in each patient on Electronic Tablet (TE)/ computer(O) and on the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, in order to check the reliability of the measurements performed by TE / O by comparing them with a well-known reference measure And is routinely practiced routinely in ophthalmology centers."
2904940|NCT03214471|No Intervention|Usual Care|usual care provided by the NHS for patients undergoing bariatric surgery.
2904941|NCT03214471|Experimental|Intervention|usual care + BARI-LIFESTYLE intervention
2904999|NCT03213951||High grade prostate cancer|Gleason grade group 3-5 on prostate biopsy or prostate cancer recurrence. Grade group scoring: 3 = Gleason 4+3, 4 = 4 + 4 or 4 + 5 or 5 + 4, 5 = 5+5.
2904942|NCT03214458|Other|Nasal high flow with oxygen|During HFNC-oxygen, oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep Arterial oxygen saturation (SaO2) > 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience.
2904943|NCT03214445|Experimental|resin composite with nanofiller.|30 restorations of resin composite occlusal, molars or premolars, with values of 3 or 4 for the parameter marginal adaptation according to the FDI criteria randomized assigned in this group
2904944|NCT03214445|Active Comparator|sealant based on resin|30 restorations of resin composite occlusal, molars or premolars, with values of 3 or 4 for the parameter marginal adaptation according to the FDI criteria randomized assigned in this group
2904945|NCT03214445|No Intervention|Control|The restorations were evaluated without treatment about defective restoration that was considered clinically acceptable.
2904946|NCT03214432||mild traumatic brain injury cohort|Patients with mild traumatic brain injury were defined as hospital admitted, emergency or outpatient treated, who were assigned the ICD-10 code for concussion (ICD-10 S06.0) in the national patient register at hospital discharge from the 1st of January 2003 - 31st of December 2007. Patients were working age adults between 18-60 years old and gainfully occupied or deemed available for work the week before the injury.
2904947|NCT03214432||non-injured control group|Controls were randomly selected from the Population register who were between 18-60 years old, had no diagnosis of mild traumatic brain injury during the period 1st of January 2003 - 31st of December 2007 and were gainfully occupied or deemed available for work the week preceding the time of injury. One control was matched for each mTBI case on gender, municipality and age (year of birth +/- 0,5 years). In case of no matching control the age criterion was expanded to (year of birth +/- 1 year), if still no matching control the age criterion was further expanded to (year of birth +/- 2 year). Additionally, controls were excluded according to the same criteria as the included cases.
2904948|NCT03214406|Experimental|Arm & Hammer Advance White Brilliant Sparkle (Test product)|2X daily brushing for 12 weeks with Arm & Hammer Advance White Brilliant Sparkle (Test product)
2904949|NCT03214406|Active Comparator|Crest Cavity Protection Regular Toothpaste (Negative Control)|2X daily brushing for 12 weeks with Crest Cavity Protection Regular Toothpaste (Negative Control)
2904950|NCT03214393||Pre-Eclampsia|pregnant women with Pre-Eclampsia will be assessed by serum antibodies and Doppler
2904951|NCT03214380|Experimental|LY900014|LY900014 given subcutaneously (SC) with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily.
2904952|NCT03214380|Active Comparator|Insulin Lispro|Insulin lispro given SC with each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily.
2904953|NCT03214367|Experimental|LY900014|LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily.
2904954|NCT03214367|Active Comparator|Insulin Lispro|Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily.
2904955|NCT03214367|Experimental|LY900014 Open Label|LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily.
2904956|NCT03214354|Experimental|Non-myeloablative conditioning|Non-myeloablative conditioning
2904957|NCT03214328||Determination of causes of fetal death|Both the extensive and selective protocols will be applied to each case of IUFD recruited, so that each case will serve as its own control. For each case, determination of cause from either protocol will be performed in a blind manner with respect to the other protocol.
2904958|NCT03214315||Prostatectomy|Visceral adipose tissue specimen sample
2904959|NCT03214302|No Intervention|control group|In this group, pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml don not use any antiviral drugs during pregnancy.healthy Pregnant women with HBsAg(-), HBeAg(-)
2904960|NCT03214302|Experimental|experimental group|pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml start to use Tenofovir Disoproxil Fumarate(TDF) antiviral treatment from the 32 weeks of gestation and drug withdrawal after delivery immediately, and drug withdrawal in the 6 weeks after delivery.
2904961|NCT03214289|Experimental|Fecal Microbiota Transplantation (FMT)|"Participants will receive a single dose of oral FMT, which is 15 capsules per day for 2 consecutive days (total of 30 capsules). All capsules administered to a participant are from the same unrelated donor. Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake. Participants will be asked to drink at least 360cc of water during administration.~Treatment will be administered on an inpatient basis. In patients with no/partial response, the FMT may be repeated from the same or a different donor.~Subjects receiving any amount of the FMT capsules will be followed for at least 6 months.Stool and blood samples will be serially collected."
2904962|NCT03214276|Active Comparator|Polyphenols|The preceding night and one hour before the endurance test, participants were asked to absorb two capsules of 250 mg of polyphenols (Vinitrox™)
2904963|NCT03214276|Placebo Comparator|placebo|The preceding night and one hour before the endurance test, participants were asked to absorb two capsules of placebo (similar appearance and flavour than active comparator).
2904964|NCT03214263||Cross-sectional samples:|Any patient followed in the DANBIO registry may be invited to participate when they meet for a scheduled routine clinical visit. These patients provide one cross-sectional blood sample.
2904965|NCT03214263||Longitudinal samples:|Any patient followed in the DANBIO registry will be invited to participate when they start treatment with a new DMARD. Switching from csDMARD to bDMARD, or from one bDMARD to another bDMARD indicates a new baseline.
2904966|NCT03214263||Samples of other biological material:|Patients followed in the DANBIO registry may be invited to participate if scheduled for one of the following procedures: joint puncture with extraction of synovial fluid, surgery or tissue sampling involving synovia, cartilage, bone, bone-marrow or other tissues. Representative samples from the synovial fluid or relevant tissue are collected after routine diagnostic or therapeutic analyses have been done
2904967|NCT03214250|Experimental|Gem/NP/nivolumab|Gemcitabine+Nab-Paclitaxel+nivolumab
2904968|NCT03214250|Experimental|Gem/NP/APX005M|Gemcitabine+Nab-Paclitaxel+APX005M
2904970|NCT03214237||Participants|Older adult inpatients on elderly care wards in acute hospitals within the Northumbria Hospitals NHS Foundation trust area, aged 70 or over and able to consent to involvement in the study
2904971|NCT03214224|Active Comparator|standard PFT|Those randomized to the control group will undergo standard pulmonary function testing as part of standard clinical procedure. In addition, they will complete monthly surveys pertaining to respiratory function.
2904972|NCT03214224|Experimental|remote PFT (rPFT)|Those randomized to the experimental group will undergo standard pulmonary function testing as part of standard clinical procedure. They will also undergo regular interim remote pulmonary function testing using the telemedicine interface and study equipment. In addition, they will complete monthly surveys pertaining to respiratory function.
2904973|NCT03214198||Vonoprazan 10 mg|The usual adult dosage is 10 mg of Vonoprazan administered orally once daily. Participants will receive interventions as part of routine medical care.
2904974|NCT03214185|Experimental|With PGS 2.0|Patients will undergo IVF/ICSI procedure, and experience oocyte aspiration, fertilization,blastocyst formation,conventional embryo morphology evaluation and trophectoderm biopsy before blastocyst cryopreservation. Preimplantation genetic screening (PGS) will be performed to select euploid embryo. The patients will go through up to three times of frozen-thawed transfers of euploid blastocysts until ongoing pregnancy or live birth is acquired. Only one euploid blastocyst will be transferred at a time.
2904975|NCT03214185|Active Comparator|Without PGS 2.0|Patients will undergo IVF/ICSI procedure, and experience oocyte aspiration, fertilization,blastocyst formation,and conventional embryo morphology evaluation before blastocyst cryopreservation. The patients will go through up to three times of frozen-thawed transfers of good quality blastocysts until ongoing pregnancy or live birth is acquired. Only one good quality blastocyst will be transferred at a time.
2904976|NCT03214172||Cancer-associated thrombosis|Adult patients with active cancer with at least one index venous thromboembolism (VTE) and no anticoagulation use during the 6-months (baseline period) prior to the index VTE event
2904977|NCT03214159|Experimental|group 1|"During the study session, healthy subjects will be administered a single dose of Ritonavir or Tablet 100mg or NORVIR tablet 100mg under fasting condition.~Intervention:~cylcle 1 Drug: Ritonavir tablet 100mg cylcle 2 Drug: NORVIR tablet 100mg cylcle 3 Drug: Ritonavir tablet 100mg cylcle 4 Drug: NORVIR tablet 100mg"
2904978|NCT03214159|Experimental|group 2|"During the study session, healthy subjects will be administered a single dose of Ritonavir or Tablet 100mg or NORVIR tablet 100mg under fasting condition.~Intervention:~cylcle 1 Drug: NORVIR tablet 100mg cylcle 2 Drug: Ritonavir tablet 100mg cylcle 3 Drug: NORVIR tablet 100mg cylcle 4 Drug: Ritonavir tablet 100mg"
2904979|NCT03214146|Experimental|HYNRCS-Allo inj.|"2 cycles of HYNRCS-Allo inj. with 6 months interval through intrathecal injection.~*1 cycle of HYNRCS-Allo inj. is 2 times administration with 28 days interval by intrathecal."
2904980|NCT03214133|Experimental|Epicatechin Dose Response|This arm will investigate varying doses of epicatchin on procollagen type I N-terminal propeptide (PINP) at varying doses CON, 1, 2, 3 mg/kg body mass.
2904981|NCT03214133|Placebo Comparator|Epicatechin-rich cocoa on performance|Athletes will ingest the optimized dose of epicatechin-rich cocoa vs placebo alongside maximum power training to determine if this nutritional intervention results in a greater increase in RFD and performance than maximum power training alone.
2904982|NCT03214107|Active Comparator|Full snack given before exercise|A snack containing ~0.5g of carbohydrates per kilogram of body weight will be given 5 minutes before exercise
2904983|NCT03214107|Active Comparator|Distributed snack over exercise period|A snack containing ~0.5g of carbohydrates per kilogram of body weight distributed this way will be given: ~40% given 5 minutes before exercise, ~30% after 20 minutes of exercise and the last ~30% after 40 minutes of exercise.
2904984|NCT03214094||Vonoprazan 10 mg|The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily. Participants will receive interventions as part of routine medical care.
2904985|NCT03214081||Vonoprazan 10 mg/20 mg|The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily; however, if the efficacy is inadequate, the dosage may be increased up to 20 mg once daily. Participants will receive interventions as part of routine medical care.
2904986|NCT03214042|Experimental|trial group|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years.
2904987|NCT03214029||Study population|Prospective, observational cohort study of consecutives patients (goal, 2000 patients over 5 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
2904988|NCT03214016|Experimental|Pilates method group|The participants will do Mat Pilates.
2904989|NCT03214016|Active Comparator|Aerobic training group|The participants will do aerobic exercise on treadmill.
2904990|NCT03214003|Experimental|SIB group|Patients in this group will receive concurrent twice-daily radiotherapy by SIB technique (95%PGTV 54Gy, 95%PTV 45Gy,both in 30 twice-daily fractions over 3 weeks, 5 days per week) and chemotherapy (etoposide and cisplatin).
2904991|NCT03214003|Active Comparator|BID group|Patients in this group will receive concurrent twice-daily standard radiotherapy (95%PTV 45Gy in 30 twice-daily fractions over 3 weeks, 5 days per week, without SIB) and chemotherapy (etoposide and cisplatin).
2904992|NCT03213990|Other|Continuous Infusion|The prescribed Beta-lactam is administered by a continuous infusion.
2904993|NCT03213990|Other|Intermittent infusion|the prescribed Beta-lactam is administered by intermittent infusion over 30 minutes
2904994|NCT03213977|Experimental|Arm I:R-DA-EPOCH|Protocol involves 8 cycles.
2904995|NCT03213977|Experimental|Arm II:R-DA-EPOCH + auto-HSCT|Protocol involves 6 cycles. Patients with complete remission or partial remission undergo auto-HSCT after 6 cycles.
2904996|NCT03213977|Active Comparator|Arm III:R-CEOP90|Protocol involves 8 cycles.
2904997|NCT03213977|Active Comparator|Arm IV:R-CEOP90 + auto-HSCT|Protocol involves 6 cycles. Patients with complete remission or partial remission undergo auto-HSCT after 6 cycles.
2904998|NCT03213964|Experimental|Arm 1|"FATE-NK100 is a donor-derived NK cell product comprising ex vivo activated effector cells with enhanced anti-tumor activity.~FATE-NK100 is administered to determine the maximum tolerated doze/maximum feasible dose (MTD/MFD).~Interleukin-2 (IL-2) remains the only FDA approved drug that is capable of promoting NK cells activation and survival.~Lymphodepletion with Cyclophosphamide and Fludarabine."
2905000|NCT03213938|Experimental|Acupuncture|The participants in the acupuncture group will receive treatment that consists of 20 acupuncture sessions over an 8-week (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks) period after baseline, each for 30 minutes. Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Sanyinjiao (SP6), Zhongliao (BL33), Shenshu (BL23), and Huiyang (BL35), were selected as acupoints protocol. SP6 is on the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus; BL32 is in the sacral region, in the second posterior sacral foramen; BL33 is in the third posterior sacral foramen; BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
2905001|NCT03213938|Sham Comparator|Sham acupuncture|The participants in the sham acupuncture group will receive shallow needling at bilateral sham BL23, BL33, BL35 and SP6. The protocol includes the same duration and frequency of sessions as for the acupuncture treatment, but the treatment was delivered superficially at non-acupuncture points 10-15 mm to the lateral of corresponding acupuncture and not above a meridian line (15mm to BL23, BL33 and BL35; 10mm to SP6). The Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be inserted with a depth of 2-3 mm without any manipulation.
2905002|NCT03213925|Experimental|RT|"After clinical response, breast magnetic resonance imaging (MRI) is performed and analyzed by two independent radiologists. Complete image response is defined by no enhanced tumor visible on any serial images.~Radiation therapy to the breast with or without regional nodal area is performed within 12 weeks after completion of chemotherapy with conventional dose (25x200cGy). Additional boost of 16 Gy in the primary involved tumor region."
2905003|NCT03213886|Experimental|Calcifediol (Vitamin D) loading-dose|Participants in the intervention group will receive calcifediol16.000 units (U) /day for five days
2905004|NCT03213886|Active Comparator|Calcifediol (Vitamin D) at clinical practice dose|Participants in the control group will receive 16.000 U / week for five weeks
2905005|NCT03213873|Experimental|HiBalance|The HiBalance program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in PD. The training will be conducted as a progressive individually adjusted group program in order to challenge the specific balance disorder of every participant and endorse progression. The intervention will be performed for an hour, 2 times/week in groups of six to eight participants for a total of 10 weeks and one home training session on their own.
2905006|NCT03213873|Active Comparator|Speech therapy|The control group will receive a group treatment (2 times/w for 10 w + 1 home training session) consisting of speech and communication therapy performed by a speech therapist. This intervention will be performed in a sitting position. The speech and communication treatment will aim at increasing vocal loudness and improving articulatory precision. Level of difficulty is gradually increased by progressing from using loud voice and clear speech in short and automatized utterances, to using the same technique in more complex sentences and situations. The group format is used to practice techniques in communicative situations and also to introduce increasing level of multitasking by combining speech training with cognitively more challenging tasks in the group training.
2905007|NCT03213860|Active Comparator|eye mask|
2905008|NCT03213860|No Intervention|Control|
2905009|NCT03213847|Other|Participants with carpal tunnel syndrome|Participants diagnosed with carpal tunnel syndrome; will be evaluated with Doppler ultrasound and superb microvascular imaging (SMI) ultrasound. The results of these two evaluations will be compared between each other in according to severity of carpal tunnel syndrome (severity will be determined by electromyography studies)
2905010|NCT03213834|Active Comparator|Thoracoscopy Arm|Consisting of chest thoracoscopy
2905011|NCT03213834|Active Comparator|Fibrinolytic Therapy Arm|Consisting of chest fibrinolytic therapy
2905012|NCT03213821|Experimental|high protein intake|Study participants will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg Ideal Body Weight)
2905013|NCT03213821|Active Comparator|GFR based protein intake|Study participants will receive GFR based protein diet to preserve renal function.
2905014|NCT03213808||respiratory allergies|respiratory allergies (asthma, rhinitis)
2905015|NCT03213808||skin allergies|skin allergies (dermatitis, urticarial, angioedema)
2905016|NCT03213808||anaphylaxis|anaphylaxis
2905017|NCT03213808||gastrointestinal allergic conditions|gastrointestinal allergic conditions
2905018|NCT03213808||ocular allergies|ocular allergies (conjunctivitis)
2905019|NCT03213782|Experimental|Experimental group|Nature based sounds are administered via head phones continuously for 20 minutes.
2905020|NCT03213782|No Intervention|Control group|Usual routine care was continued
2905021|NCT03213769|Active Comparator|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
2905022|NCT03213769|Placebo Comparator|carbapol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
2905023|NCT03213756|Experimental|Preoperative isometric exercise (PIE) group|In the PIE group, the patients will perform daily preoperative exercise protocol based on isometric exercises using hand grip and elastic bands. They will perform this protocol for at least six and ideally eight weeks before surgery.
2905024|NCT03213756|No Intervention|Control group|Control group patients will follow the usual surgical waiting list protocol (Estimated 1,5-2 months).
2905025|NCT03213743|Other|before dexmedetomidine|We took blood samples before the administration of dexmedetomidine to determine exression level of microRNA in the subjects.
2905026|NCT03213730|Experimental|Experimental group|Standard care + 3D-MOT protocol.
2905027|NCT03213730|Active Comparator|Active control group|Standard care + visual attention task (2048 online game)
2905028|NCT03213730|No Intervention|Control group|Standard care alone
2905029|NCT03213717|Experimental|Procedure 1|Wearing a weight vest with 10 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour. The reason for this is because it has been considered that the effect may be transmitted by weight loading of the lower extremities.
2905030|NCT03213717|Active Comparator|Procedure 2|Wearing a weight vest with 1 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour.
2905064|NCT03213431||IQ of <90 and ≥40|Patient-Reported Outcomes (PRO) will be evaluated in a group of 30 childhood cancer survivors with global neurocognitive impairment classified by IQ of <90 and ≥40 and 30 of their parents.
2905031|NCT03213717|Active Comparator|Procedure 3|Wearing a weight vest with 1 % of body weight sitting for seven hours. This is a control group without loading of the lower extremities. This is also the normal working position for many sedentary jobs (e.g. office workers) and why this is of special interest for further investigation. There is a large body of investigative literature showing the negative health consequences of the sitting working position.
2905032|NCT03213704|Experimental|Treatment (larotrectinib)|Patients receive larotrectinib PO or via nasogastric- or gastric-tube BID on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2905033|NCT03213691|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2905034|NCT03213678|Experimental|Treatment (PI3K/mTOR inhibitor LY3023414)|Patients receive PI3K/mTOR inhibitor LY3023414 PO BID on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unexpected toxicity.
2905035|NCT03213665|Experimental|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2905036|NCT03213652|Experimental|Treatment (ensartinib)|Patients receive ensartinib PO QD on days 1-28. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
2905037|NCT03213639|Experimental|study group|Patients will take esomeprazole single dose of 40 mg orally once a day
2905038|NCT03213639|Placebo Comparator|control group|Patients will take an inert tablet similar in appearance, color and consistency
2905039|NCT03213626|Experimental|Cabozantinib + erlotinib|
2905040|NCT03213613|Experimental|Adaptive Attention Training|The training group will engage in 15 hours of at-home training on a novel iPad-based adaptive attention training program ('Engage'). Individuals will complete thirty 30-minute sessions over six weeks. Training compliance and performance data (accuracies and reaction times) will be continuously monitored remotely and analyzed over secure online servers to ensure that participants are completing training as scheduled and to deal with any unexpected road-blocks in training.
2905041|NCT03213613|Placebo Comparator|Active Control|The active control group will engage in 15 hours of at-home training on an iPad game ('Boing'). Individuals will complete game play for the same number of hours as the training group to control for the effects of computer exposure and interaction, contact with research personnel, and monetary rewards. Compliance will be monitored similarly to the adaptive attention training group.
2905042|NCT03213613|Placebo Comparator|Low-dose Adaptive Attention Training|The low-dose training group will engage in 1 hour of at-home training on 'Engage'. Individuals will complete two 30-minute sessions at the beginning and middle of a six-week period. Compliance will be monitored similarly to the adaptive attention training group.
2905043|NCT03213600|Active Comparator|transcranial Direct Current Stimulation ( tDCS )|Intensity : 1,5mA Duration : 20 minutes stimulation over frontal (F3/F4) electrodes
2905044|NCT03213600|Sham Comparator|transcranial Direct Current Stimulation ( tDCS)|Intensity : 1,5mA Duration : 20 minutes stimulation over parietal(CP3 CP4) electrodes
2905045|NCT03213587|Experimental|apatinib|
2905046|NCT03213574|Active Comparator|Control Group|The control group will be administered intraoperative fluids throughout his or her surgery per the discretion of the anesthesiologist as is typical for this type of case. They will use an arterial line but without a FloTrac and therefore will have no data regarding the SVV.
2905047|NCT03213574|Experimental|Treatment Group|The treatment group will receive a FloTrac arterial line that will allow the anesthesiologist to administer intraoperative fluids based on the study algorithm.
2905048|NCT03213561|Experimental|Stable and Independent Communication Brain-computer Interfaces|Each arm will receive the same intervention.
2905049|NCT03213548|Experimental|Alar facial groove Incision|Alar Base surgical modification with surgical inions in the alar facial groove
2905050|NCT03213548|Active Comparator|Alar facial groove spared|Alar Base surgical modification with surgical incisions 1mm above the alar facial groove
2905051|NCT03213522|Active Comparator|Pelvic Floor Physical Therapy|PFPT group will be treated/educated with/on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
2905052|NCT03213522|Active Comparator|CranioSacral Therapy|Modified Upledger Institute 10-step protocol. Sequence of hand placements (for this protocol)/type of intervention which will mirror many of the treatment sequences described in the systematic review by Jakel and von Hauenschild (2012).
2905053|NCT03213509||Interview (Social and Verbal Autopsy)|The study involves administering verbal and social autopsies for BetterBirth Trial Participants who experienced a maternal, neonatal, or perinatal death.
2905054|NCT03213496|Experimental|Walk prescription|Walk prescription for all weeks before non-cardiac surgery. Duration of walk must be of 30-40 minutes every day for five days at the week or until complete 150 minutes at the week, for all weeks up to the surgery.
2905055|NCT03213496|Other|Conventional care|Currently patients do not receive exercise (walk)-prescription before non cardiac surgery.
2905056|NCT03213483|Active Comparator|Subepithelial connective tissue graft|Patients will receive a coronally advanced flap surgery with a subepithelial connective tissue graft for recession coverage.
2905057|NCT03213483|Experimental|De-epithelialized free gingival graft|Patients will receive a coronally advanced flap surgery with a de-epithelialized free gingival graft for recession coverage.
2905058|NCT03213470|Other|Intracranial artery dissection|Patients with intracranial artery dissection who were diagnosed at the symptom onset after Jan-01-2016
2905059|NCT03213457|Experimental|Elagolix + Estradiol/Norethindrone Acetate (E2/NETA)|Elagolix administered twice daily and Estradiol/Norethindrone Acetate (E2/NETA) administered once daily
2905060|NCT03213457|Experimental|Elagolix|It is administered twice daily.
2905061|NCT03213457|Placebo Comparator|Placebo|A matching placebo for Elagolix and E2/NETA are administered.
2905062|NCT03213444|Active Comparator|Quimioterapy 1|adjuvant chemotherapy with 5-FU isolated
2905063|NCT03213444|Active Comparator|Quimioterapy 2|adjuvant chemotherapy with 5-FU associated with oxaliplatin
2905065|NCT03213431||IQ of ≥90|Patient-Reported Outcomes (PRO) will be evaluated in a group of 10 childhood cancer survivors with global neurocognitive unimpairment classified by IQ of ≥90 and 10 of their parents.
2905066|NCT03213418|Experimental|Contingency management|
2905067|NCT03213405|Active Comparator|Conventional BCG full dose|Participants will receive one full dose of the Conventional BCG vaccine administered as an intradermal injection at study entry.
2905068|NCT03213405|Experimental|rBCG-N-hRSV 1/100 dose|Participants will receive one 1/100 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
2905069|NCT03213405|Experimental|rBCG-N-hRSV 1/10 dose|Participants will receive one 1/10 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
2905070|NCT03213405|Experimental|rBCG-N-hRSV full dose|Participants will receive one full dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
2905071|NCT03213392||SUPRA ORBITAL KEYHOLE CLIPPING/ COILING|Aneurysms should be either clipped or coiled to prevent re rupture general anesthesia is required to carry out these procedures.various anesthetic agents are used as an maintenance agents.
2905072|NCT03213379|No Intervention|Referent group|"The patient of the referent group will have 2 measures of actimetry:~A first one at baseline before the apomorphim set-up:the report will be provided to the investigator and a second one before the 6 months follow-up visit but this report will not be provided to the investigator."
2905073|NCT03213379|Experimental|Actimetry group|"The patient of the Actimetry group will have at least 4 measures of actimetry and the reports will be all provided to the investigator:~One at baseline before the apomorphim set-up/ the second one 8 days after the hospitalisation/ the third one 28 days after the hospitalisation and the last one before the 6 months follow-up visit One optional measure can be performed 84 days after the hospitalisation."
2905074|NCT03213366|Experimental|E-PrEP- Peer-Led Intervention about PrEP|8 Peer Leaders (PLs) will be randomly assigned to the E-PrEP arm. Each of the PLs will recruit at least 15 participants into a private social media group on one of several social media platforms. PLs will then deliver a behavioral intervention over a 6 week period, posting information and engaging participants in a discussion about PrEP, PrEP access, and other related health issues. All contents will be formatted to be both mobile device accessible.
2905075|NCT03213366|Active Comparator|BxNow - General Health Campaign|BxNow is an attention-matched control. Eight of the 16 PLs will be randomly assigned to the BxNow arm. The BxNow campaign will be a 6-week long social media intervention about general health wellness topics chosen and administered by the PLs assigned into this arm. Similarly to the intervention group, PLs in the BxNow arm will create private social media groups and recruit participants into these private groups. General health information in the BxNow arm will be posted with the same frequency as in the intervention arm.
2905076|NCT03213353|Experimental|Treatment sequence AB|"Treatment A (experimental): Two tablets of Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride~Treatment B (active comparator): One sachet Vicks Active SymptoMax Plus, powder for oral solution, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride"
2905077|NCT03213353|Experimental|Treatment sequence BA|"Treatment A (experimental): Two tablets of Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride~Treatment B (active comparator): One sachet Vicks Active SymptoMax Plus, powder for oral solution, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride"
2905078|NCT03213340|Experimental|Catechin Cohort 1|2 treatment - Experimental Catechin Blend; Control 1 Placebo
2905079|NCT03213340|Experimental|Curcuminoid Cohort 2|2 treatment - Experimental Curcuminoid Blend; Control 1 Placebo
2905080|NCT03213340|Experimental|Flavonoid Cohort 3|2 treatment - Experimental Flavonoid Blend; Control 2 Low-Flavonoid Blend
2905081|NCT03213327|Other|Case management|Case management program Utilization of the StayOk web application
2905082|NCT03213314|Experimental|Main cohort|Patients undergoing liver resection
2905083|NCT03213314|Experimental|Nested cohort PVE|Patients undergoing liver resection after portal vein embolisation
2905084|NCT03213314|Experimental|Nested cohort neoadjuvant chemotherapy|Patients undergoing liver resection after neoadjuvant chemotherapy
2905085|NCT03213314|Experimental|Nested cohort TACE|Patients undergoing trans arterial chemoembolisation for presumed hepatocellular carcinoma
2905086|NCT03213301|Experimental|Lurbinectedin|Lurbinectedin 3.2 mg/m2 i.v. every 3 weeks (one cycle) until progression, unacceptable toxicity or patient's withdrawal.
2905087|NCT03213288|Active Comparator|Delphinidin type anthocyanins|Bilberry extract
2905088|NCT03213288|Active Comparator|Cyanidin type anthocyanins|Black rice extract
2905089|NCT03213288|Placebo Comparator|Placebo|No anthocyanins
2905090|NCT03213262||General anesthesia|The effect of anxiety on the choice of anesthesia will be evaluated.
2905091|NCT03213262||spinal anesthesia|Cesarean patients with spinal anesthesia
2905092|NCT03213249|Active Comparator|Arm 1: Intraoperative pocket irrigation with NS|"1 gram cefazolin intravenous before surgical incision~Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists~Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling~Standard of care saline pocket irrigation will receive 500 cc of normal saline alone per pocket."
2905093|NCT03213249|Active Comparator|Arm 2: Intraoperative pocket irrigation with NS + antibiotics|"1 gram cefazolin intravenous before surgical incision~Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists~Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling~Standard of care antibiotic pocket irrigation will receive 500 cc of normal saline plus 1 gram cefazolin, 80 mg gentamicin, and 50,000 units bacitracin"
2905094|NCT03213236|Experimental|OSA Homemonitoring|Homemonitoring diagnostic system
2905095|NCT03213210|Other|Device treatment|easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane
2905096|NCT03213197|Experimental|CPR video|Patient watches a short CPR video
2905097|NCT03213171|No Intervention|Usual care|Usual care / Standard of care No intervention implemented
2905098|NCT03213171|Experimental|Intervention|Reception staff providing handout; Mobile tablet that provides the immediate opportunity for patients to register in the waiting room
2905101|NCT03213132|Experimental|SHUTi for older adults|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention optimized for older adults. They will spend 1-2 hours each week for 6-9 weeks completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention targeting issues specific to older adults. As users progress through the intervention, they will receive automated, tailored instructions for how to improve their sleep.
2905102|NCT03213132|Active Comparator|SHUTi for older adults with stepped care|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention optimized for older adults. This is the same intervention as the first arm but with the addition of personalized emails or phone calls to participants by study personnel at specific time points as a result of not completing assigned tasks.
2905103|NCT03213132|Placebo Comparator|Patient Education website|Participants will be assigned to a relevant patient education website. It will include information about insomnia symptoms, diagnosis, prognosis, and information about CBT strategies for the older adult. Unlike SHUTi, the content will not be tailored and will be presented all at once.
2905104|NCT03213119|Experimental|Caloric Vestibular Stimulation, Left-Warm|Caloric Vestibular Stimulation (CVS) stimulates the vestibular system through thermic currents applied through small quantity of water injected in the external ear. The Left-Warm condition uses water with a temperature of 44°. It induces a nystagmus with its slow phase towards the right.
2905105|NCT03213119|Experimental|Caloric Vestibular Stimulation, Left-Cold|Caloric Vestibular Stimulation (CVS) stimulates the vestibular system through thermic currents applied through small quantity of water injected in the external ear. The Left-Cold condition uses water with a temperature of 30°. It induces a nystagmus with its slow phase towards the left.
2905106|NCT03213119|Sham Comparator|Caloric Vestibular Stimulation, SHAM|The SHAM condition uses water with a temperature of 37°. It does not induce nystagmus
2905107|NCT03213106|Experimental|Transcranial Magnetic Stimulation (TMS) Stimulation|All patients will receive 5 sessions of active TMS stimulation.
2905108|NCT03213106|Sham Comparator|Sham Stimulation|All patients will receive 5 sessions of active TMS stimulation
2905109|NCT03213093|Other|Diabetic patients with a risk of diabetic foot ulcer|
2905110|NCT03213080||TLD Procedure|All subjects who are enrolled and meet the eligibility criteria will undergo Targeted Lung Denervation (TLD). TLD is a bronchoscopically-guided, minimally-invasive procedure using the Nuvaira™ Lung Devervation System. The Nuvaira System is intended for the long-term maintenance treatment of airway obstruction associated with COPD. TLD uses radiofrequency (RF) energy to ablate the airway nerve trunks of the vagus nerves that travel parallel to and outside of the main bronchi and into the lungs. Ablation of the nerves opens the airways and makes breathing easier.
2905111|NCT03213067||Mitochondrial Disease Patients|"Male and Females >18 years at the time of screening~Patients must have proven genetic disease (confirmed by assessment of heteroplasmy in blood and urine samples) of the m.3243 A>G mutation.~Capacity to provide informed consent taken before any study related activities.~Ability and willingness to adhere to the protocol, including all appointments.~Ability to read and converse in English."
2905112|NCT03213067||Healthy Control Group|"Male and Females >18 years at the time of screening~Capacity to provide informed consent taken before any study related activities.~Ability and willingness to adhere to the protocol, including all appointments.~Ability to read and converse in English."
2905113|NCT03213054|Experimental|OBP-301 + Radiation|OBP-301 administration on the Day 1, Day 18 and Day 32 with standard course of radiation(total 60 Gy) for 6 weeks.
2905114|NCT03213041|Experimental|Treatment (pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1 and carboplatin IV over 30-60 minutes on day 1 beginning with course 3. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
2905115|NCT03213028|Other|Full group|Our goal is to assess the feasibility and acceptability of incorporating family planning (FP) service delivery, using a program validated by the World Health Organization (WHO), into the established Cervical Cancer Prevention (CCP) programs of Botswana.
2905116|NCT03213015|Experimental|Experimental|Measurement of ankle dorsiflexion ROM (range of motion) with iHand app (smartphone)
2905117|NCT03213002|Experimental|Capecitabine amd Temozolomide|Oral Capecitabine at 1500 mg/m2 divided into twice daily dosing, taken on days 1-14, and Temozolomide at 150 mg/m2 - 200 mg/m2 divided into twice daily dosing, taken on days 10-14; days 15-28 off.
2905118|NCT03212989|Experimental|VOR + HXTC arm|"This is an open label single arm study. All eligible participants receive the following interventions:~Step 2 - Single dose of Vorinostat (VOR) 400 mg PO~Step 4 - Vorinostat (VOR) 400 mg PO every 72 hrs x 10 doses and 2 HXTC infusions~Step 5 - Vorinostat (VOR) 400 mg PO every 72 hrs x 10 doses and 2 HXTC infusions"
2905119|NCT03212976|Other|Study Phase 1|Patients with an intracranial pressure monitor will undergo phase contrast magnetic resonance imaging to measure their ICP.
2905120|NCT03212976|Other|Study Phase 2|Patients with shunts or CSF access devices such as Ommaya reservoir, etc will undergo phase contrast magnetic resonance imaging
2905121|NCT03212963|Experimental|Halobetasol lotion treatment arm|All subjects will receive Halobetasol Topical Lotion, 0.05%.
2905122|NCT03212950|Experimental|Fast-CL|Glucose control using DreaMed Glucositter and Fiasp® (Fast-CL)
2905123|NCT03212950|Active Comparator|Regular-CL|Glucose control using DreaMed Glucositter and regular insulin Aspart
2905124|NCT03212937|Experimental|Selinexor and ICE Chemotherapy|
2905125|NCT03212924|Experimental|Pupillometry|"Measure of pupil dilatation while listening to speech (monosyllabic words) in quiet and in noise.~Evaluation of speech comprehension in quiet~Evaluation of speech comprehension in noise~Measure of cognitive functions with the MOCA (Montreal Cognitive Assessment)~Auto evaluation of listening effort in quiet~Auto evaluation of listening effort in noise"
2905126|NCT03212911|Active Comparator|3-standard dose HBV vaccination group|participants will receive 3 standard doses of HBV vaccination at 0, 1, 6 months
2905127|NCT03212911|Active Comparator|4-standard dose HBV vaccination group|participants will receive 4 standard doses of HBV vaccination at 0, 1, 2, 6 months
2905128|NCT03212898|Experimental|Intervention|Specific pharmacist-led anticoagulation care
2905129|NCT03212898|No Intervention|Control|The control group will receive usual care; no interventions will be administered.
2905130|NCT03212885|Experimental|1|STN Monopolar Stimulation
2905131|NCT03212885|Experimental|2|rZI + STN stimulation
2905134|NCT03212859|Active Comparator|Usual Care|Usual care physiotherapy among older adults
2905135|NCT03212846|Experimental|Treatment group|Children will receive hippotherapy by a licensed physical therapist. Before riding, stretching and warming exercises of the adductor muscles will be performed. Later, the patient will be seated astride with the therapist behind. In any case, the participant had no control of the horse. Therapist will be responsible for correctly positioning the subject on the horse, but no position changes or active intervention of the subject with the therapist will be made. This positioning consists on achieving the optimal body alignment with neutral pelvis.
2905136|NCT03212846|No Intervention|Control group|Children will receive the conventional treatment, based on physiotherapy related techniques, such as neurodevelopmental treatment (twice a week).
2905137|NCT03212820|Experimental|Biologic drilling|drilling at low speed
2905138|NCT03212820|Active Comparator|conventional drilling|drilling at conventional or high speed
2905139|NCT03212807|Experimental|Investigational|Durvalumab + Lenalidomide
2905140|NCT03212794|Experimental|Experimental|Subjects randomized to the experimental arm will be assigned to a recovery coach.In addition to being linked to a community buprenorphine treatment program, the recovery coach will work to meet weekly with the subject following discharge from the hospital to provide support.
2905141|NCT03212794|No Intervention|Control|Subjects randomized to the control arm will receive treatment as usual. This means subjects are linked to ongoing outpatient treatment with buprenorphine.
2905142|NCT03212781|Experimental|intravenous iron|patients will receive intravenous iron as total dose infusion
2905143|NCT03212781|Active Comparator|oral iron|patients will receive oral iron
2905144|NCT03212755|Experimental|group 1|25 diabetic patients without diabetic nephropathy
2905145|NCT03212755|Experimental|group 2|25 type 2 diabetic patients with diabetic nephropathy
2905146|NCT03212755|Sham Comparator|group 3|25 healthy subjects
2905147|NCT03212742|Experimental|IMRT - Temozolomide - Olaparib|"The therapeutic regimen will be divided into 2 different periods:~Radiotherapy period The patient will start IMRT (60Gy/30fr/6 weeks), TMZ(Temozolomide) chemotherapy (75mg/m²/day), and olaparib on the same day, on a Monday (day 1), within 6 weeks after surgery. The daily dose of TMZ (75 mg/m²) will be continued until the end of radiotherapy (6 weeks) and olaparib will be continued with the same dose until 4 weeks after the end of IMRT, as a single agent.~Maintenance period TMZ will then be re-introduced 4 weeks after the end of IMRT at the dose of 150 mg/m2/day on days 1 to 5 every 28 days, for a total of 6 cycles. Concomitantly, olaparib will be daily given at the maintenance dose level up to confirmed disease progression or unacceptable toxicities.~We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously"
2905148|NCT03212729|Active Comparator|Control Group|CONVENTIONAL ENDODONTIC TREATMENT
2905149|NCT03212729|Experimental|Test Group|CONVENTIONAL ENDODONTIC TREATMENT ASSOCIATED WITH ANTIMICROBIAL PHOTODYNAMIC THERAPY
2905150|NCT03212716|Experimental|etilefrine|oseltamivir + etilefrine + placebo of diltiazem
2905151|NCT03212716|Experimental|diltiazem|oseltamivir + diltiazem + placebo of etilefrine
2905152|NCT03212716|Placebo Comparator|oseltamivir + double placebo|oseltamivir + placebo of etilefrine and placebo of diltiazem
2905153|NCT03212703|Active Comparator|Waitlist control (WLC)|Observation surveys over an 8-week period.
2905154|NCT03212703|Active Comparator|Mindfulness-Based Skills Training (MBST)|Attendance at weekly 1.5-hour group sessions and surveys over an 8-week period.
2905155|NCT03212690||Mechanically ventilated subjects|Subjects who are receiving invasive mechanical ventilation (Duration of ventilation <=24 hours) will be evaluated using standard care investigations.
2905156|NCT03212677|Active Comparator|Iron-deficient children|Previously iron-deficient children aged 6-24 months on iron therapy. Ferrous sulfate administered at 4 mg Fe/kg/d per standard of care.
2905157|NCT03212677|No Intervention|Non-iron-deficient children|Non-iron-deficient children aged 6-24 months used as a reference.
2905158|NCT03212677|Placebo Comparator|Adult Placebo|Iron-replete postmenopausal women, and men, receiving placebo daily for 4 weeks.
2905159|NCT03212677|Experimental|Adult Ferrous sulfate daily|Iron-replete postmenopausal women, and men, receiving ferrous sulfate daily (containing 60 mg Fe per day) for 4 weeks.
2905160|NCT03212677|Experimental|Adult ferrous sulfate weekly|Iron-replete postmenopausal women, and men, receiving ferrous sulfate weekly (containing 60 mg Fe per day) for 4 weeks.
2905161|NCT03212677|Experimental|Adult ferrous sulfate + micronutrient|Iron-replete postmenopausal women, and men, receiving ferrous sulfate + micronutrient supplement (containing 60 mg Fe per day) for 4 weeks.
2905162|NCT03212677|Experimental|Adult IHAT|Iron-replete postmenopausal women, and men, receiving IHAT (containing 60 mg Fe per day) for 4 weeks.
2905163|NCT03212677|Experimental|Adult Aspiron|Iron-replete postmenopausal women, and men, receiving Aspiron (containing 60 mg Fe per day) for 4 weeks.
2905164|NCT03212664|Other|Exercise|
2905165|NCT03212651|Experimental|Patients with MIBC (Muscle Invasive Bladder Cancer)|Cisplatinum-ineligible patients with muscle-invasive bladder cancer
2905166|NCT03212638|Experimental|Baricitinib T1 (Part A)|Baricitinib suspension administered orally without water when fasting.
2905167|NCT03212638|Experimental|Baricitinib T2 (Part A)|Baricitinib suspension administered orally with water when fasting.
2905168|NCT03212638|Experimental|Baricitinib R (Part A)|Baricitinib tablet administered orally with water when fasting.
2905169|NCT03212638|Experimental|Baricitinib TF Fasted (Part B)|Baricitinib suspension test formulation (TF) administered when fasting.
2905170|NCT03212638|Experimental|Baricitinib TF Fed (Part B)|Baricitinib suspension TF administered after a meal.
2905171|NCT03212625|Experimental|Urea cream 20%|144 patients spread urea cream (urea 20%)
2905172|NCT03212625|Placebo Comparator|Placebo|144 patients spread placebo cream (urea 0%)
2905173|NCT03212612||2 groups , control and cases|"Groupe 1: (cases) 45 women who were found to have surgically and histolopathologically -confirmed endometriosis. Endometrial samples(1-2 gram) will be taken by laparoscopy which is the gold standard for definitive diagnosis of endometriosis.~Group2:(control) 45women who were free of endometriosis. Endometrial samples(1-2 gram) will be taken by punch biopsy."
2905174|NCT03212586|Experimental|Dose escalation BAY1902607|Dose 1 to 9 of BAY1902607
2905175|NCT03212586|Placebo Comparator|Dose escalation Placebo|Dose 1 to 9 of matching placebo
2905176|NCT03212573|Experimental|ERAS protocol|ERAS protocol includes early oral intake (6 hours after surgery), early deambulation (6h after surgery) and multimodal analgesia (port-sites infiltration with Bupivacain 0.5% combined with postoperative intravenous analgesia)
2905177|NCT03212573|Active Comparator|Standard care|Oral intake and early deambulation begins 24h after surgery and analgesia consists in only intravenous drugs
2905178|NCT03212560||Newly diagnosed individuals|Newly diagnosed hematologic malignant patients included in the study. Inclusion and exclusion criteria were considered.
2905179|NCT03212560||Healthy individuals|Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
2905180|NCT03212547|Experimental|Experimental group|"Verbal interventions made on infants (accompanied by their mothers) who presents sustained social withdrawal detected on the child consultations (at 2, 6 and 12 months of corrected gestational age), made by neonatologists certifieds in the assess of Alarm Distress Baby Scale. Theintervention is described in a guide for Promotion of verbal interventions for interaction , and will be supplemented with a written guideline for parents."
2905181|NCT03212547|No Intervention|Control group|Control group: infants will assist at child consultations (at 2, 6 and 12 months of corrected gestational age) whit non trained neonatologists. However, these group will receive a development stimulation guide adapted of the ministerial guides for the stimulation of development of the Ministry of Health of Chile.
2905182|NCT03212534|Experimental|Prediction Algorithm|
2905183|NCT03212534|No Intervention|Control|
2905184|NCT03212521|Experimental|GLE/PIB|Glecaprevir (GLE)/pibrentasvir (PIB) (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
2905185|NCT03212495|Active Comparator|dexmedetomidine (D group)|intraarticular administration of dexmedetomidine at the end of surgery
2905186|NCT03212495|Active Comparator|neostigmine (N group)|intraarticular administration of neostigmine at the end of surgery.
2905187|NCT03212469|Experimental|Patients with head and neck squamous cell carcinoma|
2905188|NCT03212469|Experimental|Patients lung cancer|
2905189|NCT03212469|Experimental|Patients with oesophagus cancer|
2905190|NCT03212456|Experimental|Opioid-free|The patients of this group will receive opioid-free anesthesia
2905191|NCT03212456|Active Comparator|Non opioid-free|The patients in this group will receive the same induction and maintenance drugs of the experimental group but with fentanyl 3 - 5 mcg/kg on induction and during the procedure as needed.
2905192|NCT03212443|Sham Comparator|Group A|In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
2905193|NCT03212443|Active Comparator|Group B|In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
2905194|NCT03212417|Other|Interventional trial without phases-supportive care.|This is a feasibility pilot study project assessing the presence of compassion fatigue in clinical research nurses (cohort 1) and bone marrow transplant nurses (cohort 2). A survey will be completed by participants prior to and after an educational presentation. The intervention includes the risk factors, signs and symptoms, and interventions on compassion fatigue. The survey will be completed prior to the education, immediately following the education, one month following the education and two months following the education. A final survey will be implemented for the cohort 2 only. The objective of this concluding analysis is to gather data relative to CF and coping mechanisms.
2905195|NCT03212404|Experimental|CK-301|
2905196|NCT03212391|Experimental|Diet+Walking|52 weeks of Diet+26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking
2905197|NCT03212391|Experimental|Diet+Nordic Walking|52 weeks of Diet+26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
2905198|NCT03212378||CHIP 1 - low risk patients|
2905199|NCT03212378||CHIP 2 - medium risk patients|
2905200|NCT03212378||CHIP 3 - high risk patients|
2905201|NCT03212365|Other|Fixed Dose|Participants will receive 40 mg enoxaparin twice daily
2905202|NCT03212365|Experimental|Variable Dose|Participants will receive 0.5mg/kg enoxaparin twice daily
2905203|NCT03212352|Placebo Comparator|Misoprostol|Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive an oral placebo.
2905204|NCT03212352|Experimental|Misoprostol and Mifepristone|Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive oral mifepristone (600mg).
2905205|NCT03212339|Experimental|Mothers with children <3 years of age|Dyads of mothers with children up to 3 years of age will be attending modified Group Attachment Based Intervention (mGABI) sessions at the SPARK Center that will include a small group of other mother-child pairs and approximately two therapists. Dyads will be offered the 10 session therapeutic intervention.
2905206|NCT03212339|Experimental|Mothers with children 3-5 years of age|Dyads of mothers with children between the ages of 3 and 5 years will be attending Brief Dyadic Intervention (BDI) sessions at Child Witness to Violence and/or the SPARK Center with their child and an individual therapist. Dyads will be offered the 10 session therapeutic intervention.
2905207|NCT03212326|Experimental|Definity|Perflutren echo contrast is infused to enhance intracardiac echo imaging recorded during catheter ablation of ventricular tachycardia. We will compare areas that appear to be myocardial scar on ultrasound with areas of abnormal electrical signals obtained by direct catheter mapping.
2905208|NCT03212313|Active Comparator|Healthy Subjects|Study dose of 120 mg
2905209|NCT03212313|Experimental|Mild Hepatic Impairment|Study dose of 120 mg
2905210|NCT03212313|Experimental|Moderate Hepatic Impairment|Study dose of 120 mg
2905211|NCT03212313|Experimental|Severe Hepatic Impairment|Up to a maximum study dose of 120 mg
2905212|NCT03212300|Active Comparator|High Intensity Interval Training|patients will engage in 4 training sessions/week over a 4-week period, with 24-hour rest-periods after each training day. Each session begins with a 3 min, low intensity warm-up on a stationary cycle, then patients cycle as rapidly as they can for 20 sec, aiming to reach 85% of their maximum heart rate (HR) as established during cardiorespiratory fitness testing. This 20 sec period is followed by 40 sec of low intensity cycling. Patients complete 8 such intervals for sessions 1 and 2, 10 intervals for sessions 3 and 4, and 12 intervals thereafter
2905213|NCT03212300|No Intervention|treatment as usual|standard treatment
2905214|NCT03212274|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2905215|NCT03212261|Experimental|3RP-Lymphoma|-An adapted version of the 3RP (3RP-Lymphoma) for lymphoma survivors recently completing cancer treatment. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks.
2905216|NCT03212235|Experimental|Hypofractionated radiation therapy|"Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week.~After a 30-days break, adjuvant temozolomide days 1-5 every 28 days for 6 cycles."
2905217|NCT03212222|Experimental|Peek Acuity Screening|Cell phone application to be used for visual acuity screening.
2905218|NCT03212222|Active Comparator|Standard Visual Screening|Standard visual acuity screening administered at Duke University Eye Center regarded as the gold standard.
2905219|NCT03212209|Experimental|CPAP C- Flex-Plus by Philips Respironics|Four consecutive weeks with CPAP C- FLEX PLUS treatment. After these 4 weeks, patients will undergo full PSG with CPAP FLEX- PLUS. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
2905220|NCT03212209|Experimental|CPAP with Sensawake by Fisher and Paykel|Four consecutive weeks with CPAP Sensawake treatment. After these 4 weeks, patients will undergo full PSG with the same CPAP modality. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
2905221|NCT03212209|Active Comparator|CPAP fixed pressure|Four consecutive weeks with CPAP fixed pressure treatment. After these 4 weeks, patients will undergo full PSG with the same CPAP modality. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
2905222|NCT03212196|Active Comparator|Pancreaticogastrostomy|Pancreaticogastrostomy with external drain
2905223|NCT03212196|Active Comparator|Pancreaticojejunostomy|Pancreaticojejunostomy with transanastomotic drain
2905224|NCT03212183|Experimental|EPI-TAVIE|Patients assigned to this arm will be invited to complete a web-based nursing intervention called EPI-TAVIE.
2905225|NCT03212183|Other|Websites|Patients assigned to this arm will be invited to consult a validated list of predetermined conventional websites.
2905226|NCT03212170|Experimental|FFNP PET/MRI|18F-Fluorofuranylnorprogesterone (FFNP) administration for PET/MRI imaging to assess biopsy-proven primary PR+ breast malignancies.
2905227|NCT03212157|Experimental|GT1|Optimsation of glucose infusion protocol outside the Magnetic Resonance Imaging (MRI) scanner in healthy volunteers. To establish an optimised bolus and safety of infusion protocol of intravenous glucose to maximise exchange sensitive MRI signal.
2905228|NCT03212157|Experimental|GT2|Optimsation of glucose infusion protocol inside the Magnetic Resonance Imaging (MRI) scanner in patient volunteers. To assess the reproducibility of these techniques and initial proof-of-concept study in cancer patients
2905229|NCT03212157|Experimental|GT3|Use of glucoCEST technique in staging of head and neck SCC, lymphoma and gliomas and correlating diagnostic potential with standard imaging such as FDG PET. To apply exchange-sensitive MRI in selected cancer types to assess its diagnostic potential. To study of non-glucose endogenous exchange sensitive MRI signals in (a) Prostate Cancer and (b) high grade Glioma patients.
2905230|NCT03212144|Experimental|High Intensity Interval Training - Aerobic Exercise|Participants will engage in 4 training sessions per week over a 4-week period, with 24 hour rest-periods between each training day. Each session begins with a 3 min low intensity warm-up, and then participants exercise as rapidly as they can for 20 seconds, aiming to reach 85% of their maximum heart rate as established during the submaximal cardiopulmonary exercise testing. This 20 second period is followed by 40 seconds of low intensity exercise.
2905231|NCT03212144|Experimental|Peanut Consumption|Regular daily caloric intake of each subject will be estimated using data from 24hr recalls, the Miflin-St. Jeor equation, and stress/activity factors. Participants will consume dry roasted, unsalted peanuts equivalent to approximately 10% of daily energy intake twice a day (total=20% total daily energy intake), which will range from approximately 400kcal to 600 kcal, which corresponds to about 2.4 ounces to 3.6 ounces. Peanuts will replace protein and fat containing foods so that the daily caloric intake will not differ from participants' typical diet. To assess compliance, participants will be asked to bring back the empty, numbered peanut packets by the end of every week and will be given new packets weekly. Additionally, subjects will be informed that they will be randomly assessed weekly for compliance; they will be asked to provide details of when and where they consumed their packets the previous day. Research assistants will provide guidance on how to maintain compliance.
2905232|NCT03212131|Experimental|Normal hepatic function|Subjects with normal hepatic function
2905233|NCT03212131|Experimental|Mild hepatic impairment|Subjects with mild hepatic impairment
2905234|NCT03212131|Experimental|Moderate hepatic impairment|Subjects with moderate hepatic impairment
2905235|NCT03212118|Other|Treatment as usual|"Treatment as usual untouched. This is the standard The Norwegian Labour and Welfare Administration (NAV) procedure."
2905236|NCT03212118|Active Comparator|Two talks|Two standard talks (not including elements from motivational interviewing)
2905237|NCT03212118|Experimental|Motivational interviewing|Two standard talks with a motivational interviewing content.
2905238|NCT03212105|Active Comparator|60 Second Video|The mindfulness intervention is a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
2905239|NCT03212105|Other|Educational Pamphlet|The educational pamphlet contains information about pain and stress, which patients will be able to read within 60 seconds.
2905240|NCT03212092|Experimental|Multivitamin, mineral & n-3 FA|The daily supplementation of multivitamin- and mineral in 2 capsules and n-3 fatty acids in 2 softgel capsules.
2905309|NCT03211650|Active Comparator|hyaluronic acid|Intra-articular injections of hyaluronic acid
2905241|NCT03212092|Placebo Comparator|Placebo|The placebo consists of daily supplementation of 2 capsules with rice bran extract, hypromellose and 1.6 mg riboflavin. And 2 softgel capsules with a vegetable oil.
2905242|NCT03212079|No Intervention|Control|The participant will self motivate hi/herself to increase physical activities.
2905243|NCT03212079|Experimental|Mycoach Smart Text|The participant will receive personalized smart text messages to encourage him/her to increase physical activities
2905244|NCT03212079|Experimental|MyCoach via Amazon Alexa|The participant will interact with intelligent coach on Amazon Alexa (a digital voice assist) to help him/her become more active
2905245|NCT03212066|Experimental|Intervention|Master Mind is a 25-lesson elementary school, mindfulness education substance abuse prevention program for 4th and 5th grade classrooms.
2905246|NCT03212066|No Intervention|Wait-List Control|Business as usual
2905247|NCT03212053|Other|Patients with Essential Thrombocythemia|"patients who come in consultation at diagnosis or during the follow-up for an Essential Thrombocythemia.~They will have biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)"
2905248|NCT03212040|Active Comparator|14 gauge needle biopsy|breast biopsy will be performed with 14 gauge needle
2905249|NCT03212040|Active Comparator|16 gauge needle biopsy|breast biopsy will be performed with 16 gauge needle
2905250|NCT03212027||Patients with low-risk thymomas|low-risk thymomas include types A, AB, and B1 thymomas
2905251|NCT03212027||Patients with high-risk thymomas|high-risk thymomas include types B2 and B3 thymomas
2905252|NCT03212027||Patients with thymic carcinomas|thymic carcinomas also called types C thymomas
2905253|NCT03212014|Experimental|LSVT-BIG|Participants in this group would be treated with LSVT-BIG for three months
2905254|NCT03212014|Experimental|POWER|Participants in this group would be treated with POWER for three months
2905255|NCT03212014|Active Comparator|Traditional rehabilitation|Participants in this group would be treated with traditional exercise rehabilitation for three months
2905256|NCT03212001||Telehomecare patients (matched cohort study)|COPD and HF patients in Telehomecare program (followed up to 18 months)
2905257|NCT03212001||Usual-care patients (matched cohort study)|COPD and HF patients in 'usual care' (followed up to 18 months)
2905258|NCT03212001||Telehomecare patients (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess patient experience with Telehomecare program.~Surveys conducted up to four times using validated survey tools."
2905259|NCT03212001||Informal caregiver (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess caregiver experience with Telehomecare program.~Surveys conducted up to four times using validated survey tools."
2905260|NCT03212001||Healthcare providers (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess provider experience with Telehomecare program."
2905261|NCT03212001||Administrators and Decision Makers (observations, interviews)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess administrator/decision-maker experience with Telehomecare program."
2905262|NCT03212001||Technician (observation, interviews)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess technician experience with Telehomecare program."
2905263|NCT03211988|Other|Entinostat|Eligible patients will be enrolled according to Simon's two-stage design. The dose of Entinostat is 5 mg (one tablet) orally, once every week in a 28 day cycle.
2905264|NCT03211949|Experimental|axillary block with infiltration MCAN|With the performance of the axillary blok, 2 ml of scandicaine will be placed around the medial cutaneous ante brachial nerve (MACN)
2905265|NCT03211936|Active Comparator|PEEP 4|"We titrate peep, using tomography impedance, making ultrasound after level by level' of peep. After titrated peep we setup peep 4 and maintained during the procedure.~PEEP 4 cmH2O~Use ultrasound"
2905266|NCT03211936|Experimental|PEEP TITRATED|"We titrate peep, using tomography impedance, making ultrasound after level by level' of peep. After tritiated peep we setup the best peep for less collapse (using the tomography of electrical impedance) and maintained during the procedure.~PEEP titrated~Use ultrasound~Impedance tomography~Best PEEP for less collapse"
2905267|NCT03211923||Nemaline myopathy type 6 (NEM6)|Patients diagnosed with nemaline myopathy type 6 (mutation in KBTBD13 gene). The aim is to measure five male and five female patients.
2905268|NCT03211923||Myotonic dystrophy type 2 (DM2)|Patients diagnosed with myotonic dystrophy type 2 (pathological repeat expansion in CNBP gene). The aim is to measure five male and five female patients.
2905269|NCT03211923||McArdle disease (McA)|Patients diagnosed with McArdle disease (mutation in PYGM gene). The aim is to measure five male and five female patients.
2905270|NCT03211923||Healthy controls|14 male and 10 female healthy subjects were measured in a previous study
2905271|NCT03211923||Controls with positive muscle phenomena|9 male and 8 female subjects with positive muscle phenomena but no myopathy, ruled out by normal muscle biopsy, CK level, and genetic testing. These subjects were measured in a previous study.
2905272|NCT03211923||Brody disease|4 male patients diagnosed with Brody disease (ATP2A1 mutation). All Dutch patients suffering from Brody disease (n=4) were measured in a previous study
2905273|NCT03211910|Placebo Comparator|Standard Care of Treatment|Participants will be treated with standard of care treatment.
2905274|NCT03211910|Active Comparator|SacralSaver|SacralSaver
2905275|NCT03211897||Haloperidol 5mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
2905276|NCT03211897||Ziprasidone 20mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
2905277|NCT03211897||Olanzapine 10mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
2905278|NCT03211897||Midazolam 5mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
2905279|NCT03211884|Experimental|Problem-solving therapy|"PST consists of nine, 60-90 minute educational sessions conducted face-to-face via the Internet (through video conferencing software) approximately 2 weeks apart. After attending a preliminary 15 minute meet & greet session, participants will receive written and verbal education about solving everyday problems. Together, the participant and interventionist complete the 7 steps to solve at least one problem together before ending the training. Participants will keep a record of their problem-solving efforts between sessions and questions they have related to the application of PST. These records will be used as a basis for discussion during the intervention."
2905280|NCT03211884|No Intervention|Usual Care|Potential participants will be told that by agreeing to be randomized to UC group, and completing the study surveys over 18 months, they will contribute to our knowledge about what it is like to provide care and assistance to a post-9/11 Veteran or Service Member with a TBI, what caregiver services they use, and to learn if education in problem solving improves mental health outcomes in these military family caregiver (compared to caregivers assigned to the UC group).
2905281|NCT03211871|Active Comparator|Group D|Group D received dexmedetomidine infusion 0,5 mcg/kg/h from induction in anesthesia to extubation
2905282|NCT03211871|Placebo Comparator|Croup C|group C (control) received normal saline infusion
2905283|NCT03211858|Experimental|SAR341402|Given subcutaneously (SC) immediately before meals and snacks as mealtime rapid acting insulin on top of glargine as the basal insulin.
2905284|NCT03211858|Active Comparator|NovoLog/NovoRapid|Given SC immediately before meals and snacks as mealtime rapid acting insulin on top of glargine as the basal insulin.
2905285|NCT03211845|Experimental|Nutritional telemonitoring|Nutritional telemonitoring including self-measurements of body weight, nutritional status, appetite, diet quality and physical activity. Additionally, participants receive guidance on nutrition and physical activity by means of customized and general television messages and/or if necessary personal guidance by a nurse.
2905286|NCT03211832|No Intervention|Control|The control group will conduct usual public health practice.
2905287|NCT03211832|Active Comparator|Intervention|Participating local health departments will help develop and choose several dissemination activities they prefer for their local health department to receive. Dissemination activities may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes and chronic disease prevention and control.
2905288|NCT03211819|Experimental|computer guided placement|"In the test group, the computer guided surgical guide manufactured using zenith 3D printer (Dentis, Daegu, Korea) will be used for implant drilling and placement (s-Clean Tapered Implants, Dentis Co., Ltd., Woram-Dong, Dalseo-Gu, Daegu, South Korea) following the manufacture's instructions.~Then in implants with primary stability > 35 Ncm2, the final abutment will be placed and any further adjustment would be done immediately in the lab and repositioned in place. Then the vacuum stent will be checked in its place again intraorally, then a chair side tooth coloured autopolymerizing resin (Structur 2 SC / QM,VOCO GmbH, Germany) will be injected into the vacuum sheet corresponding to the implant site to construct the temporary crown."
2905289|NCT03211819|Active Comparator|free hand placement|in the control group, the implant will be placed it the socket using free hand technique and according to the manufacturing instruction's (s-Clean Tapered Implants, Dentis Co., Ltd., Woram-Dong, Dalseo-Gu, Daegu, South Korea) . The implants will be placed guided by the socket of the root. Then in implants with primary stability > 35 Ncm2, the final abutment will be placed and any further adjustment would be done immediately in the lab and repositioned in place. Then the vacuum stent will be checked in its place again intraorally, then a chair side tooth coloured autopolymerizing resin (Structur 2 SC / QM,VOCO GmbH,Germany)will be injected into the vacuum sheet corresponding to the implant site to construct the temporary crown.
2905290|NCT03211806|Experimental|Sedentary behavior intervention group|This group will wear an activity monitor linked to a smartphone app that will send prompts aimed at interrupting prolonged sedentary bouts
2905291|NCT03211806|Active Comparator|Monitoring-only group|This group will wear a bluetooth-enabled activity monitor but will not be prompted to change behavior
2905292|NCT03211793|Experimental|MSC injections|Intramuscular injection of mesenchymal stromal cells (50 million allogeneic MSCs in 0.9% NaCl and 10% human serum albumin).
2905293|NCT03211793|Placebo Comparator|Placebo injections|Intramuscular injection of placebo (NaCl 0.9% + 10% human serum albumin)
2905294|NCT03211780|Experimental|Ultrasound|
2905295|NCT03211767|Active Comparator|Aged garlic extract|2 capsules per day containing aged garlic extract
2905296|NCT03211767|Placebo Comparator|Placebo|2 capsules per day without aged garlic extract
2905297|NCT03211754|Experimental|Obese patients|Treatment for 8 weeks
2905298|NCT03211741|Other|open label|
2905299|NCT03211728|Experimental|experimental group|
2905300|NCT03211728|Placebo Comparator|placebo group|
2905301|NCT03211702||Elderly DLBCL patients|Elderly DLBCL patients (age>=65 years) treated with R-CHOP chemotherapy
2905302|NCT03211689|Experimental|Exercise Group|Participants will engage in up to 150 minutes of exercise per week, at a level of 11-14 on the Borg Rate of Perceived Exertion scale.
2905303|NCT03211689|No Intervention|Control Group|Participants will continue normal activities, with no new participation in exercise program (may engage in less than 75 minutes of non-structured exercise per week).
2905304|NCT03211676|Active Comparator|Theranova-500|
2905305|NCT03211676|Sham Comparator|Elisio-21H|
2905306|NCT03211663|Other|Interventional : MOTO Medial® UKA|Interventional : Patients who are planned to undergo a primary medial UKA using the MOTO Medial® will be enrolled.
2905307|NCT03211650|Experimental|hyaluronic acid + platelet-rich plasma|Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
2905308|NCT03211650|Active Comparator|platelet-rich plasma|Intra-articular injections of platelet-rich plasma
2905310|NCT03211637|Experimental|INTERVENTION GROUP|This group comprises 6 healthcare units equipped with a Family Health Strategy, where patients are seen by coordinating nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
2905311|NCT03211637|Active Comparator|CONTROL GROUP|This group comprising 5 healthcare units equipped with a Family Health Strategy. Patients were seen by coordinating nurses who used techniques and supplies with which they were already familiar. They had no protocol in place.
2905312|NCT03211624||Cushing syndrome|Male and female patients with Cushing syndrome caused by ACTH-producing pituitary adenoma or cortisol producing adrenal adenoma
2905313|NCT03211624||Controls|Healthy controls matched for age, gender, and educational level
2905314|NCT03211611||Patients with BRCA ½ mutation|Women with BRCA 1 / 2 mutation with or without cancer Age over 18
2905315|NCT03211611||GP|GP of the patients with BRCA 1 / 2 mutation
2905316|NCT03211598|Other|TACE with Surefire|Subjects enrolled in the study will have their TACE procedure with the Surefire Infusion System.
2905317|NCT03211572|Experimental|Endocrine Therapy|Anastrozole 1 mg (postmenopausal) or tamoxifen 20mg (premenopausal) are to be taken orally each evening and would be started exactly 2 weeks prior to their surgery.
2905318|NCT03211559|Active Comparator|AEROBİC EXERCİSE (walking on treadmill)|Patients walked on treadmill for 8 weeks, 3 days in a week,30-40 minutes each.
2905319|NCT03211559|Experimental|Aerobic Exercise+Clinical Pilates|Patients walked on treamill for 8 weeks, 3 days in a week, 30-40 minutes each. Additionally they did clinical pilates exercise for 8 weeks, 3 days in a week.
2905320|NCT03211546||Femoral shaft fracture|Patients (children up to 16 years old) diagnosis of isolated closed femur shaft fracture (3.2-D) and open distal physis. Treatment strategies will follow standard of care (routine) procedures, either conservative (non-surgical) treatment or surgical treatment.
2905321|NCT03211507||Case|Males with an incident diagnosis of IPF
2905322|NCT03211507||Controls|Males with an incident hospital outpatient attendance who do not have IPF
2905323|NCT03211494|Active Comparator|Conventional lung protective ventilation|Use of conventional lung protective ventilation, according to the ARDSnet guidelines
2905324|NCT03211494|Active Comparator|INTELLiVENT-ASV|Use of INTELLiVENT-ASV
2905325|NCT03211468|Experimental|Intervention Program|Clinical intervention designed to prevent eating disorders and promote healthy eating habits and body image among female adolescent athletes. The intervention program will include 10 45-min interactive sessions led by the researcher. Each session will include a brief theoretical background, experiential activities (artistic or cognitive / emotional) and group discussions.
2905326|NCT03211468|No Intervention|Control Group|No participation in intervention program.
2905327|NCT03211455|Placebo Comparator|Control|"intravenous isotonic saline administration : bolus of 0.075 ml/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (0.1 ml/kg/h, adjusted body weight) until the end of surgery decrease to 0.05 ml/kg (adjusted body weight) during 60 min in post anesthesia care unit.~Speed of infusion were calculated to be equivalent to that of lidocaine speed of injection."
2905328|NCT03211455|Experimental|Lidocaine|Intravenous Lidocaine (20mg/ml) : bolus of 1.5 mg/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (2.0 mg/kg/h, adjusted body weight) until the end of surgery decrease to 1.0 mg/kg (adjusted body weight) during 60 min in post anesthesia care unit.
2905329|NCT03211429|Active Comparator|Cognitive behavioural therapy|The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity, in order to increase their physical, social and functional activities. The cognitive behavioural intervention program, provides by psychologists, consists of eight group sessions, 60 minutes each. During each session a main theme is addressed. The themes of the program are: concerns about falls; thoughts about falling; physical exercise; asserting oneself; overcoming personal barriers; safe behaviour; and managing concerns about falls.
2905330|NCT03211429|Active Comparator|Tai chi|Subjects in the Tai Chi group undertook supervised Tai Chi training in the Yang style of 24 movements, for one hour, once a week for 8 weeks. The first 5 min was allocated for warm-up, with the rest of the time for Tai Chi practice.
2905331|NCT03211429|Active Comparator|Postural control exercise|Individually adjusted progressive and specific postural control training, provided by physiotherapists for one hour, one time per week for 8 weeks. The exercise is progressive and specific to functional postural control tasks. It comprises elements that represent activities included in, and required for, independent daily living, such as maintaining balance when sitting, standing and walking; and also reacting to loss of balance.
2905332|NCT03211416|Experimental|Treatment (sorafenib tosylate, pembrolizumab)|Patients receive sorafenib tosylate PO BID on days -28 to -1 and 1-21. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
2905333|NCT03211403|Experimental|SHR4640 2.5mg|6 subjects assigned to 2.5mg SHR4640 and 2 subjects assigned to placebo
2905334|NCT03211403|Experimental|SHR4640 10mg|6 subjects assigned to 10mg SHR4640 and 2 subjects assigned to placebo
2905335|NCT03211403|Experimental|SHR4640 20mg|6 subjects assigned to 20mg SHR4640 and 2 subjects assigned to placebo
2905336|NCT03211377||neoadjuvant therapy group|Preoperation chemotherapy treatment for patients up to four cycles
2905337|NCT03211377||adjuvant therapy|Postoperation chemotherapy treatment for patients up to six cycles
2905338|NCT03211377||Perioperative therapy|Preoperation chemotherapy treatment for patients up to four cycles and postoperation chemotherapy up to six cycles
2905339|NCT03211364|Active Comparator|Angular mobilization|Angular mobilization of the shoulder joint in the frontal plane.
2905340|NCT03211364|Active Comparator|Angular mobilization with soft tissue techniques|Angular mobilization performed in the scapular plane. Additional soft tissue techniques to eliminate limitations created by tensed muscles in order to perform capsular stretch.
2905341|NCT03211364|Placebo Comparator|Scapular mobilization|Scapular mobilization without glenohumeral movement.
2905342|NCT03211351|Experimental|Liposic|Liposic was applied to one eye of patients in this group
2905343|NCT03211351|Experimental|Tears Naturale Forte|Tears Naturale Forte was applied to one eye of patients in this group
2905375|NCT03211195|Experimental|Sotagliflozin - Commerical|Healthy volunteers will be administered a single dose Sotagliflozin (SAR439954) tablet (Commercial formulation) by mouth under fasted conditions
2905344|NCT03211338|Active Comparator|Preterm labor placentas and progesterone|IMC cells taken from preterm labor placentas after delivery will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
2905345|NCT03211338|Active Comparator|Term labor placentas and progesterone|IMC cells taken from term labor placentas after delivery will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
2905346|NCT03211338|Active Comparator|Preterm labor placentas without progesterone|IMC cells taken from preterm labor placentas after delivery will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
2905347|NCT03211338|Active Comparator|Term labor placentas without progesterone|IMC cells taken from term labor placentas after delivery will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
2905348|NCT03211338|Active Comparator|Term placentas from progesterone treated pregnancies|IMC cells taken from term labor placentas from women that were treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
2905349|NCT03211338|Active Comparator|Preterm placentas from progesterone treated pregnancies|IMC cells taken from preterm labor placentas from women that were treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
2905350|NCT03211338|Active Comparator|Term placentas not treated with progesterone in pregnancy|IMC cells taken from term placentas from women who were not treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
2905351|NCT03211338|Active Comparator|Preterm placentas not treated with progesterone in pregnancy|IMC cells taken from preterm placentas from women who were not treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
2905352|NCT03211338|Active Comparator|Term postpartum blood samples with progesterone|CD-14+ monocyte cells taken from women delivering at term will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
2905353|NCT03211338|Active Comparator|Preterm postpartum blood samples with progesterone|CD-14+ monocyte cells taken from women delivering preterm will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
2905354|NCT03211338|Active Comparator|Term postpartum blood samples without progesterone|CD-14+ monocyte cells taken from women delivering at term will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
2905355|NCT03211338|Active Comparator|Preterm postpartum blood samples without progesterone|CD-14+ monocyte cells taken from women delivering preterm will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
2905356|NCT03211325|Experimental|Healthy|"Two sequences of ten healthy volunteers each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
2905357|NCT03211325|Experimental|Primary Raynaud's phenomenon|"Two sequences of ten primary Raynaud's syndrome each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
2905358|NCT03211325|Experimental|Secondary Raynaud's phenomenon|"Two sequences of ten patients each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
2905359|NCT03211312||older people with cardiac diseases|undergoing teeth extraction surgery
2905360|NCT03211299||IHL <5%|overweight and obese humans with a liver fat percentage <5%
2905361|NCT03211299||IHL 5-10%|overweight and obese humans with a liver fat percentage 5-15%
2905362|NCT03211299||IHL >15%|overweight and obese humans with a liver fat percentage >15%
2905363|NCT03211286|Active Comparator|TXA group|Tranexamic acid, a single dose of 1 g intravenous diluted in 100 mL saline solution at the time of surgical incision
2905364|NCT03211286|Placebo Comparator|Control group|Saline solution, 100 mL intravenous at the time of surgical incision
2905365|NCT03211273||Patient cohort|Newly diagnosed breast, ovarian or colon cancer patients recruited 6 months post-diagnosis and followed up to 5 years post-diagnosis. No intervention.
2905366|NCT03211260|Experimental|EQUISTASI|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
2905367|NCT03211247|Experimental|Viaskin Peanut 250 mcg|
2905368|NCT03211247|Experimental|Viaskin Peanut 100 mcg|
2905369|NCT03211247|Placebo Comparator|Placebo|
2905370|NCT03211234|Experimental|Low Dose DE-122|Low Dose DE-122 and Lucentis
2905371|NCT03211234|Experimental|High Dose DE-122|High Dose DE-122 and Lucentis
2905372|NCT03211234|Sham Comparator|Sham|Sham and Lucentis
2905373|NCT03211221|Active Comparator|Active rTMS|Active stimulation parameters will be 1-Hz, 10 seconds per train, 10 pulses per train (3 seconds inter-train interval) for a total of 160 trains (1600 pulses/session) at 130% of resting motor threshold (MT) (using the lowest value of the dominant hemisphere), once a day, 5 day/week, for 3 weeks. The coil will be positioned over the pre-SMA, targeted using the International 10-20 EEG System. Pre-SMA is defined at 15% of the distance between inion and nasion anterior to Cz (vertex) on the sagittal midline. The coil will be placed with the handle along the sagittal midline, pointing towards the occiput to stimulate bilaterally and simultaneously the pre-SMA.
2905374|NCT03211221|Placebo Comparator|Sham rTMS|Sham TMS will be administered by tilting the coil 90° off the scalp, with one wing of the coil touching the scalp. This sham-TMS approach produces a clicking sound that is very similar to an active TMS pulse and induces a voltage in the brain that is more than 75% lower than active TMS.
2905448|NCT03210597|Experimental|hydro-power|Resistance water exercise
2905376|NCT03211195|Active Comparator|Sotagliflozin -Development|Healthy volunteers will be administered a single dose Sotagliflozin (SAR439954) tablet (Development formulation) by mouth under fasted conditions - Type: Active Comparator
2905377|NCT03211182|Experimental|lifestyle intervention group|The intervention group was given healthy lifestyle education and individualized counseling by well-trained case manager at baseline, and follow-up phone counseling thereafter.
2905378|NCT03211182|No Intervention|control group|The control group was given general verbal and written health behavior information to prevent diabetes at baseline without specific individualized advice.
2905379|NCT03211169|Experimental|Pediatric Biopsy Forceps directed biopsies|Biopsies of the stricture will be taken with Pediatric Biopsy Forceps after bile duct brushings have been obtained.
2905380|NCT03211169|Active Comparator|Cholangioscopy-directed biopsies|Biopsies of the stricture will be taken under cholangioscopic guidance after bile duct brushings have been obtained.
2905381|NCT03211156|Placebo Comparator|Placebo arm|Placebo 2 capsules PO twice a day for 7 days, n=49
2905382|NCT03211156|Experimental|Treatment arm|Amoxicillin 2 x 250 mg capsules PO twice a day for 7 days, n=49
2905383|NCT03211143|Experimental|A|"TR group~Period 1: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days~Period 2: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days"
2905384|NCT03211143|Experimental|B|"RT group~Period 1: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days~Period 2: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days"
2905385|NCT03211130|Experimental|SystemCHANGE™|
2905386|NCT03211130|Active Comparator|Attention-Control|
2905387|NCT03211117|Experimental|Cohort A (pembrolizumab, surgery, chemoradiation)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients undergo surgery. Within 42 days of surgery, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
2905388|NCT03211117|Experimental|Cohort B (pembrolizumab, chemoradiation)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
2905389|NCT03211104|Experimental|curcumin|"Curcumin extracted from curcuma longa linn.~formulation : curcumin powder 240mg/capsule~general name : Diferuloylmethane~Taking curcumin 3 times a day(1,440mg/day) for 6 months at the first off treatment in patients with prostate cancer receiving intermittent androgen deprivation therapy"
2905390|NCT03211104|Placebo Comparator|control|The control group Take a placebo containing lactose and vitamin B2. Reddish brown capsules with the same shape as curcumin.
2905391|NCT03211078|Experimental|super-D ENB guided-PDT|To test the feasibility of super-D ENB guided-PDT to treat small lung cancer which cannot be eradicated through surgical resection.
2905392|NCT03211065|Experimental|Immunoglobulin therapy|Patients with abnormal humoral function following treatment with rituximab will be treated with 20% subcutaneous immunoglobulin.
2905393|NCT03211052|Experimental|TAK-700 + LHRH agonist + Prostatectomy|Neoadjuvant TAK-700 for 6 months with LHRH agonists prior to prostatectomy
2905394|NCT03211052|Other|Prostatectomy|Prostatectomy only-Within 28 days of randomisation
2905395|NCT03211039|Other|Whole Genome Sequencing|Genetic test that looks at all coding and non-coding areas of the genome
2905396|NCT03211039|Other|Whole Exome Sequencing|Genetic test that looks at all coding areas of the genome
2905397|NCT03211013|Experimental|Immediate Oxytocin|Participants randomly assigned to this arm will receive OT nasal spray (24 IU) at laboratory visit 1 and placebo nasal spray at visit 2. The order will be masked for participants and study staff.
2905398|NCT03211013|Placebo Comparator|Delayed Oxytocin|Participants randomly assigned to this arm will receive placebo nasal spray at laboratory visit 1 and OT nasal spray (24 IU) at visit 2. The order will be masked for participants and study staff.
2905399|NCT03210987|Active Comparator|patient case presentation Bedside|In the bedside presentation group, patient case presentation and discussions will be at bedside with direct involvement of the patient as needed.
2905400|NCT03210987|Active Comparator|patient case presentation Outside-the-room|In the outside the room condition, case presentation and discussions will take place outside without the patient being present. After the case presentation and discussions the team will enter the room and give the patient a short summary of the medical situation, complete the medical information and examine the patient, as needed, and discuss the next steps.
2905401|NCT03210961|Experimental|PF-06826647 tablet|
2905402|NCT03210961|Placebo Comparator|Placebo tablet|
2905403|NCT03210961|Experimental|PF-06826647 oral suspension|
2905404|NCT03210961|Placebo Comparator|Placebo oral solution/suspension|
2905405|NCT03210948|Experimental|RTE-guided EUS-FNA|"The needle will be then inserted into the most suspicious part (dark blue) of the lesion as assessed at real time elastography."
2905406|NCT03210948|Active Comparator|Conventional EUS-FNA|A 25 G needle with a central stylet to protect the aspiration channel of the needle will be introduced though the endoscope's working channel.
2905407|NCT03210935||Merkel cell carcinoma|
2905408|NCT03210935||Advanced basal cell carcinoma|
2905409|NCT03210935||Cutaneous adnexal carcinomas|
2905410|NCT03210922|Experimental|Collar group|Standard of anesthetic care and nasointubation with patient wearing the Miami cervical collar.
2905411|NCT03210922|No Intervention|Non-collar group|Standard of anesthetic care and nasointubation with patient not wearing the Miami cervical collar.
2905412|NCT03210909|Experimental|BMS-986231 Intravenous Infusion|A single continuous intravenous infusion of BMS-986231
2905413|NCT03210896|No Intervention|Main Group|100 subjects (70 T2D and 30 Controls) consent to provide 1 venous blood sample, 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers.
2905449|NCT03210597|Experimental|hydro-combined|Water aerobics and resistance water exercise
2905414|NCT03210896|Experimental|Sub Group I|20 subjects from the main group (10 T2D and 10 Controls) to remain after providing the above samples. These patients will stay for an additional 3 hours and provide 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers at the following time intervals: 5, 30, 60, 120 & 180 minutes.
2905415|NCT03210896|No Intervention|Sub Group II|5 control subjects consent to provide 1 venous blood sample, 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers. This will be followed by 1 capillary blood sample and 3 breath samples every hour for a total of 5 hours.
2905416|NCT03210870|Other|Intervention|In-person nutritional education classes
2905417|NCT03210870|No Intervention|Control|no in-person nutritional education classes
2905418|NCT03210857|Experimental|apnea performing|"The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made."
2905419|NCT03210844||Direct anterior approach|For the DAA group, we used single-incision direct anterior approach with a standard operation table in J Arthroplasty. 2008 Oct;23(7 Suppl):64-8. Epub 2008/10/24. . The incision size was 6-10 cm depending on the body build of the patient. The acetabularreaming was performed with an offset hemispheric reamer and acetabular component was inserted underfluoroscopic guidance. Femoral broaching was performed using a double-offset broach handle.Fluoroscopy was used to check the positioning and filling of femoral stem, as well as leg lengths.
2905420|NCT03210844||Microposterior approach|The incision size was 6 - 10 cm depending on the body build of the patient. The differences of our micro-PA from Dorr's techniques were: First, no excision of the anterosuperior capsule and medial inferior capsule because the senior author believe that preservation of these structures could help to maintain the postoperative stability of the THA. Second, after the gluteus minimus muscle was elevated from the superior capsule, a superior capsulomy starting from 12 o'clock direction of acetabulum in decubitus position was made. The hip capsule was then incised in 12-to- 6-o'clock downward direction and curved down around femoral neck under the other short external rotators. We preserved short external rotators except piriformis tendon. Third, the capsular incision was continued inferiorly following 12-to- 6-o'clock downward direction of acetabulum to the transverse acetabular ligament. The tube structure of original hip capsule was divided into anterior and posterior half leaflets.
2905421|NCT03210805|Experimental|Supplementation|Omega-3 Polyunsaturated Fatty Acids
2905422|NCT03210792|Active Comparator|CCO Rib Splint|Subjects were applied Chrisofix® Chest Orthosis (Manufactured Rib Splint) for Rib Fractures treatment.
2905423|NCT03210792|Experimental|Handmade Rib Splint|Subjects were applied Handmade Rib Splint for Rib Fractures treatment.
2905424|NCT03210779|Active Comparator|L.reuteri|L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA lozenges three times daily for 16 days + L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA probiotic oil, topically, once daily for 8 days.
2905425|NCT03210779|Placebo Comparator|Placebo|Placebo lozenges three times daily for 16 days and placebo oil once daily for 8 days
2905426|NCT03210766||Nabilone|Patients affected by Failed Back Surgery Syndrome (FBSS)
2905427|NCT03210766||THC/CBD|Patients affected by Failed Back Surgery Syndrome (FBSS)
2905428|NCT03210740|Experimental|AM001 Cream, 7.5%|A white to off-white Cream free from any foreign particles
2905429|NCT03210740|Placebo Comparator|Vehicle Cream|A white to off-white Cream free from any foreign particles
2905430|NCT03210727|Other|single arm|This arm will be used to pilot test the Ready to CARE program (with the caregivers) and measure outcomes (in the patients).
2905431|NCT03210714|Experimental|Treatment (erdafitinib)|Patients receive erdafitinib PO QD on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2905432|NCT03210701|Other|Patients requesting a HIV screening test|
2905433|NCT03210688|Active Comparator|High dose prednisolone|Prednisolone 1 mg/kg/day
2905434|NCT03210688|Experimental|Alfacalcidol and low dose prednisolone|Alfacalcidol 0,5 microgram/day and Prednisolone 0,5 mg/kg/day
2905435|NCT03210675|Other|Study group|Will have a PSG at home every 6 months (± 1 month) from the age of 6 months until the age of 3 years.
2905436|NCT03210675|Other|Standard Care Group|Will have a single PSG at home which will give a reference in the Down Syndrome population of 3 years old and will be used as reference to the study group
2905437|NCT03210662|Experimental|Diffused Large B-Cell Lymphoma (DLBCL) Group|"Participants receive EBRT 1 time each day for a total of either 12 or 22 treatments, depending on type of NHL.~Starting day after EBRT begins, Pembrolizumab given by vein over about 1 hour, every 21 days for up to 35 doses."
2905438|NCT03210662|Experimental|Follicular Lymphoma (FL) Group|"Participants receive EBRT 1 time each day for a total of either 12 or 22 treatments, depending on type of NHL.~Starting day after EBRT begins, Pembrolizumab given by vein over about 1 hour, every 21 days for up to 35 doses."
2905439|NCT03210662|Experimental|Other B-Cell Non-Hodgkin's Lymphoma (OBNHCL) Group|"Participants receive EBRT 1 time each day for a total of either 12 or 22 treatments, depending on type of NHL.~Starting day after EBRT begins, Pembrolizumab given by vein over about 1 hour, every 21 days for up to 35 doses."
2905440|NCT03210662|Experimental|T-Cell lymphoma (TCL) Group|"Participants receive EBRT 1 time each day for a total of either 12 or 22 treatments, depending on type of NHL.~Starting day after EBRT begins, Pembrolizumab given by vein over about 1 hour, every 21 days for up to 35 doses."
2905441|NCT03210649|Experimental|CKD-519 400mg(PartⅠ: 1day)|CKD-519 400mg(100mg x 4tabs) or placebo
2905442|NCT03210649|Experimental|CKD-519 400mg(PartⅡ: 14days)|CKD-519 400mg(100mg x 4tabs) or placebo
2905443|NCT03210636|Experimental|With Use of LapSpace|evaluate ease of use, safety evaluations, surgeon and clinician feedback
2905444|NCT03210623|Experimental|group A|subjects applying the stent retriever(TonbridgeMT)
2905445|NCT03210623|Active Comparator|group B|subjects applying Solitaire™
2905446|NCT03210610||FMF patients|fmf patients under a constant colchicine dose
2905447|NCT03210597|Experimental|hydro-aerobic|Water aerobics exercise
2905450|NCT03210584||Imaging measurements|All subject of the study have a knee osteoarthritis (OA) and are going to have a knee prosthetic surgery with cartilage excision. Multimodal evaluation is conducted on ex vivo human cartilage samples (2 samples per patient are selected : healthy and severely degraded).
2905451|NCT03210558|Active Comparator|Group A|Testosterone cream 1% (Andro-Feme® )
2905452|NCT03210558|Placebo Comparator|Group B|Placebo cream
2905453|NCT03210545|Active Comparator|dexamethasone - physiological dose|Replacing participants hydrocortisone with a daily dose of dexamethasone in an estimated physiological dose during one treatment period.
2905454|NCT03210545|Active Comparator|dexamethasone - supra physiological dose|Replacing participants hydrocortisone with a daily dose of dexamethasone in an estimated supra physiological dose during one treatment period.
2905455|NCT03210532|Experimental|Test|qd PO, Twynsta(telmisartan/amlodipine) + Crestor(rosuvastatin)
2905456|NCT03210532|Active Comparator|Reference 1|qd PO, Micardis(telmisartan) + Crestor(rosuvastatin)
2905457|NCT03210532|Active Comparator|Reference 2|qd PO,Twynsta(telmisartan/amlodipine)
2905458|NCT03210519|Experimental|Eleutherococcus senticosus|Acanthopanax senticosus-mono formula (30mg/vial) and Fructus Ziziphi Jujube concentrated juice15ml/vial
2905459|NCT03210519|Placebo Comparator|Placebo|Fructus Ziziphi Jujube concentrated juice15ml/vial
2905460|NCT03210506|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
2905461|NCT03210506|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
2905462|NCT03210493|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
2905463|NCT03210493|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
2905464|NCT03210480|Experimental|Group 1|Lithium sulphate prolonged-release 660 mg
2905465|NCT03210480|Active Comparator|Group 2|Lithium carbonate immediate-release 150 mg and 300 mg
2905466|NCT03210467||experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
2905467|NCT03210467||control group|patients who were untreated ever in immune-active phase took entecavir(ETV) for maintenance treatment.
2905468|NCT03210454|Experimental|Treatment Group 1|Farmers associations, including men and women, will be randomized to receive the smallholder marketing intervention.
2905469|NCT03210454|Experimental|Treatment Group 2|Farmers associations, including men and women, will be randomized to receive the smallholder marketing intervention combined with the intimate partner violence (IPV) prevention training.
2905470|NCT03210454|No Intervention|Comparison Group 3|Women involved with farmers's associations that work independently of World Food Programmes (WFP's) assistance.
2905471|NCT03210441||Group 1|Patients affected by breast cancer and potentially treated with taxane chemotherapy
2905472|NCT03210441||Group 2|Patients affected by breast cancer and not potentially treated without taxane chemotherapy
2905473|NCT03210415||Study group|Pregnant women ≥35 years old would have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model.
2905474|NCT03210415||Control group|Pregnant women ≥35 years old would not have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model.
2905475|NCT03210402|Active Comparator|Elevated night pacing on|
2905476|NCT03210402|Placebo Comparator|Elevated night pacing off|
2905477|NCT03210389|Experimental|lobaplatin+5-FU|Patients enrolled in this trial would get 4-6 cycles of lobaplatin + 5-FU chemotherapy.
2905478|NCT03210376|Experimental|Deep Neuromuscular Blockade (NMB) + Sugammadex|"Deep Neuromuscular Blockade (NMB) given during surgery.~Sugammadex intravenously as a single bolus injection after surgery.~Pain assessment done at about 15, 45, and 90 minutes after surgery."
2905479|NCT03210376|Experimental|Moderate Neuromuscular Blockade (NMB) + Neostigmine|"Moderate Neuromuscular Blockade (NMB) given during surgery.~Neostigmine intravenously slowly over a period of at least 1 minute after surgery.~Pain assessment done at about 15, 45, and 90 minutes after surgery."
2905480|NCT03210363|Experimental|Guiana population|"Human Biological samples from Guiana population :~Two serum tubes of blood will be collected"
2905481|NCT03210337|Experimental|Active|A-101 Topical Solution
2905482|NCT03210337|Placebo Comparator|Vehicle|Vehicle
2905483|NCT03210324|Experimental|Mifepristone A group|Mifepristone tablets for 12 weeks with two follow-up
2905484|NCT03210324|Experimental|Mifepristone B group|Mifepristone tablets for 12 weeks with four follow-up
2905485|NCT03210324|Experimental|Mifepristone C group|Mifepristone tablets for 24 weeks with four follow-up
2905486|NCT03210311|No Intervention|control group|"Receive information: the patient receive a leaflet with information about the lymphatic system and lymphedema, clinical evaluation and conservative treatment of lymphedema~Perform skin care~Perform twice a day upper limb exercises at home. They are advised to use the arm as normal as possible."
2905487|NCT03210311|Active Comparator|intervention group|"Receive information: the patient receive a leaflet with information about the lymphatic system and lymphedema, clinical evaluation and conservative treatment of lymphedema~Perform skin care~Perform upper limb exercises at home twice a day. They are advised to use the arm as normal as possible~Wear a compression sleeve"
2905488|NCT03210285||NF2-associated VS|Patients after surgery of a NF2- associated vestibularis schwannoma: Whole exome sequencing of blood and tumor tissue
2905489|NCT03210285||Sporadic VS|Patients after surgery of a sporadic vestibularis schwannoma: : Whole exome sequencing of blood and tumor tissue
2905490|NCT03210272|Experimental|Single rising dose part|Group of healthy male volunteers receive rising single doses of BI 1358894
2905491|NCT03210272|Experimental|Food effect part|Group of healthy male volunteers receive single doses of BI 1358894 with and without food
2905492|NCT03210259|Experimental|BI 695501|
2905493|NCT03210259|Active Comparator|Humira®|
2905494|NCT03210246|Experimental|COC + Vilaprisan|COC + Vilaprisan (BAY 1002670)
2905495|NCT03210246|Placebo Comparator|COC + Placebo|COC + Placebo
2905496|NCT03210233|Experimental|Naive controls|Never received teicoplanin. Blood test, skin testing and challenge testing.
2905497|NCT03210233|Experimental|High Risk|Received teicoplanin and suffered suspected IgE mediated anaphylaxis. Blood test, skin testing and challenge testing.
2905498|NCT03210233|Experimental|Low Risk|Received teicoplanin previously with no adverse reaction Blood test, skin testing and challenge testing.
2905499|NCT03210220||pecs group|Ultrasound guided pectoral nerve block is performed right after induction, before surgery. The needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery, and 10 mL of 0.5% ropivacaine deposited. In a similar manner, 20 mL is deposited at the level of the third rib between the pectoralis minor muscle and the serratus anterior muscle .
2905500|NCT03210220||control group|There is no block.
2905501|NCT03210207||GASTROPLICATURE|"The procedure begins with division of the greater curve vessels from 4 to 5 cm proximal to the pylorus to the angle of His. Either ultrasonic energy or bipolar cautery is appropriate for this step.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum"
2905502|NCT03210194|Active Comparator|Standard Neonatal Resuscitation Training|Standard training will be conducted through a theoretical-practical course, which will be administered once during the study period, to all health professionals of the selected facilities, according to the randomization. It is an 8-hour course, with 3 hours of theory and 5 hours of practice, which will take place during a single day. The course will be performed by staff of the Neonatal Unit of the Instituto Nacional de Salud del Niño (National Institute of Child Health, Lima, Peru), and will be coordinated by an NRP instructor accredited by the American Academy of Pediatrics. Participants who have completed their attendance to theoretical sessions, participated in the simulated practices and approved the printed exams taken the same day will we granted a Standard Certification.
2905503|NCT03210194|Experimental|MP-ICT Neonatal Resuscitation Training|The Multi-platform ICT (MP-ICT) training includes continuous certification in neonatal resuscitation and is being developed for online and offline access, and will be complemented with simulated practices on every site. The platform is being improved and adjusted to the needs of the fieldwork in Ayacucho and Cusco. The adaptations include increasing hosting; ameliorate friendly usability, uploading packages and videos, improvement of examination and certifications, and tests for readiness. The MP-ICT resource will be accessed from remote Peruvian locations through computers, personal portable devices and cell phones. To be granted an MP-ICT Certification the trainee needs to have passed the online theoretical exam, assist to the practice and approve practical skills assessment.
2905504|NCT03210181|Experimental|Block|Patients will receive superficial cervical plexus block
2905505|NCT03210181|Placebo Comparator|Placebo|Patients will receive normal saline
2905506|NCT03210168|Experimental|BioFe Medical Food|Escalating consumption of BioFe in a single cohort of up to 40 subjects with iron deficiency.
2905507|NCT03210155|Active Comparator|Active Comparator|About the size of a smart phone, the Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The active intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
2905508|NCT03210155|Sham Comparator|Sham Comparator|The Alpha-Stim® AID CES sham device is identical in appearance to the active device but is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
2905509|NCT03210142|Experimental|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation for subjects undergoing an EP, cardiac catheterization or device procedure.
2905510|NCT03210129|Experimental|Motivational interviewing|Patients of the motivational interviewing group will receive standard care alongside motivational interviewing to change their behavior regarding physical activity.
2905511|NCT03210129|No Intervention|Control Group|Patients of the control group will receive standard care alone.
2905512|NCT03210103|Active Comparator|Arm 1, Radiation +/- Chemotherapy|Standard Treatment (Radiation +/- Chemotherapy)
2905513|NCT03210103|Experimental|Arm 2, TOS + Neck Dissection|Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)
2905514|NCT03210077||Entropy Group|General Anesthesia using Entropy Monitoring
2905515|NCT03210077||Control Group|General Anesthesia without Entropy (Control Group)
2905516|NCT03210064|Experimental|Apatinib and 5-Fluorouracil|Apatinib 500 mg qd po.5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
2905517|NCT03210064|Active Comparator|5-Fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
2905518|NCT03210051|Experimental|RIC & ET|Remote ischemic conditioning paired with endovascular treatment. RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times. Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association. It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
2905519|NCT03210038|Active Comparator|Rigid cystoscopy, water based gel on introitus|Rigid cystoscopy, Wolf 17FR. Pad soaked with water based gel put on introitus for 5 minutes prior to procedure.
2905520|NCT03210038|Active Comparator|Rigid cystoscopy, esracain gel based on introitus|Rigid Cystoscopy, Wolf 17FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
2905521|NCT03210038|Active Comparator|Flexible cystoscopy, water based gel on introitus|Flexible cystoscopy, Olympus 16FR. Pad soaked with water based gel put on introitus for 5 minutes prior to procedure.
2905522|NCT03210038|Active Comparator|Flexible cystoscopy, Esracain gel based on introitus|Flexible cystoscopy, Olympus 16FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
2905523|NCT03210025|Experimental|BF-Methyldopa Tablet 250mg|During the study session, healthy subjects will be administered a single dose of BF-Methyldopa Tablet 250mg after an overnight fast of approximately 10 hours
2905524|NCT03210025|Active Comparator|Metopa Tab 250mg|During the study session, healthy subjects administered a single dose of Metopa Tablet 250mg after an overnight fast of approximately 10 hours
2905525|NCT03210012||1|Three dives with different gas mixture : AIR (21% di O2 e 79% di N2), NITROX 32 (32% di O2 e 68% di N2) and TRIMIX (21% O2, 44% N2 e 35% He)
2905526|NCT03209999||Fomally Employed|Mother engaged in formal employment. No intervention was assigned as this is a cross sectional study.
2905527|NCT03209999||Informally Employed|Mother engaged in informal employment. No intervention was assigned as this is a cross sectional study.
2905528|NCT03209999||Non-employed|Mother neither formally or informally employed. No intervention was assigned as this is a cross sectional study.
2905529|NCT03209986|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8.
2905530|NCT03209986|No Intervention|control|Standard medication for viral hepatitis and cirrhosis
2905531|NCT03209973|Experimental|BGB-A317|BGB-A317 200 mg intravenously (IV) every-3-weeks (Q3W)
2905532|NCT03209947|Experimental|Ulnar nerve ultrasound|
2905533|NCT03209908||control group|In this group, pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml don not use any antiviral drugs during pregnancy.
2905534|NCT03209908||experimental group|pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml start to use Tenofovir Disoproxil Fumarate(TDF) antiviral treatment from the 32 weeks of gestation to block mother-to-child transmission of hepatitis B virus.
2905535|NCT03209895|Experimental|Joint Health Product|
2905536|NCT03209895|Placebo Comparator|Placebo|
2905537|NCT03209895|Active Comparator|Glucosamine / Chondroitin|
2905538|NCT03209882|Experimental|TILS|Six weekly sessions of TILS. The TILS will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). Each session will consist of totally 8 minutes, with eight 1-min cycles alternating between two locations on the right forehead. The laser power will be 3.4 Watts.
2905539|NCT03209882|Sham Comparator|Sham|One weekly session of sham. The sham session will be randomly assigned into the first two intervention visits. The sham will consist of using the same CG-5000 laser for totally 8 minutes, with eight 1-min cycles alternating between two locations on the right forehead. However, the laser power will be turned to be 0 Watts. Therefore the sham session will generate same instrumental sound as TILS, but the subjects won't receive any actual laser illumination.
2905540|NCT03209869|Experimental|Single arm|All subjects will receive Ex vivo Expanded and Activated Haploidentical Donor NK Cells + hu14.18-IL2
2905541|NCT03209856|Experimental|Vitamin D supplement|This group will receive weekly oral 50000 international units of vitamin D supplement for 8 weeks before the start of ICSI cycle. In addition, the routine care will be given.
2905542|NCT03209856|No Intervention|Routine care|This group will receive the routine care.
2905543|NCT03209843|Other|Successfully CTO recanalization|
2905544|NCT03209830|Experimental|Arm A|OSU6162, drug given to half of the patients after randomization
2905545|NCT03209830|Placebo Comparator|Arm B|Placebo oral tablet, drug given to halv of the patients after randomization
2905546|NCT03209817|Experimental|Red cherry tomato|300 grams of red cherry tomatoes per day for four weeks (each)
2905547|NCT03209817|Experimental|Yellow cherry tomato|300 grams of yellow cherry tomatoes per day for four weeks (each)
2905548|NCT03209817|No Intervention|Control No tomato|No tomato products consumption
2905549|NCT03209804|Other|Traditional neurosurgical techniques|Unsimultaneous endovascular interventional embolisation/radiotherapy followed by microsurgical resection, as traditional clinical routines.
2905550|NCT03209804|Experimental|Hybrid operating techniques|A one-stage hybrid operation combining endovascular intervention and microsurgical techniques will be conducted simultaneously
2905551|NCT03209791||Alcoholic Steatosis|This group will have 10 patients with alcoholic steatosis which is milder disease and muscle biopsies will be performed
2905552|NCT03209791||Cirrhosis|This group will consist of 10 patients with cirrhosis. We anticipate a 50% difference in these patients and the controls in the autophagy readouts and muscle biopsies will be performed
2905553|NCT03209791||Steatohepatitis|This group will have 10 patients with alcoholic steatohepatitis that have more severe necroinflammation in the liver but for a shorter duration of illness and muscle biopsies will be performed
2905554|NCT03209791||controls|This group will consist of 10 patients who are healthy and have no liver disease diagnosis and muscle biopsies will be performed
2905555|NCT03209778|Active Comparator|Control group|Control participants without psychiatric nor neurological history
2905556|NCT03209778|Experimental|Patients with Schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
2905557|NCT03209765|Active Comparator|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
2905558|NCT03209765|No Intervention|No reminder|
2905559|NCT03209739|Active Comparator|WhatsApp reminder|An additional WhatsApp reminder with same content of the written instruction and a video of explanation of bowel preparation by a nurse 4 days prior colonoscopy
2905560|NCT03209739|No Intervention|No reminder|No additional reminder will be given
2905561|NCT03209713|Active Comparator|Parental Education|Participants will receive parental education on HPV vaccine and the vaccine's benefits.
2905562|NCT03209713|Experimental|Parental Education + Text Messaging|Participants will receive parental education on HPV vaccine and the vaccine's benefits plus text messaging reminder.
2905563|NCT03209700|Experimental|MSC-AFP Single Treatment Group|Eligible patients will be treated, single treatment group, no placebo arm
2905564|NCT03209687|Experimental|Human menopausal gonadotropin (HMG)|This group will take daily subcutaneous 75 IU (international unit) of human menopausal gonadotropin (HMG) in addition to the usual luteal phase support from the day of ovum pickup and will be continued for 2 weeks
2905565|NCT03209687|No Intervention|Routine care|This group will receive the routine care for luteal phase support
2947803|NCT02919748|Experimental|Intervention arm|Choral Singing
2905566|NCT03209661|Active Comparator|E-Cigarette 5.4% NBV|Subjects will be asked to inhale an E-Cigarette with 5.4% NBV for 6 min.
2905567|NCT03209661|Placebo Comparator|E-Cigarette 0% NBV|Subjects will be asked to inhale an E-Cigarette with 0% NBV for 6 min.
2905568|NCT03209661|Placebo Comparator|Menthol Inhaler|Subjects will be asked to inhale a sham methole inhaler (that looks identical in looks to E-cigarette) for 6 minutes. This arm is to control for a potential effect of menthole.
2905569|NCT03209648|Experimental|Debio 1450|In Treatment Period 1, participants will receive single oral dose of Debio 1450 40 mg on Day 1. In Treatment Period 2, participants will receive itraconazole 200 mg, twice daily (BID) orally, on Day 1, followed by itraconazole 200 mg once daily (QD), on Days 2 to 4, and then single oral dose of Debio 1450 40 mg and itraconazole 200 mg on Day 5, followed by a single oral dose of itraconazole 200 mg on Days 6 and 7.
2905570|NCT03209635|Placebo Comparator|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
2905571|NCT03209635|Experimental|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
2905572|NCT03209622|Experimental|A intervention|"intervention = Nicotine replacement therapy (NRT): initiated in cardiology intensive care unit, Some hours after acute coronary syndrome.~Drug: One or two pachs for each ARM, depending of number of cigarettes consummed every day. The dose is decreased every 4 weeks. The patient leave with an appointment to the external consultation for follow-up."
2905573|NCT03209622|Active Comparator|B: control|Intervention: Nicotine replacement therapy (NRT) initiated after hospital discharge, some days after acute coronary syndrome. The patient leave with an appointment to the external consultation for follow-up without pach of nicotine.One or two pachs for each ARM, depending of number of cigarettes consummed every day. The dose is decreased every 4 weeks.
2905574|NCT03209609|Experimental|VEST supported vein graft|Coronary artery bypass vein graft supported with the VEST implant
2905575|NCT03209609|Active Comparator|Standard of care vein grafts|Coronary artery bypass vein grafts
2905576|NCT03209596|Experimental|Orange juice|Seventeen individuals received 1 liter/day of pasteurized orange juice. Participants consumed the orange juice before and post exercise, the volume of juice per serving was 500 mL. On players' rest days, the juice was consumed throughout the day.
2905577|NCT03209596|Active Comparator|Control drink|Thirteen individuals received 1 liter/day of control drink. The participants consumed the control drink before and post exercise, the volume of drink per serving was 500 mL. On players' rest days, the drink was consumed throughout the day. The control drink consisted of an aqueous solution containing sucrose (44 g), glucose (22 g), fructose (22 g), citric acid (11g) (proportionally 2:1:1:0.5) (USDA, 2016) (with the same proportion of total sugars as the orange juice, and without all others bioactive compounds of juice), dyestuff sunset yellow (0.05 g) and orange essence.
2905578|NCT03209583||Congenital Heart Disease|subjects have CHD and arrhythmias being treated with an implanted pacing device.
2905579|NCT03209570|Experimental|TENA Identifi with sensor wear data|All individuals in this arm will receive care planning using TENA Identifi sensor wear data
2905580|NCT03209570|Active Comparator|TENA Identifi without sensor wear data|All individuals in this arm will receive care planning without using TENA Identifi sensor wear data
2905581|NCT03209557|No Intervention|Control|25 pregnant women will be enrolled and provided with usual care through Healthy Beginnings or NFP but will not receive a smartwatch or the active intervention. Smoking behavior will be measured by self-report and sample testing for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly and will be identical to the intervention group. They will be compensated for sample collection and survey completion.
2905582|NCT03209557|Experimental|SmokeBeat Intervention|25 pregnant women will be enrolled and provided with a smartwatch. The smartwatch SmokeBeat application will be active. Smoking behavior will be measured by the smartwatch for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly.
2905583|NCT03209544|Experimental|Intervention group|The intervention group gains access to Think Life, an online self-help intervention. During 6 weeks they receive a new module on a weekly basis.
2905584|NCT03209544|No Intervention|Control group|Waitlist control group. They receive access to Think Life after 12 weeks.
2905585|NCT03209531|Experimental|Operant Conditioning|Participants will receive operant conditioning training and single pulse transcranial magnetic stimulation 2-3 times a week for about 8 weeks.
2905586|NCT03209531|Experimental|Control|Participants will receive single pulse transcranial magnetic stimulation 2-3 times a week for about 8 weeks without operant conditioning training.
2905587|NCT03209518||Leuprorelin acetate|Usually, for adults, 22.5 mg of Leuprorelin Acetate is subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants will receive interventions as part of routine medical care.
2905588|NCT03209505|Other|Eye 1: Low coefficient of friction|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. Eye 1 will be fit in a contact lens with a low coefficient of friction, Acuvue Oasys.
2905589|NCT03209505|Other|Eye 2: High coefficient of friction|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. Eye 2 One eye will be fit in a contact lens with a high coefficient of friction, Air Optix Night & Day Aqua
2905590|NCT03209492||Leuprorelin acetate|Usually, for adults, 22.5 mg of leuprorelin acetate is subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants will receive interventions as part of routine medical care.
2905591|NCT03209479||Glatiramer acetate|For adults, a 20 mg dose of glatiramer acetate will be subcutaneously administered once daily. Participants will receive interventions as part of routine medical care.
2905592|NCT03209466|Experimental|Standard management and Chlorhexidine gluconate at 0.125%|Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
2905593|NCT03209466|Placebo Comparator|Standard management and physiological saline sterile solution|Application every 24 hours, six weeks Intervention: Other: physiological saline sterile solution
2905594|NCT03209453|Experimental|study group|children with developmental delays, under regular rehabilitation programs, participate the family work shop family work shop: 6 families in one course, 2 hours per session, one session per week, a total of 6 weeks
2905595|NCT03209453|No Intervention|control group|children with developmental delays, under regular rehabilitation programs, not participate the family work shop
2905596|NCT03209440|Active Comparator|usual outpatient palliative care|During the usual care steps, patients will receive usual outpatient palliative care
2905597|NCT03209440|Experimental|Dignity Therapy - Nurse Led|During the experimental steps as part of routine palliative care service delivery, patients receive nurse-led DT.
2905598|NCT03209440|Experimental|Dignity Therapy - Chaplain Led|During the experimental steps as part of routine palliative care service delivery, patients will receive chaplain-led DT.
2905599|NCT03209427|Active Comparator|Group I|intrathecal injection of 100 μg morphine
2905600|NCT03209427|Active Comparator|Group II|iIntrathecal injection of 200 μg morphine
2905601|NCT03209414||Stable coronary artery disease|Patients with stable effort angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
2905602|NCT03209414||Unstable coronary artery disease|Patients with unstable angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
2905603|NCT03209414||Non-ST elevation myocardial infarction|Patients with non-ST elevation myocardial infarction wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
2905604|NCT03209414||ST-elevation myocardial infarction|Patients with ST elevation myocardial infarction wil be enrolled. In majority of patients primary percutaneous coronary intervention will be performed. Based on coronary angiography, heart team will decide on further medical treatment, percutaneous angioplasty, or bypass grafting.
2905605|NCT03209401|Experimental|Niraparib and Carboplatin|"Niraparib will be administered orally, once daily for 21 days of each 21-day cycle in escalating doses depending on cohort patient is assigned to.~Carboplatin will be administered via an injection on Day 2 of a given 21-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to."
2905606|NCT03209362|Experimental|SI-613|
2905607|NCT03209362|Placebo Comparator|Placebo|
2905608|NCT03209349|Experimental|Water Exchange Sigmoidoscopy|"As per standard practices, the patient will be walked to the procedure room and positioned in the left lateral position on the procedure bed, without pre-operative anesthesia. The procedures will be completed within the ambulatory endoscopy clinic at Kelowna General Hospital. The study will use the same colonoscopes that are already being used at KGH for colonoscopy. These are the Olympus 190 series colonoscopes. They can and will be fitted to support both water and air exchange.~For patients assigned the water exchange intervention arm, the insertion of the scope will be followed by infusion and suction of water to minimally distend the lumen. If the lumen does not open, the instrument will be retracted slightly and the infusion started again. As the scope is inserted and progressed through the intestinal lumen some of the infused water will be suctioned back constantly, exchanging clean for opaque water."
2905609|NCT03209349|Active Comparator|Air Insufflation Sigmoidoscopy|"As per standard practices, the patient will be walked to the procedure room and positioned in the left lateral position on the procedure bed, without pre-operative anesthesia. The procedures will be completed within the ambulatory endoscopy clinic at Kelowna General Hospital. The study will use the same colonoscopes that are already being used at KGH for colonoscopy. These are the Olympus 190 series colonoscopes. They can and will be fitted to support both water and air exchange.~For patients assigned to the air insufflation intervention arm, extended sigmoidoscopy will be performed with the minimum insufflation required to reach the cecum."
2905610|NCT03209336|Experimental|A group|Colorectal cancer patients first are given antineoplastic drugs and then transfer to operative room to be treated by surgical resection and the radiotherapy is given during the operation after the removal of the tumour.
2905611|NCT03209336|No Intervention|B group|Colorectal cancer patients first are given antineoplastic drugs and then transfer to operative room to be treated only by surgical resection and no radiotherapy afer the removal of the tumour.
2905612|NCT03209323|Experimental|sevoflurane - increasing concentrations|The patient was breathing spontaneously via the face mask and the sevoflurane concentration in the inhaled gas was doubled every 10 breaths starting from 0.3 vol. % in a sequence 0.3-0.6-1.2-2.4-4.8-8 vol. % until a minimal alveolar concentration (MAC) of 2 was obtained in the exhalation gas. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
2905613|NCT03209323|Experimental|sevoflurane - vital capacity|The anaesthetic circuit was prefilled with 8% sevoflurane. The patients were asked to exhale to the residual volume. Then the patients were explained to perform a vital-capacity breath with a face mask applied tightly to their faces. Then the patients were encouraged to hold their breaths as long as possible. Thereafter, the patients were asked to breathe spontaneously. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
2905614|NCT03209323|Experimental|propofol - intravenous induction|the patients were preoxygenated with 100% oxygen following which propofol was intravenously administered at a single dose of 2.5 mg/kg of body weight, after which it was infused with an infusion speed of 4 mg/kg body weight/h. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
2905615|NCT03209310||The children with Cerebral Palsy|Cerebral palsy (CP) can be defined as a group of disorders of movement and posture, causing activity limitation that are attributed to nonprogressive deficits that take place in the immature brain. The motor disorders of CP are often accompanied by deficits in sensation, cognition, communication, perception, behavioral and respiratory system.
2905616|NCT03209310||Control Group|Children with typical development were included in this study
2905617|NCT03209297|Experimental|Direct treatment|Patients receive the TMD treatment immediately
2905618|NCT03209297|Experimental|Delayed treatment|No intervention in the first 9 weeks of the study. Afterwards, the patients receive the same treatment as the other group
2905619|NCT03209284||narrow sinuses|transcrestal sinus floor elevation in narrow sinuses
2905620|NCT03209284||wide sinuses|transcrestal sinus floor elevation in wide sinuses
2905621|NCT03209271|Experimental|Body temperature fluid|500ml Ringers Acetate infused over 15 minutes warmed to 38°C
2905622|NCT03209271|Active Comparator|Room temperature fluid|500ml Ringers Acetate infused over 15 minutes cooled to 22°C
2905623|NCT03209258|Other|Goal-directed care bundle|Management policy to receive a goal-directed care bundle that involves the rapid correction (<1 hour) of physiological variables as soon as the abnormality is recognised and for the control to be maintained in patients for 7 days or hospital discharge (or death, if sooner)
2905624|NCT03209258|Other|Usual care group|Patients receive the usual management based on local guidelines and hospital's individual policy.
2905625|NCT03209245|Active Comparator|Active AIT group|"Injection immunotherapy with Purethal Mites were administered as perennial therapy using the following regimen of injections: 1 dose- 0.1 ml, 2 doses - 0.2 ml, 3 doses - 0.5 ml every week, and 0.5 ml every four weeks during 24 months.~monitoring of allergen specific IgE monitoring of allergen specific IgG4"
2905626|NCT03209245|Placebo Comparator|non-active, placebo treatment|symptomatic treatment with concomitant use of placebo injection monitoring of allergen specific IgE monitoring of allergen specific IgG4
2905627|NCT03209232|Experimental|Accelerated induction|Patients in group 1 will receive an accelerated induction of infliximab at 0,1,3 weeks (5 mg/kg) and then at week 7,11,15.
2905628|NCT03209232|Active Comparator|Per protocol|Patients in group 2 will receive a per protocol induction of infliximab at 0,2,6 weeks (5 mg/kg) and then at week 14.
2905629|NCT03209219|Experimental|Interferon Alpha 2A|Patients are treated with IFNα2a 3×10^IU α2a by subcutaneous injection or intramuscular injection daily for 4 weeks, and followed by every other day there after.
2905630|NCT03209219|Active Comparator|Cyclosporine|Patients are treated with oral CsA 100mg twice daily.
2905631|NCT03209206|Experimental|Docetaxel bladder instillation arm|After Surgery, intravesical chemotherapy with in 48 hrs (Docetaxel 75 mg diluted in 100 cc of normal saline)
2905632|NCT03209206|Placebo Comparator|Control arm|After Surgery, intravesical chemotherapy with in 48 hrs (Placebo, 100 cc of normal saline)
2905633|NCT03209193|Experimental|Sevoflurane|Sevoflurane (2 vol%) use as a maintenance volatile anesthetic drug during the surgery
2905634|NCT03209193|Experimental|Desflurane|Desflurane (6 vol%) use as a maintenance volatile anesthetic drug during the surgery
2905635|NCT03209180|Active Comparator|Carvedilol IR (Immediate Release)|Carvedilol IR 3.125mg, 6.25mg, 12.5mg, 25mg twice daily p.o. for 6 months
2905636|NCT03209180|Experimental|CarVeDilol-SR (Slow Release)|CarVeDilol-SR 8mg, 16mg, 32mg, 64mg once daily p.o. for 6 months
2905637|NCT03209167||DIEAP group|Patients who had undergone DIEAP flap breast reconstruction
2905638|NCT03209167||AP group|Patients who had undergone conventional abdominoplasty
2905639|NCT03209154|Experimental|Study Group|Study Group intervention: Therapeutic drug monitoring.
2905640|NCT03209154|Active Comparator|Control Group|Control Group intervention: No intervention first 3 months. After 3 months of follow-up, half of the patients in the Control Group will be randomized to perform home blood pressure monitoring as an intervention. No intervention in the other half.
2905641|NCT03209141||Diastolic dysfunctional hypertension|Patients with confirmed arterial hypertension and diastolic dysfunction by echocardiographic diastolic function evaluation
2905642|NCT03209141||Non diastolic dysfunctional hypertension|Patients with confirmed arterial hypertension and without diastolic dysfunction by echocardiographic diastolic function evaluation
2905643|NCT03209128||Irradiation prophyllactique cérébrale|
2905644|NCT03209115|Active Comparator|calcium hydroxide and chlorhexidine|Removal of old root canal filling and placing calcium hydroxide and chlorehexidine as intracanal medication
2905645|NCT03209115|Active Comparator|calcium hydroxide|Removal of old root canal filling and placing calcium hydroxide as intracanal medication
2905646|NCT03209102|Experimental|BPD adolescents|Adolescents suffering from Borderline Personality Disorder. Clinical assessment, Stress Elicitation Experiment, Structural and Functional MRI, salivary collections of amylase and cortisol
2905647|NCT03209102|Experimental|Healthy controls adolescents|Healthy controls adolescents. Clinical assessment, Stress Elicitation Experiment, Structural and Functional MRI, salivary collections of amylase and cortisol
2905648|NCT03209076|Experimental|Robotic|Robotic low anterior resection
2905649|NCT03209076|Active Comparator|Laparoscopic|Laparoscopic low anterior resection
2905650|NCT03209063||Group 1|"10 healthy controls (18-45 years) with no history of recurrent pregnancy loss and at least one uncomplicated full-term pregnancy."
2905651|NCT03209063||Group 2|45 patients having history of two or more pregnancy losses and no past history of Venous thromboembolism
2905652|NCT03209063||Group 3|45 patients having history of two or more pregnancy losses and past history of Venous thromboembolism
2905653|NCT03209050|Other|Central Venous Access Placement|Central venous access placement
2905654|NCT03209037|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
2905655|NCT03209037|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
2905656|NCT03209024|Other|Control|Participants complete a 3-week home blood pressure monitoring regimen using a handwritten logbook to record all blood pressure readings.
2905657|NCT03209024|Experimental|Intervention|Participants complete a 3-week home blood pressure monitoring regimen using a smartphone app and Bluetooth® technology to wirelessly record all blood pressure readings.
2905658|NCT03209011|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
2905659|NCT03209011|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
2905660|NCT03208998|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
2905661|NCT03208998|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
2905662|NCT03208985|Experimental|Use Phase (Ulipristal Acetate, 30 mg)|One tablet of 30 mg of ulipristal acetate for emergency contraception
2905663|NCT03208972|Experimental|low dose hCG (Pregnyl)|Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination 150IU low dose hCG from day 7 until final oocyte maturation.
2905664|NCT03208972|Active Comparator|hp-FSH (Menopur)|Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination with hp-FSH until final oocyte maturation.
2905665|NCT03208959|Experimental|50 mg BID (100 mg/day)|
2905666|NCT03208959|Experimental|100 mg BID (200 mg/day)|
2905667|NCT03208959|Experimental|200 mg BID (400 mg/day)|
2905668|NCT03208959|Experimental|400 mg BID (800 mg/day)|
2905669|NCT03208959|Experimental|600 mg BID (1200 mg/day)|
2905670|NCT03208946|Experimental|High-CML diet|An isocaloric, high-CML content diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat.
2905671|NCT03208946|Sham Comparator|Low-CML diet|An isocaloric, low-CML content diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat.
2905672|NCT03208933|Experimental|Pirfenidone|Participants will be administered pirfenidone 2403 milligram per day (mg/d) orally for 26 weeks in participants with IPF.
2905673|NCT03208920|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 4400 mg/day x 6 months (Nordic Naturals, Watsonville, CA, USA)
2905674|NCT03208920|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4400mg/day x 6 months
2905675|NCT03208907|Active Comparator|CQ coadministered with PQ|Chloroquine will be administered for 3 days according to the brazilian protocol and Primaquine will be administered for 14 days (0.50mg/kg/day)
2905676|NCT03208907|Experimental|DHA-PQP coadministered with PQ|Dihydroartemisinin/Piperaquine will be administered according to the weight and Primaquine (0.50mg/kg/day)
2905677|NCT03208907|Experimental|CQ and PQ starting on Day 42|Chloroquine will be administered for 3 days according to the brazilian protocol and Primaquine starting on Day 42 for 14 days (0.50mg/kg/day)
2905678|NCT03208907|Experimental|DHA-PQP and PQ starting on Day 42|Dihydroartemisinin/Piperaquine will be administered for 3 days according to the weight and Primaquine will start on Day 42 for 14 days (0.50mg/kg/day)
2905679|NCT03208894|Experimental|with salbutamol|
2905680|NCT03208894|Experimental|with furosemide|
2905681|NCT03208894|Experimental|both furosemide and salbutamol|
2905682|NCT03208894|No Intervention|no inervention|
2905683|NCT03208881||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
2905684|NCT03208868|Active Comparator|Leucine enriched essential amino acid|Patients with cirrhosis that are given a leucine enriched essential amino acid (EEA/LEU) supplement.
2905685|NCT03208868|Active Comparator|Balanced amino acid supplement|Patients with cirrhosis that are given a balanced amino acid (BAA) supplement.
2905686|NCT03208855|Experimental|CBT-I|Participants will receive 8 1-hour sessions of group Cognitive Behavioral Therapy for insomnia as part of their intensive outpatient treatment of substance use recovery
2905687|NCT03208855|No Intervention|Treatment as Usual|Participants will receive treatment as usual for substance abuse treatment as part of their intensive outpatient treatment of substance use recovery
2905688|NCT03208842||women with previous cesarean scar|"the patient will be examined son graphically at 3 visits~The first visit at less than 10 weeks gestation :trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity .~-----doppler assessment of the retro chorionic blood flow in the area behind the maximum chorionic tissue to detect sensitivity index (RI),in cases of low gestational sac Doppler assessment of peri trophoplastic blood flow will be assessed.~then the patient will be enrolled during routine ANC till delivery and data collected at32-34 weeks gestation regarding placental site will be correlated with 1st data and data at delivery ."
2905689|NCT03208842||women without previous cesarean scar|"the patient will be examined son graphically at 3 visits~The first visit at less than 10 weeks gestation :trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity .~-----doppler assessment of the retro chorionic blood flow in the area behind the maximum chorionic tissue to detect sensitivity index (RI),in cases of low gestational sac Doppler assessment of peri trophoplastic blood flow will be assessed.~then the patient will be enrolled during routine ANC till delivery and data collected at32-34 weeks gestation regarding placental site will be correlated with 1st data and data at delivery ."
2905690|NCT03208829|Experimental|Group 1|Rehabilitation Exercises Group 1 will be submitted to an exercise protocol based on muscle strength training, with duration of 6 weeks and frequency of two weekly sessions, lasting 45 minutes.
2905691|NCT03208829|Active Comparator|Group 2|Postoperative guidance Group 2 will receive an orientation booklet and weekly links from researchers to address possible questions.
2905692|NCT03208816|Other|single arm|symptom management program for chemotherapy patients
2905693|NCT03208790|Experimental|Group A|patients with oral premalignant lesions will receive thymoquinone capsules 100mg twice daily for 3 months.
2905694|NCT03208790|Experimental|Group B|patients with oral premalignant lesions will receive thymoquinone capsules 200mg twice daily for 3 months.
2905695|NCT03208790|Placebo Comparator|Group 3|patients with oral premalignant lesions will receive placebo twice daily for 3 months.
2905696|NCT03208777||control group|taking blood samples from apparently healthy people
2905697|NCT03208777||benign colorectal|taking blood samples from patients
2905698|NCT03208777||malignant colorectal|taking blood samples from patients
2905699|NCT03208764|Experimental|Nitric Oxide treatment|
2905700|NCT03208751|Other|Exercise training|All patients were included in the exercise training group
2905701|NCT03208738|No Intervention|Assessment only|
2905702|NCT03208738|Experimental|VetChange mobile app|
2905703|NCT03208738|Experimental|AFT + VetChange mobile app + supportive accountability tool|
2905704|NCT03208725||Hospitalized children|Children recited at admission to hospital and followed up for 180 days post-discharge.
2905705|NCT03208725||Community reference participants|Children recruited from the community who are seen a single appointment in the community.
2905706|NCT03208712|Experimental|Radium-223 and Atezolizumab|"Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses~Atezolizumab 1200 mg IV once every 3 weeks until investigator determined lack of benefit, unacceptable toxicity, or 17 doses"
2905707|NCT03208686|Other|Intervention Group|A single-arm intervention comprised of discussion groups, text messages, and a cloud-based cellular glucometer.
2905708|NCT03208673|Experimental|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep. The treatment regimen will be used for one month.
2905709|NCT03208660||Fycompa|Participants diagnosed with epilepsy and treated with Fycompa
2905710|NCT03208647||AA Group|All the patients of AA group met a AA diagnostic criteria；
2905711|NCT03208647||Control Group|The control group were chosen from other departments who were under acute infection (such as pneumonia), acute abdominal emergency (such as appendicitis), cataract surgery;
2905712|NCT03208634|Experimental|Robotic intervention|Robotic intervention.
2905713|NCT03208621||Observational group|The diagnostic tests to be investigated in this study is the use of PET and DLS in addition to the initial staging with gastroscopy and CT of patients with an advanced tumor (cT3-4)
2905714|NCT03208608||Normal hearing older adults|Older adults with normal hearing or age-related hearing loss
2905715|NCT03208582|Other|Single arm trial|Intervention : Risedronate Sodium (oral) Dosage: 1mg/kg/week Frequency: once/week Duration: 6 weeks
2905716|NCT03208556|Experimental|iPD1 CD19 eCAR T cells|patients will receive a lymphodepletion chemotherapy prior to CAR T cell infusion
2905717|NCT03208543|Experimental|HECT-CL|HECT-CL heat pack will be applied on CL lesions (50-52 degrees Celsius for 3 minutes on 7 consecutive days)
2905718|NCT03208530|Experimental|Intervention Arm|This is a single arm study with all enrolled patients receiving the same brief motivational interview intervention.
2905719|NCT03208517|Experimental|Arm 1: Regular Contact Group (WHELD +)|Regular Contact Group (WHELD elearning package + regular supervision support) A research associate will provide one face-to-face training session with participating care staff in the care home on how to use the online modules, providing a walk-through demonstration to ensure all are comfortable with the programme and its technology. The research associate will provide light touch support by returning fortnightly throughout the intervention period to the care home to observe/troubleshoot around online programme.
2905720|NCT03208517|Experimental|Arm 2: Online Contact Group (WHELD only)|Online Contact Group (WHELD elearning package only) The e-learning modules will be emailed to the care home with clearly written instructions on how to access the course.
2905721|NCT03208517|No Intervention|Arm 3: Enhanced usual practice Control Group|"Arm 3: Enhanced usual practice Control Group (with information/signposting re high quality on line e-learning and educational materials).~This will consist of a 2-page written guidance sheet on the best freely available dementia e-learning programmes and a one-off meeting with a research associate in the care home to explain the information/signposting"
2905722|NCT03208504|Experimental|Treatment|All subjects in treatment arm will be implanted with the Single Branch Nexus™ Aortic Arch Stent graft System.
2905723|NCT03208491|Experimental|serious games|
2905724|NCT03208491|Active Comparator|usual care|
2905725|NCT03208478|Active Comparator|Adductor Canal Nerve Block group|Adductor Canal perineural catheter placement. Adductor Canal continuous perineural infusion. Ropivacaine 0.2% will be administered at a continuous rate of 5 mL/hour through a perineural catheter placed in the adductor canal. A Nimbus pump (Infutronix) will be delivering the medication.
2905726|NCT03208478|Active Comparator|Femoral Nerve Block group|Femoral Nerve perineural catheter placement. Femoral continuous perineural infusion. Ropivacaine 0.2% will be administered at a continuous rate of 5 mL/hour through a perineural catheter placed near the femoral nerve. A Nimbus pump (Infutronix) will be delivering the medication.
2905727|NCT03208465|Experimental|Patients with Empagliflozin|
2905728|NCT03208465|Active Comparator|Patients with Sitagliptin|
2905729|NCT03208452|Placebo Comparator|Normal saline(NS) group|loading 50mL of normal saline during 10minutes before starting of surgery, after starting of surgery, continuous infusion of normal saline as placebo by 0.15mg/kg/h until the end of surgery
2905730|NCT03208452|Active Comparator|Magnesium group|loading dose of 50mg/kg magnesium sulfate during 10minutes before starting of surgery, during the surgery, continuous infusion of magnesium sulfate by 15mg/kg/h
2905731|NCT03208439|Experimental|EMG-driven NMES|subjects will receive EMG-driven NMES cycling exercise.
2905732|NCT03208439|Placebo Comparator|passive pre-programmed NMES|subjects will receive passive pre-programmed NMES during cycling exercise.
2905733|NCT03208426|Experimental|Sequential therapy for 14 days|Sequential therapy for 14 days (experimental) D1-D7: (Nexium, esomeprazole 40mg bid + amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid) for 7 days D8-D14: (Nexium, esomeprazole 40mg bid + Klaricid XL, clarithromycin 500mg bid + Flagyl, metronidazole 500mg bid) for another 7 days
2905734|NCT03208426|Active Comparator|bismuth quadruple therapy for 10 days|Bismuth quadruple therapy for 10 days (active comparator) D1-D10: (Nexium, esomeprazole 40mg bid + KCB F.C. TABLETS, dibismuth trioxide 120mg qid + Flagyl, metronidazole 500mg tid + tetracycline (Brand name: Tetracycline Capsule ) 500mg qid) for 10 days
2905735|NCT03208413|Experimental|thalidomide|Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
2905736|NCT03208400|Other|virtual reality exposure|one-session exposure conveyed via virtual reality technology
2905737|NCT03208387||Children Medulloblastoma Survivors|Participants previously treated for M0 non-disseminated medulloblastoma with cranio-spinal irradiation plus a boost to the posterior fossa
2905738|NCT03208387||Children Astrocytoma Survivors|Participants previously treated for a low grade cerebellar astrocytoma, with surgery only and neither chemotherapy nor cranial irradiation.
2905739|NCT03208387||Age-Matched Healthy Children Controls|
2905740|NCT03208374||MSK-IMPACT genetic panel testing|Participants have completed MSK-IMPACT genetic panel testing on Memorial Sloan Kettering Cancer Center protocol IRB #12-245 and/or IRB #06-107 and/or IRB # 09-141 in the last 3 years.
2905741|NCT03208361|Experimental|Penicillin V|Penicillin V, 1600000 IU every 8h during 10 days.
2905742|NCT03208361|Active Comparator|Amoxicillin|Amoxicillin, 1 g every 8h during 10 days.
2906013|NCT03206476|Experimental|Intervention group|Nutritional intervention based on the SCT and the TM
2905743|NCT03208348|Experimental|Pilot virtual reality|Children with anxiety will have a single visit to test the virtual reality system and measure its affects on their anxiety ratings.
2905744|NCT03208335|Experimental|rh-endostatin combination|Continuous intravenous pumping (CIP) recombinant human endostatin(rh-endostatin) 30mg/d, from 5 days before radiotherapy,for 7days,21 per cycle.Standard radiotherapy for HCC is conducted concurrently.Those patients will receive 3-5 cycles rh-endostatin after the radiotherapy is finished,4-6 cycles in all.
2905745|NCT03208322||DCV + ASV at a sentinel site|patients with chronic hepatitis C (CHC) who are being given at least 1 dose of daclatasvir (DCV) and asunaprevir (ASV) for the treatment and cure of CHC at the sentinel sites for the National Pharmacovigilance Center (CNFV) in Mexico.
2905746|NCT03208309|Active Comparator|Diacerein|Diacerein 50 mg immediate release capsule, once daily for the starting 28 days and Diacerein 50 mg immediate release capsule twice a day for the remainder of the study.
2905747|NCT03208309|Placebo Comparator|Placebo|Placebo capsules once a day for the starting 28 days and two times daily for the remainder of the study.
2905748|NCT03208296|Experimental|Cohort A|Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 4 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
2905749|NCT03208296|Experimental|Cohort B 1.5|Subjects with 4 or more lesions will receive 1.5 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
2905750|NCT03208296|Experimental|Cohort B 1.0|Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
2905751|NCT03208283|Active Comparator|Air insufflation group|During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
2905752|NCT03208283|Active Comparator|Water method group|During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
2905753|NCT03208270|Experimental|Antithrombin supplementation|Patients randomized to the study group will receive supplementation of antithrombin concentrate to maintain a functional antithrombin level between 80%-120%.
2905754|NCT03208270|Active Comparator|No Antithrombin supplementation|"Patients randomized to the control group will never receive supplementation of antithrombin unless heparin resistance occurs."
2905755|NCT03208257|Experimental|Esmolol|Intravenous esmolol will be administered as a continuous infusion according to protocol to control tachycardia with maximal infusion rates in the range of 10-40 mcg/kg/min.
2905756|NCT03208244|Experimental|Treatment with Direct Acting Antiviral for HCV|12 weeks of treatment with HCV Direct Acting Antiviral tablet
2905757|NCT03208231|Experimental|Arm 1: VRC01|Participants will receive VRC01 at Weeks 0, 2, 6, and 10.
2905758|NCT03208231|Placebo Comparator|Arm 2: No study treatment|Participants will not receive the study treatment.
2905759|NCT03208218|Experimental|SYP-1512|Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
2905760|NCT03208218|Active Comparator|Revlimid cap.|Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I&II D1(crossover)
2905761|NCT03208192|Experimental|Group 1|liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon) and water-jet dissector (ERBEJET 2).
2905762|NCT03208192|Experimental|Group 2|liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon), and ultrasonic aspirator (Misonix/SonaStar Ultrasonic Surgical Aspiration System)
2905763|NCT03208179|Active Comparator|IPTp-SP|Stat course of 3 tablets of quality-assured SP (tablets of 500 mg of sulphadoxine and 25 mg of pyrimethamine) at each scheduled antenatal visit
2905764|NCT03208179|Experimental|IPTp-DP|Dihydroartemisinin-piperaquine [3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days] + placebo AZ at each scheduled antenatal visit
2905765|NCT03208179|Experimental|IPTp-DPAZ|Dihydroartemisinin-piperaquine [3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days] + AZ tablet [1.5g over 3 days as 500mg per day] at each scheduled antenatal visit.
2905766|NCT03208166|Experimental|Ischemic Conditioning|Doctormate device is used daily.
2905767|NCT03208166|Other|Usual Care|Standard medical care.
2905768|NCT03208153|Experimental|Invasive|In-hospital routine coronary angiogram and revascularization if anatomically feasible
2905769|NCT03208153|Active Comparator|Conservative|In-hospital coronary angiogram only if poor clinical course
2905770|NCT03208127|Experimental|Treatment with Sofosbuvir/Velpatisvir Fixed Dose Combination|12 weeks of HCV treatment with combination tablet of Sofosbuvir + Velatisvir
2905771|NCT03208114|Experimental|Group A|Receiving the written information of the name of a breast milk substitute on the infant's discharge documents
2905772|NCT03208114|No Intervention|Group B|Not receiving the written information of the name of a breast milk substitute on the infant's discharge documents
2905773|NCT03208101|Experimental|Test group|DTP-HepB-IPV-Hib vaccine
2905774|NCT03208101|Active Comparator|Control group|DTP-HepB-Hib vaccine & IPV
2905775|NCT03208075|Experimental|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
2905776|NCT03208075|Experimental|Low-phosphorus Diet|Diet containing 500mg of phosphorus per day
2905777|NCT03208075|Experimental|High-phosphorus Die|Diet containing 2300mg of phosphorus per day
2906014|NCT03206476|Active Comparator|Control group|Nutritional information
2905778|NCT03208062||Patients|"The target group corresponds to the patients admitted to our Institute who are candidates for the following surgical or biopsy procedures and collection of waste materials:~patients with osteoarthritis of the hip or knee and rehabilitated in the institute~patients with primary and secondary tumors of the skeleton~patients undergoing prosthetic examination as a result of plant infection The population will include adult subjects(>18 years included). Patients will be considered eligible for enrollment in the project if they can provide informed written consent."
2905779|NCT03208049|Experimental|Sleep Restriction Therapy|Sleep Restriction Therapy (SR). The initial Time in Bed (TIB) prescription is calculated on the average total sleep time (TST) reported in the baseline sleep logs. After one week, depending on subject's daily sleep logs, the therapist suggests a new TIB prescription. Napping is neither prescribed nor proscribed. However, if subjects find themselves very sleepy (not just tired, but actually sleepy) they are advised to take a brief (15 to 30 minutes) nap to ensure their safety.
2905780|NCT03208049|Experimental|Cognitive Therapy|Cognitive Therapy (CT). The CT treatment module is designed to meet three general goals: 1) identification of dysfunctional sleep cognitions, 2) challenging their validity, and 3) replacing them with more adaptive substitutes. Several specific techniques designed to meet these goals are discussed in materials distributed to subjects. Similar to SR, subjects in CT are given information about relevant elements of the science of sleep and healthy sleep practices.
2905781|NCT03208036|Experimental|TDCS|TDCS offered concurrent with working memory focused cognitive training
2905782|NCT03208036|Sham Comparator|Sham|Sham stimulation offered concurrent with working memory focused cognitive training
2905783|NCT03208023|Active Comparator|Standard intraoperative care- no interventions|Standard intraoperative hemodynamic monitoring and treatment at Vanderbilt University Medical Center - No study interventions
2905784|NCT03208023|Experimental|RESIPI|Intraoperative implementation of RESIPI management strategy, a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical).
2905785|NCT03208010|Experimental|Diabetes Prevention Intervention|The intervention is 12 weeks of education on diet and physical activity, followed by 14 bi-weekly support groups for problem solving, and 3 booster sessions. Further, motivational interviewing will be integrated into all group sessions.
2905786|NCT03208010|Active Comparator|Enhanced Usual Care|"The control group will be an enhanced usual care control group that receives health care from personal physicians plus has access to: a) data collection sessions; b) individualized exit interviews with program staff after each data collection session to receive immediate feedback on lab results and trends in personal health indicators (e.g., BMI, A1C) and to ask questions; c) referral to a local physician or clinic, if needed; and d) Spanish-language materials on diabetes prevention."
2905787|NCT03207997|Experimental|Mild pulmonary fibrosis|mild pulmonary fibrosis (VFC> 75% theoretical and DLCO / VA> 55%) 2 additional unenhanced MR sequences
2905788|NCT03207997|Experimental|Moderate pulmonary fibrosis|moderate pulmonary fibrosis (VFC 50-75% and DLCO 36-55%) 2 additional unenhanced MR sequences
2905789|NCT03207997|Experimental|Severe pulmonary fibrosis|severe pulmonary fibrosis (VFC <50% theoretical or DLCO / VA <35%). 2 additional unenhanced MR sequences
2905790|NCT03207997|Active Comparator|Control group|2 additional unenhanced MR sequences
2905791|NCT03207984|Active Comparator|Control SCTG|Root coverage surgery with subepithelial connective tissue graft to treat multiple gingival recessions in aesthetic areas
2905792|NCT03207984|Experimental|Test MG|Root coverage surgery with Mucograft collagen matrix graft to treat multiple gingival recessions in aesthetic areas
2905793|NCT03207971|Active Comparator|SCTG from palatal area with predominance of lamina propria|
2905794|NCT03207971|Active Comparator|SCTG from palatal area with predominance of submucosa|
2905795|NCT03207958|Experimental|Belimumab|"Subjects meeting eligibility criteria will start treatment between Day +3- and Day +60 after alloHCT~Belimumab will be administered intravenously every 2 weeks for 3 cycles and then every 4 weeks for a total of 7 cycles (6 months)"
2905796|NCT03207945|Experimental|Alirocumab|Patients randomized into the alirocumab arm will start off with 75 mg alirocumab administered every two weeks for two doses and will be upwardly titrated to 150 mg alirocumab if subjects demonstrate LDL ≥ 50 mg/dL at week 4. Subjects demonstrating LDL-C <50mg/dl will remain on the same 75mg dose throughout the trial.
2905797|NCT03207945|Placebo Comparator|Placebo|Patients randomized into the placebo arm will receive 75 mg or 150 mg or placebo administered once every two weeks throughout the trial
2905798|NCT03207932||ultrasound|CVC insertion using ultrasound
2905799|NCT03207932||landmark technique|CVC insertion using landmark technique
2905800|NCT03207919|Experimental|Lullaby Project|
2905801|NCT03207919|No Intervention|Control Group|
2905802|NCT03207906|Active Comparator|Lower concentration VBP-926|VBP-926 solution applied to affected area BID
2905803|NCT03207906|Active Comparator|Higher concentration VBP-926|VBP-926 solution applied to affected area BID
2905804|NCT03207906|Placebo Comparator|Vehicle|Vehicle solution applied to affected area BID
2905805|NCT03207893|Experimental|GEM+CGM|GEM lifestyle modification & continuous glucose monitoring
2905806|NCT03207893|Active Comparator|Routine Care|Subject's current t2d treatment
2905807|NCT03207880|Experimental|MLPT|Multi-level pregnancy test
2905808|NCT03207867|Experimental|NIR178 + PDR001|Part 1: all patients will receive NIR178 continuously in combination with PDR001 400mg every 4 weeks. The part 1 will enroll 8 different tumor types.
2905809|NCT03207867|Experimental|NIR178 BID Intermittent + PDR001|Three different dosing schedules of NIR178 will be explored.
2905810|NCT03207867|Experimental|Part 3|Initiation of part 3 will depend on results from parts 1 and 2.
2905811|NCT03207867|Experimental|Japanese safety run-in part|Two different dosing schedules of NIR178 will be explored.
2905812|NCT03207854||Ancillary-correlative (biospecimen collection)|Patients and healthy normal volunteers undergo collection of peripheral blood samples for analysis via flow cytometry, RNASeq, immunohistochemistry, CyTOF experiments, cell cultures, and functional studies of immune cell subsets obtained by FACS. Patients also undergo collection of bone marrow and leukopheresis/leukoreduction specimens, and single cell suspensions and bulk excised tumor biopsies are obtained from routine testing for analysis via immunohistochemistry or CyTOF.
2905813|NCT03207841|Experimental|LC/HP group|Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include ~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio <1.5 and fat intake set at ~30% of the total energy intake. Dietary fat sources will focus on monounsaturated and polyunsaturated fats, e.g., plant oils and nuts; dietary carbohydrate sources will emphasize whole grains, fruits, vegetables, and legumes; and dietary protein sources will include lean meats, fish, chicken, eggs, and nonfat dairy foods, e.g., fat-free milk and low-fat cheese, consistent with American Diabetes Association and Institute of Medicine guidelines. All LC-HP meals will be provided by UAB Center for Clinical and Translational Sciences (CCTS) Bionutrition Unit and delivered to participants' homes 3 times/week (a sample menu is included in Appendix J). Every delivery will include breakfast, lunch, dinner, and snacks for 2 to 3 days.
2905814|NCT03207841|No Intervention|Control|Control group will not receive the experimental diet and will continue with their usual diets. Participants will complete three 24-hour food recalls (on 2 week days and one day in the weekend) three times (at weeks 1, 4 and 8) during the course of the study to gather dietary information including dietary intake and/or particular aspects of the diet. Participants will be asked to recall foods and beverages they consumed in the 24 hours prior to the interview. Three 24-hour food recalls appear optimal for estimating energy intake.
2905815|NCT03207828|Experimental|Behavioral activation group|This group will receive usual care for fibromyalgia with comorbid major depression plus in-group behavioral activation.
2905816|NCT03207828|Other|Usual care|"This group of participants will only receive usual care for fibromyalgia with comorbid depression.~Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) of the Red Salud Christus, the most important private medical care network in Chile. In this clinic treatment of fibromyalgia includes administering pregabalin and pain killers (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed."
2905817|NCT03207815|Experimental|Filgotinib|"All participants will receive a standardized prednisone burst of 60 mg/day at Day 1/Baseline followed by a protocol-defined mandatory taper schedule, to Week 15.~All participants will receive filgotinib for up to 52 weeks."
2905818|NCT03207815|Placebo Comparator|Placebo|"All participants will receive a standardized prednisone burst of 60 mg/day at Day 1/Baseline followed by a protocol-defined mandatory taper schedule, to Week 15.~All participants will receive placebo to match filgotinib for up to 52 weeks."
2905819|NCT03207802||Cohort 3|This cohort is living at home with a chronic condition.
2905820|NCT03207776|Other|Control|Treatment of patients in the usual manner based on their diagnosis and resources available at that site (Usual Care).
2905821|NCT03207776|Other|Intervention|A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services (COPD Clinical Pathway).
2905822|NCT03207763|Experimental|Cohort 1|Participating infants and children will receive Microneedle Formulation 1. At least 4 infants or children must complete Day 8 without halting criteria having been met before subjects will be enrolled into the next younger age group within a Cohort. At least the first 2 children will have a microneedle patch initially applied to the skin overlying the shoulder blade. If this site is well tolerated without halting criteria having been met additional microneedle patches may be applied to the same participants and in subsequent participants to the upper arm, forearm, wrist and/or thigh.
2905823|NCT03207763|Experimental|Cohort 2|Participating infants and children will receive Microneedle Formulation 2. At least 4 infants or children must complete Day 8 without halting criteria having been met before subjects will be enrolled into the next younger age group within a Cohort. At least the first 2 children will have a microneedle patch initially applied to the skin overlying the shoulder blade. If this site is well tolerated without halting criteria having been met additional microneedle patches may be applied to the same participants and in subsequent participants to the upper arm, forearm, wrist and/or thigh.
2905824|NCT03207750|Experimental|HRV Liq Group|All subjects will receive two doses of PCV-free HRV vaccine according to a 0, 2 month schedule along with a dose each of Pediarix®, Hiberix® and Prevenar 13® at Visit 1 (Day 1), Visit 2 (Month 2) and Visit 3 (Month 4).
2905825|NCT03207750|Active Comparator|HRV Lyo Group|All subjects will receive two doses of currently licensed lyophilized formulation of the HRV vaccine according to a 0, 2 month schedule along with a dose each of Pediarix®, Hiberix® and Prevenar 13® at Visit 1 (Day 1), Visit 2 (Month 2) and Visit 3 (Month 4).
2905826|NCT03207737|Experimental|MENTOR + Telehealth|This group will complete baseline testing, the MENTOR (Mindfulness, Exercise, and Nutrition To Optimize Resilience) program, and 7-days post baseline testing before beginning a one-year telehealth program.
2905827|NCT03207737|Active Comparator|Telehealth Only|This group will complete baseline and 7-days post baseline testing before beginning a one-year telehealth program.
2905828|NCT03207724|Experimental|Xilonix plus Onivyde and 5FU|interleukin-1-alpha antagonist (Xilonix) in addition to standard chemotherapy of onivyde and 5-fluorouracil/folinic acid (leucovorin)
2905829|NCT03207711|Active Comparator|Diet Education|All participants will receive instruction in the carbohydrate-restricted diet (CR).The study diet has approximately 10% of kcal coming from carbohydrate, typically 50 grams/day or fewer, not including fiber. Participants will be encouraged to eat a normal amount of protein, typically about 80-100 grams/day (about 20-25% of calories), and the rest of their calories from fat. Foods that are encouraged include green leafy and other non-starchy vegetables, nuts, seeds, oils (especially olive oil), fish, poultry, tofu, and avocados. Other foods consistent with the diet include berries (in modest amounts), meats, eggs, and cheese. Key foods to minimize include any sugar-sweetened foods or beverages, bread, pasta, potatoes, highly processed packaged foods, and other starchy foods.
2905894|NCT03207282||Participants with Diagnosis of Depression|Study population consists of participants with a clinical diagnosis of depression, being treated in a psychiatry reference site (example, clinic, ambulatory, hospital, day-hospital) in 4 Latin American countries. Participants with Major Depressive Disorder (MDD) enrolled in Phase 1, will be assessed to estimate the prevalence of Treatment Resistant Depression (TRD) and participants with this diagnosis will be included in Phase 2. Participants with TRD will be followed-up for 1 year.
2906099|NCT03205878|Active Comparator|Control group|Patients will receive standard care, being CPAP treatment
2905830|NCT03207711|Experimental|Diet Education + Mindfulness|In addition to the carbohydrate-restricted diet described above, the Ed+MBI group will receive mindfulness training consisting of two integrated components: 1) use of a mindful eating app at home to learn and practice mindfulness skills for food-cravings and eating, and 2) in-person group-based meetings to discuss and troubleshoot how the mindfulness practices are working. Key mindfulness content includes helping people improve their relationship with food and control food cravings and using mindful eating approaches including paying attention, noticing habit loops, understanding brain science and food/sugar addiction, disrupting emotional and stress eating, cultivating acceptance and curiosity, lovingkindness, detaching from thoughts, using healthy restraint, and maintaining motivation.
2905831|NCT03207698|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
2905832|NCT03207698|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
2905833|NCT03207698|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Metformin for treating furcation defect
2905834|NCT03207685|Other|All Subjects|This is a single arm study
2905835|NCT03207672|Experimental|Schedule 1: E7389-LF|Participants will receive E7389-liposomal formulation (LF) at a starting dose of 1.0 to 2.5 milligrams per meters squared (mg/m^2), administered as an intravenous (IV) infusion on Day 1 of a 21-day cycle (tri-weekly).
2905836|NCT03207672|Experimental|Schedule 2: E7389-LF|Participants will receive E7389-LF at a starting dose of 1.0 to 1.5 mg/m^2, administered as an IV infusion on Day 1 and Day 15 of a 28-day cycle (bi-weekly).
2905837|NCT03207659|Experimental|Dusting|small stones will be left to pass spontaneously.
2905838|NCT03207659|Experimental|Basketing|stones will be actively extracted.
2905839|NCT03207646|Experimental|smartphone-based cardiac rehabilitation|The BrightHeart® mobile application is installed on the smartphone and a heart coach set up and guides the participant through a cardiac care program.
2905840|NCT03207646|No Intervention|Control|Standard-of-care alone.
2905841|NCT03207633|Active Comparator|First group|First group (20 patients) receive for 10 sessions of low frequency rTMS targeting right DLPFC by means of a Butterfly coil using the following parameters: 120% RMT, 1 Hz, 3 trains, each of 500 pulses with a 40 seconds inter-train interval allowing the coil to cool.
2905842|NCT03207633|Active Comparator|Second group|The second group (20 patients) will receive 10 sessions of low-frequency rTMS over the right orbitofrontal cortex (OFC) by means of a Butterfly coil using the following parameters: 120% motor threshold, 1 Hz, 3 trains, each of 500 pulses with a 40 seconds inter-train interval allowing the coil to cool.
2905843|NCT03207633|Sham Comparator|Third group|The third group (the sham condition) (20 patients) will receive sham stimulations of rTMS with the same pulse delivery as the other groups but with the coil placed perpendicular to the scalp.
2905844|NCT03207620|Experimental|smoker asthmatics|"Asthma control questionnaire (ACQ) score~Spirometry~Sputum cytology~Airway corticosteroid sensitivity"
2905845|NCT03207620|Experimental|non-smoker asthmatics|"Asthma control questionnaire (ACQ) score~Spirometry~Sputum cytology~Airway corticosteroid sensitivity"
2905846|NCT03207607|Experimental|Control snack|Participants received control snacks prepared by real fruits (pear, orange and mango)
2905847|NCT03207607|Experimental|Maltodextrin snack|Participants received maltodextrin snacks (maltodextrin + control snack)
2905848|NCT03207607|Experimental|Whey protein snack|Participants received whey protein snacks (whey protein + control snack)
2905849|NCT03207607|Experimental|Oat snack|Participants received oat snacks (oat + maltodextrin + control snack)
2905850|NCT03207607|Experimental|Coconut oil snack|Participants received coconut oil snacks (coconut oil + control snack)
2905851|NCT03207607|Experimental|Snack skipping|Participants received snack skipping
2905852|NCT03207594|Other|Arm 1|Current smokers with cancer who are planning to get radiation therapy at MUSC.
2905853|NCT03207581|Experimental|Immediate Coaching Intervention|Immediate Coaching Intervention arm will receive professional coaching
2905854|NCT03207581|Active Comparator|Control/Delayed Coaching Intervention|Participants randomized to the Control/Delayed Coaching will receive no intervention for the first six months of the study, at which point they cross over and receive 6 professional coaching sessions
2905855|NCT03207568|Experimental|Relay Pro Device|The Relay Pro thoracic stent-graft will be used to treat pathologies eligible for thoracic endovascular aortic repair (TEVAR).
2905856|NCT03207555|Experimental|Ibrutinib|Participants take Ibrutinib by mouth 1 time every day for up to 2 years (24 cycles).
2905857|NCT03207542|Experimental|B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)|"Participants receive Daratumumab by vein over about 4 hours on Days 1, 8, 15, and 22 of Cycles 1 and 2, Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond.~Each cycle is 28 days."
2905858|NCT03207542|Experimental|T-Cell Precursor Acute Lymphoblastic Leukemia (ALL)|"Participants receive Daratumumab by vein over about 4 hours on Days 1, 8, 15, and 22 of Cycles 1 and 2, Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond.~Each cycle is 28 days."
2905859|NCT03207529|Experimental|Alpelisib + Enzalutamide|"Dose Escalation Phase: Participants take Alpelisib at starting dose of 250 mg by mouth daily. Enzalutamide taken at 160 mg fixed dose by mouth daily.~Dose Expansion Phase: If any specific molecular subtype or other signals such as PIK3CA status among responder patients are observed, 10 additional patients enrolled with that specific characteristic (e.g., TNBC patients only, or patients with PIK3CA H1047R mutation only) as an expansion cohort at RP2D. Participants take the maximum tolerated dose (MTD) of Alpelisib that was tolerated during Dose Escalation Phase. All 10 patients enrolled in the dose-expansion cohort receive one-week single agent treatment with Alpelisib.~Enzalutamide taken at 160 mg fixed dose daily.~Study cycle is 28 days."
2905860|NCT03207516|Active Comparator|Sourdough --> Brewer's Yeast|"Sourdough --> Brewer's Yeast~administration of two 100 g croissants prepared with sourdough after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points.~washout period: 7 days~administration of two 100 g croissants prepared with brewer's yeast after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points."
2905861|NCT03207516|Active Comparator|Brewer's Yeast --> Sourdough|"Brewer's Yeast --> Sourdough~administration of two 100 g croissants prepared with brewer's yeast after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points.~washout period: 7 days~administration of two 100 g croissants prepared with sourdough after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points."
2905862|NCT03207503||MDD patients|Participants ages 35-75 determined to be clinically depressed via structured clinical interview. No interventions will be administered as part of this study.
2905863|NCT03207503||non-MDD patients|Participants ages 35-75 determined to be lifetime free of psychiatric conditions as assessed by structured clinical interview. No interventions will be administered as part of this study.
2905864|NCT03207490|Experimental|Robot group|Receive 1 hour of AMADEO (robot-assisted therapy) for the hand and 1 hour of daily standard rehabilitation therapy
2905865|NCT03207477|Experimental|Prematurely born infants|Visual acuity measurement in prematurely born infants included in PREMAVISION study
2905866|NCT03207477|Active Comparator|Term born infants|Visual acuity measurement in term born control infants
2905867|NCT03207464|Experimental|Multiple Sclerosis|Subjects meeting the definition for Multiple Sclerosis by the International Panel Criteria19, with an Expanded Disability Status Scale (EDSS) less than 6.5.
2905868|NCT03207464|Experimental|Healthy Control|This group will serve as non disease population.
2905869|NCT03207451|Experimental|Vorapaxar|Subjects with multiple risk factors and antiplatelet naïve to receive Vorapaxar.
2905870|NCT03207451|Experimental|Vorapaxar and Clopidogrel|Subjects with 600 mg Load /75mg QD Clopidogrel QD for ≥ 7 days to receive Vorapaxar
2905871|NCT03207451|Experimental|Vorapaxar and Aspirin|Subjects with 81mg QD Aspirin to receive Vorapaxar
2905872|NCT03207451|Experimental|Vorapaxar, Aspirin, and Clopidogrel|Subjects with 81 mg QD Aspirin+75mg QD Clopidogrel to receive Vorapaxar.
2905873|NCT03207438|Experimental|Quetiapine XR 50mg|Quetiapine XR 50mg OD for 6 weeks
2905874|NCT03207438|Placebo Comparator|Placebo 1|Placebo OD for 6 weeks
2905875|NCT03207438|Experimental|Quetiapine XR 150-300mg|Quetiapine XR 150-300mg OD for 6 weeks
2905876|NCT03207438|Placebo Comparator|Placebo 2|Placebo OD for 6 weeks
2905877|NCT03207425|Experimental|Mild hepatic impairment group|
2905878|NCT03207425|Experimental|Moderate hepatic impairment group|
2905879|NCT03207425|Experimental|Matching healthy control group|Healthy control group will be matched with the hepatically impaired population with respect to age, sex and BMI
2905880|NCT03207412|Experimental|Minimally invasive implantation|Patients receive minimally invasive implantation, and 200 million hAECs is implanted into bilateral ovarian tissue by Ultrasound-guided puncture.
2905881|NCT03207412|Experimental|Intravenous infusion|100 million hAECs is administered by intravenous infusion every 30 days, for 3 times.
2905882|NCT03207399|Other|Epclusa|Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
2905883|NCT03207386|Experimental|Youth VIP|Youth VIP is a youth-led set of prevention strategies. Youth and their adult mentors are trained in evidence based sexual assault primary prevention strategies at a three day youth summit. The summit is followed by participation in working groups in which youth and their adult mentors will adapt best practices for sexual assault prevention to the Rapid City community and diffuse these strategies through both their own social networks and more formally in work in Rapid City middle and high schools.
2905884|NCT03207373|Experimental|Stress ECG Test|The whole study cohort undergoes the same diagnostic workup including stress test (ECG)
2905885|NCT03207360|Experimental|Pain Coping Skills|
2905886|NCT03207347|Experimental|Cohort A|This cohort will enroll patients with mesothelioma, uveal melanoma, renal cell carcinoma (clear cell type), and cholangiocarcinoma.
2905887|NCT03207347|Experimental|Cohort B|This cohort will enroll patients whose tumors have a known DNA damage response mutation in any of the following genes: ARID1A, ATM, ATR, BACH1 (BRIP1), BAP1, BARD1, BLM, CHEK1, CHEK2, CDK2, CDK4, ERCC, FAM175A, FEN1, IDH1, IDH2, MRE11A, NBN (NBS1), PALB2, POLD1, PRKDC (DNA-PK) PTEN, RAD50, RAD51, RAD52, RAD54, RPA1, SLX4, WRN, or XRCC. This cohort is open to patients with any type of malignancy (except prostate).
2905888|NCT03207334|Experimental|Midostaurin and Cytarabine|Treatment will consist of 3 phases: induction (a 28-42 day cycle), followed by consolidation (up to 4 cycles), and lastly maintenance (up to 24 cycles). Each cycle in the consolidation and maintenance phases will last 28 days. Patients will proceed from one phase to the next if they have achieved or maintained a complete remission or complete remission with incomplete blood count recovery by International Working Group 2003 response criteria. Patients may receive a allogeneic hematopoietic stem cell transplant between the end of the induction phase and the start of the maintenance phase.
2905889|NCT03207321||Intervention|In 15 intervention villages, a balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma' - was offered daily to pregnant women and children under six years of age during 1987-1990. The meal provided on average 500 kcal energy and 20-25g of protein to women and half of those amounts to children.
2905890|NCT03207321||Control|No supplement was provided in 14 control villages.
2905891|NCT03207308|Experimental|Vitamin A supplementation|55 children will receive a Mega-dose of preformed Vitamin A as recommended by the Senegalese Ministry of Health
2905892|NCT03207295|Experimental|Intervention-Nesiritide|A standard dose of Nesiritide(0.001ug/kg/min) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
2905893|NCT03207295|Placebo Comparator|Control-Normal saline|Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
2905895|NCT03207269|Experimental|High protein no carbohydrate|Dietary. Two eggs will be consumed 30 minutes prior to bedtime. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
2905966|NCT03206775||Healthy Controls, Battery A (Phase 2)|Participants will complete the Cognitive Battery A (Phase 2) developed by Posit Science while at the Minnesota State Fair.
2905896|NCT03207269|Active Comparator|High protein carbohydrate containing|Dietary. A low-fat yogurt will be consumed 30 minutes prior to bedtime. Protein will be matched to the high protein bedtime snack condition. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
2905897|NCT03207269|No Intervention|Control no snack|No snack will be consumed prior to bed.
2905898|NCT03207256|Experimental|TGR-1202|Oral TGR-1202 Daily
2905899|NCT03207256|Experimental|TGR-1202 + Ublituximab|Oral TGR-1202 in combination with Ublituximab intravenous administration
2905900|NCT03207243|Experimental|Subjects receiving GSK3772847|Eligible subjects will receive GSK3772847 once every 4 weeks via IV route along with 500/50 mcg FP/Sal twice daily for first 2 weeks and 500, 250, 100 or 50 mcg of FP twice daily for the rest of treatment phase.
2905901|NCT03207243|Placebo Comparator|Subjects receiving placebo drug|Eligible subjects will receive placebo once every 4 weeks via IV route along with 500/50 mcg FP/Sal twice daily for first 2 weeks and 500, 250, 100 or 50 mcg of FP twice daily for the rest of treatment phase.
2905902|NCT03207230|Experimental|Standard|All participants will perform the CPET at Baseline visit and will be provided with the Cardea SOLO, ActiGraph wGT3X-BT and Wavelet Wristband. The participants will be asked to response to KCCQ and Stanford 7 day recall surveys.
2905903|NCT03207217|Experimental|Phase I Knowledge Assessment|
2905904|NCT03207217|Experimental|Phase II Efficacy|
2905905|NCT03207217|Experimental|Phase II Acceptability|
2905906|NCT03207204|Active Comparator|G1 - 35% Hydrogen peroxide bleaching|In-office bleaching performed with 35% hydrogen peroxide (4 sessions, 1 session/week);
2905907|NCT03207204|Active Comparator|G2 - 30% Carbamide peroxide bleaching|In-office bleaching performed with 30% carbamide peroxide (4 sessions, 1 session/week);
2905908|NCT03207204|Experimental|G3 - Violet LED bleaching 1|In-office bleaching performed with Violet LED (405-410 nm, 4 sessions, 1 session/week);
2905909|NCT03207204|Experimental|G4 - Violet LED bleaching 2|In-office bleaching performed with Violet LED (405-410 nm, 4 sessions, 2 sessions/week);
2905910|NCT03207204|Experimental|G5 - Photochemical protocol 1|In-office bleaching performed Violet LED associated to 35% hydrogen peroxide (4 sessions, 1 session / week);
2905911|NCT03207204|Experimental|G6 - Photochemical protocol 2|In-office bleaching performed Violet LED associated to 30% carbamide peroxide (4 sessions, 1 session / week)
2905912|NCT03207204|Experimental|G7 - Hybrid technique 1|hybrid technique HP (Violet LED + application of 35% hydrogen peroxide + violet LED) (4 sessions, 1 session/week)
2905913|NCT03207204|Experimental|G8 - Hybrid technique 2|Hybrid technique CP HP (Violet LED + application of 30% carbamide peroxide + violet LED) (4 sessions, 1 session/week).
2905914|NCT03207191|Experimental|F16IL2 + BI 836858|"Successive cohorts of patients will receive increasing doses of FI6IL2 and BI 836858 until the MTD is reached. The MTD will be defined following a Bayesian logistic regression model (BLRM) with overdose control.~Patients will go off treatment after 6 months (i.e. after 6 cycles of induction combination therapy). Patients achieving CR or CRi will receive maintenance therapy for a maximum of 6 months."
2905915|NCT03207178|Experimental|Mixed CD19/CD20 CAR-T Transfer|Subjects with CD19+/CD20+ B-cell lymphomas will be infused with CD19-targeting CAR T Cells and CD20-targeting CAR T Cells in one time or in parts
2905916|NCT03207165|Active Comparator|Left ventricular [LV] +/- Biventricular dysfunction|Assessment of left ventricular [LV] or biventricular dysfunction will be based on clinical assessment, available imaging (echocardiogram, left ventriculogram, MUGA/RNA scan, cardiac MRI, etc.) and known past medical history (if available and contributory). Patients identified as having biventricular dysfunction will be randomized within the LV dysfunction arm of the trial. Patients in this arm will be randomized in a 1:1 fashion to Milrinone or Dobutamine.
2905917|NCT03207165|Active Comparator|Right ventricular [RV] dysfunction|Assessment of right ventricular [RV] dysfunction will be based on clinical assessment, available imaging (echocardiogram, left ventriculogram, MUGA/RNA scan, cardiac MRI, etc.) and known past medical history (if available and contributory). Patients in this arm will be randomized in a 1:1 fashion to Milrinone or Dobutamine.
2905918|NCT03207152|Experimental|Influenza A/California/04/2009|Participants will be inoculated with Influenza A/California/04/09 3.5x10(4) tissue culture infective dose 50% (TCID50) in 1 mL in Dulbecco's phosphate buffered saline (DPBS) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
2905919|NCT03207139|Experimental|Ga-68 PSMA ligand|
2905920|NCT03207126|Other|Women needing endometrial biopsy|All women who would be offered hysteroscopy guided biopsy as standard of care will be offered ultrasound guided biopsy first.
2905921|NCT03207113|Experimental|Ned Group|"Participants in the Ned case study (patients, caregivers, clinicians) will receive access to the Ned application.~Ned (No Evident Disease) is the first application to provide patients with access to individual-level prostate-specific antigen values streamed directly from the Ontario Laboratory Information System to their own smartphone. The application aims to promote self-care by informing patients directly of their PSA results and providing them with a personalised view of their own symptoms. It supports real-time clinical decision-making by providing clinicians with patient-reported outcomes collected in-app, and includes a curated educational feed and support group links."
2905922|NCT03207100|Experimental|Analgesia-first minimal sedation group|Using analgesia-first minimal sedation strategy to implement antihypertensive therapy.
2905923|NCT03207100|Active Comparator|Antihypertensive drug treatment group|Using routine antihypertensive drugs to implement antihypertensive therapy.
2905924|NCT03207087|Experimental|WEB Aneurysm Embolization Device|The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant. Subjects will be screened for study eligibility after giving informed consent.
2905925|NCT03207074|Other|All patients|Single study arm. All patients who participate in the study will recieve conventional histological diagnosis and diagnosis with the new technology (iKnife)
2905926|NCT03207061|Other|3D ultrasound and MRI|All patients with confirmed endometrial cancer will recieve the gold standard pre-operative imaging (MRI) but will also be offered 3D ultrasound.
2948116|NCT02918032||NLSD / TGCV|Patients who are diagnosed with NLSD / TGCV
2905927|NCT03207048|Experimental|Active rTMS|10 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for 15 mins each time, 5 times per week for up to 6 weeks (interrupt for 1-2 weeks after 10 times).
2905928|NCT03207048|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation
2905929|NCT03207035|Active Comparator|20 ml of lidocaine 2% with epinephrine|Patients will receive axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine.
2905930|NCT03207035|Experimental|40 ml 0f lidocaine 1% with epinephrine|Patients will receive axillary brachial plexus block with 20 ml of lidocaine 1% with epinephrine diluted with 20 ml of nacl 0.9% ( total 40 ml)
2905931|NCT03207022|Active Comparator|lidocaine 2% with normal saline|Patients will receive ultrasound guided axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine mixed with 2 ml of 0.9% normal saline.
2905932|NCT03207022|Experimental|lidocaine 2% with clonidine|Patients will receive ultrasound guided axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine mixed with clonidine 1µg/kg in 2 ml of 0.9% normal saline.
2905933|NCT03207009|Experimental|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product (autologous CD34+ cell-enriched population that contains cells transduced with LentiGlobin BB305 lentiviral vector encoding human βA-T87Q-globin)
2905934|NCT03206996|Experimental|Child Interventional|A 12 week patient-centered modified E/RP protocol for up to 5 participants with ASD and auditory hyper-reactivity. E/RP protocols will include face-to-face treatment sessions as well as the provision of home programs. Treatment fidelity checklists will be utilized each session to ensure that each participant receive the same general protocol/treatment process
2905935|NCT03206996|Experimental|Parental Interventional|A 12 week patient-centered modified E/RP protocol for up to 5 participants with ASD and auditory hyper-reactivity. E/RP protocols will include face-to-face treatment sessions as well as the provision of home programs. Treatment fidelity checklists will be utilized each session to ensure that each participant receive the same general protocol/treatment process
2905936|NCT03206983|Experimental|Cana's Ring group|The device Cana's Ring was used during cataract surgery on these patients.
2905937|NCT03206970|Experimental|BGB-3111|
2905938|NCT03206957|Other|Study group|Down Syndrome children
2905939|NCT03206957|Other|Control group n°1|Down Syndrome children's mothers
2905940|NCT03206957|Other|Control group n°2|Age and sex matched healthy children
2905941|NCT03206957|Other|Control group n°3|Down syndrome children's healthy siblings
2905942|NCT03206944|Experimental|Group 1 ASA|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg orally once a day in the morning.
2905943|NCT03206944|Experimental|Group 2 STE|Group 2 (STE) included 32 patients receiving tomato fruit extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally once a day in the morning.
2905944|NCT03206918|Experimental|BGB-3111|
2905945|NCT03206905|Experimental|Endoscopic Sleeve Gastroplasty|
2905946|NCT03206905|Active Comparator|Diet and exercise only.|
2905947|NCT03206892|Experimental|LESS surgery|Laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women using laparoendoscopic single-site surgery (single incision through the umbilicus using modified Hasson technique).
2905948|NCT03206892|Active Comparator|conventional multi-port laparoscopy|laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women using conventional multi-port laparoscopy (three port system using a closed technique on the umbilicus, left and right lower quadrant areas).
2905949|NCT03206866||patients with HCC|
2905950|NCT03206866||patients with hepatitis C Ab positive|
2905951|NCT03206866||patients with hepatitis C Ab negative|
2905952|NCT03206853|Experimental|Hybrid operation group|Intervene with hybrid operating techniques, eg. microsurgical clipping+endovascular coiling or with the assistant of balloon occlusion.
2905953|NCT03206853|Other|Traditional therapy group|The aneurysms will be executed by traditional procedure, including microsurgical clipping, endovascular coiling or stenting, etc.
2905954|NCT03206840|Experimental|Group 1|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
2905955|NCT03206840|Experimental|Group 2|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
2905956|NCT03206827|Active Comparator|70% animal, 30% plant proteins in diet|Dietary proteins from animal sources 70% and from plant sources 30%, representing an average Finnish diet consumed at the moment.
2905957|NCT03206827|Experimental|50% animal, 50% plant proteins in diet|Dietary proteins from animal sources 50% and from plant sources 50%, containing at most 500 g red meat/week (according to the current Finnish Nutrition Recommendations).
2905958|NCT03206827|Experimental|30% animal, 70% plant proteins in diet|Dietary proteins from animal sources 30% and from plant sources 70%.
2905959|NCT03206814|Active Comparator|Group 1 - Usual care|Standard strategy for management of hypertension, based on three-monthly visits at the referral centre.
2905960|NCT03206814|Experimental|Group 2 - POST-strategy|Patient Optimal Strategy for Treatment (POST) for management of hypertension, based on on three-monthly visits at the referral centre + providing the patients with the ESH-CARE APP system to communicate home blood pressure measurements to the referral centre, and the referral centre with an online platform to monitor the patients' status.
2905961|NCT03206801|Experimental|Intervention|Participants with high urine CXCL10 randomized to the Intervention Arm will undergo a kidney transplant biopsy to check for rejection. Biopsy-proven subclinical rejection will be treated per study protocol.
2905962|NCT03206801|No Intervention|Control|Participants with high urine CXCL10 randomized to the Control Arm will continue routine post-transplant surveillance with serum creatinine and proteinuria; serial urine samples will continue to be collected and analyzed (blinded), but not used to direct care.
2905963|NCT03206788|Experimental|losartan|25 or 50 mg of losartan twice daily, based on participant's weight.
2905964|NCT03206788|Placebo Comparator|placebo|placebo pill (matching losartan) twice daily
2905965|NCT03206775||Healthy controls (Phase 1)|Participants will participate in Cognitive Assessments (Phase 1) developed by Posit Science
2948430|NCT02915861||EXPc|Scrub typhus patients: Group C
2905967|NCT03206775||Healthy Controls, Battery B (Phase 2)|Participants will complete the Cognitive Battery B (Phase 2) developed by Posit Science while at the Minnesota State Fair.
2905968|NCT03206775||Healthy Controls, Battery C (Phase 2)|Participants will complete the Cognitive Battery C (Phase 2) developed by Posit Science while at the Minnesota State Fair.
2905969|NCT03206762|Experimental|Jetstream Atherectomy+Ranger DCB or Medtronic IN.PACT DCB|Jetstream Atherectomy used in conjunction with the Ranger DCB or Medtronic IN.PACT DCB
2905970|NCT03206762|Active Comparator|POBA+DCB (Ranger or IN.PACT)|POBA and then DCB treatment (Ranger or IN.PACT)
2905971|NCT03206749|Experimental|VX-150|
2905972|NCT03206749|Experimental|Hydrocodone bitartrate/Acetominophen (HB/APAP)|
2905973|NCT03206749|Placebo Comparator|Placebo|
2905974|NCT03206736|Experimental|Loop DS Patients|Patients who receive a Loop DS procedure
2905975|NCT03206723|Active Comparator|Group 1|1. Standard care
2905976|NCT03206723|Active Comparator|Group 2|"Standard care~Bandage contact lens"
2905977|NCT03206710||smokers who received Vitamin C|
2905978|NCT03206710||smokers who received placebo|
2905979|NCT03206710||control group non-smokers|
2905980|NCT03206697||Aneuploid mitochondria|Mitochondrial DNA content and metabolic parameters
2905981|NCT03206684|Experimental|PEG-rhG-CSF|PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，with patients' weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight <45kg were given 3mg once per chemotherapy cycle.
2905982|NCT03206684|Active Comparator|rhG-CSF|rhG-CSF was daily administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10^9/L.
2905983|NCT03206671|Experimental|R1/R2 stage I+II|Rituximab window + standard chemotherapy without anthracyclines (Vincristine not in R1)
2905984|NCT03206671|Experimental|R2 stage III experimental arm|Rituximab window + Standard chemotherapy
2905985|NCT03206671|Other|R2 stage III standard arm|Standard chemotherapy
2905986|NCT03206671|Experimental|R3/R4 rituximab plus arm|Rituximab window + standard chemotherapy plus six additional doses of rituximab
2905987|NCT03206671|Experimental|R3/R4 standard arm|Rituximab window + standard chemotherapy
2905988|NCT03206658|Placebo Comparator|placebo oral capsules|Placebo capsules equal to those in the study drug, will be administered every 24 hours for the first 5 days after entry into the critical care unit
2905989|NCT03206658|Experimental|spironolactone|capsules of spironolactone 25 mg equal to placebo, will be given every 24 hours for the first 5 days after entry to the critical care unit
2905990|NCT03206645|Experimental|Carboplatin/Paclitaxel + PTC|Carboplatin AUC 6mg/L IV on day 1; Paclitaxel 80mg/m2 IV on day 1, 8, 15; PTC596 (1.3 mg/kg in cohort 1), PO, twice a week, on day 1, 4, 8, 11, 15 and 18 per 21-day cycle for the first 3 cycles.
2905991|NCT03206632|Experimental|BI 690517 dose group 1|
2905992|NCT03206632|Experimental|BI 690517 dose group 2|
2905993|NCT03206632|Experimental|BI 690517 dose group 3|
2905994|NCT03206632|Placebo Comparator|Placebo|Matching placebo for each dose group
2905995|NCT03206619||Social, Local and Mobile|Patients having smoking cessation standard care (behavioral and pharmacological therapy) and using the SoLoMo mobile app that sends them motivational messages.
2905996|NCT03206606||Control Group|Primary care physicians and residents in family medicine of family medicine units affiliated with Laval University.
2905997|NCT03206606||Experimental Group|Primary care physicians and residents in family medicine of family medicine units affiliated with Laval University that will use the mobile application SPIRO(c) for a period of four months.
2905998|NCT03206580|Experimental|Concentric training|Concentric training
2905999|NCT03206580|Experimental|Concentric-eccentric training|Concentric-eccentric training
2906000|NCT03206567|Active Comparator|Nutrafol Supplement capsules|Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for 180 days with a substantial meal
2906001|NCT03206567|Placebo Comparator|Placebo Capsules|Subjects to take four (4) Placebo capsules by mouth daily for 180 days with a substantial meal.
2906002|NCT03206554|Active Comparator|LIA|Local infiltration analgesia
2906003|NCT03206554|Sham Comparator|sham LIA|Saline injections
2906004|NCT03206541||Cases|The cases are defined as individuals that present with new onset of a neurological syndrome of unknown etiology, including but not limited to encephalitis, myelitis, meningitis, polyneuropathy/Guillain-Barre syndrome and cranial nerve involvement.
2906005|NCT03206541||Controls|"There are two age-matched control groups:~Household controls that have lived with the case for at least three months before the onset of neurological symptoms.~Controls with a febrile syndrome of unknown etiology that do not present neurological involvement and is recruited in the same center as the case."
2906006|NCT03206528||VSMS with ear unit|application of Vital Signs Monitoring System with ear unit for 6-10 days during hospitalization (throughout their admission period)
2906007|NCT03206528||VSMS without ear unit|application of Vital Signs Monitoring System without ear unit for 6-10 days during hospitalization (throughout their admission period)
2906008|NCT03206515|Other|Group 1|Patients in Group 1 undergo Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath group
2906009|NCT03206515|Other|Group 2|Patients in Group 2 undergo Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function group
2906010|NCT03206502|Experimental|Embrace+Alert App|Participants are allowed to enter the trial (to use Embrace+Alert app) whether or not they have epilepsy. People without epilepsy may use Alert in this trial even though they are not expected to have seizures, as long as they are willing to mark false positives. Since many people with epilepsy live active lives and appear perfectly healthy outwardly, it is important that their active lifestyle data not trigger false alarms. Allowing healthy participants without epilepsy to contribute active lifestyle data helps us make the detection algorithm even stronger and better.
2906011|NCT03206489|Experimental|nHFOV|noninvasive high-frequency ventilation (nHFOV) is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
2906012|NCT03206489|Active Comparator|nCPAP|nasal continuous positive airway pressure (nCPAP) is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
2906015|NCT03206463|Experimental|Active 4 mg inhaled THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
2906016|NCT03206463|Experimental|Active 2 mg inhaled THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
2906017|NCT03206463|Placebo Comparator|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
2906018|NCT03206450||Observational (questionnaire, biospecimen collection)|Participants complete a health questionnaire over 30-45 minutes. Patients also provide saliva and semen samples and undergo collection of blood.
2906019|NCT03206437|Experimental|Mindfulness-Based Stress Reduction|This group will take the 8 week MBSR course within 4 weeks of their first testing visit. When the course is finished they will come in for their second testing visit. The course meets once a week in person for 2.5 hours and participants are expected to do practices at home.
2906020|NCT03206437|Other|Waitlist|The wait-list group will not participate in the MBSR course within 4 weeks of their first testing visit. They will wait 8-16 weeks and come on for a second testing visit. After their data is collected they will be offered an MBSR course to take.
2906021|NCT03206398|Other|pelvic fracture|patients with pelvic fracture will additionally be treated with anti-gravity treadmill
2906022|NCT03206385||CK Boost pelvis|
2906023|NCT03206372||Case group|The cases are the first-degree family members of propositi having had an thromboembolic venous disease in hormonal context.
2906024|NCT03206372||Control group|The controls are the first-degree family members of propositi who have never had an thromboembolic venous disease and have identical hormonal exposure
2906025|NCT03206359||Patients|Patients with SLE
2906026|NCT03206359||Healthy subjects|
2906027|NCT03206346|Experimental|Ingavirin|Broad spectrum antiviral drug
2906028|NCT03206346|Placebo Comparator|Placebo oral capsule|Placebo capsule identical in appearance to Ingavirin capsule
2906029|NCT03206333||Breast cancer patients treated with radiotherapy|
2906030|NCT03206320|No Intervention|Control|
2906031|NCT03206320|Active Comparator|Reference|
2906032|NCT03206320|Experimental|New|
2906033|NCT03206307||Group 1|Group 1 will be questioned 36 months (in 2017) after their medical rehabilitation which was in 2013/2014.
2906034|NCT03206307||Group 2|Group 2 has the medical rehabilitation in 2017 and will be questioned at the end of the medical rehabilitation and 6, 12 and 18 months after that
2906035|NCT03206294|Other|pharmacist assessment intervention group|St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
2906036|NCT03206281||Clinical fetal weight estimation|The fetal weight estimation will be taken by professional obstetrician durin her 39 week
2906037|NCT03206281||Sonographic fetal weight estimation|The fetal weight estimation will be taken by professional Sonographic obstetrician durin her 39 week
2906038|NCT03206268||healthy eyes|
2906039|NCT03206268||uveitis eyes|
2906040|NCT03206255||9-17y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
2906041|NCT03206255||9-14y (0,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
2906042|NCT03206255||18-26y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
2906043|NCT03206242||initial|0 month begin physiotherapy
2906044|NCT03206242||3 months after physiotherapy|3 months after physiotherapy
2906045|NCT03206242||6 months after physiotherapy|6 months after physiotherapy
2906046|NCT03206229|Experimental|TPI-120 (PEG-rhG-CSF)|PEG-rhG-CSF (recombinant granulocyte-colony stimulating factor conjugated with monomethoxypolyethylene glycol) Adello Biologics, LLC, Chicago, IL
2906047|NCT03206229|Active Comparator|Neulasta (PEG-rhG-CSF)|Neulasta®, (PEG-rhG-CSF) Amgen, Thousand Oaks, CA
2906048|NCT03206216|Experimental|Diagnostic (DLss test)|Patients undergo DLss test over 30 minutes at 9 and 21 weeks after the first day of standard of care chemotherapy.
2906049|NCT03206203|Experimental|Arm 1 (atezolizumab, carboplatin)|Patients receive atezolizumab IV over 30-60 minutes and carboplatin IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2906050|NCT03206203|Experimental|Arm 2 (atezolizumab, carboplatin)|Patients receive carboplatin as in Arm 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may cross-over to Arm 1 upon disease progression.
2906051|NCT03206190|Experimental|Mutation carrier|The participants will be tested genetically if they carry a disease causing mutation or not. Depending on their genetic test result they will at the end of the study divided into two groups. The clinician will be blinded throughout the entire study to the genetic results.
2906052|NCT03206190|Experimental|Non-mutation carrier|The participants will be tested genetically if they carry a disease causing mutation or not. Depending on their genetic test result they will at the end of the study divided into two groups. The clinician will be blinded throughout the entire study to the genetic results.
2906053|NCT03206190|Experimental|Known-mutation carriers but presymptomatic|In a third arm (open arm) we will also include positive predictive tested participants which know that they are carrying a known mutation but are at inclusion into the study asymptomatic (according to the inclusion / exclusion criteria).
2906054|NCT03206177|Experimental|Paclitaxel/Carboplatin + Galunisertib|
2906055|NCT03206164|Experimental|Asynchronous, eLearning Intervention|Participants in the asynchronous, eLearning Intervention Group will participate in the on-demand HealthMatters Program Instructor Training Course that will be continuously and readily available.
2906056|NCT03206164|Active Comparator|Synchronous, Live Webinar Comparison|Participants in the synchronous, Live Webinar Comparison Group will receive HealthMatters Program Instructor Training Course via a live instructor taught 3-part live webinar.
2948431|NCT02915861||EXC|Control group
2906057|NCT03206151|Experimental|CMAB009 + FOLFIRI|"Drug: CMAB009(recombinant chimeric anti-EGFR monoclonal antibody injection), will be administered every 7 days at an initial dose of 400mg/m^2 and 250mg/m^2 for subsequent infusions until progression of disease , withdrawal of consent, or unacceptable toxicity.~Drug: Irinotecan bi-weekly irinotecan infusion of 180mg/m^2 on Day 1. Drug: Folinic Acid infusion 400mg/m^2 of folinic acid in on Day 1. Drug: 5-Fluorouracil bolus 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-48 h continuous infusion of 2400mg/m^2.~every 2 weeks until progression of disease , withdrawal of consent, or unacceptable toxicity."
2906058|NCT03206151|Active Comparator|FOLFIRI|"FOLFIRI Drug: Irinotecan bi-weekly irinotecan infusion of 180mg/m^2 on Day 1. Drug: Folinic Acid infusion 400mg/m^2 of folinic acid in on Day 1. Drug: 5-Fluorouracil bolus 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-48 h continuous infusion of 2400mg/m^2.~every 2 weeks until progression of disease , withdrawal of consent, or unacceptable toxicity."
2906059|NCT03206138|Experimental|GX-188E, GX-I7|GX-188E + GX-I7
2906060|NCT03206138|Experimental|GX-188E, Imiquimod|GX-188E + Imiquimod
2906061|NCT03206125||ESCC Cases|ESCC Cases
2906062|NCT03206125||Controls|Controls
2906063|NCT03206112|Active Comparator|Focal Dystonia|Subjects diagnosed with Focal
2906064|NCT03206112|Placebo Comparator|Healthy|PAS25-cTBS150
2906065|NCT03206099||Probands|Probands will provide biological specimens for genetic testing and will be required to be enrolled on a primary protocol, which will execute the primary clinical and research evaluations.
2906066|NCT03206086|Experimental|Group|Eltrombopag
2906067|NCT03206073|Experimental|2/Arm A2|MTD of Pexa-Vec after the MTD is established +Durvalumab
2906068|NCT03206073|Experimental|1/Arm A1|Pexa-Vec escalation dose levels + Durvalumab
2906069|NCT03206073|Experimental|3/Arm B1|Pexa-Vec escalation dose levels + Durvalumab +Tremelimumab
2906070|NCT03206073|Experimental|4/Arm B2|MTD of Pexa-Vec after the MTD is established+Durvalumab + Tremelimumab
2906071|NCT03206060|Experimental|1/Lu-177-DOTATATE|Lu-177-DOTATATE
2906072|NCT03206047|Experimental|Cohort I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
2906073|NCT03206047|Experimental|Cohort II (guadecitabine, atezolizumab)|Patients receive guadecitabine SC on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on days 8 and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
2906074|NCT03206047|Experimental|Cohort III (guadecitabine, atezolizumab, CDX-1401 vaccine)|Patients receive guadecitabine and atezolizumab as in Cohort II. Patients also receive CDX-1401 vaccine IV on day 15 and poly ICLC SC on days 14-15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2906075|NCT03206034|Experimental|Treatment|The experimental group will meet with a study team member twice a week for 4 weeks (8 sessions) and receive memory strategy training.
2906076|NCT03206034|Placebo Comparator|Control|The control group participants will meet with a study team member twice a week for 4 weeks (8 sessions) and receive control memory exercises.
2906077|NCT03206021|Experimental|Phase I Dose-escalation|5'azacytidine will be administered on Days 1-7 at a dose of 75mg/m2/day, followed by escalating doses of Carboplatin on Day 14 in a rolling 6 design. Carboplatin will be dosed initially at AUC 4. Dose level -1 will reduce 5'azacytidine to 50mg/m2/day.
2906078|NCT03206021|Experimental|Posterior Fossa Ependymoma Expansion Arm|5'azacytidine will be administered on days 1-7 and carboplatin will be administered on day 14 at the maximum tolerated dose achieved in the Phase I dose escalation to 20 patients with recurrent/refractory posterior fossa ependymoma.
2906079|NCT03206021|Experimental|Supratentorial Ependymoma Expansion Arm|5'azacytidine will be administered on days 1-7 and carboplatin will be administered on day 14 at the maximum tolerated dose achieved in the Phase I dose escalation to 10 patients with recurrent/refractory supratentorial ependymoma.
2906080|NCT03206008|Placebo Comparator|Normal saline group|after loading normal saline 100cc in 10-20 minutes, continuous infusion of normal saline until the end of surgery
2906081|NCT03206008|Active Comparator|Magnesium group|after loading magnesium sulfate dosing 50 mg/kg (100cc) in 10-20 minutes, continuous infusion of magnesium sulfate 15 mg/kg/h until the end of surgery
2906082|NCT03205995|Experimental|OMS721|Administration of OMS721
2906083|NCT03205982|Sham Comparator|Control|WiseApp that delivers fitness reminders
2906084|NCT03205982|Experimental|Intervention|WiseApp that delivers medication adherence reminders
2906085|NCT03205969|Experimental|Functional mobile game|Functional mobile game for chemotherapy side effect education
2906086|NCT03205956|Experimental|PD Group|A broad range of Parkinson's disease severity and disease duration. Some subjects will not be treated currently with levodopa, and thus likely will be early in the disease process.
2906087|NCT03205930|Experimental|Neo-MASCT|Neoantigen Multiple Target Antigen Stimulating Cell Therapy ( Neo-MASCT)
2906088|NCT03205917|Experimental|Group 1A (PGDM1400/Placebo )|HIV-Uninfected
2906089|NCT03205917|Experimental|Group 1B (PGDM1400/Placebo)|HIV-Uninfected
2906090|NCT03205917|Experimental|Group 1C (PGDM1400/Placebo)|HIV-Uninfected
2906091|NCT03205917|Experimental|Group 2A (PGDM1400 + PGT121/Placebo)|HIV-Uninfected
2906092|NCT03205917|Experimental|Group 2B (PGDM1400 + PGT121/Placebo)|HIV-Uninfected
2906093|NCT03205917|Experimental|Group 2C (PGDM1400 + PGT121/Placebo)|HIV-Uninfected
2906094|NCT03205917|Experimental|Group 3A (PGDM1400 )|HIV-infected off ART (VL 2x103 - 1x105 copies/ml)
2906095|NCT03205917|Experimental|Group 3B (PGDM1400+PGT121 )|HIV-infected off ART (VL 2x103 - 1x105 copies/ml)
2906096|NCT03205904|Active Comparator|Intervention group|Group that will be receive the diet
2906097|NCT03205904|No Intervention|control|Group that will not receive the diet
2906098|NCT03205891|Experimental|Brentuximab Vedotin + TAK228|"Participants receive Brentuximab Vedotin by vein on Day 1 of each cycle.~Participants take TAK228 by mouth either every day, or on a 5 days on/2 days off schedule. The study doctor will tell participant how often to take the study drug.~Each cycle is 21 days.~Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug."
2906100|NCT03205878|Experimental|Intervention group|Patients will receive CPAP and telecoaching
2906101|NCT03205852||group A (benefit-inform)|filling questionnaire based on benefits of surgery
2906102|NCT03205852||group B (side effect-inform)|filling questionnaire based on side-effects of surgery
2906103|NCT03205839|Experimental|Acceptance-based self-help|"Participants in this group will receive the self-help booklet.~Surviving to Thriving: ACT self-help for living well with a visible difference in appearance"
2906104|NCT03205839|No Intervention|Waitlist control group|Participants in this group will be placed onto a waitlist for the four-week intervention period.
2906105|NCT03205826|Other|Type of sedation used|All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
2906106|NCT03205800|Active Comparator|Mini-screw placement|One mini-screw (8 mm length) will be placed at the buccal plate of the extraction socket one week after the atraumatic extraction of maxillary first or second premolars in one side.
2906107|NCT03205800|No Intervention|No treatment|The other extraction socket site will be untreated.
2906108|NCT03205787|Experimental|Trifolium pratense|Red clover extract; 2 gelatin capsules (398 mg extract) per day for 14 days
2906109|NCT03205774|Sham Comparator|Supine position|patient in supine position, lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
2906110|NCT03205774|Sham Comparator|30° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 30°), lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
2906111|NCT03205774|Sham Comparator|45° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 45°), lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
2906112|NCT03205774|Sham Comparator|90° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 90°), lying on the back, after prolonged fasting and 10 min after free oral intake of water
2906113|NCT03205761|Experimental|olaparib|Patients with a positive methylation status on at least one of the two genes and lacking of known deleterious or suspected deleterious mutations in both genes could be included in the study to receive olaparib tablet formulation at 600 mg total daily dose (given in two oral administrations of 300 mg every 12 hours approximately). Patients will continue to receive their treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
2906114|NCT03205735||normal DPD result group|patients group with a normal DPD result
2906115|NCT03205735||elevated DPD result group|patients group with an elevated DPD result
2906116|NCT03205722||Melanoma patients with 1st-line Nivo treatment|Non-Interventional. Patients with advanced melanoma treated with nivolumab monotherapy prescribed as first-line therapy between June 2015 and June 2016.
2906117|NCT03205709|Active Comparator|Training Group 1|Computerized Cognitive Training
2906118|NCT03205709|Placebo Comparator|Training Group 2|Crossword puzzles
2906119|NCT03205696||Cases|36 youth with new diagnosis of acute/recent HIV as defined by laboratory assays Fiebig1-V with standard care of antiretrovirals (ARV) regimen provided by the clinician
2906120|NCT03205696||Controls|36 youth with newly diagnosed HIV but established HIV infection (Fiebig VI) with standard care of antiretrovirals (ARV) regimen provided by the clinician
2906121|NCT03205683|Experimental|Intraneural facilitation therapy|The intraneural facilitation intervention is a novel manual physical therapy approach with anecdotal evidence in neuropathic pain symptoms through biasing blood flow from an artery through the nutrient vessels into the epineurium of an accompanying nerve. The main concept of intraneural facilitation is the use of two manual holds. The first hold is called facilitation hold and includes putting the contralateral joint in a maximal loose-pack position that is comfortable to the patient. The hypothesis with this initial hold is the nerve will have greater excursion the accompanying artery and the nutrient vessels that are clustered at the joint will be stretched. This stretch may enlarge the opening at the junction of the artery and bridging nutrient vessel, therefore consistently creating a vascular bias into the neural epineurial capillaries. Theoretically, this creates increased epifascicular vascular pressure which may be absent due to epineurial ischemia.
2906122|NCT03205683|Sham Comparator|Sham therapy|"Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm Each visit will last about 45 minutes, twice a week for 6 weeks (total 12 sessions).~Missing > 4 sessions will invalidate subject outcomes."
2906123|NCT03205670|Experimental|Urethroplasty with a tissue-engineered construct|The investigators will take a sample of the buccal mucosa to isolate epithelial cells. Autologous cells will be seeded on a hybrid matrix. Urethroplasty with this tissue-engineered construct will be performed. This is a single arm study with no control. All patients will undergo the surgical operation.
2906124|NCT03205631|Sham Comparator|Sham Natural Frequency Patch|
2906125|NCT03205631|Active Comparator|Active Natural Frequency Patch|
2906126|NCT03205618||daclatasvir patients in KSA, UAE, and Qatar|patients treated with daclatasvir-containing regimens in KSA, UAE, and Qatar
2906127|NCT03205605|Other|baseline patch|patch
2906128|NCT03205605|Other|baseline gel|gel
2906129|NCT03205605|Other|patch with heat|patch
2906130|NCT03205605|Other|gel with heat|gel
2906131|NCT03205579|Experimental|Video group|Video cancer pain education (10 minutes ) the knowledge includes cancer pain definition, cancer pain treatment, pain assessment and role of patient in cancer pain management.
2906132|NCT03205579|Active Comparator|Conventional group|Face to face cancer pain education by trained nurse (10 minutes)the knowledge includes cancer pain definition, cancer pain treatment, pain assessment and role of patient in cancer pain management.
2906133|NCT03205566|Active Comparator|Arm A Raltegravir|Raltegravir 400mg tablet, taken twice a day for 7days.
2906134|NCT03205566|Active Comparator|Arm B Raltegravir Lamivudine|Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days.
2906135|NCT03205553|Other|Standard of Care Treatment|Non-treatment group will be placed in silo at time of birth and subsequently serially reduced in silo with umbilical tape until the bowel contents are at the level of fascial and deemed suitable for closure. A drain will be placed at the top of the silo as described below to aspirate peritoneal fluid for sampling. These subjects will have no change in current clinical management by the neonatologists or pediatric surgeons and will not receive peritoneal dialysis fluid.
2906136|NCT03205553|Experimental|Investigational Treatment Group|The Investigational treatment group will be treated with direct peritoneal resuscitation (DPR). These subjects will undergo DPR during the entirety of silo placement which is usually four to five days. The silo and drain placement will be placed as described below. No additional incisions will be made. These subjects will also be serially reduced with umbilical tape and closed as staged procedure which is the same as the non-treatment group.
2906137|NCT03205540|Experimental|Epidural analgesia|Lumbar continuous epidural block
2906138|NCT03205540|Experimental|Bilateral ACB|Ultrasound-guided bilateral adductor canal blocks
2906139|NCT03205527|Experimental|Slip training for chronic stroke|Chronic stroke subjects in this training group will receive bilateral overground, slip perturbation training.
2906140|NCT03205527|No Intervention|Control for chronic stroke|Chronic stroke subjects, after baseline walking trials, will walk for about 30 trials at their preferred walking pace to match the total trials the other groups receive before receiving a single slip each randomly on their non-paretic and paretic sides.
2906141|NCT03205527|Experimental|Slip training for sub-acute stroke|Sub-acute stroke survivors in this training group will receive bilateral overground, slip perturbation training.
2906142|NCT03205527|No Intervention|Control for sub-acute stroke|Sub-acute stroke subjects, after baseline walking trials, will walk for about 30 trials at their preferred walking pace to match the total trials the other groups receive before receiving a single slip each randomly on their non-paretic and paretic sides.
2906143|NCT03205514||NSTE-ACS with intermediate stenosis and negative FFR|Patients hospitalized because of an acute coronary syndrome without ST segment elevation and with intermediate culprit lesion with negative fractional flow reserve evaluation (>0.80).
2906144|NCT03205501|Experimental|IV-tracer EMI-137|"IV-administration of EMI-137: all patients will receive 0.13 mg/kg of the fluorescent tracer EMI-137 intravenously.~Molecular Fluorescence Endoscopy: approximately 2,5 hours after tracer administration, Molecular Fluorescence Endoscopy will be performed with additional measurements of fluorescence signals."
2906145|NCT03205488|Active Comparator|Cohort 1|Moderate to Advanced PD Population Randomized 1:1:1
2906146|NCT03205488|Active Comparator|Cohort 2|Early/de novo Randomized 2:1
2906147|NCT03205475|Active Comparator|A. Above Fidelity Phase 1 and Above Fidelity Phase 2|Alternating coaching and streamed or video feedback each week through phase 1, moves to video feedback only for phase 2.
2906148|NCT03205475|Active Comparator|B. Below Fidelity Phase 1 and Above Fidelity Phase 2|Receive weekly coaching in phase 1, move to video feedback only in phase 2
2906149|NCT03205475|Active Comparator|C. Above Fidelity Phase 1, Below in Phase 2- Add Refresher|Alternating coaching and streamed or video feedback each week through phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive a one week intensive in person refresher and then continue with weekly coaching and video feedback from the Senior Trainer (Enhanced Feedback plus intensive refresher course) for the final 12 weeks.
2906150|NCT03205475|Active Comparator|D. Above Fidelity Phase 1, Below in Phase 2- Add Peer|Alternating coaching and streamed or video feedback each week through phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive weekly coaching and video feedback from the Senior Trainer plus a weekly session paired with a local interventionist at fidelity (Enhanced Feedback plus peer support).
2906151|NCT03205475|Active Comparator|E. Below Fidelity Phase 1, Below in Phase 2- Add Refresher|Receive weekly coaching in phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive a one week intensive in person refresher and then continue with weekly coaching and video feedback from the Senior Trainer (Enhanced Feedback plus intensive refresher course) for the final 12 weeks.
2906152|NCT03205475|Active Comparator|F. Below Fidelity Phase 1, Below in Phase 2- Add Peer|Receive weekly coaching in phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive weekly coaching and video feedback from the Senior Trainer plus a weekly session paired with a local interventionist at fidelity (Enhanced Feedback plus peer support).
2906153|NCT03205462|Experimental|Group 1|Fluorothyazinone in a dosage of 300 mg (1 tablet) will be administrated to 5 volunteers
2906154|NCT03205462|Experimental|Group 2|Fluorothyazinone in a dosage of 600 mg (2 tablets) will be received per os (oral administration) as a single dose
2906155|NCT03205462|Experimental|Group 3|on the first day of administration, the product is received according to the following regimen: the first dosage of 60 mg (2 tablets) should be taken orally 30 minutes after meals and swallowed with room-temperature water; the second dosage - 1 tablet (300 mg) - 12 hours later, and then for 5 days the subjects will receive 2 tablets per day. The duration of antibacterial therapy is 6 days. The total dose of Fluorothyazinone per treatment course is 3900 mg.
2906156|NCT03205449|Experimental|MaPa Programme|Masayang Pamilya Parenting Program: A 12-session, a group-based parenting programme focused on reducing violence against children and improving child wellbeing in low-income families with young children
2906157|NCT03205449|Active Comparator|Treatment-as-usual|Parenting Effectiveness Service programme: A family strengthening programme delivered by trained service providers on a monthly basis.
2906158|NCT03205436|Experimental|Graft|Affinity human amniotic membrane
2906159|NCT03205423|Placebo Comparator|Gabapentin 0 mg|once daily at 8am
2906160|NCT03205423|Active Comparator|Gabapentin 1800 mg|once daily at 8am
2906161|NCT03205410|Experimental|Patients with RIPC|intervention: remote ischemic preconditioning - three cycles of 5-min ischemia, achieved by inflation of blood-pressure cuff to 200 mmHg, followed by 5-min reperfusion while the cuff was deflated were applied to the upper left arm.
2906162|NCT03205410|Sham Comparator|Patients without RIPC|intervention: no - remote ischemic preconditioning - in controls, the cuff was placed around the arm but not inflated.
2906163|NCT03205397|Experimental|Accompanying and information procedure|Preparation for anesthesia (explanations, film, booklet), the presence of a relative in the operating room and the awakening of the child.
2906164|NCT03205397|Other|Usual care|Consultation of anesthesia and the care of the child without parental presence
2906165|NCT03205384||surgical management|Patient older than 65 years old, undergoing urgent abdominal surgery in our center
2906166|NCT03205384||not surgical management|Patients that presents a surgical disease, but we desestimate surgical procedure
2906167|NCT03205371|Experimental|MenACYW conjugate vaccine+MMR+Varicella|Participants will receive 1 dose of MenACYW conjugate vaccine, 1 dose of MMR vaccine, and 1 dose of Varicella vaccine on Day 0.
2906168|NCT03205371|Experimental|MenACYW conjugate vaccine (South Korea)|Participants will receive 1 dose of MenACYW conjugate vaccine on Day 0.
2906169|NCT03205371|Active Comparator|MMR+Varicella|Participants will receive 1 dose of MMR vaccine and 1 dose of Varicella vaccine on Day 0.
2906170|NCT03205371|Experimental|MenACYW vaccine+DTaP-IPV-HB-Hib|Participants will receive 1 dose of MenACYW conjugate vaccine and 1 dose of DTaP-IPV-HB-Hib vaccine on Day 0.
2906171|NCT03205371|Experimental|MenACYW conjugate vaccine (Mexico)|Participants will receive 1 dose of MenACYW conjugate vaccine on Day 0.
2906172|NCT03205371|Active Comparator|DTaP-IPV-HB-Hib|Participants will receive 1 dose of DTaP-IPV-HB-Hib vaccine on Day 0.
2906173|NCT03205371|Experimental|MenACYW conjugate vaccine+PCV13|Participants will receive 1 dose of MenACYW conjugate vaccine and 1 dose of PCV13 vaccine on Day 0.
2906174|NCT03205371|Experimental|MenACYW vaccine (Russian Federation)|Participants will receive 1 dose of MenACYW conjugate vaccine on Day 0.
2906175|NCT03205371|Active Comparator|PCV13|Participants will receive 1 dose of PCV13 vaccine on Day 0.
2906176|NCT03205358|Experimental|MenACYW conjugate vaccine Group|Healthy, meningococcal vaccine naïve toddlers randomized to receive a single dose of MenACYW conjugate vaccine.
2906177|NCT03205358|Active Comparator|NIMENRIX® vaccine Group|Healthy, meningococcal vaccine naïve toddlers randomized to receive a single dose of NIMENRIX®
2906178|NCT03205345|Active Comparator|Emricasan (25 mg)|Emricasan 25 mg
2906179|NCT03205345|Active Comparator|Emricasan (5 mg)|Emricasan 5mg
2906180|NCT03205345|Placebo Comparator|Placebo|Matching placebo
2906181|NCT03205332|Experimental|Concreteness Training|Participants receive 1 session of training in concrete processing during the pre-intervention visit. They are then asked to engage in 30 minutes of concreteness practice daily, for 7 days.
2906182|NCT03205332|No Intervention|Control|Assessment only.
2906183|NCT03205319|Experimental|Intervention arm / e-learning|Patients will receive e-learning instead of upper GI endoscopy.
2906184|NCT03205319|No Intervention|Control arm / upper GI endoscopy|Patients will receive the upper GI endoscopy, i.e. standard of care
2906185|NCT03205293|Experimental|Intervention Group|Female Schoolchildren, their mothers and teachers will be exposed to multiple interventions designed through a participatory approach, integrating the ecological model.
2906186|NCT03205293|No Intervention|Control Group|Regular school curriculum
2906187|NCT03205267|Experimental|Bosutinib|Drug: Bosulif 100 mg or 500 mg tablets step in dosing scheme
2906188|NCT03205254|Active Comparator|Group A|Participants randomized to group A follow the 4-day Mediterranean diet and then the 4-day fast food diet with a 4-day washout period in between.
2906189|NCT03205254|Active Comparator|Group B|Participants randomized to group B follow the 4-day fast food diet and then the 4-day Mediterranean diet with a 4-day washout period in between.
2906190|NCT03205241|Experimental|n-3 PUFA|Omega-3 polyunsaturated fatty acid - 5.7g/ day for 4 weeks
2906191|NCT03205241|Placebo Comparator|Placebo|Olive Oil - 6g/ day for 4 weeks
2906192|NCT03205228|Experimental|Flupentixol + Melitracen & placebo|Deanxit® (Flupentixol + Melitracen) 5 mg/D*4 weeks will be given
2906193|NCT03205228|Active Comparator|Proton pump inhibitor & placebo|Miracid® (Omeprazole) 20 mg/D*4 weeks will be given
2906194|NCT03205228|Active Comparator|Psychoeducation&placebo|Psychoeducation by psychologists will be advised on Day 1 and Day 14 of the study time frame
2906195|NCT03205215|Experimental|Treatment|This arm will receive hyperbaric oxygen therapy.
2906196|NCT03205215|Sham Comparator|Sham|This arm will receive a sham hyperbaric oxygen therapy.
2906197|NCT03205202|Active Comparator|Cocoa extract + multivitamin|"Dietary Supplement: Cocoa extract (2 capsules each day containing a total of 600 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine)~Dietary Supplement: Multivitamin"
2906198|NCT03205202|Active Comparator|Cocoa extract + multivitamin placebo|"Dietary Supplement: Cocoa extract (2 capsules each day containing a total of 600 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine)~Dietary Supplement: Multivitamin placebo"
2906199|NCT03205202|Active Comparator|Cocoa extract placebo + multivitamin|"Dietary Supplement: Multivitamin~Dietary Supplement: Cocoa extract placebo"
2906200|NCT03205202|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|"Dietary Supplement: Cocoa extract placebo~Dietary Supplement: Multivitamin placebo"
2906201|NCT03205189|Other|Pre-operative prescription group|This group will have a pre-operative prescription delivered during the preoperative anesthesia clinic.
2906202|NCT03205189|Other|Postoperative prescription group|This group will receive the postoperative prescription.
2906203|NCT03205176|Experimental|Cohort 1|Patients will be enrolled in Cohorts of up to 6 patients each in a dose escalating scheme. The starting dose in Cohort 1 will be 2 mg AZD5153 taken once per day for 21 days as an oral capsule. Administration of AZD5153 will continue until disease progression or other study discontinuation criteria are met.
2906204|NCT03205176|Experimental|Cohort 2|If no DLTs are seen in the previous cohort(s) then patients will be enrolled in Cohorts of up to 6 patients each in a dose escalating scheme. The dose in Cohort 2 will be 5 mg AZD5153 taken once per day for 21 days as an oral capsule. If DLTs are seen in earlier cohorts then modeling will determine the dose level in this cohort. Administration of AZD5153 will continue until disease progression or other study discontinuation criteria are met.
2906231|NCT03205033|Placebo Comparator|Placebo|Placebo Oral Capsules, once a day at bedtime
2906232|NCT03205020||women with preterm labor|
2906205|NCT03205176|Experimental|Cohort 3|If no DLTs are seen in the previous cohort(s) then patients will be enrolled in Cohorts of up to 6 patients each in a dose escalating scheme. The dose in Cohort 3 will be 10 mg AZD5153 taken once per day for 21 days as an oral capsule(s). If DLTs are seen in earlier cohorts then modeling will determine the dose level in this cohort. Administration of AZD5153 will continue until disease progression or other study discontinuation criteria are met.
2906206|NCT03205176|Experimental|Cohort 4|If no DLTs are seen in the previous cohort(s) then patients will be enrolled in Cohorts of up to 6 patients each in a dose escalating scheme. The dose in Cohort 4 will be 20 mg AZD5153 taken once per day for 21 days as an oral capsule(s). If DLTs are seen in earlier cohorts then modeling will determine the dose level in this cohort. Administration of AZD5153 will continue until disease progression or other study discontinuation criteria are met.
2906207|NCT03205176|Experimental|Cohort 5|If no DLTs are seen in the previous cohort(s) then patients will be enrolled in Cohorts of up to 6 patients each in a dose escalating scheme. The dose in Cohort 5 will be 40 mg AZD5153 taken once per day for 21 days as an oral capsule(s). If DLTs are seen in earlier cohorts then modeling will determine the dose level in this cohort. Administration of AZD5153 will continue until disease progression or other study discontinuation criteria are met.
2906208|NCT03205176|Experimental|Cohort 6a|If no DLTs are seen in the previous cohort(s) then patients will be enrolled in Cohorts of up to 6 patients each in a dose escalating scheme. The dose in Cohort 6a will be 80 mg AZD5153 taken once per day for 21 days as an oral capsule(s). If DLTs are seen in earlier cohorts then modeling will determine the dose level in this cohort. Administration of AZD5153 will continue until disease progression or other study discontinuation criteria are met.
2906209|NCT03205176|Experimental|Cohort 6b|If no DLTs are seen in the previous cohort(s) then patients will be enrolled in Cohorts of up to 6 patients each in a dose escalating scheme. The dose in Cohort 6b will be 40 mg AZD5153 taken as oral capsules two times per day for 3 consecutive days followed by 4 days of no drug for a total of 21 days. If DLTs are seen in earlier cohorts then modeling will determine the dose level in this cohort. Administration of AZD5153 will continue daily until disease progression or other study discontinuation criteria are met.
2906210|NCT03205163|Experimental|Low-Dose Cohort: Recombinant FVIII (rFVIII) and BIVV001|Participants will receive a single intravenous (IV) low dose of recombinant coagulation factor VIII (rFVIII) followed by a washout period of at least 72-hour, then a single IV low dose of BIVV001.
2906211|NCT03205163|Experimental|High-Dose Cohort: rFVIII and BIVV001|Participants will receive a single IV high dose of rFVIII, followed by a washout period of at least 96-hour, then a single IV high dose of BIVV001.
2906212|NCT03205150|Experimental|LIK066 Dose 1|LIK066 Dose 1 will be taken once daily before lunch for 12 weeks
2906213|NCT03205150|Experimental|LIK066 Dose 2|LIK066 Dose 2 will be taken once daily before lunch for 12 weeks.
2906214|NCT03205150|Experimental|Placebo|Placebo will be taken once daily before lunch for 12 weeks.
2906215|NCT03205137||Telmisartan and hydrochlorothiazide group|
2906216|NCT03205137||Telmisartan and amlodipine group|
2906217|NCT03205137||Telmisartan+hydrochlorothiazide double-pill combination group|
2906218|NCT03205137||telmisartan+amlodipine double-pill combination group|
2906219|NCT03205124|Experimental|Pre-operative stimulation|Patients randomized to this group will receive 1 hour of continuous electrical stimulation three days prior to scheduled surgical date. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit. As the nerve becomes accustomed to the sensation of the stimulation, the voltage is increased to the next tolerable threshold and this is repeated throughout the one-hour period. Once the stimulation is complete, the stimulator is detached and the patient is informed of the surgical date. The wires are taken out at the conclusion of the pre-operative appointment. These patients will have fine gauge wires for post-operative sham stimulation implanted at the time of surgery. In the post-operative recovery room the stimulator is attached to their wires. However, the voltage will only be increased to a level they are able to sense.
2906220|NCT03205124|Sham Comparator|Sham stimulation|These patients will have the stimulator attached to their wires 3 days prior to scheduled surgical date and postoperatively as were in the previous groups. However, the voltage will only be increased to a level they are able to sense. The stimulator was then be turned off without the patients' knowledge. All connections are left in place for anhour duration. These patients will similarly have their wires removed after the conclusion of their pre-operative appointment and at the first post-operative follow-up within 1 week of surgery.
2906221|NCT03205124|Experimental|Pre and Post-operative stimulation|Patients randomized to this group will receive 1 hour of continuous electrical stimulation three days prior to scheduled surgical date and then again immediately post operatively. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit. As the nerve becomes accustomed to the sensation of the stimulation, the voltage is increased to the next tolerable threshold and this is repeated throughout the one-hour period. Patients randomized to this group will also receive 1 hour of continuous electrical stimulation post-operatively. These patients will have fine gauge wires for post-operative stimulation implanted at the time of surgery. In the post-operative recovery room the stimulator is attached to their wires. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit for one hour.
2906222|NCT03205098||Runners|To assess the evolution of biological markers of mesenteric ischemia during ultratrail.
2906223|NCT03205085|Experimental|CTEPH PATIENTS|Patients undergoing pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
2906224|NCT03205085|Experimental|PAH PATIENTS|patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation
2906225|NCT03205072||ERCP & Spy Glass DS|Patients with cadaveric donor or live donor liver transplantation referred for ERCP in the setting of a clinical suspicion of post liver transplant bile duct strictures.
2906226|NCT03205059|Experimental|LST MS curriculum+ Bullying/Cyberbullying serious game|
2906227|NCT03205059|Active Comparator|LST MS curriculum|
2906228|NCT03205046|Experimental|Part 1 continuous dose for vistusertib|acalabrutinib daily + vistusertib daily
2906229|NCT03205046|Experimental|Part 1 intermittent dose for vistusertib|acalabrutinib daily + vistusertib 5 days on and 2 days off
2906230|NCT03205033|Active Comparator|Melatonin|Melatonin 20 mg Oral Capsules, once a day at bedtime
2906234|NCT03205007|Experimental|Health promotion nutrition program|Health promotion nutrition program
2906235|NCT03204994|Experimental|Tumour injection of ICG|Indocyanine green injection into tumour before or during surgery.
2906236|NCT03204981|Experimental|Intramural Needle Ablation|
2906237|NCT03204968|No Intervention|control|
2906238|NCT03204968|Active Comparator|Treated|
2906239|NCT03204955|Experimental|Sodium chloride /sodium acetate (16.4%)|50cc doses of sodium-chloride/sodium-acetate (16.4%) along with 30cc bag of dummy solution (PlasmaLyte).
2906240|NCT03204955|Active Comparator|Sodium chloride (23.4%)|30cc per dose of sodium chloride (23.4%) along with 50cc dummy solution bag (PlasmaLyte)
2906241|NCT03204942|Active Comparator|PRF on DRG|Patients will receive Pulsed Radiofrequency (PRF) on Dorsal root ganglion(DRG) of the selected metastatic painful dorsal vertebrae, with temperature 42°C for 480 sec.,2 active cycles per second of 20 milliseconds each , with a voltage output 40 to 60-V range, impedance ranges between 150 and 400 Ohms at all levels using Fluroscopic guidance (FG).
2906242|NCT03204942|Active Comparator|TRF on DRG|Patients will receive Thermal Radiofrequency (TRF) on Dorsal root ganglion(DRG) of the selected metastatic painful dorsal vertebrae, with temperature 80°C for 90 sec.,2 cycles, using Fluoroscopic guidance (FG) .
2906243|NCT03204942|Active Comparator|Control group|The control group will have identical needle placement and preparation like the 2 previous groups without the RF lesion, but with the injection of particulate Betamethasone steroids and local anesthetic on DRG of the selected metastatic painful dorsal vertebrae, using Fluoroscopic guidance (FG).
2906244|NCT03204929|Experimental|Cu(II)ATSM|Cu(II)ATSM dosed once daily
2906245|NCT03204916||Observational (cancer care delivery analysis)|"CHART REVIEW: Patient medical record data is abstracted and treatment plans are reviewed for consistency to NCCN guidelines. For each patient, induction and post-induction care is recorded as either concordant with NCCN guidelines or non-concordant with NCCN guidelines.~SITE QUESTIONNAIRE: Participating sites complete a questionnaire which is designed to capture facility-oriented data.~FOCUS GROUPS: Healthcare providers participate in focus groups over 1-2 hours to discuss facilitators and barriers to AYA ALL guideline concordance. Participants provide responses via electronic handheld technology in order to maintain anonymity followed by discussion of the ideas for clarification."
2906246|NCT03204903|Experimental|Laser acupuncture|The subjects are treated at acupoints including BL2, TE23, ST2, LI4, ST36, and GB37 using laser acupuncture during 3 sessions per week for 12 weeks.
2906247|NCT03204903|Sham Comparator|Sham laser acupuncture|The subjects are treated at acupoints including BL2, TE23, ST2, LI4, ST36, and GB37 using sham laser acupuncture (without laser output) during 3 sessions per week for 12 weeks.
2906248|NCT03204890|Experimental|TPTNS|Transcutaneous Posterior Tibial Nerve Stimulation
2906249|NCT03204877|Active Comparator|Melatonin|Four capsules of Melatonin 10 mg is administered orally every hours for four hours during the study day.
2906250|NCT03204877|Placebo Comparator|Placebo|Four capsules of placebo is administered orally every hours for four hours during the study day.
2906251|NCT03204864|Active Comparator|Conventional CS lead placement|Patients will be implanted with a CRT device with or without defibrillator (P/D) as per standard clinical practice, without CS lead pacing specific optimization.
2906252|NCT03204864|Experimental|RLD Group|Patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.
2906253|NCT03204851|Active Comparator|Venous Stasis Ulcer|Venous Stasis Ulcer
2906254|NCT03204851|Active Comparator|Pressure Ulcers|Pressure Ulcers
2906255|NCT03204851|Active Comparator|Diabetic Foot Ulcers|Diabetic Foot Ulcers
2906256|NCT03204851|Active Comparator|Wounds from a variety of etiologies|Wounds from a variety of etiologies
2906257|NCT03204838||AML patients|Adult AML patients with the IDH mutation test performed at diagnosis.
2906258|NCT03204825|Experimental|Active TENS|Participants in the TENS groups will be provided with a TENS machine and training at the baseline visit to the Clinical research Facility (CRF). They will be instructed to use it daily as their symptoms require for 6 weeks. The active group will receive High Frequency-TENS (120 Hz, 200µs and a patient-determined intensity of ''strong but comfortable'').
2906259|NCT03204825|Placebo Comparator|Placebo TENS|Placebo TENS : Participants will receive the same model, programmed settings and instructions for use as those in the active group except that the device will be set to an ineffective stimulation (120 Hz, 200µs and a patient-determined intensity of '6mA). For the purpose of blinding, participants will be told that different dosages of TENS are being tested, some of which where the stimulation might not be perceivable even though the device is working.
2906260|NCT03204825|Experimental|Patient-Centred Education|Patient-Centred Education : a one-off three-hour workshop of structured group education (4-5 persons in each group) and three 2-weekly phone calls. The aim will be to modify patients' illness beliefs and perceptions about IC/PAD by educating them on disease pathology and management philosophy. After the workshop, each patient will be supported to set goals for walking, develop an action plan regarding how these goals will be met and encouraged to repeat this process for each new walking goal.
2906261|NCT03204825|Experimental|Patient-Centred Education + Active TENS|Combination of Patient-Centred Education arm and Active TENS arm.
2906262|NCT03204812|Experimental|Durvalumab + Tremelimumab|Durvalumab (1500 mg IV q4w) in combination with tremelimumab (75 mg IV q4w) for up to 4 doses/cycles each followed by Durvalumab 1500 mg IV q4w for up to a total of 8 months
2906263|NCT03204799||normal group|normal group (without diabetes diagnosis/treatment and in normoglycemia
2906264|NCT03204799||prediabetes|high risk, impaired fasting glucose, impaired glucose tolerance
2906265|NCT03204799||drug naive type 2 diabetes|type 2 diabetes, anti-hypoglycemic drug naive
2906266|NCT03204799||type 2 diabetes with metformin monotherapy|type 2 diabetes with metformin monotherapy
2906267|NCT03204799||type 2 diabetes with SGLT2 inhibitor monotherapy|type 2 diabetes with SGLT2 inhibitor monotherapy
2906268|NCT03204799||dyslipidemia with ezetimibe therapy|dyslipidemia with ezetimibe therapy
2906269|NCT03204786|Experimental|Vasopressin-Vasopressin|8 weeks of vasopressin nasal spray (16 international units twice daily)
2906270|NCT03204786|Experimental|Placebo-Vasopressin|4 weeks of placebo nasal spray followed by 4 weeks of vasopressin nasal spray (16 international units twice daily)
2951098|NCT02896608||control without epilepsy|
2906271|NCT03204786|Placebo Comparator|Placebo-Placebo|8 weeks of placebo nasal spray; followed by a 4 week open-label extension of vasopressin nasal spray (16 international units twice daily)
2906272|NCT03204773||SPG4 patients|Patients with confirmed mutations in the SPG4 (SPAST) gene
2906273|NCT03204773||Healthy controls|healthy controls (spouses, relatives, or other healthy controls)
2906274|NCT03204760|Experimental|dexamethasone|Dexamethasone is a long-acting glucocorticoid with a half-life of 36 to 72 hours . It has been used safely in children with croup and bacterial meningitis . It is well absorbed both orally and parenterally .Single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg).
2906275|NCT03204760|Experimental|prednisolone|Prednisolone is relatively short acting with a half-life of 12 to 36 hours, thereby requiring daily dosing. Outpatient steroid therapy is effective once compliance is assured.. Prolonged treatment course, vomiting, and a bitter taste may reduce patient compliance with prednisolone. Oral prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses .
2906276|NCT03204747||Patients enrolled|"Patient with multiple sclerosis and lower urinary tract symptoms, age > 18, able to walk without human help on 50 meters, able to hold urine at least 3 minutes.~A first record of gait will be at strong desire to void. A second record will be after void Gait records consist on : 3 10meter walk test and 1 Timed up and Go test."
2906277|NCT03204734|Experimental|Capecitabine|Capecitabine by mouth twice per day for 14 days, per 21 days as a cycle, until disease progress or toxicity can not be tolerated.Capecitabine starting dose was the dose used at the end of the combined chemotherapy regimen,eg:1000mg per BSA.
2906278|NCT03204734|Experimental|endocrine therapy|endocrine therapy will been given as a sequential treatment in Metastatic breast cancer patients who are got benefit in capecitabine-base chemotherapy.The medicine will be confirmed by the patient's past-treatment.
2906279|NCT03204721|Active Comparator|Extracorporeal photophoresis|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient.
2906280|NCT03204721|No Intervention|Controll|No procedure
2906281|NCT03204708|Active Comparator|iv analgesia|patients were given intravenously 100 mg of tramadol (contramal) 30 minutes before extubation after modified radical mastectomy.
2906282|NCT03204708|Active Comparator|catheter group|patients were placed a catheter under clavipectoral fascia and 30 ml of local anesthetic solution were given via catheter for postoperative analgesia
2906283|NCT03204695|Experimental|LAA Occlusion|
2906284|NCT03204682|Experimental|Patients with chronic refractory endometriosis pain|The aim of the study is to evaluate the feasibility of transcranial magnetic stimulation (rTMS) for analgesia on chronic refractory endometriosis pain.
2906285|NCT03204643|Experimental|BH-VPN|A bundle of usual care components applied consistently and completely, plus access to mental health trained patient navigators and navigation services.
2906286|NCT03204643|No Intervention|Usual Care|The standard intervention (Control - Usual Care) is given in this population. May contain some of the BH-VPN components.
2906287|NCT03204630|Active Comparator|Bifido|Infant formula containing Bifidobacterium breve CECT7263
2906288|NCT03204630|Active Comparator|Lfer|Infant formula containing Lactobacillus fermentum CECT5716
2906289|NCT03204630|Placebo Comparator|Control|Standard infant formula
2906290|NCT03204617|Experimental|DNA.HTI 4 mg + MVA.HTI 2x10^8pfu|DNA.HTI 4 mg at weeks 0, 4 and 8 + Vaccine MVA.HTI 2x10^8pfu at weeks 12 and 20.
2906291|NCT03204617|Placebo Comparator|Placebo|0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20.
2906292|NCT03204604|Experimental|Challenge A|Challenge A includes Cognitive testing - (FCSRT, Story Recall, BVRT, CogState One Card Learning), and PET scan with low calorie Ensure® shake containing no ketone esters. Dietary Supplement: Challenge A - low calorie Ensure®
2906293|NCT03204604|Experimental|Challenge B|Challenge B includes Cognitive testing - (FCSRT, Story Recall, BVRT, CogState One Card Learning), and PET scan with an Ensure® shake containing ketone esters. Dietary Supplement: Challenge B - Ensure® plus ketone esters (KE)
2906294|NCT03204591||LC with SALI|cirrhosis patients with severe acute liver injury
2906295|NCT03204578|Experimental|AB (Midazolam OD/Dormicum)|Subjects with sequence AB will first receive the Intervention OD formulation (Period A, 30 µg Midazolam) and at the second visit the oral solution (Period B, 30 µg Dormicum ).
2906296|NCT03204578|Experimental|BA (Dormicum/midazolam OD)|Subjects with sequence BA will first receive the Intervention oral solution (Period B, 30 µg Dormicum) and at the second visit the OD disintegrating formulation (Period A, 30 µg Midazolam).
2906297|NCT03204565|Experimental|CAF + HA (Test)|coronally advanced flap with hyaluronic acid
2906298|NCT03204565|Active Comparator|CAF (control)|coronally advanced flap alone
2906299|NCT03204539|Experimental|Alternative Treatment|Half of the participants will be randomized to blinded individualized lot selection for ITI.
2906300|NCT03204539|Other|Standard Treatment|The other half of the participants will receive random lot selection for ITI.
2906301|NCT03204526|Experimental|low frequency stimulation (LFS)|Low-frequency deep brain stimulation of the subthalamic nucleus
2906302|NCT03204513|Experimental|Vanderbilt Powered Knee-Ankle Prosthesis|"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using the Vanderbilt Powered Knee-Ankle (PKA) Prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions using the Vanderbilt Powered Knee-Ankle (PKA) Prosthesis. The device participants begin with will be randomly selected but there will be an equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."
2906333|NCT03204305|Active Comparator|Nonuser controls|No cannabis administration. Non-user controls will complete a PET scan where 20 millicuries of 11C-OMAR
2906373|NCT03204019|Experimental|Tegafur and Temozolomide|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2906374|NCT03204019|Active Comparator|Tegafur and Temozolomide combined with Thalidomide|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2906303|NCT03204513|Active Comparator|Microprocessor (MP) Knee Prosthesis|"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using their own Microprocessor (MP) Knee Prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions using the Microprocessor (MP) Knee Prosthesis. The device participants begin with will be randomly selected but there will be an equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."
2906304|NCT03204500|Experimental|Active treatment with dual therapy|This group is composed by 20 ALS subjects under 600mg valproate and 600 mg of litium carbonate per day, during 21 months. The tablets are given orally with meals.
2906305|NCT03204500|Placebo Comparator|placebos|This group is composed by 20 ALS subjects under placebo. Blue tablets ( placebo of VPA) and white tablets (placebo of Li) are administered under the same conditions.
2906306|NCT03204487|Experimental|Patients with glaucoma or ocular hypertension|
2906307|NCT03204474|Experimental|Treatment A - B|Single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 200 mg administered as 2 oral tablets [100 mg each]), followed by a Wash-Out Period of at least 7 days and a single administration of the test drug (Treatment B, a single dose of LCM 200 mg administered as intravenous infusion)
2906308|NCT03204474|Experimental|Treatment B - A|Single administration of the test drug (Treatment B, a single dose of LCM 200 mg administered as intravenous infusion), followed by a Wash-Out Period of at least 7 days and a single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 200 mg administered as 2 oral tablets [100 mg each])
2906309|NCT03204461||PCOS-NIH|
2906310|NCT03204461||PCOS-Rotterdam|
2906311|NCT03204461||Controls|
2906312|NCT03204448||Relevant Disease Samples|Samples are tested on BioCLIA Ro60 instrument with Ro60 assay reagents, also as comparison, tested on BioFLASH instrument with QUANTA Flash Ro60 reagents
2906313|NCT03204448||Control Disease Samples|Samples are tested on BioCLIA Ro60 instrument with Ro60 assay reagents, also as comparison, tested on BioFLASH instrument with QUANTA Flash Ro60 reagents
2906314|NCT03204435|Other|Traditional therapy|Consists of microsurgical aneurysmal operating techniques, endovascular techniques for intracranial aneurysms, endovascular techniques for cerebrovascular stenosis, and carotid endarterectomy, which are presented by stages.
2906315|NCT03204435|Experimental|Hybrid operation|Consists of microsurgical aneurysmal operating techniques, endovascular techniques for intracranial aneurysms, endovascular techniques for cerebrovascular stenosis, and carotid endarterectomy, which are presented in one-stage in hybrid operating theater.
2906316|NCT03204422||Children's group|no intervention. participants, whose age was 8 to 18 years, were enrolled in Children's group.
2906317|NCT03204422||Adults group|no intervention. participants, whose age was over 18 years, were enrolled in Adults group.
2906318|NCT03204409||Symptomatic adults|adult patients (>18 years) presenting with febrile or rash illness of short duration (<72h)
2906319|NCT03204396|Active Comparator|Intervention group|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via pen s.c. once weekly for 12 weeks.
2906320|NCT03204396|Placebo Comparator|Placebo group|0.5 ml normal saline (0.9% sodium chloride (NaCl)), injection s.c. via syringe once weekly for 12 weeks.
2906321|NCT03204370||MPS4A patients|
2906322|NCT03204357|Experimental|Fresh Autologous whole blood transfusion|The experimental group will have 15% of the estimated blood volume of autologous blood collected. This transfusion will be given at the end of the procedure.
2906323|NCT03204357|Active Comparator|Standard of Care Expectant Management of bleeding|the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
2906324|NCT03204344|Experimental|Intervention group|"For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking.~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking."
2906325|NCT03204344|Sham Comparator|Control group|"For all patients, routine fasting (drinking water allowed) begins from 22:00 on the day before surgery， water fasting begins from 6:00 on the day of surgery.~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided from 6:00. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, magnesium sulfate) are added when becessary."
2906326|NCT03204331|Experimental|Relugolix + Low-dose Hormonal Add-back|Relugolix 40 mg oral tablet co-administered with estradiol (1.0 mg) and norethindrone acetate (0.5 mg) once daily for 24 weeks.
2906327|NCT03204331|Experimental|Relugolix + Add-back Pbo -> Relugolix + Add-back|Relugolix 40 mg oral tablet co-administered with low dose hormonal add-back placebo, once daily for 12 weeks, followed by relugolix 40 mg oral tablet co-administered with estradiol (1.0 mg) and norethindrone acetate (0.5 mg) once daily for 12 weeks.
2906328|NCT03204331|Placebo Comparator|Relugolix Placebo + Add-back Placebo|Placebo relugolix oral tablet co-administered with low dose hormonal add-back placebo, once daily for 24 weeks.
2906329|NCT03204318|Experimental|Relugolix + Low-dose Hormonal Add-back|Relugolix 40 mg oral tablet co-administered with estradiol (1.0 mg) and norethindrone acetate (0.5 mg) once daily for 24 weeks.
2906330|NCT03204318|Experimental|Relugolix + Add-back Pbo -> Relugolix + Add-back|Relugolix 40 mg oral tablet co-administered with low dose hormonal add-back placebo, once daily for 12 weeks, followed by relugolix 40 mg oral tablet co-administered with estradiol (1.0 mg) and norethindrone acetate (0.5 mg) once daily for 12 weeks.
2906331|NCT03204318|Placebo Comparator|Relugolix Placebo + Add-back Placebo|Placebo relugolix oral tablet co-administered with low dose hormonal add-back placebo, once daily for 24 weeks.
2906332|NCT03204305|Active Comparator|Cannabis users|Smoked Cannabis plant material (0 and 25 mg THC) will be administered to volunteers who are regular cannabis users. Cannabis users will also complete a PET scan where 20 millicurie of 11C-OMAR
2951139|NCT02896400|No Intervention|Control|Control arm, no intervention
2906334|NCT03204292||IVC/Ao|ultrasound, the inferior vena cava and abdominal aorta were measured. Inferior vena cava width was assessed at an interval of approximately 1 cm distal from connection of the hepatic vein to the inferior vena cava. No significant changes were observed in the width of the inferior vena cava during various respiratory phases, because of the positive pressure ventilation. The widest value was always chosen for the data. The assessment of the width of the abdominal aorta was performed above arise of the celiac trunk, at the height of the vein of the lower vena cava.
2906335|NCT03204279|Experimental|Netupitant 1.33 mg/kg plus Palonosetron|Single oral dose of Netupitant 1.33 mg/kg up to a maximum of 100 mg (for patients < 3 months of age the netupitant dose will be 0.8 mg/kg) administered with single oral dose of 20 μg/kg palonosetron up to a maximum of 1.5 mg.
2906336|NCT03204279|Experimental|Netupitant 4 mg/kg plus Palonosetron|Single oral dose of Netupitant 4 mg/kg up to a maximum of 300 mg (for patients < 3 months of age the netupitant dose will be 2.4 mg/kg) administered with single oral dose 20 μg/kg palonosetron up to a maximum of 1.5 mg.
2906337|NCT03204266|Experimental|Immunonutrition: ARS + Omega-3 Fatty Acids|"Participants take 1 ounce (30mls) of Arginine recovery supplement (ARS) four times daily 5 days preoperatively and 14 days postoperatively.~Participants also given omega-3 fatty acids, 1 gram four times a day, 4 grams total per day. This will be started 7 days preoperatively and continued 14 days postoperatively."
2906338|NCT03204266|No Intervention|No Immunonutrition|Participants receive regular enhanced recovery after surgery (ERAS)/Optimized Surgical Journey (OSJ) education and follow up.
2906339|NCT03204253|Experimental|rFSH + r-LH in combination|treatment group
2906340|NCT03204253|Active Comparator|rFSH alone|control group
2906341|NCT03204240|Experimental|Intervention|This group will receive electrical stimulation induced exercises in addition to their standard care during in-patient rehabilitation (IPR). Standard care will include respiration therapy, bed mobility, transfers, wheelchair mobility skills, bowel and bladder management, tone and spasticity management, and skills for performing other activities of daily living. Exercises will include neuromuscular electrical stimulation (NMES) induced-resistance exercise (RE) (1x/day) and NMES-aerobic exercise (1x/day) for 3 days/week.
2906342|NCT03204240|No Intervention|Control|This group will receive standard care plus passive dynamic exercise of the lower legs (sham treatment for NMES-RE, 1x/day) and transcutaneous electrical nerve stimulation (TENS, sham treatment for NMES-aerobic exercise, 1x/day) during IPR.
2906343|NCT03204227|Experimental|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
2906344|NCT03204227|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
2906345|NCT03204201|Experimental|Urethral instillation of ICG|Urethral instillation of indocyanine green (ICG)
2906346|NCT03204188|Experimental|Single Arm|IFP
2906347|NCT03204175|Experimental|Fit Plus|The experimental arm will receive the Fit For School expanded intervention, which addresses pupil handwashing, toothbrushing, and school sanitation maintenance. Interventions will begin in July 2017.
2906348|NCT03204175|Active Comparator|Comparator|This group will receive the Fit Plus intervention after the trial is complete (January 2017)
2906349|NCT03204162|No Intervention|Teams with no CPR Coach|This will be a standardized Resuscitation team with no CPR Coach
2906350|NCT03204162|Experimental|Teams with CPR Coach|This will be a standardized Resuscitation team where one member will be the CPR Coach and provide CPR Coaching to the team.
2906351|NCT03204149|Experimental|Treatment group|"The treatment group will be treated with the MC-8XL laser device, emitting 808 nm laser beam with a green laser beam.~Intervention: MC-8XL low level laser device and Standard wound care"
2906352|NCT03204149|Sham Comparator|Control group|"The control group will receive treatment with a sham laser device, emitting a low power green light with inactive Infrared (IR) laser for indication only.~Intervention: Sham laser device and Standard wound care"
2906353|NCT03204136||tarcolimus|refractory inflammatory bowel disease patents who used tarcolimus to induce and maintain remission
2906354|NCT03204136||methotrexate|refractory inflammatory bowel disease patents who used methotrexate to induce and maintain remission
2906355|NCT03204123|Active Comparator|Ga-HBED-iPSMA PET with CT or MRI|Participants will have a PET scan with Ga-HBED-iPSMA. PET may be combined with CT or MRI at the discretion of the referring clinician.
2906356|NCT03204123|Active Comparator|Ga-HBED-iPSMA PET with MRI|Participants will have a PET scan with Ga-HBED-iPSMA and will be combined with MRI. If PET/MR imaging is not available, PET/CT imaging may be substituted. This arm will be closed to accrual and these patients will be analyzed separately.
2906357|NCT03204097|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
2906358|NCT03204097|Active Comparator|group 2|SRP followed by 1% Alendronate (ALN) gel
2906359|NCT03204097|Active Comparator|group 3|SRP followed by Aloevera (AV) gel
2906360|NCT03204084||the LTP group|Patients undergoing pterygium surgery with fibrin glue and conjunctival autografting and receiving Low-temperature Plasma Surgery System(LTP group),
2906361|NCT03204084||the control group|Patients undergoing pterygium surgery with fibrin glue and conjunctival autografting and receiving the conventional method using surgical micro knife and ophthalmic hemostasis(control group)
2906362|NCT03204071|Placebo Comparator|Group 1|Placebo gel without active ingredient to be delivered at baseline, 6 and 12 months.
2906363|NCT03204071|Active Comparator|Group 2|Aloe vera gel to be delivered at baseline, 6 and 12 months.
2906364|NCT03204071|Active Comparator|Group 3|1% metformin gel to be delivered at baseline, 6 and 12 months.
2906365|NCT03204058|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
2906366|NCT03204058|Active Comparator|group 2|SRP followed by 1.2% rosuvastatin (RSV) gel
2906367|NCT03204058|Active Comparator|group 3|SRP followed by 1% Metformin ( MF) gel
2906368|NCT03204045|Active Comparator|fentanyl|fentanyl 1 ㎍/kg
2906369|NCT03204045|Active Comparator|oxycodone|oxycodone 0.08 mg/kg
2906370|NCT03204045|Placebo Comparator|control|isotonic saline
2906371|NCT03204032|Experimental|Tegafur and Temozolomide|
2906372|NCT03204032|Active Comparator|Tegafur and Temozolomide combined with Thalidomide|
2906581|NCT03202667|Placebo Comparator|Placebo|Treatment with Placebo tablets once daily for 28 days
2906375|NCT03204006|Active Comparator|Dexmedetomidine group|35 patients will receive dexmedetomidine 0.5 µg/kg was administered intravenously using a syringe pump over 10 min sterile saline pre-induction of anesthesia.
2906376|NCT03204006|Placebo Comparator|Control group|35 patients will receive sterile saline 0.5 µg/kg was administered intravenously using a syringe pump over 10 min pre-induction of anesthesia.
2906377|NCT03203967|Experimental|Epidural morphine|"Epidural morphine (2 mg morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.~Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.~Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h."
2906378|NCT03203967|Placebo Comparator|Epidural placebo|"Epidural placebo (5 ml normal saline) is administered through the epidural catheter at the end of surgery.~Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.~Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h."
2906379|NCT03203954|Active Comparator|No Training|Guided learning, standard learning: Repeat administration of standard behavioral learning task
2906380|NCT03203954|Experimental|Instructed Statistics|Guided learning, instructed statistics: Repeat administration of behavioral learning task with instructions about task statistics
2906381|NCT03203954|Experimental|Not Instructed Statistics|Guided learning, changing statistics: Repeat administration of behavioral learning task with changing task statistics
2906382|NCT03203928|Experimental|Occupational Therapy for Women with ADHD|7-week tailored intervention for women with ADHD who have difficulty carrying out student, worker, spousal, and parenting roles due to poor time management, organization of their physical environments, management of internal and external stressors, and regulation of internal and external stimulation. Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments.
2906383|NCT03203928|No Intervention|Control|No treatment provided.
2906384|NCT03203915|Experimental|Group 1|"Order of treatments:~A: Chardonnay grape pomace powder high polyphenol dose B: Chardonnay grape pomace powder low polyphenol dose C: Placebo"
2906385|NCT03203915|Experimental|Group 2|"Order of treatments:~A: Chardonnay grape pomace powder high polyphenol dose C: Placebo B: Chardonnay grape pomace powder low polyphenol dose"
2906386|NCT03203915|Experimental|Group 3|"Order of treatments:~B: Chardonnay grape pomace powder low polyphenol dose C: Placebo A: Chardonnay grape pomace powder high polyphenol dose"
2906387|NCT03203915|Experimental|Group 4|"Order of treatments:~B: Chardonnay grape pomace powder low polyphenol dose A: Chardonnay grape pomace powder high polyphenol dose C: Placebo"
2906388|NCT03203915|Experimental|Group 5|"Order of treatments:~C: Placebo A: Chardonnay grape pomace powder high polyphenol dose B: Chardonnay grape pomace powder low polyphenol dose"
2906389|NCT03203915|Experimental|Group 6|"Order of treatments:~C: Placebo B: Chardonnay grape pomace powder low polyphenol dose A: Chardonnay grape pomace powder high polyphenol dose"
2906390|NCT03203902|Active Comparator|Psychoeducation and Therapeutic Touch|"6-week psychoeducation group. The following 1-hour modules will be delivered:~Week 1: Anger Management and Conflict Negotiation Week 2: Meditation and Breathing Techniques Week 3: Nutrition Week 4: Exercise, Leisure, and Recreation Week 5: Sleep Week 6: Wellness Recovery Action Plan (WRAP)~Directly after the psychoeducation group is completed, 30-minute therapeutic touch will be administered."
2906391|NCT03203902|Placebo Comparator|Psychoeducation and Sham Therapeutic Touch|"6-week psychoeducation group. The following 1-hour modules will be delivered:~Week 1: Anger Management and Conflict Negotiation Week 2: Meditation and Breathing Techniques Week 3: Nutrition Week 4: Exercise, Leisure, and Recreation Week 5: Sleep Week 6: Wellness Recovery Action Plan (WRAP)~Directly after the psychoeducation group is completed, 30-minute sham therapeutic touch will be administered."
2906392|NCT03203902|No Intervention|Control|No intervention
2906393|NCT03203889|Experimental|CRAFT-AI|Behavioral intervention: CRAFT-AI will include a maximum of 12 CSO individual counseling sessions will be provided. A functional analysis of the IP's substance use helps to identify triggers and both positive and negative consequences of use. The CSO brainstorms and decides upon ways to sever the connection between triggers and substance use, in part by introducing alternative non-substance related positive activities. In addition, the CSO and counselor collaboratively determine how to safely allow the IP to experience negative consequences due to the substance use, thereby making it less appealing for the IP to continue to use. The CSO also brainstorms and role-plays implementing the most effective and appropriate ways to suggest that the IP enter treatment.
2906394|NCT03203889|Active Comparator|12-step facilitation for loved ones|12-step facilitation for loved ones or concerned significant others (TSF-CSO) intervention is delivered in 12 individual counseling sessions. There are 8 core components to this intervention that guide a CSO to understand that the identified person (IP) has a disease. The CSO is asked to surrender to a higher power because he or she is powerless to control the IP's substance use, and to lovingly detach from the IP. The CSO works to decrease enabling behaviors. Counselors will help the CSO to work the program of Nar/Al-Anon.
2906395|NCT03203876|Experimental|Part One Combination Therapy|Lirilumab and Nivolumab
2906396|NCT03203876|Experimental|Part 2 Combination Therapy|Lirilumab, Nivolumab and Ipilimumab
2906397|NCT03203863||Puente Alto, Chile, 2009-2011.|anthropometric measures of fatness
2906398|NCT03203850|Experimental|Deferasirox FCT Arm|randomized in a 2:1 ratio: Deferasirox to phlebotomy
2906399|NCT03203850|Experimental|Phlebotomy Arm|randomized in a 2:1 ratio: Deferasirox to phlebotomy
2906400|NCT03203837||HCC patients|HCC patients treated with radioembolization. Plasma collection will be performed at 7 timepoints in relation to treatment.
2906401|NCT03203824|Experimental|dark chocolate|Three EEG measurements will be recorded: 1) at baseline, 2) during visualization of rest for one minute, and 3) during visualization of usual vigorous exercise for one minute. Measurements 2 and 3 will be recorded savoring dark chocolate and after fully ingesting the dark chocolate respectively.
2906502|NCT03203174|Experimental|Split-hand Microneedle Botulinum Toxin A|One palm with microneedle pretreatment prior to application of topical botulinum toxin A
2906402|NCT03203824|Active Comparator|non dark chocolate|three EEG measurements will be recorded: 1) at baseline, 2) during visualization of rest for one minute, and 3) during visualization of usual vigorous exercise for one minute.
2906403|NCT03203811|Experimental|Low Dose|2mg, HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
2906404|NCT03203811|Experimental|Middle Dose|3.75mg HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
2906405|NCT03203811|Experimental|High Dose|5mg HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
2906406|NCT03203798|Active Comparator|Training of pelvic floor muscles|
2906407|NCT03203798|Experimental|Hipopressive abdominal gymnastics|
2906408|NCT03203785|Experimental|Carbohydrate|30g of carbohydrate (maltodextrin) diluted in 300ml of water. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
2906409|NCT03203785|Placebo Comparator|Placebo|300 ml of a non-caloric drink. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
2906410|NCT03203772|Experimental|Limb neuropathic conditions|Includes phantom limb pain, complex regional pain syndrome
2906411|NCT03203759|Active Comparator|Inpatient hospitalization|Control / usual care arm. Patients are admitted per usual to an inpatient service. Patients' medical records will be closely monitored. Patients will wear a vital sign and activity monitor whose data is used only retrospectively. On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
2906412|NCT03203759|Experimental|Home hospitalization|Intervention arm. Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
2906413|NCT03203746|Experimental|Group I: Lycopene + SRP|Lycopene, 0.1 ml injected once in the periodontal pocket after scaling and root planing
2906414|NCT03203746|Active Comparator|Group II: SRP only|Scaling and root planing only without lycopene
2906415|NCT03203746|No Intervention|Group III: healthy subjects|No intervention
2906416|NCT03203733|Experimental|'Cooral™'|oral cooling with use of cooling device
2906417|NCT03203733|Active Comparator|cryotherapy|Cryoterapy consists of ice cubes or crossed ice and used as standard treatment for oral cooling.
2906418|NCT03203720|No Intervention|Standard Care (SC)|Standard Care (SC) in a specialty mood disorders clinic for youth with mood disorders.
2906419|NCT03203720|Experimental|SC + Brief Motivational Intervention|Standard Care (SC) in a specialty mood disorders clinic plus a Brief Motivational Intervention (BMI) targeting medication adherence.
2906420|NCT03203707|Experimental|Interpersonal and Social Rhythm Therapy+DIR|IPSRT plus referral for community treatment for any psychiatric conditions identified through the psychiatric assessment at intake.
2906421|NCT03203707|No Intervention|Data-Informed Referral (DIR)|Referral for community treatment for any psychiatric conditions identified through the psychiatric assessment at intake.
2906422|NCT03203694|Experimental|Walking intervention|The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
2906423|NCT03203694|No Intervention|Control|Subjects will be instructed to continue their usual lifestyle for 8 weeks.
2906424|NCT03203694|Experimental|Unilateral leg heating|This intervention consists of 45 minutes of unilateral leg heating (40-42 degree C) 5 days per week for 8 weeks.
2906425|NCT03203681|Other|NATESTO(4.5% nasal testosterone)|This is a prospective case study. Subjects will have baseline FSH, LH, Estradiol, and T before beginning therapy. Subjects will undergo a total of six study visits. At the first visit they will undergo screening procedures, At visit 2 subjects will undergo a second semen analysis and blood analysis for T. After 12 weeks, subjects will return for a third visit for blood sample and semen analysis, SHIM and quality of life questionnaires. This procedure will be repeated at week 24 to get a final blood and semen analysis
2906426|NCT03203668|Other|Choline PET/CT|Choline PET/CT imaging added to conventional imaging assessment in hyperparathyroidism (parathyroid scintigraphy, ultrasound, CT or MRI if indicated)
2906427|NCT03203655|Experimental|Intervention Group|The intervention group will be enrolled in the CareMessage™ Adult Obesity texting program, which sends a text message 3 to 5 times a week, encouraging lifestyle modifications (diet and exercise education, and behavioral strategies) that can lead to healthy weight loss.
2906428|NCT03203655|Other|Control Group|The control group will receive the control condition. They will hear an initial talk about weight loss but will not be enrolled in any program or intervention.
2906429|NCT03203642|Experimental|Treatment Group|50mg tesevatinib administered once daily for up to 24 months.
2906430|NCT03203642|Placebo Comparator|Control Group|Matching placebo administered once daily for up to 24 months.
2906431|NCT03203616|Experimental|T-DM1|trastuzumab emtansine given every 3 weeks at the standard dose (3.6 mg/kg) via intravenous infusion, until disease progression, intolerable toxicity or consent withdrawal. A median of 9 cycles per patient is expected
2906432|NCT03203603||Offspring of smokers who got vitamin C|Offspring of pregnant smokers randomized to vitamin C during the initial randomized portion of the VCSIP study
2906433|NCT03203603||Offspring of smokers who got placebo|Offspring of pregnant smokers randomized to placebo during the initial randomized portion of the VCSIP study
2906434|NCT03203603||Offspring of pregnant non-smokers|Offspring of pregnant non-smokers who were followed in a similar fashion during pregnancy as the randomized pregnant smokers
2906435|NCT03203590|Active Comparator|Oral Navelbine + Carboplatin|Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with Navelbine + Carboplatin.
2906436|NCT03203590|Experimental|Gefitinib|Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with gefitinib.
2906437|NCT03203577|Active Comparator|Hospital initiation|Initiation of mechanical ventilation in hospital initiation of Home Mechanical ventilation takes place in a hospital; this makes this arm the standard care.
2906438|NCT03203577|Experimental|Home initiation|Initiation of mechanical ventilation at home Initiation of mechanical ventilation in a patient's home setting with telemonitoring
2906439|NCT03203564|Active Comparator|Modufolin® for injection, 200, 350 and 500 mg/m2|Three cohorts, 8 subjects will be randomised to Modufolin ® for injection 100 mg
2906440|NCT03203564|Placebo Comparator|0.9% NaCl sterile solution|Three cohorts, 3 subjects will be randomised to placebo
2906441|NCT03203551|Placebo Comparator|C; Control; Saline solution|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in Saline solution (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
2906442|NCT03203551|Experimental|HS0.25%; 0.25% Sodium Hypochlorite|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in 0.25% Sodium Hypochlorite (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
2906443|NCT03203551|Experimental|RC10%; 10% Ricinus communis|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in 10% Ricinus communis (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
2906444|NCT03203551|Experimental|CT0.5%; 0.5% Chloramine T|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in 0.5% Choramine T (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
2906445|NCT03203538|Experimental|Light intensity, 1000 lux (4000 K)|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 1000 lux (4000 Kelvin) administered through standard room lighting.
2906446|NCT03203538|Active Comparator|Light intensity, 100 lux (4000 K)|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 100 lux (4000 Kelvin) administered through standard room lighting.
2906447|NCT03203538|Experimental|Colour temperature, 7000 Kelvin|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 7000 K (200 lux) administered through standard room lighting.
2906448|NCT03203538|Active Comparator|Colour temperature, 2500 Kelvin|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 2500 K (200 lux) administered through standard room lighting.
2906449|NCT03203538|Experimental|Blue light, 455 nm|Participants work one night shift with blue LED-light (peak wavelength 455 nm) administered through standard room lighting.
2906450|NCT03203538|Active Comparator|Red light, 615 nm|Participants work one night shift with red LED-light (peak wavelength 615 nm) administered through standard room lighting.
2906451|NCT03203525|Experimental|mFOLFOX6 + Bevacizumab + NovoTTF-100L System|"Participants receive Oxaliplatin, Leucovorin, 5-fluorouracil, and Bevacizumab by vein on Days 1 and 15 of a 28 day cycle.~NovoTTF-100L system applied to torso where the tumor is located for at least 18 hours a day.~Up to 6 participants enrolled at each dose level. First group of participants enrolled receive a low dose level of the drug. If no bad side effects are seen in this group, the next group will be treated with a higher dose level. This will continue until the highest tolerable dose level of the combination is found. After highest tolerable dose of combination is found, additional participants enrolled at this level to further study the safety of this drug combination."
2906452|NCT03203525|Experimental|DAT + NovoTTF-100L System|"Participants receive Liposomal Doxorubicin and Bevacizumab by vein on Days 1 and 15 of a 28 day cycle. Temsirolimus given by vein on Days 1, 8, 15, and 22 of a 28 day cycle.~NovoTTF-100L system applied to torso where the tumor is located for at least 18 hours a day.~Up to 6 participants enrolled at each dose level. First group of participants enrolled receive a low dose level of the drug. If no bad side effects are seen in this group, the next group will be treated with a higher dose level. This will continue until the highest tolerable dose level of the combination is found. After highest tolerable dose of combination is found, additional participants enrolled at this level to further study the safety of this drug combination."
2906453|NCT03203512|Active Comparator|Intervention|Fish oil capsules
2906454|NCT03203512|Placebo Comparator|Placebo|High-oleic safflower oil capsules
2906455|NCT03203499|Experimental|ANS-6637|Single ascending doses of ANS-6637 administered orally
2906456|NCT03203499|Placebo Comparator|Placebo|Placebo administered orally
2906457|NCT03203486|Experimental|Meditteranean Diet|NAFLD patients attended appointments with experienced dieticians to receive nutritional guidance based on a traditional Mediterranean Diet for 6 months.
2906458|NCT03203473|Experimental|Initial Primary Treatment|"Therapy with nivolumab IV every 2 weeks~Serial imaging assessments every 8 weeks~After confirmatory scans, patients are assigned to Arm A or Arm B."
2906459|NCT03203473|Experimental|Arm A: Persistent (PR/CR)|"Serial imaging assessments every 8 weeks~Therapy with nivolumab IV every 2 weeks~If scans persistently show PR/CR, nivolumab is discontinued until progression.~Nivolumab is re-initiated, and if there is subsequent progression, ipilimumab is added for x2 doses.~Ipilimumab IV every 3 weeks (only in patients who progress after nivolumab re-initiation)~If progression after nivolumab + ipilimumab, therapy discontinued. If SD/PR/CR, nivolumab is continued until progression."
2906460|NCT03203473|Experimental|Arm B: Persistent (PD/SD)|"Therapy with nivolumab IV every 2 weeks~Ipilimumab IV every 3 weeks~Serial imaging assessments every 8 week~If scans show SD/PR/CR, nivolumab continued until progression. If progression, therapy discontinued."
2906461|NCT03203460|Experimental|Exercise Group|Supervised high-intensity aerobic interval training (HIIT) during active surveillance
2906462|NCT03203460|No Intervention|Usual Care Group|The usual care group will be provided with standard active surveillance medical care.
2906544|NCT03202914|Active Comparator|Low protein and phosphorus diet|protein: 0.58 g/kg/day with ≥0.35 g of protein high in amino acids, phosphorus: 5-10 mg/kg/day
2906463|NCT03203447|Active Comparator|Active|Lucentis (0.5 mg/0.05 mL) + CLS-TA (4 mg/0.10 mL), SC injection or Avastin (1.25 mg/0.05 mL) + CLS-TA (4 mg/0.10 mL), SC injection
2906464|NCT03203447|Sham Comparator|Control|Lucentis (0.5 mg/0.05 mL) + sham SC procedure or Avastin (1.25 mg/0.05 mL) + sham SC procedure
2906465|NCT03203434||Esophageal anastomotic leakage|
2906466|NCT03203434||Esophageal uncomplicated controls|
2906467|NCT03203434||Pancreatic anastomotic leakage|
2906468|NCT03203434||Pancreatic uncomplicated controls|
2906469|NCT03203421|Active Comparator|Low Dose (Group 1)|One low dose of ChAdOx1 LS2 (5 x 10^9 vp) on day 0.
2906470|NCT03203421|Active Comparator|Prime-Boost (Group 2)|One high dose of ChAdOx1 LS2 (2.5 x 10^10 vp) on day 0 and one dose of MVA LS2 (2 x 10^8 pfu) on day 56.
2906471|NCT03203421|No Intervention|Control Group A|No vaccinations will be administered.
2906472|NCT03203421|No Intervention|Control Group B|No vaccinations will be administered.
2906473|NCT03203408|Experimental|OSTENIL PLUS|A single intra-articular injection of sodium hyaluronate 40 mg/2.0 ml at Day 2, i.e. 2 days post Baseline (Day 0 = Week 0)
2906474|NCT03203408|Active Comparator|SYNVISC-ONE|A single intra-articular injection of hylan G-F 20 48 mg/6 ml at Day 2, i.e. 2 days post Baseline (Day 0 = Week 0)
2906475|NCT03203395|Experimental|Heart patients|Screening and counselling
2906476|NCT03203369|Experimental|Part 1: Dose Escalation|A single intravenous administration of UCART123. Dose escalation in Part 1 will include 3 doses ranging from 6.25 x 10^5 cells/kg to 6.25 x 10^6 cells/kg and continue until the Recommended Phase 2 Dose (RP2D) is identified.
2906477|NCT03203369|Experimental|Part 2: Dose Expansion|A single intravenous administration of UCART123 at the RP2D. 2 Cohorts: Patients with Relapsed/Refractory BPDCN and Newly Diagnosed BPDCN.
2906478|NCT03203356||GHD children|about 30 prepubertal children affected by overt idiopathic GHD
2906479|NCT03203356||controls|about 30 prepubertal children with constitutional short stature without endocrine disease
2906480|NCT03203343|Active Comparator|PIRS group|Patients operated laparoscopically - PIRS technique
2906481|NCT03203343|Active Comparator|Marcy group|Patients operated by open modified Marcy technique
2906482|NCT03203330|Active Comparator|Active Treatment (TG-C)|TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
2906483|NCT03203330|Placebo Comparator|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
2906484|NCT03203317|Experimental|Insulin-stimulation|2 h insulin-clamp
2906485|NCT03203317|Experimental|Exercise|10 min of maximal exercise
2906486|NCT03203304|Experimental|Nivolumab|"Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.~After the final fraction of SBRT, patients will receive treatment with nivolumab 240 mg will be initiated within 14 days. Patients will receive nivolumab infusions once every 2 weeks. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression is allowed as per irRC evaluation."
2906487|NCT03203304|Experimental|Nivolumab and ipilimumab|"Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.~After the final fraction of SBRT, treatment with nivolumab and ipilimumab will be initiated within 14 days. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression will be allowed as per irRC evaluation. Patients will receive nivolumab infusions once every 2 weeks and ipilimumab infusions once every 6 weeks."
2906488|NCT03203291|Experimental|TPAD Treatment|All participants will receive 5 consecutive days of training with the TPAD (tethered pelvic assist device) with testing completed before training, on completion of training and at a 1-week follow up.
2906489|NCT03203278|Experimental|Web-based exercise programme|Personalised exercise programme, undertaken three times a week (with no more than two rest days between sessions) for 12 weeks
2906490|NCT03203278|No Intervention|Control group|Usual care
2906491|NCT03203265|Other|A:Offline HIV testing and counseling|Participants in Group A will be invited to come to the Thai Red Cross Anonymous Clinic, RSAT or SWING drop-in centers in Bangkok, or SWING or Sisters drop-in centers in Pattaya. After registration, they will receive standard HIV Testing and Counseling (HTC) services.
2906492|NCT03203265|Other|B1:Offline|participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only.
2906493|NCT03203265|Other|B2: Online|participants will be mailed a rapid HIV test kit. A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit, obtaining blood through finger prick, performing the testing steps, and reading the test result.
2906494|NCT03203239|Experimental|Red Light treatment|This is a single arm design. All subjects will be enrolled to have peripheral blood flow measured before, during, and after red light exposure.
2906495|NCT03203226|Experimental|EXPERIMENTAL GROUP|This protocol has an unique period or phase of 30 week. Experimental group will be composed by 30 volunteer who were previously randomly assigned to this group. This group will receive a intervention based on 30 1-hour session of Feldenkrais Method (1 hour per week).
2906496|NCT03203226|No Intervention|CONTROL GROUP|This protocol has an unique period or phase of 30 week. Control group will be composed by 30 volunteer who were previously randomly assigned to this group. They will not receive any intervention.
2906497|NCT03203213|Experimental|Interventional arm|"Sampling of a few additional drops of blood and sending this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient~Oriented hair removal is also carried out if possible (small wick cut and not torn the size of a pencil mine of paper taken at the level of the occipital region). This technique has been used many times, and evaluates the previous consumption (memory consumption)~A urine sample is taken if possible."
2906498|NCT03203200|Experimental|health literacy and technology skill building|ZETRA cognitive behavioral and structural
2906499|NCT03203200|No Intervention|Standard Counselling|Standard of care prevention counselling
2906500|NCT03203187|Placebo Comparator|No mango intake|No mango intake for two weeks
2906501|NCT03203187|Experimental|330 grams of daily mango intake|330 grams (2 cups) of daily mango intake for two weeks
2906503|NCT03203174|Sham Comparator|Split-hand Sham Microneedle Botulinum Toxin A|Contralateral palm with sham microneedle pretreatment prior to application of topical botulinum toxin A
2906504|NCT03203148||CABG Surgical Patients|Patients undergoing coronary bypass grafting with cardiopulmonary bypass
2906505|NCT03203135|Experimental|Intervention Group|
2906506|NCT03203135|No Intervention|Control Group|
2906507|NCT03203122|Experimental|Study group|Patients are randomized to treatment of either right or left side. The other side works as control
2906508|NCT03203122|Sham Comparator|Comparator Group|Patients are randomized to treatment in either right or left side. The other side works as control
2906509|NCT03203096|Placebo Comparator|Placebo|identically tasting and looking Placebo
2906510|NCT03203096|Active Comparator|Magnesium|Supplementation with 400 mg Magnesium from Magnesium Citrate / Magnesium Oxide once daily
2906511|NCT03203083||physically active individuals|subjects who perform sports activities more than 6 hours per week
2906512|NCT03203083||non-physically active individuals|subjects who perform less than 2 hours per week of sport activities
2906513|NCT03203070|Active Comparator|Metamizol iv|The patients will receive only intravenous analgesia with Metamizole 2g/8 hours for control of postoperative pain.
2906514|NCT03203070|Experimental|TAP block|The patients will receive intravenous analgesia with Metamizol iv 2g/8h and intraoperative laparoscopic-guided TAP block for control of postoperative pain.
2906515|NCT03203057||control group|10 individuals get randomised to control group.
2906516|NCT03203057||short ischemic time|10 individuals get randomised to a controlled coronary occlusion for 30 seconds
2906517|NCT03203057||intermediate ischemic time|10 individuals get randomised to a controlled coronary occlusion for 60 seconds
2906518|NCT03203057||long ischemic time|10 individuals get randomised to a controlled coronary occlusion for 90 seconds
2906519|NCT03203044|No Intervention|Regular Diet Arm|Maintains a regular diet for the duration of the study.
2906520|NCT03203044|Experimental|Soylent Diet Arm|Receives a Soylent dietary intervention on days 3-6 of the study.
2906521|NCT03203031||Neonates with abdominal surgery and quadratus lumborum block|0-6 months children with abdominal surgery. After standard induction of general anesthesia, patients will receive 0.5 ml/kg of ropivacaine (2 mg/ml) in a quadratus lumborum block. Ultrasonography will be used to guide the injection. In the postoperative period, pain scores and analgesics consumption will be recorded until the 48th hour post surgery.
2906522|NCT03203018|Experimental|Women participating in HL intervention|Groups of women from disadvantaged communities will participate in a three session health literacy workshop
2906523|NCT03203005|Experimental|IMA970A plus CV8102 and Cyclophosphamide|Investigational treatment with IMA970A, CV8102, Cyclophosphamide
2906524|NCT03202992|Experimental|Dose 1 -Single Ascending Dose (SAD)|SAD Dose Level 1 of ABI-1968 topical cream applied on Day 1 of the study
2906525|NCT03202992|Experimental|Dose 2 -Single Ascending Dose (SAD)|SAD Dose Level 2 of ABI-1968 topical cream applied on Day 1 of the study
2906526|NCT03202992|Experimental|Dose 3 -Single Ascending Dose(SAD)|SAD Dose Level 3 of ABI-1968 topical cream applied on Day 1 of the study
2906527|NCT03202992|Experimental|Dose 4 -Single Ascending Dose(SAD)|SAD Dose Level 4 of ABI-1968 topical cream applied on Day 1 of the study
2906528|NCT03202992|Experimental|Dose 5 -Single Ascending Dose(SAD)|SAD Dose Level 5 of ABI-1968 topical cream applied on Day 1 of the study
2906529|NCT03202992|Experimental|Dose 1 - Multiple Ascending Dose(MAD)|MAD Dose Level 1 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
2906530|NCT03202992|Experimental|Dose 2 -Multiple Ascending Dose(MAD)|MAD Dose Level 2 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
2906531|NCT03202992|Experimental|Dose 3 -Multiple Ascending Dose(MAD)|MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
2906532|NCT03202992|Experimental|Multiple Ascending Dose (MAD) Cohort Expansion|MAD Cohort Expansion of ABI-1968 applied at Day 1, Day 8, Day 15, Day 22 and Day 29
2906533|NCT03202992|Experimental|Dose 4-Multiple Ascending Dose(MAD)|MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
2906534|NCT03202979|Experimental|Group 1|Trazodone 20 mg
2906535|NCT03202979|Experimental|Group 2|Trazodone 10 mg
2906536|NCT03202979|Placebo Comparator|Group 3|Placebo
2906537|NCT03202966|Experimental|Intervention|For each child with a developmental delay enrolled in the early intervention program, individualized rehabilitation therapy will be provided by a rehabilitation professional with a focus on the one or more domains where delays were identified (i.e. speech, motor, cognition). The intervention will be delivered either as home based rehabilitation or as centre based care. Each child will receive a minimum of one therapy session per week by the CRW and a monthly therapist visit for home based care. In center based care daily therapy will be available by either a CRW or specialist.
2906538|NCT03202953|Experimental|1:1 I:E ratio VCV (Group I)|volume controlled ventilation with 1:1 inspiratory to expiratory ratio After trendelenburg position, Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:1, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used.
2906539|NCT03202953|Active Comparator|autoflow VCV (Group A)|autoflow volume-controlled ventilation After trendelenburg position, Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:2, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used.
2906540|NCT03202940|Experimental|Cobimetinib + Alectinib|Alectinib administered twice daily at pre-determined dosage orally Cobimetinib administered daily at pre-determined dosage orally
2906541|NCT03202927|Experimental|TPI-120 (PEGFILGRASTIM)|One daily dose of TPI-120 (PEGFILGRASTIM) 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 1) of Cycle 1 followed by one daily dose of 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 22) of Cycle 2 with a gap of 21 days between two cycles
2906542|NCT03202927|Active Comparator|Neulasta (PEGFILGRASTIM)|One daily dose of Neulasta (PEGFILGRASTIM) 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 1) of Cycle 1 followed by one daily dose of 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 22) of Cycle 2 with a gap of 21 days between two cycles
2906543|NCT03202914|Active Comparator|Usual protein and phosphorus diet|protein: 1.3 g/kg/day, phosphorus: 16-20 mg/kg/day
2906580|NCT03202667|Active Comparator|Empagliflozin|Treatment with empagliflozin 25mg tablets once daily for 28 days
2906545|NCT03202914|Experimental|Very low protein and phosphorus|protein: 0.28 g/kg/day, phosphorus: 4-9 mg/kg/day; keto-acid and amino acid supplement (0.28 g/kg/day)
2906546|NCT03202901|Experimental|B-turmactive|1 pill of B-turmactive: 500 mg hydrosoluble fraction (free curcuminoid fraction) + 19.5 mg of lipid soluble fracion (curcuminoids enriched) + 22.5 mg vitamin C.
2906547|NCT03202901|Placebo Comparator|Placebo|"Yeast brew extract (200 mg)~Excipients:~120 mg cellulose (food additive E-460) 40 mg Compritol® E ATO (food additive E-471) 4 mg Magnesium stearate (food additive E-572)"
2906548|NCT03202888|Experimental|Intervention|After completing enrollment surveys, including measures of patient activation and medical knowledge, participants will be invited to use the novel IT. The technology is a mobile responsive website for survey data collection made by our technology vendor, QuesGen. Patients and family members will be able to access the website from any personal device with internet access: laptop, tablet, or smart phone. QuesGen will send a text message reminder to participants with a link to specific questionnaires at scheduled time intervals. Frequency of text messaging will likely be daily, but will ultimately reflect family and patient feedback in Aim 1. In addition to text reminders, participants will be able to answer questionnaires at-will by accessing the mobile responsive website.
2906549|NCT03202875|Experimental|Test (T)|SAR341402: single dose injection
2906550|NCT03202875|Active Comparator|Reference 1 (R1)|NovoRapid®: single dose injection
2906551|NCT03202875|Active Comparator|Reference 2 (R2)|NovoLog®: single dose injection
2906552|NCT03202862|Experimental|ESR1 mutated|ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer after previous aromatase inhibitor therapy
2906553|NCT03202849|Experimental|Vitamin D and A Supplementation|Participants receive a single dose of vitamin D and a single dose of vitamin A prior to HSCT.
2906554|NCT03202849|Active Comparator|Vitamin D Supplementation with Placebo|Participants receive a single dose of vitamin D and a single dose of placebo prior to HSCT.
2906555|NCT03202836|Experimental|vaginal progesterone|Vaginal utrogestan 400 mg, vaginal suppository, once at bed time until gestational age 37 weeks and tocolysis plus corticosteroid for 48 hours
2906556|NCT03202836|Other|no medication|only tocolysis plus corticosteroid for 48 hours
2906557|NCT03202823||Diabetics|
2906558|NCT03202823||Non-diabetics|
2906559|NCT03202797||Patients|
2906560|NCT03202784|Experimental|BCX7353 API in capsule|fasted administration of BCX7353 API in capsule
2906561|NCT03202784|Experimental|BCX7353 blend in capsule|fasted administration of BCX7353 blend in capsule
2906562|NCT03202784|Experimental|BCX7353 blend in capsule with food|administration of BCX7353 blend in capsule following high-fat meal
2906563|NCT03202771|Experimental|Home Biofeedback Therapy|Patients will use home biofeedback device to practice their maneuvers taught by the nurse.
2906564|NCT03202771|Active Comparator|Office Biofeedback Therapy|Patients will get regular office biofeedback therapy with an anal probe inserted while a nurse runs through the exercise session together.
2906565|NCT03202758|Other|Durvalumab + Tremelimumab + FOLFOX|"Durvalumab for 12 months~Tremelimumab for up to 4 doses/cycles~FOLFOX"
2906566|NCT03202745|No Intervention|Control|The control arm will not receive any communications as a result of this study.
2906567|NCT03202745|Experimental|Patient Consequences|The patient consequences arm prescribers receive an initial patient consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for patients.
2906568|NCT03202745|Experimental|Prescriber Consequences|The prescriber consequences arm prescribers receive an initial prescriber consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for prescribers.
2906569|NCT03202732|Other|DiabetesFlex|"In DiabetesFlex intervention, patients are offered 3 consultations/year. One mandatory consultations (30 minutes). The patient, an endocrinologist and a diabetes nurse attend.~Two optional consultations, patients can choose between face-to-face consultations, a telephone consultation or to cancel the consultation.~Ahead of the consultations, patients fill out the AmbuFlex Diabetes questionnaire and deliver a blood and urine sample.~Based on the patient's response to the AmbuFlex Diabetes questionnaire, the result of the blood sample and the urine sample, the diabetes nurse assign the patient to a face-to-face consultation, a telephone consultation or no consultation with an endocrinologist, a diabetes nurse or a dietician."
2906570|NCT03202732|No Intervention|Standard care|"Standard diabetes care consists of 3 consultations (15 minutes)/year with a physician or a diabetes nurse by turns.~Ahead of the consultation patients send in a blood sample for measuring HgA1c, urine sample for measuring urin-albumin creatinin ratio and other blood samples depending of arrangements made in the last consultation.~Once a year in relation to a consultation, patients fill in the Problem Area In Diabetes (PAID) (20) scale together. Furthermore, based on the patients or healthcare professional judgement, patients see a dietician when needed."
2906571|NCT03202719|Active Comparator|IPV at ages 14 weeks and 18 months|Participants in this arm will receive bivalent oral poliovirus vaccine (bOPV) at 6, 10 and 14 weeks of age and inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age
2906572|NCT03202719|Active Comparator|IPV at ages 14 weeks, 18 weeks and 18 months|Participants in this arm will receive bivalent oral poliovirus vaccine (bOPV) at 6, 10 and 14 weeks of age and inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age
2906573|NCT03202719|Active Comparator|IPV at ages 14 weeks and 9 months|Participants in this arm will inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age
2906574|NCT03202719|Active Comparator|IPV at ages 6 weeks and 9 months|Participants in this arm will inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age
2906575|NCT03202719|Active Comparator|IPV at ages 6 and 14 weeks|Participants in this arm will inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age
2906576|NCT03202706||Patients|
2906577|NCT03202693|Experimental|PA-824|[14C]-PA-824 and unlabelled PA-824 oral suspension of 1000 mg unlabeled micronized PA-824 mixed with sufficient [14C]-PA-824 to achieve a final radiolabel dose of approximately 100 µCi/dose.
2906578|NCT03202680|Active Comparator|USDA Style Diet|Healthy, low saturated fat, United States Department of Agriculture (USDA) style diet.
2906579|NCT03202680|Experimental|Lean Beef Diet|Healthy, low saturated fat, high in lean beef diet.
2953074|NCT02882191|Experimental|LevoCept IUD|LevoCept IUD placement
2906582|NCT03202654|Experimental|Corn Oil Intervention|Study products delivering 4 tablespoons/day corn oil will be administered for 4-week treatment period.
2906583|NCT03202654|Active Comparator|Coconut Oil Intervention|Study products delivering 4 tablespoons/day coconut oil will be administered for 4-week treatment period.
2906584|NCT03202641|Experimental|PEEP_titration|"There is no randomization in this interventional, crossover, physiological study. All participants will receive the same procedures in the same order. The investigators will compare two PEEPs (PEEPARDSnet vs. PEEPLRM).~Interventions:~PEEP ARDSnet: we will select the PEEP based on low PEEP/high FiO2 table (ARDSnet).~PEEP LRM: we will perform a lung recruitment maneuver (LRM) and select PEEP based on transpulmonary pressure."
2906585|NCT03202628|Experimental|Treatment (ixazomib, pomalidomide, dexamethasone, ASCT)|"INDUCTION (COURSES 1-4): Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days (courses 1-3) and 56 days (course 4) for up to 4 courses in the absence of disease progression or unacceptable toxicity.~TRANSPLANTATION (COURSE 5): Between 2-4 weeks following Induction, patients undergo ASCT.~CONSOLIDATION (COURSES 6-9): Beginning 60-120 days following ASCT, patients receive ixazomib citrate, pomalidomide, and dexamethasone as in Induction. Treatment repeats every 28 days (courses 6-8) and 56 days (course 9) for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE (COURSES 10+): Beginning 0-4 weeks following Consolidation, patients receive ixazomib citrate as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2906586|NCT03202615|Experimental|L (lactoferrin in IDA with pregnancy)|Pregnant women with IDA, in the 2nd trimester are enrolled and treated for 2 months regularly with oral administration of 100 mg bLf granules (Pravotin sachets , Hygint, Egypt) in 1/4 glass of water twice a day before meals in addition to placebo tablets three time per day on an empty stomach.
2906587|NCT03202615|Active Comparator|F (ferrous sulphate with pregnancy)|Pregnant women with IDA, in the 2nd trimester are enrolled and treated for 2 months regularly with oral administration of 150 mg of dried ferrous sulphate capsules (Ferrofol capsules, Eipico, Egypt), one capsule three times daily on an empty stomach, at least 1 hour before or 2 hours after meals, in addition to placebo sachets (starch) twice a day.
2906588|NCT03202602||Telemedicine|Patients randomized to receive telemonitoring in combination with telephone calls after CPAP start.
2906589|NCT03202602||Standard care|Patients randomized to receive usual office visits after CPAP start.
2906590|NCT03202576|No Intervention|Nasogastric tube standard securement|Standard securement of nasogastric tube with adhesive tape
2906591|NCT03202576|Experimental|Nasogastric Tube Nasal Bridle Securement|Securement of NG with AMT Micro Bridle
2906592|NCT03202563|Experimental|Gemigliptin 50mg|"the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total.~Drug: Gemigliptin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS)"
2906593|NCT03202563|Active Comparator|Dapagliflozin 10mg|"the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total.~Drug: Dapagliflozin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS)"
2906594|NCT03202550|Placebo Comparator|Placebo Arm|Two oral placebo pills (microcrystalline cellulose capsules)
2906595|NCT03202550|Active Comparator|Active Drug Arm: Lorazepam and Oxycodone|1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
2906596|NCT03202537|Experimental|dexlansoprazole|dexlansoprazole 90mg per day (60mg am, 30mg pm dosing) for 4 weeks
2906597|NCT03202524|Active Comparator|Albumin|Patients undergoing large volume paracentesis with receive 50ml of 25% albumin for every 2 L removed from their abdomen.
2906598|NCT03202524|Experimental|Fresh Frozen Plasma|Patients undergoing large volume paracentesis with receive 2 units of FFP for the first 4L removed followed by 50ml of 25% albumin for every additional 2 L removed
2906599|NCT03202511|Active Comparator|Control|The control phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) on day 1 (2 tablets) followed by 300/200 mg (1 tablet) doses on days 2 and 3.
2906600|NCT03202511|Experimental|Treatment|The treatment phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (2 tablets) along with a 2 gram oral probenecid (PRO) dose (4 tablets, 500 mg each) on day 1.
2906601|NCT03202498|Experimental|Cohort 1 (4g Yaq-001)|Standard medical treatment + Yaq-001 (4 g/ day)
2906602|NCT03202498|Placebo Comparator|Cohort 1 (4g Placebo)|Standard medical treatment + placebo-control (placebo for 4 g of Yaq-001/ day)
2906603|NCT03202498|Experimental|Cohort 2 (8g Yaq-001)|Standard medical treatment + Yaq-001 (8 g/ day)
2906604|NCT03202498|Placebo Comparator|Cohort 2 (8g Placebo)|Standard medical treatment + placebo-control (placebo for 8 g of Yaq-001/ day)
2906605|NCT03202485|Active Comparator|Toric Implantable Collamer Lens|Subjects in this group will implant Toric Implantable Collamer Lens for high myopic astigmatism
2906606|NCT03202485|Experimental|ICL+ Astigmatic keratotomy|Subjects in this group will implant Implantable Collamer Lens and combined with astigmatic keratotomy for high myopic astigmatism
2906607|NCT03202472|Experimental|Diagnostic (radiofrequency-guided localization)|Patients undergo mammogram or ultrasound for image-guided placement of the radiofrequency tag within 30 days of surgery and then undergo radiofrequency-guided localization during surgery.
2906608|NCT03202459|Active Comparator|Active Comparator: Group A - gabapentin|The patient will receive oral 600 mg gabapentin 2 h before surgery
2906609|NCT03202459|Active Comparator|Active Comparator: Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
2906610|NCT03202459|Placebo Comparator|Placebo Comparator: Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
2906611|NCT03202446|Experimental|Arm 1: LIT and Placebo|Patients receive laser-assisted immunotherapy along with Placebo cyclophosphamide tablets. Patients' laser-assisted immunotherapy treatment will be based on the number and size of laser-accessible solid tumors available at the time of treatment. In and around each photothermal laser-treated site will be injected 1 mL of 1% Glycated Chitosan (GC) Injection, with a total of up to 4 sites being treated per patient. The maximum dose of GC Injection that a patient can receive in 1 visit is 4 mL.
2906639|NCT03202303|Placebo Comparator|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo for 12 weeks
2906612|NCT03202446|Experimental|Arm 2: LIT and low-dose Cyclophosphamide|Patients will receive laser-assisted immunotherapy and low-dose cyclophosphamide (300 mg, administered orally once per week between treatment weeks 0-11 in each treatment cycle). Patients' laser-assisted immunotherapy treatment will be based on the number and size of laser-accessible solid tumors available at the time of treatment. In and around each photothermal laser-treated site will be injected 1 mL of 1% Glycated Chitosan (GC) Injection, with a total of up to 4 sites being treated per patient. The maximum dose of GC Injection that a patient can receive in 1 visit is 4 mL.
2906613|NCT03202446|Active Comparator|Arm 3: Control Arm|Patients will receive the standard of care.
2906614|NCT03202433|Experimental|Virtual Reality Distractor|The objective is to apply a technique, using virtual reality lenses, with relaxing audio-visual contents of no more than ten minutes, to reduce stress before and during the blood donation process and to respond to the level of pain perceived during donation, either post-puncture and withdrawal of the needle
2906615|NCT03202433|No Intervention|Traditional Blood Donation Process|The objective is to respond to the level of pain perceived during donation, either post-puncture and withdrawal of the needle, without virtual reality support
2906616|NCT03202420|Experimental|TOPS|Participants will attend weekly TOPS meetings with standard weekly weigh ins
2906617|NCT03202407|Placebo Comparator|calcium group|"will receive calcium-based phosphate binder (calcium carbonate ) 45-65 mg/kg orally divided 3 to 4 times/day for 3 months.~all the following investigation will be done before and after consecutive 3 months of administration :~Complete blood count~Kidney function tests (serum urea and creatinine)~Serum total calcium level.~Serum phosphorus level.~Calcium × phosphorus product.~Serum parathormone level.~Serum alkaline phosphatase level.~Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides).~Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug"
2906618|NCT03202407|Experimental|sevelamer group|"will receive the recommended daily dose of the Sevelamer hydrochloride phosphate binder 120-160 mg/kg orally 3 times per day for 3 months.~all the following investigation will be done before and after consecutive 3 months of administration :~Complete blood count~Kidney function tests (serum urea and creatinine)~Serum total calcium level.~Serum phosphorus level.~Calcium × phosphorus product.~Serum parathormone level.~Serum alkaline phosphatase level.~Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides).~Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug"
2906619|NCT03202394|Active Comparator|Active intervention|Patients will be randomized in a 1:1 ratio to either aerosolized BIO-11006 (125mg in 3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or placebo.
2906620|NCT03202394|Placebo Comparator|Placebo intervention|Patients will be randomized in a 1:1 ratio to either aerosolized placebo (3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or active drug.
2906621|NCT03202381|Experimental|Degarelix|
2906622|NCT03202368|Experimental|Tocilizumab: GCA Flare or Persistent Disease Activity|Participants who were treated with tocilizumab in Study WA28119 and experienced a new GCA flare within 3 years after completion of Study WA28119 or had persistent active GCA at the time of completion of Study WA28119, will receive SC tocilizumab in this study.
2906623|NCT03202355|Experimental|Group 1 (Control)|Subjects assigned to this group receive fixed appliance orthodontic treatment only
2906624|NCT03202355|Experimental|Group 2 (OP1)|Subjects assigned to this group receive fixed appliance orthodontic treatment in conjunction with receiving daily OrthoPulse™ treatments.
2906625|NCT03202342|Experimental|Water/gluc/gluc+EB/EB/gluc+EB_cold|First Water 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 22 C, then Ethyl butyrate 22 C and then Glucose + Ethyl butyrate 0 C
2906626|NCT03202342|Experimental|Water/gluc+EB/gluc/gluc+EB_cold/EB|First Water 22 C, then Glucose + Ethyl butyrate 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 0 C and then Ethyl butyrate 22 C
2906627|NCT03202342|Experimental|Gluc/water/EB/gluc+EB/glucose+EB_cold|First Glucose 22 C, then Water 22 C, then Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 22 C and then Glucose + Ethyl butyrate 0 C
2906628|NCT03202342|Experimental|Gluc/EB/water/gluc+EB_cold/gluc+EB|First Glucose 22 C, then Ethyl butyrate 22 C, then Water 22 C, then Glucose + Ethyl butyrate 0 C and then Glucose + Ethyl butyrate 22 C
2906629|NCT03202342|Experimental|EB/Gluc/gluc+EB_cold/water/glucose+EB|First Ethyl butyrate 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 0 C, then Water 22 C and then Glucose + Ethyl butyrate 22 C
2906630|NCT03202342|Experimental|EB/gluc+EB_cold/gluc/glucose+EB/water|First Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 0 C, then Glucose 22 C, then Glucose + Ethyl butyrate 22 C and then Water 22 C
2906631|NCT03202342|Experimental|Gluc+EB_cold/water/glucose+EB/glucose/EB|First Glucose + Ethyl butyrate 22 C, then Water 22 C, then Glucose + Ethyl butyrate 0 C, then Glucose 22 C and then Ethyl butyrate 22 C
2906632|NCT03202342|Experimental|Gluc+EB_cold/glucose+EB/water/EB/glucose|First Glucose + Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 0 C, then Water 22 C, then Ethyl butyrate 22 C and then Glucose 22 C
2906633|NCT03202342|Experimental|Gluc+EB_cold/gluc+EB/EB/water/glucose|First Glucose + Ethyl butyrate 0 C, then Glucose + Ethyl butyrate 22 C, then Ethyl butyrate 22 C, then Water 22 C and then Glucose 22 C
2906634|NCT03202342|Experimental|Gluc+EB_cold/EB/gluc+EB/glucose/water|First Glucose + Ethyl butyrate 0 C, then Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 22 C, then Glucose 22 C and then Water 22 C
2906635|NCT03202329|Other|standard care|responsible surgeon has actively to ask for cardiology support (he decides whether a heart failure specialist should see the patient post-operatively)
2906636|NCT03202329|Other|nurse-based care|heart failure nurses visit postoperatively every (working-) day to check fluid balance, medication, rhythm and general condition
2906637|NCT03202316|Experimental|Atezolizumab + Cobimetinib + Eribulin|"During Safety lead-in cycle, participants receive Atezolizumab and Cobimetinib only. During Cycles 1-4, participants receive all 3 study drugs. Starting at Cycle 5, participants only receive Atezolizumab and Cobimetinib.~Participants receive Atezolizumab every 2 weeks while on study.~Participants receive Eribulin on Days 1 and 8 of Cycles 1-4.~Safety lead-in cycle is 2 weeks, Cycles 1-3 are 21 days (about 3 weeks), Cycle 4 is 35 days (about 5 weeks), and Cycles 5 and beyond are 28 days (about 4 weeks)."
2906638|NCT03202303|Experimental|Cannabidivarin (CBDV)|Weight-based dosing of 10 mg/kg/day of CBDV for 12 weeks
2906640|NCT03202290|Other|Gambling disorder|patients suffering from gambling disorder
2906641|NCT03202290|Other|Controls|healthy controls
2906642|NCT03202277|Experimental|BeWell24 smartphone app|Smartphone app, linked with commercial activity monitor, to support lifestyle changes in physical activity, sleep, sedentary behavior, and dietary intake.
2906643|NCT03202277|Active Comparator|Health education smartphone app|Smartphone app with basic health education content, designed to control for non-specific treatment effects and match for smartphone app novelty.
2906644|NCT03202264||TAPERMD|80 Long term care residents on 5 or more medications aged over 70 from 2 long term care facilities
2906645|NCT03202238|Active Comparator|Veinlite|Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
2906646|NCT03202238|Experimental|FireFly Prototype 1|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
2906647|NCT03202238|Experimental|FireFly Prototype 2|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
2906648|NCT03202238|No Intervention|Conventional Venepuncture|Venepuncture without the use of any venepuncture assistive device
2906649|NCT03202212|Experimental|Mixed on-line hemodiafiltration|Mixed on-line hemodiafiltration (mOL-HDF using FX 1000 CorDiax, Fresenius Medical Care, Bad Homburg, Germany), three sessions per week, four hours per session
2906650|NCT03202212|Active Comparator|High flux bicarbonate dialysis|Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
2906651|NCT03202199|Experimental|PET/MRI|PET/MRI examination
2906652|NCT03202186|Placebo Comparator|Placebo|oral administration of Placebo capsule
2906653|NCT03202186|Experimental|Progesterone 200 mg|oral administration of progesterone 200 mg
2906654|NCT03202186|Experimental|Progesterone 300 mg|oral administration of progesterone 300 mg
2906655|NCT03202186|Experimental|Progesterone 400 mg|oral administration of progesterone 400 mg
2906656|NCT03202173|Active Comparator|normal mucosa|Flat and relatively uniform polygonal epithelial cells with alternating dark and light bands were noted in pCLE images of normal mucosa after intravenous injecting 10% fluorescein.
2906657|NCT03202173|Experimental|lymphoid hyperplasia|An unorganized tissue architecture, irregular cells (difference of cell shape, color and size), slightly intensified fluorescein leakage, and vessels not assessable were found in the lymphoid hyperplasia of nasopharyngeal mucosa after intravenous injecting 10% fluorescein..
2906658|NCT03202173|Experimental|nasopharyngeal carcinoma|pCLE images of nasopharyngeal carcinoma, which was associated with crowded unorganized tissue architecture (a dark-gray background without identification of mucosal structures), irregular cells like cell clusters, amplified fluorescein leakage, and irregular vessels changes after intravenous injecting 10% fluorescein.
2906659|NCT03202147|Active Comparator|ALZT-OP1a|ALZT-OP1a: cromolyn (17.1 mg, capsule) for oral inhalation via dry powder inhaler, taken twice per day (morning and evening), 8-12 hours apart.
2906660|NCT03202147|Placebo Comparator|Placebo|ALZT-OP1a: placebo capsule for oral inhalation via dry powder inhaler, taken twice per day (morning and evening), 8-12 hours apart.
2906661|NCT03202121||insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
2906662|NCT03202121||non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
2906663|NCT03202121||normal control|persons without stroke or insomnia served as normal controls that contained 25 cases.
2906664|NCT03202108|Experimental|Consumption of Krio|Incorporation of Krio into the daily diet.
2906665|NCT03202095|Experimental|Open Label Treatment with Creatine|
2906666|NCT03202082|Experimental|Neuropsychological testing|Participants from this group will be administered a neuropsychological battery in addition to the initial and follow-up surveys
2906667|NCT03202082|No Intervention|Treatment as usual|Participants from this group will be administered the initial and follow-up survey.
2906668|NCT03202069|Experimental|Even protein intake|Menu to provide 90 g of protein per day in an even distribution of 30 g at each meal.
2906669|NCT03202069|Experimental|Skewed protein intake|Menu to provide 90 g of protein per day in a skewed distribution of 10 g at breakfast, 15 g at lunch and 65 g at dinner.
2906670|NCT03202056|Experimental|Dry needling|Dry needling technique in each active myofascial trigger point once per week for 3 weeks.
2906671|NCT03202056|Sham Comparator|Sham Dry needling|Sham Dry needling technique in each active myofascial trigger point once per week for 3 weeks.
2906672|NCT03202056|No Intervention|Control|Control group. No intervention.
2906673|NCT03202043|Experimental|High dose vegetable juice|Subject will consume high dose vegetable juice daily for 8 weeks.
2906674|NCT03202043|Experimental|Medium dose vegetable juice|Subject will consume medium dose vegetable juice daily for 8 weeks.
2906675|NCT03202043|Experimental|Low dose vegetable juice|Subject will consume low dose vegetable juice daily for 8 weeks.
2906676|NCT03202043|Other|Control bottled water|Subject will consume control bottled water daily for 8 weeks.
2906677|NCT03202030|Experimental|IDR|Immediate dentoalveolar restoration conducted with bone removed from the tuber
2906678|NCT03202030|Active Comparator|Bio-oss|Bovine demineralized bone (Bio-oss Collagen) applied on the buccal resorption of the immediate implant
2906679|NCT03202017|Active Comparator|Expiratory Muscle Strength Testing (EMST)|EMST is a treatment method that has been used to improve cough function and swallowing in ALS. EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
2906680|NCT03202017|Active Comparator|EMST + Lung Volume Recruitment (LVR)|"EMST is a treatment method that has been used to improve cough function and swallowing in ALS. EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough."
2907175|NCT03199053|Placebo Comparator|Placebo arm|Oral route. Placebo tablets administered for 52 weeks
2906681|NCT03202004|Experimental|GSK2894512 1% cream group|Subjects will apply a thin layer of GSK2894512 1% (10 milligrams per gram [mg/g]) topical cream once daily to all psoriasis lesions for 12 weeks. The study staff will instruct subjects on proper topical application of cream.
2906682|NCT03202004|Placebo Comparator|Vehicle cream group|Subjects will apply a thin layer of vehicle cream once daily to all psoriasis lesions for 12 weeks. The study staff will instruct subjects on proper topical application of cream.
2906683|NCT03201991|Other|Exercise Program|Participants will be asked to take part in an exercise program that is focused on quadriceps strengthening.
2906684|NCT03201978|Experimental|GSK2894512 cream group|Subjects will receive once daily topical repeated application on approximately 5000 cm^2 intact non-occluded skin for 21 days in period 1 followed by once daily on 5000 cm^2 intact occluded skin for 21 days in period 2 (after approximately 21 days of washout period), followed by a single topical application on up to 400 cm^2 gently tape stripped skin area in period 3.
2906685|NCT03201978|Placebo Comparator|Vehicle cream group|Subjects will receive once daily topical repeated application on approximately 5000 cm^2 intact non-occluded skin for 21 days in period 1 followed by once daily on 5000 cm^2 intact occluded skin for 21 days in period 2 (after approximately 21 days of washout period), followed by a single topical application on up to 400 cm^2 gently tape stripped skin area in period 3.
2906686|NCT03201965|Active Comparator|CyBorD alone (cyclophosphamide/bortezomib/dexamethasone)|Participants will receive dexamethasone (40 milligrams [mg] orally or intravenous [IV] dose), followed by cyclophosphamide (300 milligram per meter square [mg/m^2] orally or IV dose), then bortezomib (1.3 mg/m^2 subcutaneous injection) weekly on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles.
2906687|NCT03201965|Experimental|CyBorD plus Daratumumab|Participants will receive dexamethasone (20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing) followed by 1800 mg of daratumumab subcutaneously followed by cyclophosphamide (300 mg/m^2 orally or IV dose weekly) and bortezomib (1.3 mg/m^2 subcutaneous injection weekly) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 2 years.
2906688|NCT03201952|Active Comparator|Ursodeoxycholic Acid/Placebos|During one of the subjects two randomized visits the subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation during visit #1. During visit #2 subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid.
2906689|NCT03201952|Active Comparator|Placebos/Ursodeoxycholic Acid|Subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid during visit #1. During visit #2 subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation.
2906690|NCT03201939|Active Comparator|Active Medication (Intervention arm)|ACE-inhibitor lisinopril
2906691|NCT03201939|Placebo Comparator|Placebo comparator (Control arm)|Matched placebo
2906692|NCT03201926|Experimental|mealworms|mealworms
2906693|NCT03201926|Placebo Comparator|grain powder|grain powder
2906694|NCT03201913|Experimental|Accelerated dose escalation study|"Dose escalation of TTC-352 administered as an oral capsule, twice a day for 28 days (one cycle).~Patients will receive sequential 28-day cycles of treatment until disease progression, unacceptable toxicity, patient refusal to continue treatment, any other reason to discontinue treatment (e.g., further participation is not in the patient's best interest) or study completion/termination."
2906695|NCT03201900|Experimental|E2007|The Treatment Phase consists of the 4 milligrams (mg) Treatment Phase (the Titration Period [6 weeks] and the Maintenance Period [26 weeks]) and the 8 mg Treatment Phase (the Titration Period [4 weeks] and the Maintenance Period [26 weeks]) if participants require a higher dose. In the 4 mg Titration Period (6 weeks), participants will initiate 2 mg perampanel once daily (QD) for 2 weeks and then will be up-titrated to 4 mg QD and will continue this dose for 4 weeks. If participants have no safety issues at the end of the Titration Period, they will start the 4 mg Maintenance Period for 26 weeks. Participants will only need the higher dose if they are having seizures. In the 8 mg Titration Period (4 weeks), participants will be administered 6 mg perampanel QD for 2 weeks and then will be up-titrated to 8 mg QD and will continue this dose for 2 weeks. If participants have no safety issues at the end of the Titration Period, they will start the 8 mg Maintenance Period for 26 weeks.
2906696|NCT03201887|Experimental|Sub-optimal Traumatic Brain Injury|Sub-optimal effort
2906697|NCT03201887|Experimental|Sub-optimal effort Chronic pain|Sub-optimal effort
2906698|NCT03201887|No Intervention|Traumatic Brain Injury|optimal effort
2906699|NCT03201887|No Intervention|Chronic pain|optimal effort
2906700|NCT03201874|Active Comparator|Education Control|In addition to standard medical care, youth in the education control group will be provided with access to a self-guided education study website, which will contain static education about SCD (no self-management skills, goal-setting, or social support content) to access over 8-weeks.
2906701|NCT03201874|Experimental|Pain Self-Management Intervention|In addition to standard medical SCD care, youth in the pain self-management intervention group will receive the iCanCope with SCD mobile intervention including goal-setting, peer social support, and pain self-management skills over a period of 8 weeks.
2906702|NCT03201861|Experimental|paclitaxel and cisplatin|Drug: paclitaxel, cisplatin, epirubicin and cyclophosphamide Patients will be administered paclitaxel (80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks) and cisplatin (25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 3 cycles) followed by epirubicin and cyclophosphamide (EC) (epirubicin 90mg/m² i.v.d1, cyclophosphamide 600mg/m² i.v.d1) for 4 cycles.
2906736|NCT03201640|Other|virtual|Participant receives virtual reality presentation for preoperative preparation
2906737|NCT03201627|Experimental|treatment|
2906738|NCT03201601|Experimental|550 mg of MYO and 150 mg of DCI|Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 150 mg of D-chiro-inositol.
2906739|NCT03201601|Active Comparator|550 mg of MYO and 13.8 mg of DCI|Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 13.8 mg of D-chiro-inositol.
2906703|NCT03201861|Active Comparator|epirubicin and cyclophosphamide|"Drug：epirubicin, cyclophosphamide, paclitaxel and docetaxel~Investigators will declare one of the following regimens:~Patients with hormone receptor (HR) positive breast cancer wil be administered epirubicin (90mg/m² i.v.d1 q21d) and cyclophosphamide (600mg/m² i.v.d1 q21d) for 4 cycles followed by docetaxel (75mg/m² i.v.d1 q21d) for 4 cycles.~Patients with triple-negative breast cancer will be administered epirubicin (90mg/m² i.v.d1 q21d) and cyclophosphamide (600mg/m² i.v.d1 q21d) for 4 cycles followed by weekly paclitaxel (80 mg/m² i.v.d1) for 12 weeks or docetaxel (75mg/m² i.v.d1 q21d) for 4 cycles."
2906704|NCT03201848|Experimental|Huaiqihuang Granule|Huaiqihuang Granule given to subject will be adjusted by body weight with treatment duration for 48 weeks
2906705|NCT03201848|Placebo Comparator|Placebo|Placebo given to subject will be adjusted by body weight After 24 weeks of placebo, change to Huaiqihuang Granule for another 24 weeks.
2906706|NCT03201835|Experimental|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
2906707|NCT03201835|Experimental|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
2906708|NCT03201835|Experimental|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
2906709|NCT03201835|Experimental|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
2906710|NCT03201835|Active Comparator|Sativex®|spray X 4 actuations, Each 100 μL spray contains 2.7 mg THC and 2.5 mg CBD, total per administration: 10.8 mg THC and 10 mg CBD
2906711|NCT03201822|Experimental|100 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 100 cocoa flavanol/70 kg BW
2906712|NCT03201822|Experimental|200 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 200 cocoa flavanol/70 kg BW
2906713|NCT03201822|Experimental|400 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 400 cocoa flavanol/70 kg BW
2906714|NCT03201822|Experimental|1000 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 1000 cocoa flavanol/70 kg BW
2906715|NCT03201809|Experimental|On-Q Catheter|On-Q catheters placed within the implant pocket; infusion of 0.2% Ropivacaine at 4 mL/h for a total of 400 mL (about 4 days).
2906716|NCT03201809|Active Comparator|Ultrasound Guided Pectoral Nerve Block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the pecs 2 injection
2906717|NCT03201796|Experimental|Group 1|Prulifloxacin 600 mg
2906718|NCT03201796|Active Comparator|Group 2|Levofloxacin 500 mg
2906719|NCT03201783|Other|immediate group|the intervention: immediate frozen-thawed embryo transfer (FET) which means FET will be performed in the first cycle following the stimulated IVF cycle
2906720|NCT03201783|Other|delayed group|the intervention: delayed frozen-thawed embryo transfer (FET) which means FET will be performed at least in the second cycle following the stimulated IVF cycle
2906721|NCT03201770|Experimental|Pyramax|Pyronaridine artesunate tablets (180/60mg) and granules (60/20mg)
2906722|NCT03201757|Experimental|ALKS 3831|Coated bilayer tablet
2906723|NCT03201744|Experimental|Moderate Neuromuscular Block|Train of four count of 1-2. All procedures will start with low-pressure insufflation (8 mm Hg). Surgeon assessment of the conditions will be serially performed during surgery on an established visual scale. If conditions are deemed less than adequate (score 1-2), insufflation pressure will incrementally increase up to 15 mm Hg. Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
2906724|NCT03201744|Experimental|Deep Neuromuscular Block|Post tetanic count of 1-2. All procedures will start with low-pressure insufflation (8 mm Hg). Surgeon assessment of the conditions will be serially performed during surgery on an established visual scale. If conditions are deemed less than adequate (score 1-2), insufflation pressure will incrementally increase up to 15 mm Hg. Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
2906725|NCT03201731||Cases|Those diagnosed with a non-organic, non-affective psychotic disorder for the first time after age 60, recruited from a Community Mental Health Team.
2906726|NCT03201731||Controls|Those aged 60 and above in contact with the same Community Mental Health Team for another mental health problem aside from a psychotic disorder or dementia.
2906727|NCT03201718||Hepatitis C|Participants with Hepatitis C receiving Viekiraor/Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) for 12 or 24 weeks.
2906728|NCT03201705|Experimental|Refractory neuropathic leg and low back pain|Patients with refractory neuropathic leg and low back pain as result of FBSS will be enrolled in the study and receive electrocatheter implant. Then, they will be observed for a two-weeks trial period in which the efficacy of the stimulation and the compliance of the patient is evaluated. During this trial a Tonic wave stimulation is administered by the external generator. After the trial, the definitive generator will be implanted. Tonic stimulation will be selected as wave form for four weeks. After this period, the stimulation will be switched into the combined waveform for 30 days. At the end of the study period, the final waveform setting of the SCS will be in accord with the patient's stimulation preference.
2906729|NCT03201692|Active Comparator|Treadmill Training|40' treadmill training walking holding the handrail
2906730|NCT03201692|Experimental|Virtual Reality Treadmill Training|40' treadmill training walking with virtual visual and auditory cues
2906731|NCT03201679||Patients with preoperative sepsis|Sepsis defined as SIRS plus a positive culture from any site.
2906732|NCT03201679||Patients without preoperative sepsis|
2906733|NCT03201653|Active Comparator|Conventional|Stump closure as our institute routine, using interrupted silk mattress suture and continuous prolene sutures.
2906734|NCT03201653|Experimental|Surgicel|Stump closure modified from our institute routine, using interrupted silk mattress suture and continuous prolene sutures with NU-KNIT SURGICEL overlying for reinforcement.
2906735|NCT03201640|Other|slideshow|Participant receives traditional slideshow presentation for preoperative preparation
2906740|NCT03201588|Experimental|Formulaid|Formulaid 2:1 Arachidonic acid/Docosahexaenoic acid (AA/DHA). Enteral supplement of AA (0,1-1ml) (100mg(kg/day) and DHA (50mg/kg/day) from birth to 40 weeks postmenstrual age in addition to conventional parenteral fatty acid treatment with Clinoleic
2906741|NCT03201588|No Intervention|Clinoleic|"Sterile fat emulsion [containing a mixture of refined olive oil (approximately 80%) and refined soya oil (approximately 20%)] 200 g, egg lecithin (purified egg phospholipids) 12 g, glycerol 22.5 g, sodium oleate 0.3 g and Water for Injections to 1,000 mL (final pH between 6.0-8.0).~One of the active ingredients, soya oil, contains ascorbyl palmitate as an antioxidant (free radical scavenger), in the concentration of 0.15 mg/g of oil."
2906742|NCT03201575|Experimental|Remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient. The remote ischemic conditioning consists in alternative inflations and deflations of the brachial cuff.
2906743|NCT03201575|Other|Control group|A brachial cuff is positioned around the arm of the patient. No inflation or deflation is made.
2906744|NCT03201562|Experimental|PRX-100 Ophthalmic Solution|
2906745|NCT03201562|Active Comparator|PRX-100 Component #1 Ophthalmic Solution|
2906746|NCT03201562|Sham Comparator|PRX-100 Vehicle Ophthalmic Solution|
2906747|NCT03201549|Experimental|healthy|healthy volunteers will ingest fructose and have FGF21 levels measured
2906748|NCT03201536|Active Comparator|sutures|zipLine3 device verses conventional sutures
2906749|NCT03201536|Active Comparator|Zip3 Device|
2906750|NCT03201523|Experimental|Intervention|Community members will be exposed to multiple interventions designed through the participatory approach, integrating the socio-ecological model.
2906751|NCT03201510||Observational|Observational study
2906752|NCT03201497||patients with PJP|PJP patients in ICU with or without HIV infection
2906753|NCT03201471|Experimental|treatment group|In this group, the patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1; CTX 750mg/m2, ivgtt,d2; EPI 70mg/m2, ivgtt,d2; VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2, PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18; one cycle every 21 days； abbreviation： CTX： cyclophosphamide；EPI：etoposide；VCR： vincristine；Pred：prednisone； R-CHOP：the chemo-therapy regimen composed of Rituximab, cyclophosphoamide; etoposide, vincristine and prednisone.
2906754|NCT03201458|Experimental|Arm A (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2906755|NCT03201458|Experimental|Arm B (atezolizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15 and cobimetinib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2906756|NCT03201445|Experimental|Double-Blind Filgotinib|Filgotinib for up to 26 weeks
2906757|NCT03201445|Placebo Comparator|Double-Blind Placebo|Placebo for up to 26 weeks
2906758|NCT03201445|Experimental|Monitoring Phase|Participants with ≥ 50% decline in sperm concentration will receive standard of care therapy in the monitoring phase
2906759|NCT03201445|Experimental|Long Term Extension Phase|After Week 26, participants who did not experience a decrease of ≥ 50% in sperm concentration from baseline will have the option to enter into the long-term extension (LTE) phase of the study. Responders will continue on the same blinded study drug and non-responders will continue to receive open-label filgotinib for an additional 195 weeks.
2906760|NCT03201432|Other|Bare metal stent (BES) group|Percutaneous vertebral artery stenting using bare metal stents (Boston Scientific：Express SD) in patients randomized to BES group
2906761|NCT03201432|Experimental|Drug eluting stent (DES) group|Percutaneous vertebral artery stenting using drug eluting stents (Liaoning Biomedical Materials R&D Center Co., Ltd. ：YINYI) in patients randomized to DES group
2906762|NCT03201419|Placebo Comparator|Placebo|
2906763|NCT03201419|Active Comparator|Desmopressin|Desmopressin ODT (25 μg for females and 50 μg for males)
2906764|NCT03201419|Experimental|FE 201836 (1)|Dose 1
2906765|NCT03201419|Experimental|FE 201836 (2)|Dose 2
2906766|NCT03201419|Experimental|FE 201836 (3)|Dose 3
2906767|NCT03201419|Experimental|FE 201836 (4)|Dose 4
2906768|NCT03201419|Experimental|FE 201836 (5)|Dose 5
2906769|NCT03201419|Experimental|FE 201836 (6)|Dose 6
2906770|NCT03201393|Experimental|ALLOD-2 Capsules|Component A and Component B
2906771|NCT03201393|Placebo Comparator|Placebo Capsules|Placebo for Component A and Placebo for Component B
2906772|NCT03201367|Active Comparator|study group|"acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis~- treated with rivaroxaban"
2906773|NCT03201367|Placebo Comparator|control group|acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis receive placebo
2906774|NCT03201354|Active Comparator|Filtration surgery with Express|Filtration surgery with Ex-PRESS + cataract extraction (Cataract surgery and IOL implantation)
2906775|NCT03201354|Active Comparator|Non penetrating surgery|- Filtration surgery with Non penetrating deep sclerectomy + cataract extraction (Cataract surgery and IOL implantation)
2906776|NCT03201341|Other|Behavioral protocol|To better understand the normal functioning of the brain within the framework of the representation of the body and of the space of action. During the experiment, physiological measurements will be recorded: electrical activity at the surface of the muscles (electromyography - EMG), scalp (electroencephalography - EEG) or skin (electrodermal response). Similarly, the movements of the arm will be recorded using an infrared kinematic system requiring simply the placement of markers at strategic points such as the tip of the thumb and forefinger, the wrist, the elbow ... Movements of the eyes can also be recorded, either with the aid of an electrooculograph (EOG) or with the aid of an infrared tracking device. Electrotactile stimulations of very low intensity and painless can also be administered.
2906812|NCT03201198|Experimental|Active Life|The Active Life intervention includes structured walking, functional circuit training, stretching and behavior/educational components.
2906813|NCT03201198|Sham Comparator|Chair exercises|The Chair exercise intervention includes chair exercises, behavioral relaxation and health education.
2906814|NCT03201185|Experimental|Ramipril|After transcatheter aortic valve implantation, patients will receive ramipril before discharge plus conventional treatment (in patients without ACEI).
2906777|NCT03201341|Other|Study in fMRI|To better understand the normal functioning of the brain in the representation of the body and the space of action, to identify the brain areas critical for these functions and to determine their functional roles. The examination will consist of several very short scans at the very beginning and then a scan of about ten minutes intended to take a detailed anatomical image of the brain. Then, the subject will carry out the experimental task during one or more scan (s) whose cumulative duration will not exceed 45 minutes. The task accomplished is explained in detail by the experimenter.
2906778|NCT03201341|Other|Study in MEG|To better understand the normal functioning of the brain in the representation of the body and the space of action, to identify the critical brain areas for these functions and to determine their functional roles and to study how They interact.The complete examination includes a magnetoencephalography (MEG) experiment followed by an MRI examination. The task accomplished is explained in detail by the experimenter.
2906779|NCT03201341|Other|Study in TMS|To better understand the normal functioning of the brain in the representation of the body and the space of action, to determine the functional role of the brain areas involved in these processes. Before the Transcranial magnetic stimulation (TMS) examination, MRI of the brain will be performed.The TMS review will consist of three distinct sessions separated from one another by at least one week, depending on the protocol, and which will differ simply at the site or type of stimulation.
2906780|NCT03201341|Other|Study in tDCS|To better understand the normal functioning of the brain in the representation of the body and the space of action, to determine the functional role of the cerebral areas involved in these processes. The transcranial Direct Current Stimulation (tDCS) exam will consist of three separate sessions separated from each other by at least one week and will simply differ at the stimulation site. The task accomplished is explained in detail by the experimenter.
2906781|NCT03201328|Active Comparator|healthy subjects|
2906782|NCT03201328|Experimental|patients with unilateral cochlear implants|
2906783|NCT03201328|Experimental|patients with bilateral cochlear implants|
2906784|NCT03201302|Experimental|School physical education class|Children who participated only in their school physical activity classes only for the entire school year.
2906785|NCT03201302|Experimental|Taekwondo|Children who participated in organized Taekwondo training for the entire school year.
2906786|NCT03201302|Experimental|Martial arts|Children who participated in organized Martial arts training for the entire school year.
2906787|NCT03201302|Experimental|Climbing|Children who participated in organized climbing training for the entire school year.
2906788|NCT03201302|Experimental|Volleyball|Children who participated in organized volleyball training for the entire school year.
2906789|NCT03201302|Experimental|Artistic gymnastics|Children who participated in organized artistic gymnastics training for the entire school year.
2906790|NCT03201302|Experimental|Swimming|Children who participated in organized swimming training for the entire school year.
2906791|NCT03201302|Experimental|Dance|Children who participated in organized dance training for the entire school year.
2906792|NCT03201302|Experimental|Basketball|Children who participated in organized basketball training for the entire school year.
2906793|NCT03201302|Experimental|Wrestling|Children who participated in organized wrestling training for the entire school year.
2906794|NCT03201302|Experimental|Football (soccer)|Children who participated in organized football (soccer) training for the entire school year.
2906795|NCT03201302|Experimental|Rhythmic gymnastics|Children who participated in organized rhythmic gymnastics training for the entire school year.
2906796|NCT03201302|Experimental|Track and field|Children who participated in organized track and field training for the entire school year.
2906797|NCT03201302|Experimental|Tennis|Children who participated in organized tennis training for the entire school year.
2906798|NCT03201302|Experimental|Combination of activities 1|Children who participated in two different weight-bearing activities for the entire school year.
2906799|NCT03201302|Experimental|Combination of activities 2|Children who participated in one weight-bearing and in one non weight-bearing activity for the entire school year.
2906800|NCT03201289||Cardiac surgery|
2906801|NCT03201276||Drug group|patients taking glucosamine
2906802|NCT03201263|Active Comparator|PSV group|Will be treated by standard of care for patients undergoing assisted mechanical ventilation (e.g., protective PSV settings, protocolized weaning, etc.).
2906803|NCT03201263|Experimental|PSV+Sigh group|Will be treated by standard of care for patients undergoing assisted mechanical ventilation (e.g., protective PSV settings, protocolized weaning, etc.) + Sigh (short cyclic recruitment breath once every minute) until death or spontaneous breathing trial and extubation.
2906804|NCT03201250|Experimental|Treatment|"Combination of cabozantinib, carfilzomib and dexamethasone~Cabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.~Carfilzomib: carfilzomib will be administered intravenously over 10 minutes, on two consecutive days, each week for three weeks (Days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period (Days 17 to 28). Each 28-day period is considered one treatment cycle.~Dexamethasone: dexamethasone will be administered at 40 mg orally or intravenously on days 1, 8,15 and 22 of each 28-day cycle (for patient age ≥ 75, acceptable to be given as 20 mg orally or intravenously on days 1, 2, 8, 9, 15, 16, 22, 23)"
2906805|NCT03201237|Experimental|30 min AOT|
2906806|NCT03201237|Placebo Comparator|60 min AOT|
2906807|NCT03201224||Group without image transmission|"Before Group"
2906808|NCT03201224||Group with image transmission|"After Group"
2906809|NCT03201211|Experimental|Group A|Subjects who received two doses of formulation 1 of the NTHi-Mcat investigational vaccine during STEP 2 of NTHi -Mcat-001 (201281 - NCT02547974) study and for whom blood sampling was taken at each planned visit during the NTHI Mcat-006 study, for antibody determination and assay validation/development.
2906810|NCT03201211|Experimental|Group B|Subjects who received two doses of formulation 2 of the NTHi-Mcat investigational vaccine during STEP 2 of NTHi -Mcat-001 (201281 - NCT02547974) study and for whom blood sampling was taken at each planned visit during the NTHI Mcat-006 study, for antibody determination and assay validation/development.
2906811|NCT03201211|Placebo Comparator|Group C|Subjects who received placebo during STEP 2 of NTHi -Mcat-001 (201281 - NCT02547974) study and for whom blood sampling was taken at each planned visit during the NTHI Mcat-006 study, for antibody determination and assay validation/development
2906815|NCT03201185|No Intervention|No intervention|Conventional treatment after transcatheter aortic valve implantation
2906816|NCT03201172||Univation® X|
2906817|NCT03201172||iUni®|
2906818|NCT03201159|Experimental|VLX103 150mg|In the first group, 150 mg dosing cohort, one VLX103 tablet will be administered daily for 14 days.
2906819|NCT03201159|Experimental|VLX103 300mg|In the second group, 300 mg dosing cohort, two VLX103 tablets will be administered daily for 14 days.
2906820|NCT03201159|Experimental|VLX103 450mg|In the third group, 450 mg dosing cohort, three VLX103 tablets will be administered daily for 14 days.
2906821|NCT03201146|Experimental|Apatinib 750mg + AP or AC|Phase 1 study of Apatinib in combination with platinum‐based doublet chemotherapy.
2906822|NCT03201146|Experimental|Apatinib 500mg + AP or AC|Phase 1 study of Apatinib in combination with platinum‐based doublet chemotherapy.
2906823|NCT03201146|Experimental|Apatinib 250mg + AP or AC|Phase 1 study of Apatinib in combination with platinum‐based doublet chemotherapy(PBDC).
2906824|NCT03201146|Experimental|Apatinib|Phase 2 study of Apatinib in combination with platinum‐based doublet chemotherapy(PBDC).
2906825|NCT03201146|Active Comparator|AP or AC|Pemetrexed/Cisplatin(AP) or Pemetrexed/Carboplatin(AC), The platinum‐based doublet chemotherapy, as the control group in the phase 2 study.
2906826|NCT03201133||Patellofemoral pain syndrome with changes in proximal factors|
2906827|NCT03201133||Patellofemoral pain syndrome with changes in local factors|
2906828|NCT03201133||Patellofemoral pain syndrome with changes in distal factors|
2906829|NCT03201120|Experimental|Outdoor Sun Exposure Behavior|"A convenience sample of white, English-speaking adults ages 18 to 49 will be recruited via online advertisements in Philadelphia and the surrounding region (within a 30 mile radius). The investigators will recruit 120 adults to test outdoor UV exposure messages. The investigators will quota sample to ensure representation across age and gender groups.~The inclusion criteria are that adults must be white, must be between 18-49 years old and must speak English."
2906830|NCT03201120|Experimental|Indoor Tanning Behavior|"A convenience sample of white, English-speaking females ages 18 to 25 will be recruited via online advertisements and flyers in Philadelphia and the surrounding region (within a 30 mile radius). The investigators will recruit 60 adults to test indoor tanning messages.~The inclusion criteria are that adults must be white, female, must be between 18-25 years old, must have used an indoor tanning bed at least once in the past 12 months, and must speak English."
2906831|NCT03201107|Experimental|Pilates group|This group receives physical training based on pilates exercises
2906832|NCT03201107|No Intervention|No intervention group|This group does not receive any treatment
2906833|NCT03201094|No Intervention|Standard of Care|Patients will receive standard of care mobilization and nutritional supplementation throughout the study period.
2906834|NCT03201094|Experimental|HPRO + NMES|Patients will receive high protein supplementation(HPRO) administered within 30 minutes after each NMES session and additionally once at approximately 10 PM.
2906835|NCT03201081|Experimental|training group|The training group, based on motivational strategies were performed and a moderate intensity training (8 to 12 repetitions). The load was increased: during the 12 weeks from 65% 1-RM to 80% 1-RM, performing individual more than the prescribed number of repetitions (12 repetitions). A 1-2 minutes resting period was allowed between sets. There was no attempt to control the velocity of the repetitions performed. Prior to each training session, the volunteers performed a specific warmup, consisting of 10 repetitions with approximately 50% of the load used in the first and second exercises of the training session. A total of 36 sessions were performed during the training period. This group was compared with no interventions subjects.
2906836|NCT03201081|No Intervention|control group|The control group, did not participate in the motivational resistance-training program.
2906837|NCT03201068|Experimental|Probiotic supplement|Renew Life Formulas, Inc
2906838|NCT03201068|Placebo Comparator|Placebo|Placebo capsule
2906839|NCT03201055|Experimental|Non Apnoeic Snorers|Patient's use the Snore Positive airway pressure device for 28 nights.
2906840|NCT03201042||1a:Lyme patients- Erythema Migrans(EM)rash present|Patients with newly diagnosed Lyme disease based on the presence of a physician-documented EM rash. PCR, serology and Tcell based assay.
2906841|NCT03201042||1b:Lyme patients no typical EM|Patients documented symptoms of early Lyme disease, without a typical EM rash present, and the physician's intention to treat for Lyme disease. PCR, serology and Tcell based assay
2906842|NCT03201042||Cohort 2: healthy controls|Patients drawn from Lyme disease non-endemic areas and subjects with known exposure to Lyme disease will be excluded. PCR, serology and Tcell based assay.
2906843|NCT03201003|Active Comparator|Biological/Vaccine: AR101|AR101 powder provided in capsules & sachets
2906844|NCT03201003|Placebo Comparator|Placebo|Placebo powder provided in capsules & sachets
2906845|NCT03200990|Experimental|iVAC2L pVAD|Clinically indicated ventricular support for high-risk PCI with Pulsecath iVAC2L.
2906846|NCT03200990|Active Comparator|Impella CP pVAD|Clinically indicated ventricular support for high-risk PCI with Impella CP.
2906847|NCT03200977||Exposed to nivolumab prior to allogeneic HCT|patients who were treated with nivolumab-based regimen prior to an allogeneic HCT
2906848|NCT03200977||Unexposed to nivolumab prior to allogeneic HCT|patients who were not treated with nivolumab-based regimen prior to an allogeneic HCT
2906849|NCT03200951|Experimental|Bolus group|
2906850|NCT03200951|Active Comparator|Infusion group|
2906851|NCT03200938|Experimental|PBS CIMMO|Intervention: PBS CIMMO cement
2906852|NCT03200938|Active Comparator|Zinc oxide|Intervention: Formocresol and zinc oxide
2906879|NCT03200769|Experimental|Group IIb|15 < AHI/h < 30. Randomization group. Intervention : CPAP placebo during the first 3 months. After this period, the patient will have the possibility to continue with an active CPAP.
2906880|NCT03200769|Active Comparator|Group III|AHI/h > 30. Intervention : CPAP active
2906881|NCT03200756|Experimental|Sedentary Group|The experimental group undergoes a behavioral intervention to reduce sedentary behavior which includes a patient centered approach with monitoring and goal setting.
2906882|NCT03200756|Active Comparator|Exercise Group|The Active Comparative group undergoes a standard clinical approach to increase exercise which is patient centered with monitoring and goal setting.
2906883|NCT03200743||Hpertension|
2906884|NCT03200743||Health|
2906853|NCT03200925|No Intervention|Group A - no video group|"Group A will be asked a short survey:~their intention to practice skin to skin at the time of delivery~if they participated in skin to skin in a previous pregnancy~if they had any formal education about skin to skin~if they did have formal education was it either~a.) Provided at a prenatal appointment,~b.) A formal class led by either a nurse or a lactation consultant.~We will also look at patient's medical record number, age, gestational age, any pregnancy complications, race, type of insurance, and the number of times the patient has been pregnant. We will also examine data that is already collected by this hospital after delivery regarding skin to skin. This includes gestational age in weeks at the time of delivery, 5 minute APGAR, delivery date/time, skin to skin initiation time, skin to skin end time, delivery to skin to skin duration (minutes), and skin to skin duration (minutes)."
2906854|NCT03200925|Experimental|Group B - video group|"Group B will be asked the same short survey as group A.~The patient would then immediately watch Jumping into Kangaroo Care, and then immediately take the post survey which would ask if they intended to practice skin to skin at the time of delivery.~We will also look at patient's medical record number, age, gestational age, any pregnancy complications, race, type of insurance, and the number of times the patient has been pregnant. We will also examine data that is already collected by this hospital after delivery regarding skin to skin. This includes gestational age in weeks at the time of delivery, 5 minute APGAR, delivery date/time, skin to skin initiation time, skin to skin end time, delivery to skin to skin duration (minutes), and skin to skin duration (minutes)."
2906855|NCT03200912|Active Comparator|Picato|Picato® (ingenol mebutate) gel, 0.15% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
2906856|NCT03200912|Experimental|Generic Ingenol Mebutate|Generic ingenol mebutate gel, 0.15% [Test]
2906857|NCT03200912|Placebo Comparator|Vehicle Foam|Vehicle gel of the test product
2906858|NCT03200899|Experimental|Memory, Attention, Problem Solving Skills in MS (MAPSS-MS)|Participants randomized to this arm receive the MAPSS-MS intervention. The MAPSS-MS is an an 8 week computer assisted cognitive rehabilitation intervention. The group based component of the intervention emphasizes use of compensatory cognitive strategies as well as lifestyle modifications to enhance cognition. Participants also complete home computer training (minimum 3 times per week for 45 minutes) using a special suite of games designed by Lumosity.
2906859|NCT03200899|Active Comparator|Usual Care plus Computer games|Participants randomized to this arm receive usual care and are referred to MY BRAIN GAMES web site.
2906860|NCT03200886||Sinovial H-L Group|The patients treated have received one cycle of two injections (at baseline and 15 days apart) of 1 ml of Sinovial H-L® (3.2% - 16mg + 16mg, Ibsa).
2906861|NCT03200886||Control Group|The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl).
2906862|NCT03200873|Active Comparator|high impulsivity|participants with high impulsivity (BIS >62), receiving active and sham repetitive transcranial magnetic stimulation [intermittent theta burst stimulation (iTBS)] in a randomised order
2906863|NCT03200873|Active Comparator|low impulsivity|participants with low impulsivity (BIS between 52 to 62), receiving active and sham repetitive transcranial magnetic stimulation [intermittent theta burst stimulation (iTBS)] in a randomised order
2906864|NCT03200860|Active Comparator|Empagliflozin|Empagliflozin 10 mg daily, oral, 30 days
2906865|NCT03200860|Placebo Comparator|Placebo|Matching Placebo 10 mg daily, oral, 30 days
2906866|NCT03200847|Experimental|Pembrolizumab with All-Trans Retinoic Acid|Patients will receive pembrolizumab infusions every three weeks. Patients will also receive 3 days of all-trans retinoic acid treatment surrounding each of the first 4 infusions of pembrolizumab, beginning one day prior to the infusion (a total of 12 days of all-trans retinoic acid).
2906867|NCT03200834|Active Comparator|D2 lymph node dissection for right colon cancer|Hemicolectomy for right colon cancer with D2 lymph node dissection
2906868|NCT03200834|Experimental|D3 lymph node dissection for right colon cancer|Hemicolectomy for right colon cancer with D3 lymph node dissection
2906869|NCT03200821|Experimental|G17DT|250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.
2906870|NCT03200821|Active Comparator|Gemcitabine|1000 µg/m^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
2906871|NCT03200808|Experimental|treatment group|"Methylene blue compound injection are mixed by Methylene Blue injection, Dexamethasone powder-injection, Ropivacaine injection and Normal saline injection. Each individual component can help in a very wide range of medical conditions without serious side effects.~Every patient received intradermal mixed methylene blue compound injection twice. All patients were observed during the hospitalization at the first injection, and two weeks later they received the second injection at the outpatient department."
2906872|NCT03200795|Experimental|Rebound exercise group|Participants randomized to this group will be instructed on the proper techniques of the desired movements (hopping) on the rebounder.
2906873|NCT03200795|Experimental|Circuit training group|The circuit training for the participants in this group will be designed for each participant. Training will take place 3 times a week for 8 weeks. The participants will undergo 10 minutes warm up before and 10 minutes cool down after the training. Resistance exercises will be performed on weight machines. Throughout the resistance training program, participants will be alternating between the bench press, seated row, lateral pull down, biceps forward, front thigh, back thigh, leg press and rowing.
2906874|NCT03200782|Placebo Comparator|Placebo-Placebo|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
2906875|NCT03200782|Active Comparator|Investigational Drug A Empagliflozin|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an 10mg of empagliflozin 2 hours before the test meal will be administered by an independent nurse to the blinded patient
2906876|NCT03200782|Active Comparator|Investigational Drug B Anakinra|subcutaneous injection of 100mg anakinra 3 hours before the test meal and an oral placebo (winthrop tablet)before the test meal will be administered by an Independent nurse to the blinded patient
2906877|NCT03200769|No Intervention|Group I|AHI/h < 15
2906878|NCT03200769|Experimental|Group IIa|15 < AHI/h < 30. Randomization group. Intervention : CPAP active
2906938|NCT03200392|Experimental|L-DGG/LRB|laser root surface conditioning & laser DGG harvesting
2906885|NCT03200730|Experimental|Family Dignity Intervention group|"A standard framework of 12 FDI questions is given to patient-family dyads in the intervention group during baseline to provides them with the opportunity to think about their responses. During the intervention interview scheduled 2-3 days later, the FDI therapist follows that dyad's cues, help them to organize their thoughts, facilitate disclosure of cherished memories, and encourage the expression of appreciation. The interview is be recorded, quickly transcribed verbatim then edited into a coherent narrative. A second review session is arranged to review and finalize the edited transcript with the dyads. Once the legacy documents are ready, a final family sharing session is arranged for the dyads to share and read this document to each other and their loved ones."
2906886|NCT03200730|No Intervention|Control group|Patient-family dyads in the control group have at least four interviews with a designated member of the research team via psychosocial home visits. Completing the assessments and taking part in the interviews provides them with the opportunity to share their feelings and emotions along their illness trajectory. The extent to which they feel sharing is therapeutic is explored in the interview.
2906887|NCT03200717|Experimental|pazopanib 800 mg|administered after checkpoint inhibitor treatment
2906888|NCT03200704|Active Comparator|Blue - SPY|The periareolar area of the breast will be injected twice with 0.2 ml of a 1% Isosulfan Blue solution followed by injection twice with 0.05 ml of a 2.5 mg/ml solution of IC2000. Lymph node mapping will occur first with Isosulfan Blue based on direct visualization followed by intraoperative fluorescence visualization using IC2000 and SPY-PHI. As per standard of care, all subjects will receive an injection of Tc-99m radioactive colloid either the day before or the morning of surgery. The gamma probe will be used in conjunction with Tc-99m radioactive colloid to identify the SLNs during mapping; SLN identification will be performed first in all subjects as per standard of care.
2906889|NCT03200704|Active Comparator|SPY - Blue|The periareolar area of the breast will be injected twice with 0.05 ml of a 2.5 mg/ml solution of IC2000 followed by injection twice with 0.2 ml of a 1% Isosulfan Blue solution. Lymph node mapping will occur first by intraoperative fluorescence visualization using IC2000 and SPY-PHI followed by direct visualization with Isosulfan Blue. As per standard of care, all subjects will receive an injection of Tc-99m radioactive colloid either the day before or the morning of surgery. The gamma probe will be used in conjunction with Tc-99m radioactive colloid to identify the SLNs during mapping; SLN identification will be performed first in all subjects as per standard of care.
2906890|NCT03200691|Experimental|Nimotuzumab with radiotherapy|"Patients will receive neoadjuvant radiotherapy with concurrent anti-PD-1 antibody SHR-1210. Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40Gy/20f.~SHR-1210 200mg fixed dose every 2 weeks delivered concurrent with radiation therapy.~After 2-4 weeks of neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
2906891|NCT03200678|Experimental|ACLR Group|experimental: ACL surgery Intervention: isokinetic assessment
2906892|NCT03200678|Other|Control group|other Intervention: isokinetic assessment
2906893|NCT03200665|Experimental|Ultrasound 35-36 (6 / 7 days weeks)|The patients that are randomized to this group, besides accomplishing the standard of care of national guidelines (third trimester ultrasound at 30-32 (6 / 7 days weeks)) will be submitted to an additional third trimester ultrasound at 35-36 (6 / 7 days weeks).
2906894|NCT03200665|No Intervention|Standard of Care|This is the control group that will be managed in accordance to national guidelines of screening of late fetal growth restriction in low risk pregnancies: third trimester ultrasound at 30-32 (6 / 7 days weeks).
2906895|NCT03200652|Experimental|metabolic availability of lysine in wheat|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or a baked wheat bread with or without lentils, which will all be provided by the investigators."
2906896|NCT03200639|Active Comparator|Physical training, CT|Combined Trained with no cancer (CT): Post menopausal women with no cancer submitted to 12 weeks of combined training (i.e. aerobic training plus resistance training)
2906897|NCT03200639|Active Comparator|Physical training, HIITBW|High intensity interval training with body weight with no cancer (HIITBW): Post menopausal women with no cancer submitted to 12 weeks of high intensity interval training with body weight (i.e. step climbing plus squats)
2906898|NCT03200639|Experimental|Physical training, CTc|Combined Trained with gynecological and/or breast cancer (CTc): Post menopausal women with with gynecological and/or breast cancer submitted to 12 weeks of combined training (i.e. aerobic training plus resistance training)
2906899|NCT03200639|Experimental|Physical training, HIITBWc|High intensity interval training with body weight with gynecological and/or breast cancer (HIITBWc): Post menopausal women with gynecological and/or breast cancer submitted to 12 weeks of high intensity interval training with body weight (i.e. step climbing plus squats)
2906900|NCT03200626||Cytokine alone or JIT plerixafor based mobilization|
2906901|NCT03200626||Routine plerixafor based mobilization|
2906902|NCT03200626||Chemomobilization|
2906903|NCT03200613|Experimental|Apixaban|Apixaban 2.5 mg orally twice daily
2906904|NCT03200613|Active Comparator|Low Molecular Weight Heparin|Either enoxaparin 40 mg or dalteparin 5000 units subcutaneously once daily
2906905|NCT03200600|Experimental|Dexamethasone and flurbiprofen axetil|"Dexamethasone 10 mg is administered before anesthesia induction.~Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
2906906|NCT03200600|Experimental|Dexamethasone and lipid microsphere|"Dexamethasone 10 mg is administered before anesthesia induction.~Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
2906939|NCT03200392|Experimental|B-DGG/LRB|laser root surface conditioning & blade DGG harvesting
2906907|NCT03200600|Experimental|Normal saline and flurbiprofen axetil|"Normal saline 2 ml is administered before anesthesia induction.~Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
2906908|NCT03200600|Experimental|Normal saline and lipid microsphere|"Normal saline 2 ml is administered before anesthesia induction.~Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
2906909|NCT03200587|Experimental|Avelumab and cabozantinib, all patients|
2906910|NCT03200574|Other|Aortic Valve|LivaNova bioprosthetic aortic heart valve replacement
2906911|NCT03200561|Active Comparator|S group|IVIG (2g/Kg in 12 hours)+oral prednisolone (2mg/Kg/day for 5 days)
2906912|NCT03200561|Placebo Comparator|I group|IVIG (2g/Kg in 12 hours)
2906913|NCT03200548|Experimental|Relaxing acupressure plus usual care|"There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily.The True Acupressure points were chosen based on a TCM theory for treating insomnia."
2906914|NCT03200548|Experimental|Stimulating acupressure plus usual care|There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily. Acupoints were chosen by consensus of 4 acupressure practitioners and based on a previous study design in students with sleep disturbances as well as TCM theory for treating insomnia and fatigue.
2906915|NCT03200548|Sham Comparator|Sham acupressure plus usual care|There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily. None of these points are on meridians nor are they on actual points. They were chosen to be in the same general body quadrant as the true points.
2906916|NCT03200548|Placebo Comparator|Usual care|Participants will be asked to continue following their healthcare providers' instruction for chronic SLE management. We anticipate that most women will be treated per the American College of Rheumatology clinical guidelines. Participants will be asked to continue any current treatment and not to start or stop treatments including acupuncture/acupressure over the course of the study. All treatments for pain will be recorded.
2906917|NCT03200535|No Intervention|Usual care|Usual care
2906918|NCT03200535|Active Comparator|"Electronic health record gaps"|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
2906919|NCT03200535|Active Comparator|Bulk outreach|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent
2906920|NCT03200535|Active Comparator|Personalized outreach|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent and patients will receive a personalized call by a registered dietitian
2906921|NCT03200522|Active Comparator|Prudent diet then Western diet|Participants randomized to this arm will received 6 days of meals consistent with a Prudent diet, followed by a washout period, and then 6 days of meals consistent with a Western diet.
2906922|NCT03200522|Active Comparator|Western diet then Prudent diet|Participants randomized to this arm will received 6 days of meals consistent with a Western diet, followed by a washout period, and then 6 days of meals consistent with a Prudent diet.
2906923|NCT03200509|Experimental|Physical Activity Intervention|The participants from both groups will receive a group exercise program, including a combination of general, stabilisation, strengthening and resistance exercises. In addition, the intervention group will receive health coaching sessions and an activity monitor.
2906924|NCT03200509|Sham Comparator|Control group|The participants from both groups will receive a group exercise program, including a combination of general, stabilisation, strengthening and resistance exercises. The participants allocated to the control group will receive sham health coaching and a sham activity monitor, in addition to the exercise program.
2906925|NCT03200496|Experimental|TALION®|
2906926|NCT03200496|Experimental|DA-5206(Fasting)|
2906927|NCT03200496|Experimental|DA-5206(Fed)|
2906928|NCT03200483|Experimental|Control Protocol|The volunteer will perform the exercise and recovery exposed to silence
2906929|NCT03200483|Experimental|Classical Music Protocol|The volunteer will perform the exercise and recovery exposed to classical music
2906930|NCT03200483|Experimental|Rock Music Protocol|The volunteer will perform the exercise and recovery exposed to rock musical style
2906931|NCT03200470||Suspected PJI|
2906932|NCT03200457|Experimental|Patients with hepatic iron overload or steatosis|Each patient (80) will have two MRI exams on the same day: one performed in common practice on a 1.5 Tesla MR450 device (General Electric) and the other added by the research on a 3 Tesla Verio device (Siemens).
2906933|NCT03200444|Experimental|Testing of 6 adhesive strips|"Each subject tests six adhesive strips on pre-striped skin.~Standard adhesive 1~standard adhesive 2~Standard adhesive 3~P-4~P-15~P-16~The six strips are applied on abdominal skin. The order to which the adhesive strips are located on the skin is randomized. The subjects will change the adhesive strips at home and the adhesion of the adhesive strips will be measured at 5 visits."
2906934|NCT03200431|Experimental|Test of a new adhesive strip|This is a sub-study testing the effect of real output applied under two adhesive strips on the skin after 24 hours. The adhesive strip is not yet part of a marketed ostomy device.
2906935|NCT03200418|Experimental|Test of new adhesives|"On the peristomal area four different patches are applied to the skin. There is a bag welded on each patch. The bag contains real output.~The difference between the four patches is that they consist of different adhesives.~One patch is made of a standard hydrocolloid adhesive~The primary endpoint is maesured after 8 hours and 24 hours And the three other patches consist of the newly developed adhesives. P-4 P-15 P-16"
2906936|NCT03200405|Experimental|DynaMeshVisible|the umbilical hernia will be fixed with a mesh, which is incorporated with Fe3O4 particles to become visible in MRI
2906937|NCT03200405|Active Comparator|DynaMeshCICAT|the umbilical hernia will be fixed with a Non-MRI-visible PVDF Mesh
2906942|NCT03200366|Active Comparator|DVD + Patient Navigation|Tailored digital video disc (DVD) plus Patient Navigation by a population health nurse in the healthcare system
2906943|NCT03200366|No Intervention|Usual Care|Care normally provided by a nurse in the endoscopy department of the healthcare system
2906944|NCT03200353|Experimental|Active|Each patient included receive the experimental device system NATROX during 3 to 4 weeks
2906945|NCT03200340|Placebo Comparator|Placebo|Matching placebo
2906946|NCT03200340|Experimental|EC-18 500 mg|1 capsule of EC-18
2906947|NCT03200340|Experimental|EC-18 1000 mg|2 capsules of EC-18 500 mg
2906948|NCT03200340|Experimental|EC-18 2000 mg|4 capsules of EC-18 500 mg
2906949|NCT03200327|Active Comparator|laparoscopic promontofixation|
2906950|NCT03200327|Experimental|Anterior prosthetic vaginal sacrospinofixation|
2906951|NCT03200301|Experimental|Intact Umbilical Cord Milking|Umbilical Cord Milking involves pinching of the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will be then released, allowing for a brief 2-second pause between each milking motion. This will be repeated for a total of 3 times over a duration less than 20 seconds.
2906952|NCT03200301|No Intervention|Early Cord Clamping|Umbilical cord will be clamped immediately after delivery and baby will be handed over to the neonatal team.
2906953|NCT03200288|Experimental|HL-01|Single 2 ml intra-articular injection of HL-01 (solution of high and low molecular weight hyaluronic acid (HA))
2906954|NCT03200288|Placebo Comparator|Placebo|Single 2 ml intra-articular injection of Placebo (physiological solution)
2906955|NCT03200275||HOSPITALISED PNEUMONIA PATIENTS|"All patients of more than 18 years of age, hospitalized consecutively for pneumonia irrespective of it being community or hospital acquired. All the patients included in this study will need to have acute symptoms of less than 2 weeks and radiological features which are compatible to pneumonia.~They will undergo testing for Legionella pneumophila serogroup 1 urine antigen using a qualitative rapid assay following manufacturer's instructions at baseline. The diagnosis of Legionella pneumonia is made if the Immunocatch™ Legionella Urine Antigen Test is positive."
2906956|NCT03200249|Experimental|Treatment|"- Treatment : concomitant preoperative radio-chemotherapy (during 5 weeks)~Chimiotherapy: Capecitabine 1600 mg/m2/j ; 5/7 days during the 5 weeks of radiotherapy~Radiotherapy RT + SIB-IMRT (5 weeks ; 5 sessions/week ; 25 sessions): Pelvic prophylactic dose of 45 Gy (1,8 Gy/session); boost with a dose of 60 Gy on the tumor PTV (2,4 Gy/session) - Total dose: 60 Gy in 25 sessions during 5 weeks.~- TME surgery (8 weeks after the end of treatment)"
2906957|NCT03200236|Experimental|Intensive Telephone Counseling|This arm provides a multi-faceted, 8-session intensive telephone counseling (ITC) protocol, tailored on lung cancer screening results, with 8-weeks of free nicotine replacement patches provided (Nicoderm patch, 21mg, 14mg, and 7mg) and primary care engagement.
2906958|NCT03200236|Active Comparator|Usual Care|This arm provides a multi-faceted, 3-session usual care telephone counseling (UC) protocol, with 2-weeks of free nicotine replacement patches provided (Nicoderm patch, 21mg, 14mg, and 7mg) and primary care engagement.
2906959|NCT03200223|Experimental|Personalized lifestyle intervention group|Personalized lifestyle intervention group Patients who use mobile healthcare service application and receive personal feedback from clinician
2906960|NCT03200223|No Intervention|Conventional group|Patients with conventional care
2906961|NCT03200210|Experimental|Treatment with Febuxostat|Febuxostat, starting at dose 20mg/d, once a day. And adjust dose according to serum uric acid at specific visits.
2906962|NCT03200210|Placebo Comparator|Treatment with placebo|Same dose and dose adjustment as the intervention arm.
2906963|NCT03200197|Experimental|menthol chewing gum|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This step was performed by a researcher who did not participate in the data collection. The intensity of the initial thirst was measured by means of the Verbal Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After using the intervention (menthol chewing gum) for 10 minutes, chewing at a natural rhythm and swallowing the saliva produced, the intensity and final discomfort were measured using the same scales.
2906964|NCT03200197|Active Comparator|Usual care (maintenance of fasting)|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This step was performed by a researcher who did not participate in the data collection.The intensity of the initial thirst was measured by means of the Verbal Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After maintaining the usual care, that is, reaffirming the need for fasting for 10 minutes, the intensity and final discomfort were measured using the same scales.
2906965|NCT03200184|Experimental|Treatment|Subjects will receive sofosbuvir and daclatasvir
2906966|NCT03200171||Group I|HCC patients who received DAAs for chronic HCV previously (either responders or not)
2906967|NCT03200171||Group II|HCC patients who are naive to DAAs.
2906968|NCT03200158|Other|Endoscopy biopsy and blood|The healthy volunteers were treated with endoscopy biopsy and blood.The patients were treated with bedside endoscopy biopsy and diagnosed with SRMD due to illness，then collect their blood samples.
2906969|NCT03200145||Control|The control group is made by persons living in nursing homes under usual care
2906970|NCT03200119|Experimental|Mobile application user group|In the active group, participants were educated to modify their lifestyle to lose weight by using a smart phone-based lifestyle app which was designed to collect daily activity and dietary information. The app was composed of two main modules: a diet module, and a physical activity module.
2906971|NCT03200119|No Intervention|Control group|Conventional lifestyle modification
2907005|NCT03199911|Placebo Comparator|Topical Artificial Tear Ointment|Intervention: 200 patients in the placebo group will receive artificial tear ointment to be applied to the surgical incision(s) 4 times daily for 1 week.
2907033|NCT03199742|Experimental|PTSD Coach with Automated Coaching|Participants will receive the PTSD Coach + mobile app which will provide automated, personalized coaching for 8 weeks.
2906972|NCT03200093|Experimental|Oral vancomycin|"Oral vancomycin solution 125 mg in 2.5 mL, combined with 2.5 ml Ora-Sweet solution, to total 5 mL.~Taken by mouth once daily for:~If the total duration of systemic antibiotics is less than or equal to 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus three days.~If the total duration of systemic antibiotics is greater than 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus seven days."
2906973|NCT03200093|Placebo Comparator|Placebo arm|"Ora-Sweet 5 mL~Taken by mouth once daily for:~If the total duration of systemic antibiotics is less than or equal to 14 days, placebo will be taken for the duration of the systemic antibiotics plus three days.~If the total duration of systemic antibiotics is greater than 14 days, placebo will be taken for the duration of the systemic antibiotics plus seven days."
2906974|NCT03200080|Placebo Comparator|Treatment A|Placebo oral tablet and Placebo oral capsule
2906975|NCT03200080|Experimental|Treatment B|Tozadenant 120 mg
2906976|NCT03200080|Experimental|Treatment C|Tozadenant 240 mg
2906977|NCT03200080|Experimental|Treatment D|Tozadenant 480 mg
2906978|NCT03200080|Active Comparator|Treatment E|d-amphetamine 20 mg
2906979|NCT03200080|Active Comparator|Treatment F|d-amphetamine 40 mg
2906980|NCT03200067|Experimental|Personalized rehabilitation service group|Breast cancer patients who use mobile healthcare service application and receive personal feedback from clinician
2906981|NCT03200067|No Intervention|Conventional group|Breast cancer patients with conventional care
2906982|NCT03200054|No Intervention|Clinic-based Care|Clinic-based care is the current standard of care and is defined as referral of women on antiretroviral therapy (ART) to general primary care adult ART services.
2906983|NCT03200054|Experimental|Adherence Club Care|Adherence club care involves referral of women on ART to community-based ART services in the form of adherence clubs, which are led by community health workers and supported by ART clinic nurses.
2906984|NCT03200041|Other|Low Risk|350 Low risk The only intervention is a 20 ml blood sample will be taken from each participant.
2906985|NCT03200041|Other|High Risk|150 High Risk going onto invasive diagnostic procedure. The only intervention is a 20 ml blood sample will be taken from each participant.
2906986|NCT03200028|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 30 treatment sessions, up to 5 sessions per week, 45 minutes per session.
2906987|NCT03200015|Experimental|Metformin arm|Metformin 850 mg tablets. Initial dose 425 mg twice a day for 1 week, followed by 850 mg twice a day for 1 week, titrated to a maximum dose 850 mg every 8 hours until disease response evaluation study date (Computed tomography or positron emission tomography)
2906988|NCT03200002|Experimental|Cyclophosphamide|Participants in this arm received intravenous cyclophosphamide (CYC) in the dose of 0.5 to 1 gram per m2 of body surface area.
2906989|NCT03200002|Experimental|mycophenolate mofetil|Patients in this arm received mycophenolate mofetil in the tablet form.
2906990|NCT03199989|Active Comparator|adjuvant chemotherapy group|patients enrolled int the adjuvant chemotherapy group will receive adjuvant chemotherapy[CapeOX（Capecitabine+Oxaliplatin）] by the current guidelines
2906991|NCT03199989|Experimental|observation group|patients enrolled int the adjuvant chemotherapy group will not receive adjuvant chemotherapy just for observation
2906992|NCT03199976|Experimental|Tiotropium Bromide & Salbutamol|Inhaled Tiotropium Bromide 5 µg once a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
2906993|NCT03199976|Active Comparator|Fluticasone Propionate & Salbutamol|Inhaled Fluticasone Propionate 125 µg twice a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
2906994|NCT03199976|Active Comparator|Salbutamol|Inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
2906995|NCT03199963|Experimental|BHR-700 (0.2% 4-OHT gel)|The gel formulation contains 2 mg/mL 4-OH tamoxifen (0.2%) in a clear, colorless, absorptive hydro-alcoholic gel base formulated to provide continuous release of 4-OH tamoxifen. A total of 8 mg/day (4 mg/breast) of 4-OH tamoxifen will be administered daily for 52 weeks.
2906996|NCT03199963|Placebo Comparator|Placebo|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
2906997|NCT03199950|Experimental|Prophylactic Haloperidol arm|Patients will receive oral haloperidol 2dd1mg (08.00am & 10.00pm)
2906998|NCT03199950|Placebo Comparator|No treatment|Patients will receive oral placebo 2dd (08.00am & 10.00pm)
2906999|NCT03199937|Experimental|Flexible Futures|Flexible Futures uses cognitive behavioral therapy (CBT) techniques to target flexibility and planning by teaching core skills through personal goals chosen by students during treatment. Flexible Futures focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, how thoughts and feelings affect planning and flexibility, self-advocacy skills necessary to promote independence, application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities. Guided practice begins with concrete interventionist support, and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support. Generalization is maximized with school staff as interventionists, parent training, home and classroom extension activities, and role-playing use of strategies in novel situations. Motivation is developed using student choice and natural motivators.
2907000|NCT03199937|Active Comparator|Waitlist control group|Current standard of care
2907001|NCT03199924|Active Comparator|Intravenous Magnesium sulfate combined to Diclofenac|
2907002|NCT03199924|Active Comparator|intravenous lidocaine combined to diclofenac|
2907003|NCT03199924|Active Comparator|diclofenac alone|
2907004|NCT03199911|Experimental|Topical Antibiotic Ointment|Intervention: 200 patients in the antibiotic arm will receive either erythromycin unless there is a specific contraindication (e.g. known allergy or lack of pharmacy availability). Those who are erythromycin allergic will receive bacitracin. If neither antibiotic is obtainable by the patient, polybacitracin will be prescribed instead. Antibiotic ointment is to be applied to the surgical incision(s) 4 times daily for 1 week.
2907133|NCT03199274|Active Comparator|Group II (standard of care)|Patients undergo standard of care yttrium Y-90 radioembolization.
2907006|NCT03199898||34-32 GA|premature infants born <34,6-32,1 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
2907007|NCT03199898||32-28 GA|premature infants born <32-28,1 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
2907008|NCT03199898||28-23 GA|premature infants born <28-23,0 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
2907009|NCT03199885|Experimental|Arm I (pertuzumab, trastuzumab, paclitaxel, atezolizumab)|Patients receive pertuzumab intravenously (IV) over 30-60 minutes on day 1, trastuzumab IV over 30-90 minutes on day 1, paclitaxel IV over 60 minutes on days 1, 8, and 15, and atezolizumab IV over 60 minutes on day 1. Courses for pertuzumab, trastuzumab, and atezolizumab repeat every 3 weeks and treatment with paclitaxel repeats every 3 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity. Participants may receive additional 6 courses of paclitaxel in the absence of progression at the investigator's discretion.
2907010|NCT03199885|Active Comparator|Arm II (pertuzumab, trastuzumab, paclitaxel, placebo)|Patients receive pertuzumab, trastuzumab, and paclitaxel as in Arm I. Patients also receive placebo IV over 60 minutes on day 1. Courses for pertuzumab, trastuzumab, and placebo repeat every 3 weeks and treatment with paclitaxel repeats every 3 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity. Participants may receive additional 6 courses of paclitaxel in the absence of progression at the investigator's discretion.
2907011|NCT03199872|Experimental|RV001V|RV001 Vaccine 0.1 mg/mL (RV001V). RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51.
2907012|NCT03199846||advanced melanoma patients|Part 1 will consist of a representative sample of advanced melanoma patients, irrespective of date of diagnosis of stage III unresectable and metastatic/stage IV, to address information objectives on treatment patterns, clinical outcomes, and resource use after the start of treatment post-launch of new drugs, ie, since 2011 for ipi and 2015 for ipi + nivo in advanced melanoma
2907013|NCT03199846||Ipi monotherapy|Part 2: patients must have been prescribed Ipi monotherapy during the index period between 01-Jan-2015 and 31-May-2016.
2907014|NCT03199846||Ipi + nivo combination therapy|Part 2: patients must have been prescribed Ipi + nivo combination therapy during the index period between 01-Jan-2015 and 31-May-2016.
2907015|NCT03199846||Dabrafenib + trametinib combination therapy|Part 2: patients must have been prescribed Dabrafenib + trametinib combination therapy during the index period between 01-Jan-2015 and 31-May-2016.
2907016|NCT03199846||Pembro monotherapy|Part 2: patients must have been prescribed Pembro monotherapy during the index period between 01-Jan-2015 and 31-May-2016
2907017|NCT03199846||Nivo monotherapy|Part 2: patients must have been prescribed Nivo monotherapy during the index period between 01-Jan-2015 and 31-May-2016
2907018|NCT03199833|Experimental|Arms|RETRAINER-S2 & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the RETRAINER-S2 system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
2907019|NCT03199833|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
2907020|NCT03199820|Active Comparator|Cook Cervical balloon|Cook cervical double balloon catheter
2907021|NCT03199820|Active Comparator|Prostin E2 Vaginal suppository|Prostaglandin E2 sustained release vaginal insert
2907022|NCT03199807|Experimental|NRT + radiotherapy|HCC received NRT and radiotherapy
2907023|NCT03199794||OBIZUR participants|Participants previously treated with OBIZUR and continue to be treated with OBIZUR during the study.
2907024|NCT03199781|Experimental|Intervention of mechanical massage with cosmetics|Patients will be treated with motorized mechanical massage and associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
2907025|NCT03199768||Single-bed rooms|Patients are admitted to single-bed rooms at the newly built hospital in the period 20th of March to the 1th of September 2017
2907026|NCT03199768||Multi-bed rooms|Patients are admitted at multi-bed rooms with one to two fellow patients at the old hospital in the period 15th of September 2016 to the 19th of March 2017
2907027|NCT03199755|Active Comparator|ACT|"Standard Artemisinin Combination Therapy (ACT) being used as currently approved antimalarial therapy at WHO and manufacturer recommended dosage. The specific ACT used is artemether-lumefantrine (Coartem). Form is scored tablets that each contain 20 mg artemether and 120 mg lumefantrine.~Tablets per dose, are given BID for 3 days as shown below:~Coartem tablets/dose by bodyweight; tablets/day morning and evening for total of 6 doses over 3 days~Body weight (kg) and Tablets: 5 to <15 kg, 1 tab; 15 to <25 kg, 2 tabs; 25 to <35 kg, 3 tabs; 35 kg and over, 4 tabs."
2907028|NCT03199755|Experimental|DLA1|"Dried leaf Artemisia annua (DLA) from 0.25-1 g total/day, BID. DLA is given as 500 mg tablets according to body weight (see below) for 5 days.~DLA tablets/dose by bodyweight; tablets/day, morning and evening, for total of 10 doses over 5 days.~Body weight (kg) and tablets/dose:~For DLA1x: 5 to < 15 kg, 1/4 tab; 15-30 kg, 1/2 tab; 1/2>30 kg, 1 tab."
2907029|NCT03199755|Experimental|DLA2|"Dried leaf Artemisia annua (DLA) from 0.5-2 g total/day, BID. DLA is given as 500 mg tablets according to body weight (see below) for 5 days.~DLA tablets/dose by bodyweight; tablets/day, morning and evening, for total of 10 doses over 5 days.~Body weight (kg) and tablets/dose:~For DLA2x: 5 to < 15 kg, 1/2 tab; 15-30 kg, 1 tab; >30 kg, 2 tabs."
2907030|NCT03199742|Active Comparator|PTSD Coach with no Coaching|Participants will receive the PTSD coach mobile app.
2907031|NCT03199742|Experimental|PTSD Coach with Peer Coaching|Participants will receive the PTSD Coach + mobile app which will provide routine, personalized coaching for 8 weeks from a Veteran peer.
2907032|NCT03199742|Experimental|PTSD Coach with Clinician coaching|Participants will receive the PTSD Coach + mobile app which will provide routine, personalized coaching for 8 weeks from a clinical psychologist.
2907134|NCT03199261|Experimental|rE-4 Injection|10µg, rE-4 Injection, 30 minutes prior to the start time of a standard breakfast.
2907034|NCT03199729|Experimental|Slip-only training|Overground, slip specific perturbation training only delivered in a fixed sequence. After the baseline walking trials, subjects will walk for 30-35 trials, after which training will begin consisting of a first block of 8 repeated slips (S1-S8), a block of 3 regular (non-perturbed) walking trials (W1-W3), another block of 8 slips (S9-16), a second block of 3 regular walking trials (W4-W6), and a final block of 8 slips (S17-S24) mixed with 10 regular walking trials.
2907035|NCT03199729|Experimental|Trip-only training|Trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.
2907036|NCT03199729|No Intervention|Control|Walk for about 70-75 trials at the preferred walking pace to match the total trials the other groups receive before the test perturbations.
2907037|NCT03199729|Experimental|Combined slip+trip training|Training consisting of repeated exposure to both slips and trips.
2907038|NCT03199716|Experimental|Parent Mentors and Intervention Group|Parent mentors are parents from our UC Davis Pediatrics Endocrinology clinic who have met our parent mentor inclusion criteria; the intervention group are families in our clinic who have met our mentee family inclusion criteria
2907039|NCT03199716|No Intervention|Control Group with no Parent Mentors|The control group is made up of families at our UC Davis Pediatrics Endocrinology clinic who have met the mentee family inclusion criteria but are not matched with a parent mentor
2907040|NCT03199703|Active Comparator|Baylis transseptal system group|Patients randomized to the Baylis transseptal system group (Bayliss Group) will undergo transseptal puncture with a large, preformed curve 71-cm-C1 or 98-cm-C1 18-gauge NRG needle (Baylis Medical) through a TorFlex sheath (Baylis Medical), with the sheath curve selected at the discretion of the operating physician.
2907041|NCT03199703|Active Comparator|Conventional transseptal group|Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with either a large, preformed curve 71- or 98-cm 18-gauge BRK needle (BRK, BRK-1, BRK-2 needle, St. Jude Medical) through any non-Baylis sheath (for example Schwartz SL, Biosense-Webster Preface) selected at the discretion of the operating physician.
2907042|NCT03199690|Experimental|Single arm|"Single arm trial design based on the dosing regimen below:~Day 1 - 7~- Dolutegravir 50 mg once daily with food~Day 8 - 14 - Dolutegravir 100 mg once daily with food~Day 15 - 28~- Rifampicin 600 mg once daily~Day 29 - 35 - Rifampicin 600 mg once daily & Dolutegravir 50 mg once daily~Day 36 - 42~- Rifampicin 600 mg once daily & Dolutegravir 100 mg once daily"
2907043|NCT03199677|Experimental|apatinib with 500mg qd po|Patients administrate apatinib with the dose of 500mg once per day,half an hour after a meal.
2907044|NCT03199664|Active Comparator|Group A (NB-UVB)|Intervention: patients will be treated with Narrow band ultra violet rays alone for 6 months
2907045|NCT03199664|Active Comparator|Group B ( combined NB-UVB & Tacrolimus)|Intervention: patients will be treated with NB-UVB & Tacrolimus 0.03 % ointment for 6 months
2907046|NCT03199651|Active Comparator|Arm I (UC)|Patients receive usual care and undergo collection of tumor tissue and blood sample for the repository. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
2907047|NCT03199651|Experimental|Arm II (AGIT/DS)|Patients undergo collection of tumor tissue for analysis using FoundationOne assay and blood sample for analysis using FoundationACT blood circulating tumor DNA assay. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
2907048|NCT03199638|Experimental|an exercise group|in which subjects will perform daily 'exercise snacks' within 30 min before breakfast, lunch, and/or dinner or bedtime snack, along with a placebo drink which will be given before breakfast and dinner (twice daily);
2907049|NCT03199638|Experimental|an exercise + glutamine group|in which subjects will receive a glutamine drink (0.25 g/kg per dose) before breakfast and dinner (twice daily), and perform 'exercise snacks' before each meal
2907050|NCT03199638|No Intervention|control group|"in which we will use historic data from previous study (Statins in children with type 1 diabetes: effects on metabolism, inflammation and endothelial function) by choosing 12 children between 13-19 years with type 1 diabetes and meeting the very same inclusion/ exclusion criteria. We have readily available data for their HbA1C, CGM downloads, all labs and anthropometry for 3 months. We will select age, gender, and HbA1c-matched adolescents as these data were prospectively collected."
2907051|NCT03199625|Experimental|Cognitive Therapy group|treatment with Cognitive Therapy
2907052|NCT03199625|Experimental|Behavior Therapy group|treatment with Behavior Therapy
2907053|NCT03199625|Active Comparator|SSRI antidepressants|treatment by SSRI antidepressant
2907054|NCT03199612|Active Comparator|Sildenafil|At baseline 20 mg of the drug will be administered. Then BP will be recorded every 30 minutes for two hours. If BP is stable (drop is < 5 mmHg after 2 hours and patient is asymptomatic), patients will proceed to take 20 mg of the study drug every 8 hours, starting on day 2 (total 18 doses). During clinic visit on day 8, 20 mg of the study drug will be administered and after 2 hours blood samples will be collected. After 6 hours, if BP is in the acceptable range, 40 mg of the study drug will be administered. If BP remains stable for 2 hours, then patients will continue taking 40 mg every 8 hours, starting on day 9 (total of 18 doses). During clinic visit on day 15 patients will be given a final 40 mg dose of the study drug and after 2 hours blood samples will be taken.
2907055|NCT03199612|Placebo Comparator|Placebo Oral Tablet|Negative control to understand the potential changes in platelet activation and aggregation in comparison to sildenafil.
2907056|NCT03199586|Experimental|NP-G2-044|capsule
2907057|NCT03199560|Active Comparator|Tilmanocept|Tc 99m tilmanocept
2907058|NCT03199560|Active Comparator|Sulfur Colloid|Tc 99m filtered sulfur colloid
2907059|NCT03199547|Experimental|AZITHROMYCIN|A single dose of 2G Azithromycin or Placebo will be administered orally to women in labour
2907060|NCT03199547|Placebo Comparator|Placebo oral tablet|A single dose of 2G Azithromycin or Placebo will be administered orally to women in labour
2907061|NCT03199534|Experimental|Botulinum toxin A 50u|Botulinum toxin A 50 unit injection
2907062|NCT03199534|Experimental|Botulinum toxin A 100u|Botulinum toxin A 100 unit injection
2907063|NCT03199534|Experimental|Botulinum toxin A 150u|Botulinum toxin A 150 unit injection
2907135|NCT03199261|Active Comparator|rE-4 Freeze-dried Powder|10µg, rE-4 Freeze-dried Powder, 30 minutes prior to the start time of a standard breakfast.
2907238|NCT03198650|Experimental|Acalabrutinib|Acalabrutinib
2907064|NCT03199521||Atrial Fibrillation newly diagnosed, starting apixaban|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays before and after stabilisation(4 weeks) of their anticoagulation. This will allow to compare the effect of apixaban on endogenous fibrinolysis before and after treatment.
2907065|NCT03199521||Atrial fibrillation on stable warfarin treatment|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays on stable anticoagulation treatment. This will allow to compare the effect of apixaban against warfarin on endogenous fibrinolysis on stable treatment.
2907066|NCT03199521||Atrial Fibrillation on stable aspirin treatment|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays on stable anticoagulation treatment. This will allow to compare the effect of apixaban against aspirin on endogenous fibrinolysis on stable treatment.
2907067|NCT03199508|Experimental|the 3-day voiding diary group|The 3-day voiding diary group is as the experimental group in which several centers use the 3-day voiding diary by cluster randomization. The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
2907068|NCT03199508|Active Comparator|the 7-day voiding diary group|The 7-day voiding diary group is as the control group in which several centers use the 7-day voiding diary by cluster randomization. The 7-day voiding diary is a medical record which need participants to fill in a table about urine volume and drinking water volume for 4 days and 7 nights. The 3-day voiding diary group is the experimental group in which several centers use the 3-day voiding diary by cluster randomization.
2907069|NCT03199495|Experimental|electroacupuncture|Participants were randomized divided into experimental and control groups .Acupuncture included Hegu (LI 4), Neiguan (PC6), Zusali (ST 36), Shanjuxu (ST37), Xiajuxu (ST39), Taichong (LR3) and Taibai(SP3) on both hands and legs. Acupuncture included Hegu (LI 4) and Neiguan (PC6), Zusali (ST 36) and Taichong (LR3) with electrical stimulation were conducted. The frequency of electrical stimulation was 2 Hz and the intensities of the stimulation was below 9.8 mA for 15 minutes.After 15 minutes treatment, acupuncture were removed and after 15 minutes the investigators stated to evaluate.
2907070|NCT03199495|Sham Comparator|sham electroacupuncture|Participants were randomized divided into experimental and control groups. The Vaccaria Seeds (scientific name:Vaccaria segetalis) will be applied in control group. Vaccaria Seed is a spherical, smooth and hard seed, which is commonly used on ear acupuncture point. In control group, Vaccaria Seeds will be secured on the acupuncture point the same as experimental group, and coverd by transcutaneous electrical nerve stimulation (TENS), which is actually not turned on. The intervention will last for 15 minutes.After 15 minutes treatment, acupuncture were removed and after 15 minutes the investigators stated to evaluate.
2907071|NCT03199482|Active Comparator|Drug dexamethasone|preoperative single dose of dexamethasone 0.5 mg oral tablet given to patients before starting of root canal treatment by 30 minutes.
2907072|NCT03199482|Placebo Comparator|Placebo|Placebo will be administrated to patients before stating of root canal treatment
2907073|NCT03199469|Experimental|Cohort 1|1.0 x 10^14 vg/kg of AT132 delivered intravenously one time
2907074|NCT03199469|Experimental|Cohort 2|3.0 x 10^14 vg/kg of AT132 delivered intravenously one time
2907075|NCT03199469|Experimental|Cohort 3|5.0 x 10^14 vg/kg of AT132 delivered intravenously one time
2907076|NCT03199469|No Intervention|Delayed-Treatment Control|Delayed-Treatment Control subjects will generally have the same assessments as treated subjects. Once the optimal AT132 dose is selected, delayed-treatment control subjects will undergo pre-treatment baseline procedures to confirm that they remain eligible to receive treatment with AT132. Once eligible, delayed-treatment control subjects are dosed with AT132, they will initiate the same post-dose procedures as subjects who received AT132
2907077|NCT03199456|Experimental|Zip 4 Surgical Skin Closure Device group|The subjects randomised to this arm will be treated with the Zip device for 10 days (+/-2) days.
2907078|NCT03199456|Active Comparator|Standard of Care sutures group|The subjects randomised to this arm will be treated with standard of care sutures for 10 days (+/- 2 days).
2907079|NCT03199443||Overactive bladder patients|
2907080|NCT03199443||Non Obstructive Urinary Retention patients|
2907081|NCT03199430|Placebo Comparator|Placebo|1450mg Corn flour
2907082|NCT03199430|Active Comparator|Epigallocatechin gallate|1450mg Epigallocatechin gallate
2907083|NCT03199417|Experimental|Multiprofen/interventional|"A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel. This topical formulation has been in use commercially under the trade name Multi-profen. This topical cream will be applied by the patient three times per day."
2907084|NCT03199417|Placebo Comparator|Control/Placebo Group|A identically packaged placebo cream treatment will be utilized in the control population.
2907085|NCT03199404||Treated Subjects|Subject experiencing an acute ischemic stroke in which imaging demonstrates a vascular occlusion located in the distal internal carotid artery (ICA) through the distal middle cerebral artery (MCA) and in which the TRAP technique is used for at least the first two thrombectomy passes per occluded vessel and that meet the other inclusion-exclusion criteria.
2907086|NCT03199378||Caucasian|English speaking Caucasian individuals
2907087|NCT03199378||African American|English speaking African American individuals
2907088|NCT03199378||Hispanic|Spanish speaking Hispanic individuals
2907089|NCT03199365|Experimental|Group 1|"Participants undergo immersive assessment involving examination of the home food and physical activity (PA) environments, objective and self-reported PA, nutritional intake, and demographics and relevant psychosocial measures.~Participants complete a self-administered household food inventory (HFI).~Participants to wear an accelerometer device for 7 consecutive days to measure physical activity.~Participants complete a food frequency questionnaire at the home visit, and a 24-hour recall questionnaire within 3 weeks after the home visit.~Open-ended, in-depth interviews conducted with up to 24 Latino family dyads to explore attitudes, behaviors, barriers and facilitators, and social support related to healthy eating and PA, with a particular emphasis on the family dyad context."
2907136|NCT03199248||the participant accepted needle assisted capsulotomy for DMC|
2907137|NCT03199248||the participant accepted aspiration for DMC only|
2907138|NCT03199235|Experimental|LIF + Citrus|Parents of subjects > 1 year and < 5 years with anemia (Hemoglobin < 11.0 g/dL) are provided the lucky iron fish and citrus along with instructions for use. Followed at regular intervals.
2907090|NCT03199365|Experimental|Group 2|"Participants undergo immersive assessment involving examination of the home food and physical activity (PA) environments, objective and self-reported PA, nutritional intake, and demographics and relevant psychosocial measures.~Participants complete a self-administered household food inventory (HFI).~Participants to wear an accelerometer device for 7 consecutive days to measure physical activity.~Participants complete a 24-hour recall questionnaire at the home visit, and a food frequency questionnaire within 3 weeks after the home visit.~Open-ended, in-depth interviews conducted with up to 24 Latino family dyads to explore attitudes, behaviors, barriers and facilitators, and social support related to healthy eating and PA, with a particular emphasis on the family dyad context."
2907091|NCT03199352||RYGB: Hand-sewn|This group would receive a Roux-en-y gastric bypass with the anastomosis hand-sewn using a minimally-invasive robotic surgical approach
2907092|NCT03199352||RYGB: linear-staple|This group would receive a Roux-en-y gastric bypass with the anastomosis sewn with a linear stapler using a laparoscopic surgical approach
2907093|NCT03199339|Active Comparator|SAD Part 1 Cohort 1 First Dose - Active|N = 2, 100 mg TBA-7371 or matching placebo
2907094|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 1 First Dose - Placebo|N = 1, 100 mg TBA-7371 or matching placebo
2907095|NCT03199339|Active Comparator|SAD Part 1 Cohort 1 Second Dose - Active|N = 4, 100 mg TBA-7371 or matching placebo
2907096|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 1 Second Dose -Placebo|N = 1, 100 mg TBA-7371 or matching placebo
2907097|NCT03199339|Active Comparator|SAD Part 1 Cohort 2 - Active|N= 6, 250 mg TBA-7371 or matching placebo
2907098|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 2 - Placebo|N = 2, 250 mg TBA-7371 or matching placebo
2907099|NCT03199339|Active Comparator|SAD Part 1 Cohort 3 - Active|N = 6, 500 mg TBA-7371 or matching placebo
2907100|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 3 - Placebo|N = 2, 500 mg TBA-7371 or matching placebo
2907101|NCT03199339|Active Comparator|SAD Part 1 Cohort 4 - Active|N = 6, 1000 mg TBA-7371 or matching placebo
2907102|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 4 - Placebo|N = 2, 1000 mg TBA-7371 or matching placebo
2907103|NCT03199339|Active Comparator|SAD Part 1 Cohort 5 - Active|N = 6, 1500 mg TBA-7371 or matching placebo
2907104|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 5 - Placebo|N = 2, 1500 mg TBA-7371 or matching placebo
2907105|NCT03199339|Active Comparator|MAD Part 2 Cohort 1 - Active|N = 9, 100 mg TBA-7371 or matching placebo
2907106|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 1 - Placebo|N = 3, 100 mg TBA-7371 or matching placebo for 14 days
2907107|NCT03199339|Active Comparator|MAD Part 2 Cohort 2 - Active|N = 9, 200 mg TBA-7371 or matching placebo for 14 days
2907108|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 2 - Placebo|N = 3, 200 mg TBA-7371 or matching placebo for 14 days
2907109|NCT03199339|Active Comparator|MAD Part 2 Cohort 3 - Active|N = 9, 400 mg TBA-7371 or matching placebo for 14 days
2907110|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 3 - Placebo|N = 3, 400 mg TBA-7371 or matching placebo for 14 days
2907111|NCT03199339|Active Comparator|DDI Part 3 Cohort 1|14 subjects to receive midazolam and bupropion before and after orally giving 200mg of TBA-7371, 1 per day for 14 days
2907112|NCT03199326|Experimental|Collaborative Care|CPS caseworkers will be randomized to collaborative or comparison practice. For any infant investigated by a caseworker in the collaborative practice, the caseworkers will conduct a standard CPS investigation. Additionally, caseworkers will seek parental permission to contact an identified primary health care provider at two points in the CPS investigation for information sharing related to health needs, social risks, and recommended interventions.
2907113|NCT03199326|No Intervention|Comparison Care|CPS caseworkers will be randomized to collaborative or comparison practice. For any infant investigated by a caseworker in the comparison practice, the caseworkers will conduct a standard CPS investigation.
2907114|NCT03199313|Active Comparator|Cohort 1 Sentinel Group 1 - Active|N = 2, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2
2907115|NCT03199313|Placebo Comparator|Cohort 1 Sentinel Group 1 - Placebo|N = 1, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2
2907116|NCT03199313|Active Comparator|Cohort 1 Sentinel Group 2 - Active|N = 4, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1
2907117|NCT03199313|Placebo Comparator|Cohort 1 Sentinel Group 2 - Placebo|N = 1, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1
2907118|NCT03199313|Active Comparator|Cohort 2 - Active|N = 6, 600mg sutezolid or matching placebo
2907119|NCT03199313|Placebo Comparator|Cohort 2 - Placebo|N = 2, 600mg sutezolid or matching placebo
2907120|NCT03199313|Active Comparator|Cohort 3 - Active|N = 6, 1200 mg sutezolid or matching placebo
2907121|NCT03199313|Placebo Comparator|Cohort 3 - Placebo|N = 2, 1200 mg sutezolid or matching placebo
2907122|NCT03199313|Active Comparator|Cohort 4 - Active|N = 6, 1800 mg sutezolid or matching placebo
2907123|NCT03199313|Placebo Comparator|Cohort 4 - Placebo|N = 2, 1800 mg sutezolid or matching placebo
2907124|NCT03199300||Anthracylines-treated with toxicity|Patients with toxicity during/after treatment with anthracylines.
2907125|NCT03199300||Anthracyclines-treated without toxicity|Patients without toxicity during/after treatment with anthracylines.
2907126|NCT03199300||Trastuzumab-treated with toxicity|Patients with toxicity during/after treatment with trastuzumab.
2907127|NCT03199300||Trastuzumab-treated without toxicity|Patients without toxicity during/after treatment with trastuzumab.
2907128|NCT03199300||Cisplatin-treated with toxicity|Patients with toxicity during/after treatment with cisplatin.
2907129|NCT03199300||Cisplatin-treated without toxicity|Patients without toxicity during/after treatment with cisplatin.
2907130|NCT03199300||Bleomycin-treated with toxicity|Patients with toxicity during/after treatment with bleomycin.
2907131|NCT03199300||Bleomycin-treated without toxicity|Patients without toxicity during/after treatment with bleomycin.
2907132|NCT03199274|Experimental|Group I (perflutren protein-type A microspheres, CEUS)|Patients receive perflutren protein-type A microspheres IV over 10 minutes and undergo CEUS over 60 minutes at 2-6 hours and at 7 and 14 days after yttrium Y-90 radioembolization.
2907139|NCT03199235|Active Comparator|enhanced standard of care|Parents of subjects > 1 year and < 5 years with anemia (Hemoglobin < 11.0 g/dL) are provided the oral iron supplementation consistent with standard of care, and then followed at regular intervals in addition to any care determined to be necessary by regular provider.
2907140|NCT03199222|Experimental|Arm 1: Smart socket technology w/patient prompting|The prosthetic user WILL receive prompting by the smart socket technology regarding improper fit and suggestions for how to a restore a proper fit (i.e socks). Investigators will have access to the Smart Socket Technology database.
2907141|NCT03199222|No Intervention|Arm 2: Clinical protocol. No patient prompting|The prosthetic user WILL NOT receive prompting by the smart socket technology regarding improper fit and suggestions for how to a restore a proper fit (i.e socks). However, investigators will have access to the Smart Socket Technology database.
2907142|NCT03199209|Experimental|Tu Salud, ¡Si Cuenta! Familiar (TSSC-Family) Group|"Participant and partner have 6 meetings with a community health worker who will talk about how to be more physically active and eat healthier. The community health worker comes to participant's home 1 time a month for 6 months.~Questionnaires completed 1 time at the beginning of the study, 1 time about 6 months after beginning the study, and 1 time about 12 months after beginning the study."
2907143|NCT03199209|Experimental|Contact Control Group|"Participant and partner have 6 meetings with a community health worker who will talk about ways to help participant's home be a safe and healthy place to live. The community health worker comes to participant's home 1 time a month for 6 months.~Questionnaires completed 1 time at the beginning of the study, 1 time about 6 months after beginning the study, and 1 time about 12 months after beginning the study."
2907144|NCT03199196|Experimental|Group 1 - Intervention|"Participants given an activity tracker at the given an accelerometer at each visit. Participants instructed in use of a smartphone application at the baseline visit.~Participant emailed electronic newsletters to read that may help participant be more physically active.~Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).~Study visits performed 2 times (1 time at the beginning of the study, and 1 time 16 weeks after beginning the study).~Participants complete questionnaires 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.~Participants invited to take part in a final focus group sometime after the 16-week visit."
2907145|NCT03199196|Other|Group 2 - Control|"Participants sent electronic newsletters throughout the study that may help participant be more physically active.~Study visits performed 2 times (1 time at the beginning of the study, and 1 time 16 weeks after beginning the study).~Participants complete questionnaires 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.~Participants invited to take part in a final focus group sometime after the 16-week visit."
2907146|NCT03199183||Takayasu arteritis|All recruited Takayasu arteritis patients.
2907147|NCT03199170|Sham Comparator|Intrathecal morphine|Intrathecal morphine 0.2 mg, 0.9%NSS each side
2907148|NCT03199170|Experimental|Intrathecal morphine with bilateral Quadratus Lumborum Block|Intrathecal morphine 0.2 mg, 0.25%Bupivacaine 25 ml each side
2907149|NCT03199170|Experimental|Bilateral Quadratus Lumborum Block|No intrathecal morphine, 0.25%Bupivacaine 25 ml each side
2907150|NCT03199157|Active Comparator|Fentanyl Group|Patients received the fentanyl 12 mcg transdermal patch (FG, n=38) 8 hours preoperatively and until 24 hours after the surgery
2907151|NCT03199157|No Intervention|Control group|
2907152|NCT03199144|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy delivering 30 Gy in 5 fractions over 9 days
2907153|NCT03199131|Experimental|CTEPH|Patients undergoing pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
2907154|NCT03199131|Other|Control group|Patients undergoing adult cardiac surgery without evidence of pulmonary hypertension.
2907155|NCT03199118|Experimental|CAF+SCTG+PRF|Intervention: surgical procedure : coronally advanced flap + SCTG Intervention: membrane: platelet rich fibrin Patients with class I or II gingival recession will receive treatment that consists of coronally advanced flap (CAF) with subepithelial connective tissue graft (SCTG) and platelet rich fibrin(PRF)
2907156|NCT03199118|Active Comparator|CAF+SCTG|Patients with class I or II gingival recession will receive treatment that consists of CAF+SCTG Intervention: surgical procedure : coronally advanced flap + SCTG
2907157|NCT03199105|Experimental|preoperative education and tetracaine|
2907158|NCT03199105|Experimental|tetracaine|
2907159|NCT03199092|Experimental|RRT+sat|RRT in combination with specific auditory training (sat) administered for a total of 20 hours over 10 weeks (60 minutes biweekly sessions).
2907160|NCT03199092|Experimental|Abilmente|Abilmente method administered for a total of 10 hours over 5 weeks (60 minutes biweekly sessions).
2907161|NCT03199079||Group 1: Non-pregnant women|Non-pregnant women with normal pelvic floor
2907162|NCT03199079||Group 2: Pregnant women|Pregnant women; 22-29 weeks of pregnancy
2907163|NCT03199066||All NHL subtypes|no interventions
2907164|NCT03199066||DLBCL|only patients with diffuse large B-cell lymphoma
2907165|NCT03199066||FL|only patients with follicular lymphoma
2907166|NCT03199066||MCL|only patients with mantle cell lymphoma
2907167|NCT03199066||SLL/CLL|only patients with small lymphocytic lymphoma / chronic lymphocytic leukemia
2907168|NCT03199066||MZL|only patients with marginal zone lymphoma
2907169|NCT03199066||other B-cell lymphomas|only patients with B-lymphomas not described above
2907170|NCT03199066||T-cell lymphomas|only patients with all types of T-cell lymphoma
2907171|NCT03199053|Experimental|Low dose Dapagliflozin|Oral route. Start with a low dose of dapagliflozin administered once daily and remain on the low dose regardless of your HbA1c at week 12.
2907172|NCT03199053|Experimental|Low dose/high dose Dapagliflozin|Oral route. Start with a low dose of Dapagliflozin administered once daily and up titrate to the high dose Dapagliflozin administered once daily if HbA1c >= 7% at week 12
2907173|NCT03199053|Experimental|Low dose Saxagliptin|Oral route. Start with a low dose of saxagliptin administered once daily and remain on the low dose regardless of your HbA1c at week 12
2907174|NCT03199053|Experimental|Low dose/high dose Saxagliptin|Oral route. Start with a low dose of saxagliptin administered once daily and up titrate to the high dose if HbA1c >= 7% at week 12
2954350|NCT02872857|Placebo Comparator|Placebo|
2907176|NCT03199040|Experimental|Neoantigen DNA vaccine + Durvalumab|"The first neoantigen DNA vaccine injection will take place up to 90 days following the completion of standard of care therapy. The day of the first vaccine injection will be referred to as Day 1~The schedule of vaccination is Day 1, Day 29 ± 7, Day 57 ± 7, Day 85 ± 7, Day 113 ± 7, and Day 141 ± 7 with at least 21 days between injection days~For patients who are randomized to the neoantigen DNA vaccine plus durvalumab arm, the neoantigen-specific T cell response will be assessed prior to Day 85. If a neoantigen-specific T cell response is present, durvalumab will be started on Day 85, and will be administered Q4W at a dose of 1500 mg over the course of 60 minutes. If a neoantigen-specific T cell response is not present, these patients will be replaced but may continue to receive the neoantigen DNA vaccine on study. They will not be transferred to the vaccine-only arm."
2907177|NCT03199040|Experimental|Neoantigen DNA vaccine|"The first neoantigen DNA vaccine injection will take place up to 90 days following the completion of standard of care therapy. The day of the first vaccine injection will be referred to as Day 1~The schedule of vaccination is Day 1, Day 29 ± 7, Day 57 ± 7, Day 85 ± 7, Day 113 ± 7, and Day 141 ± 7 with at least 21 days between injection days"
2907178|NCT03199027|No Intervention|Clinic-based Care|Clinic-based care is the current Standard-of-Care whereby newly initiated ART patients attend the ART clinic.
2907179|NCT03199027|Experimental|Adherence Club Care|Adherence club care involves referral to community-based ART services in the form of Adherence clubs, which are led by community health workers and supported by ART clinic nurses.
2907180|NCT03199014|Experimental|prolonged deployment strategy group|"in deploying the Drug-eluting Stents with a prolonged time group,the inflation time was more than 30 seconds when the Drug-eluting Stents deploying,unless the patients was unstable."
2907181|NCT03199014|Active Comparator|rapid deployment strategy group|"in deploying the Drug-eluting Stents with a conventional time group, a conventional method was used to deploying drug-eluting stents,the actual inflation time was within 10s determined by interventional cardiologist."
2907182|NCT03198975||Preoperative imaging features|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo preoperative Gd-EOB-DTPA enhanced magnetic resonance image.
2907183|NCT03198962||Groups A|At each visit, a series of self-administered questionnaires will be used to collect demographic, sexual behavioral risk and drug use data. HIV testing, risk reduction counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-negative participants will be actively offered to visit the clinic for pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP) or STI services and encouraged to visit the clinic outside of the scheduled visits for these services whenever they feel needed. Adherence to PrEP, PEP, STI treatment will be evaluated in those who are prescribed these medications. Among HIV seroconverters, drug use patterns will be longitudinally monitored prior to and after HIV diagnosis. HIV seroconverters at month 6 or month 12 will be transferred to groups C, D dependent on drug use history.
2907184|NCT03198962||Groups C|At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18.
2907185|NCT03198962||Group B|At each visit, a series of self-administered questionnaires will be used to collect demographic, sexual behavioral risk and drug use data. HIV testing, risk reduction counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18.
2907186|NCT03198962||Group D|At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-positive participants, if they have not yet started ART, will be referred to preferred hospitals to receive ART regardless of CD4 count according to the 2014 National Guidelines. Drug use patterns will be longitudinally monitored prior to and after ART initiation.
2907187|NCT03198949|Experimental|everolimus first arm|All subjects will receive everolimus during Core phase I and placebo during Core phase II.
2907188|NCT03198949|Placebo Comparator|placebo first arm|All subjects will receive placebo during Core phase I and everolimus during Core phase II.
2907189|NCT03198936|Experimental|Brain Pill|Dose - 2 capsules twice a day with meals
2907190|NCT03198936|Placebo Comparator|Placebo|Matching placebo capsules with microcrystalline cellulose with added colours Dose - 2 capsules twice a day with meals
2907191|NCT03198923|Experimental|natural killer and natural killer T cell|The eligible patients are infused with ten doses of (2-2.5)x10^9 NK and NKT cells in one course of treatment.
2907192|NCT03198910||Pulmonary arterial hypertension|
2907193|NCT03198910||Chronic thromboembolic pulmonary hypertension|
2907194|NCT03198897||Observation|Patients with a diagnosis of Homozygous familial Hypercholesterolemia based upon biochemical and/or genetic criteria or profound suspicion for Homozygous familial Hypercholesterolemia
2907195|NCT03198871|Experimental|Acetaminophen Injectable Product|Acetaminophen group: Half of subjects enrolled will be randomized to the acetaminophen group
2907196|NCT03198871|Placebo Comparator|Sodium Chloride 0.9%, Intravenous|Sodium Chloride 0.9% group: Half of subjects enrolled will be randomized to the acetaminophen group
2907197|NCT03198858|Other|Ablation with Carto® 3 System|Ablation with Carto® 3 System
2907198|NCT03198858|Other|Ablation CartoUnivu™|Ablation CartoUnivu™
2907199|NCT03198845|Active Comparator|video game|"Participants received a total of twelve 40-min sessions of hot pack therapy combined transcutaneous electrical nerve simulation over the knees followed by 20-min supervised video game play therapy 20-min per session for 3 times per week for a 4-week duration.~Therapeutic effects of video game intervention for patients with knee osteoarthritis were assessed."
2907239|NCT03198637|Experimental|Monitoring|Neuromuscular Blockade's monitoring
2907240|NCT03198637|Active Comparator|Clinical assessment|No active monitoring of cisatracurium
2907200|NCT03198845|Sham Comparator|exercise group|"Participants received a total of twelve 40-min sessions of hot pack therapy combined transcutaneous electrical nerve simulation over the knees followed by 20-min supervised therapeutic exercise 20-min per session for 3 times per week for a 4-week duration.~Therapeutic effects of therapeutic exercise for patients with knee osteoarthritis were assessed."
2907201|NCT03198832|Sham Comparator|Type 2 diabetes mellitus and periodontitis|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session.
2907202|NCT03198832|No Intervention|Type 2 diabetes mellitus and without periodontitis|Patients will be monitored and maintained every three months.
2907203|NCT03198819||Rifampisin group|"Researchers will administer topical Rifampicin and intravenous cefotaxime~For Rifampicin; 10 mg/kg/day, 24 h infusion on defect area during 3 days~For cefotaxime; 50 mg/kg/day, twice a day, intravenous during 5 days."
2907204|NCT03198819||Control group|"Researchers will only administer intravenous cefotaxime~1) Doses; 50 mg/kg/day, twice a day, intravenous during 5 days."
2907205|NCT03198806|Experimental|Group control in orthostatic position|Treadmill aerobic exercise without water intake
2907206|NCT03198806|Experimental|Hydration group in orthostatic position|Treadmill aerobic exercise and water intake
2907207|NCT03198806|Experimental|Group control in supine position|Treadmill aerobic exercise without water intake
2907208|NCT03198806|Experimental|Hydration group in supine position|Treadmill aerobic exercise and water intake
2907209|NCT03198793|Experimental|QGC001|Capsules of QGC001 250 mg
2907210|NCT03198780|Experimental|Breathing Awareness|"In the clinic, once patients are proficient with the proposed tool, they will (1) independently don the pulse oximeter, (2) use the prototype to perform the mindful breathing intervention. The whole session will last no longer than 60 minutes with 30 minutes for the consent and demonstrations, two minutes to don the study devices, 15 minutes to practice mindful breathing, and two minutes to doff the study devices. The mindful breathing portion will be divided into three sessions. Each session will last three minutes and display a different presentation of Heart Rate Coherence biofeedback.~At home, after completing the in-clinic study, five patients will take the mindful breathing tool home for a week to practice pursed-lip breathing at least five times. They will don the study devices, perform the intervention, and doff study devices."
2907211|NCT03198767|Experimental|LIK066 + 50% CHO|LIK066 + 50% carbohydrate breakfast
2907212|NCT03198767|Experimental|LIK066+ 25% CHO|LIK066+ 25% carbohydrate breakfast
2907213|NCT03198767|Experimental|LIK066 + 0% CHO|LIK066 + 0% carbohydrate breakfast
2907214|NCT03198767|Experimental|LIK066 + 50% CHO + psyliium|LIK066 + 50% Carbohydrate + 6 grams psyllium at breakfast
2907215|NCT03198767|Experimental|LIK066 + 50% CHO + calcium carbonate|LIK066 + 50% carbohydrate + 1 gram calcium carbonate at breakfast
2907216|NCT03198767|Experimental|LIK066 + 50% CHO + No Supplement|LIK066 + 50% carbohydrate + no supplement (NS)
2907217|NCT03198754|Experimental|Bright White Light (BWL)|10000 Lux of White Light
2907218|NCT03198754|Active Comparator|Dim White Light (DWL)|50 Lux of White Light
2907219|NCT03198741|Active Comparator|Aspirin+clopidogrel|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),continue aspirin + clopidogrel (12-month DAPT group).The treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
2907220|NCT03198741|Experimental|Aspirin|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),receive aspirin + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
2907221|NCT03198741|Experimental|Clopidogrel|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),receive clopidogrel + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
2907222|NCT03198728|Experimental|SOV2012-F1-treated|200 patients treated with SOV2012-F1, starting dose of 600 mg - (400 mg with morning meal and 200 mg with evening meal). Dose titrated up to a maximum of 600 mg TU in the morning and 400 mg in the evening or down to 200 mg TU in the morning based on plasma T at Days 14 and 42.
2907223|NCT03198728|Active Comparator|Andro-Gel treated|100 patients treated with AndroGel, starting dose of 40.5 mg QD. Dose titrated down to 20.25 mg or up to 81 mg based on serum T on Days 14 and 42.
2907224|NCT03198715|Experimental|DS-1040b 0.6 mg|Participants receive DS-1040b 0.6 mg by intravenous infusion over six hours
2907225|NCT03198715|Experimental|DS-1040b 1.2 mg|Participants receive DS-1040b 1.2 mg by intravenous infusion over six hours
2907226|NCT03198715|Experimental|DS-1040b 2.4 mg|Participants receive DS-1040b 2.4 mg by intravenous infusion over six hours
2907227|NCT03198715|Experimental|DS-1040b 4.8 mg|Participants receive DS-1040b 4.8 mg by intravenous infusion over six hours
2907228|NCT03198715|Placebo Comparator|Placebo|Participants receive saline by intravenous infusion over six hours
2907229|NCT03198702|Experimental|Toxin group|The babies receive a botulinum toxin type A injection at the age of 12 months
2907230|NCT03198702|Sham Comparator|Sham group|The babies receive a simulated injection procedure at the age of 12 months
2907231|NCT03198689|Experimental|Administration of Brentuximab vedotin|Maximum duration of treatment: 48 weeks Maximum dose allowed: 0.6 mg/kg Route of administration: intravenous use
2907232|NCT03198676|Active Comparator|A - PrEP-001 6.4 mg - 0.8 mg/spray|PrEP-001 Nasal Powder, 0.8 mg/spray (G-006) (Formulation A)
2907233|NCT03198676|Active Comparator|B - PrEP-001 6.4 mg - 1.6 mg/spray|PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)
2907234|NCT03198676|Active Comparator|C - PrEP-001 3.2 mg - 1.6 mg/spray|PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)
2907235|NCT03198676|Placebo Comparator|D - Placebo|PrEP-001 Placebo Nasal Powder (matching Formulation B)
2907236|NCT03198663|Experimental|POSSE Intervention|
2907237|NCT03198663|Other|Control|Delayed intervention
2907241|NCT03198624|Active Comparator|HTL0018318 Low dose, Part A.|Part A. 1 single dose on day 1. Discharged on day 4 of Period 1 (following 10 day washout).
2907242|NCT03198624|Active Comparator|HTL0018318 High dose, Part A|1 single dose on day 1. Discharged on day 4 of period 2 (following 10 day washout).
2907243|NCT03198624|Active Comparator|HTL0018318 Low dose, Part B|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.
2907244|NCT03198624|Placebo Comparator|Placebo oral capsule, Part B|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.
2907245|NCT03198624|Active Comparator|HTL0018318 High dose, Part B.|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.
2907246|NCT03198624|Placebo Comparator|Placebo oral capsule, Part B.|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.
2907247|NCT03198611||Normal function|No systolic dysfunction No diastolic dysfunction No right ventricular dysfunction
2907248|NCT03198611||Left ventricular systolic dysfunction|Left ventricular ejection fraction < 50%
2907249|NCT03198611||Left ventricular diastolic dysfunction|"Classification according to:~Mitral lateral annulus e' in tissue Doppler < 10 cm/s~American society of echocardiography (ASE) criteria 2009~ASE criteria 2016"
2907250|NCT03198611||Right ventricular dysfunction|Tricuspid annulus plane systolic excursion < 17 cm
2907251|NCT03198598|Experimental|MS patients with EDSS from 0 to 5.5 for yoga|Three months of Iyengar Yoga practice.
2907252|NCT03198598|No Intervention|MS patients with EDSS from 0 to 5.5 for control|
2907253|NCT03198598|Experimental|MS patients with EDSS from 6 to 8 for yoga|Receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips
2907254|NCT03198598|No Intervention|MS patients with EDSS from 6 to 8 for control|
2907255|NCT03198598|No Intervention|Healthy subjects|
2907256|NCT03198585|Active Comparator|Empagliflozin 10 mg|
2907257|NCT03198585|Placebo Comparator|Placebo|
2907258|NCT03198572|Experimental|Berberine|Berberine was taken orally 0.5g three times per day for 48 weeks, based on lifestyle intervention.
2907259|NCT03198572|Placebo Comparator|Placebo|Placebo was taken orally 0.5g three times per day for 48 weeks, based on lifestyle intervention.
2907260|NCT03198559|Experimental|Experimental|"Participants current ART regimen:~2 grams disulfiram by mouth per day for a total of 28 days~400mg vorinostat by mouth per day on days 8, 9,10 and days 22, 23, 24"
2907261|NCT03198546|Other|CAR-T cell therapy group|Appropriate patients who could benefit from the GPC3 targeting CAR-T cell therapy against HCC are chosen to be the CAR-T cell therapy group.
2907262|NCT03198533|Active Comparator|Triathlon PA|Triathlon PA (HA-surface) versus Triathlon Pressfit design: The goal with the un-cemented technique is to reach a full integration between the bone and the prosthesis. During the last years the usage of prosthesis with hydroxyapatite surface within tooth-, mandibular-surgery, hips- and knee-joints, have increased significantly. It has been shown that a thin layer of hydroxyapatite stimulates the anchorage of the implant. The goal with this sub study is to compare the stability of the fixation when using two different types of Triathlon un-cemented prosthesis designs. PA (HA-surface) versus Pressfit.
2907263|NCT03198533|Active Comparator|Triathlon Pressfit|Triathlon PA (HA-surface) versus Triathlon Pressfit design: The goal with the un-cemented technique is to reach a full integration between the bone and the prosthesis. During the last years the usage of prosthesis with hydroxyapatite surface within tooth-, mandibular-surgery, hips- and knee-joints, have increased significantly. It has been shown that a thin layer of hydroxyapatite stimulates the anchorage of the implant. The goal with this sub study is to compare the stability of the fixation when using two different types of Triathlon un-cemented prosthesis designs. PA (HA-surface) versus Pressfit.
2907264|NCT03198520|Other|Polymer Removable Partial Denture|Evaluate the change in patient Oral Health-related Quality of Life while wearing the Solvay Dental 360™ polymer Removable Partial Denture (RPD)
2907265|NCT03198507|Experimental|RHB-105|RHB-105 is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin, Omeprazole and Rifabutin as well as separate Riboflavin
2907266|NCT03198507|Active Comparator|Active Comparator|Active comparator is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin and Omeprazole as well as separate Riboflavin
2907267|NCT03198494|Experimental|Acoustic 1Hz Stimulation|1 Hz acoustic stimulation applied via headphones and downloadable phone application during sleep every night.
2907268|NCT03198494|Sham Comparator|Sham Background Noise|Background noise applied via headphones and downloadable phone application during sleep every night.
2907269|NCT03198494|No Intervention|Baseline Seizure Monitoring|No use of sound system; Patients record seizures in a diary.
2907270|NCT03198481|Active Comparator|Patient-Centered Counseling Video Group|MUS video utilizing a patient mentor.
2907271|NCT03198481|Active Comparator|Physician Counseling Video Group|MUS video by a physician.
2907272|NCT03198468|Experimental|Vapor Ablation|
2907273|NCT03198455|Experimental|Andosan|The Agaricus blazei Murill-based mushroom extract, Andosan™, is given as one dosage 60 ml/day orally for 2 months. The intervention solution is given for 1 month's consumption at a time in a neutral plastic container
2907274|NCT03198455|Placebo Comparator|Placebo|The placebo is drinking water with brownish food coloring, given as one dosage 60 ml/day orally for 2 months. The placebo solution is given for 1 month's consumption at a time in a neutral plastic container (same as for intervention/experimental solution).
2907275|NCT03198442|Experimental|Breast PET|PET imaging of breast with patient in prone position.
2907302|NCT03198286|Experimental|Supportive care (survivor care plan, survey)|Patients receive a customized treatment summary and survivor care plan via the Carevive Survivor Care Planning System and review it during their follow-up visit. Patients also complete a survey on a tablet computer over 10-20 minutes before and after their follow-up visit.
2907303|NCT03198273|Experimental|Clinical pilates exercises|Participants will exercise 3 times a week for 6 weeks (18 sessions in total, 45-60 minutes each session) in accompany with a physiotherapist. Since the chosen model for exercise training is clinical pilates exercises, separate patient training will be needed. First 3 weeks planned as Warming Phase, Exercise Phase (first 3 weeks), Cooling Phase; and Second 3 weeks planned as Warming Phase, Exercise Phase (first 3 weeks), Cooling Phase.
2907276|NCT03198429|Experimental|Embedded fathering intervention|"This condition focuses on workers' practice with fathers who have been identified as perpetrators in cases of child exposure to domestic violence. Workers randomly assigned to this condition will receive:~a one-day training at the beginning of the study on the need to engage fathers as part of intervention in cases of child exposure to DV~access to a practice leader and consultant to respond to question and concerns about working with father perpetrators of DV~access to a 30-minute presentation, once a month, on issues of practice specific to working with this population In addition,~cases being assigned to ongoing service workers will be flagged by intake at the time they are opened to ongoing services as being a potentially appropriate referral to the Caring Dads program~clients who are then referred to CD as part of clinical service will be given access to this program at the earliest possible opportunity."
2907277|NCT03198429|Experimental|Embedding mother-child intervention|"Workers in the MIM condition will receive additional training and facilitated referral to MIM for eligible clients. Specifically, workers randomly assigned to this condition will receive:~a one-day training at the beginning of the study on the impact of DV on mothers, mothering, and child development~access to a practice leader and consultant to respond to question and concerns about working with women victims of DV on parenting issues~access to a 30-minute presentation, once a month, on issues of practice specific to working with this population In addition,~cases judged by intake workers as being appropriate referrals to the MIM program (see Methods) and being assigned to these workers for ongoing service will be flagged at the time of transfer as being potentially appropriate referrals to the Mothers in Mind program~clients who are then referred to MIM as part of clinical service will be given access to this program at the earliest possible opportunity."
2907278|NCT03198429|Experimental|Combined intervention|A final group of workers will be randomly assigned to receive all the training, support, and referral opportunities associated with both the Embedded Mothers in Mind condition and the Embedded Caring Dads condition.
2907279|NCT03198429|No Intervention|Treatment as usual|Workers in the service as usual condition will continue to provide in-home support to children and families in accordance with current practice. Workers will receive regular supervision from their supervisors. A review of practice reveals that, in general, workers make referrals to intervention programs in only a small minority of cases. Such referrals will continue under this study protocol - service will proceed as usual. This condition is not a placebo, families are continuing to receive the full child protection service that they would normally have received if this trail were not being run.
2907280|NCT03198416|Experimental|Investigational Device|Consented participants who meet eligibility will have a drug induced sleep endoscopy (DISE) with the Solar GI High Resolution pharyngeal Manometry system.
2907281|NCT03198403|Experimental|Popliteal plexus block|Patients with an FTB, reporting postoperative pain (NRS > 3) will have a popliteal plexus block
2907282|NCT03198403|No Intervention|No intervention|Patients with postoperative pain NRS < or = 3
2907283|NCT03198390||Atopic dermatitis subjects|
2907284|NCT03198390||Healthy subjects|
2907285|NCT03198377|Experimental|TENS: Randomized frequency modulation|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
2907286|NCT03198377|Experimental|TENS: Scan 6/6 of frequency modulation|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
2907287|NCT03198377|Experimental|TENS: Fixed frequency|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
2907288|NCT03198377|Sham Comparator|TENS: Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
2907289|NCT03198364|Experimental|START + Mobile Augmentation|4 Sessions of In-Person Psychoeducation called Safety and Recovery Therapy (START) with 12 weeks of augmentation by use of automated software to prompt users to engage in personalized adaptive coping
2907290|NCT03198364|Active Comparator|START|4 Sessions of In-Person Psychoeducation called Safety and Recovery Therapy (START)
2907291|NCT03198351||Cohort I|Pregnant women with a confirmed diagnosis of multiple sclerosis (MS) and teriflunomide exposure during the current pregnancy
2907292|NCT03198351||Cohort II|Pregnant women with MS not exposed to teriflunomide during the current pregnancy
2907293|NCT03198351||Cohort III|Healthy pregnant women who do not have a known diagnosis of MS and have no known exposure to a known human teratogen
2907294|NCT03198351||"Registry group (not eligible for cohorts)"|Women who contact the OTIS registry study staff and who do not meet the criteria for the prospective study, for example, at time of contacting the study, having known prenatal diagnosis of congenital defect, or gestation weeks greater than 20 following a first trimester teriflunomide exposure, etc.; these participants will not be included in the primary analysis for the cohort study.
2907295|NCT03198338|Experimental|TAP group|Drug: 0.25% Bupivacaine, 0.5mL/kg
2907296|NCT03198338|Sham Comparator|Placebo group|Drug: 0.9% Normal Saline, 0.5mL/kg
2907297|NCT03198325|Experimental|Interruption of antiretroviral therapy|Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values >50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
2907298|NCT03198312|Experimental|CathiportTM|be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.
2907299|NCT03198312|Active Comparator|Implant Port|be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.
2907300|NCT03198299|Active Comparator|study group: MEI BIN insoles|Study group: participants in the study group were prescribed with customized insoles (MEI BIN insoles) to keep the subtalar joint in neutral position, for 12 weeks.
2907301|NCT03198299|No Intervention|control group: without MEI BIN insoles|Control group: participants in the control group were not prescribed with customized insoles (MEI BIN insoles) to keep the subtalar joint in neutral position, for 12 weeks.
2907304|NCT03198273|Experimental|Physiotherapy Program|Standard physiotherapy program consisting of conservative treatment is applied to both groups. The conservative treatment schedule to be applied to planned as 10 sessions, 3 times a week.
2907305|NCT03198260|Experimental|Fascial Manipulation|fascial manipulation is a manual therapy technique were to apply deep frictional massage to the deep fascial structure or point to increase its pliability
2907306|NCT03198260|Active Comparator|Running kinematics|the change in a range of joint angles during different phases of running
2907307|NCT03198247|Active Comparator|Control Group: Usual Care|"Procedure: Usual care The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
2907308|NCT03198247|Experimental|Experimental: Usual Care + PNE and CST|"Procedure: Usual care + PNE and CST. The PNE and CST program will be divided in 3 individual sessions. This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptative thoughts and behaviours"
2907309|NCT03198234|Experimental|Cohort 1|Participants will receive 1 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
2907310|NCT03198234|Experimental|Cohort 2|Participants will receive 3 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
2907311|NCT03198234|Experimental|Cohort 3|Participants will receive 9 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
2907312|NCT03198221|Active Comparator|Group A|Participants in Group A will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes. Participants must finish drinking the bowel preparation by 7:00 PM, and may continue to drink clear liquids until midnight.
2907313|NCT03198221|Active Comparator|Group B|Participants in Group B will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes for a total of 8 glasses, and must complete drinking the bowel preparation by 5:30 PM. Participants may continue to drink clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will be asked to drink an 8 ounce glass of bowel preparation every ten minutes for a total of 8 glasses over no more than 1.5 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
2907314|NCT03198221|Active Comparator|Group C|Participants in Group C will begin drinking the bowel preparation Clenpiq (sodium picosulfate, magnesium oxide, and citric acid) at 4:00 PM on the day before colonoscopy. Participants will be asked to drink 5 ounces of the bowel preparation and at least five (5) additional 8-ounce glasses of clear liquids by 9:00 PM. At 10:00 PM, participants will drink another 5 ounces of the bowel preparation, and will then be asked to drink at least three (3) additional glasses of clear liquids by midnight.
2907315|NCT03198221|Active Comparator|Group D|Participants in Group D will begin drinking the bowel preparation Clenpiq (sodium picosulfate, magnesium oxide, and citric acid) at 4:00 PM on the day before colonoscopy. Participants will be asked to drink 5 ounces of the bowel preparation and at least five (5) additional 8-ounce glasses of clear liquids by 9:00 PM, and may continue drinking clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will drink another 5 ounces of the bowel preparation and at least three (3) 8 ounce glasses of clear liquids within the next 2 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
2907316|NCT03198208||Reference group|No fentanyl dose administered during surgery
2907317|NCT03198208||Comparative group|Fentanyl dose administered during surgery
2907318|NCT03198182|Experimental|Module A|BMS-986036 Arm
2907319|NCT03198182|Placebo Comparator|Module B|Placebo Arm
2907320|NCT03198169|Experimental|Active AWC + Active ABFD|Active Antimicrobial Wound Cleanser + Active Antimicrobial Barrier Film Dressing + SOC
2907321|NCT03198169|Experimental|Active AWC + Placebo ABFD|Active Antimicrobial Wound Cleanser + Placebo Antimicrobial Barrier Film Dressing + SOC
2907322|NCT03198169|Experimental|Placebo AWC + Active ABFD|Placebo Antimicrobial Wound Cleanser + Active Antimicrobial Barrier Film Dressing + SOC
2907323|NCT03198169|Experimental|Placebo AWC + Placebo ABFD|Placebo Antimicrobial Wound Cleanser + Placebo Antimicrobial Barrier Film Dressing + SOC
2907324|NCT03198156|Experimental|Transcranial Direct Current Stimulation|Active tDCS for 30 minutes daily for 4 sessions
2907325|NCT03198156|Sham Comparator|Sham stimulation|Sham stimulation sessions will be for 30 minutes daily for each of the 4 sessions; however, active stimulation for this arm of the study is only for 30 seconds; yet, will be applied at the same intensity as the Active arm of the study, albeit for only 30 seconds.
2907326|NCT03198143|Experimental|Healthy Subjects - Ghrelin|Healthy subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of human synthetic Acyl Ghrelin at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
2907327|NCT03198143|Placebo Comparator|Healthy Subjects - Saline|Healthy subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of 0.9% saline at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
2907328|NCT03198143|Experimental|Obese Subjects - Ghrelin|Obese subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of human synthetic Acyl Ghrelin at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
2907329|NCT03198143|Placebo Comparator|Obese Subjects - Saline|Obese subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of 0.9% saline at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
2907330|NCT03198130|Experimental|REGN2810|REGN2810 administered IV over a 30 minute infusion
2907331|NCT03198117|Experimental|Huaier Granule|Huaier Granule
2907332|NCT03198117|Placebo Comparator|placebo|placebo
2954351|NCT02872857|Experimental|8mg galantamine twice daily|
2907333|NCT03198117|No Intervention|No-treatment Control|patients refused any treatment
2907334|NCT03198104||Liver disease|Paediatric patients (50-60 pts.) with liver disease who are scheduled for an ultrasound-guided liver biopsy as part of their standard care - these patients will be scanned using MRI and fibroscan, then will proceed through standard care pathway to receive blood tests and a liver biopsy. Findings from the fibroscan, blood tests and liver biopsy will be compared to the MRI data to determine it's accuracy in detecting and distinguishing different types of liver disease.
2907335|NCT03198104||Autoimmune Hepatitis Group (AIH)|Paediatric patients who have been diagnosed with autoimmune hepatitis and are about to initiate pharmacological treatment (15-30 pts.) will be scanned using MRI and fibroscan, then proceed through the standard care pathway to receive repeated blood tests and liver biopsies throughout treatment. MRI and fibroscan will be repeated before each liver biopsy. Findings from the fibroscan, blood tests and liver biopsy will be compared to MRI data to determine it's accuracy in monitoring liver disease.
2907336|NCT03198104||Healthy Volunteers|Healthy volunteers (20-30 children) will be scanned using MRI and fibroscan and used as healthy controls.
2907337|NCT03198091|Experimental|Dun Ye Guan Xin Ning mono-therapy|
2907338|NCT03198078|Experimental|Brexpiprazole (OPC-34712)|2-4 mg/day; Start at 0.5 mg/day, titrate to max of 4 mg/day
2907339|NCT03198078|Active Comparator|Aripiprazole|10-20 mg/day; Start at 2 mg per day, titrate up to max of 20 mg/day
2907340|NCT03198078|Placebo Comparator|Placebo|Matching placebo, daily
2907341|NCT03198065|Experimental|Hand-made glove setting|The patients receive Hand-made glove setting
2907342|NCT03198065|Experimental|commercialized multiport setting|The patients receive commercialized single-incision multiport setting
2907343|NCT03198052|Experimental|CAR-T cell therapy group|Appropriate cancer patients who could benefit from the PSCA, MUC1, PD-L1,or CD80/86 targeting CAR-T cell immunotherapy are chosen to be the CAR-T cell therapy group.
2907344|NCT03198039|Experimental|Group 1|Meditation twice daily for at least two weeks prior to surgery and for four weeks after surgery
2907345|NCT03198039|Experimental|Group 2|Meditation twice daily for four weeks after surgery
2907346|NCT03198039|No Intervention|Group 3|Control group - will undergo surgery and subsequent hospital stay according to the current standard of care, which does not include meditation
2907347|NCT03198026|Experimental|Treatment (ibrutinib, obinutuzumab)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab IV on days 1, 8, and 15 of course 1 and day 1 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 months after course 5, patients with stable disease will continue to receive obinutuzumab every 2 months for a total of 12 doses.
2907348|NCT03198013|Experimental|Module A|Single Ascending Dose
2907349|NCT03198013|Experimental|Module B|Multiple Ascending Dose
2907350|NCT03198000|Experimental|Formula # 13418-148|
2907351|NCT03198000|Experimental|Formula # 13418-158|
2907352|NCT03198000|Active Comparator|Control Formula # PF004390|
2907353|NCT03197987|Experimental|Endocuff colonoscopy|Endocuff-assisted colonoscopy
2907354|NCT03197987|Active Comparator|Cap colonoscopy|Cap-assisted colonoscopy
2907355|NCT03197974|Other|Mindfulness for Bipolar|Introduction to, and training in the skills of mindfulness, self-compassion, and values-oriented action, and how these can be applied to managing symptoms of bipolar disorder.
2907356|NCT03197974|Other|Psychoeducation for Bipolar|Information about bipolar disorder and the patient's role in managing the condition, including identifying triggers, and responding to early warning signs of episodes, and developing a healthy lifestyle
2907357|NCT03197961|Experimental|DMPA with tenofovir/emtricitabine PrEP|the drug combination of tenofovir disoproxil fumarate 300mg and emtricitabine 200mg which is known as Truvada® will be taken orally once daily for 14 days by all participants. Drug concentrations will be measured (blood sampling) and one dose of Depot medroxyprogesterone acetate (DMPA) 150mg will be administered to each participant as an intramuscular injection after the first course of tenofovir disoproxil fumarate/emtricitabine is completed. Then, a second round of the combination of tenofovir disoproxil fumarate 300mg and emtricitabine 200mg (Truvada®) will be taken orally once daily for 14 days by all participants.
2907358|NCT03197948||Health Services Research (electronic patient reported outcome)|Patients complete questionnaires over 15 minutes once a week over 3 months via a smartphone application. Patients rate urinary function, bowel habits, sexual function, hormonal function, and overall satisfaction. Patients with advanced disease also answer questions related to pain, fatigue/lack of energy, weight loss, and worry domains.
2907359|NCT03197935|Experimental|Atezolizumab and Chemotherapy|Participants will receive atezolizumab (840 milligrams [mg]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter [mg/m^2]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will continue to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.
2907360|NCT03197935|Placebo Comparator|Placebo and Chemotherapy|Participants will receive placebo matched to atezolizumab via IV infusion every 2 weeks in combination with nab-paclitaxel (125 mg/m^2) via IV infusion every week for 12 weeks, followed by placebo matched to atezolizumab every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will be unblinded post-surgery and will continue to be followed.
2907361|NCT03197922|Experimental|MIE Treatment for Two Weeks|Participants in this arm will receive the Multidisciplinary Intervention for Encopresis (MIE) for two weeks. MIE consists of daily clinic appointments, each of which lasts until a continent bowel movement occurs or 3 hours elapse. These participants will discontinue the use of medication previously prescribed for the treatment of constipation, other than the suppositories used in the MIE treatment. During MIE, medical professionals resolve any constipation and oversee a regimen of over the counter medications that increase the predictability of a bowel movement.
2907491|NCT03197051||Q4|Q4 means a group of highest 75~100% of serum syndecan-1 concentration.
2954352|NCT02872857|Experimental|12mg galantamine twice daily|
2907362|NCT03197922|Experimental|MIE Treatment for One Week|Participants in this arm will receive the Multidisciplinary Intervention for Encopresis (MIE) for one week. MIE consists of daily clinic appointments, each of which lasts until a continent bowel movement occurs or 3 hours elapse. These participants will discontinue the use of medication previously prescribed for the treatment of constipation, other than the suppositories used in the MIE treatment. During MIE, medical professionals resolve any constipation and oversee a regimen of over the counter medications that increase the predictability of a bowel movement.
2907363|NCT03197922|No Intervention|Treatment as Usual (TAU)|Participants randomized to the Treatment as Usual (TAU) group will continue to receive outpatient medical treatment of encopresis according to best practice guidelines by the pediatric gastroenterologist. In addition, participants in the TAU group will receive a 2-hour individual appointment in clinic with a doctoral level clinician with extensive experience in behavioral treatments for encopresis. During the appointment, the clinician will review strategies to increase continence by providing parent education on the following topics: how to collect and evaluate data on their child's bowel movements, how to establish and use a sit schedule, identifying behaviors that are precursors to bowel movements and how to use them to increase the probability of a bowel movement being continent, consequences for incontinence, and reinforcement for continence.
2907364|NCT03197909||Healthy subjects|Determination of pro-inflammatory plasma factors at Healthy subjects aged from 35 to 85 years old
2907365|NCT03197909||COPD patients|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old
2907366|NCT03197896|Experimental|Group I (prostate cancer information)|The educator reviews general information about the prostate Cancer
2907367|NCT03197896|Active Comparator|Group II (general health information)|The educator reviews topics about health promotion actions.
2907368|NCT03197883|Experimental|Group 1|Participants will apply a pea-sized quantity of test product (approximately 0.6-1 grams (g)) topically onto the fingertips and will apply twice daily (morning and evening) to the full face after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.
2907369|NCT03197883|Other|Group 2|Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.
2907370|NCT03197870|Experimental|AKB-9778 15mg BID|
2907371|NCT03197870|Experimental|AKB-9778 15mg QD|
2907372|NCT03197870|Placebo Comparator|Placebo BID|
2907373|NCT03197857|Experimental|Control|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
2907374|NCT03197857|Experimental|Control + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
2907375|NCT03197857|Experimental|Training in aquabike|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
2907376|NCT03197857|Experimental|- Training in aquabike + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
2907377|NCT03197857|Experimental|Bicycle training|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
2907378|NCT03197857|Experimental|- Bicycle training + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
2907379|NCT03197831||Private Option Expansion|This group incorporates data from the state of Arkansas and is applicable only to aims 1 and 2 where we are determining the impact of difference methods of Medicaid expansion on inpatient and ED utilization.
2907380|NCT03197831||Managed Medicaid Expansion|This group incorporates data from the state of Kentucky and is applicable only to aims 1 and 2 where we are determining the impact of difference methods of Medicaid expansion on inpatient and ED utilization.
2907381|NCT03197831||No Medicaid Expansion|This group incorporates data from the state of Florida in aims 1 and 2 and all the states which did not expand Medicaid enrollment in 2014 for aim 3.
2907382|NCT03197831||Medicaid Expansion|This group incorporates data from the state of Arkansas and Kentucky in aims 1 and 2 and all the states which expanded Medicaid enrollment in 2014 (except New Hampshire and Michigan) for aim 3.
2907383|NCT03197818|Experimental|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose (BDP/FF/GB) (Beclometasone dipropionate / Formoterol Fumarate / glycoppyronium Bromide)
2907384|NCT03197818|Active Comparator|Symbicort Turbuhaler 160/4.5 µg|Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (160µg + 4.5 µg expresses the delivered dose; 200 µg + 6 µg expresses the metered dose) ( BUD/FF) (Budesonide/Formoterol Fumarate)
2955316|NCT02866253|No Intervention|Control Group|patients without any DHEA
2907385|NCT03197805|Experimental|Use of PAM 50 test in Her2 equivocal breast cancer patient|Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio <2 and 4 ≤HER2 gene number copy < 6) will be eligible for RNA genomic test (PAM 50 test).
2907386|NCT03197792|Experimental|Pulmonary endarterectomy patients|All patients
2907387|NCT03197779|Experimental|BMS-962212 Two Hour Administration|Intravenous administered over 2 hours of BMS-962212
2907388|NCT03197779|Experimental|BMS-962212 5 Day Administration|Intravenous administered over 5 days of BMS-962212
2907389|NCT03197779|Experimental|BMS-962212 and Aspirin|BMS-962212 intravenous administration, followed by aspirin oral administration, then combination administration of BMS-962212 and aspirin
2907390|NCT03197779|Placebo Comparator|Placebo and Aspirin|Placebo intravenous administration, followed by aspirin, then combination administration of placebo and aspirin
2907391|NCT03197779|Placebo Comparator|Placebo|Placebo intravenous administration
2907392|NCT03197766|Experimental|Active BMN 111|Daily subcutaneous injection of 15 micrograms per kilogram BMN111
2907393|NCT03197766|Placebo Comparator|Placebo|Daily subcutaneous injection of placebo
2907394|NCT03197753|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion
2907395|NCT03197753|Active Comparator|Nasotracheal intubation|Nasotracheal tube insertion
2907396|NCT03197740|Active Comparator|aricept Tab 5mg|
2907397|NCT03197740|Experimental|donepezil patch 25cm2|
2907398|NCT03197740|Active Comparator|aricept Tab 10mg|
2907399|NCT03197740|Experimental|donepezil patch 50cm2|
2907400|NCT03197727|Other|GC Saliva-Check BUFFER|Saliva test pH Buffering capacity Flow rate
2907401|NCT03197714|Experimental|OPB-111077|Level 1: 200 mg daily Level 2: 250 mg daily
2907402|NCT03197688||Notapplicable|Not applicable as non-interventional study
2907403|NCT03197675|Sham Comparator|Control group|Participants who are randomized to the control group will not receive any acupuncture. Participants will however be assessed weekly to obtain the same data on their pain scale and other outcome measures as the treatment group. Participants will be evaluated in person during their standard of care clinical follow up appointments at the three month and six month points for in person interviews and data collection .
2907404|NCT03197675|Active Comparator|treatment group|Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture, 8 treatments of auricular acupuncture). Pain Numeric Rating Score (NRS) will be evaluated by the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
2907405|NCT03197662|Experimental|Experimental: Intranasal Oxytocin (IN-OXT)|Syntocinon (synthetic oxytocin) will be used in this protocol. Each subject will receive a dose of 16 IU QD and will be instructed to inhale 2 puffs per nostril (4 IU each).
2907406|NCT03197662|Placebo Comparator|Placebo Comparator: Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril (4 IU each).
2907407|NCT03197649|No Intervention|Control|No laser phototherapy treatment
2907408|NCT03197649|Experimental|Laser phototherapy treatment|Laser phototherapy treatment administered in OR
2907409|NCT03197636||Malignant melanoma patients|40 patients with metastatic melanoma are included. Patients are admitted to Department of Oncology, Aarhus University Hospital (AUH). The patients are recruited to the study from the outpatient clinic of the Department of Oncology when they are about to begin treatment with pembrolizumab.
2907410|NCT03197636||Healthy controls|20 Healthy volunteers (HV) are included, matched by age and gender.
2907411|NCT03197623|Experimental|LLP2A-ALENDRONATE|50, 150, 400 or 750 μg/kg or placebo given as a one time intravenous administration over 120 minutes.
2907412|NCT03197623|Placebo Comparator|Placebo|placebo given as a one time intravenous administration over 120 minutes.
2907413|NCT03197610|Experimental|SCTG+EMD|TEST GROUP: Langer and Langer technique was used to prepare the recipient side. The vestibule surfaces of adjacent interdental papillae were de-epithelialized. The dimensions of the recipient area were measured by periodontal probes and four bleeding centers were created in the palatinal region. The graft was placed on the recipient site and fixed with 4.0 silk sutures. Pressure was applied to the operation area for 5 minutes with saline impregnated sponges. EMD (Emdogain®, Straumann, Basel, Switzerland) was used in the test group in addition to SCTG. Prior to EMD application, the root surface was applied with 24% EDTA (PrefGel, Straumann, Basel, Switzerland) for 2 minutes. The area was washed with saline and then EMD was applied.
2907414|NCT03197610|Experimental|ONLY SCTG|CONTROL GROUP: Langer and Langer technique was used to prepare the recipient side. The anesthetic solution was applied to the donor site in the palatinal region on the same side as the operation site. The dimensions of the recipient area were measured by periodontal probes and four bleeding centers were created in the palatinal region. The graft was placed on the recipient site and fixed with 4.0 silk sutures. Pressure was applied to the operation area for 5 minutes with saline impregnated sponges.
2907415|NCT03197597||Strain isolation from the nasopharynx|A group of culture positive whooping cough patients.
2907416|NCT03197584|Experimental|NANT Ovarian Cancer Vaccine|avelumab, bevacizumab, capecitabine, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, paclitaxel, omega-3-acid ethyl esters, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6301, and hank®.
2907417|NCT03197571|Experimental|Nant Urothelial Cancer Vaccine|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab-paclitaxel, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
2907418|NCT03197545||Stress fracture group|110 recruits diagnosed (clinicaly and/or by imaging) with at least one stress fracture, during basic and advanced infantry trainig.
2907419|NCT03197545||Traumatic fracture group|110 infantry recruits with medical history of having at least one traumatic fracture, during their life (from birth up to date).
2907420|NCT03197545||Control group|220 healthy infantry recruits never diagnosed with stress fracture or traumatic fractures
2907421|NCT03197532||Group 1|Otherwise healthy, mid-reproductive aged women between the ages of 20 and 35 years previously exposed to high dose alkylating agent therapy (or have an alkylator score of 1 or more), and at least 1 year from cancer treatment.
2907422|NCT03197532||Group 2|Healthy, mid-reproductive aged women between the ages of 20 to 35 who have not been exposed to cancer therapy.
2907423|NCT03197532||Group 3|Reproductive aged women between the ages of 43-50 who have not been exposed to cancer therapy, nor have a history of infertility
2907424|NCT03197519|Experimental|Experimental group|The experimental group will receive treatment as usual, that is to say, the standard treatment based on CBT principles that is offered by the different ED units in Spain, plus an online intervention using TCApp for a period of 12 weeks.
2907425|NCT03197519|Other|TAU control group|The TAU control group will receive treatment as usual, offered by the different ED units in Spain. Patients from the control group will be offered access to TCApp after a 6-month period.
2907426|NCT03197506|Experimental|Treatment (pembrolizumab, standard therapy)|"NEOADJUVANT (COURSE 1): Patients receive pembrolizumab IV over 30 minutes on day 1.~SURGERY (COURSE 2): Patients undergo standard of care surgery within days 4-7.~CONCURRENT (COURSE 3): Starting 21-35 days after surgery, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 8-54. Patients also undergo external beam radiation therapy every 5 days per week on days 8-54.~ADJUVANT (COURSE 4-8): Within 3-5 weeks after completing radiation therapy, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 1-5 every 28 days. Treatment repeats every 63 days for up to 5 courses in the absence of disease progression or unexpected toxicity."
2907427|NCT03197493|Experimental|High Dose|carbidopa-levodopa 25-100 mg 2 tablets TID
2907428|NCT03197493|Experimental|Intermediate Dose|carbidopa-levodopa 25-100 mg 1 tablet TID
2907429|NCT03197480|Active Comparator|non responder group|"Less than 20% reduction in CRT on OCT (if VA<6/6 and CRT>=300)~Patients will undergo ozurdex(Dexamethasone intravitreal implant) injection at month 4, followed by a monthly PRN protocol of aflibercept for month 5. Retreatment criteria is any fluid/cyst on OCT."
2907430|NCT03197480|Active Comparator|responder group|"Rapid (Mac Dry at M4) Delayed: Persistent fluid at M4, but more than 20% reduction in CRT on OCT~Patients will undergo month 4 aflibercept followed by a PRN protocol for month 5. Retreatment criteria is any fluid/cyst on OCT."
2907431|NCT03197467|Experimental|Pembrolizumab|Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles
2907432|NCT03197454|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
2907433|NCT03197454|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
2907434|NCT03197441|Experimental|PRP group|Arthroscopic knee surgery plus intraoperative platelet-rich plasma
2907435|NCT03197428|Experimental|PRP group|15 patients will receive platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
2907436|NCT03197428|Placebo Comparator|Control group|15 patients will receive whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
2907437|NCT03197415|Experimental|PRP group|Intradisc injection of autologous platelet-rich plasma gel
2907438|NCT03197402|Active Comparator|Comparator group|Milk protein gel delivery system supplementation
2907439|NCT03197402|Experimental|Leucine-enriched protein group|Leucine-enriched protein gel delivery system supplementation
2907440|NCT03197389|Other|Cohort A1|Cohort A1 will include patients with a triple negative breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
2907441|NCT03197389|Other|Cohort A2|Cohort A2 will include patients with ER/PR negative and Her2 positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
2907442|NCT03197389|Other|Cohort B1|Cohort B1 will include patients with a triple negative breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
2907443|NCT03197389|Other|Cohort B2|Cohort B2 will include patients with a ER/PR negative and Her2 positive breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
2907444|NCT03197376|Experimental|Pneumosil Lot 1|Pneumosil Lot 1
2907445|NCT03197376|Experimental|Pneumosil Lot 2|Pneumosil Lot 2
2907446|NCT03197376|Experimental|Pneumosil Lot 3|Pneumosil Lot 3
2907447|NCT03197376|Active Comparator|Synflorix|Synflorix
2907448|NCT03197363||Białystok PLUS|Participation in the study will be offered to 10000 inhabitants of Bialystok aged 20-80 years. They will be randomly selected from the registry of Bialystok inhabitants. The goal of study is to discover novel risk factors and mechanisms underlying civilization diseases.
2907449|NCT03197350|Active Comparator|HFpEF|"We intend to recruit consecutive patients admitted for HFPEF in our institution during the next 4 years. Eligible patients include those with age ≥50 years, LVEF ≥45%, symptomatic HF, and either a hospitalization for HF within the prior year or an elevated natriuretic peptide level (BNP ≥100 pg/mL or NT-proBNP ≥360 pg/mL) within the 60 days before inclusion.~Intervention: cMR"
2907450|NCT03197350|Active Comparator|Controls|"We plan to recruit 10 per decade of age. These subjects will allow us to evaluate the effects of age on the parameters of our study. They will have no risk factors, a normal ECG at rest and normal heart ultrasound and no abnormalities on a stress test.~Intervention: cMR"
2907451|NCT03197337|Experimental|Control manipulation first|Patients in this group will first undergo the control manipulation while the study manipulation will follow.
2907452|NCT03197337|Experimental|Study manipulation First|Patients in this group will first undergo the study manipulation while the control manipulation will follow.
2907453|NCT03197324|Active Comparator|Digoxin Alone|
2907454|NCT03197324|Active Comparator|Digoxin with Bexagliflozin|
2907455|NCT03197311|Experimental|Mobile app group|In addition to receiving standard of care which includes prescription of postoperative narcotic and NSAID analgesics and usual postoperative instructions a customized mobile app will be downloaded to the participant's smartphone to application to monitor postoperative analgesic consumption, disposal and pain control and patient satisfaction for one week after surgery.
2907456|NCT03197311|No Intervention|Control group|The control group will receive the standard of care which includes prescription of postoperative narcotic and NSAID analgesics and usual postoperative instructions and a case report form will be used to gather data from the medical record and from a post op telephone survey a week after surgery..
2907457|NCT03197298||Clopidogrel Period|ACS patients treated by PCI with newer-generation DES before the guideline suggested change in primary DAPT-regimen
2907458|NCT03197298||Ticagrelor Period|ACS patients treated by PCI with newer-generation DES after the guideline suggested change in primary DAPT-regimen
2907459|NCT03197285|Active Comparator|Control Group|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
2907460|NCT03197285|Experimental|Experimental Group|"All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful). The ECRP developed by Revel et al.(Revel et al., 1994) was also applied to patients in the experimental group.~EYE-CERVICAL RE-EDUCATION PROGRAM (ECRP) This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area"
2907461|NCT03197272|Experimental|PiXL Protocol A|PiXL treatment with UV irradiation in a central 4 mm homogenous zone of the cornea. For myopia of less than 1.0D, 10 J/cm2 will be used, for higher levels of myopia 15J/cm2 will be used.
2907462|NCT03197272|Active Comparator|PiXL Protocol B|PiXL treatment with UV irradiation in a central ring-shaped 4-mm area of the cornea. A central 2-mm zone is left untreated, and the energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2 mm from the corneal centre. For myopia of less than 1.0D, a maximum of 10 J/cm2 will be used, for higher levels of myopia a maximum of 15J/cm2 will be used.
2907463|NCT03197246|Experimental|IVECG and chest X-ray|The patients in this group will be examined with perioperative IVECG for PICC tip placement, as well as standard postoperative chest X-ray.
2907464|NCT03197246|Active Comparator|Standard|Standard method, PICC tip placement confirmed by postoperative chest X-ray .
2907465|NCT03197220|Experimental|fish|
2907466|NCT03197220|Experimental|walnut|
2907467|NCT03197220|Experimental|fish-walnut|
2907468|NCT03197207|Experimental|lifting and thrusting|"Dragon and Tiger warring in lifting and thrusting"
2907469|NCT03197207|Experimental|twisting and rotating|"Dragon and Tiger warring in twisting-rotating"
2907470|NCT03197194|Experimental|A : Alteplase|Intravenous injection of Alteplase and one tablet of placebo
2907471|NCT03197194|Active Comparator|B : Acetylsalicylic Acid|one tablet of Acetylsalicylic Acid and one dose of IV placebo
2907472|NCT03197181|Experimental|anodal transcranial direct current stimulation|anodal transcranial direct current stimulation (current strength: 1 mA, duration: 20 min) over the frontopolar cortex
2907473|NCT03197181|Sham Comparator|sham transcranial direct current stimulation|sham transcranial direct current stimulation (current strength: 1 mA, duration: 0.5 min) over the frontopolar cortex
2907474|NCT03197168|Experimental|Intervention|Intervention to reduce self-stigma among people with mental illness + Usual care
2907475|NCT03197168|Placebo Comparator|Control|Usual care
2907476|NCT03197142||Out-of-hospital cardiac arrest|All the patients who suffered an out-of-hospital cardiac arrest in the Province of Pavia
2907477|NCT03197129|Other|first sade|children that in the first appointment will wait in the SADE waiting room and in the traditional waiting room in the second visit
2907478|NCT03197129|Other|first traditional|children that in the first appointment will wait in the traditional waiting room and in the SADE waiting room in the second visit
2907479|NCT03197116|Active Comparator|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
2907480|NCT03197116|Placebo Comparator|No reminder|No additional reminder will be offered
2907481|NCT03197103|Experimental|N-Acetylcysteine (NAC)|Breast enlargement with autologous fat graft obtained by liposuction with Pietruski solution (tumescent solution with NAC).
2907482|NCT03197103|No Intervention|Control|Contralateral breast enlargement with autologous fat graft obtained by liposuction with standard tumescent solution.
2907483|NCT03197090|Experimental|Zenicor ON|Patients allocated to the experimental group will undergo systematic short ECG monitoring
2907484|NCT03197090|No Intervention|Zenicor OFF|In patients allocated to the control group, usual diagnostic procedures for detection of atrial fibrillation will be employed according to ESC Guidlines.
2907485|NCT03197077|Experimental|Elonva|A single injection of 100 microgram corifollitropin alfa. Oocyte retrieval on day five after corifollitropin alfa injection.
2907486|NCT03197077|Active Comparator|Puregon|Three daily injections of 150 IU follitropin beta. Oocyte retrieval on day five after the first follitropin beta injection.
2907487|NCT03197064|Other|Fosaprepitant|Patients included in this study will be administered fosaprepitant 150 mg IV.
2907488|NCT03197051||Q1|Measure the Concentration of Syndecan-1, Heparan sulfate before anesthetic induction and immediately after weaning from cardiopulmonary bypass. Categorize the patients by serum syndecan-1 concentration(off-CPB) quartile. Q1 means a group of lowest 25% of serum syndecan-1 concentration.
2907489|NCT03197051||Q2|Q2 means a group of lower 25~50% of serum syndecan-1 concentration.
2907490|NCT03197051||Q3|Q3 means a group of higher 50~75% of serum syndecan-1 concentration.
2907492|NCT03197038|Experimental|Home-based walking exercise|Home-based exercise program: The exercise training group will participate in an educational session on exercise for CKD. Participants will receive a packet of information with an exercise prescription and a heart rate monitor that monitors the exercise. Participants will be asked to exercise (a brisk walk) at home, 3 times per week, for 30-60 minutes for 24 weeks. Participants will be contacted via phone biweekly or more frequently if they are behind the exercise routine, and the investigators will meet with them monthly to provide encouragement and progression of exercise, and to download the heart rate monitor.
2907493|NCT03197038|Active Comparator|Control|The control group will receive standard instructions on exercise for patients with kidney disease similar to what is commonly done in clinical practice. The control group will not receive an exercise prescription or heart rate monitor. Participants will be contacted via phone biweekly to answer any questions and ensure continued study participation. The control group will not meet with the investigators monthly.
2907494|NCT03197025|Experimental|MTD|Patients will receive infusion of E6 TCR cells followed by a maximum of two doses of Aldesleukin
2907495|NCT03197025|Experimental|Safety/Clinical Response|Patients will receive infusion of E6 TCR cells followed by a maximum of two doses of Aldesleukin
2907496|NCT03197012|Experimental|Main Study: 90Y-DOTA-TOC|90Y-DOTA-TOC will be administered one time over thirty minutes via the hepatic arterial catheter in the outpatient setting. The injected dose will be 85 to 115 mCi.
2907497|NCT03197012|Experimental|Sub-study: 90Y and 68Ga-DOTA-TOC|"90Y-DOTA-TOC will be administered one time over thirty minutes via the hepatic arterial catheter in the outpatient setting. The injected dose will be 85 to 115 mCi.~Patients enrolled in the correlative sub-study will also receive 111-259 MBq (3-7 mCi) of 68Ga-DOTA-TOC concurrent with 90Y-DOTA-TOC"
2907498|NCT03196999|Active Comparator|Personalized Attention Bias Training|Personalized version of ABM Training.
2907499|NCT03196999|Placebo Comparator|Neutral Attention Training Condition|Non-active version of ABM training.
2907500|NCT03196999|Active Comparator|Non-Personalized Attention Bias Training|Non-personalized version of ABM training.
2907501|NCT03196986|Experimental|MIL60|MIL60 (15mg/kg) was co-administered intravenously with 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent MIL60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
2907502|NCT03196986|Active Comparator|Bevacizumab|Bevacizumab (15mg/kg) was co-administered intravenously with 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent bevacizumab (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
2907503|NCT03196973|Experimental|DF289 plus DF277|Otic solution
2907504|NCT03196973|Active Comparator|DF289|Otic solution
2907505|NCT03196973|Active Comparator|DF277|Otic solution
2907506|NCT03196947|Experimental|Single arm, APO010 Dose escalation|
2907507|NCT03196921|Experimental|Symptomatic Cryptococcal Meningitis|CAMB (Encochleated Amphotericin B)
2907508|NCT03196921|Experimental|Asymptomatic Cryptococcal Antigenemia|CAMB (Encochleated Amphotericin B)
2907509|NCT03196908|Experimental|Energy Drink Brand 1|Two 16-oz bottles of Energy Drink Brand 1
2907510|NCT03196908|Experimental|Energy Drink Brand 2|Two 16-oz bottles of Energy Drink Brand 2
2907511|NCT03196908|Placebo Comparator|Placebo|Two 16-oz bottles that each contain 390 ml of carbonated water, 20 ml of reconstituted lime juice, and 70 ml of cherry flavoring
2907512|NCT03196895|Active Comparator|WR|Weight reduction training
2907513|NCT03196895|Active Comparator|GE|PPG training
2907514|NCT03196895|Experimental|GEM|PPG training + discrete BG feedback
2907515|NCT03196895|Experimental|GEM+CGM|PPG training + continuous BG feedback
2907516|NCT03196882|Active Comparator|Stratum 1: 40 mg/day of iron|"Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)"
2907517|NCT03196882|Experimental|Stratum 1: 80 mg/day of iron|"Ferrimanitol ovoalbumin. 80mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)"
2907518|NCT03196882|Active Comparator|stratum 2: 40 mg/day of iron|"Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 2: If the levels of Hb are >130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)"
2907519|NCT03196882|Experimental|stratum 2: 20 mg/day of iron|"Ferrimanitol ovoalbumin. 20mg of iron in a sachet (oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 2: If the levels of Hb are >130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)"
2907520|NCT03196869|Experimental|Chrono-chemotherapy group|Induction chrono-chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy;Delivery time is different from the control group
2907521|NCT03196869|Other|Routine intravenous drip|control group:Induction routine-chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
2907522|NCT03196856|Experimental|Yogurt Group|Group will be consuming 200g of Greek Yogurt (Plain, 0%) 3 times daily for 8 weeks
2907523|NCT03196856|Placebo Comparator|Study Designed Supplement Group|Group will consume an isoenergetic, protein void, maltodextrin-based placebo supplement during the same time points for 8 weeks as well. The Placebo contain maltodextrin and pudding powder to mimic the consistency of Greek yogurt.
2907524|NCT03196843|Experimental|Raltitrexed plus Radiation|Raltitrexed 2.5mg/m2, iv, every 3 weeks, concurrently with intensity modulated radiotherapy(IMRT)
2907525|NCT03196843|Active Comparator|Radiation|Intensity modulated radiotherapy(IMRT) alone radical radiotherapy:70Gy/2Gy/7 weeks preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 weeks
2907526|NCT03196830|Experimental|Treatment group|the group of patients who received CAR-T treatment
2907641|NCT03195985|Active Comparator|"Age Well psycho-education course"|4-week active control condition
2907527|NCT03196817|Active Comparator|Carpal tunnel injection|Carpal tunnel injection (infiltration) group of patients will be referred to the Hospital Alvorada to carry out steroid injection. The injection in carpal tunnel will be an association of 6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%, totaling 1.5 ml.
2907528|NCT03196817|Active Comparator|Wrist splinting|Wrist splinting will be use in the nigth time, remain the wrist in the 15th degree in extension, until its removal in the morning.
2907529|NCT03196804|Experimental|LC28-0126|LC28-0126(IV)
2907530|NCT03196804|Placebo Comparator|Placebo|Placebo of LC28-0126
2907531|NCT03196791|Experimental|Deep neuromuscular block group|Sugammadex sodium 4mg/kg/IV after operation
2907532|NCT03196791|Experimental|Moderate neuromuscular group|Sugammadex sodium 2mg/kg/IV after operation
2907533|NCT03196752|Experimental|Only arm|Patient's cricoid membrane is identified using both laryngeal handshake method and simple palpation
2907534|NCT03196739|Experimental|Virtual rehabilitation|Upper limb rehabilitation using virtual reality with a head-mounted display (HTC Vive; HTC Co., New Taipei City, Taiwan)
2907535|NCT03196726|Experimental|Intervention Arm|Participants will be seen by Medical Officer and manage using standard management based on Clinical Practice Guideline for management of postnatal depression. After session with Medical Officer, participants will be seen by Nurse who additionally manage them using brief Cognitive Behavioral Therapy. Participants will be follow-up at weekly basis for 6 weeks.
2907536|NCT03196726|Placebo Comparator|Control arm|Participants will be seen by Medical Officer and manage using standard management based on Clinical Practice Guideline for management of postnatal depression. Participants will be follow-up at weekly basis for 6 weeks.
2907537|NCT03196713|Other|Tailored supervision|
2907538|NCT03196713|Other|Regular supervision|
2907539|NCT03196700|Experimental|Short course radiotherapy|The radiotherapy is delivered over two days with accelerated hypo-fractionation was delivered
2907540|NCT03196674|Active Comparator|manipulated feedback|
2907541|NCT03196674|Active Comparator|non-manipulated feedback|
2907542|NCT03196661|Placebo Comparator|H7N9 split influenza vaccine (15μg/dose)|"This group was divided into three subgroups according ages of subjects, the ages of those subjects are: 3 to 11(36 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines)，12 to 17(36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines)，≥18 (36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
2907543|NCT03196661|Placebo Comparator|H7N9 split influenza vaccine (30μg/dose)|"This group was divided into three subgroups according ages of subjects, the ages of those subjects are: 3 to 11(36 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines)，12 to 17(36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines)，≥18 (36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
2907544|NCT03196661|Placebo Comparator|H7N9 whole virus influenza vaccine (7.5μg/dose)|"This group was divided into two subgroups according ages of subjects, the ages of those subjects are: 12 to 17(54 subjects got inoculated test vaccines,18 subjects got inoculated reference vaccines)，≥18 (54 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
2907545|NCT03196661|Placebo Comparator|H7N9 whole virus influenza vaccine (15μg/dose)|"This group was divided into two subgroups according ages of subjects, the ages of those subjects are: 12 to 17(54 subjects got inoculated test vaccines,18 subjects got inoculated reference vaccines)，≥18 (54 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
2907546|NCT03196648|Experimental|Gingival health formulation in accelerating device|The interventional gingival health formulation is applied to the participant's mouth by means of an intra-oral accelerating device for a single eight-minute application, daily. Participants were instructed to brush their teeth with an OTC toothpaste twice daily, morning and night.
2907547|NCT03196648|Experimental|Gingival health formulation on a toothbrush|The interventional gingival health formulation is applied to the participant's mouth by means of a toothbrush and OTC toothpaste, together with the formulation in equal amounts, for two-minute applications twice daily, morning and night.
2907548|NCT03196648|Active Comparator|Control group (Split mouth design)|The control group did not receive the interventional gingival health formulation. Participants were instructed to brush their teeth with a toothbrush and OTC toothpaste twice daily, morning and night. In addition, participants were instructed to floss only half of their mouth daily, having the non-flossed half serve as an untreated comparative control of toothbrushing alone.
2907549|NCT03196635|Experimental|All Study Participants|All subjects will undergo their regularly scheduled full-field digital mammogram, consisting of bilateral, 2-view (craniocaudal [CC] and mediolateral oblique [MLO]) image acquisition. In addition, a study-specific, unilateral 2-view image set will obtained, utilizing the PA breast compression mode.
2907550|NCT03196622|Experimental|Older people|A cross-sectional multicentre study will be performed in hospital and retirement houses on patients ages 75 years old or more.
2907551|NCT03196609|Experimental|Cohorte|"This cohort will consist of patients as described below:~15 patients with non-small cell lung cancer (NSCLC)~10 patients with hepatocellular cancer:~10 patients with colorectal cancer~10 patients with breast cancer~10 patients with prostate cancer~10 patients with glioblastoma"
2907552|NCT03196596||Computer simulation|Patients in whom a computer simulation model will be obtained based on pre procedural CT
2907553|NCT03196596||Prospective compare group|Patients in whom no computer simulation model will be obtained
2907554|NCT03196583|Experimental|Single-arm study|Velo-Lingual Bite (BVL)
2907614|NCT03196154||Metformin|Patients who are on either metformin 2g per day or metformin extended release 2g per day. Subject will be required to fast overnight. Fasting insulin levels and plasma drug levels will be measured.
2907642|NCT03195959||PH-Patients|Patients with mean pulmonary artery pressure >25mmHg and a pulmonary arterial wedge pressure <15mmHg during right heart catheterisation, which are diagnosed as having pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
2907555|NCT03196570|Experimental|Intervention|After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
2907556|NCT03196570|Active Comparator|Contact Control|Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
2907557|NCT03196557|Experimental|Arm A|Specified dose on specified days
2907558|NCT03196557|Placebo Comparator|Arm B|Specified dose on specified days
2907559|NCT03196544|Experimental|Social Approach Training (5 sessions)|
2907560|NCT03196544|Experimental|Social Approach Training (10 sessions)|
2907561|NCT03196544|No Intervention|Delayed Treatment (Waitlist)|
2907562|NCT03196531|Experimental|Cohort 1: Sequence 1 (ABAB)|Participants will receive 10 milligram (mg) loratadine (1*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
2907563|NCT03196531|Experimental|Cohort 1: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
2907564|NCT03196531|Experimental|Cohort 2: Sequence 1 (ABAB)|Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
2907565|NCT03196531|Experimental|Cohort 2: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
2907566|NCT03196518|Experimental|PET Imaging With 18F-TFB|The intervention is the administration of a single dose of approximately 5-10 mCi 18F-TFB (mass <= 50 μg) for imaging purposes. This will be followed by a 30 minute dynamic PET/CT study immediately after injection, at 60 minutes (+/- 10 min) and 4 hours (+/- 15 min) post injection. The second and third scan will last up to 30 minutes.
2907567|NCT03196505|Active Comparator|Liposomal Bupivacaine|Liposomal bupivacaine (Exparel) 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
2907568|NCT03196505|Active Comparator|Control|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
2907569|NCT03196492||No hormone|Half of the cohort (n=40) will have opted to forgo hormonal contraception (HC).
2907570|NCT03196492||Depo-provera|Half of the cohort (n=40) will have opted to initiate injectable depo-provera (DMPA).
2907571|NCT03196479|Active Comparator|ketamine:propofol ratio of 1:6|K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
2907572|NCT03196479|Active Comparator|ketamine:propofol ratio of 1:4|K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
2907573|NCT03196466||antiepileptics titration|Titration of valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol and clobazam
2907574|NCT03196453|Active Comparator|Probiotic|Lactobacillus rhamnosus GG
2907575|NCT03196453|Active Comparator|Probiotic and protein|Lactobacillus rhamnosus GG and whey protein isolate
2907576|NCT03196453|Placebo Comparator|Placebo|Placebo
2907577|NCT03196427|Experimental|Vedolizumab High Dose Group|Participants with UC or CD having baseline weight of greater than or equal to (>=) 30 kilogram (kg) will receive Vedolizumab 300 milligram (mg) and participants with UC or CD having baseline weight of less than (<) 30 kg will receive Vedolizumab 200 mg, intravenous infusion, every 8 weeks for up to 5 years.
2907578|NCT03196427|Experimental|Vedolizumab Low Dose Group|Participants with UC or CD having baseline weight of >= 30 kg will receive Vedolizumab 150 mg and participants with UC or CD having baseline weight of < 30 kg will receive Vedolizumab 100 mg intravenous infusion, every 8 weeks for up to 5 years.
2907579|NCT03196414|Experimental|CART-138/BCMA|
2907580|NCT03196401|Experimental|Durvalumab Plus Radiation Therapy|Durvalumab (1500mg administered intravenously every 28 days), concurrently with definitive radiation therapy to the solitary bone plasmacytoma to start within 14 days of the first dose of durvalumab.
2907615|NCT03196154||Metformin + Gliclazide|Patient who are on both metformin 2g per day or metformin extended release 2g per day and gliclazide 320mg per day or gliclazide modified release 120mg per day. Subject will be required to fast overnight. Fasting insulin levels and plasma drug levels will be measured.
2907581|NCT03196388|Experimental|Enzalutamide with External|On this study patients will be treated with 6 months of Xtandi (enzalutamide). Approximately one-third of the way through this treatment they will receive EBRT. Starting on Day 1, all patients will ingestenzalutamide 160 mg/day at the same time each day without breaks (except as outlined for toxicity), with or without food, for 6 (28 day +/-3 days) cycles. Dose reduction of enzalutamide to 120 mg/day is allowed with the approval of the Medical Monitor. Patients will be instructed to return all unused capsules at each study visit to assess compliance and will receive study drug every 28 days (+/-3 days) for 6 cycles (25 weeks).
2907582|NCT03196375|Experimental|Experimental|
2907583|NCT03196375|Placebo Comparator|Placebo Comparator|
2907584|NCT03196362|Active Comparator|PIO/MET|one fixed dose pioglitazone/metformin (15mg/500mg) tablet will be orally administrated twice daily
2907585|NCT03196362|Placebo Comparator|placebo|one tablet of placebo will be given twice daily
2907586|NCT03196349|Active Comparator|Warfarin|Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
2907587|NCT03196349|Active Comparator|Apixaban|Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
2907588|NCT03196349|Active Comparator|Rivaroxaban|Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 20mg daily
2907589|NCT03196336|Other|Intervention|The intervention is the pharmacotherapeutic follow-up care. This service is performed according to the Pharmacotherapy Workup method, which is a protocol for the pharmacotherapeutic follow-up. This service identify, prevent and solve drug-related problems. It consiste of five pharmaceutical consultations (every up to 2-3 months) with the patient.
2907590|NCT03196336|Other|Control|The intervention is the usual procedure of dispensation of drugs. It is performed in five meetings (every up to 2-3 months) between the investigator and the patient.
2907591|NCT03196323||Initial Cohort|"In Aim 1, the investigators will evaluate psychometrically RettBe 1.0 following, in part, previous studies including our examination of anxiety instruments and adaptation of the Anxiety, Depression and Mood Scale (ADAMS) for RTT, and their adaptations of the Aberrant Behavior Checklist-Community (ABC-C) for fragile X syndrome and Down syndrome. In Aim 1, the investigators will also refine RettBe 1.0 by adding new missing items based on parental input or clinician (PIs of sites involved) feedback. The resulting instrument, RettBe 2.0 will be tested in Aim 2."
2907592|NCT03196323||Validation Cohort|Testing of RettBe 2.0 will be carried out with a new (naïve) validation cohort of 300 subjects and two raters (preferentially both parents/caregivers, alternatively one teacher or therapist), to determine inter-rater reliability. One rater, preferentially a parent, will be asked to also complete three other behavioral measures (RSBQ, ADAMS, ABC-C) for comparisons. Scores for RettBe 2.0 will be analyzed in terms of psychometric properties, as performed for RettBe 1.0. However, in addition to structure (construct validity) and content validity, the investigators will also examine convergent and discriminant validity by correlating domain RettBe 2.0 scores with those of comparable and non-comparable domain scores of the RSBQ, ADAMS, and ABC-C, respectively.
2907593|NCT03196310|Experimental|PRP|Intra-articular injection of platelet rich plasma.
2907594|NCT03196310|Active Comparator|Corticosteroid|Intra-articular injection of kenalog.
2907595|NCT03196310|Placebo Comparator|Normal Saline|Intra-articular injection of normal saline
2907596|NCT03196297|Experimental|Concizumab|Daily administration of concizumab to both on-demand and prophylaxis patients
2907597|NCT03196284|Experimental|Concizumab|Concizumab administered in both the main phase and extension phase, with eptacog alfa administered on-demand during bleeding episodes
2907598|NCT03196284|Active Comparator|Eptacog alfa and concizumab|Eptacog alfa administered on-demand during bleeding episodes as the only intervention during the main phase. Concizumab given in the extension phase
2907599|NCT03196271|Other|Study arm|One single arm, consisting of a 3 day baseline period, a 28 day control period and a 28 day intervention period (Ketocal 2.5:1), in that order.
2907600|NCT03196258|Experimental|intervention - CBT|Participants in this arm will receive 6 weekly one-on-one, 1-hour sessions of Cognitive Behavioural Therapy session (intervention) in addition to receiving standard of care treatment for their fracture(s).
2907601|NCT03196258|No Intervention|control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
2907602|NCT03196245||Pregnant women|Pregnant women undergoing influenza vaccination or acutely infected with influenza
2907603|NCT03196232|Experimental|Treatment (epacadostat, pembrolizumab)|Patients receive epacadostat PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
2907604|NCT03196219|Other|Arm 1|Eight subjects will be enrolled in an open-label manner and will receive a daily dose of C16G2 Varnish application over 3 days followed by 14 doses of C16G2 Strip administered over 7 days. Following the three C16G2 Varnish applications, each subject will receive 7 days of AM and PM dosing with C16G2 Strip.
2907605|NCT03196219|Placebo Comparator|Arm 2|Twelve subjects will be enrolled in a single-blind manner. Subjects will receive four C16G2 Varnish or Placebo applications over 7 days (Days 0, 2, 5 & 7), followed by 3 additional weekly varnish administrations. The treatment allocation will be 1:1 (6 subjects C16G2 Varnish, 6 subjects Placebo).
2907606|NCT03196219|Other|Arm 3|If initiated, Study Arm 3 will enroll 6 subjects in an open-label manner. Subjects will receive daily single doses of C16G2 Varnish over 10 days, for a total of 10 doses.
2907607|NCT03196206|Experimental|Group A|Normal Renal Function
2907608|NCT03196206|Experimental|Group B|Moderate Renal Impairment
2907609|NCT03196206|Experimental|Group C|Severe Renal Impairment
2907610|NCT03196193|Experimental|ZNN CM Asia with AS2 technique|"Open Reduction and Internal Fixation with AS2 Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail.~Bone fragment will be stabilized by additional screw fixation (Anterior Support Screw)."
2907611|NCT03196193|Active Comparator|ZNN CM Asia without AS2 technique|Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail without additional screw fixation.
2907612|NCT03196167|Experimental|Sugammadex|Research pharmacy will provide the Sugammadex (2m/kg) vs. Placebo in a syringe.
2907613|NCT03196167|Placebo Comparator|Placebo|Research pharmacy will provide the Sugammadex (2m/kg) vs. Placebo in a syringe.
2907616|NCT03196141|Active Comparator|Healthy volunteers|"Part#1: 15 healthy volunteers; 2 assessment sessions. Session 1: StO2 vs. EndoPAT Method comparison analysis; both StO2 and EndoPAT will be applied simultaneously & pulse oximeter probes placed bilaterally on fingers. Baseline readings will be taken for 5 minutes. The blood pressure cuff will be inflated to suprasystolic pressure and StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.~Session 2: This session will occur within 1 week of session 1. This session is to determine the consistency of the response.~All probes will be applied as in session 1 and cycles of 10 minutes for 3 sessions will be done. All the measurements in session 1 will be captured in session 2.~This will determine inter-day variability. (total time is 53 min)."
2907617|NCT03196141|Active Comparator|Pregnant women with normal BP|"Part #2: 20 participants, 10 normotensive and 10 pre-eclamptic pregnant women during their visit to labor floor.~Session 1: Both StO2 and EndoPAT will be applied simultaneously to the same arm below a BP cuff. Baseline readings will be taken for 5 minutes, the blood pressure cuff will be inflated to suprasystolic pressure StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.~Additionally, vascular stiffness with be measured by SphygmoCor to measure pulse wave velocity (PWV).~Participants must also agree to participate OB/GYN biobanking protocol HIC# 1601017004 to be in this study.~All participants will have follow-up at 48 hours, including a blood draw, assessment of endothelial function and vascular stiffness."
2907618|NCT03196141|Active Comparator|Pregnant women with high BP|"Part #2: 20 participants, 10 normotensive and 10 pre-eclamptic pregnant women during their visit to labor floor.~Session 1: Both StO2 and EndoPAT will be applied simultaneously to the same arm below a BP cuff. Baseline readings will be taken for 5 minutes, the blood pressure cuff will be inflated to suprasystolic pressure StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.~Additionally, vascular stiffness with be measured by SphygmoCor to measure pulse wave velocity (PWV).~Participants must also agree to participate OB/GYN biobanking protocol HIC# 1601017004 to be in this study.~All participants will have follow-up at 48 hours, including a blood draw, assessment of endothelial function and vascular stiffness.~Participants with hypertension will be followed in conjunction with routine clinical follow-up at 2, 6 and 12 weeks post-partum."
2907619|NCT03196128|Active Comparator|Digital|
2907620|NCT03196128|Active Comparator|Non Digital|
2907621|NCT03196115||Observation|Patients at 2 months with Hyaline fibromatosis syndrome or high-grade suspicion for Hyaline fibromatosis syndrome
2907622|NCT03196102|Experimental|BTI + Cigarette smoking military tailored pamphlet|
2907623|NCT03196102|Active Comparator|Cigarette smoking military tailored pamphlet|
2907624|NCT03196102|Active Comparator|Standard smoking cessation pamphlet|
2907625|NCT03196089|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
2907626|NCT03196089|Sham Comparator|Sham room air|Room air will be applied similarly to oxygen
2907627|NCT03196076|Experimental|Perflutren Lipid Microsphere (Healthy subjects)|Healthy subjects will be imaged using contrast-enhanced ultrasound (perflutren) for image optimization prior to enrolling clinical patients.
2907628|NCT03196076|Experimental|Perflutren Lipid Microsphere (patients with kidney lesions)|Patients with kidney lesions will be imaged using contrast-enhanced ultrasound with perflutren.
2907629|NCT03196076|No Intervention|Controls: No interaction|Patients with kidney lesions will be included as control subjects. These patients will be followed, but will not receive any study intervention.
2907630|NCT03196063|Active Comparator|Eccentric|"Patients allocated in this group will perform three sets of 15 unipodal squats with the affected limb on an inclined plane. The patient will be instructed to perform only the eccentric phase of the exercise, keeping the torso erect and flexing the knee up to 90 degrees. The return to the initial position will be performed with the unaffected leg. To increase exercise load, the patient will carry a bag with washers. This protocol will last eight weeks, with 24 face-to-face sessions.~Both groups will also receive a protocol with complementary isotonic exercises, focusing on the strengthening of gluteus maximus, gluteus medius, hamstrings and calves."
2907631|NCT03196063|Experimental|Modified protocol|"Patients allocated in this group will receive treatment based on a protocol published in a clinical practice guide, with modifications to make the protocol more pragmatic. Thus, the use of mechanotherapy devices will be replaced by free weight exercises, so that the protocol can be performed in environments that do not offer this type of machinery. This protocol is composed of four exercise stages, being the first three stages performed in the presence of the physiotherapist, and will last eight weeks with approximately 24 face-to-face sessions.~Both groups will receive a protocol with complementary isotonic exercises, focusing on the strengthening of gluteus maximus, gluteus medius, hamstrings and calves."
2907632|NCT03196050|Experimental|Telemonitoring using a handheld device|Patients will be euqipped with either an app or a handheld device with a pre-installed app to communicate with the coordinating center.
2907633|NCT03196037|Experimental|Tai Chi|The Tai Chi intervention will be lead by an expert Tai Chi instructor with 15 years of teaching experience, and will take place at a local Yoga studio. The 8-week intervention entails two 75-minute sessions per week for a total of 16 sessions. Each session will begin with a 15- minute warm-up followed by 25 minutes of performing basic stances, footwork, upper-body/arm/hand movement, proper body alignment, mental/visual focus, and balance; 30 minutes of instruction in a choreographed form (first section of the Yang style long-form); and ending with a 5-minute cool-down.
2907634|NCT03196024|Experimental|Family-focused intervention arm|Family-focused intervention arm: Educational sessions will be provided to family pairs that include participants who are at-risk for type 2 diabetes or CVD and their co-participating family member.
2907635|NCT03196024|Active Comparator|Individual-focused intervention arm|Individual-focused intervention arm: Educational sessions will be provided to the individual members of the family pairs who are at-risk for type 2 diabetes or CVD.
2907636|NCT03196011|Active Comparator|TKR with mechanical alignment|TKR implanted using traditional alignment methods
2907637|NCT03196011|Experimental|TKR using alternative alignment method|TKR implanted using alternative alignment methods
2907638|NCT03195998||Group A|Gestational Age 23 0/7 - 28 6/7 weeks
2907639|NCT03195998||Group B|Gestational Age 29 0/7 weeks - 34 6/7 weeks
2907640|NCT03195985|Experimental|Mindfulness-based Intervention|Mindfulness intervention of 4 weeks
2907643|NCT03195959||Control group|Patients with clinically indicated right heart catheterisation (because of dyspnea or other signs of PH), but had no PH (no elevated mean pulmonary artery pressure (mPAP <20mmHg)).
2907644|NCT03195946|Experimental|Lu AF35700 and Cocktail of CYP450 substrates|Day 1 oral midazolam administration, Day 2 Cocktail of CYP450 substrates administration. Daily Lu AF35700 administration from Day 5 to Day 28 with co-administration on Day 27 with oral midazolam and Day 28 with CYP450 substrate cocktail
2907645|NCT03195933|Experimental|Cortisol first, Placebo second|Single oral administration of 20 mg cortisol capsule to pharmacologically elevate cortisol levels during first functional magnetic resonance imaging (fMRI) session; Identically appearing placebo capsule during second fMRI session.
2907646|NCT03195933|Experimental|Placebo first, Cortisol second|Placebo capsule during first fMRI session; Single oral administration of 20 mg cortisol capsule to pharmacologically elevate cortisol levels during second fMRI session.
2907647|NCT03195920|Experimental|Enhanced Lithotripsy System|Treatment for urinary stones with the Enhanced Lithotripsy System
2907648|NCT03195907||PPT group|Those participated in pulmonary rehabilitation program
2907649|NCT03195907||Control group|Those served as control group
2907650|NCT03195894|Experimental|Conventional treatment and TripleA|Conventional treatment and TripleA medical device consisting of alcoholometer, a Bluetooth mobile app on cell phone and information stored on computer for caregiver
2907651|NCT03195894|No Intervention|Conventional treatment|Conventional treatment
2907652|NCT03195868|Experimental|Photobiomodulation|All patients will be treated similarly in this study
2907653|NCT03195855|Experimental|Ankle and big toe mobilisations combined with home stretches|"Intervention group (n=29):~This group will undertake talocural and 1st MTP joint mobilisations (x1/week for 6 weeks) and a 6 week home programme of stretching exercises.~Mobilisations: In our study, a traction intervention consisting of two, 2-min sets of Maitland grade II joint traction will precede 2-min sets of Maitland grade III mobilisations with one minute rest in between sets. Four sets will be performed for the ankle and two for the MTP. This protocol has been used previously (19, 43). The direction of mobilisation force will be parallel to the treatment plane and perpendicular to the treatment plane during traction (75).~Home Program: There will be 3 stretches prescribed (gastrocnemius, soleus and plantar fascia). Participants will be recommended to undertake three consecutive static stretches for 20-30s with a 1 minute rest period (76). Stretches will occur in standing."
2907654|NCT03195855|No Intervention|Control group of usual care including podiatry|"Control group (n=29):~Usual care including regular monitoring of foot health by podiatrists as indicated by NICE (NG19) guidelines (78). A review of current clinical practice within the podiatry clinic indicates that people with moderate/intermediate risk are reviewed every 3 months. Interventions include nail care, callus debridement and foot care advice.~In both groups, interventions delivered by podiatrists in the study period will be determined from the clinic notes."
2907655|NCT03195842|No Intervention|Usual discharge care|Standard discharge instructions, meaning conversation with physician, usually via interpreter, along with written instructions compiled by the nurse. Written instructions include pre-translated handouts for common languages, and untranslated (English) patient-specific instructions.
2907656|NCT03195842|Experimental|Recordable card|Usual care, as above, plus patient-specific and standard instructions recorded in the patient's preferred language for care and given to them on a card to take home.
2907657|NCT03195829|Experimental|Computerized cognitive stimulation|Computerized Cognitive Stimulation was administered to intervention group (IG).
2907658|NCT03195829|Active Comparator|Multimedia-based internet activities|Multimedia-based internet activities was administered to active control group (ACG).
2907659|NCT03195816|Experimental|computerized Cognitive training|Experimental group will receive 1 year of a computer-based cognitive stimulation program.
2907660|NCT03195816|No Intervention|MCI control group|The control group will receive a usual standard care without engagement in intervention
2907661|NCT03195803|Experimental|MCI with WMH|Computerized Cognitive Stimulation was administered to this group, twice a week.
2907662|NCT03195803|Active Comparator|MCI without WMH|Computerized Cognitive Stimulation was administered to this group, twice a week.
2907663|NCT03195790|Active Comparator|Medical center treatment arm|Family-based pediatric obesity treatment delivered at an urban medical center.
2907664|NCT03195790|Experimental|Home treatment arm|Family-based pediatric obesity treatment delivered in the family's home.
2907665|NCT03195777|Experimental|Single Arm: Observation after Imaging|This is a single-arm study, where subjects will be monitored for development of PTS after baseline non-invasive imaging with FDG PET/CT. The experimental interventIon is the PET/CT imaging.
2907666|NCT03195764|Experimental|T-1101 (Tosylate)|
2907667|NCT03195751||Manual Goniometer measurements|Measurements of shoulder range of motion using manual goniometer
2907668|NCT03195751||Software development kit measurements|Measurements of shoulder range of motion using a proprietary SDK
2907669|NCT03195738|Experimental|Intervention arm|"The Cognitive Orientation to Occupational Performance (CO-OP) Approach will be delivered over 10 30-60 minute sessions over a seven week period as follows: 2 sessions/week for 3 weeks, then 1 session per week for 4 weeks. In the CO-OP intervention participants are first assisted to identify 3-5 occupation based goals which will be the focus of the intervention sessions. Over the course of the 10 intervention sessions, participants are guided to learn and practice problem solving using a metacognitive strategy, Goal-Plan-Do-Check applied to their self-identified goals. Study therapists use 'guided discovery' an iterative technique to facilitate problem solving by the participant to develop plans to work toward their goals and to evaluate their progress. Intervention takes place in the location that is most meaningful for the participant's selected goal (e.g. home, school, playground etc.). Participants are provided with a work book to track progress."
2907670|NCT03195725||Year 2013|Participant's notes will be reviewed from the year 2013
2907671|NCT03195725||Year 2015|Participant's notes will be reviewed from the year 2015
2907672|NCT03195712||Patients with Class II and III Obesity|Patients enrolled in an outpatient weight loss program from 2010-2016.
2907673|NCT03195699|Experimental|Dose escalation study|Oral administration of TTI-101 for up to 6 28-day cycles
2907674|NCT03195673|Experimental|TZ group|"Treatment:Patients in this group received standard medical therapy and Terazosin (TZ) treatment.~Drug: TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 12 months later.~Procedure: Carotid Artery Stenting"
2907675|NCT03195673|Other|control group|Treatment: Patients in this group received standard medical therapy alone. Procedure: Carotid Artery Stenting
2907676|NCT03195660|Experimental|ASV Therapy|ASV Therapy
2907677|NCT03195647|Experimental|Relaxed control|Those randomised to the 'Relaxed' Group will receive potassium supplementation only if their serum potassium drops below or equals 3.6 mEq/L.
2907678|NCT03195647|Active Comparator|Tight Control|Patients randomised to the 'Tight' group will receive potassium supplementation if their serum potassium falls below 4.5 mEq/L (current practice).
2907679|NCT03195634||HVPG group|"When HVPG > 12 mmHg, patients would be treated with carvedilol at an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate >55 beats per minute, or up to 12.5 mg/day.~After about 8 weeks, the patients treated with carvedilol will received the second HVPG monitoring wether achieved a decrease in HVPG below 12 mm Hg or>20% from baseline."
2907680|NCT03195621|Experimental|Interventional therapy group|
2907681|NCT03195621|No Intervention|Conservative treatment group|
2907682|NCT03195608|Experimental|Intervention|Participants will complete a standardized battery of paper and pencil and computer tests. Following these tests, participants will complete a baseline simulator driving assessment without any form of assistive technology. We will employ a CDS-200 driving simulator (DriveSafety Inc., Salt Lake City, UT). A trained blinded evaluator will observe the recorded drive and score the drive. After the baseline assessment, participants will engage in 3 intervention sessions (lasting 30 minutes each). During these sessions, the lane change assistance system will be introduced and participants will be taught how to use it. After the 3 sessions, participants will participate in a post-test, similar to the baseline assessment but with a different route within the simulated world. They will drive this new route with the assistive technology. One to two weeks after the post-test, participants will be invited to participate in a follow-up assessment (battery of tests and simulator assessment).
2907683|NCT03195595||mitral valve replacement|patients whom underwent Mitral valve replacement through minimal invasive incision
2907684|NCT03195595||conventional mitral valve replacement|patients whom underwent Mitral valve replacement through conventional sternotomy
2907685|NCT03195582|Experimental|Test group|"following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant .In the test group, Corsodyl gel 1% Chlorohexidine will be applied on the implant and the healing abutment. Healing abutment of 4 mm height will be screwed to the implant and flap will be sutured with silk 4-0 sutures.~Parallel radiograph will be taken after the surgery"
2907686|NCT03195582|No Intervention|CONTROL group|"following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant .In the control group, Corsodyl gel 1% Chlorohexidine will not be applied on the implant and the healing abutment). Healing abutment of 4 mm height will be screwed to the implant and flap will be sutured with silk 4-0 sutures.~Parallel radiograph will be taken after the surgery"
2907687|NCT03195569||Experimental group|QL1101 + paclitaxel/carboplatin:subjects are given 15 mg/kg QL1101 on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles.
2907688|NCT03195569||Control group|Avastin® + paclitaxel/carboplatin:subjects are given 15 mg/kg Avastin® on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles.
2907689|NCT03195556|Experimental|Healthy subjects|Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
2907690|NCT03195556|Experimental|Peripheral Artery Disease|Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
2907691|NCT03195543||Patients with PAH|Diagnostic tests will be performed on patients with Pulmonary Artery Hypertension in order to assess any blood coagulation disorders. Platelet function, coagulation and fibrinolysis will be evaluated by platelet function analyzer-100 (PFA-100), light transmission aggregometry, rotational thromboelastometry (ROTEM) and endogenous thrombin potential.
2907692|NCT03195543||Patients with CTEPH|Diagnostic tests will be performed on patients with Chronic Thromboembolic Pulmonary Hypertension in order to assess any blood coagulation disorders. Platelet function, coagulation and fibrinolysis will be evaluated by platelet function analyzer-100 (PFA-100), light transmission aggregometry, rotational thromboelastometry (ROTEM) and endogenous thrombin potential.
2907693|NCT03195530||Elderly patients|Patients over 65 years, scheduled to general surgery, requiring general anesthesia
2907694|NCT03195517|Experimental|Physical Exercise|"The exercise program was performed at C.U.R.I.A.Mo. Healthy Lifestyle Institute of Perugia University.~The program provided 24 exercise sessions supervised by 2 physical education instructors and 2 medical researchers with a maximum attendance of 5 patient/group and carried out twice a week for three months.~Each session lasted approximately 45 minutes divided into 15 minutes of cardiovascular activity performed using various ergometers and 30 minutes of weight-bearing endurance activities, resistance training and other exercise to develop balance and prevent falls, organized according to circuit training methodology.~The great part of the exercise included in the program aim to provide variably strains (compression, bending, twisting) distributed across an higher surface of the femoral neck, to produce a maximal osteogenic response in bone."
2907695|NCT03195517|No Intervention|No additional physical exercise|Usual care and no additional physical exercise
2907696|NCT03195504|Experimental|HFNC (High Flow Nasal Cannulae)|High Flow Nasal Cannulae providing humidified, high-flow oxygen during induction of anesthesia
2907697|NCT03195504|Active Comparator|CON (control)|Standard flow oxygen during induction of anesthesia
2907698|NCT03195491|Experimental|Monotherapy|Nivolumab administered every two weeks
2907699|NCT03195478|Experimental|Nivo/Ipi Combination Therapy A|Specified Dose of Nivolumab and Ipilimumab on specified days
2907700|NCT03195478|Experimental|Nivo/Ipi Combination Therapy B|Specified Dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days
2907701|NCT03195478|Experimental|Nivo/Ipi Combination Therapy C|Specified Dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days
2907847|NCT03194555|Experimental|ALLOD-2 capsules|Component A and Component B
2907702|NCT03195465|Experimental|Cacao group|1 group of subjects will all receive the high antioxidant cacao bars. 4 squares of the dark chocolate will be administered twice daily between the hours of 6 a.m. and 6 p.m.
2907703|NCT03195452|Experimental|Raltegravir|antiretroviral tritherapy: Raltegravir 600 mg tablet orally (2 tablets QD) and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)
2907704|NCT03195439|Experimental|patients in ICU|
2907705|NCT03195426|Experimental|distal nerves blocks group|"This study aims at assessing the effectiveness of combined supra scapular nerve block, infraclavicular block and supraclavicular nerve block as surgical anesthesia for patients scheduled for arthroscopic shoulder surgery.~These blocks are performed for decades in routine care. The originality of this study is to analyze the combination of these different blocks for post-operative pain relief in arthroscopic shoulder surgery. This combination can be considered as an alternative to interscalene block well known to be associated with diaphragmatic paralysis.~Local anesthetics used in this study are used for many years in routine care: Ropivacaine 0.375%. A single injection will be performed under ultrasounds. No continuous injection will be performed."
2907706|NCT03195413|Experimental|Nerve Block Arm|This group of patients will receive an ultrasound-guided forearm block intervention by the study team. The nerve block will be achieved with a solution of 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine (mixed in a 1:1 volume ratio) dosed once. A second dose will be given only in the case of complete block failure.
2907707|NCT03195413|No Intervention|Control Arm|This group will receive the standard of care in our emergency department, as determined by their primary team. If a patient here receives a nerve block from the primary team, they will be handled with intention-to-treat analysis.
2907708|NCT03195400||CC Genotype|Subjects who have not already been tested previously will be tested for the TCF7L2 genotype to determine if they are TT or CC. An anticipated 50 obese CC adolescents with IGT or pre-IGT with similar age, pubertal stage, ethnicity and Body Mass Index (BMI) will enrolled. Subjects will undergo Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test IsoG IVGT and Hyperinsulinemic Euglycemic Clamp and 2H20.
2907709|NCT03195400||TT Genotype|Subjects who have not already been tested previously will be tested for the TCF7L2 genotype to determine if they are TT or CC. An anticipated 50 TT subjects will be enrolled in this group. An anticipated 50 obese TT adolescents with IGT or pre-IGT with similar age, pubertal stage, ethnicity and Body Mass Index (BMI) will be enrolled. Subjects will undergo Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test IsoG IVGT and Hyperinsulinemic Euglycemic Clamp and 2H20
2907710|NCT03195387|Experimental|D-1/120 mg MMV390048|Treatment of cohort 1: subjects receive a single oral dose of MMV390048 on Day -1, prior to PfSPZ challenge on Day 0.
2907711|NCT03195387|Experimental|D-7/120 mg MMV390048|Treatment of cohort 2: subjects receive a single oral dose of MMV390048 on Day -7, prior to PfSPZ challenge on Day 0.
2907712|NCT03195387|Experimental|D-X/YY mg MMV390048|Treatment of cohort 3: subjects receive a single oral dose of MMV390048 (dose to be determined) on a day (to be determined) prior to PfSPZ challenge on Day 0. Dosage and day of administration will be determined on the basis of data emerging from the first two cohorts.
2907713|NCT03195387|Placebo Comparator|Placebo|MMV390048 placebo
2907714|NCT03195374||Patients with chronic non-cancer pain|Each addictovigilance centre will contact Pain Clinics in order to enroll patients meeting the inclusion criteria.
2907715|NCT03195361|Experimental|Single-arm|Subjects suffering from anterior POP-Q grade 2 (point Aa and Ba≥ -1) and above, who are scheduled for POP surgery, will be transplanted with the SRS device
2907716|NCT03195348|Experimental|HBF Bed Rest|7 days control period followed by a washout period, then 7 days of HBF.
2907717|NCT03195335||Children with cerebral palsy|Children who diagnosed as cerebral palsy by a pediatric neurologist
2907718|NCT03195322|Experimental|Pre-pectoral Tissue Expander|Pre-pectoral immediate tissue expander breast reconstruction with complete AlloDerm® coverage to reinforce breast tissues.
2907719|NCT03195309|Active Comparator|Group A|Group A patients received 0.08% ropivacaine plus 4 mcg /mL fentanyl
2907720|NCT03195309|Active Comparator|Group B|Group B patients received 0.08% ropivacaine plus 2mcg /mL fentanyl
2907721|NCT03195309|Active Comparator|Group C|Group C patients received 0.16 % ropivacaine plus 2 mcg /mL fentanyl
2907722|NCT03195296||Graves' Orbitopathy|Patients with Graves' Orbitopathy subjected to orbital decompression
2907723|NCT03195283||Traditional meal service|TMS consists of three meals served by nutritional assistants throughout the day. Preference for dinner can be indicated in the morning by the individual patient from a menu list with predefined choices for meat, potatoes/rice/pasta and vegetables with various portion sizes.
2907724|NCT03195283||FoodforCare|FfC consists of a 6-meals per day service. At bedside, patients are offered one or more small protein-rich dishes from a choice of 3. Nutritional assistants play a key role in recommending and delivering these protein-rich meals and assist patient in choosing the most optimal dish, based on the patient's nutrition order in the electronic patient record.
2907725|NCT03195270|Experimental|Single Arm|[18F]FDG PET/MRI
2907726|NCT03195257|Placebo Comparator|Hypoglycemia-saline|
2907727|NCT03195257|Experimental|Hypoglycemia-GIP|
2907728|NCT03195257|Active Comparator|Hypoglycemia-GLP-1|
2907729|NCT03195257|Experimental|Hyperglycemia-GIP|
2907730|NCT03195257|Placebo Comparator|Hyperglycemia-Saline|
2907731|NCT03195244|No Intervention|Observation|
2907732|NCT03195244|Active Comparator|One-on-one Aquatic Therapy|
2907733|NCT03195244|Experimental|Group Aquatic Therapy|
2907734|NCT03195231|Experimental|Wuling Powder Group|Take Wuling Powder 3 times a day，3 pills each time for 12 weeks
2907735|NCT03195231|Placebo Comparator|Placebo Group|Take placebo drug which cannot be distinguished from the experimental drug 3 times a day，3 pills each time for 12 weeks
2907736|NCT03195218|Experimental|HRME examination|HRME will capture images from all areas considered abnormal by VIA (visual inspection with acetic acid) and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
2907737|NCT03195205|Other|High-Risk Patients|OraQuick HCV screening for HCV-Infected Individuals on Opioid Substitution Therapy and High-Risk Populations
2907774|NCT03194958|Experimental|Specialized Quitline with Basic Needs Navigator|Participants receive enhanced quitline services with navigator
2907738|NCT03195192|Other|Single arm|This is a biomarker study analyzing tissue for baseline biomarkers and collecting tissue at progression for further analysis of biomarkers changes after treatment with CDK 4/6 inhibitors and endocrine therapy
2907739|NCT03195179||Suprapubic tube placement|Men with complete urethral injuries where a Foley catheter fails to be placed will have a suprapubic tube placed to manage the acute urethral injury.
2907740|NCT03195179||Urethral realignment|Men with complete urethral injuries where a Foley catheter fails to be placed will undergo urethral realignment with a combined antegrade / retrograde approach within 7 days of injury.
2907741|NCT03195166|Experimental|hemodynamic profile|FloTrac sensor/Vigileo
2907742|NCT03195153|Experimental|statin only|30 DAYS OF STATIN THERAPY ATORVASTATIN 80 MG)
2907743|NCT03195153|Experimental|allopurinol only|30 DAYS OF ALLOPURINOL (300 MG)
2907744|NCT03195153|Experimental|statin and allopurinol|30 DAYS OF CO-ADMINISTRATION OF ATORVASTATIN AND ALLOPURINOL
2907745|NCT03195140|Experimental|Intervention Arm|"The intervention arm (use of PLGS feature) will utilize Tandem Diabetes Care's ambulatory insulin infusion pump with integrated Dexcom G5 CGM and predictive low glucose suspend function. This pump is called the t:slim X2 with Basal-IQ Technology and is referred to in the protocol as the Tandem PLGS pump."
2907746|NCT03195140|No Intervention|Control Arm|The control arm (SAP only) will utilize an identical pump in functionality as the Tandem PLGS pump except for the lack of the PLGS feature and the associated user interface. This pump is called the t:slim X2 Dexcom G5 Mobile CGM Enabled pump, and is referred to in the protocol as the Tandem SAP pump.
2907747|NCT03195127|Experimental|multimodal physical therapy|Multimodal physical therapy sessions three times a week, for four weeks, lasting one hour. Consist of limb strengthening exercises, endurance training, and balance/coordination drills.
2907748|NCT03195127|No Intervention|Usual care|Subjects will receive the standard therapy program provided by University Specialty Hospital therapy services. To compliment the physical therapy regimen, an optimized nutritional program will be administered according accepted guidelines.
2907749|NCT03195114||Multimodality Imaging and Biomarkers|Post-TAVR patients who received commercial Medtronic Evolut-R or Evolut PRO bioprosthesis implant and found to have at least mild PVL on 1-month post-TAVR echocardiogram will undergo multimodality imaging and biomarkers evaluation at 1-month and 7-months post-TAVR.
2907750|NCT03195101|Experimental|patients with orbital tumors|patients with orbital tumors will be managed by excisional or incisional biopsy via the transconjunctival orbitotomy approach
2907751|NCT03195088|Experimental|Active Treatment|Single rising doses of BI drug
2907752|NCT03195088|Placebo Comparator|Placebo|Matching volumes of drug-free solution
2907753|NCT03195075|Active Comparator|Group 1|20 Patients with malignant biliary obstruction after failed endoscopic retrograde cholangio-pancreaticography will be subjected to endoscopic ultrasonography guided biliary drainage
2907754|NCT03195075|Active Comparator|Group 2|20 Patients with malignant biliary obstruction after failed endoscopic retrograde cholangio-pancreaticography will be subjected to percutaneous trans-hepatic biliary drainage.
2907755|NCT03195062|Experimental|Test meal|The subjects will receive a liquid test meal containing glucose and fructose with 13C fructose.
2907756|NCT03195049|Experimental|blood group|blood is collected for maternal and infant blood group,complete blood count,before, during and after the procedure of exchange transfusion .
2907757|NCT03195049|Experimental|serum bilirubin estimation|estimation of serum bilirubin before, during and after the procedure of exchange transfusion .
2907758|NCT03195036|No Intervention|Control|The control group of women/children dyads who consent and are patients at the control clinics will only have exposure to the facility- and community-based ECD programming.
2907759|NCT03195036|Experimental|Intervention Arm|The intervention group of women/children dyads who consent and are patients at the intervention clinics will receive regular home-based ECD services focused on positive parenting and early stimulation as well as exposure to facility- and community-based ECD programming.
2907760|NCT03195023|Active Comparator|RAS Blockers|Patients in this arm will receive Lisinopril 20mg/day
2907761|NCT03195023|Active Comparator|Non RAS Blockers|Patients in this arm will receive Amlodipine 10mg/day or Lercanidipine 20mg/day +/- diuretics
2907762|NCT03195010|Experimental|Group I (lower dose platelet transfusion)|Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to > 50 x 10^9 for 3 consecutive days in the absence of transfusions.
2907763|NCT03195010|Experimental|Group II (higher dose platelet transfusion)|Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to > 50 x 10^9 for 3 consecutive days in the absence of transfusions.
2907764|NCT03194997|Experimental|Dance|The group randomized to Dance intervention will receive a 3-week intervention with belly dance classes. The classes will be divided in: Warm up and stretching (10 minutes), Main part with belly dance steps and movements (40 minutes) and relaxation (10 minutes).
2907765|NCT03194997|Experimental|Pilates|The group randomized to Pilates intervention will receive a 3-week intervention with Pilates Methods. The classes will be divided in: Warm up and stretching (10 minutes), Main part with Pilates exercises (40 minutes) and relaxation (10 minutes).
2907766|NCT03194997|No Intervention|Control|The group randomized to Control group will be invited to maintain routine activities and be contacted by phone every two months and will receive an explanatory booklet on the benefits of physical activity after diagnosis of breast cancer as well as instructions on lymphedema prevention. The women in this group will not receive a dance or pilates intervention.
2907767|NCT03194984|Other|Young Patient|With 18-25 years old. Drug: Hydrogen peroxide 35%. Drug: Hydrogen peroxide 38%
2907768|NCT03194984|Other|Adult Patient|With 40-65 years old. Drug: Hydrogen peroxide 35%. Drug: Hydrogen peroxide 38%
2907769|NCT03194971||TTField at Recurrence|
2907770|NCT03194971||TTField at New Diagnosis|
2907771|NCT03194958|No Intervention|Standard Quitline|Participants will receive standard Missouri quitline services
2907772|NCT03194958|Experimental|Specialized Quitline|Participants will receive an enhanced version of the standard quitline services
2907773|NCT03194958|Experimental|Standard Quitline with Basic Needs Navigator|Participants receive standard quitline services with navigator
2907775|NCT03194945|Active Comparator|Linagliptin plus metformin|CSII followed by Linagliptin 5 mg Qd + Metformin 0.5 g bid for 48 weeks
2907776|NCT03194945|Active Comparator|Linagliptin|CSII followed by Linagliptin 5mg Qd for 48 weeks
2907777|NCT03194945|Active Comparator|Metformin|CSII followed by Metformin 0.5 bid for 48 weeks
2907778|NCT03194945|Active Comparator|Lifestyle alone|No OHA is given after CSII
2907779|NCT03194932|Experimental|Treatment|"In Part 1, venetoclax with cytarabine will initially be given at dose level 1 and escalated based on tolerability. Idarubicin will be given only at dose level 4.~Two expansion cohorts will be enrolled:~Cohort A will be a group of 12 participants receiving the maximum tolerated combination (MTC) that does not include idarubicin.~Cohort B will be a group of 12 participants receiving the MTC with idarubicin.~Intrathecal Triple Therapy (ITMHA) will be given prior to cycle 1. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA beginning on day 8 until the cerebrospinal fluid becomes free of leukemia."
2907780|NCT03194919|Experimental|Negotiating quit date|Endre: a digital smoking cessation counsellor
2907781|NCT03194919|Active Comparator|Preset quit date|Endre: a digital smoking cessation counsellor
2907782|NCT03194906|Active Comparator|Memantine|Beginning at least two weeks prior to radiation therapy, participants receive memantine. Treatment continues for 12 weeks with periodic cognitive assessments and lab work.
2907783|NCT03194906|Placebo Comparator|Placebo|Beginning at least two weeks prior to radiation therapy, participants receive a placebo. Treatment and assessment are identical to the memantine group.
2907784|NCT03194893|Experimental|Alectinib|Participants will receive alectinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
2907785|NCT03194893|Experimental|Crizotinib|Participants will receive crizotinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
2907786|NCT03194880||HIV testing|At each visit, the DIC HIV testing algorithm will be performed, and additionally, HIV testing by the Anonymous Clinic Algorithm, the Alere™ HIV Combo and the Alere™ q HIV-1/2 Detect. The latter two tests will be performed at the DICs. In case of an invalid result for the Alere™ HIV Combo or the Alere™ q HIV-1/2 Detect, the test will be repeated. If the repeated test is invalid after the second attempt, it is recorded as 'invalid result'.
2907787|NCT03194867|Experimental|Isatuximab/cemiplimab (Regimen 1)|"Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression.~Cemiplimab on Days 1 and 15 in 28-day cycle up to disease progression."
2907788|NCT03194867|Experimental|Isatuximab/cemiplimab (Regimen 2)|"Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression.~Cemiplimab on Day 1 in 28-day cycle up to disease progression."
2907789|NCT03194867|Active Comparator|Isatuximab|Isatuximab on Days 1, 8, 15 and 22, then Day 1 and 15 in 28-day cycles up to disease progression.
2907790|NCT03194854|Experimental|Fun For Wellness (FFW)|Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being.
2907791|NCT03194854|No Intervention|Usual Care (UC)|The Usual Care (UC) group will conduct their lives as usual during the 30 day intervention period.
2907792|NCT03194841|Experimental|Heart Failure Application|A mobile application that allowed for input of physiologic data, qualitative questions about symptoms and education
2907793|NCT03194828|Active Comparator|Monitoring only|Patients in this arm will be given a real-time medication use monitor to use in dispensing their topical glaucoma medication for 3 months
2907794|NCT03194828|Experimental|Monitoring and reminder|Patients in this arm will be given a real-time medication use monitor to use in dispensing their topical glaucoma medication for 3 months and will receive an automated reminder (text or voice) when a missed dose is determined by the device's system
2907795|NCT03194815|Active Comparator|Intravenous immunoglobulin and Rituximab|One cycle of intravenous immunoglobulin (IVIG) 2g/kg over 2-5 days (days 1-5) followed by (b) two infusions of 1g rituximab (the first infusion starting between days 28-35, and the second infusion 14 days later), each with 100mg methylprednisolone.
2907796|NCT03194815|Placebo Comparator|Placebo|One cycle of 0.9% saline solution over 2-5 days (days 1-5) followed by (b) two infusions of placebo solution alongside placebo pill - in equal volumes to steroid pre-medication and rituximab.
2907797|NCT03194802|Experimental|Sleeping Without Pills Program|Cognitive behavioral therapy; Motivational Interviewing; Scheduled and gradual drug tapering
2907798|NCT03194802|Active Comparator|Self-Monitoring|Daily Self-monitoring of sleep and sleep medication using sleep diary
2907799|NCT03194789|Active Comparator|Traditional Pelvic Floor Therapy|up to six sessions, with one session every alternate week.
2907800|NCT03194789|Experimental|FGBMM plus Traditional pelvic floor therapy|Treatment with FGBMM using shoes with pertupods daily at home along with traditional pelvic floor therapy sessions.
2907801|NCT03194776|Experimental|LLG783|Patients will receive LLG783 i.v. infusion every 4 weeks for 12 weeks.
2907802|NCT03194776|Placebo Comparator|Placebo|Patients will receive placebo to LLG783 i.v. infusion every 4 weeks for 12 weeks.
2907803|NCT03194750|Experimental|Share Data|
2907804|NCT03194750|Active Comparator|Do Not Share Data|
2907805|NCT03194737|Experimental|UroLift System procedure|All eligible,enroled subjects will undergo a UroLift procedure.
2907806|NCT03194737|No Intervention|Retrospective Arm|Chart review will be performed on all invasive BPH surgeries (TURP, Holmium Laser Enucleation of the prostate (HoLEP), etc) performed by the site from June 1, 2015 to December 31, 2015
2907807|NCT03194724||High Vitamin A exposure|There was no intervention
2907808|NCT03194724||Low vitamin A exposure|No intervention
2907809|NCT03194711||Patients with stable CAD|
2907810|NCT03194698|Experimental|Treatment|Treatment with 4 visits and 4 treatments of IPL and MGX
2907811|NCT03194698|Active Comparator|Control|Treatment with 4 visits and 4 treatments of MGX only
2907846|NCT03194568|Experimental|Anterior Vertebral Tethering|Subjects receiving Anterior Vertebral Tethering intervention.
2907812|NCT03194685|Experimental|Phase 1 Cohort 1: 10 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01 . The dose escalation will proceed until MTD is reached.
2907813|NCT03194685|Experimental|Phase 1 Cohort 2: 20 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01 . The dose escalation will proceed until MTD is reached.
2907814|NCT03194685|Experimental|Phase 1 Cohort 3: 35 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01 . The dose escalation will proceed until MTD is reached.
2907815|NCT03194685|Experimental|Phase 1 Cohort 4: 50 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01 . The dose escalation will proceed until MTD is reached.
2907816|NCT03194685|Experimental|Phase 1 Cohort 5: 75 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01 . The dose escalation will proceed until MTD is reached.
2907817|NCT03194685|Experimental|Phase 1 Cohort 6: 100 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01 . The dose escalation will proceed until MTD is reached.
2907818|NCT03194685|Experimental|Phase 1 Cohort 7: 150 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01 . The dose escalation will proceed until MTD is reached.
2907819|NCT03194685|Experimental|Phase 1 Cohort 8: 225 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01 . The dose escalation will proceed until MTD is reached.
2907820|NCT03194685|Experimental|Phase 1 Cohort 9: 300 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01 . The dose escalation will proceed until MTD is reached.
2907821|NCT03194685|Experimental|Phase 2a Group 1: High Dose|"Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01 .~Phase 2a, subjects will be randomly assigned to 1 of 3 dose levels in a balanced fashion. The treatment will continue until disease progression, intolerable toxicity, or investigation/subject decision."
2907822|NCT03194685|Experimental|Phase 2a Group 2: Middle Dose|"Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01 .~Phase 2a, subjects will be randomly assigned to 1 of 3 dose levels in a balanced fashion. The treatment will continue until disease progression, intolerable toxicity, or investigation/subject decision."
2907823|NCT03194685|Experimental|Phase 2a Group 3: Low Dose|"Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01 .~Phase 2a, subjects will be randomly assigned to 1 of 3 dose levels in a balanced fashion. The treatment will continue until disease progression, intolerable toxicity, or investigation/subject decision."
2907824|NCT03194672|Experimental|Intervention Condition|"This experimental condition has three major components:~Individual sessions: Roughly 12 90-minute sessions over 3 months Prenatal sessions covering contraceptive options, including long-acting reversible contraception. Prenatal and postnatal sessions will also cover (a) financial benefits of smoking cessation; (b)financial literacy/budgeting skills based upon selected components of the Money Matters curriculum; (c) establishing concrete steps to reach educational/career goals; (d) healthy eating habits; and (e) importance of HPV vaccinations and getting a medical home.~Transportation assistance for medical home appointments.~Electronic Prompts/Reminders to Encourage Completion of Goals."
2907825|NCT03194672|No Intervention|Treatment as Usual Control Condition|"The comparison group will be a Usual Care control group. The control group will have access to standard medical and behavior health services as part of routine care. Prior to randomization, each enrolled participant will receive a listing of contact information for organizations offering this routine care.~The only interaction the HAT providers will have with control group participants is to have periodic and brief phone conversations in which updated changes in contact information will be collected. The HAT providers will also obtain updated changes in contact information for HAT intervention group participants."
2907826|NCT03194659|No Intervention|Placebo|Administration of the deuterated choline chloride will take place in a grape juice cocktail solution. For individuals in the placebo arm of the trial, no additional choline chloride will be added to the cocktail.
2907827|NCT03194659|Experimental|Supplemental Choline|Administration of the deuterated choline chloride will take place in a grape juice cocktail solution. For individuals in the placebo arm of the trial, supplemental choline chloride will be added to the cocktail.
2907828|NCT03194646|Experimental|A1(3/1 regimen)|2.0 mg treatment of 12 weeks, each separated by 1 bleeding break
2907829|NCT03194646|Experimental|A2(6/2 regimen)|2.0 mg treatment period of 24 weeks, each separated by 2 bleeding break
2907830|NCT03194646|Experimental|A3(3/2 regimen)|2.0 mg treatment period of 12 weeks, each separated by 2 bleeding break
2907831|NCT03194646|Other|B(Standard of care)|Standard of care as determined by the investigators, this could be watch& wait or non-hormonal medical treatment
2907832|NCT03194633||Nifedipine controlled-release tablets(Adalat, BAYA1040)|Male and female patients with a diagnosis of CKD and hypertension (age, 18-70 years) will be enrolled.
2907833|NCT03194620|Placebo Comparator|Control|Single oral intake of flavanol-free fruit-flavored non-dairy drink
2907834|NCT03194620|Experimental|Theaflavins|Single oral intake of a fruit-flavored non-dairy drink containing a mixture of theaflavins
2907835|NCT03194620|Experimental|Procyanidin Dimer B2 (DB2)|Single oral intake of a fruit-flavored non-dairy drink containing Procyanidin Dimer B2 (DB2)
2907836|NCT03194620|Experimental|(−)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of a fruit-flavored non-dairy drink containing (−)-Epigallocatechin-3-O-gallate (EGCG)
2907837|NCT03194620|Experimental|(−)-Epicatechin-3-O-gallate (ECG)|Single oral intake of a fruit-flavored non-dairy drink containing (−)-Epicatechin-3-O-gallate (ECG)
2907838|NCT03194620|Active Comparator|(−)-Epicatechin (EC)|Single oral intake of a fruit-flavored non-dairy drink containing (−)-Epicatechin (EC)
2907839|NCT03194620|Experimental|(−)-Epigallocatechin (EGC)|Single oral intake of a fruit-flavored non-dairy drink containing (−)-Epigallocatechin (EGC)
2907840|NCT03194620|Experimental|Thearubigins|Single oral intake of a fruit-flavored non-dairy drink containing thearubigins
2907841|NCT03194607||Patients|
2907842|NCT03194607||Controls|
2907843|NCT03194594|Active Comparator|Group K (n = 31)|will receive a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, at 5 minutes after the induction of anesthesia
2907844|NCT03194594|Active Comparator|Group D (n = 31)|will receive dexamethasone 0.5 mg/kg i.v. plus 2 ml normal saline, at 5 minutes after the induction of anesthesia
2907845|NCT03194594|Experimental|Group KD (n = 31)|will receive ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v., at 5 minutes after the induction of anesthesia
2907848|NCT03194555|Placebo Comparator|Placebo capsules|Placebo for Component A and Placebo for Component B
2907849|NCT03194542|Experimental|Luspatercept in subjects with MPN-associated myelofibrosis|Subjects across each of the cohorts (Cohort 1, Cohort 2, Cohort 3A, and Cohort 3B) will receive luspatercept.
2907850|NCT03194529|Experimental|FMT in children with disease remission|All children (with Crohn's disease in remission) will receive the equivalent of 50 g of stools from a healthy donor (FMT) into the jejunum through upper endoscopy.
2907851|NCT03194503|Active Comparator|Attendings|Study intervention is a VL coaching training for site neonatology attendings. Each site leader/key educator will be trained remotely by expert co-investigators. Site leaders and key educators will train their attendings. The quality of VL coaching skills will be verified by randomly auditing 20% of attending providers at each site for their skill assessment by remote simulation during the transition/post-intervention phase.
2907852|NCT03194503|No Intervention|Trainees|Trainees will be coached as usual by attendings during their supervised intubation events
2907853|NCT03194490|Experimental|stretching, cervical passive mobilization, and range of motion|The stretching group will receive the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).
2907854|NCT03194490|Active Comparator|cervical mobilization and range of motion|The standard intervention group will receive cervical mobilization and home program (ROM exercises).
2907855|NCT03194477|Experimental|Mobile-enhanced Engagement Intervention|Mobile-enhanced engagement intervention (MEI) to support HIV-positive and high risk HIV-negative participants achieve sustained engagement and sustained retention in HIV treatment or HIV prevention (PrEP) and substance use services at 18 and 12-months respectively.
2907856|NCT03194477|No Intervention|Control - SOC Case Management|Standard of care (SOC) case management.
2907857|NCT03194464||Stroke|individuals with upper-extremity impairment following stroke
2907858|NCT03194438|Experimental|UZIT arm|Multi-modal components integrative therapy intervention program, Urban Zen Integrative Therapy.
2907859|NCT03194425|Experimental|OAB|Patients with overactive bladder on sacral neuromodulation.
2907860|NCT03194425|Experimental|NOUR|Patients with non-obstructive urinary retention on sacral neuromodulation.
2907861|NCT03194412|Experimental|Diet /nutritional|Special diet for elderly. It should be rich in the appropriately amount of protein, carotenoids, vitamins, minerals, macro and micronutrients.
2907862|NCT03194412|Experimental|Physical activity|Regular physical activity in everyday life of the elderly - exercises to improve coordination and balance, stretching exercises, strength exercises.
2907863|NCT03194412|Experimental|Comprehensive therapy|Special diet for elderly (appropriately amount of protein, carotenoids, vitamins, minerals, macro and micronutrients) and regular physical activity in everyday life of the elderly (exercises to improve coordination and balance, stretching exercises, strength exercises)
2907864|NCT03194412|Experimental|Caregivers of elderly|Education about frailty: prevention and treatment (nutrition, physical activity, dietary supplement diet).
2907865|NCT03194412|No Intervention|Control group|Without intervention
2907866|NCT03194399|Experimental|Breast cancer patients|
2907867|NCT03194386|No Intervention|Control|usual care
2907868|NCT03194386|Active Comparator|Reassurance|15 minutes psychologist visit
2907869|NCT03194386|Experimental|R-TEP EMDR|Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing (R-TEP EMDR) At the end of cares, before ED discharge, a trained psychologist will conduct a single R-TEP EMDR session. Each session may last about 60 minutes
2907870|NCT03194373|Experimental|Palbociclib and Carboplatin|"Treatment with Palbociclib and Carboplatin for up to 6 cycles:~Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days Carboplatin (IV), dose= AUC 6, day= 1, cycle length: 21 days~Maintenance Palbociclib after 6 cycles Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days"
2907871|NCT03194360||delirium group|
2907872|NCT03194360||nondelirium group|
2907873|NCT03194334|No Intervention|Control|continued their omnivorous diet throughout the entire study
2907874|NCT03194334|Experimental|Veg+Pla|vegetarian + placebo: switch to a lacto-ovo-vegetarian diet for 6 months and are supplemented with placebo pills instead of beta-alanine and creatine
2907875|NCT03194334|Experimental|Veg+Suppl|switch to a lacto-ovo-vegetarian diet for 6 months and are supplemented with 1 g of creatine monohydrate (2 capsules of 500 mg) and 0.8 g of beta-alanine (1 Carnosyn® tablet) each day
2907876|NCT03194321|Experimental|Tacrolimus extended release arm|All patients will receive tacrolimus extended-release adjusted to target trough levels, mycophenolate mofetil or mycophenolate sodium, and prednisone per CSMC practice.
2907877|NCT03194308||HIV-uninfected women|A sample of 350 HIV-uninfected women who are not currently pregnant, in a stable relationship (≥6 months) with a self-reported infected or unknown serostatus partner and personal or partner plans for pregnancy in the next 12 months. Women will be offered safer conception counseling based on South African guidelines plus daily, oral tenofovir/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) during periconception and pregnancy.
2907878|NCT03194295|Experimental|Community Support Intervention|Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Community Support Intervention Group, which requires methadone maintenance treatment (MMT) participants to attend the group with a drug-free family member or friend (community support person; CSP).
2907879|NCT03194295|Active Comparator|Standard Care|Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Substance Use Disorder Educational Group as an attention-control for the intervention described in the experimental condition.
2907880|NCT03194282|Experimental|chronic stroke patient with insole|Poor balance capacity is one of clinical symptoms of stroke patient.Poor balance, or postural stability, is significant predictors the risk of fall.
2907881|NCT03194282|Sham Comparator|chronic stroke patient without insole|Poor balance capacity is one of clinical symptoms of stroke patient.Poor balance, or postural stability, is significant predictors the risk of fall.
2907882|NCT03194269|Experimental|EARFOLD®|EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic
2907883|NCT03194256|Active Comparator|Normal Nicotine Content Cigarettes|Spectrum Research Cigarettes: 15.8 mg nicotine/g tobacco, 9 mg of tar
2909880|NCT03180567|Experimental|Warfarin resistant patients|Genetic Mutations
2907884|NCT03194256|Experimental|Very Low Nicotine Content Cigarettes|Spectrum Research Cigarettes: 0.4 mg nicotine/g tobacco, 9 mg of tar
2907885|NCT03194243||Patients admitted for acute dyspnea|Patients admitted for acute dyspnea in the emergency department
2907886|NCT03194230|No Intervention|Without cervical dilator|Induction of labour by oral of 400µg of misoprostol each 3 hours.
2907887|NCT03194230|Experimental|With cervical dilator|Induction of labour by cervical placement of hygroscopic dilators for 3 hours and oral of 400µg tablets of misoprostol each 3 hours.
2907888|NCT03194217|Experimental|BEN-2001, 0.5mg|Experimental treatment
2907889|NCT03194217|Placebo Comparator|Placebo|Placebo comparator
2907890|NCT03194217|Experimental|BEN-2001, 1.0mg|Experimental treatment
2907891|NCT03194217|Experimental|BEN-2001, 3.0mg|Experimental treatment
2907892|NCT03194204||rheumatoid arthritis patients|"matrix metalloproteinase-3(MMP-3) and matrix metalloproteinase-9(MMP-9), Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid Rheumatoid factor (RF IgM, U/L) Anti- cyclic citrullinated peptide . Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views .~Cardiac assessment :By electrocardiogram ( ECG ) and echocardiography , Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound."
2907893|NCT03194204||healthy controls|"Matrix Metalloproteinase-3 (MMP-3) and Matrix Metalloproteinase-9 (MMP-9) Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid , Rheumatoid factor (RF IgM(immunoglobulin M), U/L) Anti- cyclic citrullinated peptide. Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views.~Cardiac assessment :~By electrocardiogram ( ECG ) and echocardiography Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound."
2907894|NCT03194191|Experimental|Regular acupuncture needles|"Real acupuncture procedure The real acupuncture will be performed by means of standard stainless-steel needles (0.30-mm diameter, 30-mm length/Gauge 8 x 1.2), located bilaterally in 5 real acupoints."
2907895|NCT03194191|Sham Comparator|Sham acupuncture needles|Sham acupuncture with a no penetrating sham needle (blunt and telescopic), giving the impression of insertion but without penetrating the skin will be placed bilaterally in 5 false acupoints
2907896|NCT03194178||Pierre Robin sequence patients|Patients presenting a Pierre Robin sequence, and who have been cared in their early childhood by either the Necker or Trousseau hospitals teams, and who are between 12 and 18 years old at the beginning of the study.
2907897|NCT03194165||antiretroviral dosage|titration of Dolutegravir, Raltegravir, Rilpivirine, Nevirapine, Atazanavir, Darunavir, Ritonavir
2907898|NCT03194152|Experimental|Peanut|Daily consumption of 2 servings of roasted peanuts for 12 weeks Intervention: Dietary Supplement: Roasted peanuts
2907899|NCT03194152|Experimental|Control|Daily consumption of isocaloric matched snack food for 12 weeks Intervention: Other: High Carbohydrate Snack
2907900|NCT03194139|Experimental|Sentinel Cohort|
2907901|NCT03194139|Experimental|Crossover Design|
2907902|NCT03194126|Experimental|Mifepristone + Misoprostol OR oxytocine + laminaria|
2907903|NCT03194126|Other|Mifepristone + Misoprostol OR oxytocine|
2907904|NCT03194113|Active Comparator|Trauma-Focused Treatment|Weekly sessions of prolonged exposure
2907905|NCT03194113|Active Comparator|Emotion Regulation Treatment|weekly sessions of emotion regulation and skills training.
2907906|NCT03194113|Active Comparator|Intensive Trauma-Focused Treatment|prolonged exposure, 3 sessions per week
2907907|NCT03194100||Diabetes Mellitus|
2907908|NCT03194100||Prediabetes|
2907909|NCT03194100||Normal glucose tolerance|
2907910|NCT03194074|Experimental|propofol group|Propofol/remifentanil-based general anesthesia.
2907911|NCT03194074|Experimental|desflurane group|Desflurane/remifentanil-based general anesthesia.
2907912|NCT03194061|Experimental|Hypofractionated chemoradiation|20 fractions of 275cGy and concomitant weekly cisplatin 35mg/m2 x 4 cycles
2907913|NCT03194048|Experimental|Functional Chewing Training|Children with CP and have tongue thrust included this group.
2907914|NCT03194048|Active Comparator|Control|Children with CP and have tongue thrust included this group.
2907915|NCT03194009|Active Comparator|Lifestyle Intervention|The prediabetic individuals from the primary care centres that belong to this arm, will receive only recommendations for lifestyle modifications (physical activity and diet).
2907916|NCT03194009|Active Comparator|Metformin|The prediabetic individuals from the primary care centres that belong to this arm, will receive metformin treatment and lifestyle modifications recommendations (physical activity and diet).
2907917|NCT03193996|Other|SLIL Injury|Surgical interventions for all subjects will be determined based on combined findings of both 4DCT and standard arthroscopy.
2907918|NCT03193983|Experimental|Flaps Coverage|Surgical group will undergo surgical coverage of the fingertip defect by V-Y flap using the skin on the volar aspect of the same finger designed as V shaped then mobilized dorsally to cover the defect and stitches to be Y shaped. Stitches are removed after 2 weeks.
2907919|NCT03193983|Experimental|Occlusive Dressing|Conservative group will undergo minimal trimming of the bone end and an occlusive dressing that is changed on a weekly basis till complete healing of the defect that occurs after 6 weeks.
2907920|NCT03193970||Bladder Cancer Patients Undergoing Radical Cystectomy|Prospective registry of bladder cancer patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating centers.
2907921|NCT03193957|Experimental|SB4|SB4 (etanercept) 50 mg/mL
2907922|NCT03193944|Active Comparator|Intervention group|Intervention group will receive 50,000 U vitamin D3 per week (equivalent to 1,250 μg) for 8 weeks
2907923|NCT03193944|Placebo Comparator|control group|Control group will receive vitamin D as a placebo. placebo will be identical in appearance taste and odourless.
2907924|NCT03193931|Experimental|Arm A|Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
2907925|NCT03193931|Active Comparator|Arm B|Arm B: Methotrexate (MTX) 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
2907926|NCT03193918|Experimental|Crenolanib combined with ramucirumab/paclitaxel|
2907927|NCT03193905|Other|Cotton blanket|30 hypothermia patients undergo the standard procedure with a cotton blanket during major spinal surgery
2907928|NCT03193905|Other|Bairhugger Full Access Underbody blanket|30 hypothermia patients undergo the Bairhugger Full Access Underbody blanket procedure during major spinal surgery (new procedure)
2907929|NCT03193879||COPD group|COPD patients
2907930|NCT03193879||Asthma group|Asthma patients
2907931|NCT03193879||Health group|Healthy volunteers
2907932|NCT03193853|Experimental|Tak + cisplatin and nab paclitaxel|Patients with metastatic TNBC who meet the enrollment criteria will receive TAK-228 and TAK-117 until disease progression followed by nab paclitaxel plus cisplatin for six cycles. Patients who did not progress may continue nab paclitaxel under treating physicians discretion.
2907933|NCT03193840|Experimental|old acetabular fracture|posterior wall osteotomy would be conducted for thr patient with displaced acetabular fracture without surgical treatment over three weeks.
2907934|NCT03193827|Experimental|study group|In this group in-line filters (Pall, Dreieich, Germany) are connected to peripheral vascular access and used during anaesthesia and the following 96 postoperative hours.
2907935|NCT03193827|Active Comparator|control group|Patients randomised to standard care are managed without an in-line filter and according to local routine practice for intravenous drug administration in the adult patient.
2907936|NCT03193814|Experimental|Chemotherapy + Apatinib|chemotherapy regimens include: Folfox (Oxaplatin 85 mg/m2 IV over 2 hours, day 1; Leucovorin 400 mg/m2 over 2 hours, day 1; 5-FU 400 mg/m2 IV bolus on day 1, then 1200mg/m2/day x 2 days; repeat every 2 weeks) or Folfiri (Irinotecan 150-180 mg/m2 IV over 30-90 minutes, day 1; Leucovorin 400 mg/m2 over 2 hours, day 1; 5-FU 400 mg/m2 IV bolus on day 1, then 1200mg/m2/day x 2 days; repeat every 2 weeks)； apatinib 500mg po qd
2907937|NCT03193801|Experimental|Failing mitral transcatheter valve|Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve.
2907938|NCT03193788|Experimental|pemetrexed maintenance|"Drug: Pemetrexed Maintenance therapy: 500 mg/m^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.~Drug: folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment~Drug: vitamin B12 injection 1000 μg IM 7 days prior to treatment initiation and the every then every 3 cycles until the end of treatment~Drug: dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment"
2907939|NCT03193788|No Intervention|observation|observation group will be observed with best supportive care until progressive disease
2907940|NCT03193775|Active Comparator|chronic HBV with persistent HBsAg|"inactive carriers (n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 6 months after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or DNA disappearance in HBeAg negative patients (n=60). All showed persistent HBs antigenemia.~they were given 30 µg of HBV vaccine initiated 6 months after HBe seroconversion and disappearance of HBV DNA."
2907941|NCT03193775|No Intervention|control group|A control group (n=100) did not receive HBV vaccine
2907942|NCT03193762||Painful hospitalized patient|The anxiety of those patients will be measured with an Anxiety VAS
2907943|NCT03193749|Experimental|Amiodarone Hydrochloride|Oral treatment for at least 6 months
2907944|NCT03193749|Placebo Comparator|Placebo|Oral treatment for at least 6 months
2907945|NCT03193736|Experimental|implant|
2907946|NCT03193723|Active Comparator|Group A|US guided five step field block will be performed
2907947|NCT03193723|Active Comparator|Group B|Spinal anesthesia will be administered in sitting position
2907948|NCT03193710||Total intravenous anesthesia group|The anesthesia of patients in the total intravenous anesthesia group will be maintained with propofol and remifentanil.
2907949|NCT03193710||Inhalational anesthesia group|The anesthesia of patients in the inhalational anesthesia group will be maintained with sevoflurane and remifentanil.
2907950|NCT03193697|Experimental|control group|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
2907951|NCT03193697|Experimental|trial group|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
2907952|NCT03193684|Experimental|Treatment|dapagliflozin 10 mg per day
2907953|NCT03193684|Placebo Comparator|control|matching placebo 1 pill per day
2907954|NCT03193671||Benign|Benign tumors, pre-and postmenopausal
2907955|NCT03193671||Malignant|Malignant tumors, pre-and postmenopausal
2907956|NCT03193671||Borderline|Borderline tumors, pre-and postmenopausal
2907957|NCT03193671||Malignant+borderline|Malignant+borderline tumors, pre-and postmenopausal
2907958|NCT03193658|Active Comparator|Group T|Will receive bilateral US guided Thoracolumbar Interfascial Plane (TLIP) block at the proposed level of surgery before the start of the surgery
2907959|NCT03193658|Active Comparator|Group O|Will not receive the block and postoperative pain control will be managed by I.V drug based multi-modal approach (Opioid & acetaminophen) only.
2907960|NCT03193645||Firmagon|
2907961|NCT03193632||Study group|critically-ill patients who will be admitted to the surgical ICU for ventilatory support and will be expected to continue for more than one day US Muscle layer thickness (MLT) estimation will be used to estimate LBM and REE estimation by indirect calorimetry will be performed
2907962|NCT03193619||PTA-UltraScore Focused Force PTA balloon|Treatment with the UltraScore Focused Force PTA balloon will be per the investigational site's standard of care and adhering to the IFU.
2907963|NCT03193606|Experimental|nano silver fluoride solution|carious dentin to be treated with partial caries excavation with application of nano silver fluoride solution prior to glass ionomer restoration.
2907964|NCT03193606|No Intervention|no nano silver fluoride|carious dentin to be treated with partial caries excavation without application of nano silver fluoride solution restored directly with glass ionomer.
2907965|NCT03193593|Experimental|EB-001 Injections|
2907966|NCT03193593|Placebo Comparator|Placebo Injections|
2907967|NCT03193580|Experimental|Anodal Conventional tDCS|The intervention will be anodal conventional tDCS. Anodal tDCS: 30 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 30 second ramp down to 0 milliamp. Anode positioned over the right primary motor cortex, and the cathode over the contralateral supraorbital area.
2909881|NCT03180567|Placebo Comparator|Control|Genetic Mutations
2907968|NCT03193580|Experimental|Anodal High Definition tDCS|The intervention will be anodal high definition-tDCS. Anodal HD-tDCS: 30 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 30 second ramp down to 0milliamp. Anode entered over the right primary motor cortex, and four cathodes placed in a ring formation surrounding the anode.
2907969|NCT03193580|Sham Comparator|Sham tDCS|Sham subjects will undergo exactly the same anodal conventional tDCS protocol as outlined above. This includes the initial stimulation sequence of ramp up of 30 seconds, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist after 120 seconds of stimulation to automatically ramp down to 0milliamp over 30 seconds.
2907970|NCT03193567|Experimental|HEKT cell|Enrolled patients will receive HEKT cell injection, 10-days interval, totally 3 times.
2907971|NCT03193502|Experimental|Portal Vein thrombosis|rivaroxaban
2907972|NCT03193489|Experimental|Exercise therapy|Parkinson's group takes part in a treadmill treatment that takes place 3 times a week for 2 years.
2907973|NCT03193463|Experimental|Predominantly enhancing mass with volume of 8 cc or less|Only 1 Cleveland Multiport Catheter (CMC) will be placed and CED will be performed intra-operatively only in a magnetic resonance imaging (MRI) equipped Operating Room. Topotecan infusion will be performed over a 4-hour period, with the goal of complete tumor coverage. The initial rate will be 1.20 ml/hour and infusion will be monitored by intermittent MRI imaging. The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent. Following completion of the 4-hour infusion, the CMC will be removed. The initial rate for each subsequent patient may be adjusted upwards in increments of up to 1.20 ml/hour based upon the tumor coverage and safety characteristics of the previously treated patients.
2907974|NCT03193463|Experimental|Predominantly enhancing mass with volume of > 8 cc|2 Cleveland Multiport Catheter (CMCs) will be placed and the total infusion rate of Topotecan per CMC to be used for the first 24 hours for the first patient will be 0.834 ml/hour (3.48 microliters/minute/microcatheter). The rate used for the second 24 hours of the infusion will be 1.668 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.834 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the enhancing tumor by the infused Gadopentetic acid (Gd-DTPA), or 2) rate-limiting toxicity.
2907975|NCT03193463|Experimental|Predominantly non-enhancing mass|The total infusion rate of Topotecan per Cleveland Multiport Catheter (CMC) to be used for the first 24 hours for the first patient will be 0.29 ml/hour. The rate used for the second 24 hours of the infusion will be 0.58 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.29 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the non-enhancing tumor by the infused Gd-DTPA, or 2) rate-limiting toxicity.
2907976|NCT03193450|Experimental|Re-education group|Patients in this arm will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
2907977|NCT03193450|Active Comparator|Non re-education group|Patients in this arm only received an instruction card about the drug administration at the clinic by doctors but no re-education by telephone during treatment
2907978|NCT03193437|Experimental|Selinexor|Open Label Selinexor 60 mg
2907979|NCT03193424|Experimental|Apatinib|
2907980|NCT03193424|Active Comparator|docetaxel|
2907981|NCT03193411|Other|microkeratome group|30 eyes were treated by microkeratome
2907982|NCT03193411|Other|femtosecond group|30 eyes were treated by femtosecond laser
2907983|NCT03193398|Experimental|BTRX-246040|40 mg administered orally as 1 capsule QD for 1 week, followed by 80 mg as 2 capsules QD for 7 weeks.
2907984|NCT03193398|Placebo Comparator|Placebo|administered orally as 1 capsule QD for 1 week, followed by 2 capsules QD for 7 weeks.
2907985|NCT03193385||Closed reduction|
2907986|NCT03193372||Rosacea Concierge Program|Patients diagnosed with rosacea and currently receiving topical monotherapy with Finacea Foam
2907987|NCT03193359|Experimental|BOTOX®|BOTOX® (botulinum toxin Type A) 155U to 195U intramuscular (IM) injections to head/neck areas at Day 0 and Week 12.
2907988|NCT03193346|Experimental|BOTOX®|BOTOX® (botulinum toxin Type A) 155U to 195U intramuscular (IM) injections in head/neck areas at Day 0 and Week 12.
2907989|NCT03193346|Placebo Comparator|Placebo|Placebo matching BOTOX® [Sodium chloride 0.9 milligrams (mg)] IM injections in head/neck areas at Day 0 and Week 12.
2907990|NCT03193333|Experimental|PRO-122 group|"To validate the 3 flasks of the triple therapy will be used 1 bottle with the three active principles (PRO-122) and two placebos and thus comply with the masking.~Drug substances: Timolol 5 mg/mL, brimonidine 2 mg/mL and dorzolamide 20 mg/mL. preservative free.~Pharmaceutical form: Ophthalmic solution~Made by: Laboratorios Sophia, S.A. de C.V.~Posology: 1 drop every 12 hours for 90 days~Description of the solution: clear, visibly particle free, slightly yellow solution, preservative free~Package description: 5 m multidose dropper bottle.~Placebo (for~Two pieces of approved placebo. Administered in 2 multidose dropper bottles.~Posology: 1 drop of each dropper bottle every 12 hours for 90 days"
2907991|NCT03193333|Active Comparator|Concomitant triple therapy group|"Imot Ofteno~Drug substance: Timolol 5 mg/mL~Pharmaceutical form: Ophthalmic solution~Made by Laboratorios Sophia S.A. de C.V.~Alphagan~Drug substance Brimonidine 2 mg/mL~Pharmaceutical form: Ophthalmic solution~Made by: Allergan, Inc.~Trusopt~Drug substance: Dorzolamide 20 mg/mL~Pharmaceutical form: Ophthalmic solution~Made by: Merck Sharp and Dohme Corp.~Posology: 1 drop every 12 hours for 90 days"
2907992|NCT03193333|Active Comparator|Krytantek Ofteno Group|"To validate the three flasks of the triple therapy will be used 1 bottle with the three active principles (Krytantek) and two placebos and thus comply with the masking.~Drug substances: Timolol 5 mg/mL, brimonidine 2 mg/mL and dorzolamide 20 mg/mL.~Pharmaceutical form: Ophthalmic solution~Made by: Laboratorios Sophia, S.A. de C.V.~Posology: 1 drop every 12 hours for 90 days~Description of the solution: clear, visibly particle free, slightly yellow solution Package description: 5 m multidose dropper bottle.~Placebo (for two pieces of approved placebo. Administered in 2 multidose dropper bottles.~Posology: 1 drop of each dropper bottle every 12 hours for 90 days"
2908068|NCT03192826|Active Comparator|Brimonidine 0.2%|1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy
2907993|NCT03193320|Active Comparator|Liberal group protocol|Fluid loading with 500 ml at induction. Baseline fluid infusion - 8 ml/kg/h. Fluid challenge - if mean arterial pressure (MAP) falls to < 65 mmHg, a fluid challenge will be administered.
2907994|NCT03193320|Active Comparator|Restrictive group protocol|No fluid loading at induction. Baseline fluid infusion - 4 ml/kg/h. Fluid challenges - if mean arterial pressure (MAP) falls to < 65 mmHg, a fluid challenge will be administered.
2907995|NCT03193320|Experimental|PVI-guided group protocol|No fluid loading at induction. Baseline fluid infusion - 2 ml/kg/h. PVI will be monitored continuously since anesthesia induction. Fluid challenges - if PVI rises >=13 (or MAP falls < 65 mmHg), a fluid challenge will be administered.
2907996|NCT03193307|Experimental|All subjects|Microgynon alone (run in period) then Microgynon & BI 409306 treatment period
2907997|NCT03193294|Active Comparator|Intervention group (coronary function test results disclosed)|In the intervention group, coronary function tests are measured and disclosed to the attending clinician permitting re-evaluation of the initial diagnosis and treatment as compared with initial angiography-guided decisions. The intervention involves measurement of CFR, IMR and RRR in a target, major coronary artery followed by coronary reactivity testing using incremental doses of acetylcholine (10-4M, 10-5M, 10-6M) to assess endothelial function, bolus infusion of ACh (10-4M) for vasospasm provocation testing, followed by administration of a bolus dose (300 micrograms) of glyceryl trinitrate. Endotypes are identified based on established criteria for abnormalities in coronary vasodilator function, vasospasm and microvascular resistance. The endotypes (diagnostic strata) are: obstructive CAD, coronary artery spasm, microvascular angina, endothelial dysfunction (no angina), normal (non-cardiac). A diagnosis may be ruled-in or ruled-out based on the test results.
2907998|NCT03193294|Sham Comparator|Usual care group (coronary function results not disclosed)|Coronary function tests are measured but not disclosed to the attending clinician or the participant. The same coronary function tests are undertaken as in the intervention group. Masking is achieved by obscuring the catheter laboratory monitors from the attending clinician and participant. The effectiveness of masking is prospectively monitored.
2907999|NCT03193281|Other|Dasatinib|"All patients will begin the study on dasatinib treatment (Sprycel® 100mg once daily oral administration). Those who reach MR3.0 at 12 months (end of Study Stage 1) and achieve a confirmed result at 13 months, will switch to imatinib treatment (Imatinib-AFT 400mg once daily oral administration) for the next 24 months (Study Stage 2).~Patients who do not achieve a confirmed MR3.0 result at 13 months will not be eligible to switch to imatinib treatment and will remain on dasatinib treatment, as per Study Stage 1.~Patients will be assessed on a 3-monthly basis throughout the study. Those who discontinue dasatinib treatment during the study for reasons other than the planned treatment switch to imatinib at 13 months, will also be followed up every 3 months."
2908000|NCT03193268|Experimental|High intensity agility group|Exercise therapy
2908001|NCT03193268|Experimental|Non-agility cycling group|Parkinson's Bicycle Group, which takes 1 hour of exercise every day for 5 weeks
2908002|NCT03193268|No Intervention|No-exercise control group|Control Parkinson's disease control group thad will not receive exercise treatment
2908003|NCT03193255|Active Comparator|No daily lens rubbing|Daily lens disinfection with OPHTECS cleadew GP without lens rubbing
2908004|NCT03193255|Active Comparator|Daily rubbing|Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with cleadew GP
2908005|NCT03193255|Active Comparator|Daily rubbing with separate cleaner|Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with a daily lipid cleaner
2908006|NCT03193255|Active Comparator|Daily rubbing and weekly protein removal|Daily lens disinfection with OPHTECS cleadew GP after daily lipid cleaner followed by weekly protein removal treatment
2908007|NCT03193242|Experimental|Intervention|"Electronic Asthma Management System: eAMS Intervention~eAMS consists of simple questionnaire completed either through an app on a patient's smartphone or tablet computer, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and a printable asthma action plan that is given to patients. eAMS will also provide access to a patient-oriented asthma management tool called Breathe."
2908008|NCT03193242|No Intervention|Control|"Electronic Asthma Management System: eAMS - Control~At control sites, eligible clinicians will be offered access to the web-based clinician-oriented asthma action plan (AAP) educational module produced by the Lung Association, copies of the Canadian Asthma Guidelines, and standard fillable paper-based AAPs (the eAMS will be offered after study end)."
2908009|NCT03193229|Experimental|MapTrek|Patients in the intervention group receive a Fitbit and MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required prior to enrollment). Each week, patients are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. MapTrek also supports Street View on Google Maps, so patients can explore what they would see if they were in that location. Throughout each race, patients will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
2908010|NCT03193229|Active Comparator|Fitbit Only|Patients randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to MapTrek or simply by giving the patients a Fitbit.
2908011|NCT03193216|Experimental|Alginate group|Patients in this group will be taking the study medication -- alginate solution in addition to standard of care twice daily proton pump inhibitor therapy
2908012|NCT03193203|Experimental|Sequence 1|SB4 (etanercept) 50 mg/mL PFS and AI
2908013|NCT03193203|Experimental|Sequence 2|SB4 (etanercept) 50 mg/mL AI and PFS
2908014|NCT03193190|Active Comparator|Cohort 1: Control (Nab-Paclitaxel and Gemcitabine)|"Cohort 1: Participants will receive Nab-Paclitaxel 125 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.~Participants in the Cohort 1 control arm who experience disease progression will be given the option of enrolling into Cohort 2 (if open for enrollment), provided they meet eligibility criteria."
2908034|NCT03193086||Alemtuzumab treated MS patients|Those with Multiple Sclerosis that have commenced therapy with alemtuzumab (60 mg infusion over the course of 5 days) and completed treatment with alemtuzumab (additional 36 mg infusion during the course of 3 days, 12 months later).
2909987|NCT03179878|Experimental|SYNB1020|SYNB1020
2908015|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Selicrelumab 16 mg subcutaneous injection on Day 1 of Cycles 1−4 and every third cycle thereafter (i.e. Cycles 7, 10, 13 etc.) of each 28-day cycle.
2908016|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemo + Selicrelumab + Bevacizumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Bevacizumab 10 mg/kg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Selicrelumab 16 mg subcutaneous on Day 1 of Cycles 1−4 and every third cycle thereafter (i.e. Cycles 7, 10, 13 etc.) of each 28-day cycle.
2908017|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Bevacizumab 10 mg/kg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
2908018|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Emactuzumab|Cohort 1: Participants will receive Emactuzumab 1000 mg IV infusion on Days 1 and 15 of each 28 day cycle; Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
2908019|NCT03193190|Experimental|Cohort 2: Atezolizumab + Cobimetinib|"Cohort 2: Participants will receive Cobimetinib 60 milligrams (mg) once daily orally on Days 1-21 of each 28-day cycle; and Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28-day cycle.~Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arm is open for enrollment."
2908020|NCT03193190|Experimental|Cohort 2: Atezolizumab + PEGPH20|"Cohort 2: Participants will receive PEGPH20 3 micrograms per kilogram (mcg/kg) IV infusion on Days 1, 8 and 15 of each 21-day cycle; and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
2908021|NCT03193190|Experimental|Cohort 2: Atezolizumab + BL-8040|"Cohort 2: Participants will receive BL-8040 1.25 milligrams per kilogram (mg/kg) subcutaneously (SC) on Days 1-5 of the first week, followed by combination treatment consisting of BL-8040 1.25 mg/kg SC three times a week on non-consecutive days and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle.~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
2908022|NCT03193190|Experimental|Cohort 2: Atezolizumab + RO6874281 every 2 weeks|"Cohort 2: Participants will receive Atezolizumab 840 mg IV infusion on days 1 and 15 of each 28 day cycle; RO6874281 will be administered 10 mg by IV infusion on day 1 and 15 mg on days 8, 15, and 22 for cycle 1 (28 day cycle). RO6874281 will be administered 15 mg by IV infusion on days 1 and 15 of each subsequent 28 day cycle.~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment."
2908023|NCT03193190|Experimental|Cohort 2: Atezolizumab + RO6874281 every 3 weeks|"Cohort 2: Participants will receive Atezolizumab 1200 mg IV infusion on Day 1 of each 21 day cycle; and RO6874281 10 mg by IV infusion on day 1 of each 21 day cycle.~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment."
2908024|NCT03193190|Experimental|Cohort 2: Atezolizumab + Emactuzumab|"Cohort 2: Participants will receive Emactuzumab 1000 mg IV infusion on day 1 of each 21 day cycle; and Atezolizumab 1200 mg IV infusion on Day 1 of each 21 day cycle.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
2908025|NCT03193190|Active Comparator|Cohort 2: Control (Nab-Paclitaxel and Gemcitabine or mFOLFOX6)|"Cohort 2: Participants who progressed on a prior fluoropyrimidine-based regimen will receive Nab-paclitaxel 125 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.~Participants who progressed on a prior gemcitabine-based regimen will receive 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6). Participants will receive Oxaliplatin 85 mg/m2 IV on Days 1 and 15 of each 28 day cycle; Leucovorin 400 mg/m2 IV on Days 1 and 15 of each 28 day cycle; Fluorouracil 400 mg/m2 IV push on Days 1 and 15 of each 28 day cycle; and Fluorouracil 2400 mg/m2 IV continuous infusion over 46 hours on Days 1 and 2 and on Days 15 and 16 of each 28 day cycle.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
2908026|NCT03193177|Experimental|the 21-day fasting-like diet|Participants will be supplied with fasting-like diet containing only 5% of normal calorie intake. Physical examinations will be performed on day 0, 4,7,14,21 and 51 after the clinical trial.
2908027|NCT03193164|Experimental|group 1|Neuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.
2908028|NCT03193164|Sham Comparator|group 2|Decubitus Position with the limbs raised to 20º without NMES and after NMES.
2908029|NCT03193125|Experimental|Carnitine|500 mg of L-carnitine to be taken 3 times a day 15 minutes before meals for 14 days.
2908030|NCT03193125|Placebo Comparator|Placebo|500 mg of placebo to be taken 3 times a day 15 minutes before meals for 14 days.
2908031|NCT03193112||Study group|The investigators analyze the intraocular pressure changes on patients who have been using Agomelatine for their primary depressive disorder. For the treatment of depression, patients will have been started routinely Agomelatine tablet of 25 mg orally. The investigators measure the eye pressure for one months in those patients receiving standard depression treatment.
2908032|NCT03193099|Other|Premanifest HTT mutation carriers|
2908033|NCT03193099|Other|non HTT mutation carriers|
2908067|NCT03192826|Active Comparator|Brinzolamide/Brimonidine FC|1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy
2909988|NCT03179878|Placebo Comparator|Placebo|100 mL masking solution
2908035|NCT03193073|Active Comparator|CKD patients with different stages|"Full clinical history and through clinical examination.~Full blood count at time of diagnosis and 3 months after initiation of treatment with iron and erythropoietin Stimulating agents.~Iron study at time of diagnosis and 3 months after treatment .~Serum calcium , phosphorus, intact Parathrmone hormone. 5-24- urinary proteins or Albumin Creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually.~6- Lipid profile . 7-Estimated glomerular filtration rate by MDRD equation ."
2908036|NCT03193073|Active Comparator|Newly renal transplanted patients .|"Full clinical history and through clinical examination.~Pre transplant Serum calcium , phosphorus , I Parathrmone hormone , serial measures every / 3 months for 2 years.~Pre-transplant full blood count serial measures every / 3 months for 2 years.~Pre transplant serum Iron study and annually for 2 years.~24- urinary proteins or albumin-creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually.~Post-transplant serum FGF-23 (as independent risk factor) at 6months.~Different immunosuppressive protocols.~Pre-transplant panel reactive antibody,donor-specific antibody"
2908037|NCT03193047|Experimental|bempedoic acid|Bempedoic acid 180mg tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
2908038|NCT03193047|Placebo Comparator|placebo|Matching placebo tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
2908039|NCT03193034|Experimental|ATTUNE Cementless RP TKA|Subjects will receive a cementless, rotating platform total knee arthroplasty.
2908040|NCT03193021|Experimental|Cardiva Mid-Bore VVCS|Cardiva Mid-Bore VVCS will be used to close all femoral venous access sites at the end of the case.
2908041|NCT03193021|Active Comparator|Manual Compression|Direct manual compression to the access sites will be used to close all femoral venous access sites at the end of the case.
2908042|NCT03192995|Active Comparator|lorcaserin|
2908043|NCT03192995|Placebo Comparator|Placebo|
2908044|NCT03192982|Experimental|Foot pump (A-V Impulse, 6000 Series)|In OR before operation starts randomized to foot pump treatment post operative. Pump placed on foot immediately after operation is finished. Foot pump will be left on foot until full mobilization is reached
2908045|NCT03192982|Active Comparator|Standard treatment (compression)|"In OR before operation starts randomized to standart treatment for edema after in situ bypass.~Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg"
2908046|NCT03192969|Experimental|Abatacept Combination Therapy|Abatacept subcutaneous injection (125 mg/mL prefilled syringe weekly) in combination with glucocorticoid therapy (up to 28-week taper of oral prednisone daily)
2908047|NCT03192969|Placebo Comparator|Placebo Monotherapy- 28 Weeks|Glucocorticoid therapy (28-week taper of oral prednisone daily) in combination with placebo subcutaneous injection (1 mL pre-filled syringe weekly)
2908048|NCT03192969|Placebo Comparator|Placebo Monotherapy- 52 Weeks|Glucocorticoid therapy (52 week taper of oral prednisone daily) in combination with subcutaneous placebo weekly
2908049|NCT03192943|Experimental|Dose Escalation|monotherapy and combination therapy
2908050|NCT03192930||Saturation|Individuals exposed to prolonged hyperbaric exposure
2908051|NCT03192930||Control|Individuals not exposed to prolonged hyperbaric exposure
2908052|NCT03192917|Experimental|Active treatment|This group of participant will receive low intensity shock wave treatment accounted on their penile shaft once every week for 5 weeks.
2908053|NCT03192917|Placebo Comparator|Placebo group|this group of participant will meet up for treatment. The treatment given will be the exact same as the active group, but the transducer used for shock wave treat will me capped, meaning that no shock waves are transmitted to their penis.
2908054|NCT03192904|Experimental|Energy Instruments Group|All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use energy instruments dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
2908055|NCT03192904|Experimental|Stapling Device Group|All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use stapling device to dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
2908056|NCT03192878||Naive patients|Patients with corticosteroid- and/or traditional immunosuppressive drug-resistant Takayasu's arteritis with indication of initiating therapy with anti-TNF-alpha
2908057|NCT03192878||Switch patients|Patients with Takayasu's arteritis already in therapy with infliximab originator (Remicade) in whom the originator therapy will be replaced with infliximab biosimilar therapy
2908058|NCT03192865||diaphragmatic paralysis/paresis group|"Diaphragmatic paralysis can be associated with regional anesthesia procedure in arthroscopic shoulder surgery as phrenic nerve is close to the brachial plexus.~Diaphragmatic paralysis will be defined using ultrasounds."
2908059|NCT03192865||No diaphragmatic paralysis/paresis group|Some strategies of peripheral nerve block are able to spare diaphragmatic paralysis.
2908060|NCT03192852|Experimental|Violet LED (405 nm)+ gel placebo|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier + gel placebo
2908061|NCT03192852|Experimental|Violet LED + CP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with carbamide peroxide 35% ( Whiteform - Fórmula & Ação, São Paulo, Brazil) actived with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier
2908062|NCT03192852|Experimental|HP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with hydrogen peroxide 35% (Whiteness HP, FGM, Joinvile, SC, Brasil) and gingival barrier
2908063|NCT03192852|Experimental|HP 35% + Violet LED + Gingivoplasty|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier split-mouth at first session. After 48 hours will be do Gingivoplasty.
2908064|NCT03192839|Experimental|Low dose PUFA|
2908065|NCT03192839|Experimental|High dose PUFA|
2908066|NCT03192839|Placebo Comparator|Placebo|
2908069|NCT03192826|Placebo Comparator|Artificial tears|1 drop of artificial tears 1 hour before Nd-YAG capsulotomy
2908070|NCT03192813||Symetis ACURATE neo™ transfemoral TAVI system|Patient assigned to this group will be implanted with Symetis ACURATE neo™ transfemoral TAVI system.
2908071|NCT03192813||Medtronic CoreValve Evolut R TAVI System|Patient assigned to this group will be implanted with Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System.
2908072|NCT03192761|Active Comparator|ACL-reconstruction hamstrings|ACL reconstruction hamstrings
2908073|NCT03192761|Active Comparator|ACL-reconstruction patella tendon|ACL reconstruction patella tendon
2908074|NCT03192761|Active Comparator|ACL-reconstruction iliotibial tract|ACL reconstruction iliotibial tract
2908075|NCT03192735|Experimental|Apatinib Combined With SOX|In this group,subject will be given ApatinibMesylateTablets 500mg one time a day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 one time a day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
2908076|NCT03192722|Experimental|Immediate exposure to near vision glasses with filters|Participants immediately provided with near vision glasses with colored filters
2908077|NCT03192722|Other|Delayed exposure to near vision glasses with filters|Participants provided with near vision glasses with colored filters after 8 weeks of wearing clear near vision glasses
2908078|NCT03192709|Experimental|A|Sildenafil vaginal suppositories users
2908079|NCT03192709|Placebo Comparator|B|Daily vaginal placebo users with HMG administration
2908080|NCT03192709|Placebo Comparator|C|Daily vaginal placebo users with HMG administration day until the day of oocyte retrieval.
2908081|NCT03192696|Experimental|Treatment Cohort|Atherectomy of in-stent restenosis
2908082|NCT03192683|Active Comparator|Regular sling|
2908083|NCT03192683|Experimental|Cast-sling|
2908084|NCT03192670|Sham Comparator|Sham control group|Sham control group received same procedure without LED-T. Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)
2908085|NCT03192670|Experimental|CA(Carotid artery)-stimulation group|"In CA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
2908086|NCT03192670|Experimental|VA(Vertebral artery)-stimulation group|"In VA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
2908087|NCT03192670|Experimental|CA+VA dual stimulation group|"In CA+VA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
2908088|NCT03192657|Experimental|Basiliximab group|"Basiliximab: 20mg injection each time at day1 and day5, respectively. The first administration should be within 8 weeks after disease onset.~Calcineurin inhibitors: cyclosporin A 3-5mg/kg/d or tacrolimus 0.05-0.10mg/kg/d.~Steroids: 1mg/kg/d, calculated with prednisone."
2908089|NCT03192657|Active Comparator|control group|"Calcineurin inhibitors: cyclosporin A 3-5mg/kg/d or tacrolimus 0.05-0.10mg/kg/d.~Steroids: 1mg/kg/d, calculated with prednisone."
2908090|NCT03192644|Experimental|Group A (TAI)|
2908091|NCT03192644|Active Comparator|Group B (TACE)|
2908092|NCT03192631|Experimental|with financial incentive|Patients randomized to this arm will start with receiving the financial incentive. Cross-over after 9 months to treatment as usual.
2908093|NCT03192631|No Intervention|treatment as usual|Patients randomized to this arm will start with receiving treatment as usual, cross-over after 9 months to incentive arm.
2908094|NCT03192618|Experimental|treatment group|
2908095|NCT03192618|No Intervention|control group|
2908096|NCT03192605|Experimental|Blueberry|150 grams wild blueberries
2908097|NCT03192605|Placebo Comparator|Placebo|Placebo control
2908098|NCT03192592|Experimental|Body moisturizer Apotech®|Instructions for use: Massage the product in the body twice a day (morning and evening) with gentle movements until completely absorption. Daily use for 28 days.
2908099|NCT03192579|Experimental|Standard lipid lowering therapy|Start with only rosuvastatin 2.5mg and up to 20mg/day
2908100|NCT03192579|Active Comparator|Intensive lipid lowering therapy|Start EPA and rosuvastatin 10mg/day and up to 20mg/day
2908101|NCT03192566|Experimental|Tylenol Dosing|"Dosing of Tylenol for postoperative pain relief will include:~children < 16 years; 650 mg every 6 hours, max 2.6 gram per 24 hours and children > or equal to 16 years every 6 hours 1 g of acetaminophen, max 4 gram per 24 hours)."
2908102|NCT03192553|Experimental|Double Gloving Procedure|Participants will doff PPE using a double gloving procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
2908103|NCT03192553|Experimental|Intensified Hand Hygiene Procedure|Participants will doff PPE using an intensified hand hygiene procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
2908104|NCT03192553|Experimental|One-Step Procedure|Participants will doff PPE using a one-step procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
2908105|NCT03192553|Other|CDC Procedure (Control)|Participants will doff PPE following the CDC procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
2908106|NCT03192540|Experimental|Exercise|These are participants who will be undergoing exercise intervention.
2908107|NCT03192527|Experimental|Arm A|KN015, Triptorelin
2908108|NCT03192527|Placebo Comparator|Arm B|placebo, Triptorelin
2908109|NCT03192514|Experimental|Electronic Deprescribing tool|GPs of enrolled patients with access to the electronic Deprescribing tool
2908110|NCT03192514|No Intervention|Usual Care|Usual care By GP´s
2908111|NCT03192501||Study group (A group)|In this group, we perform whole exome or genome sequencing of tumor sample in compared to blood sample, screen tumor-related special mutations by using biomedical informatics analysis procedure and utilized the iCAGES system to rank the most appropriate drugs available and then manually examine this list to select the best therapeutic strategy for the patient based on availability of drug and expert knowledge. The PFS, OS, and quality of life (QOL) will be recorded and compared with that from standard care.
2908112|NCT03192501||Control group (B group)|In this group, patients with advanced cancers (matched with Group A) will be treated under the guidance of NCCN, without performing iCAGES analysis.
2908113|NCT03192488|Experimental|Cetirizine|10 mg of Cetirizine given 60 min before exercise
2908114|NCT03192488|Placebo Comparator|Placebo|Placebo given 60 min prior to exercise
2908115|NCT03192475|Active Comparator|GLB plus phone contacts|GLB is the core behavioral lifestyle intervention delivered from 0-4 months using an in-person group format. The active comparator receives 8 additional sessions of group interactive telephone contact delivered from 5-12 months
2908116|NCT03192475|Placebo Comparator|GLB plus newsletter contacts|GLB is the core behavioral lifestyle intervention delivered from 0-4 months using in-person group format. The placebo comparator receives 4 additional educational newsletters delivered from 5-12 months.
2908117|NCT03192462|Experimental|Group A|"Patients with locally advanced or metastatic pancreatic adenocarcinoma who are responding following 3 cycles of first line chemotherapy will receive 6 infusions with a fixed dose of multiTAA specific T cells beginning on the 4th week of the 4th cycle of chemotherapy. MultiTAA T cell infusions will occur on day 21 (a chemotherapy off week) of each chemotherapy cycle starting on chemotherapy cycle 4."
2908118|NCT03192462|Experimental|Group B|Patients with locally advanced or metastatic pancreatic adenocarcinoma who have failed first line chemotherapy or are intolerant or ineligible to receive standard of care chemotherapy will be evaluated in the clinic and receive 6 infusions (administered at monthly intervals) with a fixed dose of multiTAA specific T cells.
2908119|NCT03192462|Experimental|Group C|Patients with resectable pancreatic adenocarcinoma following completion of neoadjuvant chemotherapy, radiotherapy or combination. These patients will receive 6 infusions with a fixed dose of multiTAA specific T cells. One infusion will occur 4 weeks prior to surgical resection (with an option to infuse up to one week earlier) and after the completion of all pre-operative chemotherapy and/or radiation. The subsequent 5 infusions will occur at monthly intervals beginning 8 weeks post-surgery. Following surgery all patients will additionally receive 3 months of standard of care (SOC) chemotherapy starting week 9 after surgery. Hence, SOC chemo will occur weeks 9-11, 13-15, and 17-19 post-surgery and multiTAA T cell infusions will occur at weeks 8, 12, 16, 20, and 24 post-surgery.
2908120|NCT03192449|Experimental|Albendazole 400mg p.o. single dose|Volunteers receive 1 tablet albendazole 400mg (GSK) fasting.
2908121|NCT03192436|Active Comparator|Real Ultrasound|The subjects will receive real ultrasound intervention.
2908122|NCT03192436|Sham Comparator|Sham Ultrasound|The subjects will receive sham ultrasound intervention.
2908123|NCT03192423||Expert|The physicians in the Expert-group will perform a LP following local standard procedure protocol.
2908124|NCT03192423||Intermediate|The physicians in the Intermediate-group will perform a LP following local standard procedure protocol.
2908125|NCT03192423||Novice|The physicians in the novice-group will perform a LP following local standard procedure protocol.
2908126|NCT03192397|Experimental|Prevention (chemotherapy, TBI, cyclophosphamide)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan hydrochloride IV over 30 minutes on day -2. Patients undergo TBI on day -1.~STEM CELL INFUSION: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days 3-4, mycophenolate mofetil IV over 2 hours on days 5-35, and tacrolimus IV and then PO once tolerated on days 5-180 with a taper beginning on day 100."
2908127|NCT03192384||Before intervention|Data from clusters before educational programme intervention implemented.
2908128|NCT03192384||After intervention|Data from clusters after educational programme intervention implemented
2908129|NCT03192371|Experimental|Zagreb 2-1-1 Group|4 doses of Rabipur vaccine, administered intramuscularly according to the Zagreb (2-1-1) regimen (i.e., 2 doses of vaccine administered on Day 1 and 1 dose of vaccine administered on Days 8 and 22).
2908130|NCT03192371|Experimental|Essen 1-1-1-1-1 Group|5 doses of Rabipur vaccine, administered intramuscularly according to the Essen (1-1-1-1-1) regimen (i.e., 1 dose of vaccine administered on Days 1, 4, 8, 15, and 29).
2908131|NCT03192358||Amyotrophic Lateral Sclerosis|We will be recruiting individuals with confirmed or probably ALS, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
2908132|NCT03192358||Parkinson's Disease|We will be recruiting individuals with a diagnosis of Parkinson's disease, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
2908133|NCT03192345|Experimental|Dose Escalation SAR439459 monotherapy|SAR439459 administered intravenously every 2 weeks in a 14-day cycle with escalating doses
2908134|NCT03192345|Experimental|Dose Expansion SAR439459 monotherapy|SAR439459 administered intravenously every 2 weeks in a 14-day cycle with the previously determined recommended dose
2908135|NCT03192345|Experimental|Dose Escalation SAR439459 + REGN2810 combination|SAR439459 + REGN2810 combination administered intravenously every 2 weeks in a 14-day cycle with escalating SAR439459 doses and REGN2810 at a standard dose
2908187|NCT03192033|Other|Arterial closure device used is Proglide® (Abbott)|
2908188|NCT03192033|Other|Arterial closure device used is Femoseal® (Terumo)|
2908136|NCT03192345|Experimental|Dose Expansion SAR439459 + REGN2810 combination|SAR439459 + REGN2810 combination administered intravenously every 2 weeks in a 14-day cycle with a previously determined SAR439459 dose and REGN2810 at a standard dose
2908137|NCT03192332|Experimental|Direct mechanical thrombectomy|Treatment with direct mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.
2908138|NCT03192332|Active Comparator|Combined intravenous thrombolysis and mechanical thrombectomy|Treatment with intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA) followed by mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.
2908139|NCT03192319|Experimental|2years to 5years after HCT|Patients will be vaccinated with Zostavax from 2years to 5years after hematopoietic stem cell transplantation
2908140|NCT03192319|Active Comparator|5years to 10years after HCT|Patients will be vaccinated with Zostavax from 5years to 10years after hematopoietic stem cell transplantation
2908141|NCT03192319|Active Comparator|6 month after chemotherapy for leukemia|Patients will be vaccinated with Zostavax 6 months after the leukemia is cured with chemotherapy
2908142|NCT03192319|Active Comparator|healthy people|Healthy adults over 50 years old will be vaccinated with Zostavax
2908143|NCT03192306|Active Comparator|Merlin|glycolic acid and ethanol mixture
2908144|NCT03192306|Placebo Comparator|Ethanol|
2908145|NCT03192293|Experimental|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period:~Metformin: 850mg (one tablet) twice a day~Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle."
2908146|NCT03192280|Experimental|All study participants|"Each subject will receive single topical induction application of Leukotriene B4 (LTB4) on the inner arm.~Images of the treated area will be captured using multiple medical devices."
2908147|NCT03192267||No treatment|No treatment
2908148|NCT03192254|Active Comparator|Self-Monitoring Control|Daily tracking of fruit and vegetable consumption
2908149|NCT03192254|Experimental|Daily Incentives|Incentives for fruit and vegetable consumption delivered daily
2908150|NCT03192254|Experimental|Delayed Lump Sum Incentives|Incentives for fruit and vegetable consumption delivered in a lump sum at the end of the intervention
2908151|NCT03192241|Experimental|Pump|Mothers provided with a manual breast pump
2908152|NCT03192241|Active Comparator|book|Mothers provided with a children's book
2908153|NCT03192215|Experimental|Active agent: Apixaban|Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Apixaban
2908154|NCT03192215|Active Comparator|Active control: Aspirin|Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Aspirin
2908155|NCT03192202|Experimental|Cohort 1|1.5 mg/kg of AFM13 once weekly for weeks 1-8.
2908156|NCT03192202|Experimental|Cohort 2|1.5 mg/kg of AFM13 three times per week for weeks 1-8.
2908157|NCT03192202|Experimental|Cohort 3|0.5 mg/kg of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
2908158|NCT03192202|Experimental|Cohort 4|1.5 mg/kg in of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
2908159|NCT03192202|Experimental|Cohort 5|7.0 mg/kg of AFM13 once weekly for weeks 1-8.
2908160|NCT03192202|Experimental|Cohort 6|4.5 mg/kg of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
2908161|NCT03192189||Patients with acute kidney injury|Requiring treatment with dialysis
2908162|NCT03192176|Experimental|Lowest dose ESN364|ESN364 lowest dose twice daily (BID), oral, 12 weeks
2908163|NCT03192176|Placebo Comparator|Placebo|Placebo BID, oral, 12 weeks
2908164|NCT03192176|Experimental|Low dose ESN364|ESN364 low dose BID, oral, 12 weeks
2908165|NCT03192176|Experimental|Medium dose ESN364|ESN364 medium dose BID, oral, 12 weeks
2908166|NCT03192176|Experimental|High dose ESN364|ESN364 high dose BID, oral, 12 weeks
2908167|NCT03192176|Experimental|Low dose ESN364 + Placebo|ESN364 low dose once daily (QD) + placebo QD, oral, 12 weeks
2908168|NCT03192176|Experimental|Medium dose ESN364 + Placebo|ESN364 medium dose QD + placebo QD, oral, 12 weeks
2908169|NCT03192176|Experimental|Highest dose ESN364 + Placebo|ESN364 highest dose QD + placebo QD, oral, 12 weeks
2908170|NCT03192163||ResearchMatch Group|
2908171|NCT03192163||Northwestern Center for Ethnic Skin Group|
2908172|NCT03192150|Experimental|ISV-305|
2908173|NCT03192150|Placebo Comparator|Vehicle|
2908174|NCT03192137|Experimental|ISV-305|
2908175|NCT03192137|Placebo Comparator|Vehicle|
2908176|NCT03192111|Experimental|Mild Renal Impairment|Subjects with mild renal impairment
2908177|NCT03192111|Experimental|Moderate Renal Impairment|Subjects with moderate renal impairment
2908178|NCT03192111|Experimental|Severe Renal Impairment|Subjects with severe renal impairment
2908179|NCT03192111|Experimental|Healthy Subjects|Healthy volunteers mean-matched to the mild, moderate, and severe renal impairment patients
2908180|NCT03192098|Experimental|Progressive|Patients will be dilated > 3mm and can be dilated up to 6mm in diameter
2908181|NCT03192098|Active Comparator|Conservative (rule-of-3)|Patients will be dilated according to the rule-of-3 (i.e. dilation of no more than 3mm in diameter)
2908182|NCT03192085|Other|SITA FAST then SITA STANDARD|SITA FAST and SITA STANDARD
2908183|NCT03192085|Active Comparator|SITA STANDARD then SITA FAST|SITA FAST and SITA STANDARD
2908184|NCT03192059|Experimental|experimental arm|Pembrolizumab, immune modulatory cocktail composed of Vitamin D, Lansoprazole Teva, Cyclophosphamide and Aspirine, radiation and Curcumin
2908185|NCT03192046|Experimental|Carbon Fiber Ankle Foot Orthosis (AFO)|For the bracing group, the participants will wear custom fabricated carbon fiber braces in addition to participating in a daily walking program and 7 visits of PT.
2908186|NCT03192046|Active Comparator|Control Group, Walking Program Only|The participants in this group will be prescribed a daily home walking walking program and 7 visits of PT.
2908190|NCT03192020|Active Comparator|Collagenase clostridium histolyticum|Generic name of the drug is collagenase clostridium histolyticum. Dosage form is injectable powder, dosage 0.58 mg and frequency is one injection in four weeks up to three times.
2908191|NCT03192020|Active Comparator|Limited fasciectomy|
2908192|NCT03192007||Patients with Stable Renal Function|Patients will be given MRI
2908193|NCT03192007||Patients with Worsening Renal Function due to complications|MRI
2908194|NCT03191994|Experimental|MDD exercise group|This group will receive eight weeks of moderate exercise in addition to their usual treatment
2908195|NCT03191994|No Intervention|MDD control group|This group will receive usual care with no exercise
2908196|NCT03191994|Experimental|Healthy Exercise|This group will perform an eight week moderate intensity exercise intervention
2908197|NCT03191994|No Intervention|Healthy control|This group will not perform exercise
2908198|NCT03191981|Experimental|Treatment|Cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab
2908199|NCT03191968|Experimental|Supervised PA Plus Behavioral Counseling|25 prostate cancer survivors will receive supervised physical activity and behavioral counseling (SPA+BC) based on the M-PAC. In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
2908200|NCT03191968|Active Comparator|Supervised PA Plus Exercise Counseling|25 prostate cancer survivors will supervised physical activity and exercise counseling (SPA+EC).In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
2908201|NCT03191955||Cancer|Patients with oesophagogastric, hepatobiliary, and colorectal cancer for resectional surgery
2908202|NCT03191955||Non-cancer|Patients undergoing abdominal operation for non-inflammatory, non-cancer conditions
2908203|NCT03191942|Experimental|Modified ortho-k lenses|Participants wearing ortho-k lens with a modified BOZD of 5mm
2908204|NCT03191942|Active Comparator|Ortho-k lenses|Participants wearing ortho-k lens with a standardized BOZD of 6mm
2908205|NCT03191929|Experimental|HIT Intervention Arm|The Health Information Technology Intervention Study Arm consisted of: 1) web-based tutorial on delivering trauma-informed care, 2) Multi-media mental health risk assessment, 3) Immediate provider notification, which included flagging patients' scores that met criteria for symptoms of depression and/or PTSD, 4) subsequent integration into the patient electronic medical record, and 5) Clinical decision support adapted from the Harvard Program in Refugee Trauma.
2908206|NCT03191929|Active Comparator|Minimal Intervention Control Arm|The Minimal Intervention Control Arm consisted of: 1) web-based tutorial on delivering culturally competent health care in general, 2) Multi-media mental health risk assessment, 3) Provider notification only in the event that patients' scores evidenced symptoms of being at risk to harm either themselves or others.
2908207|NCT03191916|Experimental|Experimental group|The experimental group will receive 2 milliamps of anodal transcranial direct current stimulation for 20 minutes daily for 5 days.
2908208|NCT03191916|Sham Comparator|Sham group|The sham group will be connected to the anodal transcranial direct current stimulation device daily for 5 days. During the 20 minute sessions, the participant will only receive stimulation for a 30-second ramp up period, at which point the stimulation will be discontinued for the remainder of the time.
2908209|NCT03191903|Experimental|Cingal|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH).
2908210|NCT03191903|Active Comparator|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose
2908211|NCT03191903|Active Comparator|Triamcinolone Hexacetonide (TH)|A 1 mL unit dose of Triamcinolone Hexacetonide (TH) supplied as 20 mg/ml.
2908212|NCT03191877|Experimental|COFFEE|they will start to drink coffee 6 hours postoperative for maximum 3 doses (100ml), 8 hours apart, diet will start after 1st audible bowel sound.
2908213|NCT03191877|Active Comparator|oral fluid|"they will drink plain fluid (water) 6 hours postoperative. Diet will start after 1st audible bowel sound.~Women in this group will not receive either coffee."
2908214|NCT03191877|No Intervention|control|the control group and they will be NPO for 24 hours on IV fluid (3 LITRES/24 HOURS). Diet will start after 1st audible bowel sound
2908215|NCT03191864|Experimental|APT-1011 1.5 mg HS|Placebo after breakfast, APT-1011 1.5 mg HS
2908216|NCT03191864|Experimental|APT-1011 1.5 mg BID|APT-1011 1.5 mg after breakfast, APT-1011 1.5 mg HS
2908217|NCT03191864|Experimental|APT-1011 3 mg HS|Placebo after breakfast, APT-1011 3 mg HS
2908218|NCT03191864|Experimental|APT-1011 3 mg BID|APT-1011 3 mg after breakfast, APT-1011 3 mg HS
2908219|NCT03191864|Placebo Comparator|Placebo BID|Placebo 30 minutes after breakfast and HS
2908220|NCT03191851|Active Comparator|Standard Device|Standard device
2908221|NCT03191851|Experimental|Melody Device|Melody device without Pump
2908222|NCT03191851|Experimental|Melody Device with pump|Melody Catheter device with Andromeda Pump
2908223|NCT03191838|Experimental|Audiovisual|The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
2908224|NCT03191838|No Intervention|Controls|The control group will not be given distraction equipment.
2908225|NCT03191825|Active Comparator|Standard web-application|Endre: a digital smoking cessation counsellor
2908226|NCT03191825|Experimental|Web-based lapse management system|Endre: a digital smoking cessation counsellor + Lapse management system triggered from web-page
2908227|NCT03191825|Experimental|SMS & web-based lapse management system|Endre: a digital smoking cessation counsellor + Lapse management system triggered by SMS-textmessage
2908255|NCT03191552|Active Comparator|Control(conventional exercises)|Control group will only receive conventional exercise therapy (for two hours a day) including range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills during hospital inpatient stay throughout 2 weeks
2908228|NCT03191812|Sham Comparator|Sham Stimulation|The Sham stimulation intervention will consist of one, twenty-minute session of transcranial direct current stimulation (tDCS) that does not target a cortical area but instead, provides just enough current to create tingling sensations across the scalp to mimic the feeling of receiving the real stimulation. The sham stimulation will use the same number and placement of electrodes as the real stimulation but with a much smaller total current intensity of 0.5 milliamps (mA).
2908229|NCT03191812|Experimental|M1 Stimulation|The M1 stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex at a total current intensity of 1.5 mA.
2908230|NCT03191812|Experimental|DLPFC Stimulation|The DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex at a total current intensity of 1.5 mA.
2908231|NCT03191812|Experimental|M1+DLPFC Stimulation|The M1+DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex and the dorsolateral prefrontal cortex simultaneously at a total current intensity of 3.0 mA.
2908232|NCT03191799|Experimental|Emicizumab|Participants will receive initial weekly doses of prophylactic emicizumab subcutaneously for 4 weeks, followed by maintenance doses consisting of half the initial dose, administered subcutaneously for the remainder of the 2-year treatment period
2908233|NCT03191786|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion on Day 1 of each 21-day cycle until loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death.
2908234|NCT03191786|Active Comparator|Single Agent Chemotherapy (Vinorelbine or Gemcitabine)|Participants will receive single agent chemotherapy; either vinorelbine oral or IV, or gemcitabine IV, according to the label based on investigator's choice.
2908235|NCT03191773|Experimental|Anti-CD19 CAR transduced T cells|Patients will receive a lymphodepleting preconditioning regimen with Fludarabine and Cyclophosphamide followed by anti-CD19 CAR-transduced T cells.
2908236|NCT03191760|Experimental|Behavioral Activation and Social Engagement|Participants will attend 6 in-person therapy sessions lasting approximately 45 minutes per session, held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills. We have modified the standard Behavioral Activation intervention by reducing the number and length of sessions to accommodate the Primary Care setting. In addition, there will be a stronger emphasis on social engagement in BASE then in standard BA and social contact and support will be addressed during each treatment session.
2908237|NCT03191734|Experimental|AQUABEAM System|AQUABEAM System
2908238|NCT03191721|Experimental|Test: Triclosan toothpaste|"To brush twice a day with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.~Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction."
2908239|NCT03191721|Placebo Comparator|Control: Fluoride toothpaste|"To brush twice a day with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.~Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction."
2908240|NCT03191682|Experimental|PRL3-ZUMAB|The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression
2908241|NCT03191669||MS patients|Single group of patients with MS attending an outpatient MS clinic or hospitalization
2908242|NCT03191643||differentiated thyroid cancer|Patients with locally recurrent thyroid cancer, treated with radical radiotherapy after total thyroidectomy +/- central compartment and/or laterocervical lymphadenectomy, previously treated with one or more cycles of 131 Iodine-ablation (RAI) and TSH suppression.
2908243|NCT03191630|Experimental|Control|This arm includes participants randomized to the control group who will use activity trackers (Fitbits) only, and not receive the SystemCHANGE intervention.
2908244|NCT03191630|Experimental|Intervention|This are includes participants randomize to the intervention group who will receive the combination of the SystemCHANGE TM and activity tracker intervention
2908245|NCT03191617|Experimental|Liquid human milk fortifier|Liquid human milk fortifier which has higher protein content and also LCPUFA
2908246|NCT03191617|Active Comparator|Powder human milk fortifier|Powder human milk fortifier with less protein content and no LCPUFA
2908247|NCT03191604||Endoscopists familiar with EET|Physicians familiar with conducting endoscopic eradication therapy.
2908248|NCT03191591|Experimental|First 1,000 Days Program|
2908249|NCT03191578|Experimental|RUTI® injection|
2908250|NCT03191578|Placebo Comparator|Sodium Chloride 0.9% injection|
2908251|NCT03191565|Experimental|App-Condition|In this condition the intervention is that participants enter their skills-use and mood on a smartphone. They can follow their progress on graphs on the smartphone, get reminders to train skills, get psychoeducation about what the different emotion regulation coping skills can do, and how to do the skills. therapists can watch patient progress online, and review skill use together with the patients while in psychotherapy. The intervention is using a smartphone as an adjunct to the treatment.
2908252|NCT03191565|Active Comparator|Paperdiary-condition|Patients are, weekly, given a paper diary sheet to fill out on a daily basis at home No prompting, no accumulative overview of progress. Patients are supposed to bring this paper to the weekly therapysession
2908253|NCT03191552|Experimental|SPIO 2 hours|"All children will be hospitalized for 2 weeks and will receive conventional exercise therapy including range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills during hospital inpatient stay throughout 2 weeks 2 hours a day.~SPIO 2 hours group will receive conventional exercise therapy with the garment on for 2 hours."
2908254|NCT03191552|Experimental|SPIO 6 hours|SPIO 6 hours group will receive conventional exercise therapy with the garment on for 2 hours and worn SPIO 4 hours more in addition to 2 hour of wear during exercise therapy.
2908256|NCT03191539|Experimental|Apremilast|30 mg of Apremilast twice a day during 52 weeks. During the first 6 days will be a dose escalation as the following: Day 1: 10 mg daily Day 2: 10 mg day- 10 mg night Day 3: 10 mg day- 20 mg night Day 4: 20mg day- 20mg night Day 5: 20 mg day- 30 mg night Day 6: 30 mg day- 30 mg night
2908257|NCT03191526|Experimental|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.
2908258|NCT03191526|Placebo Comparator|Placebo (saline)|Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.
2908259|NCT03191513|Experimental|Interesterified|Interesterified blend of palm kernal and plam stearin. 50g fat.
2908260|NCT03191513|Active Comparator|Un-interesterified|Un-interesterified blend of palm kernal and plam stearin. 50g fat.
2908261|NCT03191513|Active Comparator|Control|Rapeseed oil. 50g fat.
2908262|NCT03191500|Experimental|steerable catheter|to study the safety and efficacy of a steerable catheter in the treatment of peripheral vascular disease
2908263|NCT03191487|Experimental|ChimioPal|Systematic collection of clinical and laboratory toxicities.
2908264|NCT03191487|Active Comparator|Standard|The usual management and logistic pathways will be respected.
2908265|NCT03191474|No Intervention|Standard of Care Arm|Participants will receive standard of care HIV risk assessment, PrEP education, and an appointment for a PrEP evaluation visit at an affiliated clinic.
2908266|NCT03191474|Experimental|T-POWr Intervention Arm|Participants will receive the same HIV risk assessment, PrEP education, and appointment for a PrEP evaluation visit as the Control Arm. Participants in the Intervention Arm will also receive a thorough client-centered case management evaluation that will assess needs including access to health insurance, general health care, assessment of current hormone administration, housing, mental health care, domestic violence care, substance use treatment, and other services.
2908267|NCT03191461||Cancer Patients|Cancer patients with Stage I-III breast cancer or lymphoma that have received an anthracycline agent during treatment at least 2 years prior to enrollment in this study. Adenosine stress test MRI will be performed.
2908268|NCT03191461||Healthy Controls|Age-matched Healthy Control to cancer survivor with no history of cancer or anthracycline treatment. Adenosine stress test MRI will be performed.
2908269|NCT03191448|Experimental|Ridge preservation in molar sites|"Patient who will need a single molar site extracted as part of their treatment will be screened and consented for this research study.~Ridge preservation will be performed in single molar extraction site. The site will be grafted with freezed dried bone allograft (FDBA) and covered with a collagen wound dressing (Collaplug). This is already part of clinical standard care using FDA approved products in an FDA approved fashion. The study aims at documenting the clinical outcome of such accepted procedure more precisely and compare it existing data using other materials."
2908270|NCT03191435|Experimental|Inspiratory muscle training|Patients will perform the inspiratory muscle training using a load moderate of 30% of maximal inspiratory pressure (MIP 30%).
2908271|NCT03191435|Placebo Comparator|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a load of 2% of maximal inspiratory pressure (MIP 2%).
2908272|NCT03191422|Experimental|LSVT BIG intervention recipients|Participants participated in all of the evaluation steps as well as the LSVT BIG protocol which includes 16, 1-hour intervention sessions with a certified therapist performing, targeted exercises and activities to improve participation in occupations - with a focus on large amplitude movement.
2908273|NCT03191409||Control Group|Health adults with no evidence of brain lesions on conventional magnetic resonance imaging(MRI) and no neural developmental disorders.
2908274|NCT03191409||Patients Group|ESRD patients pre-hemodialysis will be collected.The following exclusion criteria were applied in this study: (a)history of drug or alcohol abuse, (b) brain lesions such as a tumor or stroke assessed on the basis of medical history, (c) history of or current psychiatric disorders, and (d) head motion more than 1.0 mm or 1.0°during magnetic resonance imaging. All patients completed laboratory tests to evaluate renal function,serum creatinine, and urea levels within the 12 hours before magnetic resonance imaging.
2908275|NCT03191396|Experimental|Semaglutide|Half the study participants are randomised to receive semaglutide
2908276|NCT03191396|Active Comparator|Liraglutide|Half the study participants are randomised to receive liraglutide
2908277|NCT03191383|Experimental|GSK3003891A vaccine formulation 1 mother Group|Subjects in this group will receive a single 30µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
2908278|NCT03191383|Experimental|GSK3003891A vaccine formulation 2 mother Group|Subjects in this group will receive a single 60µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
2908279|NCT03191383|Experimental|GSK3003891A vaccine formulation 3 mother Group|Subjects in this group will receive a single 120µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
2908280|NCT03191383|Placebo Comparator|Control group|Subjects in this group will receive a single placebo injection, intramuscularly into the deltoid region of the non-dominant arm.
2908281|NCT03191383|No Intervention|GSK3003891A vaccine formulation 1 infant Group|Infants born to mothers vaccinated with a single 30µg dose of the investigational GSK3003891A vaccine
2908282|NCT03191383|No Intervention|GSK3003891A vaccine formulation 2 infant Group|Infants born to mothers vaccinated with a single 60µg dose of the investigational GSK3003891A vaccine
2908283|NCT03191383|No Intervention|GSK3003891A vaccine formulation 3 infant Group|Infants born to mothers vaccinated with a single 120µg dose of the investigational GSK3003891A vaccine
2908284|NCT03191383|No Intervention|Control infant Group|Infants born to mothers who received a single placebo injection
2908285|NCT03191370|Active Comparator|Local Anaesthetic, no distraction|Will receive local (co-phenylcaine) anesthetic spray (Local Anesthetics,Topical) as an active comparator without distraction during the procedure.
2908328|NCT03191097|Placebo Comparator|Placebo oral capsule|
2908286|NCT03191370|Experimental|Local Anaesthetic, with distraction|Will receive local (co-phenylcaine) anesthetic spray (Local Anesthetics,Topical) with distraction during the procedure. The simple distraction technique is the experimental intervention.
2908287|NCT03191370|No Intervention|No Local Anaesthetic without distraction|Will receive no local (co-phenylcaine) anaesthetic spray without distraction during the procedure.
2908288|NCT03191370|Experimental|No Local Anaesthetic, with distraction|Will receive no local (co-phenylcaine) anesthetic spray with distraction during the procedure. The simple distraction technique is the experimental intervention.
2908289|NCT03191357||TBI/no PH|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experienced traumatic brain injury (TBI) without psychological health (PH) concerns.~no intervention/Observational"
2908290|NCT03191357||TBI with PH|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experienced traumatic brain injury (TBI) and also have psychological health (PH) concerns.~no intervention/Observational"
2908291|NCT03191357||PH only|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experience psychological health (PH) concerns.~no intervention/Observational"
2908292|NCT03191357||Controls|"Control participants may include (i) those with exposure to primary blast without the development of TBI, (ii) those with physical injuries without experiencing head injury, and (iii) healthy participants (non-injured, non-TBI, non-PH).~no intervention/Observational"
2908293|NCT03191344||with IPSS record/IPSS|the surgoen use the IPSS in all thyroidectomy
2908294|NCT03191344||Traditionaldescription Group/TD|the surgoen without the IPSS，use Traditional description
2908295|NCT03191331|Experimental|Intervention group|Dietary intervention. Intervention group will receive written material on healthy diet during pregnancy, nutritional guidance given by public health nurses at each maternity care clinic visit and group meeting with dietician x2.
2908296|NCT03191331|No Intervention|Control group|The control group will receive written material on healthy diet during pregnancy, otherwise basic care and guidance at maternity care clinics.
2908297|NCT03191318|Active Comparator|ERAS pathway|Laparoscopic sleeve gastrectomy with ERAS pathway
2908298|NCT03191318|Active Comparator|Standard pathway|Laparoscopic sleeve gastrectomy with standard pathway
2908299|NCT03191305|Active Comparator|Coumadin Group|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day.The total duration OFf coumadin would be six months.
2908300|NCT03191305|Active Comparator|Rivoroxaban Group|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, THEN 20 mg PO qDay for 6 months.
2908301|NCT03191279||First aid correct|Patient has received first aid according to local guidelines for all indicated first aid measures from bystanders on scene of accident when the first ambulance arrives
2908302|NCT03191279||First aid attempted|Bystanders have attempted first aid for indicated first aid measures, but measures have been incorrectly performed according to local guidelines
2908303|NCT03191279||No first aid|Indicated first aid measures have not been carried out when the first ambulance arrives on scene
2908304|NCT03191266|Active Comparator|active rTMS|Active rTMS will receive an intermittent rTMS stimulation protocol.
2908305|NCT03191266|Sham Comparator|sham rTMS|Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
2908306|NCT03191253|Experimental|Intervention|The intervention consists of comprehensive, medically-appropriate food support (meals and groceries), individual nutritional counseling, and group-based nutritional education.
2908307|NCT03191253|No Intervention|Control|The control group will continue to receive their regular Project Open Hand services (standard of care) which includes 1-2 food services/day.
2908308|NCT03191240|Experimental|Vasopressins|Additional vasopressin 40 IU intravenous injection for 2 times
2908309|NCT03191240|Placebo Comparator|Normal saline|Additional normal saline intravenous injection for 2 times
2908310|NCT03191214||No Warming|Patients undergoing brief surgical procedures of >15 minutes for whom no warming devices are being employed.
2908311|NCT03191214||Forced Air Warming|Patients undergoing surgical procedures in which forced air warming, is being used
2908312|NCT03191201|Active Comparator|Ferric carboxymaltose arm|Ferric carboxymaltose (FCM), 1000 mg iron element will be administered once by drip infusion (Intravenous route). FCM will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution prior to administration. Infusion time will be 15 minutes.
2908313|NCT03191201|Placebo Comparator|Placebo arm|"A commercially available sterile, 250 mL, 0.9% sodium chloride solution will be administered by drip infusion (Intravenous route). Infusion time will be 15 minutes.~At the end of the randomised part of the study, participants initially randomised to the placebo group will be included in a non-blinded open-label extension part and receive a FCM 1000 mg injection."
2908314|NCT03191188|Experimental|Levothyroxine|
2908315|NCT03191188|Placebo Comparator|Placebo|
2908316|NCT03191175||HIV patients|
2908317|NCT03191175||Control patients|
2908318|NCT03191162|Active Comparator|B300/60|Benznidazole 300mg/day p.o. divided in two doses for 60 days
2908319|NCT03191162|Experimental|B150/60|Benznidazole 150mg/day p.o. divided in two doses for 60 days
2908320|NCT03191162|Experimental|B400/15|Benznidazole 400mg/day p.o. divided in two doses for 15 days
2908321|NCT03191149|Experimental|Treatment (osimertinib)|Patients receive osimertinib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2908322|NCT03191136|Experimental|Group1|taking YHD1119 (pregabalin 300mg) in fasted state at Period 1
2908323|NCT03191136|Experimental|Group2|taking YHD1119 (pregabalin 300mg) in fed state at Period 1
2908324|NCT03191123|Active Comparator|Hepatic resection|Indications for Hepatic resection were the presence of appropriate residual liver volume determined by volumetric computed tomography and lack of hepatic encephalopathy.
2908325|NCT03191123|Experimental|Transarterial Chemoembolization(TACE)|Transarterial Chemoembolization is performed in less than one week after clinical diagnosis.
2908326|NCT03191110||Colorectal cancer patients|
2908327|NCT03191097|Experimental|Ingavirin|
2908329|NCT03191084|Experimental|Regular Users|People who use marijuana regularly will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the five study visits.
2908330|NCT03191084|Experimental|Occasional Users|People who use marijuana occasionally will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the five study visits.
2908331|NCT03191071|Experimental|UltraPro|"General practitioners randomly assigned to the UltraPro arm will be responsible to recruit patients fulfilling the inclusion criteria and manage them using the UltraPro algorithm.~The UltraPro algorithm combines the result of a procalcitonin point-of-care test with lung ultrasound result to decide on antibiotic prescription. Blood sampling will be performed to identify potential novel biomarkers. Naso-pharyngeal swabs as well as sputum culture will allow for microbiologic identification of aetiological agents."
2908332|NCT03191071|Experimental|Procalcitonin|"General practitioners randomly assigned to the procalcitonin arm will be responsible to recruit patients fulfilling the inclusion criteria and manage them using the procalcitonin algorithm.~The procalcitonin point-of-care test will be performed, as described above, to decide on antibiotic prescription. Blood sampling will be performed to identify potential novel biomarkers. Naso-pharyngeal swabs as well as sputum culture will allow for microbiologic identification of aetiological agents."
2908333|NCT03191071|Active Comparator|Usual Care|"General practitioners randomly assigned to the usual care arm will be responsible to recruit patients fulfilling the inclusion criteria and will manage and treat these patients as they usually do. Only general practitioners who do not use procalcitonin and lung ultrasonography routinely will be included in the usual care arm.~Naso-pharyngeal swabs as well as sputum culture will be performed to allow for microbiologic identification of aetiological agents."
2908334|NCT03191058|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
2908335|NCT03191058|Active Comparator|Electroconvulsive Therapy (ECT)|ECT treatments will be administered using the MECTA spECTrum 5000Q.
2908336|NCT03191045||Healthy participants|A group of 21 healthy adult participants studied twice (test-retest)
2908337|NCT03191032|Experimental|Training Group|Early sensory re-education of the hand protocol with a sensor glove model, after a median and/or ulnar nerve injury repair
2908338|NCT03191032|No Intervention|Control Group|Conventional rehabilitation for peripheral nerve injuries if the hand, without application of any kind of early sensory re-education protocol
2908339|NCT03191019|Experimental|Mobile-phone app for smoking cessation|"The intervention arm will receive a smoking cessation program based on a mobile-phone app. The program contains strategies to support smoking cessation, including motivational messages, tips on stress management, on how to ask support from friends and family, how to use distraction techniques and how to deal with cravings, lapses and early relapse. It also includes a saving calculator, a help button which provides extra messages in case of cravings and a lapse button, which provides advice about what to do if the participant presents lapses or relapse after being abstinent at least 24 hours."
2908340|NCT03191019|Placebo Comparator|Control mobile-phone app|The control arm will receive a mobile-phone app which will send 1 message every two weeks thanking participants for taking part in the study, and encouraging them to stay in the study for the 6 month follow-up period.
2908341|NCT03191006|Active Comparator|study group: MEI BIN insoles|Participants in the study group will be prescribed with a pair of customized insoles (MEI BIN) to keep the subtalar joint in neutral position, for 12 weeks.
2908342|NCT03191006|No Intervention|control group: without MEI BIN insoles|Participants in this control group will not receive a pair of customized insoles (MEI BIN) to keep the subtalar joint in neutral position, for 12 weeks.
2908343|NCT03190993|Active Comparator|Sugar Sweetened Solid Treatment|A solidified food that is made with the SSB syrup concentrate and gelatin. It is equivalent to one 20 oz. soft drink.
2908344|NCT03190993|Active Comparator|Sugar Sweetened Beverage Treatment|20 oz. carbonated sugar sweetened beverage. Added ingredients include: ~2.1g whey protein powder.
2908345|NCT03190980|Experimental|5% glucose|neonates will receive 2 ml of 5% glucose before heel prick
2908346|NCT03190980|Experimental|30% glucose|neonates will receive 2 ml of 30% glucose before heel prick
2908347|NCT03190980|Placebo Comparator|Placebo|neonates will receive 2 ml of sterile water before heel prick
2908348|NCT03190967|Experimental|1/Phase I|T-DM1 + TMZ in dose escalation
2908349|NCT03190967|Active Comparator|2A / Phase II / T- DMl alone|T-DM1
2908350|NCT03190967|Experimental|2B/Phase II/T- DMl + TMZ|T-DM1 + TMZ at RP2D
2908351|NCT03190954|Experimental|1|Single-blind. Participants will undergo three scans with positron emission tomography (PET): one with [11C]NNC-112 to assess baseline D1R, another with [11C]raclopride after placebo to assess baseline D2R and a third one with [11C]raclopride after MP administration (60mg oral) to assess striatal DA release (assessed as the difference in specific binding of [11C]raclopride between baseline and MP). In addition, participants will undergo two imaging sessions with MRI to assess functional reactivity to drug-cues and to a measure of self-control (delayed discounting task), to assess RFC and to obtain structural brain measures (including diffusion tensor imaging, DTI). One of the sessions will be done under baseline conditions (no drug administered) and the other after MP (about one hour after the [11C]raclopride MP scan is completed). Neuropsychological tests (NP) and accelerometers will be used to assess cognitive performance and locomotor activity respectively
2908352|NCT03190941|Experimental|1-Phase I|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-KRAS G12V mTCR PBL + highdose aldesleukin
2908353|NCT03190941|Experimental|2-Phase II|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD dose of anti-KRAS G12V mTCR PBL + high-dose aldesleukin
2908354|NCT03190928||Patients|Patients with Follicular lymphoma (FL)
2908355|NCT03190915|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2908356|NCT03190902|Experimental|specific computer training (ST) - POMS|
2908357|NCT03190902|Active Comparator|nonspecific computer training (n-ST) - POMS|
2908358|NCT03190902|Experimental|specific computer training (ST) - ADHD|
2908359|NCT03190902|Active Comparator|nonspecific computer training (n-ST) - ADHD|
2908440|NCT03190304|Experimental|Neprilysin (LCZ696)|LCZ696 at a dose of 200 mg twice daily for 6 months
2908360|NCT03190889|No Intervention|STAN|Patients in the STAN group will participate in twelve sessions of supervised physical therapy over a six week period. Patients will participate in agility and plyometric drills, and continue strength exercises from the previous treatment phase. The clinic program will be performed in conjunction with a home running program. Patients in this group will not receive feedback from the therapist regarding movement quality during activities.
2908361|NCT03190889|Other|HOME|HOME Program is distinguished by patients participating in a home only intervention that consists of running and strengthening exercises performed twice a week for six weeks. No plyometric or agility drills are performed in this study arm. This represents the minimal intervention to prepare for a return to sports. No neuromuscular training or movement training beyond the sagittal plane will be performed.
2908362|NCT03190889|Experimental|TNMT|Patients who are enrolled in the TNMT group will participate in 12 sessions of supervised outpatient physical therapy over a six week period. The TNMT protocol is distinguished by performance of exercises designed to enhance core and hip strength, performance of neuromuscular training exercise that are designed to correct movement flaws associated with second ACL injury25, providing verbal and visual feedback and performance of single leg drills on both legs.
2908363|NCT03190876|No Intervention|Suction drain|Conventional body contouring procedure, application of Redon suction drains, drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7
2908364|NCT03190876|Active Comparator|Passive drain|Conventional body contouring procedure, application of drains without suction (passive drainage), drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7
2908365|NCT03190876|Active Comparator|No drain|Conventional body contouring procedure, no application of drains
2908366|NCT03190863|Experimental|Motor imagery combined with neurofeedback (MINF)|
2908367|NCT03190863|Active Comparator|Motor imagery (MI)|
2908368|NCT03190863|Sham Comparator|Control (C)|
2908369|NCT03190850|Experimental|Intervention|"Intervention: Exercises wih load Device: Powerbreathe"
2908370|NCT03190850|Placebo Comparator|Control|Control: Exercises without load
2908371|NCT03190824|Experimental|OBP-301|Eligible patients with unresectable Stage III and IV melanoma will receive up to 13 treatments of OBP 301 at a concentration of 1 × 1012 virus particles (VP)/mL for 24 weeks.
2908372|NCT03190811|Experimental|Anti-PD-1 plus DC-CIK|
2908373|NCT03190811|Active Comparator|Anti-PD-1 alone|
2908374|NCT03190798|Active Comparator|Canagliflozin Group|Assuming a 25% dropout rate, 16 individuals in the canagliflozin group
2908375|NCT03190798|Placebo Comparator|Placebo Group|Assuming a 25% dropout rate, 11 individuals in the placebo group
2908376|NCT03190785|Experimental|Benzoic acid washout and exposure|All subjects will be in this arm which employs a pre-post exposure design. Subjects will undergo a 2 week washout period where they avoid consumption of benzoate containing beverages. Then there is a 1 week exposure period comprising daily consumption of benzoate containing beverages to result in up to 5 mg/kg per day benzoic acid intake.
2908377|NCT03190772|Experimental|Positive placebo group|Participants receive a placebo nasal spray. However, they are told that it protects from experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
2908378|NCT03190772|Placebo Comparator|Placebo control group|Participants receive a placebo nasal spray and are told that it is a placebo. Participants watch a film sequence that is supposed to induce sadness.
2908379|NCT03190772|Other|No-treatment control group|Participants do not receive the nasal spray. Participants watch a film sequence that is supposed to induce sadness.
2908380|NCT03190746||No SNP|Subjects have two copies of the wild type gene
2908381|NCT03190746||SNP present|Subjects have one or two copies of the SNP
2908382|NCT03190733|Experimental|ATG 10.0mg/kg|ATG 10.0mg/kg group refers to treatment with ATG in the total dose of 10.0mg/kg.
2908383|NCT03190733|Active Comparator|ATG 12.5mg/kg|ATG 12.5mg/kg group refers to treatment with ATG in the total dose of 12.5mg/kg.
2908384|NCT03190720|Experimental|Mobile Community First|Participants will be registered to a mobile community at first. After 6 weeks, They will leave the mobile community.
2908385|NCT03190720|Experimental|Mobile Community Later|Participants will not be registered to a mobile community at first. After 6 weeks, They will be registered to the mobile community.
2908386|NCT03190707|Experimental|Intervention|The intervention consists of three key components aiming at promoting a better attachment between child and mother/parents and through that giving the child the best possible beginning of life. The three components aim at: 1) detecting ill-being in vulnerable pregnant woman and initiation of potential treatment, 2) strengthening knowledge sharing and organizing the course for the families across the sectors, 3) strengthening parenting skills.
2908387|NCT03190707|No Intervention|Control|The existing practice for psychosocial vulnerable pregnant women on Gentofte-Herlev Hospital, Denmark, will be offered for women allocated to the control group. The control group will be measured at the same follow-up periods as the intervention group.
2908388|NCT03190694|Experimental|Dapagliflozin 10mg Tablet|10 mg Green, plain, diamond shaped, film coated tablet (orally)
2908389|NCT03190694|Placebo Comparator|Placebo Matching Dapagliflozin Tablet|Green, plain, diamond shaped, film coated tablet. Does not contain active ingredient
2908390|NCT03190681|Experimental|methylphenidate|
2908391|NCT03190681|Placebo Comparator|inactive pill|
2908392|NCT03190668|Active Comparator|First Regimen Group|The first regimen will consist of a bolus dose of Cefazolin 30mg/kg up to a maximum of 2000mg IV administered prior to surgical incision. The same pre-operative dose of Cefazolin will be repeated every 3 hours until the completion of surgery. Two will paraspinal muscle microdialysis catheters and two subcutaneous microdialysis catheters will be inserted.
2908393|NCT03190668|Active Comparator|Second Regimen Group|The second regimen will consist of an initial bolus dose of 30 mg/kg up to maximum of 2000 mg. Following the initial bolus dose a continuous Cefazolin drip will start until the end of surgery. Cefazolin drip dose will be 10 mg/(kg*h) up to maximum of 667 mg/h.Two microdialysis catheters will be inserted into a paraspinal muscle and two microdialysis catheters will be inserted subcutaneously.
2908394|NCT03190655|Experimental|Aluminaid|Treatment group: Aluminaid wound dressing
2908395|NCT03190655|Active Comparator|Hydrogel|Hydrogel wound dressing (Trademark: Burnshield)
2910507|NCT03176238|Experimental|everolimus and exemestane|Everolimus (RAD001) and exemestane combination
2908396|NCT03190642|Active Comparator|1000mg methylprednisolone group|Evaluating effects of 1000mg of methylpresdnisolone administered immediately preoperatively and its effects on swelling.
2908397|NCT03190642|Active Comparator|125mg methylprednisolone group|Evaluating effects of 125mg of methylpresdnisolone administered immediately preoperatively and its effects on swelling.
2908398|NCT03190629|Active Comparator|High-flux hemodialysis|3 times per week
2908399|NCT03190629|Experimental|On line-hemodiafiltration|3 times per week
2908400|NCT03190616|Experimental|drug,apatinib|apatinib 500mg/qd, 28d/cycle
2908401|NCT03190603|Experimental|Celecoxib arm|Axial Spondyloarthritis patients who takes celecoxib 400mg for day
2908402|NCT03190590|Active Comparator|Transcranial direct current stimulator (tDCS)|tDCS is delivered noninvasively via electrodes applied to the surface of the head, and a mild electrical current is given during motor training.
2908403|NCT03190590|Active Comparator|Transcranial magnetic stimulation (TMS)|TMS is delivered noninvasively via a hand-held coil applied to the surface of the head, and a magnetic pulse probes cortical circuitry [this is not repetitive TMS and so does NOT modulate brain excitability.]
2908404|NCT03190590|Placebo Comparator|Sham-tDCS|delivered by briefly turning on and off the stimulator at the beginning of training, which mimics the sensation of true stimulation.
2908405|NCT03190577|Experimental|patients with neuropathy of unknown aetiology|from a blood sample performed at inclusion, a genetic analysis will be performed to research transthyretin mutation
2908406|NCT03190551|Active Comparator|retroclavicular approach|Patients in this group will be randomized to receive an retroclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
2908407|NCT03190551|Active Comparator|costoclavicular approach|Patients in this group will be randomized to receive an costoclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
2908408|NCT03190525||Multiple Myeloma patients|
2908409|NCT03190512|Active Comparator|Test Group|"Psychological measurements were taken from periodontal disease patients before treatment and after 6 weeks.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and the Psychological questionnaires were filled."
2908410|NCT03190512|Placebo Comparator|Control Group|"Psychological measurements were taken from periodontal disease patients at the baseline and after 6 weeks without the periodontal treatment.~Intervention: The Psychological questionnaires were filled."
2908411|NCT03190499||Children with childhood cancer|Children with childhood cancer that are having medical treatment will be assessed with family based questionnaires.
2908412|NCT03190486|Experimental|Men contact-less with children|functional Magnetic Resonance Imaging (fMRI).
2908413|NCT03190486|Experimental|Women contact-less with children|functional Magnetic Resonance Imaging (fMRI).
2908414|NCT03190486|Experimental|Father contact-less with children|functional Magnetic Resonance Imaging (fMRI).
2908415|NCT03190486|Experimental|Mother contact-less with children|functional Magnetic Resonance Imaging (fMRI).
2908416|NCT03190473|Experimental|Svelte|
2908417|NCT03190473|Active Comparator|Control|
2908418|NCT03190460|Experimental|Intervention|
2908419|NCT03190460|Other|Education|
2908420|NCT03190447|Active Comparator|Conventional dressing|The conventional dressing (sterile gauzes) will be applied
2908421|NCT03190447|Experimental|Aquacel Surgical®|Postoperative sterile dressing composed by non-woven inner pad (in contact with wound) Technology Hydrofiber® formed from sodium carboxymethylcellulose
2908422|NCT03190447|Experimental|Mepilex Border post-op®|Flexible absorbent all-in-one post-op dressing, super-absorbent fibres for high and fast absorption with optimised retention.
2908423|NCT03190447|Experimental|Opsite post-op visible®|Adhesive dressing with absorbent foam in the form of a grid to visualize the wound without lifting the dressing
2908424|NCT03190447|Experimental|Urgotul ABSORB border silicona®|A soft-adherent TLC (Technology Lipido-Colloid) layer (polymers and hydrocolloid particles) combined with an absorbent polyurethane foam pad and a highly absorbent layer. A vapour permeable waterproof outer film with silicone adhesive on the edges.
2908425|NCT03190434||amniotic fluid|amniotic fluid identification by AL-SENSE product
2908426|NCT03190421|Experimental|Expanded Urinary Culture (EQUC)|Participants in this arm will receive the expanded urine culture
2908427|NCT03190421|Active Comparator|Standard Urine Culture (SUC)|Participants in this arm will receive the standard urine culture
2908428|NCT03190408||Shock|
2908429|NCT03190395|Experimental|CPVI Group|CPVI Group: Pure Circumferential pulmonary vein isolation(CPVI)
2908430|NCT03190395|Active Comparator|CPVI+LARA Group|CPVI+LARA Group: Circumferential pulmonary vein isolation combine with Left Atrium Roofline Ablation
2908431|NCT03190382|Experimental|Received Decision Tool|Peripheral artery disease patients that received the decision support tool.
2908432|NCT03190369|Experimental|Hylan G-F 20|At Day 1, patients randomized to active treatment will receive an IA injection of Hylan G-F 20, containing hylan polymer in buffered physiological sodium chloride solution (pH 7.2 ±0.3), in the target knee.
2908433|NCT03190369|Placebo Comparator|Placebo|At Day 1, patients randomized to placebo treatment will receive an IA placebo injection in buffered saline (PBS) in the target knee.
2908434|NCT03190356||Primary diagnosis alcohol use disorder (AUD)|Primary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System
2908435|NCT03190356||Secondary diagnosis alcohol use disorder (AUD)|Secondary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System
2908436|NCT03190330|Experimental|Ibrutinib|Participants will receive ibrutinib 420 milligram (mg) (three 140 mg capsules) as a single daily dose for chronic lymphocytic leukaemia (CLL) and 560 mg (four 140 mg capsules) as a single daily dose for mantle cell lymphoma (MCL) for up to 12 months or till disease progression, whichever is earlier.
2908437|NCT03190317||HIV-infected Veterans who use MHV|This group represents the population of HIV-infected Veterans active in care at a VA health system, who have been diagnosed with HIV and use MHV.
2908438|NCT03190317||HIV-infected Veterans who do not use MHV|This group represents the population of HIV-infected Veterans active in care at a VA health system, who have been diagnosed with HIV and do not use MHV.
2908439|NCT03190304|Active Comparator|Enalapril|Enalapril at a dose of 10 mg twice daily for 6 months
2955500|NCT02865070||5 babies (premature, ages 28-31 weeks)|
2908441|NCT03190278|Experimental|Part 1: Dose Escalation|A single IV administration of UCART123 in the dose escalation phase will explore 3 doses of UCART123 ranging from 6.25x10^5 cells/kg to 6.25 x10^6 cells/kg and continue until the Recommended Phase 2 Dose (RP2D) is identified.
2908442|NCT03190278|Experimental|Part 2: Dose Expansion|A single intravenous administration of UCART123. 2 Cohorts: Relapsed and Refractory AML and newly diagnosed AML in the ELN adverse genetic risk group.
2908443|NCT03190265|Experimental|CY, Nivolumab, Ipilimumab, GVAX, CRS-207|
2908444|NCT03190265|Experimental|Nivolumab, Ipilimumab, CRS-207|
2908445|NCT03190252||Trimix|Exposure to ambient pressure of maximum 11 ATA breathing Trimix. Exposure to oxygen partial pressure of 130 kPa breathing Trimix.
2908446|NCT03190252||Control|Not diving
2908447|NCT03190239|Experimental|Apatinib|Pemetrexed 500 mg/m2, qm; Apatinib 250 mg Po qd
2908448|NCT03190226|Experimental|L-PRF membranes|"Intra-oral split thickness preparation - apically repositioned to the periosteum.~L-PRF membranes will be used to cover the site. Free Gingival Grafts will be used to cover the site."
2908449|NCT03190213|Experimental|Pembrolizumab, all patients|
2908450|NCT03190200||MRI|Subjects with healthy knees
2908451|NCT03190187|Active Comparator|Spinal manipulation|Spinal manipulation to the spine will be applied to participants enrolled in this group.
2908452|NCT03190187|Sham Comparator|Sham manipulation|Sham technique wich mimic the intervention manipulation with less force and different body location will be applied.
2908453|NCT03190174|Experimental|Arm 1|"This is an open label, dose-seeking phase 1b study using a defined dose of nivolumab and escalating doses of Nab-Rapamycin (ABI-009) given intravenously.~I. Dose Escalation Phase 1 Part of Study: The study will employ the standard cohort of three design. No intra-patient dose escalation will take place.~II. Expansion Phase 1b Part of Study: Following dose escalation, an additional 22-28 patients will receive ABI-009 at the MTD and defined doses of nivolumab to assess overall safety and potential efficacy in a greater number of patients. Patients in the expansion phase of the study may continue treatment up to 18 three-week cycles or until significant disease progression or unacceptable toxicity occurs."
2908454|NCT03190161|Experimental|Schizophrenia Patients|Clinician verification diagnosis of Schizophrenia or Schizoaffective Disorder
2908455|NCT03190148|Other|Pregnant women with RYGB-operation|Pregnant women with a history of RYGB-Operation were investigated.
2908456|NCT03190148|Other|Normal weight pregnant women|Normal weight pregnant women were investigated.
2908457|NCT03190148|Other|Obese Pregnant women|Obese pregnant women were investigated.
2908458|NCT03190135|Experimental|BOKS: 2 day per week|
2908459|NCT03190135|Experimental|BOKS: 3 day per week|
2908460|NCT03190135|No Intervention|Non-BOKS|
2908461|NCT03190122|Active Comparator|group with pealing of the outer layer of cavernous sinus|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Pealing Of The Outer Layer Of The Cavernous Sinus
2908462|NCT03190122|Experimental|group without pealing of the outer layer of cavernous sinus|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision Without Pealing Of The Outer Layer Of The Cavernous Sinus
2908463|NCT03190083|Experimental|3-dimensional tomosynthesis mammogram|The patients assigned a Breast imaging-reporting and data system (BIRADS) 5 category at the time of diagnosis and all new diagnosed breast cancer patients, will undergo a separate 2-D plus DBT in addition to the standard 2-D mammogram
2908464|NCT03190070|Experimental|Study group|All study participants are in the same group and will have their kidney function measured twice, before and after ingestion of protein, 1 g/(kg body weight). The protein will be given in the form of the protein drink Liquacel (Global Health Products, Rochester, NY).
2908465|NCT03190057||Consecutive percutaneous coronary intervention|
2908466|NCT03190044|Experimental|Migraineurs (verum)|One pill per day of PACR: magnesium 281,25 mg; partenium 150 mg (partenolides 1200mcg); andrographis 100 mg (andrographolides 10 mg); co-enzyme Q10 20 mg; riboflavin 4,8 mg.
2908467|NCT03190044|Placebo Comparator|Migranineurs (placebo)|One pill per day of placebo: Cellulose
2908468|NCT03190031|Experimental|Endurance respiratory muscle training|The intervention consists in performing isocapnic hyperpnea at 70-80% of maximal voluntary ventilation for 20 min, 5 times a week, for 8 weeks
2908469|NCT03190031|Active Comparator|Resistance inspiratory muscle training|The intervention consists in performing inspiratory resistive breathing at 70-80% of maximal inspiratory pressure for 20 min, 5 times a week, for 8 weeks
2908470|NCT03190018|Experimental|Single group with CLS PD device|Aim of the intervention is to evaluate the adsorbs of uremic toxins and certain ions with Purcart and the evaluation of the glucose-salt solution ability to achieve stable osmolality. The intervention is during an eight hour study session.
2908471|NCT03190005|Placebo Comparator|group 1|placebo control without medication.
2908472|NCT03190005|Experimental|group 2|hyper-reactive responser after clopidogrel.
2908473|NCT03190005|Experimental|group 3|hypo-reactive responser after clopidogrel.
2908474|NCT03190005|Experimental|group 4|normo-reactive responser after clopidogrel.
2908475|NCT03189992|Experimental|CC-GSYXZ|Colon cancer with Chinese medicine syndrome Yin deficiency of liver and kidney and spleen deficiency.Intervented by Bushen-Jianpi Dedoction and cinobufotalin injection
2908476|NCT03189992|Placebo Comparator|CC-WZ|Colon cancer with none Chinese medicine syndrome.Intervented by cinobufotalin injection
2908477|NCT03189992|Experimental|HCC-GSYXZ|Hepatoma cancer with Chinese medicine syndrome Yin deficiency of liver and kidney and spleen deficiency.Intervented by Bushen-Jianpi Dedoction and cinobufotalin injection.
2908478|NCT03189992|Placebo Comparator|HCC-WZ|Hepatoma cancer with none Chinese medicine syndrome.Intervented by cinobufotalin injection
2908479|NCT03189979|Experimental|Club Fit|Intervention includes exposure to physical activity and healthy eating intervention policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
2908480|NCT03189966|Experimental|Group T|Patients in transversalis fascia plane block group(Group T) will receive ultrasound-guided transversalis fascia plane block using0.3% ropivacaine(1ml/kg) after general anesthesia
2908781|NCT03187860||Non-smoking controls|"Subjects in this group have never smoked and have no known lung disorders.~Intervention: Bronchial Biopsy + ALI culture"
2908481|NCT03189966|Experimental|Group Q|Patients in quadratus lumborum block group（Group Q） will receive ultrasound-guided quadratus lumborum block using0.3%ropivacaine(1ml/kg).after general anesthesia.
2908482|NCT03189966|No Intervention|Group C|Patients in the third group as control (Group C)receive no nerve block.Patients will be extubated based on clinical criteria.
2908483|NCT03189953|Experimental|68Ga-NODAGA-exendin PET/CT|68Ga-NODAGA-exendin PET/CT
2908484|NCT03189940|Active Comparator|App user group|
2908485|NCT03189940|Sham Comparator|Control group|Control participants, the physicians could assess the lifestyle and recommend further lifestyle modification only on the basis of the participants' recalls
2908486|NCT03189927|Experimental|BD-Covered stent|Device: BD-Covered stent for refractory benign esophageal strictures with of without fistulae
2908487|NCT03189914|Experimental|RX-3117 + Abraxane|"RX-3117: oral, 500 - 700 mg/ day for 5 days on/ 2 days off for 3 weeks. 1 washout week/ cycle.~Abraxane: 75 - 125 mg/m^2, infused once per week for 3 weeks. 1 washout week/ cycle."
2908488|NCT03189901|No Intervention|Regular Management|Patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level who treated by regular strategy in guideline.
2908489|NCT03189901|Experimental|Regular management+Levosimendan|Patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level who treated by regular strategy in guideline and levosimendan.
2908490|NCT03189888|Other|apheresis|leukapheresis in ulcerative colitis
2908491|NCT03189875||Observation|Cohort of patients with moderate-to-severe SLE
2908492|NCT03189862|Experimental|CHAMP|CHAMP, is a mastery climate motor skills interventions, that provides children the opportunity to establish behaviors that reinforces decision-making while participating in a variety of challenging movement & physical activity tasks. Duration of CHAMP is 30 min/day 4 days/week for 30 weeks. CHAMP consist of a) a 2-3 min of motor skill introductory activity that includes a group motor activity, the teaches the lesson, includes a demonstration, and understanding of developmentally appropriate learning clues b) 25 min of motor skill instruction & practice where preschoolers engage in 3-4 motor activity stations that align with the TARGET structures c) & 2-3 min motor skill closure activity that involves a review of the lesson & critical elements.
2908493|NCT03189862|No Intervention|Control - Free Play|The control/free play condition will be the preschools typical activity programs (i.e., outdoor/indoor recess) and will be implemented according to the existing procedures within the preschool centers. The centers outdoor program consist of outdoor free-play activity on a large playground area with a variety of play structures (swings, slides, ladders) that promote gross movement and activity in preschoolers. For the control condition, there will be no planned instruction nor activities provided by the classroom teachers.
2908494|NCT03189836|Experimental|ACTR707 in combination with rituximab|
2908495|NCT03189810|Experimental|Active rTMS (20Hz)|Active rTMS administered with the MagProX100/R30 stimulator equipped with the B65 active coil for dorsolateral prefrontal cortex (DLPFC) stimulator (MagVenture, Farum, Denmark).The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
2908496|NCT03189810|Sham Comparator|Sham rTMS|Sham rTMS administered with the MagProX100/R30 stimulator equipped with the B65 placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark). The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
2908497|NCT03189797|Experimental|study group|"After defining the individual patient's likelihood risk status and the diagnosis for each lesion, ICCMS presents a management element to build a comprehensive patient care plan as follow:~Homecare program:~Tooth brushing 2/day with a higher efficacy fluoride toothpaste (≥ 1,450 ppm F-), or High F- prescription toothpaste following the dental team instructions~Prescribed F- mouth rinse~Clinical approaches :~Motivational engagement (discuss with patients how to improve oral health behaviours - including amount of sugar), maintain dental visits at risk-based intervals~Sealants~F- varnish 2 times /6months .~F- gels or solution~Recalls up to every 3 months: professional cleaning & topical F- application on active lesions~Dietary intake interventions~Altering medication-induced hyposalivation if exists."
2908498|NCT03189797|No Intervention|control group|Participants assigned to the control condition will be advised to maintain their existing lifestyles. For ethical reasons, if the program shows its effectiveness, it will be made available to all groups at the end of the study.
2908499|NCT03189784|Experimental|mobilization group|this group will receive mobilization with movement techniques.
2908500|NCT03189784|No Intervention|Control group|The control group will receive no intervention
2908501|NCT03189771|Experimental|occlusal surface reduction|occlusal surface reduction after single visit root canal treatment
2908502|NCT03189771|Placebo Comparator|no occlusal surface reduction|No occlusal surface reduction after single visit root canal treatment
2908503|NCT03189758|Experimental|Intervention|Participants will follow a Observational Control Diet (CON) diet followed by an Controlled Dietary Sodium Restriction (INT) diet.
2908504|NCT03189745|Experimental|MenACWY-TT Booster|10 year booster dose of MenACWY
2908505|NCT03189732|Experimental|Metformin oral +exercise|Metformin, one dose 2000mg, 2.5h before the start of 60 min physical exercise
2908506|NCT03189732|Active Comparator|Metformin local in AT +exercise|Metformin perfused into microdialysis probe inserted in adipose tissue, 0.3ug/min 1.5h before the exercise and during 60min physical exercise
2908507|NCT03189732|Active Comparator|No metformin + exercise|60min physical exercise without pretreatment of metformin
2908508|NCT03189719|Experimental|Pembrolizumab + Cisplatin + 5-FU|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W), cisplatin 80 mg/m^2 IV Q3W, and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours). All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
2908509|NCT03189719|Placebo Comparator|Placebo + Cisplatin + 5-FU|Participants receive placebo to pembrolizumab (saline) IV Q3W, cisplatin 80 mg/m^2 IV Q3W, and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours). All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
2908844|NCT03187379|Active Comparator|Control|Subjects in this arm will receive 0.25% bupivacaine alone
2908510|NCT03189706|Experimental|Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS)|Each cycle consists of four doses of hu3F8, five doses each of irinotecan and temozolomide and five doses of GM-CSF.
2908511|NCT03189693|Experimental|PVB group|Patients will receive two PVB injections at levels T12-L1 and L1-L2 using anesthetic mixture
2908512|NCT03189693|Placebo Comparator|Placebo|Patients will receive two PVB injections containing placebo at levels T12-L1 and L1-L2
2908513|NCT03189680|Experimental|Exercise therapy|Parkinson's disease group that receive 3 weeks of intensive exercise therapy in a rehabilitation center.
2908514|NCT03189680|No Intervention|Control|Parkinson's disease control group that will not receive exercise treatment.
2908515|NCT03189680|No Intervention|Healthy|A healthy group whose results will be compared with Parkinson's disease groups.
2908516|NCT03189667|Experimental|Drug coated balloon angioplasty|"Vessel preparation with Pre dilatation~Vessel treatment with Drug-coated balloon"
2908517|NCT03189667|Active Comparator|Plain balloon angioplasty|"Vessel preparation with Pre dilatation~Vessel treatment with additional Plain balloon angioplasty:"
2908518|NCT03189654||Treatment group|Non-invasive ventilation after pleurocentesis
2908519|NCT03189654||Control group|Oxygen Administration via nasal tube
2908520|NCT03189641|Experimental|Cilostazol eluting stent system (CES-1)|
2908521|NCT03189628|Experimental|stromal vascular fraction|Transplantation of resuspended SVF
2908522|NCT03189628|Placebo Comparator|saline|1 ml saline without cells will be used as placebo.
2908523|NCT03189615|Experimental|Patients with mild hepatic impairment (Group1)|
2908524|NCT03189615|Experimental|Patients with moderate hepatic impairment (Group 2)|
2908525|NCT03189615|Experimental|Healthy subjects (Group 3)|
2908526|NCT03189589|Experimental|GSK2269557 500 µg receivers|Randomized healthy subjects will receive single dose of GSK2269557 500 µg via inhalation route via the ELLIPTA DPI.
2908527|NCT03189589|Experimental|GSK2269557 750 µg receivers|Randomized healthy subjects will receive single dose of GSK2269557 750 µg via inhalation route via the ELLIPTA DPI.
2908528|NCT03189576|Other|CRC patients after primary surgery|sequential blood draw taken to monitor residual disease
2908529|NCT03189563|Placebo Comparator|Placebo|placebo, tid
2908530|NCT03189563|Experimental|DA-9805 low|DA-9805 45mg
2908531|NCT03189563|Experimental|DA-9805 high|DA-9805 90mg
2908532|NCT03189550||Historical control|Patients who underwent colorectal surgery with standard perioperative care starting from June 2014 and progressing backward in time.
2908533|NCT03189550||ERAS without SOC noninvasive hemodynamic monitoring|Patients who underwent colorectal surgery after implementation of standard of care (SOC) ERAS perioperative care from July 2014 to February 2015
2908534|NCT03189550||ERAS with SOC noninvasive hemodynamic monitoring|Patients who underwent colorectal surgery after implementation of standard of care ERAS perioperative care with standard of care noninvasive hemodynamic monitoring (with the ClearSight System, Edwards Lifesciences) after February 2015
2908535|NCT03189537|Experimental|Ingavirin|Ingavirin (Imidazolyl Ethanamide Pentandioic Acid) capsules, 90 mg once daily for 7 days
2908536|NCT03189537|Placebo Comparator|Placebo|Placebo oral capsule, once daily for 7 days
2908537|NCT03189524|Experimental|BGB-3111|"Two regimens of BGB-3111 320 mg daily (160 mg BID, administered in the morning and at night, or 320 mg QD) and 3+3 design is adopted for the study Part I to determine RP2D. The RP2D determined will be used in Part II to further evaluate the preliminary anti-tumor effects of BGB-3111 in Chinese subjects with follicular lymphoma (FL) or marginal zone lymphoma (MZL)"
2908538|NCT03189511|Experimental|Experimental|Volunteers receive calorimetric tests and FDG PET scans pre and post 2 weeks of Fluvastatine.
2908539|NCT03189498|Experimental|Group 1: Participants With Normal Renal Function|Adult participants with normal renal function (estimated glomerular filtration rate [eGFR] greater than or equal to [>=] 90 milliliter per minute [mL/min]) will receive a single oral dose of 1,000 milligram (mg) JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
2908540|NCT03189498|Experimental|Group 2: Participants With Mild Renal Impairment|Adult participants with mild impaired renal function (eGFR >=60 to less than [<] 90 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
2908541|NCT03189498|Experimental|Group 3: Participants With Moderate Renal Impairment|Adult participants with moderate impaired renal function (eGFR >=30 to <60 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
2908542|NCT03189498|Experimental|Group 4: Participants With Severe Renal Impairment|Adult participants with severe impaired renal function (eGFR >= 15 to <30 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
2908543|NCT03189498|Experimental|Group 5: Participants With ESRD With or Without Hemodialysis|Adult participants with end-stage renal disease (ESRD) (eGFR <15 mL/min if not on hemodialysis or requiring hemodialysis treatment for at least 3 months before screening if on hemodialysis) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period. Participants with ESRD on hemodialysis will be dosed on an interdialysis day within 24 hours of their last hemodialysis treatment.
2908544|NCT03189485|Experimental|Normal Controls|All subjects will receive 18F-AV-1451 PET scan.
2908545|NCT03189472|Experimental|active tDCS|
2908546|NCT03189472|Sham Comparator|sham tDCS|
2908547|NCT03189459|Active Comparator|HVP Patient-Subject|"Patients will be asked to participate in four study visits, which will involve in-home clinical assessments, a needs assessment, and completion of some questionnaires. Additional information will be obtained from patients' routine medical records: their medical and medication history, family history, neurological examination findings, and office visit records.~Completion of Home Visit Program intervention."
2908572|NCT03189290|Placebo Comparator|placebo|"Sham Comparator: saline group~- Before general anaesthesia, ultrasound guided Sham Quadratus Lumborum Block (QLB) will be performed with 30 mL saline."
2908573|NCT03189264|Active Comparator|Percutaneous nephrolithotomy with Coaxial Dilatation|Percutaneous nephrolithotomy with Coaxial Dilatation for treatment of kidney stones greater than 2 cm.
2908574|NCT03189264|Placebo Comparator|Percutaneous nephrolithotomy with Pneumatic Balloon|Percutaneous nephrolithotomy with Pneumatic Balloon for treatment of kidney stones greater than 2 cm.
2908575|NCT03189238|Placebo Comparator|Placebo|
2908548|NCT03189459|Active Comparator|HVP Caregiver-Subject|"Caregivers enrolling in the study will be asked to participate in the four home visits, which will involve in-home clinical assessments and completion of some questionnaires. After the first home visit, caregivers will be matched with a peer mentor, an individual who was a prior caregiver to someone with PD who is interested in sharing their knowledge, experience, and time to help improve the lives of current caregivers. Once a week, for a period of 4 months between home visits 2 and 3, caregivers will be asked to meet with their peer mentor, who will be trained to serve as a resource and listening ear, in addition to the medical team.~Completion of Home Visit Program and Caregiver Mentorship Program interventions."
2908549|NCT03189459|No Intervention|De-identified Control Subjects|Control subjects will be drawn from the National Parkinson Foundation Parkinson Outcomes Project (POP). Patient-caregiver dyads will be matched on patient gender, age, and HY stage.
2908550|NCT03189459|Active Comparator|HVP Peer Mentors|"Peer mentors enrolled in this study would be asked to complete a five-hour mentor training program. During this training, caregivers will be asked to complete some questionnaires about their background and caregiving experience. After completion of the mentorship training, peer mentors will be paired with a mentee who is a current caregiver enrolled in the home visit study along with their loved one with Parkinson's. Peer mentors will be asked to speak with their mentee once a week for 16 weeks. After a 16 week break, peer mentors will be paired with a second mentee and will repeat the process for another 16-week-long mentoring session.~Completion of Caregiver Mentorship Program intervention."
2908551|NCT03189446|Experimental|Vaginal Cuff Brachytherapy + Chemotherapy|Vaginal cuff brachytherapy followed by Carboplatin (AUC 6) on day 1and Paclitaxel 80 mg/m2 IV over 1 hour days 1, 8, and 15 X 3 total cycles
2908552|NCT03189433|Active Comparator|Ryanodex + Standard of Care|Ryanodex (dantrolene sodium) 50 mg/mL suspension to be administered as a rapid IV push of 2.5 mg/kg, added to Standard of Care (SOC). SOC is defined as efficient body cooling by physical methods and supportive measures [ice packs, evaporative cooling(application of room temperature water via mist with use of a fan], benzodiazepines to ameliorate shivering, IV fluids, respiratory support, and other treatments deemed necessary to treat complications or comorbidities]. Administer a single dose of Ryanodex. If a subject does not show an adequate clinical response within 10 - 30 minutes post-dose, a second IV bolus dose of 2.5 mg/kg may be administered.
2908553|NCT03189433|No Intervention|Standard of Care only (SOC)|Standard of Care is defined as efficient body cooling by physical methods and supportive methods and supportive measures[ice packs, evaporative cooling (application of room temperature water via mist with use of a fan], benzodiazepines to ameliorate shivering, IV fluids, respiratory support, and other treatments deemed necessary to treat complications or comorbidities].
2908554|NCT03189420||Glioblastoma|Samples of brain tumor diagnosed as glioblastoma
2908555|NCT03189420||Low grade glioma|Samples of brain tumor diagnosed as low grade glioma
2908556|NCT03189407|Other|Moringa oleifera tea in T2DM patients|The study was a pre/post design for type 2 diabetes mellitus patients on metformin in which each patient acted as his/her control. Intervention of twice daily pre-packed 400g dried Moringa oleifera leaves to be prepared as tea by the patients was done. Evaluation of the effect of the tea on metformin steady state concentrations and blood glucose measurements were done.
2908557|NCT03189394|Experimental|PRIDE|The in-person experimental condition, PRIDE, consists of in-person intervention activities that are scheduled over two Saturdays, back to back, approximately 3 hours each (6 hours total). This intervention consists of relationship-focused activities for couples to take part in together, focusing on relationship communication, dynamics, and sexual agreements.
2908558|NCT03189394|Experimental|ePRIDE|ePRIDE is an online adaptation of the experimental condition, PRIDE, and consists of online intervention activities that are scheduled to be completed over two weeks, lasting approximately 6 hours total. This intervention consists of relationship-focused activities for couples to take part in together, focusing on relationship communication, dynamics, and sexual agreements, and is designed for couples to take together sitting side by side.
2908559|NCT03189394|Active Comparator|Men's Health|Men's Health is the active comparator group. Participants in this group go through in-person intervention days, scheduled on Saturdays back to back, but differ from the PRIDE arm because this intervention does not focus on relationship dynamics. Instead, these two Saturday intervention days focus on general men's health, including heart health, cancer, and STDs.
2908560|NCT03189381|Experimental|Cohort A|Standard PCI dose
2908561|NCT03189381|Experimental|Cohort B|Low PCI dose
2908562|NCT03189368||Heart failure patients eligible for CRT|"Adult, consenting patients with any cardiomyopathy type and an existing I/IIa indication for a CRT-D device will receive a device with multi-site pacing capability. Initially, for 6 months, optimal, conventional, resynchronization therapy will be delivered. Following this, all patients will crossover to optimized multi-site pacing, and receive this therapy for 6 more months. Optimization of therapy will be determined based on maximization of cardiac output, i.e. maximization of left ventricular outflow tract velocity-time integral.~Baseline measurements of serum creatinine and ventriculoarterial coupling will also be acquired."
2908563|NCT03189355|Experimental|Patients With Septic Shock|Blood sampling on D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube and D4 zonulin Bioelectrical impedance vector analysis on D1 + D4 Muscular echography on D1 + D4
2908564|NCT03189342|Experimental|Single Task Training|Performed balance and gait exercises
2908565|NCT03189342|Experimental|Dual task training|Performed cognitive activity simultaneously with balance and gait exercises
2908566|NCT03189342|Experimental|Exercise-Cognitive Activity Combined Training|Performed cognitive, balance and gait activity training asynchronously at different times during the same day
2908567|NCT03189329|Active Comparator|Group L|Patients undergoing block with 2% lidocaine hydrochloride
2908568|NCT03189329|Active Comparator|Group LB|Patients undergoing block with 0.5% levobupivacaine
2908569|NCT03189316|Other|subjects with ovarian cyst|Peritoneal fluid sample obtained from coelioscopy for exploration of ovarian cysts and blood sample
2908570|NCT03189316|Other|subjects with peritoneal dialysis|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample
2908571|NCT03189290|Active Comparator|ropivacaine|"Active Comparator: ropivacaine group~- Before general anaesthesia, ultrasound guided Quadratus Lumborum Block (QLB) will be performed with 30 mL 0.33% Ropivacaine"
2908576|NCT03189238|Active Comparator|PRP|
2908845|NCT03187366|No Intervention|Status quo|Status quo pesticide use
2908577|NCT03189225|Other|Capillary And Venous Accuracy|All subjects provided blood sample(s) to be tested on three Blood Glucose Monitoring Systems ( OneTouch Ultra 2, OneTouch Verio (Rice), OneTouch SelectPlus), LifeScan reference instrument ( YSI 2300) and hospitals own biochemistry analysers.
2908578|NCT03189212|Active Comparator|Usual Care Visit|
2908579|NCT03189212|Experimental|Telemedicine Visit|
2908580|NCT03189186|Experimental|Pembrolizumab|Advanced (stage II and above with multiple tumors or vena cava) and metastatic Renal Cell Carcinoma will be first treated with cryoablation on a large primary tumor and then given 200 mg pembrolizumab every 3-week for 3 cycles, followed by cytoreductive or partial/radical nephrectomy. After the surgery, patients will resume pembrolizumab for additional 5 cycles or up to a total of 2 years if a partial response is observed at the discretion of the treating medical oncologist or urologist until a complete tumor remission, disease progression, unacceptable toxicity, subject refusal, or subject death due to any cause.
2908581|NCT03189173|Experimental|All patients|"Patients will receive all four interventions in randomized order.~Note: Data will not be analyzed separately for the 16 cross-over combinations of intervention order:~Interventions: Oral appliance | Oral appliance plus oxygen | Oxygen | No treatment"
2908582|NCT03189160|Experimental|PEG-rhGH low dose|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
2908583|NCT03189160|Experimental|PEG-rhGH high dose|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
2908584|NCT03189160|No Intervention|Non-treatment control group|
2908585|NCT03189147|Experimental|Biceps Tenodesis|Patients in this group will received biceps tenodesis intervention to address their labral lesion
2908586|NCT03189147|Active Comparator|Debridement|Patients in this group will received debridement intervention to address their labral lesion
2908587|NCT03189134|Experimental|Imaging arm|Up to 5mL of 1:1000 dilute FLUORESCITE will be applied to cardiac tissue prior to imaging with Cellvizio 100 Series System with Confocal Miniprobes
2908588|NCT03189121||Healthy Volunteers|20 overweight and obese adult men
2908589|NCT03189108||Cohort 1|Patients with a diagnosis of malignant solid tumors
2908590|NCT03189095|Experimental|Intervention|
2908591|NCT03189095|No Intervention|Wait-List Control|
2908592|NCT03189082|Experimental|Intervention group|
2908593|NCT03189069||Patients prescribed apixaban|
2908594|NCT03189069||Patients prescribed dabigatran|
2908595|NCT03189069||Patients prescribed rivaroxaban|
2908596|NCT03189069||Patients prescribed warfarin|
2908597|NCT03189056||Single cohort|"single cohort for transversal study patients presenting chronic chagas disease for all patients : clinical examination/questionnaires/ quality of life/ blood sample for renal function (creatinina) and Chagas serology control if needed/ uroflowmetry/ ultrasonography~If symptomatic patient at first exploration : urodynamic exploration is proposed (cystomanometry, urethral profile, pressure/flow study). No electromyograma. No video urodynamic procedure."
2908598|NCT03189043|Experimental|Test|Use of antimicrobial surface
2908599|NCT03189043|No Intervention|Control|No antimicrobial surface
2908600|NCT03189030|Experimental|Treatment arm|pLADD treatment cycle is once every 3 weeks; starting dose 1×10^8 colony-forming units (CFU) administered IV over 1 hour, and if tolerated increasing to 1×10^9 CFU
2908601|NCT03189017|Experimental|ICP-022|"There are 5 cohorts in the Part 1 phase of the trial. Three quarters of subjects will be randomized to receive ICP-022 in a double-blind fashion. Five dose levels will be evaluated; dose escalation steps may be modified based on the safety from the previous dose. Cohort 4 will return on Day 8 and receive a single dose of ICP-022 under fed conditions.~In Part 2 phase of the trial,three quarters of subjects will be randomized to receive the ICP-022 in a double-blind fashion in 3 cohorts. ICP-022 will be administered once a day for 14 consecutive days."
2908602|NCT03189017|Placebo Comparator|Placebos|"In part 1 phase of the trial, one quarter of subjects will be randomized to receive placebo in a double-blind fashion. Cohort 4 will return on Day 8 and receive a single dose of placebo under fed conditions.~In Part 2 phase of the trial,one quarter of subjects will be randomized to receive placebo in a double-blind fashion. Placebo will be administered once a day for 14 consecutive days."
2908603|NCT03189004|Active Comparator|Identification and registration of pregnant women and servic|Pregnant women will receive auto reminder through their mobile for ANC visit prior to their scheduled date for each visit via voice message followed by text message. The schedule visit date will be calculated by the system automatically from the LMP. The reminder will include the date, time, available facilities and services for ANC, and will be sent to the women several times to ensure their ANC visits. The system will also send auto reminder through text message to the concerned service provider to check whether the pregnant woman has received ANC or not. The service provider will provide and update the ANC services and status of the particular pregnant woman. Apart from ANC reminders, the pregnant women will also receive voice message on healthcare during pregnancy, danger signs and birth preparedness.From the LMP, the expected date of delivery (EDD) will be calculated by the system and reminder will be sent to the pregnant women automatically.
2908604|NCT03189004|Active Comparator|Birth notification|The pregnant women will be encouraged and trained to notify immediately after the delivery through SMS by themselves or by anyone on behalf of the delivered women. After receiving birth notification, system will automatically update the particulars of newborns including date of birth, PNC schedule, EPI vaccination due dates for the newborn and location of service centre. The system will also send auto reminder to the mothers with a specific time schedule for PNC visit, newborn care visit and schedule of receiving vaccines for the newborn.
2908605|NCT03189004|Active Comparator|Childhood vaccination services under EPI|After the outcome of the delivery of the registered pregnant women, the system will receive the birth notification as mentioned in the birth notification process. Mothers/caregivers of the newborn will receive auto voice/text messages one day prior to their visit to the vaccination centres. A second reminder will be sent to the parents of all the targeted children through their own phones or their family's numbers collected earlier on the vaccination day at the beginning of the vaccination session for bringing their children for vaccination. A third reminder will be sent to the mothers/caregivers of the children who were not vaccinated after receiving the second reminder as scheduled on that day. The system will also provide auto reminder to the concerned service provider including EPI session wise list of targeted children. The service providers will update the status of vaccination of session using their Smartphone
2908606|NCT03189004|Active Comparator|Newly married couple identification|The Smartphones will contain specific software for newly married couple registration where some necessary information (names of newly married couple, age, address, LMP, current contraceptive use, future fertility plan and mobile phone number) can be updated and sent to the server. A unique ID number will be automatically created. This unique ID will ensure her to get necessary family planning services within the study area. Based on the information gathered through couple registration process, the system will automatically generate the most suitable family planning options for a couple and send the information to the concerned service providers. The service provider will motivate the client for the most suitable FP method option generated by the system and after taking the consent they provide the method accordingly.
2908607|NCT03189004|Active Comparator|e-Referral|There will be online referral system for the registered women and their children for ANC, PNC, delivery care, neonatal management, IMCI and other complication management in which healthcare providers from lower facilities can refer a patient to the higher facilities. The women will be identified in the higher facilities by their unique ID. The service providers will enter referral data to the system during the referral process and the patients and providers from higher facilities will get system generated reminders about the referral. The service providers in higher facilities will be able to check the health status and cause of referral using patient's unique ID number from the system and will manage accordingly as well as update the given management to the system. If the referred woman does not visit the referral facility, she will receive repeated reminders auto-generated by the system to comply the referral
2908608|NCT03189004|Active Comparator|e-monitoring|There will be web based monitoring system to oversee the progress and status of all the activities under this study for policy makers, programme peoples and other supervisors from national to the union levels. All these data will be available in the central database which will be visualized and accessible at all concerned levels through internet in particular website. They can constantly follow up the progression and healthcare delivery system of the respective area and provide regular feedback, when necessary. There will be provision of auto-generation of reports for each and every activity through the system by area and service provider specific.
2908609|NCT03188991|Experimental|NanoPac® 6 mg/mL|Single intracystic injection of NanoPac® at a dose of 6 mg/mL in a volume equal to the amount of fluid removed from the cyst
2908610|NCT03188991|Experimental|NanoPac® 10 mg/mL|Single intracystic injection of NanoPac® at a dose of 10 mg/mL in a volume equal to the amount of fluid removed from the cyst
2908611|NCT03188991|Experimental|NanoPac® 15 mg/mL|Single intracystic injection of NanoPac® at a dose of 15 mg/mL in a volume equal to the amount of fluid removed from the cyst
2908612|NCT03188978|Experimental|Treatment|Atorvastatin 40mg once daily orally for 8 weeks starting 2 weeks before AVF creation
2908613|NCT03188978|Placebo Comparator|Placebo|1 tablet once daily orally for 8 weeks starting 2 weeks before AVF creation
2908614|NCT03188965|Experimental|Dose escalation of BAY1895344 in Part A|Single-agent dose-escalation part. Part A has the objective to define the MTD and / or RP2D.
2908615|NCT03188965|Experimental|J-arm of Part A|Single-agent dose-escalation part in Japanese patients. J-arm has the objective to confirm the MTD (or RP2D) dose is safe and tolerable in Japanese patients.
2908616|NCT03188965|Experimental|Dose expansion of BAY1895344 in Part B|Single-agent expansion part. Once the MTD has been defined, safety, PK profile, PD of target engagement, and preliminary efficacy will be further evaluated in Part B of the study. Once the MTD dose has been confirmed is safe and tolerable in Japanese patients, safety, PK profile, PD of target engagement, and preliminary efficacy will be further evaluated in Part B of the study.
2908617|NCT03188952|Active Comparator|ICDAS|International Caries Detection and Assessment System : Caries assessment system which is used to assess Any carious lesions then they are rated in codes from 0,1,2,3,4,5,6
2908618|NCT03188952|Experimental|ICCMS|International Caries Classification and Management System Any carious lesions detected are rated in score as the follow:Code 0 = ICDAS 0 Code A = ICDAS 1,2 Code B = ICDAS 3,4 Code C= ICDAS 4,6
2908619|NCT03188939|Active Comparator|G s|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction, local anesthetic (30 ml bupivacaine) is injected at the point where the subclavian artery meets the first rib
2908620|NCT03188939|Active Comparator|G ic|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction,the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
2908621|NCT03188939|Active Comparator|G d|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction,half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
2908622|NCT03188900||preeclampsia|pregnancy with preeclampsia
2908623|NCT03188900||control|pregnancy without preeclampsia
2908624|NCT03188887|Active Comparator|CONTROL|Treatment with Renin Angiotensin system (RAS) blockade.
2908625|NCT03188887|Experimental|EXPERIMENTAL|Corticotherapy + RAS blockade treatment. Drug injection (intravenous) + tablets
2908626|NCT03188848|Experimental|BPI-3016|Single-dose subcutaneous injection of BPI-3016 with escalating dose from 0.6 mg
2908627|NCT03188848|Placebo Comparator|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
2908628|NCT03188835|Other|Isocaloric Diet|Two weeks of isocaloric diet
2908629|NCT03188835|Other|Fructose diet|Two weeks of hypercaloric diet supplemented with fructose
2908630|NCT03188835|Other|Glucose diet|Two weeks of hypercaloric diet supplemented with glucose
2908631|NCT03188822|Experimental|Bioabsorbable steroid releasing sinus implant|Patients will undergo bilateral endoscopic sinus surgery which will include bilateral frontal sinusotomy of Draf 2a or 2b type as previously described in the literature. At the conclusion of the procedure, if the patient still meets all inclusion criteria, one frontal sinus will be randomly assigned using the envelop method to receive a bioabsorbable steroid releasing implant and the other frontal sinus will receive a bioabsorbable nasal dressing impregnated with steroid
2908846|NCT03187366|Active Comparator|Low risk|Villages shifted to low risk pesticides that don't kill prawns
2908632|NCT03188822|Experimental|bioabsorbable nasal dressing impregnated with steroid|Patients will undergo bilateral endoscopic sinus surgery which will include bilateral frontal sinusotomy of Draf 2a or 2b type as previously described in the literature. At the conclusion of the procedure, if the patient still meets all inclusion criteria, one frontal sinus will be randomly assigned using the envelop method to receive a bioabsorbable steroid releasing implant and the other frontal sinus will receive a bioabsorbable nasal dressing impregnated with steroid
2908633|NCT03188809|Active Comparator|femoral nerve block|Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
2908634|NCT03188809|Active Comparator|adductor canal block|Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
2908635|NCT03188796|Placebo Comparator|Placebo|oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days
2908636|NCT03188796|Experimental|High Dose Vitamin D3|"oral/enteral pharmacological dose of cholecalciferol (vitamin D3) - total dose 900,000~loading dose of 540,0000 (dissolved in 37.5 ml of medium chain triglycerides - MCT)~followed by 4000 IU daily (10 drops) for the entire active study period (90 days)"
2908637|NCT03188783|Experimental|Cohort 1: GDC-0853 Low Dose|Japanese subjects will receive a single low dose of GDC-0853 or matching placebo by mouth.
2908638|NCT03188783|Experimental|Cohort 2: GDC-0853 Intermediate Dose|Japanese subjects will receive a single intermediate dose of GDC-0853 or matching placebo by mouth. Subsequently, participants will receive twice-daily intermediate doses of GDC-0853 or matching placebo by mouth for 4 days followed by a single intermediate dose of GDC-0853 or matching placebo by mouth.
2908639|NCT03188783|Experimental|Cohort 3: GDC-0853 Intermediate Dose|Caucasian subjects will receive a single intermediate dose of GDC-0853 or matching placebo by mouth. Subsequently, participants will receive twice-daily intermediate doses of GDC-0853 or matching placebo by mouth for 4 days followed by a single intermediate dose of GDC-0853 or matching placebo by mouth.
2908640|NCT03188783|Experimental|Cohort 4: GDC-0853 Low Dose|Japanese subjects will receive a single high dose of GDC-0853 or matching placebo by mouth.
2908641|NCT03188770||Mechanical Ventilation|Patients under mechanical ventilation in the ICU
2908642|NCT03188757|Experimental|hyperglycaemic clamp|
2908643|NCT03188744|No Intervention|Control Group|Women not submitted to the exercise protocol.
2908644|NCT03188744|Experimental|Intervention Group|Women submitted to the exercise protocol.
2908645|NCT03188731||Pregnant Women|
2908646|NCT03188718|Other|WatchPAT Intervention|Wearing the WatchPAT device simultaneously while receiving a clinically indicated sleep study (polysomnogram).
2908647|NCT03188705|Experimental|Overall Cohort|Participants will receive clopidogrel treatment alone (300 mg loading dose followed by 75 mg/d for 6 days), followed by clopidogrel (75 mg) plus aspirin (324 mg) treatment on day 8.
2908648|NCT03188692|Experimental|BK1310|
2908649|NCT03188679|Other|mRNA sequencing|amniotic fluid for patients with CMV seroconversion during pregnancy will undergo mRNA sequencing
2908650|NCT03188666|Experimental|REGN2477|
2908651|NCT03188666|Experimental|Placebo|
2908652|NCT03188653|Active Comparator|CeraVe® Eczema Soothing Body Wash|One of the 7 forearm locations will be selected to receive CeraVe® Eczema Soothing Body Wash one time only.
2908653|NCT03188653|Active Comparator|Cetaphil® RestoraDerm® Eczema Calming Body Wash|One of the 7 forearm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash one time only.
2908654|NCT03188653|Active Comparator|Dove® Sensitive Skin Body Wash|One of the 7 forearm locations will be selected to receive Dove® Sensitive Skin Body Wash one time only.
2908655|NCT03188653|Active Comparator|Eucerin® Skin Calming Body Wash|One of the 7 forearm locations will be selected to receive Eucerin® Skin Calming Body Wash one time only.
2908656|NCT03188653|Active Comparator|Aveeno® Skin Relief Body Wash|One of the 7 forearm locations will be selected to receive Aveeno® Skin Relief Body Wash one time only.
2908657|NCT03188653|Active Comparator|MooGoo® Milk Wash|One of the 7 forearm locations will be selected to receive MooGoo® Milk Wash one time only.
2908658|NCT03188653|Active Comparator|Free & Clear Liquid Cleanser|One of the 7 forearm locations will be selected to receive Free & Clear Liquid Cleanser
2908659|NCT03188640|Other|Surgery|Participants will be operated using laparoscopic gastric bypass surgery.
2908660|NCT03188627|Experimental|Bronchial basal cells|Transplantation of autologous bronchial basal cells
2908661|NCT03188627|No Intervention|Control|Conventional treatment
2908662|NCT03188614|Placebo Comparator|Normal saline group|Shock patients who resuscitated with normal saline were enrolled between June, 2015-June.2016.
2908663|NCT03188614|Experimental|Balanced solution group|Shock patients who resuscitated with balanced solution were enrolled after June, 2016.
2908664|NCT03188601||Rambam|Approximately 40 patients in total.No intervention planned.
2908665|NCT03188601||Soroka|Approximately 10 patients in total.No intervention planned.
2908666|NCT03188601||Tel Aviv Souraski|Approximately 40 patients in total.No intervention planned.
2908667|NCT03188601||Jerusalem Hadassah|Approximately 50 patients in total. No intervention planned.
2908668|NCT03188575|Experimental|iCBT for Depression and Anxiety|SilverCloud Internet-Delivered Cognitive Behavioural Therapy
2908669|NCT03188575|Active Comparator|Waiting List|Waiting list control
2908670|NCT03188562|Experimental|EBUS-TBNA, EUS-NA|"PET/CT~Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA)"
2908671|NCT03188562|Experimental|TEMLA|"PET/CT~Transcervical Extended Mediastinal Lymphadenectomy (TEMLA)"
2908672|NCT03188549|Active Comparator|Departments of Branch A|Intervention: AniosGel Respiratory ICU Pediatric Cardiac Surgery, NICU Hemato-Oncology, Oncology Internal A, C, D, E, F Surgery C, Vascular Surgery and Chest Surgery Pediatric B South Imaging Orthopedics B
2908673|NCT03188549|Active Comparator|Departments of Branch B|Intervention: Softaman Neurosurgery ICU Cardiac Surgery, Cardiac ICU, Pediatric ICU Pediatric Hemato-Oncology Internal B and I, Geriatric C and D Surgery B Pediatric B North Emergency Room Orthopedics A and Hand
2908674|NCT03188549|Active Comparator|Branch C|Control Intervention - Septol without any changes All patients hospitalized in the 29 departments in Sheba, including two of the branches, during the year of the study
2908847|NCT03187366|Experimental|No agrochemcials|Villages that eliminate agrochemicals
2908675|NCT03188536||Multiple Myeloma (MM) Participants|Adult participants with a diagnosis of MM who have received at least one previous treatment line (standard care of treatment) and have experienced symptomatic relapse and/or refractory disease in the previous 6 months, who are still in follow-up at the time of the study visit. No intervention is administered in this study.
2908676|NCT03188523|Experimental|Panel A: MK-8504 100 mg|A single oral dose of MK-8504 100 mg
2908677|NCT03188523|Experimental|Panel B: MK-8504 =< 240 mg|A single oral dose of MK-8504 =< 240 mg
2908678|NCT03188523|Experimental|Panel C: MK-8504 =< 240 mg|A single oral dose of MK-8504 =< 240 mg
2908679|NCT03188523|Experimental|Panel D: MK-8504 =< 240 mg|A single oral dose of MK-8504 =< 240 mg
2908680|NCT03188510|Experimental|LY3074828 Reference|LY3074828 administered subcutaneously (SC) as 3 injections
2908681|NCT03188510|Experimental|LY3074828 Test 1|LY3074828 administered as SC injections in two prefilled syringes
2908682|NCT03188510|Experimental|LY3074828 Test 2|LY3074828 administered as SC injections in four prefilled syringes
2908683|NCT03188497|Experimental|Experience group 1|The dose of lobaplatin is 25mg/m2 on d1,d22,d43.
2908684|NCT03188497|Experimental|Experience group 2|The dose of lobaplatin is on d1,d22,d43.
2908685|NCT03188497|Experimental|Experience group 3|The dose of lobaplatin is on d1,d22,d43.
2908686|NCT03188497|Experimental|Experience group 4|The dose of lobaplatin is 40mg/m2 on d1,d22,d43.
2908687|NCT03188497|Experimental|Experience group 5|The dose of lobaplatin is 45mg/m2 on d1,d22,d43.
2908688|NCT03188497|Experimental|Experience group 6|The dose of lobaplatin is 50mg/m2 on d1,d22,d43.
2908689|NCT03188471|Experimental|GnRH antagonist|Vitamin C (1 tablet daily) as placebo of aspirin GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days
2908690|NCT03188471|Active Comparator|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days.
2908691|NCT03188458|Other|Second and third trimester Group|This study group will include infants whose mothers have received Boostrix during the second (21-27 weeks) and third trimester (above 28 weeks) of their pregnancy, as per routine practice.
2908692|NCT03188445|Experimental|IV administration|Iron isomaltoside (Monofer) Administered iv
2908693|NCT03188445|Active Comparator|Oral administration|Ferrous fumarate with ascorbic acid Administered oral
2908694|NCT03188432|Experimental|Arm I (paclitaxel, carboplatin, CRS, IP chemotherapy)|Patients receive paclitaxel IV over 60 minutes on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 4-8 weeks after 3 courses of chemotherapy, patients undergo CRS. Beginning 4-8 weeks after CRS, patients receive paclitaxel IV over 60 minutes on days 1, 8, and 15 and carboplatin IP over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
2908695|NCT03188432|Experimental|Arm II (paclitaxel, carboplatin, CRS, HIPEC)|Patients receive paclitaxel IV over 90 minutes on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 4-8 weeks after 6 courses of chemotherapy, patients undergo CRS. Patients then receive carboplatin IP over 120 minutes immediately following CRS.
2908696|NCT03188419||Previously enrolled participants|The participants whose records will be reviewed will be those who were evaluated for all HSCT or donation on an NIH primary immunodeficiency transplant protocol at a time when haplo donors were eligible
2908697|NCT03188406||Subjects with Advanced premalignant lesions|i.e., incomplete-type IM, completetype IM with extension to gastric corpus and dysplasia
2908698|NCT03188406||informative comparisons|controls with non-atrophic gastritis, a benign histologic change apparent in most H. pylori infected individuals
2908699|NCT03188406||additional case group|individuals with newly diagnosed gastric cancer will be recruited from the sameclinics
2908700|NCT03188393|Experimental|Diagnostic (biopsy of breast)|After completion of neoadjuvant therapy, patients undergo stereotactic biopsy of breast tumor any time prior to breast conserving surgery. Patients then undergo breast conserving surgery as per standard of care. Patients may also undergo postoperative radiation therapy per standard of care or adjuvant therapy at the investigator's discretion.
2908701|NCT03188380||Plain abdominal radiograph (AR)|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
2908702|NCT03188380||Abdominal ultrasound (AUS)|If plain abdominal radiography is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
2908703|NCT03188367|Active Comparator|1A - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2908704|NCT03188367|Active Comparator|1B - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 10 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2908705|NCT03188367|Active Comparator|1C - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 7 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2908706|NCT03188367|Placebo Comparator|2C - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2908707|NCT03188367|Placebo Comparator|2B - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 10 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2908708|NCT03188367|Placebo Comparator|2A - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2908709|NCT03188367|Active Comparator|1A - HV|Seventy healthy volunteers will be given 14 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2908710|NCT03188367|Active Comparator|1B - HV|Seventy healthy volunteers will be given 10 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2908711|NCT03188367|Active Comparator|1C - HV|Seventy healthy volunteers will be given 7 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2908712|NCT03188367|Placebo Comparator|2C- HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2908713|NCT03188367|Placebo Comparator|2B - HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2908714|NCT03188367|Placebo Comparator|2A - HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2908715|NCT03188354|Experimental|CNS lymphoma patients|Patients included in the study will be examined with both 18F-FDG and 18F-Fluciclovine as well as standard MRI in the PET/MRI scanner on two consecutive days, both in primary staging and for therapy assessment
2908716|NCT03188341||vascular surgery patients|"clinically concealed repolarization disturbances during vascular surgery procedure~clinically disclosed cardiac complications during and after vascular surgery procedure"
2908717|NCT03188328|Experimental|AvidinOX/177Lu-ST2210|Patients will receive an intralesion injection of AvidinOX followed by two intravenous infusions of 177Lu- ST2210 with a distance of 14 days between them
2908718|NCT03188315|Experimental|cases|HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
2908719|NCT03188315|Active Comparator|control|HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
2908720|NCT03188302|Other|Specimen collection|Collection of stool samples
2908721|NCT03188289|Placebo Comparator|Placebo gel|The placebo gel is used by all patients on one side of the mouth and serves as a control group.
2908850|NCT03187340|Active Comparator|Sleep education and relaxation 1|Behavioral education intervention about sleep and relaxation
2908722|NCT03188289|Active Comparator|Clorhexidine gel|Chlorhexidine gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
2908723|NCT03188289|Active Comparator|Clorhexidine-Chitosan gel|Clorhexidine-chitosan gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
2908724|NCT03188289|Active Comparator|Hyaluronic acid gel|Hialuronic acid gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
2908725|NCT03188276|Active Comparator|CHC patients|32 treatment-naive CHC patients treated by Ledipasvir-Sofosbuvir or Daclatasvir-Sofosbuvir.
2908726|NCT03188276|No Intervention|Healthy controls|20 Healthy controls without any treatment
2908727|NCT03188263|Experimental|Bright Light|Irradiance is 230 μW/m2 and lux is 500 lux.
2908728|NCT03188263|Placebo Comparator|Dim Light|irradiance is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
2908729|NCT03188250|Experimental|Chama cha MamaToto|Pregnant women in communities where chama cha mamatoto is taking place will be invited to join and participate in bi-weekly group meetings for a year
2908730|NCT03188250|No Intervention|Referent|Pregnant women attending at least one prenatal visit in communities where chama cha mamatoto was implemented three months later served as the comparison
2908731|NCT03188237|Experimental|AfyaJamii facility|Facilities using AfyaJamii
2908732|NCT03188237|No Intervention|Referent facility|Facilities using Focused Antenatal Care Individual Model
2908733|NCT03188224|Experimental|Intervention|MyTransition app
2908734|NCT03188224|No Intervention|Control|Usual care
2908735|NCT03188211|Other|Intervention|Clinicians allocated to intervention arm will receive an e-learning educational program based on simulation-based technologies (Dr Sim). Dr Sim provides a powerful editing system that allows to create clinical cases according to the educational need and purposes. It will be distributed on an e-learning platform, allowing the user to act in a highly interactive learning environment. Management of the virtual patients is carried out interactively and each diagnostic and or therapeutic choice will be supported by any scientific data, guidelines recommendations, drug descriptions and literature references useful to address the best choice for that specific patient as it should be in real practice.
2908736|NCT03188211|Other|Control|Clinicians allocated to control arm will not receive the e-learning educational program based on simulation-based technologies (Dr Sim).
2908737|NCT03188198|Active Comparator|Arm A - R-CHOP|"Patients receive the following treatment:Rituximab 375 mg/m2 IV infusion on Day 1 prior to CHOP chemotherapy.Cyclophosphamide 750 mg/m^2 IV on Day 1.Doxorubicin 50 mg/m^2 IV on Day 1.Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1.Prednisone 40 mg/m^2/day PO on Days 1-5.filgrastim or pegfilgrastim as defined in the protocol Required ancillary medications is administered during all cycles as defined in the protocol. Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6.~Interventions:-Biological: rituximab-Drug: cyclophosphamide-Drug: doxorubicin-Drug: vincristine-Drug: prednisone-Drug: filgrastim-Drug: pegfilgrastim"
2908738|NCT03188198|Experimental|Arm B - DA-EPOCH-R|"Patients receive the following treatment: Cycle 1 Doses:Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy. Doxorubicin 10 mg/m^2/day CIVI on Days 1-4.Etoposide 50 mg/m^2/day CIVI on Days 1-4. Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours). Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions). Prednisone 60 mg/m^2 PO BID on Days 1-5 Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC > 5000 after the nadir (nadir usually between Days 10-12) Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle. Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6.~Interventions:~-Biological: rituximab-Drug: cyclophosphamide-Drug: doxorubicin-Drug: vincristine-Drug: prednisone-Drug: etoposide-Drug: filgrastim"
2908739|NCT03188185|Experimental|ALKS 5461|Sublingual tablets
2908740|NCT03188185|Placebo Comparator|ALKS 5461 Placebo|Sublingual tablets
2908741|NCT03188172|Experimental|Trial Treatment|"Induction:~Cyclophosphamide 500mg, days 1, 8 Bortezomib 1.3mg/m2, days 1, 4, 8, 11 Lenalidomide 25mg, days 1-14 Daratumumab 16mg/kg, days 1, 8, 15 (cycles 1& 2), day 1 only from cycle 3 Dexamethasone 20-40mg, days 1, 4, 8, 11~ASCT stem cell harvest:~with Bortezomib 1.3mg/m2, (12 hours post melphalan) Bortezomib 1.3mg/m2, day +5, +14, weekly~Consolidation part 1:~Bortezomib 1.3mg/m2 days 1, 8, 15, 22 Lenalidomide 25mg days 1-21 Daratumumab 16mg/kg day 1 Dexamethasone 20-40mg days 1, 8, 15, 22~Consolidation part 2:~Bortezomib 1.3mg/m2 days 1, 8, 15 Lenalidomide 25mg days 1-21 Daratumumab 16mg/kg day 1~Maintenance:~Lenalidomide 10mg days 1-21 Daratumumab 16mg/kg day 1"
2908742|NCT03188159|Experimental|IV Vinorelbine|IV Vinorelbine 25mg/m2
2908743|NCT03188146||PBC patients with liver biopsy|Ursodeoxycholic acid will be given compliance to the treatment guideline.
2908744|NCT03188133|Experimental|VH|schizophrenia patients with visual hallucinations
2908745|NCT03188133|Active Comparator|AH/NH|schizophrenia patients with auditory hallucinations or no hallucinations
2908746|NCT03188133|Active Comparator|C|healthy controls
2908747|NCT03188120||Spiriva Respimat group|
2908748|NCT03188107||Risky Infants|Infants that have risk of developing motor impairment, or infants diagnosed as Spina Bifida, Down Syndrome ect.
2908749|NCT03188107||Healthy Infants|Healthy infants that have normal motor development
2908750|NCT03188094||South Asians with Prediabetes|
2908751|NCT03188081||Cohort A|Adult RA patients followed up according to local clinical practice only at the hospital wards
2908752|NCT03188081||Cohort B|Adult RA patients followed up according to local clinical practice at the Hospital wards and additionally at their home through a support program
2908753|NCT03188068|Active Comparator|Sirolimus plus propranolol|"Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.~Propranolol was initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2."
2908780|NCT03187873|No Intervention|Control|The CHVs in the control group will be given refresher training on health roles they are supposed to play according to the standard MOH activities
2910917|NCT03173456|Active Comparator|codeine/APAP|30 mg codeine + 300 mg acetaminophen
2908754|NCT03188068|Active Comparator|Sirolimus plus prednisolone|"Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.~Prednisolone was administered 2 mg/kg administered once daily. Should satisfactory clinical responses and hematologic stabilization ensue, prednisolone may be tapered and discontinued within the following 4-6 weeks."
2908755|NCT03188055|Experimental|Best Case/Worst Case communication tool|The patient's enrolled surgeon will have completed training on the Best Case/Worst Case communication tool and will be encouraged to use it with the patient.
2908756|NCT03188055|No Intervention|Usual Care|Usual care typically includes informed consent and a surgeon-directed deliberative phase in which surgeons present their own evaluation of the trade-offs and goals of the proposed intervention.
2908757|NCT03188042|Experimental|rtACS Stimulation Group|
2908758|NCT03188042|Sham Comparator|Sham Intervention Group|Sham stimulation looks like rtACS, but is not active rtACS.
2908759|NCT03188029|Experimental|adrenocortical function|repeated general anesthesia with 0.3 mg/kg etomidate, 0.5 mg/kg propofol and 0.5 mg/kg succinylcholine, every 2 days for 3 to 4 weeks for electroconvulsive therapy.
2908760|NCT03188016|Experimental|Intensive Interaction with music|Weekly Intensive Interaction (Nind & Hewett) from a trained support worker plus music improvised by a music therapist with the aim of enhancing child - support worker interaction
2908761|NCT03188016|Active Comparator|Standard Intensive Interaction|Weekly Intensive Interaction (Nind & Hewett) from a trained support worker
2908762|NCT03188003|Experimental|Stabilization|"This group will undergo 10 Pilates sessions with a focus on lumbo-pelvic stabilization exercises approach.~Intervention administered: Exercise Movement Techniques (Pilates Exercise) based on stabilization"
2908763|NCT03188003|Experimental|Mobilization|"This group will undergo 10 Pilates sessions with a focus on lumbo-pelvic mobilization exercises approach.~Intervention administered: Exercise Movement Techniques (Pilates Exercise) based on mobilization"
2908764|NCT03187990|Experimental|PET/MRI before biopsy|Patients with suspected areas on mpMRI will undergo additional [68Ga]PSMA-11 PET/MRI scan with subsequent mpMRI and PET/MRI guided biopsy.
2908765|NCT03187990|Experimental|PET/MRI after biopsy|Patients with unclear areas or a negative finding in the mpMRI for MRI guided biopsy but positive biopsy, which will undergo the additional [68Ga]PSMA-11 PET/MRI scan with [68Ga]PSMA.
2908766|NCT03187977|Active Comparator|Cognitive Training|Participants will participate in computer-based cognitive training at the end of therapy.
2908767|NCT03187977|No Intervention|Standard-of-Care|At the end of therapy, participants will participate in the current standard-of-care which does not include computer-based cognitive training.
2908768|NCT03187964|No Intervention|PLHIV Centralised Xpert Ultra|Patient sputum specimen collected at Kraaifontein Community Health Centre (KCHC) and sent for centralised Xpert Ultra TB testing at the National Health Laboratory Services (NHLS) facility in Greenpoint, Cape Town, South Africa. Centralised testing uses the established NHLS transportation, testing and report-back to clinic infrastructure according to the national algorithm.
2908769|NCT03187964|Active Comparator|PLHIV Point of Care Xpert Ultra|Patient sputum specimen collected at KCHC and Xpert Ultra TB testing done on site at point of care (POC).
2908770|NCT03187964|No Intervention|PLHIV Centralised Xpert VL|Patient blood specimen collected at Kraaifontein Community Health Centre (KCHC) and sent for centralised viral load testing at the NHLS facility in Tygerberg Hospital, Cape Town, South Africa. Centralised testing uses the established NHLS transportation, testing and report-back to clinic infrastructure according to the national algorithm.
2908771|NCT03187964|Active Comparator|PLHIV Point of Care Xpert VL|Patient blood specimen collected at KCHC and Xpert HIV-1 viral load testing done on site at point of care (POC).
2908772|NCT03187951|Experimental|Arm A: Standard of Care (SOC)|"After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life. Participant's hand grip strength measured. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes. Participants complete a nutritional questionnaire and receive nutritional counseling. Participants receive educational materials and personalized counseling based on participant's answers.~Participants encouraged to remain active during chemotherapy and/or radiation. Participants receive a booklet that contains a stretching guide with full-body stretches and safety."
2908773|NCT03187951|Experimental|Arm B: Multi-Modal Exercise and Nutrition Program (MMENP)|"After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, then 3-7 months after surgery: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life. Participant's hand grip strength measured. Participants arm strength measured. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes. Participants complete a nutritional questionnaire and receive nutritional counseling. Participants receive educational materials and personalized counseling based on participant's answers.~Participants complete moderate-intensity aerobic exercise 5 days each week. Participants complete strength training exercises 2 times per week.~Participants contacted by phone by member of study staff 1 time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing."
2908774|NCT03187938||Pregnant women at 24-28 weeks gestation|Pregnant women, aged 18 and older, who are seen for their prenatal care and who are between 24w0d and 28w6d weeks gestation.Their alkaline phosphatase levels will be tested in this study.
2908775|NCT03187912|Active Comparator|Riboflavin with 20% Dextran|Riboflavin drops with Dextran
2908776|NCT03187912|Active Comparator|Riboflavin with HPMC|Riboflavin drops with HPMC
2908777|NCT03187899|Sham Comparator|"Interscalene block plus sham"|"Patients in this group will receive a traditional interscalene block and a sham superficial plexus block with ropivacaine and 5-10cc of normal saline. N = 20"
2908778|NCT03187899|Active Comparator|Interscalene plus superficial plexus block|Patients in this group will receive a traditional interscalene block and a superficial plexus block with ropivacaine . N = 20
2908779|NCT03187873|Experimental|Chama cha MamaToto|Women attending chamas will meet twice per month, receive social and health education from CHVs and participate in a savings/loans program.
2955501|NCT02865070||5 babies (premature, ages 25-28 weeks)|
2908782|NCT03187860||Smokers without COPD|"Subjects in this group are smokers or former smokers who do not have signs of obstructive disease (no chronic obstructive pulmonary disease (COPD))~Intervention: Bronchial Biopsy + ALI culture"
2908783|NCT03187860||Smokers with COPD|"Subjects in this group are smokers or former smokers who have COPD~Intervention: Bronchial Biopsy + ALI culture"
2908784|NCT03187860||Severe asthma|"Subjects in this group are non-smokers or former (light) smokers who have severe asthma.~Intervention: Bronchial Biopsy + ALI culture"
2908785|NCT03187834|Active Comparator|Azithromycin|"Comparison of nasopharyngeal and rectal microbiome in children receiving Azithromycin versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm and treated for 5 days.~Children will receive treatment everyday, once a day as is:~Azithromycin: 10 mg/kg once daily on Day 1, then 5 mg/kg once daily Days 2-5"
2908786|NCT03187834|Active Comparator|Amoxicillin|"Comparison of nasopharyngeal and rectal microbiome in children receiving Amoxicillin versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.~Children will receive treatment everyday, twice a day as is:~Amoxicillin: 25 mg/kg/day, divided into twice daily doses for Days 1-5"
2908787|NCT03187834|Active Comparator|Cotrimoxazole|"Comparison of nasopharyngeal and rectal microbiome in children receiving Cotri-moxazole versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.~Children will receive treatment everyday, once a day as is:~Co-trimoxazole: 240 mg daily for Days 1-5"
2908788|NCT03187834|Placebo Comparator|Placebo|"Comparison of nasopharyngeal and rectal microbiome in children receiving placebo versus children receiving antibiotics Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.~Children will receive Placebo everyday, once a day."
2908789|NCT03187821|Active Comparator|Superior|Laser peripheral iridotomy done at superior part of iris.
2908790|NCT03187821|Active Comparator|Nasal/temporal|Laser peripheral iridotomy done at temporal/nasal part of iris.
2908791|NCT03187808|Experimental|Group A|Group A is a group of performing single thoracic manipulation at zygapophyseal joint of T6-T7.
2908792|NCT03187808|Experimental|Group B|Group B is a group of performing single thoracic manipulation combined with special massage technique (RT technique).
2908793|NCT03187795|Experimental|Oxybutynin chloride IR then Mirabegron|Subjects randomized to this group will receive oxybutynin IR (5 mg three times daily) for 6 weeks. After the initial 6 weeks, subjects in this group will then be switched to an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily).
2908794|NCT03187795|Experimental|Mirabegron then Oxybutynin chloride IR|Subjects randomized to this group will receive an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily). After the initial 6 weeks, subjects in this group will then be switched to receive oxybutynin IR (5 mg three times daily) for 6 weeks
2908795|NCT03187769|Experimental|ALKS 3831|Coated bilayer tablet
2908796|NCT03187769|Active Comparator|Olanzapine|Coated bilayer tablet
2908797|NCT03187756|Experimental|Cyclophosphamide|
2908798|NCT03187743|Experimental|Pharmacokinetics/dynamics|Blood samples at 3 visits
2908799|NCT03187730|Active Comparator|Intervention Arm|
2908800|NCT03187730|Placebo Comparator|Waitlist Control|
2908801|NCT03187717||TIVA (Total intravenous anesthesia)|Group TIVA; patients who used intravenous anesthesia procedure
2908802|NCT03187717||IA (Inhalation anesthesia)|Group IA; patients who used inhalation anesthesia procedure
2908803|NCT03187704|Active Comparator|filtration|Air filtration in homes
2908804|NCT03187704|Sham Comparator|no filtration|Sham air filtration
2908805|NCT03187691|Experimental|CAMB 200 mg|200 mg CAMB (MAT2203) Oral Amphotericin B
2908806|NCT03187691|Experimental|CAMB 400 mg|400 mg CAMB (MAT2203) Oral Amphotericin B
2908807|NCT03187691|Experimental|CAMB 800mg|800 mg CAMB (MAT2203) Oral Amphotericin B
2908808|NCT03187678|Experimental|Selexipag|Subjects with stable pulmonary arterial hypertension (PAH) and currently treated with a stable oral dose of Uptravi will be switched to i.v. selexipag from Day 2 to Day 3 (2 infusions on Day 2 and 1 infusion on Day 3). Otherwise, they will continue with their current oral selexipag treatment throughout the study.
2908809|NCT03187665||1-6 years|12 subjects in the age range of 1-6 years old.
2908810|NCT03187665||6-10 years|12 subjects in the age range of 6-10 years old.
2908811|NCT03187665||11-17 years|12 subjects in the age range of 11-17 years old.
2908812|NCT03187639|Experimental|FFRct default primary investigation|All patients undergo FFRct as the default test assuming they have no pre-specified contraindications to CT angiography. The result of the FFRct will be conveyed to the supervising physician within 24 hours and will be used to determine the subsequent management plan.
2908813|NCT03187639|Active Comparator|Standard care|All patients will be assessed and managed exactly as they are usually treated by the randomising centre and the RACP using the local algorithms interpreted from the NICE Chest Pain of Recent Onset Guidance.
2908814|NCT03187626|Experimental|Intra-articular botulinum toxin A and splinting|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made neoprene splint to be worn for 48 hours after intra-articular injection then nightly
2908815|NCT03187626|Active Comparator|Intra-articular saline and splinting|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made neoprene splint to be worn for 48 hours after intra-articular injection then nightly
2908848|NCT03187353|Active Comparator|Lisdexamfetamine|Participants will have a 50% chance of receiving the active study medication. They will begin at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 6 weeks.
2908849|NCT03187353|Placebo Comparator|Placebo|Participants will have a 50% chance of receiving the placebo for this study. They will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 6 weeks.
2908816|NCT03187600|Active Comparator|Standard of Care|Procedure: a superiorly based pharyngeal flap surgery as per Hogan and Cable and Canady. It is performed trans-orally under general anesthetic. The soft palate is divided midline to visualize the posterior pharyngeal wall. A small flap is dissected via longitudinal incisions with a superior pedicle from the posterior pharyngeal wall at the level of the velum. The flap is then brought anteriorly, the inferior portion is lined with mucosa from the nasal portion of the soft palate and sutured in-place to create an incomplete pharyngeal obstruction that acts as a dynamic valve. Nasal stents are placed in each lateral port to prevent airway compromise and maintain flap integrity. Stents are removed two days post operatively and the patient is discharged after removal of stents and deemed to have a stable airway. Dissection will be carried out to the level of the prevertebral fascia and be comprised of mucosa and pharyngeal muscle.
2908817|NCT03187600|Experimental|Experimental Group|Procedure: a modified superiorly based pharyngeal flap surgery as per Hogan and Cable and Canady. It is performed trans-orally under general anesthetic. The soft palate is divided midline to visualize the posterior pharyngeal wall. A small flap is dissected via longitudinal incisions with a superior pedicle from the posterior pharyngeal wall at the level of the velum. The flap is then brought anteriorly, the inferior portion is lined with mucosa from the nasal portion of the soft palate and sutured in-place to create an incomplete pharyngeal obstruction that acts as a dynamic valve. Nasal stents are placed in each lateral port to prevent airway compromise and maintain flap integrity. Stents are removed two days post operatively and the patient is discharged after removal of stents and deemed to have a stable airway. Dissection will be carried out only to the level of the superior constrictor muscle and comprised of mucosua/submucosa
2908818|NCT03187587|Experimental|imILT treatment|Immunostimulating Interstitial Laser Thermotherapy (imILT)
2908819|NCT03187587|Active Comparator|Standard chemotherapy treatment|This study arm recieves chemotherapy treatment as standard care at the clinical study site.
2908820|NCT03187574||Group A|group received Elevate Ant™ single-incision mesh
2908821|NCT03187574||Group B|group received Perigee™ transvaginal mesh
2908822|NCT03187561|Experimental|Family Foundations (FF)|The original Family Foundations transition-to-parenthood coparenting intervention will be implemented to all participants assigned to this arm
2908823|NCT03187561|Experimental|Sleep-adapted Family Foundations (FF+)|A sleep-adapted Family Foundations transition-to-parenthood coparenting intervention will be implemented to all participants in this arm. The adaptation will be an emphasis on coparenting in relation to infant sleep concerns and activities.
2908824|NCT03187561|Other|Control|Participants in this arm will not receive either intervention.
2908825|NCT03187548|Experimental|CPP-ACP|Casein phosphopeptide amorphous calcium phosphate dental paste
2908826|NCT03187535|Experimental|Transcutaneous Electrical Acupoint Stimulation|"Subjects in the Transcutaneous Electrical Acupoint Stimulation (TEAS) group will receive 20 minutes of TEAS via ES-130 beginning at the time ondansetron is administered (usually given 30 minutes before the end of surgery), for prevention of PONV."
2908827|NCT03187535|Sham Comparator|No Transcutaneous Electrical Acupoint Stimulation|"Subjects in the No Transcutaneous Electrical Acupoint Stimulation group will not receive any TEAS, although they will have the acupoints identified and ECG patches placed. The device will not be connected to the electrodes of the ES-130 device at the end of surgery, and no TEAS will be delivered."
2908828|NCT03187522|Experimental|TREO Stent-Graft|Patients who receive a TREO Abdominal Stent-Graft System
2908829|NCT03187509|Experimental|Weight-Based Torsemide Group|Subjects will be randomized to complete a weight-based torsemide dosing regimen for their outpatient heart failure management. These subjects will prescribed a specified dose of torsemide on discharge from the hospital and subsequently have a phone encounter with a physician three times a week where their dose of torsemide will be titrated based on an algorithm which factors in current symptoms and weight. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.
2908830|NCT03187509|Active Comparator|Standard Outpatient Management Group|Subjects will be randomized to standard outpatient heart failure management where they will be prescribed a fixed daily dose of a loop diuretic upon discharge from the hospital and have a follow-up appointment within one week of discharge. All medications including loop diuretic type, dose and frequency will be managed at the discretion of the patient's primary care physician or cardiologist. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.
2908831|NCT03187496|Experimental|Single Arm|
2908832|NCT03187483|Active Comparator|Flash-free bracket group|Orthodontic treatment with flash-free bracket system
2908833|NCT03187483|Active Comparator|Control|Orthodontic treatment with conventional adhesive-coated brackets
2908834|NCT03187457|Other|Treatment group|Metronidazole 400 mg 3 times daily for 5 days for Bacterial Vaginosis (BV) infection
2908835|NCT03187457|Other|Control group|Healthy women without Bacterial Vaginosis and without treatment
2908836|NCT03187444|Experimental|Patients with chronic inflammatory rheumatism|All patients over 18 years, with rheumatoid arthritis treated for the first time with conventional anti-TNF therapy, Abatacept, Tocilizumab, Rituximab or patients with spondyloarthritis treated for the first time with NSAIDs that may be associated with conventional background treatments for peripheral or biological (anti-TNF, Usketinumab) may be included.
2908837|NCT03187431|Experimental|IPF patients|autologous bone marrow mesenchymal stem cells
2908838|NCT03187418|Experimental|Micropulse trans-scleral CPC|A treatment session of micropulse trans-scleral cyclophotocoagulation in the affected eye, using the MicroPulse® P3 Glaucoma Device (MP3) powered by the CYCLO G6™ Glaucoma Laser System (Iridex, Mountain View, CA, USA).
2908839|NCT03187405|No Intervention|EVD alone|In the EVD alone group group, the EVD will be managed as usual - i.e. will only be used to drain CSF.
2908840|NCT03187405|Experimental|EVD + IVF with Alteplase|Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
2908841|NCT03187392|Active Comparator|lidocaine injection|
2908842|NCT03187392|Experimental|lidocaine-prilocaine cream|
2908843|NCT03187379|Experimental|Exparel, Liposomal Bupivacaine|Subjects in this arm will receive Exparel® liposomal bupivacaine injected concurrently with 0.25% bupivacaine at the incisional sites prior to closing
2908851|NCT03187340|Experimental|Sleep education and relaxation 2|Behavioral education intervention about sleep and relaxation
2908852|NCT03187314|Experimental|Experimental Group|Radiation to 60 Gy, 5 x per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
2908853|NCT03187301|Experimental|APL-130277|APL-130277 at the dose determined in the dose titration phase
2908854|NCT03187301|Placebo Comparator|Placebo|Placebo
2908855|NCT03187301|Active Comparator|moxifloxacin|moxifloxacin at a single 400mg dose
2908856|NCT03187288|Experimental|CFI-400945|CFI-400945 will be given by mouth at 64, 72, 96, 128, 176 or 224 mg/day, everyday until intolerable side effects or disease progression.
2908857|NCT03187275|Experimental|Swedish Massage Therapy|Participants in this arm will receive Swedish massage, which is the most commonly offered and best-known type of massage.
2908858|NCT03187275|Active Comparator|Light Touch Intervention|Participants in this arm will receive light touch only.
2908859|NCT03187262|Experimental|Daratumumab|"Daratumumab will be administered in three phases: Induction, consolidation and maintenance~During induction, participants will receive daratumumab on days 1, 8, 15 and 22 of each 28-day~During consolidation, daratumumab will be administered on days 1 and 15 of each 28-day cycle~During maintenance, daratumumab will be administered on day 1 of each 28-day cycle"
2908860|NCT03187249|Experimental|Cognitive Behavioral Therapy|receive cognitive-behavioral therapy for 12 weeks
2908861|NCT03187249|Experimental|Pulmonary Rehabilitation Therapy|receive pulmonary rehabilitation therapy for 12 weeks
2908862|NCT03187249|Experimental|Combined Therapy|receive both cognitive-behavioral therapy and pulmonary rehabilitation therapy for 12 weeks
2908863|NCT03187249|No Intervention|Regular Therapy|receive regular therapy for chronic obstructive pulmonary disease
2908864|NCT03187223|Active Comparator|Arm A (Mel)|Melphalan 100mg/m2/day iv days -2 and -1
2908865|NCT03187223|Experimental|Arm B (BenMel)|Melphalan 100mg/m2/day iv days -2 and -1 Bendamustine 200mg/m2/day iv days -4 and -3
2908866|NCT03187210|Experimental|Dosis finding (Phase I)|Brentuximab Vedotin at day -8 together with standard BeEAM (Bendamustine, Cytarabine, Etoposide and Melphalan) chemotherapy at days -7 to -1 followed by reinfusion of autologous stem cells at day 0
2908867|NCT03187210|Active Comparator|Arm A (Phase II)|"BeEAM Regimen:~Bendamustine intravenously once daily on days −7 and −6 at 200 mg/m2/day; Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day −5 to day−2; Etoposide 200 mg/m2/day intravenously once daily from day −5 to day −2; and Melphalan 140 mg/m2/day intravenously once on day −1, followed by reinfusion of autologous stem cells at day 0"
2908868|NCT03187210|Experimental|Arm B (Phase II)|"Brentuximab Vedotin at day -8 together with standard BeEAM chemotherapy at days -7 to -1~BeEAM Regimen:~Bendamustine intravenously once daily on days −7 and −6 at 200 mg/m2/day; Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day −5 to day−2; etoposide 200 mg/m2/day intravenously once daily from day −5 to day −2; and Melphalan 140 mg/m2/day intravenously once on day −1, followed by reinfusion of autologous stem cells at day 0"
2908869|NCT03187197||Cohort A|consented patients with NVAF in Taiwan with a previous VKA therapy, followed by switching to Pradaxa®
2908870|NCT03187197||Cohort B|patients being newly diagnosed with NVAF and initiated on Pradaxa®
2908871|NCT03187184|Experimental|OneOme RightMed® Test|OneOme RightMed® currently tests for 22 genes that impact over 340 drugs used in multiple fields of medicine, including oncology. The drugs tested for by OneOme RightMed® were generated from practice guidelines and the FDA's guidelines for genotyping, and drugs with published, clinical evidence supporting genotyping. Testing is done using a prepackaged OneOme RightMed® kit to collect a buccal swab. OneOme RightMed® PGx test uses a DNA Genotek ORAcollect OC-100 buccal swab kit to extract DNA, which is then analyzed through polymerase chain reaction (PCR).
2908872|NCT03187171|Active Comparator|Allograft Fusion Group|The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft.
2908873|NCT03187171|Active Comparator|Cohere PEEK Fusion Group|The anterior approach to the cervical spine for discectomy and fusion by the insertion of a Cohere porous PEEK fusion device.
2908874|NCT03187158||Pune Maternal Nutrition Cohort|Study has been planned on the F1 generation of the mothers recruited under the PMNS study at Diabetes Unit, KEM-Pune. Data on maternal nutrition, exposures and anthropometry have been collected, in the F1 generation. This study will be adding cross sectional lung function measurement, biochemical analyses for nutritional, immunological and inflammatory biomarkers.
2908875|NCT03187158||New Delhi Birth Cohort|Study has been planned on the F1 generation of the mothers recruited under the New Delhi Birth Cohort in New Delhi, India. Data on maternal nutrition, exposures and anthropometry have been collected, in the F1 generation, the study will be adding cross sectional lung function measurement, biochemical analyses for nutritional, immunological and inflammatory biomarkers.
2908876|NCT03187145||diabetic patients|
2908877|NCT03187145||healthy control|
2908878|NCT03187132|Experimental|Digital Pain Reduction Kit|Participants in the experimental arm will be assigned the digital pain reduction kit consisting of a biometric sensor for passive monitoring, a transcutaneous electrical nerve stimulation unit to be used as needed, and a virtual reality headset to be used as needed or at least three times a day. Remote clinical support is provided for patients who volunteer information to be viewed by clinicians.
2908879|NCT03187132|Active Comparator|Passive Monitoring|Participants in the active control arm will receive standard of care as provided by their physician in addition to a wrist-worn biometric sensor.
2908880|NCT03187119|Experimental|Pictorial Asthma Action Plan|Young people in the Pictorial Asthma Action Plan (PAAP) arm will receive a PAAP generated by their asthma provider using a software program developed for the study. The PAAP will be personalized according to the young person's gender, race, favorite sport/activity, provider's gender, provider's clinic contact details, and hospital in emergency situations. The PAAP contains minimal text, instead illustrating each participant's asthma regimen using pictures, such as color-coded daily controller and rescue inhalers. Each participant will receive multiple copies of their PAAP, after receiving a brief education session with their provider, outlining the treatment summarized in the PAAP.
2908918|NCT03186898|Experimental|Proton Therapy (Radiation Therapy)|Patients undergo proton therapy over 15-24 days for 5 or 15 fractions.
2908881|NCT03187119|Active Comparator|Written Asthma Action Plan|Young people in the Written Asthma Action Plan (WAAP) arm will receive a WAAP generated by their asthma provider using using the National Heart, Lung, and Blood Institute (NHLBI) template. The WAAP will be personalized according to the young person's treatment plan. Each participant will receive multiple copies of their WAAP, after receiving a brief education session with their provider, outlining the treatment summarized in the WAAP.
2908882|NCT03187106|Experimental|Cephalexin and metronidazole|500 mg cephalexin per oral every 8 hours for a total of 6 doses; 500 mg metronidazole per oral every 8 hours for a total of 6 doses
2908883|NCT03187106|Placebo Comparator|Placebo / standard of care|Placebo pills per oral every 8 hours for a total of 6 doses
2908884|NCT03187093|Active Comparator|Vortioxetine|
2908885|NCT03187093|Active Comparator|Escitalopram|
2908886|NCT03187080|Experimental|Group 1 Arm A|Breast reduction with Paravertebral block using local anesthetic.
2908887|NCT03187080|Sham Comparator|Group 1 Arm B|Breast reduction with Sham paravertebral block using saline.
2908888|NCT03187080|Experimental|Group 2 Arm A|Breast augmentation with Paravertebral block using local anesthetic.
2908889|NCT03187080|Sham Comparator|Group 2 Arm B|Breast augmentation with Sham paravertebral block using saline.
2908890|NCT03187080|Experimental|Group 3 Arm A|Breast reduction with Enhanced recovery after breast surgery (ERABS) strategies.
2908891|NCT03187080|No Intervention|Group 3 Arm B|Breast reduction, standard perioperative management.
2908892|NCT03187080|Experimental|Group 4 Arm A|Breast augmentation with Enhanced recovery after breast surgery (ERABS) strategies.
2908893|NCT03187080|No Intervention|Group 4 Arm B|Breast augmentation, standard perioperative management.
2908894|NCT03187067||Mozambique, cases|
2908895|NCT03187067||Mozambique, controls|
2908896|NCT03187067||Pakistan, cases|
2908897|NCT03187067||Pakistan, controls|
2908898|NCT03187054|Active Comparator|POPQ-based surgery|will undergo anterior or posterior colporrhaphy for all of anterior or posterior vaginal prolapse stage 2 or greater (i.e. point Ba or Bp ≥-1 on the POPQ examination)
2908899|NCT03187054|Experimental|Simulated apical support-based surgery|will undergo anterior or posterior colporrhaphy only for the prolapse unresolved under simulated apical support (i.e. point Ba or Bp ≥-1 under simulated apical support)
2908900|NCT03187041|Experimental|Skin surface pressures under tourniquets and sensation|"Phase 1: Each phlebotomist will apply the tourniquet 10 separate times to the right arm of each subject. The tourniquet will remain on the arm for approximately ten seconds, to be able to allot enough time to collect an accurate pressure measurement. All 10 tourniquet skin pressure measurements will take place on the same day for a subject.~Phase 2: 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 1 hour. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use."
2908901|NCT03187028|Active Comparator|Diet only|Diet counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet counseling.
2908902|NCT03187028|Experimental|Diet + Exercise|Diet and exercise counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet and exercise counseling also receiving a fitness bracelet to facilitate counseling by the certified Cancer Exercise Trainer.
2908903|NCT03187015|Other|Midazolam|Treatment A: 2 mg of Midazolam administered - Period 1, Day 1 Treatment B: 2 mg of Midazolam with 5 mg Entinostat (after 14 day minimum washout from Period 1, Day 1) - Period 2, Day 1
2908904|NCT03187002|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS)
2908905|NCT03187002|Active Comparator|Moderate IV Sedation|Fentanyl, versed
2908906|NCT03186989|Experimental|IONIS-MAPTRx|IONIS MAPTRx (Study Drug)
2908907|NCT03186989|Placebo Comparator|Placebo|Artificial CSF
2908908|NCT03186976|Experimental|Aggressive Risk Factor Control|Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
2908909|NCT03186976|Active Comparator|Standard of Care|All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.
2908910|NCT03186963|Experimental|No immobilization|Patients receive a conventional dressing made with gauze, cotton padding and inelastic bandage after the surgery. They are instructed to start light wrist movements on the first postoperative day and progress as tolerated, beginning rehabilitation with physiotherapy after 2 weeks postoperatively.
2908911|NCT03186963|Active Comparator|Volar splint|Patients receive a volar plaster splint with inelastic bandage after the surgery, and are instructed not to remove the immobilization for 2 weeks. After this period, the immobilization is removed and patients begin rehabilitation with physiotherapy.
2908912|NCT03186950|Active Comparator|Restoration with Stainless Steel Crowns|Restoration of the tooth after endodontic treatment using stainless steel crown.
2908913|NCT03186950|Experimental|Restoration using BulkFill CR|Restoration of the tooth after endodontic treatment using bulkfill composite resin
2908914|NCT03186937|Experimental|Hominex-2|"Participants will receive an individualized dietary prescription that incorporates a methionine-free amino acid-modified medical food (Hominex-2, Abbott Nutrition) supplemented with low-methionine foods. Hominex-2 contains a mixture of L-amino acids but lacks methionine.~Participants will be asked to have an optional non-contrast MRI to assess body composition prior to and at completion of the methionine-restricted (MR) diet. Not completing a scheduled MRI is not considered a protocol deviation.~Participants will be followed for 30 days after surgery or biopsy date. Subjects removed from study for unacceptable adverse events (AEs) will be followed until resolution or stabilization of the AE."
2908915|NCT03186924|Experimental|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
2908916|NCT03186924|No Intervention|Control|The control group will receive all regular medical care and advice on healthy lifestyle, including the promotion of recommended physical activity levels and health nutrition.
2908917|NCT03186911|Other|E-liquid Group|Participants will sample two different e-liquids.
2909049|NCT03186196|Active Comparator|Group 2|Diet containing 90 mcg / day of Folate
2908919|NCT03186898|Experimental|Photon Therapy (Radiation Therapy)|Patients undergo photon therapy over 15-24 days for 5 or 15 fractions.
2908920|NCT03186885|Experimental|In-Person Family Intervention|Healthy Frio In-Person Family-focused Intervention; In-person group setting at a community center
2908921|NCT03186885|Experimental|Remote Technology Family Intervention|Healthy Frio Remote Technology Family-focused Intervention; Home-based delivered remotely with technology
2908922|NCT03186885|Active Comparator|Control|Control; Participants will receive standard health education materials, a community resource guide, and encouragement to follow up with their primary care provider for office-based counseling.
2908923|NCT03186872|No Intervention|Care as usual|Participants randomized to this group will continue to see the IBD medical home team as usual
2908924|NCT03186872|Experimental|Digital behavioral program|Participants randomized to this group will see the IBD medical home team and will utilize the cognitive behavioral app as the intervention.
2908925|NCT03186859|Active Comparator|Roux-en-Y Gastric Bypass (RYGB) surgery|
2908926|NCT03186859|Active Comparator|Sleeve Gastrectomy (SG) surgery|
2908927|NCT03186846|Active Comparator|multimodal monitoring|LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
2908928|NCT03186846|Active Comparator|placebo|No multimodal monitoring will be applied in control group.
2908929|NCT03186833||Group A|males or females aged > 70 years without major systemic comorbidities (resting blood pressure <140/90 mmHg, no history diabetes mellitus according to WHO criteria).
2908930|NCT03186833||Group B|males or females aged >70 years with hypertension, defined as a documented blood pressure of Systolic Blood Pressure (SP >140 mmHg or >90mmHg Diastolic Blood Pressure) without diabetes mellitus and HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria b) need for diuretic therapy.
2908931|NCT03186833||Group C|male or female aged > 70 years with diabetes mellitus (defined according to the World Health Organization (WHO)) AND hypertension, without HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria38 b) need for diuretic therapy.
2908932|NCT03186833||Group D|male or female aged >70 years with HFPEF, defined as signs and symptoms of HF with LVEF>50% and raised natriuretic peptides (BNP>35pg/ml or NT-proBNP>125pg/ml) along with one other criteria: i) structural heart disease (left atrial enlargement or left ventricular hypertrophy) on TTE, ii) evidence of LV diastolic dysfunction based on ESC Guidelines 2016, or iii) hospitalization with heart failure within 12 months prior to study entry.
2908933|NCT03186833||Group E|male or female aged >70 years with HFREF, defined as HF with LVEF <40% on TTE)
2908934|NCT03186820|Experimental|SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
2908935|NCT03186807||low risk pregnancy|"Inclusion criteria - Women aged 18-45 years old ,Pregnant women between 14+0 and 34+0 weeks.speaking Hebrew language and eligible for obtaining informed consent.~Gestation who had a singleton fetus in cephalic presentation, with well documented gestational age by first trimester US scan CRL.~Biometric measurement within 10th to 90th percentile.and low risk for fetal brain developmental disorders."
2908936|NCT03186794|Experimental|SLE Exercise|We propose to enroll 20 sedentary, adult, women with negligible to mild SLE disease activity (SELENA-SLEDAI less than or equal to 4) in this pilot study. Subjects must also have a Fatigue Severity Scale (FSS) composite score less than or equal to 4.0. We will restrict our recruitment to women with SLE as this is a small pilot study and would like to eliminate possible gender-biased confounders of physical activity (approximately 90% of patients with SLE are women).
2908937|NCT03186781|Experimental|1|Low Dose. HA-FA/Sing, administered IM at a dosage of 20 mcg on Day 0
2908938|NCT03186781|Experimental|2|High Dose. HA-FA/Sing,administered IM at a dosage of 60 mcg Day 0 and Week 16
2908939|NCT03186781|Experimental|3|DNA A/Sing, administered IM at a dosage of 4 mg at Day 0 and HA-FA/Sing administered at a dosage of 60 mcg at Week 16
2908940|NCT03186781|Experimental|4|HA-F A/Sing, administered IM at a dosage of 60 mcg at Day 0 and Week 16
2908941|NCT03186768|Experimental|Intervention arm|Intervention arm receives a training of trainers on the soap on a rope hall pass intervention.
2908942|NCT03186768|No Intervention|Control arm|Control arm delays the training of trainers on the soap on a rope hall pass intervention until endline hand washing data has been collected.
2908943|NCT03186755|Experimental|Hylo-Dual|Hyaluronic acid 0.05% & Ectoine 2.0% (Hylo-Dual) 1 drop in both eyes 3 times/day for 8 weeks
2908944|NCT03186755|Active Comparator|Patanol|Olopatadine hydrochloride ophthalmic solution 0.1% (Olopatadine) 1 drop in both eyes 2 times/day for 8 weeks
2908945|NCT03186742|Experimental|Group A|The patients who had Eplerenone 50mg tab once a day added to their standard hypertensive treatment.
2908946|NCT03186742|No Intervention|Group B|The patients who did not receive an additional drug to their standard hypertensive treatment.
2908947|NCT03186729|Experimental|Antithrombotic treatment|For patients with indication for antiplatelet drugs: Antiplatelet drugs For patients with atrial fibrillation and indication for anticoagulant drugs: Anticoagulant drugs
2908948|NCT03186729|No Intervention|No antithrombotic treatment|For patients with indication for antiplatelet drugs: No antithrombotic drugs For patients with atrial fibrillation and indication for anticoagulant drugs: No anticoagulant drugs.
2908949|NCT03186716|Experimental|Colostrum|Intervention patients will be received enteral formula and colostrum powder 20 g/kg/day given via nasogastric tube as boluses q 4hrs.
2908950|NCT03186716|Placebo Comparator|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
2908951|NCT03186703|Experimental|Tailored knowledge translation|During the 12-week intervention, intervention group participants will have access to the Portal and will receive targeted weekly email alerts including blog posts and evidence summaries relevant to cancer prevention and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant cancer prevention information.
2908952|NCT03186703|No Intervention|Control|Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored intervention.
2908953|NCT03186690|Experimental|Biodentine|This includes teeth that were treated with Biodntine cement
2908954|NCT03186690|Experimental|Mineral Trioxide Aggregate|This includes teeth that were treated with Mineral Trioxide Aggregate (MTA) cement
2908955|NCT03186677|Experimental|Cohort 1|Single intravenous administration of BeneFIX (75 IU/kg) with 72 hours of observation, followed by single intravenous administration of ISU304/CB2679d (75 IU/kg) with 72 hours of observation
2908956|NCT03186677|Experimental|Cohort 2|Single intravenous administration of ISU304/CB2679d (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d (75 IU/kg) with 72 hours of observation
2908957|NCT03186677|Experimental|Cohort 3|Single intravenous administration of ISU304/CB2679d (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d (150 IU/kg) with 120 hours of observation
2908958|NCT03186677|Experimental|Cohort 4|One subcutaneous administration of ISU304/CB2679d (300 IU/kg) per day for 6 days with 144 hours of observation
2908959|NCT03186677|Experimental|Cohort 5|One intravenous administration of ISU304/CB2679d (75 IU/kg) followed subcutaneous administration of ISU304/CB2679d (150 IU/kg) once daily for 9 days with 312 hours of observation
2908960|NCT03186664|Experimental|A: Sativex+Lokomat Training|Patients Sativex responders will perform a neurorobotic-assisted gait training (RAGT, each session will last at least 45', 3 times per week, for a total amount of 20 treatment's sessions).
2908961|NCT03186664|Active Comparator|B: other antispastic+Lokomat Training|Patients treated with others antispastic drugs will perform a neurorobotic-assisted gait training (RAGT, each session will last at least 45', 3 times per week, for a total amount of 20 treatment's sessions).
2908962|NCT03186651|Experimental|Trans Vagina Support|Tension Free Vaginal Support (TVS):The subjects in the TVS Group used pads during week 1 (Baseline), fitted, trained and selected device size week 2 and used the selected device size during week 3 (treatment week).
2908963|NCT03186651|No Intervention|Standard Care|Standard of care (SoC): The subjects in the SoC group continued with conventional treatment i.e. using pads during week 1, 2 and 3. They were offered to use the TVS device for two weeks after completion of week 3.
2908964|NCT03186638|Experimental|Arm I (ibuprofen, pamphlet)|"Patients receive ibuprofen PO BID for 6 weeks and participate in a discussion of Chemotherapy and You pamphlet."
2908965|NCT03186638|Experimental|Arm II (placebo pamphlet)|"Patients receive placebo PO BID for 6 weeks and participate in a discussion of Chemotherapy and You pamphlet."
2908966|NCT03186638|Experimental|Arm III (placebo, exercise)|Patients receive placebo PO BID for 6 weeks. Patients also participate in home-based walking and progressive resistance exercise over 20-60 minutes 3 to 5 times per week for 6 weeks.
2908967|NCT03186638|Experimental|Arm IV (ibuprofen, exercise)|Patients receive ibuprofen PO BID for 6 weeks. Patients also participate in home-based walking and progressive resistance exercise over 20-60 minutes 3 to 5 times per week for 6 weeks.
2908968|NCT03186625|Experimental|Compound Panax Notoginseng Granule|On the basis of the standard treatment for ACS,eligible participants are randomized to receive Compound Panax Notoginseng Granule when they enroll.
2908969|NCT03186625|Placebo Comparator|Placebo Granule|On the basis of the standard treatment for ACS,eligible participants are randomized to receive Placebo Granule when they enroll.
2908970|NCT03186612|Active Comparator|OT intervention|Conventional occupational therapy (OT) treatment will consist of 20 sessions in total, during which subjects will perform activities for training manipulative and functional dexterity of the upper limb aimed at activities of daily living. These will be distributed in two OT sessions per week, each lasting 30 minutes.
2908971|NCT03186612|Experimental|OT+VR intervention|The intervention applied to the experimental group will consist of 20 sessions of conventional OT distributed in two sessions per week, each lasting 30 minutes. Additionally, they will receive 20 treatment sessions lasting 20 minutes, twice weekly of virtual reality (VR) via the online and free website motiongamingconsole.com, during which they will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro. All the interventions will consider the level of fatigue experimented by the patient by featuring a progressive increase of the treatment times according to the same.
2908972|NCT03186599|No Intervention|high adherence control group|-Patients on continuous MEMS monitoring with usual care.
2908973|NCT03186599|No Intervention|low adherence control group|-Patients on continuous MEMS monitoring with usual care.
2908974|NCT03186599|Experimental|low adherence intervention group|"Patient with the WALKON mobile application.~Patient with monthly feedback call~Patients on continuous MEMS monitoring."
2908975|NCT03186586|Experimental|Ulipristal acetate 5mg/day/five days|Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Ulipristal acetate at 5mg/day/five days Ulipristal 5mg daily for 5 days at the bleeding episode
2908976|NCT03186586|Placebo Comparator|Placebo 1 pill/day/five days|Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Placebo at 1pill/day/five days Placebo one pill a day for 5 days at the bleeding episode
2908977|NCT03186573|No Intervention|Control Group|The athletes will not receive any drink and will do the simulations of the fight.
2908978|NCT03186573|Active Comparator|Intervention group|(Intervention, grape juice) - athletes will receive 400 ml per day of grape juice (containing 66g of carbohydrates) for 14 days and will do the fight simulations.
2908979|NCT03186573|Placebo Comparator|Placebo Group|(Placebo, grape-flavored maltodextrin carbohydrate) - athletes will receive400ml of drink daily with 66g of maltodextrin for 14 days and will do the fight simulations; The amount of maltodextrin is equal to the amount of carbohydrate present in grape juice.
2908980|NCT03186560|Active Comparator|Group A: Arterial Leg Ulcer|Defined as healing/non-healing Healing defined as reduction in wound area of greater than 20% over a 2-week period
2908981|NCT03186560|Active Comparator|Group B: Mixed Leg Ulcer|only to be done once Arterial leg ulcers show change in flux ABPI of <0.8-0.6
2908982|NCT03186560|Active Comparator|Group C: Diabetic Foot Ulcer - neuropathic|On clinical inspection present as neuropathic
2908983|NCT03186560|Active Comparator|Group D: Diabetic Foot Ulcer - neuroischemic|On clinical inspection present as neuroischemic
2908984|NCT03186547|Experimental|Botulinum Toxin A Injection|this group will receive Botulinum Toxin A Injection at doses of 2.5 or 5 IU (depending on the degree of gum exposure) on each side of the nasolabial fold with follow up at at 2,4,8,12 and 24 weeks.
2908985|NCT03186547|Experimental|Modified Lip Repositioning Surgery|this group will receive Modified Lip Repositioning Surgery with follow up at at 2,4,8,12 and 24 weeks.
2908986|NCT03186534|Experimental|2GETHER|2GETHER is an HIV prevention and relationship education program designed for young male couples. 2GETHER consists of 4 sessions (2 group sessions, 2 individualized couple session) administered over the course of 1 month (1 session per week). Group sessions focus on developing skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
2908987|NCT03186534|Active Comparator|Positive Affect Enhancement|The control condition is a positive affect enhancement program for couples. This is an active and attention-matched control condition. Group sessions focus on developing various coping skills that aim to enhance positive emotions in couples, and individualized couple sessions focus on skills implementation.
2908988|NCT03186508|Active Comparator|Optimize Sleep (OS)|Optimize Sleep will focus exclusively on enhancing sleep by using effective behavioral strategies. Specific strategies to be used include: goal setting and self-monitoring, positive bedtime routines, stimulus control/sleep hygiene strategies, problem-solving regarding challenges, and review of effective strategies for relapse prevention.
2908989|NCT03186508|Active Comparator|Optimize Sleep-Plus (OS-Plus)|OS-Plus will focus on enhancing sleep and targeted eating (decreasing sugar-sweetened beverages and sweet and salty snack foods) and activity (increasing physical activity and decreasing TV viewing) behaviors. Specific strategies to be used include: goal setting and self-monitoring, positive bedtime routines, stimulus control/sleep hygiene strategies, problem-solving regarding challenges, and review of effective strategies for relapse prevention.
2908990|NCT03186495|Experimental|Normal renal function|Subjects with normal renal function
2908991|NCT03186495|Experimental|Mild renal impairment|Subjects with mild renal impairment
2908992|NCT03186495|Experimental|Moderate renal impairment|Subjects with moderate renal impairment
2908993|NCT03186495|Experimental|Severe renal impairment|Subjects with severe renal impairment
2908994|NCT03186495|Experimental|Requiring haemodialysis treatment|Subjects requiring haemodialysis treatment
2908995|NCT03186482|Active Comparator|Descovy® (TAF/FTC)|"ATC Code J05AR17. Pharmaceutical form (use standard terms): Film-Coated Tablet Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol: 56 days.~Maximum dose allowed 200mg/25mg per day. Total dose 200/25mg. Oral Use."
2908996|NCT03186482|Active Comparator|Viread® (TDF)|"ATC Code J05AF07. Pharmaceutical form (use standard terms): Film-Coated Tablet. Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol 28 days.~Maximum dose allowed: 245mg per day. Total dose: 245mg. Oral Use."
2908997|NCT03186482|Active Comparator|Rifadin® (Rifampicin)|"ATC Code J0AB02 Pharmaceutical form (use standard terms): Capsule, Hard. Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol 28 days.~Maximum dose allowed: 600mg per day. Total dose: 600mg. Oral Use."
2908998|NCT03186469|Active Comparator|Behavioral: Safety Baby shower Teen Only|Only the teen will receive the educational intervention.
2908999|NCT03186469|Active Comparator|Behavioral: Safety Baby shower Dyad|Both the teen and the teens support person will receive the educational intervention.
2909000|NCT03186469|Other|Behavioral: Standard of Care Control|Standard of care.
2909001|NCT03186456|Experimental|Group 1|Aspirin Tablet, 100mg/d; Allogeneic umbilical cord mesenchymal stem cells, 0.5-1*10^6/kg
2909002|NCT03186456|Placebo Comparator|Group 2|Aspirin Tablet, 100mg/d; Placebo
2909003|NCT03186443|Active Comparator|pregabalin|experiment group: pregabalin 300mg,q12h for 6 months
2909004|NCT03186443|Experimental|gabapentin|compared to pregabalin effect on herpetic neuralgia
2909005|NCT03186430|Experimental|Comprehensive Vaccine Promotion Package|The pediatric practices randomized to this arm will receive the comprehensive adolescent vaccine promotion package. Practice physicians and staff will be familiarized with each component, and practices will be instructed to implement each vaccine-promotion component to the best of their ability.
2909006|NCT03186430|No Intervention|Standard Vaccination Promotion|The pediatric practices randomized to the control arm will not receive the comprehensive vaccine promotion package and will instead be instructed to continue offering their standard adolescent vaccination promotion practices to adolescent patients.
2909007|NCT03186417|Experimental|Cohort 1|2 million human MSC (hMSC)/kg infusion versus placebo infusion
2909008|NCT03186417|Experimental|Cohort 2|4 million hMSC/kg infusion versus placebo infusion
2909009|NCT03186417|Experimental|Cohort 3|6 million hMSC/kg infusion versus placebo infusion
2909010|NCT03186404|Placebo Comparator|Placebos|Placebos
2909011|NCT03186404|Experimental|Statin|Atorvastatin 40mg
2909012|NCT03186391||Patients with suspected PAD|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
2909013|NCT03186378|Experimental|Exposure Group|This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.
2909014|NCT03186378|Experimental|Standard Group|This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.
2909015|NCT03186365|Experimental|8-week arm|patients receiving 8 weeks of elbasvir 50 mg/grazoprevir (Zepatier Oral Product)100 mg daily
2909016|NCT03186365|Active Comparator|12-week arm|patients receiving 12 weeks of elbasvir 50 mg/grazoprevir 100 mg (Zepatier Oral Product) daily
2909017|NCT03186352|Experimental|after intervention|sample for microbial analysis it taken with sterile a rose bur (size 014) on micro motor after intervention
2909018|NCT03186339||TAVI patients|patients undergoing TF (transfemoral) TAVI as treatment for the aortic stenosis
2909019|NCT03186339||SAVR patients|patients undergoing isolated surgical valve replacement as treatment for the aortic stenosis
2909020|NCT03186339||MM patients|patients in whom the aortic stenosis is medically managed
2909021|NCT03186326|Active Comparator|Arm A Chemotherapy (standard treatment)|FOLFOX or FOLFIRI +/- targeted therapy
2909022|NCT03186326|Experimental|Arm B - Immunotherapy (experimental arm)|Avelumab
2909023|NCT03186313|Experimental|Part A: Arm 1|Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
2909024|NCT03186313|Active Comparator|Part A: Arm 2|"Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg & Ribavirin 800 mg for 12 weeks.~Treatment assignments will be stratified according to the presence or absence of cirrhosis."
2909025|NCT03186313|Experimental|Part B: Arm 3|Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks.
2909026|NCT03186313|Active Comparator|Part B: Arm 4|Daily dose including Sofosbuvir 400 mg & Daclatasvir 60 mg for 12 weeks.
2909027|NCT03186300|Other|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
2909028|NCT03186287|Experimental|Eccentric training group|The participants in this group will actively perform eccentric phase of resistive shoulder exercises. Additionally they will receive standard physiotherapy.
2909029|NCT03186287|Experimental|Concentric training group|The participants in this group will actively perform concentric phase of resistive shoulder exercises. Additionally they will receive standard physiotherapy.
2909030|NCT03186287|Active Comparator|Control group|The participants in this group will receive only standard physiotherapy.
2909031|NCT03186274|No Intervention|Control Group|Those in the control group (CG) will write a pre and post-study reflection essay discussing their experiences with end of life discussions.
2909032|NCT03186274|Experimental|Facilitated Group Session|Participants in Facilitated Group Session (previously called Intervention Group 1) will watch a pre-recorded video describing the SPIKES model and then take part of a facilitated guided group session reviewing the model and group interview of standardized/simulated patient encounter.
2909033|NCT03186274|Experimental|CELA Session|Participants in the CELA Session (previously called Intervention Group 2) will watch a pre-recorded video describing the SPIKES model and then participate in an individualized standardized/simulated patient scenario that will be filmed at the Center for Experiential Learning and Assessment (CELA).
2909034|NCT03186261|Experimental|Nano silver fluoride solution|Nano silver fluoride solution (Prepared in Nanotech Co., Egypt) based on silver nanoparticles, chitosan and fluoride. Each tooth will receive two drops of NSF with a micro brush, equivalent to a dose of 10 mg of the solution.
2909035|NCT03186261|Active Comparator|Cavity Cleanser|Chlorhexidine digluconate 2 % solution (Cavity Cleanser, Bisco, USA). Each tooth will receive two drops of cavity cleanser with a micro brush, equivalent to a dose of 10 mg of the solution.
2909036|NCT03186248|Experimental|Short myotomy|Per oral endoscopic myotomy extending from 3 cm cephalad to 3 cm distal to EGJ
2909037|NCT03186248|Active Comparator|Long myotomy|Per oral endoscopic myotomy extending from 6-8cm cephalad to and 3 cm distal to EGJ.
2909038|NCT03186235||Group I : 20 healthy controls|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
2909039|NCT03186235||group II : 20 Hepatitis C infected patients (naïve)|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
2909040|NCT03186235||group III:15 HCV-infected patients complicated with cirrhosis|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
2909041|NCT03186235||group IV: 20 HCV-infected patients with Hepatocellular cancer|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
2909042|NCT03186235||group V: 20 HCV patients non responders to Direct antivirals|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
2909043|NCT03186235||Group VI: patients with sustained viral response (SVR).|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
2909044|NCT03186222||cases with acne vulgaris|A group of 100 patients with acne vulgaris. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
2909045|NCT03186222||control group|control group of 100 age and sex matched healthy volunteers. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
2909046|NCT03186209|Experimental|Benralizumab|Benralizumab administered subcutaneously
2909047|NCT03186209|Placebo Comparator|Placebo|Placebo administered subcutaneously
2909048|NCT03186196|Experimental|Group 1|Diet with 191 mcg/day of Folate
2909050|NCT03186183|Experimental|GPS program|"The individual GPS motivational interviewing counseling program has 4-6 sessions.~Week 1: information on sexually transmitted infections and HIV disclosure laws is reviewed. Participants are introduced to the sex diary, stress exercise, and stages of change model.~Week 2: a decisional balance exercise about the participant's current sexual behavior is completed and a behavioral goal is chosen.~Week 3: participants explore their greatest fears and hopes about the goal, and the importance of and their confidence in achieving it.~Week 4: the facilitator and participant identify triggers, automatic thoughts, counters, strategies, supports, and rewards pertaining to the pursuit of the goal and role play the new goal.~1-2 supplemental sessions may be added as needed."
2909051|NCT03186170|Experimental|SSA|"The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSA versus traditional technique of swin up) as well as embryo development.~In this arm, the sperm selection for IVF will be performed by the new proposed technique of Sperm Selection Assay which consist to expose spermatozoa a progesterone quemoatractant Sperm selection via SSA technique"
2909052|NCT03186170|Active Comparator|control|"The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up for sperm selection) as well as embryo development.~In this arm, the sperm selection for IVF will be the traditional swin up technique with different Percoll gradient Sperm selection via traditional swin-up"
2909053|NCT03186157||Decompressive craniectomy patients|All of the patients that undergo decompressive craniectomy due to intracranial mass lesion and are transferred to neuro-rehabilitation unit in our university hospital.
2909054|NCT03186144|Experimental|No arm : descriptive study|
2909055|NCT03186131|Active Comparator|Oral Ibandronate alone|Monthly Oral Intake of Ibandronate
2909056|NCT03186131|Active Comparator|Oral Ibandronate and Vitamin D|Monthly oral intake of Ibandronate and daily oral intake of Vitamin D
2909057|NCT03186118|Experimental|Cohort A|Participants in PLAT-02 who are eligible for, and consent to, PLAT-03 Cohort A may transition to PLAT-03 to receive their initial infusion of CAR-T cells, followed by up to 6 T-APC treatments.
2909058|NCT03186118|Experimental|Cohort B|Participants in PLAT-02 who are eligible for, and consent to, PLAT-03 Cohort B may transition to PLAT-03 after their initial infusion of CAR-T cells and laboratory testing on study day 14 indicates that the are at risk for early loss of CAR T cells. Up to 6 T-APC treatments will be administered to participants. If further laboratory testing prior to planned T-APC treatment indicates loss of CAR-T cells, participants may move to Cohort C.
2909059|NCT03186118|Experimental|Cohort C|Participants in PLAT-02 who are eligible for, and consent to, PLAT-03 Cohort C may transition to PLAT-03 after their initial infusion of CAR-T cells and laboratory testing shows early loss of CAR T cells between day 63 and day 183. Participants will receive another CAR-T cell infusion followed by up to 6 T-APC treatments.
2909060|NCT03186105|Experimental|Ambulatory appendicectomy|The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days.
2909061|NCT03186092|Active Comparator|Intervention Group|
2909062|NCT03186092|No Intervention|Control Group|
2909063|NCT03186079|Active Comparator|Xiaojidaozhi Decoction|Xiaojidaozhi Decoction and Fiberform and Toilet training are used for treatment of childhood Constipation
2909064|NCT03186079|Placebo Comparator|non-Xiaojidaozhi Decoction|Placebo and Fiberform and Toilet training are used for treatment of childhood Constipation
2909065|NCT03186066|Active Comparator|Standard Therapy|Buried Bumper Syndrome is treated by endoscopically dissecting the overgrown tissue with an endoscopic submucosal dissection knife.
2909066|NCT03186066|Experimental|Flamingo Device|The Flamingo device is used for treatment of Buried Bumper Syndrome.
2909067|NCT03186053|Experimental|sodium creatine phosphate|5g creatine phosphate was dissolved in 50ml saline solution. After induction of anesthesia, the patients were first given a load dose of 1g, 20min (30ml / h) , And then pumped at a rate of 1 g / h (10 ml / h).
2909068|NCT03186053|Placebo Comparator|Control|The control group was treated with saline in the same manner.
2909069|NCT03186040|Other|Lacosamide|
2909070|NCT03186027|Active Comparator|Active supplement (CoQ10 plus NADH)|"CFS/ME patients will be randomized to evaluate the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH: 20 mg/day) taking 4 tablets/day during 8-weeks in term.~Active supplement based on Coenzyme Q10 plus NADH"
2909071|NCT03186027|Placebo Comparator|Phosphoserine plus vitamin C|"CFS/ME patients will be randomized to assess the effect of placebo (phospho-serine plus vitamin C) taking 4 tablets/day for 8-weeks in term.~Placebo: phosphoserine plus vitamin C"
2909072|NCT03186014|Experimental|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
2909073|NCT03186001|Experimental|v shape|Technique 1Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a V pattern will be placed in the frontalis. The first injection between the medial brows, 2 injection 1cm below the hairline at the level of the lateral canthus and one injection equidistant to medial and lateral injection.
2909074|NCT03186001|Experimental|middle frontalis|: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a straight pattern will be placed in the frontalis. One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
2909111|NCT03185793|Experimental|10mg SHR4640|SHR4640 for 5 weeks
2909112|NCT03185793|Active Comparator|50mg benzbromarone|Benzbromarone for 5 weeks
2909075|NCT03186001|Experimental|high frontalis|: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally.Then 5 equally spaced injections, in a straight pattern 1 cm below the hairline will be placed in the frontalis. One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
2909076|NCT03185988|Experimental|GI tumor beyond CRC, ESCC, BTC,GC&GEJA|Trastuzumab (Herceptin ®): 6 mg/kg every 3 weeks (8 mg/kg as loading dose at 1st administration), iv, d1. The first infusion is to be given over 90 minutes, and subsequent infusions are to be given over 30 minutes if the first infusion is well tolerated. Combined with Irinotecan: 120 mg/m2 iv, day 1and day 8, every 3 weeks. OR 5-Fu: 720 mg/m2/day continuous iv. Infusion, d1-d5, every 3 weeks. OR Capecitabine(Xeloda®): 1000 mg/m2 bid, d1-d14, every 3 weeks. (by investigator's choice)
2909077|NCT03185988|Experimental|Esophageal squamous cell carcinoma|Trastuzumab (Herceptin ®): same as above Combined with Irinotecan: 120 mg/m2 iv, day 1and day 8, every 3 weeks.
2909078|NCT03185988|Experimental|Biliary tract cancer|Trastuzumab (Herceptin ®): same as above Combined with Irinotecan: 120 mg/m2 iv, day 1and day 8, every 3 weeks. OR 5-Fu: 720 mg/m2/day continuous iv. Infusion, d1-d5, every 3 weeks. OR Capecitabine(Xeloda®): 1000 mg/m2 bid, d1-d14, every 3 weeks. (by investigator's choice)
2909079|NCT03185975|Placebo Comparator|Control arm|Each participant will receive an at-home test kit and will be asked to test and return results to investigator.
2909080|NCT03185975|Active Comparator|Intervention Arm|Each participant will receive an at-home test kit and will be asked to take the test in conjunction with an online Motivational interviewing/certified testing and referral (MI/CTR).
2909081|NCT03185962||Successful extubation|extubated successfully
2909082|NCT03185962||Extubation failure|reintubated within 48 hours
2909083|NCT03185962||NPPV/NHF|use of non-invasive positive pressure ventilation (NPPV) or nasal high flow (NHF) within 48 hours after extubation
2909084|NCT03185936|Experimental|Optic disc pit maculopathy|pars plana vitrectomy with internal limiting membrane (ILM) peeling, endolaser
2909085|NCT03185923|Experimental|TCM plus conventional drug|The experimental group will receive three type of TCM inaddition conventional drug according to china CAP guidline 2016.
2909086|NCT03185923|Placebo Comparator|TCM placebo plus conventional drug|The control group will receive three type of placebo TCM inaddition conventional drug according to china CAP guidline 2016.
2909087|NCT03185910|Experimental|MBCP education|The intervention includes 3-hour classes per week during the duration of eight weeks and a 7- hour silent meditation practice as well.
2909088|NCT03185910|Placebo Comparator|Hospital-based antenatal education|Hospital-based antenatal education program will be held 2 hrs once a month for 2 months.
2909089|NCT03185897||Hemophilia A|Participants with hemophilia A
2909090|NCT03185897||Hemophilia B|Participants with hemophilia B
2909091|NCT03185884|Active Comparator|Control|- 237 ml beverage; consumed once per test visit
2909092|NCT03185884|Experimental|Experimental|- 237 ml beverage; consumed once per test visit
2909093|NCT03185871|Experimental|Celecoxib|"The participants will be scheduled for the two quantitative breast MRI exams. Following the first MRI exam, participants will start taking celecoxib 200mg twice a day with food. Subjects will take a minimum of 26 doses and no more than 32 doses of celecoxib during the study.~Participants will intake 200mg of celecoxib two times a day (400mg/day total) for 2 weeks after biopsy. Histologic tissue samples will be obtained for evaluation at time of biopsy of the tumor and at time of surgery removal of the tumor."
2909094|NCT03185858|Experimental|SINEMA intervention group|The intervention arm will implement the SINEMA model for one year, which consists of a provider-facing intervention aiming to strengthen the capacity of village doctors in delivering stroke secondary prevention, and a stroke survivor-facing intervention aiming to promote medication adherence and physical activity.
2909095|NCT03185858|No Intervention|Control group|Villages in the control arm continue their usual practice without the introduction of any of the SINEMA activities described above. People who have hypertension or who are at high-risk of hypertension may receive follow-up visits four times per year as part of the basic public health services required by the government.
2909096|NCT03185845|Experimental|Prolonged anticoagulation|3 months longer anticoagulation after regular treatment
2909097|NCT03185845|No Intervention|Regular anticoagulation|stop anticoagulation after regular treatment
2909098|NCT03185832||CRT-D Cohort|Composite rate of first appropriately treated ventricular arrhythmia
2909099|NCT03185832||ICD Cohort|Composite rate of first appropriately treated ventricular arrhythmia
2909100|NCT03185832||PM / CRT-P Cohort|All cause mortality
2909101|NCT03185832||Non-device Cohort|All-cause mortality in the subject cohort with 2 to 5 predefined SCD driving risk factors
2909102|NCT03185819|Placebo Comparator|Oral Midazolam + Intranasal Placebo|Participants will receive midazolam solution 0.125 milligram per kilogram (mg/kg) orally 2 times per week for 4 weeks and 3 intranasal doses of matched placebo to esketamine.
2909103|NCT03185819|Experimental|Oral Placebo + Esketamine 84 mg|Participants will receive intranasal esketamine 84 mg as 3 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
2909104|NCT03185819|Experimental|Oral Placebo + Esketamine 56 mg|Participants will receive intranasal esketamine 56 mg as 2 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
2909105|NCT03185819|Experimental|Oral Placebo + Esketamine 28 mg|Participants will receive intranasal esketamine 28 mg as 1 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
2909106|NCT03185806|Experimental|Puncture and Drainage|The enrolled SAP patients are administered puncture and drainage use 8-F or 10-F pigtail tube under guidance of B ultrasound or CT scan.
2909107|NCT03185806|No Intervention|Conservative therapy|The enrolled SAP patients are administered conservative therapy and without puncture and prolonged drainage.
2909108|NCT03185793|Placebo Comparator|Placebo|placebo for 5 weeks
2909109|NCT03185793|Experimental|2.5mg SHR4640|SHR4640 for 5 weeks
2909110|NCT03185793|Experimental|5mg SHR4640|SHR4640 for 5 weeks
2909113|NCT03185780|Experimental|Treatment|Patients will be treated with acupuncture and/or touch therapies, this in parallel to their chemo-radiation regimen. These treatments will be administered twice-weekly during active chemo-radiation treatment (6 weeks), followed by once-weekly treatment throughout the remainder of the study period (6 months)
2909114|NCT03185767|Other|SLE group|
2909115|NCT03185767|Other|control group|
2909116|NCT03185754|Experimental|early phase lung cancer|sublobar resection and lobectomy
2909117|NCT03185741|Experimental|UMS Strategy|"Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions. These materials will be generated within the electronic health record.~Prescription instructions will be adapted to the UMS format to establish four standard time intervals (morning, noon, evening, bedtime) for prescribing and dispensing of medicine. UMS instructions also use simplified text and numeric characters instead of words to detail dose.~Single-page, plain language medication information sheets with important medication-related information following health literacy best practices."
2909118|NCT03185741|Experimental|UMS Strategy + SMS Text Messaging|In addition to the components from the UMS strategy arm, patients will receive daily text message reminders for 6 months.
2909119|NCT03185741|No Intervention|Usual Care|Patients of providers randomized to the usual care arm will receive their standard care
2909120|NCT03185728|Experimental|iLookOut|Online, interactive learning program developed by study team.
2909121|NCT03185728|Active Comparator|Standard|Online mandated reporter training developed by the state of Maine during Y1, then recruited to complete iLookOut during Y2 and Y3.
2909122|NCT03185728|No Intervention|Control|No active recruitment or incentivizing of participants to complete any training on mandated reporting during Y1 and Y2, then recruited to complete iLookOut during Y3.
2909123|NCT03185715|Other|Counseling policy embryo transfer|All recipients completed a validated self-report questionnaire on the preference on the number of embryos to be transferred and the relevance for the decision-making process attributed to certain factors. The questionnaire also included questions on sociodemographic characteristics, medical-reproductive background and cycle's results and risks perception. All recipients received oral and written counselling. After counselling, during the treatment, the recipients completed a second questionnaire in order to check if their decision had changed.
2909124|NCT03185702||Patients with Turner Syndrome|Chromosomal diagnosis and typical features
2909125|NCT03185702||Unaffected controls|Normal females and unaffected family members
2909126|NCT03185689|Experimental|Intervention group|Effectiveness of an intensified DSME in T2D adult patients
2909127|NCT03185689|No Intervention|Comparison group|The comparison group have got the usual traditional way of education, which is given occasionally for all of diabetes patients at waiting area. Other than this, the comparison group didn't get an organized and intensified DSME.
2909128|NCT03185676|Experimental|Billberry|A bilberry-based probiotic beverage
2909129|NCT03185676|Active Comparator|Control|A control beverage without bilberries or probiotics
2909130|NCT03185663|Placebo Comparator|a pillow between the legs|
2909131|NCT03185663|Experimental|traction-stuck|
2909132|NCT03185650|Other|tPAD, then PARI LC Star Nebulizer|tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then PARI LC delivering 7% HS labeled with technetium-99m sulfur colloid particles.
2909133|NCT03185650|Other|PARI LC Star Nebulizer, then tPAD|PARI LC delivering 7% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles
2909134|NCT03185637||Gastroschisis|All patients presenting primarily to the institution with gastroschisis during the data collection period will be included in the study.
2909135|NCT03185637||Anorectal malformation|All patients presenting primarily to the institution with anorectal malformation during the data collection period will be included in the study.
2909136|NCT03185637||Appendicitis|All patients under 16-years of age presenting primarily to the institution with appendicitis during the data collection period will be included in the study.
2909137|NCT03185637||Intussusception|All patients under 16-years of age presenting primarily to the institution with intussusception during the data collection period will be included in the study.
2909138|NCT03185637||Inguinal hernia|All patients under 16-years of age undergoing surgery for an inguinal hernia at the institution during the data collection period will be included in the study.
2909139|NCT03185624|Experimental|Rifaximin|Prescribed Rifaximin (600mg, twice daily) for 3 months after surgery
2909140|NCT03185624|No Intervention|Blank control|No intervention after surgery
2909141|NCT03185611|Experimental|Rifaximin and Thiopurine|Prescribed Rifaximin (600mg, twice daily) combined with Azathioprine (2.0-2.5mg/kg/day) for 3 months after surgery, and then Azathioprine monotherapy (2.0-2.5mg/kg/day) for the next 3months.
2909142|NCT03185611|Active Comparator|Thiopurine|Prescribed Azathioprine (2.0-2.5mg/kg/day) for 6 months after surgery.
2909143|NCT03185598||non-MACE|no MACE occurred
2909144|NCT03185598||MACE|MACE occurred
2909145|NCT03185585||Adults 60 yrs and older|Participants will be asked to take the full MNA and COAST tools, separately .They will take a hand grip strength test to evaluate their functional status and five times Sit to Stand test as part of the COAST screening tool. Moreover, their weight, height, mid-arm circumference and calf circumference, will be measured as part of the MNA screening tool.
2909146|NCT03185559|Active Comparator|Relievion device- Treatment stimulation|Relievion Device- Treatment combined occipital and supraorbital transcutaneous nerve stimulation
2909147|NCT03185559|Sham Comparator|Relievion device- Sham Stimulation|Relievion Device- Sham combined occipital and supraorbital transcutaneous nerve stimulation
2909148|NCT03185546|Experimental|NNC cigarette + moderate nicotine e-liquid + tobacco flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
2909149|NCT03185546|Experimental|NNC cigarette + low nicotine e-liquid + tobacco flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
2955502|NCT02865070||5 babies (premature, ages 23-25 weeks)|
2909150|NCT03185546|Experimental|NNC cigarette + moderate nicotine e-liquid + variety flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.
2909151|NCT03185546|Experimental|NNC cigarette + low nicotine e-liquid + variety flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors
2909152|NCT03185546|Experimental|VLNC cigarette + moderate nicotine e-liquid + tobacco flavor|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
2909153|NCT03185546|Experimental|VLNC cigarette + low nicotine e-liquid +tobacco flavors|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
2909154|NCT03185546|Experimental|VLNC cigarette + moderate nicotine e-liquid + variety flavors|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.
2909155|NCT03185546|Experimental|VLNC cigarette + low nicotine e-liquid + variety flavors|Participants are provided with very low or nicotine-free nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors
2909156|NCT03185533||to reduce ED length of stay|to reduce ED length of stay to lessen ED crowding by using Lean-sigma management and quality improvement interventions including reducing boarding time and medical decision time.
2909157|NCT03185507|Experimental|Cryotherapy|Participants received superficial cryotherapy using the Cryohelmet(TM)
2909158|NCT03185507|No Intervention|Control|Participants sat quietly for 20 minutes
2909159|NCT03185494|Experimental|anti-CD19/22 CAR T cells|Patients receive anti-CD19/22-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
2909160|NCT03185481|Experimental|1 mg QD to 15 mg QD PF-06649751|Up titration from 1 mg QD to 15 mg QD PF-06649751
2909161|NCT03185481|Experimental|3 mg QD to 15 mg QD PF-06649751|Up titration from 3 mg QD to 15 mg QD PF-06649751
2909162|NCT03185481|Experimental|7 mg QD to 15 mg QD PF-06649751|Up titration from 7 mg QD to 15 mg QD PF-06649751
2909163|NCT03185481|Experimental|15 mg QD PF-06649751|15 mg QD PF-06649751 remains at 15 mg QD PF-06649751
2909164|NCT03185481|Experimental|1 mg to 7 mg QD PF-06649751|Up titration from 1 to 7 mg QD PF-06649751 if de-escalated in parent study
2909165|NCT03185481|Experimental|3 mg QD to 7 mg QD PF-06649751|Up titration from 3 to 7 mg QD PF-06649751 if de-escalated in parent study
2909166|NCT03185481|Experimental|7 mg QD to 7 mg QD PF-06649751|7 mg QD remains at 7 mg QD PF-06649751 if de-escalated in parent study
2909167|NCT03185481|Experimental|15 mg to 7 mg QD PF-06649751|15 mg QD de-escalated to 7 mg QD in parent study B7601003 remain at 15 mg QD PF-06649751
2909168|NCT03185468|Experimental|4SCAR-PSMA|4SCAR PSMA-modified T cells can recognize and kill tumor cells through the recognize of PSMA .This study will evaluate the side effects and effective doses of 4SCAR-PSMA T cells in treating refractory and recurrent solid tumors.
2909169|NCT03185468|Experimental|4SCAR-FRa|4SCAR FRa-modified T cells can recognize and kill tumor cells through the recognize of FRa .This study will evaluate the side effects and effective doses of 4SCAR-FRa T cells in treating refractory and recurrent solid tumors.
2909170|NCT03185455|No Intervention|Standard of Care|Those randomized to the standard protocol for blood pressure monitoring will be scheduled for an office based nursing blood pressure visits 4-6 days postpartum. Care at this visit is based on a physician derived algorithm.
2909171|NCT03185455|Experimental|Remote (text based) surveillance|Those randomized to remote surveillance will be provided with electronic blood pressure monitors prior to discharge and instructed on their use. Every day, for two weeks post-discharge, patients will receive a standard text message in the morning from a HIPAA compliant automated monitoring system reminding them to text their blood pressure. They will be asked to send in one blood pressure a day at minimum. They may be asked to send in more depending on the blood pressure result and clinical algorithm. This system will provide timely responses to patient texts and create a physician derived response to elevated blood pressures based on a programmed algorithm. Additionally, for blood pressures that reach a dangerous threshold, a clinical provider will be alerted per the algorithm and contact the patient for further evaluation.
2909172|NCT03185442|Experimental|PRF-fMRI|
2909173|NCT03185429|Experimental|Experimental|"Drug:Cyclophosphamide~Biological/Vaccine:Tumor Specific Antigen-loaded Dendritic Cells"
2909174|NCT03185416|No Intervention|Control group|The first prospective group -the control group- will consist of 30 patients receiving treatment by the Interventional Radiology team- along with their 30 primary caregivers. Neither the patient nor the caregiver will receive the palliative care training intervention. Patients and their caregivers will receive questionnaires regarding their health status (physical and psychosocial) and health services utilization at 1, 2, and 3 months post-procedure- during their follow-up visits.
2909175|NCT03185416|Experimental|Intervention Group|The second prospective component of the study -the intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
2909176|NCT03185403|Active Comparator|continous paravertebral block|"echoguided thoracic continous paravertebral block was placed before the surgery.~A bolus of 5 ml of ropivacaine 0.2% and 10µg of Sufentanil was injected in the catheter at the end of the abdominal time. A continuous infusion of ropivacaine 0.2% at 4ml/h was then initiated at the thoracic time. Postoperative patient-controlled analgesia consisted on an infusion of ropivacaine 0.2% at 6ml/h and a permitted bolus of 4ml every 15min as required."
2909202|NCT03185221|Active Comparator|XIENCE V|Everolimus Eluting Coronary Stent
2909326|NCT03184337|Active Comparator|Active Control|Participants in the active control group will receive 8 group sessions of the CDC's PreventT2 program.
2955503|NCT02865070||30 babies (any gestational age under 6 months)|
2909177|NCT03185403|Active Comparator|continous Thoracic epidural block|thoracic epidural catheter was inserted before the surgery. A bolus of 5 ml of ropivacaine 0.2% and 10µg of Sufentanil was injected in the catheter at the end of the abdominal time. A continuous infusion of ropivacaine 0.2% at 4ml/h was then initiated at the thoracic time. Postoperative patient-controlled analgesia consisted on an infusion of ropivacaine 0.2% at 6ml/h and a permitted bolus of 4ml every 15min as required.
2909178|NCT03185390|Other|ERCP guided biopsy or brush cytology|ERCP guided biopsy or brush cytology
2909179|NCT03185364|Experimental|Interventional group|Sildenafil Citrate, 20mg, tid for 12 weeks
2909180|NCT03185364|Placebo Comparator|Control group|placebo oral tablet, 12 weeks
2909181|NCT03185351|Active Comparator|BUPIVACAINE|patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB.
2909182|NCT03185351|Active Comparator|BUPIVACAINE and midazolam|patients will receive 20 ml of 0.5% bupivacaine + midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB.
2909183|NCT03185351|Active Comparator|BUPIVACAINE and i.v midazolam|patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB + 0.03 mg/kg of midazolam by I.V. route at the same time of the block
2909184|NCT03185338|Experimental|Active commuting to/from school|This intervention will be focused on children and their families following the ecological model proposed by Sallis et al., targeting mainly individual factors such as children's perceptions (safety perception on the way to school) and attitudes (independence or motivation to walk). A total of six 1-hour activities will be conducted at the classroom and two activities in the school neighborhood designed based on previous literature. Taken together, these activities will emphasize the benefits of active commuting to/from school and promote active commuting to/from school.Moreover, supporting information will be sent to families on four occasions during the intervention to encourage families to use active modes of commuting to/from school.
2909185|NCT03185338|Experimental|Active Physical Education lessons|This intervention has been developed by the Spanish Ministry of Health, Social Services and Equality and the Ministry of Education, Culture and Sport to increase the amount of children's PA during PE lessons in primary schools. At the time of this study, any school in Spain could choose to adopt this programme. This intervention includes two sets of eight active PE lessons specifically developed for third grade of primary school. These lessons will replace the original PE lessons in schools assigned to Active PE lesson intervention and integrated intervention.Additionally, this intervention provides some methodological advices to increase the PA time during the PE lesson (i.e. different ways to take attendance or deciding on the most suitable activity given the availability of resources).
2909186|NCT03185338|Experimental|Active school recess|This intervention has been designed based on previous research. The teacher will prepare the school playground offering adequate space and games to encourage children to be active. A sheet placed on the wall as a reminder will help teacher to remind children to participate and motivate them. On this sheet, each child will write the activity completed during the school recess every day during the intervention period.
2909187|NCT03185338|Experimental|Sleep health promotion|"Eight activities will be carried out at home and at school. During the first activity, parents and children will attend a general talk about sleep and health and will sign a contract for a healthy sleep at home. Also, children will complete a diary in which they will keep a record of their activities prior to going to bed and after waking up in the morning. At school, the first classroom-based activity will be based on the educational program I have a dream (Spanish adaptation of the SimplyHealthy@Schools International Program). The remaining classroom-based activities will include with a group art project with questions and answers about sleep, discussion groups about the sleep diary completed at home, and an abbreviated version of the Jacobson's progressive relaxation technique."
2909188|NCT03185338|Experimental|School global intervention|Also, a simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
2909189|NCT03185338|No Intervention|Control school|Control school will be evaluate but will not receive any intervention
2909190|NCT03185325||Non hodgkin lymphoma patients|bone marrow puncture and venous blood samples
2909191|NCT03185325||healthy voulnteers|venous blood samples
2909192|NCT03185312||patients with acne vulgaris|Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin .immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.
2909193|NCT03185312||patients with vitiligo|Clinical evaluation including full history taking and dermatological examination will be done . Assessment of disease severity will be performed using VASI score Skin biopsies will be taken from lesional and non-lesional skin .immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3..
2909194|NCT03185312||control|"Skin biopsies will be taken from skin of controls.~. Five micron thick sections will be cut from paraffin blocks for immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3."
2909195|NCT03185299|Experimental|Video|Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
2909196|NCT03185299|Experimental|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
2909197|NCT03185286|Experimental|3D-printed personalized metal implant|3D-printed personalized metal implant will be used in bone defect surgeries.
2909198|NCT03185247|Experimental|Group Intervention|10-week parent-child multi-family group
2909199|NCT03185234|Active Comparator|Real tDCS|Anodal tDCS at an intensity of 2 mA is applied for 10 minutes at a time on 5 consecutive days. The anodal electrode is placed over the left parietal cortex (P3 in 10/20 EEG) of the lesioned hemisphere, the cathodal electrode is located supraorbital on the right side. Motor tasks are performed before and after the stimulation.
2909200|NCT03185234|Sham Comparator|Sham tDCS|Sham stimulation is applied for 10 minutes at a time on 5 consecutive days. One electrode is placed over the left parietal cortex (P3 in 10/20 EEG) of the lesioned hemisphere and a second electrode supraorbital on the right side. Motor tasks are performed before and after the stimulation.
2909201|NCT03185221|Experimental|Cordimax|Rapamycin Eluting Coronary Stent
2909203|NCT03185208|Experimental|Lithium carbonate|Lithium carbonate will be initiated at 150 mg per day and increased based on blood levels until a steady blood level between 0.6 and 0.8 meq/L is achieved. Participants will continue at the dose achieved for 2 years with quarterly monitoring.
2909204|NCT03185208|Placebo Comparator|placebo|Matching placebo will be initiated and increased based on pretend blood levels. Participants will take placebo for 2 years with quarterly monitoring.
2909205|NCT03185195|Experimental|AQX-1125 Oral Tablet|AQX-1125 - Oral Tablet
2909206|NCT03185195|Experimental|[14C]-AQX-1125 IV|Radiolabelled AQX-1125 - Intravenous
2909207|NCT03185195|Experimental|[14C]-AQX-1125 Oral Solution|Radiolabelled AQX-1125 - Oral Solution
2909208|NCT03185182|Experimental|experimental group|185 megabecquerel (MBq) of Ioflupane I-123 will be administered IV to patients with suspected renal cell carcinoma, at a single occasion and followed by SPECT-analysis 5h after injection.
2909209|NCT03185169|Other|Replens and coconut oil|Commercially available Replens applied via prefilled applicator into the vagina and coconut oil applied at the vaginal introitus and vulva. Both are to be administered by the patient 2 times per week, interval between dosing to be approximately 2 days. Patients will be encouraged to apply Preseed, coconut oil, or patient's personal lubricant of choice into the vagina prior to sexual activity.
2909210|NCT03185156|Experimental|propofol group|first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
2909211|NCT03185156|Placebo Comparator|control group|first dose 0.03ml/Kg normal saline, then 0.1ml/Kg/hr micro-pump
2909212|NCT03185143|Experimental|ALLOD-2 Capsules|One capsule contains component A and one capsule contains component B
2909213|NCT03185143|Active Comparator|Sumatriptan 100 mg Capsules|One capsule contains Sumatriptan 100 mg and one capsule contains a sham comparator for component B.
2909214|NCT03185143|Placebo Comparator|Placebo Capsules|One capsule contains a sham comparator for component A and one capsule contains a sham comparator for component B .
2909215|NCT03185130|Active Comparator|Standard Treatment Arm|Standard Treatment Arm will receive: normal saline at 5 ml IV given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.
2909216|NCT03185130|Experimental|Study Arm|Study arm patients will receive: normal saline at 20 mL/kg (up to 1000 mL) given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.
2909217|NCT03185117||All patients|Adult patients scheduled to undergo a total knee arthroplasty or total hip arthroplasty, who give written informed consent to participate in the study.
2909218|NCT03185104|Experimental|Silver diamine fluoride|38% silver diamine fluoride solution (Saforide, Toyo Seiyaku Kasei Co. Ltd., Osaka, Japan) is professionally applied to exposed coronal and root surfaces of all teeth every 6 months for 36 months.
2909219|NCT03185104|Placebo Comparator|Distilled water|Distilled water is professionally applied to exposed coronal and root surfaces of all teeth every 6 months for 36 months.
2909220|NCT03185091|Other|rapid ventricular pacing|Safety of rapid ventricular pacing during neurosurgical procedures
2909221|NCT03185078|Experimental|Active Comparator: Low density ESWT Application|ESWT application will be done at energy density of 0.12 mJ/mm2 with physical therapy program.
2909222|NCT03185078|Experimental|Active Comparator: High density ESWT Application|ESWT application will be done at an energy density of 0.3 mJ/mm2 with physical therapy program.
2909223|NCT03185078|Sham Comparator|Active Control|The ESWT application will be executed when the ESWT application is in the off position. During application, pre-recorded sound beats will be played to the treatment group.
2909224|NCT03185065|Experimental|A|amantadine, placebo, modafinil, methylphenidate
2909225|NCT03185065|Experimental|B|placebo, methylphenidate, amantadine, modafinil
2909226|NCT03185065|Experimental|C|modafinil, amantadine, methylphenidate, placebo
2909227|NCT03185065|Experimental|D|methylphenidate, modafinil, placebo and amantadine
2909228|NCT03185052|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
2909229|NCT03185039|Experimental|kidney cancer|Localized, oligometastatic or metastatic
2909230|NCT03185026|Active Comparator|Relaxation group|Participants will be included in a standardized relaxation program, consisting of 10 weekly sessions lasting 2 hours. There will be 2 therapists for each patients group. Abdominal and muscular relaxation skills will be experimented.
2909231|NCT03185026|Experimental|Psychoeducational group|The patients will experiment the last innovating psychological skills in order to acquire the ability to engage in behaviors to manage their disease.
2909232|NCT03185013|Experimental|VGX-3100 + EP|IM injections with VGX-3100 followed by electroporation (EP) using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
2909233|NCT03185013|Placebo Comparator|Placebo + EP|IM injections with matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
2909234|NCT03185000|Experimental|Immediate ATIMP (AP)|Patients randomised to AP will receive Treg immunotherapy (TR004) infusion at Week 0 and Placebo infusion at Week 8.
2909235|NCT03185000|Experimental|Delayed ATIMP (PA)|Patients randomised to PA will receive Placebo infusion at Week 0 and Treg immunotherapy (TR004) infusion at Week 8.
2909236|NCT03184987|Experimental|FF/UMEC/VI 100/62.5/25 mcg closed triple therapy|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.
2909237|NCT03184987|Experimental|FF/UMEC/VI 200/62.5/25 mcg closed triple therapy|Subjects will receive FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.
2909238|NCT03184961|Experimental|lung recruitment maneuver|"Heart rate, mean arterial pressure, stroke volume, pulse pressure variations, pleth variability index, and photoplethysmographic waveform were recorded before lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s), during lung recruitment maneuver when stroke volume reached its minimal value.~Stroke volume measured before and after volume expansion (10ml/kg saline, 0.9%, infused during 10 min). Patients were considered as responders to fluid administration if stroke volume increased greater than or equal to 10%."
2909282|NCT03184675|Experimental|Functional action observation training|
2909239|NCT03184948|Active Comparator|Phase 1|"This is the first set of randomly selected hospitals to receive the intervention (Brilliance device). The intervention to be provided is the phototherapy device, Brilliance.~*No individual participants are recruited for this study."
2909240|NCT03184948|Active Comparator|Phase 2|"This is the second set of hospitals to receive the device. For the first three months, they receive no intervention, after which they become part of the active comparator arm. The intervention to be provided is the phototherapy device, Brilliance.~*No individual participants are recruited for this study."
2909241|NCT03184948|No Intervention|Phase 3|"This is the last set of hospitals to receive the device. For the first six months, they receive no intervention, after which the study is completed and they are given the device Brilliance.~*No individual participants are recruited for this study."
2909242|NCT03184935|Experimental|Experimental group|Basic medication: Decitabine; Allogeneic umbilical cord mesenchymal stem cells.
2909243|NCT03184935|Placebo Comparator|Control group|Basic medication: Decitabine; placebo: saline.
2909244|NCT03184922|Active Comparator|Fixed suspensory loop|Non-adjustable femoral cortical fixation device to be used
2909245|NCT03184922|Experimental|Adjustable suspensory loop|Adjustable femoral cortical fixation device to be used
2909246|NCT03184909|Experimental|Tulsi active|
2909247|NCT03184909|Placebo Comparator|Tulsi placebo|
2909248|NCT03184896||Hip Fracture|
2909249|NCT03184883|Experimental|single conventional denture|patients with mandibular edentulous arch by using acrylic resin denture with soft linner
2909250|NCT03184883|Active Comparator|single flexible denture|patients with mandibular edentulous arch by using flexible lower denture
2909251|NCT03184870|Experimental|Combination Therapy 1|BMS-813160 with 5-fluorouracil (5-FU), leucovorin containing regimens in combination with irinotecan
2909252|NCT03184870|Experimental|Combination Therapy 2|BMS-813160, nab/paclitaxel and gemcitabine
2909253|NCT03184870|Experimental|Combination Therapy 3|BMS-813160 and Nivolumab
2909254|NCT03184870|Experimental|Monotherapy|BMS-813160 Monotherapy
2909255|NCT03184857|Active Comparator|two stage sinus lifting using bovine bone particles|Open maxillary sinus lifting will be done with sinus augmentation using bovine bone particles
2909256|NCT03184857|Experimental|two sage sinus lifting using Nano HA bone particles|Open maxillary sinus lifting will be done with sinus augmentation using Nano HA bone particles
2909257|NCT03184844|Experimental|thalidomide thalassemia|thalidomide:50mg/d p.o
2909258|NCT03184831|Active Comparator|sinus lift, implant placement, sole bovine bone|sinus floor elevation with simultaneous implant placement together with grafting the sinus with a deproteinized bovine bone solely.
2909259|NCT03184831|Experimental|sinus lift, implant placement, injectable PRF + bovine bone|sinus floor elevation with simultaneous implant placement together with grafting the sinus with a mixture of injectable platelet rich fibrin with a deproteinized bovine bone.
2909260|NCT03184818||No antibacterial from other provider (Arm 1)|Patients with symptomatic, uncomplicated urinary tract infection presenting without a prescription for an antibacterial from another health care practitioner.
2909261|NCT03184818||Antibacterial from other provider (Arm 2)|Patients with symptomatic, uncomplicated urinary tract infection or asymptomatic bacteriuria presenting with a prescription for an antibacterial from another health care practitioner.
2909262|NCT03184805|Active Comparator|Continuing aspirin|Patients in the group may continue the administration of aspirin during perioperative period.
2909263|NCT03184805|Experimental|Stopping aspirin|Patients in the group may stop medication of antiplatelet drugs during perioperative period.
2909264|NCT03184792|Active Comparator|Transcutaneous spinal stimulation & Physical therapy|Transcutaneous cervical electrical stimulation combined with physical therapy that targets rehabilitation of upper extremity functions
2909265|NCT03184792|Active Comparator|Physical therapy only|Physical therapy that targets rehabilitation of upper extremity functions
2909266|NCT03184779|Experimental|Intervention|The intervention group will receive an educational video containing safety messages and an injury prevention component with the intent of reducing behaviours and actions on the hill than can potentially lead to injury.
2909267|NCT03184779|No Intervention|Control|The control group will receive the usual procedures associated with school outings where students have the opportunity to watch the standard welcome video (~8 minutes) with information on how their day will go and how to use and put on safety equipment. The information given in the control procedure emphasizes preparation and how to use and put on equipment rather than safety messages oriented towards preventing injury and collisions. Students in the control group will watch the video prior to participating in the ski area school program.
2909268|NCT03184766|Experimental|1|Treatment Order: Test, Comparator 1, Comparator 2
2909269|NCT03184766|Experimental|2|Treatment Order: Test, Comparator 2, Comparator 1
2909270|NCT03184766|Experimental|3|Treatment Order: Comparator 1, Test, Comparator 2
2909271|NCT03184766|Experimental|4|Treatment Order: Comparator 1, Comparator 2, Test
2909272|NCT03184766|Experimental|5|Treatment Order: Comparator 2, Test, Comparator 1
2909273|NCT03184766|Experimental|6|Treatment Order: Comparator 2, Comparator 1, Test
2909274|NCT03184753|Experimental|Single arm|OC-IgT cells to treat ovarian cancer.
2909275|NCT03184740|Experimental|Active-tDCS|A constant current (anodic) of 2mA will be applied for 20 minutes over the Primary motor cortex (M1).
2909276|NCT03184740|Sham Comparator|Sham-tDCS|A constant current (sham) of 2mA will be applied on the Primary motor cortex, but the stimulator will be turned off after 30 seconds .
2909277|NCT03184714|No Intervention|Control|
2909278|NCT03184714|Experimental|Interventional group|NIPPV as treatment of OS
2909279|NCT03184701|Experimental|Experimental|Patients assigned to this arm receive the intervention in addition to routine standard of care. Telehealth based remote monitoring of symptoms and brain tests is the intervention in this study. A device with preloaded questionaires will be given to patients randomized to this group. The patients will respond on a daily basis for the 3 months of intervention phase.
2909280|NCT03184688|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
2909281|NCT03184688|Placebo Comparator|Normal saline|Normal saline for hydrodissection
2909284|NCT03184662|Experimental|HIPA group|Twice weekly physical activity session in a dedicated structure, supervised by a graduated coach, alternating sessions of strengthening and intermittent HIPA, allowing a mixed stimulation of neuro-muscular and cardiovascular systems, and regular (every 3 months) adjustment of the intensity of the program.
2909285|NCT03184662|Active Comparator|Control group|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD (French Language Diabetes Society).
2909286|NCT03184649|Experimental|intervention arm|Ibuprofen suspension (Ibufen®, 100 mg/5 mL; fruit flavored, orange colour, Abbott) will be given 30 min before injection of local anesthesia. Then pain scores will be recorded from 0-4.
2909287|NCT03184649|Experimental|intervention|Paracetamol (Calpol™, 250 mg/5 mL; fruit flavored, orange color, GlaxoSmithKline) will be given 60 min before injection of local anesthesia.Then pain scores will be recorded from 0-4.
2909288|NCT03184649|Placebo Comparator|comparator|A fruit-flavored orange color placebo solution will be given 60 min before injection of local anesthesia.Then pain scores will be recorded from 0-4.
2909289|NCT03184610||OCT-scanning|Patients with Keratoconus are scanned with an OCT-Prototype
2909290|NCT03184610||OCT-scanning for volunteers|Volunteers with healthy eyes are scanned with an OCT-Prototype
2909291|NCT03184597|Experimental|Group with two strong risk factors|When HLA screening before commencing aromatic AEDs shows positive for both HLA-A*24:02 and HLA-B*15:02 in a patient, aromatic AEDs were not administrated for this patient.
2909292|NCT03184597|Experimental|Group with one strong risk factors|"When HLA screening before commencing aromatic AEDs shows positive for HLA-B*15:02, carbamazepine (CBZ) was not administrated, and other aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead.~When HLA screening before commencing aromatic AEDs shows positive for HLA-B*15:01 or HLA-A*24:02, aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead."
2909293|NCT03184597|Experimental|Group with one potential risk factors|When HLA screening before commencing aromatic AEDs shows positive for any potential risk allele such as HLA-B*15:11, HLA-A*02:01and HLA-DRB1*01:01, aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead.
2909294|NCT03184597|Experimental|Group without known risk factors|When HLA screening before commencing aromatic AEDs shows negative for any known HLA risk allele , aromatic AEDs was administrated to these patients.
2909295|NCT03184584|Experimental|PBI-4050|
2909296|NCT03184571|Experimental|Bemcentinib (BGB324) + pembrolizumab|Bemcentinib (BGB324) in combination with pembrolizumab. Bemcentinib capsules are administered at 400mg for days 1-3, and 200mg thereafter. Pembrolizumab is an IV infusion, administered at a dose of 200mg every 3 weeks.
2909297|NCT03184558|Experimental|Bemcentinib (BGB324) + pembrolizumab|Bemcentinib (BGB324) in combination with pembrolizumab. Bemcentinib capsules are administered at 400mg on days 1-3, and 200mg there after. Pembrolizumab is an IV infusion, administered at a dose of 200mg every 3 weeks.
2909298|NCT03184545|Experimental|EMS and PT|Group 1: Electrical Muscle stimulation (EMS) and Physical therapy (PT).
2909299|NCT03184545|Active Comparator|Only PT|Group 2: Only Physical therapy (PT).
2909300|NCT03184532||D|diabetic patients
2909301|NCT03184532||ND|non-diabetic patients
2909302|NCT03184519|Experimental|All patients|Patients will undergo 3 blood samples after IVF-ET to determine pregnancy.
2909303|NCT03184506|Sham Comparator|control group|
2909304|NCT03184506|Active Comparator|pre-warming group|
2909305|NCT03184493|Experimental|Celebrex|Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects.
2909306|NCT03184493|Experimental|Metformin|Patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.
2909307|NCT03184493|Active Comparator|Celebrex plus Metformin|Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects. In addition, patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.
2909308|NCT03184493|No Intervention|Empty control group|This group patients will not receive any postoperative adjuvant therapy.
2909309|NCT03184480||SUBJECTS RECEIVING ARNUITY ELLIPTA|Subjects with a diagnosis of asthma bronchial, for which Arnuity is indicated, who are naïve to Arnuity will be included.
2909310|NCT03184467|Placebo Comparator|Control group|Normal saline 0.9%
2909311|NCT03184467|Experimental|Study group 1|GV1001 0.56 mg
2909312|NCT03184467|Experimental|Study group 2|GV1001 1.12 mg
2909313|NCT03184454|Experimental|Medtronic PC+S Deep Brain Stimulation|"Single open label arm.~Patients with severe, treatment-refractory obsessive-compulsive disorder (OCD) will receive stimulation in two separate, but related, brain regions, the dorsolateral prefrontal cortex (dlPFC) and the ventral anterior limb of the internal capsule and adjacent ventral striatum (VC/VS) with a novel Medtronic PC+S deep brain stimulation (DBS) system."
2909314|NCT03184441|Experimental|Premie Pouch|All participants will receive the experimental treatment with the Premie Pouch device.
2909315|NCT03184428||Implantation of IOL L313|Patients who have undergone a cataract surgery with implantation of the monofocal MICS IOL L313 more than 3 Years ago will be asked about the Treatment for Postoperative observation and survey.
2909316|NCT03184415|Experimental|DWC20155/DWC20156 Combination Therapy|
2909317|NCT03184415|Active Comparator|DWC20155 Monotherapy|
2909318|NCT03184415|Active Comparator|DWC20156 Monotherapy|
2909319|NCT03184402|Experimental|DWJ1252|
2909320|NCT03184402|Active Comparator|Gasmotin|
2909321|NCT03184389|Other|Within-participant micro-randomization|Each minute when participant is available is randomly assigned to either intervention (to practice a stress management exercise) vs. no intervention prompt. When intervention occurs, participant's smartphone vibrates and relaxation app opens, prompting performance of a relaxation exercise.
2909322|NCT03184376|Experimental|Prebiotic|Prebiotic oligofructose (Orafti P95, Beneo-Orafti Inc., Tienen, Belgium) taken 8g orally per day for 12 weeks followed by 16g per day for 24 weeks.
2909323|NCT03184376|Placebo Comparator|Placebo|Placebo maltodextrin (isocaloric to prebiotic) taken 3.3g orally per day for 12 weeks followed by 6.6g per day for 24 weeks.
2909324|NCT03184363|Experimental|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
2909325|NCT03184350|Other|Adjuvant pelvic proton radiation|
2909327|NCT03184337|Experimental|Experimental|Participants in the experimental group will receive 8 group sessions of the CDC's PreventT2 Program with Added Sleep Content designed to extend and improve sleep.
2909328|NCT03184324|Experimental|DWP14012 Amg|DWP14012 Amg, tablet, orally, once daily
2909329|NCT03184324|Experimental|DWP14012 Bmg|DWP14012 Bmg, tablet, orally, once daily
2909330|NCT03184324|Experimental|DWP14012 Cmg|DWP14012 Cmg, tablet, orally, once daily
2909331|NCT03184324|Active Comparator|Esomerpazole 40mg|Esomerpazole 40mg, tablet, orally, once daily
2909332|NCT03184311|Experimental|High-intensity interval training (HIT)|A 12-week HIT will be performed 3 times per week on a bicycle ergometer according to the protocol of Wisløff et al. In the first 4 weeks of the program, all sessions will consist of moderate continuous training (MCT) at 60-80% of peak heart rate (HRpeak) for 40 minutes in order that patients get used to exercising. For weeks 4-12, the following HIT protocol is intended: Patients will warm up for 10 minutes at moderate intensity (60-70% of HRpeak, Borg 11-13) before cycling four 4-minute intervals at high intensity (85-95% of HRpeak, Borg 15-17). Each interval will be separated by a 3-minute active pause at 60-70% of HRpeak (Borg 11-13). The training session will end with a 5-minute cool-down at moderate intensity (60-70% of HRpeak). Total exercise time will be 40 minutes.
2909333|NCT03184311|Placebo Comparator|Usual care|Patients in the control group will continue to undergo usual care and be advised to follow health recommendations for patients with chronic heart failure according to an information leaflet of the Swiss Heart Foundation.
2909334|NCT03184298|Other|Social Norms Survey|The purpose of this social norms questionnaire is to collect quantitative data from an online questionnaire that will be used to describe the climate of dating and sexual activities among male Soldiers at Fort Bragg, NC.
2909335|NCT03184298|Other|Individual Interview|These standardized interviews aim to gather qualitative data related to the opinions that participants have regarding dating and sexual behaviors with women and the role that alcohol may play in relation to these behaviors.
2909336|NCT03184298|Other|Focus Groups|The purpose of the focus group discussion is to collect qualitative data using a semi-structured open-ended format. Results from the focus group will be used to further revise a program that aims to address the role that alcohol may play in the dating and sexual behaviors of Fort Bragg servicemen.
2909337|NCT03184285|Experimental|bariatric surgery|baseline alert 1; Anti-Trendelenburg-position (ATB); Anti-Trendelenburg-position (ATB) in narcosis; baseline in narcosis 1; passive leg raising; volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); baseline in narcosis 2; start capnoperitoneum; Anti-Trendelenburg-position (ATB) plus capnoperitoneum; ATB plus capnoperitoneum plus volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); ATB loss of capnoperitoneum; baseline in narcosis; baseline alert 2; torso position rising 30° at the beginning; torso position rising 30° at the end
2909338|NCT03184272|Experimental|bariatric surgery|baseline alert 1; Anti-Trendelenburg-position (ATB); Anti-Trendelenburg-position (ATB) in narcosis; baseline in narcosis 1; passive leg raising; volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); baseline in narcosis 2; start capnoperitoneum; Anti-Trendelenburg-position (ATB) plus capnoperitoneum; ATB plus capnoperitoneum plus volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); ATB loss of capnoperitoneum; baseline in narcosis; baseline alert 2; torso position rising 30° at the beginning; torso position rising 30° at the end
2909339|NCT03184259|Experimental|Ankle Robot group|subjects will wear the Ankle Robot during tasks, power assistance will be provided from the motor to the ankle joint
2909340|NCT03184259|Experimental|Knee Robot group|subjects will wear the Knee Robot during tasks, power assistance will be provided from the motor to the knee joint
2909341|NCT03184259|Placebo Comparator|Ankle Sham group|subjects will wear the Ankle Robot during tasks, but no power assistance will be provided from the motor to the ankle joint
2909342|NCT03184259|Placebo Comparator|Knee Sham group|subjects will wear the Knee Robot during tasks, but no power assistance will be provided from the motor to the knee joint
2909343|NCT03184246|Experimental|GlideScope|intubation with GlideScope
2909344|NCT03184246|Active Comparator|Direct laryngoscopy|intubation with laryngoscope
2909345|NCT03184233|Other|Cerebral aneurysm surgery with RVP|Subjects receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere (contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels will be determinated preoperatively, peroperative and at 6, 12 and 24 hours postoperative by blood sample. Maximum cTnl level and cTnl level 24 hours will be compared. Brain oxygenation (Sct O₂) by near-infrared spectroscopy will be monitored. During surgery subjects allocated in this study arm will undergo RVP.
2909346|NCT03184233|Active Comparator|Craniotomy without RVP|"Subjects receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere (contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels will be determinated preoperatively, peroperative and at 6, 12 and 24 hours postoperative by blood sample. Maximum cTnl level and cTnl level 24 hours will be compared. Brain oxygenation (Sct O₂) by near-infrared spectroscopy will be monitored.~No rapid ventricular pacing is applied perioperatively."
2909347|NCT03184220|Experimental|EXPERIMENTAL GROUP|"Patients who are pregnant, have pacemaker and those surgically operated cervical spine patients who have been treated with myofascial therapy a month earlier.~Multimodal physical therapy program includes:~Myofascial syndrome cervical therapy treatment."
2909348|NCT03184220|Experimental|CONTROL GROUP|"Multimodal physical therapy program includes:~ultrasound therapy (US),~transcutaneous electric nerve stimulation (TENS)~massage."
2909349|NCT03184194|Experimental|Nivolumab-daratumumab|daratumumab 16 mg/kg: 8 times once weekly, then 8 times every 2 weeks; then every 4 weeks; nivolumab: 240 mg every 2 weeks during first 6 cycles, followed by 480 mg every 4 weeks
2909350|NCT03184194|Experimental|Nivolumab-daratumumab with cylclophosphamide|daratumumab 16 mg/kg: weekly for 8 weeks, then Q2W for 16 weeks, ten Q4W thereafter; nivolumab: 240 mg every 2 weeks during first 6 cycles, followed by 480 mg every 4 weeks; low-dose cyclophosphamide 50mg daily on days 1-28 of each 28-day cycle;
2909351|NCT03184181|Experimental|EPTE® group|The intervention for this group consisted of Therapeutic Percutaneous Electrolysis (EPTE®). Patient received EPTE® once week for four weeks associated with eccentric exercises device at home.
2910918|NCT03173456|Active Comparator|400 ibuprofen/APAP|400 mg ibuprofen + 1000 mg acetaminophen
2909352|NCT03184181|Active Comparator|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises device at home. Patient received 3 sessions of dry needling a week for four weeks.
2909353|NCT03184168|Experimental|treatment|[14C]lorlatinib
2909354|NCT03184155|Experimental|Intracoronary Nicardipine|200 mcg intracoronary injection of nicardipine prior to PCI, with potential for additional 100 mcg nicardipine before stent placement, balloon post-dilation, and before post-PCI IMR measurement.
2909355|NCT03184155|Placebo Comparator|Sterile Saline|Injection of sterile saline prior to PCI, with potential for additional saline injections before stent placement, balloon post-dilation, and before post-PCI IMR measurement.
2909356|NCT03184142|Experimental|Simulation|During a suturing class at the simulation center, the students enter a classroom. Although the students are not aware of this, among them is an actor playing the role of a student. One of the two professors is also an actor. As the activity progresses, the professor targets the student played by an actor. The intimidation intensifies until the end. At the end of the activity, there is a debriefing explaining to the students that the bullying professor and the victim were actors.
2909357|NCT03184142|Experimental|Video|During a suturing class at the simulation center, after 55 minutes of suturing, the students will be exposed to a 15-minute video on workplace and hospital intimidation and how to manage it.
2909358|NCT03184142|Placebo Comparator|Control|During a suturing class at the simulation center, the students suture for the entire 70-minute duration of the activity. They are not exposed to intimidation (control group).
2909359|NCT03184129|Experimental|trial group|Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd., Wuhan, China (newly developed).
2909360|NCT03184129|Experimental|control group|Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
2909361|NCT03184116|Experimental|Individual intervention|Individual intervention using cognitive-behavioral principles
2909362|NCT03184116|No Intervention|Control|No additional intervention
2909363|NCT03184090|Experimental|Palbociclib + Endocrine Therapy|"Patients will receive palbociclib capsules orally for 21 days every four weeks in combination with endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole).~Treatment will continue until disease progression (with the exception of patients who develop isolated progression in the brain), unacceptable toxicity, death, or discontinuation from the study treatment for any other reason."
2909364|NCT03184077|Active Comparator|Polyglactic 910|
2909365|NCT03184077|Active Comparator|Monocryl|
2909366|NCT03184064|Experimental|Treatment arm 1|Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), citrus extract (low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
2909367|NCT03184064|Experimental|Treatment arm 2|Participants will receive the placebo, citrus extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
2909368|NCT03184064|Experimental|Treatment arm 3|Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
2909369|NCT03184064|Experimental|Treatment arm 4|Participants will receive the placebo, blackcurrant extract (low dose), citrus extract (low dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
2909370|NCT03184051||Ultrasound assessment|All subject of the study have a knee osteoarthritis (OA) and are going to have a total arthroplasty. Diagnostic performance of ultrasonography is evaluated on ex vivo cartilage samples (2 samples per patient are selected with different stage of OA : 1 with early stage and 1 with advanced stage).
2909371|NCT03184038|Other|Assessment of neurocognitive function|Patients undergo assessment of neurocognitive function at baseline and at 2, 4, 6, and 12 months after undergoing standard of care Stereotactic Radiosurgery (SRS) or Stereotactic Body Radiation Therapy (SBRT)
2909372|NCT03184025|Other|patients have class I caries|patients have received four restorations which included HEMA containing and HEMA-free dentin adhesive with or without surface sealing
2909373|NCT03184012|Experimental|NuSmile Zirconia crowns|NuSmile Zirconia crowns is an esthetic primary anterior crown used to restore carious primary anterior teeth.
2909374|NCT03184012|Experimental|Composite resin strip crowns|Composite resin strip crowns is an esthetic conventional primary anterior crown used to restore carious primary anterior teeth.
2909375|NCT03183999|Experimental|GINST group|Experimental group was randomly assigned among the volunteers who met the inclusion criteria: men between the ages of 18 and 60 who had sperm motility of less than 32%. Fermented ginseng (GINST) was supplied.
2909376|NCT03183999|Placebo Comparator|Control group|Control group was randomly assigned among the volunteers who met the inclusion criteria: men between the ages of 18 and 60 who had sperm motility of less than 32%. Placebo was supplied.
2909377|NCT03183986|Active Comparator|Phototherapy 478 nm|The jaundiced neonates receives phototherapy with blue light from above at wavelength 478 nm. They are treated for 24 hours, which is standard treatment for neonatal jaundice.
2909378|NCT03183986|Active Comparator|Phototherapy 459 nm|The jaundiced neonates receives phototherapy with blue light from above at wavelength 459 nm. They are treated for 24 hours, which is standard treatment for neonatal jaundice.
2909379|NCT03183973|Experimental|PRF group|patients who will receive Platelet Rich Fibrin (PFR) suspension
2909380|NCT03183973|Experimental|placebo group|
2909381|NCT03183960|Experimental|Mentor|An independent centralized randomization database will provide allocation concealed to the involved clinicians and assessors. A stratified block randomization of severity of impairment will be performed within each rehabilitation hospital
2909419|NCT03183700|Other|Control arm 1|The women will receive the usual recall with a new invitation letter with a prefixed appointment.
2909382|NCT03183960|Active Comparator|Traditional rehabilitation|An independent centralized randomization database will provide allocation concealed to the involved clinicians and assessors. A stratified block randomization of severity of impairment will be performed within each rehabilitation hospital
2909383|NCT03183947|Experimental|fMRI Neurofeedback regulation of left PFC|Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
2909384|NCT03183947|Experimental|fMRI Neurofeedback of right PFC|Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
2909385|NCT03183921||Cases|All ICU patients with nosocomial lower respiratory tract infection
2909386|NCT03183908|Active Comparator|Adjuvanted influenza vaccine (FLUAD)|In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.
2909387|NCT03183908|Active Comparator|High-dose influenza vaccine (Fluzone HD)|In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.
2909388|NCT03183895|Experimental|AccuCinch® Ventricular Repair System|
2909389|NCT03183882|Experimental|Normative Peer Comparison|One-time summary report of 14-month individual history of opioid prescribing WITH comparisons to (a) other providers at their site and (2) other providers at 15 ED sites with similar prescribing
2909390|NCT03183882|Active Comparator|Control Feedback|One-time summary report of their individual history of opioid prescribing
2909391|NCT03183869|Active Comparator|Early Intervention|Fecal microbiota via enema at Month 1, 2, 3. 4, 5 and month 6 along with stool, urine and blood collection. At months 7, 8, 9, 10, 11 and 12 only stool, urine and blood collection.
2909392|NCT03183869|Active Comparator|Late Intervention|At months 1, 2, 3, 4, 5 and 6, stool, urine and blood collection. Fecal microbiota via enema at month 6, 7, 8, 9, 10, 11and 12 months along with stool, urine and blood collection.
2909393|NCT03183856|Experimental|Morning walk|200 steps of gait rehabilitation using an end-effector typed gait robot with 5 minute break, 3 times a day for 10 weekdays: the end-effector type gait robot (Morning Walk®, Hyundai Heavy Industry, Republic of Korea)
2909394|NCT03183856|Active Comparator|No Morning walk|200 steps by themselves or with a help of a walker on a even floor at a comfortable pace with 5 minute break, three times a day for 10 weekdays
2909395|NCT03183843|Active Comparator|Dabigatran|Dabigatran etexilate 150 mg by mouth every 12 hours for a year
2909396|NCT03183843|Active Comparator|Warfarin|Warfarin by mouth every 24 hours in a dose providing international normalized ratio (INR) 2.5-3.5 for a year
2909397|NCT03183830|Experimental|Nitrate-rich Beetroot Juice|Individuals will receive a once daily dose of dietary nitrate in the form of a beetroot juice concentrate (70mL) containing ~5-6mmol inorganic nitrate (James White Drinks, UK) for 12 +/- 2 weeks. This dose has been chosen due to several reports demonstrating efficacy in patients with cardiovascular disease.
2909398|NCT03183830|Placebo Comparator|Nitrate-deplete Beetroot Juice|The placebo control is an identical juice from which the nitrate anion has been removed using a standard anion exchange resin. Visually there is no detectable difference between the juices and previous spectral, ion concentration, sugar levels, ascorbate analysis and taste testing has confirmed no differences in colour and constituents. The process to extract nitrate from the juice is the same technique used to remove inorganic nitrate from general drinking water supplies, and has been approved for use by Ethics Committees. The nitrate-free juice is not considered a drug or medicine, and is classified as a foodstuff.
2909399|NCT03183817|Experimental|Person-centred care at distance|Person-centred care at distance through an eHealth platform, used both by professionals, patients and relatives
2909400|NCT03183817|No Intervention|Usual Care|Evidence-based care
2909401|NCT03183804||ALLO-ASC-DFU|Subjects with ALLO-ASC-DFU treatment in phase 2 clinical trial of ALLO-ASC-DFU-201
2909402|NCT03183804||Standard therapy|Subjects with Standard therapy in phase 2 clinical trial of ALLO-ASC-DFU-201
2909403|NCT03183791|Experimental|RELAX group|the RELAXaHEAD app
2909404|NCT03183791|Active Comparator|Monitored Usual Care (MUC) group|this group receives standard of care and uses the electronic daily symptom reporting diary
2909405|NCT03183778|Experimental|First Phase|During the first phase (week 1), participants will be transitioned to a plant-rich renal diet, which contains moderate protein (10-15% of kcal), restricts dairy products (1 serving/day), and eliminates high-potassium fruits and vegetables
2909406|NCT03183778|Active Comparator|Second Phase|During the second phase (weeks 2 and 3), the diet will be altered to provide at-least half of fruits and vegetables from high-potassium sources
2909407|NCT03183765|Experimental|MMR vaccine|Measles-Mumps-Rubella Vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments
2909408|NCT03183765|Active Comparator|Cryotherapy|patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions
2909409|NCT03183752|Experimental|Metformin|patients randomized to Metformin group
2909410|NCT03183752|Placebo Comparator|Placebo|patients randomized to placebo group
2909411|NCT03183739|Experimental|ASP8062 lower dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
2909412|NCT03183739|Experimental|ASP8062 middle dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
2909413|NCT03183739|Experimental|ASP8062 higher dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
2909414|NCT03183739|Placebo Comparator|Placebo|Subjects will receive a single dose of Placebo on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
2909415|NCT03183726||ALLO-ASC-DFU treatment|Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-DFU-101
2909416|NCT03183713|Active Comparator|Comparison Group|Patients with a zero risk score will serve as a comparison group (N=20).
2909417|NCT03183713|Active Comparator|Sham Treatment|All patients at risk will be stratified by risk rating and randomly assigned to 2 groups; sham treatment (N=20) or CBT (N=20).
2909418|NCT03183713|Active Comparator|CBT|All patients at risk will be stratified by risk rating and randomly assigned to 2 groups; sham treatment (N=20) or CBT (N=20).
2909420|NCT03183700|Experimental|Intervention arm 2|Dry one, where FloqSwab, with which perform the sampling is contained and will be preserved after sampling in a tube without preservation solutions
2909421|NCT03183700|Experimental|Intervention arm 3|Wet one in which, after sampling, the FloqSwab, will be dissolved in preservation solutions.
2909422|NCT03183674|Experimental|oxytocin spray|oxytocin nose spray dose 0,4IU/kg, once unique dose
2909423|NCT03183674|Placebo Comparator|placebo|saline nose spray, 0,9 %, once unique dose
2909424|NCT03183661||ALLO-ASC-CD injection|Subjects with ALLO-ASC-CD injection in phase 1 clinical trial of ALLOASC-CD-101
2909425|NCT03183635|Experimental|Kinect based Rapid Movement Therapy|Kinect based Rapid Movement Therapy (RMT) training requires participants to move their limbs very rapidly to reach-to-grasp or step towards a virtual target appear suddenly on a screen, which is designed to their range of motion as well as response speed.
2909426|NCT03183635|Placebo Comparator|Conventional balance training|Conventional balance training involves some slow and low-impact muscle strengthening and mobilizing exercises.
2909427|NCT03183622||ALLO-ASC-DFU treatment|Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-BI-101
2909428|NCT03183609|Active Comparator|Gluten|30 grams of gluten flour daily in protein shake
2909429|NCT03183609|Placebo Comparator|Placebo|30 grams of rice flour daily in protein shake
2909430|NCT03183596|Active Comparator|Deep Serratus Anterior Block|"Patients in the deep Serratus Anterior Block (DSAB) group will have 20-60cc of 0.25% bupivacaine and 2-4mg of dexamethasone deposited deep to the serratus. The investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting."
2909431|NCT03183596|Active Comparator|Superficial Serratus Anterior Block|"Patients in the superficial Serratus Anterior Block (SSAB) group will have 20-60cc of 0.25% bupivacaine and 2-4mg of dexamethasone placed between serratus and latissimus dorsi. The investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting."
2909432|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT|7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to patients with IPF, followed by a 60-minute dynamic PET/CT scan of the lung field of view and two vertex-to-thigh PET/CT scans.
2909433|NCT03183557|Active Comparator|ZA alone|
2909434|NCT03183557|Active Comparator|ZA plus VD|
2909435|NCT03183544|Experimental|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|Single injection for diagnostic use only
2909436|NCT03183518|Experimental|Test Product|All the participants will have the test product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and the spinal mid-line.
2909437|NCT03183518|Other|Reference product|All the participants will have the reference product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and the spinal mid-line.
2909438|NCT03183505|Experimental|Anyu Peibo|Anyu Peibo Capsule, oral, 0.8g twice per day
2909439|NCT03183505|Placebo Comparator|Placebo|Placebo,oral, twice per day
2909440|NCT03183492|Experimental|HAV Group|Subjects who were vaccinated under UMV with 2 doses of Havrix® Junior at infancy and will receive a single challenge dose of Havrix Adult at Visit 1 (Day 1).
2909441|NCT03183479|Experimental|Treatment group|The patients in treatment group will receive Fibrinogen Concentrate Human administration.
2909442|NCT03183479|Placebo Comparator|Control group|The patients in control group will be administered with normal saline solution as placebo.
2909443|NCT03183466|Experimental|Patients included in inclusion criteria|
2909444|NCT03183453|Experimental|Neuropsychological treatment|The tested treatment is a combination of neuropsychological rehabilitation procedures: learning, episodic memory recall after a delay, selective attention, inhibition of predominant responses and awareness of deficits.
2909445|NCT03183453|No Intervention|Non-confabulators control group|Non-confabulators (brain injured patients but without confabulations) in this control group only performed the pre- and post-measurements without treatment.
2909446|NCT03183453|No Intervention|Healthy control group|Healthy participants in this control group only performed the pre- and post-measurements without treatment.
2909447|NCT03183440|Experimental|PREBIOTICS|188 pregnant women
2909448|NCT03183440|Placebo Comparator|PLACEBO|188 pregnant women
2909449|NCT03183427||Group of patients with pineal cyst|Group of patients with pineal cyst
2909450|NCT03183427||Control group|Group of subjects without pineal cyst
2909451|NCT03183414||cardiac surgery patients|cardiac surgery patients with a significant peroperative aortic valve stenosis (gradient>40mmHg and/or aortic valve area <1cm2). During cardiac surgery measurements of right ventricular dysfunction were taken by echocardiography
2909452|NCT03183388|Experimental|BE-SMART|Psychobehavioral intervention with focus either on teaching emotional regulation skills or regularizing daily sleep and activity levels.
2909453|NCT03183375|Experimental|Hydroxyurea arm|This arm will be given investigational drug that is Hydroxyurea .This intervention will be given along with the standard treatment that is blood transfusion and iron chelation.
2909454|NCT03183375|No Intervention|Standard arm|this arm will only receive the standard treatment which is blood transfusion and iron chelation
2909455|NCT03183362|Experimental|Barbed suture ( STRATAFIX™ )|Cesarean section incision is closed using barbed sutures
2909456|NCT03183362|Active Comparator|Conventional suture (VICRYL™)|Cesarean section incision is closed using conventional sutures
2909457|NCT03183349|Experimental|platelet rich fibrin|immediate implant grafting
2909458|NCT03183349|Active Comparator|deprotienized bovine bone (tutogen)|immediate implant grafting
2909459|NCT03183336|Experimental|Interpositional block graft|ridge split interpositional block graft
2909460|NCT03183336|Active Comparator|Onlay block graft|decortication onlay block graft
2909461|NCT03183323|Experimental|Telerehabilitation|In addition to optimal medical treatment: 3 months of twice weekly group-based telerehabilitation through a video-conferencing on a tablet platform. In addition access to instruction videos for further self-training through the same platform and throughout the whole 2-year periode. Electronic devices to trace activity.
2909501|NCT03183024|Placebo Comparator|placebo|placebo for benralizumab sc given during run-in phase
2909462|NCT03183323|No Intervention|Standard care|In addition to optimal medical treatment: Advice on physical activity. Electronic devices to trace activity.
2909463|NCT03183310|Active Comparator|Chlorpromazine|Administration of an intravenous bolus injection of 10 mg Chlorpromazine to investigate the effect on esophageal sensitivity.
2909464|NCT03183310|Placebo Comparator|Placebo (Saline)|Administration of an intravenous bolus injection of saline (placebo) as the control condition of chlorpromazine in this cross-over study.
2909465|NCT03183297|Experimental|JMI-001|JMI-001 is a combination product of naproxen 220mg and fexofenadine 60mg (Dose Level one) then a combination product of naproxen 440mg and fexofenadine 120mg (Dose Level Two).
2909466|NCT03183297|Active Comparator|Naproxen|Naproxen 220mg or 440mg
2909467|NCT03183297|Active Comparator|Fexofenadine|fexofenadine 60mg or 120mg
2909468|NCT03183297|Placebo Comparator|Placebo|
2909469|NCT03183271|Experimental|Experimental: External beam radiotherapy|A total of 20 patients will be irradiated with protons after photon IMRT
2909470|NCT03183258|Experimental|Sentinel Skin Flap|
2909471|NCT03183245|Experimental|Human Acellular Vessel (HAV)|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. It will be surgically implanted in the forearm or upper arm on Study Day 0.
2909472|NCT03183245|Active Comparator|Arteriovenous fistula (AVF)|The comparator is an autologous arteriovenous fistula created in the forearm or upper arm on Study Day 0.
2909473|NCT03183232|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor
2909474|NCT03183232|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
2909475|NCT03183232|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
2909476|NCT03183219|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor.
2909477|NCT03183219|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2909478|NCT03183219|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
2909479|NCT03183206|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery , IRE surgery or open surgery to control the local tumor
2909480|NCT03183206|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
2909481|NCT03183206|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery, IRE surgery or open surgery
2909482|NCT03183193|Placebo Comparator|Control diet|A conventional and balanced diet based on American Heart Association (AHA) guidelines and lifestyle advice to achieve the objective of American Association for the Study of Liver Diseases (AASLD): loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation.
2909483|NCT03183193|Experimental|FLiO diet|A mediterranean dietary strategy based on macronutrient distribution (quantity and quality), antioxidant capacity, meal frequency, dietary behaviour and lifestyle advice to achieve the objective of AASLD: loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation.
2909484|NCT03183141|Experimental|SER-109|SER -109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors
2909485|NCT03183128|Experimental|SER-109|SER -109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors
2909486|NCT03183128|Placebo Comparator|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline
2909487|NCT03183115|Experimental|RFA group|Balloon type RFA (12J/cm2, 1 application) will be applied for the entire speckled esophageal mucosa at the 3 months after complete ESD
2909488|NCT03183115|No Intervention|Control group|No intervention; surveillance endoscopy alone
2909489|NCT03183102|Experimental|Estrogen suppression no flax|Control subjects will not consume flaxseed, but will receive GnRH suppression
2909490|NCT03183102|Experimental|Estrogen suppression with flax|Flax subjects will consume flaxseed for 2 months in addition to GnRH suppression
2909491|NCT03183089|Experimental|Active|
2909492|NCT03183089|Active Comparator|Active Comparator|
2909493|NCT03183076|Active Comparator|modified adkins diet|modified adkins diet. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis.
2909494|NCT03183076|Active Comparator|Pharmacotherapy without diet|It consists in administer only pharmacological treatment withot a special diet, Drug-resistant epilepsy is characterized by the use of antiepileptic drugs and in optimal doses, depending on the type of epilepsy, at least on two consecutive occasions without response to management.
2909495|NCT03183063|Experimental|4DCT and SPECT/CT|15 patients with segmental or lobar pulmonary emboli on CTA. Each will receive SPECT/CT and 4DCT imaging on the same day. Both 4DCT scans will be obtained with normal breathing.
2909496|NCT03183063|Experimental|4DCT with BiPAP and SPECT/CT|5 patients with segmental or lobar pulmonary emboli on CTA. Each will receive SPECT/CT and 4DCT imaging on the same day. The second of the two 4DCT scans will be obtained with positive airway breathing via BiPAP.
2909497|NCT03183050|Experimental|Question Prompt List|This is a single-arm study. Therefore, all participants will receive the prompt list.
2909498|NCT03183037|Experimental|Acupuncture Treatment Group|Ten acupuncture treatments over the course of eight weeks, with twice weekly acupuncture treatments for the first two weeks, and then weekly treatment thereafter.
2909499|NCT03183037|Placebo Comparator|Sham Acupuncture Treatment Group|Ten sham acupuncture treatments over the course of eight weeks, with twice weekly sham acupuncture treatments for the first two weeks, and then weekly sham acupuncture treatment thereafter.
2909500|NCT03183037|Active Comparator|Usual Care Group|Twelve weeks of usual care.
2909502|NCT03183024|Experimental|benralizumab|benralizumab sc once a month for 3 months for subjects who meet inclusion/exclusion criteria after run-in phase
2909503|NCT03183011|Other|Post-CRT MRI|This study has a single arm. Enrolled patients will follow the protocol as described, including evaluation with MRI, echocardiography, and cardiopulmonary exercise testing.
2909504|NCT03182998|Experimental|Arm A (Knowing Your Options)|"Arm A (Knowing your Options) Patients receive Knowing your Options decision aid before their consultation visit."
2909505|NCT03182998|Experimental|Arm B (Prostate Choice)|"Patients receive Prostate Choice decision aid during their consultation visit."
2909506|NCT03182998|Active Comparator|Arm C (Usual Care)|Patients undergo usual care.
2909507|NCT03182985|Experimental|Time Restricted Feeding|Patients will reduce daily oral intake to 10 hours per day
2909508|NCT03182972|Experimental|Intervention|Medication reconciliation gaps discovered will be addressed
2909509|NCT03182959|Experimental|Lower dose, higher dose|"During the first cycle, the patient will self-administer Avmacol® (70 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer four tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary.~During the second cycle, the patient will self-administer Avmacol® (140 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer eight tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary."
2909510|NCT03182959|Experimental|Higher dose, lower dose|"During the first cycle, the patient will self-administer Avmacol® (140 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer eight tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary.~During the second cycle, the patient will self-administer Avmacol® (70 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer four tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary."
2909511|NCT03182933|Experimental|Liposomal bupivacaine group|20ml 1.33% liposomal bupivacaine administered in adductor canal (a type of peripheral nerve block)
2909512|NCT03182933|Active Comparator|Standard bupivacaine group|20ml 0.5% standard bupivacaine in adductor canal (a type of peripheral nerve block)
2909513|NCT03182920|Experimental|Lasmiditan (Group 1 Elderly)|Participants will receive a single oral dose of lasmiditan on Day 1 of 1 of 2 dosing periods.
2909514|NCT03182920|Placebo Comparator|Placebo (Group 1 Elderly)|Participants will receive a single oral dose of placebo on Day 1 of 1 of 2 dosing periods.
2909515|NCT03182920|Experimental|Lasmiditan (Group 2 Young)|Participants will receive a single oral dose of lasmiditan on Day 1.
2909516|NCT03182907|Experimental|Bezlotoxumab|A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
2909517|NCT03182907|Placebo Comparator|Placebo|A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose
2909518|NCT03182894|Experimental|Epacadostat + Pembrolizumab + Azacitidine|Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
2909519|NCT03182881|Experimental|Miofascial-reléase|Myofascial Release (MR), with the purpose of releasing fascial restriction zones and major fibrosis (thoraco-brachial) caused by restriction after CM tto. IM therapy was applied to the affected area. The position of the patient was identical during both treatment sessions.
2909520|NCT03182881|Active Comparator|Manual Lymphatic Drainage (MLD)|It was applied following the Leduc method with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, in the chest region and in the arm with the same sequence as Guerero et al. The objective of the application in our study is to obtain a beneficial treatment for the patient since it produces an increase of blood and lymphatic circulation, with positive effects on the peripheral vegetative nervous system.
2909521|NCT03182855|Active Comparator|Prehospital ticagrelor|"Ticagrelor 180 mg orally administered in the ambulance as soon as possible after inclusion and before coronary angiography. The two pills are chewed and swallowed with a glass of water.~In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication."
2909522|NCT03182855|Active Comparator|Inhospital cangrelor tetrasodium|"Ticagrelor 180 mg orally in combination with cangrelor intravenously (bolus 30 μg/kg within 1 minute followed by infusion (4 μg/kg/minute) for two hours) both administered immediately after coronary angiography, when PPCI is indicated.~In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication."
2909523|NCT03182842|Experimental|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM glucose values
2909524|NCT03182842|Active Comparator|SMBG - Blinded Sensor - Control|Insulin dosing based on SMBG, FreeStyle Libre FGM will be blinded.
2909525|NCT03182829||Factor Xa inhibitor|Patients on treatment with Apixaban, Edoxaban or Rivaroxaban are included into the evaluation study at the outpatient care unit. Patients receive treatment for a specific clinical indication such as non-valvular atrial fibrillation or venous thromboembolism since one week or longer. During the study visit DOAC Dipstick test and liquid-chromatography mass-specrotmery are performed to identify absence or presence of Factor Xa inhibitor in urine.
2909526|NCT03182829||Thrombin inhibitor|Patients on treatment with Dabigatran are included included into the evaluation study at the outpatient care unit. Patients receive treatment for a specific clinical indication such as non-valvular atrial fibrillation or venous thromboembolism since one week or longer. During the study visit DOAC Dipstick test and liquid-chromatography mass-specrotmery are performed to identify absence or presence of Thrombin inhibitor in urine.
2909527|NCT03182816|Experimental|anti-CTLA-4/PD-1 expressing EGFR-CAR-T|This study have only one arm that is anti-CTLA-4/PD-1 expressing EGFR-CAR-T group. All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing EGFR-targeted CAR-T cells. New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
2909528|NCT03182803|Experimental|Anti-CTLA-4/PD-1 expressing meso-CAR-T|This study have only one arm that is the CTLA-4/PD-1 antibodies expressing mesoCAR-T cells group. All patients with advanced solid tumors will take part in the screening, who matching all the conditions will be chosen for the treatment.New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
2909529|NCT03182790|Experimental|Group A|Instant Messaging IM + regular messages +AWARD advice + warning leaflet + referral card
2909530|NCT03182790|Experimental|Group B|COSH booklet + general brief advices +Placebo Messages
2909531|NCT03182777|Active Comparator|Lidocaine with epinephrine|Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% with epinephrine 1:100.000 for dental restorative procedures in patients with cardiac channelopathies.
2909532|NCT03182777|Active Comparator|Lidocaine|Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% without vasoconstrictor for dental restorative procedures in patients with cardiac channelopathies.
2909533|NCT03182764||never smokers|Never smokers are those who have never consumed cigarettes in their lifetime.
2909534|NCT03182764||Ex-smokers|Ex-smokers are those who consumed cigarettes previously but do not smoke at the time of the survey.
2909535|NCT03182764||Current smokers|Current smokers are those who, at the time of the survey, consume cigarettes daily or occasionally.
2909536|NCT03182751|Active Comparator|Tranexamic Acid Arm (TXA)|TXA will be administered intravenously via bolus dose of 1g over ten minutes and an additional 1g over the subsequent 8 hours.
2909537|NCT03182751|Placebo Comparator|Control Arm|Patients in the control group will receive a placebo medication in the Emergency Department. Neither group will receive perioperative bolus dosing of TXA.
2909538|NCT03182738|Experimental|Intervention|VIP app that delivers HIV-related symptom strategies
2909539|NCT03182738|Sham Comparator|Control|VIP app without HIV-related symptom strategies
2909540|NCT03182725|Placebo Comparator|Placebo|Patient will consume one placebo pill twice a day for one month.
2909541|NCT03182725|Experimental|Ivabradine|Patient will consume one dose of Ivabradine twice a day for one month.
2909542|NCT03182712|Experimental|n-3 PUFA Group|Subjects receiving n-3 PUFA (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks.
2909543|NCT03182712|Placebo Comparator|Placebo Group|Subjects receiving gelatin capsules (500mg). Three capsules were ingested daily for eight weeks.
2909544|NCT03182699|Experimental|Etelcalcetide|Patients will receive Etelcalcetide i.v. 3 times per week after dialysis Dose titration will take plac every 4 weeks in the first 16 weeks Dose adaptation is based on PTH, SerumCa++, SerumPhosphate Star
2909545|NCT03182699|Active Comparator|Alfacalcidol|Patients will receive Alfacalcidol i.v. 3 times per week after dialysis Dose titration will take plac every 4 weeks in the first 16 weeks Dose adaptation is based on PTH, SerumCa++, SerumPhosphate
2909546|NCT03182686|Experimental|Ampion|Ampion (<5 kilodalton (kDa) ultrafiltrate of 5% Human Serum Albumin (HSA)), solution, 4 mL, single intra-articular injection
2909547|NCT03182686|Other|Saline|Saline, solution, 4 mL, single intra-articular injection
2909548|NCT03182673|Experimental|SHR7390 and SHR-1210|60 subjects with advanced solid tumors were received single oral doses of SHR7390，then accepted two drug combination therapy, SHR7390 is administered multiple daily oral doses of SHR7390 for 28 days for a treatment cycle. At the same time, SHR-1210 was given intravenously per 2 weeks at the 200mg fixed dose(2 cycles,each cycle 28days).
2909549|NCT03182647||Non surgery|Patients were not treated with surgery initially
2909550|NCT03182647||Surgery|Patients had an initial surgical treatment
2909551|NCT03182634|Experimental|Cohort A - Extended-dose fulvestrant|Fulvestrant 500mg IM on Cycle 1 Days 1, 8 and 15 and Cycle 2 onwards Days 1 and 15
2909552|NCT03182634|Experimental|Cohort B - Neratinib|Neratinib 240mg PO on a continuous schedule starting on Cycle 1 Day 1 AND in ER positive breast cancer, fulvestrant 500mg IM on Cycle 1 Days 1 and 15 and Cycle 2 onwards Day 1
2909553|NCT03182634|Experimental|Cohort C - AZD5363 and fulvestrant|AZD5363 400mg PO BID on a 7 day schedule of 4 days on treatment followed by 3 days off treatment AND fulvestrant 500mg IM Cycle 1 Days 1 and 15 and Cycle 2 onwards Day 1
2909554|NCT03182634|Experimental|Cohort D - AZD5363|AZD5363 480mg PO BID on a 7 day schedule of 4 days on treatment followed by 3 days off treatment
2909555|NCT03182621|Experimental|THINK|The Translational Health in Nutrition and Kinesiology (THINK) program will have education and fitness sessions lasting two hours, five times a week for a total of 10 weeks. Sessions will include theory, clinical laboratory activities, and physically active games to facilitate a fun environment to enhance physical and health-related fitness, improve nutrition and exercise knowledge and behaviors, and exercise enjoyment and self-confidence.
2909556|NCT03182621|Active Comparator|SPARK|This The Sports, Play, and Active Recreation for Kids (SPARK) group will receive the traditional YMCA SPARK after-school program. They will undergo the same pre and post testing protocol as the intervention group, but will not receive the THINK program.
2909557|NCT03182608|Experimental|Group 1|In the lateral decubitus position, an investigator evaluate the L4-5 interspinous level using an anatomic landmark (Tuffier's line), and then evaluate the L4-5 interspinous level using another anatomic landmark (Tenth rib line). Another investigator evaluate the actual L4-5 interspinous level by noninvasive ultrasonography.
2909558|NCT03182608|Experimental|Group 2|In the lateral decubitus position, an investigator evaluate the L4-5 interspinous level using an anatomic landmark (Tenth rib line), and then evaluate the L4-5 interspinous level using another anatomic landmark (Tuffier's line). Another investigator evaluate the actual L4-5 interspinous level by noninvasive ultrasonography.
2909559|NCT03182595|Experimental|open--‐label|An open--‐label, single centre, nonrandomized clinical study in healthy volunteers, with intervention over a 13--‐week period.
2909595|NCT03182400|Experimental|Healthy volunteer|Neurophysiological assessment Neuropsychological assessment
2910919|NCT03173456|Active Comparator|800 ibuprofen/APAP|800 mg ibuprofen + 1000 mg acetaminophen
2909560|NCT03182582|Active Comparator|Week 1 - Erbium:Yttrium-Aluminum-Garnet Laser Debridement|"During the first treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized. During the second treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized.~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment."
2909561|NCT03182582|Active Comparator|Week 1 - Scalpel/Curette Debridement|"During the first treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized. During the second treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized.~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment."
2909562|NCT03182569|Experimental|flexible catheter|The flexible Subcutaneous catheter for insulin administration
2909563|NCT03182569|Active Comparator|hourly rigid needle puncture|Hourly rigid needle puncture for Subcutaneous insulin administration
2909564|NCT03182556|Placebo Comparator|Stretching|Stretching sessions was held twice a week in the University of Almería facilities, lasting approximately one hour and they included different muscle areas exercises as well as stretching across the board.
2909565|NCT03182556|Experimental|Aquatic Exercise|Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
2909566|NCT03182556|Experimental|Electromyography-Biofeedback training|The whole treatment will last about 12 sessions. Each one lasts about 30 and 40 minutes and will be performed continuously once a week. The frequency may be increased if the level of tonic muscle tension becomes too high.
2909567|NCT03182543|Experimental|AM1|Mango pulp beverage
2909568|NCT03182543|Experimental|AM2|Mango pulp and peel beverage
2909569|NCT03182543|Placebo Comparator|Control|Control beverage
2909570|NCT03182530|Active Comparator|ULTRA method group|
2909571|NCT03182530|Active Comparator|standard patent hemostasis group|
2909572|NCT03182530|Experimental|control group|
2909573|NCT03182517||chronic kidney diseases|patients with chronic renal failure on dialysis since 3-5 years
2909574|NCT03182504|Experimental|Nacubactam Plus Meropenem|Participants will receive a single dose of nacubactam co-administered with meropenem.
2909575|NCT03182491||Anaphylaxis|
2909576|NCT03182491||Febrile transfusion reactions|
2909577|NCT03182491||Mild allergic reactions|
2909578|NCT03182491||Healthy controls|
2909579|NCT03182478|Active Comparator|Individual Treatment|Intervention with the Rothbaum Protocol in individual format, with eight weekly sessions each one of 45 minutes, applied by a trained investigator. Session 1: Psychoeducation and self-monitoring. Session 2: habit reversal techniques. Session 3: muscle relaxation and diaphragmatic breathing. Session 4: stop the thought. Session 5: oriented internal dialogue. Session 6: cognitive techniques. Session 7: role-play. Session 8: relapse prevention
2909580|NCT03182478|Active Comparator|Group Treatment|Intervention with the Rothbaum Protocol in group format up to 10 patients, with eight weekly sessions each one of 90 minutes, applied by a trained investigator. Session 1: Psychoeducation and self-monitoring. Session 2: habit reversal techniques. Session 3: muscle relaxation and diaphragmatic breathing. Session 4: stop the thought. Session 5: oriented internal dialogue. Session 6: cognitive techniques. Session 7: role-play. Session 8: relapse prevention
2909581|NCT03182465|Other|the predictive value of ProCalcitonin|Patients with solid tumors admitted at the emergency care presenting a febrile neutropenia due to chemotherapy
2909582|NCT03182452||Pre Phase (no Alarm Advisor)|No Software installed
2909583|NCT03182452||Post Phase (Alarm Advisor installed)|Software implemented and staff trained (Interventional Phase)
2909584|NCT03182439|Active Comparator|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
2909585|NCT03182439|Active Comparator|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
2909586|NCT03182439|Active Comparator|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
2909587|NCT03182439|Active Comparator|Apple Watch|Apple Watch Heart Rate Monitoring Device
2909588|NCT03182426|Experimental|Treated arm|"For participants assigned to the treated arm, they will follow study regime below: Intervention treatment will last from Day 0 up to Month 24.~Day 0: Subjects will receive alemtuzumab (30mg iv single dose); anakinra (100 mg sc.); etanercept (50 mg sc.) and liraglutide (0.6 mg sc.).~Day 1: Subjects will receive plerixafor (0.24 mg/kg/day) sc. to mobilize CD34+ stem cells to peripheral blood.~Day 1: Continuing with anakinra 100mg sc. daily for 12 month; etanercept 50mg sc. twice weekly for first 3 months, and 50mg sc. weekly for another 9 months; liraglutide 0.6 mg sc. daily for 7 days, then 1.2 mg sc. daily (or up to 1.8mg daily) as tolerated for 24 months."
2909589|NCT03182426|Experimental|Control arm|"For participant assigned to the control arm, they will be monitored and tested for the first 12 months, and receive intervention treatment from Month 12 up to Month 24.~Month 12: Subjects will receive alemtuzumab (30mg iv single dose); anakinra (100 mg sc.); etanercept (50 mg sc.) and liraglutide (0.6 mg sc.).~Month 12 + 1 day: Subjects will receive plerixafor (0.24 mg/kg/day) sc.. Month 12 + 1 day: Continuing with anakinra 100mg sc. daily for 12 month; etanercept 50mg sc. twice weekly for first 3 months, and 50mg sc. weekly for another 9 months; liraglutide 0.6 mg sc. daily for 7 days, then 1.2 mg sc. daily (or up to 1.8mg daily) as tolerated for 12 months."
2909590|NCT03182413|Placebo Comparator|PBO|Placebo
2909591|NCT03182413|Active Comparator|MOD|Modafinil 100mg
2909592|NCT03182413|Experimental|THN102 100/1|modafinil 100 mg + 1 mg flecainide
2909593|NCT03182413|Experimental|THN102 100/3|modafinil 100 mg + 3 mg flecainide
2909594|NCT03182413|Experimental|THN102 100/9|modafinil 100 mg + 9 mg flecainide
2909666|NCT03181828|No Intervention|Non- AHA|
2909596|NCT03182374|Active Comparator|nSTRIDE APS|The nSTRIDE APS Kit is designed to be used for the safe and rapid preparation of APS from a small sample of blood at the patient's point of care. The APS is to be injected intra-articularly for the treatment of knee osteoarthritis and associated symptoms.
2909597|NCT03182374|Active Comparator|Synvisc-One|Synvisc-One is only intended for intra-articular use by a physician to treat pain associated with osteoarthritis of the knee
2909598|NCT03182361|Experimental|Study group|Everybody enrolled in the study will receive BioComp Industries cranio-maxillo-facial (CMF) screw implants
2909599|NCT03182348||Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
2909600|NCT03182335||Mechanical Ventilation (MV) with vasoactive infusions|adult ICU patients who are mechanically ventilated with sedative infusion and/or analgesic infusion and also requiring vasoactive drug infusions for the treatment of shock. Patients will be excluded if receiving dexmedetomidine as sedative.
2909601|NCT03182322|Experimental|intranasal insulin|rH-insulin formulation and for a dose of 440 IU insulin to the nasal mucosa. Treatment will be administered daily for the first 7 intervention days, and one day per week thereafter for 6 months.
2909602|NCT03182322|Placebo Comparator|intranasal placebo|Treatment with placebo nasal spray daily for the first 7 intervention days and one day per week thereafter for 6 months.
2909603|NCT03182296|Experimental|Gestational diabetes|Women with a history of gestational diabetes
2909604|NCT03182296|Active Comparator|Control|Women without a history of gestational diabetes
2909605|NCT03182283|No Intervention|Pre-intervention|All patients at the psychosis wards receive care as usual before staff goes through educational intervention.
2909606|NCT03182283|Other|Post-intervention|After staff attended educational intervention and implemented Person-centered psychosis care in the wards all patients admitted will receive person-centered care.
2909607|NCT03182270|Experimental|pancreatic cysts|
2909608|NCT03182257|Experimental|ONO-7579 Part A|Single Ascending doses of ONO-7579
2909609|NCT03182257|Experimental|ONO-7579 Part B|Expansion phase of ONO-7579
2909610|NCT03182244|Experimental|ASP2215|ASP2215 will be administered orally once daily.
2909611|NCT03182244|Active Comparator|Salvage chemotherapy|Options for salvage chemotherapy are limited to the following: Low-dose Cytarabine (LoDAC) will be administered twice daily by subcutaneous or intravenous injection for 10 days. Mitoxantrone, Etoposide, Cytarabine (MEC Induction Chemotherapy) will each be administered intravenously for 5 days (days 1 through 5). Granulocyte colony-stimulating factor (G-CSF) will be administered intravenously for 5 days (days 1 through 5) and also recommended 7 days after completing chemotherapy, Fludarabine and Cytarabine administered intravenously for 5 days (days 2 through 6) (FLAG Induction Chemotherapy).
2909612|NCT03182244|Experimental|ASP2215 PK in Chinese population|PK samples will be collected after single and multiple doses in Chinese subjects.
2909613|NCT03182231|Experimental|RYGB patients|Patients who will receive a RYGB surgery
2909614|NCT03182205|Experimental|Inspiratory muscle exercise (IME)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 40% of maximal inspiratory pressure.
2909615|NCT03182205|Sham Comparator|Sham IME|Participants will be submitted to inspiratory muscle exercise with the same equipment as the intervention group, but without a load generating resistance.
2909616|NCT03182192|Experimental|Hypoglycemia|Patients with hypoglycemia after gastric bypass
2909617|NCT03182192|Active Comparator|Control|Patients without hypoglycemia after gastric bypass
2909618|NCT03182179|Experimental|O-P sequence|Patients will receive of oral Ondansetron 4mg BD for 28 days followed by 28 days of placebo. It will be one week of washout between the two treatments.
2909619|NCT03182179|Experimental|P-O sequence|Patients will receive oral placebo for 28 days followed by Ondansetron 4mg BD for 28 days. It will be one week of washout between the two treatments.
2909620|NCT03182166|Experimental|Patients treated with golimumab|"The optimization procedure is:~For patients treated at 50 mg of golimumab every 4 weeks (less than 80 kg) will have an increase dose of golimumab: 100 mg every 4 weeks for 8 weeks. They will have rectosigmoidoscopy for measured mayo score and blood samples for measured the concentration of golimumab antibodies.~For patients treated at 100 mg of golimumab every four weeks (more than 80 kg) will have an increase dose of golimumab: treated at 100 mg every 2 weeks for 4 weeks.~They will have rectosigmoidoscopy for measured mayo score and blood samples for measured the concentration of golimumab antibodies."
2909621|NCT03182153||Enrolled subjects|Subjects who are diagnosed with HCM and require routine extended cardiac monitoring for risk stratification of sudden cardiac death. All subjects will receive 28 days of external cardiac monitoring.
2909622|NCT03182140||Kyleena|Non-interventional, observational, uncontrolled study in women that have chosen Kyleena as their contraceptive method before entering the study
2909623|NCT03182127|Other|one Group|Magnetic resonance imaging and ultrasound will be done for all patient
2909624|NCT03182114|Placebo Comparator|supine position|the patient will receive spinal anesthesia by Bupivacaine; then she will be placed in supine position
2909625|NCT03182114|Experimental|Left lateral tilted position|the patient will receive spinal anesthesia by Bupivacaine; then she will be placed in left lateral tilted position
2909626|NCT03182101|Experimental|Exposure Therapy with fidelity checklist|Therapist and parent/child participants will complete an Exposure Guide after each session.
2909627|NCT03182088|Experimental|0.025 mcg /Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.05 mcg/Kg/min) equivalent to norepinephrine infusion (0.025 mcg/Kg/min).
2909628|NCT03182088|Experimental|0.050 mcg/Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.1 mcg/Kg/min) equivalent to norepinephrine infusion (0.050 mcg/Kg/min).
2909732|NCT03181360|Active Comparator|Tenecteplase|Tenecteplase + Best standard treatment
2909629|NCT03182088|Experimental|0.075 mcg/Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.15 mcg/Kg/min) equivalent to norepinephrine infusion (0.075 mcg/Kg/min)
2909630|NCT03182075|Experimental|Active Training|OCD participants will receive active emotional reactivity training (14 sessions) via computer.
2909631|NCT03182075|Sham Comparator|Passive Training|OCD participants will receive passive computerized training (14 sessions) via computer.
2909632|NCT03182062|Active Comparator|OLA-iHFNC|"Intraoperatively ventilated patients with a tidal volume (VT) of 5-6ml / kg of ideal body weight and respiratory rate to maintain normal carbon dioxide. After intubation, in all patients will be performed an alveolar recruitment maneuver (MRA) and a PEEP titration trial (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.~Postoperatively, high flow oxygen therapy will be individually indicated by evaluating peripheral oxygen saturation."
2909633|NCT03182062|Active Comparator|STD-O2|"Intraoperatively ventilated patients with a tidal volume of 5-6 ml / kg of ideal body weightand respiratory rate to maintain normal carbon dioxide, PEEP 5 cmH2O. In this group no recruitment maneuvers or optimal PEEP setting will be performed.~Postoperatively, standard oxygen therapy."
2909634|NCT03182049||GPA (Wegener's granulomatosis) patients|
2909635|NCT03182036|Experimental|Study group|Portable pulsed oxygen
2909636|NCT03182023||ECMO mode|ECMO mode includes Venovenous- ECMO and Venoarterial- ECMO
2909637|NCT03182010|Experimental|Cesarean section incision closure using barbed sutures|Cesarean section incision is closed using barbed sutures
2909638|NCT03182010|Active Comparator|Cesarean section incision closure using conventional sutures|Cesarean section incision is closed using conventional sutures
2909639|NCT03181997||TAVI Patients with active cancer|Patients with active cancer undergoing transcatheter aortic valve implantation (TAVI) with native aortic valves.
2909640|NCT03181984|Experimental|Hemoporfin|
2909641|NCT03181971|Experimental|Water Access and Promotion|Intervention group will receive installation of water stations in high traffic areas, schoolwide promotion, and 4th graders will receive a curricula focused on increasing intake of water.
2909642|NCT03181971|No Intervention|Control|Usual care.
2909643|NCT03181958|Experimental|NHFOV|"neonates assigned to NHFOV will be started with the following boundaries:~a) Paw of 10 cmH2O (can be changed in steps of 1 cmH2O within the range range 5- 16cmH2O); Paw will be titrated (within the range) according to open lung strategy, performing alveolar recruitment, similar to what is done in endotracheal high frequency oscillatory ventilation targeting a FiO2≤25-30%. Maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90%-95%. b) frequency of 10Hz(can be changed in steps of 1Hz within the range 8-12Hz). c)Inspiratory time 50% (1:1).d)amplitude 25 cmH2O(can be changed in steps of 5 cmH2O within the range 25-50 cmH2o; amplitude will be titrated according to PaCO2."
2909644|NCT03181958|Active Comparator|NCPAP|Neonates assigned to the CPAP group were initiated on a pressure of 5 cmH2O. CPAP can be raised in steps of 1 cmH2O up to 8 cmH2O. If this is not enough to maintain SpO2 between 90% and 95%, FiO2 will be added up to 0.40.
2909645|NCT03181958|Experimental|NIPPV|neonates assigned to the NIPPV group will be started with the following parameters: a) positive end-expiratory pressure (PEEP) of 4 cmH2O (can be raised in steps of 1 cmH2O to max 8 cmH2O, according to the oxygenation).b)Peak Inspiratory Pressure (PIP) of 15 cmH2O (can be raised in steps of 1 cmH2O to max 25 cmH2O, according to oxygenation,PaCO2 levels and the chest expansion); maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90-95%. c) inspiratory time (IT) will be 0.45 - 0.5 sec(according to clinicians' evaluation of leaks and the appearance of the pressure curve: a small pressure plateau is required and flow may be set accordingly) and rate will be started at 30 bpm (can be raised in steps of 5 bpm to max 50 bpm, according to PaCO2 levels).
2909646|NCT03181945|Active Comparator|Group 4 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
2909647|NCT03181945|Active Comparator|Group 12 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
2909648|NCT03181932|Experimental|Vancomycin inhalation powder|30 mg twice daily (BID)
2909649|NCT03181932|Placebo Comparator|Placebo inhalation powder|Matching placebo inhaled twice daily (BID)
2909650|NCT03181919|Experimental|Step Up group|includes females taking Letrozole 5 mg tablets in a step-up protocol 5 mg in day one, 7.5 in day 2, 10 mg in days 3, 12.5 mg in day 4 and 15 in day 5 started in day 3 to day 7 of menstrual cycle.
2909651|NCT03181919|No Intervention|Control group|includes females taking Letrozole 5 mg tab orally once daily started in day 3 to day 7 of menstrual cycle.
2909652|NCT03181906|Experimental|Pre-Consultation Medication Reconciliation|Participants underwent medication reconciliation service before their consultation with the attending doctor. A best possible medication history (BPMH) was created and saved as an electronic draft in the electronic medical record system.
2909653|NCT03181906|No Intervention|Control|Participants in the control group proceeded with usual care, where the doctor reviewed the patient's condition and ordered an electronic prescription
2909654|NCT03181893|Placebo Comparator|Placebo ARM|
2909655|NCT03181893|Experimental|PF-06823859 Arm|
2909656|NCT03181880|Active Comparator|Aclidinium/formoterol|Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination
2909657|NCT03181880|Active Comparator|Bronchodilators|The comparator arm consists of SOC.
2909658|NCT03181867|Experimental|1-Localized High risk|18F-DCFPyL PET/CT imaging and possible prostatectomy
2909659|NCT03181867|Experimental|2-Biochemical recurrence (BCR)|18F-DCFPyL PET/CT imaging
2909660|NCT03181854|Experimental|Intervention group|Consultation with PCT doctor every 3 weeks. Telephone coaching once a week for 3 months and once in 2 weeks for another 3 months.
2909661|NCT03181854|No Intervention|Control Group|Usual palliative care can be provided if desired.
2909662|NCT03181841|Experimental|Active dose 1|Single dose of PF-06412562 in low dosage strength
2909663|NCT03181841|Experimental|Active dose 2|Single dose of PF-06412562 in medium dosage strength
2909664|NCT03181841|Experimental|Active dose 3|Single dose of PF-06412562 in higher dosage strength
2909665|NCT03181841|Placebo Comparator|Placebo|Single dose of placebo
2909667|NCT03181828|Active Comparator|AHA|All subjects (healthy adults and UCD patients) will receive a single oral dose of 60 mg/kg acetohydroxamic acid during one of the treatment periods, based on the randomization assignment determining whether treatment occurs in the first or the second treatment cycle; doses will be rounded to the nearest 250 mg to coincide with the available dosage form since the tablets cannot be scored. Patients will be instructed to fast for 4 hours prior to the study; subsequently, the 13C-Urea tracer will be administered 60 minutes after the ingestion of the acetohydroxamic acid dose.
2909668|NCT03181815|Experimental|treatment arm|The patients in this arm will receive C-CAG regimen for salvage treatment,detailed as following: Cladribine 5mg/㎡，d1-5；G-CSF 300ug,d0-9; aclarubicin 10mg,d3-6;cytarabine 10mg/㎡ q12h, SC, d3-9;4 weeks a cycle
2909669|NCT03181802|Experimental|botulinum toxin A|
2909670|NCT03181802|Placebo Comparator|Placebo|
2909671|NCT03181789|Experimental|Group 1 (Treatment): p24CE1/2 pDNA + p55^gag pDNA + IL-12 pDNA|Participants will receive the p24CE1/2 pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Month 1. They will receive the p24CE1/2 pDNA vaccine plus the p55^gag pDNA vaccine and the IL-12 pDNA adjuvant at Months 3 and 6.
2909672|NCT03181789|Placebo Comparator|Group 1 (Control): Placebo|Participants will receive placebo at Day 0 and Months 1, 3, and 6.
2909673|NCT03181789|Experimental|Group 2 (Treatment): p55^gag pDNA + IL-12 pDNA|Participants will receive the p55^gag pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Months 1, 3, and 6.
2909674|NCT03181789|Placebo Comparator|Group 2 (Control): Placebo|Participants will receive placebo at Day 0 and Months 1, 3, and 6.
2909675|NCT03181776|Experimental|left lateral tilting arm|all patients will be put in three angles of left lateral tilt in randomized order (supine position - left lateral tilting in 15 degrees - and left lateral tilting in 30 degrees) and the hemodynamic data will be compared in the three angles.
2909676|NCT03181763|Experimental|MDMA|Participants receive 100 mg MDMA
2909677|NCT03181763|Placebo Comparator|Placebo|Participants receive inactive placebo
2909678|NCT03181750|No Intervention|Control|Patients and caregivers randomized to this arm will receive a packet of educational materials in English or Spanish. These materials are written at 5-6th grade reading level. The materials focus on advance care planning, pain and symptom management, and hospice care.
2909679|NCT03181750|Experimental|Patient Navigator Intervention Group|Patient and caregivers randomized to this arm will receive the same packet of educational materials. They will also receive at least 5 visits from a bicultural bilingual patient navigator. The navigator will utilize a annualized visit guide manual to lead discussions on advance care planning, pain and symptom management, and hospice care.
2909680|NCT03181737|Experimental|Covivio|"Covivio is an internet intervention for people with diabetes mellitus type 2. Content is continuously adapted to patients´ concerns and needs. Techniques to promote the disease self-management (i.e. nutrition, exercise), the motivation for health behavior (i.e. discussing pros and cons) conveying goal setting, mediating knowledge about diabetes (i.e. basics, symptoms & complications, diagnosis, therapy) , and reducing depressive symptoms (i.e. increasing activation, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets.~Patients are also prompted complete brief adherence self-monitoring questionnaires (adherence index) regularly. Optional text messages with motivational content accompany the program daily. The program can be accessed for 56 days after registration."
2909681|NCT03181737|Active Comparator|Relaxio|Relaxio is a psychological online-relaxation-training. The purpose of the program is to improve the self-management of diabetes by relaxation and stress reduction. The program consist of three types of exercises (1) imagination (i.e. sunset, mountain lake), (2) breathing techniques (i.e. balancing, calm breathing), and (3) body exercises (i.e. relaxing body journey, progressive muscle relaxation (PMR)). The exercises are supported by audio files (optionally also for reading). Optional weekly text messages with motivational content accompany the program. The program can be accessed for 56 days after registration.
2909682|NCT03181737|No Intervention|Care-as-Usual (CAU) / wait list|In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Covivio six months post-baseline (i.e., wait list with respect to Covivio access).
2909683|NCT03181724|Active Comparator|Decision Aid|Cohort that will receive a decision aid.
2909684|NCT03181724|No Intervention|No Decision Aid (control)|One cohort will not receive the decision aid, and instead will receive only a brochure as standard treatment.
2909685|NCT03181698||first group|patients with first episode of mania
2909686|NCT03181698||second group|patients with more than one episode of mania
2909687|NCT03181698||third group|sex-matched and age- matched healthy controls
2909688|NCT03181685|Active Comparator|Treatment S (Subcutaneous)|Progesterone 25 mg subcutaneous (a single administration per day) from the day of oocyte retrieval. Controlled ovarian stimulation (COS) will be performed with recombinant FSH and cetrorelix acetate.
2909689|NCT03181685|Active Comparator|Treatment V (Vaginal)|Micronized progesterone 200 mg (3 vaginal administrations per day) from the day of oocyte retrieval. Controlled ovarian stimulation (COS) will be performed with recombinant FSH and cetrorelix acetate.
2909690|NCT03181672|Active Comparator|Stellate ganglion block|Stellate ganglion block
2909691|NCT03181672|Placebo Comparator|control group|Deltoid muscle injection
2909692|NCT03181659|Experimental|Group 1: patients with NSCLBP who do not seek care|Manual Therapy, Therapeutic Education, Therapeutic Exercice
2909693|NCT03181659|Experimental|Group 2: patients with NSCLBP who do not seek care|Therapeutic Education, Therapeutic Exercice
2909694|NCT03181659|Experimental|Group 3: patients with NSCLBP who seek care|Manual Therapy, Therapeutic Education, Therapeutic Exercice
2909695|NCT03181659|Experimental|Group 4: patients with NSCLBP who seek care|Therapeutic Education, Therapeutic Exercice
2909696|NCT03181646|No Intervention|control group|newborns with hypoxic ischemic encephalopathy grade 2/3 who will receive only supportive care
2909697|NCT03181646|Experimental|study group|newborns with hypoxic ischemic encephalopathy grade 2/3 who will receive citicoline along with supportive care
2909698|NCT03181633|Experimental|ACH-0144471|All patients will receive ACH-0144471 during the treatment period.
2909699|NCT03181620|No Intervention|Continuous Infusion Arm|Patients receive typical continuous infusions (drips) of both sedative agent and narcotic agent for sedation/pain control while mechanically ventilated based on RASS and CPOT.
2909700|NCT03181620|Experimental|Intermittent Sliding Scale Arm|Patients receive hourly boluses of both sedative agent and narcotic agent for sedation/pain control while mechanically ventilated based on a sliding scale of RASS and CPOT.
2909701|NCT03181594|Experimental|Treatment with the ClariFix Device|
2909702|NCT03181581|Experimental|High grade gliomas stage 1 ACF|In the first stage 12-15 patients with high-grade gliomas will be included in the trial (acoustic coupling fluid) group.
2909703|NCT03181581|Experimental|Low-high grade gliomas stage 2 ACF|If the interim safety assessments validate that the study can continue, the second stage involves inclusion in the trial (acoustic coupling fluid) group of 22-25 patients with both low-grade and high-grade glioma
2909704|NCT03181581|Active Comparator|High grade gliomas stage 1 control|In the first stage 12-15 patients with high-grade gliomas will be included in the Ringer's acetate (control) group.
2909705|NCT03181581|Active Comparator|Low-high grade gliomas stage 2 control|If the interim safety assessments validate that the study can continue, the second stage involves inclusion in the Ringer's acetate (control) group of 22-25 patients with both low-grade and high-grade glioma
2909706|NCT03181568|Other|Control|This arm group (control) will receive standard wound care of chronic wounds
2909707|NCT03181568|Other|Treatment|The treatment arm of the study will utilize the MolecuLight i:X Imaging Device to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present
2909708|NCT03181555|Other|Pregnant Obese African American Women|Exploratory
2909709|NCT03181542|Experimental|Infrared vein illumination|Infrared illumination of veins, using the FDA approved AccuVein device, will be used to assist in vein location when inserting an intravenous access line
2909710|NCT03181542|No Intervention|Standard Technique|Standard vein location techniques will be used when inserting an intravenous access line
2909711|NCT03181529|Experimental|Immediate Treatment|Participants will begin psilocybin intervention immediately after study enrollment.
2909712|NCT03181529|Experimental|Delayed Treatment|Participants will begin the psilocybin intervention 8 weeks after study enrollment.
2909713|NCT03181516|Experimental|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt
2909714|NCT03181516|Placebo Comparator|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12
2909715|NCT03181503|Experimental|CD14152 Dose A|Active drug
2909716|NCT03181503|Experimental|CD14152 Placebo|Placebo of active drug
2909717|NCT03181477|Other|radiotherapy + chimiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
2909718|NCT03181464|Experimental|experimental - lidocaine 4%|Continuous infusion lidocaine at 3ml/hr for 1 hour bilaterally onto the posterior wall of the nasopharynx.
2909719|NCT03181464|Placebo Comparator|placebo comparator|Continuous infusion saline at 3ml/hr for 1 hour bilaterally onto the posterior wall of the nasopharynx
2909720|NCT03181451|Active Comparator|30 mg Ferric Maltol|12 subjects will receive 30 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 30mg dose on the morning of Day 10. PK study Day 1 & Day 10.
2909721|NCT03181451|Active Comparator|16.6 mg Ferric Maltol|12 subjects will receive 16.6 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 16.6mg dose on the morning of Day 10. PK study Day 1 & Day 10.
2909722|NCT03181451|Active Comparator|7.8 mg Ferric Maltol|12 subjects will receive 7.8 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 7.8mg dose on the morning of Day 10. PK study Day 1 & Day 10.
2909723|NCT03181438|Experimental|TAP Block|"The TAP block will be performed under general anesthesia, according to the technique described below:~The patient will be placed supine with the abdomen exposed between the iliac crest and the costal margin~After skin antisepsis, a high-frequency ultrasound transducer will be placed transversely across the anterior axillary line above the iliac crest~In this region, the abdominal musculature (external oblique, internal oblique and transverse abdomen) is identified, and the transverse abdominal plane of the abdomen~The needle (BD-A-50mm) will be inserted in the technique in plane to the region of the transverse plane of the abdomen, where the solution will be administered.~In this group, will be administered 20 mL of 0.375% ropivacaine"
2909724|NCT03181438|Sham Comparator|Saline Group|"The block will be performed under general anesthesia, according to the technique described below:~The patient will be placed supine with the abdomen exposed between the iliac crest and the costal margin~After skin antisepsis, a high-frequency ultrasound transducer will be placed transversely across the anterior axillary line above the iliac crest~In this region, the abdominal musculature (external oblique, internal oblique and transverse abdomen) is identified, and the transverse abdominal plane of the abdomen~The needle (BD-A-50mm) will be inserted in the technique in plane to the region of the transverse plane of the abdomen, where the solution will be administered.~In this group, will be administered 20 mL of Saline"
2909725|NCT03181425||Imaging assessment|All subject of the study have a knee osteoarthritis (OA) and are going to have a knee prosthetic surgery with cartilage excision. Imaging measurements are conducted on human cartilage samples (2 samples per patient are selected : healthy and severely degraded).
2909726|NCT03181412||Patients with suspected ischemic stroke|The cohort will be constituted of patients treated for a stroke suspicion after calling emergency medical services of the Rhone and presenting a symptom-onset (the last time the patient was seen without deficit) less than 6 hours.
2909727|NCT03181399|Experimental|Triheptanoin|This is a single arm study.
2909728|NCT03181386|Experimental|Rivaroxaban|As the rivaroxaban is ingested 1x/day, the interval between a maximum peak concentration and the other peak is 24 hours. Therefore, the surgery will be performed between two peaks of maximum drug concentration, knowing that the maximum peak concentration is an average of two hours after ingestion. So the surgical procedure should be scheduled 14 hours (2 hours+ 12 hours) after the last medication intake.
2909729|NCT03181386|Experimental|Dabigatran and Apixaban|As dabigatran and apixaban are taken 2x/day, the interval between two peak concentration is 12 hours.Taking into account the first two hours of maximum peak concentration and half the interval between two peaks (2 hours + 6 hours = 8 hours), the surgical procedure must be programmed eight hours after the last intake of medication.
2909730|NCT03181386|Active Comparator|Warfarin|The control group will consist of patients on chronic use of warfarin. The operation will be scheduled at any time, provided that the patient has INR value between 2.0 and 3.0 and test performed in maximum 15 days before surgery.
2909731|NCT03181373||Traumatic brain injury population|Defined population : traumatic brain injury population
2909734|NCT03181347|Experimental|Roux-en-Y Gastric Bypass (RYGB)|Severely obese patients scheduled for Roux-en-Y Gastric Gypass surgery
2909735|NCT03181347|Experimental|Sleeve Gastrectomy (SG)|Severely obese patients scheduled for Sleeve Gastrectomy surgery
2909736|NCT03181347|Active Comparator|Non-surgical|Severely obese controls with dietary and activity modifications and excludes meal replacement or pharmacologic interventions
2909737|NCT03181334|Active Comparator|Condition 1: Pure Control|"Mailed fecal immunochemical test (FIT) kit including the following invitation:~Letter 1: Standard invitation to participate in free colorectal cancer (CRC) screening requesting they return the completed kit."
2909738|NCT03181334|Experimental|Condition 2: Brief Time|"Mailed fecal immunochemical test (FIT) kit including the following invitation:~Letter 2: Invitation to participate in free colorectal cancer (CRC) screening AND requesting they return the completed kit within a Brief time of only 1-week."
2909739|NCT03181334|Experimental|Condition 2: Extended Time|"Mailed fecal immunochemical test (FIT) kit including the following invitation:~Letter 3: Invitation to participate in free colorectal (CRC) screening AND requesting they return the completed kit within an Extended time of 3-weeks."
2909740|NCT03181334|Experimental|Condition 3: Time + High Incentive|"Mailed fecal immunochemical test (FIT) kit including the following invitation:~Letter 4: Invitation to participate in free colorectal (CRC) screening AND requesting they return the completed kit within 1-week for a higher monetary incentive or within 3-weeks for a lower (half of the higher) monetary incentive."
2909741|NCT03181334|Experimental|Condition 3: Time + Low Incentive|"Mailed fecal immunochemical test (FIT) kit including the following invitation:~Letter 5: Invitation to participate in free colorectal (CRC) screening AND requesting they return the completed kit within 1-week for a higher (same as lower in Letter 4) monetary incentive or within 3-weeks for a lower (half of the higher in Letter 5) monetary incentive."
2909742|NCT03181321|Experimental|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
2909743|NCT03181321|No Intervention|Control|Participants in this arm will not be asked to change anything in their lifestyle during the 6 month period.
2909744|NCT03181308|Experimental|TRC105 plus Nivolumab|
2909745|NCT03181295|No Intervention|Usual care|Standard periodic health review (PHR) appointment. [As patients will get a survey about PA levels prior to their PHR, this may affect their likelihood of addressing PA during their PHR.]
2909746|NCT03181295|Experimental|Usual care plus intervention|Standard PHR appointment plus personalized exercise Rx and resources
2909747|NCT03181282|Experimental|Physical Therapy|Participants assigned to Physical Therapy (PT) will attend a 1-hour visit with a physical therapist twice weekly for 8 weeks. The PT intervention, which will mirror traditional PT for those with PD, will include exercises designed to improve balance and gait.
2909748|NCT03181282|No Intervention|Control|Participants in the control group will receive the current standard of care following STN-DBS. As such, STN-DBS settings and anti-PD medications will be optimized according to the determination of their neurologist in the same fashion as they will be in the experimental group. Those in the control group will not receive prescribed exercise from a physical therapist.
2909749|NCT03181269|Experimental|Intervention education|Participants will receive the intervention education and data recording package.
2909750|NCT03181269|Placebo Comparator|Placebo education|Participants will receive the placebo educational and data recording package.
2909751|NCT03181256||Screening|Patients are followed up at 1, 2, 3, 4, and 5 years and undergo collection of sputum, nasal epithelium, buccal epithelium, blood, and urine samples. Patients also undergo pulmonary function tests, chest CT, and review of medical records
2909752|NCT03181243|Experimental|MadaJet|Jet injector (Madajet medical Urology) preloaded as manufacturer's instruction
2909753|NCT03181243|Experimental|Needle injection|01 sterile 10-mL syringe with small gauge needle (25 ga), solution for sterile preparation, 10 - 15 mL Lidocaine 2%
2909754|NCT03181230||Adolescents|Adolescents and young adults with Turner syndrome will undergo studies of cardiometabolism, fitness, quality of life questionnaires, and a brief interview.
2909755|NCT03181230||Parents|One parent of a participant will complete parent-report quality of life questionnaires and a brief interview.
2909756|NCT03181217|Experimental|water 22, water 0, glucose 0, glucose 22|Subjects consume 300 ml water at 22 ºC, 300 ml water at 0 ºC, 300 ml water at 0 ºC containing 75 grams glucose and 300 ml water at 22 ºC containing 75 grams glucose sequentially with a one-week washout between consumptions
2909757|NCT03181217|Experimental|water 0, glucose 22, water 22, glucose 0|Subjects consume 300 ml water at 0 ºC, 300 ml water at 22 ºC containing 75 grams glucose, 300 ml water at 22 ºC and 300 ml water at 0 ºC containing 75 grams glucose sequentially with a one-week washout between consumptions
2909758|NCT03181217|Experimental|glucose 22, glucose 0, water 0, water 22|Subjects consume 300 ml water at 22ºC containing 75 grams glucose, 300 ml water at 0 ºC containing 75 grams glucose, 300 ml water at 0 ºC and 300 ml water at 22 ºC sequentially with a one-week washout between consumptions
2909759|NCT03181217|Experimental|glucose 0, water 22, glucose 22, water 0|Subjects consume 300 ml water at 0 ºC containing 75 grams glucose, 300 ml water at 22 ºC, 300 ml water at 22 ºC containing 75 grams glucose and 300 ml water at 0 ºC sequentially with a one-week washout between consumptions
2909760|NCT03181204||Patients likely to develop COPD|"Patients in this group are relatively light smokers who have developed chronic obstructive lung disease (COPD).~Intervention: Bronchial biopsy~Intervention: Skin biopsy~Intervention: Blood sample"
2909761|NCT03181204||Patients not likely to develop COPD|"Patients in this group are heavy smokers who have no signs of chronic obstructive lung disease (COPD).~Intervention: Bronchial biopsy~Intervention: Skin biopsy~Intervention: Blood sample"
2909762|NCT03181191|Active Comparator|Totally pancreatectomised patients|Oral glucose tolerance test and biopsies
2909763|NCT03181191|Active Comparator|Type 2 diabetes patients|Oral glucose tolerance test and biopsies
2909764|NCT03181191|Active Comparator|Healthy control subjects|Oral glucose tolerance test and biopsies
2910921|NCT03173443|Experimental|double lumen tube|fiberoptic intubation with double lumen tube.
2909765|NCT03181178|Active Comparator|KokoPlus and Nutrition Education|Macro-micronutrient complementary food supplement and Nutrition Education
2909766|NCT03181178|Active Comparator|Micronutrient and Nutrition Education|A micronutrient powder and Nutrition Education
2909767|NCT03181178|Active Comparator|Nutrition Education Only|Nutrition Education
2909768|NCT03181178|No Intervention|Growth Monitoring Only|Growth monitoring
2909769|NCT03181165|Experimental|Low-carbohydrate Therapeutic Nutrition|A 12-week low-carbohydrate, energy-restricted diet will be administered using a combination of pre-packaged foods and whole foods from pre-specified lists.
2909770|NCT03181165|No Intervention|Treatment-as-usual waitlist control|Participants will receive standard lifestyle advice to follow a low-fat, low-sugar, high fibre diet and aim to accumulate 150 minutes of moderate activity per week.
2909771|NCT03181152||ACOS group|Impulse Oscillometry Bronchial Dilation Test if needed
2909772|NCT03181152||Asthma group|Impulse Oscillometry Bronchial Dilation Test if needed
2909773|NCT03181152||COPD group|Impulse Oscillometry Bronchial Dilation Test if needed
2909774|NCT03181139||pre-ERAS|Patients cared for prior to the implementation of the Enhanced Recovery after surgery for total mastectomy pathway
2909775|NCT03181139||post-ERAS|patients cared for after the implementation of the Enhanced Recovery after surgery for total mastectomy pathway. Pathway included preoperative acetaminophen and gabapentin, Pec blocks, multimodal analgesia postoperatively and aggressive PONV treatment.
2909776|NCT03181126|Experimental|Venetoclax + Navitoclax + Chemotherapy|Venetoclax weight-adjusted doses administered orally every day (QD) starting on Day 1 + navitoclax various, weight-adjusted doses administered orally QD starting on Day 3 + chemotherapy (peg-asparaginase [or any other forms of asparaginase], vincristine, dexamethasone) and tyrosine kinase inhibitor [TKI, if applicable]). This regimen and any of its components may be delayed, reduced or omitted at the discretion of the Investigator.
2909777|NCT03181113||peginterferon alfa 2b|
2909778|NCT03181113||peginterferon alfa 2a|
2909779|NCT03181100|Experimental|Induction Cohort|"Induction phase with single agent taxanes: This phase is optional and serves only as a bridge to mutation-driven treatment assignment. For example, if molecular testing is readily available, patients may be assigned to the mutation-driven cohorts and do not require induction phase.~- Nab-paclitaxel 100 mg/m2 by vein weekly for up to 3 doses (preferred)~OR~- Paclitaxel 80 mg/m2 by vein weekly for up to 3 doses"
2909780|NCT03181100|Experimental|Cohort 1|Cohort 1BRAF mutant: Vemurafenib 960 mg by mouth twice a day (day 1-21) + Cobimetinib 60 mg by mouth every day (day 1-21) run-in before starting Atezolizumab. Vemurafenib dose reduced to 720 mg twice a day (at cycle 1 day 21) and Cobimetinib 60 mg taken on days 1-21. Atezolizumab 840 mg by vein on Day 1 and Day 15 in a 28-day cycle, started on Cycle 1, Day 1. Patients who have > grade 3 LFTs (AST, ALT or total bilirubin) will not receive Atezolizumab but may continue on Vemurafenib + Cobimetinib with dose reduction. If after dose reductions, the LFTs are below grade 3, patient may start Atezolizumab.
2909781|NCT03181100|Experimental|Cohort 2|Cohort 2 RAS mutant: Atezolizumab 840 mg by vein on Day 1 and Day 15 in a 28-day cycle. Cobimetinib 60 mg by mouth on Days 1－21.
2909782|NCT03181100|Experimental|Cohort 3|Cohort 3 Non-BRAF/non-RAS mutant: Atezolizumab 1200 mg by vein every 21 days plus Bevacizumab 15 mg/kg by vein every 21 days in a 21-day cycle.
2909783|NCT03181100|Experimental|Cohort 4|"Cohort 4: Atezolizumab 1200 mg by vein every 21 days.~If participant receives Nab-paclitaxel it will be given at 100 mg/m2 by vein on days 1, 8, and 15.~If participant receives Paclitaxel, it will be given at 175 mg/m2 it by vein every 21 days."
2909784|NCT03181087|Experimental|Umbilical cord MSCs Group|1*10^7 Umbilical cord Mesenchymal Stem Cells (MSCs)
2909785|NCT03181074||CHC patients in Mexico|patients receiving daclatasvir for the treatment of Chronic Hepatitis C at participating sentinel sites for the CNFV in Mexico
2909786|NCT03181048|Experimental|Periacetabular osteotomy|Standard periacetabular osteotomy on the day of surgery.
2909787|NCT03181048|Active Comparator|Periacetabular osteotomy with hip arthroscopy|Hip arthroscopy on the day of surgery, followed by a standard periacetabular osteotomy.
2909788|NCT03181035|Experimental|FAZA and pimonidazole|(18)F-Fluoroazomycin arabinoside (FAZA) will be administered via intravenous injection at a dose of 5.2 MBq/kg with a minimum dose of 200 MBq (5.4 mCi) and a maximum dose of 600 MBq (16.2 mCi) prior to positron emission tomography (PET) imaging. A single dose of oral pimonidazole capsules at a dose of 0.5 g/m2, will be taken by participants 16-20 hours prior to tumor resection surgery.
2909789|NCT03181022|No Intervention|Phase 1a|To develop a measure of MI fidelity to ensure methodological rigor, acceptability and feasibility of administration, and clinical usefulness (Phase 1a). Ratings of 200 recordings of full patient-provider interactions with ratings of thin slices (recording 1 minute every 5 minutes) will be compared.
2909790|NCT03181022|No Intervention|Phase 1b|To conduct evidence-based tailoring of MI training for adolescent HIV care settings (Phase 1b). Coding via sequential analysis will be conducted of the 200 recordings to identify those specific provider communication behaviors that predict subsequent youth motivational statements.
2909791|NCT03181022|No Intervention|Phase 2|To collaboratively develop the implementation intervention with 2 clinic teams associated with the ATN (Phase 2). A formative evaluation will be done to provide local diagnostic data regarding barriers and facilitators to adoption and create development panels - local development teams made up of clinicians and administrators from the site, and study staff to address barriers and facilitators from formative evaluation and draft locally-customized clinical care and multi-level implementation strategies with initial sustainability plans.
2909792|NCT03181022|Experimental|Phase 3|To pilot test the implementation intervention and process/outcome evaluation protocols at two ATN sites in preparation for a full-scale trial.
2909793|NCT03181009|Experimental|Group A (300 mg maintenance dose)|After initial therapy with omalizumab Group A subjects will escalate their food flour allergens to 300 mg in 18 weeks.
2909794|NCT03181009|Active Comparator|Group B (1200 maintenance dose)|After initial therapy with omalizumab Group B subjects will escalate their food flour allergens to 1200 mg in 18 weeks.
2909795|NCT03180983|Other|INTERVENTIONAL GROUP|The intervention group will receive a blended-learning intervention.
2909796|NCT03180983|No Intervention|CONTROL GROUP|No intervention
2909797|NCT03180970|Experimental|group 1|This group patients were given dosages of 1.2% Lugol's solution for chromoendoscopy.
2955504|NCT02865070||25 neonates (ages 24-29 weeks for sub-study)|
2909798|NCT03180970|Experimental|group 2|This group patients were given dosages of 1.0% Lugol's solution for chromoendoscopy.
2909799|NCT03180970|Experimental|group 3|This group patients were given dosages of 0.8% Lugol's solution for chromoendoscopy.
2909800|NCT03180970|Experimental|group 4|This group patients were given dosages of 0.6% Lugol's solution for chromoendoscopy.
2909801|NCT03180970|Experimental|group 5|This group patients were given dosages of 0.4% Lugol's solution for chromoendoscopy.
2909802|NCT03180957|Experimental|Anti-TNF|adalimumab
2909803|NCT03180957|Placebo Comparator|Placebo|saline
2909804|NCT03180944|Experimental|group 1|This group patients were given dosages of 1.2% Lugol's solution for chromoendoscopy.
2909805|NCT03180944|Experimental|group 2|This group patients were given dosages of 1.0% Lugol's solution for chromoendoscopy.
2909806|NCT03180944|Experimental|group 3|This group patients were given dosages of 0.8% Lugol's solution for chromoendoscopy.
2909807|NCT03180944|Experimental|group 4|This group patients were given dosages of 0.6% Lugol's solution for chromoendoscopy.
2909808|NCT03180944|Experimental|group 5|This group patients were given dosages of 0.4% Lugol's solution for chromoendoscopy.
2909809|NCT03180931||Scaffold thrombosis|Any patients who suffered from scaffold thrombosis occurring beyond 1 year after implantation of a Absorb BVS 1.1 and investigated by OCT with sufficient image quality allowing for CoreLab analysis at the timepoint of thrombosis.
2909810|NCT03180918|Experimental|testicular tissue cryopreservation|
2909811|NCT03180905|Experimental|Validity|ImPACT Online a computerized test will be administered to subjects. They will also receive a battery of paper and pencil neuropsychological tests.
2909812|NCT03180905|Active Comparator|Test/Re-Test|ImPACT Online will be administered at 2 time points
2909813|NCT03180879|Experimental|1|Treatment Order: Test, Reference, Comparator
2909814|NCT03180879|Experimental|2|Treatment Order: Test, Comparator, Reference
2909815|NCT03180879|Experimental|3|Treatment Order: Reference, Test, Comparator
2909816|NCT03180879|Experimental|4|Treatment Order: Reference, Comparator, Test
2909817|NCT03180879|Experimental|5|Treatment Order: Comparator, Test, Reference
2909818|NCT03180879|Experimental|6|Treatment Order: Comparator, Reference, Test
2909819|NCT03180866|No Intervention|Non-treatment Control|Control arm will not have any intervention
2909820|NCT03180866|Experimental|Luma Light System|The experimental arm will be a combination of an occlusive dressing and NBUVB light.
2909821|NCT03180853||Relapsed Multiple Myeloma Participants|The participants in the United States with a confirmed diagnosis of relapsed multiple myeloma following 1 to 3 prior lines of therapy who initiate treatment with a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as monotherapy or combination therapy with other treatments as per routine clinical practice within 90 days prior to study enrollment. These participants will be observed for the sequence of systemic myeloma treatments used during routine clinical practice, considering the life expectancy of patients with myeloma in the registry.
2909822|NCT03180840|Experimental|Pegunigalsidase alfa|Pegunigalsidase alfa 2 mg/kg intravenous infusion every 4 weeks
2909823|NCT03180827|Experimental|ovarian tissue cryopreservation|
2909824|NCT03180814|Active Comparator|Young Group|Healthy young of both sexes between the ages of 18 and 30 years will perform a whole body vibration session
2909825|NCT03180814|Experimental|Elderly Group|Healthy elderly of both sexes between the ages of 60 and 80 years will perform a whole body vibration session
2909826|NCT03180801|Placebo Comparator|Group 1 adjuvanted placebo|0.5ml adjuvanted placebo on Day -43 and on Day -22 followed by influenza challenge on day 0
2909827|NCT03180801|Experimental|Group 2 adjuvanted FLU-v one dose|0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 followed by influenza challenge on day 0
2909828|NCT03180801|Experimental|Group 3 adjuvanted FLU-v two doses|0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 followed by influenza challenge on day 0
2909829|NCT03180788|Active Comparator|Traditional ESD|The patients in this Group will undergo traditional ESD.
2909830|NCT03180788|Experimental|Traction assisted ESD|The patients in this Group will undergo traction assisted ESD
2909831|NCT03180775|Sham Comparator|Control|Other: Cellulose (control): cellulose, water soluble powder, 2 g in one daily dose, during 30 days
2909832|NCT03180775|Experimental|Glycine (Trade name: Glycine)|Dietary Supplement: Glycine, water soluble powder, 7.8 g daily in one dose, during 30 days.
2909833|NCT03180775|Experimental|Alanine (Trade name: L-Alanine)|Dietary Supplement: Alanine, water soluble powder, 8.5 g daily in one dose, during 30 days.
2909834|NCT03180775|Experimental|Leucine (Trade name: L-Leucine)|Dietary Supplement: Leucine, water soluble powder, 14 g daily in one dose, during 30 days.
2909835|NCT03180775|Experimental|Isoleucine (Trade name: L-Isoleucine)|Dietary Supplement: Isoleucine, water soluble powder, 8.2 g daily in one dose, during 30 days.
2909836|NCT03180775|Experimental|Valine (Trade name: L-Valine)|Dietary Supplement: Valine, water soluble powder, 9 g daily in one dose, during 30 days.
2909837|NCT03180775|Experimental|Cysteine (Trade name: L-Cysteine)|Dietary Supplement: Cysteine, water soluble powder, 2.2 g daily in one dose, during 30 days.
2909838|NCT03180775|Experimental|Arginine (Trade name: L-Arginine)|Dietary Supplement: Arginine, water soluble powder, 10 g daily in one dose, during 30 days.
2909839|NCT03180775|Experimental|Methionine (Trade name: DL-Methionine)|Dietary Supplement: Methionine, water soluble powder, 4 g daily in one dose, during 30 days.
2909840|NCT03180775|Experimental|Glutamate (Trade name: L-Glutamic acid)|Dietary Supplement: Glutamate, water soluble powder, 33 g daily in one dose, during 30 days.
2909841|NCT03180775|Experimental|Glutamine (Trade name: L-Glutamine)|Dietary Supplement: Glutamine, water soluble powder, 30 g daily in one dose, during 30 days.
2909842|NCT03180762|Experimental|Part 1: Cohort 1 (JNJ-64140284 or Placebo)|Participants will receive 0.1 milligram (mg) JNJ-64140284 or matching placebo under fasted condition on Day 1.
2909843|NCT03180762|Experimental|Part 1: Cohort 2 (JNJ-64140284 or Placebo)|Participants will receive 0.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
2909844|NCT03180762|Experimental|Part 1: Cohort 3 (JNJ-64140284 or Placebo)|Participants will receive 2.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
2909845|NCT03180762|Experimental|Part 1: Cohort 4 (JNJ-64140284 or Placebo)|Participants will receive 10 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
2909846|NCT03180762|Experimental|Part 1: Cohort 5 (JNJ-64140284 or Placebo)|Participants will receive 50 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
2909847|NCT03180762|Experimental|Part 1: Cohort 6 (JNJ-64140284 or Placebo)|Participants will receive 150 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
2909848|NCT03180762|Experimental|Part 2: Cohort 7 (JNJ-64140284)|Participants will receive JNJ-64140284 (dose to be determined - the dose of JNJ-64140284 will be determined on the basis of acceptable safety, tolerability and pharmacokinetics [PK] of preceding dose levels; no more than 50 percent (%) of the highest dose tested [though as high as possible within this restriction] and considered well tolerated in Part 1) under fed conditions on Day 1.
2909849|NCT03180762|Experimental|Part 3: Cohort 8 (JNJ-64140284 or Placebo)|Participants will receive JNJ-64140284 or matching placebo (dose to be determined - dose will be determined based on PK data from previous cohorts and which will be well-tolerated in Part 1) under fasted condition on Day 1.
2909850|NCT03180749||Patients implanted with vendor B anchor|
2909851|NCT03180736|Experimental|Daratumumab+Pomalidomide+Dexamethasone|Daratumumab at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Pomalidomide 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle Dexamethasone 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
2909852|NCT03180736|Active Comparator|Pomalidomide + Dexamethasone|Pomalidomide 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle Dexamethasone 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
2909853|NCT03180723|Experimental|study group|Rituximab is given in 2 doses (1 gm each dose) to a group of15 patients with primary membranoproliferative glomerulonephritis at (0 - after 2 weeks)
2909854|NCT03180723|Active Comparator|control group|Cyclosporine is given orally in a dose of 2mg/kg/d for 3 months to another group of patients with primary membranoproliferative glomerulonephritis.
2909855|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 0.6 U/kg|Single subcutaneous injection of 0.6 U/kg
2909856|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 0.8 U/kg|Single subcutaneous dose of 0.8 U/kg
2909857|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 1.0 U/kg|Single subcutaneous dose of 1.0 U/kg
2909858|NCT03180710|Active Comparator|Humalog® Mix25 at 0.8 U/kg|Single subcutaneous dose of 0.8 U/kg
2909859|NCT03180697||APT MR imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will be asked to participate in this study. The routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy.
2909860|NCT03180684|Experimental|VGX-3100 + EP|Intramuscular (IM) injections with VGX-3100 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4, Week 12 and Week 24.
2909861|NCT03180684|Experimental|VGX-3100 + EP + Imiquimod|IM injections with VGX-3100 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4, Week 12 and Week 24. In addition, participants will apply imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
2909862|NCT03180671|No Intervention|Group 1 Control|Counselling with explanation of preventive procedures.
2909863|NCT03180671|Active Comparator|Group 2 deprogramer Sliding Guide|Intervention using the Deprogrammer Sliding Guide for 12-15 minutes.
2909864|NCT03180671|Active Comparator|Group 3 deprogrammer Dawson B-Splint|Intervention using the Dawson B-Splint for 7 days with breaks for eating/drinking and oral hygiene procedures.
2909865|NCT03180671|Active Comparator|Group 4 deprogrammer Kois|Intervention using the Kois deprogrammer for 14 days with breaks for eating/drinking and oral hygiene procedures.
2909866|NCT03180658|Experimental|experimental|GTR+CGF+bone graft, CGF
2909867|NCT03180658|Active Comparator|controlled|CGF+bone graft
2909868|NCT03180645|Other|Test product/ No treatment|Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.
2909869|NCT03180645|Other|Test product/ Positive control|Participants randomized to this arm will apply Test and positive product at allocated sites.
2909870|NCT03180645|Other|Positive control /No treatment|Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.
2909871|NCT03180632|Active Comparator|Group A|Patient will receive a single dose of either 0,5mg or 1mg of oral Lorazepam depending on their body weight.
2909872|NCT03180632|Placebo Comparator|Group B|Patient will receive a placebo similar in color, form and size.
2909873|NCT03180632|No Intervention|Group 3|Patient will receive no intervention.
2909874|NCT03180619|Experimental|Part A: Renal Impairment, Part B: Hepatic Impairment|Participants will receive TAF for 96 weeks.
2909875|NCT03180606||Predicted and personalized primary care|Elderly 75 years of age and older in primary care with high risk of being fragile and future risk of needing hospital care that receives personalized primary care
2909876|NCT03180606||Predicted but with treatment as usual|Elderly 75 years of age and older in primary care with high risk of being fragile and future risk of needing hospital care that receives treatment as usual
2909877|NCT03180593|Active Comparator|Valsartan Arm|Valsartan 80mg randomly assigned for 8 weeks to asses BP control with office and 24-hour ABPM and reduction of LVH
2909878|NCT03180593|Active Comparator|Nebivolol/Valsartan|Nebivolol/Valsartan 5/80mg randomly assigned for 8 weeks to asses Blood Pressure control with office and 24-hour Ambulatory Blood Pressure Monitoring and reduction of Left Ventricular Hypertrophy
2909879|NCT03180580|Experimental|HEAL guideline+ Healthy Tiffin box|"HEAL guideline+ Healthy Tiffin box intervention arm will receive a culturally appropriate healthy eating and active living messages including a specially designed healthy tiffin box to practice healthy eating. HEAL guideline+ Healthy Tiffin box is a combination of intervention to promote healthy eating and physical activity behavior as well as improve the practice.~HEAL guideline-Healthy Eating and Active Living (HEAL) Guideline. A complete intervention guideline for promoting healthy dietary pattern and physical activity.~Healthy Tiffin box- A five chamber snack box that will help to contain food stuffs from all 5 major food groups eg; grain, meat/fish foods, vegetables, fruits and milk or milk products. This box will help to practice healthy eating behaviors."
2909882|NCT03180554|Active Comparator|tVNS Active (Stage 1)|The transcutaneous vagus nerve stimulation (tVNS) will be delivered non-invasively via a portable take-home stimulation device which attaches to the concha of the outer ear. The tVNS system sends electrical pulses through the skin and into the auricular branch of the vagus nerve. Intensity, pulse duration, and frequency is optimised by the patient. Participants will receive a 60-minute stimulation once a day for 6 weeks.
2909883|NCT03180554|Sham Comparator|tVNS Sham Control (Stage 1)|The transcutaneous vagus nerve stimulation (tVNS) electrodes will be incorrectly attached to the center of the left ear lobe, which is known to be free of cutaneous vagal innervation. Participants will receive a 60-minute sham stimulation once a day for 6 weeks.
2909884|NCT03180554|Active Comparator|DB Active (Stage 1)|The deep breathing (DB) technique will be delivered via a take-home recorded and guided audio session. Patients will be guided through a session which will simulate diaphragmatic breathing geared toward lowering heart rate and breath rate. Participants will practice a 60-minute session once a day for 6 weeks.
2909885|NCT03180554|Sham Comparator|DB Sham Control (Stage 1)|The deep breathing (DB) sham technique will be delivered via a take-home recorded and guided audio session. Participants will be instructed to simply relax and will practice a 60-minute sham session once a day for 6 weeks.
2909886|NCT03180554|No Intervention|Untouched Controls (Stage 1)|An untouched control group is included in order to control for any Hawthorne effects.
2909887|NCT03180554|Experimental|tVNS Active (Stage 2)|The transcutaneous vagus nerve stimulation (tVNS) will be delivered non-invasively via a portable take-home stimulation device which attaches to the concha of the outer ear. The tVNS system sends electrical pulses through the skin and into the auricular branch of the vagus nerve. Intensity, pulse duration, and frequency is optimised by the patient. Participants will receive a 60-minute stimulation once a day for 6 weeks.
2909888|NCT03180554|Experimental|DB Active (Stage 2)|The deep breathing (DB) technique will be delivered via a take-home recorded and guided audio session. Patients will be guided through a session which will simulate diaphragmatic breathing geared toward lowering heart rate and breath rate. Participants will practice a 60-minute session once a day for 6 weeks.
2909889|NCT03180554|Experimental|tVNS + DB Active (Stage 2)|Transcutaneous vagus nerve stimulation (tVNS) and deep breathing (DB) will be combined and practiced at the same time, 60-minutes per day for a duration of 6 weeks.
2909890|NCT03180541|Experimental|Dialectical Behaviour Therapy|"Participants receive the standard 12 month DBT programme where all four modes of treatment are delivered including: individual therapy, group skills training, telephone coaching and DBT team consultation"
2909891|NCT03180541|No Intervention|Treatment-As-Usual|"The Treatment-As-Usual arm will include individuals who:~live in areas where no DBT intervention is currently available OR~were offered a place on the DBT programme but decided not to partake at that time"
2909892|NCT03180528|Experimental|Treatment (remetinostat)|Patients receive remetinostat topically TID for 8 weeks in the absence of disease progression or unacceptable toxicity.
2909893|NCT03180515|Experimental|Activa PC+S Neurostimulator|All patients will complete motor testing on both continuous DBS and adaptive DBS during a study visit. The UPDRS rater and the patient will be blind to which type of stimulation they are on.
2909894|NCT03180502|Active Comparator|Arm I (photon-based IMRT, temozolomide)|Patients undergo photon-based IMRT QD, 5 days a week for 6 weeks for a total of 30 fractions. Beginning 4 weeks after completion of radiation therapy, patients receive standard of care temozolomide for 5 days. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression of unacceptable toxicity.
2909895|NCT03180502|Experimental|Arm II (proton beam radiation therapy, temozolomide)|Patients undergo proton beam radiation therapy QD, 5 days a week for 6 weeks for a total of 30 fractions. Beginning 4 weeks after completion of radiation therapy, patients receive standard of care temozolomide for 5 days. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression of unacceptable toxicity.
2909896|NCT03180489|Experimental|Dapagliflozin with dietary counseling|Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
2909897|NCT03180489|Placebo Comparator|Placebo with dietary counseling|Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
2909898|NCT03180476|Experimental|apatinib|apatinib,500mg,qd，28 day/cycle until the emergence of PD, death, intolerable toxicity
2909899|NCT03180463|Experimental|Group 1|Core decompression surgery; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#).
2909900|NCT03180463|Placebo Comparator|Group 2|Core decompression surgery.
2909901|NCT03180450|Experimental|Treatment group|conventional treatment; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) by i.v.
2909902|NCT03180450|Placebo Comparator|Control group|Conventional treatment
2909903|NCT03180437|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor.
2909904|NCT03180437|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2909905|NCT03180437|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
2909906|NCT03180424|Active Comparator|L Carnitine + Exercise at home|Patients who will receive L Carnitine, in liquid form, at a dosage of 2g per day, in a single intake, in addition to physical exercise advice at home for which a manual will be delivered in the consultation, for 12 weeks.
2909907|NCT03180424|Experimental|L Carnitine + supervised exercise|Patients receiving L Carnitine, in liquid form, at doses of 2g per day, in a single intake, in addition to a supervised physical exercise plan, for 12 weeks.
2909908|NCT03180424|Placebo Comparator|Placebos + supervised exercise|Patients receiving placebo and supervised exercise plan.
2909909|NCT03180411||Cognitive Testing Phase Group|Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease.
2909910|NCT03180411||Pilot Testing Phase Group|"After Cognitive Testing Phase interview, participants may be asked to have a second one-on-one interview with research staff.~Participants may also be asked to complete a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant also asked to give participant's opinion about colorectal cancer follow-up materials."
2911250|NCT03171285||Greater than or equal to 35 years|Clinical and laboratory evaluations
2909911|NCT03180398|Experimental|Multi-parametric MRI for Prostate Cancer|MRI will be acquired for prostate cancer patients undergoing radiation treatment.
2909912|NCT03180385|Experimental|Neurally-Adjusted Ventilatory Assist (NAVA)|Synchronized biphasic non-invasive respiratory support
2909913|NCT03180385|Active Comparator|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional non-invasive respiratory support
2909914|NCT03180372|Experimental|Hybrid Fractional Laser|Hybrid fractional 2940 nm and 1470 nm laser treatment
2909915|NCT03180359|Experimental|Patient already transplanted or waiting for a transplantation|
2909916|NCT03180346|Active Comparator|Single-Use Negative Pressure Wound Therapy|
2909917|NCT03180346|Active Comparator|Standard of Care|
2909918|NCT03180333|Experimental|PNA 1|Multiple dosing tolerance test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 7 days;
2909919|NCT03180333|Placebo Comparator|PNA placebo|Multiple dosing tolerance test:Metacavir Enteric-coated Capsules placebo 160mg/320mg,once a day,continuous administration for 7 days
2909920|NCT03180333|Experimental|PNA 2|Single dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 80mg/160mg/320mg,single-dose;
2909921|NCT03180333|Experimental|PNA 3|Multiple dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 6 days;
2909922|NCT03180333|Experimental|PNA 4|The effect of diet:Metacavir Enteric-coated Capsules 160mg,before and after meal.
2909923|NCT03180320|Experimental|BESMILE-HF group|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines. In addition, patients will receive the BESMILE-HF program.
2909924|NCT03180320|Other|Control|Patients in the control group will receive only the usual medications, since patients typically do not receive exercise-based cardiac rehabilitation in this kind of setting.
2909925|NCT03180307|Sham Comparator|no fluorescent imaging|Patient injected with OTL38, but does not undergo fluorescent imaging
2909926|NCT03180307|Experimental|near infrared imaging arm|Patient injected with OTL38 and undergoes near infrared imaging
2909927|NCT03180294|Experimental|Arm A (bupropion hydrochloride, placebo)|Patients receive bupropion hydrochloride PO QD on days 1-63 and placebo PO QD on days 8-71.
2909928|NCT03180294|Experimental|Arm B (bupropion hydrochloride)|Patients receive bupropion hydrochloride PO QD on days 1-7 and 64-71, and BID on days 8-63.
2909929|NCT03180294|Placebo Comparator|Arm C (placebo)|Patients receive placebo PO QD on days 1-7 and 64-71, and BID on days 8-63.
2909930|NCT03180281|Experimental|DPP4 group|DPP4 inhibitor,1 pill qd
2909931|NCT03180281|Experimental|insulin group|insulin,glargine or detemir，0.2U/Kg,qd
2909932|NCT03180281|Placebo Comparator|SU group|SU,Glimepiride，1-2mg qd
2909933|NCT03180268|Other|Arm I (Clinical Observation)|Patients undergo observation after gross total resection.
2909934|NCT03180268|Experimental|Arm II (Radiation Therapy)|Patients undergo radiation therapy 5 days a week over 6.5-7 weeks for a total of 33 fractions after gross total resection.
2909935|NCT03180255|Experimental|EGP-437|40 mg/ml dexamethasone phosphate solution delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA
2909936|NCT03180255|Placebo Comparator|Placebo|100 mM sodium citrate buffer solution (placebo) delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA
2909937|NCT03180242|Experimental|EG12014|EG12014
2909938|NCT03180242|Active Comparator|EU-sourced Herceptin|EU-sourced Herceptin
2909939|NCT03180242|Active Comparator|US-sourced Herceptin|US-sourced Herceptin
2909940|NCT03180229|Active Comparator|Granisetron|Five minutes before the induction 1 ml (1 mg / ml) iv granisetron will use. .Then blood pressure (systolic, diastolic, mean) and heart rate will record per 5 minute during surgery.
2909941|NCT03180229|No Intervention|Control|Five minutes before the induction 1 ml saline iv use.Then blood pressure (systolic, diastolic, mean) and heart rate will record per 5 minute during surgery.
2909942|NCT03180216|Experimental|Prophylactic and treatment|"Virus Specific T cells (VSTs) for prophylactic and treatment of active viral infection(s) after HSCT.~3 different dose levels starting with 1 x 10E7 /m2 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 2 x 10E7/m2 and a final dose 5 x 10E7 VSTs/m2"
2909943|NCT03180203|Experimental|INTELLiVENT-ASV|INTELLiVENT-ASV is a full closed-loop ventilation mode,available on the mechanical ventilator S1 of Hamilton.
2909944|NCT03180203|Active Comparator|Conventional modes|Volume controlled continuous mandatory ventilation (CMV) mode with pressure support mode on the Hamilton S1 Device.
2909945|NCT03180190||patients with ocular toxicity|"Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2."
2909946|NCT03180190||patients without ocular toxicity|"Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2."
2909947|NCT03180177|Experimental|Experimental group|"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession~2 cycles of neoadjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks~Interval debulking surgery~Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession~2 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks"
2909948|NCT03180177|Active Comparator|Control group|"3 cycles of neoadjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks~Interval debulking surgery~3 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks"
2911251|NCT03171272|Experimental|Experimental Group|
2909949|NCT03180164|Other|chronic lung diseases|bronchiectasis , bronchial asthma and chronic obstructive pulmonary disease assess anxiety and depression by hospital anxiety and depression scale
2909950|NCT03180151|No Intervention|Orthodontic tooth movement group|This is the control group in which pateints will be treated by conventional orthodontic treatment and extraction of premolars without piezotome
2909951|NCT03180151|Experimental|Corticotomy assisted orthodontic group|This is the study group in which patients will be treated by conventional orthodontic treatment aided by corticotomy procedure perfumed by using a piezotome.(piezotome assisted orthodontic tooth movement)
2909952|NCT03180138|No Intervention|Controls|
2909953|NCT03180138|Active Comparator|Reminders alone|
2909954|NCT03180138|Active Comparator|Reminders + compliance-linked incentives|
2909955|NCT03180125|Experimental|sodium hyaluorinate ultrasound guided|median nerve hydro-dissection using 1% lidocain followed by low molecular weight sodium hyaluronate (Hyalgan) injection ultrasonographically guided
2909956|NCT03180125|Placebo Comparator|corticosteroid with ultrasound guided|median nerve hydro-dissection using 1% lidocain followed by injection of corticosteroid Ultrasonographically guided
2909957|NCT03180112||case group|Children suffering from Autism Spectrum disorders of variable grades attending to assiut University Children Hospital aged between six months and five years.
2909958|NCT03180112||control group|Healthy children of matching age and sex.
2909959|NCT03180099|Active Comparator|Thoracolumbar Interfascial Plane Block|Bilateral ultrasound guided thoracolumbar interfascial plane block
2909960|NCT03180099|Active Comparator|Epidural Block|Epidural Block
2909961|NCT03180086|Experimental|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
2909962|NCT03180060||SPECT|SPECT compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
2909963|NCT03180060||Stress Echo|Stress Echo compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
2909964|NCT03180060||CMR perfusion|CMR perfusion compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
2909965|NCT03180060||CT perfusion|CT perfusion compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
2909966|NCT03180060||Positron Emission Tomography|PET compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
2909967|NCT03180034|Experimental|Arm 1 (Gardasil 9 1-Dose Group)|5000 girls ages 12-16 years
2909968|NCT03180034|Experimental|Arm 2 (Cervarix 1-Dose Group)|5000 girls ages 12-16 years
2909969|NCT03180034|Active Comparator|Arm 3 (Gardasil 9 2-Dose Group)|5000 girls ages 12-16 years
2909970|NCT03180034|Active Comparator|Arm 4 (Cervarix 2-Dose Group)|5000 girls ages 12-16 years
2909971|NCT03180034|No Intervention|Epidemiologic HPV Survey Arm|4000 Unvaccinated women ages 17 to 20 (1000 women between 17 and 18; 1000 women between 18 and 19; 1000 women between 19 and 20; and 1000 women age 20); Followed for six months
2909972|NCT03180021||Patients with Lupus Nephritis|
2909973|NCT03180021||Patients with IgA Neuropathy|
2909974|NCT03180008|Active Comparator|Fit and Strong!|
2909975|NCT03180008|Experimental|Fit and Strong! Plus|
2909976|NCT03179995|Experimental|Octreotide treatment arm|Octreotide will be administered post-operatively until day 5
2909977|NCT03179995|Placebo Comparator|Placebo Arm|Normal saline will be administered post-operatively until day 5
2909978|NCT03179982|Experimental|Intervention|"Male adolescents (15-17 years) will be randomly allocated to an intervention arm based on permuted blocked randomization. The intervention arm will receive the HIV-IPV intervention called Safe South Africa.~Safe South Africa is a group-based, facilitated behavioral intervention for prevention of HIV risk and IPV perpetration specifically tailored for male adolescents. The behavioral intervention is comprised of 2-hour sessions, held once a week for a total of two weeks."
2909979|NCT03179982|No Intervention|Control|Male adolescents (15-17 years) will be randomly allocated to a control arm based on permuted blocked randomization. The control arm will consist of ordinary usual care. The ordinary usual care condition will consist of a packet of existing available brochures on HIV and other sexually transmitted diseases including testing, prevention, and treatment; IPV prevention and intervention; and places to access prevention, care, and support for these outcomes and related health outcomes.
2909980|NCT03179956|Experimental|Ribociclib|
2909981|NCT03179943|Experimental|Atezolizumab + Guadecitabine|
2909982|NCT03179930|Experimental|Entinostat and Pembrolizumab|patients will be assigned to receive therapy with entinostat given by mouth once weekly and pembrolizumab given intravenously every 3 weeks
2909983|NCT03179917|Experimental|Pembrolizumab and Involved Site Radiation Therapy|Following a PET/CT simulation to evaluate the extent of disease, pembrolizumab 200mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 4 cycles. Fourteen to 21 days after the completion of therapy, a PET/CT simulation will be repeated. Patients with complete response will proceed to 20 Gy of ISRT. Patients without a PET CR, but improvement on CT scan will have a repeat biopsy. If the biopsy is negative for Hodgkin Lymphoma, these patients will receive 30 Gy of ISRT. If the biopsy is positive for Hodgkin Lymphoma, they will receive 36-40 Gy ISRT.
2909984|NCT03179904|Experimental|Treatment (FASN inhibitor TVB-2640, paclitaxel, trastuzumab)|Patients receive FASN inhibitor TVB-2640 PO QD on days 1-28, paclitaxel IV over 1-96 hours on days 1, 8, and 15, and trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unexpected toxicity.
2909985|NCT03179891|Other|Interictal State|Pharmacokinetics and Safety of Diazepam Buccal Soluble Film during the interictal state in subjects with epilepsy
2909986|NCT03179891|Other|Ictal/peri-ictal state|Pharmacokinetics and Safety of Diazepam Buccal Soluble Film during the ictal/peri-ictal state in subjects with epilepsy
2909989|NCT03179839|Experimental|Mindfulness-based Cognitive Therapy|MBCT group is a treatment group used mindfulness-based cognitive therapy, and guided by two therapists for 10 sessions. Every collection of about 6-8 patients is a closed structural group. Each session lasts 2.5 hours once a week, and has daily homework assignments.
2909990|NCT03179839|Placebo Comparator|Psycho-education Program|The program is consists of the information and principle of treatment for OCD, group sharing, supporting and discussion.
2909991|NCT03179839|Active Comparator|SSRIs Therapy|This is a control group that can choose to use SSRI drugs which the SFDA approved for the treatment of OCD (Sertraline, Fluvoxamine, initial dose of 50 mg).
2909992|NCT03179826||Study population|Adults consulting with one of the participating general practitioners and requiring long term inhaled corticoids and monitoring.
2909993|NCT03179813|Experimental|Hydrocortisone group|Intraoperative topical use of hydrocortisone as a irrigation solution in third molar surgery.
2909994|NCT03179813|Placebo Comparator|Control Group|Intraoperative irrigation with saline solution.
2909995|NCT03179800|Experimental|MobiusHD Implantation|MobiusHD Implantation
2909996|NCT03179800|Sham Comparator|Sham Implantation|Sham Implantation
2909997|NCT03179774|Experimental|Clinical registry-ER and OMT|In clinical registry setting, participants who selected Endovascular revascularization and optimal medical therapy as the treatment for carotid artery occlusion are enrolled.
2909998|NCT03179774|No Intervention|Clinical registry-OMT|In clinical registry setting, participants who selected optimal medical therapy as the treatment for carotid artery occlusion are enrolled.
2909999|NCT03179774|Experimental|RCT-ER and OMT|In randomized control trial setting, participants who are randomized to received endovascular revascularization and optimal medical therapy for carotid artery occlusion are enrolled.
2910000|NCT03179774|No Intervention|RCT-OMT|In randomized control trial setting, participants who are randomized to received optimal medical therapy for carotid artery occlusion are enrolled.
2910001|NCT03179761|Experimental|Group I (HD-TIV)|Patients receive HD-TIV intramuscularly once at baseline and once between 28-42 days.
2910002|NCT03179761|Active Comparator|Group 1(SD-QIV)|Patients receive SD-QIV intramuscularly once at baseline and once between 28-42 days.
2910003|NCT03179748||turoctocog alfa|
2910004|NCT03179735|Experimental|Essential oils mouthwash|Essential-oils group will rinse with an alcohol-free mouthwash (twice daily use; 20 ml/30 s) containing a fixed combination of four essential oils (eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%)
2910005|NCT03179735|Experimental|Cetylpyridinium mouthwash|Cetylpyridinium chloride group will rinse with an alcohol-free mouthwash (twice daily use; 20 ml/30 s) containing cetylpyridinium chloride 0.7 mg/ml
2910006|NCT03179735|Placebo Comparator|Placebos mouthwash|Placebo group will rinse with an alcohol-free placebo solution (twice daily use; 20 ml/30 s)
2910007|NCT03179722|Experimental|Intervention group: Frenchspeaking patients|Intervention: Medication review
2910008|NCT03179722|Experimental|Intervention group: Dutchspeaking patients|Intervention: Medication review Intervention: Dutchspeaking patients are also invited to participate to Additional data collection: questionnaires
2910009|NCT03179709||Intervention|The investigators will interview physicians, nurses, respiratory therapists and other clinicians who have cared for patients enrolled in the active treatment arm of ROSE.
2910010|NCT03179709||Control|The investigators will interview physicians, nurses, respiratory therapists and other clinicians who have cared for patients enrolled in the control treatment arm of ROSE.
2910011|NCT03179709||Refusal|The investigators will interview physicians who have refused to allow their patients to be enrolled in ROSE.
2910012|NCT03179696|Experimental|Mobile-assisted CBT|Psychosocial intervention combining in-person and smartphone-based cognitive-behavioral therapy (CBT) for experiential negative symptoms in schizophrenia called, Mobile-assisted Cognitive-Behavioral Therapy for Negative symptoms (mCBTn).
2910013|NCT03179683|Active Comparator|Diode laser application|An 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side (treatment group)
2910014|NCT03179683|No Intervention|No application|no treatment were aplied
2910015|NCT03179644|Experimental|Bi-pulmonary transplantation|Adult patient admitted in the Respiratory Distress and Severe Infections Intensive Care Unit in the postoperative period following a double lung transplant after written informed consent.
2910016|NCT03179631|Experimental|Ataluren|10, 10, 20 mg/kg
2910017|NCT03179631|Placebo Comparator|Placebo|10, 10, 20 mg/kg
2910018|NCT03179618|Experimental|Qi stagnation and blood stasis|Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.
2910019|NCT03179618|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
2910020|NCT03179605|Experimental|DFD-06 Cream|This is a single arm, open label study and there will be no reference or control product used in this study
2910021|NCT03179592|Experimental|Low-volume contrast media injection protocol|Patients will receive a low-volume contrast media (Ultravist 370Mg I/Ml Solution for Injection) injection protocol that is tailored to a specific tube voltage. Tube voltages will be automatically selected by the scanner to be used for the CCTA acquisition.
2910022|NCT03179579|Experimental|Experimental group|"HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession~2 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks~Cytoreductive surgery~HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession~4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks"
2910023|NCT03179579|Active Comparator|Control group|"3 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks~Cytoreductive surgery~4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks"
2910024|NCT03179566|No Intervention|Usual Care|For the first two weeks, there will be no intervention or changes to the usual discharge instructions
2910381|NCT03177031|Experimental|Stay Safe Link (SSL)|CAPD system produced by Fresenius Medical Care in Malaysia
2910025|NCT03179566|Active Comparator|Information Sheet|At discharge, patients will receive an informational sheet detailing options for safe drug disposal
2910026|NCT03179566|Active Comparator|Deterra Drug Deactivation System|At discharge, patients will receive a Deterra Drug Deactivation System.
2910027|NCT03179553||HIE|Babies admitted to the neonatal unit with suspected mild, moderate or severe hypoxic ischaemic encephalopathy .
2910028|NCT03179553||Healthy|Babies who are inpatients in the postnatal ward, born following uncomplicated pregnancy and delivery.
2910029|NCT03179540|Experimental|non-operative management|Patients with low rectal cancer who have achieved a complete clinical response following chemoradiotherapy will undergo active follow-up with regular clinical visits, physical exam, endoscopy and imaging assessments at regular intervals for 2 years to assess for tumour re-growth or spread to the liver and lungs
2910030|NCT03179527|Experimental|Qi deficiency and blood stasis|Patients in this group will be treated by Shuanghe Decoction at the base of conventional western medicine.
2910031|NCT03179527|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
2910032|NCT03179514|Experimental|Phlegm and blood stasis|Patients in this group will be treated by Gualou Xiebai Banxia Decoction & Danshen Decoction at the base of conventional western medicine.
2910033|NCT03179514|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
2910034|NCT03179501|Experimental|NP001|NP001
2910035|NCT03179501|Placebo Comparator|Placebo|Normal saline
2910036|NCT03179488|Experimental|Spinal TENS stimulation|"Spinal TENS stimulation: A constant voltage and a symmetric biphasic current of 200 microseg pulse-width at a frequency of 100Hz. The intensity will increase until participants report a strong but comfortable sensation, just below motor threshold."
2910037|NCT03179488|Sham Comparator|Sham stimulation|The same procedures as experimental group, but but will be applied a sham electrical stimulation increasing the current intensity until sensory perception of the stimulus, and then decreased to zero where it will fix until the end of the stimulation.
2910038|NCT03179475|Other|Oxycodone Naloxone Combination|Open-Label
2910039|NCT03179462|Experimental|Pork intake|Subjects will consume 2 ounces of cooked lean pork following diet normalization for 3 days.
2910040|NCT03179462|Experimental|Mixed nuts intake|Subjects will consume 1 ounce of mixed nuts following diet normalization for 3 days.
2910041|NCT03179462|Experimental|Tofu intake|Subjects will consume 2 ounces of tofu following diet normalization for 3 days.
2910042|NCT03179449|Experimental|Diagnostic (ferumoxytol-enhanced MRI)|All subjects in the experimental arm will have a single intravenous dose of ferumoxytol (5 mg Fe/kg), to be administered 24 hours before the subject undergoes ferumoxytol-enhanced magnetic resonance imaging (MRI). These subjects will subsequently undergo surgery, and tissue analysis of surgically resected samples (specifically the number of iron-containing and non-iron-containing macrophages) will be correlated with imaging features on ferumoxytol-enhanced MRI.
2910043|NCT03179436|Experimental|Escalation: Dose Level (DL) 1 MK-1308 + Pembro: Cohort 1|On Cycle 1, Day 1 of the Escalation Phase, advanced solid tumor participants receive a single monotherapy dose lead-in with MK-1308 at dose level 1. On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive MK-1308 at dose level 1 in combination with 200 mg pembrolizumab (pembro) according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
2910044|NCT03179436|Experimental|Escalation: DL 2 MK-1308 + Pembro: Cohort 2|On Cycle 1, Day 1 of the Escalation Phase, participants with advanced solid tumors except NSCLC receive a single monotherapy dose lead-in with MK-1308 at dose level 2. On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive MK-1308 at dose level 2 in combination with 200 mg pembrolizumab according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
2910045|NCT03179436|Experimental|Escalation: DL 3 MK-1308 + Pembro: Cohort 3|On Cycle 1, Day 1 of the Escalation Phase, participants with advanced solid tumors except NSCLC receive a single monotherapy dose lead-in with MK-1308 at dose level 3. On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive MK-1308 at dose level 3 in combination with 200 mg pembrolizumab according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
2910046|NCT03179436|Experimental|Confirmation: DL 1 MK-1308 Schedule 1 + Pembro (NSCLC): Arm A|On Cycle 1, Day 1 of the Confirmation Phase and during all subsequent cycles, participants with NSCLC receive MK-1308 at dose level 1 in combination with 200 mg pembrolizumab, both according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
2910047|NCT03179436|Experimental|Confirmation: DL 1 MK-1308 Schedule 2 + Pembro (NSCLC): Arm B|On Cycle 1, Day 1 of the Confirmation Phase, participants with NSCLC receive MK-1308 at dose level 1 in combination with 200 mg pembrolizumab. On all subsequent cycles, participants receive 200 mg pembrolizumab according to Schedule 1 and MK-1308 at dose level 1 according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
2910048|NCT03179436|Experimental|Confirmation: DL 2 MK-1308 Schedule 2 + Pembro (NSCLC): Arm C|On Cycle 1, Day 1 of the Confirmation Phase, participants with NSCLC receive MK-1308 at dose level 2 in combination with 200 mg pembrolizumab. On all subsequent cycles, participants receive 200 mg pembrolizumab according to Schedule 1 and MK-1308 at dose level 2 according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
2910049|NCT03179436|Experimental|Confirmation: DL 2 MK-1308 Schedule 2 + Pembro (SCLC): Arm D|On Cycle 1, Day 1 of the Confirmation Phase, participants with SCLC receive MK-1308 at dose level 2 in combination with 200 mg pembrolizumab. On all subsequent cycles, participants receive 200 mg pembrolizumab according to Schedule 1 and MK-1308 at dose level 2 according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
2910088|NCT03179098|Active Comparator|Control group (GC)|The control group (GC) that will perform the 10 'sustained stretching tractioned by a load proportional to the force captured during a maximal voluntary isometric contraction (MVIC)
2911252|NCT03171272|Sham Comparator|Control Group|
2910050|NCT03179436|Experimental|Confirmation: DL 2 MK-1308 Schedule 1 + Pembro (NSCLC): Arm E|On Cycle 1, Day 1 of the Confirmation Phase and during all subsequent cycles, participants with NSCLC receive MK-1308 at dose level 2 in combination with 200 mg pembrolizumab according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
2910051|NCT03179423|Experimental|GNbAC1|Monthly IV repeated dose
2910052|NCT03179423|Placebo Comparator|Placebo|Monthly IV repeated dose
2910053|NCT03179410|Experimental|Neuroendocrine prostate cancer (NEPC)|Subjects with neuroendocrine prostate cancer (NEPC). Avelumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.
2910054|NCT03179397|Experimental|Model SC9|Investigational IOL
2910055|NCT03179397|Active Comparator|Model LI61SE|FDA Approved IOL
2910056|NCT03179384|Experimental|ceftriaxone treatment|
2910057|NCT03179371||1|Mothers whose fetus has CDH
2910058|NCT03179358|Experimental|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid and C-REX DMH/DMHC included in the C-REX Ring-locking Procedure.
2910059|NCT03179345|Active Comparator|Gralise® (gabapentin)|Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.
2910060|NCT03179345|Active Comparator|Neurontin® (gabapentin)|Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
2910061|NCT03179345|Active Comparator|Lyrica® (pregabalin)|Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
2910062|NCT03179345|Placebo Comparator|Placebo (sugar pill)|Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.
2910063|NCT03179332|Experimental|BioChaperone® insulin lispro|Single subcutaneous administration of BioChaperone® insulin lispro
2910064|NCT03179332|Active Comparator|Fiasp®|Single subcutaneous administration of Fiasp® (insulin aspart)
2910065|NCT03179332|Active Comparator|Novorapid®|Single subcutaneous administration of Novorapid® (insulin aspart)
2910066|NCT03179319|Experimental|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
2910067|NCT03179319|No Intervention|Standard of Care|Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
2910068|NCT03179306||Samples|de-identified images and clinical data from NCI studies.
2910069|NCT03179293|Active Comparator|Propofol|propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
2910070|NCT03179293|Placebo Comparator|Control|Normal saline will be administered IV over the next 3 min prior to the patient leaving the OR
2910071|NCT03179280|Active Comparator|Adolescents with T1D on CSII|3 standard meals with varying composition were consumed and combined with alternative types of D/WB and S/WB All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
2910072|NCT03179280|No Intervention|Healthy adolescents|3 standard meals with varying composition were consumed
2910073|NCT03179267|Experimental|SNAP40 monitor|All participants in the study will be fitted with the SNAP40 ambulatory monitoring device as well as usual monitoring as standard care
2910074|NCT03179254|Experimental|Oral hypoglycemic agent continue|Metformin continue on the day of surgery
2910075|NCT03179254|Active Comparator|Oral hypoglycemic agent discontinue|Metformin discontinue on the day of surgery
2910076|NCT03179228|Experimental|Prostate Embolization|Prostate Embolization with acrylic polymer microspheres impregnated with porcine gelatin
2910077|NCT03179202|Experimental|Peripheral Nerve Stimulation|All study subjects will have up to 4 Leads placed in their low back, will use the Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
2910078|NCT03179176|Experimental|HFUD utilisation|
2910079|NCT03179163|No Intervention|Normotensive|Blood Pressure <120/80 mmHg
2910080|NCT03179163|Experimental|Hypertensive - ACEi +SH|Captopril Pill intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
2910081|NCT03179163|Experimental|Hypertensive - ACE inhibitor (ACEi)|Enalapril Pill intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
2910082|NCT03179163|Active Comparator|Hypertensive - Diuretic|Hydrochlorothiazide intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
2910083|NCT03179150||Oncological patients with extra-thoracic cancer|Patients enrolled into the study performed CT either for staging, restaging or follow-up of extrathoracic malignancies.
2910084|NCT03179124||Hemiparetic cerebral palsy|Unilateral paresis in which upper extremities are more severely affected than lower extremities.
2910085|NCT03179124||Diparetic cerebral palsy|Lower extremities were more affected than upper extremities
2910086|NCT03179111|Experimental|Low Pressure Group|Participants will undergo elective bariatric surgery. Participants under this group will be given intra-abdominal pressure of 8-10mmHg. The number of subjects anticipated for this arm will be 47. Participants in this low pressure group are expected to encounter lesser shoulder tip pain and abdominal pain. Operating field for surgeons also expected to be better.
2910087|NCT03179111|Experimental|Standard Pressure Group|Participants will undergo elective bariatric surgery. Participants under this group will be given intra-abdominal pressure of 12-15mmHg. The number of subjects anticipated for this arm will be 47. Participants in this group are expected to have an increased amount of shoulder tip pain and higher pain score postoperatively compared to low pressure group. Operating fields for surgeons are expected to be less clear.
2910089|NCT03179098|Active Comparator|GWM|The modified Weeks Group (GWM) that will carry out the modified Weeks protocol
2910090|NCT03179085|Active Comparator|Usual Care / Delayed Intervention|Participants randomized to the control group will receive usual care by their provider for 12 months. They will also attend one group class taught by CHRs in which they will learn basic information about diabetes prevention. DI participants will receive publicly-available literature that reinforces the information given in class, and they will have no other contact with study staff aside from during study data collection visits at baseline and 12 months. After 12 months of usual care, patients will enter into the delayed intervention where they will complete 12 months of Home-Based Kidney Care (HBKC).
2910091|NCT03179085|Experimental|Home-Based Kidney Care Intervention|All subjects randomized to the HBKC arm will be visited by a CHR in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and participant preference will be incorporated into the HBKC intervention arm by allowing participants to prioritize the order in which curriculum topic areas will be emphasized by the CHRs. Topics from currently available NIDDK and IHS kidney education materials will include: (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
2910092|NCT03179059|Experimental|Pregnancy tests at baseline & follow-up|We offer free pregnancy test service at baseline and at follow-up survey.
2910093|NCT03179059|Experimental|Pregnancy tests only at baseline|We offer free pregnancy test service at baseline
2910094|NCT03179059|No Intervention|Do Not Offer Pregnancy Test|Control group. No intervention is implemented.
2910095|NCT03179020|Experimental|Checklist ICUs|Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
2910096|NCT03179020|Active Comparator|Usual Care ICUs|Management of the potential donor according usual care.
2910097|NCT03179007|Experimental|Anti-CTLA-4/PD-1 expressing MUC1-CAR-T|This study have only one arm that is anti-CTLA-4/PD-1 expressing MUC1-CAR-T group. All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing MUC1-targeted CAR-T cells. New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
2910098|NCT03178994|Experimental|2% ketoconazole cream|2% ketoconazole cream apply on face twice daily for 10 weeks.
2910099|NCT03178994|Placebo Comparator|Placebo|Hydrophilic cream (in-house preparation) apply on face twice daily for 10 weeks.
2910100|NCT03178981|Active Comparator|Conventional cigarette|Commercially-available combustible cigarette
2910101|NCT03178981|Experimental|Second-generation e-cigarette A|Prototype second-generation (closed-tank) e-cigarette
2910102|NCT03178981|Experimental|Second-generation e-cigarette B|Prototype second-generation (closed-tank) e-cigarette
2910103|NCT03178981|Experimental|Second-generation e-cigarette C|Prototype second-generation (closed-tank) e-cigarette
2910104|NCT03178981|Experimental|Second-generation e-cigarette D|Prototype second-generation (closed-tank) e-cigarette
2910105|NCT03178981|Active Comparator|Second-generation e-cigarette E|Commercially-available second-generation (closed-tank) e-cigarette
2910106|NCT03178968|Experimental|15 minutes' erosion|Orange juice is administered ex vivo and in vivo for 5 minutes and repeated a total of 3 times
2910107|NCT03178968|Experimental|30 minutes' erosion|Orange juice is administered ex vivo and in vivo for 10 minutes and repeated a total of 3 times
2910108|NCT03178968|Experimental|45 minutes' erosion|Orange juice is administered ex vivo and in vivo for 15 minutes and repeated a total of 3 times
2910109|NCT03178942|Active Comparator|Reference|Reference: Elimite™ Cream (permethrin) 5% (Prestium Pharma, Inc.)
2910110|NCT03178942|Experimental|Test|Test: Permethrin Cream, 5% (Encube Ethicals)
2910111|NCT03178929|Experimental|S-Adenosyl Methionine Treatment|"Patients will be treated with S-Adenosyl Methionine treatment after radical treatment.~2000mg, po"
2910112|NCT03178929|No Intervention|control group|Patients will be treated without S-Adenosyl Methionine treatment after radical treatment.
2910113|NCT03178916||Low risk pregnant women|evaluation of the efficacy of breastfeeding Low risk pregnant women
2910114|NCT03178916||high risk pregnant women|evaluation of the efficacy of breastfeeding high risk pregnant women
2910115|NCT03178903|Active Comparator|tDCS and Aerobic Exercise|Each participant will undergo a 20-minute session of transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks.
2910116|NCT03178903|Sham Comparator|Sham tDCS and Aerobic Exercise|Each participant will undergo a 20-minute session of sham transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks.
2910117|NCT03178890|Experimental|Osseointegrated Human Machine Gateway (OHMG)|"Patients will be upgraded to the OHMG if already users of the OPRA Implant System, or implanted with the OPRA Implant System plus OHMG. Each patient will work as his/her own control before and after implantation of the OHMG.~A single surgery is required to upgrade OPRA Implant System users to the OHMG, and no additional surgeries are required if the OHMG is implanted at the same time as the OPRA Implant System."
2910118|NCT03178877||IBS|IBS group is medical student who filled Rome IV criteria for IBS
2910119|NCT03178877||Non IBS|Non-IBS group is non IBS medical student based on Rome IV criteria
2910120|NCT03178864|Experimental|Rivaroxaban|Rivaroxaban
2910121|NCT03178864|Active Comparator|Standard of care|Unfractionated heparin Low-molecular weight heparin (dalteparin, enoxaparin, tinzaparin) Warfarin
2910122|NCT03178851|Experimental|Cohort A|Participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib and atezolizumab treatment during 28-day cycles.
2910123|NCT03178851|Experimental|Cohort B|Participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib prior to initiating atezolizumab treatment during Cycle 1. During subsequent 28-day cycles participants will initiate both atezolizumab and cobimetinib on Day 1 of each cycle. Participants in this cohort will undergo tumor biopsies before and during treatment.
2910124|NCT03178851|Experimental|Cohort C|Participants with advanced melanoma, who have not received previous treatment, will receive atezolizumab monotherapy during 21-day cycles.
2910125|NCT03178825|Experimental|Hybrid Fractional Laser|Hybrid fractional 2940 nm and 1470 nm laser treatment
2910126|NCT03178812|Active Comparator|Patients with pancreatic cysts|Fine-needle aspiration (FNA) by Endoscopic Ultrasound (EUS) will collect liquid from patients' pancreatic cysts to measure their Interleukin and TNF levels
2910127|NCT03178812|Active Comparator|Healthy volunteers|Laboratory blood test to measure Interleukin and TNF levels
2910128|NCT03178799|Experimental|FLS|Fracture Liaison Service (a care manager based coordination service for fragility fracture patients)
2910129|NCT03178799|No Intervention|UC|usual care (physicians provide usual care to fragility fracture patients based on their own practice style without care manager)
2910130|NCT03178786|Experimental|Parkinson's Disease|
2910131|NCT03178786|Sham Comparator|Healthy Control Subjects|
2910132|NCT03178773|Active Comparator|TExT-MED only|Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes. A patient-identified family member receives a social support curriculum (FANS) in traditional booklet form.
2910133|NCT03178773|Experimental|TExT-MED+FANS|Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes. A patient-identified family member receives a social support curriculum (FANS) by SMS-text-message synchronized by time and content.
2910134|NCT03178747|Active Comparator|Case|Patients who clinically diagnosed as herpes simplex, herpes zoster or varicella zoster skin infection.
2910135|NCT03178747|Sham Comparator|Negative control|Patients who develops vesicular lesion but not typically considered as herpesviral skin infection, such as acute eczema, Paederus dermatitis
2910136|NCT03178734|Other|Indwelling Foley Catheter|These patients will have a traditional foley catheter with attached drainage bag (Indwelling Foley Catheter).
2910137|NCT03178734|Other|Self-Contained Valved Catheter|These patients will have a BARD Flip Flo Catheter Valve attached to the original foley catheter (Self-Contained Valved Catheter).
2910138|NCT03178721||1|Systemic lupus erythematosus with atherosclerosis
2910139|NCT03178721||2|Systemic lupus erythematosus without atherosclerosis
2910140|NCT03178708|Active Comparator|Group A amantadine sulfate|the patients will receive amantadine sulfate infusion using the dose 200 mg slowly I.V 3 hours prior to the surgery
2910141|NCT03178708|Placebo Comparator|Group B ringer lactate|the patients will receive 500 ml ringer lactate infusion slowly i.v 3 hours prior to surgery.
2910142|NCT03178695|Experimental|Treatment Group|PRP is freshly isolated from patients with diminished ovarian reserve as determined by at least one prior IVF cycle canceled for poor follicular recruitment response, or estimated by serum AMH and/or FSH, no menses for ≥1 year. Immediately following substrate isolation and activation with calcium gluconate, approximately 5 mL of autologous PRP is injected into each ovary under direct transvaginal sonogram guidance. AMH, FSH, and serum estradiol data will be recorded at 2wk intervals post-PRP and compared to baseline (pre-PRP) values.
2910143|NCT03178695|No Intervention|Comparison Group|Data collected from all patients in the Treatment Group will be compared to a dataset compiled from 25 - 50 women of similar age having received like treatment via IVF and gonadotropin stimulation for positive fertility outcomes in past clinical work at the Center for Advanced Genetics, as a comparison model and substitute control group. The purpose of this comparison will be to determine overall efficacy of the Inovium Ovarian Rejuvenation Treatment as separated from the standard efficacy rates of CAG-established IVF processes and gonadotropins used in the trial.
2910144|NCT03178669|Experimental|Cobitolimod Dose 31 mg x 2|Dose 31 mg of cobitolimod at 2 occasions, placebo at 2 occasions
2910145|NCT03178669|Experimental|Cobitolimod Dose 125 mg x 2|Dose 125 mg of cobitolimod at 2 occasions, placebo at 2 occasions
2910146|NCT03178669|Experimental|Cobitolimod Dose 250 mg x 2|Dose 250 mg of cobitolimod at 2 occasions, placebo at 2 occasions
2910147|NCT03178669|Experimental|Cobitolimod Dose 125 mg x 4|Dose 125 mg of cobitolimod, at 4 occasions
2910148|NCT03178669|Placebo Comparator|Placebo|Placebo at four occasions
2910149|NCT03178656|Active Comparator|PVTT WITH SORAFENIB|"AASLD recommend therapy:~sorafenib tablet, 400mg, bid."
2910150|NCT03178656|Experimental|PVTT WITH OPERATION|patients suitable for surgery
2910151|NCT03178643|Active Comparator|Proguanil Oral Tablet|Proguanil is the current standard of care for chemoprevention of malaria in children with SCA in Kenya. This medication will be taken on a daily basis
2910152|NCT03178643|Active Comparator|Sulfadoxine/Pyrimethanine-Amodiaquine|Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ) is a combination therapy comprised of sulfadoxine and pyrimethamine (two antifolate antimicrobials) co-administered with amodiaquine. This medication is taken on a monthly basis.
2910153|NCT03178643|Active Comparator|Dihydroartemisinin-Piperaquine (DP)|DP is an artemisinin-combination therapy consisting of the artemisinin derivative dihydroartemisinin and the bisquinoline piperaquine. This medication is taken on a monthly basis.
2910154|NCT03178630||Patients with autoimmune liver disease|"Patients with autoimmune liver disease~Patients (6-23 y.o.) with established clinical diagnosis of AIH or suspected diagnosis of AIH based on elevated serum AST or ALT, elevated IgG level >1.1 ULN, elevated titer of autoantibodies, including ANA, SMA, LKM, LC-1 or SLA, which is consistent with the simplified criteria for the diagnosis of AIH in children will be enrolled.~Patients (6-23 y.o.) with established clinical diagnosis of PSC or Suspected diagnosis of PSC supported by abnormal cholangiogram (ERCP or MRCP) or elevated GGT>1.5 ULN and dilated bile ducts by liver ultrasound will be enrolled."
2910155|NCT03178617|Active Comparator|Arm I (standard of care LIP)|Parents or caregivers attend standard of care LIP consisting of a meeting to review results of a neurocognitive evaluation and to discuss recommendations for optimal learning and school performance for 1 session.
2910156|NCT03178617|Experimental|Arm II (HIP)|Parents or caregivers attend HIP consisting of individual parental skill training sessions with a bilingual therapist over 60-90 minutes every 2 weeks for a total of 8 sessions.
2910157|NCT03178604|Active Comparator|Moderate intensity massage|Moderate intensity massage (MIM) treatment based on petrissage. It applies: 1 minute of mild effleurage, 5 minutes of deep effleurage with the thumbs, 5 minutes of firm kneading and 1 minute of tapotement (12 minutes in total). This procedure was repeated for each muscle group.
2911342|NCT03170700|Experimental|In-person|Nutrition program with in-person parental feeding content.
2910158|NCT03178604|Active Comparator|Moderate-high intensity massage|Moderate-high intensity massage (MHIM). The participants could feel a slight discomfort, but without getting to the pain, being: 1 minute of soft effleurage, 5 minutes of deep effleurage with the fingertips firm and deep thumbs, 5 minutes of firm kneading, and 1 minute of tapotement (12 minutes in total). This procedure was repeated for each muscle group.
2910159|NCT03178604|Active Comparator|Low intensity massage|Low intensity massage (LIM) treatment. Apply 6 minutes of effleurage, 5 minutes of gentle kneading and 1 minute of tapotement (12 minutes in total). This procedure was repeated for each muscle group.
2910160|NCT03178591|Active Comparator|vildagliptin|Vildagliptin is a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) Dose of Vildagliptin is 50 mg once or twice daily.
2910161|NCT03178591|Active Comparator|Dapagliflozin|Dapagliflozin is a sodium glucose cotransporter-2 (SGLT-2 inhibitor) Dose of Dapagliflozin is 10 mg once daily.
2910162|NCT03178565|Experimental|Intervention Group|Respiratory physiotherapy using a mechanical insufflation-exsufflation device (CoughAssist)
2910163|NCT03178565|Active Comparator|Control Group|Respiratory physiotherapy according standard of care - without the use of a mechanical insufflation-exsufflation device.
2910164|NCT03178552|Experimental|Cohort A: Alectinib 600 Milligrams (mg)|This cohort includes participants with anaplastic lymphoma kinase (ALK) positive NSCLC. Participants will receive alectinib 600 mg orally twice in a day (BID) until disease progression, unacceptable toxicity, withdrawal of consent or death.
2910165|NCT03178552|Experimental|Cohort B: Dose Finding Phase (DFP) Alectinib|This cohort includes participants with rearranged during transfection (RET) positive NSCLC. Participants may receive alectinib 900 or 1200 mg orally BID until disease progression, unacceptable toxicity, withdrawal of consent or death if the recommended phase 2 dose (RP2D) is not established in any other clinical study. Participants may receive 750 mg or 600 mg, if it is unsafe to pursue the higher starting dose
2910166|NCT03178552|Experimental|Cohort B: Dose Expansion Phase (DEP) Alectinib|This cohort includes participants with RET positive NSCLC. Participants will receive alectinib at the RP2D established in the DFP of Cohort B or a separate clinical study. Participants will continue receiving study treatment until disease progression, unacceptable toxicity, withdrawal of consent or death.
2910167|NCT03178552|Experimental|Cohort C: Atezolizumab 1200 mg|This cohort includes participants with bTMB positive NSCLC. Participants will receive atezolizumab at a dose of 1200 mg administered by IV infusion every 21 days (Q21D) until disease progression, loss of clinical benefit, unacceptable toxicity, withdrawal of consent or death.
2910168|NCT03178552|Active Comparator|Cohort C: Pemetrexed, Cisplatin or Carboplatin|This cohort includes participants with bTMB positive, non-squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Carboplatin at a dose of area under the concentration-time curve (AUC) of 5 or 6 IV or cisplatin at a dose of 75 milligrams per meter square (mg/m^2) IV on Day 1 of each cycle combined with pemetrexed at a dose of 500 mg/m^2 IV on Day 1 of each cycle. Pemetrexed may be continued as maintenance therapy every 21 days (Q21D) as per local standard of care.
2910169|NCT03178552|Active Comparator|Cohort C: Gemcitabine, Cisplatin or Carboplatin|This cohort includes participants with bTMB positive, squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Gemcitabine 1250 mg/m^2 IV on Days 1 and 8 of every cycle and cisplatin 75 mg/m^2 IV on Day 1 Q21D or gemcitabine 1000 mg/m^2 IV on Days 1 and 8 of every cycle and carboplatin AUC 5 IV on Day 1 Q21D.
2910170|NCT03178539|Active Comparator|diclofenac|patients will receive intra-operative diclofenac sodium at dose of 0.3 mg/kg intravenously then will continue postoperatively on the same drug received intra-operative.
2910171|NCT03178539|Active Comparator|ketorolac|patients will receive intra-operative ketorolac tromethamine at dose of 0.5 mg/kg intravenously then will continue postoperatively on the same drug received intra-operative.
2910172|NCT03178526|Active Comparator|levostatin gel|levostatin gel 1.2% topical gel was put into the periodontal pocket using an insulin syringe
2910173|NCT03178526|Placebo Comparator|placebo gel|placebo gel 1.2% topical gel was put into the periodontal pocket using an insulin syringe
2910174|NCT03178513|Experimental|Home visit|A participant in this arm will receive a home visit after discharge from the hospital.
2910175|NCT03178513|No Intervention|Usual Care|A participant in this arm will not receive a home visit after discharge from the hospital.
2910176|NCT03178500|Experimental|Traditional|Clomiphene citrate (50mg) will be given for 5 days (days 3-7). Transvaginal ultrasound from 9th-20th every other day if ovulation occur the patient will be excluded. If no ovulation, we will wait for the next menses and increase the dose to (100mg). if no ovulation occurred increase the dose to (150mg) in the next cycle if no ovulation increase the dose to (200mg) TVUS from 9th-20th ovary other day. If no ovulation we will wait for next cycle and increase the dose to (250mg) and so till 6 cycles.
2910177|NCT03178500|Experimental|Stair step protocol|If there is no response (no follicle >10mm), so, (100mg) clomiphene will be initiated immediately for 5 days and ultrasound will be repeated 1 week after the first ultrasound. If there is no response, (150mg) clomiphene will be initiated immediately for another 5 days and TV/US will be performed 1 week after the second TV/US
2910178|NCT03178487|Active Comparator|Participants receiving Upadacitinib dose A|Participants receiving Upadacitinib dose A once daily.
2910179|NCT03178487|Placebo Comparator|Participants receiving placebo|Participants receiving placebo
2910180|NCT03178474|Active Comparator|Breast-Fed Group|The infants will be fed with human breast milk by their mother
2910181|NCT03178474|Experimental|TOFER Formula Group|TOFER Infant formula,TOFER®: Infants will be fed by using TOFER® infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age.
2910182|NCT03178474|Experimental|JINLINGGUAN Formula Group|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: Infants will be fed by using JINLINGGUAN (PRO-KIDO™ I-PROTECH®) infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age.
2910183|NCT03178461|No Intervention|Room temperature parenteral fluids|"This group will receive IV room temperature fluids, which is the standard of care.~The composition of the fluids given will be normal saline with 5% dextrose."
2910184|NCT03178461|Experimental|Body temperature parenteral fluids|"This group will receive IV warmed fluids, body temperature, which is the experimental intervention.~The composition of the fluids given will be normal saline with 5% dextrose."
2910379|NCT03177044|Experimental|Behavioural treatment|2 to 6 sessions of bowel behavioural training with a pelvic floor physiotherapist
2910185|NCT03178435|No Intervention|Observational|patients will be recruited to this arm to observe prospectively the incidence of AKI among critically ill patients.patients will receive the standard care.No other intervention will be delivered
2910186|NCT03178435|Active Comparator|Interventional|Patients in this arm will be subject to AKI risk score. This risk score was recently developed and validated in Mayo clinic the intervention will be Measures to prevent AKI among critically ill patients
2910187|NCT03178422|Experimental|CQSS2 System (nicotine 21 mg)|Active CQSS2 System (nicotine 21 mg) with Digital Coach. One active Drug Cartridge will be used to transdermally administer 21 mg nicotine via a 5.4% w/v solution in an aqueous EtOH mixture per day. Metered pulses of 125 µL of solution will automatically be delivered by the assembled CQSS2 (containing the Control Unit and Drug Cartridge) at Time = 0, 0.5, 1, 7, 7.5, and 13 hours.
2910188|NCT03178422|Active Comparator|NicoDerm® CQ® patch (21 mg)|NicoDerm® CQ® patch (21 mg) with committedquitters.com. The NicoDerm patch transdermally administers 21 mg of nicotine per day. The NicoDerm patch is applied each morning of the treatment period after waking and worn for approximately 24 hours.
2910189|NCT03178409||cHCC-MFCCC|Patients affected by combined HCC-MFCCC
2910190|NCT03178409||HCC|Patients affected by classical HCC
2910191|NCT03178409||MFCCC|Patients affected by classical MFCCC
2910192|NCT03178396|Experimental|Young, intervention|patients ages 18-45, taking melatonin
2910193|NCT03178396|No Intervention|Young, control|patients ages 18-45, usual care
2910194|NCT03178396|Experimental|Older, intervention|patients ages 60 and older, taking melatonin
2910195|NCT03178396|No Intervention|Older, control|patients ages 60 and older, usual care
2910196|NCT03178383|Experimental|Integrated Approach|
2910197|NCT03178383|Active Comparator|Standard Comparison|
2910198|NCT03178370||Diabetic Gastroparesis|
2910199|NCT03178370||Idiopathic Gastroparesis|
2910200|NCT03178357|Other|HCM patients with CR|30 HCM patients treated as standard subjected to 4-week hospital cardiac rehabilitation (CR) including psychological care (counseling and / or psychoeducation) and physical training followed by 8 weeks of telerehabilitation in the patient's home (cardiac rehabilitation + standard therapy)
2910201|NCT03178357|Other|HCM patients without CR (control group)|30 HCM patients in control group - standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling (standard therapy)
2910202|NCT03178344|Sham Comparator|Sham Stimulation|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.
2910203|NCT03178344|Experimental|Alpha Stimulation|Participants will receive 2mA of alternating current stimulation at a frequency of 10Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
2910204|NCT03178331||Grade 1 children|Areas of concern in study questionnaires: growth, physical symptom, hearing, school absenteeism, learning, concentration, behavior, emotions, getting on with others, eating, sleeping, wellbeing of family, free description of concern, wish to talk about concerns with the school doctor
2910205|NCT03178331||Grade 5 children|Areas of concern in study questionnaires: growth, physical symptom, hearing, school absenteeism, learning, concentration, behavior, emotions, getting on with others, eating, sleeping, wellbeing of family, free description of concern, wish to talk about concerns with the school doctor
2910206|NCT03178318|Other|cricothyroid membrane|ultrasound of the neck will identify the position of the upper and lower border of the cricothyroid membrane in extended position.
2910207|NCT03178305|Experimental|Intervention|"Besides the behavior change programme (Do Something Different)~All patients will receive: Fitbit, Beddit, Care-portal, Do CHANGE app (including dietary habits picture taking), CookiT (smart spatula that monitors cooking behavior)~patients with heart failure will, in addition to the above mentioned, be offered a weight scale, blood pressure monitor, and FluiT (smart cup to measure fluid intake).~Patients with hypertension will also be offered a bloodpressure monitor.~Data from these devices will be gathered and visible for patients (in patient portal) and for their health care provider (health care provider portal). In case of negative results the patient will be contacted by their health care provider (usually the cardiologist).~Once every week the patients will be contacted to discuss their progress and will be given feedback about their dietary intake."
2910208|NCT03178305|No Intervention|Care as usual|Patients in this arm will receive care as usual with no restrictions.
2910209|NCT03178292|Active Comparator|Levofloxacin|Levofloxacin 500 mg daily for 5 days
2910210|NCT03178292|Placebo Comparator|Placebo|Placebo tab daily for 5 days
2910211|NCT03178279|Experimental|Use of the Physical Health Plan|Use of the Physical Health Plan
2910212|NCT03178266||Zip Closure Device|Patients will receive the Zip Closure Device for final skin closure after knee arthroplasty.
2910213|NCT03178266||Metal Staples|Patients will receive Metal Staples for final skin closure after knee arthroplasty.
2910214|NCT03178253||3|
2910215|NCT03178240|Experimental|Intervention|45 minutes seminar on skin cancer prevention and UV-protection in general.
2910216|NCT03178240|No Intervention|Control|The control croup takes part in the survey but does not receive an intervention.
2910217|NCT03178227|Experimental|Intervention|The intervention is a school-based intervention involving photoaging of the students selfies which takes 45 minutes total.
2910218|NCT03178227|No Intervention|Control|No intervention.
2910219|NCT03178214|Experimental|Infacort - Yoghurt|One single 5mg dose of Infacort will be sprinkled onto 5mL of yoghurt and swallowed within three minutes. This will be taken with 240mL of water.
2910220|NCT03178214|Experimental|Infacort - Soft Food|One single 5mg dose of Infacort will be sprinkled onto 5mL of soft food (such as applesauce) and swallowed within three minutes. This will be taken with 240mL of water.
2910221|NCT03178214|Active Comparator|Infacort - Dry Granules|One single 5mg dose of Infacort will be administered as dry granules to the back of the tongue and swallowed. This will be taken with 240mL of water.
2910222|NCT03178201|Experimental|TGR-1202|Patients with relapsed or refractory grade 1, 2, or 3A follicular lymphoma will receive TGR-1202.
2910223|NCT03178188|Experimental|laser treated DLE lesions|DLE which received the pulsed-dye laser
2910224|NCT03178188|Sham Comparator|sham treated DLE lesions|DLE which received the sham
2955505|NCT02865057||3rd year Residents|3rd year Ob, Gyn Residents
2910225|NCT03178175|Experimental|"acupuncture with De Qi"|all participants in this group will receive the standard procedure of acupuncture.
2910226|NCT03178175|Sham Comparator|Sham acupuncture|In this group, all participants will receive acupuncture needle insertion but not exact acupoint's location and depth.
2910227|NCT03178149|Experimental|ASP7317 Dose Escalation|Successive cohorts of participants (3 participants/ 3 cohort) will be treated in each escalating dose cohort (low cells/dose; medium cells/dose; high cells/dose). All participants in the low cells/dose and medium cells/dose cohorts may be treated simultaneously. The high cells/dose cohort will require sentinel dosing. After the first participant is dosed with high cells/dose and followed for 6 weeks the independent Data Safety Monitoring Board (DSMB) will review the safety data and images and recommend if the second and third participants may be treated with high cells/dose. One of the 3 doses will be selected for evaluation of efficacy and safety during the Proof of Concept (PoC) stage of the study. All participants will receive 13 weeks of immunosuppressive therapy (IMT) starting 1 week prior to day of transplant and continuing for 12 weeks posttransplant.
2910228|NCT03178149|Experimental|ASP7317 PoC Low Dose|Low cells/ dose will be administered to the study eye via a subretinal injection. All participants randomized to receive treatment with ASP7317 will receive 13 weeks of IMT starting 1 week prior to day of transplant and continuing for 12 weeks posttransplant.
2910229|NCT03178149|Experimental|ASP7317 PoC Selected Dose from Dose Escalation|Selected cells/ dose will be administered to the study eye via a subretinal injection. All participants randomized to receive treatment with ASP7317 will receive 13 weeks of IMT starting 1 week prior to day of transplant and continuing for 12 weeks posttransplant.
2910230|NCT03178149|Placebo Comparator|Placebo untreated group|Untreated participants with age-related macular degeneration (AMD)
2910231|NCT03178149|Experimental|ASP7317 Low Dose or Selected Dose Extension|If the primary endpoint for PoC is demonstrated for the selected cells/dose or low cells/dose of ASP7317, participants in the untreated control group, who completed the 26-week visit, will be allowed to cross over to treatment with ASP7317 in an extension stage of the protocol, provided the participant continues to meet eligibility criteria and are suitable for receiving IMT.
2910232|NCT03178149|Experimental|ASP7317 Safety Surveillance|Participants consented to participate in the safety surveillance will be monitored for the participants long term safety via an annual health questionnaire.
2910233|NCT03178136||case group|There is no intervention in case group.
2910234|NCT03178136||control group|The control group as the contrast for case group.
2910235|NCT03178123|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs for 1 year (27 treatments)
2910236|NCT03178123|Active Comparator|high-dose recombinant interferon a-2B|Patients receive 15*10^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5. Treatment repeats weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.Then patients receive 15*10^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
2910237|NCT03178110|Experimental|Physical therapy and dynasplint|Participants with trismus will receive a manual therapy protocol plus exercises and the use of the dynasplint (DTS) device for a duration of 6 months. The first two weeks of treatment will include 3 days per week of manual therapy and active jaw opening exercises. Following this initial treatment phase, the DTS will be introduced and the frequency of manual therapy will be reduced to two times per week.
2910238|NCT03178084|Experimental|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|"Maraviroc (UK-427,857) 300 mg once daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily).~Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz"
2910239|NCT03178084|Active Comparator|Efavirenz QD + Zidovudine/Lamivudine BID|Efavirenz (600 mg once daily) added to Zidovudine/Lamivudine (300 mg/150 mg twice daily
2910240|NCT03178084|Experimental|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine BID|Maraviroc (UK-427,857) 300 mg twice daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily)
2910241|NCT03178058||Parturients for CS|"Parturients presenting for Cesarean section will be enrolled preoperatively. Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
2910242|NCT03178045||Team Monitoring|Team Monitoring is the current standard of care for patients at Josie Robertson Surgery Center (JRSC).
2910243|NCT03178045||Enhanced Feedback|The electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity.
2910244|NCT03178032|Experimental|single arm treatment DNX-2401|Single arm receiving virus DNX-2401 infusion after tumor biopsy
2910245|NCT03178019||Euglycemia group|Normoglycemic/normotolerant subjects
2910246|NCT03178019||Prediabetes group|Subjects with prediabetes
2910247|NCT03178019||Diabetes group|Subjects with type 2 diabetes mellitus
2910248|NCT03178006||obese plus diabetes,|BMI 30-40kg/m2 and diabetes or pre-diabetes
2910249|NCT03178006||obese|BMI 30-40kg/m2
2910250|NCT03178006||control|BMI 20-27,5kg/m2
2910251|NCT03177993|Experimental|IDA 1|"ivermectin, diethylcarbamazine and albendazole Day 0,~permethrin Day 0 if excluded from ivermectin~Details of dosing:~ivermectin: 200 mcg/kg oral~diethylcarbazine: 6mg/kg oral~albendazole 400mg oral~permethrin 5% cream topical: apply to whole body and wash o after 4hrs when less than 2 months; apply to whole body and wash off after 8hrs when 2 months and older."
2910252|NCT03177993|Experimental|IDA 2|"ivermectin, diethylcarbamazine and albendazole Day 0, ivermectin Day 8~permethrin Day 0 and Day 8 if excluded from ivermectin~Details of dosing:~ivermectin: 200 mcg/kg oral~diethylcarbazine: 6mg/kg oral~albendazole 400mg oral~permethrin 5% cream topical: apply to whole body and wash o after 4hrs when less than 2 months; apply to whole body and wash off after 8hrs when 2 months and older."
2910380|NCT03177031|Active Comparator|Stay Safe (STS)|CAPD system produced by Fresenius Medical Care in Germany
2910253|NCT03177993|Active Comparator|DA|"diethylcarbamazine and albendazole Day 0~permethrin Day 8 if scabies present in participant or household member~Details of dosing:~diethylcarbazine: 6mg/kg oral~albendazole 400mg oral~permethrin 5% cream topical: apply to whole body and wash off after 4hrs when less than 2 months; apply to whole body and wash o after 8hrs when 2 months and older."
2910254|NCT03177980||Fentanyl|All infants in need of analgesia according to an algorithm based on pain assessment results will receive fentanyl as the first analgesic drug.
2910255|NCT03177980||Fentanyl and Clonidine|Infants in need of further analgesia according to an algorithm based on pain assessment results will receive fentanyl and clonidine as the analgesic drugs.
2910256|NCT03177967|Experimental|Treatment groups spring (1,2)|"Seven sessions CBT-I treatment for two different groups of eight participants (n=16)~Interventions: Sleep restriction/Stimulus Control Discussion of adverse cognitions about sleep"
2910257|NCT03177967|Experimental|Waiting list - Treatment groups fall|"This group (n=22) receives no treatment during the spring and summer, and is measured three times as a waiting list control in this period of time. The same group will receive treatment i three different groups during sept/oct.~Interventions: Sleep restriction/Stimulus Control Discussion of adverse cognitions about sleep"
2910258|NCT03177967|Active Comparator|Psychoeducative course in Nesodden|"This group (expected to be n=16) will receive a four session psychoeducative learning based course on how to manage insomnia~Interventions: Psychoeducative advice to improve sleep"
2910259|NCT03177954|Experimental|Patient Oriented Discharge Summary|A one hour patient oriented discharge summary meeting will take place with participants.
2910260|NCT03177941|Experimental|Skin Self-Examination|"Melanoma patients (n=300) and their first-degree relatives (n=300) that are between 16-70 years old will participate in the study. Participants will be randomized to receive the intervention or the control group. Participants randomized to the control group will have access to the app later.~Assigned Interventions Behavioral: Skin self-examination structure training First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle."
2910261|NCT03177941|Active Comparator|Active Control|"Participants (n=150) will complete web-based surveys at baseline and 4-months. Control participants do not initially receive training; however, after completing the 4-month survey they will be given access to the training.~Assigned Interventions~Behavioral: Skin self-examination structured training Training will be provided via a mobile application. After completing the 4-month survey, the control participants may request the link to download the application."
2910262|NCT03177928|Active Comparator|study group|patients with myeloproliferative neoplasms and reveal cardiac complications by using echocardiogram, intervention by using transthorathic echocardiography for all patients.
2910263|NCT03177928|Active Comparator|control group|patients with hematological disorders including myeloproliferative neoplasms without cardiac affection by using echocardiogram. Intervention will be in the form of using transthorath echocardiography with all patients to reveal any cardiac abnormalities.
2910264|NCT03177928|Active Comparator|control group 2|healthy people from the same age and sex will be investigated using echocardiogram. Intervention will be in the form of using transthorathic echocardiography.
2910265|NCT03177915|Active Comparator|Sodium Hyaluronate|injection of 2 ml of 1% lidocain followed by injection of low molecular weight sodium hyaluronate nearby median nerve as hydro-dissection
2910266|NCT03177915|Active Comparator|Triamcinolone acetonide|Injection of 2 ml of 1% lidocain followed injection of 40 mg of triamcinolone acetonide as a median nerve hydro-dissection
2910267|NCT03177902||Observational group|Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy
2910268|NCT03177902||Control group|Healthy Volunteers
2910269|NCT03177889|Sham Comparator|Usual treatment|oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid]
2910270|NCT03177889|Active Comparator|TCM treatment|"Traditional Chinese Medicine plus oral mucolytics (described above);~Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g"
2910271|NCT03177876|Experimental|sinus lift implant placement Hydroxyapatite Nano particles|shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles [Nanostreams] with simultaneous implant placement
2910272|NCT03177876|Active Comparator|sinus lift implant placement tenting|shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
2910273|NCT03177863|Experimental|Study cohort|"Healthy women 25 - 30 years of age with CIN2 who consent to inclusion and with no former history of CIN (any grade). The intervention is expectancy with clinical visits every 6 months. Women will leave study cohort if found with total regression (no CIN) or CIN3"
2910274|NCT03177850|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
2910275|NCT03177850|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
2910276|NCT03177837|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
2910277|NCT03177837|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
2910278|NCT03177824|Experimental|S|Sildenafil citrate (25mg)
2910279|NCT03177824|Placebo Comparator|P|placebo oral tablet
2910280|NCT03177811|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
2910281|NCT03177811|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
2910282|NCT03177798|Experimental|Icatibant|Icatibant will be intravenously infused at a rate of 50 ug/kg/h for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)
2910283|NCT03177798|Placebo Comparator|Placebo|Placebo will be intravenously infused at the same rate of Icatibant (50 ug/kg/h) for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)
2910284|NCT03177785|Experimental|Intervention|6-weeks of telephone-delivered sessions, moderated by a trained clinician offering EverydayMatters MS.
2910285|NCT03177785|No Intervention|Control|Wait-list control
2910286|NCT03177772||LTC Facility 1|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
2910287|NCT03177772||LTC Facility 2|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
2910288|NCT03177772||LTC Facility 3|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
2910289|NCT03177746|Experimental|Dapoxetine/Tadalafil 30/20 mg film coated tablet|
2910290|NCT03177720|Active Comparator|Ciprofloxacin|Half of patients and healthy volunteers are receiving ciprofloxacin, the other half imipenem.
2910291|NCT03177720|Active Comparator|Imipenem|Half of patients and healthy volunteers are receiving ciprofloxacin, the other half imipenem.
2910292|NCT03177707|Experimental|Immediate start|Patients begin the Mindfulness-based Therapy Group for Couples treatment group immediately after enrollment
2910293|NCT03177707|Other|Delayed start|Patients begin the Mindfulness-based Therapy Group for Couples after a delay post-study enrollment (approximately 6 months)
2910294|NCT03177681|Experimental|Group 1 - Antibiotics Taken During Past 2 Weeks|"Group 1: Participant was on antibiotics anytime during the past 2 weeks prior to the time of enrollment.~Tongue assessment, stool sample, and questionnaires done at baseline and once during Days 3-7 and once during Days 8-12.~Participants wear a Holter monitor for 20-24 hours at baseline and once during Days 3-7 and once during Days 8-12.~Participants given 2 tablespoons (33 cc) of yogurt each day for 12 days."
2910295|NCT03177681|Experimental|Group 2 - No Antibiotics Taken During Past 2 Weeks|"Group 2: Participant has not been on antibiotics in the past 2 weeks.~Tongue assessment, stool sample, and questionnaires done at baseline and once during Days 3-7 and once during Days 8-12.~Participants wear a Holter monitor for 20-24 hours at baseline and once during Days 3-7 and once during Days 8-12.~Participants given 2 tablespoons (33 cc) of yogurt each day for 12 days."
2910296|NCT03177668|Experimental|YS110|"Phase 1 part: Administration of 3 different dose cohort~Phase 2 part: Administration of recommended dose determined from result of Phase 1 part"
2910297|NCT03177655|Experimental|Guided Imagery|Guided Imagery meditation
2910298|NCT03177655|Active Comparator|Journaling|Keeping a journal
2910299|NCT03177642||Data Repository Group|All adults presenting to the hand and upper extremity service at Massachusetts General Hospital.
2910300|NCT03177629|Experimental|Treatment arm: H. pylori eradication|treatment arm: H. pylori eradication at visit 1(0 month)
2910301|NCT03177629|No Intervention|Control arm -1st stage|At visit 1(0 month) no intervention, observation only from visit 1 to visit 3
2910302|NCT03177629|Active Comparator|Control arm - 2nd stage|Same patients group with control arm 1st stage. After observation for 3 months during stage 1, the patients of control arm will be treated with same regimen for H. pylori eradication at visit 4 (2nd stage).
2910303|NCT03177616|No Intervention|Usual Care|Subjects randomized to the usual care control group will continue using their usual medical care as prescribed by their physician. They are not to use any chiropractic treatment or begin new therapies.
2910304|NCT03177616|Experimental|Chiropractic Treatment + Usual Care|Patients will receive a course of 10 chiropractic treatments over a 14 week period. They are to also maintain their usual medical care as prescribed by their physician, but are not to begin any new therapies.
2910305|NCT03177603|Experimental|GSK2586881 - 0.1 mg/kg|Eligible subjects will receive a single dose of 0.1 mg/kg GSK2586881. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
2910306|NCT03177603|Experimental|GSK2586881 - 0.2 mg/kg|Eligible subjects will receive a single dose 0.2 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
2910307|NCT03177603|Experimental|GSK2586881 - 0.4 mg/kg|Eligible subjects will receive a single dose of 0.4 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
2910308|NCT03177603|Experimental|GSK2586881 - 0.8 mg/kg|Eligible subjects will receive single dose of 0.8 mg/kg of GSK2586881 IV infusion. Dose escalation will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
2910309|NCT03177590|Experimental|Recordings of facial and vocal emotional|Recordings of facial and vocal emotional productions during Children are performing three tasks
2910310|NCT03177577|Placebo Comparator|Splint Only|Subjects with carpometacarpal (CMC) osteoarthritis treated by splinting of their thumb.
2910311|NCT03177577|Active Comparator|Splint with first dorsal interosseous (FDI) strengthening|Subjects with carpometacarpal (CMC) osteoarthritis treated by splinting of their thumb combined with first dorsal interosseous (FDI) strengthening stabilization exercises.
2910312|NCT03177564|Active Comparator|Protective Ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
2910313|NCT03177564|Active Comparator|Protective Ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 5cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
2910314|NCT03177564|Experimental|Driving Pressure Limited Ventilation|The intervention arm receives driving pressure limited ventilation during one-lung ventilation
2910315|NCT03177551||Developement Cohort|Development the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
2910316|NCT03177551||Validation Cohort|Validation the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
2910317|NCT03177538|Active Comparator|Corifollitropin alfa and menotropin|Elonva 150 mcg, Merional 150-300 IU
2910318|NCT03177538|Active Comparator|Follitropin alfa and lutropin alfa|Pergoveris 300 IU
2910319|NCT03177525|Experimental|Social SUCCESS|
2910320|NCT03177525|Other|Wait List|
2910321|NCT03177512|Experimental|LYNX Mobile App|
2910322|NCT03177512|No Intervention|Control|Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
2910323|NCT03177499|Experimental|Single arm study|"Patients will receive CT angiography, Doppler ultrasound, invasive PPG, and vePPG per protocol.~Intervention: Procedure: Invasive PPG"
2910324|NCT03177473||CervicalStim PEMF group|all subjects will receive active CervicalStim bone growth stimulator
2910325|NCT03177460|Experimental|Daratumumab Group|"Daratumumab given by vein 1 time each week for 4 weeks before prostatectomy.~Radical prostatectomy dissection performed on or after Week 6."
2910326|NCT03177460|Experimental|JNJ-527 Group|"Participants receive JNJ-527 by mouth 2 times each day for up to 4 weeks before prostatectomy.~Radical prostatectomy dissection performed on or after Week 6."
2910327|NCT03177447|Other|Summative evaluation trial of ENABLE CHF-PC|Single arm summative evaluation study was selected for several reasons: 1) to continue to determine recruitment feasibility; 2) retention- our prior work has demonstrated fairly equal dropouts in the intervention and control conditions, hence we believe we will be able to judge retention in a single arm design; 3) using a small randomized controlled trial (RCT) for power estimates runs a high risk of either overestimating or underestimating treatment effects; and 4) most importantly, the primary purpose of this study is to determine intervention efficacy. Therefore delivering the intervention to the maximum number of participants given the limitations of 2-year pilot funding allows the investigators to obtain the maximal input and experience with the intervention that is needed to achieve the study's Aim 1.
2910328|NCT03177434|Active Comparator|Dicopeg Junior|"Polyethylene glycols (PEG) - 3350 Dosage form: oral solution sachets Frequency: 2 doses~Dosage:~weight up to 8 kg - 1 sachet per day~weight 8 - 12 kg - 2 sachets a day~weight 12 - 20 kg - 3 sachets a day~weight> 20 kg - 4 sachets per day, Duration: 12 weeks vs Lactulose Dosage form: oral solution Dosage: 2 ml / kg / day Frequency: 2 doses Duration: 12 weeks"
2910329|NCT03177434|Active Comparator|Lactulose|Lactulose Dosage form: oral solution Dosage: 2 ml / kg / day Frequency: 2 doses Duration: 12 weeks
2910330|NCT03177421|Experimental|Bedtime media use and sleep problems|This arm will receive screening for and associated clinical decision support on sleep problems and bedtime media use.
2910331|NCT03177421|Other|Sleep problems only|This arm will receive screening for and associated clinical decision support on sleep problems only.
2910332|NCT03177395|No Intervention|Acetylcysteine (N-acetylcysteine; NAC)|NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.
2910333|NCT03177395|Experimental|PP100-01 (Calmangafodipir)+ NAC|"In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:~Group A: PP100-01 (2 umol/kg calmangafodipir) after the loading dose of NAC~Group B: PP100-01 (5 umol/kg calmangafodipir) after the loading dose of NAC~Group C: PP100-01 (10 umol/kg calmangafodipir) after the loading dose of NAC~PP100-01 treatment is administered intravenously over 5 minutes."
2910334|NCT03177382|Experimental|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w. The TME operation will be given 3-4 weeks after the end of the total neoadjuvant treatment.
2910335|NCT03177382|Active Comparator|concurrent chemoradiotherapy group|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
2910336|NCT03177356|Experimental|extraction,implant placement,PRF|Extraction of Mandibular first molar and Implant placement followed by Placement of placement of Platelet rich fibrin as space filling material
2910337|NCT03177356|Active Comparator|Exctraction,Implant placement,Bone graft|Extraction of mandibular first molar followed by implant placement and xenogenic bone graft as space filling material
2910338|NCT03177317|Experimental|Elderly patients (>= 70 years of age)|Dexamethasone 8mg intravenously before chemotherapy
2910339|NCT03177304|Experimental|Web based IPT Training|All subjects (trainees) received the web based training, consisting of an on-line tutorial, remote live training via videoconferencing, and access to a post-training web portal
2910340|NCT03177291|Active Comparator|Squamous Cell Lung Cancer (SQCLC)|Arm A Combination Therapy: Pirfenidone combined with standard first-line chemotherapy. Participants will receive the combination of Pirfenidone and carboplatin plus paclitaxel in study treatment cycles that last 21 days. Phase 1 Dose Escalation; followed by Phase 1b Dose Expansion.
2910341|NCT03177291|Active Comparator|Non-Squamous Cell Lung Cancer (SQCLC)|Arm B Combination Therapy: Pirfenidone combined with standard first-line chemotherapy. Participants will receive the combination of Pirfenidone and carboplatin plus pemetrexed in study treatment cycles that last 21 days. Phase 1 Dose Escalation; followed by Phase 1b Dose Expansion.
2910342|NCT03177278|Experimental|Arm 1|
2955506|NCT02865057||4th Year Residents|4th year Ob, Gyn Residents
2910343|NCT03177265|Experimental|Text to Engage|This group will get 8 text messages that target common misperceptions around quitting and use of quit services prior to receiving the first counseling phone call.
2910344|NCT03177265|Other|Mail Notice|This group will only get a mailing indicating that they will receive a call from a quitline counseling in two weeks.
2910345|NCT03177265|Experimental|Text to Enhance|Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks.
2910346|NCT03177265|Active Comparator|Telephone Counseling|Telephone counseling condition will receive standard 8 weeks of telephone counseling only.
2910347|NCT03177252|Experimental|Scalp block with lidocaine and bupivacaine|"Scalp block with a mixture of 2% lidocaine and 0.5% bupivacaine~Once the surgery is completed, patients will be awaken and extubated following a basic neurological exam. If the extubation is delayed or if the patient is taken to ICU intubated, those patients will be excluded from the study."
2910348|NCT03177252|Placebo Comparator|Scalp block with saline|"Scalp block with saline~Once the surgery is completed, patients will be awaken and extubated following a basic neurological exam. If the extubation is delayed or if the patient is taken to ICU intubated, those patients will be excluded from the study."
2910349|NCT03177239|Experimental|Nivolumab and Ipilimumab|"Part 1: nivolumab 240mg IV q2w for a maximum of 12 months.~Part 2; nivolumab 240mg IV q3w in addition to ipilimumab 1mg/kg q3w x 4 cycles Then nivolumab 240mg q2w for a maximum of 12 months."
2910350|NCT03177226|Experimental|Functional TENS stimulation|Short stimulation to identifying Sensory Threshold and Motor Threshold, followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase [from full erection to ejaculation]
2910351|NCT03177226|Sham Comparator|Non-stimulation treatment|Short stimulation to identifying Sensory Threshold and Motor Threshold, followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase [from full erection to ejaculation]
2910352|NCT03177213||pemphigus vulgaris patients|20 pemphigus vulgaris patients will be included in the study, either newly diagnosed or recurrent. Patients will be recruited on admission from Dermatology department and Outpatient Clinic, Assiut University Hospitals
2910353|NCT03177213||Healthy controls|10 healthy age and sex matched subjects will be included as controls.
2910354|NCT03177187|Experimental|Phase I|Increasing doses of AZD5069 in combination with a fixed dose of enzalutamide to establish the recommended phase II dose.
2910355|NCT03177187|Experimental|Phase II|The Phase II part of the study will evaluate the recommended phase II dose identified in Phase I of the study in patients with metastatic castration resistant prostate cancer.
2910356|NCT03177174|Active Comparator|Docetaxel|
2910357|NCT03177174|Active Comparator|Cisplatin|
2910358|NCT03177174|Active Comparator|DocetaxelCisplatin|Cisplatin combined with Docetaxel
2910359|NCT03177161|Experimental|Postal Questionnaire|
2910360|NCT03177161|Experimental|Online Questionnaire|
2910361|NCT03177161|Experimental|Face-to-face Questionnaire|
2910362|NCT03177161|Experimental|Telephone Questionnaire|
2910363|NCT03177148|Active Comparator|Usual Care|"1-2 pediatric clinicians per practice will be trained in study procedures, current obesity treatment guidelines, and obesity billing and coding via telephone and webinar~NO active enrollment of parents~Secure extraction of HIPAA limited Electronic Health Record (EHR) and billing data from practices for outcomes analyses~At the end of the intervention period, 1-2 pediatric clinicians will be offered the in-person MI training and DVD materials"
2910364|NCT03177148|Experimental|Intervention by Clinicians|"Clinicians complete surveys during enrollment and end of the intervention~1-2 clinicians from each practice will receive 2.5 days of in-person MI training, two scored encounters with a standardized patient, and an interactive DVD MI booster training system focusing on pediatric obesity.~Enroll 35 eligible parents per practice~Clinicians give up to 4 in-person, MI sessions to enrolled parents over 2 years.~Dietitians will provide up to 6 telephone counseling sessions.~•Parents will complete surveys after enrollment and at the end of intervention"
2910365|NCT03177135|Experimental|AmnioSense diagnostic pantyliner|AmnioSense diagnostic pantyliner of amniotic fluid compared with standard clinical diagnosis methods
2910366|NCT03177122|Experimental|Myo-Inositol|1g Myo-inositol per day, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) + 400 ug of Folic acid
2910367|NCT03177122|No Intervention|No intervention|Standard care: 400 ug of Folic acid
2910368|NCT03177109|Active Comparator|Fluoride Varnish Group|5% fluoride varnish (Acclean) applied topically
2910369|NCT03177109|Active Comparator|Arginine paste Group|8% arginine containing paste (Colgate® Sensitive Pro-Relief™) applied topically
2910370|NCT03177109|Active Comparator|Adhesive Resin Group|Self-adhesive resin (Seal and Protect, Dentsply) applied topically
2910371|NCT03177096|Experimental|Peds QL questionnaire and diabetes modulate|Routine practice of a continuous measure sensor of the glycemia with insulin pump for children aged 2 to 13 years followed at Mulhouse Hospital for type 1 diabetes : 5 sessions after enrollment visit(V1) (1 session 2 months, 4 months, 6 months, 8 months and 10 months) This study will be proposed to patients treated for type 1 diabetes enrolled in kindergarten, primary school, attending a nursery or a childcare center (patient's participation = 10 months) and will evaluate the child quality of life and the parents and staffs in preschool and school felt too.
2910372|NCT03177083|Active Comparator|peginterferon beta-1a|
2910373|NCT03177083|Active Comparator|Current Therapy|
2910374|NCT03177070|Experimental|Methylene Blue|Intravenous administration of methylene blue and assessment of ureteric fluorescence intraoperatively.
2910375|NCT03177057|Experimental|Arm I (self-monitoring)|ARM I (SELF-MONITORING): Patients complete tanning and sun protection usage entries daily for 14 days.
2910376|NCT03177057|Experimental|Arm II (text messages)|ARM II (TEXT MESSAGES): Patients receive individualized text messages based on baseline assessment of tanning motives (appearance, enjoyment, social) daily for 14 days.
2910377|NCT03177057|Experimental|Arm III (self-monitoring, text messages)|ARM III (COMBINED GROUP): Patients complete tanning and sun protection usage entries and also receive individualized text messages daily for 14 days.
2910378|NCT03177057|Sham Comparator|Arm IV (questionnaire administration)|ARM IV (CONTROL GROUP): Patients complete study assessments.
2910382|NCT03177018|Experimental|Patients with Cardiomyocytes collection|Patients suffering from arrhythmogenic right ventricular cardiomyopathy/dysplasia cardiac and needing endocardial voltage mapping for disease diagnosis and/or prognosis assessment
2910383|NCT03176992|Active Comparator|Surgicel group|80 patients underwent formal curettage followed by insertion of 4 pieces of Surgicel inside the uterine cavity
2910384|NCT03176992|No Intervention|Thermal balloon ablation group|80 patients underwent thermal balloon ablation using bipolar radiofrequency electrical energy (Novasure)
2910385|NCT03176992|No Intervention|Endometrial resection group|80 patients underwent transcervical Hysteroscopic endometrial resection
2910386|NCT03176979|Experimental|Diagnostic (CESM with DBT)|Patients undergo a clinical breast examination and a diagnostic mammogram with or without targeted breast ultrasound to the index cancer as part of their standard of care preoperative work-up. As part of the research study, patients receive contrast agent IV and then undergo a CESM with DBT over 30 minutes. Patients also receive a contrast agent, gadolinium, IV and undergo bilateral breast CE-MRI over 10 minutes.
2910387|NCT03176966|Active Comparator|Vitamin E then Ropinirole|Patients will be provided with vitamin E, 400 international units (IU), at baseline. Patient demographics will be collected along with baseline lab data including magnesium, potassium, albumin, and total bilirubin levels. After 3 months, patients will be switched to Ropinirole. Surveys measuring muscle cramp frequency and intensity will be collected at baseline, 3 months, and 6 months.
2910388|NCT03176966|Active Comparator|Ropinirole then Vitamin E|Patients will be prescribed ropinirole at baseline. Patient demographics will be collected along with baseline lab data including magnesium, potassium, albumin, and total bilirubin levels. After 3 months, patients will be switched to vitamin E, 400 international units (IU). Surveys measuring muscle cramp frequency and intensity will be collected at baseline, 3 months, and 6 months.
2910389|NCT03176953|Experimental|prolonged exposure + topiramate|psychotherapy plus active medication
2910390|NCT03176953|Active Comparator|prolonged exposure + placebo|psychotherapy plus placebo medication
2910391|NCT03176940|Experimental|2-HOBA first dose|Dose escalation studies in humans: 50mg dose
2910392|NCT03176940|Experimental|2-HOBA second dose|Dose escalation studies in humans: 100mg dose
2910393|NCT03176940|Experimental|2-HOBA third dose|Dose escalation studies in humans: 200mg dose
2910394|NCT03176940|Experimental|2-HOBA fourth dose|Dose escalation studies in humans: 330mg dose
2910395|NCT03176940|Experimental|2-HOBA fifth dose|Dose escalation studies in humans: 550mg dose
2910396|NCT03176940|Experimental|2-HOBA sixth dose|Dose escalation studies in humans: 825mg dose
2910397|NCT03176927|Experimental|Gastroparesis|"magnetogastrogram~Diabetes with and without gastroparesis ; Idiopathic gastroparesis"
2910398|NCT03176927|Experimental|Gastrectomy|"magnetogastrogram~Total or partial gastrectomy group"
2910399|NCT03176927|Experimental|Functional dyspepsia|"magnetogastrogram~Children with functional dyspepsia"
2910400|NCT03176927|Experimental|Chronic nausea|"magnetogastrogram~Children with chronic nausea"
2910401|NCT03176927|Experimental|Control participants|"magnetogastrogram~Group without any gastrointestinal diseases."
2910402|NCT03176914|Experimental|Intervention arm|Eleven clusters (Villages) will be randomly selected. A cluster will comprises of 10-15 volunteers selected from a cohort 10-15 households. Educative sessions will be held in each cluster once every fortnight using a participatory methods by a trained Village Health Worker (VHW). A session will focus on one thematic area running for 1-2 hours. Trained volunteers will in turn replicate the session(s) in their cohorts and do home visits to monitor care practices and screen children for various ailment. Health information is collated from each cluster and consolidated by the VHW who reports monthly at the clinic.
2910403|NCT03176914|Active Comparator|Conventional Intervention arm|In the conventional mobilization system, a Village Health Worker facilitates community health programs as the sole source of health education for the entire villages. She does home visits, child growth monitoring and the various components primary health care at village level inclusive of disease surveillance and community case management using the 'supermarket approach' , whereby 3 or more themes are covered in a space of 10- 30 minutes in functions like funerals, village gatherings and other opportune moments. The Village Health worker prepares village monthly reports on all the indicators on community health and submits to the local health centre.
2910404|NCT03176901|Experimental|Mindfulness-Based Stress Reduction|8 week manualized, standardized mindfulness-based stress reduction program taught by a certified Mindfulness-Based Stress Reduction instructor
2910405|NCT03176901|Active Comparator|Health Enhancement Program|8 week manualized, standardized health enhancement program, taught by a certified health education specialist
2910406|NCT03176888|Experimental|Exercise|Patients in the Exercise group will follow a fully-supervised exercise routine (Reduced-exertion, high-intensity interval training (REHIT)) with 3 weekly 10-minute training sessions consisting of easy cycling interspersed with 2 brief 'all-out' cycle sprints. Patients in this group will also be offered up to 6 sessions of cognitive behavioral therapy. The duration of the intervention will be the weeks between enrolling in the study and surgery (~1-4 weeks), as well as an additional period of up to 6 weeks following surgery.
2910407|NCT03176888|No Intervention|Standard care|Patients allocated to the Standard Care group will receive the care they would have also received if they would not have participated in the study. They will however undergo the same testing sessions as patients in the Exercise group.
2910408|NCT03176875|Experimental|PEN group|Partial enteral nutrition (PEN) group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and a limited (25% of dietary needs = 1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
2910409|NCT03176875|Active Comparator|EEN group|Exclusive enteral nutrition (EEN) group will receive 100 % of their daily caloric requirements from a poymeric formula (Alicalm, Nutricia) for 6 weeks.
2910410|NCT03176862||CKD|40 patients per group of CKD from stage 2 to stage 5.
2910411|NCT03176862||Kidney transplant recipients|20 live-donor recipients will be studied pre-operatively and then followed up at 6 weeks and 1 years post-operatively.
2910412|NCT03176862||Controls|40 healthy controls and 40 hypertensive controls.
2910435|NCT03176745||sarcoidosis|"clinical history and/or specialist diagnosis of sarcoidosis~lymphocytic alveolitis and CD4/CD8 > 3.5 in bronchoalveolar lavage and/or noncaseating epithelioid granuloma~exclusion of alternative explanation"
2956573|NCT02857400|Experimental|Arm B (experimental)|
2910413|NCT03176849|Experimental|Single, high dose oral vitamin D3|Patients will take a single oral dose of vitamin D3 based on age and initial vitamin D level. A patient may be sufficient, insufficient, or deficient at the start of therapy. Following this dose, patients will also be given standard vitamin D3 supplementation during transplant in accordance with current standard supplementation. This supplementation is also based on a patient's initial vitamin D level. If a patient had sufficient vitamin D at the beginning, but becomes deficient or insufficient at Day +30 of transplant, they will receive increased supplementation for the remainder of transplant.
2910414|NCT03176849|Active Comparator|Standard Vitamin D Supplementation|Patients will be given standard vitamin D3 supplementation during transplant in accordance with current standard of care. This supplementation is based on a patient's initial vitamin D level. A patient may be sufficient, insufficient, or deficient at the start of transplant. If a patient had sufficient vitamin D at the beginning, but becomes deficient or insufficient at Day +30 of transplant, they will receive increased supplementation for the remainder of transplant.
2910415|NCT03176836|Experimental|MRI Imaging|"Participants will be imaged with the standard MRI technique (STIR-MRI) and also new MRI techniques called diffusion weighted or DW MRI and Positron Emission Tomography (PET)-MRI. PET-MRI will be indicated if the results from the routine MRI and DW MRI are contradictory or if laboratory results do not correspond to the standard MRI and DW MRI results."
2910416|NCT03176823|Sham Comparator|Control Arm|"Control-arm patients will be treated with standard Best Practice management of traumatic brain injury, with the addition of sham-RIC. The sham intervention will use a purpose-built device which will visually and audibly mimic a functional RIC device, with the key distinction being non-inflation of the arm cuff with resultant non-occlusion and no induced ischemia. To mask patient enrollment, all patients in both study arms will have the arm and RIC device draped in an opaque sheet so that the extremity distal to the RIC device are not visible to medical staff during the period of intervention."
2910417|NCT03176823|Experimental|RIC Arm|The RIC treatment will be applied with a purpose-built commercial RIC device which will aid in standardizing dose and delivery. Therapeutic RIC will be provided by the CellAegis Technologies autoRIC device on an upper extremity. As with the control cohort, this cohort will undergo complete extremity draping.
2910418|NCT03176810|Active Comparator|OCT-guided PCI|PCI is performed by OCT guidance.
2910419|NCT03176810|Active Comparator|Angiography-guided PCI|PCI is performed by angiography guidance alone.
2910420|NCT03176797|Experimental|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
2910421|NCT03176784|Experimental|Varenicline + Patch Standard Duration|"Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID~Standard Condition Nicotine Patches:~Patches (Nicotine): 14 mg Patches for 2 weeks prequit and then 10 weeks post-quit, then 7 mg patches for Weeks 11 and 12; Placebo patches weeks 13-24"
2910422|NCT03176784|Experimental|Varenicline Only Standard Duration|"Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID~Standard Condition Placebo Patches:~Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit"
2910423|NCT03176784|Experimental|Varenicline + Patch Extended Duration|"Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22~Extended Condition Nicotine Patches:~14 mg Patches for 2 weeks prequit and then weeks 1-22 post-quit, then 7 mg patches for Weeks 23 and 24 post-quit."
2910424|NCT03176784|Experimental|Varenicline Only Extended Duration|"Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22~Extended Condition Placebo Patches:~Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit"
2910425|NCT03176771|Experimental|MT-5199 40 mg (Double-Blind Placebo-Controlled Period)|MT-5199 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning for 6 weeks.
2910426|NCT03176771|Experimental|MT-5199 80 mg (Double-Blind Placebo-Controlled Period)|Subjects randomized to the MT-5199 80 mg dose will receive MT-5199 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by MT-5199 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning for 5 weeks.
2910427|NCT03176771|Experimental|Placebo (Double-Blind Placebo-Controlled Period)|Placebo administered as two (2) placebo capsules, taken by mouth, every morning for 6 weeks.
2910428|NCT03176771|Experimental|MT-5199 40 mg (Double-Blind Extension Period)|At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose.
2910429|NCT03176771|Experimental|MT-5199 80 mg (Double-Blind Extension Period)|At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose. Subjects re-randomized to receive MT-5199 80 mg will receive 40 mg for the first week.
2910430|NCT03176758|Active Comparator|Spinal block|"Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg ideal body weight diluted with 100cc Normal Saline~+ Total Knee Replacement ( which will not be the intervention of interest)"
2910431|NCT03176758|Active Comparator|General anesthesia|"1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg ideal body weight diluted with 100cc Normal Saline~+ Total Knee Replacement ( which will not be the intervention of interest)"
2910432|NCT03176745||healthy controls|"no history of pulmonary disease~absence of symptoms, smoking history < 10 pack years~normal lung function testing"
2910433|NCT03176745||chronic obstructive pulmonary disease|"clinical history and/or specialist diagnosis of COPD and risk factor(s)~persistent bronchial obstruction and/or hyperinflation and/or radiological sign of emphysema, each without alternative explanation~dyspnea, cough and/or sputum production"
2910434|NCT03176745||bronchial asthma|"clinical history and/or specialist diagnosis of bronchial asthma~respiratory symptoms compatible with asthma varying over time~variable and/or reversible obstructive ventilation disorder and/or airway hyperresponsiveness~exclusion of alternative explanation"
2910436|NCT03176732||Group 1: Normotensive|Categorized by 24-hr systolic BP (SBP): normotensive (< 125 mm Hg) on no BP medications
2910437|NCT03176732||Group 2: Controlled Hypertensive|Categorized by 24-hr systolic BP (SBP): controlled hypertensive (< 130 mm Hg) on BP medication(s) and/or lifestyle modification
2910438|NCT03176732||Group 3: Uncontrolled Hypertensive|Categorized by 24-hr systolic BP (SBP): uncontrolled hypertensive (≥ 130 mm Hg) on 0-2 BP medications
2910439|NCT03176732||Group 4: Hypertensive|Categorized by 24-hr systolic BP (SBP): hypertensive (≥ 135 mm Hg) resistant to 3 or more BP medications ideally including a diuretic (resistant hypertension)
2910440|NCT03176719||Children of 1 years old|200 healthy volunteers aged between 12 and 23 months
2910441|NCT03176719||Children aged 2-4|200 healthy volunteers aged between 24 and 59 months
2910442|NCT03176719||Children aged 5 - 9|200 healthy volunteers aged between 60 and 119 months
2910443|NCT03176719||Children aged 10 - 14|200 healthy volunteers aged between 120 and 179 months
2910444|NCT03176719||Adults of 15 years and older|200 healthy volunteers of 180 months or older
2910445|NCT03176706||Lebanese pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in the Lebanon.
2910446|NCT03176706||Thai pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Thailand.
2910447|NCT03176706||South African pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in South Africa.
2910448|NCT03176706||New Zealand pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in New Zealand.
2910449|NCT03176706||Swedish Pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Sweden.
2910450|NCT03176706||Peruvian pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Peru.
2910451|NCT03176693|Active Comparator|Phenoxybenzamine|3-4 weeks prior to date of surgery, patient will start phenoxybenzamine 10mg PO twice daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
2910452|NCT03176693|Experimental|Doxazosin|3-4 weeks prior to date of surgery, patient will start doxazosin 1 mg PO daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
2910453|NCT03176680|Experimental|Fluid therapy optimization|Fluid loading to optimize stroke volume after induction.
2910454|NCT03176680|No Intervention|Fluid therapy normalization|No fluid loading after induction.
2910455|NCT03176667|Experimental|ESP for VATS|Erector Spinae plane (ESP) block
2910456|NCT03176667|Active Comparator|ICB for VATS|Intercostal block (ICB)
2910457|NCT03176654|Experimental|HVLAT manipulation|An HVLAT manipulation is applied to the site of pain or restriction with the patient in supine. This technique uses both primary levers (pre-manipulation rotation - away (30 ° - 45 °) from the side of pain or limitation) and secondary levers (Side bending - towards coupled with lateral shift - away, and posterior-anterior (PA) shift (extension). This is a bimanual technique. For the applicator hand, the anterolateral portion of the first or second phalanx of the second ray was positioned on the superior joint partner of the target vertebrae using a cradle hold. The other hand is placed on the posterolateral aspect of the occiput (above the ear). While maintaining these positions the clinician performed the thrust with the arc of rotation dependent on the level of the target vertebrae.
2910458|NCT03176654|Sham Comparator|Sham HVLAT manipulation|Subjects in the control group were instructed to lay on a table in the same position as the HVLAT manipulation group. The clinician went through the same basic steps as the HVLAT manipulation, localizing the appropriate vertebral landmarks but without carrying out the final HVLA thrust procedure.
2910459|NCT03176641|Active Comparator|PRP group|30 patients will receive autologous platelet-rich plasma gel during meniscus repair surgery.
2910460|NCT03176641|Placebo Comparator|Control group|30 patients will receive meniscus repair surgery only.
2910461|NCT03176628|Experimental|Basis|Nicotinamide riboside (NR) and pterostilbene oral capsules 250mg/50mg (Step 1) twice daily for 2 days. If the study progresses to Steps 2, 3, and 4, then 2x, 3x, and 4x the doses in Step 1 will be administered.
2910462|NCT03176628|Placebo Comparator|Placebo|Capsules identical in appearance and number to the agent used in Steps 1-4.
2910463|NCT03176615|Experimental|Group A (Cross-over Group 1)|Subjects randomly assigned to two experimental diets. This arm will receive high-fat meals first, followed by a washout period of two-seven days and then low-fat meals.
2910464|NCT03176615|Experimental|Group B (Cross-over Group 2)|Subjects randomly assigned to two experimental diets. This arm will receive low-fat meals first, followed by a washout period of two-seven days and then high-fat meals.
2910465|NCT03176602||All patients admitted to the ICU|All patients ≥ 18 years old who had ≥ 24 hours length of stay in the ICU
2910466|NCT03176589|Placebo Comparator|placebo|3 cycles of 10 deep inspiration and expiration in a placebo tube without expiratory resistance
2910467|NCT03176589|Active Comparator|PEP|3 cycles of 10 deep inspiration followed by expiration with positive expiratory pressure (PEP)
2910468|NCT03176576|Experimental|Patient Navigator (PN)|Patient Navigator (PN) Intervention Group. In addition to the Baseline Questionnaire and the Follow-up Questionnaire, PN intervention participants will complete a brief Patient Navigator Satisfaction Survey.
2910469|NCT03176576|Other|Usual Care (UC)|Usual Care (UC) Control Group. Control sample of patients not receiving PN intervention will complete a Baseline Questionnaire and the six-week Follow-up Questionnaire. Participants under UC will have access to all services typically provided to Moffitt Cancer Center (MCC) patients. Any baseline distress score greater than three will be reported to the patient's primary oncologist and clinic nurse.
2910470|NCT03176563||Women treated with the herbal drug Uva Ursi|Patients of the clinical trial REGATTA (NCT03151603) who have been randomized in the Uva Ursi arm.
2910471|NCT03176563||Women treated with antibiotics|Patients of the clinical trial REGATTA (NCT03151603) who have been randomized in the fosfomycin arm.
2910474|NCT03176524|Experimental|BioChaperone® glucagon formulation 1|Single subcutaneous fixed doses (50 µg and 1.0 mg)
2910475|NCT03176524|Experimental|BioChaperone® glucagon formulation 2|Single subcutaneous fixed doses (50 µg and 1.0 mg)
2910476|NCT03176524|Active Comparator|GlucaGen® HypoKit®|Single subcutaneous fixed doses (50 µg and 1.0 mg)
2910477|NCT03176511|Experimental|MOB+DTBC Group|A Matter of Balance plus Dual-Task Balance Challenge Group. Standardized MOB classes twice/week for 4 weeks, plus 15 minutes of DTBC each class. Each class is 2 hours 15 minutes.
2910478|NCT03176511|Active Comparator|MOB Group|A Matter of Balance Group. Standardized MOB classes twice/week for 4 weeks, plus 15 minutes of social time each class. Each class is 2 hours 15 minutes.
2910479|NCT03176498|Experimental|Experimental group|Basic medication：Aspirin Enteric-coated Tablets & Atorvastatin Calcium； Allogeneic umbilical cord mesenchymal stem cells
2910480|NCT03176498|Placebo Comparator|Control group|Basic medication：Aspirin Enteric-coated Tablets & Atorvastatin Calcium; Placebo：saline
2910481|NCT03176485|Experimental|ArmA: With Solar Simulated Light Exposure|
2910482|NCT03176485|Experimental|ArmB: With Solar Simulated Light Exposure (Vemurafenib/Dabraf)|Subjects in this study arm undergo the same procedures as Arm A, with the addition of a blood test for the presence of porphyrins
2910483|NCT03176485|No Intervention|ArmC: Without Solar Simulated Light Exposure|
2910484|NCT03176472|Experimental|ricolinostat|Ricolinostat 120 mg, taken once daily (QD) by mouth; each dose in 12 mL liquid formulation (10 mg ricolinostat per mL)
2910485|NCT03176472|Placebo Comparator|placebo|Placebo, 12 mL of liquid formulation with no active ingredient (i.e., ricolinostat), taken once daily (QD) by mouth
2910486|NCT03176459|Experimental|EXPAREL+bupivacaine TAP infiltration|Receive a single 20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL.
2910487|NCT03176459|Active Comparator|Active bupivacaine TAP infiltration|Receive 20 mL 0.25% bupivacaine expanded in volume with 40 mL normal saline for a total volume of 60 mL
2910488|NCT03176446|Active Comparator|Control Group|The children anesthesia will be traditional technique
2910489|NCT03176446|Active Comparator|Computerized Group|The children anesthesia will be computerized technique
2910490|NCT03176446|Active Comparator|DentalVibe Group|The children anesthesia will be DentalVibe technique
2910491|NCT03176446|Active Comparator|Computerized+DentalVibe Group|The children anesthesia will be computerized and DentalVibe technique
2910492|NCT03176420|Experimental|Symptomayic chronically occluded cervical ICA|
2910493|NCT03176407|Experimental|HemoPill acute|"Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours.~Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days."
2910494|NCT03176394|Experimental|BLASTX Lubricated Catheter|Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with BLASTX. This gel lubricates with the same viscosity as McKesson Jelly and has a biofilm disruptive active ingredient.
2910495|NCT03176394|Placebo Comparator|McKesson Jelly Lubricated Catheter|Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with McKesson Jelly. This jelly lubricates with the same viscosity as BLASTX but has no biofilm disruptive active ingredient.
2910496|NCT03176368|Experimental|Coconut Oil|Through a interventional/cohort design, we propose to study the experience of coconut oil over a three month period, allowing patients to use Biotene© oral lubricant (or another product of their choice) as an alternative to coconut oil if they so prefer.
2910497|NCT03176355|Other|Chronic dacryocystitis patients|
2910498|NCT03176342|Experimental|patch test arm|Patch test by selected allergens and drawing blood for ELIspot and LTT
2910499|NCT03176329|Other|INTELLIVENT-ASV / Conventional mode|Full closed-loop ventilation control (INTELLIVENT-ASV) is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to conventional ventilation 30 minutes before Nursing 2
2910500|NCT03176329|Other|Conventional mode / INTELLIVENT-ASV|Conventional ventilation control is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to full closed-loop ventilation (INTELLIVENT-ASV) 30 minutes before Nursing 2.
2910501|NCT03176316|Experimental|Naloxone|1 mg/ml oral solution administered enterally (oral, nasogastric, orogastric, gastrostomy, or jejunostomy ) every 8 hours for 48 hours
2910502|NCT03176303||Pulsed Electromagnetic Field|one group all of whom will be treated with the PEMF device
2910503|NCT03176277|Experimental|ONO-7475: dose escalation|Successive dose escalation cohorts to determine MTD
2910504|NCT03176264|Experimental|PDR001|
2910505|NCT03176251|Active Comparator|Control Group: Conventional Training Group|This group will receive 4 hours of didactic and hands-on sessions on colonoscopy theory and non-technical skills. Participants will also watch a video that demonstrates an ideal endoscopic procedure. After each didactic session, a short multiple-choice questionnaire based on the topics covered in that session will be administered. In addition to didactic training, the control group will be given six hours of expert-assisted instruction on low-fidelity (1 hour) and high-fidelity (5 hours) colonoscopy simulators. Six modules of increasing difficulty in colonoscopy will be taught using one-on-one feedback from an expert academic endoscopist. The endoscopy instructor will demonstrate techniques and provide feedback. During training on the high-fidelity simulator, the last two hours will take the form of the integrated scenario, which will feature a standardized patient (SP) and standardized nurse (SN). Feedback will be given after each integrated scenario by the instructor.
2910506|NCT03176251|Experimental|Intervention Group: Gamified-Integrated Curriculum (GIC)|The intervention group will receive the same core training as the control group with additional elements of gamification: leaderboards and badges. First, leaderboards will be used to track and rank participants' performances. This will be done through an anonymized ID tag that allows a participant to identify only their position on the leaderboard. This leaderboard will include 4 components: non-technical skills, technical skills, cognitive skills, and overall ranking. Scores will be aggregated only from participants training on the same days. The leaderboard will be displayed on a central laptop and/or TV screen and will be accessible at any time throughout the day. Second, participants in the GIC group will have the opportunity to be rewarded for their performances using achievement badges which are visual cues to the player that he or she has achieved something. Awards will be given to participants at the top of the leaderboard and with the most badges.
2910508|NCT03176225|Experimental|Test Arm|In Test Arm, the subjects will be implanted with test article - XenoSure patch. The interventions include: Open heart surgery to address the heart disease; Close the defects with XenoSure Patch
2910509|NCT03176225|Active Comparator|Control Arm|In Control Arm, the subjects will be implanted with comparator device - Polyester patch by Shanghai Chest Medical Technology Co. The interventions include: Open heart surgery to address the heart disease; Close the defects with Chest Polyester Patch
2910510|NCT03176212|Active Comparator|Beverage with milk fat globule membrane|In this arm, subjects consumed a beverage
2910511|NCT03176212|Placebo Comparator|Control|In this arm, subjects consumed a beverage with identical macronutrients
2910512|NCT03176199|Experimental|Control-released oxycodone|Control-released oxycodone Q12H, initial daily dose is 20 mg + immediate-released oxycodone for PRN
2910513|NCT03176199|Active Comparator|Immediate-released oxycodone|Immediate-released oxycodone Q6H, initial daily dose is 20mg + immediate-released oxycodone for PRN
2910514|NCT03176186|No Intervention|TH/TTM|Protocol-directed standard of care (including TH/TTM) dictated by the 2015 guidelines for Post-Cardiac Arrest Care from the American Heart Association and the European Resuscitation Council. Mechanical Ventilation delivered by individual site-sanctioned ventilator.
2910515|NCT03176186|Active Comparator|TH/TTM plus Xenon|50% xenon gas in addition to standard of care, including therapeutic hypothermia/targeted temperature management (TH/TTM).
2910516|NCT03176173|Experimental|Arm I (image guided radiation therapy)|Patients undergo radical-dose image guided radiation therapy daily for up to 10 days (within 2 weeks) while undergoing standard of care immunotherapy.
2910517|NCT03176173|Active Comparator|Arm II (standard of care immunotherapy)|Patients who decline to undergo radiation therapy receive standard of care immunotherapy.
2910518|NCT03176160||Patients receiving palliative regimen consisting of LITT|Patients with WHO grade IV malignant glioma who are approved for and receive the LITT (Laser Interstitial Thermal Therapy) procedure
2910519|NCT03176147||Pregnant women|Pregnant women are included during the ultrasound of T1. Written consent will be sought after delivery of the information notice.
2910520|NCT03176134|Experimental|MK-1986: 6 to <12 Years|Participants will receive MK-1986 ~4 mg/kg (≤200 mg daily dose) IV and/or oral suspension for 6 or 10 days. Exact dose will be banded based on Baseline body weight.
2910521|NCT03176134|Active Comparator|Comparator: 6 to <12 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 or 14 days
2910522|NCT03176134|Experimental|MK-1986 2 to <6 Years|Participants will receive MK-1986 ~6 mg/kg (≤200 mg daily dose) IV and/or oral suspension for 6 or 10 days. Exact dose will be banded based on Baseline body weight.
2910523|NCT03176134|Active Comparator|Comparator: 2 to <6 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 or 14 days
2910524|NCT03176134|Experimental|MK-1986: 28 Days to <2 Years|Participants will receive MK-1986 ≤200 mg daily dose, IV and/or oral suspension for 6 or 10 days. Exact mg/kg dose is to be determined based on results of another study covering the age range.
2910525|NCT03176134|Active Comparator|Comparator: 28 Days to <2 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 or 14 days
2910526|NCT03176134|Experimental|MK-1986-018: Birth to <28 Days (Term and preterm neonates)|Participants will receive MK-1986 ≤200 mg daily dose, IV and/or oral suspension for 6 or 10 days. Exact mg/kg dose is to be determined based on results of another study covering the age range.
2910527|NCT03176134|Active Comparator|Comparator: Birth to <28 Days (Term and preterm neonates)|Participants will receive comparator IV and/or oral per local standard of care for 10 or 14 days
2910528|NCT03176121|Experimental|Oxycodone treatment|"Patients will take either control-released oxycodone (OxyContin® 10mg and 20mg) or immediate-released oxycodone (OxyNorm® 5mg) or both for initial dose and used it to titrate his/her background dose.~After regular time assessment of the pain score (NRS), if the pain control is inadequate (NRS ≥ 4), a total daily dose in 24hrs will be summed up for the next dose titration until reach a stable dose (as defined as total daily dose is fixed for at least two weeks)."
2910529|NCT03176108|Experimental|CBT Group|"The CBT group benefits of an intervention based on the program Better manage its anger and its frustrations of 15 sessions for the children.~Parents participate in an CBT intervention of 8 sessions every 15 days. The session allow to develop adapted behaviors, to manage the disruptive behaviors and to improve the relations parents/children."
2910530|NCT03176108|Sham Comparator|Control Group|"The control group participates in an intervention of body mediation (theatre) of 15 session for the children.~Parents participate in an CBT intervention of 8 sessions every 15 days. The session allow to develop adapted behaviors, to manage the disruptive behaviors and to improve the relations parents/children."
2910531|NCT03176095|Active Comparator|Probiotic Group|"The participants in the Probiotic group were provided with dietary supplements in the form as sachets with freeze dried bacteria (active lactobacilli culture) mixed with maltodextrin for daily intake (1 per day). The powder was dissolved in water or other non-alcoholic cold drink mixed with fruit before ingestion.~The probiotic product consisted of two different bacterial strains."
2910532|NCT03176095|Placebo Comparator|Placebo Group|The participants in the Placebo group were provided with dietary supplements in the form as sachets with maltodextrin for daily intake (1 per day).
2910533|NCT03176082|Experimental|Intervention Group|"Intervention group will receive:~A reminder letter indicating need for screening~A FIT kit with completion instructions~A health information card including the ability to update records for current screening and opt out from colon cancer screening communication from the Mecklenburg County Public Health Department (MCPHD)~A pre-paid return mailer for FIT Kit"
2910534|NCT03176082|Active Comparator|Comparison Group|"Comparison group will receive:~A reminder letter indicating need for screening~Instructions for obtaining a FIT kit~A health information card including the ability to update records for current screening and opt out from colon cancer screening communication from the MCPHD"
2910564|NCT03175848|Experimental|Chemotherapy,radiotherapy|Lymphatic metastasis patients undergoing 2 cycles of chemotherapy(TP/TC), blood metastasis patients receiving 4 cycles of chemotherapy, then patients with therapeutic evaluation for (CR+PR+SD) will undergo the radiotherapy (external irradiation plus brachytherapy) for primary lesion area , all patients completed total 6 cycles of chemotherapy (TP/TC), and finally will determine the of treatment plans of metastasis areas based on tolerance and discuss results by MDT.
2956574|NCT02857387|Experimental|acute coronary syndrome|
2910535|NCT03176069|Active Comparator|Group A - women diagnosed with vaginismus|"All patients will be submitted to anamnesis, physical examination, examination of the pelvic floor. The ultrasound imaging requested at the ambulatorial routine will be performed by a skilled physician and accompanied by the project author. All images will be recorded and digitally stored and will later be measured and treated statistically. The patient will be lying in a supine position (belly up), with the pelvis in a neutral position, back at 45º and feet supported in stirrups, for the verification of the musculature shape and mobility.~The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:~Kinesiotherapy Manual therapy Electrotherapy (electric electrostimulation, ultrasound) Behavioral therapy"
2910536|NCT03176069|Active Comparator|Group B - women without a diagnosis of vaginismus|All patients will be submitted to anamnesis, physical examination, examination of the pelvic floor. The ultrasound imaging requested at the ambulatorial routine will be performed by a skilled physician and accompanied by the project author. All images will be recorded and digitally stored and will later be measured and treated statistically. The patient will be lying in a supine position (belly up), with the pelvis in a neutral position, back at 45º and feet supported in stirrups, for the verification of the musculature shape and mobility.
2910537|NCT03176056|Experimental|Low carbohydrate diet|Low carbohydrate diet limits carbohydrate <=90g/day
2910538|NCT03176056|Active Comparator|Calori restricted diet|Traditional diabetic diet
2910539|NCT03176043|Experimental|Thirst Driven infusion|Subjects who are self administering fluid will be instructed when (at any point in the experiment) they are experiencing thirst to request a fluid bolus with an electronic trigger. In response to this trigger the researcher will then deliver a 200ml bolus of IV fluid. After delivery of the fluid bolus, a lockout period is set for 15mins within which the researcher will not deliver another bolus in response to the trigger.
2910540|NCT03176043|Active Comparator|NICE infusion|Subjects receiving standard fluid maintenance will receive a baseline infusion rate of 30 mL/kg/24hr (1.25 mL/kg/hr). In addition to this a 500 mL bolus will be delivered if any of the following clinical signs, indicating hypovolaemia, are observed on regular examination: low peripheral perfusion, heart rate >90 /min, systolic BP <100 mmHg, respiratory rate >20, peripheral capillary refill >2sec. A maximum of 2000 mL of fluid will be delivered by additional boluses.
2910541|NCT03176030||Fortified foods|Fortified foods will be delivered to this group for 3 consecutive days mainly on a mid-meal trolley three times a day (between breakfast and lunch around 10am, between lunch and dinner around 3 pm, and in the evening). However, fortified foods will be available 24 hours and patients will be encouraged to order as many as they like anytime during the day.
2910542|NCT03176030||Baseline|Prior to implementing the intervention, dietary intake among eligible patients offered the standard hospital menu will be measured on the study wards for 24 hours during three days in each of the study wards to estimate the energy and protein intake.
2910543|NCT03176017|Active Comparator|Holmium Laser ejaculatory sparing TUIP|Holmium Laser ejaculatory sparing TUIP
2910544|NCT03176017|Placebo Comparator|Conventional TUIP|regular non ejaculatory sparing TUIP
2910545|NCT03176004|Experimental|Attention Bias Modification|Participants play a game in which they can move up in levels by reducing their reaction time to targets presented in the location of a threatening word.
2910546|NCT03176004|Active Comparator|Active Control Condition|Participants play a game in which they can move up in levels by reducing their reaction time to targets presented in the location of a word with a specific color.
2910547|NCT03176004|No Intervention|Wait List|Participants simply return after 8 weeks.
2910548|NCT03175991||ovarian masses patients|women of different age groups diagnosed as having an ovarian mass or accidentally discovered ovarian mass in non-complaining female by ultrasonography or Patients known to have primary that may give metastasis to the ovaries.
2910549|NCT03175978|Experimental|IGF/MTX|This arm will evaluate use of IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated MDS, CMML and O-AML. 765IGF-MTX at a dose of 0.20 to 2.5 µequivalents per kg is administered as an IV infusion over 1.5 hours on days 1, 8 and 15 of a 28 day cycle. Treatment continues until disease progression, as assessed after 2 cycles, unacceptable toxicity, or patient refusal.
2910550|NCT03175952||PCI|
2910551|NCT03175939|Experimental|CCRT alone|External beam radiotherapy > 66 Gy Cisplatin 60 mg/m2 IV D1, 5-FU 600 mg/m2 IV D1-5 at week 1 and 5 of radiotherapy Modified for IMRT: Cisplatin 60 mg/m2 IV D1, 5-FU 600 mg/m2 IV D1-3 at week 1, 4 and 7 of radiotherapy
2910552|NCT03175926|Experimental|Group 1|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
2910553|NCT03175926|Experimental|Group 2|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
2910554|NCT03175926|Experimental|Group 3|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
2910555|NCT03175913|Experimental|Vapocoolant spray group|vapocoolant spray was applied for 10 second
2910556|NCT03175913|Active Comparator|Local infiltration group|3 ml of 2% lidocaine infiltrated subcutaneously
2910557|NCT03175900|Experimental|Naoan dripping pills for migraine|Drug: Naoan dripping pills, Chinese patent medicine，pill. Patients will receive treatment with Naoan dripping pills for 12 weeks, Fenbid can be taken if headache is unbearable Procedure: MRI scanning（fMRI and DTI）
2910558|NCT03175900|Placebo Comparator|Placebo|Drug: Placebo, pill. Patients will receive treatment with placebo for 12 weeks, Fenbid can be taken if headache is unbearable Procedure: MRI scanning （fMRI and DTI）
2910559|NCT03175887|Experimental|Intervention Arm|Participants will receive TMS. They will be randomized to either the left dorsolateral prefrontal cortex or the medial prefrontal cortex.
2910560|NCT03175887|Other|Treatment Arm|"After the experimental arm, if a patient was randomized to the medial prefrontal cortex during the experimental arm and it did not work for them, they have the option of returning for a session of TMS to the FDA-approved dorsolateral prefrontal cortex.~If they were assigned to the dorsolateral prefrontal cortex, they are not eligible to return for another set of treatment."
2910561|NCT03175874|Other|osteoporosis and alzheimer|patient with osteoporosis and alzheimer hospitalized for total hip prosthesis.
2910562|NCT03175874|Other|osteoporosis without alzheimer|Patient with osteoporosis without alzheimer hospitalized for total hip prosthesis.
2910563|NCT03175874|Other|Patient with arthrosis without alzheimer|Patient with arthrosis without alzheimer hospitalized for total hip prosthesis.
2910689|NCT03174912|Active Comparator|Group 3|Patients treated with BCG
2910565|NCT03175835|Experimental|Rosuvastatin 20 mg & CKD-519 200 mg|"Period 1: Treatment A(Rosuvastatin 20 mg(20 mg X 1 tablet))~Period 2: Treatment B(CKD-519 200 mg(100 mg X 2 tablets))~Period 3: Treatment C(Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets))"
2910566|NCT03175822|Experimental|Visual Arts Training|Visual Arts Training
2910567|NCT03175822|No Intervention|Waitlist Control|Waitlist Control
2910568|NCT03175809|Active Comparator|PFM training|4 sessions (40 minutes approximately), Twice a week for 2 weeks of pelvic floor training with electromyographic biofeedback.
2910569|NCT03175809|Experimental|PFM training plus dry needling|PFM training associated with the use of dry needling over abdominal, gluteal and lombar miofascial trigger points.
2910570|NCT03175796|Experimental|IMH-HV Treatment Group|Infant Mental Health-Home Visiting. Weekly home visits for up to one year by a trained IMH-HV treatment provider. Treatment delivery consistent with the IMH-HV manual.
2910571|NCT03175796|No Intervention|Treatment as Usual Control Group|No intervention provided as part of participation in this study; families are free to access community resources including any available treatment(s) in the community.
2910572|NCT03175783|Experimental|Treatment Group|Treatment group will receive intervention by putting on Fitbit Zip activity tracker with automatic step counts feedback throughout the study.
2910573|NCT03175783|Sham Comparator|Control Group|Control group will be put on intervention with same Fitbit Zip activity tracker but without automatic feedback for same duration of intervention.
2910574|NCT03175770||Patients with benign or malign tumor in the oropharynx|Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
2910575|NCT03175757|Experimental|Cholesterol Health Formulation|Turmeric and black cumin seed preparation
2910576|NCT03175757|Placebo Comparator|Placebo|Placebo
2910577|NCT03175744|Experimental|Stellarex DCB|Spectranetics Stellarex Drug Coated Balloon
2910578|NCT03175744|Active Comparator|PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter
2910579|NCT03175731|Experimental|Proton Pump Inhibitors|Pantoprazole(or other PPIs) 40-80mg intravenously everyday before endoscopic treatment. And pantorazole(or other PPIs)tablet 40mg by mouth everyday for 2 weeks after endoscopic treatment.
2910580|NCT03175731|Placebo Comparator|Placebo|Placebo 40-80mg intravenously everyday before endoscopic treatment.And placebo tablet 40mg by mouth everyday for 2 weeks after endoscopic treatment.
2910581|NCT03175718|Experimental|VAC Wound Dressing|Limb salvage surgery is performed on sarcoma patients 4-6 week post radiotherapy. These patients will be randomized to receive 2 weeks of Incisional Negative pressure wound therapy.
2910582|NCT03175718|Active Comparator|Control Wound Dressing|Limb salvage surgery is performed on sarcoma patients 4-6 week post radiotherapy. These patients will be randomized to receive 2 weeks of standard gauze dressing with no negative pressure application.
2910583|NCT03175705|Experimental|Autologous T cell therapy+Tegafur+Interleukin-2 (IL-2)|Autologous in vitro expanded HCC antigens-specific CD8+ T lymphocytes in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with relapsed/advanced HCC.
2910584|NCT03175692||critical illness in infants and children|Those infants and children who has congenital metabolism disorder or acute disorder.
2910585|NCT03175679|Experimental|Autologous iNKT Cells + Tegafur +Interleukin-2(IL-2)|Autologous in vitro expanded iNKT cells in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with advanced HCC.
2910586|NCT03175666|Experimental|Nant TNBC|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
2910587|NCT03175653|Experimental|Arm A - Oxycodone Pill A|Participants in this study arm will receive a prescription for a lower number oxycodone (oxycodone A) pills for post-cesarean pain control.
2910588|NCT03175653|Active Comparator|Arm B - Oxycodone Pill B|Participants in this study arm will receive a prescription for a higher number of oxycodone (oxycodone B) pills for post-cesarean pain control.
2910589|NCT03175640|Experimental|Implementation intervention|
2910590|NCT03175627|Active Comparator|Filtek One|Bulk fill composite material used for posterior tooth fillings.
2910591|NCT03175627|Active Comparator|Filtek Z250|Composite material used for incremental filling of posterior teeth.
2910592|NCT03175614|Active Comparator|Control: Lifestyle counseling|Counseling on physical activity and nutrition.
2910593|NCT03175614|Experimental|Intervention group|Add for three months a Smartphone with an app (EVIDENT III) and a Smartband to lose weight and improve physical activity.
2910594|NCT03175588|Experimental|virtual rehabilitation|video based exercise
2910595|NCT03175588|No Intervention|physical Activity|different type of physical Activity
2910596|NCT03175562|Experimental|Test product|All the participants will have the test product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and waistline and away from the spinal mid-line.
2910597|NCT03175562|Other|Reference product|All the participants will have the reference product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and waistline and away from the spinal mid-line.
2910598|NCT03175549|Active Comparator|Otezla (apremilast)|100 mg (50 mg/bid) taken orally for 5 days after a 9 day titration to recommended dose
2910599|NCT03175549|Placebo Comparator|Placebo|Placebo pill taken orally for 14 days
2910600|NCT03175536||HDHP with PDL|Enrollees switched from a traditional plan to a high-deductible health plan (HDHP) with a preventive drug list (PDL)
2910601|NCT03175536||HDHP without PDL|Enrollees switched from a traditional plan to a high-deductible health plan (HDHP) without a preventive drug list (PDL)
2910602|NCT03175536||traditional plan|Enrollees who remained in a traditional health plan with a deductible < $500
2910603|NCT03175523|Active Comparator|Imaging guided Bioresorbable scaffold|
2910604|NCT03175523|Experimental|QCA-guided Bioresorbable scaffold|quantitative coronary angiography guided Bioresorbable scaffold
2910605|NCT03175510||patients group|Patients with low back pain (18-65 years)
2910746|NCT03174483|Experimental|hypertonic saline|nasal spray will be used twice daily
2910606|NCT03175497|Experimental|Telatinib mesylate treatment arm|"Open label, single arm trial. For the 1st phase: three cohorts, and each with 3-6 solid tumor patients who will be treated with telatinib at predetermined dose: 600 mg bid, 900 mg bid, or 1200 mg bid, respectively.~For the 2nd phase, one cohort with 12 GC patients who will be treated with telatinib at 900 mg bid"
2910607|NCT03175484||Observation TLX|surgical specialty ( including anesthesia) residents and nurses undergoing High Fidelity Simulation scenarios.
2910608|NCT03175471||Patients with autoimmune liver disease|"Patients (6-23 y.o.) with established clinical diagnosis of AIH or suspected diagnosis of AIH based on elevated serum AST or ALT, elevated IgG level >1.1 ULN, elevated titer of autoantibodies, including ANA, SMA, LKM, LC-1 or SLA, which is consistent with the simplified criteria for the diagnosis of AIH in children will be enrolled.~Patients (6-23 y.o.) with established clinical diagnosis of PSC or Suspected diagnosis of PSC supported by abnormal cholangiogram (ERCP or MRCP) or elevated GGT>1.5 ULN and dilated bile ducts by liver ultrasound will be enrolled."
2910609|NCT03175458|Experimental|sinus lift,implant placement,tenting|elevation of the sinus membrane with simultaneous implant placement without the use of any bone graft material(tenting technique)
2910610|NCT03175458|Active Comparator|sinus lift,implant placement,bovine bone|elevation of the sinus membrane with simultaneous implant placement together with deproteinized bovine bone graft substitute for augmentation
2910611|NCT03175445||mandible CBCT scans in males|74 males CBCT scan by planmeca promax 3D Mid machine using 90 kVp, 10 mA, 14 seconds and 200×60 mm FOV with a 0.2 mm voxel size.
2910612|NCT03175445||mandible CBCT scans in female|74 females CBCT scan by planmeca promax 3D Mid machine using 90 kVp, 10 mA, 14 seconds and 200×60 mm FOV with a 0.2 mm voxel size
2910613|NCT03175432|Experimental|Cohort A - Asymptomatic|"Cohort A consists of 25 asymptomatic participants.~Participants treated with Bevacizumab and Atezolizumab administered intravenously every 3 weeks until progression or death.~Neurocognitive exam given to English speaking participants at baseline and on Day 1 of Cycles 5, 9, and every 4 cycles after that.~Questionnaires completed at baseline and on Day 1 of Cycles 5, 9, and every 4 cycles after that."
2910614|NCT03175432|Experimental|Cohort B - Mildly Symptomatic or Asymptomatic|"Cohort B consists of 15 participants that are either mildly symptomatic, or asymptomatic, but requiring a low dose of systemic steroids (no higher than 4 mg/day of oral Dexamethasone or equivalent).~Participants treated with Bevacizumab and Atezolizumab administered intravenously every 3 weeks until progression or death.~Neurocognitive exam given to English speaking participants at baseline and on Day 1 of Cycles 5, 9, and every 4 cycles after that.~Questionnaires completed at baseline and on Day 1 of Cycles 5, 9, and every 4 cycles after that."
2910615|NCT03175393||postprandial dyslipidemia|
2910616|NCT03175380|Experimental|bacillus Calmette-Guérin|All participants will receive a total of two doses of bacillus Calmette-Guérin (BCG), by intradermal injection, approximately 6 months apart. They will be observed for 284 days
2910617|NCT03175367|Experimental|Group A: dosing regimen 1|SC Evinacumab once QW for 16 weeks
2910618|NCT03175367|Experimental|Group A: dosing regimen 2|SC Evinacumab once Q2W for 16 weeks (alternating with matching placebo on opposite weeks)
2910619|NCT03175367|Experimental|Group A: dosing regimen 3|SC Evinacumab once QW for 16 weeks
2910620|NCT03175367|Experimental|Group A: matching placebo|Placebo SC once QW for 16 weeks
2910621|NCT03175367|Experimental|Group B: dosing regimen 1|Intravenous (IV) Evinacumab once Q4W for 24 weeks
2910622|NCT03175367|Experimental|Group B: dosing regimen 2|IV Evinacumab once Q4W for 24 weeks
2910623|NCT03175367|Experimental|Group B: matching placebo|Placebo IV once Q4W for 24 weeks
2910624|NCT03175354|Experimental|ALX-101 Gel 1.5% vs. ALX-101 Gel Vehicle|ALX-101 Gel 1.5% applied twice daily for 42 days to one treatment area and ALX-101 Gel Vehicle applied twice daily for 42 days to a second treatment area. Treatments will be randomly assigned to bilateral target areas.
2910625|NCT03175354|Experimental|ALX-101 Gel 5% vs. ALX-101 Gel Vehicle|ALX-101 Gel 5% applied twice daily for 42 days to one treatment area and ALX-101 Gel Vehicle applied twice daily for 42 days to a second treatment area. Treatments will be randomly assigned to bilateral target areas.
2910626|NCT03175341|Experimental|Vitamin C Supplement|"Ascorbic Acid (AA) with neoadjuvant chemotherapy. Participants received an initial loading dose of 1,5 g Ascorbic Acid (i.v in 100 ml sterile water) on Day 1 followed by 0,75g Ascorbic Acid (i.v in 100 ml sterile water) on Day 2-4 at each chemotherapy cycle and concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician.~Ascorbic Acid is administered intravenously before neoadjuvant therapy in D1"
2910627|NCT03175341|Active Comparator|Placebo|"Placebos (normal saline (0.9%) with neoadjuvant chemotherapy. 100 ml normal saline 0.9% (placebo) will be administered (i.v) by the same scheme as Ascorbic Acid on Day 1 and respectively Day 2-4 at each chemotherapy cycle.~Concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician."
2910628|NCT03175328|Experimental|early group|In the early group, continuous renal replacement therapies was started immediately after randomization.
2910629|NCT03175328|Experimental|delayed group|In the delayed group, continuous renal replacement therapies was initiated if at least one of the following criteria was met: KDIGO 3, severe hyperkalemia, metabolic acidosis, pulmonary edema, blood urea nitrogen level higher than 112 mg per deciliter, or oliguria for more than 72 hours after randomization.
2910630|NCT03175315|Experimental|FLASH|"Intervention: Conduct of the newly developed treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH).~FLASH consists of 4 lessons focusing on empowering patients to autonomously use flash glucose monitoring (FGM) in their daily routine. Patients learn to effectively interpret the different information provided by FGM in order to improve not only glycemic control but also to improve the implementation of insulin therapy in daily life. Psychological and motivational aspects of living with diabetes and handling of the FGM are addressed as well."
2910631|NCT03175315|No Intervention|Waiting List|Diabetic patients using FGM receive treatment as usual until the last measurement point. After completion of the study, they are offered participation in the FLASH program.
2910632|NCT03175302||Surgical group|Baseline preoperative digital cognitive testing performance in adults to predict frequency and severity of clinician reported outcomes within the first three months post-surgery.
2910633|NCT03175302||Control|Non-surgery matched peers with the same testing.
2910747|NCT03174483|Active Comparator|fluticasone|nasal spray will be used once daily
2910634|NCT03175289|Active Comparator|Arm I (standard of care, home exercises)|Patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. Patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. Patients also perform prescribed exercises at home daily for 3 sets of 10 repetitions.
2910635|NCT03175289|Experimental|Arm II (standard of care, home exercises, EMST)|Patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. Patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. Patients perform prescribed exercises at home daily for 3 sets of 10 repetitions. Patients also participate in an EMST session over 30 minutes comprising of 5 sets of 5 repetitions daily for 5 days per week for 6 weeks during chemoradiation therapy
2910636|NCT03175263||Patients with chronic migraine|Patients with chronic migraine refractory to conventional treatments
2910637|NCT03175250|Active Comparator|Health Education|This condition included live health education followed by health education videos on HIV risks, testing, and condom use. The videos were presented over laptop.
2910638|NCT03175250|Active Comparator|Action Plan|This condition included live health education followed by computerized procedures focusing on action plans for HIV testing and condom use and some of the same health education videos in the Health Education condition.
2910639|NCT03175250|Experimental|Memory Practice|This condition included live health education followed by computerized action plan procedures (as in the Action Plan condition), followed by several memory practice procedures also delivered over laptop. The memory practice procedures were designed to help participants more readily retrieve and use action plans in critical situations.
2910640|NCT03175237|Experimental|Group of Motor Patterns|For the mirror therapy protocol applied to the Motor Standard, each patient was treated with 15 mirror therapy sessions, 3 times a week for a total duration of 50 minutes. There were 4 exercises of voluntary range of motion involving the extension and mass flexion of the fingers, adduction and abduction of the fingers, pronation and supination of the forearm and elbow extension with associated shoulder elevation.
2910641|NCT03175237|Experimental|Group of Functional Activities|For the mirror therapy protocol applied to functional activities, four functional exercises were performed: fitting of pieces stimulating fine and thick gripping, stacking of cubes / cups and transfer of objects of different shapes and sizes. Each patient was treated with 15 mirror therapy sessions, 3 times a week with a total duration of 50 minutes
2910642|NCT03175224|Experimental|Single-Arm|CBT-101Oral Capsules
2910643|NCT03175211|Experimental|BI 456906|
2910644|NCT03175211|Placebo Comparator|Placebo|
2910645|NCT03175198||Prazaxa Capsules Group|
2910646|NCT03175185||Parents of children with ADHD|100 parents of 50 children who were diagnosed with ADHD and
2910647|NCT03175185||Parent of children without ADHD|100 parents of 50 children who are ADHD free as a control group
2910648|NCT03175172|Experimental|Experimental|CRS-207 and pembrolizumab will be administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) will be administered by intravenous infusion (IV) over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10^9 colony-forming units [CFU]) will be administered IV over 1 hour on Day 2. If the infusions are well tolerated, pembrolizumab and CRS-207 may be administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab will continue to be administered on Day 1 at each treatment cycle (every 3 weeks); CRS-207 will be administered once every 6 weeks. Treatment cycles will continue for up to 24 months as long as there is adequate safety and potential for clinical benefit.
2910649|NCT03175159|Active Comparator|Standard of Care (SOC)|Sexual risk-reduction counseling sessions.
2910650|NCT03175159|Active Comparator|Time & Intensity Matched Control|Relaxation therapy with educational support.
2910651|NCT03175159|Experimental|Behavioral Activation & Risk Reduction Counseling|Behavioral activation with risk reduction counseling.
2910652|NCT03175146|Experimental|Experimental|Stereotactic Body Radiation Therapy
2910653|NCT03175133|Experimental|Strength training|Strength exercises for ankle PF, hip abduction, and trunk muscles. Exercises will be done in three standard positions of supine, sidelying, prone, seated, and standing. Exercises during the initial 4 weeks will be completed 2x week with supervision of a physical therapist and 2x week at home, for a total of 4x week. For the final 4 weeks of the intervention will be completed 1x week with supervision and 3x week at home.
2910654|NCT03175120|Experimental|Insulin degludec/liraglutide|
2910655|NCT03175120|Active Comparator|Insulin degludec|
2910656|NCT03175107|Experimental|PD_patients|Patients with Parkinson disease or Parkinsonism (characteristic symptoms such as rigidity, extrapyramidal symptoms), with functional disorders in upper extremities and minor problems at daily activities, with the level 2-3 in the Hoehn and Yahr Scale. They will perform exergaming at home for up to 4 weeks.
2910657|NCT03175094|Experimental|Holistic Health Recovery Program for HIV+ Intervention|
2910658|NCT03175094|No Intervention|Control|
2910659|NCT03175081|Experimental|Test group|Patients will undergo elective bariatric surgery with ropivacaine diluted in normal saline injected along the stomach region at the end of the surgical procedure.
2910660|NCT03175081|Experimental|Control group|Patients will undergo elective bariatric surgery with only normal saline injected along the stomach region at the end of the surgical procedure.
2910661|NCT03175068|Active Comparator|CBT|The clinical psychologist will use a manualized CBT approach tailored to MDD or gSAD. Over a 12-week period sessions will include core CBT strategies -- psychoeducation, cognitive intervention (e.g., cognitive restructuring), behavioral changes (i.e., fear exposure, behavioral activation strategies) and relapse prevention.
2910662|NCT03175068|Placebo Comparator|ST|The clinical psychologist will use an ST approach that resembles client-centered therapy of Carl Rogers (1951) which has been used as a control psychotherapy. The manual is based on supportive psychotherapy principles. Over a 12-week period sessions will emphasize reflective listening and elicitation of affect. In contrast to CBT, therapists allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathetic comments. Therapists will refrain from delineating any CBT theoretical framework and avoided cognitive and behavioral techniques that might overlap with CBT.
2910663|NCT03175055|Experimental|Phoenix|Phoenix
2956808|NCT02855671||Severe sepsis/septic shock|
2910664|NCT03175042||Pregnant patients with anemia|Pregnant patients meeting Center for Disease Control (CDC) guidelines for anemia during pregnancy will be screened for participation in the study. In the outpatient setting at our institution it is standard of care that these women have complete blood counts (CBCs) drawn every 4-6 weeks. At the time of the routine blood draw, we will place the non invasive monitor on their finger to record the hemoglobin value. We will be comparing the hemoglobin values obtained from the CBC to that obtained from the non-invasive monitor.
2910665|NCT03175029|Experimental|TAC-302|
2910666|NCT03175029|Placebo Comparator|Placebo|
2910667|NCT03175016|Experimental|DEBIRI|Transcatheter arterial chemoembolization(TACE) with Irinotecan eluting-bead(DEBIRI)
2910668|NCT03175003|Active Comparator|Food Product 1|Macronutrient similar to experimental, micronutrient lower than experimental
2910669|NCT03175003|Active Comparator|Food Product 2|Macronutrient lower than experimental, micronutrient similar to experimental
2910670|NCT03175003|Experimental|Food Product 3|Experimental 1
2910671|NCT03175003|Experimental|Food Product 4|Experimental 2
2910672|NCT03174990||Aspirin responsive|The participant is shown to be responsive to platelet activity inhibition by aspirin, as determined by testing with VerifyNow
2910673|NCT03174990||Aspirin non-responsive|The participant is shown to be non-responsive to platelet activity inhibition by aspirin, as determined by testing with VerifyNow
2910674|NCT03174990||Clopidogrel responsive|The participant is shown to be responsive to platelet activity inhibition by clopidogrel, as determined by testing with VerifyNow
2910675|NCT03174990||Clopidogrel non-responsive|The participant is shown to be responsive to platelet activity inhibition by clopidogrel, as determined by testing with VerifyNow
2910676|NCT03174977|Experimental|18F-Raltegravir|
2910677|NCT03174964|Experimental|Treatment group|IVIg group
2910678|NCT03174964|No Intervention|Control group|Patients who do not receive any treatment despite a history of Recurrent Implantation Failure problem as controls
2910679|NCT03174951|Experimental|Treatment group|IVIg group
2910680|NCT03174951|No Intervention|control group|Patients who do not receive any treatment despite a history of Recurrent Pregnancy Loss problem as controls
2910681|NCT03174938|Other|COHORT A: Cognitively healthy younger individuals (40-65 y)|"We will recruit 250 cognitively healthy individuals from the Malmö Offspring study, which is an epidemiological study. The participants will be stratified according to a) family history of dementia in first degree relatives (with onset before 80 years of age) and b) APOE 4 genotype; i.e. 25% will have no family history and no APOE4 allele, 25% will have a family history and no APOE 4 allele, 25% will have no family history and at least one APOE 4 allele, 25% will have a family history and at least one APOE 4 allele.~FOLLOW-UP FOR 8 YEARS Every 2 years new clinical, cognitive, neurological, and psychiatric assessments will be performed as well as CSF/blood sampling.~MRI, Tau PET and Amyloid PET will be done every 4 years in all cases, and Tau PET and MRI every two years if the subject is amyloid positive at baseline.~An auxiliary cohort (termed Cohort A2) of 40 healthy individuals aged 20-40 years of age will also be included."
2910682|NCT03174938|Other|COHORT B: Cognitively healthy elderly individuals (66-100 y)|"We will recruit 250 cognitively healthy individuals from the Malmö/Lund region, where we will aim to include as many individuals as possible that did participate in the Malmö Diet and Cancer study during the early 1990's. The participants will be stratified according to a) family history of dementia in first degree relatives (with onset before 80 years of age) and b) APOE 4 genotype; i.e. 25% will have no family history and no APOE 4 allele, 25% will have a family history and no APOE 4 allele, 25% will have no family history and at least one APOE 4 allele, 25% will have a family history and at least one APOE 4 allele.~FOLLOW-UP FOR 8 YEARS Every 2 years new clinical, cognitive, neurological, and psychiatric assessments will be performed as well as CSF/blood sampling.~MRI, Tau PET and Amyloid PET will be done every 4 years in all cases, and Tau PET and MRI every two years if the subject is amyloid positive at baseline."
2910683|NCT03174938|Other|COHORT C: SCD and MCI|"300 patients with either subjective cognitive decline (SCD; n=150) or mild cognitive impairment (MCI; n=150) will be recruited in a consecutive fashion from the Skåne University Hospital and Ängelholm Hospital. We will only include cases where the medical doctor believes that the cognitive symptoms are caused by an incipient neurocognitive disorder. For example, all cases with evidence of brain amyloid pathology (i.e. an abnormal CSF Aβ42/40 ratio) will be included.~FOLLOW-UP FOR 6 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done every 2 years. Amyloid PET will be performed at baseline and after 4 years.~A auxiliary cohort (Cohort C2) 150 cases with SCD/MCI where the doctor does not suspect incipient neurocognitive disorder, will undergo the same baseline investigations, but they will be followed up clinically only after 2, 4 and 8 y."
2910684|NCT03174938|Other|COHORT D: Dementia due to Alzheimer's disease|"175 patients with mild to moderate dementia due to Alzheimer's disease (AD) will be recruited from the Skåne University Hospital and Ängelholm Hospital in southern Sweden. We will include 50 cases aged 40-65 years of age, 75 cases aged 66-79 years of age and 50 cases aged 80-100 years of age.~FOLLOW-UP FOR 2 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done at baseline and after 2 years. No Amyloid PET in this group."
2910685|NCT03174938|Other|COHORT E: Other dementias|"Patients with primary neurodegenerative disorders other than Alzheimer's disease will be recruited:~140 cases with Frontotemporal dementia (FTD)-related disorders, including behavioral variant of FTD (bvFTD) (n=50), Progressive nonfluent aphasia (PNFA) (n=20), semantic dementia (SD) (n=20), Progressive supranuclear palsy (PSP) (n=30), Corticobasal degeneration (CBD) (n=20).~50 cases with subcortical Vascular dementia (VaD).~150 cases with either Parkinson's disease (PD) (n=50), Parkinson's disease with dementia (PDD) (n=30), Dementia with Lewy Bodies (DLB) (n=50), Multiple system atrophy (MSA) (n=20).~FOLLOW-UP FOR 2 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done at baseline and after 2 years. No Amyloid PET in this group."
2910686|NCT03174925|Experimental|Diagnostic (elastography)|Patients undergo elastography over 10 minutes prior to fine needle aspiration or surgical resection of the thyroid nodule.
2910687|NCT03174912|Active Comparator|Group 1|Whole patient group (patients not treated with BCG and patients treated with BCG)
2910688|NCT03174912|No Intervention|Group 2|Patients not treated with BCG
2910690|NCT03174899|Experimental|Stage1:eGFR; ≥90 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. . ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys—and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
2910691|NCT03174899|Experimental|Stage 2: eGFR; 60-89 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys—and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
2910692|NCT03174899|Experimental|Stage 3:eGFR; 30-59 mL/min/1.73 m2|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys—and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
2910693|NCT03174899|Experimental|Stage 4:eGFR; 15-29 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaginggradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys—and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
2910694|NCT03174899|Experimental|Stage 5:eGFR; < 15 mL/min/1.73 m2.|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys—and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
2910695|NCT03174886|Experimental|AADvac1 40 µg|The intervention consists of Axon Peptide 108 coupled to keyhole limpet haemocyanin (KLH) 40 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
2910696|NCT03174886|Experimental|AADvac1 160 µg|The intervention consists of Axon Peptide 108 coupled to KLH 160 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
2910697|NCT03174873|Other|Laparoscopy for unexplained infertile couples|
2910698|NCT03174860|Experimental|Diclofenac Potassium 50mg tab|Diclofenac Potassium 50mg (Cataflam) tablet to be administered one hour before treatment.
2910699|NCT03174860|Placebo Comparator|Placebo|Placebo to be administered one hour before treatment.
2910700|NCT03174847||Medical Treatment|Patients who undergo medical treatment, in view of bilateral PA, or unilateral PA not keen for surgery, or indeterminate (lack of localisation on tests)
2910701|NCT03174847||Surgical Treatment|Patients with unilateral PA who underwent adrenalectomy
2910702|NCT03174834|Other|Bladder Stimulation Technique|Single arm study, where urine collection will be done via bladder stimulation and subsequently catheterization if they meet the eligibility criteria.
2910703|NCT03174821|Experimental|Insulin pump therapy|The total requisite amount=0.44×weight (Kg); The preprandial and basal amount respectively took up 50% of integral dose.15 minutes before meal the preprandial insulin was equally given by 3 times. The basal insulin was pumped at 00:00-3:00，3:00-8:00，8:00-14:00，14:00-20:00，20:00-24:00.
2910704|NCT03174821|No Intervention|Normal control|The subjects were asked to maintain normal diet and lifestyle until the end of the observation period.
2910705|NCT03174808|Experimental|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend group sessions led by an instructor experienced in MBSR in an academic setting.
2910706|NCT03174795|Experimental|RO7079901 and Meropenem|Participants will receive RO7079901 and meropenem. The duration of study drug treatment will be determined by the investigator after evaluation of the participant's response to study drug treatment. Participants should receive a minimum treatment period of 3 days and up to 14 days of intravenous (IV) study drug treatment.
2910707|NCT03174782|Active Comparator|Treatment|Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.
2910708|NCT03174782|Placebo Comparator|Control|Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
2910709|NCT03174769|Active Comparator|Normal Protein with weight loss|"weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age~Meal Pattern USDA Healthy U.S.-Style Eating Pattern with ~5 oz eq of protein foods for 12 wk"
2910710|NCT03174769|Experimental|High protein and weight loss|"weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age~Meal Pattern USDA Healthy U.S.-Style Eating Pattern with ~12.5 oz eq of protein foods for 12 wk"
2910711|NCT03174756|Experimental|HOCl 0.025%|15 ml of Hypochlorous acid mouthwash at 0.025%
2910712|NCT03174756|Experimental|HOCl 0.05%|15 ml of Hypochlorous acid mouthwash at 0.05%
2910713|NCT03174756|Active Comparator|CHX 0.2%|15 ml of chlorhexidine mouthwash at 0.2%
2910714|NCT03174756|Active Comparator|CHX 0.025%|15 ml of chlorhexidine at mouthwash0.025%
2910715|NCT03174756|Placebo Comparator|Placebo|15 ml of Sterile water
2910716|NCT03174743|Placebo Comparator|Convential Ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of 60%.
2910717|NCT03174743|Placebo Comparator|Convential Ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
2910718|NCT03174743|Active Comparator|Protective ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 6 cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
2910719|NCT03174743|Active Comparator|Protective ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 6 cmH2O and a FiO2 of 100% with lung recruitment maneuvers.
2910720|NCT03174730|Experimental|Growth mindset|In addition to SmartQuit (the app), study participants will receive the content in the form on one growth mindset tip (sent in an email) per day starting on the first day of the study. Email exercises will be sent out every 3 days and there are a total of 8 emails.
2910721|NCT03174730|Other|Control|Participants will get SmartQuit, but not the growth mindset intervention.
2910722|NCT03174717|Experimental|Music intervention|LTC residents will participate in an individualized music performance with a musician
2910723|NCT03174691|Experimental|Hormonal levels|Collect blood samples Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
2910724|NCT03174678|Experimental|Dexmedetomidine|Group administered 1µg/kg dexmedetomidine oral
2910725|NCT03174678|Other|Control|Apple juice
2910726|NCT03174665||Patients with Pain|"Patients who had upper limb surgery or other trauma with a history of persistent spontaneous and/or evoked pain with duration of at least 3 months.~Patients will be recruited to the study by using a postal follow up questionnaire. Patients who judge their pain at least moderate and/or affecting daily life by will be eligible and asked to participate. Patients will visit the Pain Clinic once. Oral and written information about the study will be provided, informed consent obtained. The affected nerve will be identified and the anatomy verified by ultrasound when needed."
2910727|NCT03174665||Patients with no pain|Patients operated with nerve suture surgery after a lesion of the nerves of upper extremity will be recruited to the study by using a postal follow up questionnaire. Patients with no pain will be asked to participate. Patients will visit the Pain Clinic once. Oral and written information about the study will be provided, informed consent obtained. The affected nerve will be identified and the anatomy verified by ultrasound when needed.
2910728|NCT03174639|Experimental|Inverted and free ILM insertion|Both inverted and free ILM flaps were inserted into the macular hole
2910729|NCT03174626|Experimental|WLSCC Intervention|Williams LifeSkills framework on stress management and cancer care
2910730|NCT03174626|Other|Usual Care|No intervention is provided
2910731|NCT03174613|Experimental|LC51-0255|tablets, PO
2910732|NCT03174613|Placebo Comparator|Placebo|tablets, PO
2910733|NCT03174600||Stroke patients|Stroke patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months
2910734|NCT03174587|Experimental|CS20AT04|Test group : CS20AT04 (allogenic bone marrow derived mesenchymal stem cells.)
2910735|NCT03174561|Other|Inuline, Choline and Silymarin + Diet|"Patients diagnosed with Irritable bowel syndrome who will follow diet restrictions together with a dietary supplement.~Intervention: Dietary Supplement, a combination of Inuline, Silymarin and Choline The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days"
2910736|NCT03174561|Other|Diet restriction|Patients diagnosed with Irritable bowel syndrome who will follow diet restrictions for 28 days. After the first month the patients are crossed between groups.
2910737|NCT03174548|Experimental|Fed Tablet period (Test, T)|Sotagliflozin oral in fed conditions
2910738|NCT03174548|Experimental|Fasted Tablet period (Reference, R)|Sotagliflozin oral in fasting conditions
2910739|NCT03174548|Experimental|Oral Solution period (S)|Sotagliflozin oral solution in fasting conditions
2910740|NCT03174522|Experimental|REX-001|REX-001 is a cell suspension of autologous bone marrow mononuclear cells (BM-MNCs) composed of several mature cell types.
2910741|NCT03174522|Placebo Comparator|Placebo|The final formulation of the placebo will be a diluted suspension of red blood cells.
2910742|NCT03174509|Active Comparator|Positive Pressure Extubation|Positive pressure extubation is used for patients in this group.
2910743|NCT03174509|Active Comparator|Traditional Extubation|Traditional extubation is used for patients in this group.
2910744|NCT03174496||Children aged 4-7 years|
2910745|NCT03174496||Children and adolescents aged 8-16 years|
2910748|NCT03174470|Experimental|TENS stimulator|Single day Transcutaneous electrical nerve stimulations utilizing a commercial TENS stimulator (TensMed S82 ENRAF-NONIUS)
2910749|NCT03174457||Treatment: micafungin|Participants receive once daily by intravenous infusion.
2910750|NCT03174444|Experimental|Small Media|Participants receive bilingual brochures and access to bilingual website about colorectal cancer screening.
2910751|NCT03174444|No Intervention|Control|Participants receive no information about colorectal cancer screening from the study during the intervention period, but may receive usual care from health care provider.
2910752|NCT03174431|Active Comparator|Continence Pessary|Participants randomized to the continence pessary will be fitted for a pessary by a clinician at enrollment and they will be taught how to remove and reinsert the device. Per usual clinical practice they will be instructed to call with any concerns and scheduled for a return visit in 2 weeks for a follow-up to assess fit and comfort and undergo refitting if necessary.
2910753|NCT03174431|Active Comparator|Disposable Intravaginal Device|Participants randomized to the intravaginal device will be given a sizing kit in the office, asked to select a size and provided with a 2-week supply of the appropriately sized devices. In accordance with manufacturer guidelines, participants will be instructed that the device is to be used for no more than 8 hours per 24-hour period and that each device is single use only. Participants will return in 2 weeks for a follow-up visit to assess fit and comfort, undergo resizing as necessary and receive an additional 2 week supply of the appropriately sized devices.
2910754|NCT03174418||Cohort A|Patients with bifurcated coronary lesions treated by percutaneous coronary interventions.
2910755|NCT03174418||Cohort B|Patients with untreated bifurcated coronary lesions.
2910756|NCT03174405|Experimental|AVELUMAB|
2910757|NCT03174392|Experimental|Resistance based training study:|Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
2910758|NCT03174392|Active Comparator|Speed based training study:|Each training session will begin by determining the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
2910759|NCT03174379|Placebo Comparator|Control Group|Standard of Care (SOC) treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
2910760|NCT03174379|Active Comparator|Treatment Group|60-minute treatment session twice a week for three weeks
2910761|NCT03174366|Experimental|Intervention Group, receiving medication|Subjects in this group will be receiving medication (denosumab)
2910762|NCT03174353|Experimental|Lanreotide arm|Single arm study. A single deep subcutaneous dose of lanreotide (Somatuline Depot 120 Mg/0.5Ml) will be administered prior to planned resection on the day of surgery.
2910763|NCT03174340|Experimental|Exercise + diet|"Exercise intervention:~During the first session a standardized exercise prescription will be discussed with the participant. The exercise program will be of a moderate intensity, at less than 140 heart beats/min (which corresponds to 60% of the calculated maximum heart rate (HRmax) or 50% maximum oxygen volume (VO2max) ). A session of 30 to 60 minutes/week will be organised.~Participants will be instructed to conduct a nonsedentary lifestyle. They will be encouraged to increase their number of steps on a daily basis and perform not more that 45 minutes of continuous exercise per day. Pedometers will be used to measure the compliance and as a positive feedback for motivation.~The participants will return to the exercise laboratory once per week for Actiheart data downloading, number of steps recording, exercise support and counselling, and to perform the supervised group exercise intervention.~This is in addition to the diet (see below, control group)"
2910764|NCT03174340|No Intervention|Diet only|Participants will receive diet counselling according to their characteristics. The usual recommendation is to have a fractioned normocaloric diet (unless the dietician identify a grossly hypercaloric diet), with low fat and increase in fibers content.
2910765|NCT03174327|Other|Hepatic Transplantation|
2910766|NCT03174314|Experimental|50 visually impaired|50 visually impaired subjects will provide continuity across iterations of the testing, allowing for direct comparisons of responses within an individual for a single behavioral measure across different iterations of the device architecture and output configuration.
2910767|NCT03174314|Active Comparator|50 healthy controls|50 healthy (naive) subjects invaluable insights as well as a range of body types, cognitive abilities, and other idiosyncrasies that will keep our design and testing process from tailoring the device to a small set of individuals rather than the broader population.
2910768|NCT03174288|Experimental|Exercise alone|24 weeks of exercise treatment
2910769|NCT03174288|Experimental|spironolactone alone|24 weeks of Spironolactone treatment
2910770|NCT03174288|Experimental|Exercise + Spironolactone|24 weeks of exercise + Spironolactone treatment
2910771|NCT03174275|Experimental|Low Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Part 3- patients receive adjuvant durvalumab (750 mg) once every two weeks x 3 cycles"
2910819|NCT03174015|Experimental|Intervention|"Landlords on selected plots will receive the Bauleni Secret intervention. Landlords and selected tenants will be surveyed in baseline/end-line data collection."
2910820|NCT03174015|No Intervention|Control|Landlords and selected tenants will be surveyed in baseline/end-line data collection only.
2910772|NCT03174275|Experimental|Medium Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Part 3- patients receive ipsilateral involved field radiation concurrent with weekly cisplatin 30mg/m2. Once chemoradiotherapy is complete these patients will receive durvalumab 750 mg every two weeks for 3 cycles."
2910773|NCT03174275|Experimental|High Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Part 3- All patients will be treated with intensity modulation radiation therapy (IMRT) concurrent with weekly cisplatin 30mg/m2 or other standard of care chemoradiotherapy regimen.Once chemoradiotherapy is complete these patients will receive durvalumab 750 mg every two weeks for 3 cycles."
2910774|NCT03174262|Experimental|Ergonomic Computer Workstation Training|
2910775|NCT03174262|No Intervention|Control Group|
2910776|NCT03174249|Experimental|Exposure therapy|Graded exposure therapy in vivo in combination with methods targeting cortical reorganisation.
2910777|NCT03174236|Experimental|Ceftriaxone|Arm 1 IV Ceftriaxone: Participants in this group receive 80mg/kg IV ceftriaxone once a day. IV ceftriaxone is given for a minimum of 48 hours and a usual maximum of seven days. If a child receiving IV ceftriaxone is feeding well and no longer has any signs of infection or complications after two days and before seven days, they are prescribed standard care for uncomplicated SAM with oral amoxicillin (40mg/kg every 12 hours) to complete a total of seven days of antibiotics, as per WHO guidance. If a participant has a specific and documented indication to continue ceftriaxone beyond seven days (e.g. proven bacterial meningitis), ceftriaxone is continued beyond those seven days.
2910778|NCT03174236|Active Comparator|Benzyl penicillin plus gentamicin|Arm 2 IV Benzyl penicillin plus gentamicin (usual care): Participants in this group receive 50 000 U/kg IV benzyl penicillin every six hours. In the usual care arm, as per WHO guidelines, IV benzyl penicillin plus gentamicin is given for a minimum of two days and a maximum of seven days. If a child receiving IV penicillin and gentamicin is feeding well and no longer has any signs of infection or complications after two days and before seven days, they are prescribed standard care for uncomplicated severe acute malnutrition (SAM) with oral amoxicillin (40mg/kg every 12 hours) to complete a total of seven days of antibiotics, as per WHO guidance.
2910779|NCT03174236|Experimental|Metronidazole|Arm 1 Metronidazole: Participants receive 10 to 16 mg/kg oral metronidazole twice a day for seven days.
2910780|NCT03174236|Placebo Comparator|Placebo|Arm 2 Placebo: Participants receive an oral placebo dose to match that for Metronidazole twice a day for seven days.
2910781|NCT03174223||Deep neuromuscular block|patients received a continuous rocuronium dose to maintain a depth of neuromuscular block of 1-2 twitches post tetanic count
2910782|NCT03174223||moderate neuromuscular block|patients received neuromuscular block aimed at > 0 twitches train of four
2910783|NCT03174210|Experimental|COPD patients with delivery order 1, 2|Patients will use two different Oxygen devices at rest (1.liquid oxygen device (Companion R), 2. portable Oxygen concentrator (Activox TM 4L))
2910784|NCT03174210|Experimental|COPD patients with delivery order 2,1|Patients will use two different Oxygen devices at rest (1. portable Oxygen concentrator (Activox TM 4L), 2. liquid oxygen device (Companion R))
2910785|NCT03174197|Experimental|Concurrent Phase Group|"There are 42 days (about 6 weeks) in the Concurrent Phase. Group consists of 10 participants for this safety run-in stage.~Temozolomide capsules taken by mouth every day.~Atezolizumab given by vein on Day 1. If drug tolerated well, it may be given after that on Days 15, 29, and 42 (about every 2 weeks).~Radiation therapy delivered Monday through Friday every week for 6 weeks as part of standard care.~After radiation therapy completed, participants have a break or rest period for about 21-28 days in which neither Temozolomide or Atezolizumab is received."
2910786|NCT03174197|Experimental|Adjuvant Phase Group|"Each study cycle in the Adjuvant Phase is 28 days.~Temozolomide taken by mouth on Days 1-5 of each cycle.~Atezolizumab given by vein over about 30 minutes on Days 1 and 15 of each cycle.~Temozolomide and Atezolizumab given for up to 12 cycles."
2910787|NCT03174184|Experimental|Rifampin resistant A|Participants with the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive RIFAMPIN 20mg/kg once daily (QD), MEROPENEM 2 grams (G) thrice daily (TID) intravenously, Amoxicillin/Clavulanate Potassium 500 milligrams (MG)-125 MG Oral Tablet once daily for 14 days
2910788|NCT03174184|Experimental|Rifampin resistant B|Participants with the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 2 grams TID (thrice daily) intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
2910789|NCT03174184|Experimental|Rifampin susceptible C|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive RIFAMPIN 20mg/kg once daily, MEROPENEM 2 grams TID (thrice daily) intravenously, Amx/Clv orally at a dose of 500 mg/125 mg thrice daily for 14 days
2910790|NCT03174184|Experimental|Rifampin susceptible D|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 2 grams TID intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
2910791|NCT03174184|Experimental|Rifampin susceptible E|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 1 gram TID intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
2910792|NCT03174184|Experimental|Rifampin susceptible F|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 3 grams QD intravenously, Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet once daily for 14 days
2910793|NCT03174171|Experimental|Intervention|Everolimus 0.75 mg b.i.d. orally for 14 days.
2910794|NCT03174158|Active Comparator|Brief advice|Usual care plus brief telephone advice to quit tobacco delivered by a clinical research coordinator who underwent Tobacco Treatment Specialist core training.
2910821|NCT03174002|Experimental|Low oxygenation target|Partial pressure of oxygen in arterial blood (PaO2) 8 kPa (60 mmHg)
2910795|NCT03174158|Experimental|Text messaging|Patients randomized to the text messaging program are offered a 12-week text messaging. The text messaging intervention will use content from the National Cancer Institute's SmokeFreeTXT library, content for smokers not ready to quit from SmokeFreeTXT and a pilot feasibility study conducted by the PI, and new messages supporting nicotine replacement medication adherence. The text messaging program will be personalized using subject's first name, the telephone number for the MGH tobacco cessation counseling services and the Massachusetts state quitline. Smokers receiving the intervention will be sent from 0 and 5 text messages per day.
2910796|NCT03174158|Experimental|Mailed nicotine replacement therapy|Subjects randomized to mailed nicotine replacement therapy will be offered a 2 week supply of nicotine replacement therapy mailed to their home address. Daily smokers planning to quit in the next 30 days will be offered nicotine patches (14 or 21 mg patches) and lozenges (2 or 4 mg lozenges) dosed according to package instructions. Non-daily smokers planning to quit will be offered a 2 week allotment of 2 mg lozenges alone. Smokers not planning to quit will be offered one box of lozenges (72 count box of 4 mg or 2 mg lozenges based on time to first cigarette as above per package instructions) to use when they are not smoking during their practice quit attempt.
2910797|NCT03174158|Experimental|Text messaging + mailed NRT|Subjects will be offered both the 12 week text message program and 2 weeks of mailed nicotine replacement therapy.
2910798|NCT03174145|Active Comparator|Active group|
2910799|NCT03174145|Sham Comparator|Control group|
2910800|NCT03174132|Experimental|Restylane Perlane Lidocaine|Restylane Perlane Lidocaine will be injected into one side of the nasolabial fold at day 1
2910801|NCT03174132|Active Comparator|Restylane Perlane|Restylane Perlane will be injected into the opposite side of the nasolabial fold on day 1
2910802|NCT03174119|Active Comparator|Real light exposition by the mean of Luminette®|All patients will be exposed to a real light (1500 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo ligh. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
2910803|NCT03174119|Placebo Comparator|Placebo light exposition by the mean of Luminette®|All patients will also be exposed to a placebo light (80 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo light. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
2910804|NCT03174106|Experimental|Smartphone-Application|"Patients in Smartphone-Application-arm will get Access to the Application Vett, they will be learned how to use it. They will receive feedback based on their goals and tasks in the Application for one year, and they will also receive motivational Notifications through the Application, atleast once a week in the follow-up period. Patients in this arm will also have the possibility to send questions to their supervisor through the Application, in that case they will receive answer within two working days. In addition they will receive usual care which is described below."
2910805|NCT03174106|No Intervention|Control-group|Patients in the control-group will receive usual care consisting of general advice according to a heart-friendly lifestyle and follow-up by their general practitioner.
2910806|NCT03174093|Experimental|MATCh AFib|Participants assigned to the intervention group will have the support of the MATCh AFib application during the consultations with their physician and receive individual text messaging targeting knowledge about atrial fibrillation, medication adherence and monitoring during months 1-3.
2910807|NCT03174093|No Intervention|Standard Care|Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment, INR monitoring and consultations with their physician without mHealth support)
2910808|NCT03174067|Experimental|Buprenorphine|Patient receives buprenorphine in the emergency room based on a clinical trial protocol as well as a take home prescription for buprenorphine
2910809|NCT03174067|Active Comparator|Clonidine|Patient receives clonidine in the emergency room based on a clinical trial protocol and also receives a take home prescription for clonidine
2910810|NCT03174054||Patients with no clear lesion in PET or MRI|If the clinical suspicion of cancer is low, there will be no biopsy, only follow-up. If the decision is to perform a biopsy on the prostate, it will be performed with transrectal sonar guidance and systematic biopsies will be performed (12 samples will be taken from different areas of the prostate)
2910811|NCT03174054||Patients with MRI lesions and overlapping mapping lesions|If MRI and PET are matched, a US FUSION MRI biopsy will be taken between 4-8 samples directly from the lesion as well as other systemic prostate samples according to the surgeon's decision. Will be taken and sent separately to pathology.
2910812|NCT03174054||Patients with a discrepancy between the PET and MRI|A FUSION approach will be biopsy. Four to eight samples for each lesion, as well as other systemic prostate samples will be taken according to the surgeon's decision, and the samples will be marked and sent separately to the pathology.
2910813|NCT03174041|Experimental|Part 1|Participants will receive a single dose of midazolam followed by multiple doses of GDC-0853 coadministered with a single dose of midazolam.
2910814|NCT03174041|Experimental|Part 2|Participants will receive a single dose of rosuvastatin followed by multiple doses of GDC-0853 coadministered with a single dose of rosuvastatin.
2910815|NCT03174041|Experimental|Part 3|Participants will receive a single dose of simvastatin followed by multiple doses of GDC-0853 coadministered with a single dose of simvastatin.
2910816|NCT03174041|Experimental|Part 4|Participants will receive a single dose of GDC-0853 followed by multiple doses of itraconazole coadministered with a single dose of GDC-0853.
2910817|NCT03174028|Active Comparator|laparoscopic group|laparoscopic pull-through
2910818|NCT03174028|Sham Comparator|posterior sagittal group|posterior sagittal anorectoplasty
2957296|NCT02852356|No Intervention|Control Incubator|Standard Incubator
2910822|NCT03174002|Active Comparator|High oxygenation target|Partial pressure of oxygen in arterial blood (PaO2) 12 kPa (90 mmHg)
2910823|NCT03173989|Experimental|Orthosis Exercises Orientation|Patients used orthosis, made exercises and received orientation for home.
2910824|NCT03173989|Active Comparator|Orientation|Patients received orientation for home.
2910825|NCT03173976|Experimental|Zoledronic Acid|1 cycle of Zoledronic Acid (ZA) at 4mg IVP prior to surgery and a second cycle of ZA at 4 mg IVP 3 weeks after surgery
2910826|NCT03173963|Active Comparator|Drug|Empagliflozin 10mg once a day
2910827|NCT03173963|Placebo Comparator|Placebo|1 placebo tablet a day
2910828|NCT03173950|Experimental|1/Experimental Therapy|Participants will receive nivolumab at standard dose of240mg IV every 2 weeks for cycles 1 through 4, thendoses of 480mg every 4 weeks for a total of 12 additional doses
2910829|NCT03173937|Experimental|1|CordIn(TM) is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
2910830|NCT03173924|Experimental|1|18F-NaF and 18FDCFPyL
2910831|NCT03173911|Active Comparator|Ankle|composed by 12 participants who will receive the application of the bandage for the ankle strategy in both lower limbs, being determined the application of the technique in I without fixed point, from medial malleolus to lateral malleolus passing under the hindfoot, finally a cleavage technique passing over the malleoli and ending in the anterior region of the ankle joint. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
2910832|NCT03173911|Active Comparator|Hamstrings|composed by 12 participants who will receive the application of the bandage for the posterior thigh (hamstrings) strategy in both lower limbs. The technique will be determined in I with fixed point of the skin of the ischial tuberosity and moving point until the Lateral tibia (near the head of the fibula) and medial tibia (goose-foot insertion). The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
2910833|NCT03173911|Active Comparator|Lumbar|composed by 12 participants who will receive the application of the bandage for the hip (lumbar) strategy, being determined the application of the technique in I with fixed point in the ischial tuberosity and moving point until the height of the last ribs, making a cleavage in the Height of the superior iliac spine. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
2910834|NCT03173911|Active Comparator|Total|composed by 12 participants who will receive the application of the bandage for all strategies in both lower limbs, being determined the application of the technique in I with fixed point in the II and III toes and moving point until the height of the last ribs , Passing through the entire posterior region. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
2910835|NCT03173898|Experimental|primary periodontal ligament anesthesia|PDL anesthesia versus local infiltration
2910836|NCT03173898|Active Comparator|local infiltration|PDL anesthesia versus local infiltration
2910837|NCT03173885|Experimental|PGS (genetic screening)|Intent to transfer single cryopreserved embryo, selection based on euploid status (after preimplantation genetic screening) and standard morphological assessment
2910838|NCT03173885|No Intervention|no PGS (no genetic screening)|Intent to transfer single cryopreserved embryo, selection based on standard morphological assessment
2910839|NCT03173872|Experimental|One Group Study Arm|One group study arm assesses pre Reiki and post Reiki intervention measures
2910840|NCT03173859|Experimental|Rotational|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 for 3 cycles, followed by apalutamide 240mg qD orally for 3 cycles. The duration of each cycle is 28 days
2910841|NCT03173859|Active Comparator|Sequential|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 until disease progression, followed by apalutamide 240mg qD orally until second disease progression.
2910842|NCT03173846||Adult children of AD patients|
2910843|NCT03173833|No Intervention|Control group|Participants will not receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) after the first time they fill in the questionnaire. And they will be able to discuss their care needs with their health care practitioners.
2910844|NCT03173833|Experimental|Experimental group|"Participants will receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) every time after the first time they fill in the questionnaire.~And they will be able to discuss their care needs with their health care practitioners."
2910845|NCT03173820|Placebo Comparator|Conventional|no genotype of CYP3A5 investigated to adjust tacrolimus dosage regimen
2910846|NCT03173820|Active Comparator|Genotype guided|Use CYP3A5 genotype to adjust dosage regimen for tacrolimus
2910847|NCT03173807|Active Comparator|dietary and exercise counseling|The duration of study in Arm A will be 24 months, with study assessments and interventions (review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer) done at baseline, 3 months, 6 months, 12 months and 24 months.
2910884|NCT03173625|Placebo Comparator|Placebo|For each AC-076 dose level tested, 2 healthy male subjects will receive matching placebo in the same condition
2910920|NCT03173443|Experimental|single lumen tube|fiberoptic intubation with single lumen tube with bronchial blocker.
2910848|NCT03173807|Active Comparator|standard of care|The duration of study in Arm B will be 24 months, with study assessments and interventions (review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer) done at baseline, 12 months, 15 months, 18 months and 24 months. At 12 months, participants in Arm B will be offered the same intervention that Arm A received during months 1-12.
2910849|NCT03173794|No Intervention|Usual Care Only|The control group will receive usual care, no CommunityRx-H intervention
2910850|NCT03173794|Experimental|Usual Care and Intervention|The intervention arm will receive the CommunityRx-H intervention, an information-based intervention that provides referrals to community resources
2910851|NCT03173781|Experimental|droxidopa|"Droxidopa will be supplied in 100 and 200 mg pill sizes. The subject should administer the three doses 4 hours apart with the last dose prior to 4:00 pm (example: 8:00 am, 12:00 pm, and 4:00 pm). The proposed dosing is 100mg TID at baseline, then titrate slowly up to 600 mg TID. During titration, droxidopa or placebo, initiated at 100 mg TID was titrated upward in 100-mg TID increments every 48 hours until the subject:~Reaches the maximum permitted dosage of 600 mg TID;~Has a systolic blood pressure≥160mmHg or diastolic blood pressure ≥100mmHg after 10 minutes supine on 3 consecutive measurements; or~Experiences intolerable adverse events (AEs)."
2910852|NCT03173781|Placebo Comparator|placebo|sugar pill
2910853|NCT03173768|No Intervention|pre-intervention period|The charts of patients who were prescribed intravenous antibiotics at hospital discharge were reviewed. Appropriateness of intravenous antibiotics was assessed by ID specialists.
2910854|NCT03173768|Experimental|post-intervention period|The intervention is the charts of patients who were prescribed intravenous antibiotics at hospital discharge by the primary team were prospectively reviewed and intervened by ID team (ID specialist approval)
2910855|NCT03173755||People with normal weight|
2910856|NCT03173755||people with overweight and obesity|
2910857|NCT03173742|Experimental|T1, T2, T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
2910858|NCT03173742|Experimental|T1, T3, T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
2910859|NCT03173742|Experimental|T2,T1,T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
2910860|NCT03173742|Experimental|T2,T3,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
2910861|NCT03173742|Experimental|T3,T1,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
2910862|NCT03173742|Experimental|T3,T2,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
2910863|NCT03173729||Phase 1 Cohort 1|CRC (n = 150)
2910864|NCT03173729||Phase 1 Cohort 2|Precancerous polyps (n = 150)
2910865|NCT03173729||Phase 1 Cohort 3|Normal controls (n = 150)
2910866|NCT03173729||Phase 2 Field Test|75 patients who are high risk for CRC as described in the eligibility
2910867|NCT03173729||Phase 2 Validation Study Cohort 1|Family history of CRC (n = 330)
2910868|NCT03173729||Phase 2 Validation Study Cohort 2|LGI bleeding (n = 240)
2910869|NCT03173729||Phase 2 Validation Study Cohort 3|Patients with history of CRC (n = 75)
2910870|NCT03173716|Active Comparator|Intervention Group|DEFINITY contrast will be prepared according to package insert instructions. A dose of 1.5 mL activated DEFINITY diluted in 28.5 of preservative free saline to constitute a total volume of 30 mL will be infused at a rate of 90-120 mL/hr (1.5-2.0 mL/min). RTMPE will be performed.
2910871|NCT03173716|No Intervention|Control Arm|Echocardiograms will be performed without the use of DEFINITY contrast/RTMPE.
2910872|NCT03173703|Experimental|Test Arm|Test Arm are subjects to be implanted with test article -XenoSure patch. The interventions include: Repair/reconstruction of the diseased vessel; Implant the XenoSure patch
2910873|NCT03173703|Active Comparator|Control Arm|Test Arm are subjects to be implanted with B. Braun's Vascular-Patch.The interventions include: Repair/reconstruction of the diseased vessel; Implant the Vascular-Patch.
2910874|NCT03173690|Experimental|Intervention group|Receive medication reconciliation at the ICU, pluss medication reconciliation at the ward
2910875|NCT03173690|Other|Control group|No intervention at the ICU, medication reconciliation at the ward
2910876|NCT03173677|Active Comparator|Lipid intake|12 subjects had 300 Calories of lipids or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
2910877|NCT03173677|Active Comparator|Glucose intake|12 subjects had 300 Calories of glucose or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
2910878|NCT03173677|Active Comparator|Protein intake|12 subjects had 300 Calories Whey protein intake or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
2910879|NCT03173651|Experimental|Group W|This group was intubated by Fiberoptic bronchoscope assisted by Modified Williams airway as a conduit
2910880|NCT03173651|Experimental|Group G|This group was intubated by Fiberoptic bronchoscope assisted by Modified Guedle's airway as a conduit
2910881|NCT03173651|Experimental|Group M|This group was intubated by Fiberoptic bronchoscope assisted by LMA MADgic airway as a conduit
2910882|NCT03173638|Experimental|Mesenchymal stem from valladolid (MSV)|Allogenic mesenchymal stem cells from bone marrow
2910883|NCT03173625|Experimental|AC-076 sc administration - single ascending dose|On Day 1, 48 subjects will receive AC-076 at different single dose levels in a sequential manner and in a maximum of 6 dose levels, starting from 1 mg. Subjects will be followed by an observation period of 48 h. Each dose level will be investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo)
2910885|NCT03173612|Experimental|AML-CAMS-2016 trial|AML-CAMS-2016 regimen includes risk-stratified therapy and the use of Dasatinib in CBF-AML.The induction regimen includes MAE (etoposide 150mg/㎡/d d1-5, cytarabine 200mg/㎡/d d6-12 , mitoxantrone 5 mg/㎡/d d6-10), CAG (aclacinomycin 6mg/㎡/d d1-8, Ara-C 10mg/㎡ q12h d1-14 , G-CSF 200ug/㎡/d d1-14),IAE (idarubicin 8 mg/㎡/d d1-3, Ara-C 500mg/㎡/d d1-3 d8-10, VP-16 200mg/㎡/d d8-10).Consolidation regimen includes IA (Ara-C 1g/㎡ q12h d1-4, IDA 10mg/㎡/d d1), MA (Ara-C 1g/㎡ q12h d1-4, MTZ 5mg/㎡/d d1-3), IAE (IDA 10mg/㎡/d d1, Ara-C 3g/㎡ q12h d1-3, VP-16 100mg/㎡/d d1-5), MAE (Ara-C 200mg/㎡ d4-8, VP-16 150mg/㎡/d d1-3, MTZ 5mg/㎡/d d4-6),EA (Ara-C 2g/㎡ q12h d1-5, VP-16 100mg/㎡/d d1-5),IAE (IDA 10mg/㎡/d d1, Ara-C 3g/㎡ q12h d1-3, VP-16 100mg/㎡/d d1-5),EA (Ara-C 2g/㎡ q12h d1-5, VP-16 100mg/㎡/d d1-5),MAE (Ara-C 200mg/㎡ d4-8, VP-16 150mg/㎡/d d1-3, MTZ 5mg/㎡/d d4-6). Dasatinib (60-80mg/㎡) is used in CBF-AML as a part of consolidation therapy.
2910886|NCT03173599|Experimental|PNA 40mg|"Metacavir Enteric-coated Capsules,oral before meal~The beginning dose is 40mg,If no adverse effects were observed in 40 mg, the next dose group was started of 80mg."
2910887|NCT03173599|Experimental|PNA 80mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 80mg,If no adverse effects were observed in 80 mg, the next dose group was started of 160mg."
2910888|NCT03173599|Experimental|PNA 160mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 160mg,If no adverse effects were observed in 160 mg, the next dose group was started of 240mg."
2910889|NCT03173599|Experimental|PNA 240mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 240mg,If no adverse effects were observed in 240 mg, the next dose group was started of 360mg."
2910890|NCT03173599|Experimental|PNA 360mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 360mg,If no adverse effects were observed in 360 mg, the next dose group was started of 480mg."
2910891|NCT03173599|Experimental|PNA 480mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 480mg."
2910892|NCT03173599|Placebo Comparator|PNA Placebo|"Metacavir Enteric-coated Capsules Placebo,oral before meal~The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg"
2910893|NCT03173586||NHS|"Least-squares mean (95% CI) concentrations of biomarkers by frequency of sugar sweetened beverage (SSB) intake among participants free of diabetes and cardiovascular disease in the NHS.~Least-squares mean (95% CI) concentrations of biomarkers by frequency of artificially sweetened beverage (ASB) intake among participants free of diabetes and cardiovascular disease in the NHS.~Least-squares mean (95% CI) concentrations of biomarkers by frequency of fruit juice intake among participants free of diabetes and cardiovascular disease in the NHS."
2910894|NCT03173573|Experimental|Part 1 SAD FDL176 level 1 to 6|Part 1: Single dose of FDL176 test formulation Level 1 to 6 on healthy males.
2910895|NCT03173573|Placebo Comparator|Part 1 SAD Placebo|Part 1: Single dose of Placebo for FDL176.
2910896|NCT03173573|Experimental|Part 2 SAD FDL176 at fasted state|Part 2: single dose of FDL176 test formulation, fasted state.
2910897|NCT03173573|Experimental|Part 2 SAD FDL176 at fed state|Part 2: single dose of FDL176 test formulation, fed state
2910898|NCT03173573|Experimental|Part 3 SAD FDL176 test formulation|Part 3: Single dose of FDL176 test formulation on healthy females.
2910899|NCT03173573|Placebo Comparator|Part 3 SAD placebo|Part 3: Single dose of Placebo for FDL176.
2910900|NCT03173573|Experimental|Part 4 MAD FDL176 Level 1 to 3|Part 4: Dose escalation of FDL176 test formulation Level 1 to 3.
2910901|NCT03173573|Placebo Comparator|Part 4 MAD Placebo|Part 4: Dose escalation of Placebo for FDL176 Level 1 to 3.
2910902|NCT03173573|Experimental|Part 5 SAD FDL176 test formulation|Part 5: Single dose of FDL176 test formulation.
2910903|NCT03173560|Experimental|Lenvatinib 18 mg plus everolimus 5 mg|Participants will receive oral lenvatinib 18 milligrams (mg) once daily (QD) plus oral everolimus 5 mg QD as the starting dose in Cycle 1.
2910904|NCT03173560|Experimental|Lenvatinib 14 mg plus everolimus 5 mg|Participants will receive oral lenvatinib 14 mg QD plus oral everolimus 5 mg QD as the starting dose for Cycle 1. If there are no intolerable Grade 2 or any ≥ Grade 3 treatment-emergent adverse events (TEAEs) that require dose reduction in the first 28-day cycle (ie, the first 4 weeks of treatment), the lenvatinib dose will be escalated to 18 mg QD (plus everolimus 5 mg) beginning in Cycle 2.
2910905|NCT03173547|Active Comparator|146-9251 cream|Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
2910906|NCT03173547|Placebo Comparator|Vehicle cream|Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
2910907|NCT03173534|Active Comparator|TAVR + Medical Therapy|n=156 will undergo Transcatheter Aortic Valve Replacement (TAVR) alone with medical management for atrial fibrillation
2910908|NCT03173534|Experimental|TAVR + WATCHMAN|n=156 will undergo simultaneous Transcatheter Aortic Valve Replacement (TAVR) with a WATCHMAN device.
2910909|NCT03173521|Experimental|open label|
2910910|NCT03173508|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
2910911|NCT03173508|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
2910912|NCT03173495|Experimental|FRUCTOSE|Day 0, 45 min in rest position. Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a fructose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
2910913|NCT03173495|Placebo Comparator|DEXTROSE|Day 0, 45 min in rest position. Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
2910914|NCT03173495|Active Comparator|FRUCTEX|Day 0, 45 min of 60%VO2peak aerobic exercise . Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a fructose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
2910915|NCT03173456|Active Comparator|oxycodone/APAP|5 mg oxycodone + 325 mg acetaminophen
2910916|NCT03173456|Active Comparator|hydrocodone/APAP|5 mg hydrocodone + 300 mg acetaminophen
2910922|NCT03173430|Experimental|Arm 1|An evaluable subject is any subject who completes two 28-day cycles of blinatumomab or discontinues blinatumomab after completion of less than one cycle due to toxicity.
2910923|NCT03173417|Experimental|IM19 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
2910924|NCT03173404|Experimental|Group I|Patients underwent hysteroscopy examination before IVF cycle.
2910925|NCT03173404|No Intervention|Group II|Patients underwent direct IVF cycle without previous hysteroscopy.
2910926|NCT03173391|Experimental|HMS5552|75mg BID
2910927|NCT03173391|Placebo Comparator|Placebos|BID
2910928|NCT03173378||Narcoleptic Patients|Type 1 and Type 2 narcoleptic adult patients usually followed at the Lyon Sleep Medicine and Respiratory Disease center
2910929|NCT03173378||Control|Adult age-matched family members of the patients
2910930|NCT03173365|Experimental|Brimonidine Tartrate|The respective palm to be treated with Brimonidine will be randomly assessed and will be matched for handedness to include equal numbers of dominant and non‐dominant treated palms.
2910931|NCT03173352||Infant hemangioma(IH)|Infant hemangioma(IH) is the most common benign vascular tumor of infancy with the estimated incidence varies 1% to 12%.However, in China, the incidence of infant hemangioma and related epidemiological data remains unclear. So, We designed the study to collect data about both epidemiology related risk ractors of infantile hemangioma in China.
2910932|NCT03173339|Active Comparator|Low remifentanil and high sevoflurane|Remifentanil was administered as 0.1 mcg/kg/min. Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
2910933|NCT03173339|Experimental|High remifentanil and low sevoflurane|Sevoflurane was administered as 0.5 MAC. Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
2910934|NCT03173326|Experimental|Subarachnoid block|
2910935|NCT03173326|Active Comparator|General anesthesia|
2910936|NCT03173313|Other|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after PCI.
2910937|NCT03173313|Other|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
2910938|NCT03173287|Experimental|Patients with hepatic biopsy|The patients having benefited from a hepatic biopsy for evaluation of the hepatic fibrosis, will benefit in 10 days of a MRI in the service of radiology of the hospital Gabriel Montpied.
2910939|NCT03173274|Experimental|Contingency Management (CM)|Those in the CM condition will continue to provide CO values twice-daily, and will receive escalating reinforcement values for CO values indicating continuous smoking abstinence (CO < 6 ppm).
2910940|NCT03173274|Active Comparator|Non-Contingent Reinforcement|Participants in the NC condition will also provide CO levels twice-daily. However, their reinforcement will not be contingent upon their CO level but will be yoked to someone in the CM condition so that average reinforcer values are equivalent across the 2 conditions.
2910941|NCT03173261|Other|tuberculous pleural effusion|diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
2910942|NCT03173248|Experimental|AG-120 (ivosidenib) with Azacitidine|
2910943|NCT03173248|Placebo Comparator|Placebo with Azacitidine|
2910944|NCT03173235||Infertile women|Women which desire to have children but are probable infertile between 18 and 45 year old
2910945|NCT03173235||healthy women|Healthy women without systemic diseases in the age of 18 to 45 years
2910946|NCT03173222|Active Comparator|EA1|
2910947|NCT03173222|Active Comparator|EA2|
2910948|NCT03173222|No Intervention|Control|
2910949|NCT03173209|Other|school professional development|Professional development in Calm Moments Cards program. Occupational therapists used lecture and coaching to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
2910950|NCT03173196||Sepsis group|Patients with a septic shock or a severe sepsis (surgical and non-surgical patients), staying on Intensive Care Unit, Non-invasive Multispectral Sonography - measurement
2910951|NCT03173196||Non-septic group|Patients without sepsis (surgical and non-surgical patients), staying at least 24 hours on an Intensive Care Unit, Non-invasive Multispectral Sonography - measurement
2910952|NCT03173183|Experimental|genuine regional Rhizoma Atractylodis|"Granules of genuine regional Rhizoma Atractylodis:~Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day."
2910953|NCT03173183|Active Comparator|non-genuine regional Rhizoma Atractylodis|"Granules of non-genuine regional Rhizoma Atractylodis (Luotian, Hubei province) :~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day."
2910954|NCT03173183|Placebo Comparator|placebo|placebo granules: Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd., orally administration, 9g per time, 3 times a day.
2910955|NCT03173170|Experimental|TAK-954 0.2 mg + Itraconazole 200 mg and TAK-954 0.2mg|TAK-954 0.2 milligram (mg), infusion, intravenously, once on Day 1 of First Intervention Period, followed by a minimum of 7-day washout period, further followed by Itraconazole 200 mg, capsule, orally, once daily on Days 1 to 8 along with TAK-954 0.2 mg, infusion, intravenously on Day 4 of Second Intervention Period.
2910956|NCT03173157|Experimental|Value Feedback Arm|A weekly email will be sent to all inpatient, resident-staffed cardiology teams outlining best use practices from AHA/ACC statements on trans-thoracic echoacardiography and data feedback on in-hospital charges, running 13 week average usage and previous week usage of full and limited trans thoracic echocardiograms
2910957|NCT03173131|Experimental|Opioid counseling group|Counseling provided to patients prior to surgery regarding opioid usage, side effect, long term effect and risks of opioids.
2960463|NCT02829671|Other|Patients with major depressive disorders|
2910958|NCT03173131|No Intervention|No Counseling|No preoperative counseling will be provided to this group. Standard medication information will be provided only.
2910959|NCT03173118|Other|suspected chronic pancreatitis patients|Patients with suspected chronic pancreatitis will undergo Endoscopic ultrasound elastography to assess whether this detects chronic pancreatitis.
2910960|NCT03173118|Other|Assessment of abdominal pain patients|Patients who are referred for assessment of abdominal pain without risk factors or any other tests suggesting chronic pancreatitis will undergo Endoscopic ultrasound elastography
2910961|NCT03173105|Active Comparator|Group 1 (G1)|active tDCS + dynamic proprioceptive exercises
2910962|NCT03173105|Sham Comparator|Group 2 (G2)|sham tDCS + dynamic proprioceptive exercises
2910963|NCT03173105|Active Comparator|Group 3 (G3)|active tDCS + static proprioceptive exercises
2910964|NCT03173105|Sham Comparator|Group 4 (4)|sham tDCS + static proprioceptive exercises
2910965|NCT03173092|Experimental|Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 milligram (mg), capsules, orally, once, on Days 1, 8 and 15 and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22 of a 28-day cycle for a maximum of 26 cycles until PD or unacceptable toxicity, whichever occurs for up to 2 years.
2910966|NCT03173066|Experimental|Single Arm|Patients with a clinical concern for pulmonary embolus but not able to receive iodinated contrast will be enrolled. Ferumoxytol will be administered as a contrast agent in coordination with magnetic resonance angiography to identify patency of the cardiopulmonary vasculature.
2910967|NCT03173053|Active Comparator|Search and destroy (SD) strategy|"A quick and, short topical decolonization treatment combined with systemic antibiotics for S. aureus.~Drug: Doxycycline 200mg once daily during one week Drug: Trimethoprim 200mg twice daily during one week Drug: Co-trimoxazol (Sulfamethoxazole/trimethoprim) 960mg twice daily during one week Drug: Clindamycin 600mg thrice daily during one week Drug: Clarithromycin 500mg twice daily during one week Drug: Ciprofloxacin 750mg twice daily during one week Drug: Fusidic acid (tablet) 500mg thrice daily during one week Drug: Rifampin 600mg twice daily during one week Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days"
2910968|NCT03173053|Active Comparator|Continuous suppression (CS) strategy|"A repeated, continuous, topical decolonization treatment of S. aureus~Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days"
2910969|NCT03173040|Experimental|NiuBangZi pill group|Drug: NiuBangZi pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi pill and methotrexate
2910970|NCT03173040|Placebo Comparator|Placeo group|Drug: NiuBangZi placebo pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi placebo pill and methotrexate
2910971|NCT03173027|Experimental|Experimental group|Drug: Fangji Huangqi pill 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill and Mobic
2910972|NCT03173027|Placebo Comparator|Placebo group|Drug: Fangji Huangqi pill placebo 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill placebo and Mobic
2910973|NCT03173001||Patients with colorectal cancer|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
2910974|NCT03173001||Population|The control group includes residents of Tashkent city without any complaints from gastrointestinal tract matched by gender and age to the patients with colorectal cancer.
2910975|NCT03173001||Patients with CRC without metastases|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
2910976|NCT03173001||Patients with CRC with metastases|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
2910977|NCT03173001||Patients with CRC before operation|Patients hospitalized with colorectal cancer before operation at the Department of Coloproctology of Republican Oncology Research Center.
2910978|NCT03173001||Patients with CRC after operation|Patients hospitalized with colorectal cancer after operation at the Department of Coloproctology of Republican Oncology Research Center.
2910979|NCT03173001||Patients with CRC before chemotherapy|Patients hospitalized with colorectal cancer before operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.
2910980|NCT03173001||Patients with CRC after chemotherapy|Patients hospitalized with colorectal cancer after operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.
2910981|NCT03172988|Experimental|Dexamethasone and flurbiprofen axetil|Dexamethasone 10 mg is administered before anesthesia induction. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
2910982|NCT03172988|Experimental|Dexamethasone and lipid microsphere|Dexamethasone 10 mg is administered before anesthesia induction. Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
2910983|NCT03172988|Experimental|Normal saline and flurbiprofen axetil|Normal saline 2 ml is administered before anesthesia induction. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
2911014|NCT03172832|Active Comparator|Endoscopic Retrograde Cholangiography|Subjects randomized to this arm will undergo ERC as the first drainage intervention.
2910984|NCT03172988|Placebo Comparator|Normal saline and lipid microsphere|Normal saline 2 ml is administered before anesthesia induction. Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
2910985|NCT03172975|Experimental|Na-GST-1/Alhydrogel|100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
2910986|NCT03172975|Experimental|Na-GST-1/Alhydrogel + CPG 10104|100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
2910987|NCT03172975|Experimental|Na-GST-1/Alhydrogel + GLA-AF|100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
2910988|NCT03172975|Placebo Comparator|Saline Placebo|Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
2910989|NCT03172962|Experimental|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 12 weeks
2910990|NCT03172962|Active Comparator|Usual care (control)|Will receive the usual care at the hospital
2910991|NCT03172936|Experimental|Dosing Schedule A|Patients will be treated with MIW815 (ADU-S100) via intratumoral injection for 3 weeks on followed by one week off in combination with a fixed intravenous dose of PDR001 given once per month
2910992|NCT03172936|Experimental|Dosing Schedule B|Patients will be treated with MIW815 (ADU-S100) via intratumoral injection given once a month in combination with a fixed intravenous dose of PDR001 given once per month
2910993|NCT03172923|Active Comparator|sliding hip screw|fixation of fracture with a sliding hip screw
2910994|NCT03172923|Experimental|intramedullary nail|fixation of the fracture with an intramedullary nail
2910995|NCT03172910|Experimental|Cohort 1 Arm 1|Administer ciraparantag or placebo dosing schedule 1
2910996|NCT03172910|Experimental|Cohort 2 Arm 1|Administer ciraparantag or placebo dosing schedule 2
2910997|NCT03172910|Experimental|Cohort 3 Arm 1|Administer ciraparantag or placebo dosing schedule 3
2910998|NCT03172910|Placebo Comparator|Cohort 1 Arm 2|Administer ciraparantag or placebo dosing schedule 1
2910999|NCT03172910|Placebo Comparator|Cohort 2 Arm 2|Administer ciraparantag or placebo dosing schedule 2
2911000|NCT03172910|Placebo Comparator|Cohort 3 Arm 2|Administer ciraparantag or placebo dosing schedule 3
2911001|NCT03172897|Experimental|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1 ug/kg/h for a maximum of 3 days.
2911002|NCT03172897|Placebo Comparator|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group for a maximum of 3 days.
2911003|NCT03172884|Experimental|BAY80-6946/Healthy subject|Healthy subjects
2911004|NCT03172884|Experimental|BAY80-6946/moderate hepatically impaired patients|Patients with moderate impairment of the liver (Child Pugh B)
2911005|NCT03172884|Experimental|BAY80-6946/severe renal impaired patients|Patients with severe impairment of the kidneys
2911006|NCT03172884|Experimental|BAY80-6946/severe hepatically impaired patients|Patients with severe impairment of the liver (Child Pugh C)
2911007|NCT03172871|Experimental|Aripiprazole IM Depot|"Aripiprazole IM depot group (Aripiprazole IM Depot):~The first 2 weeks of the acute treatment phase IM Injection 400 mg every 4 weeks + Aripiprazole tablets 10-20 mg per day After the first two weeks of the acute treatment phase IM Injection 400/300 mg every 4 weeks + placebo（tablets）(once a day)"
2911008|NCT03172871|Active Comparator|Aripiprazole tablet|"Oral aripiprazole group (Aripiprazole tablet):~The first 2 weeks of the acute treatment phase Placebo (Injection) every 4 weeks + Aripiprazole tablets 10-20 mg per day After the first two weeks of the acute treatment phase Placebo (Injection) every 4 weeks + Aripiprazole tablets 10-20 mg per day"
2911009|NCT03172858|Experimental|Intracervical Balloon Catheter Group|"The intracervical balloon catheter will be passed through the cervix either with a speculum exam or by a digital exam. Then the catheter balloon will be filled with 80 cc of sterile fluid. The catheter will be pulled to tension and taped to the patient's leg.~Patients will have the option to IV pain medication at the time of intracervical balloon placement. The intracervical balloon will remain in place for 6 hours unless it falls out spontaneously. At the 6 hour mark, a vaginal exam will assess if the intracervical balloon has pulled through the cervix or if it needs further tension. The intracervical balloon will remain in place a maximum of 12 hours. After a maximum of 12 hours in place the intracervical balloon will be removed and oxytocin will be started per protocol."
2911010|NCT03172858|Active Comparator|Immediate low-dose oxytocin infusion group|At our institution the policy for oxytocin infusion is to start at a low dose of 2mu/min and to increase by 2mu/min at 15 to 20 minute intervals based on how often uterine contractions are occuring. A specific order from a physician is required to increase the oxytocin dose above 20 mu/min. Oxytocin will be titrated per usual protocol.
2911011|NCT03172845|Experimental|Vulnerable plaque|Patient with true bifurcation lesion undergoing baseline coronary angiography, baseline OCT and percutaneous coronary intervention will be studied. OCT is used to assess the frequency of vulnerable plaque, its location at bifurcation lesions and compare vulnerable plaque related major adverse cardiovascular events (MACE) during one-year follow-up. Vulnerable plaque was considered as thin-cap fibro atheroma (TCFA), lipid-rich plaque (vulnerable), plaque rupture, plaque erosion, micro-vessel.
2911012|NCT03172845|Active Comparator|Stable plaque|patient with true bifurcation lesion undergoing baseline coronary angiography, baseline OCT and percutaneous coronary intervention will be studied. OCT is used to assess the frequency of non-vulnerable plaque (stable plaque), its location at bifurcation lesions and compare vulnerable plaque related major adverse cardiovascular events (MACE) during one-year follow-up. Without any vulnerable plaque characteristic
2911013|NCT03172832|Active Comparator|Percutaneous Transhepatic Drainage|Subjects randomized to this arm will undergo PTBD as the first drainage intervention.
2911015|NCT03172819|Experimental|OBP-301+Pembrolizumab|OBP-301+Pembrolizumab
2911016|NCT03172806||Study Group|All patients included in the study. First: clinical scores were collected in all patients. Second: all patients underwent a polysomnography in order to compare this results with these of the clinical scores.
2911017|NCT03172793|Experimental|Telavancin injection Dose 1 (7.5mg/kg)|The pharmacokinetics and tolerability of telavancin 7.5mg/kg q24h will be measured in 6 participants.
2911018|NCT03172793|Experimental|Telavancin injection Dose 2 (10mg/kg)|After completion and analysis of 7.5mg/kg group, the next 6 participants will receive 10mg/kg q24h, and pharmacokinetics and tolerability will be measured.
2911019|NCT03172793|Experimental|Telavancin injection Dose 3 (TBD)|The third arm will enroll 6 participants to receive the following dose of telavancin q24h: 7.5, 10, 12.5, or 15 mg/kg. The final dose will be selected based on pharmacokinetic studies from first 12 participants, tolerability, and pharmacodynamic modeling.
2911020|NCT03172780|Experimental|Diclofenac Sodium Gel|Diclofenac Sodium Gel, 1%
2911021|NCT03172780|Active Comparator|Voltaren® Gel|Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%
2911022|NCT03172780|Placebo Comparator|Placebo gel|Placebo gel
2911023|NCT03172767||Preterm Preschoolers|Preterm children who haven't attend school.
2911024|NCT03172767||Term Preschoolers|Term children who haven't attend school.
2911025|NCT03172754|Experimental|Phase I patients|Phase I patients must have received at least 1 prior tyrosine kinase inhibitor for RCC.
2911026|NCT03172754|Experimental|Phase II patients: cohort 1|Phase II cohort 1 patients must have received at least 1 prior tyrosine kinase inhibitor for RCC.
2911027|NCT03172754|Experimental|Phase II patients: cohort 2|Phase II cohort 2 patients must not have received prior systemic therapy for advanced RCC.
2911028|NCT03172741|Placebo Comparator|Placebo group: THC (0%) / CBD (0%)|The matching dose for high THC, high CBD or mixed CBD/THC is a 1 gram placebo cigarette (THC (0%) / CBD (0%)) smoked once per day of for 3 months.
2911029|NCT03172741|Experimental|CBD group:THC (<1%) / CBD (>10%)|The dose for the CBD group (THC (<1%) / CBD (>10%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
2911030|NCT03172741|Experimental|THC group: THC (>10%) / CBD (<1%) THC group|The dose for the THC group (THC (>10%) / CBD (<1%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
2911031|NCT03172741|Experimental|Mixed group:THC (5-10%) / CBD (5-10%)|The dose for the mixed group THC (5-10%) / CBD (5-10%) ) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
2911032|NCT03172728|Experimental|Therapeutic intervention- psycho-education pamphlet|"Psycho-education information (appendix 1) will be provided by research assistant in a pamphlet and audio recording, with a written referral to the women's mental health services in case symptoms arise. This psycho-education information will be sent again by Qualtrics 4 weeks later and women will be prompted to read it again. Women who do not respond within a week will be contacted by a research assistant and reminded to respond.~In the end of the reading material, there will be a reading confirmation question. In the case that a participant will not answer this question or if the answer will suggest that the participant did not read the material, the research assistant will contact her by phone to confirm the reading."
2911033|NCT03172728|No Intervention|Control group|"Control group will receive general psychoeducation about the emotional after effects of childbirth in a pamphlet and audio recording and the phone number for the women's mental health services. This psychoeducation information will be sent again by Qualtrics 4 weeks later and women will be prompted to read it again. Women who do not respond will be contacted by a research assistant within a week and reminded to respond.~In the end of the reading material, there will be a reading confirmation question. In the case that a participant will not answer this question or if the answer will suggest that the participant did not read the material, the research assistant will contact her by phone to confirm the reading."
2911034|NCT03172715|Active Comparator|ORIF (open reduction-internal fixation)|"Osteosynthesis with locking plate(s) will be performed using medial and/or lateral incision, according to morphology of the fracture. Additional osteosynthesis material will be used when necessary. The articular surface will be reduced and bone transplantation or bone substitute used if required.~Postoperatively, touch-down weight bearing will be allowed for 6 weeks, followed by 2 weeks of half-weight-bearing period. A walker or wheelchair will be used when necessary."
2911035|NCT03172715|Experimental|TKR (total knee replacement)|Arthroplasty of the knee will be performed within two weeks after the fracture. Medial parapatellar approach will be used. The minimal possible constraint of the prosthesis (cruciate retaining, posterior cruciate sacrificing or semi-constrained) will be used. A possible insufficient bone stock may be rebuilt with augments. Hinged prosthesis will be used only if stability of the medial collateral ligament is insufficient. A cemented or uncemented tibial stem extender (minimum length 50mm) will be used in all cases. Additional osteosynthesis will be used when necessary. Postoperatively, the patients will be allowed full weight bearing as tolerated.
2911036|NCT03172702|Experimental|Sodium Zirconium Cyclosilicate|Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
2911037|NCT03172689|Other|CardioQ|CardioQ will be used as CO monitor simultaneously with the standard of care PiCCO CO monitor
2911038|NCT03172676|No Intervention|Helicobacter pylori negative patients|chronic immune thrombocytopenic purpura patients who will be diagnosed negative for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients.
2911039|NCT03172676|Active Comparator|Helicobacter pylori positive patients with intervention|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients will receive treatment of Helicobacter pylori: Amoxicillin for 14 days, Clarithromycin for 14 days and Proton pump inhibitor for one month).
2911040|NCT03172676|No Intervention|Helicobacter pylori positive patients without intervention|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients will not receive treatment of Helicobacter pylori during the study,these patient group will receive treatment of Helicobacter pylori after the end of the study
2911041|NCT03172663|Experimental|group 1|
2911042|NCT03172663|Active Comparator|group 2|
2911047|NCT03172624|Experimental|R/M adenoid cystic carcinoma (ACC)|Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
2911048|NCT03172624|Experimental|R/M SGC of any histology, except ACC (Non ACC)|Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
2911049|NCT03172611|Experimental|Plant-based diet|A defined, plant-based diet was prescribed for 4 weeks.
2911050|NCT03172598|Experimental|MT-8554 low dose|Patients who meet eligibility criteria will be administered twice daily low dose of MT-8554 during the treatment period.
2911051|NCT03172598|Experimental|MT-8554 middle dose|Patients who meet eligibility criteria will be administered twice daily middle dose of MT-8554 during the treatment period.
2911052|NCT03172598|Experimental|MT-8554 high dose|Patients who meet eligibility criteria will be administered twice daily high dose of MT-8554 during the treatment period.
2911053|NCT03172598|Experimental|MT-8554, then placebo|The study participants will receive MT-8554 (TBD mg) in the first phase, followed by placebo in the second phase
2911054|NCT03172598|Experimental|Placebo, then MT-8554|The study participants will receive placebo in the first phase, followed by MT-8554 (TBD mg) in the second phase
2911055|NCT03172585|Other|High Resolution computed tomography|Patients will be included in the study when High resolution chest computed tomography without contrast enhancement is ordered by the primary physician. Before the High resolution chest computed tomography scan, a Trans thoracic ultrasonography will be performed.
2911056|NCT03172572||Indication for surgery|Solid neoplasms
2911057|NCT03172559|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy (SBRT) treatment will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues. The recommended dose will be 30 gray (Gy) in 5 fractions. The treatment will be administered in 5 alternative days. Patients will come every other day to the hospital to be treated and will not need to be admitted. Patients will not receive further SBRT on the treated tumor.
2911058|NCT03172559|No Intervention|No intervention|Follow-up will be carried out every 3 months and a computed tomography (CT) scan of the chest and abdomen or an magnetic resonance imaging (MRI), and blood work with liver function test and alpha-fetoprotein (AFP) value will be done until the patient is transplanted or drops-out of the waiting list.
2911059|NCT03172546||Anti-IIa users|Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti IIa anticoagulant including analysis of PK-PD genetic polymorphisms
2911060|NCT03172546||Anti-Xa users|Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti Xa anticoagulant including analysis of PK-PD genetic polymorphisms
2911061|NCT03172533|Active Comparator|verum group|approved oral contraceptive: ethinyl estradiol 0.03mg and dienogest 2mg (combination drug) daily intake over 10 weeks
2911062|NCT03172533|Placebo Comparator|placebo group|placebo
2911063|NCT03172520|Experimental|Facial Nerve Monitoring with APS electrode|The investigators will use the Facial Nerve Monitor along with the APS electrode during parotidectomy surgery.
2911064|NCT03172507||Atherosclerosis group|Patients with significant coronary artery disease.
2911065|NCT03172507||Control group|Healthy controls without confirmed coronary artery disease.
2911066|NCT03172494|Experimental|Insulin degludec/liraglutide|
2911067|NCT03172494|Active Comparator|Insulin degludec|
2911068|NCT03172494|Active Comparator|Liraglutide|
2911069|NCT03172481|Experimental|Active Treatment|PRC-063 25, 35, 45, 55, 70 or 85 mg
2911070|NCT03172481|Placebo Comparator|Placebo Treatment|
2911071|NCT03172468||Survivors|Patients suffering from out-of-hospital cardiac arrest (OHCA), who achieve sustained return of spontaneous circulation (ROSC) following prehospital cardiopulmonary resuscitation.
2911072|NCT03172468||Non-Survivors|Patients suffering from out-of-hospital cardiac arrest (OHCA), who are declared dead after prehospital cardiopulmonary resuscitation.
2911073|NCT03172442|Experimental|orthodontic removable traction appliance|"Patients in this group will be treated using the orthodontic removable traction appliance (vacuum plate with two hooks between lateral incisor and canine in each side). An rapid maxillary expander will be applied to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.~Class III elastic traction from upper first molar to the hook in both side. This appliance will be used full-time with Class III elastics (6- to 8-ounce) traction."
2911074|NCT03172442|No Intervention|Control group|without intervention
2911075|NCT03172429||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
2911076|NCT03172429||High altitude control|Healthy highlanders living above 2500 m.
2911077|NCT03172429||Low altitude control|Healthy lowlanders living below 1000 m.
2911078|NCT03172416|Other|3+3 dose escalation of PIPAC using oxaloplatin|
2911079|NCT03172403|Experimental|Patients with colon cancer requiring resection surgery|"Patients with colon cancer requiring resection surgery will be included. They will have measure of height and weight, blood samples, skeletal muscle force, skeletal muscle index and muscle biopsy.~V1: Inclusion will be effectuated at the time of anaesthetic consultation V2: The day before and day of resection surgery about 1 month after V3: Follow-up at 1 month V4: Follow-up at 3 months V6: Follow-up at 6 months"
2911080|NCT03172390|Experimental|Cohort of patients : ascending aorta dilatation|measure of ascending aorta quality and quantity parameters by 4D Cardiac magnetic resonance
2911081|NCT03172377|Experimental|Intervention group|Lengthening adalimumab dosing interval: The adalimumab injection interval during maintenance therapy (40 mg sc / 2 weeks) will be extended through a stepwise disease activity guided manner to 3 weeks and subsequently - after 24 weeks - to 4 weeks. If a step-down leads to recurrence of disease activity patients will return to the preceding effective dosing interval.
2911082|NCT03172377|No Intervention|Control group|Standard care: Patients will continue adalimumab treatment following their usual dose and schedule. Treatment decisions are made at the discretion of the treating physician who will be blinded for the results of additional assessments beyond standard of care.
2911083|NCT03172364|Experimental|Test product 1|All the participants in this arm will receive test product 1 (micellar cleanser) at home twice a day (morning and evening) for 21 (±2) days.
2911343|NCT03170700|Experimental|Online|Nutrition program with online parental feeding content.
2911084|NCT03172364|Experimental|Test product 2|All the participants in this arm will receive test product 2 (micellar foaming cleanser) at home twice a day (morning and evening) for 21 (±2) days.
2911085|NCT03172351|Experimental|EDoF1|
2911086|NCT03172351|Active Comparator|Monofocal|
2911087|NCT03172351|Active Comparator|EDoF2|
2911088|NCT03172325|Experimental|CinnaGen adalimumab|CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml in prefilled syringe Every other week 40 mg Adalimumab, was subcutaneously administered to rheumatic patients during 6 months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over a six-month period.
2911089|NCT03172325|Active Comparator|AbbVie adalimumab|Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml in prefilled syringe Every other week 40 mg Adalimumab, was subcutaneously administered to rheumatic patients during 6 months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over a six-month period.
2911090|NCT03172312||Total thyroidectomy|Patients need to do total thyroidectomy According to guidelines
2911091|NCT03172312||Hemithyroidectomy|Patients need to do Hemithyroidectomy According to guidelines
2911092|NCT03172299|Active Comparator|Injection of anti-VEGF|
2911093|NCT03172299|Placebo Comparator|false injection of anti-VEGF|
2911094|NCT03172286|Active Comparator|Patient treated with fake radiofrequencer|
2911095|NCT03172286|Experimental|Patient treated with radiofrequencer|
2911096|NCT03172273|Experimental|TIPS with PTFE|Transjugular Intrahepatic portosystemic shunt with PTFE covered stents
2911097|NCT03172273|Active Comparator|paracentesis|Paracentesis with albumine invision
2911098|NCT03172234|Active Comparator|amantadine group (Group A)|the patients will receive oral amantadine sulfate using the dose 100 mg 90 minute prior to the surgery
2911099|NCT03172234|Active Comparator|gabapentin group(Group B)|the patients will receive oral gabapentin using the dose 800 mg 90 minute prior to surgery.
2911100|NCT03172234|Placebo Comparator|control group (group C)|the patients will receive placebo oral tablet 90 minute prior to surgery.
2911101|NCT03172208|Experimental|Group 1: Japanese - Caplacizumab Dose 1 iv (SD)|Single dose (SD) of Caplacizumab Dose 1 administered intravenously (iv) to Japanese participants
2911102|NCT03172208|Placebo Comparator|Group 1: Japanese - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to Japanese participants
2911103|NCT03172208|Experimental|Group 2: Japanese - Caplacizumab Dose 2 iv (SD)|Single dose (SD) of Caplacizumab Dose 2 administered intravenously (iv) to Japanese participants
2911104|NCT03172208|Experimental|Group 2: Japanese - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to Japanese participants
2911105|NCT03172208|Experimental|Group 2: White - Caplacizumab Dose 2 iv (SD)|Single dose (SD) of Caplacizumab Dose 2 administered intravenously (iv) to White participants
2911106|NCT03172208|Placebo Comparator|Group 2: White - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to White participants
2911107|NCT03172208|Experimental|Group 3: Japanese - Caplacizumab Dose 2 sc (SD)|Single dose (SD) of Caplacizumab Dose 2 administered subcutaneously (sc) to Japanese participants
2911108|NCT03172208|Placebo Comparator|Group 3: Japanese - Placebo sc (SD)|Single dose (SD) of Placebo administered subcutaneously (sc) to Japanese participants
2911109|NCT03172208|Experimental|Group 3: White - Caplacizumab Dose 2 sc (SD)|Single dose (SD) of Caplacizumab Dose 2 administered subcutaneously (sc) to White participants
2911110|NCT03172208|Placebo Comparator|Group 3: White - Placebo sc (SD)|Single dose (SD) Placebo administered subcutaneously (sc) to White participants
2911111|NCT03172208|Experimental|Group 4: Japanese - Caplacizumab Dose 2 sc (MD)|Multiple doses (MD) of Caplacizumab Dose 2 administered subcutaneously (sc) to Japanese participants
2911112|NCT03172208|Placebo Comparator|Group 4: Japanese - Placebo sc (MD)|Multiple doses (MD) of Placebo administered subcutaneously (sc) to Japanese participants
2911113|NCT03172195|Experimental|Patients with ulcerative colitis|Patients with ulcerative colitis will have a rectosigmoidoscopy, biopsies and blood sample.
2911114|NCT03172182|Experimental|Virtual reality (VR) group|Immersive education using a 360-degree VR video tour at operation day
2911115|NCT03172182|No Intervention|Control Group|Conventional verbal education of preoperative proceudres
2911116|NCT03172169||Healthy control group|no intervention
2911117|NCT03172169||Difficult withdrawal group|The mechanical ventilation time was >48 hours and the first SBT failure
2911118|NCT03172169||Mechanical ventilation control group|Elective and expected postoperative control of mechanical ventilation time greater than 12h after cardiothoracic surgery
2911119|NCT03172156||Stage I NSCLC patients after surgery with ctDNA detection|Stage I NSCLC patients;ctDNA detection
2911120|NCT03172143|Active Comparator|Mesenteric sparing ileocolic resection|Ileocolic resection without removal of the lymph nodes in the mesentery.
2911121|NCT03172143|Active Comparator|High ligation ileocolic resection|Ileocolic resection with removal of lymph nodes in the mesentery
2911122|NCT03172130|Experimental|Straight CPAP|Patients randomized to straight CPAP will receive 10 cm of air pressure, or as determined by the results of polysomnography, for 6 weeks. Following the 6-week visit, patients will be placed on straight CPAP with equipment approved by insurance for an additional 6 weeks.
2911123|NCT03172130|Sham Comparator|Sham CPAP|Patients randomized to sham CPAP will receive 1-2 cm of air pressure for 6 weeks. Following the 6-week visit, patients will be placed on straight CPAP with equipment approved by insurance for an additional 6 weeks.
2911124|NCT03172117|Experimental|NEUROSTEM® (hUCB-MSCs)- low dose|human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
2911125|NCT03172117|Experimental|NEUROSTEM® (hUCB-MSCs) - high dose|human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
2911126|NCT03172117|Placebo Comparator|Placebo|normal saline 2mL, doses separated by 4 weeks for a total of 3 doses
2911167|NCT03171805|No Intervention|control group|Propranolol was not given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
2911168|NCT03171779||Usual practice|
2911344|NCT03170687|Experimental|foot cast|
2911127|NCT03172104||Very preterm group|"Preterm infants <30 weeks' GA at birth admitted to one of the neonatal nurseries at the Royal Women's Hospital in Melbourne, Australia.~Inclusion criteria: Infants admitted to the Royal Women's Hospital, Melbourne, Australia, neonatal nurseries, born <30 weeks' GA. Exclusion criteria: (i) infants with congenital abnormalities known to affect neurodevelopment and (ii) infants with non-English speaking parents."
2911128|NCT03172104||Term control group|Inclusion criteria: Infants admitted to the Royal Women's Hospital Melbourne, Australia, born >36 completed weeks' GA and weighing >2500 g. Exclusion criteria: (i) infants with congenital abnormalities known to affect neurodevelopment (ii) infants requiring admission to neonatal intensive or special care nursery and (iii) infants with non-English speaking parents.
2911129|NCT03172091|Experimental|Acute rejection|Pulmonary transplant patients with acute rejection
2911130|NCT03172091|Other|Control group|Pulmonary transplant patients without acute rejection
2911131|NCT03172078|Active Comparator|manually-control infusion|manually-control infusion (MCI) with propofol during advanced endoscopic procedure e.g. endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
2911132|NCT03172078|Active Comparator|Target-control infusion|Target-control infusion (TCI) with propofol during advanced endoscopic procedure e.g. endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
2911133|NCT03172065|Other|ketorolac group|will receive 3.5 ml (17.5 mg) hyperbaric Bupivacaine + 0.5 ml saline + 60mg ketorolac I.V infusion 30 minutes before anaesthesia induction
2911134|NCT03172065|Other|Dexmedetomidine group|will receive 3.5 ml (17.5 mg) hyperbaric Bupivacaine + 0.5 ml dexmedetomidine (0.5 mic)
2911135|NCT03172052|Experimental|streptokinase instillation|Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is >100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred and if drained fluid through the tube was <100 cc in 24 h provided that tube is patent and properly positioned.
2911136|NCT03172052|Experimental|instillation of MESNA|Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
2911137|NCT03172052|Experimental|Medical thoracoscopy procedure|Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope
2911138|NCT03172052|Experimental|Video assisted thoracoscopy (VATS)|Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
2911139|NCT03172026|Experimental|Maraviroc + Augmented Rehabilitation|Participants will take Maraviroc 300 mg daily for 60 days, plus receive rehabilitation therapy as prescribed by the doctors and via telerehabilitation.
2911140|NCT03172026|Placebo Comparator|Placebo + Augmented Rehabilitation|Participants will take placebo 300 mg daily for 60 days, plus receive rehabilitation therapy as prescribed by the doctors and via telerehabilitation.
2911141|NCT03172013||Cirrhotic ascitic patients with SBP,|Cirrhotic ascitic patients with SBP,
2911142|NCT03172013||cirrhotic ascitic patients without SBP,|cirrhotic ascitic patients without SBP,
2911143|NCT03172013||Healthy volunteers|Healthy individuals
2911144|NCT03172000|Active Comparator|Colonoscopy and biopsy|IBD patients
2911145|NCT03172000|No Intervention|Colonoscopic biopsy|Non IBD patients colonoscopic biopsy
2911146|NCT03171987|Experimental|Lidocaine patch|Lidocaine patch local application 1 piece per day for 28 days at back pain area.
2911147|NCT03171987|Active Comparator|Flurbiprofen patch|Flurbiprofen patch local application 1 piece per day for 28 days at back pain area.
2911148|NCT03171974|Experimental|treatment group|The treatment group will be injected with dexamethasone instracapsular under US according to our built protocol.
2911149|NCT03171961|Experimental|online visit group|in online visit group , subjects has online visit with dietitian every 2 weeks
2911150|NCT03171961|Experimental|clinic visit group|clinic visit group ,subject has every 2 weeks in person visit at clinic
2911151|NCT03171961|Experimental|self-directed group|self-directed group ,subjects receive nutritional information via web and their energy needs for weight loss
2911152|NCT03171948|Experimental|Almond group|Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet
2911153|NCT03171948|Experimental|Nut Free group|Nut Free group (NFG), as control group, who continue their diet without any nut consumption.
2911154|NCT03171935|Experimental|High-Flow Nasal Cannula Oxygenation|
2911155|NCT03171935|Experimental|Noninvasive Positive Pressure Ventilation|
2911156|NCT03171935|Active Comparator|Conventional Weaning|
2911157|NCT03171922|Experimental|Internet Diet|Internet Diet group have online dietary coach every 2 weeks
2911158|NCT03171922|Experimental|Clinic Diet|clinic visit based weight loss diet program group who have every 2 weeks visit at clinic.
2911159|NCT03171896|Experimental|Intervention|Medical clown
2911160|NCT03171896|Sham Comparator|No Intervention|No clown in the room
2911161|NCT03171870|Other|Idiopathic Pulmonary Fibrosis|Idiopathic pulmonary fibrosis patients on high resolution computed tomography characterized by presence of reticular opacities often associated with traction bronchiectasis
2911162|NCT03171844|Experimental|Skin to skin|Implement of skin to skin
2911163|NCT03171831|Experimental|Haploidentical HSCT|"Procedure: Haploidentical hematopoietic stem cell transplantation from a related donor (partially matched sibling, father or mother).~Conditioning: Busulfan （4 mg/kg/day,4 days） + Cyclophosphamide （50 mg/kg/day,4 days）+ Fludarabine （50 mg/m2/day,3 days）~GVHD Prophylaxis：Mycophenolate mofetil（0.25g/day）+ Tacrolimus（0.03mg/kg/day）+ Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）+ Thymoglobulin（2.5 mg/kg/day,4 days）+Basiliximab（10mg on day 0 and +4）"
2911164|NCT03171818|Experimental|Darbepoetin|Darbepoetin alfa (Aranesp, Amgen)
2911165|NCT03171818|Placebo Comparator|Placebo|Saline
2911166|NCT03171805|Experimental|Propranolol group|Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
2911248|NCT03171298|Experimental|transanal TME|Laparoscopic Assisted Transanal Total Mesorectal Excision
2911169|NCT03171779||IPEM|Interprofessional Training in Early Identification and Multidimensional Evaluation (IPEM) of patients' palliative needs
2911170|NCT03171779||IPEM and PAS|Interprofessional Early Identification Training and Multidimensional Assessment (IPEM) of patients' palliative needs, and to the Early Care Planning (SAP)
2911171|NCT03171753|Experimental|Music therapy|Listening prerecorded music through an individual headset for 30 min in before the induction of anesthesia
2911172|NCT03171753|Active Comparator|Control|patients wear headphones for 30 minuts without any sound
2911173|NCT03171740|Active Comparator|Dexmedetomidine|Children will receive 1mcg/kg intranasal dexmedetomidine and oral saline, 30 minutes before going to operation theater.
2911174|NCT03171740|Active Comparator|Midazolam oral solution|Children will receive 0,5mg/kg oral midazolam and intranasal saline, 30 minutes before going to operation theater.
2911175|NCT03171727|Experimental|study group|After TIPS procedure was performed, low molecular weight heparin was given for three days.
2911176|NCT03171727|No Intervention|control group|After TIPS procedure was performed, no low molecular weight heparin was given.
2911177|NCT03171714|Experimental|Derma-Stent|The novel silicon packing device made of a nonabsorbent material to pack a drained abscess for healing.
2911178|NCT03171714|Active Comparator|Usual Care, cotton gauze packing|Standard of care to pack a drained abscess for healing.
2911179|NCT03171701||maturation of arteriovenous fistula|
2911180|NCT03171688||Modeling|It is the cohort that will be used for selecting risk factors and models for predicting postoperative nausea and vomiting.
2911181|NCT03171688||Validation|It is the cohort that will be used for validation of risk factors and models selected in the modeling group.
2911182|NCT03171675||Preterm/Chronic Periodontitis|Included ten female patients who underwent spontaneous preterm birth and were diagnosed with chronic periodontitis upon clinical examination
2911183|NCT03171675||Preterm/Healthy Periodontium|Included ten female patients who underwent spontaneous preterm birth and who had a healthy periodontium upon clinical examination
2911184|NCT03171675||Term/Chronic Periodontitis|Included ten female patients who underwent spontaneous normal term birth and were diagnosed with chronic periodontitis upon clinical examination
2911185|NCT03171675||Term/Healthy Periodontium|Included ten female patients who underwent spontaneous normal term birth and who had a healthy periodontium upon clinical examination (Armitage1999)
2911186|NCT03171662|Experimental|group study|Imaging and Histopathological examination for Evaluation of Pediatric Appendicitis Score
2911187|NCT03171649|Experimental|RETRAINER-S1 & Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the RETRAINER-S1 system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
2911188|NCT03171649|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
2911189|NCT03171623|Experimental|SY-004 2mg|SY-004 (globalagliatin hydrochloride) 2mg by mouth, single dose
2911190|NCT03171623|Placebo Comparator|SY-004 20mg&placebo|SY-004 (globalagliatin hydrochloride) 20mg or placebo by mouth, single dose
2911191|NCT03171623|Placebo Comparator|SY-004 40mg&placebo|SY-004 (globalagliatin hydrochloride) 40mg or placebo by mouth, single dose
2911192|NCT03171623|Placebo Comparator|SY-004 80mg&placebo|SY-004 (globalagliatin hydrochloride) 80mg or placebo by mouth, single dose
2911193|NCT03171623|Placebo Comparator|SY-004 120mg&placebo|SY-004(globalagliatin hydrochloride) 120mg or placebo by mouth, single dose
2911194|NCT03171610|Experimental|Sufentanil group|Arm Description: PCA with sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml
2911195|NCT03171610|Active Comparator|Fentanyl group|PCA with fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml
2911196|NCT03171597|Other|conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
2911197|NCT03171597|Experimental|Qi deficiency and blood stasis|Patients in this group will be treated by Shuanghe Decoction at the base of conventional western medicine.
2911198|NCT03171597|Experimental|Qi stagnation and blood stasis|Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.
2911199|NCT03171597|Experimental|Phlegm and blood stasis|Patients in this group will be treated by Gualou Xiebai Banxia Decoction & Danshen Decoction at the base of conventional western medicine.
2911200|NCT03171584|Experimental|Terbinafine group|Arm (1) will receive Terbinafine (250mg/day for 6 weeks).
2911201|NCT03171584|Experimental|Fluconazole group|Arm (2) will receive Fluconazole (300mg once weekly for 3monthes).
2911202|NCT03171584|Experimental|Itraconazole group|Arm (3) will receive Itraconazole (400mg/day for one week per month followed by 3 free weeks ,, 2 pulses for finger nail)
2911203|NCT03171571|Experimental|Coaching procedure|Volunteers will received Updated National Dietary Guidelines about food and physical activity with a one year follow-up, plus connected coaching.
2911204|NCT03171558|Experimental|Gastric Pull Up|Patients randomized to undergo gastric pull up surgical reconstruction of pharyngoesophageal defect.
2911205|NCT03171558|Active Comparator|Free Flap|Patients randomized to undergo free flap (anterolateral thigh or radial forearm) surgical reconstruction of pharyngoesophageal defect.
2911206|NCT03171545|Experimental|Patient Activation|This arm includes peer mentoring by trained End Stage Renal Disease (ESRD) patients. Mentors will hold 6 multimedia-aided meetings with other patients that include skills instruction and role modeling.
2911207|NCT03171545|Experimental|Provider Education|This arm focuses on dialysis facility care teams. It includes team training, online education, and checklists.
2911208|NCT03171545|No Intervention|No Intervention|Patients in clinic receive usual care.
2911209|NCT03171545|Experimental|Patient and Provider|This arm includes both Patient Activation and Provider Education interventions
2911249|NCT03171285||Less than 35 years old|Clinical and laboratory evaluations
2911210|NCT03171532|Active Comparator|4 strand hamstring ACL reconstruction|The hamstring tendons will be harvested by standard technique and the lengths of the Semitendinosus and Gracilis tendons will be measured after clearing all adherent muscle tissue. The ends will be prepared and folded in middle to prepare4-strand graft.
2911211|NCT03171532|Active Comparator|5 strand hamstring ACL reconstruction|The hamstring tendons will be harvested by standard technique and the lengths of the Semitendinosus (ST) and Gracilis (GR) tendons will be measured after clearing all adherent muscle tissue. For 5-strand graft, minimum length of ST and GR in consideration would be 24 cm and 16 cm respectively. For 5-strand group the ST tendon will be be folded twice and sutured on itself to make a three strand graft and then GR tendon will be folded once along with it to make a final 5-strand graft.
2911212|NCT03171519|Active Comparator|Exercise|
2911213|NCT03171519|Experimental|Exercise + acupuncture|
2911214|NCT03171506|Experimental|Usual care plus ketogenic diet|
2911215|NCT03171506|Placebo Comparator|Usual care plus AND diet|
2911216|NCT03171493|Experimental|Intravesical MV-NIS therapy prior to radical cystectomy|MV-NIS will be administered via intravesical instillation as a single dose on Day 1 (7, 14, 21 or 28 days before cystectomy) or two doses on Day 1 and 15 (14 and 28 days before cystectomy).
2911217|NCT03171480|Active Comparator|Monoket pill|Isosorbide mononitrate is a drug used principally in the treatment of angina pectoris[1] and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold in the USA by Kremers Urban under the trade name Monoket, also sold in the USA under the name Imdur,
2911218|NCT03171480|Placebo Comparator|Placebo|The pharmacy has compounded an identical appearing placebo
2911219|NCT03171467|Experimental|Salpingectomy|Opportunistic salpingectomy at the time of laparoscopic cholecystectomy
2911220|NCT03171454|Experimental|Delayed Intrauterine Balloon therapy|In the delayed balloon group,a Foley catheter will be inserted into the uterine cavity 2 weeks after the surgery, the balloon will be inflated with normal saline (from 3ml to 5ml) then deflated, and the procedure repeated three time over 3 minutes or so, then the cavity will be flushed with 10 mls of normal saline solution after via the irrigating channel of the Foley catheter before removal. The whole procedure will be repeated a further 2 weeks later.
2911221|NCT03171454|Experimental|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
2911222|NCT03171441||Controls|eutrophic children
2911223|NCT03171441||Overweight|Overweight children
2911224|NCT03171441||Obese|Obese children
2911225|NCT03171428||TAA|Thoraco-Abdominal Approach: those patients with liver tumors operated with the thoracic-abdominal approach
2911226|NCT03171428||AA|Abdominal Approach: those patients with liver tumors operated with the abdominal approach (without the thoracotomy)
2911227|NCT03171415|Experimental|RZL-012|"A single-time injection, multiple subcutaneous injections of RZL-012 administered into 8-48 sites (0.1mL per site):~40mg RZL-012 -administered at 8 sites~80mg RZL-012 - administered at 16 sites~120mg RZL-012 - administered at 24 sites~240mg RZL-012 - administered at 48 sited"
2911228|NCT03171415|Placebo Comparator|Placebo|A single-time injection, multiple subcutaneous injections of Placebo administered into 8-48 sites (0.1mL per site)
2911229|NCT03171402||Low fruit and vegetable consumers|Participants with low F&V consumption, as defined by 24-hr dietary recall
2911230|NCT03171402||High fruit and vegetable consumers|Participants with high F&V consumption, as defined by 24-hr dietary recall
2911231|NCT03171389|Experimental|Cohort A|patients with primary c-KIT mutations and with either no detectable or non-exon13-secondary mutations (as measured by plasma sequencing); failure of imatinib treatment (only) Treatment with oral ponatinib 30MG (milligram) daily until progression or intolerable side effects.
2911232|NCT03171389|Experimental|Cohort B|GIST patients with primary c-KIT mutations and secondary c-KIT mutations in Exon 13; failure of imatinib treatment (only) Treatment with oral ponatinib 30MG daily until progression or intolerable side effects.
2911233|NCT03171389|Experimental|Cohort C|"GIST patients with KIT-mutations and treatment failure of imatinib, sunitinib and regorafenib.~Treatment with oral ponatinib 30MG daily until progression or intolerable side effects."
2911234|NCT03171376|Active Comparator|Intraorifice Group|After root canal treatment intraorifice barrier of glass-ionomer cement (Ketac™ Molar, 3M ESPE ) placed 3mm inside canals from root canal orifice.
2911235|NCT03171376|Active Comparator|Base Group|2mm thick base of glass-ionomer cement (Ketac™ Molar, 3M ESPE ) applied uniformly on the floor of the pulp chamber after completion root canal treatment.
2911236|NCT03171376|Active Comparator|Control Group|Neither intraorifice barrier nor base applied after completion of root canal treatment.
2911237|NCT03171363|Experimental|Gaze-contingent feedback|Participants will receive gaze-contingent feedback according to their viewing patterns
2911238|NCT03171350|Experimental|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test
2911239|NCT03171337|Experimental|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory, twice 1 week for 4 weeks，fMRI will be used to detect the cerebral function changes
2911240|NCT03171337|Active Comparator|Fu's subcutaneous needling (FSN)|FSN at the points related with CTTH, twice 1 week for 4 weeks, fMRI will be used to detect the cerebral function changes.
2911241|NCT03171337|Sham Comparator|Sham acupuncture|Streitberger placebo needles at nonacupoint for CTTH, twice 1 week for 4 weeks,fMRI will be used to detect the cerebral function changes.
2911242|NCT03171324|Experimental|AGA 6 weeks|Iron supplementation will be started at 2mg/kg from 6 weeks of age to 1 year
2911243|NCT03171324|Experimental|AGA 6 months|Iron supplementation will be started from 6 months of age to 1 year
2911244|NCT03171324|Experimental|SGA 6 weeks|Iron supplementation will be started from 6 weeks of age to 1 year
2911245|NCT03171324|Experimental|SGA 6 months|Iron supplementation will be started from 6 months of age to 1 year
2911246|NCT03171311|Active Comparator|Angiographic guided PCI|Angiographic guided PCI is revascularization by percutaneous coronary intervention (PCI) and optional use of intravascular ultrasound (IVUS).
2911247|NCT03171311|Experimental|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by systematic use of intravascular optical coherence tomography (OCT)
2911253|NCT03171246|Experimental|CD-TREAT (Solid food-based intervention)|"Solid food-based dietary intervention replicating composition of exclusive enteral nutrition (EEN).~Daily for up to 12 weeks."
2911254|NCT03171233|Active Comparator|Group mobilization with movement|Techniques to improve ankle mobility that possibily will to cause changes in the biomechanical motion of the lower limb. The patient does the movement actively, but is assisted by the therapist to mobilize.
2911255|NCT03171233|Active Comparator|Group Self mobilization with movement|Techniques to improve ankle mobility that possibily will to cause changes in the biomechanical motion of the lower limb. The patient performs the movement and the mobilization in an independently way without receiving help from the therapist
2911256|NCT03171220|Experimental|Neoantigen Reactive T Cells + SHR-1210|Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory;Both Fludarabine 30mg/m2/D and Cyclophosphamide 300mg/m2/D will be i.v. for 3 days before cell infusion; NRTs 0.5~1 x 10^10, will be i.v.Q3 weeks for total 4 doses;programmed cell death-1（PD1） inhibitor SHR-1210,200mg,will be i.v. Q3 weeks for total 4 doses,2 day2 prior to each NRTs infusion;Interleukin-2 (IL-2) will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.All Patients will receive a total of 4 cycles of treatment.
2911257|NCT03171207|Experimental|Start with Lite Run Gait Trainer|Patients start therapy with the Lite Run Gait Trainer device, followed by a Current Harness System in an ABAB design.
2911258|NCT03171207|Experimental|Start with Current Harness System|Patients start therapy with a Current Harness System, followed by the Lite Run Gait Trainer in an ABAB design.
2911259|NCT03171194|Experimental|Drug: Low Dose Mesenchymal Stem Cells ( MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
2911260|NCT03171181|Experimental|UPVD non compensated|Intervention group: 30 participants with unilateral peripheral vestibular disorders. Exposed to vestibular reeducation.
2911261|NCT03171181|No Intervention|control group|Control group, to obtain reference values.
2911262|NCT03171181|No Intervention|UPVD compensated|Registered spatial orientation in a group of 30 participants with compensated lesion.
2911263|NCT03171168|Active Comparator|Traditional Physical Therapy|Participants will have traditional physical therapy up to 20 sessions, up to two sessions per week. This will involve exercise and modalities as decided by the therapists and medical providers. Participants will have a home exercise program for the remainder of the year.
2911264|NCT03171168|Experimental|AposTherapy|Participants will have AposTherapy instead of traditional physical therapy over the course of one year. This will include 7 sessions of gait assessment and re-calibration with daily at home exercise with the device over the year.
2911265|NCT03171155|Experimental|XPro System|Implantation of XPro System during percutaneous vascular closure
2911266|NCT03171142|Active Comparator|Heliox group|receive Helium oxygen mixture 21:79 via nasal cannula 2L/min
2911267|NCT03171142|Active Comparator|Air group|receive oxygen 21%via nasal cannula 2L/min
2911268|NCT03171129|Experimental|High flow nasal cannula system w/ ADINA|The intervention is the insertion of the the ADINA device into the high flow nasal cannula system. ADINA will be placed according to weight class recommendations to increase the positive end expiratory pressure (PEEP). ADINA is actually a combination of the Neotech RAM Cannula and a clear Regulator/Pop off valve.
2911269|NCT03171129|Active Comparator|high flow nasal cannula system|High flow nasal cannula will deliver oxygen at 2-4 lpm of flow. High flow cannula are used to provide the control interface.
2911270|NCT03171116||CKD-CT|subjects with CKD stages II-V under conservative treatment
2911271|NCT03171116||CKD-HD|subjects with CKD stage V on hemodialysis
2911272|NCT03171116||RTx renal transplant|renal transplant recipients
2911273|NCT03171116||Controls|control subjects
2911274|NCT03171090|Active Comparator|sphenopalatine block using local anasthetic|
2911275|NCT03171090|Placebo Comparator|sphenopalatine block using saline|
2911276|NCT03171077|Active Comparator|Virtual Rehabilitation|"A virtual rehabilitation program (G0) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The G0 treatment program consists of the following protocols: a) protocol 1 games (Balance Bubble Plus and Tennis); b) protocol 2 games (Rhythm Parade and Boxing)."
2911277|NCT03171077|Experimental|PNF Method|A program of therapeutic exercises (G1) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The G1 treatment program consists of the following protocols: a) protocol 1 : 30 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation), and 10 minutes diagonal exercise scapula (anterior and posterior elevation); b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training;
2911278|NCT03171077|Active Comparator|Virtual Rehabilitation and PNF Method|In G2 program will be performed 20 minutes G0 protocol (1 or 2, used alternately between sessions a week) and 20 minutes G1 protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols.
2911279|NCT03171064|Experimental|Experimental intervention arm (EX)|The supervised progressive endurance and resistance exercise program will be undertaken twice weekly in small groups and will be guided by an exercise physiotherapist over 12 weeks. All sessions will start with a warm-up passing over to the endurance training part and finish with a cool-down and will take approximately 60 minutes. The moderate-to-high-intensity endurance training will be performed at the beginning of each training session on a cycle ergometer for 20 min at 75 to 80 % of peak heart rate obtained from the baseline cardiorespiratory exercise test. This training intensity is within the range of intensities recommended by the American College of Sports Medicine (ACSM) exercise guidelines for cancer survivors. The moderate-to-high-intensity progressive resistance training regime (12 repetition maxima - 3 sets for each exercise) will include 6 exercises that target major upper and lower body muscle groups.
2911345|NCT03170687|Active Comparator|short leg cast|
2911280|NCT03171064|No Intervention|Wait list - control group (UC)|Wait list control group will receive usual care. After primary endpoint assessment, UC patients will be offered to participate in the exercise interventions program.
2911281|NCT03171051|Experimental|950nm LED Device|The right flank of the abdomen will be treated with the LED device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes.
2911282|NCT03171051|Active Comparator|1050nm Diode Laser Device|The left flank of the abdomen will be treated with the diode laser device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes.
2911283|NCT03171038|Experimental|Telemonitoring group|6 months of telemonitoring (t0-t1), followed by usual care up until common long-term stopping date (t1-t2).
2911284|NCT03171038|No Intervention|Usual care group|Usual care from t0 up until the common stopping date (t2).
2911285|NCT03171025|Experimental|Nivolumab, all patients|
2911286|NCT03171012|Experimental|Lower limbs CRT+ PNF|Lower Limbs Cardiorespiratory training associated with Proprioceptive Neuromuscular Facilitation
2911287|NCT03171012|Active Comparator|Lower limbs CRT + respiration|Lower limbs Cardiorespiratory training associated with respiration
2911288|NCT03171012|Experimental|Upper limbs CRT + PNF|Upper limbs Cardiorespiratory training associated with Proprioceptive Neuromuscular Facilitation
2911289|NCT03171012|Active Comparator|Upper limbs CRT + respiration|Upper limbs Cardiorespiratory training associated with respiration
2911290|NCT03170999||Subjects included in Focus groups|Approximately 45 subjects with COPD will participate in the focus group interviews for item identification. The group may contain subjects who are functionally illiterate and at least one third women will be recruited.
2911291|NCT03170999||Subjects included in cognitive interviews|Approximately 9 subjects with COPD will be involved in cognitive interviews and will be asked to respond to all of the items in the draft item set.
2911292|NCT03170999||Subjects included in candidate item set|Approximately 150 subjects with COPD will respond to the questions in candidate item set.
2911293|NCT03170986|Experimental|Multisectoral Agriculture and Microfinance Arm|
2911294|NCT03170986|No Intervention|Control Arm|
2911295|NCT03170973|Experimental|Comparison of fatty acids before and after exercise|
2911296|NCT03170973|No Intervention|Comparison of fatty acids at baseline and 24 hours after|
2911297|NCT03170960|Experimental|Dose Escalation|"Subjects will accrue in cohorts of 3-6 subjects for evaluation of cabozantinib tablet dose of either 20 mg, 40 mg, and 60 mg orally qd in combination with standard dosing regimen of atezolizumab (1200 mg infusion q3w). A standard 3 plus 3 design will be utilized to determine a recommended combination dosing regimen for the Expansion Stage."
2911298|NCT03170960|Experimental|Expansion Cohort 1|Subjects with advanced RCC with clear cell histology who have not received prior systemic anticancer therapy.
2911299|NCT03170960|Experimental|Expansion Cohort 2|Subjects with UC with transitional cell histology (including bladder, renal pelvis, ureter, urethra) who have progressed on or after platinum-containing chemotherapy.
2911300|NCT03170960|Experimental|Expansion Cohort 3|Subjects with UC with transitional cell histology (including bladder, renal pelvis, ureter, urethra) who are ineligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy for inoperable, locally advanced, or metastatic disease.
2911301|NCT03170960|Experimental|Expansion Cohort 4|Subjects with UC with transitional cell histology (including bladder, renal pelvis, ureter, urethra) eligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy for inoperable, locally advanced, or metastatic disease.
2911302|NCT03170960|Experimental|Expansion Cohort 5|Subjects with UC with transitional cell histology (including renal pelvis, ureter, urinary bladder, urethra) who have radiographically progressed on or after one prior immune check-point inhibitor (anti-PD1 or anti-PD-L1) as the most recent therapy for the treatment of inoperable, locally advanced, or metastatic disease.
2911303|NCT03170960|Experimental|Expansion Cohort 6|Subjects with metastatic CRPC (adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features) who have radiographically progressed in soft tissue on or after enzalutamide and/or abiraterone acetate for metastatic disease.
2911304|NCT03170960|Experimental|Expansion Cohort 7|Subjects with Stage IV non-squamous NSCLC who have radiographically progressed on or after treatment with one prior immune checkpoint inhibitor (anti-PD-1 or anti-PD-L1) as the most recent therapy for metastatic disease.
2911305|NCT03170960|Experimental|Expansion Cohort 8|Subjects with Stage IV non-squamous NSCLC who have not received prior immune checkpoint inhibitor therapy (anti-PD-1 or anti-PD-L1).
2911306|NCT03170947|Experimental|Custom insoles|Custom insoles will make with CAD-CAM using a laser scanning and casting for its construction. Custom insoles will make with direct adaptation technique (TAD) being of pvc resin.
2911307|NCT03170947|Active Comparator|Standardized insoles|Standardized insoles will be done by Ethylene-vinyl acetate (EVA) material.
2911308|NCT03170921|Experimental|Angola|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
2911309|NCT03170921|Experimental|Benguela|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
2911310|NCT03170921|Experimental|São Bento|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
2911311|NCT03170908||Phase I Patients|Patients with depression receiving community-based services will receive Interpersonal Psychotherapy
2911312|NCT03170908||Phase II Patients|Patients with depression receiving community-based services will receive Interpersonal Psychotherapy
2911346|NCT03170674|Experimental|FT21039 Product Use Group|Subjects will use the electronic cigarette product (FT21039).
2911347|NCT03170674|Experimental|FT21092 Product Use Group|Subjects will use the electronic cigarette product (FT21092).
2911348|NCT03170674|Experimental|FT21018 Product Use Group|Subjects will use the electronic cigarette product (FT21018).
2960734|NCT02827552|Other|ARPEGE BioM|N/A (not a randomized study)
2911313|NCT03170895|Experimental|sorafenib and Omacetaxine Mepesuccinate|"The starting dose of sorafenib will be 400 mg twice daily. Sorafenib should be taken continuously throughout the treatment period unless there is no evidence of response at first assessment on day 28 or progressive disease at any time during the treatment.~OM will be given at 1.5 mg/m2/day (maximum dose 3 mg) for 7 days (concurrently with sorafenib) in 28-day cycle.~Sorafenib and OM will be continued until leukemia progression or allogeneic HSCT. Thereafter, patients will be followed up and information about disease status and survival will be collected."
2911314|NCT03170882|Experimental|Ixazomib plus dexamethasone|Ixazomib 4 mg as starting dose, capsules, orally on Days 1, 8, and 15 of each 28-day cycle, with escalation to 5.5 mg at Cycle 2 for participants who tolerate the 4 mg dose in Cycle 1, plus dexamethasone 20 mg (or 10 mg if participant is aged ≥75 years) tablets, orally, on Days 1, 2, 8, 9, 15, 16, 22, and 23 of every 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study (up to 63 months).
2911315|NCT03170882|Active Comparator|Pomalidomide plus dexamethasone|Pomalidomide 4 mg, capsules, orally on Days 1 to 21 of each 28-day cycle plus dexamethasone 40 mg, (or 20 mg if participant is aged ≥75 years), tablets, orally on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study (up to 63 months).
2911316|NCT03170869|Experimental|DEB-TACE Procedure with Surefire Precision Infusion System|"The study duration for each patient is 24 months and includes a baseline visit, procedure visit and follow-up visits at 1 week, 1 month, 3 months, 6 months and every 3 months until liver transplant or death.~The following evaluations/activities will be performed at baseline: Informed consent, history, physical exam, data collection of CT/ MRI within 1 month of the visit date, data collection of lab values and quality of life questionnaire.~The treatment visit includes the DEB-TACE procedure with the Surefire Precision Infusion System. After the procedure, a Cone Beam CT of the liver will be performed to determine distribution and density of the beads in the tumor and adverse events monitoring.~The following evaluations / activities will be performed during the follow-up period: physical exam, data collection of contrast enhanced CT/MRI to evaluate tumor response, data collection of lab values, adverse event monitoring and quality of life questionnaire."
2911317|NCT03170856|Experimental|Exercise Intervention Group|Thse patients will undergo a sub-maximal exercise training as treatment for concussion.
2911318|NCT03170856|No Intervention|Usual Care Group|These patients will not undergo a sub-maximal exercise training. They will follow the exercise instructions given to them by their physician.
2911319|NCT03170843|Experimental|O-Trac|The experimental group will use the plastic ring wound retractor for wound protection during the surgery.
2911320|NCT03170843|No Intervention|Surgical pad|The control group will use a conventional surgical pad for wound protection during the surgery.
2911321|NCT03170830|Experimental|Healthy control group|Age:45-75 years.Pepole who have normal ECG without the history of cardiovascular disease can be included in the healthy control group.
2911322|NCT03170830|Experimental|unstable angina disease control group|Age:>18 years.Unstable angina patients meet the diagnostic criteria.
2911323|NCT03170830|Experimental|acute myocardial infarction group|Age:>18 years.Acute myocardial infarction patients meet the diagnostic criteria.
2911324|NCT03170817||N13-ammonia Cardiac Rest/Stress PET/CT|Patients with coronary artery disease (CAD) undergo a Cardiac Perfusion Rest/Stress Digital PET/CT scan using the radiopharmaceutical N13-ammonia and Regadenoson (Lexiscan) to induce pharmacologic stress.
2911325|NCT03170791|Experimental|vagal nerve stimulation intervention|All participants consented to the study will undergo an exercise session using equipment such as pedals and cylinders to facilitate activity. During the exercise session the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. Patients will be videoed during the therapy sessions to allow researchers to retrospectively count the number and type of repetitive movements successfully performed. At the end of the exercises, the stimulator clip will be removed from the patient's ear and cleaned with an alcohol disinfectant wipe ready for next use.
2911326|NCT03170765|Experimental|GROUP A|measles vaccine at 6 months and 9 months of age
2911327|NCT03170765|Experimental|GROUP B|measles vaccine at 7.5 months and 9 months of age
2911328|NCT03170765|Active Comparator|GROUP C|measles vaccine at 9 months of age (current practice)
2911329|NCT03170752|Experimental|Intervention group|"The screening intervention Cardiovascular Assessment Screening Program (CASP) to be implemented by NPs in the intervention group has three steps:~Identification of patients (using Eligibility for Heart Health Screening Form, Heart Health Assessment Pamphlet, Tracking Form for Heart Health Screening, Algorithm for NP to Screen);~Screening utilizing appropriate tools (Cardiovascular Screening Checklist, Heart Health Screening Website/App);~Actions to follow up on the screening results (Heart Health Screening Website/App, CV Decision Tree Algorithm)."
2911330|NCT03170752|No Intervention|Control group|The NPs in the control group will be instructed to follow usual practice to screen patients for cardiovascular disease.
2911331|NCT03170739|Experimental|Dexmedetomidine|Dexmedetomidine 0.5ug/kg iv follow by 0.2ug/kg/h ivpump at the beginning of surgery.
2911332|NCT03170739|Experimental|Dopamine|Dopamine 3ug/kg/min ivpump at the beginning of surgery.
2911333|NCT03170739|Experimental|Dexmedetomidine+dopamine|Dexmedetomidine 0.5ug/kg iv follow by 0.2ug/kg/h ivpump, combined with dopamine 3ug/kg/min ivpump at the beginning of surgery.
2911334|NCT03170739|No Intervention|Control group|No intervention
2911335|NCT03170726|Active Comparator|arveles|Ibuprofen 800 mg in normal saline 150 cc and dexketoprofen (50 mg) before operation will be given in 30 minutes
2911336|NCT03170726|Active Comparator|intrafen|intrafen 800 mg in normal saline 150 cc before operation will be given in 30 minutes
2911337|NCT03170726|Placebo Comparator|plasebos|150 cc normal saline will be given in 30 minutes during preoperative period
2911338|NCT03170713|Active Comparator|arveles|800 mg ibuprofen and 50 mg arveles in 150 cc normal saline before operation will be given in 30 minutes.
2911339|NCT03170713|Active Comparator|intrafen|intrafen 800 mg in 150 cc normal saline before operation will be given in 30 minutes.
2911340|NCT03170713|Placebo Comparator|placebos|Pre-operative 150 cc normal saline will be delivered in 30 minutes
2911341|NCT03170700|No Intervention|Control|Participants will receive a nutrition program without parental feeding content. They will attend the nutrition program (Eating Smart • Being Active).
2961348|NCT02823158|Experimental|GPi DBS and best medical treatment|
2911349|NCT03170674|No Intervention|Abstinence Group|Subjects in the Abstinence Group will not be assigned any products.
2911350|NCT03170661|No Intervention|Moderate neuromuscular block|Subjects will receive moderate neuromuscular block, aimed at 1-2 twitches train of four
2911351|NCT03170661|Experimental|Deep neuromuscular block|Subjects will receive deep neuromuscular block, aimed at 1-2 twitches post tetanic count
2911352|NCT03170648|Experimental|Acupuncture|Patients will receive a 30-minute session of a standardized ear acupuncture treatment Acupuncture needles will be gently manipulated to increase stimulation For each ear acupuncture session, the patient will have ear acupuncture therapy administered to each ear
2911353|NCT03170635|Other|6 week Refreshing Recess program|Education and coaching for recess supervisors to learn about how to promote positive social interaction and active play with all students during recess. Provision of play activities for students during recess that foster active play, teamwork, and inclusion of students with disabilities and/or social challenges.
2911354|NCT03170622||IBD|Children (age <18 years) attending clinics in 3 paediatric gastroenterology referral centres in the UK in whom clinical assessment indicates that IBD is a possibility
2911355|NCT03170609|Experimental|Lowest dose formulation a|Multivalent group B streptococcus vaccine
2911356|NCT03170609|Experimental|Middle dose formulation a|Multivalent group B streptococcus vaccine
2911357|NCT03170609|Experimental|Highest dose formulation a|Multivalent group B streptococcus vaccine
2911358|NCT03170609|Experimental|Lowest dose formulation b|Multivalent group B streptococcus vaccine
2911359|NCT03170609|Experimental|Middle dose formulation b|Multivalent group B streptococcus vaccine
2911360|NCT03170609|Experimental|Highest dose formulation b|Multivalent group B streptococcus vaccine
2911361|NCT03170609|Placebo Comparator|Placebo|Saline control
2911362|NCT03170596|Experimental|Tazarotene gel arm|The treatment protocol in this arm will consist of night time application of Tazarotene 0.1% gel during the entire study period. (3 months)
2911363|NCT03170596|Active Comparator|Microneedling arm|The treatment protocol in this arm will consist of four sessions of microneedling at monthly intervals. (0, 1, 2, 3 months)
2911364|NCT03170570|Experimental|treatment|retreatment using intensity-modulated radiotherapy for cervical cancer patients with in-field recurrence
2911365|NCT03170557|Active Comparator|Traditional chinese acupuncture|Traditional chinese acupuncture. Administration of 12 sessions (2 per week for 6 weeks). Each session lasts 20-30 minutes.
2911366|NCT03170557|Sham Comparator|Aspecific needle skin stimulation|Aspecific needle skin stimulation. Administration of 12 sessions (2 per week for 6 weeks). Each session lasts 20-30 minutes.
2911367|NCT03170544|Experimental|Part 1, MK-1092, low dose 1|MK-1092, low dose 1, SC, as a single dose under the euglycemic clamp, in healthy participants
2911368|NCT03170544|Experimental|Part 1, MK-1092, low dose 2|MK-1092, low dose 2 SC, as a single dose under the euglycemic clamp, in healthy participants
2911369|NCT03170544|Experimental|Part 1, MK-1092, middle dose|MK-1092, middle dose SC, as a single dose under the euglycemic clamp, in healthy participants
2911370|NCT03170544|Experimental|Part 1, MK-1092, high dose 1|MK-1092, high dose 1 SC, as a single dose under the euglycemic clamp, in healthy participants
2911371|NCT03170544|Experimental|Part 1, MK-1092, high dose 2|MK-1092, high dose 2 SC, as a single dose under the euglycemic clamp, in healthy participants
2911372|NCT03170544|Active Comparator|Part 1, Glargine 3.0 nmol/kg|Glargine 3.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
2911373|NCT03170544|Experimental|Part 2, MK-1092 + lispro|MK-1092 + lispro, as a single dose, dose selection based on Part 1, in healthy participants
2911374|NCT03170544|Experimental|Part 3, MK-1092|MK-1092, SC, as a single dose, dose selection based on Part 1, in participants with T1DM. Up to 3 doses may be tested in participants with T1DM. Doses in Part 3 may be different from MK-1092 doses tested in Part 1.
2911375|NCT03170544|Active Comparator|Part 3, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose, in participants with T1DM
2911376|NCT03170544|Experimental|Part 4, MK-1092|MK-1092, SC, as a single dose, dose selection based on Part 1, in participants with T2DM. Up to 3 doses may be tested in participants with T2DM in 3 different treatment periods
2911377|NCT03170544|Active Comparator|Part 4, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose, in participants with T2DM
2911378|NCT03170531||Custom MR spine coil|
2911379|NCT03170518|Experimental|Single-blind run-in Period: Placebo|Participants will receive 1 placebo tablet matching canagliflozin 100 milligram (mg) once-daily during the 2-week single-blind placebo run-in period.
2911380|NCT03170518|Experimental|Double-blind Treatment Phase: Canagliflozin or Placebo|Canagliflozin 100 mg/matching placebo once-daily during first 12 weeks. At Week 13, participants who have glycated hemoglobin (HbA1c) of greater than or equal to (>=)7.0 percent (%), estimated glomerular filtration rate (eGFR) >=60 milliliter/minute/1.73 meter square (mL/min/1.73 m^2) will be re-randomized to either remain on canagliflozin 100 mg/matching placebo or up-titrate to canagliflozin 300 mg/matching placebo till Week 52.
2911381|NCT03170505||Acellular Dermal Matrix|
2911382|NCT03170505||Conchal Cartilage|
2911383|NCT03170492|Experimental|Computerized Cognitive Training|RehaCom for 480 minutes over 12 weeks.
2911384|NCT03170492|Active Comparator|Pencil-and-Paper Cognitive Training|Table-top based activities for 480 minutes over 12 weeks.
2911385|NCT03170479|Experimental|RUTF with Vitamin D|Two groups (arms) of malnourished children will be made, one study and one control group; Experimental arm will use RUTF and two mega doses of 200,000 IU vitamin D randomly first after 15 days of enrollment and second after 15 days of first dose.
2911386|NCT03170479|Placebo Comparator|RUTF with Placebo|Placebo arm will receive Ready to Use Therapeutic Food (RUTF) and extra virgin olive oil as Placebo.
2911387|NCT03170466|Experimental|Primary Palliative Care|The intervention will be delivered through four primary mechanisms. First, an existing HF nurse will deliver the intervention to patients during regularly scheduled visits. Second, telephone calls will reinforce topics. Third, patients will regularly report symptoms through the MyUPMC patient portal. Fourth, the nurse will act as a liaison to communicate concerns to the patient's cardiologist and primary care physician, as well as facilitating other resources (e.g., home health). In addition, follow-up assessments will be completed via phone or email at least 2 weeks post-intervention delivery. Caregivers will complete surveys during the first in-person visit and then during the follow-up assessments.
2911388|NCT03170466|No Intervention|Usual Care|Patients randomized to the control arm of this study will continue to receive the standard of high-quality HF care provided to all patients. Control patients may still receive palliative care outside of the study.
2911389|NCT03170453|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
2911390|NCT03170453|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.~Time commitment: about 1 hour per week; Location: Pittsburgh, PA only"
2911391|NCT03170440|Experimental|Noninvasive nerve stimulation type I|This group will receive one type of nerve stimulation
2911392|NCT03170440|Active Comparator|Noninvasive nerve stimulation type II|This group will receive second type of nerve stimulation
2911393|NCT03170427|Sham Comparator|8 mg (2 mL) levobupivacaine|8mg (2ml) levobupivacaine plus 20 µg fentanyl will be given intrathecally by spinal anesthesia. The impendance cardiography, the sensory and motor block will be monitored
2911394|NCT03170427|Active Comparator|6 mg (1.6 mL) levobupivacaine|6mg (1.6ml) levobupivacaine plus 20 µg fentanyl will be given intrathecally by spinal anesthesia. The impendance cardiography, the sensory and motor block will be monitored
2911395|NCT03170414||HIV D+/R+|HIV+ recipients who receive an organ transplant from an HIV+ donor
2911396|NCT03170401|No Intervention|no protein supplementation|trauma subjects receiving enteral nutrition without any protein supplementation
2911397|NCT03170401|Active Comparator|protein supplementation|trauma subjects receiving enteral nutrition with additional protein supplementation
2911398|NCT03170388|Experimental|IDP-126 Gel|Gel
2911399|NCT03170388|Active Comparator|IDP-126 Component A|Component A
2911400|NCT03170388|Active Comparator|IDP-126 Component B|Component B
2911401|NCT03170388|Active Comparator|IDP-126 Component C|Component C
2911402|NCT03170388|Placebo Comparator|IDP-126 Vehicle Gel|Vehicle Gel
2911403|NCT03170375|Experimental|Motivational Interviewing + WHEELS-I|In addition to motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan., participants in this arm will also receive an electronically-delivered tailored messaging intervention called Women's and Men's Hypertension Experiences and Emerging Lifestyle Intervention (WHEELS-I).
2911404|NCT03170375|Active Comparator|Motivational Interviewing|Participants in this arm will receive motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan.
2911405|NCT03170375|Experimental|DASH/SRD Diet|Participants in this arm will receive prepared, pre-packaged meals containing 1150mg of sodium.
2911406|NCT03170375|Placebo Comparator|Control Diet|Participants in this arm will receive prepared, pre-packaged meals containing 5750mg of sodium.
2911407|NCT03170362|Experimental|Intervention group|Pharmacogenetic test results will be provided to the provider within 72 hours of randomization in order to facilitate choice in selecting antidepressants.
2911408|NCT03170362|No Intervention|Delay results group|The comparator arm will not receive results at the time of randomization but will get results after the 24 week assessment (thus the results are delayed).
2911409|NCT03170349|Experimental|Edwards PASCAL Transcatheter Mitral Valve Repair System|
2911410|NCT03170336|Experimental|amiloride|Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks
2911411|NCT03170336|Active Comparator|hydrochlorothiazide|hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
2911412|NCT03170323|Experimental|Mycophenolate mofetil|Drug: Mycophenolate mofetil, high dose steroid Duration: 1 year
2911413|NCT03170323|Active Comparator|Cyclosporin|Drug: Cyclosporin, low dose steroid Duration: 1 year
2911414|NCT03170310|Experimental|Apatinib|
2911415|NCT03170284||Bevacizumab|Participants with advanced (stage IIIB/IV) NSCLC other than predominantly squamous cell histology receiving Bevacizumab in accordance with the summary product characteristics (SPC) is observed.
2911416|NCT03170271|Experimental|Benralizumab|Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
2911417|NCT03170271|Placebo Comparator|Placebo|Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
2911418|NCT03170258|Experimental|Reward-related Brain Region Feedback|Participants in this group will receive neurofeedback from a reward-related brain area (e.g., VTA, PFC) using EEG and/or fMRI during the experiment.
2911419|NCT03170258|Sham Comparator|Noise Control|Participants in this group will receive sham neurofeedback. Both groups will be debriefed at the end of the study.
2911420|NCT03170245||B thalassemia group|"Laboratory investigations :~complete blood count~renal and liver function tests~serum ferritin~lipid profile~Interleukin -6~HsC-RP~Adiponectin level~Imaging :~Abdominal ultrasound~Echocardiography~Carotid intima media thickness"
2911421|NCT03170245||Control group|"Laboratory investigations :~complete blood count~renal and liver function tests~serum ferritin~lipid profile~Interleukin -6~HsC-RP~Adiponectin level~Imaging :~Abdominal ultrasound~Echocardiography~Carotid intima media thickness"
2911422|NCT03170232|Experimental|Subjects receiving danirixin|Following screening and assessment of rescue medication use, subjects will receive one tablet of danirixin 35 mg (as hydrobromide hemihydrate salt) orally twice daily with food for 52 weeks during treatment period. Study treatment will be dispensed to subjects at the study visits.
2911633|NCT03168750|Other|Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup|All patients enrolled will receive the Medacta Masterloc Stem and MPACT cup with Highcross PE liner.
2911423|NCT03170232|Placebo Comparator|Subjects receiving placebo|Following screening and assessment of rescue medication use, subjects will receive one tablet of placebo 35 mg orally twice daily with food for 52 weeks during treatment period. Placebo will be dispensed to subjects at the study visits.
2911424|NCT03170219|Experimental|Subcutaneous Furosemide and sc2wear device|Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
2911425|NCT03170219|No Intervention|Usual Care|Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.
2911426|NCT03170206|Experimental|Binimetinib Combine with Palbociclib Phase 1|"Palbociclib will be administered orally once daily~Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle~Binimetinib will be administered orally twice daily~Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
2911427|NCT03170206|Experimental|Binimetinib Combine with Palbociclib Phase 2|"Palbociclib will be administered orally once daily~Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle~Binimetinib will be administered orally twice daily~Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
2911428|NCT03170206|Experimental|Binimetinib Phase 2|"Binimetinib will be administered orally twice daily~Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
2911429|NCT03170206|Experimental|Palbociclib Phase 2|"Palbociclib will be administered orally once daily~Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle"
2911430|NCT03170193|Experimental|AMG 529 Arm|AMG 529 of different dose levels administered to healthy volunteers
2911431|NCT03170193|Placebo Comparator|Placebo Arm|Placebo of calculated volume to match experimental drug administered to healthy volunteers
2911432|NCT03170180|Experimental|sunitinib|
2911433|NCT03170180|Experimental|gefitinib|
2911434|NCT03170180|Experimental|imatinib|
2911435|NCT03170167||Patients|This is a pre-post survey study of Communitas, a pre-existing integrative medicine and mind-body skills group visit for adolescents living with chronic illness and their parents. Approximately 50-100 patient enrollees of the Communitas group visits will be recruited to participate in this survey study optionally.
2911436|NCT03170167||Parents|This is a pre-post survey study of Communitas, a pre-existing integrative medicine and mind-body skills group visit for adolescents living with chronic illness and their parents. Approximately 50-100 parent enrollees of the Communitas group visits will be recruited to participate in this survey study optionally.
2911437|NCT03170141|Experimental|Antigen-specific IgT cells|Patients will receive non-myeloablative chemotherapy consisting of fludarabine and/or cyclophosphamide, followed by intravenous infusion of autologous IgT cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of IgT cells. The tested IgT cell dosage ranges from 1×10^5 /kg to 1×10^7 /kg
2911438|NCT03170128|Active Comparator|Outpatient Physical Therapy|
2911439|NCT03170128|Active Comparator|Home Exercises|
2911440|NCT03170115|Experimental|Aspirin|Induction chemotherapy followed by chemoradiotherapy with aspirin Aspirin 100mg daily during the chemoradiotherapy
2911441|NCT03170115|Placebo Comparator|Placebo Oral Tablet|Induction chemotherapy followed by chemoradiotherapy without aspirin Placebo daily during the chemoradiotherapy
2911442|NCT03170102|Other|Building capacity through education|Building capacity process through education - Occupational therapy students participate in online webinars and discussions following completion of readings.
2911443|NCT03170089|Active Comparator|Intervention|Professional tooth cleaning (scaling) Oral Health educational program
2911444|NCT03170089|No Intervention|Control|NO program or scaling done
2911445|NCT03170063||Parkinson's Disease Subjects|Up to 30 Parkinson's Disease patients will be enrolled.
2911446|NCT03170063||Healthy Controls|Up to 20 healthy controls will be enrolled.
2911447|NCT03170050|Experimental|YYD701-2|YYD701-2 Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
2911448|NCT03170050|Active Comparator|Restylane Perlane Lidocaine|Restylane Perlane Lidocaine Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
2911449|NCT03170037|Active Comparator|Standard V-E ventilation technique|After induction of anesthesia subject will be ventilated using the standard V-E ventilation technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute, I:E ratio of 1:2, peak inspiratory pressure of 20cmH2O and no PEEP. If the subjects can be adequately ventilated, as defined by perceivable chest movement and end tidal CO2 during the first three breaths, ventilation will continue for total ten breaths.
2911450|NCT03170037|Experimental|Reversal V-E ventilation technique|After induction of anesthesia subject will be ventilated using the reversal V-E ventilation technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute, I:E ratio of 1:2, peak inspiratory pressure of 20cmH2O and no PEEP. If the subjects can be adequately ventilated, as defined by perceivable chest movement and end tidal CO2 during the first three breaths, ventilation will continue for total ten breaths.
2911451|NCT03170011|Experimental|Intervention|The training protocol will be include 12 sessions completed over six weeks following a periodization training format. Each session will last approximately 40 minutes. At first, training will focus on high volume, low intensity, self-selected velocity with a progression to high intensity, low volume, self-selected velocity ending with a focus on power training (moderate intensity, moderate volume, high velocity movement) over the six weeks of training.
2911452|NCT03169998||GDFT group|The fluid infusion is to be performed, in accordance with GDFT protocol, on the basis of cardiac index (CI), stroke volume index(SVI) and stroke volume (SV) in addition to invasively measured arterial pressure by Vigilio / FloTrac Monitor.
2911453|NCT03169998||Control group|Patients in whom the surgery was conducted without the use of EV1000/ FloTrac monitoring among those who had undergone laparoscopic hepatobiliary or pancreatic surgery in the past.
2911634|NCT03168737|Experimental|Group A|Group A will have 5 18F-fluoroazomycin arabinoside ([18F]FAZA) PET-CT scans on Day 1 of the study and 5 imaging sessions on Day 2.
2911454|NCT03169985|Active Comparator|Rosuvastatin plus ezetimibe arm|In patients who have moderate stenosis(30-70%) in coronary artery and deferred to medical treatment by intracoronary physiologic or radiologic test, this arm will be received rosuvastatin 10 mg plus ezetimibe 10 mg qd during 12 months after randomization.
2911455|NCT03169985|Active Comparator|High-dose rosuvastatin monotherapy arm|In patients who have moderate stenosis(30-70%) in coronary artery and deferred to medical treatment by intracoronary physiologic or radiologic test, this arm will be received rosuvastatin 20 mg qd during 12 months after randomization.
2911456|NCT03169972||Previously treated patients (PTPs)|PTPs: patients who had 4 or more days to other Factor VIII (FVIII) products
2911457|NCT03169972||Previously untreated patients (PUPs)|PUPs: patients who had 3 or less previous exposure days to other products
2911458|NCT03169959|Experimental|Cohort 1: Sequence 1 (ABC)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
2911459|NCT03169959|Experimental|Cohort 1: Sequence 2 (ACB)|"Subjects were randomized to treatment sequence 1 ACB:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
2911460|NCT03169959|Experimental|Cohort 1: Sequence 3 (BAC)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
2911461|NCT03169959|Experimental|Cohort 1: Sequence 4 (BCA)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
2911462|NCT03169959|Experimental|Cohort 1: Sequence 5 (CAB)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
2911463|NCT03169959|Experimental|Cohort 1: Sequence 6 (CBA)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5mg saxagliptin / 5mg dapagliflozin / 1000 mg metformin XR without food."
2911464|NCT03169959|Experimental|Cohort 2: Sequence 1 (DEF)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
2911465|NCT03169959|Experimental|Cohort 2: Sequence 2 (DFE)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
2911466|NCT03169959|Experimental|Cohort 2: Sequence 3 (EDF)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
2911467|NCT03169959|Experimental|Cohort 2: Sequence 4 (EFD)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
2911468|NCT03169959|Experimental|Cohort 2: Sequence 5 (FDE)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
2911719|NCT03168152|Experimental|MWA|MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
2911469|NCT03169959|Experimental|COhort 2: Sequence 6 (FED)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
2911470|NCT03169946|Active Comparator|Test Group|Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement (RCT with CHX-MTZ,OFD).
2911471|NCT03169946|Active Comparator|Positive Control Group :|Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement(RCT with CHX,OFD).
2911472|NCT03169933|Other|intensified and modulated adjuvant RT|All patients underwent combined, intensified and modulated adjuvant radiotherapy for 5 days a week with the following doses: 1) pelvic node irradiation (45 Gy; 1.8 Gy/fraction) followed by boost on the prostate bed (19.8-25.2 Gy; 1.8 Gy/fraction; total dose: 64.8-70.2 Gy) or 2) exclusive prostate bed irradiation (64.8 -70.2 Gy; 1.8 Gy/fraction).
2911473|NCT03169920|Active Comparator|Test Group|Modified-Minimally Invasive Surgical Technique + PRF
2911474|NCT03169920|Active Comparator|Control Group|Modified-Minimally Invasive Surgical Technique alone.
2911475|NCT03169907|Experimental|Rh isoimmunized patients|Patients will be selected from Rh isoimmunized patients (positive titre of indirect coomb's test) who are scheduled to have intrauterine blood transfusion. This intrauterine blood transfusion is due to fetal anemia, and it is detected when the measurement of PSV (peak systolic velocity) of middle cerebral artery is more than 1.5 MoM (multiple of the median) according to Fetal Medicine unit of Cairo University protocol. All fetuses are free of structural and functional Fetal and echocardiographic anomaly scan.
2911476|NCT03169894|Experimental|MDGN-002|MDGN-002 will be supplied in vials of 150 mg/mL. MDGN-002 will be administered by SQ injection in the abdomen every 14 days at 1 of 2 dose levels: 1.0 mg/kg or 3.0 mg/kg.
2911477|NCT03169881|Experimental|Darbepoetin|Darbepoetin 10 micrograms/kg/once every week (IV or SC)
2911478|NCT03169881|Placebo Comparator|Placebo|Equal volume normal saline for IV administration, or sham dosing
2911479|NCT03169868|Experimental|Enhanced Medication reconciliation|Medication reconciliation with pharmacist using electronic health records, pharmacy dispensing data and Sano Patient Medication Profile(TM)
2911480|NCT03169868|No Intervention|Standard Medication reconciliation|Medication reconciliation with pharmacist using electronic health records and pharmacy dispensing data only
2911481|NCT03169855||Refractive media opacities: present|Refractive media opacities: present
2911482|NCT03169855||Refractive media opacities: absent|Refractive media opacities: absent
2911483|NCT03169829|Experimental|Hemodialysis Patients|Phosphorus and potassium homeostasis will be assessed based on the concentrations of phosphorus and potassium in blood samples collected in fasting, post-prandial, mid-afternoon, pre-dialysis states, as well as the concentrations of phosphorus-regulatory factors, calcitriol, parathyroid hormone and fibroblast growth factor-23. The participants will be transitioned gradually to a plant-rich diet
2911484|NCT03169816|Experimental|Lorcaserin|10 mg capsule taken twice daily of lorcaserin
2911485|NCT03169816|Placebo Comparator|Placebo|a placebo comparator capsule taken twice daily
2911486|NCT03169803|Experimental|Single arm, NeuroTronik CANS Therapy System|
2911487|NCT03169790|Experimental|Nant NHL Vaccine|avelumab, bevacizumab, capecitabine, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, lovaza, oxaliplatin, rituximab, stereotactic body radiation therapy, ALT-803,ETBX-061, and haNK.
2911488|NCT03169777|Experimental|Nant CRC Vaccine|avelumab, bevacizumab, capecitabine, cetuximab, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
2911489|NCT03169764|Experimental|Nant HNSCC Vaccine|avelumab, bevacizumab, capecitabine, cetuximab, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab-paclitaxel, nivolumab, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
2911490|NCT03169751||PNES Cohort|Participants who experience a non-epileptic event with upper extremity motor involvement, while enrolled in the trial
2911491|NCT03169751||Epileptic Cohort|Participants who experience an epileptic event with upper extremity motor involvement, while enrolled in the trial
2911492|NCT03169738|Experimental|Nant NSCLC Vaccine|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
2911493|NCT03169725|Experimental|Test group 1|Low dose (Stage2: Lot A) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
2911494|NCT03169725|Experimental|Test group 2|Middle dose (Stage2: Lot B) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
2911495|NCT03169725|Experimental|Test group 3|High dose (Stage2: Lot C) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
2911496|NCT03169725|Active Comparator|Comparator|Cormmercialized inactivated poliomyelitis vaccine based on Sabin strains (Imovax Polio)
2911497|NCT03169712|Active Comparator|CBT for PTSD|15 sessions of trauma-focused CBT
2911498|NCT03169712|Experimental|Imagery Rehearsal Therapy + CBT for PTSD|5 sessions of IRT + 15 sessions of trauma-focused CBT
2911499|NCT03169699||Cough Arm|Children age 16 years old and below with cough at presentation - Patients presenting with active or chronic or residual cough
2911500|NCT03169699||Well Arm|Children age 16 years old and below and Well with no presentation of cough
2911534|NCT03169413||control one|Twenty five diabetic children diagnosed after the age of one year subjected to genetic study to study human leucocytic antigen and possible of presence of gene mutation of the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel and possible risk factors associated with disease .
2911720|NCT03168152|Experimental|SBRT|SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
2911501|NCT03169686|Experimental|Intervention Group|"Participants who allocate to the intervention group will receive regular messages providing smoking cessation related information, such as advice, support, and distraction by professional team. One to six messages will be sent per day for the time leading up to the quit day and the following 24 weeks.~One to three messages will be sent per week until the end of the 1 year follow up. They will also be encouraged to send self-help, peer support messages in their group. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 4, 12, 24 and 1 year points."
2911502|NCT03169686|No Intervention|Control Group|Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until their free month at the end of follow up. They will be encouraged to send self-help, peer support messages in their group. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 4, 12, 24 and 1 year points.
2911503|NCT03169660|Experimental|Treatment group|Eyes with submacular hemorrhage secondary to exudative age-related macular degeneration and were treated with vascular endothelial growth factor trap-eye.
2911504|NCT03169647|Experimental|Intervention|listening-based protocol (type A)
2911505|NCT03169647|Placebo Comparator|Control|listening-based protocol (type B)
2911506|NCT03169634|Experimental|short or long stemmed rTKR cemented|
2911507|NCT03169634|Experimental|Cone with short stem|
2911508|NCT03169634|Experimental|Cone with long stem|
2911509|NCT03169621||Patients with RIF|Patients with repeated implantation failure (RIF) with indication of hysteroscopy within normal clinical practice, who will undergo FIV or ICSI and embryo transfer within their assisted reproduction treatment (ART).
2911510|NCT03169582|Active Comparator|Avanafil|Clinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil).
2911511|NCT03169582|Active Comparator|Sildenafil|Clinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil)
2911512|NCT03169569|Experimental|Hemostatic powder group (Endo-clot™ group)|Patients who will undergo ESD with Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) after hemostasis on the post-resection ulcer using conventional method and removal of specimen.
2911513|NCT03169569|Active Comparator|Hemostatic forceps Only (Coagrasper®, Olympus, Japan) group|For patients in the control group, hemostasis with conventional method (electrical coagulation and/or clip, Coagrasper®, Olympus, Japan) will be done.
2911514|NCT03169556|Experimental|video-laryngoscope guided lightwand|
2911515|NCT03169556|Active Comparator|lightwand|
2911516|NCT03169543|Experimental|Sleep deprivation|36-hours of total sleep deprivation
2911517|NCT03169530|Active Comparator|Alcohol|One standard serving of alcohol (~15 gm) daily
2911518|NCT03169530|No Intervention|Abstention|Abstention from alcohol
2911519|NCT03169517||Peripheral nerve block group|patients scheduled for elective upper or lower limb surgery with peripheral nerve block will receive LSCI measurements and pinprick sensory tests at 5 min before the block and at 5-min intervals till 30 min after the block.
2911520|NCT03169504|Experimental|Acupuncture|Patients in this arm will receive acupuncture.
2911521|NCT03169504|Experimental|Conventional drug|Patients will be individually divided into Group A, Group B, Group C and Group D according to GOLD 2017. For Group A, Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd) will be used. For Group B and Group C, Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH) will be used. As for Group D, Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH) or Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline) will be used.
2911522|NCT03169504|Experimental|Acupuncture plus conventional drug|Patients in this arm will receive both acupuncture and conventional drug.
2911523|NCT03169491|Experimental|Therapeutic|Continuous positive airway pressure (CPAP) with automatic pressure from 4 to 15 cmH2O every night for one week, afterwards use of CPAP at the P90 of pressure determinated during automatic use for one week, via oronasal interface.
2911524|NCT03169491|Sham Comparator|Suboptimal|Continuous positive airway pressure (CPAP) every night for two weeks at fixed pressure of 4 cmH2O, via oronasal interface.
2911525|NCT03169491|Other|Severe OSAS|Continuous positive airway pressure (CPAP) with automatic pressure from 4 to 15 cmH2O every night for one week, afterwards use of CPAP at the P90 of pressure determinated during automatic use for one week, via oronasal interface.
2911526|NCT03169478|No Intervention|multiple myoma control group|The control group will not have any balloon therapy. A second-look hysteroscopy will be carried out 6 weeks after the surgery.
2911527|NCT03169478|Experimental|multiple myoma IUB dilatation group|The multiple myoma study group will have Foley-catheter intrauterine balloon dilatation therapy 2 weeks and 4 weeks after hysteroscopic myomectomy. A second-look hysteroscopy will be carried out 6 weeks after the surgery.
2911528|NCT03169465|Experimental|open group|patients with posterior calcaneal deformity
2911529|NCT03169465|Active Comparator|endoscopic group|patients with posterior calcaneal deformity
2911530|NCT03169439|Other|hepatic focal lesions and pancreatic masses|
2911531|NCT03169426|Experimental|Beta Blockers Carvedilol Phosphate|"Subjects are going to take beta-blocker (carvedilol, 12.5 mg once) before undergoing remote ischemic conditioning.~Intervention: taking beta-blocker"
2911532|NCT03169426|No Intervention|Control|Subjects are going to undergo remote ischemic conditioning without taking any drug.
2911533|NCT03169413||cases|Fifty diabetic children diagnosed under the age of one year subjected to genetic analysis to study human leucocytic antigen haplotype class two (DR-DQ) and detection of mutations in the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel also possible risk factors associated with the disease.
2911630|NCT03168763|Experimental|Video 1B|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
2911721|NCT03168139|Experimental|Olaptesed pegol + Pembrolizumab|
2911535|NCT03169413||control two|Twenty five healthy children matched by age subjected to genetic study to study human leucocytic antigen and possible of presence of gene mutation of the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel and exposure to similar risk factors associated with disease .
2911536|NCT03169400||Theranova treated|We will collect pool of human sera from HD patients treated with regular bicarbonate dialysis membrane (baseline). Then, patients will be treated for 3 months with Theranove dialyzer, and sera will be collected at 1, 2, and 3 months. We will create a serum pool.
2911537|NCT03169400||Standard treated|We will collect pool of human sera from HD patients treated with regular bicarbonate dialysis membrane (baseline). Then, patients will be treated for 3 months with Theranove dialyzer, and sera will be collected at 1, 2, and 3 months. We will create a serum pool.
2911538|NCT03169387|Experimental|Virtual Reality|Microsoft's Xbox 360® will be used with Kinect™,
2911539|NCT03169387|Active Comparator|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training
2911540|NCT03169374|Experimental|Virtual Reality Technology|Virtual Reality Therapy
2911541|NCT03169361||Ixazomib 4 mg|The usual adult dosage for oral administration is 4 mg as ixazomib, in the fasting state, once a day, once a week for 3 weeks (Days 1, 8, and 15), with a 13-day washout period (Days 16 through 28). This 4-week cycle will be repeated for 6 cycles. The dose may be reduced appropriately according to the patient's condition. Participants will receive interventions as part of routine medical care.
2911542|NCT03169348|Experimental|study group|Hepatitis- C virus with thrombocytopenia
2911543|NCT03169335|Experimental|Experimental group|QL1101 + paclitaxel/carboplatin:subjects are given 15 mg/kg QL1101 on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles (at least 4 cycles).
2911544|NCT03169335|Active Comparator|Control group|Avastin® + paclitaxel/carboplatin:subjects are given 15 mg/kg Avastin® on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles (at least 4 cycles).
2911545|NCT03169322|Active Comparator|Test Group|patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing (SRP)
2911546|NCT03169322|Active Comparator|Control Group|Nose breathers having chronic periodontitis will receive scaling and root planing (SRP)
2911547|NCT03169309|Experimental|Pre and Post Intervention|One Study Arm - Quantitative and qualitative sleep quality measure will be captured at baseline (Phase I/Week 1-2), while using Brain Entrainment Technology (Phase II/Week3-4), and after using the technology.
2911548|NCT03169283|Experimental|Cereal 1|A cereal high in viscous dietary fiber B glucan
2911549|NCT03169283|Active Comparator|Cereal 2|A cereal without B glucan
2911550|NCT03169270|Experimental|COPD training group|COPD were required to be clinically stable at the time of study without episodes of exacerbation or oral steroid treatment in the previous four months. All COPD patients were on bronchodilators and inhaled corticosteroids. No patient presented severe co-morbidities. The intervention consists in an 8-week programe of exercise training.
2911551|NCT03169270|Active Comparator|Healthy training group|Healthy sedentary age-matched subjects were recruited from the outpatients' clinics of our hospital. The intervention consists in an 8-week programe of exercise training.
2911552|NCT03169257|Experimental|OB|Obese subjects according to the International Obesity Task Force (IOTF) criteria aged 6 to 16 years. OB subjects will undergo for 12 months an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes.
2911553|NCT03169257|No Intervention|NW|Normal weight subjects according to the International Obesity Task Force (IOTF) criteria aged 6 to 16 years and age, sex and pubertal status matched with the OB group
2911554|NCT03169244|Active Comparator|Bupropion|Bupropion extended release
2911555|NCT03169244|Placebo Comparator|Placebo|Placebo oral tablet
2911556|NCT03169231|Experimental|Study Group A|Single peripheral IV infusion of 25 million Longeveron Mesenchymal Stem Cells (LMSCs)
2911557|NCT03169231|Experimental|Study Group B|Single peripheral IV infusion of 50 million Longeveron Mesenchymal Stem Cells (LMSCs)
2911558|NCT03169231|Experimental|Study Group C|Single peripheral IV infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs)
2911559|NCT03169231|Experimental|Study Group D|Single peripheral IV infusion of placebo
2911560|NCT03169218|Experimental|Mirror therapy group|Mirror therapy group: exercises looking at the reflection in the mirror of the hand moving
2911561|NCT03169218|Placebo Comparator|Placebo group|Placebo group: exercises performed with the mirror turned to avoid the reflection of the hand and looking at the hand that did not remain hidden.
2911562|NCT03169205||preexisting Diabetes mellitus type 1|
2911563|NCT03169205||preexisting Diabetes mellitus type 2|
2911564|NCT03169205||Gestational Diabetes mellitus|
2911565|NCT03169192||Repeated fractures group|detection of gene mutations of osteogenesis imperfecta in single group of patients with repeated fractures then start treatment with zoledronic acid in doses children less than 5 years ( 0.025 milligram for each kilogram every 3 months for 18 months duration) children more than 5 years ( 0.05 milligram for each kilogram every 6 months for 18 months duration)
2911566|NCT03169179|Experimental|Fitbit and Bupa Boost app|Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
2911567|NCT03169166|Experimental|"Repeated 3-dose GnRHa  Triptorelin"|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart (0.3/0.2/0.2mg) when at least three follicles 18 mm in diameter have been observed by ultrasound examination.
2911568|NCT03169166|No Intervention|"Conventional 1-dose GnRHa  Triptorelin"|Triptorelin pre-filled syringes will be administered subcutaneously in a single dose (0.3 mg) when at least three follicles 18 mm in diameter have been observed by ultrasound examination.
2911631|NCT03168763|Experimental|Video 2A|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
2911722|NCT03168126||Pro-AQT-Monitoting|Patients with OSCC of the jaws and tumor resection + primary free flap reconstruction
2911569|NCT03169153|Other|Lotrafilcon B, then senofilcon C|Lotrafilcon B contact lenses worn first, followed by senofilcon C contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
2911570|NCT03169153|Other|Senofilcon C, then lotrafilcon B|Senofilcon C contact lenses worn first, followed by lotrafilcon B contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
2911571|NCT03169140|Active Comparator|Group 1|Receive a combination of products (TheraBand Kinesiology Tape and Biofreeze) to use for one week for at home pain management.
2911572|NCT03169140|Active Comparator|Group 2|Receive TheraBand Kinesiology Tape product to use for one week for at home pain management.
2911573|NCT03169140|Active Comparator|Group 3|Receive a topical product, Biofreeze, to use for one week for at home pain management
2911574|NCT03169140|Active Comparator|Group 4|Receive advice sheet outlining at home pain management strategies to use for one week.
2911575|NCT03169127|Experimental|Experimental Group Ibuprofen 600mg|Two Hundred healthy volunteers underwent removal of one lower third molar, will be treated to control pain, swelling and trismus with ibuprofen 600mg. Therefore, these 200 patients will be genotyped and phenotyped for these genes and their postoperative records with all data collected will be compared with the haplotypes found in the Brazilian population.
2911576|NCT03169114|Active Comparator|Amikacin injection|Antibiotic Non-Operative Management Strategy
2911577|NCT03169114|Active Comparator|Appendicectomy|Surgery Management Strategy
2911578|NCT03169101||HIV+|HIV-infected smokers: diagnosed with HIV infection and exhibiting viral load of less than or equal to 1000 copies/mL and CD4+ counts of greater than or equal to 200 cells/mm3 within 6 months prior to enrollment
2911579|NCT03169101||HIV-|HIV-uninfected smokers: negative HIV status will be confirmed by an on-site rapid HIV blood test
2911580|NCT03169088|Experimental|Coaching procedure|Volunteers will received Updated National Dietary Guidelines about food and physical activity with a one-year follow-up, plus connected coaching.
2911581|NCT03169075|Experimental|ARM A: A|SSPA
2911582|NCT03169075|Active Comparator|ARM B: B|PA
2911583|NCT03169062|Experimental|All patients|Gated Stationary Chest Tomosynthesis
2911584|NCT03169049|Experimental|High-Frequency|"Transcutaneous application of high frequency electrical current over the arm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
2911585|NCT03169049|Sham Comparator|Sham stimulation|Electrodes are placed over the arm for a 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel
2911586|NCT03169023|Experimental|Arm 1: ScaleDown (only first 16 patients)|"Baseline quality of life and image surveys~Weigh themselves every day on the provided Wi-Fi Scale~Personalized feedback with text message comes as soon as participants step on the scale~At the 6 month time period, quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed~At the end of 6 months, the participants will also receive the Enhanced Usual Care Packet which provides printed material from the American Cancer Society Website~Only 16 participants were in this arm because ScaleDown went out of business"
2911587|NCT03169023|Active Comparator|Arm 2: Enhanced Usual Care|"Baseline quality of life and image surveys~Brief in-person counseling session by a research assistant using the Enhanced Usual Care Handouts from the American Cancer Society website which provides guidelines on healthy eating and exercise~At the 6 month time period quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed"
2911588|NCT03169023|Experimental|Arm 3: iOTA|"Baseline quality of life and image surveys~Weigh themselves everyday using the provided Balance High Accuracy Digital Body Fat Scale~Health coach will meet one-on-one with each participant (in-person or phone) to review health risk assessment and to choose 3 behavior goals related to healthy eating and physical activity at enrollment, 3 months, and 6 months~Self-monitoring via SMS text messaging. Weekly check-ins by text providing data about weight and goals~At the 6 month time period quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed~At the end of 6 months, the participants will also receive the Enhanced Usual Care Packet which provides printed material from the American Cancer Society Website~Final weight check-in at 12 months"
2911589|NCT03169010||Idiopathic Pulmonary Artery Hypertension|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to idiopathic pulmonary artery hypertension (PAH).
2911590|NCT03169010||Hereditary PAH|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary PAH.
2911591|NCT03169010||Hereditary Hemorrhagic Telangiectasia|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary hemorrhagic telangiectasia associated PAH.
2911592|NCT03169010||Pulmonary Veno-Occlusive Disease (PVOD)|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to PVOD.
2911593|NCT03169010||Pulmonary Capillary Hemangiomatosis|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to pulmonary capillary hemangiomatosis associated PAH
2911594|NCT03169010||Cavernous Transformation of Portal Vein|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to cavernous transformation of portal vein associated PAH
2911595|NCT03169010||CTEPH|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to chronic thromboembolism pulmonary hypertension (CTEPH).
2911596|NCT03168997|Other|Mild AD|Memantine Hydrochloride 20mg tablet per day by mouth on mild AD
2911597|NCT03168997|Other|Moderate AD|Memantine Hydrochloride 20mg tablet per day by mouth on moderate AD
2911598|NCT03168997|Other|Severe AD|Memantine Hydrochloride 20mg tablet per day by mouth on severe AD
2911632|NCT03168763|Experimental|Video 2B|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
2911599|NCT03168984|Experimental|UCB0942|Cohort 1 (Japanese subjects): Single dose of UCB0942 (dosage regimen 1) Cohort 2 (Japanese subjects): Single dose of UCB0942 (dosage regimen 2) Cohort 3 (Japanese subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2) Cohort 4 (Caucasian subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2)
2911600|NCT03168984|Placebo Comparator|Placebo|Cohort 1 and Cohort 2: Single dose of Placebo Cohort 3 and Cohort 4: Single dose of Placebo followed, after maximum 21 days, by multiple doses of Placebo
2911601|NCT03168971|Experimental|Managing Anxiety from Cancer (MAC)|Older adults with cancer and their primary informal caregiver will receive a seven-session cognitive-behavior therapy intervention administered over the telephone by a trained study interventionist. The intervention is administered weekly and each session is 45-50 minutes in length. Patients and caregivers will receive the intervention independently and from separate therapists.
2911602|NCT03168971|No Intervention|Usual Care|Older adults with cancer and their primary informal caregiver will receive standard care provided by their medical team. These participants will not receive any intervention from the research team.
2911603|NCT03168958|Active Comparator|Methadone Group|Patients in this group will receive 0.4 mg/kg of methadone at induction of anesthesia
2911604|NCT03168958|Sham Comparator|Saline-Control Group|Patients in this group will receive an equal volume of saline as the active comparator group at induction of anesthesia
2911605|NCT03168945|Active Comparator|Novel diagnostics arm|The intervention is to screen a sputum specimen collected on a participant with suspected TB in the community at the point-of-contact in a mobile van using an on-site GeneXpert MTB/RIF machine
2911606|NCT03168945|Placebo Comparator|Routine screening arm|The control arm is to send a sputum specimen collected on a participant with suspected TB at the mobile van for routine smear microscopy at a laboratory
2911607|NCT03168919|Experimental|Chemoradiation with MRI assessment|This study has only one arm. The eligible subjects will receive standard of care fractionated radiation therapy along with concomitant temozolomide, which will NOT be changed based on the MRI scans obtained as a part of this study. There is no control or sham group.
2911608|NCT03168906|Experimental|NEOD001|Study Drug given IV every 28 days at 24mg/kg
2911609|NCT03168906|Placebo Comparator|Placebo|Placebo
2911610|NCT03168893|Experimental|Deep brain stimulation ON|Surgical procedure is necessary.In surgery, two cerebral electrodes (either in the Subgenual cingulate or in the Accumbens Nucleus) are connected to a subcutaneous generator at abdominal fat level, under general anesthesia. The patient will initiate the stimulation prior to discharge . At 6 months follow up, Deep brain stimulation continue 3 months more activated, patient and psychiatrist don´t know
2911611|NCT03168893|Experimental|Deep brain stimulation OFF|Surgical procedure is necessary.In surgery, two cerebral electrodes (either in the Subgenual cingulate or in the Accumbens Nucleus) are connected to a subcutaneous generator at abdominal fat level, under general anesthesia. The patient will initiate the stimulation prior to discharge . At 6 months follow up, Deep brain stimulation is stopped during 3 months , patient and psychiatrist don´t know
2911612|NCT03168880|Active Comparator|A|weekly Paclitaxel chemotherapy at the dose of 100 mg/m2/week for 8 weeks as a 1-hour infusion and AC/EC (60/600 or 90/600) / 3 weekly.
2911613|NCT03168880|Experimental|B|weekly Paclitaxel at 100mg /m2/week + weekly Carboplatin AUC-2 as an infusion over 60 minutes and AC/EC (60/600 or 90/600)/ 3 weekly.
2911614|NCT03168867|No Intervention|Standard Educational Control|Participants in the standard educational control group will be provided with standard care regarding type 1 diabetes management during their routine clinic visits as usual. The standard care will be consistent with diabetes education provided by each of the study sites.
2911615|NCT03168867|Experimental|The 3Ms Intervention + Standard Care|Parents will complete the first intervention session in the diabetes clinic immediately after baseline data collection and randomization. The subsequent two intervention sessions will also be conducted during regularly scheduled diabetes clinic visits.
2911616|NCT03168854|Experimental|GAP Arm 1|10 subjects will receive 5 vaccinations: the GAP3KO vaccine administered by the bite of approximately 200 infected A. Stephensi mosquitoes at weeks 0, 4, 8, 12, and 20 for a maximum cumulative dose of 1000 GAP3KO bites per subject
2911617|NCT03168854|Experimental|GAP Arm 2|6 subjects will receive 3 vaccinations: the GAP3KO vaccine administered by the bite of approximately 200 infected A. Stephensi mosquitoes at weeks 8, 12, and 20 for a maximum cumulative dose of 600 GAP3KO bites per subject
2911618|NCT03168854|Active Comparator|Malaria-naive Infectivity Control Arm|6 healthy volunteers will receive challenge with wild type Plasmodium falciparum NF54 sporozoites through the bites of five infectious A. stephensi moquitoes using standard CHMI procedures
2911619|NCT03168841|Experimental|Intervention Group, receiving medication|Enrolled subjects with confirmed onychomycosis will be dispensed topical medication for treatment.
2911620|NCT03168828|Experimental|TAR-302-5018|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
2911621|NCT03168815|Experimental|High Flow Nasal Cannula (HFNC)|Oxygen is delivered at 50 L/min with FiO2 50% delivered for at least 5 min prior to FOB and throughout the procedure.
2911622|NCT03168815|Active Comparator|Low Flow Nasal Cannula (LFNC)|Oxygen is delivered at 6L/min applied for at least 5 minutes prior to FOB and throughout the procedure.
2911623|NCT03168802|Experimental|MRgFUS facet treatment|MRgFUS ablation for facet joint pain once at Lumbar spine
2911624|NCT03168802|Active Comparator|Radiofreuqency ablation facet treatment|Radiofreuqency ablation for facet joint pain once at Lumbar spine
2911625|NCT03168789|Experimental|Tension Tamer (TT)|Breathing Awareness Mediation delivered by smartphone app.
2911626|NCT03168789|Active Comparator|Lifestyle education program (SPCTL)|Healthy lifestyle education provided by text messages and links to media. Runkeeper app to log physical activity.
2911627|NCT03168776|Experimental|BuMA Supreme Coronary Stent System|
2911628|NCT03168776|Active Comparator|Xience or Promus Everolimus Stent System|
2911629|NCT03168763|Experimental|Video 1A|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
2911754|NCT03167892|Experimental|Intervention|Oral screen
2911755|NCT03167892|No Intervention|Control|No intervention
2911635|NCT03168737|Experimental|Group B|Based on what is learned from Group A, Group B will have 5 or less 18F-fluoroazomycin arabinoside ([18F]FAZA) PET-CT scans on Day 1 and will have 5 or less [18F]FAZA PET-CT scans on either Day 2, 3, 4, or 5.
2911636|NCT03168724|Experimental|GMT Intervention|Over the course of 9 weeks, there are 2h-group sessions with a therapist.
2911637|NCT03168724|No Intervention|Control|Group not getting the intervention
2911638|NCT03168711|Experimental|Inosine|Subjects will be administered oral inosine daily. The dose of inosine will be titrated to obtain serum urate levels of 7 - 8 mg/dL.
2911639|NCT03168711|Placebo Comparator|Placebo|Subjects will be administered oral placebo daily. The dose of placebo will be titrated to obtain serum urate levels of 7 - 8 mg/dL.
2911640|NCT03168698|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
2911641|NCT03168698|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
2911642|NCT03168698|Active Comparator|Oxytocin 0.5IU|Oxytocin 0.5IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
2911643|NCT03168698|Active Comparator|Oxytocin 5IU|Oxytocin 5IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
2911644|NCT03168685|Experimental|Experimental|"Multiple device intervention~SureSource Engage mobile application~ActiGraph Link~weight scale"
2911645|NCT03168672|Other|Global ICON|The study device is the GLOBAL ICON stemless humeral component, consisting of the Anchor Plate and Humeral Head.
2911646|NCT03168659|Other|Treatment|Pulmonary vein isolation ablation with HeartLight Endoscopic Ablation System
2911647|NCT03168646|Active Comparator|group 1|wafer group procedure using an arthroscope through portal(radial to extensor carpi ulnaris, debridement of triangular fibro-cartilage complex 3-4 mm is shaved from the dome of the ulna by 2.9 bur.
2911648|NCT03168646|Active Comparator|group 2|ulnar shortening group :this is the most logical technique, dorsoulnar incision is made on the distal one-third of the forearm then a 6 hole 3.5 mm Dcp plate is position,osteotomy using oscillating saw in z-shaped manner.
2911649|NCT03168633|Experimental|patients receiving emails|"Diagnosed DM2 patients who meet inclusion criteria. the patients will receive emails containing information about DM2 as a method of reminding patients of the importance of adjusting post diagnosis life-style changes.~web-based DM2 information pages"
2911650|NCT03168620|Active Comparator|ITR group|In ITR group after partial caries removal(PCR), interim therapeutic restoration of glass ionomer cement (GIC) Ketac molar was placed for one month before definitive adhesive restoration
2911651|NCT03168620|Active Comparator|Non ITR group|In NON-ITR group, cavity preparation was similar to ITR group, but definitive restoration was done in the same visit
2911652|NCT03168607|Experimental|FOLFIRI|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
2911653|NCT03168594|Experimental|A:Irinotecan combined with cisplatin (IP regimen)|patients in arm A will receive chemotherapy of IP regimen: Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
2911654|NCT03168594|Experimental|B:Etoposide combined with cisplatin (EP regimen)|patients in arm B will receive chemotherapy of EP regimen: Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
2911655|NCT03168581|Experimental|CN-105|All eligible subjects will receive study drug, CN-105
2911656|NCT03168568|Experimental|Valsartan/Sacubitril|Valsartan-Sacubitril 50mg/100mg twice daily, titrated to 200mg twice daily p.o. Duration of product administration: 3 months
2911657|NCT03168568|Active Comparator|Valsartan|Valsartan 40mg/80mg twice daily, titrated to 160mg twice daily p.o Duration of product administration: 3 months
2911658|NCT03168555|Experimental|Intervention|chenodeoxycholic acid 1250mg po.
2911659|NCT03168529|Active Comparator|Ivabradine (Corlanor)|All subjects will complete the same number of follow-ups, dose titrations (if necessary) and study procedures however, subjects in this arm will be receiving active drug for study duration.
2911660|NCT03168529|Placebo Comparator|Placebo|All subjects will complete the same number of follow-ups, dose titrations (if necessary) and study procedures however, subjects in this arm will be receiving placebo for study duration.
2911661|NCT03168516|Experimental|Experimental intervention|closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)
2911662|NCT03168516|No Intervention|Control intervention|Standard care, i.e. manual adjustments of the FiO2 only
2911663|NCT03168503|Experimental|LGG+Promitor™|LGG:10^12 CFU/g Lactobacillus rhamnosus GG (commercialised as LGG) combined with Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
2911664|NCT03168503|Experimental|Promitor™|Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
2911665|NCT03168503|Experimental|LGG-PB12+Promitor™|LGG-PB12:10^12 CFU/g of a pilus-less derivative L. rhamnosus GG combined with Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
2911666|NCT03168503|Placebo Comparator|Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) 12g delivered and served as dry powders to be consumed as 250 ml beverages at breakfast.
2911667|NCT03168490|Active Comparator|1.5g low gluten friendly bread|1.5g low gluten friendly bread as15g bun/day to be consumed as 250 ml beverages at breakfast for 14 days
2911668|NCT03168490|Active Comparator|3g medium gluten friendly bread|3g medium gluten friendly bread as 30g bun to be consumed as 250 ml beverages at breakfast for 14days
2911669|NCT03168490|Active Comparator|6g high gluten friendly bread|6g high gluten friendly bread as 60g bun to be consumed as 250 ml beverages at breakfast for 14 days
2911670|NCT03168490|Placebo Comparator|Control bread|Placebo control bread as 15g bun to be consumed as 250 ml beverages at breakfast for 14 days
2911671|NCT03168490|Placebo Comparator|Gluten free bread|Gluten bread as 15g bun to be consumed as 250 ml beverages at breakfast for 14 days
2911672|NCT03168477|Experimental|dry needling and spinal manipulation|
2911673|NCT03168477|Active Comparator|manual therapy, exercise, modalities|
2912008|NCT03166111|Placebo Comparator|placebo group|placebo gel inserted vaginally
2911674|NCT03168464|Experimental|Immunotherapy + Radiation|Non-ablative radiotherapy (6GyX5) is directed to one lesion during a first immunotherapy treatment with Ipilimumab 3 mg/kg (± 24hrs from first RT dose). On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
2911675|NCT03168451|Experimental|Intervention|Members of the intervention group will receive culturally tailored text messages encouraging them to quit smoking. They will receive data collection text messages at 6, 12, 18, and 26 weeks post target quit date, assessing their current tobacco smoking behavior.
2911676|NCT03168451|No Intervention|Control|Members of the control group will receive data collection text messages at 6, 12, 18, and 26 weeks post target quit date, assessing their current tobacco smoking behavior.
2911677|NCT03168438|Experimental|Arm 1: NY-ESO-1ᶜ²⁵⁹T cells|Subjects will receive one infusion of NY-ESO-1ᶜ²⁵⁹T cells on Day 1.
2911678|NCT03168438|Experimental|Arm 2: NY-ESO-1ᶜ²⁵⁹T in combination with pembrolizumab|NY-ESO-1ᶜ²⁵⁹T cells administered on Day 1, then pembrolizumab administered on Day 22 (3 weeks after initial infusion of NY-ESO-1ᶜ²⁵⁹T)
2911679|NCT03168425|Experimental|Tailored|Participants will be prescribed an opioid based on a formula derived from inpatient opioid use
2911680|NCT03168425|Other|Control|Participants will be prescribed 30 tablets of oxycodone 5mg, which is the average prescription currently given to our population.
2911681|NCT03168412|Experimental|the Accelerated Vaccination Schedule Group|Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,7,21 day.
2911682|NCT03168412|Active Comparator|the Standard Vaccination Schedule Group|Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
2911683|NCT03168399|Experimental|Consumption of PKU Explore|Daily feed, substituting the participant's normal phe-free protein substitute for PKU Explore.
2911684|NCT03168386|Experimental|Intensive motor rehabilitation group|
2911685|NCT03168373|Experimental|Intensive group|language rehabilitation therapy by language therapist for 1 hours on every working day for 4 weeks
2911686|NCT03168373|Active Comparator|Conventional group|language rehabilitation therapy by language therapist for 30 minutes on every working day for 4 weeks
2911687|NCT03168360|Experimental|Intensive group|cognitive rehabilitation therapy for 1 hour by cognitive therapist on every working day for 4 weeks
2911688|NCT03168360|Active Comparator|Conventional group|cognitive rehabilitation therapy for 30 minutes by cognitive therapist on every working day for 4 weeks
2911689|NCT03168347|Active Comparator|Anecdotal Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on anecdotal evidence.
2911690|NCT03168347|Active Comparator|Research Study Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence.
2911691|NCT03168347|Active Comparator|Anecdotal + Research Study Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence and anecdotal evidence.
2911692|NCT03168347|Placebo Comparator|No Evidence|Scenario describes a medication's (biologic's) therapeutic effect with no mention on anecdotal nor research study evidence.
2911693|NCT03168334|Experimental|IDP-123 Lotion|lotion
2911694|NCT03168334|Placebo Comparator|IDP-123 Vehicle Lotion|Vehicle
2911695|NCT03168321|Experimental|IDP-123 Lotion|Lotion
2911696|NCT03168321|Placebo Comparator|IDP-123 Vehicle Lotion|Lotion
2911697|NCT03168308|Active Comparator|Neostigmine & Glycopyrrolate|Patients randomized to receive Neostigmine w/ Glycopyrrolate
2911698|NCT03168308|Active Comparator|Sugammadex|Patients randomized to receive Sugammadex
2911699|NCT03168295|Active Comparator|Dapa arm|After a 3-hour tracer equilibration period, each subject will receive (ii) dapagliflozin 10 mg.
2911700|NCT03168295|Placebo Comparator|Placebo arm|After a 3-hour tracer equilibration period, each subject will receive (i) placebo
2911701|NCT03168256|Experimental|CF101 2mg|CF101 2mg, orally q12 hours
2911702|NCT03168256|Experimental|CF101 3mg|CF101 3mg, orally q12 hours
2911703|NCT03168256|Active Comparator|Apremilast 30mg|Apremilast 30mg, orally q12 hours
2911704|NCT03168256|Placebo Comparator|Placebo|Placebo control , orally q12 hours
2911705|NCT03168243|Experimental|High Energy High Protein Tube Feed|As study is a single arm design, all patients will be in the intervention group. The will act as their own control by means of a 3 day baseline period. All patients in the study will receive the same intervention, the high energy high protein tube feed, in quantities specified by their dietitian based on their nutritional requirements.
2911706|NCT03168230||PVE|Patients who required PVE prior to the attempt of liver resection.
2911707|NCT03168230||No-PVE|Patients who received upfront surgery (no PVE prior to the intervention)
2911708|NCT03168204|Experimental|Risk of being frail experimental group|
2911709|NCT03168204|No Intervention|Risk of being frail control group|
2911710|NCT03168204|No Intervention|No/low risk of being frail|
2911711|NCT03168204|No Intervention|Risk of being frail care avoiders|
2911712|NCT03168191|Experimental|E-cigarette flavor|In this arm, subjects will receive an experimental flavor. Participants will be randomly assigned to low or high dose of nicotine.
2911713|NCT03168191|Experimental|Menthol Flavor|In this arm, subjects will receive a menthol flavor. Participants will be randomly assigned to low or high dose of nicotine.
2911714|NCT03168191|Placebo Comparator|No Flavor|In this arm, subjects will receive no flavor. Participants will be randomly assigned to low or high dose of nicotine.
2911715|NCT03168178|Active Comparator|Standard Antibiotic Treatment|Standard antibiotic treatment provided to patient. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.
2911716|NCT03168178|Experimental|No Antibiotic Treatment|No Antibiotic treatment given. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.
2911717|NCT03168165|No Intervention|Usual Care|Usual care, no intervention
2911718|NCT03168165|Experimental|Pain Neuroscience Education Training|The region of clinics randomized to this arm will receive PNE education, which consists of 6 weeks online training followed by an on-site training day.
2912009|NCT03166098||Diagnosis of Schizophrenia|
2911723|NCT03168113||AD and Peanut Food Allergy|"Participants with active Atopic Dermatitis (AD) and food allergy to peanut.* Twenty participants ages 4 to 17 years of age will be enrolled in this group.~*Peanut skin prick test wheal ≥ 8 mm."
2911724|NCT03168113||AD and No Food Allergy|"Participants with active Atopic Dermatitis (AD) and no food allergy.* Twenty participants ages 4 to 17 years of age will be enrolled in this group.~*Negative skin prick test (wheal < 3 mm) to peanut, milk, egg, wheat, soy, shellfish mix, tree nuts, and sesame seed."
2911725|NCT03168113||Non-Atopic Health Control|"Participants that are non-atopic, healthy controls*. Twenty participants ages 4 to 17 years of age will be enrolled in this group.~*Negative for Atopic Dermatitis (AD), asthma, or allergic rhinitis; negative for food allergy; and negative by skin prick test to peanut, milk, egg, wheat, soy, shellfish mix, tree nuts, and sesame seed, and negative to environmental allergens - cat, dog, dust mite, cockroach, and local trees/grasses/weeds/molds."
2911726|NCT03168100|Experimental|Study Treatment|Elotuzumab (10 mg Days 1 and 15), lenalidomide (15 mg Days 1-21), and dexamethasone (20 mg days 1, 8, 15, and 22) administered in 28-day cycles which will be alternated every 8 weeks with bortezomib (1.0 mg Days 1, 8, and 15), lenalidomide (15 mg Days 1-21), and dexamethasone (20 mg Days 1, 8, 15, and 22)
2911727|NCT03168087||0% dilution|Blood specimen which was diluted with 0% level using a plasmalyte-148 solution
2911728|NCT03168087||20% dilution|Blood specimen which was diluted with 20% level using a plasmalyte-148 solution
2911729|NCT03168087||40% dilution|Blood specimen which was diluted with 40% level using a plasmalyte-148 solution
2911730|NCT03168087||60% dilution|Blood specimen which was diluted with 60% level using a plasmalyte-148 solution
2911731|NCT03168074|Experimental|lenvatinib|Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).
2911732|NCT03168061|Experimental|NC-6300|"In Part 1, patients will receive an intravenous infusion of NC-6300 at escalating doses starting at a fixed dose on Day 1 of a 21-day cycle. After enrollment of the initial patient, the first patient in each cohort will not be enrolled until all patients at the immediately lower cohort have completed at least 1 full 21-day cycle. In Part 1, patients will continue to receive treatment until they experience disease progression, experience unacceptable toxicity, or withdraw voluntarily.~Part 2 will begin after the RPII dose of NC-6300 is identified. All patients in Part 2 will receive NC-6300 at the RPII dose."
2911733|NCT03168048|Experimental|Mobile application|Patients undergoing radiotherapy will receive additional therapy support by an application installed on a mobile device
2911734|NCT03168035|Experimental|NC-4016|"Dose Escalation Group: NC-4016 will be administered as 2-hour intravenous infusion once every 3 weeks. Initial dose level 15 mg/m2. The dose level of NC-4016 in subsequent cohorts determined by the toxicity profile of the previous cohort, and dose level increased to 25, 30, 40, 60, and 80 mg/m2 or higher at each subsequent cycle until the highest dose level is reached or DLT prohibits further dose-level escalation. Dose level 1 will be the starting dose level (DL). If 2 out of the first 3 patients enrolled at DL1 experience a DLT during Cycle 1 or Cycle 2,then the next cohort of patients will be enrolled at DL0 (10 mg/m2).~Dose Expansion Group: Maximum tolerated dose from Dose Escalation Group"
2911735|NCT03168022|Experimental|Treatment A|1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
2911736|NCT03168022|Experimental|Treatment B|1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
2911737|NCT03168009|Experimental|Bariatric Surgery|Patients will undergo either Omega Loop Gastric Bypass or Sleeve Gastrectomy. The decision which type of surgery will be performed, will by made by the surgeon and the patient based on clinical considerations and the patient's wishes.
2911738|NCT03167996|Experimental|Group B/ HealthPals|"Group B have access to HealthPals app where they will coordinate with a trained health coach Group B patients will only come into SSATHI clinic to see their doctor for an initial visit and 6 month follow up, and they will have a telephone visit with their doctor at 3 months instead of an in-clinic visit~Lab testing is the same for both Group A/ control and Group B patients"
2911739|NCT03167996|No Intervention|Group A/ Control|"Group B will not have access to HealthPals app~Group A patients will come into SSATHI clinic to see their doctor for an initial visit, a 3 month follow up, and a 6 month follow up~Lab testing is the same for both Group A/ control and Group B patients"
2911740|NCT03167983||dementia|patients with dementia
2911741|NCT03167983||control|healthy control
2911742|NCT03167970||Pill cam and EGD|Patients in this arm is requested to swallow the esophageal capsule and then undergo standard EGD.
2911743|NCT03167957|Experimental|CAMB 200 mg|200 mg CAMB Oral Amphotericin B
2911744|NCT03167957|Experimental|CAMB 400 mg|400 mg CAMB Oral Amphotericin B
2911745|NCT03167944|Experimental|Conventional electrocautery|
2911746|NCT03167944|Experimental|Low thermal electrosurgery system|
2911747|NCT03167931|Experimental|18-49 years group|Participants undergo 2 sessions of MRI + transcranial Magnetic Stimulation or transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
2911748|NCT03167931|Experimental|50-85 years group|Participants undergo 2 sessions of MRI + transcranial Magnetic Stimulation or transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
2911749|NCT03167918|Experimental|Calcium dobesilate|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Calcium dobesilate 0.5 g bid, PO
2911750|NCT03167918|Experimental|Xuefuzhuyu Decoction|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Xuefuzhuyu Decoction 100 ml bid，po
2911751|NCT03167918|Experimental|Xuefuzhuyu Decoction &Calcium dobesilate|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Calcium dobesilate (0.5 g bid, PO)& Xuefuzhuyu Decoction（100 ml bid，po)
2911752|NCT03167905|Experimental|Epidural group|Patients are assigned to receive epidural delivery system (fentanyl and ropivacaine) for labour as pain relief option.
2911753|NCT03167905|Active Comparator|Non-epidural group|Patients are assigned to receive entonox (laughing gas), meperidine (pethidine) or remifentanil (Ultiva) for labour as pain relief option.
2911756|NCT03167879|Experimental|SCC1--high intensity supervision|Integration of safer conception counseling into family planning services, with intensive training and supervision
2911757|NCT03167879|Experimental|SCC2-- low intensity supervision|Integration of safer conception counseling into family planning services, with less intensive training and supervision that mimics Ministry of Health approach
2911758|NCT03167879|No Intervention|Usual care family planning services|Family planning services that are currently available as part of usual care, which focus almost solely on contraception and pregnancy prevention
2911759|NCT03167866|Placebo Comparator|control group|DM patients who receive a weekly informational Short Message Service (SMS) by phone for 26 weeks. informational SMS
2911760|NCT03167866|Experimental|test group|DM patients who receive a weekly motivational Short Message Service (SMS) for 26 weeks. motivational SMS
2911761|NCT03167853|Experimental|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg per 2 weeks until disease progresses or unacceptable tolerability occurs.
2911762|NCT03167840|Experimental|Physical training alone (PT)|Physical Training (flexibility, endurance, strengthening, and balance training) for 60-90 minutes 3x/week over 12 weeks of moderate intensity.
2911763|NCT03167840|Experimental|Cognitive training alone (CT)|Cognitive training with a focus on orientation, memory, attention and executive functioning for 60-90 minutes per session, once per week for 12 weeks.
2911764|NCT03167840|Experimental|Physical and cognitive training (PACT)|Integrated cognitive training in physical exercise for 60-90 minutes per session, 3x/week over 12 weeks.
2911765|NCT03167840|No Intervention|Wait-list group (WG)|The control group on wait-list. They will be instructed to go on with their usual activities and will receive the intervention, combined physical and cognitive training, at a later date.
2911766|NCT03167827|Experimental|Group isoflavone and exercise|The isoflavone group received daily 100mg of isoflavones.
2911767|NCT03167827|Placebo Comparator|Group placebo and exercise|The placebo group received 100mg containing starch of corn.
2911768|NCT03167814|Active Comparator|Diet group|Diet group will be on no-fat diet including MCT-oil supplement starting right after surgery according to our pancreas ERAS-protocol.
2911769|NCT03167814|No Intervention|Normal food-group|This study group will follow normal ERAS-protocol after pancreas surgery and start normal diet after surgery. If chyle-leak is diagnosed then it will be treated with the same no-fat diet as the intervention group.
2911770|NCT03167801||spinal cord injury|spinal cord injury all scores AIS
2911771|NCT03167801||Healthy volunteers|Healthy volunteers for whom melatonin profiles have been taken and stored in the Lyon endocrinology laboratory's database. No healthy volunteers will be directly recruited for the study.
2911772|NCT03167788|Experimental|Intervention|Cross-matched allogeneic stored red cells will be rejuvenated using rejuvesol® Red Blood Cell Processing Solution (Citra Labs, MA, a Zimmer Biomet Company, IN, USA) with washing and re-suspension in an additive solution prior to transfusion. The rejuvenated red cells will then be administered to the patient as per standard practice and according to established institutional protocols.
2911773|NCT03167788|Active Comparator|Control|Standard care i.e. Cross-matched allogeneic stored non-rejuvenated, unwashed red cells will be administered to the patient as per standard practice and according to established institutional protocols.
2911774|NCT03167775|Experimental|Elemene + the best supportive treatment|the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment .
2911775|NCT03167762|Experimental|Study group|
2911776|NCT03167749||Patients group|Male patients with liver cirrhosis of any etiology and severity. Laboratory tests will be done
2911777|NCT03167749||Control group|Healthy males without history or features of liver disease. Laboratory tests will be done
2911778|NCT03167736|Experimental|Electric dry needling, manipulation|
2911779|NCT03167736|Active Comparator|conventional physical therapy|
2911780|NCT03167723|Experimental|28 French chest tube for hemothorax|28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
2911781|NCT03167723|Experimental|14 French chest tube for hemothorax|14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
2911782|NCT03167710|Experimental|dry needling, manipulation stretching|
2911783|NCT03167710|Active Comparator|manual therapy, exercise, ultrasound|
2911784|NCT03167697|Experimental|Synergy|This group will receive the new phenylalanine-free protein substitute daily for 28 days. Patients in this group intervention will be directed to consume one powder sachet (33 g) of daily made up with 100mL of water. The new substitute delivers 414 kJ, 20g protein equivalent and a combination of essential and non-essential amino acids as well a combination of vitamins and minerals.
2911785|NCT03167697|Active Comparator|Routine|This group will continue their usual dietary and/or protein substitute regimen (maximum of 1 protein substitute per day (equal to 20g protein equivalent) control) for 28 days.
2911786|NCT03167684|Experimental|Oral appliance therapy|Oral appliance (SomnoMed) worn nightly
2911787|NCT03167684|No Intervention|Control|Sham oral appliance device
2911788|NCT03167671|Active Comparator|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy.
2911789|NCT03167671|Experimental|AposTherapy|Treatment with at home AposTherapy with daily use of the shoe.
2911790|NCT03167658|Experimental|Treatment|Employees at treatment worksites will be given access to workplace wellness programming. Participation by employees will be voluntary, but all employees at treatment sites will be considered as part of the treatment group. Employees will also be invited to complete on-site biometric assessments and questionnaires. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
2911791|NCT03167658|No Intervention|Primary Control|Employees at primary control worksites will be invited to complete on-site biometric assessments and questionnaires, but will not have access to the workplace wellness programming. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
2911832|NCT03167333|Active Comparator|HA group|the patients received HA(hyaluronic acid) injection twice at 2-week intervals
2912010|NCT03166098||Diagnosis of Bipolar Disorder|
2912011|NCT03166098||Unaffected siblings of the SZ groups|
2911792|NCT03167658|No Intervention|Secondary Control|Employees at secondary control worksites will not participate in in-person screenings or questionnaires, and will not have access to workplace wellness programming. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
2911793|NCT03167645|Experimental|Human albumin|Substitution of human albumin until serum albumin >30g/l; dosage: (30 g/l - serum albumin [g/l] ) x 0,04 l/kg x body weight [kg] x 2
2911794|NCT03167645|No Intervention|Control|Standard clinical care
2911795|NCT03167632||dental patients|
2911796|NCT03167619|Experimental|A - olaparib alone|Twice daily oral Olaparib 300mg alone as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
2911797|NCT03167619|Experimental|B - olaparib plus durvalumab|Twice daily oral olaparib plus intravenous Durvalumab every 4 weeks as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
2911798|NCT03167606|Experimental|Immediate Intervention|Study participants randomized to the intervention arm will have access to the MyPEEPS Mobile for the next three months.
2911799|NCT03167606|Experimental|Delayed Intervention|Participants randomized to the delayed intervention arm will not have access to MyPEEPS Mobile and will be asked to complete their surveys every 3 months and return to the study site in 9 months for a follow-up visit (at which time they will receive the MyPEEPS Mobile intervention).
2911800|NCT03167593|Placebo Comparator|Control|Capsules containing 300 mg of maltodextrin.
2911801|NCT03167593|Experimental|Probiotic|Capsules containing 3x10(9) colon-forming units of the strain L. coryniformis K8 CECT5711 in a matrix of maltodextrin.
2911802|NCT03167580|Experimental|Ventilation with restricted PEEP level|Use of the restricted PEEP level (0 - 5 cm H2O, the lowest possible PEEP level) after intubation and during all mechanical ventilation.
2911803|NCT03167580|Active Comparator|Ventilation with liberal PEEP Level|Use of the liberal PEEP level (8 H2O) after intubation and during all mechanical ventilation.
2911804|NCT03167567|Experimental|intervention|These women will have a medical clown present in the room during their labor
2911805|NCT03167567|No Intervention|Control|These women will not have a medical clown in the room during their labor
2911806|NCT03167554|Sham Comparator|Sham group|Simulating of the electrolysis application.he electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.
2911807|NCT03167554|Experimental|Experimental group 1|Electrolysis application with monopolar needle.
2911808|NCT03167554|Experimental|Experimental group 2|Electrolysis application with bipolar needle.
2911809|NCT03167541|Experimental|1|Treatment Order: Test, Reference
2911810|NCT03167541|Experimental|2|Treatment Order: Reference, Test
2911811|NCT03167528|Experimental|Lung transplant|
2911812|NCT03167515|Experimental|074-6751 Lotion|
2911813|NCT03167502|Active Comparator|concentric work|patient suffering from knee osteoarthritis will follow a concentric work. This training is 2 sessions per week for 6 weeks
2911814|NCT03167502|Experimental|eccentric work|patient suffering from knee osteoarthritis will follow an eccentric work. This training is 2 sessions per week for 6 weeks
2911815|NCT03167489|Experimental|Lifestyle Plus Emotional Regulation|The core intervention will last 5 months. Nutrition content: Mediterranean diet education, social support, self-regulation techniques, and environmental support. Physical activity content: education, guidance in starting a routine, and a walking program with pedometers, weekly physical activity tips and step goals. Emotion regulation content: based on Dialectical Behavior Therapy adapted to binge eating disorders and other ER sources, emphasizing identifying emotions, recognizing the causes of emotions, accepting and tolerating negative emotions, effective self-support and self-compassion, and the ability to manage situations that elicit negative emotions, as well as re-appraisal skills, which are identified as particularly influential on eating behaviors.
2911816|NCT03167476||RLH|This group includes subjects diagnosed with reactive lymphoid hyperplasia.
2911817|NCT03167476||Lymphoma|This group includes subjects diagnosed with lymphoma.
2911818|NCT03167463|Experimental|choanoplasty with flap|flap surgery
2911819|NCT03167450||Adults|Adults have sickle cell disease
2911820|NCT03167450||Parents|Parents with children/adults who have sickle cell disease
2911821|NCT03167450||Physicians|Physicians who have delivered healthcare to individuals living with sickle cell disease for at least a year
2911822|NCT03167437|Placebo Comparator|1|Patients with moderate tosevere Crohn's disease
2911823|NCT03167424||BVS restenosis|Patients with a Bioresorbable Vascular Scaffold Restenosis
2911824|NCT03167411|Experimental|Bexagliflozin alone|
2911825|NCT03167411|Active Comparator|Bexagliflozin with exenatide injection|
2911826|NCT03167398|Experimental|CRE carriers|Fecal Microbiota Transplantation
2911827|NCT03167385|Experimental|Experitmental|Continuous oral intake of Apatinib Mesylate (500mg), once a day, until progression of disease or severe adverse effect.
2911828|NCT03167372|Experimental|Bright white light vs dim red light|"A balanced sequence (ABBA) over a 12 week period of bright white light and dim red light; alternating bright white and dim red light every 3 weeks.~Subjects will receive 2 Litebook® Advantage lightboxes - 1 bright white and 1 dim red. Information such as mood, fatigue, sleep and light therapy side effects will be self-reported using a smartphone diary; physical activity and sleep will also be reported using a Fitbit Flex2 TM. Data visualization at 12 weeks."
2911829|NCT03167372|Active Comparator|Dim white light vs dim red light|"A balanced sequence (ABBA) over a 12 week period of dim white light and dim red light; alternating dim white and dim red light every 3 weeks.~Subjects will receive 2 Litebook® Advantage lightboxes - 1 dim white and 1 dim red. Information such as mood, fatigue, sleep and light therapy side effects will be self-reported using a smartphone diary; physical activity and sleep will also be reported using a Fitbit Flex2 TM. Data visualization at 12 weeks."
2911830|NCT03167359|Experimental|Participants with Stage 0-III breast cancer|Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.
2911831|NCT03167333|Experimental|PRP group|the patients received PRP(platelet-rich-plasma) injection twice at 2-week intervals
2911833|NCT03167320||LOVIC|Irish patients with low Von Willebrand levels will be have both venous blood sampling and a bleeding score administered at study entry. A DDAVP (1-desamino-8-D-arginine vasopressin) fall off study was organised for those patients in the cohort with no previous fall offs available and no contraindications to DDAVP.
2911834|NCT03167307|Experimental|Omega-3 fatty acid oil|A daily dose of 500mg EPA/ 250mg DHA in the 8 to <13 year olds, and 1000mg EPA / 500mg DHA in the 13 to <18 years olds, respectively, will be added to standardized treatment according to the German S3 Guidelines for the treatment of depression in children and adolescents
2911835|NCT03167307|Placebo Comparator|Placebo oil|Placebo capsules will contain mostly medium chain triglycerides (MCT) and also a small amount of fish oil to mimic the fishy flavour and taste. Placebo will be added to standardized treatment according to the German S3 Guidelines for the treatment of depression in children and adolescents
2911836|NCT03167294|Other|Single Arm|AquaBeam System for resection and removal of prostatic tissue in males suffering from BPH
2911837|NCT03167281|No Intervention|tPA and DNase|10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily 24-48 hours after chest tube placed.
2911838|NCT03167281|Experimental|Early tPA and DNase|10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily with initial administration occurring at chest tube placement.
2911839|NCT03167268|Experimental|Lycopene 20mg cpr/die|Lycopene is a compound belonging to carotenoid group, largely contained in tomatoes and their derivatives, which has an extreme antioxidant activity. In Dermatology, prolonged use of β-carotenoids in general and of lycopene in particular in the diet showed to be effective in skin protection from ageing, sunlight and radiotherapy damages because these compounds may accumulate in skin and thus contribute to reduce free radicals and inflammation effects.
2911840|NCT03167268|Placebo Comparator|Placebo|"Containing same excipients than the experimental Lycopene 20 mg but not active principle (Lycopene)"
2911841|NCT03167255|Experimental|NS-065/NCNP-01 40mg/kg|Patients receiving 40mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 72 weeks
2911842|NCT03167255|Experimental|NS-065/NCNP-01 80mg/kg|Patients receiving 80mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 72 weeks
2911843|NCT03167242|Experimental|KAF156 400 mg and LUM-SDF 960 mg once daily (QD) for 1 day|Cohort 1
2911844|NCT03167242|Experimental|KAF156 800 mg and LUM-SDF 960 mg QD for 1 day|Cohort 2
2911845|NCT03167242|Experimental|KAF156 400 mg and LUM-SDF 960 mg QD for 2 days|Cohort 3
2911846|NCT03167242|Experimental|KAF156 200 mg and LUM-SDF 480 mg QD for 3 days|Cohort 4
2911847|NCT03167242|Experimental|KAF156 400 mg and LUM-SDF 480 mg QD for 3 days|Cohort 5
2911848|NCT03167242|Experimental|KAF156 400 mg and LUM-SDF 960 mg QD for 3 days|Cohort 6
2911849|NCT03167242|Active Comparator|Coartem twice a day (BID) for 3 days|Cohort 7
2911850|NCT03167242|Experimental|KAF156 200 mg and LUM-SDF 960 mg once daily for 1 day|PK Run-in Cohort
2911851|NCT03167216|Experimental|Treatment arm|Treated arm with cromolyn sodium and cetirizine hydrochloride
2911852|NCT03167203|Experimental|Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial|Participants previously enrolled into an Astellas Institute for Regenerative Medicine (AIRM) sponsored clinical trial and treated with hESC-RPE cells
2911853|NCT03167190|Other|Control|Traditional landmark-based lumbar puncture technique by palpation
2911854|NCT03167190|Experimental|Experimental (ultrasound)|Use of point-of-care ultrasound to identify bony landmarks.
2911855|NCT03167177|Experimental|NANT Melanoma Vaccine|"A combination of agents will be administered to subjects in this study:~avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, nivolumab, omega-3-acid ethyl esters, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-6207, GI-6301, and haNK."
2911856|NCT03167164|Experimental|NANT MCC Vaccine|"A combination of agents will be administered to subjects in this study:~avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ethyl esters, stereotactic body radiation therapy, ALT-803, ETBX-051, ETBX-061, GI-6301, and haNK."
2911857|NCT03167151|Experimental|Arm A Intravesical|"Intravesical Pembrolizumab (solution for infusion) 50-200 mg, given on D1, D8, D15, D22, D29, D36 & D64.~Dose to be decided after safety run-in."
2911858|NCT03167151|Active Comparator|Arm B Intravenous|Intravenous Pembrolizumab (solution for infusion), 200mg, given on D1, D22, D43, D64
2911859|NCT03167138|Experimental|Autologous micro-fragmented adipose tissue|Injection (under ultrasound guidance) of autologous micro-fragmented adipose tissue obtained from abdominal region or thighs using the Lipogems® system.
2911860|NCT03167125|Active Comparator|Automated Prompts|Patients randomized to this arm will receive automated prompts to complete and return the FIT kit.
2911861|NCT03167125|Active Comparator|Automated Plus Live Prompts|Patients randomized to this arm will receive automated prompts plus linguistically and culturally tailored live prompts to complete and return the FIT kit.
2911862|NCT03167125|No Intervention|Usual Care|Patients randomized to this arm will receive usual care screening opportunities per recommended colorectal cancer screening guidelines.
2911863|NCT03167112|Experimental|FOLFIRINOX|Oxaliplatin, Irinotecan, Leucovorin, Fluorouracil
2911864|NCT03167099|Experimental|Full Weight Bearing|Participants assigned to full weight bearing after fixation of distal femur fracture.
2911865|NCT03167099|No Intervention|Partial Weight Bearing|Participants assigned to partial weight bearing, standard of care, after fixation of distal femur fracture.
2911866|NCT03167086|Experimental|Single Session Pain Psychology Class|"From Catastrophizing to Recovery (FCR): A single-session approximately 2-hr group intervention to treat pain catastrophizing (PC)."
2911867|NCT03167086|Active Comparator|Cognitive Behavioral Therapy (CBT)|8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total).
2911868|NCT03167086|Active Comparator|Health Education (HE)|The active control treatment arm consists only of Health Education and has no psychological treatment components. It is a 2-hour HE class matched to the single-session psychological experimental arm (FCR) on 4 important factors: duration, structure, format and site.
2912005|NCT03166124|Active Comparator|Insulin Lispro (younger adult group)|Single, SC dose of insulin lispro in the younger adult group
2911869|NCT03167073|Experimental|BreastFeeding Friend (BFF)|BFF is a novel android app initially created in Microsoft PowerPoint with the results of a well-validated questionnaire administered to the target patient population, in which participants identified barriers preventing them from starting or continuing breastfeeding. The app was then modified by a multidisciplinary team of neonatologists, perinatologists, and certified lactation consultants. The finalized prototype was presented to three focus groups of test users sociodemographically similar to the target population. This approach allowed BFF to be adjusted to maximize the users' experience per their opinions. Once the focus groups' feedback was consistent, the app prototype was provided to a freelance coding team at Washington University of St. Louis, which built a native android app.
2911870|NCT03167073|Placebo Comparator|dummy app|The dummy app looks identical to BFF but is limited to a few pages of information on breastfeeding that is provided in hand-out form during routine prenatal care.
2911871|NCT03167060|Active Comparator|Active Rhinochill|Intranasal cooling device , using nasal cannula
2911872|NCT03167060|Sham Comparator|Control Rhinochill|Intranasal cooling device , using nasal cannula (difference with active device not disclosed to maintain blindness)
2911873|NCT03167047|Active Comparator|Caudal block|"Caudal epidural given for post-operative pain relief. Dose used is 1.5ml/kg of weak Levo-Bupivacaine solution (0.125%).~Patients will also receive standardised pain relief of paracetamol and fentanyl"
2911874|NCT03167047|Active Comparator|Nerve block|"Peripheral nerve block given for post operative pain relief. Levo-Bupivacaine 0.25% 2mg/Kg given under ultrasound guidance.~Patients will also receive standardised pain relief of paracetamol and fentanyl"
2911875|NCT03167034|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
2911876|NCT03167034|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
2911877|NCT03167021||Students|Students of the Auvergne Rhone Alpes region will be contacted by email thanks to the student associations and scholarity departments. Answer to the survey will be done online.
2911878|NCT03167008||idiopathic male infertility|"total of 30 male patients with idiopathic male infertility.~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010).~blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured."
2911879|NCT03167008||fertile male group|"total of 30 fertile male (as control)~Semen samples will be collected,Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010).~blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured."
2911880|NCT03166995|Experimental|Experimental group 1|Low impact aerobic exercise group. 1hour, twice a week
2911881|NCT03166995|Experimental|Experimental group 2|Postural exercises group. 1hour, twice a week
2911882|NCT03166995|No Intervention|Control propriocepcion|No exercise, just proprioceptive control.
2911883|NCT03166982|Experimental|laparoscopy|the tubo-ovarian abscess should be drained by interventional radiology, preferably by transvaginal or laparoscopic
2911884|NCT03166982|Experimental|ultrasound-guided puncture|The transvaginal echo guided puncture to replace the first laparoscopy because of its less invasive nature, this is a simple act, fast, possible under mild sedation, the cost is still lower than laparoscopy
2911885|NCT03166969|Experimental|Patients taken care in neurovascular unit|
2911886|NCT03166956|Experimental|GA (glutamine and vitamin C) group|"Interventions of glutamine and vitamin C enteral supplementations were given to surgical intensive care unit (ICU) patients.~Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan)."
2911887|NCT03166956|Placebo Comparator|Control (C) group|"Placebo:~Subjects in the C group received isocaloric maltodextrin as placebo."
2911888|NCT03166943|Experimental|study group|Systolic function by echocardiography to100 Hepatitis C virus infected patients on continuous regimen ( sofosbuvir and daclatasvir )
2911889|NCT03166943|Active Comparator|Control group|Diastolic function by echocardiography age and sex matched group of 30 patients with Hepatitis C virus who did not receive antiviral treatment ( sofosbuvir and daclatasvir )
2911890|NCT03166930|Experimental|Spasticity Take Control|Participants will attend two 2-hour classes, one week apart, consisting of a stretching program for spasticity management.
2911891|NCT03166930|Active Comparator|Stretching for People with MS: An Illustrated Manual|Participants will attend two 2-hour classes, one week apart, consisting of exercises for spasticity management from the manual.
2911892|NCT03166917|Experimental|3D printing implant|3D printing implant in bone defect
2911893|NCT03166917|Placebo Comparator|Autogenous bone grafting|autogenous bone grafting in bone defect
2911894|NCT03166904|Experimental|AZD2014|Vistusertib(AZD2014) 50mg BD continuous schedule of a 28 day cycle
2911895|NCT03166891|Experimental|chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
2911896|NCT03166878|Experimental|Treatment (UCART019)|"The UCART019 will be administered by i.v. injection over 20-30 minutes as a using a split dose approach to dosing: Day 0: 10% of total dose. Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose"
2911897|NCT03166865|Experimental|Intervention group|Intraarticular injection of 2×10~7 Umbilical-cord mesenchimal stem cells with plateler Rich Plasma(5ml)
2911898|NCT03166865|Other|Control group|Intraarticular injection of hyaluronic acid
2911899|NCT03166852|Experimental|Home-training group|High-intensity training at home 3 times/week for 5 weeks
2911900|NCT03166839||Region 1: Africa|Women living in and experiencing PPH in countries located in Africa.
2911901|NCT03166839||Region 2: Asia|Women living in and experiencing PPH in countries located in Africa.
2911902|NCT03166839||Region 3: Europe, NA, SA, Aus|Women living in and experiencing PPH in countries located in Africa.
2911903|NCT03166813|Experimental|Intervention RIPC|The intervention RIPC protocol will be induced by three cycles of inflation of a blood pressure cuff placed over the upper or lower limb, where deemed to cause minimal discomfort to patient, to 15 mmHg above the systolic blood pressure for five minutes followed by five minutes of cuff deflation to 0 mmHg.
2911904|NCT03166813|Placebo Comparator|Control|The control protocol involves only placement of blood pressure cuff but without inflation for 30 minutes.
2911905|NCT03166800|Placebo Comparator|Placebo|20 subjects will receive placebo.
2911906|NCT03166800|Active Comparator|20mg oral MitoQ|MitoQ is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. 20mg of MitoQ will be administered to 20 subjects in this trial.
2911907|NCT03166800|Active Comparator|40mg oral MitoQ|MitoQ is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. 40mg of MitoQ will be administered to 20 subjects in this trial.
2911908|NCT03166787|Experimental|Myocardial Blood Flow|Myocardial contrast echocardiography will be used to measure regional myocardial perfusion .
2911909|NCT03166787|Experimental|Assess Coronary Endothelial Function|young hookah smokers will be randomized to have coronary endothelial function assessed before and after inhaling Carbon Monoxide or room air from a Douglas bag.
2911910|NCT03166787|Experimental|Test coronary endothelial function|Test coronary endothelial function before after hookah smokers smoke charcoal-heated hookah and before and after age-matched cigarette smokers smoke 2 cigarettes. In the same subjects, we will test for acute smoking-induced changes in LV wall strain by speckle tracking. Finally, in a subset of subjects we will repeat the MCE and speckle tracking studies after pretreatment with either i.v. vitamin C or one dose of oral tadalafil.
2911911|NCT03166774||patient consulting in oncology ervice|Program of support of the sexual health in oncology by questionnaire
2911912|NCT03166761|Experimental|Dexamethasone|dexamethasone injected into the sacroiliac joint
2911913|NCT03166761|Active Comparator|Triamcinolone|triamcinolone injected into the sacroiliac joint
2911914|NCT03166748|Active Comparator|MTA pulpotomy|mineral trioxide aggregates (MTA) is accepted as an optimum material for use in vital pulp therapy of permanent teeth
2911915|NCT03166748|Experimental|Potassium Nitrate in Polycarboxylate cement|Potassium nitrate (KNO3) is a superior desensitizer for hypersensitive teeth. Used with polycarboxylate cement, it serves as an effective liner for deep carious lesions. Also when placed under deep restorations with less than 1 mm of protective dentin remaining, it was effective in preserving pulpal vitality and it diminished the incidence and severity of post-restoration pain. As temporary cement (Kno3/zinc oxide eugenol [ZOE]) It reduced pain following full crown preparation.
2911916|NCT03166735|Experimental|BI 1467335 dose 1|
2911917|NCT03166735|Experimental|BI 1467335 dose 2|
2911918|NCT03166735|Experimental|BI 1467335 dose 3|
2911919|NCT03166735|Experimental|BI 1467335 dose 4|
2911920|NCT03166735|Placebo Comparator|Placebo|
2911921|NCT03166722|Experimental|Study group: Invos 5100|"Supplemental oxygen support and respiratory/circulatory support is guided by cerebral regional tissue oxygenation (crSO2) measured with near-infrared spectroscopy (INVOS 5100 ), in addition to the SpO2/HR (oxygen saturation/heart rate) monitoring according to routine."
2911922|NCT03166722|Active Comparator|Control group: Routine care|Supplemental oxygen support and respiratory/circulatory support is guided by SpO2/HR monitoring according to routine - The resuscitation team is blinded to the crSO2 monitoring.
2911923|NCT03166709|Active Comparator|Treatment As Usual|Intensive Outpatient Program substance abuse group session focused on depression, grief, or managing emotions. Specific topic is what that Intensive Outpatient Program usually provides.
2911924|NCT03166709|Experimental|Experimental|Secondary Prevention Intervention (PARS)
2911925|NCT03166696||acute cerebral infarction|the registry and follow up of consecutive patients who were admitted and diagnosed with acute cerebral infarction
2911926|NCT03166696||acute myocardial infarction|the registry and follow up of consecutive patients who were admitted and diagnosed with acute myocardial infarction
2911927|NCT03166683|Experimental|Hemopatch|Use of hemopatch like a control of bile leakage/sealant during liver resection surgery.
2911928|NCT03166683|Active Comparator|Standard of care|Application of standards of care, may include other sealant / hemostatic devices as patches or liquid/gels, during liver resection surgery.
2911929|NCT03166670||study group|children with acute secretory diarrhea
2911930|NCT03166670||Control group|normal healthy children
2911931|NCT03166644|Experimental|Control Group|Patients with major abdominal surgery
2911932|NCT03166644|Experimental|Intervention Group|Patients with standard practice
2911933|NCT03166631|Experimental|Part A|BI 891065 alone (Solid Tumours)
2911934|NCT03166631|Experimental|Part B|BI 891065 in combination with BI 754091 (Solid Tumours)
2911935|NCT03166631|Experimental|Part C|BI 891065 in combination with BI 754091 (Non Small Cell Lung Cancer)
2911936|NCT03166618|Experimental|VOLUMA® XC Treatment|Participants will be treated with JUVÉDERM® VOLUMA® XC injectable gel in both temples (area above the eye). Participants are eligible for touch-up treatment 30 days later.
2911937|NCT03166618|No Intervention|Control_No Treatment|No treatment is administered.
2911938|NCT03166605|No Intervention|Control|"First group: Control~Follow the current standard protocol used at Albany Medical Center that includes:~Do not drink anything for an additional 2 hours after swallowing pill cam. After which patient may drink clear liquids~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.~Return to clinic (RTC) 8 hours after to remove equipment~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period"
2911939|NCT03166605|Sham Comparator|Sham|"Receive 3 ml simethicone 20 minutes prior to capsule swallowing~Do not drink anything for an additional 2 hours after swallowing pill cam. After which patient may drink clear liquids~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.~Return to clinic (RTC) 8 hours after to remove equipment~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period."
2912006|NCT03166124|Active Comparator|Insulin Lispro (elderly group)|Single, SC dose of insulin lispro in the elderly group
2912007|NCT03166111|Experimental|lidocaine group|lidocaine in-situ gel inserted vaginally
2911940|NCT03166605|Experimental|Experiment|"Receive 3 ml simethicone 20 minutes prior to capsule swallowing.~Receive 3 ml simethicone 1 hours after capsule swallowing~Receive 1.5 ml simethicone 2 hours after capsule swallowing~Do not drink anything for an additional 1 hour after taking last simethicone dose. After which patient may drink clear liquids~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.~Return to clinic (RTC) 8 hours after to remove equipment~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period."
2911941|NCT03166579|Experimental|Dialectical Behaviour Therapy|"Participants receive the standard 12 month DBT programme where all four modes of treatment are delivered including: individual therapy, group skills training, telephone coaching and DBT team consultation."
2911942|NCT03166566|Other|laminar drainage implant surgery|patients included and operated
2911943|NCT03166553|Experimental|Elemene +Oxaliplatin|the group treated with the Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin
2911944|NCT03166553|No Intervention|Oxaliplatin|the group treated with Systematic Chemotherapy including Oxaliplatin
2911945|NCT03166540|Experimental|low consumers|1 cup of espresso coffee/day at 9.00 A.M. for 1 month
2911946|NCT03166540|Experimental|high consumers|3 cup of espresso coffee/day at 9.00 A.M. 12.00 P.M. and 3.00 P.M. for 1 month
2911947|NCT03166540|Experimental|medium consumers|1 cup of espresso coffee at 9.00 A.M. + cocoa-based products containing coffee at 12.00 P.M. and 3.00 P.M. for 1 month
2911948|NCT03166527|Other|Open Label study|open label study using Panzyga immune globulin 10% intravenous solution with no placebo.
2911949|NCT03166514|Experimental|Commercially Available Food Bar|62 g. Fitjoy Bar
2911950|NCT03166514|Placebo Comparator|Placebo|25 g. Dextrose
2911951|NCT03166501|Experimental|Treatment|Lanicemine 100mg Intravenous
2911952|NCT03166501|Placebo Comparator|Placebo|Normal saline Intravenous
2911953|NCT03166488|Experimental|Tricuspid Valvular Repair Patients|Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE) within 1 month preoperatively and as close to 6 months postoperatively as reasonably achievable.
2911954|NCT03166475|Experimental|Palatal pedicle flap (Group 1)|On patients of this group were performed the palatal pedicle subepithelial connective tissue flap after the extraction, following the technique described by Khoury & Happe (2000), which consists of total detachment of the palatal flap followed by division of the flap to release the connective tissue, maintain a pedicle and sliding it to cover the fresh socket by primary intention. The sutures were removed seven to ten days of postoperative.
2911955|NCT03166475|Experimental|Graft + palatal pedicle flap (Group 2)|On patients of this group were performed the palatal pedicle flap like the group 1, however, the sockets were previously filled with a graft of synthetic bone substitute (Bone Ceramic®, Straumann, Switzerland) and then recovered with the connective flap and sutured by primary intention. The sutures were removed seven to ten days of postoperative.
2911956|NCT03166475|Experimental|Provisional ovoid pontic (Group 3)|On patients of this group, after the extraction of the tooth, were made a provisional ovoid pontic with acrylic resin or with the crown of the removed tooth itself, cut and sealed with composite resin. The pontics were placed to seal the entire gingival margin of the socket and penetrating 2 to 3 mm into it, stabilized laterally by the adjacent teeth with orthodontic and composite resin or acrylic resin. No sutures were made.
2911957|NCT03166462|No Intervention|Control|"Patients in this arm will proceed through the current standard of care for pre-operative screening performed by either the patient's primary care physician or the pre-operative anesthesia clinic which screens patients prior to total knee or total hip arthroplasty."
2911958|NCT03166462|Experimental|Intervention|Patients in this arm will be referred to the Sleep Medicine clinic at the University of Miami Hospital for additional testing and evaluation for obstructive sleep apnea. If they are successfully diagnosed, they will receive appropriate treatment and any interventions for the peri-operative period as recommended by the pulmonary medicine team.
2911959|NCT03166449|Experimental|Neomune|18 patients with traumatic brain injury were given Neomune as enteral nutrition.
2911960|NCT03166449|Active Comparator|Fresubin® HP energy|18 patients with traumatic brain injury were given Fresubin® HP energy as enteral nutrition.
2911961|NCT03166436|Experimental|RFA plus stenting|Endoluminal radiofrequency ablation followed by biliary stenting
2911962|NCT03166436|Active Comparator|Stenting alone|Biliary stenting alone
2911963|NCT03166423|Experimental|MU001 patches (Investigational)|"Patches MU001 (snail slime, calendula extract and propolis extract) more standard of care. Two or three application for week. Treatment until 60 days.~Patches MU001 (snail slime, calendula extract and propolis extract) on health zone. Three days of treatment."
2911964|NCT03166423|Experimental|Conventional patches (Control)|Conventional patches approved for diabetic foot ulcers more standard of care. Two or three application for week. Treatment until 60 days.
2911965|NCT03166410|Experimental|Cell Treatment|
2911966|NCT03166397|Experimental|ACT TIL|"Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Fludarabine (25 mg/m2 for 3 days) followed by Total Body Radiation (TBR) (2 Gray as a single treatment) for 1 day.~Preparation and administration of TIL~Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
2911967|NCT03166384|Active Comparator|control group|"For the patients in the control group, surgeon dose not use electrosurgical bipolar sealing device at all and use conventional tie and ligation methods during tissue dissection and vessel ligation.~interventions: 'conventional suture and tie'"
2911968|NCT03166384|Experimental|study group|"For the patients in the study group, the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.~interventions: electrosurgical bipolar sealing devices"
2911969|NCT03166371|Experimental|Liposomal Glutathione (GSH)|Participants will be randomized to receive two teaspoons containing 840 mg GSH (420 mg/tsp) twice daily for 90 days after discharge from Emory University Hospital (EUH).
2911970|NCT03166371|Placebo Comparator|Placebo|Participants will be randomized to receive a placebo product identical to liposomal glutathione (GSH) twice daily for 90 days after discharge from Emory University Hospital (EUH).
2911971|NCT03166358|Experimental|hatha yoga intervention|Participants randomized to the intervention are asked to attend 8 hatha yoga classes delivered in a group format.
2911972|NCT03166358|No Intervention|waitlist control|Participants randomized to the waitlist control condition complete assessments while the intervention group completes the yoga intervention. They are given the option to complete 8 hatha yoga classes delivered in group format once the waitlist period is finished.
2911973|NCT03166345|Experimental|PRP injection into Uterine Cavity|PRP injection into Uterine Cavity For Treatment of Thin Endometrium
2911974|NCT03166345|Experimental|CSF (colony stimulating factor)|CSF for Treatment of Thin Endometrium
2911975|NCT03166345|No Intervention|No intervention|The control arm.
2911976|NCT03166332|Active Comparator|Mediterranean diet|Mediterranean diet supplemented with extra-virgin olive oil and mixed nuts.
2911977|NCT03166332|Active Comparator|Mindfulness|Mindfulness-Based Stress Reduction program (MBSR)
2911978|NCT03166332|No Intervention|No intervention|No intervention strategy
2911979|NCT03166319|Experimental|Suspected CNS Vasculitis|Patients with suspected CNS vasculitis will undergo an MRI, including intracranial vessel wall imaging.
2911980|NCT03166306|Experimental|Patients with idiopathic or familial PAH|Ten patients with severe idiopathic or familial PAH will undergo PET-CT imaging with [89Zr]-bevacizumab.
2911981|NCT03166306|Experimental|Patients with exercise associated PAH|Ten patients with exercise associated PAH (EPAH) will undergo PET-CT imaging with [89Zr]-bevacizumab.
2911982|NCT03166306|Active Comparator|Healthy volunteers|Ten individuals with no known cardiopulmonary disease will undergo PET-CT imaging with [89Zr]-bevacizumab.
2911983|NCT03166293|Experimental|Immediate Group|Children will participate in intensive leg training with a physical therapist 1 hour/day, 4 days/week for 12 weeks. Children will continue to receive standard physical therapy care. Children will be followed for one year from the time of enrollment in the study.
2911984|NCT03166293|Experimental|Delay Group|Children will be monitored for 3 months with no intervention. Children will participate in intensive leg training with a physical therapist after the 3 month delay period. Training will be 1 hour/day, 4 days/week for 12 weeks. They will continue to receive standard care throughout. Children will be followed for one year from the time of enrollment in the study.
2911985|NCT03166280||hepatitisC-pre-ttt|Naïve HCV Patients (>18Y) coming to National Committee for control of viral hepatitis before receiving their treatment
2911986|NCT03166280||hepatitis C-ttt|Naïve HCV Patients (>18Y) coming to National Committee for control of viral hepatitis- 12 weeks after stoppage their treatment of sofosbuvir 400 mg/day plus Daclatasvir 60 mg/day for 12 weeks.
2911987|NCT03166254|Experimental|Personalized Vaccine + Pembrolizumab|"Surgical or core needle biopsy of an accessible site for sequence analysis to generate the personalized vaccine~6 weeks following enrollment (approximately 9 weeks following the last dose of systemic chemotherapy), a repeat CT scan will be done to document disease stability. Should disease progression be evident, patients will begin pembrolizumab until the personalized vaccine is available~All patients will begin treatment with pembrolizumab on a 21-day cycle for up to a maximum of 2 years of therapy 12 weeks after enrollment~Up to 2 doses of pembrolizumab can be given prior to vaccine preparation if there is a delay in vaccine formulation. Up to 20 personalized vaccine peptides will be administered~Vaccine administration will occur on Days 1, 4, 8, and 15 during Cycle 1 and on Day 1 of Cycles 2, 5, and 8~Patients in clinically stable condition who are considered by the investigator to be deriving clinical benefit may continue therapy after disease progression"
2911988|NCT03166241|Experimental|study group|measure serum interleukin 21 level in patients with severe adverse drug reaction who show change in serum interleukin 21 before and after therapy the following investigation will be done at the begning of the study to patients: Complete Blood Picture Erythrocyte Sedimentation Rate Random blood sugar Liver function tests Kidney function tests
2911989|NCT03166241|Placebo Comparator|control group|compare serum interleukin 21 level in patients with severe adverse drug reaction and healthy control subjects
2911990|NCT03166228|Active Comparator|normal saline0.9%|0.9% saline distension media is used as long as diathermy is not in use
2911991|NCT03166228|Placebo Comparator|1.5% GLYCINE|1.5% GLYCINE DURING OPERATIVE HYSTEROSCOPY as long as diathermy is in use
2911992|NCT03166215|Experimental|TAK-935: Part 1 (double-blind dose escalation)|TAK-935 low dose, tablets, orally or through gastronomy tube (G-tube)/percutaneous endoscopic gastronomy (PEG) tube, twice daily from Days 1 to 10 followed by TAK-935 medium dose, tablets, orally or through G-tube/PEG tube, twice daily from Days 11 to 20 followed by TAK-935 high dose, tablets, orally or through G-tube/PEG tube, twice daily from Days 21 to 30. The dose of TAK-935 will be gradually escalated or de-escalated during Part 1.
2911993|NCT03166215|Placebo Comparator|Placebo: Part 1 (double-blind dose escalation)|TAK-935 placebo-matching tablets, orally or through G-tube/PEG tube, twice daily from Days 1 for up to 30 days.
2911994|NCT03166215|Experimental|TAK-935: Part 2 (open-label dose escalation)|TAK-935 medium dose, tablets, orally or through G-tube/PEG tube, twice daily from Days 31 to 40 followed by TAK-935 low dose/ medium dose/ high dose, tablets, orally or through G-tube/PEG tube, twice daily from Days 31 to Day 85. At the end of Part 2, the dose of TAK-935 will be de-escalated before dosing is discontinued.
2911995|NCT03166189|Experimental|bone marrow-derived MSC and HRT|endometrial injection of autologous cell product of MSC with hormonal replacement therapy before frozen/thawed ET
2911996|NCT03166189|Active Comparator|hormonal replacement therapy|standard endometrial preparation for frozen/thawed ET
2911997|NCT03166163|Experimental|Azadirachta indica (Neem extract)|its herbal mouthwash that will be given to a group a Egyptian children twice a day(10 ml each) for 3 weeks
2911998|NCT03166163|Active Comparator|chlorhexidine mouthwash|its an antimoicrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily(10 ml each) for 3 weeks
2911999|NCT03166150|Experimental|Multi-modal rehabilitation program|12 weeks of various exercises
2912000|NCT03166150|Active Comparator|Pelvic Floor Physical therapy|12 weeks of standard pelvic floor physical therapy
2912001|NCT03166137|Experimental|Carbon dioxide laser group|(group A): thirty patients will be treated by application of carbon dioxide laser.
2912002|NCT03166137|Active Comparator|Cryotherapy group|(group B): thirty patients will be treated by cryotherapy application.
2912003|NCT03166124|Experimental|LY900014 (elderly group)|Single, subcutaneous (SC) dose of LY900014 in the elderly group
2912004|NCT03166124|Experimental|LY900014 (younger adult group)|Single, SC dose of LY900014 in the younger adult group
2912012|NCT03166098||Unaffected siblings of the BP group|
2912014|NCT03166085|Experimental|PU-H71 With Nab-paclitaxel (Abraxane)|PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle and nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1. Both drugs will be administered on the same day, in sequence, with nab-paclitaxel being administered first followed by administration of PU-H71 as close as possible to 6 hours later (+/-1 hour). PU-H71 will be administered intravenously over a 1 hour period; nab-paclitaxel will be administered per standard guidelines as a 30-minute intravenous infusion.
2912015|NCT03166072|Active Comparator|Low-vision rehabilitation program|Participants and their care givers in Low-vision rehabilitation program will undergo a standardized interview to measure HRQoL using the time trade-off method (TTO), depression using the Patient Health Questionnaire (PHQ-9), anxiety using Generalized Anxiety Disorder (GAD-7) and Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48) at the first study visit and after Low-vision rehabilitation program.
2912016|NCT03166072|Placebo Comparator|No Intervention|Participants and their care givers will undergo a standardized interview to measure HRQoL using the time trade-off method (TTO), depression using the Patient Health Questionnaire (PHQ-9), anxiety using Generalized Anxiety Disorder (GAD-7) and Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48) at the first study visit and will continue to receive treatment as usual.
2912017|NCT03166059|Experimental|Single arm|CaveoVasc® Thrombolysis Protection System
2912018|NCT03166046|Active Comparator|Study Group|Subjects will use the active pulsed shortwave therapy device (ActiPatch) as a prophylactic treatment for episodic migraine
2912019|NCT03166046|Placebo Comparator|Control Group|Subjects will use the placebo pulsed shortwave therapy device (Placebo ActiPatch) as a prophylactic treatment for episodic migraine
2912020|NCT03166033||Case Group|"age between 41 and 70years. People in the case group with the symptom numbness and then were clinical and neural-electrophysiological diagnosed CTS. People in the control group would be exclude the symptom numbness. The case group included clinical diagnosed carpal tunnel syndrome which was divided into 4 parts every 10 years old age. The gender of the patients of the control group was matched to the case group and divided into 4 parts by age."
2912021|NCT03166033||Control Group|The present case-control study was based on the single medical center in Shanghai, China, in which more than 5000 CTS patients per year are treated. The hospital involved in the study is a university teaching hospital. Cases were recruited from the surgical wards and appropriate outpatient clinics, while the controls were recruited from the outpatient clinics. Both groups filled out a standardized questionnaire, and a standardized patient record was filled out by a hand surgeon. In addition, participants with jobs involving lifting and carrying of loads were interviewed.
2912022|NCT03166020|Experimental|Rehabilitation with Interactive Table|Included patients will be invited to participate in 10 sessions, focused on the movement and manipulation of instrumented objects on interactive table with serious game, during 30 minutes per day, 5 days a week, for 14 days. An occupational therapist will be required only for patient installation in front of the table.
2912023|NCT03166020|Active Comparator|Self Rehabilitation|Included patients will be instructed to perform 10 self-rehabilitation sessions with 9 exercises (3 stretching, 3 reinforcement, 3 spot-oriented work) during 30 minutes per day, 5 days a week, for 14 days.
2912024|NCT03166007|Experimental|Optimised bowel care + abdominal massage|In addition to optimised bowel care as described below for the control group, the Intervention Nurse will teach the participant and/or their carer in the intervention arm how to deliver the abdominal massage. This will include viewing the massage DVD and the abdominal massage training booklet, as well as the demonstration of the technique on the participant by the Intervention Nurse.
2912025|NCT03166007|Active Comparator|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated.
2912026|NCT03165994|Experimental|APX005M with chemoradiation|"APX005M: 0.3mg/kg dose intravenously over 1 hour, every 3 weeks x 4 doses (weeks 1, 4, 7, and 10). Treatment begins 2 weeks prior to concurrent chemoradiation (chemoRT); continues during weeks 2 and 5 of chemoRT; and finishes with one final dose post-chemoRT and prior to surgery.~Daily radiation therapy (RT): 28 fractions (28 days)~Chemotherapy: Carboplatin and paclitaxel will be given intravenously over 1 hour, once weekly, for 5 weeks (days 1, 8, 15 22, and 29 of RT). Carboplatin dose will be AUC 2. Paclitaxel dose will be 50mg/m2.~Surgical resection of tumor: between weeks 11-17"
2912027|NCT03165981|Other|Simultaneous vaccination arm|In the study arm, subjects will receive PCV13, DTaP and IIV vaccines during visit 1. Approximately 2 weeks later, subjects will receive a health education visit without vaccination during study visit 2.
2912028|NCT03165981|Other|Sequential vaccination arm|In the study arm, subjects will receive PCV13 and DTaP during study visit 1. Approximately 2 weeks later, subjects will receive the IIV vaccine during study visit 2.
2912029|NCT03165955|Experimental|Oraxol|Subjects will receive Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.
2912030|NCT03165942|Experimental|Alcoholic Beverage|Participants will complete an MRI and oral ethanol infusion (MR/IV) session.
2912031|NCT03165942|Placebo Comparator|Non-Alcoholic Beverage|Participants will complete an MRI and oral ethanol infusion (MR/IV) session.
2912032|NCT03165929|Active Comparator|flurbiprofen-free gingival graft|
2912033|NCT03165929|Placebo Comparator|placebo-free gingival graft|
2912034|NCT03165929|Active Comparator|flurbiprofen-connective tissue graft|
2912035|NCT03165929|Placebo Comparator|placebo-connective tissue graft|
2912036|NCT03165916|Experimental|Reconstruction with stent placement|Subjects will undergo biliary reconstruction with stent placement at the anastomosis site.
2912037|NCT03165916|No Intervention|Reconstruction without stent placement|Subjects will undergo biliary reconstruction without stent placement.
2912038|NCT03165903|Experimental|Cue and Implementation-Intention|Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption.
2912039|NCT03165903|Other|Control Arm|Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message.
2912109|NCT03165435|Placebo Comparator|Placebo|Aluminium hydroxide adjuvant alone
2912110|NCT03165422||Adult patients with melanoma|Adult patients with melanoma at participating centers in Japan
2912040|NCT03165890|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
2912041|NCT03165890|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
2912042|NCT03165877|Experimental|Low-glycemic index|Low-glycemic index lunches and dinners (<55%)
2912043|NCT03165877|Active Comparator|Control|Medium/high glycemic index lunches and dinners (>60%)
2912044|NCT03165864|Experimental|IONIS TMPRSS6-Lrx|Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously
2912045|NCT03165864|Placebo Comparator|Placebo|Saline .9%
2912046|NCT03165851||CAMS-2005 trial|The induction course was Daunorubicin(DNR) + Cytarabine(Ara-C) or Homoharringtonine(HHT) + Ara-C or HHT + DNR + Ara-C. There are 5 consolidation course after complete remission (CR).
2912047|NCT03165851||CAMS-2009 trial|The induction course was MAE(Mitoxantrone + Cytarabine + Etoposide) or IAE(Idamycin + Cytarabine + Etoposide). Risk-stratified therapy and dose-dense intensive chemotherapy were adopted in the consolidation therapy. After the second course of therapy, patients in remission were stratified into three risk groups: low-risk children were defined as those with t(8;21) and a white blood cell count lower than 50,000/L, inv(16), or an age younger than 2 years without any high-risk factors; high-risk children were those with CR after consolidation course 1 or induction C , or with abnormalities of monosomy 7, 5q-, t(16;21), t(9;22)(Philadelphia chromosome [Ph1]); intermediate-risk children were those who were not in either a low-risk or high-risk group. Hematopoietic stem cell transplantation (HSCT) was indicated for only relapsed patients in the second CR.
2912048|NCT03165838|Experimental|Postpartum Visit 3-4 Weeks|Participants will have postpartum visit scheduled 3-4 weeks after birth
2912049|NCT03165838|Experimental|Postpartum Visit 6-8 Weeks|Participants will have postpartum visit scheduled 6-8 weeks after birth
2912050|NCT03165825|Experimental|Tranforaminal|will receive cervical epidural injection via a transforaminal route with dexamethasone steroid
2912051|NCT03165825|Active Comparator|Interlaminar|will receive cervical epidural injection via an interlaminar route with betamethasone steroid
2912052|NCT03165812|Experimental|SADJB-SG group|Patients in this group will undergo bariatric surgery. There are two parts to this procedure. One is the restrictive type of weight loss surgery, which reduces the stomach size. The other type prevents the body from absorbing fats and sugar properly, as the small intestine will be attached to the small stomach, bypassing most of the stomach and upper part of the small intestine. This surgery will be performed using a minimally invasive technique known as laparoscopic keyhole surgery.
2912053|NCT03165812|Experimental|IMT group|Patients in this group will be subjected to strict adherence to diet, optimisation of diabetic medications and close monitoring of blood glucose and HbA1c.
2912054|NCT03165799|Experimental|Mindfulness Education|"Participants viewed an informational video titled, All it Takes is 10 Mindful Minutes by mindfulness expert, Andy Puddicombe. Following the video, a guided discussion was provided that focused on how the principles of mindfulness can be used to influence a physician's state of mental presence, allowing for moments of clarity, insight, and reflection, and potentially enhance provider and patient safety."
2912055|NCT03165799|No Intervention|No Intervention|Participants did not receive mindfulness education.
2912056|NCT03165786|Experimental|FREE Group|Cognitive behavioral therapy intervention with real-time continuous glucose monitoring.
2912057|NCT03165786|No Intervention|Control Group|Real-time continuous glucose monitoring
2912058|NCT03165773|Experimental|Oatmeal|87 grams oatmeal
2912059|NCT03165773|Active Comparator|Corn grits|67 grams corn grits
2912060|NCT03165760|No Intervention|control group|Vt = 8 ml/kg of PBW and PEEP = 4 cm H2O
2912061|NCT03165760|Experimental|protective ventilation group|Vt = 6ml/kg of PBW, PEEP = 10 and RM if disconnected
2912062|NCT03165747|Experimental|VSL#3|VSL#3 two active sachets [containing 450x109 colony-forming units (CFU)/sachet], taken daily in a single administration.
2912063|NCT03165747|Placebo Comparator|Control|Placebo, no supplemental probiotics.
2912064|NCT03165734|Experimental|Pacritinib 100 mg QD|Pacritinib 100 mg (1 capsule) QD orally, at the same time of day, with or without food
2912065|NCT03165734|Experimental|Pacritinib 100 mg BID|Pacritinib 100 mg (1 capsule) BID orally, at the same time of day, with or without food
2912066|NCT03165734|Experimental|Pacritinib 200 mg BID|Pacritinib 200 mg (2 capsules) BID orally, at the same time of day, with or without food
2912067|NCT03165721|Experimental|Arm 1|SGI-110 administered subcutaneously at 45mg/m2/day x 5 days on a 28-day cycle
2912068|NCT03165708||anesthesiologist|The active comparators for this study will be expert anaesthesiologists (operator). The operators will be blinded to all visual and audible CompuFlo® real-time pressure feedbacks.Inter-rater agreement, or concordance, between an expert anaesthesiologist and the CompuFlo® Epidural Computer Controlled System for the epidural space verification will be assessed by blinded tagging of the operator's feeling of the ligamenta and epidural space on the screen of the Compuflo to be eventually compared with the pressure's variations
2912069|NCT03165695|Experimental|Ramelteon Arm|Ramelteon tablet 8 mg orally at 21:00 for 7 days or until discharge whichever comes first.
2912070|NCT03165695|Placebo Comparator|Placebo Arm|Sugar pill manufactured to mimic Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first.
2912071|NCT03165682||Group 1|Twenty-five patients with Systemic Lupus Erythematosus with prominent fatigue symptoms ( inclusion criterion: FSS of at least 4)
2912072|NCT03165682||Group 2|Twenty-five patients with Systemic Lupus Erythematosus without subjectively enhanced fatiguability
2912073|NCT03165682||Group 3|Twenty-five age, sex and educationally matched controls among the health worker.
2912111|NCT03165396|Experimental|Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 2.0~2.5μg/ml ）for maintaining
2912112|NCT03165396|Experimental|1.2 μg/ml Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 1.2 μg/ml ）combined with appropriate sevoflurane for maintaining
2912113|NCT03165396|Experimental|0.6 μg/ml Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 0.6 μg/ml ）combined with appropriate sevoflurane for maintaining
2912074|NCT03165669|Experimental|Cervical pillow|"The cervical pillow is known as the Viscospring PostuRite - medium model, made by SOFF-ART S.r.l. - Via Maestri del Lavoro 49 - 05100 Terni, Italy. The Viscospring PostuRite pillow is externally made of viscoelastic polyurethane and internally 60 independent, individually coated harmonic phosphate-coated steel springs, are thought to promote correct posture of the cervical spine, due to the adaptation of the pillow to the shape and movements of the head.~Each intervention will be supported by a 30-minutes informative session delivered by a physical therapist, and will be completed by the delivery of an informative brochure."
2912075|NCT03165669|Active Comparator|Education|The educational intervention will be conducted by a physical therapist and will consist of a advice on positions, movements and activities recommended or not recommended for people with chronic neck pain, both in the workplace and in leisure time, including nighttime postures. Each educational intervention will be carried out individually, will last half an hour and will be supported by the delivery of an informative brochure.
2912076|NCT03165656||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
2912077|NCT03165656||High altitude control|Healthy highlanders living above 2500 m.
2912078|NCT03165656||Low altitude control|Healthy lowlanders living below 1000 m.
2912079|NCT03165643||NGT-normal birth weight|
2912080|NCT03165643||NGT-macrosomia|
2912081|NCT03165643||GDM-normal birth weight|
2912082|NCT03165643||GDM-macrosomia|
2912083|NCT03165630|No Intervention|Group 1|Education or Control group.
2912084|NCT03165630|Experimental|Group 2|Transportation incentives
2912085|NCT03165630|Experimental|Group 3|Transportation and rehabilitation services incentives
2912086|NCT03165617|Experimental|QIVc (≥2 years to <18 Years of Age)|Cell-derived Seasonal Quadrivalent Influenza Vaccine
2912087|NCT03165617|Active Comparator|Non-Influenza Comparator Vaccine|Non-Influenza Comparator Vaccine
2912088|NCT03165604|Active Comparator|Normal weight|30 normal weight children will receive 2 types of information: standard information and positive information regarding a water drink before physical exercise
2912089|NCT03165604|Active Comparator|Over weight|30 over weight children will receive 2 types of information: standard information and positive information regarding a water drink before physical exercise
2912090|NCT03165591|Experimental|Experimental|Daily tablet of V3-P given orally for 2 months
2912091|NCT03165578|Experimental|Neurofeedback|Neurofeedback training.
2912092|NCT03165578|Sham Comparator|Sham Feedback|Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
2912093|NCT03165565|Experimental|MI and ACT|Participants will receive behavioral therapy including Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
2912094|NCT03165565|Active Comparator|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
2912095|NCT03165552|Experimental|Educational Arm|This group will receive an acute kidney injury educational intervention
2912096|NCT03165539||Thoracic surgery patient|Pre-operatively, patients will have baseline cognitive assessment done using the Mini-mental status test and MOCA test. Intra-operatively patients' baseline cerebral saturation (%) will be measured, and continuously monitored throughout the procedure. Post-operatively, patients will be assessed for delirium using the CAM score.
2912097|NCT03165526||First Cohort|All available Emergency and Compassionate PIVSD Occluder subject data from 2011 until the end of 2016 will be utilized to determine technical success and acute survival. All subjects belonging to this cohort must have undergone an attempt to close a post-infarct VSD using the AMPLATZER™ PIVSD Occluder.
2912098|NCT03165526||Second Cohort|"This cohort will consist of subjects over the age of 18 years who have previously been successfully implanted with the PIVSD Occluder and the~Subject or subject's legally authorized representative has provided consent to participate in this study.~Subject's post-procedure echocardiogram is evaluable and can be sent to the echocardiography core laboratory for residual shunt assessment.~Therefore, this cohort will be composed of retrospectively enrolled subjects. This cohort will be utilized to determine acute and chronic closure and chronic survival."
2912099|NCT03165513|Experimental|Experimental arm|mhGAP-IG psychosocial intervention
2912100|NCT03165500|Active Comparator|Diazepam|Sedation of the anxious patient with diazepam 5 mg for measuring vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
2912101|NCT03165500|Active Comparator|Midazolam|Sedation of the anxious patient with midazolam 7.5 mg for measurement of vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
2912102|NCT03165500|Active Comparator|Nitrous Oxide + Oxygen Gas|Inhaled sedation of the mixture of 40% of nitrous oxide and 60% of oxygen gas for measurement of vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
2912103|NCT03165487||Luminal A Breast Cancer|Luminal A Breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.
2912104|NCT03165487||Triple Negative Breast Cancer|triple Negative breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.
2912105|NCT03165474|Active Comparator|Control Arm|In the control group, children and parents will receive didactic health information and resources by email and/or text. The delivery mode of the health messages will be based on based on personal preference.
2912106|NCT03165474|Experimental|Intervention Arm|In the intervention group, children will have access to a web-based interactive nutrition comic and receive health messages from comic characters by email and/or text, while parents will receive weekly newsletters related to nutrition and health by email and/or text.
2912107|NCT03165448||Self-reported questions|All the participants will enroll the same study protocol, without any exceptions: pre-operative patient's self-reported questioning, post-operative doctor's questioning, 4-6 weeks patients retesting.
2912108|NCT03165435|Experimental|CV-MG01|The active targeted immunotherapy candidate, CV-MG01 comprises two short synthetic peptides separately conjugated to a carrier protein for the potential treatment of myasthenia gravis
2912114|NCT03165396|Experimental|Sevoflurane|administrated 1.3 minimum alveolar concentration（MAC ） sevoflurane for maintaining
2912115|NCT03165383|Active Comparator|Transversus Abdominis Plane (TAP) Block Group|Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly upto 24 hours.
2912116|NCT03165383|Placebo Comparator|Control Group (No TAP Block)|The Transversus Abdominis Plane Block was not performed. Intravenous PCA Morphine was given as rescue analgesic upto 24 hours.
2912117|NCT03165370||Insomnia|those with unsatisfactory sleep quantity and/or quality (difficulty with sleep induction, awakenings during the night, early morning awakening, total sleep time, and overall quality of sleep), complaint of a minimum frequency (at least three times a week) and duration (1 month), marked distress caused by the sleep problem and/or interference with ordinary activities of daily living
2912118|NCT03165357|Experimental|Sodium bicarbonate|"Group taking oral NaHCO3 supplementation in a progressive-dose regimen.~Interventions:~The experimental procedure for each athlete included a 10-day NaHCO3 supplementation in a progressive-dose regimen in order to reduce the likelihood of gastrointestinal side effects (from 37.5 to 150 mg ∙ kg-1). NaHCO3 was administered in the form of unmarked disk-shaped tablets (Alkala T, SANUM, Poland). The tablets were ingested with at least 250 mL of water and could be either swallowed or dissolved in the mouth. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.~Between the 10-day NaHCO3 and PLA or a PLA and NaHCO3 treatments, a 14-day washout period was introduced."
2912119|NCT03165357|Placebo Comparator|Placebo (maltodextrin)|"Group taking oral supplementation with placebo (maltodextrin).~Interventions:~The experimental procedure for each athlete included a 10-day placebo administration. Placebo was ingested with at least 250 mL of water. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.~Between the 10-day NaHCO3 and PLA or a PLA and NaHCO3 treatments, a 14-day washout period was introduced."
2912120|NCT03165344|Experimental|hydrocortisone group|
2912121|NCT03165344|Placebo Comparator|prednisone grope|
2912122|NCT03165331|Other|Intervention group|The intervention group will go through the intervention programme (UNG Face IT) - 7 weeks + post-intervention questionnaires + Treatment as usual
2912123|NCT03165331|No Intervention|Control group|Treatment as usual, which may mean some support locally.
2912124|NCT03165318|Active Comparator|Pulsed Electromagnetic Field Therapy|Active Pulsed Electromagnetic Field therapy device; exposed once weekly for 10 minutes.
2912125|NCT03165318|Sham Comparator|Sham Therapy|Inactive Pulsed Electromagnetic Field therapy device; exposed once weekly for 10 minutes.
2912126|NCT03165305|Experimental|Sustained Inflation Group|Includes the infants who administered sustained inflation for 5 seconds with a pressure of 30cm H20 immediately after the delivery.
2912127|NCT03165305|No Intervention|No Intervention group|Includes routine neonatal care in the delivery room
2912128|NCT03165292|Experimental|Arm A: High administered activity 131I- mIBG and Topotecan|"The trial will evaluate two randomised arms. Each arm includes~three cycles of Temozolomide-Irinotecan, similar in both arms,~a specific consolidation course detailed hereinafter,~a BuMel sequence, followed by an ASCT, similar in both arms,~external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate."
2912129|NCT03165292|Experimental|Arm B: High dose Thiotepa|"The trial will evaluate two randomised arms. Each arm includes~three cycles of Temozolomide-Irinotecan, similar in both arms,~a specific consolidation course detailed hereinafter,~a BuMel sequence, followed by an ASCT, similar in both arms,~external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate."
2912130|NCT03165279||Patient with AAA|Patient will receive a 'Zenith Alpha Abdominal stentgraft' as intervention to eliminate the abdominal aortic aneurysm.
2912131|NCT03165253|Active Comparator|Synbiotic Group|The patients will be treated with the standard triple therapy that consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month, and the synbiotic Bifidobacterium animalis oral product (5000000000 colony forming units/dose) plus inulin (900 mg) given a single dose for 14 days, concurrently.
2912132|NCT03165253|Other|Standard Therapy Group|The patients in this group will be treated with standard triple therapy only. The standard triple therapy consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month.
2912133|NCT03165240|Experimental|BI 690517 Dose 1|
2912134|NCT03165240|Experimental|BI 690517 Dose 2|
2912135|NCT03165240|Experimental|BI 690517 Dose 3|
2912136|NCT03165240|Experimental|BI 690517 Dose 4|
2912137|NCT03165240|Experimental|Eplerenone|
2912138|NCT03165240|Placebo Comparator|Placebo|
2912139|NCT03165227|Experimental|BI 685509 Dose 1|
2912140|NCT03165227|Experimental|BI 685509 Dose 2|
2912141|NCT03165227|Experimental|BI 685509 Dose 3|
2912142|NCT03165227|Experimental|BI 685509 Dose 4|
2912143|NCT03165227|Placebo Comparator|Placebo|
2912144|NCT03165214|Active Comparator|coil group|micro coils
2912145|NCT03165214|Experimental|glue group|hystoacryl mixed with lipidol
2912146|NCT03165175|Experimental|Intervention|The experimental group will be provided with the MedAware smartphone application in addition to treatment as usual. MedAware is an educational mobile phone app that focuses on helping military members reduce their risk for prescription drug misuse.
2912147|NCT03165175|No Intervention|Control|The control group will be provided with treatment as usual, and will also receive a list of resources for help with prescription drug and other substance abuse issues.
2912148|NCT03165162|Experimental|Study Arm|Food Order: Randomly assigned orders of 7 bowls of granola, each with a different food label.
2912149|NCT03165149|Active Comparator|Group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % )
2912150|NCT03165149|Active Comparator|Group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) a
2912151|NCT03165149|Active Comparator|Group (C)|patients will receive 3 mg / kg of Ketamine diluted by 20 ml saline (0.9 %)
2912500|NCT03162744||Suicide attempt or ideas|Elderly patients who attempted suicide or who emitted suicidal ideas
2912152|NCT03165136|Experimental|Hydroxychloroquine|The treatment will be orally administrated, at a daily dose of 400 mg of hydroxychloroquine . The treatment will be started before conception and will be stopped at the end of the tenth week of gestation or before in case of pregnancy loss.
2912153|NCT03165136|Placebo Comparator|Placebo|A similar placebo will be orally administrated every day.
2912154|NCT03165123|Placebo Comparator|placebo group|The patients will receive oral placebo tablet, one hour before induction of anesthesia and 5 mg Intra-venous dexamethasone within 1-2 minutes after the umbilical cord is clamped.
2912155|NCT03165123|Active Comparator|Erythromycin A group|The patients will receive 250 mg oral Erythromycin A tablet, one hour before induction of anesthesia and 5 mg Intra-venous dexamethasone within 1-2 minutes after the umbilical cord is clamped.
2912156|NCT03165110|Experimental|Users of the Onyx Blood Glucose Meter/ app System at home|All participants in the study have a diagnosis of either type 1 or type 2 diabetes for at least 6 months and use insulin in their diabetes management.
2912157|NCT03165097|Experimental|ACT-709478|"Up to 30 healthy male and female subjects (40 subjects if the optional fourth dose level is conducted) will receive multiple doses of ACT-709478 at the planned dose levels of 30, 100, and 200 mg.~Each dose level will be investigated in a new cohort of 10 healthy male and female subjects (4 male subjects on active drug and 1 on placebo, 4 female subjects on active drug and 1 on placebo) undergoing one treatment period with a once daily dosing scheme."
2912158|NCT03165097|Placebo Comparator|Placebo|Matched placebo administered accordingly
2912159|NCT03165084|Experimental|Intervention arm|Participants in the intervention group will receive usual care, and also use a diabetesapp and a homepage and advice personally tailored according to the personal needs to provide support for them to manage e.g. food choices, exercise, medicine, blood sugars and emotional adaptation.
2912160|NCT03165084|Other|Control arm|Participants in the control group will receive usual care and also take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
2912161|NCT03165084|Other|External comparison group|An external comparison group will be recruited from two other primary health care centers in order to analyse possible Hawthorne effects.
2912162|NCT03165071|Experimental|ACT-132577 (50 mg)|8 healthy subjects and 8 subjects with severe renal function impairment will receive a single oral dose of 50 mg ACT-132577 administered as capsule following an overnight fast
2912163|NCT03165058||Inflammatory Bowel Disease|Patients undergoing standard of care colonoscopy for inflammatory bowel disease (IBD) surveillance will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa.
2912164|NCT03165058||control|Patients undergoing standard of care colonoscopy for age appropriate screening will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa.
2912165|NCT03165045||patients treated with Spiolto® Respimat®|Patients with COPD
2912166|NCT03165032||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
2912167|NCT03165032||High altitude control|Healthy highlanders living above 2500 m.
2912168|NCT03165032||Low altitude control|Healthy lowlanders living below 1000 m.
2912169|NCT03165019||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
2912170|NCT03165019||High altitude control|Healthy highlanders living above 2500 m.
2912171|NCT03165019||Low altitude control|Healthy lowlanders living below 1000 m.
2912172|NCT03165006||Screened women with breast cancer|
2912173|NCT03164993|Placebo Comparator|Arm Chemotherapy + Placebo|Chemo (pegylated liposomal doxorubicin + cyclophosphamide) + placebo
2912174|NCT03164993|Active Comparator|Arm Chemotherapy + Atezolizumab|Chemo (pegylated liposomal doxorubicin + cyclophosphamide) + Atezolizumab
2912175|NCT03164980||Arm A|PLD followed by Trabectedin. Treatment is repeated every 3 weeks for 6 cycles or until disease progression.
2912176|NCT03164980||Arm B|"Carboplatin/PLD~Carboplatin/Gemcitabine~Carboplatin/Paclitaxel Patients will be treated for 6 cycles or until PD, unacceptable toxicity or patient's wish to discontinue, whichever occurs first."
2912177|NCT03164967|Other|Active Drug|All subjects will receive Bivigam based on their prior dosing to be adjusted as clinically necessary.
2912178|NCT03164941||Nasal SLT|This cohort will have 180 degree SLT completed on the nasal quadrants of the trabecular meshwork.
2912179|NCT03164941||Temporal SLT|This cohort will have 180 degree SLT completed on the temporal quadrants of the trabecular meshwork.
2912180|NCT03164928|Other|Placebo|SC Q6M placebo
2912181|NCT03164928|Experimental|Denosumab|1 mg/kg BW (up to a maximum of 60 mg) SC Q6M
2912182|NCT03164915|Experimental|LIV-GAMMA SN Inj.|
2912183|NCT03164902|Experimental|Digital Medicine Arm|Subjects enrolled in this single arm study will be directed to use digital medicine versions of their hepatitis C therapy for the duration of therapy.
2912184|NCT03164889|Experimental|ETV+GM-CSF|Entecavir (ETV) plus Granulocyte Macrophage-colony Stimulating Factor (GM-CSF). ETV was given 0.5mg/d, oral; GM-CSF was given 100ug, the 3th, 4th, 5th day at week1, 4, 12, 24, 48, subcutaneous injection.
2912185|NCT03164889|Active Comparator|ETV monotherapy|As standard antiviral therapy, Entecavir was given 0.5mg/d, oral.
2912186|NCT03164876|Experimental|Dose AUT00206 800 mg BD|AUT00206 800mg twice daily for 28 days
2912187|NCT03164876|Placebo Comparator|Placebo|Placebo to match AUT00206 twice daily for 28 days
2912188|NCT03164837|Experimental|68Ga-NOTA-RM26 PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-RM26 in one dose intravenously and underwent PET/CT scan 15-30 min later.
2912189|NCT03164811|Experimental|GDFT group|The GDFT group will receive 400 ml of 12.5% carbohydrate drink after 6 pm until the bed time in the day before surgery and 200 ml in the morning of the surgery day. Acetate ringer solution will be start at 7:00. After induction PPV will be measure and fluid bolus 200 ml in 10 minutes will be given if PPV >13 before prone position. During the operation, the patient in GDFT group will receipt fluid therapy according to acceptable PPV
2912190|NCT03164811|Other|controlled group|The carbohydrate drink will not be given. Fluid, blood and blood product administration will be under attending anesthesiologist order.
2912191|NCT03164785|Experimental|Treatment Group|"Treatment：subjects receive Jinshuibao Capsule. ARB will be continued as a routine therapy.~Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling"
2912192|NCT03164785|No Intervention|Control Group|Patients receive a standard dose of ARB drug as a routine therapy. Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling
2912193|NCT03164772|Experimental|Arm A|There is a dose escalation phase in which the Recommended Combination Dose is determined according to a standard 3 + 3 design. The dose escalation phase is followed by an expansion phase, in which the cohort at the Recommended Combination Dose is expanded to 20 subjects (inclusive of the subjects from the dose escalation cohort).
2912194|NCT03164772|Experimental|Arm B|"The dose escalation phase is followed by an expansion phase, in which the cohort at the Recommended Combination Dose is expanded to 20 subjects (inclusive of the subjects from the dose escalation cohort).~For Arm B, there will be an additional Control group (n = 10) added to the expansion phase in which the subjects will receive only durvalumab every 4 weeks."
2912195|NCT03164746|Active Comparator|DRY group|Dry sheet therapeutic body wraps will be conducted through twice-a-week sessions for a 3-month duration. Sessions take place in the same quiet room and they usually last 45 minutes each up to 1 hour depending on the patient's response. During sessions, the patient wearied a bathing suit. Sessions were conducted under the supervision of an occupational therapist and involved at least two members of the patient's care team.
2912196|NCT03164746|Experimental|WET Group|Wet sheet therapeutic body wraps will be conducted through twice-a-week sessions for a 3-month duration. Sessions take place in the same quiet room and they usually last 45 minutes each up to 1 hour depending on the patient's response. During sessions, the patient wearied a bathing suit. Sessions were conducted under the supervision of an occupational therapist and involved at least two members of the patient's care team.
2912197|NCT03164733||<40|patients younger than 40 years
2912198|NCT03164733||40-60|patients younger than 60 years and not older than 40 years
2912199|NCT03164733||60-80|patients younger than 80 years and not older than 80 years
2912200|NCT03164733||>80|patients older than 80 years
2912201|NCT03164694|Experimental|Apatinib|Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5) plus apatinib. Apatinib was given 850 mg per day orally at day one of chemotherapy.
2912202|NCT03164694|Active Comparator|Control|Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5).
2912203|NCT03164668|Other|Usual cigs; menthol e-cig then tobacco e-cigs|Participants can continue to smoke their usual cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes
2912204|NCT03164668|Other|Usual cigs; tobacco e-cig then menthol e-cigs|Participants can continue to smoke their usual cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes
2912205|NCT03164668|Other|avoid menthol cigs; menthol e-cig then tobacco e-cigs|Participants avoid smoking menthol cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes
2912206|NCT03164668|Other|avoid menthol cigs; tobacco e-cig then menthol e-cigs|Participants avoid smoking menthol cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes
2912207|NCT03164655|Experimental|HAI oxaliplatin combined with I.V. FOLFIRI + target therapy|"HAI oxaliplatin 100 mg/m² on D1~I.V. cetuximab 500 mg/m2 or panitumumab 6 mg/kg or bevacizumab 5 mg/kg D1 according to RAS status and prior response/tolerance to systemic induction CT~modified FOLFIRI regimen without fluorouracil bolus~I.V. irinotecan 180 mg/m2 D1~I.V. bolus 5FU: 0~I.V. leucovorin 400 mg/m² in 2 hours D1~I.V. continuous infusion 5FU 2400 mg/m² in 46 hours"
2912208|NCT03164655|Active Comparator|conventional systemic CT|"Response to systemic induction CT~Toxicity and duration of the systemic induction CT~RAS status~Current guidelines/standard of care"
2912209|NCT03164642|Experimental|LENA with Feedback|Mothers who will run the LENA system with their young children, AND who will receive feedback from their service providers on how to enhance the language the home language environment.
2912210|NCT03164642|Placebo Comparator|LENA no feedback|Mothers who will only run the LENA system with their young children. These mothers will NOT receive feedback from their service providers on how to enhance the language the home language environment.
2912211|NCT03164629|Experimental|Study Group|"The following parameters will be recorded for the study group:~Time for catheterization~Time for planning dataset for each side~Total dose area product~Dose for planning dataset for each side~Dose area product only for fluoroscopy~Total procedural time: from access to closure~Amount of contrast medium used"
2912212|NCT03164629|Active Comparator|Control Group|"The following parameters will be recorded for the control group:~Time for catheterization~Total dose area product~Dose area product only for fluoroscopy~Total procedural time: from access to closure.~Amount of contrast medium used"
2912213|NCT03164616|Experimental|Treatment Arm 1|durvalumab + tremelimumab combination therapy + SoC chemotherapy
2912214|NCT03164616|Experimental|Treatment Arm 2|durvalumab monotherapy + SoC chemotherapy
2912215|NCT03164616|Active Comparator|Treatment Arm 3|SoC chemotherapy alone
2912216|NCT03164603|Experimental|NLG8021 Dose Escalation|Approximately 6 to 36 participants will be enrolled and treated at escalating doses of NLG802. Treatment may continue until unacceptable toxicity or disease progression. Successive groups of at least 3 participants will be evaluated during a 28-day window for DLTs, which will determine the enrollment and dosing for subsequent cohorts in the dose-escalation stage.
2912217|NCT03164590|Active Comparator|ketamine|
2912218|NCT03164590|Active Comparator|dexmedetomidine|
2912219|NCT03164590|Placebo Comparator|bupivacaine|
2912220|NCT03164577|Active Comparator|DARTNA|DARTNA is a culturally-adaptable therapeutic drum behavior therapy that incorporates drumming, talking circles, and uses the 12 Steps of Alcoholics Anonymous (AA)/Narcotics Anonymous (NA) program within the conceptual framework of the Northern Plains Medicine Wheel. The Northern Plains Medicine Wheel is widely utilized as a conceptual framework and integrative approach to health and wellness for AI/ANs. This intervention consists of 12 sessions provided 2 times weekly over 6 weeks.
2912255|NCT03164330|Experimental|B75|"Group B75 is offered moderate compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - moderate compensation, Wellness Activities - high compensation"
2912221|NCT03164577|Placebo Comparator|Usual care plus|Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
2912222|NCT03164564|Experimental|Arm A: CAB + Placebo TDF/FTC + CAB LA|During Step 1, participants will receive daily oral CAB and oral TDF/FTC placebo for 5 weeks. In Step 2, participants will receive injections of CAB LA at two time points 4 weeks apart and every 8 weeks thereafter and daily oral TDF/FTC placebo beginning at Week 5. In Step 3, participants will receive daily TDF/FTC for up to 48 weeks, starting no later than 8 weeks after the last injection.
2912223|NCT03164564|Active Comparator|Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA|During Step 1, participants will receive daily TDF/FTC and oral CAB placebo for 5 weeks. In Step 2, participants will receive daily TDF/FTC and placebo for CAB LA injections at two times points 4 weeks apart and every 8 weeks thereafter beginning at Week 5. In Step 3, participants will receive daily TDF/FTC for up to 48 weeks, starting no later than 8 weeks after the last injection.
2912224|NCT03164551|Other|GERI+ Incubator|
2912225|NCT03164551|Active Comparator|Conventional incubator|
2912226|NCT03164538|Experimental|Intervention Arm|Participants will all undergo an 16-week PP-MI health behavior intervention.
2912227|NCT03164538|Active Comparator|Comparator Arm|Participants will all undergo an 16-week diabetes education intervention.
2912228|NCT03164512|Placebo Comparator|Placebo|Placebo oral and vapor
2912229|NCT03164512|Experimental|Vaporized High Cannabidiol Cannabis|Cannabis containing approximately 100mg cannabidiol and 5mg delta-9-THC
2912230|NCT03164512|Experimental|Vaporized Cannabidiol|100mg cannabidiol in vapor
2912231|NCT03164512|Experimental|Oral Cannabidiol|100mg oral cannabidiol
2912232|NCT03164499|Active Comparator|Control group|Individual counselling on lifestyles.
2912233|NCT03164499|Experimental|Intervention group|Individual counselling on lifestyles and additional group counselling on lifestyles.
2912234|NCT03164486|Experimental|18F-αvβ6-BP|Patients receive 18F-alphavbeta6-BP IV and then undergo 4 PET scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection.
2912235|NCT03164473|Experimental|Rituximab|"pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)~plus orally placebo-azathioprine for 24 months"
2912236|NCT03164473|Active Comparator|Azathioprine|"standard maintenance oral azathioprine therapy (2 mg/kg/day) for 24 months~plus 4 placebo−rituximab infusions given every 6 months for 18 months"
2912237|NCT03164460|Experimental|Stereotactic Body Radioablative Therapy (SBRT)|"Participants receive SBRT every other day for a total of 5 treatments (about 2 weeks).~Questionnaires completed at baseline, before and after radiation treatment, at each visit during radiation therapy, and 2 months after last radiation treatment and then every 3 months after that for up to 2 years."
2912238|NCT03164460|Active Comparator|Conventional Radiation Therapy IMRT/IMPT|"Participants receive conventional radiation therapy 1 time each weekday (Monday-Friday) for a total of up to 30-35 treatments (about 6-7 weeks).~Questionnaires completed at baseline, before and after radiation treatment, at each visit during radiation therapy, and 2 months after last radiation treatment and then every 3 months after that for up to 2 years."
2912239|NCT03164447|Experimental|Cohort 1|
2912240|NCT03164447|Experimental|Cohort 2|
2912241|NCT03164421|Experimental|N-Acetylcysteine|N-Acetylcysteine used by clomiphene resistant pcos women
2912242|NCT03164421|Active Comparator|L-carnitine|L-carnitine used by clomiphene resistant pcos women
2912243|NCT03164395|Experimental|Internal Cardioversion|Patients randomized to external cardioversion will undergo external synchronized cardioversion per institutional protocol.
2912244|NCT03164395|Active Comparator|External Cardioversion|Patients randomized to internal cardioversion will have a maximum energy shock delivered from the device between the RV coil and can. If cardioversion is not successful they will then undergo external cardioversion per institutional protocol.
2912245|NCT03164382|Experimental|HAIF group|FOLFOX regimen: oxaliplatin 130 mg/m2 on day 1 from hour 0 to 3; leucovorin 200 mg/m2 from hour 3 to 5, fluorouracil 400 mg/m2 bolus at hour 5, and then fluorouracil 2,400 mg/m2 over 46 hours, via hepatic artery, once every 3 weeks.
2912246|NCT03164382|Active Comparator|Sorafenib group|Sorafenib 200mg Tab, 400 mg twice per day orally. Treatment was given in 4-week cycles.
2912247|NCT03164356|No Intervention|Arm 1|In Arm 1, bioimpedance measurements are taken by research staff. The participants also wear an ActiGraph monitor for at least one week prior to their prosthetist preforming modifications to their socket.
2912248|NCT03164356|Experimental|Arm 2 - Experimental|Conclusions drawn from data gathered in Arm 1 will be given to the participant's prosthetist, along with their bioimpedance data from Arm 2, to inform the practitioner's decision on when a modification to the socket is warranted. The results will be compared to those of Arm 3.
2912249|NCT03164356|No Intervention|Arm 3 - Control|Bioimpedance data will be collected from participants in Arm 3 in parallel with those in Arm 2. However, no data will be provided to the participant's prosthetist.
2912250|NCT03164343|Experimental|Pain Neuroscience Education for children|All participants within this study will receive Pain Neuroscience Education
2912251|NCT03164330|No Intervention|Control|The control group takes a baseline survey, and thereafter has minimal interaction with the project, until a follow-up biometric screening is conducted during the one-year follow-up.
2912252|NCT03164330|Experimental|A25|"Group A25 is offered no compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - No compensation, Wellness Activities - low compensation"
2912253|NCT03164330|Experimental|A75|"Group A75 is offered no compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - No compensation, Wellness Activities - high compensation"
2912254|NCT03164330|Experimental|B25|"Group B25 is offered moderate compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - moderate compensation, Wellness Activities - high compensation"
2912256|NCT03164330|Experimental|C25|"Group C25 is offered high compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - high compensation, Wellness Activities - high compensation"
2912257|NCT03164330|Experimental|C75|"Group C75 is offered high compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - high compensation Wellness Activities - high compensation"
2912258|NCT03164317|Active Comparator|Intervention|Trained NCC together with electronic decision support system
2912259|NCT03164317|Other|Control|No trained NCC and electronic decision support system
2912260|NCT03164304|Active Comparator|One gram magnesium sulfate|Pregnant women with a diagnosis of severe pre-eclampsia will receive 1 g of mgso4 to prevent and control of convulsions
2912261|NCT03164304|Experimental|Two grams magnesium sulfate|Pregnant women with a diagnosis of severe pre-eclampsia will receive 2 g of mgso4 to prevent and control of convulsions
2912262|NCT03164291|Experimental|Rifabutin|Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections or other NTM disease who fail therapy with other drugs ( i.e., rifampin)
2912263|NCT03164278|Experimental|Immediate Training (no follow up)|Individuals may decide to participate in the research study training program, but not in any follow up questionnaires. This group will have immediate access to the independent transfer training materials. They will complete data collection measures embedded in the transfer training program, including demographics, Online Learning Readiness Scale (OLRS), Moorong Self Efficacy Scale (MSES), Patient Reported Outcome Measurement Information System (PROMIS), Transfer Assessment Instrument Questionnaire (TAI-Q), and the Wheelchair User Shoulder Pain Index (WUSPI).
2912264|NCT03164278|Experimental|Immediate Training (with follow up)|Individuals may decide to participate in the research study, but do not want to be randomized. After consent is obtained, these individuals will be directed immediately to the baseline questionnaires (see above) before and after the independent transfer training. Participants may also be asked to complete a user satisfaction survey.
2912265|NCT03164278|Experimental|Randomized Training|Individuals may decide to participate in the research study and agree to be randomized. These individuals will be immediately randomized into an immediate or a wait list control group. The immediate will receive the independent transfer training program after completing the baseline questionnaires. The wait list control group will wait approximately 6 months before receiving the independent transfer training program.
2912266|NCT03164252|Active Comparator|Grupo I- Lower laser fluency|20 patients received 660 nm red laser diode laser therapy, 30 mW power and 10 J / cm2 fluency, in the immediate period after surgical period of the third molar third molar extraction / impacted by the intraoral region
2912267|NCT03164252|Active Comparator|Grupo II- Greater laser fluency|20 patients received 660 nm red laser diode laser therapy, 30 mW power and 30J / cm2 fluency, in the immediate period after surgical of the third molar third molar extraction / impacted by the intraoral region
2912268|NCT03164252|Placebo Comparator|Grupo III- Laser sham|Application of laser sham, the handpiece of the device will be positioned intraorally and activated. However, the tip of the applicator will be covered by an opaque material that prevents radiation from passing through.
2912269|NCT03164239|Experimental|Intervention group - telephone and print exercise intervention|The intervention group (IG) received a total of three intervention packages, one every second month, during the intervention period. The first intervention package was distributed at intervention start. The intervention package consisted of a tailored exercise program, national recommendations for physical activity, prompts and reminders. Additionally the IG received fortnightly supportive motivational contact every two weeks, alternately by telephone og email
2912270|NCT03164239|No Intervention|Control group|The control group (CG) were encouraged to continue previous lifestyle.
2912271|NCT03164226|Other|Patient consulting for chest Pain in ED|Any patient ≥ 30 years consulting for chest pain in the emergency department from 8:00 am to 8:00 pm (for the unavailability of the endopat device during the guard).
2912272|NCT03164213|Experimental|Experimental tDCS|TDCS stimulation at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).
2912273|NCT03164213|Sham Comparator|sham tDCS|Sham tDCS at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).
2912274|NCT03164200|Experimental|High fat breakfast|45% fat 35% Carbohydrate 20% protein
2912275|NCT03164200|Experimental|Higher carbohydrate breakfast|60% carbohydrate 20% fat 20% protein
2912276|NCT03164187||Diabeton MR 60|
2912277|NCT03164161|Active Comparator|Cold Pressor Test Results|Participants, enrolling the healthy participants high and low pain perception groups, will undergo cold pressor test. According to the results patients will be assigned according to time (min:s) until first pain felt (pain threshold) and time (min:s) until unbearable pain and test withdraw (pain tolerance). Also, pain ratings (1-10) at same points will be used as participants alignment tool.
2912278|NCT03164161|Active Comparator|β-endorphins level in saliva|Participants will be sorted according to β-endorphin levels in saliva., therefore the β-endorphins evaluation in saliva intervention will be performed.
2912279|NCT03164161|Active Comparator|β-endorphin level in blood plasma|Participants will be sorted according to β-endorphin levels in blood plasma, therefore β-endorphins evaluation in blood plasma will be performed.
2912280|NCT03164161|No Intervention|Pain perception rating|Healthy participants will be sorted in to groups: high and low pain perception groups, according to the results of questionnaires, containing various oral surgery procedures pain ranking.
2912281|NCT03164148|Experimental|Case Evaluation by T-REX TRI00A|Case evaluation consists of confirmation of hospital visit dates, any side effects of device, T-REX TRI00A
2912282|NCT03164135|Experimental|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 before transplantation into the patient.
2912283|NCT03164122|Experimental|Intra-articular injection|
2912284|NCT03164109|Experimental|GC4419 IV|
2912285|NCT03164109|Placebo Comparator|Placebo|
2912286|NCT03164109|Active Comparator|Oral moxifloxacin|
2912287|NCT03164096|Experimental|intrathecal bupivacaine|intrathecal bupivacaine hydrochloride 0.5%,12.5mg
2912288|NCT03164083|Experimental|mesenchymal stem cell|Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection
2912289|NCT03164083|Experimental|placebo|The patients who are in control group and underwent placebo injection
2912290|NCT03164070||Patients with osteoarthritis|Patients with medium and large joint osteoarthritis
2912291|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida | AE | MA"|"Part 1 Tolerability with AZA - Low Risk~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and then receive low-risk intensifications I & II without azacitidine.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide,dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone., ITMHA."
2912292|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida | AE | MA"|"Part 1 Tolerability with DAC - Low Risk~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive low-risk Intensifications I & II without decitabine.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, ITMHA."
2912293|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida | AZA+AE | AZA+MA"|"Part 2 Dose Expansion with AZA - Low Risk~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and low- risk Intensifications I & II.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, ITMHA."
2912294|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida | DAC+AE| DAC+MA"|"Part 2 Dose Expansion with DAC - Low Risk~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and low-risk Intensifications I & II.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, ITMHA."
2912295|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida | AE | MA | Asp+AraC"|"Part 1 Tolerability with AZA - Intermediate Risk~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and then receive intermediate risk Intensifications I, II & III without azacitidine.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, erwinia asparaginase, ITMHA,"
2912296|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida | AE | MA | Asp+AraC"|"Part 1 Tolerability with DAC - Intermediate Risk~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive intermediate-risk Intensifications I, II & III without decitabine.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, erwinia asparaginase, ITMHA."
2912297|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida | AZA+AE | AZA+MA | AZA+Asp+AraC"|"Part 2 Dose Expansion with AZA - Intermediate-Risk~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and intermediate-risk Intensification I, II, and III.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, erwinia asparaginase, ITMHA."
2912298|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida | DAC+AE | DAC+MA | DAC+Asp+AraC"|"Part 2 Dose Expansion with DAC - Intermediate-Risk~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and intermediate-risk Intensifications I, II and III.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, erwinia asparaginase, ITMHA."
2912299|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG-Ida+Sor | AE | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with AZA - High Risk (no donor)~Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I & II and high-risk intensifications I, II & III without azacitidine. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
2912300|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida+Sor | AE | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with DAC - High Risk (no donor)~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive high-risk Intensifications I, II & III without decitabine. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
2912301|NCT03164057|Experimental|"AZA | + ADE | +FLAG+Ida+Sor| +AE | +MA+Sor | +Asp +AraC+Sor"|"Part 2 Dose Expansion with AZA - High Risk (no donor)~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and high-risk Intensifications I, II and III. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
2912302|NCT03164057|Experimental|"DAC |+ADE | +FLAG+Ida+Sor | +AE | +MA+Sor | +Asp +AraC+Sor"|"Part 2 Dose Expansion with DAC - High Risk (no donor)~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and high-risk Intensifications I, II and III. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
2912303|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida+Sor | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with AZA- High Risk (with donor)~Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I Induction II and high-risk Intensifications I or high risk intensification III without azacitidine. Patients will proceed to stem cell transplant. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.~Interventions: azacitidine cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant."
2912304|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida+Sor | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with DAC - High Risk (with donor)~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive high-risk Intensifications I or high risk intensification III without decitabine. Patients will proceed to stem cell transplant. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant"
2912364|NCT03163680||Low Dose PPI|patients with upper upper gastrointestinal bleeding were treated in low dose of proton Bump inhibitor meaning 40 mg twice daily
2912305|NCT03164057|Experimental|"DAC | +ADE | +FLAG+Ida+Sor | +MA+Sor | +Asp+AraC+Sor"|"Part 2 Dose Expansion with DAC - High Risk (with donor)~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and high-risk Intensifications I or high risk intensification III. Patients will proceed to stem cell transplant. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant"
2912306|NCT03164057|Experimental|"AZA | +ADE | +FLAG+Ida+Sor | +MA+Sor | +Asp+AraC+Sor"|"Part 2 Dose Expansion with AZA - High Risk (with donor)~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and high-risk Intensifications I or high risk intensification III. Patients will proceed to stem cell transplant. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant."
2912307|NCT03164044||Patients with drug allergy|Patients with drug allergy to antibiotics or NSAIDs
2912308|NCT03164031|Experimental|Close-fitting orthotic shorts condition|Orthotic shorts will be made to measure for each participant, designed to provide some compression to the hips, pelvis and thighs and to provide support. Shorts will be worn during objective testing of walking ability and then taken home. Wear will be increased gradually over 5 days but then worn every day during normal daily activity.
2912309|NCT03164031|Active Comparator|Looser fitting shorts condition|Looser shorts will be made to measure for each participant, designed to look similar to the orthotic shorts but provide minimal support or compression. Shorts will be worn during objective testing of walking ability and then taken home. Wear will be increased gradually over 5 days but then worn every day during normal daily activity.
2912310|NCT03164005||Group 1|Normal weight subjects without metabolic diseases
2912311|NCT03164005||Group 2|Normal weight subjects with metabolic diseases
2912312|NCT03164005||Group 3|Obesity subjects without metabolic diseases
2912313|NCT03164005||Group 4|Obesity subjects with metabolic diseases
2912314|NCT03163992|Experimental|pembrolizumab|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
2912315|NCT03163979|Active Comparator|PET/CT and Comet assay guided IMRT|18F-FDG PET/CT and Comet assay guide IMRT Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
2912316|NCT03163979|Active Comparator|PET/CT and Comet assay guided RapidArc|"18F-FDG PET/CT and Comet assay guide RapidArc:~1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment."
2912317|NCT03163979|Active Comparator|RapidArc|"RapidArc:~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used."
2912318|NCT03163979|Sham Comparator|7f-IMRT|seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
2912319|NCT03163966|Experimental|CR6086 30 mg|CR6086 30 mg bid for 12 weeks as add-on to methotrexate (MTX) once weekly. MTX uptitrated to stable dosing as per standard guidelines
2912320|NCT03163966|Experimental|CR6086 90 mg|CR6086 90 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
2912321|NCT03163966|Experimental|CR6086 180 mg|CR6086 180 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
2912322|NCT03163966|Experimental|Placebo|CR6086 matching placebo bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
2912323|NCT03163953|Experimental|TPAG with long break|PA coaching based on TPAG and long break or break 15 minutes for every 2 hours (TPAG with LB)
2912324|NCT03163953|Experimental|TPAG with short break|PA coaching based on TPAG and short break or break 1-2 minutes for every 1 hours (TPAG with SB)
2912325|NCT03163953|Other|Control|No intervention
2912326|NCT03163940|Experimental|Laughter Yoga (LY) Group|The LY session will be offered twice weekly, for 45 minutes each time. Each participant will be asked to attend a total of 8 groups (over 4 weeks).
2912327|NCT03163940|No Intervention|Treatment-as-usual (TAU)|The TAU will receive their usual routine community mental health care (including medications) and attend medical outpatient appointments as determined by their individual needs.
2912328|NCT03163927|Experimental|Intervention|Participants receive a 1.5-hour standardized simulation-based training course, with mastery learning.
2912329|NCT03163927|No Intervention|Control|Participants observe a procedure performed by a senior.
2912330|NCT03163914|Active Comparator|Epinephrine|Epinephrine will prepare as 5µg/ ml and epinephrine infusion rate will adjust 30 ml/h.
2912331|NCT03163914|Active Comparator|Norepinephrine|Norepinephrine will prepare as 5µg/ ml and epinephrine infusion rate will adjust 30 ml/h.
2912332|NCT03163914|Active Comparator|Phenylephrine|Phenylephrine will prepare as 100 µg/ ml and phenylephrine infusion rate will adjust 30 ml/h.
2912333|NCT03163914|Placebo Comparator|Control|Saline infusion will apply at equivalent volume till the surgical operation
2912334|NCT03163901|Active Comparator|Treatment groups|To recruit and organize patients with TBI enrolled in a standard rehabilitation program into three groups ((a) treatment group receiving OMT; (b) control group A receiving sham treatment; and (c) control group B receiving neither OMT nor sham treatment) in order to assess the feasibility and adherence to the protocol and determine participation and attrition rates in preparation for a larger study.
2912365|NCT03163667|Active Comparator|CB-839 plus everolimus|CBE: CB-839 is administered twice daily in combination with standard doses of everolimus
2912366|NCT03163667|Placebo Comparator|Placebo plus everolimus|PboE: Placebo is administered twice daily in combination with standard doses of everolimus
2912497|NCT03162770|No Intervention|No Control Group|Initially this control group will wait and after 12 weeks this group will receive the intervention
2912335|NCT03163901|Other|Effect of OMT on clinical outcome measures|Clinical outcome measures including Neurocom Balance Manager assessments (Modified Clinical Test of Sensory Interaction and Balance; Stability Evaluation Test; Rhythmic Weight Shift; Limits of Stability), Vestibular Oculomotor Screen, Motion Sensitivity Test, as well as questionnaires such as the Headache Impact Test (HIT-6), Dizziness Handicap Inventory, and the more general quality of life measures (dressing; bathing; medication management, etc. as assessed by the SF 36 QOL questionnaire).
2912336|NCT03163901|No Intervention|Anti-inflammatory Biomarkers|to analyze urine and plasma samples collected from the three groups of participants: urine and plasma samples one hour before, plasma samples one hour after and 48 hours after treatment for alterations in the levels of low molecular weight compounds or protein components to identify potential biomarkers that may correlate with the TBI condition and/or the OMT.
2912337|NCT03163901|No Intervention|Infrastructure development|to establish the infrastructure for the recording, management, and extraction of clinical data and to estimate effect sizes and variability in key outcome measures so that a larger, longer term study can be planned with sufficient statistical power to identify significant results.
2912338|NCT03163888||Navigation TKR group|TKR performed under computer navigation without violating distal femur bone marrow.
2912339|NCT03163888||Conventional TKR group|TKR performed under conventional distal femur cutting juts with violation of distal femur bone marrow.
2912340|NCT03163862|Placebo Comparator|Placebo|Patients treated with infusion of PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test
2912341|NCT03163862|Experimental|G-CSF group|"Patients treated with G-CSF if the biopsy adhesive score 1-3 only, by Endometrial scratching and adhesive factor scoring on day 21-24 cycle prior to IVF//or day 3 of IVF cycle not planned before.~The dose of G-CSF is 300 µg by trans cervical intrauterine route administered at the oocyte retrieval day, Ans subcutaneous 300µg G-CSF on the day of embryo transfer"
2912342|NCT03163862|Sham Comparator|Comparative group|patients not treated with G-CSF after scratching if the biopsy adhesive score 4 only
2912343|NCT03163849|Placebo Comparator|control group|oral tablets
2912344|NCT03163849|Experimental|Study group|sofosbuvir , daclatasvir oral tablets
2912345|NCT03163836||double valve replacement group|Patients received aortic+mitral valve replacement at Guangzhou General Hospital of Guangzhou Military Command with persistent or long-standing atrial fibrillation(AF) but did not received concomitant AF ablation. Persistent AF was defined as AF lasting more than 7 days and long-standing persistent AF as continuous AF for more than 12 months. Exclusion criteria for consideration for concomitant AF ablation includes >70 years old, left atrium (LA) diameter >7 cm, or preoperative left ventricle (LV) ejection fraction < 40% and patients falls in these criteria were excluded from this group.
2912346|NCT03163836||surgical ablation group|Patients received aortic+mitral valve replacement at Guangzhou General Hospital of Guangzhou Military Command with persistent or long-standing atrial fibrillation(AF) and received concomitant surgical ablation. Persistent AF was defined as AF lasting more than 7 days and long-standing persistent AF as continuous AF for more than 12 months.
2912347|NCT03163823|Placebo Comparator|Standard Communication|Standard of Care communication styles will be used. Patients will receive the standard communication protocol identified by the hospital.
2912348|NCT03163823|Experimental|iPad with Speech App|Use of application Proloquo2Go on iPad device. The application being used is called Proloquo2Go which is the intervention portion. The iPad is the device used to access the application.
2912349|NCT03163810|Experimental|Erchonia Verju and EVRL Laser|"The Erchonia Verju Laser has 6 diodes that each emit 17 milliwatts (mW) 532 nanometers (nm) of green laser light.~The Erchonia EVRL Laser emits 635 nanometers (nm) red light and 405 nm blue light simultaneously"
2912350|NCT03163797||Oropharyngeal cancer|A total of 160 patients with histologically proven oropharyngeal SCC subjected to chemoradiation will be enrolled. Exclusion criteria include previous head or neck malignant tumor, a second malignant tumor, distant metastasis, contraindications to MRI (renal insufficiency, cochlear implant, cardiac pacemaker placement or intracranial aneurysmal ferromagnetic clips), and serum glucose level >200 mg/dl. Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test.
2912351|NCT03163784|Placebo Comparator|Arm A|Weekly placebo (for Fecal Inoculum Capsule) treatment with placebo pre-treatment.
2912352|NCT03163784|Experimental|Arm B|Weekly Fecal Inoculum Capsule treatment with placebo pre-treatment.
2912353|NCT03163784|Experimental|Arm C|Weekly Fecal Inoculum Capsule treatment with antibiotic pre-treatment.
2912354|NCT03163758|Experimental|rTMS treatment group|The rTMS treatment group received a 10-day real repetitive transcranial magnetic stimulation (rTMS) treatment beginning within 1 week after stroke onset.
2912355|NCT03163758|Sham Comparator|sham group|The sham group received a 10-day sham repetitive transcranial magnetic stimulation (rTMS) treatment beginning within 1 week after stroke onset.
2912356|NCT03163745||Asymptomatic spontaneous bacterial peritonitis|"All the included patients will be subjected to:~Full medical History and physical examination~Laboratory investigations: Complete blood picture , kidney function tests, liver function tests ,prothrombin time and concentration~Abdominal Ultrasound~Ascitic fluid paracentesis will be done to test for total leucocyte count and polymorphonuclear count , total protein and albumin levels. Testing for cytological analysis and culture will be done."
2912357|NCT03163732|Other|Large molecular profiling panel|This panel is FOne Panel with a 315 cancer-related gene.
2912358|NCT03163732|Other|Limited molecular profiling panel|This panel is CONTROL Panel with a 74 cancer-related gene.
2912359|NCT03163719||Patients with generalized convulsive seizure|All adult patients (aged at least 18 years old) presenting to the CHU Clermont-Ferrand adult emergencies with a strong suspicion of generalized tonic-clonic seizure beginning less than 4 hours will be included. Each eligible patient will be proposed by a doctor, to participate to the study. The emergency doctor will verify the patient's inclusion and non-inclusion criteria.
2912360|NCT03163706|Experimental|Schizophrenia patients|Patients with DSM-5 criteria of schizophrenia
2912361|NCT03163706|Other|Control group|Control, no schizophrenia
2912362|NCT03163693|Experimental|Group dexmedetomidine|20 eligible patients are received 0.5ug/kg dexmedetomidine intravenously 15 minutes before surgery
2912363|NCT03163693|Placebo Comparator|Group control|20 eligible patients are received equal volumes normal saline intravenously 15 minutes before surgery
2912367|NCT03163654|Active Comparator|Experimental group|Surgery 1: The tunnel technique for covering multiple gingival recessions. Graft: porcine-derived acellular dermal collagen matrix (PADM, mucoderm® ).
2912368|NCT03163654|Active Comparator|Control group|Surgery 2: The tunnel technique for covering multiple gingival recessions. Graft: connective tissue graft
2912369|NCT03163641|Experimental|Treatment 1|Ocular Bandage Gel
2912370|NCT03163641|Experimental|Treatment 2|Ocular Bandage Gel
2912371|NCT03163641|Active Comparator|Control Group|Artificial tears with Acuvue Oasys
2912372|NCT03163628|Experimental|7 biomarkers combination|
2912373|NCT03163615|Experimental|Tibet Rhodiola Capsule|
2912374|NCT03163615|Placebo Comparator|Placebo oral capsule|
2912375|NCT03163602|Active Comparator|Control Group 1|Access flap, implant surface decontamination (saline), systemic antibiotics (amoxicillin 500 mg and metronidazole 400 g, 3 x day for 7 days)
2912376|NCT03163602|Active Comparator|Test Group 2|Access flap, implant surface debridement, systemic antibiotics (amoxicillin 500 mg, metronidazole 400 g, 3 x day for 7 days), bovine bone substitute material (BioOss®) and collagen membrane (BioGide®)
2912377|NCT03163589|Experimental|study group|Within 4 to 6 hours after birth all cases with moderate to severe hypoxic ischemic encephalopathy will be enrolled in therapeutic hypothermia using total body cooling and temperature and Receive erythropoietin (1000 U/kg intravenously) on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
2912378|NCT03163589|Placebo Comparator|control group|Within 4 to 6 hours after birth cases with moderate to severe hypoxic ischemic encephalopathy enrolled in therapeutic hypothermia using total body cooling and temperature and Receive normal saline on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
2912379|NCT03163576|Experimental|study group|patients received niacin 750 mg twice daily up to 2000 mg in addition to usual phosphate binders .
2912380|NCT03163576|Active Comparator|control group|patients received usual phosphate binders .
2912381|NCT03163563||Easywarm|Self warming blanket to prevent perioperative hypothermia
2912382|NCT03163563||BairHugger|Forced-air warming blanket to prevent perioperative hypothermia
2912383|NCT03163550|Experimental|Cohort 1|Healthy volunteers
2912384|NCT03163550|Experimental|Cohort 2|Healthy volunteers
2912385|NCT03163550|Experimental|Cohort 3|Healthy volunteers
2912386|NCT03163550|Experimental|Cohort 4|Healthy volunteers
2912387|NCT03163550|Experimental|Cohort 5|Healthy volunteers
2912388|NCT03163537||Kidney transplantation, postmortal, day|
2912389|NCT03163537||Kidney transplantation, postmortal, night|
2912390|NCT03163537||Kidney transplantation, living donor|
2912391|NCT03163524|Experimental|Treatment group (modified text)|The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
2912392|NCT03163524|Sham Comparator|Control group (standard text)|Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
2912393|NCT03163511|Experimental|Cohort 1|VC-02 Combination Product; Up to six (6) VC-02-20 implants and up to two (2) VC-02-300 implants
2912394|NCT03163511|Experimental|Cohort 2|VC-02 Combination Product; Up to six (6) VC-02-20 implants and up to four (4) VC-02-300 implants
2912395|NCT03163498||ACTIVE|Participating in this group will be 30 active hypertension patients who exercise at least 3 times a week for at least 30 minutes
2912396|NCT03163498||INACTIVE|Participating in this group will be 30 inactive hypertension patients who do not exercise.
2912397|NCT03163485|Experimental|Dialytrode|Multimodal neuro-monitoring by dialytrode (investigational medical device)
2912398|NCT03163485|Other|Standard treatment|Either EVD and/or micro-dialysis according to standard treatment
2912399|NCT03163472|Active Comparator|10 ml of lidocaine 2% with epinephrine|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
2912400|NCT03163472|Experimental|30ml of lidocaine 2% with epinephrine|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
2912401|NCT03163459|Active Comparator|mechanical thrombectomy group|Conventional mechanical thrombectomy
2912402|NCT03163459|Experimental|mechanical thrombectomy plus selective brain cooling group|A microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
2912403|NCT03163446|Experimental|CF-301|Patients will receive a single IV infusion of CF-301 in addition to standard of care (SOC) antibacterial therapy selected by the investigator.
2912404|NCT03163446|Placebo Comparator|Placebo|Patients will receive a single IV infusion of placebo in addition to standard of care (SOC) antibacterial therapy selected by the investigator.
2912405|NCT03163433|Experimental|Feedback in the consultation|Feedback in the consultation is the intervention. Patients complete PROM before each consultation and take part in a dialogue about the results with their physician.
2912406|NCT03163433|No Intervention|Control|Usual consultations
2912407|NCT03163420|Placebo Comparator|Placebo|placebo
2912408|NCT03163420|Experimental|Diclofenac potassium|Diclofenac potassium 50 mg
2912409|NCT03163407|Active Comparator|Norepinephrine group|Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
2912410|NCT03163407|Active Comparator|Ephedrine group|Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
2912411|NCT03163381|Experimental|Apatinib|Apatinib 500mg/d from day 1 to day 28, repeated every 28 days until progressive Disease(PD) .
2912412|NCT03163368|Experimental|Neoadjuvant stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to neurosurgical resection of the indexed brain metastasis. The dose of radiation to be administered to the indexed lesion will be established as a function of tumor size.
2912413|NCT03163355|Active Comparator|pureed rice with a gelling agent|3 ml of pureed rice containing a gelling agent is attempted to swallow under endoscopic examination of swallowing
2912414|NCT03163355|Placebo Comparator|standard pureed rice|3 ml of standard pureed rice is attempted to swallow under endoscopic examination of swallowing
2912415|NCT03163342|Other|Open label|Licensed seasonal influenza vaccine, intramuscular
2912416|NCT03163329|Experimental|TAVR group|
2912417|NCT03163329|Active Comparator|SAVR group|
2912418|NCT03163316||Breast cancer patients|Patients will undergo unenhanced magnetic resonance imaging on both axillae.
2912419|NCT03163303|Experimental|Tobacco Status Project + Alcohol Intervention|Tobacco and alcohol intervention on Facebook and 14-day nicotine patch
2912420|NCT03163303|Experimental|Tobacco Status Project Intervention|Tobacco intervention on Facebook and 14-day nicotine patch
2912421|NCT03163290|Experimental|Posterolateral Hip Complex Exercises|The intervention protocol will be composed of: Heating, lower limb stretching, strengthening the quadriceps, and hip abductors, lateral rotators and extensors. Posterolateral Hip Complex Exercises add extension knee in open kinetic chain, squat , abduction exercise, Clam exercise and external rotation exercise. Physiotherapy treatment sessions will last for an average of one hour, twice a week, for a period of six weeks.
2912422|NCT03163290|Active Comparator|Anteromedial Hip Complex Exercises|The intervention protocol will be composed of: Heating, lower limb stretching, strengthening the quadriceps, and hip aductors, medial rotators and flexors. Anteromedial Hip Complex Exercises add extension knee in open kinetic chain, squat ,hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise. Physiotherapy treatment sessions will last for an average of one hour, twice a week, for a period of six weeks.
2912423|NCT03163277|No Intervention|Standard of care|Continue current antiretroviral regimen
2912424|NCT03163277|Experimental|Reduced Neurotoxicity Arm|Emtricitabine plus darunavir/cobicistat plus maraviroc
2912425|NCT03163264|Experimental|PAL Intervention|"Body mass index of =30kg/m2 OR Body mass index of =25 kg/m2 with an obesity associated co-morbidity~Receiving Peer Assisted Lifestyle intervention (PAL tool, health coaching at baseline, follow-up health coaching calls, potential support of goals from primary care provider)"
2912426|NCT03163264|Active Comparator|Enhanced Usual Care (EUC)|Body mass index of =30kg/m2 OR Body mass index of =25 kg/m2 with an obesity associated co-morbidity
2912427|NCT03163251|Experimental|READ-SG Cohort|Each post-graduate year will receive the intervention of a monthly peer-facilitated small group sessions (READ-SG Sessions) based on topics that are common to residency training and based on themes regarding humanism in medicine.
2912428|NCT03163238|Active Comparator|Group D|One syringe contain dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
2912429|NCT03163238|Placebo Comparator|Group S|One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
2912430|NCT03163212|Experimental|Lactoferrin/FOS 100mg/kg|100 mg/kg enteral administration daily for 30 days
2912431|NCT03163212|Experimental|Lactoferrin/FOS 200mg/kg|200 mg/kg enteral administration daily for 30 days
2912432|NCT03163212|Experimental|Lactoferrin/FOS 300mg/kg|300 mg/kg enteral administration daily for 30 days
2912433|NCT03163173|Experimental|Single Arm - Treatment Group|30 mg (~100 μCi) dose of [14C]GC4419 administered as an IV infusion over 15 minutes on Day 1 following an overnight fast
2912434|NCT03163160|Experimental|Pelvic floor manual therapy group|Pelvic floor manual therapy is a clinical approach utilizing specifics hands-on mobilizing techniques to treat soft tissues. The technique require mobilization of soft-tissue by myofascial stretching maneuvers intended to improve bio-mechanical elasticity. The therapeutic protocol will be applied for 4 weeks.
2912435|NCT03163160|Experimental|Pelvic floor electrolysis group|Pelvic floor electrolysis technique consists in an ultrasound-guided application of a galvanic electrolytic current that causes a controlled local inflammatory process in the target tissue. This allows for phagocytosis and the subsequent regeneration of the affected tissue. The therapeutic protocol will be applied for 4 weeks.
2912436|NCT03163134|No Intervention|No Lumbar Drain Group|Group of patients that did not receive a lumbar drain after surgery
2912437|NCT03163134|Experimental|Lumbar Drain Group|Group of patients that received a lumbar drain after surgery
2912438|NCT03163121|Experimental|Group 1 - PfSPZ-GA1 Vaccine|"Group 1 will comprise of 3 volunteers who will receive one immunization of 1.35 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
2912439|NCT03163121|Experimental|Group 2 - PfSPZ-GA1 Vaccine|"Group 2 will comprise of 3 volunteers who will receive one immunization of 4.5 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
2912493|NCT03162783|Experimental|ADX-102 Ophthalmic Solution (0.5%)|
2912494|NCT03162783|Experimental|ADX-102 Ophthalmic Solution (0.1%)|
2912495|NCT03162783|Experimental|ADX-102 Ophthalmic Lipid Solution (0.5%)|
2912496|NCT03162770|Experimental|Intervention Group|This group will receive the Mindfulness meditation practice and after that patients will not receive any other intervention.
2912440|NCT03163121|Experimental|Group 3 - PfSPZ-GA1 Vaccine|"Group 3 will comprise of 13 volunteers who will receive one immunization of 9.0 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
2912441|NCT03163121|Experimental|Group 4 - PfSPZ-GA1 Vaccine|"Group 4 will comprise of 13 volunteers who will receive 3 immunizations of 9.0 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
2912442|NCT03163121|Experimental|Group 5 - PfSPZ-GA1 Vaccine|"Group 5 will comprise of 13 volunteers who will receive 3 immunizations of 4.5 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
2912443|NCT03163121|Experimental|Group 6 - PfSPZ Vaccine|"Group 6 will comprise of 13 volunteers who will receive 3 immunizations of 4.5 x 10^5 PfSPZ of PfSPZ Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
2912444|NCT03163121|Placebo Comparator|Group 7 - Normal Saline Placebo control|"Group 7 will comprise of 9 volunteers who will receive 3 injections of normal saline placebo 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
2912445|NCT03163108|No Intervention|RMC only|routine manual control (RMC) of the fraction of inspired oxygen (FIO2)
2912446|NCT03163108|Active Comparator|CLAC slow|"routine manual control (RMC) + Closed-loop automatic oxygen control (CLAC) with 180sec WAIT-Interval (slow algorithm) of the fraction of inspired oxygen (FIO2)"
2912447|NCT03163108|Experimental|CLAC fast|"routine manual control (RMC) + Closed-loop automatic oxygen control (CLAC) with 30sec WAIT-Interval (fast algorithm) of the fraction of inspired oxygen (FIO2)"
2912448|NCT03163095|Active Comparator|Open Abdomen Management with ANPPT dressing|The abdominal fascia will not be closed, but a temporally abdomenal closure (TAC) dressing (such as AbThera dressing) will be placed to protect the viscera with active Negative Pressure Peritoneal drain. Formal abdominal closure or dressing change at 24-72 hours from placement should be performed.
2912449|NCT03163095|Sham Comparator|Closed Abdomen Management|Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain). Any decision to perform a re-laparotomy will be at the discretion of the treating surgical team.
2912450|NCT03163082|Active Comparator|Cognitive Intervention|The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
2912451|NCT03163082|Active Comparator|Behavioral Intervention|The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
2912452|NCT03163082|Active Comparator|Interpretation Bias|"The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
2912453|NCT03163082|Active Comparator|Evaluative Conditioning|The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
2912454|NCT03163069|Experimental|Conventional Whitening dentifrice|in-office bleaching with the conventional whitening dentifrice
2912455|NCT03163069|Experimental|Whitening dentifrice containing blue covarine|in-office bleaching with the whitening dentifrice containing blue covarine
2912456|NCT03163069|Experimental|Regular dentifrice|in-office bleaching with the regular dentifrice
2912457|NCT03163056|Other|Cognitive-behavioral treatment (CBT)|The CBT treatment condition is implemented in group-based sessions carried out during 8 weeks. Components included: information about tobacco, behavioral contract whereby patients committed to attend sessions, self-monitoring and graphical representation of cigarette smoking, nicotine fading (a weekly reduction of 30% of nicotine intake from the first to the four week, and abstinence from the fifth week onwards), physiological feedback (CO in expired air and cotinine analyses) on cigarette intake, stimulus control, strategies for managing nicotine withdrawal symptoms, training in alternative behaviors, and relapse prevention strategies (e.g., problem solving techniques).
2912458|NCT03163056|Active Comparator|CBT+Behavioral Activation (BA)|This intervention includes both CBT and BA strategies for smoking cessation and depression management. Participants allocated to this condition received 8 therapy sessions. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
2912459|NCT03163056|Active Comparator|CBT+BA+ Contingency Management (CM)|This intervention is provided in the same manner as the above treatment protocols but with the addition of a CM procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
2912460|NCT03163043|Experimental|Active, Male and Female Children|Participants will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
2912461|NCT03163030|Experimental|Therapy|Right Cervical Vagus Nerve Stimulation (VNS)
2912462|NCT03163017|Experimental|2D Fluoroscopy then 3D Fluoroscopy|"Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al (2D Fluoroscopy). After the attending surgeon is satisfied with the reduction quality, 3D fluoroscopy will be used to generate additional images to assess syndesmotic and fibular reductions. Both 2D and 3D Fluoroscopy will be performed using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system."
2912463|NCT03163004|Experimental|Intervention group|Implementation of standing desks in the classroom
2912464|NCT03163004|No Intervention|Control group|
2912465|NCT03162991|Experimental|12-Week Aerobic Exercise Intervention|
2912466|NCT03162991|No Intervention|12-Week Control Period|
2912467|NCT03162978|Experimental|HIIT + POE|High-intensity interval training (HIIT) plus positive outcome expectations (POE) from participating in the exercise program.
2912468|NCT03162978|Experimental|HIIT only|High-intensity interval training (HIIT) only.
2912469|NCT03162965|Active Comparator|Choice|Oraquick HIV Self Test or Clinic Based HIV Counseling and Testing (HCT)
2912470|NCT03162965|Active Comparator|HIV Counseling and Testing|Clinic Based HIV Counseling and Testing (HCT)
2912471|NCT03162926|Experimental|Single-group|Up to six (6) VC-02-20 implants
2912472|NCT03162913|Experimental|Strawberry|Participants randomized into this arm of the study consume freeze-dried strawberry powder.
2912473|NCT03162913|Placebo Comparator|Placebo|Participants randomized into this arm of the study consume a strawberry placebo powder.
2912474|NCT03162900|Experimental|Glasdegib QT Therapeutic Exposure|Randomized sequence of Glasdegib clinical exposure, Placebo and moxifloxacin active control administration. This treatment will be in four separate sequences with four periods per sequence. Each period will be separated by a washout of atleast 6 days.
2912475|NCT03162900|Experimental|Glasdegib QT Supra-therapeutic Exposure|Randomized sequence of glasdegib supra-therapeutic exposure, Placebo and moxifloxacin active control administration. This treatment will be in four separate sequences with four periods per sequence. Each period will be separated by a washout of atleast 6 days.
2912476|NCT03162887|Experimental|Screening (education module, counseling)|"Participants receive a research team member-led breast cancer and mammogram educational module and undergo a web-based decision counseling session over 2 hours. Participants then receive a next steps document and may undergo an interview to discuss their decision-making process and relevant experiences during the course of the study."
2912477|NCT03162874|Placebo Comparator|PLACEBO|
2912478|NCT03162874|Experimental|PXT002331 - 10mg|
2912479|NCT03162874|Experimental|PXT002331 - 30mg|
2912480|NCT03162861|Experimental|the observation group|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
2912481|NCT03162861|Experimental|the control group|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
2912482|NCT03162848|Experimental|SystemCHANGE intervention|The SystemCHANGE™ intervention utilizes the Socioecological Model and Plan-Do-Check Act model as its framework and focuses on changing the individual's environment to change behavior using small experiments with feedback.
2912483|NCT03162848|No Intervention|Attention Control|The attention control group will receive education at baseline, 1 month, and 2 months following America Heart Association brochures.
2912484|NCT03162835||Educated group|Children within this group will receive Pain Neuroscience Education.
2912485|NCT03162835||Non-educated group|Children within this group will not receive Pain Neuroscience Education
2912486|NCT03162822|Active Comparator|Cognitive Intervention|The cognitive intervention has parents come up with reasons why their children do things they don't like, until they come up with benign attributions for those behaviors.
2912487|NCT03162822|Active Comparator|Behavioral Intervention|The behavioral intervention has the parents develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
2912488|NCT03162822|Active Comparator|Interpretation Bias Intervention|"The Interpretation Bias intervention has parents look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
2912489|NCT03162822|Active Comparator|Evaluative Conditioning Intervention|The Evaluative Conditioning intervention presents parents with pictures of ambiguous child faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., sweet; cooperative).
2912490|NCT03162796|Experimental|Group 1: Guselkumab|Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 48.
2912491|NCT03162796|Experimental|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab 100 mg at Weeks 0 and 4, then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, and 44) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48) to maintain the blind.
2912492|NCT03162796|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive SC placebo q4w from Week 0 to Week 20, and will crossover at Week 24 to receive guselkumab 100 mg q4w from Week 24 through Week 48.
2912501|NCT03162731|Experimental|Treatment ( nivolumab, ipilimumab, radiation therapy)|Patients receive nivolumab IV over 60 minutes every 2 weeks and ipilimumab IV over 90 minutes every 6 weeks. Beginning week 3, patients undergo simultaneous integrated boost intensity modulated radiation therapy or volumetric modulated arc therapy for 5 days per week over 7 weeks. Patients continue nivolumab every 2 weeks for 12 doses and ipilimumab every 6 weeks for 4 doses. Courses repeat for up to 23 weeks in the absence of disease progression or unacceptable toxicity.
2912502|NCT03162718|Other|single arm|exercise
2912503|NCT03162679|Experimental|Emotion Regulation Group Therapy|Participants assigned to this condition will receive treatment immediately after assignment.
2912504|NCT03162679|No Intervention|Wait List Control|This condition is a wait-list control and receives no intervention during the study period, but is offered treatment after the final assessment directly after the treatment phase of the intervention group.
2912505|NCT03162653|Active Comparator|Allopurinol|Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
2912506|NCT03162653|Placebo Comparator|Placebo|mannitol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
2912507|NCT03162640||P|for cannabis
2912508|NCT03162640||C|for the control group
2912509|NCT03162627|Experimental|Selumetinib + Olaparib|"Dose Escalation Phase: Participants take both Selumetinib and Olaparib by mouth 2 times each day, about 12 hours apart at the Starting Dose Level. Treatment cycle is 28 days.~When maximum tolerated dose reached, Dose Expansion Phase begins."
2912510|NCT03162627|Experimental|Ovarian Cancer with RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
2912511|NCT03162627|Experimental|Endometrial Cancer with RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
2912512|NCT03162627|Experimental|Ovarian Cancer-Progression-prior PARP Treatment|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
2912513|NCT03162627|Experimental|Solid Tumors that Harbor Somatic RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
2912514|NCT03162614|Active Comparator|AduFx|Subjects will receive RTS,S/AS01B full dose at Month 0 and Month 1 and RTS,S/AS01B fractional dose (1/5th dose) at Month 7.
2912515|NCT03162614|Experimental|2PedFx|Subjects will receive double dose of RTS,S/AS01E at Month 0 and Month 1 and double dose of RTS,S/AS01E fractional dose (1/5th dose) at Month 7.
2912516|NCT03162614|Experimental|PedFx|Subjects will receive RTS,S/AS01E full dose at Month 0 and Month 1 and RTS,S/AS01E fractional dose (1/5th dose) at Month 7.
2912517|NCT03162614|Experimental|Adu2Fx|Subjects will receive RTS,S/AS01B full dose at Month 0 and RTS,S/AS01B fractional doses (1/5th dose) at Month 1 and Month 7.
2912518|NCT03162614|Active Comparator|Adu1Fx|Subjects will receive RTS,S/AS01B full dose at Month 0 and RTS,S/AS01B fractional dose (1/5th dose) at Month 7.
2912519|NCT03162614|Other|Infectivity control|Subjects will not receive any vaccine.
2912520|NCT03162601||Neurovascular|Patients to receive percutaneous neurovascular intervention
2912521|NCT03162588|Experimental|multiple burrhole therapy and erythropoietin|pretreatment with IV erythropoietin for 3 days, 120000IU#3 then multiple burrhole procedure on the hemisphere effected is performed
2912522|NCT03162575|Experimental|Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2.5 hours
2912523|NCT03162575|No Intervention|Waiting List Control|Patients assigned to the waiting list condition will receive no intervention for three months and afterwards will receive MBCT
2912524|NCT03162562|Experimental|Oregovomab plus Poly ICLC (Hiltonol)|Oregovomab Solution, 2 mg IV, every three weeks (weeks 0, 3, 6, and 9) and then once at week 16 plus poly ICLC Suspension, 2 mg IM, 30 minutes post-oregovomab infusion and 48 hours post-oregovomab infusion (total 10 doses)
2912525|NCT03162549||Inflammatory Bowel Disease|Pts presenting to enrolling sites across the US are invited to enroll if eligible
2912526|NCT03162536|Experimental|ARQ 531|
2912527|NCT03162523||Scandinavian Prostate Cancer Group (SPCG), study number 7|Patients included in hallmark study of SPCG-7 receiving EBRT to 70 Gy in combination with lifelong anti-androgen treatment
2912528|NCT03162523||Norwegian Urologic Cancer Group (NUCG) study number 7|Patients receiving EBRT to 74 Gy in combination with hormonal therapy. Approved by ethical comittee. Questionnaires already been completed during a different study (NUCG-7). These patients will therefore not be contacted again.
2912529|NCT03162510|Experimental|SOLAR|Albumin-Bound Paclitaxel /nab-Paclitaxel (Abraxane®) 150 mg/m2 IVD 30 min followed by Oxaliplatin 60~ 85 mg/m2 IVD 2hr at D1, plus Tegafur,oral S-1 35mg/m2 and Folinic acid/LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
2912530|NCT03162497|Experimental|Azithromycin|Preservative-free azithromycin 15mg/g (Azyter® Augentropfen im Einzeldosisbehältnis, Thea, Clermont-Ferrand, France) one drop twice daily for two days then once daily for 26 days
2912531|NCT03162497|Active Comparator|Doxycycline|"Doxycycline 100mg (Doxycycline Genericon, Genericon Pharma GmbH, Graz, Austria) twice daily for 6 weeks"
2912566|NCT03162250|Experimental|DSTA4637S low dose level + SOC|DSTA4637S low dose level intravenous (IV) infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
2912598|NCT03162042||Control group|55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.
2961349|NCT02823158|Active Comparator|Best medical treatment|
2912532|NCT03162484|Experimental|Physical activity intervention group|"The intervention consisted in doing physical activities two to four times per week, each session last 60 minutes. The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.~Each session starts with a warm up. The main part of the session is divided into two sections. The first section includes different exercises to improve balance, mobility and coordination. The second section is comprised of communicative and cooperative games. The session finishes with a cool-down."
2912533|NCT03162484|No Intervention|Control group|People in control group did not receive any physical activity program.
2912534|NCT03162458|Experimental|Anaferon for children|
2912535|NCT03162458|Placebo Comparator|Placebo|
2912536|NCT03162445||Typically developing controls|Boys between ages 7 and 14 years old at study onset without medications or diseases impairing bone development
2912537|NCT03162445||Autism spectrum disorder|Boys between ages 7 and 14 years old at study onset without medications or diseases impairing bone development
2912538|NCT03162432|Experimental|Vitamin D3 Treatment|Subjects receiving Remicade will be treated with oral Vitamin D3
2912539|NCT03162419|Active Comparator|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
2912540|NCT03162419|Experimental|Standard Medical Therapy + Plasma exchange + GCSF|The patients in group B shall be given GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28 along with alternate day high volume plasma exchange sessions till a maximum of ten sessions.
2912541|NCT03162419|Experimental|Standard Medical Therapy + GCSF|"The patients in this will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.~The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28"
2912542|NCT03162406|Experimental|Vitamin D|Procedure: SRP Dietary Supplement: Vitamin D3 Oral supplementation 25000 IU once per week for 6 months Other Name: Cholecalciferol
2912543|NCT03162406|Placebo Comparator|Placebo|Procedure: SRP Dietary Supplement: Placebo Oral supplementation once per week for 6 months
2912544|NCT03162393||group 1|phrenic nerve transfer to musculocutaneous nerve; spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve
2912545|NCT03162393||group 2|phrenic nerve transfer to musculocutaneous nerve; spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch and radial nerve; contralateral C7 nerve transfer to median nerve
2912546|NCT03162393||group 3|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve and musculocutaneous nerve
2912547|NCT03162393||group 4|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch and radial nerve; contralateral C7 nerve transfer to median nerve and musculocutaneous nerve
2912548|NCT03162393||group 5|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to musculocutaneous nerve, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve and triceps branch
2912549|NCT03162393||group 6|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to musculocutaneous nerve and radial nerve; contralateral C7 nerve transfer to median nerve and triceps branch
2912550|NCT03162367|Experimental|Autologous epidermal cell suspension group|
2912551|NCT03162367|Active Comparator|Silver sulfadiazine ointment group|
2912552|NCT03162354|Experimental|Intervention Sites|"At the four intervention sites, investigators will deploy active, multifaceted, implementation strategies designed to promote CDR acceptability and application as an AHT screening tool. These strategies will include physician training with onsite visits, monthly booster training emails, access to an AHT probability calculator, audit and site-specific feedback, and local information sharing sessions designed to address local barriers to CDR acceptance and application."
2912553|NCT03162354|No Intervention|Control Sites|"At the four matched control sites, physicians will engage in AHT screening as usual."
2912554|NCT03162341|Experimental|UltraSonography and DECT|"UltraSonography and DECT will be used in patient monitoring after 6, 12 and 24 months of treatment in order to evaluate the correlation between the 2 explorations for the measurement in tophus volume change.~Those are interventions that are not part of the standard care of the patients."
2912555|NCT03162315|No Intervention|Fresh embryo transfer|fresh embryo transfer (standard of care)
2912556|NCT03162315|Experimental|Freeze all|Vitrification of all embryos and replacement of a thawed embryo in a subsequent cycle
2912557|NCT03162302||Healthy Subjects|Healthy volunteers will undergo 60 minute non-contrast enhanced Magnetic Resonance Imaging (MRI) of the abdomen using novel imaging sequences.
2912558|NCT03162302||Clinical Patients|Patients in whom an MRI is indicated for their disease condition will undergo the clinical scan, followed by up to 30 minutes non-contrast enhanced Magnetic Resonance Imaging (MRI) of the abdomen using novel imaging sequences.
2912559|NCT03162289|Active Comparator|Fasting|60-72 h-modified fasting (36-48 h before and 24 h after chemotherapy)
2912560|NCT03162289|Active Comparator|Vegan|60-72 h-vegan diet (36-48 h before and 24 h after chemotherapy)
2912561|NCT03162289|Other|Diet as usual|no changes in dietary habits
2912562|NCT03162276|Experimental|Intervention|Inquiry Based Stress Reduction
2912563|NCT03162276|Placebo Comparator|Control|The placebo group participants will receive a modified form of the intervention at the close of the study
2912564|NCT03162263|Experimental|Ekso training|All patients underwent twenty-four Ekso sessions, scheduled 3 times a week. Each session lasted about 1h, and included transferring into the device arranged on an office chair; donning, standing, walking, sitting, doffing; and transferring out of the exoskeleton.The user can stand up, sit down, and walk with help of a front-wheeled walker and with the exoskeleton attached to a ceiling rail tether. A physical therapist initially provides assistance to maintain the user's center of mass over the base of support to prevent falling.
2912565|NCT03162263|Active Comparator|Overground training|Conventional gait training overground; before the training 10 min lower limb muscular exercises and stretching were performed by the physiotherapist. The overground training had the same duration of the Ekso training.
2912567|NCT03162250|Experimental|DSTA4637S intermediate dose level+ SOC|DSTA4637S intermediate dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
2912568|NCT03162250|Experimental|DSTA4637S high dose level+ SOC|DSTA4637S high dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
2912569|NCT03162250|Placebo Comparator|Placebo + SOC|Placebo matched to DSTA4637S IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
2912570|NCT03162237|Experimental|Porcine islets and autologous treg|Porcine islets:10000 islet equivalent（IEQ）/Kg; Treg:2x10^6/Kg
2912571|NCT03162237|Active Comparator|AutologousTreg|Autologous Treg:2x10^6/Kg
2912572|NCT03162224|Experimental|HPV associated recurrent/metastatic HNSCC|Approximately 50 patients with HPV associated recurrent/metastatic HNSCC
2912573|NCT03162211|Experimental|Feedback Arm|A registry platform including access to all self-report rating scales and the feedback mechanism will be made available to all patients. Patients in the experimental group will receive automated reminders (by text message, phone and/or email) to complete outcome measures each week. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals. The intervention will last 6-months, with feedback forms being generated once per week for the first three month and then each month for a total of fifteen feedback time points. Patients in the feedback group will be encouraged to meet with their clinician each month to discuss the feedback.
2912574|NCT03162211|No Intervention|No Feedback Arm|A registry platform including access to all self-report rating scales and the feedback mechanism will be made available to all patients. Patients in the control group will not receive regular reminders or be sent feedback reports on an automatic regular basis.
2912575|NCT03162198||Cirrhosis with HCC|
2912576|NCT03162198||Cirrhosis without HCC|
2912577|NCT03162185|Experimental|Interventional group|Half of the participants (n = 30) will receive 20mg of the SSRI Escitalopram.
2912578|NCT03162185|Placebo Comparator|Control group|Half of the participants ( n= 30) will receive the placebo.
2912579|NCT03162159||cohort for model computing|patients with CAH, born between 1970 and 1993, with genetically proven CAH, available growth and bone maturation data.
2912580|NCT03162159||cohort for model validation|patients with CAH, born between 1994 and 1998, with genetically proven CAH, available growth and bone maturation data.
2912581|NCT03162146||Patient admitted to intensive care unit|All patients requiring intensive care unit stay
2912582|NCT03162133|Experimental|Baduanjin exercise group|"Participating 12 weeks of 90-minute three times per week Baduanjin exercise classes, and watching video to practice Baduanjin twice per week at home.~Sharing the exercise adherence situation to the study group by wechat (Chinese mobile messenger app )every day."
2912583|NCT03162133|No Intervention|Wait- list intervention control group|"Participants assigned to the wait-list control were told to continue performing their usual activities, and to refrain from beginning any Baduanjin practice.~After their ﬁnal assessment they were offered the yoga classes."
2912584|NCT03162120|Active Comparator|Ranolazine plus Metoprolol Combination|Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
2912585|NCT03162120|Active Comparator|FlecainidE pluS Metoprolol Combination|FlecainidE pluS Metoprolol Combination in in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
2912586|NCT03162094|Experimental|AVX-012 Opthalmic Solution Low dose|"Phase I: AVX-012 ophthalmic solution Low dose administration three times per day (TID) for 7 days~Phase II: If the low dose of AVX012 is selected on phase I, AVX-012 ophthalmic solution Low dose administration three times per day (TID) and two times per day (BID) for 28 days"
2912587|NCT03162094|Experimental|AVX-012 Opthalmic Solution High dose|"Phase I: AVX-012 ophthalmic solution High dose administration three times per day (TID) for 7 days~Phase II: If the high dose of AVX012 is selected on phase I, AVX-012 ophthalmic solution High dose administration three times per day (TID) and two times per day (BID) for 28 days"
2912588|NCT03162094|Placebo Comparator|Placebo (Vehicle) Opthalmic Solution|"Phase I: Placebo ophthalmic solution administration three times per day (TID) for 7 days~Phase II: Placebo ophthalmic solution administration three times per day (TID) and two times per day (BID) for 28 days"
2912589|NCT03162081||Users|"Elderly patients who use prescription benzodiazepines/Z-hypnotics or opiates~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Cognistat Neurobehavioural cognitive status examination (Cognistat), Neuropsychological profiling, Medication use, Comorbidity"
2912590|NCT03162081||Non-users|"Age and gender matched controls not using the above~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Cognistat Neurobehavioural cognitive status examination (Cognistat), Neuropsychological profiling, Medication use, Comorbidity"
2912591|NCT03162081||Screening group|"Patients over 65 admitted to hospital as in-patients~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Medication use, Comorbidity"
2912592|NCT03162068||Control group|Cases are recruited thanks to advertisement within CHU.
2912593|NCT03162068||Post menopausal women|Post-menopausal women are recruited within rheumatology service.
2912594|NCT03162068||Cushing' syndrome group|Cushing' syndrome patients are recruited during hospitalisation in endocrinology service
2912595|NCT03162055|Experimental|Experimental|glycopyrronium/formoterol fumarate 7.2/4.8 μg per actuation, twice daily
2912596|NCT03162055|Active Comparator|Active comparator|umeclidinium/vilanterol 62.5/ 25μg per inhalation, once daily
2912597|NCT03162042||Squamous cell carcinoma|55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.
2912599|NCT03162029||study group|CBCT imaging of patients with end stage renal failure, undergoing hemo-dialysis
2912600|NCT03162029||control group|CBCT imaging of medically-free participants
2912601|NCT03162016|Experimental|Transplants of acellular matrix|
2912602|NCT03162016|Active Comparator|Transplants of connective tissue|
2912603|NCT03162003||Cohort 1|Patient with visceral disease and/or bone lesions (excluding patients who only have nodal disease), who have commenced or are about to commence ADT and whose disease has not shown any evidence of castration resistance.
2912604|NCT03162003||Cohort 2|Patient with castrate-resistant disease at time of treatment change
2912605|NCT03161990||Transgluteal approach to the hip joint|Patients who have been revised once for an infected total hip replacement with debridement and implant retention and in whom both the primary hip arthroplasty and the revision procedure were performed through a transgluteal approach.
2912606|NCT03161990||Posterior approach to the hip joint|Patients who have been revised once for an infected total hip replacement with debridement and implant retention and in whom both the primary hip arthroplasty and the revision procedure were performed through a posterior approach.
2912607|NCT03161977||Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
2912608|NCT03161964|Experimental|Propranolol|After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Propranolol Arm will be treated with Propranolol 80 Mg Oral Capsule, Extended Release daily for four weeks.
2912609|NCT03161964|Experimental|Placebo|After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Placebo Arm will be treated with matching placebo oral capsule daily for four weeks.
2912610|NCT03161951||Neuroinfections|Patients with acute neuroinfections of bacterial and viral ethology.
2912611|NCT03161951||Intestinal Infectious Diseases|Patients with acute intestinal infectious diseases of bacterial and viral ethology.
2912612|NCT03161938|Active Comparator|Dexamethasone 48 mg|Dexamethasone 48 mg pre-operative, single shot injection
2912613|NCT03161938|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg pre-operative, single shot injection
2912614|NCT03161912||DME/naïve|patients with pre-treatment in diabetic macular edema (DME)
2912615|NCT03161912||DME/pre-treatment|patients without pre-treatment in DME
2912616|NCT03161912||RVO/pre-treatment|Macular edema secondary to RVO with prior treatment
2912617|NCT03161912||RVO/naïve|Macular edema secondary to RVO without prior treatment
2912618|NCT03161886|Experimental|Pan-enteric capsule endoscopy (PCE)|Evidence of active disease by PCE prompted a change in therapy at the discretion of the treating clinician and according to current available pediatric guidelines. The definition of medical treatment adjustment after evidence of inflammation was: the introduction of steroids or enteral nutrition, the introduction or optimization of immunosuppressives; the introduction, optimization of biologics; or the introduction of both immunosuppressive agents and biologics. In case of a negative PCE and presence of symptoms, the magnetic resonance enterography (MRE) could help in guiding therapeutic decisions.
2912619|NCT03161873||avaOnly|Participants will measure with Ava bracelet and determine ovulation with a home (luteinizing hormone) LH urine test
2912620|NCT03161873||avaSaliva|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition participants will collect saliva for the measurements of estrogen and progesterone.
2912621|NCT03161873||avaSalivaUS|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition participants will collect saliva for the measurements of estrogen and progesterone. Moreover ultrasound will be used to observe the day at which the ovum is released.
2912622|NCT03161860|Experimental|Personalised citizen assistance|The experimental group will receive the Personalised citizen assistance for social participation (APIC), i.e. weekly 3-hour personalised stimulation sessions by a trained volunteer over 12 months. Sessions will encourage empowerment, gradual mobilisation of personal and environmental resources, and community integration.
2912623|NCT03161860|No Intervention|Control group|The control group will receive the publicly-funded universal healthcare services available to all Quebecers.
2912624|NCT03161847||OPMD Subjects|The study cohort consists of individuals with genetically confirmed OPMD who will be followed longitudinally using periodic standardized assessments of clinical status in an observational, non-interventional study.
2912625|NCT03161782|Experimental|PNF Stretching group|Each subject in PNF Stretching group will receive a treatment protocol consisting of PNF stretching, cold therapy and exercise.
2912626|NCT03161782|Experimental|Static Stretching group|Each subject in Static Stretching group will receive a treatment protocol consisting of static stretching, cold therapy and exercise.
2912627|NCT03161769||Percutaneous neurovascular treatment|Procedure: Percutaneous neurovascular treatment of intracranial aneurysms
2912628|NCT03161756|Active Comparator|Arm A|Patients in Arm A will receive nivolumab 3 mg/kg intravenously (IV) every 2 weeks for 4 doses and denosumab 120 mg subcutaneously (SC) given D1, D8, D15, D29 (induction phase). Thereafter, nivolumab 480 mg IV and denosumab 120 mg SC every 4 weeks for a total of 24 months (maintenance phase).
2912629|NCT03161756|Active Comparator|Arm B|Patients in Arm B will receive ipilimumab at 3 mg/kg combined with nivolumab at 1 mg/kg IV every 3 weeks for 4 doses with denosumab 120 mg SC given D1, D8, D15, D29, D57 (induction phase). This will be followed by nivolumab 480 mg IV and denosumab 120 mg SC ever 4 weeks for a total of 24 months (maintenance phase).
2912630|NCT03161730|Experimental|McGrath videolaryngoscopy|Participants attempt to perform three intubation using McGrath videolaryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
2912631|NCT03161730|Experimental|Pentax videolaryngoscopy|Participants attempt to perform three intubation using Pentax videolaryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
2912632|NCT03161730|Active Comparator|Macintosh laryngoscopy|Participants attempt to perform three intubation using Macintosh laryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
2912633|NCT03161717|Experimental|Epidural electrical stimulation (EES)|n=20
2912634|NCT03161717|Active Comparator|Loss of resistance (LOR)|n=20
2912635|NCT03161691||Ischemic Stroke|Percutaneous neurovascular treatment of acute ischemic stroke patients.
2913206|NCT03157609|Experimental|Thermometry with SpotOn|Application of SpotOn sensor on forehead.
2912636|NCT03161678|Active Comparator|Wild-Type Genotype|Research subjects with wild type CES1 genotypes will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
2912637|NCT03161678|Experimental|Carriers of the CES1 G143E Mutation|Research subjects who carry the CES1 G143E allele (rs71647871) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
2912638|NCT03161678|Experimental|Carriers of CES1 Functional Mutation|Research subjects who carry a CES1 mutation of potential functional impact (to be determined...studies ongoing) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
2912639|NCT03161665|Experimental|BMT Roadmap|The BMT Roadmap information system will be tested in 20 caregivers of patients undergoing autologous or allogeneic BMT and in 20 patients undergoing autologous or allogeneic BMT.
2912640|NCT03161652|Placebo Comparator|DME lactose pill|Patients with DME will be randomized to take a lactose pill (placebo).
2912641|NCT03161652|Experimental|DME levosulpiride|Patients with DME will be randomized to take levosulpiride.
2912642|NCT03161652|Placebo Comparator|DR lactose pill|Patients with non-proliferative DR will be randomized to take a lactose pill (placebo)
2912643|NCT03161652|Experimental|DR levosulpiride|Patients with non-proliferative DR will be randomized to take levosulpiride
2912644|NCT03161652|Placebo Comparator|DR, vitrectomy lactose pill|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study) will be randomized to take a lactose pill (placebo).
2912645|NCT03161652|Experimental|DR, vitrectomy levosulpiride|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study) will be randomized to take levosulpiride.
2912646|NCT03161652|Placebo Comparator|DME plus ranibizumab lactose pill|Patients with DME that will receive intravitreal antiangiogenic therapy with ranibizumab will be randomized to take a lactose pill (placebo)
2912647|NCT03161652|Experimental|DME plus ranibizumab levosulpiride|Patients with DME that will receive intravitreal antiangiogenic therapy with ranibizumab will be randomized to take levosulpiride
2912648|NCT03161639|No Intervention|Operator 1|Perform the pulpectomies except the working length measurement
2912649|NCT03161639|No Intervention|Operator 2|Perform the electronic length measurement of the pulpectomies
2912650|NCT03161639|Active Comparator|Operator 3|Perform radiographic length measurement and final evaluation of the pulpectomies
2912651|NCT03161626||Moderate to Severe Factor X Deficiency|
2912652|NCT03161613||Cancer patients in Mexico|lung cancer, melanoma cancer, renal cancer, Squamous Cell Carcinoma of the Head and Neck, and chronic Hodgkin Lymphoma patients in Mexico who have failed at least one treatment before being treated with nivolumab
2912653|NCT03161587||Subjects with COPD|Subjects with diagnosis of COPD at least one year, visiting outpatient clinics in tertiary hospitals in China and in stable state at enrolment.
2912654|NCT03161574|Experimental|FOLFOXIRI|patients with CRM positive who received FOLFOXIRI alone for 6 cycles before surgery
2912655|NCT03161561|Other|capacity of primary phagocytes|capacity of primary phagocytes isolated from COPD patients' blood to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
2912656|NCT03161548|Experimental|Induction chemotherapy|Induction chemotherapy will be given every 21 days, with the DCU regimen, followed by tongue conservation surgery, and postoperative CCRT as indicated.
2912657|NCT03161535|Experimental|exercise group|
2912658|NCT03161535|No Intervention|usual-care group|
2912659|NCT03161522|Experimental|Maintenance Chemotherapy|"Participants receive Maintenance chemotherapy after 6 cycles of induction chemotherapy.~Symptom questionnaire completed at baseline consultation and subsequently for every follow up after treatment."
2912660|NCT03161522|Experimental|Local Consolidation Therapy (LCT)|"LCT may include chemotherapy with radiation and surgery after 6 cycles of induction chemotherapy.~Symptom questionnaire completed at baseline consultation and subsequently for every follow up after treatment."
2912661|NCT03161509|Experimental|paracetamol|10 participants will undergo measurement of paracetamol levels before and after sleeve gastrectomy
2912662|NCT03161509|Experimental|antiepileptic drug|Up to 10 participants in each drug (up to 4 medications, total of up to 40 participants) will undergo measurement of levels of their chronic medication after a dose before and after sleeve gastrectomy
2912663|NCT03161496||wild genotype|Through next generation sequencing, distinguish wild genotype of NOACs
2912664|NCT03161496||mutant genotype|Through next generation sequencing, distinguish mutant genotype of NOACs
2912665|NCT03161483|Experimental|CC-220 0.45 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.45 mg once daily (QD)~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.45 mg once daily (QD)"
2912666|NCT03161483|Experimental|C-220 0.3 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.3 mg once daily (QD)~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.30 mg once daily (QD)"
2912667|NCT03161483|Experimental|CC-220 0.15 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.15 mg once daily (QD)~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.15 mg once daily (QD)"
2912668|NCT03161483|Placebo Comparator|Placebo|Weeks 0 to 24: CC-220 Placebo Controlled Phase: placebo once daily (QD)
2912669|NCT03161470|Active Comparator|Standard Repositioning|Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) without the mechanical chair.
2912670|NCT03161470|Experimental|Mechanical Chair Repositioning|Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) with the mechanical chair.
2912671|NCT03161470|Sham Comparator|Sham Treatment|Participants randomly selected for the sham arm will undergo be strapped into the mechanical chair as for the treatment arm but will only undergo the test positions for BPPV-the Dix-Hallpike maneuver. No BPPV repositioning treatment will be completed at the first encounter. At the follow-up visit, standard BPPV treatments (canalith repositioning procedure) will be completed.
2912672|NCT03161457|Experimental|JHL1101|Each subject will receive 2 intravenous infusions of 1000 mg JHL1101: the first infusion on Baseline and the second on Day 15.
2912673|NCT03161457|Active Comparator|MabThera|Each subject will receive 2 intravenous infusions of 1000 mg MabThera: the first infusion on Baseline and the second on Day 15 (Visit 5).
2912674|NCT03161444|Other|Elective patient|Patient who has patricipated to the study CHIKVIH (NCT02553369) will have a blood collection during a follow up visit for HIV infection.
2912675|NCT03161431|Experimental|Monotherapy: SX-682 dose escalation|Escalating oral doses of SX-682 (study drug) of 25, 50, 100, 200 and 400 mg twice-daily (i.e., 50, 100, 200, 400 and 800 mg total each day.
2912676|NCT03161431|Experimental|Combination therapy: SX-682 dose escalation and pembrolizumab|SX-682 will be initiated at an initial SX-682 dose no more than 50% of the single-agent MTD/RP2D and will be administered in a 6 week cycle that includes 2 i.v. infusions of pembrolizumab (2 mg/kg) on days 1 and 22 of each cycle, for a total of up to 17 cycles. Once the highest safe dose of SX-682 is determined participants will be enrolled at that dose for combination therapy.
2912677|NCT03161418|Experimental|KSP-910638G 0.4 mg subjects 1-3|The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.4 mg of KSP-910638G total. For the first three subjects, 3.34 mL of KSP-910638G will be discarded. The 1.66 mL of KSP-910638G remaining in the syringe will be administered by squirting it into the mouth of the subject.
2912678|NCT03161418|Experimental|KSP-910638G 1.2 mg subjects 4-25|Following a safety review of the first three subjects receiving 0.4 mg dose, the remaining 22 subjects will receive the full 1.2 mg dose of KSP-910638G reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
2912679|NCT03161405|Experimental|TAK-906 maleate 25mg;Itraconazole 200mg + TAK-906 maleate 25mg|TAK-906 maleate 25 milligram (mg), capsule, orally, once on Day 1 of First Intervention Period, followed by a minimum of 4-day washout period, further followed by Itraconazole 200 mg, solution, orally, once daily on Days 1 to 5 along with TAK-906 maleate 25 mg, capsule, orally on Day 4 of Second Intervention Period.
2912680|NCT03161392||Ductal lesion|Subjects with a ductal lesion detected on ultrasonography.
2912681|NCT03161392||No ductal lesion|Subjects without a ductal lesion detected on ultrasonography
2912682|NCT03161379|Experimental|CY, Nivolumab, GVAX, and SBRT|CY, Nivolumab, GVAX, and SBRT
2912683|NCT03161366|Experimental|Single arm|Vaccination of contacts and contacts of contacts of a confirmed Ebola Zaire case with one dose of rVSVΔG-ZEBOV-GP (≥ 2x10^7 PFU)
2912684|NCT03161353|Experimental|Cohort A|"Cohorts A/B if there is no evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening. Interventional: Perjeta+Herceptin+Carboplatin+Docetaxel (during 4 cycles):~PET responders or not responders after surgery: Continue with Perjeta+Herceptin+ Endocrine therapy (tamoxifen or letrozole) during 12 cycles~A sub-set of 42 patients (35 patients from cohort A and 7 patients from cohort B) from 5 sites in Spain are participating in the LINGain sub-study Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain study."
2912685|NCT03161353|Experimental|Cohort B|"Cohorts A/B if there is no evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening. Interventional: Perjeta+Herceptin+Endocrine therapy (tamoxifen or letrozole) during 2 cycles.~PET responders: Perjeta+Herceptin+Endocrine therapy during 6 cycles. -Complete response: continue with Perjeta+Herceptin+ Endocrine therapy during 10 cycles -Non-complete response: Perjeta+Herceptin+ Carboplatin+ Docetaxel during 6 cycles and Perjeta+Herceptin+Endocrine therapy during 4 cycles.~PET non-responders: Perjeta+Herceptin+Carboplatin+Docetaxel during 6 cycles. Patients with or without complete response will continue with Perjeta+Herceptin+Endocrine therapy during 10 cycles.~A sub-set of 42 patients (35 patients from cohort A and 7 patients from cohort B) from 5 sites in Spain are participating in the LINGain sub-study Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain study."
2912686|NCT03161353|Experimental|Cohort C|cohorts C if there is evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening Interventional: Perjeta+Herceptin+Carboplatin+Docetaxel during 6 cycles. Patients will continue with Perjeta+Herceptin+Endocrine therapy (tamoxifen or letrozole) after surgery or no surgery.
2912687|NCT03161340|Experimental|Treatment group|Rapamycin group
2912688|NCT03161340|No Intervention|Control group|Patients who do not receive any treatment despite a history of Recurrent Implantation Failure problem
2912689|NCT03161327|Other|ABI|ABI will be performed in patient
2912690|NCT03161314||Patients with PHP|"Age between 20 - 80 years~History of PHP for at least 1 month before enrollment~Pain or tenderness on palpation of the medial calcaneal tubercle or the proximal plantar fascia~Occurring at least one of the following complaints: pain on the first step in morning or after prolonged sitting, pain on prolonged standing, or pain when running~Thickness of the plantar fascia of 4.0 mm or greater assessing by US diagnosis"
2912691|NCT03161314||Normal healthy|"Age between 20 - 80 years~No past or present history of PHP or foot pain"
2912692|NCT03161301||Group 1|IL-37 genotype 1.1
2912693|NCT03161301||Group 2|IL-37 genotype 1.2
2912694|NCT03161301||Group 3|IL-37 genotype 2.2
2912695|NCT03161288|Experimental|Cohorts 1-3|Healthy volunteers will receive single rising doses of KY1005 or placebo
2912696|NCT03161288|Experimental|Cohorts 4-8|Healthy volunteers will receive multiple rising doses of KY1005 or placebo
2912697|NCT03161275||nirs|The cerebral oxymetry saturation was monitored continuously, using a non-invasive method. The cerebral saturation was monitored intraoperatively with near infrared spectroscopy (INVOS 4100; Somanetics Inc, Troy, MI). Data acquired from the device were automatically and continuously recorded in 10-second intervals throughout the anaesthesia. A lead for the cerebral saturation monitoring was placed on degreased skin on the patient's forehead, on the right side, some 1 cm over the eyebrow. The baseline value was determined before induction of anaesthesia. The following criteria were accepted as significant reduction of the cerebral oxygenation (saturation) value: reduction of the cerebral oxymetry by over 25% in relation to the baseline; the absolute value of cerebral oxymetry below 50%.
2912698|NCT03161275||cognitive function|Upon the day preceding the actual surgery, and again at 5 days after the surgery, the Mini Mental State Examination test was completed, with a view to assessing the chang-es in the patients' cognitive function. The difference between score in Mini Mental State Examination higher than 2 points defined a diagnosis of cognitive dysfunction.
2912699|NCT03161262|Experimental|SMS-based reminders|This group will receive consistent medication reminders, as per the patient's prescribed frequency, and weekly surveys prompting them to report their pain level and an image of their surgical site. They will also receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.
2912700|NCT03161262|No Intervention|Control group|The control group will not receive medication reminders or questions regarding their pain or surgical site. This group will receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.
2912701|NCT03161249|Experimental|Experimental group|Mobile psychotherapy (5 modules) plus treatment as usual
2912702|NCT03161249|Other|Control group|"Control group: Treatment as usual~The description of this group, the control group, corresponds to the treatment to receive the usual treatment that is received on a regular basis, we will not perform any additional intervention"
2912703|NCT03161236|Experimental|home exercise program|• The exercise group will follow a home exercise protocol for eight weeks: that involves standing on one foot, walking, and doing wall squats.
2912704|NCT03161236|Active Comparator|non exercise group|• The non-exercise group will continue with their usual life style
2912705|NCT03161223|Other|A: durvalumab, pralatrexate, romidepsin|Durvalumab will be given on day 1, pralatrexate will be administered on days 1 and 15, and romidepsin will be administered on days 1 and 15.
2912706|NCT03161223|Other|B: durvalumab, 5-azacitidine, romidepsin|5-azacitidine will be taken from day 1 to day 14. durvalumab will be given on day 8 and romidepsin on days 8 and 15.
2912707|NCT03161223|Other|C: durvalumab, romidepsin|Durvalumab will be given on day 1 and romidepsin will be administered on days 1, 8, and 15.
2912708|NCT03161223|Other|D: durvalumab, 5-azacitidine|5-azacitidine will be taken from day 1 to day 14, and durvalumab will be administered on day 8.
2912709|NCT03161210|Experimental|Dextrose Prolotherapy|
2912710|NCT03161210|Active Comparator|Local Anaesthetic|
2912711|NCT03161210|Placebo Comparator|Saline|
2912712|NCT03161197|Experimental|Intervention|The intervention consists of 8-10 sessions consisting of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation exercises, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, during every point of contact subjects will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
2912713|NCT03161184|Active Comparator|Control (paper based)|"Women received prenatal household visits from CHWs who were trained on the Tanzania Ministry of Health and Social Welfare's National integrated Maternal, Newborn and Child Health (i-MNCH) paper-based protocols, i.e. received intervention SUSTAIN Paperbased training of CHW (SOC)"
2912714|NCT03161184|Experimental|Intervention (Smart phone assisted)|"Women received prenatal household visits from CHWs trained on the following:~A) National i-MNCH programme; and B) Smartphone-assisted counseling protocol: a smartphone application designed to assist with identification of danger signs during pregnancy, referral to health facilities, and MNCH counseling~, i.e. received intervention SUSTAIN Smartphone training of CHW (SP+)"
2912715|NCT03161158|Active Comparator|Ultrafiltration Group|Veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm.
2912716|NCT03161158|Other|Control group (Usual care IV diuretics)|Guideline-directed therapy including IV loop diuretics according to treatment algorithm.
2912717|NCT03161145||Unresectable or metastatic renal cell carcinoma (mRCC)|Medical records will be reviewed for treatment patterns and outcomes
2912718|NCT03161132|Experimental|Olaparib 300mg|Olaparib bid orally at 300 mg (tablet formulation) continuously, combined with chemotherapy with Pegylated Liposomal Doxorubicin (up to 6 cycles), then, as monotherapy at the same dose and frequency (300mg bid orally) until progression of disease or unaccepted toxicity.
2912719|NCT03161132|Other|Pegylated Liposomal Doxorubicin (PLD)|PLD 40mg/m2 every 28 days intravenous for up to 6 cycles. This treatment will be combined with Olaparib (as described earlier).
2912720|NCT03161119|Experimental|Catheter Cook K-Jets-551910-S|Catheter Cook K-Jets-551910-S consists of an outer firm and an inner ultrasoft catheter. The outer guiding catheter (17 cm long) is slightly stiff, with a preshaped curve and a rounded bulb tip to help negotiate the cervical canal. It has a depth marker at 4 cm from the tip, which can be pulled back to a second marker at 5 cm. The inner catheter (23 cm long) is made of a soft material with a rounded bullet tip. In general, the inner catheter does not negotiate the cervical canal directly but rather is introduced into the uterine cavity through the outer catheter.
2912721|NCT03161119|Active Comparator|Catheter Cook k-soft-5000 (or K-J-SP-681710, K-J-SPPE-68171)|This catheter system consists of an outer firm and inner soft catheter. The outer guiding catheter (15,4 cm long) is straight and made of flexible material. The inner catheter (23 cm long) is made of a very soft and flexible polyurethan. The inner catheter is introduced directly through the cervix.
2912722|NCT03161106|Experimental|Nutrional Therapy Group|Nutritional group- Protein of 1.5 gm/kg thrice daily for 6 months
2912723|NCT03161106|Active Comparator|Lactulose Group|Lactulose - 20 mL thrice daily (maximum) for 6 months
2912724|NCT03161093|Experimental|Fasinumab dosing regimen 1|Fasinumab Subcutaneous (SC) dosing regimen 1 and naproxen-matching placebo oral
2912725|NCT03161093|Experimental|Fasinumab-matching placebo and naproxen|
2912726|NCT03161093|Experimental|Fasinumab-matching placebo and naproxen-matching placebo|
2912727|NCT03161080|Experimental|Dry Eye Neovis|20 Patients with dry eye syndrome receiving Neovis Total Multi Eyedrops
2912728|NCT03161080|Experimental|Dry Eye Vismed|20 Patients with dry eye syndrome receiving Vismed Multi Eyedrops
2912729|NCT03161080|Experimental|Dry Eye Hydrabak|20 Patients with dry eye syndrome receiving Hydrabak Eyedrops
2912730|NCT03161067|Experimental|Surgical implantation of BiCNS|
2912763|NCT03160885|Experimental|Tralokinumab initial period -> Tralokinumab maintenance B|"Week 0 to Week 16:~tralokinumab loading SC injection at Day 0 - followed by tralokinumab SC injection regimen A~Week 16 to Week 52:~tralokinumab maintenance SC injection regimen B"
2912764|NCT03160885|Experimental|Tralokinumab initial period -> Placebo maintenance|"Week 0 to Week 16:~tralokinumab loading SC injection at Day 0 - followed by tralokinumab SC injection regimen A~Week 16 to Week 52:~placebo maintenance SC injection regimen A"
2912731|NCT03161054|Experimental|One arm for all patient|"Induction phase:~Patients eligible for the study will receive 6 courses (cycles of 28 days) of the DEVEC combination:DE: Prednisone, V: Vinorelbine, E: Etoposide, C: Cyclophosphamide and Rituximab; Rituximab will be administered only in patients suitable for infusion treatment and relapsed after >6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of Rituximab will not repeat it during the metronomic therapy~Maintenance Phace:~Patients in CR, CRu and PR at the end of the induction phase, will continue treatment with maintenance therapy including Vinorelbine, Cyclophosphamide, and Prednisone oral combination to be repeated every 28 days for up to 6 cycles.~Post Maintenance Phase:~Patients in CR/CRu at the EOT may, at discretion of the local investigator, continue maintenance with only Vinorelbine and Prednisone for up to further 12 months, progression or inacceptable toxicity at the same doses of maintenance"
2912732|NCT03161041|Experimental|Bevacizumab and CRS with oxaliplatin|Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin
2912733|NCT03161028|Experimental|Arm 1: Lipoic Acid|59 subjects receive oral lipoic acid 1200mg daily
2912734|NCT03161028|Placebo Comparator|Arm 2: Placebo|59 subjects receive placebo daily
2912735|NCT03161015|Experimental|GBT440 Dose 1: Severe Renal Impairment|eGFR < 30 mL/min/1.73m2, not on dialysis
2912736|NCT03161015|Experimental|GBT440 Dose 1: Moderate Renal Impairment|30 mL/min/1.73m2 = or < eGFR < 60 mL/min/1.73m2
2912737|NCT03161015|Experimental|GBT440 Dose 1: Mild Renal Impairment|60 mL/min/1.73m2 = or < eGFR < 90 mL/min/1.73m2
2912738|NCT03161015|Experimental|GBT440 Dose 1: Normal Renal function|eGFR > or = 90 mL/min/1.73m2
2912739|NCT03161002||wild genotype|Through next generation sequencing, distinguish wild genotype of ticagrelor
2912740|NCT03161002||mutant genotype|Through next generation sequencing, distinguish mutant genotype of ticagrelor
2912741|NCT03160989|Experimental|Postmenopausal and hypertensive women|The intervention will consist of a single session and after ten weeks of combined physical exercises (aerobic and resisted). All volunteers will participate in the same procedure.
2912742|NCT03160976|No Intervention|Control Group|Subjects will only receive the Evaluation Protocol and will be followed for 90 days.
2912743|NCT03160976|Active Comparator|Intervention Group|A single 50 minutes session of cold exposure with a cryolipolysis device. The parameters will be: temperature -10°C and vacuum between 60 Kpas (at beginning) and 40 Kpas (until the end).
2912744|NCT03160963||Ages 18-29|Power testing 18-29 year old men and women
2912745|NCT03160963||Ages 30-39|Power testing 30-39 year old men and women
2912746|NCT03160963||Ages 40-49|Power testing 40-49 year old men and women
2912747|NCT03160963||Ages 50-59|Power testing 50-59 year old men and women
2912748|NCT03160963||Ages 60-69|Power testing 60-69 year old men and women
2912749|NCT03160963||Ages 70-79|Power testing 70-79 year old men and women
2912750|NCT03160963||Ages 80+|Power testing men and women 80 years of age and above
2912751|NCT03160950|Experimental|LuxaCrown|
2912752|NCT03160937|Experimental|Manual therapy Foam|The subjects included rolled the foam roller down their quadriceps using short kneading-like motions until it was just above their patellae, and then rolled it back to its initial position in one fluid motion. The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets
2912753|NCT03160937|Active Comparator|Manual therapy Nerve|The subjects was positioned lying on his/her side with a pillow underside leg (without fully flexing it) and the cervical and thoracic spines flexed. The investigator flex the knee and the hip extended and then put it back to its initial position in one fluid motion. The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets
2912754|NCT03160924|Active Comparator|Enhanced Recovery After Surgery (ERAS)|"In this arm, the ERAS perioperative care program will be applied.~Preoperative counselling by surgeon, dietician and physiotherapist~Preoperative carbohydrate-loaded drink 800ml 12.5% Carbohydrate drink 8h before surgery 400ml 12.5% Carbohydrate drink 4h before surgery (Omit 4h drink if patient has DM)~Fluid restriction, avoid opioids, use of Cox-II inhibitors as analgesics~Avoid use of drains~Early resumption of diet~Early mobilisation with physiotherapist~Dietary counselling by dietician~Early discharge if fulfil discharge criteria.~Discharge criteria:~Adequate pain control with oral analgesics Ability to tolerate soft diet Passage of flatus Mobilization~Patients will be called by doctors every day after discharge to monitor their clinical status. There will be a low threshold for readmitting patients. Patients will also be given a hotline to call if they feel unwell. They will be seen in clinic on post-operative D7 and D14."
2912755|NCT03160924|No Intervention|Conventional perioperative program|"In this arm, the conventional preoperative program will be applied.~No preoperative counselling~No Preoperative carbohydrate-loaded drink~Routine anaesthesia, no specific protocol on fluid restriction, opioids will be used as usual. Tramadol would be used as postoperative pain control.~Routine use of drains~Diet will be resumed when there is flatus clinically~Mobilisation as per patient's wish~Dietary counselling by dietician~Discharge if fulfil discharge criteria.~Discharge criteria:~Adequate pain control with oral analgesics Ability to tolerate soft diet Passage of flatus Mobilization~Patients will be seen in clinic on post-operative D14."
2912756|NCT03160911|Experimental|Over-the-scope clip|The patient would receive an esophagogastroduodenoscope to identify the bleeding source. The endoscopist can decided whether to pre inject the ulcer with adrenaline. Then the OTSC is used for haemostasis.
2912757|NCT03160911|Active Comparator|Conventional endoscopic haemostasis|The patient would receive an esophagogastroduodenoscope to identify the bleeding source. Haemostasis will be performed in the conventional way, either using heater probe, endoscopic clips and/or injection of adrenaline
2912758|NCT03160898|Experimental|CK-2127107 300 mg|Participants will receive CK-2127107 300 mg for 12 weeks
2912759|NCT03160898|Experimental|CK-2127107 600 mg|Participants will receive CK-2127107 600 mg for 12 weeks
2912760|NCT03160898|Experimental|CK-2127107 900 mg|Participants will receive CK-2127107 900 mg for 12 weeks
2912761|NCT03160898|Placebo Comparator|Placebo|Participants will receive placebo for 12 weeks
2912762|NCT03160885|Experimental|Tralokinumab initial period -> Tralokinumab maintenance A|"Week 0 to Week 16:~tralokinumab loading SC injection at Day 0 - followed by tralokinumab SC injection regimen A~Week 16 to Week 52:~tralokinumab maintenance SC injection regimen A"
2913041|NCT03158844||Health systems informants|15 key Zambian health systems informants and leaders who can discuss inpatient care and the process of linking hospitalized patients to HIV care.
2912765|NCT03160885|Placebo Comparator|Placebo initial period -> Placebo maintenance|"Week 0 to Week 16:~placebo loading SC injection at Day 0 - followed by placebo SC injection regimen A~Week 16 to Week 52:~placebo maintenance SC injection regimen A"
2912766|NCT03160885|Experimental|Tralokinumab initial period -> Open-label tralokinumab|"Week 0 to Week 16:~tralokinumab loading SC injection at Day 0 - followed by tralokinumab SC injection regimen A~Week 16 to Week 52:~tralokinumab maintenance SC injection regimen A - open-label with allowed use of topical corticosteroids"
2912767|NCT03160885|Experimental|Placebo initial period -> Open-label tralokinumab|"Week 0 to Week 16:~placebo loading SC injection at Day 0 - followed by placebo SC injection regimen A~Week 16 to Week 52:~tralokinumab maintenance SC injection regimen A - open-label with allowed use of topical corticosteroids"
2912768|NCT03160872||Women who undergo donor sperm insemination|Non infertile women who undergo donor sperm insemination cycle
2912769|NCT03160859|Other|Control Method|One arm of the study will include unsedated colonoscopy with water exchange (WE) as the control method. Residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water will be removed predominantly during insertion.
2912770|NCT03160859|Other|Study Method|The other arm will include unsedated colonoscopy with water exchange (WE) and the addition of a simple commercially available accessory to the colonoscopy device: a cap (Disposable Distal Attachment, Olympus Medical Systems Corp., Tokyo, Japan) fitted to the colonoscope per manufacturer instruction. Residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water will be removed predominantly during insertion.
2912771|NCT03160833|Experimental|HMPL-453|Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE (high-density polyethylene) bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, until disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 50, 100, 200, 300, 400, and 500 mg/day
2912772|NCT03160820|Other|one dose of MMR|Subjects are vaccinated with MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 months old.
2912773|NCT03160820|Other|30 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 4 years old, sequentially.
2912774|NCT03160820|Other|42 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 5 years old, sequentially.
2912775|NCT03160820|Other|54 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 6 years old, sequentially.
2912776|NCT03160807|Experimental|Levofloxacin 5 days|Levolet 500 mg given for 5 days
2912777|NCT03160807|Active Comparator|Levofloxacin 10 days|Levolet 500 mg given for 10 days
2912778|NCT03160794|Experimental|[18F] DCFPyL PET/MRI|"[18F] DCFPyL PET/MRI scans for patients with recurrent disease after radical prostatectomy and adjuvant/salvage radiotherapy.~Lesions identified through [18F] DCFPyL PET/MRI will be treated with stereotactic ablative radiotherapy (SABR)."
2912779|NCT03160781|Experimental|Platelet Rich Plasma|Combination of Intraarticular and Intraosseous Administraion of Platelet Rich Plasma
2912780|NCT03160755||Qualitative Interviews|Adult outpatients with metabolic syndrome.
2912781|NCT03160742||Non-invasive monitoring|In addition to standard monitoring, the Mespere VENUS 200CVP system will be used to record central venous pressures.
2912782|NCT03160729|Active Comparator|High dose|Dexamethasone 24 mg
2912783|NCT03160729|Active Comparator|Low dose|Dexamethasone 8 mg
2912784|NCT03160716|Other|Treatment|
2912785|NCT03160703|Experimental|Test dentifrice 1 (RDA~58)|Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.
2912786|NCT03160703|Experimental|Test dentifrice 2 (RDA~77)|Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.
2912787|NCT03160703|Other|Reference dentifrice 1 (RDA~80)|Participants will apply dentifrice containing 1000 parts per million (ppm) fluoride as Sodium Monofluorophosphate (SMFP).
2912788|NCT03160703|Active Comparator|Reference dentifrice 2 (RDA~120)|Participants will apply dentifrice containing 0.454% SnF2.
2912789|NCT03160677|Experimental|Intensive blood pressure management|
2912790|NCT03160677|Active Comparator|Standard blood pressure management|
2912791|NCT03160664|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
2912792|NCT03160664|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
2912793|NCT03160651|Active Comparator|methylprednisolone|Patients will receive 28 days of methylprednisolone 32 mg/day
2912794|NCT03160651|Placebo Comparator|placebo|Patients will receive 28 days of matching placebo
2912795|NCT03160638|Experimental|Azithromycin arm|Patients in this arm will be treated with azithromycin 250 mg once daily on top of standard HRZE treatment.
2912796|NCT03160638|No Intervention|Standard of care arm|Patients in this arm will receive no additional treatment on top of standard HRZE treatment
2912797|NCT03160625|Active Comparator|Rate Adaptive Pacing ON|The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be programmed to level 4 (More Active Lifestyle) with ADL rate of 95 bpm or higher, and Upper sensor rate that is subject's age predicted maximum heart rate. The age predicted maximum heart rate (APMHR) will be computed as: APHMR = 220 - age
2912798|NCT03160625|Active Comparator|Rate Adaptive Pacing OFF|The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be turned off for this arm of the study.
2912799|NCT03160612|Other|Case|Transfer Training Subjects will be randomized to receive the transfer training either after baseline measures are collected (case) during visit 1.
2912800|NCT03160612|Other|Control|Transfer Training Subjects will be randomized to receive the transfer training during the follow-up testing at visit 2.
2912847|NCT03160248|Experimental|Apremilast|Patients randomized to this arm will start Apremilast with a titration phase of 5 days, followed by 30 mg Apremilast tablets twice daily (BID) by mouth (PO) for a total of 32 weeks (including titration phase).
2913132|NCT03158116|Experimental|Treatment|All participants will be receiving the study drug
2912801|NCT03160599|Experimental|Restricted Calorie Ketogenic Diet|"Calorie restriction: The basis of dietary design is 70-85% of individual's total calories. The total calorie is based on patient's activity level and their basal metabolism values, which is obtained from indirect calorimetry or harris-benedict formula.~Treatment will consist of ketogenic diet. KD will consist of 4:1-1:1[fat]:[protein+carbohydrate].Carbohydrate is limited to 10-30 g / day.The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard."
2912802|NCT03160586|Active Comparator|Stutter|Children who stuttering
2912803|NCT03160586|Active Comparator|Control|Children who non stuttering
2912804|NCT03160573|Active Comparator|Test-Unflavored Rinse|
2912805|NCT03160573|Active Comparator|Test-Flavored Rinse|
2912806|NCT03160573|Placebo Comparator|Placebo|
2912807|NCT03160560|Active Comparator|Test-Unflavored Rinse|
2912808|NCT03160560|Active Comparator|Test-Flavored Rinse|
2912809|NCT03160560|Placebo Comparator|Placebo|
2912810|NCT03160547|Active Comparator|Lower Protein/Amino Acid Group|Patients will receive a lower protein/amino acid dose (≤1.2 g/kg/d)
2912811|NCT03160547|Active Comparator|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
2912812|NCT03160534|Experimental|Intervention|Preoperative exercise intervention
2912813|NCT03160534|No Intervention|Control|Only measurements
2912814|NCT03160521|Experimental|Risperidone ISM 75 mg|Patients assigned to this arm will received 75 mg of Risperidone ISM during double-blind treatment period.
2912815|NCT03160521|Experimental|Risperidone ISM 100 mg|Patients assigned to this arm will received 100 mg of Risperidone ISM during double-blind treatment period.
2912816|NCT03160521|Placebo Comparator|Placebo|Patients assigned to this arm will received placebo of Risperidone ISM during double-blind treatment period.
2912817|NCT03160482||Papillary Carcinoma|
2912818|NCT03160482||Follicular Carcinoma|
2912819|NCT03160482||Colloid Nodule|
2912820|NCT03160482||Hyperplastic Nodule|
2912821|NCT03160482||Adenomatoid Nodule|
2912822|NCT03160482||Follicular Adenoma|
2912823|NCT03160469|Experimental|Elipse capsule insertion group|All patient who inserted elipse capsule in single clinic
2912824|NCT03160456|Experimental|Transcutaneous electrical stimulation|The group of participants receiving continuous transcutaneous electrical stimulation will be trained on the device and settings will be recorded. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Weekly phone calls and follow up visits at 6- and 12-weeks will be organized. At each visit comfort, compliance and adverse reactions will be recorded. At 12-weeks, the patients will be invited for a repeat assessment including polysomnography during a night of electrical stimulation. Usage time of the device will be discussed with the patients and recorded.
2912825|NCT03160456|Active Comparator|Continuous positive airway pressure|Participants who will be randomized to the usual care group will be given their own CPAP device, as previously prescribed. Weekly phone calls and follow up visits at 6- and 12-weeks will be organized. At the last visit, the patients will be studied during a repeat inpatient polysomnography and the initial assessment will be repeated.
2912826|NCT03160443|Other|Participants|"All participants performed the same evaluation: clinical and neuropsychological assessment.~All of them are patients with an eating disorder."
2912827|NCT03160430|Experimental|Part A PK Arm|a single 100 mg dose of RVX000222 (apabetalone) on the day of dialysis, followed by a one (1) week washout period, and a second dose of RVX000222 (apabetalone) administered on a non-dialysis day (total of two (2) 100 mg RVX000222 doses)
2912828|NCT03160430|Placebo Comparator|Part B Sequence A|RVX000222 (apabetalone) 100 mg b.i.d (total 200 mg/day) for 6 weeks; 4 Week Washout (No RVX000222/placebo administration); Placebo b.i.d for 6 weeks
2912829|NCT03160430|Placebo Comparator|Part B Sequence B|Placebo b.i.d for 6 weeks; 4 Week Washout (No RVX000222/placebo administration); RVX000222 (apabetalone) 100 mg b.i.d (total 200 mg/day) for 6 weeks
2912830|NCT03160404|Experimental|EXERCISE|Aerobic exercise (50% Reserve heart hate), 50 minutes, 3 times/week, during 6 weeks.
2912831|NCT03160404|Active Comparator|ZOLPIDEM|10 mg/night during 6 weeks
2912832|NCT03160391|Experimental|Music Training|Music Training
2912833|NCT03160391|Active Comparator|Dance Training|Dance Training
2912834|NCT03160391|No Intervention|Passive control group|Passive control group
2912835|NCT03160378|Experimental|Intervention|The participants in the intervention group will receive treatment as usual + 10 sessions of organizational skills training
2912836|NCT03160378|Other|Control|Control participants will receive treatment as usual.
2912837|NCT03160365|Other|ACQUISITION OF IMAGES|4 MRIs were performed at Day 0, day 1, day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
2912838|NCT03160352|Experimental|Exergame|The Senso is a training system (dividat, Schindellegi, Switzerland) for improving physical and cognitive function was used as exergame. With foot pushes participants triggered on a pressure-sensitive plate. The Senso game was projected with a beamer at white wall. To promote head movement during training the direction of the beamer was vertical tilted (± 15°) and horizontal turned (90°) with a remote controlled power panner.
2912839|NCT03160339|Experimental|PXVX0047 treatment group|Subjects will receive PXVX0047 vaccine and Teva Placebo-to-Match
2912840|NCT03160339|Active Comparator|Teva Ad4/Ad7 treatment group|Subjects will receive Teva Ad4/Ad7 vaccine and PXVX0047 Placebo-to-Match
2912841|NCT03160313|Experimental|InFuSE|Experimental group which will receive health education, group discussion, and supervised exercise.
2912842|NCT03160313|Active Comparator|Patient Education/Group Discussion|Active control group which will receive health education and group discussion.
2912843|NCT03160300|Experimental|Binaural Beats|Music with Binaural Beats: Binaural beat signals embedded in relaxing music, in a crossover design
2912844|NCT03160300|Sham Comparator|Placebo|Music: Relaxing music without the binaural beat component, in a crossover design
2912845|NCT03160287|Experimental|Motivational interview and text messages|Multidimensional, tailored intervention for sleep deficiency in for older adults with OA
2912846|NCT03160261|Experimental|Exenatide|Single injection of 10 μg Exenatide subcutaneously.
2912934|NCT03159611|Placebo Comparator|Placebo|
2912848|NCT03160248|Experimental|Placebo + Apremilast|Patients randomized to this arm will receive identically matching placebo (including the titration phase) by mouth for first 16 weeks. Placebo participants will be switched to receive Apremilast 30 mg BID from beginning of Week 17 for another 16 weeks. In this arm Apremilast will be started without titration.
2912849|NCT03160235|Experimental|Development of MRI protocols|MRI exam to grade differents interventions for future research
2912850|NCT03160235|Experimental|Development of EEG protocols|EEF exam to grade differents interventions for future research
2912851|NCT03160235|Experimental|Development of NIRS protocols|NIRS exam to grade differents interventions for future research
2912852|NCT03160222|Other|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
2912853|NCT03160209||300 esophageal cases|diagnosed with histologically confirmed ESCC
2912854|NCT03160209||300 patient controls|without a history of esophageal cancer or esophageal squamous dysplasia, a history of other cancer, or upper gastrointestinal diseases
2912855|NCT03160196|Experimental|Experimental practices|The decision support tool is a Web-based software program accessed via a GP computer desktop icon. Clicking the icon opens a single page of tick boxes asking for relevant aspects of the presenting illness. Most fields for relevant medical history and patient demographics are automatically populated from data in the electronic health record. Depending on diagnosis and risk estimation, the tool recommends a guideline-based management strategy. Override options exist but require a justification from the GP. The tool also provides relevant prescriptions, radiology access, and referral forms, and a variety of patient information leaflets. GPs in practices randomized to the intervention group will have to initiate the tool but will not have to follow the tool's advice.
2912856|NCT03160196|Active Comparator|Control practices|Control practices will be aware of the tool but will be unable to access it and managed patients by usual care, which could include care aligned with the Guidelines. Prior to randomization, GPs from all participating practices (control and intervention) will attend a 1-hour face-to-face didactic education session on diabetes mellitus 2 management and the Colombia diabetes mellitus 2 Guidelines. The intervention pertains to the cluster level.
2912857|NCT03160170|Experimental|Use of Cobb device|Use of SISTER device during surgery
2912858|NCT03160170|No Intervention|Control|Standard exposure technique and instruments will be used during surgery
2912859|NCT03160157||laparoscopic surgical group|"Patients suitable for elective cholecystectomy with minimally invasive approach will be consented and randomized into either the robotic or laparoscopic group and both the patient and the operating physician will be notified which technique will be performed. Patients will be randomized to a 1:1 ratio. In order to eliminate bias in randomization, the investigators will be using an online resource available at: https://www.randomizer.org.~After randomization, the investigators will complete a chart review that will follow the patients for a total of 30 days. The patient participation will be limited to the consent discussion and potential sign off. There will be no other clinic visits in regards to this research."
2912860|NCT03160157||robotic surgical group|"Patients suitable for elective cholecystectomy with minimally invasive approach will be consented and randomized into either the robotic or laparoscopic group and both the patient and the operating physician will be notified which technique will be performed. Patients will be randomized to a 1:1 ratio. In order to eliminate bias in randomization, the investigators will be using an online resource available at: https://www.randomizer.org.~After randomization, the investigators will complete a chart review that will follow the patients for a total of 30 days. The patient participation will be limited to the consent discussion and potential sign off. There will be no other clinic visits in regards to this research."
2912861|NCT03160144|Experimental|open lung approach ventilation strategy|Procedure: open lung approach ventilation strategy (OLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, a PEEP of 6 to 8 cm of water, and recruitment maneuvers repeated every 30 minutes after tracheal intubation.
2912862|NCT03160144|No Intervention|conventional ventilation strategy|Procedure: conventional ventilation strategy (NOLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, no PEEP and no recruitment maneuver.
2912863|NCT03160131|Experimental|Intervention|All participants receive NVT course training and are tested at baseline and at the end of the study for primary and secondary endpoints.
2912864|NCT03160118|Other|Seasonal,quadrivalent,influenza vaccine|1 vaccine will be administered to all participants, namely Alfa-Rix Tetra 2016-2017
2912865|NCT03160105|No Intervention|Continuing cART + Standard monitoring|Patients randomized to this arm will continue their current standard ART regimen (cART) and will continue a standard 3-monthly routine safety biological monitoring (including CD4 cell count, fasting lipids and glucose, renal and hepatic function tests) at their SHCS site.
2912866|NCT03160105|Experimental|Continuing cART + Patient-centered monitoring|Patients randomized to this arm will continue their current cART and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
2912867|NCT03160105|Experimental|Switch to DTG+FTC + Standard monitoring|Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
2912868|NCT03160105|Experimental|Switch to DTG+FTC + Patient-centered monitoring|Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed at screening and at week 48. In addition, patients will be ask to choose at least one of the following alternative options for weeks 6, 12 and 36: decentralised venipuncture and blood tests, delivery of ARV drugs by mail and Assessment and clinical interview by phone or skype call
2912963|NCT03159416|Experimental|Inclisiran (moderate renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Moderate renal impairment is defined as CrCl ranging from 30 to 59 mL/min.
2961567|NCT02821624|Experimental|Cohort 5|G1T38 or placebo
2912869|NCT03160092|Experimental|Intervention|"Clinical Participants will receive a 4 session individual intervention, which will be delivered by Assistant Practitioners and Assistant Psychologists (who will have received specific training in the delivering of the intervention).~The intervention will target the participant's attenuated positive psychotic symptoms, which will be referred to as: 'unusual' experiences (unless the participant prefers an alternative).~The therapist will focus on creating a therapeutic relationship in which the participant experiences them as warm, accepting and empathic. The aim is for the participant to feel listened to and understood.~The intervention will focus on taking a normalising and non-catastrophising approach to the individual's unusual experiences. The participants will be provided with psychoeducation to support this aim."
2912870|NCT03160079|Experimental|Blinatumomab + Pembrolizumab|
2912871|NCT03160066|Active Comparator|Active|Capsules containing 1x10^9 colony forming units of Lactobacillus Rhamnosus (JB-1) will be given once per day for 4 weeks.
2912872|NCT03160066|Placebo Comparator|Placebo|Placebo capsules identical to the probiotic in taste, smell, colour, and comprised only of the same non-active ingredients (corn starch, magnesium stearate and silicon dioxide) in the probiotic supplement will be given once per day for 4 weeks.
2912873|NCT03160053|Experimental|Treatment Group|Keloids that were randomized to the treatment group, were exposed to Narrowband-UVB (NB-UVB). Targeted UVB will be delivered to the keloid for up to 16 weeks using the Lumera UVB light phototherapy device (Daavlin, Bryan Ohio, USA).The affected skin will be irradiated using a hand-held fiber optic cable with an adjustable aperture.
2912874|NCT03160053|No Intervention|Control Group|Keloids that were randomized to a non treatment group, were not exposed to the NB-UVB light.
2912875|NCT03160040||Minocycline IV|Participants who received 2 doses over 48 hours if given once daily or 4 doses over 48 hours if given twice daily of minocycline intravenous (IV) as monotherapy, with or without transition to oral minocycline.
2912876|NCT03160027|Experimental|Immediate PBM treatment|This arm will receive photobiomodulation (PBM), delivered with the Vielight Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes (the device automatically shuts itself off after 20 minutes) for 12 weeks.
2912877|NCT03160027|No Intervention|Delayed PBM treatment|This arm will maintain usual activities for 12 weeks. After the week 12 psychometric and MRI assessment, this arm will receive PBM, delivered with the Vielight Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes (the device automatically shuts itself off after 20 minutes) for 12 weeks.
2912878|NCT03160014|Experimental|healthy volunteers|Drug: SHR3824 20mg/day, oral tablet, single dose
2912879|NCT03160014|Experimental|Mild Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
2912880|NCT03160014|Experimental|Moderate Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
2912881|NCT03160014|Experimental|Severe Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
2912882|NCT03160001|Placebo Comparator|Placebo and etanercept|Placebo lactose 500mg cap twice daily with etanercept 50mg weekly for 8 weeks
2912883|NCT03160001|Experimental|Niclosamide and etanercept|Niclosamide cap 500 mg twice daily with Etanercept 50mg weekly for 8 weeks
2912884|NCT03159988|Experimental|Non-randomized treatment group|12 weeks of daily does subcutaneous injection of Angiotensin-(1-7) 100 mcg/kg/day
2912885|NCT03159975|Experimental|Dose level 1 (GX-70 0.26mg)|Administrating GX-70 0.26mg
2912886|NCT03159975|Experimental|Dose level 2 (GX-70 1mg)|Administrating GX-70 1mg
2912887|NCT03159975|Experimental|Dose level 3 (GX-70 4mg)|Administrating GX-70 4mg
2912888|NCT03159962|Active Comparator|Treated Group 1|Patient treated with bonded RME (Rapid Maxillary Expander) with a 13-mm screw. The acrylic splints of the bonded expander extended from the first deciduous molars through the first permanent molars.
2912889|NCT03159962|Active Comparator|Treated Group 2|Patients treated with banded RME (Rapid Maxillary Expander) in the form of a butterfly palatal expander with a 13-mm screw cemented through bands on the second deciduous upper molars.
2912890|NCT03159962|No Intervention|Untreated Control Group|Matched untreated Class II control group prospectively evaluated after one year
2912891|NCT03159949|Experimental|PR- REHIIT|"PR-REHIIT participants (Sprint Snacks) will participate in 3 separate training session per day on 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day."
2912892|NCT03159949|Experimental|REHIIT|REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second sprints with three minutes rest in between, and a one-minute cool-down.
2912893|NCT03159936|Experimental|Tofacitinib citrate|All participants will take one 5 mg tablet by mouth in the morning and one tablet by mouth in the evening for the 6-month study duration.
2912894|NCT03159910|Experimental|Shoulder-Café (intervention)|A Shoulder-Café intervention consists of three café-meetings.
2912895|NCT03159910|Active Comparator|Shoulder-Guidance (control)|The Shoulder-Guidance intervention consists of an initial individual appointment and two e-mail contacts.
2912896|NCT03159897|Experimental|Comparator arm|Patients will receive 2 courses of standard ABVD (ABVD-28, d1, d15, cycles of 28 days) and then proceed to interim PET/CT evaluation. Those with a PET-2-negative scan (score 1-3 on 5PS) will continue with additional 4 ABVD courses while those with a PET-2-positive (score 4-5) scan will be diverted towards an intensification phase with either escalated BEACOPP or HDT plus ASCR, according to the preference of the centre. Upon completion of treatment, patients will be categorized for response (Lugano2014) by comparing actual PET/CT imaging with baseline, whether 6 ABVD cycles or ABVDx2 + intensification phase with BEACOPP or HDT/ASCR. A salvage rescue program will be planned for patients with Stable (<PR) or Progressive Disease. 30 Gy Involved Site Radiotherapy (ISRT) will be delivered as consolidation treatment on initial bulky site(s) and 30-36 on focal PET rests scoring ≥ 3 on 5PS.
2912964|NCT03159416|Experimental|Inclisiran (severe renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Severe renal impairment is defined as CrCl ranging from 15 to 29 mL/min.
2912965|NCT03159403||Oritavancin|Participants who received at least one dose (at least one for 3 hours per dose) of oritavancin intravenous (IV) as monotherapy or part of a broader regimen. The maximum number of doses to be received by a participant is not known at this time.
2912897|NCT03159897|Experimental|Experimental arm|Dose-dense and dose-intense ABVD regimen (ABVD DD-DI: intercycle 21 days, d1, d11; doxorubicin 35 mg/m2 DD 1 and 11) is given in cycles 1 to 4 and dose-dense ABVD (ABVD DD: intercycle 21 days, D1 and D11; conventional doxorubicin dose, e.g. 25 mg/m2 DD 1 and 11) is given as cycles 5 and 6). The treatment is not PET-adapted, and only patients with no response or progressive disease at interim FDG-PET as defined by the Lugano Classification (e.g., score 4 or 5 on 5PS with no significant change or with increased uptake matched with baseline and/or new FDG-avid foci consistent with lymphoma) will be diverted to salvage therapy. 30-36 Gy ISRT will be delivered as consolidation treatment on focal PET rests scoring ≥3 on 5PS at the end of ABVD DD-DI. No intentional consolidation radiotherapy on the initial bulky area(s) is scheduled.
2912898|NCT03159884|Experimental|3+Q12W|"The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, followed by every 12 weeks. If the subject meets the additional medication criteria in 12 weeks during treatment, additional injection can be given;"
2912899|NCT03159884|Experimental|3+TAE|"The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, then the researcher will determine the next follow-up visit time/treatment interval based on results of each follow-up assessment as per the treatment-extended dosing criteria. When the follow-up/treatment interval of the subject is extended to 12 weeks, additional safety follow-up visit can be arranged if any suspicious active lesion is deemed by the researcher; additional injection can be given if the result of safety follow-up assessment meets the extra dosing criteria."
2912900|NCT03159871|Experimental|Stratafix suture|
2912901|NCT03159871|Active Comparator|Vicryl suture|
2912902|NCT03159845|Active Comparator|Control|patients undergone autologous stem cell transplantation. They take levofloxacin 500 mg/d, aciclovir 400 mg bid, fluconazole 200 mg bid from day +10 until day +30 after stem cell transplantation
2912903|NCT03159845|Experimental|Zinc|patients undergone autologous stem cell transplantation. They take the same antimicrobial prophylaxis of patients of the Control group, and, in addition, a daily oral supplementation of Zinc Sulfate, 600 mg/die, uncoated tabs, from day +5 until day +100 after transplant
2912904|NCT03159832|Active Comparator|Normal renal function|All subjects were given SHR3824 20mg only one time.
2912905|NCT03159832|Active Comparator|Mild renal dysfunction|All subjects were given SHR3824 20mg only one time.
2912906|NCT03159832|Active Comparator|Moderate renal dysfunction|All subjects were given SHR3824 20mg only one time.
2912907|NCT03159819|Experimental|CAR-CLD18 T cells|"Autologous T Cells with a Claudin18.2-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.~Lymphodepletion conditioning regimen will be applied prior to CAR-CLD18 T cell infusion."
2912908|NCT03159806||Outpatients|Attendees at the nephrology outpatient clinic at Hammersmith Hospital will be invited to take part in microdialysis sampling
2912909|NCT03159793|Active Comparator|Group A|Live Modelling
2912910|NCT03159793|Active Comparator|Group B|Filmed Modelling
2912911|NCT03159793|No Intervention|Group C|No Modelling
2912912|NCT03159767|Experimental|Spinal Mobility Measurement: Rater A|All patients will undergo the same ViMove Spinal Sensor measurement protocol with independent raters.
2912913|NCT03159767|Experimental|Spinal Mobility Measurement: Rater B|All patients will undergo the same ViMove Spinal Sensor measurement protocol with independent raters.
2912914|NCT03159754|Experimental|Early Appendectomy|
2912915|NCT03159754|Experimental|Interval Appendectomy|
2912916|NCT03159754|Experimental|No Appendectomy|
2912917|NCT03159741|Experimental|Inhibitor + GLP-2|
2912918|NCT03159741|Experimental|Placebo + GLP-2|
2912919|NCT03159741|Active Comparator|Placebo + GIP|
2912920|NCT03159741|Placebo Comparator|Placebo + Saline|
2912921|NCT03159728|Experimental|Educative intervention|"Who wish to participate in the program Caring for Caregivers will be the intervention group. The intervention or program Caring for Caregivers to develop was proposed by the Group of Chronic Care Patient and Family School of Nursing at the National University of Colombia. This program includes four sessions or meetings with the caretaker, induction and three modules, the first is geared to strengthen the knowledge; the second, to strengthen the value and the third, to strengthen patience."
2912922|NCT03159728|No Intervention|Control group|"The control group will receive training about knowledge of chronic disease and care.~In addition, once it confirmed the effectiveness of the intervention participants in the control group will be contacted to contemplate the possibility of receiving the benefits of the intervention."
2912923|NCT03159715|Experimental|Internet-based Global Protocol|Intervention group that carries out the Internet-based Global Protocol and receives therapist support.
2912924|NCT03159715|Experimental|Internet-based Behavioral Activation Protocol|Intervention group that carries out the Internet-based Behavioral Activation Protocol and receives therapist support.
2912925|NCT03159715|Experimental|IInternet-based Positive Psychology Protocol|Intervention group that carries out the Internet-based Positive Psychology Protocol and receives therapist support.
2912926|NCT03159702|Experimental|MEL/FLU and Total-Body Irradiation|"For patients who are < 60 years.~Melphalan: 140 mg/m2/day IV on Day: -6~Fludarabine: 40 mg/ m2/day IV Days: -5 -4, -3, -2 (Adults: creatinine clearance may be estimated by the Cockcroft Formula: CrCl = [(140-age) x weight (kg) x 0.85 (for women only)]/ [72 x creat (mg/dl)].)~TBI: 200 cGy Day: -1.~For patients who are ≥ 60 years.~Melphalan: 100 mg/m2/day IV on Day: -6~Fludarabine: 40 mg/ m2/day IV Days: -5, -4, -3, -2~TBI: 200 cGy; Days: -2, -1 (total of 400cGy)~For patients who are ≥60 years and/or HCT-CI score of >3 (at the discretion of treating physician will have an option to receive):~Melphalan: 70 mg/m2/day IV on Day -6.~Fludarabine: 40 mg/m2/day IV Days -5, -4, -3, -2.~TBI: 200 cGy; Days -1."
2912927|NCT03159689|Experimental|Mixed Tree Nuts|a hypo caloric weight loss dietary plan with mixed tree nuts
2912928|NCT03159689|Active Comparator|Pretzels|a hypo caloric weight loss dietary plan with pretzels
2912929|NCT03159650|Experimental|intravascular ultrasonography guided|
2912930|NCT03159650|Active Comparator|Angiography guided|
2912931|NCT03159624|Experimental|Treatment Group|2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone
2912932|NCT03159624|Active Comparator|Control Group|Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone
2912933|NCT03159611|Experimental|Tenoten for children|
2912935|NCT03159598|Active Comparator|Tissue Glu with drains|This is standard of care to use Tissue Glu in addition to a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
2912936|NCT03159598|Experimental|Tissue Glu without drains|This group utilizes Tissue Glu without the presence of a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
2912937|NCT03159598|Active Comparator|Drains|This is standard of care to use traditional closed-suction drains. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
2912938|NCT03159585|Experimental|TAEST16001|"TAEST16001 cells are prepared by lentiviral infection. The dose-limiting toxicity was administered in a dose escalation test according to the 3 + 3 design. Three days prior to infusion of TCR-T cell, patients receive cyclophosphamide treatment at dose 1 g/day for 2 days and take a rest for one day before infusion.~A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×10^9) will be intravenously administered. Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, interleukin(IL)-2 subcutaneous injections (250,000 IU/day) will be administered for 14 days concomitantly to each subject."
2912939|NCT03159572||Ovarian cancer group|Patients who are diagnosed with ovarian cancer and have a plan of surgery.
2912940|NCT03159559|Experimental|Treatment group|In the treatment group ,patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days ;
2912941|NCT03159559|No Intervention|Control group|In the control group, patients received conventional therapy only.
2912942|NCT03159533|Active Comparator|CHW Intervention|CHW lead Sessions Session1: BP and the Cardiovascular System Session 2: Nutrition and food labels Session 3: Physical Activity and Stress Management Session 4: CVD Risk factors: cholesterol, blood sugar, & Smoking Session 5: Health Communication, Healthcare access & Review
2912943|NCT03159533|Placebo Comparator|Control Group|Wait-list
2912944|NCT03159520|Active Comparator|Advice on acupressure|Advice sheet on use of acupressure for post orthodontic pain
2912945|NCT03159520|Active Comparator|Advice on analgesics|Advice sheet on use of NSAID analgesics for post orthodontic pain
2912946|NCT03159507|Experimental|MAG-EPA|MAG-EPA softgel (500mg), daily dose between 1g and 3.5g
2912947|NCT03159494|Experimental|Intervention group|10 patients with type 2 diabetes enrolled to perform 8 times of High-Intensity Training. The subjects were tested before and after the training period.
2912948|NCT03159494|Experimental|Pilot study|6 patients with type 2 diabetes enrolled to perform 6 times of High-Intensity Training. The subjects were tested before and after the training period
2912949|NCT03159481|Experimental|Usual Care + Health Promotion Intervention|Usual glaucoma care along with telehealth-based brief culturally informed health promotion intervention
2912950|NCT03159481|No Intervention|Usual Care Only|Usual glaucoma management only, no intervention.
2912951|NCT03159468|Experimental|Cognitive Restructuring|Participants will receive a brief online training regarding the use of cognitive restructuring skills to cope with negative emotions.
2912952|NCT03159468|Experimental|Mindfulness|Participants will receive a brief online training regarding the use of mindfulness skills to cope with negative emotions.
2912953|NCT03159468|No Intervention|Nutrition Information|Participants will receive general information about nutrition.
2912954|NCT03159455|Experimental|BI 1467335|
2912955|NCT03159455|Placebo Comparator|Placebo|
2912956|NCT03159442|Experimental|Cohort 1|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 300 μg AZD8871 or placebo. This dose will be given as 1 inhalation from the 300 μg AZD8871 or placebo inhaler.~Single inhaled dose of AZD8871 or placebo will be administered on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16."
2912957|NCT03159442|Experimental|Cohort 2|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 600 μg AZD8871 as 1 inhalation from the 600 μg AZD8871 or placebo inhaler.~Single inhaled dose of AZD8871 or placebo will be administered on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16.~Dose escalation to 600 μg dose will be done only after the SRC has determined the adequacy of the dose to be given."
2912958|NCT03159442|Experimental|Cohort 3|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 900 μg AZD8871 as 1 inhalation from the 300 μg AZD8871 inhaler and 1 inhalation from the 600 μg AZD8871 inhaler, or placebo as 2 inhalations from 2 different placebo inhalers.~Single inhaled dose of AZD8871 or placebo on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16.~Dose escalation to the 900 μg dose will be done only after the SRC has determined the adequacy of the dose to be given."
2912959|NCT03159429|Experimental|Experimental arm|"Patients randomized to this arm will participate in the new rehabilitation programme.~Intervention: Nasal breathing rehabilitation"
2912960|NCT03159429|Active Comparator|Comparator arm|"Patients randomized to this arm will participate in the usual rehabilitation programme.~Intervention: Standard rehabilitation"
2912961|NCT03159416|Experimental|Inclisiran (normal renal function)|Participants will receive a single dose of 300 milligram (mg) inclisiran administered by SC injection on Day 1. Normal renal function is defined as estimated creatinine clearance (CrCl) of ≥90 milliliter (mL)/minute (min).
2912962|NCT03159416|Experimental|Inclisiran (mild renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Mild renal impairment is defined as CrCl ranging from 60 to 89 mL/min.
2912966|NCT03159390|Experimental|phenylacetate salt of ornithine|There are 4 study days of approximately 10 hours. Amino acid tracers (e.g., OP, PHE, TYR) will be provided via IV. The dosage of OP provided in this study 6 g in a period of 6 hours. 2 muscle biopsies will be completed on 2 of the study days.
2912967|NCT03159377||Patients scheduled for a chest CT|Inpatients or outpatients scheduled for a chest CT in our medical center
2912968|NCT03159364|Experimental|Infusion of pathogen-specific CTLs|Repetitive CTL infusions to treat microbial infections
2912969|NCT03159351|Experimental|active rTMS treatment|received active rTMS treatment 20 times for 20 days
2912970|NCT03159351|Sham Comparator|sham rTMS treatment|received sham rTMS treatment 20 times for 20 days
2912971|NCT03159338|Active Comparator|treatment group|One side of osteotomies will be considered as a treatment arm (randomly) which Platelet rich fibrin will be used with rigid fixation
2912972|NCT03159338|Placebo Comparator|Control group|In control site , placebo gel will be placed before rigid fixation
2912973|NCT03159325|No Intervention|Usual Care|The usual care group will receive all standard treatment, instructions and information for patients with cardiovascular disease, but no Healing Circles program.
2912974|NCT03159325|Experimental|Healing Circles|Healing Circles is an evidence-based and patient-informed novel self-management platform designed to support patients with CVD. It uses a private, secure social network that helps connect patients to one another, to personalized, disease management information , and provides functions to assist patients in self-management via evidence-based principles of behaviour change.
2912975|NCT03159312|Experimental|Assigned Interventions|Study group: 20 individuals undergoing bariatric surgery who will undergo a moderate exercise program after surgery.
2912976|NCT03159312|No Intervention|Control group|
2912977|NCT03159299|Experimental|Yo Puedo|This group will receive the modified Yo Puedo + mHealth program.
2912978|NCT03159299|No Intervention|Wait-list Control|This group will not receive the Yo Puedo + mHealth program during the 6 month data collection period, but will be invited to participate in it after data collection has finished.
2912979|NCT03159286|Experimental|Abstainer|Participants view social networking site profiles with alcohol content that references abstaining from alcohol use.
2912980|NCT03159286|Experimental|Abstainer + User|Participants view social networking site profiles with alcohol content that references both abstaining from alcohol use and using alcohol.
2912981|NCT03159286|Experimental|Control|Participants view social networking site profiles with no alcohol content.
2912982|NCT03159273|Experimental|Beetroot Juice Group|Subjects in this group are given 7 daily doses of a dietary nitrate supplement (Beet-it Sport beetroot juice shots) and asked to drink one dose daily during the week of their final academic examinations of that term in college.
2912983|NCT03159273|No Intervention|Control|Subjects in this group are not given a dietary nitrate supplement but are assessed at the same time points as those in the experimental group.
2912984|NCT03159260|Experimental|Theraworx|Subjects will receive two 3 ounce foam dispensers corresponding to their group assignment (Foam A or Foam B) and a 2-week Compliance and Symptom Log. The contents of these two foams will remain blind to the subjects and the data collectors until all 50 subjects complete the study protocol. One of the foams will contain Theraworx/[pH]uel (treatment) and the other will contain a physiologically inert substance (placebo control).
2912985|NCT03159260|Placebo Comparator|Placebo|Subjects will receive two 3 ounce foam dispensers corresponding to their group assignment (Foam A or Foam B) and a 2-week Compliance and Symptom Log. The contents of these two foams will remain blind to the subjects and the data collectors until all 50 subjects complete the study protocol. One of the foams will contain Theraworx/[pH]uel (treatment) and the other will contain a physiologically inert substance (placebo control).
2912986|NCT03159247|Experimental|eyeGuide|Two personalized eHealth interventions aimed to improve glaucoma medication adherence.
2912987|NCT03159234|Other|Diabetic pregnant women|
2912988|NCT03159221|Experimental|BFST for Teens with Type 2 Diabetes|Psychological intervention: Families randomized to the intervention group will receive 12 sessions of Behavioral Family Systems Therapy for Teens with type 2 diabetes (BFST-DM2) over 6 months.
2912989|NCT03159221|No Intervention|Control group (Standard Care)|The participants assigned to the control group will receive their standard medical care for diabetes.
2912990|NCT03159182|Experimental|Pressure garment and silicone insert|Custom measured pressure garment with a textile bonded silicone insert in either the distal or proximal portion of the pressure garment, to be worn 23 hours per day.
2912991|NCT03159182|Active Comparator|Pressure Garment|Custom measured pressure garment, to be worn 23 hours per day.
2912992|NCT03159169|Experimental|study patients|Single arm study. Patients will receive Spinal Cord Stimulation (SCS) according to standard clinical procedures.
2912993|NCT03159156|No Intervention|Blood Donation As Usual|Volunteer blood donors complete assessment materials, including assessment of respiratory activity, but otherwise undergo the typical blood donation procedure.
2912994|NCT03159156|Experimental|Applied Tension|Participants are taught a simple muscle tensing technique with a brief video presented on a notebook computer before giving blood. They are asked to engage in repeated gentle 5-sec on, 5-sec off cycles of whole body isometric muscle tension before and while giving blood.
2912995|NCT03159156|Experimental|Respiration Control|Participants are taught a simple respiration control technique with a brief video presented on a notebook computer before giving blood. They are asked to breathe in a gentle shallow but regular fashion aimed at reducing risk for hyperventilation before and while giving blood.
2912996|NCT03159156|Experimental|Applied Tension/Respiration Control|Participants are asked to practice both Applied Tension and Respiration Control before and while giving blood.
2912997|NCT03159143|Experimental|Docetaxel and Oxaliplatin|Docetaxel administered at a dose of 60mg/m^2 IV infusion, followed by oxaliplatin at a dose of 110mg/m^2 as a 2 hour IV infusion.
2912998|NCT03159130||receiving lidocaine|Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of 1% lidocaine.
2912999|NCT03159130||receiving injectable saline|Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of injectable saline.
2913646|NCT03154372|Other|deliberate practice|expert supervised practice with validated metrics
2913000|NCT03159117|Experimental|PF 06688992|This clinical study will include two parts. Part 1 will be a dose-finding phase in which patients will be treated with various doses of Pfizer PF-06688992. (PF 06688992) will be administered by the intravenous route over approximately 60 minutes every 21 days. The dose expansion phase will include a single cohort of up to 20 evaluable patients treated at the recommend dose.
2913001|NCT03159104|Experimental|Tenoten for children|
2913002|NCT03159104|Placebo Comparator|Placebo|
2913003|NCT03159091|Experimental|Rengalin|
2913004|NCT03159091|Placebo Comparator|Placebo|
2913005|NCT03159078|Other|Polymyxin B monotherapy|Intravenous piggyback with Polymyxin B and control(Normal saline)
2913006|NCT03159078|Experimental|Polymyxin B plus Carbapenem|Intravenous piggyback with Polymyxin B plus Carbapenem
2913007|NCT03159065|Experimental|Bilberry|A bilberry-based beverage with fermented oatmeal
2913008|NCT03159065|Experimental|Blackcurrant|A blackcurrant-based beverage with fermented oatmeal
2913009|NCT03159065|Experimental|Mango|A mango-based based beverage with fermented oatmeal
2913010|NCT03159065|Experimental|Beetroot|A beetroot-based based beverage with fermented oatmeal
2913011|NCT03159065|Experimental|Rose hip|A rose hip-based based beverage with fermented oatmeal
2913012|NCT03159065|Active Comparator|Glucose drink|A reference glucose drink
2913013|NCT03159052|Experimental|SHR3824 Placebo|once daily, 24 weeks
2913014|NCT03159052|Experimental|SHR3824 5 mg|once daily, 52 weeks
2913015|NCT03159052|Experimental|SHR3824 10 mg|once daily, 52 weeks
2913016|NCT03159039|Experimental|Conventional Physiotherapy (PT)|Postural drainage + manual vibration
2913017|NCT03159039|Active Comparator|Prolonged slow exhalation technique|Prolonged exhalation + Conventional PT
2913018|NCT03159013|Other|Pesticide toxicokinetics- oral|Exposure type: ORAL Toxicokinetics
2913019|NCT03159013|Other|Pesticide toxicokinetics- dermal|Exposure type: DERMAL Toxicokinetics
2913020|NCT03159000|Experimental|GONB of lidocaine/bupivacaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion bilaterally. The subject will remain in the office for 30 minutes after injection, and receive a questionnaire to be filled out at 10 and 30 minutes, and 2 and 24 hours post-injection. Subjects who are not improved after 2 hours will be allowed to use their abortive treatment.
2913021|NCT03159000|Placebo Comparator|Placebo injection of 1/3 saline|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion bilaterally. The subject will remain in the office for 30 minutes after injection, and receive a questionnaire to be filled out at 10 and 30 minutes, and 2 and 24 hours post-injection. Subjects who are not improved after 2 hours will be allowed to use their abortive treatment.
2913022|NCT03158974|Experimental|VIR007|Cream containing 10% EISO
2913023|NCT03158961|Experimental|TOETVA|a new approach in surgery which can treat the thyroid disease
2913024|NCT03158948|Experimental|MOTREM 1|0.3 mg/kg/h
2913025|NCT03158948|Experimental|MOTREM 2|1.0 mg/kg/h
2913026|NCT03158948|Experimental|MOTREM 3|3.0 mg/kg/h
2913027|NCT03158948|Placebo Comparator|Placebo|
2913028|NCT03158935|Experimental|Advanced metastatic melanoma (Cohort 1)|Cyclophosphamide and fludarabine followed by Tumor-Infiltrating Lymphocytes (TILs), Interleukin-2 (IL-2), and pembrolizumab
2913029|NCT03158935|Experimental|Advanced ovarian cancer (Cohort 2):|Cyclophosphamide followed by Tumor-Infiltrating Lymphocytes (TILs), Interleukin-2 (IL-2), and pembrolizumab
2913030|NCT03158922||Stage 1|Caucasian men aged 55-69 to undergo genetic profiling.
2913031|NCT03158922||Stage 2|Men from Stage 1 identified as having a higher genetic risk score (top 10%) for prostate cancer.
2913032|NCT03158909|Experimental|Interventional|Patients in this group will receive eyemask and earplugs, for use during the night, and orientations about space and time, every night.
2913033|NCT03158909|Active Comparator|Orientation about space and time|This group will receive orientations about space and time olny, every night.
2913034|NCT03158896|Experimental|MSCTC-0010 Dose Escalation|"Cohort 1: First 5 participants will receive a lower dose of cord-blood derived Wharton's jelly mesenchymal stem cells (MSCTC-0010) and they will be observed for 42 days after the dose for treatment-related serious adverse events (TRSAE) and response.~Cohort 2: Second 5 participants will receive an increased dose of MSCTC-0010 and will be observed for 42 days after the dose for TRSAE and response."
2913035|NCT03158883|Experimental|Non-responders|"Patients who initially progress at first response assessment on a PD-1 inhibitor will be enrolled to the non-responder arm.~Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 [±2] days).~Stereotactic ablative radiotherapy (SAR): the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated."
2913036|NCT03158883|Experimental|Progressors|"Patients who initially present with PR, CR, or SD to a PD-1 inhibitor but subsequently progress will be enrolled to the progressor arm.~Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 [±2] days).~Stereotactic ablative radiotherapy (SAR): the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated."
2913037|NCT03158870||Pheochromocytoma|Patient who underwent surgical procedure for pheochromocytoma
2913038|NCT03158857||Hepatitis C monoinfection|"Sofosbuvir 400 mg tablet once a day + Daclatasvir 60mg tablet once a day~Patients with evidence of cirrhosis will be offered treatment for 24 weeks, those who are not cirrhotic will be offered 12 weeks of treatment."
2913039|NCT03158857||Hepatitis C and HIV co-infection|"Sofosbuvir tablet 400 mg once a day + Daclatasvir tablet 90 mg once a day (increased dose in patients receiving efavirenz. Patients on an alternative HIV drug regimen will receive standard dose i.e. 60 mg)~Patients with evidence of cirrhosis will be offered treatment for 24 weeks, those who are not cirrhotic will be offered 12 weeks of treatment."
2913040|NCT03158844||HIV+ patients (Standard of care)|300 HIV-infected and hospitalized adult patients at the University Teaching Hospital (UTH) will be recruited.
2913182|NCT03157778|Experimental|Obese men|Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in obese men.
2913042|NCT03158831|Other|Placebo-Controlled Graded Drug Challenge|This is a single arm study. All patients will receive a placebo prior to a graded drug challenge. Each patient serves as his/her own control.
2913043|NCT03158818||HBV mono-infected (Standard of Care)|500 patients in Zambia
2913044|NCT03158805|Active Comparator|Active drug|LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
2913045|NCT03158805|Placebo Comparator|Placebo|Placebo (no active drug)
2913046|NCT03158792|Active Comparator|Enoxaparin 20 mg|
2913047|NCT03158792|Active Comparator|Enoxaparin 30 mg|
2913048|NCT03158779|Experimental|SBRT and chemotherapy|"Participants received 4 months of FOLFIRINOX or Gemcitabine-Abraxane before SBRT was administered. A 3-weeks break from chemotherapy and restaging with thorax-abdominal CT scan to confirm the absence of distant metastases was required before SBRT delivery.~Before SBRT simulation, patients may will have implanted fiducial into the pancreatic tumor.~The SBRT schedule will be [6 x 9 Gy = 54 Gy] delivered in consecutive days."
2913049|NCT03158766||Microdiscectomy|Patients with lumbar disc herniation who failed conservative treatment undergoing surgical treatment through microdiscectomy.
2913050|NCT03158740|Active Comparator|DII-Based Counseling System|The DII-based counseling group will utilize our 12-week IMAGINE Counseling System curriculum.The DII-based counseling group will meet once a week for 12 weeks to cook, and to engage in exercise and stress-reduction activities. Along with the initial clinic, participants will meet one-on-one for a nutrition counseling session with a registered dietitian. Participants will have access to online material through our Imagine Healthy Online Portal and will be given take-home activities, referred to as IMAGINE actions. These homework assignments will focus on goal setting for nutrition, physical activity, and stress reduction. The nutrition components of this intervention will be based on the DII and will focus on anti-inflammatory foods and components.
2913051|NCT03158740|Active Comparator|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC.
2913052|NCT03158727|Experimental|Cx611|Cx611 Subjects treated in an intensive care unit for sCABP, but that may be screened at the emergency department, will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Cx611 at a fixed dose of 160 million expanded allogeneic adipose-derived stem cells (eASCs) each
2913053|NCT03158727|Placebo Comparator|Placebo|Placebo Subjects treated in an intensive care unit for sCABP, but that may be screened at the emergency department, will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Ringer Lactate
2913054|NCT03158714|Experimental|Couples Connecting Mindfully Curriculum|Receives the Couples Connecting Mindfully curriculum over a 6 week period.
2913055|NCT03158714|Experimental|ELEVATE Curriculum|Receives the ELEVATE curriculum over a 6 week period.
2913056|NCT03158714|No Intervention|Control|No programming is offered.
2913057|NCT03158688|Active Comparator|Arm 2 - Carfilzomib and Dexamethasone|"Carfilzomib will be dosed twice weekly as an intravenous (IV) infusion and Dexamethasone will be taken orally or by IV infusion weekly. The IV administration of dexamethasone must be given on carfilzomib IV infusion days. The required order of administrationon Arm 2 is as follows: dexamethasone then carfilzomib.~For days when dexamethasone is given in the absence of carfilzomib IV infusion, it may be given orally (PO)."
2913058|NCT03158688|Active Comparator|Arm 1 - Carfilzomib, Dexamethasone and Daratumumab|Carfilzomib will be dosed twice weekly as an intravenous (IV) infusion. Daratumumab will be administered as an IV infusion - on days 1 and 2 of cycle 1 at 8 mg/kg dose each day; then at 16 mg/kg dose once weekly as a single infusion for the remaining doses of the first 2 cycles; then every 2 weeks for 4 cycles (cycles 3 to 6), and then every 4 weeks for the remaining cycles or until disease progression. Dexamethasone 40 mg will be taken orally or by IV infusion weekly. The IV administration of dexamethasone must be given on carfilzomib and/or daratumumab IV infusion days. On days when more than 1 investigational product is administered, the required order of administration is as follows: dexamethasone, pre-infusion medications for daratumumab, carfilzomib, daratumumab, and post-infusion medications for daratumumab.
2913059|NCT03158675|Experimental|Fractional co2 laser&topical steroid|"participant will be compared with one side of the body to the ather side.~Intervention:~-Procedure: Fractional carbon dioxide laser.~-Drug: Topical corticosteroid.~-Radiation: Ultraviolet B narrow band."
2913060|NCT03158649|Experimental|Positive Psychology Internet-based Intervention condition|Internet-based positive psychology training
2913061|NCT03158649|No Intervention|Waiting List condition|Waiting List control condition
2913062|NCT03158623|Experimental|Platelet Rich Plasma|30cc of PRP was administered at closure of wound
2913063|NCT03158623|Experimental|Cellerate (Activated Collegen)|1gm of Cellerate was administered at closure of wound
2913064|NCT03158610|Experimental|Capecitabine metronomic chemotherapy|Capecitabine 500mg/m2 bid po qd
2913065|NCT03158610|Active Comparator|Capecitabine standard dosage chemotherapy|Capecitabine 1000mg/m2 bid po d1-d14,q3w
2913066|NCT03158597||AMI|
2913067|NCT03158597||Control|
2913068|NCT03158584|Active Comparator|morphine 2 μg/kg|Children will receive intrathecal morphine 2 μg/kg in 2 ml volume normal saline.
2913069|NCT03158584|Active Comparator|morphine 5 μg/kg|Children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
2913070|NCT03158584|Active Comparator|morphine 10 μg/kg|Children will receive intrathecal morphine 10 μg/kg in 2 ml volume normal saline.
2913071|NCT03158558|Experimental|AM-CBCT for PTSD|Accelerated, Multi-Couple Group Cognitive-Behavioral Conjoint Therapy delivered in a single weekend retreat
2913072|NCT03158545|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
2913073|NCT03158545|Active Comparator|EPA-rich|3 x 1 g capsules daily containing EPA-enriched oil
2913074|NCT03158545|Active Comparator|DHA-rich|3 x 1 g capsules daily containing DHA-enriched oil
2913075|NCT03158532|Placebo Comparator|Placebo I/Placebo II|0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
2913076|NCT03158532|Experimental|Nitroglycerin I/Placebo II|500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
2913077|NCT03158532|Active Comparator|Placebo I /Nitroglycerin II|0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
2913078|NCT03158532|Experimental|Nitroglycerin I /Nitroglycerin II|500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
2913079|NCT03158519|Experimental|iMETX intervention|
2913080|NCT03158506|Experimental|[C14]-labelled HMS5552|
2913081|NCT03158480|Experimental|DC-CIK+interferon Group|dendritic cell-activated cytokine-induced killer cells (DC-CIK) immunotherapy plus interferon intervention
2913082|NCT03158480|Placebo Comparator|Placebo+interferon Group|saline as placebo plus interferon intervention
2913083|NCT03158467||Phase 1|
2913084|NCT03158467||Phase 2|
2913085|NCT03158454|Other|Capsula Closure|
2913086|NCT03158454|Other|Non-Capsula Closure|
2913087|NCT03158441||cases|The patients enrolled for the study will be women scheduled for breast MRI due to high risk screening or pretreatment evaluation. The patients will fill in a form regarding: age, hormonal status, risk factors, prior breast surgery or treatment (a form which is routinely filled out in our institution). They will then undergo a breast MRI scan, using the routine protocol in our institution. This will be directly followed by a DTI sequence, which takes about 10 minutes in addition to the regular examination. The DTI sequence is routinely used in other imaging institutions, as part of the breast MRI protocol.
2913088|NCT03158441||control|same patients , dynamic scan
2913089|NCT03158428|Experimental|CSD170202AA, CSD170202AB Use Group|Use of product CSD170202AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170202AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
2913090|NCT03158428|Experimental|CSD170202AB, CSD170202AA Use Group|Use of product CSD170202AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170202AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
2913091|NCT03158415|Experimental|Parents of Young Adults with T1D|Parents of young adults ages 18 to 25 years with type 1 diabetes who are transitioning to independence. During six weeks, participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.
2913092|NCT03158402|Sham Comparator|sham IMT|Preoperative Inspiratory muscle training at low intensity (15% Pimax) which is considered as a no effect training.
2913093|NCT03158402|Experimental|Hi Intensity IMT|High intensity muscle training in the preoperative period at 80% of the maximal inspiratory muscle pressure.
2913094|NCT03158389|Experimental|Subtrial A: APG101|"weekly application of 400/600/800 mg i.v. until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
2913095|NCT03158389|Experimental|Subtrial B: Alectinib|"600 mg orally twice daily (bid) for 6 until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
2913096|NCT03158389|Experimental|Subtrial C: Idasanutlin|"at escalating doses from 100 mg until maximum tolerated dose daily administered (orally) on five consecutive days of a 28-day cycle until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
2913097|NCT03158389|Experimental|Subtrial D: Atezolizumab|"application of 1200 mg i.v. every three weeks until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
2913098|NCT03158389|Experimental|Subtrial E: Vismodegib|"daily application of 150 mg orally until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
2913099|NCT03158389|Experimental|Subtrial F: Palbociclib|"75/100/125 mg orally once daily on 21/28 days~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions)~followed by a 4 weeks break (after last dose of 2nd cycle)~and with maintenance therapy with palbociclib at 125 mg daily until progression"
2913100|NCT03158389|Experimental|Subtrial G: Temsirolimus|"weekly application of 25 mg i.v. until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
2913101|NCT03158376|Experimental|gabapentin group|"the day before surgery : gabapentin 400 mg orally~preoperatively (2 hours before surgery) : 3 capsules each containing 400 mg gabapentin (total gabapentin dose 1200 mg) and intravenous infusion of 50 ml of normal saline solution~postoperative day 1 to 10 : 400 mg x 3 ( gabapentin 1200 mg daily)"
2913102|NCT03158376|Placebo Comparator|placebo group|"The day before surgery: 1 placebo capsule orally~preoperatively (2 hours before surgery) : 3 placebo capsules and intravenous infusion of 75 mg hydroxyzine~postoperative day 1 to 10: 1 placebo capsule x 3"
2913103|NCT03158363|Experimental|"LPS, 36 hour immobilization and fast"|"Interventions:~Test subjects undergo 48 hour exercise restriction and overnight fast.~Study day 1:~- LPS (1 ng/kg) will be administered. Test subjects will fast and bedrest for the rest of the study period.~Study day 2:~3 hour Basal period: Continued fast and bedrest. Phenylalanine, tyrosine, carbamide, glucose and palmitate tracers are infused. Muscle and fat biopsies are taken from m. vastus lateralis and stomach.~3 hour hyperinsulinemic euglycemic clamp period with muscle and fat biopsies.~Study day 3:~- Blood sample."
2913104|NCT03158363|No Intervention|"Control"|"Test subjects undergo overnight fast. No exercise restrictions.~3 hour Basal period: Continued fast and bedrest. Phenylalanine, tyrosine, carbamide, glucose and palmitate tracers are infused. Muscle and fat biopsies are taken from m. vastus lateralis and stomach.~3 hour hyperinsulinemic euglycemic clamp period with muscle and fat biopsies."
2913105|NCT03158350|Experimental|Stationary Bristle Technique (SBT)|Instructed brushing method. Participants are asked to brush twice daily, for 2 minutes at a time, following instructions for the Stationary Bristle Technique.
2913106|NCT03158350|No Intervention|Non-Stationary Bristle Technique (NSBT)|The control group will be asked to brush twice daily, for 2 minutes at a time, following their normal toothbrushing technique.
2913107|NCT03158337|Experimental|Aerobic exercise|Participants took part in a supervised 6-month long aerobic (walk/jog) training program held 3 days/week. Each session included a 5-min warm-up, 20-40 min of aerobic exercise (walking, jogging), 5-min cool-down, and stretching. Exercise prescriptions follow current principles and guidelines established by ACSM/AHA, including sufficient warm-up, cooldown, and ongoing provision of safety precautions/exercise tips. As participants progress, the duration of aerobic exercise increased from 20 (month 1) to 30 (months 2-3) and 40 min (months 4-6), with proportional increases to warm-up and cool-down periods. Exercise intensity is based on individual maximal oxygen uptake (VO2 max), measured at baseline. Intensity builds from 30-45% (months 1-3) to mitigate the risk of injury and will progress to 60-70% (months 4-6) heart rate reserve (HRR).
2913108|NCT03158324|Experimental|Advanced refractory solid tumors|Patients with advanced refractory solid tumors will be enrolled.
2913109|NCT03158311|Experimental|QVM149 arm 1|QVM149 150/50/80 μg o.d. delivered via Concept1
2913110|NCT03158311|Experimental|QVM149 arm 2|QVM149 150/50/160 μg o.d. delivered via Concept1
2913111|NCT03158311|Active Comparator|Salmeterol/fluticasone plus tiotropium arm|Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®
2913112|NCT03158285|Experimental|Group 1: Guselkumab|Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 100.
2913113|NCT03158285|Experimental|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab 100 mg at Weeks 0 and 4 then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, and 100) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, and 96) to maintain the blind.
2913114|NCT03158285|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive SC placebo q4w from Week 0 to Week 20 and will cross over at Week 24 to receive SC guselkumab 100 mg q4w from Week 24 through Week 100.
2913115|NCT03158272|Experimental|Monotherapy|Cabiralizumab administered as a single agent intravenous formulation
2913116|NCT03158272|Experimental|Combination Therapy|Cabiralizumab will be administered in combination with Nivolumab as an intravenous formulation
2913117|NCT03158259|Experimental|Intervention group MSU|Patient will be diagnosed (NIHSS, CT and conventional blood-measures) and given thrombolytic treatment (when indicated) prehospitally by anesthesiologist in Mobile Stroke Unit (MSU)
2913118|NCT03158259|Active Comparator|Conventional ambulance|Patient will be brought to hospital by normal ambulance according to existing procedures. Diagnosis (NIHSS, CT and conventional blood-measures) and thrombolytic treatment (when indicated) will be given in hospital.
2913119|NCT03158246|Experimental|Yigu Group|"a single 15-minute infusion of Generic Zoledronic Acid (Yigu®) (5 mg/100ml)~600mg/d calcium and 925IU/d vitamin D for oral daily, 12 months"
2913120|NCT03158246|Active Comparator|Aclasta Group|"a single 15-minute infusion of Original Zoledronic Acid (Aclasta®) (5 mg/100ml)~600mg/d calcium and 925IU/d vitamin D for oral daily, 12 months"
2913121|NCT03158220|Experimental|Adult Women 27- to 45-years Old|Adult women 27- to 45-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
2913122|NCT03158220|Active Comparator|Young Adult Women 16- to 26-years Old|Young adult women 16- to 26-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
2913123|NCT03158207|Experimental|Waters Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Warters Mask.. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
2913124|NCT03158207|Active Comparator|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
2913125|NCT03158194|Experimental|CBT for anxiety-related asthma|Ten to twelve weekly sessions of CBT targeting enhanced function and decreased symptoms of anxiety.
2913126|NCT03158168|Experimental|study group|"The first group will receive Intralesional injection of Candidal antigen with a dose of (0.1ml -0.3ml) by insulin syringe in the largest wart at the first visit.( Only those patients who showed a positive response to the Candida test antigen).I njections will be repeated for all patients into the same lesion every 3 weeks for three treatment sessions. Follow up for next six months for any recurrences.~Storage: A 1ml multidose vial of candidal antigen (Candin) which is an intradermal test antigen, stored between 2c-8c."
2913127|NCT03158168|Active Comparator|control group|"The second group will receive an IL injection of 2%Zn sulfate with a dose of (0.1ml-0.3ml) by insulin syringe ,in the largest one .the wart is injected with the solution till blanching or bleb formation. Subcutaneous injections and acral parts such as fingers and toes will be avoided, as it may cause vascular necrosis [19]. Injections will be repeated for all patients into the same lesion every 2 weeks for three treatment sessions.Follow up for next six months for any recurrences.~Preparation of 2% zinc sulfate: A measure of 2g. of zinc sulfate powder is to be dissolved in 100 ml of sterile distilled water and autoclaved at 95c for 20 min(20)."
2913128|NCT03158155||Patients with vitamin D deficiency|1. children with vitamin D deficiency with age group from 2-5 years old
2913129|NCT03158142|Experimental|Atropine group|One drop of Atropine Sulfate 1% Oph Soln will be administered either in the morning or at night in each eye. Study measurements will be taken approximately after 1, 12, 24 and 96 hours after drop instillation. After a 2 week wash out period with no eye drops, another drop of 1% atropine sulfate ophthalmic eye drops will be administered either in the morning or night (the visit that was not taken before) and study measurements will be scheduled approximately after 1, 12 24 and 96 hours after drop instillation
2913130|NCT03158129|Experimental|Nivolumab|"Participants receive Nivolumab alone.~Surgery performed after completion of induction therapy. Operative approach and extent of surgical resection based on the treating surgeon's judgment."
2913131|NCT03158129|Experimental|Ipilimumab + Nivolumab|"Participants receive Ipilimumab and Nivolumab.~Surgery performed after completion of induction therapy. Operative approach and extent of surgical resection based on the treating surgeon's judgment."
2913133|NCT03158103|Experimental|MEK162 in combination with Pexidartinib|Pexidartinib will be administered orally by the patients on a twice daily basis throughout the treatment cycle. Pexidartinib is available in 200mg tablets. MEK162 wiIl be administered orally on a twice daily basis throughout the treatment cycle. MEK162 is available in 15mg tablets. In this phase I study all patients will have a 2-week lead in of pexidartinib therapy alone. Thereafter, pexidartinib will be administered in combination with MEK162 on a consecutive daily basis. A treatment cycle consists of 28 days. In the dose escalation portion the dose of pexidartinib and MEK 162 will depend on the dose level cohort onto which the patient is enrolled.
2913134|NCT03158090||Surgical treatment|The subject was received transnasal butterfly surgery.
2913135|NCT03158090||Drug therapy|The subject was received drug treatment including somatostatin analogues such as sandostatin and lanreotide, dopamine receptor agonists and GH receptor antagonists.
2913136|NCT03158090||Radiotherapeutics|he subject was received radiotherapy methods including radiotherapy, linear accelerator X knife, gamma knife and so on.
2913137|NCT03158077||Raltegravir + ABC/3TC|Switching or switching strategy with RAL and ABC / 3TC guidelines, 48 weeks before the start of the study
2913138|NCT03158064|Experimental|Duravalumab + Tremelimumab|Duravalumab/Tremelimumab: Durvalumab and Tremelimumab will be administered by IV every 4 weeks for up to 4 doses/cycles, then Durvalumab by IV every 4 weeks starting at Week 16 for 9 doses (total treatment duration of 12 months).
2913139|NCT03158051|Experimental|Intervention|Telephone health coaching, home blood pressure monitoring, individualized goal setting, and tailored educational materials
2913140|NCT03158051|No Intervention|Usual clinical care|Usual care arm participants will receive routine hypertension clinical care per their primary care provider.
2913141|NCT03158038|Experimental|Monovalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
2913142|NCT03158038|Placebo Comparator|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
2913143|NCT03158025|Experimental|Placebo, LEM 10 mg, SUV 40 mg, LEM 20 mg, ZOL 30 mg, LEM 30 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: Placebo (3 × placebo lemborexant [LEM] tablets; 3 × placebo zolpidem [ZOL] tablets; 2 × placebo suvorexant [SUV], over-encapsulated); LEM 10 milligrams (mg) (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
2913144|NCT03158025|Experimental|LEM 10 mg, LEM 20 mg, Placebo, LEM 30 mg, SUV 40 mg, ZOL 30 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
2913145|NCT03158025|Experimental|LEM 20 mg, LEM 30 mg, LEM 10 mg, ZOL 30 mg, Placebo, SUV 40 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets). Each treatment period will be separated by a washout interval of at least 14 days.
2913146|NCT03158025|Experimental|LEM 30 mg, ZOL 30 mg, LEM 20 mg, SUV 40 mg, LEM 10 mg, Placebo|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
2913147|NCT03158025|Experimental|ZOL 30 mg, SUV 40 mg, LEM 30 mg, Placebo, LEM 20 mg, LEM 10 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
2913183|NCT03157778|Active Comparator|Normal-weight men|Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in normal-weight men.
2913184|NCT03157765|Experimental|EMB intervention|These patients receive and endometrial biopsy
2913185|NCT03157765|No Intervention|Routine care|These patient receive routine care
2913647|NCT03154372|Other|self-guided practice|self guided practice with validated metrics
2913148|NCT03158025|Experimental|SUV 40 mg, Placebo, ZOL 30 mg, LEM 10 mg, LEM 30 mg, LEM 20 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
2913149|NCT03158012|Active Comparator|Active treatment|
2913150|NCT03158012|Placebo Comparator|Placebo treatment|
2913151|NCT03157999|Experimental|Intervention group (CAST)|Participants in the intervention group will receive the CAST hospital-to-home transition intervention in addition to usual care.
2913152|NCT03157999|No Intervention|Control group (usual care)|Participants assigned to the control group will receive usual care at discharge from hospital to home.
2913153|NCT03157986|Active Comparator|Whole Body Vibration training|Balance Training on a Vibration platform
2913154|NCT03157986|Active Comparator|Conventional Balance training|Balance Training on a Balance board
2913155|NCT03157973|Experimental|Education intervention|
2913156|NCT03157973|No Intervention|Standard of Care|
2913157|NCT03157960|Experimental|Blueberry drink|Participant will receive a blueberry drink containing 18 g of fructose and 14 g of glucose.
2913158|NCT03157960|Experimental|Blueberry and pizza|Participant will receive a blueberry drink and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
2913159|NCT03157960|Experimental|Soft beverage|Participant will receive a Soft beverage (Coca-cola containing 17,5 g fructose and 17,5 g glucose)
2913160|NCT03157960|Experimental|Soft beverage and pizza|Participant will receive a Soft beverage and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
2913161|NCT03157960|Experimental|Fructose|Participant will receive a drink containing 35 g of fructose
2913162|NCT03157960|Experimental|Fructose and pizza|Participant will receive a drink containing 35 g of fructose and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
2913163|NCT03157947|Experimental|Decision Aid|Subjects will be asked to complete baseline surveys. Once the surveys are completed, subjects will review the Decision Aid tool with a study team member. Once the subjects have gone through the tool, study team members will answer any additional questions he may have regarding the tool. The subjects will then discuss with the investigator various cancer management options, quality of life implications, and any questions the subjects may have regarding cancer management options. Subjects that are ready may make a cancer management decision at this time, or choose to wait until their next scheduled visit. Subjects will be followed at subsequent urology clinic visits for up to 6 months. Subjects will complete follow-up surveys at the 3, 6, 9 and 12 month visits.
2913164|NCT03157934||Primary CSC admission|Patients with primary admission to endovascular-ready hospital (comprehensive stroke center)
2913165|NCT03157934||Primary non-CSC SU admission|Patients with primary admission to non-endovascular-ready hospital with (regional/local) stroke unit
2913166|NCT03157934||Non-acute stroke hospital admission|Patients with primary admission to non-acute stroke-ready hospital
2913167|NCT03157908|Experimental|Smartphone app|All participants in this pilot study will install the smartphone app for testing
2913168|NCT03157895|Experimental|Program group|This group receives the Connecting program with telephone support. It's anticipated the program will take up to 14 weeks to complete.
2913169|NCT03157895|No Intervention|Comparison group|This group receives Children's Administration services as usual.
2913170|NCT03157882||Study Population|Pediatric patients presenting to the emergency department with acute painful conditions (please see inclusion and exclusion criteria)
2913171|NCT03157869|Experimental|Transcranial Direct Current Stimulation|"Intervention: anodic tDCS (20 minutes ON, intensity 2milliamps) on the primary motor cortex contralateral of the trained hand (right) simultaneously to the motor training and supraorbital cathode ipsilateral~Motor training will consist of 8 blocks with 300 repetitions of sequential finger movements performed with the right hand."
2913172|NCT03157869|Sham Comparator|Control|"Intervention: simulated anodic tDCS (30 seconds ON, intensity 2milliamps) on the primary motor cortex contralateral of the trained hand (right) simultaneously to the motor training and supraorbital cathode ipsilateral~Motor training will consist of 8 blocks with 300 repetitions of sequential finger movements performed with the right hand."
2913173|NCT03157856||Experimental: fluorescence assessment|Medical device: Use of the FEMTO-ST institute medical device to detect prostatic and non prostatic tissue.
2913174|NCT03157843||Medical Patients|Medical patients who received, at admission and during all the length of recovery, antithrombotic drugs (low-molecular-weight heparin at prophylactic dosage ).
2913175|NCT03157843||Control Group|Medical patients not treated with antithrombotic drugs during the recovery. Subjects age, sex and comorbidities matched.
2913176|NCT03157830||Ocrelizumab, OCREVUS|Patients eligible for this study will be receiving OCREVUS as part of their routine care for MS treatment, and undergo the standard monitoring tests and procedures for MS patients receiving treatment. In addition, they will complete the EDSS scale on 6 occasions over a 12-month period, and the MSIS-29 on three occasions during the 12 month period for research.
2913177|NCT03157817||Chronic Obstructive Pulmonary Disease|Patients with a diagnosis of Chronic Obstructive Pulmonary Disease
2913178|NCT03157817||Healthy Volunteers|Volunteers without any respiratory condition or symptoms
2913179|NCT03157804|Experimental|Autologous CD34+ cells transducted with PGK-FANCA-Wpre *|CD34 + cells from patients with Fanconi subtype A (FA-A) transduced ex vivo with lentiviral vector carrying the gene FANCA, PGK-FANCA-Wpre*The product to be infused consist of a suspension of transduced CD34^+ cells.
2913180|NCT03157791|Experimental|Simethicone with Bowel Prep|Group A will receive 2 simethicone tablets (180mg each) so that one tablet is taken at the same time as each bowel preparation dose.
2913181|NCT03157791|No Intervention|Control|Group B will receive no simethicone tablets.
2961568|NCT02821624|Experimental|Cohort 6|G1T38 or placebo
2913186|NCT03157739|Experimental|Evaluation of Optimized Prototype|Patients and parents will use MigraineManager to complete assessment measures at baseline and post-treatment (i.e., 2 months after baseline). Answers to these measures will determine what interventions each participant will receive. Data obtained in this phase will be used to make final modifications to MigraineManager for large scale testing.
2913187|NCT03157726|Active Comparator|TUKEP(enucleation of prostate)|"Patients accept TUKEP (transurethral plasmakinetic enucleation of prostate). The TUKEP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running, the beak of resectoscope was used to enucleation of prostate and the bipolar loop was used to cutting and coagulation, There are many manufacturers of Bipolar TURP systems. Any bipolar plasmakinetic system approved by the CFDA (Chinese food and drug administration) may be used for the study.~The bipolar plasmakinetic system was set at 160 W for cutting and 100 W for coagulation."
2913188|NCT03157726|Active Comparator|TURP(resection of prostate)|"Patients accept TURP (transurethral resection of prostate). The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system approved by the CFDA (Chinese food and drug administration) may be used for the study.~The bipolar plasmakinetic system was set at 160 W for cutting and 100 W for coagulation."
2913189|NCT03157713|Experimental|Goal-Directed|Patients will receive enhanced usual care and also be informed that they will receive goal-directed financial incentives.
2913190|NCT03157713|Experimental|Outcome-Based|Patients will receive enhanced usual care and be informed that they will receive outcome-based financial incentives for significant weight losses.
2913191|NCT03157713|Other|Control-Enhanced Usual Care|Patients will only receive enhanced usual care.
2913192|NCT03157700|Experimental|REAL media|Participants in this group will be assigned to use the REAL media curriculum.
2913193|NCT03157700|No Intervention|Programming as usual|Participants in this group will participate in 4-H programming as usual. They will have the opportunity to use the REAL media curriculum at the conclusion of the study.
2913194|NCT03157687||Healthy controls|"Blood sampling for nutrition and inflammatory status~Stool sampling before preventive gastroscopy and colonoscopy~Questionnaires about general health, gastrointestinal symptoms and 3-day food record~Collection of biopsies in duodenum during gastroscopy~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
2913195|NCT03157687||Inflammatory bowel disease (IBD)|"Blood sampling for nutrition and inflammatory status~Stool sampling before indicated gastroscopy and colonoscopy~Questionnaires about general health, gastrointestinal symptoms and 3-day food record~Collection of biopsies in duodenum during gastroscopy~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
2913196|NCT03157687||Liver transplantation recipient (LTX)|"Blood sampling for nutrition and inflammatory status~Stool sampling before indicated gastroscopy and colonoscopy for evaluation of liver transplantation (LTX)~Questionnaires about general health, gastrointestinal symptoms and 3-day food record~Collection of biopsies in duodenum during gastroscopy~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
2913197|NCT03157674||HNC patients|"HNC patients who have been diagnosed with HNC between~01-Jan-2013 and 30-Sep-2016."
2913198|NCT03157661||Single group study|"The study population will involve patients presenting for elective surgery, who fulfil inclusion criteria, in all surgical disciplines with elective surgical slates in the main theatre complex, during the period of the study.~Inclusion Criteria:~Patients included in the study will be:~> 18 years of age~Non-cardiac patients~Non-obstetric patients~Patients receiving general, neuraxial, regional or local/topical anaesthesia for elective surgical intervention"
2913199|NCT03157635|Experimental|Part 1 (Healthy Volunteers): RO7112689|Healthy participants will receive a single dose of RO7112689 in each dose-escalation cohort of Part 1. RO7112689 will be administered at a starting dose of 75 milligrams (mg). Doses are planned to be escalated up to Cohort 5.
2913200|NCT03157635|Placebo Comparator|Part 1 (Healthy Volunteers): Placebo|Healthy participants will receive a single dose of RO7112689 matching placebo in each dose-escalation cohort of Part 1.
2913201|NCT03157635|Experimental|Part 2 (PNH Participants): RO7112689|PNH participants will receive 3 single ascending doses of RO7112689 on Days 1, 8, and 22 followed by weekly RO7112689 administrations up to a maximum of 5 months. Weekly RO7112689 administrations will start no earlier than Day 36. The starting dose of Part 2 will be based on data from Part 1 of the study.
2913202|NCT03157635|Experimental|Part 3 (PNH Participants): RO7112689|PNH participants will receive RO7112689 at dose and regimen based on data from Part 2 of the study, for a maximum treatment duration of 5 months.
2913203|NCT03157635|Experimental|OLE (PNH Participants): RO7112689|PNH participants who participated in Parts 2 and 3, and who derive clinical benefit from RO7112689 may enroll into OLE. Participants will initially receive the same dose regimen as they were receiving in Parts 2 and 3, respectively followed by dose regimen based on emerging safety, PK, and PD data from Parts 2 and 3, for up to a maximum treatment duration of two years from entry into OLE.
2913204|NCT03157622|Active Comparator|Exposure in vivo|In the Exposure in vivo (EXP) condition, patients are given a careful explanation of the fear-avoidance model. Patients are encouraged to adopt the model to their individual situation. Factors for the maintenance of chronic pain (such as pain cognitions and pain-related fear) are discussed. Especially, negative consequences of avoidance behavior are highlighted. In preparation of the exposure sessions, patients develop an individual fear hierarchy using the Photo Series of Daily Actives. Subsequently, patients are encouraged to test their fear-avoidance beliefs during behavioral experiments and to reduce avoidance behaviors during individually tailored exposure exercises.
2913205|NCT03157622|Active Comparator|Cognitive Behavioral Psychotherapy|In the Cognitive Behavioral Psychotherapy (CBT) condition, patients are introduced to several strategies to improve their pain management. The principle of graded activity encourages patients to re-engage in former activities by dividing these activities into smaller steps. Predetermined resting periods are offered as a form to prevent patients from phases of excessive demands followed by long terms of recovery. Progressive muscle relaxation is introduced as a technique to improve the experience of pain. The strategy of attention shifting is presented to change their perception of pain. Maladaptive pain-related cognitions are identified and challenged by cognitive interventions.
2913207|NCT03157609|Active Comparator|Thermometry with oesophageal probe|Nasal insertion of oesophageal temperature probe in the lower fourth of the oesophagus.
2913208|NCT03157596|Experimental|intervention group|"selected randomly from a list of all the 105 special education centers registered at the State Ministry of Education, and randomly allocated into intervention group.~all the children with developmental disabilities in enrolled in the school who met the eligibility criteria were examined and all their parents were interviewed.~Caregivers' baseline knowledge and attitudes towards the oral healthcare of their children was assessed by an interview questionnaire.~examination for the children with developmental disabilities was carried out to assess caregivers' practice by assessing the oral hygiene level and amount of unmet treatment needs.~educational intervention by an Oral Health Education Program for Caregivers of Children with developmental disabilities about the oral health care of Children with DD, in the form of a short video, accompanied by demonstration & followed by an interactive discussion .~the same evaluation was carried out again 3 months after the intervention."
2913209|NCT03157596|No Intervention|control group|Evaluation of the knowledge, attitude and practice of caregivers of children with developmental disabilities towards the oral health of their children at baseline and 3 months after without any intervention.
2913210|NCT03157583|Active Comparator|Reference product (for SPFi calculation)|This arm will include all the test sites on the participants back where reference product (P3 standard sunscreen) will be applied.
2913211|NCT03157583|Experimental|Test product 1|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 1 will be applied for SPF testing.
2913212|NCT03157583|Experimental|Test product 2|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 2 will be applied for SPF testing.
2913213|NCT03157583|Experimental|Test product 3|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 3 will be applied for SPF testing.
2913214|NCT03157583|Experimental|Test product 4|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 4 will be applied for SPF testing.
2913215|NCT03157583|No Intervention|Negative control (for SPFi calculation)|This arm will include all the test sites on the participants back which will be left unprotected.
2913216|NCT03157583|Active Comparator|Reference (for UVAPFi calculation)|This arm will include test plates treated with reference sunscreen formulation S2.
2913217|NCT03157583|Other|Blank control (for UVAPFi calculation)|This arm will include blank test plates treated with glycerin.
2913218|NCT03157570|Experimental|Exercise intervention group|The exercise group will participate in a 6-month home exercise along with demonstration videos. The exercise training program is an online 7-minute high-intensity interval training (HIIT) exercise through the integrated application of an exercise provision website and mobile Apps. The program will comprise of a broad range of exercises, applied at varying speeds and directions in order to increase heart rate, and to load a variety of muscle groups and skeletal regions in the upper and lower body. The exercise will be performed 5 days per week with the remaining 2 days as rest days.
2913219|NCT03157570|No Intervention|Control group|The control group have no intervention and receives only standard care.
2913220|NCT03157557|Experimental|Lifestyle treatment|Lifestyle treatment
2913221|NCT03157557|No Intervention|Treatment as Usual|Treatment as Usual
2913222|NCT03157544|Experimental|Pain Relief Kit|Immediately following baseline data collection participants will be given the Pain Relief Kit and instructed about the contents. From this kit, a sample of Biofreeze® and TheraBand® Kinesiology Tape will be applied to the participant. The contents of the Pain Relief Kit will include four modes of non-pharmacological interventions that have been previously demonstrated to relieve musculoskeletal pain. Following Baseline data collection, participants will review the content of the Pain Relief Kit with a member of the research staff. During this review the subject will be informed about the recommended use of all the four modes of the non-pharmacological interventions included in the kit. This information will also be included in written form in the Pain Relief Kit.
2913223|NCT03157518|Experimental|Treatment Arm|Patients enrolled will receive probiotic supplementation following the first bronchoscopy for four weeks. A second bronchoscopy will be performed following probiotic administration.
2913224|NCT03157505|Active Comparator|Purethal Birch immunotherapy|Purethat Birch intervention and symptomatic treatment for 24 months
2913225|NCT03157505|Placebo Comparator|placebo and symptomatic treatment|placebo intervention and symtomatic treatment during 24 months
2913226|NCT03157492|Experimental|Aural Rehabilitation Group|The AR Group will receive six 90-minute sessions including auditory training, informational counseling, and communication strategies.
2913227|NCT03157492|Sham Comparator|Cognitive Training Group|The Cognitive Training Group will receive six 90-minute sessions including training exercises (Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Difference) to improve speed and accuracy.
2913228|NCT03157479|Experimental|Protective ventilation|Volume controlled ventilation with tidal volume 6-7 ml/kg of predicted body weight (45.5 + 0.91 (height [cm] −152.4)), FiO2 0.4 and PEEP 10 cmH2O during the whole study period. Respiratory rate will be titrated to keep end-tidal CO2 values between 30 and 40 mmHg. I:E ratio will be set in order to obtain an inspiratory time of 0.8 seconds and an inspiratory pause of 0.3 seconds and FiO2 will be kept unchanged during the whole study period. In patients in this group, recruiting maneuvers will be performed throughout a stepwise 5 cmH2O PEEP increase every 30 seconds to achieve a PEEP of 35 cmH2O during Pressure Controlled Ventilation (10 cmH2O of inspiratory pressure while keeping respiratory rate unmodified), followed by a stepwise 5 cmH2O PEEP reduction every 30 seconds until the baseline set peep is reached.
2913229|NCT03157479|Active Comparator|Standard Ventilation|Volume controlled ventilation with tidal volume 10 ml/kg of PBW (45.5 + 0.91 (height [cm] −152.4)), FiO2 0.4 and PEEP 5 cmH2O during the whole study period. Respiratory rate will be titrated to keep end-tidal CO2 values between 30 mmHg and 40 mmHg. I:E ratio will be set in order to obtain an inspiratory time of 0.8-1 seconds and an inspiratory pause of 0.3 second
2913230|NCT03157427|Experimental|CRYOBEAUTY MAINS|Cryotherapy medical device designed to treat solar lentigo on the randomized hand.
2913231|NCT03157427|No Intervention|Control|The non randomized hand is not teated.
2913232|NCT03157414|Active Comparator|Empagliflozin|10 mg once daily for 24 weeks
2913233|NCT03157414|Placebo Comparator|Placebo|1 capsule once daily for 24 weeks
2913234|NCT03157401||intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
2913235|NCT03157401||intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
2913236|NCT03157401||control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
2913237|NCT03157388|Experimental|Intervention|Combined Vancomycin and Gentamycin and Meropenem
2913238|NCT03157375|Other|0°|Implantation of the intraocular lens Vivinex p261 on axis 0°
2913239|NCT03157375|Other|45°|Implantation of the intraocular lens Vivinex p261 on axis 45°
2913240|NCT03157375|Other|90°|Implantation of the intraocular lens Vivinex p261 on axis 90°
2913241|NCT03157375|Other|135°|Implantation of the intraocular lens Vivinex p261 on axis 135°
2913242|NCT03157362|Active Comparator|Time 1|Participant will be randomly assigned to one of the four interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
2913243|NCT03157362|Active Comparator|Time 2|Participant will be randomly assigned to one of the remaining three interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
2913244|NCT03157362|Active Comparator|Time 3|Participant will be randomly assigned to one of the remaining two interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
2913245|NCT03157362|Active Comparator|Time 4|Participant will complete the remaining intervention; either Near Non-Social, Near Social, Far Non-Social, or Far Social
2913246|NCT03157349|Experimental|Experimental|The experimental group will receive the active product (Biofreeze) over the course of 1 week.
2913247|NCT03157349|Sham Comparator|Placebo|The placebo will use a product created to mimic the topical analgesic Biofreeze over the course of one week. All active ingredients have been removed.
2913248|NCT03157336|Experimental|Peer-led Intervention|Peers (community women in leading roles) training other women in the wetting method for safe processing of cassava in a non-inferiority intervention trial.
2913249|NCT03157336|Experimental|Specialist-led Intervention|Specialists (nutritionists) training other women in the wetting method for safe processing of cassava in a non-inferiority intervention trial..
2913250|NCT03157323|Other|Low Glycemic Index Diet|Following a low glycemic index diet verses a standard american diet.
2913251|NCT03157310|Experimental|Gefitinib|Gefitinib is an selective small molecule epidermal growth factor receptors (EGFRs) tyrosine kinase inhibitors (EGFR-TKI) for non-small cell lung cancer.
2913252|NCT03157297|Experimental|Enrolled|Subjects enrolled in the MARVEL study. Enrolled subjects will have the MARVEL algorithm downloaded into their implanted market released Micra device.
2913253|NCT03157284|Placebo Comparator|Placebo|Placebo Group will receive 7gr Maltodextrin
2913254|NCT03157284|Experimental|Intervention Rice Flour|The Intervention Group will receive 7gr of the experimental ingredient fermented Rice Flour
2913255|NCT03157271|No Intervention|PFPS Treatment|This arm (group of patients) will receive typical/pragmatically designed treatment for patellofemoral pain syndrome.
2913256|NCT03157271|Experimental|PFPS Plus Dry Needling Treatment|This group will receive the same typical/pragmatically designed treatment for patellofemoral pain syndrome but with the addition of a dry needling intervention.
2913257|NCT03157258|Experimental|Social Network Endorsement|All participants will receive a brief single care-related counseling session and referral to HIV medical care upon enrollment. After randomization to this arm, all members of HIV+ social networks will attend a multi-session group intervention during which they will be trained to deliver messages endorsing compliance with medical guidelines and adherence to medical treatment regimens to friends. Additionally, these leaders will be trained how to deliver effective messages.
2913258|NCT03157258|Active Comparator|HIV Counseling and Referral to Care|All study participants will receive a brief single care-related counseling session and referral to HIV medical care at baseline.
2913259|NCT03157245||participant|
2913260|NCT03157232|Experimental|Test Group|All subjects are enrolled into the test group and all subjects received both the Rainbow DCI and R1-25 sensor.
2913261|NCT03157206||DME patients treated with aflibercept|angiography by ultrawide field
2913262|NCT03157193|Experimental|Test Group|Hyaluronic acid gel 0.2% at baseline and later home applications by the patients during 45 days.
2913263|NCT03157193|Sham Comparator|Control 1 Group|Hydroxypropyl guar based gel, without any biological effect.
2913264|NCT03157193|No Intervention|Control 2 Group|No gel application, only standard perimplantitis treatment.
2913265|NCT03157180||Test group|general anesthesia There is allergic reaction during anesthesia Sign informed consent
2913266|NCT03157180||Control group|general anesthesia There is no allergic reaction during anesthesia Sign informed consent
2913267|NCT03157167|Experimental|100 mcg/5 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
2913268|NCT03157167|Experimental|100 mcg/10 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 10 mCi.
2913269|NCT03157167|Experimental|200 mcg/5 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 200 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
2913270|NCT03157167|Experimental|200 mcg/10 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 200 micrograms of Tc99m tilmanocept radiolabeled with 10 mCi.
2913271|NCT03157167|Experimental|400 mcg/5 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 400 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
2913272|NCT03157167|Experimental|400 mcg/10 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 400 micrograms of Tc99m tilmanocept radiolabeled with 10 mCi.
2913273|NCT03157154||First group|Haemophilia patients with history of either cardiovascular disease or atrial fibrillation undergoing an antiplatelet or anticoagulant prophylaxis
2961569|NCT02821624|Experimental|Cohort 7|G1T38 or placebo
2913274|NCT03157154||Control group|Haemophilia patient without such history or treatment matched on age and disease status (haemophilia A or B and the severity of the disease : severe, mild, minor).
2913275|NCT03157141||Control group, CG|For the purpose of the study, forty subjects for each group will be recruited. The control group (CG group) (so-called healthy subjects) CG will be recruited following the recruitment of the AA group and of the TAR group, as a sex, age and BMI matched design will be pursued. Inclusion criteria for the CG group are no history of orthopaedic lower limb surgery and absence of any known neurological or systematic disease.
2913276|NCT03157141||Total ankle replacement group (TAR group)|The number of AA and TAR subjects used in a majority of studies to analyze the functional repercussion of an ankle arthrodesis or a total ankle replacement varied between 10 and 35 subjects.
2913277|NCT03157141||Ankle arthrodesis group (AA group)|The number of AA and TAR subjects used in a majority of studies to analyze the functional repercussion of an ankle arthrodesis or a total ankle replacement varied between 10 and 35 subjects
2913278|NCT03157128|Experimental|LOXO-292|Phase 1 - Multiple doses of LOXO-292 Phase 2 - The maximum tolerated dose (MTD)/recommended dose from Phase 1
2913279|NCT03157115|Experimental|HFrEF: Heart failure - reduced ejection fraction|Patients with heart failure and reduced ejection fraction (around 35%).
2913280|NCT03157115|Active Comparator|Control|Patients with a cardiac condition but a normal ejection fraction (>45%), without heart failure. The patients from the HFrEF group will be matched with patients from the control group for sex, age, BMI and cardiovascular treatment.
2913281|NCT03157102|Experimental|HFNC group|
2913282|NCT03157102|Other|Standard Oxygen Therapy group (STO group)|
2913283|NCT03157089|Experimental|All patients|
2913284|NCT03157076|Active Comparator|Pacing mode with CLS|
2913285|NCT03157076|Active Comparator|Intrinsic mode|
2913286|NCT03157063||Inactive, normal weight|Less than 30 minutes per day of moderate to vigorous physical activity (MVPA), and body mass index percentile (BMI%) between 5th to 75th percentile.
2913287|NCT03157063||Inactive, overweight/obese|Less than 30 minutes per day MVPA, BMI% between 85th and 99th.
2913288|NCT03157063||Active, normal weight|More than 60 minutes per day MVPA, BMI% between 5th and 75th.
2913289|NCT03157063||Active, overweight/obese|More than 60 minutes per day MVPA, BMI% between 85th and 99th.
2913290|NCT03157037|Experimental|Treatment HMed-IdeS|IdeS intravenous infusion 0.25 mg/kg BW intravenous infusion
2913291|NCT03157024|Experimental|Sham Press Needle - Ring Sham (RS)|A sterilised stainless steel press needle that only has the ring-shaped head of needle without needle body has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body while maintaining identical appearance and the third layer is attached to skin. RS will be placed on 1 cm medial to acupoint LI11 and ear wrist, a non-specific control auricular acupoint used in the previous literature of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
2913292|NCT03157024|Active Comparator|Real Needle (RN)|A sterilised stainless steel press needle (diameter 0.18 mm X length 1.5 mm, Dongbang Acupuncture Inc., Boryeong, Chungcheongnam-do, Korea) has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body and the third layer is attached to skin. RN will be placed on acupoint LI11 and ear shenmen of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
2913293|NCT03157024|Sham Comparator|Kim Sham (KS)|A sterilised stainless steel press needle (diameter 0.18 mm X length 1.5 mm, Dongbang Acupuncture Inc., Boryeong, Chungcheongnam-do, Korea) with a blunted tip has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body while maintaining identical appearance and the third layer is attached to skin. KS will be placed on 1 cm medial to acupoint LI11 and ear wrist, a non-specific control auricular acupoint used in the previous literature of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
2913294|NCT03157011|Experimental|Global symptom score (GSS) questionary|systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary.
2913295|NCT03156972|Active Comparator|Group a|
2913296|NCT03156972|Active Comparator|Group b|
2913297|NCT03156959|Experimental|EMDR plus CBT-Eb|"20 CBT-Eb sessions will be mandatory for patients with BMI>17.5 and 40 CBT-Eb sessions will be mandatory for patients with BMI≤17.5. In the EMDR plus CBT-Eb arm, 16 EMDR sessions will be mandatory in adjunction to the CBT-Eb sessions, irrespectively of the BMI. EMDR will use an eight-phase approach that will include having the patient recall distressing images while receiving one of several types of bilateral sensory input, such as side to side eye movements.~Patients will follow psychopharmacological treatment for anxiety and depression symptoms if needed, and their parents will be invited to participate to a cycle of eight family meetings on eating disorders and psychological support following ECHO approach (Rhind et al., 2014)."
2913298|NCT03156959|Active Comparator|CBT-Eb alone|"20 CBT-Eb sessions will be mandatory for patients with BMI>17.5 and 40 CBT-Eb sessions will be mandatory for patients with BMI≤17.5.~Patients will follow psychopharmacological treatment for anxiety and depression symptoms if needed, and their parents will be invited to participate to a cycle of eight family meetings on eating disorders and psychological support following ECHO approach (Rhind et al., 2014)."
2913299|NCT03156946|Experimental|Breastfeeding support program|
2913300|NCT03156946|Other|Usual or routine care|
2913301|NCT03156933||Splicing variants|Sample of acute myeloid leukaemia primary cells
2913302|NCT03156920|Active Comparator|Sumatriptan|Headache is induced with Cilostazol. This headache is pre-treated double-blinded with 2 tablets of sumatriptan 50 mg
2913303|NCT03156920|Placebo Comparator|Placebo|Headache is induced with Cilostazol. This headache is pre-treated double-blinded with 2 tablets of placebo
2913304|NCT03156907|Experimental|Chronic pain patients|The primary objective of this study is to assess the success rate at 6 months of opioid temporary rotation by High Dosage Buprenorphine (BHD) taper dose in chronic non cancer pain patients (CNCP) with physical withdrawal symptoms making opioid withdrawal impossible.
2913347|NCT03156595|Experimental|Hypnosis session|Hypnosis sessions with nurses or psychologists, with deepening sessions to facilitate self-hypnosis learning.
2913305|NCT03156881|Experimental|Treatment group|"The participants in the treatment group (anticipating 24) will be receiving four global osteopathic treatments in a six week period alongside their standard care. Their standard care is to improve diet and increase exercise.Blood work done about every 3 months to check liver enzyme levels to observe improvements or monitor severity of the disease.~This group will also complete questionnaires evaluating their quality of life (CLDQ) and their readiness to change before and after the treatment series."
2913306|NCT03156881|No Intervention|Control Group|This group will have an anticipated 24 participants and will continue their standard care as explained above along with completing two questionnaires evaluating their quality of life and readiness to change. This group will not be receiving any osteopathic treatment.
2913307|NCT03156855|Experimental|sequential therapy for 14 days (S14)|14 day sequential therapy
2913308|NCT03156855|Active Comparator|bismuth quadruple therapy (Q10)|Bismuth quadruple therapy
2913309|NCT03156842|Experimental|Fimasartan/Amlodipine, Rosuvastatin|Co-administration of a fixed dose combination of Fimasartan/Amlodipine and Rosuvastatin
2913310|NCT03156842|Active Comparator|Fimasartan/Amlodipine|a fixed dose combination of Fimasartan/Amlodipine
2913311|NCT03156842|Active Comparator|Fimasartan, Rosuvastatin|Co-administration of Fimasartan and Rosuvastatin
2913312|NCT03156829|Experimental|Splint alone|
2913313|NCT03156829|Experimental|Cortico-steroid alone|
2913314|NCT03156829|Experimental|Splint and cortico-steroid combined|
2913315|NCT03156816|Experimental|Colchicine|The patients will receive an oral bolus of colchicine of 2 mg followed by 0.5 mg b.i.d. during 5 days.
2913316|NCT03156816|Placebo Comparator|Control arm|The patients will receive an oral bolus of placebo of 2 mg followed by 0.5 mg b.i.d. during 5 days.
2913317|NCT03156803|Experimental|Healthy eating blog (HEB)|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
2913318|NCT03156803|No Intervention|Control|Mothers randomised to the control group will not have access to the healthy eating blog.
2913319|NCT03156790|Experimental|Spectrila®|recombinant L-Asparaginase
2913320|NCT03156764||Qp/Qs ratio monitoring|
2913321|NCT03156738|Experimental|Dose 1|MT-2990 or Placebo
2913322|NCT03156738|Experimental|Dose 2|MT-2990 or Placebo
2913323|NCT03156738|Experimental|Dose 3|MT-2990 or Placebo
2913324|NCT03156738|Experimental|Dose 4|MT-2990 or Placebo
2913325|NCT03156738|Experimental|Dose 5|MT-2990 or Placebo
2913326|NCT03156725|Experimental|Ferrous Sulfate|The ferrous sulfate group was required to consume a test containing ferrous sulfate (10 mg of 57Fe). Participants received a meal containing 17.6 g egg albumin, 45 g corn syrup solids, 17.5 g corn oil, 6 ml vanilla extract, and 100 ml of distilled water.
2913327|NCT03156725|Experimental|Aspiron|The Asprion group was required to follow the same protocol as the 57Fe experimental group, with the exception of taking A. Oryzae containing (8 mg natural abundace Fe and 2 mg 58Fe. Meals composition was similar to ferrous sulafte group.
2913328|NCT03156712|Experimental|FeSO4|Ferrou sulfate: Each participant was given a one time oral dose of the 10 mg iron as ferrous sulfate with the test meal (described in study design) and serum iron was measured every 30 min for 4 hours.
2913329|NCT03156712|Experimental|ASP Fe (10 mg)|ASP (10 mg Fe): Each participants was given a one time oral dose of ASP containing 10 mg iron. The capsule was consumed with the test meal and serum iron was measured every 30 min for 4 hours.
2913330|NCT03156712|Experimental|ASP Fe (20 mg)|ASP (20 mg Fe): Each participant was given a one time oral dose ASP containing of 20 mg iron The capsule was consumed with the test meal and serum iron was measured every 30 min for 4 hours.
2913331|NCT03156699||STEMI patients treated with primary PCI|Database analysis only
2913332|NCT03156686|No Intervention|Control|Patients will be randomly assigned to conventional hospital care
2913333|NCT03156686|Experimental|Home care treatment|Patients will be randomly assigned to the HOME-based hospitalization and treated with intravenous diuretics. Following discharge within 48 hours from the hospital, patients in the HC group will be treated at home.
2913334|NCT03156673|Experimental|bronchial basal cells|Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
2913335|NCT03156660|Experimental|Weight gain prevention (Group 1)|Small Changes weight stability intervention
2913336|NCT03156660|Experimental|Weight loss intervention (Group 2)|Look AHEAD weight loss intervention
2913337|NCT03156660|Active Comparator|Self-guided intervention (Group 3)|Self-guided weight management with the EatingWell Diet book
2913338|NCT03156647||idiopathic Parkinson disease|
2913339|NCT03156647||iatrogenic parkinsonian syndrome|
2913340|NCT03156634|Experimental|PALS|Participants will view materials about the antihypertensive, chlorthalidone on the Patient Activated Learning System (PALS).
2913341|NCT03156634|Active Comparator|WedMD|Participants will view materials about the antihypertensive, chlorthalidone on WebMD.
2913342|NCT03156621|Experimental|Alirocumab SC Q2W|"Alirocumab SC every 2 weeks (Q2W) from baseline (day 1) through week 10 during the double-blind treatment period~Starting at week 12, and continuing through week 22, participants will receive open-label alirocumab SC Q2W"
2913343|NCT03156621|Experimental|Placebo SC Q2W|"Matching placebo SC Q2W from baseline through week 10 during the double-blind treatment period~Starting at week 12, and continuing through week 22, participants will receive open-label alirocumab SC Q2W"
2913344|NCT03156608|Experimental|Novii Device ECG/EMG System|These patients will have the Novii ECG/EMG system placed throughout labor and delivery, unless a provider or investigator determines that a different device (internal or external) is necessary for a better signal.
2913345|NCT03156608|Active Comparator|Standard of Care External Monitor|A standard external monitor will be placed throughout labor and delivery, unless a provider or investigator determines that an internal device is necessary for a better signal.
2913346|NCT03156595|Placebo Comparator|Nurse interview|Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
2913348|NCT03156582||"all participants included Milan criteria  and AFP score"|"The first arm is made of liver recipients or dropped off list patients at the time of the Milan criteria (fixed until 2013/06/01 for transplanted patients because mandatory three months reevaluation of patients obliged the various teams to respect the criteria at this time, but until 2013/03/01 for dropped off patients because we did not want to count dropped of because of the AFP score in this arm).~The second arm is made of liver recipients or dropped off list patients at the time of the AFP score (fixed after 2013/06/01)for transplanted patients and after 2013/03/01 for dropped off patients)"
2913349|NCT03156556|Experimental|Mood Mechanic|"The Mood Mechanic Course is comprised of five online lessons completed over an 8-week period.~Lesson 1 presents information on anxiety and depression as well as on the cycle of symptoms.~Lesson 2 presents different strategies to generate helpful cognitions.~Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.~Lesson 4 describes avoidance and safety behaviors and graded exposure.~Lesson 5 is about problem solving and relapse prevention.~For each lesson, a Do It Yourself guide is included containing homework as well as case stories. Additional material on different topics is also included such as structured problem solving."
2913350|NCT03156543|Experimental|Group A|This group will have the jumpstart dressing pre-operatively and a standard dressing post operatively.
2913351|NCT03156543|Experimental|Group B|This group will have the jumpstart dressing pre-operatively and a jumpstart dressing post operatively.
2913352|NCT03156530|Experimental|Auricular acupuncture|Stimulated with needles at three joint points of the lower limb, knee and ankle. Balance assessments will be performed prior to (initial) pacing, 20 minutes after the initiation of the pacing protocol (second evaluation) and after 5 minutes the final evaluation.
2913353|NCT03156530|Placebo Comparator|Control|Not receive stimulation.
2913354|NCT03156517|Active Comparator|Deep Brain Stimulation in VIM|Patients receive stimulation in the VIM-nucleus of the thalamus
2913355|NCT03156517|Active Comparator|Deep Brain Stimulation in PSA|Patients receive stimulation in the posterior subthalamic area
2913356|NCT03156504|Experimental|Ketamine|Subjects will receive three IV Ketamine Hydrochloride infusions (0.5 mg/kg, infused over 100 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers) and following ketamine treatment (change biomarkers).
2913357|NCT03156491||Recurrent miscarriage group|Women with unexplained recurrent miscarriages (three or more first trimester miscarriages).
2913358|NCT03156491||Control group|Proven fertile women (at least 1 successful pregnancy and no more than 1 miscarriage).
2913359|NCT03156478|No Intervention|Control group|At baseline, individuals in the control group receive digital information package about lifestyle risk factors of type 2 diabetes with recommendations on healthy diet and physical activity in accordance with the Finnish Nutrition Recommendations and the national recommendation for health enhancing physical activity.
2913360|NCT03156478|Experimental|Digital lifestyle intervention group|Participants are instructed to use a digital self-help tool for 12 months. This tool is developed in the StopDia-study to enact positive changes in participantʼs health behaviour. The digital intervention consists of 2 components which motivate, enable and trigger the participants to improve their health behaviours. B.J. Fogg's Tiny Habits -ideology. The digital intervention is based on the Fogg Behaviour Model (FBM) and the Behaviour Wizard.
2913361|NCT03156478|Experimental|Combined digital and face-to-face lifestyle intervention group|Participants are using the StopDia digital solution tool as described above. In addition, they have six face-to-face group coaching (6-15 participants/group) sessions at local health centers facilitated by trained nurses. The face-to-face group intervention is based on the Self-Determination Theory and theories of self-regulation, and delivered using intrinsic motivational coaching approach designed and tested in the GOAL lifestyle intervention, and further developed in several other studies in Finland and internationally.
2913362|NCT03156465|Experimental|Hybrid L24 and Standard CI|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
2913363|NCT03156452|Experimental|Steroid & Mycophenolate mofetil 1st line|Mycophenolate mofetil: 1 gm bd Non-IMP Steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
2913364|NCT03156452|Active Comparator|Prednisolone (Steroid) alone 1st line|Non-IMP steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
2913365|NCT03156439|Experimental|BIS-001 ER|The subjects will be dosed twice daily (BID); in an on-site setting at dose initiation and at times of dose escalation to evaluate safety, and for specimen collection for routine laboratory and pharmacokinetic analysis. Subjects will be discharged and compliance of BID dosing will be monitored via twice daily phone calls by site staff. The initial dose will be 0.5mg BID with a dose escalation every 2-3 days until a maximum tolerated dose is observed or a maximum of 2.5mg BID dose is obtained.
2913366|NCT03156426||Study population|Adults with a histological, clinical or radiological diagnosis of cirrhosis who are admitted to RIE over a 4-month period will be approached by a member of their clinical care team for potential participation. Eligible patients may be recruited from accident and emergency, the acute medical unit, hepatology ward, high dependency or intensive care units. Recurrent admissions are common, so only the first admission for each recruited patient will be included. Patients will be monitored to identify acute kidney injury (AKI) during admission.
2913367|NCT03156413|Experimental|F&P Nasal Mask|Trial nasal pillows CPAP mask
2913368|NCT03156400|Active Comparator|Parkinson's disease|"Men and women can be included in the study if they are between 50 and 85 years of age and meet the following criteria:~Have received clearance from a primary physician to perform a exercise stress test.~Will be able to walk on a motorized treadmill with supporting harness system. Individual with PD who has recently had a diagnosis of Stage 1 or 2 on the Hoehn and Yahr scale."
2913369|NCT03156400|Active Comparator|Healthy Control|"Men and women can be included in the study if they are between 50 and 85 years of age and meet the following criteria:~Have received clearance from a primary physician to perform a exercise stress test.~Will be able to walk on a motorized treadmill with supporting harness system. Healthy individual with no unresolved cardiovascular, neuromuscular, and/or musculoskeletal disease."
2913502|NCT03155464|Other|Group 2|"Order of two elements of surgical procedure: Patients in group 2 will receive bypass prior to sympathectomy during the surgical procedure.~Indocyanine Green (ICG) will be used in both groups."
2913370|NCT03156387|Experimental|Diode laser|A 2.8 W, 980 nm diode laser(Sirona Advanced) in continuous wave mode with an air cooling handpiece was used in the alternative frenectomy technique. The frenulum was held with a hemostat, and a repeated continuous wave mode was applied for the excision. It was also used to remove the periosteal adhesion. The remnants of the ablated tissue were removed with saline, and no sutures were placed after the diode laser treatment.
2913371|NCT03156387|Active Comparator|Scalpel|(1) topical anesthesia (20% benzocaine), (2) local anesthesia using the bilateral vestibular infiltration technique, with 0.6 ml (1/3 of the carpule contents) of 4% articaine and 1:200,000 epinephrine, (3) hemostatic clamping of the frenulum, (4) excision of the whole band of tissue, together with its alveolar attachment, with a 15C scalpel blade, (5) relaxation and unbending of any fibrous adhesions to the underlying periosteum, and (6) simple suturing with 5-0 silk thread
2913372|NCT03156374|Experimental|Ovulation test use|Use of both ovulation tests and standardised care
2913373|NCT03156361|Experimental|HDV insulin lispro 100 UNIT/mL|Hepatic Directed Vesicle (HDV) is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
2913374|NCT03156361|Active Comparator|Insulin Lispro 100 UNIT/mL|Sterile Water for Injection (SWFI) is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
2913375|NCT03156348|Experimental|Intervented|The intervention group will receive in addition to the usual care, it will receive the Clinical Pharmacist Care during hospitalization, discharge and during 2 months post-discharge, through a home visit at 30 ± 5 days post-discharge and a telephone call at 60 ± 5 days.
2913376|NCT03156348|No Intervention|Control|"The control group will receive hospital care and discharge from a clinical team previously trained in geriatric clinical pharmacology, which includes epicrisis, indications that the physician deems pertinent to the discharge and prescriptions if necessary and a medical control at 15 days post-discharge.~Information will be collected that allows the characterization:~Sociodemographic~Morbid~Pharmaco-therapeutic~Functionality before (baseline), during and after hospitalization~A physician, a pharmacist and an occupational therapist, blind to the treatment assignment, will collect the records using a specially designed record. Post-discharge evaluations will be conducted through telephone interviews at 30, 60 and 90 days after hospital discharge."
2913377|NCT03156335|Experimental|Focused Ultrasound|
2913378|NCT03156322|Active Comparator|Group 5|5 mL epidural initiation volume (bupivacaine + fentanyl)
2913379|NCT03156322|Active Comparator|Group 10|10 mL epidural initiation volume (bupivacaine + fentanyl)
2913380|NCT03156322|Active Comparator|Group 20|20 mL epidural initiation volume (bupivacaine + fentanyl)
2913381|NCT03156296|Active Comparator|BUPIVACAINE|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
2913382|NCT03156296|Active Comparator|DEXMEDETOMIDINE|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
2913383|NCT03156283|Experimental|SleepWell24 Application|A mobile health smartphone application based on evidence-based health behavior change theory and interventions to promote adherence to positive airway pressure therapy
2913384|NCT03156283|Other|Usual Care Plus Activity Monitor|Per usual clinical care standards within the Center for Sleep Medicine at Mayo Clinic Arizona, all patients will receive instructions/education on positive airway pressure (PAP) use, multiple mask fittings, encouragement to use PAP every night, and staff is available in the event of problems. Control patients will also receive a wearable activity monitor to use during the study. The wearable sensor will be used to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
2913385|NCT03156270|Experimental|Vivaer Stylus|Thermal treatment of the submucosal tissue including cartilage in the internal nasal valve area
2913386|NCT03156257||Self-reported healthy males and females|The investigators are interested in sampling a wide variety of individuals from varying ethnic groups, sex, and age range.
2913387|NCT03156244||Caucasian|This cohort will consist of 40 white patients who are receiving either radiation or surgery for treatment of their prostate or bladder cancer.
2913388|NCT03156244||African American|This cohort will consist of 40 African American patients who are receiving either radiation or surgery for treatment of their prostate or bladder cancer.
2913389|NCT03156231|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
2913390|NCT03156231|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
2913391|NCT03156218|Experimental|Without ARDS|"Patients admitted to the ICU after cardiac surgery with a PaO2/FiO2 ratio > 300.~Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%."
2913392|NCT03156218|Experimental|With mild to moderate ARDS|"Patients admitted to the ICU after cardiac surgery with a PaO2/FiO2 ratio > 100 and < 300.~Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%."
2913393|NCT03156205|Experimental|Interactive Music Therapy|
2913394|NCT03156205|Other|passive music listening|
2913395|NCT03156205|Other|passive earphone-use|
2913396|NCT03156192|Experimental|Caregivers of ICU patients|Caregivers (family member) aged over 20 who provides care to ICU patients
2913397|NCT03156179||Girls with type 1 diabetes|
2913398|NCT03156166|Experimental|Ambu AuraGain|Ambu AuraGain is inserted in children undergoing general anesthesia. The size of AuraGain is as follows: size 1 for children <5 kg, size 1.5 for 5-10kg, size 2 for 10-20kg, size 2.5 for 20-30kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
2913399|NCT03156166|Experimental|I-gel|I-gel is inserted in children undergoing general anesthesia. The size of I-gel is as follows: size 1 for children weighing 2-5kg, size 1.5 for 5-12kg, size 2 for 10-25kg, size 2.5 for 25-35kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
2913503|NCT03155451||Epithelial ovarian cancer|patients receive the ctDNA methylation markers screening
2913400|NCT03156166|Experimental|Air-Q intubating laryngeal airway (ILA)|Air-Q ILA is inserted in children undergoing general anesthesia. The size of Air-Q ILA is as follows: size 1 for children between 4-7 kg, size 1.5 for 7-17kg, size 2 for 17-30kg, size 2.5 for 30-50kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
2913401|NCT03156153|Experimental|Bumetanide group|Double-blind phase: in the first 3 months, patients will receive the experimental treatment - bumetanide, oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, all the patients will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
2913402|NCT03156153|Placebo Comparator|Control group|Double-blind phase: in the first 3 months, patients will receive the placebo - oral intake, 0.5mg/time, twice a day; After the 3 months in the double blind trial (bumetanide versus placebo), all the Open-label phase: after 3 month double-blined treatment, patients in this group will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
2913403|NCT03156140|Experimental|motion|Right hand performs three different motion types
2913404|NCT03156127|Experimental|BR-UPS 5 mg tablet|
2913405|NCT03156127|Active Comparator|Inisia 5 mg tablet|
2913406|NCT03156114|Experimental|Part I - Dose--Escalation|
2913407|NCT03156114|Experimental|Part II - Dose-Expansion|
2913408|NCT03156101|Experimental|BinD19|BinD19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity. Minimum/maximum dose: 1x10^6/kg / 1x10^7/kg administered to patients with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma.
2913409|NCT03156088||Overactive Bladder Patients|"Overactive bladder patients treated with sacral neuromodulator InterStim"
2913410|NCT03156075|Experimental|Intervention group|"This group will receive the nutrition and exercise program intervention. Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn.~and the first one will start before discharge. The patients will receive a leaflet to describe the instructions."
2913411|NCT03156075|No Intervention|Control group|This group will be selected from the previous three months, they didn't receive any intervention and received the usual care postoperative.
2913412|NCT03156062|Experimental|study group|
2913413|NCT03156062|Active Comparator|control group|
2913414|NCT03156049|Active Comparator|Sphenopalatine block|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
2913415|NCT03156049|Active Comparator|Greater occipital nerve block|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
2913416|NCT03156036|Experimental|MGMT hypermethylated Cohort A|MGMT hypermethylated Cohort A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=86)
2913417|NCT03156036|Active Comparator|MGMT hypermethylated B|MGMT hypermethylated B Cohort patients will be randomised into preoperative CRT with capecitabine arms. (n=86)
2913418|NCT03156036|Active Comparator|MGMT unmethylated A|MGMT unmethylated A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=37)
2913419|NCT03156036|Active Comparator|MGMT unmethylated B|"MGMT unmethylated B patients will be randomised into preoperative CRT with capecitabine arms.~(n=37)"
2913420|NCT03156023|Active Comparator|Active|Receive active investigational product (AMG 570).
2913421|NCT03156023|Placebo Comparator|Placebo|Receive placebo investigational product
2913422|NCT03156010|Other|TBI Group|Subjects with history of TBI will undergo testing with all three devices.
2913423|NCT03156010|Other|Control Group|Subjects with no history of TBI will undergo testing with all three devices.
2913424|NCT03155997|Experimental|Abemaciclib + Standard Adjuvant Endocrine Therapy|Abemaciclib administered orally and standard adjuvant endocrine therapy administered according to package label.
2913425|NCT03155997|Other|Standard Adjuvant Endocrine Therapy|Standard adjuvant endocrine therapy administered according to package label.
2913426|NCT03155984||Anti-CD20 antibody|Patients with hematological malignancies receiving anti-CD20 antibody therapy
2913427|NCT03155971|Experimental|PCB group|Prospective, single center, single-group clinical study. Interventions: Patients in the PCB group will be treated (angioplasted) with Paclitaxel-Coated Balloon (SeQuent ® Please; B.Braun, Melsungen, Germany)
2913428|NCT03155945|Experimental|APD371 low dose treatment|
2913429|NCT03155945|Experimental|APD371 high dose treatment|
2913430|NCT03155932|Experimental|APD334|APD334 active treatment for 24 weeks.
2913431|NCT03155919|Experimental|TAUchoc|Treatment composed by taurine powder and chocolate milk
2913432|NCT03155919|Placebo Comparator|PLAchoc|Treatment composed by placebo (starch powder) and chocolate milk
2913433|NCT03155906|Experimental|Integrated treatment|Patients randomised to receive integrated treatment will be counselled on treatment by physician working at MAR outpatient clinic where patient receive OST care, and will receive medication and follow-up at the same MAR outpatient clinic. Treatment medication will be given in line with national guidelines with a close and integrated follow-up.
2913434|NCT03155906|Active Comparator|Standard treatment|Those randomised to receive standard treatment will be offered referral for standard HCV treatment at a medical ward hospital clinic. Treatment medication will be given in line with national guidelines.
2913435|NCT03155893|Experimental|Panel 1: Treatment A|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily from Day 1 to 16 along with single dose of AL-335 placebo (matching 1200 milligram [mg] AL-335 [3*400 mg tablets]) on Day 15 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 15 and 16 along with moxifloxacin 400 mg (1*400 mg capsule) single dose on Day 2 orally under fed conditions.
2913472|NCT03155620|Experimental|Subprotocol A (NTRK1, NTRK2, or NTRK3 gene fusion)|Patients with a NTRK1, NTRK2, or NTRK3 gene fusion receive Trk inhibitor LOXO-101 PO or via nasogastric- or gastric-tube BID on days 1-28. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
2961570|NCT02821624|Experimental|Cohort 8|G1T38 or placebo
2913436|NCT03155893|Experimental|Panel 1: Treatment B|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily from Day 1 to 16 along with single dose of AL-335 placebo (matching 1200 milligram [mg] AL-335 [3*400 mg tablets]) on Day 15 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 2 and 15 along with moxifloxacin 400 mg (1*400 mg capsule) single dose on Day 16 orally under fed conditions.
2913437|NCT03155893|Experimental|Panel 1: Treatment C|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily on Day 1 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 2, 15 and 16 along with ODV 25 mg (1*25 mg tablet) and SMV 150 mg (2*75 mg capsule) once daily on Day 2 to 16 and AL-335 1200 mg (3*400 mg tablet) single dose on Day 15 orally under fed conditions.
2913438|NCT03155893|Placebo Comparator|Panel 2: Treatment E|Participants will receive ODV placebo (matching 200 mg ODV [4*50 mg tablets]) on Days 1 and 2; ODV placebo (matching 125 mg ODV [2*50 mg tablets + 1*25 mg tablets]) on Days 3 to 7; and ODV placebo (matching 100 mg ODV [2*50 mg tablets] on Days 8 to 14, orally once daily under fed conditions.
2913439|NCT03155893|Experimental|Panel 2: Treatment F|Participants will receive ODV 200 mg (4*50 mg tablets) on Days 1 and 2; ODV 125 mg (2*50 mg tablets + 1*25 mg tablets) on Days 3 to 7, and ODV 100 mg (2*50 mg tablets) on Days 8 to 14, orally once daily under fed conditions.
2913440|NCT03155867|Active Comparator|Meal replacement A|
2913441|NCT03155867|Active Comparator|Meal replacement B|
2913442|NCT03155867|Active Comparator|Meal replacement C|
2913443|NCT03155867|Active Comparator|Meal replacement D|
2913444|NCT03155867|Active Comparator|Meal replacement E|
2913445|NCT03155867|Active Comparator|Meal replacement F|
2913446|NCT03155854|Active Comparator|Pretendinous cord excision|Patients will undergo either a targeted palmar fasciectomy procedure in which the involved Dupuytren's fascia will be excised
2913447|NCT03155854|Active Comparator|Division/manipulation of the cord|patients will undergo either a targeted palmar fasciectomy procedure in which the involved Dupuytren's fascia will be incised.
2913448|NCT03155841|Experimental|Life Skills Coaching|Participants in the experimental arm will receive access to HIV prevention and life skills content, including opportunities for goal setting, a directory of local resources in their community, and the ability to discuss their goals with Youth Navigators through a video-chat function.
2913449|NCT03155841|Active Comparator|Community Resources|Participants in the control arm will receive access to a directory of local resources in their community.
2913450|NCT03155815||Derivation Cohort|Eligible respondents to the combined 2001, 2003, 2005 and 2007 Canadian Community Health Surveys, conducted by Statistics Canada.
2913451|NCT03155815||Validation Cohort|Eligible respondents to the 2008/2009 Canadian Community Health Survey.
2913452|NCT03155789||Low Back Pain emanating from L4-5|"S TLIF at L4-5 (n=10)~MI TLIF at L4-5 (n=10)~XLIF at L4-5 (n=10)"
2913453|NCT03155789||Low Back Pain emanating from L5-S1|"S TLIF at L5-S1 (n=10)~MI TLIF at L5-S1 (n=10)~XLIF at L5-S1 (n=10)"
2913454|NCT03155789||Low Back Pain emanating from L4-5 and L5-S1|"S TLIF at L4-5 and L5-S1 (n=10)~MI TLIF at L4-5 and L5-S1 (n=10)~XLIF at L4-5 and L5-S1 (n=10)"
2913455|NCT03155776||GUS_infants|Infants patient undergoing general anesthesia for abdominal surgery
2913456|NCT03155750|Experimental|Zero Time Exercise training|Subjects in this group will attend two 2-hour ZTEx training lessons. Each subject will receive a handout and an exercise log. The handout includes a picture-illustrating ZTEx step-by-step protocol. The exercise log is for them to record their time spending on performing the ZTEx every day during the 8-week study period.
2913457|NCT03155750|Active Comparator|sleep hygiene education|Subjects in this group will receive two 2-hour lessons of sleep hygiene education delivered by a registered nurse.
2913458|NCT03155737|Experimental|Self-acupressure Training|Subjects in the self-administered acupressure exercise group will receive two 1.5 hours acupressure training sessions. The training will be conducted in a group format with 4-7 subjects per group. Each subject will then receive a handout and an acupressure log. The handout includes a picture-illustrating acupressure step-by-step protocol. They will be told to perform the self-acupressure twice per day for 6 weeks.
2913459|NCT03155737|Active Comparator|Knee Health Education|Subjects in the health education control group will receive knowledge related to knee OA. The health education will be conducted in a talk format for 1.5 hours for two sessions.
2913460|NCT03155724|Experimental|MultiPole Pacing|Traditional biventricular pacing CRT non-responders at the 3 or 6 month QP ExCELs study follow-up.
2913461|NCT03155711|Experimental|HFNC|HFNC with a 60 liters per minute flow will be given to the patients before anesthesia induction and before extubation at the end of the surgery
2913462|NCT03155711|Active Comparator|Standard|This patients will be managed as usual care. Pre-oxygenation before induction will be performed with supplemental oxygen but without positive pressure. After extubation patients will be oxygenated through a ventury mask.
2913463|NCT03155698|Experimental|microneedling,NB-UVB with & without PRP|"Each participant will be compared with one side of the body to the other side~Intervention:~Combination Product: microneedling and Platelet rich plasma.~radiation : NB-UVB phototherapy"
2913464|NCT03155659||CHNS|
2913465|NCT03155659||NHANES|
2913466|NCT03155646|Active Comparator|DEXMEDETOMIDINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%).
2913467|NCT03155646|Active Comparator|CLONIDINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%).
2913468|NCT03155646|Active Comparator|LEVOBUPIVACAINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
2913469|NCT03155633|No Intervention|Rest Group|Rest during the 9 days after the race
2913470|NCT03155633|Experimental|Running Group|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
2913471|NCT03155633|Experimental|Elliptical Group|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
2913473|NCT03155620|Experimental|Subprotocol B (FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation)|Patients with a FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation receive pan-FGFR tyrosine kinase inhibitor JNJ-42756493 PO once daily on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2913474|NCT03155620|Experimental|Subprotocol C (EZH2, SMARCB1, or SMARCA4 gene mutation)|Patients with an EZH2, SMARCB1, or SMARCA4 gene mutation receive tazemetostat PO BID on days 1-28. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
2913475|NCT03155620|Experimental|Subprotocol D (TSC1, TSC2, or PI3K/mTOR gene mutation)|Patients with a TSC1, TSC2, or PI3K/mTOR gene mutations receive PI3K/mTOR inhibitor LY3023414 PO BID on days 1-28. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
2913476|NCT03155620|Experimental|Subprotocol E (activating MAPK pathway gene mutation)|Patients with an activating MAPK pathway gene mutation receive selumetinib sulfate PO BID on days 1-28. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
2913477|NCT03155620|Experimental|Subprotocol F (ALK or ROS1 gene alteration)|Patients with an ALK or ROS1 gene alteration receive ensartinib (ALK Inhibitor X-396) PO BID on days 1-28. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
2913478|NCT03155620|Experimental|Subprotocol G (BRAF V600 gene mutation)|Patients with a BRAF V600 gene mutation receive vemurafenib PO BID on days 1-28. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
2913479|NCT03155620|Experimental|Subprotocol H (ATM, BRCA1, BRCA2, RAD51C, RAD51D mutations)|Patients deleterious ATM, BRCA1, BRCA2, RAD51C, or RAD51D gene mutations receive olaparib PO BID on days 1-28. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
2913480|NCT03155620|Experimental|Subprotocol I (Rb positive, alterations in cell cycle genes)|Patients with Rb positive advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations in cell cycle genes receive palbociclib PO QD on days 1-21. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2913481|NCT03155607|No Intervention|Standard Care|
2913482|NCT03155607|Experimental|Virtual Reality Distraction|
2913483|NCT03155594|Experimental|Single arm|Patients in this trial will receive a FreeStyle Libre patch that continuously measures glucose in addition to their standard glucose monitoring.
2913484|NCT03155581|Other|User intervention|Bilingual key women from Somalia and Pakistan trained as peer educators for their respective communities will meet the women to increase awareness regarding the importance of cervical cancer prevention and to help peers overcome detected barriers and increase attendance to screening during meetings with the women organised according to their practical needs, using videos and interactive material
2913485|NCT03155581|Other|Health professional intervention|"General practitioners working in the intervention areas are contacted by letter and an appointment is made for a short meeting to increase awareness of the health professionals involved in screening working in the chosen areas. Material is given(posters and reminding objects) to remind practitioners of the intervention and invite women attending to the center to make an appointment with their GP. No change in screening as usual will be implemented for health professionals working in the control areas."
2913486|NCT03155568|Active Comparator|sciatic nerve block|ultrasound guided sciatic nerve block by injecting 30ml of 0.5% bupivacaine and visualized circumferentially spreading around the sciatic nerve
2913487|NCT03155568|Active Comparator|ankle block|ankle block performed by injecting 20 ml of 0.5% bupivacaine in equal amounts around the five major nerves supplying the foot
2913488|NCT03155568|Active Comparator|combined popliteal and ankle block|combined block performed by the use of 20 ml of 0.25% bupivacaine for sciatic nerve block followed by the ankle block with use of 20 ml of 0.5% bupivacaine both in the same manner as other two groups.
2913489|NCT03155555||Experimental|Children aged 1-12 years undergoing major surgeries under general endotracheal anaesthesia with mechanical ventilation under neuromuscular blockade
2913490|NCT03155542||colorectal cancer patient case group|Histologically confirmed colorectal adenocarcinoma
2913491|NCT03155542||family member control group|without the diagnosis of CRC and accompanied the patient to the primary care clinic visit
2913492|NCT03155529||radical hysterectomy group|"Using dynamic MRI and 3D reconstruction to assess the effect of RH on pelvic floor muscles and pelvic organs (location and mobility of bladder neck and urethral).~Inclusion Criteria： ①Patients diagnosed as FIGO stage IA2、IB1、IIA1 cervical cancer ; ②Patients diagnosed as FIGO stage IB2、IIA2 cervical cancer, eligible for RH after neoadjuvant chemotherapy; ③Patients diagnosed as FIGO stage IIA endometrial carcinoma; ④Patients didn't have pelvic organ prolapse and urinary incontinence; ⑤Ability to hold Valsalva for dynamic MRI; ⑥Patients aged 20-70 years; ⑦Patients undergone RH surgery; ⑧Informed consent was signed.~Exclusion Criteria：~①With MRI or urodynamic examination contraindication; ②Previously undergone POP or SUI surgery; ③BMI＞30 ④With serious postoperative complications."
2913493|NCT03155516|Experimental|GPM Ward|Good Pain management ward
2913494|NCT03155516|Active Comparator|Control Ward|Current practice controlled ward
2913495|NCT03155503|Active Comparator|Single ascending dose|Single dose of SUVN-911 or placebo in healthy male subjects
2913496|NCT03155503|Active Comparator|Multiple ascending dose|Multiple doses of SUVN-911 or placebo in healthy male subjects
2913497|NCT03155490|Experimental|Leadership Training|Subjects are resident trainees with a role in the emergency department evaluation and management of trauma patients.
2913498|NCT03155490|No Intervention|Control|Subjects are resident trainees with a role in the emergency department evaluation and management of trauma patients.
2913499|NCT03155477|Experimental|"Cholecalciferol and C. Xanthorrhiza"|Subjects received Cholecalciferol 400 IU 3 times daily and C. Xanthorrhiza 20 mg 3 times daily per oral for 3 months (group II, n=19)
2913500|NCT03155477|Placebo Comparator|"Cholecalciferol and placebo"|Subjects received cholecalciferol 3×400 IU and placebo 3×1 tablet for 3 months (group I, n=20).
2913501|NCT03155464|Other|Group 1|"Order of two elements of surgical procedure: patients in group 1 will receive sympathectomy prior to bypass during the surgical procedure.~Indocyanine Green (ICG) will be used in both groups."
2913703|NCT03153956|Experimental|Active Treatment Arm|Personally calibrated bio-mechanical device
2913504|NCT03155438||Low responder|"Low responder : women aged 25-49 years old with less than 5 oocytes (1-4 oocytes) retrieved during controlled ovarian hyperstimulation~Oxidative stress-related gene expression and oocyte competence biomarkers will be performed to access the difference between low and normal responders."
2913505|NCT03155438||Normal responder|"Normal responder women aged 25-49 years old with 5-15 oocytes retrieved during controlled ovarian hyperstimulation~Oxidative stress-related gene expression and oocyte competence biomarkers will be performed to access the difference between low and normal responders."
2913506|NCT03155425|Experimental|Injection SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion over 30 minutes.
2913507|NCT03155412||Offspring of type 2 diabetic patients|Group 1: 25 healthy lean men (age 30-45, BMI <28) with genetic predisposition for type 2 diabetes mellitus (T2DM) - i.e. their two first-degree relatives (parents, siblings) or one first-degree relative and two second-degree relatives with type 2 diabetes (grandparents, uncle, aunt) were diagnosed with T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse.
2913508|NCT03155412||Control subjects|Group 2: 25 healthy lean men (age 30-45, BMI <28) without any family history of T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse. Subjects matched for BMI, fat mass and age to subjects in Group 1 will be recruited.
2913509|NCT03155399|Experimental|Proprioceptive based training (PBT)|The treatment will last one hour and will be divided as follows: 2 proprioceptive based stimulation sessions per 3 minutes for each movement, with a rest of 2 minutes between each session. Every patient will receive 15 treatments, 5 days a week, for 3 weeks.
2913510|NCT03155399|Other|Conventional neuromotor treatment (CNT)|The CNT group will be treated for one hour daily by means of a CNT programme. The treatment will last 3 weeks.
2913511|NCT03155386||Standard Angiomammography (SenoBright®)|
2913512|NCT03155386||Optimized angiomammography|
2913513|NCT03155373||A|Asymptomatic/mild symptomatic patients with normal pre-operative left ventricular function (defined as left ventricular ejection fraction >60%)
2913514|NCT03155373||B|Symptomatic patients with normal pre-operative left ventricular function (defined as left ventricular ejection fraction greater than or equal to 60%)
2913515|NCT03155373||C|Patients with impaired pre-operative left ventricular function (defined as left ventricular ejection fraction <60%)
2913516|NCT03155360||Infant with colics|"Infants with colics according to Wessel definition :~Recurrent episodes of irritability, fussing or crying from birth to 4 months of age~Episodes last for 3 hours per day ; on 3 days per week ; for 3 weeks~Episodes can not be attributed to another disorder"
2913517|NCT03155360||Infant without colics|
2913518|NCT03155347|Experimental|Tocilizumab + MTX|Participants will receive tocilizumab SC injections Q2W along with MTX orally every week (QW) for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase, irrespective if they achieve or do not achieve DAS28 low activity (DAS28-ESR <= 3.2).
2913519|NCT03155347|Experimental|Tocilizumab + Placebo Matched to MTX|Participants will receive tocilizumab SC Q2W along with placebo matched to MTX for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase. In the extension phase up to Week 48, participants who achieve DAS28 low activity (DAS28-ESR <= 3.2) will remain on the same treatment they received in double-blind phase. Participants who do not achieve DAS28-ESR <= 3.2 will receive treatment with tocilizumab 162 mg SC Q2W + MTX from Week 26 to Week 48.
2913520|NCT03155347|Active Comparator|Placebo Matched to Tocilizumab + MTX|Participants will receive placebo matched to tocilizumab along with MTX orally QW for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase. In the extension phase up to Week 48, participants who achieve DAS28 low activity (DAS28-ESR <= 3.2) will remain on the same treatment they received in double-blind phase. Participants who do not achieve DAS28-ESR <= 3.2 will receive treatment with tocilizumab 162 mg SC Q2W + MTX from Week 26 to Week 48.
2913521|NCT03155334|Other|Prevalence of CCSVI in MS|Subjects with prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases - PIS User Testing
2913522|NCT03155334|Other|BVD Exploited Against MS|Subjects suffering from Brain venous drainage exploited against Multiple Sclerosis - PIS User Testing
2913523|NCT03155321||Polish General Surgeons|The group is formed by active polish general surgeons, both specialists and in training
2913524|NCT03155308||Polyp group|Consecutive adult patients between 18 and 80 years of age, referred for elective outpatient colonoscopy and in whom polypectomy or biopsy is perform will be enrolled to be evaluated using Pentax chromoendoscopy (i-scan and Optical Enhancement)
2913525|NCT03155295||Physical reality simulation (rehearsal)|Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. Participants with patients assigned to preoperative rehearsal will undergo pre-operative simulation only once.
2913526|NCT03155295||Virtual reality simulation|The DaVinci surgical skills simulator (DVSSS) uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. Participants with patients assigned to preoperative simulation will complete a refresher module on the Virtual reality simulator.
2913527|NCT03155282||Cirrhotic group|30 patients with cirrhosis will be evaluated by EUS-E to measure liver and spleen stiffness. Different cirrhosis etiologies will be included like cirrhosis induces by alcohol, virus, autoimmune, nonalcoholic steatohepatitis (NASH), cryptogenic, primary sclerosing cholangitis and primary biliary cirrhosis. The cirrhotic status will be determinate by clinical, biochemical and/or imaging methods (abdominal ultrasound or CT scan).
2913528|NCT03155282||Control group|30 normal patients with no history of liver disease (negative hepatitis B virus and hepatitis C virus serology, insignificant alcohol intake, normal ultrasound and laboratory), in whom a EUS has to be performed to evaluate a esophageal or gastric subepithelial lesion, chronic pancreatitis, will be evaluated by EUS-E to measure liver and spleen stiffness.
2913704|NCT03153956|Placebo Comparator|Control Arm|sham-placebo device (similar shoes without bio-mechanical elements).
2913529|NCT03155269|Experimental|Group 1- Protein rich beverage powder fortified with MMN|Participants will be administered orally two doses of cereal based fortified beverage (30 grams powder made up in 200 milliliter (mL) water) daily in the morning and evening for 6 months.
2913530|NCT03155269|Other|Group 2 -Low protein non-fortified iso-caloric beverage powder|Participants will be administered orally two doses (in morning and evening) of low protein non fortified isocaloric beverage (30 grams powder made up in 200 mL water) daily for 6 months.
2913531|NCT03155256|Experimental|Coils + Cyanoacrylate Group|Patients with Gastric Varices GOV II or IGV I and with active bleeding, history of previous bleeding due to GV (secondary prophylaxis) or high-risk GV according to Baveno VI consensus for primary prophylaxis will be treated using EUS-guided injection of coils with cyanoacrylate
2913532|NCT03155256|Experimental|Coils Group|Patients with Gastric Varices GOV II or IGV I and with active bleeding, history of previous bleeding due to GV (secondary prophylaxis) or high-risk GV according to Baveno VI consensus for primary prophylaxis will be treated using EUS-guided injection of coils
2913533|NCT03155243||Participants receiving adalimumab (Humira®)|Participants with active non- infectious intermediate, posterior or panuveitis receiving adalimumab (Humira®).
2913534|NCT03155217||patients over 75 years|Patients with MM treated with single or combination therapy over 75 years of age.
2913535|NCT03155217||patients between 65 and 75 years|Patients aged 65-75 years with MM treated with single or dual therapy
2913536|NCT03155217||patients less than 65 years|patients less than 65 years with MM treated with single or dual therapy
2913537|NCT03155204|Experimental|Test Product 1|tiotropium pMDI 2 inhalations
2913538|NCT03155204|Experimental|Test Product 2|tiotropium pMDI 2 inhalations
2913539|NCT03155204|Experimental|Test Product 3|tiotropium pMDI 2 inhalations
2913540|NCT03155204|Experimental|Test Product 4|tiotropium pMDI 2 inhalations
2913541|NCT03155204|Active Comparator|Commercial Product|tiotropium Respimat 2 inhalations
2913542|NCT03155191|Experimental|Dose Level -1 to 2|0.3 to 3 x 10^6 autologous CD19-CAR-T cells/kg per patient will be administered intravenously after a conditioning chemotherapy with cyclophosphamide.
2913543|NCT03155178|Experimental|3M CHG/IPA Prep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
2913544|NCT03155178|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
2913545|NCT03155165||Group A|Patients that have a polyp already seen in a previous colonoscopy and the colonoscopy is indicated for polypectomy.
2913546|NCT03155165||Group B|The rest of colonoscopies indicated .
2913547|NCT03155152|Experimental|DECT Group|"The DECT session consists of four bouts of 4 min high-intensity decremental exercise with 3 min of active recovery between bouts. Load is progressively decreased throughout each exercise bout. The training period will last for a total of 4 weeks, with three weekly sessions of supervised training"
2913548|NCT03155152|Active Comparator|HIIT Group|"The HIIT session consists of four bouts of 4 min high-intensity decremental exercise with 3 min of active recovery between bouts. Load is kept constant throughout each exercise bout. The training period will last for a total of 4 weeks, with three weekly sessions of supervised training"
2913549|NCT03155139||Patients without primary aldosteronism (PA)|PA case detection or confirmatory tests was negative.
2913550|NCT03155139||Patients with primary aldosteronism (PA)|PA case detection and confirmatory tests were positive.
2913551|NCT03155126||Saline group|Patients resuscitated with saline
2913552|NCT03155126||Acetated Ringer's sodium group|Patients resuscitated with Acetated Ringer's sodium
2913553|NCT03155113|Other|patients with chronic HCV infection|"Patients with chronic HCV infection to be treated with any of the available DAA (without associated PEG-IFN) in daily clinical practice.~Intervention: Blood Drawing.Before starting therapy a blood sample will be collected from any subject."
2913554|NCT03155100|Experimental|Carfilzomib, elotuzumab, dexamethasone|Carfilzomib 70 milligram(mg)/m2 iv (56 mg/m2 for first five patients for cycles 1-2) once weekly, on days 1, 8 and 15 (cycles 1-8), from cycle 9 on days 1 and 15 until progression or toxicity; elotuzumab 10 mg/kg iv on days 1,8,15 for cycles 1-2, on days 1and 15 from cycle 3 until progression or toxicity; dexamethasone 40 mg weekly (shared to po and iv)
2913555|NCT03155087||T2DM patients|Metformin dosages ranged from 500 to 2000 mg per day
2913556|NCT03155087||healthy subjects|the healthy subjects was not intervened
2913557|NCT03155074|Experimental|High-Intensity Training|
2913558|NCT03155074|No Intervention|Usual Care|
2913559|NCT03155061|Experimental|Part A (Dose Escalation Part): ONO-4578 monotherapy|ONO-4578 specified dose on specified days
2913560|NCT03155061|Experimental|Part B: ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days
2913561|NCT03155035|Experimental|Intervention|Albendazole 200 mg 2 tablets single dose
2913562|NCT03155035|Placebo Comparator|Placebo|Calcium 400 mg + vitamin D 2.5 mcg 2 tablets single dose
2913563|NCT03155022|Experimental|RIC+ ICIC +|Patients with remote ischemic conditioning and intracoronary ischemic conditioning
2913564|NCT03155022|Other|RCI - ICIC -|Control group with no remote ischemic conditioning and no intracoronary ischemic conditioning
2913565|NCT03155009|Experimental|Alectinib|600 mg orally twice daily (BID) for up to 2 years
2913566|NCT03154996|Experimental|Long term CED of Topotecan|An additional 5 patients will be treated with TPT by CED maintained for 32 days. TPT infusions will be carried out for 32 days using Synchromed II infusion pumps with the same infusion parameters and experimental conditions used in the short term studies.
2913567|NCT03154983|Experimental|First-line treatment|First-line treatment：treatment including Mesylate Apatinib Combined With Docetaxel and S-1(DS).DS Docetaxel 75mg/m2 d1 iv.drop 1h（one hour）， S-1(BSA<1.25 40mg Po bid(twice a day), BSA >=1.25-<1.5 50mg Po bid, BSA >=1.5 60mg Po bid), Q21d(21 days a cycle); Mesylate Apatinib 500mg Po QD(once a day) continuous use; until disease deterioration.
2913604|NCT03154671|No Intervention|Control group|The participant will receive usual care from their treating oncology team. All participants will receive a monthly healthy aging newsletter.
2913605|NCT03154658|Experimental|Sub-serratus regional block|A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site deep to the serratus anterior muscle.
2913568|NCT03154970|Experimental|Obstructive sleep apnea group (G OSA)|The cervical stabilization will be performed with craniocervical flexion training aiming to strength the deep cervical flexors. For this purpose a pressure biofeedback device (stabilizer) that allows progressive levels of pressure during exercise(22-30 mmHg) will be used, which will be increased according to the capacity of the individuals (avoiding compensations or pain). The participant will be instructed to perform the craniocervical flexion in the supine position, the duration of the contraction will be 10 seconds followed by 10 seconds of rest (3 sets of 10 repetitions). The sessions will be held 2 times in weeks, for 6 weeks.
2913569|NCT03154970|No Intervention|Control group (GC)|The GC will be reassessed after six weeks and the same G OSA treatment will be offered after this period.
2913570|NCT03154944|Experimental|Ostomy device 1|In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film
2913571|NCT03154944|Experimental|Ostomy device 2|In this arm the subjects test a new ostomy device consisting of a new adhesive and a known top film
2913572|NCT03154944|Experimental|Ostomy device 3|In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film
2913573|NCT03154931|Active Comparator|CBT-SG|This CBT-Supportive group will focus on the interaction here-and-now, realizing that the group acts as a secure place, driven by interactions among its participants and therapist and co-therapist. The main objective is to welcome and support the participation of all patients and stimulate the group's initiatives, encouraging interpersonal interactions and mutual aid. There will be no specific therapeutic intervention in relation to any PTSD related content.
2913574|NCT03154931|Experimental|CFT-G|This CFT-group will focus on activities using specific therapeutic strategies, to learn and training compassionate skills - psychoeducation and exercises developed for use in session and at home.They will learn What is compassion and shame? Steps to the training of compassion and how Building a compassionate image. Will use Thoughts Daily Record - self critical and self compassionate. Explanation of Formulation of Strategy Threats and Security, The Three Emotional regulation systems and PTSD formulation - based on shame and guilt. They will learn how to incorporate these skills to everyday situations. At the end, will write an Autobiography writing about this experience and share with the group.
2913575|NCT03154918|Experimental|GLIDE|Treated with GLIDE regiment chemotherapy for 4 cycles.
2913576|NCT03154905||Control|Healthy controls
2913577|NCT03154905||Study group|Patient diagnosed with any disorder of the digestive system (including the alimentary tract, hepatobiliary tree, pancreas, insulin resistance or diabetes, obesity or malnutrition)
2913578|NCT03154892|Experimental|Intracameral injection|Intracameral injection of conbercept for the treatment of NVG
2913579|NCT03154892|Active Comparator|Intravitreal injection|Intravitreal injection of conbercept for the treatment of NVG
2913580|NCT03154879||Comatose cardiac arrest survivors|
2913581|NCT03154866|Experimental|Lactobacillus kefiri LKF01 DSM32079|
2913582|NCT03154866|Placebo Comparator|Placebo|
2913583|NCT03154853|No Intervention|normal foot|no intervention
2913584|NCT03154853|Experimental|functional flatfoot|Behavioral: short foot exercise
2913585|NCT03154840|Experimental|Eutropin 4IU|
2913586|NCT03154840|Experimental|Eutropin AQ 12IU|
2913587|NCT03154840|Experimental|Eutropin Pen 36IU|
2913588|NCT03154827|Experimental|Combination Treatment Single Arm|Combination Treatment of BL-8040 with Atezolizumab
2913589|NCT03154814|Experimental|ulinastatin treatment|ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
2913590|NCT03154814|Placebo Comparator|control|conventional CPB was applied without ulinastatin treatment
2913591|NCT03154801|Experimental|Paramedical care|paramedical early detection of sexual dysfunction and sexual health counseling
2913592|NCT03154775|Experimental|C-CAR011|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
2913593|NCT03154762|Experimental|NIPPV|Patients will receive NIPPV with an S bilevel device during 4 nights, the equipment will be placed ad libitum, a 12 cmH2O inspiratory pressure and a 4 cmH2O expiratory pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after intervention.
2913594|NCT03154762|Sham Comparator|CPAP|Patients will receive a 4 cmH2O continuous positive airway pressure device during 4 nights; this is the minimum pressure necessary to avoid death space with no effect on minute ventilation. The equipment will be placed ad libitum. Pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after sham intervention.
2913595|NCT03154749|Experimental|TC|docetaxel/carboplatin as Neoadjuvant Treatment for Triple-Negative Breast Cancer
2913596|NCT03154749|Active Comparator|EC-T|epirubicin/cyclophosphamide followed by docetaxe as Neoadjuvant Treatment for Triple-Negative Breast Cancer
2913597|NCT03154736|Experimental|Interview|Individual interview an in a group interview. Socio-economic questionnaire
2913598|NCT03154723|Experimental|Vitamin A Group|In vitamin A group, The extremely preterm infants will be given the daily dose 1500 IU/day in drop form added to their enteral feeds as soon as minimal feeding is introduced.The duration of vitamin A supplementation was 28 days.
2913599|NCT03154710|Experimental|SENTINEL|Patients will have a clinical and biological exam every 3 months and a web-mediated follow up. Patients will have to connect to the SENTINEL application every 14 days to complete a questionnaire about their symptoms. Imaging will be performed in the event of an alert or clinical problem
2913600|NCT03154710|No Intervention|Standard|Patients will have the usual follow up (Clinical and biological exam every 3 months and imaging every 6 months)
2913601|NCT03154684|Active Comparator|STARK intervention|New care concept for hip fracture patients
2913602|NCT03154684|Other|Standard Care|Swiss standard of care for hip fracture patients
2913603|NCT03154671|Experimental|Intervention group|At study enrollment participants allocated to the intervention arm will complete a comprehensive geriatric assessment with the study intervention team (nurse and physician). Based on these findings a care plan tailored to the needs of the older adult with cancer will be developed and implemented. The study intervention nurse will call the participant at least monthly to follow up and evaluate the care (e.g. whether adjustments are required) and more if needed. All participants will receive a monthly healthy aging newsletter.
2961571|NCT02821624|Experimental|Cohort 9 - Food Effect|G1T38
2913606|NCT03154658|Active Comparator|Supra-serratus regional block|A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site superficial to the serratus anterior muscle.
2913607|NCT03154645|Active Comparator|Ibuprofen|ibuprofen, 600mg, three times a day, through to ascent to high altitude
2913608|NCT03154645|Active Comparator|acetazolamide|acetazolamide, 125mg, two times a day, through to ascent to high altitude
2913609|NCT03154632|Active Comparator|US Group|Ultrasound Therapy
2913610|NCT03154632|Active Comparator|DCD Group|Digital Capacitive Diathermy Therapy
2913611|NCT03154619|Active Comparator|TR987|This group will receive twice-weekly applications of 0.1% TR 987 in a gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.
2913612|NCT03154619|Placebo Comparator|Placebo|This group will receive twice-weekly applications of placebo gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.
2913613|NCT03154606|Experimental|HP-Beverage Breakfast|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will vary in protein source. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
2913614|NCT03154606|Active Comparator|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will primarily as carbohydrates as a control. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
2913615|NCT03154593||Stage 1|Stage 1 will determine the prevalence of chronic oedema among patients attending weight management services at the Royal Derby Hospital and how it impacts on every day life.
2913616|NCT03154593||Stage 2|Stage 2 will determine whether bariatric surgery improves the oedema.
2913617|NCT03154580|Placebo Comparator|N-acetylcysteine 0mg X Cue Exposure (neutral)|
2913618|NCT03154580|Placebo Comparator|N-acetylcysteine 0mg X Cue Exposure (marijuana)|
2913619|NCT03154580|Active Comparator|N-acetylcysteine 2400mg X Cue Exposure (neutral)|
2913620|NCT03154580|Active Comparator|N-acetylcysteine 2400mg X Cue Exposure (marijuana)|
2913621|NCT03154567|Placebo Comparator|Yohimbine 0mg X Cue Condition (neutral)|
2913622|NCT03154567|Placebo Comparator|Yohimbine 0mg X Cue Condition (marijuana)|
2913623|NCT03154567|Active Comparator|Yohimbine 20mg X Cue Condition (neutral)|
2913624|NCT03154567|Active Comparator|Yohimbine 20mg X Cue Condition (marijuana)|
2913625|NCT03154567|Active Comparator|Yohimbine 40mg X Cue Condition (neutral)|
2913626|NCT03154567|Active Comparator|Yohimbine 40mg X Cue Condition (marijuana)|
2913627|NCT03154541|Experimental|Non Cystic Fibrosis (CF) cohort|"The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. No prescription is necessary. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline."
2913628|NCT03154541|Experimental|Cystic Fibrosis (CF) cohort|The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse.
2913629|NCT03154528||healthy control group|serum level of Vitamin D is going to be checked by ELISA in 30 healthy control volunteers
2913630|NCT03154528||case study group|serum level of Vitamin D is going to be checked by ELISA in 60 Androgenetic Alopecia patients.
2913631|NCT03154515|Experimental|Ingavirin|Imidazolyl ethanamide pentandioic acid 90 mg once daily for 5 days
2913632|NCT03154515|Placebo Comparator|Placebo|Placebo capsule identical in appearance to Ingavirin capsule
2913633|NCT03154489|Other|Acenocoumarol|
2913634|NCT03154489|Other|control group|
2913635|NCT03154476|Experimental|Sildenafil|Subjects randomized to this arm will receive sildenafil 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week, and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
2913636|NCT03154476|Placebo Comparator|Placebo|Subjects will receive placebo times per day for 12 months.
2913637|NCT03154463|Active Comparator|TAP blocks|TAP group was received TAP block using ultrasound as a guide and injected on three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points)
2913638|NCT03154463|Active Comparator|continuous epidural infusion|Epidural group received epidural regional anesthesia in sitting position, with epidural regimen of 0.25% bupivacaine without any adjuvant
2913639|NCT03154450|Experimental|Data available to team|Encore Anywhere will be installed and available for review by the clinical team
2913640|NCT03154450|Active Comparator|No Data available to team|Encore Anywhere will be installed but the data collected will not be available to the clinical team
2913641|NCT03154424|Placebo Comparator|Bridging (control group)|External fixation in treatment the distal radius fracture
2913642|NCT03154424|Active Comparator|Nonbridging (tested group)|External fixation in treatment the distal radius fracture improve grip strength?
2913643|NCT03154411|Experimental|ABY-029|ABY-029 will be administered prior to surgery and tissue will be examined ex vivo to determine binding with EGFR positive tumor tissue.
2913644|NCT03154398||1|case control
2913645|NCT03154385|Experimental|arm 1|"Two intravenous perfusions of 1 g of Rituximab (Mabthera ®) at W0 and W2 coupled with 100 mg intravenous methylprednisone to avoid potential allergic reactions.~Five belimumab (Benlysta ®) injections will be administered (W0 + 2days, W2 + 2 days, W4, W8, W12) at 10mg/kg doses. The first two injections are administered 2 days after Rituximab perfusions. The adopted experimental scheme was once used to show use of belimumab in systemic lupus erythematosus in accordance with AMM regulation"
2913648|NCT03154346||General Population|An unlimited number of participants will be accepted into a Baseline registry. From the Baseline registry, approximately 10,000 participants will be selected for the Baseline Study. Participant enrollment for the Baseline Study will be stratified by age, sex and risk factors and will aim to reflect the race and ethnicity distribution within the U.S.. The population includes a broad range of participants across the health spectrum, including exceptionally healthy participants, participants at risk of disease, and participants with current disease. The study population will be enriched for participants with an elevated risk of primary cardiovascular disease, lung cancer, and/or breast/ovarian cancers.
2913649|NCT03154333|Experimental|Diacerein 1% ointment|Diacerein 1% ointment topical formulation will be used for 8 weeks
2913650|NCT03154333|Placebo Comparator|A placebo topical ointment|Placebo topical ointment will be used for 8 weeks
2913651|NCT03154320|Active Comparator|Standard Group|On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and provide a sputum specimen for spot Xpert Ultra testing (48-hour results). Those with high clinical/radiographic suspicion for TB will start same-day TB treatment. On Day 2, participants will return for results of Xpert Ultra testing (spot specimen) and to provide a specimen for early morning Xpert Ultra testing. Those who are Xpert Ultra positive will start TB treatment. Those who are not diagnosed with TB will start ART on Day 9, after testing and treatment for other opportunistic infections. A liquid TB culture will be performed on both the spot and early morning specimens.
2913652|NCT03154320|Experimental|Same-Day Treatment Group|On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and Xpert Ultra testing with same-day results. Based on clinical symptoms, Xpert Ultra results, and chest x-ray, physician will determine whether or not the participant has tuberculosis. Those who are diagnosed with TB will start same-day TB treatment. Those who are not diagnosed with TB will start same-day ART.
2913653|NCT03154307|Experimental|Group 1: Weekly TMS|LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days) , LF-rTMS 1 session/week for 1 month (4 days), and LF-rTMS 1 session/month for 11 months
2913654|NCT03154307|Experimental|Group 2: Monthly TMS|LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days), LF-rTMS 1 session/month for 12 months
2913655|NCT03154307|Sham Comparator|Group 3: Sham TMS|Sham LF-rTMS for 2 weeks (5 days per week for a total of 10 days), sham LF-rTMS 1 session/week for 1 month (4 days), and sham LF-rTMS 1 session/month for 1 month. After the sham stimulation real LF-rTMS intervention sessions will be delivered as follows: 50% of placebo group will follow group 1 protocol and the other 50% will follow group 2 protocol
2913656|NCT03154294|Experimental|Cohort 1|Paclitaxel 60mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 100mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
2913657|NCT03154294|Experimental|Cohort 2|Paclitaxel 60mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
2913658|NCT03154294|Experimental|Cohort 3|Paclitaxel 80mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
2913659|NCT03154294|Experimental|Cohort 4|Paclitaxel 80mg/m Day 1, Day 8, Day 15 TAK-228 3mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
2913660|NCT03154294|Experimental|Cohort 5|Paclitaxel 80mg/m2 Day 1, Day 8, Day 15 TAK-228 4mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
2913661|NCT03154281|Experimental|Cohort 1|(each cycle is 28 days long) Everolimus 5mg daily on Mondays, Wednesdays, and Fridays Niraparib 100mg daily
2913662|NCT03154281|Experimental|Cohort 2|(each cycle is 28 days long) Everolimus 5 mg daily on Mondays, Wednesdays, and Fridays Niraparib 200 mg daily
2913663|NCT03154281|Experimental|Cohort 3|(each cycle is 28 days long) Everolimus 5 mg daily Niraparib 200 mg daily
2913664|NCT03154281|Experimental|Cohort 4|(each cycle is 28 days long) Everolimus 5 mg daily Niraparib 300 mg daily
2913665|NCT03154255|Experimental|Mediterranean Style-Diet Group|"These subjects will receive a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
2913666|NCT03154255|No Intervention|Standard Diet Group|These subjects will receive Standard Diet according to routine care and practice. The standard diet will be distributed with 55-60% of carbohydrates (45-50% complex and no more than 10% refined and processed sugars), 25-30% lipids and 15% proteins, and will be performedin accordance with the calories of an isocaloric balanced diet calculated throughout the Italian LARN Guidelines for age and gender (Società Italiana di Nutrizione Umana, 2014), inspired to Mediterranean pyramid.
2913667|NCT03154229|Active Comparator|Paper-based decision-support|Prior to starting the study, 10 hospitals will be made into 5 pairs. The paper versus smartphone intervention will be randomized to one member of each pair. The study arm will consist of a pre-interventional (6 weeks) followed by an interventional period (12 weeks); this arms will use paper-based decision support at the 5 hospitals designated.
2913668|NCT03154229|Active Comparator|Smartphone-based decision-support|Prior to starting the study, 10 hospitals will be made into 5 pairs. The paper versus smartphone intervention will be randomized to one member of each pair. The study arm will consist of a pre-interventional (6 weeks) followed by an interventional period (12 weeks); this arms will use smartphon-based decision support at the 5 hospitals designated.
2913669|NCT03154216|Experimental|Exercise only|90 minutes of exercise
2913670|NCT03154216|Experimental|Exercise and high glycemic index drink|90 minutes of exercise followed by consumption of high-glycemic index Gatorade drink matched for calories expended during the exercise
2913671|NCT03154216|Experimental|Exercise and low glycemic index drink|90 minutes of exercise followed by consumption of low-glycemic index milk drink matched for calories expended during the exercise
2913672|NCT03154216|No Intervention|No exercise and no beverage|No exercise and no beverage
2913673|NCT03154190|Active Comparator|Arm A (usual care)|Patients receive usual care.
2913705|NCT03153943|Experimental|Workbook support group|Printed educational workbook and pedometer.
2913706|NCT03153943|Experimental|HIP Mobile e-Monitoring support group|Remote monitoring via smart shoe insoles and a coaching with enabling educational electronic program accessed through a tablet.
2914667|NCT03147066|Experimental|Dezocine|0.1 mg/kg of intravenous dezocine 30 min before the end of surgery
2913674|NCT03154190|Experimental|Arm B (health care coach support)|Patients undergo health care coach support with a baseline introduction (either telephonic or in-person) of the program followed by a visit (telephonic or in-person) with the health care coach after the first oncology appointment to discuss goals of care. The health care coach will contact patient based on patients' ongoing needs (weekly to monthly) and will conduct symptom assessments based on patients' treatment plans and symptoms.
2913675|NCT03154177|No Intervention|Standard ANC and PNC care only|Standard care offered following national guidelines of ANC and PNC.
2913676|NCT03154177|Other|Standard Care + Ultrasound+Pregnancy Testing|Standard care in combination with early pregnancy testing and ultrasound.
2913677|NCT03154177|Experimental|Group ANC and PNC only|Health facilities randomized to provide group ANC/PNC.
2913678|NCT03154177|Experimental|Group Care + Ultrasound+Pregnancy Testing|Group ANC and PNC care, in combination with early pregnancy testing and ultrasound.
2913679|NCT03154151|Experimental|Online Cognitive-Behavioral Therapy|Through guided writing, Internet-based cognitive therapy aims to help WTC responders process any traumatic experiences they lived through during their WTC recovery work.
2913680|NCT03154151|Active Comparator|Online Supportive Therapy|Through guided writing, Internet-based supportive therapy aims to help WTC responders work through any life problems they might currently be experiencing.
2913681|NCT03154138|Experimental|Prismatic adaptation (PA) group|Patients in the experimental group will benefit from 10 sessions of adaptation prismatic (PA) by means of one daily session of 20 minutes (5 times by week; 2 weeks), performed by an experienced physical therapist or occupational therapist. All patients will also benefit from conventional rehabilitation (Standard physical therapy, standard occupational therapy, standard speech therapy …) according to the needs of the patients.
2913682|NCT03154138|Placebo Comparator|Sham group|Patients in the sham group will benefit from 10 sessions of sham adaptation prismatic (S-PA) by means of one daily session of 20 minutes (5 times by week; 2 weeks), performed by an experienced physical therapist or occupational therapist. All patients will also benefit from conventional rehabilitation (Standard physical therapy, standard occupational therapy, standard speech therapy …) according to the needs of the patients.
2913683|NCT03154125|Experimental|Abdomen|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
2913684|NCT03154125|Experimental|Upper thigh|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
2913685|NCT03154125|Experimental|Back of the upper arm|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
2913686|NCT03154086|Experimental|Part A-Cohort 1|Eligible subject will be assigned to four single dose, crossover dosing periods, 1 placebo and 3 escalating dosing (GSK3352589-2 to 400 mg) periods. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug.
2913687|NCT03154086|Experimental|Part A-Cohort 2|Eligible subjects will be assigned to either single dose of GSK3352589 (dose selected after completion of Part A-Cohort 1) or placebo administered in the fasted and then fed states. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug.
2913688|NCT03154086|Experimental|Part B- GSK3352589|Eligible subjects will receive single sequence of planned dose range is 2 mg once daily to 200 mg twice daily administered for 14 days in Cohorts (1 to 6) in the fasted and fed states. Selection of the starting dose for Part B will occur after review of the safety, tolerability and PK data of all subjects enrolled in Part A
2913689|NCT03154086|Placebo Comparator|Part B-Placebo|Eligible subjects will receive single sequence of Placebo either once daily or twice daily administered for 14 days depending on allocation to Cohorts (1 to 6). Part B will occur after review of the safety, tolerability and PK data of all subjects enrolled in Part A.
2913690|NCT03154073|Experimental|Moderate Exercise Training|Exercise training program that will focus on engaging in ~150 minutes of moderate intensity exercise per week. Exercise will be supervised by trained staff.
2913691|NCT03154073|Experimental|Vigorous Exercise Training|Exercise training program that will focus on engaging in ~150 minutes of vigorous intensity exercise per week. Exercise will be supervised by trained staff.
2913692|NCT03154060|Experimental|Intervention|Using 3 Abbott FreeStyle Libre Flash Glucose Monitoring sensors in parallel and measure 7 times a day BG by capillary finger stick testing.
2913693|NCT03154047|Experimental|Open label|Open Label Study Drug NEOD001
2913694|NCT03154034||Severe mitral regurgitation|
2913695|NCT03154021|Experimental|Gingivitis Test|All subjects will have oral examination, dental cleaning, plaque samples taken, given Colgate Total Toothpaste, Oral B Manual Toothbrush and Next Science Over the Counter (OTC) Oral Rinse with Essential Oils.
2913696|NCT03154021|Placebo Comparator|Gingivitis Placebo|All subjects will have oral examination, dental cleaning, plaque samples taken, given Colgate Total Toothpaste, Oral B Manual Toothbrush and OTC Oral Rinse Control.
2913697|NCT03154008|Experimental|Active Treatment|Group cognitive behavioral therapy (CBT) for 8 weeks.
2913698|NCT03153995|Experimental|sub-periosteal soft tissue expansion|Eight patients will receive osmotic hydrogel expanders prior to bone augmentation procedures. All expanders will be placed in sub-periosteal positions using the tunnel technique.
2913699|NCT03153995|Experimental|sub-mucosal soft tissue expansion|Eight patients will receive osmotic hydrogel expanders prior to bone augmentation procedures. All expanders will be placed in sub-mucosall positions using the tunnel technique.
2913700|NCT03153982|Experimental|Head and neck squamous cell carcinoma|"Participants will take 15 mg or 20 mg of ruxolitinib by mouth twice daily for up to 4 weeks during the pre-operative window. Dose will be assigned based on participant platelet count at baseline. The last dose will be taken the morning of planned surgery.~Ruxolitinib will be dispensed in 5 mg tablets. Participants will either take three tables (15 mg) in the morning and evening, or four tablets in the morning and evening (20 mg)."
2913701|NCT03153969|Experimental|SHOFU Beautifil II LS|Composite: SHOFU Beautifil II LS, Bonding Agent: SHOFU BeautiBond
2913702|NCT03153969|Active Comparator|3M/ESPE Filtek Supreme|Composite: 3M/ESPE Filtek Supreme, Bonding Agent: 3M/ESPE Scotchbond Universal
2913707|NCT03153930|Placebo Comparator|Sitting Only (SIT)|In-Lab (full sample): children will sit continuously for 3 hours during an OGTT Free-living (sub-sample; N=12): children will complete their habitual sedentary behaviors over 4 days; they will also wear a continuous glucose monitor
2913708|NCT03153930|Experimental|Walking Breaks (WALK)|In-Lab (full sample): children will be asked to walk on a treadmill every 30 minutes for 3 minute bouts during a 3 hour OGTT Free-living (sub-sample; N=12): children will be prompted with an ActivPAL vtap monitor on the right thigh to perform 3-minute walking bouts whenever sedentary time has lasted longer than 30 minutes over 4 days; they will also wear a continuous glucose monitor
2913709|NCT03153917|Experimental|melatonin and cortisol sampling|14 healthy volunteer nurses working on 12 hours night/day schedules in the Sleep Medicine Center of Lyon.
2913710|NCT03153904|Experimental|MATCH Training plus MATCH Consultation|Therapists at local, community clinics attend a 6-day training on the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems (MATCH; Chorpita & Weisz, 2009). After the training, therapists participate in weekly consultation meetings that are led by a MATCH Consultant from the study team. MATCH Consultants review sessions and the clinical monitoring and feedback system, provide recommendations for upcoming sessions, and review MATCH modules via role-plays and models.
2913711|NCT03153904|Active Comparator|MATCH Training only|Therapists at local, community clinics attend a 6-day training on the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems (MATCH; Chorpita & Weisz, 2009). After the training, therapists use MATCH as they think best and receive supervision from supervisors at the clinic.
2913712|NCT03153891|Experimental|Natural Environment|Participants experience a virtual reality natural environment intervention (using VR goggles with Smartphone) for 10 minutes on two occasions, 1 week apart.
2913713|NCT03153891|Experimental|Built Environment|Participants experience a virtual reality built environment intervention (using VR goggles with Smartphone) for 10 minutes on two occasions, 1 week apart.
2913714|NCT03153891|No Intervention|Control|Participants do not experience a VR intervention. Instead they visit with research assistants for 10 minutes on two occasions, 1 week apart.
2913715|NCT03153852|Experimental|Combined peeling agents|Modified Jessner's solution will be applied on the right side and glycolic acid 70% on the other side of the face.trichloroacetic acid 20% will be applied in one uniform coat to both sides
2913716|NCT03153839|Experimental|Study group|74 infants who will practice with their parents a programme of aquatic physical activity in a swimming pool for one year. They will be evaluated before and after the programme.
2913717|NCT03153839|No Intervention|Control group|71 infants who will not practice the programme. They only will be evaluated.
2913718|NCT03153826|Other|Patients|
2913719|NCT03153813|Experimental|Drug|Up to 4 patches to cover a surface of 1200 cm2 will be applied to the painful area depending on the surface of pain during 60 minutes : capsaicin 8% patches (Qutenza)
2913720|NCT03153813|Placebo Comparator|Placebo|Up to 4 patches will be applied to the painful area depending on the surface of pain during 60 minutes : placebo
2913721|NCT03153800|Experimental|Bronchial basal cells|
2913722|NCT03153787|Experimental|Not pregnancy|Vaginal probiotic administration
2913723|NCT03153774|Experimental|Heart failure patients|The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
2913724|NCT03153774|Experimental|TAVI patients|The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
2913725|NCT03153761|Experimental|CSD170201AA, CSD170201AB Use Group|Use of product CSD170201AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170201AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
2913726|NCT03153761|Experimental|CSD170201AB, CSD170201AA Use Group|Use of product CSD170201AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170201AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
2913727|NCT03153735|Experimental|CMDHA0101|Maximum injection dose : 22 ml It is a product containing 0.3% lidocaine hydrochloride, a topical anesthetic ingredient, in a crosslinked hyaluronic acid gel
2913728|NCT03153735|Active Comparator|PowerFill®|Maximum injection dose : 22 ml A white solid that was lyophilized with mixed spherical PLA (Poly-D, L-lactide) microparticles and CMC (sodium carboxymethylcellulose)
2913729|NCT03153722|Experimental|Pediatric discharge process intervention|All patients hospitalized on the pediatric ward under the pediatric hospitalist service will participate in pediatric discharge process interventions.
2913730|NCT03153696|Experimental|Cellie Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support. In this condition, children and parents will be introduced to the Cellie Intervention immediately following the completion of the T1 measures.
2913731|NCT03153696|Other|Cellie Wait-list Control|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support. In this condition, children and parents will be introduced to the Cellie Intervention via phone and mail following the completion of the T3 measures.
2913870|NCT03152578|Active Comparator|BetaC Only|1-3 mls BetaC applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
2913732|NCT03153683||Acute Ischemic Stroke Patients|This is a registry. No above standard of care interventions will take place. Participants must have an acute thromboembolus within an intracranial artery in the anterior circulation (internal carotid, anterior cerebral, middle cerebral), which undergoes mechanical thrombectomy per standard of care.
2913733|NCT03153670|Other|functional magnetic resonance imaging|1 Group Assigned
2913734|NCT03153657|Experimental|Piroxicam-beta-Cyclodextrin|Intervention: Drug Piroxicam-beta-Cyclodextrin
2913735|NCT03153657|Placebo Comparator|Placebo|Intervention: Drug Placebo
2913736|NCT03153644||Patients|Women with chronic medical conditions
2913737|NCT03153644||Primary Care Providers and Medical Staff|"Primary care providers can include doctors and advanced practice professionals, including midwives, nurse practitioners, and physician assistants.~Medical staff can include social workers, nurses, medical assistants, and administrative staff"
2913738|NCT03153644||Primary Practice|Primary care practices (family medicine, internal medicine, medicine-pediatric, or any combination of these) that at a practice-level already provide contraceptive counseling and services to reproductive-age women
2913739|NCT03153618|Experimental|VALIDATE subjects|Will be invited to interact with VALIDATE to determine if they meet referral indications for cancer predisposition assessment.
2913740|NCT03153618|No Intervention|Control|Current standard of care will be followed
2913741|NCT03153605|Experimental|SATISI_7|
2913742|NCT03153592|Active Comparator|conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure <28 cmH2O.
2913743|NCT03153592|Experimental|transpulmonary pressure strategy|13 patients will undergo volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, and with a inspiratory transpulmonary pressure less than 20 cmH2O and an expiratory transpulmonary pressure and inspired oxygen set accordingly to predefined criteria.
2913744|NCT03153579|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo or lysergic acid diethylamide (LSD)
2913745|NCT03153579|Other|LSD, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo or lysergic acid diethylamide (LSD)
2913746|NCT03153566|Experimental|study group|include (15) patients will be injected with Tuberculin vaccine 0.3 ml every 2 weeks, vaccine will be injected in the largest wart, 4 sessions will be done then patients will be followed for 2 months
2913747|NCT03153566|Active Comparator|control group|include (15) patients will be treated with cryotherapy every 2 weeks ,4 sessions will be done then patients will be followed for 2 months
2913748|NCT03153566|Experimental|combined group|include (15) patients will be treated with combined cryotherapy and Tuberculin vaccine , one week cryotherapy and the other week Tuberculin vaccine , then patients will be followed for 2 weeks
2913749|NCT03153553|Active Comparator|Ischaemic Preconditioning Group|The participant will rest in a sitting position for 10 minutes before measuring resting blood pressure. Blood pressure will be measured on the arm. IPC will be administered to the upper arm using cuff inflation pressures of 30mm Hg above the systolic BP using a manual BP. The IPC cycles comprised of three cycles of cuff inflation each lasting 5 min in duration followed by 5-min period of cuff deflation
2913750|NCT03153553|Sham Comparator|Control group|The participant will rest in a sitting position for 10 min before measuring resting blood pressure. Blood pressure will be measured on the upper arm. Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
2913751|NCT03153540|Active Comparator|Active iTBS|"Device: MagPro X100 stimulator equipped with the B65 fluid-cooled coil for dominant Inferior Frontal Gyrus (IFG) stimulation (MagPro, Medtronic).~Intervention: 10 sessions daily of iTBS over 2 weeks. Active-iTBS consists of intermittent Theta Burst Stimulation to the dominant IFG (120% of resting motor threshold, bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total over 3 min)."
2913752|NCT03153540|Sham Comparator|Sham iTBS|"Device: MagPro X100 stimulator applied to dominant inferior frontal lobe.~Intervention: 10 sessions daily of sham iTBS over 2 weeks. Sham sessions involve a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered."
2913753|NCT03153527|Placebo Comparator|Placebo arm (intervention arm)|Stop glucocorticoid treatment; administer placebo matching the verum preparation in weekly intervals.
2913754|NCT03153527|Active Comparator|Verum group (control/standard arm)|If patient is on > 7.5 mg prednisone-equivalent daily: administer 7.5 mg q.d. for 7 days, then 5 mg q.d. for 7 days, then 2.5 mg q.d. for 7 days, then 2.5 mg q.d. every second day, then stop. If patient on 7.5 mg q.d.: maintain for 7 days, then taper as above.
2913755|NCT03153514|Experimental|Obinutuzumab|"Obinutuzumab i.v.~Cycle 1: in the peri-transplant and transplantation phase~Cycle 2: if active disease and/or MRD positivity on day +60, +90, +180 or +270"
2913756|NCT03153501|Other|Diagnostic arm|Patients with pleural diseases; malignant pleural diseases, tuberculous pleurisy, and other exudate required CT-guided Abrams needle biopsy, US-guided cutting needle biopsy, and medical thoracoscopy.
2913757|NCT03153488|Experimental|Methylphenidate LA (Ritalin)|Adult subjects (ages 18-55) will be randomized to receive either Methylphenidate LA or Mixed Amphetamine Salts (XR). This dose of the stimulant will be titrated with the goal of achieving optimal response and good tolerability.
2913758|NCT03153488|Experimental|Mixed Amphetamine Salts XR (Adderall)|Adult subjects (ages 18-55) will be randomized to receive either Methylphenidate LA or Mixed Amphetamine Salts (XR). This dose of the stimulant will be titrated with the goal of achieving optimal response and good tolerability.
2913759|NCT03153475|Other|ATTUNE Revision Knee System|The ATTUNE Revision system is complementary to the ATTUNE primary knee portfolio and includes both rotating platform (RP) and fixed bearing (FB) configurations. The system includes a full compliment of implants designed to address the challenges faced in revision knee surgeries. These implants include Stemmable tibial and femoral components, augments, sleeves and offsets
2913871|NCT03152578|Placebo Comparator|Placebo|1-3 mls Placebo applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
2914926|NCT03145207|Other|name brand patch-early|name brand lidocaine patch-early
2913760|NCT03153449|Other|ATTUNE Revision knee system|The ATTUNE Revision knees system is complementary to the ATTUNE primary knee portfolio and includes both rotating platform (RP) and fixed bearing (FB) configurations. The system includes a full compliment of implants designed to address the challenges faced in complex primary knee surgeries. These implants include Stemmable tibial and femoral components, augments, sleeves and offsets
2913761|NCT03153436|Active Comparator|Normal S.A group|Infertile men with normal semen analysis. each sample is divided into 2 identical aliquots: one aliquot (Myo aliquot) is supplied with myoinositol, The other aliquot is left as it is (control aliquot).
2913762|NCT03153436|Active Comparator|Abnormal S.A group|Infertile men with abnormal semen analysis. each sample is divided into 2 identical aliquots: one aliquot (Myo aliquot) is supplied with myoinositol, The other aliquot is left as it is (control aliquot).
2913763|NCT03153423|Other|Basic intermittent exotropia patients|
2913764|NCT03153410|Experimental|Cyclophosphamide, GVAX, Pembrolizumab and IMC-CS4|
2913765|NCT03153397|Experimental|Nutraflora scFOS|prebiotic fiber-containing formula (Nutraflora scFOS)
2913766|NCT03153397|Active Comparator|Osmolite|non-prebiotic fiber containing formula (Osmolite)
2913767|NCT03153384||one both experimental and control arm|Each patient experiences two methods of blood cultures.
2913768|NCT03153371||Early-onset Alzheimer's disease|This group will include 90 patients who have been diagnosed with clinically probable early-onset Alzheimer's disease by the UCLA Neurology Clinic (60 variant phenotypes; 30 typical amnestic).
2913769|NCT03153371||Alzheimer's disease|This group will include 30 patients who have been diagnosed with clinically probable Alzheimer's disease (typical late-onset AD)
2913770|NCT03153371||Controls|Healthy age-matched individuals without clinically significant cognitive impairments will be enrolled into this study.
2913771|NCT03153358|Experimental|icotinib+SBRT|icotinib 125 milligram,three times a day for 28 days oral administration,12weeks later given the SBRT treatment depended on the outcome of icotinib
2913772|NCT03153345|Experimental|Intervention group|The intervention group participated in a conventional stroke rehabilitation program, which consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training. This program was performed for 30 minutes twice a day 5 days a week, over for at least 3 weeks. During the same period, the intervention group also took part in bedside respiratory muscle training twice a day for 7 days a week over a 3-week period.
2913773|NCT03153345|Active Comparator|Control group|The control group participated only in a conventional stroke rehabilitation program, which consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training. This program was performed for 30 minutes twice a day 5 days a week, over for at least 3 weeks.
2913774|NCT03153332||MDCT group|The MDCT images of seven hepatic tumors were loaded on software to uniform study conditions, allowing both axial and coronal scans visualization.
2913775|NCT03153332||3D visualization system group|The 3D virtual reconstructions of seven hepatic tumors were loaded on the visualization software which enables the rotation of the virtual model.
2913776|NCT03153332||3D printing group|3D-printed models of seven hepatic tumors were created based on MDCT images, participants were allowed to freely handle them.
2913777|NCT03153319|Experimental|Adalimumab|20 mg subQ every other week (weight 15to <30 kg) 40 mg subQ every other week (weight ≥30 kg). Non-responders will be escalated to weekly dosing.
2913778|NCT03153319|Placebo Comparator|Placebo|Saline placebo comparator
2913779|NCT03153319|Experimental|Open-label adalimumab|Open-label extension of adalimumab dose
2913780|NCT03153306|Experimental|"the bolus group"|10ml/kg of the natural colloid 5% albumin was given at 1 hrs.
2913781|NCT03153306|Experimental|"thecontinuous group"|10ml/kg of the natural colloid 5% albumin was given over 6 hrs
2913782|NCT03153293|Experimental|rAAV2-ND4|A Single IVT Injection of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4)（0.05ml).The dose is 1 × 10^10 vg/0.05 mL for test groups.
2913783|NCT03153280|Experimental|Lithium, Oxaliplatin & Capecitabine|Target serum concentrations of escalating doses of lithium (0.6, 0.9, 1.26 or 1.4 mmol/L) in combination standard chemotherapy - oxaliplatin and capecitabine.
2913784|NCT03153267|Active Comparator|EM-7 days doxycycline|
2913785|NCT03153267|Active Comparator|EM-14 days doxycycline|
2913786|NCT03153267|Placebo Comparator|Controls|
2913787|NCT03153254|Experimental|Healthy persons|Test upper limb robot assisted therapy device. During 1 session of 1/2 hour.
2913788|NCT03153254|Experimental|Stroke patients|Training with new upper limb robot assisted therapy device. During 2 to 5 sessions of 1/2 hour.
2913789|NCT03153228||Smokers of traditional cigarettes|29 healthy smokers of traditional cigarettes (min. 1 packyear)
2913790|NCT03153228||Smokers of e-cigarettes|29 healthy smokers of e-cigarettes (min. 1 packyear)
2913791|NCT03153228||Control|29 healthy volunteers.
2913792|NCT03153215|Active Comparator|Intervention group|women with severe IUGR
2913793|NCT03153215|Active Comparator|Control group|women with severe IUGR
2913794|NCT03153202|Experimental|Participants with CLL|Participants with relapsed/ refractory Chronic Lymphocytic Leukemia (CLL) or 17p- CLL
2913795|NCT03153202|Experimental|Participants with MCL|Participants with relapsed/ refractory Mantle Cell Lymphoma (MCL)
2913796|NCT03153176|Experimental|intervention|Training program for Physical Education teacher. Individual level: moderate to vigorous physical activity. Organizational level: school health policy for healthy lifestyle
2913797|NCT03153176|No Intervention|no intervention|Physical Education and school curriculum as usual
2913798|NCT03153163|Experimental|Trastuzumab Emtansine|Participants with HER2-positive LA/MBC who received prior trastuzumab and taxane therapy will receive trastuzumab emtansine.
2913799|NCT03153150|Experimental|Start oral anticoagulant (OAC)|"If the patient is randomized in this arm, an oral anticoagulant:~Factor Xa inhibitors: Apixaban or Rivaroxaban or Edoxaban or~Direct thrombin inhibitor: Dabigatran or~Vitamin K antagonists: Acenocoumarol or Phenindione or Warfarin chosen by the patient's physician before the randomisation, will be prescribed long-term (≥1 year) to the patient."
2913936|NCT03152097|Experimental|Commercially available Diindolylmethane|This crossover design will include 4 weeks of diindolylmethane and 4 weeks of matching placebo assignment.
2961572|NCT02821624|Experimental|Cohort 10|G1T38 or placebo
2913800|NCT03153150|No Intervention|Do not start oral anticoagulant (OAC)|"If the patient is randomized in this arm, anticoagulant drugs will not be prescribed to the patient during the entire study period. The standard clinical practice without OAC may include:~antiplatelet drug(s) or~no antithrombotic drugs."
2913801|NCT03153137|Experimental|Macitentan|Macitentan 10 mg per day; film-coated tablet; oral use
2913802|NCT03153137|Placebo Comparator|Placebo|film-coated tablet; oral use
2913803|NCT03153124|Experimental|Respiratory muscle training|- three months of intradialytic training of a physical therapy protocol with PowerBreath.
2913804|NCT03153124|No Intervention|Control|No intervention
2913805|NCT03153111|Active Comparator|Macitentan|Subjects randomized to the macitentan arm receives one tablet of macitentan 10 mg every day for 52 weeks
2913806|NCT03153111|Placebo Comparator|Placebo|Subjects randomized to the placebo arm received one tablet of placebo every day for 52 weeks
2913807|NCT03153098||Standard delivery|Participants will receive a behaviour change technique booklet, consultations (baseline, and optional at 3, 6, and 12 months), a booster phone call (week 2), motivational text messages (weeks 3, 6, and 12), and signposting to 12 weeks of exercise classes.
2913808|NCT03153098||Enhanced delivery|Participants will receive the same as intervention but the 12 weeks of exercise will be free and tailored to their needs, and there will be optional exercise 'buddies' available.
2913809|NCT03153085|Experimental|TBI-1401(HF10) + Ipilimumab|1x10^7 TCID50/mL TBI-1401(HF10) administered to a single or multiple eligible tumors in a total volume up to 5.0 mL (injection volume will be adjusted based on the size of tumor mass) by intratumoral injection and 3 mg/kg ipilimumab administered by intravenous infusions.
2913810|NCT03153072|Other|A child with supraventricular tachycardia|
2913811|NCT03153059||group 1|a large number of defecation group (≥ 2-3 times/day) - 20 subjects
2913812|NCT03153059||group 2|normal defecation group (1 time/day or 1 time/2 days) - 20 subjects
2913813|NCT03153059||group 3|a small number of defecation group (≤ 2 times/week) - 20 subjects
2913814|NCT03153046|Experimental|Prebiotics|12 week ingestion of prebiotics, Bimuno galacto-oligosaccharide (B-GOS).
2913815|NCT03153046|Placebo Comparator|Maltodextrin|12 week ingestion of maltodextrin
2913816|NCT03153020||Cohort of patients with stroke or transient ischemic attack|The cohort will be constituted of all consecutive patients admitted for a stroke or transient ischemic attack by the Rhône's emergency medical help service (SAMU), or in one of the emergency unit or stroke unit of the Rhône area, and presenting a symptom-onset (the last time the patient was seen without deficit) less than 24 hours.
2913817|NCT03153007||Subjects with DFU|Adult male or female subjects, 18 years of age or over and currently receiving treatment for a diagnosis of DFU or have received treatment for a past foot ulcer within the last 6 months, will be recruited from up to three clinical sites. They will undergo concept elicitation interviews over the telephone or in-person by trained and experienced interviewers.
2913818|NCT03152994||COPD patients with T2DM|"For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who will develope T2DM during the follow-up will be divided into the groupCOPD patients with T2DM."
2913819|NCT03152994||COPD patients without T2DM|"For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who won't develope T2DM during the follow-up will be divided into the groupCOPD patients without T2DM."
2913820|NCT03152981|Active Comparator|Desflurane group|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure
2913821|NCT03152981|Active Comparator|Propofol group|In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
2913822|NCT03152955|Experimental|Group A|Patients in Group A will receive scalp nerve block and patient-controlled analgesia which contains sufentanil and ondansetron.
2913823|NCT03152955|Experimental|Group B|In Group B, patient-controlled analgesia which contains sufentanil、ondansetron and ketamine will be applied.
2913824|NCT03152955|Sham Comparator|Group C|In Group C, patient-controlled analgesia which contains sufentanil and ondansetron will be applied.
2913825|NCT03152942|Experimental|Progesterone alone|Progesterone 400 mg once daily until 34 weeks.
2913826|NCT03152942|Active Comparator|Progesterone and aminophylline.|Progesterone 400 mg and aminophylline 225 mg once daily until 34 weeks.
2913827|NCT03152929|Active Comparator|Paravertebral Block|The Paravertebral Block is performed along the spine utilizing ultrasound guided technique (20-30 mL 0.5% Ropivacaine)
2913828|NCT03152929|Active Comparator|Pectoral Nerve Block|The Pectoral Nerve Block is performed anteriorly, at the level of the axillary line, also utilizing ultrasound guided technique (20-30 mL 0.5% Ropivacaine)
2913829|NCT03152916|Experimental|3D printing personalized plate|3D printing personalized plate will be used to guide the Kirschner wires in the joint fusion surgery.
2913830|NCT03152903|Experimental|VPM1002 (Recombinant BCG vaccine)|
2913831|NCT03152903|Placebo Comparator|Placebo|
2913832|NCT03152890|Experimental|Study group|The study group receives a linear mixed effects model-proposed dose of insulin when hyperglycemia is noticed after reperfusion of liver graft.
2913833|NCT03152877|Experimental|Liposomal bupivacaine treatment group|20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, in subjects in the experimental arm, following completion of the surgical repair.
2913834|NCT03152877|Active Comparator|0.25% plain bupivacaine treatment group|20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, in subjects in the active comparator arm, following completion of the surgical repair.
2913835|NCT03152864|Experimental|Full Package|
2913836|NCT03152864|No Intervention|Sensing Only|
2913837|NCT03152851|Experimental|Pressure stimulus group by ultrasound probe|A pressure stimulus would be applied once using a device (ultrasound probe) to the anteroposterior wall of the bladder until the anterior & posterior wall meet if the measured diameters (AP x T) is 2 X 2 or more by ultrasound
2913838|NCT03152851|No Intervention|Non-pressure stimulus group|No pressure stimulus would be given
2913937|NCT03152084|Experimental|Arm 1|T2DM subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
2914927|NCT03145207|Other|name brand patch-late|name brand lidocaine patch-late
2913839|NCT03152838||Autism Cases|"20 confirmed autism cases will be involved in this study.~The autism patients will be diagnosed according to:Gilliam Autism Rating Scale Arabic version: An assessment of the severity of autism using the Gilliam autism rating scale Arabic version: This test was used for diagnosis and assessment of the severity of autistic features for ages 3-22 years. It consists of 56 items, subdivided into 4 subscales: communication, social interaction, stereotyped behaviors, development and total score.~Fasting blood samples will be collected from autism children for DNA Methylation-and quantitative Real-time Polymerase Chain Reaction Analysis"
2913840|NCT03152838||Control|"20 age-gender matched typical development children that will be assigned to the normal control group.~Control children will be examined by a psychiatrist to exclude any sub-clinical autistic features.~Fasting blood samples will be collected from control children for DNA Methylation-and quantitative Real-time Polymerase Chain Reaction Analysis"
2913841|NCT03152825||Viable myocardium Group|"At least ONE of the following:~Late gadolinium enhancement <75%.~Improvement in segmental function ≥1 grade during low dose dobutamine"
2913842|NCT03152825||Non-viable myocardium group|"At least ONE of the following:~Late gadolinium enhancement ≥75%.~No improvement in segmental function during low dose dobutamine"
2913843|NCT03152825||Inducible ischaemia group|"At least ONE of the following:~perfusion defect (≥ 1,5 segments) assessed during peak infusion of adenosine or dobutamine~new wall motion abnormalities or worsening ≥1 grade during peak infusion of dobutamine"
2913844|NCT03152825||Non-inducible ischaemia group|"None of conditions qualifying for the Inducible ischemia group"
2913845|NCT03152812||free skin flaps|
2913846|NCT03152812||free muscle flaps|
2913847|NCT03152799|Experimental|Remote Ischaemic Pre-Conditioning (RIPC) Intervention|Remote Ischaemic Pre-Conditioning intervention to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
2913848|NCT03152799|Sham Comparator|Sham Control|Sham Control to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
2913849|NCT03152786|Experimental|Group I (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO 2 hours prior to standard of care prostatectomy.
2913850|NCT03152786|Active Comparator|Group II (no treatment)|Patients receive no treatment prior to standard of care prostatectomy.
2913851|NCT03152773|Experimental|1|Open label
2913852|NCT03152760||Alcohol use disorder participants|current drinkers
2913853|NCT03152760||Alcohol Use Disorder participants|abstinent drinkers
2913854|NCT03152760||Healthy Control|healthy volunteers
2913855|NCT03152747||A|"Group A with pre-operative complete posterior vitreous detachment Group A will be invited for one follow-up visit (two months post-operatively) followed up by telephone interviews at one, two, three and five years after surgery to determine occurrence of pseudophakic retinal detachment.~Examinations: Best corrected Visual Acuity (BCVA) , SD-OCT (spectral domain optical coherence tomography), Ultrasound B-scan (substudy only), Slit lamp examination, telephone interview"
2913856|NCT03152747||B|"Group B with no/partial PVD~Group B will be invited for follow-up examinations at two months, six months and one year after surgery to document occurrence of PVD (if a PVD is present at one of the follow-ups, no more visits are necessary). Two, three and five years after surgery, all patients from group B will be interviewed by telephone, as in group A, to document the occurrence of pseudophakic retinal detachment.~Examinations: BCVA, SD-OCT, Ultrasound B-scan (substudy only), Slit lamp examination, telephone interview"
2913857|NCT03152734||Elderly patient|Elderly patient undergoing surgical and non-surgical intervention with the use of anesthesia provided by an anesthetist
2913858|NCT03152721|Placebo Comparator|Control|Treating physician will in advance of upcoming visit be provided with the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment
2913859|NCT03152721|Experimental|Intervention|Treating physician will in advance of upcoming visit be provided with a Parkinson KinetiGraph recording report and interpretation in addition to the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment
2913860|NCT03152695|Experimental|High-intensity focused ultrasound therapy|Abdominal MRI will be used to target the tumor, and the tumor will be divided into slices with 5mm separation using MR images. By scanning the HIFU beam in successive sweeps from the deep to the shallow regions of the tumor.
2913861|NCT03152682|Experimental|Consume GoodIdea at Visit 2 and Placebo at Visit 3|
2913862|NCT03152682|Experimental|Consume Placebo at Visit 2 and GoodIdea at Visit 3|
2913863|NCT03152669||Chronic obstructive pulmonary disease|Subjects with COPD who were randomised to treatment in the original SLS
2913864|NCT03152669||Asthma|Subjects with asthma who were randomised to treatment in the original SLS.
2913865|NCT03152643|Experimental|blastocyst-stage embryo transfer group|For subjects assigned to blastocyst-stage (D5/D6) embryo transfer group, all embryos will be cultured to D5 or D6. 1 blastocysts of the best quality will be transferred in fresh cycle on D5 or D6 after oocyte retrieval (D5 embryo will be the prior choice). The surplus embryos, if any, will be vitrified for future FET in case the fresh cycle does not result in a live birth. If a patient is at a high risk of OHSS, all embryos on D5 or D6 can be cryopreserved with vitrification for patient's safety. The FET cycle will be initiated on the second menstrual cycle after oocyte retrieval. If a live birth is not achieved, single embryo transfers will be consecutively performed 5 times at most.
2913866|NCT03152643|Experimental|cleavage-stage embryo transfer group|For subjects assigned to the cleavage-stage (D2/3) embryo transfer group, 1 cleavage embryos of the best quality will be transferred in fresh cycle on Day 2/3 after oocyte retrieval. The surplus embryos, if any, will be vitrified for future FET if the fresh cycle does not result in a live birth. If a patient is at a high risk of OHSS, all embryos on Day 2/3 are allowed to be cryopreserved with vitrification for patient's safety. The FET cycle will be initiated on the second menstrual cycle after oocyte retrieval. If a live birth is not achieved, single embryo transfers will be consecutively performed 5 times at most.
2913867|NCT03152591|Experimental|LIK066|LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test
2913868|NCT03152591|Placebo Comparator|Placebo|Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test
2913869|NCT03152578|Active Comparator|BetaC + Capsacian|1-3 mls BetaC + Capsacian applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
2913872|NCT03152565|Experimental|Avelumab in combination ADC vaccine|Patients in both phases will receive Avelumab biweekly intravenous during a maximum of 12 months and biweekly 10x106 ADC vaccine (intradermal) for five doses (days 1, 14, 28, 42 and 56) followed by a maximum of 6 doses every 6 months.
2913873|NCT03152552|Experimental|LIK066|Eligible patients randomized to these treatment arms will receive different LIK066 dose regimens (dose A once daily, dose B once daily or dose C once daily) for 36 weeks.
2913874|NCT03152552|Placebo Comparator|Placebo|Patients randomized to this treatment arm will receive LIK066 matching placebo and empagliflozin matching placebo.
2913875|NCT03152552|Active Comparator|Empagliflozin|Patients randomized to this treatment arm will receive empagliflozin once daily for 36 weeks.
2913876|NCT03152539|Experimental|Development of MRI protocols|MRI exam to grade differents interventions for future research
2913877|NCT03152539|Experimental|Development of EEG protocols|EEF exam to grade differents interventions for future research
2913878|NCT03152539|Experimental|Development of NIRS protocols|NIRS exam to grade differents interventions for future research
2913879|NCT03152526|Other|Single-arm trial|Multi-center, open-label, single-arm, phase I/II clinical trial
2913880|NCT03152500|Experimental|FEMTIS IOL|The FEMTIS-IOL has a special haptic system that allows the lens to clamp into the capsulorrhexis.
2913881|NCT03152500|Active Comparator|Acrysof IOL|The Acrysof IOL has a flexible haptic design that keeps the IOL stable and centered in the capsular bag
2913882|NCT03152487|Active Comparator|Celiac Plexus Neurolysis|CPN will be undertaken at the celiac space which is located between the aorta and the celiac artery origin. A 22 or 19-gauge Fine Needle Aspiration (FNA) needle is used, and its tip is placed slightly anterior and cephalic to the origin of the celiac artery. Aspiration is first performed using a syringe to ensure that vascular puncture has not occurred. 10 mL Bupivacaine is injected first, followed by 20 mL of 98% alcohol.
2913883|NCT03152487|Active Comparator|Radiofrequency Ablation|Once the celiac ganglia are identified on EUS, a 19-gauge FNA needle is inserted into the center of the ganglion or area of celiac plexus under EUS guidance. The radiofrequency (RF) probe (EMcision, Montreal, Canada) is advanced through the FNA needle. Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest and repeated as required.
2913884|NCT03152474|Active Comparator|Solumedrol 20mg|Solumedrol injection will be given in the vein every 8 hrs. for 7 days.
2913885|NCT03152474|Active Comparator|Vitamin A 100,000 IU|Vitamin A injection will be given in the arm muscle for 7 days.
2913886|NCT03152474|Placebo Comparator|Placebo|Placebo will be given in the vein every 8 hrs. for 7 days or given in the arm muscle for 7 days.
2913887|NCT03152461||Surgical patients|Patients undergoing elective cardiac or vascular surgery involving bypass, or major spine surgery, or surgical patients presenting with acute bleeding in a post-surgical unit.
2913888|NCT03152448||Early Stage Prostate Cancer|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer
2913889|NCT03152435|Experimental|anti-tumor response of CART-EGFR|
2913890|NCT03152409|Active Comparator|Aspirin augmentation to treatment|Participants who meet inclusion criteria for the study and are randomized to the active treatment arm will be given pills for the ensuing 8 weeks, consisting of a daily dose of aspirin 325 mg to be taken every evening before bed.
2913891|NCT03152409|Placebo Comparator|Placebo augmentation to treatment|Participants randomized to the placebo arm will receive a placebo oral tablet of the same size, shape, and color as the aspirin tablet. Participants will be instructed to take their pills in the evening before bed.
2913892|NCT03152396|Other|Patients with inflammatory arthritis|All patients enrolled have a form of inflammatory arthritis and at least one uncontrolled CV risk factor (i.e. blood pressure, LDL-cholesterol, HbA1C, or current tobacco use). Pharmacist will assess each participants CV risk score using the validated RxEACH CV risk calculator. Over the 6 month intervention period, pharmacists will assist patients to modify a contributing risk factor thru treatment recommendations, prescription adaptation, and prescribing where necessary to meet treatment targets.
2913893|NCT03152383|Experimental|Autism Spectrum Disorder|Children diagnosed as having autism spectrum disorder
2913894|NCT03152383|Active Comparator|Typically developing|Children who are typically developing
2913895|NCT03152383|Active Comparator|Other Developmental Delay|Children diagnosed with a developmental delay other than autism spectrum disorder
2913896|NCT03152370|Experimental|E7046 in combination with Long Course Chemoradiotherapy (LCRT)|Participants will receive once daily (QD) doses of E7046 (recommended Phase 2 dose [RP2D] determined in the Dose-Escalation part of the study) for 10 weeks, starting on Day 1, 14 days prior to initiation of the radiotherapy. LCRT will be initiated on Day 15 and will consist of a total of 45 Grays (GY) radiation administered in 1.8 GY daily doses delivered for 5 days (Monday to Friday) every week for 5 weeks. Capecitabine (825 milligrams per meters squared [mg/m^2]) will be administered twice daily on the days of radiotherapy. Surgery will be performed 14 to 16 weeks from the first day of E7046 treatment.
2913897|NCT03152370|Experimental|E7046 in combination with SCRT followed by chemotherapy|Participants will receive QD doses of E7046 (RP2D determined in the Dose-Escalation part of the study) for 10 weeks, starting on Day 1, 14 days prior to initiation of the radiotherapy. Short course radiotherapy (SCRT) will be initiated on Day 15 and will consist of a total of 25 Gy radiation administered in 5 Gy daily doses for 5 days (Monday to Friday) for 1 week. Ten days after the end of radiotherapy, 3 cycles of the modified folinic acid/5-FU/oxaliplatin (mFOLFOX-6) regimen will be administered every 2 weeks for 2 consecutive days. Surgery will be performed 14 to 16 weeks from the first day of E7046 treatment.
2913898|NCT03152357||Patients implanted with a ConforMIS device|Previously underwent surgical implantation of a ConforMIS iUni, iDuo or iTotal knee replacement
2913899|NCT03152344||COPD patients without chronic respiratory failure|"We will recruit COPD patients in stable condition (free of exacerbation of the disease for a month), 40 without chronic respiratory failure and 40 with home oxygen therapy.~The patients will be proposed to perform the following tests and to fill in questionnaires"
2913900|NCT03152344||COPD patients with home oxygen therapy|"We will recruit COPD patients in stable condition (free of exacerbation of the disease for a month), 40 without chronic respiratory failure and 40 with home oxygen therapy.~The patients will be proposed to perform the following tests and to fill in questionnaires"
2913901|NCT03152331|Experimental|Receptive Awareness Training|
2914160|NCT03150628|Experimental|Study population|
2913902|NCT03152318|Experimental|Arm A- rQNestin|"Arm A is rQNestin34.5v.2 treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A.~Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent.~rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose"
2913903|NCT03152318|Experimental|Arm B- rQNestin+CPA|"Arm B is rQNestin34.5v.2 treatment with Cyclophosphamide (CPA) pre-treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A.~Cyclophosphamide one intravenous injection 2 days prior to procedure.~Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent.~rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose"
2913904|NCT03152305||Women with menstrual migraine|Womens presenting with regular menstrual migraine treated with triptans will be included in the study.
2913905|NCT03152305||Matched control|The potential variations will be compared to the measures done on matched healthy women outside and during menses.
2913906|NCT03152292||Group 1: Parkinson Disease Psychosis (PDP) patients|PDP patients not treated with an antipsychotic at the time of enrollment
2913907|NCT03152292||Group 2: Parkinson Disease Psychosis (PDP) patients|PDP patients treated with an antipsychotic (other than NUPLAZID®) at the time of enrollment
2913908|NCT03152292||Group 3: Parkinson Disease Psychosis (PDP) patients|PDP patients treated with NUPLAZID® at the time of enrollment
2913909|NCT03152279||Celiac Disease|Patients with suspected Celiac Disease who plan to undergo duodenal biopsy as part of routine clinical care
2913910|NCT03152279||Control|Patients scheduled for an upper endoscopy for indication other than evaluation of Celiac Disease or concern for CeD as part of routine clinical care
2913911|NCT03152253|Experimental|TMQ|smoking cessation promotion messages and medication reminders sent via text messages for up to 30 days before quit day and 8 weeks following quit day, along with access to a social support chat room
2913912|NCT03152253|Placebo Comparator|Mojo|General motivational text messages sent on the same schedule at TMQ arm of the study with access to a social support chat room.
2913913|NCT03152240||Women patients|Women patients
2913914|NCT03152240||Men patients|Men patients
2913915|NCT03152227|Experimental|ACGG & ATONU|ACGG high-producing chicks to households along with provision of technical input on production and ATONU Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
2913916|NCT03152227|Active Comparator|ACGG only|ACGG high-producing chicks to households along with provision of technical input on production
2913917|NCT03152227|No Intervention|Control|ACGG eligible households in non-ACGG villages receiving standard of care agricultural and health services as provided in Ethiopia
2913918|NCT03152214|Experimental|Team RWB + Vigorous Intensity Aerobic Exercise|"Participants assigned to the integrated arm will be prescribed the following for the course of 8 weeks:~1 session of exercise counseling~3 weekly 25-minute sessions of vigorous intensity aerobic exercise~1 weekly Team RWB event~4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
2913919|NCT03152214|Active Comparator|Team RWB|"Participants assigned to the Team RWB arm will be prescribed the following for the course of 8 weeks:~1 weekly Team RWB event~4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
2913920|NCT03152214|No Intervention|Waitlist|"Participants assigned to the waitlist arm will be prescribed the following for the course of 8 weeks:~• 4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
2913921|NCT03152188|Experimental|FMT|Fecal Microbiota Transplantation (FMT) capsules
2913922|NCT03152188|Placebo Comparator|Placebo|Placebo capsules
2913923|NCT03152175|Experimental|Propranolol Hydrochloride|1mg / kg of propranolol hydrochloride administered as a capsule 60 minutes prior to memory reactivation
2913924|NCT03152175|Placebo Comparator|Placebo|Placebo manufactured as a capsule to mimic 1mg/kg of propranolol hydrochloride administered 60 minutes prior to memory reactivation
2913925|NCT03152149|Active Comparator|1. Spiolto Respimat|Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
2913926|NCT03152149|Active Comparator|2. Relvar Ellipta|Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
2913927|NCT03152136|Experimental|TAPS|Subjects will receive a Cala ONE device that delivers TAPS, transcutaneous afferent patterned stimulation.
2913928|NCT03152136|Sham Comparator|Sham|Subjects will receive a Cala ONE device that delivers sham stimulation.
2913929|NCT03152136|No Intervention|No Intervention|Subjects will not receive a Cala ONE device, and will stay on their current treatment regimen for their essential tremor.
2913930|NCT03152123|Experimental|Pitolisant HCl, 40 mg|Pitolisant HCl, 40 mg administered as 2 capsules, each containing 1 × 20 mg pitolisant HCl tablet (over-encapsulated), and 2 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
2913931|NCT03152123|Experimental|Pitolisant HCl, 240 mg|Pitolisant HCl, 240 mg administered as 4 capsules, each containing 60 mg pitolisant HCl (3 x 20 mg pitolisant HCl tablets, encapsulated in 1 capsule)
2913932|NCT03152123|Active Comparator|Phentermine HCl, 60 mg|Phentermine HCl, 60 mg administered as 2 capsules, each containing 1 × 30 mg phentermine HCl capsule (over- encapsulated), and 2 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
2913933|NCT03152123|Placebo Comparator|Placebo|Placebo administered as 4 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
2913934|NCT03152110|Experimental|HIIT|Exercise sessions will be 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.
2913935|NCT03152097|Placebo Comparator|Placebo|This crossover design will include 4 weeks of diindolylmethane and 4 weeks of matching placebo assignment.
2914928|NCT03145207|Other|generic patch-early|generic lidocaine patch-early
2913938|NCT03152084|Experimental|Arm 2|T2DM subjects with an eGFR (CKD-EPI) between >90 and ≤130 mL/min/1.73m2 for patients aged 59 or younger, between >85 and ≤130 mL/min/1.73m2 for patients aged 60 to 69, and between >75 and ≤130 mL/min/1.73m2 for patients aged 70 or older at the Screening Visit.
2913939|NCT03152084|Experimental|Arm 3|Non-diabetic subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
2913940|NCT03152071|Experimental|Robot assisted thoracic surgery|RATS
2913941|NCT03152071|Active Comparator|Video assisted thoracic surgery|VATS
2913942|NCT03152058|Experimental|Certolizumab Pegol|"All participants are administered certolizumab [400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter.~1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
2913943|NCT03152045|Experimental|Communication Intervention|Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
2913944|NCT03152045|No Intervention|Standard Of Care|Investigators will compare patients randomized into the intervention group to those who receive standard of care.
2913945|NCT03152032|Experimental|In-House Vocational Training Programs|The In-House Vocational Training Programs were government-funded services offered to newly discharged inpatients or current outpatients with chronic psychiatric disorders in four regional psychiatric hospitals of Taiwan. The programs emphasized the utilization of the hospitals' existing spaces, facilities and manpower alongside the community sources to train participants in various job options including bakery training, culinary skill, barista training, computer data processing, auto wash and detailing, janitorial training, and wash and fold laundry service. Each program was staffed with occupational therapists and paid or volunteer job coaches, along with cross-disciplinary support from psychiatrists, psychologists, social workers, nurses, vocational specialists or others.
2913946|NCT03152019|Active Comparator|Protopic® 0.1% (Tacrolimus) ointment|Protopic® 0.1% ointment, packed in blinded tube of 30g.
2913947|NCT03152019|Placebo Comparator|Placebo ointment|Same formulation as the Protopic® 0.1% ointment but without tacrolimus, packed in blinded tube of 30g.
2913948|NCT03152006|No Intervention|Control|The control arm does not receive the ACT intervention.
2913949|NCT03152006|Experimental|ACT Intervention|Intervention activities include the three components of the ACT intervention: (1) alternating pediatric and adult clinic visits in the 12 month pre-transfer period (2) peer facilitated organized support group during the 24-month graduated transition period and (3) patient advocate and case management team to coordinate transfer process.
2913950|NCT03151993|Experimental|Recombinant staphylokinase|Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
2913951|NCT03151993|Active Comparator|Actilise|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
2913952|NCT03151980|Active Comparator|Hamam treated skin and sun exposure|
2913953|NCT03151980|Other|Untreated skin and sun exposure|
2913954|NCT03151967|Active Comparator|applicator containing active drug|Vaginal applicator containing Lactobacillus crispatus CTV-05
2913955|NCT03151967|Placebo Comparator|placebo vaginal applicator|Inactive vaginal applicator without any drug
2913956|NCT03151954|Experimental|nasal polyps|"Explore the degree of abnormal proliferation in NESCs,and analyze the relationship between the proliferation and the activation of hippo-YAP pathway,then explore the levels of LPS and Th2/17 cytokines in nasal polyps,and the relation between cytokines and the activation of hippo-YAP pathway through Immunohistochemistry and Immunofluorescence （P63、Ki67、YAP、LATS1/2 and MST1/2），as well as Western Blot and the Flow cytometry.~Explore if the LPS and LPS and Th2/17 cytokines, as well as the epidermal growth factors can effect the hippo-YAP pathway of NESCs through cell culture, Western Blot and Real time PCR,and test the YAP expression and location through Immunohistochemistry.~Explore that how the hippo-YAP effect the proliferation and differentiation of NESCs through cell transfection;~Explore the regulation of hippo-YAP pathway in NESCs."
2913957|NCT03151954|Placebo Comparator|inferior turbinate|Compared with nasal polyps,explore the levels of LPS and Th2/17 cytokines in nasal polyps,and the relation between cytokines and the activation of hippo-YAP pathway through Immunohistochemistry and Immunofluorescence（P63、Ki67、YAP、LATS1/2 and MST1/2），as well as Western Blot and the Flow cytometry.
2913958|NCT03151928||women presenting with vaginitis symptoms|"Women with vaginitis seeking routine care will be approached to have five additional swabs collected during their pelvic exam~vaginal swab for qualitative PCR using the BD Max Vaginal Panel on the automated BDMAX System~Vaginal smear for evaluation with Gram's stain and Nuget's criteria~Vaginal swab for yeast culture~Vaginal swab for Trichomonas vaginalis NAAT~Vaginal swab for discrepant analysis testing"
2913959|NCT03151915||Patients who underwent fetoscopic laser coagulation with TTTS|This is an retrospektive trial. We use data of patients who underwent fetoscopic laser coagulation with TTTS retrospectively. All patients meet eligibility criteria and give written informed consent before therapy. As part of the ongoing quality control we were able to safely store patient data relating to fetoscopic laser coagulation with TTTS.
2913960|NCT03151889|Experimental|TENS Group|TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
2913961|NCT03151889|No Intervention|Control Group|Control Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux) and Post-test evaluations.
2913962|NCT03151876|Experimental|ChiCGB|"Experimental: ChiCGB~Chidamide administered orally on D-7, -4, 0,+3~Cladribine administered at 10mg on D-6 to D-2~Gemcitabine administered at 2500 mg/m2 on days -6 and -2.~Busulfan administered at 3.2 mg/kg (adjusted ideal body weight) on days -6 to -3.~Dexamethasone 10 mg by vein daily from day -6 to day -1. Caphosol oral rinses 30 mL four times a day used from day -8.~Interventions:~Drug: Chidamide Drug: Cladribine Drug: Gemcitabine Drug: Busulfan Drug: Dexamethasone Procedure: Stem Cell Transplant"
2913963|NCT03151863|Active Comparator|Opioids, placebo|One single dose of subcutaneous opioids and intranasal placebo (NaCl0.9%).
2913964|NCT03151863|Experimental|Placebo, Dexmedetomidine|One single dose of subcutaneous placebo (NaCl0.9%) and intranasal Dexmedetomidine 1.25ug/Kg
2913965|NCT03151850||ulcerative colitis|We analysed the diversity of the fungal and bacterial in patients with Ulcerative Colitis (UC). We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
2913966|NCT03151850||Control|Analysing the diversity of the fungal and bacterial in patients without ulcerative colitis. We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
2913967|NCT03151837|Experimental|Momordica charantia|Subjects will take the capsule of Greenyn Momordica charantia extracts 600 mg/day orally for three months.
2913968|NCT03151837|Placebo Comparator|Placebo control|Subjects will take the capsule of Placebo 600 mg/day orally for three months.
2913969|NCT03151811|Experimental|Arm A: Melflufen+Dexamethasone|Melflufen 40 mg i.v. on Day 1 and dexamethasone 40 mg on Days 1, 8, 15 and 22 of each 28-day cycle. Patients are to be treated until confirmed progression, unacceptable toxicity or the patient or investigator decides it is not in the patients best interest to continue.
2913970|NCT03151811|Active Comparator|Arm B: Pomalidomide+Dexamethasone|Pomalidomide 4 mg orally daily on Days 1 to 21 and dexamethasone 40 mg on Days 1, 8, 15 and 22 of each 28-day cycle. Patients are to be treated until confirmed progression, unacceptable toxicity or the patient or investigator decides it is not in the patients best interest to continue.
2913971|NCT03151798|Experimental|Phase I: Observational studies|Patients are eligible who are undergoing either bariatric surgery or a liver biopsy for the diagnosis of nonalcoholic fatty liver disease
2913972|NCT03151798|Experimental|Phase II: Lifestyle treatment|Subjects will undergo lifestyle modification to cause weight loss and improved fitness
2913973|NCT03151798|Placebo Comparator|Phase II: Control treatment|Subjects will be given dietary advice and a stretching program.
2913974|NCT03151785|Active Comparator|Face-to-face BLS training|Pupils will receive CPR training by standardised face-to-face BLS training only
2913975|NCT03151785|Active Comparator|Lifesaver training|Pupils will receive CPR training by Lifesaver programme only
2913976|NCT03151785|Active Comparator|Lifesaver and Face-to-Face BLS training|Pupils will receive CPR training by Lifesaver and standardised face-to-face BLS training
2913977|NCT03151772|Experimental|Disulfiram|Disulfiram 200 mg twice daily and copper 2,5 mg once daily. For bioavailability purpose only, treatment is withdrawn postoperatively
2913978|NCT03151772|Experimental|Metformin|Metformin 850 mg x 3 daily. For bioavailability purpose only, treatment is withdrawn postoperatively
2913979|NCT03151759||No radiotherapy|Surgery only
2913980|NCT03151759||25 Gray radiotherapy|Surgery after short term radiotherapy
2913981|NCT03151759||50 Gray radiotherapy|Surgery after long term radiotherapy
2913982|NCT03151746|Placebo Comparator|Placebo|Placebo pill administered 1 hour before planned surgical procedure
2913983|NCT03151746|Experimental|Gabapentin|Gabapentin pill (1200mg) administered orally 1 hour prior to planned surgical procedure
2913984|NCT03151733|Experimental|single incision laparoscopic surgery|patients with colorectal cancer and undergo single incision laparoscopic surgery
2913985|NCT03151733|Placebo Comparator|Conventional laparoscopic surgery|patients with colorectal cancer and undergo conventional laparoscopic surgery
2913986|NCT03151720|Experimental|Cohort 1: Sequence 1 (ABAB)|Participants will receive 10 milligram (mg) loratadine (1*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
2913987|NCT03151720|Experimental|Cohort 1: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
2913988|NCT03151720|Experimental|Cohort 2: Sequence 1 (ABAB)|Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
2913989|NCT03151720|Experimental|Cohort 2: Sequence 1 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
2913990|NCT03151707|Experimental|Nicotinamide riboside 1000 mg/day|
2913991|NCT03151694||DRD4 and DRD2 Polymorphism Detection|The genetic component of endophenotype for responsiveness to environment (ERE) will be characterized with reference to Taq1A allele in dopamine-2 receptor (DRD2) gene and the exon 3 7-repeat allele of the dopamine-4 receptor (DRD4) gene. This will assist in understanding the role of DRD2 and DRD4 in shaping the neurocognitive functions and link to the eating behaviors of the children and other primary outcome variables.
2913992|NCT03151681|Experimental|Propranolol pill + memory reactivation|
2913993|NCT03151681|No Intervention|Waitlist|
2913994|NCT03151668|Experimental|Dexmedetomidin|
2913995|NCT03151668|No Intervention|Midazolam|
2913996|NCT03151655|Experimental|MATTeRS Video|
2913997|NCT03151655|Active Comparator|Didactic Video|
2913998|NCT03151629||Castrate Resistant Prostate Cancer|
2913999|NCT03151629||Hormone Sensitive Prostate Cancer|
2914000|NCT03151616||No anticholinergic exposure|People with an anticholinergic risk scale score of 0
2914001|NCT03151616||Moderate anticholinergic exposure|People with an anticholinergic risk scale score of 1-2
2914002|NCT03151616||High anticholinergic exposure|People with an anticholinergic risk scale score of >=3
2914003|NCT03151603|Experimental|Uva Ursi|"placebo to fosfomycin: 3 g granules orally 1x1 (day 0)~and~Uva Ursi: 105 mg (Arctuvan®) 3x2 tablets orally from day 0 for 5 days"
2914004|NCT03151603|Active Comparator|fosfomycin|"fosfomycin (Monuril®): 3 g granules orally 1x1 (day 0),~and~placebo to Uva Ursi: 3x2 tablets orally from day 0 for 5 days~If the patient returns with persistent/recurrent symptoms, antibiotic therapy according to the sensitivity test."
2914005|NCT03151577|Other|Evolution of IOP after XEN® Gel Stent implantation|To study the efficacy of the XEN® Gel Stent in lowering the IOP.
2914006|NCT03151564|Experimental|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
2914007|NCT03151564|Experimental|Computed tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
2914008|NCT03151551|Experimental|Ixekizumab|Ixekizumab given subcutaneously (SC).
2914009|NCT03151551|Active Comparator|Adalimumab|Adalimumab given SC.
2914010|NCT03151538|Experimental|Pes Planus Group|This group of patients received children with pes planus. It will be applied exercise training mixed with play
2914011|NCT03151538|Other|Controlled Group|This group of patients received healthy children.
2914012|NCT03151525|Experimental|Azathioprine|Azathioprine 2-2.5 mg/kg/day, according to approved indication
2914013|NCT03151525|Active Comparator|Infliximab|Infliximab 5 mg/kg every 8 weeks
2914014|NCT03151499|Experimental|All Subjects|Reference Treatment (BI 409306) given alone followed by Test Treatment (BI 409306 + Rifampicin)
2914015|NCT03151486|Experimental|Cohort 1:JNJ-55308942 0.5 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 0.5 milligrams (mg) or matching placebo as an oral solution after an overnight fast on Day 1 of Cohort 1 after single ascending dose (SAD).
2914016|NCT03151486|Experimental|Cohort 2: JNJ-55308942 1.5 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 1.5 mg or matching placebo as an oral solution after an overnight fast on Day 1.
2914017|NCT03151486|Experimental|Cohort 3: JNJ-55308942 4 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 4 mg or matching placebo as an oral solution after an overnight fast on Day 1.
2914018|NCT03151486|Experimental|Cohort 4: (JNJ-55308942 12 mg or Placebo (SAD Part))|Participants will be randomized to receive a single dose of JNJ-55308942 12 mg or matching placebo as an oral solution after an overnight fast on Day 1.
2914019|NCT03151486|Experimental|Cohort 5: JNJ-55308942 36 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 36 mg or matching placebo as an oral solution after an overnight fast on Day 1.
2914020|NCT03151486|Experimental|Cohort 6: JNJ-55308942 100 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 100 mg or matching placebo as an oral solution after an overnight fast on Day 1.
2914021|NCT03151486|Experimental|Cohort 7: JNJ-55308942 or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 or matching placebo as an oral solution in a fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
2914022|NCT03151486|Experimental|Cohort 1: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the multiple ascending doses (MAD) will be determined based on the data from the SAD part.
2914023|NCT03151486|Experimental|Cohort 2: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
2914024|NCT03151486|Experimental|Cohort 3: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
2914025|NCT03151460|Experimental|Parkinson|Patients with Parkinson's disease assuming or not Dopamine Agents
2914026|NCT03151460|No Intervention|Normal Controls|Age and education comparable healthy subjects
2914027|NCT03151447|Experimental|SBRT in combined with anti-PD-1 antibody|Patients will receive stereotactic body radiation therapy to metastatic lesions of liver, lung, bone, brain or lymph nodes and concurrent anti-PD-1 antibody treatment.
2914028|NCT03151434|Active Comparator|Group #1|US Guided Single Shot Paravertebral Block
2914029|NCT03151434|Active Comparator|Group #2|US Guided Paravertebral Catheter
2914030|NCT03151434|Active Comparator|Group #3|Thoracic Epidural
2914031|NCT03151421|Experimental|Home air quality monitoring and feedback|Home air quality monitoring and feedback
2914032|NCT03151408|Experimental|Pracinostat plus AZA|60 mg capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.
2914033|NCT03151408|Placebo Comparator|Placebo plus AZA|1 capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.
2914034|NCT03151395|Other|Total Group|A cohort of approximately 200 moderate to very severe COPD patients with at least 1 documented moderate or severe AECOPD in the year before enrolment and for whom sputum and blood samples will be collected during specified visits.
2914035|NCT03151382|Experimental|Experimental group|
2914036|NCT03151382|Other|Control group|
2914037|NCT03151369|Other|Morphine|patients with the visual analog scale over 3 will receive morphine
2914038|NCT03151356||Patients|Patients addressed for prostate biopsies because of clinical and/or biological suspicion of prostate cancer.
2914039|NCT03151343|Experimental|Empagliflozin|Empagliflozin, coated tablets, 25mg, once daily, for 13 weeks
2914040|NCT03151343|Placebo Comparator|Placebo|Placebo, coated tablets, once daily, for 13 weeks
2914041|NCT03151330|Other|Screened arm|This will be an arm of women who are prospectively screened and receive a risk score for preterm birth. They will be recommended treatment strategies and their outcomes compared to an historical control.
2914042|NCT03151317||With therapeutic education|Patients assigned to this group will have participated in a therapeutic education program.
2914043|NCT03151317||Without therapeutic education (control)|Patients assigned to this (control) group have not had any kind of therapeutic education.
2914161|NCT03150615|Experimental|Early enteral nutrition|Nasojejunal tube insertion was done intraopratively. Early enteral nutrition with standard enteral formulas administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
2914044|NCT03151304|Experimental|Stage 1a and 1b open-label pracinostat plus azacitidine|"open-label single arm pracinostat plus azacitidine. Pracinostat: 45 mg administered orally 3 days each week for 3 consecutive weeks, followed by 1 week of rest, in 28-day cycles.~In later cycles (i.e., after Cycle 4), pracinostat dose reduction to 45 mg orally 3 days each week × 2 weeks (instead of 3 weeks) or dose interruption is allowed to manage toxicity such as fatigue, gastrointestinal toxicity, or myelosuppression.~Azacitine: 75 mg/m2 for 7 days of each 28-day cycle. Administration will occur by subcutaneous (SC) injection, or IV infusion if SC injections are not tolerated, on one of two schedules:~Schedule 1 - daily therapy on Days 1 through 7~Schedule 2 - 5-2-2 schedule in which subjects receive azacitidine for 5 consecutive days (Days 1 through 5) with rest on Days 6 and 7, and resume azacitidine dosing the first two days of the next week (Days 8 and 9) of each 28-day cycle"
2914045|NCT03151291|No Intervention|Control group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
2914046|NCT03151291|Experimental|EMS group|"physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
2914047|NCT03151291|Experimental|HMB group|HMB supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with HMB (3 g/d)
2914048|NCT03151291|Experimental|HMB+EMS group|"HMB supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with HMB (3 g/d)"
2914049|NCT03151291|Experimental|LC group|LC supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with LC (4 g/d)
2914050|NCT03151291|Experimental|LC+EMS group|"LC supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with LC (4 g/d)"
2914051|NCT03151291|Experimental|EPA group|EPA supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with EPA (2.2 g/d)
2914052|NCT03151291|Experimental|EPA+EMS group|"EPA supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with EPA (2.2 g/d)"
2914053|NCT03151278|Experimental|Zero-fluoroscopy ablation|Atrial arrhythmias will be mapped and ablated under the guidance of Ensite NavX without fluoroscopy.
2914054|NCT03151278|Active Comparator|Conventional fluoroscopy ablation|Atrial arrhythmias will be mapped and ablated under the guidance of X-ray plus any tree dimensional mapping system.
2914055|NCT03151265|Experimental|Low Back Pain Group|"Low Back Pain (LBP) group will be assessed on two consecutive days. The first day will have no ThermaCare intervention applied, and is for a Baseline assessment of flexibility, muscle relaxation and low back pain.~The second day will have the ThermaCare Low Back Heat Wrap intervention applied, and will have the same assessments as the Baseline day."
2914056|NCT03151265|Experimental|Active in Sport Group|"Sport group will be assessed on two consecutive days. The first day will have no ThermaCare intervention applied, and is for a baseline assessment of flexibility, muscle relaxation and low back pain.~The second day will have the ThermaCare Low Back Heat Wrap intervention applied, and will have the same assessments as the Baseline day."
2914057|NCT03151252|Other|Food allergy|Patients with confirmed foodspecific- IgE antibodies in blood
2914058|NCT03151252|Other|healthy controls|participants without foodspecific- IgE antibodies in blood and other gastrointestinal symptoms
2914059|NCT03151252|Other|gastointestinal symptoms without foodallergy in blood|Patients without foodspecific- IgE antibodies in blood, but with gastrointestinal symptoms
2914060|NCT03151239|Placebo Comparator|Placebo|
2914061|NCT03151239|Experimental|NMN supplementation|
2914062|NCT03151226|Other|capnography monitoring|single arm, all subjects receiving duramorph will receive capnography monitoring
2914063|NCT03151213|Active Comparator|Pregabalin|Pregabalin 150 mg before intervention
2914064|NCT03151213|Placebo Comparator|Placebo|Placebo before intervention
2914065|NCT03151200|Active Comparator|binocular treatment|Active treatment group will receive five days of one hour visual binocular training by playing a specifically designed falling blocks video game on a computer screen that will be individually calibrated for each person with red-green glasses with treatment effect.
2914066|NCT03151200|Sham Comparator|sham treatment|Sham treatment group will receive five days of one hour sham visual binocular training by playing a specially designed falling blocks video game on a computer screen with polarized glasses with no treatment effect.
2914067|NCT03151187|Experimental|Curriculum administered prior to OSCE|Programs randomized to this arm will receive the teaching intervention (two 2 hour lectures) prior to the OSCE.
2914068|NCT03151187|Active Comparator|Curriculum administered after OSCE|Programs randomized to this arm will receive the teaching intervention (two 2 hour lectures) after the OSCE.
2914069|NCT03151174|Experimental|Vitamin D - 10000IU|These individuals have been categorized as Vitamin D deficient and will receive 10000IU of Vitamin D per day.
2914070|NCT03151174|Experimental|Vitamin D - 5000IU|These individuals have been categorized as Vitamin D insufficient and will receive 5000IU of Vitamin D per day.
2914071|NCT03151174|No Intervention|Placebo|These individuals have been categorized as Vitamin D sufficient and will receive placebo.
2914072|NCT03151161|Experimental|Experimental Group|"Chemotherapy regime: Pemetrexed (500mg/m2) + Carboplatin (AUC=5), 1 cycle every 3 weeks, maximum 4 cycles;~Intermittent regime: Icotinib 125mg, three times a day, d2-15 in each cycle; maintenance regime: icotinib 125mg, three times a day, since the last cycle until disease progression."
2914073|NCT03151161|Active Comparator|Control Group|Single drug: Icotinib 125mg, three times a day, continous until disease progression
2914162|NCT03150615|Placebo Comparator|Saline Group|Nasojejunal tube insertion was done intraopratively. Saline was administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
2914929|NCT03145207|Other|generic patch-late|generic lidocaine patch-late
2914074|NCT03151148|Experimental|TMT Lotion|The targeted microbiome transplant (TMT) lotion will be provided in single-dose sealed packets. The lotion should be stored at 4°Celsius (=39.2 degrees Fahrenheit). Participants randomized to active TMT will apply 2 grams of TMT to each ventral aspect of their arm (wrist to upper humerus). Frequency of lotion application: topical application administered twice daily for one week.
2914075|NCT03151148|Placebo Comparator|Placebo Lotion|Placebo lotion will be provided in single-dose sealed packets. The lotion should be stored at 4°Celsius (=39.2 degrees Fahrenheit). Participants randomized to placebo will apply 2 grams of placebo to each ventral aspect of their arm (wrist to upper humerus). Frequency of lotion application: topical application administered twice daily for one week.
2914076|NCT03151135||AN patients|Patients with Anorexia Nervosa (AN). No intervention, observation at end of inpatient treatment
2914077|NCT03151122|Experimental|continuous care group|continuous care group (CCG): This is the experimental group where continuous care supported would be offered by the nurse coordinated integrative health care team. which is, parents in this group receive support during infant hospitalization. The support covers both hospitalization phase and after-discharge phase. In-hospital support include educational support and promoting mother-infant attachment. Nurses will be responsible for home visits after infant discharge.
2914078|NCT03151122|Active Comparator|routine care group|Routine Care Group (RCG): This is the comparison group of preterm infants. the routine care interventions generally include telephone reminding about follow-up care of the infants and hotline for parents to call when needed.
2914079|NCT03151096|Experimental|treatment arm|5mg Riboflavin pills
2914080|NCT03151096|Placebo Comparator|Placebo arm|Placebo pills
2914081|NCT03151083|Experimental|Experimental Implementation strategy|The experimental implementation strategy consists of (1) a clinical intermediary for patient support, (2) provider/staff facilitation and education to empower adoption, (3) patient education to facilitate engagement and completion, and (4) a process of stepped-care to identify and refer individuals requiring a higher level of care.
2914082|NCT03151070||Zone 1|"Zone 1 includes the following communities from Huehuentenango Distric:~San Rafael Petzal~San Sebastian Huehuetenango~San Gaspar Ixchil~Santa Bárbara~Colotenango~Aguacatán"
2914083|NCT03151070||Zone 2|"Zone 2 includes the following communities from Alta Verapaz district:~Tamahú~San Miguel Tucurú~Panzós~Senahú~Telemán"
2914084|NCT03151070||Zone 3|"Zone 3 includes the following communities from Huehuetenango district:~San Idelfonso Ixtahuacán~La Democracia~San Juan Atitán~Tectitán~Santiago Chimaltenango"
2914085|NCT03151070||Zona 4|"Zone 4 includes the following communities from Alta Verapaz district:~Lanquín~Santa María Cahabón~Chisec~Chahal~Raxruhá~Campur"
2914086|NCT03151070||Zona 5|"Zone 5 includes the following communities from Huehuetenango district:~Nenton~Jacaltenango~Todos Santos Cuchumatán~Santa Eulalia~San Mateo Ixtatán~San Juan Ixcoy"
2914087|NCT03151070||Zona 6|"Zone 6 includes the following communities from Alta Verapaz district:~Santa Cruz Verapaz~Tactic~San Pedro Carchá~San Juan Chamelco"
2914088|NCT03151057|Experimental|Idelalisib 100mg|"Idelalisib is an orally-administered, selective inhibitor of Phosphoinositide 3 kinase (PI3K)-delta which has been shown to be extremely effective in inducing partial to complete responses in many B-cell derived malignancies.~intervention: 100mg Idelalisib twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant"
2914089|NCT03151057|Placebo Comparator|Placebo oral tablet|Placebo to be taken twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant
2914090|NCT03151044|Experimental|EPI-90|"Participants in this arm shall be given high-dose Epirubicin Combined with CVP ± Rituximab for six 21-day cycles:~High-dose Epirubicin 90mg/m2, i.v., Day 1; Cyclophosphamide 750mg/m2, i.v., Day 1; Vincristine 1.4mg/m2, i.v., Day 1; Prednisolone 100mg/m2, p.o., Day 1-5;~Plus/not plus:~Rituximab 375mg/m2, i.v., Day 0"
2914091|NCT03151044|Active Comparator|EPI-75|"Participants in this arm shall be given standard-dose Epirubicin, Combined with CVP ± Rituximab for six 21-day cycles:~Standard-dose Epirubicin 75mg/m2, i.v., Day 1; Cyclophosphamide 750mg/m2, i.v., Day 1; Vincristine 1.4mg/m2, i.v., Day 1; Prednisolone 100mg/m2, p.o., Day 1-5;~Plus/not plus:~Rituximab 375mg/m2, i.v., Day 0"
2914092|NCT03151031|Experimental|Experimental Group|In the experimental group, the participants will be asked to perform star excursion balance test (SEBT) under two conditions, before and after the application of cryotherapy
2914093|NCT03151031|No Intervention|Control Group|In the control group, the participants will be asked asked to perform star excursion balance test (SEBT) under two conditions, before and after 10 minutes rest
2914094|NCT03151018||Onyx|The patients who received PCI with Resolute Onyx stent(s)
2914095|NCT03151005|Experimental|Metformin-GLP-1 Receptor Agonist|Metformin-GLP-1 Receptor Agonist Therapy: metformin 0.5 g/time by mouth, 3 times per day, with 5 ug exenatide subcutaneous injection twice per day, for 4 weeks, then change to 10ug exenatide subcutaneous injection twice per day for 8 weeks; or metformin 0.5 g/time by mouth, 3 times per day, with 0.6mg liraglutide subcutaneous injection once per day, for 1 weeks, then change to 1.2-1.8 mg liraglutide subcutaneous injection according to patient's blood glucose condition, twice per day for 8 weeks.
2914096|NCT03151005|Active Comparator|Metformin-Oral Contraceptive(OC)|Metformin-Oral Contraceptive(OC) Therapy: metformin 0.5 g/ time by mouth, 3 times per day, with Diane 35(OC) 1 piece per day by mouth, for 12 weeks.
2914097|NCT03150992|Experimental|Elemental 028 Extra Liquid|All patients will be assessed and given an individual plan for Elemental Diet (ED) introduction. The actual amount of ED prescribed will depend on the tolerance and palatability and not nutritional status. The recommendation of a minimum of 2 cartons of ED will be drunk orally by patients, along with other clear fluids only. Following introduction of ED, patients will be discharged from hospital (if applicable) and followed up for 2 weeks. They will have a telephone follow-up assessment once a week for 2 weeks. All other assessments will follow the standard of care. During the follow-up patients will be assessed using the Memorial Symptom Assessment Scale (MSAS) and will be asked to complete a nutritional diary every day and a quality of life questionnaire at several time points.
2914163|NCT03150615|Other|ERAS Group|Nasojejunal tube insertion was done intraopratively. None was administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
2914164|NCT03150602|Experimental|Pralatrexate treatment|Pralatrexate will initially be administered at a dose of 30 mg/m2/week on days 1, 8, 15, 22, 29 and 36 for 6 weeks in a 7-week cycle (cycle: 6 weeks + 1 week rest). The scheduled date can be done within a window time of plus or minus 1 day
2914098|NCT03150979|Experimental|Provision of a cane|The experimental group will receive a single-point cane, with ergonomic handgrip, which will be individually adjusted to the participant's height. A physiotherapist will provide instructions on how to walk with the cane and the participants will practice for about 15 minutes or until they feel comfortable with the device. Then, they will take the cane home and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.
2914099|NCT03150979|Other|Control|The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
2914100|NCT03150966|Experimental|Patients who received nanocurcumin|
2914101|NCT03150966|Placebo Comparator|Patients who received placebo|
2914102|NCT03150953|No Intervention|Standard of Care|Patients will receive standard of care which is 1-2 warm blankets.
2914103|NCT03150953|Experimental|MRI-safe warming device|The MRI-safe bore covering consists of a clear covering sheet positioned over the openings of the MRI scanner.
2914104|NCT03150953|Experimental|MRI-safe warming device and Bair hugger|IN addition to positioning the MRI-safe bore covering over the opening of the MRI scanner, the opening of the covering sheet will be connected to a device which blows warm air called a Bair Hugger. The Bair Hugger is an approved device, and MRI safe.
2914105|NCT03150940||Duke University Athletes|"Division 1 Athletes, participating in obligatory screening prior to athletic competition every summer. The investigators are observing required study outcomes (ECGs, history and physicals, and ultrasounds) to see what is useful in the screening.~ECG: 12 lead electrocardiogram that visualizes cardiac activity~history and physical: background information about athlete's and their family history~ultrasound: bedside cardiac ultrasound to visualize 2D imaging of structural cardiac function"
2914106|NCT03150927|Experimental|Probiotic Microbial Composite|Probiotic Microbial Composite is a safe, 100% natural material containing all Generally Recognized as Safe (GRAS) Probiotics, combined with FDA approved food grade excipient materials. The probiotics contained within are also all 100% natural and non-Genetically Modified Organisms (non-GMO).
2914107|NCT03150927|Placebo Comparator|Placebo|Placebo is a mixture of inactive ingredients found in Probiotic Microbial Composite. These ingredients are FDA approved food grade materials, 100% natural and palatable.
2914108|NCT03150914|Placebo Comparator|Placebo|Overencapsulated matrix
2914109|NCT03150914|Active Comparator|Treatment|Over-encapsulated .5 mg or 1 mg sirolimus tablet
2914110|NCT03150901||diabetic patients|"In a prospective study, we will collect wound edge tissue specimens from 75 patients with DF during surgical debridement. From each patient, 1-4 specimens will be obtained per debridement. To evaluate debrided tissue, each specimen will be processed for paraffin embedding and stained with haematoxylin and eosin. Histopathology analysis of multiple specimens acquired from the same wound will be analysed. Full-thickness epidermis biopsies will be followed by biomarker assessment such as:~Expression of insulin-like growth factor 1 receptor (IGF-1R)~Adiponectin~Leptin~Resistin~Osteocalcin~Osteoprotegerin~Insulin, c-peptid~HOMA-IR"
2914111|NCT03150888||Hospital based hypertension cohort|
2914112|NCT03150888||Community based hypertension cohort|
2914113|NCT03150875|Experimental|IBI308|injection; dosage form: 10ml:100mg; frequency: 200mgQ3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
2914114|NCT03150875|Active Comparator|docetaxel|injection; dosage form: 1ml:40mg; Frequency: 75mg/m2 Q3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
2914115|NCT03150862|Experimental|Arm A (Dose Escalation)|Approximately 18 subjects (newly diagnosed unmethylated GB) to receive BGB-290 and radiation therapy
2914116|NCT03150862|Experimental|Arm B (Dose Escalation)|Approximately 24 subjects (newly diagnosed unmethylated GB) to receive BGB-290, radiation therapy (RT) and temozolomide (TMZ)
2914117|NCT03150862|Experimental|Arm A (Dose Expansion)|Approximately 60 subjects (newly diagnosed unmethylated GB) to receive BGB-290 and radiation therapy
2914118|NCT03150862|Experimental|Arm B (Dose Expansion)|Approximately 60 subjects (newly diagnosed unmethylated GB) to receive BGB-290, radiation therapy, and TMZ
2914119|NCT03150862|Experimental|Arm C (Dose Escalation)|Approximately 24 subjects with recurrent/refractory methylated or unmethylated GB to receive BGB-290 and TMZ
2914120|NCT03150862|Experimental|Arm C (Dose Expansion-Cohorts C1 and C2)|Approximately 120 subjects with recurrent/refractory GB (Cohort 1 - 60 subjects with unmethylated GB; Cohort 2 - 60 subjects with methylated GB) to receive BGB-290 and TMZ
2914121|NCT03150849||patient group|patient with chronic lymphocytic leukemia
2914122|NCT03150849||control group|healthy control group
2914123|NCT03150836|Experimental|Safety Lead-In, Regimen A1 Durvalumab + RT|Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (33Gy delivered as 6.6Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
2914124|NCT03150836|Experimental|Safety Lead-In, Regimen A2 Durvalumab + RT|In cohort A2 the dose of radiation will be decreased to a total dose of 30 Gy administered in 5 fractions of 6 Gy. Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (30 Gy delivered as 6.0Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
2914125|NCT03150836|Experimental|Safety Lead-In, Regimen B1 Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 2 cycles with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After two doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
2914165|NCT03150589|Experimental|SB11 (Proposed ranibizumab biosimilar)|
2914126|NCT03150836|Experimental|Safety Lead-In, Regimen B2 Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 1 cycle with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After one dose of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
2914127|NCT03150836|Experimental|Expansion Cohort, Regimen A: Durvalumab + RT|Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (either 33Gy delivered as 6.6Gy x 5 fractions or 30 Gy delivered as 6.0 Gy x 5 fractions, as determined during the safety lead-in for Regimen B) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
2914128|NCT03150836|Experimental|Expansion Cohort Regimen B: Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 1 or 2 cycles (as determined during the safety lead-in for Regimen B) with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After 1 or 2 doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
2914129|NCT03150823|Experimental|Upward Direct Current (Ascending Effect)|Group subjected to a direct current application (Longitudinal Galvanization) in which the anode is placed at the distal level and the cathode at the proximal level. This would be an excitatory effect of the nervous system.
2914130|NCT03150823|Experimental|Downward Direct Current (Descending Effect)|Group subjected to a direct current application (Longitudinal Galvanization) in which the cathode is placed at the distal level and the anode at the proximal level. This would be an inhibitory effect of the nervous system.
2914131|NCT03150823|Sham Comparator|Sham Direct Current|Group to which an electrical installation will be carried out without emission of part of the electrotherapy equipment. The electrodes will be applied longitudinally to the participants with the equipment switched off.
2914132|NCT03150810|Experimental|Arm A (Dose Escalation)|Approximately 25 subjects to receive continuous BGB-290 and TMZ (Days 1 - 7 of 28 day cycle).
2914133|NCT03150810|Experimental|Arm B (Dose Escalation)|Approximately 25 subjects to receive continuous BGB-290 and continuous TMZ (28-day cycle).
2914134|NCT03150810|Experimental|Arm C (Dose Expansion)|Approximately 100 subjects to receive BGB-290 and TMZ.
2914135|NCT03150797|Experimental|Melatonin 3mg|Melatonin 3mg
2914136|NCT03150797|Experimental|Melatonin 6mg|Melatonin 6mg
2914137|NCT03150797|Placebo Comparator|Placebo oral capsule|Placebo
2914138|NCT03150784|Experimental|Motor coordination difficulties|"Type: Experimental main~EPIC club: 60min session / 2 times weekly / 7 weeks"
2914139|NCT03150784|Other|Non motor coordination difficulties|"Type: Experimental comparator~EPIC club: 60min session / 2 times weekly / 7 weeks"
2914140|NCT03150771|Experimental|Cohort 1|Aripiprazole; single; gluteal
2914141|NCT03150771|Experimental|Cohort 2|Aripiprazole; single; gluteal
2914142|NCT03150758|Experimental|Electrical Stimulation|Each participant will be given 4 electrical stimulants with an amplitude ranging from 1mA to 30mA. The maximum stimulus without causing an erection will be recorded
2914143|NCT03150745|Other|Colposcopic group|
2914144|NCT03150745|Other|office hysteroscopic group|
2914145|NCT03150732|Active Comparator|Systemic nalbuphine group|53 patients will receive nalbuphine systemically
2914146|NCT03150732|Active Comparator|Local nalbuphine group|53 patients will receive nalbuphine with local intravenous regional anesthesia (IVRA)
2914147|NCT03150719|Experimental|Tezacaftor/Ivacaftor (TEZ/IVA)|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet in the morning; IVA 150 mg tablet in the evening.
2914148|NCT03150719|Placebo Comparator|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet in the morning; placebo matched to IVA tablet in the evening.
2914149|NCT03150706|Experimental|Avelumab|"The mismatch repair deficient or microsatellite instable, or POLE mutated metastatic colorectal cancer patients who were progressed after at least one prior systemic treatment for metastatic setting.~After checking the eligibility for the study entry, patients will be entered into the study treatment with avelumab monotherapy."
2914150|NCT03150693|Active Comparator|Arm I (frontline chemotherapy)|See detailed description.
2914151|NCT03150693|Experimental|Arm II (frontline chemotherapy, inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive remission consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and maintenance therapy as in Arm I.
2914152|NCT03150680||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
2914153|NCT03150680||0 < SYNTAX score <23|Low SYNTAX group
2914154|NCT03150680||SYNTAX score >= 23|Intermediate-High SYNTAX group
2914155|NCT03150667|Active Comparator|Ticagrelor Arm|Eligible patients randomized to the Ticagrelor arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records.
2914156|NCT03150667|Active Comparator|Clopidogrel|Eligible patients randomized to the Clopidogrel arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records
2914157|NCT03150654|Experimental|Laser pan-retinal photocoagulation|Conventional laser pan-retinal photocoagulations were performed by using green laser photocoagulator, every month for 3 months
2914158|NCT03150641|Other|Immediate cord clamping|Umbilical cord clamped within 15 seconds of delivery of baby
2914159|NCT03150641|Experimental|Delayed cord clamping|Umbilical cord clamped 60 seconds after delivery of baby
2914167|NCT03150576|Active Comparator|Control|4 cycles of: Paclitaxel 80mg/m2 Day 1, 8 & 15, every 3 weeks, Carboplatin area under the curve (AUC) 5 Day 1, every 3 weeks
2914168|NCT03150576|Experimental|Research 1|4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 & 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day -2 to Day 10 every 3 weeks
2914169|NCT03150576|Experimental|Research 2|4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 & 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day 3 to Day 14 every 3 weeks
2914170|NCT03150563|No Intervention|Control Group|The subjects of the CG will receive the same orientations of the other groups in relation to the importance of the routines of stretching activities, but during the study period, they will not be able to perform stretches during their day to day life.
2914171|NCT03150563|Experimental|Experimental Group 1|"The experimental group 1 will have the sensation of SENSATION SENSING WITHOUT DESCONFORT as an intensity for the application of the passive stretch protocol."
2914172|NCT03150563|Experimental|Experimental Group 2|"The GE2 will have the feeling of MAXIMUM DISORDER WITHOUT PAIN as the as an intensity for the application of the passive stretch protocol."
2914173|NCT03150563|Experimental|Experimental Group 3|"GE3 will have the sensation of MAXIMUM TOLERABLE PAIN as the as an intensity for the application of the passive stretch protocol."
2914174|NCT03150550|Experimental|Relapse Prevention|Each patient will perform 12 classic psychotherapeutic sessions over a period of 6 weeks.
2914175|NCT03150550|Experimental|Mindfulness Practice|Each patient will perform 12 mindfulness psychotherapeutic sessions over a period of 6 weeks.
2914176|NCT03150537|Active Comparator|Jet injector|40 participants will receive Fluviral influenza vaccine using the Med-Jet H4
2914177|NCT03150537|Active Comparator|IM injection (pre-filled syringe)|20 participants will receive Fluviral influenza vaccine using pre-filled syringes for time-motion comparison to Med-Jet H4
2914178|NCT03150537|Active Comparator|IM injection (multi-dose vial)|20 participants will receive Fluviral influenza vaccine using a multi-dose vial for time-motion comparison to Med-Jet H4
2914179|NCT03150524|Active Comparator|Nimodipine|Patients in group one will receive short-acting nimodipine every 4 hours.
2914180|NCT03150524|Active Comparator|Verapamil ER|Patients in group two will receive long-acting verapamil every 12 hours.
2914181|NCT03150511|Experimental|Tesamorelin treatment|
2914182|NCT03150511|Placebo Comparator|Placebo|
2914183|NCT03150498|Experimental|BTD-001 (fed)|
2914184|NCT03150498|Experimental|BTD-001 (fasted)|
2914185|NCT03150485|Experimental|etafilcon A Toric Multifocal|
2914186|NCT03150485|Active Comparator|etafilcon A Multifocal|
2914187|NCT03150472|Experimental|Ivory Dentin Graft (Ivory Graft Ltd.)|"Ivory Dentin Graft is a bone graft material for the repair or augmentation of bone defects in dental procedures. It consists of sterile 300 - 1200 μm porous particles or granules of hydroxyapatite which retain the natural form of the source porcine dentin and also the natural protein matrix which consists largely of porcine collagen.~This type of Graft Matrix will be administered as the intervention."
2914188|NCT03150472|Active Comparator|OsteoBiol Gen-Os ® (Tecnoss)|"A natural replicate of autologous bone, Gen-Os® conserves the same intimate structures (matrix and porous form) and presents a highly osteoconductive properties.~It is biocompatible and bioavailable, as recognized by tests made according to the ISO 10993 method conducted at Eurofins Biolab.~This type of Graft Matrix will be administered as the intervention."
2914189|NCT03150459|Experimental|Simvastatin 20 mg + Rifaximin 400 mg (group 1)|Simvastatin 20 mg/day and rifaximin 400 mg/8 hours orally for 12 weeks
2914190|NCT03150459|Experimental|Simvastatin 40 mg + Rifaximin 400 mg (group 2)|Simvastatin 40 mg/day and rifaximin 400 mg/8 hours orally for 12 weeks
2914191|NCT03150459|Placebo Comparator|Placebo of Simvastatin + Placebo of Rifaximin (group 3)|Placebo simvastatin and placebo rifaximin orally for 12 weeks
2914192|NCT03150446|Experimental|The group using flexible cystoscopy|50 patients with large upper ureteral stones underwent laparoscopic ureterolithotomy with flexible cystoscopy to confirm the correct positioning of the double-J stent. After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy.
2914193|NCT03150433|Experimental|Behavioral symptom management|Five sessions working one-on-one with a study interventionist, either in person or by telephone. Includes monitoring of the individual's sleep pattern, feedback and goals for improving sleep and pain management, and addressing cognitive and emotional strategies for managing sleep and pain.
2914194|NCT03150433|Other|Sickle cell disease management|Five sessions working one-on-one with a study interventionist, either in person or by telephone. Includes monitoring of the individual's sleep pattern, information about sickle cell disease and its management, and information about improving sleep and managing pain.
2914195|NCT03150420|Experimental|Sodium Thiosulfate|Sodium Thiosulfate Injection (25 grams sodium thiosulfate)
2914196|NCT03150420|Placebo Comparator|Placebo-Normal Saline|0.9% sodium chloride injection, USP (normal saline)
2914197|NCT03150394|Experimental|Treatment of quadruple eradication therapy with GASTRUS|
2914198|NCT03150394|Placebo Comparator|Treatment of quadruple eradication therapy with PLACEBO|
2914199|NCT03150381|Active Comparator|Weight Loss Only|Group-based behavioral weight loss intervention designed to reach clinically significant weight loss (~5-10% of baseline weight).
2914200|NCT03150381|Experimental|Weight Loss Plus|Group-based behavioral weight loss intervention designed to reach clinically significant weight loss (~5-10% of baseline weight) plus community-level strategies to support healthy weight. Strategies are based on CDC's recommended community strategies and are developed by local contractors. They include expanded farmers markets/gardens, improvement to walking trails, etc.
2914201|NCT03150381|Active Comparator|Control|Educational materials and optional participation in community-wide cancer awareness activities.
2914202|NCT03150368|Experimental|ModraDoc006/r|Weekly ModraDoc006/r treatment as ModraDoc006 (oral docetaxel) 10mg tablets combined with ritonavir 100mg tablets
2914240|NCT03150108|Experimental|Non-Hispanic Caucasians|Subjects will receive single dose of 100 microgram (mcg) rhPTH(1-84) subcutaneous (SC) injection on Day 1.
2914203|NCT03150355||open reduction and internal fixation|outcome of open reduction and internal fixation of fractures of proximal femur and acetabulum in patients aged 65 years and older
2914204|NCT03150355||Arthroplasty|outcome of arthroplasty of fractures of proximal femur and acetabulum in patients aged 65 years and older
2914205|NCT03150355||conservative management|outcome of conservative management of fractures of proximal femur and acetabulum in patients aged 65 years and older
2914206|NCT03150329|Experimental|Treatment (vorinostat, pembrolizumab)|Patients receive vorinostat PO BID on days 1-5 and 8-12 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
2914207|NCT03150316|Experimental|Treat Regimen|CKD-581(investigational Drug) Lenalidomide Dexamethasone
2914208|NCT03150303||Vitamin K Antagonists (VKA)|Patients on VKA
2914209|NCT03150303||Direct Oral Anticoagulant (DOAC)|Patients on OAD
2914210|NCT03150290|Other|ALS patients without weight loss.|18-FDG-PET. Indirect Calorimetry.
2914211|NCT03150290|Other|ALS patients with weight loss.|18-FDG-PET. Indirect Calorimetry.
2914212|NCT03150277|Experimental|Plyometric-Resistance|This group will perform plyometric exercise first and then heavy resistance exercise
2914213|NCT03150277|Experimental|Resistance-Plyometric|This group will perform resistance exercise first and then plyometric exercise
2914214|NCT03150264|Experimental|PCV-VG, PEEP5cmH₂O|Patients in this group are ventilated with pressure-controlled ventilation volume-guaranteed mode. And we use PEEP of 5cmH₂O to open the collapsed alveoli.
2914215|NCT03150264|Active Comparator|PCV, PEEP5cmH₂O|Patients in this group are ventilated with pressure-controlled ventilation mode. And we use PEEP of 5cmH₂O to open the collapsed alveoli.
2914216|NCT03150251|Experimental|Overnight Oats|40 g of overnight oats
2914217|NCT03150251|Placebo Comparator|Soaked Cream of Rice|28.8 cream of rice
2914218|NCT03150251|Placebo Comparator|Cooked Cream of Rice|28.8 cooked cream of rice
2914219|NCT03150238||Post-operative Crohn Disease patients|Adult patients, with a defined diagnosis of CD, who underwent a surgery for CD in the previous 6 months
2914220|NCT03150225|Experimental|Experimental group|It will be composed of participants randomly assigned to this group, reinforcing the importance of attendance in classes (minimum of 75% of frequency) for significant health benefits. The evaluation measures will be made through a self-administered questionnaire and physical evaluations (cardiorespiratory fitness, body mass index, percentage of fat, waist circumference and muscular strength). The intervention with the concurrent training will be carried out in a gymnasium in Florianópolis, Santa Catarina. After all the evaluation procedures have been performed, the intervention period will begin, being three times a week, lasting 60 minutes, according to the study protocol.
2914221|NCT03150225|No Intervention|Control group|Will be reinforced to the participants of this group the importance of maintaining their daily activities.
2914222|NCT03150212|Experimental|Saccharomyces cerevisiae CNCM I-3856|
2914223|NCT03150212|Placebo Comparator|Placebo|
2914224|NCT03150199|Experimental|Intervention Arm|Participants will all undergo an 8-week PP-MI health behavior intervention.
2914225|NCT03150199|Active Comparator|Comparator Arm|Participants will all undergo an 8-week MI-based health behavior education intervention.
2914226|NCT03150186||SHS exposure in homes|Measurement of nicotine level in private homes
2914227|NCT03150186||SHS exposure in private cars|Measurement of nicotine level in private cars
2914228|NCT03150186||SHS exposure in outdoor settings|Measurement of nicotine level in outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings)
2914229|NCT03150173|Experimental|O-BMT (onsite treatment)|Over 2 weeks at the syringe-exchange program, participants in the O-BMT arm will see a buprenorphine provider twice, receive weekly blister packs of medication, and then their care will be transferred to a community health center for maintenance buprenorphine treatment
2914230|NCT03150173|Active Comparator|Enhanced Referral|In the control arm, participants will receive enhanced referral to a community health center for maintenance buprenorphine treatment
2914231|NCT03150160|Experimental|Treatment Arm|brinzolamide 1% / brimonidine 0.2% (eye drops dosed in the morning and in the evening) + travoprost (eye drops dosed in the evening).
2914232|NCT03150160|Placebo Comparator|Placebo Arm|Placebo (eye drops dosed in the morning and in the evening) + travoprost (eye drops dosed in the evening).
2914233|NCT03150147|Experimental|Non-ischemic storage.|Non-ischemic hypothermic perfusion (NIHP): The device, a portable heart-lung machine, is continous/intermittent perfused the heart with a new preservation solution at a temperature of 8°C.
2914234|NCT03150147|Other|Standard ischemic storage.|Ischemic cold static storage: a crystalloid solution (cardioplegia) is used to stop and preserve the heart. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
2914235|NCT03150134|Experimental|early reduction|Usually in the absence of GvHD, immunosuppressive drugs(Cyclosporine) were gradually reduced by 6 weeks and discontinued in three months after transplant in the advanced patients while immunosuppressive agents were gradually reduced by 2 months and discontinued in four months after transplant in the advanced patients in haploidentical SCT even if complete donor chimerism (CDC) achieved. If donor chimerism had not achieved CDC with no significant acute GVHD at four weeks after HSCT, immunosuppressive agents were gradually reduced. If GvHD was present during the time of immunosuppressive agents reduction, CsA was added again and tapering was done over longer periods.
2914236|NCT03150134|Placebo Comparator|routine reduction|Arm/Group Descriptions.Immunosuppressive drugs(cyclosporine) were routine reduced by 3 months and discontinued in the 5 months without GvHD in the CR group. We used the result of chimerism as the reference.
2914237|NCT03150121|Experimental|Ovarian cancer patients|High grade ovarian/fallopian tube/primary peritoneal carcinoma patients with current active disease, at any stage and histological type, who have not yet undergone debulking surgery.
2914238|NCT03150121|Active Comparator|Non-malignant controls|Patients with non-malignant gynecological conditions indicating surgical procedure, either salpingo-oophorectomy, hysterectomy or hysteroscopy.
2914239|NCT03150121|Experimental|High risk population|Healthy women with genetically high risk for developing ovarian cancer, who have not undergone risk reducing procedure.
2914930|NCT03145207|Other|both patches|brand name and generic lidocaine patch
2914241|NCT03150108|Experimental|Japanese Descents|Subjects will receive single dose of 100 mcg rhPTH(1-84) SC injection on Day 1; On days 4 and 7, either 25 mcg or 50 mcg SC injection. A washout period of 73 hours will be maintained between each single doses (100 mcg, 50 mcg and 25 mcg) in a cross-over fashion.
2914242|NCT03150095|Experimental|Health coaching|Patients will work with a health coach to improve self-management skills
2914243|NCT03150095|No Intervention|Control|Patients will receive usual pre-transplant education to improve self-management skills
2914244|NCT03150082|Experimental|Treatment sequence: A/B|Eligible subjects will be randomized to receive a single dose of Treatment A (GR37547 500 mg tablet) followed by Treatment B (ciprofloxacin 500 mg reference tablet) administered orally on Day 1 in each treatment period. The washout period will be of at least 7 days and not more than 14 days.
2914245|NCT03150082|Experimental|Treatment sequence: B/A|Eligible subjects will be randomized to receive a single dose of Treatment B (ciprofloxacin 500 mg reference tablet) followed by Treatment A (GR37547 500 mg tablet) administered orally. The washout period will be of at least 7 days and not more than 14 days.
2914246|NCT03150069||Morquio A / Biological Mothers|Women with Morquio A who have biological children
2914247|NCT03150069||Morquio A / No Biological Children|Women with Morquio A who do not have biological children (both adoptive mothers and non-mothers)
2914248|NCT03150069||Morquio B / Biological Mothers|Women with Morquio B who have biological children
2914249|NCT03150069||Morquio B / No Biological Children|Women with Morquio B who do not have biological children (both adoptive mothers and non-mothers)
2914250|NCT03150056|Experimental|GSK525762 + abiraterone (Arm A)|Eligible subjects will receive treatment with GSK525762 in combination with abiraterone. Subjects will be abiraterone-refractory or resistant from L2 and Lx lines of therapy. Two dose combinations, 60 mg or 80 mg of GSK525762 will be administered once daily. There is also a possibility of dose reduction to 40 mg in case of toxicity. Dosing will continue until unacceptable toxicity, progression of disease, withdrawal of consent, death, or completion of study. Subjects may also receive prednisone in combination with abiraterone dosing.
2914251|NCT03150056|Experimental|GSK525762 + Enzalutamide (Arm B)|Eligible subjects will receive treatment with GSK525762 in combination with enzalutamide. Subjects will be enzalutamide -refractory or resistant from L2 and Lx lines of therapy. Two to three dose combinations 80 mg, 100 mg and 120 mg of GSK525762 will be administered once daily based on the emerging data from the dose escalation part. There is also a possibility of dose reduction to 60 mg in case of toxicity. Dosing will continue until unacceptable toxicity, progression of disease, withdrawal of consent, death, or completion of study.
2914252|NCT03150043|Other|All Participants|All patients who agree to participate in the study will have the Masimo Rainbow Pulse CO-Oximeter non-invasive hemoglobin monitor placed on their finger during cesarean delivery. A CBC will be drawn immediately prior to delivery and this value will be compared to the values obtained from the monitor. The patients will be separated into quartiles based on total drop in hemoglobin (pre-op to post-op day 1) and the values from the monitor compared between quartiles.
2914253|NCT03150030||Patients with type 2 diabetes|Insulin-treated type 2 diabetes with diabetic complications
2914254|NCT03150030||Healthy controls|Healthy control subjects
2914255|NCT03150017|Experimental|Online programme|SPIRE The programme consists of six modules over six weeks and is based on cognitive behavioural principles. It comprises psychology sessions using cognitive techniques to identify unhelpful and unrealistic thoughts and beliefs related to pain and to challenge and change them and weekly relaxation audios and a home exercise session. Goal setting by participants is used encouraged throughout the programme to aid the implementation of learned CBT techniques into daily life. Educational sessions are delivered across a range of topics including mechanisms of pain after SCI, explanations of the pain gate control theory and how CBT strategies employed can impact on the perception of pain, discussion of medication use, stress management and pacing strategies for activities of daily living.
2914256|NCT03150017|No Intervention|Usual Care|Continue to manage pain using usual care.
2914257|NCT03150004|Experimental|CLAG-M regimen|Patients treatment cycle is 30 days.
2914258|NCT03149991|Active Comparator|Ketamine/Brexpiprazole Arm|brexpiprazole up to 3 mg/day for four weeks in combination with bi-weekly administration of intranasal ketamine (40 mg) for two weeks, followed by weekly administration of intranasal ketamine (40 mg) for two weeks
2914259|NCT03149991|Placebo Comparator|Ketamine/Placebo Arm|placebo for four weeks in combination with bi-weekly administration of intranasal ketamine (40 mg) for two weeks, followed by weekly administration of intranasal ketamine (40 mg) for two weeks
2914260|NCT03149965|Active Comparator|Body mass index 18.5-24.9|The anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
2914261|NCT03149965|Experimental|body mass index ≥30|The anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
2914262|NCT03149952|Other|Patient hospitalized for allogeneic haematopoietic stem cells|
2914263|NCT03149926||Patients with Borderline Personality Disorder|
2914264|NCT03149926||Healthy controls|
2914265|NCT03149913|Experimental|Drug coated balloon|SeQuentPlease OTW paclitaxel coated balloon catheter
2914266|NCT03149913|Active Comparator|uncoated PTA balloon catheter|Standard of care uncoated BTK balloon catheter
2914297|NCT03149653|Active Comparator|2 Home Parenteral Nutrition, Cross-over|Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.
2914298|NCT03149653|No Intervention|Comparator3|Healthy Control
2914931|NCT03145194|Experimental|Ticagrelor|Patients will receive Ticagrelor 180mg (2 x 90mg tablets)
2914267|NCT03149900||Secukinumab|"Patients will be recruited in the Comprehensive Center for Inflammation Medicine. The study population will consist of 40 subjects (both male and female), aged 18 years and older, in whom treatment with Secukinumab is clinically indicated and according to the licensed product specifications. The study drug will be prescribed by a doctor who is independent of this study. Visit 1 will be carried out prior to the first injection of Secukinumab.~All patients will receive a number and the data will be recorded in a pseudo-anonymised form. No blinding is necessary for investigators or patients (open study), as all patients receive the same treatment (marketed product)."
2914268|NCT03149887|Experimental|Experimental|Injection of liposomal bupivacaine in surgical field at end of arthroscopic rotator cuff repair.
2914269|NCT03149887|Active Comparator|Control|Injection of inert placebo solution in surgical field at end of arthroscopic rotator cuff repair.
2914270|NCT03149874|Active Comparator|Hepatitis B recombinant DNA vaccine|Each Hepatitis B recombinant DNA vaccine vial contained 20 microgram of vaccine dose. Two vials will be intramuscularly injected one vial in each deltoid muscle on months zero, one, two and six.
2914271|NCT03149874|Active Comparator|Combined hepatitis A and B vaccine|Each one-milliliter dose of vaccine contains 720 ELISA units of inactivated hepatitis A virus and 20 mcg of recombinant HBsAg protein. One dose of vaccine also contains 0.45 mg of aluminum. Two vials will be intramuscularly injected one vial in each deltoid muscle on on days zero, seven, and 21.
2914272|NCT03149861|Experimental|No focal biopsy needed|Patients in which PET/MR have found no focal findings, will undergo a systemic biopsy as per standard of care, without specific cores for study purposes (Systemic TRUS guided biopsy)
2914273|NCT03149861|Experimental|Focal biopsy|Patients with a suspicious focal finding on PET/MR, will undergo systemic+focal or focal fusion biopsy (PET/MR-ultrasound guided Fusion biopsy)
2914274|NCT03149848|Experimental|Treatment A|Participants will be administered a single oral dose of CAB 30 mg after an overnight fast of at least 6 hours for 14 days in Period 1. Dosing of study medication on non-PK days may be with or without food.
2914275|NCT03149848|Experimental|Treatment B|Participants will be administered a single dose of RBT 300 mg and a single dose of CAB 30 mg after an overnight fast of at least 6 hours once daily for 14 days in Period 2. Dosing of study medication on non-PK days may be with or without food.
2914276|NCT03149835|Experimental|COPD|"After study enrollment, 15 days before the performance of the experimental protocol, patients performed neurocognitive tests (Digit Span Test, Digit Symbol-Coding, Corsi Block-tapping, Trail Making Test A and B and Stroop Test) and NIV adaptation. Pulmonary function (spirometry) was measured in all subjects after a thorough medical history and physical examination. Before initiating the protocol, patients were asked about discomfort related to NIV or any aspect of the experiment.~CBF was measured by transcranial Doppler by mean of LMCAFV immediately before NIV, during NIV at 5, 30 and 60 minutes and after NIV removal at 5 and 30 minutes. ABG were collected immediately before the experiment, after one hour of NIV breathing and 30 minutes after NIV discontinuation."
2914277|NCT03149835|Experimental|Healthy Control|"After study enrollment, 15 days before the performance of the experimental protocol, patients performed neurocognitive tests (Digit Span Test, Digit Symbol-Coding, Corsi Block-tapping, Trail Making Test A and B and Stroop Test) and NIV adaptation. Pulmonary function (spirometry) was measured in all subjects after a thorough medical history and physical examination.~CBF was measured by transcranial Doppler by mean of LMCAFV immediately before NIV, during NIV at 5, 30 and 60 minutes and after NIV removal at 5 and 30 minutes. ABG were collected immediately before the experiment, after one hour of NIV breathing and 30 minutes after NIV discontinuation."
2914278|NCT03149822|Experimental|Phase 1: Pembrolizumab 200 mg plus Cabozantinib 40mg|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib 40 mg orally once daily until disease progression, unacceptable toxicity, or consent withdrawal.
2914279|NCT03149822|Experimental|Phase 1: Pembrolizumab 200 mg plus Cabozantinib 60mg|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib 60 mg orally once daily until disease progression, unacceptable toxicity, or consent withdrawal.
2914280|NCT03149822|Experimental|Phase 2: Pembrolizumab 200 mg plus Cabozantinib at the RP2D|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib at the RP2D orally once daily until disease progression, unacceptable toxicity, or consent withdrawal.
2914281|NCT03149809|Active Comparator|Behavioral therapy|Pelvic floor muscle exercise-based behavioral therapy
2914282|NCT03149809|Active Comparator|Drug Therapy|Daily solifenacin drug therapy
2914283|NCT03149796||RA patients|"designated to be treated with tocilizumab and followed in rheumatology clinics.~Laboratory blood tests will be collected and analyzed"
2914284|NCT03149796||healthy controls|control Laboratory blood tests will be collected and analyzed
2914285|NCT03149783|Experimental|Ropivacaine|Participants will have bilateral TAP catheters placed along with continuous infusion of ropivacaine.
2914286|NCT03149783|Placebo Comparator|Placebo|Participants will have bilateral TAP catheters placed along with continuous infusion of placebo.
2914287|NCT03149770|Experimental|1|Naloxone, intranasal 4mg
2914288|NCT03149770|Placebo Comparator|2|Placebo
2914289|NCT03149757|Experimental|YouTHrive|YouTHrive is a five-month technology-based intervention that uses peer-to-peer interaction, daily self-monitoring, and tailored content to address barriers to HIV medication adherence.
2914290|NCT03149757|Active Comparator|Thrive Tips|Participants randomized to the control condition will receive a weekly email with static informational content about living with HIV and general well being.
2914291|NCT03149718|Active Comparator|SMC (n=23)|Standard Medication Counseling.
2914292|NCT03149718|Experimental|BI-MTM (n=23)|Brief Intervention Medication Therapy Management.
2914293|NCT03149692|Experimental|Penile allograft|
2914294|NCT03149679|Experimental|Cyclophosphamide arm|Dose dense cyclophosphamide (1800 Mg/m2) administered intravenously every second week.
2914295|NCT03149666||Evaluation of bitter taste|Participants will be evaluated as to the intensity of bitter taste when performing watery mouthwash with quinine.
2914296|NCT03149653|Experimental|1 Home Parenteral Nutrition, Cross-over|Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.
2914299|NCT03149640|Experimental|Inhaled amikacin|Inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
2914300|NCT03149640|Placebo Comparator|Placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
2914301|NCT03149627||Individuals from selected households|Individuals residing in selected households in Northern/Luapula Province, Zambia.
2914302|NCT03149614|Active Comparator|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000.
2914303|NCT03149614|Experimental|Vertebral Resonant Oscillation (POLD method)|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
2914304|NCT03149601||Healthy Weight|Participants with BMI < 95th percentile
2914305|NCT03149601||Obese|Participants with BMI > or = 95th percentile
2914306|NCT03149588|Experimental|propofol|
2914307|NCT03149588|Experimental|sevoflurane|
2914308|NCT03149575|Experimental|VAL-083, Dianhydrogalactitol|Up to 120 eligible patients will be randomized to receive VAL-083.
2914309|NCT03149575|Active Comparator|Physician's Choice of Salvage Therapy|"Up to 60 patients will be randomized to receive Investigator's choice of salvage therapy temozolomide, lomustine, or carboplatin"
2914310|NCT03149562||plasma transfusions|The critical ill neonates with plasma transfusions
2914311|NCT03149562||non-plasma transfusions|The critical ill neonates without plasma transfusions
2914312|NCT03149549|Experimental|CX-2009 Escalation|Monotherapy CX-2009
2914313|NCT03149549|Experimental|CX-2009 Expansion|Monotherapy CX-2009
2914314|NCT03149536|Active Comparator|Group 1|recombinant FSH starting dose: 100 IU to develop a pharmacogenetic test
2914315|NCT03149536|Active Comparator|Group 2|recombinant FSH starting dose: 125 IU to develop a pharmacogenetic test
2914316|NCT03149536|Active Comparator|Group 3|recombinant FSH starting dose: 150 IU to develop a pharmacogenetic test
2914317|NCT03149536|Active Comparator|Group 4|recombinant FSH starting dose: 175 IU to develop a pharmacogenetic test
2914318|NCT03149536|Active Comparator|Group 5|recombinant FSH starting dose: 200 IU to develop a pharmacogenetic test
2914319|NCT03149536|Active Comparator|Group 6|recombinant FSH starting dose: 225 IU to develop a pharmacogenetic test
2914320|NCT03149523||Colorectal cancer|Patient with stage III colon carcinoma
2914321|NCT03149523||Kidney cancer|Patient with clear cell kidney carcinoma more than 4 cm surgically removed
2914322|NCT03149523||Liver cancer|Patient with advanced hepatocellular carcinoma : biopsy or resected BCLC (Barcelona Clinic Liver Cancer) stage B or C for diagnostic and/or therapeutic purposes
2914323|NCT03149510|Experimental|Mobile Application|Participants will be using a mobile application, activity monitor and scale.
2914324|NCT03149510|No Intervention|Control Group|Participants will receive standard of care.
2914325|NCT03149497|Active Comparator|improved anterior approach only in traumatic cervical spine|
2914326|NCT03149497|Active Comparator|failed anterior approach only in traumatic cervical spine|
2914327|NCT03149484||Pediatric Group|Children with unilateral conductive hearing loss who are treated with bone conductive devices
2914328|NCT03149484||Parent/Guardian Group|The parent or guardian of a child with unilateral conductive hearing loss who are treated with bone conductive devices
2914329|NCT03149471||Normal endothelial function|patients diagnosed with PE and have normal endothelial function test- RHI score >=1.67
2914330|NCT03149471||Endothelial dysfunction group|patients diagnosed with PE and have endothelial function- RHI<1.67
2914331|NCT03149458|Experimental|Dance group|dance program for 8 one-hour sessions.
2914332|NCT03149458|Active Comparator|control group|upper limb rehabilitation for 8 one-hour sessions.
2914333|NCT03149445|Experimental|Tesofensine/Metoprolol|Tesofensine + metoprolol administered once a day, in the morning with a meal
2914334|NCT03149445|Placebo Comparator|Tesofensine/Metoprolol placebo|Placebo tablets matching tesofensine + metoprolol administered once a day, in the morning with meal
2914335|NCT03149432|Active Comparator|Reference analgesic|Gabapentin Rehabilitation Local care
2914336|NCT03149432|Experimental|reference analgesic and mirror therapy|Mirror Therapy Gabapentin Rehabilitation Local care
2914337|NCT03149419|Active Comparator|Paroxetine|Paroxetine 7,5 mg - 1 pill/day for 12 weeks
2914338|NCT03149419|Placebo Comparator|Placebo|Placebo oral capsule (corn starch) - 1 pill/day for 12 weeks
2914339|NCT03149406||Symptomatic patients|in the department with carotid plaque Comparing the expression of miRNAs
2914340|NCT03149406||Asymptomatic patients|in consultation with carotid plaque Comparing the expression of miRNAs
2914341|NCT03149393|Experimental|Qizhi Weitong Granules Group|Patients in this group will take Qizhi Weitong Granules for 8 weeks.
2914342|NCT03149393|Active Comparator|Mosapride Citrate Tablets Group|Patients in this group will take mosapride citrate tablets for 8 weeks.
2914343|NCT03149380|Experimental|Intervention|Subjects will be given access to educational content on AD using interactive learning strategies
2914344|NCT03149380|Sham Comparator|Time-neutral control|Subjects will be given access to time-neutral general educational content on AD
2914345|NCT03149367|Experimental|Fixed suture|
2914346|NCT03149367|Experimental|Adjustable suture|
2914347|NCT03149354|Other|Patients with HIV|Patients with HIV
2914348|NCT03149341||Study|Congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
2914349|NCT03149341||Normal Volunteers|No congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
2914350|NCT03149328|Experimental|Northern Alberta Renal Program (NARP)|Provide in NARP (intervention group), 1) an electronic tool (ePRO) that facilitates real time PRO data collection and feedback in clinical practice, and 2) educational support to multidisciplinary home dialysis clinicians about how to use PROs routinely in their practice.
2914351|NCT03149328|No Intervention|Southern Alberta Renal Program (SARP)|In SARP (comparator group), clinicians will not receive PRO feedback or education sessions.
2914352|NCT03149315|Experimental|Open Label Administration|Allergic subjects will be given ibrutinib 420mg daily for 2-7 doses to determine the shortest amount of time and fewest ibrutinib doses required to suppress food skin prick testing and basophil activation test reactivity.
2914353|NCT03149302|Experimental|Local neck treatment (LNT)|Cervical mobilization and specific therapeutic exercises
2914354|NCT03149302|Experimental|LNT plus sensorimotor exercises|Local neck treatment plus a tailored sensorimotor exercise program.
2914355|NCT03149302|Experimental|LNT plus balance exercises|Local neck treatment plus balance training program.
2914356|NCT03149302|Experimental|LNT plus sensorimotor/balance exercises|A combination of local neck treatment, sensorimotor control exercise, and balance exercise.
2914357|NCT03149289||HCV RNA positive|hemoglobinopathies with hepatites C treated with antiviral drugs
2914358|NCT03149276||Limited English Proficiency Group|"LEP persons were identified by asking, What language would you like to receive medical information and services in? Patients were considered limited English proficient when a non-English language was preferred. Interventions included professional interpreter services and occupational therapy."
2914359|NCT03149276||English Speaking Group|"English speaking persons were identified by asking, What language would you like to receive medical information and services in? Patients were considered English speaking when the English language was preferred. Intervention included occupational therapy."
2914360|NCT03149263||Toxin-clown|"Botulinum toxin injections are carried out according to the usual injection protocol.~40 children will be included into the arm toxin with clown distraction. During injections, clowns take information with the doctor before the procedure on the child's pathology, the cognitive level, the number of injections. During injections, clowns fit and distraction can change depending on the reaction of the child to their intervention."
2914361|NCT03149263||Toxin-usual distraction|"40 children will be included into the arm toxin with usual distraction The usual distraction involves discussion with the child, and its accompanying its interests, to define the use of music, songs, television, video games or other distraction during the session. If the first distraction doesn't work, it's possible to switch to another distraction during injections"
2914362|NCT03149250||Pregnant Preeclampsia|"Pregnant between 35th and 40th week of pregnancy Preeclampisa~Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling"
2914363|NCT03149250||Pregnant No-Preeclampsia|Control Group 1 Pregnant between 35th and 40th week of pregnancy No Preeclampsia Healthy Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling
2914364|NCT03149250||Not Pregnant|"Control group 2 Healthy and not pregnant control group~Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling."
2914365|NCT03149237|No Intervention|Standard of Care|The 12 clinics randomized to the control arm will continue to provide standard of care (SOC) EMTCT services that include: standard HoPS male engagement (male invitation to ANC services and couples HIV testing), opt-out rapid HIV testing of all pregnant women attending ANC, HIV-specific counseling and support for all women who test positive, provision of cotrimoxazole prophylaxis, and universal ART, as per option B+ guidelines.
2914366|NCT03149237|Experimental|Couples-based Services|The 12 clinics randomly assigned to the intervention arm will receive a combination of community and clinical EMTCT services, including: (1) ANC-based couples HIV testing, couples-based treatment enrollment, and clinical care for sero-concordant HIV+ expectant couples; (2) couple-centered treatment in the post-partum period at the EID clinic; (3) couples-based education and skills building during the ANC and post-partum period; and (4) treatment continuity support by expert-patient (peer) navigators selected among couples who have successfully navigated EMTCT.
2914367|NCT03149211|Active Comparator|Cohort 1|Subjects will receive current standard HAART treatment as the active control group.
2914368|NCT03149211|Experimental|Cohort 2|Subjects will receive UB-421 without HAART treatment by intravenous infusion at 25 mg/kg bi-weekly. After 26-week treatment period, subjects will enter 22-week follow-up period with current standard HAART treatment.
2914369|NCT03149198|Experimental|Interventional group|Mat pilates exercises
2914370|NCT03149198|Active Comparator|Control group|Aquatic aerobic exercises
2914371|NCT03149185|Active Comparator|T-CBSM|Technology based cognitive behavioral stress management.
2914372|NCT03149185|Active Comparator|T-HP|Technology based health promotion (control condition)
2914373|NCT03149172|Experimental|Equimatrix®|Equimatrix® + Mucograft or alternatives
2914374|NCT03149172|Experimental|Bio-Oss®|Bio-Oss® + Mucograft or alternatives
2914375|NCT03149172|Experimental|Endobon®|Endobon® + Mucograft or alternatives
2914376|NCT03149159|Experimental|Nivolumab + Ipilimumab + SRT|
2914377|NCT03149146|Experimental|Clinical Decision Making (CDM) Workshop|Series of CDM educational workshop will be conducted for one group of participants and they will be guided the CDM process through the two clinical practice models; Therapeutic process (TP) and International Classification of Functioning, Disability and Health (ICF).
2914378|NCT03149146|Active Comparator|Clinical Decision Making Workbook|Participants will receive Clinical Decision Making (CDM) workbook which will be used to teach the Clinical Decision Making process in the four days workshop.
2914379|NCT03149133|Experimental|Classical Hypertrophy|The classical hypertrophy group performs strength training with 75-80% of 1-Repetition Maximum.
2914380|NCT03149133|Experimental|Occlusive Training|The occlusive hypertrophy group performs strength training with %35-50 of 1-Repetition Maximum.
2914381|NCT03149120|Experimental|Nivolumab|Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
2914382|NCT03149120|Experimental|Nivolumab with Pazopanib|Pazopanib at a dose of 800mg by mouth daily.
2914383|NCT03149107|Experimental|IPPI + NAC|"IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician & rater).~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention. Double-blinded."
2914448|NCT03148626|Experimental|MINDI mindfulness curriculum|The intervention is a seven-session mindfulness curriculum to be delivered over six months to pediatric interns.
2914384|NCT03149107|Experimental|PSM + NAC|"PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician & rater).~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention. Double-blinded."
2914385|NCT03149107|Experimental|IPPI + Placebo|"IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician & rater).~Placebo will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM)."
2914386|NCT03149107|Active Comparator|PSM + Placebo|"PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician & rater).~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Placebo will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM)."
2914387|NCT03149094|Experimental|CBSM-SMI|The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
2914388|NCT03149094|Active Comparator|CBSM-SMI control|The control group will receive an app called LifeSum, which focuses on healthy lifestyles.
2914389|NCT03149081|Experimental|Boswellia|Boswellia will be given at 800mg by mouth three times a day, immediately after each meal. Boswellia will be given from the time surgical resection is scheduled until the night before surgical resection.
2914390|NCT03149068||75 patient|Seventy five (75) CKD patients in different stages will be included in our study from Nephrology unit, Internal Medicine department, Assuit University Hospital
2914391|NCT03149068||25 healthy control|twenty five (25) age and sex matched apparently healthy individuals will be enrolled as controls
2914392|NCT03149055|Experimental|Isavuconazole prophylaxis|Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose. The minimum duration of prophylaxis with isavuconazole will be through D +60. Beyond day +60 discontinuation is at the discretion of the treating physician.
2914393|NCT03149042|Experimental|CTAC Coronary|Patients who are scheduled for clinically mandated elective invasive coronary angiography (ICA) at Buffalo General Hospital.
2914394|NCT03149029|Experimental|BRAFV600 mutant|"Pembrolizumab administered intravenously every three weeks~Dabrafenib taken every twelve hours orally~Trametinib taken every twelve hours orally"
2914395|NCT03149029|Experimental|BRAFV600 wild type|"Pembrolizumab administered intravenously every three weeks~Trametinib taken every twelve hours orally"
2914396|NCT03149016|Experimental|Corticotomy-assisted Retraction|Corticotomy-assisted retraction will be performed in order to help in accelerating upper incisors' retraction
2914397|NCT03149016|No Intervention|Conventional Retraction|Conventional retraction will be used in this group of patients by sliding mechanisms
2914398|NCT03149003|Experimental|Arm 1: DSP-7888 Dosing Emulsion plus Bevacizumab|
2914399|NCT03149003|Active Comparator|Arm 2: Bevacizumab|
2914400|NCT03148990|Experimental|Measles and Rubella vaccine|Biological/Vaccine: Administration of the experimental vaccine (Measles and Rubella).
2914401|NCT03148990|Active Comparator|Measles, Mumps and Rubella vaccine|Biological/Vaccine: Administration of the comparator vaccine (Measles, Mumps and Rubella).
2914402|NCT03148977||Patients admitted to the burn center|Patients admitted to the Burn Service with acute burn injuries requiring at least one surgical excision and grafting operation.
2914403|NCT03148964||Follow-up Arm|Blood sampling only
2914404|NCT03148951||Group 1|Group 1: patients receiving general anesthesia and having a postoperative pain VAS score equal to or below 50 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
2914405|NCT03148951||Group 2|Group 2: patients receiving general anesthesia and having a postoperative pain VAS score equal to or above 60 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
2914406|NCT03148951||Group 3|Group 3: patients receiving regional (spinal) anesthesia and having a postoperative pain VAS score equal to or below 50 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
2914407|NCT03148951||Group 4|Group 4: patients receiving spinal anesthesia and having a postoperative pain VAS score equal to or above 60 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
2914408|NCT03148938|Experimental|Patients with Multiple Sclerosis|Patients will perform one or two visits at 15 days interval. Patients will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B), followed by a crossover to the other group at day 15 for patients who will do two visits.
2914409|NCT03148938|Active Comparator|Healthy volunteer|Healthy volunteers will only perform one visit. Healthy volunteers will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B).
2914410|NCT03148925|Experimental|SELA-070|
2914411|NCT03148925|Placebo Comparator|Saline|
2914412|NCT03148912|Experimental|diagnostic algorithm|Optimizing the interpretation of the more readily available anti-PF4 assay would reduce the reliance on functional testing/ confirmatory testing (Serotonin Release Assay, SRA) and the number of patients exposed to unnecessary changes in anticoagulation therapy while awaiting the timely functional test results
2914413|NCT03148899|Experimental|Visit 1 Randomization|At visit 1 (PSG 1) subjects will receive one of two interventions: either Oxytocin Intranasal Spray (40 IU) or Placebo Intranasal Spray. Subjects will be blinded as to which drug they are receiving.
2914414|NCT03148899|Experimental|Visit 2: Crossover Randomization|At visit 2 (PSG 2) subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal Spray (40 IU) or Placebo Intranasal Spray. Subjects will be blinded as to which drug they are receiving.
2914415|NCT03148886|Experimental|PA intervention|The intervention consisted in a home-based adapted PA program defined at the inclusion, according to patient's capacities.
2914416|NCT03148860|Active Comparator|Methotrexate naive - Ustekinumab and Methotrexate|Methotrexate naive subjects will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
2914417|NCT03148860|Placebo Comparator|Methotrexate naive - Ustekinumab and Placebo to Methotrexate|Methotrexate naive subjects will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
2914418|NCT03148860|Active Comparator|Methotrexate pre-treated subjects-Ustekinumab and Methotrexate|subjects pretreated with Methotrexate will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
2914419|NCT03148860|Placebo Comparator|Methotrexate pre-treated subjects-Ustekinumab and PLC|subjects pretreated with Methotrexate will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
2914420|NCT03148847||Baseline care|Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2013 and December 31, 2013
2914421|NCT03148847||Referential's dissemination|Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2017 and December 31, 2017, after referential's dissemination for management of patients with paroxysmal dyspnea due to left sided heart failure
2914422|NCT03148834|Experimental|Control Reperfusion Primary Angioplasty|Patients admitted with acute myocardial infarction and TIMI flow 0/1, will be treated with the use of an intracoronary venous blood solution and dextran to protect the myocardium during reperfusion.
2914423|NCT03148834|No Intervention|Standard Primary Coronary Angioplasty|Patients admitted with an acute myocardial infarction and TIMI flow 0/1, will be treated with primary angioplasty according to norms described in the international guidelines of treatment.
2914424|NCT03148821||Healthy volunteer participants|The investigators propose a snap shot study in a group of healthy volunteers of varying BMIs, laying on surfaces a patient would be exposed to during their hospital stay. Participants will lie on a variety of surfaces they may find themselves on during an emergency admission to hospital, including an operating table, in a variety of positions. Participants pressure distributions in each scenario will be measured with a pressure sensing mattress.
2914425|NCT03148808|Experimental|NVS Therapy|NVS Therapy will be delivered to de novo lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) during PTA in patients with symptomatic peripheral artery disease.
2914426|NCT03148795|Experimental|Talazoparib|Talazoparib 1 mg daily
2914427|NCT03148782|Experimental|OST Intervention|12 weekly in-person sessions, each lasting approximately 1 hour, targeting 3 core organizational skills domains-Tracking Assignments, Managing Materials and Time Management
2914428|NCT03148756|Experimental|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8
2914429|NCT03148756|Active Comparator|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks
2914430|NCT03148730|No Intervention|manual group|This group will have a standard of care anesthesia. All the drugs, fluid and adjustement of ventilation settings will be done manually by the supervising anesthesiologist using the same drugs and fluids as the closed-loop group
2914431|NCT03148730|Experimental|automated closed-loop group|This group will have a fully automated anesthesia, analgesia , ventilation and fluid management using 3 indenpendent closed-loop systems same drugs used in both groups ( propofol and remifentanil, Plasmalyte and /or Voluven)
2914432|NCT03148717|Active Comparator|Preoperative|"Group no.1 will receive preoperative rectal 400 microgram of misoprostol (Sigma) 2 tablets and postoperative rectal placebo2 tablets."
2914433|NCT03148717|Active Comparator|Postoperative|"Group no.2 will receive preoperative rectal placebo 2 tablets and postoperative rectal 400 microgram of misoprostol (Sigma)  2 tablets ."
2914434|NCT03148704||palonosetron palonosetron hydrochloride|A continuous sequence of patients using palonosetron palonosetron hydrochloride capsules(Ruo Shan®)
2914435|NCT03148691|Placebo Comparator|Vehicle|Vehicle Topical Solution
2914436|NCT03148691|Active Comparator|A-101 Low Dose|A-101 Low Dose Topical Solution
2914437|NCT03148691|Active Comparator|A-101 High Dose|A-101 High DoseTopical Solution
2914438|NCT03148678|Experimental|Mindfulness first; Contingent RT-fMRI-NF|"Participants start with the mindfulness intervention followed by the mind wandering intervention. The arm type experimental refers to contingent RT-fMRI-NF, during which participants are provided with contingent RT-fMRI-NF of their own brain activity."
2914439|NCT03148678|Sham Comparator|Mindfulness first; Non-Contingent Neurofeedback|"Participants start with the mindfulness intervention followed by the mind wandering intervention. The arm type sham comparator refers to non-contingent RT-fMRI-NF, during which participants are provided with sham RT-fMRI-NF of brain activity of previously recorded subject."
2914440|NCT03148678|Experimental|Mind wandering first; Contingent Neurofeedback|"Participants start with the mind wandering intervention followed by the mindfulness intervention. The arm type experimental refers to contingent RT-fMRI-NF, during which participants are provided with contingent RT-fMRI-NF of their own brain activity."
2914441|NCT03148678|Sham Comparator|Mind wandering first; Non-Contingent Neurofeedback|"Participants start with the mind wandering intervention followed by the mindfulness intervention. The arm type sham comparator refers to non-contingent RT-fMRI-NF, during which participants are provided with sham RT-fMRI-NF of brain activity of previously recorded subject."
2914442|NCT03148665|Active Comparator|Control population|Control population (n=150): absence of current or prior oropharyngeal carcinoma, no active cancer diagnosis. Control population includes at least 50 subjects who have smoked at least 100 cigarettes during lifetime OncAlert saliva-based screening, a noninvasive point of care salivary rinse test performed as a one-time test for control subjects
2914443|NCT03148665|Experimental|Cancer population|Cancer population (n=150): patients with previously untreated oral cavity or oropharynx squamous cell carcinoma with absence of distant metastasis OncAlert saliva-based screening, a noninvasive point of care salivary rinse test performed as at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
2914444|NCT03148652|Experimental|Enhanced Intervention (CBT+working memory training)|A standard, manualized cognitive behavioral therapy-based intervention for individuals interested in quitting smoking plus computerized working memory training
2914445|NCT03148652|Placebo Comparator|Control Intervention Condition|Participants will receive a manualized cognitive behavioral therapy-based intervention
2914446|NCT03148639|Experimental|Avatar therapy|Immediate Avatar therapy.
2914447|NCT03148639|Other|Treatment-as-usual|Treatment-as-usual then delayed Avatar therapy.
2914449|NCT03148626|Placebo Comparator|Control|Usual education.
2914450|NCT03148600|Active Comparator|Intervention arm|Pelvic floor and bowel behavioural training programme provided by physiotherapists over 2- 6 sessions within the 6 months following ileostomy closure for patients with an ileo-anal pouch
2914451|NCT03148600|Placebo Comparator|Standard arm|Standard post-operative nursing and medical care provided in hospital clinic
2914452|NCT03148587|Experimental|Multi-level pregnancy test (MLPT)|Patients randomized to multi-level pregnancy test (MLPT) arm will receive MLPTs to perform at home one and two weeks after taking mifepristone. They will be asked to interpret the results of the MLPT as it relates to their pregnancy termination status.
2914453|NCT03148587|Experimental|Low sensitivity pregnancy test (LSPT)|Patients randomized to low sensitivity pregnancy test (LSPT) arm will receive LSPTs to perform at home at one and two weeks after taking mifepristone. They will be asked to interpret the results of the LSPT as it relates to their pregnancy termination status.
2914454|NCT03148574|Experimental|misoprostol|intrauterine 400 microgram
2914455|NCT03148574|Active Comparator|oxytocin|intravenous infusion 10 units
2914456|NCT03148561|Other|misoprostol roup|
2914457|NCT03148561|No Intervention|Expectant group|
2914458|NCT03148548||Patients with iliofermoral thrombosis without rekanalisation|subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did not undergo recanalisation
2914459|NCT03148548||Patients with ilifermoral thrombosis with rekanalisation|subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did undergo recanalisation
2914460|NCT03148535|Experimental|lithium carbonate|recieve lithium carbonate
2914461|NCT03148535|Experimental|lithium carbonate combined with SSRI antidepressant treatment|recieve lithium carbonate combined with SSRI antidepressant treatment
2914462|NCT03148522|Experimental|escitalopram|receive escitalopram
2914463|NCT03148522|Experimental|duloxetine|receive duloxetine
2914464|NCT03148522|Experimental|mirtazapine|receive mirtazapine
2914465|NCT03148509|Experimental|bupropion|receive bupropion
2914466|NCT03148509|Experimental|risperidone|receive risperidone
2914467|NCT03148509|Experimental|aripiprazole|receive aripiprazole
2914468|NCT03148496|Experimental|Biologic Mesh and Small Bytes|Biologic mesh placement and small bytes used for suturing.
2914469|NCT03148496|Experimental|Small Bytes and No Biologic Mesh|Small bytes used for suturing with no placement of biologic mesh
2914470|NCT03148496|Experimental|Biologic mesh and Large Bytes|Biologic mesh placement and large bytes used for suturing
2914471|NCT03148496|Active Comparator|Large Bytes and no biologic mesh|Large bytes used for suturing and no placement of biologic mesh.
2914472|NCT03148483|Experimental|Early PT plus Fortified Milk|early periodontal therapy (during pregnancy) plus fortified milk
2914473|NCT03148483|Experimental|Early PT plus Plain Milk|early periodontal therapy (during pregnancy) plus plain milk
2914474|NCT03148483|Experimental|Delayed PT plus Fortified Milk|delayed periodontal therapy (after delivery) plus fortified milk
2914475|NCT03148483|Placebo Comparator|Delayed PT plus Plain Milk|delayed periodontal therapy (after delivery) plus plain milk
2914476|NCT03148470|Experimental|intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) + Sham iTBS
2914477|NCT03148470|Experimental|continuous theta burst stimulation|continuous theta burst stimulation (cTBS) + Sham cTBS
2914478|NCT03148457|Experimental|Early treatment|Early treatment of patients with ischaemic stroke related to atrial fibrillation (AF) with direct oral anticoagulations (DOACs).
2914479|NCT03148457|Other|Late treatment|Treatment with direct oral anticoagulations (DOACs) according the current standard practice in patients with acute ischemic stroke related to atrial fibrillation (AF).
2914480|NCT03148444|Experimental|Antibiotics treated|Patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) in our institution will be discharged home with recommendations to take antibiotic treatment for 5 days following the procedure (cefalexin 500 mg qid, or in the presence of beta-lactam sensitivity roxithromycin 150 mg bid)
2914481|NCT03148444|No Intervention|without Antibiotics Treatment|Patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) in our institution will be discharged home with no recommendations regarding antibiotic treatment.
2914482|NCT03148431|Experimental|LY3002815|Escalating doses of LY3002815 administered intravenously (IV) once in healthy participants
2914483|NCT03148431|Placebo Comparator|Placebo|Placebo administered IV once in healthy participants
2914484|NCT03148418|Experimental|Atezolizumab|Participants will continue to receive atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) in accordance with local prescribing information till the participant continues to derive clinical benefit or until death, withdrawal of study consent, unacceptable toxicity, pregnancy, participant non-compliance, or study termination by the Sponsor, whichever occurs first.
2914485|NCT03148392||Cryo Balloon Ablation|Arctic Front Advance Cryo Balloon: Mode of ablation determined based on patient and physician preference
2914486|NCT03148392||Radiofrequency Ablation|Contact Force Sensing Radiofrequency Catheter Ablation: Mode of ablation determined based on patient and physician preference
2914487|NCT03148379|Experimental|Customized patient instruments|Experimental group: Patients randomized into this group will undergo surgery utilizing single-use Efficiency Instruments with patient-specific technique (MyKnee® patient-matched cutting blocks)
2914488|NCT03148379|Active Comparator|Traditional metal instruments|Control Group: Patients will undergo conventional surgical technique
2914489|NCT03148366|Experimental|Levofloxacin based sequential therapy|"Levofloxacin based sequential therapy~: sequential therapy containing levofloxacin for 14 days D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days"
2914490|NCT03148366|Active Comparator|bismuth quadruple therapy (BQ)|bismuth quadruple therapy for 10 days (BQ) D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
2914491|NCT03148353|Experimental|Modified subacromial injection|"Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound~Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid)~Intervention procedure: lidocaine injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound~Drug: 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
2914492|NCT03148353|Placebo Comparator|Standardized subacromial injection|"Intervention procedure: corticoseroid injection into the subacromial bursa only~Device for guidance: high-resolution ultrasound~Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid)~Intervention procedure: lidocaine injection into the subacromial bursa only~Device for guidance: high-resolution ultrasound~Drug: 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
2914493|NCT03148340||VIPS monitoring group|The study population will consist of adult patients presenting for evaluation of acute brain pathology,
2914494|NCT03148327|Experimental|Regimen A: Phase I|The intervention will be looking at radiotherapy + drug Durvalumab (MEDI 4736)
2914495|NCT03148327|Experimental|Regimen A: Phase II|The intervention will be looking at radiotherapy + drug Durvalumab (MEDI 4736)
2914496|NCT03148327|Active Comparator|Regimen B: Phase II|Radiotherapy alone
2914497|NCT03148314|Other|hospital- based standard dose of vaginal misoprostol|
2914498|NCT03148314|Other|Home-based extended low dose of buccal/sublingual misoprostol|
2914499|NCT03148301||Patients with Spina Bifida|Adults with and parents of children with Spina Bifida followed by the team in UZ Leuven will be asked to complete a survey
2914500|NCT03148288|Experimental|Vitamin D supplementation|4000IU Vitamin D qd
2914501|NCT03148288|Placebo Comparator|placebo|
2914502|NCT03148275|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days for up to 52 courses in the absence of disease progression or unacceptable toxicity.
2914503|NCT03148262|Experimental|The high flow nasal cannula|The Comfort Flo system will be used for the high flow nasal cannula during colonoscopy
2914504|NCT03148262|Placebo Comparator|The standard nasal cannula|The Salter nasal cannula will be used during the colonoscopy
2914505|NCT03148249|Experimental|interview with an ophthalmologist|Patients get an interview with an ophthalmologist
2914506|NCT03148249|Experimental|interview/treatment by a psychiatrist|patients get an interview and a possible treatment by a psychiatrist
2914507|NCT03148236|Active Comparator|Vitamin C|
2914508|NCT03148236|Placebo Comparator|Placebo|
2914509|NCT03148223|Experimental|Intervention|Auriculotherapy with application of mustard seeds fixed with adhesive tape at specific points in the auricle during one session per week lasting 20 minutes for 3 consecutive months.
2914510|NCT03148223|Placebo Comparator|Control|Auriculotherapy with tape-only fixation in the auricle, without mustard seeds, following the same stitch protocol used with the intervention group, during a session per week lasting 20 minutes, for three consecutive months.
2914511|NCT03148210|Active Comparator|Enhanced Care|Treatment strategy using evidence-based guidelines for asthma or COPD
2914512|NCT03148210|Placebo Comparator|Standard of Care|Spirometry result sent to family MD
2914513|NCT03148197||Admitted for allogeneic HSCT|Patients admitted for performance of an allogeneic HSCT after high dosis chemotherapy.
2914514|NCT03148197||First diagnosis AML|Patients admitted with a first diagnosis of an acute myeloid leukemia for chemotherapy. Depending on factors like age or molecular risk profile some of these patients will proceed to allogeneic HSCT.
2914515|NCT03148171|No Intervention|Routine PrEP Care|Routine PrEP Care at each clinical site.
2914516|NCT03148171|Active Comparator|PrEP-R Supportive Contact|Support contact will provide emotional support and practical support in order to help their friend/family member to stay engaged in PrEP Care.
2914517|NCT03148145|Active Comparator|Constant Steps Goal|Step Goal Delivery by Smartphone
2914518|NCT03148145|Experimental|Averaged Steps Goals and Random Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
2914519|NCT03148145|Experimental|Algorithm Steps Goal and Random Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
2914520|NCT03148145|Experimental|Algorithm Steps Goal and Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
2914521|NCT03148132|Active Comparator|Bevacizumab injection|Application of Intravitreal Bevacizumab (0.50mg/0.02mL), unique dosis
2914522|NCT03148132|Experimental|Ranibizumab Ophthalmic|Application of Intravitreal Ranibizumab (0.25mg/0.025mL), unique dosis
2914523|NCT03148119|Experimental|Topical QRH Heptapeptide Administration|
2914524|NCT03148080||Age 25-29 years old|Data collection: brief cognitive testing; detailed questionnaire assessing occupation, education status, a variety of work measures, and self-reported physical, psychosocial, and cognitive function; medical history, cancer treatment information, and medication use.
2914525|NCT03148080||2-5 five years since diagnosis|Data collection: brief cognitive testing; detailed questionnaire assessing occupation, education status, a variety of work measures, and self-reported physical, psychosocial, and cognitive function; medical history, cancer treatment information, and medication use.
2914526|NCT03148080||Age 30 - 34 years old|Data collection: brief cognitive testing; detailed questionnaire assessing occupation, education status, a variety of work measures, and self-reported physical, psychosocial, and cognitive function; medical history, cancer treatment information, and medication use.
2914527|NCT03148080||6-10 years since diagnosis|Data collection: brief cognitive testing; detailed questionnaire assessing occupation, education status, a variety of work measures, and self-reported physical, psychosocial, and cognitive function; medical history, cancer treatment information, and medication use.
2914528|NCT03148067||Patients|Patients with closed or open diaphyseal femoral and tibial fractures treated through intramedullary nailing for fracture fixation
2914529|NCT03148054||Study group|Patients undergoing elective left sided colon surgery
2914530|NCT03148041|Active Comparator|intensive health education program|Participants in the intervention group will have an intensive health education program of the introductory lecture and brochures about stroke as well as they fill up the questionnaire at baseline. At week 6 and 12 of the study the participants will only fill up the questionnaire.
2914622|NCT03147365|No Intervention|Control group|Twenty five children who will not receive any physical therapy treatment.
2914531|NCT03148041|Placebo Comparator|routine care|Participants in the control group will have a routine care of different lecture and brochures than the intervention group as well as they fill up the questionnaire at baseline. At week 6 and 12 of the study the participants will only fill up the questionnaire.
2914532|NCT03148028||PID IBD patients|patients with an immunodeficiency and inflammatory bowel disease phenotype
2914533|NCT03148015||ADH/LCIS|Atypical Ductal Hyperplasia or Lobular carcinoma in situ with DCIS
2914534|NCT03148015||DCIS|Pure Ductal Carcinoma in Situ
2914535|NCT03148015||Invasive|invasive ductal carcinoma with DCIS
2914536|NCT03148002|Active Comparator|Current Bowel Protocol|Patients will receive the Current Bowel Protocol with senna. Lactulose will be used for rescue therapy.
2914537|NCT03148002|Active Comparator|PEG Bowel Protocol|Patients will receive the Protocol with Polyethylene Glycol 3350. Lactulose will be used for rescue therapy.
2914538|NCT03147989||Group 1, 0.10 mmol/kg|For patients having received MULTIHANCE at a standard dose of 0.10 mmol/kg for their clinically indicated MRI examination.
2914539|NCT03147989||Group 2, 0.05 mmol/kg|For patients having received MULTIHANCE at a dose of 0.05 mmol/kg for their clinically indicated MRI examination.
2914540|NCT03147976|Experimental|AMG 337|AMG 337 in subjects with advanced or metastatic solid tumors that overexpress MET or harbor METex14del mutations
2914541|NCT03147963|Experimental|Docetaxel 2-Weeks regimen group|Docetaxel injection 50mg/m2,iv,d1,every 2 weeks
2914542|NCT03147963|Active Comparator|Docetaxel 3-Weeks regimen group|Docetaxel injection 75mg/m2,iv,d1,every 3 weeks
2914543|NCT03147950|Active Comparator|Prone-Flexed PCNL|Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)
2914544|NCT03147950|Active Comparator|Prone PCNL|Prone Position For Percutaneous Nephrolithotomy (PCNL)
2914545|NCT03147924|Experimental|Attending Improvisation Group|Attended 3 or more Improvisation Group sessions
2914546|NCT03147911||Stroke or systemic embolism : Positive|- 583 patients
2914547|NCT03147911||Stroke or systemic embolism : Negative|- 598 patients
2914548|NCT03147898||Group 1: Toddlers|Non-intervention observational study. Toddlers will receive wP-containing combination vaccine as part of the national immunization schedule
2914549|NCT03147898||Group 2: Toddlers|Non-intervention observational study. Toddlers will receive an aP-containing combination vaccine as part of the national immunization schedule.
2914550|NCT03147898||Group 3: Preschooler|Non-intervention observational study. Preschoolers will receive a wP-containing combination vaccine as part of the national immunization schedule.
2914551|NCT03147898||Group 4: Preschooler|Non-intervention observational study. Preschoolers will receive an aP-containing combination vaccine as part of the national immunization schedule.
2914552|NCT03147885|Experimental|Treatment (selinexor, RCHOP)|Patients will receive selinexor PO on days 1, 8, and 15 of a 21 week cycle. RCHOP will be given at standard dosing every 21 days. In the phase 1 part there is dose escalation for Selinexor in a 3+3 design. Treatment will be given for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with partial response or better will receive maintenance selinexor PO on days 1, 8, 15, and 22 every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
2914553|NCT03147872|No Intervention|5% Oxygen|All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will continue to have their embryos cultured at 5% oxygen until they are deemed to be clinically usable or not clinically usable (as per standard protocol).
2914554|NCT03147872|Experimental|2% Oxygen|All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will have their embryos cultured at 2% oxygen until they are deemed to be clinically usable or not clinically usable (per standard criteria).
2914555|NCT03147859|Experimental|vedolizumab infusions and ATI|The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of vedolizumab will be administered in 3 groups of 4 participants at 75, 150 and 300 mg doses. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, ATI will begin between weeks 6 and 7, and infusions continued at weeks 8, 12, 16 and 20, for a total of up to 7 doses.
2914556|NCT03147846|Experimental|delayed cord clamping|"Keep the baby at the level or below the placenta for 45-60 seconds before clamping the cord.~Keep the room temperature at 23-25˚C and wrap the baby if possible"
2914557|NCT03147846|Active Comparator|cord milking|Do 4-5 strips from proximal (maternal) end of the cord (as proximal as possible) towards the baby abdomen with thumb and forefinger Wait for 2 seconds between each stripping Keep the baby at the level of placenta
2914558|NCT03147833|Experimental|Sport beverages Protein|Intervention group ingesting PROTEIN
2914559|NCT03147833|Active Comparator|Sports beverage Carbohydrate|Placebo group ingesting carbohydrate
2914560|NCT03147807|Experimental|betaLACTA® result given to physician|In the experimental group, betaLACTA® rapid diagnostic test guided de-escalation result will be given to physician at Day 0 and empirical carbapenems will be de-escalated to Cefepime or Ceftazidime +/- Amikacin since the second dose.
2914561|NCT03147807|No Intervention|betaLACTA® result NOT given to physician|In the control group, betaLACTA® result will not be given to physician and patients will receive empirical carbapenem during the time required to obtain final results of antibiotic susceptibility test
2914562|NCT03147794|Experimental|FES using MyndMove Technology|This is the only arm of the study. Participants will be provided with the FES intervention as part of the protocol.
2914563|NCT03147781|No Intervention|Standard care|Participants in this group only receive standard post-cesarean care of the study hospital. It includes mobility restraint, foley retention, IV fluid infusion, oral intake instructions, oral pain medications routine, and breastfeeding practice.
2914564|NCT03147781|Sham Comparator|Sham AT with Medulla Junci|Participants in this group receive auricular tape with Medulla Junci in addition to standard post-cesarean care during the early 96 postpartum hours.
2914565|NCT03147781|Experimental|True AT with magnetic pellets|Participants in this group receive auricular tape with magnetic pellets in addition to standard post-cesarean care during the early 96 postpartum hours.
2914623|NCT03147365|Experimental|Study group A|Twenty five children who will receive physical therapy treatment which include aerobic exercises.
2914668|NCT03147066|Active Comparator|Flurbiprofen axetil|1 mg/kg of intravenous flurbiprofen axetil 30 min before the end of surgery
2914566|NCT03147768|Experimental|Distal Pancreatectomy Sealing using LTW|At the completion of pancreatic resection, the cut surface of the pancreas is covered with two layers of Albu-Green solder and one layer of D-Albumin lamina, all welded with the laser. The 60 Watt custom 810nm diode laser, is set to deliver continuous energy with laser irradiation power of approximately 150 W/cm2 with a Fluence of 90 J/cm2. During soldering the tip of the custom hand piece with top hat beam profile is held 1-2 cm from the wound surface to generate a 5mm spot size. Albu-Green Solder is observed to convert from a liquid green state to a solid white crust when the laser is activated indicating the completion of welding and providing a visual cue to the operator. The amount of Albu-Green solder and size of the denatured albumin lamina used is documented. The total laser tissue welding time for the three layers and the laser tissue welding time in seconds per cm2 is documented.
2914567|NCT03147755||Dysphagia|Patients with stroke associated dysphagia
2914568|NCT03147755||No dysphagia|Patients without stroke associated dysphagia
2914569|NCT03147729|Other|Radiofrequency in anal incontinence: a pilot study|It will be a single arm study with a group of anal incontinence with 10 women with anal incontinence
2914570|NCT03147716|Active Comparator|Enrollment Flyer|Participants in this condition received one of the strategies in the Parent Engagement Package: an enrollment flyer that provided information about the Triple P Positive Parenting Program being offered at their child's school, including the location of meetings, free childcare, topics covered, choice of days/times and English or Spanish groups, and an enrollment form. Parents who returned the enrollment form received automated text, email and/or phone reminders and a confirmation letter prior to each parenting program session.
2914571|NCT03147716|Experimental|Enrollment Flyer & Testimonial Booklet|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus a two-page, testimonial booklet that included photos and quotes from parents and children describing benefits other parents reported after participating in the Triple P Positive Parenting Program and fun activities children reported about the childcare. The booklet also contained the location of meetings, free childcare, choice of days/times and English or Spanish groups, and an enrollment form.
2914572|NCT03147716|Experimental|Enrollment Flyer & Teacher Endorsement|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus a teacher endorsement of the Triple P Positive Parenting Program. The teacher also gave the participant a colorful brochure that included information about the location of meetings, free childcare, topics covered, choice of days/times and English or Spanish groups, and an enrollment form.
2914573|NCT03147716|Experimental|Enrollment Flyer & Engagement Call|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus an engagement call from a Triple P provider. Providers followed a manualized protocol for implementing the engagement call, which included strategies to increase parental motivation to participate in Triple P and reduce barriers to participation.
2914574|NCT03147716|Experimental|All Engagement Strategies|Participants in this condition received all engagement strategies in the Parent Engagement Package: enrollment flyer, testimonial booklet, teacher endorsement, and provider engagement call.
2914575|NCT03147703|Experimental|Early Eating (EE)|The intervention is Food Timing, Early Eating is defined at 13:00 hours for lunch
2914576|NCT03147703|Experimental|Late Eating (LE)|The intervention is Food Timing, Late Eating is defined for 17:30 hours for lunch
2914577|NCT03147690|Experimental|Single|All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL
2914578|NCT03147677|Experimental|Alfacalcidol and Irbesartan|The subjects in this group orally take Alfacalcidol Soft Capsules at 0.25ug/day and Irbesartan Pills at 150mg/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
2914579|NCT03147677|Active Comparator|Irbesartan|The subjects in this group orally take Irbesartan Pills at 150mg/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
2914580|NCT03147677|Active Comparator|Alfacalcidol|The subjects in this group orally takeAlfacalcidol Soft Capsules at 0.25ug/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
2914581|NCT03147664||Pediatric Pompe patients|"Visit 1: Patients arrived at that hospital at 7:00 am, vital signs were collected and a complete neuromuscular evaluation was carried out (gross motor function measure score sheet (GMFM-88), 6MWT, pre-CPET questionnaire (demographics, physical activity level, risk assessment, asthma/atopy/smoking history, family history), pulmonary function tests and CPET. Following the evaluation, at approximately 9 am, the patient started infusion of ERT.~Visit 2: Two days following visit 1, the patient arrived at the hospital at 2:00 pm, vital signs were assessed and GMFM-88, 6MWT, pulmonary function tests, and CPET were performed."
2914582|NCT03147651||Cystic Fibrosis (CF) bronchiectasis|Diagnosis of Cystic Fibrosis (CF), follow up in a CF center, evidence of bronchiectasis on computed tomography (CT).
2914583|NCT03147651||non-Cystic Fibrosis (CF) bronchiectasis|Negative evaluation for of Cystic Fibrosis (CF), evidence of bronchiectasis on computed tomography (CT).
2914584|NCT03147638|Experimental|1 month|patient treated with Anti coagulation for one month
2914585|NCT03147638|Active Comparator|3 months|standard of care , treatment for 3 months
2914586|NCT03147625|Experimental|SHAPE Intervention|Participants in this group will receive a 12-week SHAPE intervention, comprising of 2 home visits, 10 weekly group-based activity sessions and a SHAPE health-promotion booklet.
2914587|NCT03147625|No Intervention|Control group|Participants in the control group will continue to participate in activities offered in the senior activity centre, community centres and voluntary welfare organisations.
2914588|NCT03147612|Experimental|Treatment (chemotherapy, ponatinib)|See Detailed Description.
2914589|NCT03147599|Active Comparator|Mebeverine|Coloverin (Mebeverine hydrochloride 135 mg)
2914590|NCT03147599|Placebo Comparator|Placebo|Placebo
2914624|NCT03147365|Experimental|Study group B|Twenty five children who will receive physical therapy treatment which include modified strength training program.
2914591|NCT03147586|Active Comparator|Bio-tech and omega-3 plus|Bio-tech (Biopharm pharmaceutical) powder 30 mg t.d.s. (contains multivitamins and essential amino acids) plus omega-3 plus (SEDICO pharmaceutical) capsules t.d.s (source for omega-3 fatty acids) 1 week before and 2 week after surgery
2914592|NCT03147586|Placebo Comparator|placebo|placebo powder 30 mg t.d.s plus placebo capsules t.d.s for 1 week before and 2 week after surgery
2914593|NCT03147573|Experimental|Blood pressure monitoring|
2914594|NCT03147560|Experimental|Group 1|The sequential immunization strategy for group 1 on polio was Sabin IPV+ bOPV + bOPV.
2914595|NCT03147560|Experimental|Group 2|The sequential immunization strategy for group 2 on polio was Sabin IPV + Sabin IPV + bOPV.
2914596|NCT03147560|Experimental|Group 3|The sequential immunization strategy for group 3 on polio was Sabin IPV + Sabin IPV + Sabin IPV.
2914597|NCT03147547|Active Comparator|Promotional Brochure|Participants in this condition received one of the strategies in the Parent Engagement Package: a promotional brochure with information about the parenting intervention being offered at their child's school, the Triple P Positive Parenting Program. This information included the location of meetings, free childcare, topics covered, choice of English or Spanish groups, meeting day and time, and an enrollment form. Parents who returned the enrollment form received a confirmation letter prior to the first parenting program session.
2914598|NCT03147547|Experimental|Parent Engagement Package|Participants in this condition received all engagement strategies in the Parent Engagement Package, which included: 1) the promotional brochure; 2) family testimonial flyer that included photos and quotes from prior participants; 3) teacher endorsement of the Triple P program; 4) provider engagement call to motivate parents to attend; and 5) phone reminders prior to each Triple P session.
2914599|NCT03147534|Active Comparator|Children Age 1 month to 2 years|"Collecting temperatures on patients using the ARC InstaTemp MD and a Welch Allyn rectal thermometer."
2914600|NCT03147534|Active Comparator|Children > 2 to 5 years|"Collecting temperatures on patients using the ARC InstaTemp MD, the Welch Allyn rectal and Covidien tympanic thermometer."
2914601|NCT03147534|Active Comparator|Children > 5 to ≤ 10 years|"Collecting temperatures on patients using the ARC InstaTemp MD, the Welch Allyn oral and the Covidien tympanic thermometer."
2914602|NCT03147521|Experimental|Accidental falls care bundle|Care Bundle Implementation Arm
2914603|NCT03147521|Active Comparator|Accidental falls standard care|Standard Care Implementation Arm (Universal strategy application for the environmental and patient)
2914604|NCT03147508||Neck pain patients|
2914605|NCT03147495||the study group|The participants with knee varus and medial compartment knee osteoarthritis.
2914606|NCT03147495||the control group|The participants without knee varus and medial compartment knee osteoarthritis.
2914607|NCT03147469|No Intervention|Neutral|After insertion of Ambu AuraGain™, the variables will be assessed at each positions including neutral, flexion, extension, right rotation under random order.
2914608|NCT03147469|Experimental|Flexion|After positioning the subjects' neck to flexion, the variables will be assessed.
2914609|NCT03147469|Experimental|Extension|After positioning the subjects' neck to extension, the variables will be assessed.
2914610|NCT03147469|Experimental|Right rotation|After positioning the subjects' head to right rotation, the variables will be assessed.
2914611|NCT03147456|Experimental|Intervention group|Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies.Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day, over 3-5 intervals). Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient (Cubitan Protein, Nutricia, Netherlands).
2914612|NCT03147456|Placebo Comparator|Control group|Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies. Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day over 3-5 intervals).Following hospital discharge, Control patients will receive supplement contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes (preOp, Nutricia, Netherlands).
2914613|NCT03147443|Experimental|Individualized Decoction|"It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.~The Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
2914614|NCT03147443|Placebo Comparator|placebo|"Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The placebo and test drug have no differences in dosage form, appearance, color, specification, label, and so forth.~The placebo is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
2914615|NCT03147443|Active Comparator|Tested drug minus heat-clearing herbs|"It is the decoction of the Individualized Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.~This control Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
2914616|NCT03147430||Invasive Cancer|Invasive cancer confirmed by biopsy
2914617|NCT03147430||Benign or pre-invasive lesion|Benign or pre-invasive lesion confirmed by biopsy
2914618|NCT03147404|Experimental|Avelumab|Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
2914619|NCT03147391||LAA closure with LAmbre|The patients with atrial fibrillation who received left atrial appendage (LAA) closure using the LAmbre device in our center from April 2014 to November 2015.
2914620|NCT03147378|Experimental|arm A Fasting-Fed condition|ModraDoc006/r will be administered in fasting condition week 1 and in fed condition week 2
2914621|NCT03147378|Experimental|arm B Fed-Fasting condition|ModraDoc006/r will be administered in fed condition week 1 and in fasting condition week 2
2961573|NCT02821624|Experimental|Cohort 11|G1T38 or placebo
2914625|NCT03147352||NSTI patients|NSTI is an infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection in subcutis, muscle and/or fascia and that spreads along tissue structures.
2914626|NCT03147352||Orthopaedic control patients|Elective orthopaedic control patients.
2914627|NCT03147339|Experimental|AGEs restricted diet|Low calorie diet + AGEs restricted diet
2914628|NCT03147339|No Intervention|control|Low calorie diet
2914629|NCT03147326|Other|FDG-NaF-MRI|"All participants will undergo three project scans/the following interventions:~FDG-PET-CT NaF-PET-CT Whole-body MRI All participants will undergo a whole-body x-ray as part of clinical routine practice."
2914630|NCT03147313|Sham Comparator|Sham|
2914631|NCT03147313|Active Comparator|Shockwave 300 pulses|300 pulses of extracorporeal shock wave will be applied
2914632|NCT03147313|Active Comparator|Shockwave 500 pulses|500 pulses of extracorporeal shock wave will be applied
2914633|NCT03147300|Active Comparator|Östergötland region - Control group|
2914634|NCT03147300|Experimental|Östergötland region - Intervention group|
2914635|NCT03147287|Active Comparator|Fulvestrant|-Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly
2914636|NCT03147287|Experimental|Fulvestrant with Palbociclib|"Palbociclib should be taken orally, once per day for 21 days on a 28 days cyclye~Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly"
2914637|NCT03147287|Experimental|Fulvestrant with Palbociclib and Avelumab|"Palbociclib should be taken orally, once per day for 21 days on a 28 days cyclye~Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly~Avelumab will be administered intravebously once every 2 weeks"
2914638|NCT03147274|Experimental|Intervention Group|Participants in this group will receive 3 group education sessions led by a diabetes nurse educator in addition to standard care.
2914639|NCT03147274|No Intervention|Control Group|These participants will receive no intervention. They will have clinic care as usual and will receive three diabetes newsletters to match for attention.
2914640|NCT03147261|Experimental|lifestyle intervention|Intensive follow up in lifestyle factors with a reduced calorie DM , physical activity and behavioural therapy.
2914641|NCT03147261|No Intervention|No intervention|Healthy diet recommendations following the usual pediatric advice
2914642|NCT03147248|Experimental|CT-P13 IV|CT-P13 IV (Infliximab)
2914643|NCT03147248|Experimental|CT-P13 SC|CT-P13 IV (Infliximab)
2914644|NCT03147235|Experimental|vitrectomy with music listening|Patients undergoing vitrectomy surgery will listen to a designed playlist of music during the entire duration of surgery
2914645|NCT03147235|No Intervention|vitrectomy without music listening|Patients undergoing vitrectomy surgery will not be exposed to music listening.
2914646|NCT03147222|Experimental|Hip Care at Home|A trained FFC coach will visit each caregiver and hip fracture participant in the home for a 1-2 hour session once a week for 8 weeks.
2914647|NCT03147209|Experimental|Health Coaching|This group will undergo coaching and activities to improve strength and balance.
2914648|NCT03147196|Experimental|Arm A (raloxifene hydrochloride)|Patients receive low dose raloxifene hydrochloride PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2914649|NCT03147196|Experimental|Arm B (bicalutamide)|Patients receive low dose bicalutamide PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2914650|NCT03147196|Experimental|Arm C (raloxifene hydrochloride, bicalutamide)|Patients receive low dose raloxifene hydrochloride PO daily and low dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2914651|NCT03147196|Experimental|Arm D (raloxifene hydrochloride, bicalutamide)|Patients receive high dose raloxifene hydrochloride PO daily and high dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2914652|NCT03147183||candidates for renal transplant|
2914653|NCT03147157|Experimental|research group,low MR group|tacrolimus regimen guided by HLA matching rate
2914654|NCT03147157|No Intervention|observation group,low MR group|tacrolimus regimen is applied according to clinical experience
2914655|NCT03147157|Experimental|research group,middle MR group|tacrolimus regimen guided by HLA matching rate
2914656|NCT03147157|No Intervention|observation group,middle MR group|tacrolimus regimen is applied according to clinical experience
2914657|NCT03147157|Experimental|research group,high MR group|tacrolimus regimen guided by HLA matching rate
2914658|NCT03147157|No Intervention|observation group,high MR group|tacrolimus regimen is applied according to clinical experience
2914659|NCT03147131|Active Comparator|Fitmore short stem|"Intervention: Total hip arthroplasty with an uncemented femoral short stem, the Fitmore short stem (Zimmer, Warsaw, USA). Furthermore, an uncemented cup (Allofit, Zimmer, Warzaw, USA).~Device: Fitmore Short Stem"
2914660|NCT03147131|Active Comparator|CLS straight stem|"Intervention: Total hip arthroplasty with an uncemented femoral straight stem, the CLS short stem (Zimmer, Warsaw, USA).Furthermore, an uncemented cup (Allofit, Zimmer, Warzaw, USA).~Device: CLS Straight Stem"
2914661|NCT03147105|Experimental|arm ergometry|Home-based treatment after education in center, training following interval training plan on chip cards for 12 weeks at least 4-5 times/week
2914662|NCT03147105|Active Comparator|waiting group|training after 12 weeks.
2914663|NCT03147092|Experimental|Hypertension group|Hypertensive patients will be counseled to initiate life style changes as weight loss, salt reduction, exercise, reduced alcohol consumption, smoking cessation and fresh fruits and vegetables in their diets. Drug treatment will be started for subjects that are not responding to nonpharmacological treatment. The anti-hypertensive medications will be Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet, atenolol and Losartan potassium 50 mg. All of these anti-hypertensive drugs are available in the PPP. If BP control is not yet obtained, other antihypertensive drugs will be requested: clonidine, spironolactone, hydralazine and amlodipine.
2914664|NCT03147079|Experimental|Intervention|Lifestyle intervention
2914665|NCT03147079|Experimental|Internal controls|
2914666|NCT03147079|Experimental|External controls|
2914669|NCT03147053|Experimental|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules .
2914670|NCT03147053|Placebo Comparator|Placebo|Patients in this group were administered the placebo .
2914671|NCT03147040|Experimental|Carboplatin/Atezolizumab|Carboplatin AUC=1.5, weekly schedule, maximum 12 administrations Atezolizumab, 1200 mg flat dose, 3-weekly schedule, starting after two administrations of carboplatin
2914672|NCT03147027||VT ablation group|
2914673|NCT03147027||medication group|
2914674|NCT03147014|Other|Maternal Hyperoxygenation|Maternal hyperoxygenation will be offered by administering 10 liters nasal cannula by face-mask (approximately 60% fiO2) for a minimum of 10 minutes.
2914675|NCT03147001|Experimental|Protein ingestion|Subjects ingested protein drinks
2914676|NCT03147001|Placebo Comparator|Placebo|Subjects ingested a non-caloric placebo drink
2914677|NCT03146988|Experimental|RGB-02 6 mg SC (test product)|
2914678|NCT03146988|Active Comparator|Neulasta®|
2914679|NCT03146975|No Intervention|Healthy|
2914680|NCT03146975|Experimental|Periodontitis without diabetes|
2914681|NCT03146975|Experimental|Periodontitis compensated diabetes|
2914682|NCT03146975|Experimental|Periodontitis decompensated diabetes|
2914683|NCT03146975|No Intervention|Compensated diabetes non periodontitis|
2914684|NCT03146975|No Intervention|Decompensated diabetes non periodontitis|
2914685|NCT03146962|Experimental|All Subjects|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B).
2914686|NCT03146949|Active Comparator|Sorin Inspire Oxygenator|Sorin Inspire Oxygenator is used on the cardiopulmonary bypass machine
2914687|NCT03146949|Active Comparator|Medtronic Affinity Fusion Oxygenator|Medtronic Affinity Fusion Oxygenator is used on the cardiopulmonary bypass machine
2914688|NCT03146923|Active Comparator|Standard Care Arm|Patients randomised to the standard care arm will be re educated using the current low phosphorus diet prescription.
2914689|NCT03146923|Experimental|Modified Intervention Arm|Patients randomised to the intervention arm will be educated using a modified low phosphorus diet prescription.
2914690|NCT03146897|Active Comparator|Super Cereal Plus with amylase|
2914691|NCT03146897|Active Comparator|Corn-soy Blend Plus and Vegetable Oil|
2914692|NCT03146897|Active Comparator|Corn-soy Whey Blend and Vegetable Oil|
2914693|NCT03146897|Active Comparator|Ready-to-Use-Supplementary Food|
2914694|NCT03146871|Experimental|Treatment (sEphB4-HSA, azacitidine, decitabine)|Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2914695|NCT03146858|Experimental|Enoxaparin|The patients will receive a 3-6 hour infusion of enoxaparin. The effects of the infusion will be assess when used on patients will acute heart attacks and undergoing emergency treatment with PPCI.
2914696|NCT03146845|Experimental|Allevyn Life Non-Bordered|Foam Dressing
2914697|NCT03146845|Other|Standard care|Standard care dressing
2914698|NCT03146832|Experimental|Habituation|The habituation instruction focuses on changes of the initial physical fear-responses during exposure sessions. It is explained that the level of anxiety will gradually decrease, or habituate, each time someone faces a feared situation. Participants are then instructed to observe their own level of fear during the three practice trials with the thermode. Together with the experimenter, participants have to indicate their level of arousal on an 11-point scale (0= neutral, 10 = very high) in-between and after the three practice trials. After the practice trial, participants are instructed to reconsider their own development of physical responses. Participants are encouraged to remember the development of their level of arousal during the test trail with the thermode.
2914699|NCT03146832|Experimental|Expectation Violation|"The expectation violation instruction focuses on the verification of negative expectancies during exposures sessions. It is explained that exposure exercises help to create own experiences which allow to directly test negative predicted outcomes. Together with the experimenter, participants are then encouraged to formulate concrete concerns in regard to the practice trail with the thermode. Before the practice trails, participants have to indicate the likelihood of their concerns on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are instructed to evaluate their own concerns by some guided questions (e.g. What did you learn?). Participants are encouraged to keep their own experience in mind during the test trail with the thermode."
2914700|NCT03146832|No Intervention|Control|"Participants in the control group are not provided with information about exposure therapy. Instead, participants listen to a newspaper article which reports on the daily work in a botanical garden. Together with the experimenter, participants are then asked to name the most interesting aspect in the article. Before the practice trails, participants have to rate how likely it is that they would further inform themselves about botanical gardens on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are provided with some further questions about the newspaper article (e.g. Did you find the newspaper article interesting?). This cognitive exercise does not cover any pain-related topics and, therefore, does not serve as a distraction instruction."
2914701|NCT03146819||iTotal PS KRS|Patients who have had an iTotal (posterior stabilized) knee replacement at least 6 months prior to testing.
2914702|NCT03146819||Off-the-Shelf KRS|Patients who have had an off-the-shelf (posterior stabilized) knee replacement at least 6 months prior to testing.
2914703|NCT03146806|Experimental|Intranasal ketamine treatment|Study participants who are receiving intranasal ketamine treatments.
2914704|NCT03146780|Placebo Comparator|Conventional|
2914705|NCT03146780|Active Comparator|Digital 1|
2914706|NCT03146780|Active Comparator|Digital 2|
2914707|NCT03146780|Active Comparator|Digital 3|
2914708|NCT03146767|Experimental|Tetanic Group|A Tetanic stimulation (Tetanus stabilization of baseline) is administered to the monitorized arm before calibrating the neuromuscular block monitor. Then Train-of-four (TOF) stimuli are administered every 20 seconds for 20 minutes.
2914932|NCT03145194|Placebo Comparator|Placebo|Patients will receive Placebo (2 matching tablets)
2914709|NCT03146767|No Intervention|Control Group|Conventional monitor baseline stabilization: Train-of-four stimuli are administered every 20 seconds for 20 minutes
2914710|NCT03146754|Experimental|Stable ADHF patients|Lung ultrasound to access b lines
2914711|NCT03146741|Experimental|Zepatier (grazoprevir 100mg and elbasvir 50 mg) o|
2914712|NCT03146728||tetraplegia, paraplegia|motor complete spinal cord injured individuals with tetraplegia or paraplegia
2914713|NCT03146728||able-bodied|age height and weight matched able bodied
2914714|NCT03146715|Active Comparator|High-carotenoid food feeding trial|Twenty-three children were randomly assigned to a treatment with a high carotenoid baked food (4.3mg carotenoids/120g, 360 kcal)
2914715|NCT03146715|Placebo Comparator|No-carotenoid food feeding trial|Twenty-five children were randomly assigned to consume a baked food with no carotenoids (300 kcals/73g)
2914716|NCT03146689|Experimental|Topical NSAID and topical capsaicin|"Within each participant:~Topical NSAID (A) or capsaicin (B) are taken for a treatment period of four weeks. This is followed by another four week treatment period with the other treatment. These two treatment periods comprise one treatment cycle. The order of treatments within a treatment cycle is determined randomly (AB or BA).~This treatment cycle is repeated so that all participants undergo a maximum of three topical NSAID treatment periods and three topical capsaicin treatment periods (i.e., three treatment cycles). This is reduced to two cycles if they are found to meet the criteria for response at the interim analysis (after cycle two)."
2914717|NCT03146663|Experimental|NUC-1031 500 mg/m2|NUC-1031 500 mg/m2 on days 1, 8, and 15
2914718|NCT03146663|Experimental|NUC-1031 750 mg/m2|NUC-1031 750 mg/m2 on Days 1, 8, and 15
2914719|NCT03146650|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1, 15, 29, 43, 57, and 71 of course 1 and on days 1 and 15 of course 2, over 60 minutes on days 29 and 57 of course 2 and on days 1, 29, and 57 of subsequent courses. Patients also receive ipilimumab over 90 minutes on days 1 and 43. Courses repeat every 84 days in the absence of disease progression or unexpected toxicity.
2914720|NCT03146637|Experimental|Activated CIK and bispecific antibody|activated CIK and Bispecific antibody of anti-CD3-MUC1/CEA/EpCAM/GPC3
2914721|NCT03146637|Active Comparator|Activated CIK|activated CIK
2914722|NCT03146624|Experimental|attachment|attachment retained obturator
2914723|NCT03146624|Active Comparator|clasp|clasp retained obturator
2914724|NCT03146611||COPD patients|A diagnosis of COPD was made by a clinical history, examination and spirometer (forced expiratory volume in 1st second/forced vital capacity (FEV1/FVC)ratio of <0.7). The severity of COPD was graded according to the Global Initiative for Chronic Obstructive Lung Disease guidelines. [9] (Stage I, mild COPD: FEV1≥80.0% predicted; Stage II, moderate COPD: FEV1 80-50.0%; Stage III, severe COPD: FEV1 50- 30.0%; Stage IV, very severe COPD: FEV1< 30.0%). The exacerbation of COPD was defined as the patient being diagnosed with COPD with two or more of the following three symptoms of exacerbations: new or worsening cough, worsened dyspnea, and worsened sputum volume and/or change in its color.
2914725|NCT03146611||control|healthy sex and age matched group
2914726|NCT03146585||Patients on artificial ventilation|
2914727|NCT03146585||Patients on renal replacement therapy|
2914728|NCT03146585||Patients with targeted temperature management|
2914729|NCT03146572|Experimental|Intervention|Parent of child to receive intervention, Sit Down and Play
2914730|NCT03146572|Active Comparator|Control|Parent will receive handout to promote positive behavior
2914731|NCT03146559|Experimental|EMG and TENS|"Wireless Bluetooth EMG (Myo) bracelet will be placed on the healthy forearm. A voluntary dorsi flexion of the healthy wrist produces data that will be transmitted to a PC and will be used to activate (via Arduino controller) a Transcutaneous Electric Nerve Stimulator (TENS), placed on the paretic forearm, that will stimulate wrist dorsi flexors.~5 days per week, for 3 weeks, 15 minutes per day."
2914732|NCT03146559|Active Comparator|TENS only|"Custom-built software & hardware: PC + Arduino controller and Transcutaneous Electric Nerve Stimulator (TENS) device, will be used to stimulate wrist dorsi flexors of the paretic forearm.~5 days per week, for 3 weeks, 15 minutes per day."
2914733|NCT03146546||Septic Shock|Patients with septic shock as defined by the Sepsis-3 criteria(9)
2914734|NCT03146546||Septic Shock with AKI|Patients with septic shock as defined by the Sepsis-3 criteria(9) with concomitant AKI
2914735|NCT03146533|Experimental|CD19 CART|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CD19 CART cells. The CD19 CART cells are to be administered on day0,day1,day2.
2914736|NCT03146520||Colorectal (CRC)|stage I-IV CRC subjects
2914737|NCT03146520||Polyps|subjects with adenoma or polyps
2914738|NCT03146520||Other cancers|subjects with other cancers
2914739|NCT03146520||Healthy|subjects with no evidence of CRC
2914740|NCT03146494||STAAD|
2914741|NCT03146494||Normal|
2914742|NCT03146481|Experimental|Aceclofenac|Aceclofenac 100 mg tablet
2914743|NCT03146481|Placebo Comparator|placebo|Placebo
2914744|NCT03146468|Experimental|Nivolumab treatment arm|Nivolumab injection 3mg/kg intravenously every 2 weeks
2914745|NCT03146455||Health adults|(1) 18< Age <65, and Han Chinese residents living in Hunan more than 3 years. (2) Health examination population who physical examination, assistant examination and serological examination were normal; Not suffer from other diseases last 3 months; Not take any medication last 7 days.
2914746|NCT03146442|Active Comparator|Normal Protein (NP) Breakfast|The participants in the NP Breakfast group will be provided with NP Breakfasts to consume, at home, between 6:00-9:00 am each day over the 6-month intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The energy content of the breakfast meals is ~18% of daily energy intake estimated from the energy expenditure equations specific for adolescents ages 13-19y. The NP breakfasts will be 11% protein (10g protein), 63% CHO, and 26% fat. The types of protein incorporated within the NP and HP meals will include a combination of animal (egg, dairy, animal tissue) and plant-based proteins (soy, pea, gluten). An 8-d breakfast rotation will occur throughout the 6 months.
2914782|NCT03146208||Coronary artery disease patients without type 2 DM|The present study will be carried on 29 patients attending to cardiology department with coronary artery disease without type 2 diabetes (age 20-55 years).
2914783|NCT03146208||Healthy control group|we will include 54 age-matched patients with normal angiogram
2914747|NCT03146442|Experimental|High Protein (HP) Breakfast|The participants in the HP Breakfast group will be provided with HP Breakfasts to consume, at home, between 6:00-9:00 am each day over the 6-month intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The energy content of the breakfast meals is ~18% of daily energy intake estimated from the energy expenditure equations specific for adolescents ages 13-19y. The HP breakfasts will be 34% protein (30g protein), 40% CHO, and 26% fat. The types of protein incorporated within the HP and HP meals will include a combination of animal (egg, dairy, animal tissue) and plant-based proteins (soy, pea, gluten). An 8-d breakfast rotation will occur throughout the 6 months.
2914748|NCT03146442|Placebo Comparator|Breakfast Skipping (BS)|The participants in the BS group will continue to skip breakfast each day over the 6-month intervention. They will have nothing to eat or drink (besides water) until 11 am.
2914749|NCT03146416|Experimental|Cohort 1|Evinacumab SC or placebo SC
2914750|NCT03146416|Experimental|Cohort 2|Low dose regimen: evinacumab IV or placebo IV
2914751|NCT03146416|Experimental|Cohort 3|High dose regimen: evinacumab IV or placebo IV
2914752|NCT03146416|Experimental|Cohort 4|Evinacumab or placebo SC every week (QW) x 8 doses
2914753|NCT03146416|Experimental|Cohort 5|Evinacumab or placebo SC x 1 dose
2914754|NCT03146403|Experimental|GEN-003|60μg of each GEN-003 antigen with 50μg Matrix-M2 adjuvant, administered as a 0.5mL intramuscular (IM) injection
2914755|NCT03146403|Placebo Comparator|Placebo|0.9% normal saline administered as a 0.5mL intramuscular (IM) injection
2914756|NCT03146390|Active Comparator|Essential oils (Listerine Mentol)|"a single mouthwash with 20 ml of essential oils for 30 seconds~20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1)."
2914757|NCT03146390|Placebo Comparator|Water|"a single mouthwash with 20 ml of sterile water for 30 seconds~20 ml rinses for 30 seconds with sterile water/2 times daily (1/0/1)."
2914758|NCT03146390|Experimental|Alcohol free essential oils|"a single mouthwash with 20 ml of alcohol free essential oils for 30 seconds~20 ml rinses for 30 seconds with alcohol free essential oils/2 times daily (1/0/1)."
2914759|NCT03146377|Experimental|Xeloxiri|
2914760|NCT03146364|Experimental|Hospitalization patients|patients in psychiatric hospitalization will take part in tests at Virtual Reality - Virtual Interactive Supermarket environment (diagnosis)
2914761|NCT03146364|Experimental|Ambulatory patients|patients being treated in a clinic will take part in tests at Virtual Reality - Virtual Interactive Supermarket environment (diagnosis)
2914762|NCT03146351|Experimental|Early and moderate preterm group|Infants born before 34 weeks included in this group
2914763|NCT03146351|Experimental|Late preterm group|Infants born between 34 and 37 weeks included in this group
2914764|NCT03146338|Experimental|Magnesium-rich mineral water (Rozana)|Patients in this arm must take 1.5 Liter by day of a mineral water rich in magnesium (Rozana) during the treatment by anti-EGFR. The mineral water is provided.
2914765|NCT03146338|No Intervention|Standard|Patients will have the usual care (oral advice only according to the habits of the investigator)
2914766|NCT03146325|Experimental|PYLERA AND OMEPRAZOLE|14-DAY COURSE OF 3-1 PYLERA (3 CAPSULES QID) PLUS OMEPRAZOLE (BID)
2914767|NCT03146325|Placebo Comparator|PLACEBO|MATCHING PLACEBOS
2914768|NCT03146312|Experimental|MVM/phytochemical supplement|a multi-vitamin, multi-mineral, phytochemical supplement
2914769|NCT03146312|Placebo Comparator|Placebo|a placebo tablet (microcrystalline cellulose) identical in size, shape and color to the treatment
2914770|NCT03146299|Active Comparator|Group A: TLH|
2914771|NCT03146299|Active Comparator|Group B: LAVH|
2914772|NCT03146286|Placebo Comparator|Control|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O). 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
2914773|NCT03146286|Experimental|Saturated Fat|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O) containing 45g palm stearin. 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
2914774|NCT03146273|Experimental|A|The tablet/capsule will be administered as a single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs.
2914775|NCT03146273|Experimental|B|The gel will be administrated to the same group of patients in the single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs
2914776|NCT03146260|Experimental|Conventional TESE|Conventional testicular sperm extraction (TESE) will be done under anesthesia through small vertical incision in the median raphe, skin, dartos and tunica vaginalis is opened to expose tunica albuginea. The tunica albuginea is incised for about 4mm at the upper pole near the head of epididymis.
2914777|NCT03146260|Experimental|Microdissection TESE|Microdissection testicular sperm extraction (TESE)will be carried under anesthesia micro TESE will be through a transverse incision of the testis covering three-quarters of its circumference, according to a line preserving as much as possible the predominantly transversal sub albugineal vessels. The testis will be opened like a book by gently separating the lobular tissue of both sides. Then, the tissue will be examined under the microscope at ×10-24 magnification to search for areas with dilated whitish tubules, from which numerous microretrievals will be performed.
2914778|NCT03146247|Other|One arm|all patients receive same dose and dosing regimen with Apremilast
2914779|NCT03146234|Experimental|CAR-GPC3 T cells|"Autologous T Cells with a GPC3-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.~Lymphodepletion conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day -6 to Day -3 prior to CAR-GPC3 T cells infusion."
2914780|NCT03146221|Other|Person to be surgically treated for arteritis|
2914781|NCT03146208||Coronary artery disease patients with type 2 DM|Coronary artery disease patients with type 2 diabetes (age 20-55 years). The present study will be carried on 25 patients attending to cardiology department with coronary artery disease with type 2 diabetes
2914827|NCT03145896|Active Comparator|IBD patients with Vitamin D treatment|
2914828|NCT03145896|No Intervention|IBD patients with no Vitamin D treatment|
2914784|NCT03146195||POP|Female patients with pelvic organ prolapse,such as: cystocele, uterine prolapse, the vault prolapse, rectal prolapse ,undergo pelvic floor reconstruction surgery.Before and after sugery,take dynamic magnetic resonance imaging scan.
2914785|NCT03146195||Non-POP|Females with normal pelvic floor support,don't need pelvic floor reconstruction surgery,only take once dynamic magnetic resonance imaging scan.
2914786|NCT03146182|No Intervention|Control|Patients are treated according to current local guidelines on antibiotic treatment for CAP.
2914787|NCT03146182|Experimental|CRP|Patients are treated according to the CRP-algorithm. CRP is measured daily. Antibiotic treatment is stopped when CRP reach threshold value.
2914788|NCT03146182|Experimental|PCT|Patients are treated according to the PCT-algorithm. PCT is measured daily. Antibiotic treatment is stopped when PCT reach threshold value.
2914789|NCT03146169|Experimental|Training group|Four two-hour training sessions were conducted at baseline, and one week, one month and three months after the first session.
2914790|NCT03146156|Experimental|Lifestyle Intervention|Lifestyle coaches will provide personalized instruction on physical activity, dietary data, and behavioral strategies.
2914791|NCT03146156|No Intervention|Usual Care|The usual care/control groups will be followed by their primary Obstetrical provider. All overweight/obese women will be offered nutrition counseling early in pregnancy by a registered dietician to support GWG within the IOM guidelines.
2914792|NCT03146143|Experimental|ultrafiltration group|ultrafiltration after cardiopulmonary bypass in congenital cardiac surgery
2914793|NCT03146143|No Intervention|non ultrafiltration control group|no ultrafiltration will be applied in this group
2914794|NCT03146130|Active Comparator|Patient treated with N-acetylcysteine|Patients randomise in the drug group
2914795|NCT03146130|Placebo Comparator|Patient treated with placebo|Patients randomise in the placebo group
2914796|NCT03146104|Active Comparator|Group P|Maintenance of anesthesia with 100-150mcg/kg/min propofol, O2 and air and FiO2 of 40%
2914797|NCT03146104|Active Comparator|Group I|Maintenance of anesthesia with 1 MAC of isoflurane,O2 and air and FiO2 of 40%
2914798|NCT03146091|Experimental|Outpatient nonantibiotic treatment|
2914799|NCT03146091|Active Comparator|Outpatient antibiotic treatment|
2914800|NCT03146078||Primary Cohort|"Participants with baseline visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and stable fixation and clinically determined [on Octopus 900 Pro] kinetic visual field III4e area 10° or more in the study eye (primary cohort) will be enrolled into the longitudinal natural history study"
2914801|NCT03146078||Secondary Cohort|"Participants with baseline visual acuity ETDRS letter score of 53 or less [approximate Snellen equivalent 20/100 or worse] or unstable fixation or clinically determined [on Octopus 900 Pro] kinetic visual field III4e area less than 10°in the study eye (secondary cohort) will be enrolled in the cross-sectional baseline study"
2914802|NCT03146065|Experimental|PF-06730512|Study Drug being used in the study
2914803|NCT03146065|Placebo Comparator|Placebo|Placebo for IV/SC administration
2914804|NCT03146052|Experimental|Asymmetric split dose preparation|75% of the dose is given on the day before of the procedure and 25% of the dose is given on the day of the procedure
2914805|NCT03146052|Active Comparator|Symmetric split dose preparation|50% of the dose is given on the day before of the procedure and 50% of the dose is given on the day of the procedure
2914806|NCT03146039|Other|Radiation Therapy|The patient will receive Whole Pelvis Radiation Therapy 40 - 50.4 Gy in 1.8 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks followed by Stereotactic Body Radiotherapy 5.5 - 8.0 Gy per fraction x 5 fractions using arc therapy.
2914807|NCT03146026|No Intervention|No Exercise (CON)|Fifteen obese adolescent girls. This arm did not perform any exercise training for 12 weeks. Caloric intake was 1921.7 kcal/day.
2914808|NCT03146026|Experimental|Combined Exercise Training (CET)|Fifteen obese adolescent girls. This arm performed combined exercise training 3 times per a week for 12 weeks. Caloric intake was 1921.7 kcal/day.
2914809|NCT03146013||HTLV Repeat Reactive (RR) / Non Reactive (NR)|Blood donor specimens that tested repeat reactive on the first FDA licensed HTLV screening assay and non-reactive on the second FDA licensed HTLV screening assay
2914810|NCT03146000|Experimental|lidocaine-prilocaine|women will receive 5 mg lidocaine-prilocaine cream topically on the episiotomy line
2914811|NCT03146000|Active Comparator|meloxicam|women will receive one 15 mg meloxicam rectal suppository
2914812|NCT03145987|Experimental|Vitis vinifera extract|Vitis vinifera extract 250 mg/day orally administered for 12 weeks.
2914813|NCT03145987|Placebo Comparator|Placebo|Placebo orally administered once a day for 12 weeks.
2914814|NCT03145974||Hypoxemic Acute Respiratory Failure|Consecutive intubated patients receiving invasive mechanical ventilation, with a PaO2/FiO2 ≤300 mmHg under a PEEP of 5 cmH2O or more, and with a FiO2 of 0.3 or more.
2914815|NCT03145961|No Intervention|Observation|Patient will have blood samples collected for ctDNA analysis every 3 months for up to 2 years from starting ctDNA screening.
2914816|NCT03145961|Experimental|Pembrolizumab Treatment|Patients will be given pembrolizumab every 3 weeks for up to a maximum of 12 months, with blood samples collected prior to each cycle for continued ctDNA analysis. Following treatment discontinuation, blood samples will be collected for ctDNA analysis every 3 months for a further 12 months.
2914817|NCT03145948|Experimental|Arm A|Participants, who are healthy volunteers, receiving ABBV-553 dose A or placebo
2914818|NCT03145948|Experimental|Arm B|Participants, who are healthy volunteers, receiving ABBV-553 dose B or placebo
2914819|NCT03145948|Experimental|Arm C|Participants, who are healthy volunteers, receiving ABBV-553 dose C or placebo
2914820|NCT03145948|Experimental|Arm D|Participants, who are healthy volunteers, receiving ABBV-553 dose D or placebo
2914821|NCT03145948|Experimental|Arm E|Participants with psoriasis receiving ABBV-553 dose B or placebo
2914822|NCT03145948|Experimental|Arm F|Participants with psoriasis receiving ABBV-553 dose C or placebo
2914823|NCT03145922||Sarcoidosis|
2914824|NCT03145922||Healthy Controls|
2914825|NCT03145909|Experimental|Dose Escalation Cohort|ABBV-176 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached.
2914826|NCT03145909|Experimental|Expanded RPTD Cohort|ABBV-176 via intravenous administration in participants with breast cancer at the Recommended Phase Two Dose (RPTD) determined during the Dose Escalation Cohort
2914830|NCT03145883|Experimental|Home-based Aerobic Exercise|Participants will be prescribed weekly exercise goals starting with 75 minutes a week (e.g., 15 minutes per day, 5 days a week) and progressed to 200 minutes a week (e.g., 40 minutes per day, 5 days a week) by week 12. Exercise will consist of participant preference of mobility exercises, most likely walking. Aerobic exercise, similar to a brisk walk, will be recommended as the primary mode of exercise.
2914831|NCT03145870|Other|Patient with multiple symptomatic myeloma|
2914832|NCT03145857|Experimental|[68]Ga-HA-DOTATATE|All participants will be imaged with [68]Ga-HA-DOTATATE PET/CT for uptake by somatostatin receptor positive tumours.
2914833|NCT03145844||Direct Acting Agents|No Intervention
2914834|NCT03145831|Experimental|Somavaratan|fusion protein, subcutaneous bolus injection, 3.5 mg/kg twice monthly
2914835|NCT03145818||Veterans|Veterans will be the primary group for whom the VD-HCBS Program is implemented. Veterans enrolled in VD-HCBS will be functionally impaired
2914836|NCT03145818||Caregivers|Caregivers support Veterans independence in their home and community
2914837|NCT03145818||VHA Coordinators|VHA VD-HCBS Coordinators allow the program to operate within the VA
2914838|NCT03145818||ADNA Coordinators|ADNA Coordinators engage with the Veteran, Caregivers, and VA Coordinators to ensure the Veteran is able to maintain independence
2914839|NCT03145805||liver resection patients|Liver resection patients sited with an epidural catheter for bupivacaine infusion for 3-5 days postoperatively to manage postoperative pain
2914840|NCT03145792|Experimental|Seeking Safety|Behavioral therapy for trauma and addiction.
2914841|NCT03145792|Active Comparator|CBT for Pathological Gambling|Behavioral therapy for gambling problems.
2914842|NCT03145766|Experimental|Group 1|Participants who receive five vaccine injections of VRVg 2 at D0, D3, D7, D14, and D28. All patients also received human rabies immunoglobulins (HRIG) at D0.
2914843|NCT03145766|Experimental|Group 2|Participants who receive five vaccine injections of VRVg 2 at D0, D3, D7, D14, and D28. All patients also received human rabies immunoglobulins (HRIG) at D0.
2914844|NCT03145766|Experimental|Group 3|Participants who receive five vaccine injections of VRVg 2 at D0, D3, D7, D14, and D28. All patients also received human rabies immunoglobulins (HRIG) at D0.
2914845|NCT03145766|Experimental|Group 4 (VRVg 1)|Participants who receive five vaccine injections of VRVg 1 at D0, D3, D7, D14, and D28. All patients also received human rabies immunoglobulins (HRIG) at D0.
2914846|NCT03145766|Experimental|Group 5 (Imovax Rabies, control)|Participants who receive five vaccine injections of Imovax Rabies (control) at D0, D3, D7, D14, and D28. All patients also received human rabies immunoglobulins (HRIG) at D0.
2914847|NCT03145753|Experimental|HIV/HCV Education plus Testing|In this arm education should be provided and also resources for testing, HIV/HCV rapid tests and Testing staff different from clinical practice resources
2914848|NCT03145753|Active Comparator|HIV/HCV Education|In this arm only education should be provided
2914849|NCT03145740|Experimental|Intensive F.O.T.T.®|Intensive F.O.T.T.® intervention was given twice a day, approximately 20 minutes per intervention, exclusive time to position the patient. Before and after the intervention, the patient was positioned in a standardized way in side lying for 10 minutes to rest. Here, the Electromyographic Bioimpedance Measuring device (EMBI) measured the spontaneous swallowing frequency and -quality during both, the resting period and the intervention. In the intervention itself, the patient was facilitated with specific handling and interventions to swallow, according to F.O.T.T.®. The faciltation was embedded into a meaningful context for the patient, e.g. tooth brushing or eating small amounts of apple sauce, if safe.
2914850|NCT03145740|Placebo Comparator|Unspecific stimulation of face and mouth|The intervention in the control group was given twice a day, approximately 20 minutes per intervention, exclusive time to position the patient. Patients in the control group were before and after the intervention, positioned in a standardized way in side lying for 10 minutes to rest. The EMBI measured the spontaneous swallowing frequency and -quality during both, the resting period and the intervention. The intervention included unspecific stimulation of the hands and the face, without therapeutic interventions directed towards facilitation of swallowing.
2914851|NCT03145727|Placebo Comparator|Placebo Group|Placebo Group: In this group the participants received TENS with frequency of 75Hz, pulse duration of 200 microseconds. The stimulation time will be for only 10s.
2914852|NCT03145727|Experimental|Low Frequency Group|Low Frequency Group: In this group the TENS will be adjusted with frequency of 10Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
2914853|NCT03145727|Experimental|High Frequency Group|High Frequency Group: In this group the TENS will be adjusted with frequency of 150Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
2914854|NCT03145714|Experimental|Propofol/Sevoflurane (Group P)|"Standard technique of induction of anaesthesia .~Maintenance of anesthesia with intravenous (IV) Propofol Infusion at rate 100-150 mcg/kilogram/hour and Inhalational Anesthetic Sevoflurane during the surgery. Intervention is to titrate dosage of Propofol and Sevoflurane to maintain Bispectral Index between 40-60.~Total dosage of IV Propofol and Sevoflurane uptake will be calculated at the end of surgery."
2914855|NCT03145714|Active Comparator|Dexmedetomidine/Sevoflurane (Group D)|"Standard technique of induction of anaesthesia .~Maintenance of anesthesia with intravenous Dexmedetomidine Infusion at rate 1- 4 mcg/kilogram/hour and Inhalational Anesthetic Sevoflurane during the surgery.~Intervention is to titrate dosage of Dexmedetomidine and Sevoflurane to maintain Bispectral Index between 40 - 60.~Total dosage of IV Dexmedetomidine and Sevoflurane uptake will be calculated at the end of surgery."
2914856|NCT03145688|No Intervention|Control|The control group package will consist of the Canadian 24 Hour Movement Guidelines recommending 60 minutes of moderate to vigorous physical activity per day for children. The guide also contains arguments & information about the benefits of physical activity.
2914889|NCT03145467|Experimental|Paracetamol|1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
2914890|NCT03145467|Experimental|Zolmitriptan|Second Group: Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients.
2914995|NCT03144713|Active Comparator|Midodrine|Midodrine 7.5 mg thrice daily for 3 days.
2914857|NCT03145688|Experimental|Family physical activity Planning|Behavoural: Family Physical Activity Planning. The physical activity planning intervention condition will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include workbook on how to plan for family physical activity; brainstorming exercises for parents & children where they list physical activities that they have found fun in the past, as well as some new activities they would like to try & skill training content to help with goal setting & tracking of physical activity.
2914858|NCT03145688|Experimental|Family Physical Activity Habit Formation|Behavioural: Family Physical Activity Habit formation. The Habit formation intervention condition will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. The material includes a brief discussion of what habits are with some very straightforward examples such as preparing for sleep routines or initiating to drive a car to work. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms.
2914859|NCT03145675|Experimental|Enoxaparin (Staged-dose PCI Group)|Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and additional enoxaparin 0.25 mg/kg at the beginning of PCI (i.e., insertion of guiding catheter).
2914860|NCT03145675|Active Comparator|Enoxaparin (Single-dose PCI Group)|Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and NO additional enoxaparin at the beginning of PCI (i.e., insertion of guiding catheter).
2914861|NCT03145675|Experimental|Enoxaparin (High-dose Group)|Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).
2914862|NCT03145675|Active Comparator|Enoxaparin (Standard-dose Group)|Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).
2914863|NCT03145662|Active Comparator|high pressure balloon|randomized to have dialysis fistula or AV graft treated with high pressure balloon
2914864|NCT03145662|Active Comparator|cutting balloon|randomized to have dialysis fistula or AV graft treated with cutting balloon
2914865|NCT03145649||Gestational diabetes mellitus|Women with gestational diabetes mellitus and their infants. The blood glucose of women with gestational diabetes mellitus was controlled by dietary therapy or insulin injection.
2914866|NCT03145649||Healthy|Healthy mother-infant dyads
2914867|NCT03145636|Other|Observational arm|Subjects will receive the device implant and use the vBloc Achieve Weight Management Program.
2914868|NCT03145636|Other|Randomized sub-study -Treatment|Subjects will be randomly assigned (1:1) either to treatment or control. Treatment arm will receive the device and use of vBloc Achieve Weight Management Program.
2914869|NCT03145636|Other|Randomized sub-study - Control|Subjects will be randomly assigned (1:1) either to treatment or control. Control will participate in a Control Weight Management (CWM) program for 6 months prior to receiving the device implant and using the vBloc Achieve program.
2914870|NCT03145610|Placebo Comparator|Placebo toothpaste|Fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.
2914871|NCT03145610|Experimental|triclosan/copolymer/fluoride toothpaste|triclosan/copolymer/fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.
2914872|NCT03145597|Experimental|Laminate veneer of composite|Laminate veneer of composite (Estenia, Kuraray Dental), composite laminate veneer, 2-4-6 veneers per patient will be made.
2914873|NCT03145597|Experimental|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
2914874|NCT03145584|Active Comparator|Continuous Adductor Canal Saphenous Catheter|Participants in this group were randomly allocated to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A PERINEURAL CATHETER WAS INSERTED IMMEDIATELY AFTER INJECTION OF THE INITIAL BOLUS OF LOCAL ANAESTHETIC. THE CATHETER WAS CONNECTED TO A PAJUNK FUSERPUMP CONTAINING 350 ML OF 0.15625% BUPIVACAINE AND INFUSED AT 8ML/HR.
2914875|NCT03145584|Sham Comparator|Single Shot Adductor Canal Saphenous Block|Participants in this group were randomly allocated NOT to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A SHAM CATHETER WAS PLACED ON THE SURFACE OF THE LEG AND COVERED BY AN OPAQUE DRESSING TO CONCEAL THE INSERTION SITE. ALL PATIENTS HAD THE PROXIMAL END OF THEIR CATHETER ATTACHED TO PORTABLE ELASTOMERIC PUMPS (PAJUNK FUSERPUMP 350 ML) CONCEALED IN OPAQUE BAGS TO PREVENT PATIENTS AND ASSESSORS FROM DETERMINING WHICH PUMPS WERE ACTUALLY FUNCTIONING. THESE PUMPS FUNCTION WITHOUT A MOTOR AND SO MAKE NO SOUND.
2914876|NCT03145571|Other|Continuity of midwifery care|Clinics where the continuity of midwifery care program was implemented during 2013
2914877|NCT03145571|No Intervention|Control|Clinics where no structured changes had been made to the ante- and post- natal care during the period 2013-2015
2914878|NCT03145558|Experimental|Trans-Arterial Tirapazamine Embolization (TATE)|Patients will receive a fixed dose of Tirapazamine combined with embolization using Lipiodol and Gelfoam.
2914879|NCT03145558|Active Comparator|Trans-Arterial ChemoEmbolization (TACE)|Patients will receive a mixture of doxorubicin and Lipiodol into the tumor feeding artery followed by injection of Gelfoam to induce embolization per standard procedure.
2914880|NCT03145532|Experimental|Real tDCS plus robotic training|Children will receive 20 min of real tDCS stimulation per session, followed by robotic training for 1 hr.
2914881|NCT03145532|Sham Comparator|Sham tDCS plus robotic training|Children will receive 20 min of sham tDCS stimulation per session, followed by robotic training for 1 hr.
2914882|NCT03145519|Experimental|OptiVein|Placement of IV-catheter and administration of treatment using OptiVein catheter.
2914883|NCT03145519|Active Comparator|Vasofix Certo|Placement of IV-catheter and administration of treatment using Vasofix Certo catheter.
2914884|NCT03145506||Mohs Surgery Patients|Adult patients undergoing Mohs surgery for treatment of BCC or SCC
2914885|NCT03145493|Experimental|Usage of suction drains|
2914886|NCT03145493|No Intervention|No usage of suction drains|
2914887|NCT03145480|Experimental|Fit arm|ibrutinib and obinutuzumab in combination with the CHOP regimen
2914891|NCT03145454|Experimental|Pain detection|Electroencephalographical responses will be collected during surgical gesture by different intervention: electroencephalography helmet, dermal electrode, blood pressure sensors, pupillometry glasses and Holter.
2914892|NCT03145441|Experimental|CytoSorb®|The CytoSorb® filter will be installed into the cardiopulmonary bypass circle during cardiac transplantation in this study group (30 patients)
2914893|NCT03145441|No Intervention|Control|No filter will be installed into the cardiopulmonary bypass circle in this group (30 patients).
2914894|NCT03145415|Experimental|Bilateral Pudendal block|0.25 cc per kg of 0.2% ropivacaine will be injected once for right pudendal N block and the same volume for the left pudendal N block before the start of the surgery
2914895|NCT03145415|Active Comparator|Caudal block|1 cc per kg of 0.2% ropivacaine in the caudal space given before the start of surgery
2914896|NCT03145402|Experimental|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells injection in patients with Heart Failure
2914897|NCT03145402|Placebo Comparator|Placebo|Placebo injection via coronary arteries in patients with Heart Failure
2914898|NCT03145389||With epidural catheter placement|In this group of patients, after explaining about the procedure an 18 Gauge epidural catheter was placed in thoracic 11-12 inter vertebral space under strict asepsis.
2914899|NCT03145389||Without epidural catheter placement|In this group of patients epidural catheter was not inserted and post operative pain was managed by using intravenous drugs.
2914900|NCT03145376||patients before and after TAVI/MitraClip|geriatric assessment of patients before and after TAVI/Mitraclip
2914901|NCT03145363|Experimental|Intervention|receive interactive text messages
2914902|NCT03145363|Active Comparator|Control|Receive informational text messages
2914903|NCT03145350|Active Comparator|High-fat, low-carbohydrate diet|Dietary intervention: Participants will consume a diet that is rich in saturated fat (20% total energy) and low in free sugars for 4 weeks. This diet will include commonly eaten foods such as butter, cheese, and fatty meat products. Total fat intake in this intervention will be 40-45% total energy.
2914904|NCT03145350|Active Comparator|Low-fat, high-carbohydrate diet|Dietary intervention: Participants will consume a diet that is low in saturated fat (~5% total energy) and rich in free sugars (20% total energy).The diet will include commonly eaten food and drink such as sugar sweetened beverages, confectionery (e.g. fruit gums) and table sugar.
2914905|NCT03145337|Active Comparator|Cohort A|FlexHD ADM
2914906|NCT03145337|Active Comparator|Cohort B|AlloDerm RTU ADM
2914907|NCT03145311|Active Comparator|Real rTMS|Each patient received real repititive transcranial magnetic stimulation (rTMS) 20 HZ at 100% RMT (a total of 2000 pulses to each hand area consisting of 10 trains of 200 pulses with intertrain interval 30 s), over the hand motor area area for 10 consecutive days
2914908|NCT03145311|Sham Comparator|Sham rTMS|Each patient received repetitive transcranial magnetic stimulation (rTMS) with the same pulse delivery as the 1st group but with the coil placed perpendicular to the scalp.
2914909|NCT03145298|Experimental|Biological: Allogeneic Human Cardiosphere-Derived Cells (CDCs)|The Phase 1a portion (N=6 subjects) consists of an open-label, single-arm, study design - dose escalation. The potentially conducted Phase 1b portion of the study (N=20 subjects) consists of a double-blind, randomized, placebo-controlled study design.
2914910|NCT03145298|Placebo Comparator|Placebo|The placebo study arm only applies to the Phase Ib portion of the study design. The Phase Ia portion (N=6 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=20 subjects) consists of a double-blind, randomized, placebo-controlled study design with a 1:1 ratio.
2914911|NCT03145285|Experimental|Cohort 1|"Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy.~Treatment with single agent Abiraterone Acetate (AA) until progression"
2914912|NCT03145285|Experimental|Cohort 2|"Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection.~Treatment with single agent Abiraterone Acetate (AA) for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month, then Mitotane +/- chemotherapy can be started upon the clinician's decision."
2914913|NCT03145272|Experimental|Age group|"An orogastric tube will be placed in the stomach (placement verified by routine accepted clinical guidelines) under anesthesia as is part of standard routine clinical care to remove gastric contents. The same orogastric tube will be used for intragastric liquid oxycodone administration in a dose of 0.1 mg/kg before the surgical incision. This weight-adjusted dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines.~This arm can be divided into 2 subgroups; (1)12 months - 1.9 years age group. (2) 2 - 5.9 years age group."
2914914|NCT03145259|Other|diclofenac epolamine patches|diclofenac epolamine patches
2914915|NCT03145259|Other|diclofenac sodium solution|diclofenac sodium solution
2914916|NCT03145259|Other|diclofenac epolamine patches and diclofenac sodium solution|patch pieces and solution
2914917|NCT03145246||tooth loss|regeneration treated teeth loss
2914918|NCT03145246||clinical attachment loss ≥ 2 mm|regenerated treated teeth with clinical attachment loss ≥ 2 mm
2914919|NCT03145246||clinical attachment loss loss < 2 mm|regenerated treated teeth with clinical attachment loss < 2 mm
2914920|NCT03145233|Experimental|Isometric exercise|12 week Isometric exercise programme - two exercises (one side-lying and the other standing); six repetitions of each with muscle contraction sustained for 30 seconds. Exercises performed once daily with each session lasting no longer than 10 minutes.
2914921|NCT03145233|Experimental|Isotonic exercise|12 week Isotonic exercise programme - two exercises (one side-lying and the other standing); each exercise - 3 sets of 10 repetitions, each repetition 6 seconds duration. Exercises performed once daily with each session lasting no longer than 10 minutes.
2914922|NCT03145220|Active Comparator|EA-230|Intravenous infusion of EA-230, 90 mg/kg/hour. Administered from start of surgical incision until stoppage of the cardio-pulmonary bypass pump, for a maximum of 4 hours.
2914923|NCT03145220|Placebo Comparator|Placebo|Intravenous infusion of NaCl (equivalent osmolarity with active intervention EA-230). Administered from start of surgical incision until stoppage of the cardio-pulmonary bypass pump, for a maximum of 4 hours.
2914924|NCT03145207|Other|name brand patch|name brand lidocaine patch
2914933|NCT03145181|Experimental|Part 1: Dose Escalation|Participants will receive intravenous infusion of JNJ-64007957 until the completion of the End of Treatment Visit.
2914934|NCT03145181|Experimental|Part 2: Dose Expansion|Participants will receive intravenous (IV) infusion of JNJ-64007957 at each RP2D(s).
2914935|NCT03145168|Experimental|High Target Mean Arterial Pressure|
2914936|NCT03145168|Active Comparator|Low target Mean Arterial Pressure|
2914937|NCT03145155|Experimental|Intervention|Pregnant women in intervention arm will receive CoC card and health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will include CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given three times during pregnancy and one time during postpartum period.
2914938|NCT03145155|Placebo Comparator|Control|Pregnant women in control arm will receive ordinary health education on pregnancy care
2914939|NCT03145142|Active Comparator|Umbilical Cord Milking|Milking the umbilical cord 4 times towards the infant at a speed of 20cm over 2 seconds.
2914940|NCT03145142|Active Comparator|Delayed Cord Clamping|Delayed clamping of the umbilical cord for at least 60 seconds.
2914941|NCT03145129||POAG group|Patients diagnosed with POAG and OSA who require treatment with CPAP
2914942|NCT03145129||Control group|Patients with OSA and without POAG who require treatment with CPAP
2914943|NCT03145116|Experimental|509|
2914944|NCT03145103|Experimental|409M|CT ASPHINA 409M IOL
2914945|NCT03145077|Experimental|Cohort 1 - Group 1|"Participants with newly diagnosed head and neck cancer (HNC) who will be treated with radiotherapy.~MRI performed at Baseline and at each study visit.~Patient-related outcomes (PROs) questionnaires completed at Baseline, and at each study visit. These will also include questionnaires regarding daily life, diet, and ability to swallow and speak."
2914946|NCT03145077|Experimental|Cohort 1 - Group 2|"Participants with HNC who were treated with radiotherapy and are under surveillance.~MRI performed at Baseline and at each study visit.~Patient-related outcomes (PROs) questionnaires completed at Baseline, and at each study visit. These will also include questionnaires regarding daily life, diet, and ability to swallow and speak."
2914947|NCT03145077|Experimental|Cohort 2|"Participants with recurrent head and neck cancers who will be re-treated with radiotherapy.~MRI performed at Baseline and at each study visit.~Patient-related outcomes (PROs) questionnaires completed at Baseline, and at each study visit. These will also include questionnaires regarding daily life, diet, and ability to swallow and speak."
2914948|NCT03145077|Experimental|Cohort 3|"Participants who have already been treated with radiotherapy for HNC and have developed early-stage ORN.~MRI performed at Baseline and at each study visit.~Patient-related outcomes (PROs) questionnaires completed at Baseline, and at each study visit. These will also include questionnaires regarding daily life, diet, and ability to swallow and speak.."
2914949|NCT03145077|Experimental|Cohort 4|"Participant who were treated with radiotherapy for HNC and have developed late-stage ORN .~MRI performed at Baseline and at each study visit.~Patient-related outcomes (PROs) questionnaires completed at Baseline, and at each study visit. These will also include questionnaires regarding daily life, diet, and ability to swallow and speak."
2914950|NCT03145064|Experimental|Cohort1,Cohort2|
2914951|NCT03145051|Experimental|Respimer Netiflow mineral salts solution|Nasal irrigation with Respimer Netiflow mineral salts solution, 4 times/day during 8 weeks using Respimer Netiflow class I medical device
2914952|NCT03145051|Active Comparator|Saline solution|Nasal irrigation with saline solution , 4 times/day during 8 weeks using Respimer Netiflow class I medical device
2914953|NCT03145038|Experimental|Treatment A|Single oral dose of 20 x 0.5 mg vericiguat high-dose pediatric formulation, fed, American breakfast
2914954|NCT03145038|Experimental|Treatment B|Single oral dose of 20 x 0.5 mg vericiguat high-dose pediatric formulation, fasted
2914955|NCT03145038|Experimental|Treatment C|Single oral dose of 25 x 0.1 mg vericiguat high-dose pediatric formulation, fed, American breakfast
2914956|NCT03145038|Active Comparator|Treatment D|Single oral dose of 10 mg vericiguat intact IR tablet, adult formulation, fed, American breakfast
2914957|NCT03145038|Experimental|Treatment E|Single oral dose of 10 mg vericiguat crushed IR tablet, adult formulation, fed, American breakfast
2914958|NCT03145038|Experimental|Treatment F|Single oral dose of 10 mg vericiguat intact IR tablet, adult formulation, fed, continental breakfast
2914959|NCT03145012|Experimental|Treatment Group|"This is a one arm study in which all individuals receive the treatment; therefore there is no allocation or randomization.~Thirty subjects will receive ranitidine to a maximum of 900 mg/day in 2 daily doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets. The ranitidine will be taken orally."
2914960|NCT03144999|Experimental|Low Dose|AAVCAGsCD59
2914961|NCT03144999|Experimental|Mid Dose|AAVCAGsCD59
2914962|NCT03144999|Experimental|High Dose|AAVCAGsCD59
2914963|NCT03144986|Experimental|Deep insula-coil rTMS|"Active treatment phase consists of deep rTMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase.~Maintaince treatment phase includes two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks."
2914964|NCT03144960|Other|mechanical thrombectomy|The study will be performed involving ischemic stroke patients with proximal occlusion within 4.5 hours from stroke onset, mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption.
2914965|NCT03144947|Experimental|Group A|"Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.~After surgery, study patients will receive trastuzumab IV x 14 cycles"
2914966|NCT03144947|Experimental|Group B|Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles. After surgery, study patients will receive trastuzumab SC x 14 cycles
2914967|NCT03144934|Experimental|Administraion of investigational product|"0.25mg, 1mg, 3mg, 6mg, or 9mg (optional) of GX-I7~6 subjects per each cohort~twice administration with 4-week intervals"
2915059|NCT03144180|Active Comparator|Study Group|The Q-cup will be used to collect umbilical cord blood.
2914968|NCT03144934|Placebo Comparator|Administraion of placebo|"GX-I7 vehicle (formulation buffer)~2 subjects per each cohort~twice administration with 4-week intervals"
2914969|NCT03144921|Experimental|EPIC A|Group A will start the EPIC intervention immediately after assessment 1. The EPIC program consists of a 7-session, psychoeducational skills training intervention designed to provide education and skills on how to prepare for the future and reduce stress regarding memory changes and loss for both the person with early-stage dementia and their care partner. Following the 7 EPIC sessions, participants will attend 4 booster sessions over 5 months to reinforce the skills/lessons.
2914970|NCT03144921|Active Comparator|EPIC B (WLC)|Group B - the wait list comparison (WLC) group - will have a 75-minute group education session (comparator intervention) about 3 weeks after baseline assessment. The WLC session is an overview of memory loss/dementia and its related impact for EPs and CPs and an overview of aging network services in the community. They will receive a brief telephone check-in call approximately 3 weeks before the T2 assessment. The WLC group will start the complete EPIC psychoeducational skills training intervention immediately after Assessment 2. Following completion of the 7 EPIC sessions, participants will attend 4 booster sessions to reinforce the skills/lessons.
2914971|NCT03144895|Other|Arterial catheter|by anatomical placement alone
2914972|NCT03144895|Other|Placement|of an arterial catheter by ultrasound tracking
2914973|NCT03144882|Active Comparator|intervention|the trial group (n =35 )
2914974|NCT03144882|Placebo Comparator|placebo|control group
2914975|NCT03144869|Experimental|physical activity monitor only|"Children will wear a Runscribe accelerometer for two weeks. Runscribe is a small inertial sensor (weight 15g, size 35x25x7.5 mm). It can be attached to the body in several positions (wrist, waist, sacrum, chest, thigh, foot) and is used for monitoring movement. Runscribe does not beep, flash or have a visual display. It will not provide PA feedback to the individuals in real-time, only via a researcher after the data has been downloaded. In this study, we are not wishing to influence children's behaviour by providing PA feedback in real-time. We are trying to establish whether PA monitoring is feasible and acceptable - and further research could go on to explore the use of real-time PA feedback as an educational technique.~Phase 1 findings will help to determine: i) method of monitor distribution to participants (post, clinic or in-person), ii) preferred wear position."
2914976|NCT03144869|Experimental|physical activity monitor plus constant glucose monitor|Children using a personal constant glucose monitor (CGM) or CGM on loan from clinic as part of clinical care will be approached for Arm 2. These children will wear Runscribe at the same time as a CGM. Runscribe and CGM worn over the same 2 week period.
2914977|NCT03144856|Experimental|Apatinib group|Apatinib 500mg, po, QD, every 4 weeks.
2914978|NCT03144843|Experimental|Experimental group|Apatinib: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
2914979|NCT03144843|Placebo Comparator|Placebo group|Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
2914980|NCT03144830|Experimental|Overground walking program|Study participant will be involved in an indoor, overground walking program using an exoskeleton wearable walking device under the supervision of a physiotherapist.
2914981|NCT03144817|No Intervention|Control Group|
2914982|NCT03144817|Experimental|Intervention Group|Intervention group will dialyze with dialysate Na 135 mEq/L.
2914983|NCT03144804|Experimental|Lamivudine|"Lamivudine administered orally every 4 weeks~Treatment cycles will last 28 consecutive days~The dosage will be determine by the PI"
2914984|NCT03144791||elderly , young adults|Participants are in 9 light conditions, 5 minute for each condition.
2914985|NCT03144778|Experimental|Cohort 1 - Durvalumab|"Participants receive Durvalumab every 28 days for a total of 2 doses.~Symptom questionnaire completed on Day 1, Day 29, Day 5, 42 days after surgery or, if receiving standard-of-care chemotherapy/radiation therapy, within 7 days before starting the regimen, 6 months after surgery, 24 months, and 5 years after surgery.~Surgery performed as part of standard of care between Days 57 and 71.~After surgery, upon decision of physician, additional standard of care chemotherapy and/or radiation may be given."
2914986|NCT03144778|Experimental|Cohort 2 - Durvalumab + Tremelimumab|"Participants receive Durvalumab plus Tremelimumab every 28 days for a total of 2 doses.~Symptom questionnaire completed on Day 1, Day 29, Day 5, 42 days after surgery or, if receiving standard-of-care chemotherapy/radiation therapy, within 7 days before starting the regimen, 6 months after surgery, 24 months, and 5 years after surgery.~Surgery performed as part of standard of care between Days 57 and 71.~After surgery, upon decision of physician, additional standard of care chemotherapy and/or radiation may be given."
2914987|NCT03144765|Experimental|taTME|Enrolled subjects will undergo the study procedure, laparoscopically-assisted Transanal Total Mesorectal Excision (taTME).
2914988|NCT03144752||Cohort 1: Participants between 8 to 14 weeks gestation|Cohort 1 will include female participants who present for the first prenatal visit which takes place between Weeks 8 and 14 at maternity practices associated with University of North Carolina (UNC) Women's Care. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.
2914989|NCT03144752||Cohort 2: Participants between 15 to 36 weeks gestation|Cohort 2 will include female participants enrolled at various points in their pregnancy from Week 15 up through 36 weeks gestation. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.
2914990|NCT03144739|Active Comparator|Control|Children enrolled during the control phase will receive care under the Current collaborative care protocol. Participating general practitioners are currently trained to recognize child mental health problems and refer them to partner community mental health centers for treatment.
2914991|NCT03144739|Experimental|Intervention|Children enrolled during the intervention phase will receive Training in management of children's mental health problems. This will involve treatment by their general practitioner in collaboration with a partner community mental health center; children meeting certain criteria for severity, or whose parents prefer center treatment, will be immediately referred.
2914992|NCT03144726|Experimental|Negative pressure wound therapy|A vacuum assisted closure device will be applied in this arm
2914993|NCT03144726|Other|Standard dressing|Standard dressing will be applied to this arm
2914994|NCT03144713|Experimental|Terlipressin|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
2914996|NCT03144713|Active Comparator|Standard Medical Therapy|Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
2914997|NCT03144700||Compensated Cirrhosis|
2914998|NCT03144687|Experimental|Cohort A|Itacitinib plus ruxolitinib
2914999|NCT03144687|Experimental|Cohort B|Itacitinib alone
2915000|NCT03144674|Experimental|Cohort 1|Participants who have received prior ibrutinib.
2915001|NCT03144674|Experimental|Cohort 2|Participants who have not received a prior BTK inhibitor.
2915002|NCT03144661|Experimental|Part 1|Subjects with HCC, cholangiocarcinoma, or esophageal, nasopharyngeal, or serous ovarian cancers, regardless of FGF/FGFR alteration status.
2915003|NCT03144661|Experimental|Part 2 Cohort A|Subjects with HCC with FGF19 amplification.
2915004|NCT03144661|Experimental|Part 2 Cohort B|Subjects with HCC without FGF19 amplification.
2915005|NCT03144661|Experimental|Part 2 Cohort C|Subjects with cholangiocarcinoma or esophageal, nasopharyngeal, or serous ovarian cancers (regardless of FGF/FGFR status), or other solid tumor malignancies with documented FGF19/FGFR4 alteration.
2915006|NCT03144648||Cases|Incident primary invasive breast cancer cases aged 20-45 years are recruited from major cancer hospitals in four large Latin American cities (Mexico City, San Jose, Medellin, and Santiago) prior to any treatments. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses. Highly standardized immunohistochemical and molecular analyses are performed to identify cancer subtypes
2915007|NCT03144648||Controls|Women with no cancer recruited from the population residing in the same cities for at least 3 years and matched to cases on age (+/- 5 years) and health care institution. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, occupation, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses.
2915008|NCT03144635|Experimental|Grazoprevir plus Elbasvir|Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
2915009|NCT03144609|Active Comparator|PEEP 4|Active Comparator low PEEP: obese patient during oral-surgical procedures under general anesthesia ventilated with Positive endexpiratory pressure (PEEP) 4 cm H2O(water)
2915010|NCT03144609|Experimental|PEEP 7 & ARM|Experimental ARM & Experimental high PEEP: obese patient during oral-surgical procedures under general anesthesia ventilated with PEEP( positive endexpiratory pressure) 7 cm H2O with ARM(alveolar recruitment maneuver) provided every 30 min
2915011|NCT03144609|Experimental|PEEP 10 & ARM|Experimental ARM & Experimental high PEEP:obese patient during oral-surgical procedures under general anesthesia ventilated with PEEP( positive endexpiratory pressure) 10 cm H2O with ARM(alveolar recruitment maneuver) provided every 30 min
2915012|NCT03144596|Experimental|Alfuzosin Hydrochloride|Alfuzosin hydrochloride 10 mg tablet by mouth, every 24 hours for 3 months
2915013|NCT03144596|Active Comparator|Tamsulosin Hydrochloride|Tamsulosin hydrochloride 0.4 mg tablet by mouth, every 24 hours for 3 months
2915014|NCT03144583|Experimental|Adult differentiated autologous T-cells|Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z. Such cells will be administered in a single infusion intravenously at a total ARI-001 cell dose of 0.5-10 x 106 / kg body weight.
2915015|NCT03144557|Experimental|Intervention|Education protocol to correct inhalation technique
2915016|NCT03144544||Pediatric specialist hospitals|Free-standing hospitals providing tertiary pediatric referral services and performing pediatric surgical procedures
2915017|NCT03144544||Non-pediatric specialist hospitals|Other hospitals performing pediatric surgical procedures
2915018|NCT03144531|Experimental|SKIP Intervention|
2915019|NCT03144518|Experimental|Experimental|Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
2915020|NCT03144518|Active Comparator|Active Control|Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.
2915021|NCT03144505|No Intervention|Control|The control group will be invited to an orientation session, where it will be provided detailed information concerning their home base exercise program. Additionally, once in every 4 weeks, the control group will meet for thematic sessions regarding diabetes topics, such as, nutrition, physical activity, and clinical complications. Due to ethical reasons, the control group needs to be provided with a standard counseling approach, as suggested in this research project.
2915022|NCT03144505|Experimental|MCT combined with RT Group|"MCT Group is designed to have equal energy expenditure when compared with HIIT Group. We standardized the exercise prescription according to body weight (kg), predicting that physical activity guidelines of 150 min peer week moderate intensity is equivalent to 10 kcal/kg of a combined session of RT and MCT. The MCT group will perform continuous cycling 3 days per week, with an exercise intensity of 40 to 59% of the heart rate reserve (HRR).~Participants will also perform an RT circuit: 1 set of two pull upper body exercises (seated row and lat pulldown); 1 set of two push upper body exercises (chest press and shoulder press); 1 set of two leg exercises (leg press and one leg lunge); and 1 set of two core exercises (dead bug and regular plank). Each set consisting in 10 to 12 repetitions."
2915060|NCT03144167|Other|Patients, aged 18-88, with glioblastoma|
2915061|NCT03144154|Experimental|Experimental group : Hypnosis-based intervention|Groupal intervention combining self-care techniques and self-hypnosis exercises
2915062|NCT03144154|No Intervention|Control group : Usual care|Control group receiving usual care but not the intervention
2915023|NCT03144505|Experimental|HIIT combined with RT Group|"The HIIT program will perform cycle ergometer 3 days a week, and it will be divided into three phases: preparation phase (weeks 1-4), where the participants perform MCT (40-59% of the HRR); transition phase (weeks 5-8), in which the HIIT program is introduced progressively, starting with bouts of 2 minutes at 70% of the HRR, followed by 1 minute at 40-59% of the HRR (weeks 5-6), and finishing with bouts of 80% of the HRR, followed by 1 minute at 40-59% of the HRR (weeks 7-8); training phase (weeks 9-42), where the participants perform 1 minute of exercise at 90% of the HRR, followed by 1 minute resting at 40-59% of the HRR.~The HIIT session will have the same energy expenditure as the MCT group, using the 10kcal/kg week target. Participants will also fulfill the same RT as the MCT group."
2915024|NCT03144492||self-reported healthy individuals|"Self-reported healthy individuals avoiding blood draw on the days participants are feeling under the weatheror sick. In that case, study team can delay the blood draw until the subject feels better, but this would not preclude anyone from participating."
2915025|NCT03144479|Experimental|Positioning of right-sided double lumen tube with fluoroscopy|positioning of the right-sided double lumen tube with a wire guide and fluoroscopy
2915026|NCT03144479|Experimental|Positioning of right-sided double lumen tube with fibroscope|positioning of the right sided double lumen tube in the same patient but with a fibroscope
2915027|NCT03144466|Experimental|Part A - Starting dose|100mg of pembrolizumab in n=3 patients, administered in 8 cycles every 3 weeks for a total of 18 weeks commencing two weeks prior to first fraction of radiotherapy and given in combination with Radical Radiotherapy, Brachytherapy and Cisplatin Chemotherapy. Increase in cohort by three patients to n=6 patients provided no more than 1/3 patients experience a Dose Limiting Toxicity (DLT).
2915028|NCT03144466|Experimental|Part A - Escalation dose|Escalation of dose to 200mg of pembrolizumab in a further n=3 patients provided no more than 1/6 patients at starting dose experience a DLT. Increase in cohort by three patients to n=6 patients provided no more than 1/3 patients experience a Dose Limiting Toxicity (DLT).
2915029|NCT03144466|Experimental|Part B - Expansion phase|Recruitment of expansion cohort of n=14 patients using Maximum Tolerated Dose (MTD) of Pembrolizumab as determined in the dose escalation phase. MTD to be administered in 8 cycles every 3 weeks for a total of 18 weeks commencing two weeks prior to first fraction of radiotherapy and given in combination with Radical Radiotherapy, Brachytherapy and Cisplatin Chemotherapy.
2915030|NCT03144453|Experimental|Sugammadex|The patients received sugammadex as neuromuscular blockade reversal
2915031|NCT03144453|Active Comparator|Standard|The patients received neostigmine + atropine as neuromuscular blockade reversal
2915032|NCT03144427||Burns|Patients with burns to 20% or more of their BSA (body surface area) require resuscitation with intravenous crystalloid fluids in order to avoid organ failure and death
2915033|NCT03144414|Active Comparator|LAVH|Laparoscopic Assisted Vaginal Hysterectomy
2915034|NCT03144414|Active Comparator|LADH|Laparoscopic Assisted Doderlin Vaginal Hysterectomy
2915035|NCT03144401|Active Comparator|Preoperative|"• Group no.1 will receive preoperative sublingual 400 microgram of misoprostol (Sigma) 2 tablets and postoperative sublingual placebo2 tablets."
2915036|NCT03144401|Active Comparator|Postoperative|"• Group no.2 will receive preoperative sublingual placebo 2 tablets and postoperative sublingual 400 microgram of misoprostol (Sigma)  2 tablets ."
2915037|NCT03144388|Experimental|Variable Stepping Training|High intensity stepping training in multiple environments, including overground, on a treadmill and on stairs.
2915038|NCT03144388|Active Comparator|Variable Non-specific Training|High intensity non-stepping training, including balance, strength, and cycling tasks
2915039|NCT03144375|Active Comparator|Medical Optimization|Medical treatment and education x 4 months, re- eval at 4 months and possible cross-over to surgery
2915040|NCT03144375|Active Comparator|Surgical treatment|Surgical treatment up front
2915041|NCT03144362|Active Comparator|Bilateral Sliding Technique|
2915042|NCT03144362|Active Comparator|Unilateral Sliding Techniques|
2915043|NCT03144362|No Intervention|Standard care|
2915044|NCT03144336|Experimental|Intervention group|"Participants in the intervention group will be able to accumulate rewards points for correctly answering weekly quizzes regarding the HIV prevention information; these reward incentives aim to encourage retention in the study and improve HIV prevention knowledge engagement and recollection.~Intervention 'Rewards for testing HIV-negative' Every three months those in the intervention group can win a prize based on testing HIV-negative at least once during that time period. The chance of winning will increase based on the number of reward points a participant accumulates by correctly answering questions on the weekly quizzes."
2915045|NCT03144336|Active Comparator|Control group|Intervention: Information provision: Participants in the control group will receive weekly information by SMS to encourage retention in the study and improve HIV prevention knowledge engagement and recollection. They are encouraged to come to the clinic every three months to test for HIV but do not receive any incentives for answering messages or for the HIV tests.
2915046|NCT03144323|Experimental|Study group|This group will receive 4 daily electronic reminders via the Calendar app on their mobile phones, reminding them to wear their elastics.
2915047|NCT03144323|No Intervention|Control group|This group will receive their orthodontic treatment and elastics instructions as normal, without reminders.
2915048|NCT03144284||dental interns|dental interns in pediatric dentistry department, faculty of dentistry, Cairo University.
2915049|NCT03144271|Experimental|NNC 0113-0217|Dose-escalation trial
2915050|NCT03144271|Placebo Comparator|Placebo|Dose-escalation trial
2915051|NCT03144245|Experimental|AMV564|Continuous infusion of AMV564 at increasing dose levels
2915052|NCT03144232|Experimental|Active rTMS|10 Hz rTMS applied to the left DLPFC
2915053|NCT03144232|Sham Comparator|Sham rTMS|Sham rTMS applied to the left DLPFC
2915054|NCT03144206|Experimental|Hyperbaric Oxygen Group|Patients will receive Hyperbaric Oxygen treatments in the immediate postoperative period
2915055|NCT03144206|No Intervention|Standard of Care Group|Patients will not receive Hyperbaric Oxygen treatments in the immediate postoperative period
2915056|NCT03144193|Experimental|Experimental|Topical anti-aging cosmetic cream (active)
2915057|NCT03144193|Placebo Comparator|Placebo|Basic formulation without active ingredients (vehicle)
2915058|NCT03144180|No Intervention|Control|The Q-cup will not be used to collect umbilical cord blood.
2915063|NCT03144141|Other|Patients with the diagnosis of threat of uterine delivery|
2915064|NCT03144128|Placebo Comparator|Control (Ctl)|Standard of Care resistance exercise and timed protein supplementation with placebo capsule daily for 12 weeks
2915065|NCT03144128|Experimental|Vitamin D|Standard of Care resistance exercise and timed protein supplementation with 5,000IU vitamin D supplementation daily for 12 weeks
2915066|NCT03144115|Experimental|oxytocin fertility|intranasal oxytocin administration (24IU) in women's fertility phase (LH>40 mIU/ml)
2915067|NCT03144115|Placebo Comparator|placebos fertility|intranasal placebo administration (24IU) in women's fertility phase (LH>40 mIU/ml)
2915068|NCT03144115|Experimental|oxytocin luteal|intranasal oxytocin administration (24IU) in women's luteal phase (LH<30 mIU/ml)
2915069|NCT03144115|Placebo Comparator|placebos luteal|intranasal placebos administration (24IU) in women's luteal phase (LH<30 mIU/ml)
2915070|NCT03144102|Experimental|VR-based motor rehabilitation with tDCS|
2915071|NCT03144102|Active Comparator|Occupational Therapy with tDCS|
2915072|NCT03144102|Sham Comparator|VR-based motor rehabilitation with sham tDCS|
2915073|NCT03144102|Sham Comparator|Occupational Therapy with sham tDCS|
2915074|NCT03144089|Active Comparator|Guedel oral airway placed first|This group is randomized to receive the Guedel oral airway first and the Articulated Oral Airway second
2915075|NCT03144089|Experimental|Articulated Oral Airway placed first|This group is randomized to receive the Articulated Oral Airway first and the Guedel oral airway second
2915076|NCT03144076|Experimental|Group A|[Other: RSBY Health Insurance] The households in this group were offered RSBY for free. They did not have to pay the fee amount or premium amount and simply had to present their chit at the enrollment station and were enrolled. The entire premium amount including fee (Rs. 173 in Mysore, Rs. 163 in Gulbarga) has to be borne by the study. These households were automatically re-enrolled in RSBY for free for the second year of the study.
2915077|NCT03144076|Experimental|Group B|[Other: RSBY Health Insurance] The households in this treatment group were first given a cash transfer equivalent to the fee and premium for RSBY during the first visit to their household. In addition, they were offered the opportunity to purchase RSBY during a second visit to their household and get their household enrolled during that time. At that time, payment would be collected from the respondents who wanted to get enrolled and then these respondents would be taken to the enrollment stations to get them enrolled. For those households that chose to purchase RSBY for the first year of the study, their coverage was automatically extended to the second year of the study at no additional cost to them.
2915078|NCT03144076|Experimental|Group C|[Other: RSBY Health Insurance] The households in this group were simply offered an opportunity to purchase RSBY if they wished to. They were informed about this during the first visit to their household and for the households who wanted to get enrolled, the fee and premuim amount was collected and enrolment was done during the second visit to their household.
2915079|NCT03144076|No Intervention|Group D|[No intervention] The households in this group were not offered anything and were informed that they had been randomly selected to not receive anything beyond the participation incentive that all survey participants received. In addition, a short survey was administered to them at this time.
2915080|NCT03144063||Toronto Lupus Cohort|"Objective 1 and 3 Cohort:~≥4 American College of Rheumatology (ACR) criteria or 3 ACR criteria plus a typical histological lesion of SLE on renal or skin biopsy~Clinician's diagnosis based on his/her assessment~Patients from the Toronto Lupus Clinic with regular follow-up, defined as having follow up visits at 3 and 6 months from the baseline visit (1st study visit)."
2915081|NCT03144063||BLISS-52 Cohort|"Objective 2 Cohort:~Validation of the SLEDAI-2KG will be completed on BLISS-52 trial data. The extracted trial data consists of data on all patients that participated in the trial."
2915082|NCT03144063||BLISS-76 Cohort|"Objective 2 Cohort:~Validation of the SLEDAI-2KG will be completed on BLISS-76 trial data. The extracted trial data consists of data on all patients that participated in the trial."
2915083|NCT03144050||0|Control - no diabetes
2915084|NCT03144050||1|Diabetes
2915085|NCT03144050||2|Diabetes w/neuropathy
2915086|NCT03144050||3|Diabetes with vascular disease
2915087|NCT03144050||4|Diabetes w/healed ulcer
2915088|NCT03144050||5|Diabetes with current ulcer
2915089|NCT03144024|Experimental|band|
2915090|NCT03144024|Active Comparator|Rigid ring|
2915091|NCT03143998|Experimental|HCV GT1a TN|Participants with HCV GT1a infection who are TN will take MK-5172A for 12 weeks.
2915092|NCT03143998|Experimental|HCV GT1a TE|Participants with HCV GT1a infection who are TE will take MK-5172A for 12 weeks.
2915093|NCT03143998|Experimental|HCV GT1b TN|Participants with HCV GT1b infection who are TN will take MK-5172A for 12 weeks.
2915094|NCT03143998|Experimental|HCV GT1b TE|Participants with HCV GT1b infection who are TE will take MK-5172A for 12 weeks.
2915095|NCT03143985|Experimental|TEW-7197 + Pomalidomide|"TEW-7197 tablets, taken once daily for 5 days followed by 2 days without treatment, repeated for 28-day cycles until appearing evidence of progressive disease or intolerable toxicity, or subject discontinuing the study for other reasons. For dose escalation during this study, dosing will be initiated at 60 mg once daily by oral administration and will be increased to determine the MTD. Provisional subsequent doses are 60, 120, 240 mg once daily on days 1-5, 8-12, 15-19 and 22-26.~POM is administered orally (4 mg/day daily on Days 1 - 21 days). Treatment will occur in a suitable outpatient ambulatory care setting that is equipped for monitoring of patients with hematopoietic malignancies undergoing early clinical trial research."
2915096|NCT03143972|Experimental|Dexmedetomidine only|"Dexmedetomidine will be administered by effect-site TCI according to the Hannivoort model extended with an effect-site rate constant of 0.0428min-1.~A stepwise increasing dosing regimen will be given, with concentrations targeting an effect site concentration of 1 ng/ml (40 min), 3 ng/ml (50 min), 4 ng/ml (40 min), 5 ng/ml (40 min) and 8 ng/ml (70 min)."
2915097|NCT03143972|Experimental|Remifentanil only|Remifentanil will be administered by effect-site TCI according to the Eleveld model. A stepwise increasing dosing regimen will be given, with concentrations targeting an effect site concentration of 1 ng/ml (12 min), 2 ng/ml (12 min), 3 ng/ml (12 min), 5 ng/ml (12 min) and 7 ng/ml (12 min).
2915183|NCT03143400|Active Comparator|Healthy volunteers|Healthy volunteers will test each of the 3 galenic forms of Lactobacillus salivarius on 3 periods of 7 days. Each period will be separated from another with a 14-day wash-out period at least.
2915098|NCT03143972|Experimental|Dexmedetomidine-Remifentanil interaction|"A fixed background dose of dexmedetomidine will be given, this will be calculated after the first 5 subjects completed the dexmedetomidine only session. It will be set to 50% of the observed mean EC50TOL (Tolerance of Laryngoscopy).~Remifentanil infusion will be administered by effect site TCI with stepwise increasing targets of 0.5 - 1.0 - 1.5 - 2.0 - 2.5 - 3.0 - 4.0 ng/ml, each lasting for 15 minutes."
2915099|NCT03143946|Experimental|Vitamin supplement and diet advice|Single arm. Patient be prescribed vitamin supplement if vitamin deficiencies are diagnosed and will get diet advice
2915100|NCT03143933|Active Comparator|propofol|this arm will receive propofol in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins
2915101|NCT03143933|Active Comparator|propofol and fentanyl|this arm will receive propofol and fentanyl in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins
2915102|NCT03143920|Experimental|Hyperbaric Oxygen|Hyperbaric oxygen therapy-2.4 atmosphere absolute for 90 minutes with 2-five minute air breaks administered daily, 5 days per week for 8 weeks total treatment.
2915103|NCT03143907|Other|Group-A - Immediate Intervention|Immediate Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
2915104|NCT03143907|Other|Group-B - Delayed Intervention|6 month treatment as usual waitlist followed by Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
2915105|NCT03143894|Active Comparator|Active TDCS|2 mA of active tDCS applied over a 30-minute study session once per day for 5 consecutive days
2915106|NCT03143894|Sham Comparator|Sham TDCS|Stimulation mimicking the TDCS applied only briefly over a 30-minute study session once per day for 5 consecutive days
2915107|NCT03143881|Experimental|Intervention|Intervention patients will receive personalized education regarding their condition, pre- and post-testing of their HF knowledge base, and ED standard of care during the enrollment (index) visit. Patients will then be contacted via telephone 30 days post-index visit for re-testing and reinforcement of previously learned material.
2915108|NCT03143881|No Intervention|Control|Control patients will receive ED standard of care.
2915109|NCT03143868|Experimental|Aerobic Exercise|
2915110|NCT03143868|Experimental|Resistance Exercise|
2915111|NCT03143868|Placebo Comparator|No Exercise|
2915112|NCT03143855|Experimental|Lorcaserin|
2915113|NCT03143855|Placebo Comparator|Control Group|
2915114|NCT03143842|Other|Vagus Nerve Stimulation|VNS paired with word pairs, VNS unpaired with word pairs, no VNS
2915115|NCT03143829|Experimental|Intervention group|electronic Symptom Self-Management Training- CINV (eSSET-CINV) is an educational intervention administered once at the start of treatment
2915116|NCT03143829|Active Comparator|Wait Control group|The Wait control group receives the electronic Symptom Self-Management Training- CINV (eSSET-CINV) at the last study visit. Outcomes will be compared to the Intervention group at the end of the study.
2915117|NCT03143816|Active Comparator|Technosphere insulin (TI, Afrezza) -Treatment arm|
2915118|NCT03143816|No Intervention|Insulin Aspart ( Novolog) -Control arm|
2915119|NCT03143803|Active Comparator|Polyherbal|Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.
2915120|NCT03143803|Placebo Comparator|Placebo|Placebo will contain an inert substance
2915121|NCT03143790|Active Comparator|ESWT|500 shockwave 3 different points on penis bilateral
2915122|NCT03143790|Placebo Comparator|Placebo|500 shockwave 3 different points on penis bilateral
2915123|NCT03143777|No Intervention|Baseline|Standard physiotherapy and mobilisation
2915124|NCT03143777|Experimental|Sara Combilizer group|Ongoing care with the sara combilizer available for use
2915125|NCT03143751|Experimental|Continuous hyperosmolar therapy|Standard cares plus continuous hyperosmolar therapy (NaCl20%)
2915126|NCT03143751|No Intervention|Control|Standard cares alone.
2915127|NCT03143738|Experimental|continuous anesthesia of adductor canal|
2915128|NCT03143738|Experimental|continuous anesthesia of femoral nerve|
2915129|NCT03143725|Experimental|Treatment A|GLPG1972 oral solution after overnight fast
2915130|NCT03143725|Experimental|Treatment B|GLPG1972 oral DC tablet after breakfast
2915131|NCT03143725|Experimental|Treatment C|GLPG1972 oral WG tablet after overnight fast
2915132|NCT03143725|Experimental|Treatment D|GLPG1972 oral WG tablet after breakfast
2915133|NCT03143712|Experimental|Treatment A|GLPG1690 oral capsules after breakfast
2915134|NCT03143712|Experimental|Treatment B|GLPG1690 oral tablets after breakfast
2915135|NCT03143712|Experimental|Treatment C|GLPG1690 oral tablets after overnight fast
2915136|NCT03143699|Experimental|Immediate feedback|Submitted to a training on blood pressure measurement skills and an immediate feedback after their encounter with an standardized patient - SP
2915137|NCT03143699|No Intervention|Students with no immediate feedback|Submitted to a training on blood pressure measurement skills, but without an immediate feedback after their encounter with an standardized patient - SP
2915138|NCT03143686||ACURATE TA™ Transapical Aortic Bioprosthesis|The first two hundred and fifty (250) patients in whom the commercial, or CE Mark, ACURATE TATM Transapical Aortic Bioprosthesis is implanted.
2915139|NCT03143673|Experimental|ACURATE TA™|Patient implanted with ACURATE TA™ Bioprosthesis
2915140|NCT03143660|Active Comparator|Coaching|A parent support component consisting of eight weekly telephone counseling calls by centrally located nutritionists to provide parents coaching tailored to their family's unique needs to help them set goals and make targeted lifestyle changes recommended by the American Academy of Pediatrics (AAP) for Stage 1, Prevention Plus, accompanied by a parent booklet
2915141|NCT03143660|Active Comparator|Materials|Parents will receive the same educational materials provided in the Fitline family workbook mailed over 8 weeks to control for weekly contact and educational curriculum, but no Fitline counseling.
2915142|NCT03143647||Control|"Female~Over 18 years of age~American Society of Anesthesiologists physical fitness scale 1~Not pregnant"
2915143|NCT03143647||Case|"Female~Pregnant with possible pre-eclampsia~Over 18 years of age~American Society of Anesthesiologists physical fitness scale 1"
2915218|NCT03143153|Active Comparator|Cisplatin + Fluorouracil|
2961574|NCT02821624|Experimental|Cohort 12|G1T38 or placebo
2915144|NCT03143634|Experimental|The Modular Protocol for Mental Health|"The Modular Protocol for Mental Health (Psychological Therapy) will last up to 18 regular weekly face-to-face sessions. Treatment follows a standard structured treatment session as per Cognitive Behavioural Therapy. The MPMH Treatment Manual was written by clinical psychologists. The selection and ordering of the modules for treatment will be delivered and determined by the Trial Clinical Psychologist in collaboration with the service-user. The treatment modules include:~M1. Getting Acquainted M2. Understanding Emotions M3. Managing and Tolerating Emotions M4. Behavioural activation M5. Tackling Avoidance M6. Tackling Unhelpful Thoughts M7. Tackling Unhelpful Habits M8. Overcoming Repetitive Thinking M9. Managing Upsetting Memories and Images M10. Relapse Prevention and Future Orientation"
2915145|NCT03143634|Placebo Comparator|Treatment-as-usual|For Treatment-as-usual (Psychological Therapy), clinicians will be asked to provide whatever treatment they deem appropriate, including psychological services, medication and referral to other services. TAU will be delivered by high-intensity therapists or clinical psychologists.
2915146|NCT03143621|Experimental|Coffee|100 cc's of coffee administered three times per day until return to bowel function has been established.
2915147|NCT03143621|Placebo Comparator|Water|100 cc's of warm water administered three times per day until return to bowel function has been established.
2915148|NCT03143608||Indiana group|50 adult patients males and females with GERD and 2-5 cm hiatal hernias. Each had laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication
2915149|NCT03143608||Wisconsin group|49 adult patients males and females with GERD and 2-5 cm hiatal hernias. Each had laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication
2915150|NCT03143595||Control group|Patients in this group have normal cognition as assessed by the validated Mini-Cog test before the elective operation.
2915151|NCT03143595||Impaired group|Patients in this group have impaired cognition as assessed by the validated Mini-Cog test before the elective operation.
2915152|NCT03143582|Experimental|Running group|13 week, bi-weekly running group
2915153|NCT03143569|Active Comparator|aPTT nomogram|aPTT guided heparin management
2915154|NCT03143569|Experimental|Anti-factor Xa nomogram|Anti-factor Xa guided heparin management
2915155|NCT03143556|Experimental|Magnetic Stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure and randomized for magnetic stent group will receive magnetic stent and the removal of stent would be done by help of magnetic device.
2915156|NCT03143556|No Intervention|Routine stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure and randomized for routine stent would receive routine stent and the removal of stent would be done by cystoscopy
2915157|NCT03143543|Experimental|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
2915158|NCT03143543|Placebo Comparator|Group B Parallel Placebo|Placebo orally for 7 days vs Group A
2915159|NCT03143543|Experimental|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
2915160|NCT03143543|Placebo Comparator|Group B2Parallel Placebo|Placebo orally for 7 days vs Group A2
2915161|NCT03143530|Active Comparator|Pectoralis Block with Ropivacaine|General anesthesia + pectoralis block with ropivacaine injection 30ml of 0.25% (75mg)
2915162|NCT03143530|Placebo Comparator|Pectoralis Block with normal saline|General anesthesia + Pectoralis block with 30ml of normal saline injection
2915163|NCT03143517||Inflammatory Bowel Disease (IBD)|A stool sample will be collected from adult subjects with Inflammatory Bowel Disease (IBD), confirmed by endoscopy and histologic examination.
2915164|NCT03143517||Irritable Bowel Syndrome (IBS)|A stool sample will be collected from adult subjects with adult subjects with Irritable Bowel Syndrome meeting the Rome III criteria.
2915165|NCT03143517||Other GastroIntestinal (GI) Disorders|A stool sample will be collected from adult subjects with adult subjects with gastrointestinal disorders other than IBD or IBS.
2915166|NCT03143504|Other|Single arm.|All participants in the same arm.
2915167|NCT03143491|Experimental|SOR007 0.15%|1 mL of 0.15% SOR007 Ointment
2915168|NCT03143491|Experimental|SOR007 1.0%|1 mL of 1.0% SOR007 Ointment
2915169|NCT03143491|Experimental|SOR007 2.0%|1 mL of 2.0% SOR007 Ointment
2915170|NCT03143478|Experimental|M-MARK|Participants self administer rehabilitation exercises using the M-MARK device for 20 days.
2915171|NCT03143465|Experimental|CGRP|
2915172|NCT03143465|Experimental|Sildenafil|
2915173|NCT03143465|Placebo Comparator|Placebo|
2915174|NCT03143452|Active Comparator|lidocaine gel|Lidocaine gel group: received 2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
2915175|NCT03143452|Active Comparator|tetracaine eye drop|Tetracaine eye drop group: received 0.5% tetracaine eye drop 5 minutes before phacoemulsification
2915176|NCT03143439||Program group|The program group will be comprised of all individuals who enrolled in the FACT program from July 2016 through September 2019 and have active child support cases with the Contra Costa County Department of Child Support Services.
2915177|NCT03143439||Comparison group|The comparison group will be comprised of individuals with active child support cases with the Contra Costa County Department of Child Support Services who are demographically comparable to the treatment group (i.e., FACT fathers with active child support cases), yet did not participate in or receive FACT services.
2915178|NCT03143426|Experimental|3D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 3D visualisation.
2915179|NCT03143426|No Intervention|2D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 2D visualisation, the standard viewing method used during all laparoscopic surgeries currently.
2915180|NCT03143413||Systemic sclerosis|Systemic sclerosis is an autoimmune connective tissue disease with undefined etiology and characterized by progressive fibrosis of the skin and major organs. Dry eyes and / or buccal syndrome is commonly reported in patients with systemic sclerosis.
2915181|NCT03143413||Gougerot-Sjogren syndrome|Goujerot-Sjogren syndrome is a chronic autoimmune disorder that is characterized by dryness of the eyes (xerophthalmia) and / or mouth (xerostomia).
2915182|NCT03143413||Sicca-Asthenia-Polyalgia syndrome|It may be primary or secondary to another connective tissue disease (such as lupus, rheumatoid arthritis or other).
2915219|NCT03143140|Experimental|PAFA and tumor ablation|first percutaneous frequency ablation of tumor feeding artery and then ablation of tumor
2915184|NCT03143400|Active Comparator|Ileostomized patients|Ileostomized patients will only take a unique dose of each probiotic. Each intake of a different probiotic will be separated from another by a 14-day wash-out period at least.
2915185|NCT03143387|Active Comparator|Atraumatic Restorative Treatment|Partial removal of carious tissue using manual instruments.
2915186|NCT03143387|Experimental|Chemo-mechanical Removal|Partial removal of carious tissue using manual instruments and the material Chemo-mechanical removal group using Papacarie™gel.
2915187|NCT03143361||Aortic valve replacement patients|All the patients operated on aortic valve replacement in the study period at all the centers participating in the study
2915188|NCT03143348||Control/Nonsurgical|Infants with postnatally confirmed acyanotic congenital heart disease not expected to require surgery in the first six months of life.
2915189|NCT03143348||Surgery w/o bypass|Infants with postnatally confirmed congenital heart disease requiring cardiac surgery without cardiopulmonary bypass.
2915190|NCT03143348||Surgery w/ bypass|Infants with postnatally confirmed congenital heart disease requiring cardiac surgery with cardiopulmonary bypass.
2915191|NCT03143335|Active Comparator|Retropectoral immediate breast reconstruction|Participants are randomized to immediate breast reconstruction with the implant placed retropectoral.
2915192|NCT03143335|Active Comparator|Prepectoral immediate breast reconstruction|Participants are randomized to direct to immediate breast reconstruction with the implant placed prepectoral using acellular dermal matrix for support.
2915193|NCT03143322|Experimental|Systemic treatment + SBRT|Systemic treatment and SBRT to the bone metastases. Two SBRT schemes are allowed: 9 Gy x 3 fractions or 7 Gy x 5 fractions for axial and appendicular bones metastases. The choice is at the discretion of the investigator.
2915194|NCT03143322|No Intervention|Systemic treatment|Palliative radiotherapy on bone metastases is allowed if necessary (pain, fracture, spinal cord compression…)
2915195|NCT03143309|Experimental|Walking + WhatsApp|The participants assigned to the intervention group will be given a brief (15-minute) orientation where they learn about the importance of exercise, diet, and the benefits of weight reduction. They will be given further instruction on the regular use of the pedometer. They will be enrolled into a WhatsApp group. They will receive 2-3 health-promotional (walking and diet) messages per week via WhatsApp.
2915196|NCT03143309|Active Comparator|WhatsApp Only|The control participants will be enrolled into a WhatsApp group. They will receive 2-3 non-health related messages per week via WhatsApp.
2915197|NCT03143283|No Intervention|Usual care|Hospital EDs are observed under usual care conditions (families receive usual care at the ED).
2915198|NCT03143283|Experimental|Safety Study Lethal Means Counseling|During the intervention phase, mental health clinicians at EDs of participating hospitals are trained in lethal means counseling and implement the new protocol uniformly with eligible families.
2915199|NCT03143270|Experimental|Cohort 1, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Two weeks after deb-TACE, participants will begin nivolumab every two weeks for up to one year. If no participants experience a dose limiting toxicity (DLT), or 1 of 6 participants experiences a DLT, a new group of participants will be enrolled into Cohort 2.
2915200|NCT03143270|Experimental|Cohort 2, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Participants will receive nivolumab every two weeks for up to one year, starting 4 weeks prior to deb-TACE (week -4). Participants in this cohort will not receive nivolumab on the day of deb-TACE. If no participants experience a DLT in the initial group of 3 participants or if 1 of 6 participants experiences a DLT, a new group of participants will be enrolled into Cohort 3.
2915201|NCT03143270|Experimental|Cohort 3, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Nivolumab will be dosed every two weeks starting 4 weeks prior to deb-TACE (Week 4) and continue every 2 weeks for up to one year. If no participants experience a DLT in the initial group of 3 participants, an additional 3 participants will be added to confirm safety. If less than or equal to 1 of 6 participants experiences a DLT, this will be considered the optimal schedule.
2915202|NCT03143257||Subjects|Diagnosed with CHL, SSD and mixed HL who currently have or have had the Sophono implant
2915203|NCT03143244|Active Comparator|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
2915204|NCT03143244|Active Comparator|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
2915205|NCT03143244|Placebo Comparator|Control group (Normal Saline) (C)|Patients received same volume of normal slaine in two sets.
2915206|NCT03143231|Experimental|Normal saline|Sodium Chloride 0.9% will be provided
2915207|NCT03143231|Experimental|Hypertonic saline|500 ml Sodium Chloride 0.9% with 60 ml Sodium Chloride 20% will be provided
2915208|NCT03143218|Active Comparator|SMC with SP+AQ|Administration of RABIPUR® followed by 4 rounds of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.
2915209|NCT03143218|Active Comparator|RTS,S/AS01|Administration of the malaria vaccine RTS,S/AS01 followed by 4 rounds of SMC with placebo in Year 1,2 and 3.
2915210|NCT03143218|Active Comparator|RTS,S/AS01 PLUS SMC with SP+AQ|Administration of the malaria vaccine RTS,S/AS01 followed by 4 rounds of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.
2915211|NCT03143205|Experimental|AWARENESS for sexual minorities|Group receives new CBT-based intervention
2915212|NCT03143205|Active Comparator|Writing tasks|Group receives writing-based sessions
2915213|NCT03143192|Experimental|Aflibercept with Micropulse Laser|Aflibercept 2mg (0.05mL) injected intravitreally every 4 weeks or as needed Micropulse Laser at initial visit and reassessed every 12 weeks.
2915214|NCT03143192|Sham Comparator|Aflibercept with Sham Laser|Aflibercept 2mg (0.05mL) injected intravitreally every 4 weeks or as needed Sham Laser at initial visit and reassessed every 12 weeks.
2915215|NCT03143166|Experimental|All participants|Dabigatran etexilate given without rabeprazole and then Dabigatran etexilate given without rabeprazole.
2915216|NCT03143153|Experimental|Nivolumab + Ipilimumab|
2915217|NCT03143153|Experimental|Nivolumab + Cisplatin + Fluorouacil|
2915221|NCT03143114|Experimental|Myomectomy|Women will be subjected to laparotomy to remove the myomas
2915222|NCT03143114|No Intervention|Conservative management|Women will not be subjected to surgery (conservative management)
2915223|NCT03143101|Experimental|FluMist Quadrivalent 2017-18 formulation|Quadrivalent live attenuated influenza vaccine
2915224|NCT03143101|Experimental|FluMist Quadrivalent 2015-16 formulation|Quadrivalent live attenuated influenza vaccine
2915225|NCT03143101|Experimental|FluMist Trivalent 2015-16 formulation|Trivalent live attenuated influenza vaccine
2915226|NCT03143088|Active Comparator|Medical clown|Medical clown will be present in the pediatric emergency department while assessing blood pressure during triage of patients.
2915227|NCT03143088|No Intervention|Blood pressure assessment|Blood pressure will be measured by the medical center protocols.
2915228|NCT03143075|Active Comparator|Inflammation group|Subjects with CRP≥3, will receive eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, for 8 weeks, added to their pre-stabilized antidepressant medication
2915229|NCT03143075|Active Comparator|Non-inflammation group|Subjects with CRP<3, will receive eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, for 8 weeks, added to their pre-stabilized antidepressant medication
2915230|NCT03143062||Cases|150 patients that suffered an in-hospital cardiac arrest in a hospital ward.
2915231|NCT03143062||Controls|300 patients that did not suffer an in-hospital cardiac arrest but was treated in a hospital ward.
2915232|NCT03143049|Experimental|Pomalidomide, Cyclophosphamide, Dex (PCD)|
2915233|NCT03143049|Active Comparator|Pomalidomide, Dex (PD)|
2915234|NCT03143036|Experimental|Daratumumab, thalidomide and dexamethasone|
2915235|NCT03143023|Experimental|arginine toothpaste|
2915236|NCT03143023|Active Comparator|fluoride toothpaste|
2915237|NCT03143010|Placebo Comparator|control group|intrathecal Dexmedetomidine received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline .
2915238|NCT03143010|Experimental|1.5 DEX|Dexmedetomidine 1.5 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (1.5μg) dexmedetomidine
2915239|NCT03143010|Experimental|3 DEX|Dexmedetomidine 3 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (3μg) dexmedetomidine
2915240|NCT03143010|Experimental|5 DEX|Dexmedetomidine 5 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (5μg) dexmedetomidine
2915241|NCT03142997||group S|anesthetized children on spontaneous ventilation.
2915242|NCT03142997||group C|anesthetized children on controlled ventilation.
2915243|NCT03142984|Experimental|Phase 1|"An open use test in a cohort of newborn babies to confirm the tolerability and evaluate the acceptability of a new Baby Wash & Shampoo product and Baby Lotion.~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
2915244|NCT03142984|Experimental|Phase 2|"An evaluator blind, randomized, controlled trial to determine whether a wash and lotion regimen used for 12 weeks can strengthen the skin barrier in newborns when compared to standard skincare practices without massage.~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071) Alternative Baby Wash & Shampoo (GTIN/UPC # 5011451106260)"
2915245|NCT03142971|Experimental|Intervention:f-ESWT (focused shock wave therapy)|In the study-group, a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf) was used . At the beginning of each treatment session, the enthesis of the gluteal tendons at the greater trochanter (at the anterior half of its lateral facet) was targeted through a non-inline sonographic focusing, using a linear probe (7.5-12 MHz) connected to an ultrasound scanner (ESAOTE MYLAB FIVE, Genova and Florence, Italy). All patients received 1800 pulses (frequency=4Hz) of an energy flux density of 0.15 mJ/mm2 once a week for three consecutive weeks. At the first treatment session, the energy flux density was gradually increased from 0.05 to 0.15 mJ/mm2 during the first 500 pulses.
2915246|NCT03142971|Active Comparator|Intervention:UST (ultrasound therapy)|In the control-group, we used a mono-frequency device (ROLAND, RT-20 series, frequency=1MHz). We treated an area of 5cm2, softly moving the US-probe around the most painful point of the greater trochanter at the clinical palpation. UST was supplied in a continuous modality, with an intensity of 1.5 W/cm2, for ten consecutive daily sessions of ten minutes each.
2915247|NCT03142958|Other|Integra® Cadence™ Total Ankle System|
2915248|NCT03142945|Active Comparator|Traditional Physical Therapy Group|Traditional Physical Therapy Group Physical therapy-based interventions: home exercises (not repeated motions), stretching, modalities, and posture instruction.
2915249|NCT03142945|Experimental|MDT based physical therapy|MDT based physical therapy Physical therapy-based interventions: home exercises (including repeated motions), stretching, modalities, and posture instruction.
2915250|NCT03142932|Active Comparator|Control|A certified smoking cessation interventionist (SCI) will deliver standardized smoking cessation counseling using the National Cancer Institute (NCI) 5 A's model.
2915251|NCT03142932|Experimental|COach2Quit|"A certified smoking cessation interventionist (SCI) will deliver standardized smoking cessation counseling using the National Cancer Institute's 5 A's model.~Participants in the COach2Quit arm will be provided with an individualized carbon monoxide (iCO) monitor along with instructions on the use of the monitor and the COach2Quit application."
2915252|NCT03142919|Experimental|High CRP LPS Intervention|High CRP Individuals with Major Depressive Disorder receiving LPS intervention
2915253|NCT03142919|Active Comparator|Low CRP LPS Intervention|Low CRP Individuals with Major Depressive Disorder receiving LPS intervention
2915254|NCT03142919|Placebo Comparator|High CRP LPS Placebo|High CRP Individuals with Major Depressive Disorder receiving placebo
2915255|NCT03142919|Placebo Comparator|Low CRP LPS Placebo|Low CRP Individuals with Major Depressive Disorder receiving placebo
2915256|NCT03142906|Experimental|Scan group|Patients randomized to the scan group (intervention arm) will receive a preoperative point-of-care ultrasound (POCUS) exam as an adjunct to their preoperative assessment, the results of which will be disclosed to the anesthesiologist and the patient care team. This POCUS exam will include a focused cardiac ultrasound, a lung and pleural ultrasound, and a gastric volume and content ultrasound assessment. Patients randomized to this arm may also receive repeat POCUS exams as needed and as clinical conditions change. These repeat exams may be requested by the anesthesiologist or patient care team.
2915310|NCT03142555|Placebo Comparator|General Health Talk|"Subjects in this group will receive:~General health talk;~Phone follow-up/counselling service (15 - 30 mintues);~Social media ( less intensive reminders)"
2915257|NCT03142906|No Intervention|No scan group|Patients randomized to no scan (control arm) will not receive a preoperative point-of-care ultrasound exam. Patients in this arm will receive the standard-of-care; a routine preoperative assessment and physical examination by their attending anesthesiologist.
2915258|NCT03142893|Experimental|Control Condition|"8 am - Saline Solution for Injection 10 am - Placebo oral capsule~1 pm - Saline Solution for Injection 4 pm - Placebo oral capsule & start hourly blood sampling 7 pm - Gonadorelin (GnRH) and Corticorelin (CRH) injections 9 pm - Saline Solution for Injection & last blood sample"
2915259|NCT03142893|Experimental|Hypothalamic Condition|"8 am - Ganirelix 10 am - Placebo oral capsule~1 pm - Dexamethasone injection 4 pm - Placebo oral capsule and start of hourly blood sampling 7 pm - GnRH and CRH injections 9 pm - Saline Solution for Injection and last sample of blood taken"
2915260|NCT03142893|Experimental|Pituitary Condition|"8am - Saline Solution for Injection 10am - Ketoconazole Pill~1pm - Saline Solution for Injection 4pm - Ketoconazole Pill & start of hourly blood sampling 7pm - GnRH and CRH 9pm - Hydrocortisone Injection & last blood sample"
2915261|NCT03142893|Experimental|Adrenal/Testis Condition|"10pm - Ganirelix Injection & Dexamethasone Pills (night before) 8am - start of hourly blood sampling 10am - Dexamethasone Pills 11am - last hourly blood sample taken 11:30am - start of blood sampling every 10 minutes~1pm - Recombinant Human Luteinizing Hormone (rhLH) Injection 3pm - rhLH Injection 5pm - rhLH Injection 5pm - Cosyntropin Injectable product 7pm - GnRH and CRH Injections 9pm - last blood sample taken"
2915262|NCT03142880|Active Comparator|commonly hyperbaric ropivacaine group|This group will receive spinal anesthesia with commonly hyperbaric ropivacaine solution,which was made by adding 50% glucose to the plain ropivacaine commercially availablethe to make it's density is close to commonly hyperbaric bupivacaine.
2915263|NCT03142880|Experimental|marginally hyperbaric ropivacaine group|This group will receive spinal anesthesia with marginally hyperbaric ropivacaine,which was made by adding 5% glucose to the plain ropivacaine commercially availablethe to make it's density is slightly denser than cerebrospinal fluid but much less denser than commonly hyperbaric bupivacaine/ropivacaine.
2915264|NCT03142867||Control|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The control group will be made of individuals who do not meet the qualifications for a liver biopsy."
2915265|NCT03142867||NAFLD|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The NAFLD group will be made of individuals who qualify for a liver biopsy and have histologically proven NAFLD."
2915266|NCT03142867||NASH|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The NASH group will be made of individuals who qualify for a liver biopsy and have histologically proven NASH."
2915267|NCT03142854|Active Comparator|Group A: standard group|Participants are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
2915268|NCT03142854|Experimental|Group B: tailored group|"Participants are given personalized regimens for bowel preparation according to the the predictive model( a model which grades patients as low or high risk according to risk factors such as age, body mass index≧ 30 kg/m2, diabetes, constipation, pelvic surgery and tricyclic antidepressants usage).~Low risk patients are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen; High risk patients are given standard regimen: 4 L Polyethylene Glycol (PEG) regimen."
2915269|NCT03142841|No Intervention|Standard Care|Study participants will receive the usual standard care they would receive had they not been enrolled in this study
2915270|NCT03142841|Experimental|Problem Solving Intervention|The intervention consists of a problem-solving intervention and information/tools on the previously developed, evidenced-based Spanish-version of the RESCUE stroke caregiver website to improve stroke caregiver outcomes. The intervention will be conducted via telephone by a trained rehabilitation counselor. The intervention consists of four components: 1. Introduction to the RESCUE website and the problem-solving method; 2. Illustrative example on how to use the problem-solving approach and the RESCUE website to address caregiving problems; 3. Individualized practice exercise to develop a personalized problem-solving plan; and 4. Summary of the problem-solving method.
2915271|NCT03142828|Active Comparator|Test (clorhexidine gel)|The healing abutments were covered by a chlorhexidine gel after the first week of the second surgery (2-stage implants).
2915272|NCT03142828|Placebo Comparator|Placebo|The healing abutments were covered without any antiseptic gel after the first week of the second surgery (2-stage implants).
2915273|NCT03142802|Experimental|Patients with testicular germ cell cancer|Patients with testicular germ cell cancer who have either been newly diagnosed, or have stage I cancer already on surveillance program will undergo conventional and low dose CT. Based on the imaging, they may undergo a surveillance program using low-dose CT.
2915274|NCT03142789|Active Comparator|Certa Catheter|"A Certa-catheter (suture method) is inserted under ultrasound guidance at the midthigh level in the adductor canal, using an in plane technique, short/oblique axis view.~A bolus of ropivacaine will be administered during real time US imaging to ensure correct placement of the catheter (initial bolus). An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses every 8 hours until 12 pm on POD2.~2 dressings will be applied (medial and lateral) to obscure which catheter has been placed."
2915275|NCT03142789|Active Comparator|Standard Catheter|"A Standard-catheter is inserted under ultrasound guidance at the midthigh level in the adductor canal, using an in plane technique, short/oblique axis view.~A bolus of ropivacaine will be administered during real time US imaging to ensure correct placement of the catheter (initial bolus). An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses every 8 hours until 12 pm on POD2.~2 dressings will be applied (medial and lateral) to obscure which catheter has been placed."
2915309|NCT03142555|Experimental|Intensive Health Talk|"Subjects in this group will receive:~Intensive health talk (focus on smoking harms, active referral information and supplement with more videos);~Phone follow-up/counselling service (15 - 30 minutes);~Social media (intensive reminders including active referral information);~Regular personalized what's app interaction ( up to 2 months duration)"
2915311|NCT03142542|Experimental|Udenafil 75mg|Drug: Udenafil 75mg by mouth, once daily, for 32 weeks
2969903|NCT02764346|Experimental|iCanCope app|iCanCope app
2915276|NCT03142789|Active Comparator|Single Bolus|"A bolus of ropivacaine will be injected into the adductor canal, at the midthigh level, using a 80 mm x 22G Pajunk needle during real time US imaging (initial bolus).~A sham catheter (25 Certa and 25 standard catheters according to randomi-zation) will be fixed externally and covered by dressings as in the catheter groups groups (Certa and standard). Care will be taken to use approximately the same amount of time as used in the catheter groups (Certa and standard) An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses into the dressing every 8 hour until 12 PM on POD2."
2915277|NCT03142776|Placebo Comparator|Periodontal debridement|Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
2915278|NCT03142776|Active Comparator|Periodontal debridement + CLM|Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours) for 3 days.
2915279|NCT03142776|Active Comparator|Periodontal debridement + PDT|Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days) and a single application of PDT (Photodynamic Therapy).
2915280|NCT03142776|Active Comparator|Periodontal debridement + CLM + PDT|Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours for 3 days) and single application of PDT.
2915281|NCT03142763|Experimental|Egg intake|Consumption of 3 eggs per day for breakfast, 4 weeks
2915282|NCT03142763|Experimental|Choline Supplement intake|Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
2915283|NCT03142750|Experimental|Enrolled subjects|There is only one arm to this study. The intervention includes providing one week supply of each of two gastrostomy tube dressing prototypes to try at home.
2915284|NCT03142737|Experimental|Red kidney bean intake|Subjects will consume 1/2 cup of cooked red kidney bean following diet normalization for 3 days.
2915285|NCT03142737|Experimental|Eggs intake|Subjects will consume 2 cooked large eggs following diet normalization for 3 days.
2915286|NCT03142737|Experimental|Peanut butter intake|Subjects will consume 2 tablespoons of peanut butter following diet normalization for 3 days.
2915287|NCT03142737|Experimental|Ground beef intake|Subjects will consume 2 ounces of 90% lean ground beef following diet normalization for 3 days.
2915288|NCT03142737|Experimental|Intact beef intake|Subjects will consume 2 ounces of intact beef following diet normalization for 3 days.
2915289|NCT03142724|Experimental|[18F]MNI-968|To assess the safety and tolerability and to determine the radiation dosimetry of [18F]MNI-968.
2915290|NCT03142698|Experimental|Hepatic steatosis|Evaluation of different techniques in quantification of hepatic steatosis by MRImaging (PDFF 3, 6 and 11 gradient echoes and Spectroscopy) compared to the histological method (reference)
2915291|NCT03142685|Experimental|Arm B: Kub + Bowel US|Subjects clinical suspected of NEC whom are randomized into Arm B at time of consent will receive a bowel ultrasound q24 for 48 hours and a KUB q12 for 48 hours.
2915292|NCT03142685|No Intervention|Arm A: KUB Only|Subjects clinical suspected of NEC whom are randomized into Arm A at time of consent will receive a KUB q12 for 48 hours. This is the current standard-of-care procedures.
2915293|NCT03142672|Experimental|Experimental group|Pulpotomy and tooth filling
2915294|NCT03142672|Active Comparator|Control group|Tooth filling
2915295|NCT03142646|Experimental|IM19 CART|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of IM19CART cells administered intravenously.
2915296|NCT03142633||Women with Polycystic Ovary Syndrome|"Participants of the PICOLO study~Inclusion criteria:~Women aged 18-40 years when included in the PICOLO-cohort, PCOS based on the Rotterdam 2003 consensus criteria Exclusion criteria: Contraceptive pills within 6 weeks from examination, endocrinological disease (i.e. diabetes, thyroid dysfunction), endometriosis and premature ovarian insufficiency, breastfeeding women and pregnancy."
2915297|NCT03142620|Active Comparator|Triple Therapy 10 days|Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days
2915298|NCT03142620|Active Comparator|Triple Therapy 10 days+ vitamin D for 10|"Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days~+ vitamin D3 IU for 10 days"
2915299|NCT03142620|Active Comparator|Triple Therapy 10 days+vitamin D for 28|"Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days~+ vitamin D3 IU for 28 days"
2915300|NCT03142607|Active Comparator|Group A|subjects will be instructed to apply a standard 0.2 % Chlorhexidine gel (clinica gel) on the marginal gingiva for the next 14 days, twice a day for 30 minutes, after morning and evening tooth brushing
2915301|NCT03142607|Active Comparator|Group B|Subjects will be instructed to apply 0.8 % Metronidazole gel (anaerobic gel) twice daily for 30 minutes after morning and evening tooth brushing for two weeks
2915302|NCT03142607|Active Comparator|Group C|subjects will be instructed to apply 0.2 % Chlorhexidine gel (clinica gel) on the marginal gingiva after morning tooth brushing for 30 minutes and 0.8 % metronidazole gel (anaerobic gel) after evening tooth brushing for 30 minutes for two weeks. Subjects in these groups will receive the detailed and precise instruction and demonstrations on the diurnal alternate application of the two gels
2915303|NCT03142568|Experimental|Sildenafil cohort 1|Within cohort 1 infants will be randomized using a 3:1 scheme to receive sildenafil or placebo. Infants randomized to sildenafil will receive 0.125 mg/kg daily every 8 hours intravenously (IV), or 0.25 mg/kg daily every 8 hours enterally for 28 days.
2915304|NCT03142568|Placebo Comparator|Placebo cohort 1|Infants randomized to the placebo treatment group will receive the equivalent of dextrose 5% (sugar water) to be administered IV or enteral use.
2915305|NCT03142568|Experimental|Sildenafil cohort 2|Cohort 2 infants will receive sildenafil 0.5 mg/kg daily every 8 hours intravenously (IV) or 1 mg/kg daily every 8 hours enterally for 28 days.
2915306|NCT03142568|Placebo Comparator|Placebo cohort 2|Infants randomized to the placebo treatment group will receive the equivalent of dextrose 5% (sugar water) to be administered IV or enteral use.
2915307|NCT03142568|Experimental|Sildenafil cohort 3|Cohort 3 infants will receive sildenafil 1 mg/kg daily every 8 hours intravenously (IV) or 2 mg/kg daily every 8 hours enterally for 28 days.
2915308|NCT03142568|Placebo Comparator|Placebo cohort 3|Infants randomized to the placebo treatment group will receive the equivalent of dextrose 5% (sugar water) to be administered IV or enteral use.
2915312|NCT03142542|Placebo Comparator|Placebo|Drug: placebo by mouth, once daily, for 32 weeks
2915313|NCT03142529|No Intervention|Integrated Therapy|This arm is an control group,in which participants will receive conventional integrated therapy on CRF.
2915314|NCT03142529|Experimental|Integrated Therapy and colonic dialysis|This arm is a treatment group,in which participants will receive integrated therapy on CRF and traditional Chinese medicine Colonic dialysis with traditional Chinese medicine colon lotion once a day.
2915315|NCT03142516|Experimental|FOLFIRI + panitumumab|"All patients will receive panitumumab plus FOLFIRI for disease control in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:~Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy~FOLFIRI~Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
2915316|NCT03142503|Placebo Comparator|Placebo|Soybean supplementation
2915317|NCT03142503|Active Comparator|Diet + placebo|Soybean supplementation and diet intervention
2915318|NCT03142503|Experimental|Diet + Supplementation|Omega 3 and diet intervention
2915319|NCT03142490|Experimental|Treatment|In vitro fertilization patients submitted to acupuncture as a complementary therapy. Patients in both groups will be evaluated by 4 different questionnaires.
2915320|NCT03142490|Active Comparator|Control|In vitro fertilization patients not submitted to acupuncture as a complementary therapy. Patients in both groups will be evaluated by 4 different questionnaires.
2915321|NCT03142477|Other|Control|Control group patients will not receive any interventions with therapeutic touch. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
2915322|NCT03142477|Placebo Comparator|Placebo|Placebo patients group patients will receive the therapeutic touch intervention by a graduate student without any therapeutic touch training. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
2915323|NCT03142477|Experimental|Treatment|Treatment patients group patients will receive the therapeutic touch interventions with a trained therapeutic touch professional. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
2915324|NCT03142464|No Intervention|IV fluids|Regular IV fluids (Glucose 5% and Sodium Chloride 10% or Ringer) at the surgeon description
2915325|NCT03142464|Experimental|No IV fluids|No IV fluids after the termination of the operation. T
2915326|NCT03142451|Other|Vehicle|Vehicle Foam
2915327|NCT03142451|Experimental|Minocycline Foam 1.5%|FMX-103
2915328|NCT03142438|Experimental|Trial Full face or nasal mask|participants will be placed on this arm for a total of 14 +- 4 days from visit 1. participants will be using the trial mask during this treatment arm
2915329|NCT03142399|Experimental|whey protein|The whey protein group will receive whey protein supplementation 30g/day of whey protein during three months (12 weeks)
2915330|NCT03142399|Placebo Comparator|placebo group|The placebo group (maltodextrin) will receive 30g/day of maltodextrin during three months (12 weeks)
2915331|NCT03142386|Experimental|OMT group|Osteopathic manipulative treatment
2915332|NCT03142386|Active Comparator|Control Group|Physiotherapy
2915333|NCT03142373|Experimental|CV4 group|CV4 technique
2915334|NCT03142373|Experimental|RR group|Rib Raising technique
2915335|NCT03142373|Placebo Comparator|Placebo group|Light touch
2915336|NCT03142360|Experimental|Treatment group|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
2915337|NCT03142360|No Intervention|Non-Treatment group|On the other hand, the control group does not take anything.
2915338|NCT03142347|Active Comparator|Remote endarterectomy|Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.
2915339|NCT03142347|Experimental|Remote endarterectomy + DCB balloon|Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.
2915340|NCT03142334|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 17 cycles.
2915341|NCT03142334|Placebo Comparator|Placebo|Participants receive placebo (saline solution) via IV infusion on Day 1 of each 3-week cycle for up to 17 cycles.
2915342|NCT03142321|Experimental|Vedolizumab 300 MG Injection [Entyvio]|Vedolizumab will be initiated at 300 mg intravenous (IV) dosing at 0, 2 and 6 weeks followed by the 1st maintenance with 300 mg IV at week 14. Patients who have not achieved clinical response at week 14 will be eligible to undergo dose escalation to 4 weekly dosing of vedolizumab depending on the judgement of the treating gastroenterologist.
2915343|NCT03142308||Surgeons|Young surgeons in all surgical specialities
2915344|NCT03142295|Experimental|Urine transfusion|Intervention: Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
2915345|NCT03142282|Active Comparator|Maintenance chemotherapy|FDA approved drugs for the study population: Bevacizumab, Xeloda
2915346|NCT03142282|Experimental|Radiotherapy|consolidative radiotherapy plus maintenance chemotherapy
2915347|NCT03142269|Active Comparator|polished group|360°anterior capsule polishing was performed with double-ended capsule polisher randomly in one eye
2915348|NCT03142269|Placebo Comparator|unpolished group|the opposite unpolished was used as the control
2915349|NCT03142256|Active Comparator|Incentivised - Conditional Cash Transfer|Cash incentive for good drug levels assed by Dried Blood Spot
2915350|NCT03142256|No Intervention|No incentive|Truvada 200Mg-300Mg Tablet
2915351|NCT03142230|Experimental|non-nutritive suction with holed baby bottle nipple|A group using the holed baby bottle nipple
2915352|NCT03142230|Active Comparator|Simple non-nutritive suction with personal pacifier|A group using personal pacifier
2915353|NCT03142217|Other|Patient with Huntington's Disease|
2915354|NCT03142191|Experimental|CC-90001 400 mg PO QD|45 subjects will be randomized to CC-90001 400mg
2915355|NCT03142191|Experimental|CC-90001 200 mg PO QD|45 subjects will be randomized to CC-90001 200mg
2915356|NCT03142191|Placebo Comparator|Placebo PO QD|45 subjects will be randomized to placebo
2915357|NCT03142178|Experimental|Experimental 3VM1001 2g X 3 daily|3VM1001 active cream administered 2g cream three times daily for seven days
2915358|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 2g X 3 daily|3VM1001 placebo vehicle administered 2g cream three times daily for seven days
2915359|NCT03142178|Experimental|Experimental 3VM1001 3g X 3 daily|3VM1001 active cream administered 3g cream three times daily for seven days
2915360|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 3g X3 daily|3VM1001 placebo vehicle administered 3g cream three times daily for seven day
2915361|NCT03142178|Experimental|Experimental 3VM1001 3g x 4 daily|3VM1001 active cream administered 3g cream four times daily for seven days
2915362|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 3g X 4 daily|3VM1001 placebo vehicle administered 3g cream four times daily for seven days
2915363|NCT03142165|Experimental|BMS-986263|
2915364|NCT03142165|Placebo Comparator|Placebo|
2915365|NCT03142152|Experimental|Intervention Group|Carillon Mitral Contour System and Guideline Directed Heart Failure Medication
2915366|NCT03142152|Active Comparator|Control Group|Guideline Directed Heart Failure Medication
2915367|NCT03142139||Danish Birth Cohorts 1997-2012|"RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib~RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib among children who received a timely first dose of DTaP-IPV-Hib~RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated on development of Atopic Dermatitis."
2915368|NCT03142126|Experimental|Early Ambulation|To affirm the safety and efficacy of ambulation of 20 minutes after diagnostic left heart catheterization.
2915369|NCT03142100||Hebrew speaking participants|Hebrew speaking bilateral-bimodal users will be assessed using cochlear implants and hearing aids
2915370|NCT03142100||Arabic speaking participants|Arabic speaking bilateral-bimodal users will be assessed using cochlear implants and hearing aids
2915371|NCT03142087|Active Comparator|virtual reality exercises|Nintendo Wii Fit Plus Game Console is used in these group. The one session included:warm-up exercises in 5-10 minutes, games (soccer heading, ski jump, ski slalom, etc.) in 30-40 minutes, and cooling exercises in 5 minutes.
2915372|NCT03142087|Active Comparator|conventional exercises|Physiotherapy and rehabilitation session included: warm-up exercises in 5-10 minutes, balance exercises (balance board, balance ball, two and one leg stand exercises, weight bearing exercises, balance in different type of surfaces, etc.) in 30-40 minutes, and cooling exercises in 5 minutes.
2915373|NCT03142074||Ascending thoracic aortic aneurysm (ATAA)|Patients suffering from ascending thoracic aortic aneurysms (ATAA), asymptomatic or symptomatic, that are surgically treated.
2915374|NCT03142061|Experimental|ECT|
2915375|NCT03142048|Experimental|Schools of Health for the Elderly|"Participants receiving the community intervention (explained in the section Intervention)"
2915376|NCT03142048|No Intervention|Comparison Group|Participants in the study that do not receive the intervention
2915377|NCT03142035|Experimental|Dienogest|patients will receive daily dienogest (2mg) for a total of 3 months (84 days)
2915378|NCT03142035|Active Comparator|GnRH agonist|patients will receive a single GnRH-a injection (3.25mg) every 28 days for three months.
2915379|NCT03142035|Other|Control Group|patients will not receive any medical intervention and will proceed with their IFV/ICSI cycles.
2915380|NCT03142022||SDB and lung transplantation|Polysomnography at 1 year after lung transplantation.
2915381|NCT03142009|Experimental|Program group|Tribal Research Team members recruit participants by sending letters home with the fourth and fifth grade children. This letter provides an overview of the FL/CP and invite interested parents and children to learn more. TRT and UNM team members follow-up with interested parents individually. If families are committed to being a part of FL/CP, a meeting is set to conduct the informed consent process and complete pretest. Families in the program group then attend FL/CP sessions which covers the intergenerational culturally adapted curriculum. Program families also participate in various aspects of the program including completing a Community Action Project.
2915382|NCT03142009|No Intervention|Comparison group|Upon receiving the letter families that selected not to participate or who decline to participate will be invited to take part in the research study as comparison participants. Comparison participants do not attend the FL/CP sessions and only complete the pre, post and 1 year post tests.
2915383|NCT03141996|Experimental|Vibration to upper posterior neck muscles|Treatment will be performed by occupational therapist practitioners prior to regular occupational therapy session using a vibration tool.
2915384|NCT03141996|Active Comparator|Standard of care|Regular occupational therapy session
2915385|NCT03141983|Active Comparator|Anakinra|"Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1 alpha and IL-1 beta by competitively binding to the interleukin-1 type I receptor (IL-1RI). Anakinra is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra).~Anakinra will be supplied in pre-filled syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe will contain 100 mg in 0.67 ml solution (pH 6.5) containing disodium EDTA (0.12 mg), sodium chloride (5.48 mg), sodium citrate (1.29 mg), and polysorbate 80 (0.70 mg) in Water for Injection, USP."
2915386|NCT03141983|Placebo Comparator|Placebo|Saline (0.9%) will be used as the placebo, supplied in pre-filled syringes as a sterile, clear, colorless-to-white, preservative free solution.
2915387|NCT03141970|Experimental|Intervention: Prednisolone|Drug: 12- Weeks of Prednisolone Therapy Subjects will add an additional 12 weeks of Prednisolone to follow pre-randomization standard of care prednisolone. Post randomization Prednisolone therapy of 30 mg/m2 on alternate days for 4 weeks, 20 mg/m2 on alternate days for 4 weeks, and 10 mg/m2 on alternate days for 4 weeks
2915388|NCT03141970|No Intervention|No intervention|Subjects will NOT receive 12-weeks of additional Prednisolone therapy following randomization
2915389|NCT03141957||Young patients|Patients with non-small cell lung carcinoma younger than 75y
2915390|NCT03141957||Elderly patients|Patients with non-small cell lung carcinoma aged 75 or more
2915391|NCT03141944||Apathetic patients|"De novo Parkinson's Disease patients with Apathy which participated in a former study and are under dopaminergic treatment at inclusion.~All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the Starkstein scale of apathy"
2915392|NCT03141944||Non-apathetic patients|"De novo Parkinson's Disease patients without Apathy which participated in a former study and are under dopaminergic treatment at inclusion.~All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the Starkstein scale of apathy"
2915393|NCT03141931|Experimental|Lacritec|Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
2915394|NCT03141931|Placebo Comparator|Placebo|Polyethylene glycol, Oleic acid, Propylene glycol
2915395|NCT03141918|Experimental|Curcumin group 1|Intervention will be with intake of curcumin, 1000mg per 30 days
2915396|NCT03141918|Placebo Comparator|Curcumin group 2|Intervention will be with placebo intake of curcumin, 1000mg per 30 days
2915397|NCT03141905|Active Comparator|Sick-Day Protocol|
2915398|NCT03141905|Placebo Comparator|Usual Care|
2915399|NCT03141892||Diabetes Mellitus, Type 1 and Type 2|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
2915400|NCT03141879|Experimental|Physical Activity Intervention|HUR resistance training intervention
2915401|NCT03141879|No Intervention|Regular care|(Wait-list control)
2915402|NCT03141866|Experimental|Physical Activity Intervention 1: Move It Or Lose It (MIOLI)|An established chair-based physical activity programme for older adults.
2915403|NCT03141866|Experimental|Physical Activity Intervention 2: HUR resistance training|Specialised, chair-based resistance training equipment for older adults.
2915404|NCT03141853|Experimental|Equine-assisted Therapy Group|This group will interact and ride horses for 1 hour each week for 6 weeks. Horses will remain at a walk and an standard Therapeutic Riding curriculum will be used including safety, mounting, riding, tasks while riding, dismount, bonding with the horse.
2915405|NCT03141853|Placebo Comparator|Arthritis Exercise Education Group|This group will receive exercise education that targets arthritis symptoms for 1 hour each week for 6 weeks. This will be based on the exercise education from the Arthritis foundation How-to Exercise With Arthritis. (n.d.).
2915406|NCT03141840|Experimental|Experimental|Experimental group: ABL01 is to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
2915407|NCT03141840|Placebo Comparator|Control|Control group: Placebo solution to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
2915408|NCT03141827|Experimental|Insulin|Nasal spray, insulin 40 IU, single dose
2915409|NCT03141827|Placebo Comparator|Placebo|Nasal spray, placebo, single dose
2915410|NCT03141814||asthma|20 patients with ongoing ashma
2915411|NCT03141814||complete asthma remission|20 subjects with complete asthma remission
2915412|NCT03141814||clinical asthma remission|20 subjects with clinical asthma remission
2915413|NCT03141814||non-asthmatic healthy controls|20 subjects without respiratory symptoms and normal lung function and no bronchial hyperresponsiveness to methacholine and/or AMP
2915414|NCT03141801|Experimental|Eccentric Exercise with Delfi Blood Flow Restriction Training|Patients randomized to the eccentric exercise + blood flow restriction training group will receive eccentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their eccentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
2915415|NCT03141801|Experimental|Concentric Exercise with Delfi Blood Flow Restriction Training|Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions.
2915416|NCT03141801|Active Comparator|Eccentric Exercise|Patients randomized to the eccentric exercise group will receive eccentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their eccentric 1-repetition maximum for 4 sets of 10 repetitions.
2915417|NCT03141801|Active Comparator|Concentric Exercise|Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
2915418|NCT03141788|Other|Treatment of Malocclusion|Clear Aligner Treatment
2915419|NCT03141775||Treatment of CDI|Treatment of CDI for hospitalized patients with Clostridium difficile associated diarrhea
2915420|NCT03141736|Active Comparator|KMC & WHO protocol (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
2915421|NCT03141736|Active Comparator|KMC & WHO protocol (1-24 hours)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
2915422|NCT03141736|Experimental|KMC, WHO protocol & bag (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
2915423|NCT03141736|Experimental|KMC, WHO protocol & bag (1-24 hours|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
2915424|NCT03141723|Active Comparator|KMC & WHO protocol (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
2915425|NCT03141723|Active Comparator|KMC & WHO protocol (1-24 hours)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
2915426|NCT03141723|Experimental|KMC, WHO protocol & bag (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
2915427|NCT03141723|Experimental|KMC, WHO protocol & bag (1-24 hours|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
2915428|NCT03141710|Experimental|12 type 2 diabetes patients|Long-term dietary (12 weeks) intervention of 20ml of prebiotic per day
2915429|NCT03141697|Experimental|Carbon Dioxide|Colonoscopy with Insufflation of Carbon Dioxide
2915430|NCT03141697|Placebo Comparator|Room Air|Colonoscopy with Insufflatioin of Room Air
2915431|NCT03141684|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2915432|NCT03141671|Experimental|GnRH + Bicalutamide|"GnRH agonist injection monthly or every 3 months for 6 months~Bicalutamide by mouth once/day for 6 months~Salvage radiation (starting 4-10 weeks after initiation of ADT)"
2915433|NCT03141671|Experimental|GnRH+Abiraterone+Apalutamide+Prednisone|"GnRH agonist injection monthly or every 3 months for 6 months~Abiraterone acetate by mouth once/day for 6 months~Prednisone by mouth once/day for 6 months~Apalutamide by mouth once/day for 6 months~Salvage radiation (starting 4-10 weeks after initiation of ADT)"
2915434|NCT03141658|Experimental|TS-134 20 mg|
2915435|NCT03141658|Experimental|TS-134 60 mg|
2915436|NCT03141658|Experimental|Placebo|
2915437|NCT03141645|Experimental|Fluid loading group|Patients will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation
2915438|NCT03141645|Active Comparator|Ondansetron group|Patients will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation.
2915439|NCT03141645|No Intervention|Control group|Patients will receive neither preoperative intravenous fluid loading nor intravenous ondansetron.
2915440|NCT03141632|Active Comparator|Dulaglutide|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.
2915441|NCT03141632|Placebo Comparator|Placebo|0.5 ml normal saline (0.9% sodium chloride), sc once weekly for 3 weeks.
2915442|NCT03141619||Respiratory failure and/or shock|All enrolled patients will undergo 72 hours of monitoring of cerebral oxygenation with near-infrared spectroscopy.
2915443|NCT03141593|Active Comparator|Vitamin D: liquid form, start weekly|5'600 IU weekly (1.4 ml oily drops) start for 3 months, will cross-over to 24'000 IU monthly (5 ml alcoholic drops) for the following 3 months.
2915444|NCT03141593|Active Comparator|Vitamin D: solid form, start weekly|5'600 IU weekly (1 soft capsule) start for 3 months, will cross-over to 20'000 IU monthly (1 tablet) for the following 3 months.
2915445|NCT03141593|Active Comparator|Vitamin D: liquid form, start monthly|24'000 IU monthly (5 ml alcoholic drops) start for 3 months, will cross-over to 5'600 IU weekly (1.4 ml oily drops) for the following 3 months.
2915446|NCT03141593|Active Comparator|Vitamin D: solid form, start monthly|20'000 IU monthly (1 tablet) start for 3 months, will cross-over to 5'600 IU weekly (1 soft capsule) for the following 3 months.
2915447|NCT03141580|Experimental|Study group|Subjects with carotid stent who consented to undergo near-infrared spectroscopy and intravascular ultrasound imaging.
2915448|NCT03141567||Outpatient|Individuals undergoing clinically indicated Right Heart Catheterization.
2915449|NCT03141567||Inpatient|Individuals undergoing clinically indicated Right Heart Catheterization.
2915450|NCT03141554|Active Comparator|Treatment Sequence Group 1|"Treatment Sequence Group 1 = A -> B -> C~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)~Treatment C = Normal saline gargle (lukewarm)."
2915451|NCT03141554|Active Comparator|Treatment Sequence Group 2|"Treatment Sequence Group 2 = B -> C -> A~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)~Treatment C = Normal saline gargle (lukewarm).~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle"
2915452|NCT03141554|Active Comparator|Treatment Sequence Group 3|"Treatment Sequence Group 3 = C -> A -> B~Treatment C = Normal saline gargle (lukewarm).~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)"
2915666|NCT03140228|Experimental|I-Gel group|I-gel will be used for maintenance of airway during general anaesthesia
2971663|NCT02753023||acute pulmonary edema|No intervention related
2915453|NCT03141541|No Intervention|Usual care|All patients receive a thorough physical examination by a rheumatologist or a chiropractor with a subsequent examination by a physiotherapist.The patients receive general information about the nature back pain, adjustment of analgesic treatment and clarification of any need of further diagnosing or assessment by a surgeon. The physiotherapist furthermore makes an assessment of the patients' physical capacity and function and provides guidelines for any exercise programme. Based on the physiotherapist's judgement, the patient may be referred to rehabilitation in the local community
2915454|NCT03141541|Experimental|Group based pain management intervention|In addition to usual care as described for the control group, the patients in the intervention group will participate in a cognitive group-based pain management intervention. The aim of the intervention is to improve the patients' understanding of their back pain problem, and that they learn different pain coping strategies. The intervention is based on cognitive behavioural therapy including elements of acceptance and commitment therapy, and furthermore uses different relaxation and breathing exercises.
2915455|NCT03141528|Active Comparator|Instructor-led learning|This group will train their technical CPR-skills with supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
2915456|NCT03141528|Experimental|Self-learning|This group will Train alone without supervision and without communicating with the other participants.
2915457|NCT03141515|Active Comparator|Control group|After anesthesia induction patients received lung recruitment maneuver using pressure-control ventilation with a patient in supine position with 10 cmH2O level of positive end-expiratory pressure PEEP during 180 seconds. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
2915458|NCT03141515|Experimental|Recruitment maneuver group|Patients received lung recruitment maneuver with postural changes of lateral decubitus using pressure-control ventilation, 10 cmH2O level of PEEP in left and in right lateral decubitus during 90 seconds in each one. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
2915459|NCT03141502|Experimental|Skin Stretching Device (SSD)|the wound is primarily closed by aid of the SSD after necessary surgical debridement.
2915460|NCT03141502|Active Comparator|Skin Grafting (SG)|the wound is primarily closed by the technique of skin grafting after necessary surgical debridement.
2915461|NCT03141489|Experimental|NICE guidelines for refeeding syndrome|High protein enteral tubefeeding solution. NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
2915462|NCT03141489|Experimental|Diakonhjemmet Hospital Protocol(DS)|High protein enteral tubefeeding solution. The intervention group, Diakonhjemmets feeding protocol, will start at 20 calories a kg a day, and increasing until estimated needs are met within 3days
2915463|NCT03141476|Other|Cefuroxime 1,5g|BMI <30kg/m*m
2915464|NCT03141476|Other|Cefuroxime 3g|BMI 30-50kg/m*m
2915465|NCT03141476|Other|Cefuroxime 4,5g|BMI >50kg/m*m
2915466|NCT03141463|Experimental|Vvax001 therapeutic cancer vaccine|Patients will receive three consecutive doses of Vvax001, with an interval of 3 weeks
2915467|NCT03141437|Experimental|Decision Aid Website - MDACC Group|"Questionnaire completed before viewing the website about healthcare decision making and fertility.~Participant views the decision aid website about fertility preservation at home or at routine fertility consultation visit.~Questionnaire completed 1 week after viewing the website about opinions on the decision aid website.~Questionnaire completed 2 months after consultation visit about which methods of fertility preservation that were chose (if any)."
2915468|NCT03141437|Experimental|Multicomponent Decision Support (DS) - HALs Group|"Multicomponent DS intervention at selected MD Anderson Houston Area Locations (HALs)~Participant completes 3 questionnaires before viewing the website about healthcare decision making and fertility, and then at 1 week and then 2 months after viewing the website.~Participant views the decision aid website about fertility preservation at home."
2915469|NCT03141437|Active Comparator|Standard Care - HALs Group|"Standard Care intervention at selected MD Anderson Houston Area Locations (HALs)~Participants receive education materials about fertility preservation from the Livestrong organization and receive a referral for fertility preservation, if requested.~Participants complete 3 sets of questionnaires at enrollment in the study, and then at 1 week and 2 months after enrollment."
2915470|NCT03141424|Active Comparator|Group A|Usual care. Unchanged asthma medication during the entire study period.
2915471|NCT03141424|Experimental|Group B|Tapering of ICS over 8 weeks. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
2915472|NCT03141398||High-Risk Group|The objective of the study to compare the efficiency of detecting glycemic abnormalities using Continuous Glucose Monitoring (CGMs) versus Oral Glucose Tolerance Test (OGTT) and HbA1C. versus T2* MRI of the pancreas (T2* MRI of the Pancreas) in high-risk patients due to insulin deficiency (potential beta cell injury) and those with insulin resistance and to study the different factors that may affect the glycemic control in these patients in relation to their results like the Dose of corticosteroids and chemotherapy in ALL and Hemoglobinopathies,Liver function in ALL and Hemoglobinopathies, and Serum ferritin in Hemoglobinopathies and their transfusion status.
2915473|NCT03141385|Experimental|RIPC intervention|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
2915474|NCT03141385|Sham Comparator|Control|Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
2915475|NCT03141372|Active Comparator|Autofill Void Trial|"Patients who randomize to the autofill void trial will be allowed to urinate at any time within the first 3 hours after surgery. The amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR > 100 mL, the void trial will be considered failed and a Foley catheter will be replaced."
2915537|NCT03141008||Ketogenic diet exposed group|"Fibroscan changes with different diets:~Patients in a weight loss program using a ketogenic diet. Will compare differences in Fibroscan and metabolic changes."
2915476|NCT03141372|Active Comparator|Backfill Void Trial|"About 300 mL of fluid will be instilled into the bladder and the Foley will then be removed. The participant will be given up to 1 hour to urinate and the amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR > 100 mL or if the patient is unable to void within the hour, the void trial will be considered failed and a Foley catheter will be replaced."
2915477|NCT03141359|Experimental|Single Arm|SBRT + Concurrent Mediastinal Chemoradiation +/- Consolidation Chemotherapy
2915478|NCT03141346|Active Comparator|Control|Standard of care, which is a standard home visitation program to promote physical and psychosocial health provided by Antelope Valley Partners for Health.
2915479|NCT03141346|Experimental|Sugar Reduction Program Only|Standard home visitation program plus a sugar reduction program.
2915480|NCT03141346|Experimental|Sugar Reduction Program & Water Delivery|Standard home visitation program plus a sugar reduction program and home water delivery.
2915481|NCT03141333|Experimental|Teleintervention|Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
2915482|NCT03141333|No Intervention|No intervention|Participants of this group will have access to the following section of the web plate-form: information, which is consistent with the standard of care for many families of children with DCD, who only have access to online information but do not have access to any type of intervention.
2915483|NCT03141307|Active Comparator|Intervention|The EICI intervention group will receive an electronic interactive tool with movie clips and external links available through the tool. The movie intervention group will watch the educational consent movie and receive the standard paper-based brochure.
2915484|NCT03141307|Placebo Comparator|Control|This group will receive the standard of care currently used (paper-based brochure)
2915485|NCT03141294|Placebo Comparator|sd-PDT group|The investigators applied the traditional standard dilation technique when operating tracheostomy on the standard group.
2915486|NCT03141294|Experimental|re-PDT group|The investigators applied the reformative dilation technique when operating tracheostomy on the re-PDT group.
2915487|NCT03141281|Experimental|BrainHQ|Participants will be provided with a laptop computer and enrolled in a commercial web-based cognitive training program, BrainHQ, trained on how to access it, and instructed to complete a fixed number of sessions in 20 hours.
2915488|NCT03141281|Experimental|Rise of Nations|Participants will be provided with a laptop computer with the Rise of Nations video game, be trained in game play, and instructed to play the game for 20 hours
2915489|NCT03141281|Experimental|IADL training|Participants will be enrolled in AARP's web-based driver training course, trained on how to access it, and asked to complete the course, estimated to take approximately 6-8 hours. They will also be provided with web-based access to a finance and fraud avoidance training tutorial, instructed on how to access it, and be asked to complete the course, estimated to take approximately 5-7 hours. The two courses combined are estimated to take about 15 hours.
2915490|NCT03141281|Active Comparator|Active Control|Participants will be provided with a laptop computer and asked to complete 20 hr of training with Sudoku, crossword puzzles, and word search
2915491|NCT03141268||Healthy volunteers|Normal subjects aged 18-80 years. No chronic diseases.
2915492|NCT03141268||IBS patients, lactose intolerant|Subjects 18-80 years diagnosed with IBS for more than 6 months ago; lactose intolerant. No concomitant diseases.
2915493|NCT03141268||IBS patients, lactose tolerant|Subjects 18-80 years diagnosed with IBS for more than 6 months ago; lactose tolerant. No concomitant diseases.
2915494|NCT03141255|No Intervention|Control Group|Patients will receive only standard of care treatment for cardiogenic shock.
2915495|NCT03141255|Experimental|Therapeutic Hypothermia|Patients will be cooled to between 32°C and 34°C using the IVTM™ System and the Quattro® Catheter in addition to receiving standard of care treatment for cardiogenic shock.
2915496|NCT03141242|Active Comparator|ENACT Group Visit|Participants will engage in two 2-hour group visits related to advance care planning, including printed advance care planning resources.
2915497|NCT03141242|Placebo Comparator|Mailed Resources|Participants will receive printed advance care planning resources by mail.
2915498|NCT03141229|Experimental|Intervention|One school semester MBSR training for teacher; followed by one school semester mindfulness training for children and one school semester follow-up period.
2915499|NCT03141229|Other|Waitlist|One school semester waitlist; followed by one school semester MBSR training for teacher and one school semester MBSR training for children.
2915500|NCT03141216|Experimental|VCV+PSV|volume controlled cycled, assisted-controlled cycled ventilation mode + pressure support ventilation mode. Progression of invasive ventilatory assistance as the patient recovers during post-surgery.
2915501|NCT03141216|Experimental|PCV+PSV|pressure controlled cycled, assisted-controlled cycled ventilation mode + pressure support ventilation mode. Progression of invasive ventilatory assistance as the patient recovers during post-surgery.
2915502|NCT03141203|Experimental|Dose Level 1|"8mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/36mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
2915503|NCT03141203|Experimental|Dose Level 2 (starting dose)|"10mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/36mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
2915504|NCT03141203|Experimental|Dose Level 3|"10mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/45mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
2915505|NCT03141203|Experimental|Dose Level 4|"12mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/45mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
2915667|NCT03140228|Active Comparator|LMA ambu auraonce group|LMA ambu auraonce will be used for maintenance of airway during general anaesthesia
2915506|NCT03141203|Experimental|Dose Level 5|"12mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/56mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
2915507|NCT03141203|Experimental|Dose Level 6|"14mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/56mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
2915508|NCT03141190|Experimental|Mental Training for Surgeons|Mindfulness-Based Stress Reduction (MBSR, as published elsewhere extensively) slightly modified by shortening the eight weekly classes to 2 hours each and the home practice requirement to 20 minutes. Taught by a veteran MBSR teacher with greater than 10,000 hours of personal practice and nearly 10 years of formal MBSR teaching experience.
2915509|NCT03141190|Active Comparator|The Mind of a Surgeon|8 weekly classes of 2 hours each with group reading and discussion of selected articles and stories about the ethos and experience of becoming a surgeon. Designed and administered by a surgical faculty member with extensive experience in surgical education and scholarly work in the area of the 'surgical personality'.
2915510|NCT03141177|Experimental|Doublet|Nivolumab and Cabozantinib
2915511|NCT03141177|Active Comparator|Monotherapy|Sunitinib
2915512|NCT03141177|Experimental|Triplet|"Nivolumab, Ipilimumab, Cabozantinib~*Enrollment to the triplet arm was discontinued by protocol amendment"
2915513|NCT03141164|Experimental|Training|Computerized vision training
2915514|NCT03141164|Sham Comparator|Control|Sham
2915515|NCT03141151|Experimental|COACH: Healthy Bodies|This will be a staged intensity behavioral intervention. The intensive phase will last 15 weeks and consist of weekly, 90 minute, skills-building sessions. The content will focus on diet, physical activity, sleep, media use, and parenting. Behavior change techniques will include goal-setting, self-monitoring, and problem solving. Following the intensive phase, participants will enter a maintenance phase, consisting of monthly phone calls from a health coach for 3 months.
2915516|NCT03141151|Active Comparator|COACH: Strong minds|This will be a school-readiness intervention for the 3-5 year old children involved, which will meet twice a month for 3 months. Group sessions will focus on building social support around literacy skills for parents and children, as well as school advocacy.
2915517|NCT03141138|Experimental|Group 1: TDENV-PIV on Day 0|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
2915518|NCT03141138|Experimental|Group 1: TDENV-LAV F17 on Day 180|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
2915519|NCT03141138|Experimental|Group 2: TDENV-PIV on Day 0|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
2915520|NCT03141138|Experimental|Group 2:TDENV-LAV F17 on Day 90|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
2915521|NCT03141125|Experimental|Physalis angulata ethanol extract|"Physalis angulata ethanol extract was given with dosage 3 x 250 mg/day, orally, for 3 months.~In addition, patients also received standard therapy for scleroderma."
2915522|NCT03141125|Placebo Comparator|Placebo|Patients received standard therapy and placebo (amylum powder) for comparator at dosage 3 x 250 mg/day, orally, for 3 months.
2915523|NCT03141112||early CRRT initiation|Patients in ICU with severe sepsis, both gender, adult, over 18 years od age. Initiation of renal replacement therapy up to 48 hours after reaching criteria of severe sepsis.
2915524|NCT03141112||late CRRT initiation|Patients in ICU with severe sepsis, both gender, adult, over 18 years od age. Initiation of renal replacement therapy after 48 hours after reaching criteria of severe sepsis.
2915525|NCT03141099|Active Comparator|Low normal MAP and low normal PaO2|MAP 63 mmHg and PaO2 9-10 kPa during targeted temperature management (36 hours) after OHCA.
2915526|NCT03141099|Active Comparator|High normal MAP and low normal PaO2|MAP 77 mmHg and PaO2 9-10 kPa during targeted temperature management (36 hours) after OHCA.
2915527|NCT03141099|Active Comparator|Low normal MAP and high normal PaO2|MAP 63 mmHg and PaO2 13-14 kPa during targeted temperature management (36 hours) after OHCA.
2915528|NCT03141099|Active Comparator|High normal MAP and high normal PaO2|MAP 77 mmHg and PaO2 13-14 kPa during targeted temperature management (36 hours) after OHCA.
2915529|NCT03141086|Experimental|Group 1|LML134, then placebo
2915530|NCT03141086|Experimental|Group 2|Placebo, then LML134
2915531|NCT03141073|Experimental|HMS5552|75mg BID
2915532|NCT03141073|Placebo Comparator|Placebos|BID
2915533|NCT03141060|Experimental|Arm 1: Delamanid|Participants will receive delamanid (DLM) twice daily for 24 weeks. Participants will also receive non-study prescribed OBR for MDR-TB.
2915534|NCT03141047|Experimental|Lifespan Integration|This arm is given one session of Lifespan Integration. Differences on Impact of Event Scale from the first measurement at inclusion and the second measurement 20 +/- 3 days after the first measurement, and after treatment, is analyzed and compared with the results from the Group on waiting list. A third measurement and comparison is being made 6 months +/- 6 weeks after the first measurement at inclusion.
2915535|NCT03141047|No Intervention|Waiting list|This arm gets no treatment, and differences on Impact of Event Scale from the first measurement at inclusion at the second measurement 20 +/- 3 days after, without treatment, is analyzed and compared with the results from the treatment Group. A third measurement and comparison is being made 6 months +/- 6 week after the first measurement at inclusion.
2915536|NCT03141034|Experimental|Irinotecan plus ramucirumab|-Patients will receive ramucirumab intravenously on an outpatient basis at a dose of 8 mg/kg over the course of 60 minutes on Day 1 of each 14-day cycle. They will then receive irinotecan intravenously at a dose of 180 mg/m2 over the course of 90 minutes on Day 1 of each 14-day cycle.
2915668|NCT03140215|Active Comparator|Baska Device ventilation group|Device: laryngeal mask insertion (Baska)
2915538|NCT03141008||NAFLD diet exposed group|"Fibroscan changes with different diets:~Patients in a NAFLD clinic using low calorie, low fat diet. Will compare differences in Fibroscan and metabolic changes."
2915539|NCT03140995|Active Comparator|Exercise Intervention|The walking programme will consist of a total of 21 aerobic walking sessions, with 1 per week being supervised by a trained physiotherapist, spread over a maximum of eight weeks (2-3 times/week). During the first 4 weeks the intention is to increase frequency and the final 4 weeks the intensity, using the Borg Rate of Perceived exertion 6-20 or distance from 2km to 6km. The participants will attend the University of Limerick for a final assessment at week 9.
2915540|NCT03140995|No Intervention|Control Group|The control group will be given verbal and written instructions regarding the benefits of exercise in RA.
2915541|NCT03140982|Active Comparator|GR fast induction|propofol TCI effect site mode infusion using the PK Marsh model ke0 1,21 min-1 target 5.4 ug/ml (LOC EC95) util loss of consciousness (LOC) After LOC we maintain initial target during 10 min without intervention, except respiratory support if required.
2915542|NCT03140982|Active Comparator|GL slow induction|propofol infused at 10 mg/kg/h with CeCALC PK Marsh model ke0 1,21 min-1 same PK model After LOC we maintain the CeCALC observed al LOC during 10 min without intervention, except respiratory support if it was required.
2915543|NCT03140969|Experimental|QR-110|Administered every 3 months
2915544|NCT03140956|Experimental|Levodopa formulation D|Levodopa formulation D
2915545|NCT03140956|Experimental|Levodopa formulation E|Levodopa formulation E
2915546|NCT03140956|Experimental|Levodopa formulation F|Levodopa formulation F
2915547|NCT03140956|Active Comparator|Sinemet IR 100/25mg|Sinemet IR 100/25MG
2915548|NCT03140956|Active Comparator|Sinemet CR 100/25mg|Sinemet IR 100/25MG
2915549|NCT03140956|Experimental|ODM-104 100mg|ODM-104 100MG
2915550|NCT03140956|Active Comparator|Carbidopa 20mg|Carbidopa 20MG
2915551|NCT03140956|Active Comparator|Carbidopa 65mg|Carbidopa 65MG
2915552|NCT03140943|Experimental|Carfilzomib, Thalidomide and Dexamethasone|
2915553|NCT03140930|Experimental|Duodenal tastants, ileal placebo|Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of placebo (tap water)
2915554|NCT03140930|Experimental|Duodenal placebo, ileal tastants|Duodenal infusion of placebo (tap water), ileal infusion of combination of tastants (sweet, bitter and umami)
2915555|NCT03140930|Experimental|Duodenal tastants, ileal tastants|Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of combination of tastants (sweet, bitter and umami)
2915556|NCT03140930|Placebo Comparator|Duodenal placebo, ileal placebo|Duodenal infusion of placebo (tap water), ileal infusion of placebo (tap water)
2915557|NCT03140904|Other|Standard weekly visits|Standard weekly visits at the outpatient therapeutic feeding center until discharge
2915558|NCT03140904|Other|Monthly visits|Monthly visits at the outpatient therapeutic feeding center with caregiver support for home-based surveillance, with visits scheduled at weeks 4, 8, 10 and 12 until discharge
2915559|NCT03140891|Experimental|NHFOV|NHFOV is used as the supporting mode after extubation
2915560|NCT03140891|Active Comparator|NCPAP|NCPAP is used as the supporting mode after extubation
2915561|NCT03140878|Experimental|LGG|Lactobacillus rhamnosous (LGG) 450 billion CFU dissolved in water
2915562|NCT03140878|Placebo Comparator|Placebo|The placebo product is the same vegetable capsule as the experimental product, identical in composition, taste and appearance but without probiotics
2915563|NCT03140865||Cognitively Normal, Normoglycemic|This group will include 75 healthyvolunteers with no apparent memory problems and no prediabetes. Participants willcomplete an assessment at enrollment and then again 3 years later. One, two and fiveyears after the first assessment, a telephone assessment will be done. A reliable study partner will need to attend at least 1 study visit per assessment.
2915564|NCT03140865||Cognitively Normal, Prediabetic|This group will include 125 volunteers with pre-diabetes. Participants should have no apparent memory problems. This group will complete an assessment at enrollment and then again 3 years later. One, two and five years after the first assessment, a telephone assessment will be done. A reliable study partner will need to attend at least 1 study visit per assessment.
2915565|NCT03140865||Mild Cognitive Impairment/Normoglycemic|This group will include 125 volunteers who have mild memory problems that are observed during cognitive testing and no prediabetes. Those enrolled in this group will complete an assessment at enrollment and then again 3 years later. One, two and five years after the first assessment, a shortened memory and medical assessment will be done. A reliable study partner will need to attend at least 1 study visit per assessment.
2915566|NCT03140865||Mild Cognitive Impairment/Prediabetic|This group will include 125 volunteers who have mild memory problems that are observed during cognitive testing and prediabetes. Participants in this group will complete an assessment at enrollment and then again 3 years later. One, two and five years after the first assessment, a shortened memory and medical assessment will be done. A reliable study partner will need to attend at least 1 study visit per assessment.
2915567|NCT03140865||Alzheimer's disease|This group will include 50 volunteers with mild stage Alzheimer's disease dementia. Participants in this group will complete an assessment at enrollment and then again 3 years later. One, two and five years after the first assessment, a shortened memory and medical assessment will be done. A reliable study partner will need to attend at least 1 study visit per assessment.
2915568|NCT03140852|Active Comparator|Treatment|Completes the Mind Over Matter; Healthy Bowels, Healthy Bladder workshop in the spring 2017.
2915569|NCT03140852|Other|Control|Completes the Mind Over Matter; Healthy Bowels, Healthy Bladder workshop in the fall 2017.
2915570|NCT03140839|Experimental|Imaginal Rescripting|"Imaginal Rescripting (IR) targets imagery-based mental representations embedded within patients negative autobiographical memories related to social anxiety. In IR, patients progress through 3 distinct phases: (1) They relive a past negative event in their imagination, (2) are guided to actively change the original memory in their imagination to create more satisfying outcomes, and (3) relive the memory again while incorporating the new information. The IR intervention will be administered in one 90 minute session."
2915611|NCT03140527|Active Comparator|SAD HV PTI-801 Active - Complete|The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
2915571|NCT03140839|Active Comparator|Imaginal Exposure|"Imaginal Exposure (IE) involves repeatedly reliving a negative autobiographical memory related to social anxiety from a first-person perspective and actively considering alternative meanings of the memory, but differs from IR in that the original memory itself is never explicitly modified in any way. The IE intervention will be administered in one 90 minute session."
2915572|NCT03140839|Placebo Comparator|Supportive Counselling|Supportive counselling (SC) provides patients with empathic support regarding a negative autobiographical memory related to social anxiety. The SC condition controls for non-specific clinical factors such as therapeutic attention and alliance. SC will be administered in one 60-90 minute session.
2915573|NCT03140826||Meropenem arm|Patients receiving meropenem to treat an infection.
2915574|NCT03140826||Pip-Tazo arm|Patients receiving piperacillin-meropenem to treat an infection.
2915575|NCT03140813|Experimental|Placebo - Low-Dose - High-Dose|Placebo AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules
2915576|NCT03140813|Experimental|Placebo - High-Dose - Low-Dose|Placebo AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules
2915577|NCT03140813|Experimental|Low-Dose - Placebo - High-Dose|AZD7325 5mg BID in gelatin capsules Placebo AZD7325 15mg BID in gelatin capsules
2915578|NCT03140813|Experimental|Low-Dose - High-Dose - Placebo|AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules Placebo
2915579|NCT03140813|Experimental|High-Dose - Low-Dose - Placebo|AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules Placebo
2915580|NCT03140813|Experimental|High-Dose - Placebo - Low-Dose|AZD7325 15mg BID in gelatin capsules Placebo AZD7325 5mg BID in gelatin capsules
2915581|NCT03140787|Experimental|Nasal Spray of Lidocaine HCL|This group will receive treatment with an application of nasal spray for anesthetization.
2915582|NCT03140787|Active Comparator|Infiltration injection of Lidocaine HCL|Each patient in this group will receive an infiltration injection for anesthetization
2915583|NCT03140774||Cohort 1: Phase 1 participants|Previously exposed to Ebola vaccine Ad26-ZEBOV and MVA-BN-Filo.
2915584|NCT03140774||Cohort 2: Received r-VSV-ZEBOV vaccine|Previously exposed to Ebola vaccine rVSV-EBOV.
2915585|NCT03140748|Other|Patients with fungal peritonitis|
2915586|NCT03140748|Other|Patients with peritonitis without yeast|
2915587|NCT03140735|Other|Control group of 150 heart disease-free individuals|
2915588|NCT03140735|Other|Patients with aortic sclerosis|
2915589|NCT03140735|Other|Patients with moderate aortic stenting (RA)|
2915590|NCT03140735|Other|Patients with Serious Aortic Retention|
2915591|NCT03140722|Experimental|vadadustat|Vadadustat daily oral dose, adjustable based on Hb level
2915592|NCT03140722|Active Comparator|epoetin alfa|Epoetin alfa, dose adjustable based on Hb level, as clinically indicated throughout the study
2915593|NCT03140709||Induced vaginal delivery|Saliva samples will be obtained both during induction and infusion, every 15 minutes after each change in dose. An estimated total of 5 saliva samples will be collected from each patient. Therefore, the last collection point (sample 5) will be during the oxytocin infusion after the 4th dose change. In addition, 2 blood samples will be collected from 5 patients - one baseline sample and another sample at same time as last saliva sample.
2915594|NCT03140709||Cesarian delivery|A total of 3 saliva samples will be collected from each patient - one at baseline preoperative, one intrapartum at least 15 min after starting the standard 250 ml/h oxytocin infusion, and one postpartum in post-anesthesia care unit (PACU) at least 15 min after starting the standard 125 ml/h oxytocin infusion. Therefore, the last collection point (sample 3) will be during the oxytocin infusion in PACU. In addition, 1 blood sample will be collected from each patient in this cohort - at same time as last saliva sample.
2915595|NCT03140696|Experimental|Chicken egg alone|A chicken egg alone will be offered for 2 days by mouth for once a day
2915596|NCT03140696|Experimental|Egg and RUSF|A chicken egg and Ready to use supplementary food (RUSF) will be offered for 2 days by mouth for once a day
2915597|NCT03140696|Experimental|Egg and breast milk|A chicken egg and Mother's breast milk will be offered for 2 days by mouth for once a day
2915598|NCT03140670|Experimental|Single Arm|
2915599|NCT03140657|Experimental|Nanocurcumin Arm|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 month.
2915600|NCT03140657|Placebo Comparator|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 month
2915601|NCT03140644|Experimental|Patients with thoracic sarcoidosis|Patients routinely followed-up for thoracic sarcoidosis with a CT scan indicated in the follow-up
2915602|NCT03140631|No Intervention|Control|Patients in the control arm will undergo routine post-procedure management prior to removal of vascular sheaths. This includes routine measurements of ACT beginning 90 min after the cessation of the procedure with a goal ACT of <200s or return to pre-procedural baseline prior to sheath removal.
2915603|NCT03140631|Active Comparator|Protamine|Patients in the active comparator arm will receive protamine sulfate for rapid reversal of heparin prior to sheath removal. They will first receive a small test dose with close hemodynamic monitoring followed by therapeutic dose if no reaction occurs.ACT levels will then be monitored with a goal ACT of <200s or return to preprocedural baseline prior to removal of vascular sheaths.
2915604|NCT03140618|Experimental|LEPPIC|The light and environment project in psychiatric inpatient care
2915605|NCT03140566|Experimental|Clinical assessment plus IVC diameter|Decongesting treatment guided by clinical assessment and ultrasound evaluation of the inferior vena cava diameter
2915606|NCT03140566|Sham Comparator|Clinical assessment only|Decongesting treatment guided by clinical assessment alone
2915607|NCT03140553|Experimental|TCH|docetaxel/carboplatin/trastuzumab
2915608|NCT03140553|Active Comparator|EC-TH|epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab
2915609|NCT03140540|Active Comparator|Group A (stroke volume variation) guided fluid|Stroke volume variation guided intraoperative intravenous fluid will be administered.
2915610|NCT03140540|Active Comparator|Group B(Study group) TEE guided fluid|Transesophageal echocardiography will be used to guide the fluid therapy.
2915662|NCT03140254|Active Comparator|comparator|Chlorhexidine gluconate
2915663|NCT03140254|Experimental|experimental|BDIP-0001
2915664|NCT03140254|Placebo Comparator|placebo|Vehicle
2915612|NCT03140527|Placebo Comparator|SAD HV PTI-801 Placebo - Complete|The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
2915613|NCT03140527|Active Comparator|MAD HV PTI-801 Active - Complete|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
2915614|NCT03140527|Placebo Comparator|MAD HV PTI-801 Placebo - Complete|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
2915615|NCT03140527|Active Comparator|FE HV PTI-801 Active - Complete|Following the conclusion of SAD groups and after sufficient review of study data and approval by the SRC, a third set of healthy adult subjects will participate in the Food Effect cohort. Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
2915616|NCT03140527|Active Comparator|DDI HV PTI-801 Active - Complete|Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
2915617|NCT03140527|Placebo Comparator|DDI HV PTI-801 Placebo - Complete|Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
2915618|NCT03140527|Active Comparator|MAD CF PTI-801 Active|Following conclusion of the complementary HV MAD cohort in Part 1 and after sufficient review of study data and approval by the SRC, a set of adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
2915619|NCT03140527|Placebo Comparator|MAD CF PTI-801 Placebo|Following conclusion of the complementary HV MAD cohort in Part 1 and after sufficient review of study data and approval by the SRC, a set of adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
2915620|NCT03140527|Active Comparator|Cohort 4 CF PTI-801 Active co-admin with PTI-808 Active|Following conclusion of CF MAD Cohort 1 in Part 2 and after sufficient review of study data and approval by the SRC, a set of adult subjects diagnosed with CF not currently receiving or have received a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD for a total of 14 days. A follow up visit will occur on Day 21.
2915621|NCT03140527|Placebo Comparator|Cohort 4 CF PTI-801 Placebo co-admin with PTI-808 Placebo|Following conclusion of CF MAD Cohort 1 in Part 2 and after sufficient review of study data and approval by the SRC, a set of adult subjects diagnosed with CF not currently receiving or have received a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD for a total of 14 days. A follow up visit will occur on Day 21.
2915622|NCT03140514|Experimental|Intervention|Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant. Sustained elevated levels will trigger performance of a renal allograft biopsy. Any rejection will be treated. Rejection treatment according to clinical standard-of-care
2915623|NCT03140514|No Intervention|Control|Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant, but the values are concealed.
2915624|NCT03140501|Experimental|Immediate Intervention|"Participants randomized to this group will receive the intervention, the mobile application (app), immediately after baseline data are collected."
2915625|NCT03140501|Other|Delayed intervention|"Participants randomized to this group will receive the intervention, the mobile application (app), after a three month delay."
2915626|NCT03140488|No Intervention|Lean-Control|"1) Control group: Lean cohort: BMI ≤25, at <20 weeks gestation or BMI ≤28 at a term gestation, low dose oxytocin protocol~Low dose oxytocin regimen (the standard at Banner University Labor and Delivery, as well as across the United States): 30 units in 500cc 0.9% normal saline bag (60 milliunit/cc). Starting rate would be 2 milliunit/minute, or 2cc/hour. The medication will be increased by 2 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 20 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
2915627|NCT03140488|Experimental|Lean-Intervention|"2) Intervention group: Lean cohort: BMI ≤25, at <20 weeks gestation or BMI ≤28 at a term gestation, high dose oxytocin protocol~High dose oxytocin regimen (endorsed by American College of Obstetricians and Gynecologists): 90 units in 500cc 0.9% normal saline bag (180 milliunit/cc). Starting rate would be 6 milliunit/minute, or 2cc/hour. The medication will be increased by 6 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 60 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
2915665|NCT03140241|Experimental|PDR measurement|Two measurements of PDR perioperatively before and after opioid administration
2915628|NCT03140488|No Intervention|Obese-Control|"3) Control group: Obese cohort: BMI ≥30, at <20 weeks gestation or BMI ≥35 at a term gestation, low dose oxytocin protocol~Low dose oxytocin regimen (the standard at Banner University Labor and Delivery, as well as across the United States): 30 units in 500cc 0.9% normal saline bag (60 milliunit/cc). Starting rate would be 2 milliunit/minute, or 2cc/hour. The medication will be increased by 2 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 20 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
2915629|NCT03140488|Experimental|Obese-Intervention|"4) Intervention group: Obese cohort: BMI ≥30, at <20 weeks gestation or BMI ≥35 at a term gestation, high dose oxytocin protocol~High dose oxytocin regimen (endorsed by American College of Obstetricians and Gynecologists): 90 units in 500cc 0.9% normal saline bag (180 milliunit/cc). Starting rate would be 6 milliunit/minute, or 2cc/hour. The medication will be increased by 6 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 60 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
2915630|NCT03140475||Individuals with schizophrenia|"Behavioral variables:~Type 1 task (motion discrimination) accuracy (binary: correct/incorrect) / Type 1 reaction time (continuous: time to respond to the type 1 task in ms) / Confidence (continuous: visual analog scale) / Type 2 reaction time (continuous: time to report confidence in ms) / Mouse trajectory (pixel coordinates)~Physiological variables:~Electroencephalogram (continuous: 64ch. time-locked to type 1 response) / Heart rate (continuous: time-locked to type 1 response) / Galvanic skin response (continuous: time-locked to type 1 response)~Clinical variables:~Positive and Negative Syndrome Scale / Birchwood Insight Scale / Beck Cognitive Insight Scale / Personal and Social Performance Scale / Calgary Depression Scale / Chlorpromazine equivalents~Neuropsychological variables:~National Adult Reading Test (French) / Wechsler Adult Intelligence Scale version IV (WAIS-IV) subtests (matrix reasoning, vocabulary, letter-number sequencing)"
2915631|NCT03140475||Controls|"Behavioral variables:~Type 1 task (motion discrimination) accuracy (binary: correct/incorrect) / Type 1 reaction time (continuous: time to respond to the type 1 task in ms) / Confidence (continuous: visual analog scale) / Type 2 reaction time (continuous: time to report confidence in ms) / Mouse trajectory (pixel coordinates) /~Physiological variables:~Electroencephalogram (continuous: 64ch. time-locked to type 1 response) / Heart rate (continuous: time-locked to type 1 response) / Galvanic skin response (continuous: time-locked to type 1 response) /~Clinical variables:~Calgary Depression Scale~Neuropsychological variables:~National Adult Reading Test (French) / WAIS-IV subtests (matrix reasoning, vocabulary, letter-number sequencing)"
2915632|NCT03140462||liver transplant patients and donors|To study clinical and genetic factors on tacrolimus dose normalized trough concentration.
2915633|NCT03140449|Experimental|Rapamycin|Rapamycin(0.1%)
2915634|NCT03140449|Experimental|Calcitriol|Calcitriol(3mcg/g)
2915635|NCT03140449|Experimental|Rapamycin-calcitriol combination|Rapamycin(0.1%) with Calcitriol(3mcg/g)
2915636|NCT03140436|Experimental|sodium bicarbonate powders (65 µm)|sodium bicarbonate powders with grain size 65 µm
2915637|NCT03140436|Experimental|sodium bicarbonate powders (40 µm)|sodium bicarbonate powders with grain size 40 µm
2915638|NCT03140423|Active Comparator|Arm 1: Routine Care (Mupirocin/CHG)|ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing
2915639|NCT03140423|Active Comparator|Arm 2: Iodophor/CHG Decolonization|ICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing
2915640|NCT03140410||Linezolid-resistant S. epidermidis|Patients affected by blood stream infections caused by meticillin-resistant S.epidermidis strains, tested resistant to linezolid
2915641|NCT03140410||Linezolid-susceptible S.epidermidis|Patients affected by blood stream infections caused by meticillin-resistant S.epidemridis strains, tested susceptible to linezolid
2915642|NCT03140397|Placebo Comparator|Placebo|Capsules filled with mannitol and silicon dioxide
2915643|NCT03140397|Experimental|6-prenylnaringenin|500 mg 6-PN plus mannitol and silicon dioxide
2915644|NCT03140397|Experimental|8-prenylnaringenin|500 mg 8-PN plus mannitol and silicon dioxide
2915645|NCT03140384|Active Comparator|Administration of oral Misoprostol|
2915646|NCT03140384|Active Comparator|Administration of Misoprostol vaginally|
2915647|NCT03140384|Active Comparator|Administration of buccal Misoprostol|
2915648|NCT03140371|Experimental|High energy high protein peptide feed|"This is a one-arm study. Each patient recruited onto the study will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.~The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) ."
2915649|NCT03140358|Active Comparator|Premyopia atropine|On Atropine 0.01%
2915650|NCT03140358|Placebo Comparator|Premyopia placebo|On placebo
2915651|NCT03140358|Active Comparator|Low myopia atropine|On Atropine 0.01% daily or every other day
2915652|NCT03140358|Placebo Comparator|Low myopia placebo|On placebo
2915653|NCT03140332|Other|Patient with CHC|
2915654|NCT03140319|Experimental|Fibroblast|Injection of Fibroblast
2915655|NCT03140319|Placebo Comparator|Placebo|the patient receive placebo injection
2915656|NCT03140306|Experimental|Low dose CT abdomen and pelvis|Low dose computed tomography
2915657|NCT03140306|Experimental|Control dose CT abdomen and pelvis|Control dose CT abdomen and pelvis
2915658|NCT03140293|Active Comparator|Lidocaine Injection|Injection of lidocaine which is given prior to chorionic villus sampling
2915659|NCT03140293|Experimental|Gebauer Ethyl Chloride Spray|Topical anesthesia will be Gebauer Ethyl Chloride sprayed continuously from 3 - 7 seconds from a distance of 3-9 inches until the skin turns white (not frosting the skin) as per Gebauer package insert instructions.
2915660|NCT03140280|Experimental|Dietary Intervention|Freeze-dried black raspberry powder administration.
2915661|NCT03140267|Experimental|Difficult to wean patients|Maximal Inspiratory Pressure and Peak Pressure from the inclusion day to the extubation day will be measure.
2915669|NCT03140215|Active Comparator|I-Gel device ventilation group|Device: laryngeal mask insertion ( I-gel )
2915670|NCT03140202|Experimental|Guide then blind|This group use the CPRmeter visual feedback during cardiopulmonary resuscitation (screen visible) first, then have no access to the CPRmeter visual feedback during cardiopulmonary resuscitation (screen mask).
2915671|NCT03140202|Experimental|Blind then guide|This group have no access to the CPRmeter visual feedback during cardiopulmonary resuscitation (screen mask) first then use the CPRmeter visual feedback during cardiopulmonary resuscitation (screen visible).
2915672|NCT03140163|Experimental|Subjects suffering from pneumonia|CXR ULD-CT
2915673|NCT03140150|Experimental|Active Group|A single visit 1 to 3 months after implantation then followed by the attending cardiologist.
2915674|NCT03140150|Other|Control Group|A first visit 1 to 3 months after implantation and then every 6 months or every year according to the recommendations of pacemaker follow-up (ie 2 or 4 systematic visits during the follow-up of 2 years).
2915675|NCT03140124|Other|Group 1|First session: worry stone, second session: exercise peddler
2915676|NCT03140124|Other|Group 2|First session: exercise peddler, second session: worry stone
2915677|NCT03140111|Other|Treatment A, followed by Treatment B|Treatment group that will receive Treatment A for 28 days, followed by Treatment B for 28 days. There will be a minimum 7 day washout between Treatments. LAMELLEYE Dry Eye Drops and OPTIVE FUSION will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
2915678|NCT03140111|Other|Treatment B, followed by Treatment A|Treatment group that will receive Treatment B for 28 days, followed by Treatment A for 28 days. There will be a minimum 7 day washout between Treatments. LAMELLEYE Dry Eye Drops and OPTIVE FUSION will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
2915679|NCT03140085|Active Comparator|Anbiotica|
2915680|NCT03140085|Active Comparator|Bacteriophages|
2915681|NCT03140085|Placebo Comparator|Placebo|
2915682|NCT03140072|Experimental|AZD9898|In Part 1 of the study, 5 single dose cohorts are planned to be evaluated, where AZD9898 will be administered. Eight subjects will participate in each cohort. Within each cohort, 6 (alternatively 8 or 10) subjects will be randomized to receive a single dose of AZD9898. Fifteen asthma patients are planned to participate in 3 cohorts in Part 2. Five patients will participate in each cohort. Within each cohort, 4 (alternatively 6 or 8) patients will be randomized to receive a single dose of AZD9898. In Part 3, 3 dose cohorts are planned. Nine healthy subjects will participate in each cohort. Within each cohort, 6 (alternatively 8, 10 or 12) subjects will be randomized to receive AZD9898. The subjects taking part in one of the MAD cohorts under fasted conditions will also take part in Part 3B in order to explore the influence of food on the PK of AZD9898.
2915683|NCT03140072|Placebo Comparator|Placebo|In Part 1 of the study, 5 single dose cohorts are planned to be evaluated, where matching placebo will be administered. Eight subjects will participate in each cohort. Within each cohort, 2 (alternatively 3) subjects will be randomized to receive a single dose of matching placebo. Fifteen asthma patients are planned to participate in 3 cohorts in Part 2. Five patients will participate in each cohort. Within each cohort, one patient (alternatively 2 or 3 patients) will be randomized to receive a single dose of matching placebo. In Part 3, 3 dose cohorts are planned. Nine healthy subjects will participate in each cohort. Within each cohort, 3 (alternatively 4) subjects will be randomized to receive matching placebo.
2915684|NCT03140059|Active Comparator|Open flap debridement|In this group (n = 22), patients will receive open flap debridement will be performed to treat residual pockets.
2915685|NCT03140059|Active Comparator|Repeated application of aPDT|In this group (n=22), patients will receive 5 applications of antimicrobial photodynamic therapy after the scaling and root planing.
2915686|NCT03140046|Experimental|Corneal Topography|we will do Corneal Topography for every patient before doing photorefractive keratectomy (PRK) and also after it , to measure the change in the quality of vision and measure the change in the quality of vision
2915687|NCT03140033|Active Comparator|Misoprostol oral tablets|79 women will recieve 400 micrograms of misoprostol ( misotac) sublingually and 20 IU of oxytocin at cord clamping
2915688|NCT03140033|Placebo Comparator|Ranitidine oral tablets|79 women will recieve ranitidine oral tablets sublingually and 20 IU of oxytocin at cord clamping
2915689|NCT03140020||Clipping|Clipping of an aneurysm of the anterior communicating artery - A titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage. Patients will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after microsurgical aneurysm treatment. Furthermore the patients will undergo additional neuropsychological examinations 12 months after long-term recovery from microsurgical treatment.
2915690|NCT03140020||Coiling|Coiling of an aneurysm of the anterior communicating artery - Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage. Patients will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after endovascular aneurysm treatment. Furthermore the patients will undergo additional neuropsychological examinations 12 months after long-term recovery from endovascular treatment.
2915691|NCT03140020||Healthy Controls|Healthy controls will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after baseline examinations. Furthermore all subjects will undergo additional neuropsychological examinations 12 months after baseline examination.
2915692|NCT03140007|Other|Control arm - ERCP arm|Control arm- If a patient is randomized to the Control arm, then the procedure will consist of the following: ERC with recording of ERC-based impression of malignancy .ERC-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The biopsy forceps / brush will be selected per investigator preference. ERC-guided brushing will be performed, consisting of 10 through-and-fro passes through the target lesion. After this a biliary stent will be placed under ERC-guidance if needed. A biliary sphincterotomy will be performed as needed
2915693|NCT03140007|Active Comparator|Study arm - cholangioscopy arm|If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
2915698|NCT03139968|Experimental|Radiation absorbing drape|Conventional protection measurements. Additionally, a lead-free protective, disposable drape containing bismuth and antimony (RADPAD®) is placed onto the sterile drape on the patient between the operator and the image intensifier.
2915699|NCT03139968|Active Comparator|Dummy group|Conventional protection measurements. Additionally, a dummy, silicone, disposable drape (appearing identical to the experimental arm) is placed onto the sterile drape on the patient between the operator and the image intensifier.
2915700|NCT03139968|No Intervention|Control goup|Only conventional protection measurements.
2915701|NCT03139955||Bodytrak|This is a single group study. 8 participants will be recruited and will receive the same intervention of physiological data collection using Bodytrak.
2915702|NCT03139942|Experimental|Imaging using OPTIC probe|Single arm study to test the feasibility of a new device - the OPTIC imaging probe. All participants enrolled in the study may be imaged using optical spectral reflectance and autofluorescence imaging during their endoscopy procedure.
2915703|NCT03139916|Experimental|Bavituximab + Standard of Care Radiation + Temozolomide|"Bavituximab will be administered weekly intravenously~Temozolomide will be administered daily~Standard of Care Radiation will be administered per hospital guideline."
2915704|NCT03139890|Experimental|High-fat milkshake|
2915705|NCT03139890|Experimental|High-carbohydrate milkshake|
2915706|NCT03139890|Experimental|High-protein milkshake|
2915707|NCT03139877||HLP|"Intervention Cohorts:The intended target population is the adolescent with a BMI ≥ 95th percentile.~Healthy Lifestyles Program(HLP) will serve as the primary recruitment site for the intervention cohort. A prospective, longitudinal observational case control study will be performed. All participants will receive HLP standard of care (intensive lifestyle modification and access to Bull City Fit.) Groups: (1) HL-only, (2) HL + Low carbohydrate diet, (3) HL + weight loss medication(s) and (4) HL + Bariatric surgery.~Participants will be assigned to groups as per usual HLP clinical care, based on established standards and guidelines, expert medical provider recommendations, and family preference."
2915708|NCT03139877||Healthy Weight Siblings|Healthy weight siblings of HLP participants who meet age and BMI criteria will be offered enrollment at the time their overweight sibling is consented to provide comparative data. This group will be asked to provide a fecal and blood sample at one time point.
2915709|NCT03139877||Healthy Weight age/sex matched controls|"Healthy weight, age and gender matched patients will be recruited from the Duke Children's primary care practice Participants will be recruited at the time of their annual physical to provide comparative data.~This group will be asked to provide a fecal and blood sample at one time point."
2915710|NCT03139864|Experimental|type 1 diabetes|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
2915711|NCT03139864|Active Comparator|without type 1 diabetes|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
2915712|NCT03139851|Other|Cyclophosphamide et pembrolizumab|"The treatments received are:~cyclophosphamide (50 mg/day, daily, per os)~pembrolizumab (200 mg every 3 weeks, intravenously [IV]). On days 1, cyclophosphamide should be taken first and pembrolizumab infusion initiated within 1 hour after cyclophosphamide intake."
2915713|NCT03139838|Active Comparator|EHR-Based Intervention A|Intervention A (Prognostication) will be an EHR-based screen prompt triggered for eligible patients. The intervention will consist of no more than two questions that can be completed in two minutes or less. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
2915714|NCT03139838|Active Comparator|EHR-Based Intervention B|Intervention B (Accountable Justification) will be an EHR-based screen prompt triggered for eligible patients. The intervention will consist of no more than two questions that can be completed in two minutes or less. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
2915715|NCT03139838|Active Comparator|Combined EHR-Based Intervention (A+B)|Intervention A and B prompts will be combined and triggered for eligible patients simultaneously. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
2915716|NCT03139838|No Intervention|Pre-Intervention (Control)|There is no trial-driven approach to care. All hospitals contribute a minimum of 5 months of outcomes data prior to adopting the intervention. Pre-specified outcomes data will be electronically extracted for patients meeting eligibility criteria but there will be no attempt to influence delivery of usual care within the hospital. The length of the control phase will differ at each hospital, dependent on the sequence in which hospitals are assigned to switch to the intervention phase.
2915717|NCT03139825|Other|Adolescent with suicidal behavior and personality disorder|
2915718|NCT03139812|Other|30-day SiH CW, No Daily Irrigation|Control group subjects wore SiH lenses for 30-day CW under normal clinical practice guidelines with no daily morning irrigation of the eyes with sterile saline solution
2915719|NCT03139812|Other|30-day SiH CW, Daily Irrigation|Treatment group subjects wore SiH lenses for 30-day CW under normal clinical practice guidelines, and also irrigated the eyes with sterile saline solution every morning upon awakening
2915720|NCT03139799|Experimental|Puzzle Video Game Intervention|Group T will first receive the experimental and then the control intervention (T-C) In phase I both groups take a baseline measurement (pre-test), then group T is given the casual puzzle game task (experimental intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the the experimental intervention group T now serves as control. After phase II (16 weeks) both groups are post-tested again.
2915721|NCT03139799|Active Comparator|Tablet Newspaper Reading Intervention|Group C will first receive the the control intervention and then experimental and (C-T). In phase I both groups take a baseline measurement (pre-test), then group C is performing the newspaper reading task (control intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the control group C is given the experimental intervention (casual puzzle game task). After phase II (16 weeks) both groups are post-tested again.
2915722|NCT03139773|Experimental|Normal Weight|Received control breakfast beverage and breakfast beverage supplemented with omega-3 fatty acids.
2915723|NCT03139773|Experimental|Overweight/Obese|Received control breakfast beverage and breakfast beverage supplemented with omega-3 fatty acids.
2915724|NCT03139760|Experimental|POWERSforID|POWERSforID intervention group
2915725|NCT03139760|No Intervention|Control|Usual clinical care
2915727|NCT03139734|Other|Sacral neuromodulation|The purpose of this study is to find out if Sacral Neuromodulation is an effective treatment for pelvic pain associated with endometriosis.
2915728|NCT03139721||Primary cohort|Subjects requiring aortic or mitral valve replacement
2915729|NCT03139708|Experimental|Alphagan plus|Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.
2915730|NCT03139708|Experimental|Tropicamide and Phenylephrine plus|Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.
2915731|NCT03139708|Active Comparator|Tropicamide and Phenylephrine only|Tropicamide and Phenylephrine only arm is given one drop of each times one.
2915732|NCT03139695||Critically ill patients|High resolution ultrasound of the diaphragm and intercostal muscle
2915733|NCT03139669|Experimental|HPV home testing kit|The procedures will be recruitment of under-screened women in Health Districts 1, 2 and 3 of Southwest Virginia to complete HPV home testing using self-collection kits distributed by lay navigators. Regardless of HPV positivity, all women will be provided with information about cervical cancer screening (locations, cost, etc.), and will be encouraged to complete Pap screening by a clinician.
2915734|NCT03139656|Experimental|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
2915735|NCT03139656|Experimental|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer & Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
2915736|NCT03139656|Experimental|Combined (Values Clarification & Planning)|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When [I encounter the specified obstacle], I will do [X] and remember [values-based statement or image identified during values clarification exercise]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
2915737|NCT03139643|Experimental|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
2915738|NCT03139643|Experimental|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
2915739|NCT03139643|Placebo Comparator|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
2915740|NCT03139630||HIV-infected patients|HIV-infected adult male or female patients who are HIV treatment naive and initiate antiretroviral therapy including a protease inhibitor during the follow up period.
2915741|NCT03139630||HIV-uninfected patients|HIV-uninfected adult male or female patients.
2915742|NCT03139617|Active Comparator|Fascia Iliaca Compartment Block (FICB)|fascia iliaca compartment block is done using a blind technique with a blunt size 24 Gauge (G) needle. The technique is based upon the anatomical landmark and once located the space local anaesthetic ropivacaine 0.375% will be given based on the body weight.
2915743|NCT03139617|Experimental|3 in 1 femoral block (FNB)|Ultrasound guided femoral 3 in 1 block using insulated stimulating needle 22 Gauge (G). Ropivacaine 0.375% as per ideal body weight.
2915744|NCT03139604|Experimental|Itacitinib|Itacitinib plus corticosteroids
2915745|NCT03139604|Placebo Comparator|Placebo|Matching placebo plus corticosteroids
2915746|NCT03139591|Active Comparator|lidocaine inhalation|Lidocaine inhalation group: 1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection
2915747|NCT03139591|Active Comparator|intravenous dexamethasone|Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone
2915748|NCT03139578|Experimental|Investigational/Marketed Contact Lens|Subjects who are habitual wearers of spherical contact lenses, 18 to 55 years of age, will wear 2 sets of the Investigational Contact Lens and the Marketed Contact Lens simultaneously for approximately 45 minutes each set during a 1-Day visit.
2915775|NCT03139396|Experimental|tub shaped inlay bridge design|The tub-shaped reduction consist of an occlusal proximal inlay and prepared as the same geometry as the inlay shaped preparation, except that for the proximal box preparation which is not present in this preparation design.
2915749|NCT03139578|Active Comparator|Marketed/Investigational Contact Lens|Subjects who are habitual wearers of spherical contact lenses, 18 to 55 years of age, will wear 2 sets of the Investigational Contact Lens and the Marketed Contact Lens simultaneously for approximately 45 minutes each set during a 1-Day visit for an approximate total of 3 hours.
2915750|NCT03139565|Experimental|Fluzone High-dose Influenza Vaccine|This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
2915751|NCT03139565|Active Comparator|Standard 2016-2017 Flu vaccine|This will be the Standard 2016-2017 influenza vaccine made available by public health. It will contain 15 microgram of each strain and will be delivered in the deltoid muscle of non-dominant arm.
2915752|NCT03139552|Active Comparator|full sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
2915753|NCT03139552|Experimental|reduced sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
2915754|NCT03139552|Experimental|reduced sugar plus spice recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
2915755|NCT03139539|Active Comparator|Ioban|In this arm patients will be operated using Ioban as incisional drape.
2915756|NCT03139539|No Intervention|Control|In this arm patients will be operated using no incisional drape.
2915757|NCT03139513||Metastatic Melanoma|Participants with BRAF V600 mutation-positive unresectable or metastatic melanoma, having started treatment with cobimetinib in combination with vemurafenib as per local guidelines and/or routine clinical practice in context of TAU program, will be observed.
2915758|NCT03139500|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive single oral doses of JNJ-61803534 or placebo in the fasted or fed state.
2915759|NCT03139500|Experimental|Part 2: Multiple Ascending Dose (MAD)|Participants will receive JNJ-61803534 or placebo over a 14-day period.
2915760|NCT03139500|Experimental|Part 3: Drug-drug Interaction (DDI)|Participants will receive single oral doses of midazolam on Day 1 and Day 16 and will receive JNJ-61803534 daily from Day 3 through Day 16 for 14 days at a dose based on the data from the SAD and MAD part.
2915761|NCT03139487|Active Comparator|Low molecular weight heparin|Dalteparin, 200 IU/kg subcutaneously once daily for 4 weeks followed by 150 IU/kg once daily for 20 weeks
2915762|NCT03139487|Experimental|Direct oral anticoagulant|Rivaroxaban, 15 mg orally twice daily for 3 weeks followed by 20mg once daily for 21 weeks
2915763|NCT03139474|Active Comparator|agonist group|Triptorelin at a dose 1 milligram per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
2915764|NCT03139474|Active Comparator|antagonist group|•Multiple dose Gonadotrophin releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .
2915765|NCT03139461|Experimental|Intervention|Receives PT-REFER Capacity-building toolkit to facilitate partnership building with physical therapists
2915766|NCT03139461|No Intervention|Control|Does not receive PT-REFER Capacity-building toolkit to guide partnership building, instead conducting business as usual.
2915767|NCT03139448|Active Comparator|Oxygen via nasal cannula (Standard of Care)|The anesthesia provider will supply oxygen via nasal cannula at oxygen flow rates as per standard of care routine at Vanderbilt University Medical Center.
2915768|NCT03139448|Experimental|Oxygen via SuperNO2VA nasal mask|The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
2915769|NCT03139435|Experimental|Diagnostic (ultrasound)|Patients undergo peripheral nerve ultrasound. Patients also undergo skin biopsy.
2915770|NCT03139422|Active Comparator|Tranexamic Acid|Tranexamic Acid oral tablets 500 mg every six hour with the onset of the first day of menstrual cycle till the end of bleeding for 3 cycles
2915771|NCT03139422|Experimental|Calcium Dobesilate|Calcium Dobesilate oral tablets 500 mg (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.
2915772|NCT03139409|Active Comparator|conventonal adhesive|peak lc bond
2915773|NCT03139409|Other|Time variable|Diagnosis and follow up will be immediate ,6 months later and 1 year
2915774|NCT03139396|Active Comparator|inlay shaped inlay bridge design|The inlay shaped inlay bridge design preparation show three types of preparation, the inlay shaped, the tub shaped inlay bridge design and the proximal box shaped designs. Intracoronal preparation of the inlay retained prosthesis for the abutments (inlay shaped and tub shaped) should show the following criteria: The inlay shaped preparation should show an occlusal-proximal box preparation and to be designed with the line angles should be rounded, smooth and rounded corners, and rectangular flat floor with no beveling for the occlusal and gingival margins. The occlusal inlay preparation should have preparation depth allowed for a thickness of 2.0 mm for the material of the bridge. The occlusal reduction show 4 mm width with extension of 4 or 6 mm mesio distally for the posterior teeth.
2915776|NCT03139383|Placebo Comparator|normal saline solution|The patients received normal saline solution as a maintenance fluid during surgery in dose of 2 ml/kg/hour.
2971664|NCT02753023||acute aortic dissection|No intervention related
2915777|NCT03139383|Active Comparator|dextrose solution|The patients received dextrose solution as a maintenance fluid during surgery in dose of 2 ml/kg/hour.
2915778|NCT03139370|Experimental|MAGE-A3/A6 and HLA-DPB1*04:01 Positive Subjects|Phase 1A - dose escalation. Phase 1B - enrolled by tumor type
2915779|NCT03139357||Primary care patients|Patients ages 20-65 who score 5 or greater on the GAD-7 will be given the SF12, GAD7, medial utilization, and helpfulness questionnaires at 6 month intervals for a 2 year period.
2915780|NCT03139344|Experimental|Acute gene regulation|Adaptations in gene regulation in response to single-session low-frequency exercise or high-frequency exercise.
2915781|NCT03139344|Experimental|Training study|Adaptations in gene regulation, systemic metabolic markers, and patient-report metrics in response to training with high-frequency exercise.
2915782|NCT03139331|Experimental|Pazopanib, irinotecan, temozolomide (PAZIT)|Patients will receive daily oral pazopanib on days 1-21 in a 21-day cycle. This will be combined with fixed doses of intravenous or oral irinotecan and oral temozolomide on days 1-5. Dosing of irinotecan will be 50 mg/m2/day for IV dosing or 90 mg/m2/dose for oral dosing and oral temozolomide will be 100 mg/m2/day for dose levels at each assigned dose level. In the absence of disease progression or unacceptable toxicity, patients will receive cycles of therapy repeating every 21 days for a maximum of 12 months on study.
2915783|NCT03139318|Experimental|GRID Radiotherapy|Patients will be treated with GRID Radiotherapy
2915784|NCT03139305|Active Comparator|Glucagon Low Dose|
2915785|NCT03139305|Active Comparator|Glucagon High Dose|
2915786|NCT03139305|Placebo Comparator|Placebo|
2915787|NCT03139292|Experimental|ProSeal Laryngeal Mask Airway|Intravenous (0.02mg/kg Midazolam and 2 microgram/kg Fentanyl) and oxygen via a face mask will be administered. Two minutes later, general anesthesia will be induced using 2 mg/kg intravenous Propofol mixed with 25 mg Lidocaine Injected over 30 seconds, Mask ventilation commence and continue for at least 30 seconds until conditions are suitable for PLMA insertion
2915788|NCT03139292|Experimental|AmbuAuraGain Laryngeal Mask Airway|Intravenous (0.02mg/kg Midazolam and 2 microgram/kg Fentanyl) and oxygen via a face mask will be administered. Two minutes later, general anesthesia will be induced using 2 mg/kg intravenous Propofol mixed with 25 mg Lidocaine Injected over 30 seconds, Mask ventilation commence and continue for at least 30 seconds until conditions are suitable for AmbuAuraGain Laryngeal Mask Airway insertion
2915789|NCT03139279|Experimental|Dexmedetomidine and propofol|Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
2915790|NCT03139279|Placebo Comparator|Saline placebo and propofol|Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
2915791|NCT03139266|Experimental|UPLIFT|The Project UPLIFT intervention was designed for delivery to groups of six to eight people by telephone or Internet, though for this study the intervention will be web based only. The telephone intervention comprised eight hour-long sessions, each including check-in, instruction, skill building, and discussion, with homework between sessions. The Web intervention contains the same elements: check-in, video instruction, skill building, a discussion board, and homework between sessions. Instruction focuses on increasing knowledge about depression, cystic fibrosis (CF), cognitive behavioral therapy (CBT), and mindfulness and skills related to CBT and mindfulness.
2915792|NCT03139266|Other|Control Group|Treatment-as-usual
2915793|NCT03139253|Experimental|clarithromycin susceptible|"Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and clarithromycin.~Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI)."
2915794|NCT03139253|Experimental|metronidazole susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tinidazole.
2915795|NCT03139253|Experimental|levofloxacin susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and levofloxacin.
2915796|NCT03139253|Experimental|furazolidone susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and furazolidone.
2915797|NCT03139253|Experimental|tetracycline susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tetracycline.
2915798|NCT03139240|Experimental|Gestational age <7 weeks|Women with a gestational age <7 weeks will be randomized to oxycodone 10mg oral vs placebo
2915799|NCT03139240|Experimental|Gestational age 7-10w0d|Women with a gestational age 7-10w0d will be randomized to oxycodone 10mg oral vs placebo
2915800|NCT03139227|Experimental|Supportive Care (celery-banana bread)|Patients consume one serving of lower dose apigenin celery-banana bread daily on days 1-7, and then consume one serving of higher dose apigenin celery-banana bread on days 8-14. Patients undergo blood sample collection on day 1 prior to and 6 hours after bread ingestion, on day 8 prior to and 6 hours after ingestion of bread, and on day 15 (or endpoint). Patients also provide a baseline urine sample and then 24-hour urine samples on days 1, 7, 8, and 14.
2915801|NCT03139214|Experimental|Intervention|Parenting intervention, 7 weekly sessions, each session 2 hours in length.
2915802|NCT03139214|No Intervention|Control|3 mailings about child development and stress management.
2915803|NCT03139201|Experimental|OxyAqua|OxyAqua (olifilcon D) daily disposable
2915804|NCT03139201|Active Comparator|Si-Hy|Si-Hy (olifilcon B) daily disposable
2915805|NCT03139175|Experimental|temporomandibular disorder group|subjects with TMD and LBP symptoms undergo balance assessment with Biodex balance system
2915806|NCT03139175|Active Comparator|low back pain group|subjects only with LBP symptoms undergo balance assessment with Biodex balance system
2915807|NCT03139175|Other|Normal|subjects without temporomandibular disorder and low back pain symptoms undergo balance assessment with Biodex balance system
2915843|NCT03138798|No Intervention|Control Group|Patients will give consent in the first stage of labor. Subsequently, randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group B will not receive a Laboraide TM dental support device. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment.
2915948|NCT03138070|Experimental|Arm 1|14 days of BYL719 treatment, open label
2915808|NCT03139149|Active Comparator|Early surgery|After exclusion of indications for an emergency operation, conservative treatment is performed up to 12 hours from the moment of admission. Each patient receive blood test, blood lactate investigation, blood biochemistry, X-ray of the abdomen, ultrasound and CT on the admission. Each patient receive water-soluble contrast in 3 h after admission. In case of of clinical and radiologic signs of obstruction in 12 h after admission, surgery is performed. On the first stage of surgical treatment laparoscopic adhesiolysis is performed. If it is impossible to eliminate the cause of obstruction by laparoscopic technique laparotomy is performed.
2915809|NCT03139149|Active Comparator|Late surgery|After exclusion of indications for an emergency operation, conservative treatment is performed up to 48 hours from the moment of admission. Each patient receive blood test, blood lactate investigation, blood biochemistry, X-ray of the abdomen, ultrasound and CT on the admission. Each patient receive water-soluble contrast 3 h after admission. In case of present of obstruction and absence of contrast in colon in 36 h after intake (48 h after admission) a surgery is perform. On the first stage of surgical treatment laparoscopic adhesiolysis is performed. If it is impossible to eliminate the cause of obstruction by laparoscopic technique laparotomy is performed.
2915810|NCT03139136|Active Comparator|MBS2320|
2915811|NCT03139136|Placebo Comparator|Placebo|
2915812|NCT03139123||Patients with acute kidney injury|Intensive care unit patients with acute kidney injury. Patients under continuous renal replacement therapy and hemodynamic monitoring.
2915813|NCT03139110||Control|Patients treated in emergency departments without the presence of a mediator.
2915814|NCT03139110||Mediation|Patients treated in emergency departments with the presence of a mediator.
2915815|NCT03139097||Healthy Volunteers|Blood samples from healthy volunteers analyzed on the Quantra System.
2915816|NCT03139058|Other|prevalence of cirrhosis|Study the prevalence of cirrhosis in patients with VADS cancer
2915817|NCT03139045|Active Comparator|Venous puncture using VVV at the beginning of the procedure|
2915818|NCT03139045|Active Comparator|Venous puncture without VVV|
2915819|NCT03139032|Experimental|APD334|APD334 active treatment for 12 weeks.
2915820|NCT03139019|Experimental|Process incentives|Process incentives participants will receive incentives based on visit attendance in the YMCA DPP session. This incentive will be $ 15 for attending each session.
2915821|NCT03139019|Experimental|Outcome incentives|Outcome incentives participants will be weighed at 8 and 16 weeks after the program starts and if they have lost 2.5% of their body weight at each time point then they will receive $100 and $140 respectively.
2915822|NCT03139019|Experimental|Process and Outcome incentives|If assigned to the Process and Outcome arm participants will be informed that they can earn additional incentives for attending DPP classes and losing weight. Participants in this arm can earn $7.50 per DPP class (max 16) and $50 and $70 for achieving 2.5% weight loss at 8 and 16 weeks respectively.
2915823|NCT03139019|No Intervention|Control arm|If assigned to the Control arm participants will not be eligible for any additional incentives and will just learn the goals of the DPP program itself.
2915824|NCT03138993|Active Comparator|Patient decision aid|
2915825|NCT03138993|Sham Comparator|General sleep education|
2915826|NCT03138980|Experimental|Mobile application|
2915827|NCT03138967|Experimental|Sugammadex|"Participants to have cystoscopy with bladder tumor resection.~Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.~Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade."
2915828|NCT03138967|Active Comparator|Standard of Care - Neostigmine/Glycopyrrolate|"Participants to have cystoscopy with bladder tumor resection.~Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.~Neostigmine/Glycopyrrolate administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. Once T1 is at 10% or greater, a dose of 70 mcg/kg of Neostigmine with 14 mcg/kg Glycopyrrolate administered simultaneously over a period of one minute up to 5 mg."
2915829|NCT03138915|Experimental|Single arm study|Patients will receive CTA, HVPG measurement, and rHVPG per protocol. Intervention: Procedure: HVPG measurement
2915830|NCT03138902|Experimental|Glucose Tolerance Beverage|75 g. of a fruit punch flavored oral glucose solution
2915831|NCT03138889|Experimental|Combination of NKTR-214 + Pembrolizumab (Keytruda®)|NKTR-214 will be combined with pembrolizumab
2915832|NCT03138889|Experimental|Combination of NKTR-214 + Atezolizumab (Tecentriq®)|NKTR-214 will be combined with atezolizumab
2915833|NCT03138876|Other|EEG Cap|Single arm study, where every participant gets assessed by EEG cap and then standard EEG. Some subjects may be treated with anti-seizure medications before standard EEG, due to ethical responsibility, if clear NCSE is identified on cap EEG. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
2915834|NCT03138863|Experimental|Fetuses with Left CDH|Performance of fetal endoscopic tracheal occlusion (FETO) surgery by insertion of the BALT GoldbBAL2 Detachable Balloon with the BALT catheter system.
2915835|NCT03138850|Experimental|Olympus standard bite block|Standard of care using standard bite block and nasal cannula
2915836|NCT03138850|Experimental|YX Mandibular advancement bite block|Mandibular advancement bite block group
2915837|NCT03138850|Experimental|Optiflow High flow nasal cannula|High flow nasal cannula group
2915838|NCT03138824|Experimental|SPIES assisted TURBT|Storz Professional Image Enhancement System (SPIES) assisted transurethral resection of bladder tumour for Non-muscle invasive bladder cancer
2915839|NCT03138824|Experimental|WLI assisted TURBT|White Light Imaging (WLI) assisted transurethral resection of bladder tumour for Non-muscle invasive bladder cancer
2915840|NCT03138811|Experimental|CSJ117|low dose, medium dose, or high dose administered as a once daily inhaled dose
2915841|NCT03138811|Placebo Comparator|Placebo|placebo comparator administered as once daily inhaled dose
2915842|NCT03138798|Experimental|Laboraide TM dental support device|Receive Laboraide
2971665|NCT02753023||chest pain|No intervention related
2915844|NCT03138785|Experimental|conventional treatment|In this arm, patients with documented fungal keratitis undergo conventional medical treatment.
2915845|NCT03138785|Active Comparator|conventional treatment +CXL|In this arm, patients with documented fungal keratitis undergo conventional medical treatment plus CXL, beginning on the first day
2915846|NCT03138772||Healthy Controls|No intervention. Only monitoring LCI
2915847|NCT03138772||Cystic Fibrosis Patients|No intervention. Only monitoring LCI
2915848|NCT03138759|Experimental|Pexidartinib then Probenecid|Participants receive Sequence AB: Treatment A (pexidartinib) first, then Treatment B (probenecid), with a washout period between them
2915849|NCT03138759|Experimental|Probenecid then Pexidartinib|Participants receive Sequence BA: Treatment B (probenecid) first, then Treatment A (pexidartinib), with a washout period between them
2915850|NCT03138746||HBO|On day 2, the participant will undergo a 2-hour hyperbaric exposure breathing 100% oxygen
2915851|NCT03138746||Hyperbaric air|On day 2, the participant will undergo a 2-hour hyperbaric exposure breathing air
2915852|NCT03138733|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500 mg
2915853|NCT03138733|Active Comparator|Daptomycin|Daptomycin 6 mg/kg, with or without Aztreonam
2915854|NCT03138720|Experimental|Open Label|All patients will receive open label medication at set dosages unless the dosage needs to be adjusted to treat an adverse event or dose toxicity.
2915855|NCT03138694||Methotrexate injection|Patients with Ectopic pregnancy treated with Methotrexate injection.
2915856|NCT03138694||Self resolution|"Patients with Ectopic pregnancy that had signs of self resolution with our Watchful waiting protocol."
2915857|NCT03138681|Placebo Comparator|Placebo|
2915858|NCT03138681|Experimental|ATP|
2915859|NCT03138681|Experimental|phosphocreatine|
2915860|NCT03138668|Experimental|Low dose Ropivacaine|Perineural injection of 8 ml of Ropivacaine 0.75% at the lateral femoral cutaneous nerve
2915861|NCT03138668|Experimental|High dose Ropivacaine|Perineural injection of 16 ml of Ropivacaine 0.75% at the lateral femoral cutaneous nerve.
2915862|NCT03138655|Experimental|Vedolizumab High dose group|Participants with UC or CD having baseline weight of >=30 kilogram (kg) will receive Vedolizumab 300 milligram (mg) and participants with UC or CD having baseline weight of 10 kg to less than (<) 30 kg will receive Vedolizumab 200 mg, intravenous (IV) infusion, on Day 1, Weeks 2, 6 and 14.
2915863|NCT03138655|Experimental|Vedolizumab Low dose group|Participants with UC or CD having baseline weight of >=30 kg will receive Vedolizumab 150 mg and participants with UC or CD having baseline weight of 10 kg to <30 kg will receive Vedolizumab 100 mg, IV infusion, on Day 1 and Weeks 2, 6 and 14. Participants assigned to the low dose group who do not achieve clinical response (based on pediatric UC/CDAI) at Week 14 will receive vedolizumab IV high dose (that is, 300 mg for participants >=30 kg baseline weight and 200 mg for participants 10 kg to <30 kg baseline weight).
2915864|NCT03138642|Experimental|RT|The patients are prescribed a EQD2of 65-70Gy to CTV1(high-risk regions including tumor bed), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT). The Prophylactic irradiation to upper neck is is decided by radiation physicians and given a EQD2 of 70-77Gy to CTVnd (clinically negative lymph nodes), 50-55Gy to CTVn2（neck nodal regions). If there is residual tumor, a EQD2 of 70-77Gy is prescribed to GTV.
2915865|NCT03138616|Experimental|vitamin D intervention group(NGR)|"normal glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~took 1600 units of vitamin D daily for nine months and meanwhile receive lifestyle intervention."
2915866|NCT03138616|No Intervention|control group(NGR)|"normal glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~only receive lifestyle intervention."
2915867|NCT03138616|Experimental|vitamin D intervention group(IGR)|"impaired glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~took 1600 units of vitamin D daily for nine months and meanwhile receive lifestyle intervention."
2915868|NCT03138616|No Intervention|control group(IGR)|"impaired glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~only receive lifestyle intervention."
2915869|NCT03138603|Experimental|Metoprolol|Patients will receive up to 3 IV doses of study drug IV metoprolol tartrate 5mg prior to extubation, and subsequently an oral doser 25mg metoprolol tartrate) in the PACU, and then oral dosing at approx. every 8 hours thereafter through postop day 3 (72 hrs).
2915870|NCT03138603|Placebo Comparator|Placebo|Patients will receive up to 3 IV doses of placebo prior to extubation, and subsequently an oral dose placebo in the PACU, and then oral dosing at approx. every 8 hours thereafter through postop day 3 (72 hrs).
2915871|NCT03138590|Experimental|Active tDCS|Active transcranial Direct Current Stimulation targeting the trigeminal nerve
2915872|NCT03138590|Sham Comparator|Sham tDCS|Sham transcranial Direct Current Stimulation targeting the trigeminal nerve
2915873|NCT03138577|Other|Dose Cohort 1|5 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine
2915874|NCT03138577|Other|Dose Cohort 2|10 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine
2915875|NCT03138577|Other|Dose Cohort 3|15 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine
2915876|NCT03138577|Other|Dose Cohort 4|20 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine
2915877|NCT03138577|Other|Dose Cohort 5|Supraclavicular Block: 25 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine
2915878|NCT03138577|Other|Dose Cohort 6|30 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine
2915879|NCT03138577|Other|Dose Cohort 7|35 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine
2915880|NCT03138577|Other|Dose Cohort 8|40 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine
2915881|NCT03138564|Experimental|SPIRIT Clinic|Patients at clinics that have been randomized to the SPIRIT arm will be given the option to participate in the intervention. SPIRIT is a two-session, 60-minute, structured psychoeducational intervention, targeting both patient and surrogate. Using a provider manual, the care provider follows six steps: 1) assessing illness presentation, 2) identifying gaps and concerns, 3) creating conditions for conceptual change, 4) introducing replacement information, 5) summarizing, and 6) setting goals and planning.
2915945|NCT03138083|Experimental|Multiple Ascending Dose|multiple ascending dose of OMO-1 (bid) in all comer patients up to a maximally tolerated or maximally feasible dose
2971666|NCT02753023||pulmonary embolism|No intervention related
2915882|NCT03138564|Active Comparator|Comparison Condition Clinic|Patients at clinics that have been randomized to the control arm will be given the option to participate as a study control. The control clinics will have delayed implementation of the SPIRIT intervention.
2915883|NCT03138551|Experimental|Mealtime PREP|"Every participant enrolled in this single-case experimental design trial with multiple replications progressed through three phases.~A: Baseline - typical mealtimes in the home.~B: Parent-Training - parents trained in Mealtime PREP (Promoting Routines of Exploration and Play) intervention.~B-prime: Family Autonomy - parents continue to deliver treatment strategies. Therapist support withdrawn."
2915884|NCT03138538|Experimental|M8891|
2915885|NCT03138525||Multiple Sclerosis|Subjects with multiple sclerosis (MS) initiating treatment with ocrelizumab
2915886|NCT03138525||Healthy|Healthy individuals serving as controls to the subjects with MS
2915887|NCT03138512|Experimental|Module A: Nivolumab + Ipilimumab|
2915888|NCT03138512|Placebo Comparator|Module B: Placebo|
2915889|NCT03138499|Experimental|Module A|Nivolumab combined with Brentuximab
2915890|NCT03138499|Experimental|Module B|Brentuximab alone
2915891|NCT03138473||Main Group|Acute Coronary Syndrome Patients With Multi-Vessel Disease. The Residual SYNTAX score (rSS) and the SYNTAX Revascularization Index (SRI) will be calculated in this group and its relationship with patient outcomes either in hospital or in 6 months to 1 year follow-up will be evaluated.
2915892|NCT03138447|Experimental|Prospective Cohort|
2915893|NCT03138447|No Intervention|Retrospective Cohort|
2915894|NCT03138434||Optimization phase|The first five patients will be included for the optimization of the MRI sequences. This is to ensure that a standard protocol will work for different sizes of AAA. These patients will only be scanned once.
2915895|NCT03138434||Study phase|"This phase will commence after the optimization phase. This phase is where we want to assess the feasibility, reproducibility and association with disease severity between MRI parameters and AAA.~These twenty patients will be scanned twice, with an interval of 1 week ± 5 days.~The study will be completed when we have 20 patients with 2 scans for each sequence, or when a maximum number of 30 patients in the study phase have been scanned."
2915896|NCT03138421|Experimental|ABX-1431 HCl|
2915897|NCT03138421|Placebo Comparator|Placebo|
2915898|NCT03138408|Experimental|SC-004|
2915899|NCT03138408|Experimental|SC-004 and ABBV-181|
2915900|NCT03138395||Experimental: Specimen Collection|Collection of peripheral blood and bone marrow samples will occur during routine care procedures. Collection of finger stick and saliva specimens will occur on the same day as the peripheral blood and bone marrow procedure, or during routine clinical procedures.
2915901|NCT03138382|Experimental|Treatment then sham|20 subjects will be randomised to first receive active vestibular nerve stimulation during indirect calorimetry. Then 2 weeks later they will return for sham stimulation during indirect calorimetry.
2915902|NCT03138382|Experimental|Sham then treatment|20 subjects will be randomised to first receive sham stimulation during indirect calorimetry. Then 2 weeks later they will return for active vestibular nerve stimulation during indirect calorimetry.
2915903|NCT03138369|Experimental|Vestibular nerve stimulation|Usage of wearable vestibular nerve stimulator that non-invasively stimulates the vestibular nerves by administering a small electrical current through the skin behind the ears. Should be worn up to one hour a day and at least 5 hours a week.
2915904|NCT03138369|Sham Comparator|Control|Usage of wearable control device that appears identical to active device. Instead of stimulating the vestibular nerves this device will discharge its battery into an internal resistor. Should be worn up to one hour a day and at least 5 hours a week.
2915905|NCT03138356|Experimental|Cohort 1 Treatment A|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (1000 mg) XR (Extended-release) FDC (Fixed-dose combination) tablet administered orally under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
2915906|NCT03138356|Experimental|Cohort 1 Treatment B|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (850 mg) XR FDC tablet, administered orally under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
2915907|NCT03138356|Active Comparator|Cohort 1 Treatment C (Reference product)|"Single-dose of Onglyza® (2.5 mg saxagliptin), Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin XR) co-administered under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
2915908|NCT03138356|Experimental|Cohort 2 Treatment D|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (1000 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
2915909|NCT03138356|Experimental|Cohort 2 Treatment E|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (850 mg) XR FDC tablet, administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
2915910|NCT03138356|Active Comparator|Cohort 2 Treatment F (Reference Product)|"Single-dose of Onglyza® (2.5 mg saxagliptin), Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin) co-administered under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
2915911|NCT03138356|Experimental|Cohort 3 Treatment G|"Single-dose dapagliflozin (5 mg) / metformin (1000 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
2915946|NCT03138083|Experimental|biopsy|paired biopsies in patients selected for MET dependent tumours at minimally biologically active doses and above
2915912|NCT03138356|Experimental|Cohort 3 Treatment H|"Single-dose dapagliflozin (5 mg) / metformin (850 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
2915913|NCT03138356|Active Comparator|Cohort 3 Treatment I (Reference Product)|"Single-dose Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin) co-administered under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
2915914|NCT03138317|Experimental|PRP|Goup 1: knee injection of Platelet Rich Plasma (PRP)
2915915|NCT03138317|Experimental|Plasma|Group 2: knee injection of Plasma
2915916|NCT03138317|Placebo Comparator|Placebo|Group 3: knee injection of placebo (saline solution)
2915917|NCT03138304|Experimental|Adventure video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
2915918|NCT03138304|Active Comparator|Educational Program|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
2915919|NCT03138291|Experimental|Somnodent|SomnoDent is a custom-made oral appliance for the treatment of mild to moderate obstructive sleep apnea. SomnoDent is worn during sleep to provide Continuous Open Airway Therapy by moving the lower jaw slightly forward. This movement tightens the soft tissue and muscles of the upper airway, which prevents obstructive apneas while sleeping.
2915920|NCT03138278|No Intervention|Usual care|ICU with ordinary care for elderly ICU survivors and their care-givers
2915921|NCT03138278|Active Comparator|Telephone support|ICU with day-time telephone support to care-givers
2915922|NCT03138265|Experimental|High intensity exercise training|HIT training protocol.
2915923|NCT03138252|Active Comparator|Cervical Ripening Balloon Alone|Multiparous women will begin cervical ripening with a cervical ripening balloon alone. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.
2915924|NCT03138252|Active Comparator|Cervical Ripening Balloon + Oxytocin|Multiparous women will begin cervical ripening with a cervical ripening balloon and simultaneous oxytocin. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.
2915925|NCT03138239|Experimental|16 patients diagnosed with HCC|"12 patients will be tested at the stage of diagnosis (staging)~4 patients who have tested at staging, will be tested again after treatment.~4 patients with treatment failure or recurrence."
2915926|NCT03138213|Experimental|3DLPD|Three dimensional laparoscopic pancreaticoduodenectomy
2915927|NCT03138213|Experimental|OPD|Open pancreaticoduodenectomy
2915928|NCT03138200|Other|Blood transfusion based on central venous oxygen saturation|
2915929|NCT03138187|No Intervention|control|without physical exercise sessions
2915930|NCT03138187|Experimental|Moderate exercise group|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
2915931|NCT03138187|Experimental|Vigorous exercise group|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
2915932|NCT03138174||Diabetes|One group consisting of diabetic subjects
2915933|NCT03138161|Experimental|Phase 1|"Phase 1: 3-6 will be treated with escalating doses of Trabectedin every 3 weeks up to 18 doses. Dose Level 1 is 1.0 mg/m2; Dose Level 2,1.2 mg/m2; Dose Level 3,1.5 mg/m2. Beginning 2 weeks after the first dose of Trabectedin, all patients will be treated with Ipilimumab at 1 mg/kg every 12 weeks up to 5 doses, and Nivolumab at 3 mg/kg every 2 weeks up to 26 doses.~Phase 2: All patients will be treated with the maximum tolerated dose of Trabectedin every 3 weeks. Beginning 2 weeks after the first dose of Trabectedin, all patients will be treated with Ipilimumab at 1 mg/kg every 12 weeks up to 5 doses, and Nivolumab at 3 mg/kg every 2 weeks up to 26 doses."
2915934|NCT03138148||Severe patient-ventilator asynchrony|Patients in whom the total percentage of time spent in asynchrony is superior to the entire cohort's 75th percentile
2915935|NCT03138148||less severe patient-ventilator asynchrony|Patients in whom the total percentage of time spent in asynchrony is inferior to the entire cohort's 75th percentile
2915936|NCT03138135|Experimental|Intervention|The Intervention group will receive the HOME Study intervention.
2915937|NCT03138135|Active Comparator|Control|The Control group will receive standard of care.
2915938|NCT03138109||grade1&2 diastolic dysfunction|lower diastolic dysfunction exposure
2915939|NCT03138109||grade 3 diastolic dysfunction|higher diastolic dysfunction exposure
2915940|NCT03138096|Experimental|Group 1|(Group 1) will be exposed to bites of five Pb(PfCS@UIS4)-infected mosquitoes
2915941|NCT03138096|Experimental|Group 2|(group 2) will be exposed to 25 Pb(PfCS@UIS4)-infected mosquito bites
2915942|NCT03138096|Experimental|Group 3|(group 3) will be exposed to 75 Pb(PfCS@UIS4)-infected mosquito bites
2915943|NCT03138096|Other|Group 4|Infectivity control group
2915944|NCT03138096|Other|Group 5|Infectivity control group
2915947|NCT03138083|Experimental|Monotherapy dose extension|Monotherapy Extension of maximal tolerable or maximal feasible dose
2915949|NCT03138044|Experimental|Combined Treatment|The Combined Treatment: patients undergo a surgical operation of ipsilateral liver lobe devascularization and four weeks later after the operation percutaneous alcohol injection sessions.
2915950|NCT03138031|Experimental|Percutaneous Ethanol Injection (PEI)|"Those participants receive percutaneous ethanol alcohol injection for the large and unresectable HCC. Absolute alcohol; weekly sessions; under close monitoring; maximum of 30 mls; no anaesthesia needed and a maximum pain score of 8 during the procedure. Postprocedure analgesia may be required."
2915951|NCT03138018|Active Comparator|Standard instruction|
2915952|NCT03138018|Experimental|Reduced threat instruction|
2915953|NCT03138005|Active Comparator|target SpO2 98-100%|Post ROSC oxygen titrated to maintain SpO2 between 98-100%
2915954|NCT03138005|Experimental|target SpO2 90-94%|Post ROSC oxygen titrated to maintain SpO2 between 90-94%
2915955|NCT03137992|Experimental|Test Product|Single dose of test product 18 mcg for double blind portion. Once daily administration of test product 18 mcg for open-label extension (device robustness).
2915956|NCT03137992|Active Comparator|Reference Product|Single dose of reference product 18 mcg
2915957|NCT03137992|Placebo Comparator|Placebo|Single dose of placebo inhalation powder
2915958|NCT03137979|Experimental|Group A: GMSCs and collagen scaffolds|Patients in group A will receive GMSCs seeded into collagen scaffolds at the local periodontal defects immediately after open flap debridement.
2915959|NCT03137979|Experimental|Group B: collagen scaffolds|Patients in group B will receive collagen scaffolds implantation at the local periodontal defects immediately after open flap debridement.
2915960|NCT03137979|Other|Group C: comparator|Patients in comparator group will only undergo an open flap debridement.
2915961|NCT03137966|Active Comparator|Deferoxamine|Patients will be randomised to treatment with Deferoxamine (n=87). Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
2915962|NCT03137966|Placebo Comparator|Placebo|Patients will be randomised to treatment with placebo (n=87). Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
2915963|NCT03137953|Experimental|Clinical and Imaging|Subjects in this arm would undergo clinical evaluation of skin involvement followed by Radiological Imaging (CT/MRI) based evaluation of the distance between the base of the tumor and the skin. Based on this distance, the skin would either be conserved or not during tumor resection.
2915964|NCT03137940|Experimental|real tDCS|one-shot of real tDCS session (1.5mA; 0.06 mA/cm2 for 20 minutes) with BrainStim Stimulator. The anode electrode is placed in a primary motor cortex (M1) of ipsilesional hemisphere (EEG 10/20 system), while cathode is placed in the supraorbital region (SO) of the contralateral hemisphere.
2915965|NCT03137940|Sham Comparator|Sham tDCS|one-shot of sham tDCS session with BrainStim Stimulator (20 minutes). The montage of the electrodes will be placed as in the experimental session i.e.the anode electrode will be placed in a primary motor cortex (M1) of ipsilesional hemisphere (EEG 10/20 system), while cathode in the supraorbital region (SO) of the contralateral hemisphere.
2915966|NCT03137927|Experimental|Group 1 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 2,5*10*8 bacteria cells (CFU)
2915967|NCT03137927|Placebo Comparator|Group 1 placebo|3 individuals will get placebo
2915968|NCT03137927|Experimental|Group 2 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 10*9 bacteria cells(CFU)
2915969|NCT03137927|Placebo Comparator|Group 2 placebo|3 individuals will get placebo
2915970|NCT03137927|Experimental|Group 3 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 4*10*9 bacteria cells(CFU)
2915971|NCT03137927|Placebo Comparator|Group 3 placebo|3 individuals will get placebo
2915972|NCT03137914|Experimental|autologous chondrocyte transplantation|Autologous transplant of chondrocytes diluted in hyaluronic acid after orthognathic surgery. The transplantation will be performed through an intra-articular injection into the TMJ (arthrocentesis).
2915973|NCT03137888|Experimental|sMRI-Guided RT with TMZ|Patients undergo spectroscopic magnetic resonance imaging-guided dose-escalated radiation therapy daily for the first 5 days of every week (Monday - Friday) over 6 weeks. Patients also receive standard of care temozolomide PO daily during radiation therapy for up to 42 days.
2915974|NCT03137875||Patient with sputum smear positive 2+|patient who will have a positive diagnostic of tuberculosis using microscopy with a 2+ grade
2915975|NCT03137875||patient smear positive scanty or 1+|patient who will have a positive diagnostic of tuberculosis using microscopy with a scanty or 1+ grade
2915976|NCT03137875||patient smear negative|patient with a negative TB microscopy result
2915977|NCT03137862|Placebo Comparator|Arm A comparator|Arm A: patients will maintain a commercially available gluten free diet and receive bread containing 3 gr of cornstarch daily for 12 weeks; these patients will serve as controls.
2915978|NCT03137862|Experimental|Arm B|"Dietary supplement: patients will be have to continue the gluten free diet supplemented with 3 gr of gluten friendly bread daily for 12 weeks."
2915979|NCT03137862|Experimental|Arm C|"Dietary supplement: patients will be have to continue the gluten free diet supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
2915980|NCT03137849|Active Comparator|Yoga Poses + Breath control|Twice a week 75 minutes video class of yoga poses routine ( including yoga bandhas with specific muscles contractions) combined with ujjayi pranayama technique as breath control
2915981|NCT03137849|Active Comparator|Yoga Poses|Twice a week 75 minutes video class of yoga poses routine ( including yoga bandhas/ specific muscles contractions)
2915982|NCT03137849|Active Comparator|Stretching Exercises + Breath control|Twice a week 75 minutes video class of stretching exercises routine combined with ujjayi pranayama technique as breath control
2915983|NCT03137849|Active Comparator|Stretching Exercises|Twice a week 75 minutes video class of stretching exercises routine
2915984|NCT03137836|Experimental|Intervention|Sit-to-stand desks (Ergotron LearnFit®) will replace standard desks. In addition, meeting with parents and teacher's training will be conducted in order to support behavior change.
2915985|NCT03137836|No Intervention|Control|Control classroom will maintain their routine in sitting desks.
2915986|NCT03137823|Other|patients|each patient will be reviewed twice - first time culture from the tonsills and the second culture from the bucal surface.
2916049|NCT03137381|Experimental|CTP-543, 4 mg|Oral tablet, dosed twice-daily
2915987|NCT03137810|Experimental|placental cord drainage|In 90 women after vaginal delivery of the baby, the placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.
2915988|NCT03137810|Active Comparator|Non placental cord drainage|In 90 women after vaginal delivery of the baby placental end of the cut umbilical cord will be kept clamped.
2915989|NCT03137784|Other|1(NVA237 50 ug/NVA237 25 ug/placebo)|Treatment sequence: NVA 237 50 ug, 25 ug and placebo
2915990|NCT03137784|Other|2(NVA237 50 ug/placebo/NVA237 25 ug)|Treatment sequence: NVA 237 50 ug, placebo and 25 ug
2915991|NCT03137784|Other|3 (NVA237 25 ug/NVA237 50 ug/placebo)|Treatment sequence: NVA237 25 ug, 50 ug and placebo
2915992|NCT03137784|Other|4 (NVA237 25 ug/placebo/NVA237 50 ug)|Treatment sequence: NVA 237 25 ug, placebo and 50 ug
2915993|NCT03137784|Other|5 (placebo/NVA237 50 ug/ NVA237 25 ug)|Treatment sequence: Placebo, NVA237 50 ug and 25 ug
2915994|NCT03137784|Other|6 (placebo/ NVA237 25 ug/NVA237 50 ug)|Treatment sequence: placebo, NVA237 25 ug and 50 ug
2915995|NCT03137771|Active Comparator|Arm 1 (maintenance chemotherapy)|Patients may receive docetaxel IV over 60 minutes on Day 1, or gemcitabine IV over 30 minutes on Days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on Day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2915996|NCT03137771|Experimental|Arm 2 (SBRT + maintenance chemotherapy)|Patients undergo SBRT over 2-4 weeks. If SBRT cannot be used to treat primary disease sites, patients also undergo IMRT or 3D-CRT over 3-5 weeks. Within 2 weeks after completion of radiation therapy, patients receive chemotherapy as in Arm 1 (docetaxel IV over 60 minutes on Day 1, or gemcitabine IV over 30 minutes on Days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on Day 1).
2915997|NCT03137758|Experimental|Level 1 (50 mg) PCUR-101|Starting Dose, 3+3 Cohort Design
2915998|NCT03137758|Experimental|Level 2 (100 mg) PCUR-101|
2915999|NCT03137758|Experimental|Level 3 (150 mg) PCUR-101|
2916000|NCT03137758|Experimental|Level 4 (200 mg) PCUR-101|
2916001|NCT03137758|Experimental|Level 5 (250 mg) PCUR-101|
2916002|NCT03137758|Experimental|Level 6 (300 mg) PCUR-101|
2916003|NCT03137745||all patients undergoing CRS with HIPEC|thromboelastography was done in 60 patients undergoing CRS with HIPEC in RGCI FROM MARCH2015- MARCH 2016
2916004|NCT03137732|Active Comparator|Surgeon-inserted|Rectus sheath catheter will be inserted under direct vision / palpation of the space at the end of the operation.
2916005|NCT03137732|Active Comparator|Anaesthetist-inserted|Rectus sheath catheter will be inserted under ultrasound guidance by the anaethetist.
2916006|NCT03137706||Ancillary-correlative (tissue stiffness analysis)|Patients undergo fresh tumor tissue collection at the time of surgery. The fresh tumor tissue samples are analyzed for tissue stiffness measurements using optical polarimeter device and cell viability using automated cell counter.
2916007|NCT03137693|Other|Change in Procedure Scheduling|Pre-Surgery SABR: Treatment with Stereotactic Ablative Body Radiation Therapy (SABR) followed by breast-conserving surgery. The usual treatment for patients with early-stage breast cancer who have breast-conserving treatment (BCT) is to receive radiotherapy AFTER surgery, targeting either the whole breast or part of the breast.
2916008|NCT03137680|No Intervention|Control Arm|No specific exercise regime for the control group. Usual hospital SOP will be adhered to
2916009|NCT03137680|Experimental|Exercise Arm|The exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of 6 weeks. This will be performed at least 6 weeks prior to the creation of the AV fistula
2916010|NCT03137667|No Intervention|Control|No school-located influenza vaccination clinic
2916011|NCT03137667|Experimental|School-located Influenza Vaccination|Children in intervention schools were offered a chance to receive influenza vaccination at a school-located influenza vaccination clinic, if their parent or legal guardian provided permission
2916012|NCT03137654|Active Comparator|Affective Training|Subjects complete baseline assessment, 3 wks of training with versions of the tasks using emotionally-laden stimuli, and a post-training assessment. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
2916013|NCT03137654|Active Comparator|Neutral Training|Subjects complete baseline assessment, 3 wks of training with versions of the tasks using neutral stimuli, and a post-training assessment. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
2916014|NCT03137654|No Intervention|Control (Non-active)|Subjects complete a baseline assessment and a secondary assessment approximately three weeks later. No active intervention is delivered. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
2916015|NCT03137641||Nurses in contact with chemotherapies|It is a nurses cohort, who administer chemotherapies or are in charge of patients treated by chemotherapie. Three urine samples are collected: first at the beginning of the workday, the second at the end of the workday, and the third, between four and ten hours after the end of the workday.
2916016|NCT03137628||patients undergoing colectomy, GA and MV|venous blood samples collected from colorectal cancer patients undergoing selective colectomy with general anesthesia(GA) and mechanical ventilation(MV) before general anethesia and the third hour after
2916017|NCT03137628||healthy controls|donated venous blood samples from healthy people undergoing physical examination but not general anesthesia or mechanical ventilation.
2916018|NCT03137615||Pituitary Surgery|"Patients having pituitary gland surgery~Inclusion criteria - Any adult patient undergoing trans-sphenoidal pituitary surgery.~Exclusion criteria - Under 16 years of age, pregnancy, uncontrolled hypertension, allergy to any local anaesthetic, patient refusal or revision pituitary surgery"
2916019|NCT03137602|Other|ATOMIC mobile app|The proposed ATOMIC intervention consists of four primary components: (a) one-on-one chats with a PA coach, (b) informational posts, (c) PA self-monitoring through an activity tracker and (d) educational modules regarding different aspects of becoming PA delivered through our MS specific PA app.
2916020|NCT03137589|No Intervention|Control|Patients of this group are routinely treated without telemedical support.
2916021|NCT03137589|Active Comparator|Telemedical support|Patients of this group are routinely treated with telemedical support.
2916022|NCT03137576|Active Comparator|Paravertebral block (PVB)|"Intraoperative pain management~Sedation~Continuous monitoring of sedation with bispectral index. Sedation is achieved with propofol 1% (target bispectral index: 50-70), plus on-demand remifentanyl (50 mcg/ml in TCI, dose target Cet 2-8 ng/ml).~Paravertebral Block~Post operative pain management~Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
2916023|NCT03137576|Experimental|Erector Spinae Plane Block (ESPB)|"Intraoperative pain management~Sedation~Continuous monitoring of sedation with bispectral index. Sedation is achieved with propofol 1% (target bispectral index: 50-70), plus on-demand remifentanyl (50 mcg/ml in TCI, dose target Cet 2-8 ng/ml).~Erector Spinae Plane Block~Post operative pain management~Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
2916024|NCT03137563||Women eligible for cervical cancer screening|French women aged 25 to 65 years living in the Department of Hérault or Aude (France), attending one of the 8 centers where the questionnaire will be distributed
2916025|NCT03137537|Experimental|Ivabradine|"Ivabradine will be administered for a total of 6 weeks~Ivabradine is taken orally twice daily~Dosage will be adjusted according to physician determination"
2916026|NCT03137537|Placebo Comparator|Placebo Oral Tablet|"Placebo will be administered for a total of 6 weeks~Placebo is taken orally twice daily~Dosage will be adjusted according to physician determination"
2916027|NCT03137524|Experimental|Hand Held Fan Therapy|
2916028|NCT03137524|No Intervention|No Intervention|
2916029|NCT03137511|Experimental|Intervention group|"General practitioners will be invited to screen for melanoma as part of their regular consultations.~The MG collects relevant clinical information~The MG takes 2 photographs of the lesion with his smartphone.~The MG sends to the dermatologist by e-mail the 2 photographs of the lesion accompanied by relevant clinical information~The MG calls the secretariat of the dermatologist to record the admissibility of the mail, to give the identity and the coordinates of the patient whose photos have just been sent and to obtain an appointment.~The dermatologist proposes an appointment to the patient."
2916030|NCT03137511|No Intervention|Control group|"General practitioners will be invited to screen for melanoma as part of their regular consultations.~General practitioners and dermatologists continue their practice in the usual way."
2916031|NCT03137498|Experimental|Lidocaine|Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes (active experimental) and normal saline 1ml intravenous push injection (placebo)
2916032|NCT03137498|Active Comparator|Ketorolac|Ketorolac 30mg (1ml) intravenous push injection (active intervention) and Normal saline 50ml IVPB over 10 minutes (placebo)
2916033|NCT03137485|Active Comparator|Conventional|Patients in this arm will have conventional lumbar discectomy operation.
2916034|NCT03137485|Active Comparator|Endoscopic|Patients in this arm will have Endoscopic lumbar discectomy operation using Easy Go system Endoscopy
2916035|NCT03137472|Experimental|Active Treatment|Participants will receive active TMS in the target area once daily for two days
2916036|NCT03137472|Sham Comparator|Sham Treatment|Participants will receive active TMS in a non-target area once daily for two days
2916037|NCT03137459|Experimental|TTM|Participants enrolled at the intervention site will receive four contacts, at baseline, two, four and six months. Each of the first three contacts consists of an integrated assessment and intervention feedback report, using an expert system.
2916038|NCT03137459|Active Comparator|Usual Care|Participants enrolled in control sites will receive four assessment contacts on the same schedule and in the same manner as the participants enrolled in intervention sites.
2916039|NCT03137446|No Intervention|Usual Care|Participants randomized to the usual care resuscitation strategy will receive an initial 30 ml/kg bolus and then IV fluids as needed and without limit as well as IV vasopressors to maintain a MAP>65, determined by the primary care team for the duration of the study.
2916040|NCT03137446|Experimental|Restrictive Care|Participants randomized to the restrictive fluid resuscitation strategy will be LIMITED to 60 ml/kg (up to 6000 ml) of IV fluids as initial resuscitation followed by administration of IV vasopressors to maintain a MAP>65 mm Hg for the first 72 hours of care. The intervention is defined as capping the total allowed IVF administered. After 72 hours the participants are eligible for IV fluids as determined by the primary care team.
2916041|NCT03137433|Experimental|Meal-Replacements|Participants will be asked to strictly follow the individually-prescribed eating regimen, which will include shakes (breakfast and lunch) and pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables per day. Daily caloric allotment will be tailored for each individual (number of shakes and frozen meals) by calculating the average daily caloric deficit necessary to achieve negative energy balance (using the metabolic rate/energy expenditure data).
2916042|NCT03137433|Experimental|Meal-Replacements Plus|Participants will be asked to strictly follow the individually-prescribed eating regimen, which will include shakes (breakfast and lunch) and pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables per day. Daily caloric allotment will be tailored for each individual (number of shakes and frozen meals) by calculating the average daily caloric deficit necessary to achieve negative energy balance (using the metabolic rate/energy expenditure data). This group will be provided additional information to go along with meal-replacements.
2916043|NCT03137420||Severely injured patients and their relatives|Severely injured patients (ISS > 16) and their relatives. Relatives are defined as on of the following: spouse/partner, son/daughter, parent, sibling, cousin.
2916044|NCT03137420||Monotrauma patients and theri relatives|Patients with isolated non-life threatening musculo-skeletal injuries and their relatives (control). Relatives are defined as on of the following: spouse/partner, son/daughter, parent, sibling, cousin.
2916045|NCT03137407|Experimental|DaxibotulinumtoxinA 240 units|Botulinum Toxins, Type A Intramuscular Injection
2916046|NCT03137407|Placebo Comparator|Placebo|Placebo Intramuscular Injection
2916047|NCT03137394||Spinal Cord Injury|Participants with SCI in the acute, in-patient rehabilitation phase.Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury;
2916048|NCT03137394||Able-bodied control|Age- and gender-matched able-bodied individuals (matched to SCI group). Control group data will be collected at baseline and at the 1-year follow-up.
2916050|NCT03137381|Experimental|CTP-543, 8 mg|Oral tablet, dosed twice-daily
2916051|NCT03137381|Experimental|Placebo|Oral tablet, dosed twice-daily
2916052|NCT03137368|Experimental|treatment group|Exemestane Tablets combined with ovarian function suppression/ablation
2916053|NCT03137368|Active Comparator|control group|Tamoxifen Tablets combined with ovarian function suppression/ablation
2916054|NCT03137355||Leigh syndrome|All people diagnosed with Leigh syndrome.
2916055|NCT03137342|Experimental|Pepped on PrEP|"Using an efficient stepped care (adaptive) model, all participants will receive three sessions of PrEP-STEPS counseling for PrEP adherence delivered by a Masters-level or above therapist. Some individuals may require a more intensive approach. These participants will receive an additional seven counseling sessions of behavioral activation with integrated cognitive behavioral therapy (CBT) designed to reduce stimulant use and promote positive behaviors."
2916056|NCT03137342|No Intervention|Standard of Care|PrEP adherence counseling from the Miriam Hospital PrEP Clinic.
2916057|NCT03137329|Other|Weight Loss Surgery (WLS) Arm|Subjects enrolled in the WLS arm will undergo WLS as part of the routine care provided by the respective WLS centers. During routine care patients typically meet with their dietician at least twice prior to WLS and are placed on a higher protein meal replacement supplement and calorie controlled diet. For weeks 1-52, the investigators will ensure that patients are receiving 1500mg of elemental calcium and 3000 IU of vitamin D based on recent best practice guidelines. In addition, participants will complete an individualized pragmatic exercise program for the first 52 weeks after surgery. Patients will begin the program after receiving clearance from their surgeon. Patients will meet with a physical therapist at BIDMC for individual sessions.
2916058|NCT03137329|Other|Lifestyle Arm|Subjects enrolled in the lifestyle group will be prescribed a balanced high protein diet (1g high quality protein/kg body weight/day) that provides an energy deficit of 500 to 750 kcal /day from their daily energy requirements[58] and prescribed a weight loss goal of 10% over the course of 6 months. Participants will meet with a trained dietician/nutritionist at the BIDMC General Clinical Research Unit. The investigators will incorporate the HMR (Health Management Resources) high protein meal replacement supplements into participants' diet regimen for the first 24 weeks. In addition, participants will complete a comparable 52-week exercise program consisting of an individualized pragmatic exercise program.
2916059|NCT03137303|Placebo Comparator|Patient Subject Usual Care|"On the day of the outpatient visit, subjects will be advised to arrive 90 minutes prior to their clinic visit. The following will be performed.~Subject demographic and contact information~Co-morbid conditions~Smoking history~Medication history from patient and also from pharmacy used by subjects~A respiratory exacerbation history in the past year~Modified Medical Research Counsel (mMRC) dyspnea scale~Quality of life measures~Subjects will be advised to go to their clinics and be managed by their PCP thereafter.~At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry and undergo the same spirometry protocol as the intervention group."
2916060|NCT03137303|Experimental|Patient-Subject Intervention|"On the day of the outpatient visit, subjects will be advised to arrive 90 minutes prior to their clinic visit in the same building as the clinic site. The following information will be collected and procedures will be performed:~Subject demographic and contact information~Co-morbid conditions~Smoking history~Medication history from patient and also from pharmacy used by subjects~A respiratory exacerbation history in the past year~Modified Medical Research Counsel (mMRC) dyspnea scale~Quality of life measures~Pre and post-bronchodilator using Albuterol (BD) spirometry"
2916061|NCT03137290|Active Comparator|Neostigmine|1 mg of Atropine (1ml) was mixed with 2.5mg of Neostigmine (1ml) and diluted into 10mls with Normal Saline 0.9% in a 10ml standard syringe.
2916062|NCT03137290|Experimental|Sugammadex sodium|100mg Sugammadex (1ml) is diluted into 10mls in a standard 10mls syringe with Normal Saline 0.9%.
2916063|NCT03137277||Olympus 190|Olympus colonoscope 190 C (intervention group), screening colonoscopy examination with the latest generation colonoscope (190 series CF or PCF colonoscopies, Olympus Corp, Hamburg, Germany).
2916064|NCT03137277||Olympus 160/165|Olympus colonoscope 165 C (control group), screening colonoscopy examination with the 160/5 generation colonoscope (Olympus Corp, Hamburg, Germany),
2916065|NCT03137264||T790M positive|Patients determined to be T790M positive on cobas tissue and/or cobas plasma testing during Part 1 may be followed for clinical outcomes in Part 2, and will be treated in accordance with standard of care, which may include osimertinib.
2916066|NCT03137264||T790M negative|Patients determined to be T790M negative during Part 1 will not be followed for clinical outcomes in Part 2.
2916067|NCT03137251|Experimental|TENS 1|"This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour.~Dose TENS 1: Biphasic asymmetric pulse, pulse width of 100 µs and a frequency of 100 Hz. The intensity is individually titrated according to the sensitivity of the parturient."
2916068|NCT03137251|Experimental|TENS 2|"This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour.~Dose TENS 2: Biphasic asymmetric pulse, pulse width of 350 µs and a variable frequency between 80 and 100Hz. The intensity is individually titrated according to the sensitivity of the parturient."
2916069|NCT03137251|Sham Comparator|Placebo TENS|This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour. However, TENS has been modified, so that it emits light and sound but does not transmit electrical current.
2916070|NCT03137238||Early_PD|People with Parkinson's disease in the early stages with low doses of antiparkinsonian medication and no motor fluctuations.
2916071|NCT03137238||Advanced_PD|People with advanced Parkinson's disease with motor fluctuations.
2916072|NCT03137238||Early_controls|Healthy participants matched for age and gender to the 'Early_PD' group.
2916073|NCT03137238||Advanced_controls|Healthy participants matched for age and gender to the 'Advanced_PD' group.
2916109|NCT03137030|Experimental|GRT7014 - 1 Tablet (Part 1)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.~(GRT7014 - Abuse Deterrend Tablet)"
2916110|NCT03137030|Experimental|GRT7014 - 10 Tablets (Part 1)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.~(GRT7014 - Abuse Deterrend Tablet)"
2916111|NCT03137030|Active Comparator|Norco - 1 Tablet (Part 1)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
2916074|NCT03137225|Experimental|Nasal Intermittent Positive Pressure Ventilation (NIPPV) Mode|"After a one hour stabilization period, during which small adjustments to the noninvasive settings can be made to clinically optimize the settings, the study will begin. A Nellcor pulse oximeter probe will be placed on an extremity to provide a continuous non-invasive downloadable measure of saturation (blood oxygen level) and heart rate. Data from the ventilator will be downloaded in real-time to a laptop.~These data will be recorded for 4 hours continuously. After that, the ventilator will be switched to the other mode (NIPPV to NAVA), at the same PEEP (positive end-expiratory pressure) and respiratory rate. One hour will be allowed to adjust the ventilator settings. Data will then be collected for 4 hours on the second ventilation mode (NAVA)"
2916075|NCT03137225|Experimental|Neurally Adjusted Ventilatory Assist (NAVA) Mode|"After a one hour stabilization period, during which small adjustments to the noninvasive settings can be made to clinically optimize the settings, the study will begin. A Nellcor pulse oximeter probe will be placed on an extremity to provide a continuous non-invasive downloadable measure of saturation (blood oxygen level) and heart rate. Data from the ventilator will be downloaded in real-time to a laptop.~These data will be recorded for 4 hours continuously. After that, the ventilator will be switched to the other mode (NAVA to NIPPV), at the same PEEP and respiratory rate. One hour will be allowed to adjust the ventilator settings. Data will then be collected for 4 hours on the second ventilation mode (NIPPV)"
2916076|NCT03137212|Experimental|A group|STEMI patients first are given thrombolysis and then transfer to PCI center to be treated by PCI 3-6 hours after thrombolysis if the thrombolysis is successful. if the thrombolysis is not successful, patients will be treated by PCI immediately.
2916077|NCT03137212|Experimental|B group|STEMI patients first are given thrombolysis and then transfer to PCI center to be treated by PCI 6-24 hours after thrombolysis if the thrombolysis is successful. if the thrombolysis is not successful, patients will be treated by PCI immediately.
2916078|NCT03137199|Experimental|Group receiving 20 million hMSCs|3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion
2916079|NCT03137199|Experimental|Group receiving 100 million hMSCs|3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion
2916080|NCT03137186|Active Comparator|Investigational arm|Metformin will be added to standard of care
2916081|NCT03137186|No Intervention|Control arm|Patients will treated according to Standard of care only
2916082|NCT03137173|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500 mg
2916083|NCT03137173|Active Comparator|Vancomycin plus Aztreonam|Vancomycin 1000 mg (or 15 mg/kg); Aztreonam 1000 mg
2916084|NCT03137160|Experimental|Ixekizumab (Taltz)|We have received funding for only a small pilot study to prove a benefit from Interleukin-17 inhibition in Pyoderma Gangranosum . Therefore, there is only one treatment arm. The primary outcome will be a comparison of week 12 to baseline regarding a two-point improvement in the Investigator Global Assessment.
2916085|NCT03137147|Other|Cognitive-Behavioral Therapy|Intervention for Sleep and Pain in Youth, a 7-session cognitive-behavioral therapy intervention for co-morbid insomnia and headache
2916086|NCT03137134|Active Comparator|Treatment A|(reference) Crizotinib cMS 300 mg in fasted state
2916087|NCT03137134|Experimental|Treatment B|(test) Crizotinib cMS 300 mg in fed state
2916088|NCT03137134|Experimental|Treatment C|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg in fasted state
2916089|NCT03137134|Experimental|Treatment D|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg with apple sauce.
2916090|NCT03137134|Experimental|Treatment E|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg with orange juice
2916091|NCT03137121|Experimental|Group 1|Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.
2916092|NCT03137121|Placebo Comparator|Group 2|Patients will receive a placebo orally for 1 to 7 days daily.
2916093|NCT03137108|Experimental|Incomplete Spinal cord injury|
2916094|NCT03137095||Breast Cancer Patient Participants|Female breast cancer patients receiving chemotherapy
2916095|NCT03137095||Healthy, age-matched, female participants|Healthy, female, age-matched participants
2916096|NCT03137082|Experimental|Guanfacine XR 3mgs/daily|"Guanfacine XR tablet by mouth every 24 hours for 12 weeks~21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)~Full dose: 3mgs/d (day 21- day 70)~2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)"
2916097|NCT03137082|Placebo Comparator|Placebo (for guanfacine)|"Guanfacine XR tablet by mouth every 24 hours for 12 weeks~21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)~Full dose: 3mgs/d (day 21- day 70)~2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)"
2916098|NCT03137069|Experimental|GDC-0853 Cohort 1|Participants will be asked to take GDC-0853 twice daily from Day 1 to 56.
2916099|NCT03137069|Placebo Comparator|Placebo Cohort 1|Participants will be asked to take matching placebo twice daily from Day 1 to 56.
2916100|NCT03137069|Experimental|GDC-0853 Cohort 2|Participants will be asked to take low or middle dose of GDC-0853 once daily or a high dose twice daily from Day 1 to 56.
2916101|NCT03137069|Placebo Comparator|Placebo Cohort 2|Participants will be asked to take matching placebo either once daily or twice daily from Day 1 to 56.
2916102|NCT03137069|Experimental|GDC-0853 Cohort 2 (high dose)|Participants will be asked to take GDC-0853 twice daily from Day 1 to 56.
2916103|NCT03137069|Placebo Comparator|Placebo Cohort 2 (high dose)|Participants will be asked to take matching placebo twice daily from Day 1 to 56.
2916104|NCT03137056|Active Comparator|Hemodialysis with Theranova|This arm is represented by the period during which the patients will undergo dialysis with the Theranova membrane.
2916105|NCT03137056|Active Comparator|Hemodialysis with FX1000|This arm is represented by the period during which the patients will undergo dialysis with the FX1000 membrane.
2916106|NCT03137056|Active Comparator|Hemodiafiltration with FX1000|This arm is represented by the period during which the patients will undergo dialysis with the FX1000 membrane.
2916107|NCT03137043||Severe Asthmatic Subjects|Subjects requiring high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic glucocorticosteroids) to prevent it from becoming 'uncontrolled' or which remains 'uncontrolled' despite the therapy.
2916108|NCT03137043||Non-Severe Asthmatic Subjects|Subjects with intermittent, persistent mild or moderate asthma.
2971667|NCT02753023||syncope|No intervention related
2916112|NCT03137030|Active Comparator|Norco - 10 Tablets (Part 1)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
2916113|NCT03137030|Experimental|GRT7014 - 5 Tablets (Optional Part 2)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.~(GRT7014 - Abuse Deterrend Tablet)"
2916114|NCT03137030|Active Comparator|Norco - 5 Tablets (Optional Part 2)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
2916115|NCT03137017|Experimental|GRT7014 fasted|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (GRT7014 - Abuse Deterrent Tablet) under fasted conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until 4 hours after the administration of the Investigational medicinal product (IMP)."
2916116|NCT03137017|Experimental|GRT7014 fed|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (GRT7014 - Abuse Deterrent Tablet) under fed conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until they consume a high-calorie and high-fat breakfast the following morning.~The IMP must be administered as soon as the meal has been eaten."
2916117|NCT03137017|Active Comparator|Norco fasted|"Norco fixed dose combination Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet) under fasted conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until 4 hours after the administration of the IMP."
2916118|NCT03137017|Active Comparator|Norco fed|"Norco fixed dose combination Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet) under fed conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until they consume a high-calorie and high-fat breakfast the following morning.~The IMP must be administered as soon as the meal has been eaten."
2916119|NCT03137004|Experimental|biweekly DS|The biweekly DS regimen consisted of Docetaxel (50mg/m2) and S-1 (40mg/m2)
2916120|NCT03136991|Active Comparator|Cohort 1|Participants will receive AZD4831 5 mg/placebo oral suspension.
2916121|NCT03136991|Active Comparator|Cohort 2|Participants will receive AZD4831 (Additional dose 1)/placebo oral suspension.
2916122|NCT03136991|Active Comparator|Cohort 3|Participants will receive AZD4831 (Additional dose 2)/placebo oral suspension.
2916123|NCT03136991|Active Comparator|Cohort 4|Participants will receive AZD4831 (Additional dose 3)/placebo oral suspension.
2916124|NCT03136978||Endometriosis|Patients affected by endometriosis (histologically confirmed) at different stages, who will undergo laparoscopic surgery.
2916125|NCT03136978||Ovarian functional cysts|Patients affected by ovarian functional cysts, who will undergo laparoscopic surgery.
2916126|NCT03136965|Experimental|Platelet-Rich Plasma (PRP)|Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous PRP.
2916127|NCT03136965|Placebo Comparator|Dry Needling Procedure|Group 2 (dry needling) will undergo US-guided dry needling procedure similar to PRP injection.
2916128|NCT03136965|Sham Comparator|Sham Procedure|Group 3 (sham) will undergo US-guided sham dry needling procedure.
2916129|NCT03136952||Pediatric children under 1 yrs old|Observation study of two measurement points of cerebral oxygenation
2916130|NCT03136939||type 1 diabetes|
2916131|NCT03136939||type 2 diabetes|
2916132|NCT03136939||healthy people|
2916133|NCT03136913|Active Comparator|Closed Flap Technique|Healing by primary intention: Extraction and ridge preservation, utilizing non-resorbable membrane (Cytoplast® TXT-200 ) and freeze dried bone allograft (MinerOss® Cortical and Cancellous Chips (FDBA)), with flaps in primary coverage.
2916134|NCT03136913|Active Comparator|Open Flap Technique|Healing by secondary intention: Extraction and ridge preservation, utilizing non-resorbable membrane (Cytoplast® TXT-200) and freeze dried bone allograft (MinerOss® Cortical and Cancellous Chips (FDBA)), with flaps in position for healing by secondary intention.
2916135|NCT03136900|Experimental|Study Diet|Enteral diet made of Nutrilon without lactose® fortified by concentration
2916136|NCT03136900|Active Comparator|Control Diet|Enteral diet made of Nutrilon without lactose® fortified by Maltodextrin and oil supplementation.
2916137|NCT03136887||JOURNEY II XR TKA|This is a single arm study, all subjects will receive JOURNEY II XR TKA
2916138|NCT03136874||Donors who procreated|
2916139|NCT03136874||Donors who don't procreated|
2916140|NCT03136861|Experimental|AIN457|secukinumab sc injections weekly for 5 weeks followed by secukinumab sc injections every 4 weeks for the remaining 16 weeks
2916141|NCT03136861|Placebo Comparator|Placebo|placebo sc injections weekly for 5 weeks followed by secukinumab sc injections every 4 weeks for the remaining 16 weeks
2916142|NCT03136848|Experimental|Normothermic perfusion|Kidneys retrieved from deceased donors will undergo the study intervention consisting of 4-10 hours of Normothermic ex-vivo perfusion using a blood-based solution, prior to implantation in the transplant recipient
2916143|NCT03136835|Experimental|Pilot|Maternal Hyperoxygenation (4L/min via nasal prongs)
2916144|NCT03136822|Other|Control|Standard dressing
2916145|NCT03136822|Experimental|Treatment|Standard dressing + Wound dressing (DERMALIX)
2916146|NCT03136809|Experimental|Cu(II)ATSM|Cu(II)ATSM administered once daily
2916147|NCT03136783|Other|Patient with stage IV melanoma|
2916148|NCT03136770|Experimental|A|CK-30 600 mg -> red ginseng extracts 2.94 g
2916149|NCT03136770|Experimental|B|red ginseng extracts 2.94 g -> CK-30 600 mg
2916150|NCT03136744|Experimental|Sit Less with MS|The Sit Less with MS program is based on Social Cognitive Theory (SCT) and consists of strategies that will enable people with MS to 'sit less' by frequently interrupting sitting and 'move more' by replacing sitting with light-intensity activity during waking hours.
2916151|NCT03136731||Healthy family members of celiac disease|Celiac disease screening, no intervention.
2916152|NCT03136731||Celiac disease index cases|Assessment of disease related factors, no intervention.
2916153|NCT03136718||First-time hearing aid users|Individuals using hearing aids for the first-time (or if previous users, have not having worn hearing aids for more than 3 years) will have access to the mobile-enabled RLOs (mRLOs) intervention, which will be given to the participants shortly after their hearing aid is fitted.
2916248|NCT03136068|Placebo Comparator|Placebo|Subjects assigned to the control arm will receive an ultrasound-guided intrafetal saline injection of the equivalent volume
2916154|NCT03136705|Active Comparator|Lanthanum + Nicotinamide|Lanthanum Carbonate 1000mg orally three times daily with meals for 2 weeks and Nicotinamide 750mg orally twice daily for 2 weeks
2916155|NCT03136705|Active Comparator|Lanthanum + Nicotinamide Placebo|Lanthanum Carbonate 1000mg orally three times daily with meals for 2 weeks and Nicotinamide Placebo orally twice daily for 2 weeks
2916156|NCT03136705|Active Comparator|Lanthanum Placebo + Nicotinamide|Lanthanum Carbonate Placebo orally three times daily with meals for 2 weeks and Nicotinamide 750mg orally twice daily for 2 weeks
2916157|NCT03136705|Placebo Comparator|Lanthanum Placebo + Nicotinamide Placebo|Lanthanum Carbonate Placebo orally three times daily with meals for 2 weeks and Nicotinamide Placebo orally twice daily for 2 weeks
2916158|NCT03136679||Group 1 Normal|Spouse or Subject's caregiver. Blood and urine samples will be collected.
2916159|NCT03136679||Mild Cognitive Impairment|Subjects with MCI: Blood and urine samples will be collected.
2916160|NCT03136679||Alzheimer's disease|Subjects with Alzheimer's disease A. Mild B. Moderate C. Severe Blood and urine samples will be collected from these three sub-groups.
2916161|NCT03136666|Experimental|Nifedipine + Candesartan cilexetil|Coadministration of single doses of nifedipine and candesartan tablets
2916162|NCT03136653|Experimental|single arm study MP0250 plus BOR + DEX|single arm study of MP0250 plus bortezomib + dexamethasone
2916163|NCT03136640|Experimental|ModraDoc006/r|Weekly ModraDoc006/r treatment as ModraDoc006 (oral docetaxel) 10mg tablets combined with ritonavir 100mg tablets
2916164|NCT03136627|Experimental|Tivozanib (AV-951) plus Nivolumab|Tivozanib plus Nivolumab:Tivozanib will be administered once daily for 3 weeks followed by 1 week off. Nivolumab will be administered every 2 weeks starting on Day 1.
2916165|NCT03136614|Active Comparator|Preoperative|A single measurement with an Arteriograph is performed a day before an elective surgical intervention.
2916166|NCT03136614|Active Comparator|Intraoperative|An arteriograph is put on the patient for the time of operation. The device is set to measure in every 5 minutes.
2916167|NCT03136614|Active Comparator|Intensive Care Unit|Three separate measurements are performed on the subject with an Arteriograph throughout every dayshift for 3 days.
2916168|NCT03136601|Active Comparator|PTNS monthly|Patients return for PTNS maintenance monthly.
2916169|NCT03136601|Experimental|PTNS as needed|Patients return for PTNS as needed (2-12 weeks).
2916170|NCT03136588|Experimental|ICT based monitoring group|Intervention: In the ICT-based centralized monitoring group, both subjects and medical staff receive feedbacks regarding a missed dose, misuse, and overuse of the medication in the form of text messages and pill box alarms.
2916171|NCT03136588|No Intervention|Control group|Use standard questionnaire to gather information for drug adherence
2916172|NCT03136575|Active Comparator|Qigong|Patients in the Qigong group receive Qigong,a mind-body exercise, 3 times a week, for 6 weeks during radiotherapy course. The participants are given a DVD contains Qigong program, and they attend the Qigong class in a health education room at the radiation oncology department to assure their attendance.
2916173|NCT03136575|Placebo Comparator|wait-list control|Patients who are assigned to the wait-list control are told to have some exercise by their own but no actually attend the the class in fact.
2916174|NCT03136562||Kidney transplanted patients|Kidney transplanted patients in prednisolone treatment. Adrenal function is assessed by a synacthen test.
2916175|NCT03136562||Control group|Patients in dialysis not in prednisolone treatment. Adrenal function is assessed by a synacthen test.
2916176|NCT03136549|Placebo Comparator|Room temperature|The nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
2916177|NCT03136549|Experimental|Thermo-softening|The naso tracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L) at warm cabinet set to 45°C (approximately 117°F).
2916178|NCT03136510|Other|Newly diagnosed NVAF: apixaban 5 mg|blood collection for biological analyses of 30 patients new diagnosis of NVAF (VKA treatment ≤1 week) initiated with apixaban 5 mg
2916179|NCT03136510|Other|Previously diagnosed NVAF: apixaban 5 mg|blood collection for biological analyses of 30 patients previously treated by VKA for more than 3 months switched to apixaban 5 mg
2916180|NCT03136497|Experimental|ABT-199 Plus Ibrutinib and Rituximab|Cycle length will be 28 days. Venetoclax will be administered orally QD (Once Daily), continuously for 24 cycles. Ibrutinib will be administered orally QD, continuously for 24 cycles. Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1), Commercially available rituximab IV will be used.
2916181|NCT03136484|Experimental|Semaglutide + canagliflozin placebo|
2916182|NCT03136484|Active Comparator|Canagliflozin + semaglutide placebo|
2916183|NCT03136471||EMR data extraction|"EMR Data extraction from the Louisiana Clinical Data Research Network (LaCDRN). The Louisiana Clinical Data Research Network (LaCDRN) data will be requested, including patients' records of pharmacy, inpatient, outpatient and lab results from January 01, 2016 to December 31, 2021. It is a retrospective data analysis without interaction with any participants. All data is de-identified and the study participants will not be contacted in any way.~Inclusion criteria: Patients with type 2 diabetes, whose age>=18 years old will be extracted from database of LaCDRN.~Exclusion criteria: Patients without type 2 diabetes or age<18 years old."
2916184|NCT03136471||Healthcare Professionals|"Healthcare professionals (physician, nurse) will be randomly selected from LaCDRN partner health system. An email will be distributed to the registered clinicians at partner health systems.~Inclusion criteria: physicians and nurses who treat diabetes patients and work at clinic settings within LaCDRN network and consent to participate the study.~Exclusion criteria: physicians and nurses who do not treat diabetes patients or not work at clinic settings within LaCDRN network; refuse to participate the study."
2916185|NCT03136471||Patients for Qualitative Study|"Patients with diabetes who are a members of Diabetes Advisory Group or partner LaCDRN health system will be contacted via email, letter or phone call.~Inclusion criteria:~Diabetes patients who consent to participate the study.~Age 65+;~Diagnosis code for diabetes in the last 2 years;~Diagnosis code for at least one additional chronic condition in the last 2 years.~Exclusion criteria: age<65; patient with diabetes without other chronic conditions."
2916290|NCT03135834|Experimental|Group 4 (ACWY Experienced subjects, rLP2086/MenACWY-CRM)|ACWY Experienced subjects, rLP2086/MenACWY-CRM
2916186|NCT03136471||LaCDRN partner health system's medical directors|Face-to-face semi-structured interviews will be used to explore organizational cultures, their social architecture, resources, capacity, communication networks, assess barriers, and refine the data collection for the assessing the RE-AIM framework. The one time interview will take 1 hour. A 10 minutes questionnaire of Diabetes care coordination readiness assessment (DCCRA) will be emailed to them annually during entire 5 years of study period.
2916187|NCT03136471||PROMIS® survey|"Patients for PROMIS® survey (National Institutes of Health's Patient-Reported Outcome Measurement Information System Global Health Measures). Patients will be administered the surveys at the point-of-care visit (in exam rooms) using REACHnet's tablet-based application.~Inclusion criteria:~All patients age 18+ who registered at REACHnet.~Able to provide informed consent~Exclusion criteria: patients who do not provide inform consent or age<18 years old."
2916188|NCT03136471||PACIC+ survey|"Patients for PACIC+ survey (Group Health Research Institute's Patient Assessment of Care for Chronic Conditions+). Patients will be administered the surveys at the point-of-care visit (in exam rooms) using REACHnet's tablet-based application.~Inclusion criteria:~All patients age 18+ with a Diabetes diagnosis and who registered at REACHnet.~Able to provide informed consent~Exclusion criteria: patients who do not provide inform consent or without diabetes diagnosis or age<18 years old"
2916189|NCT03136458|Experimental|Real ischemic preconditioning|Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 50 mmHg above the systolic arterial pressure of the patient.
2916190|NCT03136458|Active Comparator|Dummy ischemic preconditioning|Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 10 mmHg above the diastolic arterial pressure of the patient.
2916191|NCT03136445|Experimental|Intervention Arm|Tranexamic acid (TXA). Dose schedule TXA 1g every eight hours IV or 1.5g every eight hours PO.
2916192|NCT03136445|Placebo Comparator|Control Arm|Placebo (saline) if administration is IV. Placebo capsule matched for appearance to TXA if oral.
2916193|NCT03136432||Children with cerebral palsy|Children with cerebral palsy, who can walking dependently and continuously for 6 minutes.
2916194|NCT03136419|Placebo Comparator|Control|Placebo capsules bis in die for 8 weeks
2916195|NCT03136419|Experimental|Experimental|Lactobacillus casei DG capsules bis in die for 8 weeks
2916196|NCT03136406|Experimental|NANT Pancreatic Cancer Vaccine|"A combination of agents will be administered to subjects in this study:~cyclophosphamide, oxaliplatin, capecitabine, fluorouracil, leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK, GI-4000, and ETBX-011."
2916197|NCT03136393|Active Comparator|Control|Community based antenatal counselling
2916198|NCT03136393|Experimental|Intervention|Community based dietary counselling
2916199|NCT03136380|Experimental|Part 1: Group A|Subjects will receive GSK1325756H 10 mg in P-1, GSK1325756H 50 mg in P-2 and placebo in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
2916200|NCT03136380|Experimental|Part 1: Group B|Subjects will receive GSK1325756H 10 mg in P-1, placebo in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
2916201|NCT03136380|Experimental|Part 1: Group C|Subjects will receive placebo in P-1, GSK1325756H 50 mg in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
2916202|NCT03136380|Experimental|Part 2: Group D|Subjects will receive GSK1325756H 50 mg after a low fat meal and fasted state respectively. There will be a washout period of at least 7 days between each treatment period.
2916203|NCT03136380|Experimental|Part 2: Group E|Subjects will receive GSK1325756H 50 mg after a fasted state and a low fat meal respectively. There will be a washout period of at least 7 days between each treatment period.
2916204|NCT03136367|Experimental|Arm 1: Option Grid|Patients in this arm will receive the Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
2916205|NCT03136367|Experimental|Arm 2: Picture Option Grid|Patients in this arm will receive the Picture Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
2916206|NCT03136367|No Intervention|Arm 3: Usual Care|
2916207|NCT03136354|Active Comparator|ESD Group|Endoscopic Submucosal Dissection
2916208|NCT03136354|Active Comparator|LAG Group|Laparoscopic Assisted Gastrectomy
2916209|NCT03136341|Active Comparator|Abobotulinum toxin A|
2916210|NCT03136341|Placebo Comparator|Placebo|
2916211|NCT03136328|Experimental|68Ga-DOTATOC PET/CT|Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study.
2916212|NCT03136315|Experimental|INFERNAL Arm|The INFERNAL Arm will have serum and urinary dosage for creatinine and cystanin C at the beginning and at the end of the 110 km race.
2916213|NCT03136302||Subthalamic Nucleus (STN)|Patients with Parkinson's disease
2916214|NCT03136302||Globus Pallidus (Gpi)|Patients with Dystonia
2916215|NCT03136302||Ventral intermediate nucleus of the thalamus (VIM)|Patients with Tremor
2916216|NCT03136276|Active Comparator|IPS Empress CAD|Leucite Based glass Ceramics which is etchable ceramics and proved to have good success rate if used for laminate veneers
2916217|NCT03136276|Experimental|polished Celtra Duo|Zirconia reinforced lithium silicate, it is a recent material with glass ceramics enriched with 10% zirconia that offers high strength properties
2916218|NCT03136263|Experimental|Drug order: Oxytocin - placebo|
2916219|NCT03136263|Experimental|Drug order: Placebo - oxytocin|
2916220|NCT03136250|Active Comparator|Group A (Control Group - Static Stretching)|(Control Group - Static Stretching + Standard Treatment)
2916221|NCT03136250|Experimental|Group B (Autogenic Inhibition MET)|(Autogenic Inhibition - PIR + Standard treatment)
2916222|NCT03136250|Experimental|Group C (Reciprocal Inhibition MET)|(Reciprocal Inhibition - RI + Standard treatment)
2916223|NCT03136237|Experimental|Cohort 1|Day 1: Digoxin 0.25 mg oral dose Day 11-18: BCX7353 350 mg oral dose Day 19: Digoxin 0.25 mg oral dose and BCX7353 350 mg oral dose Day 20-21: BCX7353 350 mg oral dose
2916224|NCT03136237|Experimental|Cohort 2|Day 1: Rosuvastatin 10 mg oral dose Day 7-14: BCX7353 350 mg oral dose Day 15: Rosuvastatin 10 mg oral dose and BCX7353 350 mg oral dose Day 16: BCX7353 350 mg oral dose
2916225|NCT03136237|Experimental|Cohort 3|Day 1: BCX7353 350 mg oral dose Day 14: single oral dose of Cyclosporine 600 mg and BCX7353 350 mg
2916226|NCT03136224|Experimental|Thermocautery|In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medikal, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
2916227|NCT03136224|Active Comparator|Plastic Clamping|Alisklamp (Alisklamp, Abagrup Health Services Ltd, Ankara, Turkey) was used in the plastic clamp technique. The clamp size was chosen according to the diameter of the penis of the patient. The clamp was inserted into the glans and then the skin and the mucosa were pulled to the appropriate size and clamped. The skin and mucosa were excised from the distal part of the clamp with the aid of a lancet. After the operation, the clamp was removed on the 4th day
2916228|NCT03136224|Sham Comparator|Surgical Circumcision|In classical surgical circumcision, foreskin was hung up with the clamp. The outer skin and secondly the mucosa was cut by using scissors. Following the hemorrhage intervention, the skin-mucosa integrity was sutured by using the 5/0 absorbable suture. Medical dressing was done.
2916229|NCT03136211|Experimental|EIRA intervention|"EIRA intervention It is based on the Transtheoretical Model (TTM) and States of Change and it is made by physicians and nurses in routine care of primary care practices according to the conceptual framework of the 5A: Ask, Advise, Assess, Assist, and Arrange. It consists of a first visit of screening (Ask). Subsequently, the professional develops a personalized plan that is negotiated with the participant (Advise and Assess). This plan is reviewed during successive visits and positive changes are reinforced and new objectives are negotiated (Assist and Arrange). The motivational interview is the essential tool of the intervention. The intervention is carried out to different levels: individual, group and community."
2916230|NCT03136211|No Intervention|Usual care|"Health providers of this group integrate in their practice the recommendations of the Program of Preventive Activities and Health Promotion (PAPPS). These guidelines are based on systematic screening and brief advice for the prevention of cardiovascular and mental diseases and cancer as well as vaccine recommendations."
2916231|NCT03136198|Experimental|LUS-guided strategy-of-care|Patients randomized to the LUS strategy of care arm will be treated according to protocol. This protocol only involves therapies used in everyday AHF clinical practice.
2916232|NCT03136198|Placebo Comparator|Usual care|Patients randomized to the usual care arm will also undergo lung ultrasound assessments. However, these results will not be revealed to the care team. Patients will receive treatment per usual, standard care.
2916233|NCT03136185|Experimental|IMG-7289|Single starting dose with individualized dose titrations throughout
2916234|NCT03136172||Premature infant|premature infants with 32 weeks or less gestational age or 1,500 g or less birth weight, who born in the Inha university hospital and admit to the neonatal intensive care unit of the Inha university hospital
2916235|NCT03136159|Experimental|Silver-impregnated antimicrobial dressing|All participants undergoing primary cesarean section will receive a silver impregnated antimicrobial wound dressing (Mepilex Border AG), postoperative.
2916236|NCT03136146|Experimental|CEC + Liposomal Vincristine + Dexamethasone + Bortezomib|"Induction and/or Reinduction (Cycles 1-2):~Clofarabine on Days 1-5. Etoposide on Days 1-5. Cyclophosphamide on Days 1-5. Liposomal Vincristine on Days 2 and 11. Dexamethasone on Days 1-5. Bortezomib on Days 1, 4, 8, and 11. Ofatumumab or Rituximab on Days 2 and 11. Pegfilgrastim on Day 6.~Depending on how the disease responds to induction treatment, participant may receive a 2nd induction course (reinduction) or begin consolidation treatment. If reinduction required, this will be given in 1 additional cycle.~Consolidation Phase (5 Cycles: Cycles 2-6 or 3-7):~Clofarabine on Days 1-4. Etoposide on Days 1-4. Cyclophosphamide on Days 1-4. Liposomal Vincristine on Days 2 and 11. Dexamethasone on Days 1-5. Bortezomib on Days 1, 4, 8, and 11. Pegfilgrastim on Day 6. Ofatumumab or Rituximab on Days 2 and 11 of first 4 cycles of consolidation (Cycles 2-5 or 3-6)."
2916237|NCT03136133|Active Comparator|Active protein drink|Active protein drink
2916238|NCT03136133|Placebo Comparator|Placebo drink|Placebo drink
2916239|NCT03136120||Subjects with suspected fibrotic ILD|Eligible subjects will receive nebulized ipratropium bromide 500 mcg for 10 minutes. The subjects will be sedated for bronchoscopic procedure as per routine practice for subjects having bronchoscopy. Cryobiopsy samples for this study will be taken after samples required for diagnosis has been taken and it is safe to do so. One to three endobronchial forceps biopsy samples will be taken from up to 5 subjects to allow comparison of proximal and distal drug distribution.
2916240|NCT03136107|Experimental|Test product|This arm will include all the test sites on the participants back where test product (Physiogel Daily Defence Protective Day Cream Light) will be applied.
2916241|NCT03136107|Active Comparator|Reference product|This arm will include all the test sites on the participants back where reference product (ISO 24444:2010 P3 standard sunscreen) will be applied.
2916242|NCT03136107|No Intervention|Negative control|This arm will include all the test sites on the participants back which will be left unprotected.
2916243|NCT03136094|Placebo Comparator|SBIRT Usual Care|The control arm of the trial will receive the usual care prescribed in the Screening, Brief Intervention and Referral to Treatment (SBIRT) model
2916244|NCT03136094|Experimental|SBIRT+6|The standard SBIRT model is augmented by a 6 month period during which participants received caring text messages
2916245|NCT03136094|Experimental|SBIRT+12|The standard SBIRT model is augmented by a 12 month period during which participants received caring text messages
2916246|NCT03136081||Septic shock and candidiasis|"The realized analyses will be two types:~1/an immunological analysis that is the characterization of the capacities of defense against germs and 2/a search(research) of Candida by microscopic examination and culture on circles of growth but also the research for the genome of the mushroom by a state-of-the-art technique of the laboratory of mycology ( PCR). Usual takings of research for bacteria."
2916247|NCT03136068|Experimental|Digoxin|Subjects assigned to the intervention arm will receive a 1 mg intrafetal digoxin injection under ultrasound guidance
2916249|NCT03136055|Experimental|High-Grade Extrapulmonary NEC|"Part A: 200 mg of pembrolizumab will be given every three weeks via IV infusion.~Part B: 200 mg of pembrolizumab will be given every three weeks via IV infusion and, either~125 mg/m2 of irinotecan will be given via IV infusion in a two weeks on, one week off format in 3 week cycles, or~80 mg/m2 of paclitaxel will be given every week via IV infusion."
2916250|NCT03136042|Experimental|physiotherapists maneuvers|physiotherapy techniques
2916251|NCT03136042|Active Comparator|hypertonic saline 3%|four nebulizations with 3% hypertonic saline.
2916252|NCT03136042|Active Comparator|saline + physiotherapy maneuvers|1 nebulizations + physiotherapy techniques
2916253|NCT03136029|Experimental|Oral AOx|8 week oral antioxidant treatment
2916254|NCT03136029|Placebo Comparator|Oral AOx (placebo)|Placebo for arm 1
2916255|NCT03136029|Experimental|Oral BH4|8 week oral tetrahydrobiopterin treatment
2916256|NCT03136029|Placebo Comparator|Oral BH4 (placebo)|Placebo for arm 3
2916257|NCT03136029|Experimental|Ex training|8-week knee-extensor exercise training program
2916258|NCT03136029|Sham Comparator|Ex training (attn con)|Attention control for arm 5
2916259|NCT03136016|No Intervention|control|without any activity
2916260|NCT03136016|Experimental|educational activities|The students will receive educational activities in the classroom.
2916261|NCT03136016|Experimental|nudging|The students will receive changes in the school environment (nudge strategies);
2916262|NCT03136016|Experimental|nudging + educational activities|The students will receive educational activities and changes in the school environment.
2916263|NCT03136003|Experimental|Arm A: DDAVP followed by exercise|"Intervention #1: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: Exercise"
2916264|NCT03136003|Active Comparator|Arm B: DDAVP alone|"Intervention #1: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: no further intervention (rest)"
2916265|NCT03136003|Experimental|Arm C: Exercise alone|"Intervention #1: Exercise~Intervention #2: no further intervention (rest)"
2916266|NCT03136003|Experimental|ARM D: Exercise followed by DDAVP|"Intervention #1: Exercise~Intervention #2: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril)."
2916267|NCT03135990|Experimental|CBT + VR|Cognitive Behavioral Therapy with Virtual Reality technology.
2916268|NCT03135977|Experimental|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
2916269|NCT03135964|Active Comparator|foam|PU foam dressing from KCI
2916270|NCT03135964|Active Comparator|gauze|Polyhexamethylene biguamide (PHMB) impregnated gauze (Kerlix AMD, Covidien)
2916271|NCT03135951|Experimental|SPI-2012|"SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF per cycle)~Supplied in 1 mL prefilled, single-use syringes for subcutaneous injection~Administered on Day 2 of each cycle after TC administration"
2916272|NCT03135938|Active Comparator|Grading Inferior Oblique Anterior Transposition|in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
2916273|NCT03135938|Active Comparator|Classic Inferior Oblique Anterior Transposition|in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes
2916274|NCT03135925|Other|Intervention|Exercise program
2916275|NCT03135912|Experimental|Experimental Treatment|Patients supplied with Experimental Drug SESC 01 for daily topical therapy for 4 weeks.
2916276|NCT03135912|Placebo Comparator|Vehicle Control|Patients supplied with inactive vehicle (placebo), identical to experimental treatment but without active ingredients, to be applied daily for 4 weeks.
2916277|NCT03135912|Active Comparator|Active Comparator|Terbinafine hydrochloride cream, to be applied twice daily for 4 weeks.
2916278|NCT03135899|Experimental|BI 443651|
2916279|NCT03135899|Placebo Comparator|Placebo|
2916280|NCT03135886|Experimental|HIV Testing Practice Coaching Intervention Group|The HIV Testing Practice Coaching (PC) Intervention is designed to improve the provision and sustained implementation of on-site HIV testing and linkage to care among OTP patients.
2916281|NCT03135886|Experimental|HIV and HCV Testing Practice Coaching Intervention Group|The HIV and HCV Testing Practice Coaching (PC) Intervention will leverage the HIV PC intervention and follow the same interventional steps described above, and, in addition, provide information and training to support joint HIV/HCV testing and linkage to care among OTP patients.
2916282|NCT03135886|Other|Information Control Group|The administrators of OTPs assigned to the control condition will receive a website link to and hard copy of the NIDA/SAMHSA Blending Initiative product for HIV rapid testing.
2916283|NCT03135873|Active Comparator|Mastiha|This arm of patients will receive natural Mastiha supplements at a daily dosage of 2.1 g for a 6 month period.
2916284|NCT03135873|Placebo Comparator|Placebo|This arm of patients will receive placebo for a 6 month period.
2916285|NCT03135860|Experimental|Inhaled Nitric Oxide 30mcg/kg/IBW/hr|Inhaled nitric oxide 30 mcg/kg IBW/hr NO will be administered through the InoPulse Device open label for 4 weeks
2916286|NCT03135847|Experimental|Amputee and Able Bodied Subjects|Map the locations in the skin or deeper muscle where limb movement perceptions occur. Use tactors (small robots providing touch and vibration) to mechanically provide sensation to the residual muscles in amputees and the intact muscles in able-bodied. The functional experiments will occur concurrently with development and application of new prosthetic socket designs to incorporate control and feedback.
2916287|NCT03135834|Experimental|Group 1 (ACWY Naive subjects, MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
2916288|NCT03135834|Experimental|Group 2 (ACWY Naive subjects, rLP2086/MenACWY-CRM)|ACWY Naive subjects, rLP2086/MenACWY-CRM
2916289|NCT03135834|Experimental|Group 3 (ACWY Experienced subjects, MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
2916291|NCT03135821|Placebo Comparator|10% active Placebo|"Placebo will constitute granules with 10% active core ingredients as below:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g~- 2 packets of sachets once before breakfast and once before dinner."
2916292|NCT03135821|Active Comparator|Traditional Chinese Medication (TCM) Drug A,B,C,D|"Traditional Chinese Medication (TCM) Drug A,B,C,D.~TCM Drug A:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome15g~TCM Drug B:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Liver stagnation with heaty transformation: add Scutellaria Root 5g、Prunella Spike 5g~TCM Drug C:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Prominent abdominal pain: White Peony Root to increase to 15g add Bupleurum Root 5g~TCM Drug D:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Hard stools: add Peach Kernel 5g、Areca Seed 5g"
2916293|NCT03135795|Experimental|patients undergoing pancreatectomy|patients undergoing pancreatectomy received dexmedetomidine 1μg/Kg，sufentanil 0.5μg/Kg， propofol 2mg/Kg，rocuronium 0.6mg/Kg for induction.And received sevoflurane(1-2%), remifentanil(0.1-0.2ug/kg/min) and propofol(0.3-0.6mg/kg/h) for maintenance. Parecoxib 40mg was given single intravenously before incision. And PCA with sufentanil 1ug/ml was started immediately after surgery.
2916294|NCT03135782|Experimental|Health Services Research (Chart review, training, coaching)|"MEDICAL CHART REVIEW: Medical charts from patients with diagnoses of head and neck cancer, lung cancer, prostate cancer, or breast cancer are reviewed at months 1-12 to determine the frequency of tobacco assessments and documentation of discussions with patients regarding tobacco use and utilization of cessation resources as before and after the proposed training.~PROVIDER TRAINING: Providers undergo training to use patient coaching such as the 5A's (Ask, Advise, Assess, Assist, and Arrange), to conduct regular tobacco intake assessment using motivational interviewing techniques. Providers also undergo training to use public/community tobacco cessation resources for patients ready to quit within six weeks, and have access to pharmacy residents for ad-hoc prescribing questions.~PATIENT COACHING: Patients attend 4 phone or in-person motivational interviewing coaching sessions over 30-45 minutes for 6-8 weeks or longer as needed."
2916295|NCT03135769|Experimental|Avelumab|Avelumab administration at 10 mg/kg every 14 days during 6 months maximum
2916296|NCT03135756||Depression and anxiety symptoms|
2916297|NCT03135756||Healthy controls|
2916298|NCT03135704|Active Comparator|"Re Spine Mattress"|"Adults suffering low back pain will treat their low back pain using the Re Spine mattress"
2916299|NCT03135704|Active Comparator|Physiotherapy|Adults suffering low back pain will treat their low back pain using conventional physiotherapy protocols
2916300|NCT03135691||Patients at High Risk for OSA|Patients at High Risk for Obstructive Sleep Apnea Undergoing Laparoscopic Bariatric Surgery; retrospective study, no intervention administered.
2916301|NCT03135665|Other|ScoE|This is a cross-sectional study on screened school children recommended for radiographic assessment in the scoliosis screening program of SHS in Hong Kong. Both x-ray, ultrasound and ATR measurement of the spine will be performed on the same day at Prince of Wales Hospital.
2916302|NCT03135652|Experimental|chemoradiotherapy|radiotherapy: adjuvant SBRT of liver lesions; chemotherapy: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
2916303|NCT03135652|Active Comparator|chemotherapy|chemotherapy: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
2916304|NCT03135639|Sham Comparator|Sham Stimulation|Sham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham.
2916305|NCT03135639|Experimental|Alpha Stimulation|Participants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS.
2916306|NCT03135626|Experimental|Biodentine|Biodentine pulpotomy agent
2916307|NCT03135626|Experimental|ProRoot MTA|ProRoot MTA pulpotomy agent
2916308|NCT03135626|Experimental|MTA Plus|MTA Plus pulpotomy agent
2916309|NCT03135626|Active Comparator|Ferric Sulfate 20% Dental Gel|Ferric Sulfate %20 Dental Gel pulpotomy agent
2916310|NCT03135613|Experimental|Normal|Participants of this group are as controls.
2916311|NCT03135613|Experimental|MF|Participants of this group are patients with tumor around knee after microwave ablation with plate internal fixation.
2916312|NCT03135600|Experimental|Normal|The participants from this group are healthy people.
2916313|NCT03135600|Experimental|ACLD|The participants from this group suffer from anterior cruciate ligament injury.
2916314|NCT03135587|Experimental|Weight 0|The participants will not carry any loading to walk on treadmill.
2916315|NCT03135587|Experimental|Weight 10|The participants will wear 10kg loading suit to walk on treadmill.
2916316|NCT03135587|Experimental|Weight 20|The participants will wear 20kg loading suit to walk on treadmill.
2916317|NCT03135587|Experimental|Weight 30|The participants will wear 30kg loading suit to walk on treadmill.
2916318|NCT03135587|Experimental|Weight 40|The participants will wear 40kg loading suit to walk on treadmill.
2916319|NCT03135587|Experimental|Weight 50|The participants will wear 50kg loading suit to walk on treadmill.
2916320|NCT03135561|Experimental|pedometer-plus-email|
2916321|NCT03135561|Active Comparator|pedometer-only|
2916322|NCT03135548|Experimental|BI 655130 (low dose)|
2916323|NCT03135548|Experimental|BI 655130 (high dose)|
2916324|NCT03135548|Placebo Comparator|Placebo|
2916325|NCT03135535|Experimental|Avex Footbeat|Subjects will receive a new pair of diabetic shoes with BOA shoelace closure and a pair of AVEX Footbeat insoles, which include a micro-mobile compression pump. The entire system is named 'intervention shoes' for simplicity. They will be instructed to wear the intervention shoes on daily basis for 4 weeks for duration of at least 4 hours per day.
2916326|NCT03135522|Active Comparator|Zinc Acetate 50 mg oral capsule|50 mg zinc acetate oral capsules, over-encapsulated, administered starting at 1 capsule/day and escalated to 3 capsules/day by Day 8 post-randomization (if tolerated)
2916384|NCT03135119|Active Comparator|TF-CBT|Youth will receive standard Trauma-Focused Cognitive-Behavioral Therapy
2916327|NCT03135522|Placebo Comparator|Placebo oral capsule|Placebo matched to zinc acetate 50 mg oral capsule active arm, administered starting at 1 capsule/day and escalated to 3 capsules/day by Day 8 post-randomization (if tolerated)
2916328|NCT03135509|Experimental|Treatment A (Reference)- CC-220 gelatin capsules|A single dose of 0.6 mg CC-220, administered as two 0.3-mg formulated CC-220 gelatin capsules.
2916329|NCT03135509|Experimental|Treatment B (Test)- CC-220 HPMC capsule|A single dose of 0.6 mg CC-220, administered as one 0.6-mg formulated CC-220 hydroxypropyl methylcellulose (HPMC) capsule.
2916330|NCT03135496||Surgery with CEC|
2916331|NCT03135496||Without CEC|
2916332|NCT03135470||Current practice group|All plenipotentiary ambulatory surgery patients, with informed consent, during the three month study period
2916333|NCT03135470||Standard operating protocol group|All plenipotentiary ambulatory surgery patients, with informed consent, during the three month study period after creating and informing standardized operating protocol
2916334|NCT03135470||Mobile phone app group|All plenipotentiary ambulatory surgery patients during the three month study period with informed consent to use mobile phone app in assesment of pain and pain medication
2916335|NCT03135457|Other|Group A|Patients will receive infusion of 300mL saline with a subsequent autologous Red Blood Cells (RBC) transfusion of 300 mL at a rate of 10mL/min
2916336|NCT03135457|Other|Group B|Patients will receive infusion of 300mL autologous RBC with a subsequent saline transfusion of 300 mL at a rate of 10mL/min
2916337|NCT03135444|Experimental|Provider Field Test|15 providers will be given an initial version of the PSA TOOL, over a 4 week period, they will be able to provide feedback on the tool. This will be used to revise the screening decision aid. Informal interviews with providers will also be conducted by a member of the study team to obtain feedback about ease of use and usefulness of the tool.
2916338|NCT03135444|Experimental|Patient test of revised PSA TOOL|150 patients will be asked to use the revised PSA TOOL. Pre- and Post-tests will be given to see if the tool changed the knowledge that patients have an option to be screened for prostate cancer and of specific factors to be considered in the screening decision. Informal interviews with patients who are exposed to the tool will also be conducted by a member of the study team to obtain feedback on issues addressed by the survey questions.
2916339|NCT03135431|Experimental|Salpingectomy|Bilateral salpingectomy following cesarean delivery
2916340|NCT03135431|Active Comparator|Tubal Ligation|Bilateral tubal ligation following cesarean delivery via Parkland or modified Pomeroy methods.
2916341|NCT03135418|Experimental|Intervention|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
2916342|NCT03135418|Sham Comparator|Control|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift a will be used to create an immersive visual environment.Patient will be watching the premade scenarios without interaction. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire, Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
2916343|NCT03135405|No Intervention|Usual care|
2916344|NCT03135405|Experimental|Intervention|
2916345|NCT03135392|Active Comparator|Breast Reconstruction with Artificial Implant|Participants undergoing unilateral reconstruction: patient will serve as internal control with contralateral breast and reconstructed breast will be compared to all other reconstructed breasts. Participants undergoing bilateral reconstruction: reconstructed breasts will be compared to all other reconstructed breasts
2916346|NCT03135392|Active Comparator|Autologous Breast Reconstruction without Neurotization|Participants undergoing autologous tissue (her own tissue from other areas of the body) reconstruction which do not have their nerves reconstructed during surgery
2916347|NCT03135392|Experimental|Autologous Breast Reconstruction with Neurotization|Participants undergoing autologous tissue (her own tissue from other areas of the body) reconstruction which have a nerve connected (neurotized) during surgery.
2916348|NCT03135379|Experimental|Heated gel|Patient undergoes ultrasound study using the intervention of heated ultrasound gel.
2916349|NCT03135379|Placebo Comparator|Room temperature gel|Patient undergoes ultrasound study using the intervention of room temperature gel.
2916350|NCT03135366|Active Comparator|Standard of Care (Control)|
2916351|NCT03135366|Experimental|Keheala Intervention (Treatment)|The intervention consisted of a daily request for self-verification of medication adherence, access to a supporter via a chat client, and information about TB.
2916352|NCT03135353|Experimental|3D saline infusion sonohysterography|participants presenting with abnormal uterine bleeding will undergo 3D saline infusion sonohysterography
2916353|NCT03135353|Experimental|Office hysteroscopy|after undergoing 3D SIS, cases would undergo office hysteroscopy and the investigator would be blinded to the results of SIS
2916354|NCT03135340|Experimental|WALANT|These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.
2916355|NCT03135340|Active Comparator|General/regional anesthesia|These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.
2916356|NCT03135314|Active Comparator|Hypoxia Cocoa flavanol|Exercise or cognitive test in (acute) hypoxic condition after 7 days of cocoa flavanol intake
2916357|NCT03135314|Placebo Comparator|Hypoxia Placebo|Exercise or cognitive test in (acute) hypoxic condition after 7 days of placebo intake
2916358|NCT03135314|Active Comparator|Normoxia Cocoa flavanol|Exercise or cognitive test in normoxic condition after 7 days of cocoa flavanol intake
2916359|NCT03135314|Placebo Comparator|normoxia placebo|Exercise or cognitive test in normoxic condition after 7 days of placebo intake
2972420|NCT02748135|Experimental|TB-403 100mg/kg|
2916360|NCT03135301|Experimental|letrozole plus metformin|5 mg of letrozole will be administered only for 5 days from day 3 each month of spontaneous or induced bleeding plus metformin will be started from the first day with a dose of 850 mg (1 tablet daily) and the dosage will be increased after 1 week up to 1,700 mg/day (2 tablets daily) and will be continued
2916361|NCT03135301|Active Comparator|letrozole|5 mg of letrozole will be administered only for 5 days from day 3 each month of spontaneous or induced bleeding
2916362|NCT03135288|Experimental|Cell-phone assisted|will be advised that they are going to receive a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits. They will be also provided with a cell phone number working 7 days a week to answer any query or questions regarding her family planning program.
2916363|NCT03135288|No Intervention|control group|will receive the same above adequate counseling with referral card but without any phone assistance
2916364|NCT03135275|Active Comparator|Staged complete PCI|Patients randomized to staged complete PCI will have treated during the index admission only the culprit lesion and they will be hospitalized after 19-45 days, to complete the coronary revascularization on the other significant coronary lesions. All the PCIs will be performed with Synergy™ stent.
2916365|NCT03135275|Experimental|Immediate complete PCI|Patients randomized to immediate complete PCI will have treated immediately after the revascularization of the culprit lesion during the index procedure, the other significant coronary stenosis. All the PCIs will be performed with Synergy™ stent.
2916366|NCT03135262|Experimental|Dose-Escalation Cohort: FL|Induction Treatment: Participants will receive either Regimen A or Regimen B. Regimen A: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Regimen B (in bridging cohort): Participants will receive obinutuzumab alone in Cycle 1 and obinutuzumab with idasanutlin and venetoclax (both at maximum tolerated dose [MTD] established from Regimen A) in Cycles 2 to 6. Post-Induction Treatment (Maintenance Treatment): Participants will receive obinutuzumab every 2 months for 24 months; idasanutlin and venetoclax for 6 months.
2916367|NCT03135262|Experimental|Dose-Escalation Cohort: DLBCL|Induction Treatment: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. In bridging cohort, participants will receive rituximab on Day 1 of Cycles 1 to 6 and idasanutlin and venetoclax (both at MTD) in Cycles 1 to 6. Post-Induction Treatment (Consolidation Treatment): Participants will receive obinutuzumab or rituximab (according to study treatment received in the induction) every 2 months for 6 months; idasanutlin and venetoclax for 6 months.
2916368|NCT03135262|Experimental|Expansion Cohort: FL|Induction Treatment: Participants will receive idasanutlin and venetoclax at the RP2D of the selected regimen (Regimen A or B) identified during the dose-escalation phase in combination with obinutuzumab. Regimen A: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Regimen B (in bridging cohort): Participants will receive obinutuzumab alone in Cycle 1 and obinutuzumab with idasanutlin and venetoclax in Cycles 2 to 6. Post-Induction Treatment (Maintenance Treatment): Participants will receive obinutuzumab every 2 months for 24 months; idasanutlin and venetoclax for 6 months.
2916369|NCT03135262|Experimental|Expansion Cohort: DLBCL|Induction Treatment: Participants will receive rituximab on Day 1 of Cycles 1 to 6; idasanutlin and venetoclax (both at RP2D) on Days 1 to 5 of Cycles 1 to 6 or rituximab on Day 1 of Cycles 1 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Post-Induction Treatment (Consolidation Treatment): Participants will receive rituximab every 2 months for 6 months; idasanutlin and venetoclax for 6 months.
2916370|NCT03135249|Other|Alemtuzumab treatment.|"Patients with relapsing-remitting multiple sclerosis previously treated with natalizumab, the following treatment arms with alemtuzumab will be implemented:~Year One: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for five days to be given within eight hours after dilution.~Year Two: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for three days to be given within eight hours after dilution."
2916371|NCT03135236|Experimental|Parent training|All registered participants will participate in a series of trainings (3 separate) on sexuality education.
2916372|NCT03135223|Experimental|Intervention group|Co-created, school-based intervention to promote physical activity
2916373|NCT03135223|No Intervention|Control group|
2916374|NCT03135210|Active Comparator|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
2916375|NCT03135210|Experimental|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
2916376|NCT03135197||Migalastat|Migalastat administered according to SmPC
2916377|NCT03135184|Experimental|HDL Therapeutics PDS-2™ System|Serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
2916378|NCT03135171|Experimental|Trastuzumab, Pertuzumab and Tocilizumab|
2916379|NCT03135158||Women in labor|All participants who have a vaginal delivery
2916380|NCT03135145|Active Comparator|Lite Run Gait Trainer|Participants will be using the Lite Run Gait Trainer to assist them in weightbearing and walking after SDR or SEMLS surgery.
2916381|NCT03135145|Placebo Comparator|Usual Treatments|Participants will be using current treatments used in clinical practice to assist them in weightbearing and walking after SDR or SEMLS surgery.
2916382|NCT03135132|Placebo Comparator|Control group|Usual dietary intake group
2916383|NCT03135132|Experimental|LCD group|Low calorie diet (LCD) group (300kcal/day intake reduction)
2916604|NCT03133611|Other|REM sleep behaviour disorder|Speech assessment. Routine clinical assessment.
2916385|NCT03135119|Experimental|TF-CBT+AAT|Youth will received Trauma-Focused Cognitive-Behavioral Therapy with Animal-Assisted Therapy as an adjunct.
2916386|NCT03135106|Experimental|Treatment A: Erdafitinib alone|Participants will receive single 4 milligram (mg) oral dose of erdafitinib on Day 1 in a fasted state.
2916387|NCT03135106|Experimental|Treatment B: Erdafitinib + Fluconazole|Participants will receive 400 mg fluconazole once daily orally from Day 1 to Day 11 in a fasted state and on Day 5, a single 4-mg oral dose of erdafitinib will be administered 30+/-10 minutes after the intake of 400 mg fluconazole dose.
2916388|NCT03135106|Experimental|Treatment C: Erdafitinib + Itraconazole|Participants will receive 200 mg itraconazole once daily orally from Day 1 to Day 11 and on Day 5, a single 4-mg oral dose of erdafitinib will be administered 30+/-10 minutes after the intake of 200 mg itraconazole dose.
2916389|NCT03135093||Stroke subjects|
2916390|NCT03135093||Healthy subjects|
2916391|NCT03135080|Experimental|Long-term HEAD START Training|Fifteen surgeons will participate in long-term HEAD START practice once live surgical training is complete. Each week the participant will complete 2 surgeries on the HEAD START device and mark the surgery number on the cartridge. Monthly, the participant will send the accumulated cartridges to Addis for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his/her impression of the surgeries with the participant during a regular monthly call. He/she will also note the findings on a standardized form. Practice will continue for approximately 4-6 months, depending on the length of the rainy season and time of enrollment.
2916392|NCT03135080|Active Comparator|Standard of Care|Once live surgical training is complete, fifteen surgeons will commence live surgery without supervision until the rainy season begins. Then they will break for the rainy season, per the typical practice. The trainer will assess their skill levels on live surgery at the end of training and again at the start of the surgical season in the fall.
2916393|NCT03135067|Experimental|Provision of multiple self-tests|Participants in intervention clusters will be given multiple HIV self-test kits, testing instructions, and advice to use their discretion when offering self-tests to selected sexual partners. Participants will be encouraged to offer self-tests primarily to current and potential partners with whom unprotected sex is likely. All participants will be encouraged to use condoms with sexual partners. Participants will also be advised to assess the risk of intimate partner violence (IPV) as a result of offering self-tests to partners. Participants will have opportunities to obtain additional HIV self-test kits on a monthly basis.
2916394|NCT03135067|No Intervention|Referral vouchers for VCT|Participants will be given a multiple referral vouchers for HIV testing to distribute to their sexual partners. All participants will be encouraged to use condoms with sexual partners. These referral vouchers will encourage the partners to seek HIV counseling & testing services in local clinics. Participants will also be advised to assess the risk of intimate partner violence (IPV) as a result of offering referral vouchers to partners. Participants will have opportunities to obtain additional referral vouchers on a monthly basis.
2916395|NCT03135054|Experimental|Combination|"Quizartinib is a second generation FLT3 inhibitors.The starting dose of quizartinib will be 30 mg/day oral unless the patients are taking a strong CYP3A4 inhibitor in which case the dose will be 20 mg /day. Quizartinib should be taken continuously throughout the treatment period unless there is no evidence of response at first assessment on day 28 or progressive disease at any time during the treatment.~Omacetaxine Mepesuccinate will be given at 1.5 mg/m2/day (maximum dose 3 mg) for 7 days (concurrently with quizartinib) in 28-day cycle."
2916396|NCT03135041|Experimental|Fiber-containing dietary supplement|2 x 200 ml of fiber-enriched UHT milk during 12 weeks of energy restriction
2916397|NCT03135041|Placebo Comparator|Placebo|2 x 200 ml of UHT milk with maltodextrin during 12 weeks of energy restriction
2916398|NCT03135028|Experimental|Entospletinib Monotherapy|Participants with relapsed or refractory hematologic malignancies will receive entospletinib twice daily (BID) of every 28 day cycle until participants meet treatment discontinuation criteria or do not experience clinical benefit
2916399|NCT03135028|Experimental|Entospletinib + cytarabine + daunorubicin|"Lead-in (Cycle 0): Participants with previously untreated AML will receive entospletinib BID for 14 days~Induction (Up to 2 cycles): Entospletinib in combination with daunorubicin and cytarabine for up to two 28 day cycles~Post-remission chemotherapy (at least 2 cycles, up to 4 cycles): Some participants will have the option to receive post-remission therapy with entospletinib BID in combination with high-dose cytarabine (Hi-DAC) for up to four 28 day cycles"
2916400|NCT03135015|Other|Lean|Subjects with BMI >18.5 and <25.0kg/m²
2916401|NCT03135015|Other|Overweight/Obese|Subjects with BMI ≥25.0 and <35.0kg/m²
2916402|NCT03134976||Salvage Larynx|The first group includes subjects with cancer of the voice box (laryngeal squamous cell carcinoma) that has already been treated by either chemotherapy or radiation. This group will be treated using the standard of care, which includes starting thyroid hormone replacement therapy (levothyroxine) after surgery.
2916403|NCT03134976||Non-Salvage Larynx|The second group of subjects will consist of patients who have head and neck cancer of sites other than the voice box (larynx) without prior exposure to radiation or chemotherapy who are undergoing flap reconstruction surgery. This group will not be treated with levothyroxine so long as the subject has normal thyroid function. If a subject is hypothyroid, then thyroid hormone replacement will be given as a part of routine clinical care.
2916404|NCT03134963||Mild cognitive impairment|"MCI Patient-specific Inclusion Criteria~Clinical diagnosis of MCI made by a specialist* in a patient who fulfils the established clinical consensus criteria for MCI [NIA/AA 2011] specifically:~Concern regarding a change in cognition compared to the person's previous level, by the patient and/or informant~Objective evidence of impairment of one or more cognitive domains, greater than expected for age, and educational background, over time if repeated measures are available.~Preserved independence of functional abilities and minimal to no impairment on complex instrumental functions~Not demented"
2916405|NCT03134963||Alzheimer disease|"NIA/AA criteria~Meets the criteria for dementia~o The memory impairment and cognitive deficits cause significant impairment functioning, a significant decline from a previous level of functioning, Impairment of at least two cognitive domains~Insidious or gradual onset~Clear history of worsening cognition by report or observation~The initial and most prominent cognitive deficits are evident on history and examination in one of the following domains:~Amnestic: impaired learning and recall of recently learned information~Non amnestic: language/visuospatial/executive dysfunction"
2916605|NCT03133611|Other|Healthy controls|Speech assessment. Routine clinical assessment.
2916406|NCT03134963||Vascular dementia|"NINDS-AIREN criteria for VascD, specifically:~Cerebrovascular disease defined by the presence of focal signs on neurological examination consistent with stroke and evidence of cerebrovascular disease on brain imaging.~One or more of:~Onset of dementia within 3 months of a diagnosed stroke~Abrupt deterioration in cognitive function~Fluctuating, stepwise progression of cognitive deficits"
2916407|NCT03134963||Healthy controls|"Healthy Controls-specific Inclusion Criteria~No evidence of subjective or objective memory impairment on cognitive testing~No major medical co-morbidity (outlined in detail in the exclusion criteria) or medication use that could adversely affect cognition"
2916408|NCT03134950|Experimental|ADAPT|Aim to Decrease Anxiety and Pain Treatment (ADAPT) is a tailored CBT ranging from 4 sessions (pain-focused) to 6 sessions (blend of pain and anxiety coping strategies depending on the needs of the individual patients. The first 2 sessions are in person with a trained psychologist and the following 2-4 sessions are web-based. Each web-based session is followed by phone support.
2916409|NCT03134950|No Intervention|Medical Treatment as Usual|Medical treatment as usual
2916410|NCT03134937|Other|Study Arm|Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
2916411|NCT03134924|Experimental|Experimental condition|The WASH (Women's and Sexual Health) intervention included the elements of the enhanced standard of care condition and in addition, a group-based, culturally-tailored intervention to enhance the uptake of the recommendations. Facilitators covered an intervention manual on risks associated with IVP, symptoms of vaginal infections, vaginal health, women's experience with alternative methods for vaginal care, and communication with partners about vaginal health and the risks associated with IVP.
2916412|NCT03134924|Other|Enhanced Standard of Care|"This study provided an enhanced standard of care (SOC+) comparison condition, consisting of a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV using the Nugent criteria and provision of medication (oral metronidazole) within 48 hours of the examination in women with Nugent score of 7-10, regardless of the presence of symptoms. In addition, at baseline, participants received an individual education session on the risk of engaging in IVP, advice to discontinue IVP, and tips for healthy vaginal hygiene, emphasizing avoiding IVP and suggesting replacing IVP by external vaginal cleansing."
2916413|NCT03134911||anticoagulation controlled patients|Treated with DOAC or VKA
2916414|NCT03134911||anticoagulation non controlled patients|Treated with VKA
2916415|NCT03134885||VigilanS Nord-Pas de Calais cohort|All patients leaving in the Nord-Pas de Calais region and entering in the VigilanS program after a suicide attempt
2916416|NCT03134872|Experimental|SHR-1210+Chemotherapy|Subjects receive SHR-1210 200mg and pemetrexed 500 mg/m^2 and carboplatin AUC 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional SHR-1210 200mg and pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
2916417|NCT03134872|Active Comparator|Chemotherapy|Subjects receive pemetrexed 500 mg/m^2 and carboplatin Area Under the Curve (AUC) 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD. If PD occurs, Subjects may be able to receive SHR-1210 Q3W for the remainder of the study or until documented PD.
2916418|NCT03134859|Experimental|0 to 30 min/day tummy time|Group tasked to engage in an accumulation of 0 to 30 minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
2916419|NCT03134859|Experimental|31-60 min/day tummy time|Group tasked to engage in an accumulation of 31 to 60 minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
2916420|NCT03134859|Experimental|>61 min/day tummy time|Group tasked to engage in an accumulation of 61 or more minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
2916421|NCT03134846|Experimental|Phase 1: 10mg Cetuximab-IRDye800CW|Three patients will receive 10mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
2916422|NCT03134846|Experimental|Phase 1: 25mg Cetuximab-IRDye800CW|Patients will receive 25mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
2916423|NCT03134846|Experimental|Phase 1: 50 mg Cetuximab-IRDye800CW|Patients will receive 50mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
2916424|NCT03134846|Experimental|Phase 2: ' Optimal dose' Cetuximab-IRDye800CW|After having established the optimal cetuximab-IRDye800CW dose we will extent the study by including up to 70 patients for this specific dose (as determined in phase 1).
2916425|NCT03134833|Experimental|Automated Messaging & Monitoring|"Youth randomized to the Automated Messaging and Monitoring Intervention (AMMI) arm will receive daily texts to motivate, inform, and refer youth to health care and HIV services. Message banks will focus on the HIV Prevention Continuum, with libraries of text messages dedicated to healthcare, wellness, sexual health, drug use and medication reminders (e.g., for PrEP) for young men-who-have-sex-with-men (MSM) and non-MSM.~Youth will also receive a weekly monitoring survey that covers seven domains, including: use of PrEP/PEP, condomless sex, potential symptoms of acute HIV infection, potential symptoms of STI, excessive use of alcohol and/or drugs, feelings of sadness or depression, and housing or food insecurity."
2916426|NCT03134833|Experimental|Peer Support|Youth randomized to the Peer Support arm will be enrolled in private, online peer support groups, where they can post information and have discussions with other participants, guided broadly by topics relevant to the HIV Prevention Continuum. Peer Supporters will post to encourage and broadly guide discussion, while Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content. All youth will also receive AMMI messages.
2916427|NCT03134833|Experimental|Coaching|Youth randomized to the Coaching arm will have access to a dedicated Coach for crisis management, problem-solving, linkage to HIV and related services, and care coordination. The Coach's primary means of contact with youth will be electronic - using e-mail, social media, text messages - and phone calls. In person contacts may also occur. AMMI is also provided to all youth.
2916428|NCT03134833|Experimental|Coaching + Peer Support|Youth randomized to the Coach + Peer Support arm will be enrolled in online, private peer support groups and have access to a Coach. As well as AMMI messages.
2972421|NCT02748135|Experimental|TB-403 ≤175mg/kg|
2916429|NCT03134807||Admission of elderly ICU patients (≥80)|All consecutibve admission in 3 month period or 20 pateints
2916430|NCT03134794|Experimental|Educational Intervention|"Education intervention using the TLS. The active group will received an educational intervention applying proven concepts in medical education (cognitive reflection/checklist, traffic light system (TLS). Previous research showed that TL food labels prompted individuals to consider their health and to make healthier choices. A color-coded system influences the valuation process in favor of healthier choices by interfering with automatic decisions and triggering the re-evaluation process (Ena, Krajbich et al Judgement and DM 2016).~The TLS is being implemented to facilitate the identification of patients at risk of developing a clinical and radiological progression that could result in escalation of therapy."
2916431|NCT03134794|No Intervention|Control|Usual Care. The control group will make therapeutic decisions without being exposed to the educational intervention as part of the current standard practice.
2916432|NCT03134781|Active Comparator|Control|Participated only in measurements at baseline, at 20 weeks and at 40 weeks.
2916433|NCT03134781|Experimental|Training|Participated in a supervised 40-week FFIT workout exercise training program and in measurements at baseline, at 20 weeks and at 40 weeks.
2916434|NCT03134781|Experimental|Training-Detraining|Participated in a supervised 20-week FFIT workout exercise training program and then entered a 20-week detraining period. They also participated in measurements at baseline, at 20 weeks and at 40 weeks.
2916435|NCT03134755||Study cohort (all children with asthma)|300 children with asthma will receive the same inhaled corticosteroid (ICS) for six weeks, in order to assess response to ICS.Bronchodilator response will be measured before and after ICS therapy. Stress levels (the exposure of interest) will be assessed with a validated questionnaire, before ICS administration (thus, it is an observational study of whether stress is related to treatment response)
2916436|NCT03134742||Control Group|Subjects will not have any additional scans only those that are standard of care. Their data will be used for comparison
2916437|NCT03134742||CT Scan only|Three CT Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment.
2916438|NCT03134742||DEXA Scans only|Three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment
2916439|NCT03134742||CT and DEXA Scans|Three CT Scans and three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment
2916440|NCT03134729|Experimental|Serratus Plane Loco-regional block|"Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours~plus~Ropivacaine (30 ml, 0.3%), for Serratus Plane Block"
2916441|NCT03134729|No Intervention|Standard of Care|"Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
2916442|NCT03134716||Clinical follow-up|Clinical follow-up of MS-patients for 5 years after the baseline PET imaging.
2916443|NCT03134716||Healthy controls|No follow-up for healthy controls; comparison of healthy controls' and MS patients' PET imaging data only in baseline
2916444|NCT03134703|Experimental|Methadone Treatment Group|NAS infants treated for withdrawal symptoms with methadone
2916445|NCT03134703|Active Comparator|Comparison Group|NAS infants treated for withdrawal symptoms with morphine (standard of care at Johns Hopkins All Children's Hospital)
2916446|NCT03134690|Experimental|delayed start antagonist|30 women with f poor ovarian responses undergo ovarian stimulation with delayed start antagonist.
2916447|NCT03134690|Experimental|conventional antagonist|30 women with diagnose of poor ovarian response will have undergone ovarian stimulation with conventional antagonist protocol.
2916448|NCT03134677|Experimental|Bupivacaine|We were performed spinal anesthesia sitting position by midline. After confirming the free flow of cerebrospinal fluid, bupivacaine was administered without aspiration.ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
2916449|NCT03134677|Experimental|Sevoflurane|We were performed general anesthesia with sevoflurane. Anesthesia was maintained with 2-3% sevoflurane. ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
2916450|NCT03134664|Experimental|Experimental group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.
2916451|NCT03134664|Experimental|Control group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
2916452|NCT03134651|Active Comparator|Monitoring brain function-low-anxiety|Anxiety has determined a cutoff score of 17. Patients were divided into two groups according to the recorded BAI score: a low-anxiety group and a high-anxiety group.The monitoring brain function values were recorded at baseline, 5 minutes, 15 minutes, and after anesthesia. Propofol was performed by ventilation with face mask. Monitoring brain function was keep value between 40 and 60.
2916453|NCT03134651|Active Comparator|monitoring brain function-high-anxiety|Anxiety has determined a cutoff score of 17. Patients were divided into two groups according to the recorded BAI score: a low-anxiety group and a high-anxiety group.The monitoring brain function values were recorded at baseline, 5 minutes, 15 minutes, and after anesthesia. Propofol was performed by ventilation with face mask. Monitoring brain function was keep value between 40 and 60.
2916454|NCT03134638|Experimental|Dose Escalation|Dose escalation phase to explore maximum tolerated dose across two schedules. SY-1365 will be administered intravenously on two dosing schedules, weekly and twice-weekly for 3 weeks of each 4-week cycle
2916455|NCT03134638|Experimental|Advanced Ovarian Cancer|Patients with ovarian cancer previously treated with ≥ 3 prior lines of therapy (SY-1365 single agent)
2916456|NCT03134638|Experimental|Relapsed Ovarian Cancer|Patients with ovarian cancer previously treated with ≥ 1 prior line of therapy including a platinum-based regimen (SY-1365 + carboplatinum)
2916503|NCT03134313|Experimental|R1-25 Sensor|All subjects will be enrolled in the test group and will receive Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor
2916457|NCT03134638|Experimental|Primary Platinum Refractory Ovarian Cancer|Patients with ovarian cancer considered primary platinum refractory (progression either during treatment or within 1 month after completion of a first-line platinum-based regimen). (SY-1365 single agent)
2916458|NCT03134638|Experimental|Biopsy|Biopsy cohort of approximately 10 patients with advanced solid tumors from whom pre- and post-treatment biopsies will be obtained. (SY-1365 single agent)
2916459|NCT03134638|Experimental|HR+ breast cancer|Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer (BC) that has progressed following prior treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with an aromatase inhibitor. (SY-1365 + fulvestrant)
2916460|NCT03134612|Active Comparator|Ondansetron|Ondansetron 8mg (2mg/cc) was given intravenously via a 20 G vein canula
2916461|NCT03134612|Active Comparator|Lidocain|Lidocain 40mg (20mg/cc + 2cc of normal saline) was given intravenously via a 20 G vein canula
2916462|NCT03134599|Active Comparator|etafilcon A|
2916463|NCT03134599|Active Comparator|methafilcon A - Interozzo|
2916464|NCT03134599|Active Comparator|methafilcon A - CVI|
2916465|NCT03134586|Other|trial participant|All participants undergoes the same diagnostic imaging
2916466|NCT03134573||Multiple Sclerosis|Women and men in Germany with the diagnosis of MS that are treated with Betaferon and use the myBETAapp
2916467|NCT03134560|Active Comparator|With vein display instrument|Vein cannulation was done after the vein display instrument displays the veins using infrared
2916468|NCT03134560|No Intervention|Without vein display instrument|vein cannulation was done without any vein display instrument
2916469|NCT03134547|Active Comparator|low volume volatile anesthetics|1.0 % sevoflurane sedation via face mask , low dose sevoflurane group
2916470|NCT03134547|Active Comparator|high volume volatile anesthetics|2.5 % sevoflurane sedation via face mask, high dose sevoflurane group
2916471|NCT03134534|Other|VATS group|Surgical procedure: VATS lobectomy
2916472|NCT03134534|Other|RATS group|Surgical procedure: RATS lobectomy
2916473|NCT03134508||pregnant IBD women treated|pregnant IBD women treated by antiTNFα
2916474|NCT03134508||pregnant IBD women not treated|pregnant IBD women not treated by antiTNFα
2916475|NCT03134495||PPI exposed children|all children with at least one prescription of PPI
2916476|NCT03134495||non-exposed children|all children with no prescription of PPI
2916477|NCT03134482|Experimental|In vitro maturation (IVM)|"hCG primed in vitro maturation (IVM) procedure Gonadotropin is not used in this patient group If the endometrial thickness in 6mm or more and the mean diameter of largest follicle is 11 mm or less on menstrual cycle day 9 to 12 on ultrasonography, oocyte retrieval is planned two days later.~Recombinant hCG injection (priming) is given 36 hour before oocyte retrieval, followed by intracytoplasmic sperm injection (ICSI) for oocyte fertilization.~The biochemical pregnancy is confirmed by serum beta hCG 15 days later oocyte retrieval.~The clinical pregnancy is confirmed when gestational sac is detected by transvaginal ultrasonography 3 weeks later oocyte retrieval."
2916478|NCT03134482|Active Comparator|Minimal stimulation IVF|"minimal stimulation IVF procedure These patients are stimulated with 150 or less IU of recombinant Follicle-stimulating hormone (FSH) from menstrual cycle day 3 in GnRH antagonist protocol.~If the mean diameters of two or more follicles are 17mm or more, oocyte retrieval is planned two days later.~Recombinant hCG is triggered 36 hour before oocyte retrieval, followed by intracytoplasmic sperm injection (ICSI) for oocyte fertilization if needed.~The biochemical pregnancy is confirmed by serum beta hCG 14 days later oocyte retrieval.~The clinical pregnancy is confirmed when gestational sac is detected by transvaginal ultrasonography 3 weeks later oocyte retrieval."
2916479|NCT03134469|Experimental|Probiotics|Intake of a probiotic capsule once daily
2916480|NCT03134469|Placebo Comparator|Placebo|Intake of a placebo capsule once daily
2916481|NCT03134456|Experimental|single arm: pembrolizumab Injection|Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
2916482|NCT03134443|Active Comparator|Experimental group|Xiyanping injection(andrographolide sulfonate) 10-20ml/d, with 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
2916483|NCT03134443|Placebo Comparator|control group|Xiyanping injection simulation(andrographolide sulfonate simulation) 10-20ml/d, The treatment method is the same as the experimental group.
2916484|NCT03134430|Placebo Comparator|Normal saline|equal volume of normal saline as treatment group
2916485|NCT03134430|Active Comparator|peripheral Nerve block|0.35% ropivacaine and 0.5% lidocaine in normal saline
2916486|NCT03134417|Experimental|Vitamin D and magnesium|Daily oral vitamin D (1000 IU) and magnesium (360 mg) supplement
2916487|NCT03134417|Active Comparator|Vitamin D|Daily oral vitamin D (1000 IU) supplement
2916488|NCT03134417|Placebo Comparator|Placebo|Daily oral placebo (cellulose)
2916489|NCT03134391|Active Comparator|vapocoolant spray|Subjects received Vapocoolant spray before spinal anesthesia
2916490|NCT03134391|Active Comparator|EMLA|Subjects received EMLA before spinal anesthesia
2916491|NCT03134378|Experimental|14 days triple therapy|Rabeprazole Clarithromycin Amoxicillin
2916492|NCT03134378|Placebo Comparator|10 days triple therapy|Rabeprazole Clarithromycin Amoxicillin
2916493|NCT03134365|Experimental|Mixed meal|
2916494|NCT03134365|Active Comparator|Combined meal|
2916495|NCT03134352|Experimental|ZL-3101(Fugan) bid group|Fugan AM + Fugan PM
2916496|NCT03134352|Experimental|ZL-3101(Fugan) qd group|Fugan AM + Placebo PM
2916497|NCT03134352|Placebo Comparator|placebo group|Placebo AM + Placebo PM
2916498|NCT03134339|Experimental|saline 0.00mcg/kg/s|0.00 mcg/kg/s The day order will be randomized per day
2916499|NCT03134339|Experimental|0.24mcg/kg/s|0.24 mcg/kg/s The day order will be randomized per day
2916500|NCT03134339|Experimental|0.048mcg/kg/s|0.048 mcg/kg/s The day order will be randomized per day
2916501|NCT03134339|Experimental|0.024 mcg/kg/s|0.024 mcg/kg/s The day order will be randomized per day
2916502|NCT03134326|Experimental|Test group|All subjects will be enrolled in the test group and will receive both R1-25 and R2-25 Pulse Oximeter Sensors
2916504|NCT03134300|Active Comparator|Low SES|
2916506|NCT03134287|Active Comparator|two-finger method|Those who received nasogastric tube placement by two-finger method
2916507|NCT03134287|Active Comparator|reverse sellick's method|Those who received nasogastric tube placement by reverse sellick's method
2916508|NCT03134274|Experimental|Pregnant women|Pregnant women above the age of 18 years, undergoing routine pre-natal care, who own and are familiar with use of a smartphone receive a Dip HBDA kit for home use.
2916509|NCT03134261|Other|SPECT-CT|The participants will undergo two project scans: WB-MRI and SPECT-CT
2916510|NCT03134261|Other|Cholin-PET-CT|The participants will undergo two project scans: WB-MRI and Cholin-PET-CT
2916511|NCT03134261|Other|PSMA-PET-CT|The participants will undergo two project scans: WB-MRI and PSMA-PET-CT
2916512|NCT03134248|Experimental|MyDay Toric|Participants were randomized to wear a new pair of MyDay Toric lenses each day for one week during the cross over study
2916513|NCT03134248|Active Comparator|1-Day Acuvue Moist for Astigmatism|Participants were randomized to wear a new pair of 1-Day Acuvue Moist Toric lenses each day for one week during the cross over study
2916514|NCT03134248|Active Comparator|Dailies Aquacomfort Plus Toric|Participants were randomized to wear a new pair of Dailies Aquacomfort Plus Toric lenses each day for one week during the cross over study
2916515|NCT03134235|Experimental|Raw, plant-based diet|A raw, plant-based diet was prescribed for 4 weeks.
2916516|NCT03134222|Experimental|Filgotinib|Filgotinib 200 mg + GS-9876 placebo for 24 weeks
2916517|NCT03134222|Experimental|GS-9876|GS-9876 30 mg + filgotinib placebo for 24 weeks
2916518|NCT03134222|Placebo Comparator|Placebo|Placebo for 12 weeks, then participants will be re-randomized to receive filgotinib 200 mg + GS-9876 placebo or GS-9876 30 mg + filgotinib placebo through Week 24.
2916519|NCT03134222|Experimental|Extension Period|Participants who have not permanently discontinued study drug during the first 24 weeks may enter the subsequent 24-week extension period where they will continue to receive their assigned dose of study drug, in a blinded fashion.
2916520|NCT03134209|Experimental|Zipper surgical skin closure|Zipper surgical skin closure device applied to the most superficial layer of skin following a joint arthroplasty
2916521|NCT03134209|Active Comparator|Monocryl + Dermabond|Monocryl suture plus Dermabond is a commonly used combination of wound closure techniques today.
2916522|NCT03134209|Active Comparator|Polyester mesh + Dermabond|The polyester plus Dermabond closure techniques combines the OCA topical skin adhesive with a flexible, self-adhesive polyester mesh that has proven to reduce wound cosure times and have a significant greater skin holding strength than skin staples or subcuticular sutures in one study
2916523|NCT03134196|Placebo Comparator|Placebo|Encapsulated masked placebo
2916524|NCT03134196|Active Comparator|Masked Oral Valacyclovir 1000 mg daily|Valacyclovir, 500 mg, oral pill, two 500mg pills daily
2916525|NCT03134183|Experimental|Vaginal Misoprostol|Intervention is misoprostol versus placebo 400mcg misoprostol formulated within cocoa butter suppository
2916526|NCT03134183|Experimental|Buccal Misoprostol|Intervention is misoprostol versus placebo 400mcg misoprostol formulated within mint flavored powder
2916527|NCT03134170|No Intervention|No intervention|The no intervention group will serve as control group. This group will receive standard care and will be an active comparator. At the end of the study they may join the intervention group
2916528|NCT03134170|Other|Intervention group|The intervention group will be seen by a pharmacist iin addition to their normal provider. The pharmacist will provide medication therapy review of the patient's therapy. The pharmacist will make recommendations to make revisions in the patient's therapy.
2916529|NCT03134157|Experimental|Simvastatin and vaginal placebo|The patients with leiomyoma receive simvastatin 40 mg orally+ vaginal placebo will be given every day for 3 months.
2916530|NCT03134157|Experimental|Simvastatin and oral placebo|The patients with leiomyoma receive simvastatin 40 mg orally+ oral placebo will be given every day for 3 months.
2916531|NCT03134157|Experimental|Vaginal placebo+ oral placebo|The patients with leiomyoma receive Vaginal placebo+ oral placebo every day for 3 months.
2916532|NCT03134118|Experimental|Nivolumab|Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
2916533|NCT03134105|Experimental|Monthly Feedback|Sites will receive monthly reports of their patients enrolled in the study with data for each of their patients participating in the study along with summary data for their practice and all patients participating in the study.
2916534|NCT03134105|Active Comparator|End-of-study Feedback|Sites will only receive the report of their patients at the end of the 6 month follow-up period.
2916535|NCT03134092|No Intervention|Generalized Risk Communication (GRC)|
2916536|NCT03134092|Active Comparator|Probabilistic Risk Communication (PRT)|
2916537|NCT03134092|Experimental|Narrative Enhanced Risk Tool (NERT)|
2916538|NCT03134079|Active Comparator|full sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
2916539|NCT03134079|Experimental|reduced sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
2916570|NCT03133832|Experimental|The economic benefit|Compare the economic benefit between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
2916606|NCT03133572|Experimental|Supraglottic airway|All newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a supraglottic airway and a bag.
2916540|NCT03134079|Experimental|reduced sugar plus spice recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
2916541|NCT03134066||Treatment-resistant depression patients|Subjects with TRD who have been deemed appropriate for (and have decided to receive) clinical, non-research ketamine treatment at the ketamine clinic at Massachusetts General Hospital. As this is an assessment-only observational study, no treatment assignment or randomization procedures will be used.
2916542|NCT03134053|Experimental|extracorporeal shock-wave|
2916543|NCT03134053|Sham Comparator|massage|
2916544|NCT03134040|Experimental|Incentives (Rebate)|On a weekly basis, participants receive a small monetary incentive to exercise each time they attend the YMCA.
2916545|NCT03134040|Experimental|Incentives (Donation)|On a weekly basis, a small monetary incentive to exercise is provided in the form of a donation to a charity of the participant's choice for attendance at the YMCA.
2916546|NCT03134040|Active Comparator|Control|Participants receive feedback on their exercise attendance on a weekly basis.
2916547|NCT03134027||Subjects from which PDXs have been generated.|Subjects will be identified from which PDXs have been generated from an already approved IRB protocol.
2916548|NCT03134014|No Intervention|Breakfast Skipping (BS)|The BS group will continue to skip breakfast.
2916549|NCT03134014|Active Comparator|Normal Protein Breakfast (NP)|The NP groups will be provided with the respective breakfast meals to consume, at home, between 6:00-8:00 am each day over the 4-mo intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The NP breakfasts will be 11% protein (10 g protein), 63% CHO, and 26% fat
2916550|NCT03134014|Active Comparator|High Protein Breakfast (HP)|The HP group will be provided with the respective breakfast meals to consume, at home, between 6:00-8:00 am each day over the 4-mo intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The HP breakfasts will be 34% protein (30 g protein), 40% CHO, and 26% fat.
2916551|NCT03134001|Experimental|Test Group|Patients receiving oral analgesics via the PCoA™ Acute device
2916552|NCT03134001|No Intervention|Control Group|Patients receiving oral analgesics by nurse, upon request
2916553|NCT03133975|Experimental|Treatment|Single high dose IM VIT D
2916554|NCT03133975|Active Comparator|Control|Usual diet mix of carbohydrates - lipid - protein - minerals & vitamins
2916555|NCT03133962|Other|Patients applying for CAP or long-term central catheter|
2916556|NCT03133949||Patients with idiopathic inflammatory aortitis|
2916557|NCT03133949||a group of witnesses|
2916558|NCT03133936|Experimental|influenza vaccination|Fluarix (GSK). A 0.5 mL dose will be administered at baseline.
2916559|NCT03133923|Experimental|Attenuated Mumps vaccine (KMB-17), low|Biological/Vaccine: ≥3.0logCCID50/ml but ＜3.5 logCCID50/ml Attenuated Mumps vaccine (KMB-17)[ ≥3.0logCCID50/ml but ＜3.5 logCCID50/ml] in 360 infants (8-24 months old) on 0 day
2916560|NCT03133923|Experimental|Attenuated Mumps vaccine (KMB-17), high|Biological/Vaccine: ≥4.5logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.5 logCCID50/ml] in 360 infants (8-24 months old) on 0 day
2916561|NCT03133923|Active Comparator|Measles and Mumps Combined Vaccine，Live|manufacturer：Shanghai Institute of Biological Products Co., Ltd. (SIBP ) Measles and Mumps Combined Vaccine，Live in 360 infants in 360 infants (8-24 months old) on 0 day
2916562|NCT03133897|Active Comparator|Prednisone|Prednisone group: Children will receive four doses (days) of prednisone 1 mg/kg/dose once daily (maximum dose 50 mg) following the initial dose of corticosteroid received in the ED under the Nursing Medical Directive or Pre-Printed Order form.
2916563|NCT03133897|Experimental|Dexamethasone|"Dexamethasone group: Children will receive the approximate pharmacologic equivalent of two doses (days) of dexamethasone 0.6 mg/kg/dose (maximum dose 16 mg per dose) once daily as follows. The standard dose of prednisone/prednisolone provided in the emergency department is 2 mg/kg/dose (maximum dose 50 mg), which is approximately equivalent to 0.3 mg/kg/dose of dexamethasone. Therefore, patients who received prednisone/prednisolone in emergency department as per the current Nursing Medical Directive and Pre-Printed Order form will receive a top-up These patients will then receive a dose of dexamethasone 0.6 mg/kg (maximum dose 16 mg) 24 hours after the initial corticosteroid dose received in the Emergency Department of dexamethasone 0.3 mg/kg (maximum dose 8 mg) upon enrollment."
2916564|NCT03133884|Experimental|Acupuncture|The needles will be inserted into the acupoints and the depths will be adjusted to the standard permissible layers, then even reinforcing-reducing technique will be performed on the needles until achieving deqi sensation.The needles will be retained for 30 minutes in each session and manipulated twice every 10 minutes with intermittent stimulation. Each manipulation will last for 20 seconds.
2916565|NCT03133884|Other|Superficial acupuncture|The selected acupoints will be punctured superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation.
2916566|NCT03133845|Active Comparator|General anesthesia|In this group patients will receive general anesthesia. Anesthetic induction will occur with propofol (generally 1-2 mg/kg), maintenance with a volatile anesthetic, muscle paralysis with a muscle relaxant, and pain control with fentanyl (generally 2-5 mcg/kg titrated). Patients on baseline opioids may receive additional opioids (such as dilaudid) based on clinical criteria. The anesthetic provider will be blinded to BIS values.
2916567|NCT03133845|Experimental|Spinal anesthesia with light sedation|In this group patients will receive light sedation with propofol and a spinal anesthetic. Spinal anesthesia will be obtained by injecting approximately 12 mg of 0.75% hyperbaric bupivacaine into the subarachnoid space. Up to 2 mg of midazolam may be given during spinal needle insertion. Although spinal anesthesia is sufficient for surgery, sedation is routinely administered using a propofol infusion, titrated to a BIS>70.
2916568|NCT03133832|Experimental|The cure rate between the two treatment|Compare the cure rate between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
2916569|NCT03133832|Experimental|The amount of eggs produced|Compare the amount of eggs produced between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
2916571|NCT03133819|Other|Q-Sense_QST (TSA II)|"QST measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.~Using the method of limits, a threshold will determine as the average of four successive stimuli for cold and warmth sensation and two for heat pain."
2916572|NCT03133806|Experimental|Ultrasept LAA Closure System|Interventional percutaneous transcatheter device.
2916573|NCT03133793|Placebo Comparator|Placebo Only|Participants in this group will receive placebo pills and placebo powder.
2916574|NCT03133793|Active Comparator|CoQ10 Only|Participants in this group will receive CoQ10 pills and placebo powder
2916575|NCT03133793|Active Comparator|D-ribose Only|Participants in this group will receive placebo pills and D-ribose oral powder.
2916576|NCT03133793|Experimental|CoQ10 + D-ribose|Participants in this group will receive CoQ10 pills and D-ribose oral powder.
2916577|NCT03133780|Active Comparator|Ketamine|Patients will receive IV ketamine 0.5 mg/kg for 10 min
2916578|NCT03133780|Active Comparator|Midazolam|Patients will receive IV midazolam 0.05 mg/kg for 10 min
2916579|NCT03133767|Experimental|Lactated ringers solution|Participants in this arm will receive two liters of IV Lactated Ringer's solution during their emergency department stay
2916580|NCT03133767|Experimental|Normal saline solution|Participants in this arm will receive two liters of IV 0.9% sodium chloride solution during their emergency department stay
2916581|NCT03133754|Experimental|DP-PEEP|recruitment maneuver + individualized PEEP
2916582|NCT03133754|Active Comparator|RM-5|recruitment maneuver + fixed standard PEEP
2916583|NCT03133741|Placebo Comparator|Placebo|Saline
2916584|NCT03133741|Other|GIP-A|Infusion of GIP-A alone as study tool.
2916585|NCT03133741|Other|GLP-1 receptor antagonist Exendin[9-39]|Infusion of GLP-1 receptor antagonist Exendin[9-39] alone as study tool.
2916586|NCT03133741|Other|GIP-A + Exendin[9-39]|Infusion of GIP-A + GLP-1 receptor antagonist Exendin[9-39] together as study tools.
2916587|NCT03133728||Standard of Care Testing Clinic Participants|These participants will be enrolled from and receive their care from same clinics where they receive their standard of care (SOC) HIV testing via DBS DNA PCR. Until the SOC test results are available and have been reported to the parent/guardian, HIV-exposed infants will commence on HIV prophylaxis per national guidelines. If the SOC test result is positive, the infant will be initiated on antiretroviral therapy (ART) per national guidelines. If the SOC test result is negative, the infant will continue the HIV prophylaxis until 6-weeks post-breastfeeding, per national guidelines. Follow-up care will also be conducted according to current national guidelines.
2916588|NCT03133728||Intervention (Alere Q) Testing Clinic Participants|These participants will be enrolled from and receive their care from same clinics where they receive their standard of care (SOC) HIV testing via DBS DNA PCR. However, in addition to undergoing HIV testing through SOC, they will also be tested for HIV through the point of care Alere™ q HIV 1/2 Detect platform (Alere Q). Treatment will be initiated based on the Alere Q test result. If the Alere Q test result is positive, the infant will be initiated on antiretroviral therapy (ART) per national guidelines. If the Alere Q test result is negative, the infant will continue the HIV prophylaxis until 6-weeks post-breastfeeding, per national guidelines. Follow-up care will also be conducted according to current national guidelines.
2916589|NCT03133715|Active Comparator|laparoscopic ventral hernia|laparoscopic ventral hernia repair
2916590|NCT03133715|Active Comparator|robot-assisted ventral hernia|robot-assisted ventral hernia repair
2916591|NCT03133689||EPIC-Norfolk|This cohort comprises 25,636 residents of a predefined English healthcare region (11,606 men and 14,030 women). Participants in this cohort study were originally recruited from 35 general practices in Norfolk, England as part of an investigation into diet and cancer, but the study's scope was subsequently widened to include additional outcomes including cardiovascular diseases.
2916592|NCT03133689||GAZEL|This cohort comprises 20,625 employees of French gas and electricity companies (15,011 men and 5,614 women). The cohort commenced data collection in 1989 and follow-up assessments were subsequently completed on an annual basis. The data have undergone linkage to national health administrative datasets.
2916593|NCT03133689||NSHD|This dataset comes from the 1946 National Birth Cohort study, which comprises all persons born in England, Scotland and Wales in one week in March 1946. The cohort comprises 5,362 individuals (2,815 men and 2,547 women). Data have been collected from participants on a regular basis throughout their life, including information on lifestyle and, in combination with administrative datasets, on health outcomes.
2916594|NCT03133689||Twenty-07-1930s|This cohort comprises 1,551 Scottish participants (702 men and 849 women) born around 1932 who were recruited in 1986 as part of a study of health inequalities. The repeated nature of the data collection will enable identification of longitudinal alcohol intake patterns, while linkage to Scottish health system records will enable identification of coronary heart disease onset.
2916595|NCT03133689||Twenty-07-1950s|This cohort comprises 1,444 Scottish participants (656 men and 788 women) born around 1952 who were recruited in 1986, alongside the T-07-1930s' cohort, as part of a study of health inequalities. Participant health was tracked through linkage with national health records.
2916596|NCT03133689||Whitehall II|This cohort comprises 10,308 British civil servants (6,895 men and 3,413 women). The cohort study commenced data collection in 1985 and participants have since undergone questionnaire and clinical assessments across regular intervals. Additional tracking of health outcomes has been performed through linkage with administrative databases. Demographic, behavioural and clinical data will be sourced from this cohort for the purposes of the current study.
2916597|NCT03133676|Experimental|KA34|KA34
2916598|NCT03133676|Placebo Comparator|Placebo|Placebo
2916599|NCT03133663|Active Comparator|Control group|Pulse oximeter and auscultation to determine heart rate during neonatal resuscitation. Pulse oximeter will be used to determine oxygen saturation.
2916600|NCT03133663|Experimental|Electrocardiogram group|Electrocardiogram to determine heart rate during neonatal resuscitation. Pulse oximeter will still be used per Neonatal Resuscitation Program guidelines for oxygen saturation.
2916601|NCT03133650|Experimental|Vascular-targeted photodynamic therapy (VTP) using WST11|Participants will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes, during an endoscopy procedure, followed by immediate laser light application.
2916602|NCT03133637|Experimental|Ceftriaxone Arm|
2916603|NCT03133611|Other|Parkinson's disease|Speech assessment. Routine clinical assessment.
2916607|NCT03133572|Active Comparator|Face-mask|All newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a face-mask and a bag.
2916608|NCT03133559||Cohort 1|Patients infected with HIV off antiretroviral therapy
2916609|NCT03133559||Cohort 2|Patients infected with HIV experiencing virologic control, but with blunted immunologic recovery
2916610|NCT03133559||Cohort 3|Matched healthy volunteers
2916611|NCT03133546|Experimental|Osimertinib plus Bevacizumab|Patients will receive treatment with osimertinib and bevacizumab until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.
2916612|NCT03133546|Active Comparator|Osimertinib alone|Patients will receive treatment with osimertinib until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.
2916613|NCT03133533|Active Comparator|laparoscopic|laparoscopic inguinal hernia repair
2916614|NCT03133533|Active Comparator|robot-assisted|robot-assisted inguinal hernia repair
2916615|NCT03133520|No Intervention|Standard oxygen group|This patient groups will receive only routine oxygen therapy. Routine oxygen therapy involves administering low-to-medium oxygen flows through a nasal cannula or mask to achieve SpO2≥95%.
2916616|NCT03133520|Experimental|High flow oxygen therapy group|This patients group will receive high flow oxygen therapy. High flow nasal oxygen therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, it allows the delivery of higher flow rates [of up to 60 L/min] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
2916617|NCT03133507|Experimental|Reapprasial Condition|Children in this condition will be instructed to think about how the procedure will help them become adjusted to cold weather.
2916618|NCT03133507|Experimental|Reassurance Condition|Children will receive empathic support from the experimenter.
2916619|NCT03133507|Experimental|Distraction Condition|Children in this condition will be instructed to focus their attention on a picture on a computer screen rather than on the pain.
2916620|NCT03133494|Active Comparator|Laparoscopic cholecystectomy in smokers|ABG analysis of patients with history of smoking posted for laparoscopic cholecystectomy was collected
2916621|NCT03133494|Placebo Comparator|Laparoscopic cholecystectomy nonsmokers|ABG analysis of patients without history of smoking posted for laparoscopic cholecystectomy was collected
2916622|NCT03133481|Active Comparator|Adductor Canal Nerve Block|Participants will be randomized using block randomization.
2916623|NCT03133481|Active Comparator|Femoral Nerve Block|Participants will be randomized using block randomization.
2916624|NCT03133468|Experimental|Part 1: AJM347|Caucasian and Japanese participants will be randomized to receive one of eight and four single oral doses of AJM347, respectively, administered in the fasted state on Day 1.
2916625|NCT03133468|Placebo Comparator|Part 1: Placebo|Caucasian and Japanese participants will be randomized to receive one of eight and four single oral doses of matching placebo, respectively, administered in the fasted state on Day 1.
2916626|NCT03133468|Experimental|Part 2: Low-dose AJM347|"Caucasian and Japanese participants will receive a low dose of AJM347 (at different frequencies and in either a fed or fasted state) on Day 1 of each of 6 sequential treatment periods."
2916627|NCT03133468|Experimental|Part 2: High-dose AJM347|"Caucasian and Japanese participants will receive a high dose of AJM347 (at different frequencies and in either a fed or fasted state) on Day 1 of each of 2 sequential treatment periods (the frequency and timing with respect to meals will be determined after review of the data from the low-dose AJM347 groups)."
2916628|NCT03133468|Experimental|Part 3: AJM347|Caucasian and Japanese participants will be randomized to receive one of three single doses of AJM347 on the morning of Day 1 and multiple daily doses beginning on the morning of Day 3, with the last dose received on the evening of Day 9. The actual doses, dosing frequencies, and timings with respect to meals to be employed in Part 3 of the study will be determined after review of the data from dose groups in Parts 1 and 2 of the study.
2916629|NCT03133468|Placebo Comparator|Part 3: Placebo|Caucasian and Japanese participants will be randomized to receive one of three single doses of matching placebo on the morning of Day 1 and multiple daily doses beginning on the morning of Day 3, with the last dose received on the evening of Day 9. The actual doses, dosing frequencies, and timings with respect to meals to be employed in Part 3 of the study will be determined after review of the data from dose groups in Parts 1 and 2 of the study.
2916630|NCT03133455|Other|Patient with Fibromyalgia|
2916631|NCT03133442|No Intervention|Baseline Nights|No vestibular stimulation is applied. However, the sound of the moving bed will be played back to the participant at the right sound intensity level.
2916632|NCT03133442|Experimental|Movement Nights|Vestibular stimulation, in the form of gentle rocking movements, is provided using the Somnomat V4 rocking bed. Stimulation is provided for the entire 7 hours of the night from lights off to lights on. The stimulation frequency is in the range of 0.1-0.3 Hz, with an amplitude in the range of 0.05 to 0.1m
2916633|NCT03133429|Experimental|Patients with MER stent|Patients eligible for Carotid Artery Stenting
2916634|NCT03133416|Active Comparator|PRP preparation|PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. Then about 2ml PRP will be extracted, and will be infiltrated to the lesion site under ultrasound guidance. The injection technique is similar to that described by Kesikburun .21 Patients in group 1 or group 3 will receive 2 injections of PRP, with 1 month interval.
2916635|NCT03133416|Active Comparator|Physiotherapy|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretch, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, 3 times a week, and will continue for 1.5 months. After 1.5 months' supervised training, home program exercise follows and will be continued for another 1.5 months.
2916697|NCT03132961||Block 5|Participants in the cohort will undergo testing in the order of: cVEMP, ECoG, oVEMP
2916698|NCT03132961||Block 6|Participants in the cohort will undergo testing in the order of: cVEMP, oVEMP, ECoG
2916742|NCT03132571|Experimental|Naltrexone 37.5mg|Oral Naltrexone taken once a day for 16 weeks
2916636|NCT03133416|Active Comparator|PRP and physiotherapy|PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. Then about 2ml PRP will be extracted, and will be infiltrated to the lesion site under ultrasound guidance. The injection technique is similar to that described by Kesikburun .21 Patients in group 1 or group 3 will receive 2 injections of PRP, with 1 month interval;Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretch, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, 3 times a week, and will continue for 1.5 months. After 1.5 months' supervised training, home program exercise follows and will be continued for another 1.5 months.
2916637|NCT03133390|Experimental|Arm A|Atezolizumab 1200 mg IV flat dose plus bevacizumab 15 mg/kg IV every 21 days
2916638|NCT03133390|Active Comparator|Arm B|Atezolizumab 1200 mg IV flat dose every 21 days
2916639|NCT03133377|Experimental|Early activity and Mobilisation intervention|Patients will be assessed daily by an ICU physiotherapist using the ICU Mobility Scale (IMS) to determine the dosage and type of active exercises the patient will receive, using the early activity and mobilisation protocol. This protocol is hierarchical, with the objective of each intervention session beginning with the highest level of activity possible for the longest time possible, which then steps down to lower levels of activity if the patient fatigues. The intervention will be administered on all days in which the patient is admitted to ICU during the index hospitalisation, censored at 28days after.
2916640|NCT03133377|No Intervention|Standard of care|The control group will receive standard care from physiotherapy staff not involved in delivering the intervention. We have previously established that standard care in Australia for a patient receiving prolonged IMV (control group intervention) frequently involves no active exercise out of bed.
2916641|NCT03133364|Active Comparator|Sensory optimized meals|"Intervention group is receiving:~Popular dishes selected from hospital and meal service menus optimized by sensory experts. Optimization is done with respect to taste, texture and appereance and on nutritional composition of the meals with focus on protein content."
2916642|NCT03133364|Placebo Comparator|Control|"Control group is receiving:~Popular dishes selected from hospital and meal service menus, NOT optimized by sensory experts."
2916643|NCT03133351||PCM|All enrolled subjects will have a blood sample tested using PCM.
2916644|NCT03133325|Other|All subjects|Treatment with both GP0045 and Restylane Lyft Lidocaine
2916645|NCT03133312|Experimental|Chlorhexidine Gluconate|Pre-operative vagina preparation with Chlorhexidine Gluconate Intervention: Drug: Chlorhexidine Gluconate Other Name: Chlora-Prep
2916646|NCT03133312|Experimental|Povidone-Iodine Scrub and Paint|Pre-operative vagina preparation with Povidone-Iodine Scrub and Paint Intervention: Drug: Povidone-Iodine Scrub and Paint Other Name: Betadine
2916647|NCT03133299|Active Comparator|Glucocorticoid group|Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months
2916648|NCT03133299|Experimental|Vitamin D plus Glucocorticoid group|Oral vitamin D3 tablet, 60,000 IU weekly for 2 months (8 doses) along with Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months
2916649|NCT03133273|No Intervention|Usual care|Patient is followed within the usual care for stage 4 colorectal cancer
2916650|NCT03133273|Experimental|Oncogramme®|For patients in the Oncogramme® group, chemotherapy will be adapted to Oncogramme® results.
2916651|NCT03133260||Non cardiac surgery|Determine perioperative troponin to diagnose perioperative MINS. In case of MINS acetylsalicylic acid and statins will be started if no contraindication. We will follow-up these patients for a year (including cardiologic evaluation after discharge)
2916652|NCT03133247|Experimental|SHR-1316 dose-escalation|The dose-escalation cohorts of SHR-1316 are 1 mg/kg, 3 mg/kg, 10 mg/kg, and 20 mg/kg.
2916653|NCT03133234||EGFR T790M Patients|Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI
2916654|NCT03133221|Experimental|Oral Zydelig 150 mg BID|Zydelig given orally at 150 mg twice daily continuously on 28-day cycles starting 30 to 120 days after autologous stem cell transplantation for patients with indolent or transformed indolent B-cell NHL, for up to 1 year maintenance duration. Dose withhold/modification is allowed according to tolerability/toxicity.
2916655|NCT03133208||Sepsis with AMS|Patients presenting to the ED with suspected sepsis who develop altered mental status
2916656|NCT03133208||Sepsis without AMS|Patients presenting to the ED with suspected sepsis without change in mental status
2916657|NCT03133208||Control|Patients presenting to the ED with no suspicion of systemic inflammation that need hospitalization (control category)
2916658|NCT03133195|Experimental|Teriparatide|Teriparatide 20 μg subcutaneous once daily for 12 weeks
2916659|NCT03133195|Placebo Comparator|Placebo|Placebo subcutaneous once daily for 12 weeks
2916660|NCT03133182||Polypharmacy|People taking >=5 unique prescription drugs in the 3 months prior to surgery
2916661|NCT03133182||No polypharmacy|People taking <5 unique prescription drugs in the 3 months prior to surgery
2916662|NCT03133169||Thalassemic patients|They will be investigated for erythrocyte glutamine/glutamate ratio and Tricuspid regurge velocity
2916663|NCT03133156|Experimental|Moderate Intensity Training-Healthy Lean|Eligible subjects will undergo a 10-week moderate intensity exercise program.
2916664|NCT03133156|Experimental|Moderate Intensity Training-Healthy Overweight/Obese|Eligible subjects will undergo a 10-week moderate intensity exercise program.
2916665|NCT03133156|Experimental|Moderate Intensity Training-Overweight/Obese Type 2 Diabetes|Eligible subjects will undergo a 10-week moderate intensity exercise program.
2916666|NCT03133156|Experimental|High Intensity Training-Healthy Lean.|Eligible subjects will undergo a 10-week high intensity exercise program
2916699|NCT03132948|Experimental|Physical Activity|Single arm study where patients choose from physical activities after baseline assessment by PT. Activities include the following: Nintendo WII fit console, Xbox Kinect fit console and other sport activities.
2916743|NCT03132571|Experimental|Bupropion XL (150-450mg flex dosing)|Oral Bupropion taken once a day for 16 weeks.
2916667|NCT03133143|Experimental|Overwatch (Blizzard Entertainment)|"Entertainment game not specifically designed to improve cognitive abilities of patients. Released for windows, XBox One and Playstation 4, it is a team-based multiplayer first-person shooter game. Players play in teams of six players and battle against other teams. The game play of Overwatch is fast-paced and requires quick decision-making, teamwork, staying very focused and tracking quickly appearing and disappearing objects. Each player can choose their character from four characters classes that emphasize Offense, Defence, Tank and Support type of playing."
2916668|NCT03133143|Experimental|Project:Neural|Multi-player game, specifically designed to improve ecologically valid working memory functioning. Combines the task-oriented immersion of first-person action games with the targetable high-level cognitive demands intrinsic to real-time strategy games, near the top rating level graphical quality. Unlike other products used or developed in the cognitive training field, Project:Neural (like Overwatch) is a multiplayer game. Playing with others in positive settings yields social interactions, engagement, teamwork. A multi-faceted reward system offeres a broad-spectrum of mental and social activation, empowerment and positivity, targeted and adaptive training of specific cognitive domains in attentional and executive control. Predecessor has been used in a clinical intervention trial.
2916669|NCT03133143|Active Comparator|SimCity|The patients in this group will play SimCity (Maxis, Inc.) for the same amount of time as the other intervention games. Some prior evidence has shown that, because of a lack of high-intensity action and competition, this specific game and non-competitive games like it in general do not improve attention, working memory, or other cognitive abilities despite being engaging and fun.
2916670|NCT03133130|Experimental|BMT101|cp-lasiRNA
2916671|NCT03133130|Placebo Comparator|Placebo|Normal Saline
2916672|NCT03133117|Experimental|Cerebral Bases of Central and Peripheral Visual Integration|
2916673|NCT03133104||antenatal corticosteroids|Women who received a rescue dose of steroids
2916674|NCT03133104||No antenatal corticosteroids|Women who did not received a rescue dose of steroids
2916675|NCT03133091|Active Comparator|PIEB (Patient Intermittent Epidural Bolus)|"PIEB: The boluses are programmed every 30 minutes. The patient can ask for another extra bolus in between if she wishes.~The dosis per hour are equivalent to the PCEA. We make a comparison between PCEA vs PIEB."
2916676|NCT03133091|Active Comparator|PCEA (Patient continuous Epidural Analgesia)|"PCEA: There is a continuous infusion and the patient can order extra boluses every 15 minutes.~The dosis per hour are equivalent to the other arm to the PIEB. We make a comparison between PCEA vs PIEB."
2916677|NCT03133078|Experimental|Exercise: step-down test (2 min)|The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.
2916678|NCT03133078|Experimental|Exercise: side hop test (30 s)|The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
2916679|NCT03133065|Active Comparator|Group 1: treatment after 6 months post transplantation|53 patients received Sofosbuvir+ribavirin standard of care for treatment of HCV post liver transplantation for 6 months
2916680|NCT03133065|Active Comparator|Group 2: early treatment afer 3 months post transplantation|36 patients received other DAAs regiment for treatment of HCV post liver transplantation for 3- 6 months
2916681|NCT03133052|Active Comparator|training group|Intervention: Internet-based adaptive cognitive control training program. 5 x 30 minutes per week, for 12 weeks.
2916682|NCT03133052|Placebo Comparator|control group|Intervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 12 weeks.
2916683|NCT03133039|Active Comparator|bioabsorbable screw|
2916684|NCT03133039|Active Comparator|titanium screw|
2916685|NCT03133026|Active Comparator|Sludge group|If Single operator cholangioscopy reveals only sludge then sludge will be cleared using conventional technique during ERCP.
2916686|NCT03133026|Active Comparator|Ingrowth / Overgrowth|If Single operator cholangioscopy reveals tumour ingrowth or overgrowth then to evaluate the role of biliary RFA for occluded stent due to tumour ingrowth or overgrowth
2916687|NCT03133013|Experimental|Individuals with Untreated Depression|32 participants diagnosed with Major Depressive Disorder by a psychiatric specialist of this research according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and defined as a score of 15 or higher on the clinician-administered Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.
2916688|NCT03133013|Other|Healthy Participants|32 healthy participants with absence of mental disorders, including but not limited to depression and sleep disorders, by a psychiatric specialist according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and negative Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.
2916689|NCT03132987|Experimental|Progressive strengthening program|Subjects identified as having a clinically relevant strength deficit will be asked to participate in physical therapy sessions 3 times per week for 3 weeks. The strengthening program will consist of an individualized, progressive exercise program with an emphasis on increasing lower extremity strength, power, and biomechanics.
2916690|NCT03132974|Experimental|SGHH|Admission to Sogyeonghwalhyeol-tang granule
2916691|NCT03132974|Experimental|SGHH with manipulation therapy|Admission to Sogyeonghwalhyeol-tang granule and manipulation therapy
2916692|NCT03132974|Placebo Comparator|Placebo with manipulation therapy|
2916693|NCT03132961||Block 1|Participants in the cohort will undergo testing in the order of: ECoG, oVEMP, cVEMP
2916694|NCT03132961||Block 2|Participants in the cohort will undergo testing in the order of: ECoG, cVEMP, oVEMP
2916695|NCT03132961||Block 3|Participants in the cohort will undergo testing in the order of: oVEMP, cVEMP, ECoG
2916696|NCT03132961||Block 4|Participants in the cohort will undergo testing in the order of: oVEMP, ECoG, cVEMP
2916700|NCT03132935||Telemedicine group|Telemedical care of acute coronary syndromes in the prehospital phase. Paramedics were supported by a physician in a tele consultation centre.
2916701|NCT03132935||Control group|Conventional on-scene care of acute coronary syndromes by a physician. No telemedicine system was available during this control period.
2916702|NCT03132922|Experimental|Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|
2916703|NCT03132896||Patients with moderate or severe ARDS|
2916704|NCT03132818||Patients undergoing AMP with oocyte donation|
2916705|NCT03132818||Couples supported in AMP with sperm donation|
2916706|NCT03132818||Couples supported in AMP intra torque|
2916707|NCT03132805|No Intervention|Control|Schools which receive no intervention
2916708|NCT03132805|Experimental|PATHS to PAX|Universal classroom-based preventive intervention designed to reduce aggression.
2916709|NCT03132805|Experimental|PATHS to PAX and the IncredibleYears|The combination of PATHS to PAX with the Incredible Years child and parent groups.
2916710|NCT03132792|Experimental|Autologous genetically modified AFPᶜ³³²T cells|
2916711|NCT03132779|Experimental|One armed|One group of patient will take Intralipid for all
2916712|NCT03132766|Experimental|New Hope + Elders' Resilience + CM|Participants will receive case management plus the New Hope curriculum and subsequently the Elders' Resilience curriculum.
2916713|NCT03132766|Experimental|New Hope + CM|Participants will receive case management plus the New Hope curriculum.
2916714|NCT03132766|Experimental|Elders' Resilience + CM|Participants will receive case management plus the Elders' Resilience curriculum.
2916715|NCT03132766|Active Comparator|CM alone|Participants will receive case management only.
2916716|NCT03132753|Experimental|SUPPORT Group|Subjects enrolled in the intervention.
2916717|NCT03132753|No Intervention|Treatment as Usual|Subjects enrolled in standard services.
2916718|NCT03132727||Pharyngo laryngeal MRI|Patient with a laryngeal or hypopharyngeal cancer at any stage, with a doubt about cartilage invasion and eligible for surgical treatment for which there is an indication for performing an MRI in addition to CT at the discretion of the investigator
2916719|NCT03132714|Active Comparator|PD + (AMX + MET)|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg
2916720|NCT03132714|Active Comparator|PD + CLM|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic clarithromycin 500 mg
2916721|NCT03132714|Active Comparator|PD + (AMX + MET) + sPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg and single application of PDT
2916722|NCT03132714|Active Comparator|PD + CLM + sPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Clarithromycin 500 mg and single application of PDT
2916723|NCT03132714|Active Comparator|PD + (AMX + MET) + rPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg and repeated application of PDT
2916724|NCT03132714|Active Comparator|PD + CLM + rPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Clarithromycin 500 mg and repeated application of PDT
2916725|NCT03132701|Active Comparator|Magnesium group|Mg is administered with dose of 30 mg/kg for 10 minutes and then 10 mg/kg/hr until 5 minutes before surgery ends
2916726|NCT03132701|Placebo Comparator|Control group|Saline is administered with same volume of Mg of magnesium group until 5 minutes before surgery ends
2916727|NCT03132688||children < 2 years old|Children under 2 years of age who received intravenous propofol during general anesthesia.
2916728|NCT03132675|Experimental|Treatment|intratumoral tavo-EP plus IV pembrolizumab
2916729|NCT03132662|Active Comparator|Very Low Calorie Diet|The first group will continue according to the standard bariatric preoperative protocol and will be assigned a VLCLD of 900 cal/day (Optifast ® 4 servings/day each containing: 225 cal + 0.35 g linolenic acid) for 2-3 weeks prior to surgery according to the surgeon's preferences.
2916730|NCT03132662|Experimental|Omega-3|The second group will be assigned to 3 gr. daily oral intake of Ω-3 PUFAs ((Oceano3 ® 1000 mg Krill Oil tabs (150 mg EPA + 90 mg DHA) 3 times a day) for 4 weeks with only regular dietary suggestions before surgery.
2916731|NCT03132662|No Intervention|No-treatment|The third group will not receive treatment for liver size reduction prior to surgery.
2916732|NCT03132636|Experimental|Group 1- metastatic BCC|Administration of REGN2810 in accordance with protocol dosing regimen
2916733|NCT03132636|Experimental|Group 2 - unresectable locally advanced BCC|Administration of REGN2810 in accordance with protocol dosing regimen
2916734|NCT03132623|Active Comparator|Experimental group|andrographolide sulfonate(Xiyanping injection) 10-20ml/d, With 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
2916735|NCT03132623|Placebo Comparator|control group|andrographolide sulfonate simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
2916736|NCT03132610|Active Comparator|Experimental group|Conventional Therapy + Xiyanping injection(andrographolide sulfonate)
2916737|NCT03132610|Placebo Comparator|control group|Conventional Therapy + Xiyanping injection simulation/andrographolide sulfonate simulation(0.9% normal saline)
2916738|NCT03132597|Experimental|Early Mindfulness exposure|six weeks of 2 hours class of mindfulness training and orientations for home training at the beginning of the first semester
2916739|NCT03132597|Experimental|Late Mindfulness exposure|six weeks of 2 hours class of mindfulness training and orientations for home training at the second half of the first semester
2916740|NCT03132597|No Intervention|Control (not exposed)|Students not exposed to the mindfulness mandatory course (not exposed to the intervention)
2916741|NCT03132584|Experimental|Cyclophosphamide and Alemtuzumab|"After the screening procedures confirm participation in the research study:~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have CD52 positive aggressive lymphoma. Not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.~Cyclophosphamide~Alemtuzumab"
2916744|NCT03132571|Placebo Comparator|Placebo|Oral placebo capsule taken once daily for 16 weeks.
2916745|NCT03132558||CTA|Patients with AIS only receieved cerebral CTA exam.
2916746|NCT03132558||CTA+DSA|Patients with AIS receieved cerebral CTA, followed by endovascular treatment with the guidence of digital substration angiography (DSA).
2916747|NCT03132545||PCOS|
2916748|NCT03132545||controls|
2916749|NCT03132532|Active Comparator|Chemotherapy and Proton Beam Therapy 60 gray (Gy)|Concurrent and consolidative chemotherapy carboplatin/paclitaxel & Proton Beam Therapy to 60 Gy in 2 Gy daily fractions
2916750|NCT03132532|Active Comparator|Chemotherapy and Proton Beam Therapy 66 Gy|Concurrent and consolidative chemotherapy carboplatin/paclitaxel & Proton Beam Therapy to 66 Gy in 2 Gy daily fractions
2916751|NCT03132532|Active Comparator|Chemotherapy and Proton Beam Therapy 72 Gy|Concurrent and consolidative chemotherapy carboplatin/paclitaxel & Proton Beam Therapy to 72 Gy in 2 Gy daily fractions
2916752|NCT03132519|Experimental|Sevo-2.0|This group will maintain remifentanil infusion by TCI to 2 ng/ml during emergence and extubation after have received sevoflurane during procedure.
2916753|NCT03132519|Experimental|Sevo-2.5|This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.
2916754|NCT03132519|Experimental|Des-2.0|This group will maintain the remifentanil infusion by TCI to 2.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
2916755|NCT03132519|Experimental|Des-2.5|This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
2916756|NCT03132519|Active Comparator|Sevo-Control|This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.
2916757|NCT03132519|Active Comparator|Des-Control|This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
2916758|NCT03132506||paper-based patient-reported-outcomes|
2916759|NCT03132506||on web-based patient-reported-outcomes|
2916760|NCT03132480|Experimental|hypovolemia|
2916761|NCT03132467|Experimental|Tremelimumab + Durvalumab|"Participants receive Tremelimumab on Day 1 of each cycle by vein over about 1 hour, then receive Durvalumab by vein over about 1 hour.~Participants receive study drugs in 2 study cycles that are each 4 weeks long.~Participant have a core breast tumor biopsy before participant begins treatment, at the end of Cycle 2, and during participant's surgery."
2916762|NCT03132454|Experimental|Arm A: Palbociclib + Sorafenib|"Participants take Palbociclib alone by mouth 1 time each day on Days 1-28 of Cycle 1 only.~There are 28 days in each study cycle.~In Cycle 2, participants continue to take Palbociclib on Days 1-21 of each cycle, plus Sorafenib by mouth on Days 1-28 of each cycle till maximum tolerated combination dose met.~Participants may continue receiving the study drug(s) for up to 8 cycles."
2916763|NCT03132454|Experimental|Arm B: Palbociclib + Decitabine|"Participants take Palbociclib alone by mouth 1 time each day on Days 1-28 of Cycle 1 only.~There are 28 days in each study cycle.~In Cycle 2, participants continue to take Palbociclib on Days 1-7, plus Decitabine by vein over about 1 hour on Days 8-17. Beginning in Cycle 3, participant takes Palbociclib on Days 1-7 of each cycle, and Decitabine by vein over about 1 hour on Days 8-12 of each cycle till maximum tolerated combination dose met.~Participants may continue receiving the study drug(s) for up to 8 cycles."
2916764|NCT03132454|Experimental|Arm C: Palbociclib + Dexamethasone|"This arm is open only for patients with a diagnosis of R/R ALL.~Participants take Palbociclib alone by mouth 1 time each day on Days 1-28 of Cycle 1 only.~There are 28 days in each study cycle.~In Cycle 2, participants continue to take Palbociclib on Days 1-21 of each cycle, plus Dexamethasone either by mouth or by vein over about 30 minutes on Days 1-4 and Days 15-18 of each cycle till maximum tolerated combination dose met.~Participants may continue receiving the study drug(s) for up to 8 cycles."
2916765|NCT03132441|Experimental|Cardiac Rehabilitation|"Strength Training for Frailty:~All patients enrolled will be enrolled in 6 weeks of cardiac rehabilitation for the pilot study."
2916766|NCT03132428||Premature (P) Neonates|84 P neonates (at least 27 weeks but less than 34 weeks of gestational age [GA])
2916767|NCT03132428||Term-Near-Term (TNT) Neonates|84 TNT neonates >34 weeks of age
2916768|NCT03132415|Experimental|Get Connected|Get Connected is a brief intervention focused on resolving ambivalence about HIV prevention behaviors, increasing self-efficacy for change, and enhancing motivation moving toward action.
2916769|NCT03132415|Active Comparator|Non-tailored HIV Test Locator|Participants randomized to the control condition will be directed to a website that includes information on the AIDSVU.org testing site locator. Given the availability of search engines to locate HIV/STI testing sites, the test locator condition may be considered usual care.
2916770|NCT03132389||Patients attending after a sexual assault|Patients attending and examined after sexual assault at the Sexual Assault Centre in Oslo, who have given informed consent to inclusion in the study.
2916771|NCT03132376|Experimental|Breakfast Preload Drink|"Participants were given isovolumetric drinks, to consume in the morning after an overnight fast, followed by questionnaires asking throughout the day asking participants of their perceived hunger, fullness, desire to eat, and prospective food consumption, and if they would like to eat again. Four hours following consumption, they were given an ad libitum pasta meal to consume.~The drinks consisted of the following:~Water Preload Drink, Whey Protein Isolate Drink, Micellar Casein Protein Drink, Egg White Isolate Protein Drink, and Egg White Concentrate Protein Drink"
2916772|NCT03132337||Stem Cell Transplant|Serial Blood Draws
2916773|NCT03132324|Experimental|INCB059872 QOD|Initial cohort dose of INCB059872 at the protocol-specified starting dose once every other day (QOD), with subsequent cohort escalations based on protocol-specific criteria.
2916774|NCT03132324|Experimental|INCB059872 QD|After the first 3 dose cohorts have been evaluated for tolerability of a QOD schedule, a parallel cohort will evaluate a once-daily (QD) schedule with subsequent dose escalations based on protocol-specific criteria.
2916775|NCT03132311|Experimental|HIV positive subjects|"300 HIV positive adults with CD4 > 200 cells/mm3, stratified in 3 groups (100 patients in each group) according to CD4 counts (200-350; 351-500, >500 cells/mm3).~Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)"
2916840|NCT03131830||Participants of the 9th German Urogynecological Congress|Online-based questionnaire
2916776|NCT03132311|Active Comparator|HIV negative subjects|"100 HIV negative adults.~Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)"
2916777|NCT03132298|Experimental|Implicit Theories of Personality Program|"This program is self-administered, computer-based, and 30 minutes in length. Content is designed to maximize relevance for youths with internalizing distress. The program includes 5 elements: 1. An introduction the concept of neuroplasticity; 2. Testimonials from older youths describing beliefs that people's traits are malleable, given the brain's capacity for change; 3. Further vignettes by older youths describing times when they used growth mindsets to cope with peer rejection, hopelessness, and feared embarrassment; 4. A worksheet describing strategies for applying these principles to participants' lives; 5. An exercise wherein participants write notes to younger children, using newly-gleaned information about the malleability of personal traits to help them to cope with setbacks"
2916778|NCT03132298|Active Comparator|Control Program|The Control Program is a computer-based session of supportive therapy (ST), designed to encourage youths to identify and express feelings. ST does not teach specific skills or beliefs and has been shown to be less effective than cognitive-behavioral interventions in reducing youth internalizing distress. Here, ST was designed to control for nonspecific intervention elements (eg. completing an interactive computer program) and to encourage youths to share emotions with others. ST included the same number of reading/writing activities as the experimental program and took the same amount of time (30 mins.) to complete.
2916779|NCT03132285|Other|PrePex Day 0 foreskin removal|Day 0 foreskin removal
2916780|NCT03132272|Experimental|Immunoadsorption with Globaffin for Alzheimer Dementia|Immunoadsorption with Globaffin
2916781|NCT03132259|Experimental|High dose dexmedethomidine|High dose is 0.5 microgram/kg/hr
2916782|NCT03132259|Experimental|Low dose dexmedethomidine|Low dose is 0.2 microgram/kg/hr
2916783|NCT03132246|Other|High Risk/Infected|Each patient enrolled in the study provides blood samples up to 10 times. These blood samples are to be tested using basic science techniques to determine the level of exposure to a staphylococcal biofilm each patient has experienced over a period of time.
2916784|NCT03132233|Active Comparator|Verum|Receives the investigational medicine product (IMP; Beta-hydroxybutyrate calcium and magnesium salt).
2916785|NCT03132233|Placebo Comparator|Placebo|Receives a matched placebo powder to the IMP.
2916786|NCT03132220|Active Comparator|Book Club Active Control|"The subject will participate in 16 in-person hours that are broken into sessions for the book club active control intervention. This club will be facilitated by 1-2 instructors. The club will be described as a fun activity to do outside of work to help reduce work-related stress. The club will be structured similarly to the intervention with respect to time, and homework expectations. Nurses will be prohibited from talking about work stress."
2916787|NCT03132220|Experimental|MBCT Intervention|The subject will participate in 16 in-person hours that are broken into sessions for the Mindfulness-Based Cognitive Therapy intervention. The intervention will be facilitated by 1-2 instructors who are trained in clinical psychology/ social work and are also trained in MBCT. This intervention will include mindfulness activities, didactic learning, homework assignments and group dialogue. This adapted MBCT intervention will follow the empirically-based MBCT intervention for depression structure with fidelity.
2916788|NCT03132207||Pregnant women|Pregnant women attending hospital during pregnancy monitoring and / or being hospitalized in one of the maternity wards associated with the project.
2916789|NCT03132207||Professional|health professionals in charge of the follow-up of these pregnant women and their childbirth.
2916790|NCT03132194|Experimental|DPSG 7.5%|"DPSG 7.5% (Taro Pharmaceuticals USA)~Topical, twice daily on the face for 84 days."
2916791|NCT03132194|Placebo Comparator|Vehicle Gel|"Placebo product (Taro Pharmaceuticals Inc.)~Topical, twice daily on the face for 84 days."
2916792|NCT03132194|Active Comparator|Aczone|"dapsone 7.5~Topical, twice daily on the face for 84 days."
2916793|NCT03132181|Experimental|Empagliofizin|Patients will receive empagliflozin 10 mg qd for a period of 3 months.
2916794|NCT03132181|Placebo Comparator|Placebo|Patients of the placebo arm will receive placebo tablets qd for a period of 3 months.
2916795|NCT03132168|Other|Subjects undergoing radical cystectomy|Subjects involved in the study will be evaluated with various non-invasive assessments including the Richmond Agitation-Sedation Scale, pain assessments on a Numeric Rating Scale (NRS-11), and CAM-ICU scale. Blood draws will also take place in order to perform microRNA testing in all subjects participating in the trial. Standardized anesthetic care as described by the approved protocol will be followed for each subject included in this trial.
2916796|NCT03132155|Experimental|AMG 337|AMG 337 will be administered in patients with advanced or metastatic clear cell sarcoma
2916797|NCT03132142|Experimental|Capsaicin|Capsacin (8%) patches applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms.
2916798|NCT03132142|Experimental|Trans-cinnamaldehyde|Trans-cinnamaldehyde (10%, dissolved in 90% ethanol) applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms on a cotton ball placed in a plastic chamber to limit evaporation.
2916799|NCT03132142|Experimental|L-menthol|L-menthol (40%, dissolved in 96% ethanol) applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms on a cotton ball placed in a plastic chamber to limit evaporation.
2916800|NCT03132142|Placebo Comparator|Vehicle patch|Inert vehicle patches applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms.
2916801|NCT03132129||Type 2 diabetics|
2916802|NCT03132129||Healthy controls|
2916803|NCT03132116|Experimental|Gentamicin|intra-nodal injection of gentamicin
2916804|NCT03132116|Placebo Comparator|Placebo|intra-nodal injection of placebo
2916805|NCT03132103|Experimental|Solar simulated radiation (SSR)|Solar simulated radiation (SSR)
2916806|NCT03132103|Placebo Comparator|Placebo SSR|Placebo SSR
2916807|NCT03132103|Experimental|Oral Vitamin D3|Oral Vitamin D3
2916808|NCT03132103|Placebo Comparator|Placebo Oral Vitamin D3|Placebo Oral Vitamin D3
2916809|NCT03132077||satisfaction post total knee arthroplasty|The focus of this project is exploring outcomes post-primary total knee arthroplasty (TKA) using the available pre/post-operative Oxford Knee Score (OKS), University of California Los Angeles (UCLA) Activity Score, EQ-5D General Health Questionnaire, Visual Analogue (VAS) for pain, age and smoking status data, and correlations between these data and post operation patient satisfaction.
2916810|NCT03132064||post total knee arthroplasty|The measurements will made for patients before and after total knee arthroplasty to explore the improvements and possible correlation with preoperative pain psychology and hypersensitivity
2916811|NCT03132051|Experimental|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
2916812|NCT03132038|Experimental|Nivolumab|Nivolumab will be given every two weeks for a maximum of one year (12 cycles) at a dose of 3mg/kg to be administered as a 60 minute IV infusion
2916813|NCT03132025|Experimental|"A: apatinib and capecitabine"|"Arm A: apatinib and capecitabine apatinib 250mg qdpo; capecitabine 1000mg/m2 qdpo d1-14 q3w"
2916814|NCT03132025|Active Comparator|"B: capecitabine single drug"|"Arm B: capecitabine single drug capecitabine 1000mg/m2 qdpo d1-14 q3w"
2916815|NCT03132012|Experimental|Indoor tanning intervention|Web-based intervention modules to discourage tanning.
2916816|NCT03132012|Active Comparator|standard of care control|General information regarding UV protection measures through an online Qualtrics interface. Content will mirror information provided in brochures typically available in a dermatology office or through skin cancer prevention websites.
2916817|NCT03131999|Experimental|Imatinib Mesylate 400mg capsule|56 days of Imatinib mesylate 400 mg oral daily with or without co-administration of an mTOR inhibitor for 28 days. A dose reduction to 200 mg daily is allowed for toxicity.
2916818|NCT03131999|Placebo Comparator|Placebo Capsule|56 days of Placebo with or without co-administration of an mTOR inhibitor for 28 days. A dose reduction is allowed for toxicity.
2916819|NCT03131973|Experimental|Methotrexate|Methotrexate single oral dose followed by leucovorin single oral dose on specified days followed by BMS-986195 coadministered with methotrexate single oral dose followed by leucovorin single oral dose on specified days
2916820|NCT03131973|Experimental|Cytochrome P450 and Transporter Substrates|Caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin single oral dose on specified days, BMS-986195 multiple oral dose administration on specified days, and BMS-986195 coadministered with caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin single oral dose on specified days.
2916821|NCT03131960|Experimental|VNS + Rehabilitation (1)|Study treatment is vagus nerve stimulation (VNS) delivered during rehabilitation.
2916822|NCT03131960|Active Comparator|Control VNS|Active control treatment is rehabilitation (standard-of-care treatment) with only a minimal amount of VNS at the start of each session intended to support blinding.
2916823|NCT03131947||Union|Radiological union on RUST score (figure 2) (score of 3 on at least 3 cortices in AP, lateral, medial or posterior cortex - total of 9 or more) within 6 months of surgery
2916824|NCT03131947||Delayed union|Impaired bone healing at six months (RUST score < 9)
2916825|NCT03131934|Experimental|Autologous EBV-CTL transduced with SFG-CNA12/SFG-CNA8|"All patients will receive the autologous EBV CTL retrovirally transduced with with (a) a calcineurin mutant (CNA12) that confers resistance to tacrolimus and (b) a control calcineurin mutant (CNA8). For each patient two ATIMPs will be generated:~Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12~Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8~An equal dose (10x7/m2) of CNA12+ EBV CTL and CNA8+ EBV CTL will be administered intravenously on day 0.~While awaiting ATIMP generation, patients may receive a single dose of Rituximab and other immunosuppressants (e.g. MMF) will be reduced, but tacrolimus will be maintained at therapeutic levels."
2916826|NCT03131921||Colorectal cancer|No intervention. Patients with newly diagnosed stage II-IV colorectal cancer will be enrolled.
2916827|NCT03131921||Breast cancer|No intervention. Patients with newly diagnosed stage IV breast cancer will be enrolled.
2916828|NCT03131908|Experimental|GSK2636771 + Pembrolizumab|"Phase I: Participants receive the lowest dose level of GSK2636771. Each new group receives a higher dose of GSK2636771 than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of GSK2636771 is found. Participants receive the same dose level of Pembrolizumab.~Phase II: Participants receive GSK2636771 at the highest dose that was tolerated in Phase 1. Participants receive the same dose level of Pembrolizumab."
2916829|NCT03131895|Experimental|Part 1, Sequence 1 (Regimen A, B)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once on Day 1 of Period 2 following a 10-hour fast.
2916830|NCT03131895|Experimental|Part 1, Sequence 2 (Regimen B, A)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once on Day 1 of Period 2 following a 10-hour fast.
2916831|NCT03131895|Experimental|Part 2, Sequence 3 (Regimen C, D)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once on Day 1 of Period 2 following a 10-hour fast.
2916832|NCT03131895|Experimental|Part 2, Sequence 4 (Regimen D, C)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regiment C [test]), orally, once on Day 1 of Period 2 following a 10-hour fast.
2916833|NCT03131882|Experimental|Hyaluronic acid|Hyaluronic acid
2916834|NCT03131882|Active Comparator|Triamcinolone acetonide|10mg/ml Triamcinolone acetonide
2916835|NCT03131856|Experimental|Nutritional intervention programme|An individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks).
2916836|NCT03131856|No Intervention|Usual care|Usual care which means no individual dietary plan and no nutrition follow-up visits after discharge.
2916837|NCT03131843|Experimental|Alcohol|Alcohol will be wiped on the vaccine injection site immediately before vaccine injection.
2916838|NCT03131843|Placebo Comparator|No alcohol|Alcohol will be wiped adjacent to the vaccine injection site immediately before vaccine injection.
2916839|NCT03131830||Staff of the University Clinic of Tuebingen|Online-based questionnaire
2916841|NCT03131830||All members of the German Society of Obsetrics and Gynecology|Online-based questionnaire
2916842|NCT03131830||Pregnant women from Tübingen and Heidelberg|Online-based questionnaire
2916843|NCT03131817|Experimental|PD with mood disorder or impulsivity|This is a single-center study of the neurophysiology of non-motor symptoms such as anxiety, depression, and impulsivity that are comorbid in Parkinson's Disease.
2916844|NCT03131804|Experimental|Interventional Participants|Patients will represent their own controls (pre and post intervention), in the HD unit of Al Qassimi Hospital, Sharjah, United Arab Emirates.
2916845|NCT03131791|Experimental|shock wave|The interventions were focused in the hypertonic muscles of the upper limb of 3000 impulses, a pressure of 1.5 bar and frequency of 5Hz were used to treat the biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
2916846|NCT03131791|Experimental|Botulinum toxin A|We performed BoNT-A 500 unit in 2cc 0.9% normal saline at biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
2916847|NCT03131778|Active Comparator|Open Liver Resection|Conventional open liver resection trough subcostal incision
2916848|NCT03131778|Experimental|Laparoscopic Liver Resection|Pure laparoscopic liver resection without hand assistance
2916849|NCT03131765|Experimental|YS-ON-001|"Phase 1- Dose escalation based on YS-ON-001 safety and tolerability obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur.~Phase 1b- recommended dose determined in Phase 1. Enrollment of two expansion cohorts will be restricted to the tumour types, breast cancer and liver cancer"
2916850|NCT03131752|Experimental|Intervention Group|"The patients will be evaluated on 4 phases: at the first contact (at least 24 hours after drug therapy and at most 48 hours), 7 days, 30 days and 3 months after the first contact. They will be submitted to an anamnesis, assessment of muscular strength, physical activity level, functional capacity, dyspnea on activity daily living and quality of life.~The intervention will last 7 days for all the patients. Three phases will be performed: warm up, knee muscle strengthening with elastic bands and stretch/relax."
2916851|NCT03131752|No Intervention|Control Group|"The patients will be evaluated on 4 phases: at the first contact (at least 24 hours after drug therapy and at most 48 hours), 7 days, 30 days and 3 months after the first contact. They will be submitted to an anamnesis, assessment of muscular strength, physical activity level, functional capacity, dyspnea on activity daily living and quality of life.~Patients will be not receive intervention."
2916852|NCT03131739||Community Level Assessment|65 communities will undergo assessment of community / structural variables through review of public records and 3-5 key community interviewees per community.
2916853|NCT03131739||Individual Level Assessment|A subset of 6 communities will be elected through a stratification process. Youth will complete a set of protective factors measures and outcomes. Adults will complete a section of the Neighborhood Matters survey.
2916854|NCT03131726|Experimental|Simvastatin|simvastatin 40 mg daily for 6 months
2916855|NCT03131726|Experimental|Diclofenac|diclofenac 50 mg twice a day for 6 months
2916856|NCT03131726|No Intervention|No treatment|No treatment
2916857|NCT03131713|No Intervention|Control|The control group will receive usual perioperative care including patient education on diagnosis, treatment and prognosis of skin cancer, encouragement of food and fluid intake prior to and during the surgery as needed, and acetaminophen per patient request.
2916858|NCT03131713|Experimental|Intervention|The intervention group, in addition to usual care, will receive Acetaminophen 1000mg and commercially available carbohydrate drink (two pouches of Gatorade Prime Sports Fuel drink containing 50gm carbohydrate in approximately 250ml fluid total) at the beginning of the surgery.
2916859|NCT03131700|Experimental|RPH-001|A single dose of RPH-001 will be administered (IV) 5 mg/kg dose .
2916860|NCT03131700|Active Comparator|EU sourced Avastin®|A single dose of Avastin® will be administered (IV) 5 mg/kg dose .
2916861|NCT03131687|Experimental|LY3298176 Dose 1 + Placebo|LY3298176 and placebo given subcutaneously (SC).
2916862|NCT03131687|Experimental|LY3298176 Dose 2 + Placebo|LY3298176 and placebo given SC.
2916863|NCT03131687|Experimental|LY3298176 Dose 3 + Placebo|LY3298176 and placebo given SC.
2916864|NCT03131687|Experimental|LY3298176 Dose 4 + Placebo|LY3298176 and placebo given SC.
2916865|NCT03131687|Placebo Comparator|Placebo|Placebo administered SC.
2916866|NCT03131687|Active Comparator|Dulaglutide + Placebo|Dulaglutide and placebo given SC.
2916867|NCT03131674|Experimental|Direct treatment|
2916868|NCT03131674|Experimental|Delayed treatment|
2916869|NCT03131661||SpA with DMARDs|Participants with first diagnosis or confirmed diagnosis of Spondyloarthritis (SpA) and naïve to conventional, targeted or biological Disease modifying anti-rheumatic drugs (DMARDs) will be observed in order to describe SpA characteristics and pattern of clinical presentation.
2916870|NCT03131648|Experimental|Tralokinumab initial period -> Tralokinumab maintenance A|"Week 0 to Week 16:~tralokinumab loading SC injection at Day 0 - loading dose tralokinumab SC injection regimen A~Week 16 to Week 52:~tralokinumab maintenance SC injection regimen A"
2916871|NCT03131648|Experimental|Tralokinumab initial period -> Tralokinumab maintenance B|"Week 0 to Week 16:~tralokinumab loading SC injection at Day 0 - loading dose tralokinumab SC injection regimen A~Week 16 to Week 52:~tralokinumab maintenance SC injection regimen B"
2916872|NCT03131648|Experimental|Tralokinumab initial period -> Placebo maintenance|"Week 0 to Week 16:~tralokinumab loading SC injection at Day 0 - loading dose tralokinumab SC injection regimen A~Week 16 to Week 52:~placebo maintenance SC injection regimen A"
2916873|NCT03131648|Placebo Comparator|Placebo initial period -> Placebo maintenance|"Week 0 to Week 16:~placebo loading SC injection at Day 0 - loading dose placebo SC injection regimen A~Week 16 to Week 52:~placebo maintenance SC injection regimen A"
2916874|NCT03131648|Experimental|Tralokinumab initial period -> Open-label tralokinumab|"Week 0 to Week 16:~tralokinumab loading SC injection at Day 0 - loading dose tralokinumab SC injection regimen A~Week 16 to Week 52:~tralokinumab maintenance SC injection regimen A - open-label with allowed use of topical corticosteroids"
2916875|NCT03131648|Experimental|Placebo initial period -> Open-label tralokinumab|"Week 0 to Week 16:~placebo loading SC injection at Day 0 - loading dose placebo SC injection regimen A~Week 16 to Week 52:~tralokinumab maintenance SC injection regimen A - open-label with allowed use of topical corticosteroids"
2975152|NCT02729142|Experimental|Tibial cortical density evaluation|
2916876|NCT03131635|Experimental|Developmental Reciprocity Treatment Program (DRT-P)|Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.
2916877|NCT03131635|No Intervention|Delayed Treatment Group (DTG)|
2916878|NCT03131622|Experimental|Digital Therapeutics|Patients assigned to the digital therapeutics arm will receive Ibis and all the associate services.
2916879|NCT03131622|No Intervention|Control|
2916880|NCT03131609||A: Container + Castile-soap wipe|Sterile urine collection container and Castile-soap wipe given to patient to self-obtain a clean catch mid-stream urine specimen - Control group represents usual care in the Emergency Department.
2916881|NCT03131609||B: Container + Silver impregnated wipe|Sterile urine collection container and silver-impregnated cloth-wipe given to patient to self-obtain a clean catch mid-stream urine specimen
2916882|NCT03131609||C: Funnel + Castile-soap wipe|Sterile urine collection funnel and Castile-soap wipe given to patient to self-obtain a clean catch mid-stream urine specimen
2916883|NCT03131609||D: Funnel + Silver-impregnated wipe|Urine collection funnel and sliver impregnated cloth-wipe given to patient to self-obtain a clean catch mid-stream urine specimen
2916884|NCT03131596|Experimental|IUB dilatation therapy|The patient will have Foley-catheter intrauterine balloon dilatation 2 weeks and 6 weeks after hysteroscopic adhesiolysis. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and an optional third-look hysteroscopy will be carried out 8 weeks after the surgery.
2916885|NCT03131596|No Intervention|control group|Patient will not undergo any balloon therapy. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and an optional third-look hysteroscopy will be carried out 8 weeks after the surgery.
2916886|NCT03131583|Experimental|Cohort 1|Colchicine 0.5 mg Oral Tablet Day-14~Day16 qd, Febuxostat 80 mg Oral Tablet Day1 and Day8 qd, SHR4640 10 mg Oral Tablet Day3~Day8 qd.
2916887|NCT03131570|Experimental|Group 1|6 months of Secukinumab at a dose of 300 mg with injections administered once weekly at baseline and at weeks 1, 2, 3, and 4 and then every 4 weeks for 6 months of period.
2916888|NCT03131570|Placebo Comparator|Group 2|Placebo followed by Secukinumab. 3 months of placebo followed by 3 months of Secukinumab at a dose of 300 mg with injections administered once weekly at week 12 and at weeks 13, 14, 15, and 16 and then every 4 weeks for 3 months of period.
2916889|NCT03131557|Experimental|Line extension of the Phonak Audéo B hearing aid|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
2916890|NCT03131557|Active Comparator|Phonak Audéo B hearing aid|Phonak Audéo B will be fitted to the participants individual hearing loss.
2916891|NCT03131544|Experimental|FLA for BPH Active Treatment|
2916892|NCT03131531||Hodgkin lymphoma|
2916893|NCT03131531||Non-Hodgkin lymphoma|
2916894|NCT03131531||Myeloma|
2916895|NCT03131518|Other|E-bicycle|Access to an e-bicycle will be provided.
2916896|NCT03131518|Other|Longtail bicycle|Access to a longtail bicycle will be provided.
2916897|NCT03131518|Other|Traditional bicycle|Access to a traditional bicycle will be provided.
2916898|NCT03131479|Experimental|Mild renal impairment|Patients with mild renal impairment will receive LIK066 once daily before breakfast for 7 days.
2916899|NCT03131479|Experimental|Moderate renal impairment grade A|Patients with moderate renal impairment grade A will receive LIK066 once daily before breakfast for 7 days.
2916900|NCT03131479|Experimental|Moderate renal impairment grade B|Patients with moderate renal impairment grade B will receive LIK066 once daily before breakfast for 7 days.
2916901|NCT03131479|Experimental|Severe renal impairment|Patients with severe renal impairment will receive LIK066 once daily before breakfast for 7 days.
2916902|NCT03131479|Experimental|Normal renal function|Patients with normal renal function will receive LIK066 once daily before breakfast for 7 days.
2916903|NCT03131466|Experimental|PRF Group|This group will undergo 42°C high-voltage pulsed radiofrequency treatment.
2916904|NCT03131466|Active Comparator|Nerve Block Group|This group will undergo nerve block treatment with steroid and local anesthesia.
2916905|NCT03131453|Experimental|Arm#1: CNP520 50 mg|CNP520 50 mg capsule given p.o.
2916906|NCT03131453|Experimental|Arm#2: CNP520 15 mg|CNP520 15 mg capsule given p.o.
2916907|NCT03131453|Placebo Comparator|Arm#3: Placebo|Placebo to CNP520 capsule given p.o.
2916908|NCT03131440|Experimental|Experimental Condition #1|core, support calls
2916909|NCT03131440|Experimental|Experimental Condition #2|core, support calls, app+
2916910|NCT03131440|Experimental|Experimental Condition #3|core, support calls, buddy
2916911|NCT03131440|Experimental|Experimental Condition #4|core, support calls, online gym
2916912|NCT03131440|Experimental|Experimental Condition #5|core, support calls, app notifications
2916913|NCT03131440|Experimental|Experimental Condition #6|core, app+
2916914|NCT03131440|Experimental|Experimental Condition #7|core, app+, buddy
2916915|NCT03131440|Experimental|Experimental Condition #8|core, app+, online gym
2916916|NCT03131440|Experimental|Experimental Condition #9|core, app+, app notifications
2916917|NCT03131440|Experimental|Experimental Condition #10|core, buddy
2916918|NCT03131440|Experimental|Experimental Condition #11|core, buddy, online gym
2916919|NCT03131440|Experimental|Experimental Condition #12|core, buddy, app notifications
2916920|NCT03131440|Experimental|Experimental Condition #13|core, online gym
2916921|NCT03131440|Experimental|Experimental Condition #14|core, online gym, app notifications
2916922|NCT03131440|Experimental|Experimental Condition #15|core, app notifications
2916923|NCT03131440|Experimental|Experimental Condition #16|core, support calls, app+, buddy
2916924|NCT03131440|Experimental|Experimental Condition #17|core, support calls, app+, online gym
2916925|NCT03131440|Experimental|Experimental Condition #18|core, support calls, app+, app notifications
2916926|NCT03131440|Experimental|Experimental Condition #19|core, support calls, buddy, online gym
2916927|NCT03131440|Experimental|Experimental Condition #20|core, support calls, buddy, app notifications
2976566|NCT02719860|Placebo Comparator|Placebo tea|
2916928|NCT03131440|Experimental|Experimental Condition #21|core, support calls, online gym, app notifications
2916929|NCT03131440|Experimental|Experimental Condition #22|core, app+, buddy, online gym
2916930|NCT03131440|Experimental|Experimental Condition #23|core, app+, buddy, online gym, app notifications
2916931|NCT03131440|Experimental|Experimental Condition #24|core, support calls, buddy, online gym, app notifications
2916932|NCT03131440|Experimental|Experimental Condition #25|core, buddy, online gym, app notifications
2916933|NCT03131440|Experimental|Experimental Condition #26|core, app+, online gym, app notifications
2916934|NCT03131440|Experimental|Experimental Condition #27|core, support calls, app+, buddy, online gym
2916935|NCT03131440|Experimental|Experimental Condition #28|core, support calls, app+, buddy, app notifications
2916936|NCT03131440|Experimental|Experimental Condition #29|core, support calls, app+, online gym, app notifications
2916937|NCT03131440|Experimental|Experimental Condition #30|core
2916938|NCT03131440|Experimental|Experimental Condition #31|core, app+, buddy, app notifications
2916939|NCT03131440|Experimental|Experimental Condition #32|core, support calls, app+, buddy, online gym, app notifications
2916940|NCT03131427||Wilson's Disease|Patients who were diagnosed or possibly diagnosed with Wilson's disease. The diagnosis can be made or possibly made on the basis of Wilson's disease scoring system proposed by the Working Party at the 8th International Meeting on Wilson's disease, Leipzig 2001.
2916941|NCT03131427||Hereditary Hemochromatosis|Hereditary hemochromatosis can be clinically diagnosed if: ① transferrin saturation≥45% and/or elevated ferritin; ② iron overload in liver and/or spleen on magnetic resonance imaging (MRI) of liver or on liver histology; ③ exclude causes of secondary iron overload, such as alcoholic or other chronic liver disease, iron-overloading anemia, and parenteral iron overload.
2916942|NCT03131427||Hereditary Hyperbilirubinemias|Hereditary hyperbilirubinemias involve four syndromes: Gilbert, Crigler-Najjar, Dubin-Johnson and Rotor, among which the first two are characterized by unconjugated hyperbilirubinemia and the second two by conjugated hyperbilirubinemia. Diagnosis of hereditary hyperbilirubinemia should exclude other causes of hyperbilirubinemia, such as obstructive bile duct (slerosing cholangitis, calculi, parasites), intrahepatic cholestasis(drugs, hepatitis, immune-mediated, infectious), acute or chronic hepatocellular injury(sepsis, parenteral nutrition, severe blood loss/hypotension, trauma, conjestive heart failure), increased bilirubin production(hemolysis, hematological disease), decreased bilirubin uptake (drugs, portosystemic shunting ), reduced conjugation activity (neonatal, thyroid disease, chronic hepatitis/inflammation, wilson's disease).
2916943|NCT03131427||Inherited Cholestatic Liver Disease|Patients who were diagnosed or possibly diagnosed with Inherited cholestatic liver disease, including progressive familial intrahepatic cholestasis(PFIC) and benign recurrent intrahepatic cholestasis(BRIC).
2916944|NCT03131427||Other genetic/metabolic liver diseases|Patients who were diagnosed or possibly diagnosed with genetic/metabolic liver diseases except for Wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias or inherited cholestatic liver disease.
2916945|NCT03131414||Irritable bowel syndrome|"A total of 2000 patients with IBS who have met Rome IV criteria are 13 years of age or older will be consented and recruited for this study.~IBS patients will be categorized into diarrhea predominant IBS (IBS-D), constipation predominant IBS (IBS-C) or alternating constipation and diarrhea (IBS-A) or unclassified IBS (IBS-U). A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
2916946|NCT03131414||Ulcerative colitis|"2000 CD and 2000 UC cases over the age of 4 years will be enrolled.~Montreal Classification will be used for adult UC patients, and the Paris classification for pediatric UC. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
2916947|NCT03131414||Crohn's disease|"2000 CD cases over the age of 4 years will be enrolled.~Montreal Classification will be used for adult CD patients, and the Paris classification for pediatric CD. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
2916948|NCT03131414||Healthy control|"A total of 2000 healthy family members, relative or friends of cohort participants over the age of 4 will be consented and recruited for this study.~Each control that agrees to participate will undergo an initial screening questionnaire to confirm that they are healthy and have no gastrointestinal symptoms using the ROME IV Questionnaire. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
2916949|NCT03131375|Active Comparator|Group A|In Group A: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group A receives a 50 ml NS infusion containing the drug Dexmedetomidine 1 mcg kg-1 slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.16 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.
2916950|NCT03131375|Placebo Comparator|Group B|In Group B: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group B receives a volume matched normal saline infusion slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.2 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.
2916951|NCT03131349||column heading in tables|history examinations investigation:serum zinc and iron
2916952|NCT03131349||row heading in tables|history examinations investigation:serum zinc and iron
2916953|NCT03131336|Experimental|PeproStat|PeproStat 2.5mg/mL soaked into haemostatic gelatin sponge, applied to a target bleeding site
2916954|NCT03131336|Placebo Comparator|Saline|Saline soaked into haemostatic gelatin sponge, applied to a target bleeding site
2916955|NCT03131297|Experimental|Anal fistula treated by radiofrequency|treatment by radiofrequency: patient with anal fistula treated by radiofrequency
2916956|NCT03131284|No Intervention|Control|Families of newborns whose paediatrician is assigned to the control arm, receive usual education about nutrition and lifestyle, during their child's first two years of life.
2916980|NCT03131128|Experimental|Mindfulness-based Intervention|2 sessions of diet nutrition education and 6 sessions of Mindfulness-based intervention, 1.5 hours each session.
2916957|NCT03131284|Experimental|Intensive education.|Families of newborns whose paediatrician is assigned to the intervention arm, receive standardized lifestyle counseling along with educational written material about their child's first two years of life, which corresponds to the experimental treatment.
2916958|NCT03131271|Experimental|Experimental Group|In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter. Immediately after its removal, the responsible nurse removed the catheter. A neutral instruction set was used on each patient prior to application of the ice pack. Patients in the experimental group were told that they may or may not experience pain during the catheter removal. The patients were also told that the aim of the study was to measure the effect of ice bag application upon pain during catheter removal, and that ice pack application may or may not be effective in terms of their own pain.
2916959|NCT03131271|No Intervention|Control Group|The control group received the standard clinic procedure in that the catheter was removed by the assigned nurse without any cold application to the femoral region. Each control patient was informed that some patients may experience pain during catheter removal, and that they may or may not experience pain. Patients were also told that their pain levels would be measured during catheter removal.
2916960|NCT03131258|Other|Donor Nephrectomy|Donor Nephrectomy
2916961|NCT03131219|Experimental|ALXN1210|
2916962|NCT03131206|Experimental|Phase 1 RP2D of alectinib|"The investigators are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have NSCLC, not everyone who participates in this research study will receive the same dose of the study drug. The dosage will depend on the number of participants who have been enrolled in the study and how well the dosage has been tolerated.~Alectinib~Oral, BID~A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days."
2916963|NCT03131206|Experimental|Cohort A|"Participants with RET-rearranged NSCLC with no previous history of RET-TKI therapy.~Alectinib~Oral, BID, participants will receive the RP2D identified during Phase 1.~Each treatment cycle will be defined as 28 consecutive days."
2916964|NCT03131206|Experimental|Cohort B|"Participants with RET-rearranged NSCLC with previous history of RET-TKI therapy.~Alectinib~Oral, BID, participants will receive the RP2D identified during Phase 1.~Each treatment cycle will be defined as 28 consecutive days."
2916965|NCT03131206|Experimental|Cohort C|"Participants with RET-rearranged thyroid cancer~Alectinib~Oral, BID, participants will receive the RP2D identified during Phase 1.~Each treatment cycle will be defined as 28 consecutive days."
2916966|NCT03131193|No Intervention|No provider - No cash transfer|Study primary health centers (PHC) will carry out business-as-usual, with no additional staffing or changes to usual clinic operations. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
2916967|NCT03131193|Experimental|No Provider - Cash Transfer|Study primary health centers (PHC) will carry out business-as-usual, with no additional staffing or changes to usual clinic operations. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
2916968|NCT03131193|Experimental|Physician - No Cash Transfer|Study PHCs will receive an additional health provider - a physician. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
2916969|NCT03131193|Experimental|Physician - Cash Transfer|Study PHCs will receive an additional health provider - a physician. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
2916970|NCT03131193|Experimental|Mid-level Provider - No Cash Transfer|Study PHCs will receive an additional health provider - a mid-level provider. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
2916971|NCT03131193|Experimental|Mid-level Provider - Cash Transfer|Study PHCs will receive an additional health provider - a mid-level provider. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
2916972|NCT03131180|Experimental|RLHS dashboard|Patients randomized to RLHS website access are given instructions on how the RLHS dashboard works both by phone and by email and are given open access to the RLHS dashboard website immediately after enrollment and before meeting with the CCPR clinical team for their consultation. Each user has an access code, which allows them to track their access. They maintain access to the website throughout their care in the CCPR. Patients in the RLHS access group complete the System Usability Scale (SUS; a 10 item questionnaire to evaluate software, websites, and applications) after use of the RLHS at consultation. Those in the RLHS access group also complete a 7-item exit interview either via phone or on REDCap.
2916973|NCT03131180|No Intervention|Standard consultation alone|Those not randomized to RLHS access undergo standard consultation only.
2916974|NCT03131167|Experimental|SHP639 Ophthalmic Solution Arm (n=60)|Participants are divided into groups called cohorts. There will be approximately 12 cohorts, each consisting of 7 participants. In each cohort 5 out of 7 participants will be assigned a specified concentration of SHP639 (0.1%, 0.3%, or 0.6%) ophthalmic solution and a specific dosing schedule (the study participants will be instructed to insill the study drug one, two, three, or four times a day) in both eyes during the study.
2916975|NCT03131167|Placebo Comparator|Vehicle Ophthalmic Arm (n=24)|In each cohort 2 out of 7 participants will be assigned a placebo ophthalmic solution matched to 0.1%, 0.3%, and 0.6% SHP639 ophthalmic solution and specific dosing schedule (the study participants will be instructed to instill the study drug one, two, three, or four times a day) in both eyes during the study.
2916976|NCT03131154|Experimental|ADX-102 Ophthalmic Solution (0.5%)|
2916977|NCT03131154|Placebo Comparator|Vehicle of ADX-102 Ophthalmic Solution|
2916978|NCT03131141|Experimental|Cohort A|Cohort A will receive a single IV administration of 14C-BC-3781 containing 150 mg BC-3781 and NMT 4.3 MBq (117 µCi) 14C, administered as an infusion over 60 min after a light breakfast
2916979|NCT03131141|Experimental|Cohort B|Cohort B will receive a single oral administration of 14C-BC-3781 containing 600 mg BC-3781 and NMT 4.1 MBq (112 µCi) 14C, in the fasted state
2916981|NCT03131128|Active Comparator|Health Education Intervention|2 sessions of diet nutrition education and 6 sessions of Health Education, 1.5 hours each session.
2916982|NCT03131115|Active Comparator|Lateral Crural Strut Graft|Lateral crura strut graft is a well described and universally used technique involves strengthening lateral crus of lower lateral cartilage of the nose with piece of cartilage.
2916983|NCT03131115|Active Comparator|Bone-Anchored suspension|Bone- Anchored suspension is a well described surgical technique which involves anchoring the nasal sidewall to the bony rim below the eye.
2916984|NCT03131102||Patients with epithelial ovarian cancer (EOC)|Patients undergoing cytoreductive surgery due to epithelial ovarian cancer
2916985|NCT03131102||Subgroup - Metabolomics in EOC patients without ascites|In a subgroup (n=10), patients without preoperative ascites will undergo extended metabolic measures to investigate mitochondrial dysfunction during the preoperative period.
2916986|NCT03131102||Subgroup - Metabolomics in EOC patients with ascites >500ml|In a subgroup (n=10), patients with preoperative ascites >500ml will undergo extended metabolic measures to investigate mitochondrial dysfunction during the preoperative period.
2916987|NCT03131063||Septic patient under ECMO treatment|Every adult patient admitted to ICU, under ECMO treatment, with known or suspected sepsis and receiving antibiotic therapy, was eligible for inclusion. The concentration of the studied antibiotics was determined by a combination of liquid chromatography and mass spectrometry from blood samples. For intermittent administration of antibiotic, two successive samples were performed both at 50% (Cmax) and 100% (Cmin) of the dosing interval.
2916988|NCT03131050|Experimental|High-dose scopolamine add-on therapy|Scopolamine (0.3 mg/1 ml, i.m.) Bid; escitalopram （10 mg/d p.o.）QD
2916989|NCT03131050|Experimental|Low-dose scopolamine add-on therapy|Scopolamine (0.3 mg/1 ml, i.m.) QD; placebo (1 ml saline, i.m.) QD; escitalopram （10 mg/d p.o.）QD
2916990|NCT03131050|Placebo Comparator|Placebo add-on therapy|Placebo (1 ml saline, i.m.) Bid; escitalopram （10 mg/d p.o.）QD
2916991|NCT03131037|Experimental|Study Arm|AdV-tk (aglatimagene besadenovec) + valacyclovir
2916992|NCT03131024|Experimental|Aerobic exercise|The exercise arm includes a single bout of supervised treadmill walking scheduled such that it would end approximately 24 hours prior to each of the participant's scheduled anthracycline treatment time.
2916993|NCT03131024|Experimental|50% caloric restriction|The caloric restriction arm will restrict their total caloric intake by 50% for 48 hours prior to each anthracycline treatment.
2916994|NCT03131024|No Intervention|Usual care|The usual care arm will be asked to maintain their typical exercise and diet throughout treatment.
2916995|NCT03131011|Experimental|Arm 1 - UV ink|Radiotherapy tattoos will be applied using an invisible UV fluorescent ink that can only be detected while illuminated with a special ultraviolet flashlight.
2916996|NCT03131011|No Intervention|Arm 2 - Black ink|Radiotherapy tattoos will be applied using standard black ink.
2916997|NCT03130998|No Intervention|Control - Group A|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive knowledge broker support to carry out these actions in the form of one email per month for one year. The first email will provide an electronic copy of a Cochrane review (describing the link between smoking and mood) and a short description of the integration of a depression ICP in the STOP portal. The STOP YouTube channel with detailed instructions on how to use the revised portal will be made available. Subsequent communications will be based on general needs identified at baseline and content discussed in the STOP Community of Practice (teleconferences, online forum between STOP practitioners).
2916998|NCT03130998|Experimental|Intervention - Group B|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive individualized support through a knowledge broker communicating via interactive technology (eKB). The eKB will be certified in tobacco cessation counseling through CAMH's TEACH program and will have completed a specialty course on tobacco addiction treatment in those with mental illness. The eKB will have access to the CAMH network of KBs (e.g. Evidence Exchange Network ) for guidance and support, as this has been shown to be important for KB success.
2916999|NCT03130985||Cardiac surgery patients|The study cohort will comprise of patients without a history of AF that undergo cardiac surgery (CABG or mitral valve surgery) with increased CHADSVASC scores of ≥2.
2917000|NCT03130972||developmental delay|Children who visited tertiary rehabilitation clinic for delayed motor development were all included.
2917001|NCT03130959|Experimental|Module A|nivolumab
2917002|NCT03130959|Experimental|Module B|nivolumab plus ipilimumab
2917003|NCT03130946|Experimental|Cryo-assisted core needle biopsy|Eligible patients undergo lymph node biopsy with FNA and crpo-assisted stick freeze device sequentially.
2917004|NCT03130946|Active Comparator|Fine needle aspiration alone|Patients undergo lymph node biopsy with FNA alone.
2917005|NCT03130933|Active Comparator|The first tested subgroup|The tested subgroup from the main group without prior inflammation received a prophylactic single dose of 4 x Amoxicillin 500 Mg one hour prior the lower third molar surgery.
2917006|NCT03130933|Placebo Comparator|The first control subgroup|The control subgroup from the main group without prior inflammation received a placebo one hour prior the lower third molar surgery .
2917007|NCT03130933|Active Comparator|The second tested subgroup|The tested subgroup from the main group with prior inflammation received a prophylactic single dose of 4 x Amoxicillin 500 Mg one hour prior the lower third molar surgery .
2917008|NCT03130933|Placebo Comparator|The second control subgroup|The control subgroup from the main group with prior inflammation received a placebo one hour prior the lower third molar surgery .
2917009|NCT03130920|No Intervention|Control|
2917010|NCT03130920|Active Comparator|Remote ischemic preconditioning|
2917011|NCT03130920|Active Comparator|Local ischemic preconditioning|
2917012|NCT03130907|Active Comparator|Stent|
2917013|NCT03130907|Experimental|No stent|
2917014|NCT03130894||Healthy control|A FPG concentration < 6.1 mmol/l, and a 2-h oral glucose tolerance test (OGTT) plasma glucose concentration < 7.8 mmol/l was considered normal glucose tolerance.
2917015|NCT03130894||Type 2 diabetes|Type 2 diabetes was diagnosed when fasting plasma glucose (FPG) ≥ 7.0 mmol/l, and/or 2-h post-glucose load ≥ 11.1 mmol/l.
2917016|NCT03130881|Experimental|PLB1003|ALK-positive (ALK+) advanced NSCLC
2917017|NCT03130855|Experimental|inferior alveolar nerve block with 4% articaine|inferior alveolar nerve block using 4% articaine anesthetic solution
2917018|NCT03130855|Active Comparator|buccal infiltration with 4% articaine|buccal infiltration using 4% articaine anesthetic solution
2917019|NCT03130842|Active Comparator|Sublingual alprazolam|
2917020|NCT03130842|Active Comparator|Oral midazolam|
2917021|NCT03130829|Experimental|Oligo Fucoidan|Oligo Fucoidan 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.
2917022|NCT03130829|Placebo Comparator|Placebo|Placebo 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.
2917023|NCT03130816|Experimental|allogeneic cord blood transplantation|"Intravenous(IV) infusion will be done by the following method A. After 4 hours of fasting, subjects will be sedated with chloral hydrate (Pocral®) syrup B. Intravenous infusion will be conducted in stem cell center, CHA Bundang Medical Center and the therapy will be performed by the Principal Investigator or a physician delegated from the Principal Investigator. The physician conducting the infusion will not participate in the efficacy and result analysis of this study.~C. Oxygen saturation will be monitored during therapy."
2917024|NCT03130803|No Intervention|Baseline|9 hour sleep opportunity at habitual sleep/wake times for 14 days at home and 1 day in lab repeated for visit 1 and visit 2
2917025|NCT03130803|Experimental|Insufficient Sleep|2 days with 5 hour sleep opportunities immediately following baseline on both visit 1 and visit 2.
2917026|NCT03130790|Experimental|Varlititib+mFOLFOX6|
2917027|NCT03130790|Placebo Comparator|Placebo+mFOLFOX6|
2917028|NCT03130777|Experimental|SAPIEN 3 THV|To demonstrate the safety and functionality of the Edwards Alterra Adaptive Prestent in conjunction with the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System.
2917029|NCT03130764|Experimental|Durvalumab/Tremelimumab|Patients with resected stage IB-IIIA NSCLC who have completed standard adjuvant therapy (as recommended by the treating physician) to receive durvalumab-tremelimumab will be enrolled. Patients will receive durvalumab (20 mg/kg) intravenously every 4 weeks for 1 year and tremelimumab (1 mg/kg) intravenously every 4 weeks for 4 doses.
2917030|NCT03130751|Experimental|Mobile application|
2917031|NCT03130738|Active Comparator|7-Day Miconazole Oil (Miconazole 2%)|7 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
2917032|NCT03130738|Active Comparator|14-Day Miconazole Oil (Miconazole 2%)|14 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
2917033|NCT03130738|Placebo Comparator|14-Day Placebo - Oil Vehicle|14 days of 2x per day of treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
2917034|NCT03130725|Experimental|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
2917035|NCT03130725|Active Comparator|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
2917036|NCT03130712|Experimental|GPC3-CART cells|
2917037|NCT03130699|Experimental|Dulce Digital|The first of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives one-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
2917038|NCT03130699|Experimental|Dulce Digital-Me (Automated Delivery)|The second of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
2917039|NCT03130699|Experimental|Dulce Digital-Me (Medical Assistant)|The third of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
2917040|NCT03130673||hip fracture|fracture of proximal femur
2917041|NCT03130660|Experimental|Short Axis Ultrasonography|one person does both ultrasound and line insertion
2917042|NCT03130660|Experimental|Long Axis Ultrasonography|one person does ultrasound and another inserts the central line
2917043|NCT03130647|Experimental|Focused ultrasound|Repeated measures sham control
2917044|NCT03130634|Experimental|prescription of silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
2917045|NCT03130634|No Intervention|control|During six cycles of FOLFIRI chemotherapy, the patients will not take silymarin during chemotherapy
2917046|NCT03130621||Adenocarcinoma of upper digestive tract|Early-onset carcinomas ; Family History of Malignancy; Special pathological type; MSI or dMMR; Multiple primary malignant tumors;
2917047|NCT03130621||Esophageal squamous cell carcinoma|Family History of Malignancy; Multiple primary malignant tumors; MSI or dMMR;
2917048|NCT03130608|Experimental|Inspiratory Muscle Training|"The experimental group will perform Inspiratory Muscle Training (IMT) using a THRESHOLD device, a simple hand held one way valve.~In addition, the experimental group will gradually increase their activity as part of their usual care post-transplant."
2917049|NCT03130608|No Intervention|Usual Care|Receive the usual post-liver transplant care of gradually increase their activity.
2917050|NCT03130595||PD outpatients in West Sweden|Cross-sectional random sample of patients with PD that have visited outpatient clinics in West Sweden in the last 6+6 months
2917051|NCT03130582||Disease status at mobilization PR|
2917052|NCT03130582||Disease status at mobilization PD|
2917053|NCT03130569|No Intervention|Control Group|Will simply complete surveys at baseline and at the three-month follow-up.
2917054|NCT03130569|Experimental|Web-based Module Group|Participants will complete surveys at baseline. Participants in this arm will be provided with information to access and complete a web-based educational module (AKA the intervention), at the end of which will be given the opportunity to request and complete genetic testing for skin cancer. Participants who elect to complete the genetic testing will receive their genetic testing results along with a two-week follow-up call. All participants will also complete the survey at the three month follow-up.
2917055|NCT03130556|Experimental|Glasdegib BE and Food|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects receive a 100 mg single dose ICH tablet after a high fat, high calorie meal.
2917056|NCT03130556|Experimental|Glasdegib BE and PPI Effect|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects receive a 100 mg single dose ICH tablet in the fasted state after repeated daily dosing with rabeprazole.
2917057|NCT03130543|No Intervention|Standard Formula|This is the group of subjects randomized to receive their standard formula
2917058|NCT03130543|Experimental|Standard Formula with Rice Cereal|This is the group of subjects randomized to receive their standard formula with rice cereal added
2917059|NCT03130543|Experimental|Enfamil AR|This is the group of subjects randomized to receive Enfamil AR
2917060|NCT03130530||ALF-X|all patient underwent robotic colorectal surgery using ALF-X system
2917061|NCT03130517|Other|Intervention group|Use of single dose of intravenous immunoglobulin in a dose 0.5_1gm /kg to intervention group
2917062|NCT03130517|Other|Control group|Control group will recieve phototherapy only
2917063|NCT03130504|Active Comparator|17α hydroxy progesterone caproate group|
2917064|NCT03130504|No Intervention|No intervention group|
2917065|NCT03130491|Other|TAVR + Embolic protection|subjects with severe native aortic valve stenosis who meet the commercially approved indications for transcatheter aortic valve replacement
2917066|NCT03130465||Aripiprazole Once Monthly|Patients who have received at least one AOM injection, maintenance treatment started during a schizophrenia-related hospitalization occurred in the last 3 months. From the date of the inclusion of the patient in the study, each patient who is still on the maintenance treatment of interest will be prospectively followed up until discontinuation of this maintenance treatment and up to a maximum of 12 months since the index date.
2917067|NCT03130465||Daily oral atypical AP|Patients who are on daily oral atypical AP, started during a schizophrenia-related hospitalization occurred in the last 3 months. From the date of the inclusion of the patient in the study, each patient who is still on the maintenance treatment of interest will be prospectively followed up until discontinuation of this maintenance treatment and up to a maximum of 12 months since the index date.
2917068|NCT03130452|Active Comparator|concomitant group|lansoprazole 30 mg tablet, amoxicillin 1.0 g tablet, metronidazole 500 mg tablet and clarithromycin 500 mg tablet by mouth every 12 hours for 2 weeks, regardless of 23S ribosomal RNA point mutation.
2917069|NCT03130452|Experimental|tailored treatment group I|23S ribosomal RNA point mutation negative, lansoprazole 30 mg, amoxicillin 1.0 g, and clarithromycin 500 mg were administered twice a day for 2 weeks.
2917070|NCT03130452|Experimental|tailored treatment group II|23S ribosomal RNA point mutation positive, lansoprazole 30 mg, amoxicillin 1.0 g and metronidazole 500 mg For 2 weeks.
2917071|NCT03130439|Experimental|Abemaciclib|-Abemaciclib will be administered orally, twice daily on days 1 to 28
2917072|NCT03130426|Experimental|Intervention|Drug: iGlarLixi - sc injection; Drug: metformin - oral administration; Drug: insulin glargine - sc injection; Behavioral: lifestyle therapy, diet and exercise
2917073|NCT03130426|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
2917074|NCT03130413|Experimental|Ambu Aura Gain|Ambu Aura Gain supraglottic airway size 2 or 2.5 will be inserted once patients are paralyzed
2917075|NCT03130413|Active Comparator|Air-Q|Air-Q supraglottic airway size 1.5 and 2.0will be inserted once the patients are paralyzed
2917076|NCT03130400||Normal|This group is control group. Participants in this group do not have knee diseases or any other bad injuries in lower limbs.
2917077|NCT03130400||KOA|Participants in this group have knee osteoarthritis and have no other bad injuries in lower limbs.
2917078|NCT03130400||ACLD|Participants in this group have anterior cruciate ligament deficiency with or without meniscus deficiency and have no other bad injuries in lower limbs.
2917079|NCT03130400||MD|Participants in this group have meniscus deficiency and have no other bad injuries in lower limbs.
2917080|NCT03130400||Plica|Participants in this group have plica syndrome and have no other bad injuries in lower limbs.
2917081|NCT03130387|Other|Office hysteroscopy|Examinatin with Office hysteroscope for women with abnormal uterine bleeding who had a history of previous cesarean section
2917082|NCT03130374|Experimental|Mesenchymal stem cell treated group|Patients treated according to current clinical protocols plus autologous olfactory mucosa-derived mesenchymal stem cells
2917083|NCT03130374|No Intervention|Control group|Patients treated according to current clinical protocols
2917084|NCT03130361|Experimental|Noninvasive ventilation|Participants will use the device at home by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea-recovery time over a 4-week period.
2917085|NCT03130348|Experimental|Treatment (ibrutinib, bortezomib, dexamethasone)|Patients receive ibrutinib PO QD on days 1-28. After 3 courses, patients who achieve partial response repeat treatment every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients who do not achieve partial response after 3 courses continue receiving ibrutinib PO QD on days 1-28. Beginning at course 4, patients who do not achieve partial response also receive bortezomib SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
2917086|NCT03130335|Experimental|Bone Marrow Aspirate (BMA) Injection|
2917087|NCT03130322|Experimental|NightPP|Participants of the NightPP will be subjected to one MRI session and two MEG recording sessions: the first one before a physical practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
2917088|NCT03130322|Experimental|NightMI|Participants of the NightMI will be subjected to one MRI session and two MEG recording sessions: the first one before a motor imagery practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
2917089|NCT03130322|Experimental|NightCtrl|Participants of the NightCtrl will be subjected to one MRI session and two MEG recording sessions: the first one before a mental rotation practice session, a second MEG session right after practice,and second MEG session right after practice.
2917090|NCT03130322|Experimental|Day|Participants of the NightMI will be subjected to one MRI session and two MEG recording sessions: the first one before a motor imagery practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
2917091|NCT03130283|Active Comparator|Home Hospitalization|Visit every day at home
2917092|NCT03130283|Placebo Comparator|Conventional Hospitalization|Review Clinical History
2917093|NCT03130270|Experimental|Apatinib group|Apatinib mesylate tablet：the starting dose was 500 mg, orally, qd; tolerance assessment for a cycle, patients with poorly tolerance were treated with low dose (500 mg, qd), and patients with well tolerance were treated with high dose (750 mg, qd).
2917094|NCT03130257|Active Comparator|Clinic Blood Pressure Measurement|Patients will be asked to check their blood pressure at their clinic twice within the subsequent 3 weeks.
2917095|NCT03130257|Active Comparator|Home Blood Pressure Measurement|Patients will receive a validated upper-arm home blood pressure monitor and asked to take two measurements in the morning and two in the evening for at least 5 days over 3 weeks.
2917096|NCT03130257|Active Comparator|Kiosk Blood Pressure Measurement|Patients will be asked to use a validated PharmaSmart blood pressure kiosk in their clinic or Bartell pharmacy.
2917097|NCT03130244|Active Comparator|Device Placement|The patients in this arm will receive the Incisionless Magnet Anastomosis System and an anastomosis will be created.
2917098|NCT03130244|No Intervention|Control|The patients in this arm will receive the best medical management.
2917099|NCT03130231||POD group|POD group refers to the patients who were diagnosed to be delirious by the Confusion Assessment Method.
2917100|NCT03130231||Non-POD group|Non-POD refered to the patients who did not become delirious by the Confusion Assessment Method.
2917101|NCT03130218|No Intervention|Control|Patients in the control group will not receive peppermint oil aromatherapy as a primary intervention for postoperative nausea and vomiting. Primary therapy for postoperative nausea and vomiting would entail standard antiemetic drug therapies. Patient monitoring and documentation would include the following: Patients in the control group will be assessed every 4 hours and as needed for nausea. All aspects of care from physician, nursing and all disciplines will be consistent with current practices in care of postoperative bariatric surgical patients.
2917102|NCT03130218|Experimental|Intervention|Patients in the intervention group will receive peppermint oil aromatherapy as primary treatment for postoperative nausea. Pharmacological therapy with anti-nausea drug therapies will be available as needed. All other aspects of medical, surgical and nursing care will be standard practice for pre and post-operative care related to the bariatric surgical patient. Patients in the intervention group will be assessed every 4 hours and as needed for nausea. Post-intervention, the patient will be re-assessed for level of nausea after one hour. In the event the patient refuses peppermint oil aromatherapy and requests anti-emetic drug therapies, they are able to do so.
2917103|NCT03130179|Experimental|Nicorette Strongmint lozenge 4mg|A single dose of one nicotine 4 mg lozenge will be administrated orally to slowly dissolve in the mouth for nicotine absorption via the buccal mucosa.
2917104|NCT03130179|Active Comparator|Niquitin Minimint lozenge 4mg|A single dose of one nicotine 4mg lozenge will be administrated orally to slowly dissolve in the mouth for nicotine absorption via the buccal mucosa.
2917105|NCT03130166|Experimental|Intracorporeal anastomosis|Patients undergo robotic right colectomy with intracorporeal anastomosis.
2917106|NCT03130166|Active Comparator|Extracorporeal anastomosis|Patients undergo robotic right colectomy with extracorporeal anastomosis.
2917107|NCT03130153|Experimental|hypertensives on Aspirin mouthwash|
2917108|NCT03130153|Active Comparator|non-hypertensives on Aspirin mouthwash|
2917109|NCT03130153|Active Comparator|hypertensives on Saline mouthwash|
2917110|NCT03130140|Active Comparator|Macroscopic on-site evaluation|EUS-FNA perform with a 19-gauge needle with macroscopic on-site evaluation.
2917111|NCT03130140|Sham Comparator|Control|EUS-FNA perform with a 19-gauge needle with conventional techniques.
2917112|NCT03130127|Experimental|Continuous infusion of terlipressin|In our clinical practice, continuous infusion of terlipressin is being employed.
2917113|NCT03130127|Active Comparator|Bolus infusion of terlipressin|Traditionally, a bolus infusion of terlipressin is recommended.
2917114|NCT03130114|Placebo Comparator|Control|Placebo mixture, 0.25 ml / kg / day
2917115|NCT03130114|Experimental|Azithromycin|Azithromycin mixture (40 mg / ml), 0.25 ml / kg / day
2917116|NCT03130101|Other|80% basal insulin reduction|
2917117|NCT03130101|Other|50% basal insulin reduction|
2917118|NCT03130101|Other|100% basal insulin reduction|
2917119|NCT03130062|Experimental|Exercise|Volunteers underwent a supervised resistance exercise program for 16 weeks. The subjects performed 10 exercises with 3 sets of 10 maximum repetitions in each. The training sessions were held twice a week.
2917120|NCT03130062|No Intervention|Control|Volunteers in this group were instructed not to perform systematic physical exercises for 16 weeks (the same period of the GEX group training program), and only the SSP medication treatment was maintained, and they were followed up during the study period.
2917121|NCT03130049|Experimental|Patients with postoperative pain, NRS >3|Patients reporting postoperative pain (NRS >3) localized to the center of the knee (10 patients) will receive a popliteal plexus block
2917122|NCT03130049|No Intervention|Patients with postoperative pain, NRS ≤ 3|(approx. 90 patients)
2917123|NCT03130036|Experimental|LOW-CARBOHYDRATE DIET|The low-carbohydrate diet will consist of a meal plan of less than 20 grams of carbohydrates per day to be consumed over 6 weeks. Foods that provide high levels of healthy fats (preferably low in saturated fats) will be generously included in the diet plan. Various lean meats, fish, and nutrient rich foods that meet the requirement of less than 20 grams total carbohydrates per day will be included in the meal plans. Carbohydrates will be expected to make up less than 10% of total caloric intake. Participants in the low-carbohydrate diet group will receive a supply of extra virgin olive oil at study visits to incorporate into their individualized meal plans.
2917124|NCT03130036|Experimental|LOW-FAT DIET|The low-fat diet will consist of a low-fat, higher-carbohydrate meal plan to be consumed over 6 weeks. Participants will be encouraged to limit their amount of fat intake to less than 40 grams per day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber. Various lean meats and other sources of protein will be included in the diet plan. Carbohydrates will be expected to make up 50-60% of total caloric intake.
2917125|NCT03130023|Experimental|Test group|All subjects will be enrolled in the test group and will receive Pulse Oximeter with ORI.
2917126|NCT03130010|Placebo Comparator|The control group|One hour before the end of the operation, the control group was received 20 ml of saline.
2917305|NCT03128684|Placebo Comparator|Potato Soup|
2917127|NCT03130010|Active Comparator|The Nefopam group|One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam.
2917128|NCT03129997|Active Comparator|Gluten test food|volunteers will receive 2 corn based muffins containing 7,5g of gluten/muffin to be consumed daily for 3 weeks
2917129|NCT03129997|Placebo Comparator|Placebo test food|volunteers will receive 2 corn based muffins to be consumed daily in any meal for 3 weeks
2917130|NCT03129984||The study population|The study population is comprised of all patients included in the Brizzy register, Belgium.
2917131|NCT03129971|Experimental|control group|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
2917132|NCT03129971|Experimental|experimental group|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
2917133|NCT03129945|Active Comparator|Nifedipine|Participants will be given this medication orally
2917134|NCT03129945|Active Comparator|Indomethacin|Participants will be given this medication orally
2917135|NCT03129932|Active Comparator|gluten phase|volunteers will receive 2 corn muffins containing12g of gluten/muffin to be consumed daily for 4 weeks
2917136|NCT03129932|Placebo Comparator|Placebo phase|volunteers will receive 2 corn muffins without gluten/muffin to be consumed daily for 4 weeks
2917137|NCT03129919|Experimental|Orthodontic patients treated with brackets Carriere SLX®|Subjects requiring orthodontic treatment and will be treated with passive self-ligating braces Carriere SLX®
2917138|NCT03129919|Active Comparator|Orthodontic patients treated with brackets Empower®|Subjects requiring orthodontic treatment and will be treated with interactive self-ligating braces Empower®
2917139|NCT03129906|Active Comparator|Gluten|Capsules containing 8 g/day of gluten (6,3g of protein) were blindly administered for 7 days
2917140|NCT03129906|Placebo Comparator|Rice protein|Capsules containing 6,4 g/day of rice protein were blindly administered for 7 days
2917141|NCT03129893||Patients intubated with uncuffed tracheal tubes|Portex uncuffed TT sizes selected according to local institutional guidelines. Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to institutional guidelines in uncuffed TTs.
2917142|NCT03129893||Patients intubated with cuffed tracheal tubes|Cuffed TT sizes (Microcuffw PET) selected as follows: ID 3.0 mm for birth (>3 kg body weight) to < 8 months; ID 3.5 mm for 8 to < 12 months (Salgo, Schmitz et al. 2006). Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to the depth marking in cuffed TTs.
2917143|NCT03129880|Placebo Comparator|Weekly Voice Therapy|Participants are randomized to receiving weekly voice therapy sessions
2917144|NCT03129880|Active Comparator|Intensive Voice Therapy|Participants are randomized to receiving multiple sessions of voice therapy in one day
2917145|NCT03129854|Experimental|experimental group|Prostate cryotherapy plus ADT
2917146|NCT03129854|No Intervention|control group|standard of care ADT continually
2917147|NCT03129841|Experimental|early dinner+Diet|
2917148|NCT03129841|Experimental|late dinner+Diet|
2917149|NCT03129828|Experimental|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals < 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
2917150|NCT03129776|Active Comparator|Hyperpolarized Pyruvate (13C) Injection|Participants will be injected with the study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43 ml/kg and will have their cervix imaged using MRI.
2917151|NCT03129776|Active Comparator|18F-FDG|Participants will be injected with the study drug 18F-FDG at a dose of 5 MBq/kg to a a maximum of 500 MBq (megabecquerel) and will have their cervix imaged using PET-CT imaging.
2917152|NCT03129763|Experimental|60mmHg Group|60mmHg capsule pressure expansion. This pressure depends on the ideal capsule pressure that previous study given.
2917153|NCT03129763|Experimental|70mmHg Group|70mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
2917154|NCT03129763|Experimental|80mmHg Group|80mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
2917155|NCT03129763|Experimental|90mmHg Group|90mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
2917156|NCT03129763|Experimental|100mmHg Group|100mmHg capsule pressure expansion. This pressure gradient depends on the regular expansion pressure in recent studies.
2917157|NCT03129737|Experimental|Tricuspid valve annuloplasty|Concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (>21mm /m2) with or without TR≤ moderate in pts undergoing mitral valve surgery
2917158|NCT03129737|Active Comparator|Mitral valve repair|No concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (>21mm/m2) with or without TR ≤ moderate in pts undergoing mitral valve surgery
2917159|NCT03129711|Experimental|glazed Celtra Duo|zirconia reinforced lithium silicate glass ceramic is infiltrated with 10% zirconia by weight, producing zirconia reinforced lithium silicate ceramic
2917160|NCT03129711|Active Comparator|Glazed IPS Empress CAD|glazed Leucite based glass ceramics ,Its a glass ceramic which is etchable and proved to have good esthetics if used for laminate veneers
2917161|NCT03129698|Other|Formerly Arm Label|Apatinib 250mg daily
2917162|NCT03129685|Experimental|Devascularization|Patients undergoing ipsilateral hepatic artery ligation with extrahepatic collaterals division (HALED)
2917163|NCT03129659|Experimental|CT-group|Coronary CT angiography
2917164|NCT03129646|Experimental|Arm 1 - MF/PM 14d|Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 14 days
2917165|NCT03129646|Experimental|Arm 2 - MF 28d/PM 14d|Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 28 days
2917166|NCT03129646|Active Comparator|Arm 3 - SSG/PM 17d|Sodium Stibogluconate 20 mg/kg/day IM/IV combined with Paromomycin 15 mg/kg/day IM for 17 days
2917167|NCT03129633|Experimental|Promotores Network|Promotores will engage participants using the materials A Page of My Life and the Success Plan. Promotores will ask participants to rank their satisfaction with each of the domains included in the A Page of My Life and ask them what domain they want to change. Using non-directive questions, promotores will guide the participant to draft a plan for success. The promotor/a will follow up with participants within a week of enrollment and at least monthly via phone/text during six months. During the intervention period, promotores will meet with participants (child and parent together, if applicable) at least three times in-person during which they will deliver the short (15-minutes) educational components of the intervention.
2917168|NCT03129633|No Intervention|Wait-list Control|The community liaison will deliver a short (15-minute) educational session on the benefits of a healthy lifestyle and preventive use of health care, and give participants a pamphlet with relevant local health care and social service resources.
2917169|NCT03129607||POPF group|Patients who had POPF will be included into POPF group.
2917170|NCT03129607||Observation group|Patients without POPF will be included into observation group.
2917171|NCT03129581|Active Comparator|Time Restricted|This group will receive dietary counseling.
2917172|NCT03129581|No Intervention|Time Unrestricted|This group will not receive dietary counseling.
2917173|NCT03129568|Experimental|CDC infusion|CDCs infusion by coronary intervention.
2917174|NCT03129568|No Intervention|Observation (Control group)|Coronary angiogram without placebo infusion.
2917175|NCT03129555|Active Comparator|Dabigatran|After randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
2917176|NCT03129555|Active Comparator|Rivaroxaban|After randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
2917177|NCT03129555|Active Comparator|Edoxaban|After randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
2917178|NCT03129555|Active Comparator|Apixaban|After randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
2917179|NCT03129542|Active Comparator|Midodrine Hydrochloride 10 milligrams|Three doses of oral midodrine every 8 hours will be administered in addition to usual care for sepsis. Participants randomized to the intervention group will receive a total of 3 doses of midodrine 10 milligrams every 8 hours by mouth in the form of a tablet encapsulated in order to be identical to placebo. Participants will receive treatment for a total of 16 hours, beginning with the first dose.
2917180|NCT03129542|Placebo Comparator|Placebo oral capsule|For participants randomized to the placebo arm, an identical appearing capsule containing only Lactose Monohydrate powder will be administered every 8 hours for a total of 3 doses.
2917181|NCT03129529|Experimental|focused shock wave|Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz. The intensities of FSWT were 0.10 mJ/mm2.
2917182|NCT03129529|Experimental|radial shock wave|Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz.The intensities of RSWT were 2.0 bar.
2917183|NCT03129503||Acute coronary syndrome (ACS)|Patients with STE- or NSTE-ACS (acute coronary syndrome)
2917184|NCT03129490|Active Comparator|Dabigatran|After randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
2917185|NCT03129490|Active Comparator|Rivaroxaban|After randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
2917186|NCT03129490|Active Comparator|Edoxaban|After randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
2917187|NCT03129490|Active Comparator|Apixaban|After randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
2917188|NCT03129477|Experimental|Telemonitoring in NonInvasiveVentilation|"Tele-monitoring in noninvasive ventilation with Lumis 150 and others Resmed equipments with AirView monitoring system, in COPD patients.~• Education and adaptation of the patient to NIV."
2917189|NCT03129477|No Intervention|2- conventional monitoring group|"Conventional monitoring group~• Education and adaptation of the patient to NIV."
2917190|NCT03129464|Experimental|Cold Therapy|Patients undergoing total laparoscopic hysterectomy will receive routine pre-operative multi-modal analgesia regimen and well as routine post-operative analgesia with instructions for dosing. Intervention will include the patient being asked to use a reusable cold gel pack to deliver cold therapy to their abdominal incisions every 6 hours for the first 72 hours.
2917191|NCT03129464|No Intervention|Control|Patients undergoing total laparoscopic hysterectomy will receive routine pre-operative multi-modal analgesia regimen and well as routine post-operative analgesia with instructions for dosing. They will not receive any additional intervention.
2917192|NCT03129451||Tremor-dominant|Tremor-dominant Parkinson's disease
2917193|NCT03129451||Akinetic-Rigid|Akinetic-Rigid type Parkinson's disease
2917194|NCT03129451||Multiple systems atrophy|Multiple systems atrophy PD
2917195|NCT03129451||Levodopa-naïve|Levodopa-naïve Parkinson's disease
2917196|NCT03129451||Tremor-dominant / app|Tremor-dominant Parkinson's disease with an appendectomy
2917197|NCT03129451||Akinetic-Rigid / app|Akinetic-Rigid Parkinson's disease with an appendectomy
2917198|NCT03129451||Levodopa-naïve w/app|Levodopa-naïve Parkinson's disease with an appendectomy
2917199|NCT03129438|Experimental|continuous EEG (cEEG)|Patients randomized to continuous EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last a minimum of 30 and a maximum of 48 hours. During this time, one interruption to a maximum of two hours for diagnostic purposes will be allowed. Reactivity testing using auditory and nociceptive stimuli will be performed at least twice during the recording time. Recordings will be visually interpreted by certified electroencephalographers (i.e., interpretation of the automated algorithm only won't be allowed) using the 2013 American Clinical neurophysiology nomenclature; interpretations will be communicated within two hours of their completion to the treating team.
2917200|NCT03129438|Active Comparator|routine EEG (rEEG)|Patients randomized to routine EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last between 20 and 30 minutes; two recordings will take place over a period of 24 to 48 hours. Reactivity testing using auditory and nociceptive stimuli will be performed once per recording. Recordings will be visually interpreted by certified electroencephalographers using the 2013 American Clinical neurophysiology nomenclature, as for the experimental intervention, and the interpretation will be communicated within two hours of its completion to the treating team.
2917201|NCT03129425|Experimental|Intervention group|Sessions in groups
2917202|NCT03129425|Sham Comparator|Control group|Sessions in groups
2917203|NCT03129412|Experimental|Arm 1|4-6 cycles chemotherapy and radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will assigned to those who got PR,SD after chemotherapy.
2917204|NCT03129399|Experimental|King Vision video laryngoscope|
2917205|NCT03129399|Active Comparator|McGrath MAC video laryngoscope|
2917206|NCT03129373|Experimental|Pixie group|"Cryogenic treatment of wart (liquified nitrous oxide)~Maximum 3 application by the technician in charge of the study.~Apply between 15 to 20 sec on hand and 40 sec on feet."
2917207|NCT03129373|Active Comparator|Wartner group|"Cryogenic treatment of wart (dimethylether propane-based):~Maximum 3 application by the technician in charge of the study.~Apply between 15 to 20 sec on hand and 40 sec on feet."
2917208|NCT03129373|Active Comparator|Wortie group|"Cryogenic treatment of wart (dimethylether-based product):~Maximum 3 application by the technician in charge of the study.~Apply between 15 to 20 sec on hand and 40 sec on feet."
2917209|NCT03129360|Experimental|Levetiracetam 185 mg|A single dose of 185mg of levetiracetam be administered orally to subjects. Subjects will undergo a 15-minute MRI scan using aterial spin labeling (ASL) before dosing and two hours post-dosing.
2917210|NCT03129360|Experimental|Levetiracetam 500mg|A single dose of 500mg of levetiracetam will be administered orally to subjects. Subjects will undergo a 15-minute MRI scan using aterial spin labeling (ASL) before dosing and two hours post-dosing.
2917211|NCT03129360|Placebo Comparator|Placebo|A single dose of placebo will be administered orally to subjects. Subjects will undergo a 15-minute MRI scan using aterial spin labeling (ASL) before dosing and two hours post-dosing.
2917212|NCT03129347|Experimental|Nalmefene (high dose)|Nalmefene (high dose) intranasal one time during the 17 day inpatient treatment period
2917213|NCT03129347|Experimental|Nalmefene and Intravail|Nalmefene (high dose) with Intravail intranasal one time during the 17 day inpatient treatment period
2917214|NCT03129347|Experimental|Nalmefene (low dose)|Nalmefene (low dose) intranasal one time during the 17 day inpatient treatment period
2917215|NCT03129347|Experimental|Nalmefene Intramuscular|Nalmefene intramuscular one time during the 17 day inpatient treatment period
2917216|NCT03129334|Experimental|LST Middle School Online|Students will participate in a series of e-learning modules plus classroom sessions related to drug abuse prevention, including prescription drug abuse
2917217|NCT03129334|No Intervention|Treatment as Usual (Control)|Students will not participate in the e-learning modules. They will receive any standard classroom instruction on drug abuse/health education.
2917218|NCT03129321|Experimental|Test|Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
2917219|NCT03129321|Active Comparator|Reference Standard|Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
2917220|NCT03129321|Placebo Comparator|Placebo|Placebo Cream, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
2917221|NCT03129308||HIV infected patients|4.5 ml of blood will be collected during a routine medical check-up.
2917222|NCT03129308||HIV negative control patients|4.5 ml of blood will be collected during a routine medical check-up.
2917223|NCT03129295|Experimental|MPC-SHRC|oral tablet four times a day for 3 days
2917224|NCT03129295|Placebo Comparator|Placebo|oral tablet four times a day for 3 days
2917225|NCT03129282|No Intervention|Control|"Participants allocated to the control group will receive treatment as usual for cardiac rehabilitation"
2917226|NCT03129282|Active Comparator|Intervention|"Participants allocated to the intervention group will receive treatment as usual for cardiac rehabilitation plus the home-based metacognitive therapy (Home-MCT)"
2917227|NCT03129269|Experimental|neuroimaging amyloid diagnosis by MRI and PET scan|"There is only one arm. The procedure consists in neuroimaging to diagnose the presence of amyloid plaques in the brains and permit earlier detection of Alzheimer's disease. MRI and PET Scan.~Visits will be scheduled at baseline, 1 and 2 years for a full neuropsychological, functional and physical evaluation.~In addition, at 6 and 18 months patients will be seen in consultation by a Geriatrician and research assistant for a medical check.~PET-Scan will be scheduled in the 2 months following inclusion for amyloid measurements. The MRI will be proposed, depending on the clinical relevance~A blood sample for biobank will be taken at visit 2 and at the end of the study (visit 5)."
2917228|NCT03129256|Experimental|Apatinib & S-1|Apatinib Mesylate tablet combined with S-1 Capsules Apatinib Mesylate tablet 250mg once daily combined with S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules) 40mg~60mg twice daily by mouth, d1-14, repeated every 3 weeks.
2917229|NCT03129230|Experimental|Free nonvascularized fibula autograft|Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck.
2917230|NCT03129217||Patients weaning from mechanical ventilation|
2917231|NCT03129204|Experimental|SAF-T Intervention Group|The SĀF-T intervention includes coaching from SĀF-T trained research staff on awareness of biological sensations associated with events in the ICU that are perceived stressful. The research staff member will sit across from the participant and ask them to use their eyes to follow hand movements that will induce lateral left-right (saccadic) eye movements to elicit an orienting response that activates an investigatory reflex in which first, an alert response occurs and then, a reflexive pause produces decreased arousal in the face of no threat, which elicits a calming response that rapidly eliminates negative biological sensations of stress.
2917232|NCT03129204|No Intervention|Control Group|The control group will not receive the SAF-T intervention.
2917233|NCT03129191|Active Comparator|AB arm|"Sequence:~Aided with non-invasive bone conduction hearing aid A~Aided with non-invasive bone conduction hearing aid B"
2917234|NCT03129191|Active Comparator|BA arm|"Sequence:~Aided with non-invasive bone conduction hearing aid B~Aided with non-invasive bone conduction hearing aid A"
2917235|NCT03129178|Active Comparator|Concentrated beetroot juice|Participants will be asked to consume 140ml of beetroot juice prior to their first experimental visit. Participants will then be asked to consume 70ml a day for 2 weeks and final visit the investigators once more following another 140ml drink.
2917236|NCT03129178|Placebo Comparator|Nitrate depleted beetroot juice|Participants will be asked to consume 140ml of placebo prior to their first experimental visit. Participants will then be asked to consume 70ml a day for 2 weeks and final visit the investigators once more following another 140ml drink.
2917237|NCT03129165|Experimental|Screening and prevention of CVD|
2917238|NCT03129139|Experimental|Regimen A (monotherapy)|Minnelide™Capsules given daily orally for 21 days followed by a 7 day rest period. One cycle will equal 28 days. This will be a dose escalation.
2917239|NCT03129139|Experimental|Regimen B (combination)|Minnelide™Capsules given daily for 21 days followed by a 7 day rest period in combination with protein-bound paclitaxel given intravenously on day 2, 8 and 15 of a 28 day cycle. The dose of protein-bound paclitaxel will be 125mg/m2 on days 1, 8 and 15. The dose of Minnelide™Capsules will be determined by dose escalation.
2917240|NCT03129126|Experimental|LP-10 2mg|LP-10 (intravesical tacrolimus), 2mg reconstituted in sterile water for injection, intravesical instillations, up to four instillations, instillations will occur greater than 1 day but less than 7 days apart as needed.
2917241|NCT03129126|Experimental|LP-10 4mg|LP-10 (intravesical tacrolimus), 4mg reconstituted in sterile water for injection, intravesical instillations, up to four instillations, instillations will occur greater than 1 day but less than 7 days apart as needed.
2917242|NCT03129126|Experimental|LP-10 8mg|LP-10 (intravesical tacrolimus), 8mg reconstituted in sterile water for injection, intravesical instillations, up to four instillations, instillations will occur greater than 1 day but less than 7 days apart as needed.
2917243|NCT03129126|Placebo Comparator|Placebo|Normal saline, intravesical instillations, up to four instillation.
2917244|NCT03129113|Experimental|maraviroc (Arm A)|maraviroc dosed BID p/o (dose adjusted depending on background combination antiretroviral therapy).
2917245|NCT03129113|Experimental|metformin (Arm B)|metformin 500mg BID p/o.
2917246|NCT03129113|Experimental|maraviroc + metformin (Arm C)|maraviroc dosed BID p/o (dose adjusted depending on background combination antiretroviral therapy) PLUS metformin 500mg BID p/o.
2917247|NCT03129113|No Intervention|no adjunctive therapy (Arm D)|no adjunctive therapy
2917248|NCT03129100|Experimental|Dose Schedule 1 Ixekizumab|Ixekizumab given subcutaneously (SC).
2917249|NCT03129100|Experimental|Dose Schedule 2 Ixekizumab|Ixekizumab given SC.
2917250|NCT03129100|Placebo Comparator|Placebo|Placebo given SC.
2917251|NCT03129087|Experimental|Vocal activity|The vocal activity arm will require the participant to remain in the clinic and read aloud continuously for a period of one hour after a botulinum toxin injection
2917252|NCT03129087|Experimental|Vocal rest|The vocal rest arm will require the participant to remain in the clinic and remain on complete vocal rest for a period of one hour after a botulinum toxin injection
2917253|NCT03129074|Experimental|Varlitinib given in combination with capecitabine|"PO varlitinib 300 mg BID~PO capecitabine 1000 mg/m2 BID"
2917254|NCT03129061|Experimental|Cohort 1 Patients with M/R SCCHN|"Patients with unresectable and metastatic SCCHN cancer who will receive anti-PD-1 treatment under SOC. SOC treatments currently include nivolumab and pembrolizumab (anti-PD-1 treatment). The protocol may be amended to include other agents should they become SOC. Patients will receive a baseline [18F]F-AraG PET/CT scan and another [18F]F-AraG PET/CT scan 6 to 12 weeks after anti-PD-1 dose."
2917255|NCT03129061|Experimental|Cohort 2 Patients with de novo SCCHN|Patients with de novo SCCHN prior to initiation of anti-cancer treatment (e.g., radiation, chemoradiation, or surgery). Patients will receive ONE DOSE of the anti-PD-1 treatment, after the baseline [18F]F-AraG PET/CT scan, baseline blood and tumor tissue collection. Patients will receive a second [18F]F-AraG PET/CT scan 2 - 3 weeks after the one dose of anti-PD-1 treatment.
2917256|NCT03129048|Experimental|MedDiet-WL|MedDiet-WL group, advice and exchange lists will be designed to promote a 1-2 lb. per week weight loss (approximately 30% caloric restriction or a reduction of about 600 calories per day) for an end goal of a 7% weight loss from baseline.
2917257|NCT03129048|Experimental|MedDiet-A|For the MedDiet-A group, dietary advice and corresponding exchange lists will be given within the context of promoting weight stability.
2917258|NCT03129048|Other|Typical Diet Control (TDC)|Typical Diet Control (TDC) will maintain current eating and activity patterns and weight over 14 months.
2917259|NCT03129035|Active Comparator|internal iliac artery ligation|women undergo bilateral internal iliac artery ligation after fetal extraction and before proceeding in cesarean hysterectomy
2917260|NCT03129035|Active Comparator|No internal iliac artery ligation|Women undergo cesarean hysterectomy after fetal extraction
2917261|NCT03129022|Active Comparator|Successful epidural anaesthesia|It is defined as VAS score <5, 30 min after a loading dose, given after the last attempt.
2917262|NCT03129022|Active Comparator|Failed epidural anaesthesia|It is defined as VAS score ≥5, 30 min after a loading dose, given after the last attempt.
2917263|NCT03129009|Active Comparator|Total intravenous anesthesia group|Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
2917264|NCT03129009|Experimental|Balanced anesthesia group|Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
2917265|NCT03128996|Experimental|RIC Prep Regimen & GVHD Prophylaxis|Single arm study. All patients receive the same Reduced Intensity Conditioning (RIC) regimen and GVHD prophylaxis regimen
2917266|NCT03128970|No Intervention|frozen/thawed|blastocysts with three or less grade of expansion will be thawed and then subsequently transferred into women uterus three hours post-thawing.
2917267|NCT03128970|Experimental|synchronized frozen/thawed hatching blastocysts|blastocyst thawing (with three or less grade of expansion) will take place the day before embryo transfer in order to reach hatching stage
2917268|NCT03128957|Experimental|Varying cerebral oxygenation with varying ventilation|Compare oxygenation under conditions of varying ventilation strategy. Low end tidal CO2/Low inspired oxygen vs High end tidal CO2/high inspired oxygen
2917269|NCT03128905|Active Comparator|Colchicine|Patients assigned to this group will receive the Colchicine opocalcium 1mg treatment.
2917270|NCT03128905|Experimental|Prednisone (corticoids)|Patients assigned to this group will receive Prednisone : Cortancyl 20mg.
2917271|NCT03128879|Experimental|Venetoclax + Ibrutinib|Participants receive Ibrutinib and Venetoclax by mouth once per day.
2917272|NCT03128866|Experimental|Tranexamic Acid|Participants receive Tranexamic Acid during hemipelvectomy procedure.
2917273|NCT03128866|No Intervention|No Tranexamic Acid|Participants do not receive Tranexamic Acid during hemipelvectomy procedure.
2917274|NCT03128814||Elite (pre)adolescent tennis players|
2917275|NCT03128814||Age- and gender-matched controls|
2917276|NCT03128801|Experimental|Global Stretching Program (GSP)|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active).
2917277|NCT03128801|Active Comparator|Stabilization Exercises|A exercise protocol will be administered and the criteria to increase exercise progression was previously described by Hicks et al (2005).
2917278|NCT03128788|Active Comparator|Active Comparator: supine position|Active Comparator: supine position thoracic epidural catheterization with supine position
2917279|NCT03128788|Active Comparator|Active Comparator: flexed lateral position|Active Comparator: flexed lateral position thoracic epidural catheterization with flexed lateral position
2917280|NCT03128775|Experimental|Nudge|This group will receive changes in the school environment (nudge strategies). Interventions regarding food consumption were based on nudge strategies to led students to eat more fruits and vegetables. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) are available for use in the school sports court.
2917281|NCT03128775|Experimental|Primary prevention|This group will receive educational activities in the classroom. Classroom-based educational activities will be based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans.
2917282|NCT03128775|Experimental|Primary prevention + nudge|This group will receive educational activities and in the classroomchanges in the school environment (nudge).
2917283|NCT03128775|No Intervention|Control|without any activity
2917284|NCT03128762||Cases|"Patients in this group are asthmatic (see inclusion/exclusion) criteria.~Intervention: ILC2 levels in blood"
2917285|NCT03128762||Controls|"Controls are non-asthmatic subjects that are age and gender matched to asthma cases.~Intervention: ILC2 levels in blood"
2917286|NCT03128749|Experimental|Mindfulness Based Intervention|"Mindfulness-based cognitive therapy (MBCT), adjusted to OCD patients, will be applied in 10 weekly sessions of 2 hours followed by an extra session 4 weeks later. The treatment will be applied in a group format of 10 to 12 patients.~These patients will be also attending to their regular psychiatric visits for medication control."
2917287|NCT03128749|Active Comparator|Treatment as Usual (TAU)|Patients will be attending to their regular psychiatric visits during the whole trial period.
2917288|NCT03128736|Experimental|dexlansoprazole group|dexlansoprazole 60mg
2917289|NCT03128736|Experimental|esomeprazole group|esomeprazole 40mg
2917290|NCT03128723|Experimental|Acne Mask|The light therapy acne mask is applied to the face once in the evening for a duration of 10 minutes. The cleanser is used twice daily, once in the morning and once in the evening.
2917291|NCT03128710||Survey Group|Approximately 300 patients with prostate cancer will be provided a survey investigating their treatment preferences and side effects faced during and after receiving radiation treatment.
2917292|NCT03128710||Focus Group|Approximately 75 participants will participate in a focus group. All participants will have completed radiation treatment and will discuss side effects after having received radiation, as well as their quality of life while receiving radiation.
2917293|NCT03128697|Experimental|Satiating diet-Low satiety phenotype|Low satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.
2917294|NCT03128697|Experimental|Satiating diet-High satiety phenotype|High satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.
2917295|NCT03128697|Active Comparator|Control diet-Low satiety phenotype|Low satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.
2917296|NCT03128697|Active Comparator|Control diet-High satiety phenotype|High satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.
2917297|NCT03128684|Experimental|Small Green Lentil Muffin|
2917298|NCT03128684|Experimental|Split Red Lentil Muffin|
2917299|NCT03128684|Placebo Comparator|Wheat Muffin|
2917300|NCT03128684|Experimental|Small Green Lentil Chili|
2917301|NCT03128684|Experimental|Split Red Lentil Chili|
2917302|NCT03128684|Placebo Comparator|Rice Chili|
2917303|NCT03128684|Experimental|Small Green Lentil Soup|
2917304|NCT03128684|Experimental|Split Red Lentil Soup|
2917306|NCT03128671|Experimental|FAVoR Intervention Group|In the intervention group, scripted audio messages recorded by the patient's family (FAVoR intervention) will be played for the patient at hourly intervals during daytime hours. These messages will be personalized, delivered automatically, and provide information about the ICU environment. The FAVoR intervention, a standardized protocol developed and tested in preliminary work, will be delivered by audio recording for 5 consecutive days (120 hours), or until ICU discharge if discharge occurs within the first 5 days. The number of episodes of delirium during ICU stay is the primary outcome measure. Data will also be collected at 1 month and 6 months following hospital discharge for secondary aim 3.
2917307|NCT03128671|No Intervention|Control Group|The control group will not receive the FAVoR intervention. The number of episodes of delirium during ICU stay is the primary outcome measure. Data will also be collected at 1 month and 6 months following hospital discharge for secondary aim 3.
2917308|NCT03128658||Trauma patients|Trauma patients with a systolic blood pressure of 90 mmHg or less, in need for blood product transfusion within 1 hour of admission, and/or an ISS (injury severity score) of greater than or equal to 15.
2917309|NCT03128645||Group 1|Standard method group
2917310|NCT03128645||Group 2|Abdominal corset group
2917311|NCT03128619|Experimental|Arm A (copanlisib, letrozole)|PHASE II: Patients receive copanlisib (MTD) IV over 1 hour on days 1, 8, and 15 and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression, or unacceptable toxicity.
2917312|NCT03128619|Experimental|Arm B (copanlisib, palbociclib, letrozole)|PHASE II: Patients receive copanlisib (MTD) IV over 1 hour on days 1, 8, and 15, palbociclib PO QD on days 1-21, and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2917313|NCT03128619|Experimental|Arm C (copanlisib, palbociclib, letrozole)|PHASE II: Patients receive palbociclib PO QD for days 1-14 of course 1 and letrozole PO continuously on days 1-14. Patients then undergo biopsy. Patients then receive copanlisib IV over 1 hour on days 1, 8, and 15 and letrozole PO continuously on days 1-28. Treatment with copanlisib (MTD) and letrozole repeats every 28 days for up to 3.5 courses in the absence of disease progression or unacceptable toxicity.
2917314|NCT03128619|Experimental|Phase Ib (copanlisib, palbociclib, letrozole)|PHASE Ib: Patients with metastatic breast cancer receive copanlisib IV over 1 hour on days 1, 8, and 15, palbociclib PO QD on days 1-21, and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2917315|NCT03128606|Experimental|GLPG3067 single dose|Single dose of GLPG3067 oral suspension at up to 6 dose levels in ascending order.
2917316|NCT03128606|Placebo Comparator|Placebo single dose|Single dose of Placebo oral suspension.
2917317|NCT03128606|Experimental|GLPG3067 oral suspension fed 1|Single dose 1 of GLPG3067 oral suspension after a standardized breakfast.
2917318|NCT03128606|Experimental|GLPG3067 oral tablet fed 1|Single dose 1 of GLPG3067 oral tablet after a standardized breakfast.
2917319|NCT03128606|Experimental|GLPG3067 oral tablet fasted 1|Single dose 1 of GLPG3067 oral tablet after an overnight fast.
2917320|NCT03128606|Experimental|GLPG3067 oral tablet fed 2|Single dose 2 of GLPG3067 oral tablet after a standardized breakfast.
2917321|NCT03128606|Experimental|GLPG3067 oral tablet fed 2 high-fat high-calorie|Single dose 2 of GLPG3067 oral tablet after a high-fat high-calorie breakfast
2917322|NCT03128606|Experimental|GLPG3067 multiple dose|Multiple doses of GLPG3067 oral suspension at up to 5 dose levels in ascending order.
2917323|NCT03128606|Placebo Comparator|Placebo multiple dose|Multiple doses of Placebo oral suspension.
2917324|NCT03128606|Experimental|GLPG3067/GLPG2222 multiple dose|Multiple doses of GLPG3067 oral suspension combined with GLPG2222 oral tablet up to 2 dose levels in ascending order.
2917325|NCT03128606|Placebo Comparator|GLPG3067/GLPG2222 Placebo multiple dose|Multiple doses of GLPG3067 matching placebo oral suspension combined with GLPG2222 matching placebo oral tablet.
2917326|NCT03128606|Experimental|GLPG3067/GLPG2222/GLPG2737 multiple dose|Multiple doses of GLPG3067 oral tablet combined with GLPG2222 oral tablet and GLPG2737 oral capsule at up to 2 dose levels in ascending order.
2917327|NCT03128606|Placebo Comparator|GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose|Multiple doses of GLPG3067 matching placebo oral tablet combined with GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule.
2917328|NCT03128593|Experimental|Experimental: JR-141|
2917329|NCT03128580||Natural Cycle|The patient will not undergo hyperstimulation rather a natural cycle
2917330|NCT03128580||Stimulated Cycle|The 80 patients will undergo hyperstimulation cycle as per the clinical practice planned for the patient.
2917331|NCT03128567||Stimulation of the subthalamic nucleus|25 patients with Parkinson's disease
2917332|NCT03128567||Best medical treatment|25 patients with Parkinson's disease
2917333|NCT03128554|Experimental|Intervention with Training and Materials|Clinics randomized to the intervention group will receive a one time, 2-hour Continuing Medical Education/Group Learning training session on the smoking reduction intervention model, along with provider and patient handouts.
2917334|NCT03128554|No Intervention|Usual Care|Clinics randomized to the control group will not be exposed to the intervention program.
2917335|NCT03128541||Ultrasound Spine in sitting position|Participants will be assigned to a sitting decubitus position to identify the Tuffier's Line
2917336|NCT03128541||Ultrasound Spine in lateral position|Participants will be assigned to a lateral decubitus position to identify the Tuffier's Line
2917337|NCT03128528|Placebo Comparator|Placebo Oral Tablet|Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.
2917338|NCT03128528|Active Comparator|Empagliflozin|Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.
2917339|NCT03128515|Experimental|MTD Dose Escalation|Maximum tolerated dose of Hydroxyurea, 25-30 mg/kg/day
2917340|NCT03128515|Active Comparator|Fixed Dose|Fixed dose of Hydroxyurea, 20 mg/kg/day
2917341|NCT03128502||healthy control|Ten healthy control subjects presented with clinically healthy periodontium. Control subjects had to meet the following criteria for inclusion: probing depth less than 3mm, no clinical attachment loss, no bleeding on probing, with Gingival and Plaque index 0-1.
2917462|NCT03127644|Experimental|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally three times daily for 48 hours.
2917342|NCT03128502||plaque induced gingivitis|Ten patients who had plaque induced gingivitis characterized by the presence of any of the following clinical signs: redness and edema of the gingival tissue, bleeding upon provocation, changes in contour and consistency, presence of calculus and/or plaque, with no clinical attachment loss nor radiographic evidence of bone loss.
2917343|NCT03128502||chronic periodontitis|Ten chronic moderate to severe periodontitis patients selected according to the criteria currently adopted by Armitage 1999. Moderate destruction is generally characterized by periodontal probing depths up to 6 mm with clinical attachment loss of up to 4 mm. Advanced destruction is generally characterized by periodontal probing depths greater than 6 mm with attachment loss greater than 4 mm. Radiographic evidence of bone loss is apparent, Increased tooth mobility may be present.
2917344|NCT03128502||aggressive periodontitis|Ten patients suffering generalized aggressive periodontitis, patients were less than 35 years of age and had generalized interproximal attachment loss affecting at least 3 permanent teeth other than the first molars and incisors with at least one site each with PD and CAL >5 mm, Attachment loss occurs in pronounced episodic periods of destruction, and there is familial aggregation (subjects were asked if they had at least one other member of the family presenting or with a history of periodontal diseases).
2917345|NCT03128489|Experimental|DTPa-IPV/Hib Group|All subjects will receive three doses of primary vaccination at 6, 10 and 14 weeks of age.
2917346|NCT03128476|Active Comparator|1 bottle|
2917347|NCT03128476|Active Comparator|2 bottles|
2917348|NCT03128476|Placebo Comparator|Placebo|
2917349|NCT03128463||significantly effective group|visual improvement ≥15 letters in Early Treatment Diabetic Retinopathy Study (EDTRS) table after intravitreal injection of conbercept
2917350|NCT03128463||effective group|visual improvement ≥5 letters and ＜15 letters in EDTRS table after intravitreal injection of conbercept
2917351|NCT03128463||invalid group|visual improvement ＜5 letters and visual reduction＜5 letters in EDTRS table after intravitreal injection of Combercept
2917352|NCT03128463||deterioration group|visual reduction≥5 letters in EDTRS table after intravitreal injection of conbercept
2917353|NCT03128450|Experimental|h-NSC arm|"human neural stem cell: 100ul/vessel，2 vessel/one bag，≥2×10 6cells/vessel，produced by Shanghai Angecon Biotechology Cooperate.~One enrolled PD patient was given 2 vessels h-NSC througth nasal cavity weekly for 4 weeks。Total cell number will be over ≥4×10 6cells for one time."
2917354|NCT03128437|Experimental|Aerobic Exercise Condition|6 aerobic exercise exposures will be completed over the course of 2 weeks.
2917355|NCT03128437|No Intervention|Assessment Only Condition|"Participants randomly assigned to the control condition will complete assessments at the same time intervals as the active condition, but will not participate in exercise sessions.~Assessments will take place at baseline, week 2, week 4, and week 8."
2917356|NCT03128424|Experimental|PQ Bypass Stent Graft System|The PQ Bypass™ Stent Graft System is intended for patients with atherosclerotic lesions of the SFA
2917357|NCT03128411|Experimental|Bosutinib|Bosutinib monotherapy; All patients will receive bosutinib at a starting dose of 400 mg QD. The dose of bosutinib may be escalated (up to a maximum of 600 mg QD) for unsatisfactory response or reduced for toxicity.
2917358|NCT03128385|Experimental|Intensive CIT Model Program|"In day camp model, each child is assigned to a trained therapist to maintain at least a 1:1 ratio of therapy and child. The therapist will monitor and modify the activities to fit each child's ability and need (e.g. implementing task analysis, grading the challenge for each individual with varying capabilities) to make sure the intervention quality is equivalence to the individualized treatment.The day camp model will be arranged as Magic Camp that decorating the treatment place as the magic world and dressing each child as a little witch. This novel design is mean to enhance and motivate the engagement of participation."
2917359|NCT03128385|Experimental|Distributed CIT Model Program|All treatment activities will be focused on the training of the more affected upper limbs with contextual restraint. Investigators choose this child-friendly way to restraint children's non or less impaired hand without any devices. Investigators will provide a unilateral activities and verbal cues to restraint participants' non or less affected side. All tailored activities will be designed as fun and age-appropriated based on the child's preference and parents' concerns. In order to help children to generalize the therapeutic gains to the real world environment, the intervention will take place in the natural environment such as home or school where it may be easier to identify real practical problems and makes the family or caregivers involved more closely and directly.
2917360|NCT03128372|Experimental|Desaturation|Volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
2917361|NCT03128359|Experimental|Regimen A (fludarabine, melphalan, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -3 and melphalan hydrochloride IV over 20 minutes on day -2.~Patients undergo PBSC HCT on day 0.~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
2917362|NCT03128359|Experimental|Regimen B (fludarabine, busulfan, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 1-3 hours and busulfan IV over 3 hour on days -5 to -2.~Patients undergo PBSC HCT on day 0.~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
2917363|NCT03128359|Experimental|Regimen C (fludarabine, TBI, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -5 and TBI BID on days -4 to -1.~Patients undergo PBSC HCT on day 0.~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
2917364|NCT03128346|Experimental|The nerve block group|TTP block under dynamic ultrasound guidance plus the standard care (hydromorphone, fentanyl, aspirin, acetaminophen)
2917365|NCT03128346|Active Comparator|The standard of care group|Patients in the standard care group will receive pain medications, such as hydromorphone, fentanyl, aspirin and acetaminophen.
2977139|NCT02715895|Experimental|Friso|Friso formula feeding
2917366|NCT03128333|Experimental|RunKeeper app + physiotherapy coaching|Group A will use the RunKeeper app for half a year to self-monitor leisure-time PA. Besides, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is all explained in a brief user's manual. In addition, patients will be educated about the health risks of a sedentary lifestyle, inactivity and (when applicable) other unhealthy lifestyle behaviors (e.g. unhealthy diet, overweight or obesity, sun exposure, alcohol intake). Benefits of a behavior change, becoming physically active and pursuing a healthy lifestyle will be explained by a trained physiotherapist who will also coach the patient during the PA program.
2917367|NCT03128333|Other|usual care|In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
2917368|NCT03128320|Experimental|BAY1193397/Placebo (sequence A-B-C)|Subjects with type II diabetes who follow treatment sequence A-B-C. Single oral dose of a placebo tablet in the first intervention period (Treatment A); followed by single oral dose of 1 mg BAY1193397 (Treatment B); then single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the third intervention period (Treatment C). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
2917369|NCT03128320|Experimental|BAY1193397/Placebo (sequence B-C-A)|Subjects with type II diabetes who follow treatment sequence B-C-A. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the second intervention period (Treatment C), then single oral dose of a placebo tablet under fasted conditions in the third intervention period (Treatment A). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
2917370|NCT03128320|Experimental|BAY1193397/Placebo (sequence B-A-C)|Subjects with type II diabetes who follow treatment sequence B-A-C. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of a placebo tablet in the second intervention period (Treatment A), then 5 mg BAY1193397 IR tablet under fasted conditions in the third intervention period (Treatment C). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
2917371|NCT03128294||long-term survivors of ovarian cancer|long-term survivors of ovarian cancer
2917372|NCT03128281|Experimental|Conventional Insufflation System (CIS)|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~Conventional Insufflation System (CIS) used for pneumoperitoneum during laparoscopic/robotic surgery."
2917373|NCT03128281|Experimental|ConMed AirSeal Insufflation System (AIS) at Low Pressure|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~ConMed AirSeal Insufflation System (AIS) at Low Pressure used for pneumoperitoneum during laparoscopic/robotic surgery."
2917374|NCT03128281|Active Comparator|ConMed AirSeal Insufflation System (AIS) at Higher Pressure|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~ConMed AirSeal Insufflation System (AIS) at Higher Pressure used for pneumoperitoneum during laparoscopic/robotic surgery."
2917375|NCT03128268|Experimental|All Enrollees|"Intervention: Diagnostic test~All enrollees will receive a 4D MRI as a research intervention using imaging software for 4 dimensional images for Cardiac MRI"
2917376|NCT03128255||Regular Thyroid Work-up|Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics. Data and images of patient characteristics, laboratory results, ultrasonography loops and planar 99mTcO4 scintigraphy are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
2917377|NCT03128255||Regular Thyroid Work-up and I-124 PET/US|Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics and additional I-124 PET/CT, followed by I-124 PET/US (administration of I-124 was not subject of this study). Data and images of patient characteristics, laboratory results, ultrasonography loops, planar 99mTcO4 scintigraphy as well as I-124 PET/US loops are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
2917378|NCT03128242|Experimental|oxytocin group|oxytocin treatment
2917379|NCT03128242|Placebo Comparator|placebo group|placebo treatment
2917380|NCT03128216|Active Comparator|Blind Local Anesthetic Infiltration|
2917381|NCT03128216|Active Comparator|Transversals Fascia Block|
2917382|NCT03128216|Active Comparator|Spinal Anesthesia|
2917383|NCT03128203|Experimental|Oxytocin|
2917384|NCT03128203|Placebo Comparator|Placebo|
2917385|NCT03128190|No Intervention|Control group|In the control period, patients were given intravenous fluids at the discretion of the anesthesiologist based on institutional protocol using 250ml of crystalloids or 100ml of colloids based on central venous pressure (CVP) and mean arterial pressure (MAP) measurements. The aim was to keep the CVP ≥ 8mmHg and MAP ≥ 65mmHg. Fluid boluses were administered up to a total of 1000ml, if patients did not attain a MAP of >65 mmHg, a vasopressor drug was administered.
2917386|NCT03128190|Experimental|PPV group|intraoperative fluid management was titrated to maintain PPV< 10%. fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
2917387|NCT03128177|Experimental|High sodium diet|High sodium diet is 6 g sodium per day for 10 days
2917388|NCT03128177|Experimental|Low sodium diet|Low sodium diet is 1.5 g sodium per day for 10 days
2917389|NCT03128164|Experimental|HMPL-689|HMPL-689, oral, BID, doses should be taken at ~12-hour intervals (eg, at ~8 AM and at ~8 PM)
2917390|NCT03128151||Study group|Intraoperative neuromuscular monitoring and pharmacological reversion according to data sheet
2917391|NCT03128151||Control group|Treated according to usual clinical practice
2917392|NCT03128138|Experimental|25 mg SPH3127 tablet-Dose 1|"6 Volunteers, Single dose of SPH3127 tablet, 25mg, po. 1 tablet.~2 Volunteers, Single dose of Placebo tablet, 25mg, po. 1 tablet."
2917393|NCT03128138|Experimental|50 mg SPH3127 tablet-Dose 2|"6 Volunteers, Single dose of SPH3127 tablet, 50mg, po. 1 tablet.~2 Volunteers, Single dose of Placebo tablet, 50mg, po. 1 tablet."
2917394|NCT03128138|Experimental|100 mg SPH3127 tablet-Dose 3|"6 Volunteers, Single dose of SPH3127 tablet, 100mg, po. 1 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 1 tablet."
2918068|NCT03122938|Placebo Comparator|Control Group|formula without lactoferrin supplementation
2917395|NCT03128138|Experimental|200 mg SPH3127 tablet-Dose 4|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 2 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 2 tablet."
2917396|NCT03128138|Experimental|400 mg SPH3127 tablet-Dose 5|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 4 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 4 tablet."
2917397|NCT03128138|Experimental|800 mg SPH3127 tablet-Dose 6|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 8 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 8 tablet."
2917398|NCT03128125|Experimental|High intellectual potential|Participation in the study involves the conduct of a clinical examination in neurology, the collection of anamnestic elements and a neuropsychological examination in children with high intellectual potential.
2917399|NCT03128125|Other|Control|Participation in the study involves the conduct of a clinical examination in neurology, the collection of anamnestic elements and a neuropsychological examination in control children with no particularities.
2917400|NCT03128112|No Intervention|Exam room without poster|All parents will be asked to fill out a questionnaire detailing basic demographic information as well as their perception of their child's weight. Parents who are in exam rooms without posters will be ask to fill out a second short questionnaire after seeing their physician that will ask parents whether they discussed their child's weight status with their physician and whether they believe their own child is: very overweight, overweight, healthy weight, underweight, or very underweight.
2917401|NCT03128112|Active Comparator|Exam room with poster|All parents will be asked to fill out a questionnaire detailing basic demographic information as well as their perception of their child's weight. Parents who are in exam rooms with posters will be directed to read the poster on the exam room wall. After viewing the poster and after seeing their physician, parents will be ask to fill out a second short questionnaire that will ask parents whether they discussed their child's weight status with their physician, whether this conversation was prompted by the poster, and whether they believe their own child is very overweight, overweight, healthy weight, underweight, or very underweight.
2917402|NCT03128099|Experimental|Low dose VR social skills training|In the low dose condition, participants play the video game for one hour per session. This is a behavioral intervention study. The intervention is playing the social skills virtual reality game to exercise social skills with avatar characters.
2917403|NCT03128099|Experimental|High dose Low dose VR social skills training|In the high dose condition, participants play the same video game twice per session (it takes them two hours). This is a behavioral intervention study. The intervention is playing the social skills virtual reality game to exercise social skills with avatar characters.
2917404|NCT03128086|Experimental|Protocol-directed weaning|A protocol-directed weaning in neurological patients undergoing mechanical ventilation: performing a spontaneous breathing trial through a T-tube and after that to assess the patient's capacity to maintain airway. In case of reach a score the patient will extubated.
2917405|NCT03128086|No Intervention|Conventional weaning|A control group of weaning from mechanical ventilation according to the usual procedure: performing a spontaneous breathing trial through a T-tube and then extubation if the patient success this trial.
2917406|NCT03128073|Experimental|Single group|The intervention is with the Carry Life system ultrafiltration (CLS UF) device, which administers a Glucose-salt solution intermittently to a volume of the intraperitoneal fluid in the device.
2917407|NCT03128060|Experimental|Home-based Palliative Care|Home-based palliative care features home visits by an interdisciplinary PC team (physician, nurse, social worker, and chaplain) that provides pain and symptom management, psychosocial support, advance care planning, disease management education, spiritual and grief counseling, and other services as needed.
2917408|NCT03128060|Active Comparator|Enhanced Usual Care|Enhanced usual care refers to usual primary care provided by a primary care physician who has received special training in the core elements of palliative care.
2917409|NCT03128047|Experimental|Cohort 1|"Recurrent high-grade glioma patients will receive treatment with the Optune NovoTTF-200A system as monotherapy.~Interventions: Device: Optune NovoTTF-200A System Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles."
2917410|NCT03128047|Experimental|Cohort 2|"High-grade glioma patients will receive treatment with the Optune NovoTTF-200A system in combination with temozolomide and bevacizumab.~Interventions:Device: Optune NovoTTF-200A System Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles.~Drug: Bevacizumab will be dosed at 10mg/kg/dose. Bevacizumab will be administered intravenously on Days 1 and 15 of each cycle.~Other Name: Avastin (VEGF/VECFR Inhibitor)~Drug: Temozolomide Temozolomide will be dosed at 200 mg/m2/day. Temozolomide will be given orally for 5 days during Days 1-5 of each 28-day cycle.~Other Name: Temodar (Alkylating Agent)"
2917411|NCT03128034|Experimental|Treatment (211^At-BC8-B10, PBSC)|Patients receive 211^At-BC8-B10 IV over 6-8 hours on day -7 and fludarabine phosphate IV over 30 minutes on days -4, -3 and -2. Patients undergo TBI and PBSC transplant on day 0. Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 and then tapered to day 180, or continuing to day 96 and then tapered to day 150. Patients receive mycophenolate mofetil PO or IV (first dose to occur 4-6 hours after PBSC infusion) every 12 hours on days 0-27, or every 8 hours on day 0 and then reduced to every 12 hours on days 30-40. Patients with HLA-matched unrelated donors receive sirolimus PO QD on days -3 to 150 and then tapered to day 180.
2917412|NCT03128021|Active Comparator|Escitalopram Pill|Participants in this arm will receive an initial dose of 5 mg. Further titrations will be decided based on clinical response and tolerability (maximum dose of 20 mg). The medication will be taken by mouth in pill form, once daily.
2917413|NCT03128021|Placebo Comparator|Placebo|"Participants will be given a sugar pill (placebo) to be taken by mouth once daily for the 6 week duration of Phase I. As this arm is also double-blinded, participants will receive an initial dose of 5 mg and further titrations (maximum dose of 20 mg) will be decided based on clinical response and tolerability.~Note: This arm no longer applies as of 5/16/18. Participants are now randomly assigned to Lexapro or Fetzima."
2917459|NCT03127683|Experimental|AuraGain group|"An AuraGain will be placed in all patients, and mechanical ventilation will be performed using a volume-controlled mode with a tidal volume of 10 ml/kg.~The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed first for the neutral head position and then for the extended, flexed, and rotated head positions in a random order."
2917463|NCT03127644|Experimental|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times daily for 48 hours.
2917414|NCT03128021|Other|Escitalopram Pill (Phase II)|"Participants who were in the placebo arm for Phase I who do not show signs of response to treatment by week 6 (defined as either a MADRS score of greater than 12 or less than a 30% reduction in MADRS score to be deemed a non-responder) will be given the option to have an open-label trial of escitalopram in Phase II.~Participants in this arm will receive an initial dose of 5 mg. Further titrations throughout the 6 week duration of Phase 2 (maximum dose of 20 mg) will be decided based on clinical response and tolerability. The medication will be taken by mouth in pill form, once daily.~Note: This arm no longer applies as of 5/16/18. Participants are now randomly assigned to Lexapro or Fetzima and the assignment does not change throughout the study."
2917415|NCT03128021|Active Comparator|Levomilnacipran Pill|Participants will receive an initial dose of 20 mg blinded levomilnacipran. At day 7, the doses will be titrated to 40 mg of levomilnacipran. Further titrations (maximum dose of 120 mg of levomilnacipran) will be decided based on clinical response and tolerability. The medication will be taken by mouth in pill form, once daily.
2917416|NCT03128008|Experimental|Carboplatin/Paclitaxel with radiation therapy|Single arm, non randomized, open label study. Eligible subjects will receive standard of care Carboplatin IV once a week, Paclitaxel IV once a week given concurrently with daily hyperfractionated radiation therapy (RT). RT will be delivered as 6 fractions weekly.
2917417|NCT03127995|Experimental|HYPOFRACTIONATED|"40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions per week.~If the patient is candidate for a boost it will be provided as follows:~sequential boost with 40 Gy to CTV breast in 15 fractions and 16 Gy to CTV boost in 8 fractions~or simultaneous integrated boost (SIB) with 42.3 Gy on CTV breast and 52.2 Gy on CTV boost in 18 fractions"
2917418|NCT03127995|Other|NORMOFRACTIONATED|"50 Gy / 25 fractions, 2.0 Gy per fraction, 5 fractions per week.~If the patient is candidate for a boost it will be provided as follows:~sequential boost with 50 Gy to CTV breast in 25 fractions and 16 Gy to CTV boost in 8 fractions~or simultaneous integrated boost (SIB) with 51.52 Gy on CTV breast and 63 Gy on CTV boost in 28 fractions"
2917419|NCT03127982|Experimental|Group 1|Immediately following randomization, participants in this condition attend 12-13 biweekly face-to face individual sessions that last approximately 1.5 hrs each of the cultural adaptation of the Unified Protocol trans diagnostic treatment comprising the following modules: motivation enhancement, psycho-education of emotion, emotion awareness training, cognitive reappraisal, emotion avoidance and emotion-driven behavior, tolerance training for physical sensations, emotion exposure, and relapse prevention. Treatment is provided by graduate students in clinical psychology who have been trained in the UP and receive weekly supervision by experienced clinicians and use a Workbook for homework assigned between sessions.
2917420|NCT03127982|Active Comparator|Group 2|Participants randomly assigned to this condition do not receive any active intervention during a six-week wait period after randomization, while completing assessment evaluation at the beginning and end of wait list period, after which they receive the same intervention (Unified Protocol) provided to the treatment condition (Group 1).
2917421|NCT03127969|Other|Fluidotherapy treatment|Patients who received fluidotherapy and joint protection and exercise
2917422|NCT03127969|Other|Joint protection and exercise|Patients who received joint protection and exercise
2917423|NCT03127956|Experimental|Treatment A|
2917424|NCT03127943|Active Comparator|Buffered 1% lidocaine|"In week One, Each subject would be injected intraorally with either anesthetic (Buffered 1% lidocaine with 1/100,00 epinephrine) or (Non-buffered 1% lidocaine with 1/100,00 epinephrine to block the Inferior alveolar, Lingual and Buccal nerves.~In week two the alternate anesthetic would be administered. Mandibular molar and canine tested for pulpal anesthesia."
2917425|NCT03127943|Active Comparator|Non-buffered 1% lidocaine|"In week Two, Each subject would be injected intraorally with the alternate anesthetic (Buffered 1% lidocaine with 1/100,00 epinephrine) or (Non-buffered 1% lidocaine with 1/100,00 epinephrine to block the Inferior alveolar, Lingual and Buccal nerves.~Mandibular molar and canine tested for pulpal anesthesia."
2917426|NCT03127930|Experimental|Intervention|Intervention: Participants receive both usual care including a standard brochure on patient management provided by the Alzheimer's Association plus a tailored problem-solving intervention to improve caregiver's management of medications for their family or friend care recipient who has memory deficit.
2917427|NCT03127930|No Intervention|Usual Care|No Intervention: Participants do not receive the problem solving intervention and are followed as a Usual Care condition including receiving a standard brochure on patient management provided by the Alzheimer's Association. .
2917428|NCT03127917|Experimental|CitrullinePlacebo|Subjects allocated to the CitrullinePlacebo study arm received L-citrulline first, followed by placebo.
2917429|NCT03127917|Experimental|PlaceboCitrulline|Subjects allocated to the PlaceboCitrulline study arm received placebo first, followed by L-citrulline.
2917430|NCT03127904|Experimental|Vein Fitness|"Lymphomiokinetic exercises will be performed during a 1 hour period, with the patients in a supine position, legs elevated and properly positioned on a carpet; the knees will be mildly flexed to a comfortable point. The patients will put feet on the pedals of ankle extension/flexion device. The frequency will be around 15 to 20 cycles/minute, while the amplitude will be individually adjusted according to the range of movement of each patient. During the exercises, study personnel will manually drain the lower members.~Compressive therapy will be applied as described in the control group arm.~Care of the wound will be delivered as described in the control group arm."
2917431|NCT03127904|Active Comparator|Control group|"Compressive therapy will be applied to both groups by properly trained personnel. Each layer of the compressive boot will have a 50% overlap, from the base to of the fingers to 3 cm bellow the popliteal fossa. The interface pressure used will be of at least 50mmHg in supine position.~Wound care will be delivered to every individual in both groups, 1 or 2 times each week by a nurse certified in wound management, following the principles of maintenance of a moisturized surface between the wound and its cover. The nurse will also carry out mechanical wound debriding and biofilm removal."
2917432|NCT03127891|Experimental|pranayama yoga|yoga breathing exercise
2917433|NCT03127891|Placebo Comparator|control group|no intervention
2917434|NCT03127878|Active Comparator|Active-control|High-intensity endurance exercise of lower-limb with strengthening exercise of upper- and lower-limb
2917435|NCT03127878|Experimental|Upper-limb additional training|High-intensity endurance exercise of upper- and lower-limb with strengthening exercise of upper- and lower-limb
2917460|NCT03127670|Experimental|Solanum melongena peel extract 0.05%|25 Patients Solanum melongena peel extract 0.05% Twice daily applied topically for 12 weeks
2917436|NCT03127852|Experimental|Telemonitoring (Medly)|The telemonitoring technology will enable patients with complex chronic illnesses, to take clinically relevant physiological measurements with wireless home medical devices and to answer symptom questions on the mobile phone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
2917437|NCT03127852|No Intervention|Control|Standard of care: Patients are followed in a specialty care clinic treating their primary conditions. Patients typically have scheduled appointments every six months.
2917438|NCT03127839|Active Comparator|Eccentric Strengthening Exercise|Patients will be asked to complete at least 6 outpatient PT sessions over a 4-week period. This will include an individualized impairment-focused approach, utilizing eccentric strengthening exercises of the rotator cuff to address any impairments or reinforce any standard of care manual treatment. Patients will also be given a home exercise program with instructions so that they can perform the eccentric strengthening exercises daily at home.
2917439|NCT03127839|Active Comparator|Traditional Strengthening Exercise|Patients will be asked to complete at least 6 outpatient PT sessions over a 4-week period. This will include an individualized impairment-focused approach, utilizing traditional rotator cuff strengthening exercises to address any impairments or reinforce any standard of care manual treatment. Patients will also be given a home exercise program with instructions so that they can perform the traditional rotator cuff strengthening exercises daily at home.
2917440|NCT03127839|Active Comparator|Eccentric Exercise + pain education|"In addition to the treatment provided in the Eccentric Exercise Arm patients will receive additional self-management training education focused on neuroscience of pain principles.~This will include e a 5-minute video called Understanding pain in less than 5 minutes, and what to do about it!, or aka explain pain video. The patients will also receive an interactive education booklet and review session with their PT, a series of weekly e-mails that reinforce key components of the booklet and video; and reinforcing messages when in the clinic doing their exercises."
2917441|NCT03127839|Active Comparator|Traditional Exercise + pain education|"In addition to the treatment provided in the Traditional Exercise Arm patients will receive additional self-management training education focused on neuroscience of pain principles.~This will include e a 5-minute video called Understanding pain in less than 5 minutes, and what to do about it!, or aka explain pain video. The patients will also receive an interactive education booklet and review session with their PT, a series of weekly e-mails that reinforce key components of the booklet and video; and reinforcing messages when in the clinic doing their exercises."
2917442|NCT03127826|Active Comparator|Usual Care|"Managing Low Back Pain pamphlet from DoD/VA~No specific guidance regarding physical therapy (PT) or other referrals, thus decision to refer or not will be made by the primary care manager (PCM) according to their preference"
2917443|NCT03127826|Experimental|Risk Stratified Care|"Managing Low Back Pain pamphlet from DoD/VA~Self-management education and tools~2-item spinal manipulation screening/delivery if indicated~Low Risk:~Home Exercise Program as indicated~No referral for ongoing physical therapy~Medium Risk and High Risk~Referral to physical therapy for ongoing care at physical therapists discretion~Managed by a psychologically informed physical therapy trained physical therapist"
2917444|NCT03127813|Experimental|Treated glaucoma|POAG patients established on treatment
2917445|NCT03127813|Experimental|Untreated|Newly diagnosed treatment naïve POAG patients
2917446|NCT03127813|Active Comparator|Control|Control subjects without glaucoma
2917447|NCT03127800|Experimental|Morphine sulphate|Participants will be given a first dose of morphine sulphate (intravenously) before bedtime and a second dose four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness
2917448|NCT03127787||CMV infected|CMV infected observational study testing using DxN CMV Assay. Study is observational and results not used to manage patient care.
2917449|NCT03127774|Experimental|Surgery with HIPEC|Cytoreductive surgery followed by HIPEC with cisplatin and sodium thiosulfate
2917450|NCT03127761||Allogeneic HCT|Prospectively enrolled cohort of patients receiving allogeneic hematopoietic cell transplantation for multiple myeloma
2917451|NCT03127761||Historical autoHCT|Historical cohort of patients with autologous hematopoietic cell transplantation between 2010 and 2016
2917452|NCT03127735|Experimental|BAY1436032|"Dose escalation:~Various doses of study drug will be tested on a small number of patients/dose with the goal of identifying the most appropriate dose(s) for further evaluation in dose expansion. The MTD of the study drug may or may not be identified. It is anticipated that 3-4 patients will be treated at each dose of study drug to be tested and that 15-20 total patients will be treated in this part of the trial.~Dose expansion:~Up to 2 different doses of study drug will be tested on up to 30 patients/dose with the goal of identifying the most appropriate RP2D for further clinical development. The doses to be evaluated in this part of the trial will be selected based on information obtained during dose escalation."
2917453|NCT03127722|Experimental|ESSURE (BAY1454032)|Subjects selecting hysteroscopic sterilization who are not contraindicated for the Essure procedure according to the most current approved version of the Essure IFU. Subject willing to use alternative contraception for at least 3 months post-Essure placement procedure, until a satisfactory Essure Confirmation Test is documented.
2917454|NCT03127722|Active Comparator|Laparoscopic tubal sterilization|Subjects selecting laparoscopic sterilization who are not contraindicated for laparoscopic tubal sterilization according to common clinical practice standard of care
2917455|NCT03127709||Participants with a histiocytic disorder diagnosis|Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
2917456|NCT03127696|Experimental|FMT + LMP|FMT and lifestyle modification program
2917457|NCT03127696|Experimental|FMT alone|Fecal Microbiota Transplantation
2917458|NCT03127696|Sham Comparator|Sham + LMP|Sham and lifestyle modification program
2917461|NCT03127657|Experimental|Cock's comb extract 0.01%|25 Patients Cock's comb extract 0.01% Applied topically twice daily for 12 weeks
2917532|NCT03127072|Active Comparator|Arm B|chemotherapy ± target therapy
2917464|NCT03127644|Placebo Comparator|Placebo|Placebo suspension administered orally placebo three times daily for 48 hours.
2917465|NCT03127631|Active Comparator|Randomized - Intervention|The intervention will consist of a systematic cardiovascular and lifestyle risk factor modification strategy, including dietary and exercise advice, advice to quit smoking, and the prescription of open-label antiplatelet agents, statins, ACE-I, and other antihypertensive medications where appropriate.
2917466|NCT03127631|No Intervention|Randomized - Control|The control will consist of usual clinical care, which may include a referral to a cardiologist or internist, or the use of treatments included in the intervention as clinically indicated, if part of the treating physician's standard practice.
2917467|NCT03127592|Experimental|Group 1|1 active treatment (Fixed Dose Combination) + 2 placebos
2917468|NCT03127592|Active Comparator|Group 2|1 active treatment (Cyclobenzaprine) + 2 placebos
2917469|NCT03127592|Active Comparator|Group 3|1 active treatment (Etodolac) + 2 placebos
2917470|NCT03127579|Experimental|Longer meal duration|Families eat longer as they usually do
2917471|NCT03127579|No Intervention|Usual meal duration|Families eat as long as they usually do
2917472|NCT03127553|No Intervention|A - control|Free diet with standard bread
2917473|NCT03127553|Active Comparator|B - low-salt diet with normal bread|Low-sodium diet with standard bread
2917474|NCT03127553|Experimental|C - low-salt diet with low-salt bread|Low-sodium diet with low-sodium bread
2917475|NCT03127514|Placebo Comparator|Placebo|Placebo administered twice daily p.o. for 24 weeks
2917476|NCT03127514|Experimental|AMX0035|AMX0035 administered twice daily p.o. for 24 weeks
2917477|NCT03127475|Experimental|real tDCS|Device: Transcranial direct current stimulation In tDCS,the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 min, with a linear fade in /fade out of 10 s in anodal and cathodal conditions resulting in a current density of 0.8A/M2 which is 177 times below the lesion effect of tDCS in the rats study(142.9A/m2)
2917478|NCT03127475|Sham Comparator|sham tDCS|Device: Sham tDCS Sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
2917479|NCT03127462|Experimental|Individualized Education|
2917480|NCT03127462|No Intervention|Control group|
2917481|NCT03127449|Experimental|Alflutinib|patients take Alflutinib orally once per day at different dose
2917482|NCT03127436||Acarovac Hausstaubmilbe|"This prospective open multi-centre non-interventional study was initiated to document the tolerability and the safety profile of the subcutaneous allergen-specific immunotherapy with Acarovac in house dust mite allergic patients (children and adults) in routine medical care.~During the up-dosing phase with Acarovac, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.~Data on tolerability are documented by the physicians."
2917483|NCT03127423|Experimental|Hybrid ablation group|Patients in this group will receive one-stop intervention with totally thoracoscopic surgical ablation and percutaneous catheter ablation.
2917484|NCT03127423|Active Comparator|Thoracoscopic surgical ablation group|Patients in this group will receive only totally thoracoscopic surgical ablation with Fuwai lesion set.
2917485|NCT03127410|Experimental|Traction|Intermittent lumbar traction will be performed in the prone position for 3 x 15-minute sessions at 40% of the participants body weight and will be adjusted based on the participants response.
2917486|NCT03127397|No Intervention|Standard of Care|
2917487|NCT03127397|Experimental|Praise Message|Receives up to two praise message phone calls after each completed ART appointment.
2917488|NCT03127384|Experimental|No-treatment control|
2917489|NCT03127384|Experimental|Treatment|Intradermal injection Restylane Lidocaine
2917490|NCT03127371|Experimental|Nitrous Oxide|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess using lidocaine local anesthesia administered subcutaneously. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
2917491|NCT03127371|Experimental|Oxygen|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess using lidocaine local anesthesia administered subcutaneously. The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
2917492|NCT03127358|Active Comparator|Intervention|Participants will use a-DOT technology to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12-16 weeks.
2917493|NCT03127358|Placebo Comparator|Control|Participants will receive treatment for ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12-16 weeks.
2917494|NCT03127345|Experimental|Omegaven|15 infants with esophageal atresia undergoing surgical repair will receive Omegaven 1 g/kg/day IV infused over 8-24 hours for 28 days
2917495|NCT03127345|Active Comparator|Intralipid|15 infants with esophageal atresia undergoing surgical repair will receive the standard of care lipid formulation (Intralipid) as per hospital protocol for 28 days
2917496|NCT03127319|Experimental|apatinib and docetaxel zoledronic|apatinib 500mg qd po; docetaxel 60mg/m² iv q3w; zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
2917497|NCT03127319|Active Comparator|docetaxel zoledronic|docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
2917498|NCT03127306||CAM-ICU (+) Delirious patients.|"Behavioral: BPS assessment~Polish version of BPS tool validation.~Other Names:~Pain assessment in non-verbal patients"
2917499|NCT03127306||CAM-ICU (-) Non-delirious patients.|"Behavioral: BPS assessment~Polish version of BPS tool validation.~Other Names:~Pain assessment in non-verbal patients"
2917500|NCT03127293||Hyperemesis Gravidarum group|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
2917501|NCT03127293||control group|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
2917502|NCT03127280|No Intervention|Conventional Foley Care|Following surgery, the patient's Foley catheter is removed on the morning of post-operative day one.
2917503|NCT03127280|Experimental|Fast Tract Foley care|Following surgery, the patient's Foley catheter is removed on post-operative day zero, four hours after the completion of surgery.
2917504|NCT03127267|Experimental|Masitinib|masitinib in combination with riluzole
2917505|NCT03127267|Placebo Comparator|placebo|placebo in combination with riluzole
2917506|NCT03127254|Experimental|Video Narrative with surveys|Participants will be asked to create a 10-15 minute video narrative on their experiences after being diagnosed with cancer. Participants will also be asked to complete surveys including pediatric quality of life (PedsQL), Ten Item Personality Inventory (TIPI), Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test, and The Cognitive Log (Cog-Log)
2917507|NCT03127241|Active Comparator|Armon Ayura|Upper limb assistive device with active solutions for gravity compensation. Intervention: The upper limb exoskeleton is worn by the patient on the preferred arm, and it is used during daily life activities to support arm movements, particularly getting rid of gravity arm weight.
2917508|NCT03127241|Active Comparator|Jaeco Wrex|Upper limb assistive device with passive solutions for gravity compensation. Intervention: The upper limb exoskeleton is worn by the patient on the preferred arm, and it is used during daily life activities to support arm movements, particularly getting rid of gravity arm weight.
2917509|NCT03127228|Other|Standard mechanical debridement|Debridement and surface detoxification of the implant surface and removal of the inflamed tissue with dental scalers.
2917510|NCT03127228|Experimental|Er:YAG laser-assisted debridement|Debridement and surface detoxification of the implant surface and removal of the inflamed tissue with the aid of the laser treatment.
2917511|NCT03127215|Experimental|Arm E: Olaparib / Trabectedin|Olaparib / Trabectedin
2917512|NCT03127215|Other|Arm C: Physician's choice|Physician's choice
2917513|NCT03127202|Experimental|Cardiac Resynchronization Therapy-Defibrillator|Eligible patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator
2917514|NCT03127189|Experimental|Cohort 1-RPV LA: Treatment B|Participants will receive single dose of 25 milligram (mg) rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment B containing a single intramuscular (IM) injection of 600 mg rilpivirine long-acting parenteral formulation (RPV LA) [with different particle size distribution (PSD) as compared to Treatment A, D, C and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
2917515|NCT03127189|Experimental|Cohort 1-RPV LA: Treatment D|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment D containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, C and E) on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
2917516|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment A|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment A containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment B, C, D and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
2917517|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment C|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment C containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, D and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
2917518|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment E|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment E containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, C and D] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
2917519|NCT03127176||BD with cognitive impairment|"This group will include euthymic patients with bipolar disorder type I or II (YMRS<6 and HMDRS<8) and cognitive impairment.~Intervention: Genome sequencing of fecal samples"
2917520|NCT03127176||BD without cognitive impairment|"This group will include euthymic patients with bipolar disorder type I or II (YMRS<6 and HMDRS<8) without cognitive impairment.~Intervention: Genome sequencing of fecal samples"
2917521|NCT03127176||Control group|This group will include healthy volunteers. Intervention: Genome sequencing of fecal samples
2917522|NCT03127163|Other|Mild Keratoconus|"A group of 65 patients with keratoconus who were implanted with an intrastromal corneal ring; the group was composed of 40 males (61.50%) and 25 females (38.50%), with a mean age of 27.88 ± 7.38 years (range, 17-47 years). The patients were fully informed about the study and signed a consent form previously approved by the ethics committee of our institution.~We used the Amsler-Krumeich classification and included only patients classified as grade I or II. The investigators performed the intraestromal corneal ring surgery in the selected group."
2917523|NCT03127150||CL group|Subjects who had CL after pancreatic operation will be observed.
2917524|NCT03127150||Observation group|Subjects without CL after pancreatic operation will be observed.
2917525|NCT03127137|Other|Control cohort Group|Control cohort group will receive medications not predetermined by the set protocol.
2917526|NCT03127137|Active Comparator|Experimental Group 1|Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
2917527|NCT03127137|Placebo Comparator|Experimental Group 2|Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
2917528|NCT03127124|Experimental|NANT-008 in combination with other agents|NANT-008 will be administered in combination with 5-fluorouracil, bevacizumab, leucovorin, and oxaliplatin in patients with metastatic pancreatic adenocarcinoma.
2917529|NCT03127111||Adjuvant chemotherapy|Samples from patients with stage III colorectal cancer who are going to receive fluorouracil-based adjuvant chemotherapy will be used for gene mutations analysis, gene methylation analysis, gene expression analysis, SNP analysis, and protein expression analysis.
2917530|NCT03127098|Experimental|ETBX-011 in combination with ALT-803|A combination of agents will be administered to subjects in this dose-escalation study
2917531|NCT03127072|Experimental|Arm A|RFA plus chemotherapy ± target therapy
2917533|NCT03127059|Experimental|Breathing Exercises|"Individual instruction from a nurse at baseline aimed at knowledge on pharmacological treatment and optimized inhalation techniques. The participants will be encouraged to use online video instruction.~Three physiotherapist-sessions of Breathing Exercises (BrEX) with duration of 60 minutes (the initial) and 30 minutes (other sessions) at week 1, 4, and 9. The participant is expected to do 10 minutes of home exercise twice daily. The entire intervention combines elements of the Papworth method, and the Buteyko technique."
2917534|NCT03127059|Other|Usual care|"Individual instruction from a nurse at baseline aimed at knowledge on pharmacological treatment and optimized inhalation techniques. The participants will be encouraged to use online video instruction.~Besides the individual instruction described above, patients will receive only short information given initially at recruitment. They are allowed to receive instruction in positive expiratory pressure-treatment and physiotherapy targeting other problems than dysfunctional breathing (DB)."
2917535|NCT03127046|Experimental|Group 1|Aceclofenac → Esomeprazole → Concomitant of Aceclofenac and esomeprazole
2917536|NCT03127046|Experimental|Group 2|Concomitant of Aceclofenac and esomeprazole→Aceclofenac→ Esomeprazole
2917537|NCT03127046|Experimental|Group 3|Esomeprazole →Concomitant of Aceclofenac and esomeprazole→ Aceclofenac
2917538|NCT03127046|Experimental|Group 4|Concomitant of Aceclofenac and esomeprazole→Esomeprazole→Aceclofenac
2917539|NCT03127046|Experimental|Group 5|Esomeprazole→Aceclofenac→ Concomitant of Aceclofenac and esomeprazole
2917540|NCT03127046|Experimental|Group 6|Aceclofenac→Concomitant of Aceclofenac and esomeprazole→Esomeprazole
2917541|NCT03127020|Experimental|PQR309|PQR309 being taken continuously on daily basis (60,80mg) or intermittent (120mg, 140mg, 160mg) dosing
2917542|NCT03127007|Experimental|Arm A|"Protracted IV 5-FU 225 mg/m2 is given from day 1 to 5 in parallel with radiotherapy 1.8 to 2 Gy from day 1 to 5 during 5 consecutive weeks.~Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV. Rectal surgery is planned during week 15"
2917543|NCT03127007|Active Comparator|Arm B|"Protracted IV 5-FU 225 mg/m2 is given from day 1 to 5 in parallel with radiotherapy 1.8 to 2 Gy from day 1 to 5 during 5 consecutive weeks.~Rectal surgery is planned during week 15"
2917544|NCT03126994|Experimental|PhysioWave Cardiovascular Analyzer|The Experimental Device is the PhysioWave Cardiovascular Analyzer, which will be used to measure Pulse Wave Velocity, Pulse Rate, Body Weight, and BMI. This will be compared to FDA-cleared devices to determine equivalence: AtCor XCEL PWA & PWV to measure Pulse Wave Velocity and Pulse rate, and Detecto SOLO to measure Body Weight and BMI.
2917545|NCT03126981|Experimental|Whole, natural almonds|1.5 oz of whole, natural almonds
2917546|NCT03126981|Placebo Comparator|Low-fat, high refined starches/sugars|Low-fat foods,high in refined starches and added sugars
2917547|NCT03126968|Experimental|Prophylactic topical epinephrine|Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical epinephrine in a blinded manner prior to performance of transbronchial lung biopsy.
2917548|NCT03126968|Placebo Comparator|Placebo|Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical placebo in the form of normal saline in a blinded manner prior to performance of transbronchial lung biopsy.
2917549|NCT03126955||HELPS Syndrome unable to lateralize contractions|Each patient will have the following 3 diagnostic pre-operative tests: i) MRI (CISS sequence), ii) video laryngoscopy, and iii) sequential Botox injections in their throat (left side and then 3 months later on the right side).
2917550|NCT03126942|Experimental|Novaloc, then Locator|Participants will receive the Novaloc attachment on a single implant inserted in the mandibular midline. This attachment will be used for 3 months and then changed by the Locator attachment. The second attachment will be used for another 3-month period. Participants will keep preferred attachment for further 12 months
2917551|NCT03126942|Active Comparator|Locator, then Novaloc|Participants will receive the Locator attachment on a single implant inserted in the mandibular midline. This attachment will be used for 3 months and then changed by the Novaloc attachment. The second attachment will be used for another 3-month period. Participants will keep preferred attachment for further 12 months
2917552|NCT03126929||Vegetative state|patients lack awareness of self and environment even in the presence for eye-opening and sleep-wake cycles using CRS-R and GCS
2917553|NCT03126929||Minimally conscious state|Patients display inconsistent, but reproducible and discernible signs of awareness using CRS-R and GCS
2917554|NCT03126929||Emergence from MCS|Patients regain accurate communication and/or functional use of objects using CRS-R and GCS
2917555|NCT03126916|Experimental|Arm A (chemotherapy, HSCT, EBRT)|See Arm A in detailed description.
2917556|NCT03126916|Experimental|Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)|See Arm B in detailed description.
2917557|NCT03126916|Experimental|Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)|See Arm C in detailed description.
2917558|NCT03126916|Experimental|Arm D (chemotherapy, HSCT, EBRT)|See Arm D in detailed description.
2917559|NCT03126916|Experimental|Arm E (crizotinib, chemotherapy, HSCT, EBRT)|See Arm E in detailed description.
2917560|NCT03126903|Experimental|Single-Arm|KeraKlear Non-Penetrating Keratoprosthesis
2917561|NCT03126890||Linezolid TDM (prospective)|Adult patients received linezolid at NTUH. This prospective cohort study will draw blood from every patient to measure the linezolid blood concentration. After blood concentration analysis by high pressure liquid chromatography (HPLC), the investigator will report the concentration to clinicians and dose adjustment is judged by clinician (not the investigators).
2917562|NCT03126890||Linezolid observation (retrospective)|Adult patients received linezolid at NTUH.
2917563|NCT03126877|Experimental|Optimized Ocular Surface|For patients enrolled into the treatment group for preoperative optimization of the ocular surface, utilize the LipiFlow® vectored thermal pulsating eyepieces (Activators) to gently apply heat and massage, thus evacuating the Meibomian glands. Omega-3 vitamin supplements should also be provided, initiated and dosed according to standard clinical practice, to maximize ocular surface health.
2917564|NCT03126877|Active Comparator|Non-Optimized Ocular Surface|Patients enrolled into the non-treatment group will not be optimized preoperatively for ocular surface health. No LipiFlow® Activators and no Omega-3 vitamin supplements will be provided, initiated, nor dosed.
2917597|NCT03126669|Placebo Comparator|Placebo|normal air, in the hyperbaric chamber
2917565|NCT03126864|Experimental|CD33-CAR-T cells - Adult Group|"After enrollment, steady state leukapheresis performed to collect apheresis material.~Fludarabine administered by vein on Days -5 to -3.~Cyclophosphamide administered by vein on Day -3.~CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found."
2917566|NCT03126864|Experimental|CD33-CAR-T cells - Pediatric Group|"After enrollment, steady state leukapheresis performed to collect apheresis material.~Fludarabine administered by vein on Days -5 to -3.~Cyclophosphamide administered by vein on Day -3.~CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found."
2917567|NCT03126851|Experimental|No age range / no explicit warning|Label: No age range and no explicit warning on front display panel of medication box.
2917568|NCT03126851|Experimental|age range / no explicit warning|Label: Age range present but no explicit warning on front display panel of medication box.
2917569|NCT03126851|Experimental|age range / explicit warning in words|Label: Age range present with explicit warning in words on front display panel of medication box.
2917570|NCT03126851|Experimental|age range / explicit warning+pictogram|Label: Age range present with explicit warning in words plus pictographic warning on front display panel of medication box.
2917571|NCT03126838||diaphragmatic dysfunction|diaphragmatic displacement < 10 ml, and / OR diaphragmatic thickening fraction < 36 %.
2917572|NCT03126838||non diaphragmatic dysfunction|diaphragmatic displacement > 10 ml, and / OR diaphragmatic thickening fraction > 36 %.
2917573|NCT03126825|Other|Conventional CI|The conventional CI group will receive the noise reduction on and off signal processing test programs. This is a within subject repeated measures design, so all subjects will receive the same testing but in a counterbalanced order.
2917574|NCT03126825|Other|Hybrid CI|The Hybrid CI group will receive the noise reduction on and off signal processing test programs. This is a within subject repeated measures design, so all subjects will receive the same testing but in a counterbalanced order.
2917575|NCT03126812|Experimental|Carboplatin, paclitaxel, pembrolizumab|Carboplatin AUC= 6 paclitaxel 80 mg/m2 Pembrolizumab 200 mg starting cycle 2
2917576|NCT03126799|Active Comparator|A: Erlotinib only|"Standard therapy arm:~Erlotinib 150mg. po, qd, daily, q 3weeks"
2917577|NCT03126799|Experimental|B: Erlotinib plus Bevacizumab|Study treatment arm; Erlotinib 150mg, po. qd, daily, q 3weeks plus Bevacizumab 15mg/kg, iv, on D1, q 3weeks.
2917578|NCT03126786|Active Comparator|Active|Treatment will consist of IVT injection of Aflibercept followed by an SC injection of CLS-TA
2917579|NCT03126786|Sham Comparator|Control|Treatment will consist of IVT aflibercept injection followed by a sham SC procedure
2917580|NCT03126773||BAY86-4891|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Angeliq Micro is indicated are fit for participation in this non-interventional study.
2917581|NCT03126760|Experimental|Acthar|Repository Corticotropin Injection 1 mL (80U) subcutaneously administered QD for 14 consecutive days
2917582|NCT03126760|Placebo Comparator|Placebo|Placebo 1 mL subcutaneously administered QD for 14 consecutive days.
2917583|NCT03126747||BAY86-5300_YAZ-Flex|Patients with endometriosis-associated pelvic pain or dysmenorrhea
2917584|NCT03126734|Experimental|Experimental Group|The parents of this group will receive 5 sessions of infant massage course (1 per week) between two measurements of the variables
2917585|NCT03126734|No Intervention|Control Group|The parents of this group will not receive infant massage course (1 per week) between two measurements of the variables. They will receive it after two measurements.
2917586|NCT03126721|Experimental|oral midazolam alone|single dose of oral midazolam administered alone in period 1
2917587|NCT03126721|Experimental|oral midazolam administered with multiple doses of PF-06751979|single dose of midazolam on day 10 with multiple doses of PF-06751979 once a day on Days 1-11 in period 2
2917588|NCT03126708|Experimental|chemotherapy (cisplatin plus paclitaxel) and cetuximab|
2917589|NCT03126708|Active Comparator|chemotherapy (cisplatin plus paclitaxel)|
2917590|NCT03126695|Experimental|Treatment Sequence 1 (ADBC)|"Subjects were randomized to treatment sequence ADBC:~On Day 1, following an overnight fast of at least 10 hours, each subject will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
2917591|NCT03126695|Experimental|Treatment Sequence 2 (BACD)|"Subjects were randomized to treatment sequence BACD:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
2917592|NCT03126695|Experimental|Treatment Sequence 3 (CBDA)|"Subjects were randomized to treatment sequence CBDA:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
2917593|NCT03126695|Active Comparator|Treatment Sequence 4 (DCAB)|"Subjects were randomized to treatment sequence DCAB:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
2917594|NCT03126682|Active Comparator|Wellbutrin during ECT 1|Drug - Wellbutrin SR 300Mg Extended-Release Tablet during ECT session 1
2917595|NCT03126682|Active Comparator|Wellbutrin during ECT 2|Drug - Wellbutrin SR 300Mg Extended-Release Tablet during ECT session 2.
2917596|NCT03126669|Active Comparator|Treratment|100% oxygen at 2 ATA at the hyperbaric chamber
2917628|NCT03126422|Experimental|Dexmedetomidine 0.03 μg/kg/min|
2917598|NCT03126656|Experimental|Hypogonadic with chronic heart failure|patients suffering from mild to moderate heart failure (LVEF ≥ 40%, NYHA I-II), and hypogonadism (plasma testosterone levels <11.4 nmol / L);
2917599|NCT03126656|Experimental|Hypogonadic|patients just with hypogonadism (testosterone <11.4 nmol / L) in the absence of documented cardiovascular disease
2917600|NCT03126656|No Intervention|chronic heart failure|patients suffering from mild to moderate heart failure (LVEF ≥ 40%, NYHA I-II) with normal testosterone levels(plasma testosterone levels > 11.4 nmol / L), in optimized standard therapy for heart failure
2917601|NCT03126630|Active Comparator|Group I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II.
2917602|NCT03126630|Experimental|Group II (anetumab ravtansine, pembrolizumab)|Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2917603|NCT03126604||vaginal delivery|Women underwent non complicated non instumental normal vaginal delivery
2917604|NCT03126604||Cesarean section|Women underwent elective Cesarean section
2917605|NCT03126591|Experimental|Olaratumab Dose Level 1 + Pembrolizumab|Olaratumab given intravenously (IV) and pembrolizumab given IV.
2917606|NCT03126591|Experimental|Olaratumab Dose Level 2 + Pembrolizumab|Olaratumab given IV and pembrolizumab given IV.
2917607|NCT03126591|Experimental|Olaratumab + Pembrolizumab Expansion|Olaratumab given IV and pembrolizumab given IV.
2917608|NCT03126578|Experimental|All subjects|"Part I - Maximum Tolerated Dose: All subjects will receive oral doses of LEO 32731 up-titrated from 10 mg bid on Days 1-3, 20 mg bid on Days 4-6 and 40 mg bid on Days 7-12.~Part II - Drug-Drug Interaction: All subjects will receive oral doses of LEO 32731 in dose schedule decided upon data from Part I. Subjects will receive a single oral dose of 2.5 mg midazolam on Day -1 prior to the first dose of LEO 32731 and on Days 4, 7 and 17 of multiple dosing with LEO 32731."
2917609|NCT03126565|Experimental|Group A|This group will include a cohort of 185 participants who will be monitored by the CareSage risk assessment platform. Tailored interventions, using a Stepped-Care Approach, will be targeted to patients flagged as high risk for emergency transport during the 6-month intervention period.
2917610|NCT03126565|No Intervention|Group B|This group will include a cohort of 185 participants where study staff will not see if patients are flagged by the CareSage risk assessment platform as being at high or low risk for emergency transport during the 6-month intervention period. Patients will continue to receive care as usual.
2917611|NCT03126552|Experimental|Intervention|Four healthy hookworm-naive volunteers will be infected with 50 Necator americanus L3 larvae.
2917612|NCT03126539|Experimental|Group A|Sulforaphane will be applied topically to both sites for up to 7 consecutive nights. Biopsies will be obtained prior to, and immediately after this intervention, on standard photoprotected and photoexposed sites.
2917613|NCT03126539|Experimental|Group B|Two photoprotected sites will be identified. Sulforaphane will be applied topically to a single selected site for up to 7 consecutive nights. Both site will be exposed to UV. Biopsies of both sites will be obtained prior to, and 24 hours after UV exposure.
2917614|NCT03126526|Experimental|Food specific inhibitory control training|The stimuli in this task will involve pictures of food.
2917615|NCT03126526|Active Comparator|General inhibitory control training|The stimuli in this task will not involve pictures of food, but pictures of stationary and household items.
2917616|NCT03126526|No Intervention|Baseline brain activation assessment (healthy controls)|This arm is included to assess brain activation using EEG among healthy controls at baseline in order to compare responses to participants with eating disorders.
2917617|NCT03126513|Experimental|G-POEM in refractory gastroparesis|Participants with refractory gastroparesis will be confirmed by endoscopy, clinical and scintigraphy studies.
2917618|NCT03126500||Malnourished|malnourished, geriatrics patients at hospital discharge
2917619|NCT03126487|Experimental|HIGH INTENSITY FOCUSED ULTRASOUND|HIGH INTENSITY FOCUSED ULTRASOUND
2917620|NCT03126474||Delphi panel|Group of expert surgeons who have experience dealing with distal radius fractures No intervention will be performed on a patient. Participants will discuss and aim to obtain agreement about best treatment options for a variety of cases
2917621|NCT03126461|Experimental|SAbR plus ipilimumab plus nivolumab|SAbR/GRID plus ipilimumab 3mg/kg IV q3wk x 4 plus nivolumab 1 mg/kg IV q3wk x 4, followed by nivolumab 240 mg IV q 2wk until progression or intolerable toxicity
2917622|NCT03126448|Other|Group 1: Closed Index Fractures|Group 1 is clean, closed fractures undergoing index open reduction internal fixation (ORIF), intramedullary nailing (IMN) where the fracture site is accessible, or staged treatment of a pilon or plateau that was initially treated by joint spanning external fixation. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
2917623|NCT03126448|Other|Group 2: Hardware Removal from Healed Fractures|Group 2 will include patients having a plate removed from a healed fracture without clinical evidence of infection and excluding history of open fracture. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
2917624|NCT03126448|Other|Group 3: Index Treatment of Fracture Nonunions|Group 3 will be patients that are undergoing an index procedure for fracture nonunion at a site where prior surgery has been undertaken for the fracture. Exclusions include bone grafting of 'critical' defects, active clinical infection, or < 3 months from index fracture fixation. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
2917625|NCT03126435|Experimental|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m2 twice weekly plus gemcitabine 1000mg/m² once weekly for 1 cycle (8 weeks) consisting of 3 weeks of treatment and 1 week rest followed by 3 weeks of treatment and 1 week rest until any one of the following occurs: progressive disease or unacceptable toxicity or withdrawal of consent.
2917626|NCT03126435|Other|Gemcitabine|Gemcitabine 1000mg/m² once weekly, for 1 cycle (8 weeks) consisting of 3 weeks of treatment and 1 week rest followed by 3 weeks of treatment and 1 week rest until any one of the following occurs: progressive disease or unacceptable toxicity or withdrawal of consent.
2917627|NCT03126422|Experimental|Dexmedetomidine 0 μg/kg/min|
2917631|NCT03126409|Experimental|No-Touch vein harvesting technique|During saphenous vein harvesting, surrounding tissue of the vein is preserved, and manual distension of the vein graft is avoided
2917632|NCT03126409|Active Comparator|Conventional vein harvesting|During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
2917633|NCT03126396|Experimental|Urgo 310 3166 dressing|Urgo 310 3166 dressing
2917634|NCT03126370|Experimental|TAF with a boosted PI and LDV/SOF|"Subjects who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Subjects will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide (TAF) 25 mg/emtricitabine (FTC) 200 mg (Descovy) with a boosted protease inhibitor for the next 12 weeks.~After taking TAF/FTC for 12 weeks, subjects will then start taking ledipasvir 90mg/sofosbuvir 400mg (Harvoni) in combination with TAF/FTC and a boosted protease inhibitor for 4 weeks.~Subjects will then return to taking TAF/FTC with a boosted protease inhibitor for the final 12 weeks of the study."
2917635|NCT03126357|Experimental|Product usage order ABECD|Subjects will use each of the 5 products (ABECD) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2917636|NCT03126357|Experimental|Product usage order BCADE|Subjects will use each of the 5 products (BCADE) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2917637|NCT03126357|Experimental|Product usage order CDBEA|Subjects will use each of the 5 products (CDBEA) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2917638|NCT03126357|Experimental|Product usage order DECAB|Subjects will use each of the 5 products (DECAB) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2917639|NCT03126357|Experimental|Product usage order EADBC|Subjects will use each of the 5 products (EADBC) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2917640|NCT03126357|Experimental|Product usage order DCEBA|Subjects will use each of the 5 products (DCEBA) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2917641|NCT03126357|Experimental|Product usage order EDACB|Subjects will use each of the 5 products (EDACB) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2917642|NCT03126357|Experimental|Product usage order AEBDC|Subjects will use each of the 5 products (AEBDC) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2917643|NCT03126357|Experimental|Product usage order BACED|Subjects will use each of the 5 products (BACED) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2917644|NCT03126357|Experimental|Product usage order CBDAE|Subjects will use each of the 5 products (CBDAE) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2917645|NCT03126344|Experimental|King Vision video laryngoscope|
2917646|NCT03126344|Experimental|McGrath MAC video laryngoscope|
2917647|NCT03126344|Active Comparator|Macintosh|
2917648|NCT03126331|Experimental|Intermittent Nivolumab|Nivolumab 240mg every 2 weeks as per standard dosing. Patients who have initial 10% or greater tumor burden reduction will discontinue nivolumab until they experience a pre-specified disease progression at which time nivolumab will be restarted
2917649|NCT03126318|Active Comparator|COR-001|COR-001 5, 15, 50, or 100 mg dose (depending on dose cohort assigned to patient) given by subcutaneous injection one time only
2917650|NCT03126318|Placebo Comparator|Placebo|Placebo at pH 6.0will be given in a volume to match the volume of COR-001 being given for the dose cohort by subcutaneous injection one time only
2917651|NCT03126305||OC-Go|Approximately 10-20 9-17 year-olds receiving exposure based cognitive behavior therapy for OCD through the UCLA Division of Child and Adolescent Psychiatry OCD treatment programs
2917652|NCT03126292|Experimental|Sit Down and Play|Families randomized to intervention group will receive Sit Down and Play while they wait in the waiting room to be seen by their primary care provider at current and subsequent well-child visits.
2917653|NCT03126292|Active Comparator|Handout|Families in the control group will receive handouts regarding child safety
2917654|NCT03126279||Preoperative Chronic Knee OA Patients|Patients will be recruited from orthopaedic preoperative clinics from those awaiting total knee replacement surgery.
2917655|NCT03126279||Healthy Volunteers|Healthy volunteers will be recruited that are aged match to our OA patient cohort so meaningful comparisons regarding brain activity and pain sensitisation characteristics can be assessed.
2917656|NCT03126266|Experimental|Patients receiving re-irradiation|Patients will receive 30.6 Gy or 36 Gy of a second course of radiation therapy for progressive or recurrent DIPG
2917657|NCT03126240||sleeve Gastrectomy|This is a five-trocar technique. The abdominal cavity is accessed through a 1cm supraumbilical incision using an optical trocar. The operating ports are inserted under direct vision. The gastroesophageal (GE) junction is exposed. A point on the greater curvature approximately 3-6cm to the pylorus is identified as the distal extent of the resection. Ultrasonic shears are used to divide the vessels long the greater curve up to the angle of His. Linear cutting staplers are used to vertically transect the stomach, creating a narrow gastric tube with. A 19Fr drain is placed in the subhepatic space near the staple line. The resected portion of the stomach is extracted through one of the working ports.
2917658|NCT03126227|Active Comparator|Peanut allergen formulation|Subjects will be randomized to active arm of ARC007 and will be administered IP (AR101) in escalating doses for approximately 6 months.
2917659|NCT03126227|Placebo Comparator|Placebo powder|Subjects will be randomized to placebo arm of ARC007 and will be administered escalating doses of IP (placebo) for approximately 6 months.
2917660|NCT03126214|Experimental|Active Pharmacist Arm|OAC therapy will be initiated/adjusted by the community pharmacist in accordance to the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation.
2917661|NCT03126214|Active Comparator|Enhanced Usual Care Arm|Pharmacist will be refer participants to their physician in regards to OAC therapy for atrial fibrillation. The pharmacist will provide a current medication list to the physician as well as notification of a new diagnosis of atrial fibrillation
2917662|NCT03126201||Study Group|Patients with biopsy-proven primary focal segmental glomerulosclerosis.
2917663|NCT03126188||Sertraline group|Mild and Moderate depressive episode without somatic syndrome who are treated with Sertraline. Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
2917664|NCT03126188||Dosulepin group|Mild and Moderate depressive episode with somatic syndrome who were treated with Dosulepin. Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks
2917665|NCT03126188||Venlafaxine group|Severe depressive episode without psychotic symptoms who were treated with Venlafaxine. Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
2917666|NCT03126175|Active Comparator|Above elbow immobilization|Above elbow immobililization with short radial splint that will be performed with 20cm wide gypsum cut to fit the thumb. The splint will be applied to the radial aspect of the wrist covering the volar and dorsal portion of the radius to the elbow. Additional splint with a 15cm width splint on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
2917667|NCT03126175|Experimental|Below elbow immobilization|Below elbow immobilization with exclusively short radial splint that will be performed with 20cm wide gypsum cut to fit the thumb. The splint will be applied to the radial aspect of the wrist covering the volar and dorsal portion of the radius to the elbow.
2917668|NCT03126162|Experimental|Bladder Backfilled group|Subjects randomized to the bladder backfilled group (Group A) will have 200 mL of normal saline instilled into their bladders prior to removal of the foley catheter. The foley catheter will subsequently be removed
2917669|NCT03126162|Placebo Comparator|Control group|Subjects randomized to the control group (Group B) will just have their foley catheters removed at the end of the surgery. This is routinely done post-operatively after routine gynecologic surgery.
2917670|NCT03126149|Experimental|Cohort 1_Period 1_Active|Single ascending dose of PF-06667272
2917671|NCT03126149|Placebo Comparator|Cohort 1_Period 1_Placebo|Single dose of placebo
2917672|NCT03126149|Experimental|Cohort 1_Period 2_Active|Single ascending dose of PF-06667272
2917673|NCT03126149|Placebo Comparator|Cohort 1_Period 2_Placebo|Single dose of placebo
2917674|NCT03126149|Experimental|Cohort 1_Period 3_Active|Single ascending dose of PF-06667272
2917675|NCT03126149|Placebo Comparator|Cohort 1_Period 3_Placebo|Single dose of placebo
2917676|NCT03126149|Experimental|Cohrot 1_Period 4_Active|Single ascending dose of PF-06667272
2917677|NCT03126149|Placebo Comparator|Cohort 1_Period 4_Placebo|Single dose of placebo
2917678|NCT03126149|Experimental|Cohort 2_Period 1_Active|Single ascending dose of PF-06667272
2917679|NCT03126149|Placebo Comparator|Cohort 2_Period 1_Placebo|Single dose of placebo
2917680|NCT03126149|Experimental|Cohort 2_Period 2_Active|Single ascending dose of PF-06667272
2917681|NCT03126149|Placebo Comparator|Cohort 2_Period 2_Placebo|Single dose of placebo
2917682|NCT03126149|Experimental|Cohort 2_Period 3_Active|Single ascending dose of PF-06667272
2917683|NCT03126149|Placebo Comparator|Cohort 2_Period 3_Placebo|Single dose of placebo
2917684|NCT03126149|Experimental|Cohort 2_Period 4_Active|Single ascending dose of PF-06667272
2917685|NCT03126149|Placebo Comparator|Cohort 2_Period 4_Placebo|Single dose of placebo
2917686|NCT03126136|Experimental|Pregnant women|
2917687|NCT03126123|Other|acetic acid test|Patients will receive surgical treatment for anal condylomatosis and acetic acid on the mucosa of the anal canal before the surgical procedure
2917688|NCT03126110|Experimental|INCAGN01876 + Nivolumab|INCAGN01876 combined with nivolumab.
2917689|NCT03126110|Experimental|INCAGN01876 + Ipilimumab|INCAGN01876 combined with ipilimumab.
2917690|NCT03126110|Experimental|INCAGN01876 + Nivolumab + Ipilimumab|INCAGN01876 combined with nivolumab and ipilimumab.
2917691|NCT03126097|Experimental|JNJ-64155806+COCP+JNJ-64155806 with COCP|Participants will receive JNJ-64155806 150 milligram (mg) twice daily (BID) under fed conditions on Days 1 to 7 [JNJ-64155806 Alone Phase] followed by a 10-day washout phase; followed by Ethinylestradiol/drospirenone 0.02 mg/3 mg given as a combined oral contraceptive pill (COCP) once daily (QD) on Days 18 to 41 and COCP placebo QD on Days 42 to 45 [COCP Lead-in Phase]; further followed by COCP QD on Days 46 to 69 (on Days 59 to 66 under fed condition), JNJ‑64155806 150 mg BID (under fed conditions) on Days 60 to 66, and COCP placebo QD on Days 70 to 73 [JNJ-64155806 + COCP Co-administration Phase].
2917692|NCT03126084|Active Comparator|TAP|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive transversus abdominis plane block with 20 ml of 0.25% bupivacaine preoperatively, in addition to intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
2917693|NCT03126084|Active Comparator|QLB2|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive quadratus lumborum type 2 block with 20 ml of %0.25 bupivacaine preoperatively, in addition to intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
2917694|NCT03126084|Active Comparator|CONT|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
2917695|NCT03126071|Experimental|Raltitrexed and Irinotecan（RALIRI） plus Bevacizumab(AVASTIN)|Irinotecan:250mg/m2 iv,90min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)
2917696|NCT03126071|Experimental|Raltitrexed and Oxaliplatin（RALOX） plus Bevacizumab(AVASTIN)|Oxaliplatin:130mg/m2 iv,120min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)
2917733|NCT03125785||contact lens and no eye drops|Contact lenses used for the same period of time collected from a control group that has had no surgery and no eye drops in combination with their contact lenses.
2917836|NCT03124823|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects received the Rainbow DCI Sensor
2917837|NCT03124797|Experimental|RD DCI Sensor|All subjects are enrolled into the test group and all subjects received the RD DCI Sensor
2917697|NCT03126058|Experimental|enhanced recovery after surgery|"enhanced recovery after surgery includes:~Multimodal analgesia~Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet~Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally. B: Remove catheter early.~Early activity~Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation for right hemicolectomy, Miles rectectomy and Hartman rectectomy, simple cleansing enema for left hemicolectomy,sigmoidectomy and Dixon rectectomy; C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken"
2917698|NCT03126045|Active Comparator|Standard needle|Patients perform a spinal punction according to the usual practice, with a standard needle.
2917699|NCT03126045|Experimental|Atraumatic needle|Patients perform a spinal punction according to the usual practice, with an atraumatic needle.
2917700|NCT03126032||Patients with suspected sepsis|"Patients presenting in the Emergency Room (ER) with the clinical suspicion of infection/sepsis.~Evaluation of the glycocalyx damage with the use of GlycoCheck™-System, as well as blood sample at presentation, day 1 and day 7 of their hospital stay."
2917701|NCT03126032||Non-Sepsis Patients|"Patients presenting in the Emergency Room with other conditions apart from infection/sepsis.~Evaluation of their sublingual glycocalyx and blood sample for further microbiologic and laboratory analysis at presentation."
2917702|NCT03126032||Healthy Individuals|Evaluation of their sublingual glycocalyx and blood sample for further microbiologic and laboratory analysis at presentation.
2917703|NCT03126019|Experimental|Group A|INCB050465 once daily (QD) for 8 weeks followed by INCB050465 once weekly
2917704|NCT03126019|Experimental|Group B|INCB050465 QD
2917705|NCT03126006|Experimental|NSPT plus oral hygiene|It includes pregnant women (with periodontal disease) who will be subjected to one episode of non-surgical periodontal therapy under local anesthesia during pregnancy. they will receive oral hygiene instruction also.
2917706|NCT03126006|Other|Oral hygiene alone|It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
2917707|NCT03125993|Experimental|>10000 steps brisk walking|This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: > 10000 steps, > five days, per week. For individual follow-up, body components and metabolic risk factors will be tested before and after the study.
2917708|NCT03125980|Experimental|Perioperative chemotherapy with CapOX regimen|
2917709|NCT03125980|Active Comparator|Postoperative chemotherapy with CapOX regimen|
2917710|NCT03125967|Active Comparator|Blue Light|Blue light exposure (Philips GoLite Blu HF3429/60) administered daily for 25 minutes between 8:00AM and 9:00AM
2917711|NCT03125967|Placebo Comparator|Red Light|Red light exposure (Philips LivingColor Aura 70998/60/48) administered daily for 25 minutes between 8:00AM and 9:00AM
2917712|NCT03125941|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg pre-operative
2917713|NCT03125941|Active Comparator|Dexamethasone 24 mg|Dexamethasone 24 mg pre-operative
2917714|NCT03125928|Experimental|Investigational Arm|
2917715|NCT03125915|Active Comparator|CHTC as usual|Participants receive couples HIV testing and counseling following the CDC approved protocol.
2917716|NCT03125915|Experimental|CHTC + communication skills videos|The couple views communication skills training videos together prior to participating in a CHTC session following the CDC approved protocol.
2917717|NCT03125915|Experimental|CHTC + substance use module|The couple completes a CHTC session which includes the substance use calendar and structured debriefing activity. This is administered following Step 5 in the standard CDC protocol, just prior to delivery of HIV test results.
2917718|NCT03125915|Experimental|CHTC + video + substance use module|The couple views communication skills training videos together prior to participating in a CHTC session which includes administration of the substance use calendar and structured debriefing activity.
2917719|NCT03125902|Experimental|Atezolizumab and Paclitaxel|Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
2917720|NCT03125902|Placebo Comparator|Placebo and Paclitaxel|Participants will receive placebo matching to atezolizumab via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg/m^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
2917721|NCT03125889|Experimental|Treatment Arm|Subjects will receive treatment with the AquaBeam System to remove prostatic tissue.
2917722|NCT03125876|Experimental|CT053PTSA|60mg-100mg
2917723|NCT03125863|Experimental|Treatment Arm|Subjects will receive treatment with the AquaBeam System to remove enlarged prostatic tissue. Following the aquablation intervention, a urinary catheter will be inserted to apply pressure on treated tissue for hemostasis.
2917724|NCT03125850|Experimental|day-ward group|
2917725|NCT03125850|Active Comparator|inpatient group|
2917726|NCT03125837||general anesthesia|Digital photographs of the face of each patient undergoing general anesthesia with endotracheal intubation
2917727|NCT03125824|Other|Tattoos previously treated in Soliton 2016-001 trial|Identical tattoos treated by Laser + AWD in Soliton's previous trial
2917728|NCT03125811|Active Comparator|Inhaled Isopropyl Alcohol (IPA)|Inhaled Isopropyl Alcohol (alcohol prep pad)
2917729|NCT03125811|Other|Oral Dissolvable Tablet Zofran (OZ)|4 mg Oral Dissolvable Tablet Zofran (ondansetron)
2917730|NCT03125798|Experimental|LigaSure|In this arm, LigaSure™ will be used for mediastinal lymph nodes dissection, according to standard surgical technique.
2917731|NCT03125798|Active Comparator|Monopolar electrocautery|In this arm, conventional monopolar electrocautery will be used for mediastinal lymph nodes dissection, according to standard surgical technique.
2917732|NCT03125785||contact lens and eye drops|Contact lenses collected from patients that have used eye drops containing dexamethasone and benzalkonium chloride for a set period of time and set dosage after surgery
2917831|NCT03124914|Active Comparator|Patients considered physically active|Measures of strength and determination of neuromuscular fatigue
2917734|NCT03125772|Experimental|TAXUS Element™ Paclitaxel-Eluting System|The TAXUS® Element™ stent system is a multifunctional device providing a mechanical structure for vascular lumen support and a pharmacological agent targeted toward reducing or preventing the incidence of restenosis. The TAXUS Element™ stent is a balloon expandable, stainless steel platinum alloy stent, coated with paclitaxel in a slow-release system, pre-mounted on a high-pressure Monorail delivery catheter and is intended for use in the treatment of coronary artery disease. The pharmacological agent, paclitaxel, is incorporated into a triblock polymer matrix and applied to the surface of the stent. The polymer matrix provides controlled release of available paclitaxel. The TAXUS Element™ stent design is built upon the TAXUS Express and TAXUS Liberte design experience, but incorporates several improved stent design characteristics. The TAXUS Element™ stent also has a smaller tip profile, designed to enhance the ability to cross tighter and/or more complex lesions.
2917735|NCT03125772|Active Comparator|XIENCE PRIME™ ™ Everolimus-Eluting Stent System|The everolimus-eluting stent (EES, manufactured and distributed by Abbott Vascular, Santa Clara, CA, as XIENCE PRIME™ ) is a balloon expandable stent manufactured from a flexible cobalt chromium alloy with a multicellular design and 0.0032-in strut thickness which is coated with a thin (7.8 μm) nonadhesive, durable, biocompatible acrylic polymer and fluorinated copolymer releasing everolimus. Everolimus [40-O-(2-hydroxyethyl)- rapamycin], a semisynthetic macrolide immunosuppressant, inhibits growth factor-stimulated cell proliferation by causing cell-cycle arrest in the late G1 stage, thereby suppressing neointimal formation. Comparative analysis in an in vivo rabbit aortoiliac model has shown more rapid endothelialization with the EES compared to SES, PES, and ZES.
2917736|NCT03125759||Control|patients without any history of stroke
2917737|NCT03125759||Ischemic Stroke|patients with an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction within 72 hours.
2917738|NCT03125746|Experimental|LXI-15029|
2917739|NCT03125746|Experimental|LXI-15029+Exemestane|
2917740|NCT03125733|Experimental|STESD|Submucosal tunneling endoscopic septum division
2917741|NCT03125720|Experimental|GUIDED group|Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response in the guided group.
2917742|NCT03125720|No Intervention|Control group|No Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response.
2917743|NCT03125694|Active Comparator|Sitagliptin|
2917744|NCT03125694|Active Comparator|Pioglitazone|
2917745|NCT03125681|Experimental|Remote ischemic conditioning|Applying pneumatic cuff on upper extremity (5 minutes cycles of limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times) before and after coronary anastomoses.
2917746|NCT03125681|Placebo Comparator|Control|All the procedures were the same in the control group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
2917747|NCT03125668|Experimental|Intervention Group|At the hospitalization, patients receive the educational program (Power Point®Slides, booklets and orientation) about the use of warfarin. After hospital discharge they receive a telephone follow-up (five calls) and two Face to face counseling.
2917748|NCT03125668|Active Comparator|Control Group|At the hospitalization, patients receive the educational program (Power Point®Slides, booklets and orientation) about the use of warfarin. After hospital discharge they receive two face to face counseling.
2917749|NCT03125642|Experimental|BEAM: NHL & HL|BCNU, etoposide, Ara-C and melphalan (BEAM) for all NHL and those HL patients who are unable to receive CBV
2917750|NCT03125642|Experimental|CBV: HL|Cyclophosphamide, BCNU and VP-16 (CBV) for HL patients
2917751|NCT03125642|Experimental|CY/TBI|Cyclophosphamide/Total Body Irradiation (CY/TBI) for patients with recent history of CNS lymphoma or those with allergies/contra-indications to agents used in BEAM
2917752|NCT03125629|Experimental|Diagnostic (PET/CT, PET/MRI)|Patients undergo PET/CT imaging followed by PET/MRI the same day.
2917753|NCT03125616|Active Comparator|Standard UK 4CMenB vaccine|4CMenB (Bexsero®) vaccination at 2 and 4 months and a booster at 12 months .
2917754|NCT03125616|Experimental|Additional 4CMenB Vaccine|4CMenB (Bexsero®) vaccination at 2, 3 and 4 months and a booster at 12 months.
2917755|NCT03125603||NSCLC's patients|"Patients with NSCLC treated in Cliniques Universitaires Saint-Luc with immunotherapy.~Consultation of the patient's medical files at the hospital."
2917756|NCT03125577|Experimental|4SCAR19 and 4SCAR20/CD22/CD30/CD38/CD70/CD123|Patients who have relapsed and refractory B cell malignancies after chemotherapy will be treated with CD19 and CD20/CD22/CD30/CD38/CD70/CD123-specific gene-engineered T cells.
2917757|NCT03125564|Experimental|Fecal Microbiota Transplantation|FMT infusion and Fecal and Mucosal Microbiota Assessment
2917758|NCT03125564|Sham Comparator|Sham infusion|Infusion with sham and Fecal and Mucosal Microbiota Assessment
2917759|NCT03125551|Active Comparator|Ginger|Ginger ( Zingiber officinale) 4 grams po dly for 14 days
2917760|NCT03125551|Active Comparator|Garlic|Garlic (Allium sativum) 4-12 mg alliin po dly for 14 days
2917761|NCT03125551|Active Comparator|Ginkgo Biloba|Ginkgo Biloba 40mg po tds for 14 days
2917762|NCT03125551|Active Comparator|Ginseng|Ginseng 400mg po dly for 14 days
2917763|NCT03125551|Placebo Comparator|Placebo|Placebo po dly for 14 days
2917764|NCT03125538|Experimental|Motor Imagery|Participants from the experimental group will perform MIP concomitantly with usual physical rehabilitation program.
2917765|NCT03125538|Active Comparator|Control task|Concomitantly with usual physical rehabilitation program, participants from the control group will perform a cognitive task that has no impact on motor rehabilitation (word scramble game).
2917766|NCT03125525||Active treatment patients|Patients using Cefaly device on routine daily basis
2917767|NCT03125512|Experimental|Night Shift positional device|Randomized to Night shift positional therapy first for 8 weeks, followed by CPAP for 8 weeks, with a 1 week washout period.
2917768|NCT03125512|Active Comparator|Continuous positive airway pressure|Randomized to CPAP first for 8 weeks, followed by positional therapy for 8 weeks, with a 1 week washout period.
2917832|NCT03124914|Active Comparator|Patients considered physically inactive|Measures of strength and determination of neuromuscular fatigue
2917833|NCT03124901|Experimental|Test Group|All subjects are enrolled into the test group and all subjects receive DCI pulse oximeter sensor.
2917834|NCT03124875|Experimental|Treatment|Treated with the LimFlow Stent Graft System
2917769|NCT03125473|Experimental|Dose Group 1|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1 and 8
2917770|NCT03125473|Experimental|Dose Group 2|Multiple doses of low doseVXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1, 3, and 5
2917771|NCT03125473|Experimental|Dose Group 3|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1 and 29.
2917772|NCT03125473|Experimental|Dose Group 4|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 6 tablets of VXA-G1.1-NN on Days 1 and 29
2917773|NCT03125460||Initial Enrollment|Initial enrollment of patients with history of bladder cancer
2917774|NCT03125460||Longitudinal Cohort|Longitudinal Cohort - patients considered anticipatory positive at the time of enrollment and one random disease negative patient per anticipatory positive patient
2917775|NCT03125447|Experimental|Prematurely born children|Speed and accuracy answer to visual stimuli evaluated in 3 distinct posture/mobility situations
2917776|NCT03125447|Active Comparator|Term born children|Speed and accuracy answer to visual stimuli evaluated in 3 distinct posture/mobility situations
2917777|NCT03125434|Experimental|healthy volunteers|EOS full-spine, MRI, gait analysis
2917778|NCT03125421|Other|control period|standard preventive methods of pressure sores in each center
2917779|NCT03125421|Experimental|experimental period|experimental multifaceted preventive methods of pressure sores
2917780|NCT03125408||chronic HCV Infected patients|chronic HCV patients who will undergo standard of care FDA approved antiviral therapy to treat genotype 1,2, or 3 infections and will have blood drawn at various time points and tested using the DxN HCV Assay. Study is observational and results will not be used to manage patient care.
2917781|NCT03125395|Experimental|Treatment Cohort|Subjects <6 years of age and <14 kg at enrollment: LUM 100 mg/IVA 125 mg q12h. Subjects <6 years of age and ≥14 kg at enrollment: LUM 150 mg/IVA 188 mg q12h. Subjects ≥6 years of age at enrollment, regardless of weight: LUM 200 mg/IVA 250 mg q12h.
2917782|NCT03125395|No Intervention|Observational Cohort|
2917783|NCT03125382|Active Comparator|In office standard visit-New|Patients with new implants who do not perform device data transmission through Carelink system
2917784|NCT03125382|Active Comparator|In office standard visit-Previous|Patients with previous implants who do not perform device data transmission through Carelink system
2917785|NCT03125382|Experimental|Carelink - New Implants|Patients with new implants who perform device data transmission through Carelink system
2917786|NCT03125382|Experimental|Carelink - Previous Implants|Patients with previous implants who perform device data transmission through Carelink system
2917787|NCT03125369|Experimental|Duodenojejunal bypass|patients receive sleeve gastrectomy plus duodeno-jejunal bypass
2917788|NCT03125369|Active Comparator|Roux-en-Y gastric bypass|patients receive roux-Y gastric bypass
2917789|NCT03125356|Experimental|Diet Soda|Subjects will be asked to consume a diet soda three times daily for eight weeks.
2917790|NCT03125343|Experimental|No surgery|Patients with indication of complete response on follow-up MRI will undergo endoscopy, and digital rectal examination to ascertain complete response. MRI together with documentation from endoscopy will be reviewed at the Regional University Hospital to establish agreement regarding interpretation.
2917791|NCT03125343|Active Comparator|Surgery|Patients with indication of complete response on follow-up MRI will undergo endoscopy, and digital rectal examination to ascertain complete response. MRI together with documentation from endoscopy will be reviewed at the Regional University Hospital to establish agreement regarding interpretation. Patients with complete response will be offered watch and wait strategy, but the patients that want surgery will be operated according to the multi disciplinary conference decision.
2917792|NCT03125330|Experimental|One-to-One Coaching|"Participants randomized to One-to-One Coaching meet for an initial 2-hour coaching session, followed by seven 1-hour coaching sessions every 3-weeks. These eight sessions take place over the course of 6 months.~Additional requirements for One-to-One Coaching:~Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment, (b) at 6-months after study enrollment, and (c) 12-months following study enrollment.~Complete a 15-minute VIA Character Strengths Test online prior to One-to-One Coaching.~Following the completion of the final coaching session, participants are interviewed by a con-investigator by phone call to assess the experience of coaching.~Each coaching session will be recorded, transcribed, anonymized, and analyzed to identify common themes."
2917793|NCT03125330|Active Comparator|Group Coaching|"Participants meet for 90-minutes each month for 6 months for facilitated professional coaching with a group of colleagues.~Additional requirements:~Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment, (b) at 6-months after study enrollment, and (c) 12-months following study enrollment.~Complete a 15-minute VIA Character Strengths Test online prior to Group Coaching.~Prior to your initial group coaching session, participate in a 75-minute private phone interview with the primary investigator to discuss the how you make decisions and make sense of the world.~Following the completion of the final coaching session, participants are interviewed by a con-investigator by phone call to assess the experience of coaching.~Each coaching session will be recorded, transcribed, anonymized, and analyzed to identify common themes."
2917835|NCT03124836|Experimental|R2-25 Sensor|All subjects will be enrolled in the test group and will receive R2-25 Pulse Oximeter Sensor
2918069|NCT03122925||Control|Healthy subjects
2917794|NCT03125330|No Intervention|Group Coaching Waitlist|"Participants are offered group coaching at the completion of the 12-month study period. Six 90-minute group coaching sessions will occur over the course of six months.~Additional requirements:~• Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment (b) and at 6-months after study enrollment."
2917795|NCT03125317||The music group|Participant will allow to listen any kind of music which they wish
2917796|NCT03125317||valsalva maneuver|participants will be asked to take a deep breath and exhale the air out in 15 seconds
2917797|NCT03125317||The control group|no intervention
2917798|NCT03125304|Experimental|treatment group|Treatment group will receive acupuncture at Sanyinjiao (SP 6), Zhaohai (KI 6) ,Taichong (LR 3) ,Qichong (ST 30) and Guanyuan.
2917799|NCT03125304|Placebo Comparator|control group|Control group will receive acupuncture at non-acupoints.
2917800|NCT03125291|No Intervention|Bridges Workshop|Participants will receive a one-time, 90-minute workshop.
2917801|NCT03125291|Experimental|Bridges 4-week Program|Parents and adolescents will attend separate 1.25-hour groups simultaneously and then meet together for 45 minutes. Group meetings will be conducted at the school once per week for four weeks. Each week will cover a different topic. The parent program will focus on positive parenting and goal setting, parent-adolescent relationship strengthening, behavior management, and monitoring. The adolescent program will focus on personal goals and motivation, emotion regulation, cognitive control, and adaptive coping.
2917802|NCT03125278||Medication indication on the label|Patients discharged from Regions Hospital (St. Paul, MN) where we have implemented a standard process of printing the indication for all new medications on the prescription bottle.
2917803|NCT03125278||No medication indication given|Patients discharged from Brigham and Women's Hospital (Boston, MA) where there is no requirement for providing information on medication indications to patients at discharge.
2917804|NCT03125252|Experimental|Bundle|Specific action plan : ABCDE, complemented with care related to the nursing and paramedical role concerning the patient's environmental factors
2917805|NCT03125252|Other|Control|Standard paramedical and medical practices
2917806|NCT03125239|Experimental|Merestinib and LY2874455|"Patients who fulfill eligibility criteria will be entered into the trial to receive Merestinib and LY2874455.~After the screening procedures confirm participation in the research study:~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have AML, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.~Merestinib~LY2874455"
2917807|NCT03125226|Experimental|Supportive care (TracelT hydrogel)|Patients undergo transurethral resection of bladder tumors and receive TracelT hydrogel via injection. Patients undergo standard of care radiation therapy within 8 weeks of TracelT hydrogel placement.
2917808|NCT03125213|Active Comparator|Peg-IFN plus AL-3778|
2917809|NCT03125213|Placebo Comparator|Peg-IFN plus matching placebo|
2917810|NCT03125200|Experimental|ADCT-502|"Part 1 (dose escalation): Patients will receive an infusion of ADCT-502, at escalating doses. Part 1 will continue until the maximum tolerated dose or the recommended dose(s) and schedule(s) for expansion are determined.~Part 2 (expansion): Patients will be assigned to the recommended dose level of ADCT-502 identified in Part 1 by the Dose Escalation Steering Committee."
2917811|NCT03125187|Experimental|Sodium heparin UQ First|The participants will receive the Sodium heparin UQ intravenous drug administration at first period and the Sodium heparin FK intravenous drug administration at second period
2917812|NCT03125187|Experimental|Sodium Heparin FK First|The participants will receive the Sodium heparin FK intravenous drug administration at first period and the Sodium heparin UQ intravenous drug administration at second period
2917813|NCT03125174||control|healthy individuals with no history of lung disease
2917814|NCT03125174||bronchiectasis patients|individuals with a diagnoses of bronchiectasis
2917815|NCT03125161|Experimental|Arm A|HAI plus chemotherapy ± target therapy
2917816|NCT03125161|Active Comparator|Arm B|chemotherapy ± target therapy
2917817|NCT03125148|Other|Enteral stenting intraduodenal|Enteral stent (Wallflex enteral stent) will be placed in the duodenum with the entire stent lying within the duodenum bridging the obstruction.
2917818|NCT03125148|Other|Enteral stenting transpyloric|Enteral stent (Wallflex enteral stent) will be placed in the duodenum with the stent bridging the obstruction and the pyloric opening with proximal end of the stent lying within the stomach
2917819|NCT03125083|Experimental|skin-restricted lupus (SRL) patients|Role of inflammation in psychiatric disorders in patients with cutaneous lupus
2917820|NCT03125070|Experimental|Group I (INSPIRE, survivorship care plan)|Patients receive immediate access to the INSPIRE online program and personalized survivorship care plan.
2917821|NCT03125070|Active Comparator|Group II (usual care)|Patients receive an online program linking to existing online survivor resources and a personalized survivorship care plan. Patients may receive access to the INSPIRE online program after 12 months.
2917822|NCT03125057|Experimental|low light dose|PDT is applied to the patients at low light dose : power density of 60mW/cm2 for 20 minutes
2917823|NCT03125057|Experimental|high light dose|PDT is applied to the patients at high light dose : power density of 75mW/cm2 for 20 minutes
2917824|NCT03125031|Experimental|Group- Sensor 1|All subjects are enrolled into the test group and receive the Rainbow adhesive adult/pediatric sensors.
2917825|NCT03125031|Experimental|Group- Sensor 2|All subjects are enrolled into the test group and receive the Rainbow adhesive adult/neonatal sensors.
2917826|NCT03125018|Experimental|Test Subject|All subjects are enrolled into the test group and receive the LNCS ADTX Sensor.
2917827|NCT03125005|Experimental|Rainbow Universal Pulse Oximeter Sensor|All subjects will be enrolled in the test group and will receive Rainbow Universal Pulse Oximeter Sensor.
2917828|NCT03124979|Other|Test Subject|All subjects are enrolled into the test group and all subjects received the LNCS DBI Sensor.
2917829|NCT03124966|Experimental|Noninvasive Hemoglobin Sensor|All subjects are enrolled into the test group and all will receive the pulse oximeter sensor.
2917830|NCT03124927|Experimental|Test Group|All subjects are enrolled into the test group and all subjects receive DCI pulse oximeter sensor.
2917838|NCT03124784|Experimental|RD Disposable Sensors|All subjects are enrolled into the test group and all subjects received the RD Disposable Sensors
2917839|NCT03124771|Experimental|Rainbow Resposable Adhesive Sensors|All subjects are enrolled into the test group and all subjects received the Rainbow Resposable Adhesive Sensors.
2917840|NCT03124758|Experimental|Noninvasive Hemoglobin Sensor|All subjects are enrolled into the test group and all subjects received the Noninvasive Hemoglobin Sensor (Rainbow Reusable DCI, DCIP)
2917841|NCT03124693|Experimental|Test Group|All subjects are enrolled into the test group and all subjects received the Rainbow DCI pulse oximeter sensor.
2917842|NCT03124680|Active Comparator|opioid free group|Opioid free group using dexmedetomidine, ketamine, lidocaine, MgSO4
2917843|NCT03124680|Placebo Comparator|Opioid group|Opioid group using sufentanil, lidocaine, clonidine
2917844|NCT03124667|Experimental|Gaming Condition|The games group will visit the lab on 5 separate occasions, for 2 hours each, to complete training sessions (playing seated and standing computerized games), and then complete 5 similar sessions at home (lasting 2 hours, but may be split into 1-hour sessions at their convenience), at the onset of the exercise program. The training sessions will be scheduled concurrently with exercise classes in the first month. This group will also be asked to accumulate 150 minutes of exercise by attending weekly supervised and unsupervised, group-based aerobic and resistance exercise classes, by visiting the fitness facility alone, and by walking or strength training at home when necessary to supplement fitness facility activities to fully meet public health recommendations, for a period of 12 months.
2917845|NCT03124667|Active Comparator|Video Conditoin|The videos group will visit the lab on 5 separate occasions, for 2 hours each, to view health and educational YouTube videos, and then view 5 similar sessions at home (lasting 2 hours, but may be split into 1-hour sessions at their convenience), at the onset of the exercise program. The training sessions will be scheduled concurrently with exercise classes in the first month. This group will also be asked to accumulate 150 minutes of exercise by attending weekly supervised and unsupervised, group-based aerobic and resistance exercise classes, by visiting the fitness facility alone, and by walking or strength training at home when necessary to supplement fitness facility activities to fully meet public health recommendations, for a period of 12 months.
2917846|NCT03124654||Education|
2917847|NCT03124641|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of Hypothermic machine perfusion (HOPE) for 1-2 hours
2917848|NCT03124641|Active Comparator|Conventional cold storage (CCS)|Conventional cold storage
2917849|NCT03124628|Experimental|Flywheel resistance exercise|During 8 weeks, all the subjects will follow a standard resistance exercise training program within the Stockholm Habilitation Center system. In addition, patients in this arm will perform flywheel leg press resistance exercise twice per week.
2917850|NCT03124628|Active Comparator|Weight-stack resistance exercise|During 8 weeks, all the subjects will follow a standard resistance exercise training program within the Stockholm Habilitation Center system. In addition, patients in this arm will perform conventional, weight-stack leg press resistance exercise twice per week.
2917851|NCT03124615|Experimental|Enzalutamide|Patients will have commenced standard dose enzalutamide (160mg) daily and dose will be reduced if Grade 3 fatigue or cognition change has occurred and if toxicity is attributed to enzalutamide
2917852|NCT03124589|No Intervention|No Intervention|A questionnaire that asks individuals what components of an online intervention they might find useful.
2917853|NCT03124589|Experimental|Online Gambling Internet Intervention|An online gambling Internet intervention (housed at CAMH and developed based on the self-help materials created by Professor David Hodgins)
2917854|NCT03124576||control group|Without history of atrial fibrillation/without newly developed atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder
2917855|NCT03124576||group B|Patients without history of atrial fibrillation, with new onset atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder
2917856|NCT03124576||group C|Patients with self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring
2917857|NCT03124576||group D|Patients with non-self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring
2917858|NCT03124563|Experimental|Control group|Participants will wear a Fitbit Zip to record their daily step data in a nightly questionnaire. The participants in this arm will not receive any components of the intervention including: scheduling, maps, or activity goals.
2917859|NCT03124563|Experimental|Implementation Intention Condition|Participants will wear a Fitbit Zip to record their daily step data in a nightly questionnaire.. The participants in this arm will receive all components of the intervention including: scheduling, maps, and activity goals.
2917860|NCT03124550|Experimental|Exergame Experience|Participants will use the exergame for 4 weeks, during which time game telemetry data (all interactions with the software) will be automatically logged by the system. The participants will be asked to use the game at least every other day. Caregivers will be sent an email or automated text message (through the Twilio platform) to remind them to use the system if they have not done so within three days. The Twilio platform will be used to support an experience sampling protocol via automated, two-way text messaging: once per week, participants will be sent brief questions probing their level of satisfaction with the exergame and their level of perceived connectedness to the community of other caregivers using the exergame.
2917861|NCT03124537|Experimental|App Control Condition|The control group will just have the App with the accelerometer program to set step goals and to count and record steps for 1 month
2917862|NCT03124537|Experimental|App Experimental condition|The experimental condition will set step goals and have the schedule, map, and social components for 1 month.
2917863|NCT03124524|No Intervention|Control group|33 healthy controls
2917864|NCT03124524|Active Comparator|Qlarista Group|group who were administered estradiol valerate/dienogest
2917865|NCT03124524|Active Comparator|Yasmin Group|group who were administered ethinylestradiol and drospirenone
2917866|NCT03124498|Experimental|CIK Cell|"Phase I - Three dose levels escalated according to 3+3 rule~Phase II - The recommended dose level according to the results from Phase I"
2917891|NCT03124342|Experimental|VANDERBILT ICU RECOVERY PROGRAM (VIP)|Patients assigned to the Vanderbilt ICU Recovery Program (VIP) group will receive the components of the ICU Recovery Program intervention.
2917867|NCT03124485|Experimental|Endoscopic Sleeve Gastroplasty|A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava[29] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
2917868|NCT03124485|Active Comparator|Laparoscopic Sleeve Gastrectomy|Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
2917869|NCT03124472|Active Comparator|uterine artery ligation|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta."
2917870|NCT03124472|Active Comparator|Traditional lower segment Cesarean section|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta."
2917871|NCT03124459|Experimental|Part 1 Cohort 1|ACE-083 150 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
2917872|NCT03124459|Experimental|Part 1 Cohort 2|ACE-083 200 mg IM, (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
2917873|NCT03124459|Experimental|Part 1 Cohort 3|ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
2917874|NCT03124459|Experimental|Part 2 (double-blind placebo controlled)|ACE-083 up to 250 mg IM (tibialis anterior muscle) or placebo, once every 3 weeks for up to 9 doses
2917875|NCT03124459|Experimental|Part 2 (open label)|ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 8 doses
2917876|NCT03124446|Experimental|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
2917877|NCT03124446|Active Comparator|Health education wait list control|The control condition is a health education wait list control, which participants will be offered a 15-30 minute, one-on-one meeting with the MB-College instructor. There, participants will learn about the MB-College curriculum, and have opportunities to share their relationship with common determinants of undergraduate student health and performance, described above. Together, the student and instructor will explore ways the course may assist in shifting these parts of their lives, as they see best. A deliberate relationship will be formed with the instructor.
2917878|NCT03124433|Experimental|Neoadjuvant apalutamide|Oral apaluatmide 240mg daily for 12 weeks followed by standard of care robotic radical prostatectomy and pelvic node dissection
2917879|NCT03124420|Active Comparator|Group A (Drug: 7-day triple therapy)|Intervention : Drug: 7-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 7-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 7 days)
2917880|NCT03124420|Sham Comparator|Group B (Drug: 14-day triple therapy)|Intervention : Drug: 14-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 14-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 14 days).
2917881|NCT03124407|Active Comparator|QD-Active|40 subjects receiving once daily application of complete drug product (contains 0.25% capsaicin) to the knee
2917882|NCT03124407|Placebo Comparator|QD-Vehicle|20 subjects receiving once daily application of drug product vehicle (i.e.. with no capsaicin) to the knee
2917883|NCT03124407|Active Comparator|BID-Active|40 subjects receiving twice daily application of complete drug product (contains 0.25% capsaicin) to the knee
2917884|NCT03124407|Placebo Comparator|BID-Vehicle|20 subjects receiving twice daily application of drug product vehicle (i.e.. with no capsaicin) to the knee
2917885|NCT03124394||CRS and intraoperative chemotherapy|Patients receiving cytoreductive surgery and intraoperative chemotherapy (HIPEC/PIPAC)
2917886|NCT03124368|Experimental|Sentinel Group 1|All participants will receive ACH-0144471 during the treatment period.
2917887|NCT03124368|Experimental|Group 2|All participants will receive ACH-0144471 during the treatment period.
2917888|NCT03124355|Experimental|Placebo pill with vagal/sham stimulation|Patients will receive a single oral dose of placebo sugar pill, and 1.5-2 hours later they will have two tilt table tests: one with vagal stimulation and one with sham vagal stimulation
2917889|NCT03124355|Experimental|Pyridostigmine with vagal/sham stimulation|Patients will receive a single oral dose of pyridostigmine pill 30 mg, and 1.5-2 hours later they will have two tilt table tests: one with vagal stimulation and one with sham vagal stimulation
2917890|NCT03124355|Experimental|Galantamine with vagal/sham stimulation|Patients will receive a single oral dose of galantamine pill 8 mg, and 1.5-2 hours later they will have two tilt table tests:one with vagal stimulation and one with sham vagal stimulation
2918070|NCT03122925||Friedreich's Ataxia|Diagnosed for Friedreich's Ataxia
2917892|NCT03124342|No Intervention|Usual care|Patients in the usual care group will receive care as dictated by their clinical team. In usual care in the study institution, patients frequently receive medication reconciliation by and ICU pharmacist at the time of transfer out of the ICU to the hospital ward, medication reconciliation by a physician at the time of hospital discharge, and follow up with their primary care physician within two weeks of hospital discharge. Usual care does not currently include an in-person assessment of the patient's cognitive and functional status or anticipated post-ICU needs by a nurse practitioner between ICU transfer and hospital discharge, access to a 24/7 contact line after hospital discharge, or assessment in a multi-disciplinary ICU Recovery Clinic.
2917893|NCT03124329|Experimental|Coronally Advanced Flap|
2917894|NCT03124329|Experimental|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|
2917895|NCT03124329|Experimental|Intrasulcular tunneling|
2917896|NCT03124329|Experimental|VISTA + Leukocyte-Platelet Rich Fibrin|
2917897|NCT03124316|No Intervention|Email #1: FULLY TURNED OFF|No behavioural change techniques (BCTs) 'turned on' in the email. The email would contain only standardized content.
2917898|NCT03124316|Experimental|Email #2: ANTICIPATED REGRET|Anticipated regret content + standardized content
2917899|NCT03124316|Experimental|Email #3: MATERIAL INCENTIVE|Material incentive content + standardized content
2917900|NCT03124316|Experimental|Email #4: PROBLEM SOLVING|Problem solving content + standardized content
2917901|NCT03124316|Experimental|Email #5: REGRET + INCENTIVE|Anticipated regret content + Material incentive content + standardized content
2917902|NCT03124316|Experimental|Email #6: REGRET + PROBLEM SOLVING|Anticipated regret content + Problem solving content + standardized content
2917903|NCT03124316|Experimental|Email #7: INCENTIVE + PROBLEM SOLVING|Material incentive content + Problem solving content + standardized content
2917904|NCT03124316|Experimental|Email #8: ALL BCTs|Anticipated regret content + Material incentive content + Problem solving content + standardized content
2917905|NCT03124290|Other|CPR with attention distraction first|First, they perform two-minute chest compressions with conducting the PASAT. After 20 mins' rest, they perform two-minute chest compressions without conducting the PASAT.
2917906|NCT03124290|Other|CPR without attention distraction first|First, they perform two-minute chest compressions without conducting the PASAT. After 20 mins' rest, they perform two-minute chest compressions with conducting the PASAT.
2917907|NCT03124277|Experimental|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
2917908|NCT03124277|Other|Control group|Best local diet
2917909|NCT03124238|Experimental|Massage|Massage therapy of the lumbar muscles in a prone position during 30 minutes
2917910|NCT03124238|No Intervention|Control|Rest during 5 minutes in a prone position
2917911|NCT03124225||Ultrasound|Early Arthritis Patients seeing a Rheumatologist who uses US for assessment routinely in clinic
2917912|NCT03124225||Non-Ultrasound|Early Arthritis Patients seeing a Rheumatologist who does not uses US for assessment routinely in clinic
2917913|NCT03124199|Experimental|Rifaximin|Patient with Helicobacter pylori infection with standard triple therapy prescribed by clinical practice.
2917914|NCT03124186|Experimental|Active stimulation with motor training|2 hours of active peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
2917915|NCT03124186|Active Comparator|Sham stimulation with motor training|2 hours of sham peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
2917916|NCT03124173|Other|Behavioral Tasks|Each subject will conduct 4 sessions, i.e. a training session and three fMRI sessions. The first session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
2917917|NCT03124160|Experimental|Mona Lisa® NT Cu380 Mini|Mona Lisa® NT Cu380 Mini containing 380mm2 of copper surface inserted into the uterine cavity.
2917918|NCT03124160|Active Comparator|ParaGard® CuT380A|ParaGard® CuT380A containing 380mm2 of copper surface inserted into the uterine cavity.
2917919|NCT03124147|Active Comparator|Anodal tDCS with motor training|20 minutes of anodal transcranial direct current stimulation applied to the ipsilesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
2917920|NCT03124147|Active Comparator|Cathodal tDCS with motor training|20 minutes of cathodal transcranial direct current stimulation applied to the contralesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
2917921|NCT03124147|Active Comparator|Dual tDCS with motor training|20 minutes of anodal transcranial direct current stimulation applied to the ipsilesional hemisphere and cathodal transcranial direct current stimulation applied to the contralesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
2917922|NCT03124147|Sham Comparator|Sham tDCS with motor training|20 minutes of sham transcranial direct current stimulation applied to the ipsilesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
2917923|NCT03124134|Experimental|A) Gelesis200, 50 g carbs|4.20 g of Gelesis200 before a 50 g carbohydrate breakfast
2917924|NCT03124134|Experimental|B) Gelesis200, 100 g carbs|4.20 g of Gelesis200 before a 100 g carbohydrate breakfast
2917925|NCT03124134|Placebo Comparator|C) Water, 50 g carbs|300 mL water before a 50 g carbohydrate breakfast
2917926|NCT03124134|Placebo Comparator|D) Water, 100 g carbs|300 mL water before a 100 g carbohydrate breakfast
2917927|NCT03124134|Experimental|E) Gelesis200, TBD carbs|up to 4.20 g Gelesis200 before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)
2917928|NCT03124134|Placebo Comparator|F) Water, TBD carbs|300 mL of water before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)
2917929|NCT03124108|Placebo Comparator|Placebo|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
2917930|NCT03124108|Active Comparator|Elafibranor 80 mg|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
2917931|NCT03124108|Active Comparator|Elafibranor 120 mg|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
2917932|NCT03124095|Experimental|Combined Exercise Group|The subjects of the combined training group will undergo the intervention three times a week for eight weeks. The combined group will carry out both resistance and aerobic exercises in the same session. The resistance training will be comprised by ten exercises which will alternate body segments with maximum repetitions in the first set and the lower limit of the repetitions interval in the next sets. Along the training, the number of series will be increased whereas the number of repetitions will be decreased. The intensity of the aerobic exercises will be based on the percentage of the heart rate of the anaerobic threshold on the first weeks and on the speed of the anaerobic and aerobic threshold on the last weeks
2917933|NCT03124095|No Intervention|Control Group|The control group will be advised not to change their health habits. After the intervention they will be invited to participate in a physical exercise program.
2917934|NCT03124082|Active Comparator|opioid|remifentanil 0,15-0,25 mcg/kg/h
2917935|NCT03124082|Experimental|opioid free|ketamine bolus 0,5 mg/kg + infusion 0,25 mg/kg/h lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h clonidine 4 mcg/kg
2917936|NCT03124043|Experimental|Intervention First|Participants in Intervention First were enrolled in the intervention for the first 6 months of study participation followed by a return to usual care for the following 6 months. The intervention included provision of a cellular-enable glucose meter and enrollment in the Livongo for Diabetes support program that provided both in-the-moment and scheduled support, both provided by Livongo Health Inc.
2917937|NCT03124043|Experimental|Intervention Second|"Participants in the 'Intervention Second received usual care for the first 6 months of study participation followed by enrollment in the intervention for the following 6 months. The intervention included provision of a cellular-enable glucose meter and enrollment in the Livongo for Diabetes support program that provided both in-the-moment and scheduled support, both provided by Livongo Health Inc."
2917938|NCT03124030||Direct Oral Anticoagulants|assuming Pradaxa or Apixaban or Eliquis; undergo simple dental extraction
2917939|NCT03124030||Oral Anticoagulant therapy|assuming Coumadin or Sintrom; undergo simple dental extraction
2917940|NCT03124017|Experimental|Alert Group|Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart
2917941|NCT03124017|No Intervention|Control Group|No electronic alert and no Geneva Risk Score calculation tool issued in the electronic patient chart
2917942|NCT03124004||Direct Oral Anticoagulants|assuming Pradaxa or Eliquis or Apixaban or Xarelto; undergoing periodontal debridement
2917943|NCT03124004||oral anticoagulant therapy|assuming Coumadin or Sintrom; undergoing periodontal debridement
2917944|NCT03123991|Experimental|Experimental Group|UP-A adapted as a preventive intervention. Specifically, the Spanish version of The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a 9 sessions school-based preventive intervention. The intervention is delivered in nine weekly sessions (each session lasting around 55 minutes).
2917945|NCT03123991|Other|Wait-list Control Group|Same than experimental group (EG), after EG finishes. Specifically, classes in waitlist condition will be offered the same intervention than experimental group after EG finishes the three months follow-up.Before that, waitlist means that the classess work as usual with issues of mental health.
2917946|NCT03123978|Experimental|Treatment (niclosamide, enzalutamide)|Patients receive niclosamide PO BID and enzalutamide PO QD on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2917947|NCT03123913|Experimental|Combination therapy|Testosterone Enanthate and Somatropin
2917948|NCT03123900|Experimental|Physical exercise (n= 40)|Walking program up to 45 minutes, 5 times a week for 3 months.
2917949|NCT03123900|Experimental|Cognitive training (n=40)|Computerized cognitive training up to 45 minutes, 5 times a week for 3 months.
2917950|NCT03123900|Experimental|Combined training (n=40)|Exercise and cognitive training up to 90 minutes, 5 times a week for 3 months.
2917951|NCT03123900|No Intervention|Control group (n=20)|Waiting list group.They receive no intervention during this waiting period. At the end of this period our training programs are available to them.
2917952|NCT03123887||R/r B-precursor ALL|This study selected patients with Relapsed or Refractory (R/r) B-precursor Acute Lymphoblastic Leukemia
2917953|NCT03123874|Placebo Comparator|Mom's own pump (reference)|All participants will use two pumps--Mom's own and a sterile pump (Medela Symphony). Participants will be asked to fully express one breast on two consecutive pumping sessions. The second pumping sessions will occur 3 hours (+/- 30 minutes) from the beginning of the first pumping session. Participants will be randomized to which pump is used first. One ounce of human milk will be collected from each pumping session and stored at home for 0, 2, 4, and 30 days after pumping.
2917954|NCT03123874|Experimental|Home storage|One ounce of human milk will be collected from each pumping session and stored at home for 0, 2, 4, and 30 days after pumping.
2917955|NCT03123861|Active Comparator|Gabapentin|Participants will take 300mg Gabapentin for the first 3 days after surgery, then dose escalate to 300mg BID for an additional 11 days.
2917956|NCT03123861|Placebo Comparator|Placebo oral capsule|Participants will take placebo for the 2 weeks after surgery.
2917957|NCT03123848|Experimental|Darunavir/Cobicistat FDC (Prezcobix)|Participants will receive one darunavir/cobicistat fixed-dose combination (FDC) tablet, containing 800 milligram (mg) of darunavir (DRV) and 150 mg of cobicistat (COBI) in the morning on Day 1.
2918026|NCT03123289|Experimental|68Gallium-citrate|"This arm, undergoing the 68-Gallium citrate PET/CT scan intervention, includes the PET/CT scans performed with 68Gallium-citrate radiotracer. Note that same patients scanned with different radiotracers serve in both arms."
2917958|NCT03123835|Other|Treatment|Patients meeting inclusion criteria for possible surgical therapies for their current condition (IE Achelasia, Enlarged Gastric Pouch and/or Gastrogastric Fistula after primary weight loss surgery, etc) will be educated on the different therapy options including traditional laparoscopic surgery and/or Endoscopic Interventions including POEM (Percutaneous Oral Endoscopic Myomectomy for the treatment of Achelasia) or Endoscoscopic Pouch/GastroJejunostomy repair or closure of the Gastrogastric Fistula as examples.
2917959|NCT03123822|Experimental|Single vision glasses|Typical glasses prescribed for children to correct only distance refractive error and to be worn all waking hours.
2917960|NCT03123822|Experimental|Single vision glasses with anti-glare coating|Typical glasses prescribed for children to correct only distance prescription with anti-glare coating and to be worn all waking hours.
2917961|NCT03123822|Experimental|Eyezen|Commercially available, low-powered, progressive addition lenses glasses with anti-glare coating to be worn all waking hours
2917962|NCT03123809|Active Comparator|Gastric Electrical Stimulation (GES) ON|"Gastric Electrical Stimulation (GES) system involves surgical implantation of a pulse generator in the abdominal wall and 2 electrodes into the muscularis propria of the stomach.~After surgery this group of GP patients will have their GES programed and system will be turned ON for 3 months during a double-blind phase of the study. This step will be followed with additional 3 months of active stimulation (GES System will be turned ON) as it is described in the protocol.Therefore all subjects in this arm will receive overall 6 months of intervention, which will be provided by the active stimulation of GES System (GES turned ON for 6 months)."
2917963|NCT03123809|Placebo Comparator|Gastric Electrical Stimulation (GES) OFF|"Gastric Electrical Stimulation (GES) system involves surgical implantation of a pulse generator in the abdominal wall and 2 electrodes into the muscularis propria of the stomach.~After surgery this group of GP patients will have their GES programed and system will be turned OFF for 3 months.This step will be followed with additional 3 months of active stimulation (GES System will be turned ON) as it is described in the protocol. Therefore all subjects in this arm will receive first 3 months of non GES intervention (GES System OFF), and 3 following months of active intervention which will be provided by the stimulation of GES System (GES turned ON for 3 months)."
2917964|NCT03123796||Only PPI|Kidney transplant recipients who used only proton pump inhibitors and did not use histamine H2 receptor antagonists.
2917965|NCT03123796||Only H2RA|Kidney transplant recipients who used only histamine H2 receptor antagonists and did not use proton pump inhibitors.
2917966|NCT03123796||PPI and H2RA|Kidney transplant recipients who used both proton pump inhibitors and histamine H2 receptor antagonists.
2917967|NCT03123796||No Acid Suppressive Treatment|Kidney transplant recipients who used neither proton pump inhibitors nor histamine H2 receptor antagonists.
2917968|NCT03123783|Experimental|APX005M in combination with nivolumab|Subjects will receive intravenously APX005M in combination with nivolumab until disease progression, unacceptable toxicity or death.
2917969|NCT03123770|Experimental|DC Follow T|Participants receive pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel before surgery.
2917970|NCT03123770|Active Comparator|EC Follow T|Participants receive epirubicin plus cyclophosphamide followed by docetaxel before surgery.
2917971|NCT03123757|Other|Intervention|Patients performed the 6-minute walk test and completed the EQ-5D quality of life questionnaire.
2917972|NCT03123744|Experimental|Palbociclib 125 mg|Palbociclib is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study measurements will be obtained at baseline and about every 8 weeks thereafter. Subjects will continue study drug until disease progression or unacceptable toxicity.
2917973|NCT03123731|Active Comparator|Control Arm|Participants will wear a Fitbit but will not receive any additional elements of the iSTEP intervention.
2917974|NCT03123731|Experimental|iSTEP PA intervention|Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA) and reduce sedentary behavior, including setting weekly goals to increase average daily step counts.
2917975|NCT03123731|Experimental|iSTEP PA and diet intervention|Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA), reduce sedentary behavior, and promote adherence to a Mediterranean-style diet. Participants will also be administered diet counseling from a registered dietitian and receive weekly feedback on both physical activity and diet behaviors.
2917976|NCT03123718|Other|Intrathecal Methotrexate|
2917977|NCT03123718|Active Comparator|High-dose Intravenous Methotrexate|
2917978|NCT03123692|Experimental|Treatment|14 days treatment with NBMI 300 mg/day
2917979|NCT03123692|Placebo Comparator|Placebo|14 days treatment with Placebo
2917980|NCT03123666|Experimental|Granulocyte/macrophage colony-stimulating factor (GM-CSF)|GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer OR Placebo for 7 days. Both the groups will receive standard medical care
2917981|NCT03123666|Placebo Comparator|Placebo|Placebo will be given identical to the interventional
2917982|NCT03123640|Experimental|Intervention group|Pharmacist conducts medication reconciliation and medication review while the patient is admitted to the emergency Department. The pharmacist present results from medication reconciliation to physicians at the emergency Department before the Medical history is obtained. Further the pharmacist will discuss drug related problems obtained during the medication review with the physicians to customize and optimize the medication treatment for each patient.
2917983|NCT03123640|No Intervention|Control group|Standard treatment without pharmacist intervention in the emergency department
2917984|NCT03123627|Experimental|New profilaxis|Prophylaxis is discontinued when the patient developed CMV-specific cellular immunity.
2917985|NCT03123627|Active Comparator|Profilaxis recommended by TTS|Valganciclovir prophylaxis until day +90 as recommended by the International Consensus document of the TTS.
2917986|NCT03123614|Active Comparator|Loteprednol Etabonate 0.5% Oph Gel|Group 1 will use loteprednol 0.5% gel in both eyes, starting at a frequency of four times per day for the first week and then tapered off based on clinical judgement of the corneal healing response.
2917987|NCT03123614|Active Comparator|Prednisolone acetate 1% Oph Susp|Group 2 will use prednisolone acetate 1% suspension in both eyes, starting at a frequency of four times per day for the first week, then tapered down to a regimen of fluorometholone 0.1% suspension, which will then be tapered off based on clinical judgement of the corneal healing response.
2917988|NCT03123601|Experimental|Risk sign displays|At baseline patients will undertake a screening risk assessment and it will be attributed a correspondent risk display. Study duration will be a minimum of 3 months per participant, including daily record of events and monthly interview assessments. Events data will be compared with historical data extracted retrospectively from medical and nursing charts.
2917989|NCT03123588|Experimental|Ruxolitinib|
2917990|NCT03123588|Active Comparator|Anagrelide|
2917991|NCT03123562|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
2917992|NCT03123549|Experimental|Simplify Disc|Simplify Disc at two levels of the cervical spine
2917993|NCT03123549|No Intervention|Historical Control|This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm (N=188) of a previously completed two level cervical disc trial.
2917994|NCT03123536||Point-of-care ultrasound group|High risk patients received point-of-care ultrasound assessment perioperatively, treatment was oriented by the findings of point-of-care ultrasound.
2917995|NCT03123536||Control group|High risk patients received management by the experience of the clinical team.
2917996|NCT03123523||Patients group|35 patients
2917997|NCT03123523||Healthy volunteers|20 healthy volunteers
2917998|NCT03123510|Experimental|Synbiotic supplement|Bifidobacterium spp plus bimuno- galacto-oligosaccharides
2917999|NCT03123510|Placebo Comparator|placebo|sugar pills
2918000|NCT03123497||Idiopathic Thrombocytopenic Purpura|completion of questionnaire
2918001|NCT03123484|Experimental|β-elemene+EGFR TKI|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) and β-elemene
2918002|NCT03123484|Active Comparator|EGFR TKI|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)
2918003|NCT03123471|Experimental|16-week Placebo and Apremilast 30 mg BID|Weeks 0 to 16: Double-blind, Placebo-controlled Treatment Phase: Apremilast 30 mg Twice Daily (BID) or placebo BID
2918004|NCT03123471|Experimental|Apremilast Extension Phase|Weeks 16 to 32: Apremilast Extension Phase: Apremilast 30 mg Twice Daily (BID).
2918005|NCT03123458|Experimental|Single arm, cfMSC to treat immune disorders|cfMSCs treatment
2918006|NCT03123445|Experimental|Endostar + Gemcitabine and Cisplatin|Patients in this group will be given endostar combined with gemcitabine and cisplatine.
2918007|NCT03123445|Active Comparator|Gemcitabine and Cisplatin|Patients in this group will be given gemcitabine and cisplatine.
2918008|NCT03123432|Experimental|immunomodulating nutrients enriched diet|Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the immunomodulating nutrients enriched diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, enteral nutrition (EN) was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the immunomodulating nutrients enriched diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the interventional diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.
2918009|NCT03123432|Active Comparator|standard diet|Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the standard diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, EN was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the interventional diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the standard diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.
2918010|NCT03123419|Other|Vaccine|All patients who consent to be in the study will receive Appointment reminders.
2918011|NCT03123406|Experimental|Severe SHPT|Administer Cinacalcet HCL to subjects whose iPTH>900 pg/ml from 1st to 32nd week.
2918012|NCT03123406|Experimental|Moderate SHPT|Administer Cinacalcet HCL to subjects whose 600≤iPTH<900 pg/ml from 1st to 32nd week.
2918013|NCT03123406|Experimental|Mild SHPT|Administer Cinacalcet HCL to subjects whose 300≤iPTH<600 pg/ml from 1st to 32nd week.
2918014|NCT03123393|Experimental|TAK-659|TAK-659, 60 milligram (mg) to 100 mg, tablets, orally, once daily in 28-day cycle until disease progression, unacceptable toxicities, or withdrawal for other reasons (estimated median treatment duration 6 months).
2918015|NCT03123367|Active Comparator|Group 1: Nella VuSleeve|Sleeve
2918016|NCT03123367|Active Comparator|Group 2: Nella NuSpec|Speculum
2918017|NCT03123367|Active Comparator|Group 3: NellaSpec|Speculum
2918018|NCT03123367|Active Comparator|Group 4: Nella Insert|Sleeve
2918019|NCT03123354|Experimental|Test group|All subjects are enrolled in the test group and receive an O3 regional oximeter sensor during their scheduled, general cardiac catheterization procedure.
2918020|NCT03123328|Experimental|Test Subjects|Each test subject will receive a Radical-7 Pulse CO-Oximeter and sensor that will remain on the subject for the first 24 hours following ED admission or discharge from the ICU/IMU.
2918021|NCT03123315|Experimental|Cook Bush DL™ Ureteral Illuminating Catheter|As part of this study an additional tool will be used during the hysterectomy. This tool is called a Cook Bush DL™ Ureteral Illuminating Catheter, which is a lighted ureteral stent. This is a very thin tube that goes into the ureter. A urologist, who is an expert at placing these devices, will insert a stent into each ureter during surgery. The lighted stents will help effectively find the ureters and keep track of them during the surgery. This same procedure is already being done in many other forms of abdominal surgery to help find the ureter. The stents will be removed before the surgery is complete and treatment will not differ in any other way.
2918022|NCT03123302||Group 1|Epileptic patients who are sedated with a total dose of propofol 2 mg/kg and midazolam 0.1 mg/kg.
2918023|NCT03123302||Group 2|Epileptic patients who are sedated with a total dose of pentothal 4 mg/kg and midazolam 0.1 mg/kg.
2918024|NCT03123302||Group 3|Non-epileptic patients who are sedated with a total dose of propofol 1 mg/kg and ketamine 1 mg/kg.
2918025|NCT03123302||Group 4|Non-epileptic patients who are sedated with a total dose of midazolame 0.1 mg/kg and ketamine 1 mg/kg.
2918067|NCT03122938|Experimental|Lactoferrin Group|lactoferrin-supplemented formula
2918027|NCT03123289|Experimental|18F-FDG|"This arm, undergoing the 18F FDG PET/CT scan intervention, includes the PET/CT scans performed with 18F-FDG tracer.~Note that same patients scanned with different radiotracers serve in both arms."
2918028|NCT03123276|Experimental|gemcitabine + pembrolizumab|First cohort of 6 patients may receive Gemcitabine 800 mg/m2 + Pembrolizumab 200 mg. After safety data review, if no DLTs then dose for Gemcitabine will be increased to 1000 and further 1200 mg/m2.
2918029|NCT03123250|Experimental|Aquablation procedure|
2918030|NCT03123237|Placebo Comparator|Control|"control will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
2918031|NCT03123237|Active Comparator|Diabetic|"diabetic cases will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
2918032|NCT03123237|Active Comparator|Hypertensive|"hypertesive cases will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
2918033|NCT03123237|Active Comparator|Diabetic & Hypertensive|"Diabetic & Hypertensive cases will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
2918034|NCT03123224|Experimental|Combined Aerobic and Resistance Exercise|Participants will work with study staff to develop an individualized physical training program based on their level of functioning at study entry. Exercises will focus on increasing the heart rate to a point at which participants will breathe more heavily and may sweat.
2918035|NCT03123224|Active Comparator|Balance and Flexibility|Participants will work with study staff to develop an individualized physical training program based on their level of functioning at study entry.
2918036|NCT03123198|Experimental|Dialectical Behavior Therapy|All participants receive six months of standard DBT which includes individual therapy, skills training, and as-needed phone consultation.
2918037|NCT03123185|Experimental|Single rising dose part|Groups of healthy volunteers receive rising single doses of BI 705564
2918038|NCT03123185|Experimental|Food effect part|Groups of healthy volunteers receive single doses of BI 705564 with and without food
2918039|NCT03123172|Other|co2 gap|arterial and central venous blood gases to measure Co2 gap
2918040|NCT03123159||HBV Infected patients|chronic HBV patients who will undergo standard of care FDA approved antiviral therapy to treat HBV infections. Will have blood drawn to be tested using the DxN HBV Assay. Study is observational and results will not be used to manage patient care.
2918041|NCT03123146|Experimental|Fb-Cognitive Behavioral Therapy|Functional Behavior-Based Cognitive Behavioral Therapy: Group activities, individual work in parent-child dyads, group parent training, and social skills exercises.
2918042|NCT03123146|No Intervention|Treatment as Usual (TAU)|"Children assigned to this condition received usual care, meaning that they could continue with any services. This group acted as a control group whereby access to intervention was patient-directed."
2918043|NCT03123120|Experimental|BI 655130|
2918044|NCT03123120|Placebo Comparator|Placebo|
2918045|NCT03123107|Experimental|Ascorbic Acid|4 patients will receive 15 mg/kg of ascorbic acid IV the day before and after CABG surgery; 4 patients will receive 30 mg/kg of ascorbic acid IV the day before and after CABG surgery. The maximum dose of ascorbic acid will be 2 g.
2918046|NCT03123094|Experimental|BI 655130 dose group 1 (Intravenous)|
2918047|NCT03123094|Experimental|BI 655130 dose group 2 (Intravenous)|
2918048|NCT03123094|Experimental|BI 655130 dose group 3 (Intravenous)|
2918049|NCT03123094|Experimental|BI 655130 dose group 4 (Subcutaneous)|
2918050|NCT03123094|Placebo Comparator|Matching placebo for each dose group (Intravenous)|
2918051|NCT03123094|Placebo Comparator|Matching placebo (Subcutaneous)|
2918052|NCT03123081|Experimental|Umbilical Cord Milking|Umbilical Cord Milking involves milking 30 cm length of cord at birth, after initiation of ventilation.
2918053|NCT03123081|No Intervention|Immediate Umbilical Cord Clamping|Procedure: No Intervention: Immediate Umbilical Cord Clamping or Immediate Cord Clamping.
2918054|NCT03123068|Active Comparator|Active treatment group - Group A|Participants will receive a daily oral dose of 1,000 mg cocoa flavanol (CocoaVia®) for 5 days before surgery. The daily dose will consist of 8 capsules in divided doses throughout the day.
2918055|NCT03123068|Placebo Comparator|Placebo treatment group - Group B|Participants will receive a daily oral dose of a placebo for 5 days before surgery. The daily dose will consist of 8 capsules in divided doses throughout the day.
2918056|NCT03123055|Experimental|B-701|B-701 (25 mg/kg) will be administered via IV infusion on Cycle 0 Day 1 for a single 14-day cycle.
2918057|NCT03123055|Experimental|B-701 plus pembrolizumab|B-701 (25 mg/kg [or the recommended Phase 2 dose if different than 25 mg/kg]) plus pembrolizumab (200 mg) will be administered by IV infusion on Cycle 1 Day 1 once every 3 weeks.
2918058|NCT03123042|Experimental|Sentinel basin dissection|Intervention: Sentinel basin dissection
2918059|NCT03123016|Experimental|Vitiligo with Apremilast and NB-UVB phototherapy|Each participant will be compared with one side of the body to the other side
2918060|NCT03123003|Experimental|SonicBone Ultrasound|Assessment of bone age by SonicBone Ultrasound will compared to wrist X-ray assessment
2918061|NCT03122990|Experimental|Full mouth scaling and root planing|FM-SRP No surgical periodontal treatment will be performed in all dentition within 24 hours
2918062|NCT03122990|Active Comparator|Quadrant Scaling and Root Planing|"Q-SRP No surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
2918063|NCT03122977|Experimental|Full mouth scaling and root planing|FM-SRP Non surgical periodontal treatment will be performed in all dentition within 24 hours
2918064|NCT03122977|Active Comparator|Quadrant scaling and root planing|"Q-SRP Non surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
2918065|NCT03122964||Patients with gross or microscopic hematuria|This study aims to prospectively enroll a minimum of 700 subjects, with gross or microscopic hematuria. Each site will target enrollment of 100 subjects and patient samples will be collected from consecutive patients meeting the inclusion criteria outlined below. The total study duration is expected to be 24 months.
2918066|NCT03122951|Other|ovulation test use|All voluteers will receive device for use according to instructions
2918071|NCT03122912|Experimental|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
2918072|NCT03122912|Active Comparator|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
2918073|NCT03122899|Other|SIJ fusion with iFuse 3D with 6 mo CT|These subjects will get pelvic CT at 6 months post-operatively.
2918074|NCT03122899|Other|SIJ fusion with iFuse 3D with 12 mo CT|These subjects will get pelvic CT at 12 months post-operatively.
2918075|NCT03122886|Experimental|Group I (fat emulsion)|Patients receive fat emulsion IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
2918076|NCT03122886|Placebo Comparator|Group II (placebo)|Patients receive placebo IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
2918077|NCT03122873||Myelopathy of any cause|Male or female 18 years or older with myelopathy and detectable finger extension weakness due to 1) prototypic multiple sclerosis (N=50) 2) other etiologies of myelopathy (N=50), including other inflammatory conditions (e.g. idiopathic transverse myelitis, neuromyelitis optica, acute disseminated encephalomyelitis, sarcoidosis) or other etiologies (compression, vascular disorders, degenerative disorders, neoplasms).
2918078|NCT03122873||Peripheral neuropathy|Male or female 18 years or older with C7 radiculopathy, radial neuropathy, plexopathy, peripheral neuropathy, who have detectable finger extension weakness.
2918079|NCT03122873||Healthy Controls|Male and female 18 year or older with no finger extension weakness and no known neurological conditions.
2918080|NCT03122860|Experimental|0.03 mg SM04690|Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle
2918081|NCT03122860|Experimental|0.07 mg SM04690|Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle
2918082|NCT03122860|Experimental|0.15 mg SM04690|Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle
2918083|NCT03122860|Experimental|0.23 mg SM04690|Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle
2918084|NCT03122860|Placebo Comparator|Vehicle|Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle
2918085|NCT03122860|Sham Comparator|Sham|Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle
2918086|NCT03122847||Patients|30 patients with Graves' ophthalmopathy in which treatment with intravenous methylprednisolone is indicated
2918087|NCT03122834||Cohort A|Newly diagnosed Heart Failure patients who will be treated with beta blockers (BB) and Angiotensin converting enzyme inhibitors (ACEIs)/or Angiotensin receptor blockers (ARBs) for the first time.
2918088|NCT03122834||Cohort B|Heart Failure patients who are candidate for add-on treatment with Spironolactone / Eplerenone.
2918089|NCT03122821|Active Comparator|Group 1|transcranial direct stimulation
2918090|NCT03122821|Active Comparator|Group 2|transcranial magnetic stimulation
2918091|NCT03122821|Experimental|Group 3|transcranial direct stimulation +mental imagery
2918092|NCT03122821|Experimental|Group 4|transcranial direct stimulation +mental imagery
2918093|NCT03122808||Neonatal encephalopathy|"The inclusion criteria will be:~Moderate or severe neonatal encephalopathy~Gestational age of 35+0 weeks or greater~Singleton pregnancy~Inborn~The exclusion criteria will be:~Non-hypoxic-ischaemic aetiology or postnatal hypoxic-ischaemia~Major congenital abnormalities~Less than 15 minutes of digital CTG recording from labour available"
2918094|NCT03122808||Control|"The inclusion criteria will be:~Gestational age of 35+0 weeks or greater~Singleton pregnancy~Inborn~The exclusion criteria will be:~APGAR score of less than 5 at 1 minute or less than 7 at 5 or 10 minutes~Admission to the neonatal unit~Major congenital abnormalities~Less than 15 minutes of digital CTG recording from labour available"
2918095|NCT03122795|Experimental|Microbiome transplant|The only arm of the study. Patients suffering from CRSsNP gets microbiome transplants from donors without any sinonasal health problems.
2918096|NCT03122782|Active Comparator|Tranexamic acid (TXA) Group|Subjects in the Tranexamic acd (TXA) group will receive intrauterine instillation of 500 mg (100mg/ml) Tranexamic acid per 500 ml normal salin (distention medium) during Hysteroscopic Myomectomy.
2918097|NCT03122782|Placebo Comparator|Normal Saline (control group)|Subjects in the control group will receive 500 ml intrauterine instillation of normal saline with the distention medium (normal saline) during Hysteroscopic Myomectomy.
2918098|NCT03122769|Experimental|11C-metformin|All participants allocated to the study will be included in this arm
2918099|NCT03122756|Experimental|Group (D)|will include 50 women who will receive intravenous dexamethasone.
2918100|NCT03122756|Placebo Comparator|Group (C)|will include 50 women who will receive intravenous normal saline (0.9 %).
2918101|NCT03122743||Ancillary-Correlative (collection of samples, questionnaires)|Patients undergo collection of serum samples for epinephrine and cortisol levels at baseline and 4 clinical visits. Patients also receive the Self-Perceived Stress questionnaire and the Distress Thermometer questionnaire to measure perceived stress.
2918102|NCT03122730|Experimental|VentaProst|VentaProst (epoprostenol solution for inhalation via custom drug delivery system)
2918103|NCT03122717|Experimental|Gerfitinib + Osimertinib Escalation|"Gerfitinib will administered orally at a pre determine dose daily~Osimertinib will administered orally at a pre determine dose daily"
2918104|NCT03122717|Experimental|Gerfitinib + Osimertinib Reduction|"Gerfitinib will administered orally at a pre determine dose daily~Osimertinib will administered orally at a pre determine dose daily"
2918105|NCT03122704|Experimental|Group B Streptococcus (GBS) screening|Vaginal and anal swab of patients will be screened for GBS screening
2918106|NCT03122691|Placebo Comparator|Placebo Oral Cannabis|Single acute administration of placebo cannabis baked into a brownie
2918107|NCT03122691|Experimental|Low-Dose Oral Cannabis|Single acute administration of cannabis containing 10mg THC baked into a brownie
2918108|NCT03122691|Experimental|High-Dose Oral Cannabis|Single acute administration of cannabis containing 25mg THC baked into a brownie
2918109|NCT03122691|Placebo Comparator|Placebo Vaporized Cannabis|Single acute administration of placebo cannabis via commercial vaporizer
2918110|NCT03122691|Experimental|Low-Dose Vaporized Cannabis|Single acute administration of placebo cannabis containing 5mg THC via commercial vaporizer
2918242|NCT03121755||Sangre Por Salud cohort members|Subjects entered in the Sangre Por Salud Biobank
2918111|NCT03122691|Experimental|High-Dose Vaporized Cannabis|Single acute administration of placebo cannabis containing 20mg THC via commercial vaporizer
2918112|NCT03122678|Experimental|Thiamine Supplementation Group|Patients will receive 200mg thiamine in 50mL of 5% dextrose once daily for 7 days or until discharge from the intensive care unit.
2918113|NCT03122678|Placebo Comparator|Placebo Group|Patients will receive placebo (50mL 5% dextrose) once daily for 7 days or until discharge from the intensive care unit.
2918114|NCT03122665|Active Comparator|Nefopam low dose|Nefopam continuous intravenous infusion at 0.5 mg/ml for three hours.
2918115|NCT03122665|Active Comparator|Nefopam high dose|Nefopam continuous intravenous infusion at 1.0 mg/ml for three hours.
2918116|NCT03122652|Experimental|Terifunomide|
2918117|NCT03122652|Placebo Comparator|Placebo|
2918118|NCT03122639|Active Comparator|Treatment|OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
2918119|NCT03122639|Placebo Comparator|Control|OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
2918120|NCT03122626|Experimental|Experimental Group|The intervention is a group, task-oriented exercise program involving two 1-hour exercise classes per week for 12 weeks. The class involves a seated warm-up, repetitive, progressive practice of functional balance and mobility tasks, and a seated cool down. The warm-up consists of active range-of-motion exercises, aerobic exercise, leg loading, stretching, and sit-to-stand training. The cool-down involves exercises with an emphasis on stretching and relaxation. Tasks are organized in a 3-station circuit completed by participants grouped by overall ability: Superstation 1: walking, aerobic training, and wall work (standing and reaching, wall push-ups); Superstation 2: standing weight shifts, coordinated with stepping and lunging; and Superstation 3: tap-ups, step-ups, and heel/toe raises, hamstring curls, marching-on-the-spot, and mini-squats. Participants are instructed to be physically active by walking in their neighbourhood, practicing the program exercises, or using the stairs.
2918121|NCT03122626|No Intervention|Wait-listed Control Group|The control group will receive usual care which will be monitored and is expected to consist of provision of a home exercise program and information on community resources according to current best practices. At the end of the study period, participants in the control group will be offered to participate in the 3-month exercise program.
2918122|NCT03122613|Active Comparator|Curcumin|Dietary supplements of Curcumin capsules
2918123|NCT03122613|Placebo Comparator|Curcumin Placebo|Identical looking placebo of the active arm
2918124|NCT03122600||vascular surgery group|Elderly patients undergoing vascular surgery in the lower half of the body
2918125|NCT03122587|Sham Comparator|Active Sham Stimulation|Active sham transcranial alternating current stimulation (tACS)
2918126|NCT03122587|Experimental|tACS at 10 Hz|Transcranial Alternating Current Stimulation at 10 Hz
2918127|NCT03122587|Experimental|tACS at 40 Hz|Transcranial Alternating Current Stimulation at 40 Hz
2918128|NCT03122574|Experimental|Treatment|Pure (100%) lavender aromatherapy
2918129|NCT03122574|Placebo Comparator|Placebo Control|Pure (100%) jojoba aromatherapy
2918130|NCT03122574|No Intervention|Standard of care Control|No aromatherapy control group
2918131|NCT03122561|Other|Paracetamol 500 mg tablet at Morning|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at morning
2918132|NCT03122561|Other|Paracetamol 500 mg tablet at Midday|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at midday
2918133|NCT03122561|Other|Paracetamol 500 mg tablet at Night|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at night
2918134|NCT03122548|Experimental|CRS-207 and Pembrolizumab|Treatment cycle is once every 3 weeks. Pembrolizumab: 200 mg administered IV over 30 minutes on Day 1 of each 3 week cycle. CRS-207: starting dose 1×10^9 CFU administered IV over 1 hour on Day 2 of Cycle 1, on Day 1 of Cycles 2, 3, 4; and every 6 weeks thereafter. Treatment cycles will continue up to 24 months as long as there is adequate safety and potential for clinical benefit.
2918135|NCT03122535|Active Comparator|FS-LASIK 70 degree side-cut angle|Each patient will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye.
2918136|NCT03122535|Active Comparator|FS-LASIK 110 degree side-cut angle|Each patient will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye.
2918137|NCT03122522|Experimental|ipilimumab and nivolumab|Pts will receive 2 doses of ipilimumab 3mg/kg + nivolumab 1mg/kg every 3 weeks. Week 6, if pts have achieved a favorable antitumor effect by RECIST will begin maintenance nivolumab alone at 480mg every 4 weeks for 2 doses (week 6 & week 10) & repeat response assessments at week 12. If pts don't achieve a favorable antitumor effect at week 6, pt will get 2 additional doses of ipilimumab + nivolumab every 3 weeks & then will be assessed for response at week 12. If pts haven't achieved a favorable antitumor effect by week 12, if felt in the best interest for the pt as determined by the PI, pts may continue getting additional doses of ipilimumab + nivolumab with response reassessments after every 2 doses. Maintenance nivolumab will continued until unacceptable toxicity or confirmed disease progression. If pts have had an initial clinical benefit from therapy & subsequently experience progressive disease at any time, reinduction with combination ipilimuma+ nivolumab will be allowed.
2918138|NCT03122509|Experimental|durvalumab and tremelimumab plus Radiotherapy (RT)|Patients will receive 1500 mg durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 1500 mg durvalumab q4w starting on Week 16. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice. RT will be initiated within 7 days after the first of durvalumab and tremelimumab.
2918243|NCT03121742|Placebo Comparator|Treatment as usual [TAU] plus assessment|Patients will receive standard care plus assessment.
2918244|NCT03121742|Experimental|Treatment as usual [TAU] plus intervention|Patients will receive standard care plus an ecological momentary intervention.
2918304|NCT03121248|Experimental|WBI - observational - 5|WBI 5 fractions SIB 5 fractions if needed
2977140|NCT02715895|Experimental|Wyeth|Wyeth formula feeding
2918139|NCT03122509|Experimental|durvalumab and tremelimumab plus ablation|Patients will receive 1500 mg durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 1500 mg durvalumab q4w starting on Week 16. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. The ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice. Ablation will be performed within 7 days after the first of durvalumab and tremelimumab.
2918140|NCT03122496|Experimental|durvalumab (MEDI4736) & tremelimumab with SBRT|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks. SBRT delivered to one metastatic site per standard of care using a standard 9Gy x 3 fractions will be given within 2 weeks after the completion of the first cycle of durvalumab (MEDI4736) and tremelimumab. After 4 cycles of durvalumab (MEDI4736) and tremelimumab, patients will then continue with single agent durvalumab (MEDI4736) every 4 weeks until disease progression or unacceptable toxicity or a total of 12 months from date of initial treatment.
2918141|NCT03122483||OSA|Blood biomarker results in subjects with obstructive sleep apnea.
2918142|NCT03122483||Non-OSA|Blood biomarker results in subjects without obstructive sleep apnea
2918143|NCT03122470|Experimental|MRI guided biopsy + TRUS biopsy|Patients will undergo an MRI guided biopsy and standard trans-rectal ultrasonography-guided (TRUS) biopsy. Results will be compared to see which can more accurately diagnose and manage prostate cancer
2918144|NCT03122457|Experimental|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combo|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination gel; daily use for 99 days
2918145|NCT03122444|Experimental|Imipramine|Imipramine will initially be 50mg and this will be increased by 50mg every other day as tolerated to 200 mg.
2918146|NCT03122431|Other|SLE/cutaneous lupus with thalidomide|This subproject includes only one arm of lupus patients with active and refractory cutaneous disease and eligible for Thalidomide 100mg/day for 12 months.
2918147|NCT03122431|No Intervention|Inactive SLE with standard dose of HCQ|This subproject includes 2 arms of lupus patients with inactive disease: one group will be maintained on standard dose of Hydroxychloroquine (400mg/day) and in the other, the dose will be reduced to 400mg 3 times a week for two years.
2918148|NCT03122431|Active Comparator|Inactive SLE with reduced dose of HCQ|This subproject includes 2 arms of lupus patients with inactive disease: one group will be maintained on standard dose of Hydroxychloroquine (400mg/day) for two years and in the other, the dose will be reduced to 400mg 3 times a week (Hydroxychloroquine reduced) for two years.
2918149|NCT03122431|Experimental|Active SLE with initial high dose of HCQ|This subproject includes 2 arms of lupus patients with active disease: one group will be started on standard dose of Hydroxychloroquine (400mg/day) for two years and in the other, the dose will be started at high dose 800mg/day (Hydroxychloroquine high) for three months.
2918150|NCT03122431|No Intervention|Active SLE with standard dose of HCQ|This subproject includes 2 arms of lupus patients with active disease: one group will be started on standard dose of Hydroxychloroquine (400mg/day) for three months and in the other, the dose will be started at high dose 800mg/day (Hydroxychloroquine high) for three months.
2918151|NCT03122418|Experimental|Exercise Study Group|All subjects in this study will receive a personal fitness device and be asked to participate in some routine exercise. Each participant will be compared to their own initial CFQ-R score (to measure quality of life) before and after use of the personal fitness device.
2918152|NCT03122392|Experimental|AMS 800 Artificial Urinary Sphincter|"The AMS 800™ Urinary Control System is an implantable, fluid-filled, solid silicone elastomer prosthesis used to treat urinary incontinence due to reduced outlet resistance (intrinsic sphincter deficiency) following prostate surgery. The AMS 800 Urinary Control System simulates normal sphincter function by opening and closing the urethra, under patient control. When the cuff is closed, urine stays in the bladder.~When the patient wishes to void, he simply squeezes and releases the pump several times. This causes the fluid in the cuff to move into the pressure-regulating balloon . The cuff opens and urine passes through the urethra. The balloon then automatically re-pressurizes the cuff through the pump, within several minutes, the cuff again closes the urethra.~The control pump, which in implanted in the scrotum, is also designed to allow the clinician or patient to deactivate and activate the system without additional surgery."
2918153|NCT03122353|Experimental|Calcipotriene Hydrate and Betamethasone|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
2918154|NCT03122353|Active Comparator|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
2918155|NCT03122353|Placebo Comparator|Placebo|Topical suspension without active ingredient
2918156|NCT03122340|Placebo Comparator|Placebo Group|Oil: 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
2918157|NCT03122340|Experimental|Polyprenol Group|Polyprenols (ROPREN): 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
2918158|NCT03122327||Newly diagnosed MM patients|newly diagnosed MM patients who fulfilled the inclusion criteria for this study
2918159|NCT03122314|Experimental|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solution Bristol-Myers Squibb_UK) intravenous (IV) was given 100 patients
2918160|NCT03122314|Experimental|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
2918161|NCT03122301|Active Comparator|Bupivicaine|Stellate Ganglion Block Injection with bupivicaine
2918162|NCT03122301|Sham Comparator|Saline|Saline injection
2918163|NCT03122288|Experimental|Individualized Cognitive Training|Participants randomized to this arm will receive 20 hours of computerized cognitive training in the two predominate cognitive domains in which they experience deficits that contribute to their HIV-Associated Neurocognitive Disorder diagnosis.
2918164|NCT03122288|Other|No-Contact Control|Participants in this arm will not receive any experimental or sham contact. They will only participate in the Baseline and Posttest assessments.
2918297|NCT03121287|Other|Lung or Esophageal Patients|Patients with lung or esophageal cancer undergoing conventionally-fractionated radiation therapy. Interventions to be administered include: Imaging Biomarkers using Volumetric CT Scans, Pulmonary using Pulmonary Function Test & 6Minute Hall Walk, Imaging using Cardiac MRI, Specimen Collection using Blood Draws.
2918305|NCT03121248|Active Comparator|WBI - observational - 15|WBI 15 fractions SIB 15 fractions if needed
2918165|NCT03122275|Experimental|Stepwise intervention|"Stepwise approach, with increasing complexity and cost, to improve adherence to organized cervical cancer screening, implemented through three steps:~step 1a - customized text message invitation; step 1b - customized automatic phone call invitation; step 2 - secretary phone call; step 3 - health professional phone call and face-to-face appointment.~Intervention stops whenever the participant adheres to organized screening or after undergoing the complete stepwise intervention."
2918166|NCT03122275|Active Comparator|Written Letter|Comparator will be the standard of care of invitation to cervical cancer screening: written letter
2918167|NCT03122262|Active Comparator|Tenofovir Alafenamide|Descovy: Tenofivir alafenamide tablets 25mg daily, Emtricitabine 200mg daily
2918168|NCT03122262|Active Comparator|Dolutegravir|Dolutegravir 50mg daily, Truvada 500mg daily
2918169|NCT03122262|Active Comparator|Atripla|Atripla: Efavirenz 600mg daily, Tenofovir Disoproxil Fumarate 300mg daily, Emtricitabine 200mg daily
2918170|NCT03122249|Other|OASIS|Patients that meet the eligibility criteria will be enrolled in the study and will receive the advanced cancer symptom management intervention
2918171|NCT03122236|Active Comparator|Standard walking with tDCS dosage A|Neurorehabilitation of Standard Walking and Transcranial Direct Current Stimulation (tDCS) dosage A
2918172|NCT03122236|Active Comparator|Complex walking with tDCS dosage A|Neurorehabilitation of Complex Walking and Transcranial Direct Current Stimulation (tDCS) dosage A
2918173|NCT03122236|Active Comparator|Complex walking with tDCS dosage B|Neurorehabilitation of Complex Walking and Transcranial Direct Current Stimulation (tDCS) dosage B
2918174|NCT03122223|Active Comparator|ALVAC-HIV + 100mcg Protein/MF59 + Placebo|100 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.5 mL100 mcg Protein/MF59 and 0.75 mL placebo injection in the right deltoid on Months 3 and 6.
2918175|NCT03122223|Active Comparator|ALVAC-HIV + 100mcg Protein/AS01(B) + Placebo|100 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.75 mL100 mcg Protein/AS01(B) and 0.5 mL placebo injection in the right deltoid on Months 3 and 6.
2918176|NCT03122223|Active Comparator|ALVAC-HIV + 20mcg Protein/AS01(B) + Placebo|100 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.75 mL 20 mcg Protein/AS01(B) and 0.5 mL placebo injection in the right deltoid on Months 3 and 6.
2918177|NCT03122223|Placebo Comparator|Placebo|20 participants will receive 1 mL of the placebo injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.5 mL of the placebo injection and 0.75 mL of a separate placebo injection in the right deltoid on Months 3 and 6.
2918178|NCT03122210|Other|Control group|In this group, the nursing staff administed oxygen supply if necessary with the usual pratice in care unit for 24 hours after myocard infarction. In this group the SpO2 was recorded any time with FreeO2 device - recording mode.
2918179|NCT03122210|Other|FreeO2 with SpO2 target = 92%|In this group oxygen flow was automatically adjusted with the FreeO2 device (automatic titration of oxygen flow) to achived SpO2 target set by clinicial for 24 hours after myocard infarction. In this group, the SpO2 target was set at 92%.
2918180|NCT03122210|Other|FreeO2 with SpO2 target =97%|In this group oxygen flow was automatically adjusted with the FreeO2 device (automatic titration of oxygen flow) to achived SpO2 target set by clinicial for 24 hours after myocard infarction. In this group, the SpO2 target was set at 97%.
2918181|NCT03122197|Experimental|Letrozole|Letrozole doses range includes 2.5, 3, 6, 9, and 12 mg daily.
2918182|NCT03122184|Experimental|Positive Psychology + Goal Setting|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
2918183|NCT03122184|Active Comparator|Health Behavior Education|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior (physical activity, medication adherence, diet, stress reduction) and assign an activity related to one health behavior each week.
2918184|NCT03122171|Active Comparator|Prosthesis|
2918185|NCT03122171|Experimental|No Prosthesis|
2918186|NCT03122158|Active Comparator|Major depressive disorder|In this group, adolescents with major depressive disorder will be recruited. It was planned to include 30 participants.Escitalopram treatment will be given to those with Major Depressive Disorder with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
2918187|NCT03122158|Active Comparator|Anxiety disorders|In this group, adolescents with anxiety disorders will be recruited. It was planned to include 30 participants. Additionally, the specification of which anxiety disorders are assigned to the participants will also be provided. Escitalopram treatment will be given to participants with anxiety disorders with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
2918188|NCT03122145|Experimental|Healthy Volunteers|This study will involve a single 90-minute visit. All women under the age of 62 will be asked to complete a pregnancy test as part of the screening process during to radiation exposure. Eligible participants will then undergo testing to determine their individualized Maximum Expiratory Pressure (MEP), maximum inspiratory pressures (MIP), voluntary and reflexive cough testing, tongue pressure testing and a comprehensive instrumental swallowing evaluation (that will include either videofluoroscopy, manometry, or simultaneous swallowing and manometry study). The entire duration of the exam will be under 90 minutes and the participant will be free to leave at any point during the examination.
2918189|NCT03122132||Spanish cohort with HCV treated with DAA|Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ritonavir 8 weeks and dasabuvir 8 weeks
2918190|NCT03122119|Experimental|Platelet Rich Plasma Joint Injection|Venous blood will be drawn from the patient receiving injection treatment. It will be spun down to form PRP and reinjected back into the SI joint.
2918191|NCT03122119|Active Comparator|Corticosteroid Injection|Corticosteroid injection including lidocaine and bupivicaine for local anesthetic
2918192|NCT03122119|No Intervention|Non-invasive Therapies|This may include no intervention, home remedies such as ice, heat, and massage, over the counter non-steroid anti-inflammatory drugs, physical therapy, osteopathic manipulative medicine, and massage therapy.
2918193|NCT03122106|Experimental|Personalized neoantigen DNA vaccine|"Vaccines will be weeks 1, 5, 9, 13, 17, and 21. Vaccines will occur within +/- 1 week with at least 3 weeks between vaccines. All study injections will be given intramuscularly using TDS-IM system. At each vaccination time point, patients will receive 2 injections of the neoantigen DNA vaccine, 1 injection into each deltoid or lateralis.~Minimum observation of 30 minutes. Vital signs will be taken at 30-45 minutes post-immunization. The injection sites will be inspected for evidence of local reaction. Follow up on subject well-being will be performed by telephone on the 1st or 2nd day following each injection. -Post-vaccination follow-up visits are at Week 25 ± 7 days and Week 77 ± 14 days. Additional follow-up visits or telephone contact will be scheduled at Week 129 and annually thereafter if the patient is alive and available for follow-up.~At intervals throughout the study (both before and after vaccination) subjects will have blood drawn for immunologic assays."
2918194|NCT03122093||CD-DIET Gluten-Free Diet Group|This former randomized control trial (RCT) group received a gluten-free education and continued support from a dietitian for a 1-year period via the CD-DIET Study (NCT01566110)
2918195|NCT03122093||CD-DIET Gluten-Containing Diet Group|This former RCT group did not receive a gluten-free education and 1-year support from a dietitian via the CD-DIET Study (NCT01566110), but rather a single gluten-free education session upon exiting the study.
2918196|NCT03122093||CD-DIET Ineligibles/Refusals|This group contains T1D/CD individuals who were not eligible or refused to join the CD-DIET RCT (e.g. already self-selected their diet or had no interest in being randomized). These individuals were instead redirected to the clinical route.
2918197|NCT03122080|Active Comparator|Electroacupuncture group|electroacupuncture+standard care
2918198|NCT03122080|Placebo Comparator|Control A group|placebo acupuncture+standard care
2918199|NCT03122080|Other|Control B group|standard care
2918200|NCT03122067|Experimental|oxytocin group|male participants with oxytocin treatment
2918201|NCT03122067|Placebo Comparator|placebo group|male participants with placebo treatment
2918202|NCT03122054|Other|Group L (n:88)|patients treated surgically with laparoscopic cholecystectomy immediately
2918203|NCT03122054|Other|Group D (n:88)|patients first treated medically and than treated surgically with delayed (4-8 weeks later) laparoscopic cholecystectomy
2918204|NCT03122041|Experimental|SITA|Sitagliptin (SITA) Lifestyle intervention and sitagliptin 100mg per day for 12 weeks
2918205|NCT03122041|Experimental|CON|Controls (CON) Lifestyle intervention
2918206|NCT03122028|Experimental|LAmbre closure system|
2918207|NCT03122015|Experimental|Therapeutic clown distraction|The child will interact with the therapeutic clown throughout the painful procedure. The types of distraction interventions will be determined by the clown according to the child's age, culture and behavior. The clown can use different distraction activities such as magic, humor, visualization and play. According to various writings, the presence of the clown before the procedure varied between two to 20 minutes. In our study, the presence of the clown with parents and children will be about 10 minutes before the procedure and while the nurse performs the procedure until the child leaves the room. The distraction performed by a therapeutic clown is used in St. Justine' Hospital. Indeed, a team of therapeutic clowns is present in the hospital four times a week to distract the children. However, this procedure is not applied routinely in painful procedures and no study has evaluated its usefulness or effect.
2918208|NCT03122015|No Intervention|Standard care|
2918209|NCT03122002||Patients With Ischemic Stroke|The patients with all types of ischemic stroke including TIA, small vessle diseases, MCAO, and ect. These patients will be recorded their emergency treatment, medical history, details about their drug therapy, results of their routine blood test and image scan, and whether they receive intravascular therapy in time or not.
2918210|NCT03122002||Healthy Control|The patients admitted to hospital for symptoms like dizzness and headache, which later proved to be not related to cerebral vascular diseases, would be treated as control. Their medical history and the results of their routine blood test and image scan will be recorded.
2918211|NCT03121989|Active Comparator|Hyperpolarized Pyruvate (13C) Injection|"The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.~After the injection research, MRI will be done and images evaluated."
2918212|NCT03121989|Placebo Comparator|Coil Testing|Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that acts as test object. It provides a signal that is used to ensure that the MRI system is functioning properly.
2918213|NCT03121976|Experimental|Ultrasound|Femoral catheters inserted using ultrasound only
2918214|NCT03121976|Active Comparator|Ultrasound + Nerve Stimulation|Femoral catheters inserted using ultrasound with nerve stimulation
2918215|NCT03121963|Experimental|Treatment Group|A combination regimen of oxycodone 5 mg Q6hr PRN, acetaminophen 650 mg Q6hr, celecoxib 400 mg BID post-operatively x 2 weeks, and gabapentin 400 mg loading dose, 300 mg TID to be started 1 week pre-operatively then continued post-operatively x 2 weeks.
2918216|NCT03121963|Active Comparator|Control Group|A single medication regimen of hydrocodone-acetaminophen 7.5 mg Q6hr PRN post-operatively x 2 weeks.
2918217|NCT03121950|Experimental|Dance in dementia|examine if participating in a dance class improves mobility and/or cognition in individuals with dementia.
2918218|NCT03121950|Experimental|Music and dementia|examine if listening to music improves mobility and/or cognition in individuals with dementia.
2918219|NCT03121937|Experimental|Mobile App|Participants will receive a mobile app to be used during psychotherapy that syncs information with the participant's therapist from sessions.
2918220|NCT03121937|No Intervention|Treatment as Usual|Participants will receive treatment as usual with aspects of the mobile app available through paper-based worksheets.
2918221|NCT03121924|Experimental|Immediately oocyte denudation|"After the retrieval , sybling oocytes were assigned to one o more recipient and then ,the oocytes were randomized in two arms .~The first arm is the immediately denudation and immediately ICSI of the oocytes, and in the second arm the oocyte are denuded and injected after 4 hours from the pick up ."
2918222|NCT03121924|Experimental|Delayed oocyte denudation|"After the retrieval , sybling oocytes were assigned to one o more recipient and then ,the oocytes were randomized in two arms .~In this arm, the oocyte are denuded and injected after 4 hours from the pick up ."
2918298|NCT03121274|Active Comparator|Early pushing during vaginal delivery|patients are allowed to push within one hour after full cervical dilatation whether the vertex was visible or not
2918223|NCT03121911|Experimental|Group 1 - Interval Training (IT)|"All participants will be submitted to several exams of cardiac and pulmonary functions. Then, group 1 (IT) will participate in a physical training program for 12 weeks and will be re-evaluated after this period. After discharge, they will be monitored for an aditional period of 6 months, with returns every two months to measure the energy expenditure (accelerometer). At the end of this period all the tests will be repeated.~Each exercise session will last for 60 minutes and will be divided into three parts as follows: warm up (10 minutes); interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold found in CPET (70%, 80%, 100% and 110%); cooling down (10 minutes)."
2918224|NCT03121911|Experimental|Group 2 - IT + IMT|"All participants will be submitted to the same evaluations before and after training, and 6 months after discharge. Group 2 (IT + inspiratory muscle training (IMT)) will participate in a 12 week physical training program. After discharge, they will be monitored for an aditional period of 6 months, with returns every two months to measure the energy expenditure.~The group 2 will perform the IMT session at the end of the warm-up exercises, prior to the beginning of the IT on a cycloergometer. IMT session consists of 2 series of 12 inspirations with a 60% of MIP. Participant will be asked to inhale quickly and deeply, as quickly as possible, with a 2 minutes interval between series. All the others exercises will be identical between group 1 and 2."
2918225|NCT03121911|No Intervention|Group 3 - Absence of rehabilitation|Group 3 (absence of rehabilitation) will be made up of those patients who for any reason do not agree to participate in the rehabilitation program, such as those who do not live in the city, and will remain without intervention. All participants in this group will perform all the evaluations procedures, comprised of: heart rate variability, hematological and biochemical profile, erythrocytes membrane deformability and stability, inflammatory markers, respiratory pressures, plethysmography, spirometry, carbon monoxide diffusion capacity, ankle brachial index, electrical bioimpedance, echocardiogram, quality of life questionnaires (SF-36 and MacNew QLMI), cardiopulmonary exercise testing and constant load tests.
2918226|NCT03121872|Experimental|Root Coverage Surgery with T-PRF|"Multiple gingival recessions were treated by Titanium prepared PRF (T-PRF) in 16 patients.~The T-PRF membrane that was procured was placed in the defect area 1 mm beyond the enamel-cement border.. The T-PRF was fixed in the receiver area by a mattress stitch through the apical aspect using 5-0 monofilament absorbable sutures. The flap was stitched in a manner that completely covered the graft in the coronal aspect. Thereafter, the graft was fixed to the flap on the coronal aspect with horizontal mattress sutures. Compression was applied to the receiver area with serum-impregnated sterile gauze for approximately 5 minutes, and then periodontal paste was placed onto the surgery site."
2918227|NCT03121872|Active Comparator|Root Coverage Surgery with CTG|"Multiple gingival recessions were treated by Connective Tissue Graft (CTG)in 18 patients.The CTG width was measured to include 1 mm beyond the root surface defects in the receiver area. Following anaesthesia of the palate, the borders of the start and finish incisions were marked. Subepithelial connective tissue that was 1.5-2 mm thick and excluded the periosteum was removed and maintained in physiological saline. The palate was stitched with 4-0 absorbable sutures (Pegalak, Doğsan, Turkey) and covered with a periodontal paste.~Before placing the connective tissue in the receiver area, the fat and glandular tissues and the band-shaped epithelium on the connective tissue were removed using scissors."
2918228|NCT03121859|Active Comparator|Neck stabilization exercise|The patients who had only neck stabilization exercise
2918229|NCT03121859|Active Comparator|TENS+ neck stabilization exercise|The patients who had both TENS and neck stabilization exercise
2918230|NCT03121859|Active Comparator|IFC+ neck stabilization exercise|The patients who had both interferential current therapy and neck stabilization exercise
2918231|NCT03121846|Experimental|apatinib group|apatinib 500mg po qd, 28 days for a cycle.
2918232|NCT03121833|Experimental|Endostar & AIM regimen / GT regimen|Endostar & AIM regimen / GT regimen; Endostar 15mg, into 500ml 0.9% sodium chloride intravenous infusion of 3 ~ 4h, d1 ~ d14, 21-28 days for a cycle; AIM regimen is Pirarubicin (THP) + Ifosfamide (IFO), the specific dose is IFO 8-12g / m2, given 4-5 days; THP 75mg / m2, given 1-2 days; 21-28 days for a cycle; GT regimen is Docetaxel (TXT) + Gemcitabine (GEM), specific dose of Gemcitabine 1000mg / m2 (D1, D8) and Docetaxel 75mg / m2 (D8); 21-28 days for a cycle; Preferred AIM regimen, AIM regimen chemotherapy failure or can not tolerate anthracycline chemotherapy in patients with GT regimen.
2918233|NCT03121833|Placebo Comparator|Placebo & AIM regimen / GT regimen|Placebo + AIM regimen / GT regimen; Placebo is 500ml 0.9% sodium chloride, Intravenous 3 ~ 4h, d1 ~ d14, 21-28 days for a cycle; The chemotherapy regimen is the same as the experimental group.
2918234|NCT03121820|Experimental|Memantinol tablets, 20 mg|"Treatment A: a single oral dose of memantin 20 mg film-coated tablet (JSC GEROPHARM, Russia - test)"
2918235|NCT03121820|Active Comparator|Akatinol Memantine® tablets, 20 mg|Treatment B: a single oral dose of memantin 20 mg film-coated tablet (Merz Pharma GmbH & Co. KGaA, Germany - reference)
2918236|NCT03121807|Experimental|Home parenteral nutrition|"Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.~Patients received 85 mg/m2 oxaliplatin and 200 mg/m2 leucovorin as a 2-h intravenous infusion on day 1, followed by 2400 mg/m2 5Fluorouracil as a 46-h continuous infusion. This regimen is repeated every 14 days as a cycle."
2918237|NCT03121794||Low BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI 18.5 - 25 kg/m2
2918238|NCT03121794||Moderate BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI 30-35 kg/m2 will receive ultrasound exam.
2918239|NCT03121794||High BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI > 40 kg/m2 will receive ultrasound exam.
2918240|NCT03121781|Active Comparator|CPAP with binasal prongs|Edi will be recorded while the infant is on nasal CPAP with the binasal prongs, with a PEEP of 5-8 cm H2O, for 2 hours. Then, the infant will be switched the interface to the RAM cannula, with a PEEP 2 cmH2O higher, during 2 hours.
2918241|NCT03121781|Active Comparator|CPAP with RAM cannula|Edi will be recorded while the infant is on nasal CPAP with the RAM cannula with a PEEP 2 cmH20 higher than the levels the infant was receiving before starting the study protocol, for 2 hours. Then, the infant will be switched the interface to the binasal prongs with a PEEP between 5-8 cmH2O, during 2 hours.
2918245|NCT03121729|Experimental|enhanced recovery after surgery|"enhanced recovery after surgery includes:~Multimodal analgesia~Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet~Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally B: Remove catheter early~Early activity~Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken"
2918246|NCT03121716|Experimental|SHR-1210, gemcitabine and cis-platinum|Subjects receive SHR-1210 200mg (Day 1) and gemcitabine 1000mg/m2 (Day 1 and Day 8)and cis-platinum 80mg/m2 (Day 1) of each 21-day cycle for at most 6 cycles, followed by SHR-1210 200mg every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
2918247|NCT03121703|Experimental|lumbar stabilization exercises group|diverse lumbar stabilization exercises
2918248|NCT03121703|Other|trunk muscle strengthening exercise|trunk muscle strengthening exercise
2918249|NCT03121690|Experimental|prednisone|prednisone 40 mg/day for 7 days
2918250|NCT03121690|Experimental|placebo|5ml saline /day for 7 days
2918251|NCT03121677|Experimental|Nivolumab/Poly-ICLC/Vaccine/+/- Rituximab|"All cycles are 4 weeks (wks), with nivolumab every 2 wks during Cycles 1-6 & every 4 wks during Cycles 7-12 & vaccine on Cycle 1 Days 1, 4, 8, 15; Cycle 2 Day 1; and then on Day 1 of Cycles 4, 6, 8, 10, 12~After 2 cycles, restaging will be performed, & patients with CR, PR, or SD will continue on nivolumab + vaccine. Patients with evidence of PD will initiate anti-CD20 mAb therapy (drug to be determined by the treating physician) weekly for 4 wks during Cycle 3, followed by a dose on Day 1 of every other cycle (Cycles 6, 8, 10, and 12).~After 6 cycles, restaging will be performed again, and patients with CR, PR, or SD will continue nivolumab + vaccine. Patients with PD at that time point (but not treated with anti-CD20 mAb therapy thus far on this protocol) will initiate anti-CD20 mAb (drug to be determined by the treating physician) therapy weekly for 4 wks during Cycle 7, followed by a dose Day 1 of Cycles 10 & 12 & 2 additional doses 8 wks apart."
2918252|NCT03121664|Experimental|Cohort 1|
2918253|NCT03121651|Experimental|RL-adaptive application|"Dyad is comprised of individual with disability (spina bifida or cerebral palsy) and the respective parent/legal guardian (also referred to as caregivers).~Young adult will use the RL-adaptive support application that we are developing to help manage medications."
2918254|NCT03121638|Active Comparator|VARIVAX|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm
2918255|NCT03121638|Active Comparator|ZOSTAVAX|Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm
2918256|NCT03121638|Experimental|NBP6081|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
2918257|NCT03121638|Experimental|NBP6082|Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
2918258|NCT03121638|Experimental|NBP6083|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
2918259|NCT03121625|Experimental|Autologous CAR-T cells|Patients will be be treated with autologous CAR-T cells.
2918260|NCT03121612|Experimental|Dolphin CPAP|CPAP machine with oxygen intake and an on-board air compressor, and integrated blender and humidifier, delivering heated humidified blended gases through a Fisher-Paykel nasal mask. [Also includes built-in Massimo pulse oximeter, though this is not used for this study, to prevent differential measurement error in SpO2 measurement]
2918261|NCT03121612|Active Comparator|Fisher-Paykel CPAP|Fisher-Paykel (F&P) CPAP machine with separate oxygen and medical air intakes, with third-party FP-compliant blender, and F&P blender, delivering heated humidified blended gases through a Fisher-Paykel nasal mask.
2918262|NCT03121599|Experimental|18F-FLT PET/CT|"Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-Lthymidine) PET/CT (Positron Emission Tomography/ Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. [18F] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) [18F] FLT by intravenous infusion."
2918263|NCT03121586|Experimental|Drug - Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg, + background antipsychotic, taken once daily by mouth
2918264|NCT03121573|Other|intervention|medication: duloxetine 30 to 60 mg tablets by mouth, QD to BID.
2918265|NCT03121560|Active Comparator|Hysteroscopy|Women with ≥ 18 with abnormal bleeding (post-menopausal menorrhagia or metrorrhagia), managed at bleeding clinic. Each women will undergo an hysteroscopy and a hysterosonography and will be her own control.
2918266|NCT03121560|Experimental|Hysterosonography|Women with ≥ 18 with abnormal bleeding (post-menopausal menorrhagia or metrorrhagia), managed at bleeding clinic. Each women will undergo an hysteroscopy and a hysterosonography and will be her own control.
2918267|NCT03121547|Placebo Comparator|Placebo oral tablet|One inert calcium tablet is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
2918268|NCT03121547|Experimental|Tramadol Hydrochloride 100 mg Extended Release Oral Tablet|One tablet containing 100 milligrams (mg) Mandolgin Retard, Sandoz is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
2918269|NCT03121547|Experimental|Tapentadol 50 mg Oral Tablet|One tablet containing 50 milligrams (mg) Palexia Depot, Grünenthal is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
2918299|NCT03121274|Active Comparator|Delayed pushingduring vaginal delivery|patients here are asked not to push for maximum of 3 hours or start pushing when the vertex was visible
2918300|NCT03121261|Experimental|0.5% levobupivacaine with 0.015% clonidine|0.5% levobupivacaine 15 mg with 0.015% clonidine 50 mcg and 40% glucose 0.5 ml will be preformed as subarachnoid block
2918301|NCT03121261|Active Comparator|0.5% levobupivacaine with 0.9% saline|0.5% levobupivacaine 15 mg with 0.33 ml of 0.9% saline and 40% glucose 0.5 ml will be preformed as subarachnoid block
2918270|NCT03121534|Experimental|Blinatumomab|"Induction phase consists of a single cycle of Blinatumomab therapy. Blinatumomab initiated at 9 mcg/day from day 1-7, followed by 28 mcg/day from day 8-14 (week 2). This is followed by 112 mcg/day from day 15-56. The induction cycle is 8 weeks in duration.~Patients who achieve an objective response after induction are eligible to receive one further cycle of Blinatumomab consolidation, delivered at 112 mcg/day by continuous vein infusion from day 1-28 (total of 4 weeks). Consolidation may be initiated 4-8 weeks after completion of the induction infusion of Blinatumomab.~Dexamethasone 20 mg by mouth or vein 24 hours prior to and within 1 hour before start of treatment in each treatment cycle. If treatment is interrupted for >4 hours at any point, Dexamethasone treatment given before re-initiation of therapy. Dexamethasone 8 mg by mouth or vein every 8 hours given for 48 hours at the commencement of the infusion and after each dose increment."
2918271|NCT03121521|Experimental|melatonin|Melatonin 10mg/d p.o.
2918272|NCT03121521|Placebo Comparator|placebo|placebo 10mg/d p.o.
2918273|NCT03121508|Other|TODAY Project|All participants will attend individualized self-management sessions led by an occupational therapist. The classes will focus on promoting modifying daily activities, habits, roles, and routines to promote healthy lifestyles for individuals with type 2 diabetes.
2918274|NCT03121495|Active Comparator|Second forward view exam|During withdrawal, the colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed.
2918275|NCT03121495|No Intervention|Conventional withdrawal exam|No intervention additional to the conventional withdrawal examination during withdrawal
2918276|NCT03121482|Active Comparator|HFNC alone|Control group
2918277|NCT03121482|Experimental|HFNC and NIV|
2918278|NCT03121469|Experimental|Per-Operative Radiotherapy|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
2918279|NCT03121456|Experimental|18F-FDG PET SCAN|"REALIZATION OF INITIAL 18F-FDG PET SCAN (PRE THERAPEUTIC), THEN BETWEEN CYCLE 2 DAY 10 AND CYCLE 3 DAY 1~MRI DIFFUSION REALIZATION OF INITIAL MRI DIFFUSION WITHIN 7 DAYS AFTER INITIAL 18F-FDG PET SCAN, THEN WITHIN 7 DAYS AFTER 18F-FDG PET SCAN 1."
2918280|NCT03121443||Patient position|Perfusion index
2918281|NCT03121430|Experimental|Group A|subjects using the drug eluting peripheral vascular stent system
2918282|NCT03121430|Active Comparator|Group B|subjects using the Nitinol Stent System (Cordis Corporation)
2918283|NCT03121417|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unexpected toxicity
2918284|NCT03121404||Cirrhosis Patient|Patients will be identified from the transplant list. Inclusion criteria will be all subjects with cirrhosis of any etiology who will undergo liver transplantation. . Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery. For the cirrhotic patients this includes hand grip test and dual energy x-ray absorption (DEXA).
2918285|NCT03121404||Healthy Controls|Controls will be identified from the abdominal surgery operating room lists at Cleveland Clinic. Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery which will not include DEXA or hand grip test.
2918286|NCT03121391|No Intervention|Control|The medical intensive care unit in four hospitals will comprise the clusters. All four clusters begin the study under the control condition. Ventilator withdrawal is conducted by the usual personnel in those units. Data is collected through observation of the process and the respiratory comfort of the enrolled patients. Each cluster is randomly selected to sequentially cross over to the intervention. The remaining clusters continue with usual care (control) until selected for crossover.
2918287|NCT03121391|Active Comparator|Intervention|Each cluster is randomly selected to sequentially crossover to the intervention. When crossed over to the intervention the assigned intensive care nurse conducts the ventilator withdrawal according to the algorithm. The algorithm is informed by an objective measure of patient respiratory comfort. Data is collected through observation of the process and the respiratory comfort of the enrolled patients.
2918288|NCT03121378||Hip arthroplasty with bone cement|Patients undergoing hip replacement surgery with bone cement use: blood samples taken before cement use and after cement prosthesis fixation.
2918289|NCT03121378||Non cement hip arthroplasty|Patients undergoing hip replacement surgery without bone cement. Blood samples taken before bone reaming and after implantation of femoral prosthesis.
2918290|NCT03121365|Active Comparator|Standard/Board Book Arm|Parent-infant dyads randomized to the standard/board book arm will receive developmentally appropriate early reader board books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
2918291|NCT03121365|Experimental|Digital/E-Book Arm|Parent-infant dyads randomized to the digital/e-book arm will receive developmentally appropriate e-books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
2918292|NCT03121352|Experimental|Carboplatin + Nab-paclitaxel + Pembrolizumab|Combination therapy of Carboplatin, Nab-paclitaxel, and Pembrolizumab
2918293|NCT03121339|Active Comparator|Treatment A - Fasting Condition|Radio-labeled VXA-A1.1 H1 Tablet Vaccine (small) and VXA-A1.1 H1 Tablet Vaccine (large) will be administered to fasted subjects.
2918294|NCT03121339|Active Comparator|Treatment B - Fed Condition|Radio-labeled VXA-A1.1 H1 Tablet Vaccine (small) and VXA-A1.1 H1 Tablet Vaccine (large) will be administered to subjects with a small snack.
2918295|NCT03121313|Experimental|Maintenance|"Eligible patient will be given maintenance tegafur-uracil for one year.~Dose of tegafur-uracil will be based on patient's body surface area (BSA):~BSA < 1.5 m2: tegafur-uracil 300 mg/day (1 capsule three times a day)~BSA ≥ 1.5 m2: tegafur-uracil 400 mg/day (2 capsules twice a day) Tegafur-uracil will be started after patient has complete the adjuvant radiotherapy and been enrolled into the study."
2918296|NCT03121300|Other|High Risk Lung Cancer Patients|
2918302|NCT03121248|Experimental|WBI - randomized - 5|WBI 5 fractions SIB 5 fractions if needed
2918303|NCT03121248|Active Comparator|WBI - randomized - 15|WBI 15 fractions SIB 15 fractions if needed
2918306|NCT03121248|Experimental|WBI + LNI - randomized - 5|WBI 5 fractions SIB 5 fractions if needed LNI 5 fractions
2918307|NCT03121248|Active Comparator|WBI + LNI - randomized - 15|WBI 15 fractions SIB 15 fractions if needed LNI 15 fractions
2918308|NCT03121248|Experimental|WBI with LNI - observational - 5|WBI 5 fractions SIB 5 fractions if needed LNI 5 fractions
2918309|NCT03121248|Active Comparator|WBI with LNI - observational - 15|WBI 15 fractions SIB 15 fractions if needed LNI 15 fractions
2918310|NCT03121248|Experimental|thoracic wall irradiation (TWI) +/- LNI - observational - 5|TWI 5 fractions SIB 5 fractions if needed LNI 5 fractions
2918311|NCT03121248|Active Comparator|TWI +/- LNI - observational - 15|TWI 15 fractions SIB 15 fractions if needed LNI 15 fractions
2918312|NCT03121222|Placebo Comparator|Lactose|The placebo group received orally two lactose tablets per day for 30 days. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption.
2918313|NCT03121222|Experimental|N-acetylcysteine|The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption.
2918314|NCT03121196||deprived women|Two groups of women will be compared deprived women and non-deprived women
2918315|NCT03121196||non-deprived women|Two groups of women will be compared deprived women and non-deprived women
2918316|NCT03121183||Patients who have undergone an extraction of implantable pace|
2918317|NCT03121170|Experimental|ESWT during PD|For women with primary dysmenorrhea, they have new devise Extracorporeal Shock Wave Therapy to treat. The dose is 15 hertz, 1.8-2.2bar and total 5000 frequencies approximately. The time is menstrual cycle first one and third day, and the therapy divide into two times.
2918318|NCT03121170|Experimental|ESWT before PD|For women with primary dysmenorrhea, they have new devise Extracorporeal Shock Wave Therapy to treat. The dose is 15 hertz, 1.8-2.2 bar and total 5000 frequencies approximately. The time start from the 5th and 7th day before the estimated first day of menstrual cycle and all therapy time consuming need 15 minutes.
2918319|NCT03121170|Placebo Comparator|hot compress paste|In hot compress paste group , the women with primary dysmenorrhea stick the hot compress paste on their belly autonomously.
2918320|NCT03121157|Experimental|Intervention|The intervention group will receive two sessions of computer-delivered motivational interviewing via CIAS software programmed to target adherence to medications. The intervention group will also receive text messaged adherence reminders between sessions. Both the computer-delivered sessions and text messages will be tailored to the participant using ecological momentary assessment.
2918321|NCT03121157|No Intervention|Control|Control participants complete CIAS-delivered asthma education modules matched for length, location, and method of delivery of the intervention session. Control participants complete each module at their own pace and then complete a short quiz to assess their knowledge. Control participants also receive text messages between intervention sessions. Message content is the same for all control participants and contains general facts about asthma (not tailored). Message timing is not tailored and is sent at the same time every day (4:00 PM--time chosen to avoid AM and PM medication times but to not interfere with sleep and school activities).
2918322|NCT03121131|Other|Accurate Clinical Exam Findings|Radiologists will be provided with accurate clinical exam data.
2918323|NCT03121131|Other|Inaccurate Clinical Exam Findings|Radiologists will be provided with purposefully incorrect clinical exam data
2918324|NCT03121131|Other|No Clinical Exam Findings|Radiologists will be not be provided with any clinical exam data
2918325|NCT03121118||Scan opportunity|40 dyads comprised of individuals with Mild Cognitive Impairment and a study partner who is either a family member or kin-like friend.
2918326|NCT03121118||Comparison group|40 dyads comprised of individuals with Mild Cognitive Impairment and a study partner who is either a family member or kin-like friend.
2918327|NCT03121092|No Intervention|Discontinue ACEI or ARB|Patients in this group will not take the ACE or ARB 24 hours prior to their procedure.
2918328|NCT03121092|Active Comparator|Continue ACEI or ARB|Patients in this group will take an ACE or ARB on the day of surgery.
2918329|NCT03121079|Experimental|Interferon alpha group|The patients in arm will be receive interferon alpha injection (3 million U/time)twice a week, as the intervention since the third month after HLA-identical transplantation.
2918330|NCT03121066|Active Comparator|Experimental group|Transcranial Magnetic Stimulation + Conventional intervention
2918331|NCT03121066|Sham Comparator|Sham control group|Sham Transcranial Magnetic Stimulation + Conventional intervention
2918332|NCT03121066|No Intervention|Non TMS Control group|Conventional intervention alone
2918333|NCT03121053|Active Comparator|sodium bicarbonate|250ml 1.4% sodium bicarbonate 1 h before TAVR
2918334|NCT03121053|Active Comparator|hypotone saline|0.65% sodiumchloride 1 ml/kg/h for 12 h before and 12 h after TAVR
2918335|NCT03121040|Experimental|Subjects ingested VAAM® for 10 weeks|Ten young athletes ingested Vespa amino acid mixture (VAAM®) for 10 weeks, divided into different meter race including 1500-, 800- and 400-meter races.
2918336|NCT03121040|Experimental|Subjects ingested VAAM® for 6 weeks|Ten young athletes ingested Vespa amino acid mixture (VAAM®) for 6 weeks, divided into different meter race including 1500-, 800- and 400-meter races.
2918337|NCT03121040|No Intervention|Subjects ingested nothing|Ten young athletes before ingesting Vespa amino acid mixture (VAAM®) , divided into different meter race including 1500-, 800- and 400-meter races.
2918338|NCT03121014|Experimental|Patient Treatment|Patients will receive fludarabine 40 mg/m2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2, IV busulfan targeting a 4800μM/min/ day from day -5 through day -2, and ATG (Thymoglobulin®) at 0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1 (Only for recipients of stem cells from unrelated or mismatched donors). In addition to the above conditioning regimen all patients will receive TMI at a dose of 3Gy on days -3, -2 and -1. On day 0, the stem cell product will be infused according to BMT unit policy. Graft versus host disease (GVHD) prophylaxis will consist of administration of tacrolimus and methotrexate. Post-transplant evaluation will be done as per standard care with study data collected at day 30, 60, 90, 180, 365 and 2 years.
2918872|NCT03117309|Experimental|PART B: Nivolumab + Ipilimumab|Nivolumab 3mg/kg and Ipilimumab 1mg/kg; Nivolumab 360mg
2918339|NCT03121001|Experimental|Subject treatment|Patients will receive the following conditioning regimen: ATG, fludarabine (6 days before stem cell infusion), cyclophosphamide, and total body irradiation. The stem cell product will be infused according to BMT unit policy. Patients will also receive GVHD prophylaxis which will consist of cyclophosphamide, sirolimus, and mycophenolate mofetil according to the protocol. Post-transplant evaluation will be done as per standard care with study data collected at days 30, 60, 100, 180, 365, and annually thereafter.
2918340|NCT03120988|Experimental|Lavage with Platelet Poor Plasma (PPP)|"Lavage using 50 cc of PPP in the knee joint. Using visual guidance, the PPP lavage will be conducted, introducing a solution of platelet poor plasma into the knee joint with subsequent removal of the fluid, in effect washing out the joint space."
2918341|NCT03120975|Experimental|Computerized decision support|
2918342|NCT03120975|Active Comparator|Standard antibiotic stewardship|
2918343|NCT03120962|Experimental|oxycodone|Oxycodone 20mg/day, for 4 weeks and famciclovir 500mg three-times daily for 7 days.
2918344|NCT03120962|Active Comparator|standard treatment|Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day (whichever is lower), for 4-12 weeks and famciclovir 500mg three-times daily for 7 days.
2918345|NCT03120949|Experimental|Treatment Arm 1|Olokizumab 64 mg SC q4w + Methotrexate (oral)
2918346|NCT03120949|Experimental|Treatment Arm 2|Olokizumab 64 mg SC q2w + Methotrexate (oral)
2918347|NCT03120936|Other|Main|Emtricitabine / Tenofovir Disoproxil Oral Tablet and PrEP support.
2918348|NCT03120923|Experimental|Lidocaine 3 cc & Triamcinolone Acetonide|
2918349|NCT03120923|Active Comparator|Lidocaine 9cc & Triamcinolone Acetonide|
2918350|NCT03120884|Experimental|IVF|embryos are cultured using conventional in vitro fertilization.A maximum of 2 embryos will be transferred for each treatment cycle.
2918351|NCT03120884|Experimental|ICSI|embryos are fertilized using ICSI.A maximum of 2 embryos will be transferred for each treatment cycle.
2918352|NCT03120871||All subjects|Female sex, obese, aged 9-17 years, Tanner stages 1-5.
2918353|NCT03120845|Experimental|Post operative Pain in one visit RCT|One visit RCT Ibuprofen for Post operative pain. Take 400 mg every 6 hours, a week after.
2918354|NCT03120845|Experimental|Post operative pain in two-visits RCT|Two visits RCT Ibuprofen for Post operative pain. Take 400 mg every 6-8 hours, a week after.
2918355|NCT03120832|Experimental|PAN-301-1 (SNS-301) Vaccine|PAN-301-1 vaccine is administered intradermally in 3 cohorts of patients in a dose escalation schema every 21 days
2918356|NCT03120819|Active Comparator|Oncologist Recommendation only|Medical providers in this study provide a standardized brief recommendation for exercise to a consenting patient during a clinical visit. Patients randomized to this arm receive a packet that contained a study information sheet and standard published exercise information materials. The standard materials consisted of publicly available exercise recommendations for cancer survivors from the American Cancer Society (ACS). The packet of exercise information intended to represent general information about exercise and cancer that would be readily available to patients through the internet, a medical clinic, or cancer support services.
2918357|NCT03120819|Experimental|Oncologist Recommendation + DVD|Participants in this arm receive the same oncologist's recommendation and written materials as the comparator group and also received an instructional yoga DVD. Inclusion of the video is intended to provide patients with a tool for following the oncologist's exercise recommendation. The instructional video contains a brief introduction from a breast cancer survivor, who was also featured in the exercise portion of the DVD, and safety information about lymphedema from a lymphedema therapist. The exercise program is a 30-minute, low intensity, restorative yoga program to improve whole body flexibility and to be safe for participants who were in active treatment for cancer and/or who had metastatic disease. Women are encouraged to use the DVD at least 3 times per week.
2918358|NCT03120806|Active Comparator|continous subcuticular|skin closed with continous subcuticular mattress suture using non-absorbable polypropylene
2918359|NCT03120806|Active Comparator|Interrupted subcuticular|skin closed with interrupted subcuticular mattress suture using non-absorbable polypropylene
2918360|NCT03120793||Esophageal balloon catheter placement|This is the primary and only arm of the study in which acute respiratory distress syndrome patients will have an esophageal balloon catheter placed with pressures recorded in the supine, upright and prone positions
2918361|NCT03120780|Active Comparator|Low Dose Fentanyl|Low dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 20 mcg fentanyl (Fentanyl 20 mcg)
2918362|NCT03120780|Experimental|High Dose Fentanyl|High dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 100 mcg fentanyl (Fentanyl 100 mcg)
2918363|NCT03120767|Experimental|Condition 1|enrolled in the Risk and Resilience course during Fall 2017 and directly encouraged to participate in the Founders Living and Learning Community wellness activities for the Fall of 2017 (Coordinated Wellness Programming)
2918364|NCT03120767|Active Comparator|Condition 2|enrolled in the Risk and Resilience course in Spring 2018, and not directly encouraged to participate in the WIN Living and Learning Community wellness activities
2918365|NCT03120767|No Intervention|Condition 3|a control group that receives none of the interventions during the first year. This group will instead receive an online pamphlet that contains a number of wellness tips and advice for first-year students. Condition 3 participants have access to the WIN Living and Learning Community wellness activities in Fall of 2017 and Spring of 2018, but are not directly encouraged to participate.
2918366|NCT03120754|Experimental|Experimental Group|Placement of peritoneal drainage
2918367|NCT03120754|Active Comparator|Control group|No peritoneal drainage
2918368|NCT03120728|Experimental|12-14mm leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 12-14mm on transvaginal ultrasound.
2918369|NCT03120728|Experimental|15-17mm leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 15-17mm on transvaginal ultrasound.
2918370|NCT03120728|Experimental|18mm or greater leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 18mm or greater on transvaginal ultrasound.
2918394|NCT03120533|Experimental|Treprostinil|the participant will receive 10 days of iontophoresis of treprostinil on a first site, each day the same site.
2977141|NCT02715895|Active Comparator|Breast milk|Breast milk feeding
2918371|NCT03120715|Placebo Comparator|NLMWH-A|non-low molecular weight heparin-group A(group NLMWH-A).Without administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
2918372|NCT03120715|Experimental|LMWH-B|low molecular weight heparin-group B(group LMWH-B).With administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
2918373|NCT03120689|Active Comparator|Live Surgery with VITOM|Learner will not assist during the surgery, but watch the live surgery that is projected on a screen via the VITOM camera followed by a short questionnaire.
2918374|NCT03120689|Active Comparator|Live Surgery without VITOM|Learner will assist in the traditional manner without the use of the VITOM camera followed by a short questionnaire.
2918375|NCT03120689|Active Comparator|Video viewing with VITOM|Learner will watch a video taped using the VITOM camera followed by a short questionnaire.
2918376|NCT03120689|Active Comparator|Video viewing with standard camera|Learner will watch a video taped using the standard hand-held high definition camera followed by a short questionnaire.
2918377|NCT03120676|Experimental|Atezolizumab|Treatment will be Atezolizumab administered at 1200 mg IV every 3 weeks. A cycle is defined as 3 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death for a maximum duration of treatment of 36 cycles.
2918378|NCT03120650|Experimental|Scalp acupuncture|number:58 The needle will be maintained in place for 30 minutes. Patients in both groups will receive rehabilitation five times per week (Monday through Friday) for 8 consecutive weeks.
2918379|NCT03120650|Active Comparator|Conventional rehabilitation|number:58 Rehabilitation will be conducted for 1 hour five times per week (Monday through Friday) for 8 weeks.
2918380|NCT03120637|Experimental|Methylene Blue|Methylene Blue intravenous route, 2 mg/kg Loading Dose over 30 minutes, followed by 0.5 mg/kg/hr for 6 hours
2918381|NCT03120637|No Intervention|Standard Treatment|
2918382|NCT03120624|Experimental|Treatment (VSV-hIFNbeta-NIS, SPECT/CT, biopsy)|Patients receive VSV-hIFNbeta-NIS IV over 30-60 minutes on day 1. After 3-5 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, undergo whole body planar imaging and SPECT/CT imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and undergo another planar and SPECT/CT scan 7-10 days after VSV-hIFNbeta-NIS infusion. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29.
2918383|NCT03120611|Experimental|Virtural reality exercise|Virtual reality exercise performed during the hemodialysis session, using the Kinect, specially adapted for patients undertaking hemodialysis
2918384|NCT03120611|Active Comparator|Conventional exercise intradialysis|Exercise combining both aerobic (cycling) and strengthening exercise of lower limbs for patients during the hemodialysis session
2918385|NCT03120598|Active Comparator|ATTC strategy|Behavioral: Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
2918386|NCT03120598|Experimental|ISF strategy|Behavioral: Implementation & Sustainment Facilitation (ISF) strategy: An organization-focused strategy that includes 7 discrete strategies (e.g., use of an implementation advisor, organize implementation team meetings, conduct cyclical small tests of change) and Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
2918387|NCT03120585|Experimental|Fluid Management Intervention|Restricting IV fluids to infants with respiratory distress to mimic fluid intake of normal healthy breast fed infants (less fluid that current standard of care)
2918388|NCT03120585|No Intervention|Control Group|Infants with respiratory distress will receive standard of care fluid management.
2918389|NCT03120559|No Intervention|Control|"The dental consultation was the same for all the groups.~- Examination and diagnosis (15 min).~- Motivation, discussion about desired outcomes and treatment needs followed by instrumentation (scaling, polishing) (30 min).~- Therapeutic goals, therapeutic strategies, teaching skills (brushing and interproximal control with regular waxed floss at the Control group) and scheduling of the follow-up appointment (15 min).~They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The consultation time was 60 minutes and also included specific behavior change techniques, such as reinforcement, goal-setting, and feedback."
2918390|NCT03120559|Other|NFH - New Floss Holder|The dental consultation was the same for all the groups. They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The consultation time was 60 minutes and also included specific behavior change techniques, such as reinforcement, goal-setting, and feedback. New Floss Holder - Gum Chucks
2918391|NCT03120559|Other|New Floss Holder and Short Messages|"The dental consultation was the same for all the groups. They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The Intervention time was 60 minutes and also included behavior change techniques, such as reinforcement, goal-setting, and feedback. Participants in the NFH/SMS group further received a total of 16 messages (SMS).~New Floss Holder - Gum Chucks/SMS"
2918392|NCT03120546|Experimental|Group A|rigid video stylet intubation - video laryngoscope intubation
2918393|NCT03120546|Experimental|Group B|video laryngoscope intubation - rigid video stylet intubation
2918395|NCT03120533|Placebo Comparator|Placebo|the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil
2918396|NCT03120520|Experimental|Plecanatide 0.5 mg|Taken orally once daily in the morning for 8 weeks
2918397|NCT03120520|Experimental|Plecanatide 1.0 mg|Taken orally once daily in the morning for 8 weeks
2918398|NCT03120520|Experimental|Plecanatide 1.5 mg|Taken orally once daily in the morning for 8 weeks
2918399|NCT03120520|Placebo Comparator|Matching placebo|Taken orally once daily in the morning for 8 weeks
2918400|NCT03120494|Experimental|Subjects at risk of HIV|25 high risk MSM and 50 negative partners in a sero-discordant couple will be recruited and emtricitabine and tenofovir (Truvada) for PrEP will be provided, per guidelines, for one year
2918401|NCT03120481||Normal control|
2918402|NCT03120468|Experimental|Topiramate and N-Acetyl Cysteine|Drug: Topiramate and N-Acetyl Cysteine Other Name for Topiramate: Topamax
2918403|NCT03120468|Experimental|Topiramate and Placebo|Drug: Topiramate and Placebo Other Name for Topiramate: Topamax Other Name for Placebo: Sugar Pill
2918404|NCT03120455|Experimental|Almond group (AG)|Obese or overweight female adults will be randomly allocated to have have almond as afternoon snack while they have a hypoenergetic diet.
2918405|NCT03120455|Active Comparator|Pistachio group (PG)|Obese or overweight female adults will be randomly allocated to have have Pistachio as afternoon snack while they have a hypoenergetic diet.
2918406|NCT03120455|Placebo Comparator|Nut Free (NFG, CG)|Obese or overweight female adults are asked to avoid all nuts, seeds, and nut products while they have a hypoenergetic diet. , as the control group.
2918407|NCT03120442|Experimental|Propofol-fentanyl|Fentanyl 0.5 mcg/kg Propofol Target-controlled infusion to achieve MOAA/S 3-4 as end point of sedation Bispectral index (BIS) monitoring
2918408|NCT03120442|Experimental|Dexmedetomidine|Fentanyl 0.5 mcg/kg Dexmedetomidine in incremental titrated dose for moderate sedation to achieve MOAA/S 3-4 as end-point of titration Bispectral index (BIS) monitoring
2918409|NCT03120442|Experimental|Fentanyl|Fentanyl 0.5 mcg/kg Supplemental dosage of fentanyl for intraoperative anxiolysis
2918410|NCT03120429|Experimental|Fish group|subjects will have 3 x 150 g lean fish/ week at main meal
2918411|NCT03120429|Experimental|Control group|subjects will have no seafood.
2918412|NCT03120416|Experimental|Resistance exercise training program|Eight exercises will be used to include large upper and lower body muscle groups. The baseline 1 repetition maximum (RM) will be used to set initial training loads. All exercise sessions will be performed under the supervision of an exercise physiologist. Vital signs and body weight will be recorded before each session. The workload during training will be adjusted to reflect 80% of the most recent 1 RM (approximately 8-12 RM set). In addition, patients' workloads will be progressively increased if the patients can lift the weight more than 12 repetitions. Participants will perform three sets of 8-12 repetitions on each machine per session.
2918413|NCT03120416|No Intervention|Control|Participants randomized to the control group will be offered an educational brochure regarding exercise published by the NKF.
2918414|NCT03120403|Active Comparator|intrathecal morphine 2 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique.children will receive intrathecal morphine 2 μg/kg in 2 ml volume normal saline.
2918415|NCT03120403|Active Comparator|intrathecal morphine 5 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique. children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
2918416|NCT03120403|Active Comparator|intrathecal morphine 10 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique.children will receive intrathecal morphine 10 μg/kg in 2 ml volume normal saline.
2918417|NCT03120390|Experimental|Group I (PCT)|Patients undergo supervised exercise sessions comprising of AE over 30 minutes and RE over 25 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
2918418|NCT03120390|Experimental|Group II (PAT)|Patients undergo supervised exercise sessions comprising of AE over 45-60 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
2918419|NCT03120390|Active Comparator|Group III (usual care)|Patients undergo usual care. Beginning 24 weeks, patients may undergo supervised exercise sessions comprising of AE and RE as in Group I.
2918420|NCT03120377|Active Comparator|Platform group|Group submitted to the whole body vibration training program
2918421|NCT03120377|Sham Comparator|Platform sham group|Group that will receive the whole body vibration simulation treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display on and a sound device coupled with vibration-generated noise recording, but without therapeutic purposes.
2918422|NCT03120364|Experimental|NBP608|Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm
2918423|NCT03120364|Active Comparator|Zostavax|Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm
2918424|NCT03120351|Experimental|LIDOCAINE PATCH 5%, POST OP PAIN|
2918425|NCT03120351|Placebo Comparator|ACUTE AND CHRONIC CHEST PAIN POSTOP|
2918426|NCT03120338|Experimental|The Development and Wellbeing Assessment|"The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.~The DAWBA will be administered in addition to care as usual."
2918427|NCT03120338|No Intervention|Care as Usual|Care as usual
2918428|NCT03120325|Experimental|Vagal Nerve Stimulation|All patients in trial will be giving themselves vagal nerve stimulation for five minutes twice a day in the morning and the night for four weeks starting at visit 3 and ending at visit 5.
2918429|NCT03120299|Experimental|Group A Drug|"Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks~Other Names:~Omega-3 Fatty Acid fish oil Omega 3 Treasure"
2918430|NCT03120299|Placebo Comparator|Group B Drug|Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
2918431|NCT03120286||Overweight and obesity|Women with BMI >25
2918432|NCT03120286||Normal weight group|Women with BMI =18-24
2918433|NCT03120273|Experimental|Dexlansoprazole Injection|15mg q12h,30mg q12h,15mg qd,30mg qd in dexlansoprazole treatment arm for 5 days
2918434|NCT03120273|Active Comparator|Lansoprazole Injection|30 mg q12h in lansoprazole treatment arm for 5 days.
2918435|NCT03120260|Experimental|Short Sleep|Diet+ have 5 hour sleep at night (SS)
2918436|NCT03120260|Experimental|Normal Sleep|Diet+ have 7-8 hour sleep at night (NS)
2918437|NCT03120247|Active Comparator|DEX I|OTM Dexmetetomidine 1µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
2918438|NCT03120247|Active Comparator|DEX II|OTM Dexmetetomidine0.75µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
2918439|NCT03120247|Active Comparator|DEX III|OTM Dexmetetomidine 0.5µg/kg. Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
2918440|NCT03120234|Experimental|Dexmedetomidine and ketamine|The group will receive loading dose of dexmedetomidine 1mcg/kg over 10 Min followed by a maintenance of 0.5 mcg/ kg/ hr.ketamine 0.5 mg/kg will be given as bolus at the time of induction.
2918441|NCT03120234|Experimental|fentanyl and placebo|pts will receive fentanyl 2mcg/kg as bolus over 10 Mon followed by 1 mcg/ kg/hr as maintenance, instead of ketamine placebo(0.9%saline ) will be given in control group
2918442|NCT03120221||First trimester pregnant women|
2918443|NCT03120208|Experimental|women in the nonexposed group without a hemorrhage|
2918444|NCT03120208|Experimental|women in the exposed group with a hemorrhage|
2918445|NCT03120195|Experimental|EndoRotor® ablation|Prospective pilot study, to be performed in 30 patients with Barrett's esophagus that have an indication for ablation treatment. Barrett's ablation will be performed using the EndoRotor®.
2918446|NCT03120182|Active Comparator|Aspirin Arm|The patients will receive acetylsalicylic acid (100mg once a day, orally) for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization
2918447|NCT03120182|Placebo Comparator|Placebo Arm|The patients will receive placebo oral tablets for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization
2918448|NCT03120169|Active Comparator|treadmill endurance training|
2918449|NCT03120169|Active Comparator|cycling endurance training|
2918450|NCT03120156|Active Comparator|No insoles|Control group of people with poor postural control that won't use insoles
2918451|NCT03120156|Active Comparator|Normal insoles|Control group of people with poor postural control that will get normal standard insoles.
2918452|NCT03120156|Active Comparator|Sensomotoric insoles|Control group of people with poor postural control that will get normal standard insoles.
2918453|NCT03120143|Experimental|Team sport and high protein group|This group participated in team sport based small-sided ball games with supplementation of a drink with a high content of protein after the training sessions
2918454|NCT03120143|Experimental|Team sport and low protein group|This group participated in team sport based small-sided ball games with supplementation of a drink low in protein content after the training sessions
2918455|NCT03120143|No Intervention|Control group|This group continued their usual life style without intervention
2918456|NCT03120130|Experimental|Cohort 1|This cohort will include 3 patients with the first calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity (DLT) in this group the study continues including the next cohort. However, if If only one patient in a given cohort develops DLT, three more patients will be included at that dose level, up to a maximum total of six patients per dose level. If two or more of the three patients of a certain dose level develop DLT, this dose level is considered very toxic, and the study does not proceed. If this occurs at the first dose level, the study will be finalized. If only one in six patients at a dose level develops DLTs, escalation proceeds until Tolerated Maximum Dose.
2918457|NCT03120130|Experimental|Cohort 2|This cohort will include 3 patients with the second calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
2918458|NCT03120130|Experimental|Cohort 3|This cohort will include 3 patients with the third calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
2918459|NCT03120130|Experimental|Cohort 4|This cohort will include 3 patients with the fourth calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
2918460|NCT03120130|Experimental|Cohort 5|This cohort will include 3 patients with the fifth calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
2918461|NCT03120130|Experimental|Cohort 6|This cohort will include 3 patients with the sixth calculated dose of Amblyomin-X drug, the last dose calculated. The patient will receive the intravenous drug.
2918462|NCT03120117|Experimental|Cough Test following Sling Surgery|All subjects enrolled will undergo sling surgery for treatment of stress urinary incontinence and subsequently asked to do a standing cough test.
2918463|NCT03120104|Active Comparator|Pre-intervention group|Pre-intervention group interventions:pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) just one month before the stoma closure
2918464|NCT03120104|Active Comparator|Post-intervention group|Post-intervention group: pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) two weeks after the stoma closure
2918465|NCT03120091||Enrolled Patients|A total of 20 patients were enrolled for the place of CGMS. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
2918565|NCT03119376|Experimental|COBPeer|Junior peer reviewers will be invited to participate in an online training course on peer review (COBPeer).
2918466|NCT03120065|Other|MEMS follow up|Approximately 25% of the enrolled study population will have their adherence to medicines monitored by research personnel through the use of electronic dose monitoring caps (MEMS) for a period of 3 months. The participant's ART medication regimen will be dispensed in a bottle with a cap that monitors the time and date in which the cap is opened. Each month, the participant will bring the bottle with them on their clinic day for three months and the research personnel will extract the timing information from the cap.
2918467|NCT03120039||Healthy adults|Healthy adults without any limitations in upper extremity movement or function.
2918468|NCT03120026|Experimental|Experimental Product|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
2918469|NCT03120026|Placebo Comparator|Isocaloric Placebo|Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
2918470|NCT03120013|Experimental|Real tDCS|10 days anodal cerebellar and cathodal spinal tDCS
2918471|NCT03120013|Sham Comparator|Sham tDCS|10 days sham cerebellar and sham spinal tDCS
2918472|NCT03120000|Other|PQR309|A single arm study with PQR309, a phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), 60mg/80mg given once a day, orally.
2918473|NCT03119987||UGIB|Those who was diagnosed as UGI bleeding at emergency department during the study periods. Red cell distribution widths wers checked at all patients.
2918474|NCT03119974|Other|Tpo-RA discontinuation|
2918475|NCT03119961|Experimental|SONOCLOUD®|BBB opening by ultrasound
2918476|NCT03119948|Placebo Comparator|Group 1|Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
2918477|NCT03119948|Active Comparator|Group 2|Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
2918478|NCT03119948|Active Comparator|Group 3|Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
2918479|NCT03119935|Experimental|Amflow assist ambu bag ventiation|Newely developed method (Amflow assist ambu bag ventilation)
2918480|NCT03119935|Experimental|Ambu bag ventilation|Ordinary method (ambu bag ventilation
2918481|NCT03119922||SCD french new born|New-borns diagnosed by NBS from 01/01/2006 to 31/12/2010 (AFDPHE data, France)
2918482|NCT03119909|Other|Learning of actions-events associations|Each subject will conduct 4 sessions, i.e. a training session and three fMRI sessions. The first session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
2918483|NCT03119909|Other|Learning of action-event associations not linked to action|This study is divided into two parts: a pilot behavioral study to determine the learning characteristics of non-action events and an fMRI study to study the neural networks involved in this type of learning.
2918484|NCT03119896|Experimental|Intervention Group (using Navigator Tool)|The participants will receive a copy of the Navigator Tool Intervention, a paper-based information pack including the My Pain Concerns Form, suggested questions to ask your healthcare professional, a goal setting sheet and information on common self-management strategies. They will be encouraged to fill in some of the forms before the consultation, and some during the consultation. They will have consultations with a healthcare professional who has undergone a Self-management Awareness Training with the Thistle Foundation.
2918485|NCT03119896|No Intervention|Control Group (not using Navigator Tool)|These participants will not have access to the Navigator Tool Intervention, and will have consultations with a healthcare professional who has not undergone the Self-management Awareness Training.
2918486|NCT03119883|Other|MGUS group|MGUS patients will undergo an intervention which includes an intravenous infusion of 13-Carbon labeled glutamine prior to undergoing a bone marrow aspiration to acquire their bone marrow plasma cells. The glutamine utilization by these bone marrow plasma cells will be assessed by gas-chromatography mass spectrometry by measuring the 13C isotopomer enrichment in the plasma cells.
2918487|NCT03119883|Other|Multiple Myeloma group|Multiple Myeloma patients will undergo an intervention which includes an intravenous infusion of 13-Carbon labeled glutamine prior to undergoing a bone marrow aspiration to acquire their bone marrow plasma cells. The glutamine utilization by these bone marrow plasma cells will be assessed by gas-chromatography mass spectrometry by measuring the 13C isotopomer enrichment in the plasma cells.
2918488|NCT03119870|Experimental|1|Each subject will conduct 3 sessions, i.e. a training session, an anatomical MRI session and an EEG session. The first session will be to train the subject to carry out the different behavioral tasks that he will then have to perform during the session of EEG.
2918489|NCT03119857|Active Comparator|Antiandrogen|Antiandrogen (bicalutamide 150 mg x 1) p.o. alone,
2918490|NCT03119857|Experimental|Antiandrogen + docetaxel|Antiandrogen (bicalutamide 150 mg x 1) p.o. + Docetaxel 75 mg/m2 (maximum 2.0 m2 ) i.v. q 3 weeks x up to 8-10 cycles.
2918491|NCT03119844|Experimental|Exercise and placebo phototherapy|Placebo phototherapy and Cycle ergometer exercise rehabilitation protocol
2918492|NCT03119844|Experimental|Exercise and active phototherapy|Active phototherapy and Cycle ergometer exercise rehabilitation protocol
2918493|NCT03119831|Experimental|C31G (Group A)|C31G
2918494|NCT03119831|Experimental|Alcohol-free Chlorhexidine (Group B)|Alcohol-free Chlorhexidine Gluconate 0.12%
2918495|NCT03119831|Experimental|Alcohol-based Chlorhexidine (Group C)|Alcohol-based Chlorhexidine Gluconate 0.12%
2918496|NCT03119818|Experimental|Patients suffering from ESRD treated by chronic hemodialysis|Patients aged from 18 to 80 years old, suffering from ESRD, treated by chronic hemodialysis since at least 6 months and whose phosphatemia at the beginning of HD sessions ranged from 1.5 to 3 mmol/L. Phosphorus (31P) magnetic resonance spectroscopy will be performed in these patients during hemodialysis in order to measure intracellular phosphate and ATP concentrations and intracellular pH evolution during hemodialysis.
2918627|NCT03118934|Experimental|DT1 MF|Delefilcon A multifocal contact lenses fit (both eyes) using the assigned fitting guide (current or alternative), followed by a 10 ± 3 day wear period
2918497|NCT03119792|Experimental|Investigational|An education intervention will be implemented for 600 children from the original cohort (300) and comparable cohort (300) over a four month period at community centers. These sessions will occur twice a month on the weekends. The education intervention will help increase the children's knowledge of attitudes, and habits of healthy lifestyles.
2918498|NCT03119792|Active Comparator|Control|The control group will consist of 600 children from the original cohort (300) and comparable cohort (300). The control group will meet twice a month for four months at community centers. During these sessions, investigators will teach a curriculum that is not related to knowledge, attitudes, and habits towards healthy lifestyles.
2918499|NCT03119779|Experimental|TheraCal vital pulp therapy|Using rubber dam isolation we will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. After complete removal of the caries and control of bleeding, then direct application of incremental layers of TheraCal using the tip of the syringe container of the material and each layer should not exceed 1 mm then light curing each increment. Then Riva self-cure glass-ionomer base and composite resin final restoration. We will take immediate standardized postoperative periapical radiographs.
2918500|NCT03119779|Active Comparator|MTA vital pulp therapy|Using rubber dam isolation we will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. After complete removal of the caries and control of bleeding, then direct application of freshly mixed MTA-Anglus on sterile glass slap. MTA application then gentle condensation over wet cotton till MTA thickness is about 2-3 mm thickness and removal of excess material from walls of pulp chamber. Application of wet cotton for 15 min. to achieve initial setting of MTA. Then Riva self-cure glass-ionomer base and composite resin final restoration. We will take immediate standardized postoperative periapical radiographs.
2918501|NCT03119766|Experimental|Kolofort|
2918502|NCT03119766|Placebo Comparator|Placebo|
2918503|NCT03119753|Experimental|Group R|Rapid Prototyping method of fabrication of complete denture: the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.
2918504|NCT03119753|Active Comparator|Group C|Conventional method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
2918505|NCT03119740||open appendectomy|Patients were selected retrospectively on the basis of the documented MEL code (medical service code) of open appendectomy (AE)
2918506|NCT03119740||laparoscopic appendectomy|Patients were selected retrospectively on the basis of the documented MEL code (medical service code) of open laparoscopic appendectomy (LSK AE)
2918507|NCT03119727|Other|Automated oxygen adjustment|All patient in this study have automatic oxygen titration and automatic oxygen weanning
2918508|NCT03119714|Active Comparator|Pemirolast|Pemirolast 200mg bid 14-16 days
2918509|NCT03119714|Placebo Comparator|Placebo Oral Tablet|Matching placebo bid 14-16 days
2918510|NCT03119701|Experimental|FP-1201-lyo 10 µg|"FP-12-lyo 10 µg (Interferon Beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection."
2918511|NCT03119701|Placebo Comparator|FP-1201-lyo Placebo|"FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.~Investigational placebo is lyophilisate for solution for injection which will be reconstituted in water for injection"
2918512|NCT03119688|Other|Test product|0.09 milliliters (ml) of the cleanser (test product) will be applied on the allocated site on forearm topically.
2918513|NCT03119688|Other|Positive Control|Soap bar (positive control) will be applied on the allocated site on forearm topically.
2918514|NCT03119688|Other|Reference Product|0.09 ml of sterile water (Reference Product) will be applied on the allocated site on forearm topically.
2918515|NCT03119675|Other|Photorefraction of ages 1 to 6 years|Clinical Validation of GoCheck Kids Smartphone App
2918516|NCT03119662|Experimental|Visipaque|100 mL iodixanol (Visipaque Injection 320 mg I/mL)
2918517|NCT03119662|Placebo Comparator|Placebo|Placebo (100 mL saline)
2918518|NCT03119649|Experimental|GLPG2222 dose 1 for cohort A|
2918519|NCT03119649|Experimental|GLPG2222 dose 2 for cohort A|
2918520|NCT03119649|Placebo Comparator|Placebo for cohort A|
2918521|NCT03119649|Experimental|GLPG2222 dose 1 for cohort B|
2918522|NCT03119649|Experimental|GLPG2222 dose for cohort B|
2918523|NCT03119649|Placebo Comparator|Placebo for cohort B|
2918524|NCT03119636|Experimental|NPC transplantation|The patients will receive Levodopa combined with a regular neural precursor cell (NPC) transplantation
2918525|NCT03119636|Experimental|HLA-matched NPC transplantation|The patients will receive Levodopa combined with a HLA-matched neural precursor cell (NPC) transplantation
2918526|NCT03119636|Experimental|HLA-non-matched NPC transplantation|The patients will receive Levodopa combined with a HLA-non-matched neural precursor cell (NPC) transplantation
2918527|NCT03119623|Active Comparator|Sacubitril/Valsartan|Sacubitril/valsartan 100mg (Dose Level 1) titrated up if tolerated to 200 mg twice daily (Dose Level 2)
2918528|NCT03119623|Active Comparator|Enalapril|Enalapril 5mg (Dose Level 1) titrated up if tolerated to 10mg twice daily (Dose Level 2)
2918529|NCT03119610|Experimental|Oxytocin nasal spray|Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered
2918530|NCT03119610|Experimental|Placebo nasal spray|Placebo nasal spray, 4x a day for 8 weeks, self administered
2918531|NCT03119597|Placebo Comparator|Placebo|Formulation containing approximately 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
2918532|NCT03119597|Experimental|Wild Blueberry Power-13g|Formulation containing approximately 250mg of anthocyanin+ 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
2918533|NCT03119584|Active Comparator|1)28days of linaclotide or placebo|patient will be randomized and allocated to one of the treatment arms using computerized generated simple random number in a double-blinded fashion for 28 days of therapy with the study drug, linaclotide or placebo. Patients, and trial personnel involve (other than biostatistician) in this study will not be aware of the group assignments. Patients, treatment providers and staffs will be kept blinded in this study.
2918534|NCT03119584|Active Comparator|2)28days of linaclotide or placebo|patient will be randomized and allocated to one of the treatment arms using computerized generated simple random number in a double-blinded fashion for 28 days of therapy with the study drug, linaclotide or placebo. Patients, and trial personnel involve (other than biostatistician) in this study will not be aware of the group assignments. Patients, treatment providers and staffs will be kept blinded in this study.
2918535|NCT03119571|Experimental|Initial CCL admission|Admission to the CCL to evaluate the coronary artery disease
2918536|NCT03119571|Active Comparator|Initial ICU admission|Admission to the ICU to be evaluated by clinical team and the clinical treatment will be decided by the admitting/attending team.
2918537|NCT03119558|Experimental|18F‑Florbetaben (Neuraceq®) PET/MRI|Participants with known or suspected cardiac amyloidosis will be injected with 8 mCi of 18F‑Florbetaben (Neuraceq®) and undergo the PET/MRI image acquisition 45‑60 minute post-injection. PET and MRI data will be acquired simultaneously to ensure optimal timing and spatial correspondence between MRI and PET data. Total scan time will take approximately 60 minutes.
2918538|NCT03119545|Experimental|Beardslee family centered intervention|This Group will have the family centered program.
2918539|NCT03119545|No Intervention|Comparison group|This Group will have standard care
2918540|NCT03119532|Experimental|Receive feedback email|Anesthesia care providers who receive monthly feedback emails on the participants specific quality measures
2918541|NCT03119532|No Intervention|Did not receive feedback email|Anesthesia care providers who did NOT receive monthly feedback emails on the participants specific quality measures
2918542|NCT03119519|Experimental|Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) followed by 3D-CRT (three-dimensional conformal radiotherapy) or IMRT (intensity modulated radiotherapy) to primary thoracic foci or remediable oligometastatic focus.
2918543|NCT03119519|Active Comparator|No Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
2918544|NCT03119506||Long Recess Duration/Before Lunch|
2918545|NCT03119506||Short Recess Duration/Before Lunch|
2918546|NCT03119506||Long Recess Duration/After Lunch|
2918547|NCT03119506||Short Recess Duration/After Lunch|
2918548|NCT03119493|Experimental|Periodized aerobic interval training|The experimental groups will participate in a 16 week, three times a week based-program of periodized aerobic interval training that consist in warming [5 minutes of general stretching and 5 minutes of walking on treadmill with heart rate less than 20 percent of heart rate reserve (HHR)], followed by periodized aerobic interval training on treadmill, and cooling down [5 minutes of walk in treadmill with a heart rate less than 20 percent of HRR and 5 minutes of rest]
2918549|NCT03119493|No Intervention|Control group|Participants in the control group will be instructed not to take part in any regular exercise programs during the study period.
2918550|NCT03119480||Hospital-acquired AKI|Adult patients with Hospital-acquired AKI
2918551|NCT03119467|Experimental|Single arm|RP4010 to be administered
2918552|NCT03119454||Patients receiving diprospan|Patients who are receiving diprospan in standard therapy of their existing disease, or multiple times, but following the introduction of diprospan is planned no earlier than 28 days after the first administration.
2918553|NCT03119454||Control subjects|Patients or healthy volunteers who had not received systemic or local corticosteroids in the last 12 weeks before the screening visit.
2918554|NCT03119441|Experimental|Dental water jet|Dental water jet (Jetpik JP210)
2918555|NCT03119441|Active Comparator|Dental floss|Dental floss
2918556|NCT03119428|Experimental|OMP-313M32|Intravenous (in the vein) infusions of OMP-313M32 as a single agent
2918557|NCT03119428|Experimental|OMP-313M32 and Nivolumab|Intravenous (in the vein) infusions of OMP-313M32 in combination with nivolumab
2918558|NCT03119415|Experimental|Cooperative Learning|Teachers in intervention schools are training in cooperative learning (CL).
2918559|NCT03119415|No Intervention|Business as Usual|Schools continue with business as usual.
2918560|NCT03119402|Experimental|RRT + active tDCS|Rhythmic Reading Training, administered for 5 hours over 10 days consecutive (30-minute training sessions per day) + simultaneous 20 minutes of active tDCS (1.5 mA, 5x5cm anodal electrode on left parieto-temporal regions and 5x5cm cathodal electrode on right parieto-temporal regions).
2918561|NCT03119402|Sham Comparator|RRT + sham tDCS|Rhythmic Reading Training, administered for 5 hours over 10 days consecutive (30-minute training sessions per day) + simultaneous 20 minutes of sham tDCS (with the same active tDCS setup, current applied for 30 seconds,
2918562|NCT03119389|Experimental|Donning Non-Sterile Gloves without HH|In this arm, entire units will be assigned education that hand hygiene before donning non-sterile gloves is NOT necessary. For Aim A, observations will be made on compliance at entry and exit with hand hygiene and glove use. For Aim B, samples will be obtained from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
2918563|NCT03119389|No Intervention|HH before donning Non-Sterile Gloves|In this arm, entire units will be assigned education that hand hygiene before donning non-sterile gloves IS necessary. For Aim A, observations will be made on compliance at entry and exit with hand hygiene and glove use. For Aim B, samples will be obtained from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
2918564|NCT03119376|No Intervention|USUAL PEER REVIEWER|Two researchers will read all the peer-review reports and editors' comments for the first round. The researchers will determine whether the peer-reviewers and/or editors raised some concern on the completeness of reporting of the 10 CONSORT items considered and identified a switch primary outcome(s) between the manuscript and the register. The assessment of all peer-review reports and editors' comments for each manuscript will be combined (i.e., the item will be rated as incompletely reported if at least one peer reviewer rated it as such). The 2 researchers will be blinded to the gold standard assessment.
2918566|NCT03119376|No Intervention|GOLD STANDARD|Pairs of systematic reviewers will independently extract data from eligible reports. Reviewers involved in the data extraction will have expertise in the conduct of systematic reviews and will assess the completeness of reporting from the systematic reviewer perspective. They will not have access to the tool to avoid being influenced by the tool. The systematic reviewers will also systematically compare the primary outcome(s) reported in the manuscript and the primary outcome(s) reported in the registry and will document any discrepancies.
2918567|NCT03119363|Experimental|Experimental Light|The experimental systematic light exposure consists of exposure to light to reduce cancer-related fatigue. This group will self-administer 30 minutes of light from commercially available light boxes each morning for 4 weeks. Outcomes will be assessed through standardized subjective and objective measures at five separate time points including baseline and follow-ups.
2918568|NCT03119363|Active Comparator|Comparison Light|The active comparator condition consists of exposure to light to reduce cancer-related fatigue. This group will self-administer 30 minutes of light from commercially available light boxes each morning for 4 weeks. Outcomes will be assessed through standardized subjective and objective measures at five separate time points including baseline and follow-ups.
2918569|NCT03119350|Other|Physical Training|"There was concurrent physical training intervention: strength and aerobic exercises in the same session.~Duration: 2 weeks of adaptation and learning to exercise, 8 weeks of physical training.~Frequency: 3 times per week Duration: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate."
2918570|NCT03119337|Experimental|Text-based VMMC follow-up|Follow-up conducted via daily text not through mandatory in person visits. Men may elect to come to the clinic if concerned about any complications but have no routine, scheduled follow-up visits.
2918571|NCT03119337|No Intervention|Routine VMMC follow-up care|Routine VMMC follow up care with in person visits according to national guidelines.
2918572|NCT03119324|Experimental|B-Cure® diode laser|"Thirty patients receiving LLLT by the B-Cure® diode laser (Good Energies, Haifa, Israel) 808nm low power device at 5 Joules/min, 250 milliWatts 15 KiloHertz for 8', (40 Joules each) in contact mode directly over the painful area, twice a day for 7 consecutive days.~The laser must be placed directly over the painful area, after having cleaned it with a soft cotton socket to remove skin impurities that could interfere with therapeutic light absorption.~The first application is performed at the Department of Oral Sciences of Sapienza University of Rome by a laser expert investigator and serves as instruction. The remnants must be performed by the patients themselves at home, once on the first day and twice a day in the following 6 days.~Patients were instructed to perform the applications always at the same time."
2918573|NCT03119324|Placebo Comparator|B-Cure® diode laser sham device|"Thirty patients that follows the same protocol of the SG but receive a B-Cure laser® sham device, seemingly identical to the effective one but devoid of main diode source.~The laser must be placed directly over the painful area, after having cleaned it with a soft cotton socket to remove skin impurities that could interfere with therapeutic light absorption.~The first application is performed at the Department of Oral Sciences of Sapienza University of Rome by a laser expert investigator and serves as instruction. The remnants must be performed by the patients themselves at home, once on the first day and twice a day in the following 6 days.~Patients were instructed to perform the applications always at the same time."
2918574|NCT03119324|Active Comparator|Nimesulide Ratiopharm® and Flexiban®|"Thirty patients follows the conventional drug therapy protocol, of two non‐consecutive cycles of 5 days of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® (100 mg a day), interspersed with one 5 days cycle of Myorelaxant, Flexiban® (10 mg a day).~From day 1 to 5, patients assumed 50mg of Nimesulide Ratiopharm®, twice a day; from 6th to 10th day they assumed 10mg of Flexiban® in single dose, from day 11 to 15 they assumed 50mg of Nimesulide Ratiopharm® twice a day.~Patients were instructed to assume the therapy always at the same time"
2918575|NCT03119311|Experimental|VOG group|Video-oculography
2918576|NCT03119311|Active Comparator|APCT group|alternative prism cover test
2918577|NCT03119298||High-fear-of-physical-activity group|Group members with high fear of physical activity (FActS-HF scores in the third tertile)
2918578|NCT03119298||Low-fear-of-physical-activity group|Group members with low fear of physical activity (FActS-HF scores in the first tertile)
2918579|NCT03119298||Control group|Healthy subjects matched for age and sex
2918580|NCT03119272||Anorexia Nervosa Patients|Inpatient population at Eating Disorders Unit (EDU) at the University of North Carolina Neurosciences Hospital. Recruited upon intake into the unit.
2918581|NCT03119272||Age and Sex Matched Healthy Controls|University of North Carolina Psychiatry email listserv.
2918582|NCT03119259|Active Comparator|ABC Clinical Program Only|Patients and informal caregivers randomized to the comparison group will receive care provided by the ABC Clinical Program. The ABC Clinical Program is the standard of ADRD care at both Eskenazi Health and Indiana University Health.
2918583|NCT03119259|Experimental|HABC 2.0 Mobile App Plus ABC|Patients and caregivers randomized to the intervention group will have the HABC 2.0 software installed on either the caregiver's personal mobile device (assuming it meets minimal technical requirements) or a device provided by the study, per participant preference. A research assistant will orient participants to the device, provide training on the HABC 2.0 software, and troubleshoot technical issues. Participants will receive daytime technical support by phone, electronic support request through a separate app, or printed and in-app help manuals. Hardware, software, and connectivity check-ups will be provided by study research personnel.
2918584|NCT03119246|Experimental|HD patients|
2918585|NCT03119246|Experimental|Controls|
2918586|NCT03119233|Experimental|Single-Arm|The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.
2918587|NCT03119220|Other|Low informational support|After the first week, informational support will be manipulated by providing one group with information in the form of physical activity monitoring only.
2918588|NCT03119220|Other|high informational support|The second group will additionally receive individualized information on how to change behavior by providing maps of a participant's neighborhood with distances depicted in steps, lists with age- and health-status appropriate suggestions as to how to increase numbers of steps, as well as medical information linking changes in physical activity to change in health outcomes; and information on health effects of behavior change by monitoring changes in sleep in conjunction with physical activity changes.
2918873|NCT03117296||Post procedure routine PT and or OT|Routine PT and or OT
2918589|NCT03119207|Experimental|Naptime Participants|The participants will undergo the Naptime Protocol. The study team will provide a 4 hour period nightly during which patient room activity, light levels and noise levels will be decreased. The team will monitor the changes in the number and quality of these disruptions and to monitor the changes in patient sleep and outcome following our intervention.
2918590|NCT03119207|No Intervention|Control Participants|Naptime will not be enforced. Patient room activity, light levels and noise levels are monitored. Standard care will be provided. During the intervention period patients are randomized to either control or naptime.
2918591|NCT03119207|No Intervention|Baseline Participants|Prior to the intervention period, baseline patients under usual care are monitored. Naptime will not be enforced. Patient room activity, light levels and noise levels are monitored.
2918592|NCT03119194|Experimental|Reguimen A - [14C]-BIA 9-1067|"100 mg [14C]-BIA 9-1067 Capsule containing not more than 3.3 MBq (89.2 µCi) 14C; will be administered with 240 mL water.~Single dose administration on a single occasion."
2918593|NCT03119168|Experimental|Simethicone solution + Polyethylenglycol|This arm of the study will include the patients assigned to take simethicone solution with their colon preparations
2918594|NCT03119168|Active Comparator|Polyethylenglycol|This arm of the study will include the patients assigned to take a regular bowel preparation with Polyethylenglycol
2918595|NCT03119129|Experimental|Cohort 1|Four middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 2, Academic Year (AY) 2016-2017
2918596|NCT03119129|Experimental|Cohort 2|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 3, AY 2016-2017
2918597|NCT03119129|Experimental|Cohort 3|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 2, AY 2017-2018
2918598|NCT03119129|Experimental|Cohort 4|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 3, AY 2017-2018
2918599|NCT03119116||Stroke Prevention with Rivaroxaban in NVAF Patients|All NVAF patients above 18 years for age prescribed with Rivaroxaban during the study period
2918600|NCT03119116||Stroke Prevention with Dabigatran in NVAF Patients|All NVAF patients above 18 years for age prescribed with Dabigatran during the study period
2918601|NCT03119116||Stroke Prevention with Apixaban in NVAF Patients|All NVAF patients above 18 years for age prescribed with Apixaban during the study period
2918602|NCT03119103|Other|Intervention of Functional Bed Sheet|Interventions will be non-invasive where healthy adults (over the age of 17, 10 male and 10 female) sleeps on the functional bed sheet overnight.
2918603|NCT03119077|Experimental|BAY1161116|Dose steps 1 to 6 of BAY1161116 (increasing dose levels)
2918604|NCT03119077|Placebo Comparator|Placebo|Placebo Dose 1 to 6 of BAY 1161116
2918605|NCT03119064|Experimental|Dose 1|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 1 50mg/m2 IV every 2 weeks"
2918606|NCT03119064|Experimental|Dose 2|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 2 70 mg/m2 IV every 2 weeks"
2918607|NCT03119064|Experimental|Dose 3|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 3 80mg/m2 IV every 2 weeks"
2918608|NCT03119051|Experimental|online cognitive training|Patients will receive 3-4 times of 20-30 minutes' training game every week
2918609|NCT03119051|No Intervention|no training|Patients will not undergo preoperative cognitive training.
2918610|NCT03119038|Active Comparator|Combination Medication Injection|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine, 30 mg ketorolac, 200 mcg epinephrine, and 100 mcg clonidine in a 100 mL 0.9% saline solution
2918611|NCT03119038|Active Comparator|Single Medication Injection|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine and 30 mL 0.25% bupivacaine without epinephrine
2918612|NCT03119025|Experimental|Autologous DC-vaccines|Thirty patients with chronic hepatitis C (genotype 1) will receive the initiating and maintaining courses of autologous of autologous monocyte-derived dendritic cells, generated in the presence of IFN-α/GM-CSF and pulsed with recombinant HCV Core (1-120) and NS3 (1192-1457) proteins.
2918613|NCT03119012|Active Comparator|P2Y12 receptor inhibitor monotherapy arm|In patients who do not occur a MACCE until 12-month after BRS implantation, P2Y12 receptor inhibitor monotherapy arm will be received clopidogrel 75mg qd or ticagrelor 60mg bid during follow-up period (24 months after randomization).
2918614|NCT03119012|Active Comparator|Extended DAPT arm|In patients who do not occur a MACCE until 12-month after BRS implantation, Extended DAPT arm will be received aspirin 100mg qd plus P2Y12 receptor inhibitor (clopidogrel 75mg qd or ticagrelor 60mg bid) during follow-up period (24 months after randomization).
2918615|NCT03118999|Experimental|OM3 derivatives 1|For each sequence: OM3 derivatives 1 at Period 1 or Period 2 or Period 3
2918616|NCT03118999|Experimental|OM3 derivatives 2|For each sequence: OM3 derivatives 2 at Period 1 or Period 2 or Period 3
2918617|NCT03118999|Experimental|OM3 derivatives|For each sequence: OM3 derivatives 3 at Period 1 or Period 2 or Period 3
2918618|NCT03118986|Active Comparator|Olanzapine|Standard antiemetics plus olanzapine
2918619|NCT03118986|Placebo Comparator|Placebo Oral Tablet|Standard antiemetics plus placebo
2918620|NCT03118973|Experimental|Goff|For patients in whom biliary cannulation is difficult to achieve, Goff trans-pancreatic septotomy will be performed to facilitate biliary cannulation.
2918621|NCT03118973|Experimental|Double wire|For patients in whom biliary cannulation is difficult to achieve, double wire technique will be used to facilitate biliary cannulation.
2918622|NCT03118960|Active Comparator|Freedom Bed|Bed turns and positions subjects automatically for the healing and prevention of pressure injury
2918623|NCT03118960|Active Comparator|Group II Low Air Loss/Alternating Pressure Mattress|Bed provides subjects with alternating pressure with low air loss mattress for the healing and prevention of pressure injury
2918624|NCT03118947|Experimental|Pimavanserin 20 mg OR 34 mg per day|
2918625|NCT03118934|Experimental|AOA MF|Lotrafilcon B multifocal contact lenses fit (both eyes) using the assigned fitting guide (current or alternative), followed by a 10 ± 3 day wear period
2918626|NCT03118934|Experimental|DACP MF|Nelfilcon A multifocal contact lenses fit (both eyes) using the assigned fitting guide (current or alternative), followed by a 10 ± 3 day wear period
2918948|NCT03116763|Active Comparator|Control Group|The control group will receive standard care but without the iPeer2Peer program.
2918628|NCT03118921|Experimental|Virtual reality|The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software
2918629|NCT03118908|Experimental|Amberen and Smart B|"Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months.~SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen."
2918630|NCT03118908|Placebo Comparator|Placebo|Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
2918631|NCT03118895|Experimental|Treatment Arm|Patients with coronary artery disease at high risk of bleeding receiving the BioFreedom™ BA9™ drug-coated stent
2918632|NCT03118882|Active Comparator|Diet Group|
2918633|NCT03118882|Active Comparator|Physical activity group|
2918634|NCT03118882|Active Comparator|Physical activity and diet group|
2918635|NCT03118882|No Intervention|Control group|
2918636|NCT03118856||HD-WLE|Intervention: Prediction of polyp histology with HD-WLE
2918637|NCT03118856||EC|Intervention: Prediction of polyp histology with EC
2918638|NCT03118843|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
2918639|NCT03118830|Active Comparator|Long GnRH agonist|daily SC injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium < 5 mm and low E2 < 50 and LH < 5IU/l with either HMG or rFSH in a starting dose of 150-300 IU/day
2918640|NCT03118830|Active Comparator|GnRH antagonist|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l. Daily sc rFSH injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done
2918641|NCT03118817|Experimental|HM95573|Single arm
2918642|NCT03118804||Weaning Guide by EIT|Weaning From Mechanical Ventilation Guide by Assessment of Lung Tidal Distribution With EIT
2918643|NCT03118791|Placebo Comparator|Placebo|Capsules containing maltodextrin
2918644|NCT03118791|Active Comparator|80 mg ACN|Capsules containing 80 mg anthocyanins
2918645|NCT03118791|Active Comparator|160 mg ACN|Capsules containing 160 mg anthocyanins
2918646|NCT03118791|Active Comparator|240 mg ACN|Capsules containing 240 mg anthocyanins
2918647|NCT03118791|Active Comparator|320 mg ACN|Capsules containing 320 mg anthocyanins
2918648|NCT03118791|Active Comparator|480 mg ACN|Capsules containing 480 mg anthocyanins
2918649|NCT03118765|Experimental|Test Treatment T1: GSP304 Inhalation Solution|
2918650|NCT03118765|Experimental|Test Treatment T2: GSP304 Inhalation Solution|
2918651|NCT03118765|Experimental|Test Treatment T3: GSP304 Inhalation Solution|
2918652|NCT03118765|Placebo Comparator|Test Treatment T4: GSP304 Placebo Inhalation Solution|
2918653|NCT03118765|Active Comparator|Test Treatment T5: Spiriva® Respimat® inhalation spray|
2918654|NCT03118752|Experimental|Collaborative Care|Participants randomized to collaborative care (CC) will receive a 26-week, telephone based CC intervention. Care managers will monitor participants' psychiatric symptoms, review current treatments for their psychiatric and cardiac illnesses, deliver psychotherapeutic interventions, provide education about self-monitoring for cardiac symptoms, perform motivational interviewing to encourage health behavior adherence, and coordinate care between psychiatric/cardiac specialists and participants' primary care physicians. CC will utilize a treat-to-target approach, with a goal of remission of psychiatric and cardiac symptoms.
2918655|NCT03118752|No Intervention|Enhanced Usual Care|Participants in the enhanced usual care (eUC) arm will not receive any specific intervention, though they will be free to receive any treatment for psychiatric or cardiac illness. Participants' outpatient providers will be informed of their psychiatric diagnosis, which may lead to higher-than-usual treatment for psychiatric illness.
2918656|NCT03118739|Experimental|RDEA3170 9 mg+Febuxostat 80 mg|Capsule administered orally, once daily for 24 weeks
2918657|NCT03118739|Placebo Comparator|Placebo|Capsule administered orally, once daily for 24 weeks
2918658|NCT03118726||NM Perinatal Collaborative|Hospitals working with the New Mexico Perinatal Collaborative (NMPC) on implementing immediate postpartum long-acting reversible contraception programs.
2918659|NCT03118713|Experimental|ipragliflozin and metformin|Subjects will receive daily dosage of ipragliflozin and metformin as single tablets
2918660|NCT03118713|Experimental|glimepride and metformin|Subjects will receive daily dosage of glimepride and metformin as single tablets
2918661|NCT03118700|No Intervention|Non-exercise Control|Subjects will come to the laboratory for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow. During this time, subjects will remain seated with their body posture maintained constant
2918662|NCT03118700|Experimental|Aerobic Interval Exercise|Subjects will be equipped with a heart rate (HR) monitor and perform an interval exercise bout on a cycle ergometer. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax. After the exercise, subjects will remain seated in the lab for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow.
2918693|NCT03118453|Active Comparator|Passive implementation clinics|Patients recruited by physical therapists who underwent an implementation period with passive implementations strategies, such as written material and a short web lecture. A behavioral medicine approach in physical therapy for patients with musculoskeletal pain was encouraged with these passive implementation strategies
2918949|NCT03116737|Experimental|Benzocaine Otic Solution|
2918663|NCT03118700|Experimental|Continuous Exercise|Subjects will be equipped with a heart rate (HR) monitor and perform an interval exercise bout on a cycle ergometer. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will perform a 30-minute exercise bout at a HR that elicits 75%-80% of their measured HRmax. Work rate will be adjusted, if needed, to keep HR within this value. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax. After the exercise, subjects will remain seated in the lab for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow.
2918664|NCT03118674|Experimental|Harvoni|1 tablet per day, oral, taken with or without food. 8 weeks for patients without cirrhosis, not previously treated with HCV GT1 and HCV rNA < 6 million IU/mL; 12 weeks for patients without cirrhosis; 24 weeks for patients with compensated cirrhosis
2918665|NCT03118661|Experimental|Maraviroc after allo-HCT|"Step 1: participants who have received at least 30 days of maraviroc immediately post allo-HCT can be enrolled. Blood will be drawn at 2 time points at least 2 weeks apart, but within 4 weeks, and assessed for HIV-1 reservoir using both DNA assays and cell-associated reactivation by infectivity after stimulation. If any biopsies post allo-HCT are performed as part of standard of care and available, these will also be assessed for HIV-1~Step 2: If HIV-1 reservoir is undetecable, antiretrovirals (ART) will be stopped in a structured treatment interruption (STI). HIV-1 VLs and CD4+ T-cells check weekly. Week 16, participants will have a large volume blood draw if remain suppressed. If confirmed return of viremia, ART will be reinitiated and he/she will be followed until HIV VL is <50 copies/ml. If he/she remains suppressed at Week 16 and repeat assays confirm no detectable HIV-1, HIV-1 VLs and CD4+ T-cell counts will be checked monthly until Week 52, and then quarterly until Year 5"
2918666|NCT03118648||stroke|"Patients over 18 years old leaving the correctional institution with orientation back home~First stroke deficit with non-regressive clinical expression in 24 hours~Independent in activities of daily living and living at home before stroke. This earlier independence is confirmed by the absence of professional carers in personal care activities~Proper oral understanding as measured by score 7 in the Language Screening Test (LAST) (Flamand-Roze et al, 2011)~No psychiatric history that led to hospitalization for more than six months~Written informed consent after reading the briefing note~Patient affiliated or beneficiary of a social security scheme."
2918667|NCT03118635|Experimental|Intervention|Daily, four-hour physical activity intervention
2918668|NCT03118635|No Intervention|Control|No treatment control
2918669|NCT03118622||Pentax group|Intubation using Pentax
2918670|NCT03118622||Macintosh group|Intubation using Macintosh
2918671|NCT03118609|Experimental|"Caregivers for Understanding Needs"|"5-8 informal caregiver participants in focus group will discuss current perceived needs.~Up to 150 participants will complete the Understanding Needs survey"
2918672|NCT03118596|Active Comparator|I-gel|Fibreoptic guided tracheal intubation through I-gel
2918673|NCT03118596|Active Comparator|LMA Protector|Fibreoptic guided tracheal intubation through Protector
2918674|NCT03118583|Experimental|Dietary supplement with carrageenan|300 mg/day of dietary supplement containing carrageenan
2918675|NCT03118570|Experimental|BPS804 Dose 1|BPS804 IV Infusion
2918676|NCT03118570|Experimental|BPS804 Dose 2|BPS804 IV Infusion
2918677|NCT03118570|Experimental|BPS804 Dose 3|BPS804 IV Infusion
2918678|NCT03118570|Experimental|BPS804 Dose 4|BPS804 IV Infusion
2918679|NCT03118557|Experimental|Pilates pelvic floor strengthening exercise|
2918680|NCT03118544||Patients undergoing CTO PCI|Evaluates the effect of the DyeVert System on contrast volume administration in patients undergoing clinically-indicated CTO PCI. The system allows monitoring and display of contrast volumes that are manually injected during the procedure which will be compared to physician entered contrast usage thresholds during angiographic procedures.
2918681|NCT03118531|Experimental|Coronary Stent|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System (34/38 mm)
2918682|NCT03118518|Active Comparator|Anti-arrhythmic drug|
2918683|NCT03118518|Experimental|Cryoablation|
2918684|NCT03118505|Experimental|Group 1|Infuse Bone Graft [4.2 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
2918685|NCT03118505|Experimental|Group 2|Infuse Bone Graft [6 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
2918686|NCT03118505|Experimental|Group 3|Infuse Bone Graft [12 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
2918687|NCT03118505|Active Comparator|Control|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation.
2918688|NCT03118492|Experimental|Treatment (combination chemotherapy, TBI, HCT)|Patients receive melphalan IV over 30 minutes on day -5, fludarabine IV over 30-60 minutes on days -5 to -2. Patients undergo TBI on day -1 and HCT on day 0. Patients receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Starting on day 5, patients receive tacrolimus IV then PO for 6 months followed by a taper, mycophenolate mofetil PO TID until day 35, and G-CSF IV daily until absolute neutrophil count > 1,500/mm^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
2918689|NCT03118479|Experimental|Androgen only addback|Anastrozole 10 mg orally once daily for 3 months Testosterone gel 7.5 g transdermally daily for 3 months.
2918690|NCT03118479|Experimental|Combined sex steroid addback|Placebo (sugar pill) tablet once daily for 3 months Testosterone gel 7.5 g transdermally daily for 3 months.
2918691|NCT03118466|Experimental|Lenalidomide and MEC chemotherapy|Lenalidomide is taken orally on a daily basis days 1-10. Mitoxantrone, Etoposide, and Cytarabine are administered intravenously on a daily basis for days 4 through 8 of the treatment. There is only one cycle of treatment in this study.
2918692|NCT03118453|Experimental|Active implementation clinics|Patients recruited by physical therapists who underwent an implementation period with active implementations strategies, such as supervision, web lectures, peer learning in groups consisting of colleagues. A behavioral medicine approach in physical therapy for patients with musculoskeletal pain was encouraged with these active implementation strategies.
2918694|NCT03118440|Experimental|Zero-fluoroscopy implantation|Pacemaker implantation performed for all patients in this group with zero-fluoroscopy 3D navigation.
2918950|NCT03116737|Placebo Comparator|Placebo|
2918695|NCT03118440|Active Comparator|Conventional fluoroscopy implantation|Pacemaker implantation performed for all patients with conventional x-ray navigation.
2918696|NCT03118427|Experimental|Zero-fluoroscopy implantation|Pacemaker implantation performed for all patients in this group with zero-fluoroscopy 3D navigation.
2918697|NCT03118427|Active Comparator|Conventional fluoroscopy implantation|Pacemaker implantation performed for all patients with conventional x-ray navigation.
2918698|NCT03118414|Experimental|Physical Exercise Group|Physical Exercise (PE) is an intervention that aim to improve balance and muscle strength of the elders. It composed of 3 steps; warming up exercise, core content of the exercise (strength and balance training) and cool down exercise program.
2918699|NCT03118414|Experimental|Virtual Reality|Virtual Reality (VR) VR is an intervention that aim to improve balance of the elders. It stimulates the auditory and visual function and concentration of the participants throughout the training. It composed of 10 games that included weight shifting from side to side, stepping into different directions, trunk flexion, extension and side bending, movements of the upper and lower limbs, and trunk twisting in this study.
2918700|NCT03118414|Experimental|Brain Exercise|"Brain Exercise (BE) BE is an intervention that aim to stimulate the cognitive function of the elders.~It stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training"
2918701|NCT03118414|No Intervention|Control Group|No Intervention: Healthy control No intervention was given to this group of participants. The control group was reminded not to participate in any other exercise or intervention program except their routine daily activities.
2918702|NCT03118401|Experimental|Ritual of stool|During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
2918703|NCT03118401|Other|Usual practice|"During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.~At the end of this second period, data will be collected on an individual stool diary in for 4 weeks"
2918704|NCT03118388|Experimental|36 SEI youth|36 homeless youth (ages 16-24) randomized to the SEI intervention
2918705|NCT03118388|Experimental|36 IPS youth|36 homeless youth (ages 16-24) randomized to the IPS intervention
2918706|NCT03118375||Cohort|Hearing and speech tests will be performed on the subject and repeated to compare results obtained using their current BAHA processor against results using super-power BAHA processor.
2918707|NCT03118362|Experimental|Plasmalyte®|Plasmalyte® is a balanced solution containing a low chloride concentration (i.e. 98 mmol/L), it also contains acetate (27 mmol/L) and gluconate (23 mmol/L) as buffer solutions.
2918708|NCT03118362|Experimental|Ringer Lactate®|Ringer Lactate® is a balanced solution containing a low chloride concentration (i.e. 111mmol/L), it also contains lactate (29 mmol/L) as buffer solutions.
2918709|NCT03118349|Experimental|Escalation Cohorts|MVT-5873 blocking dose and MVT-1075 dose escalation Initial to maximum tolerated dose
2918710|NCT03118349|Experimental|Expansion Cohort|MVT-5873 blocking dose and MVT-1075 Maximum tolerated dose
2918711|NCT03118336|Placebo Comparator|placebo group|
2918712|NCT03118336|Experimental|empaglifozine group|
2918713|NCT03118323||Patients in need of endodontic treatment|n = 200
2918714|NCT03118310|Placebo Comparator|Placebo|Placebo diet
2918715|NCT03118310|Experimental|5:2|5:2 diet
2918716|NCT03118310|Experimental|LCHF|LCHF diet
2918717|NCT03118297|Experimental|Ulipristal Acetate|15mg ulipristal acetate (capsule) daily for 7 days
2918718|NCT03118297|Placebo Comparator|Placebo|Identical placebo (capsule) daily for 7 days
2918719|NCT03118284||Foley catheter group|Urine collection and blood collection and NRS for pain in patients having surgery for which their surgeon has ordered placement of a Foley catheter.
2918720|NCT03118284||Healthy control group|Blood collection in healthy volunteers from the Research Participant Registry or recruited from posters around the Washington University campus
2918721|NCT03118271|Active Comparator|lumbar traction|Treatment with lumbar traction is via an OPD base. It comprised a 20 min. treatment session over a period of 2 months. If the symptoms subside before the end of 2 months' treatment, lumbar traction will be discontinued, and the treatment duration and number of treatment session will be recorded. The frequency of treatment is 3 times per week. Treatment method is according to the common clinical guidelines, starting from 25% of the subject's body weight and steadily increasing to 50% of body weight. Before traction, heat therapy will be applied to the low back of the subject, and electric therapy will also be given to the painful areas. The treatment will be conducted by the same physiotherapist.
2918722|NCT03118271|Active Comparator|spinal manipulation|Spinal manipulation will be performed by a spinal manipulator (Dr. Tso-Liang Wang) who was graduated from Los Angeles College of Chiropractic. Before performing spinal manipulation, he will exam the patient's whole body throughly, especially focusing on the lumbo-pelvic-hip region. What he exams includes pelvic and spinal alignment, tension of soft tissues, tissue texture, joint mobility, movement patterns, and muscle power. The manipulation is started with release of the hypertonic myofascial structures and thus normalize the myofascial tension of the lumbo-pelvic-hip region. Then he will align the lumbar spine, pelvis and hip joint three-dimensionally according to the findings of his examination on the same day. The manipulation will be performed up to 8 times within one month (no more than 2 manipulations a week). If the symptoms subside before the end of one-month' treatment, the manipulation is discontinued and the number of treatment session will be recorded.
2918750|NCT03118089|No Intervention|Standard Care|Participants will remain on their current oral nutritional supplement
2918751|NCT03118076|Placebo Comparator|Group R|Nerve blocks were administered with 0.3% ropivacaine without dexmedetomidine.
2918752|NCT03118076|Experimental|Group RD|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
2918753|NCT03118063|Experimental|Active trigger point|Evaluation of the dynamometry of the maximum and medium gluteus muscles and correlate with the presence or not of trigger point
2919043|NCT03116113|Experimental|High dose AAV-RPGR|Single, subretinal administration of a single high dose range AAV-RPGR
2918723|NCT03118271|Active Comparator|surgery|General anesthesia, the patient will be put in the prone and abdomen-free position. A 4-cm midline longitudinal incision will be made over the spinous processes of the L3-5 levels. It will be deepened through the fat and fascia in line with the skin incision to reach the spinous processes.The paraspinous muscles will be dissected subperiosteally down the spinous processes and along the lamina to the facet joints. Laminectomy will be done carefully at the herniated disc level for posterior decompression. The ligamentum flavum will be excised to expose the dural sac.Using blunt dissection, the investigators carefully continue down the lateral side of the dura to the floor of the spinal canal; the investigators retract the dura and its nerve root medially. After the posterior aspect of the disc space is revealed, the affected disc will be removed and discotomy will be performed.The wound will be closed in the routine fashion after meticulous hemostasis and normal saline irrigation.
2918724|NCT03118258|Experimental|"Pap test"|"Arm Pap test: Participation of a prevention consultation and a referral to health centers partners for a pap smear test"
2918725|NCT03118258|Experimental|"HPV self-sampling + Pap test"|"Arm HPV self-sampling + Pap test: Participation of a prevention consultation and proposition of vaginal HPV self-sampling and a referral to health centers partners for a pap smear test. HPV test is performed on the sample in a virology laboratory."
2918726|NCT03118245|Experimental|AuraGain group|AuraGain is inserted for maintenance of general anesthesia. The size 1 is for children <5kg, size 2 for 5-10kg, size 2 for 10-20kg, and size 2.5 for 20-30kg.
2918727|NCT03118245|Experimental|I-gel group|I-gel is s inserted for maintenance of general anesthesia. The size 1 is for children weighted 2-5kg, size 2 for 5-12kg, size 2 for 10-25kg, and size 2.5 for 25-35kg.
2918728|NCT03118232|Active Comparator|Decolonization|Nursing homes assigned to this arm will perform decolonization using topical antiseptic products.
2918729|NCT03118232|No Intervention|Routine Bathing|Routine bathing per facility protocol.
2918730|NCT03118219|Experimental|Positive adjustment coping intervention|All persons allocated to the intervention group will receive daily text messages (SMS) to their smartphones with sentences for positive adjustment over two weeks starting from the day of the egg-cell punctuation.
2918731|NCT03118219|Other|Brainteaser|All persons allocated to the comparison intervention group will receive daily text messages (SMS) to their smartphones with brainteasers over two weeks starting from the day of the egg-cell punctuation.
2918732|NCT03118206|Active Comparator|Lumbar spinal manipulation|Lumbar spinal manipulation will be performed up to 8 times within 1 month (no more than 2 times per week) by Dr. WangTso-Liang, who is a well-trained and experienced manual therapy doctor. If the symptoms subside before the end of 1 month' treatment, the manipulation is discontinued.
2918733|NCT03118206|Active Comparator|Physical therapy|Physical therapy will include treatment with therapeutic exercise and modalities (lumbar traction, heattherapy, electric stimulation, and therapeutic exercise) for 2 month with frequency 3 times per week.
2918734|NCT03118206|Active Comparator|Surgery|General anesthesia, the patient will be put in the prone and abdomen-free position. A 4-cm midline longitudinal incision will be made over the spinous processes of the L3-5 levels. It will be deepened through the fat and fascia in line with the skin incision to reach the spinous processes.The paraspinous muscles will be dissected subperiosteally down the spinous processes and along the lamina to the facet joints. Laminectomy will be done carefully at the herniated disc level for posterior decompression. The ligamentum flavum will be excised to expose the dural sac.Using blunt dissection, the investigators carefully continue down the lateral side of the dura to the floor of the spinal canal; the investigators retract the dura and its nerve root medially. After the posterior aspect of the disc space is revealed, the affected disc will be removed and discotomy will be performed.The wound will be closed in the routine fashion after meticulous hemostasis and normal saline irrigation.
2918735|NCT03118193|Experimental|Depressive patient|olfactive tests ; blood test ; optional: Tissue Pulsatility imaging ; optional: Collection of faeces
2918736|NCT03118180|Experimental|CART19 group|All patients were included for CART19 therapy
2918737|NCT03118167|Experimental|Tea polyphenols & Acrylamide|TP 0.05g, 0.1g, 0.2g (starches filled, up to 0.35g) capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
2918738|NCT03118167|Experimental|AOB-w & Acrylamide|AOB-w 0.35g capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
2918739|NCT03118167|Active Comparator|Placebo & Acrylamide|Placebo (Starches) 0.35g capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
2918740|NCT03118154||Manual Physical Therapy, retrospective|Endometriosis subjects treated at Clear Passage with follow up to assess changes in pain and overall health in a retrospective chart review.
2918741|NCT03118154||Control, prospective|Endometriosis control subjects not treated at Clear Passage that complete two questionnaires, 30 days apart, to assess changes in their pain levels.
2918742|NCT03118141|Active Comparator|PGS group|Subjects in the PGS group will have blastocyst biopsy and sequencing done with 3 good-quality embryos on Day 5. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by blastocyst morphologic score. The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
2918743|NCT03118141|Active Comparator|IVF group|Subjects in the IVF group will also comply with the principle of freeze-all and single thawed blastocyst transfer. The order of transfer will be determined by blastocyst morphologic score. The outcome of up to 3 transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
2918744|NCT03118128|Active Comparator|metformin|Metformin 850mg PO three times a day, during the pre-induction with steroids, induction remission, consolidation and maintenance
2918745|NCT03118128|No Intervention|No metformin|
2918746|NCT03118115|Experimental|Impedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
2918747|NCT03118102||anesthetist group|anesthetist doctor who subjected to noise in operating rooms
2918748|NCT03118102||control group|doctors in the same hospital who are not subjected to noise in operating rooms
2918749|NCT03118089|Experimental|Biscuit style oral nutritional supplement treatment|Participants will take the biscuit style oral nutritional supplement at an intervention level equivalent to their current oral nutritional supplement prescription
2918754|NCT03118063|Active Comparator|Latent trigger point|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
2918755|NCT03118063|Active Comparator|No trigger point|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
2918756|NCT03118050|Experimental|RT in T2DM|Type 2 diabetes subjects will undergo 3 months of resistance exercise training. Muscle size, strength and response to a low dose amino acids will be measured before and after training.
2918757|NCT03118050|Experimental|BR in healthy subjects, LAA|Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
2918758|NCT03118050|Experimental|BR in healthy subjects, HAA|Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.
2918759|NCT03118050|Experimental|BR in T2DM, LAA|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
2918760|NCT03118050|Experimental|BR in T2DM, HAA|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.
2918761|NCT03118050|Experimental|BR in healthy subjects, PT|Healthy subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
2918762|NCT03118050|Experimental|BR in T2DM, PT|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
2918763|NCT03118037||Sonata|Women who undergo transcervical radiofrequency(RF) ablation with the Sonata System for treatment of their fibroids
2918764|NCT03118024|Active Comparator|Fluid restriction|Crystalloid fluid max. 2.0 ml/kg/h, no administration of colloids, noradrenaline max. 0.15 µg/kg/min
2918765|NCT03118024|Active Comparator|Catecholamine restriction|Noradrenaline max. 0.04 µg/kg/min, fluids max. 8.0 ml/kg/h
2918766|NCT03118011|Active Comparator|No smoking|The ward where the patients can not go out to smoke
2918767|NCT03118011|Placebo Comparator|Smoking|The ward where the patients can go out to smoke.
2918768|NCT03117998|Experimental|REMD-477 Treatment A|Administered as a repeated subcutaneous (SC) doses in subjects with Type 1 Diabetes
2918769|NCT03117998|Experimental|REMD-477 Treatment B|Administered as a repeated SC doses in subjects with Type 1 Diabetes
2918770|NCT03117998|Placebo Comparator|Matching placebo|Administered as a repeated SC doses in subjects with Type 1 Diabetes
2918771|NCT03117985|Experimental|Antiretroviral therapy|Stopping antiretroviral therapy
2918772|NCT03117972|Experimental|Arm A : FOLFOXIRI - bevacizumab|FOLFOXIRI + bevacizumab, 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 or bevacizumab-capecitabine) until disease progression or limiting toxicities
2918773|NCT03117972|Active Comparator|Arm B: FOLFOX or FOLFIRI - bevacizumab|FOLFOX or FOLFIRI + bevacizumab 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 ou bevacizumab capecitabine) until disease progression or limiting toxicities
2918774|NCT03117959|Placebo Comparator|Stryker Triathlon Custom Fit Knee|implanted in standard fashion
2918775|NCT03117959|Experimental|Stryker shape match|no longer RCT
2918776|NCT03117946|Experimental|Biological samples|"Blood samples will be collected at baseline, at J15/J20 after RTCT initiation, and then 1 month, 3 months and 12 months after the end of RTCT treatment, and at disease progression if applicable.~Tumor tissues will be collected if available."
2918777|NCT03117933|Active Comparator|A: Paclitaxel|Paclitaxel, IV weekly, 80mg/m2; until progression
2918778|NCT03117933|Experimental|B: Olaparib|Olaparib, oral, 300mg twice daily; until progression
2918779|NCT03117933|Experimental|C: Olaparib and Cediranib|Olaparib, oral, 300mg twice daily and Cediranib, tablet, 20mg once daily; until progression
2918780|NCT03117920|Experimental|Minnelide|0.67 mg/m2 Minnelide daily as a 30min iv infusion on days 1-21 of each 28 day cycle, followed by a 7 day rest period (D 22-28).
2918781|NCT03117907||Infants with low infectious status|
2918782|NCT03117907||Infants with high infectious status|
2918783|NCT03117894|Active Comparator|GA with RA|Regional Anesthesia and General Anesthesia.
2918784|NCT03117894|Active Comparator|GA without RA|Only General Anesthesia (without a supplemental Regional Anesthesia).
2918785|NCT03117881|Experimental|DirectCAM|The DirectCAM arm will receive the intervention content in the rehabilitation clinic.
2918786|NCT03117881|Experimental|TeleCAM|The TeleCAM arm will receive the intervention content at home using pre-loaded tablets and Interactive Voice Response (IVR) system technology.
2918787|NCT03117855|Experimental|Treatment (capecitabine, yttrium Y-90 radioembolization)|Patients undergo yttrium Y 90 resin microspheres radioembolization over 60-90 minutes on day 1. Patients receive capecitabine PO BID on days 1-14.
2918788|NCT03117842|Experimental|Intervention Group|Participants in the intervention group will receive the 3 text or voice messages weekly. The messages will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support.
2918789|NCT03117842|No Intervention|Control Group|"Those in the control group will get one check-in text or voice message between baseline and midline and another between midline and endline."
2918790|NCT03117829|Experimental|Improve Brain Blood Flow|12 week diet and exercise program to improve brain blood flow
2918791|NCT03117816|Experimental|investigational arm A|There will be an overlapping treatment with AOP2014 and TKI for one month. After one month, the TKI therapy will be stopped and patient will receive only AOP2014 treatment for the next 14 months.
2918792|NCT03117816|Other|surveillance arm B|"This is an open-label study with a no treatment/ surveillance group as comparator arm.~Similar as in the arm A, patient will discontinue TKI therapy one month after randomization. From then on patient will receive no further treatment."
2918793|NCT03117790|Experimental|Dexmedetomidine group|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
2918794|NCT03117790|Placebo Comparator|Placebo group|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
2918795|NCT03117764|Active Comparator|Acute IV AB for exacerbation at hospital|"The study will compare muscular strength of hospitalised patients who receive specific exercise training, with patients who follow their antibiotherapy at home without specific exercise training.~Interventions: microfet dynamometer, 1 minute sit to stand test, accelerometer."
2918796|NCT03117764|Experimental|Acute IV AB for exacerbation at home|"The study will compare muscular strength of hospitalised patients who receive specific exercise training, with patients who follow their antibiotherapy at home without specific exercise training.~Interventions: microfet dynamometer, 1 minute sit to stand test, accelerometer."
2918797|NCT03117751|Experimental|B-ALL and B-LLy, Low Risk|"Patients with low-risk B ALL and LLy will have Induction (6 weeks), Consolidation (8 weeks), and Continuation (120 weeks). During Remission Induction therapy, prednisone dose is 40mg/m^2 and 1-2 doses of daunorubicin (based on day 8 peripheral blood MRD in patients with ETV6-RUNX1 or hyperdiploid) are given. Dasatinib is given for patients with ABL1-class fusion.~Interventions: Prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, rituximab, dasatinib, methotrexate, dexamethasone."
2918798|NCT03117751|Experimental|B-ALL and B-LLy, Standard Risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Continuation (120 wks). During Remission Induction therapy, prednisone dose is 40mg/m^2 and 2 doses daunorubicin are given. Dasatinib is given for patients with Ph+ and those with ABL1-class fusion. Ruxolitinib is given for patients with activation of JAK-STAT signaling; ALL patients with Day 15 MRD ≥5% or Day 42 MRD ≥1% and LLy patients who don't qualify for complete response at end of Remission Induction. Bortezomib is given to patients without targetable lesions; ALL patients with Day 15 MRD ≥5% and/or end of Remission Induction MRD ≥1% and LLy patients who don't qualify for complete response at end of Remission Induction.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, rituximab, dasatinib, bortezomib, ruxolitinib, methotrexate, dexamethasone, doxorubicin."
2918799|NCT03117751|Experimental|B-ALL and B-LLy, High Risk|"Induction (6 weeks), Early Intensification (4 weeks), Consolidation (8 weeks), and Immunotherapy. Patients who do not respond to Immunotherapy will receive Reintensification therapy. During Remission Induction therapy, prednisone dose is 40mg/m^2 and 2 doses of daunorubicin are given. Dasatinib, ruxolitinib, and bortezomib are given as done for patients with standard risk B-ALL but are discontinued in Immunotherapy and Reintensification therapy.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, rituximab, dasatinib, bortezomib, ruxolitinib, blinatumomab, etoposide, cytarabine, dexamethasone, clofarabine."
2918800|NCT03117751|Experimental|T-ALL and T-LLy, Standard Risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Continuation (120 wks). During Remission Induction therapy, prednisone dose is 60mg/m^2 and 3 doses daunorubicin are given. Dasatinib is given for patients with Ph+ and those with ABL1-class fusion. Ruxolitinib is given for patients with activation of JAK-STAT signaling; ALL patients with Day 15 MRD ≥5% or Day 42 MRD ≥1% and all patients with ETP and LLy patients who don't qualify for complete response at end of Remission Induction. Bortezomib is given to patients without targetable lesions; ALL patients with Day 15 MRD ≥5% and/or end of Remission Induction MRD ≥1% and LLy patients who don't qualify for complete response at end of Remission Induction.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, methotrexate, dexamethasone, doxorubicin, nelarabine."
2918801|NCT03117751|Experimental|T-ALL and T-LLy, High Risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Reintensification. During Remission Induction therapy, prednisone dose is 60mg/m^2 and 3 doses daunorubicin are given. Dasatinib, ruxolitinib, and bortezomib given as done for patients with standard risk T-ALL but are discontinued in Reintensification therapy.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, methotrexate, etoposide, dexamethasone, clofarabine, vorinostat, idarubicin, nelarabine."
2918802|NCT03117751|Experimental|B-ALL, Rituximab|"Patients with B-ALL will be randomized (unblinded) for administration of a dose of rituximab on Day 3 prior to the first dose of pegaspargase to prevent sensitization to asparaginase and subsequent asparaginase reaction and to improve anti-leukemia outcome.~Interventions: rituximab, pegaspargase (or Erwinase®)."
2918803|NCT03117751|Experimental|ALL, CEP72 T/T, Vincristine|"ALL (both B and T) patients with the CEP72 rs904627T/T genotype (~16% of patients) will be randomized (unblinded design, only those who evaluate neuropathy are blinded) to receive either 1.5 mg/m^2 or 1 mg/m^2 of vincristine beginning with Continuation Week 1.~Intervention: vincristine."
2918804|NCT03117751|Experimental|ALL, CEP72 C/T or C/C, Vincristine|"ALL patients (both B and T) with either a CEP72 rs904627 C/T or C/C genotype (~84% of patients) will be randomized (unblinded design, only those who evaluate neuropathy are blinded) to receive vincristine (1.5 mg/m^2 per dose) and dexamethasone pulses through Week 49 of Continuation Treatment or through Week 101 of Continuation Treatment.~Interventions: vincristine, dexamethasone, methotrexate, mercaptopurine."
2918805|NCT03117738|Experimental|AstroStem|
2918806|NCT03117738|Placebo Comparator|Placebo-Control|
2918807|NCT03117725|Experimental|melatonin administration group|"Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. After randomization, participants are to under go melatonin administration intervention from the time of controlled ovarian hyperstimulation(COH) to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.~For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval."
2918842|NCT03117478|Other|3. Participants without meditation experience|Novices. There is no meditation intervention during the study but the investigators investigate the effects of meditation by comparing 2 groups who differ in their life time meditation experience (i.e., novices vs. experts).
2918808|NCT03117725|Placebo Comparator|placebo comparator|"Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. Participants for placebo comparator are advised to take the drug (placebo) from the time of COH to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.~For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval."
2918809|NCT03117712||Delirium|patients who develop postoperative delirium after surgery with cardiopulmonary bypass measured by Delirium scores (CAM-ICU, ICDSC), TCD for detection of HITS and carotis duplex sonography
2918810|NCT03117712||No delirium|patients who develop no postoperative delirium after surgery with cardiopulmonary bypass measured by delirium scores (CAM-ICU, ICDSC), TCD for detection of HITS and carotis duplex sonography
2918811|NCT03117699|Experimental|Hemiplegic subjects|"Testing of a new device for seated-standing passages after undergoing medical evaluation included Fugl Meyer scale, Berg scale and Bergego scale.~Phase 1 :~3 seated-standing passages with a handle equipped with 6 force captors~3 seated-standing passages with the device"
2918812|NCT03117699|Experimental|Healthy volunteers|"Testing of a new device for seated-standing passages .~Phase 1 :~3 seated-standing passages without help~3 seated-standing passages with a handle equipped with 6 force captors~3 seated-standing passages with the device"
2918813|NCT03117686||healthy volunteers|10 healthy volunteers climbing Mount Kilimanjaro receiving lung ultrasound
2918814|NCT03117686||patients after lung transplantation|10 patients > 2years after lung transplantation climbing Mount Kilimanjaro receiving lung ultrasound
2918815|NCT03117673||group 1|Patients with mild to moderate TI and normal RVSP (< 40mmHg) and mean PAP (< 25mmHg)
2918816|NCT03117673||group 2|Patients with mild to moderate TI and elevated RVSP (> 40mmHg) and mean PAP (> 25mmHg)
2918817|NCT03117673||group 3|Patients with severe TI (defined as Vena contracta > or equal 7mm, reversed systolic hepatic vein flow, proximal isovelocity surface area (PISA) radius > 9 mm, and very large central jet or eccentric wall impinging jet)
2918818|NCT03117660|Experimental|Vitamin A|Subjects will receive 3-4weeks of vitamin A
2918819|NCT03117660|No Intervention|Control|Subjects will receive no treatment
2918820|NCT03117634|Active Comparator|Fixed dosing group (2Q8)|Fixed Dosing with Aflibercept 2mg will be administered at a fixed regime at 8 week intervals through to week 52.
2918821|NCT03117634|Experimental|Treat and Extend group (T&E)|Reassessment at week 12 (month 3) by repeat examination for disease activity by OCT and ICGA. Subsequent treatment regime of Treat and Extend with Aflibercept 2mg will depend on disease activity at this point.
2918822|NCT03117621||Patients initiating Blinatumomab|Patients initiating Blinatumomab after Country-Specific Reimbursement approval in routine clinical practice
2918823|NCT03117608|Experimental|AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE (aMAT)|injection of aMAT obtained with Lipogems® technology.
2918824|NCT03117608|Active Comparator|platelet-rich plasma (PRP)|single injection of platelet-rich plasma
2918825|NCT03117595|Active Comparator|BF|Interventions: Intrathecal administration -Bupivacaine 2.5mg (0.5ml) + Fentanyl 25mcg (0.5ml) + 1ml sterile water in one shot Ephedrine 3-5mg in aliquots in the event of hypotension Promethazine 12.5 - 25mg in the event of vomiting or significant pruritus naloxone 2mcg/kg in the event of respiratory distress
2918826|NCT03117595|Active Comparator|BFM|Interventions: Intrathecal administration - Bupivacaine 2.5mg (0.5ml) + fentanyl 25mcg (0.5ml) + 0.25mg morphine (0.25ml) + 0.75ml sterile water in one shot ephedrine 3-5mg in aliquots for hypotension Promethazine 12.5 - 25mg for vomiting or significant pruritus Naloxone 2mcg/kg in the event of respiratory distress
2918827|NCT03117582||Patients with C.diff infection|Patients with C.diff infection not responding to antibiotics who are now scheduled for the FMT procedure for routine care of their condition.
2918828|NCT03117569|Other|Standard monitoring schedule|Participants will have on-treatment clinic visits at weeks 4 and 8. Participants have also phone contact-based visits at weeks 4 and 8 (1-2 days prior to scheduled clinic visits).
2918829|NCT03117569|Experimental|Simplified monitoring schedule|Participants will have no on-treatment clinic visits at weeks 4 and 8. Participants have phone contact-based visits at weeks 4 and 8.
2918830|NCT03117556|Experimental|BTS Intervention|Bilateral thoracoscopic splanchnicectomy and infusaport placement will be performed on patients randomly selected for treatment with BTS and narcotic analgesia. Narcotics will still be prescribed for pain as needed.
2918831|NCT03117556|No Intervention|No BTS Intervention|Patients chosen to be treated with narcotic analgesia alone will undergo infusaport placement only.
2918832|NCT03117530|Experimental|Minocycline|
2918833|NCT03117517|Experimental|Metformin|Drug intervention: Metformin 500 mg tablet twice orally for 3 months
2918834|NCT03117517|Active Comparator|Metformin, pioglitazone|Drugs intervention: Combination of Metformin (1000 mg) and pioglitazone (30 mg) tablets will be given orally for 3 months
2918835|NCT03117504||First trimester|women during first trimester(less than 14 weeks of pregnancy) will complete self-reported questionnaires and undergo clinical examination to confirm the stress incontinence.
2918836|NCT03117504||Third trimester|women during third trimester(more than 28 weeks of pregnancy) will complete self-reported questionnaires and undergo clinical examination to confirm the stress incontinence.
2918837|NCT03117491|Active Comparator|GGNB injection technique|In GGNB group, every patient received two1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the GGNB technique
2918838|NCT03117491|Active Comparator|IANB injection technique|In IANB group, every patient received two 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the IANB technique
2918839|NCT03117491|Active Comparator|GGNB + IANB injection technique|In IANB + GGNB group, every patient received one 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the IANB technique and one 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the GGNB technique
2918840|NCT03117478|Other|1. Participants without meditation experience|Novices. Note that there is no meditation intervention in this study but that the two groups differ in their lifetime meditation experience.
2918841|NCT03117478|Other|2. Participant with a significant meditation experience|Experts : > 5000 hours of practice during their life. Note that there is no meditation intervention in this study but that the two groups differ in their lifetime meditation experience.
2918843|NCT03117478|Other|4. Participant with a significant meditation experience|Experts : > 5000 hours of practice during their life. There is no meditation intervention during the study but the investigators investigate the effects of meditation by comparing 2 groups who differ in their life time meditation experience (i.e., novices vs. experts).
2918844|NCT03117465|Experimental|the experimental group|Stroke hemiplegia patients are randomly assigned to the experimental group (scalp acupuncture + low frequency repetitive transcranial magnetic stimulation + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
2918845|NCT03117465|Other|the control group|Stroke hemiplegia patients are randomly assigned to the control group (scalp acupuncture + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
2918846|NCT03117452|Experimental|visual training condition|Participants in the visual training condition will participate in the visual training (VT) group, during which they will complete computerized visual training that targets low- and mid-level visual processes. Each group will include a maximum of 3 participants and will meet 3 times a week over a period of 12-14 weeks.
2918847|NCT03117452|No Intervention|control condition|Participants assigned to the control condition will receive standard Partial Hospital care without visual training.
2918848|NCT03117439|No Intervention|Control Group|Patients undergoing empirical anti fungal therapy. Interruption of anti fungal treatment will be decided on the basis of standard clinically and microbiologically criteria.
2918849|NCT03117439|Experimental|1-3 Beta-D-Glucan Group|Patients undergoing anti fungal de-escalation according to 1-3 Beta-D-Glucan results
2918850|NCT03117426|Experimental|SYMFONY IOL|"The unique design of this IOL merges two complementary enabling technologies: (1) its diffractive echelette design feature extends the range of vision, and (2) achromatic technology corrects chromatic aberration for enhanced contrast sensitivity. Theoretically, combining these two mechanism of action results in a continuous range of high-quality vision for far, intermediate, and near distances with the same low incidence of halos and glare associated with monofocal IOLs (see figure 2).~Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag."
2918851|NCT03117426|Active Comparator|AT LISA tri 839MP IOL|"This trifocal IOL provides three useful focal distances, far, intermediate, and near, and therefore aims to provide functional visual restoration after cataract surgery.~Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag."
2918852|NCT03117413|Other|Asymmetric hearing loss|Asymmetric hearing loss treated with a cochlear implant will undergo positron emission tomography scan.
2918853|NCT03117413|Other|Normal hearing subjects|Normal hearing subjects will undergo positron emission tomography scan.
2918854|NCT03117400||Bland blue defect|The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is blue without any other defect features (as described in the second group, 'non bland blue defect'). The blue is the result of the submucosal injection of dye (indigo carmine), used to lift lesions before starting the resection.
2918855|NCT03117400||Non bland blue defect|The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is not just blue, but contains other defect features, such as visible vessels, herniation of vessels, submucosal fat, exposed muscle, fibrous bands, submucosal haemorrhage or non stained submucosa.
2918856|NCT03117387||moderate neuromuscular block, normal body mass index|Patients with normal BMI (< 30) who will receive a moderate neuromuscular block (train of four 1-3 twitches)
2918857|NCT03117387||deep neuromuscular block, normal body mass index|Patients with normal BMI (< 30) who will receive a deep neuromuscular block (post tetanic count of 1-2 twitches)
2918858|NCT03117387||moderate neuromuscular block, high body mass index|Patients with high BMI (> 30) who will receive a moderate neuromuscular block (train of four 1-3 twitches)
2918859|NCT03117387||deep neuromuscular block, high body mass index|Patients with high BMI (> 30) who will receive a deep neuromuscular block (post tetanic count of 1-2 twitches)
2918860|NCT03117374|Experimental|Team Nutriathlon intervention|Participants were invited to participate in the Team Nutriathlon for an 8-week period
2918861|NCT03117374|No Intervention|Control|Participants were invited to follow the regular school curricular for an 8-week period
2918862|NCT03117361|Experimental|Experimental|"Plitidepsin + bortezomib + dexamethasone~Plitidepsin will be administered as a 3-hour intravenous (i.v.) infusion on Day(D) 1 and 15 , every four weeks (q4wk)~Bortezomib will be administered as a bolus subcutaneous (s.c.) injection on D 1, 4, 8 and 11,q4wk~Dexamethasone will be taken orally on D1,8,15 and 22, q4wk"
2918863|NCT03117348|Experimental|Gradual goal-dose EN|Patients in Gradual Goal-dose EN group will receive increased calories gradually by enteral nutrition and will reach the 80% of target energy by enteral nutrition at day 8.
2918864|NCT03117348|Experimental|Immediate goal-dose EN|Patients in immediate Goal-dose EN group will reach the 100% of target energy by enteral nutrition at day 3 after abdominal surgery.
2918865|NCT03117335|Active Comparator|Vinorelbine plus Cisplatin With placebos|The control group
2918866|NCT03117335|Experimental|Vinorelbine plus Cisplatin With Sulijia|The treatment group
2918867|NCT03117322|Experimental|Synbiotic|"Each participant will receive the next:~agave inulin (4 g) in powder~Lactobacillus reuteri DSM 17938 (1 x 10^8 cfu) in 5 drops daily, once a day for four weeks."
2918868|NCT03117322|Experimental|Probiotic|Lactobacillus reuteri DSM 17938 (1 x 10^8 cfu) in 5 drops and maltodextrin (4 g) in powder daily, once a day for four weeks.
2918869|NCT03117322|Experimental|Prebiotic|agave inulin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.
2918870|NCT03117322|Placebo Comparator|Placebo|maltodextrin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.
2918871|NCT03117309|Experimental|PART A: Nivolumab|Nivolumab 240mg; Nivolumab 360mg
2918874|NCT03117296||Post Procedure PT and OT pathway|Post procedure day zero nursing mobilization; post procedure day one PT and OT assessment and intervention, daily PT and OT intervention
2918875|NCT03117283|Experimental|LTG with Bursectomy|laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach
2918876|NCT03117283|Sham Comparator|LTG without Bursectomy|laparoscopic D2 radical total gastrectomy without bursectomy
2918877|NCT03117270|Experimental|oral filgotinib tablets|
2918878|NCT03117270|Placebo Comparator|placebo tablets|
2918879|NCT03117257|Experimental|the treatment group|docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy
2918880|NCT03117257|Active Comparator|the control group|TPF induction chemotherapy combined with cisplatin chemoradiotherapy
2918881|NCT03117244|Experimental|Exercise Group|
2918882|NCT03117244|Active Comparator|Exercise and NMES Group|
2918883|NCT03117244|No Intervention|Control Group|
2918884|NCT03117231|Experimental|Active tDCS|Subjects will undergo low-intensity transcranial electrical stimulation for 20 minutes.
2918885|NCT03117231|Sham Comparator|Sham tDCS|Subjects will undergo low-intensity transcranial electrical stimulation for 20 minutes.
2918886|NCT03117205|Experimental|Kinesio Taping® group|
2918887|NCT03117205|Placebo Comparator|placebo group|
2918888|NCT03117192|Experimental|Zinc sulfate|Zinc sulfate is provided in the form of syrup at a dose of 1.5 mg/kg/day, maximum 50 mg/day.
2918889|NCT03117192|Placebo Comparator|Sucrose syrup|Sucrose syrup is used as placebo, its provided in the form of syrup with similar appearance and taste.
2918890|NCT03117179|Other|Patient with an interview|
2918891|NCT03117179|Other|Patient without an interview|
2918892|NCT03117166|Experimental|Lidocaine|treatment arm
2918893|NCT03117166|Placebo Comparator|Saline|placebo arm
2918894|NCT03117153|Experimental|DA-5502 liquid toothpaste|"SMFP 760mg, CPC 50mg, tocopherol acetate 10mg, panthenol 100mg, Dipotassium glycyrrhizinate 20mg.~everyday 3 times for 6 weeks"
2918895|NCT03117153|Placebo Comparator|placebo|"no active ingredients~everyday 3 times for 6 weeks"
2918896|NCT03117140|Active Comparator|Plain Ropivacaine|Plain Ropivacaine 0.75%, (225 mg) total volume 32 cc for interscalene block given pre-operatively
2918897|NCT03117140|Experimental|Ropivacaine + Buprenorphine|A mixture of 0.75% ropivacaine with 300 mcg buprenorphine, total volume 32 cc for interscalene block given pre-operatively
2918898|NCT03117140|Experimental|Ropivacaine + Clonidine|A mixture of 0.75% ropivacaine with 75 mcg clonidine, total volume 32 cc for interscalene block given pre-operatively
2918899|NCT03117140|Experimental|Ropivaciane + Dexamethasone|A mixture of 0.75% ropivacaine with and 8 mg dexamethasone, total volume 32 cc for interscalene block given pre-operatively
2918900|NCT03117127|Active Comparator|Whole eggs|After resistance exercise, participants will ingest whole eggs (18 g protein, 17 g fat) cooked in scrambled form.
2918901|NCT03117127|Experimental|Egg Whites|After resistance exercise, participants will ingest egg whites (18 g protein, 0 g fat) cooked in scrambled form.
2918902|NCT03117114|Other|Standard Arm|Standard colonoscopy without mounted Endocuff Vision device. Therefore standard polypectomy in case of polyp resection.
2918903|NCT03117114|Active Comparator|Endocuff Vision Arm|Endocuff Vision device mounted to the endoscope prior to the beginning of the procedure. Therefore EVD assisted polypectomy in case of polyp resection.
2918904|NCT03117101|Experimental|Dose escalation/ Dose extension of Lucitanib|"Dose escalation: Dose Level -1: 5 mg.Dose Level 1:.10 mg.Dose Level 2: 15 mg.Dose Level 3: 20 mg.~Dose extension: Once the MTD was reached, the MTD-5 mg dose level was to be extended in order to enrol up to 12 patients (number of patients was to be determined regarding safety data) to better assess the toxicity profile, PK profile and antitumor activity."
2918905|NCT03117088|Active Comparator|Checklist ISBAR 3|online-based checklist for standardized handovers
2918906|NCT03117088|Placebo Comparator|Checklist VICUR|comparator Checklist
2918907|NCT03117075|Experimental|Experimental|"using device for scoring pain scale, named ANAPA®"
2918908|NCT03117062|Experimental|Occlusal Reduction|performing occlusal reduction on functional cusps until abscence of contact was confirmed
2918909|NCT03117062|No Intervention|non-occlusal reduction|occlusal surface left intact
2918910|NCT03117049|Experimental|ONO-4538 group|"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."
2918911|NCT03117049|Placebo Comparator|Placebo group|"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."
2918912|NCT03117036||Lymphoma|Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled.
2918913|NCT03117023|Experimental|dexmedetomidine group|sufentanil + dexmedetomidine
2918914|NCT03117023|No Intervention|control group|sufentanil + saline
2918915|NCT03117010||Hemophagocytosis|"Subjects should fulfill the following criteria~Subjects should have at least one of the following problems~Presence of hemophagocytosis in tissue or bone marrow~Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria~Age > 18 years~Written informed consents~Subjects receive steroids and etoposide"
2918916|NCT03116997|Experimental|Neuromuscular blockade reversed with neostigmine/gly|
2918917|NCT03116997|Active Comparator|Neuromuscular blockade reversed with sugammadex|
2919044|NCT03116087|Active Comparator|Testosterone patch|Testosterone patches
2919045|NCT03116087|Placebo Comparator|Placebo|Placebo patches
2918918|NCT03116984|Active Comparator|Transcatheter arterial chemoembolization|TACE group: The frequency of treatment is determined based on the disease condition at a 4-6 weeks interval for patients who are randomly assigned to group of Transcatheter arterial chemoembolization (TACE) treatment.TACE is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery, and micro-embolization superselective catheterization is preferred.Adriamycin(30 to 60mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion.The dose of ultra fluid lipiodol was determined by diameter and blood supply type of HCC,generally 5-20ml, and no more than 30ml once.The boundary is considered whether there are large amounts of lipiodol to deposit in the tumor and tiny branches shadow of portal veins in paracarcinoma under fluoroscopic guidance. Embolizing agents(gelatin sponge particles 350um-560um) are added after lipiodol emulsion embolization.
2918919|NCT03116984|Experimental|TACE + external-beam radiotherapy|TACE+EBRT group: Patients who were randomized to the external- beam radiotherapy (EBRT) 3-5 weeks after the completion 2 times TACE.Radiotherapy equipment is based on the conditions of the cooperative units. 3-DCRT, IMRT or IGRT will be opted based on hospital. IGRT can also be used via helical tomotherapy, Rapid Arc or VMAT. The target volume should include the visible tumor.
2918920|NCT03116971|Experimental|Phase Ib: M3814 with cisplatin and etoposide|
2918921|NCT03116971|Experimental|Phase II: M3814 (RP2D) with cisplatin and etoposide|
2918922|NCT03116971|Placebo Comparator|Phase II: M3814 matching placebo with cisplatin and etoposide|
2918923|NCT03116958|Active Comparator|Standard care|"Patients diagnosed as OSA, treated with CPAP and followed up in sleep unit as per usual care.~Patients will be fitted with a mask and given a CPAP and instructed on how to use the device. Each CPAP machine will be provided with a modem sending daily compliance and adherence information to MyOSA web site but no intervention based on these data is planned in this group. All patients will be visited at 1,3 and 6 months at sleep unit. Patients will be checked about progress and adherence to therapy and any problems with their machine. Information will be downloaded from their machines (CPAP adherence, applied CPAP pressure, mask leak, and residual respiratory events…)."
2918924|NCT03116958|Experimental|Telemedicine|"Patients diagnosed as OSA and treated with CPAP, followed up in sleep unit, adding a telemedicine integrated system.~Patients will be fitted with a mask , given a CPAP, and instructed on how to use the device. Using patients' baseline and initial follow-up data a software will provide a prediction of CPAP compliance at 6 months, and propose personalized interventions to increase compliance (smartphone app). All patients will be visited at 3 and 6 months at sleep unit. Patients will be checked about progress and adherence to therapy and any problems with their machine."
2918925|NCT03116945|Experimental|Drug; 68Gallium Citrate|Procedure: PET/CT Imaging
2918926|NCT03116932||Part A - high risk MSM|"Part A will consist of a descriptive analysis of the acceptability and knowledge on the topic of PrEP of the individuals that undergo routine HIV testing and counseling in study facilities or through outreach activities.~Part A will be focused only on high risk MSM. For this part of the study, 225 high risk will be interviewed to understand the knowledge and acceptability of PrEP in this population in Puerto Rico."
2918927|NCT03116919|Other|Potato arm|One group will be fed an extra serving of boiled, baked or mashed potatoes daily for 1 week
2918928|NCT03116919|Other|Non-starchy vegetable|Then crossover to an extra serving of a non-starchy vegetable
2918929|NCT03116906|Experimental|BI 685509|multiple rising doses of BI 685509
2918930|NCT03116906|Placebo Comparator|Placebo|matching placebo
2918931|NCT03116893|Experimental|Reference Treatment|BI 685509 given alone, fasted
2918932|NCT03116893|Experimental|Treatment 1|BI 685509, given alone, after a high fat, high calorie breakfast
2918933|NCT03116893|Experimental|Treatment 2|BI 685509, given together with itraconazole, fasted
2918934|NCT03116893|Experimental|Treatment 3|BI 685509, given together with rifampicin, fasted
2918935|NCT03116880||Image registration|
2918936|NCT03116867||patients receiving hysteroscopic tubal occlusion|This group will have sonosalpingography done for them one month after the tubal occlusion.
2918937|NCT03116841|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg orally administered once daily
2918938|NCT03116828|Experimental|eslicarbazepine acetate (arm 1)|eslicarbazepine acetate (as first add-on)mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
2918939|NCT03116828|Experimental|eslicarbazepine acetate (arm 2)|eslicarbazepine acetate (as later add-on)
2918940|NCT03116815|Other|Intervention|Intervention is the use of the MyChart web-application whereby participants record their home blood pressure readings directly into their electronic medical record. Their physicians are then alerted of these blood pressure readings.
2918941|NCT03116802|Experimental|Statin Group|A total of 35 healthy adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, pre-screened to be receiving long term statin therapy of ≥ 6 months and negative for diabetes (defined as HbA1c <6.5%) will be enrolled upon written informed consent. They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
2918942|NCT03116802|Active Comparator|Control Group|"Another 35 healthy non-diabetic adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, not receiving long-term statins will serve as controls will be enrolled upon written informed consent.~They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)"
2918943|NCT03116789|Active Comparator|VGA-1(Probiotics)|Lactobacillus rhamnosus and Lactobacillus acidophilus.
2918944|NCT03116789|Active Comparator|VGA-2(Probiotics)|Lactobacillus rhamnosus and Lactobacillus plantarum.
2918945|NCT03116776|Experimental|Walnut Shell Glasses Moxibustion|Use wire to make a glass frame which can fix two walnut shells and moxa roll in front of the eyes, the walnut shell should be soaked in medlar chrysanthemum water and use the moxibustion to treat eye disease.
2918946|NCT03116776|Active Comparator|Sodium hyaluronate eye drops|Commonly used artificial tears in clinical.
2918947|NCT03116763|Experimental|iPeer2Peer Mentorship|In addition to standard care, youth in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with JIA aged 18-22 years who have learned to function successfully with their disease). Mentors will encourage participants to develop and engage in self-management skills and provide social support.
2918951|NCT03116724|Experimental|CVC catheterization through Rt. IJV|"The depth of central venous catheter during central venous catheterization through Rt. IJV will be decided by using real-time TEE.~The position of tip of CVC will be guided by TEE to fit the tip at 2 cm away from the junction between right atrium and superior vena cava."
2918952|NCT03116711|Active Comparator|Positive CIQ plus High Carbohydrate Diet|Positive Carbohydrate Intolerance Questionnaire (CIQ) plus 30% carbohydrate, 45% protein, 25% fat diet
2918953|NCT03116711|Active Comparator|Positive CIQ plus High Protein Diet|Positive Carbohydrate Intolerance Questionnaire (CIQ) plus 20% carbohydrate, 45% protein, 35% fat diet
2918954|NCT03116711|Active Comparator|Negative CIQ plus High Carbohydrate Diet|Negative Carbohydrate Intolerance Questionnaire (CIQ) plus 30% carbohydrate, 45% protein, 25% fat diet
2918955|NCT03116711|Active Comparator|Negative CIQ plus High Protein Diet|Negative Carbohydrate Intolerance Questionnaire (CIQ) plus 20% carbohydrate, 45% protein, 35% fat diet
2918956|NCT03116698|Experimental|Low dose DFD07 once daily|
2918957|NCT03116698|Experimental|High dose DFD07 once daily|
2918958|NCT03116698|Experimental|High dose DFD07 twice daily|
2918959|NCT03116698|Placebo Comparator|Placebo twice daily|
2918960|NCT03116685|Experimental|Oxabact OC5 capsules|Oxabact OC5 - Oxalobacter formigenes HC-1
2918961|NCT03116685|Placebo Comparator|Placebo capsules|Placebo
2918962|NCT03116672|Experimental|ketorolac 10 mg|Administration of one dose Ketorolac 10 mg 15 minutes before treatment
2918963|NCT03116672|Experimental|Diclofenac|Administration of one dose Diclofenac 15 minutes before treatment
2918964|NCT03116672|Experimental|Placebo oral capsule|Administration of Placebo capsule 15 minutes before treatment
2918965|NCT03116659|Experimental|Single Arm|Doxycycline 100 mg PO BID x 14 days, then Imiquimod up to 2 packs 3/ week x 28 days
2918966|NCT03116646|Experimental|Chewing evaluation|Children with chewing disorders will be recruited. Each child is required to bite and chew a standardized biscuit for chewing evaluation. The chewing function of each child is scored with the Karaduman Chewing Performance Scale by a physical therapist. Then, the chewing function of each child is also scored with the Karaduman Chewing Performance Scale-Family report by their families.
2918967|NCT03116633||Arm A|1st line setting-approx. 150 patients. collect tissue biopsy per standard of care & one blood draw (40ml)
2918968|NCT03116633||Arm B|1st line setting- approx. 100 patients one blood draw (40ml)
2918969|NCT03116633||Arm C|Approx. 10 patients tissue collection optional 3 blood draws (40ml) over 5 days
2918970|NCT03116620|Experimental|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
2918971|NCT03116607|No Intervention|Control|The control group will receive the usual hospital care. In addition, an interview that allows the characterization of the sample and the measurement of variables such as adherence, problems related to medication and user satisfaction.
2918972|NCT03116607|Experimental|Intervened|"The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge.~In addition, an interview that allows the characterization of the sample and the measurement of variables such as adherence, problems related to medication and user satisfaction.~patient education/ recommendations to the health team"
2918973|NCT03116594|Experimental|Low potency of NBP608|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
2918974|NCT03116594|Experimental|High potency of NBP608|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
2918975|NCT03116594|Active Comparator|Zostavax|Single dose 0.65mL Zostavax by subcutaneous injection into the outer aspect of the upper arm
2918976|NCT03116581|Other|Vicarious reward|"If a decision influences the well-being of another (through monetary payoff), the decision making processes should differ from a decision that would influences only oneself. The difference will be reflected in the reaction-times and in the accuracy of the response to the task. The drift diffusion models care then used to estimate le decision parameter in each condition and understand which parameter is influenced by the beneficiary of the payoff associated with a decision.~Once the decision parameter characterized with behavioral experiment, the study aims to better understand the neural network sustaining the influence of others on the decision making process, by assessing the neural activity related to the decision making processes. Also, the research compares how the brain responses for payoff for others and payoffs for oneself, specially to confirm that these responses are located in different areas of the Anterior cingulate Cortex."
2918977|NCT03116581|Other|Audience effect|In order to clarify the complex changes in the decision-making processes induced by simple observation by others (audience) , the experiment have two levels of difficulty . These levels of difficulty will be determined in such a way as to achieve better 'public' performance than 'private' when the task is easy (high level of consistency) and poor performance when the task is difficult (low level of coherence) As described in the literature in psychology. Drift diffusion models will be used to better understand the variations in performance, to decipher between a modulation of the diffusion velocity and or of the decision threshold. This study will help characterize how observation by others modulates performance. Once the decision parameter characterized with behavioral experiment, the study aims to better understand the neural network sustaining the impact of observation by others on the decision making process.
2918978|NCT03116568||IBD Case|"Pregnant women with IBD~Newborns of pregnant women with IBD~Family member of pregnant women with IBD~Siblings of newborns"
2918979|NCT03116568||Control|"Pregnant women without IBD~Newborns of pregnant women without IBD~Family member of pregnant women without IBD~Siblings of newborns"
2918980|NCT03116555|Experimental|Irinotecan plus apatinib|"Irinotecan: 180mg/m2, ivgtt,given on the first day; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day).~Repeat the therapeutic schedule every 3 weeks till progressive disease or intolerable toxicities."
2918981|NCT03116555|Active Comparator|Irinotecan|Irinotecan: 180mg/m2, ivgtt,given on the first day; Repeat the therapeutic schedule every 3 weeks till progressive disease or intolerable toxicities.
2918982|NCT03116542|Experimental|Diagnostic (18F-FLT PET/CT)|"Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-L-thymidine) PET/CT (Positron Emission Tomography/Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. [18F] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) [18F] FLT by intravenous infusion."
2918983|NCT03116529|Experimental|Treatment|Neoadjuvant Radiation plus Durvalumab and Tremelimumab Wide Surgical Resection Adjuvant Durvalumab
2918984|NCT03116516|Other|ARM1|"In ARM1, 30 subjects will be assigned and the subjects will be administered telmisartan/amlodipine and rosuvastatin at Day1 and YHP1604 at Day22."
2918985|NCT03116516|Other|ARM2|"In ARM2, 30 subjects will be assigned and the subjects will be administered YHP1604 at Day1 and telmisartan/amlodipine and rosuvastatin at Day22."
2918986|NCT03116503|Experimental|bipolar disorder and comorbid depression|number of diagnosis of bipolar disorder and comorbid depression of suicidal behaviors in the pediatric population.
2918987|NCT03116490||group RA|the anesthesia type for patients with hip fracture surgery is regional anesthesia
2918988|NCT03116490||group GA|the anesthesia type for patients with hip fracture surgery is general anesthesia
2918989|NCT03116464|Experimental|Intervention Group|Caregiver and patient with dementia dyads who receive the family intervention.
2918990|NCT03116451|Experimental|Foot Health Promoting Program|The experimental group will receive an electronic intervention (Foot Health Promotion Program, FHPP) for 8 weeks consisting of foot self-care guidance (skin and nail self-care), foot exercises, foot stretching and professional footwear guidance. Each topic includes lectures (delivered via Adobe Presenter) and self-directed learning where participant will go through a list of links to websites and watch videos about foot self-care. In addition, the learning will be evaluated using four individual tasks related to foot self-care.
2918991|NCT03116451|No Intervention|Comparison group|The comparison group will not receive any instructions or guidance for foot self-care but participant in the comparison group will complete the same measurement points than experimental group. After the study, the comparison group will also receive the same intervention than experimental group (if effective).
2918992|NCT03116438|Experimental|CADence3 Device|If you agree to participate in this study, you will be asked to allow recording of sounds from four (4) sites on your chest using the CADence device. The CADence test will take approximately 15 minutes to complete. This is a single-arm study.
2918993|NCT03116425|Experimental|Verum 1 - Premotor|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The network including the premotor region will be targeted. The therapeutic protocol will be design to correct the rCBF anomaly."
2918994|NCT03116425|Experimental|Verum 2 - Prefrontal|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The network including the prefrontal region will be targeted. The therapeutic protocol will be design to correct the rCBF anomaly."
2918995|NCT03116425|Active Comparator|Placebo|Stimulation of a region with normal rCBF and putatively unrelated to catatonic symptoms (parietal cortex).
2918996|NCT03116412|No Intervention|Routine follow up|Follow up according to national guidelines.
2918997|NCT03116412|Experimental|Radiological assessments|Radiological assessments (CT or PET scans) at 5 occasions during 3 years.
2918998|NCT03116399|Experimental|PRISM 2.0 Condition|Exposing participants to the PRISM 2.0 interface.
2918999|NCT03116399|Placebo Comparator|Tablet Condition|Exposing participants to the regular computer/tablet
2919000|NCT03116386|Other|run-in period|"In order to improve the precision of data, the run-in period is dedicated to sensitize the caregivers about the importance of~reporting all the falls occurring during the night~tracking in each resident's file, all informations about the estimate length of time spent on floor after a fall occurring during the night~and also reporting every other events occuring at night as wandering. All the beds will progressively equipped with the Etolya-F ® devices but the Etolya-F ® ddevices will stay off."
2919001|NCT03116386|Sham Comparator|control period|We expect 30 falls will occurr at night during this 6 months period. Etolya-F ® devices will be installed on the bed of all participant residents but with limited fonctionnalities i.e. only the length of absence in the bed will be recorded (difference between time of detection of the beginning of absence in the bed and time where the resident will be found by the caregivers out of his bed).
2919002|NCT03116386|Experimental|Etolya-F ® devices|We also expect 30 falls will occur at night during this 6-month period. Etolya-F ® devices will be used with all their functionalities i.e. permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
2919003|NCT03116373|Active Comparator|maxilla fixing then mandible fixing|The tracheal tube is first fixed on the maxilla. After the measures of the outcomes, its site of fixation is changed for the mandible for the outcome measurement in the second site of fixation.
2919004|NCT03116373|Active Comparator|mandible fixing then maxilla fixing|The tracheal tube is first fixed on the mandible. After the measures of the outcomes, its site of fixation is changed for the maxilla for the outcome measurement in the second site of fixation.
2919005|NCT03116360|Experimental|Single Arm|All patients will undergo traditional xray screening as well as experimental screening with diagnostic ultrasound. All subjects will undergo confirmatory MRI.
2919006|NCT03116347|Experimental|EPOCH 1|Ramp up period for participants who were not treated with HyQvia prior to this study
2919046|NCT03116074|No Intervention|Pre-intervention 1|"Usual care.~Patients/caregivers do no have access to patient portal. Providers have access to safety dashboard without discharge preparation indicator. Providers do not have access to secure patient-provider messaging tools."
2919120|NCT03115528||Medical Oncology Physicians|Medical oncology physicians are sent the Estimation of Prognosis questionnaire by email.
2919007|NCT03116347|Experimental|EPOCH 2|Participants who were treated with HyQvia prior to this study, and those who completed the ramp up period (Epoch 1). After one year in Epoch 2, participants with anti-rHuPH20 antibody titer <160 at all time-points during the study will complete the study termination/completion visit at the next possible occasion. Participants with anti-rHuPH20 antibody titer ≥160 during the study and/or at the last measurement will continue for an additional two years of HyQvia treatment and observation.
2919008|NCT03116347|Active Comparator|Epoch 3|Safety follow-up for participants whose anti-rHuPH20 antibody titer was ≥ 160 during Epoch 1 or Epoch 2 and who experience either a related serious adverse event (SAE) or a related severe adverse event (AE)
2919009|NCT03116321|Experimental|Test 1 - TBM (Treatment A - 1 × 800 mg tablet)|"single oral dose of 800 mg (1 × 800 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
2919010|NCT03116321|Experimental|Test 2 - TBM (Treatment B - 2 × 200 mg tablet)|"single oral dose of 800 mg (4 × 200 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
2919011|NCT03116321|Active Comparator|Reference Product - MF (Treatment C - 1 × 800 mg tablet)|"single oral dose of 800 mg (1 × 800 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
2919012|NCT03116308|Experimental|50 mg OPC|Subjects received 50 mg OPC once-daily in the evening for 12 days. On D9 subjects were to receive 50 mg OPC in the evening after a minimum 6 hours fast. On D10 subjects were to receive the QD dose of 50 mg OPC thirty minutes after the start of moderate meal (with a previous 6 hours fast)
2919013|NCT03116295|Experimental|Group 1 - 25 mg OPC|In Group 1, subjects will receive randomly in Period 1 and 2, either a single 25 mg dose of OPC [AF] or a single 25 mg dose of OPC [NF]. Treatments will be administered in the fasting state, the subjects having fasted for at least 10 hours
2919014|NCT03116295|Experimental|Group 2 - 50 mg OPC|In Group 2, subjects will receive randomly on Period 1 and 2, either a single 50 mg dose of OPC [AF], or a single 50 mg dose of OPC [NF]. Treatments will be administered in the fasting state, the subjects having fasted for at least 10 hours
2919015|NCT03116282|Experimental|Intervention|Conversational therapy via video conference where participants are contacted by an alcohol therapist for the purpose of initiating a course of therapy where participants are not required to show up at a clinic.
2919016|NCT03116282|No Intervention|Control|Treatment as usual where participants receive contact information on their local alcohol treatment facility for the purpose of contacting the facility to initiate a face-to-face course of treatment at the clinic.
2919017|NCT03116269|Experimental|cilostazol group|aspirin placebo daily and 100 mg cilostazol twice daily
2919018|NCT03116269|Active Comparator|aspirin group|100 mg aspirin daily and cilostazol placebo twice daily
2919019|NCT03116256|Other|VLCD only|Very low calorie diet (VLCD) only group- participants in this group will receive complete meal replacement for 6 weeks.
2919020|NCT03116256|Active Comparator|VLCD+RET|VLCD+RET group- participants in this group will receive complete meal replacement for 6 weeks and resistance exercise training 3 times every week for 6 weeks.
2919021|NCT03116256|Active Comparator|VLCD+HIIT|VLCD+HIIT group- participants in this group will receive complete meal replacement for 6 weeks and High intensity interval training 3 times every week for 6 weeks.
2919022|NCT03116243||MSHS children and families|"Cohort includes:~children (1272)~parents (1272)~teachers (159)~teaching assistants (159)~program and center directors (253)"
2919023|NCT03116230|Experimental|Experimental Treatment A then B|Subjects will receive two treatments: (1) a non-invasive external Cutaneous Stimulation device placed on the leg of the subject consisting of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback (vibration) to the subject and (2) a commercially-available knee sleeve, separated by a washout period.
2919024|NCT03116230|Experimental|Experimental Treatment B then A|Subjects will receive two treatments: (1) a commercially-available knee sleeve and (2) a non-invasive external Cutaneous Stimulation device placed on the leg of the subject consisting of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback (vibration) to the subject, separated by a washout period.
2919025|NCT03116204||Patients hospitalized in a FRC department|
2919026|NCT03116191|Experimental|SK-1404 high dose|
2919027|NCT03116191|Experimental|SK-1404 middle dose|
2919028|NCT03116191|Experimental|SK-1404 low dose|
2919029|NCT03116191|Placebo Comparator|Placebo|
2919030|NCT03116178|Active Comparator|Group B|"Group B- intervention -Body weight guided Intraoperative fluid administered @ 6-8 ml/kg and blood loss replacement with colloid.~hourly urine output if less than 0.5ml/hr 100-200ml bolus of plasmalyte was administered."
2919031|NCT03116178|Active Comparator|Group G|Group G- intervention - PVI( Masimo co oximeter) guided fluid therapy.
2919032|NCT03116165|Experimental|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
2919033|NCT03116165|Placebo Comparator|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
2919034|NCT03116152|Experimental|IBI308|IBI308 200mg Intravenous drip every three weeks
2919035|NCT03116152|Active Comparator|paclitaxel/irinotecan|paclitaxel 175mg/㎡ Intravenous drip every three weeks； irinotecan 180mg/㎡ Intravenous drip every two weeks
2919036|NCT03116139|No Intervention|Low risk for kidney injury with use of CT|No randomization due to low risk for kidney injury. 100 patients undergoing CTPA with an estimated risk of CIN <10% (CINRisk Score <2)
2919037|NCT03116139|Active Comparator|Randomized to V/Q|150 patients with > 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to VQ imaging (unexposed control)
2919038|NCT03116139|Active Comparator|Randomized to CT|150 patients with > 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to CT (exposure to iodinated contrast media)
2919039|NCT03116126|Active Comparator|Guanfacine|
2919040|NCT03116126|Placebo Comparator|Placebo|
2919041|NCT03116113|Experimental|Low dose AAV-RPGR|Single, subretinal administration of a single low dose range AAV-RPGR
2919042|NCT03116113|Experimental|Medium dose AAV-RPGR|Single, subretinal administration of a single medium dose range AAV-RPGR
2919047|NCT03116074|Experimental|Post-intervention|"Patient-Centered Discharge Toolkit: patient portal and provider safety dashboard PLUS patient pre-discharge checklist, provider discharge preparation indicator, secure patient-provider messaging~Patients/caregivers have access to patient portal with discharge module (pre-discharge preparation checklist) and secure patient-provider messaging tools activated. Providers have access to discharge preparation indicator on safety dashboard and secure patient-provider messaging tools."
2919048|NCT03116074|No Intervention|Pre-intervention 2|"Usual care PLUS patient portal and provider safety dashboard.~Patients/caregivers have access to patient portal but not discharge module or secure patient-provider messaging tools. Providers have access to safety dashboard without discharge preparation indicator. Providers do not have access to secure patient-provider messaging tools."
2919049|NCT03116061||Multimorbidity cohort|The study population included a random sample of multimorbid patients (according to the EGPRN definition of multimorbidity). Patients were selected by 19 FPs in their offices in the county of Finistere (in north-west France) from July 2014 to December 2014. Randomization was achieved by including the first four multimorbid patients (according to the inclusion criteria) encountered during their second working day of each week. As patients were booking their appointments with the practice without the FPs' clearance, the FPs were not able to select them
2919050|NCT03116048|Other|Pecs group (study group)|Chronic pain assessment with study questionnaire
2919051|NCT03116048|Other|Control group (placebo group)|Chronic pain assessment with study questionnaire
2919052|NCT03116035|Active Comparator|Web-based decision aid|A commercially available web-based breast cancer surgery decision aid
2919053|NCT03116035|Active Comparator|Standard websites|selected, high-quality standard web-sites
2919054|NCT03116022|Active Comparator|proximal estriol group (PEG )|This arm is composed of women using estriol 1 mg / 1g in the proximal third of vagina every other night
2919055|NCT03116022|Experimental|distal estriol group (DEG)|This arm is composed of women using estriol 1 mg / 1g in the distal third of the vagina every other night
2919056|NCT03116022|Placebo Comparator|Control group (CG)|This arm is composed of women using vaginal gel lubricant base water during intercourse
2919057|NCT03116009|Active Comparator|Early diabetes screening|Participants in this group will do 1-hour GCT before 20 weeks of gestation. Those with positive test will undergo 3-hours OGTT. Diabetes will be diagnosed if they have two or more abnormal values out of the 4 values and they will be treated accordingly based on the institutional protocol. They will also have HbA1C done.
2919058|NCT03116009|Experimental|Standard diabetes screening|Participants in this group will only have HbA1C done before 20 weeks but will do the standard diabetes screening at 24 - 28 weeks. Those who have abnormal values will also be treated based on the institutional protocol.
2919059|NCT03115996|Experimental|REGN3918 (Cohorts 1-4 & 6a)|Cohorts 1-4 and 6a will receive sequential ascending doses of REGN3918
2919060|NCT03115996|Experimental|Placebo (Cohorts 1-4 & 6a)|Cohorts 1-4 and 6a will receive placebo
2919061|NCT03115996|Experimental|REGN3918 (Cohort 5 & 6b)|Cohort 5 and 6b will receive multiple doses of REGN3918
2919062|NCT03115996|Experimental|Placebo (Cohort 5 & 6b)|Cohort 5 and 6b will receive placebo
2919063|NCT03115983|Experimental|LimiFlex|Posterior dynamic stabilization with the LimiFlex Paraspinous Tension Band
2919064|NCT03115983|Active Comparator|Fusion|Transforaminal lumbar interbody fusion and concomitant posterolateral fusion with pedicle screw instrumentation
2919065|NCT03115970||Trauma patients|All patients having / suspected to have severe trauma injuries
2919066|NCT03115957|Experimental|Early PN|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 after abdominal surgery.
2919067|NCT03115957|Experimental|Delayed PN|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 8 after abdominal surgery.
2919068|NCT03115944|Experimental|UltraSpeed Treatment|UltraSpeed ultrasound treatments
2919069|NCT03115918|Active Comparator|Pancreatic Duct Stent Placement|Subject will have placement of either the Advanix or Cook Pancreatic Stent placed.
2919070|NCT03115918|Active Comparator|No Pancreatic Duct Stent Placement|Subject will not have a pancreatic Duct stent placed.
2919071|NCT03115892|Experimental|intervention arm|Green Tea With Aloe Vera mouthwash twice daily for one week
2919072|NCT03115892|Active Comparator|control arm|Chlorhexidine Mouthwash twice daily for one week
2919073|NCT03115879|Placebo Comparator|Placebo Group|Hip manipulation simulation
2919074|NCT03115879|Experimental|Manipulation Group|Hip manipulation
2919075|NCT03115866|Experimental|FRUVED|Individuals that are at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet with 50% fruit and vegetables.
2919076|NCT03115866|Experimental|FRUVED + LRC|Individuals at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet of 50% fruit and vegetables plus low refined carbohydrates.
2919077|NCT03115866|Experimental|FRUVED + LF|Individuals at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet of 50% fruit and vegetables plus low fat.
2919078|NCT03115853|Experimental|HCTZ plus Aliskiren then HCTZ and Placebo|"HCTZ 25 mg plus Aliskiren 150mg for 2weeks. Aliskiren is increased to 300mg for 4 week if 150mg was tolerated.~Then HCTZ 25 mg po plus Placebo"
2919079|NCT03115853|Experimental|HCTZ and Placebo, then HCTZ and Aliskiren|"HCTZ 25 mg po plus Placebo.~Then HCTZ 25 mg plus Aliskiren 150mg for 2weeks. Aliskiren is increased to 300mg for 4 week if 150mg was tolerated."
2919080|NCT03115840||Adult patients (≥18 years old) critical illness|
2919081|NCT03115827|Experimental|Arm 1|Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks
2919082|NCT03115801|Active Comparator|Arm A - immunotherapy alone|"Patients with Renal Cell carcinoma will receive Nivolumab alone Days 1, 15, 29, 43 and 57.~Patients with Urothelial cancer will receive Atezolizumab on Days 1, 22, 43 and 64."
2919083|NCT03115801|Active Comparator|Arm B - Radiation & immunotherapy|Radiation is given to one lesion, 30 Gy in 3 fractions of 10 Gy, every other day. On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days.
2919084|NCT03115788|Active Comparator|No Intervention Game play|The person will be instructed how to hold the iPad and how to play the game.
2919085|NCT03115788|Experimental|Thermal pain and ipad performance|Interventions: Cold induced pain and heat induced pain. The whole group gets thermal heat (n=40) and half (n=20) get cold water foot immersion and half (n=20) get body temperature foot emersion. The person will be instructed how to hold the iPad and how to play the game. The person will then be allowed to play the game until the number of trials is completed or until the person no longer wishes to play.
2919086|NCT03115775|Active Comparator|Conjugated linoleic acid (Tonalin)|Conjugated linoleic acid (4000 mg Tonalin FFA 80 per day)
2919087|NCT03115775|Active Comparator|Vitamin D|Vitamin D3 (2000 IU per day)
2919088|NCT03115775|Active Comparator|Conjugated linoleic acid and Vitamin D|Conjugated linoleic acid (4000 mg Tonalin FFA 80) and Vitamin D (2000 IU) per day
2919089|NCT03115775|Placebo Comparator|Placebo|Corn oil (4000 mg per day)
2919090|NCT03115762|Experimental|ASKB1202|Subject to receive one intravenous (i.v.) infusion of ASKB1202
2919091|NCT03115762|Active Comparator|bevacizumab A|Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in China
2919092|NCT03115762|Active Comparator|bevacizumab B|Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in Europe
2919093|NCT03115749|Sham Comparator|Crohn's disease patient group|Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
2919094|NCT03115749|Sham Comparator|Ulcerative colitis patient group|Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
2919095|NCT03115749|Sham Comparator|Control group|Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
2919096|NCT03115736|Experimental|Switch|Patients are switched from a TDF-containing antiretroviral therapy regimen to a TAF-containing regimen
2919097|NCT03115723||Group 1 : Percutaneous coronary intervention|All the patients who underwent percutaneous coronary intervention, in 9 invasive cardiology centers in the Aquitaine Region, France.
2919098|NCT03115723||Group 2 : Coronary angiography|All the patients who underwent coronary angiography, in 9 invasive cardiology centers in the Aquitaine Region, France
2919099|NCT03115697|Active Comparator|Lactulose with Rifaximin|
2919100|NCT03115697|Experimental|Plasmapheresis|Plasmapheresis will be added to the standard medical care therapy.(Maximum of 3 sessions once in 24 hours/or alternate days with an follow up for 5 days)
2919101|NCT03115671|Experimental|Intervention|Each child participant in the Intervention group will be taking 4 capsules of Vayarin per day for 3 months. Each capsule contains 167mg Lipirinen, providing 75mg Phosphatidylserine (PS), 21.5mg EPA and 8.5mg DHA. This gives a daily dosage of 300mg PS and 120mg EPA/DHA. They may continue their treatment as usual provided there is no change in medication and intervention during the trial.
2919102|NCT03115671|No Intervention|Control|Participants in the Control group will not be given Vayarin. They may continue their treatment as usual provided there is no change in medication and intervention during the trial.
2919103|NCT03115658|Experimental|Exercise Intervention|"Participants met with a PhD level psychologist experienced with health behavior change, to set a personalized exercise goal and plan. Participants were told the studies' goal to engage in 150 minutes of moderate intensity or greater physical activity each week, based on the ACSM recommendations, but participants were allowed to set any personal goal. Participants were also instructed on how to self-monitor their physical activity.~After the initial meeting all other intervention components were sent through the mail. The intervention consists of three types of print material that were mailed: stage-matched manuals, tailored feedback report, and tip sheets."
2919104|NCT03115645|Experimental|Intervention group|Participants in the intervention group will receive the Dynamic Working Intervention program, as described in the next section.
2919105|NCT03115645|No Intervention|Control group|Participants in the control group will not receive any intervention and will perform their work in the same manner as before.
2919106|NCT03115632||Obese asthmatic & lean asthmatic|
2919107|NCT03115632||Obese non-asthmatic & lean non-asthmatic|
2919108|NCT03115632||Asthmatic undergoing bariatric surgery|
2919109|NCT03115632||Non-asthmatic undergoing bariatric surgery|
2919110|NCT03115619||Participants With IPF|Observational data of participants with IPF under treatment with pirfenidone will be collected from the medical records as a part of their routine clinical visits at 12-week interval until study completion or early withdrawal (up to Week 52).
2919111|NCT03115606|Active Comparator|Videolaryngoscope|Patients intubated with C-Mac D Blade Videolaryngoscope
2919112|NCT03115606|Active Comparator|Fastrach LMA|Patients intubated with Fastrach LMA
2919113|NCT03115593|Experimental|postmenopausal patients with metrorrhagia|"Postmenopausal patients with metrorrhagia and endometrial hypertrophy defined by an endometrium ticker than 3 mm (ultrasound result).~The threshold choice of 3 mm was chosen according to a recent review of the literature to limit the risk of false negatives for cancer."
2919114|NCT03115580|Active Comparator|Rotational atherectomy|Rotational atherectomy (RA)
2919115|NCT03115580|Active Comparator|CBA/PTCA|Cutting Balloon Angioplasty (CBA) or Percutaneous transluminal coronary angioplasty (PTCA)
2919116|NCT03115567|No Intervention|Control|Patients in Control group will be instructed to follow a daily moisturizer and sunscreen regimen. Erlotinib, cetuximab, panitumumab, or afatinib will be administered as standard of care treatment.
2919117|NCT03115567|Experimental|Triamcinolone|Patients in the Triamcinolone group will be applying Triamcinolone 0.1% cream daily to their face, chest, and upper back, in addition to adhering to the same daily moisturizer and sunscreen regimen of the Control group. Erlotinib, cetuximab, panitumumab, or afatinib will be administered concomitantly as standard of care treatment.
2919118|NCT03115554|Active Comparator|PVI Plus Catheter Ablation|Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
2919119|NCT03115554|Active Comparator|PVI Alone|Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
2919146|NCT03115346|Experimental|decision aid|the experimental group will receive the decision aid
2919121|NCT03115528||Palliative Care Physicians|Palliative care physicians are sent the Estimation of Prognosis questionnaire by email.
2919122|NCT03115515|Experimental|Adjustment in number of doses of thyroid hormone per week|"Patients in this group will increase pre-pregnancy thyroid hormone dose by 2 doses/week (extra dose on Wednesday and Saturday). Further dose adjustment are made every 2-4 weeks based on serum TSH, as shown below:~TSH>10mIU/L, increase by 3 doses/week~TSH 5.0-9.9mIU/L, increase by 2 doses/week~TSH 2.0-4.9mIU/L, increase by 1 dose/week~TSH 0.4-1.9mIU/L, no change~TSH<0.4mIU/L, decrease by 1 dose/week~TSH<0.1mIU/L, decrease by 2 doses/week~Thyroid hormone dose will NOT be decreased due to TSH<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism."
2919123|NCT03115515|Experimental|Adjustment in micrograms per day of thyroid hormone|"Patients in this group adjust thyroid hormone dose based on Visit 1 TSH and pre-pregnancy thyroid hormone dose. Further dose adjustments are made every 2-4 weeks based on serum TSH, as shown below:~TSH>10mIU/L, increase dose by 50mcg/day if dose <125mcg/day or increase by 75mcg/day if dose >125mcg~TSH 5.0-9.9mIU/L, increase dose by 25mcg/day if dose <125mcg/day or increase by 50mcg/day if dose >125mcg~TSH 2.0-4.9mIU/L, increase dose by 12.5mcg/day if dose <125mcg/day or increase by 25mcg/day if dose >125mcg~TSH 0.4-1.9mIU/L, no change~TSH<0.4mIU/L, decrease dose by 12.5mcg/day if dose <125mcg/day or decrease by 25mcg/day if dose >125mcg/day~TSH<0.1mIU/L, decrease dose by 25mcg/day if dose <125mcg/day or decrease by 50mcg/day if dose >125mcg/day~Thyroid hormone dose will NOT be decreased due to TSH<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism."
2919124|NCT03115489|Placebo Comparator|Traditional Treatment (Group T)|Group T patients will be placed into burst suppression with the traditional drug infusions which include any single or combination of drugs; usually benzodiazepines, barbiturates and or propofol.
2919125|NCT03115489|Active Comparator|Ketamine Infusion (Group K)|Patients in the group K arm will receive a loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached. After 48 hours of burst suppression the ketamine dosage will be reduced by 2mg/kg/hr in a stepwise fashion to evaluated for EEG or clinical evidence of seizure recurrence.
2919126|NCT03115476|Experimental|Ingenol disoxate gel 0.018%|
2919127|NCT03115476|Experimental|Ingenol disoxate gel 0.037%|
2919128|NCT03115476|Placebo Comparator|Vehicle gel|
2919129|NCT03115463|Experimental|OX25|Resuscitation will be initiated at 30% O2. Titration of oxygen during neonatal resuscitation: Intervention is target goal saturations which will be the 10th to 25th percentile saturations observed in healthy term newborns.
2919130|NCT03115463|No Intervention|OX50|Resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines
2919131|NCT03115463|Active Comparator|OX75|Resuscitation will be initiated at 30% O2. Titration of oxygen during neonatal resuscitation: Intervention is target goal saturations which will be the 75th percentile saturations observed in healthy term newborns.
2919132|NCT03115437|Experimental|Hard cushioned running shoes|Running shoes with cushioned properties among the hardest of the market benchmark (Stiffness: +/- 90 N/mm)
2919133|NCT03115437|Experimental|Soft cushioned running shoes|Running shoes with cushioned properties among the softest of the market benchmark (Stiffness: +/- 57 N/mm)
2919134|NCT03115424|Placebo Comparator|Sleeve Gastrectomy Placebo|Subjects undergoing Sleeve Gastrectomy (SG) will be randomized 1:1 at the time of 3 month visit after bariatric surgery.
2919135|NCT03115424|Active Comparator|Sleeve Gastrectomy Saxenda|Subjects undergoing Sleeve Gastrectomy (SG) will be randomized 1:1 at the time of 3 month visit after bariatric surgery.
2919136|NCT03115424|Sham Comparator|RYGB|Twenty five subjects will be recruited from the Nutrition Clinic at Mayo Clinic Rochester prior to undergoing RYGB surgery.
2919137|NCT03115411|Experimental|Winged stent|Placement of Winged stent for management of biliary obstruction. Stent to be placed for 90 days, with laboratory studies and clinical evaluation during this period to assess for stent potency.
2919138|NCT03115398|No Intervention|Activity Monitoring with Routine Care|Subjects randomized to the control arm will wear activity trackers but will have no specific instructions to increase their activity levels.
2919139|NCT03115398|Experimental|Pedometer-based Walking Program|Subjects randomized to the experimental arm will be instructed to meet the customized daily step count goals that are displayed on their fitness trackers. Patients who fail to meet their step count goal for three consecutive days will be contacted by a study coordinator and reminded to try to meet the activity goals. If the patient reports that his or her activity is limited by treatment-related toxicities, the patient's treating physicians will be notified to ensure that supportive care needs are being met.
2919140|NCT03115385|Placebo Comparator|Placebo|Inactive ingredients include maltose, lemon flavoring (or corn starch if unflavored), and silicon dioxide.
2919141|NCT03115385|Active Comparator|VSL#3|VSL#3 is classified as a medical food that is specially formulated and processed to provide a precise mixture of 8 strains of bacterial species with potential synergistic relationships. These strains include Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii subsp. bulgaricus.
2919142|NCT03115372|Experimental|Group I (CRC education)|LWHs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a CRC educational session conducted by an LWH over 90 minutes at month 1 and 3. Participants receive phone calls from the LWH at months 2 and 4 reminding them about CRC screening.
2919143|NCT03115372|Active Comparator|Group II (CRC brochure)|LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a lecture on healthy nutrition for cardiovascular health presented by a professional health educator at months 1 and 3. After the first meeting, participants receive a brochure on CRC screening. Participants receive phone calls from the LWH at months 2 and 4 regarding changes in their nutritional behavior. Participants may attend an optional post-intervention LHW outreach session on CRC screening.
2919144|NCT03115359|Experimental|Mindfulness Meditation|Mindfulness Meditation intervention, adjunctive to usual care for opioid-treated chronic low back pain.
2919145|NCT03115359|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy intervention, adjunctive to usual care for opioid-treated chronic low back pain.
2919147|NCT03115346|No Intervention|control|the control group will only receive the survey
2919148|NCT03115333|Experimental|Diagnostic (DSC-MRI)|Patients undergo DSC-MRI within 3 days before bevacizumab initiation and at day 15.
2919149|NCT03115320|Experimental|Pregnyl (Human chorionic gonadotropin)|In this group, patients have natural cycle in frozen-thawed embryo transfer and the ovulation is confirmed by administration of hCG (Pregnyl® 5000 IU). The day of transferring embryo is depending on the day of administration of hCG and the age of the embryo. The day zero day is defined by ovulation triggered by hCG.
2919150|NCT03115320|Other|Home ovulation test|The patients randomized to the LH surge group perform the ovulation home test daily from the urine. Thus, the ovulation in this group is corfimed by the urine test. The day of transferring embryo is depending on the positive ovulation test and the age of the embryo. The day zero day is defined by positive ovulation test.
2919151|NCT03115307|Experimental|Gonapeptyl|In the intervention group the patient will get the advice to using triptoreline (Gonapeptyl®) in the eight day after the injection of hCG (Pregnyl®) in the insemination cycle.
2919152|NCT03115307|No Intervention|Control group|In the control group, there are no luteal phase medications in the insemination cycle.
2919153|NCT03115294|Experimental|Study group|Patients undergo procedure with stepwise measurements and ventilator + volume adjustment + iv theophylline
2919154|NCT03115268|Experimental|Immediate|Participants allocated to the immediate arm will receive 6 months of Social support groups delivered in EVA Park immediately after randomisation. They will be re-assessed in Month 7, then receive 6 months of usual care, followed by reassessment in month 14.
2919155|NCT03115268|Active Comparator|Wait list control|Participants allocated to the wait list control arm will receive 6 months of usual care after randomisation. They will be re-assessed in month 7, and will then receive 6 months of social support groups delivered in EVA Park, with reassessment in month 14.
2919156|NCT03115255|Experimental|serum VEGF level|Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab
2919157|NCT03115242|Experimental|Acute ischemic carotid stroke|"Patients hospitalized in the neurovascular intensive care unit for an acute ischemic stroke with a carotid plaque responding to inclusion criteria.~These patients receive a contrast injection Sonovue® will be performed during the neck vessels doppler ultrasound."
2919158|NCT03115229|No Intervention|Control Group|The control group of the RCT was composed of 35 students randomly assigned to the control group who are BMI was between 25.0-29.9 or BMI was between 18.5-24.9 and they were in the risk group in terms of obesity according to the risk rating scales.
2919159|NCT03115229|Experimental|Intervention Group|The selected students were associated with obesity risk factors about obesity (owerveight or normal weight and they were in the risk group in terms of obesity according to the risk rating scales, and between 19-24 years old) and randomly assigned to the experimental group to Protective Nursing Interventions for Reduction Obesity Risk
2919160|NCT03115216|Active Comparator|FLA-CEIOL|Femtosecond laser assisted cataract extraction and intraocular lens placement
2919161|NCT03115216|Active Comparator|CEIOL|Clear corneal incision with manual cataract extraction and intraocular lens placement
2919162|NCT03115203|Other|Facial paralysis|
2919163|NCT03115203|Other|Healthy subject|
2919164|NCT03115190|Other|General practitioner diagnosis with Heart score|Patients with chest pain who are reviewed by the general practitioner (GP) at the GP cooperation will be evaluated with the Heart score to support the GP with the diagnosis.
2919165|NCT03115190|No Intervention|Triage Nurse education|The general practitioner cooperation employs nurses for (telephone) triage. They are aided by a computer based triage system, the Netherlands triage system (NTS), a 6-level urgency triage system. With this study we aim to educate the nurses in the signs and symptoms of chest pain patients. The training program will aim to educate the triage nurses in acute coronary syndrome, including pathophysiology, symptoms and risk factors. The NTS will be incorporated within the training. The triage nurses will receive a training session by Cardiologists with information about acute coronary syndrome, the symptoms and the risks.
2919166|NCT03115190|No Intervention|Baseline registry as comparison|"All patients referred to the emergency department (ED) with suspected acute coronary syndrome (ACS) will be evaluated. They will receive a questionnaire to evaluate the accuracy of referral and the delays of ACS patients. This will be compared to the registry at baseline. Some patients will either have not contacted the general practitioner cooperation (GPC) at all, or will have been referred to the ED directly through the GPC nurse triage.~The 30 day, 6 months and one year follow-up of all patients will be via medical records, or in case of no or not enough information, by telephone."
2919167|NCT03115177|Active Comparator|Cefazolin|All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The control group will not receive any further antibiotic treatment.
2919168|NCT03115177|Active Comparator|Doxycycline+Cefazolin Group|All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision.
2919169|NCT03115164||Patients with DIA / DIG treated at the French SFCE pediatric|
2919170|NCT03115151|Experimental|Patient-Controlled Epidural Analgesia|Bupivacaine and fentanyl infusion via Continuous Lumbar Epidural Analgesia during postoperative 72 hours
2919171|NCT03115151|Sham Comparator|Intravenous patient-controlled analgesia|Postoperative intravenous patient-controlled analgesia (IV PCA) with Hydromorphone
2919172|NCT03115138|Other|Patients with glial tumor|
2919173|NCT03115125|Other|Adult patients with severe sepsis|
2919174|NCT03115112|Active Comparator|Bexagliflozin|Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the study.
2919175|NCT03115112|Active Comparator|Sitagliptin|Subjects will receive a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
2919176|NCT03115099|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo (sugar pill) administered to healthy participants in up to 1 study period in Part A
2919177|NCT03115099|Experimental|LY3325656 (Part A)|Single ascending dose of LY3325656 administered orally to healthy participants in up to 3 study periods in Part A
2919452|NCT03113097|Active Comparator|Good-quality embryo transfer|Women who had only good-quality embryo transfer
2919178|NCT03115099|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo (sugar pill) administered to participants with T2DM in 1 study period in Part B
2919179|NCT03115099|Experimental|LY3325656 (Part B)|Single oral dose of LY3325656 administered to participants with T2DM in 1 study period in Part B
2919180|NCT03115099|Active Comparator|Liraglutide (Part B)|Single subcutaneous dose of liraglutide administered to participants with T2DM in 1 study period in Part B
2919181|NCT03115099|Experimental|LY3325656 + Sitagliptin (Part B)|Single oral dose of LY3325656 and sitagliptin administered to participants with T2DM in 1 study period in Part B
2919182|NCT03115073|Experimental|0,2% Candiplus|Candiplus® 0.2%
2919183|NCT03115073|Experimental|0,3% Candiplus|Candiplus® 0.3%
2919184|NCT03115073|Experimental|0,4% Candiplus|Candiplus® 0.4%
2919185|NCT03115073|Active Comparator|Clotri mono|Clotrimazole mono
2919186|NCT03115060|Experimental|normal saline|Intravenous fluid used in these patients would be normal saline which would be given intravenously during intraoperative and postoperative period
2919187|NCT03115060|Experimental|ringer lactate|Intravenous fluid used in these patients would be ringer lactate which would be given intravenously during intraoperative and postoperative period
2919188|NCT03115060|Experimental|plasmalyte A|Intravenous fluid used in this arm in patients would be plasmalyte A which would be given intravenously during intraoperative and postoperative period
2919189|NCT03115047|Experimental|dexmedetomidine|"Unique dose of dexmedetomidine injection:~intravenous injection~0.35 mcg/kg~in two minutes~if shivering 5 minutes after delivery"
2919190|NCT03115047|Active Comparator|meperidine|"Unique dose of meperidine injection:~intravenous injection~0.35 mg/kg~in two minutes~if shivering 5 minutes after delivery"
2919191|NCT03115034|Active Comparator|CEA with melatonin|Patients under CEA with melatonin taken during perioperative period.
2919192|NCT03115034|Placebo Comparator|CEA with placebo|Patients under CEA with placebo taken during perioperative period.
2919193|NCT03115034|Sham Comparator|CEA with blank control|Patients under CEA with nothing unnecessary taken during perioperative period.
2919194|NCT03115021|Experimental|Active tPCS / Sham tDCS|All subject will receive active tPCS and sham tDCS for 20 minutes simultaneously.
2919195|NCT03115021|Experimental|Sham tPCS / Active tDCS|All subject will receive sham tPCS and active tDCS for 20 minutes simultaneously.
2919196|NCT03115021|Experimental|Sham tPCS / Sham tDCS|All subject will receive sham tPCS and sham tDCS for 20 minutes simultaneously.
2919197|NCT03115008|Experimental|Video-based terminal feedback|
2919198|NCT03115008|No Intervention|Conventional concurrent feedback|
2919199|NCT03114995|Experimental|Group A (high platelet reactivity - tirofiban)|Patients with high platelet reactivity unit (230 or higher) Tirofiban administered dose: 0.4 μg/kg/min continuous infusion for 30 min and then 0.10 μg/kg/min continuous infusion for 12 h
2919200|NCT03114995|No Intervention|Control C1 (high platelet reactivity - no tirofiban)|Patients with high platelet reactivity unit (230 or higher) Tirofiban was not administered
2919201|NCT03114995|No Intervention|Control C2 (low platelet reactivity - no tirofiban)|Patients with low platelet reactivity unit (less than 230) Tirofiban was not administered
2919202|NCT03114982|Experimental|Low potency of NBP608|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
2919203|NCT03114982|Experimental|Middle potency of NBP608|Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
2919204|NCT03114982|Experimental|High potency of NBP608|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
2919205|NCT03114982|Active Comparator|Varivax|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
2919206|NCT03114969||Subjects using RELVAR ELLIPTA|Subjects with a fixed dose combination of inhaled corticosteroids/ long-acting beta agonists (ICS/LABA) via a single DPI of RELVAR ELLIPTA for treatment of COPD will be included.
2919207|NCT03114969||Subjects using SYMBICORT TURBUHALER|Subjects with a fixed dose combination of ICS/LABA via a single DPI of SYMBICORT TURBUHALER for treatment of COPD will be included.
2919208|NCT03114969||Subjects using SERETIDE DISKUS|Subjects with a fixed dose combination of ICS/LABA via a single DPI of SERETIDE DISKUS for treatment of COPD will be included.
2919209|NCT03114969||Subjects using SPIRIVA HANDIHALER|Subjects with a fixed dose monotherapy of long-acting muscarinic antagonists (LAMA) via a single DPI of SPIRIVA HANDIHALER for treatment of COPD will be included.
2919210|NCT03114969||Subjects using INCRUSE ELLIPTA or ANORO ELLIPTA|Subjects with a fixed dose monotherapy of LAMA via a single DPI of INCRUSE ELLIPTA or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ANORO ELLIPTA for treatment of COPD will be included.
2919211|NCT03114969||Subjects using SEEBRI BREEZHALER or ULTIBRO BREEZHALER|Subjects with a fixed dose monotherapy of LAMA via a single DPI of SEEBRI BREEZHALER or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ULTIBRO BREEZHALER for treatment of COPD will be included.
2919212|NCT03114969||Subjects using RELVAR ELLIPTA with HANDIHALER/ INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via RELVAR ELLIPTA along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
2919213|NCT03114969||Subjects using TURBUHALER with HANDIHALER/INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via SYMBICORT TURBUHALER along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
2919214|NCT03114969||Subjects using DISKUS with HANDIHALER/INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via SERETIDE DISKUS along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
2919215|NCT03114956|Experimental|Group A|Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
2919216|NCT03114956|Experimental|Group B|Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.
2919217|NCT03114956|Experimental|Group C|Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.
2919453|NCT03113097|Active Comparator|good- and poor-quality embryo transfer|Women who had both good- and poor-quality embryo transfer
2919218|NCT03114956|Experimental|Group D|A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
2919219|NCT03114943|Experimental|NBP608|Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
2919220|NCT03114943|Active Comparator|Varivax|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
2919221|NCT03114930|Other|Standard output|
2919222|NCT03114930|Other|Non standard output|
2919223|NCT03114917|Experimental|CARMS therapy + TAU|Participants allocated to the CARMS therapy + TAU arm will receive their usual care and treatment from mental health services along with CARMS (Cognitive AppRoaches to coMbatting Suicidality) therapy. The CARMS therapy comprises of 24 sessions, each up to 50 minutes long over a 6 month period.
2919224|NCT03114917|No Intervention|TAU|Participants allocated to treatment as usual (TAU) will receive their usual care and treatment from mental health services.
2919225|NCT03114904|Other|"Usual weaning management"|
2919226|NCT03114904|Other|Introduction to H2 for the discontinuation of therapeutics|
2919227|NCT03114891|Experimental|fMRI-guided target|This site of stimulation will be created from participants' individualized resting connectivity data to guide stimulation that we show is especially effective in influencing downstream brain areas of interest. We will focus on a target region of the lateral prefrontal cortex (LPFC) that our data suggest is particularly effective at influencing the sgACC. Theta-burst stimulation will be administered to this target.
2919228|NCT03114891|Active Comparator|Standard brain target|As an alternative brain target, we will also test the efficacy of the dorsolateral prefrontal cortex as a target given its precedence as an FDA-approved stimulation site for remediating depressive symptoms. Theta-burst stimulation will be administered to this target.
2919229|NCT03114878|Active Comparator|TRT / EMDR|Tinnitus Retraining Therapy / Eye Movement Desensitization Reprocessing
2919230|NCT03114878|Active Comparator|TRT / CBT|Tinnitus Retraining Therapy / Cognitive Behavioral Therapy
2919231|NCT03114865|Experimental|Post-alloHSCT Maintenance|Blinatumomab will be administered as a continuous intravenous (IV) infusion over four weeks followed by a two-week treatment free interval. It is recommended that patients are hospitalized at least during the first three days of the first cycle and the first two days of the second cycles.
2919232|NCT03114852||CKD patients|"'blood collection'~Patients with chronic kidney disease in renal replacement therapy living in the sanitary administrative region of Niteroi/Rio de Janeiro. They will be interviewed about past history of familiar renal disease. They will have blood functional renal biochemistry analysed."
2919233|NCT03114852||Renal Familiar Disease|'blood collection' They will have blood tested to renal genetic diseases
2919234|NCT03114839|Experimental|Dietary Supplement: Lactobacillus casei strain Shirota (LcS)|
2919235|NCT03114826||Renal cell carcinoma in renal transplant patients|
2919236|NCT03114813||Clinically indicated primary prophylaxis|"Approach all those who have had a portal pressure measurement (HVPG) as part of their routine clinical care.~At baseline participants will consent to have an additional MRI scan before undergoing clinical screening Endoscopy.~All participants found to have oesophgeal varices that require primary prophylaxis, will be started on Carvedilol 6.25mg.~After 1 week, participants will return for dose optimisation~After 4-12 weeks of treatment, participants will have:~repeat one hour MRI scan~repeat HVPG to evaluate treatment response"
2919237|NCT03114800|Experimental|E-Scale|Weight monitoring
2919238|NCT03114787|Other|Patient receiving respiratory physiotherapy|
2919239|NCT03114787|Other|Patient not receiving respiratory physiotherapy|
2919240|NCT03114774||grup 1|Ramsay Sedation Scale (RSS) Score monitoring
2919241|NCT03114774||Grup 2|The bispectral index (BIS) monitoring
2919242|NCT03114761|Experimental|CTA-IH|
2919243|NCT03114748|Experimental|EEG|2 scalp electroencephalographic (EEG) recording will be acquired in ON and OFF DBS conditions
2919244|NCT03114748|Experimental|DBS ON and OFF|DBS is turned ON and OFF in the 2 EEG sections
2919245|NCT03114722|Active Comparator|heparin 10U/ml|Heparinised saline (10U/ml) lock in between each catheter use (with standard twice weekly normal saline flushing if catheter not being used)
2919246|NCT03114722|Experimental|citrate 4%|4% citrate lock in between each catheter use (with standard twice weekly normal saline flushing if catheter not being used)
2919247|NCT03114709|Experimental|Mindful Movement|8, 90-minute, in-person, group sessions over 8 weeks
2919248|NCT03114709|Active Comparator|10 Keys to Health & Wellbeing|8, 90-minute, in-person, group sessions over 8 weeks
2919249|NCT03114696|Experimental|IQP-AO-101|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
2919250|NCT03114696|Placebo Comparator|Placebo|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
2919251|NCT03114683|Experimental|IBI308|
2919252|NCT03114670|Experimental|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|Patients will receive a full dose CART infusion at day 0.
2919253|NCT03114657|Experimental|Crenezumab|Participants will receive IV infusion of crenezumab q4w for 100 weeks.
2919254|NCT03114657|Placebo Comparator|Placebo|Participants will receive IV infusion of placebo q4w for 100 weeks.
2919255|NCT03114644|Other|Babies born prematurely between 27 and 37 SA|
2919256|NCT03114631|Experimental|Dendritic cells lysate-pulsed group|Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with tumor lysate
2919257|NCT03114631|No Intervention|Control group|Patients treated according to clinical protocols
2919258|NCT03114631|Experimental|Dendritic cells peptide-pulsed group|Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with MUC-1/WT-1 peptides
2919259|NCT03114605|Experimental|Mindfulness|Mindfulness-based Intervention (8 sessions - 2 hours each- 1 session/week)
2919260|NCT03114605|No Intervention|Control|Waiting List
2919261|NCT03114592|No Intervention|Standard Care|"Complete a survey asking about kidney function and participant demographics.~Receive a one-month follow-up call (one month after hospital discharge date) and complete a phone survey about patient kidney function after discharge"
2919569|NCT03112382|No Intervention|no vitamins|patients will be observed for 3 months
2919262|NCT03114592|Experimental|mHealth Tool|"Complete a survey asking about kidney function and participant demographics.~Review a 15-20 minute educational tool on a tablet about kidney health~Receive a one-month follow-up call (one month after hospital discharge date) and complete a phone survey about patient kidney function after discharge"
2919263|NCT03114579|Other|Measure of the cardiac output obtained by a reference methode|
2919264|NCT03114579|Other|Measurement of cardiac output obtained by NEXFIN HD.|
2919265|NCT03114566||Consenting healthy donor|Transplant and healthy HLA typed donors
2919266|NCT03114540|Experimental|GBT440 Dose 1:Mild hepatic impairment|Child Pugh A
2919267|NCT03114540|Experimental|GBT440 Dose 1:Moderate hep. impairment|Child Pugh B
2919268|NCT03114540|Experimental|GBT440 Dose 1:Severe hepatic impairment|Child Pugh C
2919269|NCT03114540|Experimental|GBT440 Dose 1:Normal hepatic function|Healthy subjects
2919270|NCT03114527|Experimental|Dedifferentiated Liposarcoma Arm|Patients receive ribociclib orally at 300mg/day for 21 days of each 28 day cycle and everolimus 2.5mg orally on a continuous 28 day cycle.
2919271|NCT03114527|Experimental|Leiomyosarcoma Arm|Patients receive ribociclib orally at 300mg/day for 21 days of each 28 day cycle and everolimus 2.5mg orally on a continuous 28 day cycle.
2919272|NCT03114514|Experimental|PRP injection|A PRP-injection will be performed three times during the course of treatment
2919273|NCT03114501|Experimental|Yoga Program Group|"Participants take part in the partner-based yoga program.~Questionnaire completed during each week of radiation therapy about participant's feelings about the yoga sessions.~Questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later)."
2919274|NCT03114501|Experimental|Waitlist Control Group (WLC)|"Participants receive standard of care.~Questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later).~After the study has been completed, participant and caregiver/alternative caregiver offered the opportunity to take part in the partner-based yoga program."
2919275|NCT03114475|Experimental|CO2 Laser Irradiation|This group of patients will be treated by splitting the dental arches into four quadrants: upper right, upper left, lower right and lower left. Two quadrants will receive the CO2 laser irradiation whereas the remaining two quadrants will receive no treatment (i.e. the placebo light).
2919276|NCT03114475|Placebo Comparator|Placebo|A placebo light will be used as if the patient is irradiated with the laser beam.
2919277|NCT03114462|Experimental|Stereotactic Hypofractionated Radioablation (HYDRA)|"Participants receive HYDRA radiation on up to 5 days over the course of about 2 weeks, and for a total of 5 times.~Questionnaires completed at Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years."
2919278|NCT03114449|Experimental|Auricular acupuncture|Auricular acupuncture (AA) with indwelling fixed needles at specific AA points
2919279|NCT03114449|Sham Comparator|Sham auricular acupuncture|Sham auricular acupuncture with indwelling fixed needles at non- AA points
2919280|NCT03114436||Consented deceased organ donors|Includes neurological determination of death (DND) and by circulatory determination of death (DCD).
2919281|NCT03114423|Experimental|Treatment As Usual + Treatment with EMDR|
2919282|NCT03114423|Sham Comparator|Treatment As Usual + Cognitive Training|
2919283|NCT03114397|Active Comparator|anodal stimulation|Patients will receive anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes) for a total of 20 sessions.
2919284|NCT03114397|Placebo Comparator|sham stimulation|Patients will receive sham tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes) for a total of 20 sessions.
2919285|NCT03114384|Experimental|Healthy volunteers|
2919286|NCT03114371|Experimental|Oxytocin|Daily intranasal administrations of oxytocin for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be 8 International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.
2919287|NCT03114371|Placebo Comparator|Placebo|Daily intranasal administrations of placebo for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.
2919288|NCT03114358|Experimental|Early carbapenems de-escalation|De-escalation carbapenems within 24 hours or no later than 72 hours of prescription by Infectious disease specialist (early de-escalation).
2919289|NCT03114358|No Intervention|Late carbapenems de-escalation|De-escalation followed the hospital policy in which carbapenems were evaluated by ID specialist at 72 hours of admission (late de-escalation). De-escalation may occurred earlier depends upon the decision of the primary care team
2919290|NCT03114345|Other|Single arm|Measurement of interface pressure and Measurement of micro-vascularization related parameters
2919291|NCT03114332|Experimental|Study Group|Patients for whom a subcutaneous drain was used
2919292|NCT03114332|No Intervention|Control group|No drain group
2919293|NCT03114319|Experimental|TNO155|TNO155 for oral administration
2919294|NCT03114306|Experimental|local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee to achieve maximal distal block of nerve fibres. Infiltration is performed directly after knee replacement and during weaning of general anaesthesia.
2919295|NCT03114306|Active Comparator|Regional anaesthesia|Patients receive a combined anaesthesia with a regional-anaesthesiological catheter placed close to the distal Nervus saphenus and a single shot anaesthesia of Nervus ischiadicus using local anaesthetics (regional-anaesthesiological catheter analgesia).
2919296|NCT03114293|No Intervention|Waiting group|Waiting group
2919297|NCT03114293|Experimental|Smartphone intervention|Smartphone bases behavioural intervention
2919298|NCT03114280|Experimental|TPF2|docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days followed by radiotherapy (RT) combined with carboplatin
2919299|NCT03114267||Patient with chronic lymphocytic thyroiditis|
2919300|NCT03114267||Healthy subjects|
2919301|NCT03114254|Experimental|Cabazitaxel|"Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days"
2919302|NCT03114241|Active Comparator|Intervention|An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient during 3 months.
2919303|NCT03114241|No Intervention|Control|Usual care.
2919304|NCT03114215|Active Comparator|MD1003|The investigational drug will consist in capsules of 100 mg biotin and excipients (lactose, magnesium stearate, croscarmellose sodium, Silica) tid during 12 months
2919305|NCT03114215|Placebo Comparator|PLACEBO|This formulation consists in lactose powder and other excipients (magnesium stearate, croscarmellose sodium, Silica) as placebo, tid during 6 months and then switch to MD1003 tid during 6 additional months.
2919306|NCT03114202|Experimental|Intervention group|Intensive nutritional counseling: once they are admitted to the study and once a week during radiotherapy
2919307|NCT03114202|Other|Control group|Standard care: when there is demand, usually 1 to 2 times during radiotherapy
2919308|NCT03114189|Active Comparator|Footbath, care of sleep|"Warm water (37°C) filled up to the level of the ankle. Water has to be heated up to 42°C and increased to the calf 's half height within 15 minutes.~Information about wrong and correct behaviour."
2919309|NCT03114189|Active Comparator|Care of sleep|Information about wrong and correct behaviour.
2919310|NCT03114176|Experimental|Divers group|Throughout each dive, subjects performed a 20-minute long mild exercise on an underwater bike. The depth of dive was set at 15 meters, where the subjects performed an activity guided by Borg CR-10 scale at intensity level 3 (25 rpm). The ascent rate was set at 10 m/min, with a decompression stop at 5 meters for 3 min, according to the US Navy Manual Diving Table. 48 h prior to the immersions, none of the participants consumed medications or dived or flew. In the first part of the experiment, all subjects performed a dive breathing Enriched Air Nitrox (EAN, 32% ppO2). Baseline clinical measurements were collected before and after this first dive in order to have a reference [CTRL] and to measure physiological modifications due to immersion [NTRX]. After twenty days of no diving activity, subjects were engaged in a KD for seven days. At the end of this period, subjects performed a single immersion breathing EAN. The measures were performed after this single dive [KETO-NTRX]
2919311|NCT03114163||SCCHN patients in Germany|Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) in Germany
2919312|NCT03114150|Experimental|Cardiorespiratory fitness training|Cardiorespiratory fitness training will be a 24-week supervised cycling program designed to improve cardiorespiratory fitness, with supervision directly from the research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes moderate intensity cycling and 30 minutes light intensity cycling, and 5 minute cool-down per session, for 3 sessions/week. In each additional week, 6 minutes of moderate intensity cycling per session will be added, until the total time for moderate intensity is 50 minutes per session by the start of week 5 (with additional 5 minute warm-up and 5 minute cool-down).
2919313|NCT03114150|Active Comparator|Functional fitness training|Functional fitness training will be a 24-week supervised exercise program designed to focus on functional flexibility and mobility, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes of light intensity cycling and 20 minutes of dynamic stretching to increase range of motion and functional fitness, for 3 sessions/week. In each additional week, additional stretches will be added to maintain variety and improve flexibility of all major muscle groups.
2919314|NCT03114137||sickle cell patients|"age: five-year-old or more~major sickle cell syndrome confirmed by hemoglobin phenotype: SS, SC, SBeta+ or Sbeta0~steady state defined as the absence of vaso-occlusive crisis for the previous 15 days, absence of fever or infectious disease for the previous 8 days and absence of transfusion for the previous 2 months"
2919315|NCT03114137||control patients|"volunteer parents or siblings of sickle cell patients~hospital staff or their children matched on country and age +/- 3 ans with the patients"
2919316|NCT03114124|Active Comparator|Bipolar Ablation Catheter|Subjects will be randomized by random computer programming to receive standard ablation catheter for their procedure.
2919317|NCT03114124|Experimental|MIFI Ablation Catheter|Subjects will be randomized by random computer programming to receive an ablation with MIFI technology. MIFI Catheter contains tightly spaced multielectrode pattern
2919318|NCT03114111|Active Comparator|Application of ALA|The treatment will consist of split-face comparisons of no application of aminolevulinic acid (ALA) vs ALA application to either half of the face. Prior to ALA application, the face will be swabbed for microbiome analysis. After the ALA application, the subjects will incubate with the ALA on their face per the standard PDT protocol used at UC Davis Dermatology clinic for facial PDT treatments. The side of the face being treated will remain the same during all treatments.
2919319|NCT03114111|Placebo Comparator|No Application of ALA|For the placebo, Demo Levulan Kerastick, which contains no active ingredient and is enclosed in same cardboard sleeve and cap, will be applied to the other side of the face to mimic the surface of the ALA application stick. After the placebo application, the subjects will incubate with the placebo on their face per the standard PDT protocol used at UC Davis Dermatology clinic for facial PDT treatments. The side of the face being treated will remain the same during all treatments.
2919320|NCT03114098|Experimental|CYP2D6 gene abnormalities|"A salivary sample (2 ml sample) which will allow the investigation of an anomaly of the metabolism of psychotropic drug.~Blood sampling will be performed to assess treatment tolerance (6 ml). A sample (4 ml) will be kept for possible future analyzes in relation to the objectives of this study for the recruiting center of Nice.~Electrocardiogram~Clinical exam~Clinical Global Impression Scale (CGI-S)~Children's Global Assessment Scale (CGAS)~Sheehan Disability Scale (SDS)~Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III )~Wechsler Intelligence Scale for Children - 4 (WISC-4)~Wechsler Adult Intelligence Scale 4 (WAIS 4)~Diagnostic and Statistical Manual of Mental Disorders (DSM)~Autism Diagnostic Interview (ADI)"
2919321|NCT03114085|Experimental|Apatinib Combined with Capecitabine|Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group; Capecitabine,1000mg/m2,twice a day (at intervals of 12 hours,equivalent to a total daily dose of 2000 mg / m2),orally,sustained 14 days, off for 7 days, every 21 days for a cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group.
2919322|NCT03114085|Active Comparator|Apatinib|Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group;
2919323|NCT03114072|Active Comparator|Blue-blocking glasses|N=30 The Blue-blocking glasses (orange-tinted), which remove more than 99% of the blue wavelengths (wavelengths within the visible spectrum shorter than 530 nm). Luminous transmittance: 50%.
2919324|NCT03114072|Active Comparator|Light grey control glasses|N=30 Partially blue blocking light grey glasses, blocking only about 50% of blue wavelengths (wavelengths within the visible spectra shorter than 530 nm). Luminous transmittance: 55%.
2919325|NCT03114059||standalone CyPass implantation|patients who have undergone a standalone cypass implantation without cataract surgery more than 3 years ago
2919326|NCT03114046|Experimental|Baseline Phase|This project will conduct a single-subject pre-experimental AB mixed methods design, considering A phase as the baseline strand. During this phase multiple assessments will be administered. This phase will last 2 consecutive weeks, with 5 visits total.
2919327|NCT03114033|Experimental|Targeted therapeutic mild hypercapnia|Target arterial carbon dioxide range of 50-55 mmHg for 24 hours following randomisation
2919328|NCT03114033|Active Comparator|Targeted normocapnia (Standard care)|Target arterial carbon dioxide range of 35-45 mmHg for 24 hours following randomisation
2919329|NCT03114020|Experimental|Hyaluronic Acid inhalation solution|3mL of 0.03% Hyaluronic Acid inhalation solution BID for 28 days
2919330|NCT03114020|Placebo Comparator|Placebo Inhalation Solution|3mL matching placebo inhalation solution BID for 28 days
2919331|NCT03114007|Experimental|Preventure, Equipe and Inter-Action|Preventure program, Equipe program and Inter-Action services: Early personality-targeted interventions for students most at risk of mental health problems and substance misuse (Preventure program), parent program mainly for parents of high risk youth, especially those reporting discord at home (Equipe program) and integrated services for youth with significant internalizing and externalizing problems (Inter-Action services).
2919332|NCT03114007|Experimental|Preventure program and Equipe program|Early personality-targeted interventions for students most at risk of mental health problems and substance misuse (Preventure program) and parent program mainly for parents of high risk youth, especially those reporting discord at home (Equipe program)
2919333|NCT03114007|No Intervention|Control|Treatment as usual
2919334|NCT03113994|Active Comparator|Rosuvastatin|
2919335|NCT03113994|Placebo Comparator|Placebo|
2919336|NCT03113981|Experimental|ACTISURF-CERAFIT|Total hip arthroplasty (CERAFIT) grafted by PolyNass
2919337|NCT03113981|Active Comparator|CERAFIT|Total hip arthroplasty (CERAFIT) with HydroxyApatite (HA) no grafted by PolyNass
2919338|NCT03113968|Active Comparator|electroconvulsive therapy (ECT)|Treatments will be given 3 times a week up to a total of 9 treatments over 3 - 5 weeks. Initial ECT treatment is Right Unilateral (RUL) ultra-brief pulse at 6X seizure threshold. Seizure threshold and dose can be increased per investigator and patient discretion.
2919339|NCT03113968|Active Comparator|ketamine infusion|Treatments will be given 2 times a week up to a total of 6 treatment over 3 - 5 weeks. Initial standard dose will be 0.5 mg/kg infusion over 40 min. The dose can be modified if clinically warranted per investigator and patient discretion.
2919340|NCT03113955|Experimental|single -arm|A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
2919341|NCT03113942|Experimental|Pomalidomide group|Open label - all participants will receive pomalidomide 2mg orally once a day for 6 cycles (21 days on treatment and a 7 day rest period constitutes a cycle).
2919342|NCT03113929||Alcoholic Liver Disease Patients|
2919343|NCT03113916|Experimental|Behavioral|26 weekly behavioral intervention sessions 6 monthly behavioral intervention sessions Sessions focused on diet, physical activity, behavior change
2919344|NCT03113916|No Intervention|Enhanced usual care|Printed materials
2919345|NCT03113903|Experimental|scheduled surgery|
2919346|NCT03113903|Other|healthy volunteers|
2919347|NCT03113890|Experimental|Assay Guided Group (AGG)|These patients will undergo a cheek swab to collect DNA for the Genecept assay. Study doctors will receive the Genecept report prior to patient discharge and use it to guide psychoeducation and medication management.
2919348|NCT03113890|Other|Treatment as Usual (TAU)|Thus this group will serve as the control group for the outcomes related to Genecept-guided decision making. These patients will undergo a cheek swab to collect DNA for the Genecept assay. Study doctors will receive the Genecept report at the 12-week follow up visit (12 weeks after patient discharge) and will use it to guide psychoeducation. The Study Doctors will not receive the report during the patient's inpatient stay (treatment as usual, TAU). Clinicians will receive the assay report for patients in the treatment-as-usual group at the 3-month followup period.
2919349|NCT03113877||Clinical Testing for Autonomic Dysfunction|COMPASS-31 Survey completion. Autonomic Reflex Screen. Thermoregulatory Swear Test.
2919350|NCT03113864|Placebo Comparator|Placebo|Will be identical looking to treatment
2919351|NCT03113864|Experimental|Lutein|10 mg of FloraGLO Lutein
2919352|NCT03113851|Experimental|Radiotherapy and rhGM-CSF|Patients with metastatic non-small cell lung cancer received 3.5 Gy per fraction to a total dose of 35 Gy/ 10 fractions over 2 weeks, combined with rhGM-CSF (125 μg/m2).
2919353|NCT03113838||Taking YXSF Capsule Group|The overall individuals taking YXSF Capsule and achieving the inclusion criteria.
2919354|NCT03113825|Experimental|AVB-620 & Investigational Imaging Device|Eligible subjects will receive a single dose of AVB-620 as intravenous infusion before the surgical procedure. During the surgical procedure, fluorescent imaging will be undertaken to distinguish between malignant and nonmalignant tissues.
2919355|NCT03113812|Experimental|ABvac40|
2919356|NCT03113812|Placebo Comparator|Placebo|
2919357|NCT03113799|Other|Single Arm study|Single Arm study In this study, the subject will act as their own control. On Day 1 of the two day study, the subject will be observed while treated on their standard EVD. On Day 2, the subject will be treated with the Smart External Drain (SED).
2919358|NCT03113786|No Intervention|Standard of Care|Subjects randomized to standard of care will undergo a traditional lumbar discectomy procedure without any additional interventions
2919570|NCT03112369|Experimental|Narrative Exposure Therapy (NET)|Counseling program
2919359|NCT03113786|Active Comparator|CLARIX™100|Subjects randomized to the CLARIX™100 arm will undergo a traditional lumbar discectomy, after which CLARIX™100 will be applied to the affected site. The tissue will be applied to the annulus at the defect site as a patch just prior to wound closure.
2919360|NCT03113786|Active Comparator|CLARIX CORD 1K|Subjects randomized to the CLARIX CORD 1K arm will undergo a traditional lumbar discectomy, after which CLARIX CORD 1K will be applied to the affected site. The tissue will be applied to the annulus at the defect site as a patch just prior to wound closure.
2919361|NCT03113773|Experimental|Part A|Proleukin/Placebo in patients with stable ischaemic heart disease
2919362|NCT03113773|Experimental|Part B|Proleukin/Placebo in patients with cute coronary syndromes
2919363|NCT03113760|Experimental|Tadekinig alfa|Eligible subjects will be randomised to receive either Tadekinig alfa in addition of standard of care during 18 weeks of the Randomised Double Blind Placebo Control (RDBPC) phase, followed by an 8 weeks treatment in the Randomised Withdrawal (RW) phase.
2919364|NCT03113760|Placebo Comparator|Placebo|Eligible subjects will be randomised to receive the placebo in addition of standard of care, in this double blind study, during 18 weeks of the Randomised Double Blind Placebo Control (RDBPC) phase, followed by an 8 weeks treatment in the Randomised Withdrawal (RW) phase.
2919365|NCT03113747|Experimental|ALLO-ASCs|The patients receive ALLO-ADSCs. Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging
2919366|NCT03113747|No Intervention|The standard treatment|"All patients will be subjected to standard stepped treatment of burn wounds:~Infusion therapy aimed to eliminate disorders of homeostasis during burn shock and burn toxemia;~Systemic antibiotic therapy for preventing infectious complications;~Adequate analgesia and sedation;~Decompression necrotomy in the first 24 hours following the burn trauma;~Necrectomy simultaneously with imposition of lyophilized xenografts performed in the first 1-5 days after applying burn;~Autologous skin grafting 3-5 days after performed xenografts with the perforation coefficient 1:3"
2919367|NCT03113708|Sham Comparator|Heparinisation,actual body weight|In 'Heparinisation,actual body weight' group , heparin sodium; will be done according to actual body weight and ACT will be recorded prior to CPB. Before coming out CPB, protamine will be done according to heparin dose. And then ACT will be recorded.
2919368|NCT03113708|Experimental|Heparinisation, lean body weight|In 'Heparinisation, lean body weight' group heparin sodium will be done according to lean body weight and ACT will be recorded prior to CPB. Before coming out CPB, protamine will be done according to heparin dose. And then ACT will be recorded.
2919369|NCT03113695|Experimental|obinutuzumab, lenalidomide, and HDMP|
2919370|NCT03113682|Experimental|Intervention (CBT-RD)|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-RD. There is no control group.
2919371|NCT03113669|Other|Intervention (CBT-GSH)|Participants will receive a clinical intake (1 hour) and 6-sessions (approximately 25 minutes each) over 12 weeks of individual guided self-help CBT for eating disorders based on the treatment approach developed by Dr. Christopher Fairburn to use his self-help book Overcoming Binge Eating with the therapeutic guidance of clinician. Participants will be provided with a copy of Overcoming Binge Eating. The treatment is a largely behavioral treatment that focuses on helping patients engage in more regular eating, reduce dieting behaviors, and eliminate behaviors that contribute to binge eating. All participants in the study will receive the same treatment.
2919372|NCT03113656|Experimental|Weighted Blanket First|This group will receive the Weighted Blanket first and then the Non-weighted blanket
2919373|NCT03113656|Experimental|Non-weighted Blanket First|This group will receive the Non-weighted Blanket first and then the Weighted blanket
2919374|NCT03113643|Experimental|SL-401+ Azacitidine|SL-401 will be administered every 4 weeks, on a 28 day cycle; SL-401 will be given intravenously; Azacitidine will be administered every 4 weeks, on a 28 day cycle; Azacitidine will be given intravenously or subcutaneously
2919375|NCT03113630|Experimental|Acquisition on TouchScreen|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
2919376|NCT03113630|Experimental|Acquisition on Kinect|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
2919377|NCT03113630|Experimental|Acquisition on LeapMotion|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
2919378|NCT03113630|Active Comparator|Acquisition on TouchScreen Control Group|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
2919379|NCT03113630|Active Comparator|Acquisition on Kinect Control Group|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
2919380|NCT03113630|Active Comparator|Acquisition on LeapMotion Control Group|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
2919381|NCT03113617|Experimental|Diagnostic (68Ga-RM2 PET/CT)|Patients receive 68Ga-RM2 IV. Within 45-60 minutes, patients undergo a PET/CT scan. Patients may undergo a second PET/CT scan immediately after the first scan for attenuation correction. Patients may undergo also a repeat 68Ga-RM2 PET/CT scan after the completion of their treatment to evaluate response to therapy, if requested by the treating physician.
2919382|NCT03113604||Patients with untreated CHC not sorafenib|
2919383|NCT03113604||Patients with non-sorafenib CHC|
2919384|NCT03113604||Patients with CHCs responding to sorafenib|
2919385|NCT03113591|Experimental|Osteo introducer group|undergo minimal invasive total hip arthroplasty surgery
2919386|NCT03113591|Active Comparator|Control group|undergo common total hip arthroplasty surgery
2919387|NCT03113539|Experimental|Subjects awaiting for an aortic evaluation|"Subjects already waiting for an aortic evaluation, either a first diagnostic scan or follow-up of a known aneurysm.~Each subjects will have the two CT-scans on the same day."
2919388|NCT03113526|Active Comparator|Less than 30ml per 24-hour|Drain removed as early as day one as long as output less than 30ml per 24-hour
2919389|NCT03113526|Active Comparator|Less than 100ml per 24-hour|Drain removed as early as day one as long as output less than 100ml per 24-hour
2919571|NCT03112369|Experimental|Motivational Interviewing w/Skills Training (MIST)|Counseling program
2919946|NCT03109990|Placebo Comparator|saline|Same amount of saline will be administrated.
2919390|NCT03113513|Active Comparator|McCall culdoplasty|The McCall culdoplasty will be performed in a modified version as described by McCall in 1957. Specifically, two long acting bioresorbable sutures are put through the specific anatomic landmarks.
2919391|NCT03113513|Active Comparator|Sacrospinous ligament fixation|The SLF technique will be performed as described by Richter et al (Amreich, 1951). Two long acting bioresorbable sutures are passed through the right sacrospinous ligament and then fixed to the vaginal cuff.
2919392|NCT03113500|Experimental|Treatment (CHEP-BV)|"INDUCTION: Patients receive cyclophosphamide IV, doxorubicin IV on day 1, etoposide IV on days 1-3, and prednisone PO on days 1-5. Patients also receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Between 30-60 days post-consolidative autologous stem cell therapy or after completing induction course 6, patients with objective response (compete response or partial response) receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity."
2919393|NCT03113487|Experimental|Treatment (pembrolizumab, p53MVA)|Patients receive pembrolizumab IV over 30 minutes every 3 weeks and modified vaccinia virus ankara vaccine expressing p53 SC every 3 weeks for up to 3 vaccines. Courses with pembrolizumab repeat every 3 weeks for up to 49 weeks in the absence of disease progression or unacceptable toxicity.
2919394|NCT03113474|Experimental|Palatable-neutral|Participants are exposed to palatable food in the first test session, and to the neutral food in the second test session.
2919395|NCT03113474|Experimental|Neutral-palatable|Participants are exposed to neutral food in the first test session, and to the palatable food in the second test session.
2919396|NCT03113461|Experimental|CPAP adherent|Study participants in this arm are using the CPAP intervention consistently
2919397|NCT03113461|Active Comparator|CPAP non-adherent|Study participants in this arm are not using the CPAP intervention consistently
2919398|NCT03113461|No Intervention|No OSA|Study participants who do not have OSA
2919399|NCT03113448|Active Comparator|0.075% Capsaicin Lotion|0.075% Capsaicin Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
2919400|NCT03113448|Placebo Comparator|Placebo Lotion|Placebo Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
2919401|NCT03113435|No Intervention|Standard|In this group standard care will be provided to patients undergoing major abdominal surgery, regarding hemodynamic optimization
2919402|NCT03113435|Active Comparator|NICE group|In this arm patients will be treated according to stroke volume optimization described in NICE program
2919403|NCT03113435|Experimental|Oxygen consumption group|In this arm patients will receive hemodynamic optimization based on their oxygen consumption need
2919404|NCT03113422|Experimental|Induction Venetoclax|Venetoclax by mouth daily with be given in combination with obinutuzumab intravenously (IV) and bendamustine IV for up to 6 cycles.
2919405|NCT03113422|Experimental|Maintenance Venetoclax|Patients with stable or improved disease will receive venetoclax by mouth daily for 24 cycles (1 cycle=1 month) and obinutuzumab IV every 2 months for 12 cycles. Patients with no evidence of disease will receive obinutuzumab IV every 2 months for 12 cycles.
2919406|NCT03113409|Experimental|Procedure 1|Procedure 1: 5-day induction with increasing doses of oral naltrexone. Participants will receive XR-NTX on day five together with buprenorphine, and will continue receiving buprenorphine for 4 weeks until they receive 2nd XR-NTX dose.
2919407|NCT03113409|Experimental|Procedure 2|Procedure 2: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. No buprenorphine will be given beyond day 10.
2919408|NCT03113409|Experimental|Procedure 3|Procedure 3: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. Buprenorphine will continue for 4 weeks until the 2nd XR-NTX dose.
2919409|NCT03113396|Experimental|baclofen|Patients will receive baclofen (10mg t.i.d) for 2 weeks, thereafter they will be crossed over to the alternative treatment, which is placebo (identically looking capsules). After 2 weeks of treatment, patients will undergo a High Resolution Impedance Manometry (HRiM) measurement, with meal. We will record for in total 2 hours. Patients are asked to fill out questionnaires concerning their overall wellbeing.
2919410|NCT03113396|Placebo Comparator|placebo|Patients will receive placebo for 2 weeks, thereafter they will be crossed over to the alternative treatment, which is baclofen (10mg t.i.d) (identically looking capsules). After 2 weeks of treatment, patients will undergo a High Resolution Impedance Manometry (HRiM) measurement, with meal. We will record for in total 2 hours. Patients are asked to fill out questionnaires concerning their overall wellbeing.
2919411|NCT03113383|Experimental|Thoracoabdominal Aortic Aneurysm Repair|Use of the thoracic bifurcation and the visceral manifold to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy.
2919412|NCT03113370|Experimental|Fish Oil|4 grams of fish oil per day
2919413|NCT03113370|Placebo Comparator|Placebo|4 grams of olive oil capsules per day
2919414|NCT03113357|Experimental|Myofascial release technique|Subjects lied down in supine with knee flexion. Therapist seated on a stool at the head of the table. Elbows and supinated forearms on the table. Asked the client to lift their head off the table. Position the tips of the first three fingers into the soft tissue immediately inferior to the arc of atlas. The fingers are stabilized in a flexed position - around 45° at the MP and PIP joints. The subject is asked to rest their head back down so the fingertips are in the sub-occipital soft tissues and the finger pads rest firmly against the inferior aspect of the atlas. Once the position is perceived to be comfortable, a series of soft tissue responses will occur, characterized by local softening sensations followed by an increase in the weight of the head.
2919454|NCT03113084|Experimental|Group Sodium Heparin UQ First|The participants will receive the Sodium heparin UQ subcutaneous drug administration at first period and the Sodium heparin FK subcutaneous drug administration at second period
2919455|NCT03113084|Experimental|Group Sodium Heparin FK First|The participants will receive the Sodium heparin FK subcutaneous drug administration at first period and the Sodium heparin UQ subcutaneous drug administration at second period
2919415|NCT03113357|Experimental|conventional exercise therapy|Craniocervical flexion exercises, performed in supine lying, aimed to target the deep neck flexor muscles. Then they trained to be able to hold progressively increasing ranges of craniocervical flexion using feedback from an airfilled pressure sensor placed behind the neck. The muscles of the scapula, particularly the serratus anterior and lower trapezius, were trained using inner range holding exercises of scapular adduction and retraction, practiced initially in the prone lying position. The subjects were trained to sit with a natural lumbar lordosis while gently adducting and retracting their scapulas and gently flexed their cranio-cervical spine to facilitate the deep neck flexors.
2919416|NCT03113344||Children with the usage of anti-infective drugs|
2919417|NCT03113318|Experimental|Lymph node dissection and pulmonary metastasectomy|Total mediastinal lymph node dissection and pulmonary metastasectomy from colorectal cancer
2919418|NCT03113318|Active Comparator|Pulmonary metastasectomy only|Only pulmonary metastasectomy from colorectal cancer
2919419|NCT03113305||Roux-en-Y gastric bypass patients|Patients planned to undergo a Roux-en-Y gastric bypass procedure. Patients will be assessed -1 month, 3 month, 24 month and 48 months post surgery.
2919420|NCT03113305||Healthy controls|Healthy controls with no planned weight loss/gain. Control participant assessments will be time-matched with patients.
2919421|NCT03113305||One Anastomosis Gastric Bypass patients|Patients planned to undergo a One anastomosis gastric bypass procedure. Patients will be assessed -1 month, 3 month, 24 month and 48 months post surgery.
2919422|NCT03113292|Experimental|Pilates Method|Mat Pilates Program, 2x/week, for 6 weeks, supervised by a Physiotherapist. Sessions will last forty five min, with 4 individuals per session. On average, 10 to 15 exercises will be performed per session, with repetitions ranging from 10 to 20 times, according subject's limitations. If necessary, the exercises will be adapted individually for the three levels of difficulty: basic, intermediate and advanced. Progress will be dependent on the absence of postural compensations when performing the repetitions of the exercises.
2919423|NCT03113292|Active Comparator|Home Exercise Prescription|Composed by two familiarization sessions, supervised by a Physiotherapist. The protocol include postural reeducation exercises, stretching and muscle strengthening, stabilization and mobilization of the spine. Subsequently, participants will receive an educational booklet containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. Also, it will include a booklet with the prescription of therapeutic home exercises to be performed during the next 6 weeks. It will be recommended that the participants perform the exercises 2x/week. Participants will also be contacted weekly by email and/or telephone, for remote supervision and for checking the prescribed exercises.
2919424|NCT03113279||Obese older individuals|Obese older individuals
2919425|NCT03113279||Lean older individuals|Lean older individuals
2919426|NCT03113279||Young lean individuals|Young lean individuals
2919427|NCT03113266|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
2919428|NCT03113253|Experimental|Tranexamic Acid|"Patient will receive:~1g of tranexamic acid by slow intravenous injection~1g of tranexamic acid by syringe pump during 8 hours"
2919429|NCT03113253|Placebo Comparator|Placebo|"Patient will receive:~10 mL of 0.9% sodium chloride by slow intravenous injection~48 mL of 0.9% sodium chloride by syringe pump during 8 hours"
2919430|NCT03113240|Experimental|Glutamin|Intervention patients will be received enteral formula and glutamine 0.3 g/kg/day given via nasogastric tube as boluses q 4hrs.
2919431|NCT03113240|Placebo Comparator|maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
2919432|NCT03113227|Active Comparator|Successful Induction of labor group|Both transvaginal ultrasound and vaginal examination will be done for that group
2919433|NCT03113227|Active Comparator|Failed induction of labor group|Both transvaginal ultrasound and vaginal examination will be done for that group
2919434|NCT03113214|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 57.2 Gy.
2919435|NCT03113214|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 64.4 Gy.
2919436|NCT03113214|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 71.6 Gy.
2919437|NCT03113214|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 78.8 Gy.
2919438|NCT03113214|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 86 Gy.
2919439|NCT03113214|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 93.2 Gy.
2919440|NCT03113201|Experimental|Collabri Flex|Collaborative care
2919441|NCT03113201|Experimental|Consultation-Liaison|Consultations with general practitioner
2919442|NCT03113188|Experimental|CBP501, CDDP, Nivolumab|CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients with Advanced Refractory Tumors
2919443|NCT03113175|Experimental|Collabri Flex|Collaborative care
2919444|NCT03113175|Experimental|Consultation-Liaison|Consultations with general practitioner
2919445|NCT03113162|Experimental|Autologous Hematopoietic Stem Cell with BEAM Regimen|Autologous HSCT following Reduced-Intensity BEAM Regimen
2919446|NCT03113149||knee osteoarthritis|Patients with knee osteoarthritis after having started physical therapy
2919447|NCT03113136|Active Comparator|Low wattage E cigarette device|
2919448|NCT03113136|Active Comparator|High wattage E cigarette device|
2919449|NCT03113136|Active Comparator|Usual brand cigarette|
2919450|NCT03113123|Other|PrEP with Truvada®|"On demand PrEP (only for MSM - with the possibility of dosing schedule switching): 2 pills of Truvada within 24 to 2 hours prior first sexual intercourse, then 1 pill every 24 hours during the period of sexual activity with one pill after the last sexual intercourse, and one last pill 24 hours later~Continuous PrEP: 1 pill every 24 hours, at least 7 days before the first sexual intercourse. When PrEP is to be discontinued, 2 pills 24 hours apart after the last sexual intercourse then stop PrEP. If PrEP is to be resumed, 1 pill every 24 hours, started at least 7 days before the first sexual intercourse or 2 pills at least 2 hours before the first sexual intercourse and then 1 pill every 24 hours."
2919451|NCT03113110|Other|Empagliflozin Arm|Posttransplant Diabetes Mellitus (PTDM) patients after kidney transplantation receiving Empagliflozin 10 MG [Jardiance]
2919456|NCT03113071|Experimental|Newly diagnosed AML/MDS|For Group#1 a total of 37 patients with newly diagnosed MDL or MDS will be enrolled, including the eligible patients originally enrolled in the phase Ib portion (safe dose group) of the study, with the goal of determining the clinical activity of our experimental regimen. In the phase II segment, all new patients who are enrolled will initially be randomized in a 1 to 1 fashion to receive decitabine alone or decitabine plus digoxin for one cycle before receiving decitabine plus digoxin for all subsequent cycles for a total of 6 cycles.
2919457|NCT03113071|Experimental|Refractory or relapsed AML/MDS|or Group#2 the target will be to enroll a total of 60 patients with relapsed or refractory AML/MDS, including the eligible patients enrolled in the phase Ib group. This group will have randomization and treatments similar to Group#1.
2919458|NCT03113058|Experimental|study group|
2919459|NCT03113045|Experimental|Seated Time|Pts will be seated for the allocated time depending on the previous patients hypotensive response
2919460|NCT03113032|Experimental|Exercise group 1|This group of patients will receive the P-SEC exercise intervention protocol on their 'surgical' leg in addition to their normal pre-surgical care.
2919461|NCT03113032|Experimental|Exercise group 2|This group of patients will receive the P-SEC exercise intervention protocol on their 'non-surgical' leg in addition to their normal pre-surgical care.
2919462|NCT03113032|Active Comparator|Control group|This group of patients will not receive the P-SEC protocol but will follow normal pre-surgical care along with the other two groups of patients.
2919463|NCT03113019|Experimental|Immunotherapy based on dendritic cells|Intravenous administration dendritic cell and activated mononuclear cells at least 3 times 20-30 million cells / injection
2919464|NCT03113006|Active Comparator|Standard Panretinal Photocoagulation|Localized to all four retinal quadrants.
2919465|NCT03113006|Experimental|Individ. Panretinal Photocoagulation|Localized to only the affected quadrants.
2919466|NCT03112993|Experimental|Sugammadex group|2 mg/kg of sugammadex, IV once at the end of the surgery. Dosing will be based on actual body weight not ideal body weight.
2919467|NCT03112993|Active Comparator|Neostigmine group|"50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.~Dosing will be based on actual body weight not ideal body weight."
2919468|NCT03112980|Experimental|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation (TAVI) using the most appropriate CE (Conformité Européene)-marked device available, with a minimum demand of experience of 30 implanted devices/type per center.
2919469|NCT03112980|Active Comparator|Surgical aortic valve replacement|Surgical aortic valve replacement (SAVR) with free choice of surgical bioprosthesis and free choice of surgical access according to the surgeon's preference.
2919470|NCT03112967|Experimental|OSS(Suprep)|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
2919471|NCT03112967|Active Comparator|4L PEG solution(Colyte)|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
2919472|NCT03112954|Experimental|Buccal-relaxant formula|The buccal-relaxant formula used in this study contained 8 floral essences from native and non-native plants commonly grown in Brazil, developed at the Mater Gaia Institute. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days.
2919473|NCT03112954|Experimental|Placebo|Each patient received a small amber glass bottle containing the placebo, and was instructed to use four drops sublingually 4 times a day for 22 days.
2919474|NCT03112941|Experimental|control group|Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.
2919475|NCT03112941|Experimental|hyperbaric oxygen group|Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
2919476|NCT03112928|Experimental|Phantom Motor Execution (PME)|Phantom motor execution is decoded via myoelectric pattern recognition and promoted via serious gaming in virtual and augmented reality.
2919477|NCT03112928|Active Comparator|Phantom Motor Imagery (PMI)|Use the same device and visual stimulation as PME, with the difference that participants imagine to perform, rather than execute phantom movements. Myoelectric activity is used to monitor that the subjects do not produce muscular contractions but only imagine the movements.
2919478|NCT03112915|Active Comparator|QLB: Quadratus lumborum block|"QLB: Quadratus lumborum block :Quadratus Lumborum block group (QL)~patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.25 %"
2919479|NCT03112915|Active Comparator|TAP: transversus abdominis plan block|"TAP: Transversus abdominis plane block (TAP)~patients will receive a bilateral TAP block using Bupivicaine 0.25%"
2919480|NCT03112902|Active Comparator|Effects of tACS during slow wave sleep (SWS)- Phasic|
2919481|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard|
2919482|NCT03112902|Sham Comparator|Effects of tACS during SWS- Sham|
2919483|NCT03112902|Active Comparator|Effects of tACS during SWS- Nested|
2919484|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard2|
2919485|NCT03112902|Sham Comparator|Effects of tACS during SWS- Sham2|
2919486|NCT03112902|Active Comparator|Effects of tACS during SWS- Older Adults Active|
2919487|NCT03112902|Sham Comparator|Effects of tACS during SWS- Older Adults Sham|
2919488|NCT03112902|Active Comparator|Effects of tACS during SWS- MCI Active|
2919489|NCT03112902|Sham Comparator|Effects of tACS during SWS- MCI Sham|
2919490|NCT03112889|Experimental|Sodium Valproate|Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
2919631|NCT03111992|Experimental|Arm C|Dose escalation of LCL161 in combination with a fixed dose of PDR001
2919491|NCT03112876||Young Age - Healthy|These subjects are between the age of 12 and 35 years. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
2919492|NCT03112876||Old Age -Healthy|These subjects are 55 years of age and older. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
2919493|NCT03112876||Active Smoker|These subjects are active smokers who smoke often. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
2919494|NCT03112876||Dermatological skin condition: Acne vulgaris|These subjects have acne vulgaris. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
2919495|NCT03112876||Dermatological skin condition: Atopic dermatitis|These subjects have atopic dermatitis. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
2919496|NCT03112863|Experimental|Bakuchiol|
2919497|NCT03112863|Active Comparator|Retinol|
2919498|NCT03112850|Active Comparator|Group A|Participants who will be fitted with hearing aids for the first 3 months of 6 months auditory training program
2919499|NCT03112850|Active Comparator|Group B|Participants who will be fitted with hearing aids for the second 3 months of 6 months auditory training program
2919500|NCT03112837|Experimental|drug group|live Lactobacillus, Bifidobacterium and Enterococcus ( two pills two times a day)with radiotherapy and Chemotherapy
2919501|NCT03112837|No Intervention|non-drug group|only receiving radiotherapy and chemotherapy
2919502|NCT03112837|No Intervention|healthy control group|
2919503|NCT03112824|Experimental|Ashwagandaha Root Extract Capsule|Participants will take one 300 mg. Ashwaganda capsule twice a day for 12 weeks.
2919504|NCT03112824|Placebo Comparator|Placebo Capsule|Participants will take one placebo capsule twice a day for 12 weeks.
2919505|NCT03112811|Experimental|Intubated infant|
2919506|NCT03112811|Experimental|Extubated infant|
2919507|NCT03112798||Macintosh group|The patients will be intubated by using Macintosh blades and the outcomes will be compared with Miller blades.
2919508|NCT03112798||Miller group|The patients will be intubated by using Miller blades and the outcomes will be compared with Macintosh blades.
2919509|NCT03112772|Experimental|Group I|Participants who are receiving socket preservation using allograft (Puros® Allograft, Zimmer dental, Zimmer, USA) covered by membrane (size: 15x20mm) made of type I collagen fibers purified from bovine tendon (BioMend® Membrane, Zimmer dental, Zimmer, USA).
2919510|NCT03112772|Experimental|Group II|Participants who are receiving socket preservation cancellous particulate bovine bone xenograft (CopiOs® Cancellous Particulate, Zimmer dental, Zimmer, USA) covered by membrane (size: 15x20mm) made of type I collagen fibers purified from bovine tendon (BioMend® Membrane, 15x20mm, Zimmer dental, Zimmer, USA).
2919511|NCT03112772|No Intervention|Group III|No grafting materials will be inserted, so it serves as a negative control group.
2919512|NCT03112759|Experimental|Cognitive Behavioral Therapy|Patients randomly selected for CBT will attend 8 weekly one-on-one therapy sessions. Patients will be prescribed conventional narcotic therapy as needed.
2919513|NCT03112759|No Intervention|No Cognitive Behavioral Therapy|Patients randomly selected for no CBT will be treated with conventional narcotic therapy alone.
2919514|NCT03112746|Experimental|Cognitive Orientation to daily Occupational Performance|One group was submitted to the CO-OP approach to learn cognitive strategies to perform the chosen tasks.
2919515|NCT03112733||Patients with ovarian carcinoma|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of patients with a presumed diagnosis of ovarian carcinoma will be determined prior to surgery.
2919516|NCT03112733||Control group|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women without any adnexal mass nor malignancy will be determined to compare with other groups.
2919517|NCT03112733||Benign adnexal mass|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women with an adnexal mass will be determined to compare with other groups.
2919518|NCT03112720|Active Comparator|Epidural blood patch|20ml of sterile blood is obtained from the patients arm and placed in the epidural space using standard sterile epidural access.
2919519|NCT03112720|Experimental|Sphenopalatine Ganglion Block|Cotton tip applicators are used to deliver lidocaine to the posterior nares in the area of skin overlying the Sphenopalatine gangion
2919520|NCT03112707|Experimental|Study arm|1023 real world high-bleeding risk (HBR) patients with coronary artery disease (stable as well as acute coronary syndromes) who qualify for percutaneous coronary interventions will be included in the study.
2919521|NCT03112681|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet Once daily for 16 weeks
2919522|NCT03112681|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet Once daily for 16 weeks
2919523|NCT03112681|Placebo Comparator|Placebo|Placebo tablet Once daily for 16 weeks
2919524|NCT03112668|Experimental|Supportive Care (ACT)|Patients and their partners attend 6 weekly ACT sessions over 60-75 minutes. Couples learn skills of acceptance, avoidance, awareness, values and committed action, mindfulness and values in relationships, and handling persistent worries and concerns. Patients and their partners also do homework assignment after each session.
2919525|NCT03112655|Experimental|Human african trypanosomiasis patient|RNA and neopterin detection
2919526|NCT03112642|Active Comparator|Standard Group|In the Standard Group, in the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block [0.35% marcaine] will be administered into the brachial plexus of the upper limb being operated on, at the supraclavicular level.
2919567|NCT03112382|Active Comparator|zinc supplement plus vitamin A and E|patients will be receiving zinc supplement plus vitamin A and E for 3 months.
2919568|NCT03112382|Active Comparator|vitamin A and E|patients will be receiving equivalent dose of vitamin A and E only for 3 months
2919527|NCT03112642|Experimental|Test Group|"In this group, the ultrasound guided local anesthetic block into the brachial plexus at the supraclavicular level of the upper limb being operated on will be supplemented by use of a blockade monitor (Nerve stimulator device) to direct final placement of the needle for the nerve block.~Only this group of the patients will receive this intervention with sufficient detail so that it can be distinguished from the Test Group"
2919528|NCT03112629||symptomatic AS|Patients diagnosed with severe aortic stenosis in echocardiography who display one or more of the following symptoms: exertional shortness of breath, chest pain, exertional dizziness or syncope.
2919529|NCT03112629||asymptomatic AS|Patients diagnosed with severe aortic stenosis in echocardiography who do not display symptoms
2919530|NCT03112616||Left-brain damaged chronic patients|
2919531|NCT03112616||Right-brain damaged chronic patients|
2919532|NCT03112603|Experimental|Ruxolitinib|Ruxolitinib for the treatment period and extension period.
2919533|NCT03112603|Active Comparator|Best Available Therapy|Best available therapy for the treatment period and extension period, with optional crossover to ruxolitinib after Cycle 6.
2919534|NCT03112590|Experimental|Combination Therapy|"Phase 1: Participants with HER-2 positive metastatic breast cancer enrolled in groups of 3-6 or more; each group participant to be given the same dose and schedule of Interferon-gamma plus paclitaxel, trastuzumab, and pertuzumab. If group participants do not have bad side effects, the next group will be given a higher dose of Interferon-gamma. This will continue until the highest safe dose of Interferon-gamma is found. Once highest safe dose of Interferon-gamma is found, participants may be enrolled in Phase II.~Phase 2: Approximately 31 participants with Stage 2-3 HER2 positive early stage breast cancer enrolled to receive therapy with Interferon-gamma plus paclitaxel, trastuzumab, and pertuzumab. Interferon-gamma given at dose found in the Phase 1.~Phase 2: Post therapy surgery."
2919535|NCT03112577|Experimental|REGN3500|REGN3500: masked and randomized dosing regimen per protocol (part 1 only)
2919536|NCT03112577|Experimental|Dupilumab|Dupilumab: masked and randomized dosing regimen per protocol (part 1 only)
2919537|NCT03112577|Experimental|REGN3500 plus dupilumab|REGN3500 plus dupilumab: masked and randomized dosing regimen per protocol (part 1 only)
2919538|NCT03112577|Experimental|Placebo|Placebo: masked and randomized dosing regimen per protocol (part 1 only)
2919539|NCT03112577|Active Comparator|Fluticasone propionate|Fluticasone propionate: open label dosing regimen per protocol (part 2 only)
2919540|NCT03112564|Other|Sevoflurane 8% + Intravenous fentanyl|Avoidance of rocuronium/cisatracurium
2919541|NCT03112551|Active Comparator|group 1|group one will be treated with 24 hours maintenance dose of magnesium sulphate
2919542|NCT03112551|Experimental|group 2|group 2 will be treated with 12 hours maintenance dose of magnesium sulphate
2919543|NCT03112538|Active Comparator|Insulin pump|Medtronic Minimed Paradigm Veo Insulin Pump utilising rapid acting insulin Glulisine or Aspart
2919544|NCT03112538|Active Comparator|Multiple daily injections of insulin|Multiple daily injections consisting of a single basal insulin injection(Glargine) and 3 bolus insulin injections (rapid acting insulin Glulisine or Aspart) before each meal
2919545|NCT03112525||Patient under Rivaroxaban|
2919546|NCT03112525||Patient under Apixaban|
2919547|NCT03112512|Experimental|EIT|PEEP titration is performed where EIT is measured at the same time. After PEEP titration, EIT data is analyzed. Global inhomogeneity index and regional compliance based on EIT are calculated. PEEP level is selected when ventilation distribution is most homogeneous.
2919548|NCT03112512|Experimental|G5 VENTILATOR|Protective Ventilation Tool by G5(MV) to determine the optimal PEEP on ARDS patients. The results are delivered by the ventilator automatically.
2919549|NCT03112499|Active Comparator|PCNL Group|Patients with renal calculi 10-30mm in maximal diameter in who percutaneous nephrolithotomy (PCNL) will be conducted
2919550|NCT03112499|Active Comparator|mini-PCNL Group|Patients with renal calculi 10-30mm in maximal diameter in who mini- percutaneous nephrolithotomy (mini-PCNL) will be conducted
2919551|NCT03112499|Active Comparator|RIRS Group|Patients with renal calculi 10-30mm in maximal diameter in who retrograde intrarenal surgery (RIRS) will be conducted
2919552|NCT03112486||Cardiac Arrest cohort|adult patients (≥ 18 years of age) with non-traumatic out of hospital cardiac arrest
2919553|NCT03112486||Control cohort|matched control population will include hemodynamically stable patients who present to the ED with chest pain that is not of cardiac etiology (non-traumatic chief complaints).
2919554|NCT03112473|Active Comparator|Bilateral TENS (Bi-TENS) group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with bilateral electrical stimulation
2919555|NCT03112473|Placebo Comparator|Unilateral TENS (uni-TENS) group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with unilateral electrical stimulation on paretic side
2919556|NCT03112473|Placebo Comparator|Placebo group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with bilateral sham electrical stimulation
2919557|NCT03112473|No Intervention|Control group|No Active intervention
2919558|NCT03112460||all patients|all of patients who went through basic and advanced cardiopulmonary resuscitations would be analyzed
2919559|NCT03112447|Experimental|absorbable cartilage nail Group|10 males and 7 females, ages 7-15 years (average, 11.8), and 3 patients with elbow dislocation, the fractures were fixed by absorbable cartilage nail
2919560|NCT03112447|Active Comparator|traditional Kirschner wire Group|10 males and 5 females, ages 8-14 years (average, 12.6), and 4 patients with elbow dislocation, the fractures were fixed by traditional Kirschner wires
2919561|NCT03112408|Experimental|FORWARD (Axe 1)|
2919562|NCT03112408|Experimental|BACKWARD (Axe 1)|
2919563|NCT03112408|Experimental|CONTROL (Axe 1)|
2919564|NCT03112408|Experimental|ADAPTATION (Axe 2)|
2919565|NCT03112408|Experimental|CONTROL (Axe 2)|
2919566|NCT03112395|Experimental|Combined SOC/Pio treatment|Prospective trial (1 month SOC, 2 month SOC + Pio Medical Device, 1 month SOC follow-up) month, with collection of endpoints every second week
2919572|NCT03112356|Experimental|99mTc-Leukoscan® scintigraphy|Patients presenting a suspicions of infectious endocarditis on surgical materials and undergoing the 99mTc-Leukoscan® scintigraphy
2919573|NCT03112343|Active Comparator|ICT-based intervention|Subjects in the ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
2919574|NCT03112343|Placebo Comparator|Conventional intervention group|Subjects in the conventional intervention group will only save and send their health information to the server via the personal health record app
2919575|NCT03112330|Experimental|platelet rich plasma injection group|To evaluate the safety and efficacy of plasma rich platelet injection on inferior turbinate mucosa in patients with atrophic rhinitis
2919576|NCT03112317||Hypothermia|Patients with mild hypothermia at start of the surgery
2919577|NCT03112317||Normothermia|Patients with normal core temperature at start of surgery.
2919578|NCT03112304|Experimental|MATCH-ADTC Wave 1|Wave 1 clinicians received MATCH training at the beginning of the project and used MATCH to treat participating children from their clinic for two years, with weekly case consultation from MATCH experts who were part of the study team, and then received consultation from their own clinic supervisors who had been trained as MATCH Associate Consultants (ACs), supported by the TRAC system.
2919579|NCT03112304|Experimental|MATCH-ADTC Wave 2|Wave 2 clinicians provided treatment as usual (e.g., usual care) with the children they treated during the initial two years of the project. Afterwards, they trained in MATCH and used it to treat children in their clinics with weekly case consultation from our study team of MATCH experts, supported by the TRAC system.
2919580|NCT03112291|Experimental|permanent teeth apexification|They should have one permanent tooth with traumatic necrosis, which in turns should show color alteration, fistulae, periapical lesion, and/or internal or external root resorption, pain, or absence of pulp response to sensitivity tests at a clinical examination to be considered necrotic. Male and female patients who had not undergone antibiotic therapy 3 months before the treatment were included and clinical and radiographic examinations confirmed pulp necrosis. This study analyzed the clinical and microbiological results of the endodontic treatment performed on permanent teeth with necrosis caused by traumatic injury and treated using revascularization technique, double antibiotic paste, intra-canal medication, and an MTA cervical plug.
2919581|NCT03112278|Active Comparator|Ceramic restorations|Ceramic ultrathin occlusal veneers
2919582|NCT03112278|Active Comparator|Composite resin restorations|Composite resin ultrathin occlusal veneers
2919583|NCT03112265|Experimental|Child STEPS|Child STEPs includes (1) a treatment protocol, Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems (MATCH-ADTC), and (2) a youth monitoring and feedback system (MFS).
2919584|NCT03112265|Active Comparator|Usual Care|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective, and researchers will not influence their work.
2919585|NCT03112239|Active Comparator|photobiomodulation by active LEDT|The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with active photobiomodulation by LEDT to increase peripheral muscle function post resistance training.
2919586|NCT03112239|Placebo Comparator|photobiomodulation by Placebo LEDT|The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with placebo LEDT photobiomodulation to increase peripheral muscle function post resistance training.
2919587|NCT03112226|Active Comparator|GnRHant + E2|Single dose of GnRH antagonist degarelix acetate for depot injection (80mg) Transdermal estradiol add-back; Climara patch, 0.075mg/day, weekly for 12 weeks
2919588|NCT03112226|Placebo Comparator|GnRHant + Placebo|Single dose of GnRH antagonist degarelix acetate for depot injection (80mg) Transdermal placebo patch, weekly for 12 weeks
2919589|NCT03112213||Participants With RA|Participants with RA who are being treated with tocilizumab and NSAIDs will be observed for approximately 6 months to evaluate the quantitative pattern of NSAID use and the impact of treatment with tocilizumab on NSAID use.
2919590|NCT03112200|Active Comparator|Subchondroplasty with Arthroscopy|After randomization to the study group, subjects assigned to the Subchondroplasty + Arthroscopy group will undergo the Subchondroplasty portion of the procedure before or after the Arthroscopy portion per the surgeon's discretion. All operative procedures are to be performed under aseptic conditions according to the institution's standards.
2919591|NCT03112200|Sham Comparator|Arthroscopy Alone|"After randomization, subjects assigned to the Arthroscopy control group will undergo arthroscopy of the study knee with one or more of the following procedures:~Partial meniscectomy~Lavage~Debridement~Loose body removal~Synovectomy~Removal of osteophytes in the notch or locations other than those adjacent to BML(s)~Superficial skin incision(s) should be created at the typical AccuPort® access point(s) as if the subject had undergone Subchondroplasty. The incisions should be closed in the typical fashion."
2919592|NCT03112187|Experimental|Intervention|Ferfer is a food supplement in liposomal form, with essential, vitamins including Vitamin C and Vitamin B12. Ferfer directly dissolves in the mouth without the need for water. The technology of liposomal microencapsulation, allows daily iron supplementation without any of the typical side effects of conventional oral iron supplements, such as heartburn, diarrhea, constipation, nausea and coloring of the mucous membranes and of the stools, which increases patient compliance. It has no metallic taste or smell, does not color mucous membrane and has excellent tolerability
2919593|NCT03112174|Experimental|Safety Run-in Period|Subjects are enrolled into the open-label Safety Run-in Period to evaluate the occurrence of tumor lysis syndrome (TLS) and DLTs with the concurrent administration of ibrutinib and venetoclax.
2919594|NCT03112174|Experimental|Phase 3: Ibrutinb + Venetoclax|Subjects will be randomized to receive ibrutinib and venetoclax/placebo until clinical disease progression or unacceptable toxicity
2919595|NCT03112174|Placebo Comparator|Phase 3: Ibrutinib + Placebo|Subjects will be randomized to receive ibrutinib and venetoclax/placebo until clinical disease progression or unacceptable toxicity
2919596|NCT03112161|Experimental|Eucaloric|Participants will consume a eucaloric diet with a macronutrient composition of 20% protein, 30% fat and 50% carbohydrate for 4 days (Eucaloric Feeding Period). The caloric value of the diet will be calculated based on lean body mass plus an activity factor to ensure energy and macronutrient balance.
2919597|NCT03112161|Experimental|Overfed|Following 3 days of eucaloric feeding, participants will complete a 1-day overfeeding period (Overfeeding Feeding Period), during which their diet will have a daily energy value of 40% greater than the eucaloric diet (Eucaloric Arm), although the macronutrient composition will remain the same (20% protein, 30% fat, 50% carbohydrate).
2919598|NCT03112161|Experimental|Underfed|Following 3 days of eucaloric feeding, participants will complete a 1-day underfeeding period (Underfeeding Feeding Period), during which their diet will have a daily energy value of 40% less than the eucaloric diet (Eucaloric Arm), although the macronutrient composition will remain the same (20% protein, 30% fat, 50% carbohydrate).
2919599|NCT03112148|Experimental|Treatment A|Single oral 10 mg dose of tofacitinib MR-FAST administered in the fed state.
2919600|NCT03112148|Experimental|Treatment B:|Single oral 10 mg dose of tofacitinib MR-SLOW administered in the fed state.
2919601|NCT03112148|Experimental|Treatment C|Single oral 10 mg dose of tofacitinib MR-FAST administered in the fasted state.
2919602|NCT03112148|Experimental|Treatment D|Single oral 10 mg dose of tofacitinib MR-SLOW administered in the fasted state.
2919603|NCT03112148|Experimental|Treatment E|Single oral 10 mg dose of tofacitinib MR-MODERATE administered in the fasted state
2919604|NCT03112148|Experimental|Treatment F|Single oral 10 mg dose of tofacitinib IR Solution (10 mL of the 1 mg/mL solution) administered in the fasted state
2919605|NCT03112135|Active Comparator|Systemic TXA|TXA 10-15 mg i.v over 30 min. followed by infusion in a dose of 1 mg / kg /hr
2919606|NCT03112135|Active Comparator|Topical TXA|Topical TXA 1 gm diluted in 200 ml saline
2919607|NCT03112135|Active Comparator|Topical adrenaline|Topical adrenaline 1 mg diluted in 200 ml saline
2919608|NCT03112122|Active Comparator|core decompression technique|The standard surgical technique is the subchondral anterograde drilling, which permit a revascularization of the Bone Marrow Edema (BME) and a reduction of the intramedullary pressure (core decompression).
2919609|NCT03112122|Experimental|bone substitution (i-FactorTM)|i-FactorTM is a combination of the mineral component of bone (Anorganic Bone Mineral) with a peptide replicating the cell-binding domain of Type-I collagen (P-15). It has been used in bone defects and in spine fusion providing good clinical results. Thus, i-FactorTM could be a valid and efficient bone substitute to treat BMLs with subchondral injections.
2919610|NCT03112122|Experimental|injections of autologous Bone Marrow Concentrate (BMC)|injections of autologous BMC.
2919611|NCT03112109||Intervention Group|Patients receiving 'new care'
2919612|NCT03112109||Control group|Patients receiving 'old / usual care'
2919613|NCT03112096|Experimental|Cognitively Healthy Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 injection
2919614|NCT03112096|Experimental|Alzheimer's Disease Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 injection
2919615|NCT03112083|Active Comparator|Krill oil|Krill powder capsules, 4 g
2919616|NCT03112083|Placebo Comparator|Placebo|Placebo capsules, maize strach, 4 g
2919617|NCT03112070|Experimental|Water aerobic exercise session (WATER)|A continuous session of dynamic water aerobic exercise which consist of a dynamic warm-up period (5 minutes), an active exercise period (35 minutes), and a cooldown period (5 minutes) to total 45 minutes. Heart rate (HR) will be continuously measured with heart monitors (Polar) to confirm the intensity of the WATER session. The WATER intensity will be calculated according to the formula proposed by Kruel for exercise in an aquatic environment18 as follows: HR for exercise = % x (HRmax - ΔHR); % is the intensity of exercise; HRmax is the maximum HR (estimated by 220 - age); ΔHR represents the difference between resting HR on land and resting HR in the water environment. Exercise intensities: 55-60% HRmax during warm-up; 70-75% HRmax during active exercise; and 55-60% HRmax during cooldown.
2919618|NCT03112070|No Intervention|Control session (CONTROL)|A 45-min session with no exercise. During this session, participants will remain seated or standing as desired. They will read, talk, and drink water, but do nothing else.
2919619|NCT03112057|Experimental|Healthy subjects|Healthy subjects of different ages (20 persons), Interventions: harmonic generation microscopy
2919620|NCT03112057|Experimental|peripheral neuropathy|the participant have symptoms and diagnosed with peripheral neuropathy (90 persons), Interventions:harmonic generation microscopy
2919621|NCT03112057|Experimental|diabetic neuropathy|the participant have symptoms and diagnosed with diabetic neuropathy (20 persons), Interventions:harmonic generation microscopy
2919622|NCT03112057|Experimental|chemotherapy induced neuropathy|before chemotherapy, during chemotherapy, after peripheral nerve lesions were cured (30 persons). Interventions:harmonic generation microscopy
2919623|NCT03112057|Experimental|Polydactyly|Abandoned extra digit specimen of polydactyly(10 persons): the normal skin and nerve endings in extra digit: Interventions: harmonic generation microscopy
2919624|NCT03112044|Experimental|HCV+ lung transplant to HCV- recipients|HCV+ donor lungs will be treated with Normothermic Ex Vivo Lung Perfusion (EVLP) in order to reduce viral load and minimize risk of HCV transmission. Patients who become viremic defined as at least two consecutive positive samples will receive sofosbuvir/velpatasvir 400 mg/100 mg (Epclusa) for 12 weeks.
2919625|NCT03112031|Experimental|Tamoxifen augmented antifungal therapy|Tamoxifen 300mg/day for 2 weeks, combined with standard antifungal therapy (amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks)
2919626|NCT03112031|Active Comparator|Standard antifungal therapy|Amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks.
2919627|NCT03112018|Active Comparator|Standard care|"Data strengthening~modified Safe Childbirth Checklist (mSCC) implementation"
2919628|NCT03112018|Experimental|Enhanced care (intervention)|"Data strengthening~modified Safe Childbirth Checklist (mSCC) implementation~Health provider training (PRONTO)~Quality Improvement (QI) Cycles"
2919629|NCT03111992|Experimental|Arm A|Dose escalation of single agent CJM112
2919630|NCT03111992|Experimental|Arm B|Dose escalation of CJM112 in combination with a fixed dose of PDR001
2919632|NCT03111979|Experimental|Beta-alanine supplementation|Participants will be supplemented with 4.8g·d-1 β-alanine (CarnoSyn™, NAI, USA). The β-alanine dosing regimen will consist of two 800 mg tablets three times per day at 3-4 hour intervals or the same regimen for placebo tablets. The use of multiple small doses throughout the day has been used in numerous studies using β-alanine in solutions or gelatine capsules (Hoffman et al., 2008; Sale et al., 2011; Saunders et al., 2012; Sale et al., 2012; Tobias et al., 2013) in order to circumvent potential symptoms of paraesthesia (see box xii for possible risks and discomforts). Overall increases have been shown to be between 40% and 80% depending upon dose (between 3.2 and 6.4 g·d-1) and duration of administration (between 4 and 10 weeks) (Sale et al., 2012).
2919633|NCT03111979|Placebo Comparator|Placebo|Participants will be supplemented with 4.8 g·d-1 placebo (maltodextrin; NAI, USA). The regimen will consist of two 800 mg tablets three times per day at 3-4 hour intervals the same regimen for beta-alanine tablets
2919634|NCT03111966||Spanish cohort with HCV treated with DAA|
2919635|NCT03111953|Active Comparator|RYGB|Subjects received Roux-en-Y Gastric Bypass surgery.
2919636|NCT03111953|Experimental|BPD|Subjects received Biliopancreatic Diversion Surgery
2919637|NCT03111940|Experimental|PCI optimisation|Post PCI FFR below 0.9
2919638|NCT03111940|No Intervention|No PCI optimisation|Post PCI FFR 0.9 or higher
2919639|NCT03111927|No Intervention|Reference Arm: Breastfed|Epidemiological reference group of breastfed infants.
2919640|NCT03111927|Experimental|Investigational|Infant Formula: enriched level of myelin-relevant nutrients
2919641|NCT03111927|Active Comparator|Control|Infant formula: standard level of myelin-relevant nutrients
2919642|NCT03111914|Other|Dual Energy Computed Tomography (DECT)|This is a single-arm study. Each patient will receive an unenhanced dual energy CT scan followed by a contrast-enhanced scan as part of clinical routine work up. No change in the contrast material injection protocol will be performed for this this study.
2919643|NCT03111901|Experimental|Level 1|Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 12 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.
2919644|NCT03111901|Experimental|Level -1|Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 5 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.
2919645|NCT03111888|Experimental|Patient-Specific Tracheobronchial Stent|Observe and document the ability of a patient-specific tracheobronchial stent to improve a patient's quality of life and symptoms associated with airway stenosis.
2919646|NCT03111875|Active Comparator|Routine thermal management|Patients assigned to routine thermal management will not be pre-warmed and ambient intraoperative temperature will be maintained near 20°C per routine. Only transfused blood will be warmed. An upper- or lower-body forced-air cover will be positioned over an appropriate non-operative site, but will not initially be activated. Should core temperature decrease to 35.5°C, the warmer will be activated as necessary to prevent core temperature from decreasing further.
2919647|NCT03111875|Experimental|Aggressive thermal management|"Patients assigned to aggressive warming will be pre-warmed with a full-body Bair Hugger or Bair Paws cover for ≈30 minutes before induction of anesthesia. The warmer will initially be set to high which corresponds to ≈43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be aggressively warmed during surgery to a target intraoperative core temperature between 37 and 37.5°C, using two forced-air covers when clinically practical. All intravenous fluids will be warmed to body temperature."
2919648|NCT03111849||hospitalized chronic obstructive patients|
2919649|NCT03111836|Sham Comparator|Control group|The Control group received limited to general information on blood pressure management
2919650|NCT03111836|Active Comparator|Expert-driven group|The intervention will consisted of pre-determined exercise and dietary goals (e.g. increase daily steps by 1000 steps, consuming 2-3 servings of fruit and vegetables per day).
2919651|NCT03111836|Active Comparator|User-driven group|The User-driven group received an intervention that enabled participants to select their areas of lifestyle change using text and video web links embedded in the email. The trans-theoretical model was used to inform the design of the User-driven program.
2919652|NCT03111823|Experimental|Supportive Care (aerobic exercise)|Patients undergo aerobic exercise sessions consisting of cycling or walking at a low-moderate intensity and progressing to moderate intensity for 30 minutes 2 times a week for up to 8 weeks.
2919653|NCT03111810|Active Comparator|Active|Prednisolone 20mg once daily and AZD4017 400mg twice daily for 7 days.
2919654|NCT03111810|Placebo Comparator|Placebo Oral Tablet|Prednisolone 20mg once daily and placebo twice daily for 7 days.
2919655|NCT03111797||video-assisted lobectomy group|patients operated of lung lobectomy for an early stage cancer using a video-assisted surgical procedure
2919656|NCT03111797||robot-assisted lobectomy group|patients operated of lung lobectomy for an early stage cancer using a robot-assisted surgical procedure
2919657|NCT03111771||Group K +|Group K +: cancer of the upper aerodigestive tract with or without cachexia
2919658|NCT03111771||Group K-|Group K-: absence of cancer and absence of cachexia
2919659|NCT03111771||Control group|The MYOMEC study includes the inclusion of healthy patients (to form a control group
2919660|NCT03111758|Active Comparator|Geko Device|Neuromuscular Stimulator
2919661|NCT03111758|Active Comparator|IPCS|Intermittent Pneumotic Compression Stocking
2919662|NCT03111745||Patient records|The study will involve review of patient records
2919663|NCT03111732|Experimental|1/Arm 1|CAPOX and Pembrolizumab in BTC
2919664|NCT03111706||dehiscencd scar|women who are discovered with scar dehiscence during cesarean section
2919665|NCT03111706||Intact scar|women with intact scar detected during cesarean section
2919666|NCT03111693||obese patients|obese patients of our clinical nutrition service, hospitalized for nutrional assessement, are included.
2919667|NCT03111680|Experimental|intervention|this arm received an environmental intervention to make healthy eating and activity easier for residents
2919668|NCT03111680|No Intervention|control|the control participants received no interventions
2919669|NCT03111667|Experimental|Student Participants: Teen Marijuana Check Up|2 Session Motivational Enhancement Therapy intervention for adolescents who use marijuana.
2919670|NCT03111667|Other|Student Participants: Treatment As Usual|Students will receive referrals to local agencies and other resources as typically done by school based staff. At the end of research follow-up period, students in this condition will be eligible to receive the active intervention.
2919671|NCT03111667|Experimental|Interventionist Participants: Gold Standard Coaching|Interventionists will receive weekly coaching and feedback about sessions and skills from the project PI.
2919672|NCT03111667|Active Comparator|Interventionist Participants: As Needed Coaching|Interventionists will receive coaching and feedback about sessions and skills from the project PI only when sessions fall below adherent skill levels.
2919673|NCT03111667|No Intervention|Administrator Participants: Environment|School Administrators will provide data about the school environment.
2919674|NCT03111667|No Intervention|School Staff Participants: Environment|Staff will provide data about the school environment
2919675|NCT03111654|Other|Patients with pericardial closure of the auricle|
2919676|NCT03111654|Other|Patients without closure of the auricle|
2919677|NCT03111641|Experimental|Lung ultrasonography|
2919678|NCT03111628|Other|Omalizumab|Omalizumab 300mg every month for 3 doses
2919679|NCT03111615|Experimental|Aromatase Inhibitor group|Female patients of 50 and above y.o. shall initiate hormone therapy (Letrozol 2.5 mg or Anastrazol 1 mg) immediately after the diagnosis until surgery.
2919680|NCT03111615|No Intervention|Control group|Female patients of 50 and above y.o. that follow standard protocol (no pre-surgery (Letrozol 2.5 mg or Anastrazol 1 mg))
2919681|NCT03111615|Other|Aromatase Inhibitor Active surveillance|Female patients of 50 and above y.o. that refuse surgery and therefor follow standard protocol (only Letrozol 2.5mg or Anastrazol 1 mg) until disease progression, death or will of surgery In this subgroup we are going to include, under HT, female patients with CDis,that refuse the standard treatment with surgery plus eventual rt and/or ht
2919682|NCT03111615|Other|Aromatase Inhibitor Active surveillance + aas|emale patients of 50 and above y.o. that refuse surgery and therefor follow standard protocol (only Letrozol 2.5mg or Anastrazol 1 mg plus acetilsalicilic acid) until disease progression, death or will of surgery In this subgroup we are going to include, under HT, female patients with CDis,that refuse the standard treatment with surgery plus eventual rt and/or ht
2919683|NCT03111602|Experimental|interventional group|The interventional group was submitted to dietary orientation to restrict polyphenol-rich foods
2919684|NCT03111602|No Intervention|control group|healthy group as comparator
2919685|NCT03111589|Experimental|SCD patients under regular chronic exchange transfusion|Sickle cell disease patients (SCD) under regular chronic exchange transfusions. Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
2919686|NCT03111589|Experimental|SCD patients under HU treatment alone|Sickle cell disease patients (SCD) under hydroxyurea (HU) alone. Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
2919687|NCT03111589|Experimental|SCD patients under HU treatment+sporadic transfusion|Sickle cell disease patients (SCD) under hydroxyurea (HU) and receiving sporadic transfusions.Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
2919688|NCT03111589|Active Comparator|Control group|Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
2919689|NCT03111576||Normotensive|This group will include 50 pregnant women with normal blood pressure between 28 and 34 weeks.
2919690|NCT03111576||Pre-eclamptic|This group will include 50 pregnant women with diagnosis of pre-eclampsia between 28 and 34 weeks.
2919691|NCT03111563|Other|warm saline|case group ,
2919692|NCT03111563|Other|room temperature|control group
2919693|NCT03111537|Experimental|Usual Brand Cigarette|Smoking usual brand cigarette controls, who after 8-weeks will be offered alternative nicotine products and instructed for partial or complete substitution of cigarettes (subject's choice);
2919694|NCT03111537|Experimental|Complete Substitution E-Cigarette|Complete substitution (i.e., no smoking) with e-cigarette use
2919695|NCT03111537|Experimental|Partial Substitution E-Cigarette|Partial substitution, encouraged to use e-cigarettes instead of smoking usual cigarettes
2919696|NCT03111537|Experimental|Complete Substitution Nic Gum or Lozenge|Complete substitution (i.e., no smoking) to nicotine gum or lozenge use
2919697|NCT03111524|Active Comparator|Intervention school 1|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
2919698|NCT03111524|Active Comparator|Intervention school 2|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher.The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
2919699|NCT03111524|Active Comparator|Intervention school 3|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
2919700|NCT03111524|Active Comparator|Intervention school 4|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
2919701|NCT03111524|Active Comparator|Intervention school 5|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
2919702|NCT03111524|Placebo Comparator|control school 1|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
2919703|NCT03111524|Placebo Comparator|control school 2|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
2919704|NCT03111524|Placebo Comparator|control school 3|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
2919705|NCT03111524|Placebo Comparator|control school 4|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
2919706|NCT03111524|Placebo Comparator|control school 5|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
2919707|NCT03111511|Experimental|Drospirenone/Ethinylestradiol + Midazolam + JNJ-56136379|Participants will receive single dose of drospirenone/ethinylestradiol 3 milligram (mg)/0.02 mg (oral contraceptive [OC]) and single dose of midazolam 2 mg under fasted conditions on Day 1. JNJ-56136379 250 mg twice daily will be administered on Days 6, 7 and JNJ-56136379 170 mg once daily on Days 8 to 25 under fed conditions, except on Day 21 on which Single dose of JNJ-56136379 170 mg + single dose of OC and single dose of midazolam 2 mg will be administered on fasted state. A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg and midazolam 2 mg on Day 21 under fasted conditions.
2919708|NCT03111498|Other|theory-based training programme|theory-based training programme (oral presentation including a step-by-step guidance saying)
2919709|NCT03111498|Other|practice-based training|practice-based training programme (one-to-one teaching)
2919710|NCT03111485|Experimental|A (drug-placebo)|Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg) followed by a washout period and placebo oral capsule, each taken at bedtime for 2 weeks
2919711|NCT03111485|Experimental|B (placebo-drug)|Placebo oral capsule followed by a washout period and Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg), taken at bedtime for 2 weeks
2919712|NCT03111472|Experimental|Self-management guide for falls in Parkinson's|A guide for people with Parkinson's and their caregivers to self-manage falls.
2919713|NCT03111459|Experimental|Primary Study Arm|Patients meeting primary inclusion/exclusion criteria will be enrolled in this arm and treated with the Medtronic Valiant Thoracoabdominal Stent Graft System.
2919714|NCT03111459|Experimental|Expanded Selection Arm|Patients who fail to meet the inclusion criteria of the Primary Study Arm may be enrolled under the Expanded Selection Arm and be treated with the Medtronic Valiant Thoracoabdominal Stent Graft System.
2919715|NCT03111446|Active Comparator|Spinal Anesthesia|Spinal anesthesia will be used to anesthetize patients in this group for caesarian section
2919716|NCT03111446|Active Comparator|General Anesthesia|Standardized General Anesthesia will be used to anesthetize patients in this group for caesarian section
2919717|NCT03111433|Experimental|Group I|this group of patients will receive their standard insulin treatment in addition to 100 mg of coenzyme Q10 soft gelatin capsule once daily for three month
2919718|NCT03111433|Active Comparator|Group II|this group of patients will receive their standard insulin treatment only
2919719|NCT03111420|Experimental|Clopidogrel|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
2919720|NCT03111420|Experimental|Prasugrel|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
2919721|NCT03111420|Experimental|Ticagrelor|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
2919722|NCT03111407|Other|iAssist group|patients will have primary total knee arthroplasty with the iAssist. The iAssist Knee System is a computer assisted stereotaxic surgical instrument system to assist the surgeon in the positioning of orthopedic implant system components intra-operatively. It involves surgical instruments and position sensors to determine alignment axes in relation to anatomical landmarks and to precisely position alignment instruments and implant components relative to these axes.
2919723|NCT03111407|Other|conventional instrumentation|patients will have primary total knee arthroplasty with the conventional instrumentation.
2919724|NCT03111381|Experimental|Intervention Group|The intervention group in this study will receive a one-time dose of Ketorolac 30mg intravenously after undergoing general anesthesia. Because the participants will be under general anesthesia, they will not know if they received the medication. The surgeon will also be blinded to this. The anesthesiologist will not be blinded as he/she will deliver the agent and because the use of Toradol may alter their usage of other intra-operative agents and post-operative agents
2919725|NCT03111381|No Intervention|Non-Intervention Group|In the no-treatment group, participants will not receive a dose of intra-operative Ketorolac.
2919726|NCT03111368|Active Comparator|EUS- FNA Slow-pull|Endoscopic ultrasound-guided fine needle aspiration using a stylet slow-pull technique of solid pancreatic mass
2919727|NCT03111368|Active Comparator|EUS-FNA Negative Pressure|Endoscopic ultrasound-guided fine needle aspiration using negative pressure technique of solid pancreatic mass
2919728|NCT03111355|Experimental|Brazil Nut supplementation|Consumption of one Brazil nut a day for 2 months followed by 2 months without intervention
2919729|NCT03111342|Experimental|Anesthesia|A 2% lidocaine without vasoconstrictor injection into the cervix
2919730|NCT03111342|Sham Comparator|Dry-needling|A placement of thin needle into the cervix without substance injection
2919731|NCT03111342|No Intervention|No intervention|No intervention for pain relief prior to LNG-IUS insertion
2919732|NCT03111329|Experimental|GRASS - Intervention group|"The intervention group (GRASS) will receive 3 hourly feeds, with no gastric residuals being aspirated. Solely opening of the nasogastric tube once every 6 hours to relieve possible backflow of gastric content will be allowed. Amount of enteral feeds given and increase in dose will be specified in an enteral feeding plan prior to start of the study. Amount of enteral feeds given will increase every six hours with a calculated overall increase of 20 ml/kg of birth weight in the total amount given every 24 hours.~Intervention = NO aspiration of gastric residuals"
2919904|NCT03110302|Active Comparator|Home-based telehealth (HBT)|Veterans stay at home and meet with the therapist via telehealth, using videoconferencing technology
2919733|NCT03111329|No Intervention|Standard Approach group|Standard Approach group serving as control group will be treated as per standard approach - participants will be fed 3 hourly and gastric residuals checked via nasogastric tube prior to each feed. Amount of enteral feeds given and increase in dose will be specified in an enteral feeding plan prior to start of the study. Amount of enteral feeds given will increase every six hours with a calculated overall increase of 20 ml/kg of birth weight in the total amount given every 24 hours.
2919734|NCT03111316|Other|Foley Catheter & Dinoprostone Insert|transcervical Foley catheter and an intravaginal dinoprostone controlled release insert
2919735|NCT03111316|Other|Foley Catheter Alone|a Foley catheter alone
2919736|NCT03111303||HAP patients|Mechanical ventilation, patients fulfilled HAP criteria
2919737|NCT03111303||non HAP patients|Mechanical ventilation, patients without HAP
2919738|NCT03111290|Sham Comparator|Sham|Device: Direct Cortical Stimulation Sham. Trials in which stimulation is not applied. These trials are initiated using a generic trigger generator.
2919739|NCT03111290|Active Comparator|Stimulation|Device: Direct Cortical Stimulation. 150 stimulations with stimulations lasting 5 seconds at different target electrodes at two target frequencies (e.g. 5 Hz and 10 Hz) 2 milliampere in amplitude (Pulse shape - Biphasic square pulse 200 microsecond in duration per phase). Stimulation will be applied concurrently with the task and stimulation trials will be randomly interleaved with sham trials.
2919740|NCT03111277|Experimental|Experimental: ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's pain . The ExAblate uses ultrasound to heat a small spot in the brain. Ultrasound passes through the skin and skull and into the brain to focus on a spot the study investigator wants to treat.
2919741|NCT03111264|Experimental|EWE only group|Childcare centers randomly assigned the Enhancing the Wellness Environment (EWE) group will receive a intervention that promotes physical activity in the classroom by developing gross motor skills through movement and enhances the nutritional environment in the centers by exposing preschoolers to new foods.
2919742|NCT03111264|Experimental|EWE + EFE group|These childcare centers, also randomly assigned, will have the same intervention as the EWE only group and also an Enhancing the Family Environment (EFE) intervention that promotes wellness and healthy behaviors within families.
2919743|NCT03111264|No Intervention|Control|This group will not receive the Enhancing the Wellness Environment (EWE)intervention at the childcare center nor will this group receive the Enhancing the Family Environment (EFE) intervention
2919744|NCT03111251|Experimental|Provider-only intervention|New provider- and system-level evidence-based strategies for increasing HPV vaccination rates are being implemented throughout the entire clinic network. This includes provider assessment and feedback, provider reminders, provider education, and patient reminders.
2919745|NCT03111251|Experimental|Provider plus parent intervention|Clinics randomized to the provider plus parent intervention will receive both the provider intervention and the parent education intervention.
2919746|NCT03111238|Experimental|REX-001|REX-001 is a cell suspension of autologous BM-MNCs composed of several mature cell types.
2919747|NCT03111238|Placebo Comparator|Placebo|The final formulation of the placebo will be a diluted suspension of red blood cells.
2919748|NCT03111225|Experimental|CRPS patients|CRPS patients that will be examined for trigger points in the thoracic muscles. 10 out of the 23 will also be included in the intervention stage and will recieve a month of conventional physiotherapy, and a month of conventional physiotherapy with addition of massage to the thoracic area.
2919749|NCT03111225|No Intervention|healthy controls|healthy controls that will be examined for trigger points in the thoracic muscles (and will be compared to the CRPS patients)
2919750|NCT03111212|Active Comparator|Iloprost|
2919751|NCT03111212|Placebo Comparator|control|
2919752|NCT03111199|Placebo Comparator|Control Placebo Group|The subjects of this group will be submitted to TENS bound in placebo mode in the lumbar spine.
2919753|NCT03111199|Experimental|Cryotherapy Group|The subjects of this group will be submitted to Cryotherapy in the lumbar spine.
2919754|NCT03111199|Experimental|TENS Burst Group|The subjects of this group will be submitted to TENS Burst in the lumbar spine.
2919755|NCT03111199|Experimental|TENS Burst and Cryotherapy Group|The subjects of this group will be submitted to TENS Burst and Cryotherapy in the lumbar spine.
2919756|NCT03111186|Active Comparator|Opiate group|Group receiving oxycodone alone (oxycodone HCl 5 mg up to six times daily as needed for pain)
2919757|NCT03111186|Active Comparator|Non-opiate group|Group receiving ibuprofen and acetaminophen (acetaminophen 650 mg up to four times daily and ibuprofen 400 mg up to six times daily as need for pain)
2919758|NCT03111173|Other|Holter device|Holter device to be attached to a Singleton or twin pregnant women at 32 weeks gestation to full term
2919759|NCT03111160|Experimental|lower energy|SMILE procedure using lower energy (100, 105, and 110 nJ)
2919760|NCT03111160|Active Comparator|conventional energy (115 to 150 nJ)|SMILE procedure using conventional energy (115 to 150 nJ)
2919761|NCT03111147|Experimental|0 degrees humeral component version|Reverse Total Shoulder Arthroplasty with humeral component positioned in 0 degrees of version
2919762|NCT03111147|Experimental|30 degrees humeral component retroversion|Reverse Total Shoulder Arthroplasty with humeral component positioned in 30 degrees of retroversion
2919763|NCT03111134|No Intervention|Routine Abdominal Closure|
2919764|NCT03111134|Experimental|New Abdominal Closure|modified component separation technique is used to abdomen closing.
2919765|NCT03111121|Active Comparator|Group 1|Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes:Group 1 will receive reversal with neostigmine (0.04 mg/kg and glycopyrrolate (0.01 mg/kg)
2919796|NCT03110926|Experimental|Induction Chemotherapy /Chemoradiation|mFOLFOX6 for 3 cycles - Oxaliplatin 85 mg/m2, 5-fluorouracil 2400mg/m2/46 hours, 5-fluorouracil bolus 400mg/m2 and leucovorin 400 mg/m2, then chemoradiation for 5 cycles - Carboplatin AUC 2mg/mL/min, Paclitaxel 50 mg/m2 and radiation therapy.
2919978|NCT03109730|Experimental|Cohort B4|ABI-H0731 or Placebo in varying doses by mouth for 28 days
2919766|NCT03111121|Active Comparator|Group 2|Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes: Group2 will receive reversal with sugammadex 4mg/kg
2919767|NCT03111108|Experimental|EBR/GZR 8 Weeks (Arm1)|Treatment-naïve participants with stage 0-2 fibrosis (F0-F2) receive FDC of EBR/GZR (50 mg/100 mg) for 8 weeks, with 24 weeks of follow-up.
2919768|NCT03111108|Experimental|EBR/GZR 12 Weeks (Arm 2)|Treatment-naïve participants with F0-F2 stage fibrosis, treatment-naïve participants with F3-F4 stage fibrosis, and treatment-experienced participants with F0-F4 stage fibrosis receive FDC of EBR/GZR (50 mg/100 mg) for 12 weeks, with 24 weeks of follow-up.
2919769|NCT03111095|Experimental|Mobile Health Participants|Subjects will use the mobile health device to record their blood pressure and weight measurements everyday for 6 weeks postpartum.
2919770|NCT03111095|No Intervention|Standard of Care|This arm is a chart review done on hypertensive women who do not participate in using the mobile health device.
2919771|NCT03111082||Lean|BMI less than or equal to 29.9
2919772|NCT03111082||Obese|BMI between 30.0 and 39.9
2919773|NCT03111082||Morbidly Obese|BMI greater than or equal to 40.0
2919774|NCT03111069|Experimental|Resectable Intra-Abdominal/Pelvic Tumors|Participants receive complete surgical tumor resection with no gross residual disease, followed by hyperthermic intra-peritoneal chemotherapy (HIPEC) using Doxorubicin.
2919775|NCT03111069|Experimental|Unresectable Intra-Abdominal/Pelvic Tumors|"Participants receive debulking surgery followed by intra-operative radiation (IORT) in the form of brachytherapy to the gross residual pelvic tumor sites.~Participants have the option of returning for HIPEC 4 weeks (or more) after IORT, if active disease remains."
2919776|NCT03111056|Experimental|Web-Based Intervention|In an effort to reduce heavy drinking, participants will be asked to complete a daily monitoring assessment each morning for 14 days. Based on their responses, they will be provided a coping skill to either directly address their alcohol use or attempt to improve their emotion regulation and distress tolerance skills.
2919777|NCT03111056|No Intervention|Assessment Only Control|Participants will be asked to complete only the daily monitoring assessment each morning for 14 days.
2919778|NCT03111030|Experimental|ProacTive SCI|Individualized physical activity coaching sessions
2919779|NCT03111030|No Intervention|Wait-list control|Standard care, receiving physical activity coaching sessions after completing post-testing
2919780|NCT03111017|Experimental|Exercise Training|Subjects will perform continuous endurance exercise (arm and leg cycle on Schwinn AD6 Airdyne ergometer, treadmill walking) 3 days per week. During the first 4-weeks, the exercise intensity will be set at 60%-70% of heart rate reserve and will increase by 5% per month. The initial exercise duration be 30 minutes and will gradually increase by 10 minutes every month. A 5-minute warm up and cool-down will precede and follow the aerobic conditioning phase. After the aerobic training phase is completed, patients will also perform unilateral handgrip exercise at an initial intensity of 50% maximal voluntary contraction for 1 set of 10 repetitions, and the intensity and sets will increase by 5% and 1 set, respectively each month.
2919781|NCT03111017|No Intervention|Attention Control|These subjects will be asked to continue with normal activity and will not be given any exercise training. The subjects will be contacted by the study coordinator at pre-arranged times and dates once a month and involve inquiry regarding overall well-being of the subject.
2919782|NCT03111004||Study Group|The Study Group receives 'new care' (integrated health and social care)
2919783|NCT03111004||Comparator Group|The comparator group receives usual care
2919784|NCT03110991|Experimental|Cognitive-behavioral intervention via App|The participants of the two experimental groups will receive a cognitive-behavioral intervention for depression prevention via a smartphone App, adapted from an indicated depression prevention program for caregivers in face-to-face group format developed by our research team, based on the model by Lewinsohn, Hoberman, Teri, & Hautzinger (1985), which has proven to be efficacious in the prevention of the onset of new major depressive episodes and the decrease of depressive symptoms both short- and long-term (Vázquez et a., 2014, 2016). In both groups the intervention administered via App will consist of 5 modules.
2919785|NCT03110991|Experimental|Cognitive-behavioral intervention via App + multiconference|Additionally, this experimental group will receive phone group conference calls during four 30 minute-sessions.
2919786|NCT03110991|No Intervention|Usual care|Individuals assigned to this group will receive no intervention or material, but they will have unrestricted access to any routine medical or psychological care that they might want to seek to treat depressive symptoms.The use of such treatments will be recorded.
2919787|NCT03110978|Experimental|Stereotactic Ablative Radiotherapy (SABR)|Standard SABR (50 Gy in 4 fx, BED=113 Gy; or, if plans for 50 Gy/4 fx cannot meet normal-tissue dose-volume constraints, 70 Gy in 10 fx, BED=119) to the tumor.
2919788|NCT03110978|Experimental|Stereotactic Ablative Radiotherapy (SABR) + Nivolumab|"Standard SABR (50 Gy in 4 fx, BED=113 Gy; or, if plans for 50 Gy/4 fx cannot meet normal-tissue dose-volume constraints, 70 Gy in 10 fx, BED=119) to the tumor.~Nivolumab given within 24 hours before or after the first fraction of SABR and then every 2 weeks for a total of 7 doses."
2919789|NCT03110965|Experimental|Experimental arm|Patients will have an X-ray before beginning to do one or two yoga poses daily for 4 - 10 months. After that period, they will have a second X-ray.
2919790|NCT03110952|Experimental|TDENV-PIV x2|2 doses of TDENV-PIV on Day 0 and Day 28
2919791|NCT03110952|Experimental|TDENV-F17/TDENV-PIV|1 dose TDENV-F17 on Day 0 and 1 dose TDENV-PIV on Day 28
2919792|NCT03110952|Experimental|TDENV-PIV/TDENV-F17|1 dose TDENV-PIV on Day 0 and 1 dose TDENV-F17 on Day 28
2919793|NCT03110952|Placebo Comparator|Placebo|2 doses placebo (phosphate buffered saline) Day 0 and Day 28
2919794|NCT03110939|Experimental|hyperthermic perfusion group|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after standard surgery of advanced lung cancer/esophageal cancer)
2919795|NCT03110939|No Intervention|control group|standard surgery of advanced lung cancer/esophageal cancer
2919905|NCT03110302|Experimental|In home, in person (IHIP)|Therapist goes to the Veterans' homes to provide the psychotherapy
2919797|NCT03110913|Experimental|Methionine bioavailability in lentils|"Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods).~You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or a lentil stew with or without rice, which will be provided by the investigators"
2919798|NCT03110900|Active Comparator|haloperidol + lorazepam|IM haloperidol 5mg + IM lorazepam 2mg + placebo inhaler
2919799|NCT03110900|Experimental|loxapine|Inhaled loxapine 10mg + IM normal saline
2919800|NCT03110887||Preterm neonate with thrombocytopenia|Preterm neonates (GA<34 weeks) with severe thrombocytopenia
2919801|NCT03110874|Experimental|Experimental group (one-way education)|"Experimental group (one-way education)~Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)~video based education"
2919802|NCT03110874|Active Comparator|Control group(two-way education)|"Control group(two-way education)~Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)~direct education"
2919803|NCT03110861|Experimental|Transcatheter Pulmonary Valve|PULSTA® Transcatheter Pulmonary Valve (TaeWoong Medical Co., Ltd. Korea)
2919804|NCT03110848|Experimental|Statins|Atorvastatin 20 mg daily associated with intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
2919805|NCT03110848|Active Comparator|No statins|Intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
2919806|NCT03110835||15 mCi radioiodine|6 patients with low risk differentiated thyroid cancer, as determined by histology
2919807|NCT03110835||30 mCi radioiodine|6 patients with low risk differentiated thyroid cancer, as determined by histology
2919808|NCT03110822|Experimental|Rux Len and Steroid|Ruxolitinib Oral Tablet [Jakafi] at 5mg BID, Lenalidomide 5Mg Oral Capsule at QD and Methyl Prednisolonate at 40mg QOD.
2919809|NCT03110809|Placebo Comparator|BAT Positive Placebo|Participants will be confirmed positive for BAT activity, but on Placebo
2919810|NCT03110809|Placebo Comparator|BAT Negative Placebo|Participants will be confirmed negative for BAT activity, but on Placebo
2919811|NCT03110809|Experimental|BAT Positive Capsinoid|Participants will be confirmed positive for BAT activity, but taking Capsinoids. Capsinoids are a derivative of sweet peppers that may activate and recruit BAT.
2919812|NCT03110809|Experimental|BAT Negative Capsinoid|Participants will be confirmed negative for BAT activity, but taking Capsinoids. Capsinoids are a derivative of sweet peppers that may activate and recruit BAT.
2919813|NCT03110796|Experimental|LU3103209 Dose 1|Dressing with LU3103209 Dose 1
2919814|NCT03110796|Experimental|LU3103209 Dose 2|Dressing with LU3103209 Dose 2
2919815|NCT03110796|Placebo Comparator|No LU3103209|Dressing without LU3103209
2919816|NCT03110783|No Intervention|suture (control)|Subjects randomized to control will receive additional dural sutures as deemed necessary by the surgeon. CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
2919817|NCT03110783|Experimental|Bioseal|Subjects randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Up to two applications (one application includes applying up to two layers of Bioseal product followed by the CSF leakage re-evaluation with Valsalva maneuver) per subject are allowed. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
2919818|NCT03110770|Experimental|Part A, Group 1|ZIKV vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days), 4 mg of vaccine.
2919819|NCT03110770|Experimental|Part A, Group 2|ZIKV vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days), 4 mg of vaccine.
2919820|NCT03110770|Experimental|Part A, Group 3|ZIKV vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days), 8 mg of vaccine.
2919821|NCT03110770|Experimental|Part B, Group 4|ZIKV vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days), 4 mg of vaccine.
2919822|NCT03110770|Placebo Comparator|Part B, Group 5|Sterile phosphate-buffered saline (PBS) (VRC-PBSPLA043-00-VP), the placebo, in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days), 1 mL of placebo.
2919823|NCT03110757|Experimental|Group A|10mcg Sm-TSP-2/Alhydrogel® (n=8)
2919824|NCT03110757|Experimental|Group B|10mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
2919825|NCT03110757|Active Comparator|Group C|Euvax B Hepatitis B vaccine (n=4)
2919826|NCT03110757|Experimental|Group D|30mcg Sm-TSP-2/Alhydrogel® (n=8)
2919827|NCT03110757|Experimental|Group E|30mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
2919828|NCT03110757|Active Comparator|Group F|Euvax B Hepatitis B vaccine (n=4)
2919829|NCT03110757|Experimental|Group G|100mcg Sm-TSP-2/Alhydrogel® (n=8)
2919830|NCT03110757|Experimental|Group H|100mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
2919831|NCT03110757|Active Comparator|Group I|Euvax B Hepatitis B vaccine (n=4)
2919832|NCT03110744|Experimental|Palbociclib|application on 21 consecutive days of a 28 days cycle
2919833|NCT03110731|Experimental|Intervention group|Physical training (2x / week) was performed for 12 weeks
2919834|NCT03110731|No Intervention|Control Group|no intervention
2919899|NCT03110341|Placebo Comparator|Normal saline|Normal saline is administered 3ml/kg intravenously every other day for 2 weeks, starting with the first dose within 72 hours after birth. Similarly, the placebo dose consisted of 3mL of normal saline per kilogram birth weight was administered intravenously during a period of 5 minutes.
2919900|NCT03110328|Experimental|mk3475 200mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W) Open-label
2919835|NCT03110718|Experimental|ArmeoP+real MV|The patients underwent forty 1h Armeo-P training sessions (i.e. five times a week for eight consecutive weeks). During the first session, the device was adjusted to the patient's arm size and the angle of suspension. The working space and the exercises were selected once the UL had been fitted with the system. All the subjects in the arm received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air, wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude so that it was just below the threshold for perceiving an illusory movement. The investigators chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
2919836|NCT03110718|Active Comparator|ArmeoP+ Sham MV|"The patients underwent the same Armeo-P trainingas the experimental group. Only the vibration protocol was didderent. Indeed, in the control group a sham vibration was used, while in the experimental group, patients underwent a real one.~Sham vibration was delivered to the control group using the same procedure of the experimental group;however, vibration intensity was subthreshold (i.e. 50mBar below the threshold)."
2919837|NCT03110705||recreational diving group|middle-class populations registered at a leisure sports club
2919838|NCT03110705||recrational multisport course|middle-class populations registered at a leisure sports club
2919839|NCT03110692|No Intervention|Usual practice (control)|The usual practice group will rollover to the intervention arm after 3 months.
2919840|NCT03110692|Experimental|Intervention|Default initiation: Introduce a default prescription template in the palliative setting in order to reduce unnecessary daily image guided radiation.
2919841|NCT03110679|Experimental|autologous bone marrow concentrate|concentration of bone marrow taken from the patient's right tibia using Bio-MAC® suction catheter, company Biologic Therapies, Inc., and concentrated by centrifuge Bio.SPINTM Magellan®, company Biologic Therapies , Inc., and its injection in the intra-articular.
2919842|NCT03110679|Experimental|hyaluronic acid.|single injection of intra-articular hyaluronic acid 60mg (4 cc), and serve as a control.
2919843|NCT03110666|Experimental|Autologous concentrated bone marrow aspirate|autologous concentrated bone marrow aspirate obtained from the BioCUE Concentration System
2919844|NCT03110653|Active Comparator|Remifentanil|Remifentanil TCI: gradual withdrawal: reduction of 30% / 15 mins (2 -> 1.4 -> 1 -> 0.7-> 0.5 -> 0.35 -> 0.25 -> 0 ng/ml)
2919845|NCT03110653|Placebo Comparator|NaCl 0.9%|Remifentanil abrupt discontinuation / NaCl 0.9% (control group with a reduction of 30% /15 mins) (2 -> 1.4 -> 1 -> 0.7-> 0.5 -> 0.35 -> 0.25 -> 0 ng/ml)
2919846|NCT03110640|Experimental|CD9CAR-T transfer|All subjects will receive allogeneic stem cell transplantation after infusion of αCD19-TCRz-CD28 CAR-T
2919847|NCT03110627|Experimental|VDD ICD|VDD ICD - A single-lead ICD system with the ability to sense atrial rhythm from the floating electrode (a VDD-ICD known as the DX) - Experimental group
2919848|NCT03110627|Active Comparator|VVI ICD|VVI ICD - Single chamber ICD system - Control group
2919849|NCT03110601|Experimental|PM Modulation|Chronic pain modulation with PM External Modulator
2919850|NCT03110588|Experimental|PACE with Cabazitaxel @ 15 mg/m2|The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 15 mg/m2 every 3 weeks.
2919851|NCT03110588|Experimental|PACE with Cabazitaxel @ 20 mg/m2|The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 20 mg/m2 every 3 weeks.
2919852|NCT03110575|Experimental|TNX-102 SL|2 x TNX-102 SL, 2.8 mg tablets taken daily at bedtime for 12 weeks
2919853|NCT03110562|Active Comparator|selinexor+bortezomib+dexamethasone (SVd)|Selinexor will be given on Days 1, 8, 15, 22, and 29 of each 35-day cycle. Bortezomib will be given Days 1, 8, 15, and 22 of each 35-day cycle. Dexamethasone will be given Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.
2919854|NCT03110562|Active Comparator|bortezomib+dexamethasone (Vd)|Bortezomib will be given Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles. For Cycles ≥ 9, bortezomib will be given on Days 1, 8, 15, and 22 of each 35-day cycle. Dexamethasone will be given on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for the first 8 cycles. For Cycles ≥ 9, dexamethasone will be given on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.
2919855|NCT03110549|Experimental|Cohort 1 Arm A|Subcutaneous 200 mg of TMB-607 on Day 0 or Placebo
2919856|NCT03110549|Experimental|Cohort 1 Arm B|Subcutaneous 500 mg of TMB-607 on Day 0 or Placebo
2919857|NCT03110549|Experimental|Cohort 1 Arm C|Subcutaneous 1000 mg of TMB-607 on Day 0 or Placebo
2919858|NCT03110549|Experimental|Cohort 2 Arm A|Subcutaneous 100 mg of TMB-607 on Day 0 or Placebo
2919859|NCT03110549|Experimental|Cohort 2 Arm B|Subcutaneous 400 mg of TMB-607 on Day 0 or Placebo
2919860|NCT03110549|Experimental|Cohort 2 Arm C|Subcutaneous 800 mg of TMB-607 on Day 0 or Placebo
2919861|NCT03110549|Experimental|Cohort 2 Arm D|Subcutaneous 1500 mg of TMB-607 on Day 0 or Placebo
2919862|NCT03110536||2h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 2 hours.
2919863|NCT03110536||4h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 4 hours.
2919864|NCT03110536||6h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 6 hours.
2919865|NCT03110523|Experimental|X0002|X0002, BID, n=500
2919866|NCT03110523|Placebo Comparator|Placebo|Placebo, BID, n=250
2919867|NCT03110510|Experimental|FOLFIRI|D1 Irinotecan 180 mg/m2 IV D1-2 5-FU 400mg/m2 bolus and then 2400mg/m2 continuous infusion D1 Leucovorin 200 mg/m2 Until disease progression, patient's refusal or unacceptable toxicities
2919901|NCT03110315|Experimental|Suvorexant|Suvorexant - 10 mg (one tablet) taken by mouth once daily at bedtime with option to up-titrate to 20 mg (two tablets) taken by mouth once daily at bedtime.
2919902|NCT03110315|Placebo Comparator|Placebo|Placebo - one tablet taken by mouth once daily at bedtime and two tablets taken by mouth daily at bedtime if subject up-titrates.
2919903|NCT03110302|Active Comparator|Office-based telehealth (OBT)|Veterans come to a VA clinic and meet with a therapist via telehealth, using videoconferencing technology
2919868|NCT03110497|Experimental|Single application brachytherapy|After external beam radiotherapy with or without chemotherapy as per standard, each study patient will undergo single application brachytherapy to deliver 3 High Dose Rate (HDR) fractions [1st, 2nd and 3rd fractions of doses 9 Gy, 7 Gy and 7 Gy respectively] keeping 6-12 hours of interval. All patients will undergo an inter-fraction Computed Tomography (CT) scan before delivery of second fraction. Plan will be re-optimized to reduce the dose to Organs at Risk (OAR's), only if the dose exceeds the dose constraints. Dose constraints being exceedingly hard in 1st fraction or before 2nd fraction even after re-planning will deem patient non-feasible but optimization will be done to give preference to OAR's while accepting some compromise in target doses.
2919869|NCT03110484|Experimental|Pemetrexed+Tarceva|D1 Pemetrexed 500 mg/m2 IV+ D1-21 Erlotinib 100mg once daily
2919870|NCT03110471||Glangarnant Care Home|This is a 'before and after' observational study involving 10 care homes, listed below as groups. The investigators will observe the changes in detection and management of adverse drug reactions between usual care and with administration of the West Wales ADR Profile. Usual care will be provided before and during the intervention period.
2919871|NCT03110471||Fieldbay Care Homes|All groups are having identical intervention, so the above text applies to all.
2919872|NCT03110471||Neuadd Drymmau Care Home|As above
2919873|NCT03110471||Monkstone House,|As above
2919874|NCT03110471||Danygraig House|As above
2919875|NCT03110471||Ty Coch|As above
2919876|NCT03110471||Swn y mor|As above
2919877|NCT03110471||Hengoed court|As above
2919878|NCT03110471||Hengoed park|As above
2919879|NCT03110471||Cefn Lodge care home|As above
2919880|NCT03110458|Experimental|SENS-111 100mg|SENS-111 100mg: 2ODT (1 ODT SENS-111 and 1 ODT placebo)
2919881|NCT03110458|Experimental|SENS-111 200mg|SENS-111 200mg: 2 ODTs SENS-111
2919882|NCT03110458|Placebo Comparator|Placebo|Placebo: 2 placebo ODTs
2919883|NCT03110445|Experimental|rVV-740CTA vaccine|
2919884|NCT03110432||Standard lipid lowering therapy|Statins, ezetimibe, nicotinic acid, fibrates, cholestagel, omega-3 fatty acids (and any combinations of these agents)
2919885|NCT03110432||PCSK9 Inhibitor [EPC]|Evolocumab or alirocumab.
2919886|NCT03110419|Experimental|Intervention|The training group will perform a Physical Exercise as multicomponent training.
2919887|NCT03110419|No Intervention|Control|The control group will only be evaluated, without any intervention.
2919888|NCT03110406|Experimental|whole-body vibration|The whole-body vibration training will be performed with the patients in the static position, feet apart at 20 cm, semi-squat with knees at 15º flexion and upper limbs slightly flexed and supported on the platform. The exercises will be performed, in the first two weeks, for 10 minutes consisting of 60 seconds of low intensity with 30 seconds of rest standing in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. °
2919889|NCT03110406|Sham Comparator|Simulated whole-body vibration|The simulated whole-body vibration training will be performed with the patients in the static position, feet apart at 20 cm, in semi-squat with knees at 15º of flexion and upper limbs slightly flexed and supported on the platform that presents a motor that simulates the noise of the platform But does not produce any therapeutic effect
2919890|NCT03110393|Experimental|Ambu® AuraGain™|Intervention with Ambu® AuraGain™Laryngeal Mask
2919891|NCT03110393|Active Comparator|Intersurgical i-gel®|Intervention with Intersurgical i-gel® Laryngeal Mask
2919892|NCT03110380|Experimental|B/F/TAF|B/F/TAF + DTG placebo + F/TAF placebo for 48 Weeks
2919893|NCT03110380|Active Comparator|DTG + F/TAF|DTG + F/TAF + B/F/TAF placebo for 48 Weeks
2919894|NCT03110367|Active Comparator|Pain Reframing Intervention|"Participants will be randomized into this group:~- Memory reframe with parent facilitated by researcher:~Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways."
2919895|NCT03110367|Sham Comparator|Attention Control Group|"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.~Participants will be randomized into this group:~- Attention control (watch video [Planet Earth] for same amount of time): Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience."
2919896|NCT03110367|No Intervention|Normal Reminiscing|"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.~Participants will be randomized into this group:~- Normal Reminiscing: Parents and youth in the normal reminiscing group will be instructed to reminisce with their children about the in-hospital and post-surgery periods as they normally would."
2919897|NCT03110354|Experimental|DS-3201b in AML or ALL|DS-3201b is administered orally to participants with AML or ALL at a starting dose of 100 mg once a day, and then possibly at higher doses depending on safety observations
2919898|NCT03110341|Experimental|Erythropoietin|Erythropoietin is administered 750U/kg intravenously every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections regardless of gestational age), starting with the first dose within 72 hours after birth. A single dose consisted of 750U EPO per kg of birth weight dissolved in 3mL/kg normal saline was administered intravenously during a period of 5 minutes.
2919906|NCT03110289|Experimental|Superdonor FMT|Fecal microbiota transplantation from a healthy donor that was selected based on a fecal/blood screening, medical interview and on abundance of taxa of the investigators their interest
2919907|NCT03110289|Sham Comparator|Autologous FMT|Fecal microbiota transplantation derived from feces from the patient her/himself.
2919908|NCT03110276|Experimental|EYP001a|
2919909|NCT03110276|Placebo Comparator|Placebo|
2919910|NCT03110263|Experimental|Multicomponent internet-based self-help|Multicomponent internet-based self-help
2919911|NCT03110263|Experimental|Internet-based sleep restriction|Internet-based sleep restriction
2919912|NCT03110263|No Intervention|Waiting control group|Access to internet-based intervention after 8-weeks
2919913|NCT03110237|Active Comparator|Control Balance Training (BT) class|Group based circuit training class, 30 minute session, twice a week for three weeks
2919914|NCT03110237|Experimental|Fallproof Balance Training (BT) class|Group based balance training class based on the FallProof(TM) approach, 30 minute session , twice a week for three weeks
2919915|NCT03110211|Experimental|Physical Therapist Evaluation|Patients are randomized to have an initial appointment with a physical therapist for a musculoskeletal complaint. The intervention is an initial evaluation and treatment recommendations by a physical therapist.
2919916|NCT03110211|Experimental|Primary Care Physician Evaluation|Patients are randomized to have an initial appointment with a primary care physician for a musculoskeletal complaint. The intervention is an initial evaluation and treatment recommendations by a primary care physician.
2919917|NCT03110198|Experimental|Mesalazine with hydrocortisone sodium succinate|Mesalazine（4g） with hydrocortisone sodium succinate (100mg ) enema
2919918|NCT03110198|Active Comparator|Mesalazine|Mesalazine （4g）enema
2919919|NCT03110198|Active Comparator|Hydrocortisone sodium succinate|Hydrocortisone sodium succinate (100mg ) enema
2919920|NCT03110185|Other|EEG fcDOT fcMRI delirium|Patients in the cardiothoracic ICU diagnosed with postoperative delirium. Subjects will wear a diffuse optical tomography device in addition to the normal monitors. A non-contrast functional MRI will be performed.
2919921|NCT03110185|Other|EEG fcDOT fcMRI no delirium|Patients in the cardiothoracic ICU not diagnosed with postoperative delirium. Subjects will be monitored in the same way as the delirium arm
2919922|NCT03110172|Active Comparator|KSS scale|Knee Society Score with Duloxetine Hydrochloride
2919923|NCT03110172|Active Comparator|HAMD-17 scale|Hamilton Depression Score with Duloxetine Hydrochloride
2919924|NCT03110172|Active Comparator|SF-36 scale|Medical Outcomes Study Short Form-36 score with Duloxetine Hydrochloride
2919925|NCT03110172|Active Comparator|WOMAC scale|Western Ontario and McMaster Universities Index with Duloxetine Hydrochloride
2919926|NCT03110159|Experimental|Levulan® Kerastick® and blue light illumination|"Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light using the standard FDA approved treatment time for the BLU-U device of 16 minutes 40 seconds.~Each subject will be randomized to undergo treatment to one side face and one dorsal forearm/hand treatment, while the other side will serve as untreated control. Treatments will be conducted at the beginning of study Day 1 (Initial Treatment), Day 30 after the initial treatment (+ 3 days), Day 180 after initial treatment (+ 30 days), 1 year after the initial treatment (+ 30 days), and every 6 months (+ 30 days) thereafter for 2 additional years."
2919927|NCT03110133|Experimental|High Dose|High Dose Full Spectrum Microbiota
2919928|NCT03110133|Placebo Comparator|Placebo|Placebo
2919929|NCT03110120|Active Comparator|serratus|Serratus plane block and local control
2919930|NCT03110120|Sham Comparator|local|serratus control and local anesthesia
2919931|NCT03110107|Experimental|Monotherapy|Ipilimumab Monotherapy and BMS-986218 Monotherapy
2919932|NCT03110107|Experimental|Combination Therapy|BMS-986218 in combination with Nivolumab
2919933|NCT03110094|Other|Rheumatoid arthritis - Adalimumab|
2919934|NCT03110094|Other|Healthy volunteer|
2919935|NCT03110081|Experimental|Quadratus lumborum block|Quadratus lumborum (QL) block group will receive a single shot injection of 25 ml 0.25% bupivacaine pre-operatively, followed post-operatively by infusion of ropivacaine 0.2% continuously administered via the QL catheter for at least 48 hours.
2919936|NCT03110081|Active Comparator|Epidural analgesia|Midthoracic catheters will be inserted preoperatively. A bupivacaine 0.1% infusion will be started before the surgical incision, and continuously administered for at least 48 hr at an infusion rate of 5 ml/hr.
2919937|NCT03110068||Preoperative clinical/imaging features|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo contrast-enhanced computed tomography (CECT) and contrast-enhanced ultrasound (CEUS).
2919938|NCT03110055|Experimental|HCV patients with un-resectable HCC|"HCV genotype 1 (a and b) cirrhotic patients (child pugh A compensated cirrhosis) with advanced and un-resectable HCC who are eligible for TACE . The patients will receive Grazoprevir/Elbasvir and Transarterial Chemoembolization.~Their outcomes will be compared to the medical records of patients who underwent Transarterial Chemoembolization only, in the past."
2919939|NCT03110042||Observational Cohort|All patients will receive usual standard of care with the heart failure management including the routine supplemental oxygen therapy.
2919940|NCT03110029|Active Comparator|Wearing toenail polish|Subject will have Efinaconazole 10% application and nail polish
2919941|NCT03110029|Placebo Comparator|Abstain from wearing toenail polish|Subject will have Efinaconazole 10% application and no nail polish
2919942|NCT03110016|Experimental|Smartphone Application|SPSRS is a smartphone application system designed to improve self-confidence in individuals with subthreshold depression. The application presents a motion picture that displays words every 5 s for improving self-confidence of the user.
2919943|NCT03110003|Active Comparator|10 mg Bupivacaine|Subjects will receive 10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl.
2919944|NCT03110003|Active Comparator|5 mg Bupivacaine|Subjects will receive 5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
2919945|NCT03109990|Experimental|Dexmedetomidine|Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.
2919947|NCT03109977|Experimental|Zr-DFO-pertuzumab (89Zr-DFO-pertuzumab) PET/CT|Zr-DFO-pertuzumab (89Zr-DFO-pertuzumab) PET/CT will be performed in patients with known HER2-positive malignancy. Patients with multifocal disease, as demonstrated on cross-sectional imaging studies, will be preferentially recruited.
2919948|NCT03109964|Active Comparator|Hemostasis with bipolar coagulation|Patients undergoing laparoscopic ovarian cystectomy with bipolar coagulation hemostasis.
2919949|NCT03109964|Experimental|Hemostasis with SURGIFLO|Patients undergoing laparoscopic ovarian cystectomy with SURGIFLO hemostasis.
2919950|NCT03109951||Diabetes group|Type 2 diabetes patients undergoing colonoscopy with preparation with 2L of polyethylene glycol.
2919951|NCT03109925|Experimental|Radio-opaque embolic arm|"Patients will undergo intervention in the form of prostate artery embolization with the new radio-opaque embolic Lumi-Bead developed by BTG plc."
2919952|NCT03109912|No Intervention|Control|At the baseline fitness assessment, the FitBit daily step goal is set at the manufacturer standard 10,000 steps. Throughout the study, these 30 participants will receive generic, non-personalized encouragement and recommendations (if requested by the participant) for PA at routine clinic visits, baseline and follow-up assessments at 3 and 6 month clinic visits. At the 3-month and 6-month visits, exercise is reinforced with generic encouragement, export FitBit data and review any missing data concerning for equipment failure or user error.
2919953|NCT03109912|Experimental|Exercise Intervention|The baseline fitness assessment includes an additional 30-minutes for exercise prescriptions; participant FitBit daily step goal is set based on a collaborative review between the participant and PT and participants receive individualized exercise prescriptions based on their assessment. Throughout the study, these 30 participants will receive customized encouragement and personalized fitness recommendations for PA at routine visits, baseline and follow-up assessments at 3 and 6 month clinic visits. At the 3-month and 6-month visits, study team members meet again with the participant for an additional 30-45 minutes to reinforce exercise through exercise prescriptions and individualized encouragement, export FitBit data and review any missing data concerning for equipment failure or user error and address any specific exercise concerns. FitBit daily step goals may be adjusted based on collaborative review between the participant and PT.
2919954|NCT03109899|Experimental|Intervention|Participants in this arm will have access to the Sex Pro mobile app and support for HIV/STI testing and PrEP uptake.
2919955|NCT03109899|No Intervention|Control|Participants in this arm will be given the local standard of care for HIV/STI testing and PrEP access.
2919956|NCT03109886|Experimental|Milciclib maleate|milciclib maleate ,10, 50 and 100 mg hard gelatine capsules , 100 mg once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles)
2919957|NCT03109873|Experimental|Arm I (EBRT, metformin hydrochloride)|Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
2919958|NCT03109873|Placebo Comparator|Arm II (EBRT, placebo)|Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
2919959|NCT03109847|Experimental|Arm I (metformin hydrochloride)|Patients receive metformin hydrochloride PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment.
2919960|NCT03109847|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment
2919961|NCT03109834|Active Comparator|Meal replacement (MR) group|"Energy-restricted modified diet with MR for weight control dietary supplement: MR shakes, soups or bars. Duration: 3-month weight loss phase (phase 1)~During weight stabilization phase (phase 2) MR counted to food choice option."
2919962|NCT03109834|Other|Control (C) group|"Energy-restricted modified diet without MR for weight control. Duration: 3-month weight loss phase (phase 1)~During 3-month weight stabilization phase (phase 2) MR counted to food choice option."
2919963|NCT03109834|Active Comparator|Verum group|"Specific micronutrient composition with omega-3 fatty acids (capsules)~Duration: 6-month weight maintenance phase (phase 3)"
2919964|NCT03109834|Placebo Comparator|Placebo group|"Placebo capsules~Duration: 6-month weight maintenance phase (phase 3)"
2919965|NCT03109821||THA patients|
2919966|NCT03109808|Experimental|e-health strategy|Assigned intervention: e-health strategy
2919967|NCT03109808|Active Comparator|Traditional Oral Hygiene Education|Assigned intervention: traditional oral hygiene education
2919968|NCT03109795|Experimental|Clonidine|To test the magnitude by which short-term (4 weeks) sympathetic nerve activity blockade (clonidine) improves large elastic artery stiffness, vascular inflammation and baroreflex function in subjects with moderate-to-high levels of anxiety
2919969|NCT03109795|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide is a blood pressure-lowering control condition to compare to the effects of clonidine
2919970|NCT03109769|Experimental|Mobile phone application|Subjects in this group received a mobile phone application that sends active reminder notifications of oral hygiene 3 times a day.
2919971|NCT03109769|Active Comparator|Verbal oral hygiene instructions|Subjects in this group received verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
2919972|NCT03109756|Experimental|Single-dose 5 mg OV101|
2919973|NCT03109743|Experimental|Sisters-GPS: Group Clinical Visits|Those randomized to the Sisters-GPS arm will be expected to attend a total of seven group clinical visits, once a week for ~1.5 hours. Groups visits will include education, self-management skills development, and a clinical assessment by a medical provider with a focus on HIV treatment and adherence. Additionally, Sisters-GPS participants will be encouraged to participate in a private social media site specifically designed for the study, where participants will be able communicate with one another and with research staff. Group size will be 8-10 participants.
2919974|NCT03109743|Active Comparator|Control: One-on-one Adherence Counseling|Those randomized to the control condition will receive an appointment with a HIV treatment adherence counselor and will be expected to attend a minimum of three adherence counseling visits. .
2919975|NCT03109730|Experimental|Cohort B1|ABI-H0731 or Placebo in varying doses by mouth for 28 days
2919976|NCT03109730|Experimental|Cohort B2|ABI-H0731 or Placebo in varying doses by mouth for 28 days
2919977|NCT03109730|Experimental|Cohort B3|ABI-H0731 or Placebo in varying doses by mouth for 28 days
2919979|NCT03109730|Experimental|Cohort B5|ABI-H0731 or Placebo in combination with entecavir or tenofovir for 28 days
2919980|NCT03109730|Experimental|Cohort B6|ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days
2919981|NCT03109717||Treatment Resistant Depression|Screened for eligibility using several psychiatric assessments. If qualifies to participate in the study, will have to stop any antidepressants that they are taking to prepare for the use of Monoamine Oxidase Inhibitor(MAOI). After a two week washout period, subjects will have an fMRI and will be started on a MAOI. Then be followed for 8 weeks, part of routine care.
2919982|NCT03109717||Healthy Control|Screen for eligibility, then MRI.
2919983|NCT03109704|Experimental|Supine thrust manipulation|The supine upper thoracic spine thrust manipulation will be performed two times, regardless of joint cavitation.
2919984|NCT03109704|Experimental|Seated thrust manipulation|The seated upper thoracic spine thrust manipulation will be performed two times, regardless of joint cavitation.
2919985|NCT03109704|Sham Comparator|Sham manipulation|The sham manipulation will be performed two times.
2919986|NCT03109691|Active Comparator|group 1|30 patients will receive bupivacaine
2919987|NCT03109691|Active Comparator|group 2|30 patients will receive bupivacaine and Dexamethasone. .
2919988|NCT03109678|Experimental|Aura-i / Rüsch|Blind tracheal intubation: Combination of laryngeal mask Ambu Aura-i™ with Rüsch Super Safety Silk™ tracheal tube
2919989|NCT03109678|Experimental|Aura-i / LMA ETT|Blind tracheal intubation: Combination of laryngeal mask Ambu Aura-i™ with LMA ETT™ tracheal tube
2919990|NCT03109678|Experimental|Fastrach / Rüsch|Blind tracheal intubation: Combination of laryngeal mask Fastrach™ with Rüsch Super Safety Silk™ tracheal tube
2919991|NCT03109678|Experimental|Fastrach / LMA ETT|Blind tracheal intubation: Combination of laryngeal mask Fastrach™ with LMA ETT™ tracheal tube
2919992|NCT03109665||Glaucoma within NICOLA|NICOLA study Participants Eligible for GwNICOLA by meeting inclusion criteria
2919993|NCT03109652|Active Comparator|IV TXA alone|One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.
2919994|NCT03109652|Experimental|IV TXA and Oral TXA 5 days|"One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.~Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 5."
2919995|NCT03109652|Experimental|IV TXA and Oral TXA 2 days|"One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.~Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 2."
2919996|NCT03109639|Active Comparator|Group A|This group will undergo tissue acquisition using the conventional EUS-FNA needle followed by the experimental Acquire EUS- FNB needle
2919997|NCT03109639|Active Comparator|Group B|This group will undergo tissue acquisition using the experimental Acquire EUS- FNB needle followed by the conventional EUS-FNA needle
2919998|NCT03109626|Active Comparator|DHA administration|DHA 600 mg/day will be administered for 16 weeks to 5 patients in double blind
2919999|NCT03109626|Placebo Comparator|placebo administration|placebo will be made with the same colour and taste, in softgel as DHA, and will be administered for 16 weeks to 5 patients in double blind.
2920000|NCT03109613|Experimental|Positive end-expiratory pressure (PEEP) level changes|Sequential changes in PEEP level within range of 4-8 cm H2O followed by measurement of V/Q mismatch at each level.
2920001|NCT03109600|Experimental|Vi-DT (Bio Farma)|2 dose of 0.5 ml of Vi-DT Conjugated typhoid vaccine
2920002|NCT03109600|Active Comparator|Vi polysaccharide vaccine|1 dose of 0.5 ml Vi polysaccharide vaccine + 1 dose of Influenzae Vaccine
2920003|NCT03109600|Experimental|Vi-DT (Bio Farma) ~ Children|2 dose of 0.5 ml of Vi-DT Conjugated typhoid vaccine
2920004|NCT03109600|Active Comparator|Vi polysaccharide vaccine ~ Children|1 dose of 0.5 ml Vi polysaccharide vaccine + 1 dose of Pneumococcal Conjugate Vaccine
2920005|NCT03109587|Active Comparator|Vivomixx (Visbiome)|2 packets of probiotics by mouth/day for 12 weeks
2920006|NCT03109587|Placebo Comparator|Placebo|identical in appearance, but without probiotics.
2920007|NCT03109574|Other|Standard of Care Device|Current standard of care polyurethane catheter used at the hospital
2920008|NCT03109574|Other|Study Device|BioFlo DuraMax Chronic Hemodialysis Catheter
2920009|NCT03109535|Active Comparator|Fitbit-only Group|Participants received a Fitbit Zip activity monitor to wear daily for 10 weeks.
2920010|NCT03109535|Experimental|Fitbit + MapTrek Group|Participants received a Fitbit Zip activity monitor to wear daily for 10 weeks. Participants also received access to an mHealth game called MapTrek for 10 weeks. MapTrek places users in weekly walking races and sends automated text messages to participants on a daily basis. Messages include a link to the online game as well as motivational messages designed to increase physical activity.
2920011|NCT03109522|Experimental|axillary reverse mapping|Axillary reverse mapping and sentinel lymph node biopsy (ARM/SLNB) or Axillary reverse mapping and axillary lymph node dissection (ARM/ALND)
2920012|NCT03109522|Active Comparator|standard axillary surgery|The control group will have standard sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) without identifying or sparing upper-limb lymphatics and nodes (blue dye is not injected).
2920013|NCT03109509|Active Comparator|Fitbit-only Group|Participants randomized to the FB group were provided a Fitbit Zip activity monitor and were instructed on how to wear the monitor, how to pair the activity monitor to their smartphone, and asked to provide our team consent to access their Fitbit data through Fitbit's Application Programming Interface (API)
2920065|NCT03109145|No Intervention|Usual care: Control|Control group of eligible women patients between 45-60 years who do not receive the intervention at the West Palm Beach and Orlando Veterans Healthcare System. Usual care participants did not receive the educational secure messages.
2920066|NCT03109132|Active Comparator|Model 1|Device - O2/CO2 Oral/Nasal cannula sample line - Oridion smart CapnoLine® H Plus with Wedge cannula
2920014|NCT03109509|Experimental|Fitbit + Pokémon Go Group|Participants randomized to the FB+P group received the same Fitbit Zip activity monitor and text message reminders as the FB group. This group was also shown how to download the Pokémon Go application to their smartphone and were provided brief instructions on how to play the game. Participants were instructed to simply explore the game and play it at their leisure. Participants were not provided any specific goals related to game play or physical activity in general.
2920015|NCT03109496||OME Patients|Suffer from chronic Otitis Media with Effusion (OME) for at least 3 months and undergo ventilation tube placement.
2920016|NCT03109496||Healthy Control|Undergo surgery that gives access to the middle ear space (e.g. cochlear implant surgery) or adenoids, in absence of upper respiratory tract infections.
2920017|NCT03109483|Other|Geriatric Activation Program Pellenberg|intensive multicomponent physical therapy week program
2920018|NCT03109457||Oral squamous cell carcinoma|"Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.~Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining."
2920019|NCT03109457||Control|"Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.~Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining."
2920020|NCT03109444||Hip Ultrasound of Newborn infants|Newborns born at CRMC (term newborns and pre-mature newborns over 32 weeks gestational age). This will include newborns cared for in the neonatal intensive care unit (NICU) over 32 weeks gestational age, and newborns cared for on the normal labor and delivery floor. the newborn will receive an ultrasound of their hips while in the hospital (done by a trained sonographer). This will happen in the patient's room with the LAR present. An ultrasound of the hip takes approximately 15 minutes and is non-invasive, non-painful and does not utilize any ionizing radiation. Newborns will be scheduled to return once a week until the newborn's hips reach criteria for normal hip morphology or the newborn reaches 6 weeks of corrected age.
2920021|NCT03109431|Experimental|Enhanced Standard Care|"Youth randomized to the Enhanced Standard Care arm will receive an Automated Messaging and Monitoring Intervention (AMMI), which involves receiving 1-5 texts per day to motivate, inform and refer to HIV care and health services. Message banks will focus on the HIV Treatment Continuum, with libraries dedicated to healthcare, wellness, sexual health, drug use and ARV adherence for YLH.~Youth will also receive a weekly monitoring survey that covers six domains related to the HIV Treatment Continuum, including: ARV adherence, condomless sex, potential symptoms of STI, excessive use of alcohol and/or drugs, feelings of sadness or depression, and housing or food insecurity."
2920022|NCT03109431|Experimental|Stepped Care|Youth randomized to the Stepped Care arm will receive up to three levels of intervention, depending on whether or not they have achieved viral suppression at each four-month assessment point. All youth will begin at Level 1 which is the same as the Enhanced Standard Care arm. If they fail to achieve viral suppression at a reassessment in four months, they will be moved to Level 2, which includes both Level 1 and enrollment in private, online peer support groups. If they fail to achieve viral suppression at another four-month assessment point, they will be moved to Level 3, which includes both Levels 1-2 and Coaching. Coaches will provide support using a strengths-based coaching approach.
2920023|NCT03109418|Placebo Comparator|Control Group|OSA patients will receive standard inhaled anesthesia with normal saline infusion
2920024|NCT03109418|Active Comparator|Ketamine Group|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion.
2920025|NCT03109405|Experimental|stimulation-assisted|All subjects received treatment (stimulation-assisted) with the Veinplicity Device per the Instructions for Use. The subject underwent standard IV cannulation using a 20 gauge cannula into the available vein immediately after completion of device stimulation. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
2920026|NCT03109405|Other|standard IV cannulation|The subject underwent standard IV cannulation using a 20 gauge cannula into the best available vein. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
2920027|NCT03109392|Experimental|Nebulized lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
2920028|NCT03109392|Experimental|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
2920029|NCT03109392|Active Comparator|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
2920030|NCT03109379|Experimental|TAR-302-5018|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
2920031|NCT03109366|Other|Online self-management support|Access to online self-management support tool for six months
2920032|NCT03109353|Experimental|ALA-ECP|Extracorporeal photopheresis (ECP) with 5-aminolevulinic acid replacing psoralen
2920033|NCT03109340|Active Comparator|Supervised treadmill group|a. Supervised treadmill group (Group I): The participants were instructed walking exercise at their target heart rate on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
2920034|NCT03109340|Experimental|ECE PEDO pedometer group|b. ECE PEDO® pedometer group (Group II): Participants were given the walking program with ECE PEDO giving audible feedback in case of any deviation from their target range of steps per minute.
2920035|NCT03109327||Urgent Excision|Subjects with moles suspicious of melanoma and are scheduled for an urgent excision.
2920036|NCT03109327||Non-urgent Excision|Subjects with moles not-suspicious of melanoma and are scheduled for a non urgent excision.
2920067|NCT03109132|Active Comparator|Model 2|Device -O2/CO2 Oral/Nasal cannula sample line- Oridion smart CapnoLine® Plus with Non-Wedge cannula
2920068|NCT03109132|Active Comparator|Model 3|Device - Experimental sample line Model 3
2920069|NCT03109132|Active Comparator|Model 4|Device - Experimental sample line Model 4
2920070|NCT03109132|Active Comparator|Model 5|Device - Experimental sample line Model 5
2920037|NCT03109314|Active Comparator|Single-letter training group|Subjects will be trained on a low-contrast single-letter task. The task is to identify a faint letter (low-contrast). Performance will be measured as correct or incorrect. Training will consist of identifying these low-contrast letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
2920038|NCT03109314|Active Comparator|Uncrowd training group|Subjects will be trained on an uncrowd task (identifying the middle letter of groups of three letters presented). Performance will be measured as correct or incorrect. Training will consist of identifying these letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
2920039|NCT03109301|Experimental|Arm 1|Patients > 18 years of age50 mg/dose orally twice daily
2920040|NCT03109301|Experimental|Arm 2|Patients < 18 years of age25 mg/m^2/dose orally twice daily
2920041|NCT03109288|Experimental|Pioglitazone|Pioglitazone Monotherapy
2920042|NCT03109288|Experimental|Montelukast|Montelukast Monotherapy
2920043|NCT03109288|Experimental|Losartan|Losartan Monotherapy
2920044|NCT03109288|Experimental|Hydroxychloroquine|Hydroxychloroquine Monotherapy
2920045|NCT03109275|Active Comparator|Single MRI examination|40 subjects will benefit from a full MRI
2920046|NCT03109275|Sham Comparator|Reproducibility study|10 subjects will benefit from the realization of 3 MRI. An MRI examination performed at the time of inclusion and then an examination, at 3 months and at 9 months (ie 3 examinations per subject).
2920047|NCT03109262|Experimental|Diagnostic (Yttrium Y 90 glass microspheres PET/CT)|Immediately after standard of care SIRT, patients receive yttrium Y 90 glass microspheres and undergo PET/CT over 30 minutes.
2920048|NCT03109249|Experimental|SPARC1613|Intravenous administration of SPARC1613
2920049|NCT03109249|Active Comparator|Reference 1613|Intravenous administration of Reference1613
2920050|NCT03109236|Experimental|Treatment|"Patient will undergo CD133+ cells transplantation at stable compensated state. 5 dose GCSF (Neupogen) will be administered 5 days consecutively before bone marrow harvesting.~Approximately 250ml of bone marrow will be harvested and subjected to CD133 isolation using clinimacs (Miltenyi Biotec) in a closed system Under ultrasound guidance, 50 mls of 50-100 million CD133 cells will be infused directly through transhepatic route into portal venous circulation of the liver over 5 mins."
2920051|NCT03109236|Active Comparator|Control|"Non-Transplant Arm:~Patients will receive 5 doses of GCSF (Neupogen)"
2920052|NCT03109223|Active Comparator|Commercially availabel infant formula|
2920053|NCT03109223|Experimental|Test formula with 2-FL|
2920054|NCT03109223|Active Comparator|Breast Fed|
2920055|NCT03109210|No Intervention|Standard Care|Participants randomized to standard care will receive normal follow-up care with their health care provider. This will include routine assessment and adjustment of PAP therapy, and instruction in proper sleep hygiene.
2920056|NCT03109210|Experimental|Intervention|In addition to standard care procedures, participants randomized to the intervention arm will receive up to two sequential treatments. First, participants will receive Online Cognitive Behavioral Therapy (OCBT). Those who meet criteria for remission after this first treatment will continue through follow-up without further treatment. Those who do not will be randomized again to either extended OCBT, or Therapist-directed Cognitive Behavioral Therapy (TCBT).
2920057|NCT03109197||Retrospective SUDC cases|All child biospecimens (including mucosal swab or blood samples for DNA analysis, pathology slides, tissue blocks, tissue samples or organs retained at autopsy) will be transferred to NYU Biorepository
2920058|NCT03109197||Prospective SUDC cases|Heart and brain tissue will undergo full cardiac pathology consultation or neuropathology consultation will be transferred to pathologists at NYU or Mayo (based on pathologist availability). The PHI will remain intact in these cases since they will need to know how to identify the deceased with the medical records they receive and to complete the entire investigation thoroughly. A full consultation report will be sent back to Dr. Orrin Devinsky and tissue will be returned to the NYU biorepository upon completion of the cardiac or neuropathology consultation.
2920059|NCT03109184|No Intervention|Waitlist Control|Parents and teens enrolled in the study and randomized to the control condition wait until they complete their 3-month and 9-month follow-up surveys before completing the web-based program.
2920060|NCT03109184|Experimental|Project STRONG|The web-based program consists of a number of games, activities, and didactic information that teens move through with their parent. Didactic information introduces teens and parents to specific emotion management, communication, and problem solving strategies as well as sexual health and healthy relationship information. Games and activities allow parents and teens to practice and apply strategies to developmentally appropriate situations.
2920061|NCT03109171|Other|Expert rater|Pulmonologist or Otolaryngologist with experience in laryngopharyngeal sensory evaluation: who has made more than 50 laryngopharyngeal sensory tests.
2920062|NCT03109171|Other|Non-expert rater|"Pulmonologist or Otolaryngologist inexperienced in laryngopharyngeal sensory evaluation: who has made minimum 5 and maximum 50 laryngopharyngeal sensory tests.~Pulmonologist fellow who has completed the training provided for a Pulmonologist Fellow in bronchoscopy and who has performed minimum 5 and maximum 50 laryngopharyngeal sensory testing."
2920063|NCT03109158|Experimental|NC-6004 and 5-FU|"Phase I, continual reassessment method, dose-escalation study to determine the maximum tolerated dose (MTD) and an RPII dose of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.~In Part 1, patients will be assigned to receive cetuximab followed by NC-6004 and 5-FU.~Phase II, adaptive, open-label expansion study evaluating the activity, safety, and tolerability of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck at the RPII dose identified in Part 1.~In Part 2, all patients will receive NC-6004 at the RPII dose established in Part 1, in combination with cetuximab and 5-FU according to the same schedule as used in Part 1."
2920064|NCT03109145|Experimental|Menopause educational secure messaging|Secure messages that provide information about menopause and treatment option for menopause symptoms.
2920071|NCT03109132|Active Comparator|Model 6|Device - O2/CO2 cannula w/female luer (Westmed comfort plus #0504)
2920072|NCT03109119|Active Comparator|Group S|These patients will be induced and maintained with sevoflurane during anaesthesia.
2920073|NCT03109119|Sham Comparator|Group P|These patients will be induced and maintained with propofol during anaesthesia.
2920074|NCT03109106|Experimental|PCT Arm|"oAntibiotic management includes use of a validated PCT algorithm in addition to clinical judgment, other laboratory values, and microbiological pathogen identification. Subjects will be enrolled and data collected prospectively in 2017.~Patient records will be reviewed for outcomes data and the patients will receive a phone call for outcomes assessment at 30 days post discharge."
2920075|NCT03109106|No Intervention|Control Group|Patients enrolled during the control blocks will receive antibiotics for respiratory infection at the provider's discretion in keeping with current standards of care. Patient records will be reviewed for outcomes data and the patients will receive a phone call for outcomes assessment at 30 days post discharge.
2920076|NCT03109093|Experimental|Blinatumomab|"Patients will receive four cycles of treatment, unless criteria for treatment discontinuation apply. The duration of one cycle is 6 weeks, including a four week continuous intravenous infusion and a two week infusion free interval, which may be extended by a maximum of 7 days.~Transfer of patients to alloHSCT after one cycle or after subsequent cycles is considered as per protocol discontinuation and as premature treatment discontinuation In case of hematological or extramedullary relapse, the study treatment will be permanently discontinued."
2920077|NCT03109080|Experimental|Olaparib + radiation therapy|One week of Olaparib alone followed by 5 weeks of Olaparib and concurrent loco-regional radiotherapy. Five levels of dose of Olaparib are expected.
2920078|NCT03109067|Experimental|Standardized meal|"Standardized meal for :~50 patients with a TaqIB AA polymorphism 50 patients with a TaqIB GG polymorphism"
2920079|NCT03109054||Low Anxiety Level|The patients had low anxiety levels. Anxiety levels will determine with S-Anxiety TX-1 (State-Trait Anxiety Inventory Test:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879951/)
2920080|NCT03109054||High Anxiety Level|The patients had high anxiety levels. Anxiety levels will determine with S-Anxiety (State-Trait Anxiety Inventory Test: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879951/)
2920081|NCT03109041|Experimental|Directional Brachytherapy Source Implant|Patients undergoing a whipple procedure for pancreatic cancer will receive an implant at the time of surgery of the new CivaSheet directional brachytherapy device. The directional nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.
2920082|NCT03109028|Active Comparator|Treatment as Usual|Regular standard psychiatric health care including all feasible interventions including medication, psychotherapy and social work.
2920083|NCT03109028|Experimental|Stepped and Collaborative Care Modell|A stepped and collaborative treatment model with varying stepped psychotherapeutic interventions for adult and adolescent refugees.
2920084|NCT03109015|Active Comparator|Schedule 4/2|
2920085|NCT03109015|Experimental|Schedule 2/1|
2920086|NCT03109002||Cohort: Pharmacologically Treated Depression (PTD) Cases|This study is based on anonymized health services data, study population include US residents with medical insurance between 1 Jan, 2010 and 31 Dec, 2014 as described by the Truven MarketScan Medicaid (MDCD), Truven MarketScan Medicare Supplemental (MCDR), and Truven MarketScan Commercial Claims and Encounters (CCAE) databases. Within each database, pharmacologically treated depression (PTD) cases incident during 2011 will be followed for up to 4 years to ascertain their TRD status and 1-year incidence rates for PTD and TRD. Participants will not receive any intervention as a part of this study. To assure they are incident rather than prevalent cases, study participants are required to have 1 year without a dispensing of an antidepressant medication before they can join the cohort.
2920087|NCT03108989|Experimental|Sugammadex group|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
2920088|NCT03108989|Active Comparator|Neostigmine group|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
2920089|NCT03108976|Sham Comparator|Control group|Children with a typical development.
2920090|NCT03108976|Active Comparator|Case group|Children with Autism Spectrum Disorders.
2920091|NCT03108963|Experimental|L-carnitine and Metformin|L-carnitine and Metformin in Obese PCOS Women trying induction of ovulation with clomiphene citrate.
2920092|NCT03108963|Active Comparator|placebo|placebo was given toObese PCOS Women trying induction of ovulation with clomiphene citrate.
2920093|NCT03108950|Experimental|Home-Based Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
2920094|NCT03108937|Experimental|Dexmedetomidine|Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.
2920095|NCT03108937|Placebo Comparator|saline|Same amount of saline will be administrated.
2920096|NCT03108924|Experimental|Moderate RI|Participants with moderate renal insufficiency (RI) are treated with a single 50 mg dose of gefapixant
2920097|NCT03108924|Experimental|Severe RI|Participants with severe RI are treated with a single 50 mg dose of gefapixant
2920098|NCT03108924|Other|Healthy Matched Controls|Healthy, participants matched for age and body weight are treated with a single 50 mg dose of gefapixant
2920099|NCT03108924|Experimental|ESRD Requiring HD|Participants with end stage renal disease (ESRD) requiring hemodialysis (HD), are treated in Period 1 with a single 50 mg dose of gefapixan immediately after the scheduled HD; followed in Period 2 with a single 50 mg dose of gefapixan two hours prior to HD. Between the Periods 1 and 2 MK-7264 dosings there will be a 7-day washout period with 3 dialysis sessions.
2920100|NCT03108911|Experimental|Group I (GFD)|Patients receive GFD prepared by the hospital per dietary/nutrition pharmacy standards from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
2920101|NCT03108911|Experimental|Group II (standard diet)|Patients receive a standard diet for from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
2920102|NCT03108872||LAAO group|One-hundred consecutive patients who underwent left atrial appendage occlusion from October 2010 to March 2015 in 5 Korean tertiary cardiovascular centers will be retrospectively registered.
2920103|NCT03108872||NOAC group|Two-hundred age-, sex-, CHA2DS2-VASc score- and HAS-BLED score- matched control will be selected with a 1:2 ratio among all patients treated with new oral anticoagulants to prevent ischemic events from 5 centers during same periods
2920104|NCT03108846|Experimental|Escitalopram|Escitalopram up to 15mg/day taken as 1-3 capsules each containing 5mg escitalopram once per day in the morning
2920105|NCT03108846|Placebo Comparator|Placebo|1-3 capsules each containing placebo only once per day in the morning
2920106|NCT03108833|Experimental|Low Dose Experimental Group|Recombinant Human Prourokinase:40mg
2920107|NCT03108833|Experimental|High Dose Experimental Group|Recombinant Human Prourokinase:50mg
2920108|NCT03108833|Active Comparator|Active Comparator Controlled Group|Alteplase:100mg if weight>=65kg, 1.5mg/kg if weight<65kg
2920109|NCT03108820|Experimental|TMH Intervention|The multidisciplinary team which develops and carries out the intervention includes a care coordinator who will organize and align recovery resources, a Trauma Surgeon (Dr. Zarzaur), a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), and an ICU collaborative care nurse (Dr. Lasiter). Using the Healthy Aging Brain Care monitor, care protocols, specialized software, and specific care protocols, the multidisciplinary team will modulate the intensity and the type of intervention the patient's receive based on the patient's needs. The intervention will last from the time of discharge to 6 months after injury.
2920110|NCT03108820|Active Comparator|Usual Care|Review hospital discharge and rehabilitation plan, identify the primary care physician responsible for the patient care. Patients will receive education on communication skills; caregiver coping skills; and legal and financial advice. Patients randomized to usual care will receive no further interventions.
2920111|NCT03108794||Immune tolerance phase|Immune tolerance phase is diagnosed based on the presence of high serum levels of HBV-DNA, hepatitis B e antigen (HBeAg), but normal or minimally elevated serum alanine aminotransferase (ALT), and normal liver or only minimal histological activity and scant fibrosis.
2920112|NCT03108794||HBeAg positive CHB|HBeAg positive CHB is defined as those with HBsAg positive for more 6 months, HBeAg positive, high HBV DNA, elevated serum levels of ALT and histological activity.
2920113|NCT03108794||HBeAg negative CHB|HBeAg negative CHB is defined as those with HBeAg negative, anti-HBe positive, lower serum HBV DNA levels and histological necroinflammation and fibrosis.
2920114|NCT03108794||Inactive HBsAg carriers|Inactive HBsAg carriers was defined as those with HBsAg positive than 6 months, with low HBV DNA and persistently normal ALT, without evidence of cirrhosis.
2920115|NCT03108794||Compensated cirrhosis|"Diagnosis of compensated cirrhosis can be made if one of the following criteria was met:~by liver histology: Ishak fibrosis stage 5-6 or METAVIR F4.~endoscopy-proven gastroesophageal varices, afrter excluding non-cirrhotic portal hypertension.~at least 2 features of cirrhosis:~irregular liver surface, granular or nodular liver parenchyma, with or without splenomegaly (spleen thickness > 4.0cm or > 5 rib units) on ultrasound ,CT or MRI;~PLT<100×109/L without other causes;~Serum album in<35 g/L or INR>1.3 or PT prolongs>3s;~LSM>13 kpa (ALT<5×ULN)."
2920116|NCT03108794||Decompensated cirrhosis|Decompensated cirrhosis was diagnosed based on the presence of ascites, bleeding esophageal varices and/or hepatic encephalopathy in cirrhotic patients.
2920117|NCT03108794||Hepatocellular carcinoma|Diagnosis of hepatocellular carcinoma（HCC）can be established when one of the following one of the following 2 criteria:（1）in cirrhotic patients with nodules of 1cm or larger with typical features of HCC ( arterial enhancement with washout in venous or delay phase) on 2 radiological studies or with 1 radiological study and elevation of serum AFP; or（2）histological evidence of HCC.
2920118|NCT03108781|Active Comparator|Lavender Oil|
2920119|NCT03108781|Placebo Comparator|sunflower oil|
2920120|NCT03108768|Experimental|Successor of Phonak Virto V|The successor of Phonak's Virto V will be fitted to the participants individual hearing loss.
2920121|NCT03108768|Active Comparator|Phonak Virto V|Phonak Virto V will be fitted to the participants individual hearing loss.
2920122|NCT03108755|Experimental|ASP7713 Single Ascending Dose|Successive cohorts of 8 non-Japanese participants (6 ASP7713/ 2 Placebo / 1-7 cohorts) will be started on a fixed single dose of ASP7713 or matching Placebo. The first two participants will receive either ASP7713 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
2920123|NCT03108755|Placebo Comparator|Placebo Single Ascending Dose|Successive cohorts of 8 non-Japanese participants (6 ASP7713/ 2 Placebo / 1-7 cohorts) will each be started on a single fixed dose of ASP7713 or matching Placebo. The first two participants will receive either ASP7713 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
2920124|NCT03108755|Experimental|ASP7713 Multiple Ascending Dose (Adults: 18-55 years)|Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
2920125|NCT03108755|Placebo Comparator|Placebo Multiple Ascending Dose (Adults: 18-55 years)|Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
2920126|NCT03108755|Experimental|ASP7713 Multiple Ascending Dose (Elderly: 65 years or older)|Dosing of the non-Japanese elderly cohort will commence after having established the safety and tolerability of corresponding dose in adults male and female participants.
2920127|NCT03108755|Placebo Comparator|Placebo Multiple Ascending Dose (Elderly: 65 years or older)|Dosing of the non-Japanese elderly cohort will commence after having established the safety and tolerability of corresponding dose in adults male and female participants.
2920128|NCT03108742|Experimental|dermal stapler|
2920129|NCT03108742|Active Comparator|classic intradermal suture|
2920130|NCT03108729|Experimental|eslicarbazepine acetate|elicarbazepine acetate, once daily flexible dosing
2920131|NCT03108716|Experimental|hamate hook removal|The patients were assigned to hamate hook removal(n=13).
2920132|NCT03108716|Experimental|microscrew internal fixation|The patients were assigned to the microscrew internal fixation after open reduction (n=11).
2920133|NCT03108716|Experimental|short-arm tube-type plaster fixation|The patients were assigned to the short-arm tube-type plaster fixation (conservative treatment) (n=4).
2920134|NCT03108703|Experimental|SBRT|RCC patients
2920135|NCT03108690|Experimental|TDM and CI.|Continuous infusion of beta-lactam antibiotics. Therapeutic drug monitoring of beta-lactam antibiotics.
2920136|NCT03108690|No Intervention|Control|Beta-lactam antibiotics given as intermittent infusion. Samples of serum concentration of beta-lactam will be collected for comparison, but blinded during the study.
2920137|NCT03108677||metastatic|For osteosarcoma patients with metastasis, collecting blood samples.
2920138|NCT03108677||non-metastatic|For osteosarcoma patients without metastasis, collecting blood samples.
2920139|NCT03108664|Experimental|11.25 mg/mL SYL1001 ophthalmic solution|1 drop of 11.25 mg/mL SYL1001 ophthalmic solution in the affected eye(s) q.d
2920140|NCT03108664|Experimental|Vehicle ophthalmic solution|1 drop of vehicle ophthalmic solution in the affected eye(s) q.d
2920141|NCT03108651|Active Comparator|Case|Motivational message will be administrated.
2920142|NCT03108651|No Intervention|Control|Motivational message will not be administrated.
2920143|NCT03108638||R3 Supervisor Strategy Region 1|First cohort to be trained and monitored with remote coaching in the R3 model
2920144|NCT03108638||R3 Supervisor Strategy Region 2|Second cohort to be trained and monitored with remote coaching in the R3 model
2920145|NCT03108638||R3 Supervisor Strategy Region 3|Third cohort to be trained and monitored with remote coaching in the R3 model
2920146|NCT03108638||R3 Supervisor Strategy Region 4|Fourth cohort to be trained and monitored with remote coaching in the R3 model
2920147|NCT03108625|Experimental|Vortioxetine|Once daily dosing of vortioxetine (oral tablets) for 78 weeks.
2920148|NCT03108612|Experimental|Study group|Intervention: Análisis de carga de trabajo (ACT)
2920149|NCT03108599|Experimental|Intervention|All participants in the intervention arm will receive two interventions: an enhanced cab intervention alone, and then the enhanced cab conditions combined with a behavioral sleep intervention.
2920150|NCT03108599|No Intervention|Control|Usual practices with regards to cab conditions and access to workplace programs for preventing sleep and fatigue problems.
2920151|NCT03108586|Active Comparator|FDI|Diagnosis and dental treatment decision based on the criteria of the International Dental Federation (FDI).
2920152|NCT03108586|Experimental|CARS|Diagnosis and dental treatment decision according to CARS (Caries Associated with Restorations or Sealants) detection criteria.
2920153|NCT03108560|Experimental|Sublobar group|Patients receive sublobar resection, including wedge resection and segmentectomy.
2920154|NCT03108560|Active Comparator|Lobectomy group|Patients receive lobectomy.
2920155|NCT03108547||Sarcoidosis - fatigued|Men and women with sarcoidosis and a score of ≥ 22 on the Fatigue Assessment Scale. A small hair sample will be cut and the participants will be asked to complete questionnaires on fatigue, anxiety, depression, stress and quality of life.
2920156|NCT03108547||Sarcoidosis - non-fatigued|Men and women with sarcoidosis and a score of < 22 on the Fatigue Assessment Scale. A small hair sample will be cut and the participants will be asked to complete questionnaires on fatigue, anxiety, depression, stress and quality of life.
2920157|NCT03108547||Healthy controls|Hair steroid values of a previously collected normal values study in adults will be used as healthy controls
2920158|NCT03108534|Experimental|CHF1535 NEXThaler|CHF1535 100/6 NEXThaler (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)
2920159|NCT03108534|Active Comparator|CHF1535 pMDI|CHF1535 100/6 pMDI (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)
2920160|NCT03108534|Placebo Comparator|Placebo|Double dummy study: placebo is for both CHF1535 pMDI and CHF1535 NEXThaler
2920161|NCT03108521|Experimental|Liraglutide group|Patients in this group will accept Liraglutide injection as their intervention (imported drug registration No: S20110020, manufacturer： NovoNordisk A/S, production batch number: to be determined); Specification: 3ml: 18mg (pre-filled pen). Regimen: a starting dose of liraglutide for the first one week is 0.6mg Quaque Die(QD), and after that, 1.2mg.QD during the last 3 weeks.
2920162|NCT03108521|Experimental|Sitagliptin group|Patients in this group will accept Sitagliptin phosphate tablets as their intervention. Specifications: Each tablet 100mg (with sitagliptin dollars). Regimen: The recommended dose is 100mg.QD for 3 months.
2920163|NCT03108508|Experimental|Prod1|G5 Siliplant
2920164|NCT03108508|Experimental|Prod2|Orgono Powder®
2920165|NCT03108508|Experimental|Prod3|G7 ALOE
2920166|NCT03108495|Experimental|Single Arm|After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration
2920167|NCT03108482|Experimental|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two tablets of 100 mg every 12 hours. The total daily dose will be 400 mg of Co-crystal E-58425.
2920168|NCT03108482|Active Comparator|Tramadol (Ultram®)|Tramadol: One tablet of 50 mg every 6 hours. The total daily dose will be 200 mg of tramadol.
2920169|NCT03108482|Active Comparator|Celecoxib (Celebrex®)|Celecoxib: One capsule of 100 mg every 12 hours. The total daily dose will be 200 mg of celecoxib.
2920170|NCT03108482|Placebo Comparator|Placebo|Placebo: One or two tablets of 100 mg every 6 hours.
2920171|NCT03108469|Active Comparator|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.
2920172|NCT03108469|Placebo Comparator|Placebo|Those randomized to placebo will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.
2920173|NCT03108456|Active Comparator|Orbital Atherectomy (OA)|The Diamondback 360® Coronary Orbital Atherectomy System (OAS) will be used for orbital atherectomy (OA) vessel preparation prior to implantation of a drug-eluting stent.
2920174|NCT03108456|Active Comparator|Conventional Balloon Angioplasty|Coronary balloons cleared or approved for commercial use by the Food and Drug Administration will be used for conventional balloon angioplasty prior to implantation of a drug-eluting stent.
2920175|NCT03108443||Glaucoma|Subjects identified as having glaucoma. No interventions will be performed.
2920176|NCT03108443||Healthy controls|Subjects identified as having healthy eyes with no disease.
2920177|NCT03108430||Inhalation pneumonia|
2920178|NCT03108430||Proven inhalations|
2920179|NCT03108430||Suspected inhalations (coma + anamnesis)|
2920180|NCT03108417|Experimental|cNEP|continuous negative external pressure will be used nightly by all participants
2920181|NCT03108391|Experimental|Ambu AuraGain|Subjects will receive the Ambu AuraGain size 3 to size 5 based on manufacturer guidelines
2920182|NCT03108391|Active Comparator|LMA Supreme|Subjects will receive the LMA Supreme size 3 to size 5 based on manufacturer guidelines
2920183|NCT03108378||MultiHance Single Dose|Subjects who received a single dose of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
2920184|NCT03108378||MultiHance Multiple Dose|Subjects who received multiple doses of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
2920185|NCT03108378||ProHance Single Dose|Subjects who received a single dose of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
2920186|NCT03108378||ProHance Multiple Dose|Subjects who received multiple doses of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
2920187|NCT03108378||Control Subgroup|Subjects who have not received any Gd agent and who are also scheduled for orthopedic surgery
2920188|NCT03108365|Experimental|Axiostat|"Size: 1 x 1 cm~Chitosan based haemostatic dressing"
2920189|NCT03108365|Active Comparator|Cotton Gauze|Size: 1 x 1 cm
2920190|NCT03108352|Experimental|Conbercept ophthalmic injection|Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)
2920191|NCT03108352|Sham Comparator|sham/Conbercept ophthalmic injection|Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 ~ 11)
2920192|NCT03108326||Group 1a|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with biologics is not allowed.
2920193|NCT03108326||Group 1b|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with 1 biologics is allowed
2920194|NCT03108326||Group 2|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with ≥2 biologic is allowed.
2920195|NCT03108326||Group 3a|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with biologic is not allowed.
2920196|NCT03108326||Group 3b|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with 1 biologic is allowed.
2920197|NCT03108326||Group 4|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with ≥2 biologics is allowed.
2920198|NCT03108313|Experimental|aloe vera toothpaste|aloe vera toothpaste isa will be administrated 2 times per day for 30 days and salivary bacterial count will be tested before the use of toothpaste the after 15 days and 30 days
2920199|NCT03108313|Active Comparator|fluoride toothpaste|fluoride toothpaste isa herbal toothpaste will be administrated 2 times per day for 30 days and salivary bacterial count will be tested before the use of toothpaste the after 15 days and 30 days
2920200|NCT03108300|Experimental|propranolol hydrochloride with Doxorubicin|The patients suffering from metastatic soft tissue sarcoma will receive doxorubicin 60mg per square meter of body surface area every 21 days combined with propranolol hydrochloride 40mg twice daily
2920201|NCT03108287|Active Comparator|RAK therapy|rabeprazole+amoxicillin+clarithromycin
2920202|NCT03108287|Active Comparator|RBAK therapy|rabeprazole+amoxicillin+clarithromycin+bismuth subcitrate
2920203|NCT03108274|Experimental|Part 1, Period 1|Single oral dose of Midazolam Day 1
2920204|NCT03108274|Experimental|Part 1, Period 2|Multiple oral doses of ACH-0144471 Day 1-4 Single oral single dose of Midazolam on Day 4
2920205|NCT03108274|Experimental|Part 2, Period 1|Single dose of Fexofenadine on Day 1
2920206|NCT03108274|Experimental|Part 2, Period 2|Multiple doses of ACH-0144471 on Days 1-6 Single dose of Fexofenadine on Day 4
2920207|NCT03108274|Experimental|Part 3, Period 1|Single dose of Mycophenolate Mofetil on Day 1
2920208|NCT03108274|Experimental|Part 3, Period 2|Multiple doses of ACH-0144471 on Days 1-6 Single dose of Mycophenolate Mofetil on Day 4
2920209|NCT03108248||ISP-TACE group|During the study period, a total of 44 patients with HCC with PVTT underwent the irradiation stent placement and TACE were included in the ISP-TACE group.
2920210|NCT03108248||TACE group|During the study period, a total of 82 patients with HCC with PVTT underwent TACE monotherapy were included in the ISP-TACE group.
2920211|NCT03108235|Experimental|Intervention group A|a 6-week nurse-led, home-based self-management psychosocial education programme (HOM-HEMP)
2920212|NCT03108235|Experimental|Intervention group B|HOM-HEMP with the smartphone app.
2920213|NCT03108235|Active Comparator|control group|Participants will receive the standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
2920214|NCT03108222||Healthy Subjects|Healthy subjects, free of CKD
2920215|NCT03108222||Moderate CKD Subjects|Subjects with moderate-stage CKD
2920216|NCT03108209|Experimental|single arm|Signle arm study. Every subjects apply Photoderm Max lait SPF50+ and Photoderm stick SPF50+
2920217|NCT03108196|Experimental|sigmoid|"Use 15 cm detaenial sigmoid colon to reconstructed a U shape neobladder after radical cystectomy."
2920218|NCT03108196|Experimental|ileal|"Use 70 cm distal ileal segment to reconstructed a spherical shape neobladder after radical cystectomy."
2920219|NCT03108170|Active Comparator|3 programs group|The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her duo date
2920220|NCT03108170|Active Comparator|one program group|The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her duo date.
2920221|NCT03108157|Experimental|STUDY GROUP|Patients will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before the embryo transfer and then they will follow the conventional preparation protocol to receive embryos coming from an egg donation treatment.
2920222|NCT03108157|No Intervention|CONTROL GROUP|Patients will receive the conventional preparation protocol to receive embryos coming from an egg donation treatment.
2920223|NCT03108144|No Intervention|Control - Group A|When a patient is identified as consuming alcohol above CCS guidelines (based on mandatory baseline questionnaire) the practitioner in Group A will not receive computer alerts but will still have access to the alcohol consumption data as part of the baseline assessment (Screening). Healthcare providers will have access to all the same resources available as the intervention clinic (Treatment as usual).
2920224|NCT03108144|Experimental|Intervention - Group B|When a patient is identified as consuming alcohol above CCS guidelines (based on mandatory baseline questionnaire) the practitioner in Group B will receive computer alerts (Screening). The alert will provide a 5 minute script (Brief Intervention) for the health care providers to relay to patients and the ability to print or email a self-help resource to the patient each time the patient visits (Referral to Treatment).
2920225|NCT03108131|Experimental|Appendiceal Adenocarcinoma|Participants receive Cobimetinib 60 mg by mouth on Days 1−21 plus Atezolizumab 840 mg by vein on Day 1 and Day 15 in a 28-day cycle.
2920226|NCT03108131|Experimental|Cutaneous Squamous Cell Carcinoma|Participants receive Cobimetinib 60 mg by mouth on Days 1−21 plus Atezolizumab 840 mg by vein on Day 1 and Day 15 in a 28-day cycle.
2920227|NCT03108131|Experimental|Small Bowel Adenocarcinoma|Participants receive Cobimetinib 60 mg by mouth on Days 1−21 plus Atezolizumab 840 mg by vein on Day 1 and Day 15 in a 28-day cycle.
2920228|NCT03108118||Acute respiratory failure|We are enrolling patients who are intubated because of acute respiratory distress syndrome, pneumonia, septic shock, or severe acute brain injury (GCS ≤ 8 prior to intubation). This population is targeted for study because they are at relatively high risk of requiring prolonged mechanical ventilation.
2920229|NCT03108105|Experimental|AOS-C2001-B|A new 2-piece appliance composed with 2 parts: a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
2920230|NCT03108092|Experimental|STRIP intervention|The intervention will take place during the initial hospital admission (Index Hospitalisation) or an equivalent situation for outpatients. STRIP is a structured method to perform pharmacotherapy optimisation. The STRIP-intervention consists of 9 steps.
2920231|NCT03108092|Sham Comparator|Control|Participants in the control group will receive medication review by the prescribing physicians in accordance with usual care. If an extended drug review is in place in a ward/specialty corresponding characteristics are collected on cluster level.
2920232|NCT03108079|Other|Arm 1|"Women who agree to participate will undergo a standard high resolution, thin slice pelvic floor static/dynamic MRI study, first with a full bladder, and after the bladder is emptied. Bladder filling and drainage will be performed sequentially, using each of the 2 catheter types (Cystosure Urinary Access Catheter and Foley Catheter). During bladder emptying, a cine video scan will be taken at the midsagittal plane to show the dynamics of the bladder fluid and walls during emptying. Each subject will serve as their own control.~Interventions are listed in the Interventions Section."
2920233|NCT03108066|Experimental|PT2385 Tablets|Twenty-five patients will be enrolled in each stage of a two-stage design
2920234|NCT03108053|Active Comparator|Guidewire used|Patients whose semirigid ureteroscopy procedure is conducted with the use of safety guidewire
2920235|NCT03108053|Experimental|No guide wire used|Patients whose semirigid ureteroscopy procedure is conducted without the use of safety guidewire
2920236|NCT03108027|Experimental|Sequence 1|Patients will receive in a sequential order the following interventional treatments: A,B and C.
2920237|NCT03108027|Experimental|Sequence 2|Patients will receive in a sequential order the following interventional treatments: B, A and C.
2920238|NCT03108027|Experimental|Sequence 3|Patients will receive in a sequential order the following interventional treatments: C, B and A.
2920239|NCT03108027|Experimental|Sequence 4|Patients will receive in a sequential order the following interventional treatments : C, A and B.
2920240|NCT03108027|Experimental|Sequence 5|Patients will receive in a sequential order the following interventional treatments: A, C and B.
2920241|NCT03108027|Experimental|Sequence 6|Patients will receive in a sequential order the following interventional treatments: B, C and A.
2920242|NCT03108014||Breast milk fed|Fed primarily breast fed as an infant
2920243|NCT03108014||Milk based formula fed|Fed primarily milk based formula as an infant
2920244|NCT03108014||Soy based formula fed|Fed primarily soy based formula as an infant
2920245|NCT03108001||Lean mothers|Participants that were in Glowing born from Lean mothers.
2920246|NCT03108001||Overweight mothers|Participants that were in Glowing born from Overweight mothers.
2920247|NCT03108001||Obese mothers|Participants that were in Glowing born from Obese mothers.
2920248|NCT03108001||Exercise group mothers|Participants that were in Expecting born from mothers that were in the exercise group.
2920249|NCT03108001||Non Exercise group mothers|Participants that were in Expecting born from mothers that were in the non- exercise group.
2920250|NCT03107988|Experimental|Cohort A1 (Dose-finding)|Lorlatinib will be given orally once daily continuously for 28 days. The dose level of lorlatinib will be assigned at the time of study registration. The starting dose for cohort A1 is 45 mg/m2/dose
2920251|NCT03107988|Experimental|Cohort A2 (Adult and large BSA)|Lorlatinib will be given at the adult recommended phase 2 dose (RP2D) of 100 mg orally once daily continuously for 28 days.
2920252|NCT03107988|Experimental|Cohort B1 (Expansion)|Lorlatinib will be given orally once daily continuously for 28 days at the RP2D defined by cohort A1. This cohort will not begin enrollment until the recommended phase 2 dose is established from the dose escalation cohort A1.
2920253|NCT03107988|Experimental|Cohort B2 (Combined w/ chemotherapy)|Lorlatinib will be given orally once daily continuously for 28 days, at the RP2D defined by cohort A1. Lorlatinib should be administered at least one hour prior to conventional chemotherapy (Cyclophosphamide and Topotecan) on days 1-5 of each cycle.
2920254|NCT03107975|Experimental|Cell Therapy|intrathecal injection of human amniotic epithelial cells
2920255|NCT03107962|Experimental|PD-1 Blocking Antibody|Pembrolizumab
2920256|NCT03107949|Experimental|Lungpacer Diaphragm Pacing Therapy (DPTS)|The LIVE Catheter will be temporarily inserted (LIVE Catheter will be inserted into every patient enrolled and can stay in place for up to 30 days) into the left subclavian vein and connected to the Lungpacer Control Unit in order to perform diaphragm pacing to stimulate the phrenic nerves and activate the diaphragm 3 x a day on all patients until extubated/removed from mechanical ventilation or until day 30 whichever comes first.
2920257|NCT03107936|No Intervention|Sub Study 1- Focus Group|40 adolescents, aged 11-14, recruited from partner programs, who have never tried smoking will conduct focus groups.
2920258|NCT03107936|Experimental|Sub Study 2|30 adolescents, aged 11-14, who have never tried smoking will play the adapted game
2920259|NCT03107936|No Intervention|Sub Study 3- Focus group|10 girls and boys, aged 11-14, will participate in the focus groups to focus the game on e-cigarettes and other tobacco product use.
2920260|NCT03107936|Experimental|Sub Study 1- Test Game|30 girls and boys, aged 11-14, will test the first phase of the app.
2920261|NCT03107936|Experimental|Sub Study 3- Test Game|40 girls and boys, aged 11-14, will participate in the pilot test of the game with a focus on e-cigarettes and other tobacco product use.
2920262|NCT03107923||Preoperative myocardial reserve yes/no|Patients with extensive myocardial fibrosis typically presents with limited myocardial contractile reserve that can be assessed by a dobutamine stress test. The patients will be allocated to a responder and non-responder group according to the results from this test.
2920263|NCT03107910|Other|Experimental Stigma Counseling|Single session, stigma focused, anticipated HIV stigma counseling will be provided. Intervention will include a focus on barriers to testing.
2920264|NCT03107910|Other|Control Health Information|Single session, online health information seeking and evaluation. HIV/STI testing appointments are provided online. Stigma and Structural Interventions
2920265|NCT03107897|No Intervention|Pre-procedure standard of care|No prehab prior to TAVR.
2920266|NCT03107897|Active Comparator|Prehab prior to TAVR procedure.|Individuals participate in prehabilitation prior to TAVR.
2920267|NCT03107884|Experimental|Metformin|Metformin will be given to participants incrementally during a 2 week run in period such that they will receive the clinical dose (2 grams per day). During bed rest, participants will be given 1 gram of metformin two times a day (morning and evening). This dosage and frequency will occur during four consecutive days of bed rest.
2920268|NCT03107884|Placebo Comparator|Placebo|Placebo will be given to participants incrementally during a 2 week run in period such that they will receive the same amount of pills as the experimental group. During bed rest, participants will be given the same amount of pills and given at the same time of day (morning and evening) as the experimental group. This strategy will occur during four consecutive days of bed rest.
2920269|NCT03107871|Experimental|Arm A|Valganciclovir 16 mg/kg PO twice daily (BID) x 6 months
2920270|NCT03107871|Placebo Comparator|Arm B|Flavored Simple Syrup, volume equivalent to active arm dose, PO BID x 6 months
2920271|NCT03107858|Active Comparator|Norepinephrine|
2920272|NCT03107858|Active Comparator|Dopamine|
2920273|NCT03107845|Active Comparator|Cognitive Behavior Therapy|Cognitive Behavioral Therapy without psychometric Feedback.
2920274|NCT03107845|Experimental|CBT plus Feedback|Cognitive Behavioral Therapy (CBT) with Psychometric Feedback
2920275|NCT03107845|Experimental|CBT plus Feedback plus CST|Cognitive Behavioral Therapy (CBT) with Psychometric Feedback and Clinical Support Tools (CST)
2920276|NCT03107832|Active Comparator|general anesthesia|In general anesthesia group (Group G), and induction was managed using 1.5 mg/kg fentanyl and 2 mg/kg propofol; 0.5 mg/kg rocuronium and sevoflurane in a 50% oxygen /air mixture was used. Blood gas analysis monitoring was performed in the 30th minute before and after pneumoperitoneum
2920277|NCT03107832|Experimental|thoracic epidural anesthesia|In epidural anesthesia group(Group E), a catheter was installed and received 20 mg lidocaine hydrochloride, 15 mg bupivacaine, and 25 mg fentanyl citrate adjusted to 10 cc with normal saline to be injected by the epidural catheter. Bi-spectral index -controlled sedation was provided
2920278|NCT03107819||Pediatric patients undergoing EGD|Subjects ages 2-18 years undergoing upper endoscopy (EGD) will submit a blood and urine specimen for plasma and urine metabolomics profiling.
2920279|NCT03107806|Other|Glucose monitoring by OptiScanner®|Glucose monitoring and intervention guided by OptiScanner®
2920280|NCT03107806|Other|Blinded continuous glucose monitoring|Blinded continuous glucose monitoring by OptiScanner® and glucose lowering intervention guided by routine glucose measurements
2920281|NCT03107793|Experimental|All Participants|At Week (Wk) 0, all eligible participants will initiate intravenous (IV) induction treatment with ustekinumab (UST) on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg). At Week 8, all participants will receive a 90 milligram (mg) subcutaneous (SC) injection of ustekinumab. At Week 16, participants who do not achieve a Crohn's Disease Activity Index (CDAI) improvement of greater than or equal to (>=) 70 points versus Week 0 (CDAI 70) will leave the study. Remaining participants will be randomized in a 1:1 ratio to either one of two arms for open label maintenance treatment up to Week 48: the treat to target arm or the routine care arm. From Week 48, participants will continue ustekinumab treatment in the study extension period, up to Week 104. Dosing frequency will be adjusted in the extension period for the participants failing to meet the treatment target.
2920305|NCT03107611|Experimental|Test|Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for 14 days
2920306|NCT03107611|Active Comparator|Reference Standard|Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for 14 days
2920307|NCT03107611|Placebo Comparator|Placebo|Placebo cream, topical, thin layer applied to all affected skin areas twice daily for 14 days
2920282|NCT03107793|Experimental|Routine Care Arm|In the routine care arm, assessment visits will be scheduled according to the timing of maintenance treatment injections up to Week 48, which will be in compliance with the EU SmPC for ustekinumab for the treatment of Crohn's disease, in which dosing every 12 weeks is recommended. At Week 16, (that is, 8 weeks after the first SC dose) participants continuing in the study will have demonstrated a CDAI-70 response. Nonetheless, participants who have not shown adequate response based on the investigator's judgment may receive a second SC dose at Week 16. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.
2920283|NCT03107793|Experimental|Treat to Target (T2T) Arm|UST maintenance treatment assignment will be based on centrally-read colonoscopy (at Wk16). Participants with <25% improvement in SES-CD score at Wk16 will be assigned to Q8 (8-weekly) treatment and will receive UST 90mg SC at Wk16. In contrast, participants with >=25% improvement in SES-CD score at Wk16 will be assigned to Q12 treatment and will receive next UST dose (90 mg SC) at Wk20. At assessment visits (from Wk24 for participants assigned to the Q8 regimen or from Wk20 for the Q12 group) UST maintenance treatment (up to Wk 48) will be directed by T2T assessments. Participants meeting target will continue with same UST dosing frequency. The dosing frequency will be optimized for all participants failing to meet the target at assessment visit. Those previously on Q12 regimens will be adjusted to Q8 dosing; those previously on Q8 regimens will be adjusted to Q4 dosing. Participants subsequently failing to meet the target will not be able to adjust further and will leave the study.
2920284|NCT03107793|Experimental|Exploratory Extension period: From Week 48 to Week 104|At Week 48, dose de-escalation will be implemented for participants with both endoscopic remission (SES-CD score <=2) and corticosteroid-free clinical remission of at least 16 weeks duration. Participants receiving 12 weekly dosing frequency (Q12) ustekinumab will maintain this dosing frequency. Participants with either clinical remission or endoscopic remission, but not both, at Week 48 will continue with same dosing frequency or de-escalate provided maintenance of corticosteroid-free clinical remission and biomarker remission at 2 consecutive visits. Participants with neither corticosteroid-free clinical remission nor endoscopic remission will escalate dose or leave study if already on 4 weekly dosing frequency (Q4) dose. If neither clinical remission nor biomarker remission is evident at the next visit, participant will leave study. Later in the extension period, only those who achieve corticosteroid-free clinical remission and biomarker remission will undergo dose de-escalation.
2920285|NCT03107780|Experimental|Treatment (MDM2 inhibitor AMG-232)|"PART I: Patients with recurrent glioblastoma receive MDM2 inhibitor AMG-232 PO QD for 2 days. Within 3-6 hours of the last dose, patients undergo standard of care surgery. Upon recovery (within 45 days), patients with TP53 wild-type tumors continue to receive MDM2 inhibitor AMG-232 PO QD on days 1-7. Courses repeat every 21 days in absence of disease progression or unacceptable toxicity.~PART II: Within 6 weeks of standard of care surgery, patients with newly diagnosed glioblastoma undergo radiation therapy daily during weeks 1-6. Patients also receive MDM2 inhibitor AMG-232 PO once weekly for 6 weeks or 3 times weekly on days 2, 3, and 5 for 6 weeks or 2 times weekly on days 2 and 4 for 6 weeks during radiation therapy.~PART II (EXPANSION COHORT): Patients receive MDM2 inhibitor AMG-232 PO QD on days 1-7. Courses repeat every 21 days in absence of disease progression or unacceptable toxicity."
2920286|NCT03107767|Active Comparator|Prospective Cohort|The prospective cohort following introduction of the evidence based algorithm for ankle fractures.
2920287|NCT03107767|No Intervention|Historical Cohort|Patients treated before introduction of algorithm. Matched to prospective cohort for comparison
2920288|NCT03107754|Placebo Comparator|Standard paracervical block|A paracervical block will be administered with 20 cc of 1% lidocaine, which is our standard office protocol
2920289|NCT03107754|Experimental|Buffered lidocaine paracervical block|A paracervical block will be administered with 20 cc of 1% lidocaine buffered with 8.4% sodium bicarbonate
2920290|NCT03107741|No Intervention|Passive Control|Subjects in this group do not received any intervention.
2920291|NCT03107741|Placebo Comparator|Generic Fitness|Subjects in this groups will receive three fitness lessons in a week while each session last for 1 hour throughout the 12 weeks experimental period
2920292|NCT03107741|Active Comparator|Tai Chi|Subjects in this groups will receive three tai chi lessons in a week while each session last for 1 hour throughout the 12 weeks experimental period
2920293|NCT03107728|Experimental|Advanced orthotic brace|
2920294|NCT03107728|Active Comparator|Conventional orthotic brace|
2920295|NCT03107715|Active Comparator|Breastfeeding Champion|The Breastfeeding Champion Intervention (Intervention A) utilizes information about Breastfeeding Champions from the Coffective™ program: participants will be guided to tap and scroll through the content and will receive a follow up handout and encouragement to select a Champion.
2920296|NCT03107715|Active Comparator|Positive Messaging|The Positive Messaging Intervention (Intervention B) utilizes positive messaging from several sources and is modelled on the WIC Loving Support™ approach: participants will click on (istock-purchased) photographs which each reveal an informational statement about exclusive breastfeeding benefits and tips, followed by receipt of a summary handout.
2920297|NCT03107702||Melatonin and bariatric surgery|the relationship between melatonin level and analgesia requirement.
2920298|NCT03107676|Active Comparator|trunk endurance with hands above head|participants had to practice trunk extensors endurance training with having hands above head.
2920299|NCT03107676|Active Comparator|trunk endurance with hands behind head|participants had to practice trunk extensors endurance training with having hands behind head.
2920300|NCT03107676|Active Comparator|trunk endurance with hands parallel|participants had to practice trunk extensors endurance training with having hands parallel to the trunk.
2920301|NCT03107676|No Intervention|trunk endurance with no intervention|participants will be tested for trunk extensors endurance with having hands on chest but no intervention.
2920302|NCT03107663|Experimental|⁸⁹Zr-Df-IAB22M2C Infusion|3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes
2920303|NCT03107650||High risk patients|Patients with high risk of suboptimal mesorectum quality and/or positive circumferential margin after the application of the preoperative prediction model developed
2920304|NCT03107650||Low risk patients|Patients with low risk of suboptimal mesorectum quality and/or positive circumferential margin after the application of the preoperative prediction model developed
2920308|NCT03107598|Experimental|colloid preload|Group CoP: group with colloid preload The preload group received rapid infusion of 15ml/kg of 6% hydroxyethyl starch (6% HES) administered by gravity at a wide-open rate over a period of 15-30min before induction of spinal anesthesia.
2920309|NCT03107598|Placebo Comparator|crystalloid coload|Group CrC: group with crystalloid coload The coload group received a sodium chloride 0.9% perfusion as rapidly as possible starting at the time of intrathecal injection for spinal anesthesia.
2920310|NCT03107585|Experimental|bilateral cervical plexus block (GP1)|arm intervention GP1 : after skin disinfection and oral premedication , ultrasound guided cervical bilateral bloc ,with10 ml of bupivacaine 0.25 was realized in each side of deep cervical space; then general anesthesia was performed with local protocol
2920311|NCT03107585|Placebo Comparator|control(GP2)|GP2 control no specific intervention only general anesthesia was performed with local protocol
2920312|NCT03107546|Other|Skin graft|full thickness skin graft
2920313|NCT03107546|Experimental|Hyalomatrix|skin graft substitute
2920314|NCT03107533||Video recording of clinical visit|Investigators will enroll patients from the Department of Orthopedic Surgery for enrollment. The shared decision group will provide staff for data analysis.
2920315|NCT03107520|Experimental|DDH Surgical Reduction Patients|Infants treated for DDH who failed conservative measures and are undergoing intraoperative open or closed hip reduction. Intraoperative contrast-enhanced ultrasound using Lumason contrast agent will be administered to improve visualization of the epiphyseal vascularity after hip reduction and during placement of the spica cast.
2920316|NCT03107507|Active Comparator|Levetiracetam|"Levetiracetam given in oral form via oro-gastric tube, first a bolus dose 40-50mg/kg then maintenance dose 10-30 mg/kg/day divided every 12 hours.~Duration: until seizure free"
2920317|NCT03107507|Active Comparator|Phenobarbital|"Phenobarbital given in IV form, loading dose 20mg/kg that can be repeated after a 20 minute interval not to exceed 40mg/kg then maintenance dose 2-4 mg/kg/day divided every 12 hours.~Duration: until seizure free"
2920318|NCT03107494|Experimental|Treatment with GATS|Gala Airway Treatment System (GATS)
2920319|NCT03107481|Active Comparator|Acetaminophen|
2920320|NCT03107481|Active Comparator|Hydromorphone|
2920321|NCT03107468|Experimental|Mokhuri intensive treatment group|Patients in this arm will be treated with 35-week of Mokhuri intensive treatment program which compromise 10 sessions of acupuncture, Chuna and patient consultation during 5 weeks.
2920322|NCT03107468|Active Comparator|Non-surgical conventional treatment group|Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment during 5 weeks.
2920323|NCT03107442|Experimental|Exercise|12-weeks aerobic exercise intervention
2920324|NCT03107442|No Intervention|Control|Usual care, with recommendations for a healthy lifestyle.
2920325|NCT03107429|Active Comparator|Placebo and Trendelenburg Position|"Volunteers received placebo medication and placed in Trendelenburg.~IOP will be measured. Participants will then be administered with a placebo and after 2.5 hours will be placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes."
2920326|NCT03107429|Experimental|Acetazolamide and Trendelenburg Position|"Volunteer given acetazolomide and placed in Trendelenburg position and IOP measured.~IOP will be measured. Participants will then be administered with acetazolamide and after 2.5 hours placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes."
2920327|NCT03107416|Experimental|Bumetanide|Three escalating doses of bumetanide will be used: 0.01 mg/kg (level 1), 0.02 mg/kg (level 2) and 0.04 mg/kg (level 3) in a standard 3+3 design. Starting with level 1, three patients will first be enrolled at each level.
2920328|NCT03107403|Experimental|Healthy subjects|
2920329|NCT03107390|Other|Patients with CD or RCH|
2920330|NCT03107390|Other|The control population|
2920331|NCT03107377|Active Comparator|Amphora gel|A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
2920332|NCT03107377|Placebo Comparator|Placebo|An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
2920333|NCT03107364||Colorectal surgery|Patient who underwent elective colorectal surgery
2920334|NCT03107364||Hip fracture|Patient who underwent urgent surgical procedure for hip fracture
2920335|NCT03107351|Sham Comparator|repeatability measures|In this arm, healthy subjects will undergo repeated measures at different times of the day.
2920336|NCT03107351|Experimental|Contractility changes measures|In this arm, healthy subjects will have their cardiac contractility increased in a controlled way and assessed with both HK and echocardiography.
2920337|NCT03107338|Active Comparator|DEXKETOPROFEN TROMETAMOL|Patients received a dose of 25 mg DKT in an oral suspension 15 minutes before surgery
2920338|NCT03107338|Placebo Comparator|Placebo|Patients received a dose of 500 mg Vitamin C in an oral suspension 15 minutes before surgery
2920339|NCT03107325|Other|F-18 FDG|Three age groups:, < 1-4, and 6-10 YO. Depending upon the purpose of the study, the diagnostic scan may start as early as 30 min. to 1 h post-administration (PA) (cardiac, neurologic studies) to as late as 2 h PA (oncologic studies). Subjects in each group will be also imaged after 4 h. The CT image from the routine scan will be used for the 2nd scan to avoid additional CT exposure. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
2920340|NCT03107312||Known vaccination history|Single blood sample collection from subjects with verified records of vaccination or recent booster immunization against measles, mumps, rubella, varicella, tetanus, pertussis, poliomyelitis, diphtheria, meningococcal infection
2920341|NCT03107312||Migrants|Single blood sample collection from recent migrants to Germany without verified vaccination records
2920342|NCT03107299|Other|Control|
2920343|NCT03107299|Other|Send sms to patients|
2920344|NCT03107299|Other|pharmaceutical maintenance following medical consultation|
2920345|NCT03107286|Other|Tc-99m MAG3|Two age groups: < 1 YO and 4-6 YO. Routine imaging is performed immediately as a dynamic acquisition with 80 frames over 20 min. (15 s per frame). Subjects in each age group will be additionally imaged 2-3 h post-administration. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
2920346|NCT03107273||Diagnostic patient|
2920347|NCT03107273||Control|
2920348|NCT03107260|Other|Occurrence of postoperative cognitive dysfunction|
2920349|NCT03107247|Other|Tc-99m MDP|Patients ages 1-11 years old will be included. Routine SPECT imaging will be collected 3-4 h post-administration (PA) with a dual-detector rotating gamma camera over a 360˚ for 10-15 s per view using a 1282 matrix. Half of the subjects will also be imaged between 30 and 90 min, PA. The 2nd half will be at 5-6 h, PA. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
2920350|NCT03107234||Patient with breast cancer requiring surgery to|
2920351|NCT03107221|Experimental|Intervention|"Access to online self-help programme Smart Eating along with usual treatment from a specialist eating disorder service"
2920352|NCT03107221|No Intervention|Control|Usual treatment from a specialist eating disorder service
2920353|NCT03107208|Experimental|Early glargine (Lantus)|A dose of glargine (Lantus®) is given subcutaneously early in the management of DKA (i.e. while the participant is still receiving intravenous insulin). Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
2920354|NCT03107208|Other|Control group|A dose of glargine (Lantus®) is given subcutaneously after resolution of the DKA (i.e. when the intravenous insulin is stopped). This is currently the standard-of-care practice for children in DKA. Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
2920355|NCT03107195|Other|Tc-99m DMSA|Patients aged 1-6 years old will be enrolled. Routine SPECT imaging will be performed 3-4 h post-administration (PA) with a dual-detector rotating gamma camera over a 360˚ rotation for 8 s per view using a 1282 matrix. In each age group, half of the subjects will also be imaged between 30 and 90 min, post-administration. The 2nd half will be imaged at 5-6 h, post-administration. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
2920356|NCT03107182|Experimental|Induction Chemotherapy|"All enrolled patients will receive three 21-day cycles of chemotherapy consisting of nab-paclitaxel (100 mg/m2 on days 1, 8, 15; 9 doses total), carboplatin (AUC 5 on day 1; 3 doses total), and nivolumab (360 mg on days 1; 3 doses total). Growth factor support will be provided using G-CSF administered on days 16-18.~Adjuvant nivolumab will be offered to all patients for 6-months post completion of locoregional therapy."
2920357|NCT03107182|Experimental|Single Modality De-escalation Arm (SDA)|"Following the induction treatments (carboplatin, nab-paclitaxel, and nivolumab), patients will be assessed based on response to chemotherapy and high or low risk status.~Patients with low risk and small volume tonsillar disease (T1-T2, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease (T1-2 with lateralized primary ≤3 cm, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS and selective nodal dissection. De-intensified adjuvant RT will be given for adverse pathologic features. Patients may refuse TORS treatment.~Patients with low risk, who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 G."
2920358|NCT03107182|Experimental|Intermediate De-escalation Arm (IDA)|"Following the induction treatments (carboplatin, nab-paclitaxel, and nivolumab), patients will be assessed based on response to chemotherapy and high or low risk status.~Patients who have low risk disease with <50% but ≥30% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX (paclitaxel, 5-FU, hydroxyurea, dexamethasone, famotidine, and diphenhydramine) to 45 Gy (3 cycles).~Patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles)."
2920359|NCT03107182|Experimental|Regular Dose Arm (RDA)|"Following the induction treatments (carboplatin, nab-paclitaxel, and nivolumab), patients will be assessed based on response to chemotherapy and high or low risk status.~Patients who have low risk disease and <30% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX (paclitaxel, 5-FU, hydroxyurea, dexamethasone, famotidine, and diphenhydramine) to 75 Gy (5 cycles).~Patients who have high risk disease and <50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles).~Any patient who has progressive disease will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles)."
2920360|NCT03107169|Active Comparator|Vancomycin|Patients in this arm received vancomycin 250mg every 6 hrs for 10-14 days
2920361|NCT03107169|Experimental|FMT-FURM|Patients in this arm receive FMT-FURM
2920362|NCT03107143|Experimental|Treatment Group|Trial subjects have Q2 System installed on their beds in addition to receiving standard care of pressure ulcer prevention according to study hospital's policy and protocol.
2920363|NCT03107143|No Intervention|Control Group|Control subjects receive only standard care of pressure ulcer prevention according to study hospital's policy and protocol without Q2 System
2920364|NCT03107130||SUI Surgery Patients in 2015|All women 18 years of age or older, who underwent surgery for SUI between January 2015 and December 2015
2920365|NCT03107117|Experimental|Computer counseling|a computer-assisted adolescent motivational intervention called e-toke plus an online parenting program - Parenting Wisely
2920366|NCT03107117|Active Comparator|Standard care|Standard care is typically referral to counseling for substance use
2920367|NCT03107104|Experimental|Medical need for FA imaging|Subjects deemed to have a medical need for FA imaging will be imaged on the Topcon DRI OCT Triton (plus) and TRC-50DX retinal camera
2920368|NCT03107091|Experimental|Terlipressin acetate continuous infusion|Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days
2920369|NCT03107078|Experimental|Group Ia|"I:The increase of fat volume dominates .~a:The weekly protocol was as follows: 0.5 g glucocorticoids weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks."
2920370|NCT03107078|Experimental|Group Ib|"I:The increase of fat volume dominates. b:The qod protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months."
2920371|NCT03107078|Experimental|Group IIa|"II:The increase of extraocular muscles volume dominates .~a:The weekly protocol was as follows: 0.5 g glucocorticoids weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks."
2920372|NCT03107078|Experimental|Group IIb|"II:The increase of extraocular muscles volume dominates . b:The qod protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months."
2920373|NCT03107065|Experimental|single treatment|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation Used To Contract Tissue Associated With Axillary Sweat Glands
2920374|NCT03107052|Experimental|Fremanezumab - A|
2920375|NCT03107052|Experimental|Fremanezumab - B|
2920376|NCT03107052|Experimental|Fremanezumab - C|
2920377|NCT03107039|Experimental|Exercise|This arm will use a resistance exercise curriculum.
2920378|NCT03107039|Active Comparator|Health Education|This arm will use health education curriculum.
2920379|NCT03107026|Experimental|dasotraline 4mg|dasotraline 4mg once daily
2920380|NCT03107026|Experimental|dasotraline 6mg|dasotraline 6mg once daily
2920381|NCT03107026|Placebo Comparator|Placebo|Placebo, once daily
2920382|NCT03107013|Experimental|[14C]-BTD-001|
2920383|NCT03107000|Active Comparator|Trabeculectomy group|Patients with Open Angle Glaucoma requiring incisional surgery in whom specular microscopy can be performed without any delay in their treatment
2920384|NCT03107000|Active Comparator|Phako-trabeculectomy group|Patients with Open Angle Glaucoma and cataract requiring incisional surgery in whom specular microscopy can be performed without any delay in their treatment
2920385|NCT03106987|Experimental|Active Comparator: Olaparib|Olaparib 300mg tablets administered orally twice daily continuously.
2920386|NCT03106987|Placebo Comparator|Placebo Comparator: Placebo|Matching placebo 300mg tablets administered orally twice daily continuously.
2920387|NCT03106974|Active Comparator|Macintosh Laryngoscope|orotracheal intubation (OTI) with Macintosh Laryngoscope Direct laryngoscopy
2920388|NCT03106974|Active Comparator|Totaltrack VLM|orotracheal intubation (OTI) with Totaltrack VlM Indirect laryngoscopy
2920389|NCT03106948|Placebo Comparator|Low frequency angioplasty|Subjects who have had 0-1 angioplasty during the 12 months prior to randomization. Subjects will have endoluminal biopsy prior to angioplasty but will not have insertion of the ACT drug delivery catheter
2920390|NCT03106948|Active Comparator|Moderate frequency angioplasty|Subjects who have had 2-3 angioplasties during the 12 months prior to randomization. Subjects will have endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
2920391|NCT03106948|Active Comparator|High frequency angioplasty|High frequency angioplasty defined by 4 or more angioplasties 12 months prior to randomization. Subjects will receive ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
2920392|NCT03106935|Active Comparator|Obstet Gynecol,SecondSoochowU|Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1－2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
2920393|NCT03106935|No Intervention|reproductive center,SecondSoochowU|For the control group ,women with subclinical hypothyroidism are not given any drugs .
2920394|NCT03106922|Experimental|PMF104|"The day before the colonoscopy, starting in the mid-late afternoon (4-6 p.m.), by oral route:~2<=Age<6~500 ml in 1-1.5 hours <= to 18 kg~625 ml in 1-1.5 hours >18 kg 6<=Age<12:~750 ml in 1-2 hours <=25 kg~1000 ml in 1-2 hours 25-35 kg~1250 ml in 1-2 hours >35 kg 12>=Age<18 :~1500 ml in 2-3 hours <= 45 kg~1750 ml in 2-3 hours>45 kg.~Rescue dose (if no clear watery stools 3 hours after the entire solution):~250 ml 2 Age <=6;~500 ml 6 <=Age<12; up to a cumulative maximum volume of 2000 ml 12<=Age<18."
2920395|NCT03106922|Active Comparator|Klean- prep|"The day before the colonoscopy, starting in the mid-late afternoon (4-6 p.m.), by oral route:~2<=Age<6:~90 ml/kg in 1-1.5 hours 2<=Age<6~80 ml/kg in 1-1.5 hours 5<=Age<6~2<=Age<6:~80 ml/kg in 1-2 hours 6<=Age<10~70 ml/kg in 1-2 hours 10<=Age<12~12<=Age<18:~70 ml/kg in 2-3 hours. Rescue dose (if no clear watery stools 3 hours after the entire Klean-Prep solution): 50% of the initial dose."
2920396|NCT03106896||postherpetic neuralgia (PHN group)|"persist more than 3 months after the resolution of the acute shingles episode and have pain intensity greater than 4 on the visual analog scale (VAS 0, no pain; 10, worst pain imaginable)."
2920397|NCT03106896||acute herpetic pain (AHP group)|have pain (VAS≧4 ) duration of within 7 days after zoster onset at initial interview
2920398|NCT03106896||healthy control (CON group)|healthy population
2920399|NCT03106883|Experimental|Affective training|"One happy and three sad faces selected from the NimStim Set of Facial Expressions~Five five-minute blocks separate by 90-second rest periods"
2920400|NCT03106883|Sham Comparator|Sham training|"Neutral, non-affective, non-social photos of objects (i.e., cars)~Five five-minute blocks separate by 90-second rest periods"
2920401|NCT03106870|Active Comparator|oral metformin and insulin|Intervention 'Insulin Mixtard' and Intervention 'metformin' had included
2920402|NCT03106870|Active Comparator|insulin therapy only|Intervention 'Insulin Mixtard' had included
2920403|NCT03106857|Placebo Comparator|Group A|Physical activity, a low caloric diet, and the routine standard care for constipation
2920404|NCT03106857|No Intervention|Group B|No intervention
2920405|NCT03106844|Experimental|Treatment|All patients in this study will receive Fecal Microbiota Tranplantation
2920406|NCT03106831|Experimental|Pituitrin arm|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
2920407|NCT03106831|Experimental|Norepinephrine arm|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
2920408|NCT03106818|Active Comparator|group A|( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
2920409|NCT03106818|Active Comparator|group B|bupivacaine 0.125% infusion in the presternum , for 48 hours
2920410|NCT03106818|Active Comparator|Group C|will be conventional , will receive postoperative fentanyl , paracetamol , and ketorolac.
2920411|NCT03106805|Experimental|insertion by the end of the 4th week postpartum|
2920412|NCT03106805|Active Comparator|insertion by the end of the 6th week postpartum|
2920413|NCT03106792|Experimental|Hairfinity #1|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
2920414|NCT03106792|Experimental|Hairfinity #2|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
2920415|NCT03106792|Experimental|Hairfinity #3|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
2920416|NCT03106792|Placebo Comparator|Placebo|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
2920417|NCT03106779|Experimental|ABL001|patients will be treated with ABL001
2920418|NCT03106779|Active Comparator|Bosutinib|patients will be treated with bosutinib
2920419|NCT03106766|Experimental|Acne cream 1x|Twice-daily facial applications of the 1X product (avoiding contact with eyes and all mucous membranes) to the entire face for 6 months.
2920420|NCT03106766|Experimental|Acne cream 2x|Twice-daily facial applications of the 2X product (avoiding contact with eyes and all mucous membranes) to the entire face for 6 months.
2920421|NCT03106753|Active Comparator|Spinal anesthesia immediately for ECV.|The patient will have a spinal administered by the on call anesthesiologist using standard protocol (intrathecal bupivacaine 7.5 mg). The patient will then be administered 0.25 mg Terbutaline subcutaneously and the ECV will be attempted. Under ultrasound guidance the provider will attempt to lift the breech upward from the pelvis with one hand and guide the head with the other hand to produce a forward roll. If forward roll fails, a backward roll somersault may be attempted. ECV attempt will be abandoned if there is significant fetal bradycardia, discomfort to the patient, or if the procedure cannot be completed easily with these maneuvers. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.
2920422|NCT03106753|Experimental|Spinal anesthesia if no intervention fails for ECV.|The patient will be administered terbutaline 0.25 mg subcutaneously and the version will be attempted using the same procedure as above. If successful, the patient will be monitored for 30 minutes and discharged if fetal and maternal status is reassuring. If the attempt fails, the patient will be administered spinal anesthesia as above and the same maneuvers will be attempted. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.
2920423|NCT03106740|Other|Natural History Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging before a waiting period, without treatment, followed by a behavioral pain assessment.
2920424|NCT03106740|Experimental|Minocycline Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 2-week trial of Minocycline Hydrochloride, 100mg capsule
2920425|NCT03106740|Placebo Comparator|Placebo Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after 2 weeks of treatment with a placebo capsule.
2920426|NCT03106727|Active Comparator|Zalewa|Household Model Intervention introduced first - March 2017
2920427|NCT03106727|Active Comparator|Ligowe and Magaleta|Household Model Intervention to be introduced in June 2017
2920428|NCT03106727|Active Comparator|Neno District Hospital and Neno Parish|Household Model Intervention to be introduced in September 2017
2920429|NCT03106727|Active Comparator|Matope|Household Model Intervention to be introduced in December 2017
2920430|NCT03106727|Active Comparator|Matandani and Nsambe|Household Model Intervention to be introduced in March 2018
2920431|NCT03106727|Active Comparator|Luwani, Nkula, and Midzemba|Household Model Intervention to be introduced in June 2018
2920432|NCT03106714||Detectable RT-PCR ZIKV|Men and women aged 18 years and above with diagnosis of ZIKV infection
2920433|NCT03106701|Experimental|Ablation|Radiofrequency epicardial ablation
2920434|NCT03106688|Active Comparator|Low-risk group|Individuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.
2920435|NCT03106688|Active Comparator|High-risk group|Individuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.
2920436|NCT03106675|Experimental|HIFU-treatment|"Pre-treatment imaging~Pre-treatment questionnaires and laboratory blood samples~Intervention (Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T)~Follow-up (imaging, questionnaires, laboratory)~Follow-up pain medication usage"
2920437|NCT03106675|Active Comparator|Radiation therapy|"Pre-treatment imaging~Pre-treatment questionnaires and laboratory blood samples~Intervention (Varian Truebeam Radiotherapy System)~Follow-up (imaging, questionnaires, laboratory)~Follow-up pain medication usage"
2920438|NCT03106662|Experimental|Mesenchymal Stem Cell in Haplo-SCT|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10^8 cell/kg mesenchymal stem cells will be infused.
2920439|NCT03106649|Experimental|Gr (E)|The group in which the proposed algorithm for prevention and treatment of spinal hypotension will be tested with regard to fluid and vasopressor use, by means of echocardiography.
2920440|NCT03106649|No Intervention|Gr (S)|The control group in which the anesthesia (fluid and vasopressor) management will be decided by the attending anesthesiologist
2920441|NCT03106636|Experimental|KEEP-P|Caregivers are randomly assigned to one of two groups. The KEEP-P group completes a basic version of the curriculum. The intervention content is delivered by a KEEP-P group facilitator in a 2-hour weekly group format. Duration of the program is 12 weeks.
2920478|NCT03106428|Experimental|Multiple Myeloma|Patients with R/R MM who have failed prior standard therapy(ies) which should include immunomodulatory agents and proteasome inhibitors and for whom there is no standard salvage regimen.
2920479|NCT03106428|Experimental|Diffuse Large B-cell Lymphoma|Patients with R/R DLBCL who have failed prior standard therapy(ies) and for whom there is no standard salvage regimen.
2920442|NCT03106636|Experimental|KEEP-P+|Caregivers are randomly assigned to one of two groups. The KEEP-P+ group completes an augmented version of the intervention with curriculum that includes the addition of information about recent findings in early brain development and a video coaching component based on the Filming Interactions to Nurture Development (FIND) program. The intervention content is delivered by a KEEP-P group facilitator in a 2-hour weekly group format. Duration of the program is 12 weeks.
2920443|NCT03106623|Experimental|ONO-8577 Arm|Oral administration of ONO-8577 once a daily for 4 weeks
2920444|NCT03106623|Active Comparator|Active Comparator Arm|Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
2920445|NCT03106623|Placebo Comparator|Placebo Arm|Oral administration of Placebo once a daily for 4 weeks
2920446|NCT03106610|Experimental|Nivolumab|"Participants receive Nivolumab by vein over about 60 minutes on Day 1 of Cycles 1-3 before scheduled surgery. Each study cycle is 14 days (2 weeks).~Questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery."
2920447|NCT03106597|Experimental|Manidipine 20mg|50 patients will be administered orally manidipine 20mg/day after 1~2 week run-in period
2920448|NCT03106597|Active Comparator|Amlodipine 10mg|50 patients will be administered orally amlodipine 10mg/day after 1~2 week run-in period
2920449|NCT03106584|Active Comparator|Glucosamine sulphate|"Glucosamine sulphate will be consumed as either supplement A or B (i.e. blinded) for a period of 12-weeks. Glucosamine will be taken 2 times daily with food.~After 12 weeks of supplementation, participants will begin taking the alternative supplement (Aquamin-plus), after a washout period of not less than 1 month between the intervention arms of the study."
2920450|NCT03106584|Experimental|Aquamin-plus|"Aquamin-plus will be consumed as either supplement A or B (i.e. blinded) for a period of 12-weeks. Aquamin-plus will be taken 2 times daily with food.~After 12 weeks of supplementation, participants will begin taking the alternative supplement (Glucosamine sulphate), after a washout period of not less than 1 month between the intervention arms of the study."
2920451|NCT03106571|Experimental|Pomaglumetad methionil Low + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 9 days with intravenous methamphetamine challenges
2920452|NCT03106571|Experimental|Pomaglumetad methionil Mid + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 80 mg orally twice daily x 8 days with intravenous methamphetamine challenges
2920453|NCT03106571|Experimental|Pomaglumetad methionil High + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 160 mg orally twice daily x 8 days with intravenous methamphetamine challenges
2920454|NCT03106571|Placebo Comparator|Control + Methamphetamine|1-4 placebo tabs orally twice daily x 9 days (to match pomaglumetad dosing in each cohort) with intravenous methamphetamine challenges
2920455|NCT03106558|Active Comparator|Manual instrument total knee replacement|
2920456|NCT03106558|Active Comparator|Robitic arm total knee replacement|
2920457|NCT03106545|Experimental|Single mixture LB & bupivacaine|A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the distal tibial and deep peroneal nerves
2920458|NCT03106545|Active Comparator|Bupivacaine alone|Bupivacaine 0.5% (7.5 mL) injected into the distal tibial and deep peroneal nerves
2920459|NCT03106545|Sham Comparator|General anesthesia|General anesthesia
2920460|NCT03106532|Experimental|PHP-201 0.25% ophthalmic solution|PHP-201 0.25% ophthalmic solution, TID
2920461|NCT03106532|Experimental|PHP-201 0.5% ophthalmic solution|PHP-201 0.5% ophthalmic solution, TID
2920462|NCT03106532|Placebo Comparator|Placebo ophthalmic solution|Placebo ophthalmic solution, TID
2920463|NCT03106519|Experimental|Single mixture LB & bupivacaine|A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the median and ulnar nerves
2920464|NCT03106519|Active Comparator|Bupivacaine alone|Bupivacaine 0.5% (7.5 mL) injected into the median and ulnar nerves
2920465|NCT03106506|Experimental|Test-implant with graft|Patients who received a connective tissue graft around implants
2920466|NCT03106506|Active Comparator|Control-Implant without graft|Implant installation surgery with cone morse system without the placement of connective tissue graft.
2920467|NCT03106493||Primary|Singletons and 1 twin of each pair
2920468|NCT03106493||Secondary|Twin sibling of children enrolled in primary cohort
2920469|NCT03106493||Tertiary|Higher order multiples and siblings
2920470|NCT03106480||HIV and Diabetes Cohort|Participants recruited in the study will have diverse characteristics. Participants will either be HIV infected or HIV negative and among those HIV-infected there will be those on ART and those not on ART. In addition, participants will have other background characteristics like having history of tuberculosis treatment, being malnourished while starting ART, having diabetes at ART initiation etc. Investigators will also be able to examine the effect of immune activation, body composition changes, and other related factors on the risk of diabetes. This diversity of characteristics will help provide adequate data to address study outcomes.
2920471|NCT03106467|Experimental|Single-port laparoscopic appendectomy|Single-port laparoscopic appendectomy is performed through single-port which is installed in umbilicus.
2920472|NCT03106467|Active Comparator|Three-port laparoscopic appendectomy|Three-port laparoscopic appendectomy is performed using conventional three-port technique which needs two additional ports outside umbilicus in addition to trans-umbilical port
2920473|NCT03106454|Active Comparator|Combination oral contraceptive pill|Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg Taken cyclically as 24 tablets containing EE 10mcg/NET acetate 1mg 2 tablets of EE 10mcg only 2 tablets of ferrous fumarate 75mg
2920474|NCT03106454|Experimental|Progestin only pill|Norethindrone 0.35mg Marketed use for 1 tablet per day. For study dosing, patients will take 3 tablets daily for a total of 1.05mg daily.
2920475|NCT03106441|Experimental|High flow oxygen therapy by nasal cannula|Experimental Device : High flow oxygen therapy by nasal cannula.
2920476|NCT03106441|Active Comparator|Facial mask oxygenation in BIPAP ventilation|Active Comparator: Facial mask oxygenation in BIPAP ventilation
2920477|NCT03106428|Experimental|acute myeloid leukemia|Patients with R/R AML by World Health Organization (WHO) classification (Arber et al, 2016) who have failed prior standard therapy and for whom no standard therapies are available
2920555|NCT03105804|Experimental|FT21044 Group|7 day at-home use of electronic cigarette FT21044 followed by a 2 day in-clinic period.
2920480|NCT03106415|Experimental|Treatment (binimetinib, pembrolizumab)|Patients receive binimetinib PO BID on days 1-14 of course 1 and on days 1-21 of course 2 and subsequent courses. Patients also receive pembrolizumab IV over 30 minutes on day 1. Course 1 equals 14 days. Courses 2 and beyond repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2920481|NCT03106402||Treated with topical NSAID|197 eyes of - patients were treated with topical bromfenac sodium hydrate (Bronuck®, Taejoon Pharm. LTD.) 2times a day starting 1 day before surgery and continued for 2 weeks after surgery.
2920482|NCT03106402||Treated without topical NSAID|147 eyes did not receive topical NSAID after cataract surgery
2920483|NCT03106389|Active Comparator|Misoprostol|This group will receive 400 micrograms of misoprostol administered vaginally for the first dose, followed after 6 hours by 400 micrograms administered orally, repeated every 6 hours.
2920484|NCT03106389|Experimental|Misoprostol/Transcervical catheter|This group will receive the same regimen, but will have in addition a transcervical balloon (Foleys') catheter that is inflated with 30 ml. of fluid; with weighted traction using a 1000 ml fluid-filled bag applying continuous pressure to the cervix
2920485|NCT03106376|Experimental|Healthy subjects|16% O2 gas in breathed air for 30 minutes 26% O2 gas in breathed air for 30 minutes
2920486|NCT03106363|Active Comparator|Alcohol/Placebo Cannabis|Participant will drink an alcoholic beverage to obtain a target blood alcohol content of 0.08mg% and will smoke a placebo delta 9 tetrahydrocannabinol (< 0.03%) cigarette.
2920487|NCT03106363|Active Comparator|Placebo Alcohol/Cannabis|Participant will drink tonic water (capped with a minimal amount of alcohol to enhance alcohol cues) and will smoke a delta 9 tetrahydrocannabinol (potency 12.5%) cigarette.
2920488|NCT03106363|Active Comparator|Alcohol/Cannabis|Participant will drink an alcoholic beverage to obtain a target blood alcohol content of 0.08mg% and will smoke a delta 9 tetrahydrocannabinol (potency 12.5%) cigarette.
2920489|NCT03106363|Placebo Comparator|Placebo Alcohol/Placebo Cannabis|Participant will drink tonic water (capped with a minimal amount of alcohol to enhance alcohol cues) and will smoke a placebo delta 9 tetrahydrocannabinol (< 0.03%) cigarette.
2920490|NCT03106350||questionnaire|EORTC-QLQ-30 questionnaire
2920491|NCT03106337|Experimental|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
2920492|NCT03106324||TNE NDMM patients treated with lenalidomide regimen|Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen containing lenalidomide
2920493|NCT03106324||TNE NDMM patients treated with non-lenalidomide|Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen not containing lenalidomide
2920494|NCT03106311|Active Comparator|Rupture of membranes group|Pregnant women with definite rupture of membranes will undergo speculum examination. Vaginal washing will be done. The washing fluid will be taken for quantitative and qualitative assessment of beta subunit of human chorionic gonadotropin.
2920495|NCT03106311|Active Comparator|Intact membranes group|Pregnant women with intact membranes will undergo speculum examination. Vaginal washing will be done. The washing fluid will be taken for quantitative and qualitative assessment of beta subunit of human chorionic gonadotropin.
2920496|NCT03106298||Iron Sucrose Treatment|All patients with iron deficiency anemia (those without CKD or HF, those with CKD only, those with HF only, and those with CKD/HF) will be given 5 weekly doses of 200 mg of intravenous iron sucrose.
2920497|NCT03106285|Experimental|Lactobacillus reuteri DSM17938|Oil drops
2920498|NCT03106285|Placebo Comparator|Placebo|Oils drops
2920499|NCT03106259||Non-Interventional Study|Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.[NCT02221258]
2920500|NCT03106246||New onset T1DM|Newly diagnosed Type I diabetic patients who are hyperglycemic but still C-peptide positive
2920501|NCT03106246||T1DM|Patients with established type I diabetes. they are hyperglycemic but C-peptide negative
2920502|NCT03106246||T2DM|Patients with established type II diabetes.
2920503|NCT03106246||Islet Transplant|Patients who received an islet transplantation for type I diabetes
2920504|NCT03106246||Healthy Volunteers|Normoglycemic healthy volunteers
2920505|NCT03106233||LTP flap breast reconstruction|All consecutive patients who underwent LTP flap breast reconstructions (unilateral, bilateral or stacked unilateral) between September 2012 and November 2016 at three centers in Maastricht, the Netherlands, and New York and New Orleans, the United States, were included. Autologous breast reconstruction was performed by using the upper lateral thigh region as a donor site.
2920506|NCT03106220|Active Comparator|home exercise|participate in home exercise program
2920507|NCT03106220|Placebo Comparator|standard care|encouraged to join physical therapy and walking goals
2920508|NCT03106207|Other|Upper gastric endoscopy (UGE)|Patients will be submitted to a UGE before the gastric bypass surgery without a ring and at two, six and 12 months after the surgical procedure .
2920509|NCT03106194|Other|history of injection drug use|"Men and women ≥ 18 years old with a history of injection drug use, enrolled in the opiate substitution program of CAD Limburg.~Case management"
2920510|NCT03106181|Active Comparator|Cataract surgery|Conventional phacoemulsification cataract surgery and intraocular lens implantation
2920511|NCT03106181|Experimental|Cataract surgery plus iStent inject®|Conventional phacoemulsification cataract surgery and lens implantation plus insertion of iStent inject®
2920512|NCT03106168|Experimental|With periapical granuloma|Patients presenting periapical granuloma in mandibular molar teeth, diagnosed by periapical radiography
2920513|NCT03106168|Experimental|Without periapical granuloma|Patients without periapical granuloma in mandibular molar teeth, diagnosed by periapical radiography
2920514|NCT03106155|Experimental|vistusertib (AZD2014)|vistusertib (AZD2014), 50 mg,BID, per os, every 12 hours
2920515|NCT03106142|Other|Academic detailing visit arm|The GPs will receive an academic detailing visit by a medical visitor. GPs will receive information on the conservative evidence-based management of knee osteoarthritis with physiotherapy. The information will be summarized on a flyer for the GPs.
2920516|NCT03106142|No Intervention|control group|The two case vignettes will also be presented to GP who did not received the intervention.
2921302|NCT03100838|Active Comparator|Nifedipine (Generic)|1 x 60 mg Nifedipine extended-release tablet
2920517|NCT03106116|Experimental|Enhanced External Counterpulsation|Experimental: Enhanced External Counterpulsation (EECP) intervention on top of guideline- driven standard medical therapy for coronary heart disease
2920518|NCT03106116|Active Comparator|Control|Guideline- driven standard medical therapy for 7 weeks without Enhanced External Counterpulsation intervention
2920519|NCT03106103||Women with urinary incontinence|The patients were randomized in four groups: Group A received 500mg of levofloxacin, group B received placebo, group C received 80mg trimethoprim and 400mg sulfamethoxazole (SMZ-TMP) and group D received 100mg of nitrofurantoin.
2920520|NCT03106090|No Intervention|No SCP Control|Patients returning for early follow-up who did not receive SCP.
2920521|NCT03106090|No Intervention|SOC SCP Control|Patients returning for early follow-up who received a standard of care SCP.
2920522|NCT03106090|Experimental|eSCP Intervention|"Patients currently receiving treatment who will be enrolled to receive an enhanced SCP (eSCP) with additional information beyond ASCO guidelines tailored to patient concerns and preferences."
2920523|NCT03106077|Experimental|Metastatic Triple-Negative Breast Cancer (TNBC)|"Participants receive Mirvetuximab Soravtansine once every 3 weeks.~Participants treated until disease progression, therapy intolerance or withdrawal of informed consent."
2920524|NCT03106077|Experimental|Newly Diagnosed Triple-Negative Breast Cancer (TNBC)|"Participants receive Mirvetuximab Soravtansine once every 3 weeks.~Participants receive a maximum of 4 cycles of therapy prior to undergoing surgical resection. Patients allowed to discontinue therapy for intolerance, disease progression or withdrawal of consent."
2920525|NCT03106077|Experimental|Metastatic Run-In Cohort|14 participants recruited in the first stage to receive Mirvetuximab Soravtansine once every 3 weeks.
2920526|NCT03106064|Placebo Comparator|Usual Care Group|Intervention: Usual care
2920527|NCT03106064|Experimental|Intervention Group|Intervention:Promoting independence in self-care
2920528|NCT03106051||Patients with active psoriatic arthritis|Patients who suffer from active psoriatic arthritis with at least moderate disease corresponding to a PGA of ≥2
2920529|NCT03106038|Experimental|Investigational Imaging Agent|One Arm: Investigational Imaging Agent (Initial dosing cohort: 0.06 mg/kg body weight), solution, intravenous, one time administration during surgery.
2920530|NCT03106025|Experimental|Patients Receiving Ultrasound|Enrolled participants will receive a bedside ocular ultrasound of the affected eye and the ultrasound will be compared with the ophthalmologist diagnosis. The participant's medical record will also be reviewed for information regarding demographics, complications, and outcomes.
2920531|NCT03106012|Experimental|Hsyterolaparoscopy|Subjected to bath diagnostic hystroscopy and laparoscopy
2920532|NCT03105986|Experimental|Treatment sequence AB|Participants will receive Treatment A (1000 milligram (mg) oral dose of JNJ-64041575 on Day 1) in Period 1, followed by Treatment B (1000 mg oral dose of JNJ-64041575 on Day 22 along with probenecid 500 mg on Day 21 to Day 28) in Period 2. A washout Period of 21 days will be maintained between each Period.
2920533|NCT03105986|Experimental|Treatment sequence BA|Participants will receive Treatment B (1000 mg oral dose of JNJ-64041575 on Day 1 along with probenecid 500 mg on Day -1 to Day 7) in Period 1, followed by Treatment A (1000 mg oral dose of JNJ-64041575 on Day 22) in Period 2. A washout Period of 21 days will be maintained between each Period.
2920534|NCT03105973|Experimental|Open-Label Trial Arm|Will receive 4 weeks of technology-enabled CBT treatment.
2920535|NCT03105960|Experimental|garlic with lime juice mouthwash|"garlic with lime juice mouthwash is herbal antimicrobial .children were instructed to rinse for 14 days, twice daily, ,10 ml (undiluted) for 30 second and then expectorate .~To prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract."
2920536|NCT03105960|Active Comparator|chlorhexidine mouthwash|chlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days. it is commercial mouthwash
2920537|NCT03105947|Active Comparator|Coconut oil|50g extra virgin coconut oil to be consumed daily for four weeks
2920538|NCT03105947|Active Comparator|Butter|50g butter to be consumed daily for four weeks
2920539|NCT03105947|Active Comparator|Olive Oil|50g extra virgin olive oil to be consumed daily for four weeks
2920540|NCT03105934|Experimental|Pulmonary Arterial Hypertension|Patients with Pulmonary Arterial Hypertension
2920541|NCT03105921|Experimental|Electrodes|Electrodes
2920542|NCT03105908|Other|Treatment|Internet delivered Acceptance and Commitment therapy, supported by a psychologist/psychology student under supervision.
2920543|NCT03105908|Other|Waiting list control condition|Participants receive no treatment for ten weeks, i.e. waiting list condition. Following post-assessment, the control condition receive unguided iACT (i.e. the same content and structure as iACT but without systematic therapist communication).
2920544|NCT03105882|Experimental|Neuro-Spinal Scaffold|
2920545|NCT03105869|Experimental|fluorocholine PET/CT|all patients will undergo a second PET/CT with fluorocholine
2920546|NCT03105856|Active Comparator|CERVARIX|hrHPV-based screening and HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 months)
2920547|NCT03105856|Active Comparator|GARDASIL|hrHPV-based screening and Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) vaccine group according to a two-dose schedule (0-12 months)
2920548|NCT03105856|No Intervention|CONTROL GROUP|Control group who will receive only hrHPV-based screening.
2920549|NCT03105843|Experimental|Cough Variant Asthma|Individuals diagnosed with Cough variant asthma
2920550|NCT03105843|Experimental|Methacholine-induced cough|Individuals with chronic cough and negative methacholine challenge
2920551|NCT03105843|Experimental|Control|Individuals with no history of asthma or chronic cough
2920552|NCT03105830|Experimental|intervention and data collection|pain management by iv paracetamol
2920553|NCT03105804|Experimental|FT21039 Group|7 day at-home use of electronic cigarette FT21039 followed by a 2 day in-clinic period.
2920554|NCT03105804|Experimental|FT21041 Group|7 day at-home use of electronic cigarette FT21041 followed by a 2 day in-clinic period.
2921883|NCT03096795|Experimental|MAD Cohort 2|Multiple doses of MEDI3506 or placebo
2920556|NCT03105804|Experimental|FT21042 Group|7 day at-home use of electronic cigarette FT21042 followed by a 2 day in-clinic period.
2920557|NCT03105791|No Intervention|Normal pre-operative education|• Control group received normal pre-operative education regarding surgery
2920558|NCT03105791|Active Comparator|Opioid usage education|• The study group received formal education detailing recommended post-operative opioid usage, side effects, dependence, and addiction
2920559|NCT03105765|Active Comparator|Ketamine|"The patients in this Group underwent General anaesthesia with total intravenous anaesthesia containing remifentanil (0,02-0,04 mg/kg ideal Body weight), propofol (4-6 mg/kg ideal Body weight) and atracurium.~Ketamine 0,2 mg/kg ideal Body weight per hour for 24 hours."
2920560|NCT03105765|Placebo Comparator|Placebo|"The patients in this Group underwent General anaesthesia with total intravenous anaesthesia containing remifentanil (0,02-0,04 mg/kg ideal Body weight), propofol (4-6 mg/kg ideal Body weight) and atracurium.~Placebo (normal Saline) for 24 hours."
2920561|NCT03105752|Experimental|Research participants|"Each participant of a clinical trial completed the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) about its understanding of the information received. This questionnaire was retrieved immediately on the day of consent, with no possibility of referring to the content of information letter."
2920562|NCT03105739|Experimental|Anesthetised|LMA removal once the halogenated anesthetic turned off
2920563|NCT03105739|Active Comparator|Awake|LMA removal once the patient fully regained consciousness
2920564|NCT03105726||Group I|Group managed by ventricular assist devices in first intention in Bad-Oeynhausen, Germany
2920565|NCT03105726||Group II|Group managed with medical therapy, heart transplantation, or both, in first intention,in Paris, France
2920566|NCT03105713|Experimental|Patient Safety Checklist Intervention|The intervention to be administered is three patient safety checklists for patients to be performed: a) before admission to hospital; b) under hospital stay (discharge); c) after discharge from hospital.
2920567|NCT03105713|No Intervention|Controls|Patients do not receive the safety checklist intervention. Care as usual.
2920568|NCT03105700|Experimental|Low Frequency TMS Intervention|Patients will receive low-frequency TMS on an accelerated schedule over three consecutive days.
2920569|NCT03105687|No Intervention|Control|"Participants in the Control group will receive standard Pharmaceutical Care according to the principles of Good Pharmaceutical Practice and national Slovak legislation requirements only.~Participants in the control group will also receive a welcome SMS one day after enrollment and an end-of-trial SMS three months after the enrollment. Additionally, prior to their scheduled follow-up visit (Visit 2), three months following the enrollment, trial pharmacists will call the participants to remind them of their follow-up visit."
2920570|NCT03105687|Experimental|Intervention|Participants in the intervention group will also receive standard Pharmaceutical Care provided by the trial pharmacist, the welcome SMS and the end-of-trial SMS. Additionally, they will receive daily SMS reminders of their blood pressure-lowering medication intake from a trial pharmacist for a period of 3 months after the enrollment. The structure of the SMS reminder will follow the information provided as a part of the usual drug dispensation and counselling process as described in the Slovak national Decree No. 129/2012 Coll. Thus, most of the data are available on the prescription and all of the collected data are already a well-established and required part of the standard Pharmaceutical Care in Slovakia. The simple structure of the SMS reminder will allow for future reproducibility.
2920571|NCT03105674|Active Comparator|Standard Therapy|Patients will receive a combination of Marcaine and Lidocaine injection (standard local anesthetics) as a part of their peri-anal block prior to the surgery.
2920572|NCT03105674|Experimental|Multi-drug local anaesthetics|"Patients will receive a combination [Multi-drug local anesthetics (Combination)] of following drugs as a part of their peri-anal block prior to the surgery (multi-drug local anesthetics)~Ropivacaine 0.5% - 30 ml~Ketorolac 30mg/ml - 1 ml~Kenalog 10 mg/ml - 5 ml~Lidocaine 1% with Epinephrine 1:100,000 - 20ml"
2920573|NCT03105661|Active Comparator|Treatment Arm|"Patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.~Labetalol Hydrochloride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily"
2920574|NCT03105661|No Intervention|Non-treatment Arm|Patients who are randomized to the non-treatment arm will not receive antihypertensive medications.
2920575|NCT03105648||thyroid cancer|
2920576|NCT03105648||benign thyroid nodules|
2920577|NCT03105635|Other|Patients|"Participating primary care providers will be encouraged to refer their patients who could benefit from community resources to these services. They will complete the study referral form for all patients referred to a resource. They will briefly mention the study to patients who are referred to a community resource, and ask for their verbal consent to be contacted by a member of the research team to learn more about the study, and leave a patient recruitment package with them."
2920578|NCT03105635|Other|Practice and Provider|"Four to six practices will be recruited to participate in this feasibility study. Primary care members working in a participating practice will be invited to participate in the study.~All primary care providers will be encouraged to participate and at least one primary care provider is required to participate to include the practice in the study.~After the obtaining an interest from a practice member to whom the invitation email was sent, we will offer all practice members eligible for the study an information session during which the study is described and participation offered. The practice manager or lead will be provided with the Practice Information and Consent Form"
2920579|NCT03105622|Experimental|Running+screen|Running on a treadmill at 60% VO2peak for 30 minutes while watching television.
2920580|NCT03105622|Experimental|Running+music|Running on a treadmill at 60% VO2peak for 30 minutes while listening to music.
2920581|NCT03105622|Experimental|Running without stimulus (control condition)|Running on a treadmill at 60% VO2peak for 30 minutes with no other stimuli.
2920582|NCT03105609||Naive wet age-related macular degeneration|Patients recruited to the study will be patients who meet the Australian MBS criteria for treatment of exudative CNV with Lucentis. For the duration of the study, the patients will have standard induction and monthly dosing of Lucentis (Ranibizumab; intravitreal; 0.5 mg) to allow comparison with published studies. The only extra intervention for the study is the acquisition of hyperspectral mages with the hyperspectral camera and the acquisition of additional fundus autofluorescence images to the clinical norm.
2921884|NCT03096795|Experimental|MAD Cohort 3|Multiple doses of MEDI3506 or placebo
2920583|NCT03105596|Experimental|Chidamide plus DICE regimen|Chidamide combined with DICE (Dexamethasone, Ifosfamide, Cisplatin and Etoposide) regimen
2920584|NCT03105583||Pregnant women visiting the obstetrics department|
2920585|NCT03105570|Experimental|Areola sparing mastectomy.|Eligible patients undergo areola sparing mastectomy.
2920586|NCT03105544|Experimental|Intervention|Simulation-based training: Virtual-reality simulation training on the Medaphor Scantrainer Transabdominal Simulator until expert level is reached. Then training on a physical mannikin until an average OSAUS-score of 3 or more is attained.
2920587|NCT03105544|No Intervention|Control|No intervention.
2920588|NCT03105518|Experimental|Analgesia options|Protocolized analgesia based on VAS degree of discomfort and time. Analgesic options include heating pad, acetaminophen, percocet (oxycodone), fentanyl 0.5-1 mcg/kg.
2920589|NCT03105505|Active Comparator|Permethrin 5%|Contains permethrin 5% w/w (equivalent to 50 mg/g), formaldehyde solution 0.278% w/w and butylated hydroxytoluene (E321) 0.02% w/w.
2920590|NCT03105505|Active Comparator|Synthomycine 5%,|Contains chloramphenicol 5%.
2920591|NCT03105505|Active Comparator|Fusidic Acid 1%|Contains 1% w/w fusidic acid anhydrous (as the hemihydrates) and 0.011% w/w.
2920592|NCT03105492||Pregnant women|pregnant women seeking care at local prenatal testing clinics between 8 and 30 weeks gestational age
2920593|NCT03105479|Experimental|Part A / Cohort A|Subjects from 12 years to 18 years old (exclusive) will receive cadazolid 500 mg per day for 10 days. The dose may be adjusted based on the pharmacokinetic (PK) and safety data reviewed for the first 3 subjects.
2920594|NCT03105479|Experimental|Part A / Cohort B|Subjects from 6 years to 12 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort A reviewed by the Independent Data Monitoring Committee (IDMC).
2920595|NCT03105479|Experimental|Part A / Cohort C|Subjects from 2 years to 6 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort B reviewed by the IDMC.
2920596|NCT03105479|Experimental|Part A/ Cohort D|Subjects from 3 months to 2 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort C reviewed by the IDMC.
2920597|NCT03105479|Experimental|Part A/ Cohort E|Subjects from birth to 3 months old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort D reviewed by the IDMC.
2920598|NCT03105479|Experimental|Part B / Cadazolid|Subjects from birth to 18 years old (exclusive) will receive cadazolid for 10 days, at the dose defined in the corresponding age cohort in Part A.
2920599|NCT03105479|Active Comparator|Part B / Vancomycin|Subjects from birth to 18 years old (exclusive) will receive vancomycin for 10 days either as capsules (for subjects able to swallow) or oral solution (for the others) .
2920600|NCT03105466|Experimental|Acellular porcine cornea group|Participants with corneal diseases not involving the endothelial layer undergo deep anterior lamellar keratoplasty using acellular porcine cornea
2920601|NCT03105453||Study arm|Women in the study arm will undergo microbiome samplings described in the interventions section (3 sampling points)
2920602|NCT03105440|Experimental|Robotic rehabilitation|It Will be used a exoskeleton Armeo®Spring, to training to affected upper limb, the protocol of the treatment is constituted for 8 games. The equipment arm will be adjusted the volunteers height, in sitting position, allowing support against the action of gravity of the arm and forearm, supporting 45° of the shoulder flexion, which will be facilitation the member movement.
2920603|NCT03105440|Experimental|Virtual reality|"The software used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation Together with Federal University of Uberlândia. This virtual reality of projection software, which uses Kinact®, captures the patient's picture and transfers to the monitor. The exercises provided by game are similar to those performed in conventional therapy; however, in a more entertaining form.~Comprised 8 exercises to upper limbs and trunk. The patient should reach the red circle until it becomes green."
2920604|NCT03105440|Experimental|Vibration therapy|"The vibration mat used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation together with mark Vibra Ind. e Com. Prod. Electronics Ltda.~Will participate 20 woman, that stay in supine position, with the enveloped member of the vibration mat, elevated and supported. The volunteer will be submitted to 15 minutes of vibration with frequency of the 40 hertz, in both upper limbs."
2920605|NCT03105440|Experimental|Hand cycling|Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
2920606|NCT03105440|Experimental|Control group|Will participate 20 healthy woman, that won't pass to the treatment physiotherapeutic, only will be collected the electromyography and dynamometer.
2920607|NCT03105440|Experimental|Canoeing|Will participate 20 woman, submitted canoeing activates, through rowing realized in therapeutic pool, with the aid and supervision of the therapeutic. It is important highlight that the exercises intensity will be to realized according to the physical fatigue of patients.
2920608|NCT03105401||Patients affected by Parkinson's disease|Outpatients affected by Parkinson's Disease consulting in neurology can be included if volunteer
2920609|NCT03105375|Experimental|Single ascending dose of X842|Single ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
2920610|NCT03105375|Experimental|Multiple ascending dose of X842|Multiple ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
2920611|NCT03105375|Active Comparator|Losec|Standard oral dose of omeprazole administered to subjects in one cohort.
2920612|NCT03105362|Experimental|AA ORS arm|Patients will consume commercially amino acid based oral rehydration solution (enterade®).
2920613|NCT03105349|Experimental|Single arm|16 weeks treatment with elbasvir/grazoprevir plus sofosbuvir and ribavirina
2920614|NCT03105336|Experimental|axicabtagene ciloleucel|
2920649|NCT03105128|Experimental|Risankizumab Dose 1 (Period 2)|Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
2920650|NCT03105128|Experimental|Risankizumab Dose 1 (Period 1)|Subjects randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
2920615|NCT03105323||infertile women|All patients were pretreated with Gonadotropin releasing hormone agonist (decapeptyl®) 0.05 mg/day from 10 days prior to the start of menstruation. The patients'ovaries were stimulated with a recombinant follicle-stimulating hormone (FSH, subcutaneous) from day 2 of the menstrual cycle. human chorionic gonadotropin was administered when at least two follicles vary 18-22mm were observed on ultrasonography.Blood samples were collected on the day of final Human chorionic gonadotropin maturation, and serum P levels were measured.Pregnancy was defined by titers within 11 days following Embryo transfer,Clinical pregnancy was defined by the observation of intrauterine embryo heart motion by 7 weeks gestation.
2920616|NCT03105310|Active Comparator|Pegylated interferon|Pegylated interferon alfa alone 180 microgram subcutaneous weekly for 24 weeks
2920617|NCT03105310|Experimental|Pegylated interferon with ezetimibe|Pegylated interferon alfa 180 micro-gram subcutaneous weekly for 24 weeks and Ezetimibe 10 mg orally for 24 weeks
2920618|NCT03105297|Experimental|Prototype nasal dilator (All participants)|This study was a baseline-controlled study. This study consisted of four phases, Screening phase, baseline phase, and 28 days Active phase followed by a two-night cross-over Nasal resistance phase. All the participants slept in the sleep laboratory at Day 1 (Night 1) in baseline phase. Participants wore the Nasal dilator strip over a 1 month in-home use period (Active phase) and returned for sleep laboratory nights after 7 (Night 8) and 28 days (Night 29) of treatment. Participants then entered the Nasal resistance phase of the study, which consisted of two sleep laboratory nights at Day 29 and 30 (Night 30 and 31) separated by approximately two days where they were randomized to receive a sequence of either 'strip'/' no strip' or 'no strip'/'strip'.
2920619|NCT03105284|Active Comparator|Liposuction of fat|The intervention examined is the extraction method by liposuction.
2920620|NCT03105284|No Intervention|Excision of fat|Control group
2920621|NCT03105245|Active Comparator|Short time interval + Normal ventilation|
2920622|NCT03105245|Active Comparator|Short time interval + Hyperventilation|
2920623|NCT03105245|Active Comparator|Long time interval + Normal ventilation|
2920624|NCT03105245|Active Comparator|Long time interval + Hyperventilation|
2920625|NCT03105232||Group A|Morphin, Hydromorfon, Oxycodon
2920626|NCT03105232||Group B|Buprenorfin
2920627|NCT03105232||Group C|Fentanyl
2920628|NCT03105232||Group D|Opioid rotation
2920629|NCT03105219|Experimental|Ivabradine|Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
2920630|NCT03105219|Sham Comparator|Sham Comparator|Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
2920631|NCT03105206||Low Pole Renal Calculus|patients with low pole renal calculus who are suitable to treat by flexible ureteroscopy
2920632|NCT03105193|Experimental|Intraperitoneal Lignocaine|IP Lignocaine
2920633|NCT03105193|Experimental|Intravenous lignocaine|IV lignocaine
2920634|NCT03105180||0% dilution|Blood specimen which was diluted with 0% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
2920635|NCT03105180||10% dilution|Blood specimen which was diluted with 10% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
2920636|NCT03105180||20% dilution|Blood specimen which was diluted with 20% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
2920637|NCT03105180||40% dilution|Blood specimen which was diluted with 40% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
2920638|NCT03105167|Experimental|CBT-TLIF group|Patients who are randomised to the CBT-TLIF group will have cortical bone trajectory screws instead of pedicle screws During the opreation. After preventive use of antibliotics,A small skin incision was made at the fused segment, an entry point for insertion of the CBT screws was drilled in the junction of the center of the superior articular process and 1 mm inferior to the inferior border of the transverse process according to Matsukawa et al.A straight probe was used to create a trajectory for the CBT screws from the entry point to the opposite corner of the pedicle and vertebral body under anteroposterior fluoroscopic guidance.nilateral facetectomy is performed to gain access to the intervertebral disc.Afterwards, interbody fusion was performed.Device: CBT screws.
2920639|NCT03105167|Experimental|PS-TLIF group|Patients who are randomised to the PS-TLIF group will have pedicle screws During the opreation. A posterior midline incision, about 6 cm, was performed at the level of interest level under fluoroscopic guidance. Pedicle screws were inserted into the vertebral body by using freehand, and the inferior and superior articular processes and part pf the lamina were removed by using an osteotome. To expose the lateral border of the ipsilateral nerve root, the ligamentum flavum was removed. Afterwards, interbody fusion was performed.Device:traditional pedicle screws.
2920640|NCT03105154|Experimental|Prevena Dressing|Groin dressed with Prevena
2920641|NCT03105154|Active Comparator|Conventional Dressing|Groin dressed with conventional bandage
2920642|NCT03105141|Experimental|RIC substudy 1|A total of 120 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg or 40 mmHg above systolic pressure) twice daily for 12 months.
2920643|NCT03105141|Experimental|RIC substudy 2|A total of 180 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) twice daily for 12 months.
2920644|NCT03105141|Experimental|RIC substudy 3|A total of 180 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) twice daily for 12 months.
2920645|NCT03105141|Experimental|RIC substudy 4|A total of 120 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) once or twice daily for 12 months.
2920646|NCT03105128|Experimental|Risankizumab Dose 3 (Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
2920647|NCT03105128|Placebo Comparator|Placebo (Period 1)|Subjects randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
2920648|NCT03105128|Experimental|Risankizumab Dose 2 (Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
2920651|NCT03105128|Experimental|Risankizumab Dose 2 (Period 1)|Subjects randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.
2920652|NCT03105115|Active Comparator|intrathecal fentanyl|heavy bupivacaine 14mg and fentanyl 20mcg will be injected intrathecally during spinal anesthesia
2920653|NCT03105115|Experimental|bupivacaine only|heavy bupivacaine 14mg will be injected intrathecally during spinal anesthesia
2920654|NCT03105102|Placebo Comparator|Double-blind Placebo for Risankizumab (Sub-Study 1)|Participants randomized to receive double-blind placebo for risankizumab for 52 weeks.
2920655|NCT03105102|Experimental|Open-label Risankizumab (Sub-Study 3)|Participants who completed Sub-study 1 or Sub-study 2 or Study M15-989 will receive open-label risankizumab beginning at Week 56.
2920656|NCT03105102|Experimental|Double-blind Risankizumab Dose 2 (Sub-Study 1)|Participants randomized to receive double-blind risankizumab dose 2 for 52 weeks.
2920657|NCT03105102|Experimental|Maintenance Risankizumab Dose 1 (Sub-Study 2)|Participants randomized to receive 1 dose of double-blind risankizumab dose 1 followed by open-label risankizumab for 52 weeks.
2920658|NCT03105102|Experimental|Double-blind Risankizumab Dose 1 (Sub-Study 1)|Participants randomized to receive double-blind risankizumab dose 1 for 52 weeks.
2920659|NCT03105102|Experimental|Maintenance Risankizumab Dose 2 (Sub-Study 2)|Participants randomized to receive 1 dose of double-blind risankizumab dose 2 followed by open-label risankizumab for 52 weeks.
2920660|NCT03105089|Active Comparator|ischemic preconditioning|ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
2920661|NCT03105089|No Intervention|control|no intervention will be done
2920662|NCT03105076|Experimental|DAs group|Shared decision making using decision aids
2920663|NCT03105076|No Intervention|Control group|Standard oral explanation guided with booklets
2920664|NCT03105063|Experimental|US GROUP|All patients will first undergo ultrasound scan of the hip in attempt to recognize the AIIS, on the same day , the true morphology of the AIIS will be evaluated using 3d imaging
2920665|NCT03105050||Countries in Europe|All 51 countries will fill out their unique data on access to bariatric surgery in Europe
2920666|NCT03105037||control|No supraglottic airway in situ
2920667|NCT03105037||SGA|supraglottic airway in situ
2920668|NCT03105024|Experimental|Exposure + self-efficacy enhancement|After the virtual exposure session, participants will receive instructions to recall the exposure session with a focus on the personal mastery experiences/achievements made during exposure.
2920669|NCT03105024|Active Comparator|Exposure + control intervention|After the virtual exposure session, participants will receive instructions to recall the exposure session
2920670|NCT03105024|No Intervention|Exposure only|Treatment as usual: no intervention after the exposure session will be given.
2920671|NCT03105011|Experimental|EpxDiabetes software|Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes).
2920672|NCT03104998|Other|coenzyme Q10|Dose of 200 mg of CoQ10 taken daily by mouth from day 1 till 26 weeks
2920673|NCT03104985|Active Comparator|Group 1|"Conventional treatment only.~An elastic compression of lower extremities: elastic bandages or compression hosiery of class 2~Pharmacotherapy: Anavenol, Aescusan, Glyvenol; drugs of the Benzopyrone group, including Troxevasin and Venoruton. Trental, Aspirin and Ticlid (Ticlopidine). Nonsteroidal anti-inflammatory drugs (Nimesil, OKI), various ointments containing Heparin, corticosteroids, as well as nonsteroidal anti-inflammatory drugs. Antibiotic therapy.~Topical treatment: in the presence of purulent discharge (phase I of the wound healing process) - bandaging with antiseptic solutions (1% Iodopiron solution, 0.1% Chlorhexidine solution) and hydrophilic ointments (Levosin, Levomecol). In phases II and III - after ulcer cleansing the preparations based on Hyaluronic acid (Curiozin)."
2920674|NCT03104985|Experimental|Group 2|"Conventional therapy and combined LLLT (LASMIK device) was performed. External exposure was conducted on the 1-4 affected area during one session for 2 minutes per zone in pulsed mode, light pulse duration - 100-130ns, wavelength - 635nm, by a matrix emitter consisting of eight laser diodes with a surface area of 8cm2, at a distance of up to 7cm, with pulsed power of 40W. ILBI was conducted in continuous mode with wavelength between 365-405nm (UV-spectrum) and 520-525nm (green spectrum) alternately, during 12 daily treatment sessions according to the scheme:~- 365-405nm, power 1-2mW, exposure 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min"
2920675|NCT03104972|Experimental|tDCS - placebo|tDCS-placebo (sham) group to receive either transcranial direct stimulation (tDCS) or matching placebo (sham( during 5 following days (one session each day). After a one week break, there will be a crossover between the control group and the sham group: those we received tDCS in the 1st week will get sham, while those who received sham in the 1st week will received tDCS at the 3rd week.
2920676|NCT03104972|Experimental|tRNS - placebo|trans cranial random stimulation (tRNS)-sham group, who will receive the same type of intervention with the same intervals as above but with tRNS instead of tDCS.
2920677|NCT03104972|Experimental|tDCS-tRNS|tDCS-tRNS group. Here the same intervention as above will be provided with the same intervals, but real tDCS and real tRNS will be provided in a counterbalanced fashion. This would allow to compare the different treatment in a within-subject design, as well as to compare the effect of those to sham stimulation in the first two groups in a between-subject design.
2920678|NCT03104959|Placebo Comparator|Placebo|Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take placebo capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
2920679|NCT03104959|Experimental|N-acetyl cysteine|Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take N-Acetyl Cysteine capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
2920680|NCT03104946||Bronchopulmonary Dysplasia|
2920681|NCT03104946||Retinopathy|
2920682|NCT03104946||Severe Retinopathy|
2920683|NCT03104946||Neonatal Necrotizing Enterocolitis|
2920684|NCT03104946||Brain injury|
2920685|NCT03104946||sepsis|
2920686|NCT03104946||Patent Ductus Arteriosus|
2920689|NCT03104920|Experimental|ERAS program|We give an ERAS pathway, which comprises of optimized management of diet, mobilization, analgesia and GI function recovery for patients with HCC.
2920690|NCT03104920|Active Comparator|Traditional treatment|We give routine clinic practices for the treatment of HCC.
2920691|NCT03104907|Experimental|Prostatic Artery Embolization|Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
2920692|NCT03104894|Experimental|Study Group|The study group will receive meibomian glands massage and artificial drops PRN
2920693|NCT03104894|Sham Comparator|Control Group|The control group will receive sham meibomian glands massage and artificial drops PRN.
2920694|NCT03104881|Experimental|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
2920695|NCT03104881|Experimental|2D end-effector type robot|2 dimension end-effector type upper extremity robot
2920696|NCT03104868|No Intervention|Usual Care|Patients in this group will receive the usual standard of care.
2920697|NCT03104868|Experimental|Intervention|Patients in this group will receive the TAKE IT strategy components.
2920698|NCT03104855|Experimental|Single pharmacokinetics arm|
2920699|NCT03104842|Experimental|Arm A Transplantation|Patients ≤ 70 years of age and eligible for stem cell transplantation will enter study arm A They will undergo 6 cycles of Condolidation Treatment : Carfilzomin, Lenalidomid, Isatuximab (I-KRd), after intesification 4 cycles of I-KRd will be followed by IKR maintenance util pD or Toxicity
2920700|NCT03104842|Experimental|Arm B No-Transplantation|patients > 70 years or ineligible for stem cell transplantation will enter study arm B They will undergo 12 cycles of Condolidation Treatment : Carfilzomin, Lenalidomid, Isatuximab (I-KRd),to be followed by I-KR maintenance util PD or Toxicity
2920701|NCT03104829|Active Comparator|DSME|participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later
2920702|NCT03104829|Experimental|DSME+MI|participants in this arm will receive standard care for diabetes plus motivation interviewing (MI) sessions at the beginning of the study and 3 months later, will also receive motivation interviewing sessions by phone at 1, 2, 4, 5 month after the beginning of the study
2920703|NCT03104816|Experimental|Acetaminophen IV Soln 10 MG/ML (A)|Patients in group A will receive 1 g of IV acetaminophen 15 minutes prior to wound incision, and every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours.
2920704|NCT03104816|Experimental|PO acetaminophen (B)|Patients in group B will receive 1 g of PO acetaminophen prior to surgery, and 1 g of oral acetaminophen every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours.
2920705|NCT03104816|Active Comparator|Hydromorphone (control arm) (C)|Patients in the control arm (Group C) will not receive acetaminophen for 24 hours.
2920706|NCT03104803|Experimental|Long-term PAS|The intervention is given to one hand only
2920707|NCT03104803|No Intervention|No intervention|Contralateral hand of the same patient
2920708|NCT03104790|Experimental|naive|Children who have never received any influenza vaccine (The two groups are defined by immunisation history, all receive the same intervention in the study)
2920709|NCT03104790|Experimental|prior vaccinees|Children who have received at least two doses of Fluenz Tetra previously (The two groups are defined by immunisation history, all receive the same intervention in the study)
2920710|NCT03104777|No Intervention|Control Group|No intervention materials will be distributed in the control schools during the intervention period.
2920711|NCT03104777|Experimental|Intervention Group|Intervention materials will be distributed to parents of children in years 3 - 6.
2920712|NCT03104764|Active Comparator|Scalpel|Frenotomy performed with conventional scalpel
2920713|NCT03104764|Experimental|Er:YAG laser|Frenotomy performed with Er:YAG laser
2920714|NCT03104751||Infants with Complex Congenital Heart Defect|Infants diagnosed a Complex Congenital Heart Defect
2920715|NCT03104751||Comparison/Healthy Infants|Infants born without genetic syndromes or cardiac condition.
2920716|NCT03104738|No Intervention|50% reduction of basal insulin dose|This is the institutional standard of care. The evening before surgery, 20 subjects will reduce their basal insulin dose to 50%.
2920717|NCT03104738|Experimental|25% reduction of basal insulin dose|The evening before surgery, 20 subjects will reduce their basal insulin dose to 25%.
2920718|NCT03104712|Other|Glucose #1|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
2920719|NCT03104712|Active Comparator|Spaghetti|50 grams of available carbohydrate from spaghetti will be cooked according to package instructions and consumed as a test meal
2920720|NCT03104712|Active Comparator|Rice|50 grams of available carbohydrate from white rice will be cooked according to package instructions and consumed as a test meal
2920721|NCT03104712|Active Comparator|Spaghetti + tomato sauce|50 grams of available carbohydrate from spaghetti plus tomato sauce (1:1 ratio) will be cooked according to package instructions and consumed as a test meal
2920722|NCT03104712|Active Comparator|Rice + tomato sauce|50 grams of available carbohydrate from white rice plus tomato sauce (1:1 ratio) will be cooked according to package instructions and consumed as a test meal
2920723|NCT03104712|Active Comparator|Spaghetti + Pesto|50 grams of available carbohydrate from spaghetti plus pesto sauce (1:0.5 ratio) will be cooked according to package instructions and consumed as a test meal
2920724|NCT03104712|Active Comparator|Rice + Pesto|50 grams of available carbohydrate from white rice plus pesto sauce (1:0.5 ratio) will be cooked according to package instructions and consumed as a test meal
2920725|NCT03104712|Other|Glucose #2|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
2920726|NCT03104712|Other|Glucose #3|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
2920727|NCT03104699|Experimental|AGEN2034|anti-PD-1 antibody
2920728|NCT03104686|Active Comparator|Bread|Bread (50g available carbohydrate, ~122g) eaten with 500 mL of water
2920729|NCT03104686|Experimental|Short pasta (dry)|Cooked penne (142 g) eaten with 500 mL of water
2920730|NCT03104686|Experimental|Long pasta (dry)|Cooked spaghetti (142 g) eaten with 500 mL of water
2920731|NCT03104686|Active Comparator|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
2920732|NCT03104660|Experimental|CE certified mitral valve repair systems|CE certified transcatheter mitral valve repair systems
2920733|NCT03104647|Experimental|VRP-Clinic|VRP-Clinic software on a virtual reality platform
2920734|NCT03104634|Experimental|Active arm|Aclidinium bromide/formoterol fumarate dihydrate 400 mcg/12 mcg Twice daily (once in the morning, once in the evening) 7-days
2920735|NCT03104634|Placebo Comparator|Placebo arm|Placebo Twice daily (once in the morning, once in the evening) 7-days
2920736|NCT03104621|Experimental|Group 1|Group 1, for the first 6 months, the subjects of group 1 used non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) and then changed to 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product (Taflotan®)for 6 months.
2920737|NCT03104621|Experimental|Group 2|Group 2, for the first 6 months, the subjects of group 2 used 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product(Taflotan®) and then changed to non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) for 6 months.
2920738|NCT03104608|Active Comparator|Automatic Self Transcending Meditation|Participants in the ASTM group will undergo training in groups of 10 by certified teachers. Further, the following self-rated scales will be administered by a trained rater at the fourth ASTM session (week 0) as well as at weeks 4, 8, 12, and 24: Time Trade-off (TTO), Visual Function Questionnaire (VFQ-25), the Patient Health Questionnaire (PHQ-9), and Generalized Anxiety Disorder (GAD-7).
2920739|NCT03104608|Placebo Comparator|Treatment as Usual|Participants will continue to receive their treatment as usual. The following self-rated scales will be administered by a trained rater at weeks 0, 4, 8, 12 and 24: TTO, VFQ-25, PHQ-9, and GAD-7.
2920740|NCT03104595|Experimental|Cohort 1|EC-18 500 mg
2920741|NCT03104595|Experimental|Cohort 2|EC-18 1000 mg
2920742|NCT03104595|Experimental|Cohort 3|EC-18 1500 mg
2920743|NCT03104595|Experimental|Cohort 4|EC-18 2000 mg
2920744|NCT03104582|Experimental|Biliary drainage 1|Patients with advanced hilar cholangiocarcinoma need biliary drainage performed Endoscopic Retrograde Cholangiopancreatography (ERCP) drainage
2920745|NCT03104582|Active Comparator|Biliary drainage 2|Patients with advanced hilar cholangiocarcinoma need biliary drainage performed percutaneous transhepatic biliary drainage(PTBD) drainage
2920746|NCT03104569|Experimental|Injection of 37℃ contrast agent|Nonionic contrast agent is heated to 37℃ during ERCP when injection of contrast agent
2920747|NCT03104569|No Intervention|Injection of normal contrast agent|Normal temperature nonionic contrast agent can be used in ERCP when injection of contrast agent
2920748|NCT03104543|Experimental|Education|Educational materials
2920749|NCT03104543|Active Comparator|Test results|Test results only; with delayed access to the experimental materials
2920750|NCT03104530||Brown crabmeat consumers|Those habitually consuming 40 grams or more of brown crab meat each week.
2920751|NCT03104530||Control|Those consuming less than 40 grams of brown crabmeat a year, or no brown crabmeat.
2920752|NCT03104517|Experimental|AMDC-USR|AMDC-USR is the study product (autologous muscle derived cells for urinary sphincter repair).
2920753|NCT03104517|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
2920754|NCT03104504|No Intervention|No Intervention|Baseline Retrospective Chart Reviews that are conducted on subjects for the one year period prior to the implementation of the study will serve as the control.
2920755|NCT03104504|Other|Intervention|"The intervention targets will be the following suicide-related clinician behaviors.~suicide risk screening~safety planning~means restriction counseling~Post-acute care follow-up calls A Lean Implementation Strategy: The Implementation of the intervention targets guided by Lean; is expected to increase suicide-related clinician behaviors"
2920756|NCT03104491|Experimental|Inotuzumab Ozogamicin|Subjects will be assessed for safety and tolerability (including adverse events, serious adverse events, and clinical/laboratory assessments) using a continuous monitoring approach.
2920757|NCT03104465|Experimental|Mindfulness training|6 90-minute sessions interactive, web-based mindfulness training complemented with mobile application
2920758|NCT03104452||Pregnant Smokers|Participants are pregnant women who smoked in the six months prior to their pregnancy.
2920759|NCT03104439|Experimental|Nivolumab+Ipilimumab|"Nivolumab will be administered intravenously 3 times per cycle~Ipilimumab will be administered intravenously once per cycle~Radiation Therapy will be administered per hospital standard"
2920760|NCT03104426|Active Comparator|Darbepoetin alfa group|Group treated with darbepoetin alfa (Aranesp) 10microg/kg once a week for a period of 8 weeks.
2920761|NCT03104426|No Intervention|Control group|"Standard care which involves close monitoring of hemoglobin levels and if necessary, top-up red cell transfusion."
2920762|NCT03104413|Experimental|Risankizumab Dose 2 (Induction Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
2920763|NCT03104413|Experimental|Risankizumab dose 3 (Induction period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
2920764|NCT03104413|Experimental|Risankizumab Dose 2 (Induction Period 1)|Subjects randomized to receive risankizumab dose 2 in Induction Period 1
2920765|NCT03104413|Experimental|Risankizumab Dose 1 (Induction Period 2)|Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
2920766|NCT03104413|Experimental|Risankizumab Dose 1 (Induction Period 1)|Subjects randomized to receive risankizumab dose 1 in Induction Period 1.
2920767|NCT03104413|Placebo Comparator|Placebo (Induction Period 1)|Subjects randomized to receive placebo for risankizumab in Induction Period 1.
2920768|NCT03104400|Placebo Comparator|Placebo followed by ABT-494 Dose B|It is administered once daily.
2920769|NCT03104400|Active Comparator|Adalimumab|It is administered subcutaneously once every two weeks
2920770|NCT03104400|Experimental|ABT-494 Dose B|It is administered once daily.
2920771|NCT03104400|Placebo Comparator|Placebo followed by ABT-494 Dose A|It is administered once daily.
2920772|NCT03104400|Experimental|ABT-494 Dose A|It is administered once daily.
2920875|NCT03103737|No Intervention|Control|Participants receive the medical treatment deliver by the hospital. After one week, they have the possibility to receive the psychological intervention.
2920773|NCT03104387|Experimental|Diesel train - exposure scenario|"The same study person will be exposed to two different scenarios, at different times and for three consecutive days. It will be a lag time of 2 weeks between each exposure scenario. The exposure scenario is defined as a workday (6 hours) on the diesel ME-driven model regional train. The Diesel Train Scenario is performed twice. After the scenario completion (on the third day in defined train routes) the vascular function, lung function, blood and urine samplings are performed."
2920774|NCT03104387|Sham Comparator|Electric train - low exposure scenario|"The same study person will be exposed to two different scenarios, at different times and for three consecutive days. It will be a lag time of 2 weeks between each exposure scenario. The low exposure scenario is defined as a workday (6 hours) on the electric train. The Diesel Train Scenario is performed twice. After the scenario completion (on the third day in defined train routes) the vascular function, lung function, blood and urine samplings are performed."
2920775|NCT03104374|Experimental|ABT-494 Dose A|It is administered once daily.
2920776|NCT03104374|Placebo Comparator|Placebo followed by ABT-494 Dose B|It is administered once daily.
2920777|NCT03104374|Experimental|ABT-494 Dose B|It is administered once daily.
2920778|NCT03104374|Placebo Comparator|Placebo followed by ABT-494 Dose A|It is administered once daily.
2920779|NCT03104361|Experimental|Platelet-rich plasma treatment arm|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
2920780|NCT03104348|Other|COPD screening|
2920781|NCT03104335|Experimental|Study arm|every participant will recieve 750 mg daily once oral administration of apatinib for body surface area (BSA) > 1.5 and 500mg daily for BSA <1.5. Half an hour after meal and everyday at the same time is usually advised.
2920782|NCT03104322|Other|Observation sequence|Period 1: patientMpower platform+usual care for 8 weeks; Period 2: usual care alone for 8 weeks
2920783|NCT03104309|Other|Levonorgestrel intrauterine system|
2920784|NCT03104283|Experimental|Apatinib Group|take apatinib orally (425mg/d, once a day, continuously )
2920785|NCT03104270|Experimental|Elo Pom Car and Dex|"Drug dosing and administration:~All drugs are administered on a 28-day cycle.~Elotuzumab: 10 mg/kg IV on Days 1,8,15 and 22 Cycles 1 and 2 and Days 1 and 15 Cycles 3 and beyond.~Pomalidomide: 3 mg PO on days 1-21~Carfilzomib: 20 mg/m2 IV on days 1 and 2 of cycle 1. 56 mg/m2 IV on days 8 and 15 of cycle 1 and Days 1, 8 and 15 of the remaining seven cycles.~Dexamethasone: Pre-treatment with 28 mg PO 3-24 hours prior to the start of ELO on days 1,8,15 and 22 of Cycle 1 and 2 and 8mg IV 45-90 minutes prior to the start of ELO Pre-treatment with 28 mg PO on days 1 and 15 and 40 mg PO on days 8 and 22 of Cycle 3 and beyond. On Days 2 of Cycle 1, 4 mg IV at least 30 min and no more than 4 hours prior to the start of CFZ."
2920786|NCT03104257||Cannabis Dependent Subjects|Subjects who are frequent cannabis users
2920787|NCT03104257||Healthy Controls|Subjects with no current cannabis use
2920788|NCT03104244||Youth Football|5th and 6th grade tackle football players will be enrolled in 2016. They will be followed as a cohort, participating in the study each year they play tackle football, through 8th grade. Total enrollment is expected to reach 70 players.
2920789|NCT03104244||High School Football|Varsity football players from Brighton High School are eligible for the study in each year of the study. The varsity team consists of approximately 80 players. Total enrollment in this group is expected to reach 200 subjects; 80 the first year with 40 additional enrolled each subsequent year of the study.
2920790|NCT03104231|Experimental|study group|All the patients will be shown three-dimensional (3D) movie.
2920791|NCT03104218|Experimental|tDCS group|tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training). The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles), contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
2920792|NCT03104218|Sham Comparator|Placebo group|"The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition. The parameters on the tDCS will be set-up by a research assistant before each session. The treating physiotherapist will not have access to the control board of the tDCS."
2920793|NCT03104205|Experimental|Evaluate home-based MOWI|Conduct and assess the feasibility, acceptability, and potential effectiveness of home-based MOWI in improving physical function.
2920794|NCT03104192|Active Comparator|Develop & Refine MOWI w/o Amulet|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults without the use of Amulet technology.
2920795|NCT03104192|Experimental|Develop & Refine MOWI w Amulet|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults with the use of Amulet and Fitbit technology.
2920796|NCT03104192|Experimental|MOWI Weight Loss Maintenance|Evaluate the feasibility, acceptability, and potential effectiveness of an 8-session, tri-weekly, psychosocial skills group intervention to support weight loss maintenance post-MOWI.
2920797|NCT03104192|Active Comparator|Develop & Refine MOWI w Amulet/Protein|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults with the use of Amulet and Fitbit technology augmented by whey protein.
2920798|NCT03104192|Active Comparator|Develop & Refine MOWI w Fitbit|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults with the use of Fitbit technology.
2920799|NCT03104192|Active Comparator|Develop & Refine MOWI w Fitbit/Protein|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults with the use of Fitbit technology augmented by whey protein.
2920800|NCT03104179|Experimental|Treatment|CPB with Cytosorb
2920801|NCT03104179|No Intervention|Control|CPB without Cytosorb (Control)
2920802|NCT03104166|Experimental|MCO|Patients will be treated thrice weekly with Medium Cut-Off Dialysis membranes.
2920803|NCT03104166|Active Comparator|High-Flux|Patients will be treated thrice weekly with High-Flux Dialysis membranes.
2920804|NCT03104153|No Intervention|Output-based|
2920806|NCT03104140|Experimental|Ketamine group|This group of patients will receive: 1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
2920807|NCT03104140|Active Comparator|Thiopental group|2 mg/Kg thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
2920808|NCT03104127|Experimental|Alter G Bionic Leg|Participants randomised to a group including normal therapy (physiotherapy) and the use of a Alter G robotic bionic leg. All participants have previously completed normal NHS therapy.
2920809|NCT03104127|Active Comparator|Normal therapy|Participants randomised to a group including normal therapy (physiotherapy) only. All participants have previously completed normal NHS therapy.
2920810|NCT03104127|No Intervention|Usual care|Have completed normal NHS therapy and no longer (> 6 months) receive active physiotherapy.
2920811|NCT03104114|Placebo Comparator|Historical Control|Pharmacy care was standard, high-touch model where an institutional specialty pharmacy contact patients via telephone. Standard adherence and counseling was offered over the phone to patients.
2920812|NCT03104114|Experimental|Pharmacist-intervention|In-person counseling with a clinical pharmacist prior and during treatment with an oral oncology medication. Patients meet with a clinical pharmacist prior, at month 3 and month 6 during the study.
2920813|NCT03104101|Active Comparator|TPTNS|Those who received Transcutaneous posterior tibial nerve stimulation sessions only
2920814|NCT03104101|Active Comparator|TPTNS+Drug|Those who received Transcutaneous posterior tibial nerve stimulation sessions plus 20 mg Trospium chloride
2920815|NCT03104088||SPG4 patients|
2920816|NCT03104088||Healthy controls|
2920817|NCT03104075|Active Comparator|Prevnar 13|Prevnar 13 (Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein) will be administered at the single 0.5 ml dose, by intramuscular injection with routine clinical care.
2920818|NCT03104075|Active Comparator|Pneumovax 23|Pneumovax 23 (Pneumococcal Vaccine Polyvalent) will be administered at the single 0.5ml dose, by intramuscular injection with routine clinical care.
2920819|NCT03104062|Other|Ticagrelor|Patients will be randomized to have Ticagrelor 90mg BID
2920820|NCT03104062|Other|Clopidogrel|Patientes will be randomized to have Clopidogrel 75mg once a day
2920821|NCT03104049|Active Comparator|the PD NMT Group|the NMT Group were treated with NMT
2920822|NCT03104049|No Intervention|The PD Group without NMT|The patients received only their usual pharmacological PD therapy
2920823|NCT03104036|Active Comparator|Mesalazine enema|Will be treated with 4 g mesalazine enema 1x daily for 2 weeks, then every other day until the end of the 6th week.
2920824|NCT03104036|Experimental|Faecal bacterial transplantation enema|Will be applied enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline, the 1st week 5 times, than one time a week until the end of the 6th week.
2920825|NCT03104023|Active Comparator|Staple line inversion|Patients will undergo a staple line inversion with a a running suture of Polypropylene 2/0.
2920826|NCT03104023|Experimental|Staple line buttressing|The gastric section will be performed with preloaded buttress material .
2920827|NCT03104010|Experimental|PEG-rhGH-1|Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The first stage, 1-2mg/2-4mg, subcutaneous injection,weekly, 26 weeks.
2920828|NCT03104010|Experimental|PEG-rhGH-2|Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The second stage (extension period study), maximum ≤4mg/w (24IU/w), 52 weeks.
2920829|NCT03103997|Active Comparator|New Needle|EUS-guided liver biopsy with needle and suction, no preparation
2920830|NCT03103997|Experimental|Dry Heparin|EUS-guided liver biopsy with needle flushed with heparin, then flushed with air, suction then attached
2920831|NCT03103997|Experimental|Wet Heparin|EUS-guided liver biopsy with needle flushed with heparin, 2 cc of liquid added to suction then attached.
2920832|NCT03103984|Experimental|Control|The volunteers (overweight and obese) will receive nutritional counseling and a weight loss diet.
2920833|NCT03103984|Experimental|Immunosuppressed patients|The volunteers (liver transplantation) will receive nutritional counseling and a weight loss diet.
2920834|NCT03103971|Experimental|Treatment (leukapheresis, chemotherapy, huJCAR014)|Patients undergo leukapheresis. Beginning 14-16 days after leukapheresis, patients undergo lymphodepleting chemotherapy comprising either cyclophosphamide IV daily for 1 day and fludarabine IV daily for 3 days or cyclophosphamide and fludarabine IV daily for 3 days. Within 36-96 hours after completion of lymphodepleting chemotherapy, patients receive huJCAR014 IV over 20-30 minutes on day 0.
2920835|NCT03103958|Active Comparator|probiotic|Probiotic consists of Lactobacillus acidophilus NCFM, Lactobacillus rhamnosus HN001, Lactobacillus paracasei LPC-37 and Bifidobacterium lactis HN019 (Probiatop), Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
2920836|NCT03103958|Placebo Comparator|Placebo|Placebo consists of maltodextrin. Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
2920837|NCT03103945||Patients with cardiac arrhythmias undergoing RF ablation|Patients with cardiac arrhythmias will be undergoing RF ablation using the Niobe Remote Magnetic Navigation System with CDS as their standard of care. System performance data will only be collected during the RF ablation procedure. Outcome measures will be evaluated with the CDS connected and without the CDS connected within all patients.
2920838|NCT03103932|No Intervention|Usual care|Participants will be treated as is usual at each institution. Biomarkers will be measured on Day 2-3 and again prior to discharge from hospital. NTproBNP levels will not be revealed to care providers.
2920876|NCT03103724|Experimental|Enzalutamide|All subjects will receive open label enzalutamide 160 mg (4 x 40 mg capsules), orally once daily.
2921055|NCT03102567|Placebo Comparator|placebo|oral hard gelatin capsules containing placebo for q.d. administration
2920839|NCT03103932|Experimental|Biomarker guided discharge pathway|Admission NTproBNP levels will be used to stratify participants into lower and medium-higher risk care pathways. NTproBNP levels will be repeated on Day 2-3 and again prior to discharge. Each care pathway is designed to optimize discharge time according to NTproBNP levels. All NTproBNP results will be displayed on the front of the participant's chart along with the care pathway that the participant has been randomized to. The care providers will be reminded daily by the study team that the participant is in the biomarker guided discharge pathway arm of the study and that the designated care pathway should be followed as closely as possible.
2920840|NCT03103919|Active Comparator|Rotigotine + Standard Care|Subjects will use the Kinesia-ONE™ wearable device in-clinic at Visit 1 and Visit 2 for recording of specific motor symptoms. The optimal dose of Neupro for any given subject will be determined by standard clinical practice.
2920841|NCT03103919|Experimental|Rotigotine + Standard Care + Kinesia-360™ wearable device|Subjects will use the Kinesia-ONE™ wearable device in-clinic at Visit 1 and Visit 2 for recording of specific motor symptoms, and additionally subjects will use the Kinesia-360™ wearable device at home while awake for continuous measurement of motor symptoms. The Investigator will use these symptom data to provide feedback to subjects on their motor symptoms and to supplement standard of care to titrate the optimal dose of Neupro for any given subject.
2920842|NCT03103906|Experimental|Group 1 (Test Product)|Participants will apply test product (approximately 0.6-1 grams (g)) to full face topically twice daily (morning and evening) after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.
2920843|NCT03103906|Other|Group 2 (No Treatment)|Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Participants will massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.
2920844|NCT03103893|Experimental|Rapamycin|Rapamycin
2920845|NCT03103880|Experimental|Medication Adherence and Pulmonary Function Tests|
2920846|NCT03103880|Experimental|Medication Adherence and Peak Flow Measurements|
2920847|NCT03103867|Experimental|CGM augmented pump with PLGS (A)|Administration of Subcutaneous administration of Continuous subcutaneous insulin infusion with integrated continuous glucose monitoring and predicted low glucose suspense (PLGS) Randomised cross over treatment during 5 weeks
2920848|NCT03103867|Active Comparator|Insulin pump with CGM (B)|Administration of Subcutaneous administration of Continuous subcutaneous insulin infusion with second device measuring continuous glucose Randomised cross over treatment during 5 weeks
2920849|NCT03103854|Active Comparator|Control|"Patients in the Control arm of the study performed Moderate Intensity Continuous Training (MICT) and did not receive text message reminders."
2920850|NCT03103854|Experimental|BURST|"Patients in the BURST arm of the study performed BURST physical activity and did not receive text message reminders"
2920851|NCT03103854|Experimental|Text Message Reminders|"Patients in the Text Message Reminders arm of the study performed Moderate Intensity Continuous Training and received text message reminders."
2920852|NCT03103854|Experimental|BURST and Text Message Reminders|"Patients in the BURST and Text Message Reminders arm of the study performed Burst physical activity and received text message reminders"
2920853|NCT03103841||Children and young people with epilepsy|Sleep studies [Polysomnography] to assess presence and severity of obstructive sleep apnoea in children with epilepsy compared with a healthy control group
2920854|NCT03103841||Healthy controls|Sleep studies [Polysomnography] to assess presence and severity of obstructive sleep apnoea in children with epilepsy compared with a healthy control group
2920855|NCT03103828|Active Comparator|Computer-tailored intervention|
2920856|NCT03103828|Active Comparator|Motivational Interviewing|
2920857|NCT03103828|Active Comparator|Motivational Enhancement Therapy|
2920858|NCT03103828|No Intervention|Control Group|
2920859|NCT03103815|Experimental|experimental group|Experimental group will receive Amivita.
2920860|NCT03103802|Experimental|Intra-oral scanning|
2920861|NCT03103802|Experimental|extra-oral scanning of the plaster model obtained via alginate|
2920862|NCT03103802|Experimental|extra-oral scanning of plaster model obtained via rubber base|
2920863|NCT03103802|Experimental|extra-oral scanning of the rubber base impression|
2920864|NCT03103802|Experimental|extra-oral scanning of the alginate impression|
2920865|NCT03103789||GERD patients|Patients who are undergoing standard of care EGD with or without BRAVO pH capsule placement and have been diagnosed with GERD will have mucosal impedance measured by single catheter and balloon assembly.
2920866|NCT03103789||control|Patients who are undergoing standard of care EGD with or without BRAVO pH capsule placement will have mucosal impedance measured by single catheter and balloon assembly.
2920867|NCT03103776|Other|Patients who have Graves disease|
2920868|NCT03103776|Other|Patients having a goiter|
2920869|NCT03103763||Aged 90 and older|Subjects 90 years and older with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
2920870|NCT03103763||Aged 80-89|Subjects aged 80-89 with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
2920871|NCT03103763||Aged 70-79|Subjects aged 70-79 with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
2920872|NCT03103750|Experimental|Calcitriol then placebo|Healthy volunteers will receive a baseline MRI. On the night before, and day of testing subjects will receive two doses of calcitriol or placebo, followed by Raclopride injection & PET Scan #1. A minimum of six days later, subjects will receive a Dexedrine Dose followed by a second Racloporide injection and PET scan #2.
2920873|NCT03103750|Experimental|Placebo then Calcitriol|Healthy volunteers will receive a baseline MRI. On the night before, and day of testing subjects will receive two doses of calcitriol or placebo, followed by Raclopride injection & PET Scan #1. A minimum of six days later, subjects will receive a Dexedrine Dose followed by a second Racloporide injection and PET scan #2.
2920874|NCT03103737|Experimental|Intervention|Psychological intervention composed by four sessions along 1 week. Participants can interact with virtual environments and a multimedia system for reminiscence purposes.
2920877|NCT03103711|Experimental|Intervention|"The entire intervention is composed by four 30 minutes sessions along 1 week. Its focus is on the promotion of well-being by the use of two virtual environments (Emotional Parks and Walk through Nature). These environments allow participants to involve in different exercises (working with self statements, videos, images, slow breathing, focus on the present exercises) with the purpose of increase positive emotional states."
2920878|NCT03103711|No Intervention|Control|Participants receive the medical treatment deliver by the hospital. They fulfill several questionnaires at two moments (pre and post 1 week after). After this, they have the possibility to receive the psychological intervention.
2920879|NCT03103698|Other|Monitoring of perioperative analgesia by the ANI device|
2920880|NCT03103698|Other|conventional monitoring based on hemodynamic variations.|
2920881|NCT03103685|Placebo Comparator|ASA alone|The patient in this arm will be ask to stop P2Y12 inhibitor before dental procedure, 5 days for clopidogrel and ticagrelol and 7 days for prasugrel.
2920882|NCT03103685|Experimental|Uninterrupted DAPT|The patient in this arm will continue dual anti platelet until the date of dental procedure.
2920883|NCT03103672||Groupe I|Patients who will receive inhalation anesthesia
2920884|NCT03103672||Groupe 2|Patients who will receive total intravenous anesthesia
2920885|NCT03103659|Experimental|Elderly patient with cancer living in a nursing home|
2920886|NCT03103646|Experimental|Lu AF35700|Day 1: Single dose of Lu AF35700. Extensive metabolisers (EMs): 10mg. Poor metabolisers (PMs): 5 mg
2920887|NCT03103646|Experimental|Lu AF35700 AND itraconazole|Days 29 to 31: once-daily dosage of 200 mg itraconazole. Day 32: Single dose of Lu AF35700 (EMs: 10 mg, PMs: 5 mg) and 300 mg itraconazole Days 33 to 42: once-daily dosage of 200 mg itraconazole
2920888|NCT03103633|Experimental|Individualized therapy|The goal of intervention:mean artery pressure declined with less than 20% of baseline, bispectral index 45-60, Brain oxygen saturation declined with less than 20% of baseline.
2920889|NCT03103633|Sham Comparator|Controlled|"no intervention beside standard measures to maintain oxygenation (SpO2~≥94%), haemoglobin (>80 g/L), core temperature (≥36°C), and heart rate (<120 beats per min)"
2920890|NCT03103594|Active Comparator|DMSO alone|Half of the patients will undergo DMSO instillation
2920891|NCT03103594|Experimental|DMSO with Botox|The other half will be randomized to DMSO mixed with 200U of botulinum toxin instillation
2920892|NCT03103581|Experimental|BLI4700|BLI4700 Bowel Preparation
2920893|NCT03103568|Experimental|Arm A - CYP substrates|"In Arm A of the clinical study the potential effect of multiple doses of nitisinone on the blood concentration of the active substances tolbutamide, metoprolol and chlorzoxazone will be investigated. These substances are metabolized by CYP2C9, CYP2D6 and CYP2E, respectively.~A cocktail of the substances tolbutamide, metoprolol and chlorzoxazone will be given as a single dose at the beginning of the study and PK will be investigated. The participants will then administer nitisinone for two weeks until therapeutic serum concentrations level is reached. Serum and urine concentrations of nitisinone will then be investigated for 24 hours, followed by giving the substances tolbutamide, metoprolol and chlorzoxazone as a single dose together with nitisinone to investigate the PK during interaction."
2920894|NCT03103568|Experimental|Arm B - OAT substrates|"In Arm B of the clinical study the potential effect of multiple doses of nitisinone on the blood concentration of the active substances furosemide in the blood, which is transported by the transporter proteins OAT 1 and OAT 3, will be investigated.~Furosemide will be given intravenously as a single dose at the beginning of the study and PK will be investigated. The participants will then administer nitisinone for two weeks until therapeutic dose is reached. Furosemide will then be given as a single dose together with nitisinone to investigate the PK during interaction."
2920895|NCT03103555|Experimental|Bortezomib and cyclophosphamide|Two cycles of bortezomib administered subcutaneously, followed by 4 months of low dose oral cyclophosphamide.
2920896|NCT03103542|Experimental|Recombinant coagulation factor VIII Fc (rFVIIIFc)|Participants will receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 60 Weeks during the ITI Period. Participants who meet the criteria for ITI success will enter a tapering period of 16 weeks where the dose will be tapered down until a prophylactic dose, as judged by the Investigator, is achieved and thereafter a follow-up period of 32 weeks where the patient will continue to receive prophylactic treatment with rFVIIIFc.
2920897|NCT03103529|Experimental|Early Rehab|Children will begin active rehabilitation 2 weeks post-injury
2920898|NCT03103529|Active Comparator|late rehab|Children will begin active rehabilitation 4 weeks post-injury
2920899|NCT03103516|Experimental|early epidural decompression group|The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
2920900|NCT03103516|Experimental|delayed epidural decompression group|The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
2920901|NCT03103490|Other|F18 FSPG PET/MRI|Patients undergoing F18 FSPG PET/MRI scan
2920902|NCT03103477||Office|"Patients presenting for a routine office visit will be asked to donate at least 50 ml of urine. The urine specimen will be aliquoted in containers, one with and one without a PAF-AH inhibitor and kept at room temperature.~The aliquots (2mL) will be frozen at predetermined intervals of 5, 10, 20, 40 and 60 min from time of collection in liquid nitrogen and then later stored in -80 freezer."
2920903|NCT03103477||Surgery|A separate group of patients undergoing surgery lasting more than 60 min operating time, will be consented as well. These patients have Foley catheters in place during the surgery. Five cc's of urine will be collected from the catheter at pre-determined intervals 5, 10, 20, 40 and 60 minutes, aliquoted (2mL) and frozen in liquid nitrogen and later stored in the -80 freezer.
2920904|NCT03103464|Experimental|Intervention Group|Patients to receive standard-of-care physical therapy + sit-to-stand therapy using the Movi chair 3x/wk.
2920905|NCT03103464|Active Comparator|Control Group|Patients to receive standard-of-care physical therapy 3x/wk.
2920906|NCT03103451|Experimental|Cohort 1|"This cohort includes 3 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
2920907|NCT03103451|Experimental|Cohort 2|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
2920908|NCT03103451|Experimental|Cohort 3|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
2920909|NCT03103451|Experimental|Cohort 4|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
2920910|NCT03103451|Experimental|Cohort 5|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
2920911|NCT03103451|Experimental|Cohort 6|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
2920912|NCT03103451|Experimental|Cohort 7|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
2920913|NCT03103438|Experimental|Cohort 1|his cohort includes one subject who will receive the maximum safe starting dose of BCD-089 (0.06 mg/kg) subcutaneously. If the dose limitating toxicity occurs within the first seven days after injection the study will be stopped. If there is no DLT within mentioned above period then Cohort no.2 is included.
2920914|NCT03103438|Experimental|Cohort 2|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 0.3 mg/kg.If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no.3 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 3.
2920915|NCT03103438|Experimental|Cohort 3|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 0.625 mg/kg.If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 4 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 4.
2920916|NCT03103438|Experimental|Cohort 4|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 1.0 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 5 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 5.
2920917|NCT03103438|Experimental|Cohort 5|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 1.6 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 6 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 6.
2920918|NCT03103438|Experimental|Cohort 6|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 2.2 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 7 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 7.
2920919|NCT03103438|Experimental|Cohort 7|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 2.2 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level.
2920920|NCT03103412|Experimental|TD-3504 Low-Dose|6 healthy subjects and 6 ulcerative colitis subjects will be randomized to receive low-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
2920921|NCT03103412|Experimental|TD-3504 Mid-Dose|6 healthy subjects will be randomized to receive mid-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
2920922|NCT03103412|Experimental|TD-3504 High-Dose|6 healthy subjects will be randomized to receive high-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
2920923|NCT03103412|Placebo Comparator|Placebo|6 healthy subjects and 2 ulcerative colitis subjects to receive placebo orally single dose.
2920924|NCT03103399|Experimental|50 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 50 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
2920925|NCT03103399|Experimental|100 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 100 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
2920926|NCT03103399|Experimental|150 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 150 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
2920927|NCT03103399|Active Comparator|200 mg entacapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 200 mg of entacapone (Comtan®) in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
2920978|NCT03103087|Experimental|Relugolix + Pbo - Relugolix + Add-back|
2920928|NCT03103399|Placebo Comparator|Placebo|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive study treatment matching placebo tablets in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
2920929|NCT03103386|Experimental|Fermented Rye Bran group|Intake of food product with a patented fermented rye bran: A patented fermented rye bran ingredient for food purpose has been produced through a process where a specific Lactobacillus curvatis strain was incubated with rye bran by Kampffmayer Food Innovation GmbH, Germany. The dried fermented rye bran was incorporated into a whole grain rye crisp bread product (25% on weight basis) commercially available in Sweden and in a novel extruded whole grain rye product (20%) developed by Lantmännen.Two crisp rye bread pieces (2 x 12g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily. Rye puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily. Total energy: 518 kcal/day.
2920930|NCT03103386|Placebo Comparator|Refined Wheat group|Intake of food product with common refined wheat: Corresponding crisp bread and extruded product will be produced using refined wheat flour. Two crisp bread pieces (2 x 12 g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily.Wheat puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily.Total energy: 513 kcal/day.
2920931|NCT03103373|Active Comparator|Conventional monitor group|Patients will be monitoring with invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnography and electrocardiography Echocardiography group: Patients will be monitoring with echocardiography, invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnogrphy and electrocardiography
2920932|NCT03103373|Active Comparator|Echocardiography group|Patients will be monitoring with echocardiography, invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnography and electrocardiography
2920933|NCT03103334|Experimental|Experimental A|Zeneo® - Methotrexate thigh to Methotrexate Biodim® thigh
2920934|NCT03103334|Experimental|Experimental B|Methotrexate Biodim® thigh to Zeneo® - Methotrexate thigh
2920935|NCT03103334|Experimental|Experimental C|Zeneo® - Methotrexate abdomen to Methotrexate Biodim® abdomen
2920936|NCT03103334|Experimental|Experimental D|Methotrexate Biodim® abdomen to Zeneo® - Methotrexate abdomen
2920937|NCT03103321|Experimental|"Arm A (Knowing your Options, Prostate Choice)"|"Patients receive decision aids Knowing your Options before and Prostate Choice during their consultation visit."
2920938|NCT03103321|Experimental|"Arm B (Knowing your Options)"|"Patients receive Knowing your Options decision aid before their consultation visit."
2920939|NCT03103321|Experimental|"Arm C (Prostate Choice)"|"Patients receive Prostate Choice decision aid during their consultation visit."
2920940|NCT03103321|Active Comparator|Arm D (usual care)|Patients undergo usual care.
2920941|NCT03103308|Experimental|Walk training and transplant|Multidirectional walk training with activity monitoring after bone marrow transplant
2920942|NCT03103308|Experimental|Activity Monitoring and transplant|Activity monitoring alone after bone marrow transplant.
2920943|NCT03103295|Experimental|3D-Tissue Engineered Bone Equivalent|"Patients with bone defects of critical size of long bones~3D Tissue Engineered Bone Equivalent: allogeneic or xenogeneic partially demineralized bone matrix (DBM) and plasma-derived fibrin gel seeded with autologous cultured bone marrow-derived multipotent mesenchymal stromal cells (BM-MSCs), periosteal progenitor cells (PPCs), peripheral blood-derived endothelial progenitor cells (PB-EPCs)."
2920944|NCT03103269|Experimental|Challenge! Small Group Intervention only|"This group receives the Challenge! Small Group intervention consisting of curriculum related to health behavior goal setting, healthy eating, and staying active, works out with their Health Educators, and receives a year-long membership to the YMCA.~This group is in schools that were randomly assigned to NOT receive the Environmental Intervention."
2920945|NCT03103269|Experimental|Challenge! Small Group and Environmental Intervention|"This group consists of participants who receive the Challenge! Small Group Intervention AND attend a school that is randomly assigned to receive an environmental intervention.~This group receives the Challenge! Small Group intervention consisting of curriculum related to health behavior goal setting, healthy eating, and staying active, works out with their Health Educators, and receives a year-long membership to the YMCA.~The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier."
2920946|NCT03103269|Experimental|Environmental Intervention Only|"This group consists of participants who do not receive the Challenge! Small Group Intervention but attend a school that is randomly assigned to receive an environmental intervention.~This group does not receive the Challenge! Small Group Intervention.~The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier."
2920947|NCT03103269|No Intervention|Control Group|This group does not receive the Challenge! Small Group intervention and is in a school that is randomly assigned to NOT have the Environmental Intervention.
2920948|NCT03103256|Experimental|YHP1701|PO, Once daily (QD), 8 weeks
2920949|NCT03103256|Active Comparator|YHR1703|PO, Once daily (QD), 8 weeks
2920950|NCT03103256|Active Comparator|YHR1704|PO, Once daily (QD), 8 weeks
2920951|NCT03103243|Other|Intervention|This is a single arm trial. All participants will be administered two baseline fMRIs and blood analysis prior to participation in a mindfulness group and individual mindfulness intervention sessions. A post intervention fMRI and blood analysis will complete the trial participation.
2920952|NCT03103230|Experimental|Motor Evoked Potentials|Patients with aphasia after a stroke
2920953|NCT03103217|Experimental|Brief CBT intervention|
2920979|NCT03103087|Placebo Comparator|Placebo|
2920980|NCT03103074|Experimental|Botulinum B Toxin|Botulinum toxin B (Neurobloc(R)) 50 Units (U)/ml 0,05-0,1 ml/injection intradermally in a grid with 1- 1 1/2 cm between every injection in affected areas A maximum of 4000 U/patient/treatment Treatment every three months
2921172|NCT03101722|Experimental|Huperzine A intervention|Huperzine A intervention: Huperzine A with a dose 0.1~0.2 mg/time, 2 times/day.
2920954|NCT03103204|Experimental|Normal weight full-mouth disinfection|"Normal weight (body mass index 18.5 - 24.9 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
2920955|NCT03103204|Experimental|Overweight full-mouth disinfection|"Overweight (body mass index 25.0 - 29.9 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
2920956|NCT03103204|Experimental|Obesity I full-mouth disinfection|"Obesity I (body mass index 30.0 - 34.9 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
2920957|NCT03103204|Experimental|Obesity II full-mouth disinfection|"Obesity II (body mass index 35.0 - 39.9 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
2920958|NCT03103204|Experimental|Obesity III full-mouth disinfection|"Obesity III (body mass index ≥ 40.0 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
2920959|NCT03103191||Case|"50 subjects with fibrosing interstitial lung disease.~50 subjects with pulmonary fibrosis secondary to collagen diseases."
2920960|NCT03103191||Control|"75 subjects without pulmonary fibrosis but with other common respiratory diseases like asthma, COPD or bronchiectasis.~75 subjects with collagen disease without pulmonary fibrosis."
2920961|NCT03103165|Experimental|SimCoach intervention|"Participants randomized to the SimCoach intervention arm interacted with Bill Ford, a simulated human (avatar) enacted in the SimCoach program. This white male avatar representing himself as an Army veteran who spoke to participants in a conversational manner. Participants interacted with him using a chat interface, where they could type responses to him. Bill Ford asked participants a series of questions that corresponded to validated PTSD or depression screening questionnaires. SimCoach then provided personalized recommendations for a symptom if the user reported experiencing the symptom at one of the two highest frequencies on the response scale. These recommendations consisted of a behavioral recommendation with an accompanying link to a website or online article on the topic."
2920962|NCT03103165|No Intervention|Content Matched Control|Participants assigned to the Content Matched Control condition arm completed text-based versions of the PCL PTSD screening inventory and PHQ-9 depression screening inventory. These instruments used standard, validated language and did not use the modified conversational versions used in the SimCoach intervention condition. The same personalized recommendations provided to the SimCoach group were provided as conventional text and links. After receiving personalized recommendations, participants completed text versions of primary help-seeking, perceived barriers to seeking help, and secondary outcome (user experience) measures
2920963|NCT03103165|No Intervention|No-Treatment Control|Participants randomized to the No-Treatment Control arm completed measures of the primary outcome (intentions to seek help) prior to being given a choice of SimCoach or the conventional screening administered in the other two arms of the study. After the help-seeking intention questionnaire was administered, participants were told that they would be asked some questions about any PTSD or depression symptoms that they might be having and were given the choice between chatting online with a virtual human or using an online form (options were presented in random order to prevent any influence of ordering on selection of the tool). After either interacting with SimCoach or filling out an online form, participants completed a questionnaire assessing user experience.
2920964|NCT03103152|Experimental|High dose Aspirin & Vitamin D|Aspirin high dose (300mgs) daily & Vitamin D 4,000 IU (0.1mg) per day
2920965|NCT03103152|Experimental|High dose Aspirin, Vitamin D placebo|high dose aspirin (300mgs) daily and Vitamin D placebo (Miglyol®812 Oil)
2920966|NCT03103152|Experimental|Low dose Aspirin , Vitamin D|Low dose aspirin (100mgs) daily & Vitamin D 4,000 IU (0.1mg) per day
2920967|NCT03103152|Placebo Comparator|Low dose Aspirin, Vitamin D placebo|Low dose aspirin (100mgs) daily and Vitamin D placebo (Miglyol®812 Oil)
2920968|NCT03103152|Experimental|Aspirin Placebo, Vitamin D|Aspirin placebo and Vitamin D active ingredient - Vigantol® Oil
2920969|NCT03103152|Experimental|Aspirin placebo, Vitamin D placebo|Aspirin placebo and Vitamin D placebo - Miglyol®812 Oil
2920970|NCT03103139|Active Comparator|Transpapillary Stents|Stent placement across the Papilla (with a short plastic stent) for biliary leak
2920971|NCT03103139|Experimental|Stent across bile leak|Stent placement across the bile leak (with a longer stent) for biliary leak
2920972|NCT03103126|No Intervention|Control|Standard care.
2920973|NCT03103126|Experimental|Combined resistance exercise and walking|Combined resistance exercise and walking.
2920974|NCT03103100|Active Comparator|1% Lidocaine|Patients randomized into the lidocaine group will receive 10 mL of 1% lidocaine
2920975|NCT03103100|Active Comparator|0.25% Bupivacaine|Patients randomized into the bupivacaine group will receive 10 mL of 0.25% bupivacaine
2920976|NCT03103100|Active Comparator|Bupivacaine plus Lidocaine|Patients randomized into the bupivacaine group will receive 5 mL of 0.25% bupivacaine and 5 mL of 1% lidocaine.
2920977|NCT03103087|Experimental|Relugolix + Low-dose Hormonal Add-back|
2920981|NCT03103074|Placebo Comparator|Placebo|Saline (NaCl 0,9%) 0,05-0,1 ml/injection intradermally in a grid With 1- 1 1/2 cm between every injection in affected areas Treatment in placebo group (n=10) only at first intervention
2920982|NCT03103061|Experimental|Myocardial Stress CT Perfusion|Low-radiation, dynamic perfusion CT of the heart in patients with suspected ischemic chest pain and a moderate or severe stenosis seen on coronary CTA. Lexiscan(TM) will be used as the pharmacological stress agent (coronary vasodilator).
2920983|NCT03103048|Active Comparator|Group 1|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages (start); 2 - With placebo; 3 - With bandage; 4 - With tensioned bandage.
2920984|NCT03103048|Placebo Comparator|Group 2|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo (start); 3 - With bandage; 4 - With tensioned bandage.
2920985|NCT03103048|Active Comparator|Group 3|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo; 3 - With bandage (start); 4 - With tensioned bandage.
2920986|NCT03103048|Active Comparator|Group 4|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo; 3 - With bandage; 4 - With tensioned bandage (start).
2920987|NCT03103035|Experimental|Exposition to a healthy eating blog|Participants randomised to this arm are exposed to one blog post each week for a period of 6 months.
2920988|NCT03103035|No Intervention|No exposition to a healthy eating blog|Participants randomised to this arm do not have exposure to the blog.
2920989|NCT03103022|Experimental|Interventional Group|Preterm infants who met the eligibility criteria will receive both oral acetaminophen and ibuprofen. Oral acetaminophen [160 mg/5ml concentration] will be administered every 6 hours with dose of 15 mg/kg/dose for a total of twelve doses and oral ibuprofen [100 mg/5 ml] at 10 mg/kg/dose on first day followed by 5 mg/kg/dose at 24 and 48 hours for a total of three doses
2920990|NCT03103009|Experimental|pasireotide|Interventions - One patient will be given a drug, pasireotide (Signifor), on a compassionate use basis for treatment of post-gastric bypass hypoglycemia. The minimal dose will be 0.3 mg subcutaneous daily and the maximal dose will be 0.6 mg subcutaneous twice daily. The patient may continue treatment with pasireotide indefinitely unless the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued at the discretion of the treating physician or Novartis or withdrawal of consent.
2920991|NCT03102996|Experimental|Verum|Patients will receive Nephrotrans.
2920992|NCT03102996|Placebo Comparator|Placebo|Patients will receive Placebo.
2920993|NCT03102983|Experimental|Healthy Volonteers|
2920994|NCT03102957|Experimental|epileptic patients|2 functional MRI (pre and post resective surgery) with memory and language tasks
2920995|NCT03102957|Other|Healthy volunteers|1 functional MRI with memory and language tasks
2920996|NCT03102944||healthy volunteers|no intervention, extra blood tube taken with blood donation at bloodbank and blood is tested on IVD away from patient.
2920997|NCT03102931|Experimental|Reduced ROS/RNS content products|Participants will be given and asked to smoke research cigarettes for the first 4 weeks. For the final 4 weeks of the study they will be given and asked to smoke low ROS content cigarettes.
2920998|NCT03102918|Active Comparator|Cannabidiol|Epidiolex
2920999|NCT03102918|Placebo Comparator|Placebo|Placebo
2921000|NCT03102892|Active Comparator|Scaling Root Planing|Treatment by scaling and root planing. Repetition after 7 and 14 days.
2921001|NCT03102892|Experimental|Antimicrobial Photodynamic Therapy|Scaling and root planing and Antimicrobial photodynamic therapy with red laser (658 nm, 0.1 Watts, 2229 J/cm², 10s per point) and methylene blue dye (10mg/ml). Repetition after 7 and 14 days.
2921002|NCT03102879|Experimental|Regenerative Endodontic Procedure (REP)|umbilical cord-derived mesenchymal stem cells encapsulated in a plasma-derived biomaterial.
2921003|NCT03102879|Active Comparator|Conventional Root Canal Treatment|Conventional endodontic procedure
2921004|NCT03102866|Active Comparator|Arm I (usual care)|Patients receive usual care for 6 weeks during radiation therapy and for 12 weeks after completion of radiation therapy.
2921005|NCT03102866|Experimental|Arm II (aerobic and strength training exercise)|Patients undergo a supervised aerobic and strength training exercise session over 40-60 minutes 3 times weekly for 6 weeks during radiation therapy and for 12 weeks after completion of radiation therapy.
2921006|NCT03102853|Active Comparator|Nordic diet|
2921007|NCT03102853|Other|Control diet|
2921008|NCT03102840||Children nasal swab only|Pneumococcal nasopharyngeal carriage in children aged 13-48 months who have previously received PCV13
2921009|NCT03102840||Children nasal swab + serum|Pneumococcal nasopharyngeal carriage and immunogenicity in children aged 13-48 months who have previously received PCV13
2921010|NCT03102827|Active Comparator|Oxygen - ambient air|high-flow oxygen therapy administered during first night, ambient air without high-flow therapy (placebo) administered during second night
2921011|NCT03102827|Placebo Comparator|Ambient air - oxygen|Ambient air without high-flow therapy (placebo) administered during first night , high-flow oxygen therapy administered during second night
2921012|NCT03102814|Active Comparator|Current rehabilitation program|The control group will receive the rehabilitation program currently provided at each participating centre at the start of the study.
2921013|NCT03102814|Experimental|BRIDGE rehabilitation program|In intervention phase, the BRIDGE program will be added to the current program.
2921014|NCT03102801|Active Comparator|Type 2 diabetes arm|Both arms will be subjected to Hypoglycaemia and compare results
2921015|NCT03102801|Active Comparator|Non diabetics arm|Both arms will be subjected to Hypoglycaemia and compare results
2921016|NCT03102788|Active Comparator|Control|Patients in the control group will receive their first consultation in specialist health care by a rheumatologist. Rheumatologist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, and, for some patients, Intra-articular injection of long-acting Corticosteroid. The rheumatologist may also refer participants to occupational therapy if needed.
2921054|NCT03102567|Experimental|GLPG1205 50mg q.d.|oral hard gelatin capsules with 50 mg GLPG1205 for q.d. administration - compared to placebo
2921017|NCT03102788|Experimental|Intervention|Patients in the intervention group will receive their first consultation in specialist health care by an occupational therapy specialist. Occupational therapist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, teaching of hand exercises and ergonomic working methods, and, for some patients, provision assistive devices and orthoses/splints. The occupational therapist will refer patients to a short rheumatologist consultation if confirmation of diagnosis or intra-articular injections of long-acting Corticosteroid are needed.
2921018|NCT03102775|Experimental|Comprehensive follow-up program|15 offices have been randomized to experimental group. Experimental group offices implement the HOLF model developed by the Labor and Welfare Administration
2921019|NCT03102775|Active Comparator|Local family projects|14 offices have been randomized to control group. these implement local family projects. These are developed based on local practice needs
2921020|NCT03102762|Experimental|BTX-A Group|Experimental: BTX-A Group The treatment group, 80 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
2921021|NCT03102762|Placebo Comparator|Placebo Group|"Saline Group:~The control group, 80 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment."
2921022|NCT03102749||Normal weight|Included patients with a BMI < 25 will be part of this group.
2921023|NCT03102749||Overweight|Included patients with a BMI >= 25 and <30 will be part of this group.
2921024|NCT03102749||Obese|Included patients with a BMI >= 30 will be part of this group.
2921025|NCT03102736|Placebo Comparator|Placebo and Ketamine|Placebo saline given over 240 minutes + 0.5 mg/kg ketamine given over 40 minutes
2921026|NCT03102736|Experimental|Nitroprusside and Ketamine|0.5 mcg/kg nitroprusside given over 140 min + 0.5 mg/kg ketamine given over 40 min
2921027|NCT03102723|Experimental|Cangrelor|Cangrelor (single intravenous bolus followed by a 120-minute infusion) initiated prior to PPCI.
2921028|NCT03102723|Placebo Comparator|Placebo|Matching normal saline placebo (single intravenous bolus followed by a 120-minute infusion) initiated prior to PPCI.
2921029|NCT03102710|Experimental|tDCS Enhancement|In this group, the transcranial direct current stimulation (tDCS) stimulates the areas of the brain being examined in this study to increase their activity.
2921030|NCT03102710|Experimental|tDCS Inhibition|In this group, the transcranial direct current stimulation (tDCS) inhibits the areas of the brain being examined in this study to decrease their activity.
2921031|NCT03102710|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation (tDCS) does not provide real stimulation though you will not know this until your debriefing at the end of the study. Sham will be used to determine if the results of this study are due to the tDCS or other reasons.
2921032|NCT03102697||Obese individuals|Obese patients submitted to treatment using two consecutively air-filled IGB (Heliosphere® 600 cc and Heliosphere 720 cc) without any interval between the removal of the first and the placement of the second.
2921033|NCT03102684|No Intervention|No exposure|No exposure to secondhand exposure to aerosols produced by e-cigarettes
2921034|NCT03102684|Experimental|Low exposure|Secondhand exposure to e-cigarette aerosols (low)
2921035|NCT03102684|Experimental|High exposure|Secondhand exposure to e-cigarette aerosols (high)
2921036|NCT03102671|Experimental|AB sequence|Usual care followed by use of HeartHab application: Treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle), followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence.
2921037|NCT03102671|Experimental|BA sequence|Use of HeartHab application followed by usual care: patients will be followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence, followed by treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle)
2921038|NCT03102658|Experimental|Obese subjects 100mg|8 subjects with a BMI>40kg/m2 will receive 100mg Micafungin
2921039|NCT03102658|Active Comparator|Obese subjects 200mg|8 subjects with a BMI>40kg/m2 will receive 200mg Micafungin
2921040|NCT03102658|Active Comparator|non-obese subjects|8 non obese subjects with a BMI >18.5 and <25 kg/m2 will receive 100mg Micafungin
2921041|NCT03102645|Experimental|Imipramine first|A: Imipramine Hydrochloride 25 MG x2 B: Placebo Oral Tablet x2
2921042|NCT03102645|Experimental|Placebo first|A: Placebo Oral Tablet x2 B: Imipramine Hydrochloride 25 MG x2
2921043|NCT03102632|No Intervention|Usual Water Intake|For the first 6 months of the study, the participants will continue their usual water intake.
2921044|NCT03102632|Experimental|High Water Intake|After a 6 month period of usual water intake, a high water intake daily amount will be prescribed for 1 year.
2921045|NCT03102606|Experimental|20 mg/m2 Plinabulin + saline placebo|20 mg/m2 Plinabulin and 0.6 ml saline matching pegfilgrastim syringe
2921046|NCT03102606|Experimental|10 mg/m2 Plinabulin + saline placebo|10 mg/m2 Plinabulin and 0.6 ml saline matching pegfilgrastim syringe
2921047|NCT03102606|Experimental|5 mg/m2 Plinabulin + saline placebo|5 mg/m2 Plinabulin and 0.6 ml saline matching pegfilgrastim syringe
2921048|NCT03102606|Active Comparator|0.6 ml Pegfilgrastim + D5W placebo|0.6 ml Pegfilgrastim and 250 ml D5W matching plinabulin dilution
2921049|NCT03102593|Experimental|ARGX-113 Dose A + SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
2921050|NCT03102593|Experimental|ARGX-113 Dose B +SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
2921051|NCT03102593|Placebo Comparator|Placebo + SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
2921052|NCT03102580|Experimental|OA Care Plan Intervention|For intervention sites, the patient and surgeon will receive the OA Care Plan (currently under development). The OA Care plan with have Patient Reported Outcomes, feedback reports, and risk factors for shared decision making.
2921053|NCT03102580|No Intervention|Usual care|As collection of Patient Reported Outcomes (PROs) is considered standard of care in orthopedics (CMS mandate, Bundled Payment requirements, and reporting for Qualified Clinical Data Registry requirement for example), usual care patients and surgeons will have the ability to see PRO scores.
2921056|NCT03102567|Experimental|GLPG1205 250 mg loading and 50mg q.d. maintenance|open label - oral hard gelatin capsules with 50 mg GLPG1205 for one time 250 mg loading dose and subsequent 50mg q.d. administration
2921057|NCT03102554|Experimental|Genetic Testing|Subjects will provide a DNA sample, which will be screened for variants in genes related to DSD/hypospadias. Probands/parents who wish to receive results of genetic testing related to DSD/hypospadias will receive these results directly from the research study. Parents who receive results of genetic testing for probands under 12 years of age will complete questionnaires at the time of enrollment, right after receiving genetic results, and 3 months after receiving genetic results.
2921058|NCT03102541||Cardiac Surgery|214 adult patients with estimated GFR ≥60 ml/min/1.73 m2 (CKD-Epidemiology Collaboration equation) undergoing elective cardiac surgery (coronary artery bypass, valve replacements, combined or other surgery, with cardiopulmonary bypass) between November 2014 and October 2015 at the San Bortolo Hospital, Vicenza, Italy
2921059|NCT03102528||Cardiac Surgery Patients|All adult patients undergoing cardiac surgery (elective/emergent) at San Bortolo Hospital, Vicenza, Italy during November 2014 - October 2015
2921060|NCT03102515|Other|Spinal-anesthesia|Caesarean section performed under spinal anaesthesia and receiving either USG-TAP block or CIC
2921061|NCT03102515|Other|Epidural-anesthesia|Caesarean section performed under epidural anaesthesia and receiving either USG-TAP block or CIC
2921062|NCT03102502|Experimental|Enhanced External Counterpulsation|Patients receive a total of 35-36 hours of EECP treatment on top of guideline- driven standard medical therapy for coronary heart disease, 1-hour sessions every day over a 7-week period.
2921063|NCT03102502|Active Comparator|Control|Patients receive guideline- driven standard medical therapy for 7 weeks without Enhanced External Counterpulsation intervention.
2921064|NCT03102489|Experimental|BP101|Treatment with BP101
2921065|NCT03102489|Placebo Comparator|Placebo|Treatment with placebo
2921066|NCT03102476|Other|Patients with Type 1 Diabetes|Using euglycaemic clamp, the effect of different temperatures and humidity levels will be assessed on the pharmacokinetic and pharmacodynamic profiles of short-acting insulin Humalog.
2921067|NCT03102463|Sham Comparator|Water Control|
2921068|NCT03102463|Active Comparator|Milk derived hydrolysate|
2921069|NCT03102463|Active Comparator|Parent Protein|
2921070|NCT03102450|Experimental|Benzalkonium Chloride Spermicide Cream|Pharmatex 1,2% vaginal cream (benzalkonium chloride 1,2g per 100g of vaginal cream)
2921071|NCT03102437|Experimental|Optimizer Smart System|All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
2921072|NCT03102424|Experimental|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
2921073|NCT03102424|Placebo Comparator|Sham DW1330 device|The 20 weeks of treatment of the Sham DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
2921074|NCT03102398|Experimental|Single-arm and Open-label Study|
2921075|NCT03102385|Experimental|Motivational Interview|Complete an on-line motivational interview regarding participants' blood donation experience.
2921076|NCT03102385|Placebo Comparator|Knowledge Interview|Complete an on-line interview regarding participants' general knowledge about blood donation.
2921077|NCT03102372|Experimental|Protein group|4 weeks of a Very Low Calorie Diet (VLCD) + walking program. Whey protein supplementation 0.4g/kg before sleep.
2921078|NCT03102372|Placebo Comparator|Placebo group|4 weeks of a Very Low Calorie Diet (VLCD) + walking program
2921079|NCT03102359|Experimental|Selective Head Cooling|Participants received a cooling helmet filled with ice water mixture after an-esthesia induction until the end of the surgery.
2921080|NCT03102359|Experimental|Dexmedetomidine|Giving dexmedetomidine1μg/kg i.v for 10 minutes, then use computerized infusion pump at 0.5μg/kg.h until the end of the surgery.
2921081|NCT03102359|Experimental|Selective Head Cooling and Dexmedetomidine|Using selective head cooling combined with dexmedetomidine as described before
2921082|NCT03102359|No Intervention|Control|No intervention in this group
2921083|NCT03102346|Experimental|Home-based Cardiac Rehabilitation group|remote instructed exercise training at home
2921084|NCT03102346|No Intervention|routine group|no instructed exercise training
2921085|NCT03102333|Active Comparator|Constant-rate Infusion|INTERVENTION : Constant-rate Infusion mode : The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
2921086|NCT03102333|Active Comparator|Variable-rate Feedback Infusion|INTERVENTION : Variable-rate Feedback Infusion mode :The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
2921087|NCT03102320|Experimental|Cholangiocarcinoma|"Safety lead-in phase will determine the MTD of anetumab ravtansine administered in combination with cisplatin. Please note the study is no longer recruiting for the cholangiocarcinoma safety lead-in phase.~During the main study phase anetumab ravtansine will be administered at the determined MTD in combination with cisplatin. Please note the main study phase for cholangiocarcinoma will no longer be going ahead."
2921088|NCT03102320|Experimental|Adenocarcinoma of the pancreas|Safety lead-in phase will determine the MTD of anetumab ravtansine administered in combination with gemcitabine During the main study phase, anetumab ravtansine will be administered at the determined MTD in combination with gemcitabine
2921089|NCT03102320|Experimental|Other solid tumors|(Non-small cell adenocarcinoma of the lung (NSCLC adenocarcinoma), Adenocarcinoma of the breast - triple negative (TNBC), Gastric adenocarcinoma including gastroesophageal junction (GEJ Cancer, Thymic carcinoma) During the main study phase, anetumab ravtansine will be administered at dose of 6.5 mg/kg in solid tumors
2921090|NCT03102307||CNB biopsy/clip placement not done|Clinically affected lymph nodes cannot be biopsied or clip labeled. Patients are not suitable for TAD
2921091|NCT03102307||CNB/clip placement done - benign|Clinically affected lymph nodes can be biopsied and clip labeled. Needle biopsy reveals no axillary tumor spread. Patients are suitable for TAD
2921092|NCT03102307||CNB/clip placement done - malignant|Clinically affected lymph nodes can be biopsied and clip labeled. Needle biopsy reveals axillary tumor spread. Patients are suitable for TAD
2921093|NCT03102294|Active Comparator|Experimental: IMT|inspiratory muscle training (PowerBREATHE) with ~50% of maximum inspiratory pressure
2921094|NCT03102294|Placebo Comparator|Placebo: SHAM|inspiratory muscle training (PowerBREATHE) without inspiratory load
2921095|NCT03102281||recurrent group|Patients who had recurrent common bile duct stones.
2921096|NCT03102281||control group|Patients who had not recurrent common bile duct stones.
2921097|NCT03102268||cholangiocarcinoma patients|cholangiocarcinoma patients without any anti-cancer therapy
2921098|NCT03102268||benign biliary stricture patients|benign biliary stricture patients without any therapy targeting the stricture
2921099|NCT03102255|Active Comparator|Conventional|Performed nasotracheal intubation as usual. Sniffing position but doesn't lift a nasal tip.
2921100|NCT03102255|Experimental|Nasal tip lifting|Performed sniffing position and nasal tip lifting while the endotracheal tube insert patient's nasal cavity.
2921101|NCT03102242|Experimental|Treatment|"Induction immunotherapy: atezolizumab 1200 mg IV q 21 days x 4 cycles. Restaging after cycle 2 and cycle 4 induction: patients with progression of disease (PD) at the post-cycle 2 assessment will stop atezolizumab and go immediately to chemoradiotherapy if still stage III and eligible for curative intent therapy.~Chemoradiotherapy: carboplatin AUC = 2 + paclitaxel 50 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 60 Gy given in 2 Gy fractions daily M-F x 30 fractions~Consolidation chemotherapy: Carboplatin AUC = 6 + paclitaxel 200 mg/m2 IV q 21 days x 2 cycles beginning 3-5 weeks after completion of radiation.~Adjuvant immunotherapy: atezolizumab 1200 mg IV q 21 days to complete one year of therapy (from start of induction)."
2921102|NCT03102229|Experimental|Activity Monitoring|"Enhanced Supportive Care - Status Checks Would occur everyday during treatment when a patient is deemed high-risk based on activity level. Other Names: •Daily Status Checks~Enhanced Supportive Care - Referrals On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor. Other Names: •Referrals"
2921103|NCT03102216|No Intervention|Current workflow pathway|In the Current (normal) Workflow Pathway, after a patient is triaged, they are reviewed by the doctor. It is routine for the doctor to then order diagnostic tests/investigations that include blood tests, which are analysed at the laboratory, x-rays, which are performed in the Radiology department, and an ECG, which is performed by an ECG technician. Once the results of those tests are ready, the doctor will then review the patient a second time with all the results. The decision for patient disposition will then be made
2921104|NCT03102216|Experimental|Enhanced workflow pathway iSTAT|Patients will receive i-STAT point-of-care troponin, INR (International Normalised Ratio), CG4(blood gas analysis) and chem8 tests prior to seeing the doctor.
2921105|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests as well as a CBC prior to seeing the doctor.
2921106|NCT03102216|Experimental|Enhanced workflow pathway ECG|Patients will receive a 12lead, v1R-v6R(right sided ECG leads) and V7-V9 ECG prior to seeing the doctor.
2921107|NCT03102216|Experimental|Enhanced workflow pathway Lodox|Patients will receive a supine AP and lateral lodox (low dose x-ray) of their chest and abdomen prior to seeing the doctor.
2921108|NCT03102216|Experimental|Enhanced workflow pathway iSTAT ECG|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests as well as 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
2921109|NCT03102216|Experimental|Enhanced workflow pathway iSTAT, CBC ECG|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests, CBC and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
2921110|NCT03102216|Experimental|Enhanced workflow pathway iSTAT lodox|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests and Lodox prior to seeing the doctor.
2921111|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC Lodox|iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; CBC and Lodox prior to seeing the doctor.
2921112|NCT03102216|Experimental|Enhanced workflow pathway ECG Lodox|Patients will receive LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
2921113|NCT03102216|Experimental|Enhanced workflow pathway iSTAT ECG Lodox|iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor
2921114|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC ECG Lodox|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; CBC, LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
2921115|NCT03102190|Experimental|Phase Ib|The phase Ib study will consist of an accelerated titration, intrapatient dose escalation cohort, with double-dose step design of Verapamil Hydrochloride. Intranasal BID for 1 week. Dose escalation will occur weekly as a doubling of the dose from 10-120mg Verapamil delivered in 240mL buffered normal saline. If a single, any course, dose-limiting toxicity (DLT) or second, any course, IT occurs, two additional patients will be recruited at that identified dose and Phase Ib will revert to a standard 3+3 design. If any patient un-enrolls while the dose escalation is still occurring, they will be replaced to maintain 3 patient cohorts. The maximal administered dose (MAD) will be considered that at which at least 2 DLTs or 4 ITs occur and the MTD will then be assigned to the immediate preceding dose.
2921116|NCT03102190|Experimental|Phase II|The Phase II study will be an open label safety and efficacy expansion cohort using the Verapamil Hydrochloride Intranasal MTD determined in the Phase IB arm. A total of 20 patients will be administered the MTD of topical Verapamil HCl in a 240mL buffered normal nasal rinse for 4 weeks BID. Patients will then return for follow-up visits at 1 week and 4 weeks. Subjective and objective outcome measures will be collected at each visit
2921117|NCT03102177|Experimental|Stable isotope arm|Measurement of blood levels of labelled levothyroxine after administration of single oral dose of stable isotope levothyroxine
2921147|NCT03101917|Experimental|Visual assessment of electrode insertion|This arm will include the first 6 participants. In this group, a cut will be made near the eardrum and it will be lifted up so the surgeon can see the electrode as it goes into the cochlea.
2921148|NCT03101917|Experimental|Camera assessment of electrode insertion|This arm will include the next 6 participants. In this group, a tube with a camera will be inserted past the ear drum, by making a small hole in the ear drum, to see the electrode as it goes into the cochlea.
2921885|NCT03096795|Experimental|J-SD Cohort|Single dose (Day 1) of MEDI3506 or placebo
2921118|NCT03102164||cardiac rehabilitation|patients undergoing cardiologic rehabilitation according to the protocol used routinely at the Military Hospital in Wroclaw.The protocol of rehabilitation, adjusted to clinical status, individual needs and physical capability of the patient, includes gradually increasing level of physical exercise. Upon achieving relative stabilization of clinical status and excluding absolute contraindications to physical exercise, usually on the 2nd or 3rd day of hospitalization, the cardiologic rehabilitation is ordered by a physician in charge. The rehabilitation protocol comprises respiratory, assisted, active dynamic,and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase;they are conducted in a lying, sitting, or standing position.
2921119|NCT03102164||Controls|patients treated using standard pharmacotherapy within Center for Heart Disease, Military Clinical Hospital in Wroclaw.
2921120|NCT03102138||observation|subjects treated in B4711001 with PF-05206388 will be assessed
2921121|NCT03102125|Experimental|Nonspecific allograft dysfunction|Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
2921122|NCT03102125|Experimental|Normal graft function|Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
2921123|NCT03102112||Patients with glioma|Consecutive patients with privious MRI scans or symptoms that suggested a cerebral mass, not yet receive treatment.
2921124|NCT03102099||contrast-enhanced ultrasound group|The contrast-enhanced ultrasound(CEUS)patients will undergo biopsy with contrast-enhanced ultrasound guidance.
2921125|NCT03102099||conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
2921126|NCT03102073||Radner test|reading speed evaluation
2921127|NCT03102060|Experimental|Prevention (gluten free diet)|Patients undergo a gluten free diet for 30 days during initial hospitalization for allo-SCT, from the time of admission to discharge.
2921128|NCT03102047|Experimental|durvalumab|IV infusion once every 2 weeks for 4 total doses
2921129|NCT03102034|Experimental|RSV D46/NS2/N/ΔM2-2-HindIII Vaccine|Participants will receive a single dose of the D46/NS2/N/ΔM2-2-HindIII vaccine at study entry (Day 0).
2921130|NCT03102034|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
2921131|NCT03102021|Active Comparator|1|erythropoeitin
2921132|NCT03102021|Placebo Comparator|2|saline placebo
2921133|NCT03102008|No Intervention|2 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
2921134|NCT03102008|No Intervention|3 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
2921135|NCT03102008|No Intervention|4 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
2921136|NCT03102008|Experimental|16 Sessions of Therapeutic Intervention|Participants receive 50 minute sessions weekly of therapeutic intervention (Unified Protocol for the Treatment of Emotional Disorders in Adolescents). Symptom change assessed weekly on the internet or before each session (via self- and parent-report questionnaires). At the end of treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
2921137|NCT03101995|Experimental|Gemcitabine|Gemcitabine doses: 300 mg/m2/week for 6 weeks.
2921138|NCT03101982|Active Comparator|test|HBO, ASIA score, blood taking
2921139|NCT03101982|No Intervention|control|ASIA score, blood taking
2921140|NCT03101956|Experimental|L/S Manipulation Study Group|
2921141|NCT03101956|Active Comparator|Control Group|
2921142|NCT03101943|Experimental|Family Spirit Nurture (FSN)|The intervention group (n=68) will receive the Family Spirit Nurture (FSN) home-visiting module, consisting of six 45-minute lessons delivered biweekly by trained local American Indian Family Health Coaches (FHCs), from 3 to 6 months postpartum. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices. Lessons are highly visual and interactive, and will incorporate cultural teachings related to infant feeding and nutrition that support aims. All families will receive water delivery of drinking water from 6 to 9 months postpartum.
2921143|NCT03101943|Other|Control Program|The control group (n=68) will receive three home-based lessons with home safety information (injury prevention is a priority identified by Navajo leadership that does not interfere with study questions). Mothers randomized to the control group will receive 3 educational lessons on home safety and child safety proofing. These meaningful topics were selected so as not to dilute measurement on key FSN outcomes and to provide benefit to all study participants. Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing. All families will receive water delivery of drinking water from 6 to 9 months postpartum.
2921144|NCT03101930|Experimental|liraglutide|Subjects in the liraglutide group will receive subcutaneous liraglutide (0.6 mg/d for one week, 1.2 mg/d for one week, and then 1.8 mg/d for 12 weeks) and oral placebo.
2921145|NCT03101930|Active Comparator|sitagliptin|Subjects in the sitagliptin group will receive subcutaneous placebo daily and sitagliptin 100 mg/d orally for 14 weeks.
2921146|NCT03101930|Active Comparator|hypocaloric diet|Subjects in the hypocaloric diet group will be given a caloric goal designed to achieve a weight loss similar to that expected in the liraglutide treatment arm based on his or her resting energy expenditure. Subjects will be provided counseling and written instructions on how to achieve their daily caloric goal, including use of their own mobile phone applications to monitor caloric intake. To assure compliance with the prescribed caloric goal, subjects will meet with the study dietitian every other week for problem solving and review of diet intake logs.
2921149|NCT03101904|Experimental|Nitrate then Placebo|"Participants will consume a daily a beetroot shot for six days. Each shot will consist of: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate; Beet It, James White Drinks Ltd, Ipswich, UK).~Following a minimum of ten days wash out, participants will then consume a daily Nitrate-depleted beetroot shot for six days. Each shot will consist of 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate; Beet It, James White Drinks Ltd, Ipswich, UK)."
2921150|NCT03101904|Placebo Comparator|Placebo then Nitrate|"Participants will consume a daily Nitrate-depleted beetroot shot for six days. Each shot will consist of 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate; Beet It, James White Drinks Ltd, Ipswich, UK).~Following a minimum of ten days wash out, participants will then consume a daily beetroot shot for six days. Each shot will consist of: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate; Beet It, James White Drinks Ltd, Ipswich, UK)."
2921151|NCT03101891|Experimental|Serial amnioinfusions with normal saline|Patients will undergo amnioinfusions with normal saline, 0.9% injectable solution every 1-2 weeks. A spinal needle will be used to perform the infusion. The latest infusions will begin is 26 weeks gestation. Standard postnatal care will occur at the Johns Hopkins Hospital.
2921152|NCT03101891|No Intervention|Expectant|Patients will be observed serially by ultrasound. Standard postnatal care will occur at the Johns Hopkins Hospital.
2921153|NCT03101878|Experimental|Ionis AGT-LRx|Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously.
2921154|NCT03101878|Placebo Comparator|Placebo|Saline .9%
2921155|NCT03101865|Experimental|Closed loop with diluted insulin|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature using DILUTED insulin aspart over 3 weeks.
2921156|NCT03101865|Active Comparator|Closed loop with standard insulin strength|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature using STANDARD strength insulin aspart over 3 weeks.
2921157|NCT03101852|Experimental|Nutritional therapy|Children included in the study with severe acute malnutrition receive Plumpy Nut: 200kcal/kg/day, limited to 4 doses/day until they reach their target weight.
2921158|NCT03101852|Experimental|Nutritional supplementation|Children included in the study with moderate acute malnutrition receive Plumpy Sup: 75kcal/kg/day, limited to 4 doses/day until they reach their target weight.
2921159|NCT03101839|Experimental|AZD4785|This is a single-arm study in which all patients will receive AZD4785 by IV infusion. Patients will continue to receive treatment with AZD4785 until disease progression, intolerable toxicity, or discontinuation criteria are met.
2921160|NCT03101826|Experimental|Filtered Music Intervention|All participants will participate in pre-intervention assessments (6 months, 1 week prior) and post-intervention assessments (1 week, 1 month post). The Filtered Music Intervention (i.e., Listening Project Protocol) will last for 1 hour per day, for 5 consecutive days.
2921161|NCT03101800|Experimental|Azathioprine and Allopurinol|
2921162|NCT03101800|Active Comparator|Azathioprine|
2921163|NCT03101787|No Intervention|CCPR protocol|"Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and rapid transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).~Clinical Upon the patient's arrival, the standard of care (CCPR) will be continued according to ERC guidelines.~No special preparations for the trial are needed before the patient's arrival."
2921164|NCT03101787|Experimental|ECPR protocol|"Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).~Clinical The ECPR team is mobilized while the patient is transported to the hospital. Initiation of extracorporeal cardiopulmonary resuscitation (ECPR).~Time from arrest to start of cannulation is < 60 minutes."
2921165|NCT03101774|Experimental|threshold-IMT group|Using inspiratory muscle training using threshold load device for 8 weeks
2921166|NCT03101774|Experimental|resisive-IMT group|Using inspiratory muscle training using resistive device for 8 weeks
2921167|NCT03101774|Sham Comparator|control group|not conduct inspiratory muscle training for 8 weeks
2921168|NCT03101748|Experimental|Group A: HER2-Positive Breast Cancer|"Group A consists of HER2-positive metastatic or locally advanced breast cancer patients.~All participants take Neratinib 1 time a day by mouth for the first week as a 1-week pre-cycle. After that, all study cycles are 21 days long. Participants take Neratinib tablets 1 time a day by mouth with food at the same time each day (in the morning, if possible) during Cycles 1 - 4.~Participants receive Paclitaxel by vein over about 1-3 hours on Days 1, 8, and 15 of Cycles 1 - 4.~Participants receive Pertuzumab by vein over about 1 hour on Day 1 of Cycles 1 - 4.~Participants receive Trastuzumab by vein over about 1-2 hours on Day 1 of Cycles 1 - 4.~All participants take Neratinib 1 time a day by mouth for the first week as a 1-week pre-cycle. After that, all study cycles will be 21 days long."
2921169|NCT03101748|Experimental|Group B: HER2+ Locally Advanced Inflammatory Breast Cancer|"Group B consists of HER2+ locally advanced inflammatory breast cancer (IBC) patients.~All participants take Neratinib 1 time a day by mouth for the first week as a 1-week pre-cycle. After that, all study cycles are 21 days long. Participants take Neratinib tablets 1 time a day by mouth with food at the same time each day (in the morning, if possible) during Cycles 1 - 4.~Participants receive Paclitaxel by vein over about 1-3 hours on Days 1, 8, and 15 of Cycles 1-4.~Participants receive Pertuzumab by vein over about 1 hour on Day 1 of Cycles 1 - 4.~Participants receive Trastuzumab by vein over about 1 - 2 hours on Day 1 of Cycles 1 - 4.~Participants receive standard-of-care Doxorubicin and Cyclophosphamide by vein over about 90 minutes on Day 1 of Cycles 5 - 8."
2921170|NCT03101748|Experimental|Group C: HER2-/ER+ Locally Advanced IBC Patients|"Group C consists of HER2-negative/ER-positive (HER2-/ER+) locally advanced IBC patients.~All participants take Neratinib 1 time a day by mouth for the first week as a 1-week pre-cycle. After that, all study cycles are 21 days long. Participants take Neratinib tablets 1 time a day by mouth with food at the same time each day (in the morning, if possible) during Cycles 1 - 4. Participants take Neratinib tablets 1 time a day by mouth with food at the same time each day (in the morning, if possible) during Cycles 1 - 4.~Participants receive Paclitaxel by vein over about 1 - 3 hours on Days 1, 8, and 15 of Cycles 1 - 4.~Participants receive standard-of-care Doxorubicin and Cyclophosphamide by vein over about 90 minutes on Day 1 of Cycles 5 - 8."
2921171|NCT03101722|Experimental|digital hearing aids intervention|Digital hearing aid intervention to patients with best results
2921173|NCT03101722|Experimental|digital hearing aids and huperzine A|Both digital hearing aids and huperzine A 0.1~0.2 mg/time, 2times/day.
2921174|NCT03101722|Placebo Comparator|control|Placebo to control group
2921175|NCT03101709|Experimental|CART-19|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CART-19 cells. The CART-19 cells are to be administered on day0,day1,day2.
2921176|NCT03101683|Experimental|PCWRT Group|Patients with diagnosis of in situ ductal carcinoma (pTis) or invasive breast carcinoma (pT1 and pT2), submitted to NAC sparing mastectomy with prosthetic-based breast reconstruction who have some additional risk factors will receive a partial chest wall radiotherapy
2921177|NCT03101670|Experimental|filgotinib|
2921178|NCT03101670|Placebo Comparator|placebo|
2921179|NCT03101644|Other|Darunavir|All patients treated with darunavir
2921180|NCT03101631|Experimental|CASE ARM|"This is a three cohorts arm with intervention (CGA):~Nutritional Assessment: Mini Nutritional Assessment (MNA)~Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.~Cognitive Assessment: Mini-Mental State Examination (MMSE-30)~Psychological status: Geriatric Depression Scale (GDS)~Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)~Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)~Age~Haemoglobin~Creatinine Clearance (CrCl)~Presence of Geriatric Syndromes"
2921181|NCT03101631|No Intervention|CONTROL ARM|This is a three cohorts arm with no intervention
2921182|NCT03101618||Allergic LAR|Laboratory animal researchers who experienced allergic symptom during exposure to laboratory or pet animals
2921183|NCT03101618||Non-allergic LAR|Laboratory animal researchers who did not experience allergic symptom during exposure to laboratory or pet animals
2921184|NCT03101618||Allergic PO|Pet owners who experienced allergic symptom during exposure to pet animals
2921185|NCT03101618||Non-allergic PO|Pet owners who did not experience allergic symptom during exposure to pet animals
2921186|NCT03101618||Allergic PIW|Allergic pet-related industry workers who experienced allergic symptom during exposure to pet animals
2921187|NCT03101618||Non-allergic PIW|Allergic pet-related industry workers who did not experience allergic symptom during exposure to pet animals
2921188|NCT03101605|Experimental|e-learning|The intervention for this study will be the completion of an original E-learning module on AOM designed by a team of pediatric residents, pediatricians, a pediatric otolaryngologist, a pediatric emergency physician and a pediatric infectious diseases specialist. The module includes interactive sections on anatomy, epidemiology, pathophysiology, microbiology, diagnostic criteria, treatment options and prognosis. A 5 minute video demonstrating appropriate pediatric ear examination techniques is also included in the module. Throughout the module, many examples of ear pathologies captured on video during a previous study. The E-learning module should take 0.5 hr to complete.
2921189|NCT03101605|Other|Standard teaching|"The control group will receive a 2h lecture on AOM, which is the standard teaching method. Given by a pediatrician or a senior pediatric resident, this lecture, using a PowerPoint© presentation support, encompasses clinical cases, notions of anatomy, epidemiology, pathophysiology, diagnostic criteria, treatment options, and prognosis, describes different ear examination techniques, and shows examples of different pathologies."
2921190|NCT03101592|No Intervention|Standard of care ART dispensing|The standard of care arm will allow ART dispensing based on usual practice at the clinic. Standard of care is anticipated to have variability in how ART is dispensed, although the approach should be consistent with applicable country guidelines at the time of study.
2921191|NCT03101592|Experimental|Three-month ART dispensing|Providers at facilities randomized to three-month ART dispensing will be expected to provide all enrolled patients with a 90-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
2921192|NCT03101592|Experimental|Six-month ART dispensing|Providers at facilities randomized to six-month ART dispensing will be expected to provide all enrolled patients with a 180-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
2921193|NCT03101579|Experimental|Intra-pemetrexed|Patients were treated with intrathecal pemetrexed at dose escalation. The regimen of intrathecal pemetrexed is 10/15/20 mg, plus dexamethasone 5 mg, twice per week for 2 weeks, followed by once per week for 2-4 weeks. Pemetrexed is administrated by intrathecal injection via lumbar puncture. Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed. A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed，once per 3 weeks. To detect the pharmacokinetics of intrathecal pemetrexed, the serum and cerebrospinal fluid samples are collected. These samples would be analyzed by spectrometer for drug concentration.
2921194|NCT03101566|Experimental|Gemcitabine + Cisplatin + Nivolumab|"Drug: Gemcitabine 1000 mg/m2 IV over 30 minutes on days 1,8 every 3 weeks~Drug: Cisplatin 25 mg/m2 IV over 30 minutes on days 1,8 every 3 weeks~Drug: Nivolumab 360 mg IV over 30 minutes on day 1 every 3 weeks~If there is continued benefit after 6 months, then:~Drug: Nivolumab 240 mg IV over 30 minutes on day 1 every 2 weeks"
2921195|NCT03101566|Experimental|Nivolumab + Ipilimumab|"Drug: Ipilimumab~1 mg/kg over 30 minutes on day 1 every 6 weeks~Drug: Nivolumab 240 mg IV over 30 minutes on day 1 every 2 weeks"
2921196|NCT03101553|Experimental|Interpretation Bias Modification|"Treatment consists of eight brief sessions consisting of two tasks. In Task 1, participants read unique scenarios (You notice someone pointing in your direction). A sentence meant to resolve the ambiguity will appear (This person thinks they reco_nize you). After filling in the missing letter, the interpretation is reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is this person mocking you?). In Task 2, participants are shown a word denoting a threatening (mocking) or benign (cheerful) interpretation. Participants are presented with an ambiguous scenario (You hear people at a nearby table laughing) and asked to denote whether the word and the sentence are related. Participants will receive feedback based on their response."
2921261|NCT03101098|Experimental|Retroperitoneal hysterectomy|In subjects allocated to the experimental group, which the uterine vessels were ligated where it originates from the internal iliac artery,
2921197|NCT03101553|Active Comparator|Progressive Muscle Relaxation|Participants will receive eight brief sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release different muscle groups.
2921198|NCT03101540|Experimental|Supplementation|Subjects received Omega-3 PUFA supplementation
2921199|NCT03101527|Experimental|Supplementation|Subjects received Omega-3 PUFA supplementation
2921200|NCT03101514|Experimental|Kanglaite group|Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.
2921201|NCT03101488|Experimental|KN035|KN035 is to be injected subcutaneously 0.1mg/kg or 0.3mg/kg or 1mg/kg or 2.5mg/kg or 5mg/kg or 10mg/kg weekly until disease progresses or unacceptable tolerability occurs.
2921202|NCT03101475|Experimental|immunotherapy + local tumor ablation|Patients with unresectable colorectal liver metastases which show at least stable disease or partial remission after 4-6 months will receive treatment with durvalumab and tremelimumab plus local tumor ablation (Radiofrequency ablation RFA or Sterotactic body radiation therapy SBRT) of selected liver lesions, followed by maintenance treatment with durvalumab.
2921203|NCT03101462|Active Comparator|Group 1|N = 20 receive one dose of 0.5 mL Licensed Trivalent FluMist on Day 0
2921204|NCT03101462|Active Comparator|Group 2|N = 20 receive one dose of 0.5 mL Inactivated Trivalent Influenza Vaccine (TIV) on Day 0
2921205|NCT03101449|Experimental|Group 1|"20 individuals of Coral UFCSPA without voice problems carry out the exercise with Finnish tube before choir practice once a week for a period of 14 weeks. The exercise will be carried out with blowing set to sound at regular frequency, with frequency variation and with the melody of Happy Birthday; each sequence will be held for 2 minutes with 1 minute interval between them."
2921206|NCT03101449|Experimental|Group 2|"20 individuals of Coral UFCSPA without voice problems carry out the exercise straw phonation before choir practice once a week for a period of 14 weeks. The exercise will be carried out with blowing set to sound at regular frequency, with frequency variation and with the melody of Happy Birthday; each sequence will be held for 2 minutes with 1 minute interval between them."
2921207|NCT03101449|No Intervention|Group 3|10 individuals of Coral UFCSPA without voice problems. Untreated group.
2921208|NCT03101436|Experimental|Lean Subjects|"Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month)~Washout 15 days~Part 2: Mediterranean diet with added Red Wine (270 ml per day) (1 month)"
2921209|NCT03101436|Experimental|Obese Subjects|"Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month)~Washout 15 days~Part 2: Mediterranean diet with added Red Wine (270 ml per day) (1 month)"
2921210|NCT03101423|Active Comparator|interleukin-2|interleukin-2 treatment per month
2921211|NCT03101423|Active Comparator|DLI|donor lymphocyte infusion (DLI) treatment per month
2921212|NCT03101410|Experimental|gluten|Selected participants will be randomly allocated to treatment group (gluten or gluten free)
2921213|NCT03101410|Experimental|gluten fee|Selected participants will be randomly allocated to treatment group (gluten or gluten free)
2921214|NCT03101397||improved group|defined by two or more of the following: A decrease in symptoms, specifically an increase in the level of exertion required before the patient must stop because of breathlessness or a decline in the frequency or severity of cough Reduction of parenchymal abnormalities on chest CT scan Physiologic improvement defined by > 10% increase in FVC (or at least > 200-ml change) or > 15% increase in single-breath DLCO (or at least > 3 ml/min/mm Hg)
2921215|NCT03101397||deteriorated group|defined by two or more of the following: An increase in symptoms, especially dyspnea or cough; An increase in opacities on chest CT scan, especially the development of honeycombing ; deterioration in lung function with > 10% decrease in FVC ( or > 200ml change) or > 15% decrease in DLCO (or at least > 3ml/min/mm Hg change).
2921216|NCT03101397||stable group|not included in improved group or deteriorated group
2921217|NCT03101384||Patient with a diagnostic error|"Defined by one of :~Absence of prescribed test included in an accepted pulmonary diagnosis algorithm in the next 48h00 after the firts contact with a physician~Absence of prescribed test included in an accepted pulmonary diagnosis algorithm by the first contacted physician but the diagnostic is done before 48h00 because the patient went at the emergency room on his own initiative.~More than one doctor consulted before the diagnostic of pulmonary embolism (excluding the emergency physician if the patient was referred by the 1st contact doctor)"
2921218|NCT03101384||Patient without a diagnostic error|Any patient that did not meet the criteria to define the diagnostic error
2921219|NCT03101371|Active Comparator|Standard of care catheter insertion|Standard of care catheter insertion in which catheter is inserted right out of package/non-treated catheter.
2921220|NCT03101371|Experimental|Aseptic protocol for catheter insertion|Aseptic protocol for catheter insertion using Povidone Iodine treated catheter and maintaining plastic sleeve on catheter
2921221|NCT03101358|Experimental|SOR007 0.15%|0.15% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
2921222|NCT03101358|Experimental|SOR007 1.0%|1.0% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
2921223|NCT03101358|Experimental|SOR007 2.0%|2.0% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
2921224|NCT03101345|Other|nutrition product|Peptamen® 1.5 Vanilla, orally administration
2921225|NCT03101332|Experimental|VR-CBT|Virtual Reality cognitive behavior therapy. 10-12 sessions of individual Cognitive Behavior Therapy with exposure tasks carried out through Virtual Reality.
2921226|NCT03101319|Experimental|Antipsychotic and Vitamin D3|Subjects randomised to vitamin D3 arm will receive a capsule containing 60,000 IU vitamin D3 starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks. The subjects will continue to receive antipsychotics as per the decision of the treating team
2921227|NCT03101319|Placebo Comparator|Antipsychotic and Placebo|Subjects randomised to the placebo arm will receive a capsule of identical size, shape, colour and weight starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks.The subjects will continue to receive antipsychotics as per the decision of the treating team
2921228|NCT03101306|Experimental|MR scans|As part of the study patients will undergo 3 additional MR scans during radiotherapy treatment. These will take place in the 1st, 2nd and 5th weeks of treatment.
2921229|NCT03101293|Experimental|TAK-831 400 mg Fasted + TAK-831 400 mg Fed|TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 2.
2921230|NCT03101293|Experimental|TAK-831 400 mg Fed + TAK-831 400 mg Fasted|TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 2.
2921231|NCT03101280|Experimental|Dose-Finding Phase (Part 1): Rucaparib and Atezolizumab|Approximately 6-18 participants with advanced gynecological cancers will receive different doses of rucaparib administered orally (PO) twice daily (BID) with a fixed dose of atezolizumab (1200 milligrams [mg] intravenously [IV], every 21 days) in 21-day cycles, starting with 400 mg rucaparib BID. The recommended Phase II dose (RP2D), determined by the highest dose level with an acceptable safety profile and with a minimum of 6 participants at which fewer than one-third of participants experience a DLT, was identified as 600 mg rucaparib twice a day (BID).
2921232|NCT03101280|Experimental|Dose-Expansion Phase (Part 2): Rucaparib and Atezolizumab|"Two tumor-specific expansion cohorts will begin treatment with a 21-day run-in period of rucaparib monotherapy at the specified dose for rucaparib in the potential RP2D identified in Part 1 for the combination. Cohort 1 will have approximately 30 participants with advanced, platinum-sensitive ovarian cancer with tumors harboring a tBRCA mutation [tBCRA(mut)] or BRCA-like molecular signature [tBRCA(wt)/LOH(high)].~Cohort 2 will have approximately 20 participants with previously treated triple-negative breast cancer (TNBC) with a tBRCA mutation [tBCRA(mut)] or BRCA-like molecular signature [tBRCA(wt)/LOH(high)] and have not been exposed to cancer immunotherapies. Following the run in period, participants will receive the combination of rucaparib (specified dose, BID) and atezolizumab (1200 mg IV, every 21 days) in 21-day cycles."
2921233|NCT03101267|Experimental|ASP4070 Lower dose group|Intradermal vaccination at 2-week intervals
2921234|NCT03101267|Experimental|ASP4070 higher dose group|Intradermal vaccination at 2-week intervals
2921235|NCT03101267|Placebo Comparator|Placebo group|Intradermal vaccination at 2-week intervals
2921236|NCT03101254|Experimental|LY3022855 + Vemurafenib + Cobimetinib|LY3022855 administered intravenously every week Vemurafenib administered by mouth twice daily Cobimetinib administered by mouth once daily on days 1-21of each cycle
2921237|NCT03101241|Experimental|CX-8998|
2921238|NCT03101241|Placebo Comparator|Placebo|
2921239|NCT03101228|Experimental|Reduced sitting|Objectively measured daily inactive time will be reduced by one hour compared to the baseline.
2921240|NCT03101228|No Intervention|Control|Subjects will be guided to maintain their normal sedentary behaviour and physical activity habits.
2921241|NCT03101215|Placebo Comparator|Placebo|glucose drink (100g) with placebo tablets
2921242|NCT03101215|Active Comparator|phosphorus|Glucose drink (100g) with phosphorus tablets (400 mg of phosphorus)
2921243|NCT03101202|Experimental|SSD Arm|In the SSD arm, the patients will be intubated with an endotracheal tube with suglottic suction drainage (SSD tube)
2921244|NCT03101202|No Intervention|Standard Arm|In the standard arm, the patients will be intubated with the standard endotracheal tube which does not have subglottic suction.
2921245|NCT03101189|Experimental|ACT-541468 (25 mg)|8 Japanese and 8 Caucasian subjects will receive 25 mg (1 capsule) of ACT-541468 once daily for 5 days
2921246|NCT03101189|Experimental|ACT-541468 (50 mg)|8 Japanese and 8 Caucasian subjects will receive 50 mg (2 capsules) of ACT-541468 once daily for 5 days
2921247|NCT03101189|Placebo Comparator|Placebo|2 Japanese / 2 Caucasian subjects will receive 1 placebo capsule to match subjects in the ACT-541468 (25 mg) group and 2 other Japanese / 2 Caucasian subjects will receive 2 placebo capsules to match subjects in the ACT-541468 (50 mg) group
2921248|NCT03101176|Experimental|Experimental: Single Arm|All consenting patients will undergo mpUS imaging prior to surgery with the ultrasound contrast agent Sonovue for the CEUS specific mode.
2921249|NCT03101163|Experimental|Intervention|Subjects randomized to the intervention group will undergo subchondral drilling surgery according to standard protocol, and will also receive a regimen of PBSC and HA intra-articular injections and postoperative physiotherapy.
2921250|NCT03101163|Active Comparator|Standard treatment|Subjects randomized to the standard treatment-controlled parallel group will receive intra-articular HA injections and a physiotherapy regimen.
2921251|NCT03101150|Active Comparator|400 IU Vitamin D3|400IU vitamin D3 contained in antenatal multivitamin once daily by mouth starting from 14 weeks of pregnancy till delivery.
2921252|NCT03101150|Experimental|4000 IU Vitamin D3|4000 IU Vitamin D3 drops once daily by mouth starting from 14 weeks of pregnancy till delivery.
2921253|NCT03101137|Active Comparator|Caudal block with dexmedetomedine|Caudal Dexmedetomidine block group (DEXM) (n= 16) will receive caudal block using the bupivacaine 0.25% and Dexmedetomidine 1 μg/kg with the conventional general anesthesia,
2921254|NCT03101137|Active Comparator|Caudal block with dexamethasone|caudal Dexamethasone Block group (DEXA) (n =16) will receive caudal block using the bupivacaine 0.25% and Dexamethasone 0.1 mg/kg with the conventional general anesthesia,
2921255|NCT03101137|Placebo Comparator|Control (caudal block with bupivacaine)|caudal with bubivacaine (CONTROL) group (n = 16) will receive caudal block using the bupivacaine 0.25% and general anesthesia.
2921256|NCT03101124|Experimental|abdominoplasty moistening|Tranexamic Acid 25 mg/ml for wound surface moistening prior to wound closure
2921257|NCT03101124|Experimental|abdominoplasty bolus|Tranexamic Acid 5 mg/ml as bolus in wound cavity after wound closure
2921258|NCT03101124|Active Comparator|preoperative intravenous administration|Tranexamic Acid Injectable Solution administered before hip replacement surgery
2921259|NCT03101111|Experimental|MV-CHIK and Placebo|"Subjects will receive two injections on study day 0 and one injection on day 28.~On both days they will receive a 5E+05 (+/- 0.5 log) TCID50 intramuscularly in the deltoid muscle of one arm.~On day 0 they will receive a dummy injection of placebo (physiological saline) subcutaneously in the contralateral arm."
2921260|NCT03101111|Active Comparator|MMR-vaccine and Placebo|"Subjects will receive two injections on study day 0 and one injection on day 28.~On both days they will receive dummy injections of placebo (physiological saline) in the deltoid muscle of one arm.~On day 0 they will receive MMR-vaccine subcutaneously in the contralateral arm."
2921262|NCT03101098|Active Comparator|Classical hysterectomy|The operative technique of classical total laparoscopic hysterectomy (TLH) performed in the control group was comparable to that of retroperitoneal TLH, except for one that coagulation and transection of uterine artery was achieved using an energy device alongside the cervix
2921263|NCT03101085|Experimental|S-equol|Participants will receive S-equol 50mg twice daily for one month
2921264|NCT03101085|Placebo Comparator|Placebo|Participants will receive matched placebo pill to take twice daily for one month
2921265|NCT03101072|Active Comparator|"Fixed long antibiotic course"|"Patients randomized to this group will receive a fixed long antibiotic course of 14 days."
2921266|NCT03101072|Experimental|"Fixed short antibiotic course"|"Patients randomized to this group will receive a fixed short antibiotic course of 7 days."
2921267|NCT03101072|Experimental|"Individualized antibiotic course"|"Individualized antibiotic course: starting on day 5, therapy will be discontinued after the patient has been afebrile for 48 hours and the CRP level has decreased from its peak by at least 75%"
2921268|NCT03101059|Experimental|MKS pax|Munier-Kuhn Syndrome patients
2921269|NCT03101046|Active Comparator|Group1: Arm A (Standard treatment arm)|Patients with docetaxel resistant mCRPC defined as having ≥ 5 CTCs / 7.5 ml will receive 6 additional cycles of docetaxel (75 mg/m2 every 3 weeks) after randomization.
2921270|NCT03101046|Experimental|Group1: Arm B|Patients with docetaxel resistant mCRPC (defined as having ≥ 5 CTCs / 7.5 ml) will receive 6 cycles of cabazitaxel (20 mg/m2 every 3 weeks) after randomization.
2921271|NCT03101046|Other|Group 2: Cohort|Patients with docetaxel sensitive mCRPC (defined as having < 5 CTCs / 7.5 ml) will receive 6 additional cycles of docetaxel.
2921272|NCT03101033|Experimental|Epidural neuroplasty group|This group will be given epidural neuroplasty once enrolled.
2921273|NCT03101033|Active Comparator|Transforaminal steroid injection group|This group will be given transforaminal betamethasone injection once enrolled, if no obvious pain relief was reported, another epidural injection will be given one week later.
2921274|NCT03101020|Experimental|Experimental Group|The participants will receive standard care physiotherapy plus active visceral manipulation
2921275|NCT03101020|Placebo Comparator|Control Group|The participants will receive stardad care physiotherapy plus placebo visceral manipulation
2921276|NCT03101007|Experimental|ATTUNE|Total Knee Replacement Surgery with cementless ATTUNE Rotating Platform Knee Prosthesis by DePuy
2921277|NCT03101007|Active Comparator|LCS|Total Knee Replacement Surgery with cementless LCS Rotating Platform Knee Prosthesis by DePuy
2921278|NCT03100994|No Intervention|Group A|without nerve block
2921279|NCT03100994|Active Comparator|Group B|Ultrasound guided transmuscular quadratus lumborum block with 0.125% bupivacaine 30ml
2921280|NCT03100994|Active Comparator|Group C|Ultrasound guided quadratus lumborum type 2 block with 0.125% bupivacaine 30ml
2921281|NCT03100981|Experimental|Internet-delivered MBCT|The intervention group will immediately receive 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy.
2921282|NCT03100981|Other|Waitlist control|The control group will be on a waiting list to participate in Internet-delivered MBCT after the 6-months follow-up time has passed.
2921283|NCT03100968|Active Comparator|Palpation Group|The palpation group will have an epidural placed after manual palpation of the spine.
2921284|NCT03100968|Active Comparator|Ultrasound Group|The ultrasound group will have an epidural placed after identifying midline with the ultrasound.
2921285|NCT03100955|Active Comparator|EP chemotherapy|Standard treatment or active comparator group contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide.
2921286|NCT03100955|Experimental|EP chemotherapy plus apatinib|Apatinib treatment or experimental group contains standard chemotherapy and apatinib, a VEGF tyrosine kinase inhibitor. It contains a platinum drug, a topoisomerase inhibitor and a VEGF-TKI. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI=apatinib, 500 mg, oral daily after chemotherapy, until disease progression or death or un-tolerated toxicites. Used drugs=cisplatinum and etoposide and apatinib.
2921287|NCT03100942|Experimental|Filgotinib|Filgotinib + GS-9876 placebo + tirabrutinib placebo for 48 weeks
2921288|NCT03100942|Experimental|GS-9876|GS-9876 + filgotinib placebo + tirabrutinib placebo for 48 weeks
2921289|NCT03100942|Experimental|Tirabrutinib|Tirabrutinib + filgotinib placebo + GS-9876 placebo for 48 weeks
2921290|NCT03100942|Placebo Comparator|Placebo, then active treatment|Filgotinib placebo + GS-9876 placebo + tirabrutinib placebo for 24 weeks. Following completion of the Week 24 assessments and procedures, participants on placebo will be rerandomized to receive either filgotinib, GS-9876, or tirabrutinib, in a blinded fashion and will continue treatment through Week 48.
2921291|NCT03100929|Experimental|Elective cesarean section|Any patient undergoing elective cesarean section. Ultrasound
2921292|NCT03100916|Experimental|Dose Ranging Arm|
2921293|NCT03100916|Experimental|Food Effect arm|
2921294|NCT03100903|Experimental|BI 655130|
2921295|NCT03100890|No Intervention|Control|Non-active comparator
2921296|NCT03100890|Active Comparator|Balance-Proprioception (Hospital)|Preoperative training (hospital)
2921297|NCT03100890|Experimental|Balance-Proprioception (Home)|Preoperative training (home)
2921298|NCT03100877|Experimental|Treatment (mel/TMI, ASCT)|"MOBILIZATION AND APHERESIS: Patients receive cyclophosphamide IV over 2 hours. Beginning 24 hours after cyclophosphamide administration, patients receive filgrastim SC or IV. Patients also undergo apheresis over 4 hours on day 10.~CONDITIONING REGIMEN: Patients receive palifermin IV on days -8, to -6, undergo TMI on days -5 to -2, and receive melphalan IV over 30 minutes on day -1. Patients then undergo ASCT IV on day 0, receive palifermin IV on days 1-3, and receive filgrastim SC or IV on day 5.~MAINTENANCE THERAPY: Beginning 30 days after ASCT, patients receive lenalidomide PO daily."
2921299|NCT03100864|Experimental|BI 655130|
2921300|NCT03100851|Experimental|LcS intervention|Patients with constipation received dietary supplement with Lactobacaiilus casei strain Shirota.
2921301|NCT03100838|Experimental|Nifedipine (brand)|1 x 60 mg PROCARDIA XL (nifedipine) extended-release tablet
2921303|NCT03100838|Active Comparator|Nifedipine (Generic) + PPI|1 x 40 mg/1100 mg omeprazole/sodium bicarbonate capsule daily over a period of 7 days + 1 x 60 mg Nifedipine extended-release tablet on day 7
2921304|NCT03100838|Active Comparator|Nifedipine (brand) + PPI|1 x 40 mg/1100 mg omeprazole/sodium bicarbonate capsule daily over a period of 7 days + 1 x 60 mg PROCARDIA XL (nifedipine) extended-release tablet on day 7
2921305|NCT03100825|Experimental|QVM149|All eligible patients take QVM149 150/50/160 μg once daily over 52 weeks.
2921306|NCT03100812|Experimental|Group A|
2921307|NCT03100812|Experimental|Group B|
2921308|NCT03100799|Other|Patients with osteoarthritis of the knee|This is an exploratory non-drug, interventional biomarker study, however, there are study related procedures which are interventional such as arthroscopy, arthrocentesis and MRI assessment with infusion of a gadolinium-contrast agent.
2921309|NCT03100786|Active Comparator|Dexamethasone|standard anti-tuberculosis drugs plus dexamethasone for 6-8 weeks
2921310|NCT03100786|Placebo Comparator|Identical placebo|standard anti-tuberculosis drugs plus placebo for 6-8 weeks
2921311|NCT03100773|Experimental|Group control|Caries-free children submitted to four consecutive sessions of oral health educational strategy (once a week).
2921312|NCT03100773|Experimental|Group of strategy + ART|Children with at least one decayed primary molar in dentin submitted to four consecutive sessions of oral health educational strategy (once a week) followed by Atraumatic Restorative Treatment (ART)
2921313|NCT03100773|Experimental|Group of ART|Children with at least one decayed primary molar in dentin submitted to Atraumatic Restorative Treatment (ART)
2921314|NCT03100747|Active Comparator|Bilamellar 3mm|Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 3mm from the eyelid margin.
2921315|NCT03100747|Active Comparator|Bilamellar 5mm|Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 5mm from the eyelid margin.
2921316|NCT03100747|Active Comparator|Trabut 3mm|Trabut surgery involves a partial-thickness incision through the upper eyelid parallel to the eyelid margin. For this surgery, the height of the incision will be assigned at 3 mm from the eyelid margin.
2921317|NCT03100734||With RA|Participants with RA previously treated with Enbrel and transitioned to Benepali
2921318|NCT03100734||With axSpA|Participants with axSpA previously treated with Enbrel and transitioned to Benepali
2921319|NCT03100721|Experimental|PNE+Physiotherapy|Pain neuroscience education (PNE) can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system. It will be applied one time (at baseline). Physiotherapy includes kinesitherapy and exercises.
2921320|NCT03100721|Active Comparator|Physiotherapy|Physiotherapy includes kinesitherapy and exercises.
2921321|NCT03100708||Patient with peritoneal carcinomatosis|Patient with peritoneal carcinomatosis and the Indication for local therapy. The Clinics tumor-board advice is needed.
2921322|NCT03100695|No Intervention|Control|Patients will undergo operative procedure with no additional intervention.
2921323|NCT03100695|Experimental|Study|Patients will undergo usual operative procedure with the addition of an injection of autologous, concentrated PRP-BMA at the site of fixation.
2921324|NCT03100669||Pectus surgery|Single arm study: patient undergoing pectus repair surgery
2921325|NCT03100656|Other|All subjects|All subjects will undergo the same food challenge protocol
2921326|NCT03100630|Active Comparator|Treatment A: RO7239361|RO7239361 subcutaneous injections on specified days; abdomen
2921327|NCT03100630|Active Comparator|Treatment B: RO7239361|RO7239361 subcutaneous injections on specified days; arm
2921328|NCT03100630|Active Comparator|Treatment C: RO7239361|RO7239361 subcutaneous injections on specified days; thigh
2921329|NCT03100617|Experimental|REACH-VA family caregiver intervention|Behavioral intervention with several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
2921330|NCT03100604|Experimental|sevoflurane 2%, 1 MAC|Maintenance of anesthesia was provided with 2% sevoflurane in S Group, and 6-9% desflurane in D Group, with 50% air /oxygen mixture and fresh gas flow at 4 l/min in both groups.
2921331|NCT03100604|Experimental|Desfluran 6-9% 1MAC|Maintenance of anesthesia was provided with 2% sevoflurane in S Group, and 6-9% desflurane in D Group, with 50% air /oxygen mixture and fresh gas flow at 4 l/min in both groups.
2921332|NCT03100591|Experimental|14C-radiolabelled ACT-132577|On Day 1, subjects will receive a single oral dose of 25 mg 14C-radiolabeled ACT-132577, administered as an oral formulation in the fasted state
2921333|NCT03100578|Experimental|PLASTIC STENT|"Endoscopic double pigtail plastic stent, with formal indication on pancreatic collection, according to the instruction forms of the manufacturer.~Interventions associated:~EUS-guided transmural drainage of pancretic collection: PLASTIC STENT."
2921334|NCT03100578|Active Comparator|SELF EXPANDABLE METALLIC STENT|"Lumen apposing metal stent with formal indicaction on pancreatic collection, according to the manufacturer instruction forms.~Interventions associated:~EUS-guided transmural drainage of pancretic collection: METALLIC STENT."
2921335|NCT03100565|Placebo Comparator|colposcopic biopsy under local anesthetic sp|
2921336|NCT03100565|Placebo Comparator|Patients underwent colposcopic biopsy under forced coughing|
2921337|NCT03100552||Study population|Patients referred to a tertiary endoscopic resection practice found to have an SSP >= 8mm. Endoscopic imaging applied to the sessile serrated polyp (SSP) to determine the presence or absence of dysplasia.
2921338|NCT03100539|Active Comparator|Care giver treatment arm (CG-M)|"The caregiver -assisted massage (CG-M) intervention will consist of 3 treatment components:~An in-person training workshop~An instructional DVD recording to reinforce concepts taught during the in-person training session~A written treatment manual with illustrations and images to serve as a reference for participants. Participants will be asked to engage in at least 3 care giver-assisted massage sessions (30 minutes each) every week at home for the 3-month intervention period. To standardize delivery and facilitate reproducibility of CG-M, the content and general structure of the caregiver-delivered massage routine is established and will be taught during the training workshop."
2921417|NCT03100045|Experimental|ART 400 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 400 mg/day
2921339|NCT03100539|Experimental|Therapist treated massage (TT-M)|Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.
2921340|NCT03100539|No Intervention|Wait list control (WL-C)|Participants in the waitlist control will be instructed to continue their medical care as normal and to not begin any massage treatment during the 6 months of the study. At the competition of the final 6 month outcome, participants in the control arm will be eligible to attend a caregiver training session and receive a complementary massage session from a TOMCATT study therapist.
2921341|NCT03100526|Experimental|Intervention--PACT Intensive Management|The intervention is the PACT Intensive Management Program (PIM) which provides intensive interdisciplinary care planning, care coordination, patient self-management support, and tailored goal setting based on patient needs and preferences, and additional care management services.
2921342|NCT03100526|No Intervention|Usual care|High-Risk patients receiving care in PACT.
2921343|NCT03100513|Active Comparator|Lactulose|(20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate.
2921344|NCT03100513|Active Comparator|Polyeyhylene Glychol|Polyethylene Glycol 3sachets if patient <75Kg over 3 hours or 4 sachets if patient >75Kg over 4 hours dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water)
2921345|NCT03100500|Experimental|QMF149|All eligible patients take QMF149 150/320 μg once daily over 52 weeks.
2921346|NCT03100487|Experimental|Audio Record Guided Imagery (ARGI)|The audio recorded guided imagery sessions (treatment) will be delivered through a digital audio player (Apple iPod Shuffle).
2921347|NCT03100487|Experimental|Deep Breathing Exercises|The deep breathing exercises (control) will be delivered through a digital audio player (Apple iPod Shuffle).
2921348|NCT03100461|Active Comparator|HE + HE|Participants receive up to two interventions. Participants receive HE initially and then a second time if not screened after 6 months.
2921349|NCT03100461|Active Comparator|HE + I2|Participants receive up to two interventions. Participants receive HE initially and then I2 if not screened after 6 months.
2921350|NCT03100461|Experimental|I2 + I2|Participants receive up to two interventions. Participants receive I2 initially and then a second time if not screened after 6 months.
2921351|NCT03100461|Active Comparator|I2 + HE|Participants receive up to two interventions. Participants receive I2 initially and then HE if not screened after 6 months.
2921352|NCT03100448|Other|On1 Concept|On1 Concept & NobelActive implants
2921353|NCT03100435|Experimental|Er:YAG Laser|Er:YAG Laser only
2921354|NCT03100435|Active Comparator|Carbon Fiber Curette|Carbon fiber curette only
2921355|NCT03100435|Experimental|Er:YAG Laser + Carbon Fiber Curette|Combination of Er:YAG Laser and carbon fiber curette
2921356|NCT03100435|No Intervention|No Treatment|No treatment (control)
2921357|NCT03100422|Experimental|ARMin|Therapy with the arm therapy robot ARMin
2921358|NCT03100422|Active Comparator|Arm+ occupational therapy|a form of conventional occupational therapy that involves both arms
2921359|NCT03100409|Experimental|Dietary modification|Personalized dietary intervention, low residue diet
2921360|NCT03100409|No Intervention|Control|Dietary recommendations currently used in the INCan
2921361|NCT03100370|Active Comparator|tsDCS- Anodal Stimulation & robotic arm training (RAT)|anodal tsDCS over cervical spine, 2.5mA for 20 minutes
2921362|NCT03100370|Active Comparator|tsDCS- Cathodal Stimulation & RAT|cathodal tsDCS over cervical spine, 2.5mA for 20 minutes
2921363|NCT03100370|Sham Comparator|tsDCS- Sham Stimulation & RAT|sham tsDCS over cervical spine, 2.5mA for 20 minutes
2921364|NCT03100344|Experimental|Group 1|Nemolizumab (low dose)
2921365|NCT03100344|Experimental|Group 2|Nemolizumab (medium dose)
2921366|NCT03100344|Experimental|Group 3|Nemolizumab (high dose)
2921367|NCT03100344|Placebo Comparator|Group 4|Nemolizumab placebo
2921368|NCT03100331|Experimental|Single Arm; all receive neuropsychological testing & follow-up|
2921369|NCT03100318|Experimental|FYU-981|
2921370|NCT03100318|Active Comparator|Benzbromarone|
2921371|NCT03100305||Extremely preterm infants|
2921372|NCT03100305||Very preterm infants|
2921373|NCT03100305||Moderately preterm infants|
2921374|NCT03100305||Late preterm infants|
2921375|NCT03100292|Experimental|bariatric surgery|"This trial is a single-arm study and the enrolled patients are going to undergo sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB).~If the patient has Barrett's esophagus on the preoperative endoscopy, SG is not permitted. Inflammatory bowel disease and Helicobacter pylori infection on a rapid urease test are contraindications of RYGB."
2921376|NCT03100279|Experimental|CBT for Anxiety or Depression|If a youth meets criteria for a primary diagnosis of clinical or subclinical depressive disorder she or he will be assigned to Primary and Secondary Control Enhancement Therapy (PASCET; Weisz et al., 1987). If a youth meets criteria for a primary diagnosis for a clinical or subclinical anxiety disorder, she or he will be assigned to the Coping Cat (Kendall, 2000). Both CBT treatments include a therapist manual and companion workbooks for the youth. CBT teaches coping skills that help anxious and depressed youth challenge anxious and depressive thinking. It also helps the child habituate to negative physiological feelings and learn skills to cope with emotional distress.
2921377|NCT03100266|Experimental|probiotic|Lactobacillus rhamnosis GG
2921378|NCT03100266|Placebo Comparator|placebo|Inactive capsules
2921379|NCT03100253|Experimental|"Switching strategy"|Tocilizumab [RoActemra®] [ATC: L04AC07] 8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days
2921380|NCT03100253|Active Comparator|"Cycling strategy"|"Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab OR~Infliximab, adalimumab, golimumab or certolizumab if initial failure to the receptor fusion protein, etanercept."
2921381|NCT03100240|Experimental|Experimental group|Modified Supper Long Protocol
2921382|NCT03100240|No Intervention|control group|long protocol
2921418|NCT03100045|Experimental|ART 400 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 400 mg/day
2921419|NCT03100045|Experimental|ART 600 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 600 mg/day
2921383|NCT03100227|Active Comparator|PET [18F] FDG|Each subject will have a PET scan at [18F] FDG.The raw imaging data obtained from these controls will be post-processed using the Statistical Parametric Mapping software. Schematically, the data of each control will be normalized in the same anatomical space, then smoothed and averaged between the different controls. This will make it possible to constitute the normative database.
2921384|NCT03100227|Sham Comparator|Review test-retest|Of the 40 volunteers included, 10 will have test-retest exams (2 separate exams every 15 days).
2921385|NCT03100214|Active Comparator|Control|Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions.
2921386|NCT03100214|Experimental|Exercise|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
2921387|NCT03100201|Active Comparator|Intervention Armeo®Spring|The intervention group will receive conventional occupational- and physiotherapy and an additive robotic-assisted training using the Armeo®Spring robot for three weeks.
2921388|NCT03100201|Active Comparator|Control group|The control group will receive conventional occupational- and physiotherapy.
2921389|NCT03100188|Experimental|modified PD|Patients with residual renal kt/v were placed in intervention group
2921390|NCT03100175|Experimental|intervention|"the patient will be scheduled for another appointment and taught a set of exercises including strength training for upper and lower limbs (with elastic bands and weights, rising up from chair and climbing stairs), fitness work out (brisk walking) and balance exercises, as recommended by senior sport programs.~Patients will be provided with printed instructions explaining the recommended exercises, and with a diary to fill in, with days and number of repetitions of specific training elements to be checked in according to their compliance. Patients will also be equipped with a pedometer and will be asked to record the counts regularly~Patients will be met again by a physiotherapist for follow up at the start of every chemotherapy course (once in 3-4 weeks) and will be contacted by phone twice weekly to assure they stick to the training recommendations"
2921391|NCT03100175|No Intervention|control|The control group will receive standard treatment and follow-up with no special emphasis on physical activity
2921392|NCT03100162|Placebo Comparator|Placebo|Individuals receive a placebo daily, for 3 months.
2921393|NCT03100162|Active Comparator|Probiotic 2g|Individuals receive 2 g of probiotic daily, for 3 months.
2921394|NCT03100162|Active Comparator|Probiotic 4g|Individuals receive 4 g of probiotic daily, for 3 months.
2921395|NCT03100149|Experimental|Part 1: RO7046015 High Dose|Participants will receive RO7046015 at high dose level as intravenous infusion every 4 weeks (Q4W) up to 52 weeks in Part 1.
2921396|NCT03100149|Experimental|Part 1: RO7046015 Low Dose|Participants will receive RO7046015 at low dose level as intravenous infusion Q4W up to 52 weeks in Part 1.
2921397|NCT03100149|Placebo Comparator|Part1: Placebo|Participants will receive placebo as intravenous infusion Q4W up to 52 weeks in Part 1.
2921398|NCT03100149|Experimental|Part 2: RO7046015 High Dose|Part 1 RO7046015 high dose group participants and placebo group participants randomized to high dose level will receive RO7046015 at high dose level as intravenous infusion Q4W for additional 52 weeks in Part 2.
2921399|NCT03100149|Experimental|Part 2: RO7046015 Low Dose|Part 1 RO7046015 low dose group participants and placebo group participants randomized to low dose level will receive RO7046015 at low dose level as intravenous infusion Q4W for additional 52 weeks in Part 2.
2921400|NCT03100136|Experimental|[11C]PF-06809247|A dose intravenous injection of [11C]PF-06809247 followed by PET scanning.
2921401|NCT03100123|Active Comparator|Standard of Care Arm|Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.
2921402|NCT03100123|Experimental|Experimental Arm|Open-label low-dose Aspirin 81 mg daily from randomization until delivery.
2921403|NCT03100110|Experimental|NeuroCognitive Communicator|
2921404|NCT03100097|Experimental|Intervention (Aspen Horizon 627 LSO)|Patients receive a lumbar brace, Aspen Horizon 627 LSO, in addition to normal medical management
2921405|NCT03100097|No Intervention|Medical Management|Normal medical management
2921406|NCT03100084||I. Post Dates|"Pregnant women referred for clinical post term evaluation and/or labour induction.~Blood sampling."
2921407|NCT03100084||II. Induction of Labour|"Pregnant women ≥37+0 GW (gestational week) referred for labour induction (any cause).~Blood sampling."
2921408|NCT03100084||III. All Outpatients|"Pregnant women ≥37+0 GW presenting for any medical reason at OUH outpatient clinic.~Blood sampling"
2921409|NCT03100084||IV. Diabetes in Pregnancy|Pregnant women ≥36+0 GW with pregestational or gestational diabetes. Blood sampling.
2921410|NCT03100084||V. Reduced Fetal Movements|"Pregnant women ≥37+0 GW with reduced fetal movements and/or referred due to reduced symphysis-fundal height.~Blood sampling."
2921411|NCT03100084||VI. Hypertensive Disorders in Pregnancy|"Pregnant women referred for preeclampsia (or other pregnancy induced hypertensive disorders) and/or suspected fetal growth restriction; longitudinal cohorts.~Blood sampling."
2921412|NCT03100084||VII. All Labour Admissions|All pregnant women ≥37+0 GW admitted for labour. Blood sampling.
2921413|NCT03100058|Experimental|LIK066|Subjects eligible for randomization will be assigned to different dosing groups which are defined by once daily or twice daily dosing frequency for 24 weeks. Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily.
2921414|NCT03100058|Placebo Comparator|Placebo|subjects randomized to this treatment arm will receive LIK066 matching placebo tablets for 24 weeks. From week 24 to week 48, half of the patients who received placebo in the first 24 weeks will receive Dose A LIK066 once daily and other half will receive placebo
2921415|NCT03100045|Experimental|ART 200 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 200 mg/day
2921416|NCT03100045|Experimental|ART 200 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 200 mg/day
2921420|NCT03100045|Experimental|ART 600 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 600 mg/day
2921421|NCT03100032|Experimental|NVD-001|Autologous osteogenic cells in ECM with DBM
2921422|NCT03100032|Active Comparator|Standard of Care|Best standard of care in surgical practice
2921423|NCT03100019|Experimental|Resveratrol Hypoxia|500mg of trans-resveratrol, tested at a 16% atmospheric oxygen level; the equivalent to 2134m above sea level.
2921424|NCT03100019|Placebo Comparator|Placebo Hypoxia|Pharmaceutical grade fumed silica, tested at a 16% atmospheric oxygen level; the equivalent to 2134m above sea level.
2921425|NCT03100019|Experimental|Resveratrol Normoxia|500mg of trans-resveratrol, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
2921426|NCT03100019|Placebo Comparator|Placebo Normoixa|Pharmaceutical grade fumed silica, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
2921427|NCT03100006|Experimental|Nivolumab and Oregovomab|
2921428|NCT03099993|Other|A: Healthy volunteers|
2921429|NCT03099993|Other|B: Patient with heamiplegia|
2921430|NCT03099993|Other|C: Patient with heamiplegia and constraint induced therapy|arm with constraint induced therapy (done before the protocol)
2921431|NCT03099980|Experimental|Secukinumab|All participants will be assigned to receive secukinumab 300 mg (2 x 150 mg PFS subcutaneous injections) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 more weeks.
2921432|NCT03099941|Experimental|Biofeedback group|The biofeedback application which helps patient to understand neutral position and how to maintain it in exercises that are prescribed by the physical therapist
2921433|NCT03099941|Active Comparator|Physical therapist feedback group|In physical therapist feedback group feedback applied by oral and tactile stimulation of physical therapist to helps patient to understand neutral position and how to maintain it in exercises that are prescribed
2921434|NCT03099928||Qualitative Interviews|
2921435|NCT03099902||Cases|Children with asthma/wheezing whose mothers were active smokers during pregnancy
2921436|NCT03099902||Controls|Children without asthma/wheezing whose mothers were active smokers during pregnancy
2921437|NCT03099889|Experimental|Physical Activity intervention arm|Receive a tailored behavioral interventions for exercise and strength training via multiple channels including frequent mailings, integrated voice response and outreach phone calls, interactive website, and referral to local community exercise resources.
2921438|NCT03099889|No Intervention|Control arm|Receive general health mailings
2921439|NCT03099876||7 days treament group|7 days of triple therapy (Ilaprazole 10mg, Clarithromycin 500mg Amoxicillin 1000mg B.I.D)
2921440|NCT03099876||10 days treatment group|10 days of triple therapy (Ilaprazole 10mg, Clarithromycin 500mg Amoxicillin 1000mg B.I.D)
2921441|NCT03099863|Placebo Comparator|Standard Care|Standard cystoscopy with normal saline solution.
2921442|NCT03099863|Active Comparator|Neosporin G. U. Irrigant|Standard cystoscopy with normal saline solution containing Neosporin® G.U. at a 1mL/1000mL concentration.
2921443|NCT03099850||Chronic Pancreatitis|
2921444|NCT03099837||Pregnant mothers|
2921445|NCT03099837||infants|
2921446|NCT03099837||children|
2921447|NCT03099824|Active Comparator|Dose Escalation: IV GC4419 + GC4711/Placebo Oral Capsule|Part 1
2921448|NCT03099824|Experimental|Food Effect Study: IV GC4419 + GC4711 Oral Capsule|Part 2
2921449|NCT03099811|Experimental|Intervention: Financial incentives + Smoking cessation program|Caregiver and a social network member will receive financial incentives, in additional to enrollment in a state-sponsored smoking cessation program, based on nicotine biomarker measurements.
2921450|NCT03099811|Other|Intervention: Smoking cessation program|Caregiver and a social network member will be enrolled in a state-sponsored smoking cessation program.
2921451|NCT03099798||Non-Operative Management (NOM)/Observational|"Patients treated observationally for (traumatic) spleen injury."
2921452|NCT03099798||Splenic Artery Embolization|Patients treated with splenic artery embolization for (traumatic) spleen injury.
2921453|NCT03099798||Surgery|Patients treated surgically for (traumatic) spleen injury.
2921454|NCT03099785|Active Comparator|Treatment group 1: dose regimen 1|Rifamycin SV-MMX® 600 mg modified release tablets, three times daily (t.i.d.)
2921455|NCT03099785|Active Comparator|Treatment group 2: dose regimen 2|Rifamycin SV-MMX® 600 mg modified release tablets, two times daily (b.i.d.) + matching placebo daily (q.d.)
2921456|NCT03099785|Placebo Comparator|Treatment group 3: matching placebo|Rifamycin SV-MMX® matching placebo tablets, t.i.d.
2921457|NCT03099772|Experimental|CBT-IU|Cognitive-behavioral therapy for intolerance of uncertainty
2921458|NCT03099759|Active Comparator|Vitamin Dose Group 100,000 Units|100,000 units Vitamin D2 one time only.
2921459|NCT03099759|Active Comparator|Vitamin Dose Group 100,000 Units D2|100,000 units vitamin D2 weekly for three months.
2921460|NCT03099759|Active Comparator|Vitamin Dose Group 50,000/2,000 D2/D3|50,000 units Vitamin D2 for 10 days followed by 2,000 units Vitamin D3 daily the remainder of the three month study period.
2921461|NCT03099746|Experimental|INVOLVE|"The first study condition, called Interactive Virtual Decision Support for End-of-Life and Palliative Care (INVOLVE) will consist of exposures to an avatar-based decision support technology that will be administered via tablet computer and allow SDMs opportunities to practice their communication and decision making skills through interactions with avatars that portray a decision coach and various healthcare providers."
2921462|NCT03099746|Experimental|Informational Support|The second condition, called Informational Support (IS), will also be administered via tablet computers and expose SDMs to educational resources of INVOLVE without the experiential components.
2921463|NCT03099746|Experimental|Usual Care|The third condition, usual care (UC), will expose SDMs to the routine communication and decisional support practices provided by the healthcare team.
2921464|NCT03099733|Experimental|concussion|patients who present to ED with concussion
2921465|NCT03099720|Experimental|intervention group|Participants are given ropivacaine (0.5%) at a total dose of 50 ml, 30 ml of which is injected locally and 20 ml into the peritoneum once before the end of operation as pre-emptive analgesia.
2921466|NCT03099720|Placebo Comparator|control group|Participants are given a placebo in the form of fluid injection of saline (0.9%) at total of 50 ml, 30 ml of which is injected locally and 20 ml into the peritoneum once before the end of operation
2921467|NCT03099707|No Intervention|Standard of Care|Participants are administered baseline, 3 month, and 6 month questionnaires and provided with study incentive (100 Rand per survey plus an additional 200 Rand to complete all three surveys) only. This group will not receive any additional engagement to care intervention. Investigators intend to follow their clinical outcomes through medical registries, pharmacy data, and the National Health Laboratory Service (a national database for all individuals living with HIV in South Africa regarding engagement in care).
2921468|NCT03099707|Active Comparator|Treatment Ambassador Intervention|Participants are administered baseline, 3 month, and 6 month questionnaires and provided with study incentive (100 Rand per survey plus an additional 200R to complete all three surveys). For participants randomized to the intervention arm, they will immediately meet with a Treatment Ambassador to begin the 8 session intervention, which has components of motivational interviewing, peer-support, and peer navigation. The protocol is detailed in a study manual that has been reviewed and undergone multiple iterative revisions to ensure cultural acceptability.
2921469|NCT03099694|Active Comparator|nCPAP|nasal continuous positive airway pressure (nCPAP) — as a primary mode of ventilation in premature infants with RDS
2921470|NCT03099694|Active Comparator|nHFOV|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in premature infants with RDS
2921471|NCT03099681||Epitheloid Sarcoma patients|Patients with diagnosis of localized or advanced epitheloid sarcoma seen in the Italian reference centers for sarcoma treatment that receive treatment for Epitheloid Sarcoma
2921472|NCT03099668|Experimental|OSAC|Single visit to a multidisciplinary clinic (the One Stop Arthritis Clinic, OSAC), followed by routine care
2921473|NCT03099668|No Intervention|Routine care|Routine care
2921474|NCT03099655|Experimental|Attain Stability Quad Lead|Attain Stability Quad Lead (Model 4798) - Single arm study.
2921475|NCT03099642|Experimental|Ultrasound assisted lumbar puncture|The intervention of interest will be the ultrasound-assisted lumbar puncture (UALP). To do this, the treating physician will perform a bedside ultrasound of the spine to identify and mark the level of the conus medullaris and preferred puncture site prior to LP
2921476|NCT03099642|No Intervention|Standard lumbar puncture|The control group will have a standard landmark-based lumbar puncture
2921477|NCT03099629|Experimental|IMT|inspiratory muscle training
2921478|NCT03099616|Active Comparator|CLADS group|Anesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anaesthesia maintenance will be done with Propofol, with the dosing based on adjusted body weight (ABW), and administration controlled with CLADS tuned to consistent anaesthetic depth (BIS-50) feedback from the patients.
2921479|NCT03099616|Active Comparator|Desflurane group|Anesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia.Thereafter anaesthesia maintenance will be done with desflurane using an agent specific vaporiser, whose dial concentration will be adjusted to maintain a BIS of 50-55 in all the patients
2921480|NCT03099603|Placebo Comparator|0.5g|single dose of placebo to 2 healthy subjects or 0.5g HTD1801 to 6 healthy subjects
2921481|NCT03099603|Placebo Comparator|1.0g|single dose of placebo to 2 healthy subjects or 1.0g HTD1801 to 6 healthy subjects
2921482|NCT03099603|Placebo Comparator|2.0g|single dose of placebo to 2 healthy subjects or 2.0g HTD1801 to 6 healthy subjects
2921483|NCT03099603|Placebo Comparator|4.0g|single dose of placebo to 2 healthy subjects or 4.0g HTD1801 to 6 healthy subjects
2921484|NCT03099590|Experimental|Active Treatment, Alkontrol-herbal|Alkontrol-herbal, a kudzu extract which contains 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
2921485|NCT03099590|Placebo Comparator|Placebo Control|Matched dextran containing capsules will serve as placebo.
2921486|NCT03099577|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 64.8 Gy
2921487|NCT03099577|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 69.6 Gy
2921488|NCT03099577|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 74.4 Gy
2921489|NCT03099577|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 79.2 Gy
2921490|NCT03099577|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 84 Gy
2921491|NCT03099577|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 88.8 Gy
2921492|NCT03099577|Experimental|radiochemotherapy 7|Patients will be treated with radiation therapy 93.6 Gy
2921493|NCT03099564|Experimental|pembrolizumab + Y90 radioembolization|Pembrolizumab 200mg IV every 3 weeks in conjunction with Y90 radioembolization (performed one week after the first dose of pembrolizumab)
2921494|NCT03099551|Active Comparator|Manual Toothbrush users|Group using manual toothbrush Curaprox 5460 Ultra Soft
2921495|NCT03099551|Active Comparator|Sonic Toothbrush users|Group using sonic toothbrush Edel White
2921496|NCT03099538|Experimental|Ixekizumab|Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.
2921497|NCT03099525||RA-ILD|Patients who are diagnosed with ILD. No intervention in this study.
2921498|NCT03099525||RA-non ILD|Patients who are not diagnosed with ILD. No intervention in this study.
2921499|NCT03099512|Experimental|Ex+SFE Group|Individuals in this group who will perform exercises for knee and also short foot exercise
2921500|NCT03099512|Active Comparator|Ex Group|Individuals in this group who will perform exercises for knee only
2921501|NCT03099499|Experimental|ONC201 treatment Arm|
2921502|NCT03099486|Experimental|Regorafenib + 5FU/LV Treatment Arm|
2921503|NCT03099473|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve.
2921504|NCT03099473|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve.
2921666|NCT03098433|Active Comparator|Levothyroxine|Each participant will receive a single dose of levothyroxine
2921505|NCT03099473|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
2921506|NCT03099460|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve.
2921507|NCT03099460|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve.
2921508|NCT03099460|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
2921509|NCT03099447|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
2921510|NCT03099447|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
2921511|NCT03099447|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
2921512|NCT03099434|Active Comparator|Live Donor Champion + Facebook App|The LDC program consists of 6 monthly sessions of approx. 1 hour each. Each LDC session is led by a transplant physician or clinical coordinator. LDC sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LDC sessions are as follows: 1) education about ESRD, KT, and LDKT 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) encouraging candidate self-efficacy. At session 3, the the Facebook app will be incorporated and given to candidates. The Facebook app provides step-by-step instructions for creating a Facebook post that details each waitlist candidate's struggle with ESRD and their need for a live donor. The post is then uploaded to Facebook so it can be shared with the candidate's Facebook social network.
2921513|NCT03099434|Active Comparator|Facebook App|The Facebook app provides step-by-step instructions for creating a Facebook post that details each waitlist candidate's struggle with ESRD and their need for a live donor. The post is then uploaded to Facebook so it can be shared with the candidate's Facebook social network. The Facebook App prompts users with specific questions to create a narrative. Links to supplemental resources are auto-populated into the post to provide anyone that views the post with vetted information about the risks, benefits, and process of live donation. Candidates using the Facebook app attend one focus group session held at the transplant center where they are provided with verbal instructions and visual demonstrations of installation and use of the Facebook app.
2921514|NCT03099434|No Intervention|Standard of Care|Standard of Care does not include any of the interventions detailed above, but rather normal routine care as this is the control group.
2921515|NCT03099421|Experimental|Prostatic Artery Embolization|Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
2921516|NCT03099408|Active Comparator|Metronidazole Oral|Metronidazole Oral
2921517|NCT03099408|Active Comparator|"Metronidazole and Lactobacillus"|"Metronidazole and Lactobacillus"
2921518|NCT03099395||No re-MI, one re-MI, > one re-MI|From a population with MI surviving one year (78 468 pts) the number of pts with no re-MI, one re-MI or > re-MI will be described.
2921519|NCT03099382|Experimental|SHR-1210|
2921520|NCT03099382|Active Comparator|Investigator's Choice Standard Therapy|Docetaxel or Irinotecan
2921521|NCT03099369|Experimental|Daily Step-based Exercise Group|"The experimental group will receive the following 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day (based on evidence that at least 5,000 a day is associated with better health). The Fitbit Fitness Monitor used for tracking.~Week 1: walk at least 3,000 steps every day.~Week 2: walk at least 3,500 steps every day.~Week 3: walk at least 4,000 steps every day.~Week 4: walk at least 4,500 steps every day.~Weeks 5-12: walk at least 5,000 steps every day."
2921522|NCT03099369|Active Comparator|Symptom-based Exercise Group|"The active comparator group (ie. control group) will receive the following 12-week symptom-based exercise prescription (adapted from practice guidelines).~Walk on a flat surface at a constant speed until there is mild to moderate pain~Rest until the pain has completely ceased~Resume walking at the same speed~Increase the speed when you can walk 8 minutes without stopping for leg symptoms~Continue this exercise routine for 45 consecutive minutes, 3 to 5 days a week."
2921523|NCT03099356|Experimental|Cyclophosphamide and Sirolimus|Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
2921524|NCT03099343|Experimental|Location-based Tailored Messaging|Participants receive location-based tailored messaging via a mobile application throughout the 8-week research study.
2921525|NCT03099343|No Intervention|Control Group|Participants follow their usual eating pattern and will not have access to the application throughout the 8-week research study.
2921526|NCT03099330|Experimental|TQ-B3139|TQ-B3139 p.o. qd
2921527|NCT03099317|Experimental|Sinew acupuncture|Subject in the arm will receive real acupuncture intervention.
2921528|NCT03099317|Sham Comparator|Sham acupuncture|Subject in the arm will receive sham acupuncture intervention.
2921529|NCT03099304|Experimental|INCB018424 cream 1.5% twice daily (BID)|INCB018424 cream 1.5% BID for 52 weeks, followed by INCB018424 cream 1.5% BID in a 52-week open-label extension.
2921530|NCT03099304|Experimental|INCB018424 cream 1.5% once daily (QD)|INCB018424 cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by INCB018424 cream 1.5% BID in a 52-week open-label extension.
2921531|NCT03099304|Experimental|INCB018424 cream 0.5% QD|INCB018424 cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by INCB018424 cream 1.5% BID in a 52-week open-label extension.
2921532|NCT03099304|Experimental|INCB018424 cream 0.15% QD|INCB018424 cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (opportunity for re-randomization to a higher dose at Week 24 if < 25% improvement in F-VASI score), followed by INCB018424 cream 1.5% BID in a 52-week open-label extension.
2921533|NCT03099304|Placebo Comparator|Vehicle BID|Vehicle cream BID for 24 weeks, followed by re-randomization to INCB018424 cream 1.5% BID, 1.5% QD, or 0.5% QD for Weeks 24 to 52, followed by INCB018424 cream 1.5% BID in a 52-week open-label extension.
2921534|NCT03099291|Experimental|RSV D46/NS2/N/ΔM2-2-HindIII Vaccine|Participants will receive a single dose of the RSV D46/NS2/N/ΔM2-2-HindIII vaccine at study entry (Day 0).
2921535|NCT03099291|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
2921536|NCT03099278|Experimental|Ezetimibe|
2921537|NCT03099265|Experimental|patients with borderline resectable pancreatic adenocarcinoma|Borderline resectable disease will be defined by NCCN criteria, and determined centrally by review of a diagnostic pancreas protocol CT scan and/or MRI scan with contrast by a dedicated surgical oncologist and radiologist.
2921538|NCT03099252|Experimental|Intervention Group|"Parent-targeted BSweet2Babies video, in addition to 2 HCP-targeted resources~While the hospitals are the cluster, parents on the mother baby units at each intervention hospital are the participants receiving the intervention (i.e. the video)."
2921539|NCT03099252|Active Comparator|Control Group|2 HCP-targeted resources
2921540|NCT03099239|Experimental|Single hCT-MSC infusion|Subjects 1-3 will receive a single infusion of hCT-MSCs.
2921541|NCT03099239|Experimental|Two hCT-MSC infusions|Subjects 4-6 will receive two infusions of hCT-MSCs.
2921542|NCT03099239|Experimental|Three hCT-MSC infusions|Subjects 6-12 will receive three infusions of hCT-MSCs.
2921543|NCT03099226|Experimental|Group 1 - BIA 5-453 50 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.~The patients were administered between 7:00 and 9:00 o'clock a.m"
2921544|NCT03099226|Experimental|Group 2 - BIA 5-453 100 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.~The patients were administered between 7:00 and 9:00 o'clock a.m"
2921545|NCT03099226|Experimental|Group 3 - BIA 5-453 200 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.~The patients were administered between 7:00 and 9:00 o'clock a.m"
2921546|NCT03099213|Experimental|Ramipril|Receiving ramipril with the recommended initial dose of 2.5 mg once daily; depending on the tolerability, the dose should be gradually increased. The increase should be implemented by doubling the dose after one to two weeks. Three or four weeks later, the dose should be doubled again up to the usual maintenance dose of 10 mg once daily.
2921547|NCT03099200||Cohort 1|Participants with early breast cancer currently undergoing treatment (either chemotherapy and targeted HER2 therapy OR targeted HER2 therapy alone) will be observed.
2921548|NCT03099200||Cohort 2|Participants with early breast cancer who have completed treatment and are in disease-free survival (i.e. no longer receiving loco-regional treatment, chemotherapy or targeted HER2 therapy; participants may still be receiving hormone therapy) will be observed.
2921549|NCT03099200||Cohort 3|Participants receiving treatment for metastatic breast cancer will be observed.
2921550|NCT03099187|Experimental|Pirfenidone|Participants will receive pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
2921551|NCT03099187|Experimental|Placebo|Participants will receive matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
2921552|NCT03099174|Experimental|Cohort A|Xentuzumab + Abemaciclib (Dose 1)
2921553|NCT03099174|Experimental|Cohort B|Xentuzumab + Abemaciclib + Letrozole (Dose 2)
2921554|NCT03099174|Experimental|Cohort C|Xentuzumab + Abemaciclib + Anastrozole (Dose 3)
2921555|NCT03099174|Experimental|Cohort D|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
2921556|NCT03099174|Experimental|Cohort E|Xentuzumab + Abemaciclib (Dose 1)
2921557|NCT03099174|Experimental|Cohort F|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
2921558|NCT03099161|Experimental|Preladenant|During an initial dose evaluation phase, participants will receive dose A, B, C, D of preladenant on Day 1 of each infusion cycle (for a maximum of 35 cycles) until the RPTD has been established. The RPTD will be established based on the number of dose limiting toxicities (DLTs) at each dose level. Once the RPTD is established, participants will continue receiving the RPTD of preladenant on Day 1 of each infusion cycle until the 35-cycle limit is reached.
2921559|NCT03099161|Experimental|preladenant + pembrolizumab|During an initial dose evaluation phase, participants will receive Dose A, B, C, D of preladenant in combination with 200 mg pembrolizumab on Day 1 of each infusion cycle (for a maximum of 35 cycles) until the RPTD of preladenant has been established. The RPTD will be established based on the number of DLTs at each dose level. Once the RPTD of preladenant is established, participants will continue receiving the RPTD of preladenant in combination with 200 mg pembrolizumab on Day 1 of each infusion cycle until the 35-cycle limit is reached.
2921560|NCT03099148|Experimental|LY3337641 (R-fasted)|A single dose of LY3337641 reference formulation (R) given orally with water after an overnight fast in one of four periods.
2921561|NCT03099148|Experimental|LY3337641 (T1-fasted)|A single dose of LY3337641 test formulation 1 (T1) given orally with water after an overnight fast in one of four periods.
2921562|NCT03099148|Experimental|LY3337641 (T1-fed)|A single dose of LY3337641 test formulation 1 (T1) given orally with water after a high fat meal in one of four periods.
2921563|NCT03099148|Experimental|LY3337641 (T2-fasted)|A single dose of LY3337641 test formulation 2 (T2) given orally with water after an overnight fast in one of four periods.
2921564|NCT03099135|Other|Odalasvir and AL-335 With or Without Simeprevir|Participants who completed the LPVPS (Phase 2 or Phase 3 study), in which they received a regimen containing Odalasvir and AL-335 With or Without Simeprevir for the treatment of HCV infection, and who agree to participate in this follow-up study will be assessed for durability of SVR, incidence of late viral relapse, presence and long term-persistence of resistance associated substitutions (RAS) and liver disease status.
2921565|NCT03099122|Experimental|Thymoglobuline|"A cumulative dose of Thymoglobuline will be given intravenously, with a variable interval dose. Methylprednisolone will be given as induction therapy, according to institutional practice.~Tacrolimus, mycophenolate, and prednisone will be given as maintenance therapies."
2921566|NCT03099109|Experimental|LY3321367 Dose Escalation|LY3321367 given intravenously (IV).
2921567|NCT03099109|Experimental|LY3321367 + LY3300054 Dose Escalation|LY3321367 and LY3300054 given IV.
2921568|NCT03099109|Experimental|LY3321367 Dose Expansion|LY3321367 given IV.
2921569|NCT03099109|Experimental|LY3321367 + LY3300054 Dose Expansion|LY3321367 and LY3300054 given IV.
2921570|NCT03099096|Experimental|Mepolizumab SC 100 mg/milliliter (mL) in autoinjector|Three doses of mepolizumab liquid drug product in autoinjector will be self-administered by the subject/caregiver at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
2921571|NCT03099083||Participants receiving adalimumab|Participants with Psoriasis receiving adalimumab
2921572|NCT03099070|No Intervention|Control, Not-Fasting|Participants will experience the control intervention and will not fast prior to the lab visit.
2921573|NCT03099070|Experimental|Control, Fasting|Participants will experience the control intervention and will fast prior to the lab visit.
2921574|NCT03099070|Experimental|Stress, Not-Fasting|Participants will experience the stress intervention and will not fast prior to the lab visit.
2921575|NCT03099070|Experimental|Stress, Fasting|Participants will experience the stress intervention and will fast prior to the lab visit.
2921576|NCT03099044|Active Comparator|Single Active Dose|Subjects are assigned to receive a single Active beverage and a single placebo beverage.
2921577|NCT03099044|Active Comparator|Double Active Dose|Subjects are assigned to receive 2 doses of Active beverage.
2921578|NCT03099044|Placebo Comparator|Placebo comparator|Subjects are assigned to receive 2 doses of a placebo beverage.
2921579|NCT03099031||Tinzaparin|Patients with objectively confirmed cancer associated venous thromboembolism receiving tinzaparin treatment to prevent recurrence of venous thromboembolism
2921580|NCT03099005|Active Comparator|Low CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.6% THC + 0.09 CBD. They will then undergo experimental testing as described below under Outcome Measures.
2921581|NCT03099005|Active Comparator|Medium CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis 4 puffs will contain 1.6% THC + 0.09 CBD and 4 puffs will contain 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.
2921582|NCT03099005|Active Comparator|High CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.
2921583|NCT03098992|Active Comparator|Fotona Dynamis Er:YAG Laser System|Active treatment with Fotona Dynamis Er:YAG Laser System
2921584|NCT03098992|Sham Comparator|Fotona Dynamis Er:YAG Laser System with Sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
2921585|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (5 mg)|Chronic heart failure with preserved ejection fraction
2921586|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (10 mg)|Chronic heart failure with preserved ejection fraction
2921587|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (20 mg)|Chronic heart failure with preserved ejection fraction
2921588|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (30 mg)|Chronic heart failure with preserved ejection fraction
2921589|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (40 mg)|Chronic heart failure with preserved ejection fraction
2921590|NCT03098979|Placebo Comparator|Placebo|Chronic heart failure with preserved ejection fraction
2921591|NCT03098953|Experimental|Loteprednol Etabonate Ophthalmic Gel|one drop per eye for each eye
2921592|NCT03098940|Experimental|Chewing gum|Chewing gum with various doses of dronabinol
2921593|NCT03098940|Active Comparator|Capsule (Marinol)|Marinol is a product manufactured by AbbVie Capsule with various strengths of Marinol
2921594|NCT03098927|Active Comparator|Early intervention|Early intervention patients will undergo 3 weeks of motor imagery training immediately upon enrolling in the study between 3 and 6 months post spinal cord injury.
2921595|NCT03098927|Active Comparator|Late intervention|Late intervention patients will undergo 3 weeks of motor imagery training after 6 weeks of standard of care physical rehabilitation following enrollment.
2921596|NCT03098914||Beijing Haidian Hospital|
2921597|NCT03098914||Chinese PLA General Hospital|
2921598|NCT03098914||Beijing Tsinghua Chang gung Hospital|
2921599|NCT03098901|Other|no other arm|
2921600|NCT03098875|Active Comparator|Sevoflurane|"General anesthesia using sevoflurane as a hypnotic agent, and remifentanil as an analgesic.~Two steady state periods of 10 minutes each, one with a steady bispectral index at 25 +/- 5, the other with a steady bispectral index at 55 +/- 5. Continuous recording of heart rate during the last minute of each steady-state. Off-line spectral analysis of heart rate variability."
2921601|NCT03098875|Active Comparator|Propofol|"General anesthesia using propofol as a hypnotic agent, and remifentanil as an analgesic.~Two steady state periods of 10 minutes each, one with a steady bispectral index at 25 +/- 5, the other with a steady bispectral index at 55 +/- 5. Continuous recording of heart rate during the last minute of each steady-state. Off-line spectral analysis of heart rate variability."
2921602|NCT03098862||1|EVD survivors
2921603|NCT03098862||2|close contacts of survivors
2921604|NCT03098862||3|EVD healthcare workers
2921605|NCT03098862||4|individuals who have received investigational Ebola vaccines (population controls)
2921606|NCT03098849|Experimental|Buteyko Training|Breathing exercises according to the Buteyko Breathing Technique
2921607|NCT03098849|No Intervention|Control Group|Standard care as usual
2921608|NCT03098836|Experimental|Caucasian|
2921609|NCT03098836|Experimental|African American|
2921610|NCT03098823|Experimental|RAYOS®|
2921611|NCT03098823|Active Comparator|IR prednisone|
2921612|NCT03098810|Placebo Comparator|Normal children|Placebo
2921613|NCT03098810|Experimental|Malnourished children|Oral zinc sulphate syrup
2921614|NCT03098797|Experimental|Experimental: Elamipretide|Patients will be randomized to receive 12 weeks of elamipretide in one of the two treatment periods. All subjects will receive 12 weeks of elamipretide and 12 weeks of placebo.
2921615|NCT03098797|Placebo Comparator|Placebo|Patients will be randomized to receive 12 weeks of placebo in one of the two treatment periods. All subjects will receive 12 weeks of placebo and 12 weeks of elamipretide.
2921616|NCT03098784||Air France employees working near runways|"Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports.~Intervention: Exposure to aircraft exhaust"
2921617|NCT03098784||Air France employees working inside|"Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports.~Intervention: Non exposure to aircraft exhaust"
2921618|NCT03098771|Experimental|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
2921619|NCT03098771|Experimental|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
2921620|NCT03098745|Active Comparator|Omafilcon A|Participants are randomized to wear omafilcon A lens pair bilaterally for 1 hour during the study.
2921621|NCT03098745|Active Comparator|Somofilcon A|Participants are randomized to wear somofilcon A lens pair bilaterally for 1 hour during the study.
2921622|NCT03098745|Active Comparator|Omafilcon A - Proclear (PC)|Participants are randomized to wear omafilcon A - PC lens pair bilaterally for 1 hour during the study.
2921623|NCT03098732|Experimental|Magnetically Enhanced Diffusion (MED)|The Experimental Treatment will receive the complete MED System Procedure consisting of MED MicroBeads and the MED Workstation magnet procedure for 60 minutes in addition to IV tissue plasminogen activator (tPA or Alteplase).
2921624|NCT03098732|Sham Comparator|MED Workstation Magnet Sham Control|The MED Workstation Magnet Sham Comparator will not receive MED MicroBeads while the MED Workstation Magnet will be activated as a Sham control for 60 minutes in addition to IV tissue plasminogen activator (tPA or Alteplase).
2921625|NCT03098719|Experimental|Intervention|
2921626|NCT03098719|No Intervention|Control|
2921627|NCT03098706|Other|NT normothermia|After information for donation and research has been explained, organ donors in the normothermia (NT) group will either be maintained to spontaneously reach a body temperature of 36,5 °C-37,5°, until transfer to the operating room.
2921628|NCT03098706|Experimental|HT mild hypothermia|The intervention will take place after information for donation and research has been explained . Organ donors in the intervention group will either be actively warmed or allowed to reach a body temperature of 34 °C-35°C, until transfer to the operating room.
2921629|NCT03098693||Sero-discordant Couple Cohort|We will enroll and track a cohort of 60 serodiscordant couples (120 individuals). The HIV-positive couple members will be offered anti-retroviral therapy (ART) and the HIV-negative couple members will be offered pre-exposure prophylaxis (PrEP). We will monitor monthly clinic visits for the couple and will conduct in-depth behavioral surveys at baseline, 6-, 12-, and 18-months.
2921630|NCT03098680|Experimental|Group A (Placebo, Salbutamol, Nicardipine, Dobutamine)|"Participants will receive each drug, to be given on separate study days. The drugs will be given as a 3 stage infusion with dose increasing at each stage. Each stage will be 30 minutes in duration.~Placebo; Salbutamol(Albuterol) Sulfate (Dose: 2mcg/min, 5mcg/min, 10mcg/min); Nicardipine Hydrochloride (Dose: 1mg/hr, 2.5mg/hr, 5mg/hr); Dobutamine Hydrochloride (Dose: 1mcg/kg/min, 2.5mcg/kg/min, 5mcg/kg/min)"
2921631|NCT03098680|Experimental|Group B (Placebo, Phenylephrine, Verapamil, Phentolamine)|"Participants will receive each drug, to be given on separate study days. The drugs will be given as a 3 stage bolus with dose increasing at each stage. Each stage will be 30 minutes apart.~Placebo; Phenylephrine Hydrochloride (Dose: 100mcg, 200mcg, 300mcg); Verapamil Hydrochloride (Dose: 1mg, 2.5mg, 5mg); Phentolamine Mesylate (Dose: 1mg, 2mg, 3mg)"
2921632|NCT03098667|Experimental|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated
2921667|NCT03098433|Placebo Comparator|Placebo|Each participant will receive a single dose of placebo
2921633|NCT03098667|Active Comparator|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
2921634|NCT03098654|Experimental|Enhanced Intervention|"Members will have DM and HTN managed at the CTC together with their HIV care. Interventions include:~Community mobilization activities to inform community members of available services~Support at the local health center to aid clinicians in managing uncontrolled cases of DM and HTN, including training for clinical staff, glucometers/test strips, and BP monitors.~HIV counseling and serial rapid HIV testing~Blood glucose and blood pressure testing~DM/HTN medications as needed~Personalized diet and lifestyle counseling for all participants with elevated glucose or BP that includes education, dietary assessment and recommendations, advice on physical activity, and the need to regularly monitor their glucose/BP."
2921635|NCT03098654|No Intervention|Control|Members in the control arm will receive community-level rapid HIV testing at the CTCs, which is the standard of care. HIV testing performed by the CTC is according to the National HIV Testing Algorithm (serial rapid testing using Determine HIV 1/2 and Uni-Gold HIV 1/2) which follows Tanzanian and international (WHO/CDC) standards for provision of HIV counseling and testing. Those who test positive for HIV will be referred to the CTC for the standard Tanzanian level of HIV care, which includes counseling and ART medication managed at the CTCs.
2921636|NCT03098628|Active Comparator|V - PCV10 vaccine, 0+1|PCV10, 0+1 schedule. PCV vaccine at 12 months of age
2921637|NCT03098628|Active Comparator|W - PCV13 vaccine, 0+1|PCV13 in 0+1 schedule. PCV vaccine at 12 months of age
2921638|NCT03098628|Active Comparator|X - PCV10 vaccine, 1+1|PCV10, 1+1 schedule. PCV vaccine given at 2 and 12 months of age
2921639|NCT03098628|Active Comparator|Y - PCV13 vaccine, 1+1|PCV13, 1+1 schedule. PCV vaccine at 2 and 12 months of age
2921640|NCT03098628|Other|Z - Control|Control group. PCV vaccine given at end of study (24 months)
2921641|NCT03098615|Other|Jublia (Efinaconazole 10% Topical Solution) + nail polish|Subjects with distal lateral subungual onychomycosis (DLSO) with dermatophytoma.
2921642|NCT03098589||Patients with T-cell leukemia lymphoma treated with Revlimid|Among patients with relapsed or refractory adult T-cell leukemia lymphoma, patients who received Revlimid will be targeted in this surveillance
2921643|NCT03098576||Matched|Matched targeted drug treatment
2921644|NCT03098576||Control|Unmatched standard of care
2921645|NCT03098563|Experimental|Arm 1|Blinded study medication. This is a within-subject study so all session procedures will be identical. The specific medications administered that study day will be the only change each session. Study days will last approximately 8 hours and will be conducted on an outpatient basis. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
2921646|NCT03098563|Experimental|Arm 2|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
2921647|NCT03098563|Experimental|Arm 3|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
2921648|NCT03098563|Experimental|Arm 4|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
2921649|NCT03098550|Experimental|Immunotherapy Combination|TNBC and PAC participants who are deriving clinical benefit will continue to be treated with the nivolumab plus daratumumab combination therapy
2921650|NCT03098550|Experimental|Nivolumab Monotherapy|NSCLC patients who are deriving clinical benefit will be treated with nivolumab monotherapy
2921651|NCT03098537|Active Comparator|Enteral nutrion only|
2921652|NCT03098537|Other|Enteral nutrion + proton pump inhibitor|
2921653|NCT03098524|Experimental|Low tidal volume ventilation (LTV arm)|During cardiopulmonary bypass, mechanical ventilation is maintained with 5 acts/minute, tidal volume = 3 ml/kg (ideal body weight) with positive end-expiratory pressure = 5 cmH2O
2921654|NCT03098524|Placebo Comparator|No ventilation (noV arm)|No mechanical ventilation during cardiopulmonary bypass.
2921655|NCT03098511|Other|Neurological Diagnostic Evaluation|Exams performed according to a determined schedule following admission in the intensive care unit in order to validate CT-perfusion as an accurate ancillary test for neurological diagnostic.
2921656|NCT03098498|Experimental|Two-Stage Subgingival Debridement|Initially soft subgingival bacterial biofilms are removed from periodontal lesions by an airpolishing device and erythritol cleaning powder. 6 weeks later subgingival calculus is mechanically removed in a second step by mechanical scaling and root planing
2921657|NCT03098498|Active Comparator|One-Stage Subgingival Debridement|Soft subgingival bacterial biofilms, as well as subgingival calculus are concomitantly removed from periodontal lesions by mechanical scaling and root planing
2921658|NCT03098485|Experimental|Levofloxacin|1 750mg tab of levofloxacin by mouth for 5 days
2921659|NCT03098485|Experimental|Azithromycin|1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)
2921660|NCT03098485|Experimental|Cefpodoxime|200mg tab by mouth twice per day for 5 days
2921661|NCT03098485|Experimental|Azithromycin and cefpodoxime|"Azithromycin: 1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)~Cefpodoxime: 200mg tab by mouth twice per day for 5 days"
2921662|NCT03098459||Critically Ill Trauma Patients|Non-intervention observational prospective cohort study
2921663|NCT03098446|Experimental|Prolonged sitting with exercise|Subjects will be asked to undergo prolonged sitting (~14-hours/day) for 4 days. On the evening of day 4, they will be asked to run at 65% of VO2max for 1-hour.
2921664|NCT03098446|Experimental|Prolonged sitting without exercise|Subjects will be asked to undergo prolonged sitting (~14-hours/day) for 4 days. Subjects will not be asked to complete the acute bout of exercise to serve as a control.
2921665|NCT03098433|Experimental|Liothyronine|Each participant will receive a single dose of lithyronine
2921668|NCT03098420|Placebo Comparator|Control Group|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of ropivacaine) and 1mL of normal saline bilaterally (control) with standard intrathecal bupivacaine and morphine.
2921669|NCT03098420|Active Comparator|2mg Dexamethasone|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline split between 2 sides with standard intrathecal bupivacaine and morphine.
2921670|NCT03098420|Active Comparator|4mg Dexamethasone|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 20mL of 0.5% ropivacaine) and 1 mL (4mg) of dexamethasone between 2 sides with standard intrathecal bupivacaine and morphine.
2921671|NCT03098407|Other|Buprenorphine Maintenance Treatment|Buprenorphine Maintenance Treatment patients will receive instructions regarding a follow-up, outpatient appointment with the Pregnancy Recovery Center at Magee-Womens Hospital, which specializes in Opioid maintenance treatment for pregnant patients, for the next day following enrollment in the study for induction onto buprenorphine maintenance treatment.
2921672|NCT03098407|Other|Methadone Maintenance Treatment|Methadone Maintenance Treatment patients will be immediately admitted to Magee-Womens Hospital for an inpatient induction onto methadone maintenance treatment.
2921673|NCT03098394|Experimental|Rapid Turnaround Test|Patients randomized to this arm will be tested for a sexually transmitted infection (STI) with both the rapid nucleic acid amplification test (NAAT) as well as the conventional polymerase chain reaction (PCR) test. The results from the rapid turnaround test will guide providers on treatment decisions for a possible STI. The results from the PCR test will be used to verify the results of the rapid turnaround test.
2921674|NCT03098394|Active Comparator|Usual Care|Patients randomized to this arm will be tested for a sexually transmitted infection (STI) using the conventional PCR test. The results from the PCR test normally take approximately 48-72 hours and these patients will likely receive treatment based on the decision of the clinical provider. The results from the PCR test will be used to verify the decision of the clinical provider to treat or withhold treatment for a possible STI.
2921675|NCT03098368|Active Comparator|Patient (active) group|"Rotigotine titration up to 16 mg/24 hr~Starting dose 2 mg/24 hr up titrate 2 mg weekly to optimal/maximum dose~Duration up to 12 weeks~The treatment was titrated until optimal dosage~(that which patient/ caregiver felt that nocturnal hypokinesia and/or early morning akinesia was adequately controlled)~(or patient can not tolerated the side effects such as dyskinesia)~All previous dopaminergic medications were not allowed to adjusted during the study period."
2921676|NCT03098368|Placebo Comparator|Control (placebo) group|"Placebo transdermal patch were titration with the same protocol as active group.~Duration up to 12 weeks~The treatment (placebo patch) was titrated until optimal dosage~(that which patient/ caregiver felt that nocturnal hypokinesia and/or early morning akinesia was adequately controlled)~(or patient can not tolerated the side effects such as dyskinesia)~All previous dopaminergic medications were not allowed to adjusted during the study period."
2921677|NCT03098355|Experimental|4SCAR19/22 T cells and interleukin-2|Patients with resistant or refractory B cell acute lymphoblastic leukemia (ALL) or non-hodgkin's lymphoma (NHL) will receive CAR-T cells at a total dose of 0.5-5x10^6/kg and regular subcutaneous injection of interleukin-2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months after their serum interleukin-6 levels returned to normal range from day 28 after CAR-T cell infusion.
2921678|NCT03098342|Experimental|MB-PDT for Onychomycosis|
2921679|NCT03098342|Active Comparator|Amorolfine for Onychomycosis|
2921680|NCT03098329|Experimental|Ct/GC screening|Community screening of men for Ct and GC is not normally done. We are testing to see if this intervention will impact the rates of Ct and GC among women
2921681|NCT03098316||POAG|Primary open angle glaucoma patients
2921682|NCT03098316||NTG|Normal/Low tension glaucoma patients
2921683|NCT03098316||Control|Patients with cataract and without glaucoma or other eye diseases
2921684|NCT03098290||Intermittent Claudication|Mild to severe claudication
2921685|NCT03098290||Ischaemic Rest Pain|
2921686|NCT03098290||Critical Limb Threatening Ischaemia|Ulcers, Necrosis, Gangrene
2921687|NCT03098277|Experimental|Observational (physical activity, accelerometer, PROs)|Patients perform 2 physical activities in an exam room that are recorded using a Microsoft Kinect 2 stationary movement tracking device on days 1 and 21. The first activity is rising from a chair, walking 10 feet, and returning to the chair. The second activity is moving from the chair to the step-up examination table. Patients also wear a movement tracking wristband, Microsoft Band 2, around their wrist, complete a smartphone application based PRO questionnaire, and weigh themselves daily for 60 days.
2921688|NCT03098264|Experimental|Simultaneous surgery|to perform surgery both on biliary stone and portal hypertension
2921689|NCT03098264|Active Comparator|Staged surgery|to perform surgery on biliary stone and portal hypertension by staged surgery
2921690|NCT03098251|Experimental|3D typing|typing the patient with 3D typing system and give treatment according preestablished algorism in our center.
2921691|NCT03098251|Active Comparator|routine typing|typing the patient with routine typing system and give treatment according preestablished algorism in our center.
2921692|NCT03098238|Other|Patients without humoral rejection or DSA|Renal transplant patients with systematic kidney biopsy at 3 months and 12 months Patients without humoral rejection or DSA (Donor Specific Antibodies)
2921693|NCT03098238|Other|Patient without humoral rejection with a DSA|Patient without humoral rejection with a DSA (Donor Specific Antibodies)Patients with a graft biopsy for a donor-specific anti-HLA antibody
2921694|NCT03098238|Other|Patients with humoral rejection|Patients with humoral rejection
2921695|NCT03098225|Experimental|Radiotherapy|Patients with moderately severe GO treated with Intravenous glucocorticoids associated with orbital radiotherapy
2921696|NCT03098225|Active Comparator|No Radiotherapy|Patients with moderately severe GO treated with Intravenous glucocorticoids alone
2921697|NCT03098212|Experimental|Aromatherapy|Receive essential oil diffuse by Aroma diffuser during labor. Pain score and dose of analgesics drug are recorded
2921698|NCT03098212|No Intervention|Non-aromatherapy|This group receive pain control by standard of care without essential oil (aromatherapy)
2921699|NCT03098199|Experimental|AMH<1.5, 300IU Gonal-F + 150 IU Menopur|dosage at 300IU Gonal-F + 150IU Menopur
2921700|NCT03098199|Experimental|AMH 1.6-2.5, 225IU Gonal-F+75IU Menopur|dosage of 225IU Gonal-F + 75IU Menopur
2921701|NCT03098199|Experimental|AMH 2.6-6.9, 150IU Gonal-F+75IU Menopur|start dosage of 150IU Gonal-F and 75IU Menopur
2921702|NCT03098199|Experimental|AMH >=7.0, 75IU Gonal-F+75U Menopur|start dosage of 75IU Gonal-F and 75U Menopur
2921703|NCT03098186|Active Comparator|Intervention SMS|"SMS aimed to improved adherence to medications used in secondary prevention of cardiovascular disease.~Control SMS: SMS to thanks for participation in the trial and reminders of trial appointments."
2921704|NCT03098186|Placebo Comparator|Control SMS|SMS to thanks for participation in the trial and reminders of trial appointments.
2921705|NCT03098173|Experimental|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
2921706|NCT03098173|Active Comparator|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
2921707|NCT03098160|Experimental|Evofosfamide plus Ipilimumab|Ipilimumab to be administered at same dose. Evofosfamide dose to be determined during duration of trial
2921708|NCT03098134|Experimental|VR-Video-Exposure|
2921709|NCT03098134|Active Comparator|Education-Video-|
2921710|NCT03098121|Experimental|peginterferon experienced patients with genotype 1|Intervention is to add grazoprevir 100mg and elbasvir 50mg in peginterferon alfa plus ribavirin experienced patients with genotype 1 HCV and HIV co-infection
2921711|NCT03098108|Experimental|CCPT|
2921712|NCT03098095|Experimental|Experimental group|Device smartphone. Participants will be trained with a supervised physical activity for 3 days a week for 16 weeks with the use of a smartphone application
2921713|NCT03098095|Experimental|Control Group|Participants will train alone with an exercise program for 16 weeks without the use of a smartphone application
2921714|NCT03098082|Other|Actim Pancreatitis Dipstick Test|All enrolled subjects who meet inclusion/exclusion criteria will have the Urine Trypsinogen 2 Dipstick test done.
2921715|NCT03098069||KMC Scale up in a district|This is an implementation research project on scaling up KMC in selected government and private health facilities in an entire district, aiming to cover newborns weighing less than 2000gms at birth.
2921716|NCT03098056|Experimental|PROG2|All subjects will be participating in a lifestyle change program - specifically a high protein, limited carbohydrate food plan (High Phyto-PRO food plan), physical activity and a cognitive behavioral program consisting of 11 group visit. Participants will be recieving nutritional Supplements.
2921717|NCT03098030|Experimental|Part 1: Dinutuximab + Irinotecan|Dinutuximab (10 mg/m^2 IV) + Irinotecan (350 mg/m^2 IV) on Day 1 of every 21 days (q21d). Dinutuximab dose will be escalated in 2 mg/m^2 increments per cycle if maximal pain is <Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m^2 IV.
2921718|NCT03098030|Active Comparator|Part 2: Irinotecan|Irinotecan (350 mg/m^2 IV) on Day 1 of each q21d cycle.
2921719|NCT03098030|Experimental|Part 2: Dinutuximab + Irinotecan|Dinutuximab (10 mg/m^2 IV) + Irinotecan (350 mg/m^2 IV) on Day 1 of each q21d cycle. Dinutuximab dose will be escalated in 2 mg/m^2 increments per cycle if maximal pain is <Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m^2 IV.
2921720|NCT03098030|Active Comparator|Part 2: Topotecan|Topotecan (1.5 mg/m^2 IV) on Days 1 to 5 of each q21d cycle.
2921721|NCT03098017|Active Comparator|Couscous (dry)|Cooked couscous (50g available carbohydrate, ~70g uncooked) eaten with 500 mL of water
2921722|NCT03098017|Experimental|Short pasta (dry)|Cooked penne (50g available carbohydrate, ~71g uncooked) eaten with 500 mL of water
2921723|NCT03098017|Experimental|Long pasta (dry)|Cooked spaghetti (50g available carbohydrate, ~71g uncooked) eaten with 500 mL of water
2921724|NCT03098017|Active Comparator|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
2921725|NCT03098004|Experimental|Sweet-Flavored e-Cigarette|Participants will self-administer a sweet-flavored e-cigarette containing 3 mg/mL of nicotine.
2921726|NCT03098004|Active Comparator|Tobacco-Flavored e-Cigarette|Participants will self-administer a tobacco-flavored e-cigarette containing 3 mg/mL of nicotine.
2921727|NCT03097991|Experimental|Intervention: Treatment as Usual + Focused Coparenting Consult|Receipt of Treatment As Usual/Resource and Referral supports, plus opportunity to complete six 90-minute Focused Coparenting Consultation (FCC) sessions followed by one postnatal booster session designed to strengthen the mother-father coparenting alliance
2921728|NCT03097991|No Intervention|Control: Treatment as Usual|Receipt of TAU/Resource and Referral supports
2921729|NCT03097978|Experimental|RIC arm system with pattern recognition|Subject will be fit with a custom socket and receive training on pattern recognition with the RIC arm prosthesis. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
2921730|NCT03097978|Experimental|RIC arm system with direct control|Subject will be fit with a custom socket and receive training on direct control with the RIC arm prosthesis. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
2921731|NCT03097978|Experimental|Commercial system with PR control|Subject will be fit with a custom socket and receive training on pattern recognition with a conventional, commercial prosthesis system. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
2921732|NCT03097978|Experimental|Commercial system with Direct Control|Subject will be fit with a custom socket and receive training on direct control with a conventional, commercial prosthesis system. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
2921733|NCT03097965|Active Comparator|DIET|"High Phyto-PRO food plan~Physical activity~Cognitive behavioral program"
2921734|NCT03097965|Experimental|PROGRAM|"High Phyto-PRO food plan~Physical activity~Cognitive Behavioral Program~Protein Shakes~Phytosterols supplement~Berberine supplement~Anti-oxidant supplement~Probiotic supplement~Fish Oil supplement~Multiple Vitamin/Multiple Mineral supplement"
2921735|NCT03097939|Experimental|Nivolumab and Ipilimumab|
2921736|NCT03097926|Active Comparator|Standard BPD-DS|Standard BPD-DS with a 250-cm alimentary limb and 100-cm common channel
2921842|NCT03097094|Active Comparator|Female dog|Female dog extract used for skin prick test and conjunctival provocation
2921737|NCT03097926|Experimental|Long alimentary limb BPD-DS|BPD-DS with a 100-cm common channel, a 100-cm biliary limb, the remaining bowel as the strict alimentary channel
2921738|NCT03097913||video-stylet tube assembly|patients who undergo oxo-maxillofacial surgery with nasotracheal intubation general anesthesia are recruited
2921739|NCT03097900|Active Comparator|Treatment (Caffeine Citrate) group|25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
2921740|NCT03097900|Placebo Comparator|Placebo (Water) group|25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
2921741|NCT03097887|Active Comparator|Anti-reflux sutures|Omega Loop Gastric Bypass with anti-reflux sutures using V-Loc sewing device. Biliary reflux measured using Bilitec 2000™.
2921742|NCT03097887|Active Comparator|No anti-reflux sutures|Omega Loop Gastric Bypass without anti-reflux sutures. Biliary reflux measured using Bilitec 2000™.
2921743|NCT03097874|Experimental|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
2921744|NCT03097874|Experimental|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment plus Intensive Parental Coaching if weight milestones are not met by session 4.
2921745|NCT03097861|Active Comparator|Lubiprostone Capsule|24 mcg lubiprostone Capsule twice daily
2921746|NCT03097861|Experimental|Lubiprostone Sprinkle Formulation|24 mcg lubiprostone Sprinkle twice daily
2921747|NCT03097861|Placebo Comparator|Placebo|0 mcg twice daily
2921748|NCT03097848|Experimental|Sorafenib+RFA group|for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
2921749|NCT03097848|Active Comparator|RFA group|for eligible cases, RFA will be given only.
2921750|NCT03097835|Other|Group A|Group A will be treated with Hyper-Diluted Botox on day 1 and on day 30 they will be treated with 0.9% saline solution.
2921751|NCT03097835|Other|Group B|Group B will be treated with 0.9% saline solution on day 1 and on day 30 they will be treated with Hyper-Diluted Botox.
2921752|NCT03097809||Epilepsy Subjects|Subjects will be recruited from the epilepsy-monitoring unit. These subjects would have been already assessed by the Epilepsy Center at the Cleveland Clinic for surgical treatment of medically refractory epilepsy and would have already had SEEG electrodes placed in cortical and limbic areas for clinical diagnostic purposes.
2921753|NCT03097796|Experimental|PUL-042|PUL-042 Inhalation Solution
2921754|NCT03097783|Experimental|Restylane Perlane Lidocaine|Single injection and optional touch up injection with Restylane Perlane Lidocaine in Midface
2921755|NCT03097783|No Intervention|No intervention arm|No treatment
2921756|NCT03097770|Experimental|anti-CD19/20 CAR T cells|Patients receive anti-CD19/20-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
2921757|NCT03097757|No Intervention|(standard of care fracture reduction|Fracture reduction as per standard of care involves closed fracture reduction without real-time imaging, or with c-arm or portable x-ray.
2921758|NCT03097757|Experimental|ultrasound guided fracture reduction|Ultrasound guided Fracture reduction involves closed fracture reduction with the use of real-time ultrasound imaging, prior to, during and after the reduction procedure. C-arm or portable x-ray may also be used as an adjunct.
2921759|NCT03097718||Non-specific low back pain|Individuals with recurrent non-specific low back pain
2921760|NCT03097718||Healthy control subjects|Healthy individuals without low back pain
2921761|NCT03097705|Other|IOP and OCT RNFL measurements|all subjects will undergo ophthalmological exams including IOP and RNFL OCT measurements
2921762|NCT03097692|Active Comparator|Ischemic preconditioing|50 patients ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
2921763|NCT03097692|Active Comparator|Pharmacologic preconditioing|by sevoflurane anesthesia
2921764|NCT03097679|Active Comparator|low COF-group|The low COF-group receives a thin-strut stent (Pulsar, Biotronik AG, Bülach, Switzerland) with minimal oversizing (according to manufacturer's Instructions For Use)
2921765|NCT03097679|Active Comparator|high COF-group|The high COF-group receives a stiffer-stent (Lifestent Flexstar, Bard Peripheral Vascular Inc., Tempe, AZ, USA) with maximal oversizing (according to manufacturer's Instructions For Use).
2921766|NCT03097666|Other|C2 Cryoballoon Swipe Ablation System|C2 Cryoballoon Swipe Ablation System
2921767|NCT03097653|Experimental|Decision-aid|
2921768|NCT03097653|Active Comparator|Standard information|
2921769|NCT03097640|Experimental|CHAMP|Participants enrolled in CHAMP are followed by a team of a social worker and physician across the care continuum. CHAMP team members visit patients in the ED and on inpatient floors. Along with the patient's input, the team develops an Individualized Care Plan outlining the patient's medical and social history and providing recommendations to other providers on specific aspects of their care. Care plans are reviewed with patients on an individual basis and reviewed periodically by the CHAMP providers. CHAMP-enrolled participants are scheduled for physician and social worker follow-up appointments at the CHAMP clinic; this time is used to provide intensive case management, medical care, and psychosocial support.
2921770|NCT03097640|No Intervention|Standard Care|Individuals in the standard care arm will receive care as they do normally when hospitalized, including medical and inpatient social work services, as well as outpatient care from their providers.
2921771|NCT03097627|Experimental|ICG Intervention|The intervention to be administered is intravenous indocyanine green for intra-thoracic lesion localization and use of a near infrared camera to detect the ICG. All study subjects will receive this same intervention; there is only one arm.
2921772|NCT03097614|Experimental|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
2921773|NCT03097601||sunitinib cohort|independent cohorts of patients who received sunitinib for metastic kidney cancer, on who we intend to demonstrate that ELR+CXCL cytokines levels are of sunitinib response
2921774|NCT03097588|Experimental|Supportive care (NEPA)|Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.
2921775|NCT03097575|Experimental|ICG Intervention|The intervention to be administered is the indocyanine green for NIR Lymphatic Mapping. All study subjects will receive this same intervention; there is only one arm.
2921776|NCT03097562|Experimental|CT1|"FLACS- Initial Wound parameters (CT1)~Sample size calculation based on woundleak incidence estimated from preliminary results:~For CT1 vs MT, we will only need 10 per group to have 80% power assuming a 1:1 ratio of CT to MT and 5% type 1 error.~For CT1 vs CT2, we will need 22 per group to have 80% power (assuming 60% wound leakage in CT1 and 20% wound leakage in CT2, a 1:1 ratio, and a 5% type 1 error rate)~A total of 253 patients are eligible for this study, 101 with FLACS and 152 with Manual Cataract Surgery. We thus expect that our study population will allow adequate analysis of the main outcome parameters proposed herein."
2921777|NCT03097562|Experimental|CT2|"The revised profile CT2, consists of a wider anterior side cut angle (beveled corneal undercut) and a narrower posterior side cut angle compared to the initial CT1 profile. This new corneal incision profile is constructed to ensure a tigher wound closure and a better corneal wound reapposition.~The traditional manual wound performed with a standard keratome wil be used as a reference."
2921778|NCT03097562|Active Comparator|MT control group|Standard manual technique (MT)
2921779|NCT03097549|Experimental|Tät®II Treatment app|Comprehensive treatment programme with information and exercises. Individual advices.
2921780|NCT03097549|Other|Tät®II Information app|Information only.
2921781|NCT03097536|Experimental|Luna Bar Intervention|Participants will be asked to monitor their blood sugar during migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. This information will be recorded at times when a Luna bar is not consumed, and at times when a Luna Bar is consumed. Participants will serve as their own controls.
2921782|NCT03097536|No Intervention|Morning Migraine|Participants will be asked to monitor their blood sugar on headache free days as well as during migraine. This arm is only for participants who identify as having morning migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. Participants will serve as their own controls.
2921783|NCT03097523|Experimental|Study Arm|"Patients with intraventricular catheter meeting eligibility criteria will undergo the following procedures:~Blood pressure, heart rate, electrocardiogram and Intracranial Pressure (ICP) monitoring after standard of care procedures are completed~Continuous ICP monitoring using a disposable pressure transducer (i.e., TruWaveTM)~Sequential placement in an upright, seated, supine 0°, and supine 15° head down tilt (HDT) positions for approximately 15 minutes for stabilization, followed by: Non-invasive ICP, intra-ocular pressure (IOP) assessment, femoral vascular ultrasound, jugular vascular ultrasound, and assessment of adverse events"
2921784|NCT03097510|Experimental|Transcendental Meditation|The TM technique is a simple, natural, effortless technique that allows the mind to experience finer levels of the thinking process until the mind transcends and experiences the source of thought, a state of deep, integrated relaxation. During the meditation session, the active mind settles down to a silent yet fully awake state of awareness. TM was taught to study participants by certified instructors, using standardized procedures for teaching.
2921785|NCT03097510|No Intervention|Wait list control|This wait list group served as the control group. After the study was completed, the wait-list controls were given the option to learn the TM technique as their reward for participating as controls during the 4 month study.
2921786|NCT03097497|Experimental|Physiotherapy re-education program|Physiotherapy re-education program based on the pre-activation of the transverse abdominal muscle, performed with progressive difficulty and supervised at all times by an expert physiotherapist. The intervention will last 4 weeks, with two weekly sessions of 30-35 minutes each. Sessions will be held individually.
2921787|NCT03097497|Active Comparator|Conventional treatment by GP|"Will follow conventional treatment prescribed by the general practitioner in a primary care consultation. This conventional treatment is based on the clinical guidlines of the Institut Català de la Salut~http://www.gencat.cat/ics/professionals/guies/docs/guia_lumbalgies.pdf"
2921788|NCT03097484|Experimental|Standard therapy plus Aromatherapy|These infants will receive aromatherapy, consisting of Lavender and Chamomile essential oils, in addition to standard care, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
2921789|NCT03097484|No Intervention|Standard therapy ALONE|These infants receive standard care ONLY, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
2921790|NCT03097458|Experimental|Counselling|short-term counselling for families
2921791|NCT03097458|No Intervention|Wait-list control group|Wait-list control group
2921792|NCT03097445|Experimental|Nicotine Replacement Therapy|mailed 5 week course of transdermal nicotine patches
2921793|NCT03097445|No Intervention|Control|No intervention control group
2921794|NCT03097432||ORALVAC COMPACT BÄUME|This non-interventional study was initiated to document the up-dosing period of children and adults with allergic rhinoconjunctivitis and/or allergic asthma treated with a SLIT containing purified, aqueous extracts of birch, alder, and hazel pollen. The following up-dosing schemes were freely selectable: scheme A consists of an up-dosing period of 12 days at the patient´s home using the standardized pollen extract in three different solution strengths to reach the maximum dose; scheme B performed only with the highest solution strength at the physician's office within 2 hours; and the new scheme C which is a regimen for initiation at the physician`s office and continuation at the patient`s home also exclusively using the highest solution strength and takes 4 days.
2921795|NCT03097419|Experimental|Intervention|Remote post-ischemic conditioning
2921796|NCT03097419|No Intervention|Control|Standard medical care by the primary treatment team.
2921797|NCT03097406||Osteoarthritis group|Patients with osteoarthritis (2017-2019) at Herlev Hospital treated with Global Unite total shoulder arthroplasty
2921798|NCT03097406||Osteoarthritis control group|Patients with osteoarthritis (2013-2016) at Herlev Hospital treated with a Global Advantage
2921799|NCT03097406||Fracture group|Patients with a fracture of the proximal humerus (2017-2019) at Køge and Herlev Hospital treated with Global Unite hemiarthroplasty
2921882|NCT03096795|Experimental|MAD Cohort 1|Multiple doses of MEDI3506 or placebo
2921800|NCT03097406||Fracture control group|Patients with a fracture of the proximal humerus (2013-2016) at Køge and Herlev Hospital treated with Global FX hemiarthroplasty
2921801|NCT03097393||AKI GROUP|measure Procalcitonin among Patient developed Acute kidney injury during ICU stay
2921802|NCT03097393||Non-AKI group|measure Procalcitonin among Patient did not develop Acute kidney injury during ICU stay
2921803|NCT03097380|Experimental|AZD2115|
2921804|NCT03097380|Active Comparator|Spiriva (Tiotropium)|
2921805|NCT03097380|Experimental|[11C]AZ13754366|
2921806|NCT03097354||Non-students|Ad-hoc sample of German adults, not currently enrolled at a university, lifetime alcohol users, no intervention/observational survey study design
2921807|NCT03097354||University students|Ad-hoc sample of German adults, currently enrolled at a university (most likely in Dresden, Germany), lifetime alcohol users, no intervention/observational survey study design
2921808|NCT03097341|Experimental|xisomab 3G3|
2921809|NCT03097341|Placebo Comparator|Placebo|
2921810|NCT03097328|Experimental|TAK-228|"TAK-228 will be taken orally on a weekly basis for 4 weeks per cycle~Dosage will be determined by the study team"
2921811|NCT03097315|Experimental|4mg CLS-TA Suprachoriodal Injection|Suprachoroidal injection of 40 mg/mL (4 mg in 100 μL) of CLS-TA
2921812|NCT03097289|Experimental|Platelets stored in InterSol|Platelets collected on the Trima Accel system and stored in 65% InterSol/35% plasma
2921813|NCT03097276|Other|Patients who underwent open decompression surgery|
2921814|NCT03097263||Patients|Patients included for rehabilitation program
2921815|NCT03097250||PKU Subjects|Subjects with PKU will be asked to undergo an MRI and blood draw on Day 1 and Day 2 of the study. They will also receive neuropsychological testing on Day 1 of the study
2921816|NCT03097250||Controls|Controls will undergo only one MRI and blood draw on Day 1 of the study. They will also receive neuropsychological testing on Day 1 of the study.
2921817|NCT03097237|Experimental|Wholegrain rye|Wholegrain rye products with a high content of dietary fiber
2921818|NCT03097237|Active Comparator|Refined wheat|Refined wheat products with a low content of dietary fiber
2921819|NCT03097224|Experimental|Prehabilitation group|Tele-supervised prehabilitation
2921820|NCT03097224|No Intervention|Control group|Usual care
2921821|NCT03097211|Experimental|Group 1: BIA 6-512 25 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
2921822|NCT03097211|Experimental|Group 2: BIA 6-512 50 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
2921823|NCT03097211|Experimental|Group 3: BIA 6-512 75 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
2921824|NCT03097211|Experimental|Group 4: BIA 6-512 100 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
2921825|NCT03097198|Experimental|PbN-TED|Treated with plum-blossom needle first for 10 times during 20 days, followed with a one-month wash-out period and a 10-day period with Tropicamide Eye Drops.
2921826|NCT03097198|Experimental|TED-PbN|Treated with Tropicamide Eye Drops for 10 days first, followed with a one-month wash-out period and 10 times of plum-blossom needle treatment for 20 days.
2921827|NCT03097172||Group 1|"Stable elective patients Stenotic coronary artery 10 x LAD 10 x RCA 10 x Cx~30 patients total"
2921828|NCT03097172||Group 2|"Stable elective patients Chronic total occlusion of one artery~10 x LAD 10 x RCA~20 patients total"
2921829|NCT03097159||Costoclavicular block|For anesthesia, this group of patients will be received ultrasound guided costoclavicular block
2921830|NCT03097159||Supraclavicular block|For anesthesia, this group of patients will be received ultrasound guided supraclavicular block
2921831|NCT03097146|Other|comprehensive multidisciplinary stroke care|
2921832|NCT03097133|Experimental|Esketamine + Standard of care|Participants will receive intranasal esketamine 84 milligram (mg) on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.
2921833|NCT03097133|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.
2921834|NCT03097120|Active Comparator|unopposed estrogen|0.625 mg of conjugated equine estrogen
2921835|NCT03097120|Active Comparator|estrogen-plus-medroxyprogesterone|0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate
2921836|NCT03097120|Placebo Comparator|placebo|placebo
2921837|NCT03097107|Experimental|Saroglitazar magnesium 1 mg|Saroglitazar magnesium 1 mg tablet orally once a day for 12 weeks
2921838|NCT03097107|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet orally once a day for 12 weeks
2921839|NCT03097107|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet orally once a day for 12 weeks
2921840|NCT03097107|Placebo Comparator|Placebo|Placebo tablet orally once a day for 12 weeks
2921841|NCT03097094|Active Comparator|Male dog|Male dog extract used for skin prick test and conjunctival provocation
2921843|NCT03097081|Experimental|No orthosis|The intervention consists of a deviation of the standard protocol; patients post-operatively do not receive an orthosis.
2921844|NCT03097081|Active Comparator|Orthosis|As in correspondence with local and international guidelines, patients receive an orthosis as standard post-operative care. This is considered the control group.
2921845|NCT03097055|Experimental|Traditional Acupuncture|"Traditional acupoints and traditional deqi manipulation"
2921846|NCT03097055|Sham Comparator|Minimal Acupuncture|To avoid traditional acupoints and minimal manipulation
2921847|NCT03097042|Active Comparator|Study group|The catheter will be pulled back slowly and without rotation
2921848|NCT03097042|Active Comparator|Control Group|The catheter will be pulled back by rotating 360 degrees round itself
2921849|NCT03097029|Experimental|Pancreatic Enzymes|All subjects in this study will have exposure to therapy with pancreatic enzymes for a period of about ten days.
2921850|NCT03097016|Experimental|Single oral dose of 3 mg CC-122|All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
2921851|NCT03097003||Use of Apremilast in patient with plaque psoriasis|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
2921852|NCT03096990||Use of apremilast in patients with active PsA|Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
2921853|NCT03096977|Experimental|CHUB-TST02 patients|All patients who participated in the NCT02805634 (CHUB-TST02) study.
2921854|NCT03096964|Experimental|Nordic walking|Experimental: Nordic walking Training The total period of training was composed by 8-week of walking with poles, three sessions per week. The cycles were divided into eight microcycles composed by three training sessions. Each training session took 60 min. Nordic walking aerobics training were used during the training period. These exercises were performed alternating volume and intensity. Exercise intensities were controlled using the cardiac monitor, and the zone was since 70% to 105% of the heart rate at the second ventilatory threshold. And volume was controlled using the time of the session.
2921855|NCT03096964|Experimental|Free Walking|Experimental: Free walking Training The total period of training was composed by a 8-week cycles of walking without poles, with three sessions per week. The cycles were divided into eight microcycles composed by three training sessions. Each training session took 60 min. Free walking aerobics training were used during the training period. These exercises were performed alternating volume and intensity. Exercise intensities were controlled using the cardiac monitor, and the zone was since 70% to 105% of the heart rate at the second ventilatory threshold. And volume was controlled using the time of the session.
2921856|NCT03096951|Experimental|Prehabilitation group|Preoperative and postoperative telerehabilitation
2921857|NCT03096951|Active Comparator|Rehabilitation group|Postoperative telerehabilitation
2921858|NCT03096938|Placebo Comparator|Normal screening group|patients receive the routine screening examination
2921859|NCT03096938|Experimental|methylation markers screening group|patients receive the methylation markers screening
2921860|NCT03096925|Experimental|Intervention group|The intervention group will receive guided self-help comprising six web-based sessions, comprising information, exposure to physical activity, how worry can excess pain, physical reactions to pain and worry, consequences of avoidance, and specific panic treatment. The first session will be done at the hospital before discharge, the others at home. Between sessions there will be a brief telephone contact with a project worker.
2921861|NCT03096925|No Intervention|Control group|This group will receive treatment as usual, which is no specific treatment. They can however use the general health system as they like.
2921862|NCT03096912|Experimental|Ribociclib|Oral, ribociclib 600 mg x 1 a day, 21 days on 7 days off
2921863|NCT03096886|Experimental|CCBT Immediate|"Intervention: Computer-Augmented Cognitive Behavioral Therapy~Half of participants presenting with MDD will be randomized to receive 8 weeks of Computer-Augmented Cognitive Behavior Therapy (CCBT) immediately after completing pre-treatment assessments; imaging data will be collected pre- and post-treatment."
2921864|NCT03096886|Experimental|Waitlist, followed by CCBT|"Intervention: Waitlist followed by Computer-Augmented Cognitive Behavioral Therapy~Half of participants presenting with MDD will be randomized to be waitlisted during the first 8 weeks and will receive CCBT between weeks 9-18; imaging data will also be collected pre--treatment, following 8 weeks of waitlist, and post-treatment of CCBT.~This arm will serve as the equivalent of a placebo comparator arm during weeks 1-8; and then as an experimental arm during weeks 9-18."
2921865|NCT03096886|No Intervention|Matched Comparison|"No Intervention: Matched Comparison~Healthy controls will act as a matched comparator. Participants will complete pre-treatment assessments and imaging."
2921866|NCT03096873|No Intervention|No Exercise (CON)|Twenty obese adolescent girls. This arm did not perform any exercise training for 12 weeks.
2921867|NCT03096873|Experimental|Exercise (EX)|Twenty obese adolescent girls. This arm performed combined exercise training 3 times a week for 12 weeks.
2921868|NCT03096860|Experimental|Alcohol consumption and hookah|
2921869|NCT03096860|Placebo Comparator|Placebo consumption and hookah|
2921870|NCT03096847|Experimental|ribociclib + letrozole|"All patients will receive ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.~Premenopausal patients additionally receive goserelin 3.6 mg i.m. monthly"
2921871|NCT03096834|Placebo Comparator|Placebo|Matching placebo injection, subcutaneous
2921872|NCT03096834|Experimental|AMG 334|AMG 334 injection, subcutaneous
2921873|NCT03096821|Other|ngFDS selected treatment|Treatment with commercially available treatments (per package insert instructions) chosen via next-generation functional drug screening (ngFDS).
2921874|NCT03096808|Experimental|Adaptive Radiotherapy|Eligible patients will receive IMRT of 60-70Gy in 30-35 once-daily fractions with or without concurrent chemotherapy according to the current standard of care.
2921875|NCT03096795|Experimental|SAD Cohort 1|Single dose (Day1) of MEDI3506 or placebo
2921876|NCT03096795|Experimental|SAD Cohort 2|Single dose (Day1) of MEDI3506 or placebo
2921877|NCT03096795|Experimental|SAD Cohort 3|Single dose (Day1) of MEDI3506 or placebo
2921878|NCT03096795|Experimental|SAD Cohort 4|Single dose (Day1) of MEDI3506 or placebo
2921879|NCT03096795|Experimental|SAD Cohort 5|Single dose (Day1) of MEDI3506 or placebo
2921880|NCT03096795|Experimental|SAD Cohort 6|Single dose (Day1) of MEDI3506 or placebo
2921881|NCT03096795|Experimental|SAD Cohort 7|Single dose (Day1) of MEDI3506 or placebo
2921886|NCT03096782|Experimental|Plan 1: Fludarabine/Clofarabine/Busulfan/Rituximab/TBI|"If participant between 1 and 55 years of age and can receive high-dose chemotherapy, or if participant between 55 and 65 years old and participant's doctor agrees, participant receives fludarabine, clofarabine, busulfan, antithymocyte globulin (ATG), total body irradiation, and possibly rituximab.~Test dose of busulfan given as outpatient or inpatient.~Rituximab given by decision of physician on Day -11.~ATG given on Days -9 and -8.~Fludarabine, clofarabine, and busulfan given on Days -7 through -4.~Single treatment of low-dose total body irradiation n Day -3.~Cord blood transplant given on Day 0.~MMF starting on Day -3 twice a day.~Tacrolimus on Day -2 until able to take it by mouth. Then tacrolimus by mouth 2 times a day for about 6 months.~Filgrastim (G-CSF) 1 time a day every day starting on Day 0 until white blood count begins to recover."
2921887|NCT03096782|Experimental|Plan 2: Fludarabine/Melphalan|"If participant's doctor chooses fludarabine and melphalan:~On Day -9, participant admitted to the hospital and receives fluids by vein.~On Days -8 and -7, participant receives ATG by vein over about 4 hours.~On Days -5, -4, and -3, participant receives fludarabine by vein over about 30 minutes.~On Day -2, participant receives fludarabine by vein over about 30 minutes and melphalan by vein over about 30 minutes.~On Day 0, participant receives cord blood transplant through the CVC.~MMF starting on Day -3 twice a day.~Tacrolimus on Day -2 until able to take it by mouth. Then tacrolimus by mouth 2 times a day for about 6 months.~Filgrastim (G-CSF) 1 time a day every day starting on Day 0 until white blood count begins to recover."
2921888|NCT03096782|Experimental|Plan 3: Fludarabine/Cyclophosphamide/Total Body Irradiation|"If participant's doctor chooses fludarabine, cyclophosphamide, and total body irradiation:~On Days -8 and -7, participant receives ATG by vein over about 4 hours.~On Day -6, participant receives fludarabine and cyclophosphamide. Mesna given before and after the cyclophosphamide dose.~On Days -5, -4, and -3, participant receives fludarabine.~On Day -1, participant receives a single treatment of low-dose total body irradiation.~On Day 0, participant receives cord blood transplant through the CVC.~MMF starting on Day -3 twice a day.~Tacrolimus on Day -2 until able to take it by mouth. Then tacrolimus by mouth 2 times a day for about 6 months.~Filgrastim (G-CSF) 1 time a day every day starting on Day 0 until white blood count begins to recover."
2921889|NCT03096769|Other|Study Arm|
2921890|NCT03096756|Other|Part 1: Single Ascending Dose Escalation GC4702|Serially increase dose escalation of orally formulated GC4702 or placebo (6:2 ratio), preceded by single dose of active comparator, GC4419 IV.
2921891|NCT03096756|Experimental|Part 2: Food Effect Study|Following Part 1 dose find, single dose level of GC4702 administered under fasting for and fed condition.
2921892|NCT03096743|Experimental|Patients with increased intracranial hypertension|Patients will receive the MR elastography, MRI structural brain imaging, Optical Coherence Tomography (OCT) imaging, Optic nerve B-scan ultrasound and Lumbar puncture.
2921893|NCT03096743|Experimental|Patient without raised intracranial hypertension|Patients will receive the MR elastography, MRI structural brain imaging, Optical Coherence Tomography (OCT) imaging, and Optic nerve B-scan ultrasound. Some patients will receive lumbar punctures.
2921894|NCT03096730|Placebo Comparator|Normal Saline|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
2921895|NCT03096730|Sham Comparator|Sufentanil|Normal saline is intravenously admistrated before anesthesia induction and intraoperative pain management was with sufentanil
2921896|NCT03096730|Active Comparator|Dexmedetomidine|Dexmedetomidine is intravenously administrated at a dose of 0.5ug/kg 10min before anesthesia induction and intraoperative pain management was with remifentanil
2921897|NCT03096730|Active Comparator|Nalmefene|Nalmefene is intravenously administrated at a dose of 0.2ug/kg before anesthesia induction and intraoperative pain management was with remifentanil
2921898|NCT03096730|Active Comparator|Dexmedetomidine-Nalmefene|A dose of 0.2ug/kg nalmefene and a dose of 0.5ug/kg dexmedetomidine for 10 minutes before anesthesia induction and intraoperative pain management was with remifentanil
2921899|NCT03096704||slow transit time constipation|
2921900|NCT03096691|Active Comparator|short cervix group|cervical pessary in group with first pregnancy or no preterm labor
2921901|NCT03096691|Active Comparator|group with cervical insufficiency|cervical pessary in group with multiple preterm labor
2921902|NCT03096678||LBBB without LV dysfunction|LVEDD>55mm or LVEF<55%
2921903|NCT03096678||LBBB with LV dysfunction|LVEDD<55mm and LVEF>55%
2921904|NCT03096665||Blood test group|All patients receive the three types of blood test (venous blood test, skin puncture blood (capillary blood) test and arterial blood gas analysis
2921905|NCT03096652|Active Comparator|Midline approach|Standard midline incision, then optimal debulking (hysterectomy + lymphadenectomy +/- omentectomy).
2921906|NCT03096652|Active Comparator|Modified approach|Panniculectomy with vertical incision of the rectus sheath then optimal debulking (hysterectomy + lymphadenectomy +/- omentectomy).
2921907|NCT03096639|Active Comparator|Diaphragm Pacing Therapy DPTS|Diaphragm Pacing intervention will be conducted 3x a day using the Diaphragmatic Pacing Therapy System (DPTS). The DPTS includes the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) which is inserted temporarily into the left subclavian vein, the Lungpacer Control Unit (LCU external unit) and an intermediate cable that connects the LCU to the LIVE Catheter.
2921908|NCT03096639|No Intervention|Control Group|Standard of care treatment of weaning failure, no intervention is involved in this control group.
2921909|NCT03096613|Experimental|Levothyroxine group|The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.
2921910|NCT03096613|No Intervention|Standard therapy group|The patients in this group receive standard therapy in consistent with the local clinical practice.
2921911|NCT03096587|Experimental|XP Endo Finisher file|XP Endo Finisher file is used to activate irrigation as a final step in irrigation protocol
2921912|NCT03096587|Active Comparator|ultrasonic activated irrigation|ultrasonic activated irrigation as a final step in irrigation protocol
2921913|NCT03096574||Pregnant women|"Over the age of 16~Under the care of staff working in: University Hospital Southampton NHS Foundation Trust, St Georges Healthcare NHS Trust, Oxford University Hospitals NHS Foundation Trust or University Hospitals Bristol NHS Foundation Trust~Able to read and write in English and give fully informed consent"
2922025|NCT03095716||elderly patients|Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
2921914|NCT03096574||Clinical Staff|"Over the age of 18~Working in obstetrics or midwifery who regularly care for women in pregnancy at University Hospital Southampton NHS Foundation Trust, St Georges Healthcare NHS Trust, Oxford University Hospitals NHS Foundation Trust or University Hospitals Bristol NHS Foundation Trust~Able to read and write in English and give fully informed consent"
2921915|NCT03096561|Other|Hypothermia related cardiac arrest|blood draw from three different vessels punctured in the emergency room (central vein, peripheral vein, artery) and comparison of potassium rate and other biological values between the different sites of blood draw and two different measuring techniques (laboratory vs. blood gas analyser)
2921916|NCT03096548|Experimental|Sun Safety Ink! Program|A program to (1) increase full-body sun comprehensive sun protection practices, (2) decrease sunburning and tanning and (3) decrease positive attitudes regarding tanning and tanning attractiveness of tattoo studio clients. The program is comprised of a video based communication strategy training presented by research staff to artists of tattoo studios.
2921917|NCT03096548|Active Comparator|Attention Control|The attention control group will provide standard tattoo aftercare instructions to their clients.
2921918|NCT03096535|Experimental|Cooling|Individualized cooling protocol.
2921919|NCT03096535|Experimental|Thermoneutral|Thermoneutral condition day.
2921920|NCT03096522|Active Comparator|Phenytoin 2% spray|Patients undergoing anal fistulotomy with postoperative topical phenytoin therapy
2921921|NCT03096522|Active Comparator|Anal fistulotomy|Patients undergoing anal fistulotomy without postoperative topical therapy
2921922|NCT03096496||GIMEMA APL0406 patients|APL survivors previously enrolled in GIMEMA APL0406 clinical trial and in 1st molecular CR after third consolidation treatment.
2921923|NCT03096483|Experimental|OEC Elite Imaging Arm|Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system
2921924|NCT03096470||anesthesia|The children were treated with closed reduction with anesthesia after prolonged traction
2921925|NCT03096470||No anesthesia|The children were treated with closed reduction with no anesthesia after prolonged traction
2921926|NCT03096457|Experimental|Group 1 - Paromomycin cream|40 subjects will be included to receive 15% paromomycin in aquafilm base twice a day during 20 consecutive days. The lesion will be cleaned , then, a generous amount of the study drug (an amount sufficient to cover the area of the ulcer and the lesion border) will be applied to the lesion and rubbed into the ulcer using a gloved finger by a member of the clinical study staff. After application of the study drug, the patient will be observed for 15 minutes for signs of adverse events. If there are no signs of local toxicity, the area of the ulcer will be covered with extra study drug. For Days 2-20, the study drug will be applied and the lesion covered with a sterile gauze and tape dressing as on Day 1.
2921927|NCT03096457|Active Comparator|Group 2. Local Injectable Pentamidine|"20 subjects will be included to receive IL pentamidine [Pentacarinat® Sanofi-Aventis: 30 mg/ml] will administered at a dose of 120 ug (4 ul) per mm2 of lesion area 3 times (on days 1, 3, and 5) as per our previous experience.~A small button of Xylocaine® will be applied by means of a thin needle at the four cardinal points of the lesion and then a small gauge (23g) needle will introduce the drug in each cardinal point. The needle will be moved in all directions to infiltrate of whole lesion and surrounding infiltrated area."
2921928|NCT03096457|Placebo Comparator|Group 3. Vehicle control|10% Urea en parafilm cream will be used in similar ways as paromomycin cream in group 1
2921929|NCT03096444|Experimental|Topical KeAmLi combo|Topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
2921930|NCT03096444|Experimental|Topical ketamine|Topical ketamine 10% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
2921931|NCT03096444|Experimental|Topical amitriptyline|Topical amitriptyline 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
2921932|NCT03096444|Experimental|Topical lidocaine|Topical lidocaine 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
2921933|NCT03096444|Placebo Comparator|Topical vehicle|Topical vehicle (PCCA Lipoderm) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
2921934|NCT03096431|Active Comparator|Arm 1: Physical activity intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 1: intervention of physical activity begins. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
2921935|NCT03096431|Active Comparator|Arm 2:Physical activity and cognitive intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 2: intervention of both cognitive rehabilitation and physical activity begins. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
2922026|NCT03095703|Experimental|Sirolimus|All patients will receive sirolimus for the duration of the study, with a trough level target range of 5-8 ng/ml.
2922027|NCT03095690|Other|Idiopathic Parkinson's Disease patients|High resolution peripheral scanner (HRpQCT).
2921936|NCT03096431|Active Comparator|Arm 3: Cognitive and begin physical activity intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 3: Intervention of cognitive rehabilitation begins prior to and is concurrent with WBRT/SRS treatment. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 3: continue intervention of cognitive rehabilitation; add intervention of physical activity. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
2921937|NCT03096418|Experimental|Weekly Paclitaxel|"Paclitaxel 80 mg/m2 will be initiated as standard infusion on days 1, 8, 15 of a 21-day cycle.~Participants will continue with paclitaxel 80 mg/m2 for cycles 2-4 prior to surgery."
2921938|NCT03096392|Experimental|HDV insulin lispro 100 UNT/mL|insulin lispro with 0.8 ml HDV added to a 10 ml vial of insulin lispro, injected subcutaneous before meals as needed. Study duration of 7 weeks (6 weeks of treatment)
2921939|NCT03096392|Active Comparator|insulin lispro 100 UNT/ML|insulin lispro with 0.8 ml sterile water for injection added to a 10 ml vial of insulin lispro, injected subcutaneous before meals as needed. Study duration of 7 weeks (6 weeks of treatment)
2921940|NCT03096379||Magnetic resonance imaging|Patients with new-onset of lower gastrointestinal symptoms and ileocecal mucosal lesions of uncertain diagnosis as evidenced by the presence of inflammation, ulceration, strictures or nodules on colonoscopy.
2921941|NCT03096366|Experimental|Physical therapy (PT) plus blood flow restriction (BFR)|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion. With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
2921942|NCT03096366|Active Comparator|Physical therapy|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
2921943|NCT03096353||Healthy Volunteers|Healthy Volunteers
2921944|NCT03096340|Experimental|IT-141|
2921945|NCT03096327|Experimental|Intervention (Montelukast)|Aireez contains Montelukast which is a potent and selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
2921946|NCT03096327|Placebo Comparator|Placebo|Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured.
2921947|NCT03096314|Active Comparator|High dose vitamin D formulation|A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
2921948|NCT03096314|Placebo Comparator|Placebo|A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
2921949|NCT03096301|Experimental|Low-intensity laser|Twelve laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2, in accordance with the protocol suggested by Venezian et al. (2010) and Carvalho et al. (2010). The laser will be applied to 3 points of the masseter muscle (upper, middle, and lower bundles) and 1 point in the anterior temporalis on each side of the face
2921950|NCT03096301|Active Comparator|Occlusal Plate|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
2921951|NCT03096301|Placebo Comparator|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
2921952|NCT03096288|Experimental|Evolocumab|Evolocumab (Repatha) 420 mg s.c. single injection
2921953|NCT03096288|Placebo Comparator|Placebo|0.9% sodium chloride s.c. single injection
2921954|NCT03096275|Experimental|MMF+MTX+Glucocorticoids|Patients were treated with Glucocorticoids combined with mycphenolate mofetil(MMF) as well as methotrexate(MTX) treatment for 52 weeks and were followed for 52 weeks.
2921955|NCT03096275|Active Comparator|CYC/AZA+Glucocoticoids|Patients were treated with Glucocorticoids combined with cyclophosphamide(CYC)/azathioprine(AZA) for 52 weeks and were followed for 52 weeks
2921956|NCT03096262|Experimental|Stroke Patients|
2921957|NCT03096262|Active Comparator|Healthy Controls|
2921958|NCT03096249|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716) will be used for intranasal administration of a single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
2921959|NCT03096249|Placebo Comparator|Placebo|Physiological water (sodium chloride (NaCl) solution) Administration via nasal spray
2921960|NCT03096223|Experimental|KHK4083|
2921961|NCT03096210|Other|Titanium-Prepared Platelet Rich Fibrin|After careful elevation of the schneiderian membrane without perforation,T-PRFs were only used in the test group.
2921962|NCT03096210|Other|Allograft|After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
2921963|NCT03096197|Experimental|EAW + TLS|The EAW+TLS training group will receive 60 minutes of exoskeleton-assisted walking overground per session, for a total of 80 sessions (3x/week, 28 wks.) with simultaneous transcutaneous lumbosacral stimulation (TLS) intervention followed by 15 minutes of over ground training without the exoskeleton. component is added to the exoskeleton assisted walking component in this group. TLS will involve placing self-adhesive stimulating electrodes bilaterally over the T11/T12 lumbar region. Correct placement will be confirmed by the elicitation of posterior root muscle reflexes in the lower limb muscles. A constant-voltage stimulator (RT 50 Sage stimulator) will deliver pulses of 2 ms width. TLS will be applied while the participant walks in the Exo-skeleton-assisted walking (EAW).
2921964|NCT03096197|Experimental|EAW without TLS|EAW, exoskeleton-assisted walking, an activity based therapy is a training which involves using the same exoskeleton device for all the participants. Each participant will undergo, 60 minutes of EAW as above. Each participant will undergo a stand evaluation and be instructed in proper use of the device. During the initial 3 sessions of training, the exoskeleton device will be tethered to an overhead pulley system during training to allow subjects to safely adapt to trunk, balance gait activities while walking in the exoskeleton. EAW overground walking will follow each training session with the 6-minute walk test, 10 meter walk test .
2921965|NCT03096184|Experimental|Study Group|Apatinib Mesylate Tablets and Tegafur Gimeracil Oteracil Potassium Capsules administered as a daily oral treatment
2921966|NCT03096171|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
2921967|NCT03096171|Experimental|Flourishing App Program|This group will receive the intervention Flourishing App Program for 16 weeks.
2921968|NCT03096158|Experimental|Functional Electrical Stimulation (FES)|FES (Physiological Electrical stimulator - LYNX - FMUSP, São Paulo, Brazil) will be applied at a frequency of 80 Hz with a 0.5 ms pulse width, a 5 s contraction time, a 10 s rest time and at the maximum tolerable intensity for 20 minutes/session during the period of hospitalization of the participants, to perform a full knee extension. Self-adhesive electrodes will placed on the inguinal region and on the vastus medialis and vastus lateralis of the femoral quadriceps of both thighs, which caused alternating contractions between the lower limbs to full extension of knees, placed at 60o of flexion. It will be occur once per day until the hospital exit.
2921969|NCT03096158|Experimental|Ventilatory Muscle Training (TREMVEN)|The enrolled participants will perform inspiratory muscle training (IMT) for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit.
2921970|NCT03096158|Experimental|Aerobic Training (AERO)|It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, oxygen saturation (SpO2) and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit.
2921971|NCT03096158|Experimental|Isometric Handgrip Training (ISO)|Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit.
2921972|NCT03096145|Experimental|Behavioral Intervention|Behavioral: telephone counseling 1 sessions, mobile texting, and health incentive
2921973|NCT03096132|Active Comparator|Family Based Behavioral Treatment|The program includes information about diet and physical activity education, in addition to parent management skills and behavior therapy strategies in a weekly group setting.
2921974|NCT03096132|Experimental|Guided Self-Help Fam. Based Bx Treatment|The program includes information about diet and physical activity education, in addition to parent management skills and behavior therapy strategies in a guided self-help manual.
2921975|NCT03096093|Experimental|Immunotherapy - pancreatic cancer|Intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with pancreatic or haematological cancer. Treatment will run concurrently with standard chemotherapy.
2921976|NCT03096093|Experimental|Immunotherapy - other late stage cancers|Intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with other late stage cancers, not receiving any other standard treatment.
2921977|NCT03096080|Experimental|Cohort 1|Single 0.25 mg/kg dose of tesevatinib
2921978|NCT03096080|Experimental|Cohort 2|Single 0.50 mg/kg dose of tesevatinib
2921979|NCT03096080|Experimental|Cohort 3|Single 1.00 mg/kg dose of tesevatinib
2921980|NCT03096067|Active Comparator|Heavy slow resistance group|Heavy slow resistance training. Three times weekly for 12 weeks.
2921981|NCT03096067|Experimental|Moderate slow resistance group|Moderate slow resistance training. Three times weekly for 12 weeks.
2921982|NCT03096054|Experimental|Part 1 a dose escalation|Phase where groups of patients will receive increasing doses of LY3143921 hydrate to find a safe dose and a dose that best targets the cancer cells.
2921983|NCT03096054|Experimental|Part 2 an expansion|Phase where a larger group of patients will receive the highest dose of LY3143921 hydrate considered to be safe from Part 1, to find out more about how the drug is working.
2921984|NCT03096041|Experimental|Experimental arm|Auriculotherapy for analgesic use
2921985|NCT03096041|Placebo Comparator|Controle arm|Placebo auriculotherapy
2921986|NCT03096028||PMNS cohort|The Pune Maternal Nutrition Study (PMNS) is a preconceptional birth cohort established in 1993 at Diabetes unit KEM hospital research center, Pune. 700 offsprings of the cohort are being followed every 6 years. Maternal vitamin B12 folate level during pregnancy were measured at 18 & 28 weeks.
2921987|NCT03096015|Experimental|Intensive Treatment for Aphasia|
2921988|NCT03096002||Lifestyle change (one-treatment group)|The lifestyle change program is a 3-week program that will introduce participants to a regular healthy lifestyle that includes exercising at least three times per week and the program will highlight simple dietary strategies. There is no randomization to this program - all individuals enrolled will partake in the same program and will be followed up for 12 months after the program has concluded.
2921989|NCT03095989|Experimental|Mindfulness|Subjects in the intervention group will participate in an online mindfulness program developed in the first phase of the study, in addition to standard clinical care.
2921990|NCT03095989|No Intervention|Waiting list|Participants from the control group will be placed on a waiting list and will receive the standard care, that they would receive if not in the study. They will be assessed according to the assessment schedule, exactly as subjects in the intervention group. After the last assessment (six months after recruitment), they will receive the option to enter the mindfulness program.
2922028|NCT03095677|Experimental|Apnea Group (GApn)|Program of training with exercises including apneas
2921991|NCT03095976|Experimental|Test group|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects.
2921992|NCT03095963|Active Comparator|Probiotics|The study group took a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®) in addition to levothyroxine
2921993|NCT03095963|Active Comparator|Levothyroxine|The control group took levothyroxine only
2921994|NCT03095950|Active Comparator|News with Spin|News items reporting results of RCTs with spin
2921995|NCT03095950|Experimental|News without spin|News items reporting results of RCTs without spin
2921996|NCT03095924|Active Comparator|News with Spin|News items reporting results of RCTs with spin
2921997|NCT03095924|Experimental|News without spin|News items reporting results of RCTs without spin
2921998|NCT03095911|Active Comparator|News with Spin|News items reporting results of RCTs with spin
2921999|NCT03095911|Experimental|News without spin|News items reporting results of RCTs without spin
2922000|NCT03095898|Experimental|True Acupuncture|
2922001|NCT03095898|Sham Comparator|Sham Acupuncture|
2922002|NCT03095898|No Intervention|Control Group|
2922003|NCT03095885|Other|Oxalate-rich Test Meal|The study intervention is a controlled oxalate-rich test meal containing approximately 400-600 mg oxalate, 250-350 mg calcium and 700-1000 mg sodium.
2922004|NCT03095872|Experimental|Bepanthen/Vaseline|One half of the wound occuring after CO2 laser therapy of photo-damaged skin is treated with Bepanthen and the other half with Vaseline.
2922005|NCT03095859|Active Comparator|Control|Standard care (once daily physical rehabilitation, approx. 30 minutes). Standard care will consist of physical exercise, such as early mobility, endurance training, upper limb, lower limb and trunk activity. This will involve non-physical interventions including respiratory therapy, airway clearance and patient and carer education.
2922006|NCT03095859|Experimental|Experimental|Early intensive physical rehabilitation, which will consist of standard care plus one additional treatment per day. The additional early intensive physical rehabilitation session provided to the experimental group will allow for progression of aerobic, strength and flexibility exercise and / or completion of a more comprehensive physical rehabilitation program.
2922007|NCT03095846|Experimental|Winter Swimmers|Individualized cooling protocol
2922008|NCT03095846|Experimental|Not-winter Swimmers|Individualized cooling protocol
2922009|NCT03095833|Other|Influence of cognitive biases on food intake|Determine how high-level cognitive control can affect the price to pay for a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
2922010|NCT03095833|Other|Modulation of the floral flavor of a wine|Highlight the brain regions involved in the visual bias related to the intensity of a wine's dress combined with the floral character evaluation of its flavor.
2922011|NCT03095820|Active Comparator|Supportive therapy|The control group received supportive therapy for 12 weeks. In addition to a telephone call once a week and a home visit once a month, this program consisted of identification of physical problems, encouragement of general exercise, encouragement of pleasant activities, and so forth. The control program did not feature any specific goal setting by the participants, specific education about the benefits of achievement of such goals, or symbolic prizes.
2922012|NCT03095820|Experimental|Multidomain intervention|"As a multidomain intervention, four evidence-based therapeutic approaches (physical activity, healthy diet, social activity, and emotional regulation) were incorporated into the program.~In terms of the healthy diet intervention, we encouraged participants to perform at least 30 min of above-moderate physical activity, three times per week. In terms of the healthy diet intervention, the intervention consisted of encouraging participants to consume high quantities of fish, olive oil, legumes, vegetables, and fruit, at a frequency of at least twice a week. In terms of the social activity intervention, we encouraged participants to participate in social organizations, such as the senior center, the hall of the elderly, a fraternity, a reunion, and a clan gathering, at least once a week. In terms of the emotional regulation intervention, we a performed brief cognitive restructuring task for 20 min per visit."
2922013|NCT03095807|Experimental|NNC9204-1706 A|
2922014|NCT03095807|Placebo Comparator|Placebo|
2922015|NCT03095794|Experimental|neural mechanisms of decision making|Previous studies on how brain manages a value-based decision have been bounded to individual decisions. The current study will extend the understanding of social dimensions by answering four questions.
2922016|NCT03095781|Experimental|Treatment (pembrolizumab, XL888)|Patients receive pembrolizumab IV over 30 minutes on day 1 and XL888 PO on days 1, 4, 8, 11, 15, and 18. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2922017|NCT03095768|Experimental|Intervention|Lifestyle Education and Cooking Demonstration
2922018|NCT03095755|Experimental|Ischemic Conditioning|The investigators will perform ischemic conditioning on the paretic leg by inflating a blood pressure cuff to 225 mmHg to occlude blood flow to the leg for 5 minutes. This will be repeated for 5 cycles, with 5 minutes of rest between each cycle. The intervention will be performed for a maximum of 12 times within a 4 week period.
2922019|NCT03095755|Sham Comparator|Sham|The investigators will perform sham ischemic conditioning on the paretic leg by inflating a blood pressure cuff to only 25 mmHg on the leg for 5 minutes. This will be repeated for 5 cycles, with 5 minutes of rest between each cycle. The intervention will be performed for a maximum of 12 times within a 4 week period.
2922020|NCT03095742|Placebo Comparator|Low MAP|Low mean arterial pressure. 40 patients were blindly randomized to normal range (MAP 65 mmHg) during the peri-cardiac arrest period.
2922021|NCT03095742|Active Comparator|High MAP|High mean arterial pressure. 40 patients were blindly randomized to intervention group (MAP 75 mmHg) during the peri-cardiac arrest period.
2922022|NCT03095729||Healthy|40 healthy subjects, during quiet breathing and under an inspiratory load (inspiratory threshold loading)
2922023|NCT03095729||Ondine syndrome|12 patients presenting with central hypoventilation syndrome or Ondine's curse syndrome, during spontaneous breathing and with Non Invasive Ventilation
2922024|NCT03095729||Amyotrophic Lateral Sclerosis|30 patients presenting with Amyotrophic Lateral Sclerosis during spontaneous breathing and with Non Invasive Ventilation
2922029|NCT03095677|Other|Control Group (GC)|Program of training with exercises without apnea
2922030|NCT03095664|Experimental|Intervention group|6 months after surgical treatment, women in the experimental group will attend a counseling program to promote healthy eating and physical activity.
2922031|NCT03095664|No Intervention|Control group|Control group will receive usual care (verbal nutritional counseling after surgical treatment, at discharge).
2922032|NCT03095651|Experimental|T1DM MK-5160 low dose|T1DM MK-5160, low dose, subcutaneous daily for 12 days
2922033|NCT03095651|Experimental|T1DM MK-5160 medium dose|T1DM MK-5160, medium dose, subcutaneous daily for 12 days
2922034|NCT03095651|Experimental|T1DM MK-5160 high dose|T1DM MK-5160 high dose, subcutaneous daily for 12 days
2922035|NCT03095651|Active Comparator|T1DM Glargine 0.4 U/kg|T1DM Glargine 0.4 U/kg, subcutaneous daily for 12 days
2922036|NCT03095651|Experimental|T2DM MK-5160 low dose|T2DM MK-5160 low dose, subcutaneous daily for 12 days
2922037|NCT03095651|Experimental|T2DM MK-5160 medium dose|T2DM MK-5160 medium dose, subcutaneous daily for 12 days
2922038|NCT03095651|Experimental|T2DM MK-5160 high dose|T2DM MK-5160 high dose, subcutaneous daily for 12 days
2922039|NCT03095651|Active Comparator|T2DM Glargine 0.6 U/kg|T2DM Glargine 0.6 U/kg, subcutaneous daily for 12 days
2922040|NCT03095638|Experimental|Treatment sequence A/B: Part 1|Eligible subjects will be randomized in sequence A/B in Part 1 and will receive A: conventional 10 mg DTG tablet (5 tablets) in Period 1 and B: conventional 50 mg DTG tablet in Period 2, administered directly to mouth.
2922041|NCT03095638|Experimental|Treatment sequence B/A: Part 1|Eligible subjects will be randomized in sequence B/A in Part 1 and will receive B: conventional 50 mg DTG tablet in Period 1 and A: conventional 10 mg DTG tablet (5 tablets) in Period 2, administered directly to mouth.
2922042|NCT03095638|Experimental|Treatment sequence C/D/E: Part 2|Eligible subjects will be randomized in sequence C/D/E in Part 2 and will receive C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 1, D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 2 and E: conventional 25 mg DTG tablet administered as direct to mouth in Period 3.
2922043|NCT03095638|Experimental|Treatment sequence D/E/C: Part 2|Eligible subjects will be randomized in sequence D/E/C in Part 2 and will receive D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 1, E: conventional 25 mg DTG tablet administered as direct to mouth in Period 2 and C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 3.
2922044|NCT03095638|Experimental|Treatment sequence E/C/D: Part 2|Eligible subjects will be randomized in sequence E/C/D in Part 2 and will receive E: conventional 25 mg DTG tablet administered as direct to mouth in Period 1, C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 2 and D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 3.
2922045|NCT03095638|Experimental|Treatment sequence C/E/D: Part 2|Eligible subjects will be randomized in sequence C/E/D in Part 2 and will receive C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 1, E: conventional 25 mg DTG tablet administered as direct to mouth in Period 2 and D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 3.
2922046|NCT03095638|Experimental|Treatment sequence D/C/E: Part 2|Eligible subjects will be randomized in sequence D/C/E in Part 2 and will receive D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 1, C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 2 and E: conventional 25 mg DTG tablet administered as direct to mouth in Period 3.
2922047|NCT03095638|Experimental|Treatment sequence E/D/C: Part 2|Eligible subjects will be randomized in sequence E/D/C in Part 2 and will receive E: conventional 25 mg DTG tablet administered as direct to mouth in Period 1, D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 2 and C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 3.
2922048|NCT03095612|Experimental|Selinexor in Combination with Docetaxel|Selinexor will be administered once weekly starting one week before chemotherapy initiation in combination with docetaxel. Docetaxel will be given once every 3 weeks. Treatment will be administered in 21-day cycles. Selinexor dose escalation: 60, 80, 100, 40 mg once weekly. Docetaxel 75 mg/m2 IV, 60 every 3 weeks.
2922049|NCT03095599|Experimental|Vaccine|"IVACFLU-S~IVACFLU-S is seasonal inactivated, split virion, trivalent influenza vaccine (A/H3N2, A/H1N1, and B), produced in GCP facility by IVAC uses embryonated chicken eggs. This vaccine is purified by sucrose gradient ultracentrifugation (Alfa Wassermann, West Caldwell, NJ), and inactivated with formaldehyde. It contains~NYMC X-179A (A/California/7/2009) (H1N1) - 15μg HA~NYMC X-263B (A/HongKong/4801/2014) (H3N2) - 15μg HA~NYMC BX-35 (B/Brisbane/60/2008) (B) - 15μg HA per 0.5 mL dose of vaccine."
2922050|NCT03095599|Placebo Comparator|Placebo|PBS with pH 7.2; 0.5 ml/per dose
2922051|NCT03095586|Active Comparator|News with Spin|News items reporting results of RCTs with spin
2922052|NCT03095586|Experimental|News without spin|News items reporting results of RCTs without spin
2922053|NCT03095573|Experimental|Lateral-viewing capsule|Examination of the small bowel by means of the lateral-viewing CapsoCam device
2922054|NCT03095573|Active Comparator|Axial-viewing capsule|Examination of the small bowel by means of the axial-viewing capsule
2922055|NCT03095560|Experimental|Semi-immersive virtual training with shadow (S-IVTS)|All the participants underwent a neurocognitive-rehabilitative training consisting of 24 sessions of BTsN. Each treatment session lasted 45 minutes, and was repeated three times a week for 8 weeks. in the BTsN device used in the S-IVTS group the projector is located behind the patient, thus the shadow of the patient is projected on the screen.
2922056|NCT03095560|Experimental|Semi-immersive virtual training without shadow (S-IVT)|All the participants underwent a neurocognitive-rehabilitative training consisting of 24 sessions of BTsN. Each treatment session lasted 45 minutes, and was repeated three times a week for 8 weeks. in the BTsN device used in the S-IVT group the projector is located in front of the patient and the shadow is not visible.
2922057|NCT03095547|Experimental|F901318 & cyclosporine A & tacrolimus|Interaction between cyclosporine A and tacrolimus with F901318
2922058|NCT03095547|Experimental|F901318 & posaconazole|Interaction between posaconazole and F901318
2922059|NCT03095547|Experimental|F901318 & pantoprazole|Interaction between pantoprazole and F901318
2922060|NCT03095547|Experimental|F901318|F901318 alone
2922756|NCT03090906|Experimental|Test group: SCTG from tuberosity|Soft tissue augmentation tuberosity
2922061|NCT03095534|Experimental|3-Step Workout for Life|Participants will exercise at the moderate intensity three times a week for 10 weeks. The total of 30 workout sessions will consist of 18 sessions of group single-joint resistance exercise, 6 sessions of one-on-one multiple-joint resistance exercise, and 6 sessions of one-on-one activities of daily living exercise. During the resistance exercise sessions, participants will use resistance tubing to strengthen major muscle groups of the upper extremity and lower extremity. During the activities of daily living exercise, participants will practice daily tasks around the home. The community fitness staff will modify the task demand to increase the physical challenge of the task to each participant, for example, increasing travel distance.
2922062|NCT03095521|Experimental|Arm A|Patients will receive Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if this will happen earlier than 4th day of treatment.
2922063|NCT03095521|Active Comparator|Arm B|Patients will receive ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if this will happen earlier than 5th day of treatment.
2922064|NCT03095508|Experimental|Arm A|Patients will receive Angal S, topical spray [Menthol], 0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
2922065|NCT03095508|Active Comparator|Arm B|"Patients will receive ANTI-ANGIN® FORMULA, topical metered spray, 0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution"
2922066|NCT03095495|Experimental|Early use of HHHFNC|Heated Humidified High Flow Nasal Cannula
2922067|NCT03095495|Active Comparator|Standard Therapy and Rescue HHHFNC|Low Flow Nasal Cannula only if the patient needs oxygenation and Rescue HHHFNC if the patient needs PICU
2922068|NCT03095482|Active Comparator|tDCS (mPFC+) + In Vivo Exposure|Participants assigned to this condition will receive excitatory transcranial direct current stimulation (tDCS) of the left medial prefrontal cortex (lmPFC) and inhibitory tDCS of right dorsolateral prefrontal cortex (rdlPFC). tDCS will be administered for 20 minutes at 2 mA, followed by 30 minutes of in vivo exposure therapy.
2922069|NCT03095482|Active Comparator|tDCS (mPFC-) + In Vivo Exposure|Participants assigned to this condition will receive inhibitory transcranial direct current stimulation (tDCS) of the left medial prefrontal cortex (lmPFC) and excitatory tDCS of right dorsolateral prefrontal cortex (rdlPFC). tDCS will be administered for 20 minutes at 2 mA. tDCS will be administered for 20 minutes at 2 mA, followed by 30 minutes of in vivo exposure therapy.
2922070|NCT03095482|Sham Comparator|sham tDCS + In Vivo Exposure|Participants assigned to this condition will receive sham transcranial direct current stimulation (tDCS), which will consist of 30 seconds of stimulation at the beginning and end of tDCS administration. Electrode positioning will be counterbalanced across participants (i.e., either mPFC+ or mPFC-, with same electrode positioning as the active comparators). Sham tDCS will be administered for 20 minutes, followed by 30 minutes of in vivo exposure therapy.
2922071|NCT03095469|Experimental|study group|when the operation begin,dexmedetomidine will be pumped at 0.4μg/kg•h for 15 minutes ,then reduce the dose to 0.2μg/kg•h until 24 h after PCI.
2922072|NCT03095469|Placebo Comparator|control group|0.9%NaCl solution 0.1ml/kg•h when the operation begin and stopped until 24 h after PCI.
2922073|NCT03095456|Experimental|Revefenacin|Active Revefenacin and Tiotropium placebo
2922074|NCT03095456|Active Comparator|Tiotropium|Active Tiotropium and Revefenacin placebo
2922075|NCT03095443|Experimental|Personalized Music|Receives personalized playlist twice a day.
2922076|NCT03095443|Active Comparator|Non Personalized Music|Receives standardized low beats per minute playlist twice a day.
2922077|NCT03095443|Active Comparator|Attention Control|Receives audio-book twice a day.
2922078|NCT03095430||ESPI Group|General Anesthesia using Entropy and Surgical Pleth Index Monitoring
2922079|NCT03095430||Control Group|General Anesthesia without Entropy and Surgical Pleth Index (Control Group)
2922080|NCT03095417|Experimental|Physical Exercise and Cognitive Training|"Physical Exercise Intervention: The physical exercise portion of the combined intervention consists of 45 minutes of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. The study team will deliver 3 sessions per week for 3 months.~Cognitive Intervention: The cognitive portion of the combined intervention consists of a suite of 24 programs called Brain HQ developed by Posit Science Inc., organized into six categories: attention, speed, memory, people skills, intelligence, and navigation. The DDD-ECT trial will use 45-minute sessions of Brain HQ exercises. The modules are designed to improve time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory."
2922081|NCT03095417|Active Comparator|Physical Exercise and Cognitive Control|"Physical Exercise Intervention: The physical exercise portion of the combined intervention consists of 45 minutes of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. The study team will deliver 3 sessions per week for 3 months.~Cognitive Control: This consists of up to 20 minutes of puzzles and games, 2 days per week for 3 months. The participants will use on-line Brain HQ Control Games hosted by Posit Science, Inc. as an attention control."
2922082|NCT03095417|Active Comparator|Cognitive Training and Stretching Control|"Stretching Control: This consists of up to 10 minutes of gentle stretching. The study team will deliver 3 sessions per week for 3 months.~Cognitive Intervention: The cognitive portion of the combined intervention consists of a suite of 24 programs called Brain HQ developed by Posit Science Inc., organized into six categories: attention, speed, memory, people skills, intelligence, and navigation. The DDD-ECT trial will use 45-minute sessions of Brain HQ exercises. The modules are designed to improve time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory. ly directing one session per week and available as needed for rest of the sessions."
2922083|NCT03095417|Sham Comparator|Cognitive Control and Stretching Control|"Stretching Control: This consists of up to 10 minutes of stretching. The study team will deliver 3 sessions per week for 3 months.~Cognitive Control: This consists of up to 20 minutes of puzzles and games, 2 days per week for 3 months. The participants will use on-line Brain HQ Control Games hosted by Posit Science, Inc. as an attention control."
2922084|NCT03095404|Experimental|Low Dose Lidocaine|60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula
2922085|NCT03095404|Experimental|High Dose Lidocaine|60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
2922086|NCT03095391|Experimental|Cohort 1|GFR: ≥ 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: none Comparator dose: none
2922087|NCT03095391|Experimental|Cohort 2|GFR: ≥ 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 2 Comparator: Iohexol 5 mL Comparator dose: 1
2922088|NCT03095391|Experimental|Cohort 3|GFR: ≥ 30 and < 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: Iohexol 5 mL Comparator dose: 1
2922089|NCT03095391|Experimental|Cohort 4|GFR: ≥ 15 and < 30 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: Iohexol 5 mL Comparator dose: 1
2922090|NCT03095378|Active Comparator|Control|Root treatment with scaling and root planing.
2922091|NCT03095378|Experimental|Citric acid plus tetracycline|Root treatment with 50% citric acid plus 10% tetracycline, pH1, passive application for 90s.
2922092|NCT03095378|Experimental|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy with toluidine blue O (100ug/ml - 60s pre-irradiation - pH4) and red laser (660nm, 30 milliwatts, 45 joules per square centimeter, sweeping mode, 90s)
2922093|NCT03095365|Active Comparator|Dry needling|Received Dry needling in the neck muscles.
2922094|NCT03095365|Active Comparator|Conventional treatment|the participants received the conventional treatment for non-specific neck pain.
2922095|NCT03095365|Experimental|Dry needling and pain neuroscience education|Received the same treatment as dry needling group and pain education.
2922096|NCT03095352|Experimental|Arm A|Arm A: Patients receive carboplatin intravenously (IV) and pembrolizumab IV over 30 minutes on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Treatment repeats every 3 weeks for a least 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 cycles of carboplatin and pembrolizumab, patients then receive pembrolizumab alone on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity
2922097|NCT03095352|Experimental|Arm B|Arm B: Patients receive carboplatin IV on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression then receive pembrolizumab IV over 30 minutes on day 1 in the cross over (Arm Bx). Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
2922098|NCT03095339|Active Comparator|Educational package|The educational package included the offering of the Self-Esteem , Associative strengths, Resourcefulness, Action-planning and Responsibility (SARAR) Participatory Hygiene and Sanitation Transformation (PHAST) approach, a 52 minutes educational movie and accompanying cartoon booklet. The package was developed using the PRECEDE approach.
2922099|NCT03095339|No Intervention|Control|The control group did not receive any intervention
2922100|NCT03095326|Experimental|Zinc Syrup 1.5 mg/kgbw/day|Patient were given zinc formula in the form of syrup with dosage of 1.5 mg/kg body weight/day with a maximum dose of 50 mg/day. The amount of syrup given is estimated to be enough for 4 weeks.
2922101|NCT03095326|Placebo Comparator|Sucrose syrup|Patient were given sucrose syrup as placebo. The syrup was made in the same flavor and consistency as the zinc syrup.
2922102|NCT03095313|Experimental|18F-NaF PET and CT scanning|18F-NaF PET-CT scan (at Baseline visit only) Contrast-enhanced CT Scan (at Baseline and Year 2 only) with possible beta-blocker and nitroglycerin, if medically safe.
2922103|NCT03095287|Experimental|Alphanate|Daily intravenous infusion of Alphanate 100 IU/kg/day
2922104|NCT03095274|Experimental|Durvalumab|"Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) for 12 months in patients ≥ 30kg.~Weight-based dosing should be used for patients <30 kg: durvalumab 20 mg/kg."
2922105|NCT03095274|Experimental|Tremelimumab|"Tremelimumab 75 mg Q4W (equivalent to 1 mg/kg Q4W) for up to 4 doses/cycles in patients ≥ 30kg.~Weight-based dosing should be used for patients <30 kg: tremelimumab 1 mg/kg Q4."
2922106|NCT03095261|Experimental|Self-monitoring (financial incentives then virtual rewards)|Participants will be asked to track their exercise daily, using an online tool called ExTracker.ca, for 52 weeks. Date, type of exercise, time spent exercising, and distance covered will be self-reported, as will steps per day and 10-minute bouts of MVPA per day (measured by an accelerometer). In the first six months, participants will earn financial incentive (ex. grocery vouchers) each day exercise is tracked. In the second six months, participants will earn virtual rewards (i.e. heart badges) each day exercise is tracked.
2922107|NCT03095261|Active Comparator|Self-monitoring (virtual rewards then financial incentives)|Participants will be asked to track their exercise daily, using an online tool called ExTrack.ca, for 52 weeks. Date, type of exercise, time spent exercising, and distance covered will be self-reported, as will steps per day and 10-minute bouts of MVPA per day (measured by an accelerometer). In the first six months, participants will earn virtual rewards (i.e. heart badges) each day exercise is tracked. In the second six months, participants will earn financial incentive (ex. grocery vouchers) each day exercise is tracked.
2922108|NCT03095248|Experimental|Stratum 1 - NF2 related vestibular schwannomas|Stratum 1 will include patients with NF2 with vestibular schwannomas who exhibit hearing loss. Participants will receive continuous twice daily dosing of selumetinib. Dosing for children (less than 18 is 25 mg/m2/dose) and dosing for adults is fixed 75 mg/dose.
2922109|NCT03095248|Experimental|Stratum 2: other NF2 related tumors (meningiomas and ependymom|Stratum 2 will include patients who have progressive lesions other than VS (including non-vestibular schwannomas, meningiomas, and spinal cord lesions). Participants will receive continuous twice daily dosing of selumentinib. Dosing for children (less than 18 is 25 mg/m2/dose) and dosing for adults is fixed 75 mg/dose.
2922110|NCT03095235|Experimental|Treatment with riboflavin|Patients will take 400 mg dietary riboflavin per day and go outside without sunglasses for 15 minutes per day to evaluate the effects of riboflavin B2 and natural UV light from sun exposure on cornea cross linking and stabilization of ectatic disease.
2922111|NCT03095222|Active Comparator|Group 1: Daily|Daily ketamine infusions of 5 hours in length. Duration of participation will last 4 days.
2922112|NCT03095222|Active Comparator|Group 2: Continuous|Continuous ketamine infusions (24 hours/day). Duration of participation will last 4 days.
2922113|NCT03095209||Standard of care concurrent chemo-radiation therapy|
2922114|NCT03095196||T2DM, treated by multipolar CRT-d|Type 2 diabetes (T2DM) affected by heart failure (HF), treated by multipolar CRT-d, plus maximal drug therapy.
2922115|NCT03095196||T2DM, treated by bipolar CRT-d|Type 2 diabetes (T2DM) affected by heart failure (HF), treated by bipolar CRT-d, plus maximal drug therapy.
2922116|NCT03095183|Placebo Comparator|Traditional Tongue Depressor|The posterior oropharynx exam was performed with a traditional, unflavored Puritan Regular tongue depressor.
2922117|NCT03095183|Active Comparator|Flavored Tongue Depressor|The posterior oropharynx exam was performed with a grape flavored, commercially available, Puritan Junior tongue depressor.
2922118|NCT03095170|Experimental|Computerized brain fitness training|"Will receive a 10 day intervention program (over 2 weeks) consisting of Computer Brain Fitness Training, Calendar Training and Support Group.~After the initial two week intervention, there will be an extended period during which participants will continue the computerized brain fitness for another 24 weeks.Participants are encouraged to do at least two hours per week."
2922119|NCT03095170|Experimental|Yoga|"Will receive a 10 day intervention program (over 2 weeks) consisting of Yoga, Calendar Training, and Support Group.~After the initial two week intervention, there will be an extended period during which participants will continue yoga for 24 weeks. Participants assigned to the yoga intervention will continue to meet with their group and their yoga instructor for one hour per week and will be expected to do at least an additional hour of yoga by themselves every week."
2922120|NCT03095170|Active Comparator|Wellness Education|Will receive a 10 day intervention program (over 2 weeks) consisting of Wellness Education, Calendar Training and Support Group.
2922121|NCT03095157|Placebo Comparator|Placebo|
2922122|NCT03095157|Experimental|Treatment|
2922123|NCT03095144||Spinal anesthesia|Lumbar puncture was performed with a midline approach through either the fourth or fifth lumbar space using a 22 or 25 -gauge 4 cm disposable styletted needle. Spinal isobaric Bupivacaine 0.5%, 0.8-1 mg.kg-1 without epinephrine was injected using a 1ml tuberculin syringe.
2922124|NCT03095144||General anesthesia|The General anesthesia is preformed by intravenous Propofol (2-4 mg.kg-1) and Fentanyl (1-2 µg.kg-1) and Rocuronium bromide (0.5mg.kg-1) administration to facilitate endotracheal intubation, assisted by Sellick manoeuvre. Anaesthesia maintenance with Sevoflurane (2-3%) in an air/oxygen mixture, intravenous Fentanyl as required.
2922125|NCT03095131|Experimental|12-lead ECG|
2922126|NCT03095118|Experimental|Daratumumab|Daratumumab will be given intravenously at a dose of 16 mg/kg once weekly for 8 weeks followed by once every 2 weeks for 8 additional doses
2922127|NCT03095105|Experimental|Young group|"The study was performed in two consecutive phases: single-dose and multiple-dose.~Subjects were institutionalised on Day 0, the day prior to the single-dose administration (Day 1). Single dose (dose 1) of BIA 6-512 200 mg was administered on Day 1 and subjects remained confined in the Unit until the 24 h post-dose procedures (Day 2). Then, subjects started being administered BIA 6-512 200 mg thrice-daily until the morning of Day 4 (Dose 8). Blood samples were taken at pre-determined time-points for the assay of BIA 6-512"
2922128|NCT03095105|Experimental|Elderly group|"The study was performed in two consecutive phases: single-dose and multiple-dose.~Subjects were institutionalised on Day 0, the day prior to the single-dose administration (Day 1). Single dose (dose 1) of BIA 6-512 200 mg was administered on Day 1 and subjects remained confined in the Unit until the 24 h post-dose procedures (Day 2). Then, subjects started being administered BIA 6-512 200 mg thrice-daily until the morning of Day 4 (Dose 8). Blood samples were taken at pre-determined time-points for the assay of BIA 6-512"
2922129|NCT03095092|Experimental|BIA 6-512 fed|BIA 6-512 400 mg following a standard meal
2922130|NCT03095092|Experimental|BIA 6-512 fasting|BIA 6-512 400 mg following at least 8 h of fasting
2922131|NCT03095079|Experimental|EDP|Dacarbazine,DTIC： 250 mg/m2/d，IV, d1-5 Cisplatin PDD：75 mg/m2，IV Endostar ENDO：15 mg/m2/d，CIV,d1~14
2922132|NCT03095066|Experimental|AVP-786|Dose 1 capsules administered twice a day over a 12-week period
2922133|NCT03095066|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
2922134|NCT03095053|Active Comparator|CCS|comprehensive chromosome screening
2922135|NCT03095053|No Intervention|Morphology|morphological assessment of blastocyst by light microscope
2922136|NCT03095040|Experimental|CM082 combined with everolimus|
2922137|NCT03095040|Experimental|CM082|
2922138|NCT03095040|Active Comparator|Everolimus|
2922139|NCT03095014|Experimental|Cesarean Myomectomy|Myomectomy plus Cesarean section
2922140|NCT03095014|Active Comparator|Cesarean section|Cesarean section only
2922141|NCT03095001|Experimental|Intraperitoneal bevacizumab+ carboplatin|"Intraperitoneal administration: intraperitoneal bevacizumab plus carboplatin every 3 weeks for 4-6 cycles~Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles"
2922142|NCT03095001|Active Comparator|Intraperitoneal carboplatin|"Intraperitoneal administration: intraperitoneal carboplatin every 3 weeks~Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles"
2922143|NCT03094988|Other|Control|The active attention control group will receive a binder with information about personal health including sleep hygiene, nutritional changes, and stress reduction. In addition, they will participate in a control version of the cognitive training program. They will receive weekly phone calls by cognitive and physical therapy teams to address issues with any aspects of the program.
2922144|NCT03094988|Experimental|Cognitive and physical prehabilitation|The intervention group will receive the prehabilitation program consisting of a guided progressive program of home-based aerobic and resistance training exercise, which will be adapted based on kinesiologist recommendation for each individual and the individual's perceived exertion. In addition, they will have access to the full cognitive training program. They will receive weekly phone calls by cognitive and physical therapy teams to address issues with any aspects of the program.
2922145|NCT03094962|Other|Motion capture, MR scan, CT scan|All volunteers will go through the same data collection process
2922146|NCT03094949|Active Comparator|Partial Nephrectomy|a kind of operation for renal tumor
2922147|NCT03094949|Experimental|microwave ablation|a kind of minimally invasive therapy by using microwave device for renal tumors
2922148|NCT03094936|Other|Group A|This group own twenty patients who met all the inclusion criteria. These will be treated with APC.
2922245|NCT03094260|Experimental|High intensity light therapy|Treatment with light therapy in high intensity (10,000 lux)
2922149|NCT03094936|Active Comparator|Group B|This group own twenty patients who met all the inclusion criteria. These will be treated with APC plus Endoscopic Suture Technique (OverStitch TM).
2922150|NCT03094923|Experimental|Inspiratory muscle training|Inspiratory muscle training with threshold device and workloud 30% of the peak inpiratory preassure, during two weeks prior to surgery, seven days a week, twice a day, three sets of ten repetitions with supervision.
2922151|NCT03094923|No Intervention|Control group|Control group will receive a supportive educational component in the preoperative period.
2922152|NCT03094910|Other|123I-MIBG|Only the group of participants with primary Raynaud's phenomenon (Raynaud's disease) is also scheduled for this intervention, the 123I-MIBG.
2922153|NCT03094910|Other|All participants|Examination of vibration perception threshold in fingertips, thermography, Ewing's test, tilt table test, blood samples.
2922154|NCT03094897|Experimental|18F-Al-NOTA-MATBBN PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT
2922155|NCT03094884|Experimental|Pulsed Low dose radiation with Carboplatin/Paclitaxel|Pulsed Low Dose Radiation concurrent with Carboplatin and Paclitaxel
2922156|NCT03094871|Experimental|Intervention group|FACE-PC comprises 3 weekly and 2 bi-weekly sessions (total 5 sessions), delivered by a bachelors' prepared nurse care manager (CM) over 8 weeks. Over the five sessions, the nurse care manager will (1) review the patient medical history and set health goals for depression and chronic condition with the dyad, (2) review all medication, the level of adherence, challenges and facilitating factors of adherence, (3) deliver brief behavioral activation therapy.
2922157|NCT03094871|No Intervention|Enhanced usual care group|Participants in this group will receive a typical primary care enhanced with reporting of their depression status and their goal for medical condition to their PCP for 8 weeks. Upon enrolment, a research nurse will review the patient medical history and identify goals for depression and a chronic condition with the dyad.
2922158|NCT03094858|Active Comparator|Comparison group|Equipment only comparison group will use Smartphone and Wristband to monitor sedentary behavior
2922159|NCT03094858|Experimental|Intervention group|Intervention group will receive prompts from Smartphone to reduce sedentary behavior using information from Wristband
2922160|NCT03094845|Placebo Comparator|Placebo|
2922161|NCT03094845|Experimental|hdmASIT+TM|
2922162|NCT03094832|Experimental|ARQ 092|Subjects will receive ARQ 092 orally at the dose level and administration schedule specified for their respective dose cohort on a 28 day cycle. Subjects will receive treatment with ARQ 092 until unacceptable toxicity or another discontinuation criterion is met. It is expected that most subjects will receive between 3 and 9 cycles of ARQ 092 for a treatment period of 12 to 36 weeks.
2922163|NCT03094819|No Intervention|Group 1|Participants randomized to Group 1 will be the control group. They will be observed while they receive usual eye care without any study intervention.
2922164|NCT03094819|Experimental|Financial Incentive|Participants randomized to the Financial Incentive group will be offered a financial incentive in conjunction with their usual eye care. They will receive usual care and a $25 payment if they obtain a confirmed eye examination.
2922165|NCT03094819|Experimental|Retinal Care DR|Participants randomized to the Retinal Care DR Service group will receive: (1) point of care risk assessment for vision-threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision-threatening diabetic retinopathy.
2922166|NCT03094806|Experimental|Acapella Vibratory PEP Therapy Device|Subject will use the device 3 times a day throughout hospital stay
2922167|NCT03094806|Placebo Comparator|Sham Acapella Vibratory PEP Device|Subject will use the sham device 3 times a day throughout hospital stay
2922168|NCT03094793|Experimental|abnormal EEGs|
2922169|NCT03094780|Other|Quality of Life Counseling|
2922170|NCT03094767|Experimental|Control Group|Patients will be submitted only to the initial protocol of rehabilitation, i. e., they will have only one session on the initial day and one session on the final day, after 12 weeks.
2922171|NCT03094767|Experimental|Interventional Group|Patients will participate in the cardiovascular rehabilitation program during 12 weeks.
2922172|NCT03094741|Experimental|CancerLife Feasibility Group|Participants will be recruited through advertisements targeted to a specific audience using the keywords cancer and cancer survivors
2922173|NCT03094728||Liver transplantation receipients|All patients underwent Living donor liver transplantation at Ain Shams center for organ transplantation (ASCOT) during the designed study period
2922174|NCT03094715|Active Comparator|Thrombectomy|Endovascular thrombectomy and best medical care
2922175|NCT03094715|Other|Best medical care|Best medical treatment
2922176|NCT03094689|No Intervention|Control group|
2922177|NCT03094689|Experimental|Immersion group|They will be immersed in a barrel of 200 liters of water (without ice) at room temperature, according to local conditions of temperature and humidity (Natal county - RN). They will be immersed to the height of the iliac crests for 10 minutes.
2922178|NCT03094689|Experimental|Cold water immersion group|They will be immersed in a barrel of 200 liters of ice water at an average temperature of 10 ° C for 10 minutes. They will be immersed to the height of the iliac crests.
2922179|NCT03094676|No Intervention|Control|Only the HRV will be followed for two hours without intervention.
2922180|NCT03094676|Experimental|Only Massage|Only the massage, and will have the monitoring of the HRV on the techniques and accompanied for two hours.
2922181|NCT03094676|Experimental|Only Exercise|Only the exercise, and will have the monitoring of the HRV on the techniques and accompanied for two hours.
2922182|NCT03094676|Experimental|Exercise and Massage immediately|Performing the exercise and massage immediately after, will be accompanied by the HRV during the techniques and two hours after.
2922183|NCT03094676|Experimental|Exercise and Massage after recovery|Performing the exercise and massage will be applicated after recovery of HRV, will be accompanied by the HRV during the techniques and two hours afte
2922184|NCT03094663|Active Comparator|Peri-Articular Injections only|"Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)~Injection prior to cementation~bupivacaine 0.5% with epinephrine 30cc;~methylprednisolone, 40 mg/ml, 1 ml~cefazolin, 500 mg in 10 ml~normal saline, 22cc~Superficial injection prior to closure.~20cc 0.25% bupivacaine~2 mg IV dexamethasone."
2922246|NCT03094260|Placebo Comparator|Low intensity light therapy|Treatment with light therapy in low intensity (<500 lux)
2922185|NCT03094663|Experimental|Peri-Articular Injections, Adductor Canal Block, and IPACK|"Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)~Injection prior to cementation~bupivacaine 0.25% with epinephrine 30cc;~methylprednisolone, 40 mg/ml, 1 ml~cefazolin, 500 mg in 10 ml~normal saline, 22cc~Superficial injection prior to closure.~a. 20cc 0.25% bupivacaine~Adductor canal block technique (supine position, post IV sedation)~a. Mid-thigh injection of 15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone~IPACK technique (supine position) a. 25 cc 0.25% bupivacaine"
2922186|NCT03094650|Experimental|MindMotion PRO|The training sessions consist of virtual reality based rehabilitation exercises using the MindMotion PRO device.
2922187|NCT03094637|Experimental|MDS - Previously Untreated|"Participants receive Azacitidine on Days 1-7 of each cycle.~Participants receive Pembrolizumab on Day 1 of Cycle 1, and then every 3 weeks after that.~Each study cycle is 4 weeks (28 days)."
2922188|NCT03094637|Experimental|MDS - Hypomethylating Agent (HMA) Failure|"Participants receive Azacitidine on Days 1-7 of each cycle.~Participants receive Pembrolizumab on Day 1 of Cycle 1, and then every 3 weeks after that.~Each study cycle is 4 weeks (28 days)."
2922189|NCT03094624|Experimental|Amusia|Since 2006, recruitment of amusia participants has been organized in the Lyon region, and some 20 participants (and their matched controls in terms of age, sex, laterality, musical practice, number of years of study) have already taken part various studies conducted at the CRNL. The recruitment of amusia participants and controls is continued in order to maintain a sufficient number of participants and compensate for the withdrawals within the cohort already constituted (lack of availability, geographical distance, etc.).
2922190|NCT03094624|Sham Comparator|Matched controls|Matched controls of age, sex, laterality, musical practice, number of years of studies.
2922191|NCT03094611|Experimental|Inotuzumab Ozogamicin|Participants receive Inotuzumab Ozogamicin at the dose of 0.8 mg/m2 on Day 1, and 0.5 mg/m2 on Days 8 and 15 of cycle 1. Subsequent cycles consist of Inotuzumab Ozogamicin at the dose of 0.6 mg/m2 on Day 1 and 0.3 mg/m2 on Day 8. A maximum of 6 cycles administered. Cycles are 28 days.
2922192|NCT03094598|No Intervention|Control|No intervention
2922193|NCT03094598|Experimental|Leaflet|The leaflet is based on information and journalism theories, paying attention primarily to reader appeal and readability.
2922194|NCT03094598|Experimental|Brochure|The brochure is based on practical communication experience, focusing primarily on logical composition and presentation of condensed information.
2922195|NCT03094598|Experimental|Booklet|The booklet is also based on practical communication experience, but give more elaborate explanations.
2922196|NCT03094585|No Intervention|No information|The nurses in this group are offered no booklet or oral information
2922197|NCT03094585|Experimental|Written and oral information|The nurses in this group are offered written information which consisted of a booklet describing basic aspects of clinical research including aim, background, formalities, ethics, informed consent, randomisation, blinding, placebo, drug development, and financial aspects. Furthermore, they are offered oral information which consisted of group sessions focusing on active feedback
2922198|NCT03094585|Experimental|Written information|The nurses in this group are offered written information which consisted of a booklet describing basic aspects of clinical research including aim, background, formalities, ethics, informed consent, randomisation, blinding, placebo, drug development, and financial aspects.
2922199|NCT03094572|No Intervention|visual motor tasks with dominant arm (1)|experimental arm for the first sub-study healthy volunteer
2922200|NCT03094572|No Intervention|control tasks with dominant arm|control arm for the first sub-study healthy volunteer
2922201|NCT03094572|No Intervention|visual motor tasks with non-dominant arm|control arm for the second sub-study healthy volunteer
2922202|NCT03094572|No Intervention|visual motor tasks on dominant arm, flexion movement|experimental arm for the third sub-study healthy volunteer
2922203|NCT03094572|No Intervention|visual motor tasks on dominant arm, extension movement|experimental arm for the third sub-study healthy volunteer
2922204|NCT03094572|Experimental|visual motor tasks|fourth sub-study with hemiplegic patient
2922205|NCT03094572|No Intervention|visual motor tasks with dominant arm (2)|experimental arm for the second sub-study healthy volunteer
2922206|NCT03094559|Experimental|FlowMet device|This is a feasibility study
2922207|NCT03094546|Experimental|Polyamine supplementation|Intervention: Dietary Supplement (Polyamine supplementation):
2922208|NCT03094546|Placebo Comparator|Placebo|Intervention: Dietary Supplement Placebo:
2922209|NCT03094533|Active Comparator|Total intravenous anesthesia|In the total intravenous anesthesia(TIVA) group, target controlled infusion (TCI) I was performed with propofol 4 mcg / ml. When the consciousness of the patient is lost, Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
2922210|NCT03094533|Active Comparator|volatileinduction maintenance anesthesia|In the volatile induction and maintenance anesthesia(VIMA) group, when 8% sevoflurane is inhaled with 100% oxygen at 6 L / min and the consciousness is lost, the concentration of sevoflurane is reduced to 2-3% and then the mask is ventilated.Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
2922211|NCT03094520|Experimental|Anodal tDCS + semantic, motor, attentional tasks|Combination of gestural (subjects have to indicate if the gesture is related to the word), attentional and motor tasks with anodal stimulation
2922212|NCT03094520|Sham Comparator|Sham tDCS + semantic, motor, attentional tasks|Combination of gestural (subjects have to indicate if the gesture is related to the word), attentional and motor tasks with sham stimulation
2922213|NCT03094507|Experimental|Group One|Tivicay (Dolutegravir 50 mg) for 14 days OD (days 1-14) WASH OUT for 7 days (days 15-21) Tivicay (Dolutegravir 50 mg) OD plus Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 22-35) WASH OUT for 7 days (days 36-42) Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 43-56)
2922214|NCT03094507|Experimental|Group Two|Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 1-14) WASH OUT for 7 days (days 15-21) Tivicay (Dolutegravir 50 mg) OD plus Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 22-35) WASH OUT for 7 days (days 36-42) Tivicay (Dolutegravir 50 mg) for 14 days OD (days 43-56)
2922215|NCT03094494||Double Carbapenem Group|Patients underwent Double carbapenem treatment
2922216|NCT03094494||Standard Treatment Group|Patients who were not treated with the double carbapenem
2922217|NCT03094481|Active Comparator|US guided SCPB medial fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
2922218|NCT03094481|Active Comparator|US guided ISB medial fracture|Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
2922219|NCT03094481|Active Comparator|US guided SCPB + ISB medial fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
2922220|NCT03094481|Active Comparator|US guided SCPB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
2922221|NCT03094481|Active Comparator|US guided ISB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
2922222|NCT03094481|Active Comparator|US guided SCPB + ISB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
2922223|NCT03094468|Experimental|P-3058|
2922224|NCT03094468|Placebo Comparator|Vehicle|
2922225|NCT03094455|Experimental|Experimental group|AOT is based on the observation of meaningful actions followed by their execution
2922226|NCT03094455|Other|Control group|Children will continue standard care for 3 weeks and then will receive the AOT as the Experimental group
2922227|NCT03094442|Active Comparator|Dexamethasone|"Dexamethasone is a potent corticosteroid that has been widely used for chemotherapy induced nausea and vomiting. The mechanism of action is not completely understood. It has been proposed that a single dose may hinder the production and release of anti-inflammatory mediators. Dexamethasone also has a central antiemetic effect by inhibition of prostaglandin and/or release of endogenous opioids. A recent metanalysis concluded that Dexamethasone administration at induction is safe.~We will be using a 8mg dose of Dexamethasone, that is equivalent to 2ml of injectable drug."
2922228|NCT03094442|Placebo Comparator|Saline|Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
2922229|NCT03094429|Active Comparator|NaBen® - 2000 mg/day|Two NaBen® ( 500 mg) will be taken twice daily at a total dose of 2000 mg/day during this study.
2922230|NCT03094429|Active Comparator|NaBen® - 1000 mg/day|One NaBen® (500 mg) and one placebo will be taken twice daily at a total dose of 1000 mg/day during this study.
2922231|NCT03094429|Placebo Comparator|Placebo - 0 mg/day|The control treatment is placebo.
2922232|NCT03094416|Experimental|levothyroxine sodium capsules|levothyroxine sodium capsules 88 to 250 mcg/day (depending on individual needs) for 3 months
2922233|NCT03094403|Experimental|Azelaic Acid 15% topical gel|Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face
2922234|NCT03094403|Active Comparator|Finacea® (azelaic acid) Gel, 15%|Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face
2922235|NCT03094403|Placebo Comparator|Placebo|Topically to the face, twice a day A thin layer of study treatment was gently massaged into the affected areas on the face
2922236|NCT03094377|Experimental|Multisensory therapy group|The Multisensory therapy (MT) group received a 12-weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session began with 15 minutes of sensory stimulation (cold and vibration), 45 minutes of motor training and 30 minutes of self-care training.
2922237|NCT03094377|Active Comparator|Conventional training group|The conventional training (CT) group included 12 weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session included 60 minutes of upper extremity motor practice (same as in MT group) and 30 minutes of self-care training (same as in MT group).
2922238|NCT03094364|Active Comparator|Immediate Treatment|"Patients will receive an in-home consultation with an occupational/physical therapist in which they are educated about the intervention, the system is set up, and they are guided through use of the system. After initial contact, therapist support will be available via telephone to address specific difficulties with operating the system, as well as three additional home visits throughout the 3 week intervention.~The rehabilitation program requires use of the rehabilitation gaming system for 1.5 hours daily for 21 consecutive days (equivalent dosage to standard CI therapy), limb activation device worn for 90% of waking hours, and completion of the automated transfer package to facilitate real-world arm use (e.g., problem-solving modules, daily monitoring of arm use). After completing the intervention, the patient will receive additional consultation with the therapist to formulate goals for follow-up. Follow-up assessments will be conducted to assess long-term retention of motor gains."
2922239|NCT03094364|Active Comparator|Delayed Treatment|"Patients will receive an in-home consultation with an occupational/physical therapist in which they are educated about the intervention, the system is set up, and they are guided through use of the system. After initial contact, therapist support will be available via telephone to address specific difficulties with operating the system, as well as three additional home visits throughout the 3 week intervention.~The rehabilitation program requires use of the rehabilitation gaming system for 1.5 hours daily for 21 consecutive days (equivalent dosage to standard CI therapy), limb activation device worn for 90% of waking hours, and completion of the automated transfer package to facilitate real-world arm use (e.g., problem-solving modules, daily monitoring of arm use). After completing the intervention, the patient will receive additional consultation with the therapist to formulate goals for follow-up. Follow-up assessments will be conducted to assess long-term retention of motor gains."
2922240|NCT03094351|Experimental|Robot assisted esophagectomy|Robot-assisted thoraco-laparoscopic esophagectomy with gastric conduit formation.
2922241|NCT03094351|Active Comparator|Thoraco-laparoscopic esophagectomy|Conventional thoraco-laparoscopic esophagectomy with gastric conduit formation.
2922242|NCT03094325|Experimental|Septal myectomy|
2922243|NCT03094312|Experimental|Dynamic Spectral Imaging (ISD)|Evaluation of cognitive functions by ISD
2922244|NCT03094286|Experimental|Arm 1|Durvalumab (MEDI4736) monotherapy at the recommended dose of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients
2922247|NCT03094247|Active Comparator|Conventional RUTF (C-RUTF)|This is the control group for the study, which will receive the international standard of care therapeutic food. C-RUTF is made with conventional peanuts, which are inherently high in omega-6 linoleic acid.
2922248|NCT03094247|Experimental|High oleic RUTF (HO-RUTF)|The treatment provided to children randomized to this arm of the study includes nutritional content comparable to C-RUTF with the exception of a low lineoleic acid/high oleic acid ratio formulated with high oleic content peanuts.
2922249|NCT03094247|Experimental|DHA-supplemented HO-RUTF (D-HO-RUTF)|The treatment provided to children randomized to this arm of the study mirrors that provided by HO-RUTF with that addition of supplemental DHA at a level higher than attainable with optimal precursors.
2922250|NCT03094234|Active Comparator|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
2922251|NCT03094234|Active Comparator|EVL plus propranolol|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
2922252|NCT03094221||Arrhythmia Mapping|The study sample includes patients referred for three different types of cardiac arrhythmias, which will be the studied categories: 1) atrial flutter/fibrillation, 2) atrial tachycardia, 3) ventricular tachycardia. Patients will undergo standard of care mapping and ablation procedures.
2922253|NCT03094208|Experimental|study group|muscle strengthening, weight transfer, dual task balance exercises, dual task gait exercises.
2922254|NCT03094208|Active Comparator|control group|muscle strengthening, weight transfer, balance exercises, gait exercises.
2922255|NCT03094195|Experimental|EMA401 Dose A|
2922256|NCT03094195|Experimental|EMA401 Dose B|
2922257|NCT03094195|Experimental|EMA401 Dose C|
2922258|NCT03094195|Placebo Comparator|Placebo|
2922259|NCT03094182|Experimental|ulinastatin group|Patients in the ulinastatin group are given Intravenous iron isomaltoside during operation.
2922260|NCT03094182|Placebo Comparator|control group|Patients in the control group receive the same volume of normal saline during operation.
2922261|NCT03094169|Experimental|Dose escalation|Minimum of 1 to 3 patients per dose cohort; approximately 4 dose cohorts to be evaluated to establish the Maximum tolerated dose.
2922262|NCT03094156|Experimental|Placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the Placebo morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
2922263|NCT03094156|Experimental|BIA 6-512 25 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 25 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 25 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
2922264|NCT03094156|Experimental|BIA 6-512 50 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 50 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 50 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
2922265|NCT03094156|Experimental|BIA 6-512 75 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 75 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 75 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
2922266|NCT03094156|Experimental|BIA 6-512 100 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 100 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 100 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
2922267|NCT03094143|Experimental|Group A: Early intervention|Patients will be referred immediately for aortic valve intervention.
2922268|NCT03094143|No Intervention|Group B: Routine care|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the participant's clinical team (cardiologist and cardiac surgeon).
2922269|NCT03094143|No Intervention|Group C: Routine care|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the patient's clinical team (cardiologist and cardiac surgeon). Group C will appear identical to Group B
2922270|NCT03094143|No Intervention|Group D: No further study follow up|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the patient's clinical team (cardiologist and cardiac surgeon). No further study follow up will take place but personal data will be retained for future data linkage.
2922271|NCT03094130|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
2922272|NCT03094130|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
2922273|NCT03094117|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
2922274|NCT03094117|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
2922275|NCT03094104|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
2922276|NCT03094104|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
2922277|NCT03094091|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
2922278|NCT03094091|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
2922279|NCT03094078|Active Comparator|News with Spin|News items reporting results of pre-clinical studies with spin
2922280|NCT03094078|Experimental|News without spin|News items reporting results of pre-clinical studies without spin
2922281|NCT03094065|Active Comparator|News with Spin|News items reporting results of pre-clinical studies with spin.
2922282|NCT03094065|Experimental|News without spin|News items reporting results of pre-clinical studies without spin.
2922283|NCT03094052|Experimental|Neratinib, trastuzumab, crofelemer, loperamide|"Neratinib 240 mg orally once a day for up to 52 weeks while receiving concurrent trastuzumab. After the completion of trastuzumab maintenance therapy, neratinib will continue as monotherapy for 12 months. Neratinib is to be taken continuously in 21-day cycles with no rest between cycles unless related to toxicity.~Intensive daily loperamide prophylaxis for the first 2 cycles (42 days) and then as needed. Days 1-14: 4 mg 3 times daily. Days 15-42: 4 mg twice per day.~Crofelemer 125 mg bid for the first 2 cycles then as needed.~Trastuzumab as indicated by the treating physician. Patients must plan to receive at least 4 months of trastuzumab (and thus 4 months of concurrent neratinib) to be eligible for this study"
2922284|NCT03094039|Experimental|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
2922285|NCT03094039|Active Comparator|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
2922286|NCT03094026|Experimental|Intervention|The arm will begin the Lumosity program at enrollment in the study.
2922287|NCT03094026|Active Comparator|Wait List Control|The arm will begin the Lumosity program 3 months after enrollment in the study.
2922288|NCT03094000|Experimental|Experimental group (CBTE-MIND)|Adding a mindfulness skills intervention to group psychotherapy according to the principles of the Enhanced Cognitive-Behavioral Therapy (CBT-E) for eating disorders (Fairburn, 2008)
2922289|NCT03094000|Active Comparator|Control group (CBTE)|Group psychotherapy according to the principles of the Enhanced Cognitive-Behavioral Therapy (CBT-E) for eating disorders (Fairburn, 2008), without a mindfulness skills intervention
2922290|NCT03093987|No Intervention|control group|usual care
2922291|NCT03093987|Experimental|critical care ultrasound|Circulation management will be adjusted according to the results of critical ultrasound combined with clearance of lactic acid in patients with shock.
2922292|NCT03093974|Experimental|treatment|Inhaled colistimethate sodium twice daily
2922293|NCT03093974|Placebo Comparator|Saline solution|inhaled placebo twice daily
2922294|NCT03093961|Experimental|Intervention|IASD Implantation
2922295|NCT03093948|Experimental|Remote Ischemic post-conditioning|
2922296|NCT03093948|No Intervention|standard of care|
2922297|NCT03093935|Experimental|StimRouter Neuromodulation System|"All eligible patients who are enrolled in this study will be treated with StimRouter stimulation therapy as part of standard of care for the entire duration of the study (6 months) and observed for post-market population-specific data.~Standard recommended stimulation parameters for post-stroke shoulder pain include settings to elicit sensory response (paresthesia) as well as motor response (muscle contraction)."
2922298|NCT03093922|Experimental|Atezolizumab alone with Gemcitabine and Cisplatin|Atezolizumab alone for 2 cycles. One treatment cycle equals 21 days. Then patient will receive combined atezolizumab and Gemcitabine and Cisplatin for 6 cycles. All 8 treatment cycles will take approximately 24 weeks. If carboplatin is substituted for cisplatin, eGFR for dosing may be calculated by institutional standard formulas, at the discretion of the treating investigator.
2922299|NCT03093922|Experimental|Atezolizumab with Gemcitabine and Cisplatin|Gemcitabine and Cisplatin for 2 cycles. One treatment cycle equals 21 days. After 2 cycles of Gemcitabine and Cisplatin patient will receive combined atezolizumab and Gemcitabine and Cisplatin for 4 cycles. All 6 treatment cycles will take approximately 18 weeks. If carboplatin is substituted for cisplatin, eGFR for dosing may be calculated by institutional standard formulas, at the discretion of the treating investigator.
2922300|NCT03093909|Experimental|Aerosol Gemcitabine (GCB)|"Dose Escalation Cohort: Participants take Gemcitabine by mist 2 times each week for 4 weeks (28 days).~Expansion Cohort: Participants with OS lung metastases receive study drug at the maximum tolerated dose from Dose Escalation Cohort.~Participants may continue to receive the study drug for up to 12 cycles per decision of doctor."
2922301|NCT03093896|Placebo Comparator|snack mix|snack mix, 3 ounces: dried coconut, meat jerky, butter, cereal party mix
2922302|NCT03093896|Active Comparator|almonds, 1.5 ounces|almonds, 1.5 ounces/day
2922303|NCT03093896|Active Comparator|almonds, 3 ounces|almonds, 3 ounces/day
2922304|NCT03093883|Experimental|Test product|Iron sucrose injection solution 100mg (5 mL single dose vial 20mg/mL elemental iron as iron sucrose for injection).
2922305|NCT03093883|Active Comparator|Reference product|Iron sucrose injection solution 100mg (5 mL single dose ampoule 20mg/mL elemental iron as iron sucrose for injection).
2922306|NCT03093870|Experimental|Varlitinib and Capecitabine|
2922307|NCT03093870|Placebo Comparator|Placebo and Capecitabine|
2922308|NCT03093844|Experimental|Miltenyi CliniMACS® CD34 Reagent System|"The haploidentical donor will be mobilized by G-CSF and undergo one apheresis to collect CD34+ selected stem cell product after Miltenyi CliniMACS® CD34+ selection. The products will be cryopreserved until the time of transplantation.~Recipients will receive a standard conditioning regimen. After the conditioning regimen, the subjects will receive an allograft on day 0 containing donor CD34+ cells that have been positively selected and T-cell depleted following G-CSF mobilization combined with a single UCB unit. UCB unit will not be manipulated, and will be prepared and infused separately following standard of care procedure."
2922309|NCT03093831|Experimental|Ibrutinib|
2922310|NCT03093818|Experimental|Pharmacogenomic testing arm|"4,050 patients will provide a DNA sample. A pharmacogenomic test is performed. Results of this test are incorporated in the (electronic) medical record and combined with a clinical decision support system. Physicians and pharmacists may choose to use these results to guide drug and dose selection as per the Dutch Pharmacogenomics Working Group guidelines. Patients will receive a Safety-Code card containing their personal pharmacogenomics results, which can be used by other physicians or pharmacists during subsequent prescriptions."
2922351|NCT03093623|No Intervention|Non-Physical activity|the non-physical activity group,investigators do not give them any physical interventions
2922311|NCT03093818|No Intervention|Standard of care arm|"4,050 patients will provide a DNA sample. However, no pharmacogenomic test is performed until the study is completed. Physicians and pharmacists will prescribe and dispense drugs routinely, without using pharmacogenomic test results to guide drug and dose selection. Patients will receive a mock Safety-Code card, which does not contain personal pharmacogenomics results."
2922312|NCT03093805|Experimental|Calcipotriene|Patients will apply Calcipotriene cream 2 times per day for 7 days.
2922313|NCT03093792|Placebo Comparator|Control|(no diet or exercise intervention)
2922314|NCT03093792|Experimental|American Heart Association|(AHA: 55% carbohydrate, 15% protein, 30% fat - diet plus exercise)
2922315|NCT03093792|Active Comparator|Curves Complete - I|(CC - I: 30% carbohydrate, 45% protein, 25% fat - diet plus exercise)
2922316|NCT03093792|Active Comparator|Curves Complete - II|(CC - II: 20% carbohydrate, 45% protein, 35% fat - diet plus exercise)
2922317|NCT03093779||Deaf|Individuals who are deaf and use sign language to communicate.
2922318|NCT03093779||Hearing|Individuals with no hearing loss and who communicate in spoken English.
2922319|NCT03093753|Placebo Comparator|Control (study 1)|Control will be 50g glucose dissolved in 200 mL water
2922320|NCT03093753|Experimental|Test (study 1)|The test meals will comprise 50 g glucose plus 50 mg oleuropein from olives dissolved in 200 mL water
2922321|NCT03093753|Placebo Comparator|Control (study 2)|Control will be white bread (109 g) to give 50 g available carbohydrates with 200 mL water
2922322|NCT03093753|Experimental|Test (study 2)|The test meals will comprise 109 g white bread plus 50 mg oleuropein from olives
2922323|NCT03093753|Placebo Comparator|Control (study 3)|Control will be whole-meal bread (132 g) to give 50 g available carbohydrates with 200 mL water
2922324|NCT03093753|Experimental|Test (study 3)|The test meals will comprise whole-meal bread (132 g) with 50 mg oleuropein dissolved in 200 mL water
2922325|NCT03093753|Placebo Comparator|Control (study 4)|Control will be 50 g sucrose dissolved in 200 mL water
2922326|NCT03093753|Experimental|Test (study 4)|The test meals will comprise 50 mg oleuropein and 50 g sucrose dissolved in 200 ml water
2922327|NCT03093753|Placebo Comparator|Control (study 5)|Control will be 25 g sucrose dissolved in 200 mL water
2922328|NCT03093753|Experimental|Test (study 5)|The test meals will comprise 160 mg oleuropein and 25 g sucrose dissolved in 200 ml water
2922329|NCT03093753|Placebo Comparator|Control (study 6)|Normal diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
2922330|NCT03093753|Experimental|Test (study 6)|High carbohydrate diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
2922331|NCT03093753|Placebo Comparator|Control (study 7)|Normal diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
2922332|NCT03093753|Experimental|Test (study 7)|High fat diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
2922333|NCT03093740|Experimental|HCV treatment - no viral resistance|Based on the genotype and negative viral resistance testing of the donor, (determined within the first week) we will initiate a genotype specific regimen of Zepatier
2922334|NCT03093740|Experimental|HCV treatment - viral resistance|Based on the genotype and positive viral resistance testing of the donor, (determined within the first week) we will initiate a genotype specific regimen of Zepatier plus Sofosbuvir
2922335|NCT03093714|Experimental|FDL 169 test formulation (Dose Level 1)|Multiple dose (Dose Level 1) FDL 169 test formulation administered as repeat doses in CF subjects
2922336|NCT03093714|Experimental|FDL 169 test formulation (Dose Level 2)|Multiple dose (Dose Level 2) FDL 169 test formulation administered as repeat doses in CF subjects
2922337|NCT03093714|Experimental|FDL 169 test formulation ( Dose Level 3)|Multiple dose (Dose Level 3) FDL 169 test formulation administered as repeat doses in CF subjects
2922338|NCT03093714|Placebo Comparator|Placebo|Multiple dose placebo as repeat doses in CF subjects
2922339|NCT03093701|Experimental|Group 1|TLC399 (ProDex)
2922340|NCT03093701|Experimental|Group 2|TLC399 (ProDex)
2922341|NCT03093701|Experimental|Group 3|TLC399 (ProDex)
2922342|NCT03093688|Experimental|treatment|The eligible patient receive the experimental infusion of iNKT cells and CD8+T cells .
2922343|NCT03093675|Experimental|TELELAP ALF-X Robotic Surgical System|The patients will undergo surgical procedures using the innovative TELELAP ALF-X robotic system.
2922344|NCT03093662|Experimental|Ventilation with nasal cannula first|Non-invasive positive pressure ventilation with nasal cannula first followed by non-invasive positive pressure ventilation without nasal cannula.
2922345|NCT03093662|Active Comparator|Ventilation without nasal cannula first|Non-invasive positive pressure ventilation without nasal cannula first followed by non-invasive positive pressure ventilation with nasal cannula.
2922346|NCT03093649|Experimental|patient reported group|Patients reported adverse events using patient reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) through Application (APP) during the treatment. The summary report was transferred to their clinician immediately. Oncologists would be alarmed if patients reports exceeding the pre-defined threshold.
2922347|NCT03093649|Active Comparator|non-reported group|Patients in this group received normal care during the treatment without completing patient reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE)
2922348|NCT03093636|Experimental|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App, study insulin, and study CGM at home for 12 weeks.
2922349|NCT03093636|Placebo Comparator|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use study insulin and the study CGM alone at home for 12 weeks.
2922350|NCT03093623|Experimental|Physical activity|In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points * time of each exercise (hours) * Number of times per week + moderate level 5 points * time per activity (hours) * number of times per week + low level 3 points * time per activity (hours) * number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
2922352|NCT03093610|Active Comparator|Traditional|The chest tube in the traditional Group will be managed according to the current Guidelines of the investigators' department.
2922353|NCT03093610|Active Comparator|Test group|"The chest tube in the Test Group will constitute the experimental Group. The chest tube will be removed when the fluid production over 24h has reached a weight related threshold."
2922354|NCT03093597|Active Comparator|virgin coconut oil|All subjects will apply virgin coconut oil to a previously randomize section of the skin on the left or right forearm.
2922355|NCT03093597|Active Comparator|virgin jojoba oil|All subjects will apply virgin jojoba oil to a previously randomize section of the skin on the left or right forearm
2922356|NCT03093597|Active Comparator|virgin almond oil|All subjects will apply virgin almond oil to a previously randomize section of the skin on the left or right forearm
2922357|NCT03093597|Active Comparator|white petrolatum ointment|All subjects will apply white petrolatum ointment to a previously randomize section of the skin on the left or right forearm.
2922358|NCT03093584|Active Comparator|Auricular stimulation|Auricular acupuncture with indwelling fixed auricular acupuncture needles
2922359|NCT03093584|Experimental|Expressive writing|Expressive writing - sharing the emotional expectations in front of forthcoming exam
2922360|NCT03093584|No Intervention|No intervention|No intervention, just observation and monitoring of outcome measures
2922361|NCT03093571|Experimental|Auricular stimulation|Auricular stimulation using indwelling auricular acupuncture needles
2922362|NCT03093571|Experimental|Muscle relaxation|Progressive muscle relaxation according to Jacobsen
2922363|NCT03093571|No Intervention|No intervention|No intervention, just monitoring of outcome parameters
2922364|NCT03093558|Experimental|Intervention arm|Receive the ECA/Kardia for 30-day use.
2922365|NCT03093558|No Intervention|Usual care arm|Receive a journal for observation of adherence and symptoms.
2922366|NCT03093545|Other|Normal BMI or underweight (< 24 Kg/m2)|
2922367|NCT03093545|Experimental|Obese (BMI > 30 Kg/m2)|
2922368|NCT03093532|No Intervention|Usual Care|The Usual Care group arm will received pre-printed discharge instructions and an outpatient referral. (This group represents standard of care.)
2922369|NCT03093532|Active Comparator|ED SBIRT-HTN|"The ED SBIRT-HTN (The Emergency Department Screening Brief Intervention and Referral for Treatment) arm consists of a series of risk assessment tools (surveys, video, and noninvasive bedside assessments) designed to be efficient, patient-centered and educational for participants in an emergency department setting. Through the intervention, participants will learn more about hypertension management and complications associated with uncontrolled BP. Participants in the ED-SBIRT-HTN group will receive the following interventions:~1) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease)."
2922370|NCT03093532|Active Comparator|E SBIRT-HTN + PACTH-c|Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
2922371|NCT03093519|Experimental|KHK6640|Intravenous administration
2922372|NCT03093519|Placebo Comparator|Placebo|Intravenous administration
2922373|NCT03093506|Active Comparator|Low-dose rhEpo|RhEpo 60IU/kg/week
2922374|NCT03093506|Active Comparator|Micro-dose rhEpo|RhEpo 20IU/kg/week
2922375|NCT03093506|Placebo Comparator|Placebo Control|Saline
2922376|NCT03093493||EDS patients|Medical records from other institutions and clinical notes for visits in Dr. Holick's clinic will be reviewed to obtain the following information: previous diagnosis at other institutions, age, clinical signs and symptoms of EDS, Joints Hypermobility Syndrome (JHS), and other metabolic or genetic disorders and laboratory results, radiology reports and images, and genetic testing that supports EDS diagnoses. Genotyping will be done.
2922377|NCT03093493||EDS family members with or without EDS|Family members of EDS patients with or without EDS. Genotyping will be done.
2922378|NCT03093480|Experimental|Recombinant coagulation factor VIII Fc (rFVIIIFc)|Participants will receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 48 Weeks in ITI Period. Participants who meet the criteria for immune tolerance induction (ITI) success will enter the tapering period and will receive rFVIIIFc at a dose adjusted according to Investigator judgment based on the FVIII activity levels and with the aim of tapering the rFVIIIFc dose to reach a prophylactic dosing regimen within 16 weeks (4 months). Follow-Up will be 32 weeks under an adjusted prophylactic regimen according to Investigator judgment.
2922379|NCT03093467|Experimental|Experimental|Participants receive psychiatric treatment and psychotherapy as usual. In addition, participants have access to the internet-based program ASCENSO: an adjunct support and monitoring system for the treatment of depression.
2922380|NCT03093467|Active Comparator|Control|Patients receive psychiatric treatment and psychotherapy as usual.
2922381|NCT03093454|No Intervention|Control|No intervention patient will receive current standard of care treatment and will answer surveys to collect data.
2922382|NCT03093454|Experimental|Lavender Group|Patient will receive lavender essential oil topically and by inhalation during their hospital stay while at the same time receiving regular standard of care.
2922383|NCT03093441|Experimental|Multimodal|Multimodal High-Intensity Interval Training Intervention. This group will train using multimodal exercises for 5 sets of 60 seconds of all out work, followed by 3 minutes of rest. Each session will have the same exercises within each set, but every session will be different than the others for movements utilized. There will be three movements used in each set. The first movement will be a strength movement for 4-6 repetitions. The second movement follows the first immediately and is a faster body weight or light implement power movement for 6-8 repetitions. The third movement follows the second immediately and is a very fast, sprint-like movement for the remainder of the 60 seconds. The intent of each set is to be completed with as much effort as possible across the full 60 seconds.
2922421|NCT03093194|Active Comparator|Women going CS without vaginal preparation before surgery|Women going CS without vaginal preparation before surgery. No vaginal preparation before CS with Septal soap and septol.
2922384|NCT03093441|Active Comparator|Rowing|Multimodal High-Intensity Interval Training Intervention. This group will train using a rowing ergometer for 5 sets of 60 seconds of all out work, followed by 3 minutes of rest (a total of 20 minutes each session). Each training session will be the same across the 12 weeks. The intent of each set is to be completed with as much effort as possible across the full 60 seconds.
2922385|NCT03093441|No Intervention|Control|Multimodal High-Intensity Interval Training Intervention. This group will be instructed to continue with any activity they were involved in prior to the study and to not begin any new exercise programs during the course of the study. To incentive participation in this group, the control group will be offered the MM-HIIT intervention the following semester at no cost.
2922386|NCT03093428|Experimental|Radium-223|-Radium-223 will be administered intravenously every 4 weeks at a pre-determined dose
2922387|NCT03093428|Experimental|Pembrolizumab Plus Radium-223|"Radium-223 will be administered intravenously every 4 weeks at a pre-determined dose~Pembrolizumab will be administered intravenously every 3 weeks at a pre-determined dose"
2922388|NCT03093415|Active Comparator|Old Town Clinic, Medication Assisted Therapy group|25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
2922389|NCT03093415|Active Comparator|Outside In Clinic, Needle Exchange Program|25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
2922390|NCT03093415|Other|OHSU Hepatology Clinic, Academic center Retrospective Cohort|50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
2922391|NCT03093402|Experimental|JBT-101: 5 mg Twice Daily|Eligible subjects will receive assigned study treatment of JBT-101 5 mg administered twice daily.
2922392|NCT03093402|Experimental|JBT-101: 20 mg & Placebo|Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and 20 mg Placebo (P.M. Study Product).
2922393|NCT03093402|Experimental|JBT-101: 20 mg Twice Daily|Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and JBT-101 20 mg (P.M. Study Product).
2922394|NCT03093402|Placebo Comparator|Placebo + Placebo|Eligible subjects will receive assigned study treatment of Placebo (A.M.) and Placebo (P.M.) for (JBT-101).
2922395|NCT03093389|Experimental|BIA 6-512 25 mg or Placebo|1 capsule of BIA 6-512 25 mg or 1 capsule of placebo.
2922396|NCT03093389|Experimental|BIA 6-512 50 mg or Placebo|1 capsule of BIA 6-512 50 mg or 1 capsule of placebo.
2922397|NCT03093389|Experimental|BIA 6-512 100 mg or Placebo|1 capsule of BIA 6-512 100 mg or 1 capsule of placebo.
2922398|NCT03093389|Experimental|BIA 6-512 150 mg or Placebo|1 capsule of BIA 6-512 150 mg or 1 capsule of placebo.
2922399|NCT03093376|Experimental|Effortful Control Camp|"Children will participate in an interactive, child-friendly camp comprised of short, game-like exercises to teach inhibitory and attentional control, as well as visuospatial and working memory skills."
2922400|NCT03093376|Placebo Comparator|Waitlist Control|No intervention between pre and post assessment. After post-waitlist assessment, children will be given a set of written materials, adapted from the Effortful Control Camp protocol, to complete at home with their caregivers.
2922401|NCT03093363|Other|Intervention group|Asthmatic patients with the pharmacist's intervention
2922402|NCT03093363|Other|Control group|Asthmatic patients without the pharmacist's intervention (only questionnaires)
2922403|NCT03093350|Experimental|TAA-Specific CTLs|Patients receiving TAA-specific CTLs as therapy for breast cancer.
2922404|NCT03093337|Experimental|Psychomotor therapy|Early post hospital discharge psychomotor therapy.
2922405|NCT03093337|No Intervention|Control|No specific support.
2922406|NCT03093324|Experimental|ALKS 8700|Capsules, administered orally
2922407|NCT03093324|Active Comparator|Dimethyl Fumarate|Capsules, administered orally
2922408|NCT03093311|Experimental|Arm A|Brain tissue oxygenation is measured by NIRS. In time of desaturation the interventions according to NIRS based protocol start.
2922409|NCT03093311|No Intervention|Arm B|Brain tissue oxygenation is not measured.
2922410|NCT03093298|Experimental|Obesity|Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling
2922411|NCT03093285||dysthyoidic female|sexually active, hypothyroidic or hyperthyroidic women of childbearing age
2922412|NCT03093272|Experimental|ARN-509 Combined With Docetaxel|"Apalutamide (ARN-509) will be taken orally at home daily~Docetaxel will be administered every 3 weeks intravenously~Prednisone will be taken orally twice daily~Leuprolide Acetate will be administered at the specification of the physician"
2922413|NCT03093259|Experimental|ABX464 Treatment Arm|Subjects will receive 50 mg of ABX464 orally once daily for 56 days.
2922414|NCT03093259|Placebo Comparator|ABX464 matching placebo Treatment Arm|Subjects will receive 50 mg of ABX464 matching Placebo orally once daily for 56 days.
2922415|NCT03093246|Placebo Comparator|Control group|In this group (n = 19), patients will take placebo pills and full-mouth ultrasonic debridement will be performed to treat diseased sites.
2922416|NCT03093246|Experimental|Test Group|In this group (n = 19), patients will take 3 g of omega-3 polyunsaturated fatty acids and 100 mg of aspirin daily over a period of 180 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
2922417|NCT03093233||VKA- and NOAC-related ICH|"Analysis of hematoma enlargement: prevalence, risk factor, associations with therapeutic interventions (in patients with cranial follow-up imaging)~Association of hematoma evacuation surgery with clinical outcomes~Associations of antithrombotic management with ischemic and hemorrhagic complications~Safety of intraventricular fibrinolysis (in patients with severe intraventricular hemorrhage)"
2922418|NCT03093220||community-acquired pneumonia|all adult patients (aged > 16 years) admit to the 4 hospitals between March 2017 and March 2018 with CAP will be enrolled
2922419|NCT03093207|Placebo Comparator|Control group|In this group (n = 17), patients will take placebo pills and open flap debridement will be performed to treat residual pockets.
2922420|NCT03093207|Experimental|Test Group|In this group (n = 17), patients will take 3 g of omega-3 polyunsaturated fatty acids plus 100 mg of aspirin daily supplementation over a period of 180 days and open flap debridement will be performed to treat residual pockets.
2922713|NCT03091270||BOLD-fMRI|Identifying the motor functional cortex in glioma patients with BOLD-fMRI.
2922422|NCT03093194|Placebo Comparator|Women going CS with vaginal preparation before surgery|Women going CS with vaginal preparation before surgery. vaginal preparation before CS with Septal soap and septol.
2922423|NCT03093181|Placebo Comparator|No treatment and Standard cleanser|Participants randomised to the no treatment regimen will use the standard cleanser (only) twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours.
2922424|NCT03093181|Experimental|Test product and Standard cleanser|Participants randomised to test product regimen will be instructed to use the standard cleanser and test product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the test product cream immediately after cleansing.
2922425|NCT03093181|Active Comparator|Positive control and positive cleanser|Participants randomised to positive control regimen will be instructed to use the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the positive control cream immediately after cleansing.
2922426|NCT03093168|Experimental|anti-BCMA CAR-T|Administration of anti-BCMA:TCRζ-4-1-BB CAR-T cells to patients with multiple myeloma
2922427|NCT03093155|Active Comparator|Ixabepilone|Ixabepilone 20 mg/m2 days 1, 8, 15 Q 28 days
2922428|NCT03093155|Experimental|Ixabepilone + Bevacizumab|"Ixabepilone 20 mg/m2 days 1, 8, 15~+ Bevacizumab 10 mg/kg days 1, 15 Q 28 days"
2922429|NCT03093142|Experimental|tDCS & neurofeedback|30 minutes tDCS & 30 minutes neurofeedback
2922430|NCT03093142|Active Comparator|real neurofeedback|30 minutes real neurofeedback.
2922431|NCT03093142|Sham Comparator|sham neurofeedback|30 minutes sham neurofeedback.
2922432|NCT03093129|Active Comparator|artesunate|Patients will receive 200 mg artesunate (Arinate®) per oral (PO) once daily (OD) for fourteen days prior to their planned surgery and then be followed up for 5 years following surgery.
2922433|NCT03093129|Placebo Comparator|placebo|Patients will receive matching placebo tablets per oral (PO) once daily (OD) for fourteen days prior to their planned surgery and then be followed up for 5 years following surgery.
2922434|NCT03093116|Experimental|TPX-0005|Oral TPX-0005
2922435|NCT03093103|Active Comparator|empagliflozin 10mg|Empagliflozin (Jardiance) 10mg is an SGLT-2inhibitor. The drug will be taken qd for 4 weeks.
2922436|NCT03093103|Placebo Comparator|Placebo|Placebo will be taken qd for 4 weeks.
2922437|NCT03093090|Active Comparator|Water First|20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
2922438|NCT03093090|Active Comparator|Milk First|Parmalat™ Whole Milk 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
2922439|NCT03093090|Active Comparator|Baby formula first|Similac Pro-Advance™ 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
2922440|NCT03093090|Active Comparator|Ensure Plus first|Ensure Plus™ 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
2922441|NCT03093077|Experimental|Anatomic alignment|The aim of anatomic alignment is to recreate an individual's pre-operative alignment using the DePuy ATTUNE total knee arthroplasty system.
2922442|NCT03093077|Active Comparator|Mechanical alignment|The aim of mechanical alignment is to achieve a neutral mechanical alignment regardless of pre-operative status, using the DePuy ATTUNE total knee arthroplasty system.
2922443|NCT03093064|Experimental|Patient Group: Natalizumab|
2922444|NCT03093064|Placebo Comparator|Patient Group: Placebo|
2922445|NCT03093038|Active Comparator|H-MAX stem & Delta-TT cup + polyethylene|H-MAX femoral stem and the Delta-TT cup with polyethylene insert
2922446|NCT03093038|Experimental|H-MAX stem & Delta-TT cup + ceramic|H-MAX femoral stem and the Delta-TT cup with ceramic insert
2922447|NCT03093038|Experimental|C2 stem & Delta-TT cup + ceramic|C2 femoral stem and the Delta-TT cup with ceramic insert
2922448|NCT03093025|Experimental|TS-121 10mg|
2922449|NCT03093025|Experimental|TS-121 50mg|
2922450|NCT03093025|Placebo Comparator|Placebo|
2922451|NCT03092999|Experimental|Healthy subjects|healthy subjects
2922452|NCT03092999|Experimental|Subjects with mild hepatic impairment|hepatically impaired patients (classified as Child Pugh A)
2922453|NCT03092999|Experimental|Subjects with moderate hepatic impairment|hepatically impaired patients (classified as Child Pugh B)
2922454|NCT03092986|Active Comparator|chemotherapy with paclitaxel and carboplatin|Intervention: paclitaxel 200 mg/m2 AUC and carboplatin AUC 6 on day 1 every 3 wks for 2 cycles followed by three dimensional conformal radiotherapy on day 42
2922455|NCT03092986|Experimental|chemotherapy with cisplatin and vinblastine|Intervention : cisplatin 100 mg/m2 on day 1 and 29 and vinblastine 5mg/m2 on days 1,8,15,22 and 29 followed by three dimensional conformal radiotherapy on day 50
2922456|NCT03092973||Epistaxis Group|
2922457|NCT03092973||Control Group|
2922458|NCT03092960|Active Comparator|Minimal intensity intervention|Patients assigned to this group will received the Minimal intensity intervention.
2922459|NCT03092960|Experimental|HOMBRE|Patients assigned to this group will receive the HOMBRE intervention
2922460|NCT03092934|Experimental|LY3295668 (Phase 1)|Escalating doses ranging from 50 milligrams up to 1600 milligrams daily, administered orally in 21-day cycles
2922461|NCT03092934|Experimental|LY3295668 (Phase 2)|Daily dose level established in phase 1, administered orally in 21-day cycles
2922462|NCT03092921|Experimental|F&P Mask Seal|Participants to use trial seal in-home for 1 week
2922463|NCT03092921|Experimental|F&P Mask|Participants to use trial mask in-home for 2 weeks
2922464|NCT03092908|Placebo Comparator|Control group|Administer 5 ml placebo (purified water) three times a day.
2922465|NCT03092908|Experimental|Intervention group|Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.
2922466|NCT03092895|Experimental|SHR-1210+Apatinib(Arm A）|
2922467|NCT03092895|Experimental|SHR-1210+FOLFOX4 or GEMOX regimen(Arm B）|
2922468|NCT03092882|Experimental|Intervention|Diabetes Self-Management Program
2922469|NCT03092882|No Intervention|Control|
2922470|NCT03092869|Experimental|Experimental Group|Feet and Ankle Mobilization
2922471|NCT03092869|Active Comparator|Control Group|Proprioceptive Training
2922714|NCT03091270||ZOOMit-fMRI|Identifying the motor functional cortex in glioma patients with ZOOMit-fMRI.
2922472|NCT03092856|Experimental|Arm I (axitinib, anti-OX40 antibody PF-04518600)|Patients receive axitinib PO BID on days 1-14 and anti-OX40 antibody PF-04518600 IV over 60 minutes on day 1 beginning with course 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2922473|NCT03092856|Active Comparator|Arm II (axitinib, placebo)|Patients receive axitinib as in Arm I and placebo IV on day 1 beginning with course 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2922474|NCT03092843||No functional capacity testing|6 minute walk Quality of life Questionaire
2922475|NCT03092843||Functional Capacity Testing|6 minute walk Quality of Life Questionnaire Metabolic stress test
2922476|NCT03092830||1-arm, 500 participates|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
2922477|NCT03092817|Active Comparator|Dexamethasone|standard anti-tuberculosis drugs plus dexamethasone for 6-8 weeks
2922478|NCT03092817|Placebo Comparator|Identical placebo|standard anti-tuberculosis drugs plus placebo for 6-8 weeks
2922479|NCT03092804||normal pressure hydrocephalus|"Included will be subjects with a probable diagnosis of NPH. The diagnosis will be based primarily on presence of gait impairment plus at least one other impairment in urinary symptoms, cognition impairment or both~The NPH patients will undergo the CSF tap test and then receive the ventriculo-peritoneal shunting surgery. They will have the examination of brain constructure neuroimaging and functional MRI prior to and posterior to the shunting."
2922480|NCT03092804||normal control|Healthy volunteers will undergo the examination of brain constructure and functional MRI.
2922481|NCT03092791|Experimental|Adult Lead-in Cohort: sIPV High Dose|Sabin-based inactivated poliomyelitis vaccine (sIPV) containing 3, 100, and 100 D-Ag units (DU) of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
2922482|NCT03092791|Placebo Comparator|Adult Lead-in Cohort: Placebo|Placebo, intramuscular injection on Day 1.
2922483|NCT03092791|Experimental|Toddler Lead-in Cohort: sIPV High Dose|sIPV containing 3, 100, and 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
2922484|NCT03092791|Active Comparator|Toddler Lead-in Cohort: Reference IPV|Reference IPV, intramuscular injection on Day 1.
2922485|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV Low Dose|sIPV containing 0.75, 25, 25 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29, 57 and 365.
2922486|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV Medium Dose|sIPV containing 1.5, 50, 50 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
2922487|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV High Dose|sIPV containing 3, 100, 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
2922488|NCT03092791|Active Comparator|Infant Dose Ranging Cohort: Reference IPV|Reference IPV, intramuscular injection on Days 1, 29 57 and 365.
2922489|NCT03092778|Experimental|Cryoablation Group|Participants with mild to moderate obesity will undergo a cryoablation procedure to the vagal nerve.
2922490|NCT03092765|Experimental|low-dose, high-frequency E6011; high-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively higher frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
2922491|NCT03092765|Experimental|low-dose, high-frequency E6011; low-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively higher frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
2922492|NCT03092765|Experimental|high-dose, low-frequency E6011; high-dose, low-frequency E6011|Participants will receive high-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
2922493|NCT03092765|Experimental|high-dose, low-frequency E6011; low-dose, low-frequency E6011|Participants will receive high-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
2922494|NCT03092765|Experimental|low-dose, low-frequency E6011; high-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
2922495|NCT03092765|Experimental|low-dose, low-frequency E6011; low-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
2922496|NCT03092765|Experimental|Placebo; high-dose, low-frequency E6011|Participants will receive placebo up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
2922497|NCT03092765|Experimental|Placebo; low-dose, low-frequency E6011|Participants will receive placebo up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
2922498|NCT03092752||Patients with T2DM|
2922499|NCT03092739||Cytological and Histological Samples|Cytological and histological specimens that meet the eligibility criteria will be analyzed only from those participants who have consented to biomarker research, according to local regulations and ethical guidelines. Cytological samples may originate from fine needle aspirations. Pleural effusions or bronchial cytology samples (brushings and washings) may be allowed. Histological samples may originate from core needle biopsies, bronchial biopsies (thoracoscopy or mediastinoscopy) or surgical tissue resections.
2922500|NCT03092726|Experimental|ASP8062|A single oral dose to be taken preferably in the morning with or without food
2922501|NCT03092726|Placebo Comparator|Placebo|A single oral dose to be taken preferably in the morning with or without food
2922502|NCT03092713|Active Comparator|Cognitive Intervention and Supported Employment (CCI-SE)|Combined cognitive and vocational rehabilitation in a mixed design.
2922503|NCT03092713|Active Comparator|Control group|Usual follow-up assessment and treatment provided by the multidisciplinary TBI rehabilitation team.
2922504|NCT03092687||psychiatric disorders|decedents with and without psychiatric use disorders
2922505|NCT03092687||substance disorders|decedents with and without substance use disorders
2922506|NCT03092674|Active Comparator|Arm A (azacitidine)|Patients receive azacitidine SC or IV daily on days 1-7 or days 1-5 and 8-9. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2922507|NCT03092674|Experimental|Arm B (azacitidine, nivolumab)|Patients receive azacitidine as in Arm A and nivolumab IV over 30-60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2922508|NCT03092674|Experimental|Arm C (azacitidine, midostaurin)|Patients receive azacitidine as in Arm A and midostaurin orally (PO) twice daily (BID) on days 8-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2922509|NCT03092674|Experimental|Arm D (decitabine, cytarabine)|"INDUCTION: Patients receive decitabine IV over 2 hours on days 1-5 and cytarabine IV continuously on days 6-11. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients deemed stable at the discretion of the treating physician receive decitabine as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2922510|NCT03092648|Experimental|Bronchial basal cells|
2922511|NCT03092648|No Intervention|Control|
2922512|NCT03092635|Experimental|Metformin + OPC|"During week 1, subjects will take one metformin tablet in the morning and one OPC tablet in the morning and in the evening, about 12 hours apart.~During weeks 2-12 the metformin tablet will be taken approximately 12 hours apart and one OPC about 12 hours apart, in the morning and in the evening."
2922513|NCT03092622|Experimental|exercise training|Outpatients treadmill interval training, 4x4 minutes with 3 minutes in between at lower intensity. 3 sessions weekly for 10 weeks to a total of 30 sessions.
2922514|NCT03092609|Experimental|Attention Bias Modification|
2922515|NCT03092609|Active Comparator|Attention Control|
2922516|NCT03092596|Experimental|Patient-administered screening tool|Patients will complete a screener for alcohol and drug misuse.
2922517|NCT03092596|Experimental|Patient health navigator-administered screening tool|Patient health navigators will administer a screener for alcohol and drug misuse to patients.
2922518|NCT03092596|Experimental|Patient health navigator-assisted linkage to treatment|Patient health navigators will be trained in motivational interviewing to engage patients about linkage to substance abuse treatment.
2922519|NCT03092596|No Intervention|Treatment as usual|Patients will receive standard care.
2922520|NCT03092583|Experimental|Patient group|Subjects must meet the modified New York criteria for AS, or the ASAS criteria for Ax-SpA, and must be naïve of biologic therapy (anti-TNF-α agents) at the time of inclusion, or have received but subsequently discontinued anti-TNF-α therapy at least 3 months before inclusion. A blood sample will be drawn (35 mL) to these patients.
2922521|NCT03092583|Other|Control group|Subjects must be free from any inflammatory or auto-immune disease. A blood sample will be drawn (35 mL) to these controls subjects.
2922522|NCT03092570|Experimental|tDCS Post-CVA|The participants will get a 20min stimulation at a maximal intensity of 2mA
2922523|NCT03092570|Sham Comparator|Sham Post-CVA|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
2922524|NCT03092570|Experimental|tDCS Young Healthy|The participants will get a 20min stimulation at a maximal intensity of 2mA
2922525|NCT03092570|Sham Comparator|Sham Young Healthy|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
2922526|NCT03092570|Experimental|tDCS Older Healthy|The participants will get a 20min stimulation at a maximal intensity of 2mA
2922527|NCT03092570|Sham Comparator|Sham Older Healthy|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
2922528|NCT03092557|Experimental|Determination of local pleural strain|Patients will receive four different tidal volumes in random order (6 mL/kg, 8 mL/kg, 10 mL/kg, 12 mL/kg).
2922529|NCT03092544|Active Comparator|RRMS on therapy|18 subjects with a diagnosis of Relapsing Remitting (RRMS) ages 18-55, that are scheduled to begin on dimethyl fumarate
2922530|NCT03092544|Active Comparator|SPMS on therapy|18 subjects with a diagnosis of Secondary Progressive (SPMS) ages 25-65 without clinical or MRI evidence of relapse in two years that are scheduled to begin on dimethyl fumarate
2922531|NCT03092544|No Intervention|SPMS not on therapy|18 subjects with a diagnosis of SPMS ages 25-65 without clinical or MRI evidence of relapse in two years, that are NOT scheduled to begin on dimethyl fumarate
2922532|NCT03092544|No Intervention|Normal Control 1|10 normal controls (younger cohort, mean age 38)
2922533|NCT03092544|No Intervention|Normal Control 2|10 normal controls (younger cohort, mean age 58)
2922534|NCT03092531|Experimental|Positive STEPS|"Step 1) all participants randomized to the experimental condition will receive low-intensity, daily two-way SMS texts of personalized reminders to take medications as prescribed (social-cognitive cues). If a participants demonstrates >90% adherence they will remain on step one. Participants who continue to have difficulty adhering to their HIV medications at one month after baseline or anytime up to the end of month three (weeks five through twelve) will progress to~Step 2) Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes."
2922535|NCT03092531|No Intervention|Standard of Care|The standard health services offered at each site (e.g., mental health services, case management) and a brief adherence educational session. This will consist of a review of medications and recommended dosing (i.e., to understand regimen), adherence expectations, toxicity expectations and medication misperceptions.The participant will then view a 20-minute animated tutorial which explains the importance of adherence to antiretroviral medication effectiveness.
2922536|NCT03092518|Experimental|1/Arm 1|HIPEC with gastrectomy
2922537|NCT03092505||Females|Females participants who are about to start first line antiretroviral therapy.
2922538|NCT03092492||1|Late age-related macular degeneration (AMD)
2922539|NCT03092492||2|early reticular pseudodrusen (RPD)
2922540|NCT03092492||3|control group
2922541|NCT03092479|Experimental|Behavioral Intervention|4-month bi-weekly comprehensive postoperative behavioral support program addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
2922542|NCT03092479|No Intervention|Usual Care|Usual postoperative follow-up per the GHS Center for Nutrition and Weight Management guidelines.
2922543|NCT03092466|Active Comparator|femoral group|Group 1: placement of a femoral nerve catheter plus femoral block with 15 ml of a Ropivacaine 0,75% solution through the femoral catheter
2922715|NCT03091257|Experimental|Dabrafenib|"Determine if mutation in BRAF, KRAS, NRAS~BRAF V600 mutated~Treat cohort with Dabrafenib~Analysis~Treat cohort with Dabrafenib"
2922544|NCT03092466|Placebo Comparator|control group|Group 2: placement of a femoral nerve catheter plus the administration of an equivalent volume (15 ml) of a saline solution through the femoral catheter
2922545|NCT03092453|Experimental|Mature dendritic cell (DC) vaccine|Mature DC 7.5-15 million/peptide given day 1, every six weeks for 2 doses followed by standard of care anti PD-1 therapy
2922546|NCT03092440||"Nursing students group"|nursing students
2922547|NCT03092440||"New nurses group"|Nurses with < 2 years experience
2922548|NCT03092440||"Expert nurses group"|Intensive nurses (with ≥ 4 years experience post graduate)
2922549|NCT03092427|Experimental|Probiotic VSL#3|
2922550|NCT03092427|Placebo Comparator|Placebo|
2922551|NCT03092414|Experimental|Group A|Patients with indications for gastroduodenoscopy will be evaluated with WLE and then LCI.
2922552|NCT03092414|Experimental|Group B|Patients with indications for gastroduodenoscopy will be evaluated with LCI and then WLE.
2922553|NCT03092401||hepatic transplant patients with hepatopulmonary syndrome|
2922554|NCT03092401||hepatic transplant patients without hepatopulmonary syndrome|
2922555|NCT03092388|Experimental|Study Group Basic|Patients receive Multi Frequency Bioimpedance Analysis (mfBIA) before and after sleep recording by Polysomnography/Polygraphy (PSG/PG) in hospital. Capillary Blood Gas Analysis (CBGA) is performed before and after sleep according to mfBIA.
2922556|NCT03092388|Experimental|Study Group Extended|"Patients receive Multi Frequency Bioimpedance Analysis (mfBIA) before and after sleep recording by Polysomnography/Polygraphy (PSG/PG) in hospital. Capillary Blood Gas Analysis (CBGA) is performed before and after sleep according to mfBIA.~Additionally, during daytime a special test with random parts of the study group basic is performed:~A tilting table with hemodynamic monitoring is used to induce an artificial LFS by moving patients from vertical into horizontal position. Bodyfluid changes are monitored by mfBIA during this procedure."
2922557|NCT03092375|Experimental|Arm A: G/P 300 mg/120 mg QD for 12 Wks|Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg Tablets once-daily by mouth) for 12 weeks.
2922558|NCT03092375|Experimental|Arm B: G/P 300 mg/120 mg QD for 16 Wks|Non-cirrhotic subjects will take 3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg tablets once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)
2922559|NCT03092375|Experimental|Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks|Cirrhotic subjects will take 3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg tablets once-daily plus Ribavirin (RBV) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)
2922560|NCT03092375|Experimental|Arm D: G/P 300 mg/120 mg QD for 16 Wks|Cirrhotic subjects will take 3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg tablets once-daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)
2922561|NCT03092336|Experimental|Electrical Stimulation|"The training with electrostimulation will be performed with the following intensity:~Medium frequency current: 2.500Hz Modulation frequency: up to 50Hz Time on / off: 1: 2 Average session time 10 to 15 min Being applied in the same muscle groups that will be trained in the group that will perform strength training."
2922562|NCT03092336|Experimental|Strength training|There will be 10 exercises: upper limbs: Supine with dumbbells; High pulley pull; Alternating thread with dumbbells; Triceps dumbbell test; Lower limbs: knee extensor, squatting with body weight, plantar flexion, knee flexion and plantar dorsiflexion. The session time will be from 45 minutes to one hour 2 times weekly totaling at the end of the 12 weeks, 24 strength training sessions.
2922563|NCT03092323|Experimental|Treatment|Neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab.
2922564|NCT03092323|No Intervention|Standard of Care|Neoadjuvant radiotherapy followed by surgical resection.
2922565|NCT03092310|Experimental|Artificial Pancreas|The artificial pancreas device will employ its enhanced Model Predictive Control (MPC) algorithm with a target glucose level of 110 mg/dL with a trust index for MPC-predicted glucose values, weighing future glucose predictions and only acting on predictions with higher weight in the trust index. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device.
2922566|NCT03092297||ICU patients with anaemia|At admission to the ICU all patients, or their legal representatives, expected to stay at the ICU for longer than 24 hours will be asked to participate in the study and will be asked informed consent. ICU patients with anaemia in whom a central venous catheter is already in place and in whom a red cell transfusion is planned, will be included in the study.
2922567|NCT03092284|Active Comparator|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Allogeneic adipose derived stromal cells
2922568|NCT03092284|Placebo Comparator|Placebo|Saline
2922569|NCT03092271|Active Comparator|Zero Suicide Quality Improvement (ZSQI)|Zero suicide best practices as implemented through a health system zero suicide quality improvement initiative
2922570|NCT03092271|Experimental|Stepped Care for Suicide Prevention|ZSQI plus a stepped care intervention that matches intensity of services to youth risk level.
2922571|NCT03092245|Active Comparator|OctaplasLG|OctaplasLG® is an industrial donor plasma product pooled from 630 -1520 single donor units. It possesses unique features when compared to standard FFP, such as having a standardized concentration of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen-free.12 Most importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration. The manufacturing process also inactivates viral, bacterial and prion pathogen by immune neutralization, solvent-detergent treatment and a prion specific ligand affinity chromatography step.
2922572|NCT03092245|Placebo Comparator|Ringer-Acetate|standard of care resuscitation fluid Ringer-acetate is a mixture of electrolytes in water to a slightly hypotonic solution.
2922573|NCT03092232|Experimental|Cohort 1_Active and Matching Placebo|
2922574|NCT03092232|Experimental|Cohort 2_Active and Matching Placebo|
2922575|NCT03092232|Experimental|Cohort 3_Active and Matching Placebo|
2922576|NCT03092206|Experimental|Group 1|F/TAF ; oral; Dose: 25/200 mg; Frequency: QD
2922577|NCT03092206|Experimental|Group 2|Group 2: E/C/F/TAF; oral; Dose: 150/150/200/10 mg; Frequency: QD
2922578|NCT03092206|Experimental|Group 3|Group 3: R/F/TAF; oral; Dose: 25/200/25 mg; Frequency: QD
2922921|NCT03089736|Other|Treatment as usual (TAU)|Treatment as usual (TAU; i.e. pharmacological treatments and advices)
2922579|NCT03092193|Experimental|Naproxen|20 patients will receive naproxen (one tablet 500 mg) to collected saliva samples for pharmacokinetic and pharmacogenetic studies
2922580|NCT03092193|Experimental|Naproxen-esomeprazole|20 patients will receive after one month of first collection (with naproxen 500 mg), naproxen-esomeprazole (one tablet 500mg+20mg) to collected saliva samples for pharmacokinetic and pharmacogenetic studies
2922581|NCT03092180||Idiopathic inflammatory myopathies 1|Intravenous infusion with methyprednisolone / human intravenous immunoglobulin at disease onset
2922582|NCT03092180||Idiopathic inflammatory myopathies 2|Intravenous infusion with methyprednisolone at disease onset
2922583|NCT03092167|Active Comparator|Case|Patients: this group will be submitted to 12-weeks, twice/week, physical exercises.
2922584|NCT03092167|No Intervention|Control|Patients: this group will not be submitted to 12-weeks, twice/week, physical exercises.
2922585|NCT03092167|No Intervention|Healthy control|Volunteers: this group will not be submitted to 12-weeks, twice/week, physical exercises.
2922586|NCT03092154|Experimental|Exposed|Patients will receive lipid-lowering agents (Artovastatin) for at least 12-weeks
2922587|NCT03092154|No Intervention|No intervention|Patients will not receive artovastatin (lipid-lowering agents)
2922588|NCT03092141|Active Comparator|Patients|Patients will be submitted to physical training (12-weeks, twice/week)
2922589|NCT03092141|Active Comparator|Control group|Healthy individuals will be submitted to physical training (12-weeks, twice/week)
2922590|NCT03092128||sensitive group; non-sensitive group|sensitive patients were defined as patients reached CR or PR after first month administration,SD after first three months administration. non-sensitive patients were defined as patients reached PD after first month administration and first three months administration.
2922591|NCT03092115|Experimental|HIV medication adherence app|Youth in this arm will receive a medication adherence application to help them remember to take their HIV treatment medication (antiretroviral therapy) as a supplement to current HIV standard of care.
2922592|NCT03092102|Placebo Comparator|HEC585 single doses|
2922593|NCT03092102|Placebo Comparator|HEC585 multiple dose|
2922594|NCT03092102|Placebo Comparator|HEC585 food effect|
2922595|NCT03092089|Experimental|Adult patients with high risk STEMI|Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)
2922596|NCT03092076|Experimental|Pharmacokinetics|The pharmacokinetics characteristic of ticagrelor in healthy Chinese is investigated to provide the basis for its efficacy and safety of clinical treatment.
2922597|NCT03092076|Experimental|Antiplatelet effects|The antiplatelet effects of ticagrelor in healthy Chinese is investigated to provide the basis for its efficacy and safety of clinical treatment.
2922598|NCT03092076|No Intervention|The impact of genotype|The recovery time of platelet function following the administration of ticagrelor is widely varied that genetic variants maybe an underlying factor.The impact of genotype on pharmacokinetic parameters and ADP of ticagrelor is compared among different genotypes.
2922599|NCT03092063|Experimental|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families.
2922600|NCT03092063|Experimental|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by community health workers (promotoras) working with individual patients and families.
2922601|NCT03092063|Experimental|Enhanced Engagement-Nurse|Tomando Control de su Diabetes-Nurse is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families. If subjects do not benefit sufficiently, the subject may be randomized to receive three home visits to facilitate engagement with treatment.
2922602|NCT03092063|Experimental|Enhanced Engagement-Promotora|Tomando Control de su Diabetes-Promotora is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families. If subjects do not benefit sufficiently, the subject may be randomized to receive three home visits to facilitate engagement with treatment.
2922603|NCT03092063|Experimental|Multifamily Group-Promotora|"If subjects do not benefit sufficiently from the initial Tomando Control intervention offered by the promotoras, they may be randomized to receive a multifamily group intervention consisting of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
2922604|NCT03092063|Experimental|Multifamily Group-Nurses|"If subjects do not benefit sufficiently from the initial Tomando Control intervention offered by the nurses, they may be randomized to receive a multifamily group intervention consisting of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
2922605|NCT03092050|Active Comparator|Facilitated Discussion|Weekly facilitated discussion for 4 weeks
2922606|NCT03092050|Experimental|Guided Imagery and mindfulness|Weekly guided imagery and mindfulness for 4 weeks
2922607|NCT03092037||Cases (rapid/ultrarapid metabolizers)|Cases (rapid/ultrarapid metabolizers) will have their blood drawn. DNA will be extracted from whole blood, and serum will be analyzed for ENG concentrations. The 25% of participants with the lowest serum ENG concentrations will be considered cases (rapid/ultrarapid metabolizers).
2922608|NCT03092037||Controls|Controls will have their blood drawn. DNA will be extracted from whole blood and serum will be analyzed for ENG concentrations. The 75% of participants with the highest serum ENG concentrations will be considered controls (poor and normal metabolizers).
2922609|NCT03092024|Experimental|SPIN-HAND program|
2922610|NCT03092024|No Intervention|Not Offered the SPIN-HAND program|Treatment as usual
2922611|NCT03092011|Experimental|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours
2922612|NCT03092011|Active Comparator|Morphine|Morphine Sulfate at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours
2922613|NCT03091998|Active Comparator|Study Drug (CD-NP)|Participants will receive a single subcutaneous injection of CD-NP (5 ug/kg) for 3 days running
2922614|NCT03091998|Placebo Comparator|Placebo (saline)|Participants will receive a single subcutaneous injection (~1 mL) of normal saline for 3 days running
2922615|NCT03091985|Experimental|Group A|"Drainage of the lactating breast using:~PersonalFit - Breast shield & Brownie - Breast shield~Breast shields are each to be used for 15 min pumping with the symphony breastpump"
2922616|NCT03091985|Experimental|Group B|"Drainage of the lactating breast using:~Brownie - Breast shield & PersonalFit - Breast shield~Breast shields are each to be used for 15 min pumping with the symphony breastpump"
2922617|NCT03091972|Experimental|Contact force assisted linear ablation|Left atrial linear ablation performed using the contact force sensing catheter after pulmonary vein isolation
2922618|NCT03091972|Active Comparator|control|Left atrial linear ablation performed using the catheter without contact force sensing after pulmonary vein isolation
2922619|NCT03091946|Placebo Comparator|Cooked cream of rice|Cream of rice with additional dried fruits, nuts and seeds cooked just prior to its consumption and served with skim milk as a beverage
2922620|NCT03091946|Experimental|Overnight oats|Oats with additional dried fruits, nuts and seeds soaked overnight in skim milk
2922621|NCT03091933|Experimental|GLIDE|GLIDE single infusion at a target dose of 4x107 viable T-cells/m2
2922622|NCT03091920|Experimental|QD/QD|"Drug: IW-1973 + Placebo~On Days 1-14: 40 mg taken once daily (QD) in AM and placebo taken QD in PM."
2922623|NCT03091920|Experimental|BID/QD|"Drug: IW-1973 + Placebo~On Days 1-7: 20 mg taken in AM and 20 mg taken in PM. On Days 8-14: 40 mg taken QD in AM and placebo taken QD in PM."
2922624|NCT03091920|Placebo Comparator|PBO/PBO|"Drug: Matching Placebo Oral Tablet~On Days 1-14: Placebo taken in AM and in PM."
2922625|NCT03091907||Case|Children with a history of necrotizing enterocolitis
2922626|NCT03091907||control|Children with no history of necrotizing enterocolitis
2922627|NCT03091894|Active Comparator|propofol|patients will receive only propofol intravenous infusion for sedation
2922628|NCT03091894|Active Comparator|propofol-dex.|patients will receive dexmedetomidine in addition to propofol intravenous infusion for sedation
2922629|NCT03091881|Active Comparator|Granisetron group|patients in this group will receive intravenous Granisetron 0.1 MG/ML 10 minutes before spinal anesthesia
2922630|NCT03091881|Placebo Comparator|Placebo group|Patients in this group will receive 10 ml normal saline as placebos considering the same timing and color of solution
2922631|NCT03091868|Experimental|Group 1 (BIA 6-512 25 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 25 mg dose = 1 capsule of 25 mg plus 1 capsule of placebo In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
2922632|NCT03091868|Experimental|Group 2 (BIA 6-512 50 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 50 mg dose = 2 capsules of 25 mg In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
2922633|NCT03091868|Experimental|Group 3 (BIA 6-512 100 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 100 mg dose = 1 capsule of 100 mg plus 1 capsule of placebo In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
2922634|NCT03091868|Experimental|Group 4 (BIA 6-512 200 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 200 mg dose = 2 capsules of 100 mg In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
2922635|NCT03091842|Experimental|Group I (CARE program)|Patients undergo supervised CARE program over 50 minutes comprising of warm up over 5 minutes, moderate to vigorous aerobic and resistance exercises over 40 minutes, and cool down over 5 minutes 3 days per week for 16 weeks.
2922636|NCT03091842|Experimental|Group II (TARE program)|Patients undergo supervised TARE program over 80 minutes comprising of warm up over 5 minutes, aerobic exercise over 15 minutes, resistance exercise over 55 minutes, and cool down over 5 minutes 3 days per week for 16 weeks.
2922637|NCT03091842|Active Comparator|Group III (home-based stretching program)|Patients undergo home-based stretching program comprising of one set of 3-4 static stretching exercises held for 30 seconds 3 days per week for 16 weeks. Patients receive instructional DVD and booklet of the flexibility exercises. Patients also complete a weekly activity log. After completion of the stretching program, patients may optionally undergo the CARE program as in group I.
2922638|NCT03091816|Experimental|Diagnostic (DPCT)|Patients undergo DPCT at baseline, during SBRT (after 2 of 3 fractions or 3 of 5 fractions), and then at 1 and 3 months post stereotactic body radiation therapy.
2922639|NCT03091803|Experimental|Arm I (QSM, T1WI, gadobenate dimeglumine, GOCART DCE MRI)|Patients undergo standard of care QSM and T1WI. Patients then receive gadobenate dimeglumine IV and undergo GOCART DCE MRI over 60 minutes.
2922640|NCT03091803|Experimental|Arm II (QSM, T1WI, gadoterate meglumine, GOCART DCE MRI)|Patients undergo standard of care QSM and T1WI. Patients then receive gadoterate meglumine IV and undergo GOCART DCE MRI over 60 minutes.
2922641|NCT03091790|Active Comparator|Synthetic Mesh|Synthetic mesh (mid-density polypropylene (generic) Bard soft mesh) will be used in open ventral hernia repair
2922642|NCT03091790|Active Comparator|Biologic Mesh|Biologic mesh (non cross linked porcine acellular dermal matrix: Strattice) will be used in open ventral hernia repair
2922643|NCT03091777|Experimental|Test Drug|GDC-229 gel applied vaginally as directed.
2922644|NCT03091777|Active Comparator|Reference Drug|Metronidazole Vaginal Gel, 0.75% applied vaginally as directed.
2922645|NCT03091777|Placebo Comparator|Vehicle Placebo Gel|GDC-229 Vehicle
2922646|NCT03091764||NMIBC Patient High Risk|"Any of the following:~T1 tumours~CIS (carcinoma in situ)~Multiple and recurring and large (>3cm) Ta, G1, G2 tumours (all these conditions must be presented)~(Patients requiring intravesical Bacillus Calmette-Guérin (BCG) (immunotherapy), which starts with 6 week induction treatment and continues with maintenance for 1 to 3 years)"
2922647|NCT03091764||NMIBC Patient Intermediate Risk|"All cases between High and Low Risk~(Patients requiring intravesical therapy which lasts between 6 weeks to 3 years)"
2922648|NCT03091764||NMIBC Patient Low Risk|"Primary, solitary, Ta, LG/G1, <3cm, no CIS~(Patients receiving frequent cystoscopies, possible tumour resections and single instillations of postoperative chemotherapy)"
2922754|NCT03090919|Experimental|Platelet transfusion|Subjects randomized to platelet transfusion will receive a unit of platelets (~250cc in volume).
2922649|NCT03091751|Experimental|BeneFIX|BeneFIX is a recombinant FIX provided in a vial containing 100 IU/mL lyophilized nonacog alfa accompanied with solvent for reconstitution and injection.
2922650|NCT03091738|Experimental|Ramelteon Pill|Patients given ramelteon and re-evaluated after 15 days of therapy
2922651|NCT03091725|Experimental|RYGB group|Subjects in this group are scheduled to undergo Roux-en-Y gastric bypass surgery and will be assessed after 16-18% weight-loss
2922652|NCT03091725|Active Comparator|VLCD Group|Subjects in this group will participate in a very low-calorie diet intervention to obtain a 16-18% weight loss.
2922653|NCT03091712|Experimental|Usual care and Glooko MIDS|"Glooko mobile insulin dosing system(MIDS), using the STEP WISE degludec titration algorithm.~The eligible subjects will be started on insulin degludec (Tresiba® U-200 FlexTouch®). Subjects will use MIDS for insulin degludec titration management. The clinician will configure MIDS Prescription Instruction Form(PIF) using pre-configured Novo Nordisk, Tresiba Protocol Dosing Treatment Plan which is based on the Novo Tresiba degludec Stepwise Program. The Clinician can alter this as appropriate based on medical judgment. Subjects will be started on MIDS and trained on use of Glooko MIDS mobile app. Subjects will get dose adjustment check up on the app and also alert to contact physician if subject experiences hyperglycemia or hypoglycemia."
2922654|NCT03091712|No Intervention|Usual care|"Usual care for insulin degludec (Tresiba® U-200 FlexTouch® pens) titration using the STEP WISE degludec titration algorithm.The eligible subjects will be started on insulin degludec(Tresiba® U-200 FlexTouch®).~Subjects in this group will be provided with a one-page description of the pre-configured Novo Nordisk, Tresiba Protocol Dosing Treatment Plan which is based on the Novo Tresiba degludec Stepwise Program and how to follow it. The Clinician can alter this as appropriate based on medical judgment. This document will also include instructions to contact the HCP if the subject experiences hyperglycemia or hypoglycemia."
2922655|NCT03091699|Experimental|Moderate intensity exercise|The Exercise intervention will persist of a 20-minute bout of moderate intensity aerobic exercise which by definition is 40-65% of Maximum Heart Rate. Exercise consisted of a 2-minute warm-up, followed by 15 min of walking at a rate, which will allow you to reach 2/3 of your max heart rate, and then a 3-minute cool down on a treadmill equaling 20 minutes. Heart Rate will be examined with Polar Wearlink coded Heart Rate monitors to attain the specific exercise intensity.
2922656|NCT03091699|Active Comparator|Nicotine Inhalation|The nicotine inhalation group will smoke a cigarette to completion of their choice, in the 20 minute time period allocated in the Exercise and Health Psychology Lab psychological assessment room (the room will be equipped with windows that allow for ventilation and an air purifier. During this time the participant will refrain from conversation.
2922657|NCT03091686|Experimental|Experimental Group (HAPA SB)|"Experimental (same outcome questionnaire but with informational slideshow focusing on sedentary behaviour and diabetes risk)~HAPA SB Intervention Slideshow"
2922658|NCT03091686|Active Comparator|Attention-Control Group (HAPA MVPA)|"Attention-Control (same outcome questionnaire but with slideshow focusing on benefits of moderate-vigorous physical activity)~HAPA MVPA Intervention Slideshow"
2922659|NCT03091686|No Intervention|Control Group|"Control (outcome questionnaire without any slideshow)~Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaire."
2922660|NCT03091673|Experimental|G-Pen™ (glucagon injection) 0.5 mg|A single 0.5 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection)
2922661|NCT03091673|Experimental|G-Pen™ (glucagon injection) 1.0 mg|A single 1.0 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection)
2922662|NCT03091660|Active Comparator|Arm I (BCG solution)|INDUCTION: Patients receive TICE BCG solution intravesically once a week for 6 weeks. MAINTENANCE: Patients receive TICE BCG solution once a week for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 for up to 7 doses.
2922663|NCT03091660|Experimental|Arm II (Tokyo-172 strain BCG solution)|INDUCTION: Patients receive Tokyo-172 strain BCG solution intravesically once a week for 6 weeks. MAINTENANCE: Patients receive Tokyo-172 strain BCG solution once a week for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 for up to 7 doses.
2922664|NCT03091660|Experimental|Arm III (Tokyo-172 strain BCG solution with priming)|PRIME: Patients receive Tokyo-172 strain BCG vaccine once ID. INDUCTION: Within 21 days, patients receive Tokyo-172 strain BCG solution as in Arm II. MAINTENANCE: Patients receive Tokyo-172 strain BCG solution as in Arm II.
2922665|NCT03091647|Experimental|acupressure intervention|Practice acupressure at home and complete daily logs
2922666|NCT03091647|Placebo Comparator|usual care|Receive usual care and complete daily logs
2922667|NCT03091634|Experimental|test group|the patients in this group take 6 xue-fu-zhu-yu capsules once, twice a day, for 7weeks.
2922668|NCT03091634|Placebo Comparator|control group|the patients in this group take 6 xue-fu-zhu-yu capsule simulated agents once, twice a day, for 7weeks..
2922669|NCT03091608||The individuals taking XLGB Granule|The overall individuals taking XLGB Granule with recommended dosage and achieving the inclusion criteria.
2922670|NCT03091595|Experimental|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.
2922671|NCT03091595|Active Comparator|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.
2922672|NCT03091582|Experimental|Cognitive behavioral therapy|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive factors and behavioral factors on affective distress.
2922673|NCT03091582|Experimental|Behavioral Activation|Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
2922674|NCT03091569|Active Comparator|Vitamin K|
2922675|NCT03091569|Placebo Comparator|Control|
2922676|NCT03091556||The individuals taking XLGB Pill|The overall individuals taking XLGB Pill with recommended dosage and achieving the inclusion criteria.
2922716|NCT03091257|Experimental|Dabrafenib and Trametinib|"Determine if mutation in BRAF, KRAS, NRAS~BRAF V600 mutated, BRAF/KRAS mutated, or BRAF/NRAS mutated, or BRAF non-V600 mutated~Treat cohort with Dabrafenib and Trametinib~Analysis~Treat cohort with Dabrafenib and Trametinib"
2922677|NCT03091543|Experimental|Sequence A (25 mg - 50 mg - 100 mg - 200 mg - Placebo)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
2922678|NCT03091543|Experimental|Sequence B (Placebo - 25 mg - 50 mg - 100 mg - 200 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
2922679|NCT03091543|Experimental|Sequence C (200 mg - Placebo - 25 mg - 50 mg - 100 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
2922680|NCT03091543|Experimental|Sequence D (100 mg - 200 mg - Placebo - 25 mg - 50 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
2922681|NCT03091543|Experimental|Sequence E (50 mg - 100 mg - 200 mg - Placebo - 25 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
2922682|NCT03091530|Experimental|Sleeper Stretch THEN Balloon Blow|Sleeper Stretch CROSSOVER TO 90/90 Hip Lift with Balloon Blow Exercise
2922683|NCT03091530|Experimental|Balloon Blow THEN Sleeper Stretch|90/90 Hip Lift with Balloon Blow Exercise CROSSOVER TO Sleeper Stretch
2922684|NCT03091517|Other|GlycoLeap|Since this is a single arm study, all participants will receive the GlycoLeap intervention.
2922685|NCT03091504|Experimental|Albuterol via High flow nasal cannula|Enrolled patients inhale bronchodilator (Albuterol Sulfate) with different concentration via High flow nasal cannula, prepared albuterol concentrations are 0.5mg, 1.0mg, 2.0mg and 4.0mg, patients will be assessed by spirometry after each concentration until bronchodilator response is positive and does not improve after the next dose.
2922686|NCT03091491|Experimental|Nivolumab|
2922687|NCT03091491|Experimental|Nivolumab and Ipilimumab|
2922688|NCT03091478|Experimental|Pembrolizumab 200 mg|
2922689|NCT03091465||Metastatic Renal Cell Carcinoma patients|This is a nation-wide retrospective observational study with patients treated with first-line pazopanib for mRCC in daily clinical practice since April 2011 (date of approval of pazopanib in Spain), January 2016.
2922690|NCT03091439|Experimental|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
2922691|NCT03091439|Active Comparator|Standard-of-Care|Patients will receive an antibiotic consistent with Standard of Care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment will be 4-6 weeks.
2922692|NCT03091426|Experimental|Omiganan 1%|
2922693|NCT03091426|Experimental|Omiganan 1.75%|
2922694|NCT03091426|Experimental|Omiganan 2.5%|
2922695|NCT03091426|Placebo Comparator|Vehicle|
2922696|NCT03091413||case group|diaphragm ultrasounds during weaning and Pimax measures
2922697|NCT03091400|Experimental|Atomoxetine|Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
2922698|NCT03091400|Placebo Comparator|Placebo|Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
2922699|NCT03091374|Experimental|Growth Hormone|
2922700|NCT03091361||All patients (imaging/no intervention)|There is only one group in this study, the imaging/no intervention group. These patients will meet all enrollment criteria and bacterial (red or cyan) fluorescence will be visualized within or around their wound with the MolecuLight i:X imaging device. A targeted curettage sample will be taken from the site of fluorescence and sent for microbiological analysis. There will be no intervention or followup.
2922701|NCT03091348|Experimental|SQ - IM|Subcutaneous testosterone injection followed by intramuscular testosterone injection
2922702|NCT03091348|Experimental|IM - SQ|Intramuscular testosterone injection followed by subcutaneous testosterone injection
2922703|NCT03091335|Experimental|Music-listening group|Patients in this group will listen to music of their choosing during the entirety of the awake portion of deep brain stimulation surgery
2922704|NCT03091335|No Intervention|Head-phone only group|Patients in this group will receive the same noise-canceling headphones as the patients in the music-listening group. However, they will remain without music per standard of care for awake deep brain stimulation procedures
2922705|NCT03091322||SR-T group|single chamber pacemaker
2922706|NCT03091322||DR-T group|dual chamber pacemaker
2922707|NCT03091322||HF-T group|triple chamber pacemaker (IS-1 connector)
2922708|NCT03091322||HF-T QP group|triple chamber pacemaker (with IS4 connector) and a lead of the Sentus QP lead family
2922709|NCT03091309|Experimental|Intervention|Patients randomized to the intervention group will receive a multi-faceted intervention consisting of: (1) Interactive educational video; (2) Initial in-person counseling with an IBD nurse; (3) Motivational interviewing; (4) Telemedicine-based follow-up; (5) Monthly follow-up questionnaires; and (6) Comprehensive questionnaires.
2922710|NCT03091309|Active Comparator|Control|Patients randomized to the control group will complete the comprehensive questionnaires and will continue to receive the standard of care consistent with their condition, at their respective institution.
2922711|NCT03091296||Men with testosterone deficiency|Screening testosterone concentration of less than 350 ng/dL
2922712|NCT03091296||Men without testosterone deficiency|Screening testosterone concentration of greater than 350 ng/dL
2922717|NCT03091257|Experimental|Trametinib|"Determine if mutation in BRAF, KRAS, NRAS~KRAS or NRAS mutated~Treat cohort with Trametinib~Analysis~Treat cohort with Trametinib"
2922718|NCT03091244||The individuals taking XLGB Capsule|The overall individuals taking XLGB Capsule with recommended dosage and achieving the inclusion criteria.
2922719|NCT03091218||The individuals taking RZZY Capsule|The overall individuals taking RZZY Capsule with recommended dosage and achieving the inclusion criteria.
2922720|NCT03091192|Experimental|Savolitinib|See: intervention description
2922721|NCT03091192|Active Comparator|Sunitinib|See: intervention description
2922722|NCT03091179|Experimental|THRIVE|high flow nasal oxygen
2922723|NCT03091179|Active Comparator|Endotracheal tube|tracheal intubation
2922724|NCT03091166|Active Comparator|Dexmedetomidine|
2922725|NCT03091166|No Intervention|No Dexmedetomidine|
2922726|NCT03091153|No Intervention|Control|Standard care. Annual medication review
2922727|NCT03091153|Experimental|Intervention|In depth medication review with a focus on deprescribing
2922728|NCT03091140||Group A|patients with primary hyperparathyroidism, undergoing parathyroidectomy, as a therapeutic intervention
2922729|NCT03091140||Group B|patients with primary hyperparathyroidism, not undergoing parathyroidectomy and receiving conservative treatment. This group will be considered as control group.
2922730|NCT03091140||Group C|patients undergoing thyroid surgery due to nontoxic multinodular goiter or solitary nontoxic thyroid adenoma. This group will be considered as control group.
2922731|NCT03091140||Group D|healthy subjects. This group will be considered as control group.
2922732|NCT03091101|Experimental|Scleral lens wearing keratoconics|Newly diagnosed keratoconics with no previous rigid lens wear fitted with Sceral contact lenses
2922733|NCT03091088|Active Comparator|Control|walking at an intense pace
2922734|NCT03091088|Experimental|Experimental|osteoporosis specific-oriented training
2922735|NCT03091075|Experimental|Treatment Group|receiving oral Oxandrolone 24 mg (12mg tablets) per day if male and 12 mg Oxandrolone per day if female, with dosing starting at time of surgery and continuing 12 weeks postoperative
2922736|NCT03091075|Placebo Comparator|Placebo Group|receiving placebo medication (Placebo Oral Tablet), oral tablet, with dosing beginning at time of surgery and continuing for 12 weeks postoperative
2922737|NCT03091062|Experimental|Study Group|Study subjects will serve as their own control and all will receive treatment with two different Airway Clearance Systems- the Vest® Airway Clearance System and the Monarch™ System. Subjects will be randomized to which treatment is received first.
2922738|NCT03091049||EMLA anesthetic ointment (AO)|In AO group a layer of 2.5 gr EMLA cream (standard adult dose) is applied to both wrists, 1 cm above the styloid process of the radius 30 minutes before the puncture, by an experienced cathlab nurse
2922739|NCT03091049||Local Skin Anesthetic Injection (LA)|In LA group the radial artery is infiltrated with 1-2 mL of 2% lidocaine, using a 26 G needle, 0.5-1 cm proximal to the styloid process one minute before the puncture
2922740|NCT03091036|Other|Proactive healthcare intervention|Participants who were included before (single-arm pre-post study), now a proactive and integrated intervention program for the health is performed of the complex chronic patient, based in an improvement of the care process.
2922741|NCT03091023|Active Comparator|Natural cycle|"Endometrial biopsies and endometrial fluid obtained from healthy females throughout the menstrual cycle at each of these stages:~Early proliferative (EP; days 0-8), late proliferative (LP; days 9-14), early secretory (ES; days 15-18), mid-secretory or receptive (MS; days 19-23), and late secretory (LS; days 24-30)"
2922742|NCT03091023|Active Comparator|ERA in HRT cycle|Endometrial biopsy and endometrial fluid obtained from woman undergoing to Endometrial Receptivity Analysis (ERA) in a hormonal replacement therapy (HRT) cycle.
2922743|NCT03091010|Experimental|Fecal Microbiota Transplantation|
2922744|NCT03091010|Active Comparator|Steroid|
2922745|NCT03090997|Placebo Comparator|Group 1|vitamin C (500 mg/day/orally) + placebo
2922746|NCT03090997|Placebo Comparator|Group 2|resveratrol (500 mg/day/orally) + placebo
2922747|NCT03090997|Active Comparator|Group 3|vitamin C (500 mg/day/orally) + resveratrol (500 mg/day/orally)
2922748|NCT03090984|Active Comparator|PMMA (BKU)|"Patients included in the study will undergo 3 hemodialysis treatments. During the PMMA Arm, patient will be dialyzed using a BKU 1.6 (Toray) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.~During each study treatment, blood samples will be taken at specified time points (T0, T5, T15, T30, T90, T240) to assess overall coagulation activation (TAT, PF1+2, d-dimers), contact phase activation (kallikrein, fXIa, fXIIa), and activation of the extrinsic coagulation pathway (TF)."
2922749|NCT03090984|Active Comparator|PS (Phylter)|Patients included in the study will undergo 3 hemodialysis treatments. During the PS Arm, patient will be dialyzed using a Phylter 1.7 (Bellco) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
2922750|NCT03090984|Active Comparator|AN69ST (Evodial)|Patients included in the study will undergo 3 hemodialysis treatments. During the AN69ST Arm, patient will be dialyzed using a Evodial 1.6 (Gambro) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
2922751|NCT03090971|Experimental|Cutaneous neurofibromas|Each subject will have two treatment neurofibromas and two control neurofibromas. Following microporation, the two treatment neurofibromas will be treated with topical diclofenac while the two control neurofibromas will be treated with topical saline.
2922752|NCT03090958|Experimental|AllyQuest Pilot|The research assistant (RA) will meet with participants in person to explain the study in detail, facilitate app download and login onto participants' phones, and provide an app site tour to highlight features. Participants will complete a baseline demographic and risk assessment administered via a computer assisted survey instrument (CASI). At the end of the one-month field trial, participants will undergo a debriefing session to evaluate their experience using the app, overall satisfaction and any problems they encountered.
2922753|NCT03090919|Placebo Comparator|Saline|Subjects randomized to the Saline arm will receive 250cc of physiological saline.
2922755|NCT03090906|Experimental|Control group: SCTG from palate|Soft tissue augmentation palate
2922757|NCT03090893|Experimental|Infusion group|Subjects will receive ATryn continuous infusion for maintaining serum antithrombin III levels between 80 - 100
2922758|NCT03090880|No Intervention|Control|usual care,
2922759|NCT03090880|Experimental|Experimental|tinzaparin sodium
2922760|NCT03090867|Active Comparator|Conventional arm|The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
2922761|NCT03090867|Experimental|The relative/surrogate will be encouraged to perform care|"The relative or surrogate will perform at least two cares a week . A manual will be given to the relative or surrogate, explaining the different care he can choose to perform on the patient.~The care proposed are: feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.~All care are planned and perform under the supervision or/and in collaboration with a caregiver.~Each care is written down on a collecting sheet."
2922762|NCT03090854||Alzheimer disease patients|
2922763|NCT03090841||CMV cases|bio-specimen collected for pregnant women with CMV infection
2922764|NCT03090841||Control cases|bio-specimen collected for pregnant women carrying a fetus with aneuploidy-dysgonosomy
2922765|NCT03090828|No Intervention|control|treatment as usual will be provided to patients
2922766|NCT03090828|Active Comparator|app-based therapeutic education|patients will have access to the app providing information of the disease as well as educational guidelines
2922767|NCT03090828|Experimental|enhanced app-based therapeutic education|patients will also have access to a chat room and discussion forum
2922768|NCT03090815||Patient receiving TKI|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive TKI
2922769|NCT03090815||Patient receiving ALK-TKI|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive ALK-TKI
2922770|NCT03090815||Patient receiving chemotherapy|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive chemotherapy
2922771|NCT03090802|Experimental|Intervention|The participants of the program arm will have 15 group sessions with mentor mother and up to 2 home visits from 3 weeks-6 months postpartum, which is package as the Mentoring Adolescent Mothers at School (MAMAS) program. Further, adolescent mothers in the intervention arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum.
2922772|NCT03090802|No Intervention|Control|Adolescent mothers in the control arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum.
2922773|NCT03090789||Study Participant|Study participants can be individuals with either a clinical diagnosis or genetic confirmation of Friedreich ataxia. In addition, this study enrolls Friedreich ataxia carriers and unaffected controls.
2922774|NCT03090776|Other|unenriched|all eligible women for partial or total mastectomy intervention will be ketamine or placebo saline
2922775|NCT03090776|Other|enriched for PPMP risk|women at high risk for persistent pain after partial or total mastectomy intervention will be ketamine or placebo saline
2922776|NCT03090763||Study population|100 Subjects followed in our department for the diagnosis of aortic aneurysm. On admission, the demographic data (see Appendix 1) will be recorded. Furthermore, within the routine clinically indicated laboratory samples, the levels of selected biochemical markers will be recorded (see Appendix 1). Follow up control laboratory will be performed one year, again within the routine samples.
2922777|NCT03090763||Control population|The control population also includes 100 subjects in total. These will be chosen from aged and sex matched individuals seen in our clinic without disease of the aorta. All subjects included in trial must be at least 18 years old and must sign the informed consent to participation in the study. In the control population, also demographic data will be obtained and the levels of selected biochemical markers will be recorded within the routine clinically indicated laboratory samples.
2922778|NCT03090750|Experimental|Lavender|Lavender oil
2922779|NCT03090750|Experimental|Bergamot|Bergamot oil
2922780|NCT03090750|Placebo Comparator|Water|Water
2922781|NCT03090737|Experimental|Nivolumab|Specified Dose on Specified Days
2922782|NCT03090724|Experimental|BIA 5-453 (Young)|"Each subject participated in the study for approximately 7 weeks. Participation included the screening evaluations within 28 days before the first administration, phase A (single dose, a 2-day inpatient period followed by 4 ambulatory visits), phase B (multiple-dose during 7 days, 6 ambulatory visits, followed by a 2-day inpatient period and by 5 ambulatory visits) and a follow-up visit 7 to 10 days after the last administration.~Phase A: single-dose on Day 1, followed by a wash out period Phase B: repeated dose from Day 6 to Day 12 (7 days, steady-state)"
2922783|NCT03090724|Experimental|BIA 5-453 (Elderly)|"Each subject participated in the study for approximately 7 weeks. Participation included the screening evaluations within 28 days before the first administration, phase A (single dose, a 2-day inpatient period followed by 4 ambulatory visits), phase B (multiple-dose during 7 days, 6 ambulatory visits, followed by a 2-day inpatient period and by 5 ambulatory visits) and a follow-up visit 7 to 10 days after the last administration.~Phase A: single-dose on Day 1, followed by a wash out period Phase B: repeated dose from Day 6 to Day 12 (7 days, steady-state)"
2922784|NCT03090711|Experimental|TMS|Real transcranial magnetic stimulation (TMS).
2922785|NCT03090711|Sham Comparator|sham TMS|Sham transcranial magnetic stimulation (TMS) as a comparison.
2922786|NCT03090711|Experimental|TMS and tACS|Real transcranial magnetic stimulation (TMS) and real transcranial alternating current stimulation (tACS).
2922787|NCT03090711|Sham Comparator|TMS and sham tACS|Real transcranial magnetic stimulation (TMS) and sham transcranial alternating current stimulation (tACS) as a comparison.
2922788|NCT03090698|Active Comparator|Hylan|Intra-articular (knee) 6ml Hylan GF20 administration (single shot)
2922789|NCT03090698|Active Comparator|Hylan + Corticosteroid|Intra-articular (knee) 6ml Hylan GF20 and 1ml Triamcinolone 20mg/ml administration (single shot)
2922790|NCT03090698|Active Comparator|Corticosteroid|Intra-articular (knee) 1ml Triamcinolone administration (single shot)
2922791|NCT03090685|Experimental|True auriculotherapy with seeds|Auriculotherapy complementary to the usual drug treatment. At each ear, selected points edible seeds of roasted mustard with a size of approximately 2 mm will be used, since it is natural and non-toxic. The seeds will be stored in ear plate and applied with the use of micropore clamp and tape in 4 to 5 specific points to control for musculoskeletal pain.
2925369|NCT03072719|Active Comparator|Dentifrice containing Sodium Monofluorophosphate|Toothpaste
2922792|NCT03090685|Placebo Comparator|Placebo Auriculotherapy with seeds|Placebo Auriculotherapy complementary to usual drug treatment. Seeds will be used in 4 auricular points in the lobe of the ear that have no specific relation to the musculoskeletal pain in the lower limbs and with the innervation of the vagus nerve.
2922793|NCT03090672|Experimental|tSVF + PRP Arm1|Stromal Vascular Fraction tSVF + Platelet Rich Plasma (PRP) concentrate
2922794|NCT03090672|Experimental|tSVF + PRP + cSVF Enrichment Arm 2|tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) concentration + (cSVF)
2922795|NCT03090672|Experimental|Normal Saline IV + cSVF Arm 3|Cellular Stromal Vascular Fraction (cSVF); Normal Saline IV introduction
2922796|NCT03090659|Experimental|LCAR-B38M treatment group|r/r multiple myeloma patients be treated with a split doses of LCAR-B38M cells. Total dose of 0.5-5 millions /kg cells will be administered at day 0, day 2 and day 6 by split dose (20%, 30% and 50% respectively).
2922797|NCT03090646|No Intervention|Standard of Care|The control participants will be instructed to attend required follow-up as is standard of care, but will not receive the financial intervention.
2922798|NCT03090646|Experimental|Financial Incentive|Participants in the intervention arm will be flagged in the secure RedCap research database to receive the financial intervention of up to three gift cards to a major online retailer in the mail upon completion of 6 month, 1 year, and 2 year required follow-up activities. If local, participants will attend clinic visits with standard of care clinical interview, physical exam, and laboratory draws. If remote, participants will submit a questionnaire documenting their remote standard of care clinic visit and the required laboratory values.
2922799|NCT03090633|Experimental|Fetoscopy|All participants will undergo fetoscopic repair of fetal spina bifida.
2922800|NCT03090620|Experimental|Physostigmine|Physostigmine 0.02 mg/kg IV bolus (max of 2 mg), which can be repeated at 10 minutes, followed by a 0.02 mg/kg/hr (max of 2 mg/hr) infusion for 4 hours.
2922801|NCT03090620|Experimental|Lorazepam|Lorazepam 0.05 mg/kg IV bolus (max 2 mg), which can be repeated at 10 minutes if inadequate patient response, followed by a Normal Saline infusion for 4 hours.
2922802|NCT03090607|Experimental|Aluvra™|Endoscopic injection of bulking agent (Aluvra) to the lower esophageal sphincter
2922803|NCT03090607|Sham Comparator|Saline|Endoscopic injection of saline
2922804|NCT03090594|Other|Biopsy|Transbronchial biopsies with cryoprobe.
2922805|NCT03090581|Active Comparator|Biopsies CP 1|Obtain transbronchial lung biopsies with cryoprobe (CP) 1
2922806|NCT03090581|Active Comparator|Biopsies CP 2|Obtain transbronchial lung biopsies with cryoprobe (CP) 2
2922807|NCT03090581|Active Comparator|Biopsies FC|Obtain transbronchial lung biopsies with forceps (FC).
2922808|NCT03090568|Experimental|BIA 5-453 Fasting|BIA 5-453 200 mg in fasting conditions
2922809|NCT03090568|Experimental|BIA 5-453 Fed|BIA 5-453 200 mg in fed conditions
2922810|NCT03090555|Experimental|Translational Manipulation|"Participants received an interscalene block on the affected side. Then, a physical therapist performed thrust manipulations on the affected shoulder until full passive physiologic motion was restored. These participants returned to the clinic approximately 3 days later for the first of 6 manual therapy (MT) sessions.~The first clinic treatment session included instruction in a home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program."
2922811|NCT03090555|Active Comparator|Comparison Group|Participants in the comparison group did not undergo a session of translational manipulation. In order to equalize the number of intervention sessions, members of this group underwent 7 in-clinic sessions of manual therapy (MT). The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and MT by a physical therapist that included all indicated grades of non-thrust manipulation. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
2922812|NCT03090542|No Intervention|Control|
2922813|NCT03090542|Active Comparator|Product|
2922814|NCT03090529|Experimental|Exercise group|The 12-week exercise-training program will include three sessions of aerobic exercise per week
2922815|NCT03090529|No Intervention|Control group|The control group will receive usual medical care
2922816|NCT03090516|Experimental|Arm A ：Donepezil|A：People are randomly divided into three groups according to the educational conditiono，gender and age.
2922817|NCT03090516|Experimental|Arm B ：Donepezil and Ginkgo biloba dispersible tablets|B：People are randomly divided into three groups according to the educational conditiono，gender and age.
2922818|NCT03090516|Experimental|Arm C：Ginkgo biloba dispersible tablets|C：People are randomly divided into three groups according to the educational conditiono，gender and age.
2922819|NCT03090503|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
2922820|NCT03090503|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
2922821|NCT03090490|Experimental|Intervention group|Antipsychotic treatment discontinuation (DT)
2922822|NCT03090490|Active Comparator|Control group|Maintenance antipsychotic treatment (MT)
2922823|NCT03090477|Experimental|Pharmaceutical care and adherence aids|
2922824|NCT03090477|No Intervention|Control (dispensing of TKI & instruction about administration)|
2922825|NCT03090464||Standard of Care (SOC)|Participants have standard of care with no access to digital disease management tool
2922826|NCT03090464||SOC + digital disease management|Participants have access to the digital disease management tool in addition to standard of care
2922827|NCT03090451|Experimental|Moderate Aerobic Exercise|Subjects will undergo moderate aerobic physical exercise (40-45% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
2922828|NCT03090451|Experimental|Intense Aerobic Exercise|Subjects will undergo intense aerobic physical exercise (60-65% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
2923047|NCT03088800|Active Comparator|Oral Ibuprofen|Oral Ibuprofen at 10mg/kg dose and placebo of equal volume
2922829|NCT03090438|Active Comparator|Varicocele embolization before IVF|Participants will have catheterization and embolization of varicoceles six months before beginning IVF
2922830|NCT03090438|No Intervention|IVF without varicocele embolization|Participants will proceed from enrollment directly to IVF
2922831|NCT03090412|Experimental|Arm I (surgery)|Patients undergo standard of care surgery on day 1.
2922832|NCT03090412|Experimental|Arm II (HPPH, PDT)|Patients receive HPPH IV over 1 hour on day 0 and undergo PDT on day 1.
2922833|NCT03090399|No Intervention|control group|patients in which standard fluid administration was applied
2922834|NCT03090399|Active Comparator|case group|patients in which fluids were administered according to FloTrac parameters
2922835|NCT03090373|Sham Comparator|Control Group|"At catheter replacement subjects will have a sham UroShield device attached to the external portion of the catheter and have it activated for 30 days.~Standard of care for the upkeep and cleanliness of the catheter will be adhered to.~At both the baseline and at the conclusion of 30 days, the distal end of the catheter will be collected as well as a sample of retained urine from the bladder and these samples will be evaluated for bacterial colonization."
2922836|NCT03090373|Active Comparator|Treatment Group|"At catheter replacement subjects will have an active UroShield device attached to the external portion of the catheter and have it activated for 30 days.~Standard of care for the upkeep and cleanliness of the catheter will be adhered to.~At both the baseline and at the conclusion of 30 days, the distal end of the catheter will be collected as well as a sample of retained urine from the bladder and these samples will be evaluated for bacterial colonization."
2922837|NCT03090360|Placebo Comparator|Placebo comparator (Control)|Starter infant formula with a probiotic and without a prebiotic. Volumes of feed depend on age, weight and appetite.
2922838|NCT03090360|Experimental|Experimental Formula (Test)|Starter infant formula with a probiotic and prebiotic. Volumes of feed depend on age, weight and appetite.
2922839|NCT03090360|No Intervention|Breastfed reference group|Breastfed reference group
2922840|NCT03090334|Experimental|De-escalation|"In this group, investigators will manage the antifungal therapy according to the BG levels as follows:~antifungal therapy will be stopped immediately after the BG response in case of serum BG <80 pg/ml in presence of clinical stability (CS);~antifungal therapy will be continued until further BG determination, both for BG levels between 80-200 pg/ml and for BG <80 pg/ml in patients without CS. In these cases, if the following BG value is <80 pg/ml antifungal therapy will be stopped independently from the CS achievement.~antifungal therapy will be continued until day 10 for BG levels >200 pg/ml"
2922841|NCT03090334|No Intervention|Standard of care|"In this group antifungal treatment will be continued until clinician's decision.~Investigators will be blinded to the BG levels of patients enrolled in this arm, The BG results will be faxed directly to the coordinating center."
2922842|NCT03090321|Active Comparator|Stand Prompt|Behavioral Intervention Prompt- Participant will receive a notification asking them to stand and walk if they have been sitting for longer than 60 minutes.
2922843|NCT03090321|Active Comparator|Step Prompt|The participant will receive a notification if they are below 5000 steps by 3pm each day asking them to get to 10000 steps.
2922844|NCT03090321|Active Comparator|Cluster Prompt|The participant will receive daily information notifications specific to the activity cluster they fall into based on the activity data collected in phase 1 of the study.
2922845|NCT03090321|Placebo Comparator|Newsfeed|Daily reminder to read the newsfeed article in the app.
2922846|NCT03090321|No Intervention|Baseline monitoring|No feedback is provided to the users. This is the control arm.
2922847|NCT03090295|Experimental|Palpation and Accuro|The placement site for the spinal anesthesia will be identified using both palpation and Accuro.
2922848|NCT03090269|Experimental|Methylphenidate pill|"18 mg tablets with a 3-week titration phase to a maximum dose of 108 mg per day, orally~Associated with phone interviews every month, urine drug toxicologies and blood sampling (PK/PD)"
2922849|NCT03090243||Study Group|measurements of IOP before and after virtual colonoscopy
2922850|NCT03090230|Experimental|Relay Pro Thoracic Stent-Graft System|The Relay Pro arm includes subjects who receive the device to treat traumatic injury of the descending thoracic aorta with the RelayPro Thoracic Stent-Graft System
2922851|NCT03090217|Experimental|Pelvic physiotherapy (PP)|Pelvic Physiotherapy include daily pelvic floor muscle training (PFMT). PFMT starts at first session of the brachytherapy and will be conduced during the twelve weeks treatment.
2922852|NCT03090217|Active Comparator|Stander Care (SC)|The stander care (SC) includes a guideline for gynecological cancer patients under radiotherapy/brachytherapy: 1) daily vaginal dilator therapy (10 to 15 minutes); and 2) usual care management. This SC starts at first session of the brachytherapy and will be conduced during the twelve weeks treatment.
2922853|NCT03090204|Other|ultrasound measurements|ultrasound measurements of myocardial deformation of free wall right ventricle during a sharp decline of right ventricle preload induced during a session of Intermittent hemodialysis.
2922854|NCT03090191|Experimental|Clostridium difficile vaccine|
2922855|NCT03090191|Placebo Comparator|Placebo|
2922856|NCT03090178|Experimental|Patients|"Wear a wristband actigraph while sleeping and answer to quality of questionnaires on a smartphone application:~sleep diary~Pruritus~dermatology life quality index"
2922857|NCT03090178|Active Comparator|Healthy Volunteers|"Wear of a wristband actigraph while sleeping and answer to quality of questionnaires on a smartphone application:~sleep diary~Pruritus~dermatology life quality index"
2922858|NCT03090165|Experimental|Arm A - Phase I|"Dose Escalation Cohort 1 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-21 of a 28 day cycle.~Cohort 2 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-28 of a 28 day cycle.~Cohort 3 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 600mg PO daily on days 1-21 of a 28 day cycle.~Experimental: Arm B - Phase II Investigational Treatment The maximum safe dose of ribociclib in combination with bicalutamide will be given to up to 46 patients."
2922894|NCT03089957|Experimental|Ulinastatin group|200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.
2922895|NCT03089957|Placebo Comparator|Control group|Control group will be in usual care without any intervention.
2922859|NCT03090152|Active Comparator|Periarticular Injection (PAI)|"Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.~Peri-articular injection in the operating room~Combined Spinal Epidural with 1.5% Mepivacaine 4cc~A pain regimen while in the hospital that includes EPCA (saline) Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
2922860|NCT03090152|Active Comparator|Epidural Patient-Controlled Analg (EPCA)|"Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.~Combined Spinal Epidural with 1.5% Mepivacaine 4cc~A pain regimen while in the hospital that consists of Epidural PCA (EPCA) with 0.06% bupivacaine. Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
2922861|NCT03090152|Experimental|PAI + EPCA|"Aspirin and nerve pain medications including duloxetine and clonidine~Combined Spinal Epidural with 1.5% Mepivacaine 4cc~Anesthetic, Antiemetic and peri-articular injection in the operating room~A pain regimen while in the hospital that consists of EPCA (with 0.06% bupivacaine) Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
2922862|NCT03090139||All Participants|All participants with diagnosis of UC and CD, who initiated treatment with anti-TNF therapy from 01 March 2010 up to 01 March 2015 will be observed. Retrospective data extraction will be done for eligible participants from March 2017 up to approximately February 2018.
2922863|NCT03090126||Alveolar hypoventilation|
2922864|NCT03090113|Experimental|Shuxuetong Injection|Shuxuetong Injection,12ml,ivgtt,day1; Shuxuetong Injection,6ml,ivgtt,day2 to day10;
2922865|NCT03090113|Placebo Comparator|Placebo Injection|Placebo Injection,12ml,ivgtt,day1; Placebo Injection,6ml,ivgtt,day2 to day10;
2922866|NCT03090100|Experimental|Group I: Guselkumab Plus Placebo|Participants will receive 1 injection of active guselkumab and 1 injection of placebo when guselkumab is scheduled to be administered (Weeks 0, 4, 12, 20, 28, 36, and 44) or 2 injections of placebo when no guselkumab is scheduled to be administered (Weeks 1, 2, 3, 8, 16, 24, 32, and 40). Placebo injections will be administered to maintain the blind.
2922867|NCT03090100|Active Comparator|Group II: Secukinumab|Participants will receive 2 injections of active secukinumab subcutaneously (SC) at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
2922868|NCT03090087|Experimental|Healthy person|The purpose is to investigate the effect of A2A adrenoceptor stimulation using the drug regadenoson (Rapiscan) on the diameter of retinal arterioles during hypoxia in vivo.
2922869|NCT03090074|Active Comparator|Moderate carbohydrate restriction and traditional support|Moderate carbohydrate restriction and traditional support with group meetings
2922870|NCT03090074|Active Comparator|Extreme low carbohydrate diet and traditional support|Extreme carbohydrate restriction and traditional support with group meetings
2922871|NCT03090074|Active Comparator|Moderate carbohydrate restriction and ACT support|Moderate carbohydrate restriction and psychological support based on acceptance and commitment therapy
2922872|NCT03090074|Active Comparator|Extreme carbohydrate restriction and ACT support|Extreme carbohydrate restriction and psychological support based on acceptance and commitment therapy
2922873|NCT03090061|Experimental|Light induced fluorescence intraoral camera|
2922874|NCT03090061|Active Comparator|Visual-tactile assessment method according to FDI criteria|
2922875|NCT03090048|Experimental|Vitamin A|retinyl palmitate USP
2922876|NCT03090048|Experimental|Azithromycin with Vitamin A|USP grade ingredients
2922877|NCT03090048|Active Comparator|Azithromycin|azithromycin monohydrate
2922878|NCT03090035|Experimental|chronic hepatitis C genotype 2 or 3|In all patients Pegylated Interferon α2 (pegIFN) plus Ribavirin were given in standard doses. Peg-INF was given in a dose of 180 μg/week and ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 & 3
2922879|NCT03090022|Active Comparator|Mesh implantation|Prior to closure of the abdominal wall a mesh will be implanted in a standardized fashion
2922880|NCT03090022|Active Comparator|Single running suture of abdominal fascia|The closure of the abdominal wall a Standard technique will be applied using a running suture
2922881|NCT03090009|Active Comparator|Flurbiprofen|Flurbiprofen 100 mg bid.
2922882|NCT03090009|Placebo Comparator|Placebo|Placebo taken bid
2922883|NCT03089996|Experimental|Piezocision|Piezocision-assisted canine retraction x Control (split mouth design)
2922884|NCT03089996|Experimental|Corticotomy|Corticotomy-assisted canine retraction x Control (split mouth design)
2922885|NCT03089996|Experimental|Piezocision x Corticotomy|Piezocision-assisted retraction x Corticotomy-assisted retraction (split mouth design)
2922886|NCT03089983|Active Comparator|No medication-assisted treatment (control group)|The control group will choose to receive no opioid agonist treatment upon release from prison.
2922887|NCT03089983|Active Comparator|Methadone maintenance treatment (MMT)|Methadone maintenance treatment (MMT) is the standard of care in Malaysia, and participants who choose this arm will receive MMT upon release from prison.
2922888|NCT03089983|Experimental|Naltrexone (NTX)|Participants who choose naltrexone (NTX) will receive an NTX implant that lasts for 90 days upon release from prison.
2922889|NCT03089983|Active Comparator|Standard Isoniazid (INH) for 26 weeks|Participants will be randomized to receive INH, the standard of care in Malaysia, for 26 weeks while in prison.
2922890|NCT03089983|Experimental|Short-course isoniazid + rifapentine (INH + RIF) for 12 weeks|Participants will be randomized to receive INH + RIF as TB treatment while in prison.
2922891|NCT03089970||Healthy asthma|Asthmatic patients not with an exacerbation, i.e., stable asthmatics
2922892|NCT03089970||Rhinovirus-infected asthmatics|Asthmatics with an exacerbation and associated rhinovirus infection
2922893|NCT03089970||Influenza A-infected asthmatics|Asthmatics with an exacerbation and associated influenza A infection
2922896|NCT03089944|Experimental|Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks|Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
2922897|NCT03089918|Experimental|Part A (Healthy Adult Male Participants)|Participants will receive intravenous (IV) injection with 370 megabecquerel (MBq) 11C-JNJ-63779586 on Day 1 of Part A.
2922898|NCT03089918|Experimental|Part B (Mild AD and Healthy age- and Gender-Matched Controls)|Participants will receive single IV injection of 11C-JNJ-63779586 on Day 1 of Part B followed by saline flush. During Part B, the dose may be reduced based on whole body dosimetric findings and image quality seen in Part A.
2922899|NCT03089905|Experimental|Sevoflurane/dexmedetomidine/remifentanil|"Dexmedetomidine: loading dose of 1mcg/kg over 10 minutes followed by an infusion of at 1 mcg/kg/hr.~Remifentanil: loading dose 1 mcg/kg over 2 minutes followed by an infusion starting at 0.1 mcg/kg/min or greater.~Sevoflurane: end tidal concentration of 0.6 -0.8% or less."
2922900|NCT03089905|Active Comparator|Sevoflurane|End tidal concentration of 2.5-3.0% or greater.
2922901|NCT03089892||Gynecologic cancer patients|Gynecologic cancer patients under chemotherapy
2922902|NCT03089879|Experimental|GVGH 1790GAHB Group|Male and female healthy subjects, previously primed with 3 doses of the 1790GAHB vaccine in the parent study H03_01E1TP, received one intramuscular booster dose of the same vaccine in study H03_01TP at Day 1 compared to 1 dose of the 1790GAHB vaccine, administered intramuscularly at Day 1 in subjects who previously received placebo in H03_01TP parent study or naïve subjects who were not part of the H03_01TP study.
2922903|NCT03089866||ASA Patients I or II|Participants are healthy (BMI <35), 55years and older, and have the ability to follow instructions. In this population we will quantify the effects of sedation with midazolam on auditory activation and cognitive performance (mini Mental State exam and complex reaction time).
2922904|NCT03089853|Experimental|Intervention Arm|Subjects randomized to intervention arm will have a device applied to their thigh on either side, and subject to neuromuscular electrical stimulation for 30 minutes daily for 2 weeks, followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
2922905|NCT03089853|No Intervention|Usual Care Arm|Usual care will consist of a protocolized regimen of 5 days of systemic steroids, unless the treating physician determines a different regimen, in which case the change will be documented.
2922906|NCT03089840|Experimental|Normothermic Machine Perfusion (OrganOx metra)|Donor livers will be placed on the OrganOx metra device for normothermic perfusion before transplantation.
2922907|NCT03089814|Active Comparator|Healthy volunteers|Healthy male volunteers will receive ischemic conditioning (4 cycles of 5-min ischemia followed by 5-min reperfusion on upper extremity) while measuring changes in tissue microcirculation at the thenar muscle.
2922908|NCT03089814|Active Comparator|Cardiac surgery patients|Patients scheduled for cardiac surgery will receive ischemic conditioning (4 cycles of 5-min ischemia followed by 5-min reperfusion on upper extremity) while measuring changes in tissue microcirculation at the thenar muscle.
2922909|NCT03089801||Tablet Recipients|Veteran patients who have received a VA-issued tablet for tablet-enabled video telehealth.
2922910|NCT03089801||Usual Care|Veteran patients who match tablet recipients based on sociodemographic/clinical characteristics but have not received a VA-issued tablet.
2922911|NCT03089788|Other|Home-based test and skin test|
2922912|NCT03089775|Experimental|BBI-2000|Cohort A
2922913|NCT03089775|Placebo Comparator|Vehicle|Cohort A
2922914|NCT03089775|Other|Multiple treatments|Cohort B
2922915|NCT03089762|Experimental|SVF and PRP|
2922916|NCT03089749||Control|Participants with no history of Traumatic Brain Injury, Traumatic Spinal Cord Injury or Intracranial Neoplasm. A single draw of 5 mL of blood will be obtained as well as demographic information and a brief medical history to act as comparison data to the other groups.
2922917|NCT03089749||Traumatic Brain Injury (TBI)|"Patients with Acute Severe TBI (post-resuscitation GCS of 8 or less). Participants will have blood draws at the time points identified below:~At 24h from the time of CNS insult~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~At 3, 6, and 12 months from the time of CNS insult~Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained from the participant. Demographic data will be collected, including:~Age~Sex~History of prior CNS insult~Clinical indicators of severity including baseline, post-resuscitation Glasgow Coma Scale (GCS) scores for brain injury patients~Radiographic indicators of severity including volume of intracranial hemorrhage, effacement of basal cisterns, amount of midline shift as well as Marshall and Rotterdam CT head scores for TBI.~Outcome data including discharge, 3-, 6-, and 12-month extended Glasgow Outcome Scale (GOS) scores"
2922918|NCT03089749||Spinal Cord Injury (SCI)|"Patients with acute spinal cord injury (SCI) (post-resuscitation ASIA score of C, B or A). Participants will have blood draws at the time points identified below:~At 24h from the time of CNS insult~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~At 3, 6, and 12 months from the time of CNS insult~Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:~Age~Sex~History of prior CNS insult~Clinical indicators of severity including baseline post-resuscitation American Spinal Injury Association (ASIA) score and ASIA impairment scale (AIS) grade for patients with spinal cord injury (SCI)~Radiographic indicators of severity including the degree of cord compression, area of cord signal change and the SFGH MRI scale will be employed.~Outcome data including discharge, 3-, 6-, and 12-month ASIA scores for SCI patients"
2922919|NCT03089749||Intracranial Neoplasm|"Patients undergoing resection of intra-axial brain tumors (commonly gliomas such as glioblastoma multiforme, astrocytomas and oligodendrogliomas). All participants will have blood draws at the time points identified below:~At 24h from the time of CNS insult~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~At 3, 6, and 12 months from the time of CNS insult~Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:~Age~Sex~History of prior CNS insult~Clinical indicators of severity including baseline, Karnofsky and Modified Rankin performance status scores for oncology patients.~Radiographic indicators of severity including the pre- and postoperative tumor volumes that will be quantitated.~Outcome data including discharge, 3-, 6-, and 12-month Karnofsky and Modified Rankin scores for oncology patients."
2922920|NCT03089736|Experimental|TAU + Education and self care|Treatment as usual (TAU; i.e. pharmacological treatments and advices) + structured education + instructions on self care
2922922|NCT03089723|Experimental|Lavage with Saline (LS)|"Under sterile conditions, the 1st carpometacarpal (CMC) will be locally anesthetized with ropivacaine and will be submitted to joint lavage with physiologic saline solution 2 to 5 mL (injection with a 30x8 needle and drained with the same needle after removal of the syringe. After emptying of the joint, 1mL saline solution will be injected.~Patients will ask to answer Visual Analog Scale (VAS) questionnaire, Range of Motion (ROM), Quick DASH, Sollerman Test, and functional grip strength (palmar grip strength, lateral grip strength and pulp-pulp pinch strength) evaluations immediately prior to the procedure and after 1, 3 and 6 months of each joint."
2922923|NCT03089723|Experimental|Lavage with Osteonil® Mini (LO)|"Under sterile conditions, the 1st carpometacarpal (CMC) will be locally anesthetized with ropivacaine and will be submitted to lavage with physiologic saline solution and Osteonil® Mini 1mL of 10mg will be injected in the 1st CMC joint.~Patients will ask to answer Visual Analog Scale (VAS) questionnaire, Range of Motion (ROM), Quick DASH, Sollerman Test, and functional grip strength (palmar grip strength, lateral grip strength and pulp-pulp pinch strength) evaluations immediately prior to the procedure and after 1, 3 and 6 months of each joint."
2922924|NCT03089710|Experimental|Mini-Fluid Challenge arm|"Fluid challenge test will be presented after induction of anesthesia at a steady state. Fluid challenge test includes 2 components: 100 ml colloid infusion in 1 min followed by 400 ml colloid infusion in 14 mins. Hemodynamic parameter after 1 minute of the end of the 1st and 2nd colloid infusion bolus will be collected.~Applied colloid: hydroxyethyl starch"
2922925|NCT03089697|Experimental|N-Rephasin® SAL200|To assign the study group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with N-Rephasin® SAL200 (3mg/kg); N-Rephasin® SAL 200 is given by intravenous only once at Day 1.
2922926|NCT03089697|Placebo Comparator|Placebo|To assign the control group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with Formulation buffer (placebo); Placebo (INT200) is given by intravenous only once at Day 1 (same way with Experimental group)
2922927|NCT03089671|Experimental|Vitamin B|Vitamin B: Patients in this arm will receive 100mg of riboflavin (vitamin B2) 60 to 120 minutes prior to surgery for the purpose of turning the urine bright yellow to see if this helps with detection of ureteric jets during cystoscopy which will be done using normal saline.
2922928|NCT03089671|Active Comparator|D5W (5% dextrose in water)|5% Dextrose in Water: Patients in this arm will receive a placebo in the pre-operative area (for the purpose of blinding the surgical team) 60 to 120 minutes prior to surgery. Intraoperative cystoscopy will then be performed using D5W to see if this helps with detection of ureteric jets.
2922929|NCT03089645|Experimental|Part 1|MEDI5083 monotherapy
2922930|NCT03089645|Experimental|Part 2|MEDI5083 with durvalumab
2922931|NCT03089632|Experimental|Gluten-free diet|All patients will follow a strict gluten-free diet for 1 month. Measurement will be conducted at baseline and after the intervention.
2922932|NCT03089619|Active Comparator|Human-Spongiosa (IMP: drug)|Product Name: Human-Spongiosa,gefriergetrocknet, CHB / Pharmaceutical form: Granules / Routes of Administration: Dental use / Marketing authorisation number : 3004134.00.00 / Marketing Authorisation Holder: Institute of Transfusion Medicine, Tissue bank, Charité university of medicine Berlin / Used by socket preservation
2922933|NCT03089619|Active Comparator|collacone® (IMP: medical device)|Product Name: Collacone / Pharmaceutical form: Absorbable, local Hemostat, porcine collagen / Routes of Administration: Dental use / Medical device with a CE mark / Used by socket preservation
2922934|NCT03089606|Other|C11-AMT PET|"Whole body FDG PET/CT scan with IV contrast will be performed at least 24 hours before C11-AMT PET scanning, as per standard of care.~C11-AMT PET will be performed at least 24 hours before pembrolizumab treatment and at least 24 hours after FDG PET/CT scan.~Pembrolizumab 200mg by IV flat dose will be administered over 30 minutes on Day 1; Pembrolizumab dosing will be repeated every 3 weeks until progression or subject withdrawal for other reasons.~Whole body FDG PET/CT scan with IV contrast at end of treatment."
2922935|NCT03089593|Experimental|Extract of ginger|Healthy and eutrophic women will receive two capsules of 200 mg of ginger extract (5% gingerols) to be taken along with a standardized breakfast.
2922936|NCT03089593|Placebo Comparator|Cellulose|Healthy and eutrophic women will receive two capsules of 200 mg of placebo (cellulose) to be taken along with a standardized breakfast.
2922937|NCT03089580|Experimental|Intense Pulsed Light Treatment|Participants will have one eye randomized to receive the intense pulsed light (IPL) therapy treatment. Participants will receive approximately 15 light spots to areas around the eye, lower eyelid, cheek, side of the nose and temple. The energy level will be based on skin type. IPL will be administered 4 times throughout the study.
2922938|NCT03089580|Placebo Comparator|Sham Treatment|Participants will have the other eye randomized to receive a sham treatment. The sham treatment will be conducted by placing the intense pulsed light (IPL) device to approximately 15 areas around the eye, lower eyelid, cheek, side of nose and temple without delivery of the light. The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
2922939|NCT03089567|No Intervention|CONTROL GROUP|Patients waiting for treatment under general Anesthesia without any intervention
2922940|NCT03089567|Active Comparator|Sodium Fluoride Varnish|Sodium Fluoride Varnish will be applied at 0,1,3 months Follow ups while waiting to receive dental treatment under general anesthesia
2922941|NCT03089567|Experimental|Silver Diamine Fluoride|Silver Diamine Fluoride will be applied at 0,1,3 months Follow ups while waiting to receive dental treatment under general anesthesia
2922942|NCT03089554|Experimental|Therapeutic Intervention|Therapeutic Intervention
2922943|NCT03089541|Experimental|Survey Arm|Will receive incentives for completing surveys and evidence of tobacco use status daily for 1 week
2922944|NCT03089528|Experimental|Videolaryngoscopy|the trachea will be intubated using a videolaringoscope
2922945|NCT03089528|Active Comparator|Direct laringoscopy|the trachea will be intubated using a laringoscope
2922946|NCT03089515|Active Comparator|Healthy Controls|
2922947|NCT03089515|Experimental|Survivors|
2922948|NCT03089502|Experimental|Exercise Rehabilitation|The intervention group will participate in the exercise rehabilitation program for a total of 12 weeks. This includes performing aerobic training five times per week and resistance training two to three times per week. Participants will also be expected to attend the education sessions following their supervised exercise rehabilitation sessions each week.
2922949|NCT03089502|No Intervention|Usual Care|Participants in the control group will be encouraged to continue with their regular physical activity routine and will receive regular standard of care by their Cardiologist and Oncologist.
2922950|NCT03089489||Lung recipients with PGD|in the first 72 hours following lung transplantation, the lung recipients have blood gases and chest X-Ray to assess the occurrence of primary graft dysfunction. Chest X-Ray infiltrate and pathological PaO2/FiO2 ratio describe PGD occurence
2922951|NCT03089489||Lung recipients PGD Free|In the first 72 hoours following lung transplantation, if the Cest X-ray is normal, the patient is considered PGD-free
2922952|NCT03089476|Other|High Risk Atopic Infants|Infants, who are at high risk of atopy, which will be determined by a validated questionnaire, will be enrolled. Infants will undergo skin tape stripping (STS), transepidermal water loss assessment (TEWL), bacterial swabs, and parental questionnaires at each visit (3 visits total). At the latter 2 visits, infants will also undergo skin prick testing to evaluate for food sensitization.
2922953|NCT03089476|Other|Atopic Adults|Parents of infants enrolled in the study will undergo skin tape stripping (STS), transepidermal water loss assessment (TEWL), and complete questionnaires at the first visit.
2922954|NCT03089463||Observation group|The entire participants in this study will be included in this group.
2922955|NCT03089450|Experimental|CGBIO stent (DES)|The Co-Cr biodegradable polymer DES Sirolimus DRUG Ascorbic Acid(Vitamin C)
2922956|NCT03089450|Active Comparator|Biomatrix flex(DES)|The abluminal biodegradable polymer DES BA9™ (BIOLIMUS A9™) DRUG
2922957|NCT03089437|Experimental|Prolonged Standing|Subject stand for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
2922958|NCT03089437|Experimental|Prolonged Sitting|Subject sit for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
2922959|NCT03089424|Placebo Comparator|Placebo PBMT|Application of PBMT (Photobiomodulation Therapy) without any dose (0 Joule) and The Back Book (educational information booklet).
2922960|NCT03089424|Active Comparator|PBMT active|Application of PBMT (Photobiomodulation Therapy) active and The Back Book (educational information booklet).
2922961|NCT03089398|Active Comparator|Hybrid Coronary Revascularization Group|HCR is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization, combined with percutaneous revascularization of at least one non-LAD target.
2922962|NCT03089398|Active Comparator|Percutaneous Coronary Intervention|PCI will be performed using standard techniques at the discretion of the operator. Only Food and Drug Administration (FDA) and Health Canada approved commercially available metallic drug-eluting stents may be used in this protocol.
2922963|NCT03089385|Experimental|Implementation group|This group will have the hypertension tool implemented on them.
2922964|NCT03089385|No Intervention|Control group|This group will not have the tool implemented.
2922965|NCT03089372|Active Comparator|Group A|Patients will receive two sessions of LI-ESWT per week for a 3 week period (6 sessions totally)
2922966|NCT03089372|Active Comparator|Group B|Patients will receive one session of LI-ESWT per week for a 6 week period (6 sessions totally)
2922967|NCT03089346|Other|Asthma|"Patients with diagnosis of asthma according to 2016 Global Strategy for Asthma Management and Prevention (GINA) definition"
2922968|NCT03089333|Experimental|Dapagliflozin|Dapagliflozin 10mg daily for 12 weeks.
2922969|NCT03089333|Active Comparator|Glibenclamide|Glibenclamide 5mg daily for 12 weeks.
2922970|NCT03089320|No Intervention|Treatment As Usual (TAU)|"We have elected to compare the CM plus stepped care condition to TAU to test its efficacy against a real world control and because CM plus stepped care is a comprehensive stand alone intervention that would substitute for TAU. While annual AUDIT-C screening is mandatory at the 7 sites, providing interventions for patients with unhealthy alcohol use is a matter of physician judgment and individual clinical practice with wide practice variation. HIV clinicians will not receive knowledge of the results of follow-up research assessments. We will conduct a Treatment Services Review at each follow-up to assess for receipt of addiction treatment services received since the last assessment and assess for contamination."
2922971|NCT03089320|Experimental|Contingency Management plus Stepped Care (Step 2)|"Step 1: Contingency management; Step 2: Addiction physician management and motivational enhancement therapy~Consistent with tenets of stepped care designs we provide a priori intervals and criteria (drinking targets) that dictate increasing the intensity of treatment (stepping up) based on research and standards in the field. All CM plus stepped care subjects will undergo PEth testing at 3 months to determine the efficacy of Step 1. Patients with a PEth > 8 ng/ml will continue on to Step 2."
2922972|NCT03089307|Active Comparator|Group A|Patients will receive one session of low intensity extracorporeal shock wave treatment (LI-ESWT) per week for 6 weeks (6 sessions totally).
2922973|NCT03089307|Active Comparator|Group B|Patients will receive two sessions of low intensity extracorporeal wave treatment (LI-ESWT) per week for 6 weeks (12 sessions totally).
2922974|NCT03089294|Active Comparator|Group A|Patients will receive 2 sessions of LI-ESWT per week for a 6 week period with energy level 4 (12 sessions totally)
2922975|NCT03089294|Active Comparator|Group B|Patients will receive 3 sessions of LI-ESWT per week for a 4 week period with energy level 4 (12 sessions totally)
2922976|NCT03089294|Active Comparator|Group C|Patients will receive 2 sessions of LI-ESWT per week for a 6 week period with energy level 7 (12 sessions totally)
2922977|NCT03089294|Active Comparator|Group D|Patients will receive 3 sessions of LI-ESWT per week for a 4 week period with energy level 7 (12 sessions totally)
2922978|NCT03089281|Other|SmartDelay™ algorithm|For those subjects implanted with a Boston Scientific CRT-D identified with an RV-LV ≥70ms, 1:1 randomization will occur via the electronic data capture (EDC) system. Subjects will be randomized to have either an AV Delay and pacing chamber determined by SmartDelay or a Fixed AV Delay of 120ms with BiV pacing.
2922979|NCT03089281|Other|Fixed AV Delay with BiV pacing|For those subjects implanted with a Boston Scientific CRT-D identified with an RV-LV ≥70ms, 1:1 randomization will occur via the electronic data capture (EDC) system. Subjects will be randomized to have either an AV Delay and pacing chamber determined by SmartDelay or a Fixed AV Delay of 120ms with BiV pacing.
2923048|NCT03088800|Active Comparator|Oral APAP|Oral APAP at 15 mg/kg and placebo of equal volume
2922980|NCT03089268||Group 1|"Individuals scheduled for colonoscopy at Hospital Universitari i Politècnic La Fe, participating in the Valencian CRC screening program, will be recruited.~Polypectomy or biopsy will be performed if necessary (following current guidelines).~Specific molecular analysis of serrated lesions and CRC will be carried out."
2922981|NCT03089229|Experimental|HAT01H cream|HAT01H medicated cream will come in a blinded tube. This topical medicated cream will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
2922982|NCT03089229|Placebo Comparator|Vehicle cream|Vehicle cream will come in a blinded tube. This topical medicated vehicle will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
2922983|NCT03089216|Experimental|Combined Bleaching(2x20)|In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide
2922984|NCT03089216|Experimental|Combined Bleaching(2x20) with arginine|Combined Bleaching(2x20) with arginine In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide Desensitizing agent: dentifrice containing 8% arginine and calcium carbonate.
2922985|NCT03089216|Experimental|Combined Bleaching(1x20)|In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide
2922986|NCT03089216|Experimental|Combined Bleaching(1x20) with arginine|Combined Bleaching(1x20) with arginine In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide Desensitizing agent: dentifrice containing 8% arginine and calcium carbonate.
2922987|NCT03089203|Experimental|Cohort 1|CART T cells 1-3x10^7 day 0
2922988|NCT03089203|Experimental|Cohort 2|Cart T cells 1-3x10^8 day 0
2922989|NCT03089203|Experimental|Cohort 3|Cyclophosphamide 1g/m^2 day -3 followed by Cart T cells maximum tolerated dose
2922990|NCT03089190|Active Comparator|DC7-2 alone|Administration of DC7-2, a meat-derived octapeptide.
2922991|NCT03089190|Active Comparator|DC7-2 + potato protein isolate|Administration of DC7-2, a meat-derived octapeptide, combined with potato protein isolate that protects DC7-2 from degradation in the GI tract.
2922992|NCT03089190|Active Comparator|Potato protein isolate + placebo|Administration of potato protein isolate combined with inactive whey protein as placebo.
2922993|NCT03089190|Placebo Comparator|Placebo|administration of inactive whey protein
2922994|NCT03089177|Experimental|Community Garden Intervention Group|Participants randomized to the Community Garden Intervention Group will receive the garden intervention. Participants will be assigned a plot for one season and will receive a standard package of services and amenities to support participation in the community garden.
2922995|NCT03089177|No Intervention|Wait List Control Group|Participants randomized to the Wait List Control Group will remain on community gardening waiting lists and will not receive the garden intervention.
2922996|NCT03089151|Experimental|Community Garden Intervention Group|Participants randomized to the Community Garden Intervention Group will receive the garden intervention. Participants will be assigned a plot for one season and will receive a standard package of services and amenities to support participation in the community garden, including seeds and transplants, tools, new garden classes and access to master community gardeners in Denver.
2922997|NCT03089151|No Intervention|Wait List Control Group|The non-gardening group will remain on the DUG wait lists and will not receive the garden intervention.
2922998|NCT03089138|Experimental|Regan Tangjiang，Simulation Shufengjiere Capsules|
2922999|NCT03089138|Active Comparator|Simulation Regan Tangjiang，Shufengjiere Capsules|
2923000|NCT03089138|Placebo Comparator|Simulation Regan Tangjiang and Shufengjiere Capsules|
2923001|NCT03089125|Active Comparator|Usual Care|Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians.
2923002|NCT03089125|Experimental|Dyspnea Intervention|"Dyspnea intervention will be administered over two sessions~Patients will receive:~Psychoeducation~Relaxation training for reducing physiological stress~Behavioral techniques for managing acute breathlessness"
2923003|NCT03089112|Experimental|Seguence 1|Period 1 : HGP1607 Period 2 : HGP1501 Period 3 : HGP1607+HGP1501
2923004|NCT03089112|Experimental|Seguence 2|Period 1 : HGP1607 Period 2 : HGP1607+HGP1501 Period 3 : HGP1501
2923005|NCT03089112|Experimental|Seguence 3|Period 1 : HGP1501 Period 2 : HGP1607 Period 3 : HGP1607+HGP1501
2923006|NCT03089112|Experimental|Seguence 4|Period 1 : HGP1501 Period 2 : HGP1607+HGP1501 Period 3 : HGP1607
2923007|NCT03089112|Experimental|Seguence 5|Period 1 : HGP1607+HGP1501 Period 2 : HGP1607 Period 3 : HGP1501
2923008|NCT03089112|Experimental|Seguence 6|Period 1 : HGP1607+HGP1501 Period 2 : HGP1501 Period 3 : HGP1607
2923009|NCT03089086|Active Comparator|Group A|Students within schools randomised to group A will receive two doses of licensed 4CMenB vaccine after baseline oropharyngeal swab with an interval of 1 to 2 months between doses, with the first dose given at the baseline visit in 2017.
2923010|NCT03089086|No Intervention|Group B|Students within schools randomised to group B will receive the licensed 4CMenB vaccine following completion of baseline and 12 month oropharyngeal swab in 2018.
2923011|NCT03089060|Experimental|Silicone Finger Cap|Patients randomized to this arm will be treated with the novel silicone finger cap for the first two weeks of treatment.
2923012|NCT03089060|Active Comparator|Film dressing|Patients randomized to this arm will be treated with conventional film dressings for the first two weeks of treatment.
2923013|NCT03089047|Experimental|Rejuvenated RBC Transfusion|Washed and Rejuvenated autologous blood
2923014|NCT03089047|Sham Comparator|Standard RBC Transfusion|Washed autologous blood (so as to maintain equivalent unit volume and Hct)
2923015|NCT03089021|Experimental|mulligan mobilization|mobilization for spinous process or facet with neck movement 10 repetetions for 3 times.
2923016|NCT03089021|Experimental|maitland mobilization|maitland mobilization for spinous process or facet joint for 2 min and repeated 3 times.
2923049|NCT03088800|Active Comparator|Oral Ibuprofen and Oral APAP|Oral Ibuprofen at 10mg/kg dose and APAP at 15mg/kg dose.
2923050|NCT03088787||Patients for TAVR|Patients for TAVR
2923051|NCT03088774|Experimental|New web-application|Information material developed in a participatory design together with patients.
2923052|NCT03088774|Experimental|Patient Handbook|Public available information.
2925370|NCT03072706|Active Comparator|Standard group|2D X-ray templating technology
2923017|NCT03089008|Experimental|Eccentric exercises|The patients were instructed to stand with straight legs on a small step, lift up on the toes, hereafter put the weight on the injured leg and slowly lower the heel as far as possible until they felt a maximal stretch of the calf muscles and/or the Achilles tendon. The exercises were repeated 15 times. Then the patients were told to repeat the exercises with semi-flexed knee. If possible the series should be repeated twice increasing to three times at each session. If pain decreased they should increase the load on the Achilles tendons by wearing a rug sack and increasing the weight of the rug sack by adding weights (5kg each). The patients were told that some pain was to be expected from the tendon during exercise, but that increasing daily pain or morning stiffness indicated that the exercises had been progressed too fast.
2923018|NCT03089008|Other|Control treatment, stretching exercises|The patients were instructed in standing stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee). The stretch was slowly increased and maintained for 30s. This stretch was to be repeated five times during each session. The patients were instructed that the stretching should be pain free, although a small degree of unpleasantness was allowed.
2923019|NCT03088982||Lanmeur multimorbid patients|All multimorbid patients who met 12 FPs in the Lanmeur residential care home in the county of Finistere (in north-west France) from July 2014 to December 2014. These FPs were drawn from those physicians associated with the Lanmeur residential care home.
2923020|NCT03088969||patient with a chronic back pain|
2923021|NCT03088956||bvFTD|Participants with behavioral variant frontotemporal dementia (bvFTD) (n=40)
2923022|NCT03088956||Healthy|Healthy Participants (n=30)
2923023|NCT03088943|Other|TTE Apical 4 Chamber View|Patients will receive TTE apical 4chamber echo examinations prior to induction and after induction
2923024|NCT03088943|Other|TEE dTG View|Patients will receive TEE deep transgastric echo examinations after induction and after cardiopulmonary bypass induction (paced at 80, 100, and 120 bpm)
2923025|NCT03088943|Other|TEE ME 4C View|Patients will receive TEE midesophageal 4chamber echo examinations after induction and after cardiopulmonary bypass induction (paced at 80, 100, and 120 bpm)
2923026|NCT03088930|Experimental|Neoadjuvant treatment with Crizotinib|Patients enrolled in this study will be treated with 6 weeks of induction therapy with crizotinib. On the last day of dosing, patients will then undergo surgical resection. 5 years of follow-up will be done via chart review.
2923027|NCT03088917||lost to follow-up patients|This so-called lost population consists of all patients, that in the past have been diagnosed with hepatitis C at the Radboudumc but who are currently lost to or have been withdrawn from follow-up. The time-span of interest will be 2000-2015.
2923028|NCT03088904|Experimental|Group A: MZ twins (IIV4)|Group A: Up to 40 healthy monozygotic (MZ) individual twin volunteers, 12-49 years old, will be given inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2923029|NCT03088904|Experimental|Group B: DZ twins (IIV4)|Group B: Up to 40 healthy dizygotic (DZ) individual twin volunteers, 12-49 years old, will be given inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), and Day 6-8 and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2923030|NCT03088904|Experimental|Group C: MZ twins (IIV4 or LAIV4)|"Group C: Up to 40 healthy monozygotic (MZ) individual twin volunteers, 12-49 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).~This group was terminated in 2016 due to ACIP recommendations against the use of LAIV but may be reopened in 2018 pending LAIV4 availability."
2923031|NCT03088891|Experimental|Antioxidant-rich snacks|The participants received antioxidant-rich snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included fruits and vegetable smoothies, dark chocolate, walnuts, dried fruits and berries.
2923032|NCT03088891|Placebo Comparator|Control snacks|The participants received antioxidant-depleted snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included milkshake, and other milk-based drinks, biscuits (both sweet and salty), white chocolate.
2923033|NCT03088878|Experimental|Phase 1b - Dose Finding|Cirmutuzumab followed by Cirmtuzumab plus ibrutinib
2923034|NCT03088878|Experimental|Phase 1b - Dose Expansion|Cirmtuzumab plus ibrutinib
2923035|NCT03088878|Experimental|Phase 2 - Cirmtuzumab plus ibrutinib|Phase 2 safety and efficacy evaluation
2923036|NCT03088878|Active Comparator|Phase 2 - Ibrutinib|Phase 2 safety and efficacy evaluation
2923037|NCT03088865|Experimental|Initial Specimen Diversion|Aspirating first blood volume into a regular blood collection tube
2923038|NCT03088865|Active Comparator|Standard practice|Aspirating first blood into blood culture bottles (Standard practice)
2923039|NCT03088852|Active Comparator|Experimental group|After initial intravenous treatment, participants (those with magnesium level ≥1 mg/dL) will be randomized, and oral magnesium therapy ( or no treatment) will be started. The experimental group will receive 400mg magnesium daily in two divided doses. Patients in the experimental group will be discharged with one month's supply of magnesium and continued for at least three months.
2923040|NCT03088852|No Intervention|Control group|control group will receive standard care (no treatment). Patient will have their blood tested and will come for follow up visit every month for 3 months after discharge.
2923041|NCT03088839||30 ALS patients|
2923042|NCT03088839||30 healthy controls|
2923043|NCT03088826|Active Comparator|MSIR and Acetaminophen Group|The patients in this group will receive 1 tablet 15mg PO morphine sulfate immediate release combined with 650mg of Acetaminophen
2923044|NCT03088826|Active Comparator|Oxycodone and Acetaminophen Group|The patients in this group will receive 1 tablet 10mg Oxycodone combined with 650mg of Acetaminophen
2923045|NCT03088813|Experimental|Experimental Arm|Irinotecan liposome injection
2923046|NCT03088813|Active Comparator|Control Arm|Topotecan
2923053|NCT03088761||cuffed tube pressure group|"The pressures of cuffed tracheal tubes will be monitored simultaneously with a cuff manometer and pressure transducer. The measurements will be observed continuously. When the cuff pressure is noted to exceed 15 cmH2O, the cuff will be deflated immediately to less than 15 cmH2O. The time when the correction occurred, the time interval between corrections and the number of corrections during surgery will be recorded.~The baseline cuff pressure will be assessed in the supine position after which time a second measurement will be made in the prone position. A blind investigator will check and record the findings of cuffed tracheal tube."
2923054|NCT03088748||Smith & Nephew Journey II PCR TKA|Subjects implanted with a Smith & Nephew Journey II posterior cruciate retaining total knee arthroplasty
2923055|NCT03088748||Smith & Nephew Journey II BCR TKA|Subjects implanted with a Smith & Nephew Journey II posterior bi-cruciate retaining total knee arthroplasty
2923056|NCT03088735|Experimental|Blastocyst-stage embryo transfer strategy|
2923057|NCT03088735|Active Comparator|Cleavage-stage embryo transfer strategy|
2923058|NCT03088722|Experimental|Community health extension workers|Community health extension workers providing contraceptive implants
2923059|NCT03088722|No Intervention|Nurses and midwives|Nurses and midwives providing contraceptive implants (existing care)
2923060|NCT03088709|Experimental|All patients will receive Haploidentical|"The choice of the chemotherapy treatment for transplantation will be up to the investigator. Post-transplant cyclophosphamide will serve as the backbone of the immunosuppression treatment to prevent GVHD. All patients will receive a Haplo-identical stem cell transplantation.~GVHD Prevention Treatment:~Cyclophosphamide 50mg/kg will be administered IV on Day 3 and Day 5 post transplant.~Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth starting on day of transplant and continue approximately 100 days post-transplant.~Mycophenolate mofetil 15mg/kg will be administered twice a day IV until patient can take it by mouth starting on Day 1 post transplant until 28 days."
2923061|NCT03088696|Active Comparator|stimulation of the acupuncture point|"a acupuncture needle and bandage will be applied at pericardium channel 6, point Neiguan"
2923062|NCT03088696|Placebo Comparator|no stimulation of the acupuncture point|"only a bandage will be applied at pericardium channel 6, point Neiguan"
2923063|NCT03088683|Active Comparator|Nathanson Retractor|Nathanson retractor will be used
2923064|NCT03088683|Active Comparator|Reveel Retractor|Reveel retractor will be used
2923065|NCT03088670|Experimental|Gosogliptin treatment group|12 weeks of monotherapy and 24 weeks of combination with Metformin
2923066|NCT03088670|Active Comparator|Vildagliptin treatment group|12 weeks of monotherapy and 24 weeks of combination with Metformin
2923067|NCT03088644|Experimental|Part A: 18F-JNJ-64413739|Subjects will receive an intravenous (IV) bolus injection of 18F-JNJ-64413739 at a dose between 150 and 185 megaBecquerel (MBq) on Day 1 of Part A to investigate the total body biodistribution and measure the radiation dosimetry.
2923068|NCT03088644|Experimental|Part B: 18F-JNJ-64413739|Subjects will receive an IV bolus injection of 18F-JNJ-64413739 at a dose between 150 and 185 MBq on Day 1 of Part B to measure the uptake, distribution, and clearance in brain.
2923069|NCT03088644|Experimental|Part C: 18F-JNJ-64413739|Subjects will receive an IV bolus injection of 18F-JNJ-64413739 for a PET/MR scan on Day 1 and a repeat 18F-JNJ-64413739 PET/magnetic resonance (MR) scan at least 1 week later to determine the test-retest variability in V[t]. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
2923070|NCT03088644|Experimental|Part D: JNJ-54175446 + 18F-JNJ-64413739|Subjects will have a baseline 18F-JNJ-64413739 PET/MR scan on Day 1. On Day 2 they will receive JNJ-54175446 (maximum 600 milligram [mg]) orally (after light breakfast) and then an IV injection of 18F-JNJ-64413739 four hours after dosing for a PET/MR scan. At least 1 week later, they will receive another dose of JNJ-54175446, and then an IV injection of 18F-JNJ-64413739 four hours later for a second post-treatment PET/MR scan. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
2923071|NCT03088631|Active Comparator|Metformin group|
2923072|NCT03088631|Placebo Comparator|Placebo group|
2923073|NCT03088618|Experimental|Patients with septal deformity|To evaluate the safety and efficacy of surgical material for nasal septoplasty in septal deformity patients with nasal obstruction
2923074|NCT03088605|Experimental|Active|TOP1630 Ophthalmic Solution
2923075|NCT03088605|Placebo Comparator|Placebo|Placebo (Vehicle) Ophthalmic Solution
2923076|NCT03088592|Other|Deep Brain Stimulation|After informed consent is obtained, the patients will undergo routine DBS pre-operative evaluation and diagnostic testing. This includes a pre-operative 3T-MRI with and without gadolinium as well as pre-operative medical clearance by the patient's PCP or general practitioner and/or other medical specialist if necessary. They will also receive a baseline clinical evaluation including both motor function (Unified Parkinson's Disease Rating Scale on and off anti-parkinsonian medication) quality of life assessment (Parkinson's disease Questionnaire-39) and a full neuropsychological evaluation, if not already completed as part of the routine DBS candidacy evaluation within 2 months of surgery. Subjects will have medical clearance from their specialists and be be evaluated by an internal medicine physician prior to surgery and cleared to proceed.
2923077|NCT03088566|Experimental|The D-Foot method|The patients are being foot screened following the routine that is programmed in the D-Foot.
2923078|NCT03088566|Active Comparator|Conventional foot screening|The patients are being foot screened according to conventional methods.
2923079|NCT03088540|Active Comparator|Standard-of-care chemotherapy|"Standard-of-care chemotherapy will administered from these options:~Doses of Paclitaxel + cisplatin OR Doses Paclitaxel + carboplatin OR Doses Gemcitabine + cisplatin or Doses Gemcitabine + carboplatin OR Doses Pemetrexed + cisplatin followed by optional pemetrexed maintenance OR Doses Pemetrexed + carboplatin followed by optional pemetrexed maintenance"
2923080|NCT03088540|Experimental|REGN2810|REGN2810 regimen as monotherapy as per study protocol
2923081|NCT03088527|Experimental|RAD140|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of RAD140.~Part B, Safety Expansion: Once the maximum tolerated dose (MTD) has been identified and/or a recommended dose escalation (RDE) has been determined, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary clinical activity of the recommended dose."
2923082|NCT03088514|Experimental|NITRATE-LVH intervention|70ml of beetroot juice (approximately 6-8 mmol of inorganic nitrate) once a day for 4 months
2923083|NCT03088514|Placebo Comparator|NITRATE-LVH placebo|70ml of beetroot juice (no inorganic nitrate) once a day for 4 months
2923084|NCT03088514|Experimental|NITRATE-CBP intervention|70ml of beetroot juice (approximately 6-8 mmol of inorganic nitrate) once a day for 4 month
2923085|NCT03088514|Placebo Comparator|NITRATE-CBP placebo|70ml of beetroot juice (no inorganic nitrate) once a day for 4 months
2923086|NCT03088501|Experimental|Interactive Voice Response System|Through IVRS, women will receive a 2-3 minute call that informs them about their lab test, next follow-up visit, breastfeeding, introduction of solid foods, immunization, motor development, and sleep.
2923087|NCT03088501|Experimental|Mother and Baby Affairs (MBA) workshops|"This will involve antenatal workshop and counselling for parents.~Brief talk by health professionals.~Role-plays"
2923088|NCT03088501|No Intervention|Control Arm|The participants in this group do not get any specific interventions but would receive standard instructions to attend follow-up.
2923089|NCT03088488||Periodontally healthy subjects|
2923090|NCT03088488||Chronic periodontitis patients|
2923091|NCT03088475|Experimental|Experimental Group|A six-month nurse-led smartphone-based self-management programme (i.e. NSSMP) will be provided to the participants in the experimental group.
2923092|NCT03088475|Active Comparator|Control Group|the patients in the control group will receive the exiting nurse-led diabetes service (i.e. NDS) provided by the hospital
2923093|NCT03088462|Active Comparator|Treatment As Usual|Any treatment for bipolar disorder participant is involved in.
2923094|NCT03088462|Experimental|Treatment As Usual + LiveWell Program|Treatment as usual combined with the LiveWell program.
2923095|NCT03088410|Experimental|Nevirapine|150 HIV-Exposed Uninfected (HEU) infants on Nevirapine (NVP) Prophylaxis
2923096|NCT03088410|Active Comparator|Zidovudine|150 HIV-Exposed Uninfected (HEU) infants on Zidovudine (AZT) Prophylaxis
2923097|NCT03088410|No Intervention|HIV- unexposed Uninfected (HUU) Infants|150 HIV- unexposed Uninfected (HUU) Infants
2923098|NCT03088397|Experimental|Patient decision aid|Group receives the patient decision aid, POCO (POstpartum Contraceptive Options), a grid with various contraceptive options across the columns and characteristics of each option in rows. Group receives Shared Decision Making counseling afterwards.
2923099|NCT03088397|Active Comparator|Website information|Group receives directions on how to get to bedsider.org information pages regarding contraceptive choices. Group receives Shared Decision Making counseling afterwards.
2923100|NCT03088397|Active Comparator|Standard of care|Group receives standard brochure on contraception in their postpartum packet. Group receives Shared Decision Making counseling afterwards.
2923101|NCT03088384||Combat Veterans|Eligible participants must be military veterans who have served in a combat zone as evidenced by documentation on the subject's DD214 (or equivalent if he/she served in a foreign military). Participants must have a diagnosis of post traumatic stress disorder that was as a result of their military combat experience.
2923102|NCT03088371|Other|Psoas Sciatic blockade|Psoas Sciatic blockade with 20 ml lidocaine 1% and 20 ml bupivacaine 0.25% pajunk needle used for the block and 5 ml Lidocaine 2% used for post-operative pain.
2923103|NCT03088371|Other|Combined spinal epidural|Spinal anaesthesia with 2.5 ml (12.5 mg) of heavy Bupivacaine 0.5%. Epidural for post-operative pain with Bupivacaine 0.125 %in a rate of 7-10 ml/hour Portex combined spinal epidural kit needle through needle.
2923104|NCT03088358|Experimental|TeaRx 50 mg|TeaRx: 50 mg per day PO (active 25 mg + placebo 50 mg every 12 hours) during 12 days (±2 days)
2923105|NCT03088358|Experimental|TeaRx 100 mg|TeaRx: 100 mg per day PO (placebo 25 mg + active 50 mg every 12 hours) during 12 days (±2 days)
2923106|NCT03088358|Experimental|TeaRx 150 mg|TeaRx: 150 mg per day PO (active 25 mg + active 50 mg every 12 hours) during 12 days (±2 days)
2923107|NCT03088358|Active Comparator|Enoxaparin|Enoxaparin 40 mg subcutaneous per day (24 hours interval) during 12 days (±2 days)
2923108|NCT03088345|Experimental|Vasopressin, Arginine|Patients randomized to this arm will receive a continuous arginine vasopressin infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.
2923109|NCT03088345|Placebo Comparator|Placebo|Patients randomized to this arm will receive a continuous normal saline infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.
2923110|NCT03088332|Experimental|Endoscopic gastroplasty|Make a gastric tube similar to that obtained in surgical gastroplication however it will be created using intragastric endoscopic sutures.
2923111|NCT03088306|Active Comparator|Standard analgesia use|A strategy to manage pain in the peri-operative period that is in common clinical use.
2923112|NCT03088306|Active Comparator|Multi-modal pain management|A strategy to manage pain in the peri-operative period that is in common clinical use that is designed to reduce the need for post-operative opioid medication.
2923113|NCT03088293|Experimental|infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
2923114|NCT03088293|Experimental|cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
2923115|NCT03088280|Experimental|3mg/kg Group|Patients will received Thymoglobuline 3mg/Kg (reduced dose)
2923116|NCT03088280|Active Comparator|6mg/kg Group|Patients will received Thymoglobuline 6mg/Kg (standard dose)
2923117|NCT03088267|Active Comparator|Active Treatment|Double blind amphetamine extended-release oral suspension, 2.5 mg/mL, 6, 7 or 8 mL po QAM
2923118|NCT03088267|Placebo Comparator|Placebo Treatment|Double blind placebo, 6, 7 or 8 mL po QAM
2923119|NCT03088254|Experimental|Group I|Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin 20 mg for 8 weeks
2923120|NCT03088254|Active Comparator|Group II|Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo for 8 weeks
2923121|NCT03088254|Active Comparator|Group III|Treatment of Telmisartan 80 mg, Amodipine placebo, Rosuvastatin 20 mg for 8 weeks
2923122|NCT03088241|Experimental|Intervention|switch to second-line ART
2923123|NCT03088241|No Intervention|Control|Standard of care: no switch to second-line ART
2923124|NCT03088228||healthy pregnants|
2923125|NCT03088228||mild preeclampsia|
2923126|NCT03088228||severe preeclampsia|
2923127|NCT03088215|Experimental|A / Shock-waves|Will receive shock-waves
2923128|NCT03088215|No Intervention|B / Nothing|Will not receive shock-waves
2923129|NCT03088202|Experimental|Intervention arm|Educational program Standardized care pathways Early palliative care
2923130|NCT03088202|No Intervention|Control arm|Usual care
2923131|NCT03088189||Vitamin B12 group|Mothers in the group are receiving vitamin B12 2µg supplements daily
2923132|NCT03088189||Multiple micronutrient group|mothers in this group are receiving vitamin B12 2µg plus multiple micronutrients (MMN) plus 20g of milk powder
2923133|NCT03088189||Placebo|Mothers are receiving placebo
2923134|NCT03088176|Experimental|Combination|"Talimogene laherperepvec intratumoral injection up to 4ml of 10^6 PFU/mL on Day 1, followed by up to 4mL of 10^8 PFU/mL 3 weeks later, followed by every 2 weeks thereafter for up to two years.~Dabrafenib 150mg orally twice daily for up to two years Trametinib 2mg orally once daily for up to two years"
2923135|NCT03088163|Experimental|DWI-MRI|
2923136|NCT03088150|Active Comparator|Surgical resection|Patients included will undergo resection of hepatic metastases, allowing thermal ablation for additional unresectable lesions.
2923137|NCT03088150|Experimental|Thermal ablation|Patients included will undergo ultrasound guided thermal ablation of hepatic metastases, allowing resection for additional unablatable lesions.
2923138|NCT03088137|Experimental|Primapur (Follitropin alfa)|
2923139|NCT03088137|Active Comparator|Gonal-f (Follitropin alfa)|
2923140|NCT03088124|No Intervention|active surveillance|Active surveillance without androgen deprivation
2923141|NCT03088124|Experimental|active surveillance with Apalutamide|Active surveillance during and after 6 months treatment with Apalutamide
2923142|NCT03088111|Other|Obiltoxaximab|"This is an open label, 24-week, single arm field study that will be implemented for subjects who receive FDA-approved obiltoxaximab as part of their medical treatment for inhalational anthrax infection in the United States. Adult subjects will be administered a single, intravenous (IV) dose of 16 mg/kg obiltoxaximab given as part of their medical care. Children will receive a weight-adjusted dose.~The primary purpose of the study is to collect data from subjects who have been treated with obiltoxaximab as part of their medical care for inhalational anthrax and to collect additional blood samples for measurement of obiltoxaximab concentrations and presence of anti-therapeutic antibodies (ATA)."
2923143|NCT03088098|Active Comparator|Treatment|Patient receiving LAAO
2923144|NCT03088098|No Intervention|Control|Patient undergoing medical therapy for stroke prevention
2923145|NCT03088085|Experimental|Self-mobilization|Use of foam roller to mobilize thoracic spine and ribs every night before going to bed
2923146|NCT03088085|Active Comparator|Sleep Education|Education on sleep hygiene with tips for improving sleep.
2923147|NCT03088072|Other|Edoxaban Arm|All patients enrolled in the study will receive 6 weeks of edoxaban therapy, at which time a TEE will be performed. If the result is acceptable, edoxaban will be discontinued, and the patient will be treated with dual antiplatelet therapy (aspirin and clopidogrel) until 6 month follow-up. If device thrombus is present at 6 week TEE, patient will be transitioned to aspirin and adjusted-dose warfarin and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference. Subjects will have a 6 month follow-up visit prior to study completion. After study completion, patients may be treated with aspirin monotherapy according to the FDA instructions for use for the WATCHMAN device, or according to operator discretion.
2923148|NCT03088059|Experimental|Patient Cohort 1|Patients who are p16 negative and have an EGFR amplification/mutation or PTEN high or HER2 mutation/amplification will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care).
2923149|NCT03088059|Experimental|Patient Cohort 2|Patients who are p16 negative and cetuximab naïve will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
2923150|NCT03088059|Experimental|Patient Cohort 3|Patients who are p16 negative and have an amplification of CCND1 will be randomized between palbociclib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
2923151|NCT03088059|Experimental|Patient Cohort 4|Patients who are anti-PD(L)1-naïeve or resistant (primary or secondary resistance) will receive IPH2201 antibody (monalizumab).
2923152|NCT03088046|Other|Micronized Progesterone|Administration of 200 mg of vaginal Micronized Progesterone (100 mg every 12 hours) for a 7-day course
2923153|NCT03088033|Experimental|Treatment|Patients randomized to the treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and IASD System II implant procedure.
2923154|NCT03088033|Sham Comparator|Control|Patients randomized to the control arm will undergo ICE from the femoral vein or TEE for examination of the atrial septum and left atrium.
2923155|NCT03088007||IME attending ID children|Children with mild to moderate Intellectual Deficiency attending school at IME (Instituts Médico-Educatifs, which are special schools mandated to accommodate children and young people with Intellectual Disability at any level of disability).
2923156|NCT03088007||ULIS attending ID children|Children with mild to moderate Intellectual Deficiency attending school at ULIS (Unités Localisées pour l'Inclusion Scolaire, which enables disabled children to attend regular schools)
2923157|NCT03087994|Experimental|girls with obesity attending a dietary intervention|Participants in this group will attend 12 meetings of dietary interventions that will be guided by a dietician.
2923158|NCT03087994|Active Comparator|girls with obesity|participants in this group will only receive nutrition guidance twice during the study
2923159|NCT03087994|Active Comparator|girls with normal weight|participants in this group will only receive nutrition guidance twice during the study
2923160|NCT03087968|Experimental|GS-4997 + Prednisolone|"GS-4997 + Prednisolone for 28 days~HepQuant SHUNT Test"
2923161|NCT03087968|Placebo Comparator|Prednisolone + Placebo|"Placebo + Prednisolone for 28 days~HepQuant SHUNT Test"
2923162|NCT03087955|Experimental|SCYX-7158|SCYX-7158, in 320-mg tablets, administered by the oral route to patients in the fasting state according to the following dosing regimen: 960 mg (3 tablets) in a single intake on Day 1.
2923163|NCT03087942|Experimental|Group 1|ESRD patients
2923164|NCT03087942|Experimental|Group 2|healthy volunteers
2923165|NCT03087942|Experimental|Group 3|severe and moderate renal impaired patients
2923166|NCT03087942|Experimental|Group 4|mild renal impaired patients
2923167|NCT03087929||Treatment Arm|Patients who had previously undergone high dose therapy with stem cell support followed by consolidation with Rituximab and alpha-interferon as part of the trial Treatment of Follicular non-Hodgkin's Lymphoma with High Dose Therapy and Stem Cell Support Followed by Consolidative Immunotherapy with Rituximab and Alpha Interferon. The patients in this arm have consented to long-term follow up.
2923168|NCT03087903|Experimental|150 mg of Grape Seed Extract (GSE)|150 mg of GSE twice daily in the form of 75 mg capsule of Leucoselect Phytosome preparation.
2923169|NCT03087890|Active Comparator|Cotrimoxazole|Patients in the Cotrimoxazole study arm will receive 2 tablets daily of Cotrimoxazole (trimethoprim 80mg + sulfamethoxazole 400mg), these tablets are purchased locally in Tanzania, and are the same as used for pneumocystis preventive therapy under the National AIDS control programme.
2923170|NCT03087890|Placebo Comparator|Placebo|Participants in the Placebo arm will receive 2 placebo tablets daily. These tablets have been manufactured by Kragero Tablettproduksjon AS, Norway, and care has been taken to make them look as similar as possible to the locally purchased cotrimoxazole tablets from Tanzania. Neither study participants, care providers, investigators or outcome assessors will know which patients receive cotrimoxazole or placebo
2923171|NCT03087864|Experimental|Atezolizumab and Chemoradiation|Atezolizumab 1200 mg i.v. day 1-22-43-64-85 Carboplatin AUC = 2 i.v day 1-8-15-22-29 Paclitaxel 50 mg/m2 i.v day 1-8-15-22-29 Radiotherapy 23 x 1.8 Gy
2923172|NCT03087851|Active Comparator|6-month group|Zoledronic acid will be administered at study day 0. If s-CTX increases above 1.26 ug/l during the 2nd year a second infusion of zoledronic acid will be administered.
2923173|NCT03087851|Active Comparator|9-months group|"Zoledronic acid will be administered depending on increase in s-CTX (above 1.26 ug/l) or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 3.~If s-CTX increases above 1.26 ug/l during the 2nd year a second infusion of zoledronic acid will be administered."
2923174|NCT03087851|Active Comparator|Observation group|"Zoledronic acid will be administered depending on increase in s-CTX (above 1.26 ug/l), decrease in BMD (more than 5% at any site), or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 6.~If s-CTX increases above 1.26 ug/l during the 2nd year a second infusion of zoledronic acid will be administered."
2923175|NCT03087838||delirium group|CAM-ICU is positive within the first 24 hours after operation
2923176|NCT03087838||non-delirium group|CAM-ICU is negative within the first 24 hours after operation
2923177|NCT03087825|Sham Comparator|spontaneous breathing|preoxygenation through spontaneous breathing of 100% oxygen gas flow with or without an inward air leak
2923178|NCT03087825|Active Comparator|pressure support ventilation|preoxygenation through non invasive pressure support ventilation of 100% oxygen gas flow (inspiratory trigger sensitivity set at -2 l.min-1, the positive inspiratory support set at +6 cmH2O, the PEEP set at +5 cmH2O and the maximal airway pressure was limited at 15 cmH2O.) with or without an inward air leak
2923179|NCT03087799|Experimental|Brief Behavioral Treatment for Sleep|
2923180|NCT03087799|No Intervention|Wait List Control|
2923181|NCT03087786|Experimental|Nicotine Bitartrate 4mg Lozenge|Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
2923182|NCT03087786|Active Comparator|Nicotine Polacrilex 4mg Lozenge|Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
2923183|NCT03087773|Active Comparator|Empagliflozin|The subjects will receive Empagliflozin 10mg.
2923184|NCT03087773|Placebo Comparator|Placebo Oral Tablet|The subjects will receive placebo.
2923185|NCT03087760|Experimental|Single Arm|Single Arm, Open Label
2923186|NCT03087747||Group 1|Patients older than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).
2923187|NCT03087747||Group 2|Patients younger than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).
2923188|NCT03087734|Active Comparator|Perpendicular stabilizer|Implantation of regular bar with perpendicular stabilizers
2923189|NCT03087734|Experimental|Oblique stabilizer|Implantation of new model of bar with oblique stabilizers
2923190|NCT03087721|Experimental|1x2 HIIT-LV, 3 times a week, 24 min|
2923191|NCT03087721|Active Comparator|CAE, moderate intensity, 3 times a week, 36 min|
2923192|NCT03087708|Active Comparator|Group I (lower dose naloxegol, placebo)|Patients receive lower dose naloxegol PO QD and placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
2923193|NCT03087708|Active Comparator|Group II (placebo, higher dose naloxegol)|Patients receive placebo PO QD and higher dose naloxegol PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
2923194|NCT03087708|Placebo Comparator|Group III (placebo)|Patients receive placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
2923195|NCT03087669|Experimental|Observation of hemodynamic parameters|"LVAD flow velocity setting-Rounds Per Minute(RPM) intervention: Change of LVAD RPM while observing Central hemodynamic, echocardiographic and CBFV effects.~MAP intervention: Stepwise Change of MAP from 60-70-80 to 90 mmHg with a fixed set of LVAD RPM. After a 5 minute steady state for each level of MAP, the observations of central hemodynamics, echocardiographic measures and CBFV measurements will be repeated."
2923196|NCT03087656|Active Comparator|Antibiotic arm|The drugs ceftriaxone and levofloxacin will be administered to patients in the antibiotic arm.
2923197|NCT03087656|No Intervention|No Antibiotic arm|No prophylactic antibiotics will be administered.
2923198|NCT03087643|Experimental|Passive mobilization - PM|Participants will receive 2 times a day, for 5 days a week 30 minutes of passive leg movement treatment including knee flexo-extension in addition to their standard therapies.
2923199|NCT03087643|No Intervention|Control group - ctrl|Participants will receive ther standard therapies.
2923200|NCT03087630|Experimental|Reasoned-Based Intervention|Receives reason-based intervention.
2923201|NCT03087630|Experimental|Social-Based Intervention|Receives social-based intervention.
2923202|NCT03087630|Experimental|Integrated Intervention|Receives integrated intervention.
2923203|NCT03087630|Experimental|Attention Control|Receives attention control feedback.
2923251|NCT03087240|Experimental|Test|Dental Prophylaxis at fist visit (T0), after 2 weeks (T1) and after 3 months (T2)
2923204|NCT03087617|Active Comparator|Usual Care|Usual Care includes a lung cancer screening CT exam. Following the screen, a radiologist will analyze the CT scan image and send the results to the patient's Primary Care Physician (PCP). If the scan is read as a category 1 or 2 in the Lung Reporting and Data System (Lung-RADS), patients are provided a letter in the mail with their results. If the scan is read as a category 3, 4A, 4B, or 4X in Lung-RADS the patient will be contacted by their primary care physician's office and told to schedule a follow up appointment. Either in the letter or at the follow up appointment, patients will be given a Quitline number created specifically for this trial and maintained for the duration.
2923205|NCT03087617|Experimental|Usual Care + Imbio Smoking Cessation Report|In this arm, patients will receive the Usual Care described above and will additionally be provided with the Report. In this arm, the Report will provide the Quitline number.
2923206|NCT03087617|Active Comparator|Usual Care + Counseling|In addition to the Usual Care described above, patients in this arm will participate in a 45 minute smoking cessation counseling session. Approximately three Tobacco Treatment Specialists will be trained to ensure consistent counseling methodology. Counselors will utilize a patient centered approach grounded in Motivational Interviewing skills to elicit perceived benefits for stopping smoking and to enhance self-efficacy for stopping. A major emphasis of a call is to enroll the caller in formal cessation programs and/or convince them to use FDA approved medication as part of a quit attempt. Study participants who desire further smoking cessation support after their session will be connected with the appropriate organization.
2923207|NCT03087617|Experimental|Usual Care + Imbio Smoking Cessation Report + Counseling|In addition to the Usual Care and Counseling described above, patients in this arm will also receive the Report.
2923208|NCT03087604|Active Comparator|Traditional Technique Group|In the traditional loss of resistance technique group, the epidural catheter will be placed after achieving loss of resistance to air. After placement of the catheter a standard test dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine will be administered.Solution for Thoracic epidural block.
2923209|NCT03087604|Experimental|Electric Stimulation Group|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall. After placement of the catheter a standard test dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine will be administered.Solution for Thoracic epidural block.Thoracic epidural block with Electrical Nerve stimulation
2923210|NCT03087591|Experimental|Treatment (APN401)|Patients receive siRNA-transfected peripheral blood mononuclear cells APN401 IV over 30 minutes on days 1, 29, and 57 in the absence of disease progression or unacceptable toxicity.
2923211|NCT03087578|Experimental|EA|Patients undergoing electroacupuncture weekly for 6 weeks for 30 minutes/session.
2923212|NCT03087578|Active Comparator|Medication|Patients will receive 50 mg of mirabegron daily for 6 weeks. Patients may continue to take this medication after the study if they have improvement in symptoms.
2923213|NCT03087565|Active Comparator|subtotal hystrectomy|"Careful examination under anesthesia. Catheterization by N. 18 Foley's catheter . A transverse lower abdominal incision (Pfannenstiel incision) . the corpus is amputated just below the level of the isthmus and then the endocervical canal is electrocoagulated using monopolar electrocautery. The cervical stump is closed using vicryl 0 sutures.~Intraoperative antibiotics The abdomen is closed in layers; the wound is covered with a sterile dressing. All specimens were sent for pathological examination ."
2923214|NCT03087565|Active Comparator|Total hyterectomy|examination under anesthesia. Catheterization by N. 18 Foley's catheter A transverse lower abdominal incision (Pfannenstiel incision) The urinary bladder is dissected off the lower uterine segment of the uterus and cervix by blunt or sharp dissection. Blunt dissection is done . Sharp dissection using Metzenbaum scissors is performed in patients with previous cesarean sections Revision of all pedicles to ensure hemostasis. Intraoperative antibiotics The abdomen is closed in layers; the wound is covered with a sterile dressing. All specimens were sent for pathological examination .
2923215|NCT03087552||Transradial balloon aortic valvuloplasty|Consecutive patients with severe aortic stenosis and receiving as first attempt balloon aortic valvuloplasty by transradial access.
2923216|NCT03087539|Experimental|Clotinab (Abciximab)|0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours
2923217|NCT03087539|Placebo Comparator|Placebo|0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours
2923218|NCT03087526|Experimental|Couple at risk of transmitting a triplet-repeat disease|Expectant couple (pregnant woman between 9 and 34 weeks of gestation and her spouse) at risk of transmitting a triplet-repeat related genetic disease among Huntington disease, Myotonic Dystrophy type 1, Fragile X syndrome, Spinocerebellar Ataxia type 1, Spinocerebellar Ataxia type 2, Spinocerebellar Ataxia type 3
2923219|NCT03087513|Experimental|sugammadex|The study participants will receive a 10ml syringe containing sugammadex in the first phase, followed by placebo in the second phase.
2923220|NCT03087513|Placebo Comparator|Placebo|The study participants will receive a 10ml syringe containing placebo in the first phase, followed by sugammadex in the second phase.
2923221|NCT03087500||Down Syndrome (DS)|120 clinically confirmed full trisomy 21, age 3-50 years of both sexes will be recruited as the target study population. Half of the individuals (n=60) will be children (3-17 years of age) while half (n=60) will be adults (18-50 years of age)
2923222|NCT03087500||Typically Developing Controls|60 typically developing individuals age 3-50, age and gender matched to at least one participant with DS. Half of the controls (n=30) will be age and gender match to children with DS and half (n=30) will be age and gender matched to adults with DS.
2923223|NCT03087487||NVAF patients on Warfarin|NVAF patients newly initiated with Warfarin. Non-Interventional.
2923224|NCT03087487||NVAF patients on Apixaban|NVAF patients newly initiated on Apixaban. Non-Interventional.
2923225|NCT03087487||NVAF patients on Dabigatran|NVAF patients newly initiated with Dabigatran. Non-Interventional.
2923226|NCT03087487||NVAF patients on Rivaroxaban|NVAF patients newly initiated with Rivaroxaban. Non-Interventional.
2923227|NCT03087474||VKA patients|Vitamin K antagonist (VKA) patients
2923228|NCT03087474||NOAC patients|nonvitamin K antagonist oral anticoagulants (NOAC) patients
2923252|NCT03087240|Other|Control|Wait & Control Study Design: Dental Prophylaxis after 3 months (T2) only
2923696|NCT03084198|Experimental|Experimental group|Continuous treatment with the hiHep bioartificial liver support system.
2923229|NCT03087461|Experimental|Intervention Group|"The intervention group will receive a multi-component KT intervention. This will include exercise and self-management components.~The exercise intervention will involve a moderate intensity aerobic exercise program, using recumbent bikes, delivered within the cancer institution. Participants will take part in the 30-minute sessions 8 times. The intervention will be supervised by a physiotherapist (PT) educated in cancer rehabilitation.~The SM component will include educational modules created by a PT. Participants will view these 30 minute modules prior to each exercise intervention, over the same 8 sessions."
2923230|NCT03087461|No Intervention|Usual Care|Control group receiving usual care (no exercise or self-management education within the institution).
2923231|NCT03087448|Experimental|Ceritinib + Trametinib|"PHASE 1 Standard 3+3 dose escalation starting at dose level 1. Patients with ALK-rearranged, or ROS-1 rearranged NSCLC. 6-18 patients will be enrolled.~Ceritinib dose: 300-450mg orally, once daily over 28 day cycles. Trametinib dose: 1.5mg-2.0mg orally, once daily over 28 day cycles.~PHASE II Cohort A (ALKi Naïve): those who have had no prior ALK inhibitor therapy (prior chemotherapy or immunotherapy is allowed). Aim 20 evaluable patients.~Cohort B (Post-crizotinib PD): those who have received prior treatment with crizotinib and documented disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Aim 21 evaluable patients.~Cohort C (PD on 2nd generation ALKi): those who have received prior treatment with 2nd generation ALKi (e.g. ceritinib, alectinib, loratinib, or brigatinib) and documented disease progression by RECIST 1.1 criteria. Aim 10 evaluable patients.~The Phase II doses will be determined by Phase I dose escalation study"
2923232|NCT03087422|Experimental|intervention|"The patients in this group will receive daily a text message (SMS) with some orientation about Homecare as an attempt to minimize the side effects of chemotherapy.~The text messages are based on oncology guidelines.The text messages contain information about water intake, emotional support, hygiene, immunity, nutrition, and physical activity. In addition, text messages about prevention and management of symptoms were also developed: nausea and vomiting, diarrhea, constipation, gas, changes in the skin and taste.~Also, the patients allocated in this group will receive the standard care."
2923233|NCT03087422|No Intervention|control|The patients allocated in this group will receive the standard care.
2923234|NCT03087383||Prospective Cohort|In adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm, investigator will collect data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions. Data collection will be established with just observing and recording values displayed in screens of monitoring devices, and reviewing patient charts.
2923235|NCT03087383||Retrospective Cohort|In previous study performed in adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm (NCT02700126, 4-2015-1195), investigator enrolled patients and collected data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions.
2923236|NCT03087357||Low Risk|The Low Risk group will consist of 2,400 pregnancies with no high risk findings (e.g., abnormal ultrasound, positive serum screen) who are undergoing initial clinical cfDNA screening. To simulate a general pregnancy population, approximately 20% of these women will be age 35 and older. An estimated 2% (48) of these LR women will have a failed/no call cfDNA test. Consenting women will provide samples for SmartNIPT testing.
2923237|NCT03087357||High Risk|The High Risk group will consist of 250 women with a positive cfDNA screen reported by a Clinical Laboratory Improvement Amendments (CLIA)-approved commercial laboratory, and who present for consideration of a confirmatory diagnostic test, (i.e., CVS or amniocentesis). Consenting women will provide samples for SmartNIPT testing.
2923238|NCT03087344|Experimental|Chronic liver disease|patient who will undergo liver biopsy will undergo liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
2923239|NCT03087331|Experimental|Pharmacist intervention|Within the pharmacist intervention arm, pharmacists will do medication reviews, assessment, recommendations, education.
2923240|NCT03087318|Experimental|Rehabilitation medical center|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~during 3 months."
2923241|NCT03087318|Experimental|Private sport club|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~during 3 months."
2923242|NCT03087318|Experimental|Sport association|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~during 3 months."
2923243|NCT03087305||1|All patients age 20yrs or greater referred for EBUS-TBNA with suspicion for primary lung cancer
2923244|NCT03087292|Active Comparator|Resistance training group|"Patients to be randomly assigned to the resistance training group will have resistance training with vascular occlusion 2 times per week for a period of 8 weeks on unilateral leg extension machine. During each training, they will performed 3 sets of 15 repetitions at the intensity of 30% 1 RM (repetition maximum). Each training set will separated by a 30 second rest period."
2923245|NCT03087292|No Intervention|Control group|Patients to be randomly assigned to the control group (normal physical activity) will continue with their usual physical activity regime.
2923246|NCT03087279|Experimental|Texas I-CAN Active Math Lessons|Texas I-CAN Active math lesson in academic classroom
2923247|NCT03087279|Experimental|Texas I-CAN Active Language Arts Lessons|Texas I-CAN Active language arts lessons in academic classroom
2923248|NCT03087279|No Intervention|Control|Regular, Sedentary academic lessons in math and language arts
2923249|NCT03087266|Experimental|Full- Mouth Scaling and Root Planing|FM-SRP Non-surgical periodontal treatment will be performed in all dentition within 24 hours.
2923250|NCT03087266|Active Comparator|Quadrant Scaling and Root Planing|"Q-SRP Non-surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed with one week interval. In each appointment only a quadrant of the dentition will be instrumented."
2923253|NCT03087227|Experimental|NEUTROSIS Intervention Group|The NEUTROSIS Intervention group captures daily its temperature and the occurrence of other symptoms on the smartphone application. This information is then transmitted instantly to the hospital care team through the NEUTROSIS shared information system. The medical oncologist will be alerted in case of fever and will contact the patient.
2923254|NCT03087227|No Intervention|CONTROL Group|The control group will monitor daily its temperature and the occurrence of other symptoms on a paper surveillance diary and will have to contact the health team in case of fever as done in the usual care.
2923255|NCT03087201|Experimental|nabiximols, oromucosal spray|1-12 puffs nabiximols / day, Duration of treatment: 13 weeks
2923256|NCT03087201|Placebo Comparator|placebo, oromucosal spray|1-12 puffs placebo / day, Duration of treatment: 13 weeks
2923257|NCT03087188||Utilization of inhalator|Film sequences will be shown to patients using incorrect application technique in order to improve technique. Learning success will be assessed subsequently and at a follow-up visit after 2-8 weeks
2923258|NCT03087175|Experimental|MGuard stent|MGuard stent is a novel thin-strut metal stent with a polyethylene terephthalate micronet covering designed to trap and exclude thrombus and friable atheromatous debris to prevent distal embolization
2923259|NCT03087175|Active Comparator|Drug eluting stent and bare metal stent|Drug eluting stent and bare metal stent
2923260|NCT03087162|Experimental|Once daily dose dexlansoprazole|Group 1 Dexlansoprazole 60 mg by oral once daily for 14 days (Levofloxacin 500 mg by oral once daily for 14 days Amoxicillin 1000 mg by oral bid for 14 days Bismuth 1048 mg by oral bid for 14 days)
2923261|NCT03087162|Active Comparator|Twice daily dose dexlansoprazole|Group 2 Dexlansoprazole 60 mg oral bid 14 Days (Levofloxacin 500 mg od oral 14 Days Amoxicillin 1000 mg bid oral 14 Days Bismuth 1048 mg bid oral 14 Days)
2923262|NCT03087149|Experimental|monitored group|The monitored group will received monitored vit D supplementation
2923263|NCT03087149|Active Comparator|standard group|The standard group will receive standard vit D supplementation
2923264|NCT03087123|Active Comparator|2-Week Baseline|Families will be randomized to a 2-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
2923265|NCT03087123|Active Comparator|4-Week Baseline|Families will be randomized to a 4-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
2923266|NCT03087123|Active Comparator|6-Week Baseline|Families will be randomized to a 6-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
2923267|NCT03087110|Experimental|Cord blood infusion|Matched sibling donor cord blood cell infusion
2923268|NCT03087097|Experimental|Fecal Microbiota Transplant|FMT by enema: 10mL/kg (maximum 150mL) of donor fecal material will be infused.
2923269|NCT03087097|Placebo Comparator|Placebo|Placebo by enema: 10mL/kg (maximum 150mL) of placebo material will be infused.
2923270|NCT03087084|Experimental|Cardiac Pacing and Impedance Measurement system|
2923271|NCT03087071|Experimental|Cohort 1|"Cohort 1 comprised of patients with detectable EGFR S492R or other ectodomain mutations in circulating free tumor DNA.~Participants receive Panitumumab until disease progression.~If the disease appears to get worse, participants may be able to cross-over to group 2 and begin to receive the panitumumab and trametinib combination therapy."
2923272|NCT03087071|Experimental|Cohort 2|"Cohort 2 comprised of patients with detectable KRAS or NRAS mutations in exons 2, 3, or 4; or BRAF codon 600 mutations in circulating free tumor DNA.~Participants receive Panitumumab and Trametinib combination therapy until disease progression."
2923273|NCT03087071|Experimental|Cohort 3|"Cohort 3 comprised of patients who do not have any of the detectable mutations listed in Cohort 1 or 2.~Participants receive Panitumumab until disease progression.~If the disease appears to get worse, participants may be able to cross-over to group 2 and begin to receive the Panitumumab and Trametinib combination therapy."
2923274|NCT03087058|Experimental|Cohort 1|Patiromer for age 12 ‒ < 18 years
2923275|NCT03087058|Experimental|Cohort 2|Patiromer for age 6 ‒ < 12 years
2923276|NCT03087058|Experimental|Cohort 3|Patiromer for age 2 ‒ < 6 years
2923277|NCT03087032|Experimental|Liraglutide|Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
2923278|NCT03087032|Active Comparator|Insulin Glargine|Patients will receive adding insulin Glargine to prandial insulin Lispro.Dose of insulin will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.
2923279|NCT03087019|Experimental|Pembrolizumab + Radiation|"Up to 5 metastatic lesions targeted with radiation~Over 5 fractions starting within 7 calendar days following the first dose of pembrolizumab~Pembrolizumab will be administered on day 1 of each 21day cycle~Pembrolizumab is delivered intravenously"
2923280|NCT03087019|Experimental|Pembrolizumab|"Pembrolizumab will be administered on day 1 of each 21day cycle~Pembrolizumab is delivered intravenously"
2923304|NCT03086850|Active Comparator|Conventional management|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
2924796|NCT03076827|Experimental|Group P|Group to begin surgery(total hip replacement or hip hemi-arthroplasty) in the afternoon
2923281|NCT03087006|Active Comparator|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) may help with depression, anxiety, stress, PTSD, and may have a positive impact on quality of life of participants diagnosed with dry eye disease. ASTM is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.
2923282|NCT03087006|Placebo Comparator|Treatment as Usual (TAU)|Participants continue to receive treatment as usual including dry eye disease medications.
2923283|NCT03086993|Experimental|Melphalan/PHP|Patients may receive up to 6 treatments of Melphalan/HDS 3.0 mg/kg IBW. Each treatment cycle consists of 6 weeks with an acceptable delay for an additional 2 weeks (i.e. 8 weeks in total). The maximum dose of melphalan will be 220 mg per treatment.
2923284|NCT03086993|Active Comparator|Cisplatin and Gemcitabine|Each Cis/Gem treatment cycle will comprise cisplatin, dosed at 25 mg per square meter of body surface area, and gemcitabine, dosed at 1000 mg per square meter of body surface area. Each will be administered on Days 1 and 8 every 3 weeks.
2923285|NCT03086980|Active Comparator|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.Research suggests that ASTM may help reduce depression and anxiety.
2923286|NCT03086980|Placebo Comparator|Treatment as Usual (TAU)|The usual standard of care for patients with glaucoma includes starting them on first line of drugs. Participants will be initiated and maintained on appropriate dosages of such medications as part of standard of care. The usual standard of care also includes an ophthalmic examination measuring best-corrected Snellen VA and pinhole acuities and a follow-up visit once a year.
2923287|NCT03086967|Active Comparator|Six Hour|Placement of foley catheter and extrusion after 6 hours followed by induction.
2923288|NCT03086967|Active Comparator|Twelve Hour|Placement of foley catheter and extrusion after 12 hours followed by induction.
2923289|NCT03086954|Experimental|single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:The first day,the second day,29 days,injection once a day in this three days Duration:Only injection three times
2923290|NCT03086941|Active Comparator|Group B(blibd)|group B (blind); an appropriate size endotracheal tube will be introduced through I-gel blindly. Only smooth intubation without force together with manoeuvres necessary to correct the position of tracheal tube will be allowed. Only one attempt of blind intubation is allowed to avoid airway injury. Any resistance to first attempt tube insertion will indicate failure of blind tube insertion.
2923291|NCT03086941|Active Comparator|Group C(control)|group C (control), a paediatric fibrescope will be primed with an appropriate size tracheal tube. The fibrescope will be introduced through I-gel and guide tracheal intubation. After insertion of tube and confirmation of position, the fiberscope will be removed
2923292|NCT03086928|Experimental|lava ultimate|lava ultimate is Resin nano-ceramic which is a mixture of a resin composite matrix and nano-ceramic fillers of approximately 80% by weight. The main advantages of this material over the glass ceramics are the stress absorbing action or stress distribution by having modulus of elasticity near to the tooth dentin and can be individualized intra-orally or extra-orally, either before or after definitive cementation.
2923293|NCT03086928|Active Comparator|E.max cad|E.max is lithium disilicate glass ceramic, composed of quartz, lithium dioxide, phosphor oxide, alumina oxide, and potassium oxide with superior mechanical and optical properties if used for laminate veneers
2923294|NCT03086915||Patients with neuromuscular block|Neuromuscular blocking agent administrated during surgery to the paediatric patient
2923295|NCT03086902|Experimental|Cryo Ablation|PVCs will be mapped and ablated with a Cryo Ablation catheter
2923296|NCT03086902|Active Comparator|Radiofrequency Ablation|In this arm PVCs will be mapped and ablated with a Radiofrequency Ablation catheter
2923297|NCT03086889|Experimental|The intervention group|The intervention group will participate in immersion virtual reality based rehabilitation training for 3 weeks.
2923298|NCT03086889|Other|The control group|The control group will receive for traditional rehabilitation training for 3 weeks.
2923299|NCT03086876|Experimental|Stepping Stones Triple P|Trained practitioners will deliver Level 4 SSTP to parents in 6 weekly group sessions and will also provide 3 telephone of face to face contacts to each participant but they will not be involved in routine care for participants in either arm. Each therapist responsible for delivering SSTP will be trained in the Group Stepping Stones Training and Accreditation programme which includes three training days and a further half day accreditation workshop after 6 weeks. The group sessions not only educate but actively train the parents in skills and the individual consultations aim to facilitate independent problem solving. The learning objectives focus on maintaining behavioural change, using skills within a group learning environment, learning from peers in the group and sharing difficulties or achievements, providing support, considering if more intensive work is required, referring further if needed, talking about risk and protective factors operating within families.
2923300|NCT03086876|No Intervention|Treatment as usual|"TAU will be available to participants in both arms of the trial. It may include a range of services such as:~1. Health visitor services; 2. Primary care engagement and advice; 3. Potentially some version of early intervention maybe provided by either community paediatric services or Child and Adolescent Mental Health Services, although our understanding is that very little is available for children of this age. 4. Parenting advice and support sessions by carers groups or other third sector organisations.~Parents allocated to TAU will receive a list of national and local resources and the Contact a Family guide to challenging behavior with tips and advice on social and health care supports."
2923301|NCT03086863|Experimental|verum electroacupuncture|"Electroacupuncture on LI4, LI15, TE14, SI9, SI11, and GB21, unilaterally~Needle insertion by 10-15 mm and de qi sensation~Park sham guide tubes~Low frequency electronic stimulation (30 Hz)~Retention for 20 minutes."
2923302|NCT03086863|Sham Comparator|sham electroacupuncture|"Park sham device on on LI4, LI15, TE14, SI9, SI11, and GB21, unilaterally~Needle installation without penetration~Park sham guide tubes~Low frequency electronic stimulation (30 Hz) for a fake noise without conduction~Retention for 20 minutes."
2923303|NCT03086850|Experimental|Pedometer|Standard recommendations on healthy habits and lifestyle plus daily recording of steeps with a pedometer
2923305|NCT03086837|Experimental|Mobile phone based intervention|Participants in the intervention group will receive a 12 week mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to increase active transportation. Feedback will be provided on personal goals.
2923306|NCT03086837|No Intervention|Control|No information
2923307|NCT03086824|Experimental|MRgFUS|Patients with painful bone metastases receiving magnetic resonance-guided focused ultrasound treatment.
2923308|NCT03086811|Experimental|intervention group|First time mothers, when infants were ages 4-6 months old, took part in a training program in small group setting (10-12 mother-infants). the program continued for a month, with 4 weekly meetings. group coordinators were a highly experienced pediatric dietitian, and a social worker. Training topics addressed were infant healthy nutrition and growth, feeding skills, obesity and emotional feeding prevention, parenting. Thereafter, mothers were encouraged to stay in contact with the trainers, till infants reached age 12 months and data was collected using video taping of mealtime feeding interactions at home setting environment. Mother Infant Feeding Interaction very early training
2923309|NCT03086811|No Intervention|control group|Control group first time mothers were recruited when infants were around 11-12 months of age for data collection of mealtime feeding interactions taping at home setting environment. They received during this year the official support and training given in municipality care centers.
2923310|NCT03086798|Experimental|Magill forceps|experimental Magill forceps group: Magill forceps technique to facilitate nasotracheal tube advancement into trachea
2923311|NCT03086798|Experimental|cuff inflation|experimental cuff inflation group: cuff inflation technique to facilitate nasotracheal tube advancement into trachea
2923312|NCT03086785|Experimental|apatinib|apatinib 500mg qd po or combined Capecitabine 1000mg/m2 bid d1-d14 q3w
2923313|NCT03086772|Experimental|Tai Chi|Individuals in the Tai Chi intervention group participated in a 12-week Tai Chi program.
2923314|NCT03086772|Active Comparator|Light Exercise|Individuals in the exercise control group performed a 12-week light exercise program.
2923315|NCT03086759|Experimental|Platelet rich plasm group|
2923316|NCT03086759|Active Comparator|Triamcinolone Hexacetonide group|
2923317|NCT03086759|Placebo Comparator|Isotonic Saline Solution group|
2923318|NCT03086733|Experimental|Metformin|14 to 21 days of pre-operative Metformin tablets First 5 days 850 mg OD v/o 850 mg BID thereafter until 21 days are completed.
2923319|NCT03086720|Experimental|Sodium hypochlorite|Dentin pre-treatment with a experimental solution (sodium hupochlorite), after the dentin acid etching
2923320|NCT03086720|Placebo Comparator|Water|Application of water (placebo) after dentin acid etching
2923321|NCT03086707|Active Comparator|Cigarette smokers|"Subjects who have smoked at least 20 cigarettes per day for at least the past 5 years.~Subjects will be allowed to use their own brand of non-menthol cigarettes. There will be no smoking restriction after the discharge at Visit 3 and during the 1 day follow-up period."
2923322|NCT03086707|No Intervention|Never smokers|"Subjects who have smoked less than 100 cigarettes throughout their lifetime and no cigarettes in the past 3 years.~Subjects will not be allowed to smoke until discharge at Visit 3."
2923323|NCT03086694||group surgery|using medications to maintain low stable blood pressure
2923324|NCT03086681|Experimental|concurrent chemoradiotherapy + endostar|4 cycles of Endostar and 5 cycles of DDP concurrent with radiotherapy
2923325|NCT03086681|Active Comparator|concurrent chemoradiotherapy|5 cycles of DDP concurrent with radiotherapy
2923326|NCT03086668|Experimental|Conventional Jaw thrust Group|an assembly of video-stylet and double curve endotracheal tube with conventional jaw thrust technique to facilitate nasotracheal intubation
2923327|NCT03086668|Experimental|Fingers hook Group|an assembly of video-stylet and double curve endotracheal tube with fingers-hook technique to facilitate nasotracheal intubation
2923328|NCT03086655|Experimental|Tel-me-box with reminder features|Participants randomly assigned to the intervention reminder condition will choose from the reminders available and convey their preferences regarding when reminders should be sent for the tel-me-box device.
2923329|NCT03086655|Other|Tel-me-box with no reminder features|The control arm will include tel-me-box monitoring only. No reminder features will be included with the device.
2923330|NCT03086642|Experimental|T-Vec|All enrolled patients will receive a test dose of talimogene laherparepvec (10^6 PFU/ml) on day 1, followed by treatment doses at escalating concentrations weeks 4, 7, and 10. A biopsy will be obtained during each scheduled endoscopy prior to talimogene laherparepvec injection.
2923331|NCT03086629|Other|PCI Group|Participants who are patients of consultants randomized to this group will use the PCI during clinics.
2923332|NCT03086629|Other|Non PCI Group|Participants who are patients of consultants randomized to this group will not use the PCI during clinics.
2923333|NCT03086616|Experimental|Newly Diagnosed DIPG|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI): Nal-IRI given directly into the tumor using a method called CED to newly diagnosed DIPG subjects after completion of radiotherapy. CED will be performed every 4-6 weeks. Drug concentration will start at 20mg/ml and escalate up to 40 mg/ml concentration.
2923334|NCT03086590||Group 1|COPD mild. The individuals allocated to this group have FEV1 ≥ 80% predicted.
2923335|NCT03086590||Group 2|COPD Moderate. The individuals allocated to this group have 50% ≤ FEV1 < 80% predicted.
2923336|NCT03086590||Group 3|COPD Severe. The individuals allocated to this group have 30% ≤ FEV1 < 50% predicted.
2923337|NCT03086590||Group 4|COPD Very severe. The individuals allocated to this group have FEV1 < 30% predicted.
2923338|NCT03086564|Experimental|ADCC & TACE|"The first course :~Patients in the first day of a clinical course will be performed TACE solely and keep 40ml blood sample as baseline sample for scientific research;in the 17th day, 10ml blood will be taken to culture activated dendritic cells;in 29th day, cyclophosphamide(CY) 250mg/m2 is used through an intravenous drip;in 31th day,patients are going to be performed TACE,1-2*10^8 activated dendritic cells are dripped through peripheral vein, 40ml blood sample will be taken for clinical research, simultaneously.~The 31th day in the first course is the same as the first day of the second course, then we come to next therapy course.~31 days are a course of treatment, health conditions of patients who participate in will be monitored closely in the process. After previous 3-courses followed-up period, one course will be changed into 93 days."
2924877|NCT03076177|Experimental|Kinesio taping group|Participants receiving kinesio taping application
2923339|NCT03086564|Active Comparator|TACE|"Every course:~In the first day,patients are performed TACE solely and taken 40ml blood as baseline sample for scientific research;in the 29th day,patients are needed to reach hospital to check related indicators. In the 31th day, patients are performed TACE again.~The 31th day is the same as the first day in the second course.~31 days are a course of treatment, health conditions of patients who participate in will be monitored closely in the process. After previous 3-courses followed-up period, one course will be changed into 93 days."
2923340|NCT03086551|Experimental|Experimental|Application of active continuous theta burst stimulation over dorsolateral prefrontal cortex prior to upper limb motor practice.
2923341|NCT03086551|Placebo Comparator|Control|Application of sham continuous theta burst stimulation over dorsolateral prefrontal cortex prior to upper limb motor practice.
2923342|NCT03086538|Experimental|Pemetrexed+Tarceva|Pemetrexed 500 mg/m2 IV Q 3 weeks Tarceva 100mg once daily, continous
2923343|NCT03086525||Musculoskeletal pain|Participants Healthy male and female students, students of the University of Málaga, will be recruited. . The inclusion criteria are as follows: (i) men / women over 18 years; (ii) students of the University of Málaga.
2923344|NCT03086512|Active Comparator|Group I|Group I consists of 45 patients receiving a subtalar fusion with the Acutrak 2® - Fully Threaded Screw.
2923345|NCT03086512|Sham Comparator|Group II|Group II consists of 45 patients receiving a subtalar fusion with the Partially Threaded Synthes® 7.3 Cannulated Screw.
2923346|NCT03086499||The study population|Patients with pectus excavatum having consulted at the Montpellier University Hospital and who have had corrective surgery.
2923347|NCT03086486|Experimental|1200mg L x 26 weeks + Pa + B + 300 mg placebo|"2 linezolid 600 mg active tablets once daily for 26 weeks plus 1 placebo linezolid 300 mg half tablet once daily for 26 weeks plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
2923348|NCT03086486|Experimental|1200 mg L x 9 weeks + Pa + B + 300 mg placebo|"2 linezolid 600 mg active tablets once daily for 9 weeks, 1 placebo linezolid 300 mg half tablet once daily for 9 weeks (for Weeks 1-9); 2 placebo linezolid 600 mg tablets once daily for 17 weeks, 1 placebo linezolid 300 mg half tablet once daily for 17 weeks (for Weeks 10-26) plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
2923349|NCT03086486|Experimental|600 mg L x 26 weeks + Pa + B + 300 mg placebo|"1 linezolid 600 mg active tablet once daily for 26 weeks, 1 placebo linezolid 600 mg tablet once daily for 26 weeks, 1 placebo linezolid 300 mg half tablet once daily for 26 weeks plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
2923350|NCT03086486|Experimental|600 mg L x 9 weeks + Pa + B + 300 mg placebo|"1 linezolid 600 mg active tablets once daily for 8 weeks, 1 placebo linezolid 600 mg half tablet once daily for 9 weeks, 1 placebo linezolid 300 mg half tablet once daily for 9 weeks (for Weeks 1-9); 2 placebo linezolid 600 mg tablets once daily for 17 weeks, 1 placebo linezolid 300 mg half tablet once daily for 17 weeks (for Weeks 10-26) plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
2923351|NCT03086473|Other|Caffeine|Participant will receive caffeine citrate 20mg/kg IV within 2 hours of life and placebo (normal saline IV) at 12 hours of life. Both infusions will be of identical volumes and appearance, and will be administered over 30 minutes.
2923352|NCT03086473|Other|Placebo|Participant will receive placebo (normal saline IV) within 2 hours of life and caffeine citrate 20mg/kg IV at 12 hours of life. Both infusions will be of identical volumes and appearance, and will be administered over 30 minutes.
2923353|NCT03086460|Experimental|Treatment A|CHF 1531 pMDI Dose 1
2923354|NCT03086460|Experimental|Treatment B|CHF 1531 pMDI Dose 2
2923355|NCT03086460|Experimental|Treatment C|CHF 1531 pMDI Dose 3
2923356|NCT03086460|Experimental|Treatment D|CHF 1531 pMDI Dose 4
2923357|NCT03086460|Experimental|Treatment E|Matched placebo
2923358|NCT03086460|Active Comparator|Treatment F|Formoterol fumarate inhalation solution, 20μg
2923359|NCT03086447|Experimental|Experimental: Participating Subjects|Subjects who are habitual soft toric contact lens wearers, aged 18 to 40 years of age, will be dispensed the investigational contact lens to be worn from 28-36 days, to include a total of 5 visits.
2923360|NCT03086447|Active Comparator|Control: Participating Subjects|Subjects who are habitual soft toric contact lens wearers, aged 18 to 40 years of age, will be dispensed marketed contact lens to be worn from 28-36 days, to include a total of 5 visits.
2923361|NCT03086434|Experimental|Culturally tailored intervention|The participants of the experimental condition will receive the intervention in a talking circle format. They will meet for 10 weekly 50 minute sessions.
2923362|NCT03086434|Active Comparator|Standard Substance Abuse Education|The control condition participants are assigned to the standard substance abuse education program which is delivered in a classroom format format. They will meet for 10 weekly 50 minute classroom sessions.
2923363|NCT03086421||Brain Tumor Participants|Participants with a diagnosis of brain tumor who are between the ages of 4 and 6 years old and are 6 to 12 months post-completion of treatment. They will complete several standard questionnaires.
2925371|NCT03072706|Experimental|Corin OPS™|Corin Optimised Positioning System (OPS) Dynamic Hip Analysis
2923364|NCT03086421||Solid Tumor Participants|Participants with a diagnosis of non-Central Nervous System (non-CNS) solid tumor who are between the ages of 4 and 6 years old and are 6 to 12 months post-completion of treatment. They will complete several standard questionnaires.
2923365|NCT03086408|Experimental|THRIVE|high flow nasal oxygen
2923366|NCT03086408|Active Comparator|endotracheal tube or supraglottic airway|tracheal intubation or supraglottic airway device
2923367|NCT03086395|Experimental|Obinutuzumab|Patients will be treated with a total of 2 cycles of obinutuzumab.
2923368|NCT03086382|Experimental|Treatment A - B|Single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions
2923369|NCT03086382|Experimental|Treatment B - A|Single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg) under fasting conditions
2923370|NCT03086369|Experimental|Olaratumab + Nab-paclitaxel + Gemcitabine (Dose Escalation)|(Open Label) Olaratumab, nab-paclitaxel and gemcitabine given intravenously (IV).
2923371|NCT03086369|Experimental|Olaratumab + Nab-paclitaxel + Gemcitabine (Cohort Expansion)|(Open Label) Olaratumab, nab-paclitaxel and gemcitabine given IV.
2923372|NCT03086369|Experimental|Olaratumab + Nab-paclitaxel + Gemcitabine (Treatment)|(Double Blind) Olaratumab, nab-paclitaxel and gemcitabine given IV.
2923373|NCT03086369|Placebo Comparator|Placebo + Nab-paclitaxel + Gemcitabine|(Double Blind) Placebo, nab-paclitaxel and gemcitabine given IV.
2923374|NCT03086356|Experimental|All Subjects|Dabigatran etexilate alone (days 1-4) and (days 8-10) and with Idarucizumab (day 11)
2923375|NCT03086343|Active Comparator|Abatacept followed by upadacitinib|Intravenous (IV) infusion of abatacept at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20 followed by upadacitinib starting at week 24 up to 5 years.
2923376|NCT03086343|Experimental|Upadacitinib|Once daily for 24 weeks during Period 1 and up to 5 years during Period 2.
2923377|NCT03086330|Experimental|Semaglutide|
2923378|NCT03086330|Placebo Comparator|Placebo|
2923379|NCT03086317|Active Comparator|Standard Catheter-Directed Thrombolysis|Participants randomized to this arm will receive standard catheter-directed thrombolysis, per standard of care, as treatment for acute submassive pulmonary embolism.
2923380|NCT03086317|Active Comparator|Ultrasound-Accelerated Thrombolysis|Participants randomized to this arm will receive ultrasound-accelerated thrombolysis, per standard of care, as treatment for acute submassive pulmonary embolism.
2923381|NCT03086304|Experimental|TEAS group|Choose several acupoints,give 2/10 hz dilatational wave stimulation.Complete the 30 minutes intervention after extubation and 1-3 days after surgery.Give a health education on the first postoperative day.
2923382|NCT03086304|Experimental|no TEAS group|The choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation,the others steps are same with TEAS group.
2923383|NCT03086291|Experimental|simvastatin|One arm Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days Cohort 1: 7.5 mg/kg bid for 7 days 14 days off Cohort 2: 10 mg/kg bid for 7 days 14 days off Cohort 3: ( ) mg/kg bid for 7 days 14 days off (to be determined based on PK data of cohort 1 and 2) Q 3 weeks
2923384|NCT03086278|Experimental|Part 1 - SAD Portion|
2923385|NCT03086278|Experimental|Part 2 - MAD Portion|
2923386|NCT03086265|Experimental|THRIVE|high flow nasal oxygen
2923387|NCT03086265|Active Comparator|Endotracheal tube|tracheal intubation
2923388|NCT03086252|Experimental|Supportive care (patient-driven RBCT)|Patients undergo red blood cell transfusions (RBCT) based on their perception and/or the presence of anemia symptoms for up to 6 months.
2923389|NCT03086239|Experimental|Part A: Rovalpituzumab tesirine|Part A Dose Escalation: Rovalpituzumab tesirine intravenous (IV) (various doses and dose regimens) on Day 1 of each 6-week cycle
2923390|NCT03086239|Experimental|Part B: Rovalpituzumab tesirine|Part B Dose Expansion: Rovalpituzumab tesirine dosed at regimen(s) previously demonstrated in Part A to not to exceed the maximum tolerated dose (MTD).
2923391|NCT03086226|Experimental|Fosravuconazole 300 mg|"Given throughout the study for 12 months as the experimental arm.~Both experimental arms will be evaluated at 3 months. At this time-point, one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity."
2923392|NCT03086226|Experimental|Fosravuconazole 200 mg weekly|"Given throughout the study for 12 months as the experimental arm.~Both experimental arms will be evaluated at 3 months. At this time-point, one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity."
2923393|NCT03086226|Active Comparator|Itraconazole 400mg daily|Given throughout the study for 12 months as the comparator arm.
2923394|NCT03086213|Experimental|paravertebral nerve block group|non-intubated thoracic paravertebral nerve block of regional anesthesia Thoracic paravertebral nerve block of regional anesthesia at the T4 thoracic interspace
2923395|NCT03086213|Active Comparator|intercostals nerve block group|non-intubated intercostal nerve block of regional anesthesia Thoracic intercostal nerve block of regional anesthesia at the T3/4/5 thoracic interspace
2923396|NCT03086200|No Intervention|iTAB + SOC Control Arm|Participants will receive PrEP and standard of care (SOC) including health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psychosocial barriers, and adherence counseling. In addition to SOC, participants will receive daily text messages (iTAB) as reminders for medication adherence. Text messages will be setup during the Baseline visit in coordination with the participant's preferences.
2923397|NCT03086200|Experimental|iTAB + MI-b Intervention Arm|Participants will receive the same PrEP, SOC procedures, and iTAB support as that of the Control Arm. Participants in the Intervention Arm will also receive brief motivational interviewing counseling sessions if adherence becomes suboptimal. Adherence will be monitored by responses to the iTAB system; if Intervention Arm participants reply with 3 consecutive negative or non-responses, MI-b counselors will perform 15-minute over-the-phone motivational interviewing counseling sessions with the participant.
2923457|NCT03085758|Experimental|Treatment Arm B|Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab (treatment arm B)
2923398|NCT03086187|Other|Hephaistos unloading orthosis|Hephaistos unloading orthosis: Calf muscle unloading: The 11 male subjects had to wear a novel orthosis for 8 weeks, which greatly reduces plantarflexor forces during gait.
2923399|NCT03086174|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg Q2w PLUS axitinib 5 mg orally Q2w until disease progresses or unacceptable tolerability occurs
2923400|NCT03086161|Active Comparator|Treatment-as-usual|Treatment-as-usual alone provided in the context of a multi-disciplinary teen pregnancy clinic providing wrap-around medical, nutrition, and social work care.
2923401|NCT03086161|Experimental|Interpersonal Psychotherapy|Treatment-as-usual plus a six-session interpersonal psychotherapy program delivered as individual sessions by a trained facilitator every 2-3 weeks throughout pregnancy.
2923402|NCT03086148|Experimental|ketamine group|
2923403|NCT03086148|Placebo Comparator|normal saline group|
2923404|NCT03086135|Experimental|Bone-conduction hearing device|The bone-conduction hearing device Osia system allows a direct bone-conduction through an osseointegrated implant. A magnet allows the external Sound Processor to be placed in the correct position over the implanted system including an inner magnet.
2923405|NCT03086122|No Intervention|Obstructive Sleep Apnea (OSA)|OSA patients without erectile dysfunction (ED).
2923406|NCT03086122|No Intervention|OSA + ED|OSA patients with erectile dysfunction diagnosis who are randomly allocated to not receive continuous positive airway pressure (CPAP).
2923407|NCT03086122|Experimental|OSA + ED + CPAP|OSA patients with erectile dysfunction diagnosis who are randomly allocated to receive CPAP.
2923408|NCT03086083|Experimental|EMDR standard protocol|Standard EMDR protocol, once.
2923409|NCT03086083|Active Comparator|protocol without brain stimulation|Standard EMDR protocol without brain stimulation, once
2923410|NCT03086070|Experimental|Treatment arm|omeprazole 20 mg capsule once daily for 8 weeks
2923411|NCT03086070|Placebo Comparator|Placebo arm|matching placebo capsules ones daily for 8 weeks
2923412|NCT03086057|Experimental|Strength Based Case Management|Stage 1: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
2923413|NCT03086057|Experimental|PrEP adherence training and counseling|Stage 2: Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
2923414|NCT03086057|No Intervention|Standard of Care:Stage 1|Stage 1: Referral to The Miriam Hospital PrEP Clinic.
2923415|NCT03086057|No Intervention|Standard of Care: Stage 2|Stage 2: Doctor visit every three months to assess for side effects and receive a HIV test.
2923416|NCT03086044|Experimental|HCV NAT Positive Donor|"Intervention: 4 week treatment course with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily~Participants who receive either heart or lung allografts from a donor who is HCV NAT positive will receive treatment with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily, beginning on the day of transplant or as soon as the recipient is able to tolerate oral medications after transplantation."
2923417|NCT03086044|Experimental|HCV NAT Negative, HCV Ab Positive Donor|"Intervention: HCV viral load monitoring~Participants who receive either heart or lung allografts from a donor who is HCV Ab positive and NAT negative will have close serial HCV viral load monitoring and will be treated with a direct acting antiviral, 400mg / velpatasvir 100mg daily, for 6 weeks if HCV viremia develops."
2923418|NCT03086031|Experimental|Program-based vocational rehabilitation|Combined intervention with a neuropsychological, social and community intervention followed by a vocational rehabilitation programme with a total length of 6-9 months.
2923419|NCT03086031|Active Comparator|Conventional vocational rehabilitation(controls)|Individuals allocated to the control group will receive the conventional VR program provided by the four municipalities over the same period of time. Thus, the participants in the control group will receive VR support by the local municipal authority that may vary in content and intensity. As for the intervention group, each individual in the control group will select a family caregiver that will go through the same questionnaires as the caregivers in the VR intervention group regarding health-related quality of life and functional level. Furthermore, the case manager at the municipalities will oblige to (1) hand out the baseline questionnaires to the participants and their family caregivers, (2) complete a questionnaire about each participants at the beginning, the end of the study, and again at 6-month of follow-up.
2923420|NCT03086018|Experimental|Successor hearing aid to Juna|The intervention is the new device which is the successor to the Juna device. The participants will use their current device as a control. The will wear the intervention device for approximately two weeks.
2923421|NCT03086005|Experimental|Metformin|Metformin 500mg tablet by mouth, every 12 hours, from the first day of oral contraceptive pills taken to the day of oocyte retrieval
2923422|NCT03086005|Placebo Comparator|Placebo|Placebo(identical in appearance to metformin), every 12 hours, from the first day of oral contraceptive pills taken to the day of oocyte retrieval
2923423|NCT03085992|Experimental|Single Arm|INDUCTION TREATMENT WITH FOLFOXIRI PLUS BEVACIZUMAB FOLLOWED BY PREOPERATIVE CHEMORADIOTHERAPY PLUS BEVACIZUMAB
2923424|NCT03085979|Experimental|Burch|Burch Colposuspension
2923425|NCT03085979|Experimental|Trans Obturator Tape|Trans Obturator Tape sling
2923426|NCT03085979|Experimental|Tension free vaginal tape|Tension free vaginal tape sling
2923427|NCT03085966|Experimental|autologous immune cell therapy|Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
2923428|NCT03085953|Experimental|Experimental: Supervisor Intervention|Supervisors in the intervention group will go through the Veteran Supervisor Supportiveness Training.
2923429|NCT03085953|Other|Waitlist Control Group|Supervisors will receive intervention following all measurement points, to serve as a waitlist control comparison group
2923430|NCT03085940|Experimental|Hydroxychloroquine|
2923431|NCT03085940|Placebo Comparator|Placebo|
2923458|NCT03085758|Placebo Comparator|Control group|Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab (control group)
2923459|NCT03085745|Experimental|Transcranial Magnetic Stimulation (TMS)|15 patients suffering from a writer's cramp, aged 20-80 who are currently treated with botulinum toxin will receive single pulse TMS
2925372|NCT03072693|Active Comparator|Group 1|Home-based remote heart failure management
2923432|NCT03085927|Experimental|Arm 1-Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
2923433|NCT03085927|Experimental|Arm II- Audio-Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
2923434|NCT03085914|Experimental|Treatment Group A|Epacadostat + pembrolizumab + mFOLFOX6 (oxaliplatin, leucovorin, 5-fluorouracil)
2923435|NCT03085914|Experimental|Treatment Group B|Epacadostat + pembrolizumab + gemcitabine and nab-paclitaxel
2923436|NCT03085914|Experimental|Treatment Group C|Epacadostat + pembrolizumab + carboplatin and paclitaxel
2923437|NCT03085914|Experimental|Treatment Group D|Epacadostat + pembrolizumab + pemetrexed and investigators choice of platinum agent
2923438|NCT03085914|Experimental|Treatment Group E|Epacadostat + pembrolizumab + cyclophosphamide
2923439|NCT03085914|Experimental|Treatment Group F|Epacadostat + pembrolizumab + gemcitabine and investigators choice of platinum agent
2923440|NCT03085914|Experimental|Treatment Group G|Epacadostat + pembrolizumab + investigators choice of platinum agent and 5-fluorouracil
2923441|NCT03085901|Active Comparator|Precizon toric intraocular lens|Cataract surgery and implantation of Precizon toric intraocular lens
2923442|NCT03085901|Active Comparator|Tecnis toric intraocular lens|Cataract surgery and implantation of Tecnis toric intraocular lens
2923443|NCT03085888||Prospective Cohort|This is a prospectively enrolling cohort study with a pre-specified molecular analysis plan. A stratified case-cohort design will be employed to select cancer cases and non-cancer subjects who will be assayed. All cases of cancer (breast and non-breast cancer) will be selected. A random subset of the overall study cohort will also be selected.
2923444|NCT03085862||Lung ultrasound and EVLW|This prospective study involved 60 patients without known cardiac or pulmonary diseases admitted to the intensive care unit at our hospital after elective abdominal or vascular surgery. The inferior vena cava collapsibility index (IVCcl), PaO2/FiO2 ratio, and appearance of B-lines ≤7 mm were determined upon admission to the intensive care unit and at 6, 12, and 24 h later. Fluid overload was defined as IVCcl ≤ 40% and the presence of B-lines ≤7 mm. Tissue oxygenation impairment was defined as a PaO2/FiO2 ratio < 200.
2923445|NCT03085849|Experimental|Treatment|"Subjects with ES-SCLC, progressive after platinum-based first-line chemotherapy will receive SGI-110 followed by combined durvalumab plus tremelimumab.~Dose escalation phase: 6-12 patients~MTD expansion cohort: 10 patients"
2923446|NCT03085836|Experimental|TAK-438 10 milligram (mg) QD|TAK-438 10 mg, tablets, orally, once daily on Days 1, 3-9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.
2923447|NCT03085836|Experimental|TAK-438 20 mg QD|TAK-438 20 mg, tablets, orally, once daily on Days 1, 3-9. Participants were asked to fast for a minimum of 10 hours prior administration of assigned treatment.
2923448|NCT03085836|Experimental|TAK-438 20 mg BID|TAK-438 20 mg, tablets, orally, once on Day 1 and twice daily on Days 3-9. Participants were asked to fast for a minimum of 10 hours prior administration of assigned treatment.
2923449|NCT03085810|Experimental|Ocrelizumab|Ocrelizumab will be administered intravenously (IV) as two 300-milligram (mg) infusions (infusion length=2.5 hours) on Days 1 and 15, followed by one 600-mg infusion dose every 24 weeks for a maximum of 8 doses throughout the 192 weeks treatment period.
2923450|NCT03085797|Experimental|Mepolizumab 100 mg SC + MF|Participants will receive total thirteen doses of 100 mg SC of mepolizumab in thigh, abdomen or upper arm every 4 weeks for 52 weeks on top of SoC which includes daily nasal spray of mometasone furoate.
2923451|NCT03085797|Placebo Comparator|Placebo SC + MF|Participants will receive total thirteen doses of SC matching placebo in thigh, abdomen or upper arm every 4 weeks for 52 weeks on top of SoC which includes daily nasal spray of mometasone furoate.
2923452|NCT03085784|Experimental|Loading Dose|"15 Patients will receive 4, 2 mg IVT Aflibercept (IAI) a month apart, screening/baseline, weeks 4, 8, & 12. At week 12, patient will be followed & treated per treat & extend protocol.~Treat & Extend Protocol entails patients being extended as long as:~Absence of retinal fluid (resolution of intraretinal & subretinal fluid on SD-OCT; Small intraretinal cysts that don't distort foveal contour on SD-OCT are acceptable & can be considered dry.) AND~< 5 ETDRS letter loss from previous visit, due to new or persistent retinal edema.~Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached."
2923453|NCT03085784|Experimental|Treat and Extend|"15 Patients will receive 2 mg IVT Aflibercept (IAI) at screening/baseline followed by a visit at week 4. At week 4, patient will be treated & followed per the treat & extend protocol.~Treat & Extend Protocol entails patients being extended as long as:~Absence of retinal fluid (resolution of intraretinal & subretinal fluid on SD-OCT; Small intraretinal cysts that don't distort foveal contour on SD-OCT are acceptable & can be considered dry.) AND~< 5 ETDRS letter loss from previous visit, due to new or persistent retinal edema.~Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached."
2923454|NCT03085771|Placebo Comparator|Desferal treatment|Patients will be randomized (by block randomization) to Desferal (DFO) treatment.
2923455|NCT03085771|Placebo Comparator|Isotonic saline treatment|Patients will be randomized (by block randomization) to isotonic saline treatment.
2923456|NCT03085758|Experimental|Treatment Arm A|Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab (treatment arm A)
2923492|NCT03085485|Placebo Comparator|Placebo|matching placebo
2923460|NCT03085732|Active Comparator|Irrigation with saline solution|during abdominal hysterectomy after vaginal cuff closure abdominal saline irrigation will be done
2923461|NCT03085732|No Intervention|control|routine abdominal hysterectomy will be performed and no abdominal saline irrigation
2923462|NCT03085719|Experimental|High Dose Radiation + Pembrolizumab|"High dose radiation will be given in 3 fractions~Pembrolizumab administered intravenously on day one of each cycle."
2923463|NCT03085719|Experimental|High Dose + Low Dose Radiation + Pembrolizumab|"High Dose radiation will be given in 3 fractions~Low Dose Radiation will be given in 2 fractions~Pembrolizumab administered intravenously on day one of each cycle."
2923464|NCT03085706|Experimental|PBMC autotransplantation|Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
2923465|NCT03085680|Experimental|Curcumin|Participants will be given identical capsules containing curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
2923466|NCT03085680|Placebo Comparator|Placebo|Participants will be given identical capsules containing placebo (microcrystalline cellulose) and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
2923467|NCT03085654|Experimental|High anxiety group (single dose)|Oxytocin nasal spray or placebo nasal of one dose in subjects with high trait anxiety.
2923468|NCT03085654|Experimental|High anxiety group (3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with high trait anxiety.
2923469|NCT03085654|Experimental|High anxiety group (5 doses)|Oxytocin nasal spray or placebo nasal spray for 5 days,24 IU per day in subjects with high trait anxiety.
2923470|NCT03085654|Experimental|Low anxiety group (single dose)|Oxytocin nasal spray or placebo nasal spray of one dose in subjects with low trait anxiety.
2923471|NCT03085654|Experimental|Low anxiety group (3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with low trait anxiety.
2923472|NCT03085654|Experimental|Low anxiety group (5 doses)|Oxytocin nasal spray or placebo nasal spray for 5 days in subjects with low trait anxiety.
2923473|NCT03085641|Experimental|Nasal high flow oxygen therapy|"The patient is hospitalized for one night.~Initially patients will start with a flow rate of 10 L/min and when they are asleep during the night 90-minute periods of the following settings will be performed:~Moderate flow rate: 20 L/min without additional oxygen (with room air, which means a fractional inspired oxygen (FiO2) of 21%)~High flow rate: 40-50 L/min without additional oxygen~Moderate flow rate: 20 L/min with FiO2 of 28% (comparable to the 2 L/min additional oxygen through a nasal cannula)~High flow rate: 40-50 L/min with FiO2 of 28%"
2923474|NCT03085628|Experimental|Oxytocin|Oxytoxin nasal spray
2923475|NCT03085628|Placebo Comparator|Placebo|Placebo nasal spray
2923476|NCT03085615|Experimental|100%NRG|Patient will receive the enteral nutrition product Jevity 1.5 starting at 20mL per hour and increasing by 20mL every four hours until a goal rate delivering 25-30kcals/kg is achieved. If feeding is interrupted, flow rate will be adjusted to compensate for nutritional loss.
2923477|NCT03085615|Active Comparator|40%NRG|Patient will receive the enteral nutrition product Jevity 1.5 starting at 20mL per hour and increasing by 20mL every four hours until a goal rate delivering 12-14 kcals/kg is achieved. If feeding is interrupted, flow rate will be adjusted to compensate for nutritional loss.
2923478|NCT03085602|Experimental|CBT Treatment|Participants receive Cognitive behavioral therapy (CBT). Participants will receive 4 one hour CBT treatments.
2923479|NCT03085602|Active Comparator|Control Group|Participants receive health education treatment. Participants will attend treatment sessions that match the CBT Treatment arm with respect to time and contact.
2923480|NCT03085602|No Intervention|Control Group - Scans|Participants in this new arm to the study will receive no intervention and will receive three scans.
2923481|NCT03085589||Amulet adaptation and validation|The Amulet development team will develop and configure applications assessing: steps/distance; strength; activity type; gait speed; and real-time, self-monitored activity feedback. Objective measures will be validated with the Amulet from 60 participants ensuring usability and feasibility. Each participant will be asked to come into the clinic for one afternoon for about 2-3 hours.
2923482|NCT03085563|Active Comparator|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method.
2923483|NCT03085563|Active Comparator|Intranasal Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'.
2923484|NCT03085550|No Intervention|Control|Conventional dressings management
2923485|NCT03085550|Experimental|Fat grafting only|Patients will undergo conventional fat harvesting as per Coleman technique and infiltration of fat into diabetic ulcer wound bed in 1cc:10cm2 fat:wound size ratio
2923486|NCT03085550|Experimental|Fat grafting + Platelet rich plasma|Patients will undergo conventional fat harvesting as per Coleman technique. Fat will be mixed with autologous PRP and infiltrated into diabetic ulcer wound bed in 1cc:10cm2 fat:wound size ratio
2923487|NCT03085524||Surgical Bypass|Subjects in the BEST-CLI trial assigned to surgical revascularization.
2923488|NCT03085524||Endovascular|Subjects in the BEST-CLI trial assigned to endovascular revascularization.
2923489|NCT03085511|Experimental|Egg Breakfast (EB)|"The EB will receive the following breakfast:~2 scrambled eggs, 120 mL skim milk, 2 slices of Mrs. Bairds® Extra Thin White Bread, 5 g of butter, and 18 g of Smuckers® Strawberry Jam."
2923490|NCT03085511|Active Comparator|Cereal Breakfast (CB)|"The CB will receive the following breakfast:~1.5 cups of Special K® Ready-to-Eat Original Cereal, 200 ml Silk® Original Soymilk, 1 slice of Nature's Own® Double Fiber Wheat Bread, 13 g of butter, and 10 g of Smuckers® Sugar-Free Strawberry Jam."
2923491|NCT03085485|Active Comparator|Ivacaftor|Ivacaftor, 150 mg PO every 12 hrs for 84 days
2923493|NCT03085472||benigh hematoma|Patients with novel imaging markers or clinical features suggestive of a relatively benigh hematoma (less likely to expand and have a relatively good outcome).
2923494|NCT03085472||malignant hematoma|Patients with novel imaging markers or clinical features suggestive of a relatively bad hematoma (more likely to expand and have a relatively poor outcome).
2923495|NCT03085459||Nurse level N0|who got college degree or above, nurse qualification certificate and working time less than one year
2923496|NCT03085459||Nurse level N1|who got nurse qualification certificate and working time between 1~3 years
2923497|NCT03085459||Nurse level N2|who got nurse qualification certificate and working time between 3~5 years
2923498|NCT03085459||Nurse level N3|who got nurse qualification certificate and working time more than 5 years
2923499|NCT03085446|Experimental|PDM nutritional intervention|
2923500|NCT03085446|Experimental|control|General information on nutrition and health
2923501|NCT03085433|Experimental|Microfluidic sperm sorting|Couples undergoing in vitro fertilization randomized to microfluidic sperm sorting will have raw semen sorted by the microfluidics chip prior to fertilization with IVF/ICSI.
2923502|NCT03085433|Active Comparator|Conventional sperm preparation|Couples undergoing in vitro fertilization randomized to conventional methods for sperm processing will undergo separation of semen by density gradient centrifugation prior to IVF/ICSI.
2923503|NCT03085420|Experimental|≥30% TBSA burn injury|For patients in Group 1 with ≥30% TBSA, a baseline Echocardiogram (ECHO) will be obtained approximately one week from admission and monthly (+/- 1 week) or at an interval determined by cardiology during the acute inpatient stay. ECHO tests will be discontinued after 3 negative exams or when discontinued by cardiology, whichever comes first.
2923504|NCT03085420|No Intervention|<30% TBSA burn injury|For patients in Group 2 with <30% TBSA and presence of a cardiac abnormality standard clinical care appropriate for the type of arrhythmia will be followed.
2923505|NCT03085407|Active Comparator|early cholecystectomy|Early cholecystectomy was done within 48 after admission
2923506|NCT03085407|Sham Comparator|delayed cholecystectomy|Delayed cholecystectomy was done after 30 days after randomization.
2923507|NCT03085394|Active Comparator|Treatment arm|Preoperative intravenous administration of 2g tranexamic acid in 10ml fluid.
2923508|NCT03085394|Placebo Comparator|Control Arm|Preoperative intravenous administration of 10ml normal saline.
2923509|NCT03085381|Experimental|HPV vaccine|Subjects received 3 doses of HPV vaccine according to a 0, 2, 6-month schedule.
2923510|NCT03085381|Placebo Comparator|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
2923511|NCT03085368|Experimental|EC→PL(Epirubicin+Cyclophosphamide--Docetaxel+lapatinib)|Epirubicin 80 mg/ IV day M2 Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles sequential Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: lapatinib in the first injection of docetaxel drug taking, once a day, oral dose of 1000mg, a total of over 1 years;
2923512|NCT03085368|Experimental|PEL(Paclitaxel+epirubicin+Lapatinib)|80mg/ M2 day 1 IV epirubicin Paclitaxel 150mg/m2 IV day 1 14 days for a total of 1 cycles (intensive chemotherapy), with a total of 6 cycles Also given Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: lapatinib in the first injection of paclitaxel drug taking, once a day, oral dose of 1000mg, a total of over 1 years;
2923513|NCT03085368|Active Comparator|EC→PH(Epirubicin+Cyclophosphamide--Docetaxel+herceptin)|Table 80mg/ day 1 IV Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg) Note: trastuzumab was administered at the beginning of the first injection of paclitaxel, with an injection dose of 2mg/kg, 1 times a week, for a total of up to 1 years; followed by trastuzumab 2mg/kg IV, once every 3 weeks for a total of one year
2923514|NCT03085368|Active Comparator|EPH(Paclitaxel+epirubicin+herceptin)|80mg/ M2 day 1 IV epirubicin Paclitaxel 150mg/m2 IV day 1 14 days for a total of 1 cycles, with a total of 6 cycles Also given Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg) Note: trastuzumab was administered at the beginning of the first injection of paclitaxel, with an injection dose of 2mg/kg, 1 times a week, for a total of up to 1 years; followed by trastuzumab 2mg/kg IV, once every 3 weeks for a total of one year
2923515|NCT03085355|Active Comparator|Exercises and PNE|Individuals with neck pain will receive a exercises program and pain neuroscience education. Participants will receive treatments during 4 weeks, 1 treatment per week
2923516|NCT03085355|Experimental|Osteopathic manipulative treatment|Individuals with neck pain in this group will also receive a exercises program and pain neuroscience education and the participants will receive treatments during 4 weeks, 1 treatment per week associated with Osteopathic Manipulative Treatment (OMT)
2923517|NCT03085342|Experimental|Liver MRI|Liver MRI including noncontrast (precontrast) flow measurement, DCE, DWI using multiple b-values, MRE and MR fat quantification.
2923518|NCT03085329|Experimental|Seattle-PAP|bubble nasal cpap respiratory support with Seattle-PAP bubbler device, with all other aspects of care per usual care noninvasive respiratory support
2923519|NCT03085329|Experimental|Conventional bubble nasal CPAP|qualified and enrolled infants randomized to this arm will receive noninvasive respiratory support by bubble nasal CPAP, using the Fisher & Paykel bubbler, which is the standard of care at Nationwide Children's.
2923520|NCT03085316|Experimental|Investigational Device|Patient who meets eligibility to be implanted with the St. Jude Medical Infinity™ Implantable Pulse Generator System (P140049), St. Jude Medical Infinity™ Deep Brain Stimulation (DBS) Directional Lead and Extension (P140009), Swift-Lock™ Anchor (K092371), Butterfly anchor (P140009), manufactured by St. Jude Medical, Inc.
2923521|NCT03085303|Experimental|Blue light at 415nm|Full body irradiation for 30min (15 min. each body side) with blue light at 415nm peak wavelength with full body blue device.
2923522|NCT03085303|Experimental|Blue light at 450nm|Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with full body blue device.
2923523|NCT03085303|Placebo Comparator|Placebo|Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with a low dose setting (not therapeutically active) of the full body blue device.
2923524|NCT03085290|Experimental|Group A|Subjects assigned to this arm will receive autologous serum eye drops first, followed by a washout period and then allogeneic serum eye drops.
2923525|NCT03085290|Experimental|Group B|Subjects assigned to this arm will receive allogeneic serum eye drops first, followed by a washout period and then autologous serum eye drops.
2923526|NCT03085277|Active Comparator|Control group|MM is always the first priority, when available. When MM is not available, or the available amounts do not fulfill the needs, infants in this group will receive preterm formula, as the supplementary diets following the standard feeding guidelines in the participating hospitals.
2923527|NCT03085277|Experimental|Intervention group|MM is always the first priority, when available. When MM is not available, or the available amounts do not fulfill the needs, infants in this group will receive BC, as the supplementary diets. BC feeding follows the same guideline as the control group in terms of initiation time (within 24-48h of age) and volume (5-10 ml/kg) and advancing rate (5-20 ml/kg/d). BC intervention should not exceed postnatal day 14.
2923528|NCT03085264|Experimental|Community Health Worker|Patients are paired with community health workers for 30 days after hospital discharge to assist with patient care
2923529|NCT03085264|No Intervention|Usual Care|Patients are not paired with community health workers for 30 days after hospital discharge to assist with patient care
2923530|NCT03085251|Experimental|Blood glucose measurement|
2923531|NCT03085238|Experimental|M-Trap|
2923532|NCT03085225|Experimental|Combination of trabectedin with durvalumab|"Trabectedin will be administered intraveinously, on day 1 of each cycle, every three weeks, as appropriate for assigned dose level.~Durvalumab will be administered intraveinously, at fixed doses of 1120 mg (equivalent to 15 mg/kg), on day 2 of each cycle, every three weeks."
2923533|NCT03085212|Experimental|Online stress management program|Participants will receive free access to Stress Free Now, which is an online stress management program developed by the Cleveland Clinic that uses mindfulness and cognitive-behavior therapy to help individuals learn to manage their stress.
2923534|NCT03085212|Active Comparator|Wait list control|Participants in this arm will receive free access to the Stress Free Now program at the end of the study.
2923535|NCT03085199|Other|Laparoscopic reinforcement suture|After cutting of duodenal stump of about 2 cm length using linear stapler, laparoscopic reinforcement suture commenced from upper to lower part on staple-line of duodenal stump. Continuous suture with invagination was performed using a barbed suture. In case of patient with short duodenal stump because of chronic ulcer or ectopic pancreas at duodenal bulb, 2 or 3 interrupted sutures without invagination of duodenal stump was conducted using barbed sutures.
2923536|NCT03085173|Experimental|EGFRt/19-28z/4-1BBL CAR T cells|Following enrollment, patients will undergo leukapheresis of peripheral blood for further T cell enrichment, activation and genetic modification using a retroviral vector encoding a CD19targeted CAR, the co-stimulatory ligand 4-1BBL and the EGFRt safety system (EGFRt/19-28z/4-1BBL). These T cells will be expanded and after the appropriate number of cells is generated, the modified T cells may be infused fresh or frozen for later use according to standard operation procedures. Modified T cell infusions will be administered 2-7 days following completion of the treating investigator's choice of conditioning chemotherapy. Serial sampling of blood and bone marrow will be performed following treatment to assess toxicity, therapeutic effects, and survival of the genetically modified T cells.
2923537|NCT03085160|Experimental|Learning to Breathe|Six-week mindfulness-based group program for adolescents
2923538|NCT03085160|Active Comparator|Health Education|Six-week health education group program for adolescents
2923539|NCT03085147|Experimental|Fluorescent PARPi Binding Imaging Agent PARPi-FL|In the phase I of the study, increasing concentrations of PARPi-FL will be used in up to 12 patients with OSCC to determine concentration that results in the highest contrast between tumor and normal mucosa. Dose escalation will be performed in groups of three patients until image contrast decreases, side effects are noted or the concentration of PARPi-FL exceeds 1μM. Imaging will be performed in the Department of Surgery during a presurgical visit including clinical examination of the oral cavity. In the phase II part of the study the concentration of PARPi-FL determined in phase I will be used to image 18 patients with OSCC on the day of surgery. Imaging findings will be correlated with histopathologic findings in the surgically resected specimens.
2923540|NCT03085134|Experimental|Test infant formula with HMOs|Extensively hydrolysed infant formula with HMOs taken by infant according to age, weight and appetite.
2923541|NCT03085134|Active Comparator|Control infant formula without HMOs|Extensively hydrolysed infant formula without HMOs taken by infant according to age, weight and appetite
2923542|NCT03085121|Experimental|Male Extramedullary|In this group, patients are male and femoral extramedullary resection would be used.
2923543|NCT03085121|Experimental|Female Extramedullary|In this group, patients are female and femoral extramedullary resection would be used.
2923544|NCT03085121|Active Comparator|Male Intramedullary|In this group, patients are male and femoral Intramedullary resection would be used.
2923545|NCT03085121|Active Comparator|Female Intramedullary|In this group, patients are female and femoral Intramedullary resection would be used.
2923546|NCT03085108||SIBAT, the S-STS CMCM, and the C-SSRS + CGI-SS-R|Participants randomized to Cohort A will be consented for video-recorded interviews on 3 distinct suicide assessment instruments (the Suicide Ideation and Behavior Assessment Tool [SIBAT], the Sheehan-Suicidality Tracking Scale Clinically Meaningful Change Measure [S-STS CMCM] and the Columbia-Suicide Severity Rating Scale [C-SSRS] + Clinical Global Impression of Severity of Suicidality (Revised) [CGI SS-R]). These participants will be interviewed 3 times within the single study visit by 3 different trained clinical raters, using semi-structured interviews that have been developed for each of the 3 suicide assessment instruments.
2923547|NCT03085108||SIBAT|Participants who are not videotaped for the 3 interviews will only be assessed by SIBAT.
2923548|NCT03085095|Experimental|Relugolix|
2923549|NCT03085095|Active Comparator|Leuprolide Acetate|
2923550|NCT03085082||skeletal class II subjects|patients with wits appraisal more than 3 mm measured on a cephalometric x ray obtained during diagnosis
2923551|NCT03085082||skeletal class III subjects|patients with wits appraisal less than -3 mm measured on a cephalometric x ray obtained during diagnosis
2923552|NCT03085082||skeletal class I patients|patients with Wits appraisal between -3 and +3 that is measured from a cephalometric x ray obtained during diagnosis of arch length discrepancy. this group will serve as control and obtained after recruitment of the other 2 groups in 1 to 1 fashion
2923553|NCT03085069|Experimental|PD-L1 expression in tumor ≥ 50%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
2923554|NCT03085069|Experimental|PD-L1 expression in tumor ≥25-50%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
2923555|NCT03085069|Experimental|PD-L1 expression in tumor ≥ 1-25%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
2923556|NCT03085069|Experimental|PD-L1 expression in tumor < 1%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
2923557|NCT03085056|Experimental|Trametinib in Combination With Paclitaxel|Patients will receive paclitaxel 80mg/m^2 weekly for 3 out of 4 weeks, which is a standard regimen in the treatment of anaplastic thyroid cancer, in combination with trametinib 2mg daily during each 4 week cycle.
2923558|NCT03085043|Experimental|Whole-Body MRI Imaging|"Participant has a whole body MRI along with standard-of-care MRI of the pelvis.~Participant also has standard-of-care bone scan and a computed tomography (CT) scan of abdomen and pelvis.~Scans performed at baseline and at 6 months."
2923559|NCT03085030|Experimental|antioxidant group|This group will take antioxidant formula tablet once daily orally for one month before IVF/ICSI cycle
2923560|NCT03085030|Placebo Comparator|control group|This group will take placebo tablet once daily orally for one month before IVF/ICSI cycle
2923561|NCT03085017|Active Comparator|Ostene|
2923562|NCT03085017|Experimental|BoneSeal|
2923563|NCT03085004|Active Comparator|Control Group|Cyst will be lavaged for 3 minutes with 98% ethanol. Following lavage with 98% ethanol, cyst will be infused with an admixture of(Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
2923564|NCT03085004|Experimental|Study group|Cyst will be lavaged for 3 minutes with normal saline. Following lavage with normal saline, The cyst will be infused with an admixture of(Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
2923565|NCT03084991||OCT group|1500 STEMI patients with OCT imaging during PPCI
2923566|NCT03084991||CAG group|3000 STEMI patients without OCT imaging during PPCI
2923567|NCT03084978|Active Comparator|General Anesthesia|Subjects will undergo general anesthesia with endotracheal intubation.
2923568|NCT03084978|Experimental|Conscious Sedation|Subjects will undergo conscious sedation anesthesia.
2923569|NCT03084952|Experimental|1 mg/day|
2923570|NCT03084952|Experimental|4 mg/day|
2923571|NCT03084952|Experimental|8 mg/day|
2923572|NCT03084952|Experimental|12 mg/day|
2923573|NCT03084952|Active Comparator|Glucantime|
2923574|NCT03084952|Experimental|Best dose 18-MC|
2923575|NCT03084952|Experimental|Minimum effective dose 18-MC|
2923576|NCT03084939|Experimental|Trastuzumab Emtansine|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with trastuzumab emtansine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
2923577|NCT03084939|Active Comparator|Control (lapatinib + capecitabine)|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with lapatinib plus capecitabine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
2923578|NCT03084926|Experimental|MP0274|
2923579|NCT03084913|Active Comparator|Prostate Cancer Foundation diet|Intervention: 8-weeks of a Prostate Cancer Foundation diet
2923580|NCT03084913|Experimental|plant- based, olive oil diet|Intervention: 8 weeks of a plant-based, olive oil diet
2923581|NCT03084900|Experimental|Patient-Centered Decision Support|Intervention - computer decision support in diabetes clinic. Investigators will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures. The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
2923582|NCT03084900|No Intervention|Standard Care|Standard pediatric diabetes care will be compared to the computerized decision support system.
2923583|NCT03084887|Experimental|manuals and follow-up|distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
2923584|NCT03084887|No Intervention|controlled group|no intervention until secondary hospital
2923585|NCT03084874|Experimental|Intervention group|Patients in the intervention group will receive an individualized coaching program to increase physical activity and reduce sedentary behavior during 12 weeks
2923586|NCT03084874|No Intervention|Control group|Patients in the control group will receive the standard care for patients with COPD during 12 weeks.
2923587|NCT03084861|Experimental|cord blood eye drops|Experimental drug: cord blood eye drops Description: eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 19 vials of 1 mL per vial Route of administration: ophthalmic/ocular
2923588|NCT03084861|Active Comparator|Conventional treatment|"Conventional treatment:~Artificial tears Description: Lubristil ® (single dose) Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 20 or 30 vials of 0.3 mL per vial Route of administration: ophthalmic~Therapeutic Contact lens Description: Air Optix Night&Day Dosage regimen: 1 contact lens per visit Pharmaceutical form: contact lens Presentation: 1 unit per case Route of administration: ophthalmic/ocular"
2923589|NCT03084848|Experimental|Active control|
2923590|NCT03084848|Experimental|Inhibitor control|
2923591|NCT03084835|Active Comparator|UC|Usual Care
2923592|NCT03084835|Active Comparator|WEB+TXT|Digital Intervention
2923593|NCT03084835|Active Comparator|WEB+TXT+TTS|Digital plus Counseling Intervention
2923594|NCT03084822|Experimental|FAITH! App digital intervention|The digital app will include 10 education modules addressing the major CVD risk factors to be delivered on-demand through an innovative, interactive video series. The digital app will also support the multi-media education modules, interactive surveys/quizzes, self-monitoring (diet, physical activity), and social networking (discussion board) functionality.
2923693|NCT03084211|No Intervention|Control Group|The control group will be instructed to gradually return to activities.
2923595|NCT03084809|Experimental|Cytokine-induced killer cells + FOLFOX4|"Cytokine-induced killer cells + FOLFOX4 intervention:~Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL 5% dextrose in water (D5W); Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags; Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours.The treatment is given for 4-6 cycles, every 3 weeks.~Collected cytokine-induced killer cells (CIK) cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days."
2923596|NCT03084809|Experimental|FOLFOX4|"FOLFOX4 intervention:~Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL 5% dextrose in water (D5W); Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags; Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks."
2923597|NCT03084796|Experimental|Treatment A|CHF 5259 pMDI Dose 1
2923598|NCT03084796|Experimental|Treatment B|CHF 5259 pMDI Dose 2
2923599|NCT03084796|Experimental|Treatment C|CHF 5259 pMDI Dose 3
2923600|NCT03084796|Experimental|Treatment D|CHF 5259 pMDI Dose 4
2923601|NCT03084796|Placebo Comparator|Treatment E|Placebo Control
2923602|NCT03084796|Active Comparator|Treatment F|Tiotropium Bromide inhalation powder, 18 µg
2923603|NCT03084783|Experimental|Intervention group|Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
2923604|NCT03084783|No Intervention|Control group|Participants receive standard care and no dexamethasone.
2923605|NCT03084770||Active surveillance group|Advised surveillance strategy consists of imaging studies (MR or EUS or US), every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. During surveillance, a high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making.
2923606|NCT03084770||Surgical resection group|Timing and type of resection will be established by the treating physician. Follow up strategy after surgery consists of imaging studies (MR or CT), every 6 months for the first two years and yearly thereafter for five years. An high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making. Date of surgery does not change the timing of follow up which starts from the date of enrolment.
2923607|NCT03084757|Experimental|research of druggable molecular alterations on tumor biopsy|
2923608|NCT03084744|Experimental|Schema therapy|Schema therapy in an individual format will be implemented by clinical psychologists. The treatment period will be 2 years with biweekly 50-minute sessions (up to 48 sessions).
2923609|NCT03084744|Placebo Comparator|Active monitoring|Active monitoring by telephone will be implemented by clinical psychologists. The treatment period will be 2 years with monthly 10-minute sessions (up to 24 sessions).
2923610|NCT03084731|Experimental|Goup 1:Children with moderate stunting and wasting|Test 3 prototype MDCFs and the current rice-lentil RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week 2x /day intervention, with a 2 week post-intervention phase to assess durability of MDCF-induced changes in the microbiota.
2923611|NCT03084731|Experimental|Goup 2:Children with moderate stunting and wasting|Select most efficacious MDCF from study 1 and compare with 2 additional MDCF prototypes using the same design used in study 1.
2923612|NCT03084731|Experimental|Goup3:Children with moderate stunting and wasting|Select lead MDCF from studies 1, 2 and conduct final 'bake-off' vs current RUSF and also examine the impact of 1x vs 2x per day administration with a 4 week post-intervention period to provide additional information on the durability of MDCF-sponsored changes in the microbiota.
2923613|NCT03084731|No Intervention|Healthy controls|In order to construct a library of gut microbiota of healthy growing children of the same community, one spot fecal sample (1-2 gm) and spot blood sample (2 mL) will be collected from 30 children each who would be aged 12-18 months of either sex, having WLZ and LAZ : >-1
2923614|NCT03084718|Experimental|Treatment A|CHF 718 pMDI Dose 1
2923615|NCT03084718|Experimental|Treatment B|CHF 718 pMDI Dose 2
2923616|NCT03084718|Experimental|Treatment C|CHF 718 pMDI Dose 3
2923617|NCT03084718|Placebo Comparator|Treatment D|Placebo Control, Placebos
2923618|NCT03084718|Active Comparator|Treatment E|Beclomethasone dipropionate HFA, 80µg (pMDI)
2923619|NCT03084705|Experimental|Manumeter with interactive feedback|Study participants will receive an experimental manumeter and interactive feedback from the manumeter to monitor and motivate their upper extremity functional activities.
2923620|NCT03084705|Experimental|Manumeter without interactive feedback|Study participants will receive an experimental manumeter but receive no feedback from the manumeter, and will be given the current standard-of-care for increasing upper extremity exercise booklet to perform at home.
2923621|NCT03084692|Experimental|Therapeutic Yoga and Resistance Exercise|The individuals with lung cancer and their caregivers will participate in a combined intervention of yoga and resistance exercise for 8-week, two times/week. The dyad will attend a one-hour resistance exercise intervention at the start of the week and a one-hour yoga class with a break of one day between both interventions. The resistance exercise training will involve one-on-one personal exercise session, while the yoga intervention will be offered in a class setting. The participants will be allowed to make up for any missed resistance exercise session based on the available time. Pamphlets will be given demonstrating breathing exercises, meditation, postures, and core resistance exercises to facilitate programming.
2923622|NCT03084679|No Intervention|Conventional Clinical Care - HFpEF|Heart Failure patients with preserved ejection fraction (HFpEF) randomized to this arm will keep receiving their conventional clinical care, being instructed to continue and maintain their usual daily activities.
2923623|NCT03084679|Other|Supervised Exercise Training- HFpEF|Heart Failure patients with preserved ejection fraction (HFpEF) randomized to this arm will keep receiving their conventional clinical care and participate in a supervised, facility based training program consisting of stretching exercises and aerobic exercise in treadmill.
2923624|NCT03084679|No Intervention|Conventional Clinical Care - HFrEF|Heart Failure patients with reduced ejection fraction (HFrEF) randomized to this arm will keep receiving their conventional clinical care, being instructed to continue and maintain their usual daily activities.
2923625|NCT03084679|Other|Supervised Exercise Training - HFrEF|Heart Failure patients with reduced ejection fraction (HFrEF) randomized to this arm will keep receiving their conventional clinical care and participate in a supervised, facility based training program consisting of stretching exercises and aerobic exercise in treadmill.
2923626|NCT03084666|Experimental|Treatment Group|The treatment will receive 200 mmHg of pressure from a Zimmer ATS tourniquet system for three 5 minute intervals.
2923627|NCT03084666|Experimental|Control Group|Our control group will receive 20 mmHg of pressure from a Zimmer ATS tourniquet system for three 5 minute intervals.
2923628|NCT03084653||Survey|Close-ended survey questions were formed and will be sent to general surgeons by e-mail containing the web address of the survey.
2923629|NCT03084640|Experimental|CMP-001 5 mg plus Pembrolizumab|Part 1 SC Dose Escalation/Expansion Phase
2923630|NCT03084640|Experimental|CMP-001 7.5 mg plus Pembrolizumab|Part 1 SC Dose Escalation/Expansion Phase
2923631|NCT03084640|Experimental|CMP-001 10 mg plus Pembrolizumab|Part 1 SC Dose Escalation/Expansion Phase
2923632|NCT03084640|Experimental|CMP-001 SC and IT RP2D plus Pembrolizumab|Part 2 RP2D SC dosing for 2 weekly doses, followed by IT for 4 weekly doses, then SC every 3 weeks thereafter in combination with Pembrolizumab
2923633|NCT03084627|No Intervention|Generic dietary advice for pregnancy|
2923634|NCT03084627|Experimental|Generic dietary advice for pregnancy + Tailored dietary advice|
2923635|NCT03084614||Group A|Adults with atopic dermatitis
2923636|NCT03084614||Group B|Pediatrics with atopic dermatitis
2923637|NCT03084601|Active Comparator|calcium hydroxide iodoform paste|intervention administered to control group is a combination of drugs as follow: ciprofloxacin 500mg, cefixime 500 mg, metronidazole 500 mg, simvastain 40mg. all are mixed, placed in pulp chamber only one time and tooth is restored
2923638|NCT03084601|Experimental|3-mixtatin|intervention administered to experimental group is a ready made mixture of calcium hydroxide and iodoform, placed in pulp chamber only one time and tooth is restored
2923639|NCT03084588|Active Comparator|Methadone|Patients in the methadone group will receive a single dose of methadone 0.2 mg/kg at induction of anesthesia
2923640|NCT03084588|Active Comparator|Interscalene block|Patients in the intersclene block group will receive an interscalene block prior to induction of anesthesia
2923641|NCT03084575|Active Comparator|Thermal Radiofrequency group|"Group 1 RF group: in which patients will receive thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy."
2923642|NCT03084575|Active Comparator|phenol group|"Group 2 phenol group: in which patients will recieve hyperbaric chemical saddle rhizotomy using 6% phenol in glycerin."
2923643|NCT03084562||Dipyridamole|stress test impossible or contraindicated (first intention)
2923644|NCT03084562||Regadenoson|stress test and dipyridamole impossible or contraindicated. In particular, patients with severe COPD or asthmatic patient. (second intention)
2923645|NCT03084549|Experimental|Ropivacaïne|
2923646|NCT03084549|Placebo Comparator|Placebo|
2923647|NCT03084536|Active Comparator|Preoperative PECS blocks|"PECS I & II block will be administered preoperatively~For unilateral surgeries, PECS I block will be performed bupivacaine. The PECS II block will be performed with the same solution. If there is a contralateral surgery (simple mastectomy) a PECS II block will also be performed on the other side.~To ensure blind integrity, study drug syringes will be marked only study drug and subject number~Perioperative analgesic will be standardized. Gabapentin 300mg, celecoxib 200mg and acetaminophen 1000mg will be administered to all patients following arrival to the preoperative area. All patients will receive premedication of 1-2 mg midazolam IV (age < 65) and 50-100 μg fentanyl IV prior to the block placement or entry to the operating room at the discretion of the regional team or operating room anesthesiologist"
2923648|NCT03084536|Placebo Comparator|Placebo PECS blocks|"A sham block (normal saline) will be placed preoperatively~To ensure blind integrity, study drug syringes will be marked only study drug and subject number.~Perioperative analgesic regimen will be standardized for research subjects. Gabapentin 300mg, celecoxib 200mg and acetaminophen 1000mg will be administered to all patients following arrival to the preoperative holding area. On the day of surgery all patients will receive premedication of 1-2 mg midazolam IV (age < 65) and 50-100 μg fentanyl IV prior to the block placement or entry to the operating room at the discretion of the regional team or operating room anesthesiologist."
2923649|NCT03084523|Experimental|1|60 patients with intracranial atherosclerosis
2923650|NCT03084523|Experimental|2|20 patients with intracranial aneurysm
2923651|NCT03084510|Experimental|Lotus™ Valve System|The Lotus Valve System is intended to improve the aortic valve function for symptomatic patients with severe calcific aortic stenosis (aortic valve area [AVA] of <1.0 cm2 or index of <0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
2923652|NCT03084497|Experimental|Group receiving Infant Massage|The subjects of this group will receive a total of 5 sessions of Infat Massage.
2923653|NCT03084497|No Intervention|Group without intervention|The subjects of this group won´t receive any intervention.
2923654|NCT03084484|Experimental|Test Group|"Subjects affected by periodontitis were examined and included in the study. After 2 months subjects also received non-surgical periodontal treatment and then followed for additional 3 months.~Subjects in the test group were instructed to eat two kiwifruit per day during the whole study period."
2923655|NCT03084484|Active Comparator|Control Group|"Subjects affected by periodontitis were examined and included in the study. After 2 months subjects also received non-surgical periodontal treatment and then followed for additional 3 months.~Subjects in the control group didi not receive any dietary advice."
2923656|NCT03084471|Experimental|Combination therapy|"Combination therapy (durvalumab + tremelimumab) : Patients will receive the combination therapy followed by monotherapy via intravenous (IV) infusion once Q4W:~Durvalumab 1,500 mg + tremelimumab 75 mg on Week 0, for up to a maximum of 4 doses (or cycles) and~Durvalumab 1,500 mg starting 4 weeks after the last infusion of the combination or discontinuation of tremelimumab."
2923657|NCT03084471|Experimental|Monotherapy|Monotherapy (Durvalumab 1,500 mg): Patients will receive durvalumab 1,500 mg via IV infusion Q4W on Week 0.
2923694|NCT03084211|Experimental|Prescribed Light Exercise Group|Intervention: Prescribed Light Exercise Group will receive discharge instructions prescribing 30 minutes of light exercise (ie: walking).
2923695|NCT03084198|Active Comparator|Control group|Standard care for ALF
2923658|NCT03084458|No Intervention|Control|Once consented, recruited ICD patients will complete the baseline psychosocial and quality of life measures. At the first and final visit, a 6-minute walk test will be administered. Participants will be sent text messages to encourage physical activity. Participants will be re-assessed with psychosocial and quality of life measures at 30 and 90 days post enrollment. At the final (90 day) visit participants ICD will be interrogated to obtain accelerometer activity data.
2923659|NCT03084458|Experimental|Fitbit|Same as control condition. In addition, participants in the experimental group will receive a Fitbit device with full instructions and troubleshooting. These participants will be given daily step goals, which will be increased during the course of the study, and be able to monitor their progress using the Fitbit app.
2923660|NCT03084432||caffeine group|22 preterm infants received caffeine (starting from day 2 of life and received for more than 7 days) for apnea prophylaxis or treatment according to protocol of Ain Shams University neonatal intensive care unit [apnea prophylaxis for preterm ≤32 weeks gestation and apnea treatment for those 33 or 34 weeks gestation]. Dual Energy X-ray Absorptiometry was done 5th-6th week post-natal age
2923661|NCT03084432||control group|20 preterm infants for whom caffeine was not given, either it was not indicated, not available or parents refused its use.Dual Energy X-ray Absorptiometry was done 5th-6th week post-natal age
2923662|NCT03084419|Experimental|Abatacept in patients with RA-ILD|Thirty participants with RA-ILD will be treated with abatacept infusions, which will be given fortnightly for the first 4 weeks, then every 4 weeks for a total of 20 weeks.
2923663|NCT03084406|Experimental|Enhanced Implementation (EI)|Providers in the Free Talk EI condition will receive access to CV-ATOD. They will participate in an online training course that mirrors the training in the IAU condition. EI providers will also receive access to interactive online exercises and practice activities within the training module. They will have online access to the Free Talk: Group MI for Teens searchable manual and materials via CV-ATOD. Providers may complete an optional CE course following the completion of the training module. EI providers will have access to all EBP implementation tools provided by CV-ATOD. Student providers in the CHOICE EI condition will receive access to CV-ATOD. They will participate in an online training course that mirrors the training in the IAU condition. However, EI providers will also receive access to interactive online exercises and practice activities within the training module. They will have online access to the CHOICE: Group MI for Teens searchable manual and materials via CV-ATOD.
2923664|NCT03084406|No Intervention|Implementation As Usual (IAU)|CMH providers in the Free Talk IAU condition will receive access to the Group MI for Teens website that provides asynchronous, self-paced training videos as well as downloadable intervention materials and resources. CMH providers in this condition are only required to watch the first two training videos before receiving access to download the Free Talk training manual and materials. Providers may also complete an optional CE course following the completion of all training videos. Student providers in the CHOICE IAU condition will receive access to the Group MI for Teens website that provides online training videos as well as downloadable intervention materials and resources. IAU providers are only required to watch the first two training videos before receiving access to download the CHOICE training manual and materials. Providers may also complete an optional EBP knowledge test following the completion of all training videos.
2923665|NCT03084393||study group|1000 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. The investigators do the Mini-Mental score examination (MMSE) and neuropsychological tests 1 day before (baseline) and 1 week,3 months,1 year after surgery without safety issue.
2923666|NCT03084393||control group|The investigators enroll 30 healthy volunteers and do the Mini-Mental score examination (MMSE) and neuropsychological tests at 1 day (baseline), 1 week, 3 months, 1 year without safety issue.
2923667|NCT03084380|Experimental|anti-GPC3 CAR-T|Transcatheter arterial chemoembolization (TACE) combine with GPC3-CART infusion
2923668|NCT03084367||iFR post angiographically successful PCI|
2923669|NCT03084341|Active Comparator|NMEE Group|Neuromuscular Electrical Elongation
2923670|NCT03084341|Active Comparator|PNF Group|Proprioceptive Neuromuscular Facilitation stretching
2923671|NCT03084341|No Intervention|Control Group|No intervention
2923672|NCT03084328||Patients with Vitamin D level of <30ng/dL|This is a cohort of patients with fatty liver disease and also have low levels of vitamin D
2923673|NCT03084328||Patients with Vitamin D level of >30ng/dL|This is a cohort of patients with fatty liver disease and have normal levels of vitamin D
2923674|NCT03084315|Sham Comparator|E-Cig Zero Nicotine|E-Cigarette with no nicotine added
2923675|NCT03084315|Active Comparator|E-Cig 24mg Nicotine|E-cigarette with 24mg of nicotine added
2923676|NCT03084302||Pregnant women|Women in their first trimester of pregnancy, aged 18-45, who plan to receive their prenatal care from University of Pittsburgh Medical Center providers.
2923677|NCT03084289|Experimental|Group 1|Group 1 will receive ChAd63-METRAP at the dose of 5x10^8 vp i.v.
2923678|NCT03084289|Experimental|Group 2|Group 2 will receive ChAd63-METRAP at the dose of 5x10^9 vp i.v.
2923679|NCT03084289|Experimental|Group 3|Group 3 will receive ChAd63-METRAP at the dose of 5x10^10 vp i.v.
2923680|NCT03084289|Experimental|Group 4|Group 4 will receive ChAd63-METRAP at the dose of 5x10^10 vp s.c.
2923681|NCT03084289|Experimental|Group 5|Group 5 will receive ChAd63-METRAP at the dose of 2x10^11 vp s.c.
2923682|NCT03084289|Experimental|Group 6|Group 6 will receive MVA METRAP at the dose of 2 x 10^6 pfu i.v.
2923683|NCT03084289|Experimental|Group 7|Group 7 will receive MVA METRAP at the dose of 2 x 10^7 pfu i.v.
2923684|NCT03084289|Experimental|Group 8|Group 8 will receive MVA METRAP at the dose of 2 x 10^8 pfu i.v.
2923685|NCT03084276|Experimental|High-fat meal|
2923686|NCT03084276|Active Comparator|Low-fat meal|
2923687|NCT03084263|Experimental|AORIF of Ankle Fractures|Arthroscopic Assisted Open Reduction Internal Fixation of ankle fracture.
2923688|NCT03084263|Active Comparator|ORIF of Ankle Fractures|Open Reduction Internal Fixation of ankle fracture.
2923689|NCT03084250|Experimental|Combination|The subjects will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a
2923690|NCT03084250|Active Comparator|nucleotide analogue|The subjects will be treated by nucleotide analogue (NA) only
2923691|NCT03084237|Experimental|HLX02+docetaxel|
2923692|NCT03084237|Active Comparator|Herceptin®+docetaxel|
2923697|NCT03084172||chronic kidney disease patients group|These patients were screened from 2000000 of the population. The investigator will compare the prevalence rate, awareness rate and treatment rate before and after the completion of the system. The degree of decreased glomerular filtration rate is also an important evaluation index.
2923698|NCT03084159|Experimental|Participatory design and intervention|Patients in this arm will receive the intervention of using an education worksheet during their appointment with their provider. They will be asked to complete post intervention surveys. Providers and staff at this site have been involved in the design of the intervention process, to make it streamlined and efficient for application in practice.
2923699|NCT03084159|Experimental|Intervention Only|A future arm will include patients at another site that will also receive the intervention of using an education worksheet during their appointment and fill out post intervention surveys. Providers/staff have not been involved in the initial design of the intervention process but will use it as part of the intervention delivery.
2923700|NCT03084159|No Intervention|Usual Care|A third site will include usual care, which does not include the intervention. Participants will be given post visit surveys similar to those in the two other study / intervention arms. This site will serve as a usual care comparison.
2923701|NCT03084146|Experimental|Psoriasis|Psoriasis patients will be placed on an individualized 12-week elimination diet
2923702|NCT03084146|No Intervention|Healthy Control|Healthy Control patients will receive no intervention
2923703|NCT03084133|Experimental|Therapeutic Education Strategy|"Means a screening information and education system in which the particularities of the index cases likely to require adaptation of the device will be collected, analyzed and taken into account.~Intervention 'Therapeutic Education Strategy'"
2923704|NCT03084133|No Intervention|Control group|Provision of information on the need for screening colonoscopy in first-degree relatives of case-index patients by the practitioner taking charge of the index case according to its usual practice
2923705|NCT03084120|Other|Gastric bypass surgery|"Pregnant women having undergone a Gastric bypass surgery before the pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
2923706|NCT03084120|Other|Reference group|"Pregnant women having a body mass index <25 kg/m2 at the early pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
2923707|NCT03084120|Other|Overweight|"Pregnant women having a body mass index 25-30 kg/m2 at the early pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
2923708|NCT03084120|Other|Obesity|"Pregnant women having a body mass index > 30 kg/m2 at the early pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
2923709|NCT03084107|Experimental|Questionnaire|technology acceptance model (TAM) questionnaire
2923710|NCT03084094|Experimental|M1|Transcranial direct current Stimulation in primary motor cortex
2923711|NCT03084094|Experimental|DLPFC|Transcranial direct current Stimulation in the dorsolateral pre-frontal cortex
2923712|NCT03084094|Sham Comparator|Sham|sham stimulation
2923713|NCT03084081|Active Comparator|CO2 standard therapy|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
2923714|NCT03084081|Experimental|CryoPen|Single freeze treatment consists of one five-minute freeze
2923715|NCT03084081|Experimental|Thermocoagulator|Thermoablation for 60-seconds at 100 degrees Celsius
2923716|NCT03084068|Experimental|Human umbilical cord allograft|Open Rotator Cuff Repair patched with human dehydrated umbilical cord allograft
2923717|NCT03084068|Placebo Comparator|Placebo Control|Open Rotator Cuff Repair with standard suture repair
2923718|NCT03084055|Experimental|eMotion intervention|Subjects randomised to the intervention arm will receive eMotion for two months. eMotion is comprised of a series of weekly audio visual modules designed to increase exposure to positive activities and physical activity.
2923719|NCT03084055|No Intervention|Waiting list control|Subjects in the waiting list control group will be given no intervention for two months; the control group will then be able to access eMotion if they wish but this will not form part of the research project
2923720|NCT03084042||Depression patients (MDD)|Patients with diagnosis of major depression according to DSM criteria
2923721|NCT03084042||Anxiety patients (GAD)|Patients with generalized anxiety disorder according to DSM criteria
2923722|NCT03084042||Healthy controls|Demographically matched healthy controls.
2923723|NCT03084029|Experimental|male participants - oxytocin nasal spray|male participants - receiving a single dose of 40 IU intranasal oxytocin
2923724|NCT03084029|Experimental|female participants - oxytocin nasal spray|female participants - receiving a single dose of 40 IU intranasal oxytocin
2923725|NCT03084029|Placebo Comparator|male participants - placebo nasal spray|male participants - receiving a single dose of 40 IU intranasal placebo
2923726|NCT03084029|Placebo Comparator|female participants - placebo nasal spray|female participants - receiving a single dose of 40 IU intranasal placebo
2923727|NCT03084016||Acute asthma exacerbation|Recruited in secondary care when presenting with acute asthma exacerbation.
2923728|NCT03084016||At risk of acute asthma exacerbation|Recruited in outpatient clinics. Acute exacerbation within the previous 12 months.
2923729|NCT03084003|Experimental|Almond group|2 oz. of almonds everyday for 8 weeks
2923730|NCT03084003|Active Comparator|Control group|Isoenergetic control group 5 graham cracker sheets everyday for 8 weeks
2923731|NCT03083990|Experimental|Group A|IBI 305 ,3mg/kg, infusion in 90 minutes
2923732|NCT03083990|Active Comparator|Group B|Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes
2925373|NCT03072693|Placebo Comparator|Group 2|Home-based physiological parameter recording only
2923733|NCT03083977|Experimental|Intervention group|This group will listen to 1 hour of processed music (Safe and Sound Protocol) for 5 days
2923734|NCT03083964|Active Comparator|Usual Care|Usual care involves a lifestyle coaching intervention delivered in primary care sites.
2923735|NCT03083964|Experimental|Priming|Priming involves usual care plus just in time reminder messages related to mindful eating and physical activity.
2923736|NCT03083951|Experimental|Complete Mesocolon Excision|A high tie of the inferior mesenteric artery (IMA) should be attempted. The inferior mesenteric vein section at the Treitz angle should be performed. The lymphatic tissue that accompanies the inferior mesenteric vein should be added.
2923737|NCT03083951|Active Comparator|Conventional Locoregional Lymphadenectomy|A high tie of the inferior mesenteric artery (IMA) should be attempted. Lymphadenectomy of the lymphatic tissue that accompanies the IMA will be performed. The inferior mesenteric vein section could be performed at the discretion of the surgeon.
2923738|NCT03083938|Experimental|Omental Roll-up|
2923739|NCT03083938|No Intervention|No Omental Roll-up|
2923740|NCT03083925||Bare metal stent (BMS) TIPS|retrospective patients receiving BMS-TIPS for treatment of complications of portal hypertension.
2923741|NCT03083925||Regular Viatorr (RV) TIPS|retrospective patients receiving RV-TIPS for treatment of complications of portal hypertension.
2923742|NCT03083925||Viatorr Control Expansion (VCX)TIPS|prospective patients receiving VCX-TIPS for treatment of complications of portal hypertension.
2923743|NCT03083912||Fortimel Complete|All of the residents included receive ONS
2923744|NCT03083899|Experimental|Diatast|Free use of out-patient services
2923745|NCT03083899|Placebo Comparator|Control|Scheduled diabetes control
2923746|NCT03083886|Active Comparator|Usual PCP led care|
2923747|NCT03083886|Experimental|Identify, Coordinated, Enhanced (ICE) Decision Making|
2923748|NCT03083886|Experimental|Individualized Postural Therapy (IPT)|
2923749|NCT03083873|Experimental|Single Arm|LN-145 autologous tumor infiltrating lymphocytes
2923750|NCT03083860|Other|Arm I|15-45 participants will be monitored for 4-6 weeks, using the App in a Closed version followed by 4-6 weeks, using the App in an Open version (A version of the app the generates recommendations of ADL interventions) , with feedback based on diary information and BEI; followed by 4-6 weeks using the App in an Open version, with feedback based on diary information only.
2923751|NCT03083860|Other|Arm II|15-45 participants will be monitored for 4-6 weeks, using the App in a Closed version followed by 4-6 weeks, using the App in an Open version with feedback based on diary information only followed by 4-6 weeks; followed by 4-6 weeks using the App in an Open version, with feedback based on diary information and BEI. Note the difference between Arm I and Arm II is the order of use of BEI in addition to the diary feedback.
2923752|NCT03083847|Experimental|1|Arm 1 is a pilot arm to determine dose of sporozoites and prrimethamine for Arm 2
2923753|NCT03083847|Experimental|2 and 3|Arms 2 (2a, 2b) and 3 are main study arms under pyrimethamine only for Arm 2; and chloroquine prophylaxis only for Arm 3
2923754|NCT03083847|Experimental|4|Arm 4 (4a, 4b) is the infectivity control arm for Arms 2 and 3 during CHMI
2923755|NCT03083847|Experimental|5|Arm 5 is a pilot arm to determine a safe dose of sporozoites under chloroquine prophylaxis for Arm 3
2923756|NCT03083834|Experimental|healthy subjects|low-dose cosyntropin stimulation test
2923757|NCT03083834|Experimental|hypoadrenal mitotane treated patients|low-dose cosyntropin stimulation test
2923758|NCT03083834|Experimental|hypoadrenal no-mitotane treated patients|low-dose cosyntropin stimulation test
2923759|NCT03083821|Experimental|Arm A|
2923760|NCT03083808|Experimental|Pembrolizumab 200mg IV every 21 days|Patients who have been treated with a PD-1 or PD-L1 inhibitor and experienced a PFS of ≥3 months will be enrolled within 6 weeks of last dose of PD-1 or PD-L1 inhibitor. On Day 1 of each 3-week cycle, subjects will first receive pembrolizumab at a dose of 200mg IV every three weeks in combination with chemotherapy. Partner chemotherapy will be either gemcitabine 1000mg/m^2 IV D1 and D8 every three weeks, docetaxel 75mg/m^2 IV D1 every three weeks, or pemetrexed 500mg/m^2 IV D1 every 3 weeks (pemetrexed for non-squamous histologies only). Subjects will continue to receive this combination until progression or intolerable toxicity.
2923761|NCT03083795|Experimental|Social relationships intervention|"Participants randomized to the social interaction cohort will be split into two groups of 12. Each group of 12 will meet together once a month for a two-hour support group. Each participant will be allowed five minutes to check-in with the support group. During the 5 minute period the participant is encouraged to share their innermost thoughts and feelings in the knowledge that this information will not be shared outside the group.~Participants will additionally be paired with another study participant in the same cohort and will be asked to meet outside group sessions once a week for a minimum of 45 minutes. The pairing process will take place by study investigators and will be sensitive to gender, age, and neighbourhood of residence. Participants who find that their paired partner is not suitable may ask the facilitators to help find a more suitable match.~These participants will continue to receive BC Diabetes standard care."
2923762|NCT03083795|No Intervention|Control cohort|Patients in the control group will receive BC Diabetes standard care.
2923763|NCT03083782|Active Comparator|Treatment A: Apixaban alone|Oral apixaban will be administered in healthy volunteers to define baseline apixaban pharmacokinetics
2923764|NCT03083782|Experimental|Treatment B: Cyclosporine with apixaban|Oral cyclosporine will be administered to steady state in healthy volunteers followed by a single oral dose of apixaban to define apixaban pharmacokinetics in the presence of cyclosporine
2923765|NCT03083782|Experimental|Treatment C: Tacrolimus with apixaban|Oral tacrolimus will be administered to steady state in healthy volunteers followed by a single oral dose of apixaban to define apixaban pharmacokinetics in the presence of tacrolimus
2923766|NCT03083769||Cohort 1|The retrospective cohort consists of about 500 kidney transplant recipients from Nanfang Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.
2923767|NCT03083769||Cohort 2|The retrospective cohort consists of about 500 kidney transplant recipients from Guilin 181st Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.
2923805|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 10g|Plant-based protein hydrolysate 2 (10 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
2923768|NCT03083769||Cohort 3|The prospective cohort consists of about 300 kidney transplant recipients from Nanfang Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.All the patients will be stratified to different groups according to the different genotypes. The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be monitored.
2923769|NCT03083769||Cohort 4|The prospective cohort consists of about 200 liver transplant recipients from the Third Affiliated Hospital in Sun Yat-Sen University. These patients used tacrolimus as immunosuppressive drug for preventing the rejection. All the patients will be stratified to different groups according to the different donors' genotypes and recipients' genotypes. The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be monitored.
2923770|NCT03083743|Experimental|Recombinant human Apo-2 ligand|Recombinant human Apo-2 ligand for Injection
2923771|NCT03083743|Placebo Comparator|Placebo|Mimetic agent for recombinant human Apo-2 ligand for injection
2923772|NCT03083730|Experimental|Atopic Dermatitis Cohort|"Narrow band UVB treatment (NB-UVB) NB-UVB light treatment 3x/week for 12 weeks (36 visits)~Healthy Control Cohort will be obtained to take baseline blood work as a reference value for baseline expression of blood markers."
2923773|NCT03083717||Patients with compensated heart failure|
2923774|NCT03083717||Patients with decompensated heart failure|
2923775|NCT03083717||Healthy subjects|
2923776|NCT03083704|Experimental|Cohort 1|
2923777|NCT03083704|Experimental|Cohort 2|
2923778|NCT03083704|Experimental|Cohort 3|
2923779|NCT03083704|Experimental|Cohort 4|
2923780|NCT03083704|Experimental|Cohort 5|
2923781|NCT03083704|Experimental|Cohort 6|
2923782|NCT03083704|Experimental|Cohort 7|
2923783|NCT03083704|Experimental|Cohort 8|
2923784|NCT03083704|Experimental|Cohort 9|
2923785|NCT03083704|Experimental|Cohort 10|
2923786|NCT03083704|Experimental|Cohort 11|
2923787|NCT03083691|Other|Cohort 1, NSCLC|During Treatment Part A nivolumab 240 mg IV q2w as monotherapy is administered. At the time of disease progression a re-biopsy is performed before initiation of combination therapy (Treatment Part B). Within Treatment Part B, nivolumab is given in a dose of 3 mg/kg q2w together with ipilimumab 1 mg/kg IV q6w.
2923788|NCT03083691|Other|Cohort 2, SCLC|Within Treatment Part A, nivolumab 1 mg/kg q3w together with ipilimumab 3 mg/kg q3w for a total of four doses is administered. After the four combined doses have been administered, a re-biopsy is performed before initiation of Treatment Part B. In Treatment Part B, nivolumab 240 mg q2w monotherapy is administered until disease progression or unacceptable toxicity
2923789|NCT03083678|Experimental|Afatinib|Afatinib active treatment.
2923790|NCT03083665|Placebo Comparator|Placebo|12 weeks Treatment Period: Subjects will receive PBO 4 weeks Down-Titration Period: Subjects will receive PBO
2923791|NCT03083665|Experimental|BRV 50 mg/day|"12 weeks Treatment Period: Subjects will receive BRV 50 mg/day~- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 50 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day~- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 25 mg/day for 1 week followed by PBO for 3 weeks, followed by a Study Drug-Free Period"
2923792|NCT03083665|Experimental|BRV 200 mg/day|"12 weeks Treatment Period: Subjects will receive BRV 200 mg/day~- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 150 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day~- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 150 mg/day for 1 week followed by BRV 100 mg/day for 1 week, followed by BRV 50 mg/day for 1 week, followed by BRV 25 mg/day for 1 week followed by a Study Drug-Free Period"
2923793|NCT03083652|Sham Comparator|Control|Conventional physiotherapy with NMEs device not activated
2923794|NCT03083652|Experimental|Intervention|Conventional physiotherapy with daily 30-minutes NMEs (5 days/week)
2923795|NCT03083639|Experimental|Esomeprazole 40 mg Capsule + Esomeprazole 40 mg Tablet|Esomeprazole 40 mg, capsule, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg tablet, orally, once on Day 1 of Intervention Period 2.
2923796|NCT03083639|Experimental|Esomeprazole 40 mg Tablet + Esomeprazole 40 mg Capsule|Esomeprazole 40 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg capsule, orally, once on Day 1 of Intervention Period 2.
2923797|NCT03083626||Prescription opioid abusers|Patients 21-65 years old taking suboxone or methadone, currently experiencing chronic pain, not taking any opioid analgesic medication for painful condition on a regular basis, not have any current psychiatric or neurological illnesses, not have a history of heart disease in order to be healthy enough to complete the cold pressor test.
2923798|NCT03083626||Healthy control participants|Patients 21-65 years old not taking suboxone or methadone, not experiencing chronic pain, not taking any opioid analgesic medication for painful condition on a regular basis, not have any current psychiatric or neurological illnesses, not have a history of heart disease in order to be healthy enough to complete the cold pressor test.
2923799|NCT03083613|Experimental|Raltitrexed and Paclitaxel|"All patients receive the combination therapy of Raltitrexed and Paclitaxel for a maximum of 6 cycles~Raltitrexed:3mg/m2,d1 Paclitaxel:80mg/m2,d1,d8,~Eery 3 weeks"
2923800|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 5g|plant-based protein hydrolysate 1 (5g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times per day for 12-weeks
2923801|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 10g|Plant-based protein hydrolysate 1 (10 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
2923802|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 15 g|Plant-based 1 protein hydrolysate (15 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
2923803|NCT03083600|Placebo Comparator|Placebo|Cellulose Placebo stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks.
2923804|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 5g|Plant-based protein hydrolysate 2 (5 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
2923806|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 15g|Plant-based protein hydrolysate 2 (15 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
2923807|NCT03083587|Active Comparator|No intervention|Normal lifestyle. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
2923808|NCT03083587|Experimental|Exercise intervention|Followed by a 1 week normal run in period subjects will undergo a 3 min bout, every half hour between 8 am and 6 pm comprises of simple low-intensity exercise such as moderate walking about or climbing a flight of stairs over a 3-week period. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
2923809|NCT03083574|Experimental|Photopheresis Theraflex ECP™|All patients will initially be treated by 6 cycles of extracorporeal photopheresis (i.e. extracorporeal photopheresis on two consecutive days) administered every 2 weeks. Patients will then be evaluated after 3 months and treatment continuation will be decided based on response.
2923810|NCT03083561|Experimental|LY3337641 Multiple Dose|Multiple doses of LY3337641 administered orally, with a two week follow-up period.
2923811|NCT03083561|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered orally, with a two week follow-up period.
2923812|NCT03083561|Experimental|LY3337641 Single Dose|Single dose of LY3337641 administered orally, with a two week follow-up period.
2923813|NCT03083561|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered orally, with a two week follow-up period.
2923814|NCT03083548||Hand osteoarthritis|Men and women (40-70 years) with a diagnosis of hand OA based on clinical or ultrasound examination are included. Patients with systemic inflammatory joint diseases, psoriasis and hemochromatosis are excluded.
2923815|NCT03083535|Active Comparator|Tooth Brushing|Tooth brushing with dentifrice and standardized tooth brush
2923816|NCT03083535|Experimental|Aloe vera massaging|Tooth brushing with dentifrice and standardized tooth brush followed by massaging with aloe vera gel
2923817|NCT03083535|Experimental|SRP with aloe vera massaging|Scaling and root planning was done with ultrasonic scalar. It was followed by aloe vera massaging on half arch for 3 minutes daily
2923818|NCT03083522|Experimental|OJS group|admission to Ojeok-san granule
2923819|NCT03083522|Placebo Comparator|Placebo Group|admission to placebo
2923820|NCT03083509|Other|Group1 (Resistance trained individuals)|Resistance trained individuals (>3 sessions per weeks for ≥2 years with a minimum of 1 session per week including leg-based exercises)
2923821|NCT03083509|Other|Group 2 (Trained cyclists)|Trained cyclists (competing at a minimum of Category 3 road racing/estimated 10 mile TT of <25 minutes and a training history of ≥5 hours per week for ≥2 years)
2923822|NCT03083509|Other|Group 3 (Team sports players)|Team sports players (minimum of University 1st team level e.g. soccer, rugby union, rugby league, hockey and basketball, playing competitively ≥1x per week for ≥2 years)
2923823|NCT03083496|Active Comparator|Potassium Oxalate 5%|Prophylaxis of the teeth; an application every 48 hours; 4 sessions
2923824|NCT03083496|Active Comparator|Potassium Oxalate 10%|Prophylaxis of the teeth; an application every 48 hours; 4 sessions
2923825|NCT03083483|Experimental|Bilateral M1, active tDCS|This is an arm of the first phase of the study utilizing tDCS in two different configurations (bilateral M1 vs SMA).
2923826|NCT03083483|Experimental|SMA, active tDCS|This is an arm of the first phase of the study utilizing tDCS in two different configurations (bilateral M1 vs SMA).
2923827|NCT03083483|Sham Comparator|sham tDCS|This is an arm of the first phase of the study utilizing tDCS in two different configurations (bilateral M1 vs SMA). Half of these subjects will be placed in the SMA configuration and the other half in the bilateral M1 electrode configuration.
2923828|NCT03083470|Experimental|SOR007 0.15%|SOR007 Ointment 0.15% applied to the face twice daily for 28 days
2923829|NCT03083470|Experimental|SOR007 0.3%|SOR007 Ointment 0.3% applied to the face twice daily for 28 days
2923830|NCT03083470|Experimental|SOR007 1.0%|SOR007 Ointment 1.0% applied to the face twice daily for 28 days
2923831|NCT03083470|Experimental|SOR007|SOR007 Ointment 2.0% applied to the face twice daily for 28 days
2923832|NCT03083470|Sham Comparator|Ointment Vehicle|SOR007 Ointment vehicle applied to the face twice daily for 28 days
2923833|NCT03083457|Experimental|PEEP2 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=2 cmH2O and scheduled recruiting maneuvers at the beginning of each PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
2923834|NCT03083457|Experimental|PEEP7 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=7 cmH2O and scheduled recruiting maneuvers at the beginning of the PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
2923835|NCT03083457|Experimental|PEEP12 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=12 cmH2O and scheduled recruiting maneuvers at the beginning of the PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
2923836|NCT03083457|Experimental|PEEP2 - RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=2 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
2923837|NCT03083457|Experimental|PEEP7 - RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=7 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
2923838|NCT03083457|Experimental|PEEP12 - RM.|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=12 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
2923918|NCT03082833|Experimental|AZD2014 50mg BD|AZD2014 50mg BD continuous schedule of a 28 day cycle
2923839|NCT03083431|Experimental|Propranolol|Oral propranolol (1.6 mg propranolol-HCl/kg·d in 3-4 divided dosages) given for 4 10 weeks (depending on postmenstrual gestational age at birth)
2923840|NCT03083431|Placebo Comparator|Placebo|Placebo (same duration as oral propranolol solution)
2923841|NCT03083418|Experimental|Control group|No EDP treatment.
2923842|NCT03083418|Experimental|EDP therapy group|30 minutes continuous stimulation each time, two times a day, a total of one weeks of treatment .Parameters: 30min stimulation time, pacing frequency of 9 beats / min, pulse frequency is 40 hertz, the stimulus intensity (output pulse amplitude) is in the range of 0~30 units, which should be adjusted according to the daily maximum tolerance (patients with no pain and tension).
2923843|NCT03083405||Clonidine group|Patients diagnosed with SB and clonidine intervention .
2923844|NCT03083405||Buspirone group|Patients diagnosed with SB and buspirone intervention.
2923845|NCT03083405||SB group|Patients diagnosed with SB and no drug intervention.
2923846|NCT03083405||Healthy controls|Patients without diagnosed SB.
2923847|NCT03083392|Experimental|Treatment|treatment of chronic maxillary sinusitis using DIVA system
2923848|NCT03083379|Active Comparator|Volumetric Incentive Spirometry|Incentive Spirometry
2923849|NCT03083379|Experimental|EzPAP® POSITIVE AIRWAY PRESSURE|EzPAP
2923850|NCT03083366|Experimental|Sacral neuromodulation|Bilateral sacral neuromodulation will start within 3 months of spinal cord injury, as well as standard neurogenic bladder care.
2923851|NCT03083366|No Intervention|Standard care|Patients will receive standard neurogenic bladder care.
2923852|NCT03083353|Experimental|CET + ISR|Cue Exposure Treatment with Isradipine. Medication will be in pill form containing 15mg of immediate release isradipine. Participants will receive the pill 75 minutes prior to the 1st CET.
2923853|NCT03083353|Placebo Comparator|CET + PBO|Cue Exposure Treatment with Placebo. Placebo pills will be given to the participants 75 minutes prior to the 1st CET.
2923854|NCT03083340|Experimental|Deprexis|Participants will complete 8 weeks of online treatment via a web-based program, Deprexis.
2923855|NCT03083327|Active Comparator|Standard Care|The control group in this study is pragmatic standard nutrition care. Currently after a bone marrow transplant in Australia, patients are normally fed orally for as long as possible. If oral intake fails to provide sufficient calories for a period of two to three days, enteral or parenteral nutrition may be provided.
2923856|NCT03083327|Active Comparator|Early supplemental parenteral nutrition|"Supplemental prophylactic early parenteral nutrition will be commenced 1 day prior to conditioning chemoradiotherapy in patients who are not already malnourished. Supplemental parenteral nutrition continues throughout conditioning chemoradiotherapy and stem cell transplant.~The dose of supplemental parenteral nutrition will be dependent on the total calories also received from oral and/or enteral nutrition intake."
2923857|NCT03083314|Experimental|SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)|
2923858|NCT03083314|Active Comparator|COMPLETE AXILLARY DISSECTION (ALND)|
2923859|NCT03083301||Cardiac insufficiency|Patients with cardiac insufficiency (i.e in NYHA class III or IV) or refractory to optimal medical treatment (155 patients since 2003) in the Brugmann University Hospital, in the cardiac surgery department
2923860|NCT03083288|Experimental|Single Arm|
2923861|NCT03083275|Experimental|Resistance Training|
2923862|NCT03083275|No Intervention|Control|
2923863|NCT03083223||lung disease|Patients with lung disease
2923864|NCT03083210|Experimental|Lanreotide|Lanreotide, at a dose of 120mg will be administered without dose adjustment, by means of deep subcutaneous injection every 28 days.
2923865|NCT03083197|Active Comparator|Doxycycline 7 days|loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
2923866|NCT03083197|Active Comparator|Doxycycline 3 days|loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
2923867|NCT03083197|Active Comparator|Azithromycin 3 days|loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
2923868|NCT03083184|Experimental|Intervention group|Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).
2923869|NCT03083184|Other|control group|Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).
2923870|NCT03083171|Placebo Comparator|Placebo|
2923871|NCT03083171|Active Comparator|Adrecizumab 0.5 mg/kg|A single intravenous dose of 0.5 mg/kg Adrecizumab given over a 1 hour period.
2923872|NCT03083171|Active Comparator|Adrecizumab 2.0 mg/kg|A single intravenous dose of 2.0 mg/kg Adrecizumab given over a 1 hour period.
2923873|NCT03083171|Active Comparator|Adrecizumab 8.0 mg/kg|A single intravenous dose of 8.0 mg/kg Adrecizumab given over a 1 hour period.
2923874|NCT03083158|Other|Group 1|Older adults, aged 61-80 years
2923875|NCT03083158|Other|Group 2|Younger adults, aged 40-60 years
2923876|NCT03083145|Active Comparator|Educational Messaging|Whey protein beverage and pea protein beverages administered in a randomized order with a one- to two-week washout period between beverages.
2923877|NCT03083145|Active Comparator|No Messaging|Whey protein beverage and pea protein beverages administered in a randomized order with a one- to two-week washout period between beverages.
2923878|NCT03083132|Active Comparator|Early-start|24 weeks of modafinil 50 mg oral daily
2923879|NCT03083132|Placebo Comparator|Delayed-start|12 weeks of oral placebo followed by 12 weeks of modafinil 50 mg oral daily
2923880|NCT03083119|Experimental|Xuesaitong soft capsule group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
2923881|NCT03083119|Placebo Comparator|Placebo Comparator|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
2923882|NCT03083093||CTEPH patients|the initial CTPA scan will be reviewed in patients diagnosed with CTEPH after an episode of an acute PE
2923883|NCT03083093||non CTEPH patients|the initial CTPA scan will be reviewed in patients after an episode of an acute PE in whom CTEPH was excluded
2923951|NCT03082599|Active Comparator|Emmetropia both eyes (OU) group|Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
2923884|NCT03083080|Experimental|VATS block (ropivacaine + epinephrine)|VATS block is the peripheral nerve block for video-assisted thoracic surgery, whose injection is administered at the site of chest wall incision.
2923885|NCT03083067|Experimental|Salvational intervention(SI) group|Budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug on the foundation of original treatment.
2923886|NCT03083067|Active Comparator|Control(CT) group|CT group maintain the original treatment
2923887|NCT03083054|Experimental|Patients|High Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia
2923888|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 250mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 250mg, PO, QD
2923889|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 500mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 500mg, PO, QD
2923890|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 375mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
2923891|NCT03083028|Active Comparator|Non Operative|"Non-Operative~Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon."
2923892|NCT03083028|Active Comparator|Operative|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks
2923893|NCT03083015|Experimental|Revascularization|Blood clot initiation and grey MTA ( Mineral Tri-oxide Aggregate) cervically compacted.
2923894|NCT03083015|Active Comparator|Apexfication|Apexification using grey MTA apically compacted without mechanical preparation.
2923895|NCT03082989||fractional flow reserve performed|consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography where the operator decided to use fractional flow reserve to drive the revascularization
2923896|NCT03082989||fractional flow reserve not performed|consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography and satisfying prespecified criteria where the operator decided to not use fractional flow reserve to drive the revascularization
2923897|NCT03082963|Other|EMR Feasibility|In this feasibility study, all ten patients will undergo EMR mapping which will be used to guide ablation.
2923898|NCT03082950||1|human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions
2923899|NCT03082950||2|non-human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions
2923900|NCT03082937|Experimental|3 mg [14C]-A4250 capsule|
2923901|NCT03082924|Experimental|Control group|Neither cycle training nor inspiratory muscle training.
2923902|NCT03082924|Experimental|Cycle training group|A calibrated cycle ergometer is used to do 30-minute cycling training session 3 days a week.
2923903|NCT03082924|Experimental|Inspiratory training group|A threshold loading device is used to perform 21-minute inspiratory muscle training 3 days a week.
2923904|NCT03082924|Experimental|Combined group|Calibrated cycle ergometer and threshold loading device are applied.A 30-minute cycle training is performed using calibrated cycle ergometer and a 21-minute inspiratory muscle training using threshold loading device 3 days a week.
2923905|NCT03082911|Experimental|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group).~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention.~Each phone call will last approximately 5 minutes."
2923906|NCT03082911|Active Comparator|Standard procedure|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample.
2923907|NCT03082898|Experimental|AIS A or B using Indego Exoskeleton|Patients with American Spinal Injury Association Injury Scale (AIS) A or B (non- ambulatory) will receive regular dosing of exoskeleton walking.
2923908|NCT03082898|Experimental|AIS C or D using Indego Exoskeleton|Patients with American Spinal Injury Association Injury Scale (AIS) C or D (Poorly ambulatory) will receive regular dosing of exoskeleton walking.
2923909|NCT03082885|Experimental|Thymosin-α1 group|Patients receive treatment based on standard Therapy with additional Thymosin-α1
2923910|NCT03082885|No Intervention|control group|Patients receive treatment based on standard Therapy
2923911|NCT03082872|Experimental|Cemented K-wire Fixation|Fractures were transverse (n=32), short oblique or spiral (n=5), and comminuted (n=14) fractures.
2923912|NCT03082872|Experimental|Open Transfixion Pinning|Fractures were transverse (n=28), short oblique or spiral (n=4), and comminuted (n=15) fractures.
2923913|NCT03082859|Experimental|Reduced-exertion high-intensity interval training|Cycling Exercise. 2 x 20-sec sprints.
2923914|NCT03082859|Experimental|High Intensity Interval Training (HIT)|Cycling Exercise. 10 x 1 min at approx 85% peak power output (Wmax)
2923915|NCT03082859|Experimental|Moderate Intensity Continuous Exercise|Cycling exercise. 30 min at 50% peak power output (Wmax)
2923916|NCT03082859|No Intervention|Sedentary (no exercise)|No exercise. Rest.
2923917|NCT03082846|Experimental|hypofractionated group|hypofractionated group using hypofractionated radiation with temozolomide chemotherapy: Malignant gliomas patients received concurrent postoperative radiotherapy and chemotherapy.Intensity-modulated radiotherapy is adopted, the dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1. The planning target volume (PTV2) remain unchanged with 2.5 Gy each time and a total of 50 Gy/20 f. Temozolomide is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
2923919|NCT03082820||Patients|Pain-related evoked potentials (PREP), Quantitative Sensory Testing (QST) and nerve conduction studies (NCS) were performed with patients with peripheral nerve injury.
2923920|NCT03082820||Controls|Pain-related evoked potentials (PREP) and Quantitative Sensory Testing (QST) were performed with healthy adults.
2923921|NCT03082807|Experimental|Study group I|Study group I (18 participants) received the NCD with exercise (NCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
2923922|NCT03082807|Experimental|Study group II|Study group II (19 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
2923923|NCT03082794|Experimental|Study group I|Study group I (53 participants) received the NCD (details of diet: 15% protein, 75% carbohydrates, 10% fat). Both groups had 15% caloric restriction from their maintenance energy requirements.
2923924|NCT03082794|Experimental|Study group II|Study group II (51 participants) received the LCD or healthy weight maintenance diet (details of diet: 15% protein, 55% carbohydrates, 30% fat).Both groups had 15% caloric restriction from their maintenance energy requirements.
2923925|NCT03082781|Experimental|Study group I|Study group I (57 participants) received the NCD with exercise (NCDsport).This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
2923926|NCT03082781|Experimental|Study group II|Study group II (54 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
2923927|NCT03082768|Experimental|[18F]MNI-968|To evaluate [18F]MNI-968 (aka PF-06730110) as a D1 receptor targeted radiopharmaceutical
2923928|NCT03082755|Experimental|Gabapentin Enacarbil (GEn)|1 to 2 GEn tablets (300 mg) will be administered by mouth (PO) once a day in the evening (about 5 pm) for 8 weeks then tapered for 1 week. The study drug will be adjusted up to a maximum dosage of 600 mg as tolerated.
2923929|NCT03082755|Placebo Comparator|Placebo|1 to 2 Placebo Oral Tablet(s) will be administered once a day in the evening (about 5 pm) for 8 weeks then tapered for 1 week. The placebo drug will be adjusted up to a maximum dosage of 2 tablets as tolerated.
2923930|NCT03082742|Active Comparator|Furosemide|Use of Furosemide, 40mg (1 tablet) per day, over 12 months
2923931|NCT03082742|Active Comparator|Hydrochlorothiazide|Use of Hydrochlorothiazide, 25mg (1 tablet) per day, over 12 months
2923932|NCT03082729|Other|Apremilast|Apremilast (Otezla), 30mg oral tablet twice per day for 52 weeks. Single arm, open label study.
2923933|NCT03082716|Active Comparator|blood cardioplegia group|patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
2923934|NCT03082716|Experimental|custodiol group|patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
2923935|NCT03082703|Experimental|Text Messaging|
2923936|NCT03082703|No Intervention|Control|
2923937|NCT03082690|Experimental|DuoGel|IQP-0528 1% gel administered rectally one time
2923938|NCT03082677|Experimental|ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off). The patients will continue on this same dose until taper off from immunosuppressants or 1 year post-HSCT is reached (whichever occurs first) or until the patient develops GVHD or malignant disease relapse/progression occurs.
2923939|NCT03082664|No Intervention|Standard dressing|Standard dressing will be applied after C-section.
2923940|NCT03082664|Experimental|PICO dressing|Device: PICO Single Use Negative Pressure Wound Therapy
2923941|NCT03082651|Active Comparator|Constant training/Constant footwear|Group 1 - Runners will be assigned identical training sessions over a 7-day period and will perform these runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus). The weekly training volume will increase on a weekly basis in order to progressively increase training load in preparation for the half-marathon event.
2923942|NCT03082651|Experimental|Alternate training/Constant footwear|Group 2 - Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period. As with Group 1, weekly training volume will increase on a weekly basis. Runners in Group 2 will perform these runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
2923943|NCT03082651|Experimental|Constant training/Alternating footwear|Group 3 - Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.
2923944|NCT03082651|Experimental|Alternating training/Alternating footwear|Group 4 - Runners will be assigned a variation of workouts throughout each 7-day period and will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak).
2923945|NCT03082638||Control|served in Gulf War during 1990 - 1991 and have no symptoms of Gulf War Illness based on criteria
2923946|NCT03082638||Case|Served in Gulf War during 1990 -1991 and have Gulf War Illness
2923947|NCT03082625|Experimental|Transdermal Magnesium|5 sprays each on the 2 most effected areas for muscle cramps twice a day
2923948|NCT03082625|Placebo Comparator|Placebo|5 sprays each on the 2 most effected areas for muscle cramps twice a day
2923949|NCT03082612|Experimental|Intervention plus usual care|Participants (patients and their family caregivers) in this study arm will receive the Overcoming Psychological Distress through Hymns Intervention.
2923950|NCT03082612|Active Comparator|Usual care|Immediately after randomization and completion of baseline measures, participants in this study arm will receive usual care. Patients and their family caregivers will receive the Overcoming Psychological Distress through Hymns Intervention after the 3 week period of usual care.
2923952|NCT03082599|Experimental|Nanovision group|Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
2923953|NCT03082586|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 57.2 Gy.
2923954|NCT03082586|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 64.4 Gy.
2923955|NCT03082586|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 71.6 Gy.
2923956|NCT03082586|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 78.8 Gy.
2923957|NCT03082586|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 86 Gy.
2923958|NCT03082586|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 93.2 Gy.
2923959|NCT03082573|Active Comparator|Group A|"Will be receiving the same background medications and H.P. Acthar gel 40 units twice weekly for 12 weeks.~Patients in group A, can be cross over to group B on week 13 if disease is uncontrolled for continuation until week 24. If their disease is under control then they will continue with the same dosage until week 24.~If the disease is under control, then tapering the steroid dosage can be attempted at the principal investigation's discretion."
2923960|NCT03082573|Active Comparator|Group B|"Will be receiving the same background medications and H.P. Acthar gel 80 units twice weekly for 12 weeks.~if the disease is not under control, will continue with same dosage until week 24. If the disease is under control, will be given the option to reduce the dosage to 40 units twice weekly only if patient is suffering from H.P. Acthar gel related adverse effects.~If the disease is under control, then tapering the steroid dosage can be attempted at the principal investigation's discretion."
2923961|NCT03082560||Group 1|Healthy adult patients with lichen planopilaris
2923962|NCT03082547||Headache Groub|Headache patients with myofascial trigger points.
2923963|NCT03082547||Healthy Groub|No headache or other diseases can cause headaches of healthy people.
2923964|NCT03082534|Experimental|Cohort 1|"PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
2923965|NCT03082534|Experimental|Cohort 2|"PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
2923966|NCT03082534|Experimental|Cohort 3|"PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
2923967|NCT03082534|Experimental|Cohort 4|"cutaneous HNSCC~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
2923968|NCT03082508|Experimental|Algisyl|Algisyl device (implants) administered during a surgical procedure.
2923969|NCT03082508|Active Comparator|Standard Medical Therapy|as per protocol
2923970|NCT03082495|Experimental|Exercise|Aerobic exercise
2923971|NCT03082495|No Intervention|Usual Care|Standard medical care
2923972|NCT03082482|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment will receive a smartphone with active service, brief advice to quit smoking (self-help materials), and 8-week supply of nicotine replacement therapy (patches), and provided 5 proactive phone counseling sessions by a trained Certified Tobacco Treatment Specialist.
2923973|NCT03082482|Experimental|Automated Treatment|Participants randomized to Automated Treatment will receive smartphone-delivered automated treatment that will provide tailored smoking cessation treatment by way of video clips, text and graphical messages. Participants will receive notifications on the study provided smartphone once a week for an 8-week treatment period. Content delivered will be specific to the participants smoking status and motivation to quit.
2923974|NCT03082469|Active Comparator|CytoSorb|CytoSorb therapy for 48h
2923975|NCT03082469|No Intervention|Matched controls|60 matched controls with SAP and transpulmonary thermodilution monitoring
2923976|NCT03082456|Other|Three breast screening modalities|Subjects who have had mammography less than two years ago will receive MBI and breast ultrasound only. Other participants will receive three interventions including molecular breast imaging, mammography and breast ultrasound. The interval between each examination will be less than 6 months.
2923977|NCT03082443|Experimental|Therapeutic group|
2923978|NCT03082443|No Intervention|Control group|
2923979|NCT03082430|Other|knee osteoarthritis patients.|therapeutic management of symptomatic knee osteoarthritis (resistant to medical first-line treatment) by intra-articular injection of autologous PRP prepared in the same procedure and using a dedicated CE marked medical device and a validated and reproducible method of preparation.
2923980|NCT03082417|No Intervention|Pre-Implementation|"Medical records of patients with a fracture visiting the Emergency departments will be reviewed.~Data will be collected as a baseline prior to the intervention regarding how nurses and physicians working at Emergency Departments manage acute pain in targeted population."
2924018|NCT03082235|Placebo Comparator|Cohort 7: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
2924019|NCT03082222||Group 1|Participants with epilepsy, partial onset seizures with or without secondary generalization with one concomitant antiepileptic drug (AED) at baseline
2923981|NCT03082417|Experimental|Implementation|"In this stepped-wedge trial design, the experimental arm refers to the time period during patients advertising and educational interventions. It consists in:~Informing patients visiting Emergency department for fracture about Pain Management Nurses and physicians working at the Emergency Departments will receive an educational interventions focused on optimal acute pain management in older adults with fracture."
2923982|NCT03082417|No Intervention|Post-Implementation|Data will be collected after the intervention regarding how the intervention impacted nurses' and physicians' work in the pain management in older adults with fracture visiting Emergency Departments manage acute pain in older adults.
2923983|NCT03082404|Experimental|Inspiratory muscle training group|Six times a week (three supervised at hemodialysis unit and other three times at home), 5 series, 10 repetitions, two-minutes interval or according to the patient tolerance.
2923984|NCT03082404|No Intervention|Control group|The patients in this group will be evaluated at baseline and reassessed after five weeks of follow-up.
2923985|NCT03082391|Active Comparator|Heavyweight Mesh|Intervention: Patients will undergo ventral hernia repair with implantation of a heavyweight mesh.
2923986|NCT03082391|Active Comparator|Mediumweight Mesh|Intervention: Patients will undergo ventral hernia repair with implantation of a mediumweight mesh.
2923987|NCT03082365||pre-dialysis|
2923988|NCT03082365||end stage renal disease|
2923989|NCT03082352|Experimental|BF-Metoprolol Tablet 100mg|During the study session, healthy subjects will be administered a single dose of BF-Metoprolol Tablet 100mg after an overnight fast of approximately 10 hours
2923990|NCT03082352|Active Comparator|Betaloc Tablet 100mg|During the study session, healthy subjects will be administered a single dose of Betaloc Tablet 100mg after an overnight fast of approximately 10 hours
2923991|NCT03082339||Neurology|Patients with inflammatory disease, especially multiple sclerosis, who underwent therapy with cortisone (>=40mg/d)
2923992|NCT03082339||Pulmonology|Patients after LTX (under medication possible prologing QTc-interval), who underwent therapy with cortisone (>=40mg/d)
2923993|NCT03082313|Experimental|Movement intervention|The intervention promotes movement experience from 3 months to sitting onset in infants at risk for developmental delay (AR). The goal of the intervention is to increase amount and type of infant leg movement experience above 1200 movements per hour of awake time with 1/3 single and 2/3 bilateral leg movements.
2923994|NCT03082300|Experimental|Pharmacokinetic phase: ASP8273 Tablet then Capsule Sequence|Subjects will receive a single oral dose in tablet formulation on Day 1 of period 1 under fasted condition, then subjects will receive a single oral dose of ASP8273 in capsule formulation on Day 1 of period 2 under fasted condition. Each period will be for 5 days
2923995|NCT03082300|Experimental|Pharmacokinetic phase: ASP8273 Capsule then Tablet Sequence|Subjects will receive a single oral dose in capsule formulation on Day 1 of period 1 under fasted condition, then subjects will receive a single oral dose of ASP8273 in tablet formulation on Day 1 of period 2 under fasted condition. Each period will be for 5 days
2923996|NCT03082300|Experimental|Postpharmacokinetic phase: ASP8273 Capsule Formulation|All subjects will receive ASP8273 capsules in once-daily dosing for 1 cycle (28 days)
2923997|NCT03082287||IBD|Adult subjects diagnosed with IBD via endoscopy and histological findings.
2923998|NCT03082287||IBS|Adult subjects with IBS as per the Rome IV criteria.
2923999|NCT03082287||Other GI Disorders|Adult subjects with gastrointestinal disorders not meeting the Rome IV criteria or IBD diagnosis.
2924000|NCT03082287||Healthy Subjects|Adult subjects without any gastrointestinal complaints.
2924001|NCT03082274||Men age 40-85 years with an initial negative prostate biopsy|Men age 40 - 85 years of age Previous negative prostate biopsy within 30 months.
2924002|NCT03082261|Other|All enrolled subjects|All subjects enrolled into the study with intent to treat with either a Prodigy, Prodigy MRI, or Proclaim Elite IPG.
2924003|NCT03082248|Other|Physical Therapy Group|10-week supervised physiotherapeutic intervention; all patients will receive educational leaflets and folders for maintenance and adherence to the treatment program.
2924004|NCT03082248|Other|Spinal Surgery Group|Surgical procedures and techniques specific for the low back region, previously discussed and agreed upon among surgeons according to patients description.
2924005|NCT03082235|Experimental|Cohort 1: 10 mg E6742|Participants will receive 10 milligrams (mg) E6742 as a single oral dose in the fasted state.
2924006|NCT03082235|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
2924007|NCT03082235|Experimental|Cohort 2: 25 mg E6742|Participants will receive 25 mg E6742 as a single oral dose in the fasted state.
2924008|NCT03082235|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
2924009|NCT03082235|Experimental|Cohort 3: 50 mg E6742|Participants will receive 50 mg E6742 as a single oral dose in the fasted state.
2924010|NCT03082235|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
2924011|NCT03082235|Experimental|Cohort 4: 100 mg E6742|Participants will receive 100 mg E6742 as a single oral dose in the fasted state. Participants will then receive the same single oral dose of E6742 again in the fed state after a washout interval (at least 7 days or 5 half-lives of E6742, whichever is longer) for the evaluation of food effect.
2924012|NCT03082235|Placebo Comparator|Cohort 4: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state. Participants will then receive the same single oral dose of placebo again in the fed state after a washout interval (at least 7 days ) for the evaluation of food effect.
2924013|NCT03082235|Experimental|Cohort 5: 200 mg E6742|Participants will receive 200 mg E6742 as a single oral dose in the fasted state.
2924014|NCT03082235|Placebo Comparator|Cohort 5: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
2924015|NCT03082235|Experimental|Cohort 6: 400 mg E6742|Participants will receive 400 mg E6742 as a single oral dose in the fasted state.
2924016|NCT03082235|Placebo Comparator|Cohort 6: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
2924017|NCT03082235|Experimental|Cohort 7: 800 mg E6742|Participants will receive 800 mg E6742 as a single oral dose in the fasted state.
2924020|NCT03082222||Group 2|Participants with epilepsy, partial onset seizures with or without secondary generalization with two or more concomitant AEDs at baseline
2924021|NCT03082222||Group 3|Participants with epilepsy, partial onset seizures with or without secondary generalization with eslicarbazepine acetate (ESL) as anticonvulsant monotherapy
2924022|NCT03082209|Experimental|Dose Escalation|ABBV-621 via intravenous administration at escalating dose levels in participants with solid tumors including Non-Hodgkin Lymphoma (NHL).
2924023|NCT03082209|Experimental|Dose Optimization for KRAS-mutant CRC|Participants with colorectal cancer (CRC) will be treated with single-agent ABBV-621 to enable selection of the RP2D.
2924024|NCT03082209|Experimental|Dose Optimization for Pancreatic Cancer|Participants with pancreatic cancer will be treated with single-agent ABBV-621 to enable selection of the recommended Phase 2 dose (RP2D).
2924025|NCT03082209|Experimental|ABBV-621 + Venetoclax for DLBCL|Participants with diffuse large B-cell lymphoma (DLBCL) will be treated with a combination of ABBV-621 and venetoclax.
2924026|NCT03082209|Experimental|ABBV-621 Monotherapy for AML|Participants with Acute Myeloid Leukemia (AML) will be treated with ABBV-621 monotherapy.
2924027|NCT03082209|Experimental|ABBV-621 + Venetoclax for AML|Additional participants with AML will be enrolled and will be treated with a combination of ABBV-621 and venetoclax.
2924028|NCT03082196|Experimental|Test varnish|Advantage Anti-Caries Varnish. The active ingredients are Povidone Iodine and Sodium Fluoride .
2924029|NCT03082196|Active Comparator|Standard varnish|The active control varnish will be the same fluoride varnish without iodine with an appropriate FDA approved food dye added to match the color of the test agent. There will be no difference in the treatment and control varnishes except for the povidone iodine.
2924030|NCT03082183|Experimental|All participants|BI 425809 given alone in first period, then in combination with Rifampicin in second period
2924031|NCT03082170|Other|Data review|The investigators will go over the data from the test summary of participants who have already undergone post operative swallowing assessment.
2924032|NCT03082170|Experimental|FEES and SDQ|The participants will undergo six months or more after surgery swallowing assessment which will include the FEES test and the SDQ questionnaire.
2924033|NCT03082157|Experimental|Mighty Men Intervention|Mighty Men weight-loss intervention
2924034|NCT03082157|No Intervention|Comparison|Health education sessions
2924035|NCT03082144|Active Comparator|Group 1: RT-Intra-MTX|Intrathecal chemotherapy: MTX 15 mg, plus dexamethasone 5 mg, via lumbar puncture,once per week, 4 weeks in total.
2924036|NCT03082144|Experimental|Group2: RT-Intra-Ara-C|Intrathecal chemotherapy:Ara-C 50 mg, plus dexamethasone 5 mg, via lumbar puncture, once per week, 4 weeks in total.
2924037|NCT03082131|Experimental|Group 1|"Order of treatments:~A. Resistant Starch Wheat B. Regular Wheat"
2924038|NCT03082131|Experimental|Group 2|"Order of treatments:~A. Regular Wheat B. Resistant Starch Wheat"
2924039|NCT03082118|Experimental|Vesair Arm|Subjects treated with the Vesair Bladder Control System at enrollment.
2924040|NCT03082105|Experimental|Winter snow|First test series breathing in dry snow in winter
2924041|NCT03082105|Experimental|Intermediate snow|Second test series breathing in dry/wet snow in intermediate season
2924042|NCT03082105|Experimental|Spring snow|Third test series breathing in very wet snow in spring
2924043|NCT03082092|Experimental|Methylprednisolone Group|The intervention group will receive a single dose intravenous 125mg methylprednisolone diluted in 2.1ml of diluent on induction of total knee replacement.
2924044|NCT03082092|Placebo Comparator|Placebo Group|The placebo group will receive a single dose intravenous 2.1ml of 0.9% IV saline, which is transparent and has no difference in appearance to methylprednisolone, on induction of total knee replacement
2924045|NCT03082079|Experimental|ESD group|Patient in this group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate.
2924046|NCT03082079|No Intervention|Follow-up group|Patient in this group are given no intervention,the investigators record the tumor size and EUS features of the first endoscopic examination.Regular follow-up are carried out for these patients on 3 month,6 month,1 year,2 year,3 year,4 year,5 year after this check.Then,tumor size and EUS features of each time are collected accurately.
2924047|NCT03082066||Children|Younger 18 years: Newborns, infants, small child, school child, teens
2924048|NCT03082066||Adults|Even or older 18 years
2924049|NCT03082053|Experimental|Study I|Varlitinib given as monotherapy to Japanese subjects with advanced or metastatic solid tumors
2924050|NCT03082053|Experimental|Study II|Varlitinib given in combination with capecitabine to Japanese subjects with advanced or metastatic biliary tract cancer
2924051|NCT03082040|Experimental|intervention group|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks
2924052|NCT03082040|Other|waiting-list control group|Participants in the control condition will conduct the same breathing training as the intervention group after a four-week waiting list period
2924053|NCT03082027||ultrasonography|diagnostic tool
2924054|NCT03082027||operative release|
2924055|NCT03082014|Active Comparator|Arm A|Amlodipine for 4 weeks, Losartan for 4 weeks, Atenolol for 4 weeks.
2924056|NCT03082014|Active Comparator|Arm B|Atenolol for 4 weeks, Amlodipine for 4 weeks, Losartan for 4 weeks.
2924057|NCT03082014|Active Comparator|Arm C|Losartan for 4 weeks, Atenolol for 4 weeks, Amlodipine for 4 weeks.
2924058|NCT03082001|Active Comparator|24% Sucrose|"The enrolled infants were administered sterile solution of 0.2 ml of 24% sucrose (active control) 2 min prior to procedure.~24% sucrose was prepared by mixing 2.4gm of sucrose in 10ml distilled water."
2924089|NCT03081793||Patients with sinus Rhythm|Patients with sinus rhythm at the beginning of monitoring
2924090|NCT03081793||Atrial fibrillation|Patients with atrial fibrillation at the beginning of monitoring
2924091|NCT03081780|Experimental|FATE NK-100|
2924092|NCT03081767|Other|Patients undergoing digital PET/CT|Single arm prospective study of paired imaging studies. Patients who are referred to Nuclear Medicine and are scheduled to undergo imaging on the standard PET/CT will also have imaging performed on the digital PET/CT.
2924059|NCT03082001|Experimental|12% Sucrose|"The enrolled infants were administered 0.2 ml of 12% sucrose 2 min prior to procedure.~These solution were prepared under all sterile precautions by the laboratory staff unrelated to the study. 12%sucrose was prepared by mixing 1.2 gm of sucrose in 10 ml of distilled water. here were two study groups A & B. The enrolled infants were administered sterile solution of 0.2 ml of 24% sucrose (active control) 2 min prior to procedure.~Out of these solutions 1ml was measured by 1 ml syringe and packed and covered with serially numbered opaque sealed envelopes. At the initiation of venepuncture 2 min prior to procedure 0.2 ml of solution marked with patient serial no was administered by a pre-filled syringe to the patient on the anterior aspect of the tongue avoiding spillage, by the personnel carrying out the procedure. The above mentioned personnel was blinded to the contents of the solution."
2924060|NCT03081988||Responder|"Complete Remission after chemoradiotherapy in locally advanced or advanced esophageal cancer~evaluation of disease status: endoscopy, CT, and/or PET-CT"
2924061|NCT03081988||non-responder|"Progressive disease or stationary state after chemoradiotherapy in locally advanced or advanced esophageal cancer~evaluation of disease status: endoscopy, CT, and/or PET-CT"
2924062|NCT03081975|Active Comparator|HD white light|Colonoscopy was performed by use of HD-WLC or HD-NBI upon withdrawal
2924063|NCT03081975|Active Comparator|HD narrow band imaging|Colonoscopy was performed by use of HD-WLC or HD-NBI upon withdrawal
2924064|NCT03081962|Experimental|Bundle application|The patients in this group will undergo an intraperitoneal irrigation with clindamycin and gentamicin solution, fascial closure with triclosan impregnated sutures and application of Mupirocin ointment over the skin staples
2924065|NCT03081962|Active Comparator|Standard care|The patients in this group will follow a standard care, including decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
2924066|NCT03081949|Active Comparator|Treatment|Oral Sodium Selenite 200 µg/day for 3 months
2924067|NCT03081949|No Intervention|Control|No treatment
2924068|NCT03081936|Active Comparator|A1 formula|Oral consumption of Nutricia Aptamil Stage 1 formula (traditional cow milk)
2924069|NCT03081936|Experimental|A2 formula|Oral consumption of a2® Platinum Stage 1 formula (containing 100% A2® beta -casein)
2924070|NCT03081936|Active Comparator|Breast feeding|Oral consumption of breast milk
2924071|NCT03081923|Experimental|Durvalumab|Durvalumab, 1500 mg IV, q4 weeks, until disease progression or onset of unacceptable toxicity
2924072|NCT03081923|Experimental|Duralumab and Tremelimumab|Durvalumab, 1500 mg IV, on day 1 and q4 weeks, until disease progression or onset of unacceptable toxicity Tremelimumab, 75 mg IV, both on day 1 and q4 weeks, until disease progression or onset of unacceptable toxicity
2924073|NCT03081910|Experimental|CD5.CAR/28zeta CAR T cells|Three dose levels will be evaluated. The T cells will be administered with Cytoxan and fludarabine.
2924074|NCT03081897|Experimental|SPRANC Block group|General anaesthesia and additional regional anaesthesia (cervical plexus block) on the tumor side.
2924075|NCT03081897|Active Comparator|SPRANC Control group|General anaesthesia
2924076|NCT03081884|Experimental|FACBC PET-CT Imaging|Individuals who have been diagnosed with primary prostate carcinoma and do not have definitive findings of systemic metastasis with conventional imaging will have a whole body FACBC PET-CT scan.
2924077|NCT03081871|Experimental|Web and mobile app access|Subjects will have access to both the mobile and web-app versions of the study Personal Health Record to communicate with the study pharmacist and enter and track their health data.
2924078|NCT03081871|Active Comparator|Web app only access|Subjects will have access to the web-app version of the study Personal Health Record (and not the mobile app version) to communicate with the study pharmacist and enter and track their health data.
2924079|NCT03081858|Experimental|TSD-001 Administration Part 1, Cohort 1|Part 1, Cohort 1: For the first 3 subjects enrolled, the initial dose will be 10 mg in Sterile Water for Injection (SWFI). TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If Dose Limiting Toxicity(DLT) does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (25, 50, 75, 100, 150 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged [greater than 14 days] grade 2 toxicity) is observed.
2924080|NCT03081858|Experimental|TSD-001 Administration Part 1, Cohort 2|"Part 1, Cohort 1: For the next 3 subjects enrolled, the initial dose will be 150 mg in SWFI. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If DLT does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (225, 300, 375, 450 and 600 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged [greater than 14 days] grade 2 toxicity) is observed.~If no DLT is observed in the first 6 subjects (cohorts 1 and 2) after titration up to 600 mg, then the maximum deliverable dose (MDD), and the maximum tolerable dose (MTD), will be 600 mg, and will be the dose recommended for part 2 of the study."
2924081|NCT03081858|Experimental|TSD-001 Administration Part 2|"In part 2, the dose will be selected as the MTD, established in part 1 and provided weekly via the intravesical route.~During part 2, up to 10 additional subjects will receive intravesical instillations of TSD 001 via urethral catheterization of the urinary bladder at the MTD established in part 1 at weekly intervals for 6 consecutive weeks. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure)."
2924082|NCT03081845|Experimental|Sequence A1-A2|Oral consumption of milk A1 in study phase 1. Oral consumption of milk A2 in study phase 2.
2924083|NCT03081845|Experimental|Sequence A2-A1|Oral consumption of milk A2 in study phase 1. Oral consumption of milk A1 in study phase 2.
2924084|NCT03081832|Experimental|Oxytocin|Groups of children with Prader Willi Syndrome treated by oxytocin for 7 days during their first 6 months of life.
2924085|NCT03081832|Experimental|Control|Groups of children with Prader Willi Syndrome not treated by oxytocin for 7 days during their first 6 months of life.
2924086|NCT03081819|Experimental|SH003|Participant will take SH003 for 3 weeks.
2924087|NCT03081806|Experimental|Active drug|X0002, BID (approximately every 12 hours; n=400)
2924088|NCT03081806|Placebo Comparator|Placebo|Placebo, BID (approximately every 12 hours; n=200)
2924093|NCT03081754||IUGR|Fifty women with intrauterine growth restricted fetuses were included in the study. Gestational age was based on the precisely dated last menstrual period and ultra-sonographic examination of crown-rump length in the first trimester. Intrauterine growth restriction was diagnosed when fetal abdominal circumference was more than two standard deviations below the mean for gestational age and also confirmed by the serial assessment of the fetal growth parameters (Chitty and Altman, 1999). Detailed obstetric history was available for each patient. Caesarean sections were performed on clinical grounds
2924094|NCT03081754||control group|Twenty five uneventful pregnancies with appropriate for gestational age fetuses are selected as control. Obstetric history Doppler results and placenta were examined for any remarkable pathology. Caesarean sections were performed on clinical grounds. The indications for Caesarean section of the controls, which were tried to be at equivalent gestational ages with the study group, were presentation abnormalities or previous Caesarean section
2924095|NCT03081728|Experimental|block|will be given block and continuous infusion with bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
2924096|NCT03081728|Experimental|control|IV analgesia only with diclofenac and paracetamol
2924097|NCT03081715|Experimental|Experimental Group|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PD-1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. To avoid allergic reactions, 50 mg hydrocortisone was intramuscularly injected into patient 30 min before cells infusion every time. Best supportive care was also provided for patients.~A total of 5.0 x 10^8/kg PD-1 Knockout T cells will be infused in one cycle. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT and PET-CT or they withdrew consent."
2924098|NCT03081702|Experimental|Hydroxychloroquine and Itraconazole|"Hydroxychloroquine, orally (by mouth), at a dose of 100 mg, 200 mg, 400 mg, or 600 mg, twice a day, every day.~Itraconazole, orally (by mouth) at 300 mg, twice a day, every day."
2924099|NCT03081689|Experimental|Arm 1|Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
2924100|NCT03081676|Active Comparator|Glimepiride + GIP|Tablet Glimepiride + infusion of GIP
2924101|NCT03081676|Active Comparator|Placebo + GIP|Placebo tablet + infusion of GIP
2924102|NCT03081676|Active Comparator|Glimepiride + GLP-1|Glimepiride + infusion of GLP-1
2924103|NCT03081676|Active Comparator|Placebo + GLP-1|Placebo tablet + infusion of GLP-1
2924104|NCT03081676|Active Comparator|Glimepiride + Placebo|Glimepiride + infusion of placebo (saline)
2924105|NCT03081676|Placebo Comparator|Placebo + Placebo|Placebo tablel + infusion of placebo (saline)
2924106|NCT03081663|Experimental|Quads-Sparing Approach with Tourniquet|Participants will have a navigated total knee arthroplasty with a quadriceps-sparing mid-vastus approach and a tourniquet.
2924107|NCT03081663|Active Comparator|Medial Para-Patellar with Tourniquet|Participants will undergo total knee arthroplasty with a medial para-patellar approach and a tourniquet. An intramedullary femoral guide and extramedullary tibial guide will be used during the surgery.
2924108|NCT03081663|Active Comparator|Quads-Sparing Approach w/o Tourniquet|Participants will have a navigated total knee arthroplasty with a quadriceps-sparing mid-vastus approach and no tourniquet.
2924109|NCT03081663|Active Comparator|Medial Para-Patellar w/o Tourniquet|Participants will undergo total knee arthroplasty with a medial para-patellar approach and no tourniquet. An intramedullary femoral guide and extramedullary tibial guide will be used during the surgery.
2924110|NCT03081650|Experimental|Prospective Open label|"All of the patients that will be Selected to participate in the study will be given an AIRVO humidifier by the study sponsor. Patients will be connected to and instructed in the use of the AIRVO. The total flow will be set at 20-25 L/min, exact flow rate will be dependent on the patient's preference. Optiflow oxygen catheter will be used to ensure against unpleasant sensation due to high flow and to avoid push back in the system.~When acceptable flow rated has been established, it is recorded in the patient's folder. The patients is then instructed to use the AIRVO for a minimum eight (8) hour period, preferably at night. Using the humidifier for a longer period of time is allowed. The total number of hours the humidifier was operational will be recorded at the end of the study"
2924111|NCT03081624||Preterm Preschoolers|Preterm children who haven't attend school.
2924112|NCT03081624||Term Preschoolers|Term children who haven't attend school.
2924113|NCT03081611|Experimental|Ram cannula|NIPPV VIA Ram cannula
2924114|NCT03081611|Active Comparator|Short nasal prongs|NIPPV VIA short nasal prongs
2924115|NCT03081598|Placebo Comparator|Placebo|Daily dose of 6 capsules of placebo
2924116|NCT03081598|Active Comparator|PBI-4050 400 mg|Daily dose of 2 capsules of PBI-4050 and 4 capsules of placebo
2924117|NCT03081598|Active Comparator|PBI-4050 800 mg|Daily dose of 4 capsules of PBI-4050 and 2 capsules of placebo
2924118|NCT03081598|Active Comparator|PBI-4050 1200 mg|Daily dose of 6 capsules of PBI-4050
2924119|NCT03081585||Healthy Controls|Normal weight, healthy female participants
2924120|NCT03081572||Abacavir Group|HIV positive individuals currently taking an abacavir based regimen
2924121|NCT03081572||Tenofovir Group|HIV positive individuals currently taking a tenofovir based regime
2924122|NCT03081559|Experimental|Intervention|Healthy Divas intervention
2924123|NCT03081559|No Intervention|Control|Treatment as usual
2924124|NCT03081546||Mild Cognitive Impairment (MCI)|"Persons with age-related Mild Cognitive Impairment (MCI) according to clinical diagnosis, consistent with Alzheimer's Association (AA) and the National Institute on Aging (NIA) diagnostic criteria.~Must be concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376)."
2924125|NCT03081546||Healthy Controls|Community dwelling controls older than 55 years of age that are concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376).
2924159|NCT03081299||Major Abdominal Surgery|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
2924126|NCT03081533|Experimental|Circle Dance Program|The 12-week circular dance program twice a week will be offered to the intervention group. Each dance class will last for an hour, and the number of participants per class will range from 10 to 15. An physical education professional with Circle Dances certified will lead the classes. The Circle Dances consist of a simple way of dancing choreographies of various peoples and cultures, adapted for a circle dance, hand in hand, where it is not necessary to know how to dance, because no technique or experience is required.
2924127|NCT03081533|No Intervention|Control group|Participants in the control group will not receive intervention and will be instructed not to take part in any regular exercise programs during the study period. At the end of the study, if the benefits of the intervention are proven, Circular Dances classes will be offered to the control group twice a week for 12 weeks.
2924128|NCT03081520|Experimental|Affective response MIT|Moderate intensity continuous training 50 min with walking or running on approximately 75% of HRmax
2924129|NCT03081520|Experimental|Affective response HAIT|High-Intensity Aerobic Interval Training 4x4 min with walking or running on 85-95% of HRmax 3 min active recovery between sets, intensity of approximately 70% of HRmax
2924130|NCT03081520|Experimental|Affective response HIIT|High-Intensity Interval Training 4-6 x 30-sec sprints on tread mill, >95% HRmax during sprints 4 min recovery between sprints, intensity of approximately 70% of HRmax
2924131|NCT03081507|Experimental|LHW-led small media intervention arm (SM-LHW)|
2924132|NCT03081507|Experimental|LHW-led plus small media intervention arm (PN-LHW)|
2924133|NCT03081494|Experimental|PDR001|
2924134|NCT03081481|Experimental|PRX302|intraprostatic administration
2924135|NCT03081468||Healthy volunteers|Fifty healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration. Participants will undergo pupillometry examination using the binocular OCT prototype and Konan RAPDx.
2924136|NCT03081468||Participants with confirmed relative afferent pupillary defect|Fifty participants with with eye disease (retinal disease, glaucoma, and neuro-ophthalmic conditions) and confirmed relative afferent pupillary defect. Each participant will attend for a single study visit, lasting approximately 1 hour in duration. Participants will undergo pupillometry examination using the binocular OCT prototype and Konan RAPDx.
2924137|NCT03081455||Women meeting guidelines for genetic testing|Women who present for an OB/GYN office visit (new patient visit, well woman visit, or problem visit) and who meet guidelines for genetic diagnostic testing will provide a blood or saliva sample for genetic diagnostic testing and complete a satisfaction survey.
2924138|NCT03081442|Active Comparator|Misoprostol group|Sixty women received 600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion.
2924139|NCT03081442|Placebo Comparator|placebo group|Sixty women received the placebo vaginally six hours before IUD insertion. Placebo is the same in size, color and shape to misoprostol.
2924140|NCT03081429||Perioperative covert stroke|
2924141|NCT03081429||Postoperative cognitive dysfunction|
2924142|NCT03081416|Experimental|Intranasal Ketamine arm|Intranasal ketamine administered to participant
2924143|NCT03081416|Active Comparator|Standard Therapy|Reglan 10 mg; Benadryl 25 mg administered to all participants Toradol 15-30 mg; dexamethasone 10 mg added at treating providers discretion.
2924144|NCT03081403|Other|Subjects with sensitive skin|Subjects with a score greater than 50 on the sensitive scale
2924145|NCT03081403|Other|Subjects without sensitive skin|Subjects with result lower than 20 on the sensitive scale
2924146|NCT03081390|Experimental|No migraine, normal weight|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
2924147|NCT03081390|Experimental|No migraine, obese|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
2924148|NCT03081390|Experimental|Migraine, normal weight|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
2924149|NCT03081390|Experimental|Migraine, obese|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
2924150|NCT03081364||Outpatients|MRI; Critical Care Monitoring, Device Programming
2924151|NCT03081351|Experimental|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
2924152|NCT03081351|Experimental|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
2924153|NCT03081338||Study cohort|A mix of incident and prevalent patient cases will be included in order to capture patients at different stages of the disease trajectory.
2924154|NCT03081325|Experimental|lymphocyte immunotherapy on uRM and RIF|Donor (husband or third party) lymphocytes were prepared by Ficoll-Paque centrifugation; the cells were washed with sterile saline and resuspended in 1 ml at a concentration of 20-40 × 106 cells/ml. The cells were given to the female partner by 4-6 intradermal injected. In this study, the lymphocyte immunization therapies were performed every 3 weeks for 3 times. After that we test Th1/Th2/Treg, if they become normal, the patients can prepare for pregnancy.
2924155|NCT03081299||Total Knee Arthroplasty|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
2924156|NCT03081299||Total Hip Arthroplasty|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
2924157|NCT03081299||Mastectomy|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
2924158|NCT03081299||Thoracic Surgery|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
2925374|NCT03072693|No Intervention|Group 3|Patients will receive usual care.
2924160|NCT03081299||Spinal Fusion|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
2924161|NCT03081286|Experimental|Fat grafting|Following liposuction the fat is decanted and used for fat grafting to the area of pain after breast cancer surgery.
2924162|NCT03081286|Sham Comparator|Sham grafting|Following liposuction the fat is discarded. Instead approximately 50mL of saline is used instead of fat and injected into the area of pain after breast cancer surgery.
2924163|NCT03081260|Other|Patellar resurfacing|Patellar resurfacing during the total knee prosthesis Anatomic surgery
2924164|NCT03081260|Other|Patellar non-resurfacing|Patellar non-resurfacing during the total knee prosthesis Anatomic surgery
2924165|NCT03081247|Experimental|BGF 320/14.4/9.6 µg MDI BID|Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
2924166|NCT03081247|Experimental|BFF 320/9.6 µg MDI BID|Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
2924167|NCT03081234|Experimental|Ribociclib + adjuvant endocrine therapy|Ribociclib in combination with standard adjuvant endocrine therapy
2924168|NCT03081234|Active Comparator|Placebo + adjuvant endocrine therapy|Placebo in combination with standard adjuvant endocrine therapy
2924169|NCT03081208|Experimental|Nolasiban 900 mg|
2924170|NCT03081208|Placebo Comparator|Placebo|
2924171|NCT03081195|Experimental|MFG-delivered by trained family peers|"MFG delivered by trained parent peers drawn from local school planning councils:~10 schools; 60 parent peers (6 per school x 10); 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
2924172|NCT03081195|Experimental|MFG-delivered by CHWs|"MFG delivered by community health workers (CHW) drawn from local primary care clinics:~10 schools; 60 community health workers (6 assigned to children per school x 10); 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
2924173|NCT03081195|No Intervention|Bolstered care|"Comparison (Bolstered care): Mental health wellness materials and educational supports (e.g. books, uniforms)~10 schools; 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
2924174|NCT03081182||Pediatric Chronic Pancreatitis|
2924175|NCT03081169|Active Comparator|Early (24 hours)|Patients will receive VTE prophylaxis (heparin 5000 U q 8 hrs or enoxaparin 30 mg q 12 hrs) 24 hours after injury if CT head is stable.
2924176|NCT03081169|Active Comparator|Late (72 hours)|Patients will receive VTE prophylaxis (heparin 5000 U q 8 hrs or enoxaparin 30 mg q 12 hrs) 72 hours after injury if CT head is stable.
2924177|NCT03081156|Active Comparator|Glycopyrrolate/Formeterol Inhaler|Treatment for 2 weeks with Bevespi Aerosphere (Glycopyrrolate/Formeterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
2924178|NCT03081156|Placebo Comparator|Placebo|Treatment for 2 weeks with a placebo Bevespi Aerosphere (Glycopyrrolate/Formeterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
2924179|NCT03081143|Experimental|FOLFIRI plus Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus FOLFIRI (Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle)
2924180|NCT03081143|Active Comparator|Paclitaxel plus Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus Paclitaxel 80 mg/m2 on day 1, 8, 15
2924181|NCT03081130||Intravenous laser irradiation treatment|We will recruit 30 poor ovarian responders and thin endometrium patients and treat with intravenous laser irradiation of blood (ILIB) via an intravenous catheter for irradiation of the blood under a period of 60 minutes for 10 days.
2924182|NCT03081130||control|We will recruit 30 poor ovarian responders and thin endometrium patients and treat with oral estradiol 8 mg per day and oestrogen gel 4 g per day for 14 days
2924183|NCT03081117|Experimental|Insulin, intranasal|Regular insulin, 20 IU intranasal twice a day for 24 weeks; 0.2 mL per dose
2924184|NCT03081117|Placebo Comparator|Placebo, intranasal|Saline solution (placebo), intranasal twice a day for 24 weeks; 0.2 mL per dose
2924185|NCT03081104|Active Comparator|hystroscopy|The procedure will be performed by a gynecological surgeon, under general anaesthesia with the patient in lithotomy position. Antibiotic prophylaxis may be administered, the cervix is grasped with pozzi forceps and dilated up to hegar 9 to facilitate insertion of the hysteroscopy. The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
2924186|NCT03081104|Active Comparator|ultrasound guided aspiration|The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control. It was possible to keep the dilators and the suction cannula under constant view by slightly tilting the transducer as required. Advancement of any instrument was allowed only under direct ultrasound control.The completeness of the evacuation was confirmed by the scan in these cases.
2924187|NCT03081104|Active Comparator|blind aspiration|The women were allowed to empty their urinary bladder before induction of anesthesia, but catheterization was not performed. After positioning the patient appropriately on the operating table, bimanual pelvic examination was performed under anesthesia to assess the axis and the size of the uterus. A Sim's speculum was inserted into the vagina; the cervix was visualized and grasped using the Vulsellum forceps. The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used. The aspirate was examined to confirm the presence of products of conception. The completeness of the evacuation was checked by gentle sharp curettage and final suctioning at the end of procedure.
2924188|NCT03081091|Active Comparator|Intervention group (A) Acupuncture|The treatments performed will be personalized and the treatment criteria will be based on the use of the Yuan and Luo points. In clinical practice, the Yuan (source) points and the Luo (connecting) points can be used jointly, linking the two associated meridians (external-internal) in such a way that, after assessing the state of a meridian's path, its Yuan point will be combined with the Luo point of its coupled meridian and vice versa; all this depending on the condition of the muscle fibres and on the path that wants to be treated for these.
2924189|NCT03081091|Sham Comparator|Control group (C) Sham Acupuncture:|"The course of action with the patient from the group that will use sham acupuncture will be the same as in the group that receives real treatment: patient in supine position, cleaning of the treated area, use of eye mask during the treatments and selection of points following the previously described Yuan and Luo points' criteria, based on traditional Chinese medicine.~The difference of sham acupuncture will lie on the way of performing the acupuncture technique. It will follow the validated technique of sham acupuncture with the Park device, without needle penetration in the patient's body."
2924190|NCT03081078|Experimental|TAU w/ mobile app + volunteer support|Participants will be receiving usual medical treatment from the hospitals with a mobile app engagement intervention, plus support from volunteers.
2924191|NCT03081078|Experimental|TAU w/ mobile app engagement|Participants will be receiving usual medical treatment from the hospitals with a mobile app engagement intervention.
2924192|NCT03081078|No Intervention|Treatment as Usual (TAU)|Participants will be receiving usual medical treatment from the hospitals, and without the interventions (i.e., mobile app and/or volunteer support) introduced through this randomized control trial.
2924193|NCT03081065|Experimental|Mediterranean Diet+ extra virgin olive oil|Free supply with extra virgin olive oil and nuts plus educational advice
2924194|NCT03081065|Experimental|Mediterranean Diet+ tree nuts|Free supply with tree nuts plus educational advice
2924195|NCT03081065|No Intervention|Control|Usual care
2924196|NCT03081052|Active Comparator|Lung transplant with iNO|
2924197|NCT03081052|Active Comparator|Lung transplant with iEPO|
2924198|NCT03081052|Active Comparator|Heart transplant & LVAD implantation with iNO|
2924199|NCT03081052|Active Comparator|Heart transplant & LVAD implantation with iEPO|
2924200|NCT03081039|Active Comparator|Arm A|Cisplatin or Carboplatin with Gemcitabine for 6 cycles
2924201|NCT03081039|Active Comparator|Arm B|Gemcitabine alone for 6 cycles
2924202|NCT03081026||Ages less than 12|Those having ACL Reconstruction surgery during the desired dates at age 12 or less.d
2924203|NCT03081026||Ages 12-13|Those having ACL Reconstruction surgery during the desired dates at ages 12 and 13.
2924204|NCT03081026||Ages 14 - 16|Those having ACL Reconstruction surgery during the desired dates at ages 14 - 16.
2924205|NCT03081013|Active Comparator|Private Arm|At the end of each week, participants will be provided with the number of steps logged by the participants in their group. The number of steps will be ranked from highest to the lowest without any identifiable information about the participants.
2924206|NCT03081013|Experimental|Public Arm|At the end of each week, participants will be provided with the number of steps logged by the participants in their group. The number of steps will be ranked from highest to the lowest with the full names of the participants corresponding to the number of steps.
2924207|NCT03080987|Experimental|Part 1: Cohort 1 (0.3 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 0.3 milligram per kilogram (mg/kg) intravenous (IV) dose of JNJ-64179375 or matching Placebo on Day 1.
2924208|NCT03080987|Experimental|Part 1: Cohort 2 (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 1.0 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.
2924209|NCT03080987|Experimental|Part 1: Cohort 3 (2.5 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 2.5 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.
2924210|NCT03080987|Experimental|Part 1: Optional Cohort 1 (JNJ-64179375 or Placebo)|Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.
2924211|NCT03080987|Experimental|Part 1: Optional Cohort 2 (JNJ-64179375 or Placebo)|Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.
2924212|NCT03080987|Experimental|Part 2: SC Cohort (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375 or matching Placebo on Day 1.
2924213|NCT03080974|Experimental|Single Arm|All patients undergoing irreversible electroporation will be treated with nivolumab
2924214|NCT03080961|Experimental|Before and after VIBLOK|The degree to which HSV-2 is blocked by the VIBLOK cream is determined by comparing the amount of HSV in the external genital area before and after application of the cream. So participants are their own control.
2924215|NCT03080948||History of Melanoma (cases)|Participants at high-risk for melanoma (that is, those having many nevi and morphologically atypical nevi) who either have a history of invasive melanoma (cases) or do not have a history of melanoma (controls) and will perform comprehensive total body imaging of their moles in order to identify phenotypic markers of melanoma risk that aid in melanoma risk stratification. In addition, we will investigate histopathologic and molecular features of moles that are associated with melanoma risk and with melanoma subtypes. The evaluations needed for this study protocol will be primarily performed during routine clinical care.
2924216|NCT03080948||No Melanoma History (controls)|Participants at high-risk for melanoma (that is, those having many nevi and morphologically atypical nevi) who either have a history of invasive melanoma (cases) or do not have a history of melanoma (controls) and will perform comprehensive total body imaging of their moles in order to identify phenotypic markers of melanoma risk that aid in melanoma risk stratification. In addition, we will investigate histopathologic and molecular features of moles that are associated with melanoma risk and with melanoma subtypes. The evaluations needed for this study protocol will be primarily performed during routine clinical care.
2924217|NCT03080935|Experimental|Evolocumab|Single arm study administering Evolocumab.
2924218|NCT03080922|Experimental|hematopoietic stem cell|high dose of donor granulocyte colony-stimulating factor（G-CSF）mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
2924522|NCT03078712|Active Comparator|Peripheral Perfusion guided resuscitation|Resuscitation will be aimed at normalization of capillary refill time.
2924219|NCT03080909|Active Comparator|Encapsulated nutients|"Encapsulated nutrients known to be able to stimulate GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum) expected to start approximately 3 hour following ingestion.~The encapsulated nutrients will be provided 30 minutes prior to the standardized fixed breakfast (providing 2000 kJ) and 60 minutes prior to the standardized fixed mid-morning snack (providing 1500 kJ), i.e. test products will be provided 6 hour and 4 hour before the ad libitum test meal, respectively."
2924220|NCT03080909|Placebo Comparator|Placebo|"Nutrients known to have limited stimulation on GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum) expected to start approximately 3 hour following ingestion.~The placebo products will be provided 30 minutes prior to the standardized fixed breakfast (providing 2000 kJ) and 60 minutes prior to the standardized fixed mid-morning snack (providing 1500 kJ), i.e. placebo products will be provided 6 hour and 4 hour before the ad libitum test meal, respectively."
2924221|NCT03080896|Active Comparator|control group videolaryngoscope/preformed stylet|The control group will intubate using the video-laryngoscope / pre formed stylet. Will convert to using video-laryngoscope and fiber-optic bronchoscope (aScope III) if failure to intubate occurs
2924222|NCT03080896|Experimental|Interventional Group videolaryngoscope/fibeoptic bronch|The interventional group will Intubate using the video-laryngoscope and the fiber-optic bronchoscope (aScope III)
2924223|NCT03080883|Experimental|Group I (lower dose apixaban)|Patients receive lower dose apixaban PO BID for 365 days.
2924224|NCT03080883|Experimental|Group II (higher dose apixaban)|Patients receive higher dose apixaban PO BID for 365 days.
2924225|NCT03080870|Experimental|Intervention|"Art groups are held once a week, each with the duration of 60 minutes. They begin with a 45 minute art intervention and conclude with a 15 minute discussion. The art groups include music, dance and visual arts, which is psychologically, socially, and physically activating. Music has the main emphasis in art intervention. The preferences of the subjects are taken into consideration in art intervention. Art intervention is conducted by trained and experienced art pedagogues.~Art intervention aims to revive previously learned art-related skills, to learn and enhance new skills, and to improve and intensify physiological, emotional, social, motoric, and cognitive abilities."
2924226|NCT03080870|No Intervention|Control|Baseline and follow-up measurements.
2924227|NCT03080857|Experimental|Virtual Platform|Patients will be provided with a computer simulated tool to assist with education and support relating to atrial fibrillation.
2924228|NCT03080844|Experimental|Practice|Participants will be asked to delay time to smoking first cigarette of the day for up to two weeks.
2924229|NCT03080844|Active Comparator|No Practice|Participants will continue with their normal smoking behavior.
2924230|NCT03080831|Active Comparator|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|
2924231|NCT03080831|Active Comparator|Glucion 5%|
2924232|NCT03080818|Experimental|Probiotic|Participants in this arm will receive probiotic supplementation for 12 weeks (Lactobacillus Rhamnosus GG)
2924233|NCT03080818|Placebo Comparator|Control|Participants in this arm will receive placebo that look similar to probiotics
2924234|NCT03080805|Experimental|Pyrotinib Plus Capecitabine|
2924235|NCT03080805|Active Comparator|Lapatinib Plus Capecitabine|
2924236|NCT03080792|Experimental|Exercise|Exercise Intervention, moderate to high-intensity endurance and resistance exercise
2924237|NCT03080779||ADP Group|Index group includes participants who have suffered an accidental dural puncture with a 16 gauge Tuohy needle
2924238|NCT03080779||Non-ADP group|Control group includes participants who received an uneventful epidural analgesia with a 16 gauge Tuohy needle
2924239|NCT03080766|Experimental|decitabine|"Decitabine is a white to almost white powder for concentrate for solution for infusion. It is supplied as a lyophilized preparation in a clear colorless 20ml glass vial containing 50 mg decitabine.~The concentrate should be aseptically reconstituted with 10 ml of water for injections. After reconstitution, the concentrate must be diluted within 15 minutes using cooled infusion fluids and completely administered to patients within 5 hours.~The drug will then be administrated intravenously.~Dosage 20 mg/m2~28-day course, for each course, receive decitabine for 10 days"
2924240|NCT03080753|Experimental|Intersphincteric implants|Treatment with intersphincteric implants in the anal sphincter using Sphinkeeper
2924241|NCT03080740|Active Comparator|Clindamycin palmitate hydrochloride|Clindamycin palmitate hydrochloride dispersible tablet 300mg, oral after meal, twice daily, a total of 7days
2924242|NCT03080740|Active Comparator|Metronidazole|Metronidazole Tablet 400mg, oral after meal , twice daily, a total of 7days
2924243|NCT03080714|Active Comparator|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
2924244|NCT03080714|Active Comparator|Subjects presenting with Retinal Disease|Subjects with Retinal diseases will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
2924245|NCT03080714|Active Comparator|Subjects presenting with Glaucoma|Subjects with Glaucoma will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
2924246|NCT03080701|No Intervention|Group 1 - Automated Mailing|The mailing process will be identical to those used in the SOS study. Mailing 1 includes an introductory letter on CRC screening and a pamphlet on CRC testing choices (colonoscopy every 10 years, FIT testing yearly, or flexible sigmoidoscopy every 10 years combined with interval FIT testing), and pros and cons of each. The letter will state that they will soon be receiving a FIT kit in the mail, and a number to call if they prefer another option. Mailing 2 includes a brief letter reaffirming the importance of screening, a FIT kit (the one used by Group Health), pictograph instructions, and a postage-paid return envelope. Mailing 3 a reminder letter, is sent to participants not completing the FIT kit after 3 weeks. The intervention for Group 1 includes no incentive.
2924247|NCT03080701|Experimental|Group 2 - Auto Mailing Plus Money|Receives the same number of mailings and materials as group 1 with the following modifications. In Mailing 1 the letter will include the intervention notification that they will receive a monetary thank you gift for completing testing (FIT colonoscopy or flex sig within 6 months). Mailing 2 and mailing 3 (reminder letters for those still not returning kits) will include the same information about the monetary thank you gift for CRC screening completion. Mailing 4 will include the money with a thank you letter for those who complete the screening
2924523|NCT03078712|Active Comparator|Lactate guided resuscitation|Resuscitation will be aimed at normalization or significant decrease in lactate levels.
2924248|NCT03080701|Experimental|Group 3 - Auto Mailing Plus Lottery|Receives the same number of mailings and materials as group 1 with the following modifications. In Mailing 1 the letter will include the intervention notification that they will have a 1 in 10 chance of winning money (FIT, colonoscopy or flex sig within 6 months). Mailing 2 and mailing 3 (reminder letters for those still not returning kits) will include the same information about the 1 in 10 chance of winning the lottery for CRC screening completion. Mailing 4 will include a thank you letter with money for those who complete their screening and win the lottery. Participants who do not win the lottery will receive a thank you letter.
2924249|NCT03080688||Prizma|Measurement of oxyhemoglobin saturation by OSM-3 oximeter and Prizma oxygen saturation measurement
2924250|NCT03080675|Experimental|Experimental|Nutritional blend of ingrédients including vitamins and fish oil
2924251|NCT03080675|Placebo Comparator|Control comparator:|control product does not contain any of the active ingredients and is matched for carbohydrate content to the active intervention.
2924252|NCT03080662|Sham Comparator|Sham valve (Placebo)|Sham Inspiratory valve (without resistance)
2924253|NCT03080662|Experimental|Intervention|Inspiratory valve with increase resistance
2924254|NCT03080649|Active Comparator|Rotary bur|Device rotary bur
2924255|NCT03080649|Experimental|Er:YAG laser|Device Er:YAG laser
2924256|NCT03080636|Experimental|Men|11 men randomly underwent three experimental sessions in early morning prior to their work routine.
2924257|NCT03080636|Experimental|Women|9 women randomly underwent three experimental sessions in early morning prior to their work routine.
2924258|NCT03080623||Suspicious breast lesions|women with Suspicious breast lesions, who need to receive breast ultrasound will be collected in this cohort. According to the diagnosis of breast ultrasound，patients will be assigned to breast biopsy or follow-up
2924259|NCT03080597|Experimental|Smartphone app condition|"English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called PrEP Smart."
2924260|NCT03080584|Experimental|acupucture arm|all participants undergo 12 weeks of acupuncture
2924261|NCT03080571|Experimental|Stem cell group|autologous BMMNC stem cells with standard care
2924262|NCT03080571|Active Comparator|Control|Patients randomised in this group received standard care only
2924263|NCT03080558|Experimental|endometriosis recto vaginal node|
2924264|NCT03080545|Experimental|Open Label Enstilar|open label
2924265|NCT03080532||european population|
2924266|NCT03080519|Experimental|Endovascular Therapy|Renal artery revascularization
2924267|NCT03080506|Experimental|Binder|Each woman will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
2924268|NCT03080506|No Intervention|No binder|The women will not be given a chance to wear abdominal binder or the likes.
2924269|NCT03080493|Active Comparator|Gabapentin|"Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)~Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight"
2924270|NCT03080493|Placebo Comparator|Placebo oral capsule|"Matched placebo~Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight"
2924271|NCT03080480|Experimental|Pioglitazone|Treatment for chronic granulomatous disease patients with severe infection.
2924272|NCT03080467||Suture|Wound repair with suture
2924273|NCT03080467||Tissue adhesive|Wound repair with tissue adhesive
2924274|NCT03080454|Active Comparator|Doublestim anodal stimulation|
2924275|NCT03080454|Sham Comparator|Doublestim sham stimulation|
2924276|NCT03080441|Experimental|Phase 1 Group 1|pressure stockings worn during dialysis treatment
2924277|NCT03080441|Experimental|Phase 1 Group 2|Midodrine before dialysis treatment
2924278|NCT03080441|Experimental|Phase 1 Group 3|pressure stocking and Midodrine
2924279|NCT03080428|Active Comparator|Endopredict®|genomic test Endopredict® realized on surgery tumour samples
2924280|NCT03080428|Active Comparator|Prosigna®|genomic test Prosigna® realized on surgery tumour samples
2924281|NCT03080428|Active Comparator|OncotypeDX®|genomic test OncotypeDX® realized on surgery tumour samples
2924282|NCT03080428|Active Comparator|Mammaprint® assay|genomic test Mammaprint® assay realized on surgery tumour samples
2924283|NCT03080415|Experimental|Combined Therapy SOF and DCV|
2924284|NCT03080402|Experimental|High KAM|Mechanically-driven neuromuscular training. 2 times per week for 6 weeks for a total of 12 sessions. Perturbation training
2924285|NCT03080402|No Intervention|Normal KAM|No intervention
2924286|NCT03080389||Extended urine culture|Each patient will be their own control and two specimens will be obtained from each participant. The first will be a catheterized urine sample to be sent for routine culture and the second will be collected from the same catheterized specimen and sent for extended culture.
2924287|NCT03080376|Experimental|Web-based intervention without support|3 months Web-based intervention without support
2924288|NCT03080376|Experimental|Web-based intervention with support|3 months Web-based intervention with support (e-mails)
2924289|NCT03080376|Active Comparator|Traditional intervention|3 months of Printed-based intervention
2924290|NCT03080363|Active Comparator|Quadratus Lumborum Block|Ultrasound guided Quadratus Lumborum Block with 10 ml %0.5 bupivacaine and 10 ml %2 lidocaine
2924291|NCT03080363|No Intervention|Group Control|No intervention
2924292|NCT03080350|Experimental|Fentanyl sublingual + Placebo ev|Fentanyl 100 µg sublingual in acute sever pain + NaCl 0,9% endovenous to mimic fentanyl ev
2924293|NCT03080350|Active Comparator|Fentanyl ev + Placebo sublingual|Fentanyl ev in acute sever pain + Sugar pill manufactured to mimic fentanyl sublingual
2924449|NCT03079193||No vedioscopic larygeoscopic examination|50 patients post thyroidectomy will be followed up and will not do vedeoscopic videoscopic laryngeal examination routinely they will do it if indicated
2924294|NCT03080337|No Intervention|Traditional Care|If the participant is randomized to the individual prenatal care model, she will continue to receive individualized care in the prenatal clinic. This includes being seen by both a MFM specialist and possibly an endocrinologist at each prenatal visit. During the prenatal visit, the individual caregivers are responsible for discussing educational topics that they feel are relevant to the patient. Patients are seen every two weeks for Traditional Care.
2924295|NCT03080337|Experimental|Group Care|If the participant is randomized into the group prenatal care model she will be placed in a group of approximately 6-10 women of approximately the same gestational age. These women will then have sessions scheduled at the same intervals they would have had their traditional prenatal visits, every two weeks until 36 weeks and then weekly until delivery, 12 sessions in total. Each session will last between 90-120 minutes. In the group prenatal care model, the entire visit time will be face to face with a provider and the group. Billing will be done through the standard reimbursement system since the program will follow the schedule of prenatal visits recommended by the American Congress of Obstetricians and Gynecologist.
2924296|NCT03080324|Experimental|Fentanyl sublingual + Placebo ev|Fentanyl 100 µg sublingual in acute sever pain + NaCl 0,9% endovenous to mimic fentanyl ev
2924297|NCT03080324|Active Comparator|Fentanyl ev + Placebo sublingual|Fentanyl ev in acute sever pain + Sugar pill manufactured to mimic fentanyl sublingual
2924298|NCT03080311|Experimental|APG-1252|An accelerated dose escalation scheme will be utilized initially with one patient enrolled per cohort. If at 10 mg or 20 mg dose level, any occurrence in cycle 1 of one ≥ Grade 2 adverse event related or possibly related to APG-1252 (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) is the trigger for converting to a standard 3+3 design at that dose level.
2924299|NCT03080298|Experimental|Treatment with BP101|
2924300|NCT03080298|Placebo Comparator|Treatment with placebo|
2924301|NCT03080285|Active Comparator|Conventional patch|"The patients were prescribed 2 hours of patching per day for the sound eye and the spectacles were to be worn full-time.~Conventional patch is occlusion treatment sticker (Opticlude Eye Patch, 3M, Maplewood, MN, USA) with an adhesive material attached to the skin and serves to cover the eyes."
2924302|NCT03080285|Experimental|over-glasses patch|"the patients were prescribed 2 hours of patching per day for the sound eye and the spectacles were to be worn full-time.~Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is made of fabric and covers the glasses, hence serves to cover the eyes."
2924303|NCT03080272||Spinal Surgery|No intervention will take place. Recruiting Autumn 2017 until spring 2018
2924304|NCT03080272||Gastric sleeve|No intervention will take place. Recruiting Autumn 2017 until spring 2018
2924305|NCT03080272||Total knee arthroplasty|No intervention will take place. Recruiting Spring 2018 until Summer 2018
2924306|NCT03080272||Shoulder arthroplasty|No intervention will take place. Recruiting Winter 2017 until Summer 2018
2924307|NCT03080272||Maxillofacial surgery|No intervention will take place. Recruiting 6 march 2017 until Autumn 2017
2924308|NCT03080259|Active Comparator|Stimulant Diversion Prevention|Providers will be trained in methods to prevent or decrease the likelihood of stimulant diversion by their adolescent patients (education and counseling, strategies for use by patients and parents, and treatment adjustments).
2924309|NCT03080259|No Intervention|Treatment As Usual|Standard clinical care
2924310|NCT03080246|Active Comparator|Strength Training Group|This group will begin coming to the Clinical Research Center (near the undergraduate campus of Wake Forest University) for exercise classes 3 days per week for about an hour each day. The class will consist of a 10-minute warm-up, a 20-minute strength training period, 15-minutes of neuromuscular (balance/coordination) training, and a 15-minute cool down. These regular exercise classes at Wake Forest will go on for 9 months, followed by another 9 months of follow-up via email and 2 group meetings at Fleet Feet (at months 12 and 15).
2924311|NCT03080246|No Intervention|Running Group|This group will be observed as they follow their usual run-training routine over the course of 18 months. Emails will be sent biweekly for 18 months to update the research team on injury/training status. The group will attend 5 group meetings at Fleet Feet (at months 1, 3, 6, 12, and 15). After the 18 months, they will be offered a free 6-week strength training program at the Clinical Research Center.
2924312|NCT03080233||Pakistani adult|"Men and women aged 18 years or above,presenting with neurological deficit consistent with stroke in the Emergency Department at Aga Khan University Hospital~Consenting to participate in the study"
2924313|NCT03080220|Experimental|Astym|The Astym treatment (AT) is specifically used by medical professionals to treat musculoskeletal dysfunctions by stimulating the body's ability to break down adhesions and reabsorb dysfunctional tissue (scar tissue).6-16,19 The treatment induces collagen building, fibroblastic activity, and phagocytosis.17,18 Part of the treatment includes utilizing a series of instruments glided across the skin tissue, in a non-invasive manner, along the route of the underlying muscle fibers' direction. The treatment specifically spares healthy tissue and stimulates growth factors and cellular mediators that stimulate the repair of dysfunctional tissue in the body's internal mechanisms.17,18 Astym is an FDA approved device. Specifically, Astym is registered as having a device class as 1 and regulation number as 890.5660.
2924314|NCT03080220|Experimental|Stick|The Stick treatment (ST) utilizes an instrument to convert non-compliant muscle to compliant muscle by compressing the muscle. The individual spindles of The Stick create a stripping massage by applying progressively deeper strokes over the soft tissue.38 The Stick permits individuals to perform trigger point release on own person, allowing the muscle to become compliant to the wanted movement.
2924315|NCT03080220|Placebo Comparator|Massage|Similar to the protocol previously outlined for the other two independent variables, the massage treatment (MT) will progress from anterior, to medial, to lateral and posterior shank, thigh, and hip. The treatment on each muscle tissue will follow the similar protocol as the Astym treatment (AT) group. However, the flat, non-treatment edge of the Evaluator®, Localizer®, and Isolator® will be put in contact with the muscle tissues in a direction parallel to the muscle fibers being treated, but without over pressure.7 The traditional treatment edge of the instrument has a tapered, machine edge and creates shear forces when glided across the tissue at an angle between 60 and 80 degrees.
2924316|NCT03080207|Experimental|Platelets / Platelet Enriched Plasma Regard (PRP) Method|
2924317|NCT03080207|Experimental|Complex Decongestive Physiotherapy|
2924318|NCT03080207|Experimental|Low Level Laser|
2924319|NCT03080194|Experimental|paliperidone palmitate group|The subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement.
2924320|NCT03080194|Active Comparator|control group|The subjects in control group will be applied with oral antipsychotics or other conventional medication.
2924321|NCT03080181|Experimental|pasireotide|Pasireotide was administered in a 12 months period
2924322|NCT03080168||Actigraph|"All participants will wear an Actigraph (monitoring device) for the duration of their inpatient stay.~NOTE: In clarification, for both this section and Section 4, this devices is an FDA-regulated monitoring device, but NOT an Intervention in this study."
2924323|NCT03080155|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
2924324|NCT03080142|Experimental|Group 1|Single injection of Exparel
2924325|NCT03080142|Active Comparator|Group 2|Injection of Ropivicaine (Naropin) bolus and placement of Ropivicaine catheters
2924326|NCT03080129|Experimental|Cirrhosis + sarcopenia|Patients with cirrhosis will receive 200ml of an oral nutritional supplement daily for 7 days.
2924327|NCT03080129|No Intervention|Control|Patients with sarcopenia and no evidence of cirrhosis and healthy controls
2924328|NCT03080116|Experimental|ARN-509 + degarelix|Treatment period of 12 weeks before RP + PLND.
2924329|NCT03080116|Active Comparator|placebo + degarelix|Treatment period of 12 weeks before RP + PLND.
2924330|NCT03080103||Patients submitted to appendectomy as first-line treatment|"Open or Laparoscopic Appendectomy The assignment of each patient to either the antibiotic-first management arm or the immediate surgery arm, will be non-randomized and decided independently by the Staff Specialist Surgeon on Call, upon careful assessment of AIR score, laboratory findings and imaging. The decision of the management pathway will not be influenced in any case by the participation of the patient in the study, and the assignment of the treatment will be decided by the consultant surgeon according to current good surgical practice and standard practice patterns in Italy."
2924331|NCT03080103||Patients treated with antibiotic-first strategy|Antibiotic therapy.maging. Patients managed conservatively will receive one of the following parenteral antibiotic treatments: Piperacillin/Tazobactam (4.5 g) three intravenous administration per day; Ceftriaxone (2 g) once per day or Ciprofloxacin (500 mg) twice per day plus Metronidazole (500 mg) three times per day; Amoxicillin/Clavulanic acid (2 g) four times per day for a length depending on the clinical conditions; Ertapenem (1 g) one administration per day for three days. Patients were discharged with oral antibiotics (amoxicillin/clavulanic acid or ciprofloxacin) for at least four days.
2924332|NCT03080090|Experimental|High Intensity Exercise|Individuals in this condition will engage in aerobic exercise 3 times a week for 25 minutes each at 77% to 85% of age-predicted HRmax and smoking cessation intervention through a national quitline while using nicotine replacement patches.
2924333|NCT03080090|Active Comparator|Low Intensity Exercise|The intervention procedures for this group are identical to the Experimental Group group except that the target training intensity will be low intensity exercise, self-selected at 50% to 60% of age-predicted HRmax.
2924334|NCT03080077|Active Comparator|Epi-Off CXL|Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of ~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
2924335|NCT03080077|Experimental|Epi-On CXL|The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
2924336|NCT03080064|Experimental|Health Coach Intervention|The investigators connected participants at enrollment (median gestation of 12.5 weeks, IQR: 11-15) with a trained health coach who called participants every 2-3 weeks until 36 weeks of gestation. During these phone calls, health coaches helped participants adopt and maintain new healthful lifestyle behaviors that were evidence-based, simple, and easy to track. Goals aimed to promote appropriate gestational weight gain and covered several domains including diet, physical activity, screen time, and sleep.
2924337|NCT03080051|Experimental|[18F]MNI-952|To evaluate [18F]MNI-952 (also known as [18F]UCB-K), a tau targeted PET radioligand.
2924338|NCT03080038|No Intervention|Usual Care Resuscitation Strategy|Decisions regarding the IV/IO administration of isotonic fluid boluses and/or the initiation and escalation of vasoactive medication infusions are left to the discretion of the treating physician and medical team. We ask that vasoactive medications not be initiated until at least 60 mL/kg (3 litres for children ≥ 50 kg) of isotonic fluid bolus therapy has been administered. The treating physician and medical team are advised to follow ACCM guidelines for the resuscitation of neonatal and pediatric septic shock and to target ACCM recommended therapeutic endpoints.
2924339|NCT03080038|Experimental|Fluid Sparing Resuscitation Strategy|The treating physician and medical team are advised to follow the assigned Fluid Sparing Resuscitation Strategy to guide decisions regarding the IV/IO administration of further isotonic fluid boluses, and the timing of initiation and escalation of vasoactive medication infusions to target the therapeutic endpoints recommended in the ACCM guidelines for the resuscitation of neonatal and pediatric septic shock.
2924340|NCT03080025|Experimental|CBCT® for Couples|"The CBCT® (Cognitively Based Compassion-Training) for couples (CBCT®-fC) consists of a ten-week training program with a 2h group session weekly and daily home practice based on prerecorded guided mediations (Emory University, Atlanta, USA; Ozawa-de Silva & Negi, 2013). The ten weeks start with an overview and a take-home ideas for continuing practice. Furthermore the first and the 3rd module will be repeated once resulting in a total of ten weeks. Further couple- and dyadic exercises are added.~It focuses on six essential key parts for the development of compassion:~Developing attentional stability and clarity of the mind (Mindfulness)~Cultivating insight into the nature of mental experience~Cultivating self-compassion~Developing impartiality~Developing appreciation and affection for others~Developing empathy and realizing engaged compassion"
2924341|NCT03080025|No Intervention|Treatment as usual (TAU)|"Treatment as usual: Primary care according to guidelines from the S3- and national healthcare guideline Unipolar Depression [S3-Leitlinie und Nationale VersorgungsLeitlinie (NVL) Unipolare Depression, Ärztliches Zentrum für Qualität in der Medizin], but excluding current psychotherapy after probatory session."
2924342|NCT03079999|Experimental|Aspirin|Patients on the experimental arm will receive blinded aspirin. Pediatric subjects who weigh less than 110 lbs will take 81mg aspirin twice a day. All other subjects will take 325mg aspirin twice a day.
2924343|NCT03079999|Placebo Comparator|Placebo|Patients on the placebo arm will receive blinded placebo and take it twice a day.
2924344|NCT03079986|Experimental|Ignoring CL (group A)|Standard care irrespective of CL.
2924345|NCT03079986|Active Comparator|Dietary treatment (group B)|Dietary treatment with medium-chain triglyceride diet (MCT-diet) until resolution of CL.
2924346|NCT03079973|Experimental|P-3073|
2924347|NCT03079973|Placebo Comparator|Vehicle|
2924348|NCT03079960|Experimental|Electrophysiological recording and measurement devices|"DBS implantation: patients undergo standard stereotactical neurosurgery for DBS implantation. Decision for DBS treatment has been made prior to inclusion into this study.~Cables and connectors of the macro electrodes will stay externalized for cDBS adjustment procedures. The externalized connectors of the macroelectrodes allow for simultaneous stimulation of the STN and obtaining LFP recordings with electrophysiological recording and measurement devices from the STN for the fitting of DBS parameters, according to the standard clinical procedure."
2924349|NCT03079947||Non-hodgkin Lymphoma|300 Non-hodgkin Lymphoma patients (age >=18y) without previous treatment would be administered, including DLBCLs and PTCLs.
2924350|NCT03079934||Absorb-BVS|Bioresorbable vascular scaffold implantation
2924351|NCT03079921|Active Comparator|Group 1-Propranolol Intra-hepatic islet|The dose of propranolol will be 0.48 μg/kilogram•minute, which will provide a total dose of 0.10 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
2924352|NCT03079921|Active Comparator|Group 1-Phentolamine Intra-hepatic islet|The dose of phentolamine will be 0.95 μg/kg•min, which will provide a total dose of 0.20 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
2924353|NCT03079921|Placebo Comparator|Group 1- Placebo Intra-hepatic islet|Placebo in 100mL NSS. Infuse Intravenously at 0.0095 ML/KG/MIN. 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
2924354|NCT03079921|No Intervention|Group 2 - Extra-hepatic islet|Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.
2924355|NCT03079921|No Intervention|Group 3 - Intra-hepatic auto islet|Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.
2924356|NCT03079908|Experimental|Da Vinci Skills Simulator®|Participants in this group will undergo robotic virtual reality surgical simulator training (Da Vinci Mimics) and will subsequently be evaluated on a dry lab laparoscopic box
2924357|NCT03079908|Active Comparator|LapSim®|Participants in this group will undergo laparoscopic virtual reality surgical simulator Training (LapSim) and will subsequently be evaluated on a dry lab laparoscopic box
2924358|NCT03079908|Placebo Comparator|Dry lab box laparoscopic training|Participants in this group will undergo dry lab box laparoscopic training only
2924359|NCT03079895|No Intervention|Control Arm|After enrollment in the study, the subject will continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being.
2924360|NCT03079895|Experimental|Intervention Arm|"After enrollment in the study, the subject will be granted 8 weeks of access to Thrive, an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy. During the first 4 weeks, they will receive 4 coaching emails and/or phone calls encouraging their participation in the study, and answering any program-related questions. The subject will also continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being."
2924361|NCT03079882||living donor recipients|Recipients of renal transplants with the transplanted organ originating from living donors
2924362|NCT03079882||deceased donor recipients|Recipients of renal transplants with the transplanted organ originating from deceased donors
2924363|NCT03079869|Other|Ferric Citrate|Auryxia, 210 mg ferric iron tablets equivalent to 1 g of ferric citrate are supplied as 200 tablets in 400-cc high-density polyethylene bottles.
2924364|NCT03079856|Experimental|Brief Intervention|ED-based computer-guided intervention for substance use and HIV risk reduction utilizing Motivational Interviewing
2924365|NCT03079856|No Intervention|Enhanced Usual Care|Substance use and sexual health services information within a brochure provided to participants
2924366|NCT03079843|Experimental|facemask first then no face mask|wearing of mask each day for the two hours of exposure for the first week of exposure then not wearing the mask each day for the two hours of exposure for the second week of exposure
2924367|NCT03079843|Experimental|no face mask followed by wearing face mask|not wearing the mask each day for the two hours of exposure for the first week of exposure then wearing the mask each day for the two hours of exposure for the second week of exposure
2924368|NCT03079830|Active Comparator|Ropivacaine continous infusion|Piritramid
2924369|NCT03079830|Sham Comparator|Saline continous|Piritramid
2924370|NCT03079817|Active Comparator|Proprioceptive Drills|Includes drills during which participants perform multiplestances on a pillow, a number of different cone and line drills, reaching drills, object retrieval drills and drills using balls to disturb balance.
2924371|NCT03079817|Experimental|Yoga Meditation|The meditation program will use simple poses during which the participant will not move and will concentrate on each of the participant's body parts and where they are in space.
2924372|NCT03079804|Experimental|Experimental MWM|"Other names:~4 mobilizations - 10 seconds 20 seconds of rest"
2924373|NCT03079804|Active Comparator|Experimental Thrust|"Other names:~1 traction with caudal direction in high speed and low amplitude increasing dorsiflexion."
2924524|NCT03078699|Experimental|stereotactic body radiation therapy|
2924374|NCT03079804|Placebo Comparator|Placebo|"Other names:~It will accurately reproduce the positioning of the hand in the specific treatment condition (Thrust or MWM), however, without applying any movement or force. All interactions, procedures and deadlines will be identical."
2924375|NCT03079778|Active Comparator|TACE alone|Transarterial chemoembolization (TACE)
2924376|NCT03079778|Experimental|TACE plus RT|Combination of transarterial chemoembolization and radiation (TACERT)
2924377|NCT03079765|Experimental|Baseline|Participants will be given a written protocol for conducting the relevant assessment procedure (e.g., open-ended interview).
2924378|NCT03079765|Active Comparator|Telehealth Treatment|Participants will receive feedback and error correction on their implementation of the relevant assessment procedure to improve their performance.
2924379|NCT03079752|Active Comparator|Developmental Screening|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age.
2924380|NCT03079752|Active Comparator|Screening plus Transportation|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two).
2924381|NCT03079752|Active Comparator|Screening, Transport, Prenatal Visits|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy.
2924382|NCT03079752|Experimental|Screen, Transport, Prenatal/Inf Visits|Participants received regular sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy and through child age two.
2924383|NCT03079739||fractional flow reserve group|consecutive patients undergoing coronary artery angiography for established or suspected ischemic heart disease and receiving in at least one lesion FFR assessment
2924384|NCT03079726||Frail individuals (case)|Individuals classified as frail based on several clinical metrics
2924385|NCT03079726||Non-frail individuals|Individuals failing to meet criteria for frailty based on clinical metrics
2924386|NCT03079713|Experimental|Vibratory Anesthesia|Following administration of topical anesthetic and betadine, wearable vibrator will be triggered prior to and during the intravitreal injection
2924387|NCT03079713|Sham Comparator|Standard Injection.|Following administration of topical anesthetic and betadine, wearable vibrator will be placed against the lower lid but NOT triggered prior to and during the intravitreal injection
2924388|NCT03079713|Experimental|Vibratory Anesthesia with Corneal/Conjunctival Sensation Test|Healthy patients not requiring intravitreal injection will be subjected to corneal and conjunctival aesthesiometry with and without the vibrator triggered while in contact with the lower eyelid of a single eye.
2924389|NCT03079674||NICE patients|Non-disabling ischemic cerebrovascular events patients indicate patients with transient ischemic attack and minor stroke (National Institute of Health stroke scale, NIHSS≤3).
2924390|NCT03079648|Experimental|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 8 weeks.
2924391|NCT03079648|Placebo Comparator|Placebo|Placebo for 8 weeks
2924392|NCT03079635|Active Comparator|Normal Weight|This group will be administered two breakfast beverages with a one- to two-week washout period between beverages. The beverages will be a control or an isocaloric, macronutrient matched breakfast beverage with omega-3 fatty acids.
2924393|NCT03079635|Active Comparator|Overweight and Obese|This group will be administered two breakfast beverages with a one- to two-week washout period between beverages. The beverages will be a control or an isocaloric, macronutrient matched breakfast beverage with omega-3 fatty acids.
2924394|NCT03079622|Active Comparator|Electric vacuum aspiration|Electric vacuum aspiration will be performed with Synevac® Vacuum Curettage System 10 (Richmond, CA, USA) with a rigid cannula.
2924395|NCT03079622|Active Comparator|Manual vacuum aspiration|Manual vacuum aspiration will be performed using the 60-mL double valve aspirator, manufactured by Ipas (Chapel Hill, NC, USA) with a flexible cannula.
2924396|NCT03079609|Experimental|microsurgery urology|20 patients with varicocele (grade II or III) undergoing subinguinal microsurgery varicocelectomy due to infertility and/or pain in the scrotum.
2924397|NCT03079609|Active Comparator|open general surgery|20 patients (without varicocele) undergoing open hernia repair.
2924398|NCT03079596|Active Comparator|ERAS perioperative cares|Patients planned to undergoing laparoscopic total gastrectomy, following the ERAS protocols
2924399|NCT03079596|Active Comparator|Conventional perioperative cares|Patents will be managed by our hospital's critical pathways
2924400|NCT03079583|Placebo Comparator|Control-group|Control Rice used for meal, normal zinc level
2924401|NCT03079583|Active Comparator|Intervention-group|Biofortified Rice used for meal, around 30% higher zinc level
2924402|NCT03079557|Experimental|Intragastric botulinum toxin type A|Botulinum toxin A (Allergan) injected intragastrically in the antrum
2924403|NCT03079531|Experimental|secukinumab arm|This is an open label study without placebo and it is a single arm study
2924404|NCT03079518|Active Comparator|Patients with HFREF & CKD|treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal
2924405|NCT03079518|Active Comparator|Patients with HFREF|treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal
2924406|NCT03079505|Active Comparator|Dasatinib|Dasatinib 100mg, once daily (QD), will be given to 25 patients, orally
2924407|NCT03079505|Experimental|Nilotinib|Nilotinib 300mg, twice daily (BID), will be given to 25 patients, orally
2924408|NCT03079479||Two Years Group|
2924409|NCT03079479||Five Years Group|
2924410|NCT03079479||Ten Years Group|
2924411|NCT03079479||Control Group|
2924412|NCT03079466|Active Comparator|Treatment CPAP|A group treated with CPAP
2924413|NCT03079466|Sham Comparator|group without treatment|
2924518|NCT03078738|Placebo Comparator|Placebo MAD|Multiple dose levels 1 - 4 of matching placebo over 14 days Oral, healthy young male
2925377|NCT03072680|Active Comparator|CONTROL|Participants practice DAILY ACTIVITIES for the two weeks.
2924414|NCT03079453|Active Comparator|Group 1|The patients in Group 1 (n:15) were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly at three points (three points on the connection of the uvula, and palatum molle) before tonsillectomy .
2924415|NCT03079453|No Intervention|Group 2|Group 2 (n:15) patients had tonsillectomy without dexamethasone injection.
2924416|NCT03079440|Experimental|TEMCAP|Temozolomide plus Capecitabine
2924417|NCT03079427|Active Comparator|Capecitabine|Adjuvant Capecitabine
2924418|NCT03079427|Experimental|Gemcitabine plus cisplatin|Adjuvant Gemcitabine plus Cisplatin
2924419|NCT03079414||Unexplained Aborted Cardiac Arrest|Survivors of sudden cardiac death with no identifiable etiology following initial diagnostic workup.
2924420|NCT03079401|Experimental|Treatment Arm|"Those randomized to the treatment arm will receive MPCs injected directly into the LV endocardium following clinical surgical maneuvers to recruit the LV (mitral valve repair, aortic valve repair, and/or resection of endocardial fibroelastosis) or BDG.~MPCs will be delivered directly into the LV endocardium via a 23-25 gauge needle following completion of all surgical procedures. A total dose of 20 million cells will be delivered, divided evenly into ~11 injections of 50 µL each. The total volume is not to exceed 2.0 mL."
2924421|NCT03079401|No Intervention|Control Arm|Those subjects randomized to the control arm will receive standard LV recruitment or BDG with no injection.
2924422|NCT03079388|Experimental|Ready-to-use supplementary food + anti-infective bundle|The women randomized to this arm will receive a ready-to-use-supplementary food (RUSF) designed specifically for pregnancy. The RUSF will provide a total of 520 kcal, 18 g protein, and 200% of recommended daily allowance (RDA) for most micronutrients during pregnancy. The supplement is also optimized to provide excellent protein quality and optimal polyunsaturated fatty acid composition. These women will receive 5 anti-infective interventions: 1) insecticide-treated mosquito net, 2) monthly intermittent preventive treatment of malaria during pregnancy (IPTp) 3) azithromycin at the second and third trimester 4) albendazole given in second trimester, and 5) bacterial vaginosis testing and treatment at enrollment and again at weeks 28-34
2924423|NCT03079388|Active Comparator|Corn-soy-blend|The women randomized to this arm will receive the standard of care for Sierra Leone. The treatment provided to women in this group includes 3.5 kg super cereal with 350 g vegetable oil every two weeks. This provides 250 mg portion/day of the super cereal and 25g oil/day for the mother. Women will receive the food for the duration of their pregnancy. These women will receive the current recommendations of the government of Sierra Leone, which includes standard intermittent preventive treatment of malaria during pregnancy (IPTp) of 2 doses of sulfadoxine/ pyrimethamine, iron and folic acid supplement with a goal of 90 pills/pregnancy, an insecticide-treated mosquito net, and albendazole for deworming in the second trimester.
2924424|NCT03079375|No Intervention|usual care|no pharmaceutical intervention.
2924425|NCT03079375|Sham Comparator|basic intervention|Medication review
2924426|NCT03079375|Sham Comparator|extended intervention|medication review, medication interview before discharge and follow-up with patient, GP and if relevant pharmacy and nursing home.
2924427|NCT03079362||Children|Children who underwent selective dorsal rhizotomy (SDR) including intraoperative neuromonitoring (IOM)
2924428|NCT03079349|Active Comparator|Traditional Classroom|Medical Education
2924429|NCT03079349|Experimental|Online Synchronous Classroom|Medical Education
2924430|NCT03079336|Experimental|State of the art (SOTA) check-in phase|The therapists will apply the usual SOTA check-in phase lasting between 5 and 10 minutes, as recommended in the preexisting guideline including reviewing progress in self-help and agenda setting (Zinbarg et al., 2006).
2924431|NCT03079336|Experimental|Prolonged focus on subtle changes|Based on the robust findings that over 90% of the patients will experience subtle changes, the therapists will extend the above mentioned check-in phase by systematized focus for 7 to 20 minutes capitalizing on small and subtle changes and exceptions.
2924432|NCT03079323|Experimental|PART-trial|External beam radiotherapy
2924433|NCT03079310|Experimental|Spinal cord stimulation|Boston Scientific SCS system
2924434|NCT03079297|Experimental|L-leucine|4 gm L-leucine by mouth twice daily for two weeks
2924435|NCT03079297|Placebo Comparator|Maltodextrin|4 gm maltodextrin by mouth twice daily for two weeks
2924436|NCT03079284|Experimental|Holding Group|After meeting inclusion criteria and consenting to participation, mothers of infants who have completed at least 24 hours of therapeutic hypothermia treatment will be allowed to hold their infant who will remain on the cooling blanket for a 30-minute period with the use of a thermal barrier. Vital signs will be measured before holding begins, during holding and following completion of holding. Temperature will be recorded every two minutes during holding. Afterwards, a Likert scale questionnaire to assess the mother's and nurse's reactions will be administered.
2924437|NCT03079271|Other|open label|
2924438|NCT03079258|Experimental|Exercise|Participants randomized to the exercise intervention group will be required to complete a 24-wk partially supervised exercise programme consisting of 3-4 sessions per week of 15 minutes progressing to 30 minutes over time.
2924439|NCT03079258|No Intervention|Control|Those randomized to the control group will continue with their standard care.
2924440|NCT03079245|Other|NICU A - E+, CDS, and PAF|This site was assigned to three interventions, Education Plus (E+), Clinical Decision Support (CDS), and Prescriber Audit and Feedback (PAB).
2924441|NCT03079245|Other|NICU B - E+ and CDS|This site was assigned to two interventions, Education Plus (E+) and Clinical Decision Support (CDS).
2924442|NCT03079245|Other|NICU C - E+|This site was assigned to one intervention, Education Plus (E+).
2924443|NCT03079245|No Intervention|NICU D - Usual Care|This site was not introduced to an interdisciplinary intervention.
2924444|NCT03079232|Experimental|OCTAV|The patients who will have a biopsy of skin suspected to be a melanoma, basal cell carcinoma or squamous cell carcinoma will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
2924445|NCT03079219|Experimental|Experimental|Aprepitant, Ondansetron, Dexamethasone and Olanzapine
2924446|NCT03079219|Other|Standard|Aprepitant, Ondansetron, Dexamethasone
2924447|NCT03079206|Experimental|Hazelnut allergy|patients with positive case history of hazelnut allergy and a positive skin testing are undergoing a food challenge and blood sampling for basophile activation testing
2924448|NCT03079193||videoscopic laryngeal examination|50 patients post thyroidectomy will do mandatory post thyroidectomy videoscopic examination of the larynx
2924450|NCT03079180|Experimental|Aged & strength training at 80% 1RM|"Subjects: 20 subjects aged between 65 and 85 years~Training programs:~Frequency: 3 training sessions per week. Duration: 12 weeks. Intensity: 80% of one repetition maximum (1RM). The 1RM of the participants in each of the 3 exercises performed in the training program will be reviewed every 2 weeks during training. If 1RM increase, the training load will be adjusted accordingly.~Training exercises: A Warm‐up will first be performed on a cycle ergometer during 10min. The training intervention will then consist in performing two sets on each one of the two exercises used for Patellar tendon stress: leg extension and leg press. To stress Achilles tendon, the subjects will perform four (4) sets using a calf raise machine. The subjects will perform 4 to 8 repetitions at 80% 1RM.~All training sessions will take place under appropriate supervision in UTC for the duration of the interventions according to the study design."
2924451|NCT03079180|Experimental|Aged & strength training at 55% 1RM|"Subjects: 20 subjects aged between 65 and 85 years~The training program and training exercises in this group are the same as for the Aged & strength training at 80% 1RM arm except for the two following parameters.~Training intensity: Intensity of exercises will be 55% of one repetition maximum (1RM).~The subjects will perform 6 to 12 repetitions at 55% 1RM.~The two training programs (55% or 80% of 1RM) are designed to be equal in volume (resistance x repetitions x sets)."
2924452|NCT03079180|Experimental|Young & strength training at 55% 1RM|"Subjects: 20 subjects aged between 18 and 30 years~The training program and training exercises in this group are the same as for the Aged & strength training at 55% 1RM arm"
2924453|NCT03079167|Experimental|Erythropoietin|Erythropoietin (epoetin alfa) 1000 IU/kg birth weight (capped at 4000IU daily) IV infusion, on Days 1, 2, 3, 5 and 7 of age
2924454|NCT03079167|Placebo Comparator|Placebo|IV normal saline (equiv. volume), on Days 1, 2, 3, 5 and 7 of age
2924455|NCT03079154|Experimental|Teacher-led MBCT course|Eight-session mindfulness-based cognitive therapy course, including an initial orientation session, led by a qualified mindfulness teacher working with the Sussex Mindfulness Centre, a part of the NHS Sussex Partnership Mental Health Trust.
2924456|NCT03079154|Active Comparator|Self-guided MBCT course|Mindfulness-based cognitive therapy course, after an initial information session, which is self-guided using the audiobook Mindfulness: A practical guide to finding peace in a frantic world by Mark Williams and Danny Penman (2011). It consists of eight substantive chapters that map on to the eight-session MBCT course taught by teachers to groups of students. Students will be asked to work through one chapter a week, thus matching the pace of the teacher-led intervention.
2924457|NCT03079154|No Intervention|Wait list control|Students in the wait list (control) arm do not receive any intervention for the same length of time as the experimental and active comparator arms of the intervention are taking place. Students are invited to complete the self-guided MBCT course after the end of the research project.
2924458|NCT03079141|Active Comparator|Half-dose photodynamic therapy (PDT)|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment."
2924459|NCT03079141|Active Comparator|Oral eplerenone treatment|"Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment."
2924460|NCT03079128|Experimental|Intervention|Weight Watchers Intervention
2924461|NCT03079115|Active Comparator|High-dose Atorvastatin Arm|High dose Atorvastatin (80 mg QD from 3 days before to 3 days after carotid artery stenting, thereafter conventional dose of Atorvastatin with 20mg QD until 30 days after CAS)
2924462|NCT03079115|Other|Conventional-dose Atorvastatin Arm|Conventional dose Atorvastatin (20mg QD from 3 days before to 30 days after CAS)
2924463|NCT03079102|Experimental|inhaled nitric oxide (iNO)|20 ppm iNO delivered via mechanical ventilator connected to the iNO ventilator delivery system (iNOvent). Drug will be started as soon as possible after return of spontaneous circulation (ROSC) but no later than 4h after ROSC. Study drug will be dosed for 12h then tapered off over 1h.
2924464|NCT03079102|Placebo Comparator|Placebo|Nitrogen carrier gas delivered by identical system with similar dose/taper.
2924465|NCT03079089|Other|Relapsed or refractory lymphoid hematological disorders|Patients in refractory or relapses with an indication of allo-HSC used the combination of an SET followed by the RIC with the PDLI
2924466|NCT03079076|Active Comparator|thoracolumbar interfascial plane block|Bilateral ultrasound guided thoracolumbar interfascial plane block with 20 ml %0,25 bupivacaine
2924467|NCT03079076|Placebo Comparator|sham block|Bilateral ultrasound guided sham block with 2 ml saline subcutaneously
2924468|NCT03079063|Experimental|Eptacog alfa biosimilar for PK|Randomized, double-blind, single dose cross-over for PK, with 12 months follow up with eptacog alfa biosimilar provided for treatment of bleeding on demand - or - prophylaxis.
2924469|NCT03079063|Experimental|Eptacog alfa biosimilar, additional immunogenicity cohort|Additional patients receiving eptacog alfa biosimilar for treatment of bleeding on demand - or - prophylaxis, over a 12 months period
2924470|NCT03079050|Experimental|1|34 patients will be assigned to take Dexlansoprazole 60mg over the 2nd, 3rd, and 4th weeks of the month of Ramadan.
2924471|NCT03079037||Stimulation|Traditional deep brain stimulation
2924472|NCT03079024|Experimental|Targeted Cognitive Training (TCT)|Neuroadaptive Cognitive Training
2924473|NCT03079024|Experimental|General Cognitive Exercises (GCE)|Neuroadaptive cognitive training
2924474|NCT03079024|No Intervention|Treatment as Usual|Treatment as Usual
2924519|NCT03078738|Placebo Comparator|Placebo-Gender|Single dose of matching Placebo Oral, healthy non-child bearing potential female
2924520|NCT03078725|Active Comparator|Glyburide|hypoglycemic agent approved for treatment of GDMA2
2924521|NCT03078725|Active Comparator|Metformin|hypoglycemic agent approved for treatment of GDMA2
2924475|NCT03079011|Experimental|A- palbociclib + AI|After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme.
2924476|NCT03079011|Experimental|B- Palbociclib + fulvestrant|After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with fulvestrant, a selective estrogen receptor down-regulator, 500 mg administered intramuscularly on Days 1, 15, and 29 and once monthly thereafter.
2924477|NCT03079011|Experimental|Selection - Palbociclib + AI|All patients included into the study will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme
2924478|NCT03078998|Experimental|Juvenile idiopathic Arthritis|
2924479|NCT03078998|Experimental|Obstetric Brachial Plexus Palsy|
2924480|NCT03078998|Experimental|Cerebral Palsy|
2924481|NCT03078985|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device ( Vision-MR ablation catheter )
2924482|NCT03078972||Advanced Heart Failure|40 patients with advanced heart failure scheduled to undergo Left Ventricular Assist Device (LVAD) insertion will be recruited for testing. Test subjects will complete testing prior to, and following LVAD implantation.
2924483|NCT03078972||Healthy controls|10 age-matched healthy individuals will be recruited to establish normal/reference values.
2924484|NCT03078972||Mild Heart Failure|A second control group comprised of 10 age-matched individuals will be recruited to establish normal/reference values for individuals with mild, medically managed heart failure.
2924485|NCT03078946|Active Comparator|Dexmedetomidine Group (N=30)|
2924486|NCT03078946|Active Comparator|Morphine with Midazolam (N=30)|
2924487|NCT03078933|Active Comparator|Standard of Care|Standard of care for diabetic foot ulcer wound care
2924488|NCT03078933|Experimental|APT001NitricOxide tx 2x week 6 min+ SOC|APT001 Nitric OxideTherapy 2x week for 6 min. treatment time plus standard of care
2924489|NCT03078933|Experimental|APT001Nitric Oxide tx 2x week 12 min+SOC|APT001Nitric Oxide Therapy 2x week for 12 min. treatment time plus standard of care
2924490|NCT03078933|Experimental|APT001Nitric Oxide tx 4x week 6 min+SOC|APT001 Nitric Oxide Therapy 4x week for 6 min. treatment time plus standard of care
2924491|NCT03078933|Experimental|APT001Nitric Oxide tx 4x week 12 min+SOC|APT001Nitric Oxide Therapy 4x week for 12 min. treatment time plus standard of care
2924492|NCT03078920|Other|11 unilateral adult cochlear implant users|Speech Reception Threshold (SRT) measured with an adaptive test
2924493|NCT03078907|Experimental|Selexipag|Selexipag is up-titrated from Day 1 to Week 12 to the individualized highest tolerated dose (HTD), which can range from 200 mcg b.i.d. to 1600 mcg b.i.d., in 200 mcg steps starting with 200 mcg b.i.d. Then, the dose is increased in increments of 200 mcg b.i.d., usually at weekly intervals, depending on the dose tolerability. Up-titration is followed by a stable maintenance treatment period at the highest tolerated dose, from Week 13 to Week 24.
2924494|NCT03078907|Placebo Comparator|Placebo|Regimen and titration scheme similar to those in the selexipag group
2924495|NCT03078894||Districts: Contaminated Water|Subjects in this group are from districts that have contaminated water sources.
2924496|NCT03078894||Districts: Uncontaminated Water|Subjects in this group are from districts that do not have contaminated water sources.
2924497|NCT03078868|Experimental|Single-point intervention|magnetic resonance scanner
2924498|NCT03078855|Experimental|Vitamin D plus rituximab|
2924499|NCT03078855|Placebo Comparator|Placebo plus rituximab|
2924500|NCT03078842|Active Comparator|Zinc-20|Zinc tablets, 20 mg per day
2924501|NCT03078842|Experimental|Zinc-10|Zinc tablets, 10 mg per day
2924502|NCT03078842|Experimental|Zinc-05|Zinc tablets, 5 mg per day
2924503|NCT03078829||Trans female adolescents|All transgender males to females youth in pubertal stage Tanner stage 4-5, starting GnRH agonist and estrogen treatment
2924504|NCT03078816|Experimental|DBS active|"All participants will be enrolled in DBS placement and active stimulation. The following components will be used:~Activa PC Primary Cell Neurostimulator - (Model 37601)~Activa RC Rechargeable Neurostimulator - (Model 37612)~Activa SC Single Cell Neurostimulator (Models 37602 and 37603)~DBS Lead - (Model 3387)~DBS Extension - (Models 37085/6)~Patient Programmer - (Model 37642)~Test Stimulator - (Model 3625)~N'Vision Clinician Programmer - (Model 8840)~N'Vision Software Application Card - (Model 8870)"
2924505|NCT03078803|Experimental|Fecal microbiota transplant|Transfer of healthy human gut bacteria
2924506|NCT03078803|Placebo Comparator|Placebo|Water
2924507|NCT03078790|Experimental|meditation module|The patients in this arm will be offered the meditation/deep breathing module in the pre-operative area.
2924508|NCT03078777|Experimental|Pre-Dialysis|Patients will take 120 mg of fexofenadine three hours prior to dialysis and plasma concentration measured three hours following dosing.
2924509|NCT03078777|Experimental|Post-Dialysis|Patients will take 120 mg of fexofenadine at the end of their dialysis session and plasma concentration measured three hours following dosing.
2924510|NCT03078764|Experimental|Patient Arm using mHealth|Patients with uncontrolled type 2 diabetes
2924511|NCT03078764|Experimental|Community nurses|Nurses who receive mHealth report about patients in the patients' arm.
2924512|NCT03078751|Experimental|Ribociclib + adjuvant endocrine therapy|Ribociclib in combination with standard adjuvant endocrine therapy
2924513|NCT03078738|Experimental|OMT-28-SAD|OMT-28-SAD, Single ascending dose levels 1 - 5 of OMT-28 (15, 45, 120, 240, 360 mg) Oral, healthy young male
2924514|NCT03078738|Experimental|OMT-28-MAD|Multiple ascending dose of dose levels 1 - 4 of OMT-28 over 14 days Oral, healthy young male
2924515|NCT03078738|Experimental|OMT-28- Food Effect|Single dose of OMT-28 Oral, healthy young male
2924516|NCT03078738|Experimental|OMT-28-Gender|Single dose of OMT-28 Oral, healthy non-child bearing potential female
2924517|NCT03078738|Placebo Comparator|Placebo-SAD|Single dose levels 1 - 5 of matching placebo, Oral, healthy young male
2924525|NCT03078686|Active Comparator|Control ARM 1|Control: 1) HD-PRP + Matristem Matrix (ACell) (Current Standard of Care); 2) Platelet Rich Plasma Concentrate)
2924526|NCT03078686|Experimental|Emulsification tSVF + PRP ARM 2|HD-PRP + Emulsified AD-tSVF; Intervention: Platelet Rich Plasma Concentrate
2924527|NCT03078686|Experimental|Emulsification tSVF + PRP + cSVF ARM 3|tSVF; PRP; cSVF cell enriched biocellular therapeutic mix
2924528|NCT03078686|Experimental|cSVF in Normal Saline IV ARM 4|cSVF + Normal Saline IV (500 cc) Infusion
2924529|NCT03078673|Experimental|Motor skill training|training intervention. Poling specific indoor motor skill exercises performed 3 times pr week for 10 weeks in addition to regular training
2924530|NCT03078673|Experimental|Maximal strength training|training intervention. Maximal strength exercises performed 3 times pr week for 10 weeks in addition to regular training
2924531|NCT03078673|Experimental|Control group|Only regular training
2924532|NCT03078660|Experimental|Smartphone Application|Participants will have access to a smartphone application that provides a healthy shopping list based on requirements, budget and discounts to improve dietary practices and weight
2924533|NCT03078660|Active Comparator|Traditional Nutritional Counseling|Participants will participant in a face-to-face counseling session with a registered dietitian.
2924534|NCT03078647|Experimental|Profound treatment to small areas|Single Profound treatment with the Dermal and/or SubQ cartridges to bra bulge, above the knees or upper arms
2924535|NCT03078634|Active Comparator|Multi-Disciplinary clinic|
2924536|NCT03078634|Placebo Comparator|Standard Gastrointestinal clinic|
2924537|NCT03078621|Experimental|Stem Cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
2924538|NCT03078608|Experimental|Intervention arm|Participants in the intervention arm will receive access to a mobile app-based/online mindfulness meditation program and asked to practice meditation daily for 8 weeks.
2924539|NCT03078608|Active Comparator|Active control arm|Participants in this arm will receive access to a mobile app-based/online progressive muscle relaxation (PMR) program and asked to practice PMR daily for 8 weeks.
2924540|NCT03078608|Other|Wait list control arm|Participants in the wait list control arm will also receive access to a mobile app-based/online mindfulness meditation program and asked to practice meditation daily for 8 weeks, but they will not receive access to the program until after the intervention group completes the intervention (8 weeks later).
2924541|NCT03078595||von Willebrand disease type 2 and 3|Examinations (haematologically and periodontally) of von Willebrand disease patients with type 2 and 3 and healthy controls to evaluate whether type 2 and 3 VWD determines an increased susceptibility to gingival bleeding in response to the oral biofilm
2924542|NCT03078595||controls|For each case (VWD) a respective haematologically healthy control is recruited from the gingivitis and periodontitis patients of the Department of Periodontology, Centre for Dentistry and Oral Medicine (Carolinum), Johann Wolfgang Goethe-University Frankfurt/Main. Each control is matched to one of the respective cases for sex, age (±5 years), self-reported smoking status (current smoker/non-smoker), number of remaining teeth (±2 teeth), and periodontal diagnosis (gingivitis, chronic or aggressive periodontitis).
2924543|NCT03078582|Experimental|RA101495|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
2924544|NCT03078569|Experimental|testosterone gel|testosterone gel treatment group
2924545|NCT03078569|No Intervention|Control group|without testosterone treatment
2924546|NCT03078556|Experimental|Treatment sequence A/B: Part 1|Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 1, B: DTG 3TC FDC formulation 1 tablet in Period 2.
2924547|NCT03078556|Experimental|Treatment sequence B/A: Part 1|Eligible subjects will be randomized in sequence B/A and will receive B: DTG 3TC FDC formulation 1 tablet in Period 1 and A: DTG 50 mg and 3TC 300 mg single entities in Period 2.
2924548|NCT03078556|Experimental|Subjects receiving high fat meal: Part 1|Eligible subjects will be administered single dose of DTG 3TC FDC formulation 1 tablet with high fat meal in Period 3 to study the effect of food on tablet.
2924549|NCT03078556|Experimental|Treatment sequence A/C: Part 2|Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 mg and 3TC 300 mg single entities in Period 1 and C: DTG 3TC FDC formulation 2 tablet in Period 2.
2924550|NCT03078556|Experimental|Treatment sequence C/A: Part 2|Eligible subjects will be randomized in sequence C/A and will receive C: DTG 3TC FDC formulation 2 tablet in Period 1 and A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 2.
2924551|NCT03078556|Experimental|Subjects receiving high fat meal: Part 2|Eligible subjects will be administered single dose of DTG 3TC FDC formulation 2 tablet with high fat meal in Period 3 to study the effect of food on tablet.
2924552|NCT03078543|Other|ANTHEM™ Total Knee System implant|The ANTHEM™ Total Knee System will demonstrate non-inferiority of 10 year implant survivorship in patients undergoing total knee arthroplasty for osteoarthritis compared to reported literature
2924553|NCT03078530|Placebo Comparator|Placebo|Placebo (not an active drug/ Inactive component) is given to this group
2924554|NCT03078530|Experimental|Visbiome|Visbiome (probiotic mixture) is given to this group.
2924555|NCT03078530|Experimental|VSL #3|VSL #3 (probiotic mixture) is given to this group
2924556|NCT03078517|Active Comparator|I-gel group|After the induction of anesthesia, I-gel is inserted into the oropharyngeal space.
2924557|NCT03078517|Experimental|LMA protector group|After the induction of anesthesia, laryngeal mask airway protector is inserted into the oropharyngeal space.
2924558|NCT03078491|Experimental|Intervention|The intervention group will use eCGM (CGM with Diabetes Management Platform(DMP)) and an activity meter. The DMP will be pre-loaded with geriatric-specific education material, weblink to online education and surveys. The CGM, insulin delivery, and activity data uploaded from the DMP will be analyzed by the clinical decision support system (CDS), which will provide insulin dosing recommendations to the study physicians, who will then accept or reject changes in therapy. The DMP can also be configured to route the insulin regimen change approved by the study physician to the designated care providers of the patient. Blue-tooth unabled insulin pens will also provide additional data to verify if the patient is taking recommended insulin doses.
2924595|NCT03078205|Experimental|The dual therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy.
2924559|NCT03078491|No Intervention|Attention Control|The attention control group will receive an android tablet pre-loaded with activity monitor devices, education material, and weblink to online education and surveys. However, the data will not be analyzed by CDS. An independent physician and a study staff member- only caring for the control group subjects will review the insulin and glucose data at in-person and remote study visits and make appropriate dosing adjustments based on self monitoring glucose levels
2924560|NCT03078478|Experimental|IDeg 200 U/mL|
2924561|NCT03078478|Active Comparator|IGlar 300 U/mL|
2924562|NCT03078465|Experimental|Ticagrelor|Administration of ticagrelor 180mg/day for 12 months.
2924563|NCT03078465|Active Comparator|Clopidogrel|Administration of clopidogrel 150 mg/day for 12 months
2924564|NCT03078452|Experimental|Arm I (biopsy using power drill)|Patients undergo bone marrow biopsy using the power drill. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.
2924565|NCT03078452|Active Comparator|Arm II (biopsy using Jamshidi needle)|Patients undergo bone marrow biopsy using the traditional Jamshidi needle. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.
2924566|NCT03078426|Experimental|Group 1 : UIP pattern|18 patients with UIP pattern at HRCT and IPF as a definite diagnosis.
2924567|NCT03078426|Experimental|Group 2 : possible UIP pattern|"7 patients with  possible  UIP pattern at HRCT with histopathology given by surgical lung biopsy making the diagnosis of IPF."
2924568|NCT03078426|Experimental|Group 3 : diagnosis of fibrosing sarcoidosis|15 patients with the diagnosis of fibrosing sarcoidosis after multidisciplinary discussion.
2924569|NCT03078426|Experimental|Group 4 : lung diseases without reticulations|20 patients with lung diseases without reticulations (acute or sub-acute hypersensitivity pneumonitis, organizing pneumonia, isolated pleural plaques) .
2924570|NCT03078400|Experimental|Safety Phase|"Six to 12 subjects~Cohort 1 SPL-108 injection daily + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles~Cohort 2 SPL-108 BID injection + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles"
2924571|NCT03078400|Experimental|Exploratory Expansion Phase|"Up to 12 subjects~• Cohort 3: SPL-108 daily dose (to be determined in Arm I) + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles."
2924572|NCT03078374|Other|Reduced Anticoagulation|Reduced anticoagulation
2924573|NCT03078361|Active Comparator|LATINOS CARES Toolkit|Participants assigned to the LATINOS CARES condition will receive an I-FOBT kit, DVD and photonovella booklet from the study coordinator. The participant will view the DVD in a private area (headphones are available) using a portable DVD player in clinic before seeing the provider. The DVD will be about 8-10 minutes long. The participant will take the LATINOS CARES toolkit and I-FOBT home after the clinic visit. The participant will be instructed to re-review the materials and complete the I-FOBT stool sampling at home.
2924574|NCT03078361|Active Comparator|Standard Intervention (SI)|Participants assigned to the standard brochure (SI) will be provided a packet containing the CDC Spanish-language tri-fold brochure titled Screen for Life and an I-FOBT card. The participant will be instructed to review the materials in clinic and complete the I-FOBT stool sampling at home. This brochure describes CRC, risk factors, symptoms, screening tests, benefits of screening, and insurance coverage.
2924575|NCT03078348|Active Comparator|Targeted Psychoeducational Photo Novella|"Fecal Immunochemical Test (FIT) Kit + Culturally targeted Photo Novella Booklet + culturally targeted reminders. This study involves participation at distinct time points:~Baseline~6 month follow-up"
2924576|NCT03078348|Active Comparator|Standard Brochure Intervention|"FIT Kit + Screen for Life Brochure + standard reminders. This study involves participation at distinct time points:~Baseline~Post 6 month follow-up"
2924577|NCT03078335|Experimental|Glove based care|The intervention is the use of non-sterile gloves, after standard hand hygiene for all routine patient care needs.
2924578|NCT03078335|Active Comparator|Standard care|The control group will provide standard care, that is, hand hygiene before all patient, bed, and intravenous catheter contact.
2924579|NCT03078322|Experimental|AV-101|L-4-chlorokynurenine 1440 mg daily for 14 days
2924580|NCT03078322|Placebo Comparator|Placebo|Placebo
2924581|NCT03078309|Experimental|healthy|All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.
2924582|NCT03078309|Experimental|Retinitis Pigmentosa|All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.
2924583|NCT03078296||Members of the AAGL|Physicians and other providers who are members of the AAGL.
2924584|NCT03078283|Experimental|Participants|Consumption of a given type of high-fiber snack food, with each individual functioning as her own control
2924585|NCT03078270|Other|Open-label|10 participants will be recruited for an open-label study. All will receive the active medication and complete depression and anxiety surveys at baseline, 4-weeks, and 8-weeks post injection. All participants will receive botulinum toxin A.
2924586|NCT03078270|Placebo Comparator|Double-Blind|30 participants will be recruited for a double-blind, comparison study. Participants will be randomized to the active or control groups. Each will receive an injection (active medication or placebo) and will complete a depression and anxiety survey at baseline, 4-weeks and 8-weeks post injection. Participants in the active group will receive botulinum toxin A; participants in the control group will receive a placebo.
2924587|NCT03078257|Experimental|dual antiplatelet therapy|clopidogrel +aspirin
2924588|NCT03078257|Experimental|tirofiban in PV|clopidogrel +aspirin + tirofiban in PV
2924589|NCT03078257|Experimental|tirofiban in IC|clopidogrel +aspirin +tirofiban in IC
2924590|NCT03078257|Experimental|antiplatelet thrombolysin|clopidogrel +aspirin +antiplatelet thrombolysin
2924591|NCT03078257|Placebo Comparator|placebo|clopidogrel +aspirin +placebo
2924592|NCT03078218|No Intervention|Before period group|Strictly observational in order to assess the current screening strategy as it is conducted in real life
2924593|NCT03078218|Experimental|After period group|Consist in a systematic pulse oximetry screening where all eligible newborns will be included in the same maternity wards
2924594|NCT03078205|No Intervention|The control group|No Intervention
2924596|NCT03078205|Experimental|The triple therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM.
2924597|NCT03078192|Experimental|PVD, left heart disease, lung disease|Patients with Pulmonary Vascular Disease (10 subjects), isolated left sided heart failure (10 subjects), and isolated lung disease(10 subjects) will undergo Xe MRI scans with GE-141, Hyperpolarized 129Xenon gas to develop diagnostic criteria for optimizing the sensitivity and specificity of XeMRI for the diagnosis of PVD
2924598|NCT03078192|Experimental|Pulmonary Vascular Disease Patients|92 subjects being evaluated for Pulmonary arterial hypertension for testing of diagnostic accuracy of XeMRI for diagnosis of PVD
2924599|NCT03078179|Experimental|Commercial Cow Milk with Probiotic|"Probiotic enriched cow milk:~200 ml of commercial nutritive milk fortified with probiotic Lactobacillus rhamnosus and Bifidobacterium longum once a day."
2924600|NCT03078179|Placebo Comparator|Commercial Dairy Cow Milk|200 ml of commercial nutritive milk without probiotic, once a day,
2924601|NCT03078153|Experimental|Financial Incentive|Provided financial incentive at 3-month and 6-month follow-up visits
2924602|NCT03078153|Experimental|Social Media Group|Provided social media support through a facebook group for 6 months
2924603|NCT03078153|No Intervention|Control|No intervention
2924604|NCT03078140|Active Comparator|Triferdine|Triferdine 1 tablet by mouth daily. Start after 1st trimester until delivery
2924605|NCT03078140|Active Comparator|Triferdine/Ferli-6|Triferdine or ferli-6 1 tablet by mouth daily base on iodine status. The supplement will give after 1st trimester until delivery
2924606|NCT03078127|Placebo Comparator|Huff-Cough Alone|"Subjects will provide two huffs (forced expiratory maneuver with open glottis) followed by a cough every six minutes for a total of six Huff-Coughs."
2924607|NCT03078127|Active Comparator|Oscillatory Positive Expiatory Pressure Device (OPEP)|Subjects will use an Areobika® branded OPEP device (10 breaths through highest tolerated resistance) prior to undergoing a Huff-Cough. Subjects will use the device six times every six minutes.
2924608|NCT03078127|Active Comparator|Whole Body Vibration|Subjects will be seated on a PowerPlate® whole-body vibration platform for 90 seconds prior to Huff-Cough. Six intervals on the platform will be completed six minutes apart.
2924609|NCT03078127|Active Comparator|High Frequency Chest Wall Oscillatory Vest|"Subjects will use TheVest® using a standardized Minnesota Protocol divided into six, four-minute segments, each followed by a Huff-Cough."
2924610|NCT03078114|Experimental|Spinal Manipulation|Subjects with subacute low back pain. Subjects will receive 6 treatments of Spinal Manipulation (SM) over 2 consecutive weeks
2924611|NCT03078114|Placebo Comparator|Placebo Spinal Manipulation|Subjects with subacute low back pain. Subjects will be asked to visit the clinic for 6 times. The clinician will go through SM motions but the spine will not actually be manipulated.
2924612|NCT03078101|Experimental|Group A|Diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]
2924613|NCT03078101|Placebo Comparator|Group B|Diabetic CKD patients receiving Placebo Oral Tablet
2924614|NCT03078101|Experimental|Group C|Non-diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]
2924615|NCT03078101|Placebo Comparator|Group D|Non-diabetic CKD patients receiving 'Placebo Oral Tablet
2924616|NCT03078088|Placebo Comparator|saline|normal saline
2924617|NCT03078088|Experimental|treatment|tham
2924618|NCT03078075|Experimental|Active Medication Combination (AMC)|injectable extended release naltrexone plus once daily oral extended-release bupropion tablets
2924619|NCT03078075|Placebo Comparator|Matched Placebo (PLB)|injectable matching placebo plus once-daily oral placebo tablets
2924620|NCT03078062|Active Comparator|Dexamethasone|During the performance of spinal anesthesia using isobaric 0.5% bupivacaine 12 mg, an intravenous infusion of dexamethasone 8 mg (2 ml) will be initiated. The study drug will be administered over 5 -10 minutes diluted in a 500 ml bag of Normal Saline for a total volume of 502 ml. The study drug will be prepared by an independent assistant.
2924621|NCT03078062|Placebo Comparator|Normal Saline|During the performance of spinal anesthesia using isobaric 0.5% bupivacaine 12 mg, an intravenous infusion of 502 ml of Normal Saline will be initiated. The infusion will be administered over 5 -10 minutes. The study drug will be prepared by an independent assistant.
2924622|NCT03078049||Dapagliflozin|Patients taking dapagliflozin
2924623|NCT03078049||Sitagliptin|Patients take sitagliptin
2924624|NCT03078036||Observation|Human epidermal growth factor receptor 2 negative metastic breast cancer patients who have started 1st line systemic cytotoxic chemotheraphy and are considered to have exhausted hormone therapy options (if HR+ve), per investigator's opinion.
2924625|NCT03078023|Experimental|swallowed sponge device|Swallowing a sponge prior to a clinical upper endoscopy. Patients diagnosed with Eosinophilic Esophagitis (EoE) > than 15 Eosinophils per high power field (phf) and failed to respond to Proton Pump Inhibitors (PPI) therapy. Will be asked to swallow a sponge, this is a 10 minute procedure done in the office prior to their clinical upper endoscopy. This will be sent for histology, >15 Eos phf would be considered active disease. We will compare the results of the sponge using the EPO staining technique compared to histologic response.
2924626|NCT03078010|Active Comparator|Piperacillin-tazobactam|
2924627|NCT03078010|Experimental|cefepime|
2924628|NCT03077997|Experimental|Space from Diabetes|Participants will be assigned the 'Space from Diabetes' intervention in a supported mode for 8 weeks. Participants are assigned a clinical supporter, who will be a psychological well-being practitioner in an NHS Mental Health Service. As the participant works through the programme content, the supporter will provide them with a review of their progress and interactions with the platform 6 times over the 8 week supported period.
2924629|NCT03077984|Experimental|the cohort of Chinese medicine treatment|The cohort of Chinese medicine treatment uses its comprehensive program of TCM on the basis of treatment with western medicine, including Chinese Herbs, acupuncture and acupoint application therapies.
2924630|NCT03077984|No Intervention|the cohort of western medicine treatment|The cohort of Western medicine treatment refers to the treatment of cerebrovascular disease prevention and cure guideline of China-related programmes, including anti-platelet aggregation, blood pressure,blood glucose,Blood Lipids lowering therapies.
2924631|NCT03077971|Experimental|ACT Self-Help|Participants in this arm will receive a self-help book based on Acceptance and Commitment Therapy (ACT). Participants will receive chapters each week, either electronically or by post, for 8 weeks.
2924632|NCT03077971|Experimental|ACT Self-Help with Telephone Support|Participants in this arm will receive a self-help book based on Acceptance and Commitment Therapy (ACT). Participants will receive chapters each week, either electronically or by post, for 8 weeks. In addition to this, participants will have weekly telephone calls to support the use of the book.
2924633|NCT03077971|No Intervention|Treatment As Usual|Participants in this arm will have no intervention as part of the trial.
2924634|NCT03077945|Experimental|Intervention Condition|This group will receive the heart rate variability biofeedback intervention in addition to the cognitive reappraisal of stress intervention
2924635|NCT03077945|Placebo Comparator|Control Condition|This group will complete control tasks, including viewing neutral videos.
2924636|NCT03077932|Other|App Development and Open Pilot|"Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients with OUDs.~Phase 2 (open pilot) will involve conducting a 4-week open pilot trial (n=50) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate replacement therapy"
2924637|NCT03077919|Active Comparator|Stellate Ganglion Block (SGB)|7-10 mL 0.5% ropivacaine injected under ultrasound visualization ventral to right longus coli muscle (around and into the ventral fascia) and into the longus coli immediately dorsal to the presumed ventral fascia, at the level of the C6 anterior tubercle (landmarks for stellate ganglion).
2924638|NCT03077919|Sham Comparator|Sham Treatment|1-2 mL preservative-free normal saline, injected under ultrasound visualization anterolateral to right anterior tubercle of C6.
2924639|NCT03077906||Existing gastroœsophageal reflux|"Patients who benefited from a sleeve gastrectomy surgery between 2008 and the end of 2015 in the department of digestive surgery of the CHU Brugmann.~Patients who already had a disabling gastroœsophageal reflux resistant to medical treatment in pre-op, and lost it in post-op."
2924640|NCT03077906||De novo gastroœsophageal reflux|"Patients who benefited from a sleeve gastrectomy surgery between 2008 and the end of 2015 in the department of digestive surgery of the CHU Brugmann.~Patients who developped gastroœsophageal reflux de novo."
2924641|NCT03077893|Experimental|Active Group|Treatment with active Provant Therapy System
2924642|NCT03077893|Sham Comparator|Sham Group|Treatment with Inactive (sham) Provant Therapy System
2924643|NCT03077880||thin soft tissue|full thickness thin mucosal soft tissue at the periodontal probe measured intra-operatory measurement during implant placement
2924644|NCT03077880||thick soft tissue|full thickness thick mucosal soft tissue at the periodontal probe measured intra-operatory measurement during implant placement
2924645|NCT03077867|Experimental|test HA|synthetic hydroxyapatite alone sinus floor augmentation with bone graft
2924646|NCT03077867|Experimental|test HA vicryl|synthetic hydroxyapatite mixed with polylactic-polyglycolic acid sinus floor augmentation with bone graft
2924647|NCT03077867|Experimental|test HA-PRF|synthetic hydroxyapatite mixed with i-PRF sinus floor augmentation with bone graft
2924648|NCT03077867|Active Comparator|control|anorganic bovine bone sinus floor augmentation with bone graft
2924649|NCT03077854|Experimental|Functional Lung Avoidance-TRT|"Functional Lung Avoidance Thoracic Radiotherapy~The avoidance thoracic radiotherapy treatment plan will be designed to optimize such that radiation dose to functional lung identified by four-dimensional (4D) CT ventilation imaging is as low as reasonably achievable"
2924650|NCT03077854|Active Comparator|Standard-TRT|"Standard Thoracic Radiotherapy~The standard thoracic radiotherapy treatment plan will be designed without reference to the functional lung 4D CT ventilation imaging"
2924651|NCT03077841|Experimental|Hypofractionated Partial Breast Irradiation|"Participants receive about 2 weeks of radiation (10 treatments) to the part of the breast where the disease first started.~Questionnaires completed at baseline and at 6 months and 1, 2, 3, 4, and 5 years after receiving radiation."
2924652|NCT03077828|Experimental|Treatment (pembrolizumab, etoposide, carboplatin, ifosfamide)|Patients receive pembrolizumab IV over 30 minutes on day 1, etoposide IV over 60 minutes on days 1-3 of courses 1-2, carboplatin IV over 60 minutes on day 2 of courses 1-2, and ifosfamide IV over 24 hours on day 2 of courses 1-2. Pembrolizumab in combination with ICE chemotherapy repeats every 21 days for 2 courses, patients will then receive pembrolizumab as monotherapy on course 3.
2924653|NCT03077815|Other|arm movement more than a total of at least 30 minutes a day|Using the provided rubber ball grip the ball movement on a daily basis, and grip the ball at a time 3-5 seconds, every 5 minutes, daily at least 6 rounds (for example, according to the daily morning, noon and night-time sports training in the two groups), to reach an arm movement more than a total of at least 30 minutes a day
2924654|NCT03077815|Other|arm movement and local press strength 50 mmHg at the upper arm|Using the provided rubber ball grip the ball movement on a daily basis, and grip the ball at a time 3-5 seconds, every 5 minutes, daily at least 6 rounds (for example, according to the daily morning, noon and night-time sports training in the two groups), to reach an arm movement more than a total of at least 30 minutes a day with Elbow proximal 4 (2~6) local press strength 50 mmHg at the upper arm
2924655|NCT03077802|Experimental|Modified Seldinger technique, short axis|Under short-axis ultrasound-guide, use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
2924656|NCT03077802|Active Comparator|Seldinger technique, short aixs|Under short-axis ultrasound-guide, the desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
2924657|NCT03077802|Experimental|Modified Seldinger technique, long axis|Under long-axis ultrasound-guide, use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
2924658|NCT03077802|Active Comparator|Seldinger technique, short axis|Under long-axis ultrasound-guide, the desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
2924659|NCT03077789|Experimental|TRABECULOTOMY|
2924699|NCT03077542|Experimental|recipient|recipient
2925583|NCT03071081|Experimental|TOP1288 Xg (where X is <=1g) BID|7 days dosing
2924660|NCT03077776|Experimental|All included patients|"Patients will undergo a biopsy and provide a blood sample prior to initiating standard neoadjuvant chemotherapy. Additional tissue samples will be collected at the following time points:~(optional) biopsy of primary tumour after 4 cycles of neoadjuvant chemotherapy~At the time of surgery (samples of the primary tumour and lymph nodes which are surplus to diagnostic requirements).~Biopsy of a metastatic site in the event of disease recurrence.~Blood samples will be obtained during neoadjuvant chemotherapy, prior to surgery and at 6-month intervals for up to 5 years post-surgery. In the event of recurrent disease, blood samples will be collected i) at the time of recurrence, ii) at the first CT scan on treatment and iii) at each subsequent relapse for up to 5 years post-surgery."
2924661|NCT03077763|Active Comparator|Normoxia and Nitrite (3umol/min-1)|Sodium nitrite stock solution: 100umol/10ml, prepared to concentration according to oxygen sequence. Normoxia (3umol/min-1).
2924662|NCT03077763|Active Comparator|Hypoxia and Nitrite (1umol/min-1)|This will be repeated as per the normoxia cohort, but at a reduced dose of sodium nitrite (1umol/min-1 for 30 minutes) and the volunteers will be asked to breathe 12% oxygen/88% nitrogen for 1-5 minutes before Plethysmography is performed (to get the volunteer to an oxygen saturation of 83-88% peripherally).
2924663|NCT03077750|Experimental|VBP-245|VBP-245 Topical Gel Applied to Affected Area BID
2924664|NCT03077750|Placebo Comparator|Vehicle|Vehicle Gel Applied to Affected Area BID
2924665|NCT03077737|Experimental|Population health management|Population health management for smoking cessation in low-income smokers: the Choose to Change intervention
2924666|NCT03077737|Active Comparator|Enhanced usual care|Usual clinic-based care enhanced by an EHR system that can deliver an electronic referral for quitline treatment
2924667|NCT03077724|Experimental|Fish Oil|4.2 grams per day of n-3 long chain polyunsaturated fatty acids (LCPUFA)
2924668|NCT03077724|Placebo Comparator|Placebos|Olive oil supplements
2924669|NCT03077711|Active Comparator|Patients with recurrent UTIs arm 1|Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.
2924670|NCT03077711|Active Comparator|Patients with recurrent UTIs arm 2|Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections.
2924671|NCT03077698|Experimental|Sodium Cridanimod & progestin therapy|Sodium Cridanimod and progestin therapy (megestrol acetate) combination
2924672|NCT03077685|Experimental|NanoPac® 6 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
2924673|NCT03077685|Experimental|NanoPac® 10 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
2924674|NCT03077685|Experimental|NanoPac® 15 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
2924675|NCT03077672||NYP-WCM|The NYP-WCM cohort will consist of patients presenting to the NewYork-Presbyterian/Weill Cornell Medicine Emergency Department with suspected sepsis.
2924676|NCT03077672||NYP-BMH|The NYP-BMH cohort will consist of patients presenting to the NewYork-Presbyterian Brooklyn Methodist Hospital Emergency Department with suspected sepsis.
2924677|NCT03077659|Experimental|NanoPac® 6 mg/mL|NanoPac® 6 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
2924678|NCT03077659|Experimental|NanoPac® 10 mg/mL|NanoPac® 10 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
2924679|NCT03077659|Experimental|NanoPac® 15 mg/mL|NanoPac® 15 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
2924680|NCT03077646|Experimental|Be SMART alone|Parents/guardians in this study group will watch a 5.5 minute Be SMART video and receive the handouts reviewing the information.
2924681|NCT03077646|Experimental|Be SMART + MD review|Parents/guardians in this study group will watch a 5.5 minute Be SMART video and receive the handouts reviewing the information and will also have an MD review the information (via a checklist to standardize the MD review).
2924682|NCT03077646|Active Comparator|Control: TSE materials|"Parents/guardians in this study group will watch a video Kids and Smoke Don't Mix and receive handouts reviewing information on tobacco smoke exposure (TSE)."
2924683|NCT03077633|Active Comparator|Cervical Cerclage + Progesterone|Placement of a Cervical Cerclage plus the daily administration of vaginal progesterone (200mg tab)
2924684|NCT03077633|Placebo Comparator|Progesterone|Daily administration of vaginal progesterone (200mg tab)
2924685|NCT03077620|Experimental|Poor sleep group treatment|10mg Suvorexant tablet h.s. for two consecutive nights
2924686|NCT03077620|Placebo Comparator|Poor sleep group control|Participant will receive placebo for two consecutive nights and sleep as normal under the same controlled conditions in a clinical research unit.
2924687|NCT03077620|Placebo Comparator|Good sleep group|Participant will receive placebo for two consecutive nights and sleep as normal under the same controlled conditions in a clinical research unit.
2924688|NCT03077607|Experimental|Arm A|Subjects will receive a 0.5 mg talazoparib and 100 mg itraconazole.
2924689|NCT03077607|Experimental|Arm B|Subjects will receive 1 mg talazoparib and 600 mg rifampin.
2924690|NCT03077594|Other|Successfully ablated patients|Mucosal impedance will be performed at the time of clinically indicated endoscopy. Research biopsies will be obtained during clinically indicated endoscopy.
2924691|NCT03077594|Other|Successfully ablated patients - VLE|Mucosal impedance will be performed at the time of clinically indicated endoscopy. Research biopsies will be obtained during clinically indicated endoscopy. Volumetric laser endomicroscopy (VLE) will be done.
2924692|NCT03077581|Active Comparator|Transevrsus abdominus plane block group|
2924693|NCT03077581|Active Comparator|Rectus sheath block group|
2924694|NCT03077581|Active Comparator|local infiltration group|
2924695|NCT03077568|Experimental|My Stress Control|This group gets access to the web-based program for stress-management. They will, by their own, go through the automated program. Measurements are conducted before, after as well as 3 months after the intervention.
2924696|NCT03077568|No Intervention|Wait-list group|The wait-list grop will complete the same measures as the intervention group completes before and after the intervention with similar time spread. The wait-list group will then get access to the web-based program.
2924697|NCT03077555|Active Comparator|Meliane ED|20 mcg ethinyl estradiol/70 mcg gestodene
2924698|NCT03077555|Experimental|Zoely|1.5 mg estradiol/2.5 mg nomegestrol acetate
2924700|NCT03077529|Experimental|Galacto-oligosaccharide|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
2924701|NCT03077529|Placebo Comparator|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
2924702|NCT03077516||Mobi-C|Prior recipient of Mobi-C Disc in IDE/Post Approval Study
2924703|NCT03077516||ACDF|Prior control subject in IDE/Post Approval Study
2924704|NCT03077503|Experimental|Dexmedetomidine (Group A)|In induction period, group A received dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline 10 minute through a syringe pump. Three minutes before application of skull pins, group A received infusion of 2 ml of 0.9% normal saline.
2924705|NCT03077503|Active Comparator|Fentanyl (group B)|In induction period, group B received 20ml of 0.9% normal saline.Three minutes before application of skull pins, group B received infusion of fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline
2924706|NCT03077490||Single center vs. multicenter|Both Groups operated on by the same device (Transvaginal mesh Uphold TM Vaginal Support System) and in the same manner.
2924707|NCT03077477|Placebo Comparator|SAD|"Cohort will have a total 6 subjects: SAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate);~SAD cohorts are defined as follows:~Cohort 1: One placebo and one AMXT 1501 dicaprate subject will be treated as sentinel subjects receiving one tablet each of their assigned treatment. Assuming no intolerance is noted after at least 3 days, the remaining cohort subjects (placebo, 1 subject and AMXT 1501 dicaprate, 3 subjects) will be treated.~Cohort 2: 2 subjects 2 placebo each and 4 subjects 2 AMXT 1501 dicaprate tablets each~Cohort 3: 2 subjects 4 placebos each and 4 subjects 4 AMXT 1501 dicaprate tablets each~Cohort 4: 2 subjects 8 placebos each and 4 subjects 8 AMXT 1501 dicaprate tablets each"
2924708|NCT03077477|Placebo Comparator|MAD|"Each cohort will have a total 6 subjects: MAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate); MAD cohorts will receive dosing once daily for 14 consecutive days. Dosing will be contingent on adequate tolerance in Cohorts 1-5.~Cohort 6: 2 subjects 2 placebos each; 4 subjects 2 AMXT 1501 dicaprate tablets each~Cohort 7: 2 subjects 4 placebos each; 4 subjects 4 AMXT 1501 dicaprate tablets each~Cohort 8: 2 subjects 8 placebos each; 4 subjects 8 AMXT 1501 dicaprate tablets each"
2924709|NCT03077477|Active Comparator|FE|"Each cohort will have a total 6 subjects: FE crossover (6 subjects receiving active AMXT 1501 dicaprate).~FE Crossover:~• Cohort 5: 6 new subjects will be randomized to a fed (n=3 standard meal) or fasted (n=3) group and administered the highest dose of AMXT 1501 dicaprate tolerated by previous cohorts. First dose and accompanying assessments will be referred to as Period 1. Subjects will then crossover to the opposite diet plan (fed or fasted) and receive a second administration of study treatment at the same dose level. The second dose and assessments are referred to as Period 2. There will be a 7-day washout between doses administered in Periods 1 and 2."
2924710|NCT03077464|Active Comparator|behavioral nutrition education|Set of curricular nutrition education modules, previously developed and based on Social Cognitive Theory, for the HOP'N After-School program, with additional materials from MyPlate. Materials were employed to increase healthy eating behavioral capability, self-efficacy, attitudes, and enjoyment. Topics included: 1) nutrition label literacy; 2) drinking water; 3) eating colors of the rainbow; 4) healthful snacks; 5) benefits of fruit and vegetable consumption; 6) moving more and sitting less; and 7) taking healthy habits home.
2924711|NCT03077464|Experimental|behavioral nutrition education plus skills|Set of curricular nutrition education modules, previously developed and based on Social Cognitive Theory for the HOP'N After-School program, with additional materials from MyPlate. Materials were employed to increase healthy eating behavioral capability, self-efficacy, attitudes, and enjoyment. Topics included:1) nutrition label literacy;2) drinking water;3) eating colors of the rainbow;4) healthful snacks;5) benefits of fruit and vegetable consumption;6) moving more and sitting less;and 7) taking healthy habits home. Designed to differ from behavioral nutrition education condition by devoting at least 15 minutes of each session to an additional behavioral skills training component. The behavioral skills component was designed to bolster behavioral capability, healthy eating attitudes, self-efficacy, and proxy efficacy with activities such as snack preparation sessions, role-playing games, fruit and vegetable tasting, and playing games that promoted healthier dietary behaviors.
2924712|NCT03077451|Experimental|Treatment (nelfinavir mesylate)|"DOSE NELFINAVIR MESYLATE: Patients receive standard dose nelfinavir mesylate PO BID for 4 weeks in the absence of PD. Patients with PD at 4 weeks proceed to high-dose nelfinavir. At week 8, if there is SD or PR, patients advance to high-dose nelfinavir mesylate. Patients discontinue standard dose nelfinavir mesylate 4 weeks after documentation of CR.~HIGH DOSE NELFINAVIR MESYLATE: Patients with PD continue to receive high-dose nelfinavir mesylate PO BID for 4 more weeks. If there is PD documented after 4 weeks at the high dose level, nelfinavir is discontinued. If there is SD or PR, patients continue receiving nelfinavir mesylate for 16 weeks. If there is CR, patients discontinue high-dose nelfinavir mesylate 4 weeks after documentation of CR."
2924713|NCT03077438|Experimental|MenACYW conjugate vaccine|Participants randomized to receive MenACYW conjugate vaccine
2924714|NCT03077438|Active Comparator|MENVEO®|Participants randomized to receive MENVEO®
2924715|NCT03077425|Experimental|Intervention|An RCT will enroll 360 mothers (total) of children 4-6 month olds from New York City (n=3) and New Jersey (n=2) pediatric practices. Half (180) will be assigned to the Community Health Worker intervention comprised of: a) home visits with mothers/families (n=6 visits over one year) and follow up telephone support; b) patient navigation to make/keep timely dental visits (2x by 18 months).
2924716|NCT03077425|Placebo Comparator|Enhanced Usual Care (EUC)|"Community Health Workers (CHWs)- will deliver the EUC to all study participants at their 6 month well-child visit, which will occur just after their T0 Baseline Interview, just prior to randomization. EUC Components: 1) Pamphlet- CHWs will hand out and review deliver and review a pamphlet with basic ECC and Obesity prevention messages for parents of 6-18 month olds; and 2) Dental Referral List of dentists who will see 12 month olds, and who accept most insurance plans in the pediatric practices we are recruiting from.~Thus, the EUC will be delivered to n=180 families in the EUC Control and n=180 families in the Intervention group."
2924717|NCT03077412|Experimental|Filgotinib Dose A|Filgotinib dose A + placebo to match filgotinib dose B for 24 weeks
2924718|NCT03077412|Experimental|Filgotinib Dose B|Filgotinib dose B + placebo to match filgotinib dose A for 24 weeks
2924719|NCT03077412|Experimental|Placebo|Placebo to match filgotinib dose A + placebo to match filgotinib dose B for 24 weeks
2924720|NCT03077399||stroke|stroke patients, application of SCALA
2924722|NCT03077386|Experimental|Community Health Worker Intervention|Patients enrolled in the intervention will be matched to a Community Health Worker (CHW) from their primary care practice. Based on an initial needs assessment, patients receiving the intervention will have support from a CHW with any of the following: scheduling appointments, language interpretation, obtaining financial and social resources, filling out forms, health system navigation, transportation facilitation, barrier identification, patient advocacy, understanding of treatment plans and communication with health care providers.
2924723|NCT03077386|No Intervention|Usual care|Patients not enrolled in the intervention will continue to receive care as usual until their clinic receives the intervention (determined by lottery).
2924724|NCT03077373|Experimental|Counseling letter (intervention group)|Intervention group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both at the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call. According to the assessments (baseline, month 4, and month 7), participants receive three counseling letters aiming to increase moderate-to-vigorous physical activity and to reduce sedentary time. Additionally, individuals who were daily smokers at baseline, receive three counseling letters aiming to foster the motivation to quit smoking. The first letter is accompanied by a self-help manual covering specific information relevant for the particular stage of motivation to change smoking behavior.
2924725|NCT03077373|No Intervention|No counseling letter (control group)|Control group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both in the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call.
2924726|NCT03077360|Experimental|Weight loss only|
2924727|NCT03077360|Experimental|Exercise Only|
2924728|NCT03077360|No Intervention|Delayed Intervention Control|
2924729|NCT03077347|Experimental|Experimental Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex
2924730|NCT03077347|Placebo Comparator|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
2924731|NCT03077334||K-type|FDG uptake in pancreatic cancer is similar to that of kidney
2924732|NCT03077334||non K-type|FDG uptake in pancreatic cancer is lower than that of kidney
2924733|NCT03077321|Active Comparator|CARE|The parent-child dyads in the CARE arm will receive the standard CARE program.
2924734|NCT03077321|Experimental|CARE plus peer mentor|The parent-child dyads in the CARE plus peer mentor arm will receive the CARE program that is delivered with the peer mentor.
2924735|NCT03077308||Rett Syndrome|Auditory and Visual event-related potentials (ERP) and EEG in 60 individuals with Rett syndrome.
2924736|NCT03077308||MECP2 Duplication Syndrome|Auditory and Visual event-related potentials (ERP) and EEG in 18 individuals with MECP2 Duplication syndrome.
2924737|NCT03077308||Rett-related disorders|Auditory and Visual event-related potentials (ERP) and EEG in 18 individuals with CDKL5 syndrome and 14 individuals with FOXG1 syndrome.
2924738|NCT03077308||Controls|Auditory and Visual event-related potentials (ERP) and EEG in 60 Control individuals (30 males and 30 females).
2924739|NCT03077295|Experimental|High Fibre to High-Protein (HF-HP)|"Phase 1: no intervention, habitual diet for 4 days and then 3day maintenance diet~Phase 2: consumption of HF meals for 4 weeks~Phase 3: washout for 1 week, controlled maintenance diet~Phase 4: consumption of HP meals for 4 weeks"
2924740|NCT03077295|Experimental|High Protein to High-Fibre (HP-HF)|"Phase 1: no intervention, habitual diet for 4 days and then 3day maintenance diet~Phase 2: consumption of HP meals for 4 weeks~Phase 3: washout for 1 week, controlled maintenance diet~Phase 4: consumption of HF meals for 4 weeks"
2924741|NCT03077282|Experimental|group1|Group1 will take Prasaprohyai 95% ethanolic extract capsules at a dose of 100 mg three times a day before meals (for 6 weeks)
2924742|NCT03077282|Experimental|group2|Group2 will take Prasaprohyai 95% ethanolic extract capsules at a dose of 200 mg three times a day before meals (for 6 weeks)
2924743|NCT03077243|Experimental|≤ 10 pack years smoking history|
2924744|NCT03077243|Experimental|> 10 py smoking history, no p53 mutation|
2924745|NCT03077243|Active Comparator|> 10 py smoking history, p53 mutation|
2924746|NCT03077230|Experimental|Pre/Post Test of a Lung Cancer Screening Decision Aid|
2924747|NCT03077217|Active Comparator|high-dose rifaximin|
2924748|NCT03077217|No Intervention|control group|
2924749|NCT03077204|Other|BIO4 treatment|Patients undergoing 1 or 2-level Anterior Cervical Discectomy and Fusion (ACDF) spine surgery utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).
2924750|NCT03077191||Quality of life|Quality of life of breast cancer patients treated with conservative surgery (quadrantectomy) and adjuvant hypofractionated whole breast radiotherapy according to the institutional standard regimen, to a total dose of 40 Gy in 15 fraction over 3 weeks will be measured with EORTC quality of life questionnaires QLQ-C30 and QLQ-BR 23, before the start of the radiotherapy, at the end of the radiotherapy and then at every follow-up visit ( the first at 6 months after the end of the treatment, then annually for 5 consecutive years after the first follow up visit).
2924751|NCT03077178|Experimental|Prospective cohort|Geriatric assessment
2924752|NCT03077165|Experimental|Group A|S42909 dose 100 mg p.o., 50 mg bid
2924753|NCT03077165|Experimental|Group B|S42909 dose 200 mg p.o., 100 mg bid
2924754|NCT03077165|Experimental|Group C|S42909 dose 400 mg p.o., 200 mg bid
2924755|NCT03077165|Experimental|Group D|S42909 dose 800 mg p.o., 400 mg bid
2924756|NCT03077165|Experimental|Group E|S42909 dose 1200 mg p.o., 600 mg bid
2924757|NCT03077165|Placebo Comparator|Group F|Placebo p.o. bid
2924758|NCT03077139|Experimental|Arms|Pacing wires used to stimulate ventricles in a synchronous matter
2924759|NCT03077126|Other|Pre-surgery Ultrasound|Aixplorer® ShearWave Elastography (SWE™) Ultrasound. Participants will undergo ultrasound prep with Fleet Enema and ultrasound procedure at their pre-op visit one to two weeks before their standard of care prostatectomy.
2924760|NCT03077113|Other|Ventilation Images for Comparison|"Standard of Care: 4-D CT scan will be used to make a radiation treatment plan.~SPECT-CT Scan: This second scan will be done on another day to make a treatment plan for comparison to the first plan."
2924878|NCT03076177|Sham Comparator|Non specific taping|Participants receiving non specific taping application
2924761|NCT03077100||Newborns with positive cultures|Positive cultures of newborns hospitalized in the NICU in the past 5 years will undergo laboratory examination and identification
2924762|NCT03077087|Experimental|Single-stage Integra|"Composed of a porous collagen-chondroitin 6-sulfate fibrillary mat covered with a thin sheet of silastic, it serves to cover wound beds of freshly excised burns and allow for the infiltration of fibroblasts, capillaries, and macrophages, essentially creating a neodermis while also acting as a barrier against infection and a blockade against heat and moisture loss"
2924763|NCT03077074|Experimental|Low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
2924764|NCT03077061|Active Comparator|Control - Open flap debridement|The surgical procedure includes flap elevation, debridement of the peri-implant defect and decontamination of the implant surfaces using saline for irrigation. Flaps are replaced in their original position and carefully sutured. Patients are provided with post-surgical information and thereafter called in for regular follow-up visits.
2924765|NCT03077061|Experimental|Test - Bone replacement graft|The surgical procedure is identical to the control procedure with the exception of the application of the bone replacement graft. Following decontamination, Bio-Oss Collagen® is placed into the peri-implant bony defect. Flaps are carefully sutured and patients are provided with the same information and follow-up as patients in the control group.
2924766|NCT03077048|No Intervention|Low protein diet|Low protein diet with 0.6 g protein/kg BW/day (20-30% high biological value) and an energy intake of 30-35 kcal/kg BW/day
2924767|NCT03077048|Experimental|Supplemented low protein diet|Ketosteril® supplemented low protein diet (sLPD), (1 tablet/5 kg BW/day) with 0.6 g protein/kg BW/day (20-30% high biological value) and an energy intake of 30-35 kcal/kg BW/day
2924768|NCT03077035|Experimental|glass ionomer sealant|
2924769|NCT03077035|Active Comparator|resin-based sealant|
2924770|NCT03077022||Femoracetabular impingent (FAI)|Subjects will be given a prescription for physical therapy specifically for Femoracetabular impingent (FAI). They will then be followed clinically per the investigator's normal routine and the gold standard.
2924771|NCT03077009|Experimental|Treatment arm|Patients with confirmed plantaris friction syndrome will be offered hyaluronic acid injection into the space between the Plantaris and Achilles tendons
2924772|NCT03076996|Experimental|Online support group|Participants will be enrolled to receive six sessions from the Positive Connections curriculum through the m/eHealth intervention that will use Facebook to conduct online structured support groups.
2924773|NCT03076983||ICU Patients|Patients currently on or scheduled for ventilator care in the intensive-care-unit (ICU)
2924774|NCT03076983||OLV Patients|Patients scheduled for elective surgery receiving one-lung-ventilation (OLV)
2924775|NCT03076970|Experimental|Lasmiditan 200 mg|single oral tablet
2924776|NCT03076970|Active Comparator|Sumatriptan 100 mg|single oral tablet
2924777|NCT03076970|Experimental|Combination of lasmiditan and sumatriptan|single oral tablet of each
2924778|NCT03076957|Experimental|Treat Regimen|CKD-516(investigational Drug) Irinotecan
2924779|NCT03076944|Active Comparator|Neural agent|UltraEZ. Prophylaxis of the teeth; an application every 48 hours; 4 sessions
2924780|NCT03076944|Active Comparator|Obliterator agent|Enamelast. Prophylaxis of the teeth; an application every 48 hours; 4 sessions
2924781|NCT03076944|Active Comparator|Associative approach|UltraEZ and Enamelast. Prophylaxis of the teeth; an application every 48 hours; 4 sessions. In each session, fistly the UltraEZ (neural agent) will be applied and after the Enamelast (obliterator agent.)
2924782|NCT03076931|Experimental|Study: Airway Reconstruction Patients|These participants have significant airway abnormalities that require invasive surgery, such as Laryngotracheoplasty, to rectify, and whose voice quality may suffer as a result of the surgery. The goal of this study is to improve voice outcomes of these patients, and their clinical data will be collected.
2924783|NCT03076931|Experimental|Control: Normal Airway Patients|These participants have normal airways and voice who will undergo a microlaryngoscopy and voice evaluation, the data from which will be compared to study patients.
2924784|NCT03076918|Active Comparator|Conventional PDT|Aktilite® Galderma
2924785|NCT03076918|Experimental|FLEXITHERALIGHT PDT|Light Emitting Textile Device
2924786|NCT03076905|Experimental|IV drug|AUC0-t of single intravenous dose of F901318
2924787|NCT03076892|Active Comparator|Conventional PDT|Aktilite® Galderma
2924788|NCT03076892|Experimental|PHOS ISTOS PDT|Light Emitting textile device
2924789|NCT03076879|Experimental|Intervention group|The selected ASM was associated with risk factors related to direct cervical cancer in Turkey (using age 5 or older oral contraceptives, having three or more children, initiating sexual intercourse 16 years or older, at least one parenthesized smear test between 40-55 years) And randomly assigned to the experimental group to promoting participation in cervical cancer screening
2924790|NCT03076879|No Intervention|Control Group|The selected ASM is the most common and associated with direct cervical cancer-related risk factors in Turkey (using oral contraceptives for longer than five years, having three or more children, starting sexual intercourse at the age of 16 and before, Women who are randomly assigned to the control group of women who have at least one pap smear test between the ages of 40 and 55 and who have at least one pap smear test in the family (especially a mother and a sister)
2924791|NCT03076853||Patients with Pharmaceutical Record|
2924792|NCT03076840|Active Comparator|Kinesio tape group|treatment by: application of Kinesio tape in the hamstring muscle by using a 1 strip Y shape of (Kinesio Tex® Tape 5cm) insertion to origin technique to relieve the hamstring tightness while the muscle in stretched position for 15 second (hip flexion and knee extension and then application of the tape) with 25% stretch of the tape
2924793|NCT03076840|Sham Comparator|sham tape group|treatment by: application of Kinesio tape in the hamstring muscle by using a 1 strip I shape of (Kinesio Tex® Tape 5cm) with no stretch in the hamstring musculature and the tape applied perpendicular over the upper third of the hamstring muscle while the muscle in stretched position
2924794|NCT03076840|No Intervention|control group|The student in this group had no treatment in the same position of the previous groups (the hamstring muscle maintained in a stretching position for 15 second)
2924795|NCT03076827|Experimental|Group A|Group to begin surgery(total hip replacement or hip hemi-arthroplasty) in the morning
2924797|NCT03076801|Experimental|Choral Singing Intervention|In addition to usual medical care, participants in the intervention group will participate in choral singing.
2924798|NCT03076801|No Intervention|Control|The control group will receive usual medical care only. If control group participants join an external singing group during the study period they will not be excluded, but this data will be collected and considered.
2924799|NCT03076788||Athletes|"Professional and amateur athletes examined during the medical follow-up at the medical sport centre of Caen University Hospital.~The medical examination consists in a clinical exam, an electrocardiogram and an echocardiography."
2924800|NCT03076788||Sedentary controls|"Sedentary patients assessed in the cardiology unit with a normal heart function.~The medical examination consists in a clinical exam, an electrocardiogram and an echocardiography."
2924801|NCT03076775|Experimental|Intervention|Women will undergo regular maternal blood glucose screening and treatment of hyperglycemia following BMZ administration to achieve maternal glycemic control until delivery or hospital discharge, for a maximum of 5 days.
2924802|NCT03076775|No Intervention|Usual Care|Routine antenatal care will be performed without any maternal blood glucose screening nor treatment as is usual care at each of the study sites.
2924803|NCT03076762|Experimental|Intravesical suburothelial injection|Patients assigned for suburothelial injections received 100 U of onabotulinumtoxinA in 20 sites injected in the bladder body on treatment day and follow-up
2924804|NCT03076762|Active Comparator|Intravesical trigonal injection|Patients assigned trigonal injections will receive 100U of onabotulinumtoxinA at 10 sites injected at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone) on treatment day and follow-up.
2924805|NCT03076736|Active Comparator|Resource pack|Aphasia resource pack
2924806|NCT03076736|Experimental|Singing group + resource pack|Singing group + Aphasia resource pack
2924807|NCT03076723|Sham Comparator|Fixed opening pressure|The shunt opening pressure is changed to the same setting as at surgery.
2924808|NCT03076723|Experimental|Individual shunt opening pressure|The shunt opening pressure is adjusted (up one step, down one step or unchanged) according to an individual analysis of the pulsatility curve (as assessed after shunt surgery).
2924809|NCT03076710||Opioids delivered through PCA|PCA devices used to deliver opioids
2924810|NCT03076710||EXPAREL® infiltration|EXPAREL® infiltration at the site of surgery and nurse-administered opioid as needed
2924811|NCT03076697||Diabetic Eye Disease|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing diabetic retinopathy along with the stage of diabetic retinopathy. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of diabetic retinopathy diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
2924812|NCT03076697||Glaucoma|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing glaucoma. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional optic disc photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of glaucoma. We will also assess the sensitivity and specificity of glaucoma diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
2924813|NCT03076697||Age related macular degeneration (AMD)|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing age-related macular degeneration along with the stage. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of age-related macular degeneration diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
2924814|NCT03076697||Retinopathy of Prematurity (ROP)|Photographs will be taken with our smartphone-based camera along with the standard of care, including Retcam photography or traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing ROP. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of ROP diagnosis with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
2924815|NCT03076684|Experimental|low-fructose diet|Intervention: low-fructose Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to <5% of energy and keeping their weight stable.
2924816|NCT03076684|Experimental|allopurinol treatment|Subjects participating in the allopurinol treatment arm will begin with an initial dose of drug of 100 mg/d p.o. daily for 2 wks. The dose is then slowly increased over the next 8 wks to achieve a serum uric acid concentration of 6 mg/dL (maximum allopurinol dose is 800 mg/d). Once uric acid reaches 6 mg/dL, the subject stays on this dose and is seen for the interim visit (4 months), at which time all procedures are repeated. After this, drug treatment continues for another 4 months and the subject returns for the final visit at 8 months. The same procedures performed at baseline are repeated at this time. The dose of allopurinol will be taken the morning of the final visit.
2924817|NCT03076684|No Intervention|control arm|After completion of the baseline visit (procedures described above), subjects participating in the control arm are not seen again until the 4-month time point, when the same procedures performed at baseline are repeated, except for the MRI. Following this, they are seen again at 8-months, when all baseline procedures are repeated. Cardiac MRI and labeled water consumption occur at the baseline and final visits.
2924818|NCT03076671|No Intervention|Standard of Care|Patients to get usual care from their established neurology care team that is enrolled in the study.
2924819|NCT03076671|Experimental|Standard of Care plus Palliative Care|Patients to get usual care, augmented by palliative care, provided by their established neurology care team that is affiliated with the study, with additional support provided by the University of Colorado Denver Neurology Palliative Care team.
2924820|NCT03076671|Experimental|Clinicians|Clinicians enrolled in the study will receive an 8-hour supportive and palliative care training, followed by monthly coaching and the availability of telemedicine visits for enrolled patients with the university neuro-palliative care team. The unit of randomization is the time when they receive training. Four to five clinical practices will receive training every 6 months during years 2 and 3, at which time all of their enrolled patients will be switched from usual care to the intervention arm.
2924821|NCT03076658|Other|asymptomatic EOS Imaging|patients that qualify for study and EOS imaging to analyze spino-pelvic parameters
2924822|NCT03076645|Experimental|Experimental|The Experimental Group will be placed in a group using the matching algorithm. Facilitator support and education intervention
2924823|NCT03076632|Active Comparator|Non-disabled volunteers|"Volunteers without neurological injury.~Interventions:~Cervical plus transcranial stimulation~Cervical stimulation plus hand/wrist exercise~Electromyographic (EMG)-triggered (closed-loop) stimulation"
2924824|NCT03076632|Active Comparator|Spinal cord injury|"Volunteers with motor-incomplete cervical spinal cord injury.~Interventions:~Cervical plus transcranial stimulation~Cervical stimulation plus hand/wrist exercise~Electromyographic (EMG)-triggered (closed-loop) stimulation"
2924825|NCT03076632|Active Comparator|Amyotrophic lateral sclerosis|"Volunteers with amyotrophic lateral sclerosis.~Interventions:~Cervical plus transcranial stimulation~Cervical stimulation plus hand/wrist exercise~Electromyographic (EMG)-triggered (closed-loop) stimulation"
2924826|NCT03076619||Clinical ophthalmoscopy in PIH|"An observational study in which the patients for the study are selected from antenatal clinic, antenatal ward and preeclampsia and eclampsia room in Department of Obstetrics and Gynecology and general ophthalmic OPD in case of ambulatory patients during the period of November 2003 to June 2006 randomly."
2924827|NCT03076580||cardiomyopathy|Patients are diagnosed as cardiomyopathy by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
2924828|NCT03076580||disease control|Patients have similar symptoms with cardiomyopathy patients, and are further excluded by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
2924829|NCT03076580||healthy control|Healthy subjects are recruited in Beijing Anzhen Hospital, with negative results of echocardiography and clinical lab examination.
2924830|NCT03076567||samples OH95-C-N027-G|Testing pre-existing serum samples from 2 ongoing studies
2924831|NCT03076567||samples PH99-C-N031-H|
2924832|NCT03076554|Experimental|Arm 1 Avelumab|Avelumab will be administered at a dose of 10 mg/kg intravenously once every two weeks until disease progression or development of intolerable adverseevents.
2924833|NCT03076541||patients with restless legs syndrome|
2924834|NCT03076528|Experimental|Intervention with game-based exercise|Subjects will be receiving sensor-based interactive ankle & foot exercise program (game-based exercise) during hemo-dialysis, approximately 30 minutes, twice per week and for 4 weeks.
2924835|NCT03076528|Active Comparator|Non-technology foot and ankle exercise program|Subjects will be receiving non-technology foot and ankle exercise program during hemodialysis, approximately 30 minutes, twice per week and for 4 weeks.
2924836|NCT03076515|Active Comparator|Nerivio Migra active|
2924837|NCT03076515|Sham Comparator|Nerivio Migra placebo|
2924838|NCT03076489|Experimental|high consumption habits|high consumption habits of fatty and sugary foods
2924839|NCT03076489|Experimental|low consumption habits|low consumption habits of fatty and sugary foods
2924840|NCT03076476|Active Comparator|DES-std group|(DES: drug-eluting stent). Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.
2924841|NCT03076476|Experimental|DES-slow group|"(DES: drug-eluting stent). Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.~After the interim analysis DES-slow to be compared with BVS."
2924842|NCT03076476|Experimental|BVS group|(Bioresorbable Vascular Scaffold) Introduced after the interim analysis (phase 2) for comparison with DES-slow.
2924843|NCT03076463|Experimental|GRAPOM|Daily consumption for 6 weeks of 10 g of dried and milled grape pomaces solved in water. Samples will be collected at the beginning and the end of this period
2924844|NCT03076463|No Intervention|CTR|Follow-up for 6 weeks without intervention. Samples will be collected at the beginning and the end of this period
2924845|NCT03076450|Active Comparator|Maximum Oxygenation|Using PVC to set the initial peep, check ABG real-time, and according to PaO2+PaCO2≥400mmHg whether or not to adjust maintain PEEP.
2924846|NCT03076450|Experimental|Lung Ultrasound Re-aeration Score|Combine POC-LUS with PVC in set the initial peep, and then dynamic record LUS-RAS to feedback regulate PEEP.
2924847|NCT03076437|Experimental|Anti-CD19-CAR transduced T cells|"Patients will receive a lymphodepleting preconditioning regimen followed by anti-CD19- CAR-transduced T cells.~Interventions:~Drug: Fludarabine Drug: Cyclophosphamide Biological: Anti-CD19-CAR transduced T cells"
2924848|NCT03076424||1|Obese patients (BMI greater than or equal to 30 kg/m2) with Type 2 Diabetes Mellitus.
2924849|NCT03076424||2|Obese patients (BMI greater than or equal to 30 kg/m2) without Type 2 Diabetes Mellitus.
2924850|NCT03076424||3|Normal weight lean controls without Type 2 Diabetes Mellitus.
2924851|NCT03076385|Experimental|VAL-506440|
2924852|NCT03076385|Placebo Comparator|Placebo|
2924853|NCT03076372|Experimental|MM-310 monotherapy|MM-310 will be administered by IV infusion over 90 minutes on the first day of each 21 day cycle.
2924854|NCT03076359|Active Comparator|Standard of Care|Intervention: This group will receive only standard of care HIV treatment, including ART medications (First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
2924967|NCT03075436|Active Comparator|Standard of care|The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
2924855|NCT03076359|Experimental|Traditional Healer Support Program|"This group will receive standard of care as described above. In addition, the investigators will assess an intervention partnership with traditional healer including: community and clinic based support from a trained traditional healer.~The intervention includes: (1) healer visits to the patient at home, healer support for couples counseling, healer provision of nutritional advice, and healer counsel about the importance of adherence. If anything is amiss, the healer will accompany the patient to the health facility for additional clinical services. In addition, the healer will accompany the patient on all regularly scheduled clinical visits."
2924856|NCT03076333|Experimental|Single Arm: PET/MR|Each patient will undergo three combined PET/MR scans. The pre-treatment PET, mid-treatment PET and MR, and post-treatment PET are for research purposes and not part of the patient's standard of care (pre-treatment MR and post-treatment MR).
2924857|NCT03076320|Experimental|PFD+M-DDO|"Pirfenidone with M-DDO Active ingredients: Pirfenidone 10% with modified oxide diallyl disulfide (M-DDO) 0.016% Dosage form: gel. Dosage: standard finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency an duration: topically applied every 12 hours for 6 months."
2924858|NCT03076320|Active Comparator|A+PBO|"Adapalene with benzoyl peroxide Active ingredients: 0.1% Adapalene with 2.5% benzoyl peroxide. Dosage form: gel. Dosage: standard finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency and duration: topically applied every 12 hours for 6 month"
2924859|NCT03076307|Experimental|Parkinson's disease|
2924860|NCT03076307|Active Comparator|Control group|
2924861|NCT03076294|Experimental|MT after rTMS group|High frequency TMS will be applied with an eight-shaped coil angled at zero degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1). Twenty four stimulus trains will be provided at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 1200 pulses for approximately 12 minutes, with 90% of resting motor threshold (RMT). After TMS, patients will be submitted to 45 minutes of manual therapy protocol.
2924862|NCT03076294|Experimental|rTMS after MT group|Patients will be submitted to 45 minutes of manual therapy protocol. After that, high frequency TMS will be applied with an eight-shaped coil angled at zero degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1). Twenty four stimulus trains will be provided at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 1200 pulses for approximately 12 minutes, with 90% of resting motor threshold (RMT).
2924863|NCT03076294|Sham Comparator|Control group|In this group, the order of interventions will be randomized. Therefore, the volunteer can start with manual therapy or sham TMS. In manual therapy, patients will be submitted to 45 minutes of a protocol. In addition, with regard to sham TMS, the same parameters will be used, however, it will be performed using two coils, one connected to the magnetic stimulator, away from the patient's scalp and another uncoupled from the stimulator and positioned in the same way as in real stimulation.
2924864|NCT03076281|Experimental|Arm A (metformin hydrochloride)|Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery in the absence of disease progression or unacceptable toxicity
2924865|NCT03076281|Experimental|Arm B (doxycycline)|Patients receive doxycycline PO every 12 hours on days 1 to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
2924866|NCT03076281|Experimental|Arm C (metformin hydrochloride, doxycycline)|Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery and doxycycline PO every 12 hours on days 1to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
2924867|NCT03076268|Experimental|Treatment Group|The investigators will deliver the TMP Curriculum to 45 Treatment families. The TMP Curriculum is comprised of 1) 12 educational modules, 2) animations and videos of real parent-child interactions to teach parents about the science behind child brain development, and model strategies for improving parents' child-directed speech, 3) video modeling and collaborative goal setting, and 4) quantitative linguistic feedback from Language ENvironment Analysis (LENA) recordings. This curriculum is delivered in Spanish.
2924868|NCT03076268|No Intervention|Control Group|The investigators will deliver a Nutrition Curriculum to 45Control families. The Nutrition Curriculum provides information about the importance of healthy nutrition for child development, strategies for healthy eating, and meal preparation.This curriculum is delivered in Spanish.
2924869|NCT03076255|Experimental|Supportive care (MID)|Patients undergo Computed Tomography (CT) simulation with thermoplastic mask and maskless immobilization device (MID) for radiation therapy (RT) planning on day 1. Patients undergo standard of care RT using thermoplastic mask only and cone-beam computed tomography (CBCT) imaging with thermoplastic mask and MID on day 8 and 15.
2924870|NCT03076242||Gem Registry|Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
2924871|NCT03076229|Experimental|Healthy Marriage: Treatment|Intervention: Behavioral: Healthy Marriage Program
2924872|NCT03076229|Experimental|Healthy Marriage: Wait-list Control|Intervention: Behavioral: Healthy Marriage Program
2924873|NCT03076216|Other|OncoSil™ plus SOC Chemotherapy|OncoSil™ implanted with concurrent Standard of Care chemotherapy either gemcitabine or gemcitabine + Abraxane
2924874|NCT03076203|Experimental|Treatment (niraparib, radium Ra 223 dichloride)|Patients receive niraparib orally daily and radium Ra 223 dichloride IV over 1 minute every 4 weeks. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2924875|NCT03076190|No Intervention|Active Control Group (Health Education)|"Prior to surgery:~Demographics survey~Baseline surveys~Participants receive online information regarding nutrition and exercise that are relevant for people recovering from surgery. Participants are encouraged to incorporate healthy lifestyle choices into their daily routines as they recover from surgery.~Follow-up questions about the handouts (detailed above)~Post-surgery:~Daily surveys (detailed above)~Follow-up surveys (2, 4, 8, and 12 weeks after surgery)"
2924876|NCT03076190|Experimental|My Surgical Success Treatment Group|"Prior to surgery:~Demographics survey~Baseline surveys~Intervention:~90-minute psychoeducational My Surgical Success video that emphasizes catastrophizing treatment.~audio file~personalized plan that incorporates the information learned in the video.~Follow-up questions about the video (detailed above)~Post-surgery:~Daily surveys (detailed above)~Follow-up surveys (2, 4, 8, and 12 weeks after surgery)"
2924879|NCT03076164|Experimental|Trametinib 1.5mg + Erlotinib 75mg|Phase 1: Accrue 6 patients on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily Phase 2: Accrue 24 patients (including 6 patients treated during Phase 1) on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily or Trametinib 1.0mg + Erlotinib 100mg by mouth once daily.
2924880|NCT03076151|Experimental|Tacrolimus monohydrate (ADOPORT®)|patients with de novo Kidney Transplantation under Tacrolimus (ADOPORT®) treatment.
2924881|NCT03076138|Experimental|Test group|Bone grafting with gene-activated matrix (OCP + plasmid DNA with VEGF gene)
2924882|NCT03076125|Experimental|SCORRE group|Stroke risk factor brochure, stroke champions video, counseling on accuracy of perceived stroke risk and strategies to reduce stroke risk, weekly motivational health behavior tips (for physical activity, diet, or smoking cessation) text messages for 8 weeks.
2924883|NCT03076125|Sham Comparator|Attention Control Group|Sexual health education brochure and Safe in the City video, weekly sexual health tips text messages for 8 weeks.
2924884|NCT03076112|Experimental|Ipragliflozin|"Ipragliflozin 50 mg in addition to their preexisting sulfonylurea and metformin~** Metformin and sulfonylurea's dosages~Metformin 500 mg ‒ 2550 mg~Sulfonylurea: Glimepiride 1 mg ‒ 8 mg or Gliclazide MR 30 mg ‒ 120 mg"
2924885|NCT03076112|Active Comparator|Sitagliptin|"Sitagliptin 100 mg in addition to their preexisting sulfonylurea and metformin~** Metformin and sulfonylurea's dosages~Metformin 500 mg ‒ 2550 mg~Sulfonylurea: Glimepiride 1 mg ‒ 8 mg or Gliclazide MR 30 mg ‒ 120 mg"
2924886|NCT03076099|Experimental|Dexmedetomidine|Dexmedetomidine was administered intravenously when tracheal extubation, 1.2μg/kg Dexmedetomidine was mixed with 100 ml normal saline and maintained 4 hours constantly.
2924887|NCT03076099|Placebo Comparator|Control group|Normal Saline was administered intravenously when tracheal extubation,equal volume of normal saline was mixed with 100 ml normal saline and maintained 4 hours constantly.
2924888|NCT03076086|Experimental|induced sputum procedure|Biomarker assessment (concentration of PiP3 and phosphoproteins in sputum samples) baseline and reproducibility twice in a 3 week interval of the different donors.
2924889|NCT03076073|No Intervention|Evaluating Tendons Structures|Ultrasound measurements of Patellar Tendon and Achilles Tendon Structures
2924890|NCT03076073|Active Comparator|Impact of physical activity on tendons|Ultrasound measurements of Patellar Tendon and Achilles Tendon Structures following different types and different intensity of physical activity
2924891|NCT03076060|Experimental|Migraineurs|"Overweighted or Obese migraineurs that refer to a dietician clinic to treat their ponderal condition.~Intervention: 4-week of VLCKD by meal replacements poor in fats and carbohydrates."
2924892|NCT03076060|Sham Comparator|Sham diet migraineurs|"Overweighted or Obese migraineurs that refer to a dietician clinic to treat their ponderal condition.~Intervention: 4-week of non-ketogenic VLCD by meal replacements poor in fats and proteins."
2924893|NCT03076047||end tidal CO2 (ETCO2) monitoring|We will continuously record capnography data from the patients while they are in the post-anesthesia care unit (PACU). Study personnel will visit each patient while the patient is in the PACU to promote compliance with continuous CO2 monitoring.
2924894|NCT03076034|Experimental|Post-menopausal women|We will use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.
2924895|NCT03076034|Experimental|Males over 50 years|We will recruit males to this second study arm, to use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.
2924896|NCT03076021|Other|Adolescents|dextromethorphan pre- and post isotretinoin
2924897|NCT03076008||MPFL Reconstruction|Subjects undergoing MPFL Reconstruction
2924898|NCT03075995|Experimental|lapatinib administered with hight-fat breakfast|
2924899|NCT03075956|Experimental|5 mg E4 single-dose|Group A: a single 5 mg E4 dose will be administered under fasted conditions during period 1.
2924900|NCT03075956|Experimental|15 mg E4 single-dose|Group B: a single 15 mg E4 dose will be administered under fasted conditions during period 1.
2924901|NCT03075956|Experimental|45 mg E4 single-dose|Group C: a single 45 mg E4 dose will be administered under fasted conditions during Period 1.
2924902|NCT03075956|Experimental|15 mg E4 multiple-dose|15 mg E4 dose will be administered once daily for 14 consecutive days during Period 2.
2924903|NCT03075943|Experimental|InSea2|2 capsules/day of InSea2 administered 30 min before a meal (breakfast, lunch or diner) combined with weight loss program (individualized nutritional intervention with a daily restriction of 500 kcal)
2924904|NCT03075943|Placebo Comparator|Placebo|2 capsules/day of Placebo administered 30 min before a meal (breakfast, lunch or diner) combined with weight loss program (individualized nutritional intervention with a daily restriction of 500 kcal)
2924905|NCT03075930||Extended Electrocardiogram|Elective patients receiving an AF ablation receiving a extended ECG
2924906|NCT03075930||Body surface potential map|Elective patients receiving an AF ablation receiving a body surface potential map
2924907|NCT03075917|Experimental|Experimental|questionnaire for allergic rhinitis control children from 5 to 11 years old who complete a self questionnaire regarding allergic rhinitis control during the consultation and after 15 days
2924908|NCT03075904|Experimental|Cohort 1|SYNT001 Dose 1
2924909|NCT03075904|Experimental|Cohort 2|SYNT001 Dose 2
2924910|NCT03075904|Experimental|Cohort 3|SYNT001 Dose 3
2924911|NCT03075891|Experimental|Ivermectin 1% cream + Doxycycline 40 mg MR capsules|
2924912|NCT03075891|Placebo Comparator|Ivermectin 1% cream + Oral placebo capsules|
2924913|NCT03075878|Experimental|Cohort 1|SYNT001 Dose 1
2924914|NCT03075878|Experimental|Cohort 2|SYNT001 Dose 2
2924915|NCT03075865||OmniMax MMF|Patients involved in trauma events will receive intermaxillary fixation with OmniMax MMF system for temporary stabilization of mandibular fracture(s) to maintain proper occlusion during surgery and allow for postoperative fracture healing.
2924916|NCT03075852||3D VRS Patients|Those who undergo surgery with NGENUITY (3D VRS-Vitreoretinal surgery)
2924917|NCT03075852||Standard operating microscope|Those who undergo surgery with the standard operating microscope
2924918|NCT03075839|Experimental|Cigarette Brand Switching|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes
2924968|NCT03075423|Experimental|Ipilimumab plus nivolumab|Ipilimumab 1mg/kg plus nivolumab 3mg/kg, both, will be administered i.v. every 3 weeks for 4 times as an induction therapy followed by a maintenance therapy with a flat dose of 240 mg nivolumab biweekly until progression.
2924919|NCT03075826|Other|Open Label-Single Arm|This is a single arm, open-label study of SGI-110 in patients with MPN. SGI-110 will be administered subcutaneously at a dose of 60 mg/m2 on days 1-5, repeated every 28 days. Toxicity will be evaluated using the NCI Common Terminology Criteria for Adverse Events Active Version 4. The frequency of toxicities per organ system will be tabulated using descriptive statistics. All patients who receive any amount of the study drug will be evaluable for toxicity
2924920|NCT03075813|Experimental|Intervention Cluster|"Surgical surveillance data submitted to the DICON Surgical Database will undergo immediate analysis by optimized SPC methods. If a signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is required.~Optimized SPC methods include the application of two SPC charts. The investigator determined that when either chart identifies a signal, the study will have approximately 90% sensitivity and 65% specificity to identify important increases in rates of SSI."
2924921|NCT03075813|No Intervention|Control Cluster|Local personnel in clusters randomized to traditional surveillance and feedback will receive bar graph reports and data interpretation per routine DICON surveillance. These reports will be provided every 6 months.
2924922|NCT03075800|No Intervention|Assertive Community Treatment (ACT) - Only|ACT is a multidisciplinary, team-based approach to providing a range of treatment, rehabilitation, and support services to high-need, high-risk people with severe mental illness who tend not to use clinic-based services; most services are provided on an outreach basis (e.g., in the person's home) and services are available 24 /7(27).
2924923|NCT03075800|Experimental|Assertive Community Treatment+Illness Management and Recovery|IMR follows a manualized curriculum to help clients pursue personal recovery goals and to teach them information, strategies, and skills over 11 modules (e.g., using medications, coping with stress) to manage their psychiatric illness. IMR can be provided in individual or group formats. The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
2924924|NCT03075787||patients with obstructive sleep apneas|
2924925|NCT03075761|Experimental|Intervention|Participants randomized to the intervention arm will receive a Fitbit, formal 30-minute education session on post-thrombotic syndrome (PTS) and benefits of increased physical activity. An individualized activity prescription will be provided and participants will be asked to maintain the target level of activity for 12 weeks after determining their habitual activity in the first 4 weeks.
2924926|NCT03075761|Active Comparator|Control|Participants randomized to the control arm will receive a formal 30-minute education session on post-thrombotic syndrome (PTS) and the benefits of increased physical activity. Their physical activity will be self-reported in an activity log and by the Gordin activity questionnaire over the 16-week intervention period.
2924927|NCT03075748|Experimental|Primary study|Patients meeting primary inclusion/exclusion criteria will be enrolled in primary study arm and be treated with the TAAA Debranching Stent Graft System.
2924928|NCT03075748|Experimental|Expanded selection|Patients who fail to meet inclusion criteria for the primary study arm may be enrolled under the expanded selection arm and be treated with the TAAA Debranching Stent Graft System.
2924929|NCT03075735||Metastatic castration resistant patients|The exposition to the primary analysis risk factor (germline deleterious mutation in BRCA1, BRCA2, ATM or PALB2 gene) will be determined after inclusion. Briefly, a NGS targeted-panel based on the majority of genes included in the BROCA panel and additional DNA-repair related genes has been designed based on the available technology. The pathogenicity of germline variants will be determined according to established American College of Medical Genetics and Genomics and Association for Molecular Pathology current consensus at the time of final primary outcome analyses. Variants will also be reviewed against published literature and public databases. According to their mutation-carrier status patients will be classified as: A) Mutation Carriers in BRCA1, BRCA2, ATM and PALB2 genes; B) Mutation carriers in other genes included in the BROCA panel; C) Mutation carriers in others DNA-repair genes D)Non-carriers
2924930|NCT03075722|Experimental|Saturn nasal mask|Participants to use nasal mask in-home for 7 ± 3 days
2924931|NCT03075709||Experimental - CPW (Urban)|We are working with Regina Qu'Appelle Health Region (RQHR), a primarily urban health region, to develop and implement a clinical pathway (CPW). The CPW will improve care through the following steps: standardizing diagnostic, coordinating and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices.
2924932|NCT03075709||Experimental - CPW (Rural)|Following implementation in RQHR a rural health region will be chosen as an intervention site for a second CPW. The CPW will improve care through the following steps: standardizing diagnostic, coordinating and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices.
2924933|NCT03075709||Control - Standard Care (Urban)|Saskatoon Health Region (SHR) will act as the urban control site. No attempts will made to alter care in SHR and therefore patients will continue to receive the current standard of care.
2924934|NCT03075709||Control - Standard Care (Rural)|Following implementation in RQHR a rural health region will be chosen to act as the rural control site. No attempts will made to alter care in this health region and therefore patients will continue to receive the current standard of care.
2924935|NCT03075696|Experimental|Part I: Dose Escalation|Participants (single participant cohorts) will receive obinutuzumab (Gpt) 1000 milligrams (mg) single dose IV infusion on Day -7 (pre-treatment) followed by RO7082859 IV infusion on Day 1 and Day 8 of Cycle 1. From Cycle 2 onwards, ascending doses of RO7082859 will be administered on Day 1 of every 2 week cycle up to Cycle 12 (24 weeks) or until unacceptable toxicity or disease progression. RO7082859 dosing will be initiated at 5 micrograms (mcg) (flat dose) followed by doses of 15 mcg, 45 mcg, 135 mcg, 405 mcg and 810 mcg. Tocilizumab will be administered if required, for the management of severe Cytokine Release Syndrome (CRS) (if a study participant experiences severe CRS during or after any infusion of RO7082859).
2924969|NCT03075423|Active Comparator|Sunitinib|Sunitinib will be administered at a starting dose of 50 mg/die p.o. for 4 weeks on and 2 weeks off per cycle until progression.
2925584|NCT03071081|Placebo Comparator|Placebo to TOP1288 Xg|7 days dosing
2924936|NCT03075696|Experimental|Part II: Dose Escalation|"Participants will receive 1000 mg Gpt single dose IV infusion on Day -7 (pre-treatment). Participants (multiple participant cohorts) will start when either RO7082859 flat dose of 810 mcg is reached or a RO7082859-related greater than or equal to (>/=) Grade 2 AE or DLT occurs, whichever comes first. Participants will receive RO7082859 IV infusion on Day 1 of Cycle 1.~Monotherapy, RO7082859 as a single agent: From Cycle 2 onwards, ascending doses of RO7082859 will be administered on Day 1 of every 2 or 3 week cycle until either the MTD/OBD is defined.~Combination Therapy: From Cycle 2 onwards, a fixed dose of 1000 mg Gpt will be administered via IV infusion in combination with ascending doses of RO7082859 on Day 1 of every 3 week cycle until either the MTD/OBD is defined."
2924937|NCT03075696|Experimental|Part III: Dose Expansion|"Part III will start once OBD is defined. Participants will receive Gpt 1000 mg single dose IV infusion on Day -7 (pre-treatment) followed by RO7082859 IV infusion at OBD on Day 1 of Cycle 1.~Monotherapy:~From Cycle 2 onwards, RO7082859 will be administered at OBD on Day 1 of every 3 week cycle up to Cycle 8 (24 weeks) or until unacceptable toxicity or disease progression.~Combination Therapy: From Cycle 2 onwards, a fixed dose of 1000 mg Gpt will be administered via IV infusion in combination with RO7082859 at OBD."
2924938|NCT03075683|Experimental|Cognitive behavioural therapy|Internet-based cognitive behavioural therapy for insomnia
2924939|NCT03075683|Active Comparator|Applied relaxation|Internet-based applied relaxation
2924940|NCT03075670|Experimental|N9-GP|
2924941|NCT03075670|Active Comparator|ALPROLIX®|
2924942|NCT03075657|Active Comparator|Risperidone group|Schizophrenia patients with predominant negative symptoms on Risperidone monotherapy
2924943|NCT03075657|Experimental|Risperidone with Ramelteon group|Schizophrenia patients with predominant negative symptoms on Risperidone with add-on Ramelteon therapy
2924944|NCT03075657|Active Comparator|Haloperidol group|Schizophrenia patients with predominant positive symptoms on Haloperidol monotherapy
2924945|NCT03075657|Experimental|Haloperidol with Ramelteon group|Schizophrenia patients with predominant positive symptoms on Haloperidol with add-on Ramelteon therapy
2924946|NCT03075644|Experimental|Somapacitan|
2924947|NCT03075644|Active Comparator|Norditropin|
2924948|NCT03075631||Patients with Acute Pancreatitis|Patients with Acute Pancreatitis
2924949|NCT03075618||Acute Pancreatitis|Patients with Acute Pancreatitis.
2924950|NCT03075605||Subjects with acute pancreatitis|Subjects with acute pancreatitis
2924951|NCT03075605||Subjects with previous attack|Subjects with previous attack
2924952|NCT03075605||Controls|Controls
2924953|NCT03075592||ERCP candidates|ERCP candidates
2924954|NCT03075553|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive nivolumab IV over 60 minutes on day 1 of course 9. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
2924955|NCT03075540|Other|YouTube Video|Participants will watch a 15-minute YouTube video. The video will provide information about hereditary breast and ovarian cancer and about the process of genetic counseling and testing.
2924956|NCT03075527|Experimental|Tremelimumab + Durvalumab|Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression.
2924957|NCT03075514|Active Comparator|Modified ketogenic diet (MKD)|MKD: 80% fat and 5% carbohydrate (% of total energy requirements per day).
2924958|NCT03075514|Active Comparator|Medium chain triglyceride (MCT) diet|MCT: 75% fat (30% of which is medium chain fatty acids taken as a supplement) and 5% carbohydrate (% of total energy requirements per day).
2924959|NCT03075501|Active Comparator|Paired|Individuals receive 20mg methamphetamine on two separate occasions and placebo on two separate occasions. Paired group subjects always receive drug in the same room and placebo in the other room.
2924960|NCT03075501|Other|Unpaired|Individuals receive 20mg methamphetamine on two separate occasions and placebo on two separate occasions. Unpaired group subjects receive drug and placebo once in each room.
2924961|NCT03075488|Active Comparator|Conventional landmark-guided technique|In this arm spinal anesthesia will be performed by using conventional cutaneous landmarks
2924962|NCT03075488|Experimental|Accuro device guided technique|In this arm spinal anesthesia will be performed only after having detected the intralaminar space, the mid-line, the depth and the orientation for spinal needle insertion with pre-procedural scan performed with Accuro device
2924963|NCT03075475|Experimental|CETA Treatment|For treatment group participants, they will then have weekly Common Elements Treatment Approach (CETA) counseling sessions with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10-12 sessions. They will then repeat the assessment instrument after their last session, as well as 6 months after finishing treatment, and these meetings will again last no more than 1.5 hours. All total, it is expected that treatment group participants will have 13 meetings with a study team member or counselor over the course of their participation.
2924964|NCT03075475|No Intervention|Waitlist|Waitlist group participants be contacted by a study team member from the local partner organization regularly (weekly) while they are on the wait list. These contacts from the study team will be short and last less than 30 minutes and will be used to briefly assess symptom levels and safety. At the end of their wait period, they will be asked to complete the assessment instrument a second time and this meeting will take no more than 1.5 hours. For participants in the waitlist group, we estimate 13 meetings total during their wait period (2 meetings of no more than 1.5 hours, 10 contacts less than 30 minutes).
2924965|NCT03075462|Experimental|Fluzoparib + Apatinib|Fluzoparib and apatinib will be separately administered to patients on the 1st and 4th day, respectively. Then from the 7th day they are administered continuously and orally in combination, 28 days per cycle, until disease progression or unacceptable toxicity.
2924966|NCT03075436|Experimental|Enhanced demand-side sanitation, hygiene|The intervention group will receive a package of enhanced, demand-side sanitation and hygiene interventions that are informed by formative research and facilitated by local government and Emory Ethiopia partners.
2925375|NCT03072680|Experimental|BPS PAST + BPS FUT|Participants practice BPS PAST the first week, then they switch fot BPS FUT.
2924970|NCT03075410|Experimental|Cohort 1- GSK3036656 in Part A|During Part A (Cohort 1), Subjects will receive a single dose of GSK3036656 in the morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. The total daily dose for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The starting dose in Part A will be 5 mg and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
2924971|NCT03075410|Placebo Comparator|Cohort 1- Placebo in Part A|During Part A (Cohort 1), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. Placebo for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
2924972|NCT03075410|Experimental|Cohort 2- GSK3036656 in Part A|During Part A (Cohort 2), Subjects will receive a single dose of GSK3036656 in morning on Day 1 in each period after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. The total dose for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The dose will be selected on basis of safety, tolerability and PK data from the previous treatment period or cohort and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
2924973|NCT03075410|Placebo Comparator|Cohort 2- Placebo in Part A|During Part A (Cohort 2), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. Placebo for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
2924974|NCT03075410|Experimental|Cohort 3- GSK3036656 in Part B|During Part B (Cohort 3), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from Part A. Subjects will be followed up to 2 weeks from the last dose.
2924975|NCT03075410|Placebo Comparator|Cohort 3- Placebo in Part B|During Part B (Cohort 3), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
2924976|NCT03075410|Experimental|Cohort 4- GSK3036656 in Part B|During Part B (Cohort 4), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
2924977|NCT03075410|Placebo Comparator|Cohort 4- Placebo in Part B|During Part B (Cohort 4), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
2924978|NCT03075410|Experimental|Cohort 5- GSK3036656 in Part B|During Part B (Cohort 5), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
2925376|NCT03072680|Experimental|BPS FUT|Participants practice BPS FUT during the two weeks.
2924979|NCT03075410|Placebo Comparator|Cohort 5- Placebo in Part B|During Part B (Cohort 5), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
2924980|NCT03075410|Experimental|Cohort 6- GSK3036656 in Part B|During Part B (Cohort 6), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
2924981|NCT03075410|Placebo Comparator|Cohort 6- Placebo in Part B|During Part B (Cohort 6), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
2924982|NCT03075397|Other|HIV-1 infected patients|Blood sample and sperm sample are collected
2924983|NCT03075384||open reduction and internal fixation|A classic method was used to treat unilateral complicated zygomatic fractures without the assistance of computer-assisted navigation system
2924984|NCT03075371|Active Comparator|intragastric glucose administration|
2924985|NCT03075371|Placebo Comparator|intragastric water administration|
2924986|NCT03075358|Experimental|Lidocaine spray|
2924987|NCT03075358|Sham Comparator|Normal saline spray|
2924988|NCT03075358|No Intervention|No spray|
2924989|NCT03075345|Active Comparator|Treatment as usual (weight management intervention)|6 session weight management programme (over 12 weeks).
2924990|NCT03075345|Experimental|Treatment as usual plus acceptance and commitment therapy|6 session weight management programme (over 12 weeks) plus a 4 session acceptance and commitment therapy (ACT) programme. The ACT part will commence straight after the conclusion of the weight management programme.
2924991|NCT03075332|Experimental|protocol with physical exercise|Both groups underwent a combined training intervention consisting of aerobic and resisted exercises in the same training session
2924992|NCT03075319|Experimental|Received perioperative photograph|Perioperative knee range of motion (ROM) were measured with long arm goniometer immediately after close the wound. Perioperative knee photographs in full flexion and extension positions were taken and gave to experimental group in the day after surgery.
2924993|NCT03075319|Active Comparator|Didn't receive perioperative photograph|Perioperative knee range of motion (ROM) were measured with long arm goniometer immediately after close the wound. Perioperative knee photographs in full flexion and extension positions were taken but participants in this group didn't receive perioperative photographs.
2924994|NCT03075306|No Intervention|usual care|usual care and materials on healthy weight
2924995|NCT03075306|Experimental|intervention|the 12-month CHAMPION intervention with 1) a health coach, a trained mental health program employee, who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents; and 2) support from health providers who will provide basic weight management messages and encouragement for behavior change.
2924996|NCT03075293||Children with appendicitis|All children who came to the ER with appendicitis
2924997|NCT03075280|Experimental|High carbohydrate liquid diet|No need preoperative fasting more than 6 hours. Uptake 400ml high carbohydrate liquid diet 2 hours before ERCP.
2924998|NCT03075280|No Intervention|Routine ERCP group|Preoperative fasting more than 6 hours as usual.
2924999|NCT03075267|Experimental|PT010 (BGF MDI) 320/14.4/9.6 µg|PT010 Budesonide, Glycopyrronium and Formoterol Fumurate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg
2925000|NCT03075267|Experimental|PT010 (BGF MDI) 160/14.4/9.6 µg|PT010 (BGF MDI) 160/14.4/9.6 µg
2925001|NCT03075267|Experimental|PT003 (GFF MDI) 14.4/9.6 µg|PT003 (GFF MDI) 14.4/9.6 µg
2925002|NCT03075254|Active Comparator|Healthy Control|normal volunteers (HC) Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
2925003|NCT03075254|Experimental|Fibromyalgia Only|The diagnosis of FM will require a history of chronic widespread pain as well as the presence of at least eleven out of eighteen paired tender points. Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
2925004|NCT03075254|Experimental|Chronic fatigue and Fibromyalgia Syndrome|Diagnosis of ME/CFS will require a history of chronic fatigue persisting or relapsing for more than 6 months as well as the presence of at least four out of eight designated symptoms. Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
2925005|NCT03075241|Experimental|Zolpidem|Study group will receive zolpidem 10mg capsules, 10pm (before bedtime) for 14 nights
2925006|NCT03075241|Experimental|Zoplicone|Study group will receive zoplicone 7.5mg capsules, 10pm (before bedtime) for 14 nights
2925007|NCT03075241|Placebo Comparator|Placebo|Study group will receive inactive or inert capsules, which will be used as a comparator, 10pm (before bedtime) for 14 nights
2925008|NCT03075228||Lean subjects|Lean is defined as having a BMI of 19-23 kg/m2, waist circumference <80 cm and fasting glucose levels <6.1 mmol/L.
2925009|NCT03075228||Obese subjects|Obese is defined as having a BMI of 30-35 kg/m2, waist circumference >88 cm and fasting glucose levels >=6.1 and <7.5 mmol/L
2925100|NCT03074591|Active Comparator|Treatment|Active treatment: Ferric Carboxymaltose solution (Ferinject®) for parenteral application, 50 mg/mL iron. Medication will be given as a short time infusion over 15 minutes in 100mL NaCl.
2925629|NCT03070782|Experimental|ISIS 681257 Dose 5|Cohort E
2925010|NCT03075189|Experimental|Protein supplement|"During hospitalization the intervention group will receive a protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.~Diet registration and testing at baseline, discharge and follow-up."
2925011|NCT03075189|No Intervention|Standard treatment|"The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.~Diet registration and testing at baseline, discharge and follow-up."
2925012|NCT03075176|Active Comparator|Wavefront optimized LASIK|
2925013|NCT03075176|Active Comparator|Wavefront optimized Photorefractive Keratectomy|
2925014|NCT03075176|Active Comparator|Topography-guided LASIK|
2925015|NCT03075176|Active Comparator|Topography-guided Photorefractive Keratectomy|
2925016|NCT03075163|Experimental|Acupressure|Manual pressure will be applied on the wrists bilaterally.
2925017|NCT03075163|Active Comparator|Ondansetron|Ondansetron (Zofran) is used for the treatment of nausea and vomiting.
2925018|NCT03075150||Group 1|Tidal volume of 6 ml/kg IBW
2925019|NCT03075150||Group 2|Tidal volume of 8 ml/kg IBW
2925020|NCT03075137|Experimental|External Counter Pulsation (ECP) group|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
2925021|NCT03075137|No Intervention|Control group|Guideline-driven standard medical treatment
2925022|NCT03075124|Experimental|External Counter Pulsation group|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
2925023|NCT03075124|No Intervention|Control group|Guideline-driven standard medical treatment
2925024|NCT03075098|Experimental|colposcopy of intraepithelial carcinoma|Digital colposcope will be used to detect the swede score of the lesion
2925025|NCT03075085|Active Comparator|Basic WISE strategy|These participants will be asked to implement the basic WISE strategy used in previous studies.
2925026|NCT03075085|Experimental|Enhanced WISE strategy|These participants will be asked to implement the enhanced WISE strategy.
2925027|NCT03075072|Active Comparator|Whole Brain Radiation|"MRI will be performed prior to radiation is administered~A hippocampal sparing approach will be used when possible~Dose will be 30 Gy in 10 fractions"
2925028|NCT03075072|Experimental|Stereotactic Radiation (SRS)|"MRI will be performed prior to radiation is administered~Radiation will be given in 1-5 fractions (dose depends on the size of the tumor that will be treated)"
2925029|NCT03075059|Experimental|Intervention|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
2925030|NCT03075059|No Intervention|Control|Patients randomized to the control group will not receive the preoperative phone call or written materials and will only receive SOC Child Life services on the day of surgery.
2925031|NCT03075046|Experimental|blue LED 405 nm in vulvovaginal candidiasis|It will be applied the a 405 nm blue LED in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session. This part of the study will see if there is fungicidal effect of the blue led 405 nm
2925032|NCT03075046|Experimental|blue LED 405 nm in healthy women|It will be applied the a 405 nm blue LED in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.This part of the study will see the security and the effects of the blue led 405 nm in healthy vaginal microflora
2925033|NCT03075046|No Intervention|Sociodemographic data of women with vulvovaginal candidiasis|The women will answer some questions of the anamnesis as: Age, weight, height, form of intimate hygiene, and others to evaluate possible correlations of these data with the presence of vulvovaginal candidiasis
2925034|NCT03075033|Active Comparator|SOS gruop|Use of The Shikani Optical Stylet In Patients At Risk Of Secondary Cervical Spine Injury
2925035|NCT03075033|Active Comparator|Awake Fiberoptic Intubation|Use of Awake Fiberoptic Intubation In Patients At Risk Of Secondary Cervical Spine Injury
2925036|NCT03075020|Active Comparator|Active carbon monoxide|Inhalation of carbon monoxide up to a carboxyhemoglobin concentration 22%
2925037|NCT03075020|Placebo Comparator|Air|
2925038|NCT03075007||Group A|All participants will undergo an amyloid PET scan with Florbetaben F 18 contrast as well as a transcranial Doppler ultrasound.
2925039|NCT03074994|Experimental|Peri-articular tranexamic acid injection|TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue+Medial gutter area+Lateral gutter area)
2925040|NCT03074994|Experimental|Intraarticular tranexamic acid injection|TXA inject into intraaricular knee capsule after multimodal local anesthetic infiltration
2925041|NCT03074994|No Intervention|Control group|Don't receive any route of TXA
2925042|NCT03074981|Experimental|Combined TopClosure & Vcare Alpha Treatment|"The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks."
2925043|NCT03074968|Placebo Comparator|control|normal saline
2925044|NCT03074968|Active Comparator|benzydamine hydrochloride|Benzydamine Hydrochloride
2925045|NCT03074955|Active Comparator|Control|"leg wrapping without tension & maintain supine position~Apply elastic bandages to both legs without tension.~Maintain supine position after injecting propofol.~After 3 minutes from propofol injection, remove elastic bandages~induction using propofol 2mg/kg~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg~intubate patient between 3 and 4 minutes after propofol injection~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection~phenylephrine injection if hypotension develops"
2925046|NCT03074955|Experimental|Trendelenburg only|"leg wrapping without tension & apply Trendelenburg position~Apply elastic bandages to both legs without tension.~After injecting propofol, apply Trendelenburg position ( 10 degree )~After 3 minutes from propofol injection, remove elastic bandage and revert to supine position.~induction using propofol 2mg/kg~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg~intubate patient between 3 and 4 minutes after propofol injection~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection~phenylephrine injection if hypotension develops"
2925047|NCT03074955|Experimental|Trendelenburg & leg wrapping|"leg wrapping with tension & apply Trendelenburg position~Apply elastic bandages to both legs with tension.~After injecting propofol, apply Trendelenburg position ( 10 degree )~After 3 minutes from propofol injection, remove elastic bandage and revert to supine position.~induction using propofol 2mg/kg~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg~intubate patient between 3 and 4 minutes after propofol injection~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection~phenylephrine injection if hypotension develops"
2925048|NCT03074942|Experimental|Reslizumab|Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
2925049|NCT03074929|Experimental|Novel risk communication|Intervention parents will receive a novel risk communication message via a tablet app. Parents will also receive height, weight, and BMI percentile information typically provided by a provider during well-child visits as usual.
2925050|NCT03074929|No Intervention|Usual Care|Parents will receive height, weight, and BMI percentile information typically provided by a provider during well-child visits as usual.
2925051|NCT03074916||DIP arthroplasty|
2925052|NCT03074916||DIP arthrodesis|
2925053|NCT03074903||Early cycle insertion|Participants in this group have the intrauterine system inserted during the first seven days of their menstrual cycle.
2925054|NCT03074903||Late cycle insertion|Participants in this group have the intrauterine system inserted during the remainder of their cycle.
2925055|NCT03074890|Experimental|Intervention (cases)|Intervention: Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC:FFP:PLT) and conventional coagulation tests guiding further resuscitation with blood products and procoagulant factors
2925056|NCT03074890|No Intervention|No Intervention (control))|all patients with massive haemorrhage in which the massive transfusion protocol didn´t apply
2925057|NCT03074877|Experimental|Family Check-Up (FCU)|"Families recruited in Year 1 who are randomized to the FCU group will be provided with the Family Check-Up (FCU) after the initial in-home assessment and after 1 year follow-up assessment. The FCU is a brief (i.e., typically 3-5 sessions per year) family-centered intervention. The FCU intervention process consists of 3, and in some cases, 4 components: a) family assessment, b) a Get to Know You session, c) feedback, and d) follow-up treatment sessions."
2925058|NCT03074877|Experimental|Waitlist Group|Families recruited in Year 1 who are randomized to the wait-list group, and all families recruited in Year 2 will be assigned to the wait-list group. This group will receive the materials provided to all families, noted above, and the initial in-home assessment within 2 weeks of the screening to be conducted by a trained research assistant. At 1 year post-screening, the families in the wait-list group will be administered the follow-up assessment and will begin the Family Check-Up (FCU) intervention.
2925059|NCT03074877|No Intervention|Control Group|These families will be recruited in Year 3 of the study. These families will be provided the materials noted above and will receive the in-home assessments conducted by a trained research assistant. The initial in-home assessments will be conducted within 2 weeks of the screening, and follow-up assessments conducted 1 year post-screening.
2925060|NCT03074864|Experimental|EGFR-mutant IIIA/IIIB NSCLC|Erlotinib Hydrochloride 150mg daily intercalated with radiotherapy
2925061|NCT03074851|Experimental|Salt Substitute|To seek the relationship between blood pressure and low sodium salt.
2925062|NCT03074851|Other|informational intervention|to give 1 month informational intervention
2925063|NCT03074838|Experimental|Transarterial aortic valve implantation|Patients that are treated by trans arterial valve implantation (TAVI)
2925064|NCT03074838|Active Comparator|Surgical aortic valve replacement|Patients that are treated by surgical aortic valve replacement (SAVR)
2925065|NCT03074825|Experimental|chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
2925066|NCT03074812|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation where current will be reduced to zero after standardized ramp up to 2 mA
2925067|NCT03074812|Experimental|Active tDCS|Transcranial direct current stimulation according to protocol maintained for 30 minutes after ramping up to 2 mA
2925101|NCT03074591|Placebo Comparator|Placebo|Placebo: Normal saline (0.9% weight/volume (w/v) NaCl) administered in analogy to active treatment procedures.
2925102|NCT03074578|Experimental|Night-time desensitization|Watching a video containing verbal and visual violence in the evening, and again in the next morning
2925068|NCT03074799|Active Comparator|TST-based Screening (Child contacts)|In the control clinics, decision regarding IPT will be made based on TST results, as is now the standard of care in this South African health district. In this setting, all TST negative children are initiated on IPT by the nurse at the local clinic. TST positive children are all referred to the district hospital for further evaluation of TB disease regardless of clinical symptoms. Again, clinical outcome data will be obtained from patient records and the same longitudinal child contact register.
2925069|NCT03074799|Experimental|Symptom -based Screening(Child Contacts)|In the intervention clinics, decisions regarding IPT will be made on a clinical basis. If the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT. Children will be followed at least monthly for the duration of the six month course of isoniazid, as is standard of care in South Africa at this time. Clinical outcome data will be obtained from patient records and implementation of a contact register aimed at improving longitudinal care of children on isoniazid preventive therapy.
2925070|NCT03074786|Experimental|Vaginal Matrix Ring|Dapivirine vaginal ring containing 25 mg of dapivirine to be replaced each month.
2925071|NCT03074786|Experimental|Oral Emtricitanbine/Tenofovir Disoproxil|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) tablets to be taken orally daily
2925072|NCT03074773|Active Comparator|paravertebral block with bupivacaine|this group will receive 0.5mg/kg bupivacaine 0.25% diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
2925073|NCT03074773|Active Comparator|paravertebral block with bupivacaine and dexamethasone|this group will receive 0.5mg/kg bupivacaine 0.25% mixed to 0.1 mg/kg dexamethasone diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
2925074|NCT03074760||Contaminated acequias|
2925075|NCT03074760||Non-contaminated acequias|
2925076|NCT03074734|Other|Exposure to secondhand tobacco smoke|Exposure to secondhand tobacco smoke in outside smoking areas
2925077|NCT03074721|Other|PCI with PCI Suite Software|
2925078|NCT03074721|Other|conventional PCI|
2925079|NCT03074708|Other|3D visualization and 3D printing|From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.
2925080|NCT03074695|Experimental|BMI =/> 50 and DPE (Dural Puncture Epidural)|Those with BMI greater than or equal to 50 with receive a dural puncture labor epidural
2925081|NCT03074695|Experimental|BMI <50 and DPE|Those with BMI less than 50 with receive a dural puncture labor epidural
2925082|NCT03074695|Active Comparator|BMI > 50 EPL (Epidural)|Those with BMI greater than or equal to 50 with receive a standard labor epidural
2925083|NCT03074695|Active Comparator|BMI <50 EPL|Those with BMI less than 50 with receive a standard labor epidural
2925084|NCT03074682|Experimental|Lifeflow|Participants in this arm will use the Lifeflow device to administer fluid in a simulation in a simulation setting.
2925085|NCT03074682|Active Comparator|Push/Pull|Participants in this arm will use the Push/Pull method to administer fluid in a simulation in a simulation setting.
2925086|NCT03074682|Active Comparator|Pressure Bag|Participants in this arm will use a Pressure Bag to administer fluid in a simulation in a simulation setting.
2925087|NCT03074669|Experimental|ACT program|Participants from the active treatment group will be granted access to seven modules that are structured like chapters of a self-help book adapted for the online environment. In addition, participants from the experimental arm will be guided by an on-line therapist throughout the program duration. The on-line therapists are graduate students in clinical psychology who work under the supervision of an experienced psychotherapist. Participants will be asked to fill in a series of self-report measures to monitor their anxiety and some ACT specific processes (i.e., acceptance, mindfulness, experiential avoidance) throughout the intervention.
2925088|NCT03074669|No Intervention|Wait-list control group|During the first seven weeks, participants in the wait-list control group will only be asked to fill in a series of self-report measures to monitor their anxiety and some ACT specific processes (i.e., acceptance, mindfulness, experiential avoidance). Following the experimental group's completion of the program, participants in this group will also receive the intervention. All participants will be contacted 6 months after the intervention has concluded in order to conduct a follow-up assessment.
2925089|NCT03074656|Experimental|Therapeutic drug monitoring|Administration of infliximab according to a treatment strategy based on therapeutic drug monitoring and assessments of anti-drug antibodies
2925090|NCT03074656|Active Comparator|Standard care|Administration of infliximab according to standard clinical care, without knowledge of drug levels or status of anti-drug antibodies
2925091|NCT03074643|Placebo Comparator|RecProt|Lower protein / higher CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Carbohydrate supplement for months 0-6 (blinded). Follow-up months 7-18.
2925092|NCT03074643|Active Comparator|6-mon HiProt|Higher protein / lower CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Follow-up months 7-18.
2925093|NCT03074643|Active Comparator|18-mon HiProt|"Higher protein / lower CHO diet for the 6-month weight loss and 12-month follow-up phases.~Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Protein supplement for follow-up months 7-18."
2925094|NCT03074630|Experimental|Dapagliflozin 10mg and Rosuvastatin 10mg|Rosuvastatin 10mg once daily for 9 weeks, with 5 weeks of once daily Dapagliflozin 10mg added
2925095|NCT03074617|Experimental|LTE field|
2925096|NCT03074617|Sham Comparator|sham field|
2925097|NCT03074604|Experimental|aortic no-touch OPCABG|aortic no-touch OPCABG
2925098|NCT03074604|Experimental|OPCABG with partial clamp applying carbon dioxide|OPCABG with partial clamp applying carbon dioxide
2925099|NCT03074604|Active Comparator|OPCABG with partial clamp|OPCABG with partial clamp
2925199|NCT03073967|Experimental|Part B, Pritelivir|Oral tablets, 100mg/day (400mg loading dose on day 1) over 4 weeks
2925103|NCT03074578|Sham Comparator|Daytime desensitization|Watching a video containing verbal and visual non-violence in the morning, and then again the evening of the same day
2925104|NCT03074565|Experimental|Ultrasonic alone|Sanative therapy using ultrasonic instrumentation only.
2925105|NCT03074565|Active Comparator|Ultrasonic+|Sanative therapy using ultrasonic plus hand instrumentation.
2925106|NCT03074552|Experimental|Probiotics|The probiotic preparation [ LactoLevure] will consist a combination of four probiotics.
2925107|NCT03074552|Placebo Comparator|Placebo|Placebo will consist of identical capsules of powdered glucose polymer, and they will be constructed by the same industry that manufactures the probiotics capsules.
2925108|NCT03074539|Active Comparator|Pulmonary Endarteriectomy - PEA|"CTEPH treatment via PEA. This arm includes patients who will receive Pulmonary Endarteriectomy (PEA) according to local CTEPH board recommendation. A standardized polygraphy will be conducted before the PEA - intervention, to obtain information concerning Sleep Disorder Breathing. 6 months after the PEA surgery another polygraphy will be accomplished and the results compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
2925109|NCT03074539|Active Comparator|Balloon Pulmonary Angioplasty - BPA|"CTEPH treatment via BPA. Patients who are suitable for Balloon Pulmonary Angioplasty (BPA) according to the recommendation of the local CTEPH board (e.g. patients not suitable for Pulmonary Endarteriectomy). A standardized polygraphy will be conducted before the first BPA intervention, to gain information about possible sleep-disordered breathing. 6 months after the first BPA intervention another polygraphy will be accomplished and the results compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
2925110|NCT03074539|Active Comparator|Medical Treatment|"CTEPH treatment via Medical Treatment. Patients who are inoperable (not suitable for Pulmonary Endarteriectomy) and not eligible for BPA according to the recommendation of the local CTEPH board will get medical treatment with Riociguat. The treatment will be assigned according to the currently valid guidelines (2015 European Respiratory Society / European Society of Cardiology guidelines on the diagnosis and treatment of pulmonary hypertension). A standardized polygraphy will be conducted before the medical treatment starts, another polygraphy will be conducted after 6 months of treatment if Riociguat. The results will be compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
2925111|NCT03074526|Active Comparator|4mL amniotic fluid|Amniotic Fluid: 4mL dose of amniotic fluid
2925112|NCT03074526|Active Comparator|4mL2x amniotic fluid|Amniotic Fluid: 4mL 2x dose of amniotic fluid
2925113|NCT03074526|Placebo Comparator|4mL Saline Placebo|Normal Saline
2925114|NCT03074513|Experimental|Appendiceal Adenocarcinoma, KRAS-Wild Type|"Participants receive Atezolizumab and Bevacizumab on Day 1 of each cycle.~Each cycle is 21 days.~Participant may continue taking the study drugs for as long as the doctor thinks it is in their best interest.~About every 3 months after end-of-treatment visit, participant or caregiver called by study staff."
2925115|NCT03074513|Experimental|Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma|"Participants receive Atezolizumab and Bevacizumab on Day 1 of each cycle.~Each cycle is 21 days.~Participant may continue taking the study drugs for as long as the doctor thinks it is in their best interest.~About every 3 months after end-of-treatment visit, participant or caregiver called by study staff."
2925116|NCT03074513|Experimental|Human Papilloma Virus-Associated Cancers|"Participants receive Atezolizumab and Bevacizumab on Day 1 of each cycle.~Each cycle is 21 days.~Participant may continue taking the study drugs for as long as the doctor thinks it is in their best interest.~About every 3 months after end-of-treatment visit, participant or caregiver called by study staff."
2925117|NCT03074513|Experimental|Merkel Cell Carcinoma|"Participants receive Atezolizumab and Bevacizumab on Day 1 of each cycle.~Each cycle is 21 days.~Participant may continue taking the study drugs for as long as the doctor thinks it is in their best interest.~About every 3 months after end-of-treatment visit, participant or caregiver called by study staff."
2925118|NCT03074513|Experimental|Neuroendocrine Tumors, Pancreatic|"Participants receive Atezolizumab and Bevacizumab on Day 1 of each cycle.~Each cycle is 21 days.~Participant may continue taking the study drugs for as long as the doctor thinks it is in their best interest.~About every 3 months after end-of-treatment visit, participant or caregiver called by study staff."
2925119|NCT03074513|Experimental|Neuroendocrine Tumors, Extrapancreatic|"Participants receive Atezolizumab and Bevacizumab on Day 1 of each cycle.~Each cycle is 21 days.~Participant may continue taking the study drugs for as long as the doctor thinks it is in their best interest.~About every 3 months after end-of-treatment visit, participant or caregiver called by study staff."
2925120|NCT03074513|Experimental|Peritoneal Mesothelioma|"Participants receive Atezolizumab and Bevacizumab on Day 1 of each cycle.~Each cycle is 21 days.~Participant may continue taking the study drugs for as long as the doctor thinks it is in their best interest.~About every 3 months after end-of-treatment visit, participant or caregiver called by study staff."
2925121|NCT03074513|Experimental|Pleural Mesothelioma|"Participants receive Atezolizumab and Bevacizumab on Day 1 of each cycle.~Each cycle is 21 days.~Participant may continue taking the study drugs for as long as the doctor thinks it is in their best interest.~About every 3 months after end-of-treatment visit, participant or caregiver called by study staff."
2925122|NCT03074500|Experimental|Kinesiotaping|Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
2925123|NCT03074500|Sham Comparator|Sham taping|Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
2925124|NCT03074500|Other|Control|Stretching and strengthening exercises of wrist
2925125|NCT03074474|Other|OviTex Permanent 1S|All subjects included in this post-market study will have a ventral hernia repaired with OviTex Permanent 1S reinforced bioscaffold.
2925126|NCT03074461|Experimental|Side-to-End|Side-to-End Anastomosis as neorectal reconstruction technique in low anterior resection (LAR)
2925127|NCT03074461|Active Comparator|Transverse Coloplasty|Transverse Coloplasty pouch as neorectal reconstruction technique in low anterior resection (LAR)
2925333|NCT03073018|Active Comparator|Pravastatin + Placebo|Pravastatin (40 mg) + fosinopril placebo once daily for 4 years
2925128|NCT03074448|Active Comparator|Sodium Picosulfate solution (Picoprep)|On the eve of the examination, all participants on Sodium picosulfate will take four tablets of Dulcolax with tea or water in the morning, liquid diet (juice, tea or water) at lunch, two capsules of 25mg Dramamine Capsgel in the afternoon, Sodium picosulfate dissolved in 150mL of cold water thirty minutes after, followed by drinking at least five 250-ml cups of water or other light liquids until midnight, with absolute fasting up to the time when the colonoscopy will be performed.
2925129|NCT03074448|Experimental|Aquanet bowel cleansing devices|For bowel preparation with the bowel cleansing device, intestinal lavage will be performed with the device, making use of water, pressure, and gravity to enhance bowel cleansing. The water used in this procedure was previously triple-filtered by passage on carbon, micro-pellets and ultraviolet light. The preparation will be carried out by a trained nurse.
2925130|NCT03074435|No Intervention|Control|No intervention
2925131|NCT03074435|Experimental|insecticidal paint|The insecticidal paint contains two organophosphates, chlorpyriphos(1.5%) and diazinon (1.5%), and an insect growth regulator (IGR),pyriproxyfen (0.063%), as active ingredients.
2925132|NCT03074435|Experimental|Larvicides|The larvicide is a slow release formulation containing Bacillus thuringiensis Var Israelensis.
2925133|NCT03074435|Experimental|Ivermectin|This arm consists in an injectable dose of Ivermectin given to peri-domestic animals.
2925134|NCT03074435|Experimental|Information, Education, Communication|After a sociological study during the pre-intervention year, this arm will consist in a reinforced communication strategy relative to the nationwide current one
2925135|NCT03074422|Experimental|Hypsnosis|During the fixation of the stereotactic frame, a single hypnosis session is performed by a certified senior anesthesiologist. Blood pressure, heart rate and respiratory rate are continuously monitored by the mean of a regular scope. Pain perceived during and after the procedure is quantifies by the mean of the Visual Analogue Scale (VAS) questionnaire. An open, standardized question will be asked to participants concerning feelings and thoughts about the frame fixation. Answers will be audio recorded. A standardized perceived distress questionnaire (PDI-13) will be performed.
2925136|NCT03074422|No Intervention|Control|Local anesthesia after clear and complete information of the procedure given the day prior to the surgery. In order to determine the pain perceived during the procedure, a VAS questionnaire will be used, directly after the frame disposal. The rest of the procédure is similar to the hypnosis group.
2925137|NCT03074409|Experimental|oxytocin|intranasal administration of oxytocin
2925138|NCT03074409|Placebo Comparator|placebo|intranasal administration of the same ingredient except oxytocin
2925139|NCT03074396|Other|before and after use of program|one arm (10 patients and 4 physicians) before and after use of dialysisNet (for doctors) and Avatar Beans (for patients)
2925140|NCT03074383|Experimental|Workshop|Self-Care Multidisciplinary Workshop for Diabetes consist in individual meetings with a multidisciplinary team (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) in which education and self-care topics will be approached. The workshop will be offered in 3 different modules with 2-4 weeks difference between them.
2925141|NCT03074383|Active Comparator|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
2925142|NCT03074344|Experimental|XLHA+CoQ10|XLHA+CoQ10 eye drop administered four times a day for 12 weeks (90 days).
2925143|NCT03074344|Active Comparator|Hyaluronic acid (HA)|Hyaluronic acid (HA) eye drop administered four times a day for 12 weeks (90 days).
2925144|NCT03074331|Experimental|SOF/VEL|SOF/VEL for 12 weeks
2925145|NCT03074318|Experimental|Treatment (avelumab, trabectedin)|Patients receive avelumab IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients also receive trabectedin IV over 24 hours on day 1. Courses repeat every 3 weeks and may repeat up to every 5 weeks after 2 courses in the absence of disease progression or unacceptable toxicity.
2925146|NCT03074305|Active Comparator|DEB strategy|"DEB procedure will be standardized in order to maximize drug delivery into target segment. Commercially available DEB will be used (Sequent Please, B Braun, Germany or Pantera Lux, Biotronik, German). The below requirements will be mandatorily recommended.~Residual stenosis after lesion preparation : %DS <20%~Delivery time : < 30 seconds~Total inflation time : > at least 1 minute~Previous BVS : DEB diameter ratio : > 1.0:1~Maximum inflation pressure : at least above nominal pressure of DEB"
2925147|NCT03074305|Active Comparator|DES strategy|The implantation of 2nd generation DES will be performed as universally recommended. In the DES group, the newest version of 2nd generation everolimus-eluting stent (Xience Alpine, Abbott Vascular, USA) will be recommended.
2925148|NCT03074292|Active Comparator|conventional phototherapy|neonates with unconjugated hyperbilirubinemia exposed to conventional phototherapy
2925149|NCT03074292|Active Comparator|extensive phototherapy|neonates with unconjugated hyperbilirubinemia exposed to extensive phototherapy
2925150|NCT03074292|Active Comparator|LED phototherapy|neonates with unconjugated hyperbilirubinemia exposed to LED phototherapy
2925151|NCT03074279||Cases|Patient with epilepsy who died as a result of confirmed or probable SUDEP and NEAR SUDEP during the study period.
2925152|NCT03074279||Controls|Patient with epilepsy matched by: âge, etiology and type of epilepsy, level of seizure control
2925153|NCT03074266||Blood coagulation test 1|"Therapeutic: Waste blood from heparinized patients undergoing interventional procedures (standard of care) in different clinical settings will be used to conduct coagulation tests using GEM Hemochron 100 during the course of the procedure before (baseline) and after heparin administration.~There is no drug administration or therapeutic intervention in this study. The interventional procedure (described above) is standard of care and all results of blood coagulation testing using GEM Hemochron 100 performed in this study are not used to influence that care."
2925154|NCT03074266||Blood coagulation test 2|"Therapeutic: Waste blood from heparinized patients undergoing interventional procedures (standard of care) in different clinical settings will be used to conduct duplicate coagulation tests using Signature Elite during the course of the procedure before (baseline) and after heparin administration.~There is no drug administration or therapeutic intervention conducted in the course of this study. The interventional procedure (described above) is standard of care. The only difference in standard of care is that the blood coagulation test is run in duplicate."
2925334|NCT03073018|Placebo Comparator|Double Placebo|Fosinopril placebo and pravastatin placebo once daily for 4 years
2925155|NCT03074240|Active Comparator|TAPB Group|Compare the instance in the TAPB group of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia when undergoing TAPB to anesthetize the abdominal wall.
2925156|NCT03074240|Active Comparator|RSB Group|Compare the instance in the RSB group of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia when undergoing RSB to anesthetize the abdominal wall.
2925157|NCT03074227|Active Comparator|Allogeneic faecal transplantation|Faecal transplantation of donor stool
2925158|NCT03074227|Placebo Comparator|Autologous faecal transplantation|Faecal transplantation of own stool
2925159|NCT03074214||STEMI patients receiving PCI|patients with STEMI receiving percutaneous coronary intervention
2925160|NCT03074201|Experimental|Cholangioscopy|Participants in this arm undergo radiation-free ERCP facilitated by cholangioscopy
2925161|NCT03074188||pre-dialysis patients|
2925162|NCT03074188||end stage renal disease|
2925163|NCT03074175|Experimental|hyperfractionated radiotherapy group|According to the size of lung lesions,we divided the patients with lesion ≤5cm in diameterand into hyperfractionated radiotherapy group（50Gy/11F/2W).
2925164|NCT03074175|Experimental|conventional fractionated radiotherapy group|According to the size of lung lesions,we divided the patients with lesion >5cm in diameterand into conventional fractionated radiotherapy group（60Gy/30F/6W）.
2925165|NCT03074162|Experimental|Diclofenac Sodium (A)|
2925166|NCT03074162|Experimental|Diclofenac & Capsaicin (B)|
2925167|NCT03074162|Active Comparator|Diclofenac Sodium Topical Gel|
2925168|NCT03074149||Idiopathic Pulmonary Disease patients|IPF patients/ only one group
2925169|NCT03074136|Experimental|Photodinamic therapy|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that, HELBO treatment (Helbo Photodynamic System, Bredent, Senden, Germany) will be applied.
2925170|NCT03074136|Experimental|Diode laser|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that high power diode laser therapy will be applied by using Epic diode laser (Biolase® Technology, Inc., San Clemente, CA, USA).
2925171|NCT03074136|Experimental|0.5% Sodium hypochlorite|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius).
2925172|NCT03074123|Experimental|healthy subjects|20 healthy subjects will undergo low dose cosyntropin stimulation test. Serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
2925173|NCT03074110|Active Comparator|Isocapnic hyperventilation|After end of surgery, hyperventilation and administration of a small, precalculated amount of CO2 into the breathing circuit will be performed.
2925174|NCT03074110|No Intervention|Standard procedure|After end of surgery, patients will be subdued to a standard weaning procedure.
2925175|NCT03074097|Active Comparator|Rectus Sheath|Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
2925176|NCT03074097|No Intervention|Control|Control group: the patients did not receive any intervention after anaesthesia induction.
2925177|NCT03074071|Active Comparator|Breast Cancer patient|Patients with Stage IV breast cancer will be taught to build hope by defining attainable goals for themselves in a Hope Enhancement Workshop.
2925178|NCT03074071|Active Comparator|Oncologists|Oncologists will will be taught to build hope by defining attainable goals for themselves and for their patients in a Hope Enhancement Workshop.
2925179|NCT03074058|Experimental|Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)|Fosrenol BAY 77-1931 orally disintegrating tablet (ODT) 500 mg in Period 1 (day 1-3) and Fosrenol chewable tablet 500mg in Period 2 (day 4-6). The washout interval between period 1 and 2 will be at least 14 days.
2925180|NCT03074058|Active Comparator|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)|Fosrenol BAY77-1931 chewable tablet in Period 1 and Fosrenol BAY 77-1931 ODT 500 mg in Period 2. The washout interval between period 1 and 2 will be at least 14 days.
2925181|NCT03074045|Experimental|Test|LCS16 (Low-dose LNG IUS)
2925182|NCT03074045|Active Comparator|Reference|COC (Yarina)
2925183|NCT03074032|Experimental|ONC1-0013B 40 mg|ONC1-0013B 40 mg per os daily
2925184|NCT03074032|Experimental|ONC1-0013B 80 mg|ONC1-0013B 80 mg per os daily
2925185|NCT03074032|Experimental|ONC1-0013B 160 mg|ONC1-0013B 160 mg per os daily
2925186|NCT03074032|Experimental|ONC1-0013B 320 mg|ONC1-0013B 320 mg per os daily
2925187|NCT03074019|Experimental|Xylooligosaccharide (Low Dose)|1.5g XOS95 + 1.5g Maltodextrin powder, taken orally mixed in water, once daily
2925188|NCT03074019|Experimental|Xylooligosaccharide (High Dose)|3g XOS95 powder, taken orally mixed in water, once daily
2925189|NCT03074019|Placebo Comparator|Placebo|3g maltodextrin powder, taken orally mixed in water, once daily
2925190|NCT03074006|Experimental|low dose|
2925191|NCT03074006|Experimental|high dose|
2925192|NCT03073993|Active Comparator|Nasogastric|Feeding tube insertion in nasogastric group
2925193|NCT03073993|Active Comparator|Orogastric|Feeding tube insertion in orogastric group
2925194|NCT03073980|Experimental|Group 1: IV tylenol|In the PACU, 30 minutes before the planned start of the procedure, will receive IV 1 gram acetaminophen and PO placebo; followed by standard propofol for conscious sedation
2925195|NCT03073980|Active Comparator|Group 2: PO Tylenol|In the PACU, 30 minutes before the planned start of the procedure, will receive PO 1 gram acetaminophen and IV placebo, followed by IV fentanyl and standard propofol for conscious sedation
2925196|NCT03073980|Placebo Comparator|Group 3: Placebo / Standard of care|In the PACU, 30 minutes before the planned start of the procedure, will receive the current standard of care of IV placebo and PO placebo, followed by IV fentanyl and standard propofol for conscious sedation
2925197|NCT03073967|Experimental|Part A, Pritelivir|Oral tablets, 100mg/day (400mg loading dose on day 1) over 4 weeks
2925198|NCT03073967|Active Comparator|Part A, Foscarnet|iv solution, 40 mg/kg tid or 60mg/kg bid.
2925200|NCT03073954|Active Comparator|Working memory training|Working memory training that increases with difficulty if participants answer two subsequent questions correctly, and standardised healthy lifestyle coaching.
2925201|NCT03073954|Sham Comparator|Sham working memory training|Working memory training that does not increase in difficulty, and standardised healthy lifestyle coaching.
2925202|NCT03073941|Active Comparator|Persona CR Total Knee System|All patients randomized into this group will have the Intervention: Persona total knee system
2925203|NCT03073941|Active Comparator|NexGen CR Total Knee System|All patients randomized into this group will have the Intervention: Nexgen total knee system
2925204|NCT03073928|Active Comparator|Interscalene Block|"Receives interscalene block with 15mL of ropivacaine 0.5% at the level of C6. A total of 15mL will be injected with repeated aspirations to rule out intravascular placement of the needle tip. Once this is done, the needle tip will be moved to the lateral edge of sternocleidomastoid muscle and additional 3mL of 0.5% ropivacaine will be injected between the deep fascia of the sternocleidomastoid and deep investing fascia of the neck (superficial cervical plexus block SCP).~We will administer injection of saline similar to experimental group to blind the patient"
2925205|NCT03073928|Experimental|Paracoracoid SPB|Receives paracoracoid subscapularis plane block with the ultrasound. Using a 50mm 22G block needle 15ml of 0.5% Ropivacaine will be deposited anterior to the fascia of subscapularis muscle after eliciting a motor response with 0.6mA current delivered through the needle. Following this, superficial cervical plexus block will be done using 3mL of 0.5% ropivacaine similar to group 1.
2925206|NCT03073902|Experimental|a prospective, open, self-controlled phase II clinical study|The project is planned to explore the correlation of PD-L1 expression in non-small lung cancer tissue and peripheral blood T cell and serum.The investigators have designed to detected the expression levels of PD-L1 protein in cancer tissue and detected the expression levels of PD-L1 in peripheral blood T cell and serum by using variance analysis of repeated measures design information.
2925207|NCT03073889|Experimental|Block|Scalp nerve block with 10ml solution of 0.75% ropivacaine before skin incision, n=15
2925208|NCT03073889|Active Comparator|Infiltration|Scalp infiltration with 10ml solution of 0.75% ropivacaine before incision, n=15
2925209|NCT03073889|No Intervention|Control|the control group has no treatment, n=15
2925210|NCT03073876|Experimental|Drug|Participants in the Drug group received oral 5mg of Donepezil Hydrochloride daily for 6 months. The Drug group was assessed at baseline, after approximately 6 weeks and after 6 months of treatment. The baseline to 6 weeks phase was part of the double-blind, placebo controlled portion of the trial.
2925211|NCT03073876|Placebo Comparator|Placebo|"Participants in the placebo group first received oral administration of a placebo pill for approximately 6 weeks. After that initial interval, the study was unblinded and participants in the placebo group then received 5mg of donepezil hydrochloride treatment for 6 months.~The Placebo group was evaluated at baseline, after 6 weeks of placebo, after 6 weeks of donepezil hydrochloride drug treatment, and 6 months of donepezil hydrochloride treatment."
2925212|NCT03073863|Active Comparator|Atorvastatin 10mg|5006 patients received continuous medication with atorvastatin 10mg/day after run-in period.
2925213|NCT03073863|Experimental|Atorvastatin 80mg|4995 patients received medication with atorvastatin 80mg/day after run-in period.
2925214|NCT03073850|Experimental|Antiplatelet therapy|acetylsalicylic acid (ASA) 100mg or clopidogrel 75mg if intolerant to ASA
2925215|NCT03073850|Experimental|Low-dose OAC therapy|Edoxaban of 30mg (Reduced dose of 15mg if body weight < 60kg, CCr< 50 ml/min, concomittant use of P-gp)
2925216|NCT03073850|Active Comparator|Standard-dose OAC therapy|Edoxaban of 60mg (Reduced dose of 30mg if body weight < 60kg, CCr< 50 ml/min, concomittant use of P-gp)
2925217|NCT03073837|Other|Rhinovirus Challenge|Challenge with HRV-16
2925218|NCT03073824|Experimental|vSculpt, model #VS1100|A novel intravaginal device for females
2925219|NCT03073811|Experimental|PeriHab|Provided nutrition counseling and prescribed to consume 1.6 g/kg/body weight as well as provided 30 grams of high quality protein three times per day for two weeks before and two weeks after surgery.
2925220|NCT03073811|Active Comparator|PoshControl|Provided nutrition counseling and prescribed to consume 1.0 g/kg/body weight in the form of educational handouts explained by a Registered Dietitian.
2925221|NCT03073798|Active Comparator|Medication|Roflumilast. 500 mcg of Roflumilast daily for 4 weeks, then there will be a 4 week wash-out phase (no medication) and a second 4 week period of placebo.
2925222|NCT03073798|Placebo Comparator|Placebo|Placebo. 500 mcg of Placebo daily for 4 weeks, then there will be a 4 week wash-out phase (no medication) and a second 4 week period of Roflumilast
2925223|NCT03073785|Active Comparator|Arm A (chemotherapy, radiation therapy)|Patients undergo hypofractionated stereotactic body radiation therapy in 5 fractions on days 1-5. Patients receive fluorouracil IV over 24 hours on day 1 weekly for 4 weeks or capecitabine PO every 12 hours starting the evening before day 1 of radiation therapy for 4 weeks as per standard of care. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
2925224|NCT03073785|Experimental|Arm B (zoledronic acid, chemotherapy, radiation therapy)|Patients receive zoledronic acid IV over no less than 15 minutes 1 week prior to radiation therapy.Patients undergo hypofractionated stereotactic body radiation therapy and receive treatment with fluorouracil IV or capecitabine PO as in Arm A. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
2925225|NCT03073772|No Intervention|Continued multimodal rehabilitation|No addition of extra training in this group. Only ordinary continued multimodal rehabilitation.
2925226|NCT03073772|Active Comparator|Computer-based cognitive training|This arm also consisted of continued multimodal rehabilitation.
2925227|NCT03073772|Active Comparator|Physical fitness training|This arm also consisted of continued multimodal rehabilitation.
2925228|NCT03073759|Experimental|dTCS|Patient will receive dTCS with direct current (maximum of 2 mA) stimulation delivered through surface electrodes (TransQE from IOMED®, surface area: 25 cm2) using a Phoresor® II Auto (Model No. PM850, IOMED®, Salt Lake City, Utah 84120, USA) or Sham stimulation.
2925229|NCT03073746|Experimental|Health Search|Access to Health Knowledge Panels and Symptom Search Tool.
2925230|NCT03073746|Experimental|Standard Search|No access to Health Knowledge Panels and Symptom Search Tool, but access to prior version of Google search.
2925231|NCT03073746|No Intervention|No Search|No access to Health Knowledge Panels, Symptom Search Tool, prior version of Google search, or mobile device.
2925232|NCT03073733|Experimental|Test (jCell injection) dose level 1|single intravitreal injection of 3.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
2925233|NCT03073733|Other|Sham treated Control|"a mock injection will be performed on the eye with the poorest vision in each Control subject (designated as the study eye)"
2925234|NCT03073733|Experimental|test (jCell injection) dose level 2|single intravitreal injection of 6.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
2925235|NCT03073707||Household|Sample collection will be anticipated for 20 cases of NTS infections and household/environment in order to analyze 10 combinations of NTS strains in the index patient and its environment
2925236|NCT03073694|Active Comparator|Mitomycin C Group|Mitomycin-C initial dose of 15 mg/m2 (milligrams per meter squared) 45 minutes into the perfusion, a maintenance dose of 5 mg/m2 will be administered.
2925237|NCT03073694|Experimental|Melphalan Group|Melphalan 60 mg/m2 (milligrams per meter squared) 45 minutes into the perfusion.
2925238|NCT03073681||Historical controls|This group of historical controls makes up patients who have previously undergone cataract surgery with a 3.0 add ReSTOR lens in each eye. This group has already completed a satisfaction questionnaire identical to what will be posed in the 2.5/3.0 add lens group.
2925239|NCT03073681||2.5 and 3.0 add lenses|This group will have undergone cataract surgery at least 2 months before conducting a questionnaire. Patients enrolled in this group had cataract surgery with a 2.5 add ReSTOR lens in one eye and a 3.0 add lens in the other.
2925240|NCT03073668|Experimental|Heart Failure Patients|After obtaining written informed consent, patients will undergo induction with general anesthesia as per clinical practice. The chest will be open but pericardium left intact. Cardiac hemodynamics will be measured using PA catheter already in place at rest, and then during conditions of increased cardiac preload, induced by passive leg elevation and saline bolus (300 ml administered over 1-2 minutes). The surgical team will perform anterior pericardiotomy. This will not be a complete pericardiectomy but rather a limited anterior incision to gain access to the heart for surgical exposure. The surgical team will then repeat hemodynamic assessments at rest and with acute volume loading (leg raise + saline) in exactly the same manner as with the pericardium intact.
2925241|NCT03073655|Experimental|Group 1|it has been limited evidence of KT is effective
2925242|NCT03073655|Experimental|Group 2|it has been not known that KT is effective or not
2925243|NCT03073655|Experimental|Group 3|it has been known that KT has excellent result
2925244|NCT03073642|Active Comparator|Hydrotherapy|"Patients allocated to this group will perform 12 weeks of hydrotherapy treatment, with global exercises. Hydrotherapy sessions will last 45 minutes and will be performed twice a week.~Exercises will involve aerobic exercises (in the pool) with exercises for upper and lower limbs, and trunk."
2925245|NCT03073642|Experimental|Hydrotherapy and Pain Education|"Patients allocated to this group will perform 12 weeks of hydrotherapy treatment, with global exercises. Hydrotherapy sessions will last 45 minutes and will be performed twice a week.~Exercises will involve aerobic exercises (in the pool) with exercises for upper and lower limbs, and trunk.~During the 12 weeks of hydrotherapy treatment, volunteers will also receive 4 sessions of Pain Therapeutic Education, which is also known as Pain Neuroscience Education, which involves patient education on pain neurophysiology, pain chronification and amplification mechanisms, and chronic pain management. These sessions will be performed in specific dates scheduled according to the volunteers' availability, and with intervals that can last from one to two weeks."
2925246|NCT03073629|Active Comparator|Clinical Pathway Cohort|Patients with isolated RV failure will be evaluated and managed in a specialized cardiovascular clinic.
2925247|NCT03073629|No Intervention|Standard Care|Patients with isolated RV failure will receive standard care and follow up.
2925248|NCT03073616||Lung ultrasound|Every patient will receive a chest RX and lung US
2925249|NCT03073603|Active Comparator|Drug Continuation Arm|Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
2925250|NCT03073603|Experimental|Drug Discontinuation Arm|Participants who will discontinue their Disease Modifying Therapies (DMTs). No other changes to their treatment occur. DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
2925251|NCT03073590|Experimental|Intervention with lunch|Intervention factory with hot lunch program A. Nutritionally enhanced lunch meal program B. Once weekly iron/folate supplement C. Behavior change communications program
2925252|NCT03073590|Active Comparator|Control with lunch|Control factory with lunch program A. Regular lunch meal program B. Behavior change communications program
2925253|NCT03073590|Experimental|Intervention without lunch|Intervention factory without lunch program A. Twice weekly provision of iron/folate supplements B. Enhanced behavior change communications program
2925254|NCT03073590|Active Comparator|Control without lunch|Control factory without lunch program A. Behavior change communications program
2925255|NCT03073577|Experimental|Treatment Group|PKX-001 will be supplemented to islet preservation CMRL-1066 medium at final concentration of 3 mg/mL during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays. Islets are maintained for minimal 6 hours up to 72 hours in supplemented CMRL1066-based media containing PKX-001 until the time of transplant. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally.
2925256|NCT03073564|No Intervention|Incremental cardiopulmonary test|Incremental cardiopulmonary test for upper limbs will be performed only to identify patients who exhibit dynamic hyperinflation during upper limb exercise.
2925257|NCT03073564|Experimental|Endurance test|The endurance test for upper limbs will be performed in two conditions: In the first the patients perform the test in usual breathing, without the use of EPAP. In the second the test will be performed using the EPAP mask.
2925258|NCT03073564|Experimental|Functional test|The functional test for upper limbs will be performed from protocol already published for the 6-min pegboard and ring test (6PBRT). In this stage the patients will perform the 6PBRT in usual breathing and as the use of the EPAP mask.
2925259|NCT03073551|No Intervention|Control Group|Participants in this group will receive diabetic care and education as per the standard of care. They will also be given a pedometer and will be instructed to record their number of steps at the end of each day
2925260|NCT03073551|Active Comparator|Wii Group|Participants in this group will receive diabetic care and education as per the standard of care. They will also be given a Wii console and game to take home. Participants will be instructed on how to set up and use the Wii. These participants will also be given a pedometer and will be instructed to record their number of steps at the end of each day.
2925261|NCT03073525|Experimental|Vigil then Vigil + Atezolizumab|Vigil immunotherapy will be administered at a concentration of 1x10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses for 2 cycles (1 cycle = 21 days). Combination of Vigil and Atezolizumab thereafter with maximum duration of 36 weeks, inclusive of monotherapy and combination therapy.
2925262|NCT03073525|Active Comparator|Atezolizumab then Vigil + Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg as an intravenous infusion every 3 weeks for 2 cycles (1 cycle = 21 days). The initial dose is to be administered over one hour and if well tolerated, subsequent infusions may be administered over 30 minutes. Combination of Vigil and Atezolizumab thereafter with maximum duration of 36 weeks, inclusive of monotherapy and combination therapy.
2925263|NCT03073512|Other|Ultrasound examination|Participants will undergo an ultrasound examination at 32 weeks gestation.
2925264|NCT03073499|Experimental|Intervention|(Partial) Oncological Home Hospitalization
2925265|NCT03073499|No Intervention|Control|Standard oncological treatment at the hospital day care unit
2925266|NCT03073486|Experimental|Treatment A|Olumacostat Glasaretil Gel
2925267|NCT03073486|Placebo Comparator|Treatment B|Vehicle
2925268|NCT03073473||Concordant with GPS Cancer Test|Patients with advanced cancer who undergo GPS Cancer testing whose therapy matches the recommendations from the NantHealth GPS Cancer Test.
2925269|NCT03073473||Discordant with GPS Cancer Test|Patients with advanced cancer who undergo GPS Cancer testing whose therapy does not match the recommendations from the NantHealth GPS Cancer Test.
2925270|NCT03073473||CNA controls without testing|Retrospective patients in the COTA database matched by similar characteristics (CNA matched).
2925271|NCT03073460|Other|Ultrasound examination|Participants will undergo an ultrasound examination at 40 weeks gestation to assess the fetal ductus arteriosis.
2925272|NCT03073447|Other|women under 50 years with acute MI|this clinical study is to systematically pool clinical, morphological and biological data of young women (< 50 years) presenting an Acute MI and to assess their short-term (in-hospital) and mid-term (12 months) prognosis. The usual blood tests will be performed at the patient's admission and then repeated at least 24 hours after coronary angiography, including repeated sampling assays for troponin, in order to measure the peak, following the routine of the department The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge.
2925273|NCT03073421|Other|HIV positive pregnant women|HIV positive pregnant women who took part in the P3 program will take part in a 2-hour qualitative interview.
2925274|NCT03073408|Active Comparator|1: Manual control group|The propofol infusion rate is adjusted manually in a pump by the investigator to maintain BIS between 40 and 60. For this titration it is necessary continuous monitoring, clinical experience, and pharmacokinetic/pharmacodynamic knowledge.
2925275|NCT03073408|Experimental|2: PI +Smith group|The closed loop control automatically adjust propofol infusion rate guided by the feedback of the real value of BIS. The automatic system has to achieve a target BIS of 50 and maintain it between 40 and 60.
2925276|NCT03073395|Experimental|Dynamic group|Dynamic imaging of suspected metastatic lesions with the investigation drug [68Ga]P16-093 in patients with a history of histologically confirmed cancer.
2925277|NCT03073395|Experimental|Biodistribution group|Whole body imaging to determine human dosimetry of the investigational drug [68Ga]P16-093
2925278|NCT03073369|Active Comparator|Oral Ergocalciferol|Oral Ergocalciferol 50000 IU once daily for 6 weeks
2925279|NCT03073369|Placebo Comparator|Placebo|
2925280|NCT03073356|Experimental|Control - Healthy test subjects|Age matched subjects without symptoms of heart failure or ischemic heart disease N=10
2925281|NCT03073356|Experimental|HFrEF - Heart failure patients investigated by PET|Patients with heart failure (HFrEF) N=12
2925282|NCT03073356|Experimental|HFrEF - Right heart catheterization|Patients with heart failure (HFrEF) N=12
2925283|NCT03073356|Experimental|HFrEF - Right heart catheterization study 2|Dose finding study (increasing dosage of 3-OHB)
2925284|NCT03073343|Active Comparator|diabetic patients with NAFLD|Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks.
2925285|NCT03073343|Active Comparator|non-diabetics with NAFLD|Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks.
2925286|NCT03073330|Experimental|One Step|The intervention is gestational diabetes screening with 2 hour GTT 75 g load.
2925287|NCT03073330|Active Comparator|Two Step|There is no intervention is this arm as patients will subjected to routine gestational diabetes screening with one hour glucola, 50 g load.
2925288|NCT03073317|Experimental|INTERVENTION|Clinical protocol using FullPIERS and sFlit/PLGF ratio (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)
2925289|NCT03073317|No Intervention|CONTROL|Usual clinic control
2925290|NCT03073304|Active Comparator|Control|Erythrocyte based prime solution
2925291|NCT03073304|Experimental|Intervention|Crystalloid based prime solution
2925292|NCT03073291|Experimental|Responsible Marijuana Vendor Training|The TrainToTend online responsible marijuana vendor training teaches responsible sales practices in five modules: Module 1, The Laws; Module 2, ID Checking; Module 3, Health Effects; Module 4, Customer Service, and Module 5, Rules of the Trade. The training content will be conveyed using online educational activities providing application and feedback such as in tabs with appropriate graphics and interactive simulations where users apply the skill and receive informative/corrective feedback.
2925368|NCT03072719|Experimental|Dentifrice containing stannous fluoride|Toothpaste
2925293|NCT03073291|No Intervention|Usual and Customary Sales Practices Training|Usual and customary training in retail sales practices delivered to employees at retail recreational marijuana stores by store managers. Some retail stores in Colorado may receive responsible marijuana vendor training of some type from another state-approved training provider. Thus, we consider the outlets in the control group to have usual and customer sales training but not to be entirely untrained.
2925294|NCT03073278|Other|Group 1|This group of 12 patients will be given 36Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
2925295|NCT03073278|Other|Group 2|This group (12 patients) will be given 38Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
2925296|NCT03073278|Other|group 3|This group (12 patients) will be given 40Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
2925297|NCT03073265||Patients on apixaban|Patients currently on apixaban who meet inclusion/exclusion criteria A blood draw will be done on each patient to measure apixaban concentration in plasma using anti-Xa assay and LCMS.
2925298|NCT03073252|Experimental|Normal Protein|Consumption of normal protein (NP) meal
2925299|NCT03073252|Experimental|High Protein|Consumption of high protein (HP) meal
2925300|NCT03073239||ALS epidemiological characterization|epidemiological characterization
2925301|NCT03073239||Genetic findings in ALS patients|genética characterization
2925302|NCT03073226|Experimental|Barrett's surveillance Olympus Spectrum|Barrett's surveillance with Olympus Spectrum.
2925303|NCT03073226|Experimental|Barrett's Surveillance Olympus Elite|Barrett's surveillance with Olympus ELITE.
2925304|NCT03073226|Experimental|Polyp Surveillance Olympus Spectrum|Colonic polyp surveillance/screening with Olympus Spectrum.
2925305|NCT03073226|Experimental|Polyp Surveillancewith Olympus ELITE.|Colonic polyp surveillance/screening with Olympus ELITE.
2925306|NCT03073213|Experimental|Ixekizumab single dose|Ixekizumab administered subcutaneously (SC) once
2925307|NCT03073213|Experimental|Ixekizumab Multiple Regimen 1|Ixekizumab administered SC on multiple occasions
2925308|NCT03073213|Experimental|Ixekizumab Multiple Regimen 2|Ixekizumab administered SC on multiple occasions
2925309|NCT03073200|Experimental|Ixekizumab|Ixekizumab given subcutaneously (SC) during the double-blind treatment period and the open-label maintenance period.
2925310|NCT03073200|Placebo Comparator|Placebo|Placebo given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period.
2925311|NCT03073187||Students: Step 1 Interviews|20 adolescents with uncontrolled asthma and poor sleep [10 from New York City (NYC); 10 from Rhode Island (RI)] will provide information regarding their asthma and sleep routines, and on what they would like to see in an intervention targeting co-morbid asthma and poor sleep.
2925312|NCT03073187||Caregivers: Step 1 Interviews|The caregivers of the 20 adolescents in this step [10 from NYC; 10 from RI] will be asked to provide information regarding their teenager's asthma and sleep routines, and on what they would like to see in an intervention targeting co-morbid asthma and poor sleep.
2925313|NCT03073187||Teachers: Step 2 Interviews|4 high school teachers, 2 from NYC and 2 from RI, will review the developed intervention. They will provide their opinions about the appropriateness of the teaching methods and literacy level for adolescents.
2925314|NCT03073187||Students: Step 3 Focus Groups|20 adolescents with uncontrolled asthma and poor sleep [10 from NYC; 10 from RI] will review the intervention providing feedback on its appropriateness and utility.
2925315|NCT03073187||Caregivers: Step 3 Focus Groups|The caregivers of the 20 adolescents in this step [10 from NYC; 10 from RI] will review the intervention providing feedback on its appropriateness and utility in small groups.
2925316|NCT03073135|Experimental|Psychodrama Group Therapy (PGT)|The PGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience. The process will be divided into three stages: the first (5 sessions) will be focused on the management of the individual's relationship challenges. The second stage (5 sessions) will focus on the association between the subject's management of their relationships and the excoriation disorder (ED) symptoms. The third (5 sessions) will focus on the development of new skills for the management of ED. Psychodramatic methods will be used throughout the process.
2925317|NCT03073135|Active Comparator|Supportive Group Therapy (SGT)|The SGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience.
2925318|NCT03073122||TGA Case|Brain MRI, Neurocognitive and psychological testing
2925319|NCT03073096|Other|Intervention arm|LVA at time of nodal dissection
2925320|NCT03073083|Active Comparator|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon autograft
2925321|NCT03073083|Active Comparator|Patella tendon autograft|ACL reconstruction surgery with pattella tendon autograft
2925322|NCT03073083|Active Comparator|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon autograft
2925323|NCT03073070|Experimental|Biotin labeled RBCs in 4-10 year old diabetes children|Biotin labeled autologous RBCs will be transfused to the subjects
2925324|NCT03073070|Experimental|Biotin labeled RBCs in 10-18 year old diabetes children|Biotin labeled autologous red blood cells will be transfused to the subjects
2925325|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler A|160/4.5microg/inhalation Charcoal
2925326|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler B|160/4.5microg/inhalation Charcoal
2925327|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler C|160/4.5microg/inhalation Charcoal
2925328|NCT03073057|Active Comparator|Charcoal and Symbicort Turbuhaler|160/4.5microg/inhalation Charcoal
2925329|NCT03073031|Active Comparator|Intervention|Patients report their adverse events on a tablet once a week (intervention) as a supplement to having them monitored every 3 weeks by a physician
2925330|NCT03073031|No Intervention|Control|Patients have their side effects monitored by a physician every 3 weeks (control)
2925331|NCT03073018|Experimental|Fosinopril + Pravastatin|Fosinopril (20 mg) + pravastatin (40 mg) once daily for 4 years
2925332|NCT03073018|Active Comparator|Fosinopril + Placebo|Fosinopril (20 mg) + pravastatin placebo once daily for 4 years
2925335|NCT03073005|No Intervention|Traditional VAD training|Patients and caregivers will receive traditional training for their VAD via a video produced by the VAD manufacturer.
2925336|NCT03073005|Experimental|Simulation-based VAD training|Patients and caregivers will receive traditional training for their VAD via a video produced by the VAD manufacturer and then participate in simulation-based mastery learning for VAD management
2925337|NCT03072992|Active Comparator|Group A: Paclitaxel & Curcumin|75 patients, treatment with Curcumin (CUC-01, yellow solution), 300mg i.v. plus i.v. Paclitaxel (colorless solution) 80 mg /m2 BS i.e., once weekly for 12 weeks.
2925338|NCT03072992|Placebo Comparator|Group B: Paclitaxel & Placebo|Group B, 75 patients, treatment with Paclitaxel (colorless solution) 80 mg /m2 BS, i.v. plus placebo i.v. solution (250 ml, yellow solution for masking/blinding), once weekly for 12 weeks.
2925339|NCT03072966|Experimental|Distress screening group|Physical activities will be monitored by wearable device. Patient-reported outcomes including distress, depression, physical activities and quality of life are going to be collected by questionnaires based on smartphone application and paper. The algorithm of distress screening will be developed with the analysis of patterns of physical activities.
2925340|NCT03072953|Other|APD334|APD334 active treatment for 12 weeks.
2925341|NCT03072940||Patients with idiopathic RBD|
2925342|NCT03072940||Healthy volunteers|
2925343|NCT03072927||MILD|All Medicare patients treated with MILD as reported via CPT® Code 0275T (or successor code(s)).
2925344|NCT03072927||Interspinous Process Decompression|All Medicare patients treated with interspinous process decompression (CPT Code 22869 or 22870, or successor code(s)) for the treatment of LSS with NC.
2925345|NCT03072914|No Intervention|The control group|The control group has a sphygmomanometer wound around the upper arm or lower extremity and applies the same pressure, but a 3-way stopcock is installed in the middle so that no pressure is applied.
2925346|NCT03072914|Active Comparator|RIPC with RIPostC group|The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
2925347|NCT03072901||EndoBarrier Gastrointestinal Liner|244 subjects; The registry will be open to subjects who meet the EndoBarrier's Indications for Use and none of the Contraindications in the device's Instructions For Use document. Subjects who successfully receive the device implant at a participating registry center will be included in the registry.
2925348|NCT03072888|Experimental|TENS|TENS treatment will be apply with 30 minutes sessions seven times per day at the intensity between 9-15 milliamps (mA) which will be adjusted depending on the sensitivity of each individual patient.
2925349|NCT03072888|Sham Comparator|Control|Patients will receive 30 minutes sessions seven times per day of sham TENS therapy without the intensity impulse.
2925350|NCT03072875|Experimental|CAMS-RAS|In this single-arm study design, all enrolled patient participants are asked to provide feedback on the CAMS-RAS prototype as it is developed for this study. Feedback will be gathered via survey measure and interview.
2925351|NCT03072862||Commercial Nucleus Cochlear Implant Systems|
2925352|NCT03072849||Stem Cell Transplant Recipients|Pediatric patients ages 6-18 years who have received allogenic hematopoietic stem cell transplant for any reason.
2925353|NCT03072836|Experimental|CD alone|
2925354|NCT03072836|Experimental|SPA alone|
2925355|NCT03072836|Experimental|CD + SPA|
2925356|NCT03072823|Active Comparator|n-3 polyunsaturated fatty acids|n-3 polyunsaturated fatty acids dosage of 2 g of Eicosapentaenoic acid(EPA) and 1 g of Docosahexaenoic acid (DHA).
2925357|NCT03072823|Placebo Comparator|placebo|olive oil ethyl esters
2925358|NCT03072810|Experimental|Positive mindfulness program|Participants will receive a 4 week online positive mindfulness program as described in previous sections.
2925359|NCT03072810|Other|Waitlist control|Participants will receive the same intervention as the intervention arm (positive mindfulness program) but will be required to wait 4 weeks before commencing.
2925360|NCT03072784|Active Comparator|group S|short time <90 m aortic cross clamping
2925361|NCT03072784|Active Comparator|group L|> 90 minutes aortic cross clamping
2925362|NCT03072771|Experimental|ASCT + BEAM + Blinatumomab|"Standard of care ASCT with BEAM conditioning (carmustine/etoposide/cytarabine/melphalan) - guidelines below:~carmustine is typically given intravenously (IV) at a dose of 300 mg/m^2 on Day -7~etoposide is typically given IV at a dose of 100 mg/m^2 twice per day (BID) on Days -6, -5, -4, and -3 (8 doses)~cytarabine is typically given IV at a dose of 100 mg/m^2 BID on Days -6, -5, -4, and -3 (8 doses)~melphalan is typically given IV at a dose of 140 mg/m*2 on Day -2~Auto-SCT will take place on Day 0 as per institutional guidelines~Consolidation with blinatumomab will start 6 weeks following auto-SCT. Patients with CR based on pre-transplant PET/CT will receive blinatumomab as a continuous IV infusion (CIVI) at 9μg/day for 1 week, then 28μg/day for 3 weeks (total of 4 weeks). Patients with PR based on pre-transplant PET/CT will receive blinatumomab CIVI 9μg/day for 1 week, then 28μg/day for 1week, then 112μg/day for 6 weeks (total of 8 weeks)"
2925363|NCT03072758|Experimental|Men's Club Intervention Group|Participants randomized to this group will receive interventions from the study team.
2925364|NCT03072758|No Intervention|Men's Club Control Group|Male participants in the control group will receive only education pamphlets related to breastfeeding during the 3rd trimester of their female partner's pregnancy
2925365|NCT03072745|Experimental|Neuropsychological assessment|Assessment with a neuropsychological test battery and self-report measures.
2925366|NCT03072732|Other|study arm 1-below left armpit|20 patients undergoing hemodialysis, with at least 10 of these patients having congestive heart failure, will have the u-Cor system placed below left armpit and the ZOE Fluid Status Monitor
2925367|NCT03072732|Other|study arm 2-upper front chest|20 patients undergoing hemodialysis, with at least 10 of these patients having congestive heart failure, will have the u-Cor system placed on the upper front chest and the ZOE Fluid Status Monitor
2925378|NCT03072641|Experimental|ProBion Clinica|Probiotic tablets yielding a daily dose of 1.4 x 10 ˄ 10 Bifidobacterium lactis Bl-04 (ATCC SD5219), 7x10 ˄ 9 Lactobacillus acidophilus NCFM (ATCC 700396), and 0.63 g inulin.
2925379|NCT03072641|No Intervention|Control|
2925380|NCT03072628|Experimental|Nicotine: use e-cig with nicotine|One time exposure to e-cig with nicotine
2925381|NCT03072628|Experimental|no nicotine: use e-cig without nicotine|One time exposure to e-cig without nicotine
2925382|NCT03072628|Experimental|Nicotine inhaler: use a nictoine inhaler|One time exposure to nicotine inhaler
2925383|NCT03072628|Sham Comparator|Sham control|Use an empty e-cigarette
2925384|NCT03072615||1|receiving TE before and 30 min after TIPS
2925385|NCT03072615||2|receiving SWE before and 7 days, 6 weeks and 3 months after TIPS
2925386|NCT03072602|Experimental|African-American|Healthy self-identified African-American participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB). On 4th day, participants will come to the clinic in fasting state and drink 75 gm of oral glucose solution, followed by blood collection every hour for 8 hours.
2925387|NCT03072602|Active Comparator|Whites|Healthy self-identified white participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB). On 4th day, participants will come to the clinic in fasting state and drink 75 gm of oral glucose solution, followed by blood collection every hour for 8 hours.
2925388|NCT03072589|Experimental|Regadenoson infusion|Dose escalation of Regadenoson infusion
2925389|NCT03072550|Experimental|Multi-center open label|Thirty Subjects with 20-75% Distal Subungual Onychomycosis (mild to moderate DSO) infection of their big toe (hallux) nail infected by the dermatophytes Trichophyton (T.) rubrum or T. mentagrophytes will be enrolled. All Subjects will receive three 45-minute plasma treatments performed over a week.
2925390|NCT03072524||Stroke patients|Stroke patients who will undergo the FAST PLUS test within 12 hours from the stroke onset.
2925391|NCT03072511|Experimental|Spotlight on Smoke-Free Living|Treatment will include a 1.5-hour intervention session combined with daily text-messaging for up to 1 week pre-quit and 4 weeks post-quit. The intervention includes: mindful breathing, visualization, and identification and thinking about goals and priorities inconsistent with smoking. During the text-messaging phase, elements of the intervention discussed during the in-person session will be reinforced. Participants will be provided transdermal nicotine patches (TNP). TNP are a safe and effective approach to nicotine replacement when an individual attempts to stop smoking and are safe for use without prescription. Participants will begin the regimen on the scheduled quit date with an initial dose of 21 mg (4 weeks), followed by 14 mg (2 weeks), and 7 mg (2 weeks). Alterations to dosing will be allowed when appropriate and consistent with manufacturer's recommendations. While TNP will be offered to all participants, they can decline or discontinue use of TNP at any time.
2925392|NCT03072511|Active Comparator|Standard Informational Treatment|Standard informational treatment is based on conventional, information-based smoking cessation approaches commonly found in public health settings. This will include the following information: prevalence/incidence of cigarette smoking and negative health outcomes associated with cigarette smoking (e.g., cancer, respiratory disease, complications), other health consequences resulting from diseases associated with cigarette smoking, personal/financial/social consequences of cigarette smoking. During the text-messaging phase, information about the consequences of smoking discussed during the in-person session will be reiterated. As with the experimental condition, participants will be provided with 8-weeks TNP.
2925393|NCT03072485|Other|Sirolimus, metformin, diclofenac|First five enrolled participants
2925394|NCT03072485|Other|Metformin, diclofenac|Sixth to tenth enrolled participants
2925395|NCT03072472|Experimental|Endocuff-assisted Flexible Sigmoidoscopy|Patients in this arm will receive their screening sigmoidoscopy with the Endocuff Vision in situ on the scope
2925396|NCT03072472|No Intervention|Standard Flexible Sigmoidoscopy|Patients in this arm will receive their screening sigmoidoscopy without the Endocuff on the scope
2925397|NCT03072446|Experimental|Gel-Beads arm|This group will undergo embolization of symptomatic uterine fibroids with Gel-Beads embolic agent
2925398|NCT03072433|Active Comparator|Standard of Care|Comparison group will receive the current standard of care. Nurses are instructed to tell mothers about nutrition and water, sanitation and hygiene at any point prior to discharge from hospital. In addition, nurses will tell primary caregivers to play with their children even while they are receiving treatment in a play area with toys available.
2925399|NCT03072433|Experimental|Counseling Intervention Package|Primary caregivers in the intervention group receive group education sessions involving psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene components during a total of four days.
2925400|NCT03072420|Experimental|Group no manual work or activity|Subject with an office or student job.
2925401|NCT03072420|Sham Comparator|Group manual work|Subject working in a manual or predominantly manual.
2925402|NCT03072407|Placebo Comparator|PB-119 injection placebo|totally 8 subjects will have PB-119 injection placebo once per weekly for 4 weeks.
2925403|NCT03072407|Experimental|PB-119 injection 25ug|totally 8 subjects will have PB-119 injection 25 ug once per weekly for 4 weeks
2925404|NCT03072407|Experimental|PB-119 injection 50ug|totally 8 subjects will have PB-119 injection 50 ug once per weekly for 4 weeks
2925405|NCT03072407|Experimental|PB-119 injection 100ug|totally 8 subjects will have PB-119 injection 100 ug once per weekly for 4 weeks
2925406|NCT03072407|Experimental|PB-119 injection 200ug|totally 8 subjects will have PB-119 injection 200 ug once per weekly for 4 weeks
2925407|NCT03072394|Experimental|EMLA anesthetic ointment (AO)|In AO group a layer of 2.5 gr EMLA cream (standard adult dose) is applied to both wrists, 1 cm above the styloid process of the radius 30 minutes before the puncture, by an experienced cathlab nurse.
2925408|NCT03072394|Active Comparator|Local Skin Anesthetic Injection (LA)|In LA group the radial artery is infiltrated with 1-2 mL of 2% lidocaine, using a 26 G needle, 0.5-1 cm proximal to the styloid process one minute before the puncture
2925483|NCT03071822|Experimental|PIGLETs|Patient will be given this combination of chemotherapy (cisplatin, ifosfamide, gemcitabine, L-asparaginase, etoposide and dexamethasone) for a total of 6 courses
2925409|NCT03072381|Active Comparator|Platelet Rich Plasma - Group 1|"Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).~If a subject has bilateral elbow common extensor tendon pain, both elbows will be treated in the same study arm."
2925410|NCT03072381|Placebo Comparator|Corticosteroid Control - Group 2|"Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.~If a subject has bilateral elbow common extensor tendon pain, both elbows will be treated in the same study arm."
2925411|NCT03072368|Active Comparator|Blue eyes|50 babies born with blue eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
2925412|NCT03072368|Active Comparator|Brown eyes|50 babies born with brown eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
2925413|NCT03072368|Active Comparator|Green eyes|50 babies born with green eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
2925414|NCT03072368|Active Comparator|Hazel eyes|50 babies born with hazel eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
2925415|NCT03072355|Active Comparator|Elastic Band|Perform the maximum of the possible repetition with a load of 50% of the 1RM (performing 1½ seconds in the concentric phase and 1½ seconds in the eccentric phase).
2925416|NCT03072355|Active Comparator|Isokinetic dynamometer|Realization of the maximum of the possible repetition to 50% of the MIVM in the speed of 60º / s for abduction and 500º / s in the return of the movement.
2925417|NCT03072342|Active Comparator|Intensive Periodontal Treatment (IPT)|
2925418|NCT03072342|Placebo Comparator|Control Periodontal Treatment (CPT)|
2925419|NCT03072329|Experimental|Pudendal nerve block|Bilateral pudendal nerve block with the administration of 0.1 mL/kg Bupivacaïne 0.5%, regardless of neurostimulation response.
2925420|NCT03072316||SSM immediate DIEP|Unilateral skin sparing mastectomy with immediate DIEP
2925421|NCT03072316||SSM immediate DIEP and PMRT|Unilateral skin sparing mastectomy with immediate DIEP flap reconstruction and post mastectomy radiotherapy
2925422|NCT03072316||mastectomy, PMRT, delayed DIEP|simple mastectomy, post mastectomy radiotherapy adn then delayed DIEP reconstruction
2925423|NCT03072316||SSM, temporizing implant, PMRT then DIEP|Unilateral SSM with temporizing implant, PMRT and subsequent
2925424|NCT03072290|Experimental|low dose steroid|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
2925425|NCT03072290|Active Comparator|comparator|ultrasound-guided steroid injection using 1ml of 40 mg (40mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
2925426|NCT03072277|Active Comparator|Docosa Hexaenoic Acid (DHA)|Omega 3 Fatty Acid
2925427|NCT03072277|Placebo Comparator|Placebo|Corn/Soy Oil
2925428|NCT03072264|Experimental|Body in Mind Training (BMT)|This is a group intervention (10-15 participants) that consists of 5 weekly sessions lasting 2 hours. In our protocol, we added 3 more final sessions of 2 hours in order to emphasize the practices, specially in self-compassion, resulting in 8 weeks of intervention.
2925429|NCT03072264|Active Comparator|Medication|In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
2925430|NCT03072264|Active Comparator|Quality of Life Group|This is a group intervention (10-15 participants) that consists of 8 weekly sessions lasting 2 hour in which individuals will receive psychoeducation on various aspects of quality of life that have na impact in reducing anxiety.
2925431|NCT03072251||Anyone|Any individual may complete this survey
2925432|NCT03072238|Experimental|Ipatasertib + Abiraterone|Ipatasertib and abiraterone, administered orally, in 28-day cycles
2925433|NCT03072238|Active Comparator|Placebo + Abiraterone|Placebo plus abiraterone, administered orally, in 28-day cycles
2925434|NCT03072225|Experimental|Herbal Medicine C-117|Herbal Medicine C-117 Prescription (6g/bag，one bag each time, twice a day.) for 6 months
2925435|NCT03072225|Placebo Comparator|The Placebo of Herbal Medicine C-117|Placebo of Herbal Medicine C-117 (6g/bag，one bag each time, twice a day.) for 6 months
2925436|NCT03072212||HIV infected with stroke|No intervention will be administered
2925437|NCT03072212||HIV uninfected with stroke|No intervention will be administered
2925438|NCT03072199|Experimental|Rituximab|
2925439|NCT03072173|Experimental|PSG with Xylometazoline then placebo|"Patients are administered nasal CPAP with humidifier prior to PSG~Patients in this arm receive Xylometazoline on night 2 of PSG and placebo on night 3 of PSG."
2925440|NCT03072173|Experimental|PSG with placebo then Xylometazoline|"Patients are administered nasal CPAP with humidifier prior to PSG~Patients in this arm receive placebo on night 2 of PSG and Xylometazoline on night 3 of PSG."
2925441|NCT03072160|Experimental|1|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
2925442|NCT03072147|Active Comparator|Group 1- Treatment|20 mcg dosage amounts of teriparatide, in the FDA approved form Forteo, manufactured by Lilly, LLC, are loaded into a 2.4 ml prefilled delivery device (multi injection pen) that administers 28 equal doses as subcutaneous injections in the thigh or abdominal wall. Subjects will inject themselves once a day for 24 weeks.
2925443|NCT03072147|Placebo Comparator|Group 2- Placebo|Saline placebo is packaged by the manufacturer (Lilly, LLC) in the same 2.4 ml injection pen that is used for teriparatide; it will provide 28 doses of placebo. Subjects will inject themselves once a day for 24 weeks.
2925444|NCT03072134|Experimental|Unresectable disease|Patients with unresectable tumors will undergo a biopsy followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.
2925445|NCT03072134|Experimental|Resectable disease|Patients with resectable tumors will undergo a resection followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.
2925446|NCT03072121|Experimental|Shexiang baoxin pill|Shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months & Conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
2925447|NCT03072121|Placebo Comparator|SBP placebo|Placebo shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months & Conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
2925448|NCT03072108|Experimental|Bonolive|
2925449|NCT03072108|Placebo Comparator|Placebo|
2925450|NCT03072095|Experimental|Text-only|Text-only outreach
2925451|NCT03072095|Experimental|Text + Lottery|Text outreach + financial incentive
2925452|NCT03072082|Experimental|Danlou Tablet|Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months & conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
2925453|NCT03072082|Placebo Comparator|Danlou Tablet placebo|Placebo Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months & conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
2925454|NCT03072056|Experimental|Extensive Metabolizers, 4 mg|subjects will receive 32 mL of MIN-101 as a 0.125 mg/mL oral solution
2925455|NCT03072056|Experimental|Extensive Metabolizers, 8 mg|subjects will receive 32 mL of MIN-101 as a 0.25 mg/mL oral solution
2925456|NCT03072056|Experimental|Extensive Metabolizers, 16 mg|subjects will receive 32 mL of MIN-101 as a 0.5 mg/mL oral solution
2925457|NCT03072056|Experimental|Poor Metabolizers, 4 mg|subjects will receive 32 mL of MIN-101 as a 0.125 mg/mL oral solution
2925458|NCT03072056|Experimental|Poor Metabolizers, 8 mg|subjects will receive 32 mL of MIN-101 as a 0.25 mg/mL oral solution
2925459|NCT03072056|Experimental|Poor Metabolizers, 16 mg|subjects will receive 32 mL of MIN-101 as a 0.5 mg/mL oral solution
2925460|NCT03072043|Experimental|Phase 1b Dose Escalation|Participants will receive intravenous infusions of APR-246 as a lead-in phase on days -14 to -11 starting at Dose Level 1 prior to starting cycle #1 of combination therapy with azacitidine. Combination therapy will consist of APR-246 on days 1-4 and azacitidine on days 4-10 (or days 4-5 and 8-12) of a 28 day cycle.
2925461|NCT03072043|Experimental|Phase 2 Treatment|Participants will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing schedule as in Phase 1b.
2925462|NCT03072030|Experimental|Active Drug Group|1900 volunteers will be immunized with vaccine GamEvac-Combi They will receive product twice according to the following dosing regimen: on Day 1 (component A) and Day 21 of the study (component B) in the dose of 0.5 ml
2925463|NCT03072030|Placebo Comparator|Placebo Drug Group|100 volunteers will be immunized with placebo They will receive product twice according to the following dosing regimen: on Day 1 (placebo - component A) and Day 21 of the study (placebo- component B) in the dose of 0.5 ml
2925464|NCT03072017|Experimental|MBAT|Monitored breathing awareness therapy administered using a mobile device on a nightly basis during sleep onset.
2925465|NCT03072004|Sham Comparator|Control|"Leprosy patients with focal demyelinating neuropathy in compression sites of the ulnar and common peroneal nerves who will receive application sham LLLT. The laser will be turned off, but the procedure will be the same as with the Low Level Laser Therapy (LLLT) group"
2925466|NCT03072004|Experimental|Low Level Laser Therapy|Leprosy patients with focal demyelinating neuropathy in compression sites of the ulnar and common peroneal nerves who will receive intervention with low-intensity laser therapy (LLLT).
2925467|NCT03071991||Study group|Preincisional bupivacain will be used
2925468|NCT03071991||Control group|No preincisional anesthetic drug will be used
2925469|NCT03071978||LV-fusion pacing|Left Ventricular pacing (without Right Ventricular pacing)
2925470|NCT03071978||BV pacing|Bi-Ventricular pacing
2925471|NCT03071965|Experimental|Cohort 1|Participants completed protocol NTMT-01. All participants received surgery to implant NT-501. All participants received ciliary neurotrophic factor (CNTF).
2925472|NCT03071965|Experimental|Cohort 2|Participants completed protocol NTMT-02. Participants received surgery to implant NT-501 or sham surgery to mimic implant procedure. Participants that received NT-501 implant were exposed to ciliary neurotrophic factor (CNTF).
2925473|NCT03071939|Other|patients with schizophrenia and their designated relatives|Evaluation of the patient's insight (an inclusion phase, followed by two evaluation phases on D0 and D7) by the patient, his / her close and two caregivers (inter-judicial fidelity)
2925474|NCT03071926|Experimental|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin: 20 mg, qw, first 6 weeks ,every 8 weeks
2925475|NCT03071913||Ancillary-correlative (biospecimen collection)|As part of pre-operative standard of care, patients receive levetiracetam by injection and cefazolin by injection. Patients are also offered lorazepam in the pre-operative area. At the time of surgery, patients undergo approximately 2 tissue biopsies from 3-4 tumor locations. This tissue is removed as part of the planned surgery, but it is also tested for research purposes. During surgery, a blood sample is collected every 20-30 minutes beginning at the time of skin incision until all of the research tumor samples have been removed. A minimum of 3 blood samples are collected up to a maximum of 12.
2925476|NCT03071900|Experimental|SCCHN|squamous cell carcinoma of the head and neck
2925477|NCT03071900|Experimental|Control|health volunteers
2925478|NCT03071887|Experimental|Intervention|Treatment arm - Relaxation Response Resiliency Program (3RP) (this is an open pilot; the treatment arm is the only arm)
2925479|NCT03071874|Experimental|AZD2014|"AZD2014 will be administered orally at a pre-determine dose~Twice daily for two consecutive days out of every seven days~Cycles will last 28 days"
2925480|NCT03071861|Experimental|Darbepoetin Alpha|IV,10 mcg/kg/dose, Darbepoetin Alpha, one dose at <24 hours of age
2925481|NCT03071861|Placebo Comparator|Placebo|IV, Normal saline (placebo dose), one dose at <24 hours of age
2925482|NCT03071848||Bevacizumab|Participants with advanced cervical cancer (metastatic, recurrent or persistent) who have received treatment with bevacizumab from 01 January 2015 to 01 January 2016 (retrospective and independent from this study) combined with standard chemotherapy (cisplatin/carboplatin or topotecan and paclitaxel) will be observed.
2925484|NCT03071809||Early stage neoplasm|Patients with stage I-III early stage non-hematologic neoplasm
2925485|NCT03071809||Healthy Control|Patients undergoing surgery for a non-malignant condition with no prior history of malignancy.
2925486|NCT03071796|Experimental|multivitamin supplement|liquid multivitamin supplement for 12 weeks
2925487|NCT03071796|Placebo Comparator|placebo|liquids with similar appearance and taste like multivitamin supplement for 12 weeks
2925488|NCT03071783|Experimental|Vacuum extraction intelligent system|Measurement and intra-operative feed back of vacuum extraction data: notification signal based an algorithm calculation using traction force (peak and time force integral) and time.
2925489|NCT03071783|No Intervention|conventional|conventional handle
2925490|NCT03071770|Experimental|ivosidenib (AG-120)|
2925491|NCT03071757|Experimental|Part 1A: Monotherapy Dose Escalation|Part 1A: ABBV-368 (various dose levels) intravenous administration every 2 weeks (Q2W). One cycle of treatment is 28 days, thus there will be 2 doses with ABBV-368 per cycle.
2925492|NCT03071757|Experimental|Part 2A: Monotherapy Cohort Expansion|Part 2A: Additional participants (triple negative breast cancer [TNBC]) will be enrolled in a dose expansion cohort that will further evaluate ABBV-368 (various dose levels) intravenous administration Q4W.
2925493|NCT03071757|Experimental|Part 2B: Combination Therapy Cohort Expansion|Part 2B: Additional participants (with Head and Neck carcinoma) will be enrolled in a dose expansion cohort that will further evaluate ABBV-368 (various dose levels) intravenous administration Q4W plus ABBV-181.
2925494|NCT03071744|Other|Lazanda|"Study drug, Lazanda, will be self-administered intranasally during this study. The dose of Lazanda is not predicted from the daily maintenance dose of opioid used to manage persistent cancer pain and must be determined by dose titration. The minimal effective intranasal dose from the radiation therapy simulation will be the dose used as pre-medication prior to any further radiation therapy fractions (up to 10 fractions).~Lazanda should be administered 15 (T-15) minutes prior to laying on the hard surface for each simulation visit. If the response to the titrated Lazanda dose markedly changes, an adjustment of dose may be necessary to ensure that an appropriate dose is maintained as deemed by the investigator."
2925495|NCT03071731|Experimental|Bronchodilators|Nebulization of ipratropium bromide/salbutamol sulfate (500 µg/2.5 mg) before the administration of the Glittre ADL-test
2925496|NCT03071731|Placebo Comparator|Placebo|Nebulization of a placebo before the administration of the Glittre ADL-test
2925497|NCT03071718|Experimental|Med-D|Subjects will follow a Mediterranean diet for two months
2925498|NCT03071718|Active Comparator|Cont-D|Subjects will follow a control diet for two months
2925499|NCT03071705|Experimental|Intervention|TKI plus Metformin
2925500|NCT03071705|Active Comparator|Control|TKI
2925501|NCT03071692|Experimental|Treatment Group|K-877 (pemafibrate) tablet twice daily.
2925502|NCT03071692|Placebo Comparator|Control Group|Matching K-877 placebo tablet twice daily.
2925503|NCT03071679|Experimental|Omiganan|
2925504|NCT03071679|Experimental|Imiquimod|
2925505|NCT03071679|Experimental|Omiganan 1% and Imiquimod|
2925506|NCT03071679|Experimental|Omiganan 2.5% and Imiquimod|
2925507|NCT03071679|Placebo Comparator|Placebo|Vehicle
2925508|NCT03071666|Experimental|Vitamin B12|cobalamin, 50 µg per day throughout pregnancy and during the first 6 months postpartum.
2925509|NCT03071666|Placebo Comparator|Placebo|Identical taste and appearance with the Experimental arm. Contains no cobalamin
2925510|NCT03071653|Active Comparator|Left Cardiac Sympathetic Denervation (LCSD)|Left Cardiac Sympathetic Denervation (LCSD) in addition to Optimal Medical Therapy (OMT)
2925511|NCT03071653|Other|OMT only|Optimal Medical Therapy (OMT) only
2925512|NCT03071627|Active Comparator|News with Spin|News items reporting results of animal studies with spin.
2925513|NCT03071627|Experimental|News without spin|News items reporting results of animal studies without spin.
2925514|NCT03071614|Active Comparator|News with Spin|News items reporting results of animal studies with spin.
2925515|NCT03071614|Experimental|News without spin|News items reporting results of animal studies without spin.
2925516|NCT03071601|Experimental|Topical anesthesia|Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5% Prilocaine applied for at least 30 minutes before laceration repair.
2925517|NCT03071601|Experimental|Subcutaneous injection anesthesia|Local anesthesia by a subcutaneous injection of a solution containing 1% Lidocaine and 0.005 mg/mL Epinephrine in the minutes before laceration repair.
2925518|NCT03071588|Active Comparator|Control|the conventional protocol in indirect pulp capping include the use of mechanical rotary burs for caries removal in teeth with reversible pulpitis.
2925519|NCT03071588|Experimental|Conservative|the conservative protocol of indirect pulp capping include the use of Carisolv gel for caries removal in teeth with reversible pulpitis.
2925520|NCT03071575|Active Comparator|Group A:|Group A will receive a measles-rubella vaccine dose at 6 and 9 months
2925521|NCT03071575|Active Comparator|Group B:|Group B will receive a measles-rubella dose at 9 months only
2925522|NCT03071562|Experimental|Yoga-mindfulness|Groups of 4-5 participants will engage in group-based sessions supervised by yoga-certified physiotherapists, 60 minutes per intervention/session, 3 sessions/week for 12 weeks. The yoga-mindfulness group will participate in a 60-minute Hatha-style yoga class, with meditation, active postures for strengthening and balance, and breathing exercises. Participants will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
2925523|NCT03071562|No Intervention|Control|Participants in this group will not participate in an exercise program. They will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
2925524|NCT03071549|Active Comparator|combined azaleic and salicylic acids|Combined azaleic acid 20% with salicylic acid 20% peel every 2 weeks for 4 sessions
2925525|NCT03071549|Active Comparator|Trichloroacetic acid peel|Trichloroacetic acid 25% peel every 2 weeks for 4 sessions
2925526|NCT03071536|Experimental|Furosemide|"Single dose of furosemide 1.5 mg/kg intravenously will be given to all participants at 3 hours post-reperfusion of kidney allograft.~Urine output will be recorded hourly for 6 hours."
2925577|NCT03071107|No Intervention|Control arm|Standard of care
2925578|NCT03071094|Experimental|Pexa-Vec combined with Nivolumab|
2925579|NCT03071081|Experimental|TOP1288 200mg BID|1 day dosing
2925580|NCT03071081|Placebo Comparator|Placebo to TOP1288 200mg BID|1 day dosing
2925527|NCT03071523|Experimental|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
2925528|NCT03071523|Active Comparator|periosteal releasing incision technique|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
2925529|NCT03071497||Study Group|Detecting iron deficiency using various methods. All patients that fit the inclusion criteria and are willing to participate in the study will be included in this group.
2925530|NCT03071484|Experimental|Transcranial Direct Current Stimulation|After being randomly allocated, the experimental group will receive a 20 minutes of active 2-mA tDCS once a day on 10 consecutive weekdays.
2925531|NCT03071484|Placebo Comparator|Sham - tDCS|The control group will receive a sham stimulation, which chosen parameters consists in after 40 seconds of real stimulation (2 mA), only a small current pulse occurred every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
2925532|NCT03071458||Patients with HCC|The cohort is composed of patients with HCC with available tumor and non tumor samples collected retrospectively. These patients have HCC of different stages (localized and advanced stages) It is an observational retrospective study.
2925533|NCT03071432|Active Comparator|Non-diabetic patients|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
2925534|NCT03071432|Active Comparator|Diabetic patients with cardiovascular autonomic neuropathy|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
2925535|NCT03071432|Active Comparator|Diabetic patients without cardiovascular autonomic neuropathy|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
2925536|NCT03071419|Experimental|Nutrition and Parenting Intervention|Participants (n=30, father/child dyads in groups of 10) will receive an 8 session (2 hours/session) community-based intervention including nutrition and parent education with between-session technology enhancements.
2925537|NCT03071419|Active Comparator|Wait-list Control|Participants (n=30, father/child dyads in groups of 10) will serve as a wait-list control group and receive the same Nutrition and Parenting Intervention after completing pre and post assessments several weeks apart.
2925538|NCT03071406|Active Comparator|Arm A: Nivolumab + Ipilimumab|Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity.
2925539|NCT03071406|Active Comparator|Arm B: Nivolumab + Ipilimumab + SBRT|Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity. Stereotactic Body Radiation Therapy (SBRT) to be given at the start of week 2.
2925540|NCT03071393|Active Comparator|Acute Intermittent Hypoxia|Subjects with chronic spinal cord injury will undergo an acute intermittent hypoxia protocol with low oxygen air (9-15% inspired oxygen.
2925541|NCT03071393|Sham Comparator|Sham Intermittent Hypoxia|Subjects with chronic spinal cord injury will undergo a sham placebo protocol with normal oxygen air (21% inspired oxygen).
2925542|NCT03071380|Experimental|T test|Test drug (Repatoxaban) 1 tablet contains 10 mg rivaroxaban
2925543|NCT03071380|Active Comparator|B reference|Reference drug (Xarelto) 1 tablet contains 0 mg rivaroxaban
2925544|NCT03071367|Experimental|Clinical Simulation|
2925545|NCT03071367|No Intervention|Classical Learning|
2925546|NCT03071354|Experimental|HMB Protein Supplementation Group|"Intervention patients will receive 2 x 237mL bottles of the commercially available liquid HMB protein supplement (3g) (Ensure Active™ Muscle Health) throughout the study.~In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards."
2925581|NCT03071081|Experimental|TOP1288 1g BID|1 day dosing
2925582|NCT03071081|Placebo Comparator|Placebo to TOP1288 1g BID|1 day dosing
2925547|NCT03071354|Active Comparator|Control Group|"Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) throughout the study.~In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards."
2925548|NCT03071341|Experimental|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) fusion protein
2925549|NCT03071328|Experimental|Bone metastatic site|
2925550|NCT03071328|Experimental|Liver metastatic site|
2925551|NCT03071328|Experimental|Lymph node metastatic site|
2925552|NCT03071315||CCT participants|Center-based compulsory treatment (CCT) participants who were placed into compulsory treatment centers for two years for a range of punitive treatment such as education, moral teaching, labor work. Very basic health care is provided in the CCT centers.
2925553|NCT03071315||MMT participants|Methadone maintenance treatment (MMT) participants who have been receiving MMT treatment. In Hai Phong City, during the period of this study, voluntary MMT was provided in the community free for people who were assessed as dependent on heroin.
2925554|NCT03071302|Active Comparator|keratoconus|"Evaluation of Visual System Homeobox 1 (VSX1), Superoxide Dismutase (SOD1), Tissue Inhibitors of Metalloproteinases (TIMP3) genes. Keratoconus with fellow eye without topographic and tomographic keratoconous pattern.Evaluation of tomographic datas. Sometimes we picked up the sample of corneal epithelium, and peripheral blood sample from corneal cross linking surgeries, in that case of keratoconus progression.~Group A Keratoconus/ like sound cornea. Group C Keratoconus / Keratoconus~Group C Keratoconus / Keratoconus"
2925555|NCT03071302|Placebo Comparator|sound cornea|"Evaluation of VSX1, SOD1, and TIMP3 genes. To analyze tomographic aspects, we evaluated the patients that underwent to LASIK (Lasei in situ Keratomileusis) with 2 year with follow up without any sign of ectasia To analyze the genes we picked up the sample of corneal epithelium, and peripheral blood sample from PRK (PhotoRefractive Keratectomy) surgeries. These patients showed topographic and tomographic normal pattern.~Group B Sound Cornea / Sound Cornea"
2925556|NCT03071289|Active Comparator|The control group (Group A)|In Group A, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method A. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
2925557|NCT03071289|Experimental|The experiment group (Group B)|In Group B, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method B. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
2925558|NCT03071276|Experimental|Treatment Arm|Interventions: Selinexor, Fludarabine, and Cytarabine. Methotrexate/hydrocortisone/cytarabine (intrathecal triples) will be given prior to cycle 1.
2925559|NCT03071263|Experimental|Group 1 - Patiromer|spironolactone + blinded patiromer
2925560|NCT03071263|Experimental|Group 2 - Placebo|spironolactone + blinded placebo
2925561|NCT03071237||Observational group|Patients who would receive total gastrectomy or distal gastrectomy are enrolled in to the study and this group. An optional reconstruction of IPA by enhanced CT scan can be performed before surgery but not a definite require. During the operation, IPA origin location will be photoed or video-recorded before its transection.
2925562|NCT03071224|Experimental|[18F]MNI-946|To evaluate [18F]MK-6240 (also known as [18F]MNI-946) a tau targeted radiopharmaceutical.
2925563|NCT03071211|Experimental|Plug-unplug Group|Participants randomized to plug-unplug catheter management. Participants plug and unplug catheters when they feel urge to void or at least every 4 hours during the day. Participants are given the option to use a large drainage bag for convenience overnight.
2925564|NCT03071211|Active Comparator|Continuous Drainage Group|Participants randomized to continuous drainage catheter management. Catheters are attached to a leg bag during the day and large drainage bag for convenience overnight.
2925565|NCT03071211|No Intervention|Reference Group|Participants that do not fail inpatient voiding trial and go home without a catheter.
2925566|NCT03071198|Experimental|Preoperative neoadjuvant CT|Give neoadjuvant chemotherapy for four cycle ,if achieve cCR or cPR after four cycles neoadjuvant chemotherapy , receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
2925567|NCT03071198|Experimental|Preoperative neoadjuvant CT-RCT|Give neoadjuvant chemotherapy for four cycle ,if not achieve cCR or cPR after four cycle neoadjuvant chemotherapy ,give concurrent chemo-radiotherapy,then additional neoadjuvant chemotherapy for 2 cycles ,then receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
2925568|NCT03071198|Active Comparator|Concurrent chemo-radiotherapy|Give concurrent chemo-radiotherapy ,then receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
2925569|NCT03071185|Experimental|Group PCA+B|Both intravenous PCA and lower limb blocks were used. For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve block with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.The interventions are femoral nerve block, common peroneal nerve block.
2925570|NCT03071185|No Intervention|Group PCA|Only intravenous patient controlled analgesia (PCA) was used postoperatively.
2925571|NCT03071172|Experimental|Recombinant Human Follitropin|Experimental group (domestic rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
2925572|NCT03071172|Active Comparator|Gonal-F|Positive control group (imported rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
2925573|NCT03071159|Other|cases|children (4-18 years) with type 1 diabetes mellitis using the FreeStyle Flash Libre glucose monitoring system (standard care)
2925574|NCT03071146||Bard® LifeStent® 5F Vascular Stent System|Patients with lesion(s) in the infra-inguinal segment (SFA and/or popliteal artery) will be treated with percutaneous transluminal angioplasty (PTA) and the Bard® LifeStent® 5F Vascular Stent System.
2925575|NCT03071120|Experimental|Parent-Mediated Intervention with ASD|In-home intervention (1-2x/week) will occur with families with children with ASD, including direct intervention, parent coaching, and parent training.
2925576|NCT03071107|Active Comparator|Multi-disciplinary intervention arm|Multi-disciplinary intervention on frailty parameters including input from dietitian, physiotherapist and medical team
2925585|NCT03071068|Experimental|THR-317 4mg|anti-PlGF recombinant monoclonal antibody, 4mg dose
2925586|NCT03071068|Experimental|THR-317 8mg|anti-PlGF recombinant monoclonal antibody, 8mg dose
2925587|NCT03071055|Active Comparator|ranibizumab|ranibizumab 0.5mg in commercially available vial
2925588|NCT03071055|Experimental|ranibizumab pre filled-syringe|ranibizumab 0.5mg in soon to be available pre-filled syringe
2925589|NCT03071042|Experimental|Apatinib plus Docetaxel|Each subject will receive one dose of Apatinib in the whole cycle (21 days), during which single dose induced DLT and safety monitoring will be performed. If the initial dose is well tolerated, next cycle the subject will receive more Apatinib as respectively. This study will enroll in 4 cohorts of Apatinib; cohort 1 at the dose of 425mg Apatinib, which followed by cohort 2(500mg), cohort 3(675mg) and cohort 4(750mg).
2925590|NCT03071029|Experimental|Intervention (receive data updates)|Intervention clinics will receive a monthly poster that centres will receive which informs service providers of the PAFP LARC uptake rate at their centre. This is a step-wedged randomised controlled trial where all the clinics will eventually receive an intervention by the end of the study.
2925591|NCT03071029|No Intervention|Control (no data updates)|Service providers at these clinics will not receive monthly information on PAFP LARC rates.
2925592|NCT03071003|Experimental|Cohort 1 SENS 401 & Placebo|12 subjects will receive 29 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) once daily for 7 days.
2925593|NCT03071003|Experimental|Cohort 2 SENS 401 & Placebo|12 subjects will receive 29 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) twice daily for 6 days and a single dose of 29 mg SENS-401 or placebo in the morning on Day 7.
2925594|NCT03071003|Experimental|Cohort 3 SENS 401 & Placebo|12 subjects will receive 43.5 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) twice daily for 6 days and a single dose of 43.5 mg SENS-401 or placebo in the morning on Day 7.
2925595|NCT03070990|Experimental|Arm A: Enfortumab vedotin Dose A|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
2925596|NCT03070990|Experimental|Arm B: Enfortumab vedotin Dose B|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
2925597|NCT03070977|Experimental|Interprofessional study unit|In 2015, Psychiatry in Slagelse established an interprofessional clinical study unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the study unit there are more students than in the other standard psychiatric wards and several professions are included.
2925598|NCT03070977|No Intervention|Standard unit|Students in the control group receive training in standard psychiatric wards.
2925599|NCT03070964|Experimental|Plitidepsin|
2925600|NCT03070951|Experimental|OBE2109 dose 1 + Placebo Add-back|
2925601|NCT03070951|Experimental|OBE2109 dose 1 + Add-back|
2925602|NCT03070951|Experimental|OBE2109 dose 2 + Placebo Add-back|
2925603|NCT03070951|Experimental|OBE2109 dose 2 + Add-back|
2925604|NCT03070951|Placebo Comparator|Placebo + Placebo Add-back / OBE2109 dose 3 + Add-back|
2925605|NCT03070899|Experimental|OBE2109 dose 1 + Placebo Add-back|
2925606|NCT03070899|Experimental|OBE2109 dose 1 + Add-back|
2925607|NCT03070899|Experimental|OBE2109 dose 2 + Placebo Add-back|
2925608|NCT03070899|Experimental|OBE2109 dose 2 + Add-back|
2925609|NCT03070899|Placebo Comparator|Placebo + Placebo Add-back / OBE2109 dose 3 + Add-back|
2925610|NCT03070886|Active Comparator|Arm I (androgen deprivation therapy, EBRT)|Patients receive androgen deprivation therapy comprising leuprolide acetate, goserelin acetate, bicalutamide, flutamide, or nilutamide for 6 months. Beginning 8 weeks after the start of androgen deprivation therapy, patients receive EBRT for 7.5 weeks.
2925611|NCT03070886|Experimental|Arm II (androgen deprivation therapy, EBRT, docetaxel)|Patients receive androgen deprivation therapy and EBRT as in Arm I. Within 4-6 weeks after completion of radiation therapy, patients receive docetaxel IV on day 1 of every 21 days for 6 courses in the absence of disease progression or unexpected toxicity.
2925612|NCT03070873|Experimental|group A|accepted Perigee and Apogee mesh(PA)
2925613|NCT03070873|Experimental|group B|accepted Gynecare prolift mesh
2925614|NCT03070873|Placebo Comparator|group C|Traditional surgery without any mesh
2925615|NCT03070860|Experimental|PXE Patient|positron emission tomography scanner (PET scan) 18-FDG and 18-NAF: conventionnal use.
2925616|NCT03070847|Experimental|Very low dose|Will receive single bolus of Tranexamic acid. Dose: 5mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
2925617|NCT03070847|Active Comparator|Low dose|Will receive single bolus of Tranexamic acid. Dose: 10mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
2925618|NCT03070834|Experimental|rIVCF|Randomized to receive insertion of retrievable inferior vena cava filter until chemical anticoagulation can be safely administered.
2925619|NCT03070834|No Intervention|Standard Care|Randomized to not receive insertion of retrievable inferior vena cava filter.
2925620|NCT03070821|Experimental|Healthy elderly experimental group|Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
2925621|NCT03070821|Experimental|Patient group|Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
2925622|NCT03070821|Sham Comparator|Healthy elderly sham-feedback group|Feedback of the postcentral gyrus using rtfMRI neurofeedback training (using 3T MRI).
2925623|NCT03070795|Experimental|early feeding|patients undergoing elective cesarean section will be allowed to feed (sips) four hours after cesarean section.
2925624|NCT03070795|Active Comparator|delayed feeding|patients undergoing elective cesarean section will be allowed to feed on post operation day 1 (12 hours post op).
2925625|NCT03070782|Experimental|ISIS 681257 Dose 1|Cohort A
2925626|NCT03070782|Experimental|ISIS 681257 Dose 2|Cohort B
2925627|NCT03070782|Experimental|ISIS 681257 Dose 3|Cohort C
2925628|NCT03070782|Experimental|ISIS 681257 Dose 4|Cohort D
2925630|NCT03070782|Placebo Comparator|Placebo: Sterile Normal Saline|Sterile Normal Saline (0.9% NaCl) by volume to match dose and regimen of active comparator depending on Cohort assignment
2925631|NCT03070769||Control|Subjects without Obstructive sleep apnea (Apnea-hypopnea index-AHI<5). Venous blood collection for biomarkers measurements.
2925632|NCT03070769||Obstructive sleep apnea (OSA) patients|Patients with Obstructive sleep apnea (AHI> or =5). Venous blood collection for biomarkers measurements.
2925633|NCT03070756|Other|treatment group (auto-CPAP)|"Participants of this study undergo an diagnostic PSG night. The diagnostic night is followed by an auto-CPAP treatment night.~Interventions:~The treatment night is in line with the routine procedure of the laboratory except the following intervention: the device settings for the treatment night are applied according to the study protocol (minimal intervention)."
2925634|NCT03070743||PCDR surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
2925635|NCT03070730|Other|Atenolol|"In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients."
2925636|NCT03070730|Other|Placebos|"In this arm subjects are randomized to placebo tid.~Placebo is used to control the administration effect."
2925637|NCT03070730|Other|Droxidopa|"In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients."
2925638|NCT03070717||All patients|Patients with diagnosis of high myopia secondary to an anterior-posterior elongation of the bulbus confirmed by ocular examination in either eye using specific criteria.
2925639|NCT03070704||Insulin degludec /liraglutide|
2925640|NCT03070691|Active Comparator|LDE225 0.75% cream|
2925641|NCT03070691|Placebo Comparator|Vehicle|
2925642|NCT03070678|Experimental|SAR439954 with or without mefenamic acid|Period 1: single oral dose of 400 mg sotagliflozin Period 2: initial loading dose of 500 mg in the morning of Day 1, followed by 250 mg from Day 1 H6 to Day 7 of mefenamic acid and a single oral dose of sotagliflozin on Day 2
2925643|NCT03070665|Experimental|Increasing blood pressure|Using norepinephrine pump as the initial dose is 0.05μg/Kg.min to increase the patient's blood pressure up to about 150 mmHg for 5 min during ESD.
2925644|NCT03070665|No Intervention|Control group|Patients received normal ESD manipulation.
2925645|NCT03070652|Experimental|NBO, Newborn behavioral observation|In the intervention group new parents will receive the NBO delivered in connection with the examination of the newborn in a shared observation with the parents in the homevisit of the health visitor 3 weeks post partum
2925646|NCT03070652|Experimental|Practice as usual|In the comparison group new parents will receive practice as usual due to the examination of their newborn in the homevisit of the health visitor 3 weeks post partum
2925647|NCT03070639|No Intervention|Standard Care Study Condition|The Standard of Care control group will not receive any additional services at the newborn visit.
2925648|NCT03070639|Active Comparator|Attention-Matched Control Condition|The Attention-Matched Control Condition will include the Scald Prevention Intervention.
2925649|NCT03070639|Experimental|Safe Sleep Intervention Condition|The Intervention Condition will include the Safe Sleep Intervention.
2925650|NCT03070626|Experimental|Interventional group|Carbohydrate-rich, dietary supplement: PreOp® 800ml day before surgery and PreOp® 400ml 2-4hours preoperative.
2925651|NCT03070626|No Intervention|Control group|Standard of care: Fasting from 24hours (midnight), night before surgery.
2925652|NCT03070613|Experimental|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda will be sprayed onto the colonic surface during colonoscopy or TEM surgery.
2925653|NCT03070600|Active Comparator|Universal PrEP Counselling|All enrolled women receiving antenatal care at facilities assigned to Universal PrEP arm will receive standardized HIV risk counseling and then self-select whether they want to use PrEP.
2925654|NCT03070600|Experimental|Targeted PrEP Clinics|All enrolled women receiving antenatal care at facilities assigned to the Targeted PrEP arm will be assessed for HIV-risk prior to receiving targeted PrEP counseling.
2925655|NCT03070587|Experimental|Positive Affect Training for SAD|The intervention will be conducted in groups with 68 participants and 2 facilitators/therapists per group. The groups will meet once a week for 12 successive weeks and each session will be approximately 60 minutes long.
2925656|NCT03070587|No Intervention|Wait list Control|These participants will not be given an intervention until after they have completed the study.
2925657|NCT03070574|Experimental|2400 MG Mesalamine total|2400mg (1200mg mesalamine/1200mg) mesalamine once daily in the morning for the treatment phase of the study (24 months)
2925658|NCT03070574|Experimental|1200 MG Mesalamine total|placebo/1200mg mesalamine once daily in the morning for the treatment phase of the study (24 months)
2925659|NCT03070574|Placebo Comparator|Placebo|placebo/placebo once daily in the morning for the treatment phase of the study (24 months)
2925660|NCT03070561|Experimental|Sublingual film with peanut extract|
2925661|NCT03070548|Experimental|ADME|1 mg talazoparib containing100 μCi of 14C-radiolabeled talazoparib
2925662|NCT03070535|Experimental|HIGH meal|The HIGH meal is a 700 calorie breakfast style meal, with 50% total fat (25% saturated fat), 30% carbohydrates with a glycemic index of >70, and 20% protein.
2925663|NCT03070535|Experimental|LOW meal|The LOW meal is a 700 calorie breakfast style meal, with 25% of those calories coming from fat (5% saturated fat), 55% carbohydrate (with a glycemic index of <55), and 20% protein.
2925664|NCT03070522|Active Comparator|Placebo|Placebo
2925665|NCT03070522|Active Comparator|Treatment|Prednisone
2925666|NCT03070509|Experimental|RYGB|Single dose of lisdexamfetamine 50 mg in RYGB patients
2925667|NCT03070509|Experimental|Nonsurgical Controls|Single dose of lisdexamfetamine 50 mg in non-surgical controls
2925668|NCT03070496|Experimental|STEMI cohort|"Patients recruited in the cohort will have 4 additional interventions compared to the usual follow-up :~an additional blood sampling at 6 months~an additional electrocardiogram (ECG) at 6 months~Magnetic Resonance Imaging (MRI)~Quality of life questionnaire"
2925669|NCT03070483|Experimental|Vitamin D|Participants will all receive supplementation with cholecalciferol 5000 IU and calcium citrate 1000 mg daily for 3 months
2925670|NCT03070470|Active Comparator|Ranolazine|Ranolazine 1500 mg two times per day for 2.5 days
2925671|NCT03070470|Active Comparator|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3
2925672|NCT03070470|Active Comparator|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days
2925673|NCT03070470|Active Comparator|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3
2925674|NCT03070470|Placebo Comparator|Placebo|Placebo capsules
2925675|NCT03070470|Active Comparator|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
2925676|NCT03070457|Experimental|Early discharge group|Patients with a shorter hospital stay, 23 hours after surgery
2925677|NCT03070457|Active Comparator|Conventional discharge|Patients with conventional protocol and 48-72 hours of hospital stay
2925678|NCT03070444|Experimental|Group A: CTC retainer + Essix retainer|"The CTC is bonded directly after debonding. The Essix retainer maxilla is handed out to the patient the same day after removal of fixed appliances.~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits."
2925679|NCT03070444|Active Comparator|Group B: Essix retainer + Essix retainer|"The Essix retainer maxilla and Essix retainer mandible are handed out to the patient the same day after removal of fixed appliances.~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits."
2925680|NCT03070431|Experimental|High-precision RT 5x5 Gy in 1 week|Patients with motor deficits of the lower extremities due to metastatic spinal cord compression (MSCC) will receive 5x5 Gy of high-precision RT in 1 week.
2925681|NCT03070418|Experimental|Abdulhai|One show man technique, it is the same of AO Dynamic Hip Screw (DHS) technique using 4 holes plate or smaller, in this case it is enough to make just a 3 cm skin incision.
2925682|NCT03070405|Active Comparator|Tenofovir|Tenofovir disoproxil fumarate 300mg single dose administration
2925683|NCT03070405|Experimental|Tenofovir + PAS|Tenofovir disoproxil fumarate 300mg single dose, Para-aminosalicylic acid Ca Granule 5.28 g BID seven dose administration
2925684|NCT03070392|Experimental|IMCgp100|Biologic:IMCgp100 (Soluble gp 100-specific T cell receptor with anti - CD3 scFV: IMCgp100)
2925685|NCT03070392|Active Comparator|Investigator's Choice|"1 of 3 Investigator's Choice options: Systemic Dacarbazine~1 of 3 Investigator's Choice options: Systemic Ipilimumab~1 of 3 Investigator's Choice options: Systemic Pembrolizumab"
2925686|NCT03070379|Experimental|Experimental group|Topical lidocaine pharyngeal anesthesia was performed.
2925687|NCT03070379|No Intervention|Control group|No topical lidocaine pharyngeal anesthesia was performed.
2925688|NCT03070366|Active Comparator|Chemotherapy combined with stereotactic radiotherapy (RT)|"Chemotherapy is based on patient Performance Status (PS) and comorbidities:~PS 0-1: standard treatment: 6 cycles, every 3 weeks cisplatin (100 mg/m² iv on D1), 5FU (4000 mg/m² total dose starting on Day 1 to Day 4 and during 96h in continuous infusion)~PS 2/cardiac contra-indication to 5 Fluorouracil (5FU): 6 cycles, every 3-4 weeks cisplatin (100 mg/m² iv on Day 1) or carboplatin Area Under Curve (AUC) 4 or 5 on Day 1 In both case: Cetuximab (loading dose 400 mg/m² iv on Day1, then 250 mg/m² weekly or 500mg/m² every 2 weeks).~Cycle 1 of systemic treatment will be administered before the start of the stereotactic RT. Then, following cycles will be performed after the end of stereotactic irradiation.~Cetuximab maintenance: 250 mg/m² iv weekly. It will be given only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until progression or unacceptable toxicity."
2925689|NCT03070366|Experimental|stereotactic radiotherapy|Splitting will be based on the tumor diameter, and proximity of organs at risk which constitutes any limiting toxicities. It will be 3 or 5 fractions based on the recommendations (CARO-Stereotactic Body Radiation Therapy (SBRT) 2012) and for the purpose of harmonization practices. The prescription dose is 3 x 10 = 30 Gy 3 x 11 = 33 Gy or 3 x 15 = 45 Gy (if 3 fractions) with the possibility of 3 x 20 Gy to the peripheral lung nodules with tracking in Cyberknife or 5 x 7 = 35 Gy or 5 Gy x 10 = 50 (if 5 fractions). Beyond 3 cm of tumor diameter and / or to a distance of less than 1 cm from the GTV in an organ critical risk (eg spinal cord), a splitting up into 5 sessions must be privileged.
2925690|NCT03070353|Experimental|Dextran 40|Dextran 40 infusion
2925691|NCT03070340|Experimental|Breast MRI and Contrast Enhanced Mammography (CEDM)|Breast MRI and CEDM will be performed within 30 days of one another after neoadjuvant therapy
2925692|NCT03070327|Experimental|BCMA Targeted CAR T Cells with or without Lenalidomide|
2925693|NCT03070314|Experimental|Echinaforce junior|Echinaforce is an ethanolic extract from Echinacea purpurea fresh plant and root. The product is registered in Switzerland for children from age 4 years on for Treatment and prevention of respiratory tract infections.
2925694|NCT03070301|Experimental|LEE011 and everolimus|Everolimus will was administered orally at the dose of 2.5 mg daily, as established in LEE011X2106 for the first 10 patients enrolled to this study. Subsequent enrolled patients will receive the oral combination of LEE011 200 mg once daily and everolimus 5 mg daily, based on more recent data from CLEE011XUS29 (TRINITI-1) study in metastatic breast cancer.
2925695|NCT03070288||Group 1|Red-green-blue measurements of nasal mucosa images of patients with allergic rhinitis
2925696|NCT03070288||Group 2|Red-green-blue measurements of nasal mucosa images of normal healthy individuals
2925697|NCT03070275|Experimental|Group-A|In the experimental Group (Group-A), a two-stage implant will be placed in parallel with an overlying biocomplex (aBM-MSCs/fibrin glue/collagen fleece) that comprises autologous alveolar bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue.
2925873|NCT03069066|Experimental|BVS implantation in patients with ISR|BVS implantation in patients with ISR after scoring balloon pre-dilatation
2925698|NCT03070275|Active Comparator|Control Group-B|In Group-B, a two-stage surgical implant placement on the alveolar crest is followed based on the manufacturer's guidelines with no use of adjunctive grafting materials.
2925699|NCT03070262|Experimental|CA group|caffeic acid (300mg, tid, po) continue given until progression of disease or death, or patients are unable to bear the side effects
2925700|NCT03070262|Placebo Comparator|placebo group|the same shape placebo tablets continue given until progression of disease or death, or patients are unable to bear the side effects
2925701|NCT03070249||Emergency Department Healthcare Providers|This study will assess compassion fatigue among healthcare providers in a single emergency department (ED) using the Professional Quality of Life (ProQoL) scale.
2925702|NCT03070236|Experimental|Patient-reported Outcomes Survey|The survey will administered online, over the phone, or via mail.
2925703|NCT03070223||Experimental: Pitavastatin|Participants who receive pitavastatin in the main study REPRIEVE (A5332).
2925704|NCT03070223||Placebo Comparator: Placebo|Participants who receive placebo for pitavastatin in the main study REPRIEVE (A5332).
2925705|NCT03070210|Other|EUS-celiac plexus block (EUS-CPB)|"This is the standard technique. In this approach, the needle is passed through the body of the stomach adjacent the celiac artery into the retroperitoneal space in 1 or 2 passes. The injectate (bupivacaine or alcohol) is injected and spreads through the retroperitoneal space, effectively bathing all the ganglia."
2925706|NCT03070210|Active Comparator|EUS-celiac ganglia block (EUS-CGB)|This is a more recent technique which has been often used. In this procedure, the needle is inserted under EUS guidance directly into as many ganglia as possible. For celiac ganglia <1cm in diameter, the solution is injected into the central point; for those ≥1 cm, a needle is advanced to the deepest point into the ganglia and solution is injected as the needle is slowly withdrawn. Injections are continued until an echogenic pattern is produced over the entire celiac ganglia.
2925707|NCT03070197||Case/CHD with deleterious mutations|Participants with CHD with damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing
2925708|NCT03070197||Control/CHD without deleterious mutations|Participants with CHD without damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing
2925709|NCT03070184|Experimental|African-American|Healthy lean (BMI 18-25 kg/m2) African-American participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will perform exercise capacity VO2 max determination test, followed by 3 days of standardized meals and exercise challenge test. After exercise challenge test, all the participants will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day.
2925710|NCT03070184|Active Comparator|Caucasians (White)|Healthy lean (BMI 18-25 kg/m2) white participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will perform exercise capacity VO2 max determination test, followed by 3 days of standardized meals and exercise challenge test. After exercise challenge test, all the participants will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day.
2925711|NCT03070171|Experimental|Dabigatran Etexilate Capsule|
2925712|NCT03070171|Experimental|Dabigatran Etexilate Tablet|
2925713|NCT03070158|Experimental|Attachment Promotion Intervention|Mothers will receive the intervention which includes an education session about newborn care, training in multisensory stimulation with the intervention ATVV and two domiciliary visits to follow up the mother and her premature infant.
2925714|NCT03070158|No Intervention|Usual Care|Mothers will continue to receive usual which consist in education session about newborn care in home.
2925715|NCT03070145|Experimental|Exercise Intervention|"12-weeks brisk walking and strength training~150 minute moderate aerobic activities, such as brisk walking~Strength training 3 days /week~One on one sessions with exercise physiologist~Optional group sessions"
2925716|NCT03070145|No Intervention|Usual Care|Usual Care provided
2925717|NCT03070132|Experimental|BIIB074|Optimized oral dose three times daily (TID)
2925718|NCT03070132|Experimental|Placebo|Administered orally TID
2925719|NCT03070119|Experimental|BIIB067 Low dose|
2925720|NCT03070119|Experimental|BIIB067 Mid dose|
2925721|NCT03070119|Experimental|BIIB067 High dose A|
2925722|NCT03070119|Experimental|BIIB067 High dose B|
2925723|NCT03070106|No Intervention|Usual Care|usual care delivered by an endocrinologist
2925724|NCT03070106|Active Comparator|Functional Medicine + Usual Care|Functional Medicine in addition to usual care delivered by an endocrinologist
2925725|NCT03070080|Active Comparator|restrictive group|restrictive fluid strategy, 6 ml/kg/hour of lactated Ringer, during intraoperative period
2925726|NCT03070080|Active Comparator|conservative group|conservative fluid strategy, 12 ml/kg/hour of lactated Ringer, during intraoperative period
2925727|NCT03070067||Mild ACVS—definite|Clinical diagnosis of ACVS, and imaging positive (either DWI+ or CT/CTA+).
2925728|NCT03070067||Mild ACVS—possible|Clinical diagnosis of ACVS, and DWI- and/or CTA-.
2925729|NCT03070067||Mimic|Clinical diagnosis of mimic and imaging negative.
2925730|NCT03070054|No Intervention|Control|non-LIA group prior to surgery
2925731|NCT03070054|Experimental|Treatment|Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
2925732|NCT03070041|Experimental|Mothers and staff members|The mothers who will give birth at the study hospital and all the staff members taking care about mothers and/or infants
2925733|NCT03070028|Experimental|Phenol|crystallised phenol application
2925734|NCT03070028|Experimental|platelet rich plasma|PRP application
2925735|NCT03070015|Experimental|Nutrisystem|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem program for a total of 12 weeks (4 weeks for Part A, and an additional 8 weeks for Part B)
2925736|NCT03070015|Active Comparator|Self-Directed DASH|All subjects provided publically available information on the DASH diet and a sample meal plan. Subjects were instructed to follow a reduced calorie DASH diet meal plan on their own for 4 weeks (Part A only).
2925737|NCT03070002|Experimental|Treatment (denosumab)|Patients receive denosumab SC on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression, unexpected toxicity, or patient withdrawal or death.
2925738|NCT03069989|Experimental|Cohort 1 GSK3008348|Participants will receive a single nebulized dose of GSK3008348 during each of 2 planned dosing periods and up to 3 microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
2925739|NCT03069989|Placebo Comparator|Cohort 1 Placebo|Participants will receive a single nebulized dose of placebo during each of 2 planned dosing periods and up to 3 microdose of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
2925740|NCT03069989|Experimental|Cohort 2 GSK3008348|Participants will receive a single nebulized dose of GSK3008348 during each of 2 planned dosing periods and up to 3 microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
2925741|NCT03069989|Placebo Comparator|Cohort 2 Placebo|Participants will receive a single nebulized dose of placebo during each of 2 planned dosing periods and up to 3 microdose of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
2925742|NCT03069976|Experimental|1|All included patients, diagnosed with Overlap Syndrome or Primary Sclerosing Cholangitis, will receive treatment (Metronidazole x 14 days) hence single arm study.
2925743|NCT03069963|Experimental|Sequence 1 (Z0063 to Gaviscon)|The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose
2925744|NCT03069963|Experimental|Sequence 2 (Gaviscon to Z0063)|The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose
2925745|NCT03069950|Experimental|HAI FUDR/Dex in addition to Pmab plus FOLFIRI|Panitumumab plus FOLFIRI on Day 1 and Day 15 of each cycle. HAI pump therapy with FUDR and Dex on Day 1 of each cycle. Patients will start protocol therapy approximately 2 weeks after surgery. All patients will receive Panitumumab (6 mg/kg IV over 60 min). The HAI FUDR group will receive FOLFIRI in the following dosing; 5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
2925746|NCT03069950|Experimental|Pmab plus FOLFIRI alone|The dosing of FOLFIRI in the systemic arm will be 5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), bolus 5FU 400mg/ m2 and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and 15.
2925747|NCT03069937|Experimental|Docetaxel + Degarelix|Docetaxel (TAXOTERE) will be given for up to 6 cycles every 21 days. During the 5th and 6th cycles, degarelix (Firmagon) will be administered on Cycle 5 day 1 and cycle 6 day 8. After cycle 6, degarelix will continue to be given every 28 days for a 5 more doses, for a total of 7 doses.
2925748|NCT03069924|Active Comparator|No NRT - No Messaging|Brief counseling, but no NRT and no gain-framed messaging.
2925749|NCT03069924|Active Comparator|NRT - No Messaging|Brief counseling plus NRT but no gain-framed messaging.
2925750|NCT03069924|Active Comparator|No NRT - Messaging|Brief counseling plus gain-framed messaging but no NRT.
2925751|NCT03069924|Experimental|NRT plus Messaging|Brief counseling plus NRT and gain-framed messaging.
2925752|NCT03069911|Experimental|Intervention|One injection of onabotulinumtoxinA (29 units for women and 40 units for men) will be injected into two facial muscles - the corrugator and procerus.
2925753|NCT03069911|Placebo Comparator|Control|One injection of saline solution will be injected into two facial muscles - the corrugator and procerus.
2925754|NCT03069898|Experimental|TRUE Dads program track|In the TRUE Dads program, fathers and co-parents begin with a Core workshop meeting weekly for 6 weeks. After a check-in, a male-female group leader team focuses on a single topic that represents one of the three main goals of the project as a whole: Co-parenting relationships, Parenting, or Employment and financial stability. From 10 to 18 couples, seated at small tables in a large room, hear mini-lectures, watch videos, and engage in interactive exercises. Fathers then choose to attend one of three intensive workshops focused on couple relationships OR parenting OR economic self-sufficiency meeting 3 hours per week for the next 6 weeks. On an as-needed basis, fathers may be referred for employment programs and fathers and co-parents may be referred for mental health or other services.
2925755|NCT03069898|No Intervention|Control condition study track|Participants (fathers and co-parents) complete intake interview and fill out Baseline survey. They fill out follow-up survey one year later
2925756|NCT03069885|Active Comparator|Standard postoperative dressing group|30 patients treated with conventional post-operative dressing.
2925757|NCT03069885|Experimental|Prevena group|30 patients treated with PrevenaTM (incisional negative pressure wound therapy)
2925758|NCT03069872|Experimental|Intervention|All GPs in Central Denmark Region, are planned to be enrolled in the study during the one year study period.
2925759|NCT03069859|Experimental|TXA (1g)|For vaginal, TXA (1g) will be administered upon delivery of the anterior shoulder. For c-section, TXA (1g) will be administered when the obstetrician begins to cleanse the incision site
2925760|NCT03069859|Placebo Comparator|Placebo (0.9% saline)|For vaginal, placebo (0.9% saline) will be administered upon delivery of the anterior shoulder. For c-section, placebo (0.9% saline) will be administered when the obstetrician begins to cleanse the incision site
2925761|NCT03069846|Experimental|Measurement using Spectra-Scope|Short pulsed Nd:YAG laser irradiation onto the skin lesion / measurement with Spectra-Scope
2925762|NCT03069833|Experimental|Computer-aided diagnosis|
2925763|NCT03069833|No Intervention|traditional diagnosis|
2925764|NCT03069820|Experimental|Study Population|Patients with advanced nasopharyngeal carcinoma scheduled to receive the first line, first cycle TP (docetaxel and cisplatin) chemotherapy
2925765|NCT03069807|Experimental|Intervention|Participants with LTBI will be treated in the Community/Primary Care.
2925766|NCT03069807|Active Comparator|Control|Participants with LTBI will be treated in the Hospital/TB Clinic
2925767|NCT03069794|Other|Use of stable force platform|Ennrollment of every patient programmed for spinal surgery in orthopaedic service
2925768|NCT03069781|Experimental|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of 17β-estradiol (Estrace, Acerus Pharmaceuticals Corporation, Mississauga, ON, Canada). 7 Day Breg Knee Brace unilateral immobilization.
2925769|NCT03069781|Placebo Comparator|Placebo|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada).7 Day Breg Knee Brace unilateral immobilization.
2925770|NCT03069768|Experimental|mSMART|Smokers in this group will have the mSMART application installed on their smartphones. The mSMART application will provide information about varenicline (Chantix) and reminders when it's time to take the medication.
2925771|NCT03069768|Active Comparator|Control|Smokers in this group will not be given the mSMART application.
2925772|NCT03069742|Experimental|Decision Aid|Women at high risk for developing breast cancer will use a decision support tool, RealRisks, that facilitates discussion of breast cancer risk with their providers who will have access to the BNAV provider clinical decision support tool.
2925773|NCT03069742|No Intervention|Control Group|Women at high risk for developing breast cancer will receive standard breast health education brochures.
2925774|NCT03069729||Control group|non-diabetic; no intervention
2925775|NCT03069729||Diabetics without DPN|diabetics without DPN; no intervention
2925776|NCT03069729||Diabetics with DPN|diabetics with DPN; no intervention
2925777|NCT03069716|Experimental|Smartphone Text Messaging|"Group receives personalized, health coaching via smart text messages."
2925778|NCT03069716|Other|No Smartphone Text Messaging|"Group does not receive personalized, health coaching via smart text messages."
2925779|NCT03069703|Active Comparator|Prime-boost strategy|a single dose of 13-valent pneumococcal conjugate vaccine (Prevenar, PCV13) at Day 0 (lying within a window of ± 2 days of the first infusion of rituximab), followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPV23) at month 5 (M5)
2925780|NCT03069703|Experimental|Innovative vaccine strategy 1|2 doses of PCV13 at Day 0 and 2 doses of PCV13 at Day 7, followed by a single dose of PPV23 at M5
2925781|NCT03069703|Experimental|Innovative vaccine strategy 2|4 doses of PCV13 at Day 0, followed by a single dose of PPV23 at M5
2925782|NCT03069690|Experimental|HABITpreg; TAUpost|Participants will receive study intervention during pregnant and treatment as usual postpartum.
2925783|NCT03069690|Experimental|HABITpreg, HABITpost|Participants will receive study intervention during pregnancy and study intervention during the postpartum period.
2925784|NCT03069690|Experimental|TAUpreg; HABITpost|Participants will receive treatment as usual during pregnancy and study intervention during the postpartum period.
2925785|NCT03069690|No Intervention|TAUpreg; TAUpost|Participates will receive treatment as usual during pregnancy and treatment as usual during the postpartum period.
2925786|NCT03069677|Active Comparator|Music group|research-selected music
2925787|NCT03069677|Active Comparator|Midazolam group|IV midazolam (0.5mg to 2mg max)
2925788|NCT03069664|Active Comparator|Covered Self-expandable Metal Stent|ERCP (endoscopic retrograde cholangiopancreatography) and placement of a pancreatic duct stent
2925789|NCT03069664|No Intervention|Control group|
2925790|NCT03069651|Active Comparator|Virtual Care|"Subjects randomly allocated to receive 'virtual care' will be shown how to use the oximeter and spirometer, as well as the videoconferencing software.~'Virtual care' subjects will be asked to perform a lung function test (using the spirometer) and record their oxygen saturations (using the oximeter) twice weekly during the videoconference with the CF team."
2925791|NCT03069651|Placebo Comparator|Routine Care|Usual clinical care.
2925792|NCT03069638|Experimental|Intranasal dexmedetomidine|Dexmedetomidine is given once 4 micrograms per kilogram intranasally. If the sedation is not successful another 2 microgram per kilogram intranasal dose is given. Intravenous dexmedetomidine solution is administrated intranasally with MAD nasal drug delivery device and a syringe.
2925793|NCT03069638|Active Comparator|Nitrous oxide inhalation|Dinitrousoxide (N2O) is given with Livopan administrating device. Livopan consists of 50% oxygen and 50% nitrous oxide. Gas mixture is inhaled 5 minutes before the injection procedure and during the injection procedure.
2925794|NCT03069625|Experimental|Sit-to-stand test|Children and adolescents will perform 2 STS tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
2925795|NCT03069625|Active Comparator|6-Minute Walk Test|Children and adolescents will perform 2 6MWT tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
2925796|NCT03069612|Experimental|rTMS Active Group|Repetitive transcranial magnetic stimulation (rTMS) will be administered bilaterally to the dorsolateral prefrontal cortex (DLPFC) at 20 Hz, 90% RMT in 25 trains.
2925797|NCT03069612|Sham Comparator|rTMS Sham Group|Repetitive transcranial magnetic stimulation (rTMS) will be administered bilaterally to the dorsolateral prefrontal cortex (DLPFC) at 20 Hz, 90% RMT in 25 trains with a sham coil.
2925798|NCT03069599||10 IRE locally advanced|patients undergoing in situ IRE for locally advanced pancreatic
2925799|NCT03069599||10 IRE borderline resection|patients undergoing margin accentuation IRE for borderline resectable disease
2925800|NCT03069599||10 resection only|patients undergoing surgical resection only
2925801|NCT03069586|Other|Low pressure pneumoperitoneum|Surgery on low pressure pneumoperitoneum (8 - 10 mmHg).
2925802|NCT03069586|Active Comparator|low pressure peritoneum and pulmonary recruitment|Surgery on low pressure pneumoperitoneum (8 - 10 mmHg) and at the end of surgery a manual pulmonary recruitment manoeuver (2 x 5sec max 40cmH2O) will be done
2925803|NCT03069573||Eosinophilic Esophagitis - EoE|The diagnose of pediatric EoE under current guideline. Samples collection by blood, saliva, esophageal mucus and esophageal tissue are taken for biomarkers investigation
2925804|NCT03069573||Gastroesophageal reflux disease - GERD|The diagnose of pediatric GERD under current guideline. Samples collection by blood, saliva, esophageal mucus and esophageal tissue are taken for biomarkers investigation
2925805|NCT03069573||Control|The exclusion diagnose of EoE or GERD. Samples collection by blood, saliva, esophageal mucus and esophageal tissue are taken for biomarkers investigation
2925806|NCT03069560|Experimental|SMS|The patients will receive from the caregiver a first SMS 48 hours after their discharge from the hospital then a total of 4 messages : 48 hours, S1, S2, and S4.
2925807|NCT03069547|Active Comparator|Quadriceps Exercise program|The Quadricepts Exercise (QE) program runs for 12 weeks, with exercise sessions 3 times per week. Each training session is scheduled to last approximately 30 minutes. The exercise program is home based with monthly supervision visits at the clinic.
2925808|NCT03069547|Active Comparator|Hip Exercise program|The Hip Exercise (HE) program runs for 12 weeks, with exercise sessions 3 times per week. Each training session is scheduled to last approximately 30 minutes. The exercise program is home based with monthly supervision visits at the clinic.
2925874|NCT03069040|Experimental|nerve-sparing radical hysterectomy|The patient recived surgury of nerve-sparing radical hysterectomy.
2925875|NCT03069040|Active Comparator|radical hysterectomy|The patient recived surgury of radical hysterectomy.
2925809|NCT03069534|Experimental|rhIL-2 Group|The patients in rhIL-2 Group were given consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotherapy. rhIL-2 (500，000U/m)regiman was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7. Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months.
2925810|NCT03069534|No Intervention|Control Group|The patients in Control Group were given standard anti-tuberculosis chemotherapy regiman.Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months
2925811|NCT03069521|Other|EndoArt™|EndoArt™ Artificial Endothelial Layer
2925812|NCT03069508|Experimental|200 mg TID|200 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
2925813|NCT03069508|Experimental|300 mg TID|300 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
2925814|NCT03069508|Experimental|400 mg TID|400 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
2925815|NCT03069508|Experimental|500 mg TID|500 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
2925816|NCT03069495||Healthy Control Adult Subjects|Healthy adult subjects between the ages of 19-50 years will be enrolled.
2925817|NCT03069495||Asthmatic Adult Subjects|Adult subjects between the ages of 19-50 years with mild-to-moderate asthma seen within the UNMC Allergy and Pulmonary Clinics will be invited to be enrolled.
2925818|NCT03069495||Chronic Urticaria Adult Subjects|Adult subjects between the ages of 19-50 years with chronic urticaria seen within the UNMC Allergy Clinics will be invited to be enrolled.
2925819|NCT03069482|Experimental|Learn to Quit|A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms.
2925820|NCT03069482|Active Comparator|NCI QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.
2925821|NCT03069469|Other|Experimental Treatment|"Escalation Phase: Increasing doses of DCC-3014 beginning at 10 mg QD for 28 day cycles until disease progression or unacceptable toxicity.~Expansion Phase: Dosing of different patient cohorts at the dose level determined from the escalation phase of the study."
2925822|NCT03069456|Active Comparator|BIS group|Combined sigmoidal Emax models from the BIS data
2925823|NCT03069456|Experimental|ADMS group|Combined sigmoidal Emax models from the ADMS data
2925824|NCT03069443|Experimental|IHG+Hypertension lifestyle guidelines|Participants in this group will follow a home-based IHG training protocol. The IHG training will be structured with four sets of 2-minute contractions for each hand, 3 days per week for 20 weeks. In addition, the IHG group will receive information about hypertension-guidelines on lifestyle changes.
2925825|NCT03069443|No Intervention|Hypertension lifestyle guidelines|The usual care group will receive information about hypertension-guidelines on lifestyle changes. The usual care group will have the same amount of hospital visits for measurements of blood pressure and maximal muscle tests as the intervention group in order to ensure similar attention provided by the healthcare professionals.
2925826|NCT03069417|Experimental|Intervention: INSPireD|"This 5-8 session group intervention, Integrating Nuanced Support for Perinatal adherence and Depression, aims to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women. Intervention content is based on two established cognitive-behavioral interventions: problem-solving therapy and Cognitive Behavioral Therapy for Adherence and Depression."
2925827|NCT03069417|Other|Wait-list control|The Wait-list control group will be referred to standard of care counseling services, and will start the intervention upon completion of the first experimental group. They will receive the intervention with the next experimental group cycle.
2925828|NCT03069391|Active Comparator|physical, cognitive, then interactive|physical exercise alone (PES) first, then iPACES
2925829|NCT03069391|Active Comparator|cognitive, physical, then interactive|cognitive exercise alone (iCE) first, then iPACES
2925830|NCT03069378|Experimental|Talimogene Laherparepvec (T-VEC) Administered with Pembrolizu|Patients will initiate treatment with talimogene laherparepvec given intralesionally and pembrolizumab.
2925831|NCT03069365|Experimental|Arm B: GLE/PIB for 12 weeks|Arm B: HCV GT1, 2, 4 - 6 participants with cirrhosis who are TN or TE and HCV GT 3 participants with cirrhosis who are TN treated with GLE/PIB 300 mg/120 mg QD for 12 weeks.
2925832|NCT03069365|Experimental|Arm C: GLE/PIB for 16 weeks|Arm C: All HCV GT3 participants who are TE will be treated with GLE/PIB 300 mg/120 mg QD for 16 weeks.
2925833|NCT03069365|Experimental|Arm A: GLE/PIB for 8 weeks|Arm A: Hepatitis C Virus (HCV) Genotype (GT)1, 2, 4 - 6 participants without cirrhosis who are treatment naïve (TN) or treatment experienced (TE) and HCV GT 3 participants without cirrhosis who are TN treated with Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
2925834|NCT03069352|Experimental|Venetoclax + Low Dose Cytarabine (LDAC)|Venetoclax 600 mg orally every day (QD) QD on Days 1 - 28 plus LDAC 20 mg/m^2 subcutaneously QD on Days 1 - 10 (28 day cycle)
2925835|NCT03069352|Placebo Comparator|Placebo + LDAC|Matching Placebo for Venetoclax 600 mg orally QD on Days 1 - 28 plus LDAC 20 mg/m^2 subcutaneous QD on Days 1 - 10 (28 day cycle)
2925836|NCT03069339|Experimental|Carvedilol+EVL|
2925837|NCT03069339|Experimental|Carvedilol|
2925838|NCT03069339|Active Comparator|EVL|
2925839|NCT03069326|Experimental|Ruxolitinib and Thalidomide|After 3 cycles of ruxolitinib treatment, either prior to study enrollment or through the ruxolitinib run-in phase, patients who meet eligibility criteria will be treated with ruxolitinib and thalidomide orally on days 1-28 of a 28 day cycle. Cycles will be continued until the patient wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs.
2925840|NCT03069313|Experimental|Arm I|Oral Vitamin B12
2925876|NCT03069027|Placebo Comparator|Group I(control)|patients allocated for external nasal nerve block with saline adrenaline 1/200,000 (placebo)
2925841|NCT03069300|Experimental|prednisolone+NAC|40mg prednisolone once a day for 28 days and 30 minutes of intravenous NAC at 150mg/kg in 250ml 5% dextrose solution followed by 4 hours of intravenous NAC at 50mg/kg in 500ml 5% dextrose solution, followed by 16 hours of intravenous NAC at 100 mg/kg in 1000ml 5% dextrose solution, followed by 4 days of intravenous NAC at 100mg/kg/day in 1000ml 5% dextrose solution
2925842|NCT03069300|No Intervention|prednisolone|40mg prednisolone for 28 days
2925843|NCT03069287|Experimental|Patient-caregiver dyads|Dyads will include family caregivers and patients with a diagnosis of cancer who agreed to participate in a therapeutic clinical trial.
2925844|NCT03069274|Other|Control|Only general nutritional recommendations were given.
2925845|NCT03069274|Experimental|Intervention|General nutritional recommendations, change their drinking habits.
2925846|NCT03069261||Intervention - ICG angiography|ICG-angiography was used intraoperatively after placement of the flap at the recipient cite, evaluating the viability and perfusion of the flap. Poor perfused areas were excised
2925847|NCT03069261||Control - clinical assessment|A control group receiving identical operations but without ICG-angiography evaluation.
2925848|NCT03069248|Experimental|treatment arm|Salvage treatment with CHOP or DHAP followed by high dose therapy and stem cell support prior to consolidative immunotherapy with Rituximab and Alpha interferon.
2925849|NCT03069235|Active Comparator|Standard of Care|group/individual counselling.
2925850|NCT03069235|Experimental|Family member / peer support|Structured family member / peer support.
2925851|NCT03069235|Experimental|Special infant feeding counselor support|Enhanced intervention with counselor support
2925852|NCT03069222||Patient|SCI patients enrolled at Kessler Institute Rehabiliation
2925853|NCT03069222||Control|age and gender matched with patient enrolled
2925854|NCT03069209|Experimental|Stem Cells|Intervention: Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
2925855|NCT03069183|Active Comparator|0.5% Ropivacaine|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
2925856|NCT03069183|Placebo Comparator|Normal Saline|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
2925857|NCT03069170|Experimental|Stem Cells|Intravenous administration of purified autologous bone marrow-derived stem cells.
2925858|NCT03069170|Experimental|Stem Cell Transplantation|Intrathecal administration of purified autolgous bone-marrow derived stem cells.
2925859|NCT03069157|No Intervention|Without lung recruitment maneuver|patient ventilation will be maintained After induction of anesthesia all patients will be ventilated using pressure controlled mode targeting tidal volume 6-8 ml/kg with inspiratory to expiratory ( I: E) ratio 1:1.5 without recruitment but with PEEP 5cm H2O.
2925860|NCT03069157|Active Comparator|recruitment group|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O.
2925861|NCT03069144|Experimental|HAT1 topical solution|HAT1 topical solution will come in a labeled spray bottle. This topical medicated solution will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
2925862|NCT03069144|Active Comparator|Calcipotriol ointment (0.005%)|Calcipotriol ointment (0.005%) will come in a labeled tube. The medicated cream will be be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
2925863|NCT03069131|Experimental|Active rifaximin|
2925864|NCT03069131|Placebo Comparator|Rifaximin placebo|
2925865|NCT03069118|Experimental|Treatment|Three-month intervention on the online Workit Health platform
2925866|NCT03069118|Placebo Comparator|Control|A list of online resources/waitlist
2925867|NCT03069105||Family caregivers|The sample for this study will consist of caregivers of patients with cancer. Eligible subjects who agrees to participate in the research study and sign the consent form will participate by completing paper and pencil or electronic questionnaires.
2925868|NCT03069092|Experimental|Aerobic exercise (AE)|AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.
2925869|NCT03069092|Experimental|Resistance exercise (RE)|RE will consist of 3 sets of 8-15 repetitions at 50-80% of 1 rep-max of each exercise for 12 exercises (chest press, shoulder press, pull-down, back extension, abdominal crunch, torso rotation, biceps curl, triceps extension, leg press, leg extension, leg curl, and calf raise). Weight loads will be increased gradually. With one minute of rest between sets, this plan is estimated to take approximately 60 minutes per session. Sessions will occur 3 times per week for the duration of the 1 year trial.
2925870|NCT03069092|Experimental|Combined Resistance and Aerobic Exercise|Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
2925871|NCT03069092|No Intervention|No training control|Participants in this group will be asked to maintain their current level of activity during the 1 year study period. After 1 year, they will be offered the training program of their choice (AE, RE, or combined).
2925872|NCT03069079|Experimental|Non surgical Periodontal therapy|"All children will be offered an oral hygiene and tooth scaling and polishing session. For children affected by periodontal disease, subgingival debridement will also be performed according to needs, with the aim to disrupt the subgingival biofilm responsible for the onset and progression of the periodontal pathology. This can be accompanied, when appropriate, by the use of local anaesthesia and adjunctive antimicrobials (systemic or locally applied subgingivally), according to the clinical presentation and the child's medical conditions. In addition, when required, nitrous oxide sedation (NOS) could be used before treatment.~Caries will be treated as necessary (shared care with the general dental practitioners / community dental services). Children with mucosal lesions requiring treatment will be given a letter for their GDP suggesting referral to a collaborating expert in Oral Medicine (Prof. Stephen Porter)."
2925877|NCT03069027|Active Comparator|Group II(block)|'External nasal nerve block by Xylocaine, adrenaline'
2925878|NCT03069014|Active Comparator|400mg LM11A-31-BHS|400mg LM11A-31-BHS and 400mg Placebo per day
2925879|NCT03069014|Active Comparator|800mg LM11A-31-BHS|800mg LM11A-31-BHS
2925880|NCT03069014|Placebo Comparator|Placebos|800mg (microcrystalline cellulose with 0.5 - 1% magnesium stearate) per day
2925881|NCT03069001|Active Comparator|Sofosbuvir-Simeprevir|"Sofosbuvir 400 mg orally once-daily.~Simeprevir 150 mg orally once-daily.~Group A included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks."
2925882|NCT03069001|Active Comparator|Sofosbuvir-Ribavirin|"Sofosbuvir 400 mg orally once-daily.~Ribavirin orally twice-daily (according to body weight: 1000 mg daily in patients with a body weight of <75 kg and 1200 mg daily in patients with a body weight of ≥75 kg).~Group B included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks."
2925883|NCT03068988|Experimental|mesenchymal stem cells|mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
2925884|NCT03068988|Placebo Comparator|without mesenchymal stem cells|rotator cuff surgery without mesenchymal stem cells
2925885|NCT03068975|Experimental|Alvimopan|Patients in the study group will be administered a post operative dose of Alvimopan
2925886|NCT03068975|Placebo Comparator|Placebo|Patients in the Placebo group will receive a placebo pill and will be compared with the study group
2925887|NCT03068962|Experimental|beetroot juice|Rinse mouth with low nitrate Buxton mineral water followed by holding 10 ml of beetroot juice for 5 min,
2925888|NCT03068962|Experimental|low mineral water (Buxton water)|Rinse mouth with low nitrate Buxton mineral water followed by holding 10 ml of low nitrate mineral water in the mouth for 5 min or
2925889|NCT03068962|Experimental|antiseptic mouthwash then beetroot juice|Rinse with antiseptic mouthwash before holding 10 ml of beetroot juice in the mouth for 5 min
2925890|NCT03068949|Active Comparator|FluBlok|
2925891|NCT03068949|Active Comparator|Fluzone|
2925892|NCT03068949|Active Comparator|FluCelVax|
2925893|NCT03068936|Experimental|IMRT group|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
2925894|NCT03068936|Other|IMRT plus cisplatin group|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy),plus synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
2925895|NCT03068910|Experimental|Spironolactone|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with spironolactone (50 mg twice daily).
2925896|NCT03068910|Placebo Comparator|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
2925897|NCT03068897|Active Comparator|Metaxalone|"Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
2925898|NCT03068897|Active Comparator|Tizanidine|"Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
2925899|NCT03068897|Active Comparator|Baclofen|"Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
2925900|NCT03068897|Placebo Comparator|Placebo|"Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
2925901|NCT03068884|Sham Comparator|Tdcs sham|
2925902|NCT03068884|Placebo Comparator|Placebo|
2925903|NCT03068884|Experimental|Tdcs cathodal|
2925904|NCT03068884|Experimental|Tyrosine|
2925905|NCT03068871|Experimental|CET|CET - Coping Effectiveness Training group.
2925906|NCT03068871|Experimental|ACT|ACT - Acceptance and Commitment Therapy group
2925907|NCT03068858|Experimental|SYNTAX score category feedback group|A real-time SYNTAX score category feedback from angiographic core lab will be given to the cardiologists rightafter the angiographies.
2925908|NCT03068858|No Intervention|Controlled group|Cardiologists' subjective SYNTAX score category judgement will be recorded during the angiography.
2925909|NCT03068845|Experimental|Drug-eluting Balloon Angioplasty (DEBA)|After predilatation of the target lesion with conventional balloon angioplasty, a drug-eluting balloon will be inflated to an appropriate inflation pressure, but not exceeding the rated burst pressure of the balloon, for at least a minute.
2925910|NCT03068845|Active Comparator|Conventional Balloon Angioplasty (CBA)|The target lesion will be dilated with a conventional angioplasty balloon to an appropriate inflation pressure, but not exceeding the rated burst pressure of the balloon, for at least a minute.
2925911|NCT03068832|Experimental|Personalized peptide vaccine and poly-ICLC|"The synthetic long peptide(s) and poly-ICLC will be given on Cycle 1 Day 1 when available.~Additional peptide vaccine doses will be administered again on Days 4, 8, 15, and 22 of the first cycle as a priming strategy. On all subsequent cycles, the peptide vaccine will be given on Day 1.~Peptide vaccine administration will continue until supply is exhausted or development of intolerance or disease progression in the case of fatal high grade neoplasms. Otherwise, vaccination will continue until supply is exhausted or intolerance or one year for non-fatal tumors. Additionally, patients with non-fatal tumors who complete one year of vaccinations and have stable disease will be given the option of resuming vaccinations if they develop subsequent progression if remaining vaccine is available."
2925912|NCT03068819|Experimental|CIML NK cell after T cell DLT|-The recipient will receive standard of care salvage chemotherapy consisting of fludarabine, ara-C, and G-CSF (FLAG) to be started 2 to 4 weeks prior to the CIML NK cell infusion, with Day -1 the day of T cell DLI, and Day 0 denoting the CIML NK cell infusion day. The donor will undergo non-mobilized large volume (20L) leukapheresis on Day -2 or -1, anticipating processing for T cell DLI and NK cell isolation on Day -1.
2925913|NCT03068806||Patients with Schizophrenia|Individuals who have been previously diagnosed with schizophrenia and meet our research criteria for symptoms indicative of schizophrenia within their lifetime.
2925914|NCT03068806||Healthy Controls|Individuals who have not met criteria for a psychiatric disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric disorder.
2925915|NCT03068793||Patients with Recent Onset Schizophrenia|Individuals who have been diagnosed with Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder within the past five years and meet our research criteria for symptoms indicative of these diseases within the past five years.
2925916|NCT03068793||Healthy Controls|Individuals who have not met criteria for a psychiatric disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric disorder.
2925917|NCT03068780|Experimental|Oleogel-S10|
2925918|NCT03068780|Placebo Comparator|Placebo|
2925919|NCT03068767|Experimental|Vitamin D group|Patients receiving vitamin D supplement (2000 IU/day) for 2 months
2925920|NCT03068767|No Intervention|Control group|Patients without receiving vitamin D supplement
2925921|NCT03068754|Active Comparator|Acthar|
2925922|NCT03068754|Placebo Comparator|Placebo|
2925923|NCT03068741|Active Comparator|Comparison 1: Prehospital Ceftriaxone|1g of Ceftriaxone will be administered by immediate intramuscular (IM) injection. The drug is provided in a sterile and completely covered vial as a white, odourless powder
2925924|NCT03068741|Placebo Comparator|Comparison 1: Placebo|The placebo is provided in a sterile and completely covered vial.
2925925|NCT03068741|Experimental|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous 0.9% saline solution to all participants in this arm regardless of blood pressure, reassessing for signs of volume overload after each 250ml.
2925926|NCT03068741|Active Comparator|Comparison 2: Conservative fluids|Paramedics will administer 0.9% saline solution to participants who have systolic blood pressure <90mmHg, and will only continue the infusion until the systolic blood pressure is >=100mmHg.
2925927|NCT03068728|Active Comparator|Arista|
2925928|NCT03068728|Active Comparator|Nexafoam|
2925929|NCT03068728|Active Comparator|Sinufoam|
2925930|NCT03068728|Active Comparator|Nasopore|
2925931|NCT03068728|Active Comparator|Posisep Hemostat Dressing|
2925932|NCT03068728|Active Comparator|Posisep X Hemostat Dressing|
2925933|NCT03068715|Experimental|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
2925934|NCT03068715|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation. Participants will have the option of open label TBS-DLPFC treatment following study completion.
2925935|NCT03068702||African Canadians|African Canadians with sickle cell disease maculopathy diagnosed by OCTA.
2925936|NCT03068689|Experimental|Intervention (RIPC)|RIPC treatment prior to partial nephrectomy.
2925937|NCT03068689|Placebo Comparator|Placebo Control|Placebo prior to partial nephrectomy.
2925938|NCT03068676|Experimental|Space from depression|Space from Depression is an eight-module online CBT-based intervention for depression, composed of cognitive and behavioral components including self-monitoring and thought recording, behavioral activation, cognitive restructuring, and challenging core beliefs. Each module follows a structured format that incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.
2925939|NCT03068676|Experimental|Space from Anxiety|Space from Anxiety is an eight-module online CBT-based intervention for depression, composed of cognitive and behavioral components including self-monitoring and thought recording, behavioral activation, cognitive restructuring, and challenging core beliefs. Each module follows a structured format that incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.
2925940|NCT03068663|Experimental|Pchir|"Non small cell lung carcinoma patients designated for immediate surgery. Intervention in this group is sampling. The sampling will be done for:~blood and saliva: at consultations after inclusion in the study~faeces: day before the surgery~lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy"
2925941|NCT03068663|Experimental|Pct-chir|"Non small cell lung carcinoma patients who will receive neoadjuvant chemotherapy before the surgery. Intervention in this group is sampling. The sampling will be done for:~blood and saliva: 1st time at consultations after inclusion in the study, 2nd time at consultations after chemotherapy and before surgery~faeces: 1st time the day before the chemotherapy, 2nd time the day before the surgery~lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy"
2925942|NCT03068637|Experimental|Care planning platform usage|This intervention will focus on the use of the Carevive care planning software for multiple myeloma patients age 65 and older who are at a treatment decision-making timepoint.
2925943|NCT03068624|Experimental|CD 8+ T cells|"Dose Escalation Run-In Cohort:~The first cohort of patients receive a single infusion of 3.3 x 10^9 cells/m2 on Day 0 and observed for any signs of toxicity. If no dose-limiting toxicity (DLT) is seen in any of the three patients, then escalation to the next dose level is permitted. Treatment continues in cohorts of three until maximum tolerated dose achieved."
2925944|NCT03068624|Experimental|CD 8+ T Cells + Cyclophosphamide + IL-2 + Ipilimumab|"Expansion Cohort:~Cyclophosphamide administered at 300 mg/m2 by vein 48 to 72 hours prior (Day -3 to Day -2) to T cell infusion as an outpatient procedure. Maximum tolerated dose of CD 8+ T Cells from Dose Escalation Run-In given on Day 0. Low-dose IL-2 initiated within 6 hours of T cell infusion. IL-2 administered at 250,000 U/m2 subcutaneously twice daily for 14 days. Ipilimumab administration initiated approximately 24 hours after the T cell infusion at a dose of 3mg/kg over approximately 90 minutes by vein and every 3 weeks thereafter for a total of 4 doses."
2925945|NCT03068611|Active Comparator|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
2925946|NCT03068611|Experimental|Alcohol-focused Web-Based Smoking Cessation|A modified version of the website and text messaging program that is publicly available through BecomeAnEX.com. This version includes specific information and feedback on alcohol use, allows participants to consider benefits of changing drinking, plans for changing drinking, and strategies. Participants have access to the website whenever they wish.
2925947|NCT03068598|Experimental|sleep monitoring|The sleep tracker and a smartphone will be given to the patient after discharge. The patient will recieve a brief training on how to use the PulseOn watch or the Suunto Spartan Ultra watch. Patient will be proposed to monitor his sleep during the five nights following the discharge.
2925948|NCT03068585|Experimental|Neovasculgen|DNA encoding the 165-amino-acid isoform of human vascular endothelial growth factor (pCMV - VEGF165)
2925949|NCT03068585|No Intervention|Control|Control therapy
2925950|NCT03068572||NERD group|45 GERD patients without obviously abnormality were examined by conventional white-light endoscopy and then followed by Linked Color imaging(LCI) to evaluate minimal change esophagitis and observation agreement of Los Angeles classification system GERD patients with the absence of mucosal breaks at conventional endoscopy,and those patients was given standard or double dose of oral proton pump inhibitor (PPI) for 2 weeks to determine the efficacy of anti-secretory therapy (the so-called PPI test).The response to PPI treatment comprised the NERD group.
2925951|NCT03068572||Control group|45 control patients were examined by white-light endoscopy and then followed by Linked Color imaging(LCI) to evaluate minimal change esophagitis and observation agreement of Los Angeles classification system,those subjects who had undergone endoscopy solely for the purpose of a health check-up at the same time of the study period
2925952|NCT03068559||Study population|"Patient must have an initial confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx.~Patient has to be aged ≥ 18~Patient has to be able to complete questionnaire in French~Patient must benefit from health insurance~Patient must sign an informed consent form~Patient treatment must be validated in a medical multidisciplinary team meeting: surgery, radiotherapy (RT), chemotherapy (CT), radiochemotherapy (RTCT), induction chemotherapy followed by radiochemotherapy (IND+RTCT), surgery followed by radiotherapy (surgery+RT), surgery followed by radiochemotherapy (surgery+RTCT)."
2925953|NCT03068546||NCI Employees|Employees
2925954|NCT03068533|Active Comparator|Strontium acetate toothpaste|All eligible patients will receive mechanical debridement in 1 or 2 sessions within 1 week before final evaluation.
2925955|NCT03068533|Experimental|Arginine/calcium carbonate toothpaste|All eligible patients will receive mechanical debridement in 1 or 2 sessions within 1 week before final evaluation.
2925956|NCT03068520|Other|PRIMARY BRAIN TUMOR (PBT)|patients with PBT (Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma), before treatment with radiation and chemotherapy.will be followed with PET MRI
2925957|NCT03068520|Other|METASTATIC BT TREATED BY SRS|"patients with lung or breast metastasis to brain treated by SRS in which at least one lesion showed deterioration by MR performed after treatment.~will be followed with PET MRI"
2925958|NCT03068520|Other|METASTATIC BT NOT TREATED BY SRS|"patients with lung or breast metastasis to brain where the SRS treatment was postponed for clinical reasons (getting mutation information for targeted treatment) the lesion size measures 5-40 mm.~will be followed with PET MRI"
2925959|NCT03068507|Experimental|Prehabilitation group|Trimodal prehabilitation management
2925960|NCT03068507|No Intervention|Control group|The patients will receive the conventional clinical guidance according to Peking Union Medical College Hospital, including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence.
2925961|NCT03068494||Coronary Bifurcation Lesion|
2925962|NCT03068481|Experimental|Healthy volunteer part -Single dose|Single oral dose of KDT-3594
2925963|NCT03068481|Experimental|Healthy volunteer part -Multiple dose|Multiple oral doses of KDT-3594
2925964|NCT03068481|Placebo Comparator|Healthy volunteer part -Placebo|Multiple oral doses of Placebo
2925965|NCT03068481|Experimental|Patient part -Single dose|Single oral dose of KDT-3594
2925966|NCT03068481|Experimental|Patient part -Multiple dose|Multiple oral doses of KDT-3594
2925967|NCT03068468|Experimental|BIIB092|Participants will receive BIIB092 50 mg/ml intravenous (IV) infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
2925968|NCT03068468|Placebo Comparator|Placebo|Participants will receive BIIB092 matching placebo IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
2925969|NCT03068455|Experimental|nivolumab + ipilimumab|Specified Dose on Specified Days
2925970|NCT03068455|Experimental|nivolumab|Specified Dose on Specified Days
2925971|NCT03068442|Experimental|Carotid atherosclerosis group|This group includes all enrolled subjects (those with carotid disease and plans to undergo surgery).
2925972|NCT03068429|Experimental|Sertraline open label|Sertraline hydrochloride up to 200mg/day or maximum tolerated dosage for 4-weeks.
2925973|NCT03068416|Experimental|CAR T cells|Autologous 3rd generation CD19-targeting CAR T cells
2925974|NCT03068403|Other|Chemotherapy and Radiochemotherapy|
2925975|NCT03068403|Other|Radiochemotherapy|
2925976|NCT03068390|Experimental|RICHH Intervention|The RICHH intervention is an educational-behavioral and counseling intervention that promotes caregivers' knowledge, skills and motivation to engage in CVD risk reduction. The intervention is delivered individually to caregivers in their homes using video-conferencing technology on mini-iPads that we provide for all participants. Participants keep the mini-iPads at the end of the study. The program consists of 12 weekly sessions [30-45 minutes] followed by 8 bi-weekly [every other week] booster sessions and 6 monthly booster sessions that will be held at the caregivers' preferred times using a video conferencing program. A cardiac psychiatric advanced practice nurse certified cognitive behavioral therapy will deliver the intervention.
2925977|NCT03068390|Active Comparator|Usual care|The usual care control group will receive an attention placebo intervention in which the caregivers will receive mini-iPads loaded with Caregiver and CVD risk reduction pamphlets in PDF format along with the associated links from the American Heart Association. Because the investigators may identify CVD risk factors in baseline testing in participants who do not know they have them, it would be unethical not to provide at least usual care for these. Thus, all individuals enrolled in the study and in whom the investigators identify CVD risk factors will receive referral to a primary care provider for management of the CVD risk factors identified.
2925978|NCT03068377|Placebo Comparator|Placebo|Soft gel capsules without test material
2925979|NCT03068377|Experimental|Experimental|Soft gel capsules containing a mixture of tomato extract, lutein, zeaxanthin as well as other phytonutrients and vitamins
2926065|NCT03067688|Experimental|"Combination drug:Temisartan+Amlodipine+Rosuvastatin"|"60 subjects will be assigned and the subjects will be administered Temisartan+Amlodipine+Rosuvastatin for 8 weeks."
2926166|NCT03066999|Active Comparator|DirectVision|will have catheter placement using DirectVision.
2925980|NCT03068351|Experimental|RO6870810|Participants will be administered RO6870810 monotherapy at ascending-dose levels during the dose escalation phase followed by an expansion phase during which RO6870810 will be administered as monotherapy at the recommended dose. Participants will continue to receive study drug as long as they experience clinical benefit in the opinion of the Investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression, as determined by the Investigator after an integrated assessment of IMWG response criteria, biopsies/aspirate (if applicable), and clinical status, or withdrawal of consent.
2925981|NCT03068351|Experimental|RO6870810 + Daratumumab|Participants will be administered RO6870810 at ascending-dose levels in combination with daratumumab at the recommended dose during the dose escalation phase followed by an expansion phase during which both RO6870810 and daratumumab will be administered each at their recommended dose. Participants will continue to receive the study drugs as long as they experience clinical benefit in the opinion of the Investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression, as determined by the Investigator after an integrated assessment of IMWG response criteria, biopsies/aspirate (if applicable), and clinical status, or withdrawal of consent.
2925982|NCT03068338|Active Comparator|Conventional therapy|Intermittent pneumatic compression devices are used for prevention of DVT.
2925983|NCT03068338|Experimental|Robotic Sock|Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
2925984|NCT03068325|Experimental|TF-EAT|
2925985|NCT03068312|Experimental|Sequence 1: First Ivacaftor Then Placebo|Subjects will be randomized to receive Ivacaftor, 150 mg every 12 hours (q12h) for 8 weeks in Treatment Period 1 followed by Placebo matching Ivacaftor for 8 weeks in Treatment Period 2. A washout period of 8 weeks will be maintained between the 2 periods.
2925986|NCT03068312|Experimental|Sequence 2: First Placebo Then Ivacaftor|Subjects will be randomized to receive Placebo matching to Ivacaftor for 8 weeks in Treatment Period 1 followed by Ivacaftor 150 mg q12h for 8 weeks in Treatment Period 2. A washout period of 8 weeks will be maintained between the 2 periods.
2925987|NCT03068299|Experimental|Dance|n=29 participants randomized. Cognition performance, frailty and burden will be measured at baseline and after of interventions (6 months after baseline). Instruments of measurement described in Time Frame.
2925988|NCT03068299|Experimental|Health care guidance|n=29 participants randomized. Cognition performance, frailty and burden will be measured at baseline and after of interventions (6 months after baseline). Instruments of measurement described in Time Frame.
2925989|NCT03068286|Experimental|Space in Diabetes|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Psychoeducational content in the diabetes programme focusses on the impact that mood can have on self-management and self-care when living with diabetes.
2925990|NCT03068286|Experimental|Space in COPD|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.
2925991|NCT03068286|Experimental|Space in Chronic Pain|"The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. A module on health anxiety, titled Anxiety and your Health, has been added to the chronic pain programme. This module provides psychoeducational content on health anxiety, the unhelpful behaviours that accompany it and how these can negatively impact on the experience of pain."
2925992|NCT03068273|Experimental|Intervention|For type 2 patients in the intervention group, CGM data will be viewed real-time.
2925993|NCT03068273|Experimental|Control|For type 2 patients in the control group, CGM data is blinded to all and only gathered for comparison purposes to intervention group.
2925994|NCT03068260|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 ml ropivacaine 0,375% single shot.~In both arms, the participants receive 1g Acetaminophen and 400 mg Ibuprofen / 100 mg Celebra. Morphine will be administered IV as part of a PCA-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
2925995|NCT03068260|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 ml saline single shot.~In both arms, the participants receive 1g Acetaminophen and 400 mg Ibuprofen / 100 mg Celebra. Morphine will be administered IV as part of a PCA-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
2925996|NCT03068247|Experimental|Interventional|10 weeks of duloxetine beginning at 30 mg per day for week 1, then 60 mg / day thereafter.
2925997|NCT03068247|Placebo Comparator|Placebo|10 weeks of placebo once daily for 1 week, then twice daily therafter.
2925998|NCT03068234|Experimental|Pirfenidone group|The subjects will receive pirfenidone from 200mg three times a day, oral administrated, with low dose steroids.
2925999|NCT03068234|Placebo Comparator|Control group|The subjects will receive placebo within first 24-week, and pirfenidone 200mg three times a day for the second 24-week, with low dose steroids.
2926000|NCT03068221|Active Comparator|Poly Cystic Ovary Syndrome|anaerobic exercise in overweight patients with PCOS
2926001|NCT03068221|Active Comparator|non Poly Cystic Ovary Syndrome|anaerobic exercise in overweight patients without PCOS
2926002|NCT03068208|Experimental|MB-PDT|
2926003|NCT03068208|No Intervention|Control|
2926004|NCT03068195|Experimental|laparoscopic microwave ablation|laparoscopic microwave ablation will be performed before the renal cysts are decorticated
2926005|NCT03068195|Experimental|percutaneous microwave ablation|percutaneous microwave ablation will be performed to treat the renal cysts without decorticating.
2926006|NCT03068195|Active Comparator|laparoscopic decortication|conventional laparoscopic decortication will be performed to treat the renal cysts.
2926007|NCT03068182|Experimental|Arm crank Exercise|Sixty-five participated in an arm crank moderate intensity exercise for 40 minutes.
2926008|NCT03068182|Experimental|Treadmill Exercise|Sixty-five participated in a treadmill moderate intensity exercise for 40 minutes.
2926009|NCT03068156|Experimental|excimer laser|
2926010|NCT03068156|No Intervention|Control|
2926011|NCT03068130|Experimental|Bardoxolone methyl 10 mg|Bardoxolone methyl will be administered orally once daily at 10 mg until it becomes commercially available. Dose de-escalation (down to 5 mg) is permitted during the study, if indicated clinically.
2926012|NCT03068117|Experimental|RESSCT plus Standard Care/Therapy|"Regular Early Specialist Symptom Control Treatment (RESSCT) and Standard Therapy.~Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
2926013|NCT03068117|No Intervention|Standard Care/Therapy|The standard care/therapy control group will continue to receive all appropriate, standard treatment for Malignant Pleural Mesothelioma (MPM) currently available to them and will be initiated by the patient's General Practitioner (GP), the cancer MDT or lead respiratory physician as required.
2926014|NCT03068091|Other|Pulmonary Assessment|All participants will undergo a Chest CT scan and pulmonary function testing
2926015|NCT03068078|No Intervention|Control-group|The control group will be eating a regular diabetes diet according to the Danish National Recommendations
2926016|NCT03068078|Experimental|Intervention-group|Intervention-group will be eating a low carbohydrate diet, high in monounsaturated fats
2926017|NCT03068065|Active Comparator|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
2926018|NCT03068065|Active Comparator|Metformin|the dosage of merformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
2926019|NCT03068065|Active Comparator|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of <7.0 mmol/L
2926020|NCT03068052|Active Comparator|No incentive|Colon cancer risk assessment and direct access colonoscopy scheduling for those that are eligible.
2926021|NCT03068052|Experimental|Incentive|Loss-framed incentive to participate in risk assessment and additional unconditional pro-social incentive to complete colorectal cancer screening.
2926022|NCT03068039|Active Comparator|OATS PORRIDGE|Oats breakfast porridge 220 kcal served with 240 mL water
2926023|NCT03068039|Active Comparator|PEARL (BAJRA) MILLET PORRIDGE|Pearl (bajra) millet breakfast porridge isoenergetic (220 kcal) served with 300 mL water to make it also isovolumteric with the Oats arm
2926024|NCT03068026|Experimental|Continuous exercise|Patients will undergo a constant load exercise protocol with gas exchange analysis on a cycle ergometer. The exercise protocol will be consisted of repeated 6-min exercise bouts, separated by 2-min rest periods in between work bouts in order to allow application of the VitaBreath device. During the 1st min of each resting period participants will breathe either via the VitaBreath device or normally adopting the pursed lip breathing technique. During the 2nd min of each resting period participants will breathe normally and perform an IC maneuver to assess the magnitude of dynamic hyperinflation.
2926025|NCT03068026|Experimental|Interval exercise|Patients will undergo an interval exercise protocol with gas exchange analysis on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min resting periods in between work bouts in order to allow application of the VitaBreath device. During the 1st min of each resting period participants will breathe either via the VitaBreath device or normally adopting the pursed lip breathing technique. During the 2nd min of each rest period participants will breathe normally and perform an IC maneuver, to assess the magnitude of dynamic hyperinflation.
2926026|NCT03068013|Experimental|Managing Cancer Living Meaningfully|Patients in the experimental group will receive the brief, individual, manualized CALM intervention, a semi-structured psychotherapy designed for patients with advanced cancer. CALM was developed based on empirical results, clinical observation and the theoretical foundations of supportive-expressive and existential approaches, as well psychodynamic and attachment theories. The sessions are delivered bimonthly over a period of 6 months without the possibility of telephone sessions. Sessions are audio-recorded and reviewed to ensure treatment fidelity.
2926027|NCT03068013|Active Comparator|Supportive psycho-oncology intervention|Supportive psycho-oncology intervention (SPI) includes counseling, information, crisis intervention, which is the usual care intervention provided in our center.
2926028|NCT03068000|Experimental|Judo training|Judo intervention will take place twice a week, lasting 50 minutes per session, for 3 months, divided into general exercises: warm-up and stretching specific to the sport; Specific exercises of the sport: shock absorption, falls cushioning (Ukemi-waza), immobilization techniques (hon-kesa-gatame and tate-shiho-gatame) and projection (o-soto-gari, o-goshi, ashi-guruma, koshi-guruma, tai-otoshi and others); And fight simulation: randori.
2926029|NCT03068000|Active Comparator|Ball games|The Ball Games will take place twice a week, with a duration of 50 minutes per session, for 3 months, divided into general exercises: heating and specific stretching with ball; Specific exercises of the sport: fundamentals of sports with ball, exercises with ball; And games: games will be given at the end of the lesson to work out all the fundamentals and specific exercises in general.
2926030|NCT03067987|Active Comparator|720 shockwave therapy|5 daily sessions of shockwave therapy within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).
2926031|NCT03067987|Active Comparator|600 shockwave therapy|"Three sessions of shockwave therapy per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~Following the last treatment session, each patient will resume his baseline consumption of phosphodiesterase 5 inhibitor, in terms of type and dose of drug, for the remainder of study duration."
2926032|NCT03067974|Experimental|Intranasal ketamine arm|10mg/kg intranasal ketamine administered one time
2926033|NCT03067961|Experimental|Wild type S. Typhi Quailes strain|Administered by the oral route with sodium bicarbonate at a dose of 1-5x10 4 CFU.
2926034|NCT03067961|Experimental|Quailes typhoid toxin knock-out|Administered by the oral route with sodium bicarbonate at a dose of 1-5x10 4 CFU.
2926066|NCT03067688|Active Comparator|Temisartan+Amlodipine|"60 subjects will be assigned and the subjects will be administered Twynsta Tab.(Temisartan+Amlodipine) for 8 weeks."
2926035|NCT03067948|Experimental|Intervention - Positive Screen Shared|In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to the participant's next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to the next HIV primary care visit.
2926036|NCT03067909||Patients undergoing CIED surgery|Patients with standard indications to CIED implantations/replacements receiving concomitant antithrombotic therapy (either or both antiplatelet agents and/or anticoagulants).
2926037|NCT03067896|Active Comparator|Group C|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
2926038|NCT03067896|Active Comparator|Group D|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline .
2926039|NCT03067896|Active Comparator|Group M|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with magnesium sulfate 50 mg in 0.5 ml normal saline .
2926040|NCT03067883|Experimental|interventional Qurevo group|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.~These patients will receive intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.~Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).~Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
2926041|NCT03067870|Experimental|Stem Cells|Autologous bone marrow-derived stem cell transplantation.
2926042|NCT03067857|Experimental|Stem Cells|Intravenous and Intrathecal thecal transplantation via interventional radiology of purified autologous bone-marrow derived specific stem cell populations.
2926043|NCT03067844|Experimental|Alirocumab|Alirocumab 150 mg/mL, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.
2926044|NCT03067844|Placebo Comparator|Placebo|Placebo, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.
2926045|NCT03067831|Experimental|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
2926046|NCT03067818|Experimental|Unaffected Hemisphere|"Application of Unaffected Transcranial Magnetic Stimulation to unaffected hemisphere site prior to physical practice"
2926047|NCT03067818|Experimental|Affected Hemisphere|"Application of Affected Transcranial Magnetic Stimulation to affected hemisphere site prior to physical practice"
2926048|NCT03067818|Active Comparator|Control Site|"Application of Control Transcranial Magnetic Stimulation to control site prior to practice"
2926049|NCT03067805|Experimental|Oxytocin|Oxytocin nasal spray
2926050|NCT03067805|Placebo Comparator|Placebo|Placebo nasal spray
2926051|NCT03067792|Active Comparator|FOLFIRI|2nd palliative chemotherapy with FOLFIRI regimen,In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5- fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle. Response evaluation would be done after 3 cycle of chemotherapy in DP group
2926052|NCT03067792|Active Comparator|DP|2nd palliative chemotherapy with Docetaxel/cisplatin regimen, In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle. Response evaluation would be done after 2 cycle of chemotherapy in DP group
2926053|NCT03067779|Other|Survey and mHealth Tool|"A survey has been designed that evaluates CRIC participants' computer and mobile phone usage, and perceived e-health literacy.~There is also a mobile health-based (mHealth) patient safety educational curriculum that evaluates CRIC participants' knowledge of patient safety hazards in CKD. The mHealth patient safety curriculum tool is also known as eCRIC."
2926054|NCT03067766|Experimental|Workshop A (10 weeks - comic art creation workshop)|Patients and a family member, caretaker, or friend participate in an artist-led comic art therapy workshop over 2 hours once a week for 10 weeks. Patients and participants receive a range of assignments that focus on creative art and experimentation with materials and storytelling in order to make a series of small handmade books that relate directly or indirectly to their experience with cancer. Patients undergo a qualitative interview over approximately 45 minutes and complete validated questionnaires within 4 weeks prior to the workshop and midway through the workshop.
2926055|NCT03067766|Experimental|Workshop B and C (5 weeks - comic art creation workshop)|Patients participate in an artist-led comic art therapy workshop over 3 hours once a week for 5 weeks. Patients receive a range of assignments that focus on creative art and experimentation with materials and storytelling in order to make a series of small handmade books that relate directly or indirectly to their experience with cancer. Patients undergo a qualitative interview over approximately 45 minutes and complete validated questionnaires within 4 weeks prior to the workshop.
2926056|NCT03067753|Active Comparator|Pulsed steroid|Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
2926057|NCT03067753|Experimental|Monosialoganglioside ganglioside|Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
2926058|NCT03067740|Active Comparator|Bupivacaine group|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
2926059|NCT03067740|Experimental|Bupivacaine-Dexmedetomidine group|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
2926060|NCT03067727|Experimental|Dinoprostone vaginal insert|
2926061|NCT03067727|Placebo Comparator|Placebo|
2926062|NCT03067714|Experimental|Active product: partially hydrolysed formula + synbiotics|
2926063|NCT03067714|Active Comparator|Control product: standard formula (intact protein)|
2926064|NCT03067701|Experimental|Carbon Monoxide Inhalation|In healthy young adults 18-39 years of age, The Investigator will determine if intermittent inhalation a 0.1% CO, from a 1-liter bag once every minute for 30-40 minutes, at a level that approaches the CO boost with hookah smoking, augments endothelial function, thus implicating CO as the major endothelial vasodilator substance in hookah smoke.
2926304|NCT03066011||Posaconazole Group|Oral and Intravenous
2926067|NCT03067688|Active Comparator|Temisartan+Rosuvastatin|"60 subjects will be assigned and the subjects will be administered Micardis Tab. and Crestor Tab.(Temisartan+Rosuvastatin) for 8 weeks."
2926068|NCT03067675||Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device
2926069|NCT03067662|Experimental|Supervised exercise intervention|Women in the intervention group will perform low intensity aerobic exercise three times per week at 30% HRR (Heart Rate Reserve), under continuous heart rate monitoring. Duration of each session will progress from 26 minutes the first week to 40 minutes (by increasing 2 min/week).
2926070|NCT03067662|No Intervention|Current standard of care|Women in the control group will receive standard physical exercise recommendations.
2926071|NCT03067649|Experimental|Motivational Interview|After the assessment, parents were provided with a 90-minute intervention aimed at increasing the likelihood that the parent would seek treatment for psychiatric problems for themselves.
2926072|NCT03067649|Other|Information only control|After the assessment, parents were given pamphlet with referral information for psychiatric services.
2926073|NCT03067636|Active Comparator|Physical exercise + stress management activity A|Eight week program of concurrent exercise and stress management training.
2926074|NCT03067636|Active Comparator|Physical exercise + stress management activity B|Eight week program of concurrent exercise and stress management training.
2926075|NCT03067636|No Intervention|Lifestyle as usual|"Eight weeks period with no alteration of usual lifestyle.~Participants randomized to this arm are eligible for re-randomisation to one of the active conditions at the conclusion of week eight."
2926076|NCT03067623|Experimental|PRP-infusion|PRP will be obtained from a fresh whole blood collected from a peripheral vein; the blood sample will be centrifuged at 1500g (RCF) for 10 minutes and the repeated reversal of the tube will allow obtaining the PRP at the concentration required. Then 0,5-1ml of PRP will be infused into the uterine cavity through a Tomcat catheter. The endometrial thickening will be evaluated by ultrasonography 24-48h after the instillation and, if the endometrial lining reaches 7mm the Embryo-transfer will be arranged.
2926077|NCT03067610|Experimental|Radiation Therapy|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
2926078|NCT03067597|Experimental|Dinoprostone vaginal insert (DVI)|
2926079|NCT03067571|Experimental|Daratumumab|Participants receive Daratumumab by vein on Days 1, 8, 15, and 22 of Cycles 1 and 2, on Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond for up to 1 year or unless the disease stops responding to treatment, whichever is earlier.
2926080|NCT03067558||Accuracy evaulation|Three age groups (young infants 0 to <2 months, children 2 to <12 months and 12 to 59 months) will participate in the accuracy evaluation. Participants will be enrolled in a ratio 3:1 fast to normal breathers, by age group. Respiratory rate evaluations will be done using the ARIDA test device and the MK2 ARI timer (standard practice).
2926081|NCT03067558||Consistency evaluation|Two age groups (children 2 to <12 months and 12 to 59 months) will participate in the consistency evaluation. Participants will be enrolled in a ratio 3:1 fast to normal breathers, by age group. Respiratory rate evaluations will be done using the ARIDA test device and the MK2 ARI timer (standard practice).
2926082|NCT03067558||Respiratory rate fluctuation evaulation|Two age groups (children 2 to <12 months and 12 to 59 months) will participate in the respiratory rate fluctuation evaluation. All participants will be normal breathers.Respiratory rate evaluations will be done using the MK2 ARI timer (standard practice). The ARIDA test device will be strapped to the child during the manual RR count with MK2 ARI timer (standard practice).
2926083|NCT03067545|Experimental|step rate increase|increase in running stride rate by 10%
2926084|NCT03067532|Experimental|A|
2926085|NCT03067532|Active Comparator|B|
2926086|NCT03067519|Experimental|Fast track surgery|Intervention: Fast track surgery patients underwent early feeding and mobilization after surgery
2926087|NCT03067519|Active Comparator|Conventional management|usual postoperative care per surgeon
2926088|NCT03067506||Participants With Major Depressive Disorder (MDD)|Participants with MDD will be provided with an Apple watch on which brief cognitive and mood tests will be evaluated daily up to 6 weeks.
2926089|NCT03067493|Experimental|Neo-MASCT group|Patients in the treatment group will receive a total of 6 courses of Neo-MASCT treatment. The whole period of Neo-MASCT treatment for each patient will be up to 24 months.Three stratification factors are considered, i.e.tumor size (2.1-3.0cm, 3.1-5.0cm), tumor number (1, >1) and type of surgery (RFA，hepatectomy).
2926090|NCT03067493|No Intervention|Control group|Patients in the control group will be actively monitored during the trial period. Patients will receive assessment every 3 months in the first year and every 4 months in the second and third year.
2926091|NCT03067480|Experimental|3-Month iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
2926092|NCT03067480|Experimental|6-Month iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
2926093|NCT03067467|Active Comparator|Brain Tumor Patients|Brain Tumor patients will receive a bolus of Hyperpolarized 13C-pyruvate during MRSI.
2926094|NCT03067467|Active Comparator|Controls|Healthy Control subjects will receive a bolus of Hyperpolarized 13C-pyruvate during MRSI. This will be followed by a Brain MRI with gadolinium-based contrast.
2926095|NCT03067454|Other|conservative group|Treatment with early mobilisation
2926096|NCT03067454|Other|operative group|Treatment with operation
2926097|NCT03067441|Experimental|Open-Label bempedoic acid|bempedoic acid 180 mg tablet
2926098|NCT03067428|Active Comparator|Glucose|Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as glucose powder.
2926099|NCT03067428|Placebo Comparator|Fructose|Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as fructose powder.
2926100|NCT03067415|Experimental|D565H(Latanoprost 25㎍/㎖)|D565H(Latanoprost 25㎍/㎖)
2926101|NCT03067415|Active Comparator|D565(Latanoprost 50㎍/㎖)|D565(Latanoprost 50㎍/㎖)
2926102|NCT03067402|Other|Observation|Patient receives standard observation, i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years.
2926103|NCT03067402|Experimental|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
2926104|NCT03067389||History of invasive breast cancer|Subjects with a diagnosis of invasive breast cancer within the past 12 months will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.
2926105|NCT03067389||No history of invasive breast cancer|Subjects with no history of breast cancer will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.
2926106|NCT03067376|Experimental|[14C]--CORT125134|2 capsules each containing 125 milligrams (mg) [14C[-CORT125134 administered to each subject on 1 occasion
2926107|NCT03067363|Experimental|Part 1, MOR107 Dose level 1|MOR107, single subcutaneous injection
2926108|NCT03067363|Experimental|Part 1, MOR107 Dose level 2|MOR107, single subcutaneous injection
2926109|NCT03067363|Experimental|Part 1, MOR107 Dose level 3|MOR107, single subcutaneous injection
2926110|NCT03067363|Experimental|Part 1, MOR107 Dose level 4|MOR107, single subcutaneous injection
2926111|NCT03067363|Experimental|Part 1, MOR107 Dose level 5|MOR107, single subcutaneous injection
2926112|NCT03067363|Experimental|Part 1, MOR107 Dose level 6|MOR107, single subcutaneous injection
2926113|NCT03067363|Placebo Comparator|Part 1, Placebo|Placebo, single subcutaneous injection
2926114|NCT03067363|Experimental|Part 2: MOR107 low dose|MOR107 low dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
2926115|NCT03067363|Experimental|Part 2: MOR107 medium dose|MOR107 medium dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
2926116|NCT03067363|Experimental|Part 2: MOR107 high dose|MOR107 high dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
2926117|NCT03067363|Placebo Comparator|Part 2: Placebo|Placebo single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
2926118|NCT03067337|Experimental|Stainless Steel Crowns (Group A)|Groups that received Stainless Steel Crowns
2926119|NCT03067337|Experimental|Zirconia crowns (Group B)|Groups that received Zirconia crowns
2926120|NCT03067311|Experimental|I-CAT|A novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping given by trained clinicians.
2926121|NCT03067311|Active Comparator|Treatment as Usual|Usual treatment provided at the UNC OASIS Clinics by trained clinicians.
2926122|NCT03067285|Active Comparator|Arm 1|Patients who postpone switching from DTG/3TC/ABC to ELV/COBI/FTC/TAF four weeks:
2926123|NCT03067285|Experimental|Arm 2|Patients who switch from DTG/3TC/ABC to ELV/COBI/FTC/TAF during the baseline visit
2926124|NCT03067272|Experimental|FemBloc® Permanent Contraceptive System|Treatment of women who desire permanent birth control (female sterilization) by occlusion of the fallopian tubes.
2926125|NCT03067259|No Intervention|Control Group|It comprises patients who will not undergo any surgical / anesthetic act
2926126|NCT03067259|Other|Exposure Group|It comprises those patients that will undergo sedation for diagnostic procedure or some surgical / anesthetic process
2926127|NCT03067246|Active Comparator|VBM Intubating Laryngeal Tube|Device: VBM Intubating Laryngeal Tube Intervention: VBM Intubating Laryngeal Tube insertion, seal pressure, endotracheal intubation
2926128|NCT03067246|Active Comparator|I-Gel|Device: I-Gel Intervention: I-Gel insertion, seal pressure, endotracheal intubation
2926129|NCT03067233|Experimental|Polysomnography|Three polysomnographic recordings will be made on 3 consecutive nights with Electroencephalogry.
2926130|NCT03067220|Other|Standard outpatient clinic appointment|Patients will be sent an appointment letter to return to a scheduled outpatient clinic for review approximately 6 weeks after their discharge from hospital
2926131|NCT03067220|Experimental|Virtual out patient clinic appointment|Patients will be sent an appointment letter stating a specific day approximately 6 weeks after their discharge from hospital in which they will be contacted by telephone for a review by a junior doctor from the discharging team.
2926132|NCT03067207|Experimental|Experimental|The experimental arm will consist of four groups with a target of 15 participants each: one early intervention group, one wait-list in-person group, one early e-Health group and one wait-list e-health group. All participants will receive the mindfulness intervention, MARS-A, either in-person or via e-health by the end of the 6-month study period. Participants in the in-person groups will meet at in hospital at a designated teen-friendly room containing chairs and yoga mats. Participants in the e-health groups will be encouraged to find a quiet room in their home and will be required to have access to the Internet, a desktop/laptop computer equipped with a webcam or a tablet/smartphone with webcam function.
2926133|NCT03067207|Other|Feasibility|The feasibility arm, which will only take place if the targeted number of study participants (60) is not reached for the experimental arm, will be offered to participants who are not able to commit to the in-person mode of delivery. It will consist of two groups, one early e-health group and one wait-list e-Health group. The intervention delivered, MARS-A, will be identical as the intervention delivered to e-health groups in the experimental arm.
2926134|NCT03067194|Active Comparator|Celecoxib 100mg|Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
2926135|NCT03067194|Active Comparator|Celecoxib 200mg|Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
2926136|NCT03067181|Experimental|Arm I (bleomycin, carboplatin, etoposide)|Patients receive bleomycin IV over 10 minutes and carboplatin IV over 1 hour on day 1. Patients also receive etoposide IV over 1-2 hours on days 1-5. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2926137|NCT03067181|Experimental|Arm II (bleomycin, etoposide, cisplatin)|Patients receive bleomycin IV over 10 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2926164|NCT03067012|Experimental|Oncometabolic reconstruction|Patients undergoing oncometablic surgery
2926165|NCT03066999|Active Comparator|Cystoscopy|will have catheter placement using the cystoscopy method
2926138|NCT03067181|Experimental|Arm III (bleomycin, etoposide, carboplatin)|Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
2926139|NCT03067181|Experimental|Arm IV (bleomycin, etoposide, cisplatin)|Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
2926140|NCT03067181|Experimental|Low-Risk (observation)|Patients with stage I grade 2, 3 ovarian immature teratoma or low-risk stage I malignant germ cell tumors undergo observation and can transfer to standard risk arm when eligibility criteria are met.
2926141|NCT03067168|Active Comparator|Bupivacaine Arm|The subjects of this arm will receive an injection of 5mL of 0.5% bupivacaine, 1-2 cm deep to the surface of the vaginal epithelium into the levator ani muscle, puborectalis. A second injection of 5mL of 0.5% bupivacaine, 1-2 cm deep to the surface of the vaginal epithelium will be repeated on the same side, approximately 2-3 cm cephalad of the first injection at the iliococcygeus muscle. These 2 injections will then be repeated on the contralateral side.
2926142|NCT03067168|Placebo Comparator|Placebo Arm|The subjects of this arm will receive an injection of 5mL of 0.9% normal saline, 1-2 cm deep to the surface of the vaginal epithelium into the levator ani muscle, puborectalis. A second injection of 0.9% normal saline, 1-2 cm deep to the surface of the vaginal epithelium will be repeated on the same side, approximately 2-3 cm cephalic from first injection at the iliococcygeus muscle. These 2 injections will then be repeated on the contralateral side.
2926143|NCT03067155|Experimental|Treatment group|The patients for which a suitable donor product can be obtained will be included in the treatment arm of the protocol. Treatment consists of the administration of CMV-specific T-cells, administered through intravenous transfusion. Depending on response in viral load and GVHD status, a second and/or third administration is possible.
2926144|NCT03067155|Active Comparator|Control group|Patients for which the investigator can't obtain a suitable donor product, will be included in the control group consisting of standard anti-viral treatment.
2926145|NCT03067142||Cohort 1 (Phase 1): PH1|Cross-Sectional/Observational
2926146|NCT03067142||Cohort 2 (Phase 1): Controls|Cross-Sectional/Observational
2926147|NCT03067142||Cohort 3 (Phase 2): PH1|Longitudinal/Observational
2926148|NCT03067129|Experimental|Cohort 1: Adult formulation GLE/PIB subjects 12 to < 18yrs|Cohort 1: Adult formulation Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8, 12, or 16 weeks depending on their hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to < 18 years of age.
2926149|NCT03067129|Experimental|Cohort 4: Pediatric formulation GLE/PIB subjects 3 to < 6yrs|Cohort 4: Pediatric formulation GLE/PIB for 8, 12, or 16 weeks depending on their HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to < 6 years of age. Formulation details on GLE/PIB to be provided as part of a study protocol amendment.
2926150|NCT03067129|Experimental|Cohort 3: Pediatric formulation GLE/PIB subjects 6 to < 9yrs|Cohort 3: Pediatric formulation GLE/PIB for 8, 12, or 16 weeks depending on their HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to < 9 years of age. Formulation details on GLE/PIB to be provided as part of a study protocol amendment.
2926151|NCT03067129|Experimental|Cohort 2: Pediatric formulation GLE/PIB subjects 9 to < 12yrs|Cohort 2: Pediatric formulation GLE/PIB for 8, 12, or 16 weeks depending on their HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to < 12 years of age. Formulation details on GLE/PIB to be provided as part of a study protocol amendment.
2926152|NCT03067116||Subjects|Adult, healthy pregnant women undergoing Posturography Evaluation, Anthropometrics, Vitals and answering Health and daily activity questionnaires
2926153|NCT03067103|Active Comparator|tramadol|Tramadol group will receive 2 mg/kg (2 ml) through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
2926154|NCT03067103|Active Comparator|ketamine|Ketamine group will receive 0.5 mg/kg (2cc) through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
2926155|NCT03067103|Placebo Comparator|Placebo|Placebo group will receive 2mL of saline solution through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
2926156|NCT03067090|Experimental|Intra-articular Aquamid Reconstruction|Intra-articular injection of 3 ml aquamid reconstruction (AR) to the knee. A second injection of 3 ml will take place after 1 month (+/- 2 weeks).
2926157|NCT03067077|Active Comparator|SMILE|SMILE surgery
2926158|NCT03067077|Active Comparator|Wavefront-guided LASIK|Wavefront-guided LASIK
2926159|NCT03067051|Experimental|PDT and verteporfin dose finding|"Verteporfin and Interstitial Photodynamic Therapy are the interventions in this dose titration study.~The interventions will be light dose (as laser) using the SpectraCure P18 System and drug intervention with verteporfin as a photosensitizer.~The study will be conducted as a dose titration study to determine the light and drug threshold dose using the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software) and verteporfin for injection (VFI).~The light is delivered to the tumor via optical fibers and each dose arm will receive Interventional Photodynamic Therapy of Prostate Cancer combined with the drug verteporfin as a photosensitizer ."
2926160|NCT03067038|Active Comparator|Single incision LC|Single incision laparoscopic cholecystectomy (SILC) performed through a single infra-umbilical incision using a single port device or three ports closely placed.
2926161|NCT03067038|Sham Comparator|Three port LC|Three port laparoscopic cholecystectomy (TPLC) performed through three different placed trocars
2926162|NCT03067025||30 youth with MS|
2926163|NCT03067025||30 healthy control participants|
2926167|NCT03066986|Experimental|25mcg JJA venom|Subjects will receive semi-rush JJA VIT (without delta-inulin) aiming to achieve a maintenance dose of JJA venom of 25mcg (dose finding comparison).
2926168|NCT03066986|Experimental|25mcg JJA venom + 5mg delta-inulin|Subjects will receive semi-rush JJA VIT with delta-inulin (at a fixed dose of 5 mg with each dose of venom) aiming to achieve a maintenance dose of JJA venom of 25mcg (dose finding comparison, adjuvant comparison).
2926169|NCT03066986|Active Comparator|50mcg JJA venom|Subjects will receive semi-rush JJA VIT (without delta-inulin) aiming to achieve a maintenance dose of JJA venom of 50mcg, ie. the current standard of care.
2926170|NCT03066986|Experimental|50mcg JJA venom + 5mg delta-inulin|Subjects will receive semi-rush JJA VIT with delta-inulin (at a fixed dose of 5 mg with each dose of venom) aiming to achieve a maintenance dose of JJA venom of 50mcg (adjuvant comparison).
2926171|NCT03066973|Experimental|Intervention group|The trial compares nulliparous pregnant in the second stage of labor instructed regarding breathing exercise with a control group that received standard care service.
2926172|NCT03066973|No Intervention|Control group|control group that received standard care service.
2926173|NCT03066960|Active Comparator|Radiofrequency neurotomy group|Unilateral radiofrequency neurotomy of medial branches to the dorsal ramus at one or two cervical levels
2926174|NCT03066960|Sham Comparator|Sham group|Unilateral sham treatment of medial branches to the dorsal ramus at one or two cervical levels
2926175|NCT03066947|Experimental|SV-BR-1-GM Monotherapy|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation
2926176|NCT03066921|Placebo Comparator|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
2926177|NCT03066921|Experimental|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
2926178|NCT03066908|Experimental|Single Arm|Sinopsys® Lacrimal Stent
2926179|NCT03066895|Experimental|Experimental|BabyGentleStick
2926180|NCT03066895|Active Comparator|Standard of Care|HMC Standard Lancing Device
2926181|NCT03066882|Experimental|Study group I|Study group I (19 participants) received the NCD (details of diet: 15% protein, 75% carbohydrates, 10% fat). Both groups had 15% caloric restriction from their maintenance energy requirements.
2926182|NCT03066882|Experimental|Study group II|Study group II (18 participants) received the LCD or healthy weight maintenance diet (details of diet: 15% protein, 55% carbohydrates, 30% fat).Both groups had 15% caloric restriction from their maintenance energy requirements.
2926183|NCT03066869|Experimental|H.P. ACTHAR GEL|
2926184|NCT03066856|Experimental|Intervention|After baseline examinations, participants are randomized to an active dietary intervention group.The intervention group is invited to attend six full days of life-style intervention activities over the next six months. These activities include six cookery courses followed by lunch, six physical activity sessions (walking for 45 minutes) and six conferences. The intervention and control groups both complete questionnaires on adherence to the Mediterranean diet (MEDAS) at baseline and at the end of the study, and are asked for at least two 24-hour recalls of the previous day's food intake, and details of their physical exercise during the six-month intervention.
2926185|NCT03066856|No Intervention|Control|All participants receive general recommendations for the dietary prevention of cancer. After baseline examinations, women randomized in the control group carry on following the baseline recommendations.
2926186|NCT03066843|Experimental|Zero incubation with ALA (5-aminolevulinic acid)|Subjects will receive zero time of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.
2926187|NCT03066843|Experimental|One hour incubation with ALA (5-aminolevulinic acid)|Subjects will receive one hour of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.
2926188|NCT03066830|Experimental|Sotagliflozin|A dose of sotagliflozin will be administered as 2 tablets, once daily, before the first meal of the day
2926189|NCT03066830|Placebo Comparator|Placebo|A matching placebo will be administered as 2 tablets, once daily, before the first meal of the day
2926190|NCT03066817|Placebo Comparator|Vitamin D control|The control cohort will receive 50cc of propylene glycol as placebo via oral, nasogastric tube, or gastrostomy route on hospital admission.
2926191|NCT03066817|Experimental|Vitamin D intervention cohort|The intervention cohort will receive a one-time 400,000 IU liquid ergocalciferol (50cc of Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]) via oral, nasogastric tube, or gastrostomy route on hospital admission.
2926192|NCT03066804|Experimental|sacubitril/valsartan (LCZ696)|"All patients who fulfill the inclusion/exclusion criteria will be stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi. Patients in the ACEi strata will receive LCZ696 or enalapril. Patients in the ARB strata will receive LCZ696 or valsartan. Patients in the no RASi strata will receive LCZ696 or matching placebo.~Patients in the ACEi and ARB strata will take two pills twice daily for each dose: one tablet from the LCZ696 pack and one tablet from the comparator pack. Patients in the no RASi strata will take only one tablet twice daily (LCZ696 or matching placebo).~In the LCZ696 arm, patients will receive active LCZ696 in titrated doses from level 1 up to level 3 (50 mg, 100 mg and 200 mg twice daily orally)."
2926193|NCT03066804|Active Comparator|Comparator|"Patients randomized to the comparator arm will receive either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).~Patients in the ACE stratum randomized to comparator, will receive enalapril in titrated doses from level 1 up to level 3 (2.5 mg, 5 mg and 10 mg twice daily).~Patients in the ARB stratum randomized to comparator will receive valsartan in titrated doses from level 1 up to level 3 (40 mg , 80 mg and 160 mg twice daily).~Patients in the no RASi stratum randomized to comparator will receive LCZ696 matching placebo."
2926194|NCT03066791|Active Comparator|Turmeric group|"Turmeric Tablets:~Each tablet contains 1,000 mg of Turmeric (Curcuma Longa) per tablet. Dose: subjects will take 6 tablets per day, with a total daily dose of 6,000 mg.~Supplied by Sabinsa Corporation"
2926195|NCT03066791|Active Comparator|Curcumin Group|"Curcumin and Bioperine tablets:~Each tablet contains 1,000mg Curcumin + 1.25mg black pepper. Dose: subjects will take 6 tablets per day, with a total dose of 6,000mg curcumin.~Supplied by Sabinsa corporation"
2926196|NCT03066791|Placebo Comparator|Placebo Group|"Placebo tablets made to look like the turmeric and curcumin tablets~Each placebo tablet will contain: microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~Dose: subjects in this group will take 6 placebo tablets per day"
2926197|NCT03066778|Experimental|Pembrolizumab+EP|During each 21-day cycle, participants receive pembrolizumab 200 mg intravenously (IV) Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1).
2926198|NCT03066778|Active Comparator|Placebo+EP|During each 21-day cycle, participants receive placebo (normal saline solution) IV on Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an AUC 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1).
2926199|NCT03066765|Experimental|LTR Treatment|An implant device (Linguaflex Tongue Retractor) will be placed in the tongue and assessed for safety and efficacy
2926200|NCT03066752||7 pediatric-onset multiple sclerosis|
2926201|NCT03066752||7 non-patient healthy volunteers|
2926202|NCT03066739|Active Comparator|LO-low dose remifentanil|low dose remifentanil (LO, 0.1 micrograms/kg/mL),
2926203|NCT03066739|Active Comparator|HI-high dose remifentanil with placebo|high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)
2926204|NCT03066739|Active Comparator|HN-high dose remifentanil with ultra-low dose naloxone|high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone).
2926205|NCT03066726||CPR less than the 10%le|Group of patients with fetuses with cerebroplacental ratio less than 10%le
2926206|NCT03066726||CPR greater or equal than 10%le|Group of patients with fetuses with cerebroplacental ratio greater or equal than 10%le
2926207|NCT03066713|Experimental|Experimental: A|Skin On French Fry - breakfast Skin On French Fry - lunch Mashed Potatoes - dinner
2926208|NCT03066713|Experimental|Experimental: B|Skin Off French Fry - breakfast Skin Off French Fry - lunch Mashed Potatoes - dinner
2926209|NCT03066713|Experimental|Experimental: C|Hash brown - breakfast Hash brown - lunch Mashed Potato - dinner
2926210|NCT03066713|Experimental|Experimental: D|Pancake - breakfast Pretzels - lunch Macaroni - dinner
2926211|NCT03066700||Hemospray application|The patients with GI bleeding from tumor and received Hemospray as a hemostasis method.
2926212|NCT03066687|Experimental|Treatment Sequence 1: Erdafitinib 9 mg|Participants will receive 9 milligram (mg) dose of erdafitinib under fasted condition [Treatment A] in Period 1, and under fed (with high-fat and high-calorie breakfast) condition [Treatment B] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.
2926213|NCT03066687|Experimental|Treatment Sequence 2: Erdafitinib 9 mg|Participants will receive 9 mg dose of erdafitinib under fed (high-fat and high-calorie breakfast) condition [Treatment B] in Period 1, and under fasted condition [Treatment A] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.
2926214|NCT03066674|Experimental|McKenzie group|This group will receive Hand-on technique on the lumbar spine.
2926215|NCT03066674|Experimental|Control group|The Group will not receive Hand-on technique on the lumbar spine.
2926216|NCT03066648|Experimental|Decitabine and PDR001|Decitabine in combination with PDR001
2926217|NCT03066648|Experimental|Decitabine and MBG453|Decitabine in combination with MBG453
2926218|NCT03066648|Experimental|Decitabine, PDR001 and MBG453|Decitabine in combination with PDR001 and MBG453
2926219|NCT03066648|Experimental|MBG453|MBG453 alone
2926220|NCT03066648|Experimental|MBG453 and PDR001|MBG453 in combination with PDR001
2926221|NCT03066635|Experimental|Botulinum Toxin 25 IU|5 patients will be injected with 25 IU of Botulinum Toxin Type A towards the otic ganglion in the symptomatic side (ipsilateral to the pain)
2926222|NCT03066635|Experimental|Botulinum Toxin 12.5 IU|5 patients will be injected with 12.5 IU of Botulinum Toxin Type A towards the otic ganglion in the symptomatic side (ipsilateral to the pain)
2926223|NCT03066622|Active Comparator|Standard of Care|IV Morphine or any medication per attending decision
2926224|NCT03066622|Experimental|Olanzapine|oral rapidly dissolving olanzapine (Zydis) 5 mg for analgesia in acute primary headaches.
2926225|NCT03066609|Experimental|Secukinumab 150mg|Secukinumab 150mg s.c.
2926226|NCT03066609|Experimental|Secukinumab 300mg|Secukinumab 300mg s.c.
2926227|NCT03066609|Placebo Comparator|Placebo|Placebo to secukinumab s.c
2926228|NCT03066596|Experimental|PRAGMATIC|Intervention practices will receive guideline information and assess children's asthma severity and control. For children with persistent/uncontrolled asthma, academic detailing and prompt in EHR following asthma guidelines will guide asthma management; outreach worker will follow up with patients referred to the by providers to receive care coordination to assure that provider management plan is followed by patient at home.
2926229|NCT03066583|Placebo Comparator|trephination with placebo|meniscal repair with trephination and placebo
2926230|NCT03066583|Experimental|trephination with platelet rich plasma|meniscal repair with trephination and platelet rich plasma
2926231|NCT03066570|Experimental|Single case study|Single case study using Graded exposure.
2926232|NCT03066557|Active Comparator|study group|TACE and Apatinib
2926233|NCT03066557|Experimental|control group|TACE alone
2926234|NCT03066544|Active Comparator|bupivacaine (Exparel)|subjects assigned by clinician's judgment - standard care choice A
2926235|NCT03066544|Active Comparator|naratriptan pill (Amerge)|subjects assigned by clinician's judgment - standard care choice B
2926236|NCT03066544|Active Comparator|dexamethasone tablet (Decadron)|subjects assigned by clinician's judgment - standard care choice C
2926237|NCT03066544|Active Comparator|ketorolac (Toradol)|subjects assigned by clinician's judgment - standard care choice D
2926238|NCT03066531|Experimental|ACT-based intervention|The ACT-based intervention integrates educational topics on heart healthy behaviours with mindfulness and acceptance training regarding difficult thoughts and feelings, clarification of health-related values and commitment to behave in the valued direction while contacting difficult experiences.
2926239|NCT03066531|Active Comparator|CBT-based intervention included in Usual Care|"These programs are based on current guidelines for the long- term multi-disciplinary rehabilitation and prevention of obese patients, including Cognitive Behavioral Therapy (CBT), in a group setting, as Gold Standard.~Assigned Interventions: Behavioral: usual care (CBT)"
2926240|NCT03066518|Placebo Comparator|Melatonin|Melatonin 5 mg, daily, eight weeks
2926241|NCT03066518|Placebo Comparator|placebo|Placebo, daily, eight weeks
2926242|NCT03066505|Active Comparator|Active MeRT Treatment|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks.
2926243|NCT03066505|Sham Comparator|Sham MeRT Treatment|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks. Sham treatment mimicks same noise and sensation of active treatment but provides no treatment.
2926244|NCT03066492|Active Comparator|Federally Qualified Health Center|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
2926245|NCT03066492|Experimental|Northwestern Follow Up Care Coordination|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
2926246|NCT03066479|Experimental|Fitbit|Patients will wear a Fitbit bracelet during their sleep study.
2926247|NCT03066466|Experimental|Arm A: Atorvastatin|The preventative atorvastatin treatment 40mg daily by mouth for GVHD will start at 14 days prior to transplant & continue until 365 days post-transplant or if significant adverse events occur. Patients will also receive our standard of care for graft versus host disease prevention which consists of two drugs, Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate 5mg/metered square will be administered IV post-transplant on Days 1, 3 & 6. Tacrolimus will be administered 2 days prior to transplant & continue approximately 180 days post-transplant. Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth.
2926248|NCT03066466|Active Comparator|Arm B: Standard of Care|Patients will receive our standard of care for graft versus host disease prevention which consists of two drugs, Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate 5mg/metered square will be administered IV post-transplant on Days 1, 3 & 6. Tacrolimus will be administered 2 days prior to transplant & continue approximately 180 days post-transplant. Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth.
2926249|NCT03066453|Experimental|Standard cure|Antibiotic IV (Nebcin) 14 days and 14 days of tobramycin IV
2926250|NCT03066453|Experimental|Short cure|antibiotic IV (Nebcin)14 days but with only 5 days of tobramycin IV followed 9 days of inhaled tobramycin (Tobi Inhalant Product)
2926251|NCT03066440|Placebo Comparator|Normal Saline|Intervention: intravenous solutions containing only normal saline as the primary base during the entire treatment of diabetic ketoacidosis.
2926252|NCT03066440|Experimental|Lactated Ringers|Intervention: intravenous solutions containing only lactated ringers as the primary base during the entire treatment of diabetic ketoacidosis.
2926253|NCT03066427|Experimental|Sunitinib|Sunitinib 50 mg/day, 4 weeks on/2weeks off
2926254|NCT03066414||non-obese patients with genetic hemochromatosis|"PATIENTS: Non-obese patients with genetic hemochromatosis undergoing a therapeutic bleeding.~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver."
2926255|NCT03066401||obese patients with dysmetabolic hyperferritinemia|"PATIENTS: obese patients with dysmetabolic hyperferritinemia undergoing a therapeutic bleeding.~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver."
2926256|NCT03066388|Experimental|Pulse pressure variations|Pulse pressure variations, stroke volume, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Pulse pressure variations are obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices.
2926257|NCT03066375|Experimental|Echocardiography-Doppler|Ultrasonographic recordings, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
2926258|NCT03066362|Experimental|Echocardiography-Doppler|Ultrasonographic recordings, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
2926259|NCT03066349||Patients with PCOS undergoing conventional ovarian stimulation|
2926260|NCT03066349||Patients with PCOS undergoing IVM|
2926261|NCT03066336|Experimental|Erchonia LunulaLaser|The Erchonia LunulaLaser emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
2926262|NCT03066323|Active Comparator|Tea extract|Rice with tea extract
2926263|NCT03066323|Placebo Comparator|No tea extract|Rice without tea extract
2926264|NCT03066310||Diagnosed Urinary Bladder Cancers|Patients who are being monitored for bladder cancer will be the experimental group to test the urine-DNA by next generation sequencing for bladder cancer biomarkers
2926265|NCT03066310||Non-Urinary Bladder Cancers|Patients being treated for gross hematuria will provide a negative control to provide data from testing by next generation sequencing for biomarkers in patients being treated for other diseases.
2926266|NCT03066297||Lobectomy|Lobectomy will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
2926267|NCT03066297||Segmentectomy|Segmentectomy will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
2926268|NCT03066297||Wide wedge resection|Wide wedge resection will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
2927042|NCT03060928|Active Comparator|Control|Arthroscopic Rotator Cuff Repair with standard treatment
2926269|NCT03066271|Experimental|Exercise + usual care|"The supervised exercise training is carried out on a ergometer cycle as individual daily (mon-fri) training and each exercise training session consists of 20min.~The training comprised a warm-up phase followed by 3 exercise phases. Warm-up consisted of 5min light stationary cycling, adjusted to 50-60% of the patients peak power output determine at the incremental cycle test (iPPO). The first exercise phase comprised of 5min interval training consisting of 5x30 sec intervals at 80-95% of the patient's iPPO. Between each interval, there is a 30 sec pause. The 2nd exercise phase consisted of 5min continuous cycling at an intensity equaling 80% of the patient's iPPO. The 3rd exercise phase was similar to the first exercise phase. Intensities increased progressively from the first week to the last week (from 50%, 80% and 70% of iPPO according to the three different phases to 60%, 95% and 80 % of iPPO respectively."
2926270|NCT03066271|Experimental|Control - usual care|The patients randomized to the control group received no training but will be wearing the activity tracker during the intervention.
2926271|NCT03066258|Experimental|Dose 1|3E9 GC of RGX-314
2926272|NCT03066258|Experimental|Dose 2|1E10 GC of RGX-314
2926273|NCT03066258|Experimental|Dose 3|6E10 GC of RGX-314
2926274|NCT03066258|Experimental|Dose 4|1.6E11 GC of RGX-314
2926275|NCT03066245|Experimental|MSC-PLGA|The lesion will be treated with curettage then 1 million of bone marrow derived MSC seeded on 5x5 mm2 PLGA scaffold will be engrafted in the cyst of ABC patient.
2926276|NCT03066219|Active Comparator|BRM421 Ophthalmic Solution|The active control with BRM421 solution
2926277|NCT03066219|Placebo Comparator|Placebo|The vehicle solution
2926278|NCT03066206|Experimental|Poziotinib - EGFR exon 20 mutant NSCLC|"Participant takes 2 Poziotinib tablets by mouth 1 time every day.~Each study cycle is 28 days.~Participant may continue taking the study drug for as long as the doctor thinks it is in their best interest."
2926279|NCT03066206|Experimental|Poziotinib - HER2 exon 20 mutant NSCLC|"Participant takes 2 Poziotinib tablets by mouth 1 time every day.~Each study cycle is 28 days.~Participant may continue taking the study drug for as long as the doctor thinks it is in their best interest."
2926280|NCT03066193|Experimental|Dronabinol|All participants will be titrated up on Dronabinol dose during the first week of the trial (2.5mg Dronabinol for 3 days and then 5mg Dronabinol for 4 days increasing to 10mg Dronabinol for the remainder of the trial). Dronabinol will only be increased to 10mg at the week 1 assessment if the subject is tolerating the 5mg dose of Dronabinol and the Dronabinol may be reduced based on patient side-effects. Participants will be receiving PEA concomitantly.
2926281|NCT03066193|Experimental|Palmitoylethanolamide|All participants will receive two 400mg tablets of PEA daily for the same 12 weeks that they receive the Dronabinol.
2926282|NCT03066180|Experimental|Group 1|Single study treatment (Viveve SUI treatment) will be administered.
2926283|NCT03066180|Experimental|Group 2|Two study treatments (Viveve SUI treatments) will be administered approximately 6 weeks apart.
2926284|NCT03066167||Patients|Patients with oesophageal cancer and dysphagia
2926285|NCT03066167||Controls|Healthy Controls with no known dysphagia
2926286|NCT03066154|Experimental|N15DOP|Chemoradiation with ModraDoc/r and radiotherapy of the prostate in dose escalation design, followed by maintenance treatment.
2926287|NCT03066141||CAD with OSA|coronary artery disease with Obstructive sleep apnea
2926288|NCT03066141||CAD without OSA|coronary artery disease without Obstructive sleep apnea
2926289|NCT03066128|Experimental|Intervention|Participants in the Intervention Group will receive chronic ART management from a Professional Nurse and/or Enrolled Nurse every 2 months, and if stable after 6 months, community pharmacy ART collection through CCMDD. Viral load monitoring will be by a point-of-care viral load testing.
2926290|NCT03066128|Experimental|Standard of Care|Participants in the Standard-of-Care control arm will receive the standard-of-care for the clinic consisting of visits with a professional clinician (Physician or Professional Nurse) and once stable, community pharmacy ART collection through CCMDD.Viral load monitoring will be by lab-based viral load testing
2926291|NCT03066115|Experimental|NOS, COX, and ROS Inhibition|Subjects will receive L-NMMA, ketorolac, then ascorbic acid via intravenous catheter. L-NMMA will have a 3 mg kg-1 loading dose over 5-minutes (36 mg kg-1 hr-1), followed by a maintenance dose of 1 mg kg-1 hr-1. Ketorolac will have a 0.3 mg kg-1 loading dose over 5 minutes (3.6 mg kg-1 hr-1) with a minimum loading dose of 15 mg. This will be followed by a maintenance dose of 0.03 mg kg-1 hr-1. Ascorbic acid will have a loading dose of 0.035 g kg fat-free mass-1 over 5-minutes (0.42 g kg fat-free mass-1 hr-1), followed by a maintenance dose of 0.060 g kg fat-free mass-1 hr-1. Cerebral blood flow velocity will be measured throughout the drug infusions via transcranial Doppler ultrasound.
2926292|NCT03066115|Experimental|COX, NOS, and ROS Inhibition|"Subjects will receive ketorolac, L-NMMA, then ascorbic acid via intravenous catheter.~Ketorolac will have a 0.3 mg kg-1 loading dose over 5 minutes (3.6 mg kg-1 hr-1) with a minimum loading dose of 15 mg. This will be followed by a maintenance dose of 0.03 mg kg-1 hr-1. L-NMMA will have a 3 mg kg-1 loading dose over 5-minutes (36 mg kg-1 hr-1), followed by a maintenance dose of 1 mg kg-1 hr-1. Ascorbic acid will have a loading dose of 0.035 g kg fat-free mass-1 over 5-minutes (0.42 g kg fat-free mass-1 hr-1), followed by a maintenance dose of 0.060 g kg fat-free mass-1 hr-1. Cerebral blood flow velocity will be measured throughout the drug infusions via transcranial Doppler ultrasound."
2926293|NCT03066089|Experimental|Group A|Fenfuro 500 mg capsule by mouth, BD (two times a day), till next follow-up
2926294|NCT03066089|No Intervention|Group B|Investigational product is not being administered to this arm. This arm will regularly be observed on follow-up and laboratory investigations will be performed.
2926295|NCT03066076|Active Comparator|Thyroidectomy|Total thyroidectomy
2926296|NCT03066076|Active Comparator|Antithyroid drug|Thiamazol, Propylthiouracil
2926297|NCT03066050||SMR MV Repair|This group of patients had been randomized in the SMR study to mitral valve repair with annuloplasty ring.
2926298|NCT03066050||MV Replacement|This group of patients had been randomized in the SMR study to mitral valve replacement.
2926299|NCT03066050||MMR MV Repair|This group of patients had been randomized in the MMR study to mitral valve repair with annuloplasty ring.
2926300|NCT03066050||CABG|This group of patients had been randomized in the MMR study to receive CABG
2926301|NCT03066024||Children and adolescents|Children and adolescents for elective surgery
2926302|NCT03066011||Isavuconazonium sulfate Group|Oral and Intravenous
2926303|NCT03066011||Voriconazole Group|Oral and Intravenous
2926305|NCT03065998|Active Comparator|Drug-A|opripramol 150 mg per day (3*50) Opipramol is a selective agonist for sigma-1 receptor. It is clinically used as an antidepressant and anxiolytic agent.
2926306|NCT03065998|Active Comparator|Drug-B|baclofen 90 mg per day (3*30) Baclofen is a GABAb-1 antagonist and has shown partial efficacy in suppressing withdrawal symptoms in alcohol addicts and cocaine.
2926307|NCT03065985|Experimental|chemotherapy plus 3 radiofrequency ablation procedures|
2926308|NCT03065985|Active Comparator|standard chemotherapy|
2926309|NCT03065972|Active Comparator|Surgical fistula creation from patient's anatomy|Patients randomized to surgical arteriovenous fistula will have a fistula surgically created from their anatomy to be used for hemodialysis access.
2926310|NCT03065972|Active Comparator|Surgical graft implant|Patients randomized to surgical graft, will have a commercially available graft surgically implanted to be used for hemodialysis access.
2926311|NCT03065959|Experimental|CK-2127107, then Placebo|Participants will first receive CK-2127107 tablets (twice daily) for 14 days. After a 14 day wash out period participants will then receive matching placebo.
2926312|NCT03065959|Experimental|Placebo, then CK-2127107|Participants will first receive Placebo tablets (twice daily) for 14 days. After a 14 day wash out period participants will then receive matching CK-2127107.
2926313|NCT03065946||Case series|Early wakening
2926314|NCT03065933|Experimental|clonidine as an antimanic agent|Subjects with Bipolar Disorder, Mania receive an extended-release form of clonidine on the second day of this 3-day study. Rating scales, record of sleep, and a questionnaire of adverse effects is recorded on each of the three days.
2926315|NCT03065907|Active Comparator|Vision Rehabilitation Group 1|Vision rehabilitation assessment will be scheduled within 1 months of randomization; interventions will be scheduled and vision rehabilitation appointments will be scheduled accordingly.
2926316|NCT03065907|Active Comparator|Vision Rehabilitation Group 2|Vision rehabilitation assessment will be scheduled within 7 months of randomization; interventions will be scheduled and vision rehabilitation appointments will be scheduled accordingly.
2926317|NCT03065894|Experimental|Stratified Care|"In three Participating Sites from Family Medicine sites, the Keele STarT Back Screening Tool will be administered to patients with acute and chronic low back pain and based on patients' responses, patients will be stratified into one of three risk groups: low, medium or high-risk. Patients in the medium- and high-risk groups will be referred to physical therapy for a matched physical therapy (PT) intervention based on the risk strata. Patients in the low-risk group will be managed in Family Medicine with an intervention that includes advice, reassurance, patient education, and NSAIDs (with no referral for imaging or specialist care)."
2926318|NCT03065894|Active Comparator|Current Care|"In three Comparator Sites from Family Medicine, providers will give the current care at The University of Vermont Medical Center for patients with acute and chronic low back pain."
2926319|NCT03065881|Active Comparator|Dilated versus Natural pupil|
2926320|NCT03065881|Active Comparator|Normal retina versus abnormal retina|
2926321|NCT03065868|Experimental|eradictaion|H. pylori eradication group
2926322|NCT03065868|No Intervention|non-eradication|H. pylori non-eradication group
2926323|NCT03065855|Experimental|Early removal group|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 2 days following surgery.
2926324|NCT03065855|Active Comparator|Normal removal group|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
2926325|NCT03065842|Experimental|Abortion- and contraceptive-use stigma reduction program|Four sessions (à 120 min), every week in 1 month.
2926326|NCT03065842|Active Comparator|Usual standards|Usual standards
2926327|NCT03065829|Experimental|ASSIST|The ASSIST intervention will deliver daily doses of MMT and vary dose intensity of all components each day based on the subject's biophysical data. Across a 30-day period, the ASSIST intervention will capture and analyze data to deliver on-demand MMT, guided practices to promote sleep hygiene and physical activity. Each day, subjects will receive at least one prompt to practice MMT (about 5 minutes at a time). However, based on the subject's biophysical sensor data, subjects could receive a maximum of 5 alerts or prompts per day from the device to enhance stress reduction, sleep hygiene, or physical activity.
2926328|NCT03065829|Experimental|Attention-Control|This intervention exposes subjects to the wearable technology without the self-management components to minimize novelty effects. Subjects assigned to this condition will wear the device for 30 days, which offers them an opportunity to experientially learn to self-monitor and employ self-regulatory skills by viewing the display biophysical data. Subjects in this condition will not receive any prompts from the device.
2926329|NCT03065816|Experimental|Sequence 1 (Z0063 to Gaviscon)|The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose
2926330|NCT03065816|Experimental|Sequence 2 (Gaviscon to Z0063)|The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose
2926331|NCT03065803|Active Comparator|Buccal plate expansion technique in dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
2926364|NCT03065530|Experimental|Dexmedetomidine 0.05ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.05ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
2926332|NCT03065803|Other|Guided Bone regeneration technique for socket preservation|On buccal side, two vertical incisions will be made at mesial and distal papilla of the adjoining teeth. These incisions will be stretched out past mucogingival junction. After full‑thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed. The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension‑free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0) (Sadeghi et al., 2016).
2926333|NCT03065777|Experimental|ONE ENDO|Single file rotary system
2926334|NCT03065777|Experimental|F6 SKYTaper|Single file rotary system
2926335|NCT03065777|Active Comparator|ProTaper Universal|Muti-file rotary system
2926336|NCT03065764|Other|Patients|For the first 3 patients, PET scans will be obtained at 1, 72 and 120 hours post tracer injection to determine the optimal scan time point and to perform biodistribution measurements and dosimetry. All subsequent 7 patients receive only 1 PET scan post-injection (i.e. two PET scans).
2926337|NCT03065751|Active Comparator|TPE|
2926338|NCT03065751|No Intervention|Kontroll|
2926339|NCT03065738|Experimental|osteoarthritis knee ,severe varus deformity|reduction osteotomy in total knee replacement
2926340|NCT03065712|Experimental|FES PET/CT|"This is a single arm study that involves FES PET/CT.~Procedure: Computed Tomography~Drug: [F-18] fluoroestradiol: [F-18]FES~Other: Laboratory Biomarker Analysis~Procedure: Positron Emission Tomography"
2926341|NCT03065699|No Intervention|Standard of Care|For patients with ACLF grade 1 or 2 and randomised to the 'Standard of care' arm, the location of treatment (ICU or general ward) will be determined by their clinical need and will be decided by the site Principal Investigator. They will receive standard of care.
2926342|NCT03065699|Active Comparator|DIALIVE Liver Dialysis Device treatment arm|Patients with ACLF grade 1 and ACLF grade 2 on the background of alcoholic cirrhosis randomized to the DIALIVE arm will receive treatment in an intensive care (ICU) or renal dialysis unit setting. They will receive DIALIVE treatment according to a fixed treatment schedule over a period of 10 days post-randomization.
2926343|NCT03065686|Experimental|Identification of genetic factors|Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
2926344|NCT03065673|Active Comparator|Potassium Oxalate 5% gel|The patient will receive the application of potassium oxalate 5% gel on vestibular surface teeth, for 10 minutes.
2926345|NCT03065673|Placebo Comparator|Placebo gel|The patient will receive the application placebo gel on vestibular surface teeth, for 10 minutes.
2926346|NCT03065660|Active Comparator|Mifepristone|A single dose of oral mifepristone 200mg, followed by a single dose of vaginal, oral or sublingual misoprostol 800mcg 2 days later
2926347|NCT03065660|Placebo Comparator|Placebo|Oral placebo tablet followed by a single dose of vaginal, oral or sublingual misoprostol 800mcg 2 days later.
2926348|NCT03065647|No Intervention|Standard Care|Basic Life Support (BLS) and Advanced Cardiovascular Life Support (ACLS) by Emergency Medical Services (EMS) per existing EMS protocols at the scene of the cardiac arrest.
2926349|NCT03065647|Experimental|Expedited Transport|"Intervention: Expedited Transport with Mechanical CPR.~After initial Basic Life Support (BLS) and Advanced Cardiovascular Life Support (ACLS) by Emergency Medical Services (EMS) per existing EMS protocols, patients with refractory cardiac arrest are transported to an ECPR capable emergency department with ongoing mechanical CPR and ACLS for possible initiation of extracorporeal cardiopulmonary resuscitation (ECPR)."
2926350|NCT03065634|Experimental|Manualized RELIANCE intervention|Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions.
2926351|NCT03065634|Active Comparator|Non-manualized socio-legal counseling|two socio-legal counseling sessions delivered by a social worker
2926352|NCT03065621|Experimental|Palbociclib with Endocrine Therapy|All subjects will receive palbociclib 125 mg for 4 cycles, orally, once a day, for 21 days followed by 7 days of rest (4 cycles of 28 day long). After the final rest week (therefore post cycle 4), subjects will receive 3 to 7 additional days of palbociclib, as necessary, at the same dose and posology, until the day before curative intent surgery. Depending upon the menopausal status, the patient will receive either letrozole or tamoxifen continuously during the palbociclib treatment (which consists of 4 cycles of 28 days).
2926353|NCT03065608||Study Group|The study group included 36 patients with pain form of dysfunction.
2926354|NCT03065608||Control Group|The control group consisted of 36 patients with painless form of disorder.
2926355|NCT03065595|Placebo Comparator|Intervention|Ophicephalus striatus extract
2926356|NCT03065595|Active Comparator|Control|Placebo drug
2926357|NCT03065582|Experimental|Sunscreen application|All subjects will undergo topical application of 3 products and an additional site will serve as a control
2926358|NCT03065569|Active Comparator|Standard Epidural Technique|Epidural will be performed Initial dose of 16 mL of 0.125% bupivacaine will be given Upon patient request, rescue bolus based on protocol will be administered.
2926359|NCT03065569|Experimental|Combined Spinal Epidural Technique|CSE will be performed Initial dose of 16 mL of 0.125% bupivacaine will be given Upon patient request, rescue bolus based on protocol will be administered.
2926360|NCT03065556|Experimental|188-0551 Solution|188-0551 Solution applied topically twice daily
2926361|NCT03065556|Placebo Comparator|Vehicle Solution|Vehicle Solution applied topically twice daily
2926362|NCT03065530|Placebo Comparator|control group|"The placebo group will pumped in the same volume of saline 0.9% as calculated by parturients' weight in 30 min and receive 1mg butorphanol after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
2926363|NCT03065530|Experimental|Dexmedetomidine 0.03ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.03ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
2926480|NCT03064698||Abnormal second trimester Doppler|This group consists of women who had abnormal doppler ultrasound results at second trimester
2926365|NCT03065530|Experimental|Dexmedetomidine 0.08ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.08ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
2926366|NCT03065517|Experimental|VillageWhere App|Parent-youth dyads assigned to the VillageWhere condition will be asked to use the VillageWhere App that has been developed for this study. Parent and youth will be asked upload the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 16 week trial. The app is designed to be used several times throughout each day.
2926367|NCT03065517|Placebo Comparator|Attention-Control Placebo App|Parent-youth dyads assigned to the control condition will be asked to use a free placebo control app that is well-liked by parents and youth but void of content already part of an existing evidence-based treatment for youth with conduct problems (e.g., geolocation tracking). Parent and youth will be asked upload the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 16 week trial.
2926368|NCT03065504|Active Comparator|Turmeric group|"2,000 mg turmeric per day - supplied by Banyan® Botanicals )~o Each tablet contains 500 mg of Turmeric (Curcuma longa). Subjects will take 2 tablets twice per day, with a total daily dose of 2,000 mg."
2926369|NCT03065504|Active Comparator|Turmeric-containing combination tablets|"• 2,000 mg Healthy Skin™ Tablets, contains:~Turmeric (Curcuma longa) - 50 mg/tablet~Hemidesmus Indicus root (Anantamul)~Indian Madder root~Neem leaf~Gotu Kola leaf~Indian TInospora stem~Amla fruit~Licorice root~Phyllanthus Amarus herb Each tablet contains 500mg total of the above herbs. There is 50 mg of Turmeric in each Healthy Skin ™ tablet. Subjects will take 2 tablets twice per day, which will be a total daily dose of 200 mg of Turmeric. This is comparable to the daily amount of Turmeric in many commercially-available Turmeric supplements; therefore, it is valuable to compare this formulation to the turmeric-only tablets."
2926370|NCT03065504|Placebo Comparator|Placebo tablets group|"Supplement appearing similar to those in the turmeric and curcumin groups, supplied by Banyan® Botanicals~Ingredients (all organic): Placebo ingredients: Rice hulls concentrate, Maltodextrin, Micro Crystalline Cellulose, Beet Root Powder, Dutch coco powder~Dose: subjects in this group will take 2 tablets twice per day"
2926371|NCT03065491|Active Comparator|Active treatment|Combined nutraceutical
2926372|NCT03065491|Placebo Comparator|Placebo|Placebo
2926373|NCT03065478||Colon carcinoma|"Dietary supplementation with OnLife to improve signs and symptoms of CIPN in adult colon cancer patients who experienced a CIPN after adjuvant oxaliplatin-containing chemotherapy."
2926374|NCT03065478||Mamma carcinoma|"Dietary supplementation with OnLife to improve signs and symptoms of CIPN in adult breast cancer patients who experienced a CIPN after adjuvant paclitaxel regimen."
2926375|NCT03065465|Other|Standard endoscopic treatment|For those assigned to the standard endoscopy group, endoscopic hemostasis will be performed using usual Center for Ulcer Research and Education (CURE) hemostasis therapy for the focal GI lesions: injection of dilute (e.g. 1:20,000) epinephrine (in 1-2 cc aliquots in 4 quadrants next to the stigmata of recent hemorrhage - SRH), coaptive coagulation with multipolar electrocautery (MPEC) probe, and/or standard through the endoscope hemoclips along the course of the underlying artery as detected by Doppler endoscopic probe (DEP). Hemostasis will be performed until active bleeding stops and/or the SRH is obliterated.
2926376|NCT03065465|Experimental|Over-the-scope hemoclipping device|For those assigned OTSC, the device will be used according to manufacturer instructions. Once the endoscopic diagnosis is made, the endoscope will be removed and affixed with the OTSC of appropriate size for the endoscope and the lesion in question. The endoscope will be re-introduced to the bleeding site. The SRH will be centered in the field of view and within the cap of the OTSC deployment device. The lesion and SRH will be captured into the cap and the OTSC will be deployed by rotating the handle and thereby compressing the bleeding lesion and surrounding tissue for mechanical hemostasis. If initial deployment is unsuccessful due to technical factors or if hemostasis is not achieved, a second deployment will be allowed.
2926377|NCT03065452||Patients who underwent open decompression surgery|Observational study on patients who underwent open decompression surgery
2926378|NCT03065439|Experimental|STarT Back Tool group 3|Patients scored as high risk patients by the STarT Back Tool
2926379|NCT03065439|Experimental|STarT Back Tool groups 1+2|Patients scored as low risk or medium risk patients by the STarT Back Tool
2926380|NCT03065426||Roux-en-Y Gastric Bypass|Patients planning to undergo Roux-en-Y Gastric Bypass will be invited to participate in this study.
2926381|NCT03065426||Sleeve Gastrectomy|Patients planning to undergo Sleeve Gastrectomy will be invited to participate in this study.
2926382|NCT03065400|Experimental|Pembolizumab|
2926383|NCT03065387|Experimental|Neratinib and Everolimus|"Neratinib by mouth 1 time a day with food, preferably in the morning, every day.~Everolimus by mouth 1 time a day with Neratinib every day.~Study cycle is 28 days."
2926384|NCT03065387|Experimental|Neratinib and Palbociclib|"Palbociclib by mouth 1 time a day with Neratinib, every day for 3 weeks followed by a 1-week rest period during each cycle.~Study cycle is 28 days."
2926385|NCT03065387|Experimental|Neratinib and Trametinib|"Trametinib by mouth 1 time a day with Neratinib every day.~Study cycle is 28 days."
2926386|NCT03065374|Experimental|Treatment arm A|IMM-529, 1000 mg three times daily, orally
2926387|NCT03065374|Placebo Comparator|Treatment arm B|Matching Placebo, three times daily, orally
2926388|NCT03065361||Group A|"Group composed of 21 children and adolescents aged between 9 and 19 years old, treated by hemodialysis in two hospitals of Belo Horizonte. Just in case of some evidence of difference in the results within group A, because of the two types of dialysis (via fistula or catheter), this group can be subdivided in subgroups A1 (n=10) and A2 (n=11), respectively.~Group A was already on hemodialysis, the intervention was not performed by the researcher. Our goal was only to evaluate some characteristics of these individuals."
2926389|NCT03065361||Group B|Group composed of 21 children and adolescents matching age and gender for the Group A participants. The individuals were recruited in schools of Belo Horizonte.
2926473|NCT03064776|Experimental|m-RESIST Caregivers|m-RESIST is a system designed to improve illness self-knowledge and facilitate the involvement of caregivers in treatment of individuals with treatment-resistant schizophrenia.
2926516|NCT03064386|Experimental|screw group|internal fixation with the screw
2926390|NCT03065348|Experimental|Intervention|"Around 2 to 4 weeks before surgery:~Fried frailty score~CARE score assessment~NRS Kondrup assessment~Plasma albumin and CRP values~Start with daily oral whey protein administration until evening before surgery45~Around 5-7 days before surgery:~- Start with immunonutrition~Evening before surgery:~CARE score assessment~NRS Kondrup~CERAD cognition test assessment~Plasma albumin and CRP values, urine specific gravity~Carbohydrate loading~If urine specific gravity is >1.020 then additional tap water drinking will be encouraged~Day of surgery:~Carbohydrate loading~Start anesthesia with spinal anesthesia (continuous)~POD 7:~CARE assessment~CERAD assessment~Plasma albumin and CRP values~POD14:~CARE assessment~Plasma albumin and CRP value~POD 30:~CARE assessment~NRS Kondrup~CERAD assessment~Plasma albumin and CRP values~POD 90:~CARE assessment~NRS Kondrup~CERAD assessment"
2926391|NCT03065335|Placebo Comparator|Phase II Arm 2a|Double-blind, single dose of 0.5 mg/kg IV saline
2926392|NCT03065335|Experimental|Phase II Arm 1a|Double-blind, single dose of 0.5 mg/kg IV ketamine concurrently with MEG
2926393|NCT03065335|Experimental|Phase III|Double-blind, repeated dose of 0.5 mg/kg or 0.1 mg/kg IV ketamine
2926394|NCT03065335|No Intervention|Phase IV|Follow-up evaluations
2926395|NCT03065335|No Intervention|Phase I|Medication taper, drug-free period, and baseline assessments
2926396|NCT03065335|Placebo Comparator|Phase II Arm 2b|Double-blind, single dose of 0.5 mg/kg IV saline, concurrently with fMRI+EEG or MEG.
2926397|NCT03065335|Experimental|Phase II Arm 1b|Double-blind, single dose of 0.5 mg/kg IV ketamine, concurrently with fMRI+EEG
2926398|NCT03065335|Experimental|Metabolites Substudy|Open-label, single dose of 0.5 mg/kg IV ketamine
2926399|NCT03065322||Women with PCOS|Women with confirmed diagnosis of PCOS, based on the Rotterdam Criteria. To assess risk of OSA: the risk of OSA will be assessed using the Berlin questionnaire and the Epworth Sleepiness Scale (ESS). Women with at high risk of OSA will have home-based sleep studies performed.
2926400|NCT03065309|Experimental|Single Arm|Patients will receive bolus dose of remifentanil before intubation
2926401|NCT03065296|Experimental|Musculoskeletal (MSK) Exercise Prescription|"Phase I: Residents will be surveyed as to their knowledge and confidence in both diagnosing specific musculoskeletal (MSK) issues and prescribing the correct home rehabilitation regimen.~In between phase 1 and phase 2 there will be a series of didactic lectures to educate resident on home exercise prescription and get them familiarized with the handouts.~Phase II: Residents will be surveyed again in May 2017 with the same multiple choice questions and Likert style confidence scales from phase 1~The survey will consist of multiple choice and short essay questions, focused on the most common musculoskeletal (MSK) injuries seen in the primary care setting."
2926402|NCT03065283|Active Comparator|Diaphragmatic release|The stretching of the peripheral fibers of the diaphragm
2926403|NCT03065283|Placebo Comparator|Diaphragmatic release control|In both placebo techniques, only the light touching of the contacts of the volunteers' skin
2926404|NCT03065270|Experimental|A group|
2926405|NCT03065270|Experimental|B group|
2926406|NCT03065257||Endoscopic Resection|Patients undergoing Endoscopic Resection
2926407|NCT03065244|Active Comparator|IVIG|Patient will be randomly assigned to receive a second IVIG infusion: 2 g/kg IV over 8-10 hours single infusion
2926408|NCT03065244|Active Comparator|Infliximab|Patient will be randomly assigned to receive Infliximab 10 mg/kg IV over 2 hours
2926409|NCT03065231|Active Comparator|EVD|Patients will have extraventricular drain to manage CSF subarachnoid blood.
2926410|NCT03065231|Active Comparator|LD|Patients will have lumbar drain to manage CSF subarachnoid blood.
2926411|NCT03065218|Experimental|99mTc sestamilbi|25 mCi 99mTc sestamibi intravenous injection, once. Then imaged for 45 minutes. More imaging might be required and this will be determined by a nuclear medicine physician onsite
2926412|NCT03065205|Experimental|Single Arm|Patients will have adherence monitoring devices placed on their asthma inhalers (both daily and rescue medication). Adherence information will be sent to their PCP, specialist and school nurse monthly. Additionally, the navigator will speak with families every 2 months to discuss adherence data and address barriers.
2926413|NCT03065192|Experimental|VY-AADC01 Single Dose|9.4 x 10^12 vector genomes of VY-AADC01
2926414|NCT03065179|Experimental|Nivolumab/Ipilimumab plus SBRT|Induction Dual Immune Checkpoint Inhibition with nivolumab and ipilimumab plus SBRT to 1-2 metastatic sites, followed by nivolumab monotherapy
2926415|NCT03065166|Experimental|Raisin Treatment|3.2 ounces of dried Cabernet wine grapes.
2926416|NCT03065166|Other|Bagel Control|One 95g whole wheat bagel.
2926417|NCT03065153||Healthy|Healthy individuals without any neurological or orthopaedic disorder that could influence motor performance and balance
2926418|NCT03065153||Stroke|Individuals suffered from a haemorrhagic or ischaemic stroke. Diagnosis has to be confirmed on the basis of CT or MRI imaging.
2926419|NCT03065140|Experimental|Healthy Volunteers|"Healthy volunteers will undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy Followed by a period of detraining.~They will then undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy"
2926420|NCT03065140|Experimental|Diabetic Patients|"Diabetic patients will undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy They will then undergo a supervised training period.~They will then undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy"
2926421|NCT03065127|Experimental|Cognitive Training|"Participants will independently complete cognitive exercises on the Smartbrain Pro computer software. These exercises aim to train different aspects of executive function. The difficulty level of each exercise will increase relative to each participant's progress. Sessions will last for one hour, occurring twice weekly for a period of 4 weeks."
2926422|NCT03065127|Experimental|Cognitive Behavioural Therapy|Participants will undergo one-on-one sessions of cognitive-behavioural therapy (CBT) working with a therapist to establish an individualized CBT plan which will focus on symptoms of anxiety. Participants will complete a total of eight one-hour sessions over 4 weeks.
2926474|NCT03064763|Experimental|talimogene laherparepvec|All subjects will receive open-label talimogene laherparepvec
2926475|NCT03064750|Experimental|Pre-surgery exercise|pelvic floor exercises individually and in groups
2926476|NCT03064750|Other|Waiting list|wait as usual until surgery
2926477|NCT03064737|Other|This study is a non-drug one arm study|Skin biopsy for genetic analyze
2926423|NCT03065127|Experimental|Proprioceptive Training|Participants will complete one-on-one sessions a target matching proprioceptive training protocol using their upper and lower limbs. For the upper limb target-reaching task, participants will be seated in front of a surface marked with ten targets. They will first visualize a specified target, then blindfolded and asked to reach towards that target with the blindfold on. The blindfold will then be removed allowing participants to view their performance relative to the target. This task will be repeated for the remaining targets on both sides and for both upper and lower limbs. Participants will complete a total of eight one-hour sessions over 4 weeks.
2926424|NCT03065114||PGSno.|blastocysts from patients underwent preimplantational genetic screen (PGS) prtocols. only euploid embryos were selected to transfer.
2926425|NCT03065101|Other|Trigen Intertan|"Unique integrated interlocking screw and trapezoidal nail shape~Resistance to femoral head rotation and cut-out~Active compression through linear motion without rotation~Single subtrochanteric lag screw option for stable fractures below lesser trochanter~Preloaded cannulated set screw converts construct to fixed angle device~Small proximal diameter of the nail promotes preservation of the lateral wall of the greater trochanter and gluteus medius tendon~Clothespin tip for stress modulation in femoral shaft~Potential for improved patient mobility and recovery~Manufactured by Smith & Nephew Inc., 1450 Brooks Road, Memphis, TN 38116, U.S.A.~Interventions:~Randomisation to either Trigen Intertan or Sliding Hip Screw, Post-Surgery Follow Up"
2926426|NCT03065101|Other|Sliding Hip Screw|"SHS is a generic term for a group of devices used for internal fixation of trochanteric hip fractures. Also known as Compression Hip Screw or Dynamic Hip Screw. All devices feature a lag screw inserted into the femoral neck and a side plate held in place by cortical screws inserted into the proximal femoral shaft.~Therapeutic effect is achieved by guided collapse, where the lag screw can slide in the barrel of the side plate which compresses the fracture as the patient begins to weight-bear.~Participating sites may use whichever brand of SHS is currently in use.~Interventions:~Randomisation to either Trigen Intertan or Sliding Hip Screw, Post-Surgery Follow Up"
2926427|NCT03065088|Experimental|aLiFE|The aLiFE programme is developed for young older adults, where balance activities, strengthening activities, and specific recommendations for increasing physical activity, are embedded within everyday activities, so that the activities can be performed multiple times throughout the day. The programme is presented by an instructor by use of a paper based manual during a 6 month intervention period in participants homes.
2926428|NCT03065088|Experimental|eLiFE|The aLiFE programme is transferred to a mobile health system, called the eLiFE. The intervention is delivered on smartphones and smartwatches including inertial sensors well suited to monitor physical activity and movement quality in daily life. An instructor teaches the participants how to use the mobile health system during home visits and phone calls during the 6 month intervention period. A virtual instructor teaches the participants the eLiFE programme. Pictures and videos of the aLiFE activities are delivered by use of the system. Behavioural change strategies are also included in the system.
2926429|NCT03065088|Active Comparator|control|The control group follows the World Health Organization's recommendations of physical activity.
2926430|NCT03065075|Experimental|Phenazopyridine|Participant is given Phenazopyridine
2926431|NCT03065075|No Intervention|No Phenazopyridine|Participant is not given Phenazopyridine
2926432|NCT03065062|Experimental|Combination Of Palbociclib and Gedatolisib|"Palbociclib will be administered orally once daily on Days 1-21 for each of the 4-week cycles at a pre-determined dose.~Gedatolisib will be administered intravenously once weekly on the first day for each of the four weeks during the 4-week cycles at a pre-determined dose."
2926433|NCT03065049|Other|Transforming Recovery with Exercise and Community (TREC)|Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.
2926434|NCT03065036|Experimental|Hydrus Aqueous Implant|Hydrus implanted into Schlemm's Canal.
2926435|NCT03065036|Other|IOL placement and Hydrus implant|Cataract Extraction with IOL placement and Hydrus implant into Schlemm's canal
2926436|NCT03065023|Experimental|Group A: Cutaenous lesions|"Subjects with transdermally/transmucosally injectable tumors including cutaneous, sub-cutaneous or lymph node injectable tumors.~RGT100-PEI will be injected intratumorally/intralesionally twice a week over a period of 4 weeks."
2926437|NCT03065023|Experimental|Group B: Liver lesions|"Subjects with injectable liver tumors or liver metastases.~RGT100-PEI will be injected into liver lesions once a week over a period of 4 weeks."
2926438|NCT03065010|Other|BCD-115 in dose escalation regimen|BCD-115 will be administered p.o. with intrapatient dose escalation in the population of patients with ER(+) HER2(-) advanced breast cancer in combination with a standard dose of endocrine therapy.
2926439|NCT03064997|Active Comparator|Prebiotic Synergy 1-supplemented GFD|The application of a prebiotic Synergy 1 together with a strict gluten-free diet
2926440|NCT03064997|Placebo Comparator|Placebo-supplemented GFD|The application of a placebo together with a strict gluten-free diet
2926441|NCT03064984|Active Comparator|CBS eyedrops|Eyedrops prepared from CBS (Cord Blood Serum), and administered 1 drop/each eye/8 times per day, for 30 days
2926442|NCT03064984|Active Comparator|PBS eyedrops|Eyedrops prepared from PBS (Peripheral Blood Serum) from adult donor subjects, administered 1 drop/each eye/8 times per day, for 30 days
2926443|NCT03064971|Experimental|Standard care + PTF DVD|The intervention will include the standard care, with the addition of the PTF DVD. Participants randomized to this condition will receive Pathways to Freedom: Leading the Way to a Smoke-Free Community© (PTF). The content of the intervention parallels the types of education, advice, and cessation/relapse prevention strategies that are delivered in clinic and quitline contexts, except for the focus on the specific needs of the Black community. The 60- minute DVD consists of 7 sections. The cultural adaptations (e.g., focus on menthol, focus on religion/spirituality, Black images and music) were infused throughout the DVD. The PTF DVD is useable at varying levels along the readiness to quit smoking continuum, as viewers are empowered to view sections that match their interests and goals. Quit Coaches will be trained to refer participants to appropriate sections for additional help.
2926478|NCT03064724|Experimental|Smoking Cessation Group|Patients received the interactive mobile doctor (iMD) intervention.
2926479|NCT03064698||Normal second trimester Doppler|This group consists of women who had normal doppler ultrasound results at second trimester
2926633|NCT03063645|Experimental|Group CAB|AC-SD-01 (75g), AC-1202, AC-SD-01 (50g)
2926444|NCT03064971|Active Comparator|Standard care + standard smoking cessation DVD|"This arm includes standard care, plus a standard smoking cessation DVD. The evidence-based How to Quit DVD contains 60 minutes of smoking cessation information and strategies. Narrated by a physician, it describes the process of quitting and strategies for increasing physical activity and healthy nutrition. It includes testimonials from former smokers and dialogue among smokers in a group counseling setting. The information is presented in a standard format, intended for the general population of smokers."
2926445|NCT03064971|Active Comparator|Standard care only|Following the first counseling session, participants may receive up to 3 additional proactive counseling calls. Follow-up calls focus on challenges that may have occurred on the quit date or with the use of medication. Quit Coaches® review and modify the person's quit plan, and provide support as appropriate. Participants also receive standard self-help materials by mail, which is often referred to by Quit Coaches. For individuals who have successfully quit, the Coach will focus on relapse prevention strategies. Quit Coaches provide medication education to all participants eligible and interested in using cessation medications. This study will provide starter NRT kits (2 weeks supply) to all participants. Coaches provide decision support using a database-supported algorithm based on current scientific evidence and the product manufacturer use instructions for each drug.
2926446|NCT03064958|Active Comparator|Control|Consumption of a high fat meal (1000kcal, 45g fat)
2926447|NCT03064958|Experimental|Spice 2g|Consumption of a high fat meal (1000kcal, 45g fat) with 2g of spice (mix of black pepper, basil, bay leaf, cinnamon, coriander, cumin, ginger, oregano, parsley, rosemary, red pepper, turmeric and thyme) incorporated into the meal.
2926448|NCT03064958|Experimental|Spice 6g|Consumption of a high fat meal (1000kcal, 45g fat) with 6g of spice (mix of black pepper, basil, bay leaf, cinnamon, coriander, cumin, ginger, oregano, parsley, rosemary, red pepper, turmeric and thyme) incorporated into the meal.
2926449|NCT03064945|Sham Comparator|Shame device|
2926450|NCT03064945|Experimental|Livia® Transcutaneous Electrical Nerve Stimulation (TENS)|
2926451|NCT03064932|Active Comparator|SD-Low|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a minimal amount of spices (<1g/day for all diets).~Post prandial test meal will be contain minimal amounts of spice."
2926452|NCT03064932|Experimental|SD-Mod|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a moderate amount of spices (~3g/day in the 2100kcal diet).~Post prandial test meal will be contain a moderate amount of spice."
2926453|NCT03064932|Experimental|SD-Culinary|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a culinary dose of spices (6g/day in the 2100kcal diet).~Post prandial test meal will be contain a culinary amount of spice."
2926454|NCT03064919|Experimental|Curriculum Testing|Test an evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals.
2926455|NCT03064906|Other|Meal Performance and/or Exercise|"This study is a two-part, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting using the Insulet AP (artificial pancreas) system.~Subjects may participate in hybrid closed-loop session Option A - Meal Performance and/or Option B - Exercise, but are not required to participate in both. If participating in both, Option A and Option B must be conducted in separate sessions."
2926456|NCT03064893|Active Comparator|Dermacell|Device for immediate implant based breast reconstruction
2926457|NCT03064893|Active Comparator|Alloderm|Device for immediate implant based breast reconstruction
2926458|NCT03064880|Active Comparator|SV maximization|Dynamic fluid responsiveness parameters, such as stroke volume (SV) response to fluid therapy, are precise fluid indicators that specifically determine patient volume status and are helpful for clinicians to determine the appropriate time for fluid bolus. For SV maximization, the investigators maximize SV after anesthetic induction by fluid therapy up to achieve maximized SV maintained.
2926459|NCT03064880|No Intervention|SV normalization|NO active fluid therapy.
2926460|NCT03064867|Experimental|Venetoclax + RICE|Venetoclax with rituximab, ifosfamide, carboplatin, and etoposide
2926461|NCT03064854|Experimental|Group A: squamous, gem/cis+PDR001|
2926462|NCT03064854|Experimental|Group B: non-squamous, pem/cis+PDR001|
2926463|NCT03064854|Experimental|Group C: paclitaxel/carbo+PDR001|
2926464|NCT03064854|Experimental|Group D non-squamous, ARM 1 or ARM 2|
2926465|NCT03064841||Outpatient with confirmed T2DM|subjects with confirmed T2DM
2926466|NCT03064828|Active Comparator|CT colonoscopy(normal dose)|Perform CT colonoscopy with full bowel preparation and inflated colon, CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kilovolts peak (kVp), 100-200mA
2926467|NCT03064828|Experimental|CT colonoscopy(low dose)|Perform CT colonoscopy with full bowel preparation and inflated colon, CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
2926468|NCT03064815|Experimental|Spondylarthropathies with GI symptoms|Subjects in this arm will have spondylarthropathies and gastrointestinal symptoms and will undergo a colonoscopy, videocapsule endoscopy, biomarker testing (PROMETHEUS® IBD sgi Diagnostic™ and fecal calprotectin)
2926469|NCT03064815|Experimental|Spondylarthropathies without GI symptoms|Subjects in this arm will have spondylarthropathies without gastrointestinal symptoms and will undergo a colonoscopy, videocapsule endoscopy, biomarker testing (PROMETHEUS® IBD sgi Diagnostic™ and fecal calprotectin)
2926470|NCT03064802||BioBurst Fluid, Burst Allograft|Spinal Fusion with BioBurst Fluid or Burst Allograft
2926471|NCT03064789||Women with candidiases infection|Women that are prescribed treatment with clotrimazole: 500 mg. and probiotics (routine clinical practice)
2926472|NCT03064776|Experimental|m-RESIST Patients|"m-RESIST is a system designed to improve illness self-management and facilitate recovery in individuals with Treatment-resistant schizophrenia (TRS). The system will be used to~Continuously capture multidimensional behavior as it occurs in real-time and in real-world environments, using continuous collection and analysis of sensor data.~Detect individual early warning signs, and trigger targeted interventions that may mitigate the severity of worsening or prevent their recurrence altogether, using the clinical decision-suport system (CDSS) and Recommender operation.~The m-RESIST will deliver both system initiated (i.e. pre-programmed) and patient initiated (i.e. on demand) real-time assessments, to the participants and in their own environment."
2927077|NCT03060642||Controls|Non-BE endoscopic controls
2926481|NCT03064685||Group I - Cases|Patients older than 18 years of age with a history of liver transplantation since January 2002 for any cause and who have undergone medical follow-up at HIBA and had at least one event of pyogenic liver abscess after transplantation.
2926482|NCT03064685||Group II - Controls|Patients older than 18 years with a history of liver transplantation since January 2002 for any cause and who have performed their medical follow-up at HIBA without developing any event of pyogenic liver abscess after transplantation
2926483|NCT03064672|Experimental|induction by transcervical Balloon Catheters insertion|
2926484|NCT03064672|No Intervention|induction without transcervical Balloon Catheters|
2926485|NCT03064646|Experimental|Organ Preservation|The experimental strategy is the omission of radical surgery if complete or almost complete response after neoadjuvant treatment for locally advanced rectal cancer
2926486|NCT03064633|Active Comparator|Dexamethasone arm (group A)|The local anesthetic solution mixture consists of dexamethasone 8 mg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 2 ml dexamethasone = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
2926487|NCT03064633|Active Comparator|Dexmedetomidine arm (group B)|The local anesthetic solution mixture consists of dexmedetomidine 80 µg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 80 µg dexmedetomidine in 2 ml = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
2926488|NCT03064620||Israel PCV13|Children and their parents living in central Israel and visiting primary pediatric clinics of Hashfela District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.
2926489|NCT03064620||East Jerusalem PCV13|Children and their parents living in East Jerusalem and visiting primary pediatric clinics of Jerusalem District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.
2926490|NCT03064620||Palestine PCV7 PCV10|Children and their parents living in major cities of the Palestinian Authority and visiting private primary pediatric clinics, for any reason during the surveillance period each year.
2926491|NCT03064607||pregnant women|Women undergoing c-section or EXIT procedure
2926492|NCT03064594||cornuostomy|cornuostomy
2926493|NCT03064594||wedge resection|wedge resection
2926494|NCT03064581|Experimental|Intervention|Gender-specific culturally tailored social-support informed educational intervention session.
2926495|NCT03064581|No Intervention|Control|Usual care with delayed intervention at the end of study.
2926496|NCT03064568|Experimental|Misoprostol|Patients will receive misoprostol 400mcg per rectum 30 minutes preoperatively.
2926497|NCT03064568|Placebo Comparator|Placebo|Patients will receive identical inert tablets per rectum 30 minutes preoperatively.
2926498|NCT03064555||Participants with end stage renal disease|"Cardiopulmonary exercise test~Cardiopulmonary exercise testing will be conducted on an electronically braked cycle ergometer using a ramped protocol with participants being required to pedal until exhaustion.~Constant load exercise test~Constant load exercise will be performed for 30 min on an electronically braked cycle ergometer whilst seated in a dialysis chair. Blood sampling and echocardiogram will be measured throughout."
2926499|NCT03064555||Healthy participants|"Cardiopulmonary exercise test~Cardiopulmonary exercise testing will be conducted on an electronically braked cycle ergometer using a ramped protocol with participants being required to pedal until exhaustion.~Constant load exercise test~Constant load exercise will be performed for 30 min on an electronically braked cycle ergometer whilst seated in a dialysis chair. Blood sampling and echocardiogram will be measured throughout."
2926500|NCT03064529|Experimental|Accelerometer Participants|All participants receive an accelerometer to wear around their wrist to measure physical activity continuously beginning 1 week before surgery (when the accelerometer is put on the wrist) and ending 2 weeks after surgery (when the accelerometer is removed from the wrist).
2926501|NCT03064516|Experimental|Endocrown|Restorations with ceramic endocrown in endodontically treated teeth
2926502|NCT03064516|Active Comparator|Onlay and fiber pin|Restorations with onlay ceramic and glass fiber pin in endodontically treated teeth
2926503|NCT03064503|Experimental|Healthy volunteers|Sedentary healthy subjects will be recruited in this study. MRI, skin auto-fluorescence measures and blood sampling will be performed
2926504|NCT03064490|Other|Single arm interventional study|Single arm, non randomized, open label study. Subjects will receive three doses of neoadjuvant pembrolizumab (200 mg administered as an intravenous infusion over 30 minutes every 3 weeks). Pembrolizumab will be administered with weekly standard of care Carboplatin/Paclitaxel concurrent chemo-radiation therapy in the neo-adjuvant setting. Postoperatively, three additional cycles of pembrolizumab (200 mg every 3 weeks) will be administered as adjuvant therapy.
2926505|NCT03064477|Experimental|Unified Protocol (UP)|"Investigators in the present study have adapted the UP to implement it in group format in a Public Mental Health setting in Spain. This adaptation is composed of 12 treatment sessions of two hours of duration each, at a rate of one per week.~Participants in the UP will receive UP treatment in group format instead of the usual Cognitive Behavioral Therapy in individual format. Patients in the UP condition will receive pharmacological treatment (i.e., antidepressants and / or anxiolytics) as usual."
2926506|NCT03064477|Active Comparator|Treatment As Usual (TAU)|Cognitive Behavioral Therapy in individual format is the treatment of choice (TAU) by psychologists and psychiatrists at the collaborating Public Mental Health Centers and Primary Care Centers, together with pharmacological treatment (i.e., antidepressants and / or anxiolytics).
2926507|NCT03064464||CA-MRSA infection|None intervention
2926508|NCT03064464||HA-MRSA infection|None intervention
2926509|NCT03064464||CA-MSSA infection|None intervention
2926510|NCT03064451|Experimental|Intervention|cartofinder guided ablation followed by PVI
2926511|NCT03064438|Experimental|ACCU-D1|ACCU-D1 applied to the face twice daily for 12 weeks.
2926512|NCT03064438|Placebo Comparator|Vehicle Control|Vehicle applied to the face twice daily for 12 weeks.
2926513|NCT03064399|Experimental|lateral ligament repairment|
2926514|NCT03064399|Experimental|without lateral ligament repairment|
2926515|NCT03064386|Experimental|plate group|internal fixation with the plate
2926517|NCT03064360||Biomarker Testing, PROs, PRIs|Biomarker testing for cardiac biomarkers, B-type natriuretic peptide (BNP) and Troponin I (Tnl), symptom and quality of life questionnaires, and patient metrics (activity, sleep, heart rate, heart rate variability).
2926518|NCT03064347|Active Comparator|Coated Sucrose plus Whole Milk|200kcal sucrose plus whole milk powder in enteric coating as single dose
2926519|NCT03064347|Placebo Comparator|Non Coated Sucrose plus Whole Milk|200kcal sucrose plus whole milk powder with separate enteric coating materials as single dose
2926520|NCT03064347|Active Comparator|Enteric Coated Sucrose|200kcal sucrose in enteric coating as single dose
2926521|NCT03064347|Placebo Comparator|Non-Enteric Coated Sucrose|200kcal sucrose with separate enteric coating materials as single dose
2926522|NCT03064347|Active Comparator|Enteric Coated Whey Protein|200kcal whey protein in enteric coating as single dose
2926523|NCT03064347|Placebo Comparator|Non-Enteric Coated Whey Protein|200kcal whey protein with separate enteric coating materials as single dose
2926524|NCT03064347|Active Comparator|Enteric Coated Pea Protein|200kcal pea protein in enteric coating as single dose
2926525|NCT03064347|Placebo Comparator|Non-Enteric Coated Pea Protein|200kcal pea protein with separate enteric coating materials as single dose
2926526|NCT03064334||one medium of focus groups|"The present study aims to understand patient experiences and outcomes post- Total Knee Arthroplasty(TKA). Therefore, a qualitative approach will be most appropriate to facilitate the collection of in-depth experiences and perceptions of patients post-TKA.~The medium of focus groups (with 8-10 patients) is preferred to allow a group of patients to share their perceptions and experiences post-surgery, with sufficient quantity and diversity of views while balancing the facilitator's ability to manage all patients' participation for 90-120 minutes (Bloor, 2006)."
2926527|NCT03064321|Experimental|Insomnia Intervention|Insomnia intervention delivered via web using Cognitive Behavior Treatment
2926528|NCT03064321|Other|Information Control|General health information website
2926529|NCT03064308|No Intervention|Control|Participants will receive standard NHS care with no intervention.
2926530|NCT03064308|Other|Exercise|Participants will receive standard NHS care and complete the exercise programme, the intervention.
2926531|NCT03064295||Healthy Volunteers|60 healthy male or female (18 or older) adults will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent
2926532|NCT03064295||CAD Patients|110 male or female adults (18 or older) who have undergone clinical myocardial perfusion imaging at CSMC and been diagnosed with Coronary Disease (CAD) will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent.
2926533|NCT03064295||CMD Patients|50 female adults (21 or older) who have undergone coronary reactivity testing at CSMC and been diagnosed with coronary microvascular disease (CMD) will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent.
2926534|NCT03064282|Placebo Comparator|Placebo|Drug free base as placebo
2926535|NCT03064282|Experimental|group two- papaverine arm|papaverine in a suitable base
2926536|NCT03064269|Experimental|Arm 1|CD19 CAR-T cells treated central nervous system B-cell acute lymphocytic leukemia.
2926537|NCT03064256|Experimental|Physical training program|"Intervention participants are submitted to supervised aerobic physical training at the predetermined intensity, which is composed of three weekly sessions, lasting one hour, over a period of 12 weeks.~All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise."
2926538|NCT03064256|No Intervention|Control Group|Control participants receive routine outpatient care for a 12-week period.
2926539|NCT03064243|Experimental|apatinib group|apatinib 500mg po qd
2926540|NCT03064230||Athletes agonists (Experimental Group)|"I) age between 14 and 40 years who met the definition of competitive sports athletes adopted by the Italian Ministry of Health II) absence of malignancies; III) informed consent obtained from the patient; IV) no previous surgical, chemotherapic and/or radiotherapic treatments.~We excluded all patients who presented any conditions that could alter quality of life such as: I) recent traumas; II) recent surgeries; III) oncologic history; IV) uncontrolled systemic illnesses; V) severe or uncontrolled infection; VI) mental illness; VII) pregnancy.~QoL questionnaire SF-12 and and a screening questionnaire were requested"
2926541|NCT03064230||women not agonists (Control Group)|"I) age between 14 and 40 years who did not met the definition of competitive sports athletes adopted by the Italian Ministry of Health; II) absence of malignancies; III) informed consent obtained from the patient; IV) no previous surgical, chemotherapic and/or radiotherapic treatments.~We excluded all patients who presented any conditions that could alter quality of life such as: I) recent traumas; II) recent surgeries; III) oncologic history; IV) uncontrolled systemic illnesses; V) severe or uncontrolled infection; VI) mental illness; VII) pregnancy. QoL questionnaire SF-12 and and a screening questionnaire were requested"
2926542|NCT03064217|Active Comparator|CLP and 12 weeks waiting|After core build-up and initial tooth preparation, a clinical crown lengthening procedure (CLP) will be performed. Restorative treatments will be initiated 12 weeks after CLPs.
2926543|NCT03064217|Experimental|Digital impression taken at surgery|The final impression will be taken at surgery. The final crown will be delivered at suture removal.
2926544|NCT03064204||OSA+CPAP+HIV+|Individuals (40 years or older) diagnosed with OSA and using CPAP, also with HIV treated to viral suppression.
2926545|NCT03064204||OSA+CPAP+HIV-|Individuals (40 years or older) diagnosed with OSA and using CPAP.
2926546|NCT03064191|Active Comparator|calcium hydroxide chlorhexidine|intervention: calcium hydroxide chlorhexidine combination an intra-canal medication composed of calcium hydroxide powder and chlorhexidine solution as a combination to be administered as intra-canal paste for decreasing postoperative symptoms
2926547|NCT03064191|Active Comparator|calcium hydroxide|intervention: calcium hydroxide an intra-canal medicament composed of calcium hydroxide paste for decreasing postoperative symptoms and signs .
2926548|NCT03064165|Experimental|Obturator nerve block|Postoperative obturator nerve block with 15 mL bupivacain 5 mg/mL and epinephrine 5 µg/mL.
2926549|NCT03064165|Placebo Comparator|Sham block|Postoperative sham-block with normal saline.
2926550|NCT03064152|No Intervention|Control|Patients who experience postpartum hemorrhage will receive standard of care for labor and delivery, cesarean delivery, and postpartum care. Transfusion will be based on standard of care utilizing clinical criteria of hemodynamics (noninvasive blood pressure, heart rate, arterial line if deemed clinically useful) and coagulation labs (PT, activated partial thromboplastin time (aPTT), fibrinogen, complete blood count). In addition to standard of care, additional ROTEM blood assays will be performed at any time routine coagulation labs are sent. Providers in the control group will be blinded to ROTEM results.
2926551|NCT03064152|Experimental|ROTEM|Patients will receive standard of care for labor and delivery, cesarean delivery, and postpartum care. Transfusion will be based on standard of care utilizing clinical criteria of hemodynamics (noninvasive blood pressure, heart rate, arterial line if deemed clinically useful) and coagulation labs (PT, aPTT, fibrinogen, complete blood count). In addition to standard of care, additional ROTEM blood assays will be performed at any time routine coagulation labs are sent. Providers in the ROTEM group will receive real-time ROTEM results and a previously validated ROTEM-based transfusion algorithm for PPH.
2926552|NCT03064139|Experimental|Mindful Walking|Participants will be trained in mindful walking technique
2926553|NCT03064139|Active Comparator|Attention Matched Control|Participants will receive education in management of knee OA
2926554|NCT03064126|Experimental|RANGER™ Paclitaxel Coated Balloon|"RANGER™ Paclitaxel Coated Balloon Catheter angioplasty in the SFA/PPA at the index procedure.~Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon."
2926555|NCT03064126|Active Comparator|Standard Balloon Angioplasty|Standard Balloon Catheter angioplasty in the SFA/PPA at the index procedure. Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon.
2926556|NCT03064113|Placebo Comparator|Placebo|"Sequence 1:~Period 1 = Placebo; Period 2 = TD-4208 700 μg; Period 3 = TD-4208 350 μg; Period 4 = Ipratropium 500 μg"
2926557|NCT03064113|Experimental|TD-4208 700 μg|"Sequence 2:~Period 1 = TD-4208 700 μg; Period 2 = Ipratropium 500 μg; Period 3 = Placebo; Period 4 = TD-4208 350 μg"
2926558|NCT03064113|Experimental|TD-4208 350 μg|"Sequence 3:~Period 1 = TD-4208 350 μg; Period 2 = Placebo; Period 3 = Ipratropium 500 μg; Period 4 = TD-4208 700 μg"
2926559|NCT03064113|Active Comparator|Ipratropium 500 μg|"Sequence 4:~Period 1 = Ipratropium 500 μg; Period 2 = TD-4208 350 μg; Period 3 = TD-4208 700 μg; Period 4 = Placebo"
2926560|NCT03064100||Specimens that meet inclusion criteria|
2926561|NCT03064074|Experimental|Stage 1 Low dose|"There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 1 mg/kg of fresolimumab (n=4).~At each study visit, the participant may have the following testing done:~Physical exam~Vitals~Blood draw for safety labs, pharmacokinetics, etc~If the participant is female, she will have a pregnancy test~EKG~DXA~Infusion of the study drug"
2926562|NCT03064074|Experimental|Stage 2 High dose|"There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 4 mg/kg of fresolimumab (n=4).~At each study visit, the participant may have the following testing done:~Physical exam~Vitals~Blood draw for safety labs, pharmacokinetics, etc~If the participant is female, she will have a pregnancy test~EKG~DXA~Infusion of the study drug"
2926563|NCT03064074|Experimental|Stage 2 Repeat dose every 6 months|"Fresolimumab will be administered every six months for a total treatment period of 12 months (n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength.~At each study visit, participants may have the following testing done:~Physical exam~Vitals~Blood draw for safety labs, pharmacokinetics, etc~If the participant is female, she will have a pregnancy test~EKG~DXA~Infusion of the study drug~Skeletal survey~Peripheral quantitative CT (pQCT) of the forearm~Quality of Life Surveys~Pulmonary function test~Walk test"
2926564|NCT03064074|Experimental|Stage 2 Repeat doses every 3 months|"Fresolimumab will be administered every three months for a total treatment period of 12 months (n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength.~At each study visit, participants may have the following testing done:~Physical exam~Vitals~Blood draw for safety labs, pharmacokinetics, etc~If the participant is female, she will have a pregnancy test~EKG~DXA~Infusion of the study drug~Skeletal survey~Peripheral quantitative CT (pQCT) of the forearm~Quality of Life Surveys~Pulmonary function test~Walk test"
2926565|NCT03064061|Sham Comparator|Virtual Reality Neutral|neutral VR session before oocytes retrieval
2926566|NCT03064061|Active Comparator|Virtual reality Anxiety|VR session with the goal of reducing anxiety before oocytes retrieval
2926567|NCT03064048|Active Comparator|Neo-ASA|During this arm the participant will receive a lozenge with nitric oxide as a dietary supplement twice daily.
2926568|NCT03064048|Placebo Comparator|Placebo|During this arm the participant will receive a lozenge which will not contain nitric oxide as a dietary supplement twice daily.
2926569|NCT03064035|Experimental|Fixed dose 4FPCC|"Incorporating a fixed dose of 1500 IU.~If the patient receiving the 1500 IU fixed dose remains in a bleeding state and the INR remains above goal, an additional 500 IU may be administered at the physician's discretion to minimize bleeding and attempt to achieve hemostasis."
2926570|NCT03064035|Active Comparator|Variable dose 4FPCC|"The FDA-approved variable dosing algorithm is as follows:~initial INR 2-3.9: 25 IU/kg (maximum dose 2500 IU), initial INR 4-6: 35 IU/kg (maximum dose 3500 IU), and initial INR >6: 50 IU/kg (maximum dose 5000 IU). The patient weight will be obtained using a scale and documented by the treating registered nurse"
2926571|NCT03064022||Size < the 3rd or 10th percentiles|Infant size smaller than the 3rd or 10th percentiles relative to the Fenton growth chart for weight or head circumference at discharge from neonatal intensive care
2926572|NCT03064022||Rapid early growth|Rapid early growth will be defined as exceeding birthweight in the first week of life
2926573|NCT03064022||Growth velocity calculation methods|We will compare a variety of growth velocity calculation methods used in clinical care and research to compare and assess growth velocity calculation methods
2926574|NCT03064009||Open Fractures|Patients with Open fractures between the distal radius and the distal tibia
2926575|NCT03063996|Other|Standard of Care (peripheral IV access)|Patient with a history of difficult access or a patient that currently has difficult peripheral IV access.
2926576|NCT03063996|Active Comparator|Peripheral IJ access|Patient with a history of difficult access or a patient that currently has difficult peripheral IV access and is randomized into the group that gets peripheral IJ access.
2926577|NCT03063983|Experimental|Maintenance therapy|104 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX) following 31 weeks of MAP
2926578|NCT03063983|No Intervention|Control|31 weeks of MAP
2926579|NCT03063970|Experimental|Experimental Group|Wear of the tailor made Dynamic Lycra Orthosis for up to eight hours every day for eight weeks Usual rehabilitation
2926580|NCT03063970|Active Comparator|Comparison Group|Usual rehabilitation
2926581|NCT03063957||Microscopic Colitis|Patients with confirmed microscopic colitis
2926582|NCT03063957||Control|Patients that are not diagnosed with microscopic colitis
2926583|NCT03063944|Experimental|Treatment (STAT inhibitor OPB-111077, decitabine)|Patients receive STAT inhibitor OPB-111077 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive decitabine IV on days 8-12. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2926584|NCT03063931|Experimental|magnesium|
2926585|NCT03063931|Placebo Comparator|placebo|
2926586|NCT03063918|Experimental|Supportive Care (personalized dietary intervention)|At 6 months after standard of care treatment, patients receive 10 sessions of personalized dietary intervention over 30 minutes each over 4 months via the telephone. Patients also receive a workbook including reference materials and intervention content.
2926587|NCT03063905||Opioid Taper|Patients tapering off their buprenorphine treatment
2926588|NCT03063905||Opioid Maintenance|Patients starting their buprenorphine treatment
2926589|NCT03063892|Placebo Comparator|Control Arm|Will receive intravenous Saline solution placebo bolus dose in the Emergency Center over 10 minutes. The subject will also receive intravenous Saline solution over 8 hours prior to surgery. Another dose will be administered at the time of incision and the final dose three hours later.
2926590|NCT03063892|Experimental|Experimental Arm|Will receive intravenous Tranexamic Acid (TXA) 15mg/kg (maximum 1 gram) bolus dose over 10 minutes in the Emergency Center. The subject will also receive an intravenous dose of Tranexamic Acid (TXA) 15mg/kg over 8 hours prior to surgery. Another 15mg/kg dose of Tranexamic Acid (TXA) will be administered over 10 minutes at the time of incision and the final dose (15mg/kg) of Tranexamic Acid (TXA) intravenously over 10 minutes three hours later.
2926591|NCT03063879|Experimental|Sovodak|Sofosbuvir 400 mg and daclatasvir 60 mg
2926592|NCT03063866|Active Comparator|M group|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg
2926593|NCT03063866|Active Comparator|P Group|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v
2926594|NCT03063853|Other|POD4|REMOVAL OF SURGICAL STAPLES AT POSTOPERATIVE DAY 4
2926595|NCT03063853|Other|POD8|REMOVAL OF SURGICAL STAPLES AT POSTOPERATIVE DAY 8
2926596|NCT03063840|Experimental|Microwave ablation (MWA)|Microwave ablation (MWA)
2926597|NCT03063827||Treatment group|Patients with chronic SCI causing NDO and urinary incontinence
2926598|NCT03063827||Control group|Female patients who underwent anti-incontinence suregery without lower urinary tract symptoms
2926599|NCT03063814|Experimental|APP|In the APP group, a video sequence of each exercise, supported by short written descriptions (in accordance to 'Get set - Train smarter', (9) on how to perform the exercise correctly, was shown to the participants on an iPad. The video-recorded exercises were performed by the same physiotherapist who supervised PHY participants. If required, the participants in the APP group were allowed to watch the video and description several times between trials of the same exercise. The participants approved their own trials when they believed that the exercises had been performed as described.
2926600|NCT03063814|Active Comparator|PHY|In PHY, a physiotherapist demonstrated and explained the focus areas of each of the five exercises before the participant performed the exercises. If needed, verbal feedback was given between trials to correct the performance of the exercise. The physiotherapist approved trials that were performed with proper technique.
2926601|NCT03063801||Cardiac surgery|All adult patients having undergone surgery between January 2006 and December 2016 within the CHU Brugmann hospital.
2926602|NCT03063788|Experimental|HIV uninfected|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 2 HIV uninfected individuals
2926603|NCT03063788|Experimental|HIV infected viremic|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 4 HIV infected individuals with viremia who are not receiving antiretroviral therapy
2926604|NCT03063788|Experimental|HIV infected aviremic|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 4 HIV infected individuals with undetectable HIV viral load who are receiving antiretroviral therapy
2926605|NCT03063775|Active Comparator|1. Mucograft® Seal + Bio-Oss®|
2926606|NCT03063775|Active Comparator|2. FGG + Bio-Oss®|
2926607|NCT03063775|Active Comparator|3. FGG + Gelatine sponge (Spongostan®)|
2926608|NCT03063775|Active Comparator|4. Spongostan®+ Mucograft® Seal|
2926609|NCT03063775|No Intervention|5. Spongostan®|
2926610|NCT03063762|Experimental|Escalation Part (Arm A): Atezolizumab, RO6874281|Participants will receive RO6874281 in combination with atezolizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has complete response (CR), treatment may be discontinued and reintroduced if progressive disease (PD), for a maximum duration of 24 months.
2926611|NCT03063762|Experimental|Escalation Part (Arm B): Atezolizumab, Bevacizumab, RO6874281|Participants will receive RO6874281 in combination with atezolizumab and bevacizumab until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
2926700|NCT03063190|Active Comparator|Hyperparathyroidism_1|Chronic Kidney Disease patients with parathyroid hormone higher than 300pg/ml
2926701|NCT03063190|Placebo Comparator|Adynamic_0|Chronic Kidney Disease patients with parathyroid hormone lower than 150pg/ml
2926612|NCT03063762|Experimental|Extension Part (Arm A): Atezolizumab, RO6874281|Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
2926613|NCT03063762|Experimental|Extension Part (Arm B): Atezolizumab, Bevacizumab, RO6874281|Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab and bevacizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
2926614|NCT03063762|Experimental|Extension Part (Arm C): Atezolizumab, RO6874281|Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab once every 3 weeks until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
2926615|NCT03063762|Experimental|Extension Part (Arm D): Atezolizumab, Bevacizumab, RO6874281|Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab and bevacizumab once every 3 weeks until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
2926616|NCT03063749||Primary Cohort|Subjects receiving stents 2.0 mm - 4.0 mm in diameter will be included in the Primary Cohort.
2926617|NCT03063749||Extra Large Vessel (XLV) Cohort.|Subjects receiving stents 4.5 mm or 5.0 mm in diameter will be included in the Extra Large Vessel (XLV) Cohort.
2926618|NCT03063736|Experimental|Td vaccine with entolimod|Td vaccine (4 ug) + Entolimod (1 ug) (n=25)
2926619|NCT03063736|Placebo Comparator|Td vaccine only|Td vaccine (4 ug) (n=15)
2926620|NCT03063723||CHC patients|15 treatment-naive CHC patients treated by Ledipasvir-Sofosbuvir orDaclatasvir-Sofosbuvir.
2926621|NCT03063723||Healthy controls|10 Healthy controls without any treatment
2926622|NCT03063697||patients who check the safety data after taking Dilatrend SR|
2926623|NCT03063684|Experimental|Vaginal atrophy|"With decreasing estrogen levels occurring following menopause, changes of the vaginal mucosa appear: it becomes thin and pale and loses its elasticity. The blood supply decreases, normal secretion is reduced, the epithelial cells do not undergo the normal differentiation process, the bacterial population changes with loss of lactobacilli and pH increases. These changes are associated with morphological and histological changes, manifested, among other findings, by alterations in the collagen composition, loss of the trabecular organization of collagen and reduced amount of elastic fibers. Women with reduced vaginal estrogen content may report dryness, itching, discomfort, burning sensation during micturition, pain and dyspareunia. These changes are reversible: topical or systemic estrogen change the vaginal mucosa's characteristics and may also alleviate complaints arising from estrogen deficiency.~The intervention is 3 treatments with fractional / Pixel CO2 Laser"
2926624|NCT03063684|Experimental|Lichen sclerosus|"Lichen sclerosus is a chronic cutaneous disease involving the vulvar and peri-anal skin. The involved skin becomes thin and white, with frequently present bruises or petechiae and anatomic changes.~Lichen sclerosus is thought to be an auto-immune disorder and its most frequent signs are itching, irritation or burning. The discoloration may involve the entire vulvar and peri-anal area (sometimes having the form of an 8 or a keyhole surrounding the vulva and anus) or appear as separated spots of various sizes occupying only part of the skin. At advanced stages of lichen sclerosus, scarring may appear, with loss of the labia minor and adhesions which may entirely cover the clitoris.~The treatment is of topical steroid. Lichen sclerosus is a chronic disorder, and even with good treatment, in a certain proportion of cases the skin does not return to its original appearance.~The intervention is 3 treatments with fractional / Pixel CO2 Laser"
2926625|NCT03063671|Active Comparator|bupivacine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% as one shot 15 minutes before general anesthesia postoperative analgesia done by infusion of bupivacaine 0.125% (5ml/hour through thoracic epidural catheter for 12 hours).
2926626|NCT03063671|Active Comparator|ketamine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus ketamine in a dose 0.5 mg/kg 15 minutes before general anesthesia postoperative analgesia will be preformed by infusion of mixture of (bupivacaine 0.125% plus ketamine 0.5 mg/ml ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours
2926627|NCT03063671|Active Comparator|dexmedetomidine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus dexmedetomidine in a dose 1 ug/kg 15 minutes before general anesthesia Postoperative analgesia will be performed using infusion of mixture of (bupivacaine 0.125% plus dexmedetomedine 2μg/ ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours.
2926628|NCT03063671|Active Comparator|ketamine-dexmedetomidine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus both ketamine in a dose 0.3 mg/kg and dexmedetomidine in a dose 0.1 ug/kg 15 minutes before general anesthesia Postoperative analgesia will be performed using infusion of mixture of (bupivacaine 0.125% plus dexmedetomedine 2μg/ ml and and ketamine 0.5 mg/ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours.
2926629|NCT03063658|Active Comparator|Paracetamol|Paracetamol (Paracerol) 1 gram will be administered intravenously. The first dose will be infused for 10 minutes after the induction of anesthesia and before the first surgical incision. The remaining three doses will be administered every 6 hours for postoperative 24 hours.
2926630|NCT03063658|Active Comparator|Ibuprofen|Ibuprofen (Intrafen) 800 mg will be administered intravenously. The first dose will be infused for 10 minutes after the induction of anesthesia and before the first surgical incision. The remaining three doses will be administered every 6 hours for postoperative 24 hours.
2926631|NCT03063645|Experimental|Group ABC|AC-1202, AC-SD-01 (50g), AC-SD-01 (75g)
2926632|NCT03063645|Experimental|Group BCA|AC-SD-01 (50g), AC-SD-01 (75g), AC-1202
2926634|NCT03063632|Experimental|Treatment (pembrolizumab, interferon gamma-1b)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unexpected toxicity. Patients also receive interferon gamma-1b SC 3 times per week for 12 weeks, and then follow 3 weeks on and 3 weeks off schedule for up to 2 years in the absence of disease progression or unexpected toxicity.
2926635|NCT03063619|Placebo Comparator|Arm A (placebo)|Patients apply placebo gel topically to each breast QD for up to 52 weeks.
2926636|NCT03063619|Experimental|Arm B (afimoxifene)|Patients apply afimoxifene gel topically to each breast QD for up to 52 weeks.
2926637|NCT03063606|Experimental|Cognitive-Behavioral Therapy (CBT)|"CBT is a specialist focal treatment with three overlapping phases. (1) Establishing a collaborative therapeutic relationship while focusing on educating patients about the nature of binge eating and factors thought to maintain the problem. Specific behavioral strategies (e.g., self-monitoring) are used to help patients identify problematic eating behaviors while establishing a normal structured eating pattern. (2) Integrating cognitive restructuring procedures, focusing on helping patients learn to identify and challenge maladaptive cognitions regarding eating and weight/shape and thoughts that trigger binge eating. (3) Maintaining change and preventing relapse."
2926638|NCT03063606|Active Comparator|Naltrexone/bupropion (NB) (on-going from acute stage)|Participants will continue acute blinded pharmacotherapy (consisting of either naltrexone/bupropion combination or placebo), but without added cognitive-behavioral therapy.
2926639|NCT03063580|Experimental|SAR439954 with or without rifampicin|Period 1: single oral dose of 400 mg sotagliflozinon Day 1 morning Period 2: once-daily oral doses of 600 mg rifampicin from Days 1 to 10 and a single oral dose of 400 mg sotagliflozin
2926640|NCT03063567|Other|one month trial of Nasal Mask|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
2926641|NCT03063567|Other|One month trial of Oronasal mask|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
2926642|NCT03063567|Other|One month trial of Nasal pillows|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
2926643|NCT03063554|Active Comparator|Endoscopic Ultrasound Guided Biliary Drainage|Endoscopic Ultrasound Guided biliary drainage with stent placement. EUS via either stomach or duodenum.
2926644|NCT03063554|Placebo Comparator|ERCP|Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement only.
2926645|NCT03063541|Experimental|Acetylsalicylic acid, BP-target 120|100 mg ASA plus intensified blood pressure management. Recommended systolic blood pressure 120 mm/Hg
2926646|NCT03063541|No Intervention|standard care|blood pressure management according to guidelines
2926647|NCT03063528|Experimental|Healthy Eating/Physical Activity (HEPA)|"The goals of the HEPA condition are to encourage healthy eating and physical activity behaviors for gaining a healthy amount of weight during pregnancy and to provide motivation and social support to help overcome challenges to eating healthier and becoming more physically active while pregnant.~12 weeks of group-based health behavior (nutrition/PA focused) challenges and weight tracking; podcasts (10); weekly pregnancy tips~website and mobile app"
2926648|NCT03063528|Experimental|Stress Reduction/Management (SRAM)|"The goals of the SRAM condition are to encourage stress reduction and management techniques as well as to provide motivation and social support to reduce stress levels during pregnancy.~12 weeks of group-based health behavior (stress reduction/management) challenges and weight tracking; podcasts (10); weekly pregnancy tips~website and mobile app"
2926649|NCT03063515|No Intervention|IVGTT without pyridostigmine|An intravenous glucose tolerance test (IVGTT) will be performed without any medication for baseline comparison.
2926650|NCT03063515|Active Comparator|IVGTT with pyridostigmine|An IVGTT will be performed 2 hours after taking one single dose of pyridostigmine 60 mg
2926651|NCT03063489|Experimental|Loteprednol Etabonate Ophthalmic Gel|Formulated LE into a gel (loteprednol etabonate ophthalmic gel, [Lotemax® gel])
2926652|NCT03063476|Experimental|Healthy|"Two healthy subjects will be enrolled and each will undergo study procedures at one visit. After screening and consent have been conducted over the phone, subjects will participate in the study procedures. Subjects will arrive in a fasting state (no eat or drink for 8 hours, excluding water). Following collection of blood pressure, height, weight, and a urine and blood sample, subjects will be given an oral bolus of C-13 labeled lysine (5 g) in 50 ml water. This amount of lysine is equivalent to that which is found in a 5oz. serving of beef. Subjects will provide additional urine and blood samples serially post-ingestion. Because blood draws will be collected through an IV, Normal (0.9%) Saline (NS) will be infused at a rate of approximately 10 ml/hr to flush the canula prior to each blood draw.~All subjects will undergo the same procedures and interventions."
2926653|NCT03063463||Pneumatic Dilation|Subject with achalasia undergoing routine care EGD (Esophagogastroduodenoscopy) with pneumatic dilation
2926654|NCT03063463||Surgical Myotomy|Subject with achalasia undergoing routine care EGD with surgical myotomy
2926655|NCT03063450|Experimental|Nivolumab|Nivolumab 240mg flat dose Q2W over 30 minutes IV until disease progression, to a maximum of 12 months
2926656|NCT03063450|Placebo Comparator|Placebo|Sterile 0.9% sodium chloride Q2W over 30 minutes IV until disease progression, to a maximum of 12 months
2926657|NCT03063437|Experimental|Active|encapsulated fecal microbiota preparation
2926658|NCT03063437|Placebo Comparator|Placebo|encapsulated placebo
2926659|NCT03063424|Other|Healthy subjects|
2926660|NCT03063424|Other|Asthmatics with EIB|
2926661|NCT03063411|Experimental|Executive function intervention|The intervention comprises four weekly sessions lasting 15-20 minutes. In these sessions, children complete computerised tasks requiring working memory and inhibitory control. These tasks are child friendly and are based on established measures of executive function. The working memory tasks involve maintaining information in mind and processing information (for example, finding items hiding in different locations that move around) and suppressing a dominant but incorrect response (for example, a game where children try to catch fish but not sharks). Children receive feedback on their responses. If children score 75% or more correct in a session the difficulty level increases in the following session.
2926702|NCT03063190|Active Comparator|Adynamic_1|Chronic Kidney Disease patients with parathyroid hormone lower than 150pg/ml
2926662|NCT03063411|Active Comparator|Visual search and simple decision making|The control task program, like the intervention, comprises four weekly sessions lasting 15-20 minutes. In these sessions, children complete computerised tasks not requiring executive function skills. Instead, they require simple attention and decision making skills and visual search skills. For example, finding an item among distractors (e.g., a spaceship), or deciding which of two animals can fly (out of a bird and a fish). Children receive feedback on their responses.
2926663|NCT03063398||Patients after acute pancreaittis|Such patients will be followed and assessed for the development of Exocrine Pancreatic Insufficiency. 'No intervention, this is an observational study.
2926664|NCT03063385|Experimental|Parental communication intervention|The parental experimental intervention consists of a 60-minute web-based intervention consisting of several modules.
2926665|NCT03063385|Active Comparator|Health promotion control condition.|The Health promotion control condition will be web-based and provide useful information for Puerto Rican parents and youth.
2926666|NCT03063372|Experimental|Pomegranate Supplement|"Participants in this arm will take a capsule with 500 mg of Pomella pomegranate extract twice each day for 28 days."
2926667|NCT03063372|Placebo Comparator|Placebo|Participants in this arm will take a gelatin placebo capsule twice each day for 28 days.
2926668|NCT03063359|Experimental|intranasal fentanyl and oral placebo|Administration of intranasal fentanyl (1.5µg/kg) and oral placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
2926669|NCT03063359|Active Comparator|oral morphine and intranasal placebo|Administration of oral morphine (0.4mg/kg) and intranasal placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
2926670|NCT03063346|Experimental|Protein hydrolysate high dose|
2926671|NCT03063346|Experimental|Protein hydrolysate low dose|
2926672|NCT03063346|Placebo Comparator|Placebo|
2926673|NCT03063333|Experimental|Coping-oriented hypnosis|
2926674|NCT03063333|Placebo Comparator|Neutral hypnosis|
2926675|NCT03063333|No Intervention|current treatment only|
2926676|NCT03063320|Active Comparator|Low Spice|The test meal (~1200kcal and 44g fat) will contain ~0.6g of spice blend
2926677|NCT03063320|Experimental|Moderate Spice|The test meal (~1200kcal and 44g fat) will contain ~3.7g of spice blend
2926678|NCT03063320|Experimental|Culinary Spice|The test meal (~1200kcal and 44g fat) will contain ~7.4g of spice blend
2926679|NCT03063307|Active Comparator|Atraumatic Restorative Treatment|
2926680|NCT03063307|Experimental|Silver Diamine Fluoride|
2926681|NCT03063294|Active Comparator|Toolkit only|Clinics in this arm are given access to an online care coordination toolkit.
2926682|NCT03063294|Experimental|Toolkit plus coaching|Clinics in this arm are given access to an online care coordination toolkit plus quality improvement support from a distance-based coach.
2926683|NCT03063281||SLE patient|165 SLE patients. Subgroup : 77 with active lupus and 88 in disease remission. in the active subgroup : 36 with lupus nephritis and 41 without. Biological analysis were performed.
2926684|NCT03063281||healthy patients|48 healthy patients. Biological analysis were performed.
2926685|NCT03063268|Experimental|Trust-Enhanced Messaged with Interactive Features on E-Consent|Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
2926686|NCT03063268|Experimental|Interactive Features on E-Consent|Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
2926687|NCT03063268|Active Comparator|Standard E-Consent|Standardized text currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
2926688|NCT03063255|Active Comparator|Obturator block|Comparing the incidence of adductor spasm in patients undergoing general anesthesia with obturator block.
2926689|NCT03063255|Active Comparator|Neuromuscular block|Comparing the incidence of adductor spasm in patients undergoing general anesthesia with neuromuscular blocking agents.
2926690|NCT03063242|Experimental|Project I: Healthy participants|5 healthy participants will be used to optimize the dosage and timing of sargramostim administration with regard to the primary and secondary outcomes. Blood samples will be drawn and analyzed for mDC levels.
2926691|NCT03063242|Experimental|Project II: Patients with CKD stage IV/V|5 Patients with CKD stage IV/V who are cytomegalovirus (CMV) seropositive with mean blood mDC levels <1.0x104/mL will receive sargramostim treatment once all 5 healthy participants have completed treatment and the data have been analyzed to guide subsequent dosing. Blood samples will be drawn and analyzed for mDC levels.
2926692|NCT03063242|Experimental|Project III: kidney transplant patients|5 Kidney transplant recipients who are CMV seropositive with neutropenia (defined as absolute neutrophil count <1.0 x103/mm3) and/or CMV viremia will receive sargramostim treatment once all 5 Project I participants have completed treatment and the data have been analyzed to guide subsequent dosing. Blood samples will be drawn and analyzed for mDC levels.
2926693|NCT03063229|Active Comparator|Islet Transplant Patients|Patients with Type 1 Diabetes who are on the waiting list to undergo an islet transplant.
2926694|NCT03063229|Active Comparator|Insulin Pump Therapy Patients|Patients with Type 1 Diabetes waiting to start on an Insulin Pump.
2926695|NCT03063229|Other|Healthy Volunteers|Participants with no Diabetes.
2926696|NCT03063216||Congenital cataract group|Cataract patients diagnosed with congenital cataract.
2926697|NCT03063216||Traumatic cataract group|Cataract patients diagnosed with traumatic cataract.
2926698|NCT03063203|Experimental|Decitabine|"Cycle 1: All patients will receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle~Cycle 2: Patients with bone marrow blast counts < 5% may receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-5 of a 28-day cycle. All other patients will receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle.~Cycle 3 and subsequent cycles: All patients will receive 20 mg/m^2 IV infusion per day over one hour on Days 1-5 of the 28-day cycle"
2926699|NCT03063190|Placebo Comparator|Hyperparathyroidism_0|Chronic Kidney Disease patients with parathyroid hormone higher than 300pg/ml
2926703|NCT03063177|Experimental|1840Newtons/s(N/s);125ms;250 Newtons(N)|Participants will receive a spinal manipulative therapy of 20 Newtons (N) preload leading to a peak force of 250N over 125ms (rate of force application of 1840N/s).
2926704|NCT03063177|Experimental|920N/s;125ms;135N|Participants will receive a spinal manipulative therapy of 20N preload leading to a peak force of 135N over 125ms (rate of force application of 920N/s).
2926705|NCT03063177|Experimental|920N/s;250ms;250N|Participants will receive a spinal manipulative therapy of 20N preload leading to a peak force of 250N over 250ms (rate of force application of 920N/s).
2926706|NCT03063177|No Intervention|control|Spinal stiffness will be assessed at each sesssion, however, participants won't receive any spinal manipulative therapy.
2926707|NCT03063164|Active Comparator|Intralase IFS|Intralase IFS vs. Visumax
2926708|NCT03063164|Active Comparator|Visumax|Visumax vs. Intralase iFS
2926709|NCT03063151|Experimental|Study Group|The Maximum isometric Voluntary Contraction (MVC) was measured by standard muscle testing. Then the subject sat in front of a table with his forearm resting in a comfortable position. The Hand Reaching Spatial Device (HRSD) was located at the maximal hand-reaching range of motion. Participants were requested to point on each target 5 times according to voice prompting that was activated by the EMG software every 10 seconds, for 45 pointing movements. The order of pointing targets was constant for all the participants.
2926710|NCT03063151|Experimental|Control Group|The Maximum isometric Voluntary Contraction (MVC) was measured by standard muscle testing. Then the subject sat in front of a table with his forearm resting in a comfortable position. The Hand Reaching Spatial Device (HRSD) was located at the maximal hand-reaching range of motion. Participants were requested to point on each target 5 times according to voice prompting that was activated by the EMG software every 10 seconds, for 45 pointing movements. The order of pointing targets was constant for all the participants.
2926711|NCT03063125||Bladder Cancer Patients|Patients with bladder cancer scheduled to undergo radical cystectomy (RC).
2926712|NCT03063112|Active Comparator|Group 1( radiofrequency group )|Bilateral thoracic splanchnic nerves block will be performed by radiofrequency thermocoagulation at two level of vertebra T10 and T11 by using radiofrequency generator device and lidocaine 2% before thermal lesion
2926713|NCT03063112|Placebo Comparator|Group 2 ( alcohol group )|Bilateral thoracic splanchnic nerves block will be performed by ethyl alcohol at one level of vertebraT11 by using of C arm fluoroscopic device.
2926714|NCT03063099|Experimental|ReNu™ Injection|ReNu™ is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
2926715|NCT03063086|Active Comparator|Sequence 1|A-B-C
2926716|NCT03063086|Active Comparator|Sequence 2|A-C-B
2926717|NCT03063086|Active Comparator|Sequence 3|B-C-A
2926718|NCT03063086|Active Comparator|Sequence 4|B-A-C
2926719|NCT03063086|Active Comparator|Sequence 5|C-A-B
2926720|NCT03063086|Active Comparator|Sequence 6|C-B-A
2926721|NCT03063073|Placebo Comparator|Group I (Bupivacaine group)|ultrasound guided modified Pec`s block with 30 mL of 0.25% bupivacaine divided into 10 ml injected between the pectoralis muscles and 20 ml between the Pectoralis minor muscle and the serratus muscle
2926722|NCT03063073|Active Comparator|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine Injection [Precedex] (1 µg/kg) divided into 20 ml injected between the pectoralis muscles and 10 ml injected between the Pectoralis minor muscle and the serratus muscle.
2926723|NCT03063060||total thyroidectomy|patients who underwent total thyroidectomy with available vitamin D levels before surgery, as well as pre and post-operative PTH and calcium levels.
2926724|NCT03063047|Active Comparator|PD21871AA, PD21872AA|Subjects will use PD21871AA for 1 week and then PD21872AA for 1 week.
2926725|NCT03063047|Active Comparator|PD21872AA, PD21871AA|Subjects will use PD21872AA for 1 week and then PD21871AA for 1 week.
2926726|NCT03063034|Active Comparator|PD21864AA, PD21864AB|Subjects will use PD21864AA for 1 week and then PD21864AB for 1 week.
2926727|NCT03063034|Active Comparator|PD21864AB, PD21864AA|Subjects will use PD21864AB for 1 week and then PD21864AA for 1 week.
2926728|NCT03063021|Experimental|Experimental Arm (carbonyl content >0.6, GSH/GSSG <3)|Subjects with RP will be enrolled in the experimental arm if they have a high carbonyl content (>0.6) and a reduced GSH/GSSG ratio (<3.0) in the aqueous.
2926729|NCT03063021|Experimental|Exploratory Arm (carbonyl content <0.6, GSH/GSSG >3)|Subjects with RP who don't have a high carbonyl content (>0.6) and a reduced GSH/GSSG ratio (<3.0) but otherwise are good candidates for the study will be enrolled in the exploratory arm.
2926730|NCT03063008|Other|Lumbar fusion with PEEK cage|Control arm
2926731|NCT03063008|Other|Lumbar fusion with TiPEEK cage|Study arm
2926732|NCT03062995|Experimental|Active product: partially hydrolysed formula + synbiotics|
2926733|NCT03062995|Active Comparator|Control product: standard formula (intact protein)|
2926734|NCT03062982|Experimental|Group A|Administration of 120mg in fed state in Dosing Period 1 followed by administration of 120mg in fasted state in Dosing Period 2
2926735|NCT03062982|Experimental|Group B|Administration of 120mg in fasted state in Dosing Period 1 followed by administration of 120mg in fed state in Dosing Period 2
2926736|NCT03062969||Cleavage stage biopsy group|Patients undergoing a PGS cycle with single blastomere biopsy on day 3 and analysis using comparative genomic hybridation bacterial artificial chromosome (BAC) arrays (aCGH) If euploid blastocysts were available, patients underwent fresh blastocyst transfer on day 5.
2926737|NCT03062969||Trophectoderm biopsy group|Patients undergoing a PGS cycle with blastocyst biopsy on day 5-7 and analysis using comparative genomic hybridation bacterial artificial chromosome (BAC) arrays (aCGH). If euploid blastocysts were available, patients underwent frozen-thawed blastocyst transfer.
2926738|NCT03062956|Experimental|Single oral dose of MYK-491|single-dose, oral suspension
2926739|NCT03062956|Placebo Comparator|Single oral dose of placebo|single-dose, oral suspension
2926740|NCT03062943|Experimental|Nintedanib 150mg BID|nintedanib soft gelatine capsules Dose: 150 mg bid Mode of admin. : Oral Duration of treatment: 1 year Duration of follow-up: 12 months after treatment discontinuation
2926741|NCT03062930|Active Comparator|Track 1|Training of non-paretic arm for 3 weeks consisting of occupational therapy and kinematic tasks followed by sham condition (playing board games/computer games) for 3 weeks
2926742|NCT03062930|Sham Comparator|Track 2|Sham condition (playing board games/computer games) for 3 weeks followed by training of the non-paretic arm for 3 weeks consisting of occupational therapy and kinematic tasks
2926743|NCT03062917|Other|Emergency Department|Babies with suspected respiratory tract infection (RTI) in the ED
2926744|NCT03062917|Other|Paediatric Wards|Babies with diagnosed RSV infection admitted to paediatric wards
2926745|NCT03062917|Other|Paediatric Intensive Care|Babies with diagnosed severe RSV infection in PICU requiring mechanical ventilation
2926746|NCT03062917|Other|Health Controls|Babies without respiratory symptoms, attending routine outpatient appointments or undergoing elective surgical procedures
2926747|NCT03062917|Other|Controls in Paediatric Intensive Care|Babies without RSV infection but requiring mechanical ventilation in PICU
2926748|NCT03062904|Experimental|drug|
2926749|NCT03062891|Experimental|Online CBT for insomnia|"CBT participants will receive six weekly sessions delivered by an animated 'virtual therapist' (The Prof) via the online platform 'Sleepio'. The programme comprises a fully automated media-rich web application, driven dynamically by baseline, adherence, performance and progress data, and provides additional access to elements such as an online library with background information, a community of fellow users, and support, prompts and reminders sent by e-mail.~CBT content was consistent with the literature (4) and covered behavioral (e.g., sleep restriction, stimulus control) and cognitive (e.g., putting the day to rest, thought restructuring, imagery, articulatory suppression, paradoxical intention, mindfulness) strategies, as well as additional relaxation strategies (progressive muscle relaxation and autogenic training) and advice on lifestyle and bedroom factors (sleep hygiene). The intervention was based upon a previously validated manual (4)."
2926750|NCT03062891|No Intervention|Puzzles|Each week participants will be sent a puzzle to complete online (e.g. logic puzzles, crosswords etc). The puzzles have been designed to be cognitively engaging and take a similar amount of time to one session of Sleepio (20-25 minutes).
2926751|NCT03062878||Breast Cancer/Lymphoma Patient|Breast cancer or lymphoma patients currently undergoing anthracycline-based chemotherapy treatment. Patients are eligible if they have completed at least 1 cycle of chemotherapy. Free of known clinical cardiovascular disease.
2926752|NCT03062878||Breast Cancer/Lymphoma Survivor|Individuals with history of breast cancer or lymphoma (1-5 years removed from last date of chemotherapy) who have a treatment history of anthracycline-based chemotherapy. Free of known clinical cardiovascular disease.
2926753|NCT03062878||Control|Individuals with no history of caner or chemotherapy. Free of known clinical cardiovascular disease
2926754|NCT03062852|Experimental|Medication safety vest|During administration rounds, nurses will wear the medication safety vest.
2926755|NCT03062852|No Intervention|Control|During administration rounds, nurses will be dressed as usual without a safety vest.
2926756|NCT03062839|Experimental|Melatonin|Melatonin 5 mg taken 30 minutes before bed time
2926757|NCT03062839|Placebo Comparator|Placebo|Placebo identical to melatonin capsule taken 30 min before bed time
2926758|NCT03062813|Experimental|Tacrolimus & entecavir|Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.
2926759|NCT03062813|Active Comparator|placebo & entecavir|Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.
2926760|NCT03062800|Experimental|P+Cisplatin/Carboplatin+T|"Induction therapy (Platinum based chemotherapy combined with antiangiogenic therapy 4-6 cycles):~Pemetrexed + Platinum + Thalidomide [pemetrexed (500mg/m^2)+cisplatin(75mg/m^2)or carboplatin(AUC=5) on day 1 of 21-days cycle, ivgtt +thalidomide 100-200mg/d ,oral, qn ]~Continue maintenance therapy (It is defined when a drug included in the induction treatment is used as maintenance .Patients who had not progressed during induction phase will be in this phase):~Thalidomide 100mg/d ,oral, qn, until either disease progression or unacceptable toxicity."
2926761|NCT03062800|Experimental|P+Cisplatin/Carboplatin|"Induction therapy ( Platinum based chemotherapy 4-6 cycles):~Pemetrexed + Platinum [pemetrexed (500mg/m^2)+cisplatin(75mg/m^2)or carboplatin(AUC=5) on day 1 of 21-days cycle,ivgtt ]~Maintenance therapy (It is defined when a drug included in the induction treatment is used as maintenance .Patients who had not progressed during induction phase will be in this phase):~Pemetrexed (500mg/m^2) on day 1 of 21-days cycle, ivgtt.until either disease progression or unacceptable toxicity"
2926762|NCT03062787|Experimental|Cingal®|Single 4 ml intra-articular injection of Hyaluronic Acid plus Triamcinolone Hexacetonide
2926763|NCT03062787|Active Comparator|Monovisc®|Single 4 ml intra-articular injection of Sodium Hyaluronate
2926764|NCT03062774|Experimental|PB-119|intervention: PB-119 injection
2926765|NCT03062761|Experimental|Active product: partially hydrolysed proteins|Partially hydrolysed whey protein based infant formula containing prebiotics.
2926766|NCT03062761|Active Comparator|Control product: standard formula (intact protein)|Intact cow's milk protein based infant formula containing prebiotics.
2926767|NCT03062735|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training intervention (Sham-IMT) groups during a 3 months training season. A pressure threshold device (POWERbreathe - HaB International Ltd., UK) will be used to IMT. The IMT group will perform 30 inspiratory efforts, 5 times a week, twice daily, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure (MIP).
2926768|NCT03062735|Sham Comparator|Sham Inspiratory Muscle Training|Sham-IMT group will follow a similar protocol, except the inspiratory effort that will be made against 15% MIP. The duration of each IMT session will be 30 inspirations. After the initial setting of training loads, the IMT group will be instructed to periodically increase load so that only 30 maneuvers could be completed. The Sham-IMT group will not receive these instructions. All the IMT sessions, in both groups will take place before swimming training and will be supervised throughout the intervention period to ensure that technique and load will be appropriate.
2926769|NCT03062722|Experimental|keyhole approach|open minimally invasive approach
2926770|NCT03062709|Experimental|All Participants|Breathe Easy Coalition written materials provided to parent/guardian, plus Maine Tobacco Helpline referral provided to smoking adult in the home, plus testing of the child's urine cotinine and results reported to parent/guardian
2926771|NCT03062696|Experimental|Intervention (CBT-RD)|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-RD. There is no control group.
2926772|NCT03062683||Non-convulsive syncope patients|Patients with a non-convulsive syncope triggered by a tilting table examination and whose serum lactate, prolactin and creatine kinase conc. in blood samples had been measured after the event.
2926773|NCT03062683||Convulsive syncope patients|Patients with a convulsive syncope triggered by a tilting table examination and whose serum lactate, prolactin and creatine kinase conc. in blood samples had been measured after the event.
2926774|NCT03062670|Experimental|Retreat|A full day off-site training session
2926775|NCT03062670|No Intervention|Control|Care teams normal process
2926776|NCT03062657|Experimental|PRESTIGE LP|Patients receive surgical treatment with the PRESTIGE LP™ Cervical Disc at two contiguous cervical levels from C3-C7.
2926777|NCT03062644|Experimental|MR308 100 mg bid|Tramadol/Celecoxib)
2926778|NCT03062644|Experimental|MR308 150 mg bid|Tramadol/Celecoxib
2926779|NCT03062644|Experimental|MR308 200 mg bid|Tramadol/Celecoxib
2926780|NCT03062644|Active Comparator|Tramadol 100 mg qid|Tramadol
2926781|NCT03062644|Active Comparator|Celecoxib 100 mg bid|Celecoxib
2926782|NCT03062644|Placebo Comparator|Placebo|Placebo
2926783|NCT03062618|Experimental|Part A: Single Dose|Two escalating sequences of single oral doses of PRCL-02, in 3 periods, starting at 4 milligrams (mg)
2926784|NCT03062618|Placebo Comparator|Part A: Single Dose (Placebo)|Two escalating sequences of matching placebo oral tablets, in 3 periods
2926785|NCT03062618|Experimental|Part B: Multiple Dose|Multiple oral doses of PRCL-02 for 28 days, at up to 3 dose levels
2926786|NCT03062618|Placebo Comparator|Part B: Multiple Dose (Placebo)|Multiple oral doses of placebo for 28 days, at matching dose levels
2926787|NCT03062618|Experimental|Part C: Multiple Dose|Multiple oral doses of PRCL-02 for 28 days, at up to 3 dose levels
2926788|NCT03062618|Placebo Comparator|Part C: Multiple Dose (Placebo)|Multiple oral doses of placebo for 28 days, at matching dose levels
2926789|NCT03062605|Active Comparator|Treatment(TX)|. Participants were assigned randomly to one of two treatment groups and continued in parallel for the three-month duration of the study. The first treatment group (TX) rinsed with NaOCL (0.3%) for one minute followed by rinsing with iodine (10%) for one minute
2926790|NCT03062605|Active Comparator|Control (CT)|. Participants were assigned randomly to one of two treatment groups and continued in parallel for the three-month duration of the study. The control group (CT) rinsed with iodine (10%) for minute. The CT group was a positive control. Both of these treatments were done only once at the baseline. The reminder of the three-month study was to obtain saliva samples at specific times to determining microbial levels.
2926791|NCT03062592|No Intervention|Screening/Baseline|A standard OGTT with no supplementation/intervention
2926792|NCT03062592|Experimental|Non-hydrolyzed pine nut oil|Standard OGTT supplemented with 1 g of non-hydrolyzed pine nut oil
2926793|NCT03062592|Experimental|hydrolyzed pine nut oil|Standard OGTT supplemented with 1 g of hydrolyzed pine nut oil
2926794|NCT03062579|Experimental|ACTEMRA® (Tocilizumab)|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible.
2926795|NCT03062566||Severe TBI patients|GCS 3-8
2926796|NCT03062553|Experimental|MCT + Neuromodulation (MCT-N)|"Participants (n=50) randomly assigned to the MCT-N condition will undergo transcranial alternating current stimulation (tACS) prior to participation in MCT.~Neuromodulation involving tACS will target increasing the power of the alpha band at dorsomedial prefrontal regions, and this is expected to also decrease the power of the beta band in ventro-medial regions. This will be confirmed by EEG recordings and source estimation during a task.~The Metacognitive Training (MCT) group intervention will consist of an 8‐module cycle occurring twice a week for 4 weeks, for a total of 8 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects."
2926797|NCT03062553|Experimental|Sham/MCT group (MCT- S)|"Participants (n=50) randomly assigned to the Sham/MCT (MCT-S) condition will undergo the application of random patterns of low-grade currents to the same brain region as the neuromodulation condition prior to participation in MCT.~MCT is a four week program with eight one-hour sessions. MCT can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of an 8‐module cycles occurring twice a week for 4 weeks, for a total of 8 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects."
2926798|NCT03062553|Experimental|Neuromodulation/Treatment as Usual TAU-N|"Participants (n=50) randomly assigned to the Neuromodulation/TAU (TAU - N) condition will undergo transcranial alternating current stimulation (tACS) prior to being placed on the TAU waitlist.~Neuromodulation involving tACS will target increasing the power of the alpha band at dorsomedial prefrontal regions, and this is expected to also decrease the power of the beta band in ventro-medial regions. This will be confirmed by EEG recordings and source estimation during a task.~TAU is a four week waitlist control group."
2926799|NCT03062540|Experimental|TNX-102 SL Tablet, 2.8 mg|2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
2926800|NCT03062540|Placebo Comparator|Placebo SL Tablet|2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
2926801|NCT03062527|Experimental|Low Glycemic Index Diet|"Group consuming low glycemic index diet. Calculated glycemic index of daily diet was lower than 40. Carbohydrate- containing foods included whole rye bread, pumpernickel bread, whole oats, wheat brans, brown rice, buckwheat, vegetables (besides corn, cooked carrots, potatoes and pumpkin) and fruit such as apples, pears, grapefruits, tangerines, prunes, dried apricots and unripe bananas.~Interventions:~The experimental procedure for each participant included a 3-week low glycemic index diet. Between the 3-week low and moderate glycemic index diets or a moderate and low glycemic index treatment, a 14-day washout period was introduced."
2926802|NCT03062527|Experimental|Moderate Glycemic Index Diet|"Group consuming moderate glycemic index diet. Calculated glycemic index of diet was higher than 60. Carbohydrate- containing foods included wheat bread, wheat rolls, potatoes, instant oats, cornflakes, white rice, millet, boiled carrots and fruit (ripe bananas, grapes, raisins, dates, cranberry, honey and high sugar jams)~Interventions:~The experimental procedure for each participant included a 3-week moderate glycemic index diet. Between the 3-week low and moderate glycemic index diets or a moderate and low glycemic index treatment, a 14-day washout period was introduced."
2926803|NCT03062514|Experimental|Experimental|Subjects'Vagus Nerve stimulator is on always
2926804|NCT03062514|Sham Comparator|Control|Subjects'Vagus Nerve stimulator is off from enrollment to 3 month
2926805|NCT03062501|No Intervention|Control (No Hydroxyurea)|Patients in VOC will be treated according to the center's usual practice and analgesia protocol.
2926806|NCT03062501|Experimental|Hydroxyurea|Patients in VOC will receive up to three daily doses of 30-40 mg / kg hydroxyurea.
2926807|NCT03062488|Active Comparator|opioid only|2 mcg/Kg of fentanyl
2926808|NCT03062488|Active Comparator|opioid plus PO analgesic|2 mcg/Kg of fentanyl plus PO acetaminophen 15 mg/Kg
2926809|NCT03062488|Active Comparator|opioid plus IV acetaminophen|2 mcg/Kg of fentanyl plus 15mg/Kg of IV acetaminophen
2926810|NCT03062475|Experimental|lifestyle intervention group|Pregnant women allocated to this group receive lifestyle intervention. With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake. With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed or encourage them to do moderate cycling.
2926811|NCT03062475|No Intervention|control group|Pregnant women allocated to this group receive standard prenatal care.
2926812|NCT03062462|Active Comparator|clopidogrel|To observe double standard-dose clopidogrel on platelet aggregation in clopidogrel resistance's patients with coronary heart disease
2926813|NCT03062462|Experimental|ticagrelor|To observe low-dose of ticagrelor on platelet aggregation in clopidogrel resistance's patients with coronary heart disease
2926814|NCT03062449|Active Comparator|L-Serine Gummy Arm|L-serine will be presented in gummies containing 1g serine each. Subjects randomized into the L-serine arm will take 15 grams of L-Serine (15 gummies containing 1g of L-serine) orally twice daily for 246 days after the initial ascending dose period to confirm tolerability of the dose.
2926815|NCT03062449|Placebo Comparator|Placebo Gummy Arm|Placebo gummies containing no L-serine will be packaged in the same manner as that of the L-Serine gummy arm and be given to patients to take two times a day.
2926816|NCT03062436|Experimental|Sustained molecular remission|Patients of CML who remain in sustained molecular remission at 12 months after Stopping the standard drug therapy
2926817|NCT03062423|Experimental|T test|Test drug (Sofodelevier)1 tablet contains 400 mg Sofosbuvir
2926818|NCT03062423|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
2926819|NCT03062423|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
2926820|NCT03062410|Other|Electronic PRO|All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
2926821|NCT03062397|Experimental|Low-dose group|JPI-289 Low dose or placebo
2926822|NCT03062397|Experimental|High-dose group|JPI-289 High dose or placebo
2926823|NCT03062397|Placebo Comparator|Placebo group|Same dosage of JPI-289 low and high dose
2926824|NCT03062384|Experimental|AT-001|Yeast-selenium supplement
2926825|NCT03062384|Placebo Comparator|Placebo|Yeast supplement devoid of selenium
2926826|NCT03062371|Experimental|Playgroup Intervention|The approach of the playgroup is to promote healthy family play routines with an emphasis on child and family well-being. The intervention types for playgroup sessions included the occupation of play, activities to promote play and participation, educating caregivers through modeling and coaching, advocating for the child and family, and the use of group sessions. Specific playgroup strategies included a predictable routine, following the child's lead, imitating the child, modeling of new behaviors, and scaffolding play - within both the social and physical environment. When developing activities, play objects that families have at home and are easily obtained were used and positioned intentionally with respect to the child-caregiver dyad and the group as a whole.
2926827|NCT03062358|Experimental|pembrolizumab + BSC|Participants receive pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.
2926828|NCT03062358|Placebo Comparator|placebo + BSC|Participants receive placebo by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.
2926829|NCT03062345|Experimental|Single-User Mode first, Multi-User Mode second|
2926830|NCT03062345|Experimental|Multi-User Mode first, Single-User Mode second|
2926831|NCT03062332||Bipolar disorder,mania|The group includes subjects who are diagnosed to mania episode of bipolar disorder.
2926832|NCT03062332||Bipolar disorder,depressive|The group includes subjects who are diagnosed to depression episode of bipolar disorder.
2926833|NCT03062332||Bipolar disorder,mixed|The group includes subjects who are diagnosed to mixed episode of bipolar disorder.
2926834|NCT03062332||First episode major depression|The group includes subjects who are diagnosed to first episode of major depression.
2926835|NCT03062332||major depression，recurrent|The group includes subjects who are diagnosed to recurrent episode of major depression.
2926836|NCT03062332||Healthy control|The group includes subjects who are Healthy control.
2926837|NCT03062319|Active Comparator|Dual-therapy group|Dual-therapy group: single anticoagulant drug and single antiplatelet drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years is recommended according to the Japanese guidelines.
2926838|NCT03062319|Active Comparator|Single-therapy group|Single-therapy group: single anticoagulant drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years is recommended according to the Japanese guidelines.
2926839|NCT03062293|Experimental|Functional Re-adaptive Exercise Device|Single arm for within subject repeated measures design.
2926840|NCT03062280|Experimental|Chronocort®|Chronocort® modified release hydrocortisone
2926841|NCT03062267|No Intervention|Treatment as Usual|Treatment as usual for 3 months.
2928160|NCT03053375|Experimental|Acute/subacute; active device|MDCure active device
2926842|NCT03062267|Experimental|Mobile Interventionist|Participants will exchange text messages with a mobile interventionist throughout the day for 3 months.
2926843|NCT03062254|Experimental|Radium-223|
2926844|NCT03062241|Experimental|Cryoablation|The pulmonary vein (PV) isolation in patients randomized to intervention group.
2926845|NCT03062241|No Intervention|Conventional treatment|Pharmacological treatment according to 2016 ESC (European Society of Cardiology) guidelines for the diagnosis and treatment of acute and chronic heart failure and to 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with European Association for Cardio-Thoracic Surgery (EACTS).
2926846|NCT03062228||Controls|"Healthy, Ghanaian women who have recently delivered a live birth at the Korle Bu Teaching Hospital.~No interventions will be administered."
2926847|NCT03062215|Experimental|Space from depression|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions depression. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page. Also, users have a supporter, who will give feedback asynchronously (D Richards et al., 2015). Research on the SilverCloud interventions has yielded significant clinical outcomes (D Richards et al., 2015).
2926848|NCT03062215|No Intervention|Control Group|Waiting list
2926849|NCT03062202|Experimental|Depression group|SilverCloud iCBT for depression.
2926850|NCT03062202|Experimental|Anxiety group|SilverCloud iCBT anxiety disorders.
2926851|NCT03062202|Experimental|Comorbid Depression and Anxiety group|SilverCloud iCBT for comorbid depression and anxiety.
2926852|NCT03062176|Experimental|Active Treatment|Anakinra (Kineret)
2926853|NCT03062163|Experimental|Resveratrol lipoic Acid|lipoic and resveratrol was loaded on the patch
2926854|NCT03062163|Experimental|Placebo|normal saline was loaded on transdermal patch
2926855|NCT03062150|Placebo Comparator|Placebo+Placebo|Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.
2926856|NCT03062150|Active Comparator|Fludrocortisone+Placebo|"Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH~Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH."
2926857|NCT03062150|Active Comparator|Placebo+D-Cycloserine|"Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd"
2926858|NCT03062150|Active Comparator|Fludrocortison+D-Cycloserine|"Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd"
2926859|NCT03062111|Active Comparator|ProTouch Laser Enucleation of Prostate|The intervention for this group is that the patient will undergo endoscopic ProTouch Laser Enucleation of Prostate (LEP).The laser is used to enucleate large pieces of prostatic tissue which is followed by further ablation of the tissue so that no fragments are left in the bladder
2926860|NCT03062111|Active Comparator|Transurethral Resection of Prostate|The intervention for this group that the patient will undergo endoscopic Transurethral Resection of Prostate (TURP) using bipolar cautery. The prostate is essentially shaved down using sequential cuts and cautery.
2926861|NCT03062098|Experimental|IVF patients|IVF patients before embryo transfer. Before performing embryo transfer in the routine manner, ten patients will be asked to participate in the study. After signing informed consent, participants will undergo the experimental procedure: Speculum will be placed to visualize the cervix. The thin ultrasound probe will be places posterior to the cervix. While viewing the image on the ultrasound screen, the probe will be moved manually to obtain the best imaging of the cervical canal. An empty embryo transfer catheter will be introduced to the cervical canal and will be advanced under ultrasound imaging up to the internal os. The catheter will be withdrawn, and routine embryo transfer will follow.
2926862|NCT03062085||High myopic cataract group|Cataract patients with high myopia.
2926863|NCT03062085||Age-related cataract group|Age-related cataract patients.
2926864|NCT03062085||Ametropic cataract group|Cataract patients with ametropia.
2926865|NCT03062059|No Intervention|Control arm|
2926866|NCT03062059|Experimental|Intervention arm|Intravesical 2000mg/52.6ml gemcitabine instillation during radical nephroureterectomy
2926867|NCT03062046|Experimental|RF ablation|Subjects undergoing RF ablation with the Thermocool SmartTouch® (ST) or SmartTouch Surroundflow® (STSF) catheter for treatment of drug resistant symptomatic paroxysmal AF
2926868|NCT03062033||Cohort 1|Patients without visible signs of involuntary movements (possible TD) at time of clinician assessment
2926869|NCT03062033||Cohort 2|Patients with visible signs of involuntary movements (possible TD) at the time of clinician assessment
2926870|NCT03062020|Experimental|Intervention group: QUIPP tool arm|In this group, QUIPP tool will be used to select and manage patients attending our PBPC: high-risk patients will be followed-up in our PBPC and low-risk patients will be discharged from PBPC and managed in a low-risk unit.
2926871|NCT03062020|No Intervention|Control group: no QUIPP tool arm|Women will be managed according to current clinical practice.
2926872|NCT03062007|Experimental|BI-CON-02|The start dose of BI-CON-02 will be 0,3 mg/kg and it will be possible to increase gradually BI-CON-02 doses up to 0,6 mg/kg; 1,2 mg/kg; 2,4 mg/kg; 3,6 mg/kg and 4,8 mg/kg for subsequent dose cohorts. A possibility to include a new dose cohort in the study will be considered by the Data and Safety Monitoring Committee, basing on the data of BI-CON-02 safety and tolerability, received at the Visit (Week 3, Day1) in the previous dose cohort (3 weeks after - 21st day of therapy).
2926873|NCT03061994||Cardiomyopathy|"Children(older than 18 years old) are diagnosed as cardiomyopathy by three cardiologists and recruited in pediatric heart center,Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.~Adults are diagnosed as cardiomyopathy by three cardiologists and recruited in the department of cardiology ,Beijing Anzhen Hospital."
2926874|NCT03061994||Control|Healthy children and adults are recruited in Beijing Anzhen Hospital, with negative results of echocardiography and clinical lab examination.
2926875|NCT03061981|Active Comparator|DA-1241:8 subjects in each cohort(Cohort 1-6)|Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
2926876|NCT03061981|Placebo Comparator|Placebo: 2 subjects in each cohort(Cohort 1-6)|Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
2926877|NCT03061981|Other|DA-1241 in IE Cohort: 8 subjects in choosen cohort|One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
2926878|NCT03061981|Other|Placebo in IE Cohort: 2 subjects in choosen cohort|One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
2926879|NCT03061968|Experimental|experimental group|The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
2926880|NCT03061968|No Intervention|control group|The control group only receive routine care in sick baby room unite.
2926881|NCT03061942|Active Comparator|Conventional|Arthroscopic rotator cuff repair without synovectomy
2926882|NCT03061942|Experimental|Synovectomy|Arthroscopic rotator cuff repair with synovectomy
2926883|NCT03061929||Undernourised|Mother's with BMI less than 18.5
2926884|NCT03061929||Normally Nourished|Mother's with BMI greater than or equal to 18.5 to less than or equal to 25.
2926885|NCT03061929||Overnourished|Mother's with BMI over 25 to less than or equal to 35.
2926886|NCT03061916|Experimental|Cinnamon|20% cinnamon will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving cinnamon 20%
2926887|NCT03061916|Experimental|Ginger|20% ginger will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving ginger 20%
2926888|NCT03061916|Active Comparator|Chlorhexidine|Chlorhexidine gluconate 0.2%,will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving chlorhexidine.
2926889|NCT03061903|Experimental|Prevena|Subjects will receive PREVENA after surgery.
2926890|NCT03061903|Active Comparator|Aquacel|Subjects will receive AQUACEL Ag after surgery.
2926891|NCT03061890||Prematurity and Respiratory Outcomes Program (PROP)|extant, NIH-supported preterm birth cohort NCT01435187
2926892|NCT03061890||Trial of Late Surfactant (TOLSURF)|extant, NIH-supported preterm birth cohort NCT01022580
2926893|NCT03061890||NICU Hospital Exposures and Long-Term Health (NICU-HEALTH)|extant, NIH-supported preterm birth cohort NCT01963065
2926894|NCT03061890||Preterm Erythropoietin Neuroprotection Trial (PENUT)|extant, NIH-supported preterm birth cohort NCT01378273
2926895|NCT03061877||Anxiety or depression|
2926896|NCT03061877||Non-anxiety or depression|
2926897|NCT03061864|No Intervention|Standard Counseling|Patients at risk of delivery between 20 and 25+6 weeks gestation will receive the normal counseling from Ob/gyn and Neonatology.
2926898|NCT03061864|Experimental|Periviable Birth Plan|Patients at risk of delivery between 20 and 25+6 weeks gestation will receive the normal counseling from Ob/gyn and Neonatology with completion of the written periviable birth plan.
2926899|NCT03061851|Experimental|conventional treatment|given conventional hypoglycemic drug treatment, the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
2926900|NCT03061851|Experimental|conventional treatment + maltose app|the patients were treated with conventional hypoglycemic drugs. The treatment plan was decided by the investigators according to the patient's condition. The intervention was not done in this study.And joint: maltose App intervention.
2926901|NCT03061838|Active Comparator|MabThera®|2 intravenous infusions on Week 0 and Week 2 (14-day interval).
2926902|NCT03061838|Experimental|Ritumax®|2 intravenous infusions on Week 0 and Week 2 (14-day interval).
2926903|NCT03061812|Experimental|Rovalpituzumab tesirine|Rovalpituzumab tesirine intravenous administration on Day 1 of a 42-Day cycle for 2 cycles.
2926904|NCT03061812|Active Comparator|Topotecan|Topotecan intravenous on Days 1 through 5 of each 21-Day cycle.
2926905|NCT03061799|Experimental|HPC-03|"To experimental arm randomly assigned, HPC-03 will administrated twice a day , two capsules each time (total dose of HPC-03: 2g/day) for 12 weeks (84days).~*(HPC-03: extracts of angelica gigas nakai, cnidium rhizome, and cinnamon bark.)"
2926906|NCT03061799|Placebo Comparator|Placebo|To control arm randomly assigned, placebo will administrated twice a day , two capsules each time for 12 weeks (84days).
2926907|NCT03061786||AKI|
2926908|NCT03061786||non-AKI|
2926909|NCT03061773|Experimental|Exercise group|Exercise group: physical training lasting 12 weeks, after detraining and in the end the control group receives physical training
2926910|NCT03061773|Active Comparator|Group did not exercise|Group did not exercise: conventional hospital treatment
2926911|NCT03061760||1. OAB (-) BOO (-)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with no overactive bladder (OAB) symptoms and without bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
2926912|NCT03061760||2. OAB (-) BOO (+)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with no overactive bladder (OAB) symptoms and with bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
2926913|NCT03061760||3. OAB (+) BOO (+)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with overactive bladder (OAB) symptoms and with bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
2926914|NCT03061760||4.OAB (+) BOO (-)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with overactive bladder (OAB) symptoms and without bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
2926915|NCT03061760||5.Control group|Healthy volunteer individuals aged 20-40. 'Initial evaluation' made only once.
2926916|NCT03061734|Experimental|ALLOD-2 Capsules|Each patient receives one capsule containing component A (regular dose) and one capsule containing component B and uses both capsules together for treatment of a qualified Migraine attack
2926917|NCT03061734|Experimental|ALLOD-2H Capsules|Each patient receives one capsule containing component A (high dose) and one capsule containing component B and uses both capsules together for treatment of a qualified Migraine attack
2926918|NCT03061734|Active Comparator|Active Comparator Component A Capsules|Each patient receives one capsule containing component A of ALLOD-2 and one capsule containing a placebo comparator for component B of ALLOD-2 and uses both capsules together for treatment of a qualified Migraine attack
2926919|NCT03061734|Active Comparator|Active Comparator Component B Capsules|Each patient receives one capsule containing component B of ALLOD-2 and one capsule containing a placebo comparator for component A of ALLOD-2 and uses both capsules together for treatment of a qualified Migraine attack
2926920|NCT03061734|Placebo Comparator|Placebo Capsules|Each patient receives one capsule containing a placebo comparator for component A of ALLOD-2 and one capsule containing a placebo comparator for component B of ALLOD-2 and uses both capsules together for treatment of a qualified Migraine attack
2926921|NCT03061721|Experimental|Saroglitazar magnesium 1 mg|Saroglitazar magnesium 1 mg tablet orally once daily in the morning before breakfast for 16 weeks.
2926922|NCT03061721|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet orally once daily in the morning before breakfast for 16 weeks.
2926923|NCT03061721|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet orally once daily in the morning before breakfast for 16 weeks.
2926924|NCT03061721|Placebo Comparator|Placebos|Placebo tablet orally once daily in the morning before breakfast for 16 weeks.
2926925|NCT03061708|Experimental|AZD2014 50mg BD continuous schedule of a 28 day cycle|AZD2014 50mg BD continuous schedule of a 28 day cycle
2926926|NCT03061682|Experimental|Add on lens|
2926927|NCT03061656|Experimental|High risk neuroblastoma|"Conventional chemotherapy (9 cycles)~Surgery conventional chemotherapy (after 6 cycles of chemotherapy)~Tandem HDCT/autoSCT~First HDCT (cyclophosphamide, etoposide, carboplatin)~Second HDCT (high-dose 131I-MIBG, thiotepa, melphalan)~Local radiotherapy~Retinoic acid, interleukin-2"
2926928|NCT03061643|Experimental|Docetaxel PLUS ADT|receive docetaxel 40 mg/m2 IV every 2 weeks plus ADT
2926929|NCT03061630|Experimental|gemcitabine|cisplatin 60 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15. On day 1
2926930|NCT03061617|Other|volume controlled ventilation (VCV)|VCV mode, tide volume 6ml/kg, f 12-14, set fixed tide volume for each breath
2926931|NCT03061617|Experimental|pressure controlled ventilation (PCV)|PCV mode, pressure is adjusted to achieve tide volume 6ml/kg, f 12-14
2926932|NCT03061604|Experimental|Hemospray|"All subjects will be treated by medical treatment in the terms of combination of vasoactive medication, blood transfusion and Ceftriaxone PLUS Hemospray treatment within 2 hours of admission.~The medical treatment will be continued till 12 hours after admission and then second endoscopy will be performed (12-24 hours after admission)."
2926933|NCT03061604|Active Comparator|Non Hemospray|"All subjects will be treated by medical treatment in the terms of combination of Octreotide, blood transfusion and Ceftriaxone.~The medical treatment will be continued till 12 hours after admission and then second endoscopy will be performed (12-24 hours after admission)."
2926934|NCT03061591|Active Comparator|Wholistic Turmeric capsules|"Oral capsules of wholistic Turmeric capsules (Pukka herbs) (each capsule 100 mg curcumin) divided twice daily, or an identical placebo in 2 divided doses daily all taken before meals.~Pukka's Wholistic Turmeric"
2926935|NCT03061591|Placebo Comparator|Placebo|Identical placebo capsules
2926936|NCT03061578||NDE|"Non Dry Eye (NDE) group will be used as control for DES diagnosis.~Subjects in the non-dry eye criteria must meet all of the following criteria:~Have a Schirmer's Test (without anesthesia) of ≥10mm/5min in both eyes~OSDI questionnaire score <13.~Fluorescein TBUT > 7 s in both eyes.~CFS of 0 in all areas in both eyes.~The NDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
2926937|NCT03061578||ADDE|"Aqueous Deficiency Dry Eye (ADDE) group will be define by commonly known signs and symptoms.~In order to classify subjects to the moderate to severe ADDE group, subjects must meet a predefined medical condition (Rheumatoid Arthritis, Dermatomyositis, Lupus or Sjögren's syndrome) and meet at least one of the following conditions:~Have a Schirmer's Test (without anesthesia) of ≤5mm/5min in either eye~Mean CFS of ≥1 in either eye.~Fluorescein TBUT ≤5 s in either eye.~OSDI questionnaire score ≥20~The ADDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
2926938|NCT03061578||LDDE|"Lipid Deficiency Dry Eye (LDDE) group will be define by commonly known signs and symptoms.~In order to classify subjects to the moderate to severe LDDE group, subjects must have moderate to severe Meibomian Gland Dysfunction (MGD score of 3-6) and meet at least one of the following conditions:~Have a Schirmer's Test (without anesthesia) of ≤5mm/5min in either eye~Mean CFS of ≥1 in either eye.~Fluorescein TBUT ≤5 s in either eye.~OSDI questionnaire score ≥20~The LDDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
2926939|NCT03061565||Erythropoietin|Patients were treated with EPO during the EPO-TBI study in 2010-2014.
2926940|NCT03061565||Placebo|Patients were treated with placebo during the EPO-TBI study in 2010-2014.
2926941|NCT03061552|Experimental|IVCD arm|IVCD-assisted determination of target post-dialysis weight
2926942|NCT03061552|No Intervention|conventional arm|conventional determination of target post-dialysis weight
2926943|NCT03061539|Experimental|Nivolumab & Ipilimumab|Patients will receive Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every three weeks for a maximum of 4 doses followed by a 6 week gap after last combination dose. The patients will then receive 480 mg flat dose of nivolumab every 4 weeks for up to one year, or until progression, unacceptable toxicity or withdrawal of consent.
2926944|NCT03061513|Active Comparator|Ubiquinol|600mg ubiquinol daily for 24 weeks
2926945|NCT03061513|Placebo Comparator|Placebo|Placebo daily for 24 weeks
2926946|NCT03061487||Group I|"Patients affected by central and peripheral aneurismatic disease with maximum statin daily dose ( Atorvastatin 80 mg, Simvastatin 40 mg, Rosuvastatin 40 mg).~Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).~The investigation consist in:~taking a preoperative blood sample to evaluate the MMPs circulating levels~taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels"
2927039|NCT03060941|Experimental|Group 14|Physical activity education, facility access, self-monitoring (Fitbit), and active living counseling
2928161|NCT03053375|Placebo Comparator|Acute/subacute; sham|MDCure sham device
2926947|NCT03061487||Group II|"Patients affected by central and peripheral aneurismatic disease with minimum statin daily dose.~Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).~The investigation consist in:~taking a preoperative blood sample to evaluate the MMPs circulating levels~taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels"
2926948|NCT03061474|Experimental|Nicotinamide|1500mg twice daily: 2, 750mg tablets taken orally twice daily
2926949|NCT03061474|Placebo Comparator|Placebo|1500mg twice daily: 2, 750mg tablets taken orally twice daily
2926950|NCT03061461|Active Comparator|rESWT|"Treatment of chronic wounds with the Swiss DolorClast (Electro Medical Systems S.A., Nyon, Switzerland) and the EvoBlue handpiece as follows:~Use of the 15-mm applicator or the 36-mm applicator of the Swiss DolorClast according to the individual wound size.~Six treatment sessions, two treatment sessions per week.~1000 radial shock waves per cm^2 wound and treatment session.~Energy flux density 0.07 mJ/mm^2 (i.e., setting of the air pressure of the Swiss DolorClast at 2 bar when using the 15-mm applicator, and at 4 bar when using the 36-mm applicator).~Frequency of the radial shock waves set at 15 Hz."
2926951|NCT03061461|Sham Comparator|Sham rESWT|"Treatment of chronic wounds with the Swiss DolorClast (Electro Medical Systems S.A., Nyon, Switzerland) and the placebo EvoBlue handpiece of the Swiss DolorClast (that looks and sounds like the EvoBlue handpiece of the Swiss DolorClast, but does not generate radial shock waves) as follows:~Use of the 15-mm applicator or the 36-mm applicator of the Swiss DolorClast according to the individual wound size.~Six treatment sessions, two treatment sessions per week.~1000 sham radial shock waves per cm^2 wound and treatment session.~Energy flux density 0.00 mJ/mm^2 (setting of the air pressure of the Swiss DolorClast at 2 bar when using the 15-mm applicator, and at 4 bar when using the 36-mm applicator).~Frequency of the sham radial shock waves set at 15 Hz."
2926952|NCT03061448|Experimental|Inhibitory learning based treatment|The experimental group will go through Internet-based treatment. The exposure treatment is 8 weeks long and based on the principles of inhibitory learning, i.e. the participant is instructed to stay in the frightening situation until his/her expectancy has been maximally violated.
2926953|NCT03061448|Active Comparator|Habituation based treatment|The active comparator group will also go through Internet-based treatment. The exposure treatment is 8 weeks long and based on the principles of emotional processing theory, i.e. the participant is instructed to stay in the frightening situation until anxiety has declined (habituated).
2926954|NCT03061435|Other|Screening anal Pap Smear - Negative (75%)|All patients will receive an anal Pap test. 75% of patients with a negative anal Pap will complete study with no further intervention.
2926955|NCT03061435|Other|Screening anal Pap Smear - Negative (25%)|All patients will receive an anal Pap test. Remaining 25% of patients will proceed to high-resolution anoscopy (HRA) clinic to assess the negative predictive rate of HRA.
2926956|NCT03061435|Other|Screening anal Pap Smear - Positive|All patients will receive an anal Pap test. Any patient with abnormal cytology on their Pap test will be referred to HRA clinic for management. This includes potential biopsy and treatment.
2926957|NCT03061422|Experimental|xylitol chewing gum|intervention
2926958|NCT03061422|Experimental|xylitol with bicarbonate chewing gum|intervention
2926959|NCT03061422|Active Comparator|Paraffin pellet|comparator
2926960|NCT03061409|Experimental|Pharmavite Nature Made Multi for Him 50+|A supplement containing vitamins and minerals
2926961|NCT03061409|Placebo Comparator|placebo|tablets contain microcrystalline cellulose containing 0.5% magnesium stearate
2926962|NCT03061396|Experimental|Electroacupuncture Single point|Single point PC6 means there is only one acupoint to be chosen: Neiguan(PC6)
2926963|NCT03061396|Experimental|Electroacupuncture Matching points|There are three acupoints to be chosen:Bilateral Neiguan(PC6)and Zhongwan(CV12)
2926964|NCT03061383|Active Comparator|8% Arginine based toothpaste|The procedure will be performed after scaling in group D1 using 8% arginine based toothpaste (Colgate Pro-relief) . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
2926965|NCT03061383|Active Comparator|8% Strontium acetate based toothpaste|The procedure will be performed after scaling in group D2 using 8% strontium acetate based toothpaste (Sensodyne Rapid Action) . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
2926966|NCT03061383|Placebo Comparator|tooth past without active ingredient|The procedure will be performed after scaling in group D3 control group using placebo . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
2926967|NCT03061357|Experimental|Activity tracker group|Participants in intervention arm were provided with a small and lightweight activity tracker, Misfit Flash (Misfit Wearables Co., Burlingame, CA), that can be worn with a clasp or watch band. A handout detailing the step-by-step instructions for utilizing the activity tracker with Misfit App on their smartphone was provided. There was no intervention component mandated in the curriculum of intervention PAIP courses; rather, participants were continuously encouraged by the instructors to track their activity levels and use all the features in Misfit App on a daily basis as they learned health benefits of PA and as to how to develop individualized, life-long PA plan during the course of semester.
2926968|NCT03061357|No Intervention|Control group|Participants in control arm did not receive any additional instructions other than the scheduled class activities based on the standardized core-curriculum of PAIP
2926969|NCT03061344|Experimental|liquid buccal mucosa graft|DVIU treated with liquid buccal mucosal graft; endoscopic injection of morcellated buccal mucosal graft mixed with fibrin glue
2926970|NCT03061331|Experimental|Treatment Sequence 1|LUM/IVA in Treatment Period 1; washout; placebo in Treatment Period 2
2926971|NCT03061331|Experimental|Treatment Sequence 2|Placebo in Treatment Period 1; washout; LUM/IVA in Treatment Period 2
2926972|NCT03061292|Experimental|Pectoral Nerve Block|Patients undergoing cardiac implantable electronic device implantation with local anaesthesia and sedation with pectoral nerve block
2926973|NCT03061292|Sham Comparator|Without Pectoral Nerve Block|Patients undergoing cardiac implantable electronic device implantation with local anaesthesia and sedation without pectoral nerve block
2926974|NCT03061279|Experimental|Fixation by Acutrak headless screw|
2926975|NCT03061279|Active Comparator|Fixation by headed screws, plates and or wire|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes LC-DCP Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire.
2926976|NCT03061266|Experimental|E-health education group|E-health education group will be received the shared care program using e-health education.
2926977|NCT03061266|Other|Routine care|Control group will be received the shared care program as advised by clinical professionals, which included medications, dietary control and general physical activities.
2926978|NCT03061253|Experimental|Nicotine-inclusive e-cigarettes|Participants will receive e-cigarettes (nicotine-inclusive) combined with behavioural change support over a 3 month period.
2926979|NCT03061253|Experimental|Nicotine-free e-cigarettes|Participants will receive e-cigarettes (nicotine-free) combined with behavioural change support over a 3 month period.
2926980|NCT03061253|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy combined with behavioural change support over a 3 month period.
2926981|NCT03061240|Experimental|Postoperative patients|We recruit postoperative patients who undergo open surgery and are not receiving local anesthesia. We install a smart pain assessment tool on patient's skin to capture different type of data.
2926982|NCT03061227|Active Comparator|Intravenous glucagon|Low-dose glucagon infusion (0.5 pmol/min/kg body weight) over 150 minutes during a standardized 75 g oral glucose tolerance test
2926983|NCT03061227|Placebo Comparator|Intravenous saline|Saline infusion over 150 minutes during a standardized 75 g oral glucose tolerance test
2926984|NCT03061214|Experimental|Semaglutide 0.5 mg OW + sitagliptin placebo OD|
2926985|NCT03061214|Experimental|Semaglutide 1 mg OW + sitagliptin placebo OD|
2926986|NCT03061214|Active Comparator|Sitagliptin OD + semaglutide placebo 0.5 mg OW|
2926987|NCT03061214|Active Comparator|Sitagliptin OD + semaglutide placebo 1 mg OW|
2926988|NCT03061201|Experimental|Sequential dose escalation|SB-525 is administered as a single infusion
2926989|NCT03061188|Experimental|Treatment (veliparib, nivolumab)|Patients receive veliparib PO BID on day 1 and nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4 and IV over 60 minutes on day 1 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2926990|NCT03061175|Experimental|Arm I (usual care)|Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM.
2926991|NCT03061175|Experimental|Arm II (web-based CPM-DA)|Patients receive a website address, a secure username and password, and instructions for using the web-based CPM-DA.
2926992|NCT03061162|Experimental|Study Arm|Gastric cancer patients with peritoneal metastasis undergo pulsed low dose rate 3-dimensional conformal radiation therapy, QD, 5 days a week for 25 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
2926993|NCT03061149|Experimental|Group with low-level laser treatment|"The group received low-level laser therapy (LLLT). The application of a GaAlAs infrared laser with a pencil probe (BTL 5000 Combi, United Kingdom; at 830 nm, 9J/cm2 per point, power output of 100 mW, beam diameter of 5 mm) was performed at five points along the median nerve on the palmar side of the wrist 7. The time of exposure was 10 minutes (2 minutes per point). Both the patient and the therapist wore protective glasses during every session.A total of 10 therapeutic sessions were performed during a period of two weeks (five session times per week).~Additionally, nerve and gliding exercises were administered."
2926994|NCT03061149|Active Comparator|Group with ultrasound treament|The group underwent ultrasound treatment. Ultrasound treatment was administered at a frequency of 1 MHz, intensity of 1 W/cm2 ,pulsed mode duty cycle of 1:4 and with a handhold transducer of 5 cm2 (BTL 5000 Combi, UK). The time of application was 6 minutes over the area of the carpal tunnel. Aquasonic gel was used as a couplant. A total of 10 therapeutic sessions were performed during a period of two weeks (five session times per week). Additionally, nerve and gliding exercises were administered.
2926995|NCT03061136|Placebo Comparator|Placebo|Placebo administered orally
2926996|NCT03061136|Experimental|Clonazepam 0.1mg|0.1mg clonazepam administered orally
2926997|NCT03061136|Experimental|Clonazepam 0.2mg|0.2mg clonazepam administered orally
2926998|NCT03061136|Experimental|Clonazepam 0.3mg|0.3mg clonazepam administered orally
2926999|NCT03061110|Active Comparator|Usual Care|Subjects in the Usual Care arm will receive typical therapies to manage the symptoms of dry mouth including but not limited to: chewing gum, sucking sugar-free candy, sipping water, mouth rinses and over-the-counter artificial saliva preparations.
2927000|NCT03061110|Experimental|Stromal Vascular Fraction|Subjects in the Stromal Vascular Fraction arm will receive single injections into each of the six (6) peri-oral salivary glands (parotid, submandibular, sublingual).
2927001|NCT03061097|Experimental|Treatment (autologous fecal microbiota preparation)|"Autologous treatment preparation: Patient stool will be collected and processed into an auto-fecal microbiota preparation (FMP) formulation. In this treatment arm, the auto-FMP will be administered to the participant following an infectious episode requiring antibiotics.~V-A Auto-FMP Enema (125 mL):~Route of Administration: Enema nozzle will be inserted into rectum and contents expelled into the distal colon. Target dwell time is 1 hour. Participants will lie in the left lateral decubitas position but if mobility permits will rotate to supine and right lateral decubitus position.~Dosing Regimen: 125mL x 1 dose"
2927002|NCT03061097|Placebo Comparator|Placebo|"Participants randomized to the placebo arm will receive a placebo FMT via enema. The placebo enema preparation interventional enema in appearance.~The placebo enema preparation will be comprised of Sodium Chloride (0.9%, USP), Glycerol (12.5%, USP), and 8-12 drops brown food coloring (<1%), to prevent unmasking of the trial arms."
2927003|NCT03061071|Experimental|Randomized to SPT First: APAP Second|Randomized to order of treatment (SPT first or APAP first) for a total of 6 weeks home use with each treatment.
2927004|NCT03061071|Experimental|Randomized to APAP First: SPT Second|Randomized to order of treatment (APAP first or SPT first) for a total of 6 weeks home use with each treatment.
2927040|NCT03060941|Experimental|Group 15|Physical activity education, supervised exercise sessions, self-monitoring (Fitbit), and active living counseling
2927041|NCT03060941|Experimental|Group 16|Physical activity education, facility access, supervised exercise sessions, self-monitoring (Fitbit), and active living counseling
2927005|NCT03061058|Experimental|Individualized Group|"mRNA levels of BRCA1, topoisomerase I (TOPO1), and thymidylate synthase (TS) were assessed in tumor tissue. Chemotherapeutic agents were selected based on the mRNA levels.~Patients with high level BRCA1 will receive intraperitoneal docetaxel (15mg/m^2, d1, d15, q4w), intravenous docetaxel (30mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).~Patients with low level BRCA1 will receive intraperitoneal cisplatin (25mg/m^2, d1, d15, q4w), intravenous oxaliplatin (75mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).~Patients with middle level BRCA1 and high level TOPO1 will receive intraperitoneal irinotecan (45mg/m^2, d1, d15, q4w), intravenous docetaxel (90mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).~Patients with middle level BRCA1, low or middle level TOPO1, and low level TS will receive intraperitoneal pemetrexed (150mg/m^2, d1, q3w), and intravenous pemetrexed (350mg/m^2, d1, q3w)."
2927006|NCT03061058|Active Comparator|Control Group|"mRNA levels of BRCA1, TOPO1, and TS were assessed in tumor tissue for every enrolled patients.~Patients in control group will receive intravenous docetaxel (45mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w)."
2927007|NCT03061045|Experimental|Contrast Enhanced Brain Ultrasound|Neonates with post-hemorrhagic hydrocephalus recruited for this study will all undergo contrast enhanced ultrasound examination of the head, a diagnostic intervention for the study.
2927008|NCT03061032|Experimental|Sofosbuvir/Ledipasvir for 12W|"Patients without cirrhosis and previous history of treatment will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks."
2927009|NCT03061032|Experimental|Sofosbuvir/Ledipasvir+Ribavirin for 12W|"Patients with compensated cirrhosis and/or previous history of treatment will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks."
2927010|NCT03061032|Experimental|Sofosbuvir/Ledipasvir for 24W|"Patients with compensated or decompensated cirrhosis and/or previous history of treatment and with contraindication of Ribavirin will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks."
2927011|NCT03061032|Experimental|Sofosbuvir/Ledipasvir+Ribavirin for 24W|Patients with decompensated cirrhosis will be treated with this regimen. Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
2927012|NCT03061019|Active Comparator|Myofunctional Oral Exercices|Parents and participants of this group will receive instructions for nasal and oral myo-functional exercises, to perform at home each day, for 5 to 10 minutes. A booklet (measure of adherence) and an Phone application for Android/Apple with descriptions/videos of those exercices will be given to them. These exercises will include nasal hygiene procedures, nasal cartilage exercices, lingual posture rehabilitation exercises, lip tone enhancement exercises, and swallowing rehabilitation exercises.
2927013|NCT03061019|Experimental|Soft Oral Appliance|Parents and participants will be instructed in wearing the soft/flexible oral appliance and how to perform nasal hygiene in order to better tolerate the device. The oral appliance comes in several sizes, adapted to the age of the child; it is constructed in a soft elastomer material, in a position of slight propulsion and opening of the mandible to help clear the pharynx. It has a ramp to guide the tongue in a good position, a labial screen to stretch the labial strap and prevent the tongue from protruding between front teeth.
2927014|NCT03061019|No Intervention|Control Group|Parents and Participants of this group will be reminded the nasal hygiene procedures (application of saline in each nostril three times a day), and given a diary to report daily use.
2927015|NCT03061006|Experimental|Dabigatran Etexilate|150 mg BID (CrCL > 30 mL/min) or 75 mg BID (CrCL 15-30 mL/min)
2927016|NCT03061006|Active Comparator|Warfarin|Dose-adjusted warfarin (INR: 2.0-3.0)
2927017|NCT03060993|Placebo Comparator|Placebo|35 mg of tetrahydrocannabinol/cannabidiol (LT1.0/LT1.0 %) in vaporized form. Placebo will be vaporized using the Volcano Medic vaporizer. Total volume of vapour administered to each patient will be 5.5 L.
2927018|NCT03060993|Active Comparator|Cannabis|35 mg of cannabis (tetrahydrocannabinol/cannabidiol; 18.0/LT1.0 %) in vaporized form. THC/CBD will be vaporized using the Volcano Medic vaporizer. Total volume of vapour administered to each patient will be 5.5 L.
2927019|NCT03060980|Experimental|Experimental: Group 1|ITCA 650 20/60 mcg/day
2927020|NCT03060980|Experimental|Experimental: Group 2|Empagliflozin 10 mg/day and 25 mg/day
2927021|NCT03060980|Experimental|Experimental: Group 3|Glimepiride 1-6 mg/day
2927022|NCT03060967|Experimental|Depressed patients|Computer-based tasks evaluating size and time discrimination capacities of food and control images
2927023|NCT03060967|Experimental|Normal Healthy Volunteers|Computer-based tasks evaluating size and time discrimination capacities of food and control images
2927024|NCT03060954|Experimental|MINI WELL READY ®|BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY
2927025|NCT03060954|Other|FineVision ®|FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
2927026|NCT03060941|Experimental|Group 1|Physical activity education
2927027|NCT03060941|Experimental|Group 2|Physical activity education and facility access
2927028|NCT03060941|Experimental|Group 3|Physical activity education and supervised exercise sessions
2927029|NCT03060941|Experimental|Group 4|Physical activity education and self-monitoring (Fitbit)
2927030|NCT03060941|Experimental|Group 5|Physical activity education and active living counseling
2927031|NCT03060941|Experimental|Group 6|Physical activity education, facility access, and supervised exercise sessions
2927032|NCT03060941|Experimental|Group 7|Physical activity education, facility access, and self-monitoring (Fitbit)
2927033|NCT03060941|Experimental|Group 8|Physical activity education, facility access, and active living counseling
2927034|NCT03060941|Experimental|Group 9|Physical activity education, supervised exercise sessions, and self-monitoring (Fitbit)
2927035|NCT03060941|Experimental|Group 10|Physical activity education, supervised exercise sessions, and active living counseling
2927036|NCT03060941|Experimental|Group 11|Physical activity education, self-monitoring (Fitbit), and active living counseling
2927037|NCT03060941|Experimental|Group 12|Physical activity education, facility access, supervised exercise sessions, and self-monitoring (Fitbit)
2927038|NCT03060941|Experimental|Group 13|Physical activity education, facility access, supervised exercise sessions, and active living counseling
2927043|NCT03060928|Experimental|Experimental 1|Arthroscopic Rotator Cuff Repair with standard treatment + biological stimulation with micro-perforations
2927044|NCT03060928|Experimental|Experimental 2|Arthroscopic Rotator Cuff Repair with standard treatment + biological stimulation with the combination of micro-perforations and use of Artelon® Tissue Reinforcement
2927045|NCT03060915|Other|Polysomnography and actigraphy|Polysomnography and actigraphy
2927046|NCT03060902|Experimental|Dialectical Behavior Therapy Skills|Dialectical Behavior Therapy SKills; 2.5 hour group session/week; 1 year
2927047|NCT03060902|No Intervention|Family Services as Usual|Mothers will continue with services they are receiving in the community
2927048|NCT03060889|Active Comparator|Cases|Tranexamic acid 10 mg/ kg body weight will be given by intravenous infusion with induction of anesthesia in elective cesarean section for non complicated cases of placenta previa
2927049|NCT03060889|No Intervention|Controls|Control group will not receive Tranexamic acid
2927050|NCT03060863|No Intervention|1. Comparison|Families in this group will not receive any of the interventions.
2927051|NCT03060863|Experimental|2. Executive functioning|"Children in this arm will have the opportunity to use a computer-based working memory training game to practice recalling stimuli with an increasing number of presentations prior (n-back task)."
2927052|NCT03060863|Experimental|3. Food Bias|Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
2927053|NCT03060863|Experimental|4. Emotion Regulation|Children in this arm will use a computer-based, game-like relaxation training to teach emotion regulation and coping strategies.
2927054|NCT03060863|Experimental|5. Future orientation|Children in this arm will participate in an interview training protocol to promote their capacity to utilize and articulate a future oriented perspective.
2927055|NCT03060850|Experimental|AC0010MA|This is dose escalation study. Patients will receive AC0010MA 200mg bid,300mg bid,400mg bid or 500mg bid by mouth (the dose escalation whether ended depends on DLT and occupancy) everyday until intolerable toxicity or disease progression
2927056|NCT03060837|Active Comparator|Patients given single lung ventilation|The first group will have single lung ventilation applied to ensure reduction. Preoperative Parameters : Hmg, serum creatinine levels Peroperative Parameters : Scope duration, perforation, hemorrhage, etc. complications) Postoperative parameters (stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc) Movement of kidney : Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
2927057|NCT03060837|Active Comparator|Patients given standard ventilation|This group will have standard ventilation. Preoperative Parameters : Hmg, serum creatinine levels Peroperative Parameters : Scope duration, perforation, hemorrhage, etc. complications) Postoperative parameters (stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc) Movement of kidney : Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
2927058|NCT03060824||CABG with the aid of CPB.|Cardiac surgical patients subjected to coronary artery bypass grafting with the aid of Cardiopulmonary Bypass. Perioperative measurements of osmolality in plasma.
2927059|NCT03060785|Experimental|TFV/FTC dosing in Transgender women|Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada)for 7days in transgender women taking feminizing hormones
2927060|NCT03060785|Active Comparator|TFV/FTC dosing in Cis men|Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) for 7days in cis men
2927061|NCT03060772|Experimental|Alcohol use disorder - Pioglitazone Treatment|Participants with alcohol use disorder randomized to this group will receive pioglitazone. Study procedures include a bronchoscopy at baseline and an additional bronchoscopy after taking the study medication for 2 to 4 weeks.
2927062|NCT03060772|No Intervention|Alcohol use disorder - No Pioglitazone|Participants with alcohol use disorder randomized to this group will receive their usual care but will not receive pioglitazone. Study procedures include a bronchoscopy at baseline and an additional bronchoscopy 2 to 4 weeks later.
2927063|NCT03060772|No Intervention|Healthy controls without alcohol use disorder|Healthy individuals who do not have alcohol use disorder will be enrolled will serve as a control group. Healthy controls will be a matched to participants receiving the treatment based on age, gender, and smoking status. This group will have a single bronchoscopy.
2927064|NCT03060759|Active Comparator|Light Therapy-Spectrum 1|Light from 'active' spectrum
2927065|NCT03060759|Placebo Comparator|Light Therapy-Spectrum 2|Light from 'placebo' spectrum
2927066|NCT03060707|Experimental|Continuous infusion|The group of participants who are designated to receive continuously infused rocuronium.
2927067|NCT03060707|Active Comparator|Bolus administration|The group of participants who are designated to receive bolus administered rocuronium.
2927068|NCT03060694||Diabetes group|Patients in this group are recruited from both departments of endocrinology and gastroenterology. The diagnosis of diabetes is confirmed by medical history, using anti-diabetic medicines or laboratory tests.
2927069|NCT03060694||Non-diabetes group|Patients in this group are recruited from department of gastroenterology. The exclusion of diabetes is confirmed by medical history or laboratory tests.
2927070|NCT03060681|Experimental|T group|Ultrasound guided Bilateral TLIP Block will be performed 15 minute before the start of surgery Using 15 ml of bupivacaine 0.25 for each side.
2927071|NCT03060681|No Intervention|C group|
2927072|NCT03060668|Experimental|Study Group|"Caloric needs will be determined by indirect calorimetry. Patients in this group will receive 2.0 to 2.2 grams/kg/day of protein.~Nutritional therapy will be initiated in the first 24 hours after admission.~Nutritional formula will be Peptamen Intense (1.0 kcal/ml, 93 g/L protein (Nestle Health Care)."
2927073|NCT03060668|Active Comparator|Control Group|"Patients in this group will receive 25 Kcal/kg/day and 1.4 to 1.5 grams/kg/day of protein.~Nutritional formula in this group will be Novasource senior (Nestle Health Care).~Nutritional therapy will be initiated in the first 24 hours after admission."
2927074|NCT03060655|Placebo Comparator|PLGA-Mg material|The fixation of fragments of study group was accomplished with PLGA-Mg material.
2927075|NCT03060655|Placebo Comparator|titanium alloy|The fixation of fragments of control group was accomplished with titanium alloy material.
2927076|NCT03060642||Barrett's esophagus|Barrett's esophagus, without or with dysplasia or adenocarcnoma
2927078|NCT03060629|Experimental|Group 1|Participants will receive Ad26.Mos4.HIV 5*10^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) injection into the left deltoid on Months 0, 3, 6, and 12 and Clade C gp140 (250 [microgram] mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
2927079|NCT03060629|Placebo Comparator|Group 2|Participants will receive Placebo for Ad26.Mos4.HIV as 0.5 mL into the left deltoid on Months 0, 3, 6, and 12 and Placebo for Clade C gp140 / Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
2927080|NCT03060603||Erythropoietin|Recombinant Human Erythropoietin, EPREX 4000 IU/0.4 ml, three times in a week, until the correction of anemia, approximately two months.
2927081|NCT03060577|Experimental|Inclisiran|Participants will receive subcutaneous injections of inclisiran 300 milligrams (mg) on Day 1 and every 180 days thereafter for up to 4 years.
2927082|NCT03060577|Active Comparator|Evolocumab|Participants will receive self-administered subcutaneous injections of evolocumab 140 mg on Day 1 and every 14 days thereafter until Day 336. Then, the participants will receive subcutaneous injections of inclisiran 300 mg on Day 360 and every 180 days thereafter for up to 4 years.
2927083|NCT03060564|Experimental|AC repair with tendon graft|acromioclavicular repair with tendon graft.
2927084|NCT03060564|Active Comparator|AC repair with no tendon graft|acromioclavicular repair without tendon graft/no intervention
2927085|NCT03060551|Experimental|SVF injection|SVF was obtained from lipoaspirates, using an automated processing system, and subsequently injected into the subcutaneous tissue of each finger in contact with neurovascular pedicles
2927086|NCT03060538|Experimental|Multiple Ascending Dose BFKB8488A|Participants will be randomized to receive BFKB8488A. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort.
2927087|NCT03060538|Placebo Comparator|Placebo|Participants will receive BFKB8488A-matching placebo.
2927088|NCT03060525|Experimental|Immediate Group Intervention|This arm will receive the DWW 2.0 Group intervention in Year 1 of the clinical trial. The group intervention will consist of groups of approximately 6-8 subjects who meet together for 16 weeks, for two hours each week. A trained, deaf, American Sign Language (ASL)-fluent DWW 2.0 counselor will lead the sessions. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, group sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
2927089|NCT03060525|Experimental|Immediate Videophone Intervention|This arm will receive the DWW 2.0 Individual Videophone intervention in Year 1 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
2927090|NCT03060525|Other|Delayed Group Intervention|This arm will receive the DWW 2.0 Group intervention in Year 2 of the clinical trial. The group intervention will consist of groups of approximately 6-8 subjects who meet together for 16 weeks, for two hours each week. A trained, deaf, American Sign Language (ASL)-fluent DWW 2.0 counselor will lead the sessions. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, group sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
2927091|NCT03060525|Other|Delayed Videophone Intervention|This arm will receive the DWW 2.0 Individual Videophone intervention in Year 2 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
2927092|NCT03060512|Active Comparator|Crossover Group 1|"Crossover Group Movantik to Polyethylene Glycol 3350~2-period, 2-treatment cross-over model: Subjects will be randomized to Movantik during Treatment period 1 (2 weeks), then crossed over to receive Polyethylene Glycol 3350 for Treatment period 2 (2 weeks) after 1 week washout."
2927093|NCT03060512|Active Comparator|Crossover Group 2|"Crossover group Polyethylene Glycol 3350 to Movantik~2-period, 2-treatment cross-over model: Subjects will be randomized to Polyethylene Glycol 3350 during Treatment period 1 (2 weeks), then crossed over to receive Movantik for Treatment period 2 (2 weeks) after 1 week washout."
2927094|NCT03060486|Experimental|HYBENX®|1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
2927095|NCT03060473|Experimental|Azithromycin|Ampicillin 2 gm IV every 6 hours followed by amoxicillin 500 mg PO every 8 hours with Azithromycin 1 gm PO once at randomization.
2927096|NCT03060473|Active Comparator|Erythromycin|Ampicillin 2 gm IV every 6 hours followed by amoxicillin 250 mg PO every 8 hours for 5 days with erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
2927097|NCT03060460|Experimental|Ultrasound arm - Randomized group|Ultrasound guided sheath insertion
2927098|NCT03060460|No Intervention|Conventional arm - Randomized group|Conventional arm during randomized phase
2927099|NCT03060460|No Intervention|Historical control group|Conventional arm, non-randomization phase
2927178|NCT03059927|Active Comparator|Knee arthroplasty, Anterior stabilized|Total knee replacement with sacrificed posterior cruciate ligament and an anterior stabilized insert.
2927179|NCT03059927|Active Comparator|Knee arthroplasty, Posterior stabilized|Total knee replacement with sacrificed posterior cruciate ligament and a posterior stabilized design.
2927100|NCT03060447|Experimental|Vesatolimod|"Period 1: Participants will receive up to 10 doses of vesatolimod. Participants will continue to take their prescribed ART during this period.~Period 2: All participants will discontinue ART and be monitored for rebound in HIV-1 plasma viremia.~Period 3: Participants may either enter in an optional analytical treatment interruption (ATI) extension period where they will continue to be off ART for up to an additional 6 months or restart ART and be monitored for additional 6 months."
2927101|NCT03060447|Experimental|Vesatolimod placebo|"Period 1: Participants will receive up to 10 doses of vesatolimod placebo. Participants will continue to take their prescribed ART during this period.~Period 2: All participants will discontinue ART and be monitored for rebound in HIV-1 plasma viremia.~Period 3: Participants may either enter in an optional analytical treatment interruption (ATI) extension period where they will continue to be off ART for up to an additional 6 months or restart ART and be monitored for additional 6 months."
2927102|NCT03060434|Active Comparator|Control|Ibuprofen
2927103|NCT03060434|Experimental|Pentoxifylline|Pentoxifylline oral tablets
2927104|NCT03060421||Aquamid Reconstruction|Patients that have been treated with at least one intra-articular injection of aquamid as a treatment of osteoarthritis of the knee
2927105|NCT03060408||Open|Patients underwent open distal pancreatectomy
2927106|NCT03060408||Laparoscopic|Patients underwent laparoscopic distal pancreatectomy
2927107|NCT03060395|Sham Comparator|A1/A2 milk|"Commercial conventional A1/A2 semi-skimmed fresh pasteurised cow milk. Progressive intake of intervention milk as follows:~Days 1 and 2: 100 mL twice a day~Days 3 and 4: 150 mL twice a day~Days 5 and 6: 200 mL twice a day~Days 7 to 14: 250 mL twice a day"
2927108|NCT03060395|Active Comparator|A2 milk|"Commercial A2 semi-skimmed fresh pasteurised cow milk.~Progressive intake of intervention milk as follows:~Days 1 and 2: 100 mL twice a day~Days 3 and 4: 150 mL twice a day~Days 5 and 6: 200 mL twice a day~Days 7 to 14: 250 mL twice a day"
2927109|NCT03060382|Experimental|balanced buttress absorbable spacer|For the patients of study group, a balanced buttress absorbable spacer was placed into tibia.
2927110|NCT03060382|Placebo Comparator|total knee arthroplasty|For the patients of control group, total knee arthroplasty was conducted.
2927111|NCT03060369||Established Shock (Cohort A)|"Meeting criteria i or ii, AND iii:~i. SBP ≤ 90mm Hg for greater than 30 minutes ii. Requirement for vasopressor or ionotrope to maintain SBP > 90mm Hg iii. New dysfunction of at least one organ, including altered mental status, acute renal failure (increase from baseline in serum creatinine >0.3 mg/dL or by 50%), oliguria (<0.5 mL/kg/h for >6h) , or hepatic injury (ALT, AST, or total bilirubin >2xULN)suspected by the treating physician to be caused by organ hypoperfusion"
2927112|NCT03060369||Emerging Shock (Cohort B)|"Meeting criteria i or ii, AND iii:~i. New SBP ≤ 90mm Hg for greater than 30 minutes or recurrent shorter episodes, requiring use of or clinical anticipation of the need for fluid resuscitation or vasopressor/inotropic support to maintain SBP > 90 mm Hg ii. New dysfunction of at least one organ (as defined above), including altered mental status, acute renal failure, oliguria, or hepatic injury not explained by a specific non-hemodynamic cause iii. Does not meet criteria for Established Shock"
2927113|NCT03060356|Active Comparator|Melanoma|Intravenous infusion 1x10^8 total T cells modified with RNA anti-cMET CAR
2927114|NCT03060356|Active Comparator|Breast|Intravenous infusion 1x10^8 total T cells modified with RNA anti-cMET CAR
2927115|NCT03060343|Experimental|Zeushield Cytotoxic T Lymphocytes|Enrolled patients will receive Zeushield Cytotoxic T Lymphocytes by infusion
2927116|NCT03060330|Experimental|LVMR|Laparoscopic Ventral Mesh Rectopexy
2927117|NCT03060330|Experimental|LVMR with STARR|Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection
2927118|NCT03060317||Validation group DOC|Examination with neurological scales.
2927119|NCT03060304|Experimental|study group|Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8. Follicle diameters are monitored by transvaginal ultrasound and serum levels of E2, P are tested on day 9. If there is a dominant follicle (almost 12 × 12 mm in diameter), endometrial thickness and endometrial pattern, as well as follicular diameters, were monitored daily or every other day till embryo transfer. Serum levels of E2, P are tested on the day before ovulation. If there isn't dominant follicle and intramuscular human menopausal gonadotropin at a dose of 75-150 IU was administered each day after day 12 if there follicle development was poor. The embryo transfer day is decided according embryo development.
2927120|NCT03060304|Active Comparator|control group|Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3. Follicle diameters are monitored by transvaginal ultrasound and serum levels of E2, P are tested on day 9. If endometrial thickness <7mm and E2＜100pg/ml, the dose of estradiol valerate can increase or combine other estradiol. Endometrial thickness and endometrial pattern, as well as follicular diameters, were monitored daily or every other day till embryo transfer. Serum levels of E2, P are tested on the day before endometrium transformation. The embryo transfer day is decided according embryo development. Serum levels of E2, P are tested on the day before embryo transfer.
2927121|NCT03060291|Experimental|Web/ Mobile-only|Participants will complete the FCU online independently, without the help of a coach.
2927122|NCT03060291|Active Comparator|Web/mobile + coach|Participants will complete the FCU online and will be contacted by a family coach. The coach will conduct motivational interviewing and provide support to parents via phone. Participants in this condition will have contact with a coach at least 2 times.
2927123|NCT03060291|No Intervention|Wait list control|"Participants in this condition will receive middle school as usual, meaning that they will continue to receive whatever services are normally provided by the middle school during the year of their participation in the study. Once their research participation is completed (i.e., after they complete their final follow-up survey), participants in this condition will be offered the opportunity to use the FCU-Online website if they wish, without the support of a coach. No additional data will be collected."
2927124|NCT03060278|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment will receive a smartphone with active service, brief advice to quit smoking (self-help materials), an 8-week supply of nicotine replacement therapy (patches), and provided 5 proactive phone counseling sessions by a trained Certified Tobacco Treatment Specialist.
2927180|NCT03059914|Experimental|InterOss|Maxillary sinus augmentation using ABBM Inteross ( Xenograft)
2927181|NCT03059914|Active Comparator|Bio-oss|Maxillary sinus augmentation using ABBM Bio-oss ( Xenograft)
2927125|NCT03060278|Experimental|Automated Treatment|Participants randomized to Automated Treatment will receive smartphone-delivered automated treatment that will provide tailored smoking cessation treatment by way of video clips, text and graphical messages. Participants will receive notifications on study provided smartphone once a week for an 8-week treatment period. Content delivered will be specific to the participants smoking status and motivation to quit.
2927126|NCT03060265|Active Comparator|Paracetamol|Paracetamol Braun Germany 1 gram in 100ml normal saline, one dose IV
2927127|NCT03060265|Placebo Comparator|Placebo|100ml normal saline, one dose IV
2927128|NCT03060252||The overall individuals taking ZGGJ Pill|The overall individuals taking ZGGJ Pill with recommended dosage and achieving the inclusion criteria.
2927129|NCT03060239|Experimental|Experimental arm|Patients with Parkinson's disease with severe REM sleep behaviour disorder according to International Classification of Sleep Disorders (ICSD2) criteria.
2927130|NCT03060226|Other|Control group|
2927131|NCT03060226|Other|radiosensibility group|
2927132|NCT03060213|Experimental|Fun For Wellness (FFW)|Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being.
2927133|NCT03060213|No Intervention|Usual Care (UC)|The Usual Care (UC) group will conduct their lives as usual during the 30 day intervention period.
2927134|NCT03060200|Experimental|Active intervention|Self-administered online CBT plus therapist check in. Moderately depressed participants will be testing a depression app, employing a self administered plus therapist check in, online CBT intervention, for 6 weeks.
2927135|NCT03060200|No Intervention|Waiting list|Moderately depressed participants will be put on a wait list for 6 weeks, after which access to the depression app will be given.
2927136|NCT03060200|Placebo Comparator|Placebo|Sham self-administered online CBT plus therapist check in. Moderately depressed participants will be using a depression app - the same platform and largely in the same format as the tested app, employing a self administered plus therapist check in, online sham intervention, for 6 weeks. The intervention will include the same sections and features as the original app, except for the complete exercises and behavioral activation sections. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense information on psychological well being.
2927137|NCT03060187||KU Score|Participants asked to answer questions for the KU Score exam
2927138|NCT03060174|Other|monitoring and non-medical prophylaxis of delirium|The treatment group will receive monitoring and prophylaxis of delirium. The study arm designed to prevent delirium incorporates reorientation (watches, calendar, family photos, use of hearing aids, glasses and dentures, cognitive stimulation (newspaper, magazines, radio, television), early mobilisation, early enteral nutrition, early removal of drains or catheters, normalizing sleep-awake-rhythm.
2927139|NCT03060174|No Intervention|Standard|The standard group will receive standard monitoring and standard treatment. The indication, choice and dosage of the medication used to treat delirium will be at the discretion of the ward doctor and will not be influenced by this study. The chosen medication as well as its dosage will be documented.
2927140|NCT03060161|Experimental|Health in the right measure|"Nutrition counseling and guidance for regular physical activity. An individualized physical exercise program will be proposed according to each participant's level of physical activity and health conditions.~Participants will also receive individualized nutritional guidance. Throughout the project, collective motivational activities will be carried out to promote healthy eating (culinary workshops, talk wheels and others) and individual activities with all participants, in order to evaluate the adherence of nutritional guidelines and to exchange experiences among them."
2927141|NCT03060148|Active Comparator|Spinal cord stimulation|Medtronic neurostimulation system for spinal cord stimulation
2927142|NCT03060148|No Intervention|Control|No implantation of Medtronic neurostimulation system
2927143|NCT03060135|No Intervention|No Intervention: Control|A questionnaire that asks individuals what components of an online intervention they might find useful.
2927144|NCT03060135|Active Comparator|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
2927145|NCT03060135|Experimental|Hello Sunday Morning|Internet based program designed to assess drinking patterns, and support self-determined goals for abstinence, by providing users with an online platform and community to discuss progress and goals.
2927146|NCT03060122|No Intervention|Standard Care|Patient's randomized to this arm will receive standard post operative/post immobilization physical therapy or occupational therapy rehabilitation care without the use of NIN or CES.
2927147|NCT03060122|Experimental|NIN (InterX) and CES (Alpha-Stim)|"The Alpha-Stim Cranial Electrical Stimulation device applies a micro-current trans-cranially via electrodes attached to the ear.The electrical current is controlled through a handheld device. Standard treatment sessions lasting approximately 20-60 minutes.~InterX Therapy (non-invasive) has been developed specifically for the treatment of acute and chronic pain. It is delivered on the skin of the involved area. The device will be applied by a trained therapist along the course of the dermatomes in the affected area. Electrical current is controlled through a handheld device. Standard treatment sessions last approx 20-45 min.~The treatment will be delivered in conjunction with the rehab visit (physical or occupational therapy)"
2927148|NCT03060122|Active Comparator|NIN (InterX) and sham CES|"The Alpha-Stim Cranial Electrical Stimulation device intensity will be preset and locked by the manufacturer at its lowest therapeutic dose at 100 mA, a sub-sensory level that serves as a sham treatment.~InterX Therapy (non-invasive) has been developed specifically for the treatment of acute and chronic pain. It is delivered on the skin of the involved area. The device will be applied by a trained therapist along the course of the dermatomes in the affected area.Electrical current is controlled through a handheld device. Standard treatment sessions last approx 20-45 min.~The treatment will be delivered in conjunction with the rehab visit (physical or occupational therapy)"
2927149|NCT03060109||Suspected traumatic brain injury|
2927182|NCT03059901|Experimental|More App Notifications|Participants receive more notifications than the Active Comparator group from the Caminamos app to walk.
2927150|NCT03060096|Experimental|Moderate Anxiety/depression: Low Intensity Stepped care|participants with moderate symptoms (PHQ-9-14; GAD-7: 10-14) will be randomized to either low-intensity stepped care or enhanced usual care. Stepped care consist of a self-guided cognitive behavioral therapy (CBT) workbook to reduce anxiety and depressive symptoms and biweekly (every two weeks) check-in calls from research staff to assess changes in symptom severity/immediate need for psychiatric treatment and provide minimal support.
2927151|NCT03060096|Experimental|Severe Anxiety/depression: High Intensity Stepped Care|Participants with severe symptoms (PHQ-9: 15-27; GAD-7: 15-21) will be randomized to high intensity stepped care (consist of a CBT workbook with accompanying psychotherapy by a Master's-level therapist delivered by telephone) or EUC. EUC consist of information about referrals/resources locally and nationally.
2927152|NCT03060096|Active Comparator|Enhanced Usual Care Control (EUC)|"Participants randomized to EUC will receive information about local referrals/resources (support groups, mental health providers, etc.). They will also be provided Facing Forward: Life after Cancer Treatment, a book developed by the NCI to assist with transition from active treatment to survivorship. Participants will receive information on self-help workbooks for anxiety & depressive symptoms. EUC control will receive a copy of the CBT workbook on completion of the study."
2927153|NCT03060083|Experimental|Switch to VLNC cigarettes|Participants will be instructed to use nicotine patches and gradually switch to very low nicotine content (VLNC) cigarettes throughout the study period. They will receive regular nicotine cigarettes (16.5 mg/g) during week 1, 11.26 mg/g cigarettes during week 2, 5.54 mg/g cigarettes during week 3, 2.54 mg/g cigarettes during week 4, and 0.44 mg/g cigarettes during week 5.
2927154|NCT03060083|Experimental|Reduce CPD|Participants will be instructed to use nicotine patches and gradually reduce the number of regular nicotine content cigarettes that they smoke throughout the study period. They will receive regular nicotine content cigarettes (16.5 mg/g) throughout the study study period. After establishing a baseline CPD during week 1, participants will receive 70% of their baseline CPD during week 2, 35% during week 3, 15% during week 4, and 3% during week 5. Participants will receive a minimum of 1 CPD during week 5.
2927155|NCT03060070|Placebo Comparator|control group,|saline in the same volume will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
2927156|NCT03060070|Active Comparator|ketamine group,|ketamine in a dose of 0.5mg/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
2927157|NCT03060070|Active Comparator|dexmedetomidine group|dexmedetomidine in a dose of 1ug/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
2927158|NCT03060044|Experimental|Salmeterol/fluticasone Easyhaler|single dose of Salmeterol/fluticasone Easyhaler
2927159|NCT03060044|Experimental|Salmeterol/fluticasone Easyhaler with charcoal|Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration
2927160|NCT03060044|Active Comparator|Seretide Diskus|Single dose of Seretide Diskus
2927161|NCT03060044|Active Comparator|Seretide Diskus with charcoal|Single dose of Seretide Diskus with concomitant charcoal administration
2927162|NCT03060031|Experimental|Oxytocin|Each participant will undergo pain tasks after self-administration of oxytocin
2927163|NCT03060031|Placebo Comparator|Placebo|Each participant will undergo pain tasks after self-administration of placebo
2927164|NCT03060018|Experimental|All included patients|All included patients will undergo the intervention of transcutaneous sensor placement
2927165|NCT03060005|Experimental|primary Sjögren's syndrome|The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.
2927166|NCT03060005|Experimental|secondary Sjögren's syndrome|The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.
2927167|NCT03060005|Experimental|meibomian gland dysfunction|The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.
2927168|NCT03060005|Experimental|control|the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.
2927169|NCT03059992|Experimental|SCY-078|
2927170|NCT03059979|Active Comparator|Methylprednisolone 1000 mg|the methylprednisolone is dissolved in 100 cc of sodium chloride (NaCl 0.9%) by intravenous infusion in 30 minutes on three consecutive days
2927171|NCT03059979|Placebo Comparator|sodium chloride|The placebo intervention with physiologic salt solution is identical in appearance
2927172|NCT03059966|Experimental|Enamel Matrix Derivative|Microsurgery for root coverage associated with Enamel Matrix Derivative
2927173|NCT03059966|Placebo Comparator|Placebo|Microsurgery for root coverage associated with a Placebo comparator
2927174|NCT03059940|Experimental|Quitline (QL) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider. Participants given shared decision making and discussion about screening with the LDCT provider.~Participants referred to the Quitline for counseling and NRT (nicotine patch). Participants have 5 smoking cessation counseling sessions over the next 12 weeks."
2927175|NCT03059940|Experimental|Quitline-Rx (QL-Rx) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider.~LDCT provider and patient discuss options for pharmacotherapy.~Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks."
2927176|NCT03059940|Experimental|Integrated Care (IC) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider.~Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,"
2927177|NCT03059927|Active Comparator|Knee arthroplasty, Cruciate retaining|Total knee replacement with preserved posterior cruciate ligament and a cruciate retaining insert.
2927183|NCT03059901|Active Comparator|Normal App Notifications|Participants receive less notifications than the Experimental group from the Caminamos app to walk.
2927184|NCT03059888|Experimental|Abatacept|125mg abatacept in 1ml solution administered once per week by subcutaneous injection
2927185|NCT03059875|Other|Strategy A|Comprehensive Geriatric Assessment before the surgery of breast
2927186|NCT03059875|Other|Strategy B|Comprehensive Geriatric Assessment after the surgery of breast
2927187|NCT03059862|Experimental|Low-tryptophan diet and L-tryptophan.|Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + L-tryptophan supplements (3 g/day).
2927188|NCT03059862|Placebo Comparator|Low-tryptophan diet and placebo|Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + placebo.
2927189|NCT03059849|Active Comparator|Temporary increase in adalimumab|
2927190|NCT03059849|No Intervention|Continued monitoring as per standard of care|
2927191|NCT03059836|Experimental|n3 PUFA|Intervention: n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)
2927192|NCT03059836|Placebo Comparator|Placebo|Intervention: Organic Sunflower Oil 5000mg per day
2927193|NCT03059823|Experimental|Dose Escalation-Q2W|INCMGA00012 treatment once every 2 weeks
2927194|NCT03059823|Experimental|Dose Escalation- Q4W|INCMGA00012 treatment once every 4 weeks
2927195|NCT03059823|Experimental|Expansion Cohort|INCMGA00012 treatment for locally advanced or metastatic solid tumors
2927196|NCT03059797|Experimental|Anlotinib|Anlotinib p.o. qd
2927197|NCT03059797|Placebo Comparator|Placebo|Placebo p.o. qd
2927198|NCT03059784|Experimental|intervention|APP-based multifaceted management, including sending education material, everyday medication reminder, giving risk factor control support, clinical support to patients after PCI through APP.
2927199|NCT03059784|No Intervention|control|usual care without APP
2927200|NCT03059771|Experimental|Mobile Enhancement of Motivation (MEMS)|Facilitators will first collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006). Participants will then receive three sets of interactive text messages each weekday for eight weeks to reinforce and cue goal completion.
2927201|NCT03059771|Active Comparator|Control|Participants will only engage in a goal-setting session where facilitators will collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006).
2927202|NCT03059758|Experimental|Brain activity during reasoning and measure of math skill|Brain activity during reasoning and measure of math skill
2927203|NCT03059745||Cholecystitis|Patients consented for robotic assisted cholecystectomy evaluated in study.
2927204|NCT03059732||Thailand|Thai patients who diagnosed gastric cancer
2927205|NCT03059732||Japan|Japanese patients who diagnosed gastric cancer
2927206|NCT03059719|Experimental|PB-119 injection|PB119 injection 25ug or 50ug once each week, for three months
2927207|NCT03059719|Active Comparator|Exenatide Injection (Byetta)|Byetta 5ug or 10ug twice each day, for three months
2927208|NCT03059706|Experimental|RegenoGel-OSP™|
2927209|NCT03059706|Placebo Comparator|Placebo|
2927210|NCT03059693|Experimental|HAT1 topical cream|HAT1 medicated cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The medicated cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. Treatment will continue daily until next visit. If a lesion disappears, patients will continue applying the cream twice daily to the area.
2927211|NCT03059693|Placebo Comparator|Vehicle cream|Vehicle cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The vehicle cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. This will be continued daily until next visit.
2927212|NCT03059680|Experimental|High potassium diet group|Individuals in this arm were asked to increase dietary potassium intake over a 4 week period. This was achieved through an increase in consumption of fruits and vegetables.
2927213|NCT03059680|No Intervention|Usual diet group|Individuals in this group were asked to continue habitual dietary intake
2927214|NCT03059667|Active Comparator|Arm A : chemotherapy|"Patients randomly assigned to the control arm will receive either:~topotecan (oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended)~or re-induction by carboplatin - etoposide chemotherapy."
2927215|NCT03059667|Experimental|Arm B : immune therapy|Patients randomly assigned to the experimental arm will receive Anti PDL1 ATEZOLIZUMAB (MPDL3280A) at a fixed dose of 1200 mg IV every three weeks until progression or unacceptable toxicity.
2927216|NCT03059654|Active Comparator|Ultrasound PCT|Ultrasound guide Percutaneous tracheostomy
2927217|NCT03059654|Active Comparator|Surgical tracheostomy|Surgical tracheostomy
2927218|NCT03059628|Experimental|Personalized Normative Feedback group|A personalized normative feedback using a tablet application will be performed after the BTI at ED. The application installed on the patient's smartphone will automatically repeat the PNF, using a local algorithm, once a month over a 6-months period after discharge, and once every two months in the following 6-month period. It will be also possible to perform the PNF on the server website.
2927219|NCT03059628|Other|Control group|The control group will not receive further counseling or information after the baseline BTI at ED. The application installed in this group will be only used for the evaluation questionnaire at 6 and 12 months
2927220|NCT03059615|Experimental|Nerofe 48mg/m2|48mg/m2 IV Nerofe - three times a week
2927221|NCT03059615|Experimental|Nerofe 96mg/m2|96mg/m2 IV Nerofe - three times a week
2927222|NCT03059615|Experimental|Nerofe 48mg/m2 + Doxorubicin 10mg/m2|48mg/m2 IV Nerofe + Doxorubicin 10mg/m2 - once a week
2927223|NCT03059615|Experimental|Nerofe 96mg/m2 + Doxorubicin 10mg/m2|96mg/m2 IV Nerofe + Doxorubicin 10mg/m2 - once a week
2927224|NCT03059602||Knee group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing total knee arthroplasty.
2927225|NCT03059602||Hip group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing total hip arthroplasty.
2927262|NCT03059316|Active Comparator|nitroglycerin group|this group will receive nitroglycerin infusion for controlled hypotension.0.5-5ug/kg/min to keep MAP 55-65mmhg then Massimo device will be attached to the patients when MAP reached the desired level
2927226|NCT03059602||Spine group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing Cervical/Thoracic Lumbar Spine Surgery (Discectomy, Foraminotomy, Laminectomy, Fusion, Nerve Root Decompression)
2927227|NCT03059563|Experimental|Varenicline|A standard dose titration regimen that is used for smoking-cessation will be followed. The pharmacist will prepare capsules of varenicline for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing 0.5 mg VAR each day (0900 h) for 3 days, then one capsule containing 0.5 mg VAR twice daily (0900 h, 2100 h) for 4 days, and finally a capsule containing 1 mg VAR twice daily (0900 h, 2100 h) for the next 2 weeks.
2927228|NCT03059563|Placebo Comparator|Placebo|The same procedure used for varenicline treatment will be followed. The pharmacist will prepare capsules of placebo for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing placebo each day (0900 h) for 3 days, then one capsule containing placebo twice daily (0900 h, 2100 h) for 4 days, and finally a capsule containing placebo twice daily (0900 h, 2100 h) for the next 2 weeks.
2927229|NCT03059550||cardiac rehabilitation|Patients reffered to cardiac Rehabilitation after an acute coronary syndrome
2927230|NCT03059550||Whole French population post-ACS|The whole French population who presented an acute coronary syndrome (ACS) in the years 2013 and 2014.
2927231|NCT03059537|Experimental|Stimulation Test|Study meal plus chenodeoxycholic acid: 1,250 mg single dose stimulation
2927232|NCT03059524||patients with multiple organ failure|
2927233|NCT03059524||patients without multiple organ failure|
2927234|NCT03059524||normal subjects|
2927235|NCT03059511|Active Comparator|intravenous|single iv application of nalbuphine 0.05mg/kg
2927236|NCT03059511|Active Comparator|intranasal|single intranasal application of nalbuphine 0.1mg/kg in infants.
2927237|NCT03059498|Active Comparator|unilateral PECS block patients|unilateral PECS I and II block using bupivacaine
2927238|NCT03059498|Active Comparator|bilateral PECS block patients|bilateral PECS I and II block using bupivacaine
2927239|NCT03059485|Experimental|DC/AML Vaccine|- Patients will be vaccinated with DC/AML Fusion Vaccine
2927240|NCT03059485|Experimental|Observation|- Patients will be monitored with routine labs and bone marrow biopsies
2927241|NCT03059472|Experimental|Group 1 (Intervention)|Full Intervention participants will meet twice per week for one hour each time, for approximately 6 months. Participants will learn and practice good nutrition and physical activity for improved individual, family and community health.
2927242|NCT03059472|Experimental|Group 2 (Delayed intervention)|Delayed intervention participants will participate in the same activities as Group 1 but 6 months after Group 1.
2927243|NCT03059446|Experimental|Cenicriviroc|Cenicriviroc (CVC) 150 mg tablet once daily in the morning with food until CVC is commercially available or the study is terminated.
2927244|NCT03059433||AVID Intervention|175 students will be randomized via lottery by the participating high school to be part of the AVID program. These students will receive 4 surveys (8th, 9th, 10th, and 11th grade).
2927245|NCT03059433||Non AVID|175 students will be randomized via lottery by the participating high school to be part of our control group. This group of students will be similar to the AVID group, except they will not be in the AVID program. They will also complete 4 surveys (8th, 9th, 10th, and 11th grade).
2927246|NCT03059433||High Performing|175 students who are identified as high performing (middle school grade point average >3.5) by the participating high school. They will also complete 4 surveys (8th, 9th, 10th, and 11th grade).
2927247|NCT03059407|Other|Dog therapy only|Canine assisted therapy only during echocardiogram
2927248|NCT03059407|Other|Dog plus standard distraction tech|Canine assisted therapy plus standard distraction techniques during echocardiogram
2927249|NCT03059407|Other|Standard distraction technique only|Standard distraction techniques only during echocardiogram.
2927250|NCT03059381||Fycompa-treated epilepsy participants|Adolescent epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa
2927251|NCT03059368|Experimental|new bone fixation plate with screw|Fracture ends and injured posterior cruciate ligament will be exposed in twenty patients with tibial avulsion fracture of posterior cruciate ligament of knee through posterior approach. Open reduction will be conducted. The posterior cruciate ligament will be reconstructed with a new bone fixation plate with screw(cancellous bone screw).
2927252|NCT03059355|Experimental|Pilot Phase: Group 1 (UCMSCs)|Three (3) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.
2927253|NCT03059355|Experimental|Pilot Phase: Group 2 (UCMSCs - 100 million)|Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
2927254|NCT03059355|Experimental|Pilot Phase: Group 3 (BMMSCs - 20 million)|Three (3) subjects will be treated with a single IV administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.
2927255|NCT03059355|Experimental|Pilot Phase: Group 4 (BMMSCs -100 million)|Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) BMMSCs delivered via peripheral intravenous infusion.
2927256|NCT03059355|Experimental|Group A (UCMSCs - 20 Million)|Five (5) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.
2927257|NCT03059355|Experimental|Group B (UCMSCs - 100 million)|Five (5) subjects will be treated with a single administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
2927258|NCT03059355|Experimental|Group C (BMMSCs - 20 million)|Five (5) subjects will be treated with a single administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.
2927259|NCT03059355|Experimental|Group D (BMMSCs - 100 million)|Five (5) subjects will be treated with a single administration of 1 x 10^8 (100 million) BMMSC delivered via peripheral intravenous infusion.
2927260|NCT03059355|Placebo Comparator|Group E (Placebo)|Five (5) subjects will be treated with a single administration of placebo delivered via peripheral intravenous infusion.
2927261|NCT03059329||Fycompa-treated epilepsy participants|Adult epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa
2927263|NCT03059316|Active Comparator|labetalol group|this group will receive labetalol infusion fo controlled hypotension 0.4-3mg/kg/hr to keep MAP 55-65mmhg.then Massimo device will be attached to the patients when MAP reached the desired level
2927264|NCT03059303|Experimental|Part 1: Treatment A: FDC [SMV(75mg)+ODV(25mg)+AL-335(800mg)]|Participants will receive single oral dose of simeprevir (SMV) 75 milligram (mg), odalasvir (ODV) 25 mg, and AL-335 800 mg, given as a fixed-dose combination (FDC) tablet (G008 formulation) after a standardized breakfast on Day 1.
2927265|NCT03059303|Experimental|Part 1: Treatment B: FDC [SMV(75mg)+ODV(12.5mg)+AL-335(800mg)]|Participants will receive single oral dose of SMV 75 mg, ODV 12.5 mg, and AL-335 800 mg, given as an FDC tablet (G007 formulation) after a standardized breakfast on Day 1.
2927266|NCT03059303|Experimental|Part 1: Treatment C: Simeprevir, Odalasvir, and AL-335|Participants will receive single oral dose of 75 mg SMV, 25 mg ODV, and 800 mg AL-335, given as 3 single agents after a standardized breakfast on Day 1.
2927267|NCT03059303|Experimental|Part 1: Treatment D: Lansoprazole + FDC [SMV+ODV+AL-335]|Participants will receive 30 mg lansoprazole once daily in the morning under fasted conditions on Days 1 to 4, and together with a single oral dose of an FDC containing 75 mg SMV, 25 mg ODV, and 800 mg AL-335 (G008 formulation) after a standardized breakfast, which is served 2 hours after lansoprazole dosing, on Day 5.
2927268|NCT03059303|Experimental|Part 1: Treatment E: Omeprazole + FDC [SMV+ODV+AL-335]|Participants will receive 20 mg omeprazole once daily in the morning immediately before a (non-standardized) breakfast on Days 1 to 4, and immediately before a standardized breakfast and within 1 hour before a single oral dose of an FDC containing 75 mg SMV, 25 mg ODV, and 800 mg AL-335 (G008 formulation) after a standardized breakfast on Day 5. Treatment E will only be started in case a drug-drug interaction (DDI) is observed for Treatment D.
2927269|NCT03059303|Experimental|Part 2: Treatment Sequence A2-F|Participants will receive single oral dose of simeprevir (SMV) 75 milligram (mg), odalasvir (ODV) 25 mg, and AL-335 800 mg, given as an FDC (Treatment A2 - G008 formulation) on Day 1 of Period 1, and then single oral dose of SMV 75 mg, ODV 25 mg, and AL-335 800 mg, given as an FDC (Treatment F - G012 formulation) on Day 1 of Period 2, under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
2927270|NCT03059303|Experimental|Part 2: Treatment Sequence F-A2|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment A2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
2927271|NCT03059303|Experimental|Part 2: Treatment Sequence C2-F|Participants will receive single oral dose of 75 mg SMV, 25 mg ODV, and 800 mg AL-335, given as 3 single agents (Treatment C2) on Day 1 of Period 1 and then Treatment F on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
2927272|NCT03059303|Experimental|Part 2: Treatment Sequence F-C2|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment C2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
2927273|NCT03059303|Experimental|Part 2: Treatment Sequence C2-G|Participants will receive Treatment C2 on Day 1 of Period 1 and then 2 tablets of SMV 37.5 mg, ODV 37.5 mg, and AL-335 400 mg, given as FDC (Treatment G - G013 formulation) on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
2927274|NCT03059303|Experimental|Part 2: Treatment Sequence G-C2|Participants will receive Treatment G on Day 1 of Period 1 and then Treatment C2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
2927275|NCT03059303|Experimental|Part 2: Treatment Sequence F-G|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment G on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
2927276|NCT03059303|Experimental|Part 2: Treatment Sequence G-F|Participants will receive Treatment G on Day 1 of Period 1 and then Treatment F on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
2927277|NCT03059290|Active Comparator|protaper next file|the PROTAPER NEXT™ X1 (017/04) file, in one or more passes until the working length is reached. Use PROTAPER NEXT X2 (025/06), exactly as described for PROTAPER NEXT X1 file, until the working length is passively reached. Gauge the foramen with a size 025 hand file and, if this file binds at length, the canal is shaped and ready for disinfection. If the size 025 hand file is loose at length, then continue shaping with the PROTAPER NEXT X3 (30/07) and, when necessary, the PROTAPER NEXT X4 (040/06) or PROTAPER NEXT X5 (050/06), gauging after each instrument with the 030, 040 or 050 hand files, respectively. During canal shaping, irrigate, recapitulate with a small-sized hand file after each sequential PROTAPER NEXT instrument, then re-irrigate. in an endodontic motor according to the manufacturer instructions (X-Smart, Dentsply Maillefer, USA.), with torque 2.0 N.cm and speed 300 rpm.
2927278|NCT03059277|Experimental|Intravitreal Aflibercept|Intravitreal Aflibercept Injection (IAI)
2927279|NCT03059264||CDM|Children with Congenital Myotonic Dystrophy
2927280|NCT03059264||Control|Healthy Children
2927281|NCT03059251||Obinutuzumab|All participants with chronic lymphocytic leukemia (CLL) who have received the indication for treatment with Obinutuzumab, as per routine clinical practice in Argentina.
2927282|NCT03059238|Experimental|Celecoxib group|Celecoxib 200mg oral capsule, 200 mg, orally one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
2927283|NCT03059238|Experimental|Parecoxib group|Parecoxib sodium , 40 mg, dissolved in 3 mL 0.9% sodium chloride intravenously one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
2927284|NCT03059238|Experimental|Oxycodone group|Controlled-release oxycodone, 10 mg, orally one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
2927285|NCT03059225|Experimental|Experimental|repetitive transcranial magnetic stimulation (rTMS) intervention for 10-min of contralesional 1Hz-repetitive transcranial magnetic stimulation(rTMS) or 10-min ipsilesional 5-Hz rTMS for 10 daily sessions; Computer-integrated Speech Training for 20 mins
2927286|NCT03059225|Sham Comparator|Sham stimulation|Sham treatment for 2-week inhibitory non-dominate hemisphere rTMS program. Computer-integrated Speech Training for 20 mins
2927287|NCT03059212|Experimental|5Hz rTMS|rTMS group
2927289|NCT03059199|Experimental|Single-Arm Feasibility Study|12-week, 1x/week, 90-minute face-to-face sessions.
2927290|NCT03059186|Experimental|Intervention|Online daily gratitude journal.
2927291|NCT03059186|No Intervention|Control|
2927292|NCT03059173|Active Comparator|Inositol + Clomiphene Citrate|The experimental group will receive the dietary supplement: 1.2 g of MYO + 0.4 mg of FA per day per os (in 2 capsules per day) in addition to the standard therapy Clomiphene citrate (CC).
2927293|NCT03059173|Placebo Comparator|Placebo + Clomiphene Citrate|The control group will receive the standard therapy CC and a placebo containing only 0.4 mg of FA.
2927294|NCT03059160|Experimental|open label|
2927295|NCT03059147|Experimental|SF1126|SF1126 900-1100 mg/m2 IV twice weekly
2927296|NCT03059134|Experimental|Mirabegron 25mg for 12 weeks|Mirabegron 25mg once-daily for 4 weeks, and continue the same dose of mirabegron for another 8 weeks
2927297|NCT03059134|Active Comparator|Mirabegron 25mg followed by 50mg|Mirabegron 25mg once-daily for 4 weeks, and increase the dose to 50mg for another 8 weeks
2927298|NCT03059134|Active Comparator|Mirabegron 25mg followed by solifenacin|Mirabegron 25mg once-daily for 4 weeks, and shift to solifenacin 5mg for another 8 weeks
2927299|NCT03059134|Active Comparator|Mirabegron 25mg add-on solifenacin|Mirabegron 25mg once-daily for 4 weeks, and add-on solifenacin 5mg for another 8 weeks,
2927300|NCT03059108|Experimental|Early Loading|Implant early loading: prosthesis delivery 4 weeks after implant placement
2927301|NCT03059108|Active Comparator|Conventional Loading|Implant conventional loading: prosthesis delivery 8 weeks after implant placement
2927302|NCT03059095|Experimental|Yoga and Meditation|Yoga and Meditation online sessions 2x's a week.
2927303|NCT03059082|Other|Continued Interaction|"This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months.They will then have a 3 month and 6 month follow up visit with the PI. There is no drug or treatment administered to the subject. The intervention is the conversation/contact with the Recovery Navigator, in this arm, it is continued throughout the study.~Note: The first 10 subjects will not be randomized and will be assigned to this Arm. The purpose of this is to ensure the fidelity of the intervention. The remaining 60 subjects will be randomized equally among the three Arms. Data from the first 10 subjects will not be considered for the outcome measures."
2927304|NCT03059082|Other|Single interaction|This group will undergo one interaction with the Recovery Navigator prior to the hospital discharge. They will then have a 3 month and 6 month follow up visit with the PI. There is no drug or treatment administered to the subject.The intervention is the conversation/contact with the Recovery Navigator, in this arm, it is conducted once.
2927305|NCT03059082|Other|Control|This group will not have any interaction with the Recovery Navigator. They will then have a 3 month and 6 month follow up visit. There is no drug or treatment administered to the subject.
2927306|NCT03059069|Experimental|Glitamin|800mg/day
2927307|NCT03059069|Placebo Comparator|Placebo|same shape, color, size tablet as Glitamin
2927308|NCT03059056|Experimental|pharmacokinetic evaluation|Empagliflozin 25 mg
2927309|NCT03059043|Experimental|viscoelastic-free system|Subjects in this group will use viscoelastic-free implantation system during the surgery
2927310|NCT03059043|Active Comparator|viscoelastic-assisted system|Subjects in this group will utilize the standard viscoelastic-assisted Implantation system during the surgery
2927311|NCT03059030|Experimental|Subjects with thrombocytopenia secondary to cirrhosis|Evaluate the safety and efficacy of 90Y radioembolization for the management of thrombocytopenia.
2927312|NCT03059017|Experimental|Niosomal salbutamol sulphate inhalers|Niosomes
2927313|NCT03059017|Placebo Comparator|salbutamol sulphate inhalers|control testing
2927314|NCT03059004|Experimental|1. Home Exercise Program|The Home Exercise group receives the TeMPO Home Exercise Program (including a set of weights, a DVD showing how to complete the TeMPO exercises, and a pamphlet outlining instructions on how to complete the exercises and how often should they be done).
2927315|NCT03059004|Experimental|2. Home Exercise Program + SMS Messages|Subjects in this arm receive the TeMPO Home Exercise Program and motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise regimen.
2927316|NCT03059004|Experimental|3. In-Clinic Topical Therapy|Subjects in this arm receive the TeMPO Home Exercise Program, motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise Program, and 14 in-clinic sessions with a trained physical therapist. The therapist will apply topical therapies: ultrasound, gel, and manual therapy.
2927317|NCT03059004|Experimental|4. In-Clinic Exercise Therapy|Subjects in this arm will receive the TeMPO Home Exercise Program, SMS motivational messages to encourage them to adhere to the TeMPO Home Exercise Program and 14 in-clinic sessions with a trained physical therapist. The therapist will supervise the participant in a rigorous set of strengthening and stretching exercises.
2927318|NCT03058991|Experimental|Distress Tolerance Intervention|For the Distress Tolerance Intervention, the investigators will use a Mindfulness Based Stress Reduction (MBSR) program that has been adapted for use with adolescents. This version of MBSR follows closely the original conceptualization developed by Kabat-Zinn. The focus is on formal and informal mindfulness practices, which encourage participants to foster intention, attention and attitude. The investigators will make slight modifications to the delivery of the MBSR intervention to take into account the developmental period of their participants (e.g., attention span) to encourage retention and increase relevancy. These changes will also allow the investigators to match the duration with their Working Memory Intervention.
2927319|NCT03058991|Experimental|Working Memory Intervention|"For the working memory training, the investigators will use the Cogmed RM program. Participants will be asked to use the program, while supervised twice a week, each time for an hour, for 8 weeks. Participants will also be asked to use the program on the other days for 25-35 minutes. The program resembles a video game, and comprises several different games that require visuo-spatial working memory (remembering the position of objects) and a combination of verbal and visual working memory (remembering phonemes, letters, and digits). The program adapts to the user's performance, such that trainees are able to perform at the limit of their ability, stimulating WM capacity adaptation."
2927355|NCT03058770|Experimental|sensorimotor retraining program|Fifteen 40-minute sensorimotor retraining sessions will be provided over a 5-week period.
2927356|NCT03058770|Active Comparator|Relaxation technique|Subjects will perform fifteen 40-minute relaxation sessions over a 5-week period.
2927320|NCT03058991|Active Comparator|Control Informational Intervention|This Control Informational Intervention has been used in the investigators' and other's previous studies. In the current application, it will match the session time of the Distress Tolerance and Working Memory interventions and will omit a focus on smoking (which is specific to the SPII intervention provided across all interventions), and will consist of discussions of a variety of healthy lifestyle topics, such as healthy eating, stress/time management, and recommended health screenings.
2927321|NCT03058965|Experimental|[18F]MNI-958|To evaluate [18F]MNI-958, a tau targeted PET radioligand.
2927322|NCT03058952|Experimental|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
2927323|NCT03058952|Active Comparator|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
2927324|NCT03058939|Experimental|Paclitaxel|Investigators plan to treat patients with paclitaxel weekly for a total of approximately 16 weeks (8 weeks before ultrasonography for response assessment and 8 weeks before surgery in good responders). Paclitaxel 80mg/m2 will be given on days 1, 8, 15 and so on for a total of 8 doses.
2927325|NCT03058939|Other|Carboplatin|After first 8 weeks of paclitaxel, those with progressive disease (based on breast US assessment) or partial response but inoperable will have carboplatin added to their regimen. Patients will receive 8 cycles of weekly paclitaxel and carboplatin (PC).
2927326|NCT03058939|Other|Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)|Patients with poor response to 8 courses of paclitaxel followed by 8 courses of PC based on ultrasound assessment will be regarded as failing to respond to treatment. These patients will receive 4 cycles of 3-weekly FEC and will be followed up.
2927327|NCT03058939|Other|LHRH (luteinizing hormone-releasing hormone)|All Premenopausal patients will receive LHRH agonist for two years for contraception and fertility preservation.
2927328|NCT03058939|Other|Tamoxifen or letrozole|Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors and according to the state of primary menopause at the onset of the study.
2927329|NCT03058939|Other|Herceptin SC and Perjeta|Patients with HER2-positive disease (see glossary and section 10.3) will receive 5 three-weekly courses of trastuzumab (Herceptin SC) with pertuzumab (Perjeta). After that pts will continue receiving trastuzumab to complete total of 18 doses within 1 year of treatment.
2927330|NCT03058926||Chronic Pancreatitis|
2927331|NCT03058926||Diabetes|
2927332|NCT03058926||Pancreatic Cancer|
2927333|NCT03058900|Experimental|Fecal microbiota transplantation (FMT)|
2927334|NCT03058900|Sham Comparator|Placebo (saline)|
2927335|NCT03058887|Experimental|Arm cranking|exercising for 3 months twice per week.
2927336|NCT03058887|Experimental|Cycling|exercising for 3 months twice per week.
2927337|NCT03058887|No Intervention|Control group|No exercise intervention.
2927338|NCT03058874|Placebo Comparator|Control arm|Standard protocol of fluid management in hemodialysis
2927339|NCT03058874|Experimental|Active arm|Extra-vascular lung water measurements by ultrasound (LW-US)
2927340|NCT03058861|Experimental|Discipline education - Play Nicely program|Parents in the intervention group will receive 1) a copy of the Play Nicely Healthy Discipline Handbook (see www.playnicely.org), 2) information about how to view the Play Nicely multimedia program online and 3) the TN ACEs Handout.
2927341|NCT03058861|No Intervention|Control Group|Routine primary care will be provided.
2927342|NCT03058848|Experimental|Consumption of PKU Start|Daily feed, substituting the participant's normal phe-free formula for PKU Start.
2927343|NCT03058835|Experimental|PrEP with Truvada|All study participants will be assigned to this arm and will receive Truvada tablets (tenofovir disoproxil and emtricitabine) for PrEP
2927344|NCT03058822|Experimental|Prefilled Syringe Upper Arm|Single subcutaneous dose from prefilled syringe into upper arm of BMS-931699
2927345|NCT03058822|Experimental|Prefilled Syringe Thigh|Single subcutaneous dose from prefilled syringe into thigh of BMS-931699
2927346|NCT03058822|Experimental|Prefilled Syringe Abdomen|Single subcutaneous dose from prefilled syringe into abdomen of BMS-931699
2927347|NCT03058822|Experimental|Drug in Vial Upper Arm|Single subcutaneous dose from drug in vial into upper arm of BMS-931699
2927348|NCT03058822|Experimental|Drug in Vial Thigh|Single subcutaneous dose from drug in vial into thigh of BMS-931699
2927349|NCT03058822|Experimental|Drug in Vial Abdomen|Single subcutaneous dose from drug in vial into abdomen of BMS-931699
2927350|NCT03058809|Experimental|Metastatic Breast, Colon and Prostate Cancer|Metastatic breast, colon or prostate cancer patients will have their CTC levels determined on 3 days before treatment with the Viatar Oncopheresis System to establish a baseline value, a pretreatment value, a post treatment value and on 4 additional instances over a period of 7 days post treatment to establish a CTC rebound profile using a validated CTC enumeration system.
2927351|NCT03058796|Active Comparator|CCFES Therapy|CCFES uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. CCFES enables stroke survivors to open and close their paretic hand and practice using it in therapy sessions. The treatment regimen includes CCFES-mediated: 1) home-based self-administered hand opening exercises, and 2) lab-based therapist-guided functional task practice.
2927352|NCT03058796|Experimental|CCFES Video Game Therapy|CCFES Video Game Therapy integrates custom designed hand therapy video games with CCFES which enables participants to use the video game component at home instead of repetitive hand opening exercises.
2927353|NCT03058783|Experimental|IDP-124 Lotion|Lotion
2927354|NCT03058783|Active Comparator|IDP-124 Vehicle Lotion|Vehicle
2927358|NCT03058757|Experimental|Intervention arm|neoadjuvant intravesical mitomycin-C 40mg/20ml instillation
2927359|NCT03058744|Experimental|IDP-118 Lotion|8 Weeks
2927360|NCT03058744|Experimental|HP Monad Lotion|8 Weeks
2927361|NCT03058744|Active Comparator|Ultravate Cream|2 Weeks
2927362|NCT03058744|Active Comparator|Tazorac Cream|4 Weeks
2927363|NCT03058731||Matristem|Hernia repair with MatriStem Surgical Matrix
2927364|NCT03058731||Control|Other biological mesh
2927365|NCT03058718|Experimental|Procalcitonin-guided antibiotic treatment group|"Patients were divided into 2 subgroups:~No infection group (including patients with procalcitonin<0.1 ng/ml at enrollment, and patients with 0.1 ng/ml ≤procalcitonin ≤0.25 ng/ml at enrollment who are with stable respiratory and hemodynamics, and without serious complications) : the group is not given the application of antibiotics.~Infection group (including patients with procalcitonin>0.25 ng/ml at the time of enrollment, and patients with 0.1 ng/ml ≤ procalcitonin≤0.25 ng/ml at enrollment who have severe disease, unstable hemodynamics, and severe complications or intensive care unit treatment): the group is given the application of antibiotics. According to the guidelines for severe sepsis / septic shock treatment, the standard for discontinuation of antimicrobial agents: If the procalcitonin level falls below <0.1 ng/ml or more than 80%, compared with the baseline before enrollment, it is recommended to discontinue the antimicrobial agent."
2927366|NCT03058718|Active Comparator|Standard antibiotic therapy group|The application of antibiotics is given to patiens according to the doctor's experience.
2927367|NCT03058705|Experimental|Hexaminolevinulate HCL with Near Infrared Fluorescence (NIRF)|During the transurethral resection of the bladder procedure, the bladder will initially be examined in a systematic meridian fashion. Suspicious tumors identified by white light only, NIRF only, and both will be identified. If intense fluorescence is observed in the initial patient(s) at 10 min, dwell duration will be reduced to 5 min for the next patient(s); if abundant fluorescence is detected there as well, dwell duration will be shortened again to 2.5 min. At least three patients will be studied at each duration to document intense fluorescence before proceeding to shorter instillation durations in subsequent patients.
2927368|NCT03058692|Experimental|M-001 + IIV4|0.4 ml injection of M-001 (1 mg dose) intramuscularly on Day 1 and Day 22, followed by 0.5 ml injection of IIV4 (60 mcg HA) intramuscularly on Day 172 (n=60)
2927369|NCT03058692|Placebo Comparator|Placebo+ IIV4|0.4 ml injection of placebo intramuscularly on Day 1 and Day 22, followed by 0.5 ml injection of IIV4 (60 mcg HA) intramuscularly on Day 172 (n=60)
2927370|NCT03058679|Experimental|Specific Carbohydrate Diet|
2927371|NCT03058679|Active Comparator|Mediterranean Style Diet|
2927372|NCT03058666|Experimental|Aerosolized Calfactant|"NICU Patients with a clinical diagnosis of RDS~Inspired oxygen ≥21% to maintain adequate oxygen saturation~Not Intubated~Requiring Nasal continuous positive airway pressure"
2927373|NCT03058666|No Intervention|Usual Care|There will be no protocol driven interventions in the usual care group.
2927374|NCT03058653|Experimental|Study patients|Small fluid boluses - The first 250ml of fluid will be given in 50ml boluses using a 50ml syringe
2927375|NCT03058640|Experimental|Karate Intervention|Participants will be enrolled into PKSA karate classes which includes at least two, standardized 1-hour classes per week for 12 weeks. Participants must attend at LEAST 20/24 classes. Attendance sheets will be signed by parents at each site. Practice at home will also be encouraged. Log sheets will be provided to participants to log their practice
2927376|NCT03058640|No Intervention|Standard Care|Participants will have no initial intervention. Investigators will request that participants do not enroll in a structured martial arts class during the one-year period. Participants will, however, be given the option of receiving the structured karate program at 6 months, once measurements are completed
2927377|NCT03058627|No Intervention|TAVI only|TAVI is performed according to current guidelines and the choice of valve prosthesis is at the operators' discretion.
2927378|NCT03058627|Experimental|TAVI + FFR-guided complete revascularization|TAVI is performed according to current guidelines and the choice of transcatheter heart valve is at the operators' discretion. PCI is performed in any suitable lesion with diameter stenosis > 90% or FFR < 0.80 in vessels ≥ 2.5 mm in diameter .
2927379|NCT03058614|Active Comparator|CEUS arm|On postoperative day 1 (unless not clinically indicated), each subject will undergo CEUS with an administration of Lumason via their pre-placed nephrostomy tube.
2927380|NCT03058614|Active Comparator|CT scan plus capping trial arm|On postoperative day 1 (unless not clinically indicated), subjects' pre-placed nephrostomy tube will be capped and they will undergo a low dose non-contrast abdominal CT scan.
2927381|NCT03058588||Analysis with molecular biology|"Any patient with acute leukemia or other myeloid malignancy AND~a first- or second-degree relative with acute leukemia or other myeloid malignancies~a first- or second-degree relative with lymphoproliferative neoplasms~or with clinical features that resemble one of the familial myeloid malignancies predisposition syndromes"
2927382|NCT03058575|Experimental|Dietary MACs|Dietary fiber supplement (blend of resistant starch and dietary fiber food ingredients providing 15g of microbiota accessible carbohydrate/1 scoop serving) will be provided in a powder that will be mixed with 6-10 oz of water (depending on desired thickness) and consumed as a chocolate shake.
2927383|NCT03058575|Other|Control|No Intervention
2927384|NCT03058562|Experimental|Crossover Sequence A|"Each in the fasting state:~Period 1: Single-dose matching placebo~Period 2: Single-dose ABX-1431"
2927385|NCT03058562|Experimental|Crossover Sequence B|"Each in the fasting state:~Period 1: Single-dose ABX-1431~Period 2: Single-dose matching placebo"
2927386|NCT03058562|Experimental|Crossover Sequence C|"Each with a standard high fat meal:~Period 3: Single-dose matching placebo~Period 4: Single-dose ABX-1431"
2927387|NCT03058562|Experimental|Crossover Sequence D|"Each with a standard high fat meal:~Period 3: Single-dose ABX-1431~Period 4: Single-dose matching placebo"
2927388|NCT03058549|Experimental|Intervention: Family Expectations|Family Expectations includes 36 hours of relationship education and parenting content, coaching sessions for couples, and group case management/referral information about local resources. Each couple will also complete an initial case management assessment, followed by referrals to any needed services, such as employment, substance abuse, mental health, housing, etc. Based on need, couples will have the option of additional case management/coaching services during their involvement in Family Expectations.
2927658|NCT03056872||AnxD+AUD- No CBT|AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual only.
2927389|NCT03058549|No Intervention|Control Group|The control group will not receive the intervention though they are able to seek and obtain any services they wish in the community (Treatment as Usual).
2927390|NCT03058536|Active Comparator|Progesterone|400 mg micronized vaginal progesterone daily from randomization to 36 weeks
2927391|NCT03058536|Active Comparator|Arabin Pessary and Progesterone|"Arabin Pessary and Natural Micronized Progesterone~400 mg micronized vaginal progesterone daily from randomization to 36 weeks~The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) in combination with vaginal progesterone."
2927392|NCT03058536|Active Comparator|Arabin Pessary|The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) without vaginal progesterone use.
2927393|NCT03058536|No Intervention|No intervention|Expectant management
2927394|NCT03058523||Non-Pregnant|30 non-pregnant women of childbearing age
2927395|NCT03058523||Pregnant|30 pregnant women
2927396|NCT03058510||Stable CAD Patients|Stable CAD patients with calcified bifurcation lesion
2927397|NCT03058497|Active Comparator|Temperature-Controlled Laminar Airflow Device Active|Temperature-Controlled Laminar Airflow Device
2927398|NCT03058497|Placebo Comparator|Temperature-Controlled Laminar Airflow Device Placebo|Temperature-Controlled Laminar Airflow Device
2927399|NCT03058484|No Intervention|Control|Standard of care, i.e. regular clinic services are provided prior to the study.
2927400|NCT03058484|Experimental|Community Health Worker Intervention|This arm is a four-part behavioral intervention that includes: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
2927401|NCT03058471|Active Comparator|methotrexate|mehotrexate 10 mg weekly, to be increased by 5 mg in each visit to a maximum of 25 mg
2927402|NCT03058471|Active Comparator|non steroidal anti inflammatory drugs|NSAID in full dose with Pantoprazole. If remission not achieved at 2 months, will be given methotrexate as in methotrexate arm
2927403|NCT03058458|Experimental|SAD PIN201104 in Healthy Volunteers (HV)|PIN201104 or placebo IV administration, single dose, 10 dose cohorts
2927404|NCT03058458|Experimental|Repeat dose PIN201104 in HV|PIN201104 or placebo IV administration, 3 doses on single day, 1 cohort
2927405|NCT03058458|Experimental|Single dose PIN201104 in asthma patients|PIN201104 or placebo IV administration, single dose, 2 cohorts
2927406|NCT03058458|Experimental|Single SC dose in HV|PIN201104 or placebo SC administration, single dose, 1 cohort
2927407|NCT03058445|Experimental|Main group|This the only arm in the study Intervention: Echocariography and assessing T2T and CXR CVC tip to carina distance
2927408|NCT03058432|Experimental|Intensity-modulated Radiotherapy|Radiotherapy alone was given.
2927409|NCT03058432|Active Comparator|Concurrent chemoradiotherapy|Concurrent cisplatin-based radiotherapy was given.
2927410|NCT03058419|Experimental|Drug Cocktail + JNJ-54175446|All subjects will receive a single dose of drug cocktail (consisting of midazolam [2 milligram (mg)], warfarin [10 mg], caffeine [50 mg], dextromethorphan [30 mg], bupropion [150 mg] and omeprazole [20 mg]) on Day 1, 7 and 11; JNJ-54175446 150 mg on Day 7, 9, 10 and 11 and JNJ-54175446 600 mg on Day 8.
2927411|NCT03058406||Eribulin mesylate|
2927412|NCT03058393|Experimental|Teach-Back Group|A teach-back lesson will be provided to physician participants (Teach-Back Group), who are participating in challenging clinical discussions with patients
2927413|NCT03058380||Stated-Preferences Evaluation Group|A stated-preferences evaluation instrument will be provided to participants with knee pain in the Stated-Preferences Evaluation Group. The instrument will measure patient preferences for total knee replacement versus unicompartmental knee replacement.
2927414|NCT03058367|Experimental|High dose IQP-AE-103 (1980mg)|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
2927415|NCT03058367|Experimental|Low dose IQP-AE-103 (990mg)|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
2927416|NCT03058367|Placebo Comparator|Placebo|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
2927417|NCT03058354||Group TIVA|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using intraoperative TIVA with propofol.
2927418|NCT03058354||Group GA|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using general anaesthesia methods other than intraoperative TIVA with propofol.
2927419|NCT03058341|Sham Comparator|Group S|Patients will be anaesthetized by inhalational anaesthesia using sevoflurane.
2927420|NCT03058341|Experimental|Group P|Patients will be anaesthetized using total intravenous propofol.
2927421|NCT03058315||Low back pain patients|Cohort of 800 consecutive low back pain patients, 18 years +, who have been referred from general practice to the secondary sector for further examination and MR scan.
2927422|NCT03058302|Experimental|Full CETA|Full CETA participants will complete 12 CETA sessions. this is the same version of CETA that has been tested in other sites. They will be monitored weekly for clinical purposes (symptoms and safety) during treatment. they will also receive monthly research assessments (research outcomes) for 6 months after baseline assessment and commencement of treatment.
2927423|NCT03058302|Experimental|Brief CETA|Brief CETA participants is a new shorter version of CETA that has the same content as Full CETA but provided in fewer sessions. Each participant will complete 5 CETA sessions and will be monitored weekly for clinical purposes (symptoms and safety) during treatment and thereafter monthly for research purposes (research outcomes) for 6 months after baseline assessment and commencement of treatment.
2927424|NCT03058302|No Intervention|Wait-Control|Wait-control participants will undergo monthly monitoring after enrollment in the study for research purposes (research outcomes) for 6 months after baseline assessment.
2927425|NCT03058289|Experimental|Cohort A|INT230-6 injections every 28 days for 5 sessions into only superficial tumors, low starting dose, low concentration per tumor.
2927426|NCT03058289|Experimental|Cohort B1|INT230-6 injections every 28 days for 5 sessions into superficial or deep tumors, low starting dose, low drug concentration per tumor
2927427|NCT03058289|Experimental|Cohort B2|INT230-6 injections every 28 days for 5 sessions into superficial or deep tumors, medium starting dose, low drug concentration per tumor
2927659|NCT03056872||Healthy Controls|Community sample
2927428|NCT03058289|Experimental|Cohort B3|INT230-6 injections every 28 days for 5 sessions into superficial or deep tumors, high starting dose, low drug concentration per tumor
2927429|NCT03058289|Experimental|Cohort C1|INT230-6 injections every 28 days for 5 sessions into superficial or deep tumors, low starting dose, high drug concentration per tumor
2927430|NCT03058289|Experimental|Cohort C2|INT230-6 injections every 28 days for 5 sessions into superficial or deep tumors, medium starting dose, high drug concentration per tumor
2927431|NCT03058289|Experimental|Cohort C3|INT230-6 injections every 28 days for 5 sessions into superficial or deep tumors, high starting dose, high drug concentration per tumor
2927432|NCT03058289|Experimental|Cohort D|INT230-6 injections every 28 days for 5 sessions into superficial or deep tumors, dosing per any B or C cohorts (having acceptable tolerability) with addition of anti-PD-1 antibodies
2927433|NCT03058289|Experimental|Cohort E|INT230-6 injections every 14 days for 5 sessions into superficial or deep tumors treated, dosing per any of A, B, C or D cohorts (having acceptable tolerability) an anti-PD-1 antibody could be added with regimens set by the Study Steering Committee.
2927434|NCT03058276|Experimental|Exposure|Exposure to a 5 minutes video related to alcohol consumption (updating/retrieval), followed by 10 minutes of the alcohol- AAT(Approach Avoidance Task) (extinction), during 4 days of training (2 weeks).
2927435|NCT03058276|Active Comparator|No exposure|Exposure to a 5 minutes video with neutral content (no retrieval) followed by 10 minutes of the alcohol- AAT (Approach Avoidance Task) , during 4 days of training.
2927436|NCT03058276|Experimental|Active rTMS|Each session (5 sessions along 2 weeks), patients receive active stimulation with repetitive transcraneal magnetic stimulation (rTMS) of the right dorsolateral prefrontal cortex.
2927437|NCT03058276|Sham Comparator|SAM|Pacients receiving a sham stimulation (SAM), with a similar procedure to the experimental condition
2927438|NCT03058263|Experimental|partial dose of neostigmine|Those who received partial dose of neostigmine as rocuronium reversal
2927439|NCT03058263|Experimental|TOF ratio-based dose of neostigmine|Those who received TOF ratio-based dose of neostigmine as rocuronium reversal
2927440|NCT03058250|No Intervention|Control|Standard of care, no intervention
2927441|NCT03058250|Active Comparator|Transesophageal echocardiography|Patients will have intraoperative transesophageal echocardiography along with standard of care for management.
2927442|NCT03058237|Experimental|Part 1: Regimen A|"One low dose Arbaclofen Placarbil MR Prototype A tablet taken under fasting conditions.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
2927443|NCT03058237|Experimental|Part 1: Regimen B|"One low dose Arbaclofen Placarbil MR Prototype B tablet taken under fasting conditions.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
2927444|NCT03058237|Active Comparator|Part 1: Regimen C|"One low dose Arbaclofen Placarbil SR tablet taken under fasting conditions as the reference product.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
2927445|NCT03058237|Experimental|Part 1: Regimen D|"One low dose tablet of the selected Arbaclofen Placarbil MR Prototype administered with 0.6 g/kg of beverage in orange juice.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
2927446|NCT03058237|Experimental|Part 1: Regimen E|"An optional regimen of one low dose tablet of the selected Arbaclofen Placarbil MR Prototype administered with 0.6 g/kg of beverage in orange juice.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
2927447|NCT03058237|Experimental|Part 2: Regimen F|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
2927448|NCT03058237|Active Comparator|Part 2: Regimen G|"One low dose Arbaclofen Placarbil IR capsule taken under fasting conditions as the reference product.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
2927449|NCT03058237|Experimental|Part 2: Regimen H|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
2927450|NCT03058237|Experimental|Part 2: Regimen I|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
2927451|NCT03058237|Experimental|Part 2: Regimen J|One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions, or a previously dosed MR prototype in the fed state. Part 2 participants receive Regimens F, G, H, I and J in a sequential manner.
2927452|NCT03058237|Experimental|Part 3: Regimen K|"One low dose selected Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 2) taken under fasting conditions.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
2927453|NCT03058237|Experimental|Part 3: Regimen L|"One low dose selected Arbaclofen Placarbil MR prototype tablet administered with 0.6 g/kg of beverage in orange juice or in the fed state, or one mid-low dose of the selected Arbaclofen Placarbil MR prototype tablet.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
2927454|NCT03058237|Experimental|Part 3: Regimen M|"An optional regimen of one mid-low dose of the selected Arbaclofen Placarbil MR prototype tablet (if not previously dosed in Regimen L) or one mid-high dose of the selected Arbaclofen Placarbil MR prototype tablet taken under fasting conditions.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
2927455|NCT03058237|Experimental|Part 3: Regimen N|"An optional regimen of one mid-high dose of the selected Arbaclofen Placarbil MR prototype tablet (if not previously dosed in Regimen M) or two mid-low dose of the selected Arbaclofen Placarbil MR prototype tablets.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
2927456|NCT03058224|Experimental|IGN-ES001|Polyclonal avian immunoglobulin IgY containing specific IgY against E. coli F18ab and S. typhimurium in partially delipidated avian egg yolk powder
2927457|NCT03058224|Placebo Comparator|Placebo|Polyclonal avian immunoglobulin IgY containing unspecific IgY in partially delipidated avian egg yolk powder
2927458|NCT03058211||pneumococcal pneumonia|Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
2927459|NCT03058211||non-pneumococcal pneumonia|Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
2927460|NCT03058198|Experimental|High Grade Glioma|"We plan to perform PET scanning on the patients with high grade gliomas after the injection of the second generation of EGFR tracer ,89Zr-ABT806（1-2mCi）, which can be specifically binded to EGFR vⅢ . After fusing the PET and MRI images, we precisely obtained the tissue from thehot-spot on the PET image through multimodal-neuronavigation-guided tumor biopsy. EGFRvⅢ status was detected by Sanger sequencing to analyze the correlation with the 89Zr-ABT806 PET image qualitatively and quantitatively. The final goal was to detect EGFR vⅢ by noninvasive molecular imaging procedure for the clinical outcome prediction and the selection of EGFR-targeted therapies."
2927461|NCT03058172|Other|Odors (food and non-food)|Odorants diluted in mineral oil.
2927462|NCT03058172|Other|Pictures (food and non-food)|Pictures of objects or scenes.
2927463|NCT03058159|Other|Subjects with a high dream recall frequency|
2927464|NCT03058159|Other|Subjects with a law dream recall frequency|
2927465|NCT03058146|Experimental|Mobile Health Walking Condition|Physically inactive older adults in this condition (N=30) will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
2927466|NCT03058146|Active Comparator|Healthy Aging Education Condition|The education control condition (N=30) will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
2927467|NCT03058133|Other|fMRI study|
2927468|NCT03058120|No Intervention|Stress testing|Patient with chest pain, low risk by modified HEART score, undergoes whatever admission and stress testing plan is determined by ED and inheriting decision unit physicians.
2927469|NCT03058120|Active Comparator|Early discharge|Patient with chest pain, low risk by modified HEART score, is discharged from the emergency room without admission nor stress testing.
2927470|NCT03058107|Experimental|Nutrition Therapy (NT) group|Nutrition Therapy is intensive dietary counseling based on practical measurements of energy expenditure, rather than calculating it using theoretic formulas or no method at all.
2927471|NCT03058107|Active Comparator|Control Therapy (CT) group|Control Therapy is standard dietary counseling bij state-wide recognized onco-dietitians. Energy expenditure is never measured in this standard protocol.
2927472|NCT03058094|Experimental|AC0010|AC0010, 300mg, orally, BID with a 21-day cycle
2927473|NCT03058094|Active Comparator|Chemotherapy|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 on day one of 21-day cycle, with total of 4-6 cycles.
2927474|NCT03058081|Experimental|High Flow Nasal Test|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with High Flow Nasal at 60L/min (with or without additional oxygen)
2927475|NCT03058081|No Intervention|Control Test|Patient will perform one Constant Work-Rate Exercise Test at 80% of maximum workload on room air or with oxygen supplementation
2927476|NCT03058068|Experimental|Safety Run-In: Treatment 1 Allo-hMSCs|Treatment 1: 1 subject will receive a single administration of allogeneic MSCs: 20 x 10^6 MSCs (20 million) cells delivered via peripheral intravenous infusion.
2927477|NCT03058068|Experimental|Safety Run-In: Treatment 2 Allo-hMSCs|2 subjects will receive a single administration of allogeneic MSCs: 100 x 10^6 MSCs (100 million) cells delivered via peripheral intravenous infusion.
2927478|NCT03058068|Experimental|Randomized: Cohort 1 Allo-hMSCs|Cohort 1 (5 subjects): 20 million MSCs A single peripheral intravenous infusion of 20 x 10^6 MSCs (20 million cells) will be administered to each subject.
2927479|NCT03058068|Experimental|Randomized: Cohort 2 Allo-hMSCs|Cohort 2 (5 subjects): 100 million MSCs A single peripheral intravenous infusion of 100 x 10^6 MSCs (100 million cells) will be administered to each subject.
2927480|NCT03058068|Placebo Comparator|Randomized: Cohort 3 Allo-hMSCs|Cohort 3 (5 subjects): Placebo A single peripheral intravenous infusion of placebo (PlasmaLyte A containing 1% HSA) will be administered to each subject.
2927481|NCT03058055|Placebo Comparator|Placebo|Usual lifestyle activities
2927482|NCT03058055|Experimental|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
2927483|NCT03058055|Experimental|Reading|Daily reading (out loud into a voice recorder) for one hour
2927484|NCT03058042|Experimental|Home pelvic floor muscle training|Patients will perform strength training of the pelvic floor muscles daily at home. The training protocol consists of three sets of 30 slow contractions (type I muscle fibers), with maintenance contraction according to the initial evaluation, followed by three rapid contractions (type II muscle fibers) after each slow contraction. The protocol will account for 90 contractions of the pelvic floor muscles per day. At the end of one month, the patients will return for consultation, in which the MAP evaluation and training progression will be performed.
2927485|NCT03058042|Sham Comparator|Outpatient pelvic floor muscle training|The patients will perform 24 outpatient sessions of pelvic floor muscle strength training and home training. The training protocol consists of three sets of 30 slow contractions (type I muscle fibers), with maintenance contraction according to the initial evaluation, followed by three rapid contractions (type II muscle fibers) after each slow contraction. The protocol will account for 90 contractions of the pelvic floor muscles per day. At the end of one month, the patients will perform the evaluation of the MAP and progression of the training.
2927486|NCT03058029|Experimental|Gelesis200|Gelesis200: Three (3) Gelesis200 capsules (2.10 gram (g)) two (2) times per day (id est (i.e.), lunch and dinner
2927487|NCT03058029|Placebo Comparator|Placebo|Placebo: Three (3) placebo capsules two (2) times per day (i.e., lunch and dinner
2927488|NCT03058016|Experimental|Personalized recommendations for diet|"After measurement of individual's parameters changes as blood tests, gut microbiome, urine tests, blood pressure, heart performance, body circumferences, mood and mental status as well as monitoring each individual's food intake - a model to predict individual's body reaction according to lifestyle, eating and activity habits will be built.~Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions will be provided on a bi-weekly basis, all Lab tests and dietician control will be performed twice a month."
2927489|NCT03058003||Patients|subjects suffering from chronic pain undergoing Posturography Evaluation and Central Sensitization Inventory
2927490|NCT03058003||Healthy|subjects self assessed to be in good health undergoing Posturography Evaluation and Central Sensitization Inventory
2927491|NCT03057990|Experimental|Pyrimethamine Treatment (Intra-patient)|50mg/100mg/150mg once daily on days 1-28 of each 28-day cycle. Administered using intra-patient dose escalation, starting at 50 mg and up to 150 mg.
2927492|NCT03057977|Experimental|Empagliflozin|
2927493|NCT03057977|Placebo Comparator|Placebo|
2927494|NCT03057964|Experimental|PDL (Pulsed Dye Laser) and Fractional Photothermolysis|
2927495|NCT03057964|No Intervention|Control|
2927496|NCT03057951|Experimental|Empagliflozin|
2927497|NCT03057951|Placebo Comparator|Placebo|
2927498|NCT03057938|Experimental|18F-Florbetaben (FBB)|18F-Florbetaben
2927499|NCT03057925|Experimental|Group A|MWA Percutaneous Microwave Ablation intervention procedure: Ultrasound-guided Percutaneous Microwave Ablation
2927500|NCT03057925|No Intervention|Group B|untreated no treatment; regular ultrasonic image follow-up
2927501|NCT03057912|Experimental|TALEN|TALEN (TALEN-HPV16 E6/E7 or TALEN-HPV18 E6/E7) plasmid in gel, administered twice one week for 4 weeks.
2927502|NCT03057912|Experimental|CRISPR/Cas9|CRISPR/Cas9 (CRISPR/Cas9-HPV16 E6/E7T1 or CRISPR/Cas9-HPV18 E6/E7T2 ）plasmid in gel, administered twice one week for 4 weeks.
2927503|NCT03057912|No Intervention|Control group|Observation
2927504|NCT03057899|Experimental|fenugreek seed and Lespedeza cuneata (TFG)|Patients who received investigational products (200 mg TFG) twice per day for 8 weeks at least 30 minutes after food intake
2927505|NCT03057899|Placebo Comparator|Placebo|Patients who received placebo twice per day for 8 weeks at least 30 minutes after food intake
2927506|NCT03057886||Compare the Spot On with others consecrated thermometers|This study intends to compare the accuracy of the new device(SPOT ON thermometer) with the oral and esophageal in participants submitted to general and spinal anesthesia, in different types of population (pediatric and adult)
2927507|NCT03057873|Experimental|High protein, high fiber|Participants receive a high protein, high fiber dietary supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
2927508|NCT03057873|Placebo Comparator|Low protein, low fiber|Participants receive a low protein, low fiber supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
2927509|NCT03057847|Experimental|SOF/VEL|Sofosbuvir/Velpatasvir, One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
2927510|NCT03057834|Active Comparator|Functionally impaired|Women with urinary incontinence and short physical performance battery score of <9
2927511|NCT03057834|Placebo Comparator|Functionally normal|Women with urinary incontinence and short physical performance battery score of > 10
2927512|NCT03057821|No Intervention|Control|The control group will not receive any hydrogen peroxide skin preparation
2927513|NCT03057821|Experimental|Treatment|The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
2927514|NCT03057808|Experimental|Gestational weight gain intervention (GWG-only)|The GWG intervention will begin upon randomization to the GWG-only or the GWG+PPWL arm, and continue until the birth of the participant's child.
2927515|NCT03057808|Experimental|Postpartum weight loss intervention (PPWL-only)|The PPWL intervention will begin at 6-weeks postpartum (when most women will be approved for weight loss and exercise by their obstetrician) for those participants randomized to the PPWL only or the GWG+PPWL arms, and will continue until 6-months postpartum.
2927516|NCT03057808|Experimental|Combined|During the gestational phase participants will receive the same intervention as the GWG only group. During the postpartum phase participants will receive the the same intervention as the PPWL group.
2927517|NCT03057795|Experimental|Treatment (brentuximab vedotin, nivolumab)|Beginning 30-60 days post-ASCT, patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
2927518|NCT03057782||Group A|"Plan for major surgery anticipated to cause pain and agitation (i.e. esophageal atresia treatment);~Patients who are anticipated to receive prolonged post-surgical neuromuscular blockade (NMB)~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. These subjects will also receive EMG monitoring. Subjects in this group will also have video recordings that may be used for novel analysis such as subdermal blood flow or micro-movement."
2927519|NCT03057782||Group B|"Plan for major surgery anticipated to cause pain and agitation (i.e. bowel surgery);~Patients who are not anticipated to receive acute post-surgical NMB~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
2927520|NCT03057782||Group C|"Plan for minor surgery anticipated to cause pain and agitation (i.e. hernia repair)~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
2927521|NCT03057782||Group D|"No plan for surgery~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
2927657|NCT03056872||AnxD+AUD-CBT|AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual in addition to CBT for co-occurring AUD+AnxD
2927522|NCT03057769|Experimental|PES group|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
2927523|NCT03057769|Placebo Comparator|Control group|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
2927524|NCT03057756||TB-MR patients|Patients older than 15 years old receiving Km+ Mfx+ Pto + H + Cfz +E+Z
2927525|NCT03057730|Experimental|Group 1: Thin Biotype|"Gingival thickness < 0.8 mm~Acellular Dermal Matrix (ADM) will be used according to manufacturer's instructions during mucogingival surgery. Subjects will be anesthetized using local anesthesia. An envelope flap design will be involved with no releasing incisions. The ADM will be placed beneath the flap. The flap will then be advanced to the level of cemento-enamel junction (CEJ). The area will be sutured.~Mean root coverage, CPD, CAL, RH, RW, KTW, GT, and CRC will be measured and compared at 3 months, 6 months, 12 months, 24 months and 48 months post-surgery."
2927526|NCT03057730|Experimental|Group 2: Thick Biotype|"Gingival thickness ≥ 0.8 mm~Acellular Dermal Matrix (ADM) will be used according to manufacturer's instructions during mucogingival surgery. Subjects will be anesthetized using local anesthesia. An envelope flap design will be involved with no releasing incisions. The ADM will be placed beneath the flap. The flap will then be advanced to the level of cemento-enamel junction (CEJ). The area will be sutured.~Mean root coverage, CPD, CAL, RH, RW, KTW, GT, and CRC will be measured and compared at 3 months, 6 months, 12 months, 24 months and 48 months post-surgery."
2927527|NCT03057717|Other|Ultrasound|All participants in the study will have fetal thymus size measured using ultrasound.
2927528|NCT03057704|Active Comparator|Intravenous lidocaine: flushed|Lidocaine injection flushed
2927529|NCT03057704|Experimental|Intravenous lidocaine: tourniquet|Lidocaine injection tourniquet
2927530|NCT03057691||control|patients suffered from ACS without major depressive disorder or generalized anxiety disorder after PCI
2927531|NCT03057691||MDD impove|patients suffered from post-ACS major depressive disorder whose depression has been improved though antidepressive therapy or not after PCI
2927532|NCT03057691||MDD not improve|patients suffered from post-ACS major depressive disorder whose depression hasn't been improved though antidepressive therapy or not after PCI
2927533|NCT03057691||GAD impove|patients suffered from post-ACS generalized anxiety disorder whose anxiety syndromes have been improved though anti-anxiety therapy or not after PCI
2927534|NCT03057691||GAD not improve|patients suffered from post-ACS generalized anxiety disorder whose anxiety syndromes havn't been improved though anti-anxiety therapy or not after PCI
2927535|NCT03057678|Experimental|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
2927536|NCT03057665||Pregnant Women|Measure magnetic field versus time for fetus, using atomic biomagnetometer.
2927537|NCT03057652|Experimental|ReWalk, then EKSO, then REX|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
2927538|NCT03057652|Experimental|ReWalk, then REX, then EKSO|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
2927539|NCT03057652|Experimental|EKSO, then ReWalk, then REX|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
2927540|NCT03057652|Experimental|EKSO, then REX, then ReWalk|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
2927541|NCT03057652|Experimental|REX, then EKSO, then ReWalk|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
2927542|NCT03057652|Experimental|REX, then ReWalk, then EKSO|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
2927543|NCT03057639||Observational (questionnaires)|Patients complete questionnaires at referral, week 4-8, week 10-12, and at the completion of systemic therapy.
2927544|NCT03057626||Observational (specimen collection)|Patients undergo collection of blood and urine samples on day 1. Patients also undergo clinical assessments, laboratory, radiographic, and other ancillary studies on day 1.
2927545|NCT03057613|Experimental|Pembrolizumab + post operative radiotherapy|IMRT 60-66Gy for 6 weeks in combination with Pembrolizumab every 3 weeks for 16 weeks
2927546|NCT03057600|Experimental|Cohort 1 - African ancestry, 3rd line+|"Intervention = Pac-CB combination~Patients must self-identify as African ancestry (AA; includes African American).~At least 2 prior lines of systemic therapy for advanced/metastatic disease including a taxane.~Prior taxane (paclitaxel, docetaxel, or nab-paclitaxel) for advanced/metastatic disease is required but must not have been received in the immediate prior line of therapy.~Systemic neoadjuvant and/or adjuvant therapy is considered a line of therapy for advanced/metastatic disease if the time to recurrence from completion of treatment was ≤ 12 mo."
2927547|NCT03057600|Experimental|Cohort 2 - African ancestry, 1st line|"Intervention = Pac-CB combination~Patients must self-identify as African ancestry (includes African American).~No prior systemic therapy for advanced or metastatic disease.~Systemic neoadjuvant or adjuvant therapy, including taxane, is allowed if time to recurrence was > 12 mo."
2927548|NCT03057600|Experimental|Cohort 3 - Non-AA, 3rd line+|"Intervention = Pac-CB combination~Patients do not self-identify as African ancestry.~Otherwise have the same criteria as Cohort 1."
2927549|NCT03057600|Experimental|Cohort 4 - Non-AA, 1st line|"Intervention = Pac-CB combination~Patients do not self-identify as African ancestry.~Otherwise have the same criteria as Cohort 2."
2927550|NCT03057587||NIRS Monitoring|A NIRS sensor will be placed on the forehead of the patient upon entry to the operating room and will remain on, as tolerated, for the duration of surgery
2927551|NCT03057574|Experimental|Treatment|Follitropin Alfa (Gonapure)
2927552|NCT03057561|Experimental|1.5 Tesla MRI|"30 randomly selected patients with suspected or known cardiovascular disease will be imaged using Dotarem enhanced LGE-CMR.~30 randomly selected patients with suspected or known cardiovascular disease will be imaged using Magnevist enhanced LGE-CMR."
2927553|NCT03057561|Experimental|3.0 Tesla MRI|"30 randomly selected patients with suspected or known cardiovascular disease will be imaged using Dotarem enhanced LGE-CMR.~30 randomly selected patients with suspected or known cardiovascular disease will be imaged using Magnevist enhanced LGE-CMR."
2927554|NCT03057548|Active Comparator|Pulmonary Vein Isolation (PVI)|"Cryoablation only of Pulmonary Veins~or~Radiofrequency ablation only of Pulmonary Veins~Pulmonary Vein Isolation (PVI) alone."
2927555|NCT03057548|Experimental|PVI & Posterior Left Atrial Ablation|"Cryoablation of Pulmonary Veins plus RF ablation of Posterior Left Atrial Wall~or~Radiofrequency ablation of Pulmonary Veins plus RF ablation of Posterior Left Atrial Wall~PVI ablation plus ablation of the Posterior Left Atrial Wall (PLAW)"
2927556|NCT03057535|Experimental|Sodium Bicarbonate|Ingestion of sodium bicarbonate (0.3 g/kg of body mass)
2927557|NCT03057535|Placebo Comparator|Sodium Chloride|Ingestion of sodium chloride (4 g)
2927558|NCT03057522|Experimental|Intervention Group|This group will undergo home exercise program designed to increase their running cadence.
2927559|NCT03057522|No Intervention|Control Group|This group will not receive any intervention.
2927560|NCT03057509|Experimental|Gallium PET/MR Imaging|"Siemens PET/MR scanner at Martinos Center for Biomedical Imaging will be use.~Standard Siemens software will be used to perform image analysis and measure parameters such as SUVmean, SUVmax and MTV.~Standard LAR Octreotide will be administered.~Ga-68-DOTA-TOC that will be administered prior to PET/MR imaging at 7 days after standard LAR octreotide administration and again at 28 day.~Ga-68-DOTA-TOC will be administered as a single intravenous dose at a pre-determine dosage."
2927561|NCT03057496|Experimental|Intervention|Participants will use the collision warning device as much as possible for two months during everyday activities, when walking indoors and outdoors.
2927562|NCT03057483||Elderly|People over 60 years of age. seasonal influenza vaccine
2927563|NCT03057483||Health care workers|People working in health care services seasonal influenza vaccine
2927564|NCT03057483||Pregnant women|Pregnant women seasonal influenza vaccine
2927565|NCT03057483||Post partum women|Women who have given birth < 45 days seasonal influenza vaccine
2927566|NCT03057483||Children|Children from 6 months to 5 years of age seasonal influenza vaccine
2927567|NCT03057470|Active Comparator|0% Bolus Insulin Correction|0% Bolus Insulin Correction
2927568|NCT03057470|Active Comparator|50% Bolus Insulin Correction|50% Bolus Insulin Correction
2927569|NCT03057470|Active Comparator|100% Bolus Insulin Correction|100% Bolus Insulin Correction
2927570|NCT03057470|Active Comparator|150% Bolus Insulin Correction|150% Bolus Insulin Correction
2927571|NCT03057457||Kidney Injury|
2927572|NCT03057444|Experimental|Intervention group|"The patients get 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.~Study examinations are before intervention, after 4 weeks and 8 weeks. Stool samples are collected before intervention and each 14 days consecutively until the end of intervention."
2927573|NCT03057431|Placebo Comparator|Placebo|Once daily for 3 years
2927574|NCT03057431|Experimental|12.5 mg hydrochlorothiazide|Once daily for 3 years
2927575|NCT03057431|Experimental|25.0 mg hydrochlorothiazide|Once daily for 3 years
2927576|NCT03057431|Experimental|50.0 mg hydrochlorothiazide|Once daily for 3 years
2927577|NCT03057418|Experimental|Aurixim|"Dosage: 125 mg/m2, 250 mg/m2, 375 mg/m2 and 500 mg/m2. Formulation: concentrate for preparation of infusions 500 mg/50 ml and 100 mg/10 ml.~Mode of administration: intravenous."
2927578|NCT03057405||intra-operative CBCT|
2927579|NCT03057405||3D virtual planning + intra-operative navigation|
2927580|NCT03057405||3D virtual planning + intraoperative navigation + IO CBCT|
2927581|NCT03057392|Experimental|immersion and them sham procedure|"hemodialysis patients will do a 3 hours dialysis session while sitting in a bath and then have a dry session outside the bath"
2927582|NCT03057392|Sham Comparator|sham session and then immersion|dialysis patients will have a 3 hour dialysis session (dry session) and then immersion
2927583|NCT03057379|No Intervention|Control arm|Usual source of care
2927584|NCT03057379|Experimental|1 R/R per Dose|Sending up to one recall notice per dose of HPV vaccine needed
2927585|NCT03057379|Experimental|2 R/R per dose|Sending up to two recall notice per dose of HPV vaccine needed
2927586|NCT03057379|Experimental|3 R/R per dose|Sending up to three recall notice per dose of HPV vaccine needed
2927587|NCT03057366|Experimental|[14C]-Pevonedistat 25 mg/m^2|[14C]-pevonedistat (containing approximately 60-98 mCi [approximately 2.22-3.626 MBq] of radioactive tracer), infusion, intravenously, single dose on Day 1 of Week 1 in Part A. After completion of Part A, participants will have opportunity to continue into Part B. Participant will receive Pevonedistat 25 mg/m^2, infusion, intravenously, single dose on Days 1, 3 and 5 of each 21 day cycle, for up to 12 cycles along with docetaxel 75 mg/m^2, infusion, intravenously, over 1 hour on Day 1 of each 21 day cycle; or pevonedistat 20 mg/m^2, infusion, intravenously, single dose on Days 1, 3 and 5 of each 21 day cycle, for up to 12 cycles, followed by paclitaxel 175 mg/m^2, infusion, intravenously, over 3 hours along with carboplatin 20 mg/m^2, infusion, intravenously, over 30 minutes on Day 1 of 21 each cycle up to 12 cycles.
2927588|NCT03057353||lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
2927589|NCT03057340|Experimental|DRibble vaccine|Blood samples collection: collect of 10ml patients peripheral blood, separate PBMC;Day 1: DRibble group guided by ultrasound in patients with inguinal lymph nodes injected the DRibble vaccine;Day8: collecte 50 ml peripheral blood and separate monocytes and lymphocytes;Intensify immune cells amplification;Identification of immune cell;Detection of Immune cells microbial;20-22 days: immune cells back to patients;55 days: collecte 10 ml peripheral blood, after the separation of PBMC in vitro induced to DC, cocultivate with DRibble and subcutaneous injection at 60th day;Day 75: collecte 10 ml peripheral blood, separate PBMC and detecte T cell immune response ability.
2927590|NCT03057327|Active Comparator|comparator|As women exit the changing are they will be asked if they regularly check their skin for concerning moles
2927591|NCT03057327|Experimental|Improve awareness of checking moles|Posters, brochures, and skin self-examination kits consisting of a ruler, and a lighted magnifying lens will be placed into each of the 8 changing rooms in the mammogram facility.
2927592|NCT03057314|Experimental|Amorphous calcium carbonate|"The investigation product will include:~ACC tablets, containing 200 mg elemental calcium~1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension"
2927593|NCT03057288|Experimental|fiducial markers placement|Prospective study with one arm evaluating the feasibility of fiducial markers placement under echoendoscopic guidance, for patients with esophageal or rectal cancer
2927594|NCT03057275||Threatened PTL|abdominal fetal/maternal monitoring
2927595|NCT03057275||Delivered PTL|abdominal fetal/maternal monitoring
2927596|NCT03057262||Study group|Study group consisted of 56 subjects of both genders with unilateral or bilateral disc displacement(s) with reduction and pain in the area of temporomandibular joint. Patients were recruited from the Consulting Room of Temporomandibular Joint Dysfunction at the Jagiellonian University in Krakow during the years 2014-2016. In the study group was used the typical acrylic anterior repositioning splint fabricated in tete-a-tete (incisal) jaws position, covered the lower teeth arch to recapture a displaced disc(s) and decrease the intensity of pain. The anterior repositioning splint was recommended to 20 - hour use for a period of four months.
2927597|NCT03057262||Control group|Control group consisted of 56 subjects of both genders with unilateral or bilateral disc displacement(s) with reduction and pain in the area of temporomandibular joint. Patients were recruited from the Consulting Room of Temporomandibular Joint Dysfunction at the Jagiellonian University in Krakow during the years 2014-2016. In the control group the investigators used the biostymulation laser (Terapus 2, Accuro, Poland), wave length 808 nm, power 32 J in the form of 12 session (duration of a single session was 3 min 45 s), performed every second day, on the area of the both temporomandibular joints (distance to the skin was 1 cm) with opened mouth and systematic performing of muscles self-exercises with a dominant protrusive position of mandible.
2927598|NCT03057236|No Intervention|Standard of Care|This arm does not receive the behavioral intervention. Participants will complete HCV treatment per standard of care.
2927599|NCT03057236|Experimental|Cognitive Behavior Coping Skills|The CBCS intervention is a structured module-based group intervention involving 9, 2-hour sessions. Participants will participate in 4 weekly sessions before HCV treatment to learn and practice new cognitive behavioral skills, and 5 sessions during HCV treatment at weeks 2, 4, 6, 8, and 12.
2927600|NCT03057223|Experimental|3D Jaw Plate|3D Jaw Plate will be used in internal fixation.
2927601|NCT03057210|No Intervention|S1 (Basal)|The behavior of the variables of functional and clinical outcome will be analyzed under no stress or recovery technique. In this stage, only the functional tests and the collection of clinical data will be performed.
2927602|NCT03057210|Experimental|S2 (Massage)|The behavior of the variables of functional and clinical outcome will be analyzed under stress or recovery technique. In this stage, only the functional tests and the collection of clinical data will be performed.
2927603|NCT03057210|Experimental|S3 (Exercise)|The behavior of the variables of functional, clinical and metabolic outcome will be analyzed before the exercise protocol is performed. In this stage the volunteers will first perform the protocol for exhaustion, and in specific moments the blood lactate and clinical data will be collected, and 2h after the beginning of the exercise protocol, the functional tests will be performed.
2927604|NCT03057210|Experimental|S4 (Exercise + Immediate Massage)|In this stage, the behavior of the variables of functional, clinical and metabolic outcome will be analyzed from the exercise protocol, followed by massage. Firstly the volunteers will carry out the protocol for exhaustion and the massage application will be done immediately after the end of the exercise. Blood lactate and clinical data will be collected at specific times during this stage. After 2h of the beginning of the stress protocol, the functional tests will be performed.
2927605|NCT03057210|Experimental|• S5 (Exercise + Active Recovery + Delayed Massage)|In this stage, the behavior of the variables of functional, clinical and metabolic outcome will be analyzed before the exhaustion protocol and the application of the massage after 1h of passive recovery. Firstly the volunteers will perform the protocol for exercise, followed by a passive recovery of 1h and then the massage application. The functional tests will be performed 2 hours after the stress protocol begins. Again, blood lactate collection and clinical data will occur at specific times.
2927606|NCT03057197|No Intervention|Group A|Conventional method group (n=85): caudal injection after advancement of the needle into the sacral canal. Ultrasound is used to achieve accurate needle placement and we will check intravascular injection using digital subtraction angiography.
2927607|NCT03057197|Experimental|Group B|New method group (n=85): same as conventional method group except caudal injection right after penetrating the sacrococcygeal ligament.
2927608|NCT03057184|Experimental|Intervention group|behavioral intervention program
2927609|NCT03057184|No Intervention|Usual care|Usual care
2927610|NCT03057171||Gastric ulcer|patients who will undergo EGD for gastric ulcer
2927611|NCT03057171||Duodenal ulcer|patients who will undergo EGD for duodenal ulcer
2927612|NCT03057171||Stomach cancer|patients who will undergo EGD for stomach cance
2927613|NCT03057171||health individuals|patients who will undergo screening EGD
2927614|NCT03057158||1|Women with Urgency Incontinence (At least three times per week) greater than three months, and without insulin resistance.
2927615|NCT03057158||2|Women with insulin resistance (pre-diabetes or diabetes based on Hemoglobin A1C).
2927616|NCT03057158||3|Women with both UUI (at least three times per week for over three months) and Insulin Resistance (pre-diabetes or diabetes based on Hemoglobin A1C).
2927617|NCT03057145|Experimental|Prexasertib Combine with Olaparib|"Olaparib will be administered orally on an intermittent schedule during each 28-day cycle. Exact administration schedule will depend on assigned dose level.~Prexasertib will be administered intravenously on Days 1 and 15 of a cycle"
2927618|NCT03057132|Experimental|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
2927619|NCT03057119|Experimental|SBIRT Intervention|The interventionist will discuss substance use and misuse, HIV, and the interaction of aging and substance use; will give the patient feedback on their NM-ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change; motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues. Identifying and prioritizing need; problem-solving techniques to help patients identify which services may best help them work towards their goals; will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
2927708|NCT03056573|Experimental|Transaortic|Transaortic access route
2927620|NCT03057119|No Intervention|Treatment as Usual|Participants in the enhanced care treatment as usual group will receive the same illustrated handout depicting their substance use screening score and the same referral resource guide provided to those in the control group. These will be provided with only a quick introduction by the research assistant to minimize intervention elements in the control condition and to resemble the notification and referral strategy that would be standard care.
2927621|NCT03057106|Active Comparator|Durvalumab and Tremelimumab|Durvalumab q4 weeks until PD + Tremelimumab q 4 wk x 4 doses
2927622|NCT03057106|Active Comparator|Platinum based chemotherapy + Durvalumab + Tremelimumab|"4 cycles platinum plus gem or pem + Durva + Treme (q 3 wk x 4 cycles)~Followed by:~Squamous Cell: Maintenance Durva q 4 wk until PD Non-Squamous Cell: Pemetrexed + Durva q 4 wk until PD"
2927623|NCT03057093||TIII>TI|Subjects with TIII>TI in initial ECG
2927624|NCT03057093||Non TIII>TI|Subjects without TIII>TI in initial ECG
2927625|NCT03057080|Other|PTA procedure|Percutaneous transluminal angioplasty (PTA) in patients with ischemic leg ulcer
2927626|NCT03057067|Experimental|pelvic vein embolization|female patients referred for assessment of chronic pelvic pain at the gynecological outpatient clinic or the Multidisciplinary Pain Clinic at St. Olavs Hospital, Trondheim, Norway
2927627|NCT03057054|Experimental|Arm I (Lactobacillus plantarum, alloHCT)|Patients receive Lactobacillus plantarum strains 299 and 299v PO or through NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
2927628|NCT03057054|Placebo Comparator|Arm II (placebo, alloHCT)|Patients receive placebo PO or through NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
2927629|NCT03057041|Experimental|Fentanyl|
2927630|NCT03057041|Placebo Comparator|Placebo|
2927631|NCT03057028|Experimental|anakinra|Patients will be treated with anakinra, injected SQ daily in a dose of 100mg for 14 days. Before and after this intervention, patients will undergo cardiopulmonary exercise testing (as well as echocardiography, EKG analysis, and serologic analysis). Subjects will be assessed for changes in exercise capacity, as determined by peak oxygen uptake and ventilatory efficiency to CO2 production slope.
2927632|NCT03057015|Experimental|Clonidine|50 mcg clonidine + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution
2927633|NCT03057015|Placebo Comparator|Placebo|0.5 ml normal saline + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution
2927634|NCT03057002||HCM Group|HCM patients will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.
2927635|NCT03057002||Control Group|Healthy control subjects will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.
2927636|NCT03056989|Experimental|SPX-101 Low Dose|Inhalation Solution twice daily for 7 days.
2927637|NCT03056989|Experimental|SPX-101 Mid Dose|Inhalation Solution twice daily for 7 days.
2927638|NCT03056989|Experimental|SPX-101 High Dose|Inhalation Solution twice daily for 7 days.
2927639|NCT03056976|Experimental|Single-implant mandibular overdenture|A single midline implant and an O'ring/ball attachment to retain a mandibular overdenture
2927640|NCT03056976|Experimental|Two-implant mandibular overdenture|Two implants in the canine region and two O'ring/ball attachments to retain a mandibular overdenture
2927641|NCT03056976|Experimental|Fixed mandibular denture|A fixed four-implant mandibular denture
2927642|NCT03056963|Experimental|Positive Self-Reference Training|Participants in this arm will complete the Positive Self-Reference Training (PSRT).
2927643|NCT03056963|Placebo Comparator|Neutral Training Control|Participants in this arm will complete the neutral training paradigm.
2927644|NCT03056950|No Intervention|non-oclusion training group|The control (non-occlusion training) group will follow the standard s/p distal radius fracture rehabilitation protocol. Treatment will include passive, active assistive,active range of motion (P/AA/AROM) to wrist, forearm and hand; desensitization as needed; edema control as needed; heat/cold modalities as needed; and strengthening exercises.
2927645|NCT03056950|Active Comparator|occlusion traingn with tourniquet|The occlusion training group will follow the same protocol as described above but will utilize occlusion training with the strengthening exercises. Investigators will use an established occlusion training protocol already being used. Intervention: Occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
2927646|NCT03056937||Obese with metabolic syndrome|bariatric surgery
2927647|NCT03056937||Obese without metabolic syndrome|bariatric surgery
2927648|NCT03056937||Healthy|Control
2927649|NCT03056924||Vedolizumab monotherapy|IBD patients on vedolizumab monotherapy, all patients will be treated with the standard vedolizumab dosing regimen of 300 mg infusions at 8 week intervals and receive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
2927650|NCT03056924||vedolizumab + immunomodulator|IBD patients receiving combination treatment with vedolizumab and concomitant immunomodulator therapy (methotrexate, azathioprine, or 6-mercaptopurine), will be treated with the standard vedolizumab dosing regimen of 300 mg infusions at 8 week intervals and/or receive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
2927651|NCT03056924||biologic + immunomodulator|IBD patients on other biologic therapy (infliximab, adalimumab, certolizumab, golimumab, ustekinumab) with concomitant immunomodulator therapy (methotrexate, azathioprine, or 6-mercaptopurine) and receivePneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
2927652|NCT03056924||non-immunosuppressive therapy|IBD patients not taking any immunosuppressive therapy (these patients may be taking oral or topical 5-aminosalicylates) and recive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
2927653|NCT03056911||ozone|Chemonucleolysis by ozone therapy Patients visiting the pain clinic of the hospital who had cervical discogenic or radicular pain that did not resolve after the use of conventional therapy. Written informed consent was obtained from all participants.
2927654|NCT03056885|Experimental|Conventional One-lung ventilation|The patients received a Tidal volume of 10 ml/kg (based on Predicted body weight)
2927655|NCT03056885|Experimental|Protective One-Lung Ventilation|The patients received a Tidal volume of 5 ml/kg (based on Predicted body weight)
2927656|NCT03056872||AUD only|AUD treatment inpatients without a co-occurring AnxD receiving AUD treatment as usual
2927660|NCT03056859||Enrolled Patients|Procedure: Central venous catheter placement with extravascular blood pressure transducer
2927661|NCT03056846|Placebo Comparator|Placebo|Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
2927662|NCT03056846|Experimental|Probiotic Combination|A commercially available probiotic mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
2927663|NCT03056846|Experimental|Bifidobacterium bifidum|A commercially available probiotic strain (Bifidobacterium bifidum) will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
2927664|NCT03056846|Experimental|Bifidobacterium longum|A commercially available probiotic strain (Bifidobacterium longum) will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
2927665|NCT03056833|Experimental|Ribociclib|Ribociclib (LEE-011) will be used as concurrent therapy with platinum-based chemotherapy in platinum-sensitive recurrent ovarian cancer. Participants will receive 200, 400, or 600mg of ribociclib per day in combination with carboplatin + paclitaxel. Subjects will receive 6 cycles of carboplatin + paclitaxel given weekly with ribociclib.
2927666|NCT03056820|Active Comparator|A - 25° head-up position|Participants will be positioned at 25° angle for procedure.
2927667|NCT03056820|Active Comparator|B - 55° head-up position|Participants will be positioned at 55° angle for procedure.
2927668|NCT03056807|Active Comparator|A - 25° head-up position|Participants will be positioned at a 25° head-up position for procedure.
2927669|NCT03056807|Active Comparator|B - 55° head-up position|Participants will be positioned at a 55° head-up position for procedure.
2927670|NCT03056794||PDC Deficiency|Pyruvate Dehydrogenase Complex Deficiency Disease
2927671|NCT03056781|Experimental|social interaction|Participants will engage in a social interaction with another person
2927672|NCT03056781|Experimental|food consumption|Participants will be offered food stuffs to eat/drink
2927673|NCT03056768|Active Comparator|active control|Health promotion provided by local health bureau.
2927674|NCT03056768|Experimental|multidomain intervention|1-year multidomain health promotion (physical activities, cognitive training, nutritional sessions)
2927675|NCT03056755|Experimental|alpelisib + fulvestrant|Patients who received any CDK 4/6 inhibitor plus aromatase inhibitor as treatment (immediately prior) will receive alpelisib + fulvestrant
2927676|NCT03056755|Experimental|alpelisib + letrozole|Patients who received any CDK 4/6 inhibitor plus fulvestrant as treatment (immediately prior) will receive alpelisib + letrozole
2927677|NCT03056742|Experimental|Stem cells|Patients will receive intramuscular and local injection of stempeucel(R) in addition to standard protocol of care
2927678|NCT03056729|Experimental|Cohort HV1|
2927679|NCT03056729|Experimental|Cohort HV2|
2927680|NCT03056729|Experimental|Cohort HV3|
2927681|NCT03056729|Experimental|Cohort HV4|
2927682|NCT03056729|Experimental|Cohort HV5|
2927683|NCT03056729|Experimental|Cohort AD1|
2927684|NCT03056729|Experimental|Cohort AD2|
2927685|NCT03056716|Experimental|Silastic drain|Placement of 19FR silastic drain as basal drain
2927686|NCT03056716|Active Comparator|Conventional drain|Placement of 32FR conventional drain as basal drain
2927687|NCT03056703|Experimental|Acetylsalicylic acid [1000mg]|
2927688|NCT03056703|Active Comparator|Acetylsalicylic acid [500mg]|
2927689|NCT03056690|Experimental|ASP0819|A single oral dose to be taken preferably in the morning with or without food
2927690|NCT03056690|Placebo Comparator|Placebo|A single oral dose to be taken preferably in the morning with or without food
2927691|NCT03056677|Experimental|Control|No Whey Protein
2927692|NCT03056677|Experimental|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
2927693|NCT03056677|Experimental|Modified Whey|Modified whey protein will be given
2927694|NCT03056664|Experimental|MSC-1|Patient in this arm will receive routine surgery and local MSC injection of 3×10E6/kg
2927695|NCT03056664|Experimental|MSC-2|Patient in this arm will receive routine surgery and local MSC injection of 6×10E6/kg
2927696|NCT03056664|Experimental|Ctrl|Patient in this arm will receive routine surgery and local NS injection
2927697|NCT03056651|Other|DayCare-HF|Comprehensive service in day-care unit, including education, diagnostic tools (i.e. electrocardiography, transthoracic echocardiography, implanted cardioverter defibrillator (ICD) / cardiac resynchronization therapy device (CRT) interrogation and possibility of intravenous drug administration (i.e. loop diuretics, dobutamine).
2927698|NCT03056638|Experimental|Degarelix in conjunction with stereotactic body radiosurgery|Degarelix monthly for 6 months SBRT 8 Gy x 5
2927699|NCT03056638|Experimental|stereotactic body radiosurgery (SBRT)|SBRT 8 Gy x 5
2927700|NCT03056625|Experimental|Fortified rice|Participant will be given vitamin A fortified rice 1 meal/day
2927701|NCT03056625|Placebo Comparator|Control|Participant will be given normal rice 1 meal/day
2927702|NCT03056612||Group 1|Group 1 patients with high risk of ACLF development (CLIF-C AD score ≥ 50)
2927703|NCT03056612||Group 2|Group 2 patients with low risk of ACLF (CLIF-C AD score <50)
2927704|NCT03056599|Experimental|Multiple drug microinjection|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected one to three days prior to surgery using the CIVO device. Minute volumes (up to 8.3 microliters) of saline (negative control) or microdoses of anti-cancer agents will be percutaneously injected in a columnar fashion through each of 8 needles into a single enlarged solid tumor.
2927705|NCT03056586|Experimental|1. study group|"100 patients who agree to participate in the study, will be operate according to our protocol for pelvic organ prolapse. At the end of the operation a vaginal pessary will be inserted and suture to the vaginal walls for a 4 week period.~Follow-up will be after 3, 6, and 12 month period."
2927706|NCT03056586|No Intervention|2. control|100 Women who will refuse to participate in the study, will agree to be follow-up by our team for 3, 6, and 12 month post operative.
2927707|NCT03056573|Experimental|Subclavian/axillary|Subclavian/axillary access route
2927712|NCT03056521|Experimental|Info|"In this arm the patients are counseled preoperatively about post operative pain.~Specific information about post operative pain which includes both pharmacologic and non-pharmacologic treatments, complications of pain and benefits of good pain management. This is in addition to the routine care provided"
2927713|NCT03056521|No Intervention|No info|These patients are in the control group. They are left to receive only the routine preoperative care as made available to them while on ward.
2927714|NCT03056508|Experimental|Exercise plus Nutrition|6 months of supervised group exercise plus education and strategy training to alter diet to be consistent with recommendations outlined in our brain health food guide (BHFG).
2927715|NCT03056508|Active Comparator|Exercise|Identical exercise to the experimental plus education and passive discussion about brain health and healthy lifestyle to control for experimental group nutrition sessions.
2927716|NCT03056495|Experimental|Investigational drug|N-hydroxy-N'-phenyl-octanediamide (Vorinostat) capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
2927717|NCT03056482|Active Comparator|Ondansetron 8mg|8mg Ondansetron prepared in a 100mL normal saline mini-bag
2927718|NCT03056482|Experimental|Haloperidol 0.05mg/kg|0.05mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag
2927719|NCT03056482|Experimental|Haloperidol 0.1mg/kg|0.1mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag
2927720|NCT03056469|Active Comparator|Care providers do have access to PROs|Participants complete patient-reported outcome (PRO) questionnaires. Care providers do have access to the PROs and use them in clinical decision making.
2927721|NCT03056469|Active Comparator|Care providers do not have access to PROs|The participants complete patient-reported outcome (PRO) questionnaires. Care providers do not have access to the PROs.
2927722|NCT03056469|No Intervention|Control group|Standard follow-up. The participants do not complete PRO questionnaires.
2927723|NCT03056456|Experimental|LY900014|LY900014 delivered via an insulin pump as a continuous infusion under the skin, with various intermittent bolus doses during meals for two 3-day periods.
2927724|NCT03056456|Active Comparator|Insulin Lispro|Insulin lispro delivered via an insulin pump as a continuous infusion under the skin, with various intermittent bolus doses during meals for two 3-day periods.
2927725|NCT03056443|Experimental|Continuous Positive Airway Pressure-CPAP|CPAP education and discharge with auto-adjusting Continuous Positive Airway Pressure (CPAP) in addition to usual standards of clinical care for heart failure.
2927726|NCT03056443|No Intervention|Standard of Care|CPAP initiation per standard of care based on approval by insurance company and DME company with management as per usual standards of clinical care for heart failure.
2927727|NCT03056430|Experimental|Training Group 1|Slackline training
2927728|NCT03056430|Experimental|Training Group 2|Slackline training
2927729|NCT03056417|Experimental|Intervention|Participants in the Complete Health Improvement Program.
2927730|NCT03056417|No Intervention|Control|Participants who choose not to participate in the Complete Health Improvement Program.
2927731|NCT03056404|Experimental|control subject|additional blood sample and 15 control subjects will be seen in consultations in the service of pneumology. The visit will include an auscultation, a respiratory functional exploration and a blood test (2 tubes of 7 ml of total blood). A questionnaire of exhibition will be realized to collect the species of birds and the times of exhibition.
2927732|NCT03056391|Experimental|Paracetamol|">50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine."
2927733|NCT03056391|No Intervention|No Paracetamol|"No Paracetamol plus IV artesunate or oral artemether/lumefantrine.~If temperature >39.5°C, tepid sponging and mechanical antipyresis will be performed by research staff and/or relatives."
2927734|NCT03056378|Experimental|Pooled RBCs|Transfusion of an investigational transfusion blood component: POOLED-RBCs Phenotype matched/ compatible for ABO, D, C, E, and K (blood type of pool will be match patient's type), leukoreduced, and irradiated
2927735|NCT03056378|Active Comparator|Standard RBCs|Transfusion of standard transfusion blood component: additive solution leukoreduced, irradiated RBC product Phenotype matched/ compatible for ABO, D, C, E, and K (blood type of pool will be match patient's type)
2927736|NCT03056365|Experimental|Advanced Nurse (AN)|The outpatient detoxication procedure will be entirely managed by an advanced nurse team, using a predefined protocol decision algorithm. The protocol allows that the AN team autonomously manages the diazepam dosing during the detox period. Addiction physicians only intervenes in case of severe withdrawal symptoms or serious adverse events.
2927737|NCT03056365|Active Comparator|General Practitioner (GP)|"The outpatient detoxication procedure is entrusted to a GP who will manage patients and diazepam dosing as he/she thinks best (as usual control group)"
2927738|NCT03056352|Experimental|Metoclopramide|Metoclopramide 20mg + diphenhydramine 25mg administered intravenously over 15 minutes
2927739|NCT03056339|Experimental|Fludarabine + Cyclophosphamide + CAR-NK Cells|"On Days -5, -4, and -3, participants receive Fludarabine and Cyclophosphamide. Participants also receive Mesna before and after the cyclophosphamide dose.~On Day 0, participants receive genetically modified NK cells as a cell infusion.~If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they receive AP1903 by vein and possibly steroids by mouth or by vein."
2927740|NCT03056326|Experimental|CHF6333 Active|
2927741|NCT03056326|Placebo Comparator|Placebo|
2927742|NCT03056313|Experimental|proactive support of labor|delayed labor; 1 cm opening and painful contractions
2927743|NCT03056313|Active Comparator|support of labor as usual|delayed labor; 3-4 cm opening of the cervix and regular contractions
2927744|NCT03056300|Experimental|Powered vascular stapler|Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler
2927745|NCT03056287|Experimental|Aerobic Exercise|Treadmill aerobic exercise
2927746|NCT03056287|Experimental|rTMS|repetitive transcranial magnetic stimulation
2927747|NCT03056287|Experimental|AET+rTMS|Combined aerobic exercise and rTMS
2927748|NCT03056287|Sham Comparator|Sham|Sham rTMS
2927749|NCT03056274|Active Comparator|Metformin arm|Metformin
2927750|NCT03056274|Active Comparator|Ursodeoxycholic acid|Ursodeoxycholic acid
2927751|NCT03056261|Experimental|Combined general and epidural|Combined general and epidural anesthesia in infants UNDERGOING INTESTINAL SURGERY
2927752|NCT03056261|Placebo Comparator|General anaesthesia|General anesthesia in infants UNDERGOING INTESTINAL SURGERY
2927753|NCT03056248|Active Comparator|Lithium|Patients will be identified by chart review and be explained the purpose of the study and informed consent taken
2927754|NCT03056248|Placebo Comparator|Placebo|Patients will be identified by chart review and be explained the purpose of the study and informed consent taken
2927755|NCT03056235|Experimental|ELAPR002f|ELAPR002f is a tropoelastin gel cross-linked with derivatised hyaluronic acid
2927756|NCT03056235|Placebo Comparator|Saline control|Saline
2927757|NCT03056222|Active Comparator|HeartLight® EGLA|Participants will be treated with the endoscopically guided laser ablation catheter
2927758|NCT03056222|Active Comparator|Contact Force Sensing Irrigated RF ablation|Participants will be treated with a contact force sensing irrigated radiofrequency ablation catheter
2927759|NCT03056209|Experimental|KL1333 25mg|Group 1
2927760|NCT03056209|Experimental|KL1333 50mg|Group 2
2927761|NCT03056209|Experimental|KL1333 100mg|Group 3
2927762|NCT03056209|Experimental|KL1333 200mg|Group 4
2927763|NCT03056209|Experimental|KL1333 400mg|Group 5
2927764|NCT03056209|Experimental|KL1333 600mg|Group 6
2927765|NCT03056209|Experimental|KL1333 800mg|Group 7
2927766|NCT03056183|Experimental|Treatment Group|Patients in the Depression Care Transitions intervention will have a Transitional Care Social Worker who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
2927767|NCT03056183|No Intervention|Control Group - Standard of Care|To be followed per standard of care and data from their medical records will be reviewed.
2927768|NCT03056170|Active Comparator|Active tDCS|The anode is placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode is placed over the left temporo-parietal cortex (TPJ) In active stimulation with a Transcranial Direct Current Stimulation, the device will deliver a charge of 1 mA for 30 minutes.
2927769|NCT03056170|Sham Comparator|Sham tDCS|In sham stimulation, with a Transcranial Direct Current Stimulation, no current will be delivered from one electrode to the other except one 30 s ramp up and down at the beginning and one at the end of the sham stimulation duration (30 min) Same electrode montage than in the active group.
2927770|NCT03056157|Experimental|Adaptive Disclosure for Moral Injury and Loss|Ad-MIL is a 12-session treatment designed to address shame and guilt and to develop compassion for the self and the other. At the outset of AD-MIL, the investigators ask Veterans to enlist a family member or friend to provide support and to reinforce their plan for adaptive, purposeful functioning moving forward. The sessions that follow homework assignments involve a discussion to reinforce positive steps taken and identifying obstacles to completion (e.g., self-defeating beliefs). There is a special emphasis on discussing self-handicapping, namely feeling unworthy of getting better or living a good life. The goal is not only for Veterans to develop a sense of mastery in accomplishing tasks and to experience the benefits of the activities, but also to work on overcoming feelings of unworthiness.
2927771|NCT03056157|Active Comparator|Present Centered Therapy|PCT is a manualized evidenced-based PTSD treatment used in several large-scale PTSD trials. It incorporates the essential therapeutic elements common to different types of psychotherapies, including supportive empathic listening and unconditional positive regard. The therapist plays an active role, but does not impart any systematic training. The focus is to create an understanding of how the symptoms of PTSD are related to day-to-day difficulties and to help patients develop new, more adaptive responses to these stressors with a problem-focused and problem-solving approach. In prior trials, PCT showed equivalent change to active therapies at the last follow-up. The VA offers PCT as an evidence-based therapy for PTSD.
2927772|NCT03056144|Experimental|Intervention group|The participants will undergo the whole body vibration therapy 1 session per day, 3 days per week for 4 weeks. The whole total whole body therapy session will last 18 minutes with 9 minutes of vibration.
2927773|NCT03056131|Experimental|Diacutaneous Fibrolysis Treatment|
2927774|NCT03056131|No Intervention|Control Group|
2927775|NCT03056118|Experimental|6-month dual anti-platelet therapy|maintain dual anti-platelet agents for 6 months
2927776|NCT03056118|Active Comparator|12-month dual anti-platelet therapy|maintain dual anti-platelet agents for 12 months
2927777|NCT03056118|Active Comparator|Zotarolimus eluting stent arm|implant with zotarolimus eluting stent (Resolute Integrity)
2927778|NCT03056118|Active Comparator|Biolimus eluting stent arm|implant with biolimus eluting stent (Biomatrix)
2927779|NCT03056105||Retreat|Participants registered for a one-month, residential Insight Meditation retreat held at Spirit Rock Meditation Center in either February or March, 2013
2927780|NCT03056105||Comparison|Experienced meditators from the Spirit Rock Meditation Community
2927781|NCT03056092|Other|AMD/RVO/DME|Patients presenting to St. Michael's Hospital retina clinic with neovascular age related macular degeneration, macular edema secondary to RVO and diabetic macular edema treated with intravitreal ranibizumab in a variable dosing regimen.
2927782|NCT03056079|Other|AMD/RVO/DME|Patients presenting to St. Michael's Hospital retina clinic with neovascular AMD, macular edema secondary to retinal vein occlusion and diabetic macular edema treated with intravitreal aflibercept in a variable dosing regimen.
2927783|NCT03056053|Other|Zolpidem|Commercially available zolpidem (5 or 10 mg) will be administered orally once daily during the treatment period (Day 1 to Day 14) following prescribing information from each country participating in this study
2927784|NCT03056040|Experimental|ALXN1210|
2927785|NCT03056040|Active Comparator|Eculizumab|
2927786|NCT03056027||Group Open|Patient submitted to open inguinal hernia repair
2927787|NCT03056027||Group extraperitoneal laparoscopic|Patients submitted to total extraperitoneal laparoscopic inguinal hernia repair
2927788|NCT03056014|Active Comparator|N-acetylcysteine 600 mg|
2927789|NCT03056014|Active Comparator|N-acetylcysteine 1200 mg|
2927790|NCT03056014|Placebo Comparator|placebo|
2927791|NCT03056014|Active Comparator|PUFA 1000 mg|
2927794|NCT03056001|Experimental|Pembrolizumab + doxorubicin|Participants receive pembrolizumab IV infusion and doxorubicin IV injection on Day 1 of each cycle.
2927795|NCT03055988|Experimental|Tiotropium/Olodaterol Fixed Dose Combination|
2927796|NCT03055988|Active Comparator|Fluticasone Propionate + Salmeterol Fixed Dose Combination|
2927797|NCT03055975||Primary treatments|Patients undergoing primary root canal treatments. Only teeth which have not previously been accessed are included in this cohort.The source population are adults aged 18-65, referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital
2927798|NCT03055975||Re-treatments|Patients undergoing re-treatments. Only teeth which had a previous root canal treatment which failed are included in this cohort.The source population are adults aged 18-65, referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital
2927799|NCT03055962|Experimental|E2609 50 mg|Participants will receive E2609 50 milligrams (mg) orally once a day for 14 days.
2927800|NCT03055962|Placebo Comparator|Placebo|Participants will receive matching placebo orally once a day for 14 days.
2927801|NCT03055949|No Intervention|pre-ERP|A group of the surgical ICU patients who had standard care before Asan medical center developed an early rehabilitation program (ERP)
2927802|NCT03055949|Experimental|post-ERP|A group of the surgical ICU patients who had an early rehabilitation program (ERP) within SICU care
2927803|NCT03055936|Experimental|levodopa with carbidopa lower doses|levodopa 50 mg, carbidopa 12,5 mg
2927804|NCT03055936|Experimental|levodopa with carbidopa and ODM-104|levodopa 50 mg or 100 mg or 150 mg, carbidopa 65 mg and ODM-104 50 mg or 100 mg
2927805|NCT03055936|Experimental|levodopa with carbidopa higher doses|levodopa 150 mg, carbidopa 37,5 mg
2927806|NCT03055936|Active Comparator|levodopa 100 mg with carbidopa|levodopa 100 mg (levodopa IR), carbidopa 65 or 25 mg
2927807|NCT03055923||Asthma Patients|30 people who suffer from a confirmed diagnosis of asthma
2927808|NCT03055923||Chronic Obstructive Pulmonary Disease Patients|30 people who suffer from a confirmed diagnosis of COPD
2927809|NCT03055923||Healthy Controls|30 healthy volunteers who have no known diagnosis of Lung disease
2927810|NCT03055884|Experimental|active tDCS with repeated retrieval practice|active tDCS with verbal paired-associate learning task with repeated retrieval practice
2927811|NCT03055884|Experimental|active tDCS without repeated retrieval practice|active tDCS with verbal paired-associate learning task without repeated retrieval practice
2927812|NCT03055884|Sham Comparator|Sham tDCS with repeated retrieval practice|sham tDCS with verbal paired-associate learning task with repeated retrieval practice
2927813|NCT03055884|Sham Comparator|Sham tDCS without repeated retrieval practice|shamtDCS with verbal paired-associate learning task without repeated retrieval practice
2927814|NCT03055871|No Intervention|Standard education control group|The control group package will consist of Canada's PA guidelines recommending 180 min per week for young children, transitioning to 60 minutes of activity a day for children at five and a breakdown of ways for the parent to help their child achieve this PA (unstructured, endurance, strength, activities) commensurate with this guide. The guide also contains arguments and information about the benefits of PA.
2927815|NCT03055871|Other|Physical activity planning intervention|The physical activity planning intervention condition will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include workbook on how to plan for family physical activity; brainstorming exercise for children where they list physical activities that they have found fun in the past, as well as activities that they would find enjoyable to do as a family.
2927816|NCT03055871|Other|Habit formation intervention|The habit formation intervention condition will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. The material includes a brief discussion of what habits are with some very straightforward examples such as preparing for sleep routines, or initiating to drive a car to work. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms.
2927817|NCT03055858|Experimental|PDA closure|
2927818|NCT03055845|Experimental|STA363 dose 1|
2927819|NCT03055845|Experimental|STA363 dose 2|
2927820|NCT03055845|Experimental|STA363 dose 3|
2927821|NCT03055845|Placebo Comparator|Placebo|
2927822|NCT03055819|Experimental|ZiftLift Tissue Anchor|Use of ZiftLift Tissue Anchors for Brow Lift
2927823|NCT03055806|Experimental|IX-01 1200 mg|1200 mg dose comprising three 400 mg caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
2927824|NCT03055806|Placebo Comparator|Placebo|Three placebo caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
2927825|NCT03055806|Experimental|IX-01 800 mg|800 mg dose comprising two 400 mg caplets and one placebo caplet administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
2927826|NCT03055806|Experimental|IX-01 400 mg|400 mg dose comprising one 400 mg caplet and two placebo caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
2927827|NCT03055780||CT-FFR. CTA. FFR|59 patients with suspected CAD that have been scheduled for an interventional FFR study
2927828|NCT03055767|Other|OnabotulinumtoxinA/Saline Placebo|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
2927829|NCT03055767|Other|Saline Placebo/OnabotulinumtoxinA|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
2927830|NCT03055754|Experimental|Argon randomized arm|Endoscopic procedure with a full inventory, measurement of the anastomosis diameter, and an argon plasma coagulation. Followup of all patients by a multidisciplinary team (life, food orientations).
2927831|NCT03055754|Active Comparator|Control arm|Full inventory and measurement of the anastomosis diameter, without any intervention. Followup of all patients by a multidisciplinary team (life, food orientations).
2927832|NCT03055741|Experimental|Group 1|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Total 500mg is orally administrated in two divided doses a day for 24 weeks"
2927833|NCT03055741|Experimental|Group 2|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Total 1,000mg is orally administrated in two divided doses a day for 24 weeks"
2927834|NCT03055741|Placebo Comparator|Group 3|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Placebo is orally administrated in two divided doses a day for 24 weeks"
2927835|NCT03055728||Group 1 / Study Group|Subjects presenting with signs or symptoms of acute pharyngitis, with a history of culture-proven GAS infection and subsequent 10-day antibiotic treatment within the preceding 28 days. Subjects will have a rapid strep antigen detection test and a throat culture to determine presence of strep.
2927836|NCT03055728||Group 2 / Control Group|Subjects presenting with signs or symptoms of acute pharyngitis, without a recent history of GAS infection. Subjects will have a rapid strep antigen detection test and a throat culture to determine presence of strep.
2927837|NCT03055715||Locally advanced NSCLC-patients|Inoperable stage III (A and B) non-small-cell lung cancer (NSCLC) with indication for radical radiotherapy.
2927838|NCT03055702|Experimental|SMS group|receive a mobile phone text reminder for scheduled clinic appointment 24-72 hours before,
2927839|NCT03055702|No Intervention|Usual care group|Usual care, either telephone reminder or no reminder
2927840|NCT03055689|Experimental|Educational telephone intervention|This group will receive a nurse-led educational telephone intervention for bowel preparation 24-48 before the colonoscopy
2927841|NCT03055689|Active Comparator|Standard education for colonoscopy|The control group will receive standard education for bowel preparation at the time of colonoscopy scheduling
2927842|NCT03055676|Experimental|Early drain removal|Removing drain(s) on postoperative day 3 (n = 166)
2927843|NCT03055676|Active Comparator|Late drain removal|Removing drain(s) on postoperative day 5 or later (n = 166)
2927844|NCT03055663|Experimental|Virtual reality sedation|Patients watches virtual reality sedation program that shows underwater world with comfortable music and narrations during surgery.
2927845|NCT03055663|Active Comparator|Sedation with intravenous sedatives|Patients receives intravenous sedative of midazolam (initial bolus 1-2 mg with maintenance dose of 1 mg every 10 - 30 min).
2927846|NCT03055637|Active Comparator|patients with isolated cleft palate|Patients requiring isolated cleft palate repair
2927847|NCT03055637|Active Comparator|Patients with isolated cleft palate|Patients requiring isolated cleft palate repair
2927848|NCT03055624|Experimental|Prostate artery embolization|Single arm study of patients undergoing the prostate artery embolization procedure with Embosphere particles.
2927849|NCT03055611||Haemophilia A patients|Elocta will be prescribed according to local practice and administered by patients with haemophilia A for prophylactic treatment
2927850|NCT03055611||Haemophilia B patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
2927851|NCT03055598|Experimental|Ferric Citrate|Ferric Citrate (Auryxia) will be dosed initially at 2 tablets three times a day (with meals).
2927852|NCT03055585|Experimental|Intervention arm|Deployment of Wolbachia-infected Aedes aegypti mosquitoes
2927853|NCT03055585|Other|Comparison arm|Standard practice dengue control activities
2927854|NCT03055572|Experimental|Olfactory Training with Essential Oils|Participants assigned to this group will do olfactory training using essential oils, while continuing the medical therapy prescribed by their provider.
2927855|NCT03055572|Active Comparator|Olfactory Training with Pure Fragrance Oils|Participants assigned to this group will do olfactory training using pure fragrance oils, while continuing the medical therapy prescribed by their provider.
2927856|NCT03055572|No Intervention|Control Group|The control group will continue the medical therapy prescribed by their provider.
2927857|NCT03055559||Globifer Forte|
2927858|NCT03055546|Experimental|Oxytocin|intranasal administration of oxytocin
2927859|NCT03055546|Placebo Comparator|Placebo|intranasal administration of placebo
2927860|NCT03055533|Experimental|Immediate intervention with Headsprout reading program|Participants randomized to this study arm will begin treatment with the Headsprout program right away. Reading assessments will occur at the beginning and end of 12 weeks of treatment.
2927861|NCT03055533|No Intervention|Delayed intervention|Participants randomized to this study arm will have reading assessments at the beginning and end of the study, but they will not begin treatment with the Headsprout program until after their participation in the study ends (12 weeks).
2927862|NCT03055520|Experimental|arithmetic training (Kumon method)|
2927863|NCT03055520|Placebo Comparator|nonspecific recreation|
2927864|NCT03055507|Active Comparator|Control|Standard pain regimen of acetaminophen 650 mg q6hrs while awake until cessation of need for scheduled pain medication with the addition of oxycodone 5 mg q3 hrs PRN pain.
2927865|NCT03055507|Experimental|Ibuprofen|Alternating every 3 hours acetaminophen 650 mg and ibuprofen 400 mg while awake until cessation of need for schedule pain medication with the addition of oxycodone 5 mg q3hr PRN pain.
2927866|NCT03055494|Experimental|Secukinumab|Eligible patients will receive secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3 and 4 followed by monthly dosing up to Week 48
2927867|NCT03055494|Placebo Comparator|Placebo|Eligible patients will receive placebo at randomization, Weeks 1, 2, 3, 4, and 8. At Week 12, patients will be switched to treatment with secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
2927868|NCT03055481|Active Comparator|High level irradiation|High level irradiation: the target irradiance level is 30-35uW per square centimeter per nano-meter of wavelength.
2927869|NCT03055481|Experimental|Low level irradiation|Low level irradiation: the target irradiance level is 12-15uW per square centimeter per nano-meter of wavelength.
2927870|NCT03055468|Experimental|Peer Support|Participants in this group will receive peer support as well as antidepressant medications comprised of either Fluoxetine 20mg O.D or Imipramine 75mg nocte.
2928162|NCT03053375|Experimental|Chronic; active device|MDCure active device
2927871|NCT03055468|Active Comparator|No Peer support|Participants will only receive antidepressant medications comprised of either Fluoxetine 20mg O.D or Imipramine 75mg nocte.
2927872|NCT03055455||Sepsis|Children with severe sepsis or septic shock
2927873|NCT03055442||Follicular Fluids|Follicular fluids obtained by 8 oocyte donors
2927874|NCT03055429|Experimental|Full Scale Unit|Testing of 6 modules
2927875|NCT03055416|Other|Mobile Men App Prototype|Prototype of physical activity mobile app geared for African-American men.
2927876|NCT03055403|Experimental|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
2927877|NCT03055403|Placebo Comparator|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
2927878|NCT03055390|Placebo Comparator|Control|They received two ml of normal saline intravenously as a placebo
2927879|NCT03055390|Active Comparator|20 mg hyoscine butylbromide|They received (20mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
2927880|NCT03055390|Active Comparator|40 mg hyoscine butylbromide|They received (40mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
2927881|NCT03055377|Experimental|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 12 weeks
2927882|NCT03055377|Placebo Comparator|Placebo|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks
2927883|NCT03055351|No Intervention|Control group|Participants will complete the outcome measures but will not receive any intervention.
2927884|NCT03055351|Experimental|Stop&Go Intervention|Participants in this group will participate in an intervention aimed at promoting a healthy and physically active lifestyle. The intervention will be based on Self-determination theory postulates and will have two axes: training and motivation.
2927885|NCT03055338|Experimental|MK-8189|Participants will receive double-blind MK-8189 4 mg controlled release (CR) tablet(s) once daily (QD) over 4 weeks. In a 3-step dose escalation regimen over 1 week, participants will receive MK-8189 at the following dose strengths: 4 mg (1 tablet) QD, 8 mg (2 tablets) QD, and 12 mg (3 tablets) QD. Participants will achieve the final dose of 12 mg, as tolerated.
2927886|NCT03055338|Active Comparator|Risperidone|Participants will receive double-blind Risperidone 2 mg capsule(s) QD over 4 weeks. In a 3-step dose escalation regimen over 1 week, participants will receive Risperidone at the following dose strengths: 2 mg (1 capsule) QD, 4 mg (2 capsules) QD, and 6 mg (3 capsules) QD. Participants will achieve the final dose of 6 mg, as tolerated.
2927887|NCT03055338|Placebo Comparator|Placebo|Participants will receive double-blind matching placebo for the MK-8189 and Risperidone arms: 1 placebo tablet for MK-8189 4g QD, and 1 placebo capsule for Risperidone 2 mg QD. Participants will receive matching double-blind placebo over 1 week in mock dose escalation consistent with that of the MK-8189 and Risperidone doses.
2927888|NCT03055325||Surgical patients|Cognitive testing, testing of heart rate variability and collection of blood samples
2927889|NCT03055312|Active Comparator|TPC chemotherapy|"Conventional chemotherapy(choose a):~TX (Taxotere and Xeloda),GT (Gemcitabine and Paclitaxel),GC (Gemcitabine and Carboplatin)"
2927890|NCT03055312|Experimental|Bicalutamide|Bicalutamide 150mg/day every 28 days
2927891|NCT03055299|Experimental|COMEX|Patients receive comprehensive exercise intervention
2927892|NCT03055286|Experimental|CWP232291 in combination with cytarabine (ara-C)|
2927893|NCT03055273|Experimental|SOCIABLE IMMEDIATE|Receive services now
2927894|NCT03055273|Active Comparator|SOCIABLE wait list|Receive services four months post-enrollment
2927895|NCT03055260|Experimental|Blood flow restriction cuff|This group will receive an active cuff that partially restricts blood flow to the experimental limb.
2927896|NCT03055260|Placebo Comparator|Blood Flow restriction Cuff-Placebo|This group will wear a placebo cuff, of which will not restrict blood flow at all.
2927897|NCT03055247|Experimental|XCGD mobilization|Treatment with combination of Ibuprofen, Myelostim and Mozobil
2927898|NCT03055234|Experimental|Oral Treprostinil|Extended-release oral tablet for three times daily (TID) administration
2927899|NCT03055234|Placebo Comparator|Placebo|Placebo (sugar pill) for TID administration
2927900|NCT03055221|Experimental|Intravenous Treprostinil|Intravenous treprostinil was supplied as 1 mg/mL.
2927901|NCT03055208|Experimental|Radiosurgery|"Following intraoperative confirmation of glioblastoma (frozen section):~Early (24-72h post surgery) stereotactic ablation (gamma knife radiosurgery) of residual tumor (defined in early postoperative T1-weighted MRI scanning with and without contrast), followed by standard-of-care therapy (chemo-radiotherapy with 60 Gy external beam radiation therapy (EBRT) and 75 mg/m2/d temozolomide, followed by adjuvant chemotherapy with 150-200 mg/m2/d/cycle temozolomide in a 5/28 days schedule)."
2927902|NCT03055195|Experimental|Mepolizumab|Eligible subjects will receive mepolizumab 100 mg subcutaneously every 4 weeks on Day 1, Week 4, Week 8, and Week 12
2927903|NCT03055195|Placebo Comparator|Placebo|Eligible subjects will receive matching placebo subcutaneously every 4 weeks on Day 1, Week 4, Week 8, and Week 12
2927904|NCT03055182|Experimental|Low back pain patients|Subjects included in physical rehabilitation program.
2927905|NCT03055182|No Intervention|Control subjects|No intervention administered
2927906|NCT03055169||intensive care patients|patients with a least one organ dysfunction
2927907|NCT03055156|Experimental|Low rebound mattress toppers|sleep with mattress topper during overnight diagnostic sleep study
2927908|NCT03055156|Experimental|High rebound mattress toppers|sleep with mattress topper during overnight diagnostic sleep study
2927909|NCT03055143|Experimental|SPARC-08-038|2 mg/ml
2927910|NCT03055143|Active Comparator|Ref-08-038|
2927911|NCT03055130||Case group|Female IBD patients who had sexual life between 21-60 years-old were recruited.
2927912|NCT03055130||control group|Female people who perform physical examination in our hospital between 21-60 years-old were recruited as control during the study period.
2927913|NCT03055117|Experimental|Group-based exercise rehabilitation|Group-based rehabilitation: Group-based sessions (4-8 patients per group) with physiotherapist and home training for 8 weeks (maximum of 12 training sessions).
2927914|NCT03055117|Active Comparator|Individual exercise rehabilitation|Individual rehabilitation: One-on-one sessions with physiotherapist and home training for 8 weeks (maximum of 12 training sessions).
2928023|NCT03054298|Active Comparator|Cohort 1|Single dose of 1-3x10^7/m^2 lentiviral transduced huCART-meso cells
2927915|NCT03055117|Active Comparator|Home exercise|Home exercise: Instruction in home exercise by physiotherapist, with maximum of 4 follow-up consultations over a period of 8 weeks.
2927916|NCT03055104||severe malnutrition|Patients with severe malnutrition (BMI＜13 kg/m2), admitted to Peking University Third Hospital from JAN 2008 are involved in this study. After admission, a multidisciplinary team, consisting of specialists in the field of intensive care, pharmacy, psychology, and physical therapy assessed all patients. Management and treatment of these patients are in accordance with guideline for the management of severe malnutrition in PUTH.
2927917|NCT03055091|Experimental|Treatment group|Participants in the treatment arm will receive a Xylitol syrup.
2927918|NCT03055091|Placebo Comparator|Placebo|Participants in the placebo arm will receive sorbitol syrup.
2927919|NCT03055078|Experimental|mesenchymal stem cells|According to the inclusion and exclusion criteria, selected patients were divided into a cell therapy group and a control group. Umbilical cord derived mesenchymal stem cells at a dose of 100-300 million by intravenous infusion.
2927920|NCT03055052|Active Comparator|Control Formula|Standard formula for preterm infants.
2927921|NCT03055052|Experimental|Experimental formula|Formula with higher protein and new fat blend for preterm infants.
2927922|NCT03055026|Experimental|Rivaroxaban|Orally administered, at the dose of 10 mg OD for 3 weeks (extended prophylaxis)
2927923|NCT03055026|Placebo Comparator|Placebo|Orally administered, OD for 3 weeks (extended prophylaxis)
2927924|NCT03055013|Experimental|Arm I (nivolumab, nephrectomy)|Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 2 courses. Patients then undergo partial or radical nephrectomy. Patient then receive nivolumab IV on day 1. Treatment repeats every 14 days for 6 courses, and then every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
2927925|NCT03055013|Active Comparator|Arm II (nephrectomy)|Patients undergo partial or radical nephrectomy followed by observation.
2927926|NCT03055000|Experimental|1|AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
2927927|NCT03055000|Experimental|2|ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL)on Day 0 and on Day 21
2927928|NCT03055000|Placebo Comparator|3|WFI (0.5mL) on Day 0 and Day 21
2927929|NCT03054987|Active Comparator|EUS-BD|EUS-BD is a minimally invasive technique where the common bile duct (choledochoduodenostomy) is punctured under EUS-guidance and after transmural dilation, a stent is deployed for biliary drainage.
2927930|NCT03054987|Active Comparator|ERCP|At ERCP, the common bile duct will be selectively cannulated using a sphincterotome and guide wire technique. Once biliary access is obtained a stent will be deployed to facilitate biliary drainage.
2927931|NCT03054974|Experimental|Modern rehabilitation treatment|Modern rehabilitation treatment
2927932|NCT03054974|Experimental|Modern rehabilitation &TCM|Modern rehabilitation treatment and traditional Chinese medicine
2927933|NCT03054974|Experimental|modern rehabilitation &Baimai Ruangao|modern rehabilitation treatment and Baimai Ruangao
2927934|NCT03054974|Experimental|modern rehabilitation &Tibetan medicine|modern rehabilitation treatment and Tibetan medicine treatment
2927935|NCT03054961||Epilepsy patients|Near-infrared spectroscopy for subjects with partial (focal) epilepsy seizures being studied in the EMU.
2927936|NCT03054948|Experimental|SMOFLipid|Patients in this arm with be randomized to SMOFlipid as their lipid emulsion
2927937|NCT03054948|Active Comparator|Standard therapy|Patients in this arm will be continue with their current lipid emulsion
2927938|NCT03054935||Subject-CD|Subjects with Crohn's Disease in active or quiescent phase, classified according to Crohn's Disease Activity Index (CDAI >150 active; CDAI < 150 quiescent)
2927939|NCT03054922|Active Comparator|Normal Saline|0.9% Sodium Chloride
2927940|NCT03054922|Active Comparator|Lactated Ringers|"Each 100 mL of Lactated Ringer's Injection USP contains:~Sodium Chloride USP 0.6 g; Sodium Lactate USP 0.31 g; Potassium Chloride USP 0.03 g; Calcium Chloride Dihydrate USP 0.02 g; Water for Injection USP qs"
2927941|NCT03054922|Active Comparator|Normosol-R|Each 100 mL of Normosol-R contains sodium chloride, 526 mg; sodium acetate, 222 mg; sodium gluconate, 502 mg; potassium chloride, 37 mg; magnesium chloride hexahydrate, 30 mg.
2927942|NCT03054909|Experimental|Arm 1: ALT-803 subcutaneous only|
2927943|NCT03054909|Experimental|Arm 2: ALT-803 intraperitoneal and subcutaneous|
2927944|NCT03054896|Experimental|Venetoclax|"Standard chemotherapy regimen, DA-EPOCH-R, with a novel oral Bcl-2 inhibitor, venetoclax will be administered to patients~Chemotherapy cycles will be administered approximately every 3 weeks~Initial venetoclax dose ramp-up will be done in a condensed fashion over approximately 5 days, followed by continuous daily dosing"
2927945|NCT03054870|Active Comparator|Xe-133|"Xe-133 ventilation planar scintigraphy, performed per site standard of care procedures for subject medical need.~Subjects will be administered approximately 10 to 30 millicurie (mCi) of Xe-133 by inhalation."
2927946|NCT03054870|Experimental|Technegas|Technegas ventilation planar scintigraphy Subjects will receive approximately 1.1 mCi of Technegas (Technetium-99m labeled carbon particles) by inhalation.
2927947|NCT03054857|Experimental|Dex group|After skin incision, the Dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
2927948|NCT03054857|Placebo Comparator|Placebo group|The control group received a loading dose and continuous IV infusion of normal saline at the same rate.
2927949|NCT03054844|Experimental|PREMED|Patients will receive 0.25 mL of IN 4% lidocaine (10 mg) in each naris (total of 0.5 mL/20 mg for both nares) preceding adminstration of IN midazolam.
2927950|NCT03054844|Experimental|PREMIX|Patients will receive midazolam mixed with 0.5 mL of 4% lidocaine (20 mg).
2927951|NCT03054831|Active Comparator|Age 2-5 years-Before GA|The group will include 25 patients (children 2-5 years old). In this group the children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube before the procedure at the beginning of general anesthesia (after intubation).
2927952|NCT03054831|Active Comparator|Age 2-5 years-After GA|In this group 25 children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube after the procedure at the end of general anesthesia (before extubation).
2927953|NCT03054831|Active Comparator|Age 6-8 years-Before GA|The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally before the surgery in pre-op holding.
2927954|NCT03054831|Active Comparator|Age 6-8 years-After GA|The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU).
2927955|NCT03054805|Experimental|Magnesium oxide and MIYAIRI-BM|"Magnesium oxide 125 mg twice per day for children with weight < 15 kg, 250 mg twice per day for weight <15-30 kg, and 500 mg twice per day for weight > 30 kg for 12 weeks.~MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight < 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight > 30 kg for 12 weeks."
2927956|NCT03054805|Active Comparator|Magnesium oxide|MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight < 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight > 30 kg for 12 weeks.
2927957|NCT03054805|No Intervention|Healthy Children|Healthy Children
2927958|NCT03054792|Experimental|FAZA - BOLD- DW- MRS|"18F-FAZA (F18-Fluoroazomycin Arabinoside) is a radioactive agent developed as a non-invasive probe for the assessment of cellular hypoxia. 18F-FAZA Injection is indicated in a single dose of (5.2 MBq/kg [0.14 mCi/kg]) Route/method of administration: intravenous injection.~Blood Oxygen Level Dependent [BOLD], Diffusion-Weighted [DW] MRI, MR Spectroscopy [MRS]"
2927959|NCT03054779|Experimental|Canola oil|regular canola oil
2927960|NCT03054779|Experimental|High oleic acid canola oil|high stability/high oleic canola oil
2927961|NCT03054779|Active Comparator|Western diet oil combination|"a typical Western diet fat intake comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA"
2927962|NCT03054766|Experimental|Ranibizumab only|"Sham macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization~Interventions :Ranibizumab injection Interventions :Sham macular laser"
2927963|NCT03054766|Experimental|Ranibizumab combined macular laser|"Macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization~Interventions :Ranibizumab injection Interventions :Macular laser photocoagulation"
2927964|NCT03054753|Other|Abduction brace wearing time analysis|The abduction brace wearing time analysis is performed in patients, who undergo a rotator cuff repair with postoperative abduction brace treatment
2927965|NCT03054740|Active Comparator|Gebauer Ethyl Chloride|Device: Vapocoolant (Ethyl Chloride Mist Spray)
2927966|NCT03054740|Placebo Comparator|Nature's Tears|Device: Sterile Water
2927967|NCT03054727||Villalta phone score > or = to 5|patients with VTE in the OPTIMEV cohort with an Utne and Sandset Villalta phone score > or = to 5 at the end of the follow-up call AND a random selection of patients free from any VTE after the first 3 years of follow-up in OPTIMEV with an Utne and Sandset Villalta phone score > or = to 5 at the end of the follow-up call
2927968|NCT03054727||Villalta phone score < 5|patients with VTE in the OPTIMEV cohort with an Utne and Sandset Villalta phone score < 5 at the end of the follow-up call AND random selection of patients free from any VTE after the first 3 years of follow-up in OPTIMEV with an Utne and Sandset Villalta phone score < 5 at the end of the follow-up call
2927969|NCT03054714|Active Comparator|group A|exchange of the infected catheter with a new one over a guidewire
2927970|NCT03054714|Active Comparator|group B|removal of the infected catheter followed by delayed placement of a new catheter 3 to 10 days later
2927971|NCT03054701|Experimental|Sidelying hip abduction exercise|"Participants will be lying on the side with both legs stretched and with their head resting on a pillow. Participants will be allowed to place their hand in front of them to fixate their body and maintain balance. The participants will be instructed to abduct their hip to 45 degrees and return to the resting position afterwards. An elastic band will be used as resistance. This exercise will be applied only on the test limb. A digital metronome will be used to maintain the pace during the exercise.~Load: 12 repetition maximum; Nr. of repetition: 12; Nr. of sets: 3; Rest between sets: 120 seconds; Time under tension: 8 seconds; Distribution of load: Concentric (3 seconds), Eccentric (3 seconds), Isometric (2 seconds)."
2927972|NCT03054701|Active Comparator|Sitting knee extension exercise|"Participants will be seated at the end of an examination couch with the hip and knee relaxed in a 90 degrees angel. Participants will be allowed to place their hands on the side of the couch and the stabilizing foot may have contact with the floor. The participants will be instructed to extend their knee to a 180-degree angle and return to the resting position afterwards. An elastic band will be used as resistance. This exercise will be applied only on the test limb. A digital metronome will be used to maintain the pace during the exercise.~Load: 12 repetition maximum; Nr. of repetition: 12; Nr. of sets: 3; Rest between sets: 120 seconds; Time under tension: 8 seconds; Distribution of load: Concentric (3 seconds), Eccentric (3 seconds), Isometric (2 seconds)."
2927973|NCT03054688|Experimental|Somnotouch NIBP|Blood pressure measurement with Somnotouch-NIBP device in addition to standard cuff based device
2927974|NCT03054675||Pneumonia|"Patients suffering from postoperative pneumonia including all three of the following:~Clinical signs of a pulmonary infection (i.e. fever ≥ 38°C combined with productive cough and/or dyspnea)~A new rise of inflammatory markers (i.e. WBC count ≥ 10.5 x 109 and elevated CRP)~New radiographic infiltrates on chest x-ray without another explanation. Patients with pneumonia undergo spirometry before and on every second day after lung surgery"
2927975|NCT03054675||No Pneumonia|Patients without pneumonia undergo spirometry before and on every second day after lung surgery
2927976|NCT03054675||Open (no pneumonia)|"Patients undergoing open anatomical lung resection who did not show postoperative pneumonia.~All patients undergo spirometry before and on every second day after lung surgery."
2927977|NCT03054675||Minimally invasive (no pneumonia)|"Patients undergoing minimally invasive anatomical lung resection who did not show postoperative pneumonia.~All patients undergo spirometry before and on every second day after lung surgery."
2927978|NCT03054662|Experimental|Patients with Haemophilia|Male patients with severe and moderate haemophilia A and B in Ivory Coast
2927979|NCT03054662|Experimental|Carriers for Haemophilia|Carriers for severe and moderate haemophilia A and B in Ivory Coast
2927980|NCT03054623||DRIL procedure|Adult (>18 yo) patients with chronic kidney disease with functioning antecubital-based arteriovenous fistulae and evidence of ischemic steal symptoms
2927981|NCT03054610|Active Comparator|Control|5 ml of local anesthetic (ropivacaine 7.5%)
2928163|NCT03053375|Placebo Comparator|Chronic; sham|MDCure sham device
2927982|NCT03054610|Active Comparator|Steroid|1ml of steroid Betamethason Sodium Phosphate (Celestone®) and local anesthetic (ropivacaine 7.5%)
2927983|NCT03054610|Experimental|BTX-A|200U Botulinum Toxins, Type A
2927984|NCT03054597|Experimental|Adults|"The arm consisted of adult participants who underwent:~Circular Light Motion exercises: 4 times over 2 weeks Diagonal Light Motion exercises: 4 times over 2 weeks Peripheral Light Motion exercises: 4 times over 2 weeks"
2927985|NCT03054597|Experimental|Children|"The arm consisted of child participants who underwent:~Circular Light Motion exercises: 4 times over 2 weeks Diagonal Light Motion exercises: 4 times over 2 weeks"
2927986|NCT03054558||patients with recurrent unexplained pregnancy loss|Patients with history of two or more recurrent pregnancy loss (RPL) and no history of living babies who had performed all investigations for recurrent miscarriage (RM) including : laboratory investigation ,trans vaginal ultrasound (TVS) ,autoimmune work up and hystroscopy and all results were free
2927987|NCT03054558||Healthy fertile patients|Healthy fertile patients with no history of previous miscarriage and have at least one uncomplicated pregnancy with no pelvic pathology
2927988|NCT03054545|Experimental|Iguratimod treating group|Iguratimod 25mg twice a day, oral administrated.
2927989|NCT03054532|Experimental|Durvalumab and lenalidomide|"Open-label use of 2 drugs:~Durvalumab 1500 mg intravenously on day 1 of a 28-day cycle until progressive disease or intolerance.~Lenalidomide orally on days 1 through 21 of each 28-day cycle for 6 cycles."
2927990|NCT03054519|Active Comparator|Metformin|Metformin daily
2927991|NCT03054519|Placebo Comparator|Placebo|Placebo daily for six months.
2927992|NCT03054506|Experimental|CSP01|Subjects in the experimental group will receive CSP01, a non-systemic, orally administered hydrogel capsule, twice a day. CSP01 capsules are taken prior to a meal with water, after which the small particles within the capsules hydrate and expand in the stomach and small intestine. By acting as a bulking agent and possibly reducing colonic transit time through increase of colonic water content, CSP01 may contribute to constipation relief.
2927993|NCT03054506|Active Comparator|Carboxymethylcellulose (CMC)|Subjects in the active control group will receive orally administered 3 capsules of carboxymethylcellulose (CMC) capsules twice a day.
2927994|NCT03054506|Placebo Comparator|Placebo|Matching placebo consists of an inert mixture supplied by Gelesis Inc. in identical-appearing capsules.Subjects in the placebo group will be administered 3 capsules of placebo twice a day.
2927995|NCT03054480|Experimental|Fractional Micro-Needle Radiofrequency|each patient will be treated with FMR DeAge®, applicator device at 4-week intervals for 2 sessions of treatment. This applicator consists of rows of 36 (6x6 needles) insulated microneedles that form an array of positively and negatively charged electrodes. The microneedles will deliver bipolar radiofrequency energy in a fractional manner that extends from 3.0 mm below the surface of the skin. All subjects will be prepared by local anesthesia to induce numbness at the axilla prior to treatment. The targeted axillary side will be treated with a total of 4 passes.
2927996|NCT03054480|Active Comparator|Botulinum toxin type A|50 units of Botulinum toxin type A will be intradermal injected over axillary area. The protocol by using 1-2 units per 1 injection area with the coverage of 1x1 cm2 will be treated.
2927997|NCT03054467|Active Comparator|CADUET 10mg-20mg|Patients are assigned to receive either amlodipine therapy (NORVASC 10 mg/day) for 6 months.
2927998|NCT03054467|Active Comparator|NORVASC|Patients are assigned to receive amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months
2927999|NCT03054454|Active Comparator|intervention|This group will receive Podiatry treatment and care from the MDT which is the intervention group.
2928000|NCT03054454|No Intervention|comparator|This group will receive usual care
2928001|NCT03054441||Experimental group|Children, Adolescents and Young with hemiplegia
2928002|NCT03054441||Control group|Children, Adolescents and Young with typical development
2928003|NCT03054428|Experimental|Arm 1|Dose regimen 1 - Drug: Dupilumab
2928004|NCT03054428|Experimental|Arm 2|Dose regimen 2 - Drug: Dupilumab
2928005|NCT03054428|Experimental|Arm 3|Placebo
2928006|NCT03054415|Other|Healthy Subjects|
2928007|NCT03054402|Experimental|Dose escalation/BAY1834845|Subjects will receive a single dose of BAY1834845 in the morning of the PK profile day
2928008|NCT03054402|Placebo Comparator|Placebo|Subjects will receive a single dose of placebo in the morning of the PK profile day
2928009|NCT03054389||Participants/ Patients|Participants/ Patients from the AskBio009-101 Study
2928010|NCT03054389||Investigators and Study Coordinators|Investigators and Study Coordinators from the AskBio009-101 Study
2928011|NCT03054376|Active Comparator|Immobilization|After baseline studies, the subjects will have one leg immobilized by full length plaster for two weeks. During the two weeks, the other leg will not be trained. After the two weeks the subjects will train both legs for four weeks.
2928012|NCT03054376|Active Comparator|Training of non-immobilized leg|After baseline studies, the subjects will have one leg immobilized by full length plaster for two weeks. During the two weeks, the other leg will be trained. After the two weeks the subjects will train both legs for four weeks.
2928013|NCT03054363|Experimental|Tucatinib in Combination with Palbociclib and Letrozole|During phase 1b part of this trial (N=20 patients), treatment will be administered in cycles of 28 days and consist of tucatinib 300 mg PO BID, palbociclib 125 mg PO daily for 21 days followed by 7 days off, and letrozole 2.5 mg PO daily. Dose modifications of tucatinib, palbociclib and letrozole will be allowed per protocol. There will be an interim safety analysis performed after enrollment of 10 patients. Safety analysis will take into account proportion of patients requiring dose modifications or interruption for therapy because of toxicity. If excessive toxicity or significant changes in PKs are found, further patients will be enrolled at a lower starting dose level. There will be a second interim safety analysis after enrollment of 20 patients in the study. Once the recommended phase II dose (RP2D) has been determined, testing of this drug combination will be expanded in the phase II part of this trial (N=20 patients) to determine the progression-free survival (PFS) rate.
2928014|NCT03054350|Experimental|Vadadustat, Dose 1|Daily oral dose
2928015|NCT03054350|Experimental|Vadadustat, Dose 2|Daily oral dose
2928016|NCT03054350|Experimental|Vadadustat, Dose 3|Daily oral dose
2928017|NCT03054350|Placebo Comparator|Placebo|Daily oral dose
2928018|NCT03054337|Experimental|Vadadustat, Dose 1|Daily oral dose
2928019|NCT03054337|Experimental|Vadadustat, Dose 2|Daily oral dose
2928024|NCT03054298|Active Comparator|Cohort 2|Cyclophosphamide 1 grams/m^2 administered 2-4 days prior to a single dose of 1-3x10^7 /m^2 lentiviral transduced huCART-meso cells
2928025|NCT03054298|Active Comparator|Cohort 3|Single dose of 1-3x10^8 /m^2 lentiviral transduced huCART-meso cells
2928026|NCT03054298|Active Comparator|Cohort 4|Cyclophosphamide 1 grams/m^2 administered 2-4 days prior to a single dose of 1-3x10^8 /m^2 lentiviral transduced huCART-meso cells
2928027|NCT03054298|Active Comparator|Cohort 5|Single dose of 1-3x10^7 /m^2 lentiviral transduced huCART-meso cells on day 0 by intrapleural infusion (IP) through an indwelling pleural catheter. Subjects in this cohort will be enrolled after safety is demonstrated at this dose level by completion of Cohorts 1 and 2.Subjects in Cohort 5 may be enrolled in parallel to Cohorts 3 and 4.
2928028|NCT03054285|No Intervention|No seizure prophylaxis|Participants randomized to this arm will not receive anti-seizure prophylaxis
2928029|NCT03054285|Experimental|Seizure Prophylaxis|Participants randomized to this arm will receive the anti-seizure prophylaxis drug Levetiracetam for seven days post traumatic brain injury.
2928030|NCT03054272||Residents|Anesthesia residents from University of Montreal Anesthesia Department who were watching the video
2928031|NCT03054272||Attending Physicians|Attending physicians from University of Montreal Anesthesia Department who were watching the video
2928032|NCT03054259|Experimental|Intervention|2 x 1000mg Rituximab and 100mg methylprednisolone
2928033|NCT03054259|Placebo Comparator|Control|2 x 100mg methylprednisolone plus placebo
2928034|NCT03054246|Other|Healthy volunteers|Seventy-five healthy volunteers with no oral/dental problems with Angle I occlusion relationship and without any missing teeth will be included in the study. Evaluation of chewing side preference and laterality will be performed.
2928035|NCT03054233|Experimental|Obese|Obese pregnant women received spinal anesthesia using Quincke Needle 25G/27G in crossed leg sitting position for caesarean section
2928036|NCT03054233|Experimental|Non-obese|Non-obese pregnant women received spinal anesthesia using Quincke Needle 25G/27G in crossed leg sitting position for caesarean section
2928037|NCT03054220|Experimental|CYP2D6 gene score 1|carriers of 1 fully functional and 1non functional CYP2D6 alleles
2928038|NCT03054220|Experimental|CYP2D6 gene score 2|carriers of 2 fully functional CYP2D6 alleles
2928039|NCT03054207|Experimental|HIV clopidogrel|clopidogrel 300 mg single dose oral route
2928040|NCT03054207|Experimental|HIV prasugrel|prasugrel 60 mg single dose oral route
2928041|NCT03054207|Active Comparator|Control clopidogrel|clopidogrel 300 mg single dose oral route
2928042|NCT03054207|Active Comparator|Control prasugrel|prasugrel 60 mg single dose oral route
2928043|NCT03054194|Experimental|Cohort 1: Dose 1 E2730|Participants will receive Dose 1 of oral E2730 on Day 1.
2928044|NCT03054194|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive matching oral placebo on Day 1.
2928045|NCT03054194|Experimental|Cohort 2: Dose 2 E2730|Participants will receive Dose 2 of oral E2730 on Day 1.
2928046|NCT03054194|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive oral matching placebo on Day 1.
2928047|NCT03054194|Experimental|Cohort 3: Dose 3 E2730|Participants will receive Dose 3 of oral E2730 on Day 1.
2928048|NCT03054194|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive oral matching placebo on Day 1.
2928049|NCT03054181||HyQvia|Recombinant human hyaluronidase and normal immunoglobulin 10%
2928050|NCT03054168|Experimental|Old Testosterone trained|"8 old participants (65-75 years old) who will receive resistance exercise training and Testosterone (Sustanon 250: 250 mg every 2wks)~Drug name: Sustanon 250 Generic Name: Testosterone Proprietary Name: N/A Formulation: 250mg of Testosterone in 1ml volume Dose: 250mg of testosterone Frequency: every 2 weeks Route: intramuscular injection"
2928051|NCT03054168|Placebo Comparator|Old Placebo trained|8 old participants (65-75 years old) who will receive resistance exercise training and Placebo every two weeks.
2928052|NCT03054168|Experimental|Young Zoladex trained|"8 young participants (18-30 years old) who will receive resistance exercise training and Testosterone inhibitor (3.6mg Zoladex subcutaneous injection, one time over the study)~Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single injection one time over the study. Route: Subcutaneous injection (abdomen) performed by clinician."
2928053|NCT03054168|Placebo Comparator|Young placebo trained|8 young participants (18-30 years old) who will receive resistance exercise training and placebo, one time over the study.
2928054|NCT03054155|Experimental|Treatment Arm|For each patient, one side of the body will be treated with the Alexandrite laser (the treatment arm) and the other will not be treated to serve as control (the control arm). For example, if a patient has the disease in both axillae, one will treatment and the other control
2928055|NCT03054155|No Intervention|Control Arm|For each patient, one side of the body will be treated with the Alexandrite laser (the treatment arm) and the other will not be treated to serve as control (the control arm). For example, if a patient has the disease in both axillae, one will treatment and the other control
2928056|NCT03054142||AKI|
2928057|NCT03054142||non-AKI|
2928058|NCT03054129|Experimental|Rehabilitation and balance training|"Each patient will attend rehabilitation program for three days per week for six weeks. Patients will receive balance training in addition to supervised rehabilitation program which is including patient education, stretching and strengthening exercises.~Patients will also implement home exercise program. Balance training will be non-supervised program."
2928059|NCT03054129|Active Comparator|Rehabilitation program|"Each patient will attend rehabilitation program for three days per week for six weeks.~Patients will receive supervised rehabilitation program which is including patient education, stretching and strengthening exercises.~Patients will also implement home exercise program."
2928060|NCT03054103|Placebo Comparator|Midazolam alone|Drug: Midazolam titrated 0.5-2.0 mg + normal saline placebo
2928061|NCT03054103|Active Comparator|Midazolam + Ketamine 5 mg|Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 0.5 ML
2928062|NCT03054103|Active Comparator|Midazolam + Ketamine 10 mg|Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 1 ML
2928063|NCT03054090|Other|Quality Improvement support|A blended support strategy will include practice facilitation, expert consultation, collaborative learning events, an online support center, and data feedback and benchmarking.
2928064|NCT03054077|No Intervention|Control or Group 1|This group receives standard of care for the child receiving a sedated procedure. There is no intervention for this group.
2928065|NCT03054077|Experimental|Intervention group or Group 2|This group receives an iPad with downloaded games to play while waiting for the sedation/procedure and then resume play upon return to the recovery area and awakening.
2928066|NCT03054064|Experimental|All Enrolled Subjects|All enrolled subjects will receive gait training with the Indego.
2928067|NCT03054051|Experimental|Tumaini Mobile Phone Game|Participants randomized to this arm will be invited to play the Tumaini game.
2928068|NCT03054051|No Intervention|Standard of Care|Participants randomized to this arm will receive no intervention beyond the current standard of care for sexual education.
2928069|NCT03054038|Experimental|Experimental|Patients receive afatinib PO QD on days 1-28 and necitumumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2928070|NCT03054025|Experimental|Supportive care (smart phone application)|Participants download the physical activity readiness smart phone application onto their personal smartphone and receive training on how to use the app which includes animated video clips, tailored email reminders, and feedback on progress for 3 weeks.
2928071|NCT03054012||CAS group|computer-assisted surgery group
2928072|NCT03053999||Parathyroidectomy Tissue and Data|"Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.~Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels)."
2928073|NCT03053986|Active Comparator|Apple polyphenols|White capsule containing 300 mg of apple extract (Malus Domestica) with glycosilated polyphenols (≥90%) including glycosilated phloritzin (15-30%), chlorogenic acid (10-25%) and quercetin (15-25%)
2928074|NCT03053986|Placebo Comparator|Placebo|Indistinguishable capsules with similar dimension, colour, odour and taste
2928075|NCT03053973|Experimental|NIV directly started arm|Patients randomised to this arm will start noninvasive ventilation after baseline measurements are performed.
2928076|NCT03053973|Other|NIV postponed arm|Patients randomised to this arm will, after baseline measurements have been done, first be followed for 3 months while on standard care, and thus serve as the control arm. After this 3 months period, measurements are repeated and patients will also be initiated on noninvasive ventilation.
2928077|NCT03053960||Diagnostic (helical CT, PET/CT, MRI, CBCT)|Patients undergo helical (Computed Tomography) CT,(Positron Emission Tomography and Computed Tomography) PET/CT, (Magnetic Resonance Imaging) MRI, and (Cone-Beam Computed Tomography) CBCT scans. Patients also undergo therapeutic conventional surgical resection of tumor.
2928078|NCT03053947|Other|Ketamine IN|All participants will receive intranasal Ketamine between 3mg/kg up to 9 mg/kg, once.
2928079|NCT03053934|Active Comparator|Traditional in-person|Participants randomised to this arm will receive traditional in-person counselling (i.e., treatment will be conducted with the client and clinician occupying the same physical location/room)
2928080|NCT03053934|Experimental|Online counselling|Participants randomised to this arm will receive treatment from a clinician via videoconferencing (i.e., communication between the client and clinician will occur via webcam)
2928081|NCT03053921|Placebo Comparator|recession coverage|30 recession defects treated with Zucchelli's technique.
2928082|NCT03053921|Active Comparator|recession coverage and membrane|30 recession defects treated with Zucchelli's technique along with placental membrane.
2928083|NCT03053908|Experimental|Elderly Patients|
2928084|NCT03053895|Experimental|CSDH Bedside twist drill technique|For patients randomized to bedside drainage of Chronic Subdural Hematoma, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic.
2928085|NCT03053895|Active Comparator|CSDH Operating Room Burr-hole technique|For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
2928086|NCT03053882|Active Comparator|green tea and peppermint|
2928087|NCT03053882|Active Comparator|peppermint and green tea|
2928088|NCT03053869|Experimental|Benzodiazepine - Limited use strategy|"No routine use of any intraoperative benzodiazepines.~Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
2928089|NCT03053869|Active Comparator|Benzodiazepine - Ad libitum strategy|"Administration of some benzodiazepine to most patients undergoing cardiac surgery.~Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
2928090|NCT03053856|Experimental|Pembrolizumab arm|Adjuvant Pembrolizumab
2928091|NCT03053843|Experimental|Mediterranean diet plus extra virgin olive oil|These patients will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months.
2928092|NCT03053843|No Intervention|no specific diet|The control group will be assigned to the usual care and patients assigned to this group will not receive any special intervention to follow a particular diet, as occurs in the current clinical practice.
2928093|NCT03053830|Experimental|Intervention Group|Veterans with Major Depressive Disorder getting up to 6 infusions of 0.5mg/kg ketamine in normal saline; one infusion per week, 40 minutes per infusion with time points lasting up to 5 hours.
2928094|NCT03053817|Experimental|Exercise group|The 45 minute exercise program will be performed 3 times a week and will consist of aerobic exercise and resistance training for 12 weeks.
2928095|NCT03053817|No Intervention|Control|No treatment
2928096|NCT03053804|Experimental|MR/PET|hypothesize that MR/PET can have better information than current CT image study
2928097|NCT03053791|Experimental|Intervention group|Single-armed study. All patients will receive treatment.
2928098|NCT03053778|Experimental|Intervention|Early follow-up after discharge
2928099|NCT03053765|Active Comparator|Individual Supervision in IPT|Bi-weekly individual case supervision in IPT
2928100|NCT03053765|Experimental|Group Supervision in IPT|Bi-weekly group supervision in IPT in groups of 4-6 therapists
2928101|NCT03053765|Experimental|Internet-Based Training in IPT|Access to internet-based training in IPT to review information learned in initial 2-day training
2928102|NCT03053765|No Intervention|Autodidactic Training in IPT|Clinicians allowed access to training materials and can engage in self-study
2928103|NCT03053752|Experimental|Transcutaneous Electric Stimulation|Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.
2928104|NCT03053739|Active Comparator|Combination arm A-Sildenafil and Bosentan|"Combination Arm A -Intervention- Drug~Tab Sildenafil 20 mg - three times a day for 6 months,and~Tab Bosentan 62.5mg - twice a day for 6 months"
2928105|NCT03053739|Placebo Comparator|Monotherapy arm-Sildenafil and Placebo|Monotherapy arm B Intervention-Drugs Tab Sildenafil 20mg- three times a day for 6 months, and Placebo tab (matched for bosentan) for 6 months
2928106|NCT03053726|Experimental|Variable Frequency Stimulation|Subjects in this group received variable frequency stimulation of deep brain stimulation
2928107|NCT03053726|Sham Comparator|Constant Frequency Stimulation|Subjects in this group received constant frequency stimulation of deep brain
2928108|NCT03053713|Active Comparator|Mediterranean Diet Pattern|Mediterranean diet pattern x 12 weeks.
2928109|NCT03053713|Placebo Comparator|Habitual Diet|Habitual diet (control) x 12 weeks.
2928110|NCT03053700|Active Comparator|Treatment with bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would recieve this treatment alone.
2928111|NCT03053700|Active Comparator|Treatment with bromonide 0.33% gel & IPL|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
2928112|NCT03053687|Experimental|Nutritional Standardized Supplementation Formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
2928113|NCT03053687|Placebo Comparator|Placebo|Low caloric formula (Powder added to water) without added vitamins and mineral
2928114|NCT03053674|Experimental|Explanation|Explanation to parents on importance of post-partum influenza vaccination on health of their newborn infant with a follow-up questionnaire to determine rate of vaccination
2928115|NCT03053674|Active Comparator|No explanation|No explanation will be given to parents but they will be followed-up with a questionnaire to determine rate of vaccination
2928116|NCT03053661||primary surgery + adj. C)RT|treatment naive patients to be treated by conventional primary surgery followed by adjuvant (chemo-)radiotherapy with curative intent
2928117|NCT03053661||primary chemoradiation|treatment naive patients to be treated by conventional primary chemoradiotherapy with curative intent
2928118|NCT03053648|Experimental|Self-acupressure Group|Subjects in this group will attend two weekly 120-minute self-acupressure training sessions in a classroom at the School of Nursing, the Hong Kong Polytechnic University. The subjects will be instructed on how to perform the self-acupressure treatment by a trained instructor. To enhance interaction and ensure the quality of teaching, each course will be conducted in a small group of 6 participants. Subjects will perform self-acupressure daily for 4 consecutive weeks.
2928119|NCT03053648|Active Comparator|Sleep Hygiene Education Group|To control the contact time with professional person in the treatment group, participants in this group will receive two sessions of 120-minute sleep hygiene training session. The participants will be asked to follow the health hygiene instructions daily for 4 consecutive weeks.
2928120|NCT03053635|Experimental|0.35 mg/cm^2 TLD1433 Bladder Dose|"TLD1433 infusion and photodynamic therapy treatment (PDT):~TLD1433 is infused for 1 hour and photodynamic therapy treatment is performed after TLD1433 has been rinsed from the bladder. If treatment with the maximum recommended starting dose of 0.35mg/cm^2 does not raise significant safety concerns as determined by the safety monitoring committee, the therapeutic dose of TLD1433 (0.70mg/cm^2) will be used."
2928121|NCT03053622|Experimental|Mirikizumab Test Subcutaneous (SC) 1|Mirikizumab test formulation given as a single injection under the skin in healthy participants
2928122|NCT03053622|Experimental|Mirikizumab Test SC 2|Mirikizumab test formulation given as two injections under the skin in healthy participants
2928123|NCT03053622|Experimental|Mirikizumab Test Intravenous (IV)|Mirikizumab test formulation given as an infusion into the vein in healthy participants
2928124|NCT03053622|Active Comparator|Mirikizumab Reference|Mirikizumab reference formulation given as three injections under the skin in healthy participants
2928125|NCT03053583|Active Comparator|Miller Laryngoscope blade|A photo of the best glottic view will be taken during laryngoscopy using Miller blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
2928126|NCT03053583|Active Comparator|Wis-Hipple Laryngoscope blade|A photo of the best glottic view will be taken during laryngoscopy using Wis- Hipple blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
2928127|NCT03053583|Active Comparator|C-Mac Laryngoscope blade|An image of the best glottic view will be saved on C-MAC monitor's SD card during laryngoscopy using C-MAC straight blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
2928128|NCT03053570|Experimental|Cryoballoon|
2928129|NCT03053570|Experimental|Radiofrequency Energy(Contact Force)|
2928130|NCT03053557|Experimental|Social Skills Coach|The Social Skills Coach arm of the study will be provided access, instruction, and support for using the newly developed multi-platform device to address social impairments among individuals with schizophrenia, based on the evidence-based Social Skills Training (SST) intervention.
2928131|NCT03053557|No Intervention|Social Skills Training course|Social Skills Training classes are widely available and regularly used in the study setting. As such, this group will serve as a treatment as usual control group.
2928159|NCT03053388|Active Comparator|Group 2 - Control treatment|• Group 2 (Control) - will receive inhalations O2/air using the same treatment schedule and equipment as group 1, in addition to standard supportive treatment.
2928132|NCT03053544|Experimental|Metformin|Participants will self‐administer 500mg metformin twice daily by mouth: 1) beginning 1 to 2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
2928133|NCT03053531|Experimental|HERO-ED RCT|Subjects will be instructed on use of the HAD. The model that we will use is the PockeTalker Mini-Cog. This is a small (9.0cm X 5.5cm X 2.0cm) battery-powered electronic box that can be worn around the neck which connects via wires to both earphones and headphones (we will supply both earpieces, and let the patient choose). The RA, trained on use of the HAD by an experienced research audiologist, will instruct the patient in use of the HAD, and test the device to ensure proper functioning. The patient will also receive an instruction sheet (Appendix 3). Subjects will be encouraged to use the HAD during any encounters with ED staff.
2928134|NCT03053518|Active Comparator|Life Style|
2928135|NCT03053518|Experimental|Life Style + Metformin|
2928136|NCT03053505|Experimental|Recurrent CDI FMT|"Non-randomized group (R) for treatment of recurrent CDI with FMT"
2928137|NCT03053505|Active Comparator|Primary CDI antibiotic|"Randomized group (F AB) for the treatment of primary CDI with antibiotics (vancomycin or fidaxomicin)"
2928138|NCT03053505|Experimental|Primary CDI FMT|"Randomized group (F FMT) for the treatment of primary CDI with FMT"
2928139|NCT03053492|Experimental|Duck Duck Punch|Subjects in this arm will engage in Duck Duck Punch Play, a custom designed computer game developed for stroke rehabilitation for 6 weeks.
2928140|NCT03053492|Active Comparator|Commercially Available Game|Subjects in this arm will engage in a Commercially Available Game Play off-the-shelf computer game for 6 weeks.
2928141|NCT03053479|Experimental|Laparoscopic sacrocolpopexy|Laparoscopic sacrocolpopexy will be performed in the following way: Identification of the promontory, dissection of the peritoneum above the promontory and preparation of the ligamentum longitudinale anterior, peritoneum dissection, dissection of the vesicovaginal septum up to the bladder neck, dissection of the rectovaginal septum towards the perineum, application of Y mesh, fixation to the vaginal apex using non-absorbable sutures, and for anterior and posterior vaginal wall absorbable sutures. Fixation of the upper mesh arm to the ligamentum longitudinale anterior using non-absorbable suture, following with complete peritoneum closure above the mesh. The procedure could include salpingo-oophorectomy, supracervical hysterectomy or total hysterectomy (concomitant procedures are not exclusion criteria).
2928142|NCT03053479|Experimental|Transvaginal mesh procedure|Hydrodissection of the anterior vaginal wall, midline anterior colporrhaphy, preparation beyond the endopelvic fascia, mesh kit with bilateral fixation to sacrospinous ligaments should be used. The procedure could include salpingo-oophorectomy, total hysterectomy and posterior vaginal wall repair (concomitant procedures are not exclusion criteria).
2928143|NCT03053479|Experimental|Amreich-Richter procedure:|At least unilateral fixation with non-absorbable suture to sacrospinous ligament (fixation could be performed from the anterior approach). At the time of anterior vaginal wall repair or traditional posterior approach, it is possible to use a device for stich fixation (for example Capio, I- stitch etc). The procedure could include salpingo-oophorectomy, total hysterectomy and posterior vaginal wall repair (concomitant procedures are not exclusion criteria).
2928144|NCT03053466|Experimental|Single-Arm|CBT-501
2928145|NCT03053453|Active Comparator|Standard of Care Spinal Surgery|Patients will be given spinal anesthesia with 2.6 mL of 0.5% isobaric bupivacaine.
2928146|NCT03053453|Experimental|Sensor Guided Spinal Surgery|The Verasense Knee System device (OrthoSensor inc., Dania Beach, Florida) is a sterile sensor system that replaces the tibial insert trials used during surgery. The sensor contains a microprocessor and integrated nanosensor system, which wirelessly transmits real-time data to a portable graphic display unit used for read-out of the data. The sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces. Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
2928147|NCT03053440|Experimental|Arm A (Experimental Arm-BGB-3111)|Approximately 94 subjects with the MYD88 mutation will be enrolled in Cohort 1 and receive BGB-3111 in treatment [Arm A]
2928148|NCT03053440|Active Comparator|Arm B (Active Comparator-Ibrutinib)|Approximately 94 subjects with the MYD88 mutation will be enrolled in Cohort 1 and receive Ibrutinib in treatment [Arm B]
2928149|NCT03053440|Experimental|Arm C (Experimental Arm-BGB-3111)|Approximately 22 subjects found to have MYD88 wild type will be enrolled in Cohort 2 and receive BGB-3111 in treatment [Arm C]
2928150|NCT03053427|Experimental|Gabapentin enacarbil group|Gabapentin enacarbil will be administered orally once daily after the evening meal. Dosing is adjusted in accordance with renal function, as represented by creatinine clearance (60 mL/min or more and less than 90 mL/min and 90 mL/min or more).
2928151|NCT03053427|Placebo Comparator|Placebo group|Placebo will be administered orally once daily after the evening meal.
2928152|NCT03053414|Active Comparator|Treatment Arm # 1|50,000 IU oral vitamin D2 per week for 12 weeks + Dietary counseling
2928153|NCT03053414|Active Comparator|Treatment Arm # 2|50,000 IU oral vitamin D2 per week x 12 weeks then 800 IU/day oral vitamin D3 for 6 months + Dietary counseling
2928154|NCT03053414|Active Comparator|Treatment Arm # 3|50,000 IU oral vitamin D2 per week x 12 weeks then 5,000 IU/day oral vitamin D3 for 6 months+ Dietary counseling
2928155|NCT03053414|Active Comparator|Treatment Arm # 4|5,000 IU oral daily vitamin D3 for 9 months + Dietary counseling
2928156|NCT03053401|Active Comparator|Adductor Canal block|Adductor Canal Block performed at mid-thigh level to block the saphenous nerve under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
2928157|NCT03053401|Active Comparator|Femoral Nerve block|Femoral Nerve Block performed under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
2928158|NCT03053388|Experimental|Group 1 - Nitric Oxide treatment|• Group 1 (NO treatment) - will receive inhalations of 160 ppm NO combined with O2/air for 30 minutes, every 3-4.5 hours, five times a day (24 hours), for up to 5 days (maximum 25 inhalations), in addition to standard supportive treatment.
2928164|NCT03053362|Experimental|Major Depressive Disorder Population|"100 Individuals with DSM-5-defined MDD, aged 18-65~All participants receiving vortioxetine for a total of 8 weeks. Participants will receive10 mg/day on days 1-14 of the study treatment period, with the option to increase to vortioxetine 20 mg/day at the end of Week 2 based on physician's judgment. For the remaining 6 weeks, the dose of vortioxetine will be flexible at 10 or 20 mg/day as decided by a research doctor.~Patients will receive the THINC-it over 3 time frame periods. The THINC-it comprised of: Spotter, Symbol Check, Codebreaker, Trails, and PDQ-5-D."
2928165|NCT03053362|Other|Healthy Control Population|50 Healthy Controls (18-65 years of age) matched on sex, age, and years of education
2928166|NCT03053336|Experimental|App-technology group|"Participants in the intervention group (App-technology) will use a newly developed smartphone application (app) in which steps are automatically measured and laboratory values from blood sampling within primary care will be shown.~Intervention: App-technology to increase physical activity"
2928167|NCT03053336|No Intervention|Control group|The control group will receive standard care
2928168|NCT03053323|Experimental|Lifestyle Intervention|
2928169|NCT03053310||Primary (P) - group|"Patients with a primary diagnosis~Patients treated with curative intent (stage I-IVb)"
2928170|NCT03053310||Relapse (R) - group|"Patients with a recurrent (loco)regional tumour~Patients treated with curative intent (stage I-IVb)"
2928171|NCT03053297||Patients with EGFR mutation (+) NSCLC|Patients with EGFR mutation-positive locally advanced or metastatic NSCLC who have progressed while on or after receiving front-line EGFR-TKI therapy (e.g., gefitinib, erlotinib, afatinib, or icotinib).
2928172|NCT03053297||Patients newly diagnosed NSCLC|Patients newly diagnosed with locally advanced or metastatic NSCLC who are treatment naive or patients who were diagnosed at an earlier stage but have progressed to metastatic NSCLC during the selection period.
2928173|NCT03053284|Placebo Comparator|Placebo|Normal saline s.c. injection once
2928174|NCT03053284|Experimental|Pasireotide|Pasireotide 0.6mg s.c. once
2928175|NCT03053271|Experimental|ATR-101|During the 4-week randomized withdrawal period, eligible subjects will receive ATR-101 at the same dose level being used at the completion of the open-label dose-escalation period.
2928176|NCT03053271|Placebo Comparator|Placebos|During the 4-week randomized withdrawal period, eligible subjects will receive a placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
2928177|NCT03053258||Diagnostic Breath Analysis: VAP|Collection of exhaled breath samples
2928178|NCT03053245|Experimental|Mobile Critical Care Recovery Program|The group will receive the Mobile Critical Care Recovery Program (m-CCRP) intervention which includes care coordination and collaborative care model for one year post enrollment.
2928179|NCT03053245|Active Comparator|Attention Control|The attention control group will receive telephone based check ins related to their health from the research study team.
2928180|NCT03053232|Experimental|Purse string suture device|Use of purse string suture device to close gastrointestinal perforation.
2928181|NCT03053232|Active Comparator|Endoclips|Use of endoclips to close gastrointestinal perforation.
2928182|NCT03053219|Experimental|AC0010|each participant will be given AC0010 300mg bid
2928183|NCT03053206|Experimental|ADE arm|"ADE arm~Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days"
2928184|NCT03053193||MammaPrint and BluePrint testing|All patients will receive MammaPrint and BluePrint testing using the full-genome testing data chip. Treatment will be at the discretion of the physician while adhering to NCCN guidelines.
2928185|NCT03053180||HCV Gt1b infection and compensated liver cirrhosis|Participants with chronic hepatitis C (CHC) genotype 1b (GT1b) and compensated liver cirrhosis receiving combination therapy with the interferon-free paritaprevir/r - ombitasvir with dasabuvir (ABBVIE REGIMEN) without ribavirin (RBV)
2928186|NCT03053167|Experimental|Irinotecan & Raltitrexed|"advanced colorectal cancer patients treated with irinotecan plus raltitrexed as second-line treatment.~Irinotecan:180mg/㎡+NS250ml, ivgtt, 90min, d1~Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks"
2928187|NCT03053154||Experimental group1|15 stroke patients with right side affection, their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
2928188|NCT03053154||Experimental group2|15 stroke patients with left side affection, their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
2928189|NCT03053154||Control group|15 Normal subjects without any diseases or dysfunctions , their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
2928190|NCT03053141||All Subjects|All subjects are included in this cohort and are treated with the Rhythmia Mapping System
2928191|NCT03053128|Experimental|CSWT group|Patients in CSWT group will receive cardiac shock wave therapy for three moths, every first week of the month.
2928192|NCT03053128|Sham Comparator|Sham CSWT group|Patients in sham CSWT group will receive sham cardiac shock wave, which segregated by an air-cushion.
2928193|NCT03053115|Experimental|CASES|treatment with levothyroxine and liothyronine
2928194|NCT03053115|Active Comparator|CONTROLS|treatment with levothyroxine and placebo
2928195|NCT03053102|Experimental|ACH-0144471|All patients will receive ACH-0144471 during the treatment period.
2928196|NCT03053089|Experimental|Stage 1 (adult)|AGT-181
2928197|NCT03053089|Experimental|Stage 2 (children)|AGT-181
2928198|NCT03053076|Placebo Comparator|Placebo1|0.9% sodium chloride infusion 48 hours after birth ,the infusion speed is 4ml/kg/h， 8-12h，
2928199|NCT03053076|Experimental|CBMNC|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 48 hours after birth ,dose is 25 million cells/kg ，the infusion speed is 4ml/kg/h， 8-12h，
2928200|NCT03053063|Experimental|SEL 6 mg|SEL 6 mg plus placebo for up to 240 weeks
2928201|NCT03053063|Experimental|SEL 18 mg|SEL 18 mg plus placebo for up to 240 weeks
2928202|NCT03053063|Placebo Comparator|Placebo|Placebo for up to 240 weeks
2928203|NCT03053050|Experimental|SEL 6 mg|SEL 6 mg plus placebo for up to 240 weeks
2928204|NCT03053050|Experimental|SEL 18 mg|SEL 18 mg plus placebo for up to 240 weeks
2928205|NCT03053050|Placebo Comparator|Placebo|Placebo for up to 240 weeks
2928206|NCT03053037|Active Comparator|Group S|mesial canals in Group S will be instrumented to size 25
2928207|NCT03053037|Active Comparator|Group L|mesial canals in Group L will be instrumented to size 35
2928208|NCT03053024||Cohort 1: Relapse/refractory MCL (rrMCL ) Participants|Participants characteristics and treatment pattern of relapsed/refractory mantel cell lymphoma [rrMCL]) participants treated by Bortezomib (BTZ) will be observed for cohort 1.
2928209|NCT03053024||Cohort 2: Newly Diagnosed MCL Participants|Participants characteristics and treatment pattern of newly diagnosed MCL participants (if more than 20% of total BTZ-treated MCL) will be analysed for cohort 2.
2928210|NCT03053011|Experimental|Vibrating bracelet|A bracelet with vibrations triggered randomly overnight
2928211|NCT03052998|Active Comparator|Ivermectin|Ivermectin and anti-epileptic treatment
2928212|NCT03052998|No Intervention|no treatment|only anti-epileptic treatment
2928213|NCT03052972|Experimental|Amyloid Positive|Clinically normal amyloid positive subjects from BIOCARD study will receive 370 MBq (10 mCi) 18F-AV-1451
2928214|NCT03052972|Experimental|Amyloid Negative|Clinically normal amyloid negative subjects from BIOCARD study will receive 370 MBq (10 mCi) 18F-AV-1451
2928215|NCT03052959|Experimental|Immediate Intervention|
2928216|NCT03052959|Other|Wait List Intervention|
2928217|NCT03052946|Active Comparator|Bulking agent|Bulking agent in fecal incontinence
2928218|NCT03052946|Placebo Comparator|Endoanal electrostimulation|Endoanal electrostimulation in fecal incontinence
2928219|NCT03052933|Experimental|Copanlisib/gemcitabine|
2928220|NCT03052920|Experimental|Cochlear Implantation|Cochlear implantation of the poor hearing ear
2928221|NCT03052907|Other|BSPAN Expansion|We will expand BSPAN's reach and sustainability by systematizing how to enable counties to assume responsibility for one or two of the components while Moncrief/UTSW continues to provide centralized financial review and reimbursement as the Texas BCCS contractor. We will prospectively identify which counties have the necessary program capacity, then test whether implementation of BSPAN tailored to a county's capacity and local needs can lead to equivalent program success in an additional 12 rural counties (BSPAN2 total= 17 counties). Findings will be used to develop a model by which BSPAN benefits can be brought to rural communities across the country.
2928222|NCT03052894|Experimental|Hydraulic Monitoring Device|Monitoring device to be compared to electromyographic (EMG) device in the same patient; measures depth of neuromuscular blockade during general anesthesia based on the pressure exerted by the muscles of the thumb.
2928223|NCT03052894|Active Comparator|Standard EMG Monitoring Device|Currently used standard monitoring device; measures depth of neuromuscular blockade during general anesthesia based on the action potential of the muscles of the thumb.
2928224|NCT03052881|Experimental|Robot assisted surgery|To investigate use of an intraocular robotic system to assist the surgeon in performing one of two operation: i) epiretinal, or inner limiting, membrane peel and ii) displacement of sub macular haemorrhage.
2928225|NCT03052881|No Intervention|Control|A control group of patients underwent either i) epiretinal, or inner limiting, membrane peel and ii) displacement of sub macular haemorrhage without the use of a robot i.e. the surgery was done in the standard manner.
2928226|NCT03052868|Other|Data Collection|The study visit will be scheduled for three to six months after completing adjuvant chemotherapy treatment. At the study visit, informed consent will be obtained and neurocognitive attention testing will be performed. The assessments chosen were carefully selected based on breadth, psychometric properties, standardized broad clinical use, good external validity and time efficiency. The testing time for the battery of neuropsychological tests is approximately 45-60 minutes. Participants will also be asked to complete a packet of several questionnaires including several self-rated measures of mood and quality of life, in addition to a brief questionnaire to obtain information about exercise, sleep, and education and employment backgrounds. It is estimated that questionnaire completion will require no more than 30 minutes. Participants will be seen on only one occasion, and may receive, upon request, written feedback about the results of the evaluation.
2928227|NCT03052855|Other|Participants|All the participants of the 3 groups (depressed patients with suicide attempt, depressed patients without suicide attempt, healthy volunteers) will have to realize a MRI and biological samples.
2928228|NCT03052842|Other|Arm 1|Study subjects will be randomized to receive 9.2 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
2928229|NCT03052842|Other|Arm 2|Study subjects will be randomized to receive 18.4 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
2928230|NCT03052842|Other|Arm 3|Study subjects will be randomized to receive 36.8 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects).
2928231|NCT03052829|Experimental|Physical Activity Counseling|Subjects will be given counseling on the benefits of increasing activity, instructions on how to slowly increase their activity over 12 weeks with walking, record their daily step counts, and have bi-weekly phone calls with study staff to reinforce the training and help them overcome barriers to being physically active.
2928232|NCT03052829|Placebo Comparator|Patient Usual Care|Subjects will undergo usual care without intervention in this study arm
2928233|NCT03052816|Experimental|ICE T|"ICE PACKS applied to the perineum every hour for 20 minutes ATC until discharge.~6 hours from the time of first dose of surgery patients will receive 30mg of IV toradol ATC until discharge.~Once out of the PACU will receive 1 gram of Tylenol every 6 hours for a total of 4 grams daily ATC until discharge~Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.~Patients will be discharged home with PO Tylenol and PO toradol PRN."
2928234|NCT03052816|Active Comparator|Standard|"Motrin 600mg PO Q4h PRN pain 1-3~Percocet 1 tab PO Q4-6 hours PRN 4-6 pain~Percocet 2 tabs PO Q 7-10 hours PRN 7-10 pain~Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.~Patients will be discharged home with Motrin and Percocet for pain PRN."
2928266|NCT03052543||BISvisible|BISvisible group will have the BIS monitor and data available for the anesthesiologist to view. The patient will receive an anesthetic as per the anesthesiologist's particular care plan, unaltered by the study.
2928475|NCT03051087|Active Comparator|Orgalutran (ganirelix acetate)|Prefilled syringe / 0.25mg/0.5mL
2928235|NCT03052790|Active Comparator|manually instrumented total knee arthroplasty|Manually instrumented implantation of a total knee prosthesis involves use of cutting guides or jigs that are secured to the femur and the tibia. The femoral guide is secured to the femur after an intramedullary referenced guide is placed into the femur and the rotational alignment is then assessed with use of the epicondylar axis. An extra-medullary tibial alignment guide will be used to create the tibial cut.
2928236|NCT03052790|Experimental|robotic assisted total knee arthroplasty|Robotically assisted surgery is used in conjunction with the preoperative CT scan and intra-operative bony registration of the patient's knee. Femoral and tibial trackers are placed and then the bone is registered using bony landmarks to allow the computer and robot to know where the patients' femur and tibia are in space. Once this is complete the preoperative templated surgical plan (performed by the PI) is used to register where to make the bony cuts in order to implant the knee components. The cutting process is performed by the surgeon with the robot assisting in guiding the cuts based on the registered CT anatomy. The surgeon has complete control of the cutting process with the assistance of the robot for placement of the cuts.
2928237|NCT03052777|Experimental|Telephone Counselling|Participants will be asked to increase their exercise by at least 60 minutes per week and will receive a copy of Canada's Physical Activity Guideline plus 12 weekly telephone counseling sessions aimed at helping survivors follow-through on their exercise intention.
2928238|NCT03052777|No Intervention|Control|Participants will be asked to increase their exercise by at least 60 minutes per week and will be self-directed, only receiving a copy of Canada's Physical Activity Guideline as standard of care.
2928239|NCT03052764|Active Comparator|BOTOX® 100 U/BOTOX® 100 U|BOTOX® (onabotulinumtoxinA) 100 U injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
2928240|NCT03052764|Placebo Comparator|Placebo/BOTOX® 100 U|Placebo (saline) injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
2928241|NCT03052751|Experimental|Dosage Regimen 1|Subjects randomized in dosage regimen 1 will receive 3 doses of UCB7655 (dose 1) in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).
2928242|NCT03052751|Experimental|Dosage Regimen 2|Subjects randomized in dosage regimen 2 will receive 3 doses of placebo in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).
2928243|NCT03052725|Experimental|reslizumab|
2928244|NCT03052712|Active Comparator|Patients|battery of tests of social cognition
2928245|NCT03052712|Active Comparator|Control|battery of tests of social cognition
2928246|NCT03052699||vaginal Cesarean Section|patients operated to vaginal Cesarean Section
2928247|NCT03052686||Childbirth with uterine rupture|No intervention. Follow-up of women with uterine rupture at the childbirth.
2928248|NCT03052673|Active Comparator|Ketamine + Fentanyl Group|"Patients will receive pre-induction fentanyl 1-mcg/kg, ketamine 0.5-mg/kg after induction, followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr + ketamine infusion of 0.2-mg/kg/hr.~Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval."
2928249|NCT03052673|Active Comparator|Fentanyl Group|"Patients will receive pre-induction fentanyl 1-mcg/kg,followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr.~Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval."
2928250|NCT03052660|Experimental|Midazolam|Midazolam, 3.75 mg , oral, once, 30-45 minutes before surgery
2928251|NCT03052660|Placebo Comparator|Placebo|Placebo, oral, once, 30-45 minutes before surgery
2928252|NCT03052647|Active Comparator|Subcuticular arm|closure technique that the Adhesive Latch arem (dermaclip) arm is being compared to
2928253|NCT03052647|Active Comparator|Adhesive Latch Arm (Demaclip arm)|This is the arm which the adhesive latch system is used and it is being compared to the arm of subcuticular
2928254|NCT03052634|Experimental|RC48-ADC|"Phase Ib: Patients will receive RC48-ADC 1.5 mg/kg or 2.0mg/kg or 2.5mg/kg intravenously (IV) administered once every 2 weeks.~Phase II: Patients will receive a suitable RC48-ADC dose which was selected according to the Ib phase of the experimental results RC48-ADC via IV administered once every 2 weeks."
2928255|NCT03052634|Active Comparator|Lapatinib plus capecitabine|"Phase II： Active Comparator:Lapatinib+capecitabine Lapatinib repeating dose taken orally every day for 3 weeks as a treatment cycle.~Capecitabine :1000 mg/m2 bid, oral. Days: 1-14 every three weeks."
2928256|NCT03052621||Curative group|Locally advance breast cancer and locally recurrent breast cancer without metastasis underwent omental transposition
2928257|NCT03052621||Palliative group|Locally advance breast cancer and locally recurrent breast cancer with metastasis underwent omental transposition
2928258|NCT03052608|Experimental|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
2928259|NCT03052608|Active Comparator|Crizotinib|Crizotinib single agent, 250 mg (1 x 250) oral capsules, BID, continuously
2928260|NCT03052595||SM|Patients with newly diagnosed multiple sclerosis undergo Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load
2928261|NCT03052595||Control|Age, sex, BMI matched healthy subjects undergo Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load
2928262|NCT03052582|Active Comparator|Team 1: skimmed/whole|Milktype: 3 weeks with skimmed milk followed by 3 weeks with whole milk
2928263|NCT03052582|Active Comparator|Team 2: whole/skimmed|Milktype: 3 weeks with whole milk followed by 3 weeks with skimmed milk
2928264|NCT03052556|Other|Cohort of women with cystic fibrosis|Includable patients are adult women, transplanted or not, followed at Lyon CRCM (Centre de Ressources et de Compétences de la Mucoviscidose).
2928265|NCT03052543||BISblind|The BISblind group will have the BIS monitor and data physically hidden from the anesthesiologist. The patient will receive an anesthetic as per the anesthesiologist's particular care plan, unaltered by the study.
2928267|NCT03052530|Experimental|Sapphire II PRO|Single arm with investigational Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters
2928271|NCT03052504||Cx prospective|Cystectomy patients followed with prospective registration of complications
2928272|NCT03052504||Cx retrospective|Cystectomy patients followed with retrospective registration of complications
2928273|NCT03052504||Nx prospective|Nephrectomy patients followed with prospective registration of complications
2928274|NCT03052504||Nx retrospective|Nephrectomy patients followed with retrospective registration of complications
2928275|NCT03052491|Experimental|Stem Cell 100+ Intervention|Subjects take one 650 mg capsule by mouth twice daily for an average of 15 weeks
2928276|NCT03052478|Experimental|vismodegib arm|. Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
2928277|NCT03052465|Experimental|Feeding|Test soup meal feeding intervention
2928278|NCT03052439|Active Comparator|Order 1|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
2928279|NCT03052439|Active Comparator|Order 2|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
2928280|NCT03052439|Active Comparator|Order 3|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
2928281|NCT03052439|Active Comparator|Order 4|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
2928282|NCT03052439|Active Comparator|Order 5|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
2928283|NCT03052426|Active Comparator|30 Minute Group|This group will be required to alternate periods of sitting and standing every 30 minutes throughout their workday using the sit to stand workstation.
2928284|NCT03052426|Active Comparator|60 Minute Group|This group will be required to alternate periods of sitting and standing every 60 minutes throughout their workday using the sit to stand workstation.
2928285|NCT03052426|Active Comparator|90 Minute Group|This group will be required to alternate periods of sitting and standing every 90 minutes throughout their workday using the sit to stand workstation.
2928286|NCT03052413|Active Comparator|Active|
2928287|NCT03052413|Placebo Comparator|Placebo|
2928288|NCT03052400|Experimental|Mifepristone 600 mg daily|Mifepristone 300 mg po daily x 2 weeks, followed by mifepristone 600 mg po daily x 10 weeks
2928289|NCT03052400|Placebo Comparator|Placebo|Matching, blinded placebo 1 tablet po daily x 2 weeks, followed by matching, blinded placebo 2 tablets po daily x 10 weeks
2928290|NCT03052387|Placebo Comparator|control|"Crestal pyramidal flap will be done with 2 releasing incisions for adequate exposure.~Buccal& palatal full reflection for adequate exposure and to avoid the interference between the onlay graft and the residual bone.~Decortication of the bone bed to increase the blood supply to the onlay graft.~The block graft harvested from the chin is placed crestal to the residual ridge and stabilized in place using dental implant immediately.~Periosteal incisions are usually needed to allow tension free sutures.~Vicryl 3/0 sutures for closer.~augmentin 1g twice daily for 5 days.~catflam 50g twice daily for 3 days"
2928291|NCT03052387|Active Comparator|Comparator|"Crestal incision with labial flap reflected leaving the palatal tissues without elevation.~Marking of the 3 bony cuts ( 2 vertical cuts & 1 horizontal cut ) using fine fissure bur in the form of perforations along the cuts position.~Drilling of pilot drill and first drill only.~3 full thickness cuts will be performed (2 vertical stop cuts will be made by using the tungsten carbide disc at the distal ends of the horizontal bony cut on the facial surface of alveolar ridge.~splitting osteotomes are used and mallet to complete the splitting of the bony segment.~After bony separation the rectangular bony segment (transport segment) will be mobilized occlusally and pedicled on the palatal mucoperiosteum.~The autogenous block graft harvested from the chin area is placed in the space gained under the mobile bony segment.~Drilling through the bony segment and the block graft.~Immediate implant placement~chin graft block dental implants"
2928292|NCT03052374|No Intervention|Control Group|Mothers will receive standard care such as referral to psychotherapy (intervention mothers will have the same access) over the same length of time.
2928293|NCT03052374|Experimental|VID-KIDS Intervention Program Group|RN review photos of infant engagement/disengagement cues. NCAST Teaching Activity, mothers asked to perform task advanced for infant's level, recorded. 1st-View, no feedback, mothers reveal infant cues. RN records infant/mother's response, later discussion. 2nd, RN and mother co-view interaction with time for replay/review parts of sensitivity and responsiveness. RN feedback: praising desired maternal behaviours; information on infant cues; maternal response to infant distress; and use of cognitive growth fostering language. 3rd, all concepts discussed in past views, use positive reinforcement to affirm aspects of sensitivity, useful feedback for areas of growth. Post-Debrief, RN and mother discuss interests of the mother. Mothers encouraged to note infants' engagement/disengagement cues.
2928294|NCT03052361|Experimental|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage. Posology of ondansetron will be adapted to weight: doses of 2 mg for children weighting between 8 and 15 kg, 4 mg for children weighting between 15 to 30 kg and 8 mg for children heavier than 30 kg
2928295|NCT03052361|Placebo Comparator|control|Patients allocated to this arm will receive an identical looking/tasting placebo in the ED triage.
2928296|NCT03052348|Active Comparator|Group R|Polyethylene glycol hexadecyl ether & betamethasone valerate cream 0.1% . ( 4 applications per day for 14 days treatment to taper fortnightly)
2928297|NCT03052348|Experimental|Group A|Fusidic acid & Polyethylene glycol hexadecyl ether,& betamethasone valerate cream 0.1%). ( 4 applications per day for 14 days treatment to taper fortnightly)
2928298|NCT03052335|Experimental|Pillcam® COLON 2 Capsule and colonoscopy|Persons with positive immunochemical fecal occult blood tests will be examined by second generation colon capsule endoscopy (CCE2) and optical colonoscopy afterwards.
2928299|NCT03052322|Experimental|MSB11022|
2928300|NCT03052322|Active Comparator|Humira®|
2928301|NCT03052283||Patients with CF|
2928302|NCT03052283||Age-matched healthy controls|
2928477|NCT03051074|Active Comparator|Comparison condition|The participant will watch a relaxing 90 minute film as a comparison condition
2928303|NCT03052270|Experimental|Vaginal progesterone and Pessary|"Short cervical length equal or less than 20 mm~Singleton pregnant women between 18 -24 weeks with no prior history of preterm deliveries.~18 years or older at the time of enrollment.~Consent to participate in the study~Vaginal progesterone as standard of care plus Arabin pessary"
2928304|NCT03052270|No Intervention|Vaginal progesterone only|"Short cervical length equal or less than 20 mm~Singleton pregnant women between 18 -24 weeks with no prior history of preterm deliveries.~18 years or older at the time of enrollment.~Consent to participate in the study~Vaginal progesterone as standard of care"
2928305|NCT03052257|Experimental|Intervention|"Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
2928306|NCT03052257|Active Comparator|Control|"Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
2928307|NCT03052244|Experimental|intervention tDCS+VI|The anode will be placed over C3-C4 (EEG 10/20 system) to target M1 and the cathode over the contralateral supraorbital area. The stimulation will apply to the hemisphere which contralateral to the more painful hemi body. 2mA will be delivered over 20 min via neuroConn DC stimulator combined with video presenting walking legs. A total of 10 sessions (5 per week) will be administrated at the same manner.
2928308|NCT03052244|Sham Comparator|tDCS Sham+VI Sham|The stimulation will be turned on for only short duration (up to 30 sec), the video film will contains graphical illustrations or nature movie without human movement.
2928309|NCT03052231|Active Comparator|Interactive Mobile Health Information|Receives Interactive Mobile Health Information via caremessage. EAI staff focus group content will include qualitative descriptions of their experiences with training and actual use of the Caremessages.org service, as well as to elicit comments about contributing features and other mitigating or enhancing factors of the intervention's implementation, outreach and promotion, and integration into workflow practices.
2928310|NCT03052231|No Intervention|Usual care|Usual care - clinic education, medication refills without reminders, appointments without reminders
2928311|NCT03052218|Experimental|single arm study|pupillometry, CYP2D6 genotyping and phenotyping
2928312|NCT03052205|Experimental|IMO-2125 at escalating dose levels|IMO-2125 at escalating dose levels by intratumoral injection
2928313|NCT03052192||FAM group (n=98)|"≥65 years. Acutely admitted medical patients.~Included consecutively at admission to the Acute Medical Department at Amager and Hvidovre Hospital and Rigshospitalet - Glostrup.~Follow-up at 4 weeks and 56 weeks after discharge and at any readmissions in the study period.~Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality.~If a patient uses ≥5 prescribed drugs before hospitalization, a medication review will be performed by a clinical pharmacist and a geriatrician.~Sample size calculations were performed for each primary outcome, and the final sample size was based on the calculation for the eating validation scheme which resulted in the largest sample size."
2928314|NCT03052192||Control group 1 (n=54)|"≥65 years. No hospital admissions within the past two years.~Matched individually with patients in the FAM group by age, sex, and municipality.~Examined at inclusion and 52 weeks after inclusion.~Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality."
2928315|NCT03052192||Control group 2 (n=60)|"20-35 years No admissions due to chronic or critical illness within the past 5 years (except admissions related to child birth, abortion, appendicitis, poisoning, traumas, concussion etc.)~Examined at inclusion and 4 weeks after inclusion. The examination includes a questionnaire about life style, a physical examination, and blood samples."
2928316|NCT03052179|Active Comparator|VSL#3|VSL#3 poly-biotic 450 billion in sachet orally, two sachets in the morning and two sahcets in the evening for 30 days
2928317|NCT03052179|Placebo Comparator|Placebo|Maltose in sachet orally, two sachets in the morning and two sahcets in the evening for 30 days
2928318|NCT03052166||Cohort A|The group of asymptomatic subjects who have been given BI-RADS 1 or 2 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan.
2928319|NCT03052166||Cohort B|The group of asymptomatic women who have been given BI-RADS categories 4 or 4a, 4b, 4c or 5 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan.
2928320|NCT03052166||Cohort C|The group of women who have been given BI-RADS categories 1, 2, 3, 4 or (4a, 4b, 4c), 5 or 6 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan. Subjects are assigned to Cohort C when it has been determined they cannot be assigned to Cohort A or Cohort B.
2928321|NCT03052153||Lung Transplant Surgery|Subjects included in the study will have undergone a single or bilateral lung transplant surgery at The Ohio State University Wexner Medical Center between 01 JAN 2014 and 18 NOV 2016. No investigational intervention performed for this study.
2928322|NCT03052140|Other|Treatment A, followed by Treatment B|Treatment group that will receive Treatment A for 14 days, followed by Treatment B for 14 days. There will be a minimum 7 day washout between Treatments. Lamelleye Dry Eye Drops and Optive Plus will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
2928323|NCT03052140|Other|Treatment B, followed by Treatment A|Treatment group that will receive Treatment B for 14 days, followed by Treatment A for 14 days. There will be a minimum 7 day washout between Treatments. Lamelleye Dry Eye Drops and Optive Plus will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
2928324|NCT03052127|Experimental|Single Low Dose Light-activated AU-011|Low dose Light-activated AU-011 followed by a single laser light application
2928325|NCT03052127|Experimental|Single Medium Dose Light-activated AU-011|Medium dose Light-activated AU-011 followed by a single laser light application
2928326|NCT03052127|Experimental|Single High Dose Light-activated AU-011|High dose Light-activated AU-011 followed by a single laser light application
2928327|NCT03052127|Experimental|2 Repeat Medium Dose Light-activated AU-011|2 repeat medium doses of Light-activated AU-011 each followed by a single laser light application
2928328|NCT03052127|Experimental|3 Repeat Medium Dose Light-activated AU-011|3 repeat medium doses of Light-activated AU-011 followed by a single laser light application
2928329|NCT03052127|Experimental|Single High Dose Light-activated AU-011 x 2 lasers|High dose Light-activated AU-011 followed by two laser light applications
2928330|NCT03052127|Experimental|3 Repeat High Dose Light-activated AU-011|3 repeat high doses of Light-activated AU-011 each followed by a single laser light application
2928331|NCT03052127|Experimental|3 Repeat High Dose Light-activated AU-011 x 2 lasers|3 repeat high doses of Light-activated AU-011 each followed by two laser light applications
2928332|NCT03052114||Stroke|Electrical Impedance Tomography with scalp electrodes
2928333|NCT03052114||Head Injury|Electrical Impedance Tomography with scalp electrodes
2928334|NCT03052075||Parathyroidectomy Data Review|The research plan is for a retrospective review to be performed of a prospectively maintained parathyroid database within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center.
2928335|NCT03052062|Experimental|Lipidrive|Dose 1 : 2,6 g (4 capsules) Lipidrive per day during 12 weeks Dose 2 : 5,2 g (8 capsules) Lipidrive per day during 12 weeks, 2 weeks (wash-out period) between the 2 doses
2928336|NCT03052049|Experimental|Prostate Artery Embolization|There is only one arm of this study where patients receive Prostate Artery Embolization
2928337|NCT03052036|Other|Invasive Treatment|Coronary angiography with a view to coronary revascularisation
2928338|NCT03052036|Other|Optimal Medical Therapy|Patients to be treated with guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE inhibitors, betabloackers
2928339|NCT03052023|Experimental|group A (dual approach lap hernioplasty)|dual approach laparoscopic inguinal hernioplasty by combination of TAPP (group B) and pneumo-dissection preperitoneal instead of sharp dissection
2928340|NCT03052023|Active Comparator|group B (TAPP)|trans-abdominal preperitoneal hernioplasty (TAPP) after induction of pneumoperitoneum through peritoneal approach peritoneal incision and preperitoneal dissection then mesh fixation done
2928341|NCT03052023|Active Comparator|group C (Lichtenstein hernioplasty)|open inguinal hernioplasty (lichtenstein) repair through inguinal incision and dissection of the sac anteriorly , excision of the sac and then mesh fixation in the posterior wall of inguinal canal
2928342|NCT03052010|Other|PrEP for HIV-1 uninfected partners and ART for HIV-1 infected|Integrated PrEP as a bridge to ART HIV-1 prevention strategy
2928343|NCT03051997|Experimental|Caregiver Contingency Management + Usual Drug Court Treatment|This group will receive a caregiver contingency management intervention plus the standard outpatient substance abuse treatment services provided at JDC.
2928344|NCT03051997|Active Comparator|Usual Drug Court Treatment|This group will receive the standard outpatient substance abuse treatment services provided at JDC.
2928345|NCT03051984|Experimental|NMES|Neuromuscular electrical stimulation (NMES) will be administered for 5 weeks post-TKA in the quadriceps of the surgical leg. Treatment will occur 5 days per week, twice daily for 45 minutes on each occasion.
2928346|NCT03051984|No Intervention|Control|No intervention will be administered during the 5 weeks post-TKA in the surgical leg.
2928347|NCT03051971|Active Comparator|Jet nebulizer|short-acting bronchodilator (albuterol and/or ipratropium bromide) according to standard of care practices and physician discretion will be administered with a jet nebulizer
2928348|NCT03051971|Active Comparator|Vibrating Mesh Nebulizer|short-acting bronchodilator (albuterol and/or ipratropium bromide) according to standard of care practices and physician discretion will be administered with a vibrating mesh nebulizer
2928349|NCT03051958|Experimental|Internet mindfulness&exposure treatment|A 12-week treatment where the main treatment components are mindfulness, exposure and response prevention, a form of cognitive behavior therapy. The treatment entails methods to increase acceptance and non-reactivity to aversive thoughts and emotions associated with AD. The treatment is delivered via the Internet and comprises 10 modules, each with a specific theme. Throughout treatment, the patient is given structured exercises to work with on a daily basis.
2928350|NCT03051958|Active Comparator|Treatment as usual|"Participants receive information about moisturizer and anti-inflammatory lotion treatment which is treatment as usual.~After 12 weeks, patients in this arm are crossed over to treatment."
2928351|NCT03051945|Experimental|Ketamine|Ketamine will be infused via intravenous catheter over 40 minutes (0.75 mg/kg/hr over 40 minutes, 0.5 mg/kg total).
2928352|NCT03051945|Placebo Comparator|Placebo|Normal saline will be infused via intravenous catheter over 40 minutes (0.75 mg/kg/hr over 40 minutes, 0.5 mg/kg total).
2928353|NCT03051932|Active Comparator|Ofiramev®( IV Acetaminophen)|Patients randomized to the treatment arm will receive 1 g (100 mL) intravenous acetaminophen infused over 15-minutes every 6 hours for 4 doses total.
2928354|NCT03051932|Placebo Comparator|Placebo IV administration|Patients randomized to the placebo arm will receive 100 mL of normal saline infused over 15 minutes every 6 hours for 4 doses total
2928355|NCT03051919||no reinforcement|Group I: 25 patients; no reinforcement (NoR) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
2928356|NCT03051919||fibrin glue|Group II: 26 patients; fibrin glue (FG) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
2928357|NCT03051919||suture reinforcement|Group III: 44 patients; suture reinforcement with 2-0 polypropylene suture (S) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
2928358|NCT03051919||biological buttressing materaia|Group IV: 14 patients; biological buttressing material Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
2928359|NCT03051906|Experimental|Experimental|Durvalumab, Cetuximab and Radiotherapy followed by adjuvant Durvalumab (6 months)
2928360|NCT03051893|Experimental|Part A1|Three formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
2928361|NCT03051893|Experimental|Part A2|Three additional formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
2928362|NCT03051893|Experimental|Part B|The best formulation of Chronocort was then selected from Parts A1 & A2. This was then administered in four separate treatment periods, in dosages of 5mg, 10mg, 20mg and 30mg. Each treatment was administered in a randomised, crossover manner.
2928363|NCT03051880|Experimental|Repair Control EGF®|EGF cream was applied. One half side of face and one hand were treated with emollient containing EGF.
2928364|NCT03051880|Placebo Comparator|Cream without rhEGF|Placebo cream without EGF was applied. The other half side of face and the other hand were treated with only emollient which was not containing EGF.
2928365|NCT03051867||Third-trimester pregnant women|Women differing in their reproductive state (pregnant versus nonpregnant) will consume equivalent dietary intakes of vitamin D and related nutrients as part of a feeding study.
2928366|NCT03051867||Nonpregnant control women|Women differing in their reproductive state (pregnant versus nonpregnant) will consume equivalent dietary intakes of vitamin D and related nutrients as part of a feeding study.
2928367|NCT03051854|Experimental|ICC-T|Intervention: Interaction Competencies with children - for teachers (ICC-T) 5.5 days with 8 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
2928368|NCT03051854|No Intervention|Control schools|The control school do not receive any intervention.
2928369|NCT03051841|Experimental|Treat Regimen|CKD-581(investigational Drug) Bortezomib Dexamethasone
2928370|NCT03051828||fencing and patients with breast cancer|patients operated for breast cancer followed at the Hospital Rene Dubos
2928371|NCT03051789|Experimental|Menstrual Cup|One menstrual cup (Mooncup®), an insertable menstrual hygiene product, together with handwash soap termly; puberty and hygiene education and cup training given at intervention.
2928372|NCT03051789|Experimental|Cash Transfer|Cash transfer (CT; girls' pocket money; of Ksh 1500 per term) via local community/mobile banking with financial literacy, puberty and hygiene education and cash pocket money financial literacy training given at intervention.
2928373|NCT03051789|Experimental|Cups and Cash|A combination of cup and cash transfer interventions; puberty and hygiene education, cup training, and cash pocket money financial literacy training given at intervention.
2928374|NCT03051789|No Intervention|Control|'Usual practice' (control) with handwash soap termly; puberty and hygiene education given at intervention.
2928375|NCT03051776|Experimental|Kinesio Taping|It was done a four week phase with Kinesio Taping in the arm affected with lymphedema.
2928376|NCT03051776|Active Comparator|Compression garment|It was done a four week phase with Compression garment in the arm affected with lymphedema.
2928377|NCT03051750|Active Comparator|CPT+P|Complex Physical Therapy plus Pressotherapy during three weeks
2928378|NCT03051750|Experimental|Kinesio Taping|Kinesio Taping during three weeks
2928379|NCT03051724|Experimental|Intervention group|"These OSA patient's are not familiarized with the use of internet and mobile technologies and with CPAP prescription. They follow the intervetion follow up that consists in an adaptation session where the tecnitian delivers them an automatic CPAP machine. Patient's are titrated with this automatic device in 5-7 days and are treated with the automatic device during 3 months.~The other part of the follow up consists on a voicemail where the patient can contact us 24h a day and on an , with an internet-connected tablet with a special app where the patient's answer a questionnaire once two weeks."
2928380|NCT03051724|No Intervention|Control group|These patient's are patient's that follow the process that all patient's take during CPAP treatment. During the three months of study, the follow up will be the usual.
2928381|NCT03051711|Experimental|GBT440 Dose 1|Dose 1
2928382|NCT03051711|Experimental|GBT440 Dose 2|Dose 2
2928383|NCT03051698|Experimental|C1-inhibitor|One gift of intravenous administration of C1-inhibitor (Cinryze, 100U/kg) during one hour
2928384|NCT03051698|Placebo Comparator|Saline|One gift of intravenous administration of 0.9% NaCl during one hour.
2928385|NCT03051698|Experimental|Antibiotics|broad spectrum antibiotics (vancomycin, ciprofloxacin, metronidazole) for 7 days (washout 36 hours before study day).
2928386|NCT03051685|Experimental|DFN-15 Dose 1|
2928387|NCT03051685|Experimental|DFN-15 Dose 2|
2928388|NCT03051685|Experimental|DFN-15 Dose 3|
2928389|NCT03051685|Active Comparator|Active Comparator|
2928390|NCT03051672|Experimental|Pembrolizumab With Radiation|"Pembrolizumab will be administered intravenously prior to radiation~Pembrolizumab will be administered every 21 days~Palliative radiotherapy will be given for 5 treatments"
2928391|NCT03051659|Experimental|Eribulin Mesylate|"Eribulin mesylate will be administered on Days 1 and 8 of each 21 day cycle.~Eribulin mesylate will be administered intravenously"
2928392|NCT03051659|Experimental|Eribulin Mesylate Combine with Pembrolizumab|"Pembrolizumab will be administered in clinic once per cycle~Pembrolizumab will be given intravenously prior to Eribulin Mesylate~Eribulin mesylate will be administered on Days 1 and 8 of each 21 day cycle.~Eribulin mesylate will be administered intravenously"
2928393|NCT03051646|Experimental|Acetylsalicylic acid|Participant is administered acetylsalicylic acid, an intervention to improve exercise performance (i.e., increase time to exhaustion) one hour prior to exercise.
2928394|NCT03051646|Placebo Comparator|Placebo oral capsule|Participant is administered placebo one hour prior to exercise.
2928395|NCT03051633|Experimental|Be Under Your Own Influence Intervention|School-based anti-substance use communications campaign
2928396|NCT03051633|No Intervention|Control|Assessment only
2928397|NCT03051607|Experimental|Tozadenant|120 mg twice daily. At Week 2 or thereafter doses of 60 mg BID and 120 mg BID will be permitted.
2928398|NCT03051594|Active Comparator|visual tactile assessment|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after visual tactile assessment.
2928899|NCT03048292||Mobilized Neurointervention Team|Patients undergoing endovascular stroke interventions.
2928399|NCT03051594|Active Comparator|caries detector dye|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after after using caries detector dye to determine the excavation endpoint.
2928400|NCT03051594|Experimental|fluorescent camera|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after after using fluorescent camera to determine the excavation endpoint.
2928401|NCT03051581|Experimental|18F-FDG PET/CT-based prognostic model of PTCL|The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
2928402|NCT03051568|Experimental|PTCL patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
2928403|NCT03051555|Experimental|18F-FDG PET/CT-based prognostic model of NK/T-cell lymphoma|The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
2928404|NCT03051542|Experimental|NK/T-cell lymphoma patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
2928405|NCT03051529||combined spinal epidural|24 patients with dilated cardiomyopathy undergoing vascular surgery in the lower half of the body under combined spinal epidural anesthesia will be enrolled in the study
2928406|NCT03051516|Experimental|Arm I (recombinant human papillomavirus nonavalent vaccine)|Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline, 2 months, and 6 months.
2928407|NCT03051516|Placebo Comparator|Arm II (placebo)|Patients receive placebo IM at baseline, 2 months, and 6 months.
2928408|NCT03051503|Active Comparator|The Transdermal Therapeutic System-Fentanyl (TTS-F) group|(TTS-F) group (n=30) 50ug/h patch, placed 12 hs preoperatively.
2928409|NCT03051503|Placebo Comparator|Intravenous patient-controlled analgesia (PCA) morphine|IV (PCA) morphine for pain in the postoperative period.
2928410|NCT03051490|Experimental|Liprotamase|Individually-optimized dose to be administered orally
2928411|NCT03051490|Active Comparator|porcine PERT|Individually-optimized dose to be administered orally
2928412|NCT03051477|Experimental|Helixor® M|Advanced solid tumors
2928413|NCT03051464|Experimental|Chemoradiation + EBRT Boost|standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5; Complete responders and Non-complete responders
2928414|NCT03051464|Experimental|Chemoradiation + HDRBT Boost|standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions; Complete responders and Non-complete responders
2928415|NCT03051451|Active Comparator|combination metformin hydrochloride/ fluoxetine 500/20 mg|"Dosage: The dose will depend on the period of treatment in which the patient is:~Single dose treatment (from visit 2 (from day 0 to day 30 ± 7), the patient will take 1 metformin hydrochloride tablet 500 mg / fluoxetine 20 mg and 1 placebo tablet , every 24 hours in the morning for 30 days).~Treatment at double dose (from visit 3 and until visit 8), the patient will take 2 tablets of metformin hydrochloride 500 mg / fluoxetine 20 mg and 2 tablets of Placebo, every 24 hours in the morning for 150 days)."
2928416|NCT03051451|Active Comparator|combination metformin hydrochloride/ fluoxetine 1000/20mg|"Dosage: The dose will depend on the period of treatment in which the patient is:~Single dose treatment (from visit 2 (from day 0 to day 30 ± 7), the patient will take 1 metformin hydrochloride tablet 850 mg / fluoxetine 20 mg and 1 placebo tablet , every 24 hours in the morning for 30 days).~Treatment at double dose (from visit 3 and until visit 8), the patient will take 2 tablets of metformin hydrochloride 850 mg / fluoxetine 20 mg and 2 tablets of Placebo, every 24 hours in the morning for 150 days)."
2928417|NCT03051451|Placebo Comparator|Placebo Oral Tablet|Placebo
2928418|NCT03051438|Other|Subxiphoid uniportal VATS|retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
2928419|NCT03051438|Other|Three-port VATS|retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
2928420|NCT03051425|Experimental|Test group|Probiotic yogurt supplementation
2928421|NCT03051425|Placebo Comparator|Placebo group|Placebo supplementation
2928422|NCT03051412||Current Patellofemoral Pain|This group has current patellofemoral pain
2928423|NCT03051412||Recovered|This group has a previous history of patellofemoral pain, but currently self reports as recovered.
2928424|NCT03051412||Control|This is a control group with no history of knee pain.
2928425|NCT03051399|Placebo Comparator|Placebo|Maltodextrin, 500 mg/day, single serving
2928426|NCT03051399|Active Comparator|EpiCor|EpiCor, 500 mg/day, single serving
2928427|NCT03051386|Experimental|VEE Vaccine|0.5 mL of VEE vaccine, Live, Attenuated TC-83, NDBR 102, Lot 4, Run 3
2928428|NCT03051373|Experimental|nab-paclitaxel plus S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
2928429|NCT03051373|Active Comparator|Gemcitabine plus cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
2928430|NCT03051360|Active Comparator|PCSK9 inhibitor|Patients will receive bi-weekly PCSK9 inhibitor .
2928431|NCT03051360|Placebo Comparator|Placebo|Patients will receive bi-weekly placebo.
2928432|NCT03051347|Other|Itch Questionnaire and Interview|Up to 30 dyads of patients ages 8-17 and their parents/caregivers, as well as up to 20 parents of children ages 6mo-7 years, will participate in semi-structured interviews to evaluate the new and modified items (questions) written for the PIQ-C questionnaire
2928433|NCT03051347|Other|Stigma Questionnaire and Interview|To assess stigma, up to 20 children ages 8-17 and 20 parents of children ages 5-12, will participate in semi-structured interviews to evaluate the modified Neuro-QoL stigma questionnaire. This questionnaire includes new skin-specific stigma items and existing items modified for use with children having a skin or other condition that may negatively affect their appearance
2928476|NCT03051074|Experimental|Floating|The participant will float supine in water with a high concentration of Epsom salt for up to 90 minutes on three separate occasions
2928900|NCT03048292||Mobilized Patient|
2928434|NCT03051347|Other|Validation Questionnaire and Interview|For validation, up to 200 parent/child dyads ages 5-17 with a diagnosis of moderate to severe AD during the previous 6 months will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status.
2928435|NCT03051334||BiAV|Bicuspid aortic valve
2928436|NCT03051334||TAV|Tricuspid aortic valve
2928437|NCT03051321|Experimental|Wellness toileting system|Subjects given SchwabCare Wellness Toileting system
2928438|NCT03051308|Experimental|First Application in Hour 0|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 0' non-cold ischemia tissue group
2928439|NCT03051308|Experimental|First Application in Hour 6|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 6' cold ischemic tissue group
2928440|NCT03051308|Experimental|First Application in Hour 12|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 12' cold ischemic tissue group
2928441|NCT03051308|Experimental|First Application in Hour 18|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 18' cold ischemic tissue group
2928442|NCT03051308|Experimental|First Application in Hour 24|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour' 24 cold ischemic tissue group
2928443|NCT03051295|Active Comparator|Diagnostic percentages.|Dentist receives diagnostic test results presented in conditional probabilities.
2928444|NCT03051295|Experimental|Diagnostic frequencies|Dentist receives diagnostic test results presented in natural frequencies.
2928445|NCT03051295|Active Comparator|Treatment percentages.|Dentist receives treatment efficacy presented in percentages.
2928446|NCT03051295|Experimental|Treatment frequencies.|Dentist receives treatment efficacy presented in natural frequencies.
2928447|NCT03051282|Active Comparator|non-carrier control group|Subjects who do not carry the CES1 variant G143E (rs71647871) will receive 10 mg Enalapril orally once daily for 7 consecutive days.
2928448|NCT03051282|Active Comparator|G143E carriers group|Subjects who carry the CES1 variant G143E (rs71647871) will receive 10 mg Enalapril orally once daily for 7 consecutive days.
2928449|NCT03051269|Experimental|calcium chloride|Only one arm. All 6 enrolled patients are treated with calcium electroporation.
2928450|NCT03051256|Experimental|REL-1017 25 mg|REL-1017 75 mg of powder in 100 mL of Ocean Spray® Diet Cranberry Juice daily on Day 1, 25 mg of powder in 100 mL Ocean Spray® Diet Cranberry Juice daily on Day 2-7.
2928451|NCT03051256|Experimental|REL-1017 50 mg|REL-1017 100 mg of powder in 100 mL of Ocean Spray® Diet Cranberry Juice daily on Day 1, 50 mg of powder in 100 mL Ocean Spray® Diet Cranberry Juice daily on Day 2-7.
2928452|NCT03051256|Placebo Comparator|Placebo|100 mL Ocean Spray® Diet Cranberry Juice will be administered as a single oral dose daily for 7 days.
2928453|NCT03051243|Active Comparator|Linagliptin and Basal Insulin|linagliptin (trajenta) 5mg once daily combined with basal insulin (glargine Lantus; sanofi) 0.15-0.3 units/kg TDD before bed time.
2928454|NCT03051243|Active Comparator|Basal Insulin and Bolus Insulin|Basal Insulin (Glargine Lantus; Sanofi) based therapy once daily before bedtime and glulisine (Apidra; sanofi) before meals. insulin dose will be 0.5 units/kg divided half as insulin glargine once daily and half as insulin glulisine before meals.
2928455|NCT03051230||Studied group|Women exposed to ovarian hyperstimulation for In Vitro fertilisation
2928456|NCT03051217|Placebo Comparator|Placebo|Placebo subcutaneous (sc) injection every two weeks (Q2W)
2928457|NCT03051217|Experimental|CZP 200 mg|Certolizumab Pegol subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by Certolizumab Pegol subcutaneous (sc) injection 200 mg every two weeks (Q2W) with PBO administered to maintain the blind, starting at Week 6
2928458|NCT03051217|Experimental|CZP 400 mg|Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W).
2928459|NCT03051191||1: No ACVD/NIHF or cancers|The patients who do not have ACVD, NIHF or cancers
2928460|NCT03051191||2: Cancers but no ACVD/NIHF|The patients who have cancers but no ACVD/NIHF
2928461|NCT03051191||3: ACVD and cancers|The patients who have ACVD and cancers
2928462|NCT03051191||4: ACVD but no cancers|The patients who have ACVD but no cancers
2928463|NCT03051191||5: NIHF and cancers|The patients who have NIHF and cancers
2928464|NCT03051191||6: NIHF but no cancers|The patients who have NIHF but no cancers
2928465|NCT03051178|Experimental|Subjects with Essential Tremor|This cohort will receive deep brain stimulation (DBS) therapy responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.
2928466|NCT03051165|Other|Hypoglossal Nerve Stimulation Treatment Withdrawal|Recipients of hypoglossal nerve stimulation (HGNS) who agree to participate in the study will have additional tests done to monitor cardiovascular responses to HGNS therapy and the temporary withdrawal of treatment.
2928467|NCT03051152|Experimental|Elderly with CCS>5 - D1 gastrectomy|Patients aged >75 years with Charlson Comorbidity Score > 5 undergoing gastrectomy with limited lymphadenectomy
2928468|NCT03051152|Experimental|Elderly with CCS>5 - D2 gastrectomy|Patients aged >75 years with Charlson Comorbidity Score > 5 undergoing gastrectomy with extended lymphadenectomy
2928469|NCT03051139|Experimental|ICU A and ICU B|This is the intervention group.
2928470|NCT03051139|No Intervention|ICU C and ICU D|This is the usual care group.
2928471|NCT03051126||Parathyroid Disease Tissue Bank|Participants scheduled for surgical treatment of parathyroid disease and/or patients with MEN1, and/or those presenting with hyperparathyroidism and/or pancreatic lesion, who are scheduled for pancreas tumor intervention.
2928472|NCT03051100|Experimental|Triplet Therapy|Bempedoic acid 180 mg, ezetimibe 10 mg, and atorvastatin 20 mg taken orally, daily.
2928473|NCT03051100|Placebo Comparator|placebo|Matching placebos taken orally, daily.
2928474|NCT03051087|Experimental|Ganilever (ganirelix acetate)|Prefilled syringe / 0.25mg/0.5mL
2928478|NCT03051048||Group 1|The patient received reperfusion therapy between 1999 January 1 and 2009 December 31
2928479|NCT03051048||Group 2|The patient received reperfusion therapy between 2010 January 1 and 2016 December 31
2928480|NCT03051035|Experimental|KO-947|
2928481|NCT03051022|Active Comparator|Dexamethasone 8 mg|Bupivacaine 0,125% 12,5 mg combined with dexamethasone 8 mg plus NaCl 0,9% until the volume was 10 cc, prepared in a 10 cc syringe.
2928482|NCT03051022|Active Comparator|Morphine 2 mg|Bupivacaine 0,125% 12,5 mg combined with morphine 2 mg plus NaCl 0,9% until the volume was 10 cc, prepared in a 10 cc syringe.
2928483|NCT03051009|Experimental|Desmopressin ODT 25 μg (female previous on 25 μg)|Subjects received 25 μg in trial 000129.
2928484|NCT03051009|Experimental|Desmopressin ODT 25 μg (female previously on placebo)|Subjects received placebo in trial 000129
2928485|NCT03051009|Experimental|Desmopressin ODT 25 μg (female)|New female subjects
2928486|NCT03051009|Experimental|Desmopressin ODT 25 μg (male previous on 25 μg)|Subjects received 25 μg in trial 000130
2928487|NCT03051009|Experimental|Desmopressin ODT 50 μg (male previous on 50 μg)|Subjects received 50 μg in trial 000130
2928488|NCT03051009|Experimental|Desmopressin ODT 50 μg (male previous on placebo)|Subjects received placebo in trial 000130
2928489|NCT03051009|Experimental|Desmopressin ODT 25 μg (male)|Subjects received placebo in trial 000130
2928490|NCT03051009|Experimental|Desmopressin ODT 50 μg (male)|New male subjects
2928491|NCT03050996||robotic radical prostatectomy patients|Patient scheduled to undergo robotic assisted radical prostatectomy
2928492|NCT03050983||Phase I|Prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring prior to enabling IPI.
2928493|NCT03050983||Phase II|Enable the Integrated Pulmonary Index (IPI) and IPI alarm for the prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring.
2928494|NCT03050957|Experimental|menthol 10 mM (millimolar)|Patients were studied during the deglutition of one series of 5, 10 and 20 mL nectar control boluses and two series of 5, 10 and 20 mL nectar boluses supplemented with the corresponding concentration of menthol 10 mM
2928495|NCT03050957|Experimental|menthol 1 mM|Patients were studied during the deglutition of one series of 5, 10 and 20 mL nectar control boluses and two series of 5, 10 and 20 mL nectar boluses supplemented with the corresponding concentration of menthol 1 mM
2928496|NCT03050944||Cases|Lifestyle behaviour and dietary habits assessment in couples achieving pregnancy after in vitro fertilization process.
2928497|NCT03050944||Controls|Lifestyle behaviour and dietary habits assessment in couples failed to achieve pregnancy after in vitro fertilization process.
2928498|NCT03050931||Epilepsy with intracranial electrodes|Electrical Impedance Tomography with depth electrodes or intracranial electrode mats
2928499|NCT03050931||Epilepsy with scalp electrodes|Electrical Impedance Tomography with scalp electrodes
2928500|NCT03050918|Active Comparator|Phone Call Group (Intervention Arm)|Follow-up phone call intervention: Patients will first be called within 72 hours discharge with a maximum of 3 call attempts by the study nurse made up until post-discharge day 7. The semi-structured script imbedded within the Discharge Phone Call Starform is used to guide a conversation to obtain information on potential causes of hospital readmission that can be identified and addressed to improve each patient's transition to outpatient care.
2928501|NCT03050918|No Intervention|Usual Care Group (Control Arm)|Patients assigned to the Control Group receive standard discharge planning and follow-up per the usual care of their medical providers.
2928502|NCT03050905|Experimental|Treatment|The study will include 1 group. Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (VEKIRAX) and Dasabuvir (EXVIERA).
2928503|NCT03050879|Experimental|Indocyanine Green Tracer|Indocyanine Green Tracer will be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
2928504|NCT03050879|Active Comparator|No Indocyanine Green Tracer|Indocyanine Green Tracer will not be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
2928505|NCT03050866|Other|Treatment|Treatment intervention with Cabazitaxel with premedication as necessary (antihistamine, corticosteroid, H2 antagonist, antiemetic prophylaxis)
2928506|NCT03050853|Experimental|E-Cigarette|The E-cigarette arm will be asked to use e-cigarettes in place of regular tobacco products. The group will be assessed at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 13 weeks, and 26 weeks.
2928507|NCT03050853|No Intervention|Assessments only|The Assessment only group will be asked to refrain from use of e-cigarettes during participation. The group will be assessed at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 13 weeks, and 26 weeks.
2928508|NCT03050840|Other|Self-monitoring|Participants will wear a Fitbit, to self-monitor steps per day, and will report sugar sweetened beverage (SSB) consumption via text messaging. The Way to Health platform will record data.
2928509|NCT03050840|Experimental|Self-monitoring plus gamification|Participants will wear a Fitbit, to self-monitor steps per day, and will report sugar sweetened beverage consumption via text messaging. Participants will be awarded medals and points based on meeting step per day and SSB consumption goals The Way to Health platform will be used to record data.
2928510|NCT03050827|Active Comparator|3% oxybutynin|Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the active drug arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
2928511|NCT03050827|Placebo Comparator|Placebo|Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the placebo group arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
2928512|NCT03050814|Active Comparator|A /FOLFOX-A alone|Suubjects will receive FOLFOX + bevacizumab + for up to 12 2-week cycles followed by maintenance therapy with bevacizumab + capecitabine until disease progression.
2928547|NCT03050541|Experimental|MDMA at Memory Retrieval|20 healthy adult volunteers will be randomly assigned to the retrevial group (MDMA at Retrevial). This group will receive placebo before viewing the study materials, and MDMA at retrieval two days later..
2928901|NCT03048292||Core Comprehensive Stroke Center Treatment|
2928513|NCT03050814|Experimental|B/Lead in, FOLFOX-A + aVELUMAB + Ad-CEA|Subjects will receive FOLFOX + bevacizumab + avelumab + Ad-CEA vaccine (given weeks 0,2,4,8,12,16 and then every 12 weeks) for up to 12 2-week cycles followed by maintenance therapy with bevacizumab + capecitabine + avelumab + Ad-CEA vaccine (following the every 12 week dosing schedule) until disease progression.
2928514|NCT03050801|Experimental|Frontal rTMS|Prefrontal rTMS
2928515|NCT03050801|Experimental|Parietal rTMS|Parietal rTMS
2928516|NCT03050801|Active Comparator|Vertex rTMS|Vertex rTMS
2928517|NCT03050788|Experimental|Smartphone confocal microscopy imaging|Subject's skin lesion will be imaged with the smartphone confocal microscopy.
2928518|NCT03050775|Experimental|Heated Ventilator Circuit|Heated and humidified inspired gases using the ANAPOD™ Heat and Humidification System (Westmed; Tucson, Arizona, USA) circuit prior to induction of general anesthesia in addition to standard ventilation and temperature management.
2928519|NCT03050775|Active Comparator|Standard Ventilator Circuit|Standard ventilation and temperature management.
2928520|NCT03050762||Endocrine Disease Group|"Information from the medical record recorded and entered into a research database.~Starting about 2-3 years after testing and/or diagnosis and/or treatment and continuing for up to 15 years after surgery, research team will contact participant by phone to follow up."
2928521|NCT03050749|Other|Princess® VOLUME|
2928522|NCT03050736|Experimental|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 20 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
2928523|NCT03050723|Other|Princess® FILLER|
2928524|NCT03050710|Other|Princess® VOLUME Lidocaine|
2928525|NCT03050684|Active Comparator|vaginal lavage group|We will make vaginal lavage with steril %0.9 NaCl serum ( 20cc) before inserting dinoprostone (Propess ®) 10 mg vaginal ovule
2928526|NCT03050684|Placebo Comparator|Control group|We will insert dinoprostone (Propess ®) vaginal ovule without vaginal lavage.
2928527|NCT03050671|Active Comparator|Rapid calf-IPC|Cyclic external compression in both calves through a cuff connected to VenaFlow® Elite System, DJO, CA, USA
2928528|NCT03050671|Active Comparator|subjects under slow calf-IPC|Cyclic external compression in both calves through a cuff connected to Kendall SCD™ 700, Covidien, Medtronic, USA
2928529|NCT03050645||previous GDM|Women with previous GDM
2928530|NCT03050645||no previous GDM|Women without previous GDM matched on age, pregestational body mass index end time of pregnancy.
2928531|NCT03050632|Experimental|Working Memory Intervention (N-back)|Participants will complete the working memory priming task either for the first 3 days of the intervention or the last 3 days of the intervention, with order counterbalanced across participants. The working memory prime is the N-back test, a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back) (Jaeggi et al., 2010).
2928532|NCT03050632|Placebo Comparator|"White Bear Task"|Participants will complete this non-working-memory control task either for the first 3 days of the intervention or the last 3 days of the intervention, depending on counterbalanced order. The task consists of a procedure developed by Wegner and colleagues (1987) in a study of thought suppression, which instructs participants to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
2928533|NCT03050619||Empagliflozin|New users of empagliflozin
2928534|NCT03050619||Other SGLT2 inhibitors|New users of other SGLT2 inhibitors
2928535|NCT03050619||Other non-insulin GLDs|New users of other non-insulin GLDs
2928536|NCT03050606|Experimental|Pilates|"This group will perform a modified Pilates exercise program, which will be performed using mat, accessories and studio apparatus, in individual sessions, twice a week, lasting 60 minutes.~Both groups will also receive an educational booklet with information on fibromyalgia and self-care strategies for pain management, sleep improvement, depression improvement, stress and fatigue control."
2928537|NCT03050606|Active Comparator|Aerobic|"This group will perform aerobic exercise, performed on the treadmill or stationary bike according to the choice of the patient. The training will be performed controlling the heart rate of training. The exercises will be performed individually, twice a week and each session will last 60 minutes.~Both groups will also receive an educational booklet with information on fibromyalgia and self-care strategies for pain management, sleep improvement, depression improvement, stress and fatigue control."
2928538|NCT03050593||HFpEF group|clinical or radiographic evidence of heart failure and left ventricular ejection fraction > 50% on transthoracic echocardiography
2928539|NCT03050593||HFrEF group|Clinical or radiographic evidence of heart failure and left ventricular ejection fraction < 40% on transthoracic echocardiography
2928540|NCT03050593||Healthy control group|Asymptomatic controls (age and sex-matched) without known heart disease
2928541|NCT03050580|Experimental|Self-esteem enhancement group|The self-esteem enhancement group service for abused women will receive a six-session program for recognizing strengths and resources through group activities and sharing.
2928542|NCT03050580|Active Comparator|Standard care|The shelter standard care for abused women includes residential accommodations, emotional support, legal, housing and financial advice and referral service.
2928543|NCT03050567||Healthy Volunteers|Healthy volunteers with no previous history of cerebrovascular disease and aged over 18 years old.
2928544|NCT03050567||Subjects with symptomatic carotid artery stenosis|Patients with symptomatic cerebrovascular event (stroke, transient ischaemic attack or amaurosis fugax) and image confirmed carotid artery stenosis of >30%. This will include patients scheduled for carotid endarterectomy (>50% for men and >70% for women, by North American Symptomatic Carotid Endarterectomy Trial criteria) or treated conservatively with an optimal medical therapy (if patient declined surgical intervention or is outside surgical criteria for carotid endarterectomy).
2928545|NCT03050554|Experimental|SBRT+Avelumab|"SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)~Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles"
2928546|NCT03050541|Experimental|MDMA at Memory Encoding|20 healthy adult volunteers will be randomly assigned to the encoding group (MDMA at Encoding). This group will receive capsules before viewing the study materials, and at retrieval two days later, but they will receive MDMA only in the capsule appropriate to their condition, and the next session capsule will contain placebo.
2929014|NCT03047499||Scar Length|
2928548|NCT03050541|Placebo Comparator|Placebo at both sessions|20 healthy adult volunteers will be randomly assigned to the placebo group (no drug at either session). This group will receive only placebo during study, session before viewing the study materials, and at retrieval two days later.
2928549|NCT03050528|Experimental|Combined Exercise and ACT treatment|Participants will attend a weekly group-based multidisciplinary pain programme for a period of eight weeks. The programme will combine exercise with the psychological approach acceptance and commitment therapy (ACT).
2928550|NCT03050528|Active Comparator|Standalone supervised exercise|Participants will attend a weekly group-based supervised exercise class for a period of eight weeks.
2928551|NCT03050515|Experimental|Fecal Transplant|"Enrolled and screened patients will receive a donor directed fecal transplant via retention enema. This procedure will take place at the University of California Irvine Women's Health Center on the day of the participant's choosing.~The day prior to the procedure, the participant will undergo a bowel prep and stop all prophylactic antibiotics. On the day of procedure, the patient will present to the clinic and undergo a simple, retention enema. This procedure takes about 30-40 minutes to complete and does not require any anesthesia or sedation."
2928552|NCT03050502|Active Comparator|Chest tube drain|A chest tube placed with the intent of draining all intra-pleural blood.
2928553|NCT03050502|Sham Comparator|Expectant management|No chest tube, but will undergo standard observation/conservative management by the trauma service.
2928554|NCT03050489||On-Pump CABG|Patients with coronary artery bypass graft (CABG) surgery performed with cardiopulmonary bypass.
2928555|NCT03050489||Off-Pump CABG|Patients with coronary artery bypass graft (CABG) surgery performed without cardiopulmonary bypass.
2928556|NCT03050489||BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation.
2928557|NCT03050476|Experimental|bRESCAP|Bolus of 1000 IU of bovine intestinal alkaline phosphatase on induction of anaesthesia, followed by an infusion of 9000 IU over the next 24 hours.
2928558|NCT03050476|Placebo Comparator|Placebo|Bolus of of media on induction of anaesthesia, followed by an infusion of media over the next 24 hours.
2928559|NCT03050463||breast cancer with bilateral mastectomy|This group has patients with breast cancer who have chosen to have a bilateral mastectomy. Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
2928560|NCT03050463||breast cancer without bilateral mastectomy|This group has patients diagnosed with breast cancer who have chosen not to have bilateral mastectomy (e.g. they may have unilateral mastectomy, lumpectomy, radiation, etc. but not bilateral mastectomy). Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
2928561|NCT03050463||healthy subjects|Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
2928562|NCT03050450|Experimental|dose level 1|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
2928563|NCT03050450|Experimental|dose level 2|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
2928564|NCT03050450|Experimental|dose level 3|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
2928565|NCT03050450|Experimental|dose level 4|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
2928566|NCT03050450|Experimental|dose level 5|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)
2928567|NCT03050437|Experimental|Pem/Cis|Pem/Cis IV every 3 weeks
2928568|NCT03050437|Active Comparator|Pem alone|Pem IV alone every 3 weeks
2928569|NCT03050424|Experimental|Active|Ferric Carboxymaltose (FCM) (Ferinject) at 15 mg iron/kg body weight
2928570|NCT03050424|Placebo Comparator|Placebo|Sodium Chloride 0.9%
2928571|NCT03050411|Experimental|Apatinib|Apatinib in combination with EGFR-TKIs
2928572|NCT03050398|Experimental|ribociclib + letrozole|ribociclib with letrozole
2928573|NCT03050385|Active Comparator|active stimulation during cognitive rehabilitation|"active transcranial direct current stimulation 20 minutes per session twice a day interval between sessions: more than 20 minutes 7 cm x 5 cm electrodes anodal electrode on F3 cathodal electrode on right forehead 2 mA(milliampere)~cognitive rehabilitation 10-minute calculation task followed by 10-minute task of local (Japanese) language test"
2928574|NCT03050385|Sham Comparator|sham stimulation during cognitive rehabilitation|"sham transcranial direct current stimulation 20 minutes per session twice a day interval between sessions: more than 20 minutes 7 cm x 5 cm electrodes anodal electrode on F3 cathodal electrode on right forehead 2 mA~cognitive rehabilitation 10-minute calculation task followed by 10-minute task of local (Japanese) language test"
2928575|NCT03050372|Experimental|Active Low Field Magnetic Stimulation|LFMS - Active
2928576|NCT03050372|Sham Comparator|Sham Low Field Magnetic Stimulation|LFMS - Sham
2928577|NCT03050359|Experimental|TAK-438 20 mg (HP- Participants)|TAK-438 20 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.
2928578|NCT03050359|Experimental|TAK-438 20 mg (HP+ Participants)|TAK-438 20 mg, tablets, orally, twice daily and lansoprazole placebo-matching capsules, orally, twice daily for first 2 weeks. Then TAK-438 20 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily from Week 3 to Week 6. Bismuth-Containing Quadruple Therapy (Amoxicillin 1g, clarithromycin 500 mg, and bismuth potassium citrate 220 mg, orally, twice daily) for first 2 weeks.
2928579|NCT03050359|Active Comparator|Lansoprazole 30 mg (HP- Participants)|Lansoprazole 30 mg, capsules, orally, once daily and TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
2928580|NCT03050359|Active Comparator|Lansoprazole 30 mg (HP+ Participants)|Lansoprazole 30 mg, capsules, orally, twice daily and TAK-438 placebo-matching tablets, orally, twice daily for first 2 weeks. Then lansoprazole 30 mg, capsules, orally, once daily and TAK-438 placebo-matching tablets, orally, once daily from Week 3 to Week 6. Bismuth-Containing Quadruple Therapy (Amoxicillin 1g, clarithromycin 500 mg, and bismuth potassium citrate 220 mg, orally, twice daily) for first 2 weeks.
2928656|NCT03049930|Placebo Comparator|Placebo|Participants randomized to this arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
2928581|NCT03050346||CAD patients|Consecutive patients scheduled for a coronary angiography on the basis of cardiac symptoms and a test positive for inducible coronary ischemia, who are affected by one-vessel or two-vessel CAD at the time of the OS-CMR with breathing maneuvers (HVBH).
2928582|NCT03050346||Healthy subjects|Subjects without current or pre-existing cardiovascular and lung disease and absence of medication with cardiovascular effects.
2928583|NCT03050320|Experimental|Exercise|The participants in this arm will be asked to attend 3 group classes per week for 12 weeks taught by a certified exercise instructor. Five class times will be offered per week. These classes included a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
2928584|NCT03050320|Other|No Exercise|The participants in this arm will be asked to refrain from changing their physical activity over the 12 weeks and maintain any strategies typically used to manage knee and/or hip pain. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the no exercise group will be offered the same exercise program following completion of the study. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
2928585|NCT03050307|Experimental|TAK-438 20 mg (HP- Participants)|TAK-438 20 mg, tablet, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily for up to 8 weeks.
2928586|NCT03050307|Experimental|TAK-438 20 mg (HP+ Participants)|TAK-438 20 mg, tablet, orally, twice daily and lansoprazole placebo-matching capsule, orally, twice daily along with bismuth-containing quadruple therapy (amoxicillin 1 g, twice daily, clarithromycin 500 mg twice daily, and bismuth potassium citrate 600 mg [equivalent to 220 mg bismuth] twice daily) for first 2 weeks. TAK-438 20 mg, tablet, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily for up to 6 weeks.
2928587|NCT03050307|Active Comparator|Lansoprazole 30 mg (HP- Participants)|Lansoprazole 30 mg, capsule, orally, once daily and TAK-438 placebo-matching tablet, orally, once daily for up to 8 weeks.
2928588|NCT03050307|Active Comparator|Lansoprazole 30 mg (HP+ Participants)|Lansoprazole 30 mg, capsule, orally, twice daily and TAK-438 placebo-matching tablet, orally, twice daily along with bismuth-containing quadruple therapy (amoxicillin 1 g, twice daily, clarithromycin 500 mg, twice daily, and bismuth potassium citrate 600 mg [equivalent to 220 mg bismuth] twice daily) for first 2 weeks. Lansoprazole 30 mg, capsule, orally, once daily and TAK-438 placebo-matching tablet, orally, once daily for up to 6 weeks.
2928589|NCT03050294|Active Comparator|Control- Atopic Dermatitis|Participants with atopic dermatitis will receive desoximetasone and no calls.
2928590|NCT03050294|Experimental|Atopic Dermatitis Intervention|Participants with atopic dermatitis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication.
2928591|NCT03050294|Active Comparator|Control- Psoriasis|Participants with psoriasis will receive desoximetasone and no calls.
2928592|NCT03050294|Experimental|Psoriasis Intervention|Participants with psoriasis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication.
2928593|NCT03050281|Experimental|Simulation/Cadaver Workshop|2-day workshop using the Simulation/Cadaver Lab
2928594|NCT03050281|Placebo Comparator|Didactic Workshop|Lectures
2928595|NCT03050255|Experimental|ESWT order 1|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~medical air (MA)~Oxygen (2 Liter/min)~Oxygen (4 Liter/min)"
2928596|NCT03050255|Experimental|ESWT order 2|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~medical air (MA)~Oxygen (4 Liter/min)~Oxygen (2 Liter/min)"
2928597|NCT03050255|Experimental|ESWT order 3|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (2 Liter/min)~Medical air (MA)~Oxygen (4 Liter/min)"
2928598|NCT03050255|Experimental|ESWT order 4|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (2 Liter/min)~Oxygen (4 Liter/min)~Medical air (MA)"
2928599|NCT03050255|Experimental|ESWT order 5|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (4 Liter/min)~Medical air (MA)~Oxygen (2 Liter/min)"
2928600|NCT03050255|Experimental|ESWT order 6|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (4 Liter/min)~Oxygen (2 Liter/min)~Medical air (MA)"
2928601|NCT03050242|Experimental|Glycopyrrolate|Glycopyrrolate 0.005mg/kg is administered intramuscularly, one hour before the surgery.
2928602|NCT03050242|No Intervention|Control|No injection is conducted in this group.
2928603|NCT03050229|Experimental|Empagliflozin|Empagliflozin 10mg/day is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker [ARB]) and diabetes.
2928604|NCT03050229|Placebo Comparator|Placebo|Placebo is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker [ARB]) and diabetes.
2928605|NCT03050216|Experimental|Cy, FLU, Haplo NK and ALT-803|"Preparative Regimen of Fludarabine and Cyclophosphamide~ALT-803 Activation of Donor NK Cells~ALT-803 to Facilitate NK Cell Survival and Expansion"
2928606|NCT03050203|Experimental|custom pack|
2928607|NCT03050203|Active Comparator|standard care|
2928608|NCT03050190|Experimental|Therapeutic 4SCAR19 cells|Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.
2928609|NCT03050177|Experimental|Gefitinib Tablet 250mg of Hunan Kelun|During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fed conditions.
2928610|NCT03050177|Active Comparator|Iressa® Tablet 250mg of AZN|During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fed conditions.
2928611|NCT03050164|Experimental|Gefitinib Tablet 250mg of Hunan Kelun|During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fasting conditions.
2929015|NCT03047499||Vancouver scar scale|
2928612|NCT03050164|Active Comparator|Iressa® Tablet 250mg of AZN|During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fasting conditions.
2928613|NCT03050151|Experimental|1 - Dupilumab (Part A)|Dose (dose 1) as per protocol delivered by auto-injector device
2928614|NCT03050151|Experimental|2 - Dupilumab (Part A)|Dose (dose 1) as per protocol delivered by prefilled syringe
2928615|NCT03050151|Experimental|3 - Dupilumab (Part B)|Dose (dose 2) as per protocol delivered by auto-injector device
2928616|NCT03050151|Experimental|4 - Dupilumab (Part B)|Dose (dose 2) as per protocol delivered by prefilled syringe
2928617|NCT03050138||Dabigatran|In the RE-COVER- and RE-COVER II studies, one group of DVT and/or PE patients were randomized to receive 6 months of treatment with dabigatran (150 mg twice daily). All patients received an initial 5-7 day phase of parenteral anticoagulant treatment.
2928618|NCT03050138||Warfarin|In the RE-COVER- and RE-COVER II studies, the other group of DVT and/or PE patients were randomized to receive 6 months of treatment with warfarin (once daily to maintain international normalized ratio (INR) 2.0-3.0). All patients received an initial 5-7 day phase of parenteral anticoagulant treatment.
2928619|NCT03050125|Experimental|Hypo-osmolar drop 1|Subject will receive regular instillations of hypo-osmolar sterile saline drops with the lowest osmolarity of the two hypo-osmolar drops.
2928620|NCT03050125|Experimental|Hypo-osmolar drop 2|Subject will receive regular instillations of hypo-osmolar sterile saline drops with the highest osmolarity of the two hypo-osmolar drops.
2928621|NCT03050125|Experimental|Iso-osmolar drop|Subject will receive regular instillations of sterile iso-osmolar saline drops.
2928622|NCT03050112|Experimental|Congenital cardiopathy|Patients having had surgery in adulthood for a congenital heart disease, at the Brugmann University Hospital. The group consists in patients aged 16 years or older, having had surgery between 01/01/1998 and 31/12/2015.
2928623|NCT03050099||Mild ACVS—definite|Clinical diagnosis of ACVS, and imaging positive (either DWI+ or CT/CTA+).
2928624|NCT03050099||Mild ACVS—possible|Clinical diagnosis of ACVS, and DWI- and/or CTA-
2928625|NCT03050099||Mimic|Clinical diagnosis of mimic and imaging negative.
2928626|NCT03050086|Experimental|BPX-04 1% Minocycline Topical Gel|once daily topical administration of 1% minocycline gel to the face
2928627|NCT03050086|Experimental|BPX-04 2% Minocycline Topical Gel|once daily topical administration of 2% minocycline gel to the face
2928628|NCT03050086|Placebo Comparator|BPX-01 Vehicle Topical Gel|once daily topical administration of vehicle gel to the face
2928629|NCT03050060|Experimental|Treatment (nelfinavir, immunotherapy, radiation therapy)|Beginning 7-14 days prior to start of pembrolizumab, nivolumab, or atezolizumab, patients receive nelfinavir mesylate PO BID on days 1-14 up to 11-12 weeks. Patients also receive pembrolizumab, nivolumab or atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 14-21 days in the absence of disease progression or unacceptable toxicity. Patients then undergo hypofractionated radiation therapy over 3-14 days starting after course 1 and before course 3 of pembrolizumab, nivolumab or atezolizumab.
2928630|NCT03050047|Experimental|BCD-100 0.3 mg/kg|Patients who receive BCD-100 in a dose of 0.3 mg/kg
2928631|NCT03050047|Experimental|BCD-100 1 mg/kg|Patients who receive BCD-100 in a dose of 1 mg/kg
2928632|NCT03050047|Experimental|BCD-100 3 mg/kg|Patients who receive BCD-100 in a dose of 3 mg/kg
2928633|NCT03050047|Experimental|BCD-100 10 mg/kg|Patients who receive BCD-100 in a dose of 10 mg/kg
2928634|NCT03050034|Experimental|Vital signs wireless monitoring system|All patients with MEWS (Modified Early Warning Score) greater than or equal to 3 and/or NEWS (National Early Warning Score) greater than or equal to 5, at admission, regardless of the reason for hospitalization and all patients with glycemic decompensation and/or severe fluid and electrolyte imbalance, regardless of MEWS/ NEWS, undergone to continuous monitoring with wireless monitoring system WIN @ Hospital.
2928635|NCT03050034|Active Comparator|Control arm|All patients with MEWS (Modified Early Warning Score) greater than or equal to 3 and/or NEWS (National Early Warning Score) greater than or equal to 5, at admission, regardless of the reason for admission and all patients with glycemic decompensation and/or severe fluid and electrolyte imbalance, regardless of MEWS NEWS undergone to traditional monitoring performed at regular intervals by the nursing staff.
2928636|NCT03050021||Delirium positive|delirium patients in critically ill surgical patients
2928637|NCT03050021||Delirium negative|non delirium patients in critically ill surgical patients
2928638|NCT03050008|Other|FLACS USFREE|Cataract Surgery with Femtosecond Laser Without Ultrasound
2928639|NCT03050008|Other|Traditional Surgery|Traditional phacoemulsification cataract surgery using ultrasound
2928640|NCT03049995||CHEF:Cardiac Resynchronization therapy Forecast|Patients evaluated prior to cardiac resynchronization therapy (CRT), with class I, IIa or IIb for CRT according to ESC 2016 guidelines, and with ejection fraction ≤ 35% and QRS duration ≥ 130 ms. Contractile reserve will be assessed through variations in Wall Motion Score Index and with more advanced parameters such as left ventricular elastance reserve, as the peak stress/baseline ratio of end - systolic pressure/ end-systolic volume (Left ventricular contractile reserve SE). All patients will be followed-up with resting echocardiographic examination to assess left ventricular remodelling and recovery of function. A sample size of 277 patients is required and about the same number is required to predict the response to medical therapy in patients eventually not undergoing CRT (4).
2928641|NCT03049995||BHEF: B-lines in HEart Failure|B- lines are a semiquantitative sign of extravascular lung water present in 1 out of 3 HF patients at rest and in 1 out of 2 during stress, and potentially useful for refining prognostic stratification and titrating diuretic therapy in these patients. We will enroll patients referred to SE with known or suspected HF, with either reduced or preserved ejection fraction. B-lines will be detected using the B-lines SE intervention. A sample size of about 2500 patients is required if the effect on mortality is evaluated.
2928657|NCT03049917|No Intervention|No incentive|No incentive
2928658|NCT03049917|Experimental|KES financial incentive 1|Kenyan Shillings conditional cash transfer upon HIV testing
2928659|NCT03049917|Experimental|KES financial incentive 2|Kenyan Shillings conditional cash transfer upon HIV testing
2928660|NCT03049917|Experimental|KES financial incentive 3|Kenyan Shillings conditional cash transfer upon HIV testing
2928661|NCT03049917|Experimental|KES financial incentive 4|Kenyan Shillings conditional cash transfer upon HIV testing
2929016|NCT03047499||Scar width|
2928642|NCT03049995||SEHCA: SE in Hypertrophic Cardiomyopathy|Current guidelines recommend SE in hypertrophic cardiomyopathy (HC) solely for evaluation of left ventricular outflow tract obstruction. Large-scale registry data show that SE positivity for ischemic criteria rather than provocable gradients predict adverse outcome in HC. Low-to-intermediate risk symptomatic or asymptomatic HC patients will undergo exercise SE with assessment at each stage and during recovery of wall motion, mitral insufficiency, left ventricular outflow tract gradient (in orthostatic position)(following specific SE protocol), E/e', B-lines and, if feasible, coronary flow velocity reserve. A sample size of about 250 patients is required.
2928643|NCT03049995||SEDIA: SE in Diastolic Heart failure|Patients with suspected diastolic heart failure according to guidelines (3) will be selected (1).The diastolic assessment should be included into all exercise SE tests by measuring standard Doppler-derived mitral inflow velocity, pulsed Tissue Doppler of mitral annulus, and retrograde tricuspid gradient of tricuspid regurgitation as well as diastolic left ventricular volume index and B-lines (to provide a direct imaging of extra-vascular lung water accumulation as a direct cause of dyspnea). The test is considered positive for diastolic dysfunction when all of the following three conditions are met during exercise: average E/e' > 14 or septal E/e' ratio > 15, peak tricuspid regurgitant jet velocity >2.8 m/sec and septal e' velocity < 7 cm/s. A sample size of about 250 patients is required.
2928644|NCT03049995||SETA: SE in Transcatheter Aortic Valve implantation|Transcatheter Aortic Valve Implantation is an extraordinarily effective novel technology, and its short and long term morbidity and mortality remains significant. Patients with previous (from 6 months to 10 years) surgical or Transcatheter Aortic Valve Implantation capable of exercising will be enrolled and studied with semisupine SE. The full quantitative evaluation of mitral regurgitation and aortic stenosis will be performed. A sample size of about 100 patients is required to detect a significant stress-induced increase in mitral regurgitation severity. For the prognostic analysis 250 patients with 3 years follow-up are required.
2928645|NCT03049995||SEO: SE in Outdoor in Extreme conditions|SE can also be performed outdoors, with pocket size or portable instruments, in a setting of ecological stress entirely different from standard indoor testing. The diagnostic target is the early subclinical identification of pulmonary edema. Subjects involved in extreme sporting events (competitive triathlon, marathon, apnea diving etc) or ordinary exercise in extreme environments (trekking at high altitude) will undergo lung ultrasound scan for B-lines before, soon after (within 10 minutes) and (when positive) soon after, later after (6 to 24 h) the acute extreme exercise. A sample size of 80 patients is required to detect a significant stress-induced increase in B-lines in each of the three major study subgroups: high altitude trekkers (n=100); marathon runners (n=80) and apnea divers (n=70).
2928646|NCT03049995||SETOF: SE in operated Tetralogy of Fallot|Patients with repaired Tetralogy of Fallot or Fallot-like pathology (double-outlet right ventricle Fallot type, tetralogy of Fallot with pulmonary atresia), evaluated at least 1 year after the last surgical or percutaneous procedure, will be recruited by regional reference centers for congenital heart disease. Additional inclusion criteria are age > 10 years, height > 140 cm, New York Heart Association class I or II. Right ventricular function will be assessed at baseline and peak stress with variations (rest and peak stress) of tricuspid annular plane systolic excursion. A sample size of about 250 patients is required to detect a significant stress-induced increase in tricuspid annular plane systolic excursion.
2928647|NCT03049995||DOSPAH: Doppler SE in Pulmonary Arterial Hypertension|Patients at risk, borderline, or early established pulmonary hypertension capable of exercising will be recruited by regional reference centers, a physical stress will be performed and the hemodynamic assessment will include the assessment of pulmonary hemodynamics. The primary positivity criteria are the increase in systolic pulmonary artery pressure (> 40 mmHg) and the flow-adjusted variation in pulmonary vascular resistances. A sample size of about 250 patients is required to detect a significant stress-induced hemodynamic changes with a 3 -year follow-up.
2928648|NCT03049995||DITSE: Diagnosis of CAD by imaging SE|"A clear step-up in diagnostic sensitivity (with a modest loss in specificity) and risk stratification capability is obtained with assessment of coronary flow velocity reserve in the left anterior descending coronary artery,left ventricular contractile reserve through changes in left ventricular elastance, and B-lines. Allcomers referred to the SE lab with suspected CAD will be evaluated with standard regional wall motion analysis and also - whenever feasible - with left ventricular coronary flow reserve and left ventricular elastance reserve and - when possible- B-lines (quadruple imaging).A sample size of about 5,000 patients will be required."
2928649|NCT03049995||GENES: Genetic Stress echocardiography|The identification of phenotype-negative and genotype positive carriers of pathologic mutations is an important, still elusive, target. We will initially select 75 patients (25 for each disease) with documented disease and mutant gene. We will enroll 250 first-degree relatives of the initially considered probands, with normal findings at rest and age range preferentially between 10 and 21 years. SE testing will be tailored on the specific question: hypertrophic cardiomyopathy as in protocol 3 (left ventricular outflow tract gradient); pulmonary hypertension as in protocol 8 (pulmonary vascular resistances);dilated cardiomyopathy as in protocol 1 (left ventricular elastance). A sample size of about 80 patients for each disease will be required.
2928650|NCT03049982|Other|AMP test group|All individuals will undergo a test using the auto-titrating mandibular positioner.
2928651|NCT03049969|Experimental|Cognitive Remediation|For the 20 cognitive remediation sessions, eligible participants will receive 20 minutes of active tDCS stimulation (up to 2.0 mA, dorsolateral prefrontal cortex (dlPFC) motage) while they complete the cognitive training tasks. Once the participant has completed his/her 20 sessions a follow-up neuropsychological assessment will be completed.
2928652|NCT03049956|Experimental|Patients with clinical suspicion of ocular myasthenia gravis|
2928653|NCT03049943|Active Comparator|Laser wavelength of 830 nm|This group comprised 15 female patients with hyposalivation whose major salivary glands were treated for 10 consecutive days with low level laser therapy of 830 nm.The whole unstimulated and stimulated saliva was measured each day during 10 days, before and after laser treatment and 10th day after treatment was ended.
2928654|NCT03049943|Experimental|Laser wavelength of 685 nm|This group comprised 15 female patients with hyposalivation whose major salivary glands were treated for 10 consecutive days with low level laser therapy of 685 nm.The whole unstimulated and stimulated saliva was measured each day during 10 days, before and after laser treatment and 10th day after treatment was ended.
2928655|NCT03049930|Experimental|Ketamine|Participants randomized to this arm will receive ketamine (1 mg/ml solution) infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
2928662|NCT03049904|No Intervention|Wait List Control|Participants wait 3 weeks before receiving the intervention.
2928663|NCT03049904|Experimental|Experimental Vr2L 2Spirit|Participants immediately begin their participation in the virtual world.
2928664|NCT03049891||Children down-referred from DNH|This group includes children who were transferred from DNH to a study facility. The investigators will first abstract data from the electronic data system 'Tier.net' for these children, which will tell us where they were down-referred. For children who were labeled as down-referred from DNH in Tier.net, data abstraction of the child's clinical data will be conducted at the down-referral site and from the National Health Laboratory Service (NHLS) data.
2928665|NCT03049891||Children LTF from DNH|This group includes children who began ART at DNH and were subsequently LTF. The investigators will first abstract data from the electronic data system 'Tier.net', which will classify them as LTF followed by examination of the the NHLS laboratory data to determine whether these children had received care at another facility since they were LTF.
2928666|NCT03049891||Caregivers of LTF|This group includes the caregivers of a subset of children in the 'LTF from DNH' and 'down-referred from DNH' groups. Among those children down-referred and LTF from DNH, the investigators will use their clinical and laboratory data to determine whether they are still receiving care or not. For children identified as LTF based on their abstracted data will be traced in order to contact their caregivers. If located, caregivers will be interviewed to ascertain if and why these children are no longer in care through a 'Tracing questionnaire'.
2928667|NCT03049891||DNH only|This group includes children who are still in care at DNH, died while in care at DNH, or were transferred to facilities from tier.net will not have any additional information collected other than what is recorded in the Tier.net database.
2928668|NCT03049878|Active Comparator|analgesic group|preoperative oral dose of paracetamol-codeine
2928669|NCT03049878|Placebo Comparator|placebo group|preoperative placebo (starch)
2928670|NCT03049852|Experimental|CBT-001 Ophthalmic Solution|One drop in the study administered three times daily (TID)
2928671|NCT03049852|Placebo Comparator|Vehicle|One drop in the study administered three times daily (TID)
2928672|NCT03049839|Experimental|Intervention_ structured|One year Structured intervention program for members of high-risk group (People with glucose intolerance in the OGTT and FINDRISC score ≥12 points) 10 educational group sessions where they will receive information to change lifestyle (1 per 1.5 month)
2928673|NCT03049839|Experimental|Intervention_ Informative|"Program information intervention for the group with moderate risk. One year Informative intervention program (People with normotolerant or impaired fasting glucose in the OGTT and FINDRISC score ≥12 points).~There is a single group session where they receive information to prevent cardiomatabolic risk factors"
2928674|NCT03049839|Experimental|Intervention_ Communitarian|"One year, Intervention program at Community level. People with a FINDRISC less than 12 points.~Campaigns are carried out at the community level with different strategies (leaflets, booklets) to prevent cardiomatabolic risk factors"
2928675|NCT03049826|Experimental|Stem cell transplantation (SCT)|Children undergoing stem cell transplantation (SCT)
2928676|NCT03049826|No Intervention|Home parenteral nutrition (HPN)|Children receiving home parenteral nutrition
2928677|NCT03049826|No Intervention|Healthy reference group|Healthy children
2928678|NCT03049813|Experimental|Virtual Reality Job Interview Training|Virtual Reality Job Interview Training
2928679|NCT03049813|Other|Supported Employment (Services as Usual)|Supported Employment (Services as Usual)
2928680|NCT03049800|Active Comparator|Treatment as Usual|patients who receive treatment as usual while participating in a randomized controlled trial examining the effect of computerized cognitive training.
2928681|NCT03049800|Experimental|Targeted Cognitive Training|patients who receive targeted training while participating in a randomized controlled trial examining the effect of computerized cognitive training.
2928682|NCT03049800|Placebo Comparator|Healthy Controls|age and gender matched controls who are psychologically and physically healthy will be recruited from the community to participate in this cohort.
2928683|NCT03049787|Experimental|home exercise|For the home exercise protocol alone arm, subjects will be given an experimental home exercise program and study team will demonstrate the exercises in the clinic and will direct the subjects to perform the exercises 1-2 times daily until symptom resolution.
2928684|NCT03049787|Active Comparator|physical therapy|Patients will be prescribed routine physical therapy protocol where they will see a physical therapist twice a week and will be instructed by the physical therapist to perform physical therapy exercises at home daily until symptom resolution, as is the routine practice.
2928685|NCT03049761|Active Comparator|Water Flosser|Power interdental Cleaning Device
2928686|NCT03049761|Active Comparator|String floss|Manual interdental cleaning device
2928687|NCT03049761|Active Comparator|Manual Toothbrush|ADA standard manual toothbrush
2928688|NCT03049748|Active Comparator|Control Group|Participants in the control group (20 LVAD patients and 20 caregivers) will receive usual care over 6 months. Usual care consists of routine clinic visits/follow-up at 1, 3, and 6 months post hospital discharge. A customary LVAD self-management/discharge education and training will be provided to patients and caregiver before hospital discharge and as need throughout the duration of the study. The control group will NOT receive the VAD Care App.
2928689|NCT03049748|Experimental|Intervention Group|Participants in the experimental group (20 LVAD patients and 20 caregivers) will receive usual care plus VAD Care App. They will implement LVAD self-management as directed by VAD Care App. The app will be used daily by patients and/or caregivers for over 6 months. Their LVAD self-management competencies will be assessed at months 1 and 5 post hospital discharge with a review of LVAD self-management skills provided by the LVAD RN Coordinator.
2928690|NCT03049735|Experimental|Relugolix + Low-dose Hormonal Add-back|
2928691|NCT03049735|Experimental|Relugolix + Pbo - Relugolix + Add-back|
2928692|NCT03049735|Placebo Comparator|Placebo|
2928693|NCT03049722|Experimental|AVOPT Patient|
2928694|NCT03049709||cardiovascular disease|patients with cardiovascular disease, invasive and non-invasive determination of central blood pressure
2928695|NCT03049709||healthy controls|healthy controls, invasive and non-invasive determination of central blood pressure
2928722|NCT03049501|Placebo Comparator|Nutrition Condition|Participants will receive a computer tablet and have access to web-based training sessions on different topics related to nutrition
2928696|NCT03049696|No Intervention|Control Group (Standard of Care)|All patients will receive the Centre for Metabolic and Bariatric Surgery (CMBS) standard of care including two to four multidisciplinary visits over six months, exercise counseling (kinesiologist), completion of a the CMBS behavior modification program (Craving ChangeTM), and achievement of lifestyle and dietary modification goals in order to be scheduled for surgery. The standard of care will be used as the control group (n=24). Matched historical controls (1:1) will be selected (based on age, gender, and body mass index) from the existing CMBS database.
2928697|NCT03049696|Experimental|Intervention Group-ENCOURAGEING START|Intervention group participants (n=24) will receive the standard of care and complete a 16-week supervised physical activity/behaviour modification program at no cost. The first eight weeks of the program involves structured exercise (two per week) and education classes that patients must attend. Progression to a moderate/high-intensity interval program based the patient's capabilities will occur. Participants will also attend education sessions on risk factor reduction, healthy eating, exercise, stress management and promotion of self-managed care. During the second eight week period, participants will be given access to attend drop-in exercise classes or can opt to complete at home exercise. Participants will have an opportunity to meet with the kinesiologist on at least 4 occasions (60 minutes/meeting) for additional physical activity counseling and assistance with overcoming barriers preventing physical activity.
2928698|NCT03049683||Normal subjects|Thirty healthy volunteers without a previous history of vertigo or neuro-otologic diseases will be enrolled in this study. The subjects will be also screened with a full history on vestibular disorders, with pure tone audiogram, and head-impulse tests to exclude the possibility of previous vestibular disorders or migraine which may cause abnormal VEMPs.
2928699|NCT03049683||Acute unilateral vestibular neuritis|The criteria for inclusion as a patient with vestibular neuritis involving the superior division (superior VN) included the following: (1) acute onset of vertigo, (2) the appearance of mixed horizontal and torsional nystagmus, (3) impaired horizontal semicircular canal (SCC) function on head-impulse test and a unilaterally absent or reduced caloric response (i.e., a caloric paresis score > 25%), (4) intact inferior division of vestibular nerve as evidenced by normal cVEMP and normal head-impulse test for vertical SCCs, and (5) the absence of auditory and neurologic signs. Thirty patients (aged 32-82 years; mean age, 51.7 years; 16 males) fulfilled the criteria of superior VN.
2928700|NCT03049670||latent available chlorine (LAC)|applying LAC on infected wounds
2928701|NCT03049657|Active Comparator|ANGIOLITE|Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.
2928702|NCT03049657|Active Comparator|Xience|Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.
2928703|NCT03049644|Active Comparator|Mechanical Diagnosis and Therapy|Mechanical diagnosis refers to the classification based on examination of posture and range of motion of the spine, associated with the assessment of subjective symptomatic responses.
2928704|NCT03049644|Active Comparator|Manual Therapy|Manual therapy (MT) is a broad term encompassing many techniques which attempt to affect possible pain contributors such as joints, tendons, ligaments, and muscles, typically using the therapist's hands but may also utilize a tool or instrument in the case of some soft tissue mobilization therapies as well as low force instrument assisted spinal manipulation therapy.
2928705|NCT03049631|Active Comparator|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
2928706|NCT03049631|Experimental|Raspberry|Red raspberries (1 cup equivalent)
2928707|NCT03049618|Experimental|Treatment (pembrolizumab, sEphB4-HSA)|Patients receive pembrolizumab IV over 30 minutes on day 1 and recombinant EphB4-HSA fusion protein IV over 30 minutes on days 1, 8, and 15. Courses repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
2928708|NCT03049605|Experimental|Magnetic Therapy|Twenty five patient were exposed to low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss for 30 minutes / session for 2 times per week for 3 months .
2928709|NCT03049605|Experimental|Laser Therapy|Twenty five patients were treated with 24 sessions of laser therapy at a rate of two sessions / week for three months. Each patient will be exposed to Helium neon infrared laser (850 nano-meter continuous wave mode from a comfortable prone lying position.
2928710|NCT03049605|Experimental|Medical therapy|Fifteen patients were received only medical treatment .
2928711|NCT03049592|Experimental|HIBISCUS counseling|Subject receives a third trimester prenatal appointment with a family planning specialist for contraceptive counseling (utilizing the Contraceptive CHOICE counseling script emphasizing the WHO birth-to-pregnancy recommendation of 18 months) and a follow up postpartum contraception visit with a family planning specialist.
2928712|NCT03049592|No Intervention|Standard counseling|Subect receives standard high-risk prenatal care and postpartum contraception provision by the referring community clinic. The community clinic offer standard family planning counseling that does not emphasize utilizing of long-acting reversible contraception to promote birth-to-pregnancy spacing of 18 months. This scenario is current the standard practice at the institutions.
2928713|NCT03049579|Experimental|Weiquan Yogurt with probiotics|Weiquan Yogurt with probiotics contained Lactobacillus paracasei (108 colony forming units (CFU)/ml), Lactobacillus casei 431® (108 CFU/ml) and Lactobacillus fermentum PCC® (106 CFU/ml)
2928714|NCT03049579|Placebo Comparator|Weiquan Yogurt without probiotics|Weiquan Yogurt devoid of probiotics, but otherwise similar to the experimental product.
2928715|NCT03049566||preoperative questionnaires|Patients on long-term acetylsalicylic acid undergoing non-cardiac surgery
2928716|NCT03049553|Experimental|Intervention arm|Cobas HPV-DNA test is performed on the cervical sample in addition to the usual cytology
2928717|NCT03049553|Other|Control arm|Screening with cytology as usual in the cervical screening program
2928718|NCT03049540|Active Comparator|Tadalafil|Tadalafil 20 MG, p.o., once per day for 3 years
2928719|NCT03049540|Placebo Comparator|Placebo|Placebo 20 MG, p.o., once per day for 3 years
2928720|NCT03049527|Experimental|Education, Incentives and Feedback|Education, Incentives and Feedback are all directed to all study participants.
2928721|NCT03049501|Experimental|Caregiving Condition|Participants will receive a computer tablet and have access to web-based skill building sessions, videos from experts, annotated resources and information and tips on caregiving-related topics
2929309|NCT03045367||Outpatients|Phacoemulsification, intraocular lens implant, vitrectomy.
2928723|NCT03049488|Experimental|Group 1, Group 2|DS-Cav 1 or DS-Cav 1 + alum administered at 50 mcg with needle and syringe at day 0 and week 12.
2928724|NCT03049488|Experimental|Group 3, Group 4|DS-Cav 1 or DS-Cav 1 + alum administered at 150 mcg with needle and syringe at day 0 and week 12.
2928725|NCT03049488|Experimental|Group 5, Group 6|DS-Cav 1 or DS-Cav 1 + alum administered at 500 mcg with needle and syringe at day 0 and week 12.
2928726|NCT03049475||Sickle Cell Disease|All genotypes
2928727|NCT03049475||Healthy Volunteers|Healthy Volunteers
2928728|NCT03049462|Experimental|1-Women|Women taking 100 mg of mirabegraon
2928729|NCT03049462|Active Comparator|3-Men mirabegron|Men taking 200 mg of mirabegron
2928730|NCT03049462|Placebo Comparator|2-Men-placebo|Men taking placebo
2928731|NCT03049449|Experimental|Cohort 1|All patients will be receiving starting dose: 0.3x106 CAR+ T cells/kg (weight based dosing)(up to a maximum dose of 18x106 CAR+ T cells /kg)infuse on day 0 and Cyclophosphamide: 300 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3 and Fludarabine: 30 mg /m2 IV infusion over 30 minutes administered immediately following the cyclophosphamid on days -5, -4,and -3
2928732|NCT03049436||Patients with program of adapted physical activity|
2928733|NCT03049423||the trial group|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
2928734|NCT03049423||the control group|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
2928735|NCT03049410|Active Comparator|iRARC|Intracorporeal Robot Assisted Radical Cystectomy
2928736|NCT03049410|Active Comparator|Open Radical Cystectomy (ORC)|Open Radical Cystectomy
2928737|NCT03049397|Experimental|Supportive Care (Enhancing Connections program)|Patients and co-parents participate in the Enhancing Connections program consisting of 5 sessions over 1 hour each in the clinic or over the telephone. Session topics include managing cancer-related emotions when talking to children, developing deep listening skills, initiating difficult cancer-related conversations with children, interpreting a child's behavior, recognizing newly acquired gains from the program, and identifying available resources that can be used after program completion.
2928738|NCT03049384|Active Comparator|Traditional Exercise|A classical exercise intervention based on current guidelines for cancer survivors.
2928739|NCT03049384|Experimental|Tailored Exercise|A tailored and individualized exercise intervention based on the results of pre-intervention testing.
2928740|NCT03049371|Other|sample size 100|24 post-op and 100 pre- non- and post-op TGW Study participants need to be of Thai nationality, at least 18 years old, male at birth and self-identify as post-op TGW for participation in study. Signed informed consent is required for study participation
2928741|NCT03049358|Experimental|Arm I (olfactory training)|Patients undergo olfactory training by smelling 4 essential oils in vials (rose, lemon, clove, and eucalyptus) over 15 seconds each, twice daily for 12 weeks.
2928742|NCT03049358|Sham Comparator|Arm II (sham training)|Patients undergo sham training by smelling canola oil in 4 vials over 15 seconds each, twice daily for 12 weeks.
2928743|NCT03049345|Experimental|Sentinel Node Sampling Arm|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Patients will then under regular gastric cancer resection with D2 lymphadenectomy as per routine in our institution.
2928744|NCT03049332|Experimental|All participants|HIV+ Chinese women in China and a family member will be recruited for the pilot testing of the intervention.
2928745|NCT03049319|Experimental|Laser|All six interventions will be applied to patient's back.
2928746|NCT03049306|Placebo Comparator|Placebo Oral Tablet|Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, placebo of propranolol LA (Inderal ® LA) 80 mg will be administered orally at 7 PM, after dinner. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will is crossed-over with active drug 1 week before or after this study night.
2928747|NCT03049306|Active Comparator|Propranolol Oral Tablet|Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, Propranolol LA (Inderal ® LA) 80 mg will be administered orally before sleep, at 7 PM, after dinner. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will be crossed-over to placebo 1 week later. This arm will is crossed-over with active drug 1 week before or after this study night.
2928748|NCT03049306|Active Comparator|CPAP|Subjects will be admitted to the clinical research unit. They will sleep wearing CPAP according to their usual home settings. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides.
2928749|NCT03049293|No Intervention|Control group using Propofol|Sedation will be established by administering 100mcs of Fentanyl, and 1-1.5mg/kg of body weight of Propofol.
2928750|NCT03049293|Experimental|Study group Midazolam group|Sedation will be established by administering Midazolam 1mg, 100mcs of Fentanyl, and 0.5-1mg/kg of body weight of Propofol. Further boluses of Propofol will be given according to the need of the patient and time consumed for oocyte retrieval.
2928751|NCT03049280|Experimental|Transoral robotic surgery|
2928752|NCT03049267|Experimental|Apremilast|N=15
2928753|NCT03049267|Placebo Comparator|Placebo Oral Tablet|N=5
2928754|NCT03049254||Proband|Proband - the person who is the first to present with a diagnosis of AVC
2928793|NCT03049020||Without levator ani avulsion|Patients indicated for sacrocolpopexy for pelvic organ prolapse and without levator ani avulsion
2928755|NCT03049254||Family members (consultands)|First-degree relatives of probands with AVC (who may be living or deceased) In some circumstances where multiple family members are or may be affected, they may be eligible.
2928756|NCT03049241||knee extensors|
2928757|NCT03049241||ankle plantar|
2928758|NCT03049228||Type 2 Diabetic Patients|"Obese (BMI > 27 kg/m2 < 35 kg/m2)~Non-insulin dependent; they must be on sulphonylurea(SU)- derivate or metformin therapy for at least six months with a constant dose for at least two months, or on dietary treatment for at least six months~They should have a (moderately) well-controlled diabetes (defined by a HbA1c<8%)"
2928759|NCT03049228||Obese Subjects|"A similar BMI as T2DM patients (BMI > 27 kg/m2< 35)~Normo-glycemic with fasting plasma glucose levels lower than 6,1 mmol/L."
2928760|NCT03049228||Lean subjects|"BMI between 20-25 kg/m2~Normo-glycemic with fasting plasma glucose levels lower than 6,1 mmol/L."
2928761|NCT03049215|Active Comparator|Lumen Apposing Metal Stent (LAMS)|Subjects randomized to LAMS alone will undergo EUS-guided transmural placement of an Axios stent with a 15 mm luminal diameter.
2928762|NCT03049215|Active Comparator|LAMS plus double pigtail stent|Subjects randomized to LAMS plus double pigtail stent will undergo EUS-guided transmural placement of a single Axios stent with a 15 mm luminal diameter. Following this, wire access across the stent lumen will be achieved using a 0.035 inch hydrophilic guidewire, and a double pigtail plastic biliary stent (6 French, 7 French, or 10 French at the discretion of the endoscopist) will be deployed over the wire.
2928763|NCT03049202||Never-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that have never smoked. Definition of never-smoker: Lifetime consumption of <100 cigarettes. No cigarettes the past 2 years.
2928764|NCT03049202||Ex-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that stopped smoking. Definition of smoking: > 10 pack years. Definition of ex-smoker: > 2 years since smoke cessation.
2928765|NCT03049202||Current-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that are currently smoking. Definition of smoking: > 10 pack years. Definition of current-smoker: > 10/cigarettes/dat the past 6 months.
2928766|NCT03049202||Current-smoker healthy controls|Current-smokers that are otherwise healthy, with normal lung function. Definition of smoking: > 10 pack years. Definition of current-smoker: > 10/cigarettes/dat the past 6 months.
2928767|NCT03049202||Never-smoker healthy controls|Healthy participants that have never smoked. Definition of never-smoker: Lifetime consumption of <100 cigarettes. No cigarettes the past 2 years.
2928768|NCT03049189|Experimental|177Lu-edotreotide PRRT|"177Lu-edotreotide (177Lu-DOTATOC)~A maximum of four cycles of 7.5 ± 0.7 GBq (gigabequerel) 177Lu-edotreotide, each.~Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 4 cycles, 90 days apart (total duration: 270 days/9 months)"
2928769|NCT03049189|Active Comparator|Everolimus|"Everolimus (Afinitor ®)~Doses: 10 mg/d Route of administration: Oral Duration of treatment: Continuous daily treatment until diagnosis of progression or End of Study (EOS)"
2928770|NCT03049176||HIV+male/HIV-female|discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or semen washing
2928771|NCT03049176||HIV+female/HIV-male|discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or artificial vaginal insemination
2928772|NCT03049163|Other|vitrectomy under retrobulbar anesthesia|27-gauge vitrectomy for vitreous floaters under traditional retrobulbar anesthesia
2928773|NCT03049163|Experimental|vitrectomy under topical anesthesia|27-gauge vitrectomy for vitreous floaters under topical anesthesia
2928774|NCT03049137|Experimental|Computer Guided Stent Augmentation|Patients with defective maxillary anterior alveolar ridges requiring implant insertion will have simultaneous implant placement with ridge augmentation using autogenous bone ring graft covering them with Platelet-rich fibrin (PRF) using computer guided stent.
2928775|NCT03049137|Active Comparator|Free Hand Augmentation|Patients with defective maxillary anterior alveolar ridges requiring implant insertion will have simultaneous implant placement with ridge augmentation using Free hand simultaneous implant placement with ridge augmentation and covering them with Platelet-rich fibrin (PRF).
2928776|NCT03049124|Experimental|Exercise|Participants will be asked to complete a 12-week exercise intervention and all study assessments.
2928777|NCT03049111|Experimental|Inhaled Allergen Challenge|Der f sensitive, mild asthmatic subjects will undergo inhaled allergen challenge
2928778|NCT03049098||Success at the simulation|Participant could correctly set the pacing unit to obtain electrical and mechanical pacing of the mannequin in nine minutes.
2928779|NCT03049098||Failed the simulation|Participant could not correctly set the pacing unit to obtain electrical and mechanical pacing of the mannequin in nine minutes.
2928780|NCT03049085|Active Comparator|Aspirin group|a 75 mg uncoated aspirin is administered 2 hours prior to OPCAB
2928781|NCT03049085|Placebo Comparator|Placebo group|75 mg Vit. C is administered 2 hours prior OPCAB
2928782|NCT03049072||Ion beam therapy|All patients treated with ion beam therapy at MedAustron who consent to the participation in the registry.
2928783|NCT03049059|Experimental|Fractional Picosecond 1,064 nm laser and 4% hydroquinone cream|
2928784|NCT03049059|Active Comparator|4% hydroquinone cream alone|
2928785|NCT03049046|Active Comparator|CC100 250 mg|CC100 250 mg once daily by mouth for 7 days
2928786|NCT03049046|Active Comparator|CC100 500 mg|CC100 500 mg once daily by mouth for 7 days
2928787|NCT03049046|Active Comparator|CC100 1000 mg|CC100 1000 mg once daily by mouth for 7 days
2928788|NCT03049046|Placebo Comparator|Placebo|Placebo once daily by mouth for 7 days
2928789|NCT03049033|Experimental|Neurologic Music Therapy (NMT)|Neurologic Music Therapy is a 5-week intervention using different musical instruments and growing tempo to specifically improve fine motor movements.
2928790|NCT03049033|Active Comparator|Occupational Therapy (OT)|Standard of care occupational therapy uses traditional motor training.
2928791|NCT03049033|No Intervention|Waitlist Control|Participants assigned to the waitlist-control condition will not immediately receive services. The no-treatment duration for these participants is yoked to the amount of time their respective NMT- and OT-condition participants receive services (5 weeks). After the wait period, these participants will then be randomized to receive either NMT or OT sessions.
2928792|NCT03049020||With levator ani avulsion|Patients indicated for sacrocolpopexy for pelvic organ prolapse and suffering with levator ani avulsion
2928794|NCT03049007||Partner|Spousal bereaved individuals (age 25-85) in the Central Denmark Region identified through a data extraction of the Danish Civil Registration System (CPR) every sixth week over a period of one year. The group will complete a survey at respectively 2, 6, and 11 months post-loss.
2928795|NCT03049007||Child|Parental bereaved individuals (age 18 or above) that are children of the partner group. The group will complete a survey at respectively 2, 6, and 11 months post-loss.
2928796|NCT03048994|Placebo Comparator|Placebo|Placebo
2928797|NCT03048994|Active Comparator|Glutamine|Glutamine
2928798|NCT03048981|Experimental|Fish oil intake|Healthy volunteers given maximum dose of fish oil for 10 days.
2928799|NCT03048968|Experimental|study group1: elderly adults|Gait, sit-to-stand movement and stair climbing with GEMS and without GEMS
2928800|NCT03048968|Experimental|study group2: stroke patients|Sit-to-stand movement and treadmill gait with GEMS and without GEMS
2928801|NCT03048955|Active Comparator|Indirect Decompression System|Superion® IDS surgical procedure
2928802|NCT03048955|Active Comparator|Direct decompression Surgery|Open, direct decompression surgical procedure
2928803|NCT03048942|Experimental|Cabazitaxel|6 cycles of cabazitaxel intravenous chemotherapy 25mg/m2 on day 1 of each 21 day cycle
2928804|NCT03048942|Active Comparator|Paclitaxel|6 cycles of Paclitaxel intravenous chemotherapy 80mg/m2 on days 1,8 and 15 of each 21 day cycle.
2928805|NCT03048929|Active Comparator|Typhoid Vi Polysaccharide Vaccine|Patients will receive one intramuscular 0.5 mL injection of Typhoid Vi Polysaccharide Vaccine containing 0.025 mg purified Vi polysaccharide.
2928806|NCT03048929|Placebo Comparator|Placebo|Patients will receive one intramuscular 0.5 mL injection of saline placebo.
2928807|NCT03048916|Other|general swallowing therapy|"including:~oral exercises~tactile stimulation~compensatory techniques~swallowing maneuvers"
2928808|NCT03048916|Experimental|the NMES therapy with VitalStim therapeutic device|The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS
2928809|NCT03048916|Active Comparator|: the combined NMES and general swallowing therapies|
2928810|NCT03048903|Experimental|Rheum Palmatum Root|Rheum Palmatum Root is commercially certified rhubarb(Rheum palmatum ,Sichuan origin, provided by the pharmacy of my hospital)
2928811|NCT03048903|Placebo Comparator|Starch Corn|Medical Starch is harmless to people
2928812|NCT03048890||Patients with PAD|Patients with PAD will be in 1 cohort and will have their physical activity levels closely monitored by researchers and physicians.
2928813|NCT03048890||Patients without PAD|Patients without PAD will be allowed to contribute their data to the application, but they will not be as closely monitored.
2928814|NCT03048877|Experimental|Apatinib|Apatinib Mesylate Tablets
2928815|NCT03048877|Placebo Comparator|Placebo|Placebo Tablets
2928816|NCT03048851|Experimental|Low dosage SES group|Low dosage SES group received the low dosage SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
2928817|NCT03048851|Experimental|High dosage SES group|High dosage SES group received the high dosage SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
2928818|NCT03048851|Experimental|VRCIT group|VRCIT group received the VRCIT training in addition to traditional rehabilitation.Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 1.5 hours per day.
2928819|NCT03048851|Experimental|VRCIT+SES group|VRCIT+SES group received the VRCIT and SES training in addition to traditional rehabilitation.
2928820|NCT03048851|Active Comparator|traditional rehabilitation group|Shame control group received the shame SES and traditional rehabilitation programs.
2928821|NCT03048838|Experimental|Risk reduction behavioral intervention|"Couples randomized to the risk reduction behavioral intervention (Conectando Latinos en Pareja) will participate in four weekly sessions with a facilitator. Each session will last 2 hours. Participants will receive information and complete activities, participate in games and discussions to improve their relationship and improve health."
2928822|NCT03048838|Active Comparator|Wellness Promotion Intervention|Couples randomized to the wellness promotion control group will receive the same number of hours of attention as the active experimental group but will not receive the risk reduction intervention. Information presented will consist of topics related to general health.
2928823|NCT03048825|Experimental|Colchicine + Spironolactone +/- SYNERGY Stent|"Colchicine 0.5 mg tablet + Spironolactone 25 mg tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
2928824|NCT03048825|Experimental|Spironolactone +/- SYNERGY Stent|"Colchicine-placebo tablet + Spironolactone 25 mg tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
2928825|NCT03048825|Experimental|Colchicine +/- SYNERGY Stent|"Colchicine 0.5 mg tablet + Spironolactone-placebo tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
2928826|NCT03048825|Placebo Comparator|Placebo +/- SYNERGY Stent|"Colchicine-placebo tablet + Spironolactone-placebo tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
2928827|NCT03048812|Experimental|O`Ring attachment (A)|One arm of our research will receive O`Ring attachment for 3 months and after this period they will recieve the second attachment Equator for more 3 months
2928828|NCT03048812|Experimental|Equator attachment (B)|The second arm of our research will receive Equator attachment for 3 months and after this period they will recieve the second attachement O Ring for more 3 months
2928860|NCT03048565|No Intervention|Usual care|No intervention
2928861|NCT03048565|Experimental|Mindfulness based Stress Reduction|This is an active intervention The MBSR programme is delivered online with weekly telephone and email contact from a trained mindfulness teacher. Participants are encouraged to practice mindfulness exercises and homework between sessions. The online programme was developed be a trained mindfulness teacher.
2928829|NCT03048799|Active Comparator|Radiofrequency on and Kinesiotherapy|The radiofrequency application protocol with CAPENERGY device, which has two electrodes: an active one, which will be introduced into the anal region, using a condom and gel to The emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The temperature used in the treatment will be 41 ° C, which this parameter will be placed in the equipment, maintained for 2 minutes. Five RF sessions will be performed, with a seven-day interval between them. For the application, participants will be placed in lateral decubitus position. The session will be quick, with an average duration of 20 minutes.Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given.
2928830|NCT03048799|Placebo Comparator|Radiofrequency off and Kinesiotherapy|"The patient will be in lateral decubitus, the anal probe of the radiofrequency apparatus will be introduced, with the gel previously heated. The radio frequency will be off.~Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given. In addition, at this point will be advised on the performance of The Knack, which is a pre-contraction of the PA during the performance of some abdominal effort such as coughing, sneezing or laughing."
2928831|NCT03048786|Active Comparator|Control Arm|Participants will receive automated text messages drawn from the script used by SmokefreeTXT.
2928832|NCT03048786|Experimental|Peer Mentoring Arm|Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor.
2928833|NCT03048773|Experimental|shockwave therapy|"0.24mJ/mm2，1600 shots over 8 assigned sites of single knee with jelly between applicator pad (20) and handpiece~Physical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
2928834|NCT03048773|Placebo Comparator|placebo|"0.24mJ/mm2，1600 shots over 8 assigned sites of single knee without jelly between applicator pad (20) and handpiece~Physical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
2928835|NCT03048760|Experimental|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scan & 1 after approx. 2 weeks of radiotherapy treatment.
2928836|NCT03048747|Experimental|Tolvaptan|Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
2928837|NCT03048734||Group (1): Men with Nocturia ≥2.|
2928838|NCT03048734||Group (2): Men with no nocturia (0-1).|
2928839|NCT03048721|Experimental|Psoriasis|Participants with psoriasis will undergo both skin tape stripping and punch biopsy.
2928840|NCT03048721|Experimental|Control|Participants without psoriasis will undergo both skin tape stripping and punch biopsy.
2928841|NCT03048708|Experimental|Obese patients treated with bariatric surgery|Patients with morbid obesity who were eligible for and willing to have bariatric surgery performed
2928842|NCT03048708|No Intervention|Obese patients not treated with bariatric surgery|Age and BMI matched patients with morbid obesity who either were not eligible for or were not willing to have bariatric surgery performed - no sufficient number of matched patients has completed the study; the arm of obese patients not treated with bariatric surgery has been discarded for the purpose of the analyses
2928843|NCT03048695|Experimental|Goal Management Training|Cognitive rehabilitation
2928844|NCT03048695|No Intervention|Waiting list|
2928845|NCT03048682|Experimental|Early Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in this group will have their repeat voiding trial on post-op day #2, 3, or 4"
2928846|NCT03048682|Active Comparator|Late Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in this group will have their repeat voiding trial on post-op day #7 or after. This is our current practice."
2928847|NCT03048669|Experimental|Continuous quality improvement (CQI)|Quality improvement initiatives implemented at facility level using participatory data-driven approaches and on-site monitoring and supervisory support
2928848|NCT03048669|No Intervention|Standard of care|In health districts randomized to standard of care, the same strengthening of the data collection system for the monitoring of indicators as in the intervention group will be implemented. At least once a month, a study staff will visit each clinics irrespective of their randomization to extract information for the mother-infant register into an electronic database. No report on indicators will be produced for those clinic for the duration of the study. Staff from clinics and health district bureau in the standard of care group will not be associated with the quarterly review of the indicators. The study will not influence with any other HIV service provision activity in the standard of care group.
2928849|NCT03048656|Experimental|Individuals with leg-length discrepancy|Patients of Department of Paediatric Orthopaedics and Traumatology, Poznan University of Medical Sciences diagnosed with leg-length discrepancy. The examination of participants included a measurement of the length of lower limbs and the weight distribution as well as performing the static posturography.
2928850|NCT03048656|Active Comparator|control group|The group with healthy individuals; without leg-length discrepancy. The examination of participants included a measurement of the weight distribution as well as performing the static posturography.
2928851|NCT03048643|No Intervention|Standard of Care|Subjects will receive medication-assisted treatment for opioid use disorder and will complete IV antibiotic therapy for infective endocarditis according to usual care.
2928852|NCT03048643|Experimental|Outpatient Parenteral Antibiotic Therapy|Subjects will receive medication-assisted treatment for opioid use disorder and will complete IV antibiotic therapy via outpatient parenteral antibiotic therapy (OPAT).
2928853|NCT03048630|Experimental|Knowledge and behavioral intervention|Owner and worker trainings regarding knowledge and behaviors associated with workplace chemical exposure reduction
2928854|NCT03048630|Other|Delayed intervention|Delayed knowledge and behavioral intervention
2928855|NCT03048604|Experimental|Genio(TM) system therapy|
2928856|NCT03048591|Experimental|Electroacupuncture group|
2928857|NCT03048591|No Intervention|control group|
2928858|NCT03048578|Experimental|Saxenda|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
2928859|NCT03048578|Placebo Comparator|Placebo|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
2928862|NCT03048552|No Intervention|Standard of Care|This arm is comprised of caregiver-youth dyads randomized to work with the youth's probation officer as usual to link youth to substance use services.
2928863|NCT03048552|Experimental|Family CONNECT|This arm is comprised of caregiver-youth dyads randomized to work with linkage specialists to link youth to substance use services.
2928864|NCT03048539||Transoral endoscopic thyroidectomy|Patient who fit with the eligible criteria and choose endoscopic thyroidectomy by himself.
2928865|NCT03048539||Conventional thyroidectomy|Patient who fit with the eligible criteria and choose conventional thyroidectomy by himself.
2928866|NCT03048526|Experimental|NovaTears®|
2928867|NCT03048526|Active Comparator|Hydrabak®|Unpreserved sodium chloride (0.9%) eye drops in ABAK® system
2928868|NCT03048500|Experimental|Treatment (metformin hydrochloride, nivolumab)|Patients receive metformin hydrochloride PO once QD on days -7 to -1 and 1-28. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4, then over 60 minutes on day 1 beginning course 5. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.
2928869|NCT03048474|Experimental|Nivolumab and Ipilimumab|Nivolumab will be administered at a fixed dose of 240 mg every 2 weeks for a maximum period of 2 years. Nivolumab will be given in combination with ipilimumab on week 1, 7, 13 and 19. Ipilimumab will be administered at the dose of 1 mg/Kg.
2928870|NCT03048461|Experimental|Platelet Rich Plasma|Participants will receive intradermal injections autologous PRP to an area (100cm2) of alopecia on the scalp.Two treatments will be performed 3 months apart
2928871|NCT03048461|Placebo Comparator|Placebo (sterile saline)|Participants will receive intradermal injections of sterile normal saline to an area (100cm2) of alopecia on the scalp. Two treatments will be performed 3 months apart
2928872|NCT03048448|Experimental|Fevipiprant 450mg|450mg Film Coated Tablet
2928873|NCT03048435||Cervical Cancer Patients|Adult, English-speaking cervical cancer patients, who have been treated with curative intent chemo-radiotherapy.
2928874|NCT03048435||Oncologist|Oncologists who treat cervix cancer, with at least one consenting patient enrolled in the study.
2928875|NCT03048422|Experimental|Arm 1: Maternal DTG+FTC/TAF|Mothers will receive dolutegravir (DTG) plus emtricitabine/tenofovir alafenamide (FTC/TAF) during pregnancy, through delivery, and for 50 weeks postpartum.
2928876|NCT03048422|Experimental|Arm 2: Maternal DTG+FTC/TDF|Mothers will receive DTG plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.
2928877|NCT03048422|Active Comparator|Arm 3: Maternal EFV/FTC/TDF|Mothers will receive efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.
2928878|NCT03048409||Enteral tube fed adults|Enteral formula
2928879|NCT03048396|Experimental|Uterus transplantation|
2928880|NCT03048383|Active Comparator|OnabotulinumtoxinA Injectable Product|onabotulinumtoxinA (Botox®, Allergan) administered for n=15 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
2928881|NCT03048383|Active Comparator|AbobotulinumtoxinA Injectable Product|abobotulinumtoxinA (Dysport®, Medicis) administered for n=13 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
2928882|NCT03048383|Active Comparator|Incobotulinumtoxin A Injectable Product|incobotulinumtoxinA (Xeomin®, Merz) administered for n=10 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
2928883|NCT03048370|Experimental|Left body temperature VS|Left body temperature (37°C) vestibular stimulation
2928884|NCT03048370|Experimental|Right body temperature VS|Right body temperature (37°C) vestibular stimulation
2928885|NCT03048370|Experimental|Left warm CVS|Left warm (44°C) caloric vestibular stimulation
2928886|NCT03048370|Experimental|Left cold CVS|Left cold (30°C) caloric vestibular stimulation
2928887|NCT03048370|Experimental|Right cold CVS|Right cold (30°C) caloric vestibular stimulation
2928888|NCT03048370|Experimental|Right warm CVS|Right warm (44°C) caloric vestibular stimulation
2928889|NCT03048370|Experimental|Left ice cold CVS|Left ice cold (4°C) caloric vestibular stimulation
2928890|NCT03048370|Experimental|Right ice cold CVS|Right ice cold (4°C) caloric vestibular stimulation
2928891|NCT03048357|Active Comparator|Freedom Bed|Freedom Bed Continuous Lateral Rotation Therapy System
2928892|NCT03048357|Other|Standard Hospital Bed & Protocol|Standard Hospital Bed with manual caregiver re-positioning every 2 hours
2928893|NCT03048344|Experimental|Part 1|Subjects will receive oral ORH-2014 at a planned starting dose of 5 mg once daily (QD) in the fasted state. If escalation criteria are met, the administered dose will increase by 5 mg increments to a maximum of 50 mg QD. The starting daily dose is approximately half the typical IV dose (0.15 milligram per kilogram [mg/kg]) extrapolated to a 70-kg person.
2928894|NCT03048344|Experimental|Part 2|Subjects will receive a daily oral dose of ORH-2014 at the recommended dose identified in Part 1. ORH-2014 will be administered in the fasted state.
2928895|NCT03048331|Experimental|Functional Electrical Stimulation|"Before surgery, the donor muscle is stimulated via surface electrodes in a loaded position or against resistance 3 times a week for 30 minutes.~After surgery, the patients receive the same standard therapy as the control group. The electrical stimulation is performed once a day in combination with standard therapy for 30 minutes against gravity or resistance or in a loaded position."
2928896|NCT03048331|No Intervention|Standard therapy|Postoperatively, 20 min passive and active movements of the hand or arm are applied manually by a therapist. Additionally, the patients actively perform the same exercises once a day for 20 min. The movements are based on a standardised post-surgical treatment protocol.
2928897|NCT03048318|Experimental|Arterial and Portal Flushing of Graft|Back table flush of portal vein and graft artery
2928898|NCT03048318|Active Comparator|Portal Flushing only of Graft|Back table flush of portal vein only
2928902|NCT03048279||Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2|Consented individuals will be interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.
2928903|NCT03048279||Close Relatives of Registered MDACC MEN Patients|Participants will be asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail.
2928904|NCT03048266||MEN1 Patients Who Have Developed Aggressive PNETs-Cases|
2928905|NCT03048266||MEN1 Patients Who Have Developed Non-Aggressive PNETs-Controls|
2928906|NCT03048240|Experimental|"perPDT"|Single arm : per-operative PhotoDynamic Therapy (perPDT) during the surgery of Glioblastoma excision.
2928907|NCT03048227|Experimental|Continuous Glucose Measurement (CGM)|Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
2928908|NCT03048227|No Intervention|Control|Patients will manage their diabetes as usual as recommended by their care team.
2928909|NCT03048214|Sham Comparator|General Anaesthesia|Patients would receive routine general anaesthesia for their distal radial fracture surgery
2928910|NCT03048214|Experimental|Regional Anaesthesia|Patients would receive routine infraclavicular nerve block for their distal radial fracture surgery
2928911|NCT03048201|Other|Physica KR|Subjects that receive the Physica Kinematic Retaining Knee System
2928912|NCT03048201|Other|Physica CR|Subjects that receive the Physica Cruciate Retaining Knee System
2928913|NCT03048201|Other|Physica PS|Subjects that receive the Physica Posterior Stabilized Knee System
2928914|NCT03048188|Experimental|Burn with or without split-skin graft|Second degree burns and third degree burns with split-skin graft that need wound dressings
2928915|NCT03048175|Experimental|Cases: wisdom tooth pathology|Subjects affected by bilateral wisdom tooth pathology, undergoing surgical removal
2928916|NCT03048175|No Intervention|Controls: no wisdom tooth pathology|Subjects showing agenesia/previous extraction/no symptoms of the lower third molars.
2928917|NCT03048162|Active Comparator|sodium chloride|0.9% isotonic sodium chloride, 500 ml, one package in 30 minutes
2928918|NCT03048162|Active Comparator|Hydroxyethylstarch|6% hydroxyethylstarch, 500 ml, one package in 30 minutes
2928919|NCT03048162|Active Comparator|Ringer-Lactate Infusion Solution Bag|Ringer's lactate, 500 ml, one package in 30 minutes
2928920|NCT03048136|Experimental|Flat-Dose|Nivolumab flat dose + Ipilimumab
2928921|NCT03048136|Experimental|Weight-Based Dose|Nivolumab weight-based dose + Ipilimumab
2928922|NCT03048123|Experimental|Hepatic arterial infusion chemotherapy|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: Folfox Protocol. Hepatic intraarterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
2928923|NCT03048123|Active Comparator|Transarterial chemoembolization|Procedure/Surgery: Transarterial chemoembolization Drug: TACE Drug Protocol. Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA)
2928924|NCT03048110|Experimental|ODM-201|All subjects will receive a single dose of BAY1841788 (ODM-201) (600 mg) in the first treatment period of the study, then all subjects will receive twice daily 200 mg itraconazole on 1 day and once daily 200 mg itraconazole for the following 6 days and a single dose of BAY1841788 (ODM-201) (600 mg) in the second treatment period, then all subjects will receive once a day 600 mg rifampicin for 10 days and a single dose of BAY1841788 (ODM-201) (600 mg) in the third treatment period
2928925|NCT03048097|Experimental|All Participants|Subjects with high-likelihood of cardiac sarcoidosis.
2928926|NCT03048084|Active Comparator|Levetiracetam|Patients in this treatment arm will receive levetiracetam monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d levetiracetam in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d levetiracetam. In step 4, levetiracetam is increased to 2x1500mg/d. In the fifth treatment step, patients will receive 2x1500 mg/d levetiracetam, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.
2928927|NCT03048084|Active Comparator|Valproic acid|Patients in this treatment arm will receive valproic acid monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d valproic acid in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d valproic acid. In step 4, valproic acid dosage is increased to a maximum of 2x1250mg/d. In the fifth treatment step, patients will receive 2x1250mg valproic acid, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.
2928928|NCT03048071||Homograft in pulmonary position replacement|All patients having had the replacement of an homograft in pulmonary position between January 1999 and October 2016, within the Queen Fabiola Children Hospital of Brussels, Belgium.
2928929|NCT03048071||Contegra conduct replacement|All patients having had the replacement of a Contegra conduct between January 1999 and October 2016, within the Queen Fabiola Children Hospital of Brussels, Belgium.
2928930|NCT03048058|Experimental|brimonidine topical gel 0.33% & survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
2928931|NCT03048058|Active Comparator|brimonidine topical gel 0.33% & SOC|Topical drug and standard of care follow-up, no weekly survey; only survey during 3 month and 6 month visits
2928932|NCT03048045||Supportive Periodontal Treatment (SPT)|"at least 18 years old.~periodontal treatment (antiinfective therapy with subgingival debridement under local anesthesia and if required periodontal surgery) at the Dept. of Periodontology starting after April 2005 durchgeführt.~complete periodontal charting (PPD and PAL-V at 6 sites per tooth, furcation involvement [Hamp et al. 1975] at all furcation sites of multi-rooted teeth) prior to treatment (baseline, T0) and after completion of active periodontal treatment (APT) (reevaluation 1 or 2/start of supportive periodontal therapy, T1)~radiographs of all teeth (periapical radiographs or panoramic radiograph) from baseline~written informed consent"
2928933|NCT03048032||Acute heart failure patients|Adult patients (18 years and older) who are admitted to the emergency department (Vilnius University Hospital Santariškių Klinikos and Hospital of Lithuanian University of Health Sciences Kauno Klinikos) due to acute dyspnea and have an adjudicated diagnosis of acute heart failure. Blood sampling and echocardiography examination will be performed.
2928934|NCT03048032||Control group|Patients who are admitted to the emergency departments of participating centers due to acute dyspnea with an adjudicated diagnosis other than heart failure (pulmonary causes of dyspnea such as pulmonary embolism, acute infections, cancer and other reasons). Blood sampling and echocardiography examination will be performed.
2928935|NCT03048019||Tirofiban Therapy|
2928936|NCT03048019||Cangrelor Therapy|
2928937|NCT03048006||All included patients|All included patients underwent MRI with Dotarem
2928938|NCT03047993|Experimental|CB-839 + Azacitidine|"Phase 1b: Participants take CB-839 at Starting Level by mouth 2 times per day while on the study.~Participants receive Azacitidine by vein or as an injection under the skin about 1 hour after taking CB-839 on Days 1-7 of every 28 day cycle.~Phase II: Participants receive CB-839 at RP2D Level by mouth 2 times per day of every 28 day cycle while on the study.~Participants receive Azacitidine by vein or as an injection under the skin about 1 hour after taking CB-839 on Days 1-7 of every 28 day cycle.~Participants continue on study therapy unless they have evidence of progressive disease or unacceptable toxicity."
2928939|NCT03047980|Experimental|Sirolimus|All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis. The drug will be taken for six months.
2928940|NCT03047967|Experimental|PTSE|Prenatal tobacco smoke exposed newborns. Lung function test Nasal brushing
2928941|NCT03047967|Experimental|control|Prenatal tobacco smoke non exposed newborns Lung function test Nasal brushing
2928942|NCT03047954|Experimental|Broncho-Vaxom|1 capsule (3.5 mg) per day, administered over 9 months
2928943|NCT03047954|Placebo Comparator|Placebo|Matching placebo capsule
2928944|NCT03047941||All patients|All patients included in the present study
2928945|NCT03047928|Experimental|Patient group|"All patients receive the same treatment. Patients included in the protocol are treated with Nivolumab according to usual guidelines, implying outpatient IV infusions of 3 mg/kg biweekly until progression.~The vaccine is administered on the same day as the administration start of Nivolumab. The vaccination is given biweekly for a total of 6 times, then every fourth week up to week 47, whereupon no additional vaccines will be given. In total, 15 vaccines will be administered. A vaccine consist of 100 μg IDO long peptide, 100 μg PD-L1 long1 peptide and 500 microliters Montanide as adjuvant.~Patients who complete all vaccines will continue Nivolumab treatment after standard guidelines."
2928946|NCT03047915|No Intervention|Control Group|All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects randomized to the control group will continue the ED visit as usual.
2928947|NCT03047915|Experimental|Music Group|All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects who are randomized to receive a music-listening intervention will listen to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones. An hour after enrollment, participants will be asked the same questions assessing anxiety and pain, and will also have blood pressure and heart rate taken again.
2928948|NCT03047902|Active Comparator|Parent Present|"The adolescents in group 1 (Parent Present) will be aware that their parents will be able to share the information on the questionnaire, but they will be assured of the confidentiality of the CO test. This will also be explained to the parent.~Intervention: Parents will be present for the questionnaire but not for the CO test."
2928949|NCT03047902|Active Comparator|Parent Absent|"The adolescents in group 2 (parents not present) will be assured of the confidentiality of the questionnaire and CO test. The confidentiality of the test will also be explained to the parent.~Intervention: Parents will not be present for the questionnaire or the CO test"
2928950|NCT03047876||All neonates and infants undergoing aortic arch surgery|Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
2928951|NCT03047863|Experimental|Repair Control EGF®|EGF cream was applied. Half of face was treated with emollient containing EGF.
2928952|NCT03047863|Placebo Comparator|Cream without rhEGF|Placebo cream without EGF was applied. The other half of face was treated with only emollient which was not containing EGF.
2928953|NCT03047850||Study Group|All patients included in this study.
2928954|NCT03047837|Placebo Comparator|Arm A|placebo Aspirin (1 tablet daily) + placebo Metformin (1 tablet BID)
2928955|NCT03047837|Experimental|Arm B|placebo Aspirin (1 tablet daily) + active Metformin (850 mg, 1 tablet BID)
2928956|NCT03047837|Experimental|Arm C|active Aspirin (100 mg, 1 tablet daily) + placebo Metformin (1 tablet BID)
2928957|NCT03047837|Experimental|Arm D|active Asprin (100 mg, 1 tablet daily) + active Metformin (850 mg, 1 tablet BID)
2928958|NCT03047824|Other|Continuous monitoring-guided therapy|Healthcare providers were allowed to use the blood glucose values displayed on the intravascular continuous monitoring to adapt insulin therapy
2928959|NCT03047824|Other|Standard of care|Healthcare providers used the usual intermittent method to adapt insulin therapy; the blood glucose values measured by the intravascular continuous monitoring were not displayed but recorded. Usual care involves the adjustment of insulin infusion based on BG values measured with a blood gas analyser 4-6 times per day.
2928960|NCT03047811|Experimental|TCR - T cell therapy|Peripheral blood mononuclear cells collected: draw 100-150 ml of peripheral blood in patients and separate of the peripheral blood mononuclear cells, the total number of cells 1.5 * 10 ^ 7 / kg - 1 * 10 ^ 8 / kg Fludarabine 25 mg/m2 + NS 250 ml, ivgtt qdx5d, CTX 60 mg/kg + NS 250 ml, ivgtt qd x2d, should be in front of the TCR - T cells infusion of 4 days reinfusion the total number of T cells （1* 10 ^ 8 / kg - 10 * 10 ^ 8 / kg） in 3 days , infusion 10-15 minutes, should not be more than 20 minutes.
2928961|NCT03047798|Experimental|aqueous single-phase mouthrinse|This contained sodium fluoride and the additional ingredients of bamboo salt, magnolia bark and centella asiatica extracts in aqueous single-phase form.
2928962|NCT03047798|Experimental|oil-water two-phase mouthrinse|This contained sodium fluoride and the additional ingredients of bamboo salt, magnolia bark and centella asiatica extracts in oil-water two-phase form.
2928963|NCT03047798|Placebo Comparator|Control|The control mouthrinse only contained sodium fluoride
2928964|NCT03047785||Hospital population|All patients who have had a biochemistry blood tests requested at the trust will have a troponin blood level determined.
2928965|NCT03047772|Placebo Comparator|Phase A: Atorvastatin|Atorvastatin routine dose + placebo transplantation
2928966|NCT03047772|Experimental|Phase A: Low dose BMMSC|Atorvastatin routine dose + low dose BMMSC Transplantation
2928967|NCT03047772|Experimental|Phase A: Middle dose BMMSC|Atorvastatin routine dose + middle dose BMMSC Transplantation
2928968|NCT03047772|Experimental|Phase A: High dose BMMSC|Atorvastatin routine dose + high dose BMMSC Transplantation
2928969|NCT03047772|Placebo Comparator|Phase B: Atorvastatin|Atorvastatin routine dose + placebo transplantation
2928970|NCT03047772|Active Comparator|Phase B: Atorvastatin+Transplantation|Atorvastatin routine dose+ Optimal dose BMMSC Transplantation
2928971|NCT03047772|Placebo Comparator|Phase B: Intensive Atorvastatin|Atorvastatin Intensive dose + placebo transplantation
2928972|NCT03047772|Experimental|Phase B: Intensive Atorvastatin+Transplantation|Atorvastatin Intensive dose + Optimal dose BMMSC Transplantation
2928973|NCT03047759|Active Comparator|Intervention A|water flosser
2928974|NCT03047759|Active Comparator|Intervention B|air floss
2928975|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF with trilineage aplasia|Patients with acquired or inherited bone marrow failure (iBMF) with trilineage aplasia will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
2928976|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF w/o trilineage aplasia|Patients with acquired or inherited bone marrow failure (iBMF) without trilineage aplasia will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
2928977|NCT03047733|Active Comparator|continuously excimer laser treatment|"In this group, lesions treated twice weekly through out the whole trial length (9 months).~Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months)."
2928978|NCT03047733|Experimental|cyclic excimer laser treatment|"In this group, one cycle consists of a 2-month treatment period (on) and a consecutive 1-month intermission period (off).~Total 3 cycles of cyclic treatment through out the whole trial length (9 months). During the treatment period, lesions treated twice weekly.~Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months)."
2928979|NCT03047720|Other|One|The therapeutic phase of this study for the participant in Arm One will be: 6 weeks of behavioral modifications plus the Lully device (S1), followed by 6 weeks of behavioral modifications only without the device (S2)
2928980|NCT03047720|Other|Two|The therapeutic phase of this study for the participant in Arm Two will be: 6 weeks of behavioral modifications only without the device (S2), followed by 6 weeks of behavioral modifications plus use of the Lully device(S1)
2928981|NCT03047707|Experimental|S-Shearwave and TE|
2928982|NCT03047694|Experimental|Tablet group|Patients will continue their usual care (1 or more sessions of weekly speech therapy) and will benefit from the therapy on tablet for 3 months.
2928983|NCT03047694|Active Comparator|Control group|Patients will continue their usual care (1 or more sessions of weekly speech therapy)
2928984|NCT03047681||Study group|patients undergoin transcatheter aortic valve implantation
2928985|NCT03047681||Control group|patient undergoing diagnostic coronary angiography
2928986|NCT03047668|Active Comparator|low-carb with PUFA|49 weeks of hypo- to isocaloric low-carb diet (< 40 EI% carbs), amplified with walnuts and walnut-sunflower muffins
2928987|NCT03047668|Active Comparator|low-carb without PUFA|49 weeks of hypo- to isocaloric low-carb diet (< 40 EI% carbs), without walnuts / walnut-sunflower muffins
2928988|NCT03047668|Active Comparator|low-fat with PUFA|49 weeks of hypo- to isocaloric low-fat diet (< 30 EI% fat), amplified with walnuts and walnut-sunflower muffins
2928989|NCT03047668|Active Comparator|low-fat without PUFA|49 weeks of hypo- to isocaloric low-fat diet (< 30 EI% fat), without walnuts / walnut-sunflower muffins
2928990|NCT03047655|Active Comparator|Physical activity only|pedometers have to be used throughout all days; daily amount of steps is reported via App or website; 10000 steps are defined as daily goal
2928991|NCT03047655|Active Comparator|Physical activity + Dietary treatment|"pedometers have to be used throughout all days; daily amount of steps is reported via App or website; 10000 steps are defined as daily goal~additionally, subjects will be provided with one healthy muffin per day (450 kcal; low GI, high load of PUFA and isomaltulose) over 6 weeks"
2928992|NCT03047629|Experimental|ENT-01|ENT-01 at a to-be-determined dose taken by mouth every day upon awakening.
2928993|NCT03047629|Placebo Comparator|Placebo Comparator|Placebo to be taken by mouth every day upon awakening
2928994|NCT03047603||Healthy control|The healthy control group consist of people undergoing routine medical examination. Serum samples are collected.
2928995|NCT03047603||Metastatic liver cancer patients|Serum samples are collected.
2928996|NCT03047603||Hepatocellular carcinoma patients|Serum samples are collected before liver resection.
2928997|NCT03047603||Chronic liver disease patients|This group is comprised of liver cirrhosis and chronic hepatitis B patients. The diagnosis of liver cirrhosis are based on triple-phase contrast enhanced computed tomography, magnetic resonance imaging.
2928998|NCT03047590|Experimental|Choice-No Affect|These participants self-select (i.e., choose) their exercise intensity with the goal of walking 30-60 minutes on most days of the week. For safety reasons, they are instructed not to exceed 59% of their heart rate reserve. This is choice-based exercise intensity with no focus on positive affect.
2928999|NCT03047590|Experimental|Choice-Affect|These participants self-select their exercise intensity with the goal of walking 30-60 minutes on most days of the week. They're instructed to choose the intensity that makes them feel the best. For safety reasons, they are instructed not to exceed 59% of their heart rate reserve. This is choice-based exercise intensity with a focus on positive affect.
2929000|NCT03047590|Experimental|No Choice-Affect|"These participants regulate their exercise intensity using their heart rate, with the goal of walking 30-60 minutes on most days of the week. The intensity is moderate according to the American College of Sports Medicine (40-59% of their heart rate reserve). Meanwhile, these participants are instructed to focus on the good feelings that come with exercise. this is heart rate-based exercise intensity with a focus on positive affect."
2929001|NCT03047590|Active Comparator|No Choice-No Affect|"These participants regulate their exercise intensity using their heart rate, with the goal of walking 30-60 minutes on most days of the week. The intensity is moderate according to the American College of Sports Medicine (40-59% of their heart rate reserve). This is heart rate-based exercise intensity with no focus on positive affect."
2929002|NCT03047577|No Intervention|Standard care arm|Treatment as usual and discussion according to the treating clinicians in the hospital
2929003|NCT03047577|Other|Intervention arm|Patients receive a brief intervention, including a short discussion, opportunity for an appointment with a social worker and written information about effects of alcohol on health and contact information for seeking additional support
2929004|NCT03047564|Experimental|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
2929005|NCT03047564|Active Comparator|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
2929006|NCT03047551|Active Comparator|Transabdominal Sonography|"Subjects will receive transabdominal sonography using a standard ultrasound device to determine medical abortion eligibility.~A transabdominal ultrasound is used to look at the pelvic organs. Gel is placed on your abdomen. Then a small, handheld unit called a transducer is gently moved around to view the pelvic organs. The transducer sound waves make a picture on the TV screen."
2929007|NCT03047551|Active Comparator|Transvaginal Sonography|"Subjects will receive transvaginal sonography using a standard ultrasound device to determine medical abortion eligibility.~Transvaginal ultrasound is an examination of the female pelvis and urogenital tract (kidneys and bladder). It differs from an abdominal ultrasound as it looks at the pelvic organs from inside the vagina."
2929008|NCT03047538|Active Comparator|Free combination|Free combination of atorvastatin, perindopril and amlodipine will be given for 8 weeks. After 8 weeks free combination will be changed to fixed combination. The dose of each drug will be selected according to clinical judgement of each investigator, but can not be changed during the coarse of the study.
2929009|NCT03047538|Active Comparator|Fixed combination|Fixed combination of atorvastatin, perindopril and amlodipine will be given for 8 weeks. After 8 weeks fixed combination will be changed to free combination. The dose of each drug will be selected according to clinical judgement of each investigator, but can not be changed during the coarse of the study.
2929010|NCT03047525|No Intervention|control group|patients will just regularly chemotherapy
2929011|NCT03047525|Experimental|DC-CIK and CIK Immunotherapy|patients will receive chemotherapy with 4 cycles of DC-CIK treatment and 4 cycles of CIK treatment .
2929012|NCT03047512|Experimental|Internet-based program|The internet based program includes the following modules: (1) information and psychoeducational material, (2) symptom monitoring with personalized automatic feedback, (3) forum (peer support moderated by mental health professionals) and (4) chat (individualized support by mental health professionals). It also considers (5) the referral to face-to-face treatment of cases with symptoms that require it. (6) In addition to the web page in the institutions, there will be a monthly health promotion booth during breaks.
2929013|NCT03047512|No Intervention|Control Group|The control group will receive two psychoeducational workshops / conferences. In addition, the adolescents in the control group can participate in the monthly health promotion booths offered by the program.
2929017|NCT03047473|Experimental|patients with newly diagnosed GBM receiving standard therapy|single arm study open label single dose avelumab will be added to standard therapy to all patients
2929018|NCT03047460||healthy|healthy volunteers, 18 to 58 years old, with no neurological disease that could affect evoked potential responses
2929019|NCT03047460||multiple sclerosis|"All types of Multiple sclerosis patients:~Aged 18 to 58 years old, inclusive, at the time of informed consent.~Expanded Disability Status Scale (EDSS) 0.0 to 6.5.~Have measurable responses on both MEP and SSEP in at least one upper and one lower limb. The MEP and SSEP responses do not need to be in the same limb~Have no comorbid condition (ie neuropathy) that could affect testing."
2929020|NCT03047447|Experimental|Ketogenic group|10-week diet with controlled glycemic indices provided for ketogenic group. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
2929021|NCT03047447|Active Comparator|Exercise group|Exercise group maintained normal diet for 10-weeks and exercised 3-5 days per week. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
2929022|NCT03047447|Active Comparator|Non-exercise|Non-exercise group maintained normal diet for 10-weeks with no exercise. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
2929023|NCT03047421||All patients included|For all patients scheduled for an anesthetic preoperative consultation, a comparison of accuracy of DES-OSA and P-SAP scores with PSG (polysomnography) will be performed.
2929024|NCT03047408|Experimental|patients with PD-RBD|"patients with PD-RBD having already underwent vPSG, clinical and neuropsychological in clinical setting or in the study RBHP 2013 DURIF  at least three years ago."
2929025|NCT03047395|Experimental|Risankizumab|Participants will receive risankizumab administered by subcutaneous injection.
2929026|NCT03047382|Active Comparator|Worthing Hospital site|AKI Care bundle instituted at Worthing site
2929027|NCT03047382|No Intervention|Chichester Hospital site|Continues standard care
2929028|NCT03047356|Experimental|"First-person if-then plan"|"Participants are asked to form if-then plans and the instructions are presented in the first person (if I...then I...). Ifs are critical situations, thens are appropriate responses."
2929029|NCT03047356|Experimental|"Second-person if-then plan"|"Participants are asked to form if-then plans and the instructions are presented in the second person (if you...then you...). Ifs are critical situations, thens are appropriate responses."
2929030|NCT03047356|Placebo Comparator|Control|"Participants are presented with ifs (critical situations) and thens but are not asked to form if-then plans."
2929031|NCT03047343||Uni-ventricular reparation|All patients treated with pulmonary artery strapping between 2005 and 2016 at the Queen Fabiola Children Hospital. Patients benefiting from an uni-ventricular reparation.
2929032|NCT03047343||Bi-ventricular reparation|All patients treated with pulmonary artery strapping between 2005 and 2016 at the Queen Fabiola Children Hospital. Patients benefiting from an bi-ventricular reparation.
2929033|NCT03047330|Experimental|Unfragmented sleep|All subjects will receive one dose of Leuprolide Acetate and will have some unfragmented sleep periods.
2929034|NCT03047330|Experimental|Fragmented sleep|All subjects will receive one dose of Leuprolide Acetate and will have some fragmented sleep periods.
2929035|NCT03047317|Experimental|MABp1|
2929036|NCT03047304|Other|Women in risk for preterm labor|Women in risk for preterm labor treated with magnesium.
2929037|NCT03047291|Placebo Comparator|Control group: placebo oral tablet|Placebo tablets. Intervention: 30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
2929038|NCT03047291|Experimental|Test group: probiotic oral tablet|Probiotic tablets (Periobalance®, Sunstar, Switzerland). Intervention: 30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
2929039|NCT03047278|Active Comparator|Control Group|Adult patients (18 - 59 years old) with neuropathic pain of score ≥ 4 that do not use gabapentin are being recruited. All patients are receiving oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting (phase I). To investigate GBP pharmacokinetics, blood samples are being collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients is being collected up to 36 hours after GBP administration. The intensity of pain is being evaluated in each time of blood sampling through the visual analog scale (0-10). In phase II, after 15 days (wash-out) from phase I, cetirizine hydrochloride (10 mg) is being administered orally, twice a day, as pills, for five days. On the last day of cetirizine treatment, an oral single dose of gabapentin (300 mg), as capsule, is being administered. Serial blood and urine samples are being collected up to 36 hours after GBP administration. The intensity of pain is being evaluated in each time of blood sampling.
2929040|NCT03047278|Experimental|Controlled Diabetes Group|Adult patients (18 - 59 years old) with controlled type 2 diabetes (glycated hemoglobin ≤ 7.0%) and diabetic neuropathy of score ≥ 4 that do not use gabapentin are being recruited. All patients are receiving oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting. To investigate GBP pharmacokinetics, blood samples are being collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients is being collected up to 36 hours after GBP administration. The intensity of pain is being evaluated in each time of blood sampling through the visual analog scale (0-10).
2929041|NCT03047278|Experimental|Uncontrolled Diabetes Group|Adult patients (18 - 59 years old) with uncontrolled type 2 diabetes (glycated hemoglobin Adult patients (18 - 59 years old) with controlled type 2 diabetes (glycated hemoglobin ≥ 7.0%) and diabetic neuropathy of score ≥ 4 that do not use gabapentin are being recruited. All patients are receiving oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting. To investigate GBP pharmacokinetics, blood samples are being collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients is being collected up to 36 hours after GBP administration. The intensity of pain is being evaluated in each time of blood sampling through the visual analog scale (0-10).
2929042|NCT03047265|Experimental|Paclitaxel|Paclitaxel plus Cisplatin combine with IMRT
2929043|NCT03047265|Active Comparator|Cisplatin|Cisplatin combine with IMRT
2929310|NCT03045354|Experimental|Mashed potatoes|Eggs with a side of mashed potatoes
2929044|NCT03047252|Experimental|Experimental group|"Home-based rehabilitation sessions performed with the novel digital biofeedback system.~Patients will be instructed to perform exercise sessions in at least 5 days per week, but compliance to this schedule is not mandatory per protocol."
2929045|NCT03047252|Active Comparator|Conventional rehabilitation group|Home-based rehabilitation sessions provided by a Physical Therapist, 3 times a week for 8 weeks. Each session will have a duration of 60 minutes. Patients will be instructed to perform additional unsupervised sessions in at least two other days, but compliance to these extra sessions is not mandatory per protocol.
2929046|NCT03047239|Experimental|Open angle glaucoma|SENSIMED Triggerfish
2929047|NCT03047213|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2929048|NCT03047187||ACLR patients|anterior cruciate ligament reconstruction patients
2929049|NCT03047174|Experimental|Arm A: Treatment with Mepitel® Film|"Arm A:~Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing."
2929050|NCT03047174|Active Comparator|Arm B: Treatment with Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.~Mometasone furoate cream is used in the treatment of inflammatory skin disorders. In terms of steroid strength, it is more potent than hydrocortisone, and less potent than dexamethasone. It reduces inflammation by causing several effects such as reversing the activation of inflammatory proteins, activating the secretion of anti-inflammatory proteins, stabilizing cell membranes, and decreasing the influx of inflammatory cells. The exact anti-inflammatory mechanism of action is unknown."
2929051|NCT03047161||High-risk pregnancy|abnormal fetal heart rate or rhythm or risk of abnormal fetal heart rate or rhythm
2929052|NCT03047161||Uncomplicated pregnancy|uncomplicated pregnancy
2929053|NCT03047148||Regional Anesthesia|Hospital records from patients who have undergone surgery in regional anesthesia.
2929054|NCT03047148||General Anesthesia|Hospital records from patients who have undergone surgery in General anesthesia.
2929055|NCT03047135|Experimental|Olaparib 300 mg BID|Patients will be administered olaparib orally twice daily at 300mg bid continually. Two 150mg of olaparib tablets should be taken twice daily, approximately 12 hours apart with one glass of water.
2929056|NCT03047109|Active Comparator|Group P|Patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
2929057|NCT03047109|Active Comparator|Group E|Patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
2929058|NCT03047096|Experimental|HA & CS group|hyaluronic acid and corticosteroids
2929059|NCT03047096|Experimental|HA group|hyaluronic acid
2929060|NCT03047083||IC eligible AML patients with FLT3 mutation|Newly diagnosed AML patients
2929061|NCT03047083||IC ineligible patients with FLT3 mutation|Newly diagnosed AML patients
2929062|NCT03047083||AML patients after R/R with FLT3 mutation|R/R are relapse/refractory patients
2929063|NCT03047083||IC eligible patients without FLT3 mutation|Newly diagnosed AML patients
2929064|NCT03047083||IC ineligible patients without FLT3 mutation|Newly diagnosed AML patients
2929065|NCT03047083||AML patients after R/R without FLT3 mutation|R/R are relapse/refractory patients
2929066|NCT03047070|Active Comparator|Lidocaine|IV Lidocaine infusion
2929067|NCT03047070|Placebo Comparator|Control|IV normal saline infusion
2929068|NCT03047057|Experimental|Lidocaine|IV Lidocaine infusion
2929069|NCT03047057|Placebo Comparator|Control|IV normal saline infusion
2929070|NCT03047044|Active Comparator|Conventional PCA mode|(Mode setting; total volume: 140 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 15 minutes)
2929071|NCT03047044|Experimental|Optimizing B.I (New) PCA mode|(Mode setting; total volume: 140 ml, flow rate: changable by patients' requirement, bolus volume: 0.5 ml, and LOT: 15 minutes)
2929072|NCT03047031||Group A|Patients who started treatment with nintedanib after 23rd January, 2017 and have permanently discontinued the drug (as decided by the investigator) at the time of participation in the active surveillance.
2929073|NCT03047031||Group B|Patients who started treatment with nintedanib after 23rd January, 2017 and are continuing the drug at the time of participation in the active surveillance.
2929074|NCT03047031||Group C|Patients who have been newly prescribed nintedanib at the time of participation in the active surveillance
2929075|NCT03047018|Experimental|CHANGE Program|Participants with ASD will complete the The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) program.
2929076|NCT03047005|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
2929077|NCT03047005|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
2929078|NCT03046992|Experimental|YH25448|"Dose Escalation Phase: Consists of 7 Cohorts~Dose Expansion Phase: Consists of 5 Cohorts~Dose Extension Phase: Consists of 2 Cohorts"
2929079|NCT03046979|Experimental|Apatinib|a molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
2929080|NCT03046966|Other|Intervention Control: No Training|Does not receive hands-on intubation training in the Simulation Lab.
2929081|NCT03046966|Other|Intervention: Receives Training|Receives hands-on intubation training in the Simulation Lab.
2929082|NCT03046953|Experimental|Avleumab|Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days.
2929083|NCT03046940|No Intervention|Control group|No communication with a doctor
2929084|NCT03046940|Experimental|Patient-centered|Participants communicate with a doctor that uses a patient-centered style of communication
2929085|NCT03046940|Experimental|Doctor-centered|Participants communicate with a doctor that uses a doctor-centered style of communication
2929311|NCT03045354|Experimental|French fries|Eggs with a side of French fries
2929086|NCT03046927|Experimental|Ergocalciferol|Oral administration of 50,000 IU of ergocalciferol one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
2929087|NCT03046927|Placebo Comparator|Placebo|Oral administration of placebo one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
2929088|NCT03046914|Experimental|HLA-B*5801 screen test|An arm in which a participant takes HLA-B*5801 test before administration of allopurinol
2929089|NCT03046901|Experimental|Vancomycin group|It is a single arm open label study and will constitute only one group that will be taking vancomycin for recurrent PSC post liver transplantation.
2929090|NCT03046888|Experimental|PCNL|Percutant nephrolithotomy is a standard procedure for stones treatment over 2 cm.The puncture will be performed with an 18-G nephrostomy needle. The access thus gained guaranteed the transpapillary route of the percutaneous tract, a basic condition for the prevention of bleeding. Subsequently, following withdrawal of the puncture needle and urine drainage, a flexible guidewire will be inserted and advanced to the upper calyx or ureter.
2929091|NCT03046888|Experimental|Robot assisted pyelolithotomy|Robot assisted pyelolithotomy, is a new technique to remove stones of more than 2 cm. A 12-mm camera port is placed at the level of the umbilicus and lateral. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
2929092|NCT03046875|Experimental|Transcutaneous Spinal Cord Stimulation|Subjects will participate in a single session of Transcutaneous Spinal Cord Stimulation, involving 30 minutes of stimulation with isokinetic strength testing of knee extension.
2929093|NCT03046875|Sham Comparator|Sham|Subjects will participate in a single session of isokinetic strength testing of knee extension with sham stimulation.
2929094|NCT03046862|Experimental|Durvalumab/Tremelimumab+chemotherapy|Durvalumab and Tremelimumab in combination with gemcitabine/cisplatin.
2929095|NCT03046836|Experimental|Oxytocin|Each participant will self-administer 40 IU intranasal Oxytocin
2929096|NCT03046836|Placebo Comparator|Control|Each participant will self-administer matching saline placebo
2929097|NCT03046810|Experimental|Wellness toileting system|This group will use the wellness toileting system for their perineal hygiene and treatment of dermatitis
2929098|NCT03046797|Experimental|B group|Mask ventilation will be continued and fiberoptic intubation will be performed from Boussignac valve opening by an experienced anesthetist.
2929099|NCT03046797|Active Comparator|C group|mask ventilation will be terminated then fiberoptic intubation will be done by an experienced anesthetist.
2929100|NCT03046784||Pregnant women in third trimester|"Non-labouring pregnant women hospitalised during their third trimester of pregnancy has an haemodynamic evaluation with Nexfin technology and transthoracic cardiac ultrasonography.~Evaluation is performed in two positions : dorsal decubitus and left lateral decubitus."
2929101|NCT03046771|Experimental|Transport PLUS group|EMTs randomized to the Transport Plus group will view a 60-minute training video and then complete a 60-minute simulation training exercise on how to conduct the home fall hazard assessment (FHA) and the discharge comprehension assessment (DCA) and how to complete the FHA and DCA checklists. The FHA involves performing a visual assessment of the home environment and noting certain fall hazards. The DCA involves engaging the patient or caregiver in a conversation to assess their level of understanding of the elements of the discharge instructions. The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence
2929102|NCT03046771|No Intervention|Routine Care|Providers randomized to routine care will not be trained on the FHA or DCA or the completion of the checklists. All EMTs in both groups (Transport Plus and standard education), will be asked to answer some demographic questions and will be trained to collect responses to 3questions commonly used to assess a patient's risk of falling and to collect best contact information for phone follow up from patients or their caregivers and to obtain permission for a follow-up phone call from research personnel.
2929103|NCT03046758|Experimental|Participants|
2929104|NCT03046745||Gastric cancer group|The patients aged more than 18 years who were diagnosed primary gastric adenocarcinoma.
2929105|NCT03046745||Control group|The participants aged more than 40 years without previous history of gastric cancer.
2929106|NCT03046732|Experimental|Explore Transplant Ontario|"Intervention 'Implementing Explore Transplant Education'"
2929107|NCT03046732|No Intervention|Control|The control arm (Usual Treatment) is at the Toronto General Hospital dialysis center.
2929108|NCT03046719|Active Comparator|Bupivacaine 0,5%|Subjects received subconjunctival bupivacaine 0,5% 2,5ml in between stitches.
2929109|NCT03046719|Placebo Comparator|NaCl 0,9%|Subjects received subconjunctival NaCl 0,9% in between stitches.
2929110|NCT03046706|Active Comparator|standard voice rest|This group maintains postoperative voice rest. Namely, absolute voice rest for a week, followed by a week of relative voice rest sound (talking is allowed for 20 minutes a day). post operative voice rest
2929111|NCT03046706|Experimental|no voice rest|This group has no limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions.
2929112|NCT03046693|Experimental|Group A|Subjects in group A get citicoline 1000 mg per day for 60 days
2929113|NCT03046693|Placebo Comparator|Group B|Subjects in group B get placebo for 60 days.
2929114|NCT03046680|Experimental|Health Coaching|Individualized follow-up, supporting the individual for a better autonomy in personal care.
2929115|NCT03046680|Active Comparator|Multiprofessional Team|Physician, nurse, nutrionist usual care.
2929116|NCT03046667|Experimental|Test drink|Test drink: Barley β-glucan
2929117|NCT03046667|Placebo Comparator|Control drink|Control drink: barley beverage
2929118|NCT03046654|Experimental|Cervical cerclage|Women with a poor obstetric history that require cervical cerclage in order to avoid late abortion/early delivery.
2929119|NCT03046641|Experimental|continuous training group|With the continuous training program
2929120|NCT03046641|Experimental|interval training group|With the interval training program
2929121|NCT03046628|Experimental|Patients with diabetic feet ulcers|Each patient will be examined twice, first with TcPO2 (TCM400, Radiometer Medical ApS, Denmark) and then with a green laser (harmonic of continuous neodymium-doped yttrium aluminium garnet laser 532-nm wavelength and fast camera (PixelLink PLE531) system.
2929122|NCT03046615|Experimental|EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that is commonly used for recording.
2929123|NCT03046615|Active Comparator|Standard Needles|The current solution to monitor eye movement during surgery is to place standard needles in the muscles surrounding the eye.
2929124|NCT03046589|Experimental|Treatment Period 1|DP13 capsules (dose level 1 ) and placebo capsules
2929125|NCT03046589|Experimental|Treatment Period 2|DP13 capsules (dose level 2) and placebo capsules
2929126|NCT03046589|Experimental|Treatment Period 3|DP13 capsules (dose level 3) and placebo capsules
2929127|NCT03046589|Experimental|Treatment Period 4|DP13 capsules (dose level 4) and placebo capsules
2929128|NCT03046589|Experimental|Treatment Period 5|DP13 capsules (dose level 5) and placebo capsules
2929129|NCT03046589|Experimental|Treatment Period 6|DP13 capsules (dose level 6) and placebo capsules
2929130|NCT03046563|Experimental|Acupressure and Abdominal Massage|Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail.
2929131|NCT03046563|Sham Comparator|Pressing the sham points|Pressing the sham points for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail.
2929132|NCT03046550|Experimental|Cohort A|Cohort A will have 8 total subjects. 6 subjects will receive 0.33 mg/kg of NTM-1634 and 2 subjects will receive placebo.
2929133|NCT03046550|Experimental|Cohort B|Cohort B will have 8 total subjects. 6 subjects will receive 0.66 mg/kg of NTM-1634 and 2 subjects will receive placebo.
2929134|NCT03046550|Experimental|Cohort C|Cohort C will have 8 total subjects. 6 subjects will receive 1 mg/kg of NTM-1634 and 2 subjects will receive placebo.
2929135|NCT03046537|Active Comparator|ovulatory|Comparison in metabolic state between ovulatory and PCOS women by collecting breath test from participant.
2929136|NCT03046537|Active Comparator|PCOS|Comparison in metabolic state between ovulatory and PCOS women by collecting breath test from participant
2929137|NCT03046524||Parathyroid Carcinoma|Charts from participants with histopathological diagnosis of parathyroid carcinoma.
2929138|NCT03046524||Atypical Parathyroid Neoplasm|Charts from participants with parathyroid tumors with some atypical features found in parathyroid carcinoma, but not enough histologic criteria to make the diagnosis of parathyroid carcinoma.
2929139|NCT03046511|Experimental|Intraperitoneal|One single dose of intraperitoneal Cefazolin 1000 mg via the recently inserted peritoneal catheter
2929140|NCT03046511|Active Comparator|Intravenous|One single dose of intravenous Cefazolin 1000 mg one hour before catheter insertion
2929141|NCT03046498|Experimental|Program participants|Patients enrolled in the DSMP and DPP who provide consent.
2929142|NCT03046485|Experimental|Self management program|Self management program 'Living with Vision Loss' 6 week course that met for 2 hours each week led by a trained leader.
2929143|NCT03046485|No Intervention|Wait list control|Wait list control
2929144|NCT03046472|Experimental|Once a month and once a week.|"Personally meeting once a month of Physical Therapy treatment for Postural Behavior.~In addition exercise group meeting once a week. The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day. The Participants in this group will get also a group exercise meeting once a week That meeting will long 45 minutes and will include the exercise that were given as home work and more.~Total duration 12 weeks/3 months"
2929145|NCT03046472|Active Comparator|Once a month only.|"Personally meeting once a month only for Physical Therapy treatment for Postural Behavior.~The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day. Total duration 12 weeks/3 months"
2929146|NCT03046459|Experimental|BNZ132-1-40|a range of IV doses
2929147|NCT03046446|Experimental|FX006 32 mg|Single intra-articular injection
2929148|NCT03046407|Experimental|retinal pigment epithelium transplantation|transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
2929149|NCT03046394|Active Comparator|C-SACH|All the interventions will be administered to the patient in this single-subject trial, each 6 times
2929150|NCT03046394|Active Comparator|B-DER|All the interventions will be administered to the patient in this single-subject trial, each 6 times
2929151|NCT03046394|Active Comparator|A-DER|All the interventions will be administered to the patient in this single-subject trial, each 6 times
2929152|NCT03046381|Other|Tocilizumab|Tocilizumab 162mg 1x weekly as subcutaneous syringe
2929153|NCT03046368|No Intervention|Standard cover letter|"The group will receive a standard cover letter to the survey that is designed to have broad appeal:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark."
2929154|NCT03046368|Experimental|Targeted cover letter 1|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and sleep problems."
2929155|NCT03046368|Experimental|Targeted cover letter 2|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and contact to family and friends."
2929156|NCT03046368|Experimental|Targeted cover letter 3|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and sex"
2929157|NCT03046368|Experimental|Targeted cover letter 4|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sleep problems and contact to family and friends."
2929158|NCT03046368|Experimental|Targeted cover letter 5|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sleep problems and sex."
2929159|NCT03046368|Experimental|Targeted cover letter 6|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sex and contact to family and friends."
2929160|NCT03046368|Experimental|Targeted cover letter 7|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, sleep problems and contact to family and friends."
2929161|NCT03046368|Experimental|Targeted cover letter 8|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, sleep problems and alcohol."
2929162|NCT03046368|Experimental|Targeted cover letter 9|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, alcohol and contact to family and friends."
2929163|NCT03046368|Experimental|Targeted cover letter 10|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as alcohol, sleep problem and contact to family and friends."
2929164|NCT03046355|Experimental|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
2929165|NCT03046355|Active Comparator|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
2929166|NCT03046316|Experimental|local consolidative treatment|Patients will be referred to multiple disciplinary treatment discussion for the decision of local consolidative treatment to primary or metastatic lesions including surgery, radiotherapy or interventional therapy.
2929167|NCT03046316|No Intervention|physicians' choice|Up to physicians' choice for maintenance therapy or observation.
2929168|NCT03046303|Experimental|ERAS group|Patients were admitted 1-3 days prior to their respective dates of operation. A ERAS protocol was used in the ERAS group.
2929169|NCT03046303|No Intervention|conventional pathway group|The conventional pathway group received conventional care.
2929170|NCT03046290|Active Comparator|Pudendal Block|The anesthesia is produced by blocking the pudendal nerves near the ischial spine of the pelvis.Local anesthetic (mixed of ropivacaine and lidocaine) is injected into the pudendal canal where the pudendal nerve is located.
2929171|NCT03046290|Active Comparator|Penian Block|The anesthesia is produced by blocking the dorsal penile nerves. Local anesthetic (mixed of ropivacaine and lidocaine)is injected under the pubis symphysis just below the Buck fascia where the nerve is located.
2929172|NCT03046264||coronary angiography|patients undergoing routine coronary angiography, invasive and non-invasive determination of central blood pressure
2929173|NCT03046251|Other|natalizumab|Participants in this group are those who opt to receive treatment with natalizumab IV 300mg/day given q 4 weeks for 48 weeks.
2929174|NCT03046251|No Intervention|Control|Participants in this group may initiate any FDA approved DMT at any time post delivery or remain on no therapy.
2929175|NCT03046238|Active Comparator|dexmetedomedine|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
2929176|NCT03046238|Placebo Comparator|control|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
2929177|NCT03046225|Experimental|Electrical stimulation|This group received application of transcutaneous electrical nerve stimulation (TENS) associated with conventional physical therapy (continuous passive movement device and exercises).
2929178|NCT03046225|Active Comparator|Physical therapy|This group received only conventional physical therapy (continuous passive movement device and exercises).
2929179|NCT03046212|Experimental|Electrical stimulation|This group received application of transcutaneous electrical nerve stimulation (TENS) associated with conventional physical therapy (exercises).
2929180|NCT03046212|Active Comparator|Physical therapy|This group received only conventional physical therapy (exercises).
2929181|NCT03046199|No Intervention|Control|
2929182|NCT03046199|Experimental|Questionnaire|
2929183|NCT03046199|Experimental|Coordination|
2929184|NCT03046199|Experimental|Questionnaire + coordination|
2929185|NCT03046186||Gastric sleeve operated subjects|12 patients who have undergone gastric sleeve operation >12 month prior to inclution.
2929186|NCT03046186||Control Subjects|12 Healthy un-operated control subjects matched to the gastric sleeve group in a one to one manner with respect to BMI, sex and age
2929187|NCT03046186||Gastric bypass operated subjects|12 patients, who have undergone Roux-en-Y gastric bypass >12 month prior to inclution, matched to the gastric sleeve group in a one to one manner with respect to pre-operative BMI, post-operative BMI, sex and age.
2929188|NCT03046173|Experimental|the experimental group|These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
2929189|NCT03046173|Experimental|the control group|These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
2929215|NCT03046017|Active Comparator|real tDCS|In this group, the tDCS stimulates areas of the brain being examined in this study to increase their activity.
2929312|NCT03045354|Experimental|Beans|Eggs with a side of beans
2929313|NCT03045354|Experimental|Traditional breakfast|Cereal, milk, toast and jam
2929190|NCT03046160|Experimental|experimental group|"where treatment will involve conventional and Manual therapy (Mobilization with movement)+ tape (postural correction of scapular anterior tilt)~The Manual therapy (Mobilization with movement)intervention was of grade III mobilizations with movement performed in sitting for 6-10 repetitions for 3 sets~tape (postural correction of scapular anterior tilt)~A program of 12 neck and scapular exercises."
2929191|NCT03046160|Active Comparator|control group|"treatment will consist of the conventional approach+ tape (postural correction of scapular anterior tilt)~tape (postural correction of scapular anterior tilt)~A program of 12 neck and scapular exercises."
2929192|NCT03046147||RYGB patients with preoperative type diabetes|Recruited from a previously investigated cohort (NCT 01202526)
2929193|NCT03046147||RYGB patients with preoperative normal glucose tolerance|Recruited from a previously investigated cohort (NCT 01202526)
2929194|NCT03046121|Experimental|Fam-FFC|The intervention consists of :Component 1- Environmental and Policy Assessments; Component II- Education of Nursing Staff; Component III-Ongoing Training/Motivation of Nursing Staff. The Fam-FFC Nurse will work with the champions to mentor and motivate nursing staff to provide: (a) role modeling Fam-FFC, reinforcing performance of Fam-FFC, and brainstorming about ways to overcome challenges; (b) highlighting staff role models; Component IV Implementation of the FamPath Pathway which includes: (a) information on the admitting condition, diagnostics, treatment;(b) family/patient education; (c) transitional hand-off to post-acute providers; and (d) post-acute follow-up to provide ongoing education and modification of the function-focused care plan.
2929195|NCT03046121|No Intervention|Attention Control (Fam- FFC Ed-only)|Education of the nursing staff in participating hospital units (exactly as offered in treatment sites), and education of family caregivers about hospital orientation and reinforcement of discharge teaching (medications/treatments, medical follow-up).
2929196|NCT03046108|Active Comparator|blind injection of Morton neuroma|"Percoutaneous blind injection in Morton neuroma by subcutaneous needle group 1 are going to be injected by an experimented orthopaedic surgeon based on anatomic landmark. There is no internal control of the needle placement.~Mixture of 1 cc of 2% mepivacaine (Mepivacaina Normon 2%® )+ 40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected.~Up to 4 injections are allow in the first three months of follow-up"
2929197|NCT03046108|Active Comparator|blind injection of Mepivacaine|"1 cc of 2% mepivacaine (Mepivacaina Normon 2%® )+ 40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected.~Up to 4 injections are allow in the first three months of follow-up"
2929198|NCT03046108|Active Comparator|blind injection of Triamcinolone|40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected. Up to 4 injections are allow in the first three months of follow-up
2929199|NCT03046108|Experimental|ultrasound guided injection|US guided injection in Morton neuroma by subcutaneous needle. group 2 are going to be injected by an experimented musculoskeletal radiologist under ultrasound guidance. There is internal control of needle placement by ultrasound.
2929200|NCT03046108|Experimental|guided injection of mepivacaine|"2% mepivacaine (Mepivacaina Normon 2%® ) in each of the web spaces affected with Morton neuroma is injected.~Up to 4 injections are allow in the first three months of follow-up"
2929201|NCT03046108|Experimental|guided injection of Triamcinolone|40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected. Up to 4 injections are allow in the first three months of follow-up
2929202|NCT03046095|Experimental|Unilateral Resistance Exercise|One of the participant's legs will be randomized to a unilateral resistance training arm for 10 weeks in duration. The leg chosen to be trained will undergo resistance exercise three days per week (Monday, Wednesday, and Friday) for the entirety of the study.
2929203|NCT03046095|Experimental|Immobilization|One of the participant's legs will be chosen to be immobilized during the last two weeks of the study. Therefore, one leg will be resistance exercising from week 0-10 whereas the other leg will be immobilized during weeks 8-10.
2929204|NCT03046069||Subjects included in telephone interviews|Approximately 10 subjects with COPD per country will be included in qualitative concept elicitation telephone interviews.
2929205|NCT03046069||Subjects included in in-person focus groups|1 in-person focus-group per country including up to 5 subjects with COPD will be included in the qualitative analysis.
2929206|NCT03046069||Subjects included in DCE surveys- cognitive interviews|Up to six subjects with COPD in each of the UK, US and Germany will be asked to complete and provide feedback on the surveys.
2929207|NCT03046069||Subjects included in modified DCEs|Up to 20 subjects with COPD in each country will be included in pilot testing of the modified DCEs.
2929208|NCT03046069||Subjects included in Final DCE|150 subjects with COPD in each of the UK, US and Germany will be included in the final online market specific DCE survey.
2929209|NCT03046056|Experimental|Filgotinib Dose A|Filgotinib dose A + placebo to match filgotinib dose B for 24 weeks
2929210|NCT03046056|Experimental|Filgotinib Dose B|Filgotinib dose B + placebo to match filgotinib dose A for 24 weeks
2929211|NCT03046056|Placebo Comparator|Placebo|Placebo to match filgotinib dose A + placebo to match filgotinib dose B for 24 weeks
2929212|NCT03046043|Experimental|Low-Voltage & CFAE guided ablation|"Pulmonary isolation will be performed~Complex fractionated atrial electrogram(CFAE) and voltage mapping will be performed if atrial fibrillation the patient is still in atrial fibrillation after pulmonary vein isolation~CFAE and voltage mapping will be performed simultaneously using small electrode Pentaray® Catheter with CARTO®3 MEM version or CARTO®3 CONFIDENSE™~Automatic characterization of CFAE signals will be performed with an CARTO® CFAE software module.~CFAE areas within low voltage zone in the left atrium should be targeted first. If atrial fibrillation persist after left atrial ablation, target areas in the right atrium should be mapped and ablated. (Low-Voltage & CFAE guided ablation)"
2929213|NCT03046043|Active Comparator|PV Isolation Only|"Pulmonary vein isolation will be performed.~Electrical cardioversion to sinus rhythm will be performed if the patient is still in atrial fibrillation after pulmonary vein isolation."
2929214|NCT03046030|Experimental|Healthy Volunteers|In this experiment, we will apply a crossover design in healthy subjects. Each subject will receive four treatments in four separate sessions: 1) VGAIT, 2) VGAIT control condition, 3) real acupuncture, and 4) sham acupuncture. Each session will be separated by at least 7 days. Subjects will participate in five experimental sessions: a training and familiarity behavioral session and four fMRI sessions during which the subject will receive one of the four treatments.
2929216|NCT03046017|Sham Comparator|sham tDCS|In this group, sham tDCS does not provide real stimulation though participants will not know this until the debriefing at the end of the study. Sham will be used to determine if the results of this study are due to the tDCS or other reasons.
2929217|NCT03046017|Other|control group|In this group, participants will receive tDCS but will only receive a cream on their lower back.
2929218|NCT03046004|Experimental|Decision aid|Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
2929219|NCT03046004|Active Comparator|Control|Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
2929220|NCT03045991|Experimental|Sequential training group|"The participants in the SEQ group will first undergo aerobic exercise training for 30 minutes followed by 30 minutes of cognitive-based training.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
2929221|NCT03045991|Active Comparator|Control intervention group|"The CON group will receive 30 minutes non-aerobic exercise training in addition to one 30-minute session of unstructured mental activities.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
2929222|NCT03045965|Experimental|Salpingectomy|Concomitant salpingectomy at the time of hysterectomy for a benign reason
2929223|NCT03045965|No Intervention|No salpingectomy|No salpingectomy at the time of hysterectomy for a benign reason
2929224|NCT03045952|Experimental|microwave ablation|Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
2929225|NCT03045939|Other|12 hours|This arm is the standard management that includes insertion of the DBD into the cervical canal according to manufacture guidelines, removal after 12 hours followed by artificial rupture of membranes and oxytocin infusion according to departments protocol. (a total of 10 units of oxytocin is infused, initiated with 10 cc/h, increased by 10cc every 20-30 min until 3-5 contractions are present, total of not more than 120 cc\h)
2929226|NCT03045939|Active Comparator|6 hours|Removal of the DBD after 6 hours, followed by artificial rupture of membranes and oxytocin infusion according to departments protocol. (a total of 10 units of oxytocin is infused, initiated with 10 cc/h, increased by 10cc every 20-30 min until 3-5 contractions are present, total of not more than 120 cc\h)
2929227|NCT03045926|Experimental|Diosmectite (Smecta®)|5 weeks of diosmectite 3g, 3 times daily.
2929228|NCT03045913||Genoss DES|Subject implanted Genoss DES for coronary artery disease
2929229|NCT03045900|Active Comparator|Translucent bulk-fill resin composite|*Shaded bulk-fill resin composite. Bulk-fill resin composite which has no shade and could match any other shade. It will be compared for shade accuracy to the haded bulk-fill resin composite.
2929230|NCT03045900|Experimental|Shaded bulk-fill resin composite|*Translucent bulk-fill resin composite Bulk-fill resin composite which has a specific shade and should only be filled in teeth with the corresponding shade
2929231|NCT03045887|Experimental|Part A Cohort 1: Placebo- GSK2292767 (GSK) 200 µg-GSK 1000 µg|Subjects will receive an inhaled single dose of placebo in Period 1, GSK2292767 200 µg in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
2929232|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg-Placebo-GSK 1000 µg|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, placebo in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
2929233|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg- GSK 200 µg-Placebo|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, GSK2292767 200 µg in Period 2, and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.
2929234|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg-GSK 200 µg-GSK 1000 µg|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, GSK2292767 200 µg in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
2929235|NCT03045887|Experimental|Part A Cohort 2: Placebo-GSK 500 µg-GSK 2000 µg|Subjects will receive an inhaled single dose of placebo in Period 1, GSK2292767 500 µg in Period 2, and GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
2929236|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-Placebo- GSK 2000 µg|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, placebo in Period 2, and GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
2929237|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-GSK 500 µg-Placebo|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, GSK2292767 500 µg in Period 2 and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.
2929238|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-GSK 500 µg-GSK 2000 µg|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, GSK2292767 500 µg in Period 2, GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
2929239|NCT03045887|Experimental|Part B: GSK|Subjects will receive inhaled repeat dose of GSK2292767 2000 µg once daily for 14 days.
2929240|NCT03045887|Experimental|Part B: Placebo|Subjects will receive inhaled repeat dose of placebo once daily for 14 days.
2929241|NCT03045874||30 parent-child dyads|Stratified purposive sampling will assure representation proportional to the minority representation in the community and will include equal subsamples (15 families each) of families with children 6-18 months of age and children aged 19-36 months.
2929242|NCT03045874||30 primary care providers|"Investigators will purposively recruit 30 primary care providers to assure proportional representation of physicians and NPs with a snowball method. The sample sizes should be sufficient to achieve saturation of the data for qualitative analyses, but we will recruit more participants if saturation is not obtained with the planned sample."
2929243|NCT03045874||focus groups|The investigators will hold separate focus groups for parents of the two age groups and clinicians. We anticipate conducting approximately 6 focus groups with 8-10 participants in each to review and refine the sleep program.
2929244|NCT03045861|Experimental|Cohort 1-GSK2838232 100 mg + Cobicistat 150 mg in Part A|During Part A (Cohort 1), subjects will receive a single dose of GSK2838232 100 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
2929245|NCT03045861|Experimental|Cohort 2-GSK2838232 200 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 2), subjects will receive a single dose of GSK2838232 200 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
2929246|NCT03045861|Experimental|Cohort 3-GSK2838232 50 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 3), subjects will receive a single dose of GSK2838232 50 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
2929247|NCT03045861|Experimental|Cohort 4-GSK2838232 20 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 4), subjects will receive a single dose of GSK2838232 20 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
2929248|NCT03045848||Biofreedom drug-coated stent|Subject implanted Biofreedom DCS for coronary artery disease
2929249|NCT03045835|Experimental|BASKA mask|Selection of size : size 3 (30-50kg), size 4 (50-70kg), size 5 (70-100kg)
2929250|NCT03045835|Active Comparator|Endotracheal intubation|Selection of size : ID 7.0-7.5mm (women), ID 7.5-8.0mm (men)
2929251|NCT03045822|Experimental|Patients with cardiac implantable electronic devices|
2929252|NCT03045809||Women at risk of urogenital infections|Adult women living in the city of Kigali who are at high risk of HIV/urogenital infections (defined as having had more than one sexual partner in the last 12 months OR having been treated for a sexually transmitted infection (STI) in the last 12 months) regardless of the presence of current urogenital symptoms. Women who are known to be HIV-positive and/or pregnant are not excluded. All eligible women will be offered urogenital infection point-of-care tests.
2929253|NCT03045796||Maintenance Hemodialysis Patients|Following the initial recruitment, all individuals who are willing to participate and sign the informed consent document will be provided with a medical history form to complete. In addition, we will ask them to sign a HIPAA authorization form in order to look into their medical records for monthly blood work (blood chemistry), anthropometric data (height and weight), interdialytic weight gain (weight gain since last treatment) history, and current medications.
2929254|NCT03045783|Experimental|Prophylactic use of antibiotics group|Prophylactic use of antibiotics during endoscopic treatment, cefotiam 2.0g intravenous
2929255|NCT03045783|No Intervention|On-demand group|Routine endoscopic examination and treatment. Antibiotics are not used during endoscopic treatment
2929256|NCT03045770|Experimental|mFOLFOX|The mFOLFOX regimen consisted of oxaliplatin (85 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
2929257|NCT03045770|Experimental|mFOLFIRI|The mFOLFIRI regimen consisted of irinotecan (180 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
2929258|NCT03045770|Experimental|FOLFPTX|The FOLFPTX regimen consisted of paclitaxel (95 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
2929259|NCT03045757||Healthy Newborn|Healthy Newborn
2929260|NCT03045757||CHD Neonates|Neonates born with CHD before and after surgical repair
2929261|NCT03045744|Experimental|incomplete SCI patients|
2929262|NCT03045731||Kidney transplant recipients|Patients who have received kidney transplantation in Zhongshan Hospital.
2929263|NCT03045718|Experimental|Horticultural Therapy|Horticultural Therapy will consists of 1 hour sessions, weekly for 9 months, to engage subjects in gardening-based activities.
2929264|NCT03045718|Other|Waitlist Control|The control group will be placed on a waiting list and only be contacted for assessments. They will receive the same Horticultural Therapy intervention after the active treatment group at a later date.
2929265|NCT03045705|Active Comparator|Labor+routine pain management|Women that will be treated by the medical team in the delivery room as if not part of a study regarding pain management.
2929266|NCT03045705|Active Comparator|Labor+experimental pain management|Women that will not be asked at all by the medical team in the delivery room regarding analgesia during labor but will be able to receive analgesia at wish at the time of choice.
2929267|NCT03045692|Active Comparator|Control group|creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
2929268|NCT03045692|Experimental|Study group|4 hour creatinine clearance is used to decide colistin maintenance dosage.
2929269|NCT03045679|Experimental|RYGB-group|Patients who undergo laparoscopic RYGB (150 cm alimentary limb, 50 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
2929270|NCT03045679|Experimental|OAGB/MGB-group|Patients who undergo laparoscopic OAGB/MGB (200 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
2929271|NCT03045666|Experimental|Intervention group|Patients stable on Macitentan therapy will exercise twice a week for 12 weeks, supervised by physiotherapists. The exercise program includes aerobic and strength exercises, at 2-3 minutes intervals.
2929272|NCT03045666|No Intervention|Control Group|Patients stable on Macitentan therapy that will continue to receive it, without exercise.
2929273|NCT03045653|Experimental|treatment arm|receiving a treatment of tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
2929274|NCT03045640|Experimental|FSI ECD|"Vulnerable Households (ubudehe 1 or 2) in the Government of Rwanda's poverty classification system, when categories ranged from 1 to 6; the system has since been restructured to have four categories only. Often a way to identify households for public works opportunities or other government assistance programs. For this arm, families had to be Ubudehe 1 or 2 and have a child aged 0-3 years. Households meeting these criteria in the catchment area(s) received the FSI ECD home-based parenting intervention from bachelor-level interventionists/coaches."
2929275|NCT03045627|Active Comparator|Experimental|"Ara-C, Aclarubicin Combined PEG-G-CSF~ARA-C subcutaneously in a 12-hour infusion on days 1 through 14, Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8, PEG-G-CSF 6mg subcutaneously on days 0. One course includes 28 days."
2929276|NCT03045627|Active Comparator|Active comparator|"Ara-C, Aclarubicin Combined G-CSF~ARA-C subcutaneously in a 12-hour infusion on days 1 through 14, Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8, G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14. G-CSF was postponed or interrupted in case of white blood cell (WBC) count greater than 20 × 109/L .~One course includes 28 days."
2929277|NCT03045601|Experimental|CT-FFR|Analyse With New CT-FFR Method
2929278|NCT03045601|Active Comparator|Stress echocardiography|Analyse With invasive FFR and stress echocardiography
2929279|NCT03045588|Experimental|Low group|This subjects in this group conducts all their morning exercise sessions with high fat oxidation (in a fasted condition). Thus, the subjects in this group after high intensity exercise in the evening do not get any carbohydrates to eat after training until the exercise session the following morning has been conducted.
2929280|NCT03045588|Active Comparator|High group|This subjects in this group conducts all their morning exercise sessions with low fat oxidation (in a fed condition). Thus, the subjects in this group after high intensity exercise in the evening do get carbohydrates to eat after training until the exercise session the following morning has been conducted.
2929281|NCT03045562|Placebo Comparator|Control group|Patients will be assigned to receive 100ml of normal saline
2929282|NCT03045562|Experimental|Experimental group|Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline
2929283|NCT03045549|Experimental|Experimental group|Home-based rehabilitation sessions performed with the digital biofeedback system. Patients will be instructed to perform exercise sessions at least 5 days a week, but compliance to this schedule is not mandatory.
2929284|NCT03045549|Active Comparator|Conventional rehabilitation group|Home-based rehabilitation sessions provided by a Physical Therapist, 3 times a week, each with 1h duration. Patients will be instructed to perform 2 additional unsupervised sessions per week, but compliance to these sessions is not mandatory.
2929285|NCT03045536||Patients with TFR|Patients treated with TFR for oncologic or non-oncologic reason
2929286|NCT03045523|Experimental|GLPG2222 Dose 1|
2929287|NCT03045523|Experimental|GLPG2222 Dose 2|
2929288|NCT03045523|Placebo Comparator|Placebo|
2929289|NCT03045510|Experimental|Ultra small dose decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 5d, every four weeks for one cycle. It will be given six cycles.
2929290|NCT03045497|Experimental|Diagnostic (contrast-enhanced ultrasound)|Patients receive perflutren lipid microspheres IV and then undergo contrast-enhanced ultrasound imaging over approximately 1 hour prior to transarterial chemoembolization with drug eluting beads, at 1-2 weeks and 1 month post transarterial chemoembolization with drug eluting beads. Patients also undergo contrast-enhanced MRI at 1 month post-treatment per standard of care.
2929291|NCT03045484|Experimental|The moderate group|Patient who was suffering from moderate pain in the mouth, pharynx, or larynx during the treatment of chemoradiotherapy consented to take controlled-release oxycodone, oxycodone was begun at the level of mild pain. We called this the moderate group. Controlled-release oxycodone was used to relieve oral mucositis pain induced by chemoradiotherapy in this group.
2929292|NCT03045484|Experimental|The severe group|Patients who did not ask for controlled-release oxycodone until the pain reached a moderate level during the treatment of chemoradiotherapywere called the severe group. Controlled-release oxycodone was also used to relieve oral mucositis pain induced by chemoradiotherapy in this group..
2929293|NCT03045471||R-EPOCH|
2929294|NCT03045471||R-CHOP|
2929295|NCT03045458|Active Comparator|Tissue level dental implant|Tissue level dental implants (Straumann AG, Waldenburg, Switzerland) were inserted in patients group I (n=20).
2929296|NCT03045458|Active Comparator|Bone level dental implant|Bone level dental implants (Straumann AG, Waldenburg, Switzerland ) were inserted in patients group II (n=20).
2929297|NCT03045445|Experimental|Double Low-Dose protocol CT|Low radiation dose + low amount of iodine contrast media at spectral CT (Philips Healthcare)
2929298|NCT03045445|Active Comparator|Standard protocol CT|Standard protocol quadriphasic liver CT according to current liver CT protocol in our institution, at spectral CT (Philips Healthcare)
2929299|NCT03045432|Experimental|video-teaching materials|"regular passive ROM exercise~regular rehabilitation programe~alternative video-teaching materials"
2929300|NCT03045432|Other|control group|"regular passive ROM exercise~regular rehabilitation programe~regular oral-teaching materials"
2929301|NCT03045419||Patients group|"with small hepatic nodules (10-19mm) or atypical hepatic nodule (= or > 20mm) and high-risk group of HCC~scheduled for gadoxetic acid-enhanced liver MRI or liver nodule biopsy"
2929302|NCT03045419||Living liver donor candidates|"living liver donor candidates without history of liver disease~schedule for gadoxetic acid-enhanced liver MRI as preoperative workup~only used for control of normal liver parenchymal enhancement on hepatobiliary phase"
2929303|NCT03045406|Experimental|Apixaban|orally administered, at the dose of 10 mg bid for 7 days, followed by 5 mg bid (total period of treatment: six months)
2929304|NCT03045406|Active Comparator|Dalteparin|subcutaneously administered, at a dose of 200 IU/kg SC o.i.d for 1 month. Thereafter, dalteparin will be administered at a dose of 150 IU/kg o.i.d. for 5 months
2929305|NCT03045393|Experimental|Mirvetuximab Soravtansine|Participants will receive 2 doses of Mirvetuximab Soravtansine after neoadjuvant chemotherapy and before surgical resection of tumor.
2929306|NCT03045380|Experimental|Game based rehabilitation|Game based rehabilitation will be administered once a week for 8 weeks.
2929307|NCT03045380|Active Comparator|Conventional rehabilitation|Conventional physiotherapy program will be administered once a week for 8 weeks.
2929308|NCT03045380|No Intervention|No intervention|Waitlist
2929315|NCT03045341|Experimental|BWL + NB medication|Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
2929316|NCT03045341|Experimental|BWL + Placebo|Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and placebo. Placebo will be inactive and taken daily in pill form.
2929317|NCT03045341|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
2929318|NCT03045341|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
2929319|NCT03045328|Experimental|Treatment (ibrutinib, venetoclax)|Patients receive ibrutinib PO QD beginning on week 1 day 1. Treatment with ibrutinib continues in the absence of disease progression or unacceptable toxicity. Patients also receive venetoclax PO QD beginning on week 9 day 1. Treatment with venetoclax continues up to week 61 day 7 in the absence of disease progression or unacceptable toxicity.
2929320|NCT03045315|Experimental|women included in a IVF program|
2929321|NCT03045302|Experimental|BIM23B065|
2929322|NCT03045289|Experimental|Intervention group|Subjects are provided three meals daily, attend weekly office visits, take a daily multivitamin.
2929323|NCT03045289|No Intervention|Control Group|Women instructed to maintain current intake and take a provided multivitamin.
2929324|NCT03045276|Active Comparator|Arm 1 - No Feedback, Minimum Incentive|Subjects will receive daily text message reminders and report real-time treatment adherence with photos. They will receive compensation to encourage real-time adherence reporting. Subjects will also be able to log into a personal dashboard with a visual display of their weekly adherence performance and educational resources related to their primary disease. Every month, participants will receive a text encouraging them to visit their personal dashboard. The dashboard is able to track usage of the modules by individual. Parents/legal guardians will have access to these same educational materials via their own portals. Additionally, to mitigate the minimal risk of this study, parents/legal guardians will be notified if their child is excessively non-adherent.
2929325|NCT03045276|Active Comparator|Arm 2 - Feedback, Maximum Incentive|Subjects will receive daily text message reminders and report real-time treatment adherence with photos, and will have web access to the educational modules through their portal. Every month, participants will receive a text encouraging them to visit their portals. In contrast to Arm 1, they will receive their weekly performance results by text to their phone with tailored feedback. In Arm 2, subjects will receive a larger incentive if they perform their desired treatment behavior. Incentive notification will be texted to participants. Similarly to Arm 1, parents/legal guardians will have access to the same educational materials via their own WTH portals. Additionally, to mitigate the minimal risk of this study, parents/legal guardians will be notified if their child is excessively non-adherent.
2929326|NCT03045263|Active Comparator|Pivotal Response Treatment|Pivotal Response Training with children ages 3-6 years of age with an Autism Spectrum Disorder diagnosis
2929327|NCT03045263|No Intervention|Waitlist Control|Children in WL will be offered treatment following WL condition.
2929328|NCT03045250|Active Comparator|Subjects with known Type 1 Diabetes|Subjects with known Type 1 diabetes
2929329|NCT03045250|Placebo Comparator|Healthy Controls|Healthy controls
2929330|NCT03045237|Experimental|Intervention Group|The program consists in 3 physical exercise classes, one of them in the pool.
2929331|NCT03045237|No Intervention|Control Group|The control group has the basic information through health professionals.
2929332|NCT03045211|Experimental|In-Home Standing Table|"Participants in this arm will receive a dynamic standing table to be used in their home for at least two hours per day for at least five days per week for a 16-week period. Specific activities will be tracked with a logbook. PD subjects will be coached by a physical therapist on proper body positioning at the table, use of anti-fatigue mat, and optimal monitor height. The physical therapist will adhere to the neutral body positioning guidelines as provided by the OSHA. The physical therapist will also perform an in-home safety assessment of the office or room in which the table will be placed to ensure safety not only for the users but also for family members or children. The physical therapist will monitor each participant throughout the study by making biweekly compliance phone calls.~In addition, this group will received standard of care, which is weekly group exercise sessions during the 16-week period of table use."
2929333|NCT03045211|No Intervention|Standard of Care|this group will received standard of care only, which is weekly group exercise sessions during a 16-week period. Instructions, coaching, and compliance phone calls will also be provided to the participants of this arm such that both arms have the same amount of contact time with the physical therapist.
2929334|NCT03045198|Experimental|Azithromycin|oral Azithromycin 10 mg/kg Body weight, max. 500 mg every Monday, Wednesday and Friday for 4 weeks
2929335|NCT03045185|Experimental|Treatment Group|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.
2929336|NCT03045172|Active Comparator|Group 1|20 subjects with PRP injections
2929337|NCT03045172|Placebo Comparator|Group 2|10 subjects with saline injections
2929338|NCT03045159|Experimental|Strong Families|parenting program
2929339|NCT03045159|Active Comparator|Strong Parents|self-care program
2929340|NCT03045146||Multimodal brain imaging|Consecutive patients experiencing an acute ischemic stroke treated by thrombectomy according to the current recommendations. Clinical outcome will be compared according to the baseline imaging profile processed after patient treatment.
2929341|NCT03045133|Active Comparator|MT group|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
2929342|NCT03045133|Active Comparator|MF group|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
2929343|NCT03045120||dasatinib cohort|Intended to characterize the impact of dasatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
2929344|NCT03045120||imatinib cohort|Intended to characterize the impact of imatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
2929345|NCT03045120||nilotinib cohort|Intended to characterize the impact of nilotinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
2929346|NCT03045107|Experimental|Intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected and a side-to-side anastomosis is fashioned with a laparoscopic stapler.
2929347|NCT03045107|Active Comparator|Extracorporeal ileocolic anastomosis|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. Then, a primary ileocolic side-to-side handsewn or mechanical anastomosis is fashioned extracorporeally.
2929348|NCT03045081|No Intervention|Usual care|Patients receive outcome tracking tool, PainTracker, but no additional web-based support for self-management
2929349|NCT03045081|Experimental|PainTracker Self-Manager|Patients are invited to complete the web-based PainTracker Self-Manager and interact with a nurse care manager who supports chronic pain self-management
2929350|NCT03045068|Experimental|Study Group|"Platelet Transfusion Management~Pre-Termination of CPB- Platelet Transfusion 10ml/kg to be administered to the patient via central venous access when the patient has been rewarmed to 35*C, (the Sano or BT shunt clip is still on in children with SV physiology)~Post CPB- Platelet transfusion 10ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion."
2929351|NCT03045068|Active Comparator|Control Group|"Platelet Transfusion Management~Pre-Termination of CPB- No intervention~Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion."
2929352|NCT03045055|Experimental|RIC group|RIC (remote ischemic conditioning) paired with endovascular treatment.
2929353|NCT03045055|Sham Comparator|Sham group|Sham RIC (remote ischemic conditioning) paired with endovascular treatment.
2929354|NCT03045042||Treated patients|Patients with late onset Pompe disease treated with the enzyme replacement therapy
2929355|NCT03045042||Non treated patients|Patients with late onset Pompe disease non treated with the enzyme replacement therapy
2929356|NCT03045029||Oral treprostinil|Sustained-release oral tablets for three times daily (TID) administration in prostacyclin naive and prostacyclin transition patients
2929357|NCT03045016|Experimental|Prazosin, ALPRESS® LP 2,5 et 5 mg|Patients included in this study will be adults with acute stress as a result of a direct experience traumatic event. They will be treated with Prazosin, ALPRESS® LP 2,5 et 5 mg during 28 days.
2929358|NCT03045003|Other|Arm A: Low Intensity|RESIL Intervention provided by nurses and oncologists of the outpatient oncology unit.
2929359|NCT03045003|Other|Arm B: High Intensity|RESIL Intervention provided by nurses and oncologists of the outpatient oncology unit plus 5 nurse-led consultations (3 face-to-face and 2 telephone consultations)
2929360|NCT03044977|Experimental|Cohort 1|"This is the initial treatment arm. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 150 centiGray (cGy) Radiation exposure to the kidneys is limited to 1900 centiGray (cGy)"
2929361|NCT03044977|Experimental|Cohort 2|"This treatment arm is opened if Cohort 1 is successful. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 200 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)"
2929362|NCT03044977|Experimental|Cohort 3|"This treatment arm is opened if Cohort 2 is successful. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 250 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)"
2929363|NCT03044977|Experimental|Cohort -1 (alternative cohort)|"This treatment arm is opened if Cohort 1 is not tolerated.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 100 centiGray (cGy) Radiation exposure to the kidneys is limited to 1500 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
2929364|NCT03044977|Experimental|Cohort 2.1 (renal alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 200 centiGray (cGy) Radiation exposure to the kidneys is limited to 1500 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
2929365|NCT03044977|Experimental|Cohort 2.2 (bone marrow alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 100 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
2929366|NCT03044977|Experimental|Cohort 3.1 (renal alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 3.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 250 centiGray (cGy) Radiation exposure to the kidneys is limited to 1900 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
2929367|NCT03044977|Experimental|Cohort 3.2 (bone marrow alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 150 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
2929368|NCT03044964|Active Comparator|Ranolazine|At randomization, patients will be started on 500mg of Ranolazine, twice daily for 1 week. After 1 week, the dosage may be increased to 1000mg of Ranolazine, twice daily for 5 weeks.
2929369|NCT03044964|Placebo Comparator|Placebo|At Randomization, patients will be started on 500mg of a placebo, twice daily for 1 week. After 1 week, the dosage of the placebo may be increased to 1000mg, twice daily for 5 weeks.
2929370|NCT03044951|Experimental|cryoballoon ablation|patients who accept cryoballoon ablation
2929371|NCT03044951|Active Comparator|radiofrequency ablation|patients who accept radiofrequency ablation
2930017|NCT03040271|No Intervention|Control group|Group of students not receiving any intervention
2929372|NCT03044938|Experimental|Salbutamol|Salbutamol is a bronchodilator that relaxes the muscles of the airways and increases the flow of air to the lungs. With the aid of a spacer, 400mcg of the drug will be administered once during the protocol.
2929373|NCT03044938|Placebo Comparator|Placebo|Inoculant treatment through a substance that does not have an inherent power to produce an effect that is desired or expected. Four placebo puffs will be offered through a device similar to the salbutamol intervention device.
2929374|NCT03044925|Experimental|Remote magnetic navigation|Persistent atrial fibrillation ablation with remote magnetic navigation
2929375|NCT03044925|Active Comparator|Cryoablation|Persistent atrial fibrillation ablation with cryoballoon
2929376|NCT03044912|Experimental|treatment group|Mirabegron 50 mg for comparison
2929377|NCT03044912|Active Comparator|Comparative group|Patient take Mirabegron 25 mg
2929378|NCT03044899||Adult surgical patients|All surgeries in adult patients
2929379|NCT03044886|Experimental|2000IU/day|Subjects took 2000IU vitamin D per day
2929380|NCT03044886|Experimental|1000IU/day|Subjects took 1000IU vitamin D per day
2929381|NCT03044886|Placebo Comparator|Placebo|Subjects took placebo
2929382|NCT03044873|Experimental|BMS 986165 and Rosuvastatin|
2929383|NCT03044860|Experimental|Type 2 diabetes|Adult patients with type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.
2929384|NCT03044860|Experimental|Healthy|Adult subjects without type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.
2929385|NCT03044847||COPD group|The post-bronchodilator FEV1/FVC ratio < 0.70 was used as definition of COPD, which was proposed by the Global Initiative for Chronic Obstructive Lung Disease
2929386|NCT03044847||GOLD 0 group|GOLD 0 is defined as having chronic respiratory symptoms and/or high risk factors, but without airflow (post-BD FEV1/FVC ≥ 0.7). Chronic respiratory symptoms is defined as chronic cough, phlegm production, chest tightness, short of breath, dyspnea, wheeze, ect. High risk factors is defined as cigarette smoking, passive smoking, occupational exposures, bio-fuels exposures ect.
2929387|NCT03044834||Pleuropulmonary Blastoma|"Patients born between 01/01/2000 and 01/01/2016 ;~Followed up for PPB~Treated in a French department of paediatric oncology or paediatric surgery~Study agreement"
2929388|NCT03044821|Experimental|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
2929389|NCT03044808|Experimental|Lidocain|Patient gets the experimental treatment with IV lidocain 0,5mg/ml, 1,5mg/kg bolus before induction of anesthesia, after that infusion of 1,5mg/kg/h is started and continued until 2 hours after end of surgery.
2929390|NCT03044808|Placebo Comparator|Control|Patients get the same amount in ml and duration as if it was the experimental arm. Only in this arm it is isotonic saline instead.
2929391|NCT03044795|Experimental|Part A|Patients with TNBC, platinum sensitive high grade serous ovarian cancer or BRCA-mutated (non-)breast and (non-)ovarian cancer will be included prior to the RAD51 assay and treated with veliparib irrespective of the assay result. All patients, including TNBC patients, will receive veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment.
2929392|NCT03044795|Experimental|Part B|Only patients with a RAD51 assay HR deficiency will be included. First there will be a pre-screening procedure followed by a tumor lesion biopsy on which the RAD51 assay will be performed. In case of a RAD51 assay indicating HR proficiency, patients will not be eligible for treatment in this study and cannot be included. Patients with a RAD51 assay indicating HR deficiency will be included. Eligible patients will be treated with veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment. In case of 0/15 patients within one patient subgroup having RAD51 tests showing HR-deficiency inclusion for this sub-group will be closed.
2929393|NCT03044769||Patient with CLA with surgery|
2929394|NCT03044769||Patient with CLA without surgery|
2929395|NCT03044756|Experimental|-ve arm|The women who do not receive the GnRH antagonist dose on the day of triggering of ovulation (omitted GnRH antagonist arm)
2929396|NCT03044756|No Intervention|+ve arm|The women who receive the routine dose of GnRH antagonist on the day of triggering of ovulation (the usual protocol)
2929397|NCT03044743|Experimental|PD-1 knockout EBV-CTL|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISP-Cas9 system and EBV-CTL will be generated in the laboratory (PD-1 Knockout EBV-CTL).~Fludarabine at 30mg/m2 and Cyclophosphamide at 300mg/m2 single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10^7/kg PD-1 Knockout CTL will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.~Interleukin-2 (IL-2) will be given daily( iv) since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit（IU）/day . Patients will receive a total of four cycles of treatment."
2929398|NCT03044730|Experimental|Treatment (pembrolizumab, capecitabine)|Patients receive pembrolizumab IV on day 1 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2929399|NCT03044717||Cardiology fellows and faculty|"Fill out a nutrition survey three times at 0, 3, and 6 months and be present at a prevention educational conference every 5 weeks until the end of the study.~This group will also complete a 3-hour nutrition module prior to study completion."
2929400|NCT03044691|Placebo Comparator|Control Clinic|The control group will have to complete the Adaptive Reserve and Change Process Capability Questionnaire and Clinician Survey at baseline and 9 months. Clinicians will provide their usual care related to tobacco and nicotine product use screening and cessation recommendations. Medical record of patients will be reviewed at baseline and at 6 months.
2929401|NCT03044691|Experimental|Intervention Clinic|Intervention practices will complete the Adaptive Reserve and Change Process Capability Questionnaire and Clinician Survey at baseline and 9 months and participate in the medical record review at baseline and 6 months. The clinic will first administer the eligibility questionnaire to determine if patients are between the ages of 11-17 years old. Then they will be asked to complete the Youth Tobacco and Nicotine Product Questionnaire and Parent Brief Questionnaire (PBQ) using the ResearchACTS software at the point of care. A follow-up survey Youth Tobacco and Nicotine Product Primary Care survey will be administered to participants at least 30 days after their clinic visit.
2929442|NCT03044444|Experimental|low dose citrus extract|this group will receive a low dose (400mg/day) of the citrus extract for 8 weeks
2929402|NCT03044678|Experimental|Experimental: REACH for Success|Experimental: Exposure-based, cognitive and behavioral, social skills training intervention 6-weeks - 6 session -20-30 min each
2929403|NCT03044678|Active Comparator|Active Comparator: Self-study|"Active Comparator: Books What to do when you are scared and worried?How to do homework without throwing-up? How to get organized without losing it? Reading at home"
2929404|NCT03044665|Active Comparator|High-intensity statin monotherapy|Statin monotherapy
2929405|NCT03044665|Experimental|Statin plus ezetimibe combination therapy|Statin plus ezetimibe combination therapy
2929406|NCT03044652|Experimental|Medical Device: WO2085 Moisturising Cream|"WO2085 is a hormone-free Moisturizing Cream and is used to treat vulvovaginal dryness symptoms."
2929407|NCT03044652|Active Comparator|Drug: Estriol Cream 0.1%|Estriol Cream 0.1% is a standard therapy for the treatment of vulvovaginal atrophy in postmenopausal women.
2929408|NCT03044639|Experimental|Provision of LCT emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of LCT-based lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
2929409|NCT03044639|Experimental|Provision of MCT/LCT emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of MCT/LCT lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
2929410|NCT03044639|Experimental|Provision of Olive oil emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of Olive-oil/ LCT lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
2929411|NCT03044639|Experimental|Provision of SMOF lipid emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of SMOF lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
2929412|NCT03044626|Experimental|study group A|"Patients with metastatic non-squamous NSCLC with the necessity of radiotherapy of a metastatic site (e.g. bone) in 2nd-line or 3rd-line treatment:~Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"
2929413|NCT03044626|Other|study group B|"Patients with metastatic non-squamous NSCLC without the necessity of radiotherapy in 2nd-line or 3rd-line treatment:~Nivolumab 240 mg fixed dose (q2w)."
2929414|NCT03044613|Experimental|Arm A|Nivolumab 240mg administered IV over 30 minutes every 2 weeks for 2 cycles and then nivolumab 240mg administered IV over 30 minutes every 2 weeks for 3 cycles when given concurrently with standard of care chemoradiation (weekly carboplatin/paclitaxel and concurrent radiation
2929415|NCT03044613|Experimental|Arm B|Nivolumab 240mg administered IV over 30 minutes followed by relatlimab 80mg administered IV over 60 minutes on Day 1 every 2 weeks for 2 cycles and then every 2 weeks for 3 cycles when given concurrently with standard of care chemoradiation (weekly carboplatin/paclitaxel and concurrent radiation).
2929416|NCT03044600||Young MEN1 Negative Group|Participants under 50 years of age who have been diagnosed with MEN1-negative primary hyperparathyroidism.
2929417|NCT03044587|Experimental|Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|Nal-IRI [Irinotecan liposome], 5-FU [5-Fluorouracil], Leucovorin Cycle q2w
2929418|NCT03044587|Other|Arm Cisplatin + Gemcitabine (Arm B, standard of care)|Cisplatin, Gemcitabine Cycle q3w
2929419|NCT03044574|Experimental|Main group|
2929420|NCT03044574|Active Comparator|Control group|
2929421|NCT03044561|Experimental|Sildenafil citrate|
2929422|NCT03044561|Placebo Comparator|placebo|
2929423|NCT03044548|Experimental|Experimental|Supportive supervision
2929424|NCT03044548|No Intervention|Control|No intervention
2929425|NCT03044535||Group 1: Longitudinal assessment|Assessments will be performed pre-MCS, 3 months post-MCS and 6 months post-MCS. Participants in this group must be scheduled for MCS implant.
2929426|NCT03044535||Group 2: Cross-sectional assessment|A one-time assessment will be performed on participants who are post-MCS implant (between 3 months and 4 years post-implant). Participants in this group must already have an MCS device in place.
2929427|NCT03044535||Group 3: Post-MCS|MCS patients who are 3 months post-MCS implant who have a smartphone will be asked to download the mobile CAT app and complete MCS A-QOL CAT measures at approximately 3, 4, and 5 months after implant.
2929428|NCT03044522|No Intervention|No Nurse Education|Subjects who are enrolled into study arm with no Nurse Pain Educator will be monitored every month to assess their use of their medication, quality of life, physical and mental well-being. No intervention will be conducted with these subjects beyond that of standard of care at the facility.
2929429|NCT03044522|Other|Nurse Education|Subject enrolled into the Nurse Pain Educator arm will be educated (Opioid Education) on different opioid pain management topics with a focus on safe and appropriate use and consumption of opioid analgesics.
2929430|NCT03044509||TB exposure|
2929431|NCT03044509||TB infection (latent TB)|
2929432|NCT03044509||TB disease (active TB)|
2929433|NCT03044496||Supraclavicular Nerve Block|Patients undergoing vascular surgery for creation or revision of an arterio-venous fistula. Intervention: supraclavicular plexus block for anaesthesia. NIRS measurement before and after brachial plexus block.
2929434|NCT03044483||18-34 year olds|Healthy adults aged 18-34 years old
2929435|NCT03044483||35-54 year olds|Healthy adults aged 35-54 years old
2929436|NCT03044483||55 and over year olds|Healthy adults aged 55 years old and over
2929437|NCT03044470|Experimental|Cold saline|Saline stored at 4 degrees centigrade
2929438|NCT03044470|Experimental|Normal Saline|Saline stored at room temperature
2929439|NCT03044457|Experimental|TKA by reversed gap technique|new operative technique of positioning the femoral and tibial component based on soft tissue tension and femoral 3D geometry.
2929440|NCT03044457|Active Comparator|TKA by gap technique|standard operative technique serving as control. tibia component positioning according to the mechanical axis, femoral component positioning according to the mechanical axis and soft tissue tension in flexion
2929441|NCT03044444|Experimental|high dose citrus extract|this group will receive a high dose (500mg/day) of the citrus extract for 8 weeks
2929443|NCT03044444|Placebo Comparator|placebo|this group will receive a placebo (500mg maltodextrin per day) for 8 weeks
2929444|NCT03044431||Cell therapy treated|All patients/participants enrolled will undergo cell therapy
2929445|NCT03044418|Other|anesthesia with laser tube|The parameters and side effects of anesthesia are tested during endolaryngeal laser surgery. Anesthesia type is the total intravenous anesthesia with propofol. We tested the application of ET laser tube in propofol anesthesia.
2929446|NCT03044405|Other|Responders and non-responders|Fluid challenge of 500 ml of crystalloids over 15 minutes is given. Positive fluid responsiveness is defined by an increase in stroke volume (SV) of at least 15% assessed by focused transthoracic echocardiography.
2929447|NCT03044392|Active Comparator|Next Bolus Interval 15 minutes|Next Bolus Interval 15 minutes
2929448|NCT03044392|Active Comparator|Next Bolus Interval 30 minutes|Next Bolus Interval 30 minutes
2929449|NCT03044392|Active Comparator|Next Bolus Interval 45 minutes|Next Bolus Interval 45 minutes
2929450|NCT03044379|Active Comparator|Dapivirine Gel|Participants will be randomized to receive a single dose of dapivirine gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.
2929451|NCT03044379|Placebo Comparator|Placebo Gel HEC|Participants will be randomized to receive the universal HEC placebo gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.
2929452|NCT03044366||Characteristics of Anesthesia management|Evaluate the average value of these data.
2929453|NCT03044366||Comorbidities|Evaluate the average value of these data.
2929454|NCT03044353|Experimental|GSK2135698+GSK2398852|"GSK2315698 20mg/hour, IV (in the vein) for up to 72hours prior to GSK2398852 administration, followed by 60mg three times daily subcutaneous injection for 11 days. Dose level and frequency adjusted according to renal function.~GSK2398852 up to 1200mg, IV divided over days 1 and 3. Dose level adjusted based on tolerability. Number of cycles: up to 6."
2929455|NCT03044340|Experimental|erythermalgia patient|patient will be measured chlorine ions impedance with the SUDOSCAN and evaluation on pain du to temperature with the THERMOTEST
2929456|NCT03044327|Other|LPS challenge|LPS inhalation and bronchial instillation
2929457|NCT03044314|Experimental|Iloprost and nitric oxide administration|Each patient will receive 40 ppm inhaled nitric oxide and 2.5-5 mcg inhaled iloprost in the catheterization laboratory with assessment of hemodynamic response. Patients will also receive 2.5-5 mcg iloprost during echocardiographic assessment.
2929458|NCT03044301|Other|BMI < 25kg/m²|Subcutaneous high ZENEO® injection Intramuscular ZENEO® injection
2929459|NCT03044301|Other|27.5 > BMI > 25 kg/m²|Intramuscular ZENEO® injection
2929460|NCT03044301|Other|BMI > 27.5 kg/m²|Intramuscular ZENEO® injection
2929461|NCT03044301|Other|No special BMI|Subcutaneous low ZENEO® injection
2929462|NCT03044288|Experimental|Cohort 9|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin.~Standard adhesive strip and a strip with a newly developed adhesive (new adhesive strip)"
2929463|NCT03044275|Experimental|Cohort 8|"This is a sub-study testing the effect of real output on the skin applied under two adhesive strips.~New adhesive strip Standard adhesive strip"
2929464|NCT03044262|Experimental|Cohort 7|This is a sub-study testing the effect of real output applied under two adhesive strips (standard adhesive strip and new adhesive strip) on the skin after 8 hours.
2929465|NCT03044249|Experimental|MP-101|Escalating dose administered orally once daily, starting at 20 milligrams up to 60 milligrams
2929466|NCT03044249|Placebo Comparator|Placebo|Administered orally once daily
2929467|NCT03044236|Experimental|Novel Stretching Technique|Participants will perform the novel stretch in a supine position. Participants will place a small ball between their knees and squeeze the ball. Participants will be then bridge as high as possible . Participants will then flex their shoulder and elbow to 90°, and actively rotate to the end of ROM. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
2929468|NCT03044236|Active Comparator|Traditional Stretching Technique|Participants will perform the modified sleeper stretch in a side-lying position on the side of the throwing shoulder with the throwing shoulder and elbow flexed to 90° . The participants will be instructed to allow the throwing shoulder to naturally fall into internal rotation to the end ROM where resistance will be felt . The participants will be then instructed to use the non-throwing hand to push the throwing shoulder into further internal rotation to the point of mild discomfort by applying pressure at the area of the wrist joint.
2929469|NCT03044210|Other|Cockayne patients|"Interventions performed:~blood sample~urinary collection~metabolic evaluation~clinical evaluation"
2929470|NCT03044210|Other|Control subjects|"Interventions performed:~urinary collection~metabolic evaluation~clinical evaluation"
2929471|NCT03044197|Experimental|MRI/ultrasound transperineal fusion-guided prostate biopsy|In arm A, all patients with positive mpMRI evidence of lesions suspicious for PCa, i.e. PI RADS ≥ 3 will be submitted to transperineal mpMRI-targeted prostate biopsy (arm A MRI+). The gland and the regions of interest will be contoured, and the prostate contour will be fused in real time with the TRUS image. Biopsies will be performed via a transperineal approach in the operating room. The patient will be placed in dorsal lithotomy position. mpMRI-targeted biopsies will be performed on regions of interest, and three to six cores will be obtained for biopsy from each lesion and is standard of care according to START criteria for targeted biopsy. In cases of negative mpMRI results i.e. PI RADS<3, arm A patients will undergo TRUS-guided transrectal 12-core prostate biopsy (arm A MRI-) as described in arm B.
2929472|NCT03044197|Active Comparator|Systematic transrectal ultrasound-guided prostate biopsy|TRUS-guided transrectal prostate biopsy will be performed using a disposable 18-gauge biopsy gun with a specimen size of 18-22 mm (Bard Medical, Covington, GA, USA). The 12 cores will be obtained from 12 separate anatomical regions of the prostate which is standard practice in performing TRUS-guided transrectal prostate biopsy: left medial apex, left lateral apex, left medial midgland, left lateral midgland, left medial base, left lateral base, right medial apex, right lateral apex, right medial midgland, right lateral midgland, right medial base and right lateral base.
2929503|NCT03043989|Active Comparator|Docetaxel and clarithromycin combination|"Docetaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2."
2929473|NCT03044184|Active Comparator|Intervention|"Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage~AND~Patients will have 1gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) intravenously infused over 10 minutes within 3 hours of symptom presentation and another 1 gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) infused over 8 hours."
2929474|NCT03044184|No Intervention|Control|"Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage~AND~Patients will 100ml of normal saline 0.9% intravenously infused over 10 minutes within 3 hours of symptom presentation and another 100ml of normal saline 0.9% infused over 8 hours."
2929475|NCT03044171|Experimental|G-FLUOR+LASER|The corresponding hemiarcade received the application of Low Level Laser Therapy as a desensitizing treatment prior to in-office dental bleaching, followed by the application of 1.1% sodium fluoride after dental bleaching.
2929476|NCT03044171|Experimental|G-FLUOR|The correspondent hemiarcade received only the positioning of the inactive laser tip (placebo), prior to in-office dental bleaching, followed by the application of 1.1% sodium fluoride as a desensitizing treatment after dental bleaching
2929477|NCT03044158|No Intervention|Control group|Onsite ZN or LED fluorescence microscopy + hub-based GeneXpert testing per existing protocols
2929478|NCT03044158|Experimental|Intervention|Onsite molecular testing for TB with GeneXpert + process redesign to facilitate same-day TB diagnosis and treatment + performance feedback
2929479|NCT03044145|Experimental|Project 1: The Cultural Formulation Interview-Engagement Aid|The first project is creating the intervention through patient and clinician feedback at JHMC and expert consensus with the K23 mentoring team. The CFI-EA is a list of questions that clinicians can use to customize patient treatment plans based on a cultural competence assessment.
2929480|NCT03044145|Experimental|Project 2: The Cultural Formulation Interview-Engagement Aid|In this arm the study team will test the revised CFI-EA against treatment as usual in a pilot trial.
2929481|NCT03044145|Active Comparator|Project 2: Treatment as usual|Treatment as usual at JHMC consists of clinicians creating treatment plans for patients without any specific training in medical communication or treatment negotiation.
2929482|NCT03044132|Experimental|DermACELL AWM|Human acellular dermal matrix (ADM) recovered from human donors, decellularized, provided with at least 97% DNA removal, terminally sterilized in its final package, and ready to use.
2929483|NCT03044119|Active Comparator|Dental Implant with PRFM|Intervention in the form of Dental Implants placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix a biological material procured from patient's peripheral blood
2929484|NCT03044119|Experimental|Dental Implant with PRFM and PBMSCs|Intervention in the form of Dental Implant placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix and peripheral blood mesenchymal stem cells which are the biological materials procured from patient's peripheral blood
2929485|NCT03044106|Active Comparator|CLRT|"Subject will don protective eyewear. The hamstring reflexes are two lines on the posterior portion of the top of the head. The direction of stimulation will be determined by a brief manual muscle test.~Once direction is chosen, the aperture of the laser probe will be placed at one end of the reflex (a), turned on and moved to the end of the reflex (b) at a speed of approximately 2 cm/s. The laser will be turned off and quickly returned to point (a), turned on and moved to point (b) again. This will be repeated for a total of 30 times."
2929486|NCT03044106|Sham Comparator|Sham|The Sham procedure will be identical to CLRT except the laser device will be in placebo mode: all device indicator lights and sounds will be functional but no laser light will be emitted from probe aperture.
2929487|NCT03044093|Active Comparator|MISOPROSTOL alone|the common practice currently in our medical center for second trimester medical abortion/ Placebo
2929488|NCT03044093|Experimental|Mifepristone and Misoprostol|"in addition to the common practice currently in our medical center for second trimester medical abortion we will add Mifepristone before administering Misoprostol.~Mifepristone"
2929489|NCT03044080|Active Comparator|IncobotulinumtoxinA|Injection of 200-300 units of IncobotulinumtoxinA (Xeomin ®)
2929490|NCT03044080|Active Comparator|OnabotulinumtoxinA|Injection of 200-300 units of onabotulinumtoxiA (Botox®)
2929491|NCT03044067|Experimental|Pain neuroscience education + Exercise|Pain neuroscience education can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system. It will be applied three times (at baseline, one week and one month after intervention). Exercise will be based on a set of 4 exercise implicating flexion, extension, lateral rotation and abduction of lower and upper extremities.
2929492|NCT03044067|Active Comparator|Exercise|Exercise will be based on a set of 4 exercise implicating flexion, extension, lateral rotation and abduction of lower and upper extremities. Participants will attend three appointments per week over three weeks. They will complete three sets of 10 repetitions, with the exercises progressed in difficulty at each appointment.
2929493|NCT03044054|Experimental|ECHOPULSE|ECHOPULSE HIFU
2929494|NCT03044041|Experimental|Low dose|single dose of intra-articular Tranexamic acid 500 miligrams
2929495|NCT03044041|Active Comparator|High dose|Single dose of intra-articular Tranexamic acid 3 grams
2929496|NCT03044028|Experimental|NMES preoperative and postoperative|Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use preoperative and will continue to use postoperatively until end of study
2929497|NCT03044028|Experimental|NMES postoperative only|Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use postoperatively and will continue to use until end of study
2929498|NCT03044028|No Intervention|No intervention|Subject will not be given device and will undergo the standard rehab protocol alone
2929499|NCT03044015|Experimental|Intervention|a defined strategy for the identification of OF. To carry out a primary care based intervention about lifestyle, diet and drug prescription, if needed, with an intensive follow-up
2929500|NCT03044015|Active Comparator|Control|Intervention as usual
2929501|NCT03044002||4French Intervention|Patient with infrainguinal Peripheral Artery Disease (PAD), requiring endovascular treatment
2929502|NCT03044002||6French Intervention|Patient with infrainguinal Peripheral Artery Disease (PAD), requiring endovascular treatment
2929535|NCT03043820|Placebo Comparator|Placebo|Placebo 2 tablets daily for 12 weeks.
2929504|NCT03043989|Active Comparator|Cabazitaxel and clarithromycin combination|"Cabazitaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2."
2929505|NCT03043976|Active Comparator|feedback and goal-setting group|At the baseline, patients will fill a questionnaire about their quality of life (SF36), will perform a 6'walk test (6MWT), will undertake a blood sample (BNP). In the run-in period (1 week) patients will wear an Actigraph GT9X Link device which only displays the time and the battery level; all activity data will be recorded. Then participants will wear an Actigraph GT9X Link device which shows real time data about the number of steps and will upload their data via the Study Admin Mobile application for smartphones/tablets. Patients will be asked to aim for an average specified number of steps/day week by week and will receive a weekly report with results from the previous week and targets to achieve. After 8 weeks, patients will attend visit 2 (6MWT, SF36 and BNP assessment) and will carry on wearing the activated device for 8 weeks receiving weekly feedbacks and targets. After 8 weeks patients will attend visit 3 (6MWD, SF36 and BNP will be assessed) which is the end of the study.
2929506|NCT03043976|Active Comparator|Control group|At the baseline, patients will fill a questionnaire about their quality of life (SF36), will perform a 6'WT and will undertake a blood sample (BNP). After a run-in period (1 week) with an Actigraph GT9X Link device disabled from showing the number of steps, patients will wear an Actigraph GT9X Link device which still only displays time and battery level and will upload data via the Study Admin Mobile application for smartphones/tablets without receiving any feedback. After 8 weeks, patients will be assessed (SF36, 6'WT, BNP) and will start to wear a new device enabled to display the daily step count. Patients will be asked to aim for an average specified number of steps/day, receiving a weekly summary of the previous week with targets to achieve week by week. After 8 weeks, patients will be assessed (6'WT, SF36, BNP) and will carry on wearing the device and receiving feedbacks and targets for a further 8 week period, after that patients will be finally assessed (SF36, 6'WT, BNP)
2929507|NCT03043976|Placebo Comparator|newly diagnosed patients|"In the week leading up to their inpatient admission for diagnostic investigations, patients who are treatment-naïve will be given the Actigraph GT9X Link device which will only display the time and the charge level of the battery. Patients will be asked, as well, to fill a questionnaire about their quality of life, to perform a 6MWT and a blood sample (BNP). As soon as patients start the drug therapy, patients will wear a second Actigraph GT9X Link device still disabled from showing real time data about the number of daily steps. Participants will not receive any feedback during the whole period and will be asked, as well, to upload the data collected through the remote mobile system. At their first clinical assessment (after about 4 or 5 weeks), 6'WT, BNP and questionnaire about quality of life will be reassessed.~If patients are not being started on drug therapy then they will be withdrawn from the study"
2929508|NCT03043963|Active Comparator|Sleep Timing|Intervention will include basic education concerning sleep hygiene and regularity of sleep timing
2929509|NCT03043963|Experimental|Sleep Extension|Intervention will include basic education concerning sleep hygiene and an extension of the sleep period.
2929510|NCT03043950||low risk|Low risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
2929511|NCT03043950||medium risk|Medium risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
2929512|NCT03043950||high risk|High risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
2929513|NCT03043937||cardiac patients WHO class 1,2|
2929514|NCT03043937||cardiac patients WHO class 3,4|
2929515|NCT03043924|Other|PCOS women|26 PCOS women who receive consultation for hyperandrogenism needing treatment with Cyproterone Acetate + estradiol will be recruited.
2929516|NCT03043924|Other|Healthy volunteers|26 Healthy volunteers subjects who receive consultation contemplating oral contraceptives (Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet ) will be recruited.
2929517|NCT03043898||Part A(i) Healthy Volunteers|50 healthy volunteers. Intervention: Lung sound recording for part A(i) of the study.
2929518|NCT03043898||Part A(ii) Patients|100 patients with wheezing and/or crackles due to respiratory disease. Intervention: Lung sound recording for part A(ii) of the study.
2929519|NCT03043898||Part B(i) 'normal' lung structure|"25 patients who are scheduled to have a Bronchoscopy as part of their standard care and are identified by a medical professional as having a 'normal' lung structure.~Intervention: Lung sound transmission measurement for part B(i) of the study."
2929520|NCT03043898||Part B(ii) 'abnormal' lung structure|"25 patients who are scheduled to have a Bronchoscopy as part of their standard care and are identified by a medical professional as having an 'abnormal' lung structure.~Intervention: Lung sound transmission measurement for part B(ii) of the study."
2929521|NCT03043885|Experimental|PRF|
2929522|NCT03043885|Experimental|PRF+FDBA|
2929523|NCT03043885|Active Comparator|FDBA|
2929524|NCT03043885|Active Comparator|Blood Clot|
2929525|NCT03043872|Experimental|Arm 1|durvalumab+tremelimumab+EP (carboplatin or cisplatin + etoposide)
2929526|NCT03043872|Experimental|Arm 2|durvalumab+EP (carboplatin or cisplatin + etoposide)
2929527|NCT03043872|Active Comparator|Arm 3|EP (carboplatin or cisplatin + etoposide)
2929528|NCT03043859|Experimental|Pure Prairie Living Program|Participants in the intervention arm will participate in 5 weekly education sessions ( 2hours / session) on nutrition education and healthy lifestyle.
2929529|NCT03043859|No Intervention|Wait Listed Control|Participants in the control arm will not receive any intervention.
2929530|NCT03043846||Tight control and Treat to Target arm|For this group, the treating rheumatologist will agree to monitor very closely (at least every 4 weeks) and also to treat their patients in accordance with a pre-defined strategy.
2929531|NCT03043846||Usual care arm|For this arm, the treating rheumatologists will continue to manage the enrolled patients in accordance to their usual care.
2929532|NCT03043833|Experimental|Wellbeing Course|Will receive the French-Canadian version of the Wellbeing Course consisting of five lessons based on cognitive behavior therapy delivered through the Internet over eight weeks.
2929533|NCT03043833|No Intervention|Waitlist-control|The Waitlist Control Group will receive the French-Canadian version of the Wellbeing Course once the treatment group will have completed treatment.
2929534|NCT03043820|Active Comparator|Raloxifene|Raloxifene 120 mg (2 tablets of 60mg) daily for 12 weeks.
2929536|NCT03043807|Experimental|chemohormonal and definitive therapy after prostatectomy|(1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of adjuvant androgen deprivation (Leuprolide Acetate) and up to 6 cycles of chemotherapy (Docetaxel), (2nd) definitive local tumor control with adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions. The men will receive a total of 2 years of androgen deprivation. Androgen blockade (Bicalutamide) will be the same throughout the course of treatment.
2929537|NCT03043794|Experimental|SBRT to the breast then surgery|Stereotactic Body Radiation of 21 gy followed by standard of care surgery
2929538|NCT03043781|Experimental|Intermittent epidural bolus (IEB)|Bolus of 5 ml every hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
2929539|NCT03043781|Active Comparator|Continuous epidural infusion (CEI)|Continuous epidural infusion of 5 ml / hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
2929540|NCT03043768||PD patients|Male and female PD patients (idiopathic parkinsonism, Hoehn and Yahr [H&Y] scores 1-2) aged 35 to 80 years
2929541|NCT03043768||Control subjects|Age-and gender matched healthy control subjects
2929542|NCT03043742|Experimental|Phase I Open Label|"open label bone marrow derived autologous CD133+ selected stem cell application in patients receiving trans-myocardial laser revascularization to improve regional myocardial function as detailed below:~Drug: CD133+ selected stem cells Dosage: Single injection of 0.1-0.2 ml around each laser channel Frequency: 10-20 channels Duration: Trans-Myocardial Revascularization"
2929543|NCT03043729|Active Comparator|Arm A|6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusion q2w followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
2929544|NCT03043729|Experimental|Arm B|6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusionq2w + Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (6th cycle without Aflibercept) followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
2929545|NCT03043703|Experimental|AirSense 10 AutoSet for Her|Treatment for 1 night with ResMed AirSense 10 AutoSet for Her. Intervention: Administration of PAP Treatment with suboptimal pressure for 1 night.
2929546|NCT03043690||Ammonium succinate|Patients in main pooled study group received 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
2929547|NCT03043690||Placebo|Patients in placebo study group received 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
2929548|NCT03043677||Non-inflamed|
2929549|NCT03043677||Inflamed ulcerative colitis|
2929550|NCT03043677||inflamed Crohn´s disease|
2929551|NCT03043664|Experimental|Arm 1|Keytruda (pembrolizumab) 200 mg intravenous (IV) every 3 weeks and Somatuline Depot (lanreotide depot) 90mg subcutaneous (SQ) every 3 weeks
2929552|NCT03043651|Experimental|Oral treprostinil|Sustained-Release tablets for three times daily (TID) administration
2929553|NCT03043638|Experimental|CAF+ADM+PRP|Surgery will include Coronally advanced flap(CAF) plus acellular dermal matrix (ADM) combined with platelet rich plasma (PRP)
2929554|NCT03043638|Active Comparator|CAF+ADM|Surgery will include only Coronally advanced flap CAF technique including ADM placement without PRP
2929555|NCT03043625|Experimental|Visceral manipulation Group (VMG)|The VMG wil be treated with visceral manipulation to the stomach and liver
2929556|NCT03043625|Placebo Comparator|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
2929557|NCT03043612|Experimental|Ureteral Study Stent|Commercially available Cook Sof-Flex® Double Pigtail Ureteral Stent that is coextruded with an alpha-blocker medication
2929558|NCT03043612|Active Comparator|Ureteral Control Stent|Commercially available Cook Sof-Flex® Double Pigtail Ureteral Stent
2929559|NCT03043599|Experimental|Combination Therapy|Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy. Radiotherapy, followed by a 14 to 21 day break between radiotherapy and the beginning of study drug treatment.
2929560|NCT03043586||Treatment Pattern|The first phase of this study will be to contact all subjects in the cohort by a mailing introducing them to the study. This will be followed by a phone call and administration of a questionnaire by phone or by mail. A phone script will be utilized to obtain verbal informed consent from subjects for this phase of the study. The questionnaire will collect current information on acromegaly treatment, morbidities and other relevant history. Subjects will provide verbal consent to participate in this questionnaire part of the study and review of their medical records by the PI and study staff.
2929561|NCT03043573|Experimental|PATH-MCI|Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.
2929562|NCT03043573|Active Comparator|Supportive Therapy|Supportive Therapy focuses on: 1. Facilitating expression of affect; 2. Conveying to the patient that he or she is understood; 3. Offering empathy; and 4. Highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
2929563|NCT03043560|Experimental|Ezogabine|Participants will receive treatment with ezogabine up to 900mg/day.
2929564|NCT03043560|Placebo Comparator|Placebo|Participants will receive treatment with a matching placebo pill.
2929565|NCT03043547|Experimental|Nal-IRI + 5-FU + leucovorin (Arm A)|nal-IRI [Irinotecan liposome] (80 mg/m2 as a 1.5 hour infusion), 5-FU [5-Fluorouracil] (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)
2929566|NCT03043547|Other|5-FU + leucovorin (Arm B)|Control intervention/standard arm: 5-FU (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)
2929567|NCT03043534|Experimental|Gel and Brush|The Experimental group of subjects will be given the study product Pre-Shave Gel and Brush. The gel and brush will be used prior to their normal shave routine. Subjects will shave at least 3 times weekly.
2929568|NCT03043534|No Intervention|Control|Subjects will use their normal razors and shave products during the six week study. Subjects must shave at least 3 times weekly. No change in normal shaving is done in this group
2929569|NCT03043521|Experimental|CJ-12420 50mg|T1=CJ-12420 50mg QD evening (9PM)
2929570|NCT03043521|Experimental|CJ-12420 100mg|T2=CJ-12420 100mg QD evening (9PM)
2929571|NCT03043521|Experimental|CJ-12420 200mg|T3=CJ-12420 200mg QD evening (9PM)
2929572|NCT03043521|Active Comparator|Dexlansopazole 60mg|R=dexlansoprazole 60mg QD evening (9p.m)
2929573|NCT03043508||Participants With Confirmed MEN1 With PNET|"Retrospective review of a prospectively maintained MEN1 database.~Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history."
2929574|NCT03043508||Participants With Confirmed MEN1 Without PNET|"Retrospective review of a prospectively maintained MEN1 database.~Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history."
2929575|NCT03043495|Active Comparator|Group A|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 0.5ml (2mg) Dexamethasone, 1.5ml Normal saline.
2929576|NCT03043495|Active Comparator|Group B|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 1ml (4mg) Dexamethasone, 1ml Normal saline.
2929577|NCT03043495|Active Comparator|Group C|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml (8mg) Dexamethasone.
2929578|NCT03043495|Active Comparator|Group Control|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml Normal saline.
2929579|NCT03043482|Experimental|Single VS-105/placebo to healthy|Single ascending dose VS-105 or placebo to healthy subjects
2929580|NCT03043482|Experimental|Multiple VS-105/placebo to healthy|Multiple ascending dose VS-105 or placebo to healthy subjects
2929581|NCT03043482|Experimental|Multiple VS-105/placebo to HD subjects|Multiple ascending dose VS-105 or placebo to hemodialysis (HD) subjects
2929582|NCT03043469||Healthy participants|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
2929583|NCT03043469||Restrictive lung disease group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
2929584|NCT03043469||Primary dysfunctional Breathing group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
2929585|NCT03043469||Secondary dysfunctional breathing group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, Asthma Control Questionnaire, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
2929586|NCT03043456|Active Comparator|Thermoplastic Resin group|Thermoplastic complete denture placement is done (Thermoplastic Comfort Systems, inc.)
2929587|NCT03043456|Placebo Comparator|conventional acrylic resin group|Conventional acrylic resin complete denture placement is done. (Acrostone, inc.)
2929588|NCT03043443|Placebo Comparator|Placebo|participants will receive placebo 1 capsule/day 1 hour before sleeping for 4 weeks
2929589|NCT03043443|Active Comparator|Melatonin|participants will receive melatonin 1 capsule (5mg)/day 1 hour before sleeping for 4 weeks
2929590|NCT03043430|Experimental|Ketamine|Ketamine 100 mg/mL concentration administered in a single 1.0 mg/kg dose with a maximum of 50mg intranasal via mucosal atomization device.
2929591|NCT03043430|Active Comparator|Midazolam|Midazolam 5 mg/mL concentration administered in a single administered in a single 0.3 mg/kg dose with a maximum of 5mg intranasal via mucosal atomization device.
2929592|NCT03043417|Experimental|CHC's given the intervention|Three CHC sites where all staff receive all components of the intervention. Training, Media, Art workshops, and a Policy analysis as well as survey completion.
2929593|NCT03043417|No Intervention|CHC's with NO intervention|Three CHC sites where all staff and a selection of clients complete surveys but receive no intervention.
2929594|NCT03043404|Experimental|Lotus Valve Flex System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve FLEX System
2929595|NCT03043391|Experimental|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO is an altered form of the live polio vaccine. It was produced by removing a piece of the virus and replacing it with a piece from a common cold virus. This was done to make sure PVSRIPO cannot cause polio even when injected into the brain.
2929596|NCT03043378||Chronic Non-Malignant Pain - Cancer Patients|Chronic non-malignant pain among cancer patients undergoing a consultation at the outpatient Supportive Care Clinic at MD Anderson Cancer Center.
2929597|NCT03043365|Experimental|Group 1|Subjects randomized to the control fish oil arm will take the equivalent to 3g of control /day (12 gel capsules/day) for 8 plus or less 2 weeks and cross-over to the LCMUFA-rich saury oil capsule arm
2929795|NCT03041857||GMK PS|Subjects with a unilateral Medacta GMK Primary PS Fixed Bearing TKA
2929598|NCT03043365|Experimental|Group 2|Subjects randomized to the LCMUFA-rich saury oil arm will take the equivalent to 3g of control/day (12 gel capsules/day) for 8 plus or less 2 weeks and crossoverto the control fish oil capsule arm
2929599|NCT03043352|Experimental|Group A (intervention)|'Management of SAM at home' LHWs will identify and treat all cases of severe acute malnutrition (SAM) as per the study eligibility criteria (MUAC < 11.5 cm) and manage all cases of SAM without complications at home with 'Standard CMAM program'. The LHWs will also identify SAM with complications for further assessment to the BHU Doctor and subsequent referral to the stabilization center . They will also provide one to one health and Infant and Young Child Feeding (IYCF) counselling to care takers of children in their catchment area.
2929600|NCT03043352|Active Comparator|Group B (Control)|'Management of SAM at facility' LHWs will identify SAM as per 'Standard CMAM program' (MUAC < 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
2929601|NCT03043339||Renal transplant recipient|"Participants who are scheduled for a planned renal transplant as the recipient of the kidney.~All participants will complete the following interventions:~Stool Specimen Collection~Anal Swab Sampling~Short Diet Assessment (SDA)~NHANES Dietary Screener Questionnaire (DSQ)"
2929602|NCT03043339||Renal transplant donor|"Participants who are scheduled for a planned renal transplant as the donor of the kidney.~All participants will complete the following interventions:~Stool Specimen Collection~Anal Swab Sampling~Short Diet Assessment (SDA)~NHANES Dietary Screener Questionnaire (DSQ)"
2929603|NCT03043313|Experimental|Treatment (ErbB-2 inhibitor tucatinib, trastuzumab)|Patients receive ErbB-2 inhibitor tucatinib PO BID on days 1-21 and trastuzumab IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2929604|NCT03043300||US Travelers to South or Southeast Asia|"Adult individuals who are planning a short term trip to South or Southeast Asia and meet all eligibility criteria will complete the questionnaires and/or provide stool specimens at the following time points:~No greater than 4 weeks prior to travel departure: Screening Criteria Review~One week prior to travel departure: Pre-Travel Questionnaire and Pre-Travel Stool Specimen Collection~Two weeks after return from travel: Short-Term Post-Travel Questionnaire and Short-Term Post-Travel Stool Specimen Collection~14 weeks after return from travel: Long-Term Post-Travel Questionnaire and Long-Term Post-Travel Stool Specimen Collection"
2929605|NCT03043287||BOTOX®|Participants who received 100 to 200 units (U) onabotulinumtoxinA (BOTOX®) as treatment for OAB. No study drug is administered in this study.
2929606|NCT03043274|Experimental|Cangrelor|Approximately 30 patients in this arm will receive standard STEMI care but will also receive standard dosing of cangrelor at the time of their PCI.
2929607|NCT03043274|No Intervention|No cangrelor|Approximately 30 patients in this arm will receive standard STEMI but will not receive cangrelor at the time of their PCI.
2929608|NCT03043261|Experimental|Psycho-Behavioral Intervention|"Williams LifeSkills modules which cover 10 core skills designed to improve coping skills, stress management and interpersonal relationships: 1) being aware of negative thoughts and feelings, 2) making a decision, 3) deflection skills, 4) problem solving or action skills, 5) assertion, 6) saying no, in addition to the following preventive skills: 7) speaking up, 8) listening, 9) empathy and 10) increasing positives"
2929609|NCT03043248|Experimental|Cohort A|TRK-700 + Digoxin
2929610|NCT03043248|Experimental|Cohort B|TRK-700 + Midazolam
2929611|NCT03043235||African American Females|No intervention
2929612|NCT03043235||African American Males|No intervention
2929613|NCT03043235||Caucasian Females|No intervention
2929614|NCT03043235||Caucasian Males|No intervention
2929615|NCT03043222|Experimental|PAE-Prostate Arterial Embolization|PAE-Prostate Arterial Embolization
2929616|NCT03043222|Active Comparator|PUL- Prostatic urethral lift|PUL- Prostatic urethral lift
2929617|NCT03043209||Genomic sequencing|Perform Genomic sequencing in peripheral blood DNA and discarded myocardium from cardiac procedures
2929618|NCT03043196|Active Comparator|Rosuvastatin Group|Oral prophylaxis followed by 1.2% Rosuvastatin drug in gel form placed in intrabony defects
2929619|NCT03043196|Placebo Comparator|Placebo Group|Oral prophylaxis followed by placebo gel placement in intrabony defects
2929620|NCT03043183|Experimental|Preoperational nutrition support group|Scored patient-generated subjective global assessment(PG-SGA) ≥2，＜9 Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
2929621|NCT03043183|No Intervention|Conventional group|PG-SGA ≥2，＜9
2929622|NCT03043157|Other|Dose-finding group|The first patient will receive rocuronium 0,6mg/kg. After that, every patient's dose will depend on the outcome of the previous patient. It will go up 0,1mg/kg if the laparoscopic conditions were not excellent or go down 0,1mg/kg otherwise.
2929623|NCT03043144||End stage renal disease|Observational study, no intervention
2929624|NCT03043131|Active Comparator|Ringer Lactate|patients randomized to this arm are given ringer's lactate solution for cardiopulmonary bypass prime, which is the standard practice
2929625|NCT03043131|Experimental|Plasmalyte A|patients randomized to this arm are given Plasma Lyte - A solution for cardiopulmonary bypass prime
2929626|NCT03043118|Experimental|Variety|Children receive three servings of vegetables each prepared with a different herb and spice blend.
2929627|NCT03043118|No Intervention|No Variety - Control|Children receive three servings of vegetables each prepared with the same herb and spice blend.
2929628|NCT03043105|Experimental|TCP regimen|Thalidomide, cyclophosphamide and prednisone （TCP regimen）would be used for newly-diagnosed symptomatic MCD patients
2929629|NCT03043092||Critically ill patients with cardiovascular risk factors|Critically ill patients with cardiovascular risk factors (age>50 yrs old for male, age >60 yrs for female, dyslipidemia, hypertension, diabetes, smoking, stroke, peripheral arteriopathy, chronic kidney disease) AND without neurological disorders.
2929630|NCT03043092||Critically ill patients without cardiovascular risk factors|Critically ill patients without cardiovascular risk factors and without neurological disorders.
2929631|NCT03043079|Experimental|Ventral Hernia|Twenty-five patients diagnosed with ventral hernia
2929632|NCT03043079|Other|Healthy Volunteers|Twenty-five volunteers without ventral hernia
2929633|NCT03043079|Other|Active Health Volunteers|Ten healthy volunteers with an International Physical Activity Questionnaire (IPAQ) with the scoring result of High or Vigorous Intensity
2929634|NCT03043066|Placebo Comparator|Group A -control group|15 subjects underwent scaling and root planing
2929635|NCT03043066|Active Comparator|Group B-Interventional group|15 subjects underwent scaling and root planing along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
2929636|NCT03043053|Experimental|oxytocin|oxytocin nasal spray (24 IU nasal spray, 4 times per day for 8 weeks)
2929637|NCT03043053|Placebo Comparator|placebo|placebo nasal spray (4 times per day for 8 weeks)
2929638|NCT03043040|Experimental|Telephone follow up|"Patients discharged from hospital A and B after a suicide attempt receive a protocolized telephone follow which is added to their usual treatment (TAU). Calls are made by nurses at weeks 1,2,4,12 and 24 after the index suicide attempt.~TAU: Includes whatever treatment the doctor decides to offer to that patient (psychopharmacology, psychotherapy etc)."
2929639|NCT03043040|Active Comparator|Control|Patients discharged from hospital C after a suicide attempt receive treatment as usual (whatever treatment the doctor decides to offer to that patient: psychopharmacology, psychotherapy etc).
2929640|NCT03043027|Experimental|Liposomal bupivicaine|
2929641|NCT03043027|Active Comparator|bupivicaine|
2929642|NCT03043027|Placebo Comparator|saline|
2929643|NCT03043014|Experimental|Mifépristone group|
2929644|NCT03043014|Active Comparator|misoprostol group|
2929645|NCT03043001|Other|add-on memantine therapy|add-on memantine treatment
2929646|NCT03042988|Experimental|Heat Stress|Passive heat-stress using a commercial heating pad applied on the trunk
2929647|NCT03042988|Sham Comparator|Control (Non-heating)|Commercial heating pad applied on the trunk but turned off
2929648|NCT03042975||Spasmodic dysphonia|Patients with spasmodic dysphonia will undergo MRI of the brain and blood draw.
2929649|NCT03042975||Unaffected relatives|Unaffected relatives of patients with spasmodic dysphonia will undergo MRI of the brain and blood draw.
2929650|NCT03042975||Healthy volunteers|Healthy subjects without any neurological, psychiatric or otolaryngological problems will undergo MRI of the brain and blood draw.
2929651|NCT03042962||Patients with dystonia|Patients with dystonia (spasmodic dysphonia, singer's dystonia, writer's cramp, musician's focal hand dystonia) will undergo MRI of the brain and blood draw.
2929652|NCT03042962||Healthy volunteers|Healthy subjects without any neurological, psychiatric or otolaryngological problems will undergo MRI of the brain and blood draw.
2929653|NCT03042949|Experimental|Blood pressure measurement|Patients requiring blood pressure measurement will have their blood pressure measured in the standard manner by plethysmography, and then with the Elfor -1 device , the new optical sensor, in order to determine the performance of the new sensor.
2929654|NCT03042936|Experimental|Arm 1|Insulin Superheroes Club Curriculum
2929655|NCT03042923||Treatment|Twenty patients, known to us through care at Women's Surgery Center and the private practice of Dr. R. Scott Furr, will be invited to enroll based on a history of pelvic pain and a plan for surgical evaluation and intervention
2929656|NCT03042923||Control|Ten healthy female patients, without pelvic pain or history of autoimmune disease, will be asked to participate as controls.
2929657|NCT03042910|Experimental|Patients with advanced solid tumors|Talazoparib 1 mg daily
2929658|NCT03042897|Experimental|Supportive Care (exercise and diet)|Patients undergo aerobic exercise thrice weekly over 95 minutes for up to 16 weeks. Patients also undergo multi-lifestyle interventions based on the DASH diet once weekly over 1 hour for up to 16 weeks.
2929659|NCT03042884|Experimental|Wearable Exercise Trackers - Inpatient Group|"Questionnaires completed at baseline and within 24 hours of discharge.~Participant given a wearable exercise tracker to be worn 24 hours a day while in the acute inpatient rehabilitation unit."
2929660|NCT03042884|Experimental|Wearable Exercise Trackers - Outpatient Group|"Questionnaires completed at baseline and again in 14 days.~Participant given a wearable exercise tracker to be worn 24 hours a day for 14 days."
2929661|NCT03042871|Active Comparator|Group A|Group A included 30 patients treated with one 0.5mg intravitreal ranibizumab injection. All patients were followed monthly for 12 months with additional injections performed as needed.
2929662|NCT03042871|Active Comparator|Group B|Group B included 30 patients treated with three monthly 0.5mg intravitreal ranibizumab injections. All patients were followed monthly for 12 months with additional injections performed as needed.
2929663|NCT03042858||Infants with PPV|During laparoscopy for pyloric stenosis, the surgeon will turn the camera downward to answer the first question, whether the inguinal canal is patent or closed. If a PPV is present, the subject will be followed for up to 18 years of age.
2929664|NCT03042858||Infants without PPV|During laparoscopy for pyloric stenosis, the surgeon will turn the camera downward to answer the first question, whether the inguinal canal is patent or closed. If there is no PPV, meaning they have normal anatomy, the patient demographic data will be recorded and this will terminate their participation.
2929665|NCT03042845|Active Comparator|Judkins L3.5/R4 cardiac catheters|
2929666|NCT03042845|Experimental|Tiger cardiac catheter|
2929667|NCT03042832|Experimental|LOCI|Leadership development with coaching and organizational change support
2929668|NCT03042832|Active Comparator|WEBINAR|Webinar leadership training
2929669|NCT03042819|Experimental|Selinexor plus Doxorubicin|"Selinexor will be given by mouth (orally) once a week:~Dose Level -1 = 40 mg Dose Level 1 (Starting Dose) = 60 mg Dose Level 2 = 80 mg~Doxorubicin will be given by vein (intravenously) at a dose of 75 mg/m2 once every 3 weeks."
2929670|NCT03042806|Other|experimental group|COPD patients will be asked to fill in the Maugeri Physical Activity Questionnaire (MaPAct) to assess self perceived physical activity.
2929671|NCT03042793|Experimental|Vaccination|Vaccine: PD-L1 peptide.
2929672|NCT03042780|Experimental|FOLFIRINOX Treatment|Participants will receive modified FOLFIRINOX which consists of 85 mg/m^2 of oxaliplatin, 400 mg/m^2 of leucovorin over the first 2 hours, 165 mg/m^2 of irinotecan in a 90-minute infusion on day 1, followed by a continuous, 46-hour infusion of 5-FU at a dosage of 2,400 mg/m^2. A cycle will be repeated every 14 days. Granulocyte colony-stimulating factor (G-CSF) prophylaxis will be allowed after each cycle. Participants will undergo re-staging studies every 8 weeks. Participants will receive up to 12 cycles during the study. Additional cycles will be determined per investigators' discretion.
2929796|NCT03041857||GMK UC|Subjects with a unilateral Medacta GMK Primary UC Fixed Bearing TKA
2929673|NCT03042767|Experimental|IMM-124E Group|Participants with nonalcoholic fatty liver disease (NAFLD) will receive 600mg of IMM-124E powder three times daily for twelve weeks.
2929674|NCT03042767|Placebo Comparator|Placebo Group|Participants with nonalcoholic fatty liver disease (NAFLD) will receive placebo powder three times daily for twelve weeks.
2929675|NCT03042754|Other|suspected TB|Patients suspected with TB will be sent for XpertMTB/RIF and urine LAM test
2929676|NCT03042741|Experimental|V6 recipients|Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive V6 - oral atherosclerosis vaccine administered once per day for one month
2929677|NCT03042741|Placebo Comparator|Placebo recipients|Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive placebo pills given once per day as a single pill for one month
2929678|NCT03042728|Active Comparator|Dog interaction|Dog interaction will be received by patients in addition to usual care of fibromyalgia.
2929679|NCT03042728|Active Comparator|Human Interaction|Human interaction will be received by patients in addition to usual care of fibromyalgia.
2929680|NCT03042715||Psychological Intervention|"Eight weekly sessions in-person or via telephone~Qualitative interviews~Feedback from 5-10 caregivers to refine the intervention."
2929681|NCT03042702|Experimental|Cohort 1|Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends
2929682|NCT03042702|Experimental|Cohort 2|Kevetrin 350 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (1050 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends
2929683|NCT03042689|Experimental|Regorafenib|
2929684|NCT03042663|Experimental|Intervention group|In patients meeting the inclusion criteria and with absence of any exclusion criteria, and after taking PI and Doppler Blood flow values hourly for 3 hours (control values), the procedure for administering the USG Stellate ganglion block on the side of the arterial cannula will be started
2929685|NCT03042650|Experimental|Intensive Referral Intervention Group|Intensive Referral Intervention will by done by trained probation officers
2929686|NCT03042650|Active Comparator|Standard Practice Facilitated Group|Standard Current Practice will be provided by untrained probation officers
2929687|NCT03042637||Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus
2929688|NCT03042624|Experimental|Fermented rice|7 g of fermented rice flour powder obtained from Lactobacillus paracasei CBA L74 to be diluted in milk or water
2929689|NCT03042624|Placebo Comparator|Maltodextrins|7 g of maltodextrins powder to be diluted in milk or water
2929690|NCT03042611|Experimental|Apatinib|
2929691|NCT03042611|Experimental|Placebo|
2929692|NCT03042598|Experimental|Biphasic Cuirass Ventilation|Patients requiring emergent intubation in the Emergency Department will be provided ventilation during the apnic phase of intubation via the use of BCV.
2929693|NCT03042585|Experimental|Dose Level 1|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.64 Gy per Fraction for a total of 8 Fractions. The total amount would be 13.12 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
2929694|NCT03042585|Experimental|Dose Level 2|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.76 Gy per Fraction for a total of 8 Fractions. The total amount would be 14.08 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
2929695|NCT03042585|Experimental|Dose Level 3|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.88 Gy per Fraction for a total of 8 Fractions. The total amount would be 15.04 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
2929696|NCT03042585|Experimental|Dose Level 4|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 2.00 Gy per Fraction for a total of 8 Fractions. The total amount would be 16 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
2929697|NCT03042572|Experimental|Allogeneic Mesenchymal Stromal Cell|Intramuscular Allogeneic Bone marrow-derived Mesenchymal Stromal Cell Injection
2929698|NCT03042572|Placebo Comparator|Placebo|Intramuscular placebo injection
2929699|NCT03042559|Active Comparator|Protonics knee brace|All subjects were fitted with a regular-sized Protonics knee brace with resistive settings to resist knee flexion.
2929700|NCT03042559|Experimental|Sport cords|Resistive sports cord to resist knee flexion.
2929701|NCT03042546|Active Comparator|Calcium Sulphate|
2929702|NCT03042546|Active Comparator|PMMA|
2929703|NCT03042546|Active Comparator|Nothing|
2929704|NCT03042533|Active Comparator|Conventional Compression|Nail will be seated using conventional compression technique
2929705|NCT03042533|Active Comparator|Standard Backslapping|Nail will be seated using standard backslapping technique
2929706|NCT03042533|Active Comparator|Dynamic Locking with Backslapping|Nail will be seated using backslapping with dynamic locking
2929707|NCT03042520||IFN-based therapy historical controls|Patients who had ever participated the parent studies, GS-US-334-0115 or GS-US-337-0131, will be invited to participate the current study in outpatient clinic. For the patients who have participated study will be invited to participate the current study as matched historical control n our outpatient clinic,
2929797|NCT03041844|Experimental|Low Frequency, Low Intensity Ultrasound|Low Frequency, Low Intensity therapeutic ultrasound applied weekly for up to 16 weeks.
2929708|NCT03042520||Sofosbuvir-based therapy observational group|"Patients ≥ 20 of years who had ever participated in parent studies, GS-US-337-0131 (NCT02021656) or GS-US-334-0115 (NCT02021643)~Patients who had received at least one dose of sofosbuvir-based therapy in the parent studies.~Who IFN-based therapy historical controls, matched with sex, age, level of liver fibrosis and virological response:~Patients ≥ 20 of years who had received peginterferon plus ribavirin therapy with match of sex, age, level of liver fibrosis and virological response~Patients who have ever participated study will be collected as historical control."
2929709|NCT03042507|Other|Open Trial|This is a non-randomized open trial of a behavioral intervention for young children with tics
2929710|NCT03042494|Placebo Comparator|Control|Isocaloric food without the test prebiotic.
2929711|NCT03042494|Experimental|Prebiotic|Prebiotic consumed as one daily serving of 7 g in Group 1 and consumed as one daily serving of 2.5-3 g in Group 2.
2929712|NCT03042468|Experimental|All subjects|"177Lu-PSMA-617 [50mCi (1.85GBq) - 300mCi (11.1GBq)] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)~68Ga-PSMA-HBED-CC [5 ±2mCi or 185 ±74MBq] intravenous during screening and at 12 weeks with standard imaging"
2929713|NCT03042455|Experimental|Robot and rTMS|Robot-Assisted upper arm training and Repetitive Transcranial Magnetic Stimulation group(intervention group 1)
2929714|NCT03042455|Experimental|Robot|Robot-Assisted upper arm training group(intervention group2)
2929715|NCT03042455|Active Comparator|Conventional|Conventional training group(control group)
2929716|NCT03042442||Patients with pancreatic cancer|Patients with pancreatic ductal adenocarcinoma, based on the results of an endoscopic ultrasonography (EUS) biopsy or surgery were enrolled at the diagnosis, before any therapeutic intervention.
2929717|NCT03042442||health patients (controls)|Health patients
2929718|NCT03042429|Experimental|experimental arm|Drug: Cycles N8, N5, and N6 Drug: topotecan, cyclophosphamide, and etoposide (N8 cycle) followed by Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)
2929719|NCT03042429|Active Comparator|standard arm|Drug: Cycles N5 and N6 Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)
2929720|NCT03042416|Experimental|18F-DOPA scan|18F-DOPA (4 MBq/kg, minimum 110 MBq, maximum 600 MBq) intravenous. Single-dose 20-80 minutes prior to PET/CT scan of brain or whole body (depending on specific imaging protocol for patient).
2929721|NCT03042403||Breath stacking|During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds. During the 20 seconds of applying of technic, in the three series the maximum inspiratory and expiratory pressures reached during the carrying out of technic. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
2929722|NCT03042390||DArunavir/cobicistat|Patients starting treatment with a regimen containing Darunavir / cobicistat for at least 24 weeks
2929723|NCT03042377|Active Comparator|Single-Visit Retreatment|Root canal retreatment were performed according to the guidelines for single-visit endodontic treatments.
2929724|NCT03042377|Active Comparator|"Multiple-Visit-Calcium Hydroxide"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
2929725|NCT03042377|Active Comparator|"Multiple-Visit-Corticosteroid Paste"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
2929726|NCT03042377|Active Comparator|"Multiple-Visit-Antibiotic Paste"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
2929727|NCT03042364|No Intervention|No intervention|Standard treatment
2929728|NCT03042364|Experimental|Intervention|Endometrial scratching before standard treatment
2929729|NCT03042351|Other|Unique arm|Magic Kegel app
2929730|NCT03042338|Experimental|Central Executive Training1|Training tasks targeting working memory
2929731|NCT03042338|Active Comparator|Central Executive Training2|Training tasks targeting inhibitory control and response speed
2929732|NCT03042325|Experimental|Alogliptin|Alogliptin 25 mg, tablets, orally, once, daily for 26 weeks in addition to standard care for the management of Type 2 Diabetes Mellitus (T2DM). Dose will be adjusted as per creatinine clearance [CrCl].
2929733|NCT03042312|Experimental|Lu177-PSMA-617-dose 1|Repeated i.v. application of 6.0 GBq (gigabequerel )(±10%, arm 1) every 8±1 weeks;RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
2929734|NCT03042312|Experimental|Lu177-PSMA-617- dose 2|Repeated i.v. application of 7.4 GBq (±10%, arm 2) of drug every 8±1 weeks;RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
2929735|NCT03042299|Experimental|TAK-536 10 mg Cohort a|"In Period 1, the participant will orally receive one sachet of TAK-536 granules containing 10 mg TAK-536 with 200 mL water under fasted conditions in the morning (fasted for more than 10 hours after the last meal on the day before the study drug administration [Day 1]).~In Period 2, the participant will orally receive one TAK-536 10mg tablet with 200 mL water under fasted conditions in the morning (fasted for more than 10 hours after the last meal on the day before the study drug administration [Day 1])."
2929736|NCT03042299|Experimental|TAK-536 10 mg Cohort b|"In Period 1, the participant will orally receive one TAK-536 10 mg tablet with 200 mL water under fasted conditions in the morning (fasted for more than 10 hours after the last meal on the day before the study drug administration [Day 1]).~In Period 2, the participant will orally receive one sachet of TAK-536 granules containing 10 mg TAK-536 with 200 mL water under fasted conditions in the morning (fasted for more than 10 hours after the last meal on the day before the study drug administration [Day 1])."
2929737|NCT03042273|Experimental|High Strength Cranberry|1 capsule of High Strength Cranberry (25,000mg Vaccinium macrocarpon) orally daily for 6 months
2929738|NCT03042273|Placebo Comparator|Placebo|1 capsule of Matching Placebo orally daily for 6 months
2929739|NCT03042260|Experimental|Trimethoprim-Sulfamethoxazole (TMP-SMX)|Trimethoprim-Sulfamethoxazole 180mg/800mg oral tablet, 3 times a week, for 6 months. Subjects may remain on the drug longer (maximum 1 year), if they continue to receive intermediate or high dose steroids at the end of 6 months.
2929740|NCT03042260|Placebo Comparator|Placebo|"Tablets that look exactly the same as the experimental drug, 3 times a week, for 6 months.~Subjects may remain on the placebo longer (maximum 1 year), if they continue to receive intermediate or high dose steroids at the end of 6 months."
2929741|NCT03042234|Experimental|Group I|Adolescents obese with insulin resistance
2929742|NCT03042234|Experimental|Group II|Adolescents obese without insulin resistance
2929743|NCT03042234|Experimental|Group III|Adolescents eutrophyc
2929744|NCT03042208|Experimental|Intervention|Access to Weight Watchers in-person meetings and online tools.
2929745|NCT03042208|Other|Self-Guided Control Group|Received handout with basic weight management advice.
2929746|NCT03042195|Active Comparator|Intervention group|Supplementary parenteral nutrition
2929747|NCT03042195|No Intervention|Control group|The control group will receive standard nutritional care
2929748|NCT03042182|Experimental|Single pill of V3-X vaccine administered once daily|One pill of oral therapeutic vaccine V3-X administered to patients with cholangiocarcinoma for two months and changes in CA19.9 tumor marker from baseline levels versus post-treatment levels will be assessed as correlates of changes in tumor burden
2929749|NCT03042169|Active Comparator|Chemotherapy|Patients assigned to standard treatment will continue to receive the same chemotherapy regimen they received before randomization; alternative chemotherapy regimen might be discussed, according to local standards and national guidelines, in case of poor tolerance or pathological tumour progression (www.tncd.org).
2929750|NCT03042169|Experimental|Surgery|Patients assigned to surgical treatment will undergo gastrectomy between D1 and D30 after randomization, either subtotal or total gastrectomy, depending on the location of the primary tumour.Subtotal gastrectomy is recommended if allowing a complete resection of the primary tumour to limit postoperative morbidity
2929751|NCT03042143|Experimental|Human umbilical cord derived CD362 enriched MSCs|Maximum tolerated dose from the phase 1 trial will be infused over 30 to 90 mins
2929752|NCT03042143|Placebo Comparator|Placebo (Plasma-Lyte 148) infusion|Plasma-Lyte 148 infused over 30 to 90 mins
2929753|NCT03042130|Experimental|Iron Carboxymaltose|"standard of care + double dose of IV iron ferinject~the medicine will be given twice within one week."
2929754|NCT03042130|Other|control|standard of care
2929755|NCT03042117||No Coronary Artery Disease (CAD)|Patients with no known cardiovascular disease.
2929756|NCT03042117||CAD without Myocardial Infarction (MI)|Patients with cardiovascular disease without a myocardial infarction.
2929757|NCT03042117||CAD with MI|Patients with cardiovascular disease with previous history of a myocardial infarction.
2929758|NCT03042104|Experimental|TAVR|Transcatheter aortic valve replacement (TAVR) arm will have intervention with the Edwards SAPIEN 3 THV.
2929759|NCT03042104|No Intervention|CS|Clinical surveillance
2929760|NCT03042091|Active Comparator|Arm I (mechanical bowel prep, oral antibiotics)|Patients receive polyethylene glycol orally (PO), neomycin PO, and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.
2929761|NCT03042091|Experimental|Arm II (oral antibiotics)|Patients receive neomycin PO and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.
2929762|NCT03042078|Experimental|Zero-fluoroscopic ablation|Paroxysmal supraventricular tachycardia will be ablated under the guidance of Ensite NavX and without the use of fluoroscopy.
2929763|NCT03042078|Active Comparator|Conventional fluoroscopic ablation|Paroxysmal supraventricular tachycardia will be ablated under the guidance of Ensite NavX plus fluoroscopy.
2929764|NCT03042065|Experimental|vibrating Mesh nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer
2929765|NCT03042065|Active Comparator|jet nebulizer|Receive, in the same aerosol solution, 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using a jet nebulizer
2929766|NCT03042052||Patients suffering from NDO managed with Botox|"Doses used were 300 units Botox® from January 2001 to January 2011 and 200 units after 2011~Frequency depended on patient's symptoms~Duration was an outcome of the study"
2929767|NCT03042039||Study group 'New Care'|Frail elderly receiving care within new organisational models delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform) as provided by pilot sites individually.
2929768|NCT03042026||Acromegaly patients|Acromegaly patients
2929769|NCT03042026||Healthy subjects|Healthy volunteers
2929770|NCT03042013|Experimental|ASP8273|Subjects will receive a once or twice daily oral dose of ASP8273 (3 dose strengths)
2929771|NCT03042000|Experimental|Group A1|Patients with cT3a-bN0-1aM0 mid rectal cancer who undergo the treatment modality of 'radical surgery + adjuvant chemotherapy (ACT)'
2929772|NCT03042000|Active Comparator|Group A2|Patients with cT3a-bN0-1aM0 mid rectal cancer who undergo the treatment modality of 'NCRT + radical surgery + ACT'
2929773|NCT03042000|Experimental|Group B1|Patients with cT4NanyM0 or cTanyN2M0 mid/low rectal cancer who undergo the treatment modality of 'NCRT with combined chemotherapy (Capox regimen) + radical surgery + ACT'
2929774|NCT03042000|Active Comparator|Group B2|Patients with cT4NanyM0 or cTanyN2M0 mid/low rectal cancer who undergo the treatment modality of 'NCRT with single-agent chemotherapy (Capecitabine) + radical surgery + ACT'
2929775|NCT03042000|Experimental|Group C1|Patients with locally advanced rectal cancer, being clinically staged cCR after NCRT, who undergo the transanal endoscopic microsurgery (TEM) excision of the lesion.
2929776|NCT03042000|Active Comparator|Group C2|Patients with locally advanced rectal cancer, being clinically staged cCR after NCRT, who undergo the radical resection of the lesion.
2929798|NCT03041844|Sham Comparator|Sham Ultrasound|Sham ultrasound applied weekly for up to 16 weeks.
2929838|NCT03041558|Experimental|SafeCare+ (SC+)|SafeCare intervention with the additional Healthy Relationships (HR) module
2929839|NCT03041558|Active Comparator|SafeCare (SC)|SafeCare intervention as usual
2929777|NCT03041987||Chronic Kidney Disease|"Specified estimated glomerular filtration rate (eGFR) range according to different CKD etiologies. For glomerular nephrology patients, the eGFR should be ≥15 ml/minute per 1.73m(2). For diabetic nephrology patients, the defining eligibility was 15 ml/minute per 1.73m(2)≤eGFR <60 ml/minute per 1.73m(2) or eGFR≥ 60 ml/minute per 1.73m(2) with nephrotic range proteinuria, which is defined as 24-hour urinary protein ≥3.5 g or urinary albumin creatinine ratio ≥2 000 mg/g or corresponding values of urine dipstick test or urinary protein creatinine ratio. For non-glomerular nephrology and non-diabetic nephrology patients, 15 ml/minute per 1.73m(2) ≤eGFR<60 ml/minute per 1.73m(2) is set for enrollment."
2929778|NCT03041974||Transfused critical care patients|Patients included in the Age of BLood Evaluation (ABLE) trial in either arms and included in a French center.
2929779|NCT03041961|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 1-hard capsule regimen (500 mg)
2929780|NCT03041961|Active Comparator|Aronia full spectrum|Formulation of an aronia full spectrum ingredient in a 1-hard capsule regimen (500 mg)
2929781|NCT03041961|Active Comparator|Aronia extract|Formulation of an aronia extract ingredient in a 1-hard capsule regimen (500 mg)
2929782|NCT03041948|Active Comparator|Caudal-epidural nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The CE group will receive an US-confirmed CE nerve block with 0.8 mL/kg of 0.2% ropivacaine (maximum 15 mL).
2929783|NCT03041948|Experimental|ilioinguinal/iliohypogastric nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The IIG/IHG group will receive a unilateral US guided IIG/IHG with 0.4mL/kg of ropivacaine 0.2% (max 12 mL).
2929784|NCT03041935|Active Comparator|Caudal-epidural nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The CE group will receive an US-confirmed CE nerve block with 0.8 mL/kg of 0.2% ropivacaine (maximum 15 mL). An additional 0.2 mL/kg of ropivacaine 0.2% (max 4mL) will be used for scrotal skin infiltration.
2929785|NCT03041935|Experimental|Ilioinguinal/iliohypogastric nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The IIG/IHG group will receive a unilateral US guided IIG/IHG with 0.4mL/kg of ropivacaine 0.2% (max 12 mL). An additional 0.2 mL/kg of ropivacaine 0.2% (max 4mL) will be used for scrotal skin infiltration.
2929786|NCT03041922||Healthy group|Every participant passes one ultrasound exam for soft tissues in buttocks in order to measure the elasticity of soft tissues in sitting and lying down positions. This kind of exam may help to predict a development in pressure ulcers
2929787|NCT03041909|Experimental|Single Arm|Single Arm / open label
2929788|NCT03041896||Decompression|Standard of care decompression for spinal stenosis, 1 or 2 levels.
2929789|NCT03041896||Fusion|Standard pedical and rod fixation with standard decompression, 1 or 2 levels.
2929790|NCT03041896||coflex®|Decompression surgery with the coflex® Interlaminar Technology, 1 or 2 levels.
2929791|NCT03041883|Experimental|Kpro with crosslinked graft-support|Patient will receive a crosslinked corneal graft-support for the KPro type I. Under sterile conditions, the corneo-scleral button will be inspected, then placed on an artificial anterior chamber. The epithelium of the donor will be removed mechanically. Then one drop of riboflavin 0.1%/dextran 20% will be applied to 3 minutes on the de-epithelialized cornea for 15 minutes. Then, the source of ultraviolet A (UVA) will be irradiating the cornea for 30 minutes with a wavelength of 370 nanometer(nm) length with 5.4 joules(J)/ square centimeter (cm2) and 3 milliwatts(mW)/cm2. Meanwhile, the instillation of a drop of 0.1% riboflavin/dextran 20% continues every 5 minutes. Goggles against UVA are mandatory. The crosslinked graft-support will be forwarded to the surgeon according to standard procedure.
2929792|NCT03041883|Active Comparator|KPro with normal graft-support|Patient wil receive a normal graft-support for the KPro type I. Under sterile conditions, the corneo-scleral button will be inspected, then placed on an artificial anterior chamber. The epithelium of the donor will be removed mechanically. Then, one drop of riboflavin 0.1% / dextran 20% will be applied to 30 secondes for 5 minutes on the de-epithelialized cornea.The minimally manipulated normal graft-support will be forwarded to the surgeon according to standard procedure.
2929793|NCT03041870|Experimental|Dominance|Healthy subjects
2929794|NCT03041857||GMK Sphere|Subjects with a unilateral Medacta GMK Sphere TKA
2929799|NCT03041831||Older adult individual interviews|The investigators will conduct 8 semi-structured 60-minute interviews with patient participants.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
2929800|NCT03041831||Clinician individual interviews|The investigators will conduct 6 semi-structured 60-minute interviews with primary care clinicians who care for older adult populations.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
2929801|NCT03041831||Community leader individual interviews|The investigators will conduct 4 semi-structured 60-minute interviews with community leaders.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
2929802|NCT03041831||Focus group discussions|The investigators will lead four 90-minute focus group discussions consisting of 6-8 older adult participants each. The goal of these focus groups is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
2929803|NCT03041818|Experimental|hippotherapy|16 sessions of horseback riding therapy
2929804|NCT03041792|Experimental|Active|Liraglutide
2929805|NCT03041792|Placebo Comparator|Placebo|Placebo comparator
2929806|NCT03041779|Active Comparator|Paracetamol|Paracetamol 500Mg Suppository
2929807|NCT03041779|Active Comparator|Voltaren|Diclofenac Sodium 50Mg Suppository
2929808|NCT03041766|Experimental|Group 1|Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
2929809|NCT03041766|Experimental|Group 2|Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 5.0 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
2929810|NCT03041753||Intervention group|ischemic stroke patients in the anterior circulation territory (NIHSS ≥7) within 12 hours from last seen well, treated either with systemic thrombolysis or endovascular treatment.
2929811|NCT03041740|No Intervention|Usual Care (Control) Group|Control subjects will be maintained on mechanical ventilation and treated per standard of care.
2929812|NCT03041740|Active Comparator|Perfluorooctylbromide (PFOB) Group|Subjects in the Perfluorooctylbromide (PFOB) Group will be administered a series of doses of Perfluorooctylbromide (PFOB) instilled via the endotracheal tube until a visible meniscus is obtained. Subjects will be evaluated every 2-4 hours for up to 10 days after initial dose of PFOB to maintain a visible PFOB meniscus.
2929813|NCT03041727|Active Comparator|Standard Group|"The subjects will be treated with a standard protocol of stretching and strengthening exercises , we require them to do the exercises by themselves during five weeks, one a day.~To make sure that they will do the protocol, we'll give them a diary to sign the daily section."
2929814|NCT03041727|Experimental|Intervention group|The subjects will be treated with the same protocol of the Standard Group, but in two section, they will receive a Fascial Manipulation approach.
2929815|NCT03041714||Normal volunteers|people who are healthy and without tremor
2929816|NCT03041714||Essential tremor|Patients with essential tremor
2929817|NCT03041714||Dystonic tremor|patient with tremor who also have dystonia
2929818|NCT03041701|Experimental|Phase I|Phase I: Combination of ganitumab and dasatinib with limited dose escalation of dasatinib
2929819|NCT03041701|Experimental|Phase II|Phase II: Combination of ganitumab and dasatinib at the MTD (or highest safe dose)
2929820|NCT03041688|Experimental|Treatment (decitabine, MDM2 inhibitor AMG-232)|Patients receive decitabine IV over 1 hour on days 1-10 and MDM2 inhibitor AMG-232 PO QD on days 4-10 and 18-24. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2929821|NCT03041675|Experimental|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
2929822|NCT03041675|Sham Comparator|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
2929823|NCT03041649|Active Comparator|GT button change - Mic-Key|Subjects randomized to the Mic-Key arm will have the Mic-Key button placed initially at surgery, and at the first gastrostomy change in the clinic at 2 months, will change to the Mini One button. At the routine 4-month visit, parents will be asked which button they prefer to keep.
2929824|NCT03041649|Active Comparator|GT button change - Mini One|Subjects randomized to the Mini One arm will have the Mini One button placed initially at surgery, and at the first gastrostomy change in the clinic at 2 months, will change to the Mic-Key button. At the routine 4-month visit, parents will be asked which button they prefer to keep.
2929825|NCT03041636|Experimental|Ruxolitinib|Participants receive Ruxolitinib pills by mouth 2 times each day for up to 3 years.
2929826|NCT03041610|Experimental|Walking intervention|
2929827|NCT03041610|No Intervention|Control|
2929828|NCT03041597|Experimental|Immediate loading|
2929829|NCT03041597|Active Comparator|delayed loading|
2929830|NCT03041584|Experimental|Materialise Universal®/ mucosa (Mat Mu)|
2929831|NCT03041584|Experimental|Materialise Universal®/ bone (Mat Bo)|
2929832|NCT03041584|Experimental|FacilitateTM/ mucosa (Fac Mu)|
2929833|NCT03041584|Experimental|FacilitateTM/ bone (Fac Bo)|
2929834|NCT03041584|Active Comparator|mental navigation (Mental)|
2929835|NCT03041584|Active Comparator|pilot-drill template (Templ)|
2929836|NCT03041571||Medical Honors Students|The Medical Honors Program students will fill out the Patient Provider Orientation Scale (PPOS). MHP students will then interview a patient with a chronic or life limiting illness.
2929837|NCT03041571||Patients with chronic illnesses|The patients will fill out the PPOS scale. The patient will then have an Interview performed by MHP student
2930014|NCT03040297|Active Comparator|TGI 0 L/min|Tracheal gas insufflation catheter, without gas flow
2929840|NCT03041545||Fitbit|All participants will be asked to wear the Fitbit as much as possible and to sync it at least once a week, from one week prior to start of chemotherapy treatment to six months after ending chemotherapy.
2929841|NCT03041532|Experimental|proximal retroflexion|Procedure: The endoscopy explore right colon with frontal view and a second look with proximal retroflexion
2929842|NCT03041532|Active Comparator|frontal view of right colon|Procedure: The endoscopy explore right colon with frontal view and frontal view
2929843|NCT03041519|Experimental|Zero-fluoroscopy ablation|Zero-fluoroscopy ablation will be performed under the guidance of Ensite NavX for mapping and ablation and fluoroscopy will not be used during the procedure.
2929844|NCT03041519|Active Comparator|Conventional fluoroscopy ablation|Conventional fluoroscopy ablation will be performed under fluoroscopic guidance plus Ensite NavX for mapping and ablation during the procedure.
2929845|NCT03041506|Active Comparator|Sedation|"Analgesia and sedation through IV medication for pain relief will be administered to the patient.~Midazolam: up to a maximum dosage of 0.1 mg/kg (bolus of 1 mg by titration every 30-60 second).~Ketamine: up to maximum dosage of 100 mg IV (bolus of 25 mg by titration every 30-60 seconds)."
2929846|NCT03041506|Experimental|US guided ISCB|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15-20 ml."
2929847|NCT03041493|Experimental|Electronic cigarettes (EC) smokers|
2929848|NCT03041493|Experimental|traditional cigarette (TC) smokers|
2929849|NCT03041493|Active Comparator|nonsmokers|
2929850|NCT03041480||GROUP I|Estimation of serum lipid levels and Lp-PLA2 in generalized severe chronic periodontitis
2929851|NCT03041480||GROUP II|Estimation of serum lipid levels and Lp-PLA2 in generalized moderate chronic periodontitis
2929852|NCT03041480||GROUP III|Estimation of serum lipid levels and Lp-PLA2 in systemically and periodontally healthy controls
2929853|NCT03041454|Experimental|Novel systematic review format|A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers. Participants receiving the intervention will be asked to read and answer questions using a novel systematic review format.
2929854|NCT03041454|No Intervention|Traditional systematic review format|Control participants will be asked to read and answer questions using a traditional systematic review format.
2929855|NCT03041441|Experimental|MRICP method|
2929856|NCT03041428|Experimental|Recruited patients|Ultraprotective ventilation
2929857|NCT03041415|Active Comparator|ALED Alone Physical Activity Program|"The Active Living Every Day (ALED) comprehensive 12-week PA training and support program is appropriate for delivery by trained instructors from diverse backgrounds.~Participants are taught self-regulatory skills aimed at increasing and sustaining regular physical activities such as walking."
2929858|NCT03041415|Experimental|ALED + Our Voice PA Program|"The ALED physical activity program is combined with the Our Voice citizen science engagement program, which teaches participants how to assess the barriers and enablers of neighborhood physical activity using a simple mobile app.~Residents then share their data and build consensus around major barriers and potential solutions, which they share with local decision makers."
2929859|NCT03041402|Active Comparator|PSP ventilation|PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow
2929860|NCT03041402|Active Comparator|NAVA ventilation|NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O
2929861|NCT03041402|Experimental|PSN ventilation|PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
2929862|NCT03041389|Experimental|CCBT-I Group|The patients who will be randomized to CCBT-I group will get Cleveland Clinic CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program). The program involves a 6-week effective sleep therapy, an online sleep log and daily sleep score, six specially crafted relaxation practices, daily sleep improvement recommendations, activities to help the patient get the sleep needed, daily e-mails from the patient's program coach, daily articles to help the patient get the most out of the program and a mobile application for easy sleep tracking.
2929863|NCT03041389|Active Comparator|Control Group|"The patients who will be randomized control group will be given a reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. The control group will have access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.~To identify PD-specific barriers to Internet usage and CCBT-I, all patients at the end of the study or at the time of drop out will have a questionnaire on the barriers to CCBT-I."
2929864|NCT03041376|Experimental|Walking intervention|
2929865|NCT03041376|No Intervention|Control|
2929866|NCT03041363|Experimental|Triheptanoin|Dose 1 C7 administered as 40% daily caloric intake. Dose 2. C7 administered as 45% daily caloric intake.
2929867|NCT03041350|Experimental|Smartphone video-assisted ALS & Conventional CPR|"In study period, using this video medical control, high-quality CPR, cardiac arrest rhythm confirmation, defibrillation, proper drug administration instructions, advanced airway insertion, etc. are performed. The medical director then decides on patient transfer if the asystole and pulseless electrical activity findings are persistent even after more than 20-minutes of ALS.~The conventional CPR is Basic life support only in the automatic external defibrillator (AED) mode 5-10 minutes at the scene, are not allowed to stop resuscitation at the scene unless there is a return of spontaneous circulation (ROSC) or pre-hospital cardiac arrest patient has already been transported to a hospital."
2929868|NCT03041337||Healthy subjects|Cohort of patients referred to our echocardiography laboratory to work assessment procedures and without any cardiovascular risk factor. They will underwent stress echocardiography.
2929869|NCT03041337||cardio-respiratory diseases|patients with any possible cardiovascular and respiratory condition. They will underwent stress echocardiography.
2929870|NCT03041324|Experimental|Cohort 1|Single IV infusion of SB-913 at low dose
2929871|NCT03041324|Experimental|Cohort 2|Single IV infusion of SB-913 at medium dose
2929872|NCT03041324|Experimental|Cohort 3|Single IV infusion of SB-913 at high dose
2930015|NCT03040284|Experimental|aneurysmal subarachnoid hemorrhage|
2929873|NCT03041311|Experimental|trilaciclib+etoposide/carboplatin/atezolizumab|"Induction: Patients will receive trilaciclib 240 mg/m2 administered IV once daily on Days 1, 2 and 3 of each 21-day E/P/A therapy cycle (up to 4 cycles in total). Etoposide 100 mg/m2 will be administered IV daily on Days 1, 2, and 3 of each 21-day cycle. Carboplatin will be administered on Day 1 of each 21-day cycle using the Calvert formula with a target AUC = 5 milligrams per milliliter per minute (mg/mL/min) to calculate the dose. Atezolizumab 1200 mg will be administered as an IV on Day 1 of each 21-day cycle.~Maintenance: Following the induction phase, patients will receive maintenance atezolizumab at a dose of 1200 mg on Day 1 of every 21-day cycle until disease progression, withdrawal of consent, death, or study termination by the Sponsor."
2929874|NCT03041311|Experimental|placebo+etoposide/carboplatin/atezolizumab|"Induction: Patients will receive placebo administered IV once daily on Days 1, 2 and 3 of each 21-day E/P/A therapy cycle (up to 4 cycles in total). Etoposide 100 mg/m2 will be administered IV daily on Days 1, 2, and 3 of each 21-day cycle. Carboplatin will be administered on Day 1 of each 21-day cycle using the Calvert formula with a target AUC = 5 milligrams per milliliter per minute (mg/mL/min) to calculate the dose. Atezolizumab 1200 mg will be administered as an IV on Day 1 of each 21-day cycle.~Maintenance: Following the induction phase, patients will receive maintenance atezolizumab at a dose of 1200 mg on Day 1 of every 21-day cycle until disease progression, withdrawal of consent, death, or study termination by the Sponsor."
2929875|NCT03041298||All included patients|All included patients underwent MR mammography with Dotarem
2929876|NCT03041285|Experimental|Group 1 NOX66 400mg and SBRT|Group 1 patients will receive 400mg of Idronoxil (NOX66) suppository (1 suppository) daily from Day 14 to Day 26 of the treatment course. Stereotactic Body Radiation Therapy will be given on Days1-5 and Days15-19. Total treatment course is 26 days.
2929877|NCT03041285|Experimental|Group 2 NOX66 800mg and SBRT|Group 2 patients will receive 800mg of Idronoxil (NOX66) suppository (2 suppositories) daily from Day 14 to Day 26 of the treatment course. Stereotactic Body Radiation Therapy will be given on Days1-5 and Days15-19. Total treatment course is 26 days.
2929878|NCT03041272||Nurses and nursing personnel|All registered nurses and assistive nursing personnel, including patient care associates (PCAs) , patient care technicians (PCTs), clinical technicians (CTs), primary employment on the study unit, minimum of 24 hours per week of employment on study unit.
2929879|NCT03041259|Experimental|Rejuveinix Low Dose|Intravenous dosing of two doses per week of Rejuveinix
2929880|NCT03041259|Experimental|Rejuveinix High Dose|Intravenous dosing of two doses per week of Rejuveinix
2929881|NCT03041246|Experimental|Study group - Treatment with PFFM|Manual treatment for the pelvic floor will be provided in two sessions two weeks apart as long as guidance towards exercise for strengthening of the pelvic floor
2929882|NCT03041246|No Intervention|Control group -|Guidance towards exercise for strengthening of the pelvic floor with no other interventional treatment.
2929883|NCT03041220||cesarean section|Obese pregnant patients who have had a cesarean section.
2929884|NCT03041207||Pre-antibiotic guideline|Infants for whom antibiotics have been initiated for suspected ventilator-associated infection prior to the implementation of the antibiotic guideline
2929885|NCT03041207||After antibiotic guideline implementation|Infants for whom antibiotics have been initiated for suspected ventilator-associated infection after the implementation of the antibiotic guideline
2929886|NCT03041207||Microbiome Study Group|Infants intubated and anticipated to require mechanical ventilation for at least several days
2929887|NCT03041181|Experimental|Arm A|"Single Agent Chemotherapy of choice plus nivolumab:~Taxotere Pemetrexed Gemcitabine"
2929888|NCT03041181|Active Comparator|Arm B|Single Agent Chemotherapy of choice Taxotere Pemetrexed Gemcitabine
2929889|NCT03041155|Experimental|treatment|Muscle respiratory training
2929890|NCT03041155|No Intervention|control|No intervention
2929891|NCT03041142|Experimental|Interdisciplinary Intervention|"Children 3 sessions/week 50-60 minutes of physical activity;~1 session/week 60 minutes nutrition education week;~1 session/week 120 minutes behaviour therapy.~Mothers~1 sessions/week 50-60 minutes of physical activity;~1 session/week 60 minutes nutrition education week;~1 session/week 120 minutes behaviour therapy."
2929892|NCT03041142|Active Comparator|Routine|Mothers and children followed their routine activities
2929893|NCT03041129||Untreated PCOS|PCOS per NIH criteria. Obese Lifestyle treatment only.
2929894|NCT03041129||Metformin PCOS|PCOS per NIH criteria. Obese Taking 1500 mg of metformin or more per day for at least 6 months.
2929895|NCT03041129||Oral Contraceptive PCOS|PCOS per NIH criteria. Obese Taking 30 mcg of ethanyl estradiol or more per day for at least 6 months.
2929896|NCT03041129||Obese Control group|Obese Regular menses at least 18 months post-menarche Females only
2929897|NCT03041116|Experimental|fosmetpantotenate (RE-024)|Administered as powder for reconstitution.
2929898|NCT03041116|Placebo Comparator|Placebo|Administered as powder for reconstitution.
2929899|NCT03041103|Experimental|Adult|Food Product 1:50 grams of fortified nutritious product from legumes administered to adults, for 2 weeks
2929900|NCT03041103|Experimental|Children|Food Product 1: 50 grams of fortified nutritious product from legumes administered to children 9-13 years of age, for 1 weeks
2929901|NCT03041077|Experimental|Instaflex Advanced|Dietary supplement: Joint function
2929902|NCT03041077|Placebo Comparator|Placebo|Dietary supplement: Placebo
2929903|NCT03041064|Experimental|SPF 50/SPF 100|SPF 50 assigned to left side of face and body. SPF 100 assigned to right side of face and body
2929904|NCT03041064|Experimental|SPF 100/SPF 50|SPF 100 assigned to left side of face and body. SPF 50 assigned to right side of face and body
2929905|NCT03041051|Experimental|PCV13|
2929906|NCT03041051|Experimental|PPV23|
2929907|NCT03041038|Experimental|Secukinumab|Secukinumab 300mg (liquid formation) administered subcutaneously weekly for 5 weeks then monthly until end of trial
2929908|NCT03041038|Placebo Comparator|Placebo|Placebo (sterile saline) 2ml administered subcutaneously weekly for 5 weeks then monthly until end of trial
2929909|NCT03041025|Experimental|Cohort 1: GSK2330811 100 mg|During Cohort 1, participants will receive a single dose of GSK2330811 100 mg by SC injection via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
2930095|NCT03039699|Placebo Comparator|Placebo|1 tablet 3 times a day
2929910|NCT03041025|Experimental|Cohort 2: GSK2330811 300 mg|During Cohort 2, participants will receive a single dose of GSK2330811 300 mg by SC injection (3 vials of 1 mL each of GSK2330811 100 mg) via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
2929911|NCT03041025|Placebo Comparator|Cohort 1: Placebo|During Cohort 1, participants will receive a single dose of placebo by SC injection via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
2929912|NCT03041025|Placebo Comparator|Cohort 2: Placebo|During Cohort 2, participants will receive a single dose of placebo by SC injection (3 vials of 1 mL each) via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
2929913|NCT03041012|Placebo Comparator|antiretrovirals|Standard of care
2929914|NCT03041012|Active Comparator|antiretrovirals + romidepsin|Standard of care + LRA
2929915|NCT03041012|Active Comparator|antiretrovirals + 3BNC117|Standard of care + bNAb
2929916|NCT03041012|Active Comparator|antiretrovirals + romidepsin + 3BNC117|Standard of care + LRA + bNAb
2929917|NCT03040999|Experimental|Pembrolizumab + Cisplatin + CRT|Participants receive a priming dose of pembrolizumab before initiation of CRT (either accelerated or standard fractionation radiotherapy regimen). During CRT, participants receive 2 doses of pembrolizumab and up to 3 cycles of Cisplatin (2 cycles during accelerated and 3 cycles during standard fractionation radiotherapy). Participants also receive up to an additional 14 cycles of pembrolizumab alone as maintenance therapy for a total of 17 cycles of pembrolizumab. If cisplatin and/or radiation therapy is discontinued, the participant may continue on treatment with pembrolizumab.
2929918|NCT03040999|Placebo Comparator|Placebo + Cisplatin + CRT|Participants receive placebo before initiation of CRT (either accelerated or standard fractionation radiotherapy regimen). During CRT, participants receive 2 doses of placebo and up to 3 cycles of Cisplatin (2 cycles during accelerated and 3 cycles during standard fractionation radiotherapy). Participants also receive up to an additional 14 cycles of placebo alone for a total of 17 cycles of placebo. If cisplatin and/or radiation therapy is discontinued, the participant may continue on treatment with placebo.
2929919|NCT03040986|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID. Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity
2929920|NCT03040973|Experimental|INC280|The starting dose of study treatment for patients in this protocol should be the same as the dose provided in the parent INC280 protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
2929921|NCT03040947||Healthy Volunteer|Healthy Volunteers will undergo a cardiovascular magnetic resonance imaging scan.
2929922|NCT03040947||Diseased (Suspected or Known Cardiomyopathies)|Patients will undergo a cardiovascular magnetic resonance imaging scan.
2929923|NCT03040934|Active Comparator|Firehawk implantation|98 subjects will be enrolled to receive a test device (Firehawk™).
2929924|NCT03040934|Active Comparator|XIENCE implantation|98 subjects will be enrolled to receive a control device (XIENCE).
2929925|NCT03040921|Experimental|Uterine Transposition|Patients submitted to uterine transposition.
2929926|NCT03040895|Experimental|ICDP-intervention for caregivers|Group-based ICDP-intervention for caregivers through a sequence of eight meetings. The groups are led by facilitators trained in the ICDP.
2929927|NCT03040895|Other|Treatment as usual|Participants may use other health services (GP, other interventions) as usual through the data Collection period (6 months). Afther this period, they will have the opportunity to join an ICDP-Group if they still want.
2929928|NCT03040882|Experimental|cotton sock|
2929929|NCT03040882|Active Comparator|Elastic Compression Wraps|
2929930|NCT03040869||CHD Patients|coronary angioplasty confirmed coronary heart disease.
2929931|NCT03040869||non-CHD patients|coronary angioplasty confirmed no coronary heart disease.
2929932|NCT03040856|Experimental|Alpha Linolenic Acid enriched diet|Enriched diet with 2 capsules of ALA supplementation a day - 630 mg in each capsule. Total amount of 1260 mg (Daily recommended dose is 1-2 g).
2929933|NCT03040856|Experimental|Omega 3 enriched diet ( DHA+EPA)|Enriched diet with 2 capsules of DHA+EPA supplementation a day (Each capsule consist of 240 mg DHA and 360 mg EPA).
2929934|NCT03040856|Placebo Comparator|Placebo|Control group - Will receive 2 placebo capsule a day - containing olive oil
2929935|NCT03040830|Experimental|Egg retrieval arm|67 ICSI cases are started daily 100 mg IM prontogest on the day of egg retrieval until the day of pregnancy test.
2929936|NCT03040830|Active Comparator|Embryo transfer arm|66 ICSI cases are started daily 100 mg IM prontogest on the day of embryo transfer until the day of pregnancy test.
2929937|NCT03040817|Experimental|G-POEM|Each participant receive gastric peroral endoscopic pyloromyotomy (G-POEM).
2929938|NCT03040817|Active Comparator|Esomeprazole + Mosapride|Each participant receive Esomeprazole+ Mosapride. The dosages are：Nexium 40mg bid， Mosapride Citrate Tablets 5mg tid.
2929939|NCT03040804|Experimental|Low Dose Radiotherapy|Patients will receive skin-directed radiotherapy, using a total prescription dose of 7.5 gy in five fractions of 1.5 gy over one week
2929940|NCT03040791|Experimental|Nivolumab|All patients will receive Nivolumab 240 mg every 14 days until progression or unacceptable toxicity
2929941|NCT03040778|Experimental|Standard of Care + PENTO|The current standard of care for MRONJ as outlined by the American Association of Oral and Maxillofacial Surgeons position paper based on stage of disease (Ruggiero 2014) AND PENTO regimen consisting of 400mg pentoxifylline (PTX) and 400IU tocopherol twice-daily PO for a total of 800mg/day PTX and 800 IU/day tocopherol
2929942|NCT03040778|Placebo Comparator|Standard of Care|The current standard of care for MRONJ as outlined by the American Association of Oral and Maxillofacial Surgeons position paper based on stage of disease (Ruggiero 2014). Placebo drugs to be taken in the control group 2 pills BID.
2929943|NCT03040765|Active Comparator|Denosumab|"Denosumab 60 MG/ML Prefilled Syringe~Denosumab Dose: 60 milligrams, subcutaneous injection, every 6 months (twice a year)"
2929944|NCT03040765|Active Comparator|Zoledronic Acid|"Zoledronic Acid 5Mg/Bag 100Ml Inj~Zoledronic acid will be 5 milligrams, Intravenous injection, once a year"
2929945|NCT03040752|Active Comparator|Nifedipine|nifedipine 20 mg tablets (Epilat Retard®, EIPICO, Egypt) twice daily, starting 12 hours after arrest of threatened preterm labor
2929946|NCT03040752|Active Comparator|Ritodrine|Ritodrine 5 mg tablets (Yutopar®, PHARCO, Alexandria) every 6 hours, starting 12 hours after arrest of threatened preterm labor.
2929947|NCT03040739||case|
2929948|NCT03040739||control|
2929949|NCT03040726|Experimental|Netupitant + Palonosetron (NEPA) Group|"Symptom questionnaires completed at baseline and at Day 15.~For the Day 1 dose, participant will not know if they are receiving the study drug or the placebo.~Participants take NEPA orally on Day 6 and on Day 11 of the double-blind treatment period, and on Day 16 and on Day 21 of the open-label extension phase.~Participants keep a patient diary to keep track of nausea, vomiting, and doses 1 time a day on Days 1-15."
2929950|NCT03040726|Placebo Comparator|Placebo Group|"Symptom questionnaires completed at baseline and at Day 15.~For the Day 1 dose, participant will not know if they are receiving the study drug or the placebo.~Participants take placebo orally on Day 6 and on Day 11 of the double-blind treatment period, and on Day 16 and on Day 21 of the open-label extension phase.~Participants keep a patient diary to keep track of nausea, vomiting, and doses 1 time a day on Days 1-15."
2929951|NCT03040713|Experimental|FTD Subjects|Subjects diagnosed by dementia specialist with a clinical Frontotemporal Dementia (FTD) syndrome and expected tau or TDP-43 pathology.
2929952|NCT03040700|No Intervention|Clinical|Regular medical visits every 6 months.
2929953|NCT03040700|Experimental|Myocardial Perfusion Scan|Myocardial perfusion stress test using cardiac scintigraphy (Sestamibi) at rest and during pharmacological stress (dipyridamole)
2929954|NCT03040700|Experimental|Coronary CTA|Coronary computed tomography angiography
2929955|NCT03040687|Experimental|Anti-CS6 group|Anti-CS6 BSIgG and challenge strain CS6-expressing ETEC (B7A)
2929956|NCT03040687|Experimental|Anti-whole cell B7A|Anti- whole cell B7A (killed) BSIgG and challenge strain CS6-expressing ETEC (B7A)
2929957|NCT03040687|Experimental|control Immunoglobulin group|Negative Control (Nonhyperimmune BSIgG placebo) and challenge strain CS6-expressing ETEC (B7A)
2929958|NCT03040674||Cell therapy treated|All patients/participants enrolled will undergo cell therapy
2929959|NCT03040661|Experimental|Figure of 8 Suture|Hemostasis after an ablation for atrial fibrillation with a figure of 8 suture.
2929960|NCT03040661|Active Comparator|Manual Hemostasis Group|Hemostasis after an ablation for atrial fibrillation with the Manual Hemostasis Technique.
2929961|NCT03040648|Experimental|cervical TFEB under DSA|cervical TFEB was performed under DSA
2929962|NCT03040648|Active Comparator|TFEB under RTF|cervical TFEB was performed under RTF
2929963|NCT03040635|Experimental|RO7034067 '2' Milligrams (mg)|A single dose of 2 mg RO7034067 will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
2929964|NCT03040635|Experimental|RO7034067 '6' mg|A single dose of 6 mg RO7034067 will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
2929965|NCT03040635|Experimental|RO7034067 '12' mg|A single dose of 12 mg RO7034067 will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
2929966|NCT03040635|Placebo Comparator|Placebo|A single dose of placebo will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
2929967|NCT03040622||Watchman Left Atrial Appendage Closure|
2929968|NCT03040609||Group 1|The duration of follow-up of group 1 in the study is 1 day.
2929969|NCT03040609||Group 2|The duration of follow-up of group 2 in the study is 2 weeks.
2929970|NCT03040609||Group 3|The duration of follow-up of group 3 in the study is 6 months.
2929971|NCT03040596|Experimental|inhaled steroid + voice therapy|fluticasone inhaler, 88mcg (2 puffs), twice a day for 4 weeks + standard voice therapy
2929972|NCT03040596|Other|voice therapy only|standard voice therapy
2929973|NCT03040583||ASSESS (PHRC) patients|Primary Sjögren's Syndrome Patients who have already participated to the study ASSESS
2929974|NCT03040570|Experimental|Conservative oxygenation target|Children in the conservative oxygenation target group receive treatment targeting oxygen saturation values of 88-92%.
2929975|NCT03040570|Active Comparator|Liberal oxygenation target|Children in the liberal oxygenation target group receive treatment targeting oxygen saturation values of >94%.
2929976|NCT03040557|Active Comparator|Flexible footwear|The intervention with flexible footwear in women with plantar fasciitis (GIC, acute n=15 and chronic=15) will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
2929977|NCT03040557|Active Comparator|Orthopedic insole|The intervention with orthopedic insole in women with plantar fasciitis (GIC, acute n=15 and chronic=15) will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
2929978|NCT03040544|Experimental|LTB-Curriculum|First group/arm undergo MIS training according to the LTB curriculum after the first own laparoscopic cholecystectomy in the OR as a baseline. After 6 weeks, the participants in this group/arm will perform their second CHE. The video recordings of the MIS procedures will be analysed and compared using the Global Operational Assessment of Laparoscopic Skill (GOALS) score.
2929979|NCT03040544|Active Comparator|no LTB-Curriculums|Second group/arm will not undergo any MIS trains after their first laparoscopic CHE in the OR. After 6 weeks, the participants in this group/arm will perform their second CHE. The video recordings of the MIS procedures will be analysed and compared using GOALS score.
2929980|NCT03040531|Experimental|Genistein|"Each tablet will contain 27 mg of 98% pure genistein + 500mg Calcium + 200 IU Vit. D3. Subjects will receive 2 tablets per day 6 days/week for all the duration of the study.~Once a week subjects will receive a tablet containing only 500mg Calcium + 200 IU Vit. D3."
2929981|NCT03040531|Active Comparator|Alendronate|"Each tablet will contain 500mg Calcium + 200 IU Vit. D3. Subjects will receive 2 tablets per day 6 days/week for all the duration of the study.~Once a week subjects will take one tablet containing 70mg alendronate."
2929982|NCT03040518|Experimental|Narrative SMS|"Participants will receive narrative SMS for 12 months.~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
2930016|NCT03040271|Experimental|Intervention group- Health-E-PALS|Group of students receiving the school-based intervention: Health-E-PALS, it consists of in class activities and lessons.
2929983|NCT03040518|Experimental|Narrative SMS and Endowment Incentive|"Participants will receive narrative SMS for 12 months. In addition, they will receive an endowment incentive for verified weight loss.~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
2929984|NCT03040518|No Intervention|Waiting List Control Group|"Participants will be on a waiting list for 12 months to receive the narrative SMS which will commence after 12 month outcome data has been collected. There will be no interim measurements or contacts by the research team. Men are therefore free to choose whether to try to lose weight during the 12 months.~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
2929985|NCT03040505||Patients with schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
2929986|NCT03040505||Control participants|- Control participants without psychiatric nor neurological history
2929987|NCT03040479|Experimental|Mild hepatic impairment|lasmiditan 200 mg single dose
2929988|NCT03040479|Experimental|Moderate hepatic impairment|lasmiditan 200 mg single dose
2929989|NCT03040479|Experimental|Healthy participants|lasmiditan 200 mg single dose
2929990|NCT03040466|Active Comparator|reusable fiberoptic ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using reusable fiberoptic flexible ureteroscope (URF-P6, Olympus). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
2929991|NCT03040466|Active Comparator|reusable digital ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using reusable digital flexible ureteroscope (URF-V2, Olympus). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
2929992|NCT03040466|Experimental|disposable digital ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using disposable digital flexible ureteroscope (LithoVue, Boston Scientific). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
2929993|NCT03040453|Other|Microwave ablation|20 patients will be treated with microwave ablation
2929994|NCT03040453|Other|Irreversible electroporation|20 patients will be treated with irreversible electroporation
2929995|NCT03040440|Active Comparator|Cylindrical endotracheal tube|Cylindrical endotracheal tube was intubated in 32 participants
2929996|NCT03040440|Experimental|TaperGuard endotracheal tube|TaperGuard endotracheal tube was intubated in 32 participants
2929997|NCT03040427|Experimental|AL or TTR type amyloidosis|The participants will undergo F-18 florbetapir PET scan.
2929998|NCT03040414|Active Comparator|PID Algorithm|Participants will receive insulin delivered by the Medtronic 670G hybrid closed loop system using a PID algorithm.
2929999|NCT03040414|Experimental|PID + Fuzzy Logic Algorithm|Participants will receive insulin delivered by the Medtronic advanced hybrid closed loop system using Fuzzy Logic + PID algorithm.
2930000|NCT03040401|Experimental|Cohort 1: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.~Cohort 1 will receive only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4."
2930001|NCT03040401|Experimental|Cohort 2: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.~Cohort 2 will receive Ceplene® in combination with Proleukin® during all treatment cycles (1-4)."
2930002|NCT03040401|Experimental|Cohort 3: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.~Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2."
2930003|NCT03040375|Experimental|Peer counselling|There were two types of intervention: one providing breast-feeding and complementary feeding counselling + psychosocial stimulation interventions.
2930004|NCT03040375|No Intervention|Non peer counselling|Usual health messages
2930005|NCT03040362|Experimental|[14C]-lasmiditan|[14C]-lasmiditan administered as a 200 mg (approximately 100 µCi) oral solution
2930006|NCT03040349|Experimental|TiTAN Intervention|The TiTAN Crete program has adapted the existing curricula and resources originally developed at the University of Ottawa Heart Institute and which are specific to primary practice settings. To facilitate maximum uptake the intervention program was adapted to reflect: language; cultural appropriateness; local patient beliefs and attitudes regarding tobacco-use and cessation; local social and clinical norms; provider perceptions surrounding 5As delivery; and, practice characteristics. The TiTAN multi-component training includes: 1) a 1-day foundational tobacco treatment training program for general practitioners, 2) the dissemination of provider and patient tools, and 3) E-blasts and webinars to supplement skills development and continuing medical education through e-learning.
2930007|NCT03040336|Experimental|Prehabilitation|Standard of care + Prehabilitation
2930008|NCT03040336|No Intervention|Standard of Care|Standard of Care
2930009|NCT03040323|Experimental|biopsy with Lumason|liver biopsy performed with prior contrast enhancement with Lumason 60.7Mg Powder for Injection (experimental method)
2930010|NCT03040323|Placebo Comparator|biopsy with placebos|liver biopsy performed without prior contrast enhancement (standard method)
2930011|NCT03040310|Experimental|Back Rx program|Study patients will use their smartphone apps to view their Back Rx program content, exercises, and videos.
2930012|NCT03040297|Active Comparator|TGI 6 L/min|Tracheal gas insufflation 6 L/min
2930013|NCT03040297|Active Comparator|TGI 11 L/min|Tracheal gas insufflation 11 L/min
2930018|NCT03040258|Experimental|Intervention group- Health-E-PALS-Pilot|Group of students receiving the school-based intervention: Health-E-PALS (pilot), it consists of in class activities and lessons.
2930019|NCT03040258|No Intervention|Control group|Group of students not receiving any intervention
2930020|NCT03040245||intervention group|The intervention group was instructed to complete the questionnaires at least 48 hours after the intervention that is, after reading the information booklet
2930021|NCT03040245||control group|The same items were included as in the initial folder, with an additional questionnaire enabling the intervention group to qualitatively assess the information booklet. If there was no response, reminders were sent by email, then by telephone, and lastly by post.
2930022|NCT03040232|Experimental|MPFl Reconstruction|subjects that have had MPFL reconstruction surgery
2930023|NCT03040232|Active Comparator|Active Controls|subjects that have not had MPFL reconstruction surgery
2930024|NCT03040219|Active Comparator|Treatment group|
2930025|NCT03040219|Placebo Comparator|Control|
2930026|NCT03040206||Nodal PTCL|"newly-diagnosed, pathologically-proven nodal PTCLs (PTCL, NOS; Angioimmunblastic T-cell lymphoma; anaplastic large cell lymphoma [ALCL], anaplastic lymphoma kinase [ALK]-negative) between January 1, 2005 and Jun 30, 2016~initially treated with curative intent~Standard PET or PET-CT data available at the time of diagnosis and at the end of primary treatment"
2930027|NCT03040193|Experimental|Nebulized Lignocaine|4% Lignocaine administered as nebulization for topical anaesthesia during bronchoscopy procedure
2930028|NCT03040193|Placebo Comparator|Nebulized Saline|Normal Saline administered as nebulization for topical anaesthesia during bronchoscopy procedure
2930029|NCT03040180|Experimental|Electrochemotherapy with bleomycin|"Systemic injection of bleomycin followed by electroporation of the primary tumor. Bleomycin administration: 15.000 IU/m2 BSA.~BSA by Du Bois formula."
2930030|NCT03040180|No Intervention|Standard care|Standard care
2930031|NCT03040167|Placebo Comparator|Control group|PEC 1 block with injection of 0.4 mL/kg of normal saline under echoguidance.
2930032|NCT03040167|Active Comparator|Treatment group|PEC 1 block with injection of 0.4 mL/kg of 0.25% bupivacaine with 1/400 000 epinephrine under echoguidance.
2930033|NCT03040154|Experimental|Intervention Arm|Culturally-tailored video that includes parent testimonials, health and mental health clinicians, community-based providers, and church leaders
2930034|NCT03040154|Other|Control Arm|Usual care video publicly available describing the evidence-based parenting intervention
2930035|NCT03040141|Experimental|VIS410 low dose|Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
2930036|NCT03040141|Experimental|VIS410 high dose|Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
2930037|NCT03040141|Placebo Comparator|Placebo|Single intravenous infusion of placebo in addition to oseltamivir
2930038|NCT03040128|Placebo Comparator|placebo|normal saline infusion
2930039|NCT03040128|Experimental|minocycline|intravenous minocycline
2930040|NCT03040102|Experimental|Hospice Video Educational Tool|"The hospice video educational tool is a 6 minute video~Participants will watch an approximately 6-minute digital video regarding hospice on an iPad"
2930041|NCT03040102|Active Comparator|Hospice Verbal Narrative|"The RA will read a verbal narrative that is identical to the narrative of the video to participants~Standard of Care practice is used"
2930042|NCT03040089|Experimental|picosecond laser & 2% hydroquinone cream|PICO+4 laser system and Neoquine Cream 2% (2% hydroquinone cream) for melasma
2930043|NCT03040089|Sham Comparator|2% hydroquinone cream|Only Neoquine Cream 2% (2% hydroquinone cream) for melasma
2930044|NCT03040076|Experimental|Cognitive Bias Treatment|Intervention condition
2930045|NCT03040076|Active Comparator|Relaxation Condition|Active control condition
2930046|NCT03040063|Experimental|Combined endovascular approach|Combined endovascular approach using covered stent and flexible stent in the popliteal artery
2930047|NCT03040063|Experimental|Standard optimal therapy (OPT)|standard therapy of popliteal artery aneurysm using thrombolysis and surgery
2930048|NCT03040050|Other|Men scheduled for prostate biopsy randomized to Control|
2930049|NCT03040050|Experimental|Men scheduled for a prostate biopsy randomized to Intervention|
2930050|NCT03040024|Experimental|Ketamine 0.5 mg/kg|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV ketamine at 0.5 mg/kg.
2930051|NCT03040024|Experimental|Ketamine 1.0 mg/kg|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV ketamine at 1.0 mg/kg.
2930052|NCT03040024|Placebo Comparator|Placebo|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV saline/placebo.
2930053|NCT03040011|Experimental|Bupivacaine/Dexamethasone Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of a mixture of 20 milliliters of 0.25% bupivacaine (2.5mg/milliliter ) and 2 milliliters of dexamethasone (4mg/milliliter). The total amount of the bupivacaine/dexamethasone solution will be divided equally between the four injection sites.
2930054|NCT03040011|Active Comparator|Bupivacaine Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.25% bupivacaine (2.5mg/milliliter). The total amount will be divided equally between the four injection sites.
2930055|NCT03040011|Placebo Comparator|Placebo Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.9% saline (normal saline). The total amount will be divided equally between the four injection sites.
2930056|NCT03039998||HAP Patients|HAP, intubated and mechanically ventilated.
2930057|NCT03039985|Experimental|Bruxism + lithium disilicate crown|Participant with sleep bruxism receives a monolithic molar crown manufactured from lithium disilicate.
2930058|NCT03039985|Experimental|No bruxism + lithium disilicate crown|Participant without sleep bruxism receives a monolithic molar crown manufactured from lithium disilicate.
2930059|NCT03039985|Experimental|Bruxism + zirconia crown|Participant with sleep bruxism receives a monolithic molar crown manufactured from zirconia.
2930060|NCT03039985|Experimental|No bruxism + zirconia crown|Participant without sleep bruxism receives a monolithic molar crown manufactured from zirconia.
2930061|NCT03039972||Pulmonary Hypertension|Patients with pulmonary hypertension irrespective of WHO class and all chronic kidney disease stages
2930062|NCT03039959||Pulmonary Hypertension|Patient with diagnosed pulmonary hypertension irrespective of WHO class undergoing right heart catherization
2930063|NCT03039946|Experimental|Closed-loop GDFT|This group consists of patients undergoing laparoscopic and/or robotic abdominal surgery where fluid maintenance with Plasmalyte is carried out using a closed-loop system guided by the Clearsight non-invasive hemodynamic flow monitor.
2930064|NCT03039946|Active Comparator|Restrictive fluid therapy|This group consists of patients undergoing laparoscopic and/or robotic abdominal surgery where fluid management is based on a restrictive (4ml/kg/h) Plasmalyte infusion.
2930065|NCT03039933|Active Comparator|Fear of Hypoglycemia Intervention|
2930066|NCT03039933|Other|Treatment As Usual|
2930067|NCT03039920|Active Comparator|Electronic cigarette with or without nicotine|Electronic cigarette assisted cessation program
2930068|NCT03039920|Active Comparator|Smoker control|Conventional cigarette smoking continuation
2930069|NCT03039894||Intervention|The middle school selected 2 advisory classrooms to participate in the Gradebook game during 6th grade. Students in these 2 classrooms were block randomized to teams by baseline grade book and student engagement scores. These small student teams stay together for an entire year and meet once or twice a week. Teams are led by 8th grade student team captains, picked by school staff for their positive leadership skills. Every 2 weeks throughout the year, teams are randomly matched in head-to-head competition. In each 2-week-long game (i.e. Gradebook Game), individual team members accrue points from teachers and administrators for academic performance, effort, and school behavior. Team wins are announced and public scoreboards are updated frequently. The investigators will collect student survey data at baseline and after the intervention, approximately 5-6 months apart.
2930070|NCT03039894||Control|The middle school has chosen three 6th grade classrooms that will not play the Gradebook game. The investigators will collect school gradebook and behavior information weekly for 8 to 10 time points before and after the intervention is implemented. Students will complete a survey at baseline and after the intervention, approximately 5-6 months apart.
2930071|NCT03039868||Normal Pap smears|This is the control group.
2930072|NCT03039868||Abnormal Pap smears|This is the case group.
2930073|NCT03039855|Experimental|Treatment|Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system
2930074|NCT03039842|Experimental|30 mg DM|30mg dextromethorphan+valproate
2930075|NCT03039842|Experimental|5 mg MM|5mg memantine+valproate
2930076|NCT03039842|Experimental|DM+MM|dextromethorphan+memantine+ valproate
2930077|NCT03039842|Placebo Comparator|placebo|Placebo+valproate
2930078|NCT03039829|Experimental|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine; 1.0 gram nitrate, 3.0 grams dextrose)
2930079|NCT03039829|Active Comparator|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine; 2.0 grams nitrate)
2930080|NCT03039829|Placebo Comparator|Placebo|Placebo at 6.0 grams dextrose
2930081|NCT03039816|Active Comparator|Active|The patients were randomly assigned to active (Nasaleze cellulose powder) or placebo groups using an identical device to be puffed in each nostril 3 times daily. The nasal powders were supplied in plastic containers, which deliver the powder from a nozzle when squeezed. The exact amount delivered is not standardized and the variation in the patterns of deposition in the nose is not known. The placebo was a lactose powder with the same particle size, appearance and the same tinge of mint taste as the cellulose powder.
2930082|NCT03039816|Placebo Comparator|Placebo|The patients were randomly assigned to active or placebo groups using an identical device to be puffed in each nostril 3 times daily. The nasal powders were supplied in plastic containers, which deliver the powder from a nozzle when squeezed. The exact amount delivered is not standardized and the variation in the patterns of deposition in the nose is not known. The placebo was a lactose powder with the same particle size, appearance and the same tinge of mint taste as the cellulose powder.
2930083|NCT03039803|Active Comparator|single-layer continuous uterotomy suture|Single-layer continuous uterotomy suture
2930084|NCT03039803|Active Comparator|double-layer continuous uterotomy suture|double-layer continuous uterotomy suture
2930085|NCT03039790|Experimental|NoV Vaccine|Participants who previously received Norovirus GI.1/GII.4 bivalent Virus-Like Particle (VLP) vaccine (NoV Vaccine) as planned in studies NOR-107, NOR-210, NOR-204 and NOR-222 will be assessed over 5 years.
2930086|NCT03039764|No Intervention|Standard occupational therapy|This group will receiving standard occupational therapy for the treatment of acute stroke.
2930087|NCT03039764|Experimental|SOT plus VR Rapael|This group will receive virtual reality-based rehabilitation intervention wearing Rapael glove made by Neofect supplemented with standard occupational services per conventional protocols.
2930088|NCT03039751|Experimental|AdvVEGF-D|Intramyocardial AdVEGF-D
2930089|NCT03039751|Placebo Comparator|Control|Intramyocardial placebo (buffer solution without gene)
2930090|NCT03039738|Active Comparator|Telemetry Monitoring Arm|The telemetry group will serve as the control group and will be monitored via the site's standard of care telemetry protocols.
2930091|NCT03039738|Experimental|Surveillance Monitoring Arm|Subjects in the surveillance monitoring group will alternatively be admitted to medical surgical unit and be monitored via the surveillance monitoring platform.
2930092|NCT03039712||Micra leadless pacemaker therapy|All Medicare patients implanted with Micra leadless pacemaker system
2930093|NCT03039712||Single Chamber Transvenous pacemaker|All Medicare patients implanted with full system (e.g. lead and generator) single- chamber ventricular transvenous pacemakers
2930094|NCT03039699|Experimental|Ergoferon|1 tablet 3 times a day
2930096|NCT03039686|Experimental|RO7239361, dose 1|Take RO7239361 subcutaneously on specified days over a 48 week blinded period
2930097|NCT03039686|Experimental|RO7239361, dose 2|Take RO7239361 subcutaneously on specified days over a 48 week blinded period
2930098|NCT03039686|Placebo Comparator|Placebo|Placebo solution taken subcutaneously on specified days over a 48 week blinded period
2930099|NCT03039673|Experimental|low dose interleukin-2|"Patients randomized to this arm will receive subcutaneous injections of low-dose interleukin-2 in addition to oral Riluzole treatment.~Intervention: Riluzole Intervention: IL-2"
2930100|NCT03039673|Placebo Comparator|Placebo|"Patients randomized to this arm will receive subcutaneious placebo injections (5% glucose water solution) in addition to oral Riluzole treatment.~Intervention: Riluzole Intervention: 5% glucose water solution"
2930101|NCT03039660|Experimental|RefreshMD|An online course for sleep improvement in medical students
2930102|NCT03039660|Placebo Comparator|Bond Between Us|An online course covering communication skills and the physician-patient relationship
2930103|NCT03039647||Entry Point IR (SSPG, HOMA-IR)|All subjects will undergo baseline indirect (HOMA-IR) and direct (SSPG) measures of IR. The investigators hypothesize that a higher entry point IR will predict steeper decline in memory and executive function performance and hippocampal connectivity.
2930104|NCT03039647||Change in IR (HOMA-IR)|The investigators predict that change in IR (as measured by HOMA-IR) will predict the pattern of decline in memory and executive function performance and hippocampal connectivity.
2930105|NCT03039621|Experimental|Ergoferon|1 tablet 3 times a day
2930106|NCT03039621|Placebo Comparator|Placebo|1 tablet 3 times a day
2930107|NCT03039608|Experimental|combination group|combination of local steroid injection（triamcinolone ）with oral steroid administration（prednisone）
2930108|NCT03039608|Active Comparator|control group|oral steroid administration（prednisone）
2930109|NCT03039582||Probable grad 2|Perineal laceration Probable grad 2
2930110|NCT03039582||Suspected grade 3|Perineal laceration Suspected grade 3
2930111|NCT03039582||Probable grad 3|Perineal laceration Probable grad 3
2930112|NCT03039569|Experimental|Text messaging|Participants will receive 3 messages weekly consisting of nutrition education and diabetes self-management information and skills for 3 months (12 weeks).
2930113|NCT03039569|No Intervention|Control|Participants will not receive text message intervention. This is the measurement-only group
2930114|NCT03039556|Experimental|Change in physical activity for older adults|Older adult participants undergo alterations in daily ambulation by completing Normal Daily Steps for one week, followed by a two-week Step-Reduction and a subsequent Return to Normal Daily Steps for two weeks
2930115|NCT03039543|Active Comparator|moderate neuromuscular blockade|During operation, intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2). Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2.
2930116|NCT03039543|Experimental|deep neuromuscular blockade|During operation, intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade. Patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
2930117|NCT03039530|Experimental|Treatment Group|Group CBT for PPD. Women in the treatment group will attend a 9-week group CBT intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week.
2930118|NCT03039530|Active Comparator|Control Group|Standard Care. The usual care group will receive standard care from their family physician and midwife or obstetrician. They will also be made aware of the perinatal programming available to them through Niagara Region Public Health. Women and family physicians will also receive a copy of the Canadian Practice Guidelines for the Treatment of Perinatal Depression.
2930119|NCT03039517|Experimental|ACTitouch - ACT-Adaptive Compression Therapy|a dual treatment pneumatic compression device offering two operational modes: sustained compression mode and intermittent compression mode. The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
2930120|NCT03039517|Experimental|Standard Compression Stocking|The control group will receive care using elastic compression stocking.
2930121|NCT03039504|Experimental|Potensa|succinate-based dietary supplement
2930122|NCT03039504|Placebo Comparator|Placebo|placebo
2930123|NCT03039491|Experimental|HIV+ 50-65, CD4>200 PCV/PPV|"HIV+ individuals , 50-65 years of age with a nadir cluster of differentiation (CD) 4 count >200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
2930124|NCT03039491|Experimental|HIV+ 50-65, CD4<200 PCV/PPV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count <200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
2930125|NCT03039491|Experimental|HIV+ 50-65, CD4>200 PPV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count >200 to receive PPV23 only~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
2930126|NCT03039491|Experimental|HIV+ 50-65, CD4<200 PCV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count <200 to receive PPV23 only~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
2930127|NCT03039491|Active Comparator|HIV- 50-65, PCV/PPV|"HIV- individuals , 50-65 years of age immunized with PCV13 followed by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
2930128|NCT03039491|Active Comparator|HIV- 50-65, PPV|"HIV- individuals, 50-65 years of age immunized with PPV23 only.~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
2930129|NCT03039491|Active Comparator|HIV+ 21-40, CD4>200 PCV/PPV|"HIV+ individuals , 21-40 years of age with a nadir CD4 count >200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
2930130|NCT03039491|Active Comparator|HIV+ 21-40, CD4<200 PCV/PPV|"HIV+ individuals , 21-40 years of age with a nadir CD4 count <200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
2930131|NCT03039478|Active Comparator|Xylitol 7g in 300mL tap water|12 volunteers receive 7g xylitol in 300mL tap water via a nasogastric tube
2930132|NCT03039478|Active Comparator|Xylitol 17g in 300mL tap water|12 volunteers receive 17g xylitol in 300mL tap water via a nasogastric tube
2930133|NCT03039478|Active Comparator|Xylitol 35g in 300mL tap water|12 volunteers receive 35g xylitol in 300mL tap water via a nasogastric tube
2930134|NCT03039478|Active Comparator|Erythritol 10g in 300mL tap water|12 volunteers receive 10g erythritol in 300mL tap water via a nasogastric tube
2930135|NCT03039478|Active Comparator|Erythritol 25g in 300mL tap water|12 volunteers receive 25g erythritol in 300mL tap water via a nasogastric tube
2930136|NCT03039478|Active Comparator|Erythritol 50g in 300mL tap water|12 volunteers receive 50g erythritol in 300mL tap water via a nasogastric tube
2930137|NCT03039465|Experimental|Modified Trans-Esophageal Prosthesis|Patients satisfying the selection criteria would be subjected to the insertion of the TEP and evaluated at subsequent time points for the success of the procedure.
2930138|NCT03039452|Experimental|High intensity interval training|
2930139|NCT03039439||Normal Parathyroid Tissue|Group I represents 70 samples of normal parathyroid tissue or blood.
2930140|NCT03039439||Benign Sporadic Parathyroid Adenomas|Group II consists of 70 samples of benign sporadic parathyroid adenomas or blood.
2930141|NCT03039439||Parathyroid Neoplasm|Group III includes 70 samples from patients with parathyroid neoplasm or carcinoma or blood.
2930142|NCT03039426|Experimental|Group Bupivacaine|0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
2930143|NCT03039426|Active Comparator|Group Diclofenac|diclofenac 75 mg intramuscular, 2 hours postoperation
2930144|NCT03039413|Experimental|Diagnostic (Copper Cu 64 TP3805 PET/CT)|Patients receive copper Cu 64 TP3805 IV and undergo PET/CT after 60 minutes. Patients then undergo standard of care cystectomy and/or biopsy 1 to 4 weeks later.
2930145|NCT03039400|Experimental|Web-based physio group|Those in the web-based physio group will have an individual exercise program set up by a treating physiotherapist on webbasedphysio.com after an initial face-to-face assessment. They will be encouraged to undertake their exercise program at least twice per week and diarize their work. Participants will receive a weekly phone call from their treating physiotherapist for the first two weeks. The treating physiotherapist will review the exercise diary of each participant every two weeks, and remotely alter the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.
2930146|NCT03039400|Active Comparator|Standard care group|Those in the standard care group will have their exercise program explained to them at an initial face-to-face assessment with a treating physiotherapist as per usual care. They will receive a written, home-based exercise program. Participants in the usual care group will also be encouraged to undertake their exercise program at least twice per week, and will be asked to keep an exercise diary, in paper format. Participants in the usual care group will also receive a weekly phone call from the physiotherapist for the first two weeks to check on progress.
2930147|NCT03039387|Active Comparator|anodal tDCS|transcranial direct current stimulation of the left dlPFC with 1mA
2930148|NCT03039387|Placebo Comparator|Sham stimulation|Double blind sham stimulation (stimulation will be ramped down after 30 sec.)
2930149|NCT03039374||OASI patients|All patients older than 18 and a 3rd or 4th degree perineal tear during birth meet the inclusion criteria. All women who have obtained such a injury during birth in the Vaasa or Seinäjoki Central hospitals will be evaluated for eligibility.
2930150|NCT03039361|Experimental|Equine Assisted Psychotherapy|6 week Equine Assisted Psychotherapy program
2930151|NCT03039361|No Intervention|Control|Standard of Care, Existing PTSD therapy
2930152|NCT03039348||Breast reconstruction|The patients choosing for breast reconstruction after mastectomy for breast cancer.
2930153|NCT03039348||No breast reconstruction|The patients not choosing breast reconstruction after mastectomy for breast cancer.
2930154|NCT03039335||Adults with an AAT Deficiency|Subjects over the age of 18 that have been recently diagnosed with an Alpha-1 Antitrypsin deficiency will be enrolled into the study to observe the interval between first symptom and initial diagnosis.
2930155|NCT03039322||HCC|
2930156|NCT03039322||liver cirrhosis No HCC|
2930157|NCT03039296||One side endoscopic rhizotomy|Endoscopic rhizotomy will be provided only on one back side according pain
2930158|NCT03039296||Both sides endoscopic rhizotomy|Endoscopic rhizotomy will be provided on both back sides according pain
2930159|NCT03039283||Nucleus CI532 cochlear implant|
2930160|NCT03039270|Active Comparator|Control (Without sonic activation)|Desensitizing gel applied without sonic activation, for 10 minutes, previously to the in-office bleaching.
2930161|NCT03039270|Experimental|With sonic activation (SMART Device®)|Desensitizing gel applied with sonic activation, 30 seconds per tooth, previously to the in-office bleaching.
2930162|NCT03039257|Other|Vitamin A|Participants receive single dose vitamin A supplementation prior to HSCT. A 3x3 dose escalation/de-escalation design will be used for this study.
2930163|NCT03039244|Experimental|Test Group|After Scaling and root planing, periodontal pockets will receive the antimicrobial (aPDT) photodynamic therapy. Shortly phenothiazine hydrochloride photosensitizing is applied at a concentration of 10mg/mL from the pocket bottom to the gingival margin. After 1 minute, irrigation is performed from periodontal pockets with distilled water to remove excess dye. The stained area is then irradiated with a diode laser with 660 nm of wavelength and maximum power of 60 mW/cm², through a fiber-optic probe of 0.6 mm diameter. Exposure to radiation will occur at six sites per tooth under treatment, making the total time of 1 minute per element, or the equivalent of 10 seconds per site. The aPDT applications will be repeated in the same way until the second week in the days 2, 7 and 14.
2930164|NCT03039244|Sham Comparator|Control Group|A sham procedure will be held simultaneously in pairs of contralateral teeth selected that will not receive the aPDT (control group).
2930199|NCT03039023|Experimental|Choline Bitartrate Tablets|Subjects will consume two (2) 500mg choline bitartrate tablets per day for 28 days.
2930165|NCT03039231|Experimental|Freespira Breathing System (FBS)|The Freespira Breathing System (FBS) developed by Palo Alto Health Sciences, Inc, is a portable home device used for breathing biofeedback in adults with panic disorder (PD). FBS has received FDA clearance for the treatment of PD adults and is currently commercially available with more than 150 therapist providing the treatment nationally. FBS has not yet been tested for efficacy in an adult post traumatic stress disorder (PTSD) population. It has been suggested that there is overlap in the presence and persistence of symptoms between PD and PTSD patients. The primary goal of this study is to determine whether the FBS will produce similar benefit (both in quality and magnitude) in the defined population of patients with PTSD.
2930166|NCT03039218|Active Comparator|Active|Subjects assigned to this group will receive Active treatments using the Dornier Aries 2.
2930167|NCT03039218|Placebo Comparator|Placebo / Sham|Subjects assigned to this group will receive placebo / sham (no active treatment).
2930168|NCT03039205|Active Comparator|Chronic kidney dysfunction Clopidogrel|Patients with creatinine clearance <60ml/min/m2 (estimated by MDRD formula) randomized to clopidogrel group
2930169|NCT03039205|Active Comparator|Chronic kidney dysfunction Ticagrelor|Patients with creatinine clearance <60ml/min/m2 (estimated by MDRD formula) randomized to ticagrelor group
2930170|NCT03039205|Active Comparator|Normal kidney function Clopidogrel|Patients with creatinine clearance ≥60ml/min/m2 (estimated by MDRD formula) randomized to clopidogrel group
2930171|NCT03039205|Active Comparator|Normal kidney function Ticagrelor|Patients with creatinine clearance ≥60ml/min/m2 (estimated by MDRD formula) randomized to ticagrelor group
2930172|NCT03039192|Experimental|Esketamine|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
2930173|NCT03039192|Placebo Comparator|Placebo|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
2930174|NCT03039179|Experimental|Polyurethane foam|
2930175|NCT03039179|No Intervention|standard care|Only application of the Walker in the immediate postoperative period.
2930176|NCT03039166|Experimental|parkinson|
2930177|NCT03039166|Experimental|partial epilepsy|
2930178|NCT03039166|Experimental|alzheimer disease|
2930179|NCT03039166|Experimental|multiple sclerosis|
2930180|NCT03039166|Experimental|amyotrophic lateral sclerosis|
2930181|NCT03039166|Active Comparator|healthy control patients|
2930182|NCT03039140|Experimental|Supportive care (CR program)|Patients participate in a CR program consisting of 1-hour CR intervention sessions, based on a personalized exercise prescription, 3 times per week for 14 weeks (a total of 36 sessions). Components of the exercise prescription includes intensity, mode, duration, and frequency. Intensity of exercise is guided by the results of a graded exercise stress test, RPE, heart rate, and symptoms, such as chest pain/angina or shortness of breath. If exercise is well-tolerated during CR sessions, patients are encouraged to supplement their exercise program at home, increasing their exercise frequency to up to 5 times per week. Patients may attend weekly educational sessions offered by the Phase 2 CR program which covers topics such as stress management, smoking cessation, nutrition, and weight loss.
2930183|NCT03039127|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
2930184|NCT03039114|Experimental|INCB050465 + Hexal and Gazyvaro|
2930185|NCT03039101|Experimental|Montelukast|Subjects take 1 montelukast 10mg tablet orally, daily and effect on nasal allergen challenge (based on results of epicutaneous skin testing) induced recruitment of cd49d neutrophils in the peripheral blood and nasal lavage determined at 1 week
2930186|NCT03039101|Placebo Comparator|Placebo|Subjects take 1 placebo oral pill, daily and effect on nasal allergen challenge (based on results of epicutaneous skin testing) induced recruitment of cd49d neutrophils in the peripheral blood and nasal lavage determined at 1 week.
2930187|NCT03039088||Anti-TNF naïve patients|Anti-TNF naïve patients at the inclusion of the study
2930188|NCT03039088||Anti-TNF experienced patients.|Anti-TNF pre-exposed patients at the inclusion of the study
2930189|NCT03039075|Active Comparator|Metformin SR Tablet|Metformin hydrochloride sustained-release tablets made in Conquer pharmaceutical co., LTD
2930190|NCT03039075|Active Comparator|Glucophage|The original drug of metformin
2930191|NCT03039062||Chemotherapy group|A total of 120 malignant tumor patients who need to receive chemotherapy are involved for miR-122 detection. They are from 3 centers, 40 for each center. For the first cycle of chemotherapy, the investigators will collect 0.5-1ml blood from the remained blood sample after routine blood test during chemotherapy for each patient.Each patient will have a routine blood test before(±3 days) each cycle of chemotherapy and 7(±3)days after chemotherapy. A routine blood test will include the test of ALT,AST,ALP and TBIL. Sample collection will stop after 4 cycles of chemotherapy. All blood samples collected by investigators are the remained sample after routine tests. Patients in routine care will also have blood tests before each cycle and on day 7(+/- 3) of each cycle of chemotherapy. These patients will also have blood test at these time points even if they are not in this trial.
2930192|NCT03039062||Healthy population|Twenty healthy women or men who come to hospitals for annual physical examinations are enrolled in this study for miR-122 detection. Investigators will collect 0.5-1 ml blood from the remained blood samples after routine blood tests during their annual physical examinations.
2930193|NCT03039062||Patients of intensive care unit|Fourty patients are enrolled in this group for miR-122 detection. The investigators will collect 0.5-1ml blood from the remained blood samples of their routine blood tests or when they need blood tests.
2930194|NCT03039049|Experimental|GnRH agonist|"Drug: Triptorelin 0.1mg Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg.~Other Names:~• Decapeptyl 0.1 mg"
2930195|NCT03039049|No Intervention|Control|No intervention
2930196|NCT03039036|Experimental|Early Amniotomy|Patients undergoing induction of labor with foley catheter, with or without concurrent use of misoprostol, will undergo amniotomy within 1 hour of Foley catheter removal.
2930197|NCT03039036|Active Comparator|Delayed Amniotomy|Patients undergoing induction of labor with foley catheter, with or without concurrent use of misoprostol, will undergo amniotomy no sooner than 4 hours following removal of Foley catheter.
2930198|NCT03039023|Experimental|Whole Hardboiled Eggs|Subjects will consume four (4) pre-cooked, pre-peeled whole hardboiled eggs per day for 28 days.
2930200|NCT03039023|Experimental|Hardboiled Eggs + Choline Bitartrate Tablets|Subjects will consume both four (4) whole, pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.
2930201|NCT03039023|Experimental|Egg Whites + Choline Bitartrate Tablets|Subjects will consume both the egg whites (no yolks) of four (4) pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.
2930202|NCT03038984|Experimental|Every 3 months|screening every 3rd month: (home monitoring: FC and DA)
2930203|NCT03038984|Active Comparator|On demand|screening On demand: (home monitoring: FC and DA)
2930204|NCT03038971|Other|Concentration 1: Short and Tall Ragweed Mix|
2930205|NCT03038971|Other|Concentration 2: Short and Tall Ragweed Mix|
2930206|NCT03038971|Other|Placebo: Saline with 0.4% Phenol|
2930207|NCT03038958|Active Comparator|Isobaric 2-chloroprocaine|The 50 mg dose of isobaric 2-chloroprocaine will be administered to patients undergoing ambulatory knee arthroscopy
2930208|NCT03038958|Active Comparator|Hyperbaric prilocaine 2%|The dose of 50 mg of Hyperbaric prilocaine 2% will be administered to patients undergoing ambulatory knee arthroscopy
2930209|NCT03038945|Experimental|2/0 barbed suture|Use barbed suture for the closure of the vaginal vault in patients with total Laparoscopic hysterectomy caused by a benign gynecologist pathology
2930210|NCT03038945|Active Comparator|Vicryl suture|Use VICRYL suture for the closure of the vaginal vault in patients with total Laparoscopic hysterectomy caused by a benign gynecologist pathology
2930211|NCT03038932||Discovery Cohort|"A minimum of 50 recurrent Atopic Dermatitis with a history of Eczema Herpeticum(ADEH+), 500 Atopic Dermatitis without a history of Eczema Herpeticum (ADEH-), and 237 Non-Atopic (NA) European American participants from the Atopic Dermatitis Research Network (ADRN) DNA Repository.~The study will learn from this cohort:~All Single Nucleotide Variants (SNVs) in ADEH+~ADEH+ specific deleterious SNVs~The study will determine the function of:~4. ADEH+ risk variants"
2930212|NCT03038932||Independent populations of participants|"Two independent populations of participants:~Children, aged 3-17 years and~Adults 18-64 years of age.~A minimum of 12 recurrent Atopic Dermatitis with a history of Eczema Herpeticum (ADEH+) with ≥3 Eczema Herpeticum (EH) episodes, 12 Atopic Dermatitis without a history of Eczema Herpeticum (ADEH-) and 12 Non-Atopic (NA) participants will be enrolled in each of the two populations."
2930213|NCT03038919|Experimental|Anabolic patients|Intramuscular injection of testosterone cypionate 200mg every 15 days in addition to standard nutrition and physical therapy at ICU.
2930214|NCT03038919|Other|Control|Standard nutrition and physical therapy at ICU without administration of testosterone cypionate
2930215|NCT03038906||Cohort|Patients enrolling in NHLBI PETAL Network ROSE study of cisatracurium for moderate/severe ARDS at participating centers
2930216|NCT03038893|Experimental|POCUS + EDUS|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
2930217|NCT03038893|Active Comparator|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
2930218|NCT03038880|Experimental|RO6867461 (Short interval)|RO6867461 will be given via intravitreal (IVT) administration at a short interval duration during the 52 weeks treatment period.
2930219|NCT03038880|Experimental|RO6867461 (Long interval)|RO6867461 will be given via IVT administration at a long interval duration during the 52 weeks treatment period.
2930220|NCT03038880|Sham Comparator|Ranibizumab|Ranibizumab will be given via IVT administration during the 52 weeks treatment period.
2930221|NCT03038867|Experimental|Duloxetine|Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week
2930222|NCT03038867|Placebo Comparator|Placebo|Placebo
2930223|NCT03038854|Experimental|Test GUM|This group will drink a test toddler growing up milk (GUM) with higher amounts of key nutrients
2930224|NCT03038854|Active Comparator|Standard GUM|This group will drink a standard toddler growing up milk (GUM)
2930225|NCT03038854|Placebo Comparator|Comparator Group|This group will drink liquid full fat cows' milk
2930226|NCT03038854|No Intervention|Population Group|This group will eat and drink their usual foods with no interventions.
2930227|NCT03038828|Experimental|Arm A|Cohort A - 200IU Leukocyte Interleukin, Injection 5 days/week x 2 weeks, off two weeks, then repeat 200IU 5 days/week x 2 weeks.
2930228|NCT03038828|Experimental|Arm B|Arm B - 400IU Leukocyte Interleukin, Injection 5 days/week x 2 weeks, off 2 weeks, 400IU 5 days/week x 2 weeks.
2930229|NCT03038815|No Intervention|Control group|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed. For control, the participants are wearing Sport shoes.
2930230|NCT03038815|Experimental|VACOped|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed.
2930231|NCT03038815|Experimental|Ortho Tri-Phase|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed.
2930232|NCT03038802|Active Comparator|Standard vaccine|Subjects will receive regular intramuscular injections of a commercial hepatitis B vaccine (HBsAg containing aluminium hydroxide adjuvant) according to the same study schedule as the subjects in the experimental arm
2930233|NCT03038802|Experimental|Experimental therapeutic vaccine|Subjects will receive regular intramuscular injections of the experimental therapeutic hepatitis B vaccine (preS HBsAg containing Advax-2 adjuvant) in two cycles with the first cycle of four immunisations administered on days 0, 14, 28, 42. and the second cycle of four immunisations on days 70, 84, 98, and 112.
2930234|NCT03038776|Experimental|1|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen)
2930235|NCT03038776|Experimental|2|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-1 adjuvant
2930236|NCT03038776|Experimental|3|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-2 adjuvant
2930237|NCT03038776|Experimental|4|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) antigen
2930238|NCT03038776|Experimental|5|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-1 adjuvant
2930239|NCT03038776|Experimental|6|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-2 adjuvant
2930240|NCT03038763||Mothers|Black or white mothers who have or have had hepatitis C and were born between 1945-1964. Participants must have at least one child over the age of 18.
2930241|NCT03038763||Adult Children|Adult children of Black or white mothers who have or have had hepatitis C and were born between 1945-1964. From speaking with these mothers, it must be possible that participants were exposed to hepatitis C virus while in the womb.
2930242|NCT03038750||EDNRA Sub-study|"Study population will be split into two groups defined by the allele of EDNRA the participant possesses:~Participants Homozygous for the A-allele of EDNRA, are assigned to the 'case' group.~Participants that are Homozygous for the G-allele will be assigned to the 'control' group.~20 participants will be recruited to each group, 40 in total."
2930243|NCT03038750||PNPLA3 Sub-study|"Study population will be split into two groups defined by the allele of PNPLA3 the participant possesses:~Participants Homozygous for the G-allele of PNPLA3, are assigned to the 'case' group.~Participants that are Homozygous for the C-allele of PNPLA3 will be assigned to the 'control' group.~60 participants will be recruited to each group, 120 in total."
2930244|NCT03038750||PROCR Sub-study|"Study population will be split into two groups defined by the allele of PROCR the participant possesses:~Participants Homozygous for the G-allele of PROCR, are assigned to the 'case' group.~Participants that are Homozygous for the A-allele of PROCR will be assigned to the 'control' group.~30 participants will be recruited to each group, 60 in total."
2930245|NCT03038737|Active Comparator|group 1|patients will receive partial denture constructed from breflex material
2930246|NCT03038737|Experimental|group 2|patients will receive partial denture constructed from PEEK material
2930247|NCT03038724|Other|Targeted testing|Patients complete a questionnaire on risk factors for HIV acquisition and are offered rapid (fingerprick) HIV testing if their questionnaire responses indicate they have HIV risk factors
2930248|NCT03038724|Other|Non-targeted screening|Patients offered a brief information on HIV and HIV testing and are then offered rapid (fingerprick) HIV testing without completing an HIV risk factor assessment
2930249|NCT03038711|Experimental|Dose Panel 1|BMS-986166 or Placebo matching BMS-986166
2930250|NCT03038711|Experimental|Dose Panel 2|BMS-986166 or Placebo matching BMS-986166
2930251|NCT03038711|Experimental|Dose Panel 3|BMS-986166 or Placebo matching BMS-986166
2930252|NCT03038685|Experimental|prospective, multicenter cohort|A group of 175 patients will be recruited in 4 Belgian stroke centers during the six months period. All data will be collected prospectively and patients will be treated during six months period.
2930253|NCT03038685|No Intervention|historical, single center cohort|A historical cohort of Sint-Janhospital (2011 - Bruges, Belgium) with prospectively collected data will be used as comparator for the experimental arm. These data were published in Vanacker P, Couvreur T, Vanhooren G. Can we improve cerebrovascular risk reduction in real-life? A single centre's experience. Cerebrovasc Dis 2011;31(suppl 2):289
2930254|NCT03038672|Active Comparator|Group I (nivolumab)|Patients receive nivolumab IV over 60 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may cross over to Group II at the time of disease progression.
2930255|NCT03038672|Experimental|Group II (varlilumab, nivolumab)|Patients receive varlilumab IV over 90 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 60 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity.
2930256|NCT03038659||Penile Duplex|Measuring intima media thickness
2930257|NCT03038646|Experimental|Regimen A|32 mg MIN-101 of the current modified-release formulation (comparator) identified as MR-32 formulation administered in the fasted state
2930258|NCT03038646|Experimental|Regimen B|32 mg MIN-101 MR administered in the fasted state
2930259|NCT03038646|Experimental|Regimen C|32 mg MIN-101 MR administered in the fasted state
2930260|NCT03038646|Experimental|Part 2 selected dose|32 mg MIN-101 of MR administered in the fed state
2930261|NCT03038633|Experimental|Cohort 1|"900 mg novel medical food containing 22.2mg iron~receive 900 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~receive a phone call from coordinator between Day 5-9 to assess side effects and medications~return to General Clinical Research Center, (GCRC) for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
2930262|NCT03038633|Experimental|Cohort 2|"1800 mg novel medical food containing 44.4 mg of iron~receive 1800 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~receive a phone call from coordinator between Day 5-9 to assess side effects and medications~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
2930263|NCT03038633|Experimental|Cohort 3|"2700 mg novel medical food containing 66.6 mg of iron~receive 2700 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~receive a phone call from coordinator between Day 5-9 to assess side effects and medications~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
2930264|NCT03038633|Experimental|Cohort 4|"3600 mg novel medical food containing 88.8 mg of iron~receive 3600 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~receive a phone call from coordinator between Day 5-9 to assess side effects and medications~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
2930265|NCT03038620|Experimental|Liraglutide 3.0 mg|"Drug: Liraglutide Active Drug~Other Names:~Saxenda~Escalate the liraglutide (active) dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection."
2930266|NCT03038620|Placebo Comparator|Placebo|"Drug: Placebo (for Liraglutide at a concentration of 6.0 mg/mL) Placebo tablet manufactured to mimic Liraglutide at a concentration of 6.0 mg/mL~Other Names:~Placebo~Saline injection~Escalate the Placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection."
2930267|NCT03038607|Active Comparator|Aspirin group|
2930268|NCT03038607|No Intervention|No intervention|
2930269|NCT03038594|Experimental|Growth Hormone|Daily subcutaneous injections of 0.05 mg/kg/day of Growth Hormone [somatropin, Genotropin, Pfizer, New York, NY] will be administered, from one week prior to discharge until 9 months post-burn.
2930270|NCT03038594|Placebo Comparator|0.09% saline solution|Daily subcutaneous injections of 0.09% of saline solution will be administered, from one week prior to discharge until 9 months post-burn.
2930271|NCT03038581||Self-inflicted wrist injury|Wrist injury by self-infliction
2930272|NCT03038581||Traumatic wrist injury|Wrist injury by not self-inflicted trauma
2930273|NCT03038568||Cohort 1|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 12
2930274|NCT03038568||Cohort 2|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 14
2930275|NCT03038568||Cohort 3|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 16
2930276|NCT03038568||Cohort 4|-10 second time gap between routine abdominal CT and add on CT, Noise index 12
2930277|NCT03038568||Cohort 5|-10 second time gap between routine abdominal CT and add on CT, Noise index 14
2930278|NCT03038568||Cohort 6|-10 second time gap between routine abdominal CT and add on CT, Noise index 16
2930279|NCT03038568||Cohort 7|- 5 second time gap between routine abdominal CT and add on CT, Noise index 12
2930280|NCT03038568||Cohort 8|- 5 second time gap between routine abdominal CT and add on CT, Noise index 14
2930281|NCT03038568||Cohort 9|- 5 second time gap between routine abdominal CT and add on CT, Noise index 16
2930282|NCT03038568||Cohort 10|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 12
2930283|NCT03038568||Cohort 11|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 14
2930284|NCT03038568||Cohort 12|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 16
2930285|NCT03038568||Cohort 13|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 12
2930286|NCT03038568||Cohort 14|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 14
2930287|NCT03038568||Cohort 15|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 16
2930288|NCT03038568||Cohort 16|+ 15 second time gap between routine abdominal CT and add on CT, Noise 12
2930289|NCT03038568||Cohort 17|+ 15 second time gap between routine abdominal CT and add on CT, Noise 14
2930290|NCT03038568||Cohort 18|+ 15 second time gap between routine abdominal CT and add on CT, Noise 16
2930291|NCT03038555||Disease group (subject to strategy)|Choose subjects that have ever got PE before as the diseases group.
2930292|NCT03038555||Control group|Pair the same age, gestational weeks, children's gender and healthy subject as a control group in the ratio of 1:1. The control group should exclude subject that have ever got heart or lung diseases, diabetes, chronic nephrosis, immune disease and other hereditary disease.
2930293|NCT03038542|Experimental|Treatment Text Arm|
2930294|NCT03038542|Active Comparator|Standard Text Arm|
2930295|NCT03038529|Other|A: Classic approach|"Intradiscal O3 injection through classic postrolateral extraarticular percutaneous approach.~The participants will receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2. The ozone-oxygen mixture was produced in real-time by a medical ozone generator (Ozonline E 80, Medica srl, Bologna Italy)."
2930296|NCT03038529|Active Comparator|B: Transforaminal approach (Yess approach )|"Participants will receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through postrolateral transforaminal approach (Yess approach).~The ozone-oxygen mixture was produced in real-time by a medical ozone generator (Ozonline E 80, Medica srl, Bologna Italy)."
2930297|NCT03038516|Active Comparator|Vitamin D|Cholecalciferol (Detremin) solved in MIGLYOL® 812
2930298|NCT03038516|Placebo Comparator|Placebo|MIGLYOL® 812
2930299|NCT03038503|No Intervention|A|standard care septic shock according sepsis bundles
2930300|NCT03038503|Experimental|B|after defined refractory shock (adequate fluid resuscitation + add NE>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr*4 hr (intervention add on to standard care)
2930301|NCT03038503|Experimental|C|after defined refractory shock (adequate fluid resuscitation + add NE>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
2930302|NCT03038490|Experimental|Study group|The treatment group would be given 2 Sackets of an oral mixture of arginine, glutamine and HMB (ABOUND) every day for a maximum period of 4 weeks, either orally or via enteral feeding.
2930303|NCT03038490|No Intervention|Control group|All patients would be assessed by a dietitian to ensure them receiving nutritional support of at least 30 kcal/kg/day and of at least 1.2 g/kg/day of protein regardless of feeding method. During the study period, vitamin C and zinc supplement would not be given.
2930304|NCT03038477|Experimental|Durvalumab|Patients in Arm A will be given anti-PD-L1 antibody, durvalumab, every 2 weeks for a maximum of 26 doses if there is no radiographic evidence of disease recurrence. For Arm A, one cycle constitutes two durvalumab treatments on Day 1 and Day 15, respectively, repeated every 28 days.
2930305|NCT03038477|No Intervention|No Durvalumab|Patients in Arm B will be observed.
2930306|NCT03038451|Experimental|s-amlodipine besylate 2,5 and 5 mg tablets|
2930307|NCT03038425|Placebo Comparator|Saline infusion|Participants in this group will receive normal saline infusion (5ml/hr, patient controlled bolus 5ml, lockout 30min) in the adductor canal, starting in PACU on post-operative day 0 and continuing for 96 hours
2930308|NCT03038425|Active Comparator|Ropivacaine infusion|Participants in this group will receive ropivacaine 0.2% infusion (5ml/hr, patient controlled bolus 5ml, lockout 30min) in the adductor canal, starting in PACU on post-operative day 0 and continuing for 96 hours
2930309|NCT03038399|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
2930310|NCT03038399|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
2930311|NCT03038399|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
2930312|NCT03038399|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
2930346|NCT03038204||MVA+CABG|patients with ischemic cardiomyopathy who underwent coronary artery bypass grafting and mitral valve annuloplasty.
2930644|NCT03036319|Experimental|Active and Sham TES|Participants will receive active and sham TES
2930313|NCT03038386|Other|Dual Energy CT|In this study all patients undergo DECT scan to assess the value of DECT scan in diagnosing acute arthritis caused by gout. If the DECT scan demonstrates MSU depositions and the diagnosis of gout was not ascertained prior to DECT scanning by MSU crystals in the synovial fluid, then additional ultrasound guided aspiration will take place, with knowledge of DECT results, followed by repeat microscopy
2930314|NCT03038373||Group I|Morbid Obese Type 2 Diabetics, undergo Laparoscopic Sleeve Gastrectomy
2930315|NCT03038373||Group II|Morbid Obese Non Diabetics, undergo Laparoscopic Sleeve Gastrectomy
2930316|NCT03038373||Group III|Lean Diabetics, No surgery
2930317|NCT03038373||Group IV|Lean Non Diabetics, No surgery
2930318|NCT03038347|Experimental|Training|In the training group, participants work six weeks on the training program, one module per week. The modules contain PDF-files with text-based information, video files, case studies with associated questions as well as practical exercises that participants perform independently. The main purpose of this intervention is the improvement of cross-cultural competencies in psychotherapists
2930319|NCT03038347|Active Comparator|Education only|In the education only group, participants work six weeks on a slimmed down version of the training program. The modules only contain text-based information without any exercises. After completion, participants receive access to the practical exercises, case studies and video files as well. Main purpose of the education only group is to determine whether the practical part of the training program can offer additional benefit.
2930320|NCT03038347|No Intervention|Waiting control|Initially, participants do not receive any training contents. After a six week waiting period, they can participate in the training program as well. Modules are equivalent to those of the training group. Purpose of this group is to determine whether the training program is effective.
2930321|NCT03038334|Experimental|Magnesium sulfate|All participants will apply magnesium sulfate transdermally a total of 250mg equivalent to 2 mEq every four hours per day for 90 days.
2930322|NCT03038321|Active Comparator|solifenacin|(Sofenacin ''solifenacin 10 m'') [Marcyrl Pharmaceutical Industries - Egypt]
2930323|NCT03038321|Active Comparator|levofloxacin|(Tavanic ''levofloxacin 500 mg'') [Sanofi-Aventis - Egypt]
2930324|NCT03038321|Active Comparator|lornoxicam|(Xefo ''lornoxicam 8 mg'') [Multi-Apex - Egypt, under license of: NYCOMED, Austria]
2930325|NCT03038308|Experimental|Drug|
2930326|NCT03038295|Experimental|oral propranol group|"Enrolled preterm newborns will receive oral propranolol 0.25mg/kg daily(every 24 hours).~The treatment will be started as soon as the diagnosis of stage 1 or 2 ROP without plus is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days."
2930327|NCT03038295|Placebo Comparator|oral placebo group|Enrolled preterm newborns will receive oral normal saline 0.25mg/kg daily(every 24 hours) and other disposals will be done similarily to the oral propranol group.
2930328|NCT03038295|Experimental|eye drop propranol group|"Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%). 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette,in each eye, four times daily (every 6 hours) .~The treatment will be started as soon as the diagnosis of stage 1 or 2 ROP without plus is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days."
2930329|NCT03038295|Placebo Comparator|eye drop placebo group|Enrolled preterm newborns will receive placebo as ophthalmic solution in the same way of eye drop propranolol and other disposals will be done similarily to the eye drop propranol group.
2930330|NCT03038282|Experimental|Chromium Chloride|Participants transdermal chromium chloride 50 to 600 mcg/day.
2930331|NCT03038282|Experimental|Individual Exercise|Exercise 150 minutes per week (over 3 to 5 days) for 12 weeks.
2930332|NCT03038282|No Intervention|Control Group|Participants or participant's caregiver will be provided educational materials on starting an exercise program and instructions for the application of transdermal chromium chloride, but will receive no formal support for their exercise program.
2930333|NCT03038269|Sham Comparator|Sham tDCS|Participant will receive a placebo-type stimulation followed by upper extremity robotic training.
2930334|NCT03038269|Active Comparator|Active tDCS|Participant will receive active transcranial direct current stimulation followed by upper extremity robotic training.
2930335|NCT03038256|Experimental|4 Cycles XELOX pre- TME|experimental group (arm B): concurrent capecitabine-based long-term radiotherapy, 4 cycles of XELOX as neoadjuvant chemotherapy and TME surgery
2930336|NCT03038256|Active Comparator|6 Cycles XELOX post- TME|control group (arm A): concurrent capecitabine-based long-term radiotherapy, TME surgery and 6 cycles of XELOX as adjuvant chemotherapy.
2930337|NCT03038243|Experimental|Cohort 1|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
2930338|NCT03038243|Experimental|Cohort 2|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
2930339|NCT03038243|Experimental|Cohort 3|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
2930340|NCT03038230|Experimental|MCLA-117 bispecific antibody|"Dose escalation cohorts, with escalating doses of MCLA-117 until MTD or RP2D is reached. The dose is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment.~Part 2-Expansion Cohort: The RP2D of MCLA-117 is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment."
2930341|NCT03038217|Experimental|ACT group|Group of patients with pathologically confirmed Stage II-III colorectal cancer who receive postoperative treatment with chemotherapeutic agent (ACT) using Capecitabine +/- Oxaliplatin.
2930342|NCT03038217|Experimental|Non-ACT group|Group of patients with pathologically confirmed stage II colorectal cancer who receive no adjuvant chemotherapy.
2930343|NCT03038217|Experimental|LR group|Group of patients with clinically staged T1-2N0 rectal cancer who undergo local resection (LR)
2930344|NCT03038217|Experimental|RR group|Group of patients with clinically staged T1-2N0 rectal cancer who undergo radical resection (RR)
2930345|NCT03038204||PMA+MVA+CABG|patients with ischemic cardiomyopathy and mitral regurgitation who underwent coronary artery bypass grafting, mitral annuloplasty, and papillary muscles approximation.
2930714|NCT03035955|No Intervention|no treatment|no treatment on the other side of the face
2930347|NCT03038178|Experimental|LAI plus multi-drug regimen|once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines
2930348|NCT03038152|Experimental|Magseed® Magnetic Seed Axillary Lymph Node Localization|"Magseed marker injected into or near in or near the lymph node under arm up to thirty days prior to surgery.~During surgery, doctor uses a handheld device to scan under arm and locate the marker."
2930349|NCT03038139|Experimental|Cervical exercises|"Group A= Cervical correction program The cervical exercise program consist of 3 strengthening exercises and 2 stretching exercises.~Applying exercises 3 times per week."
2930350|NCT03038139|Experimental|Lumbosacral exercises|"Group B= Cervical + Lumbosacral correction program The cervical exercise program consist of 3 strengthening exercises and 2 stretching exercises.~The lumbosacral exercise program consist of 2 strengthening exercises and 4 stretching exercises.~Applying exercises 3 times per week."
2930351|NCT03038126|Active Comparator|CCHT|Veterans Administration (VA) CCHT with an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).
2930352|NCT03038126|Placebo Comparator|Usual care|
2930353|NCT03038113|Experimental|Part 1: Single-Ascending Dose (SAD)|Healthy volunteers will be enrolled in up to 8 cohorts with doses starting from 0.1 mg/kg and escalating sequentially after review of safety and pharmacokinetic (PK) data.
2930354|NCT03038113|Experimental|Part 2: Multiple Ascending Dose|Participants with Chronic Hepatitis B will enrolled in Part 2. In Part 2a, participants will receive two monthly injections of either 3 doses equivalent to a multiple of the saturation dose or placebo in a 1:1:1:1 ratio. In Part 2b a dose selected from Part 2a based on HBsAg decline or the max dose well tolerated, will be administered to participants randomized in 2 parallel cohorts where they will receive either the full dose every two weeks (3 doses), or half the dose weekly (5 doses). Each of the two cohorts in Part 2b will include participants receiving active drug or placebo in a 3:1 ratio.
2930355|NCT03038100|Experimental|Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab|Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
2930356|NCT03038100|Placebo Comparator|Placebo With Paclitaxel, Carboplatin and Bevacizumab|Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and placebo for additional 16 cycles.
2930357|NCT03038087|Experimental|SENSE Device Monitoring in ICH Patients|
2930358|NCT03038061|Experimental|Experimental group|Patients undergoing Laparoscopic Surgery
2930359|NCT03038048|Experimental|33 g needle - right eye|33 g needle for intravitreal injection of Lucentis or Eylea for right eye and 30 g needle for left eye
2930360|NCT03038048|Experimental|33 g needle - left eye|33 g needle for intravitreal injection of Lucentis or Eylea for left eye and 30 g needle for right eye
2930361|NCT03038035|Active Comparator|MLC901|"NeuroAid II MLC901 is a derivative product of NeuroAid MLC601. It is a simplified formula based on the 9 Herbal ingredients that are present in NeuroAid MLC 601. Neuroaid II has been approved for sale as a Chinese Proprietary Medicine in Singapore by the HSA since March 2010. 24 weeks intervention. Dosage: 2 capsules 3 times a a day~Upon completion of 24 weeks, subject will be given an option to continue an open-label extension for another 24 weeks."
2930362|NCT03038035|Placebo Comparator|Placebo|"24 weeks intervention with orally placebo. 2 capsules 3 times a day.~Upon completion of 24 weeks, subject will be given an option to continue an open-label extension for another 24 weeks."
2930363|NCT03038022|Experimental|MGL-3196|Study Drug
2930364|NCT03038022|Placebo Comparator|Placebo|Matching Placebo
2930365|NCT03038009|Active Comparator|One-month therapy|Pantoprazole, 40mg, tablet, oral, once daily for 1 month.
2930366|NCT03038009|Experimental|Twelve-month therapy|Pantoprazole, 40mg, tablet, oral, once daily for 12 months.
2930367|NCT03037983|Active Comparator|Active|Subjects will receive actual rTMS treatment.
2930368|NCT03037983|Sham Comparator|Sham|Subjects will attend and sit through the session, but no rTMS treatment will be actually delivered to them.
2930369|NCT03037970|Experimental|ABSOLVE|Type I collagen sheet soaked in a solution containing rhPDGF-BB.
2930370|NCT03037970|Placebo Comparator|Placebo|Collagen sheet soaked with saline solution.
2930371|NCT03037957||Group A Strep Assay|
2930372|NCT03037944|Experimental|Group A-LNG|"The Levonorgestrel releasing intrauterine device - IUD- will be Metraplant-E, which is used in this study for group A, is a modified Levonorgestrel-releasing intrauterine system from the old IUD Metraplant, Metraplant-E design has a T-shaped frame containing Levonorgestrel and Ethylene Vinyl Acetate as well as Barium Sulphate to make it radio-opaque, All the T frame, the bulb of 20 mm length and sleeves contain: Ethylene Vinyl Acetate, Levonorgestrel and Barium Sulphate, ensure more exposure of the endometrial surface to the system and hence expect more endometrial suppression."
2930373|NCT03037944|Experimental|Group B-COCs|Group B will receive combined oral contraceptive pills (Yasmin) COCs which will be Monophasic pills that have a constant dose of both estrogen and progestins in each of the hormonal active pills throughout the entire cycle . Yasmin (ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets, provides an oral contraceptive regimen, it will be used continuously for 6 months with stoppage after 3 months for withdrawal bleeding.
2930447|NCT03037515|Active Comparator|Oral Tranexamic Acid|The oral TXA group will receive 1950 mg TXA (3 tablets of 650 mg) approximately 2 hours before incision.
2930374|NCT03037931|Active Comparator|Ferric Carboxymaltose|Ferric Carboxymaltose 2 doses intravenously of 15mg/kg to a maximum individual dose of 750mg 7 days apart and a maximum combined dose of 1500mg - repeated every 6 months as indicated by iron indices
2930375|NCT03037931|Placebo Comparator|Placebos|Normal saline 15ml - 2 doses 7 days apart repeated every 6 months.
2930376|NCT03037918|Experimental|Treatment Group|"Participants will receive 2 x 65mL doses of Yakult light per day, for 28 days.~Participants will consume a high-fat (65% of kilocalories) high-calorie (150% of requirements) diet from day 21 to day 28."
2930377|NCT03037918|No Intervention|Control Group|Participants will consume a high-fat (65% of kilocalories) high-calorie (150% of requirements) diet from day 21 to day 28.
2930378|NCT03037905|Experimental|SignatureSuite OR|The intervention is exposure to the operating room environment created by the device SignatureSuite OR Integration System by STERIS Corporation.
2930379|NCT03037905|No Intervention|Standard OR|Standard operating room without SignatureSuite OR Integration System by STERIS Corporation.
2930380|NCT03037892|Active Comparator|Midazolam and Fentanyl|Midazolam and Fentanyl Two minutes before the colonoscopy procedure, a bolus of midazolam 0.03mg/Kg and 1.5microgram/Kg fentanyl will be given intravenously over 60 sec in group 1. 0.5 mg of midazolam intravenously can be given every two minutes till the patient is sufficiently sedated (sleeping but arousable on calling). The colonoscopy can start at this end point. Increments of 0.5mcg/Kg of fentanyl will be given if patient complains of pain, which can be repeated every 5 minutes if there is persistent pain
2930381|NCT03037892|Experimental|Midazolam and Remifentanil|Midazolam and Remifentanil Target controlled infusion of Remifentanil to 3.0 ng/ml will be started 2 minutes before procedure. The patient will then be given same doses of midazolam in 0.5 mg increments till sedated sufficiently (sleeping but arousable on verbal command). During Colonoscopy the dose of Remifentanil could be increased by 0.5ng/ml if patient complained of pain upto 4.0ng/ml.
2930382|NCT03037892|Experimental|Remifentanil|Remifentanil Group Patients will receive only Remifentanil in the same doses as given in group 2. During the procedure if the pain is excessive and persistent in spite of increasing the respective doses as prescribed in each group, or causing loss of cooperation of patient and interfering in the performance of procedure, the patients will be given sleep dose of Inj Propofol and further anaesthesia care as required will be provided for same.
2930383|NCT03037879|Experimental|SPT|Speed of Processing Training
2930384|NCT03037879|Active Comparator|Control Group SPT|Control group to SPT treatment group
2930385|NCT03037879|Experimental|mSMT|Story Memory Technique
2930386|NCT03037879|Active Comparator|Control mSMT|Control group to mSMT treatment group
2930387|NCT03037866|Experimental|LifeSkills Training for College|All students who consent to participate in the proposed study will complete pre, post, six- and 12-month follow-up surveys. Those randomized to the intervention group (n=2000) will participate in the LST program adapted for college which consists of six 30-minute online sessions (content-specific instruction and skills building activities along with opportunities to apply newly acquired knowledge and practice new skills) and three 60-minute small groups sessions (facilitator-led sessions with fellow incoming students that complement the online modules).
2930388|NCT03037866|No Intervention|Treatment as Usual (Control)|All students who consent to participate in the proposed study will complete pre, post, six- and 12-month follow-up surveys. Those randomized to the control group (n=2000) will not participate in LST but will receive the sexual violence and substance abuse educational content normally provided by their schools.
2930389|NCT03037853||Healthy volunteers|Healthy volunteers
2930390|NCT03037840||cancer patients|Low intensity amplitude-modulated RF EMFs
2930391|NCT03037840||healthy participators|Low intensity amplitude-modulated RF EMFs
2930392|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 5W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 0.7 mm/s, laser power 5 W, LEED 71 J/cm
2930393|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 7W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 1 mm/s, laser power 7 W, LEED 70 J/cm
2930394|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 10W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 1.5 mm/s, laser power 10 W, LEED 67 J/cm
2930395|NCT03037814|Other|Compomer|Adhesive agent+Compomer
2930396|NCT03037814|Other|RMGIC|Primer+RMGIC
2930397|NCT03037814|Other|Giomer|Adhesive Agent+ Giomer
2930398|NCT03037814|Other|Amalgam|Amalgam
2930399|NCT03037801|No Intervention|Control|
2930400|NCT03037801|Experimental|Intrapulmonary Percussive Ventilation|15 minutes of IPV physiotherapy
2930401|NCT03037788|Experimental|WO3979|Formulation containing WO3979 for topical application
2930402|NCT03037788|Experimental|WO3970|Formulation containing WO3970 for topical application
2930403|NCT03037788|Experimental|WO3992|Formulation containing WO3992 for topical application
2930404|NCT03037788|Placebo Comparator|Placebo of WO3988|Formulation containing Placebo of WO3988 for topical application
2930405|NCT03037775|Other|Investigated group|Subjects underwent procedures: hemodynamic indices will be measured at baseline and during 1/ e-cigarette without nicotine smoking, 2/ e-cigarette with nicotine and during 3/ traditional cigarette smoking in random order
2930406|NCT03037749|Experimental|Distressed Violent Partners|Distressed violent partners engage in a placebo-controlled alcohol administration study with an emotion-regulation task.
2930407|NCT03037749|Experimental|Distressed Nonviolent Partners|Distressed nonviolent partners engage in a placebo-controlled alcohol administration study with an emotion-regulation task.
2930408|NCT03037736|Placebo Comparator|Placebo|Patients will receive 0.1mL of normal saline injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
2930409|NCT03037736|Active Comparator|5-Fluorouracil|Patients will receive 0.1mL of 5-Fluorouracil, 5mg/0.1mL, injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
2930410|NCT03037736|Active Comparator|Bevacizumab|Patients will receive 0.1mL of bevacizumab, 2.5mg/0.1mL, injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
2930512|NCT03037073|Active Comparator|Group D|35 patients will receive duloxetine (Cymbalta; Eli Lilly & Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
2930411|NCT03037723|Other|Prone/Supine Simulation|It is institutional policy to perform CT simulation in left-sided breast cancer patients with and without the respiratory gating (this is one CT scan), in the face-up position. It is also standard of care to perform the face-down CT simulation in large breasted women. Both of these simulations are meant to reduce the exposure of the heart and lungs to radiation. In this study, all left-sided breast cancer patients that consent will receive face-up CT simulation with and without gating AND face-down CT simulation, regardless of breast size; thus, each patient is their own control.
2930412|NCT03037697|Experimental|TheraTogs Arm|TheraTogs Arm The participating children will wear TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day, to allow the children to become acclimated to the system+ Traditional treatment 3 months
2930413|NCT03037697|Active Comparator|Traditional Treatment Arm|"Traditional Treatment Arm~1-Trunk control exercises 2-Core stability training 3-Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board~3 months"
2930414|NCT03037684||chronic pain|individuals suffering from chronic pain
2930415|NCT03037684||neuropathic pain|individuals suffering from neuropathic pain
2930416|NCT03037671||CGM Monitored Cohort|The continuous glucose monitor (CGM) used during this study will be the Abbot Freestyle Libre Professional Continuous Glucose Monitoring System.
2930417|NCT03037658|Experimental|Personal - self|Participants had the opportunity to earn money for themselves by increasing their average steps per day.
2930418|NCT03037658|Experimental|Prosocial - loved one|Participants had the opportunity to earn money for a loved one of their choice by increasing their average steps per day.
2930419|NCT03037658|Experimental|Prosocial - charity|Participants had the opportunity to earn money for a charity of their choice by increasing their average steps per day.
2930420|NCT03037658|Experimental|Choice|Participants were given the choice to earn money either for themselves, a loved one, or a charity by increasing their average steps per day.
2930421|NCT03037658|No Intervention|Control|Participants were not offered a financial incentive to increase their average steps per day. They simply wore the pedometer for three weeks.
2930422|NCT03037645|Experimental|Dose escalating cohorts of SNS-062|Sequential groups, 25, 50, 100, 200, 300, 400 and 500 mg twice daily on to determine maximum tolerated dose and recommended dose (RD) in the treatment of various hematological cancers followed by expansion of the recommended dose cohort in Phase 2 of the study treating hematological cancers.
2930423|NCT03037632|Experimental|Communication Tool|
2930424|NCT03037632|No Intervention|No Communication Tool|
2930425|NCT03037619|Experimental|Fitbit|Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months.
2930426|NCT03037619|Experimental|Fitbit+Support|"Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months."
2930427|NCT03037606|Experimental|Rabelis DDR 50 mg Capsules and 1 placebo tablet|Placebo as comparator group is not used. Since study is double-blind, one placebo capsule and tablet is added to treatment groups in order to remove the discrepancy between investigational products.
2930428|NCT03037606|Active Comparator|Pariet 20 mg Enteric Coated Tablets and 1 placebo capsule|Placebo as comparator group is not used. Since study is double-blind, one placebo capsule and tablet is added to treatment groups in order to remove the discrepancy between investigational products.
2930429|NCT03037593|Experimental|Intervention|4000 IU vitamin D3 +prenatal vitamin
2930430|NCT03037593|No Intervention|Control|standard prenatal vitamin
2930431|NCT03037580|Experimental|Oral treprostinil|Sustained-release oral tablets for three times daily (TID) administration
2930432|NCT03037580|Placebo Comparator|Placebo|Placebo (sugar pill) for TID oral administration
2930433|NCT03037567|Experimental|Modified Weight Watchers plan|Modified Weight Watchers Plan which includes a food plan, activity plan, group support and cognitive behavior modification. Weekly study-specific group meetings; electronic tools through iPhone app for 24 weeks.
2930434|NCT03037554|Experimental|Lateralized Thermal Sleepwear|For six consecutive nights subjects will wear Sleepwear with Lateralized Thermal Characteristics
2930435|NCT03037554|Sham Comparator|Sham-Lateralized Sleepwear|For six consecutive nights subjects will wear Sham-Lateralized Sleepwear
2930436|NCT03037541|Experimental|Group 1 Carac (fluorouracil) 0.5% cream|Carac cream (fluorouracil) 0.5% applied daily on the face for one week
2930437|NCT03037541|Placebo Comparator|Group 2 Placebo|Placebo Cetaphil cream applied daily on the face for one week
2930438|NCT03037528|Experimental|Positive Affect, Mindfulness, Tracking|Participants will receive information about positive affect and mindfulness, in addition to being asked to actively track what they eat and receiving the core program
2930439|NCT03037528|Experimental|Mindfulness, Tracking|Participants will receive information about mindfulness, be asked to actively track what they eat, and receive the core program.
2930440|NCT03037528|Experimental|Positive Affect, Tracking|Participants will receive information about positive affect, be asked to actively track what they eat, and receive the core program.
2930441|NCT03037528|Experimental|Tracking|Participants will be asked to actively track what they eat in addition to receiving the core program.
2930442|NCT03037528|Experimental|Positive Affect, Mindfulness|Participants will receive information about positive affect and mindfulness in addition to the core program.
2930443|NCT03037528|Experimental|Positive Affect|Participants will receive information about positive affect in addition to the core program.
2930444|NCT03037528|Experimental|Mindfulness|Participants will receive information about mindfulness in addition to the core program.
2930445|NCT03037528|Experimental|No Extras|Participants will receive the core program.
2930446|NCT03037515|Active Comparator|Intravenous Tranexamic Acid|The IV TXA group will receive the standard dosing for our institution of 1 g TXA (diluted in 100 mL normal saline) given as an IV bolus immediately before incision and another 1 g TXA given before closure.
2930554|NCT03036826||Meropenem|Group of patients receiving Meropenem as antiinfective therapy
2930448|NCT03037502|Experimental|Intervention|Intervention Arm: In the pilot intervention, participants will receive: tailored goals/ messages, self-monitoring, small groups (led by a personal trainer) and educational and community-based information and resources. These intervention components were selected based on investigator's formative research and experience using them in prior studies. These components will be implemented simultaneously as they complement one another. While all of these components have not been tested together in an intervention for this population, they are variations and enhancements of previous interventions by the investigators.
2930449|NCT03037502|No Intervention|Control|"Control Condition: Participants in the attention control group will receive self-help materials on how to improve healthy eating, physical activity and weight loss from the NIDDK Weight-control Information Network and the three assessments with blood work and anthropometric measures. Participants in this condition will receive a copy of their assessment data and the nurses will provide this personalized information as well as answer any questions participants may have about their assessment results. At baseline, participants will receive the Better Health and You Tips for Adults brochure and at the 3-month assessment attention control group participants will receive the Active at Any Size and the Tips to Help You Get Active brochures."
2930450|NCT03037489|Experimental|MIV-711|MIV-711 for a total of 26 weeks
2930451|NCT03037476|Experimental|Web-Based PFI|Participants randomized to the web-based PFI in Studies 2 and 3 will receive a 5 component Personalized Feedback Tool. The first component is presented immediately after the baseline survey and a link to each of the remaining 4 components is sent to participants spaced 1 to 2 weeks apart. The PFI components cover: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol. Each component is comprised of personalized feedback presented in text and graphic format, and each component includes links to tips for making changes if and when the participant is contemplating or ready to commit to change. These tips include general relapse prevention strategies, as well as information about the importance of regular class attendance, study habits, and sleep habits for academic success. General educational tips/strategies for time management, as well as tips for initiating behavior change are also included. Each component takes approximately 5-10 minutes to review.
2930452|NCT03037476|Experimental|In-person PFI|Participants randomized to the in-person PFI condition in Study 3 will be scheduled to meet with a trained intervention provider in a Student Counseling and Health Center setting for a 1.5 hour session to discuss the student's PSM misuse, alcohol and other drug use, and review personalized graphic feedback. The intervention provider will utilize a motivational interviewing approach in reviewing the students personalized feedback with them. They will use the student's past experiences with PSM as a starting point and will help the student to develop discrepancies, elicit change talk, provide students with opportunities to more thoroughly explore and question their beliefs, and offer alternatives by reviewing their personalized responses.
2930453|NCT03037476|No Intervention|Control|The control group will only receive assessments in Studies 2 and 3.
2930454|NCT03037463||Parkinson's Disease|
2930455|NCT03037463||Control|
2930456|NCT03037450|Other|Miniinvasive corneal neurotization|
2930457|NCT03037437|Experimental|No prior systemic treatment|Sorafenib (SOR)-naïve patients receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1). In clinical practice, dose reduction of SOR is often required. Therefore, on C1D15, the clinician will dose-reduce sorafenib based on toxicity and hydroxychloroquine (HCQ) 400 mg PO daily will be started. C2D1 of each cohort, toxicity of HCQ will be assessed. Dose reductions due to adverse events (AEs) to each agent are allowed for SOR per standard of care and/or HCQ for grade 3+ AE.
2930458|NCT03037437|Experimental|Progress on sorafenib|As second-line treatment, we will add hydroxychloroquine (HCQ) to sorafenib (SOR) dose the patient was tolerating at the time of progression.
2930459|NCT03037424|Active Comparator|Fibrinogen concentrate Octafibrin|
2930460|NCT03037424|Active Comparator|Cryoprecipitate|
2930461|NCT03037411||ELUVIA stent implantation|Peripheral stenting
2930462|NCT03037398|Active Comparator|Novel Arm|Programming completed by a novel method
2930463|NCT03037398|Other|Standard of Care Arm|Programming completed as Standard of care
2930464|NCT03037385|Experimental|BLU-667|"Dose Escalation: Multiple doses of BLU-667 for oral administration.~Dose Expansion: Oral dose of BLU-667 as determined during Dose Escalation."
2930465|NCT03037372|Experimental|ART-Atorvastatin adjunct therapy|ART, atorvastatin
2930466|NCT03037372|Experimental|ART-Rosuvastatin adjunct therapy|ART, rosuvastatin
2930467|NCT03037372|Experimental|ART-without statin adjunct therapy|ART, no statin
2930468|NCT03037372|Experimental|Healthy-HIV-negative|Age-matched HIV-negative, healthy volunteers from the same community
2930469|NCT03037359||Bivigam|Patients with primary immunodeficiency disease treated with Bivigam™
2930470|NCT03037359||Other IGIV|Patients with primary immunodeficiency disease treated with other IGIVs
2930471|NCT03037346|Experimental|Participant - Medical Power of Attorney|Questionnaires and surveys completed at new patient appointment and 3 months later during follow-up.
2930472|NCT03037346|Experimental|Family/Caregiver - Medical Power of Attorney|Questionnaires completed at at new patient appointment and 3 months later.
2930473|NCT03037333|Other|fluoroscopy|
2930474|NCT03037333|Other|ECG/ECHO|
2930475|NCT03037320|Experimental|group A|root coverage to be performed by semilunar vestibular incision technique
2930476|NCT03037320|Other|group B|root coverage by coronally advanced flap
2930477|NCT03037307|Experimental|Test product|Participants will topically apply the test product to clean wet denture (upper denture) fit surface in a pattern consistent with product label and application instructions.
2930478|NCT03037307|Active Comparator|Positive Control|Participants will topically apply the positive control to clean wet denture (upper denture) fit surface in a pattern consistent with product label and application instructions.
2930479|NCT03037307|Other|Negative Control|Participants of this group will not be assigned to any treatment.
2930480|NCT03037294|No Intervention|Control group|Subjects in the control group will receive no intervention.
2930481|NCT03037294|Experimental|Protein group|Subjects in the protein group will receive a daily 40 g pre-sleep protein supplement during the 2-week preoperative period.
2930482|NCT03037294|Experimental|Corticosteroid group|Subjects in the corticosteroid group will receive a single intra-articular corticosteroid injection in the affected knee on the first day of the 2-week preoperative period.
2930483|NCT03037281||Septic|Patients admitted to the intensive care unit with a diagnosis of sepsis. For the purposes of this study, patients must have a diagnosis of sepsis; SIRS (2 of pulse >90, WCC, BP, Oxygen(Dellinger et al., 2013)) with microbiological evidence of infection (positive blood culture, urine dipstick, compatible history or examination, radiographic evidence)
2930484|NCT03037281||Healthy volunteers|Healthy volunteers will be approached within the Department of Cardiovascular Sciences, and provided with the PIS, with consent taken by one of the investigating team.
2930485|NCT03037268||Patients undergoing dilated examination|"examined in the Retina Service of Wills Eye Hospital~with and without visually significant posterior retinal or optic nerve pathology~imaged with a Lytro Plenoptic Camera and 28D lens"
2930486|NCT03037242|Other|Transtibial pullout technique|Evaluation of the clinical and radiographic outcomes for patients undergoing a meniscus root repair (MRR) using a transtibial pullout technique.
2930487|NCT03037229||STEMI|"Subjects in which a STEMI protocol has been initiated.~An attempt will be made to do the standard 12-lead ECG first, followed immediately after by the Smartphone ECG~If the initial standard 12-lead ECG was already obtained, such as when the patient was first diagnosed with STEMI, a repeat ECG will be performed at the same time as the Smartphone ECG~If possible, the two ECGs will be taken in the Emergency Department, the critical care unit (CCU), or the catheterization laboratory just prior to cardiac catheterization. If not, then the two ECG's will be taken just after the cardiac catheterization is completed (i.e., within one hour of the procedure) while the patient is still in the catheterization laboratory and waiting for transport to the CCU~Both ECGs will be sent to the designated ECG reading station, to be read and evaluated by three independent cardiologists"
2930488|NCT03037229||Chest Pain|"Subjects presenting at the emergency department with chest pain.~An attempt will be made to do the standard 12-lead ECG first, followed immediately after by the Smartphone ECG~If the initial standard 12-lead ECG was already obtained, such as when the patient was first diagnosed with STEMI, a repeat ECG will be performed at the same time as the Smartphone ECG~If possible, the two ECGs will be taken in the Emergency Department, the critical care unit (CCU), or the catheterization laboratory just prior to cardiac catheterization. If not, then the two ECG's will be taken just after the cardiac catheterization is completed (i.e., within one hour of the procedure) while the patient is still in the catheterization laboratory and waiting for transport to the CCU~Both ECGs will be sent to the designated ECG reading station, to be read and evaluated by three independent cardiologists"
2930489|NCT03037216|Experimental|Experimental Exercise-Training Intervention|Subjects will undergo a 10-week aerobic exercise protocol.
2930490|NCT03037203|Experimental|Arm A|JZP-110 and Placebo
2930491|NCT03037203|Experimental|Arm B|JZP-110 and Placebo
2930492|NCT03037203|Placebo Comparator|Arm C|Placebo
2930493|NCT03037190|Experimental|Group A|Group A:withdrawal of gluten from the diet, Group A will have a gluten free diet for a year after the onset of diabetes
2930494|NCT03037190|No Intervention|B normal diet|Group B will have normal not glutenfree diet, no planned intervention
2930495|NCT03037177||CHL like GZL|Classical Hodgkin Lymphoma like Grey Zone Lymphoma (morphology of CHL and phenotype of PMBCL)
2930496|NCT03037177||PMBCL like GZL|Primary Mediastinal B Cell Lymphoma like Grey Zone Lymphoma(morphology of PMBCL and phenotype of CHL)
2930497|NCT03037177||Composite|with a morphology of CHL on the one side and of PMBCL on the other side of the same diagnosis biopsy
2930498|NCT03037164|Experimental|INTERCEPT (Test)|Red blood cell components treated with the INTERCEPT Blood System for Red Blood Cells ordered and administered to study patients by their treating physicians according to the local standards of care
2930499|NCT03037164|Active Comparator|Conventional (Control)|Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
2930500|NCT03037151|Experimental|HCV mono-infection Treatment naives|HCV treatment-naïve patients will be treated with the combination of grazoprevir plus elbasvir for 12 weeks.
2930501|NCT03037151|Experimental|HCV mono-infection Treatment experienced|HCV treatment-experienced patients, including null responders, partial responders or post-treatment relapsers, will be assigned to treat with the combination plus weight-based RBV for 16 weeks.
2930502|NCT03037151|Experimental|HCV/HIV co-infection Treatment naives|HCV/HIV coinfected, treatment-naïve patients will be treated with the combination of grazoprevir plus elbasvir for 12 weeks.
2930503|NCT03037151|Experimental|HCV/HIV co-infection Treatment experienced|HCV/HIV co-infected treatment-experienced patients, including null responders, partial responders or post-treatment relapsers, will be assigned to treat with the combination plus weight-based RBV for 16 weeks.
2930504|NCT03037138|Other|Washed-out scale after using BFR profiling|Blood flow profiling will be used as intervention for washed-out dialysis patients
2930505|NCT03037125|Active Comparator|Control Arm|Split crest without PRF
2930506|NCT03037125|Experimental|Intervention Arm|Split crest with PRF
2930507|NCT03037112|Active Comparator|Education|All providers will receive identical training on the appropriate prescribing of antibiotics for ARTIs in a 20 minute presentation. Follow up refresher video clips will also be available for all providers to view at their convenience throughout the study. Parents in both arms will receive identical high quality education on the pros and cons of antibiotics and tips for communicating with their provider.
2930508|NCT03037112|Active Comparator|Communication Skills|Providers randomized to the communication intervention will receive additional training on communication skills in a 40 minute communication skills training session. This training session will include good and bad communication examples, training on positive and negative behavioral framing, and education regarding key drivers of patient satisfaction.
2930509|NCT03037099|Experimental|Enhanced GI Concept Education|This group will receive enhanced GI concept nutrition education including GI values of foods, low GI recipes, menus, and application through websites with chat rooms, online videos and print materials. These will be reinforced through email, text messaging/phone calls, and postal mail.
2930510|NCT03037099|No Intervention|Usual Care|Usual care group will receive only standard printed copies of Canada Food Guide and Canadian Diabetes Association GI resources.
2930511|NCT03037086||One single cohort|One single cohort of NSCLC patients with disease diagnosis between January 2010 and December 2014. The locally advanced or metastatic NSCLC patients should have initiated 1st line palliative chemotherapy by end of 2014.
2930555|NCT03036826||Vancomycin|Group of patients receiving Vancomycin as antiinfective therapy
2930513|NCT03037073|Active Comparator|Group C|35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
2930514|NCT03037060|Experimental|Experimental|"5 experimental sessions per participant:~(1) [11C]-(+)-PHNO PET scan, (2), Alcohol Self-Administration, (3) Craving Task, (4) MRI scan and (5) Neuropsychological Assessment."
2930515|NCT03037047|Placebo Comparator|Control group|patients will be treated by 0.9% sodium chloride injection on the basis of conventional therapy for 14 days.
2930516|NCT03037047|Experimental|Experimental group|patients will be treated by salvianolate injection on the basis of conventional therapy for 14 days.
2930517|NCT03037034|Experimental|Forcep Strip Method Treatment|patients who have Gastrointestinal Subepithelial Tumors Originating from the Muscularis Propria are enrolled
2930518|NCT03037021||SCD Adult Patients|Focus group or individual interview and survey
2930519|NCT03037021||SCD Adolescent Patients|Focus group or individual interview and survey
2930520|NCT03037021||SCD Healthcare Providers|Focus group or individual interview and survey
2930521|NCT03037021||Parents of SCD Adolescents|Focus group or individual interview and survey
2930522|NCT03037008|Active Comparator|continent men after RALP|perineal sonography, questionnaires, 24h pad tests
2930523|NCT03037008|Active Comparator|incontinent men after RALP|perineal sonography, questionnaires, 24h pad tests
2930524|NCT03036995|Experimental|Apremilast - Group A|Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
2930525|NCT03036995|Placebo Comparator|Placebo - Group B|Patient will receive UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment and placebo during 24 weeks.
2930526|NCT03036982||Use of Mobile ACT|Will answer ACT (or cACT) and other asthma questions using mobile app
2930527|NCT03036969||Non-urgent emergencies|Outpatients in the Emergency Department with the MTS-Triage category blue, green or yellow
2930528|NCT03036943|Experimental|Fluciclovine (18F) PET/CT|
2930529|NCT03036930|Experimental|Prevention (Gardasil 9 HPV vaccine)|Participants receive the first dose of the recombinant human papillomavirus nonavalent vaccine IM at baseline, at least 30 days prior to the kidney transplant surgery. The second dose is given at least one month after the first dose. The third dose is given at least five months after the first dose and at least three months after the second dose. The timing of the second and third doses is dependent on the scheduling of the kidney transplant surgery. Participants are followed up at 6- and 12-months after the kidney transplant surgery to measure vaccine-induced immune responses. Participants may receive either one, two, or all three vaccine doses prior to the kidney transplant surgery, and are offered additional visits at least one year after the surgery to complete any remaining doses of the three-dose vaccine series.
2930530|NCT03036904|Experimental|Venetoclax plus DA-EPOCH-R|Venetoclax will be given in conjunction with 6 cycles of DA-EPOCH-R (doxorubicin hydrochloride, etoposide, vincristine sulfate, cyclophosphamide, prednisone, rituximab). The dosing schedule and regimen for DA-EPOCH-R will follow established protocols. Venetoclax will be administered days 1-10 of each 21-day cycle, with the exception of cycle 1, during which venetoclax dose will commence on day 3 and continue through day 12, so as to clarify attribution of any observed TLS and/or infusion reactions, and minimize tumor lysis syndrome (TLS) risk.
2930531|NCT03036891|Experimental|Study Group|Naloxegol 25 mg, oral tablet, daily for 4 weeks
2930532|NCT03036891|Placebo Comparator|Placebo Control|Placebo Oral Tablet, 25 mg, oral tablet, daily for 4 weeks
2930533|NCT03036878|Experimental|ReNu Injection|Injection of ReNu allograft into the joint capsule.
2930534|NCT03036865|Experimental|Cohort 1: 1 mg, IV BOS161721|Each participant will receive a single intravenous (IV) dose of BOS161721 1 milligram (mg).
2930535|NCT03036865|Placebo Comparator|Cohort 1: matching placebo|Each participant will receive matching IV placebo.
2930536|NCT03036865|Experimental|Cohort 2: 3 mg, SC BOS161721|Each participant will receive a single subcutaneous (SC) dose of BOS161721 3 mg.
2930537|NCT03036865|Placebo Comparator|Cohort 2: matching placebo|Each participant will receive matching SC placebo.
2930538|NCT03036865|Experimental|Cohort 3: 10 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 10 mg.
2930539|NCT03036865|Placebo Comparator|Cohort 3: matching placebo|Each participant will receive matching SC placebo.
2930540|NCT03036865|Experimental|Cohort 4: 30 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 30 mg.
2930541|NCT03036865|Placebo Comparator|Cohort 4: matching placebo|Each participant will receive matching SC placebo.
2930542|NCT03036865|Experimental|Cohort 5: 60 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 60 mg.
2930543|NCT03036865|Placebo Comparator|Cohort 5: matching placebo|Each participant will receive matching SC placebo.
2930544|NCT03036865|Experimental|Cohort 6: 22 mg, IV BOS161721|Each participant will receive a single IV dose of BOS161721 22 mg.
2930545|NCT03036865|Experimental|Cohort 7: 120 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 120 mg.
2930546|NCT03036865|Placebo Comparator|Cohort 7: matching placebo|Each participant will receive matching SC placebo.
2930547|NCT03036865|Experimental|Cohort 8: 240 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 240 mg.
2930548|NCT03036865|Placebo Comparator|Cohort 8: matching placebo|Each participant will receive matching SC placebo.
2930549|NCT03036852|Experimental|SOF/VEL|SOF/VEL for 12 weeks
2930550|NCT03036839|Experimental|LDV/SOF for 8 weeks|Treatment-naive participants with genotype 1 without cirrhosis will receive LDV/SOF for 8 weeks
2930551|NCT03036839|Experimental|LDV/SOF for 12 weeks|Treatment-experienced participants with genotype 1 and treatment-naive or treatment-experienced participants with genotype 4, 5, 6 without cirrhosis will receive LDV/SOF for 12 weeks
2930552|NCT03036839|Experimental|LDV/SOF for 24 weeks|Participants with compensated cirrhosis will receive LDV/SOF for 24 weeks
2930553|NCT03036826||Piperacillin/Tazobactam|Group of patients receiving Piperacillin/Tazobactam as antiinfective therapy
2930556|NCT03036813|Active Comparator|Dose 1|GBT440
2930559|NCT03036800|Experimental|Targeted Prescribing Pathway (LIRA 3mg + Standard Care)|Standard care plus targeted use of the intervention Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply
2930560|NCT03036800|Active Comparator|Standard Care|standard Tier 3 obesity specialist service care
2930561|NCT03036787||moderate-early preterm infants|infant who births in 32 weeks to 37 weeks with family based intervention
2930562|NCT03036787||extremely-very preterm infants|infant who births in 27 weeks to 32 weeks with family based intervention
2930563|NCT03036774|Experimental|Diabetic patient|
2930564|NCT03036774|Other|Non diabetic patient|
2930565|NCT03036761|Experimental|Auriculotherapy|
2930566|NCT03036761|No Intervention|No auriculotherapy|
2930567|NCT03036748|Experimental|Kidney transplant recipients with ACR <30mg/g|
2930568|NCT03036748|Experimental|Kidney transplant recipients with ACR> 300mg/g|
2930569|NCT03036735|Experimental|Steroid Eluting Spacer|"Subjects will receive one steroid eluting spacer (Restora Mometasone Furate Eluting Spacer) placed into the surgical site on one side, and one spacer without drug (Silastic spacer) placed on the other side.~The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer."
2930570|NCT03036722|Experimental|Flaxseed porridge group|22 volunteer will be given 80g of a pre prepared porridge meal containing 40 g of ground (flaxseed) to consume daily.
2930571|NCT03036722|Placebo Comparator|Placebo control porridge group|22 volunteer will be given 78.5g preprepared control porridge matched for energy and fat content to consume daily ( Matching food products: 22g MCT (medium chain Triglyceride), 5.5g pure egg white powder, 11g cream of rice).
2930572|NCT03036709|Experimental|VRC-HIVMAB01060-00-AB (VRC01)|"VRC01 is a monoclonal antibody directed towards the site of CD4 attachment on the HIV-1 gp120 envelope (Env) glycoprotein.~VRC01 will be administered at a dose of 40 mg/kg intravenously every three weeks to participants assigned to the intervention arm of the trial for a total duration of 24 weeks or until ART resumption criteria are met, whichever comes first."
2930573|NCT03036709|Placebo Comparator|Sodium Chloride for Injection USP, 0.9%|Normal saline (Sodium Chloride for Injection USP, 0.9%) will be administered intravenously every three weeks to participants assigned to the placebo arm of the trial for a total duration of 24 weeks or until ART resumption criteria are met, whichever comes first.
2930574|NCT03036696||Pregnant Mothers Interview|(1) 18 years old or over, (2) between 28-38 weeks of pregnancy, (3) lives in Gainesville, Florida, and (4) are committed to exclusively breastfeeding through 6 months.
2930575|NCT03036696||Breastfeeding Mothers Interview|(1) 18 years old or over, (2) actively breastfeeding infant less than 12 months of age, and (3) lives in Gainesville, Florida.
2930576|NCT03036683|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal transcranial direct current stimulation (tDCS). tDCS will be delivered by a battery-driven, constant-current stimulator connected to two saline-soaked surface sponge electrodes. An anodal electrode (25cm2) will be placed over the right dorsolateral prefrontal cortex and one cathodal electrode (100cm2) will be placed over the left supraorbital area at least 5cm from the anode. Scalp electrodes will be positioned according to the 10-20 EEG international system. A current of 2mA will be applied for 20 minutes and the current will be ramped up and down over 20 seconds at the beginning and end of the stimulation period.
2930577|NCT03036683|Sham Comparator|Sham stimulation|The sham tDCS condition will involve the same placement of the electrodes, current intensity, and ramp-up/down time as the active tDCS condition, but stimulation will only last for 30 seconds.
2930578|NCT03036657|Experimental|Manual Acupuncture|"Device:~Sterile single-use MAC acupuncture needles - 0.22 x 25 mm, TianJin Haing Lim Sou Won Medical Equipment Co, Ltd, South Korea~Used for Intervention:~Manual Acupuncture to PC3, PC5 or HT3, HT4 for 20 min"
2930579|NCT03036657|Experimental|Low-Frequency Electroacupuncture|"Device:~Electrostimulator 6c.Pro, Pantheon Research, Venice, CA~Used for Intervention:~Low-frequency Continuous Electroacupuncture (2Hz) to PC3, PC5 or HT3, HT4 for 20 min"
2930580|NCT03036657|Experimental|High-Frequency Electroacupuncture|"Device:~Electrostimulator 6c.Pro, Pantheon Research, Venice, CA~Used for Intervention:~High-frequency Continuous Electroacupuncture (100 Hz) to PC3, PC5 or HT3, HT4 for 20 min"
2930581|NCT03036644|Experimental|e-cigarette nic_O LT|e-cigarette (without nicotine; low temperature)
2930582|NCT03036644|Experimental|e-cigarette Nic_1 LT|e-cigarette (with nicotine; low temperature)
2930583|NCT03036644|Experimental|e-cigarette Nic_0 HT|e-cigarette (without nicotine; high temperature)
2930584|NCT03036644|Experimental|e-cigarette NIC_1 HT|e-cigarette (with nicotine; high temperature)
2930585|NCT03036644|Active Comparator|Tobacco cigarette|Tobacco cigarette
2930586|NCT03036644|Placebo Comparator|Placebo|No E-cigarettes, Nor tobocco cigarettes
2930587|NCT03036631||Conscious Sedation/Monitored Anesthesia Care|
2930588|NCT03036631||General Anesthesia|
2930589|NCT03036618|Placebo Comparator|Wheat|Test wheat bread roll (approximately 160g weight) without quinoa.
2930590|NCT03036618|Experimental|Quinoa|Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
2930591|NCT03036605|Active Comparator|Group Bupivacaine|4 ml %0.5 bupivacaine and 1 ml %0.9 NaCl infiltration into nasal packing to both sides
2930592|NCT03036605|Active Comparator|Group Bupivacaine+Dexamethasone|4 ml %0.5 bupivacaine and 4mg(1 ml) dexamethasone infiltration into nasal packing to both sides
2930593|NCT03036592|Experimental|MTNR1B CC|Test glucose tolerance in homozygous non-carriers (CC) for MTNR1B rs10830963 in Early OGTT and Late OGTT
2930594|NCT03036592|Experimental|MTNR1B GG|Test glucose tolerance in homozygous (GG) risk allele carriers for MTNR1B rs10830963 in Early OGTT and Late OGTT
2930595|NCT03036592|Experimental|MTNR1B CG|Test glucose tolerance in heterozygous (CG) risk allele carriers for MTNR1B rs10830963 in Early OGTT and Late OGTT
2930596|NCT03036579|Experimental|Glazed Fired, Calibra Céram|Celtra Duo crowns will be glaze-fired in a porcelain oven and cemented with Calibra Ceram Cement
2930597|NCT03036579|Experimental|Hand Polished, Calibra Universal|Celtra Duo crowns will be hand-polished and cemented with Calibra Universal Cement
2930598|NCT03036566|Experimental|Bridge|Three unit high strength ceramic (lithium disilicate/emaxCAD by Ivoclar) bridges replacing a single tooth.
2930715|NCT03035942|Experimental|D Group|Dexamethasone 8 mg
2930716|NCT03035942|Experimental|O group|Ondansetron 4 mg
2930599|NCT03036553||Chronic musculoskeletal pain|"(i) men / women over the age of 18 (ii) participants with musculoskeletal pain (pain intensity of 3 or more on a numerical scale of pain 0-10) will be included in this study, among all of the following conditions: pain around the axial skeleton (neck, lower back And / or pelvis) or peripheral joints (shoulder, elbow, wrist, knee and / or ankle). We included people with clinical diagnoses of chronic pain (shoulder pain, neck pain, whiplash disorder, temporomandibular joint disorders, pelvic pain syndrome, ankle pain and epicondylalgia), non-specific low back pain, fibromyalgia, chronic fatigue syndrome and those with a radiological diagnosis of osteoarthritis.~(iii) duration of symptoms: more than 3 months."
2930600|NCT03036527|Experimental|Activity-based locomotor training|To understand the effects of weight-bearing activity-based locomotor therapy on bladder function and sexual function. Activity-based locomotor training interventions include locomotor step training with a harness and body-weight support, 5 days a week for a total of 80, 1-hour sessions.
2930601|NCT03036527|Experimental|Activity-based stand training|To understand the effects of weight-bearing activity-based stand therapy on bladder and sexual function. Activity-based stand training interventions include stand training with a harness and body-weight support or stand training over ground, 5 days a week for a total of 80, 1-hour sessions.
2930602|NCT03036527|Experimental|Activity-based upper arm ergometry|To understand the effects of non-weight-bearing activity-based stand therapy on bladder and sexual function. Activity-based upper arm ergometry interventions may include arm crank training (upper arm ergometry) in while seated in the wheelchair 5 days a week for a total of 80, 1-hour sessions.
2930603|NCT03036514|Experimental|Case|Sublingual sufentanil tablet system (SSTS) for postoperative pain relief after laminectomy or spinal fusion in the first 72 hour period. Orange-coloured tablets containing 15mcg sufentanil, the patient-controlled device is designed to deliver a single tablet with a minimum lockout interval of 20 minutes.
2930604|NCT03036514|Active Comparator|Control|Patient-controlled intravenous analgesia (PCIA) for postoperative pain relief after laminectomy or spinal fusion in the first 72 hour period. This classic patient-controlled IV-pump contains 1mg/ml morphine and 50mcg/ml dehydrobenzperidol. Pump characteristics include 1ml each asked bolus, lockout interval of 8 minutes.
2930605|NCT03036501|Experimental|[^14C]-RO7034067|Participants will be administered with [^14C]-RO7034067 solution orally under fasted conditions on Day 1.
2930606|NCT03036488|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab every 3 weeks (Q3W) + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by pembrolizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of pembrolizumab Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.
2930607|NCT03036488|Active Comparator|Placebo + Chemotherapy|Participants receive placebo (normal saline solution) Q3W + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by placebo + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of placebo Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.
2930608|NCT03036462|Experimental|Verum group (FCM)|I.v. iron administration in the form of FCM will be carried out according to SmPC. I.v. iron bolus administration (1000 mg) will be followed by an optional administration of 500-1000 mg within the first 4 weeks, (up to a total of 2000 mg which is in-label), according to the approved dosing rules, followed by administration of 500 mg FCM at every 4 months, except when haemoglobin is > 16.0 g/dL or ferritin is > 800 µg/L .In the verum group, all patients will receive a saline administration, when no iron is indicated at the time of the visit and according to the values listed above.
2930609|NCT03036462|Placebo Comparator|Placebo group (NaCL)|Administration of i.v. NaCl at a volume according to the dosing rules for FCM, i.e. as described for the verum group.
2930610|NCT03036449||A|Group A: Phase 1: Observations (Baseline rate of errors); Phase 2: Main Educational program; Phase 3: Observations; Phase 4: Maintenance Educational program; Phase 5: Observations; Phase 6: Maintenance Educational program; Phase 7: Observations; Phase 8: Maintenance Educational program; Phase 9: Observations.
2930611|NCT03036449||B|Group B: Phase 1: Observations (Baseline rate of errors); Phase 2: No intervention; Phase 3: Observations (Baseline rate of errors); Phase 4: Main Educational program; Phase 5: Observations; Phase 6: Maintenance Educational program; Phase 7: Observations; Phase 8: Maintenance Educational program; Phase 9: Observations.
2930612|NCT03036449||C|Group C: Phase 1: Observations (Baseline rate of errors); Phase 2: No intervention; Phase 3: Observations (Baseline rate of errors); Phase 4: No intervention; Phase 5: Observations (Baseline rate of errors); Phase 6: Main educational program; Phase 7: Observations; Phase 8: Maintenance educational program; Phase 9: Observations.
2930613|NCT03036436|Experimental|Intervention|Participants in this group will receive the intervention. They will receive a Fitbit activity tracker, and will also receive support and goal setting with a view to improving their daily physical activity.
2930614|NCT03036423|Active Comparator|Online video education|Participants will have computer access to a library of videos, including various lectures and demonstrations of interest, from which to select and view.
2930615|NCT03036423|Active Comparator|Computerized mental exercises|Participants will use a computer to do a variety of activities which are customizable to their own abilities and progress.
2930616|NCT03036410|Other|bimodal user|wearing one hearing aid and one CI Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
2930617|NCT03036410|Other|unilateral hearing aid users|wearing one hearing aid Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
2930618|NCT03036410|Other|bilateral hearing aid users|wearing two hearing aids Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
2930619|NCT03036410|Other|CI users|wearing CI Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
2930620|NCT03036397|Experimental|SRX then PLC|SRX246 for 5-7 days, then placebo for 5-7 days
2930621|NCT03036397|Experimental|PLC then SRX|PLC for 5-7 days, then SRX246 for 5-7 days
2930622|NCT03036384|Experimental|Cohort 1 : HB prilocaine 2%, 60mg|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.
2930717|NCT03035942|Placebo Comparator|S group|Normal saline (5 mL total volume)
2930623|NCT03036384|Experimental|Cohort 2 : HB prilocaine 2%, (45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.
2930624|NCT03036384|Experimental|Cohort 3 : HB prilocaine 2%, (45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.
2930625|NCT03036384|Experimental|Cohort 4 : HB prilocaine 2%, (45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.
2930626|NCT03036384|Experimental|Cohort 5 : HB prilocaine 2%, (45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.
2930627|NCT03036384|Experimental|Cohort 6 : HB prilocaine 2%, (45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.
2930628|NCT03036384|Experimental|Cohort 7 : HB prilocaine 2%, (45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.
2930629|NCT03036384|Experimental|Cohort 8 : HB prilocaine 2%, (45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.
2930630|NCT03036384|Experimental|Cohort 9 : HB prilocaine 2%, (45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.
2930631|NCT03036384|Experimental|Cohort 10 : HB prilocaine 2%, (45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 45, 50, 55, 60, 65, 70mg.
2930632|NCT03036371|Experimental|High Intensity Interval Exercise|home exercise sessions
2930633|NCT03036358|Other|Teledermatology consult|To determine the benefit of teledermatology to differentiate cellulitis from pseudocellulitis in emergency departments through the analysis of time spent in the emergency department (ED), admission to the inpatient hospital, antibiotic use, time to improvement, and 30-day remission rate. This arm will undergo imaging, a dermatologic assessment will be performed, AND this assessment will be entered into the patients chart.
2930634|NCT03036358|Other|Routine Care|To determine the benefit of teledermatology to differentiate cellulitis from pseudocellulitis in emergency departments through the analysis of time spent in the emergency department (ED), admission to the inpatient hospital, antibiotic use, time to improvement, and 30-day remission rate. This arm will undergo imaging, a dermatologic assessment will be performed, AND this assessment WILL NOT be entered into the patients chart
2930635|NCT03036345|Experimental|Surgery patients|Patients receiving shoulder surgery in the Beach Chair Position, and monitored by both INVOS and FORE-SIGHT monitors.
2930636|NCT03036332|Experimental|intervention|Aerobic interval training
2930637|NCT03036332|No Intervention|Control group|The participants performed only initial evaluation and at the end of the study
2930638|NCT03036319|Experimental|Active TES|"Participants will receive real tES (tDCS, tACS, tRNS) in which they receive up to 4 milliamps (mA) of stimulation for up to 40 minutes for up to 30 sessions. As this may be a cross-over design, some participants may receive active and sham conditions."
2930639|NCT03036319|Placebo Comparator|Sham TES|Participants undergoing this condition will have the exact same procedures as the active group, with the exception that they will receive only sham stimulation for up to 30 sessions.
2930640|NCT03036319|Experimental|Cognitively based intervention|Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation.
2930641|NCT03036319|Experimental|Active TES + Cognitively based intervention|This condition combines active TES and cognitively based interventions for some or all of the study sessions
2930642|NCT03036319|Experimental|Sham TES + Cognitively based intervention|This condition combines sham TES and cognitively based interventions for some or all of the study sessions
2930643|NCT03036319|Experimental|Active TES, Sham TES, Cognitively based interventions|This condition combines active and sham TES with cognitively based interventions using a cross-over design
2930645|NCT03036306|Experimental|1.0 % SCX-001 cream|Subjects randomized to this arm will have one lateral hip wound treated with 1.0% SCX-001 cream and one wound treated with placebo. Intra-subject hip wound treatment is randomly allocated
2930646|NCT03036306|Experimental|3.0% SCX-001 cream|Subjects randomized to this arm will have one lateral hip wound treated with 3.0% SCX-001 cream and one wound treated with placebo. Intra-subject hip wound treatment is randomly allocated
2930647|NCT03036306|Placebo Comparator|Placebo cream|Subjects randomized to this arm will have both lateral hip wounds treated with Placebo cream. Intra-subject hip wound treatment is randomly allocated
2930648|NCT03036293|Experimental|Tenoten, 2 tablets twice a day (4 tablets a day)|
2930649|NCT03036293|Placebo Comparator|Placebo, 2 tablets twice a day (4 tablets a day)|
2930650|NCT03036293|Experimental|Tenoten, 2 tablets 4 times daily (8 tablets a day)|
2930651|NCT03036293|Placebo Comparator|Placebo, 2 tablets 4 times daily (8 tablets a day)|
2930652|NCT03036280|Experimental|elenbecestat (E2609) 50 mg|Participants will receive one 50 milligram (mg) elenbecestat (E2609) tablet orally once a day in the morning.
2930653|NCT03036280|Placebo Comparator|Placebo|Participants will receive one matching placebo tablet orally once a day in the morning.
2930654|NCT03036267|Experimental|BREATHE|7-minute brief shared decision-making intervention using a 4-step motivational interviewing approach
2930655|NCT03036267|Active Comparator|Attention Control Condition|7-minute diet and exercise discussion
2930656|NCT03036254|Experimental|HBOT intervention|The multiplace HBOT unit at Asaf Harofeh. The inside looks like an airplane, with comfortable chairs for 11 subjects and the nurse who stays throughout the session. The HBOT protocol is 90 minutes, 5 times/week, 60 sessions, 100% oxygen at 2 ATA with 5 minute air breaks every 30 minutes.
2930657|NCT03036254|Sham Comparator|Sham intervention|Except for pressure, all the conditions of the HBOT intervention are provided in the sham intervention (nurse measures vitals and asks about health before entering the chamber, time in the chamber, number of sessions per week and overall, nurse in the chamber at all times, mask on the face, etc.).
2930658|NCT03036241|Experimental|Drug-eluting balloon|
2930659|NCT03036241|Active Comparator|Conventional angioplasty|
2930660|NCT03036228|Experimental|Dose escalation|Karonudib is an oral inhibitor of MTH1 and will be supplied as an oral solution to be taken every other day. There are eight planned dose cohorts. Patients will be given every second day dosing from week 1 (after evaluation of PK data and safety).
2930661|NCT03036215|No Intervention|Traditional Self-Care Control Arm|Traditional self-care includes focusing on rest and healing through changes in chewing, diet, heat/cold, over the counter analgesics, and reducing strain from oral and sleeping habits. Participants will also participate in usual care from the dentist such as a splint or anti-inflammatory medications. Participants will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end). .
2930662|NCT03036215|Experimental|PACT Experimental Arm|If selected for the PACT care arm, participant will be prompted to complete a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. Participant will also participate in usual care from the dentist such as a splint or anti- inflammatory medications.Participant will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end).
2930663|NCT03036202||one group|All patients treated for cardiac arrest, meeting our inclusions criteria will be enrolled in the study. No interventions regarding the national guidelines will be jeopardized, as the plasma concentration following a single dose of epinephrine will be measured in all patient.
2930664|NCT03036189|Experimental|Intervention arm|There are no devices or drugs used in this trial. The treatment is the same for the intervention arm and the wait-list control arm. The treatment is group trial of 7 meetings designed to improve chronic illness self-management. The name of the treatment is baa nnilah.
2930665|NCT03036189|Experimental|Wait-list control arm|There are no devices or drugs used in this trial. The treatment is the same for the intervention arm and the wait-list control arm. The treatment is group trial of 7 meetings designed to improve chronic illness self-management. The name of the treatment is baa nnilah.
2930666|NCT03036176|Other|SAM intervention group|Children in the intervention group received routine medical treatment and nutritional rehabilitation services in hospital; their primary caregivers were given basic orientations on child care, feeding and nutrition. Children attended play-based stimulation sessions in which trained nurses demonstrated caregivers on how to stimulate the SAM child using play materials and facilities at playroom and playground of the hospital. After discharge from hospital, they were followed up at home and visited three times over a period of six months. During the visits, new play materials were provided and caregivers were shown how to use them to stimulate the SAM child.
2930667|NCT03036176|Other|SAM control Group|The control children received routine medical treatment and nutritional rehabilitation services in hospital. Though they had access to playground facilities neither the control children nor their caregivers had access to the playroom materials and the basic orientation on child care, feeding and stimulation.
2930668|NCT03036163|Experimental|Cohort 1|6 man healthy volunteers each of whom received once single oral dose of PBTZ169 - 40 mg (1 capsule)
2930669|NCT03036163|Experimental|Cohort 2|6 man healthy volunteers each of whom received once single oral dose of PBTZ169 - 80 mg (2 capsules)
2930670|NCT03036163|Experimental|Cohort 3|6 man healthy volunteers each of whom received once single oral dose of PBTZ169 - 160 mg (4 capsules)
2930671|NCT03036163|Experimental|Cohort 4|6 man healthy volunteers each of whom received once single oral dose of PBTZ169 - 320 mg (8 capsules)
2930672|NCT03036163|Experimental|Cohort 5|6 man healthy volunteers each of whom received once single oral dose of PBTZ169 - 640 mg (16 capsules)
2930673|NCT03036163|Experimental|Cohort 6|6 man healthy volunteers each of whom received once daily for 14 days 320 mg of PBTZ169 (8 capsules 40 mg)
2930674|NCT03036163|Experimental|Cohort 7|6 man healthy volunteers each of whom received once daily for 14 days 640 mg of PBTZ169 (16 capsules 40 mg)
2930675|NCT03036150|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
2930676|NCT03036150|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
2931171|NCT03032640|Active Comparator|Group 2- Healthy Lean subjects|Group 2 will receive Placebo 500mg capsule, 2x/day, Day 1-14
2930677|NCT03036137|Active Comparator|Active tDCS|Subjects will receive 20 minutes of active tDCS for five consecutive days, current of 2 mA, in the temporoparietal left area, and right prefrontal cortex.
2930678|NCT03036137|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham tDCS for five consecutive days in the temporoparietal left area, and right prefrontal cortex.
2930679|NCT03036124|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
2930680|NCT03036124|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
2930681|NCT03036111|Sham Comparator|Hemorrhoidectomy|Patients will undergo Millgan-Morgan hemorrhoidectomy as classically described before
2930682|NCT03036111|Active Comparator|trimebutine|Patients will undergo Millgan-Morgan hemorrhoidectomy then triembutine suppository will be inserted in the anal canal intraoperatively and then every six hours for 24 hours.
2930683|NCT03036098|Experimental|Arm A: Investigational immunotherapy|Specified dose of nivolumab and ipilimumab on specified days
2930684|NCT03036098|Active Comparator|Arm B: Standard of care chemotherapy|Specified dose of gemcitabine / cisplatin or gemcitabine / carboplatin on specified days
2930685|NCT03036098|Experimental|Arm C: Investigational immunotherapy|Specified dose of nivolumab plus gemcitabine-cisplatin followed by nivolumab only on specified days
2930686|NCT03036098|Active Comparator|Arm D: Standard of care chemotherapy|Specified dose of gemcitabine-cisplatin only on specified days
2930687|NCT03036085|Active Comparator|Bupivacaine|Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with 0.5% bupivacaine with 1% epinephrine. In the bupivacaine group 20 ml of 0.5% bupivacaine with 1% epinephrine will be diluted to a total volume of 40 ml using 20 ml normal saline. From those 40 ml, 30 ml will be used for the posterior intercostal nerve block and 10 ml will be injected locally into the surgical wounds.
2930688|NCT03036085|Experimental|Liposomal bupivacaine|Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine (13.3 mg/ml). In the liposomal bupivacaine group, a total dose of 266 mg of liposomal bupivacaine (one 20 ml vial of 13.3 mg/ml) per patient will be diluted to a total volume of 40 ml using 20 ml normal saline.
2930689|NCT03036072|Active Comparator|Strict Normothermia|Patients will be rewarmed to 36.5 degrees centigrade in the operating room and maintained here by conventional means in the PICU.
2930690|NCT03036072|Experimental|Delayed Rewarming|Patient will be rewarmed to 35.0 degrees centigrade in the operating room, then slowly rewarmed to normal physiologic temperature over 12 hours by using a servo-controlled cooling blanket. Normothermia will be maintained by the cooling blanket for an additional 12 hours.
2930691|NCT03036059|Active Comparator|Control group|400 μg/kg Ivermectin + 400 mg Albendazole Tablets given every year for 2 years
2930692|NCT03036059|Experimental|Expanded frequency group|400 μg/kg Ivermectin + 400 mg Albendazole, Tablets given every 6 months for 2 years
2930693|NCT03036046|Experimental|F901318 with fluconazole low dose|safety assessment
2930694|NCT03036046|Experimental|F901318 with fluconazole high dose|safety assessment
2930695|NCT03036046|Experimental|F901318 with posaconazole|safety assessment
2930696|NCT03036033|Experimental|SaeboGlove Therapy|All participants will be given a SaeboGlove for a 4-week period to use along side their routine functional based training program.
2930697|NCT03036020|Experimental|Contraindication anesthesiologists|Ability of anesthesiologists to detect contraindications to thrombolysis in acute stroke patients prehospital by interpretation of prehospital cerebral CT scans
2930698|NCT03036007|Active Comparator|Prescribed Physical Activity|General physical exercises combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
2930699|NCT03036007|Experimental|Exercises with Internet support|Neck-specific exercises with Internet support combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
2930700|NCT03035994|Experimental|Overloading|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at 10% greater than the participant's baseline vertical ground reaction force. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
2930701|NCT03035994|Experimental|Underloading|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at 10% lower than the participant's baseline vertical ground reaction force. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
2930702|NCT03035994|Experimental|Average|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at the average of each participant's baseline vertical ground reaction force between limbs. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
2930703|NCT03035994|No Intervention|Control|Participants will walk for 20 minutes on a force-instrumented treadmill and will not be provided biofeedback.
2930704|NCT03035981|Experimental|White rice, low amylose|Cooked white rice with low amylose content
2930705|NCT03035981|Experimental|White rice, high amylose|Cooked white rice with high amylose content
2930706|NCT03035981|Experimental|White rice, slow|Cooked white rice with slow digesting starch
2930707|NCT03035981|Experimental|White rice, resistant|Cooked white rice with resistant starch
2930708|NCT03035981|Experimental|Brown rice, low amylose|Cooked brown rice with low amylose content
2930709|NCT03035981|Experimental|Brown rice, high amylose|Cooked brown rice with high amylose content
2930710|NCT03035981|Experimental|Fructooligosaccharide (FOS)|Fermentable carbohydrate solution
2930711|NCT03035968|Experimental|Vojta arm|Patients in the interventional arm are treated with Vojta therapy from randomization until discharge.
2930712|NCT03035968|Active Comparator|conventional physiotherapy arm|Patients in this control arm are treated with conventional physiotherapy for motor improvement from randomization until discharge.
2930713|NCT03035955|Active Comparator|Azelaic acid|azelaic acid (Finacea® Gel, 15%) twice daily on either the left side or the right side of the face and no treatment on the other side of the face
2930718|NCT03035929|Experimental|Healthy|"10 Healthy subjects will be enrolled and each will undergo study procedures at three study visits.~All subjects will undergo the same procedures and interventions."
2930719|NCT03035916|Experimental|Transversus abdominis plane block|The TAP group receives ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia.
2930720|NCT03035916|Active Comparator|Epidural anesthesia|The Epidural group receives epidural block (T8-9) 2 mL of 1.6% lidocaine as a test dose and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
2930721|NCT03035916|Placebo Comparator|Control|The Control group receives standard IV-inhaled general anesthesia.
2930722|NCT03035903|Experimental|Not holding, then holding the MedGem®|Subjects will be seated in an armless chair and have a RMR measurement taken while not holding, then holding a MedGem® Indirect Calorimeter.
2930723|NCT03035903|Active Comparator|Holding, then not holding the MedGem®|Subjects will be seated in an armless chair and have a RMR measurement taken holding, then not holding a MedGem® Indirect Calorimeter.
2930724|NCT03035890|Experimental|Radiation Therapy + Immunotherapy|3-5 fraction course of radiation therapy to target lesion concurrent with an immuno-therapeutic agent
2930725|NCT03035877|Experimental|Multisystemic Therapy-Emerging Adults|This group will receive Multisystemic Therapy-Emerging Adults.
2930726|NCT03035877|Active Comparator|Enhanced Treatment as Usual|This group will have access to an enhanced version of services typically delivered to young adults who have a substance use disorder and have been in trouble with the law.
2930727|NCT03035864|Experimental|rhNGF 20 µg/ml|Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
2930728|NCT03035864|Placebo Comparator|Vehicle|Vehicle eye drops six times daily
2930729|NCT03035851|Experimental|Aerobic exercise|Participants will take part in a supervised 6-month-long aerobic (walk/jog) training program held 3 days/week. Each session will include a 5-min warm-up, 20-40 min of aerobic exercise (walking, jogging), 5-min cool-down, and stretching. Exercise prescriptions will follow current principles and guidelines established by ACSM/AHA, including sufficient warm-up, cool-down, and ongoing provision of safety precautions/exercise tips. As participants progress, the duration of aerobic exercise will increase from 20 (month 1) to 30 (months 2-3) and 40 min (months 4-6), with proportional increases to warm-up and cool-down periods. Exercise intensity will be based on individual maximal oxygen uptake (VO2 max), measured at baseline. Intensity will build from 30-45% (months 1-3) to mitigate the risk of injury and will progress to 60-70% (months 4-6) heart rate reserve (HRR).
2930730|NCT03035851|Other|Stretch and Strength|A control group will meet on a similar schedule as the exercise group for sessions on stretching and toning but without aerobic exercise. Based on prior RCTs of similar interventions the investigators expect this control to be ineffective or minimally effective, but anticipate that it will increase participant enthusiasm and retention. All assessments will be conducted in this arm.
2930731|NCT03035838|Other|Treatment|There is only one arm in this study. Intracranial pressure and brain swelling will be monitored before and after administration of fosaprepitant
2930732|NCT03035825|Experimental|Oral Moisturizing Jelly|Daily intake of oral moisturizing jelly 5 times/day for two months
2930733|NCT03035825|Active Comparator|Artificial saliva|Daily use of non-edible oral lubricating gel 5 times/day for two months
2930734|NCT03035812|Experimental|Alkali|Patients in whom an oral alkalinization whatever the formulation
2930735|NCT03035799|Experimental|Paleolithic Diet|Paleolithic Diet
2930736|NCT03035799|Active Comparator|General Healthful Diet|General Healthful Diet
2930737|NCT03035773|Experimental|ARM A|SCP document delivered to the patient & Primary Care Provider
2930738|NCT03035773|Experimental|ARM B|SCP document provided to the patient in an in-person survivorship visit and copy sent to PCP
2930739|NCT03035773|Experimental|ARM C|SCP document provided to the patient in an in-person survivorship visit with an additional follow-up visit and copy of the document sent to PCP
2930740|NCT03035760|Experimental|1|3 mg/kg orally once daily for 5 days (n = 8)
2930741|NCT03035760|Experimental|2|7.5 mg/kg orally once daily for 5 days (n = 8)
2930742|NCT03035760|Experimental|3|15 mg/kg orally once daily for 5 days (n = 8)
2930743|NCT03035760|Experimental|4|3 mg/kg orally, one dose received following a fast (n=6) or high fat meal (n=6) on Day 1 and crossed over to opposite arm to receive drug following high fat meal or fast on Day 8
2930744|NCT03035734|Active Comparator|A|Single oral dose BMS-986141 Form A tablet under fasting conditions
2930745|NCT03035734|Experimental|B|Single oral dose BMS-986141 Form B tablet (low-dose) under fasting conditions
2930746|NCT03035734|Experimental|C|Single oral dose BMS-986141 Form B tablet (high-dose) under fasting conditions
2930747|NCT03035734|Experimental|D|Single oral dose BMS-986141 Form B tablet (high-dose) under fed conditions
2930748|NCT03035721|Experimental|Low protein formula group|Full term healthy infants randomized to receive a low protein formula for the first 4 months of life
2930749|NCT03035721|Active Comparator|Standard protein formula group|Full term healthy infants randomized to receive a standard protein formula for the first 4 months of life
2930750|NCT03035721|No Intervention|Breastfeeding group|Breastfed full term healthy infants
2930751|NCT03035708|Experimental|varenicline|1 mg BID (2 capsules BID)
2930752|NCT03035708|Placebo Comparator|Placebo|1 mg BID (2 capsules BID)
2930753|NCT03035695|Experimental|Axiostat® Size|"Device: Axiostat® Size: 8 x 5 cm Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.~Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
2930754|NCT03035695|Active Comparator|Cotton Gauze|Cotton Gauze Size: 8 x 5 cm
2930755|NCT03035682|Active Comparator|Traditional Group|The control group will receive traditional PT services as deemed clinically appropriate via examination to include traditional home exercise prescription.
2930756|NCT03035682|Experimental|Augmented Media Group|The Augmented Media group will receive traditional PT services as deemed clinically appropriate via examination and include home exercise prescription via a mobile health application.
2931312|NCT03031613|Experimental|PEEP group|Application of 5 cmH2O PEEP during mechanical ventilation
2930757|NCT03035669|Experimental|Mindfulness group|Mindfulness based stress reduction: 8 week program, including meditation, body-awareness, and yoga practices. Daily assignments and home practices during 50 minutes per day.
2930758|NCT03035669|Active Comparator|Reading group|Reading and sharing group: 8 week program, including readings, interpersonal exchanges, group discussion, listening and role playing exercises. Daily assignments and home practices during 50 minutes per day.
2930759|NCT03035656|Experimental|Experimental|Administration of epidural Ropivaciane
2930760|NCT03035656|Placebo Comparator|Control|Administration of saline
2930761|NCT03035643|Experimental|Ascyrus Medical Dissection Stent|Ascyrus Medical Dissection Stent placement
2930762|NCT03035630|Experimental|Avelumab then Sunitinib for Investigational Arm A|"First-Line Medication:~Avelumab 10mg/kg IV on D1 and D15 of every 28 day cycle, until irRECIST 1.1 disease progression criteria is documented.~Subjects will have a mandatory an inter-line washout period (14-60 days) before receiving first dose of second-line medication.~Second-Line Medication:~Sunitinib 50 mg po once daily from D1 to D14 of every 21 day cycle until RECIST 1.1 disease progression criteria is documented.~Subjects who do not have disease progression at end of first-line treatment and are removed due to toxicities or personal decision, may switch to either the second-line therapy or be monitored during the inter-line period until progression, which may be longer than 60 days."
2930763|NCT03035630|Experimental|Sunitinib then Avelumab for Investigational Arm B|"First-Line Medication:~Sunitinib 50 mg po once daily from D1 to D14 of every 21 day cycle until RECIST 1.1 disease progression criteria is documented.~Subjects will have a mandatory inter-line washout period (14-60 days) before receiving first dose of second-line medication.~Second-Line Medication:~Avelumab 10mg/kg IV on D1 and D15 of every 28 day cycle, until irRECIST 1.1 disease progression criteria is documented.~Subjects who do not have disease progression at end of first-line treatment and are removed due to toxicities or personal decision, may switch to either the second-line therapy or be monitored during the inter-line period until progression, which may be longer than 60 days."
2930764|NCT03035617|Placebo Comparator|Controlled Arm|Mesh will be soaked in normal saline solution as is routinely done.
2930765|NCT03035617|Experimental|Intervention Arm|Mesh will be soaked in .5% bupivacaine solution before application.
2930766|NCT03035604||Older Participants with Cancer|Comprehensive nutritional geriatric assessments every three months for 12 months, via either phone call or on-site interview.
2930767|NCT03035591|Experimental|ODM-207|Escalating doses of ODM-207
2930768|NCT03035578|Experimental|Morphine Blood and Saliva sampling|"The infants will receive a 50 mcg/kg loading dose of morphine followed by a constant infusion.Morphine Injection: 10mg/mL, 1mL ampoules.Two strengths of stock syringes:~a)patients <1.5kg, morphine 0.5mg/25mL; b)patients 1.5kg to <5kg, morphine 1mg/25mL.~Time blood samples will be collected for measurement of whole blood concentration of morphine in 24h. Total morphine, morphine-3-glucuronide and morphine-6-glucuronide concentrations; volume of blood required is 0.25 ml. Sparse sampling strategy will be used for those neonates < 1250; total volume of blood required is 0.50 ml. Frequent sampling strategy will be used for those neonates ≥ 1250 gm; total volume of blood required is 0.50 ml.Saliva samples will be collected at 10 and 30 minutes and at 6, 12 and 24h after morphine infusion started.100 uL of saliva, captured using a collection swab."
2930769|NCT03035565|Experimental|Computerized Cognitive Training Brain HQ|Computerized cognitive training intervention using Brain HQ initiated and continued 1 hour/day, 5 days/week for 8 weeks
2930770|NCT03035565|Active Comparator|Computerized Crossword Puzzles|General cognitive stimulation puzzles intervention initiated and continued 1 hour/day, 5 days/week for 8 weeks
2930771|NCT03035565|No Intervention|Usual Care|No computerized cognitive intervention
2930772|NCT03035552|Experimental|Treatment prior to surgery|Infants randomized to receive the pacifier activated music player and mother's voice treatment prior to surgery for 5 sessions, and mother's voice playing freely post surgery.
2930773|NCT03035552|Experimental|Treatment post surgery|Infants randomized to receive the mother's voice playing freely prior to surgery,and pacifier activated music player and mother's voice treatment post surgery for 5 sessions.
2930774|NCT03035539|Active Comparator|Standard treatment|Standard treatment after randomization
2930775|NCT03035539|Experimental|Cardiac Rehabilitation|The rehabilitation programme includes education, physical exercise, optimisation of the medical treatment, and discussion of implications for the daily life of each participant.
2930776|NCT03035526||3161 men (45-84 years old)|3161 men without known coronary artery disease
2930777|NCT03035513||CSWS patients|The data of CSWS patients will be statistically compared to healthy volunteers
2930778|NCT03035513||healthy volunteers|The data of CSWS patients will be statistically compared to healthy volunteers
2930779|NCT03035500|Experimental|Supportive Care (long-term follow-up)|Patients undergo long-term follow-up and receive a written survivorship care plan including comprehensive health evaluation and health education beginning 1 year post surgery.
2930780|NCT03035487|Experimental|Micro-ultrasound|"Transrectal micro-ultrasound guided prostate biopsy, where images will be compared with images from standard of care modalities:~Low resolution transrectal ultrasound examination (LR-TRUS)~Multi-parametric MRI (mpMRI) examination performed according to the PI-RADS v2 protocol"
2930781|NCT03035474|Other|Direct & Digital|Health system engagement to improve local QI programs and patient engagement to improve self-management/medication adherence
2930782|NCT03035474|Other|Direct & Registry|Health system engagement to improve local QI programs and patient and control
2930783|NCT03035474|Other|Digital & Registry|Patient engagement to improve self-management/medication adherence and control
2930784|NCT03035474|No Intervention|Registry|Control
2930785|NCT03035448|Experimental|Video 1: Counselor Alone|"Participants complete 3 assessment questionnaires during an already-scheduled office visit.~Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services."
2930851|NCT03034967|Experimental|Danirixin 50 mg|Eligible participants will receive danirixin 50 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
2930852|NCT03034967|Placebo Comparator|Placebo|Eligible participants will receive placebo tablet with food twice daily along with standard care of treatment for 24 weeks.
2930786|NCT03035448|Experimental|Video 2: Doctor + Counselor|"Participants complete 3 assessment questionnaires during an already-scheduled office visit.~Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services."
2930787|NCT03035435||study group|fast-track rehabilitation
2930788|NCT03035435||control group|standard care rehabilitation
2930789|NCT03035422|Other|Patients with primary refractory acute myeloid leukemia|Patients with primary refractory acute myeloid leukemia
2930790|NCT03035409|Experimental|Anamorelin|"Participants take Anamorelin by mouth 1 time each day for 6 weeks.~Participants perform resistance exercises and a walking program at home for 6 weeks while also taking Anamorelin.~Assessment questionnaires completed at baseline, on Days 8, 15, 21, 29, 36, and 43.~Participants meet with a dietitian for nutrition counseling on Day 21, and an exercise specialist on Day 15."
2930791|NCT03035396|Experimental|Diassess Influenza A and B Test|
2930792|NCT03035383|Experimental|Purse String Technique|Thyroidectomy closure is performed using purse string technique.
2930793|NCT03035383|Active Comparator|Conventional technique|Thyroidectomy closure is performed using conventional technique.
2930794|NCT03035370|Experimental|Viaskin PT 25 mcg|Viaskin PT 25 mcg
2930795|NCT03035370|Experimental|Viaskin PT 50 mcg|Viaskin PT 50 mcg
2930796|NCT03035370|Placebo Comparator|Viaskin PT Placebo|Viaskin PT Placebo
2930797|NCT03035357|Experimental|Daratumumab|Participants receive Daratumumab by vein over about 1 hour 1 time a week during Weeks 1-4.
2930798|NCT03035344||ALL paediatric patients|Metabolome study in children diagnosed with ALL after bone marrow biopsy
2930799|NCT03035344||Healthy matched controls|Metabolome study in healthy children matched for gender and age with the patients group
2930800|NCT03035331|Experimental|Treatment (pembrolizumab, dendritic cell therapy, cryosurgery)|Patients receive pembrolizumab IV on day 1. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients also receive dendritic cell therapy IT on days 2, 8, and 15 of courses 2 and 3, and day 2 of courses 4 and 5. Patients undergo cryosurgery on day 2 of course 2 and receive pneumococcal 13-valent conjugate vaccine by injection on day 2 of courses 2-5. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
2930801|NCT03035305|Experimental|SMC and LNS (intervention group)|Children included in the 9 health areas of the intervention group receiving both lipid-based nutrient supplement and seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine
2930802|NCT03035305|Other|SMC only (control group)|Children included in the 9 health areas of the control group receiving seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine
2930803|NCT03035279|Experimental|Arm A|SC-006 Dose regimen finding
2930804|NCT03035279|Experimental|Arm B|SC-006 Dose expansion
2930805|NCT03035279|Experimental|Arm C|SC-006 and ABBV-181 Combination escalation and expansion
2930806|NCT03035266|Experimental|Blood Flow Restriction (BFR)|All subjects will perform traditional post-operative rehabilitation until discharge from the hospital following surgery and continue until formal discharge from physical therapy upon completion of rehabilitation. One week following surgery, subjects randomized to the BFR group will begin combining BFR with all lower extremity strengthening exercises supervised in clinic up to 3 times per week for 12 weeks.
2930807|NCT03035266|Active Comparator|Standard rehabilitation (control group)|All subjects will perform traditional post-operative rehabilitation until discharge from the hospital following surgery and continue until formal discharge from physical therapy upon completion of rehabilitation.
2930808|NCT03035253|Experimental|OMP-305B83 combined with FOLFIRI or FOLFOX|
2930809|NCT03035240|Experimental|Financial Education Intervention|
2930810|NCT03035240|No Intervention|No Financial Education Intervention|
2930811|NCT03035227|Active Comparator|Catheter Ablation|Catheter ablation procedure of atrial and/or ventricular arrhythmias.
2930812|NCT03035227|Active Comparator|Medical Therapy|Medical management using antiarrhythmic drugs per standard of care of treating physician.
2930813|NCT03035214|Other|Prevention of dysplasia through steroids|Failure of lung tolerance to oxygen reduction will be defined as oxygen saturation 80 to 87% for 5 minutes, or <80% for 1 minute, then inspired oxygen will be increased back to the base line. This will be considered as an early predictor of evolving bronchopulmonary dysplasia. If there is no hypoventilation, dexamethasone will be given 0.25 mg/ kg/ d divided twice for 5 days intravenous.
2930814|NCT03035201||Cocoa extract + multivitamin|2 capsules containing 750 mg/d cocoa extract; daily MTV
2930815|NCT03035201||Cocoa extract + multivitamin placebo|2 capsules containing 750 mg/d cocoa extract; daily MTV placebo
2930816|NCT03035201||Cocoa extract placebo + multivitamin|Cocoa extract placebo (2 capsules/d); daily MTV
2930817|NCT03035201||Cocoa extract placebo + multivitamin placebo|Cocoa extract placebo (2 capsules/d); daily MTV placebo
2930818|NCT03035188|Experimental|Vismodegib|Continuous once-daily oral dosing of vismodegib at a dosage of 150 mg per administration
2930819|NCT03035175|Experimental|Video Laryngoscopy Group|Subjects enrolled in this arm received real-time guidance from a supervisor utilizing the screen of the video laryngoscope while the subjects performed direct neonatal intubations in the NICU.
2930820|NCT03035175|Active Comparator|Traditional Laryngoscopy Group|Subjects enrolled in this arm, received traditional guidance while they performed direct neonatal intubations in the NICU.
2930821|NCT03035162|Experimental|Active tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow continuously during 20 minutes for the active conditions. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
2930853|NCT03034954|Active Comparator|Active HD-tDCS|"Participants will receive real HD-tDCS (3 milliamps for 20 minutes) for a single session."
2931313|NCT03031613|Active Comparator|ZEEP group|No application of PEEP during mechanical ventilation
2930822|NCT03035162|Active Comparator|Sham tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow only 2 minutes for the sham conditions. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
2930823|NCT03035149|Experimental|Weight Management Program|Obese subjects participate in a year long medically supervised weight management program.
2930824|NCT03035149|No Intervention|Normal Weight Controls|Normal weight age and sex-matched controls. Unlike the obese subjects, the controls did not participate in the Weight Management Program. Pulmonary function, exercise performance and dyspnea results for normal weight controls were compared against the results for obese subjects.
2930825|NCT03035136||Patients with colorectal lesions|Patients with a full colonoscopy that showed either a cancer or a polyp.
2930826|NCT03035136||Patients without colorectal lesions|Patients with a full colonoscopy that showed no polyps.
2930827|NCT03035123|No Intervention|"Usual care"|Patients will attend an appointment with the therapeutic education nurse before discharge, after which they will have no further contact with the education team. The Research team members will telephone the patient three times during the year (after 2, 6 and 12 months) to collect data on HF treatments, blood tests results, health-related events and hospitalizations.
2930828|NCT03035123|Experimental|Interventional|"Before discharge, patients will attend an appointment with a nurse trained in therapeutic education, in which the nurse will evaluate the overall knowledge and the skills of the patient about HF. The nurse will then define specific educational objectives with the patient, based on the patient's medical history, state of disease, comorbidities, alarm signs, fears and knowledge.~Each patient will receive six telephone calls and two home-visits during the 1 year of follow-up. Each contact between the nurse and the patient will be dedicated to HF education. The patient will also receive regular short text messages containing health advice and appointment reminders.~To help the patient regain his/her autonomy, intervals between education sessions will be progressively longer."
2930829|NCT03035110|Experimental|Dialectical Behavioural Therapy (DBT) skills group|Four group sessions, based on DBT, over two weeks, with a group of four to eight participants in attendance located on the hospital ward where the participant is a patient.
2930830|NCT03035084|Experimental|Group-2-D3|Subjects with total 25(OH)D more= 20 nmol/l and less= 40 nmol/l will receive vitamin D2 then randomly assigned to vitamin D3
2930831|NCT03035084|Placebo Comparator|Group-2-Placebo|Subjects with total 25(OH)D more= 20 nmol/l and less= 40 nmol/l will receive vitamin D2 then randomly assigned to placebo oral capsule.
2930832|NCT03035084|Experimental|Group-1-D2|Subjects with 25(OH)D3 more= 40 nmol/l and total 25(OH)D less= 65 nmol/l will be randomly assigned to vitamin D2.
2930833|NCT03035084|Placebo Comparator|Group-1-Placebo|Subjects with 25(OH)D3 more= 40 nmol/l and total 25(OH)D less =65 nmol/l will be randomly assigned to placebo oral capsule.
2930834|NCT03035071|Experimental|minimally invasive esophagectomy|minimally invasive (laparoscopic) gastric mobilisation and gastric tube formation.
2930835|NCT03035071|Active Comparator|open esophagectomy|open gastric mobilization and gastric tube formation
2930836|NCT03035058|Experimental|Vedolizumab IV 300 mg Q4W|Vedolizumab 300 mg, intravenous (IV), once at Day 1 and Week 2; followed by vedolizumab 300 mg, IV, once every 4 weeks (Q4W) starting from Week 6 to Week 102.
2930837|NCT03035058|Experimental|Vedolizumab IV 300 mg Q8W + Placebo|Vedolizumab 300 mg, IV, once at Day 1 and Week 2; followed by vedolizumab 300 mg, IV, once every 8 weeks (Q8W) starting from Week 6 to Week 102 (and placebo, IV, Q8W starting from Week 10 to Week 98.
2930838|NCT03035058|Placebo Comparator|Placebo|Vedolizumab placebo-matching, IV, at Day 1 and Week 2; followed by Vedolizumab placebo-matching, IV, Q4W starting from Week 6 to Week 102.
2930839|NCT03035045|Experimental|Comparator1: Paracetamol 650 mg (325 mg/tablet) oral|Drug: Paracetamol Comparison pain score between paracetamol and placebo
2930840|NCT03035045|Placebo Comparator|Comparator 2: Placebo oral|Drug: placebo Comparison pain score between paracetamol and placebo
2930841|NCT03035032|Experimental|Leuprolide group|Leuprolide will be administered for 18 months.
2930842|NCT03035019|Experimental|Lantern for primary care patients|All patients between the ages of 20-65 at specific primary care practices and score 5 or greater on the GAD7 questionnaire are offered the Lantern app to help with stress/anxiety.
2930843|NCT03035006|Experimental|Lipotecan based chemoradiotherapy|Patients will receive Lipotecan based CCRT. Lipotecan will be given as a 30-minute (±3 minutes) iv infusion qw for 6 weeks at the predefined dose level for each cohort. A total of 6 doses of Lipotecan will be administered to each patient in conjunction with RT at 3.5 Gy per fraction for 16 fractions. During CCRT period, Lipotecan should be given within 2 hours prior to the start of RT, and the Lipotecan and RT should be delivered on the same day, unless any conditions fulfils with the dose interruption standards. Radiotherapy treatment, at the allocated dose level, is only permitted if the normal tissue dose constrain criteria are maintained
2930844|NCT03034993|Experimental|Text Messaging|This group will receive text messages with appointment reminders, medication taking education and motivation, and for reporting of mood.
2930845|NCT03034993|Placebo Comparator|Control|This group will receive simple text messages about general health promotion, such as about the importance of drinking water on hot days, using sunscreen, etc.
2930846|NCT03034980||Coronary Artery Disease (CAD) patients|Patients with proven coronary artery disease, who underwent the full cardiac revalidation program at Jessa Hospital from 10-1-2013 till 12-9-2016.
2930847|NCT03034967|Experimental|Danirixin 5 mg|Eligible participants will receive danirixin 5 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
2930848|NCT03034967|Experimental|Danirixin 10 mg|Eligible participants will receive danirixin 10 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
2930849|NCT03034967|Experimental|Danirixin 25 mg|Eligible participants will receive danirixin 25 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
2930850|NCT03034967|Experimental|Danirixin 35 mg|Eligible participants will receive danirixin 35 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
2930854|NCT03034954|Sham Comparator|Sham HD-tDCS|Participants will undergo the exact same procedures as the active group but will receive sham stimulation for a single session.
2930855|NCT03034941|Active Comparator|metformin group|Drug: metformin
2930856|NCT03034941|Active Comparator|COMBI group|Drug: liraglutide + metformin
2930857|NCT03034941|No Intervention|CONTROL group|control group of obese PCOS patients without therapy
2930858|NCT03034915|Experimental|UMEC/VI 62.5/25 mcg via ELLIPTA + placebo via DISKUS|Subjects will be instructed to self-administer one dose of UMEC/VI 62.5/25 mcg inhalation powder each morning via ELLIPTA DPI and placebo twice daily (morning and evening) via DISKUS DPI.
2930859|NCT03034915|Experimental|UMEC 62.5 mcg via ELLIPTA + placebo via DISKUS|Subjects will be instructed to self-administer one dose of UMEC 62.5 mcg inhalation powder each morning via ELLIPTA DPI and placebo twice daily (morning and evening) via DISKUS DPI.
2930860|NCT03034915|Experimental|Salmeterol 50 mcg via DISKUS + placebo via ELLIPTA|Subjects will be instructed to self-administer one dose of salmeterol 50 mcg twice daily (morning and evening) via DISKUS DPI and placebo once daily morning via ELLIPTA DPI.
2930861|NCT03034889||Exposed|Children age 4-10 who required general anesthesia before the age of 36 months in the context of surgical and diagnostic procedures or sedation during intensive care, excluding neurosurgical interventions or cardiac surgery as well as preexisting hereditary or acquired neurocognitive deficits
2930862|NCT03034889||Control|Children age 4-10 who did not require any anesthesia before the age of 36 months. Excluding preexisting hereditary or acquired neurocognitive deficits.
2930863|NCT03034863|Experimental|Treatment|SAFER: A novel, 5-session intervention to enhance currently mandated VA suicide safety planning by involving family members to support its implementation. Incorporation of education about suicide risk factors and teaching communication skills of active listening and making a positive request will supply Veterans and family members with the knowledge and tools needed to 1) identify potential warning signs, and 2) discuss Veteran ideation or family concerns with assurance that such requests will be listened to with validation and support, creating an ally for the suicidal Veteran in his struggle. As discussed above, research has demonstrated compellingly that suicidal desire is motivated by two interpersonal factors; perceived burdensomeness and thwarted belongingness. SAFER aims to increase family support for the Veteran to directly mitigate Veteran loneliness and sense of being a burden to others.
2930864|NCT03034863|Active Comparator|Control|The comparison condition will be an assessment-only enhanced treatment-as-usual (E-TAU), incorporating weekly scripted check-in phone calls to review mood symptoms and use of the safety plan, which will then be given as feedback to the Veteran?s primary mental health provider.
2930865|NCT03034850||CRS/HIPEC|Patients with a confirmed histological diagnosis of peritoneal disease treated by cytoreductive surgery (CRS) with hyperthermic intraperitoneal peroperative chemotherapy (HIPEC).
2930866|NCT03034837|Active Comparator|Resin sealant|"Sealing pit and fissures of the included permanent first molars using SDI conseal f resin sealant material once at the baseline of the study."
2930867|NCT03034837|Experimental|ART sealant|"Sealing pit and fissures of the included permanent first molars using 3M ESPE KetacTM Molar Easymix glass ionomer cement material once at the baseline of the study."
2930868|NCT03034824|Experimental|Scaling and root planing (SRP)-Control|Only non-surgical initial periodontal treatment (scaling and root planing)
2930869|NCT03034824|Experimental|SRP+940±15 nm diode laser|In addition to non-surgical initial periodontal treatment (scaling and root planing), individuals received 940±15 nm Diode laser
2930870|NCT03034824|Experimental|SRP+Er,Cr:YSGG laser|In addition to non-surgical initial periodontal treatment (scaling and root planing), individuals received Er,Cr:YSGG laser
2930871|NCT03034811|Other|PPK subjects|Subjects that receive the Persona Partial Knee system
2930872|NCT03034798||Type 1 Diabetes Exercisers|Participants performed 2 different forms of exercise of identical duration and similar total energy expenditure. One form was purely aerobic in nature and the other was intermittent, high-intensity exercise.
2930873|NCT03034785|Experimental|Group 1|Very low birth weight infants
2930874|NCT03034785|Active Comparator|Group 2|Healthy infants
2930875|NCT03034772|Active Comparator|Dorzolamide-timolol|Topical dorzolamide-timolol twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
2930876|NCT03034772|Placebo Comparator|Artificial tears|Topical artificial tears twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
2930877|NCT03034759|Experimental|All participants|+Pediatric patients with T1D. All comparisons will be made within group pre and post intervention.
2930878|NCT03034746|Experimental|Alzheimer's Disease (G1)|(G1) physical activity (PA)
2930879|NCT03034746|Experimental|Alzheimer's Disease (G2)|(G2) cognitive treatment (CT)
2930880|NCT03034746|No Intervention|Healthy Old Subjects (G1)|Control group old
2930881|NCT03034746|No Intervention|Healthy young Subjects (G2)|Control group young
2930882|NCT03034733|Experimental|dexamethasone 0,15 mg/kg|single-dose intravenous dexamethasone 0,15 mg/kg, intraoperative
2930883|NCT03034733|Experimental|dexamethasone 0,25 mg/kg|single-dose intravenous dexamethasone 0,25 mg/kg, intraoperative
2930884|NCT03034733|Placebo Comparator|Sodium Chloride, (24)NaCl 0,9%|single-dose intravenous saline, intraoperative
2930885|NCT03034720|Experimental|Intervention|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
2930886|NCT03034720|No Intervention|Control|Adolescent subjects in the control group will receive care as usual from their health care providers, a standard that is ethically acceptable.
2930887|NCT03034707|Experimental|Biotin arm|biotin 10 mg/day for 7 days
2931139|NCT03032848|Active Comparator|Promestriene Group|use of 1 gram per day
2930888|NCT03034694|Placebo Comparator|Routine Care|The first group will be randomized to routine care of receiving or not receiving a dermatology consult in the hospitalized setting based on the clinical decision of the hospitalist. The patients will see the research coordinator who will take images and for a teledermatology assessment, however, these assessments will not be placed in the chart and the treating hospitalist will not know.
2930889|NCT03034694|Experimental|Teledermatology INtervention|The second arm will be patient randomized to teledermatology intervention. These patients will be imaged by the research coordinator, then the assessment will be placed in the chart for the hospitalist to see although final treatment decisions are still made by the hospitalist.
2930890|NCT03034681|Other|Vojta|Vojta therapy consists in activating certain overall and innate locomotion patterns or complexes: reflex creeping and reflex rolling, which provokes the contraction of striated muscle in the entire body in a determined coordination with the central nervous system (CNS). These patterns are triggered from different positions (prone, supine and side lying) and only with certain stimulation. They contain all the locomotion components: automatic postural control, uprighting and phase movements. This therapy allows for the changing from pathological patterns to painless and cheaper patterns. This group received 15 sessions of treatment. Treatment lasted 30 minutes per sesion.
2930891|NCT03034681|Active Comparator|TENS|TENS procedure used at our unit consists in applying a high frequency current (80Hz), which is the most effective way to combat pain, for a phase duration of 60-200 microseconds at a comfortable range. Electrodes are placed on the skin over the sciatic nerve path, the (-) cathode on the most painful area as it is the most stimulating and the (+) another is placed distal. This group received 15 sessions of treatment. Treatment lasted 30 minutes per sesion.
2930892|NCT03034668|Experimental|CS16-003 Full dose|350 mg capsule QD Rhodiola rosea L. & Rhaptonticum carthamoides extracts
2930893|NCT03034668|Experimental|CS16-003 Half dose|175 mg capsule QD 50% Rhodiola rosea L. & Rhaptonticum carthamoides extracts + 50% Maltodextrin
2930894|NCT03034668|Placebo Comparator|Placebo|Maltodextrin
2930895|NCT03034655|Experimental|CDP exercises (10 sessions)|Group A. The Smart Equitest program was used with a protocol of 10 exercises per session, which were customized depending on each patient´s deficit. The exercises involve visual biofeedback together with sensitive, real-time monitoring of movement. In some exercises, patients must maintain their center of gravity (COG) over the base of support, while in others the COG must be moved to a series of targets. In addition, the support surface and/or visual surround may also move in response to the patient´s own movement. The exercise difficulty was progressively increased throughout the rehabilitation sessions. The duration of each session was approximately 15 minutes. The distribution of sessions was one per day and five per week (2 weeks).
2930896|NCT03034655|Experimental|CDP exercises (5 sessions)|Group B. Same as group A, except for the number of sessions (5) and the distribution of sessions (one daily, every other day, two weeks).
2930897|NCT03034655|Experimental|Mobile posturography exercises (10 sess)|Group C. Up to six tasks with the most prominent deviations from normative control values were included in the training program. Training was performed by using the training function of Vertiguard1-RT device. This neurofeedback system contains one vibration stimulator on the front, back, left and right side, respectively. Training was performed daily under supervision of a physician over 2 weeks (10 sessions, weekend was excluded). A training session consisted of 5 repetitions of six selected training tasks. The patient received a vibrotactile feedback signal during training in those directions which showed a higher body sway than preset thresholds. Vibration was reinforced with increasing sway No vibrotactile feedback was applied if the patient's sway was below preset thresholds. The exercise difficulty was progressively increase throughout the rehabilitation sessions.
2930898|NCT03034655|Experimental|Mobile posturography exercises (5 sess)|Group D. Same as group A, except for the number of sessions (5) and the distribution of sessions (one daily, every other day, two weeks).
2930899|NCT03034642|Experimental|Healthy Participants|"Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages.~Drugs: No test substances, only moderate conscious sedation using standard medications.~Devices: No test devices."
2930900|NCT03034642|Experimental|COPD participants|"Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages.~Drugs: No test substances, only moderate conscious sedation using standard medications.~Devices: No test devices."
2930901|NCT03034629|Experimental|Short-term aerobic exercise|One bout of moderate intensity exercise (75% of maximal predicated heart rate).
2930902|NCT03034616|Experimental|ex vivo activation|"'OLIVA device' in patients that undergo oophorectomy on the cortex of the removed ovary we will perform 5 parallel slashes 3 cm long.~this will be followed by investigation by the pathologist as to the depth of cuts."
2930903|NCT03034616|Active Comparator|in vivo activation|'OLIVA device' in patients undergoing oophorectomy before the resection from is pedicle on cortex of the ovary we will perform 5 parallel slashes 3 cm long. following oophorectomy investigation by the pathologist as to the depth of cuts and proximity to blood vessels.
2930904|NCT03034616|Active Comparator|POI OLIVA|'OLIVA device' in patients with premature ovarian failure and following safety data from arm 2 activation by ovarian slashing will be performed laparoscopically by closed cutting device (OLIVA). follow-up by sonography and hormonal markers of ovarian activity
2930905|NCT03034603|Experimental|Nutri-jelly with PEITC|Continuous intake of Nutri-jelly with PEITC for 200 milligrams per day, five days per week for 3 months.
2930906|NCT03034603|Placebo Comparator|Nutri-jelly|Continuous intake of Nutri-jelly for 200 milligrams per day, five days per week for 3 months.
2930907|NCT03034577|Active Comparator|ModNMB|"Moderate Neuromuscular block: participants will receive moderate neuromuscular blockade with rocuronium aiming for TOF 0-2 twitches, with neostigmine reversal when the TOF at least 3 twitches. The depth of neuromuscular block may be reduced after completion of the majority of surgical excision to TOF 3 or more~Neostigmine"
2930908|NCT03034577|Active Comparator|DeepNB|Deep Neuromuscular block: participants will receive DNB aiming for a post tetanic count of 1-2, which will be maintained until removal of the laparoscopic ports, with reversal using sugammadex
2930909|NCT03034564|Active Comparator|1|Active group started 100 mg TID, increased by 100 mg per interval (i.e. 100 TID) every 2 days till on 600 TID, or until intolerable dose is achieved at which time the next highest dose will be maintained (increments of 100 TID will be used).
2930910|NCT03034564|Placebo Comparator|2|Dosing regimen identical to active group
2931140|NCT03032848|Active Comparator|Estriol Group|use of 1 gram per day
2930911|NCT03034551|Experimental|Intervention Arm|Subjects in the treatment arm will be offered a $150 incentive to use the Wellth app each day to log one daily self-weighing and one medication check-in. If a sudden jump in weight is detected among any subjects receiving the Financial Incentive, Mobile Phone App, and Cellular Scale, a UMCPP physician or nurse will then call the patient to assess the patient's symptoms (i.e. increasing shortness of breath or decreases in exertional tolerance, medication and dietary adherence).
2930912|NCT03034551|No Intervention|Standard of Care (Control) Arm|Patients randomized to the standard of care arm will not receive the Wellth app or scale. They will have the usual discharge instructions as prescribed by their health care team.
2930913|NCT03034538|Active Comparator|100mg|Zonegran 100mg
2930914|NCT03034538|Active Comparator|200mg|Zonegran 200mg
2930915|NCT03034512||Patients with Alpers-Huttenlocher|Patients confirmed to have Alpers Huttenlocher Syndrome
2930916|NCT03034512||Siblings|Siblings of patients with Alpers Huttenlocher Syndrome
2930917|NCT03034499|Active Comparator|Single-port sacrocolpopexy|Patients with vaginal apex prolapse randomized to undergo repair by single-port sacrocolpopexy.
2930918|NCT03034499|Active Comparator|Multi-port sacrocolpopexy|Patients with vaginal apex prolapse randomized to undergo repair by multi- port sacrocolpopexy.
2930919|NCT03034486|Experimental|A single sequence, 3-period|
2930920|NCT03034473|Other|Blood and tissue samples during therapy|Collection of blood and tissue samples during preoperative multimodal treatment (Radiochemotherapy (RCTx) followed by total mesorectal excision (TME) and Chemotherapy (CT)) in rectal cancer.
2930921|NCT03034460|Experimental|CD5024 1% cream|Active drug;
2930922|NCT03034460|Placebo Comparator|CD5024 cream placebo|Placebo of active drug;
2930923|NCT03034460|Other|CD0271/CD1579 gel|Positive control;
2930924|NCT03034460|Other|CD0271/CD1579 gel placebo|Placebo of positive control;
2930925|NCT03034447|Other|Asthma|Children and teenagers with persistent asthma will perform questionnaires, lung function test, and home sleep study
2930926|NCT03034434||Patients after vaginal delivery|Patients after vaginal delivery willing to undergo 3 trans-vaginal ultrasounds within the 48 hours after delivery.
2930927|NCT03034421|Active Comparator|Modified medical care|Patients will undergo 48-hours bed rest after endoscopic valve implantation.
2930928|NCT03034421|No Intervention|Standard medical care|Patients will be treated with standard medical care without restriction to bed rest after endoscopic valve implantation.
2930929|NCT03034408|Other|Alcohol Use Disorder|30 patients with DSM-5 Diagnosis of Alcohol Use Disorder, at least moderate (303.90/F10.20) : Nalmefene 18mg, Baclofen 10mg, Placebo Oral Capsule
2930930|NCT03034408|Other|Healthy Control|30 sex and age-matched healthy controls : Nalmefene 18mg, Baclofen 10mg, Placebo Oral Capsule
2930931|NCT03034395|Other|Wide Local Excision 1cm|
2930932|NCT03034395|Other|Wide Local Excision 2cm|
2930933|NCT03034382|Experimental|Morphine|5 mg morphine in 5ml volume injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.
2930934|NCT03034382|Experimental|Nalbuphine|5 mg nalbuphine in 5ml volume injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.
2930935|NCT03034382|Experimental|Morphine and Nalbuphine|"5 mg morphine and 5 mg nalbuphine in 5 ml volume are injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.~combination of 5 mg morphine and 5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block"
2930936|NCT03034382|Placebo Comparator|Bupivacaine 0.5%|10 ml of lidocaine 1% and epinephrine 1:400,000 and 5 ml of Bupivacaine 0.5% in interscalene block.
2930937|NCT03034369||Safety Net Clinic Patients|A Cohort of patients in 12 different primary care clinics will be studied to measure how changes in different integration factors impacts the following patient reported outcomes at baseline and 12 months: Access to Care, Patient-Provider Relationship, Patient-Clinic Interactions, Stigma, Provider Continuity, Symptom Severity, Diagnoses, and Social Support. Health care claims data will be accessed to analyze Depression Screening, Preventive Screening, Inpatient Hospitalization Utilization, Inpatient Readmissions, and Post-Admission follow-up at baseline and 12 months.
2930938|NCT03034356|Experimental|Levetiracetam, Then Placebo|4 weeks of levetiracetam administration (125 mg pill, bid), followed by a 4-week washout, then 4 weeks of placebo pill administration (bid).
2930939|NCT03034356|Experimental|Placebo, Then Levetiracetam|4 weeks of placebo administration (bid), followed by a 4-week washout, then 4 weeks of levetiracetam administration (125 mg pill, bid).
2930940|NCT03034343|Experimental|TAU+mindfulness applied face to face|4 sessions of 90 minutes/session Mindfulness based intervention applied in groups of 10-12 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is one month.
2930941|NCT03034343|Experimental|TAU + Mindfulness ICTs intervention|4 sessions of 60 minutes/session Mindfulness based intervention applied by ICTs (Internet-based program). The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the online program is two months.
2930942|NCT03034343|No Intervention|Usual medical treatment (TAU)|In this group the general practitioner will apply the usual treatment (medication) but there will be no psychological treatment.
2930943|NCT03034330|Experimental|Two-Tier Stroke Family Empowerment|The intervention is individualized, tailor-made according to caregivers' needs. The intervention will last for 2 to 3 months with 6 to 10 weekly sessions at the home of caregivers or stroke survivors. Each session will last for 60 to 90 minutes. The care managers will determine the intensity of the intervention after the initial family assessment.
2930944|NCT03034330|Active Comparator|Volunteer Support Psychoeducation|The intervention will last for 2 months with 4 weekly sessions at the home of caregivers or stroke survivors in the first month and 2 telephone contacts in the second month (6 contact points in total). Each session will last for 60 to 90 minutes. Care managers will not provide any direct intervention for participants in the control group.
2930945|NCT03034317|Active Comparator|NeuRx DPS|Subjects who have initiated noninvasive ventilation (NIV) and receive the NeuRx diaphragm pacing system (DPS).
2930946|NCT03034317|No Intervention|No DPS|Subjects who have initiated noninvasive ventilation (NIV) and do not receive the DPS device.
2931141|NCT03032848|Placebo Comparator|Vaginal Moisturizer Cream|use of 1 gram per day
2930947|NCT03034304|Experimental|MASCT-I alone or in combination with ifosfamide.|"Bladder cancer both two stage and Soft tissue sarcoma of stage I: treatment with MASCT-I alone, conducted until disease progression, intolerance or end of study.~Soft tissue sarcoma of stage II: treatment with MASCT-I in combination with ifosfamide. Treatment with MASCT-I is conducted until disease progression, intolerance or end of study. Ifosfamide is used from the first day after apheresis. If disease progression or intolerance occurred, ifosfamide is stopped."
2930948|NCT03034291|Experimental|Cacao 70%|Consumption for eight weeks of 50 grams of chocolate with 70% cocoa solids equivalent to not less than 430 mg of cocoa polyphenols at each dose.
2930949|NCT03034291|Placebo Comparator|White chocolate|Consumption for eight weeks of 50 grams of chocolate free of cocoa solids as placebo.
2930950|NCT03034278||Post surgery patients|Patients prescribed with opioid analgesic medications following surgery.
2930951|NCT03034239|Experimental|Insect protein group|Exercise + insect protein 8 weeks of 4/week progressive resistance training (2 days upper body, 2 days lower body). Insect protein supplementation (4g/kg) after each training + before sleep at training days, and once in the morning at non training days.
2930952|NCT03034239|Placebo Comparator|Placebo group|Exercise + isocaloric carbohydrate 8 weeks of 4/week progressive resistance training (2 days upper body, 2 days lower body). Carbohydrate supplementation (isocaloric to protein group) after each training + before sleep at training days, and once in the morning at non training days.
2930953|NCT03034226|Active Comparator|Single episode of hypoglycemia|Day 1: Hyperinsulinemic hypoglycemic clamp 30 min Day 2: Hyperinsulinemic euglycemic clamp and hyperinsulinemic hypoglycemic clamp 7 hours
2930954|NCT03034226|Active Comparator|Two episodes of hypoglycemia|Day 3: No intervention (normal blood glucose) Day 4: Hyperinsulinemic euglycemic clamp and hyperinsulinemic hypoglycemic clamp 7 hours
2930955|NCT03034213|Active Comparator|Treatment|Gentrix(TM) Surgical Matrix
2930956|NCT03034213|Active Comparator|Control|Standard of care mesh
2930957|NCT03034200|Experimental|ONC201|625mg by mouth weekly for up to 1 year
2930958|NCT03034174||tigecycline|"Each patient will receive: tigecycline (200 mg q 12 hours i.v.), meropenem (2 g q 8 hours i.v). In each case CVVHD will be started.~Blood samples (3 mL) will be collected 2, 4, 8 and 12 hours after each dose of tigecycline for 3 consecutive days."
2930959|NCT03034161||Stage I Pressure Ulcer|Ten patients with a Stage I decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
2930960|NCT03034161||Stage II Pressure Ulcer|Ten patients with a Stage II decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
2930961|NCT03034161||Stage III Pressure Ulcer|Ten patients with a Stage III decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
2930962|NCT03034161||Stage IV Pressure Ulcer|Ten patients with a Stage IV decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
2930963|NCT03034148|Other|Coronary artery disease|blood sampling for biomarkers assessment in a population undergoing coronary angiogram
2930964|NCT03034135|Experimental|DSF-Cu|Disulfiram/copper (oral capsules) dosed 80 mg/1.5 mg three times a day for approximately 6 months.
2930965|NCT03034109|Experimental|tDCS conventional stimulation|"Transcranial Direct Current Stimulation:~The anode will be placed over the left dorsal lateral prefrontal cortex (DLPFC) and the cathode will be placed over the right supraorbital cortex. This is the standard 1 anode by 1 cathodal convention. Stimulation will last 20 minutes."
2930966|NCT03034109|Experimental|High Definition (HD)-tDCS stimulation|"Transcranial Direct Current Stimulation:~The anode will be placed over the left DLPFC and 4 cathodes will be placed surrounding the anode. This is the 4 cathode by 1 anode HD-tDCS montage for more focal stimulation. Stimulation will last 20 minutes."
2930967|NCT03034109|Sham Comparator|tDCS sham stimulation|"Transcranial Direct Current Stimulation:~The anode will be placed over the left DLPFC and the cathode over the right supraorbital cortex. A short stimulation will be given to the subjects that will mimic the sensation of an actual stimulation but will last much shorter. The session will still last 20 minutes in total to blind both subjects and investigators."
2930968|NCT03034096|Experimental|Propofol infusion|Maintenance of general anesthesia with propofol infusion
2930969|NCT03034096|Experimental|Volatile agent|Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)
2930970|NCT03034083||Couples Elevate Weekly Series|Participants in a couple relationship receive needs assessment and 8 hours of classes over a 4-week period in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
2930971|NCT03034083||Foster Parents Elevate Weekend Intensive|Foster parent participants receive 8 hours of classes over a weekend in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
2930972|NCT03034070|Other|Diagnostic performance 3D T1|A 3D T1-weighted GE mDixon MR imaging sequence will be added to the routine 3D T1-weighted FSE sequence. mDixon sub-sequences (Fat and In Phase) are compared to 3D T1-weighted FSE in terms of diagnostic accuracy for M and N staging in prostate cancer patients: Fat, In Phase, Fat+In Phase and the routine 3D T1 will be analyzed separately, blindly and randomly.
2930973|NCT03034057|Other|sayana press|single arm
2930974|NCT03034018|Experimental|suvorexant|suvorexant 10-20 mg taken at bedtime for four weeks
2930975|NCT03034018|Placebo Comparator|placebo|placebo taken at bedtime for four weeks
2930976|NCT03034005|Experimental|Patients with asthma|6 weeks treatment with 1600 ug budesonide
2930977|NCT03034005|No Intervention|Healthy Controls|Healthy controls to establish baseline level of Na/K pumps.
2930978|NCT03033992|Experimental|Treatment (Optune System)|Patients must have a histologically confirmed diagnosis of supratentorial high-grade glioma or supratentorial ependymoma that is recurrent, progressive or refractory. All patients will use the study device Optune System (Tumor Treating Fields, TTFields).
2930979|NCT03033953|Placebo Comparator|Milk supplementation|11 (elderly) or 12 (young) weeks of strength training and daily supplementation of 2x20g milk protein.
2930980|NCT03033953|Experimental|Native whey|11 (elderly) or 12 (young) weeks of strength training and daily supplementation of 2x20g native whey protein.
2930981|NCT03033940||ATTUNE TM subjects|
2930982|NCT03033940||PFC Sigma subjects|
2930983|NCT03033927||Participants with Stage IV Pancreatic Cancer|
2931142|NCT03032835||Study participants|No intervention
2930984|NCT03033914|Experimental|< 60 years of age with advanced stage (HL) untreated|The study will employ a 3+3 design and include 3 treatment cohorts. In each cohort, patients will receive 6 cycles of A(B)VD and 8 doses of nivolumab. In dose level 1, patients will receive nivolumab in combination with AVD during cycle 6 only followed by 6 additional doses of nivolumab. In subsequent dose levels, nivolumab will be combined with increasing numbers of cycles of AVD. Based upon safety data from another study with Nivolumab, we will no longer need to evaluate dose level 2. If we determine that dose level 1 is safe, the next group of patients will enroll onto dose level 3. A PET scan will be performed after 2 cycles of ABVD and those with a PET-negative response (defined by Deauville 1, 2 or 3) will proceed with 4 additional cycles of ABVD or AVD (per treating physician preference).
2930985|NCT03033914|Experimental|60 years of age and older with HL (any stage) untreated|The study will employ a 3+3 design and include 3 treatment cohorts. In each cohort, patients will receive 6 cycles of AVD and 12 doses of nivolumab. In this cohort, patients will receive nivolumab in combination with AVD during cycles 5 and 6 only, followed by 8 additional doses of nivolumab. In subsequent cohorts, nivolumab will be combined with increasing numbers of cycles of AVD. Based upon safety data from another study with Nivolumab, we will no longer need to evaluate dose level 2. If we determine that dose level 1 is safe, the next group of patients will enroll onto dose level 3.
2930986|NCT03033888|Other|Intervention Group|Intervention includes: Trained community health workers will deliver 1) 1.5-2 hour health literacy training offered in a group format at an approved community site that is most convenient to the majority of participants ; and 2) monthly phone follow-up and navigation assistance for 6 months. We will offer a Human Papilloma Virus (HPV) mobile app for participant's adolescent/young adult child (11-26 yrs), as an option rather than part of the standardized protocol. The app will be introduced at the end of the health literacy group training session for the intervention group; those who choose to download the app will be given a link with study specific password. They will be encouraged to go through the key HPV related contents with their children at home at a time that is most convenient for them.
2930987|NCT03033888|No Intervention|Control Group|
2930988|NCT03033875|Experimental|Tele-Savvy Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to participate in the Tele-Savvy program.
2930989|NCT03033875|Other|Attention Control Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to participate in the Tele-Savvy program and the Healthy Living Education Program.
2930990|NCT03033862||Intervention with Bioresorbable Vascular Scaffold|
2930991|NCT03033862||Intervention with Drug Eluting Stent|
2930992|NCT03033849|Experimental|Blood glucose measurement|Every study subject shall test three out of the five devices. The testing order of the BGMS will be changed on each subject to minimize any order effects on measurement results.
2930993|NCT03033836|Experimental|single arm|ARV treatment based on Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine
2930994|NCT03033823|Experimental|Intervention|Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).
2930995|NCT03033823|Placebo Comparator|Control|Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
2930996|NCT03033810||Consecutive patients with FFR and iFR|Patients with stable angina pectoris with suitable for coronary angiography will be suitable for the study
2930997|NCT03033797|Experimental|MoviLetrando-MoveHero|Half of the children will play first two different levels of the game MoviLetrando (2 minutes each) and, after the game MoveHero, more 2 minutes
2930998|NCT03033797|Experimental|MoveHero-MoviLetrando|The other half of the children will play first 2 minutes of the game MoveHero and after, two different levels of the Game MoviLetrando, two minutes each.
2930999|NCT03033784|Experimental|Autism Spectrum Disorder (ASD)|Male participants diagnosed with ASD will receive 12 puffs (6 in each nostril) of intranasal oxytocin (syntocinon) and placebo (assigned randomly) during 4 study visits.
2931000|NCT03033784|Placebo Comparator|Healthy Control|Age matched healthy controls will receive placebo intranasal spray (12 puffs, 6 per nostril) during one study visit.
2931001|NCT03033771|Experimental|Treatment|Patients presenting with chronic type B aortic dissection will have the MFM implanted.
2931002|NCT03033745|Experimental|IgPro20 (Pump-Assisted Volume Cohort)|Weekly volumes per injection site of 25 mL up to 50 mL administered subcutaneously.
2931003|NCT03033745|Experimental|IgPro20 (Pump Assisted Flow Rate Cohort)|Weekly flow rates per injection site of 25 mL/hour up to 100 mL/hour administered subcutaneously.
2931004|NCT03033745|Experimental|IgPro20 (Manual Push Flow Rate Cohort)|Frequent (ie, 2 to 7 times per week) flow rates per injection site of 25 to 30 mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute) administered subcutaneously.
2931005|NCT03033732|Other|Methadone|Opioid agonist treatment for opioid use disorder. Ingested in liquid oral form via strict initial daily witnessed ingestion as per local guidelines.
2931006|NCT03033732|Other|Buprenorphine/Naloxone|Opioid agonist treatment for opioid use disorder. Ingested orally via sublingual tablet form, flexible take home dosing.
2931007|NCT03033719|Active Comparator|Laparotomy|Open surgery
2931008|NCT03033719|Experimental|Laparoscopy|Minimally invasive surgery
2931009|NCT03033706|Active Comparator|Study group|Brain tumor excision under general anesthesia. Intervention (Pulse pressure variation guided fluid therapy): Study group will receive restricted fluid management with 1 ml/Kg/hr with concomitant PPV monitoring. PPV will be measured using invasive blood pressure monitor. Fluid bolus of 3 ml/Kg of ringer solution will be administrated whenever PPV is higher than 10%.
2931010|NCT03033706|Placebo Comparator|Control group|Brain tumor excision under general anesthesia. Intervention (Traditional fluid therapy): Control Group will receive standard fluid management of 4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
2931011|NCT03033693|Other|The deep anesthesia group|
2931012|NCT03033693|Other|The light anesthesia group|
2931143|NCT03032822||All Patients|All cystectomy patients who consent for the study
2931424|NCT03030963|Experimental|Equal-ratio ventilation(ERV) group|ventilator inspiration to expiration ratio will be set 1:1.
2931013|NCT03033680|Experimental|Multiple Systems Atrophy (MSA-C)|Four subjects with a probable MSA-C diagnosis will be recruited for this study. To be eligible, the subjects must be between 18 and 60 years of age, have an available brain MRI, and motor symptom onset less than two years prior. Each subject will undergo a [F-18]PBR06 PET scan at baseline, and at 9 months follow-up.
2931014|NCT03033667|Experimental|Glucose group (G group)|patients received 500 cc of glucose 10% that containing 50 g of glucose and provides patients with 200 Kcal with 556 mosmoles/L.
2931015|NCT03033667|Experimental|Lipid Group (L group)|patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid and provides patients with 200 Kcal with osmolarity of 380 mosmoles /L.
2931016|NCT03033667|Experimental|Control Group (C group)|patients was fasting overnight from 11 pm till 9 am except for clear fluids that was allowed till 5 am.
2931017|NCT03033654|Experimental|Intervention|Two Consecutive Sunscreen Applications
2931018|NCT03033641|Experimental|Ablation procedure|
2931019|NCT03033628|Experimental|DV group|"Device: injection using DentalVibe comfort system. giving maxillary infiltration dental local anesthesia with the aid of DentalVibe comfort system on one side of the maxillary arch prior extraction of primary molar tooth"
2931020|NCT03033628|Active Comparator|C group|"Device: traditional dental injection giving maxillary infiltration dental local anesthesia without the aid of DentalVibe comfort system on the other side of the maxillary arch prior extraction of primary molar tooth"
2931021|NCT03033615|Active Comparator|Chest CT|Conventional processing vs. PixelShine processing
2931022|NCT03033615|Active Comparator|Abdominal CT|Conventional processing vs. PixelShine processing
2931023|NCT03033602|Experimental|Written exposure therapy|5 sessions of imaginal exposure therapy.
2931024|NCT03033602|Active Comparator|CPT, cognitive only|12 sessions of cognitive therapy.
2931025|NCT03033589|Active Comparator|Adductor Canal Nerve Block|
2931026|NCT03033589|Active Comparator|Femoral Nerve block|
2931027|NCT03033576|Active Comparator|Arm I (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2931028|NCT03033576|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2931029|NCT03033563||Testicular tissue versus ejaculate|Evaluation of ICSI outcome.
2931030|NCT03033550|Experimental|single|single arm- behavioral educational intervention of a brief negotiated mobile application
2931031|NCT03033537||Verapamil|Intracavernosal injection of Verapamil
2931032|NCT03033537||Phentolamine|Intracavernosal injection of Phentolamine to treat erectile dysfunction for a period of 2 wweks
2931033|NCT03033524|Experimental|Cohort 1|Patients will be treated with 8mg/kg of TTAC-0001 on day 1, day 8 and day 15 in every 4 weeks of cycle.
2931034|NCT03033524|Experimental|Cohort 2|Patients will be treated with 12mg/kg of TTAC-0001 on day 1, day 8 and day 15 in every 4 weeks of cycle.
2931035|NCT03033524|Experimental|Cohort 3|Patients will be treated with 12mg/kg of TTAC-0001 weekly in every 4 weeks of cycle.
2931036|NCT03033511|Experimental|Rovalpituzumab tesirine/dexamthasone|Rovalpituzumab tesirine/dexamethasone every 6 weeks (q6 wk); omitting every third cycle
2931037|NCT03033511|Experimental|Placebo|Placebo q6 wk; omitting every third cycle
2931038|NCT03033498|Experimental|ABBV-951 Dose 1|Participants will receive dose 1 of ABBV-951.
2931039|NCT03033498|Experimental|ABBV-951 Dose 2|Participants will receive dose 2 of ABBV-951.
2931040|NCT03033498|Experimental|ABBV-951 Dose 3|Participants will receive dose 3 of ABBV-951.
2931041|NCT03033498|Experimental|ABBV-951 Dose 4|Participants will receive dose 4 of ABBV-951.
2931042|NCT03033498|Experimental|ABBV-951 Dose 5|Participants will receive dose 5 of ABBV-951.
2931043|NCT03033498|Experimental|ABBV-951 Dose 6|Participants will receive dose 6 of ABBV-951.
2931044|NCT03033498|Experimental|ABBV-951 Dose 7|Participants will receive dose 7 of ABBV-951.
2931045|NCT03033498|Experimental|ABBV-951 Dose 8|Participants will receive dose 8 of ABBV-951.
2931046|NCT03033485|Experimental|Melanoma patients|Melanoma patients enrolled for the clinical diagnosis study are performed with both 18F-P3BZA PET/CT and18F-FDG PET/CT scans before surgery.
2931047|NCT03033472|Experimental|Clindamycin|600 mg of Clindamycin orally 30 minutes before root canal treatment
2931048|NCT03033472|Placebo Comparator|Placebo|placebo 30 minutes Orally before treatment
2931049|NCT03033459|Experimental|Motivational Interviewing|Participants assigned to the Motivational Interviewing condition will receive an approximately 45 (± 5) minute intervention provided by a female masters-level supervised psychologist with training in Motivational Interviewing.
2931050|NCT03033459|Active Comparator|Psychoeducation Control|Participants who have been randomly assigned to participate in the attention-control group session will receive approximately 45 (± 5) minutes of psychoeducation on typical developmental stages and infant feeding methods. The psychoeducation will be provided by a female masters-level supervised psychologist.
2931051|NCT03033446|Experimental|Y90-Radioembolization and Nivolumab|
2931052|NCT03033433|Experimental|DCB-DM101, 500 mg tablet, determination of optimal dose|Stage 1:Dose level 1(1 tablet of DCB-DM101 q.d. for 7 days orally);Dose level 2(2 tablets of DCB-DM101 q.d. for 7 days orally);Dose level 3(4 tablets of DCB-DM101 q.d. for 7 days orally) Stage 2:Optimum dose of DCB-DM101 determined in Stage 1 as add-on treatment in T2DM patients for 14 days, q.d., orally
2931053|NCT03033420|Experimental|Intervention group|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
2931054|NCT03033420|No Intervention|Control group|Treatment-as-usual
2931055|NCT03033407|Experimental|Intervention-Maintenance group|Intervention was adding 'Tailored mobile coaching messages' onto conventional diabetes management. This study was divided into two phases. In six-month phase 1 study, the participants in I-M group received tailored mobile coaching. And during the second half six-month phase 2 study, they could receive only regular information messages without individualized coaching.
2931056|NCT03033407|Active Comparator|Control-Intervention group|Intervention was adding 'Tailored mobile coaching messages' onto conventional diabetes management. In six-month phase 1 study, the participants in Control-Intervention group maintained usual care for diabetes. During the second half six-month phase 2 study, they received tailored mobile coaching.
2931057|NCT03033394||Beta-lactam antibiotic|Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.
2931058|NCT03033381|Active Comparator|operated side testis|Operated side testis volume and blood flow will be evaluated with color doppler ultrasound before and after the surgery (Preoperative, 7 day and 30 day)
2931059|NCT03033381|Sham Comparator|Contralateral testis|Nonoperated side testis volume and blood flow will be evaluated with color doppler ultrasound before and after the surgery (Preoperative, 7 day and 30 day)
2931060|NCT03033368|Experimental|opened label|Open-label, single-arm study, rilpivirine is the study drug
2931061|NCT03033355||Pre- BTX-A injection|Female patients with confirmed diagnosis of Multiple Sclerosis referred to our Neurourology clinic with neurogenic lower urinary tract dysfunction prior to receiving intradetrusor injection of Botulinum Toxin-A.
2931062|NCT03033355||Post- BTX-A injection|Female patients with confirmed diagnosis of Multiple Sclerosis referred to our Neurourology clinic with neurogenic lower urinary tract dysfunction who receive intradetrusor Botulinum Toxin-A.
2931063|NCT03033342|Experimental|Oral single doses of MRX-4|Single escalating oral doses of MRX-4 from 250 mg to 3000 mg
2931064|NCT03033342|Experimental|Oral multiple doses of MRX-4|Twice daily escalating oral doses of MRX-4 for 10 days: 500 mg, 750 mg, 1000 mg, and 1500 mg
2931065|NCT03033342|Experimental|MRX-4 co-administered with omeprazole|Impact of concomitant food or omeprazole on the pharmacokinetics of oral MRX-4.
2931066|NCT03033342|Placebo Comparator|Oral single doses of placebo|Single oral doses of placebo to match MRX-4
2931067|NCT03033342|Placebo Comparator|Oral multiple doses of placebo|Multiple oral doses of placebo given twice daily for 10 days to match MRX-4
2931068|NCT03033342|Placebo Comparator|Placebo co-administered with omeprazole|Oral placebo given on Day 1, Day 7 to match MRX-4 dosing with omeprazole
2931069|NCT03033329|Experimental|Single intravenous doses of MRX-4|Single escalating intravenous doses of MRX-4 from 150 mg to 1800 mg
2931070|NCT03033329|Placebo Comparator|Single intravenous doses of placebo|Single intravenous doses of placebo to match MRX-4
2931071|NCT03033329|Active Comparator|Multiple intravenous doses of MRX-4|Twice daily escalating intravenous doses of MRX-4 for 10 days: 600 mg, 900 mg, 1200 mg, and 1500 mg
2931072|NCT03033329|Placebo Comparator|Multiple intravenous doses of placebo|Twice daily intravenous doses of placebo to match MRX-4 for 10 days
2931073|NCT03033329|Active Comparator|Single dose of intravenous and oral MRX-4|Crossover of single dose of intravenous and oral MRX-4
2931074|NCT03033316|Experimental|IV Liposomal Dexamethasone|IV Liposomal Dexamethasone given 1 to 4 times in total over period of maximally 4 weeks
2931075|NCT03033303|Experimental|Hu3F8/GM-CSF Plus Isotretinoin|In this phase II single arm trial, patients with HR-NB in first CR or VGPR undergo consolidation by using hu3F8/GM-CSF x5 cycles and isotretinoin x6 cycles. Isotretinoin starts after cycle 2 of hu3F8/GM-CSF.
2931076|NCT03033290|Experimental|Bu-Zhong-Yi-Qi-Tang (BZYQT)|capsule of BZYQT, 4gm tid, 12gm a day for 2 months
2931077|NCT03033290|Placebo Comparator|placebo control|similar placebo capsule 4gm tid, 12gm a day for 2 months
2931078|NCT03033277|Placebo Comparator|Control group|Hormone replacement therapy, placebo transplantation.
2931079|NCT03033277|Experimental|Experimental group|Hormone replacement therapy,HUC-MSCs transplantation.
2931080|NCT03033264|Experimental|BMI>30+Dinoprostone|Women with a BMI>30 at term that will be induced for obstetrical indications with 10 mg of a Dinoprostone vaginal insert.
2931081|NCT03033264|Experimental|BMI<30+Dinoprostone|Women with a BMI<30 at term that will be induced for obstetrical indications with 10 mg of a Dinoprostone vaginal insert.
2931082|NCT03033264|Experimental|BMI>30+Cervical ripening balloon|Women with a BMI>30 at term that will be induced for obstetrical indications with a double lumen cervical ripening balloon.
2931083|NCT03033264|Experimental|BMI<30+Cervical ripening balloon|Women with a BMI<30 at term that will be induced for obstetrical indications with a double lumen cervical ripening balloon.
2931084|NCT03033251|Active Comparator|Non invasive ventilation|Patients will receive non invasive ventilation with setting decided by the attending physician.
2931085|NCT03033251|Active Comparator|High Flow 50 L/min|High Flow Oxygen Cannula with a flow set at 50 L/min.
2931086|NCT03033251|Active Comparator|High Flow 30 L/min|High Flow Oxygen Cannula with a flow set at 30 L/min.
2931087|NCT03033238||Early or mild knee symptoms|"Existing Cohort study participants (3,026) were enrolled in 2003-2005, Surviving participants without endstage knee osteoarthritis will be asked to participate in the 144-, 152, 160- and 168-month follow-up contacts.~New Cohort study participants (1,500) will be recruited and enrolled in 2016-2018."
2931088|NCT03033225|Experimental|PDT|Participants will undergo 'Verteporfin PDT' photodynamic therapy for pancreatic tumors
2931089|NCT03033212|Experimental|Early Structured Rehabilitation|Patients will begin Therapist-Guided Rehabilitation at 7 weeks postoperatively with a certified physical therapy. The patients will perform rehabilitation for 10 total weeks.
2931090|NCT03033212|Experimental|Delayed Rehabilitation|Patients will begin Therapist-Guided Rehabilitation at 13 weeks postoperatively with a certified physical therapy. The patients will perform rehabilitation for 10 total weeks.
2931091|NCT03033212|Active Comparator|Self Rehabilitation|Patients will begin Self-Guided Rehabilitation at 7 weeks postoperatively in a self-guided fashion. They will be provided with instructions for recommended exercises. They will undergo rehabilitation for a total of 10 weeks.
2931092|NCT03033199|Active Comparator|Probiotic Agent Combining HD-DXM|"probiotic capsules containing three viable and freezedried strains—Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.~Dexamethasone 40mg per day, 4 consecutive day"
2931093|NCT03033199|Active Comparator|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days
2931144|NCT03032809||Intracranial vasculopathy|Patients diagnosed intracranial vasculopathy will be imaged further by high resolution vessel wall MR imaging on a 3Tesla MR scanner.
2931145|NCT03032796|Experimental|BBT|Body-Brain Trainer
2931094|NCT03033186||Everolimus (afinitor)|Patients using everolimus as therapy for cancer: Advanced (Hormone-Receptor [HR]-positive, HER2-negative) breast cancer (BC), advanced or unresectable neuroendocrine tumours of pancreatic (pNET), gastrointestinal or lung origin and metastatic renal cell carcinoma (mRCC)
2931095|NCT03033173||CTS group|
2931096|NCT03033173||Healthy subjects|
2931097|NCT03033160|Experimental|Estradiol Ring|Estradiol Ring per vagina every 3 months
2931098|NCT03033160|No Intervention|Observation|Observation
2931099|NCT03033147|Experimental|Amoxicillin/Clavulanate Potassium|Amoxicillin/Clavulanate Potassium 875 mg-125 mg orally 30 minutes before root canal treatment
2931100|NCT03033147|Placebo Comparator|Placebo|placebo 30 minutes before root canal treatment
2931101|NCT03033134|Experimental|BSJ003W|BSJ003W implant group
2931102|NCT03033121|Active Comparator|group A|Sixteen growth hormone (GH) deficiency children were assigned to receive daily growth hormone therapy for 12 months. The investigators used an initial weekly dose of 0.175 mg/kg (corresponding to the daily dose of 0.025 mg/Kg) of GH with a gradual increase every 6 months in order to always maintain the insulin growth factor (IGF)-I levels in the normal range. In detail, from months 1 to 6 the investigators used the mean weekly dose of 0.175 mg/kg and from months 6 to 12 the mean weekly dose of 0.20 mg/kg.
2931103|NCT03033121|Active Comparator|group B|Sixteen growth hormone (GH) deficiency children were assigned to receive three time weekly growth hormone therapy for 12 months. The investigators used an initial weekly dose of 0.175 mg/kg (corresponding to the daily dose of 0.025 mg/Kg) of GH with a gradual increase every 6 months in order to always maintain the insulin growth factor (IGF)-I levels in the normal range. In detail, from months 1 to 6 the investigators used the mean weekly dose of 0.175 mg/kg and from months 6 to 12 the mean weekly dose of 0.20 mg/kg.
2931104|NCT03033108|Experimental|Emixustat Dose 1|
2931105|NCT03033108|Experimental|Emixustat Dose 2|
2931106|NCT03033108|Experimental|Emixustat Dose 3|
2931107|NCT03033095|Experimental|etanercept|"The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.~Modality of administration :~Etanercept : 50 mg / week subcutaneously, every 7 days The clinical response will be evaluated after 6 months of etanercept treatment, at the M6 visit."
2931108|NCT03033082||Erectile dysfunction patients|Questionnaire sheets.
2931109|NCT03033082||Normal males|Questionnaire sheets.
2931110|NCT03033069|Experimental|Brexpiprazole Monotherapy|Flexible dose
2931111|NCT03033069|Active Comparator|Brexpiprazole & Zoloft (sertaline) Combination Therapy|Flexible dose
2931112|NCT03033069|Active Comparator|Zoloft (setraline) monotherapy|Flexible dose
2931113|NCT03033069|Placebo Comparator|Placebo|Placebo
2931114|NCT03033056||Anxiety Clinic Patients|Adult males and females being treated at the anxiety disorders clinic at the University of Minnesota predominantly for clinical anxiety.
2931115|NCT03033056||Healthy Comparisons|Sex, age, and socioeconomically matched healthy controls
2931116|NCT03033043|Experimental|Experimental: Relay Pro|The Relay Pro arm includes subjects who receive the device. The Relay Pro Stent Graft System is administered to treat complicated Type B aortic dissections.
2931117|NCT03033030||Tomosynthesis|Patients undergoing Digital Breast Tomosynthesis
2931118|NCT03033017||HIV-infected on antiretroviral therapy 2 years|HIV-infected participants who have been on antiretroviral therapy (ART) for at least two years.
2931119|NCT03033004|Active Comparator|Conventional Cryolipolysis|Subjects will receive one treatment session of conventional cryolipolisys. Subcutaneous fat tissue will be cooled with the cryolipolitic device for 60 minutes. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
2931120|NCT03033004|Active Comparator|Contrast Cryolipolysis|Subjects will receive one treatment session of contrast cryolipolisys. Subcutaneous fat tissue will be heated for 10 minutes, cooled for 60 minutes, and heated again for 10 minutes with the cryolipolitic device. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
2931121|NCT03033004|Active Comparator|Reperfusion Cryolipolysis|Subjects will receive one treatment session of Reperfusion Cryolipolysis. Subcutaneous fat tissue will be cooled with the cryolipolitic device for 60 minutes and heated for 10 minutes. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
2931122|NCT03032991||Control|Children at 8 years old born from healthy pregnancies
2931123|NCT03032991||GDM|Children at 8 years old born from mothers with gestational diabetes during pregnancy
2931124|NCT03032978|Experimental|Calcium silicate|intervention
2931125|NCT03032978|Active Comparator|Calcium Hydroxide|Comparator
2931126|NCT03032965|Experimental|Adenosine and Isoproterenol|Patients in this group will receive 12-24mg of adenosine for each PV in order to assess dormant PV conduction.
2931127|NCT03032965|Other|Isoproterenol|This group will not receive adenosine during the procedure.
2931128|NCT03032952|Experimental|"Feel Stress Free"|"Access to the Feel Stress Free mobile application intervention for 12 weeks. Instructed to use it at least once per week for 15 minutes, for the first 6 weeks, then given free access thereafter."
2931129|NCT03032952|No Intervention|Wait list control|Given access to the intervention at the end of the 12 weeks of the trial.
2931130|NCT03032926||Open Trial|N/A - Open Trial
2931131|NCT03032913||Pancreatic ductal adenocarcinoma patients|Patients with recent diagnosis of pancreatic ductal adenocarcinoma (PDAC) or with strong suspicion PDAC
2931132|NCT03032913||Non-cancer patients|Patients with no Cancer
2931133|NCT03032887|Experimental|voice prompts|Agitation (education, reminders and optimising materials) plus voice prompts
2931134|NCT03032887|Other|no voice prompts|only Agitation (education, reminders and optimising materials); no voice prompts
2931135|NCT03032874||Training set|All the patients with rectal bleeding who had colonoscopy performed at Obafemi Awolowo University Teaching Hospitals Complex
2931136|NCT03032874||Validation set|All the patients with rectal bleeding who had colonoscopy performed at University College Hospital, Ibadan and University of Ilorin Teaching Hospital
2931137|NCT03032861|Experimental|Orange juice|Ten women will consume 100% orange juice (300 mL/day) during 60 days.
2931138|NCT03032848|Active Comparator|Conjugated Estrogen Group|use of 1 gram per day
2931146|NCT03032796|Active Comparator|Body Trainer|Participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present, while completing all of the physical aspects of BBT. Thus this will be a physical training protocol.
2931147|NCT03032796|Active Comparator|Brain Trainer|"The Brain Trainer group will train using the same platform as the BBT group, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects)."
2931148|NCT03032796|Placebo Comparator|Expectancy Matched Control Group|The placebo-matched control group will engage in a battery of three apps in the laboratory that we believe will have no significant impact on cognition
2931149|NCT03032783|Experimental|Treatment (TBI, DLI, chemotherapy, HSCT)|Patients undergo Total-Body Irradiation (TBI) twice daily on days -10 to -8 and and donor lymphocyte infusion (DLI) on day -6. Patients receive cyclophosphamide IV over 2 hours on days -3 and -2, tacrolimus IV beginning on day -1 and then orally at least 2 or 3 days prior to discharge with taper starting on day 42, and mycophenolate mofetil IV twice daily on days -1 to 28. Patients undergo Allogeneic Hematopoietic Stem Cell Transplantation on day 0.
2931150|NCT03032770||placenta accreta|Having at least one sign suggestive of placenta accreta
2931151|NCT03032770||normal placenta|Never having any of the signs suggestive of placenta accreta
2931152|NCT03032757|Experimental|Resting leg of young males|
2931153|NCT03032757|Experimental|Exercising leg of young males|
2931154|NCT03032757|Experimental|Resting leg of elderly males|
2931155|NCT03032757|Experimental|Exercising leg of elderly males|
2931156|NCT03032744|Experimental|Intervention|Controller at school
2931157|NCT03032744|Active Comparator|Usual Care|Controller at home
2931158|NCT03032731|Experimental|Website and pedometer Intervention|Participants allocated to this group will be given a one-off set-up session in which a researcher will show them the intervention website, create a user profile for them and provide guidance on how to use the site to gain health information, set personal behavioural goals and record and monitor their behaviour in relation to their goals. The researcher will also provide the participant with a pedometer and instruct them how to use this and where they can record their daily steps on the website. For 6 weeks, participants will be asked to use the website and be sent weekly email reminders to do so and log their goal progress. After 6 weeks, no further emails will be sent but participants will still be able to access the website and use the pedometer if they wish.
2931159|NCT03032731|Other|Control|Participants allocated to this group will be given a one-off session in which a researcher shows them publicly available web-based resources for health behaviour change (provided by the National Health Service (NHS)). Like those participants in the intervention group, they will be assessed again after 6 and 12 weeks. Participants in the control arm will be offered the intervention (access to the study website and a pedometer) after 12 weeks.
2931160|NCT03032718|Experimental|Intervention|Patients in the intervention group will receive a defined exercise program twice a week in addition to their usual treatment. Training sessions start immediately after randomization and will be supervised by trained sport students. They will take place twice a week, for twelve weeks in specific training rooms designed to meet the needs of oncological patients in the respective centers. The vibration exercises will take place on a side-alternating vibration platform (GalileoTM, Pforzheim, Germany) ®) according to the previously determined optimal (highest neuromuscular response) setting for each individual. Each session will last for about 15 to 30 minutes, leaving sufficient time for regeneration. Training will consist of four vibration exercises, chosen from a standardized pool of exercises with increasing difficulty in order to allow for individual, optimal progression. All sessions will be documented by the supervisor.
2931161|NCT03032718|No Intervention|Control|Patients in the control group will receive treatment as usual and will be given the opportunity to participate in the intervention after completion of the study.
2931162|NCT03032705|Experimental|SonicFill™ 2|Composite: SonicFill™ 2; Bonding Agent: Optibond XRT
2931163|NCT03032705|Active Comparator|Filtek™ Supreme|Composite: Filtek™ Supreme Ultra Universal Restorative; Bonding Agent: Scotchbond™ Universal Adhesive
2931164|NCT03032692|Experimental|SWORD and exercise with biofeedback|The patient will perform one repetition of the exercise shoulder flexion with elbow flexion at 90 degrees under monitoring from SWORD. The recorded parameters will be used to define: baseline and target angle; execution time; maximum postural sway. Two additional repetitions will be performed to ensure reproducibility. During the session, SWORD will be providing real-time audiovisual feedback. The patient has to start in the baseline position and fill the progress bar without violating movement or posture constraints. If the patient does not reach the goal or violates constraints he will receive a negative audio feedback, the progress bar will turn red and be reset. The patient has to return to the baseline position to restart the movement.
2931165|NCT03032692|Active Comparator|SWORD and exercise without biofeedback|The patient will perform one repetition of the exercise shoulder flexion with elbow flexion at 90 degrees under monitoring from SWORD. The recorded parameters will be used to define: baseline and target angle; execution time; maximum postural sway. Two additional repetitions will be performed to ensure reproducibility. The patient will then be instructed to perform as many movements as possible during the allocated time (4 minutes), at a comfortable pace, starting at or below the baseline and trying to reach maximum flexion without significant pain or discomfort. During the session, the SWORD system will be recording the patient´s movement without providing feedback to the patient.
2931166|NCT03032679||Single group of patients|Non interventional study. Observational with questionnaires
2931167|NCT03032666|Experimental|sofosbuvir/velpatasvir|Epclusa
2931168|NCT03032653|Active Comparator|Late WB|Intervention: Patients receive a plaster splint in the operating room. They are not permitted to WB or ROM on the affected limb at this stage. At the first follow-up appointment (two weeks post-op), the splint is removed and a removable pre-fabricated walking boot applied. At this stage the patient is permitted to WB as tolerated while wearing the boot, and to perform ROM exercises with the boot removed. At six weeks post-op, the boot is discontinued and full unrestricted and unprotected weightbearing and ROM is permitted.
2931169|NCT03032653|Experimental|Immediate unprotected WB and ROM|Patient do NOT receive a brace or splint of any kind. They are permitted to weightbear and range of motion as tolerated within the limitations of their own comfort. Use of ambulatory aids of any kind is permitted as needed without restrictions.
2931170|NCT03032640|Active Comparator|Group 1- Healthy Lean subjects|Group 1 will receive Sodium Saccharin 200mg capsule, 2x/day, Day 1-14
2931172|NCT03032640|Active Comparator|Group 3- Healthy Lean subjects|Group 3 will receive Sodium Saccharin 200mg + lactisole 335mg capsule, 2x/day, Day 1-14
2931173|NCT03032640|Active Comparator|Group 4- Healthy Lean subjects|Group 4 will receive Lactisole 335mg capsule, 2x/day, Day 1-14
2931174|NCT03032627|Other|Cardiac surgery|Subjects will be recruited by a coordinator through electronic medical record (EMR) searches to identify those undergoing left ventricle assist device (LVAD) implantation and explantation, heart transplant, valve replacement or repair, endomyocardial biopsy during catheterization, and arterial bypass surgery. Prior to the procedure, potential subjects will be informed about the clinical study and if interested, they will be consented.
2931175|NCT03032614|Experimental|Combination of Carboplatin, Eribulin, and Veliparib|Eribulin will be administered intravenously (IV) on days 1 and 8 of each cycle at a dose of 1.1 mg/m2 over a 2-5 minute time period; on cycle day 1. Carboplatin will be administered intravenously at a dose of AUC 5 on day 1 of each cycle, over 30 min, immediately following eribulin infusion, per institutional guidelines. Veliparib will be given at 120 mg bid (two times a day), on days 2-12 for the first cycle of the safety run-in period and thereafter at 240 mg bid.
2931176|NCT03032601|Active Comparator|N-acetyl Cysteine Cohort|Intravenous N-acetyl Cysteine - 50mg in 200ml of D5W over one hour 1 x per week Oral N-acetyl Cysteine - 1 600mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
2931177|NCT03032601|No Intervention|Control Cohort|Standard of Care Treatment
2931178|NCT03032588|Experimental|Group 1: sIPV|Participants will receive single intramuscular injection of the trivalent inactivated poliovirus vaccine based on Sabin strains produced on PER.C6 cells (sIPV) on Day 1.
2931179|NCT03032588|Active Comparator|Group 2: cIPV|Participants will receive single intramuscular injection of the currently used trivalent inactivated poliovirus vaccine IMOVAX POLIO, based on the conventional Salk poliovirus strains produced on Vero cells (cIPV) on Day 1.
2931180|NCT03032575|Other|sample size 100|Study Design: This is a prospective observational cohort of Thai MSM who initiated ART at the time of AHI, defined as the first 30 days after HIV acquisition (Fiebig stages 1 through 5). Volunteers will be examined at baseline to determine the prevalence of HPV infection and HSIL at HIV diagnosis. They will then be followed longitudinally for new incidence of HPV and HSIL, as well as progression or regression of existing lesions.
2931181|NCT03032562||1|Patients with neuromuscular disease
2931182|NCT03032562||2|Patients with chronic obstructive pulmonary disease
2931183|NCT03032549|Experimental|RTD|2.1 g. beta alanine, 1.3 g arginine nitrate, 200 mg caffeine, 65 mg niacin, 325 mcg folic acid, 45 mcg vitamin B12
2931184|NCT03032549|Placebo Comparator|Placebo|dextrose and non-caloric flavoring
2931185|NCT03032536|Experimental|Treatments A, B, C|"Part 1: Cross-Over~Treatment A: AL-3778 6 x 100-mg capsules (fasted) once.~Treatment B: AL-3778 2 x 300-mg tablets (fasted) once~Treatment C: AL-3778 2 x 300-mg tablets (high-fat meal) once."
2931186|NCT03032536|Experimental|Treatments D, E, F|"Part 2 (optional): Cross-Over~Treatment D: AL-3778 2×300-mg tablets (fasted) once.~Treatment E: AL-3778 tablet Dose (fasted) once. Dose will match Treatment F dose and will be:~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg~Treatment F: AL-3778 tablet Dose (high-fat meal) once. Dose will match Treatment E dose and will be:~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg"
2931187|NCT03032536|Experimental|Treatment G|"Part 3: AL-3778 twice daily administered under fasted conditions for 14 days.~Dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:~600mg: 2 x 300-mg OR~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg"
2931188|NCT03032536|Active Comparator|Treatment H|Part 3: Entecavir 0.5 mg once daily administered under fasted conditions for 14 days
2931189|NCT03032536|Experimental|Treatment I|"Part 3: AL-3778 twice daily with entecavir 0.5 mg once daily both administered under fasted conditions for 14 days.~AL-3778 dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:~600mg: 2 x 300-mg OR~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg"
2931190|NCT03032536|Active Comparator|Treatment J|Part 3: Tenofovir disoproxil fumarate 300 mg once daily administered under fasted conditions for 14 days
2931191|NCT03032536|Experimental|Treatment K|"Part 3: AL-3778 twice daily and tenofovir disoproxil fumarate 300 mg once daily both administered under fasted conditions for 14 days.~AL-3778 dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:~600mg: 2 x 300-mg OR~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg"
2931192|NCT03032523|Experimental|Remote Monitoring CGM Group|Participants wear a CGM that is blinded at bedside (to participant and clinical staff) but remotely monitored by study staff. If a blood sugar less than 46 mg/dl occurs, the study staff receive a notification and ask the clinical staff to perform a confirmation standard of care glucose test.
2931193|NCT03032523|No Intervention|Blinded CGM Group|Participants wear a blinded CGM during the study period. Values are blinded to study staff, participant, and clinical staff.
2931194|NCT03032510|Experimental|Eravacycline (Intravenous)/Levofloxacin (Oral)|
2931195|NCT03032510|Active Comparator|Ertapenem (Intravenous)/Levofloxacin (Oral)|
2931196|NCT03032497|Experimental|EEG-based BCI analysis of fear avoidance|"All participants complete two experiments one after another-EEG patterns, skin conductance and pulse rate are recorded. The EEG cap is mounted on the participant's head, the GSR sensor secured on the fingers and the PPG sensor secured on the wrist using a Velcro strap. Exp 1-participants watch a series of 15, 1 min videos of people doing daily activities. Exp 2-participants do 15 movements (15 reps each in 1 min) as guided by a physiotherapist. 2 identical buzzers (labelled lesser pain and more pain) are available to press accordingly should participants experience 'lesser' or 'more' pain any time during the experiment. If 'more' pain experienced, participants' condition will be assessed and they can choose to continue the experiment at a lower intensity or stop."
2931197|NCT03032484|Experimental|Bevacizumab and TVB-2640|Bevacizumab every 2 weeks in combination with TVB-2640 dosed at 100mg/m2 daily (rounded to 50mg tab dose), from day 1 until day 28 of the first cycle.
2931198|NCT03032484|Experimental|Bevacizumab|Bevacizumab alone every 2 weeks, on days 1 and 15 until day 28 of the first cycle.
2931305|NCT03031665||Remitted MDD|Subjects who have a history of Major Depressive Disorder, but have not had a depressive episode for at least two months.
2931306|NCT03031665||Control Subjects|Subjects who have no history of clinical depression or other psychological disorder.
2931199|NCT03032471||DCI group|"Patients that experience DCI, defined as~Cerebral infarction identified on imaging or proven at autopsy, after exclusion of procedure-related infarctions; and~Clinical deterioration caused by DCI, after exclusion of other potential causes of clinical deterioration will be assigned to the DCI group."
2931200|NCT03032471||non-DCI group|Patients not experiencing DCI as defined above.
2931201|NCT03032458|Active Comparator|Pethidine|Pethidine 25 mg IV bolus (Pethidine hydrochloride 50mg ampule, Roche Pharmaceutical Company - Egypt)
2931202|NCT03032458|Active Comparator|Ketorolac|Ketolac 30 mg (ketorolac, Amriya Pharmaceutical Industries - Egypt)
2931203|NCT03032458|Active Comparator|Xylocaine Gel|Xylocaine gel (lidocaine 2%, AstraZeneca Pharmaceutical Company - Egypt)
2931204|NCT03032445|Experimental|Alcoholic beer|At least 6% alcohol content
2931205|NCT03032445|Placebo Comparator|Non alcoholic beer|Less than 0.5% alcohol content
2931206|NCT03032432|Experimental|Dynamic elastic garment and injection|
2931207|NCT03032432|Active Comparator|Corticosteroid injection|
2931208|NCT03032419|Experimental|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral aspect of the right thigh. Each subject randomised to this group will receive three primary injection at 6, 10, and 14 weeks of age and one booster injection at 9 months of age
2931209|NCT03032419|Active Comparator|IPV SSI|IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral aspect of the right thigh. Each subject randomised to this group will receive three primary injection at 6, 10, and 14 weeks of age and one booster injection at 9 months of age
2931210|NCT03032406|Experimental|HCQ alone (Arm A)|
2931211|NCT03032406|Experimental|EVE alone (Arm B)|
2931212|NCT03032406|Experimental|combination HCQ and EVE (Arm C)|
2931213|NCT03032406|Experimental|observation (Arm D)|
2931214|NCT03032393|Experimental|Dominant|
2931215|NCT03032393|Active Comparator|Submissive|
2931216|NCT03032380|Experimental|S-649266|Participants will receive 2 g S-649266 administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.
2931217|NCT03032380|Active Comparator|Meropenem|Participants will receive 2 g meropenem administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.
2931218|NCT03032367|Other|Sequence 1|Bedaquiline 4 x 100mg administered in a whole tablet form, followed by bedaquiline 4 x 100mg administered in crushed form as a once only oral dose
2931219|NCT03032367|Other|Sequence 2|Bedaquiline 4x 100mg administered in crushed form, followed by bedaquiline 4 x 100mg administered in a whole tablet form, as a once only oral dose
2931220|NCT03032354|Experimental|Probiotics arm: Probiotics group|combination of probiotics: Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12 in the same capsule
2931221|NCT03032354|Placebo Comparator|Placebo arm: Placebo group|Placebo - maltodextrin
2931222|NCT03032341||Patient group|20 patient in poor mobility group (MAT-sf < 51.38 in men and <45.61 in women), mid-mobility group (51.38< MAT-sf≤65.5 in men and 45.61≤MAT-sf<54.02) and high mobility group (MAT-sf>65.5 in men and MAT-sf>54.02 in women) for a total of 60 patients.
2931223|NCT03032341||Surrogate group|A family member/caregiver that attends visits with the patient and will be asked to answer the Mobility Assessment Test questionnaire on behalf of the patient at the initial visit and the follow up visit 1-14 days later.
2931224|NCT03032328|Experimental|vitamin D supplement|patient's will be given a vitamin D
2931225|NCT03032315|Experimental|TAH(80/10/12.5) tablet|Telmisartan/Amlodipine besylate/Hydrochlorothiazide(80/10/12.5) tablet
2931226|NCT03032315|Active Comparator|Telmisartan+Amlodipine besylate+Hydrochlorothiazide|coadministration of Telmisartan, Amlodipine besylate and Hydrochlorothiazide
2931227|NCT03032302|Experimental|Multivitamin|Swisse Womens 50+ Ultivite Multivitamin. Once daily.
2931228|NCT03032302|Experimental|Omega-3 Fatty Acids|Holland and Barrett Triple Strength Omega-3 Fish Oils. Once Daily
2931229|NCT03032302|No Intervention|Control|Treatment as usual (cognitive rehabilitation, occupational therapy, physiotherapy; as required)
2931230|NCT03032276|Experimental|Intervention|"'Safe motherhood and newborn health promotion package' will be implemented in the intervention arm which comprise 15 randomly selected unions (lowest level of administrative unit)."
2931231|NCT03032276|No Intervention|Comparison|Another 15 union will be selected where no intervention will be implemented
2931232|NCT03032263|Active Comparator|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
2931233|NCT03032263|Experimental|Video Laryngoscopy|These patients will undergo Video Laryngoscopy for nasal intubation. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
2931234|NCT03032250|Experimental|Supportive Care (Prepare to Care kit)|Caregivers watch introduction video on a DVD over 10 minutes at baseline. Caregivers receive Prepare to Care kit including 8 workbook modules and complete at least 1 module over 30-45 minutes each week. Caregivers also attend interventionist session over 10-30 minutes weekly.
2931235|NCT03032237|Experimental|Protein-rich assortment|The intervention groups receives protein-rich meals and protein-rich dairy products.
2931236|NCT03032237|Placebo Comparator|Standard assortment|The control group receives standard meals and food products.
2931237|NCT03032211|Experimental|Treatment|Alfapump
2931238|NCT03032198|Experimental|Imagio OA/US Scan|Imagio opto-acoustic gray-scale ultrasound scan
2931239|NCT03032185|Active Comparator|Active TENS|Active TENS, 10 Hz/200 μs
2931240|NCT03032185|Sham Comparator|Not Active TENS|Sham TENS
2931241|NCT03032172|Experimental|RO7034067|Participants will receive multiple doses of RO7034067 orally once daily for 24 months.
2931307|NCT03031652||Enrolled group|Patients who had senile cataract and underwent phacoemulsification with topical anesthesia.
2931308|NCT03031639||Endoscopic|This group is the patients who underwent endoscopic approaches thyroidectomy.
2931242|NCT03032159|No Intervention|Control Group|Participants randomized to the control group will receive their usual asthma care from their provider. Additionally, participants in the control group will receive reminder texts to schedule with their child's PCP and to get an annual flu shot. Participants will be surveyed over the phone for 20-30 minutes 3, 6, 12, 18, and 24 months after enrollment.
2931243|NCT03032159|Experimental|Text2Breathe Study Group|"The study group spends about 10-20 minutes learning about ways to have better communication with their child's primary care provider about his/her asthma. Additionally this group is enrolled in the Text2Breathe messaging program which sends asthma related educational text messages 2 times a week for 3 months. Participants randomized to the study group will also receive reminder texts to schedule with their child's PCP and to get an annual flu shot. Participants will be surveyed over the phone for 20-30 minutes 3, 6, 12, 18, and 24 months after enrollment."
2931244|NCT03032146|Experimental|participation in cardiac rehabilitation|Patients with at least a month of cardiac rehabilitation at The Emek Medical Center, Afula. Rehabilitation includes a multidisciplinary program based on physical exercise.
2931245|NCT03032146|No Intervention|control|Patients who chose not to participate in the rehabilitation program, despite being offered the option.
2931246|NCT03032133|Active Comparator|Regional pain control|Regional pain catheter
2931247|NCT03032133|Experimental|Local pain control|Local intraarticular pain catheter
2931248|NCT03032120|Experimental|Fresh orange juice|Intervention: The subjects drank 5 mL/kg body weight of fresh-squeezed orange juice (FOJ).
2931249|NCT03032120|Experimental|Processed orange juice|Intervention: The subjects drank 5 mL/kg body weight of processed orange juice (POJ).
2931250|NCT03032120|Experimental|Control|The subjects drank 5 mL/kg body weight of control drink compounded by water mixed with sugars in a similar concentration of orange juices (5.2% of sucrose, 2.5% of fructose, 2.1% of glucose, 0.75% of citric acid, and malic acid 0.25%, flavored and colored with some drops of orange essence).
2931251|NCT03032107|Experimental|Pembrolizumab Combine With Trastuzumab Emtansine|"Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle~Pembrolizumab will be administered prior to T-DM1 administration~Pembrolizumab will be given at a predetermine dose~T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle~T-DM1 will be given at a predetermine dose"
2931252|NCT03032094|Active Comparator|1mm thick graft|connective tissue graft of 1mm thickness
2931253|NCT03032094|Active Comparator|2mm thick graft|connective tissue graft of 2mm thickness
2931254|NCT03032081|Experimental|High Intensity Group|3 set of 4 minutes of cycling intense exercise, 4 days per week, for 8 weeks at about 80% to 90% of heart rate reserve
2931255|NCT03032081|Active Comparator|Moderate Intensity Group|40 to 47 minutes of continuous cycling exercise at 50% to 60% of heart rate reserve, 4 days per week, for 8 weeks.
2931256|NCT03032068|Experimental|At-Home Monitoring|Patients will follow-up in clinic postoperatively at 4, 8, and 12 weeks and their recovery will also be monitored using sensors and communication devices while they are at home after surgery.
2931257|NCT03032055||VOC|"Patients who won't develop a secondary Acute chest syndrome during a vaso occlusive crisis within 15 days after admission.~Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate and chest pain or decreased breath sounds .~A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults. It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries."
2931258|NCT03032055||2°ACS|"Patients who will develop a secondary acute chest syndrome during a vaso occlusive crisis within 15 days after admission.~Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate AND chest pain or decreased breath sounds .~A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults.It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries."
2931259|NCT03032042|Experimental|albendazole at day 0, azithromycin at day 7|
2931260|NCT03032042|Experimental|azithromycin at day 0, albendazole at day 7|
2931261|NCT03032042|Experimental|albendazole at day 0, azithromycin at day 0|
2931262|NCT03032042|Other|Delayed treatment|albendazole at day 7, azithromycin at day 7
2931263|NCT03032016||sVOD patient treated with defibrotide|Patient diagnosed with severe hepatic VOD and treated with defibrotide
2931264|NCT03032016||sVOD patient under supportive care|Patient diagnosed with severe hepatic VOD and treated with supportive care only
2931265|NCT03032003|Active Comparator|Cysticlean arm|Cysticlean (2 BID for 15 days)
2931266|NCT03032003|Placebo Comparator|Placebo arm|Placebo (2 BID for 15 days)
2931267|NCT03031990|Experimental|Yoga intervention|The participants who elect to include yoga as part of their infertility treatments will self select one of three groups: 1) In person yoga for fertility group; 2) Online yoga for fertility group; 3) In person discussion only group
2931268|NCT03031990|No Intervention|Control|These are patients that have a history of IVF failure or who are undergoing elective egg freezing who elect to be included in the study but are not interested in including yoga as a part of their treatment.
2931269|NCT03031977|Experimental|visceral mobilization|Conventional physical therapy and visceral mobilization. The experimental group was also submitted to mobilization of the ascending colon, descending colon, sigmoid colon and sphincters (cardiac, pyloric, Oddi, duodenojejunal and ileocecal) with the patient in the supine position, knees flexed, feet supported and abdomen exposed. Contact was made with the region to be treated, leading it in the direction of immobility, with pressure maintained for one minute on each region with intensity based on the sensitivity to tension observed on the feedback of the individual.
2931270|NCT03031977|Sham Comparator|sham mobilization|Conventional physical therapy and sham mobilization. In the control group, sham mobilization was performed, which consisted of superficial contact with no pressure on the abdominal region corresponding to the loops of the large intestine.
2931271|NCT03031964||revision multihole acetabular cup|Revision total hip arthroplasty using multihole revision acetabular cup
2931272|NCT03031951|Experimental|Lifestyle Intervention Group|Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 3 months. Sessions will last 90-120 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum.Participants will be instructed and motivated to make small but enduring reductions in caloric intake and to increase energy expenditure to induce a daily energy deficit of approximately 300 kcal. Weight will be monitored weekly.
2931273|NCT03031951|No Intervention|Control Group - Waiting List|"Participants assigned to the control group will have access to the intervention after the 9-month period - waiting list. Meanwhile, participants will receive multimedia health information fortnightly by e-mail over the first 3-month period. The health information covers healthy lifestyle topics.~During the 9 months of study participation, control group participants will be instructed to maintain their baseline level of physical activity. Individuals assigned to the control group will be asked to maintain their current nutritional practices and physical activity patterns."
2931274|NCT03031938|Other|Cohort 1|Long term observational study of subjects from tanezumab parent study
2931275|NCT03031925|Experimental|SLE patients|Systemic Lupus Erythematosus
2931276|NCT03031925|Active Comparator|control subjects|age- and sex-matched control subjects
2931277|NCT03031912|Active Comparator|Group 1: 50 HIV-infected adults CD4 ≥ 500 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
2931278|NCT03031912|Active Comparator|Group 2: 50 HIV-infected adults CD4 > 350 and < 500 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
2931279|NCT03031912|Active Comparator|Group 3: 50 HIV-infected adults CD4 ≥ 200 and ≤ 350 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of theV920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
2931280|NCT03031912|Active Comparator|Group 4: HIV infected adolescents CD4 ≥ 200 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
2931281|NCT03031899|Experimental|Rose Bengal positive lesion|Lesions that were stained positive with rose bengal were biopsied and assessed for dysplasia
2931282|NCT03031899|Active Comparator|toluidine blue positive lesions and biopsy|Lesions that were stained positive with toluidine blue were biopsied and assessed for dysplasia
2931283|NCT03031886|Experimental|high GI|Cereal, milk, tea, cheese, steamed glutinous rice with chicken, carrots, bread, strawberry jam, margarine, high GI sweetener (sucrose).
2931284|NCT03031886|Experimental|Low GI|Cereal, milk, tea, steamed basmati rice with chicken, spinach, bread, strawberry jam, low GI sweetener (isomaltulose).
2931285|NCT03031873|Other|MRI perfusion imaging|"SWAN imaging on the GE 3 T has been attempted but the preliminary evidence suggest that the images are of low resolution and difficult to interpret. Similarly, early experience with TRMRA suggest poor spatial and temporal resolution using the standard out-of-the-box protocols.~Thus, there is a significant opportunity to improve SWAN and TRMRA, to evaluate the evolution of progressive obliteration of the AVM nidus. Specifically, this is attractive for brain AVMs that are treated with radiosurgery as MRI is required for clinical grounds for treatment planning purposes."
2931286|NCT03031847|Other|Pacemaker|Cardiac resynchronization therapy Pacemaker
2931287|NCT03031847|Other|Defibrillator|Cardiac resynchronization therapy Defibrillator
2931288|NCT03031821|Experimental|Metformin|Metformin 850 mg PO BID X 18 months
2931289|NCT03031821|Placebo Comparator|Placebo|"Placebo Oral Tablet~1 tablet PO BID X 18 months"
2931290|NCT03031808|Other|Lidocaine spray|Endotracheal lidocaine spray prior to intubation
2931291|NCT03031808|Other|Muscle relaxant|Muscle relaxant prior to intubation
2931292|NCT03031808|Other|No Muscle relaxant, no Lidocaine|'No Muscle relaxant, no Lidocaine Control group
2931293|NCT03031795|Experimental|experimental|ketorolac, oral, 20 mg, 1 dose, 45 minutes prior to IUD placement
2931294|NCT03031795|Placebo Comparator|placebo|look alike placebo
2931295|NCT03031782|Experimental|Treatment Period 2 - active|secukinumab (AIN457 - pre-filled syringe) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
2931296|NCT03031782|Placebo Comparator|Treatment Period 2 - placebo|Placebo comparator (matched to secukinumab treatment) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
2931297|NCT03031756|Experimental|test|SRP was performed using routine ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) and hand instrumentation, glycine powder air-polishing (GPAP) was performed for 10 seconds per surface after the instrumentation (Air-Flows Perio Powder, EMS, Nyon, Switzerland) was applied using a Perio-Flows hand-piece connected to an airflow unit (Air-Flow Masters, EMS).
2931298|NCT03031756|Active Comparator|control|In the control group, SRP was performed using routine ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) and hand instrumentation.
2931299|NCT03031743||rotavirus (Rotarix TM) vaccination|Infants who received rotavirus vaccination (Rotarix TM) at 6 and 10 weeks, 10 and 14 weeks or 6,10, and 14 weeks. This is a nested study and infants received the vaccination in the overarching study: The Immunogenicity of ROtavirus Vaccine Under Different Age Schedules and the Impact of Withholding Breast Feeding around the Time of Vaccination on the Immunogenicity of Rotarix Vaccine (clinicaltrials.gov: NCT01199874)
2931300|NCT03031730|Experimental|Treatment (AMG 232, carfilzomib, lenalidomide, dexamethasone)|Patients receive MDM2 inhibitor AMG-232 PO QD on days 1-7, carfilzomib IV over 10-30 minutes on days 1-2, 8-9, and 15-16 of courses 1-12 and on days 1-2 and 15-16 of courses 13-18, lenalidomide PO on days 1-21, and dexamethasone PO or IV on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unexpected toxicity.
2931301|NCT03031704||Endoscopic mucosectomy|
2931302|NCT03031691|Experimental|Brontictuzumab and trifluridine/tipiracil|Brontictuzumab will be administered per protocol and trifluridine/tipiracil per label.
2931303|NCT03031678|Other|Study procedures|
2931304|NCT03031665||Current MDD|Subjects experiencing a current episode of Major Depressive Disorder.
2931309|NCT03031639||Conventional|This group is the patients who underwent conventional approach thyroidectomy
2931314|NCT03031600|Active Comparator|Radiodilution via Daxor BVA-100|In study arm 1, actual blood volume will be measured using the Daxor Blood Volume Analyzer-100 (BVA-100). In this technique, the subject is injected with 1 ml of human serum albumin labeled with iodine131 (25 microcuries). A small amount of blood is collected from the subject just before injection and at 12, 18, 24, 30, and 36 min after injection.
2931315|NCT03031600|Experimental|Hemodilution via hematocrit measurement|In study arm 2, estimated blood volume will measured via hemodilution. . A blood sample (5 ml) will be drawn for baseline determination of hematocrit via iSTAT and lab measurement from the non-dominant arm. After the baseline hematocrit blood sample is drawn, a volume of normal saline equivalent to 10% of the subject's ideal blood volume will be administered over a 12-minute period through the dominant arm IV catheter. Twelve minutes after the infusion is complete, a second blood sample (5 ml) will be drawn from the non-dominant arm for determination of post-bolus hematocrit via iSTAT and lab. Subjects will then be asked to void into a urinal, and urine output will be measured in ml.
2931316|NCT03031587|Experimental|MRI examination|Each patient coming to the hospital for cardiac MRI examination can participate to the study if he/she meets the eligibility criteria
2931317|NCT03031574|Active Comparator|Food Effect|SUVN-D4010 tablets single dose
2931318|NCT03031574|Active Comparator|Gender Effect|SUVN-D4010 tablets single dose
2931319|NCT03031574|Active Comparator|Age Effect|SUVN-D4010 tablets single dose
2931320|NCT03031561|Experimental|Diagnostic (standard ultrasound, MicroPure, biopsy)|Patients undergo grayscale and MicroPure ultrasound imaging followed by sonographic or stereotactic guided core needle biopsy or surgical resection. Surgical specimens are then x-rayed.
2931321|NCT03031548||ultrasound exam|Child undergoing procedure in CVL requiring ETT and point-of-care ultrasound exam
2931322|NCT03031548||Chest X-ray|Child undergoing procedure in CVL requiring and ETT and CXR by fluoroscopy
2931323|NCT03031535|Experimental|Study Part 1 - Arm 1|Day 1 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 7 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms.
2931324|NCT03031535|Experimental|Study Part 1 - Arm 2|Day 1 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 5 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 2000 micrograms.
2931325|NCT03031535|Experimental|Study Part 1 - Arm 3|Day 1 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 3 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 1200 micrograms.
2931326|NCT03031535|Experimental|Study Part 1 - Arm 4|Day 1 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 400 micrograms.
2931327|NCT03031535|Experimental|Study Part 2 - Arm 1|Day 1 - 1 microgram/kilogram of growth hormone-releasing hormone (GHRH) + 30 grams arginine hydrochloride; Day 3 - Intranasal octreotide acetate (DP1038) - dose to be determined from Study Part 1 PK results + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 5 - SC octreotide acetate (Sandostatin Injection) 100 micrograms + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride.
2931328|NCT03031535|Experimental|Study Part 2 - Arm 2|Day 1 - 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 3 - SC octreotide acetate (Sandostatin Injection) 100 micrograms + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 5 - Intranasal octreotide acetate (DP1038) - dose to be determined from Study Part 1 PK results + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride.
2931329|NCT03031522|Experimental|18F-IRS : EGFR+ Patients|Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study.
2931330|NCT03031522|Experimental|18F-IRS :post-TKI EGFR+ Patients|Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study .
2931331|NCT03031522|Experimental|18F-IRS:post-chemo EGFR+|18F-IRS:post-chemo EGFR+ Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study.
2931332|NCT03031522|Experimental|18F-IRS:EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
2931333|NCT03031522|Experimental|18F-IRS:post-chemo EGFR wild type|Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study.
2931334|NCT03031522|Experimental|18F-IRS:unknown EGFR mutational status|Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group
2931335|NCT03031509|Experimental|hAECs treatment|Human Amniotic Epithelial Cells of 50 million transplant to nonunion site after debridement surgery
2931336|NCT03031509|Sham Comparator|debridement surgery|debridement surgery
2931337|NCT03031496|Experimental|Test A followed by Ref B of HCTZ 50mg+ Amiloride HCl 5mg|Eligible participants following an overnight fast of at least 10 hours, will be administered the study drug orally with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
2931338|NCT03031496|Experimental|Ref B followed by test A of HCTZ 50mg + Amiloride HCl 5mg|Eligible participants following an overnight fast of at least 10 hours, will be administered the study drug orally with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
2931339|NCT03031483|Experimental|Experimental: clarithromycin and lenalidomide|CLARITHROMYCIN: daily orally administration in cycles of 28 days; 500mg film-coated tablets LENALIDOMIDE: every cycle of treatment lasts 28 days; daily orally administration is of 21 consecutive days with a week of rest. 20mg capsule hard. The maximum treatment duration is 12 months.
2931340|NCT03031470|Experimental|Reparixin|Reparixin 2.772 mg/kg/hour 168 hrs continuous intravenous infusion
2931341|NCT03031470|Other|Standard Care Procedures|No treatment; standard care procedure
2931342|NCT03031457||1|Patients undergo primary fascial closure of abdominal donor-site
2931422|NCT03030976|Experimental|Reduce B cells|Patients receive cyclophosphamide to reduce B cells before CD19-CART infusion. It will also reduce the side effects of cell damage due to antitumor activity.
2931343|NCT03031444|Active Comparator|chemotherapy plus cetuximab|Cetuximab plus FOLFIRI/FOLFOX:FOLFIRI plus cetuximab [Irinotecan 180 mg/m2 IV over 30-90 minutes, day 1;Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion, day 1;5-fluoruracil(5-FU) 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion.Repeat every 2 weeks.Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks] or FOLFOX plus Cetuximab [Oxaliplatin 85 mg/m2 IV over 2 hours, day 1 Leucovorin 400 mg/m2 IV over 2 hours, day 1 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks;Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks]
2931344|NCT03031444|Active Comparator|perioperative chemotherapy alone|FOLFIRI/FOLFOX/CapeOX:routine perioperative chemotherapy including FOLFIRI[Irinotecan 180 mg/m2 IV over 30-90 minutes, day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion, day 1 5-FU 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks] or FOLFOX[Oxaliplatin 85 mg/m2 IV over 2 hours, day 1;Leucovorin 400 mg/m2 IV over 2 hours, day 1 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks] or CapeOX[Oxaliplatin 130 mg/m2 IV over 2 hours, day 1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks] was adopted in this control arm.
2931345|NCT03031431|Experimental|Non-Electric Infant Warmer|In line with current recommended practice, mothers will be encouraged to provide Kangaroo Mother Care (KMC) whenever possible. If an infant's temp is not rising by ½ degree C per hour with KMC alone, the infant warmer will be offered as an addition by the study team. If the mother is not available for KMC at any time, the infant will be warmed exclusively with the warmer. Bundling in clothes will only be used in addition to the warmer per carer preference. Temp measurement of the infant, warmer, and ambient air will be measured every 15 mins for the first hr, then hrly and as needed for the remainder of use or until warmer endpoint is reached (warmer temp below 36 degrees or phase-change material hardens [soft, semisoft, or hardened]).
2931346|NCT03031418||Cohort 1|Enroll up to 500 patients to confirm performance of ExoDx Prostate IntelliScore (EPI) for men scheduled for initial biopsy. The treating physician will collect a urine sample from from a consented subject to test before their scheduled prostate biopsy (during your established clinic visit).
2931347|NCT03031418||Cohort 2|Enroll up to 500 patients to evaluate how the results of the urine test influences the decision process for determining whether to perform a prostate biopsy. The treating physician will collect a urine sample for testing and 2 weeks later discuss whether to perform a prostate biopsy with the subject knowing the results of the urine test and comparing them to the overall consensus report from Cohort 1 as well as other clinical factors the treating physician would otherwise use to determine whether they should have a prostate biopsy.
2931348|NCT03031405|Experimental|Oxytocin and trauma film paradigm|
2931349|NCT03031405|Placebo Comparator|Placebo and trauma film paradigm|
2931350|NCT03031392||Peri-implantitis|Individuals with implants ≥2mm of radiographic bone loss
2931351|NCT03031392||non-peri-implantitis patients|Individuals with implants <2mm of radiographic bone loss
2931352|NCT03031379|No Intervention|A - control|standard fast, at least 6 hours prior to tracheotomy
2931353|NCT03031379|Experimental|B - shortened fast|fast of only 45 minutes prior to incision
2931354|NCT03031366|Experimental|3D roadmap|TIPS was established using 3d roadmap guidance
2931355|NCT03031366|Active Comparator|conventional TIPS|conventional TIPS procedure using wedged hepatic venography
2931356|NCT03031353|Experimental|Misoprostol|After preparing for elective caesarean section, the pessary will be given containing the misoprostol medication 1 hour before , women in the operating room, and the anaesthetic and surgical techniques will be standardized
2931357|NCT03031353|Active Comparator|Placebo|After preparing for elective caesarean section, the pessary will be given containing placebo 1 hour before , women in the operating room, and the anaesthetic and surgical techniques will be standardized
2931358|NCT03031340|Placebo Comparator|Placebo|
2931359|NCT03031340|Experimental|Pregabalin|
2931360|NCT03031327|Experimental|Lubricin 20µg/ml eye drops|Lubricin 20µg/ml eye drops 3 times per day
2931361|NCT03031327|Experimental|Lubricin 50µg/ml eye drops|Lubricin 50µg/ml eye drops 3 times per day
2931362|NCT03031327|Active Comparator|Sodium hyaluronate (HA) 0.18% eye drops|Sodium hyaluronate (HA) 0.18% eye drops 3 times per day
2931363|NCT03031314|Active Comparator|Standard suture|standard suture used (monocryl)
2931364|NCT03031314|Active Comparator|Barbed suture|barbed suture used (Quill suture, Surgical Specialties)
2931365|NCT03031301|Active Comparator|Vibrant capsule|Patients will receive the Vibrant capsule 5 times a week for 8 weeks of treatment
2931366|NCT03031301|Sham Comparator|Sham capsule|Patients will receive the sham capsule (activated, non-vibrating) 5 times a week for 8 weeks of treatment
2931367|NCT03031288|Experimental|"Start feeding with Device A, standard"|Alternatively feeding with standard feeding bottle (Device A) and vented base feeding bottle (Device B)
2931368|NCT03031288|Experimental|"Start feeding with Device B, vented"|Alternatively feeding with vented base feeding bottle (Device B) and standard feeding bottle (Device A)
2931369|NCT03031262|Active Comparator|High Dose of Cytarabine|CBF Patients who reach CR after reduction therapy receive high dose of cytarabine.
2931370|NCT03031262|Experimental|HDAC + Chidamide|CBF Patients who reach CR after reduction therapy receive high dose of cytarabine plus chidamide.
2931371|NCT03031249|Active Comparator|High Dose of Cytarabine|Patients receive high dose of cytarabine.
2931372|NCT03031249|Experimental|HDAC + ATRA + ATO|Patients receive high dose of cytarabine plus ATRA and ATO treatment.
2931373|NCT03031236|Active Comparator|ECD+|Behavioral: Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
2931374|NCT03031236|No Intervention|Only regular health messages|Only regular health message from government health services
2931425|NCT03030963|Active Comparator|Control group|ventilator inspiration to expiration ratio will be set 1:2.
2931375|NCT03031223|Experimental|low-level laser therapy|"The treatment group will receive LLLT following the protocol outlined below:~LLLT protocol - radiance will be administered to the injury site transcutaneously at a wavelength of 808 nm using a Twin Flex Evolution diode laser (MMO Equipamento Opto-Eletronicos, Brazil). Twelve sessions will be held (three per week over four weeks). The dose administered to the surface of the skin will be 983 J/cm2 per session, with a treatment area of 4.72 W/cm² and total radiant energy of 25 J. According to the literature, this dose is capable of enhancing functional recovery following an injury."
2931376|NCT03031223|Placebo Comparator|placebo|laser therapy is applied at low intensity without emitting radiation.
2931377|NCT03031210|Experimental|Twice a day regimen|Patients will received a prescription of amoxicillin (90mg/kg/day) divided in two doses daily.
2931378|NCT03031210|Active Comparator|Thrice a day regimen|Patients will received a prescription of amoxicillin (90mg/kg/day) divided in three doses daily.
2931379|NCT03031197|Experimental|Tailored realtime triggered reminder pkg|The core intervention will utilize innovative wireless technology to provide patients with 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. The core intervention will be personalized by each intervention arm patient, who may choose features to suit their preferences.
2931380|NCT03031197|No Intervention|Control|Comparison subjects will receive usual care and an offer of counseling at monthly clinic visits.
2931381|NCT03031184|Experimental|Mirtazapine|15mg of Mirtazapine over encapsulated to produce a blinded product that looks identical to the other arms. Starting dose is one capsule per day, escalating to 2 capsules per day after 2 weeks if no side effects and up to 3 capsules per day after 4 weeks.
2931382|NCT03031184|Experimental|Carbamazepine|100mg of extended release Carbamazepine over encapsulated to produce a blinded product that looks identical to the other arms. Starting dose is one capsule per day, escalating to 2 capsules per day after 2 weeks if no side effects and up to 3 capsules per day after 4 weeks.
2931383|NCT03031184|Placebo Comparator|Placebo|Lactose powder encapsulated to produce a blinded product that looks identical to the other arms. Starting dose is one capsule per day, escalating to 2 capsules per day after 2 weeks if no side effects and up to 3 capsules per day after 4 weeks.
2931384|NCT03031171|Experimental|Navigated: Screening patient navigation|Clinic patients who received navigation
2931385|NCT03031171|Active Comparator|Non-Navigated|Randomly matched sample of non-navigated clinic patients
2931386|NCT03031158|Experimental|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles.
2931387|NCT03031158|Active Comparator|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles.
2931388|NCT03031145|Active Comparator|Felis Domesticus treated Non-smoker|
2931389|NCT03031145|Active Comparator|Felis Domesticus treated E-cigarette smoker|
2931390|NCT03031145|Active Comparator|Felis Domesticus treated Cigarette smoker|
2931391|NCT03031132|Experimental|HP-Beverage Breakfast|For 7 days, the participants will consume high protein beverage breakfast meals each morning. These meals will consist of shakes and will be 350 kcal. The macronutrient composition of these meals will contain 30 g of dietary protein, 35g CHO, and 10g fat. The HP-S and HP-B meals will be matched for energy density, sugar content, macronutrient content and types of proteins.
2931392|NCT03031132|Experimental|HP-Solid Breakfast|For 7 days, the participants will consume high protein solid breakfast meals each morning. These meals will consist of traditional solid breakfast meals and will include commonly consumed breakfast foods (e.g., burritos, waffles, etc.) and will be 350 kcal. The macronutrient composition of these meals will contain 30 g of dietary protein, 35 g CHO, and 10 g fat. The HP-S and HP-B meals will be matched for energy density, sugar content, macronutrient content and types of proteins.
2931393|NCT03031132|Experimental|Breakfast Skipping|For 7 days, the participants will skip the morning meal. No food or calorie-containing beverages will be consumed before 12pm on acclimation days and no food consumed until ~5h post habitual breakfast time on testing day 7.
2931394|NCT03031119|Placebo Comparator|Placebo|Tablets administered once or twice daily, with food, in Part A for 14 days.
2931395|NCT03031119|Experimental|PF-06835919|Tablets administered once or twice daily, with food, in Part A for 14 days. Tablets administered once or twice daily, for 4 days at a low dose and for 4 days at a higher dose, with food and atorvastatin in Part B.
2931396|NCT03031119|Experimental|atorvastatin|In Part B, tablets administered once or twice daily, with food, with and without a low dose of PF-06835919 for 4 days and a higher dose of PF-06835919 for 4 days.
2931397|NCT03031093|Experimental|Healthy, non obese + HFNC|Healthy, non obese participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
2931398|NCT03031093|Active Comparator|Healthy, non obese|Healthy, non obese participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
2931423|NCT03030976|Experimental|Treatment of SLE|Patients receive anti-CD19-CAR-T cells to treatment of SLE. The purpose of this study is to assess the safety and efficacy of CD19 CAR-T cells in the treatment of SLE.
2931399|NCT03031093|Experimental|COPD, non obese + HFNC|non obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
2931400|NCT03031093|Active Comparator|COPD, non obese|non obese COPD participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
2931401|NCT03031093|Experimental|healthy, obese + HFNC|Healthy obese participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
2931402|NCT03031093|Active Comparator|healthy, obese|Healthy obese participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
2931403|NCT03031093|Experimental|COPD, obese + HFNC|Obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
2931404|NCT03031093|Active Comparator|COPD, obese|Obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
2931405|NCT03031080|Active Comparator|Splinted|Patients will be given Thermoplastic Hand Splint to wear overnight for 12 weeks.
2931406|NCT03031080|No Intervention|Un-Splinted|Patients will not wear a night splint
2931407|NCT03031067|Experimental|Machine perfusion - Kidney|The marginal kidney will be perfused with oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion.
2931408|NCT03031067|No Intervention|Static cold storage - Kidney|The marginal kidney that was stored to cold (SCS), previously.
2931409|NCT03031067|Experimental|Machine perfusion - Liver|The marginal liver will be perfused with oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion.
2931410|NCT03031067|No Intervention|Static cold storage - Liver|The marginal liver that was stored to cold (SCS), previously.
2931411|NCT03031054|Experimental|hyaluronic acid hydrodissection|Ultrasound-guided hydrodissection with 2.5cc hyaluronic acid between carpal tunnel and median nerve.
2931412|NCT03031054|Active Comparator|Normal saline hydrodissection|Ultrasound-guided hydrodissection with 2.5cc normal saline between carpal tunnel and median nerve.
2931413|NCT03031041|Experimental|Short-axis hydrodissection|Ultrasound-guided short-axis hydrodissection with normal saline between carpal tunnel and median nerve
2931414|NCT03031041|Active Comparator|Long-axis hydrodissection|Ultrasound-guided long-axis hydrodissection with normal saline between carpal tunnel and median nerve
2931415|NCT03031028|Other|ketogenic diet|Ketogenic diet
2931416|NCT03031015|Experimental|Cemented K-wire Fixation|The mean age of group A was 41 years (range, 18-63 years). There were 56 male and 11 female patients. The mean time from injury to operation was 5±4.53 days. Injured digits included index (n=24), long (n=19), ring (n=9), and little (n=15) fingers. Types of fractures were transversal (n=31), oblique or spiral (n=14), and comminuted (n=22) fractures. The patients were treated with Cemented K-wire Fixation.
2931417|NCT03031015|Active Comparator|Plating|The mean age of group A was 39 years (range, 19-61 years). There were 51 male and 13 female patients. The mean time from injury to operation was 6±5.53 days. Injured digits included index (n=21), long (n=17), ring (n=10), and little (n=16) fingers. Types of fractures were transversal (n=34), oblique or spiral (n=11), and comminuted (n=19) fractures.The patients were treated with Plating.
2931418|NCT03031002|Experimental|Exposure Treatment|Participants of this arm receive two 60-minute sessions of exposure treatment for spider fear
2931419|NCT03031002|No Intervention|No Exposure Treatment|Participants of this arm receive no exposure or other adequate treatment
2931420|NCT03030989|Active Comparator|Chlorhexidine Gluconate 2% Wipe|
2931421|NCT03030989|Placebo Comparator|Placebo wipe|
2931426|NCT03030950|Experimental|Dexmedetomidine group|Adductor canal block will be performed before induction of general anesthesia. Patients will be positioned in the supine position with knee slightly flexed and leg externally rotated followed by ultrasound scanning of the middle of thigh using 13-6 MHz linear array probe. The ultrasound probe will be placed over the anterior aspect of the patient's thigh, mid-point between the inguinal crease and medial femoral condyle. The scan will be focused on the femoral artery pulsations aiming to try to visualize the nerves in the adductor canal on both sides (lateral and medial) of the pulsating femoral artery. 20 ml bupivacaine 0.25% combined with 75 mcg dexmedetomidine will be injected. The study solution will be injected underneath the fascia of sartorius muscle.
2931427|NCT03030950|Placebo Comparator|Control group|Adductor canal block will be performed before induction of general anesthesia. Patients will be positioned in the supine position with knee slightly flexed and leg externally rotated followed by ultrasound scanning of the middle of thigh using 13-6 MHz linear array probe. The ultrasound probe will be placed over the anterior aspect of the patient's thigh, mid-point between the inguinal crease and medial femoral condyle. The scan will be focused on the femoral artery pulsations aiming to try to visualize the nerves in the adductor canal on both sides (lateral and medial) of the pulsating femoral artery. 20 ml bupivacaine 0.25% combined with 75 mcg dexmedetomidine will be injected. The study solution will be injected underneath the fascia of sartorius muscle.
2931428|NCT03030937|Experimental|Irinotecan plus apatinib|"Irinotecan:160mg/m2, ivgtt,given on the eighth day; Apatinib:initial dose:250mg,oral,once a day, after meal ( try to take the medicine at the same time of the dauntoy ).~Repeat the therapeutic schedule every 2 weeks till progressive disease or intolerable toxicities."
2931429|NCT03030937|Active Comparator|Irinotecan|Irinotecan:180mg/m2, ivgtt,given on the eighth day. Repeat the therapeutic schedule every 2 weeks till progressive disease or intolerable toxicities.
2931430|NCT03030911|Active Comparator|Dexmedetomidine group|"Patients will receive analgesia with fentanyl at a ﬁxed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug.~Group I patients will have dexmedetomidine (0.075 µg.kg-1.mL-1). Dexmedetomidine infusion will be started at 0.15 µg.kg-1.hr-1 (2 mL.hr-1) and will be adjusted by 0.15 µg.kg-1.h-1 increments to a maximum of 0.75 µg/kg/h (10 ml.h-1)~Intervention: indirect calorimetry"
2931431|NCT03030911|Placebo Comparator|midazolam group|"Patients will receive analgesia with fentanyl at a ﬁxed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug.~Group II patients will have midazolam (0.5 mg.mL-1). Midazolam will be started at 1 mg.h-1 (2 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (10 mL.h-1). All infusions will be adjusted by increments of 2 mL.hr-1 to maintain blinding. Patients in either group not adequately sedated by the maximum infusion rate of the study medication will receive a bolus dose of fentanyl 0.5 µg.kg-1.~Intervention: indirect calorimetry"
2931432|NCT03030898|Other|respiratory variation of the right internal jugular vein|
2931433|NCT03030885|Experimental|131I-MIP-1095|"FirstTherapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose.~2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53"
2931434|NCT03030872||Predicate and Investigational|"Compare the diagnostic value of MR DSC-Perfusion (Perfusion Module), MR DWI (Diffusion Module) and MR DTI (Diffusion Module) in CARESTREAM Vue PACS (investigational device) to the Olea Sphere PACS with Perfusion and DWI Modules (predicate device)."
2931435|NCT03030859|Experimental|Group I (Usual Care)|Patients receive monthly automated system telephone call for 12 months.
2931436|NCT03030859|Experimental|Group II (Usual Care plus LEF-SCP)|Patients undergo LEF-SCP training comprising of MI session over 1 hour and LEF self-care training session over 1 hour weekly for 3 weeks. Patients receive monthly automated system telephone call for 12 months. Patients also review LEF self-care educational manual and watch self-care videos monthly or more frequently as needed.
2931437|NCT03030859|Experimental|Group III (Usual Care plus LEF-SCP plus Follow-Up)|Patients undergo LEF-SCP training comprising of MI session over 1 hour and LEF self-care training session over 1 hour weekly for 3 weeks. Patients receive monthly automated system telephone call for 12 months. Patients review LEF self-care educational manual and watch self-care videos monthly or more frequently as needed. Patients also meet with the study lymphedema therapist over 1 hour at 3, 6, and 9 months.
2931438|NCT03030846|Experimental|stabilization exercises|stabilization exercises for 6 weeks, 3 sessions per week and each session was 40 minutes for the training group.
2931439|NCT03030846|Experimental|control group|electrotherapy include of 20 minutes TENS conventional and Ultrasound pulse for 10 minutes without any exercises for the control group.
2931440|NCT03030820|Experimental|Dental cleaning|Patients with cirrhosis and healthy controls will undergo dental examination and subsequent dental cleaning if necessary.
2931441|NCT03030794|Active Comparator|Repetitive TMS|Subjects will receive the repetitive transcranial magnetic stimulation study procedure.
2931442|NCT03030794|Placebo Comparator|No (blocked) repetitive TMS|Subjects will not receive the repetitive transcranial magnetic stimulation study procedure by blocking the stimulation between the coil and the head, but the audiovisual conditions will be mimicked.
2931443|NCT03030768||HIV-1 serodiscordant couples|Couples where one partner is HIV-1 infected and the other is uninfected, who will receive counseling on timed condomless sex, ART and PrEP adherence. The study intervention focuses on ART use by the HIV-1 infected partner, PrEP (Truvada) use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
2931444|NCT03030742||Post-cesarean delivery|Women who have undergone cesarean delivery
2931445|NCT03030742||Post-vaginal delivery|Women who have undergone vaginal delivery
2931446|NCT03030729||Intermediate AMD|
2931447|NCT03030729||Advanced AMD|
2931448|NCT03030729||DR without macular edema|
2931449|NCT03030729||DR with macular edema|
2931450|NCT03030716|Experimental|0.03 mg 95% condensed proanthocyanidin|0.03 g 95% condensed proanthocyanidins from grape seed extract at week 0 0.03 g 95% condensed proanthocyanidins from grape seed extract at week 4
2931451|NCT03030716|Experimental|0.25 g 95% condensed proanthocyanidin|0.25 g 95% condensed proanthocyanidins from grape seed extract at week 0 0.25 g 95% condensed proanthocyanidins from grape seed extract at week 4
2931452|NCT03030716|Experimental|1.5 g 95% condensed proanthocyanidin|1.5 g 95% condensed proanthocyanidins from grape seed extract at week 0 1.5 g 95% condensed proanthocyanidins from grape seed extract at week 4
2931453|NCT03030703|Experimental|350 mg phytic acid|350 mg phytic acid (inositol hexaphosphate) at week 0 (before supplementation) and at week 4 (after supplementation)
2931454|NCT03030690|Experimental|Glass Carbomer Cement|GCP Glass Fill, Glass Carbomer™Tech, Ridderkerk, Netherlands
2931455|NCT03030690|Active Comparator|Resin Modified Glass Ionomer Cement|GC Fuji II LC Capsule, GC International, Tokyo, Japan
2931456|NCT03030690|Active Comparator|Composite Resin|Filtek Z250, 3M ESPE, St Paul, MN, USA
2931457|NCT03030677|Experimental|Interventional Without Lidocaine Dissectioin|confirming insertion of B Braun Catheter Kit Contiplex with 18 Gauge needle using ultrasound without injecting 10 ml of lidocaine 1% as a dissecting solution
2931458|NCT03030677|Experimental|Interventional With Lidocaine Dissectioin|confirming insertion of B Braun Catheter Kit Contiplex with 18 Gauge needle using ultrasound after injecting 10 ml of lidocaine 1% as a dissecting solution
2931459|NCT03030664|Active Comparator|L.reuteri|probiotics: L.reuteri produced by Biogaia 5 drops per day: 10exp(8) colony forming unit will be delivered
2931460|NCT03030664|Placebo Comparator|Placebo|Same formulation as probiotics, without active substance. 5 drops per day will be delivered
2931461|NCT03030651|Experimental|Breastfeeding Education and Support|Pregnant women in the intervention arm will receive breastfeeding education and support intervention for nine months starting in their third trimester
2931462|NCT03030651|No Intervention|Usual or routine care|Pregnant women in the intervention arm will continue to receive the usual/routine care.
2931463|NCT03030638||Olodaterol|Patients initiating Olodaterol for the first time
2931464|NCT03030638||Indacaterol|Patients initiating Indacaterol for the first time
2931465|NCT03030625|Other|IGRT/VMAT focal therapy boost to DIL|Localized prostate cancer (PCa) of intermediate and high risk according to NCCN criteria
2931466|NCT03030612|Experimental|ARGX-110 with AZA|"Phase I:~ARGX-110: 1 mg/kg body weight IV (cohort 1), 3 mg/kg body weight IV (cohort 2), 10 mg/kg body weight IV (cohort 3) or 20 mg/kg body weight IV (cohort 4) in combination with~AZA standard dose of 75 mg/m² BSA , administered SC~Phase 2:~ARGX-110: selected dose from Phase I, IV, in combination with~AZA standard dose of 75 mg/m² BSA , administered SC"
2931467|NCT03030599|Placebo Comparator|Placebo|Placebo
2931468|NCT03030599|Experimental|JZP-258|JZP-258
2931469|NCT03030586||Alzheimer|400 patients in total, with approximately 200 patients with mild Alzheimer's disease and 200 patients with moderate to severe Alzheimer's disease will be recruited for sampling blood, urine (and other peripheral body fluids: tears and saliva as optional) for validation of biomarkers
2931470|NCT03030586||Non-Alzheimer neurodegenerative disease|"200 patients comprising:~75 patients with behavioural variant of Fronto-Temporal Lobe Degeneration (FTD),~50 patients with Parkinson's disease dementia (PDD),~50 patients with Dementia with Lewy Bodies (DLB) and~25 patients with Progressive Supranuclear Palsy (PSP) or cortico-basal degeneration (CBD)"
2931471|NCT03030586||Healthy Controls|200 healthy subjects
2931472|NCT03030573|Other|Device: Round ligament and the bile duct|The investigators describe the safety and efficacy of the reconstruction of the bile duct with the Round ligament.
2931473|NCT03030560|Active Comparator|Lidocaine group|Patients will receive lidocaine infusion.
2931474|NCT03030560|Placebo Comparator|Control group|Patients will receive 0.9% Sodium-chloride infusion infusion
2931475|NCT03030547|Experimental|Muscle Disease Group|Adult patients with muscle diseases diagnosed by neurologist, will wear SenseWear activity monitor for 5 days
2931476|NCT03030547|Active Comparator|Healthy Individuals Group|Healthy individuals with similar demographic characteristics as adult patients with muscle diseases, will wear SenseWear activity monitor for 5 days
2931477|NCT03030534|Experimental|Experimental Group|Educational Package and software package
2931478|NCT03030534|Active Comparator|Control group|Health promotion tips
2931479|NCT03030521||experimental group|In this group, the specimen of aortic wall is bound by a band to restrict its dilation in the fourth step of the aortic delamination test.
2931480|NCT03030521||control group|In this group, the specimen of aortic wall is not bound by a band to restrict its dilation in the fourth step of the aortic delamination test.
2931481|NCT03030508||Group cap|Patients receiving capecitabine chemotherapy after operation
2931482|NCT03030495||Overt microvascular disease|Fractional flow reserve>0.80, coronary flow reserve<2 & Index of microvascular resistance>25U
2931483|NCT03030495||No Overt microvascular disease|Fractional flow reserve>0.80, coronary flow reserve>2 & Index of microvascular resistance<25U
2931484|NCT03030482|Experimental|Touch massage|Patients will have a touch massage session during 30 minutes the intervention will take place remotely (1 h) of all events that can generate anxiety
2931485|NCT03030482|No Intervention|control|standard care ICU
2931486|NCT03030469|Experimental|10-pill default|"The intervention condition consists of a change to the electronic health record so that new opioid analgesic prescriptions automatically default to 10 pills (i.e., the quantity dispensed field is pre-populated). This value is modifiable by providers who can tailor the prescription based on clinical factors."
2931487|NCT03030469|Experimental|5-pill default|New opioid analgesic prescriptions will automatically default to 5 pills.
2931488|NCT03030469|No Intervention|Standard of care|The control condition will be the usual electronic health record interface. The default number of pills varies by medication, most medications currently have either a blank default or a default of 30 pills.
2931489|NCT03030456|No Intervention|Control Group|Elderly women receiving a list of general health orientations through an 8 week period
2931490|NCT03030456|Experimental|Power Plate®|Power Plate®: training of elderly women
2931519|NCT03030209||Distal Pancreatectomy|Patients undergoing distal pancreatectomy
2931520|NCT03030196|Active Comparator|Denosumab|subcutaneous injection with 60 mg Denosumab once
2931521|NCT03030196|Placebo Comparator|Placebo|subcutaneous injection with NaCl once
2931491|NCT03030443||Oral Sedation|"Patients in this group will receive a standard procedure first trimester abortion using oral sedation for pain management following the clinic's protocol.~Patients in both groups will be administered a Visual Analog Scale (VAS) assessing pain on an unmarked 100mm VAS scale with anchors at 0mm (left) being no pain and 100mm (right) being pain as bad as it could be before their procedure and immediately following procedure completion."
2931492|NCT03030443||Nitrous Oxide|"Patients in this group will receive a standard procedure first trimester abortion using titrated nitrous oxide for pain management following the clinic's protocol.~Patients in both groups will be administered a Visual Analog Scale (VAS) assessing pain on an unmarked 100mm VAS scale with anchors at 0mm (left) being no pain and 100mm (right) being pain as bad as it could be before their procedure and immediately following procedure completion."
2931493|NCT03030430|Experimental|BAT1706|BAT1706 injection
2931494|NCT03030430|Active Comparator|EU-sourced Avastin|EU-sourced Avastin
2931495|NCT03030430|Active Comparator|US-sourced Avastin|US-sourced Avastin
2931496|NCT03030417|Experimental|Treatment Arm|LMP744 will be administered IV over 1 hour on days 1-5 of each 28-day cycle
2931497|NCT03030378|Experimental|Treatment (recombinant interleukin-12, pembrolizumab)|Patients receive recombinant interleukin-12 SC on days 2, 5, 9, and 12 and pembrolizumab IV over 30 minutes on day 8 of course 1 and day 1 of subsequent courses. Treatment continues for 28 days for course 1 and repeats every 21 days for subsequent courses for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients then receive recombinant interleukin-12 SC on days 2, 5, 9, and 12. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
2931498|NCT03030365||Healthy Controls|"Age matched controls for the various clinical groups will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi (millicurie) of 18F (fluorodeoxyglucose) -FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
2931499|NCT03030365||Amnestic Mild cognitive impaired|"Patients diagnosed with mild cognitive impairment, exhibiting impairment mostly in memory that is significant but does not interfere with everyday activities.~Subjects will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
2931500|NCT03030365||Alzheimer's disease patients|"Patients exhibiting significant loss of intellectual ability that interferes with everyday functioning that meet Alzheimer's pattern of decline, and following exclusion of alternative neurodegenerative, cerebrovascular, and metabolic etiologies.~Subjects will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
2931501|NCT03030352|Experimental|How-to Parenting Program|The How-to Parenting Program consists of seven 2 ½-hour weekly sessions. It is a manual-based program in which participants have their own exercise booklet containing parenting skills and exercises. Groups are led by 2 group leaders and formed of 6 to 10 parents.
2931502|NCT03030352|No Intervention|Wait-list Control Group|Parents assigned to the wait-list control group will receive no intervention for the duration of the trial. The How-to Parenting Program will be delivered to them the following year. This delayed participation is ethically sound, as the program does not target at-risk families.
2931503|NCT03030339||Group 1: High VA intake, recent VAS|Children who are exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake
2931504|NCT03030339||Group 2: High VA intake|Children who are exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
2931505|NCT03030339||Group 3: Low/adequate VA intake|Children who are not exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
2931506|NCT03030326|Experimental|Heart rate variability biofeedback|This group will receive treatment in the first three months of the study and will be observed during the second three months
2931507|NCT03030326|No Intervention|Observation first|This group will be observed during the first three months and given biofeedback during the second three months
2931508|NCT03030313|Experimental|Respiration rate monitoring|Reassure Non-Contact Respiration Monitor
2931509|NCT03030300|Experimental|Novolin 30R;Pioglitazone;Metformin|Drugs: Insulin (Novolin 30R) monotherapy or combined with one or two oral drugs (metformin 0.5 mg tid and pioglitazone hydrochloride 15 mg qd).
2931510|NCT03030287|Experimental|OMP-305B83 plus paclitaxel|
2931511|NCT03030274|Experimental|Occlutech AFR Device|
2931512|NCT03030261|Experimental|Elotuzumab + Pomalidomide + Dexamethasone + ASCT|"(4) 28-day cycles of Elo-Pom-Dex induction:~Elotuzumab on Days 1, 8, 15, and 22 for Cycles 1-2 and on Days 1 and 15 for Cycles 3-4~Pomalidomide daily on Days 1-21 of all cycles~Dexamethasone on Days 1, 8, 15, and 22 of all cycles~Following Elo-Pom-Dex induction, patients will undergo standard of care ASCT melphalan conditioning. Administration of melphalan and the second ASCT will be done as part of routine care and procedures are not dictated by this protocol.~Continuation therapy with Elo-Pom-Dex will begin between Days 80 and 120 following the second ASCT:~Elotuzumab on Days 1 and 15 for Cycles 1-6 followed by 20 mg/kg on Day 1 for Cycles 7+~Pomalidomide daily on Days 1-21 of all cycles~Dexamethasone on Days 1 and 15 of all cycles~Continuation therapy may continue until relapse or progression."
2931513|NCT03030248|Active Comparator|Vancomycin treated group|This group will be given vancomycin oral capsules, 125 mg, every 6 hours, for 14 days.
2931514|NCT03030248|Placebo Comparator|Placebo group|This group will be given placebo oral capsules every 6 hours for 14 days.
2931515|NCT03030235|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg oral tablet, once daily, for 12 weeks
2931516|NCT03030235|Placebo Comparator|Placebo|Dapagliflozin matching placebo oral tablet, once daily, for 12 weeks
2931517|NCT03030222|Active Comparator|Empagliflozin|Empagliflozin 10 mg tab, once daily, for 12 weeks
2931518|NCT03030222|Placebo Comparator|Placebo|Empagliflozin matching placebo oral tablet, once daily for 12 weeks
2931522|NCT03030183|Experimental|RA101495|Subjects will receive RA101495 at the dose of 0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
2931523|NCT03030170|Experimental|Experimental|Stapling of the pancreas with ENDO GIA Reinforced reload
2931524|NCT03030170|Active Comparator|Control|Stapling of the pancreas with ENDO GIA X-tra Thick reload
2931525|NCT03030157|Experimental|Long-term Intravesical Instillation of pirarubicin(THP)|A single instillation of pirarubicin (THP) plus one year long-term intravesical instillation after nephroureterectomy was performed. The ﬁrst instillation was initiated within 24 hours after surgery, followed by four times weekly and 11 times monthly (16 times in total in one year time) . Every time, THP 30 mg in 30 mL of normal saline was delivered into the bladder through a catheter and was retained for 30 minutes.
2931526|NCT03030157|Active Comparator|Single Intravesical Instillation of pirarubicin|A single intravesical instillation of THP after nephroureterectomy was performed. This instillation was initiated within 24 hours after surgery . THP 30 mg in 30 mL of normal saline was delivered into the bladder through a catheter and was retained for 30 minutes.
2931527|NCT03030144|No Intervention|Control group|Routine nursing care
2931528|NCT03030144|Other|Intervention group|Evidence based nursing recommendations for the management of urinary incontinence will be introduced.
2931529|NCT03030131|Experimental|Durvalumab|durvalumab 750 mg IV J1, J15, J29
2931530|NCT03030118|Active Comparator|Hydroxychloroquine|Hydroxychloroquine will be administered as a once daily dose of 200 or 400 mg, based on the patient's weight. Treatment will be for 96 weeks.
2931531|NCT03030118|Placebo Comparator|Placebo oral capsule|Placebo will be administered as one or two capsules as a single daily dose, based on the patient's weight. Treatment will be for 96 weeks.
2931532|NCT03030105|Placebo Comparator|A) P:P:P|Scopolamine placebo : BPN14770 placebo : Donepezil placebo
2931533|NCT03030105|Placebo Comparator|B) S:P:P|Scopolamine 0.5mg : BPN14770 placebo : Donepezil placebo
2931534|NCT03030105|Experimental|C) S:B:P|Scopolamine 0.5mg : BPN14770 10mg : Donepezil placebo
2931535|NCT03030105|Experimental|D) S:B:P|Scopolamine 0.5mg : BPN14770 50mg : Donepezil placebo
2931536|NCT03030105|Active Comparator|E) S:P:D|Scopolamine 0.5mg : BPN14770 placebo : Donepezil 10mg
2931537|NCT03030105|Experimental|F) S:B:D|Scopolamine 0.5mg : BPN14770 50mg : Donepezil 10mg
2931538|NCT03030092|No Intervention|Control group|Today's standard care
2931539|NCT03030092|Experimental|Intervention group|Maximal Strength Training
2931540|NCT03030079|Experimental|High intensity electrical stimulation|Explore the efficacy of an electrical stimulus regimen on the treatment of chronic phantom limb pain using a standard-of-care electrical stimulation system
2931541|NCT03030066|Experimental|Experimental Drug DS-1001b|Oral administration
2931542|NCT03030053|Experimental|Active|Cocoa-Flavanol Supplements: 3 capsules per day each containing 300mg (total dose of 900mg daily) for 24 weeks
2931543|NCT03030053|Placebo Comparator|Control|Control Supplements: 0mg cocoa-flavanols per day for 24 weeks
2931544|NCT03030040|Experimental|MBCT-SH|MBCT-SH will be an unguided, mindfulness-based cognitive therapy, book-based self-help intervention.
2931545|NCT03030040|No Intervention|Control|A wait list control group who will receive no intervention during the 21 weeks of the study. Control participants will be provided with the self-help book that the MBCT-SH group received after week 21.
2931546|NCT03030027|Experimental|Connecting Through Caregiving|This arm focuses on perspective-taking reappraisal procedures.
2931547|NCT03030027|Other|Basic Skills Building|This arm focuses on skill building.
2931548|NCT03030014|Experimental|educational programm|"Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.~Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children."
2931549|NCT03030014|Placebo Comparator|no educational programm|without educational program Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
2931550|NCT03030001|Experimental|PD-1 antibody expressing CAR-T cells|PD-1 antibody expressing mesothelin specific CAR-T cells
2931551|NCT03029988|Experimental|Cohort 1|Subjects will receive 50 µg tilmanocept radiolabeled with 2.0 mCi Tc99m through a single IV injection.
2931552|NCT03029988|Experimental|Cohort 2|Subjects will receive 200 µg tilmanocept radiolabeled with 2.0 mCi Tc99m through a single IV injection.
2931553|NCT03029975|Active Comparator|RDA|Participants will be asked to consume the RDA for protein for a 10 week period while also undergoing progressive resistance training exercise three times a week. Beef protein consumption will be emphasized and participants will consume a beef meal after each training session.
2931554|NCT03029975|Experimental|2x RDA|Participants will be asked to consume the twice the RDA for protein for a 10 week period while also undergoing progressive resistance training exercise three times a week. Beef protein will be emphasized and participants will consume a beef meal after each training session.
2931555|NCT03029962|Experimental|Experimental: Girl2Girl|Girl2Girl is a 7-week teenage pregnancy prevention program delivered daily via text messaging to 14-18 year old females who self-identify as lesbian, bisexual, gay, or other sexual minority. In addition to program content, participants are paired with another participant (i.e., a Text Buddy) with whom they can text throughout the program to provide support; and an on-demand advice line, Girl2Genie, which shares information about sex, relationships, and the lesbian, gay, bisexual, transgender (LGBT) community.
2931556|NCT03029962|No Intervention|No Intervention: Health Lifestyle|The attention-matched control arm message content consists of information publicly available online related to living a healthy lifestyle. Content discussed includes: nutrition and sleep hygiene, self-esteem and body image, bullying, and drugs and alcohol. The control arm is 7-weeks in length (Week 7 is a review booster) and is delivered via text messaging. Messages are didactic and not tailored to user sexual experience. Additionally, the Text Buddy and G2Genie intervention program components are not available.
2931557|NCT03029949|Experimental|ACT with VR|acceptance and commitment therapy with vestibular rehabilitation in addition to clinical management
2931558|NCT03029949|Active Comparator|Self-treatment VR|self-treatment vestibular rehabilitation in addition to clinical management
2931559|NCT03029936||Obesity Group|
2931560|NCT03029936||Asthma Group|
2931561|NCT03029936||Obesity-Asthma Group|
2931562|NCT03029936||Control|
2931563|NCT03029923|Experimental|Smoking Cessation and Mood Management|Participants will receive standard smoking cessation plus Behavioral Activation based mood management. Will be offered the nicotine patch if medically cleared.
2931564|NCT03029923|Active Comparator|Smoking cessation and Health and Wellness|Participants will receive standard smoking cessation plus health and wellness education. Will be offered the nicotine patch if medically cleared.
2931565|NCT03029910|Experimental|Cryotherapy and eccentric exercise|
2931566|NCT03029910|Experimental|Vibration and eccentric exercise|
2931567|NCT03029910|No Intervention|Control|
2931568|NCT03029897|Experimental|experimental|Patients are educated on the use of a mobile application to report adverse drug reactions
2931569|NCT03029897|No Intervention|control|Patients are not educated on the use of a mobile application to report adverse drug reactions
2931570|NCT03029884|Active Comparator|Active DBS|Chronic brain recording and stimulation with unilateral or bilateral implantation in pain-related brain regions. Both thalamic pain syndrome and phantom pain participants will participate in active DBS, blinded to the participant.
2931571|NCT03029884|Sham Comparator|Inactive DBS|Non-active chronic brain stimulation in pain-related brain regions. Brain recordings will remain active during this period. Both thalamic pain syndrome and phantom pain participants will participate in inactive DBS, blinded to the participant.
2931572|NCT03029871|Experimental|Arm 1|Nine subjects (3 cohorts, 3 subjects/cohort) with medically inoperable stage I/IIA (T1a - T2b) NSCLC with tumors measuring > 2 to ≤ 5 cm will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-ADP adenovirus at one of three dose levels (1 x 1011 vp, 3 x 1011 vp, 1 x 1012 vp). Depending on the location of the target lesion, the adenovirus will be injected either transbronchially (central tumors) or percutaneously under computed tomography (CT)-guidance (peripheral tumors). Two days later, subjects will be administered (orally) a 10 day course of 5-fluorocytosine (5-FC) and valganciclovir (vGCV) prodrug therapy along with 48 Gy (4 fractions of 12 Gy) of SBRT. Prior to and following the adenovirus injection, subjects will be administered [18F]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify HSV-1 TK gene expression.
2931573|NCT03029845|Active Comparator|propranolol 1|20 mg propranolol twice a day
2931574|NCT03029845|Active Comparator|propranolol 2|10 mg propranolol twice a day
2931575|NCT03029845|Placebo Comparator|Placebo|Placebo twice a day
2931576|NCT03029832|Experimental|MOXR0916 plus Atezolizumab|
2931577|NCT03029832|Active Comparator|Atezolizumab|
2931578|NCT03029819|Active Comparator|Mindfulness-based Addiction Treatment (MBAT)|Nicotine patch; self-help guide; MBAT
2931579|NCT03029819|Experimental|iQuit Mindfully|Nicotine patch; self-help guide; MBAT; text messaging
2931580|NCT03029806|Active Comparator|Afr-Amer risk allele|African Americans carrying the LSD1 affected allele
2931581|NCT03029806|Placebo Comparator|Cauc risk allele|Caucasians carrying the LSD1 affected allele
2931582|NCT03029806|Placebo Comparator|Afr-Amer non-risk allele|African Americans carrying the LSD1 non-risk allele
2931583|NCT03029806|Placebo Comparator|Cauc non-risk allele|Caucasians carrying the LSD1 non-risk allele
2931584|NCT03029793||Biomarkers and Imaging analysis|This study will prospectively collect the tissue and blood samples of locally advanced esophageal cancer patients, perform CRT resistance biomarkers testing and functional imaging analysis including SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI before treatment, 2-3 weeks after the initiation of CRT, and 4 weeks post-nCRT. The investigators will use advanced statistical tools to establish the model and further validate the model in another group of patients. The investigators will also establish a model for survival prediction.
2931585|NCT03029780|Experimental|Co-Administration|Nivolumab and Ipilimumab Co-Administration
2931586|NCT03029780|Experimental|Sequential Administration|Nivolumab and Ipilimumab Sequential Administration
2931587|NCT03029767|Experimental|Aerobic exercise|Aerobic exercise training will be carried out as an intervention activity
2931588|NCT03029767|Experimental|Resistance exercise|Resistance exercise training will be conducted as an intervention activity
2931589|NCT03029767|Experimental|Aerobic and resistance exercise|Aerobic and resistance training will be implemented
2931590|NCT03029767|No Intervention|Control group|standard or usual activity carried out.Additional intervention will not be given.
2931591|NCT03029754|Experimental|Passive leg raise|Participant's legs will be raised with a bolster prior to IV insertion.
2931592|NCT03029754|No Intervention|No leg raise|Participants will lie flat prior to IV insertion.
2931593|NCT03029741|Experimental|Bioavailability of AZD0284|"To assess the absolute bioavailability of a single oral dose of AZD0284 in healthy subjects.~To assess the pharmacokinetics (PK) of a single intravenous (IV) microdose of [14C]AZD0284 in healthy subjects."
2931594|NCT03029728||Observation|Patients at 2 months with hereditary angioedema disease type 1 or high-grade suspicion for hereditary angioedema disease type 1
2931595|NCT03029715|Other|Sleeve gastrectomy 1|Propofol Dexmedetomidine Remifentanil
2931596|NCT03029715|Other|Sleeve gastrectomy 2|Desflurane Remifentanil
2931597|NCT03029702|Active Comparator|Usual Care|Participants will undergo standard counseling and be prescribed a treatment for their GDM. Treatments include insulin, glyburide, and metformin.
2931598|NCT03029702|Active Comparator|Individualized Treatment|Participants will undergo standard counseling and be matched to therapy based on their GDM mechanism. Treatments include insulin, glyburide, and metformin.
2931599|NCT03029689|Experimental|Current ART + Raltegravir|Current ART + Raltegravir
2931600|NCT03029689|Placebo Comparator|Current ART + placebo|Current ART + placebo
2931601|NCT03029676|Experimental|Group B|spinal anesthesia premedication with benzodiazepine and opioid
2931602|NCT03029676|Active Comparator|Group K|spinal anesthesia premedication with opioid
2931680|NCT03029195|No Intervention|Control group|No nasoalveolar molding therapy for cleft lip and palate infants
2931603|NCT03029650|Active Comparator|Transderm Scop®|Each of the subjects will receive a single intravenous dose of 0.4 mg scopolamine hydrobromide and will wear the Transderm Scop® patch (1.5 mg) for 3 days in a crossover design with adequate washout in between. Subjects will be randomized to Group 1 (Transderm Scop® first followed by intravenous scopolamine hydrobromide) and remaining subjects will be randomized to Group 2 (intravenous scopolamine hydrobromide first followed by Transderm Scop®).
2931604|NCT03029650|Experimental|Intravenous scopolamine hydrobromide|Each of the subjects will receive a single intravenous dose of 0.4 mg scopolamine hydrobromide and will wear the Transderm Scop® patch (1.5 mg) for 3 days in a crossover design with adequate washout in between. Subjects will be randomized to Group 1 (Transderm Scop® first followed by intravenous scopolamine hydrobromide) and remaining subjects will be randomized to Group 2 (intravenous scopolamine hydrobromide first followed by Transderm Scop®).
2931605|NCT03029637|Experimental|No preparation resin bonded bridges|RBBs with no or minimal preparation of their abutment teeth
2931606|NCT03029637|Active Comparator|Routine resin bonded bridges|RBBs with routine tooth preparation of their abutment teeth
2931607|NCT03029624|Experimental|Treatment Arm|Treatment Arm receives implanted eCoin device and therapy is turned ON.
2931608|NCT03029611|Experimental|Treatment (chemotherapy, IGFBP-2 vaccine)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour followed by IGFBP-2 vaccine ID 2 weeks later. Treatment repeats every 3 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. After completion of 3 courses, patients then undergo cytoreductive surgery.
2931609|NCT03029598|Experimental|Treatment (pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1 and carboplatin IV over 30 minutes on days 8 and 15. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
2931610|NCT03029585|Experimental|NanoPac® 100 mg/m2|Intraperitoneal NanoPac® 100 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
2931611|NCT03029585|Experimental|NanoPac® 200 mg/m2|Intraperitoneal NanoPac® 200 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
2931612|NCT03029585|Experimental|NanoPac® 300 mg/m2|Intraperitoneal NanoPac® 300 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
2931613|NCT03029585|Experimental|NanoPac® 400 mg/m2|Intraperitoneal NanoPac® 400 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
2931614|NCT03029585|Active Comparator|Standard of Care Intravenous Chemotherapy|Standard of care intravenous chemotherapy (with platinum and taxane agents) administered per institutional standards.
2931615|NCT03029572|Active Comparator|Standard diet|Standard healthy diet after RYGB surgery
2931616|NCT03029572|Experimental|Micro-nutriments' supplementation|Healthy diet and probiotics, minerals, aminoacids, omega-3 acids vitamin and mineral supplementation after RYGB surgery
2931617|NCT03029559|Experimental|IH + ITL|Subjects will be exposed to a session of Intermittent hypoxia (IH) (45 minutes, 2 minutes of hypoxia alternating with 1 minute of hyperoxia) followed by 5 sets of Inspiratory threshold loading (ITL) at 80%MIP (10 breaths per set).
2931618|NCT03029559|Experimental|Intermittent hypoxia (IH)|Subjects will only be exposed to a session of intermittent hypoxia.
2931619|NCT03029559|Experimental|Sham IH + ITL|Sham Intermittent Hypoxia + Inspiratory threshold loading (ITL) subjects will be exposed to a single 45-minute session of sham IH (normoxia). This will consist of the subject breathing room air (FiO2=21%) through a 4 way valve connected to the hypoxicator. Exposure to normoxia will be followed by 5 sets of ITL at 80%MIP (10 breaths per set).
2931620|NCT03029559|Sham Comparator|Sham IH|Sham intermittent hypoxia subjects will be exposed to a single 45-minute session of sham IH alone.
2931621|NCT03029546||Glucose load|"50 subjects undergoing routine gestational diabetes screen with 50g glucose load.~5 subjects undergoing follow-up gestational diabetes screen with 100g glucose load."
2931622|NCT03029546||Control|50 subjects undergoing water ingestion with the same study measurements as the glucose load group at the same time intervals.
2931623|NCT03029533|Experimental|DWJ108J (leuprolide acetate)|DWJ108J (leuprolide acetate)
2931624|NCT03029533|Active Comparator|Leuplin DPS Inj|Leuplin DPS Inj
2931625|NCT03029520|Active Comparator|pain iRoot SP sealer Vital Pulp|Evaluation of Postoperative pain after root canal obturation with iRoot SP sealer (Innovative BioCeramix Inc., Vancouver, Canada) with patients who has (mandibular premolar/molar) vital pulp.
2931626|NCT03029520|Active Comparator|pain iRoot SP sealer Devital pulp|Evaluation of Postoperative pain after root canal obturation with iRoot SP sealer (Innovative BioCeramix Inc., Vancouver, Canada) with patients who has (mandibular premolar/molar) devital pulp.
2931627|NCT03029520|Active Comparator|pain AHPlus Vital pulp|Evaluation of Postoperative pain after root canal obturation with AH Plus sealer (Dentsply Maillefer, Ballaigues, Switzerland) with patients who has (mandibular premolar/molar) vital pulp.
2931628|NCT03029520|Active Comparator|pain AHPlus Devital Pulp|Evaluation of Postoperative pain after root canal obturation with AH Plus sealer (Dentsply Maillefer, Ballaigues, Switzerland) with patients who has (mandibular premolar/molar) devital pulp.
2931629|NCT03029507|Experimental|ACT enhanced ShipShape (ACT +SS)|"The ACT+SS intervention will be delivered in 8 1.5-hour weekly group sessions. The ACT~+SS protocol integrates ACT concepts and strategies within the existing standard SS protocol."
2931630|NCT03029507|Active Comparator|Standard ShipShape (SS)|Standard ShipShape (SS) The standard SS-only protocol will be delivered in 8 1.5-hour weekly group psychoeducation sessions.
2931631|NCT03029494|Experimental|Treatment 1: stabilization splint, placebo oral tablet|stabilization splint during night and 1 placebo oral tablet daily, for 6 months
2931632|NCT03029494|Active Comparator|Treatment 2: placebo splint, vitamin C|placebo splint during night and 1000 mg Vitamin C tablet daily, for 6 months
2931633|NCT03029494|No Intervention|Control group|determination of oxidative stress biomarkers and cortisol in saliva of healthy control subjects
2931681|NCT03029195|No Intervention|Age matched Norms|Normal (non-cleft) age matched infants
2931682|NCT03029182|Experimental|Walking+simulated-altitude|8-week exercise training program that involves 3 supervised, treadmill walking sessions each week with 16% oxygen, which will be administered through an exercise mask.
2931634|NCT03029468|Experimental|Computerized CBT|Computerized cognitive behavioral therapy (cCBT) for pain via an integrated smartphone and web-based skills training program: The training plan will help users learn how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation. The cCBT arm emphasizes skills acquisition and learning through practice; thus, the program involves regular homework assignments, and follow-up with the care coach and social network about issues faced and what skills were or could be used. This intervention is consistent with the tailored behavioral services patients would receive individually or as a group when working with a psychologist or behavioral pain specialist.
2931635|NCT03029468|Active Comparator|e-Education|Participants will receive pain education through online modules that they will be asked to complete using their study-provided smartphone. Each module includes learning tasks, a reading assignment, and a short quiz based on material from Painaction.com. The education group will receive care coach contact on the same schedule as the cCBT group. The care coach will provide supportive therapy and encouragement to complete modules and apply the lessons to their daily life.
2931636|NCT03029468|No Intervention|Usual Care|Participants who are not eligible or who are not randomized into one of the intervention arms of this study will serve as a comparison group to ensure we are treating a representative sample of patients. Further, patients who were eligible but were not randomized into one of the intervention arms will serve as a usual care control group.
2931637|NCT03029455|Experimental|Part A: VX-659 or Matching Placebo|Part A includes single-dose escalation.
2931638|NCT03029455|Experimental|Part B: VX-659 or Matching Placebo|Part B includes multiple-dose escalation.
2931639|NCT03029455|Experimental|Part C: VX-659 in TC with TEZ/IVA or Matching Triple Placebo|Part C includes multiple dose escalation of VX-659 administered in Triple Combination (TC).
2931640|NCT03029455|Experimental|Part D: VX-659 in TC with TEZ/IVA or Matching Triple Placebo|Part D includes subjects with CF. Participants will receive TC or matching placebos.
2931641|NCT03029442|Experimental|Denosumab, AIS Grade C (non-ambulatory)|8 subjects with AIS grade C will be randomized to receive Denosumab (Prolia 120mg SC) administered at baseline and 6 months.
2931642|NCT03029442|Placebo Comparator|Placebo, AIS Grade C (non-ambulatory)|8 subjects with AIS grade C will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
2931643|NCT03029442|Experimental|Denosumab, AIS Grade D (ambulatory)|8 subjects with AIS grade D will be randomized to receive Denosumab (Prolia 120mg SC) administered at baseline and 6 months.
2931644|NCT03029442|Placebo Comparator|Placebo, AIS Grade D (ambulatory)|8 subjects with AIS grade D will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
2931645|NCT03029429|Experimental|Theophylline|Theophylline capsules by mouth once daily or Theophylline elixir by mouth q6h (dose determined by serum drug levels)
2931646|NCT03029429|Placebo Comparator|Placebos|Theophylline capsule by mouth once daily or Theophylline elixir by mouth q6h
2931647|NCT03029416|Experimental|Single Fraction of SBRT|Stereotactic Body Radiation Therapy delivered in a single session on one day
2931648|NCT03029416|Experimental|Fractionated SBRT|Stereotactic Body Radiation Therapy delivered in three to five fractions with one fraction delivered every other day
2931649|NCT03029403|Experimental|Dose Escalation|Patients with epithelial ovarian, fallopian tube or primary peritoneal cancer.
2931650|NCT03029403|Experimental|Dose Expansion - Cohort A|Patients with platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.
2931651|NCT03029403|Experimental|Dose Expansion - Cohort B|Patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
2931652|NCT03029403|Experimental|Dose Expansion - Cohort C|Patients with recurrent advanced epithelial ovarian, fallopian tube and primary peritoneal patients with uncommon tumor histologies, including clear cell, mucinous and low grade serous or low grade endometrioid ovarian subtypes.
2931653|NCT03029390|Experimental|Berberine hydrochloride|"Berberine capsules, 500 mg, three per day before each meal during 12 weeks.~The patients will have a forced titration period:~First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study, they will be receive three 500 mg capsules (before each meal)"
2931654|NCT03029390|Experimental|Metformin|"Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 12 weeks.~The patients will have a forced titration period:~First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).~From the third week until the end of the study, they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal)."
2931655|NCT03029377|Experimental|Chronic Fatigue Patients|Patients between 18-60 years of age with fatigue symptoms who meet preliminary chronic fatigue phenotype criteria and complete preliminary screening surveys. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
2931656|NCT03029377|Active Comparator|Healthy Controls|Patients between 18-60 years of age with no known conditions or prescription medications who meet preliminary screening criteria. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
2931657|NCT03029364||Male and Female Adults|Completion of Study Protocol
2931658|NCT03029351|Experimental|Exenatide extended release|Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.
2931659|NCT03029351|Placebo Comparator|Placebo|Placebo treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to Exenatide extended release.
2931660|NCT03029338|Experimental|CD19 CAR T cells|CD19 CAR T cells will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2.
2931683|NCT03029182|Active Comparator|Walking (control)|8-week exercise training program that involves 3 supervised, treadmill walking session each week.
2931773|NCT03028571|Placebo Comparator|Intact Day|The rates of endogenous glucose appearance (Ra) and peripheral glucose uptake (Rd) will be measured during a regular insulin clamp with concomitant infusion of saline at 48 ml/hr IV
2931661|NCT03029312|Experimental|Whole Body Vibration|Twice daily WBVT at home using the Galileo M device, 3x3 min, with 3 minute breaks (total daily WBVT 18 min) for 5 months. Children stand upright on the device, with knees bent (10-45 degrees, semi-squat or squat position). A schedule of increasing intensity of vibration exercise was used over time, allowing some adjustment to the patient's physical capability. Amplitude 1 was used for the first 2 weeks, then increased to amplitude 2 and further increased up to amplitude 3, if individually possible, always using frequencies between 20-25Hz. Children also perform exercises on the platform, including shifting their weight from one side to the other, increase/decrease their knee and hip angle, weight shift with trunk rotation, and alternate flexion and extension of knees.
2931662|NCT03029312|No Intervention|Regular Care|Regular Care, including physiotherapy for 5 months
2931663|NCT03029299|No Intervention|Control|Subjects receive standard of care testing as determined by the clinician.
2931664|NCT03029299|Experimental|Intervention|Subjects are tested using the FilmArray RP EZ and the results are provided to the clinician for use in determination of patient care (along with any other clinician-ordered testing)
2931665|NCT03029286|Experimental|Personalized Web Intervention Arm|Women will be assigned to view a tailored website featuring their personalized risk information for breast cancer related to breast density and other factors.
2931666|NCT03029286|Active Comparator|Usual Care Arm|Women will be assigned to view a website that will take them to the American Cancer Society website to view general risk information for breast cancer related to breast density.
2931667|NCT03029273|Experimental|Anti-NY-ESO-1 TCR-transduced T cells|"NYESO-1 TCR-T cell are prepared via lentiviral infection. DLT was administered in a dose escalation test according to the 3 + 3 design. Three days prior to infusion of TCR-T cell, subjects receive cyclophosphamide treatment at dose 1 g/day for 2 days and take a rest for one day before infusion.~A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (250,000 IU/day) will be administered for 14 days concomitantly to each subject."
2931668|NCT03029260|Experimental|Neural mobilization - tension|It is anticipated that 30 participants will be in this group. They will receive tension type neural mobilization of the peroneal nerve in the dominant limb. This will consist of positioning the lower limb with inversion and plantar flexion of the ankle, extension of the knee and maximum flexion of the hip without pain. A physiotherapists will move the hip from this maximum position of flexion in direction to extension (for example if the participants reaches 80º of flexion the mobilization will be between 40º and 80º of flexion). Each participant will receive four series of 10 mobilizations with 1 minute rest between series.
2931669|NCT03029260|Active Comparator|Neural mobilization - sliding|It is anticipated that 30 participants will be in this group. They will receive sliding neural mobilization of the peroneal nerve in the dominant limb. Each participant will receive four series of 10 mobilizations with 1 minute rest between series of the following combination of movement: from ankle dorsiflexion, knee extension and hip extension to ankle plantarflexion, knee and hip flexion.
2931670|NCT03029247|Experimental|Epotein alfa 100 U/kg IV (Acute Challenge 1 and 2)|On Day 1, subjects will undergo 24-hr Acute Challenge 1 (AC1), in which subjects will receive a single dose of 100 U/kg epoeitn alfa IV. After completing AC1, subjects will enter in an 8-week Hgb maintenance period. At the end of Hgb maintenance period Acute Challenge 2 (on Day 57) will be performed utilizing the same treatment as of AC1.
2931671|NCT03029247|Experimental|Daprodustat 24 mg (Acute Challenge 1 and 2)|On Day 1, subjects will undergo 24-hr Acute Challenge 1 (AC1), in which , subjects will receive a 24 mg daprodustat After completing AC1, subjects will enter in an 8-week Hgb maintenance period. At the end of Hgb maintenance period Acute Challenge 2 (on Day 57) will be performed utilizing the same treatment as of AC1
2931672|NCT03029234|Experimental|Carfilzomib with Dexamethasone|On Cycle 1, Days 1 and 2, subjects will receive carfilzomib 20mg/m2. If tolerated (defined as absence of any treatment-related adverse event [AE] requiring dose reduction, delay, or the dose to be held), the dose will be escalated to 27 mg/m2 on Cycle 1 Day 8 and all subsequent doses.
2931673|NCT03029221||Marriage & Relationship Ed Skills-Couples|This group will receive the PREP 8.0 curriculum developed by PREP. In Years 2-5, 4 7-week class series will be held each year in Clearfield and Centre Counties (PA); 32 adults will be served each year. In Year 1, 8 adults will be served. Couples will receive 11 hours of curriculum instruction. This group will also receive two 30-minute presentations on available financial management, and job and career advancement services through two partnering organizations (CareerLink and Central PA Community Action, Inc.). Participants will also have access to optional parenting skills training provided by CAS (i.e., Triple P - Positive parenting Program). Referrals to community agencies based on individual/family needs will be provided by participant's case managers, as needed.
2931674|NCT03029221||Marriage & Relationship Ed Skills-Individuals|This group will receive the Within My Reach curriculum developed by PREP. In Years 2-5, 4 9-week class series will be held each year in Clearfield and Centre Counties (PA); 32 adults will be served each year. In Year 1, 8 adults will be served. Participants will receive 15 hours of curriculum instruction. This group will also receive two 30-minute presentations on available financial management, and job and career advancement services through two partnering organizations (CareerLink and Central PA Community Action, Inc.). Participants will also have access to optional parenting skills training provided by CAS (i.e., Triple P - Positive parenting Program). Referrals to community agencies based on individual/family needs will be provided by participant's case managers, as needed.
2931675|NCT03029221||Pre-Marital Ed and Marriage Skills|This group will receive healthy marriage and relationship education to pre-marital couples using Within Our Reach 8 Hours curriculum developed by PREP. In Years 2-5, 9 10-hour weekend workshops will be held each year in nine central PA counties; 72 adults will be served each year. In Year 1, 24 adults will be served.
2931676|NCT03029221||Marriage Enhancement and Marriage Skills|This group will receive healthy marriage and relationship education to married couples using Within Our Reach 8 Hours curriculum developed by PREP. In Years 2-5, 9 12-hour weekend workshops will be held each year in nine central PA counties; 174 adults will be served each year. In Year 1, 60 adults will be served.
2931677|NCT03029208|Experimental|Daprodustat treated anemic subjects|Subjects will receive oral daprodustat once daily.
2931678|NCT03029208|Active Comparator|Darbepoetin alfa treated anemic subjects|Subjects will receive darbepoetin alfa subcutaneously or intravenously.
2931679|NCT03029195|Experimental|Study group|Nasoalveolar molding therapy for cleft lip and palate infants
2931684|NCT03029169|Active Comparator|Propafenone i.v.|"Patients in septic shock with a new onset supraventricular arrhythmia are randomized either to arm treated with propafenone or with amiodarone. Both arms will have standard treatment, there are no limits to indicated electric cardioversion as part of treatment.~Intervention: Bolus of 35-70 mg intravenous propafenone followed by continuous infusion of 400-840 mg/24h."
2931685|NCT03029169|Active Comparator|Amiodarone i.v.|"Patients in septic shock with a new onset supraventricular arrhythmia are randomized either to arm treated with propafenone or with amiodarone. Both arms will have standard treatment, there are no limits to indicated electric cardioversion as part of treatment.~Intervention: Bolus of 150-300 mg of intravenous amiodarone followed by continuous infusion of 600-1800 mg/24h."
2931686|NCT03029156|Active Comparator|Small volume jet nebulizer|Administration of bronchodilator through small volume jet nebulizer. The nebulized solution contains ipratropium / albuterol.
2931687|NCT03029156|Experimental|Aeroneb nebulizer|Administration of bronchodilator via Aeroneb nebulizer. The nebulized solution contains ipratropium / albuterol.
2931688|NCT03029143|Experimental|Vedolizumab IV Standard Treatment Arm|Vedolizumab 300 milligram (mg), IV infusion on Day 1 and Week 2 as induction therapy in Lead-in Period followed by vedolizumab 300 mg, IV infusion, once in every 8 weeks (Q8W) (Weeks 6, 14, and 22) as standard treatment.
2931689|NCT03029143|Experimental|Vedolizumab IV Dose Optimized Arm|Vedolizumab 300 mg, IV infusion on Day 1 and Week 2 as induction therapy in Lead-in Period followed by Regimen A: vedolizumab 600 mg, IV infusion at Week 6 and 300 mg once in every 4 weeks (Q4W) thereafter (Weeks 10, 14, 18, 22 and 26), or Regimen B: vedolizumab 600 mg, IV infusion Q4W (Weeks 6, 10, 14, 18, 22 and 26). At Week 14 and beyond, dosing in the dose optimized arm will continue as previously assigned unless the subjects most recent preceding serum vedolizumab concentration is >90 microg/mL. In the event that steady-state Ctrough levels exceed safety exposure limits of 90 microg/mL, the next dose will be withheld and another Pharmacokinetics (PK) sample will be taken 1 week prior to the next scheduled dose. If at the next scheduled visit the Ctrough is still >90 microg/mL, the next dose will be similarly held and the PK repeated 1 week prior to the next scheduled dose. Once Ctrough is <90 microg/mL, the subject will move to the next lowest dose.
2931690|NCT03029130|Experimental|Catheter Extension|Patients in this arm will have a foley catheter re-passed, to remain in situ for an additional 14 days, after which time the catheter will be removed and the patient discharged to return for follow up exam at 3 months postop.
2931691|NCT03029130|No Intervention|Discharge|Patients in this arm will be discharged, to return for follow up exam at 3 months postop.
2931692|NCT03029117||corrected and uncorrected rheumatic valve lesions|
2931693|NCT03029104|Active Comparator|Group 1|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
2931694|NCT03029104|Active Comparator|Group 2|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 6 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
2931695|NCT03029104|Active Comparator|Group 3|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 30 minutes.
2931696|NCT03029091|Experimental|Losartan treatment|Treatment with Losartan potassium
2931697|NCT03029078|Experimental|Fecal transplantation|"Patient will be transplanted with a healthy donor microbiota, free from XDR bacteria, in order to evaluate the impact on the digestive tract colonization Whole process of feces screening and reconstitution was under the responsibility of the pharmacists in charge of the study.~Patient will benefit of a naso-duodenal tube in order to perform a bowel lavage prio to the fecal microbiota transplant.~Patient will be monitored for 24h to rule out potential adverse events."
2931698|NCT03029065||lung adenocarcinoma with brain (meningeal) metastasis|
2931699|NCT03029052|No Intervention|Control group|Medical and pharmaceutical management (at admission, during hospitalization and at discharge) will follow standard healthcare procedures of the department.
2931700|NCT03029052|Experimental|Reconciliation group|Standard healthcare procedures and pharmacist's involvement
2931701|NCT03029039||patients with severe sepsis|Blood samples will be collected at inclusion.
2931702|NCT03029039||patients with inflammatory syndrome without sepsis|Blood samples will be collected at inclusion.
2931703|NCT03029039||blood donor voluntary|Blood samples will be collected.
2931704|NCT03029026||Those patients for TAVR|Those patients who are undergoing TAVR (clinical decision) who are recruited at the Barts Heart Centre will undergo clinical echocardiography, research DPD scintigraphy and clinical TAVR work-up CT (with research post contrast acquisitions at 3-5 minutes), unless already performed prior to recruitment. Those patients undergoing TAVR (clinical decision) who are recruited at the John Radcliffe Hospital will undergo clinical echocardiography and research DPD scintigraphy only. N=150.
2931705|NCT03029026||Those patients for sAVR|Those patients who are undergoing sAVR (clinical decision) will undergo clinical echocardiography, research DPD scintigraphy, research CMR and endomyocardial biopsy at the time of surgery. N=50.
2931706|NCT03029026||Those patients for medical management|Those patients who are decided for medical management (clinical decision) will undergo clinical echocardiography, research DPD scintigraphy and any other imaging as per work-up/trial prior to no intervention decision. N=50.
2931707|NCT03029013|Experimental|experimental group|Apatinib and chemotherapy
2931708|NCT03029000|Experimental|tbo-filgrastim|solution for subcutaneous (sc) injection
2931709|NCT03028987|Other|LAIV randomized|Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® .
2931710|NCT03028987|Other|IIV4 randomized|Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone®
2931772|NCT03028584||Clinicians and Patients|"Surveys of N=30 breast cancer, colon cancer, and prostate cancer patients. Subjects will complete 1st survey electronically in-clinic. Subjects will either be e-mailed or mailed a survey at 4 weeks.~Survey of clinicians will be sent via e-mail."
2931711|NCT03028974|Other|Group A: 2-4 yo LAIV4 (Return)|Participants are given quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® . For children requiring 2 doses of vaccine, a second immunization will be given at Day 28-32 after Dose 1. All participants in this group will be asked to return annually for repeat immunization per ACIP guidelines and blood sample collection.
2931712|NCT03028974|Other|Group B: 2-4 yo LAIV4 (Single Year)|Participants are given LAIV4/ FluMist® and participate for single year. For children requiring 2 doses of vaccine, a second immunization will be given at Day 28-32 after Dose 1.
2931713|NCT03028974|Other|Group C: 2-4 yo LAIV4 (Swab/Single Yr)|Participants are given LAIV4/ FluMist® and participate for single year. NP swabs are collected; no blood samples will be collected for this group. For children requiring 2 doses of vaccine, a second immunization will be given at least 28 days after Dose 1.
2931714|NCT03028974|Other|Group D: 6 - 23 mos old IIV4 (Returning)|Participants are given a quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® . For children requiring 2 doses of vaccine (vaccine-naïve), a second immunization will be given at Day 28-32 after Dose 1. Participants are asked to return annually for repeat immunization per ACIP guidelines and blood sample collection.
2931715|NCT03028974|Other|Group E: 6 - 23 mos old IIV4 (Single Yr)|Participants are given IIV4/ Fluzone® and participate for a single year. For children requiring 2 doses of vaccine (vaccine-naïve), a second immunization will be given at Day 28-32 after Dose 1.
2931716|NCT03028974|Other|Group F: 9-13/18-40 yo LAIV4 (Single Yr)|Participants 9-13 year old and 18-49 year old are given LAIV4/ FluMist® . Participants will participate for a single year.
2931717|NCT03028974|Other|Group G: 9-13/18-40 yo IIV4 (Single Yr)|Participants 9-13 year old and 18-49 year old are given IIV4/ Fluzone® and participate for single year.
2931718|NCT03028961|Experimental|Group I (Stanford Letter, interview)|Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the Stanford Letter and complete and return the form by the day of BMT. After completion of the Stanford Letter, patients undergo a semi-structured, research staff-led interview to evaluate personal perceptions of uncertainty with end-of-life decisions, understanding of the ACP form received, and satisfaction with the ACP form.
2931719|NCT03028961|Active Comparator|Group II (traditional advance directive, interview)|Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the CA Advance Health Care Directive Form and complete and return the form by the day of BMT. After completion of the CA Advance Health Care Directive Form, patients undergo interview as in Group I.
2931720|NCT03028948|Experimental|Arm I (ITW)|Patients access ITW and complete each module over 30-40 minutes. All patients in Phase II complete surveys over 20-40 minutes at 8, 24, and 48 weeks.
2931721|NCT03028948|Active Comparator|Arm II (usual care)|Patients receive usual care and are then offered ITW. All patients in Phase II complete surveys over 20-40 minutes at 8, 24, and 48 weeks.
2931722|NCT03028935|Experimental|Prevention (exercise, nutrition education program)|Exercise Intervention & Nutritional Intervention. Participants undergo instructor-led exercise and nutrition education classes for 60 minutes twice a week for 12 weeks.
2931723|NCT03028922|Other|creos xenogain|Patients in need of bone augmentation prior to implant insertion will undergo GBR procedure using Creos xenogain bone graft substitute
2931724|NCT03028909|Experimental|Oseltamivir + low dose MEDI8852|Low Dose of MEDI8852 + Oseltamivir will be studied
2931725|NCT03028909|Experimental|Oseltamivir + high dose MEDI8852|High dose of MEDI8852 + Oseltamivir will be studied.
2931726|NCT03028909|Active Comparator|Oseltamivir + Placebo|Oseltamivir in conjunction with placebo will be studied.
2931727|NCT03028896|No Intervention|standard technique|In the neck flexed and the head extended position, hold mask like a pen with the index finger placed anteriorly at the junction of the cuff and tube, push the mask backwards maintaining pressure against the palate until resistance is felt.
2931728|NCT03028896|Experimental|rotational technique|After insertion of the entire cuff inside the mouth, the LMA FlexibleTM was rotated counter-clockwise through 90° and was advanced through the right side of the tongue until the resistance was felt, and then was returned back in the hypopharynx.
2931729|NCT03028883||buprenorphine dose adjustments|To determine if a relationship exists between buprenorphine dose adjustments and gestational age in opioid-maintained pregnant women
2931730|NCT03028870|Experimental|V120083 30 mg|V120083 30-mg capsules taken orally twice daily
2931731|NCT03028870|Experimental|V120083 60 mg|V120083 60-mg (2 x 30 mg) capsules taken orally twice daily
2931732|NCT03028870|Active Comparator|Naproxen|Naproxen 500-mg capsules taken orally twice daily
2931733|NCT03028870|Placebo Comparator|Placebo|Capsules to match V120083 and/or naproxen taken orally twice daily
2931734|NCT03028857|Placebo Comparator|Participants will take placebo|Participants will take placebo. Corn oil every day in place of choline
2931735|NCT03028857|Active Comparator|Drug: Choline|Participants will take 4500 mg of phosphatidylcholine twice per day, the equivalent of approximately 1250 mg of choline per day until delivery
2931736|NCT03028844|No Intervention|Sucrose alone|"These infants will receive an oral sucrose solution (Sweetease) only prior to venepuncture"
2931737|NCT03028844|Experimental|Music intervention plus sucrose|These infants will receive both oral sucrose solution and music therapy prior to venepuncture.
2931738|NCT03028831|Active Comparator|Resistant Starch|70g high-amylose maize starch which contains 42g of type 2 resistant starch
2931739|NCT03028831|Placebo Comparator|Digestible Starch|70g of fully digestible starch comprised of amylopectin corn starch.
2931740|NCT03028805|No Intervention|Usual care and order set A|Usual care. Providers may still search for a COPD order set, and in this arm will see version A, the static list of orders, which is the current state.
2931741|NCT03028805|Active Comparator|Usual care and order set B|Usual care in the sense that COPD orders are not automatically included in admission orders despite likelihood of a COPD admission based on the predictive model. However, providers may still search for a COPD order set, and in this arm will see version B, the dynamic list of orders that has been end user tested prior to launch.
2931742|NCT03028805|Active Comparator|Automatic inclusion and order set A|COPD order set is automatically included in admission orders as a static list.
2931743|NCT03028805|Active Comparator|Automatic inclusion and order set B|COPD order set is automatically included in admission orders as a dynamic and end user tested version.
2931744|NCT03028792|Experimental|Attention Modification Training|Attention Modification Program Active computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief. AMP is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral stimuli.
2931745|NCT03028792|Sham Comparator|Attention Control Training|Placebo Comparator: Attention Control Condition Control computer-based attention training task, which is not designed to modify biased attention patterns in anxious patients. ACC is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. In this case, the probe randomly replaces the neutral stimuli or the threat stimuli.
2931746|NCT03028779|Experimental|Fast-track total hip or knee arthroplasty|Be able to return patient home on the same day of a total hip or knee surgery.
2931747|NCT03028766|Experimental|Group A - Pre-operative|Patients will receive the cohort specified dose of AZD1775 by mouth, twice a day for 3 days, commencing on days 1 and 8. Cisplatin 40mg/m2 IV delivered over 1 hour on day 8. Patients in this group will commence surgery within 42 days of commencing pre-operative chemotherapy.
2931748|NCT03028766|Experimental|Group B - Post-operative:|Patients will received the cohort specified dose of AZD1775 by mouth, twice a day for 3 days on days 2, 9, 23 and 30. Cisplatin 40mg/m2 IV delivered over 1 hour on days 2, 9, 16, 23 and 30. Intensity Modulated Radiotherapy will be delivered 5 days a week (once daily, Monday to Friday) for 6 weeks commencing within 3 months of surgery.
2931749|NCT03028753|Experimental|All subjects|All subjects enrolled in the study will have a back-fill voiding trial performed at the time of catheter removal after urogynecologic surgery.
2931750|NCT03028740|Experimental|Drug: Cenicriviroc|150 mg cenicriviroc
2931751|NCT03028740|Placebo Comparator|Drug: Placebo|Placebo
2931752|NCT03028727|Active Comparator|Ultrasonic Scaling, Root planing|Ultrasonic Scaling and Root planing at day 0 and at 1 week.
2931753|NCT03028727|Experimental|980 nm diode Laser irradiation|Irradiation of periodontal pockets with with 980 nm diode Laser after scaling and root planing at day 0 and after 1 week.
2931754|NCT03028714|Experimental|Technology-based nutrition education|Participants will receive access to a website including educational information about nutrition and related topics. Through the website they will be asked to play online quiz-games relevant to the content of the website to improve their knowledge.
2931755|NCT03028714|No Intervention|Control group|Participants in the control group will receive no intervention.
2931756|NCT03028701|Experimental|Formoterol/Budesonide 12/400 mcg Discair|Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
2931757|NCT03028688|No Intervention|Current standard of care|Participants in the current standard of care will receive the usual anesthesia care for upper GI endoscopy. In addition participants will have transcutaneous PCO2 measurements performed.
2931758|NCT03028688|Experimental|High flow nasal cannula group|Participants in the high flow nasal cannula group will receive high flow nasal cannula oxygen and will also have transcutaneous PCO2 measurements performed.
2931759|NCT03028675|Experimental|Multiple Sclerosis|
2931760|NCT03028675|Experimental|Healthy Volunteer|10 age-matched control volunteers
2931761|NCT03028662|Experimental|Immediate exposure|Exposure to video on alcohol (update phase) followed (10 minutes) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
2931762|NCT03028662|Active Comparator|Delayed exposure|Exposure to a video of alcohol consumption (update phase) followed (6 hours) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
2931763|NCT03028662|Active Comparator|No exposure|Exposure to a video of neutral situations (update phase) followed (10 minutes) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
2931764|NCT03028649|Experimental|β-hydroxy-β-methylbutyrate (HMB)|"Group taking oral supplementation with calcium salt of β-hydroxy-β-methylbutyric acid produced by Olimp Laboratories. A single capsule contained 1250 mg Ca-HMB, which corresponds to 1000 mg of β-hydroxy-β-methylbutyrate.~Interventions:~The experimental procedure for each athlete included a 12-week HMB supplementation - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day.~Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced."
2931765|NCT03028649|Placebo Comparator|Placebo (maltodextrin)|"Group taking oral supplementation with placebo (maltodextrin). A single capsule contained 1000 mg of maltodextrin.~Interventions:~The experimental procedure for each athlete included a 12-week placebo administration - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day.~Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced."
2931766|NCT03028623|Other|Control|Tubal sterilization will be performed by standard tubal ligation, either Parkland or Pomeroy technique, at the time of cesarean section
2931767|NCT03028623|Experimental|Experimental|Tubal sterilization will be performed by bilateral salpingectomy using a ligasure device at the time of cesarean section.
2931768|NCT03028610|Experimental|Acessa™ System|radiofrequency generator
2931769|NCT03028597|Experimental|Intervention Values Affirmation|The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
2931770|NCT03028597|Active Comparator|Control Values Affirmation|The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
2931771|NCT03028584||Clinicians|"Observe up to N=10 clinicians. Observations will include:~Oncology history and care plan development by clinicians including use of EHR technology to develop care plans and methods used to secure necessary information for care plan creation~Provision and coordination of survivorship care occurring during care team meetings, discussions among clinicians, and survivor visits with clinicians, especially visits in which a care plan is provided to a survivor~Clinician seeking survivorship related information or resources through use of technology or discussion with other clinicians~Survivorship work or tasks performed by the clinician including adding, modifying or extracting information from the EHR and adding or modifying information in the care plan"
2931774|NCT03028571|Experimental|Blocked Day|The rates of endogenous glucose appearance (Ra) and peripheral glucose uptake (Rd) will be measured during a regular insulin clamp with concomitant infusion of trimethaphan (4mg/min) IV.
2931775|NCT03028558||HEALTHY VOLUNTEER RESEARCH SUBJECTS|"Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population.~Between the ages of 21-35 years old."
2931776|NCT03028558||HEALTHY E-CIGARETTE SMOKING SUBJECTS|Criteria is identical to the healthy never-smoker group except that they must have a history of smoking e-cigarettes >5 days/wk for a minimum of 6 months with no prior traditional tobacco exposure.
2931777|NCT03028545|Other|schizophrenia|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in schizophrenia
2931778|NCT03028545|Other|bipolar disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in bipolar disorders
2931779|NCT03028545|Other|eating disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in eating disorders
2931780|NCT03028545|Other|personality disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in personality disorders
2931781|NCT03028532|Experimental|Clomid|All participants will be receiving Clomid and will follow the same study procedures.
2931782|NCT03028519|Experimental|Treatment|Vitamin D levels will be measured at the time of routine blood work. If Vitamin D levels are found to be low, patients will take 50,000 IU of vitamin D3 weekly daily as maintenance therapy. There is no prospective control arm.
2931783|NCT03028493|Experimental|Adapted SAFE Intervention|Adapted version of the SAFE Health Behavior and Exercise intervention.
2931784|NCT03028493|Active Comparator|Original SAFE Intervention|Original version of the SAFE intervention.
2931785|NCT03028480||Subjects with Bronchial asthma|Subjects with a refractory asthma whose symptoms are inadequately controlled despite receiving standard asthma medications will be enrolled
2931786|NCT03028467|Experimental|GSK3196165 45 mg|Participants will receive GSK3196165 45 milligram (mg) weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
2931787|NCT03028467|Experimental|GSK3196165 90 mg|Participants will receive GSK3196165 90 mg weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
2931788|NCT03028467|Experimental|GSK3196165 180 mg|Participants will receive GSK3196165 180 mg weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
2931789|NCT03028467|Placebo Comparator|Placebo|Participants will receive placebo weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
2931790|NCT03028454|Experimental|Ginger Root Capsule|
2931791|NCT03028454|Placebo Comparator|Placebo Capsule|
2931792|NCT03028441|Experimental|Group 1- low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day1 and at Day 29 for 25 subjects, placebo for 5 subjects
2931793|NCT03028441|Experimental|Group 2-low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day 1 and at Day 85 for 25 subjects, placebo for 5 subjects
2931794|NCT03028441|Experimental|Group 3-low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day 1and at Day 169 for 25 subjects, placebo for 5 subjects
2931795|NCT03028441|Experimental|Group 4 -high dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1 and at Day 29 for 25 subjects, placebo for 5 subjects
2931796|NCT03028441|Experimental|Group 5-high dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1and at Day 85 for 25 subjects, placebo for 5 subjects
2931797|NCT03028441|Experimental|Group 6-dose-High Dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1and at Day 169 for 25 subjects, placebo for 5 subjects
2931798|NCT03028428|Experimental|Placenta Derived Mesenchymal Stem Cell|Placenta Derived Mesenchymal Stem Cell administered into the knee joint once
2931799|NCT03028428|Active Comparator|sodium hyaluronate|Sodium hyaluronate administered into the knee joint once
2931800|NCT03028415|Experimental|AMPLEX®|
2931801|NCT03028415|Active Comparator|Autogenous Bone Graft (ABG)|
2931802|NCT03028402||Asymptomatic Controls|Individuals who have no history of neck pain, trauma or surgery, similar in age and sex to the surgical patients
2931803|NCT03028402||C5-C6 arthrodesis|Patients scheduled to undergo C5-C6 anterior cervical arthrodesis
2931804|NCT03028402||C6-C7 arthrodesis|Patients scheduled to undergo C6-C7 anterior cervical arthrodesis
2931805|NCT03028402||C4-C5-C6 arthrodesis|Patients scheduled to undergo C4-C5-C6 anterior cervical arthrodesis
2931806|NCT03028402||C5-C6-C7 arthrodesis|Patients scheduled to undergo C5-C6-C7 anterior cervical arthrodesis
2931807|NCT03028389|Experimental|Limb RIPC|The limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
2931808|NCT03028389|No Intervention|Convention|Elderly patients undergoing non-cardiac surgery received no treatment after induction of anaesthesia
2931809|NCT03028376||Moderate TBI patients|GCS 9-13
2931810|NCT03028363|Experimental|Treatment A|Olumacostat Glasaretil Gel
2931811|NCT03028363|Placebo Comparator|Treatment B|Vehicle
2931812|NCT03028350|Experimental|Ifetroban Oral Capsule|Oral ifetroban, 200 mg daily for 8 weeks
2931813|NCT03028350|Placebo Comparator|Placebo Oral Capsule|Oral placebo daily for 8 weeks
2931814|NCT03028337|Experimental|Spine Radiosurgery - 1 Dose|Participants receive spine radiosurgery in a single large dose.
2931815|NCT03028337|Active Comparator|Spine Radiosurgery - 3 Doses|Participants receive spine radiosurgery over 3 smaller doses.
2931816|NCT03028324|Experimental|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
2931817|NCT03028311|Active Comparator|SIR-Spheres - Two Sessions|First 2 participants has SIR-Spheres treatment delivered over 2 sessions within 2-4 weeks, which is the standard of care.
2931818|NCT03028311|Experimental|SIR-Spheres - One Session|After first 2 participants, SIR-Spheres treatment delivered in 1 session.
2931819|NCT03028298|Experimental|Low dose sildenafil|Twelve patients with cerebral vasospasm following aneurysmal subarachnoid hemorrhage will be assigned to low dose sildenafil citrate and will receive a 20mg oral dose and a subsequent 10mg intravenous dose of sildenafil citrate.
2931820|NCT03028298|Experimental|High dose sildenafil|Twelve patients with cerebral vasospasm following aneurysmal subarachnoid hemorrhage will be assigned to high dose sildenafil citrate and will receive a 60mg oral dose and a subsequent 30mg intravenous dose of sildenafil citrate.
2931821|NCT03028285|Experimental|Unifusol 250 ml IV, 3 ml/mil|Twelve healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at a dose 250 ml and infusion rate 3 ml/min.
2931822|NCT03028285|Experimental|Unifusol 250 ml IV, 4.5 ml/min|Twenty-four healthy volunteers will receive arginine sodium succinate 1.4% solution (Unifusol) intravenously at a dose 250 ml and infusion rate 4.5 ml/min
2931823|NCT03028285|Experimental|Unifusol 500 ml IV, 4.5 ml/min|Twelve healthy volunteers will receive arginine sodium succinate 1.4% solution (Unifusol) intravenously at a dose 500 ml and infusion rate 4.5 ml/min
2931824|NCT03028272|Active Comparator|Fascia|Autologous donor substrate
2931825|NCT03028272|Experimental|Skye Barrier|Amniotic membrane allograft
2931826|NCT03028259||lab results|monitoring of
2931827|NCT03028246|Experimental|ExAblate 4000 System|MR-Guided Focused Ultrasound
2931828|NCT03028233|Experimental|Healthy Lifestyles|The study will test the impact of a community health worker (CHW)-delivered intervention aimed at helping families overcome barriers to childhood obesity prevention. Barriers include social, environmental, and family issues.
2931829|NCT03028233|Active Comparator|Positive Parenting|The control condition consists of a community health worker (CHW)-delivered intervention aimed at helping families improve positive parenting skills.
2931830|NCT03028220|Active Comparator|Real time continuous glucose monitoring|Use of Dexcom G5 continuous glucose monitoring
2931831|NCT03028220|Active Comparator|Flash glucose monitoring|Use of Abbott FreeStyle Libre flash glucose monitoring
2931832|NCT03028207||COPD|Subjects with FEV1/FVC score less than 0.70 post-bronchodilator test will be allocated to COPD group and the prevalence of COPD will be evaluated. Subjects in this group will be categorized in 4 groups namely GOLD I - IV depending on the disease severity.
2931833|NCT03028207||Non-COPD|Subjects with FEV1/FVC score greater than or equal to 0.70 post-bronchodilator test will be allocated to non-COPD group.
2931834|NCT03028194|Experimental|Curettage|Postpartum uterine curettage performed immediately after delivery of the placenta.
2931835|NCT03028194|Placebo Comparator|Placebo|No procedure performed after delivery of the placenta.
2931836|NCT03028181||1|Control group non-exposed to tobacco smoking
2931837|NCT03028181||2|Control group exposed to tobacco smoking
2931838|NCT03028181||3|Patients with acute pancreatitis non-exposed to tobacco smoking
2931839|NCT03028181||4|Patients with acute pancreatitis exposed to tobacco smoking
2931840|NCT03028168|Experimental|Intervention Yôga|Active protocol with yôga body movements performed along with respiratory vigorous, without contentions. Two sessions per week, with 45 minutes duration.
2931841|NCT03028168|Experimental|Intervention breathing technique|Passive protocol, seated patient, no significant body movements. Breathing technique, with alternate nostril breathing combined to inspiratory and expiratory retentions.Two sessions per week, with 45 minutes duration
2931842|NCT03028168|Experimental|Control group|Control group (standard pharmacological treatment). Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization.
2931843|NCT03028155|Active Comparator|Oxaliplatin: BSA-based HIPEC|Intervention: oxaliplatin: BSA-based HIPEC HIPEC will be performed using oxaliplatin as chemotherapeutic agent at a dose of 460 mg/m2 mixed in 0.9% saline carrier solution during 30 minutes. Volume of the carrier solution: depended on the capacity of the abdominal cavity of the patient.
2931844|NCT03028155|Active Comparator|Oxaliplatin: Concentration-based HIPEC|Intervention: oxaliplatin: concentration-based HIPEC HIPEC will be performed using oxaliplatin as chemotherapeutic agent at a dose of 460 mg/m2 mixed in 0.9% saline carrier solution at 2L/m2, which equals a concentration of 230 mg/L during 30 minutes.
2931845|NCT03028142|Experimental|Lower Dose Nebulised Treatment|1.5 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
2931846|NCT03028142|Experimental|Higher Dose Nebulised Treatment|6 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
2931847|NCT03028142|Placebo Comparator|Placebo|Nebulised RPL554 matched placebo twice daily plus 10 mcg tiotropium DPI once daily for 3 days
2931848|NCT03028129|Experimental|Treatment|Each subject in the treatment group will receive two oral supervised weekly doses of isoniazid 900 milligrasm for 52 weeks.
2931849|NCT03028129|Placebo Comparator|Control|Subjects in the control group will receive two weekly supervised oral doses of placebo for 52 weeks.
2931850|NCT03028116|Active Comparator|Allantoic split inactivated seasonal influenza vaccine|Allantoic split inactivated seasonal influenza vaccine
2931851|NCT03028116|Placebo Comparator|Placebo|Water for Injection
2931889|NCT03027791|Experimental|Parishoners at HUMC|African-American adults aged 18-85 who attend services at Holman United Methodist Church will be exposed to Group Sessions for 12 weeks and Virtual Reality for 6 weeks.
2931890|NCT03027778|Experimental|Exercise|Participants will engage in pedalling exercise 3 times per week during the first 2 hours of dialysis treatment for the duration of 4 months.
2931891|NCT03027778|No Intervention|Usual care|Participants receive their usual dialysis for the duration of 4 months.
2931852|NCT03028103|Experimental|Part A and B|"Part A: Subjects enrolled in Part A will receive treatment with oral tazemetostat tablets 400 mg BID for 24 days beginning on Day 1. Subjects will receive fluconazole 400 mg once daily for 4 days starting on Day 16. Tazemetostat 400 mg BID will continue through Day 24. Subjects will then receive tazemetostat 800 mg BID starting on Day 25.~Part B: Subjects enrolled in Part B will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg on Day 1. Administration of tazemetostat 800 mg BID will begin on Day 2. On Day 16, subjects again will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg approximately 1 hour after the morning dose of tazemetostat. Subjects also will receive omeprazole 20 mg once daily in the morning on Days 16 through 19."
2931853|NCT03028077|Experimental|GS-3K8|GS-3K8 (6 cap/day, 500 mg/cap) for 12 weeks
2931854|NCT03028077|Experimental|GINst15|GINst15 (6 cap/day, 500 mg/cap) for 12 weeks
2931855|NCT03028077|Placebo Comparator|Placebo|Placebo for 12 weeks
2931856|NCT03028051||chronic pain patients|Finnish speaking, adult chronic pain patients, aged 18 - 75 years, referred to pain clinic
2931857|NCT03028038|Experimental|Platelet Rich Plasma|Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.
2931858|NCT03028038|Experimental|No Platelet Rich Plasma|No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.
2931859|NCT03028025|Active Comparator|TR Band Only|TR Band: Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
2931860|NCT03028025|Experimental|Statseal with TR Band|StatSeal: Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
2931861|NCT03028012|Experimental|Ketorolac|Participants may be randomized to receive Ketorolac for their TPI.
2931862|NCT03028012|Experimental|Lidocaine|Participants may be randomized to receive Lidocaine for their TPI.
2931863|NCT03028012|Experimental|Dexamethasone|Participants may be randomized to receive Dexamethasone for their TPI.
2931864|NCT03027999|Experimental|Patient with tight nursing follow-up|Compared as usual, Patient with tight nursing follow-up will be contacted
2931865|NCT03027999|No Intervention|Patient without tight nursing follow-up|Compared as usual, Patient without tight nursing follow-up will not have interventions
2931866|NCT03027986|Experimental|postural rehabilitation program based on sensory-motor control|
2931867|NCT03027986|No Intervention|Standard physiotherapy|
2931868|NCT03027973|Experimental|UPA Treatment Group|UPA 5mg capsule daily + Placebo 2 capsules 4 times a day
2931869|NCT03027973|Active Comparator|TEA Treatment Group|TEA 500mg 2 capsules 4 times a day + Placebo 1 capsule daily
2931870|NCT03027960|Experimental|Placebo, then empagliflozin|"Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy."
2931871|NCT03027960|Experimental|Empagliflozin, then Placebo|"Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy."
2931872|NCT03027947|Experimental|Spinal cord stimulation|"Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.~Participants in this study receive spinal cord stimulation will be trans-tibial and trans-femoral amputees that are at least six month post--amputation. Subjects will have varying levels of phantom limb sensation and pain, but should have no other significant neurological disorders."
2931873|NCT03027934|Active Comparator|Group 1|
2931874|NCT03027934|Active Comparator|Group 2|
2931875|NCT03027921|Experimental|hepatic ultrasound|all patients will have hepatic ultrasound
2931876|NCT03027908|Experimental|Fluoride Toothpaste 1|Toothpaste containing Sodium Fluoride at 1450 ppm F
2931877|NCT03027908|Active Comparator|Fluoride Toothpaste 2|Toothpaste containing Sodium Fluoride at 1450 ppm F
2931878|NCT03027895|Experimental|Lumen-apposing metal stent(LAMS)|Lumen-apposing metal stent(LAMS) will be deployed by endoscopist under the guidance of EUS
2931879|NCT03027895|Active Comparator|Double pigtail plastic stent(DPPS)|Double pigtail plastic stent(DPPS) will be deployed by endoscopist under the guidance of EUS
2931880|NCT03027869|Active Comparator|Real Left DLPFC tDCS|Real tDCS on the left dorsolateral prefrontal cortex
2931881|NCT03027869|Sham Comparator|Sham tDCS|30sec ramp-up and 30sec ramp-down
2931882|NCT03027869|Active Comparator|Real Right DLPFC tDCS|Real tDCS on the right dorsolateral prefrontal cortex
2931883|NCT03027856|Experimental|Magmaris|Implantation of sirolimus eluting bioresorbable magnesium stent
2931884|NCT03027843|Active Comparator|GH group|patients in group mini-dose GnRH-a long protocol combine with growth hormone
2931885|NCT03027843|No Intervention|control group|patients in group mini-dose GnRH-a long protocol without growth hormone
2931886|NCT03027830|Experimental|iFR pressure-wire|
2931887|NCT03027830|Active Comparator|Conventional|
2931888|NCT03027804||Ross Operation|Patients undergone Ross Operation. Patients requiring reoperation
2931892|NCT03027765||Egyptian children|"Population1:~Egyptian children with constructed space maintainers at Cairo University."
2931893|NCT03027765||Pediatric dentists|"Population2:~Pediatric dentists at Cairo University."
2931894|NCT03027752|Active Comparator|carotid endarterectomy patch angioplasty|Carotid endarterectomy with longitudinal incision carotid endarterectomy patch angioplasty
2931895|NCT03027752|Experimental|Carotid endarterectomy with autoarterial remodeling|Carotid endarterectomy with autoarterial remodeling of bifurcation of the common carotid artery
2931896|NCT03027739|Experimental|Arm 1|CART-19 cells treated
2931897|NCT03027726|Active Comparator|Control group|Family-based lifestyle education and psycho-educational program
2931898|NCT03027726|Experimental|Exercise group|Supervised exercise plus family-based lifestyle education and psycho-educational program
2931899|NCT03027713|Other|NAVA group with a specific catheter|The patients were allocated in the NAVA weaning protocol group
2931900|NCT03027713|Other|PSV group without a specific catheter|The patients were allocated in the PSV (pressure-support ventilation) weaning protocol group
2931901|NCT03027700|Active Comparator|Health/Normal Controls|Health/normal control subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
2931902|NCT03027700|Active Comparator|F1/F2 fibrosis|Type 1 and 2 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
2931903|NCT03027700|Active Comparator|F3/F4 fibrosis|Type 2 and 3 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
2931904|NCT03027700|Active Comparator|Hepatic steatosis with fibrosis|Hepatic steatosis with liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
2931905|NCT03027687|Experimental|Real transcranial Direct Current Stimulation|This group will receive bilateral tDCS (left cathodal/right anodal) over the DLPFC. The stimulation will take place two times daily for 13 minutes with a rest interval of 20 minutes for three days in one week.
2931906|NCT03027687|Sham Comparator|Sham tDCS|The control group receives sham, for which the stimulator will be gradually turned off after 30 seconds.
2931907|NCT03027674|Experimental|10% nifedipine cream|Patient hands (right versus left) were randomized to treatment with topical sildenafil or nifedipine cream. The thumbs of both hands didn't receive any cream so that each subject served as her own control. Subjects were instructed to apply 5 grams of 10% nifedipine cream in one hand and 5 grams of 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve the absorption of the cream into the hand, leaving the thumb of both hands out of the glove without any cream.
2931908|NCT03027674|Active Comparator|5% sildenafil cream|Patient hands (right versus left) were randomized to treatment with topical sildenafil or nifedipine cream. The thumbs of both hands didn't receive any cream so that each subject served as her own control. Subjects were instructed to apply 5 grams of topical10% nifedipine cream in one hand and 5 grams of topical 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve the absorption of the cream into the hand, leaving the thumb of both hands out of the glove without any cream.
2931909|NCT03027661|Placebo Comparator|Control Group|Injection of 10 mL of 0.9% sodium chloride into the cervical stroma divided between 3 and 9 o'clock
2931910|NCT03027661|Active Comparator|Study Group|Injection of 10 mL of 0.5% bupivacaine into the cervical stroma divided between 3 and 9 o'clock.
2931911|NCT03027648|Other|patients with LNG-IUS|Placement of levonorgestrel-releasing intrauterine system
2931912|NCT03027635|Experimental|PleurX|The PleurX catheter is a tunnelated peritoneal catheter, designed for permanent placement in the peritoneal cavity. The catheter is placed by a physician under sterile conditions. Drainage of ascites is done using vacuum bottles connected to the catheter. This can be managed by a home nurse or the patient.
2931913|NCT03027635|Active Comparator|Large Volume Paracentesis|Large volume paracentesis is performed in sterile technique, a small incision is made through the skin, and a catheter is inserted through muscle and peritoneum. After the procedure, the patient remains in hospital for observation until the fluid is drained.
2931914|NCT03027622||long term quality of life|to evaluate conservatively managed third molars with mild pericoronitis at first, third and sixth months by using OHIP-14 TR
2931915|NCT03027609|Experimental|AR-105|One intravenous infusion of AR-105 20mg/'kg
2931916|NCT03027609|Placebo Comparator|Control|Matching placebo
2931917|NCT03027596|Experimental|Remote ischemic conditioning|Four cycles of 5 min occlusion and reperfusion in an extremity using a tourniquet.
2931918|NCT03027596|No Intervention|Control group|no intervention
2931919|NCT03027583|Experimental|Probiotic|63 subjects will be randomized to the experimental arm. The experimental product is a vegetable capsule containing a probiotic strain. Subjects will consume 1-2 capsules daily together with breakfast, equivalent to a dose of 50 bill CFU for 6 weeks.
2931920|NCT03027583|Placebo Comparator|Placebo|63 subjects will be randomized to the placebo arm.The placebo product is the same vegetable capsule as the experimental product, identical in composition, taste and appearance but without probiotics. Subjects will consume 1-2 capsules daily with breakfast for 6 weeks.
2931921|NCT03027570|Experimental|Control|Five-month program at two centers for the treatment of overweight children.
2931922|NCT03027570|Experimental|Exergame activity_EXG|Adding an exergame activity application to the regimen at a center for the treatment of overweight children.
2931923|NCT03027557|Experimental|Combined treatment.|20 subjects will be treated with combined 60mg denosumab bi-annually , 30 mg cinacalcet daily and 50 micrograms vitamin-D daily.
2931924|NCT03027557|Active Comparator|Monotherapy|20 subjects will receive 60mg denosumab bi-annually, placebo and 50 micrograms vitamin-D daily.
2931925|NCT03027557|Placebo Comparator|Placebo|20 subjects will receive a saline injection bi-annually (blinded), placebo-tablets and 50 micrograms vitamin-D daily.
2932003|NCT03026946|Active Comparator|Alitretinoin|Patients with severe recurrent vesicular hand eczema, randomized to treatment with alitretinoin.
2932403|NCT03024073||CG|Control group (age-matched participants without pseudophakic presbyopic correction)
2931926|NCT03027544|Experimental|experimental arm|"Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases.~Intervention：tomotherapy"
2931927|NCT03027531|Experimental|Control|Control group entered sexual history via computer assisted self-interview and provided specimens for chlamydia, gonorrhea and pregnancy(females) testing. The do not receive the feedback intervention of eKISS: electronic KIOSK for safer-sex
2931928|NCT03027531|Experimental|Intervention|Intervention group entered sexual history via computer assisted self-interview and received the interactive computer-based intervention with individualized feedback eKISS: electronic KIOSK for safer-sex. They provided specimens for chlamydia, gonorrhea and pregnancy(females) testing.
2931929|NCT03027518|Other|Group 1|Group 1 will be active in the WILD 5 Wellness program the first 30 days and inactive the 2nd 30 days.
2931930|NCT03027518|Other|Group 2|Group 2 will be inactive in the WILD 5 Wellness program the first 30 days and active the 2nd 30 days.
2931931|NCT03027505|Experimental|MUAC<125mm|no medical complication
2931932|NCT03027492|Active Comparator|1. NCWS retrospective patients|The clinical charts of NCWS female patients attending the outpatient centers of the Department of Internal Medicine at the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca will be reviewed with a retrospective method. They had all been diagnosed with NCWS between January 2001 and June 2011 and included in a previously published study. These charts included specific sections for associated gynaecological disorders. Incomplete clinical charts will be excluded. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
2931933|NCT03027492|Active Comparator|2. CD retrospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of CD female patients had been randomly chosen by a computer-generated method from female patients diagnosed during the same period (2001-2011) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group was asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
2931934|NCT03027492|Active Comparator|3. IBS retrospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of IBS female patients had been randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2001-2011) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group was asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
2931935|NCT03027492|Active Comparator|4. NCWS prospective patients|The investigators prospectively will survey adult female patients with functional gastroenterological symptoms according to the Rome III criteria, and a suspected diagnosis of NCWS. The patients will be recruited between January 2017 and January 2018 at the same 2 centers. Most of the patients will be referred owing to gastrointestinal and extraintestinal symptoms, the onset of which, they reported, could be related to wheat ingestion. In addition, patients will be asked about the presence and characteristics of gynaecological disorders using an ad hoc questionnaire. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
2931936|NCT03027492|Active Comparator|5. CD prospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of CD female patients will be randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2017-2018) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group will be asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
2931937|NCT03027492|Active Comparator|6. IBS prospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of IBS female patients will be randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2017-2018) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group will be asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
2931938|NCT03027479|Experimental|Case group|women with ovarian and/or endometrial cancer and weight loss will have muscle, adipose tissue, ovarian tumor and blood samples
2931939|NCT03027479|Other|Control group|women scheduled for an intervention for benign ovarian/ endometrial disease and no weight loss will have muscle, adipose tissue and blood samples
2931940|NCT03027427||Patients|Patients with confirmation of, or suspicion of, a heritable gastric malignancy disorder
2931941|NCT03027401||Group A|Adult/pediatric with suspected or confirmed malignancy, family history of malignancy, undergoing surgery with no malignancy; tissues collected previously under CLIA or for research.
2931942|NCT03027388|Experimental|1/LB100|Treatment with LB100
2931943|NCT03027375|Experimental|Qishen granules|The QSG treatment group will receive Qishen granules (13.6 g/pouch, twice per day—30 minutes after breakfast and dinner—for 12 weeks; dosage based on the requirements of Pharmacopoeia of the People's Republic of China).
2931944|NCT03027375|Placebo Comparator|placebo granules|The placebo group will receive placebo granules (13.6 g/pouch, twice per day—30 minutes after breakfast and dinner—for 12 weeks).
2931945|NCT03027362|Experimental|Cognitive behavioral therapy (CBT) and medication|Following clinical ketamine treatment, the intervention includes sixteen CBT sessions over 14 weeks. In addition, standard of care medications for treatment of depression, will be prescribed by the principal investigator or by a psychiatrist unaffiliated with the trial. Participants will remain on the medication they were prescribed when they entered the study and will be expected not to adjust the medication unless clinically urgent.
2931946|NCT03027362|Active Comparator|Psychoeducation and medication|Following clinical ketamine treatment, the intervention includes psychoeducational sessions over 14 weeks.In addition, standard of care medications for treatment of depression, will be prescribed by the principal investigator or a by psychiatrist unaffiliated with the trial.
2931947|NCT03027349||Study group|"Patients aged between 18-90 years old with primary hyperparathyroidism who had been diagnosed in the Unit of Endocrinology of the University of Modena and Reggio Emilia.~The exclusion criteria will be:~age younger than 18 years~renal and liver failure and insufficiency~active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc)~any type of cancer~malnutrition, severe obesity (BMI > 40 kg/m2) and malabsorption~transplantation~sarcoidosis~endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism~familial hypocalciuric hypercalcemia~hypophosphoremia sustained by genetic causes or secondary to other causes."
2931948|NCT03027349||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their parathyroid function and calcium metabolism state with results into the normal ranges.~The exclusion criteria will be:~age younger than 18 years~renal and liver failure and insufficiency~active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc)~any type of cancer~malnutrition, severe obesity (BMI > 40 kg/m2) and malabsorption~transplantation~sarcoidosis~endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism~familial hypocalciuric hypercalcemia~hypophosphoremia sustained by genetic causes or secondary to other causes."
2931949|NCT03027336|Experimental|coleosoma|coleosoma 500mg tablet daily
2931950|NCT03027336|Placebo Comparator|placebo|placebo tablets
2931951|NCT03027323|Other|AxoTrack System guided CVC insertion|AxoTrack System guided CVC
2931952|NCT03027323|No Intervention|CVC insertion guided by landmark|Anatomical landmarks to guide CVC
2931953|NCT03027284|Experimental|Merestinib (Part A Dose Level 1)|Merestinib administered orally. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
2931954|NCT03027284|Experimental|Merestinib (Part A Dose Level 2)|Merestinib administered orally. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
2931955|NCT03027284|Experimental|Merestinib + Cisplatin + Gemcitabine (Part B)|Merestinib administered orally with cisplatin and gemcitabine administered intravenously (IV). Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met, but Cisplatin and gemcitabine treatment will be limited to a maximum of 8 cycles.
2931956|NCT03027258|Experimental|Intervention|mHealth intervention
2931957|NCT03027245||Eribulin-treated participants|Participants treated with eribulin according to Fachinformation and managed according to clinical practice
2931958|NCT03027206|Experimental|Vibration technique|Rhythmic and rapid movements of isometric contraction of the forearm, applied manually over the anterior region of the thorax
2931959|NCT03027206|Experimental|Acceleration of expiratory flow|Soft compression of the thorax applied with one hand on the lower ribs and the other using the ulnar border on the supramammary line
2931960|NCT03027193|Experimental|Group 1|Group 1 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 5 x 10^9 vp through intramuscular route.
2931961|NCT03027193|Experimental|Group 2|Group 2 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 2.5 x 10^10 vp through intramuscular route.
2931962|NCT03027193|Experimental|Group 3|Group 3 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 5 x 10^10 vp through intramuscular route.
2931963|NCT03027193|Experimental|Group 4|Group 4 volunteers (n= 3) will be administered MVA HAV, 5 x 10^7 pfu through intramuscular route.
2931964|NCT03027193|Experimental|Group 5|Group 5 volunteers (n= 3) will be administered MVA HAV, 2 x 10^8 pfu through intramuscular route.
2931965|NCT03027193|Experimental|Group 6|Group 6 volunteers (n= 10) will be administered ChAdOx2 HAV, 5 x 10^10 vp followed by MVA HAV, 2 x 10^8 pfu (8 weeks apart) through intramuscular route.
2931966|NCT03027180|Active Comparator|0 (zero) cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 0 cmH2O
2931967|NCT03027180|Experimental|4 cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 4 cmH2O
2931968|NCT03027180|Experimental|15 cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 15 cmH2O
2931969|NCT03027167|Active Comparator|Aspirin and MCDs|ASA with MCDs- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will receive MCDs for a period of 10 days post-surgery. ASA 325mg BID will be prescribed for a period of 6 weeks.
2931970|NCT03027167|Experimental|Aspirin only|ASA only- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will NOT receive MCDs after being discharged from hospital. ASA 325mg BID will be prescribed for a period of 6 weeks.
2931971|NCT03027154|Experimental|TB subjects in 5-18 years old|24 cases TB subjects in 5-18 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
2931972|NCT03027154|Experimental|non-TB subjects in 5-18 years old|24 cases non-TB subjects in 5-18 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
2932002|NCT03026959|No Intervention|Social (control) Group|Participants assigned to the social group will also attend four weekly sessions that are each 1.5 hours in length. Each session will have participants focus on a creative tasks while permitting task related discussion. In this way the format is designed to parallel the mindfulness group, where participants engage in a new activity each week and have an opportunity to discuss the activities with the group without engaging in any formal intervention.
2931973|NCT03027154|Experimental|TB subjects under 5 years old|24 cases TB subjects under 5 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
2931974|NCT03027154|Experimental|non-TB subjects under 5 years old|24 cases non-TB subjects under 5 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
2931975|NCT03027141|Active Comparator|Pre-Transplant Time Point|Participants will be imaged in the Magnetic Resonance Imaging scanner (MRI)
2931976|NCT03027141|Experimental|Post-Transplant Time Point|Participants will be imaged in the Magnetic Resonance Imaging scanner (MRI). Patients for whom a pre-transplant fMRI was obtained will undergo functional MRI scanning at three-points post-transplant (approximately 2 and 4 months +/- 2 months post-operation and again at 1 year +/- 3 months post-transplant).
2931977|NCT03027128|Experimental|haNK™ for Infusion|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous Infusion
2931978|NCT03027115|Experimental|Treatment|treatment with a selective alpha1-adrenoceptor antagonist
2931979|NCT03027115|No Intervention|Control|no treatment
2931980|NCT03027102|Experimental|Patient Arm|Patients will receive DNT cells from healthy donors.
2931981|NCT03027102|No Intervention|Donor Arm|Healthy volunteer donors will donate blood.
2931982|NCT03027076||Men with UCPPS|Genitourinary Specimen Collection for microbiome evaluation
2931983|NCT03027076||Asymptomatic Men|Genitourinary Specimen Collection for microbiome evaluation
2931984|NCT03027076||Women with UCPPS|Collect midstream urine samples
2931985|NCT03027076||Asymptomatic Women|Collect midstream urine samples
2931986|NCT03027063|Experimental|10,000 steps|"For the 10,000 steps group, participants will be asked to achieve a goal of 10,000 steps a day and to engage in 30 minutes of continuous exercise every day. Steps will be monitored with the under Armour fitness tracker which participants will receive.~For motivation, messages will be sent to study participants in this group via the messaging center in the Under Armor application three times a week. The frequency of messaging will be increased for participants who fail to meet their goals for three consecutive days. Study participants will also receive a weekly call to assess for side effects and provide additional encouragement."
2931987|NCT03027063|Active Comparator|Usual care|This will be the usual care group. Participants will also receive a fitness tracker to enable monitoring of steps and will be given a flyer that references the ACC/AHA guidelines for exercise and physical activity for the general population. Participants will not receive text messages or phone calls.
2931988|NCT03027050|Experimental|Titanium-prepared platelet rich fibrine|T-PRF was applied with open flap debridement in test group.
2931989|NCT03027050|Active Comparator|Open Flap Debridement alone|T-PRF was not applied to control groups. Only open flap debridement was applied to control groups.
2931990|NCT03027037||Remitted Major Depression Group|Women in this group will have experienced at least one episode of major depression in their lifetime, but no episodes in the two months prior to study enrollment.
2931991|NCT03027037||Control Group|Women in this group will never have experienced any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition Axis I psychological disorder.
2931992|NCT03027024|Experimental|IOL Implantation|Implantation of IOL: PhysIOL POD F GF
2931993|NCT03027011|Active Comparator|Remote Ischemic Preconditioning(RIPC)|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
2931994|NCT03027011|Placebo Comparator|Control|Control group without remote ischemic preconditioning
2931995|NCT03026998|Other|MRI|
2931996|NCT03026985||Observational cohort|"Ultrasound measurement of quadriceps muscle size and echogenicity will be obtained at baseline (within 48 hours of ECMO commencement), 10 days and 20 days after baseline measurement.~Measures of muscle strength and highest mobility level will be obtained at day 10 and day 20 after baseline measurement in order to determine the relationship between these volitional measures and the ultrasound parameters."
2931997|NCT03026972|Experimental|Population I|Population I has 25 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of placebo or low dose adjuvant or low dose vaccine.
2931998|NCT03026972|Experimental|Population II|Population II is considered as Tuberculin purified protein derivative(TB-PPD) skin test , ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result all negative.It has 30 subjects.Population II are coxal muscle injection of placebo or high dose adjuvant or high dose vaccine.
2931999|NCT03026972|Experimental|Population III|Population III is considered as ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result negive,but Tuberculin purified protein derivative(TB-PPD) skin test positive.Population IV is needed 30 subjects.These subjects are coxal muscle injection of placebo or high dose adjuvant or high dose vaccine.This arm is uninfected TB PPD positve population.
2932000|NCT03026972|Experimental|Population IV|Population IV is considered as Tuberculin purified protein derivative(TB-PPD) skin test and ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result all positive.We are called latent infection population,and need to screen 50 subjects through these three selection method.Population III are coxal muscle injection of placebo or adjuvant( including low dose adjuvant or high dose adjuvant) or vaccine(including low dose vaccine high dose vaccine).
2932001|NCT03026959|Experimental|Mindfulness Group|Participants assigned to the mindfulness group will attend four weekly sessions that are each 1.5 hours in length. The sessions will follow the structure described by Short, Mazmanian, Ozen, & Bédard (2015). The structure is designed to first enhance learners' foundation skills in mindfulness and progresses into teaching learners more advanced mindfulness skills.
2932132|NCT03026036||MDD|Patients with current Major Depressive Disorder
2932004|NCT03026946|Active Comparator|Cyclosporin A|Patients with severe recurrent vesicular hand eczema, randomized to treatment with cyclosporin A.
2932005|NCT03026933|Experimental|Treatment|KI1107
2932006|NCT03026933|Active Comparator|Control|Rosuvastatin calcium
2932007|NCT03026920|Experimental|clinical outcome|Less invasive method was applied to pelvic or acetabular fracture of old people. Thus, the clinical outcome of Pelvic or acetabular fractures in old man was assessed.
2932008|NCT03026907|Active Comparator|Alitretinoin|Patients with severe chronic non-hyperkeratotic hand eczema, randomized to treatment with alitretinoin.
2932009|NCT03026907|Active Comparator|Azathioprine|Patients with severe chronic non-hyperkeratotic hand eczema, randomized to treatment with azathioprine.
2932010|NCT03026894|Active Comparator|CD group|Panoramic Radiographs and T-Scan III occlusal system
2932011|NCT03026894|Active Comparator|IOD group|Panoramic Radiographs and T-Scan III occlusal system
2932012|NCT03026881|Experimental|Fluzoparib + Apatinib + Paclitaxel|
2932013|NCT03026868|Experimental|quadrilateral surface plate|The fragments of the acetabulum were fixed with novel quadrilateral surface plate through Stoppa approach.
2932014|NCT03026855|Experimental|Autologous PRP Gel and PRP Injection|Autologous PRP will be prepared using an advanced rapid point-of-care technology, the Res-Q™ 60 PRP system at the patient's bed side. The Activator solution for PRP gel will be prepared by combining human thrombin (500 IU/ml) with 1% Calcium Chloride.
2932015|NCT03026842|Experimental|Decitabine|Six cycles of decitabine IV over one hour at 20 mg/m2/day for 5 days, every 6 weeks
2932016|NCT03026842|Active Comparator|Conventional chemotherapy|Four cycles of conventional chemotherapy for 5 days, every 12 weeks. conventional chemotherapy includes in: DA regimen: Daunorubicin 45 mg/m2/day for 3 days, cytarabine 100 mg/m2/day for 5 days; MA regimen: Mitoxantrone 8 mg/m2/day for 3 days, cytarabine 100 mg/m2/day for 5 days; AA regimen: Aclacinomycin 20 mg/day for 5 days, cytarabine 100 mg/m2/day for 5 days.
2932017|NCT03026829|Experimental|CART sound therapy|
2932018|NCT03026816|Experimental|Epidural Spinal Cord Stimulation|Epidural Spinal Cord Stimulation
2932019|NCT03026803|Experimental|Oxaliplatin and Capecitabine|21 day cycle with Oxaliplatin 50mg/m2 day 1 and day 8 administered IV, Capecitabine 750 mg/m2 bid p.o. daily from day 1 to day 14
2932020|NCT03026790|Active Comparator|Telecare collaborative management (TCM)|Uses medication management approach delivered by a clinical pharmacist care manager with a collaborating physician to address common barriers to effective pain medication management in primary care.
2932021|NCT03026790|Active Comparator|Integrated pain team (IPT)|Uses a biopsychosocial management approach delivered by a multidisciplinary team that emphasizes non-pharmacological pain management options.
2932022|NCT03026790|Active Comparator|Standard taper options|The standard taper options arm uses patient education and shared decision-making to guide opioid medication management.
2932023|NCT03026790|Active Comparator|Expanded taper options|The expanded taper options arm uses patient education and shared decision-making to guide opioid medication management and includes the additional option of rotation to buprenorphine-naloxone.
2932024|NCT03026777|Experimental|Fluid Loading|(1) 500 milliliters of an intravenous crystalloid solution of the operator's choosing will be (2) infused at any time after randomization and prior to the administration of procedural medications from (3) above the level of the central or peripheral intravenous or intraosseus access used and allowed to infuse by gravity and (4) stopped after 500 mL have infused. All intravenous infusions preceding the decision to perform endotracheal intubation will not be altered.
2932025|NCT03026777|No Intervention|Usual Care|No intravenous fluids are started after the decision is made to perform endotracheal intubation. All intravenous infusions preceding the decision to perform endotracheal intubation will not be altered.
2932026|NCT03026764|Experimental|Outpatient|Patients in the outpatient group (same day discharge following THA) are discharged the same day following surgery. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
2932027|NCT03026764|Active Comparator|Inpatient|Patients in the inpatient group (following day discharge following THA) stay in the hospital overnight and then are discharged home the next day. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
2932028|NCT03026738|Experimental|Laparoscopic anterior mesh rectopexy|A superficial peritoneal window will be made over the right part of the sacral promontory and extended caudally over the right outer border of the mesorectum down to the right side of the pouch of Douglas. In females, the vagina will be retracted anteriorly and a careful dissection of the rectovaginal septum will be performed down to the pelvic floor. A strip of polypropylene (3×20 cm) mesh will be introduced and sutured as distally as possible on the anterior rectal wall/ perineal body with three, interrupted nonabsorbable sutures.The posterior wall of the vagina will be fixed to the mesh using absorbable sutures. The mesh is then secured tension-free to the sacral promontory using three absorbable sutures. The mesh will be peritonealized by suturing the free edges of the previously divided peritoneum over the mesh to provide additional ventral elevation of the enterocele and avoid small bowel adhesions to the mesh.
2932029|NCT03026738|Active Comparator|Laparoscopic posterior mesh rectopexy|"Mobilization of the mesorectum posteriorly from the sacral promontory to the pelvic floor. Lateral stalks will not be divided. Bowel resection and circumferential division of the peritoneum will not be done in this study. A T-shaped polypropylene mesh will be placed with the vertical leg laying flush with the anterior surface of the sacrum, and secured to the promontory and sacrum with three absorbable sutures. The mesh wings will be sutured to the lateral sides of the rectum/mesorectum with two absorbable sutures on each side. The visceral peritoneum will be left open."
2932030|NCT03026725|Experimental|Tri-calcium Phosphate|clinpro tooth creme, i.e. Tri-calcium Phosphate, for 30 min/day after bleaching 4h with carbamide peroxide 20%
2932031|NCT03026725|Placebo Comparator|Placebo|a placebo creme will be applied for 30 min/day after bleaching 4h with carbamide peroxide 20%
2932032|NCT03026712|Experimental|Real tDCS|
2932033|NCT03026712|Sham Comparator|Sham tDCS|
2932034|NCT03026699||Intervention - Primary Brain Tumor|eSNAP Intervention Plus Questionnaires: Family caregivers of primary brain tumor patients.
2932035|NCT03026699||Intervention - Secondary Brain Tumor|eSNAP Intervention Plus Questionnaires: Family caregivers of secondary brain tumor patients.
2932036|NCT03026699||Control - Primary Brain Tumor|Questionnaires Only Control: Family caregivers of primary brain tumor patients.
2932037|NCT03026699||Control - Secondary Brain Tumor|Questionnaires Only Control: Family caregivers of secondary brain tumor patients.
2932038|NCT03026686||readmit|women who were re-admitted in the post partum period for a hypertensive disorder
2932039|NCT03026686||Controls|women with similar risk factors but did not require readmission
2932040|NCT03026673||NSAID use|The purpose of this study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
2932041|NCT03026660|Experimental|Moringa treatment|Moringa Oleifera was distributed in two 500mg capsules of dried and powdered Moringa Oleifera leaves. Two capsules were taken daily.
2932042|NCT03026660|Placebo Comparator|Placebo|The placebo consisted of dried and powdered cabbage in two 500mg capsules. Two capsules were taken daily.
2932043|NCT03026621|Placebo Comparator|Placebo|This will be an herbal tea the looks similar to the control.
2932044|NCT03026621|Experimental|Lignite Extract|This will be the Restore gut supplement
2932045|NCT03026608|Experimental|Intervention Group|Communities randomized to the intervention group receive the Veggie Van program shortly after randomization.
2932046|NCT03026608|Active Comparator|Delayed Intervention Control Group|This group will receive the Veggie Van intervention approximately 6 months after baseline data collection and randomization (after the collection of 6 months outcomes data).
2932047|NCT03026569|Experimental|Orange juice|Orange juice: twenty-three patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were supplemented with 100% commercial pasteurized orange juice (500 mL/d) during 8 weeks.
2932048|NCT03026569|No Intervention|Control|Control: twenty patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were monitored for consumption of orange juice during 12 weeks.
2932049|NCT03026556||Dabigatran vs. Rivaroxaban|OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, rivaroxaban (new oral anticoagulant or NOAC).
2932050|NCT03026556||Dabigatran vs. Apixaban|OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, or apixaban (new oral anticoagulant or NOAC).
2932051|NCT03026543|Experimental|Pulmonary recruitment maneuver|One minute of ventilator-piloted PRM at the end of laparoscopic cholecystectomy, intending to remove residual carbon dioxide (CO2) from the abdomen.
2932052|NCT03026543|Active Comparator|Control group|Ordinary ventilation at the end of laparoscopic cholecystectomy.
2932053|NCT03026530|Experimental|Pulmonary recruitment maneuver|Ventilator-piloted pulmonary recruitment maneuver at the end of laparoscopic bariatric surgery.
2932054|NCT03026530|Active Comparator|Control group|Ordinary ventilation at the end of laparoscopic bariatric surgery.
2932055|NCT03026517|Experimental|Dabrafenib, Trametinib & Phenformin|This is a multi-institution single-arm phase I trial with an expansion cohort at the MTD of Phenformin, in patients with metastatic BRAFV600E/K mutated melanoma. In the dose escalation phase, cohorts of patients will be treated with standard dose Dabrafenib (150 mg PO BID) plus Trametinib (2 mg PO QD) and increasing doses of Phenformin. In the dose-escalation phase of the trial, both patients who have already been treated with a BRAF and/or MEK inhibitor, and treatment-naïve patients will be eligible. The dose-expansion cohort will enroll up to 10 patients who are treatment- naïve for BRAF inhibitor.
2932056|NCT03026504|Experimental|Baricitinib Therapy|4 milligrams oral Baricitinib daily for 52 weeks
2932057|NCT03026491||Children with chewing dysfunction|Descriptive characteristics including age, height, weight, transition time to additional food, meal time, number of meals, initial teething time, and number of teeth, were noted. The presence of open mouth, open bite, high palate, gag reflex, and oral hygiene were scored as absent or present as an observational oral motor assessment. Chewing evaluation was performed and scored with the Karaduman Chewing Performance Scale (KCPS). The International Dysphagia Diet Standardisation Initiative (IDDSI) was used to determine the tolerated food texture of children.
2932058|NCT03026491||Children without chewing dysfunction|Descriptive characteristics including age, height, weight, transition time to additional food, meal time, number of meals, initial teething time, and number of teeth, were noted. The presence of open mouth, open bite, high palate, gag reflex, and oral hygiene were scored as absent or present as an observational oral motor assessment. Chewing evaluation was performed and scored with the Karaduman Chewing Performance Scale (KCPS). The International Dysphagia Diet Standardisation Initiative (IDDSI) was used to determine the tolerated food texture of children.
2932059|NCT03026478|Experimental|Betamethasone dipropionate 0.05%|topical Betamethasone dipropionate 0.05% in orabase with clotrimazole 1% in oral lichen planus two times a day for one month
2932060|NCT03026478|Active Comparator|Clobetasol propionate 0.05%|Topical Clobetasol propionate 0.05% in orabase with clotrimazole 1% in oral lichen planus patients two times a day for a month
2932061|NCT03026465|Experimental|Coroflex ISAR stent|PCI with a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR stent) with very thin struts (50 µm). During the PCI, an OCT assessment (baseline and post-implantation) will be performed.
2932062|NCT03026465|Active Comparator|Biomatrix stent|PCI with a biodegradable-polymer biolimus-eluting stent (Biomatrix stent) with 120 µm struts. During the PCI, an OCT assessment (baseline and post-implantation) will be performed.
2932063|NCT03026452|Experimental|RFA(radiofrequency ablation)|The investigators used percutaneously US-guided RFA(radiofrequency ablation) for small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
2932064|NCT03026439||Non-dyspneic smokers/ normal spirometry|Male or female current or former smokers. Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) >0.7. FVC >lower limit of normal (LLN). Modified Medical Research Council (mMRC) dyspnea score = 0.
2932065|NCT03026439||Dyspneic smokers/ normal spirometry|Male or female current or former smokers. FEV1/FVC >0.7. FVC >LLN. mMRC dyspnea score ≥1.
2932066|NCT03026439||Non-dyspneic mild COPD patients|Male or female current or former smokers. FEV1/FVC ≤0.7. FEV1 >80% of predicted value. mMRC dyspnea score =0.
2932133|NCT03026036||rMDD|Patients with a history of Major Depressive Disorder
2932134|NCT03026036||HC|Healthy control participants
2932067|NCT03026439||Dyspneic mild COPD patients|Male or female current or former smokers. FEV1/FVC ≤0.7. FEV1 >80% of predicted value. mMRC dyspnea score ≥1.
2932068|NCT03026426|Experimental|CONEMO|"Participants in the intervention arm will receive a smartphone with CONEMO, an application with 18 sessions that are delivered 3 times a week for 6 weeks.~Additionally, all study participants, including those in the intervention arm, who present a high risk of suicide and/or have a PHQ-9 score ≥20 are referred to the system for follow up. Participants with lower levels of depressive symptoms receive the recommendation of going to a mental health professional."
2932069|NCT03026426|No Intervention|Control Group|Participants in the control group will receive enhanced usual care. Participants who present a high risk of suicide and/or have a PHQ-9 score ≥20 are referred to the system for follow up. Participants with lower levels of depressive symptoms receive the recommendation of going to a mental health professional.
2932070|NCT03026413|Experimental|PVAM|pulomonary vein antrum modification with contact force monitoring for AF
2932071|NCT03026413|Active Comparator|Control arm|pulmonary vein isolation without contact force
2932072|NCT03026400|Other|Subumbilical incision|The subumbilical incision was standardised. A curvilinear horizontal incision was performed to be able to reach the base of the umbilicus. The aponeurosis was incised with a scalpel and the peritoneal layer was open with a Kelly clamp. The incision was completed with the Hasson technique and a X-stitch was used for closure.
2932073|NCT03026400|Other|Transumbilical incision|The transumbilical incision was also standardised, inverting the umbilicus with graspers, then incising vertically the skin to reach the umbilical physiological hernia to enlarge it. The incision was also completed with the Hasson technique and a X-stitch was used for closure.
2932074|NCT03026387|Other|Neuropsychological battery tests|"All participants performed the same evaluation: clinical and neuropsychological assessment.~All of them are suicide attempters without psychotic features"
2932075|NCT03026374|Experimental|intervention group|The BRBC program consists of education and group discussion, and lasted for 12 months. Women in IG attended weekly meetings lasting for 120 minutes. Education took approximately 45 minute. Qualified professionals from various disciplines were invited to provide lessons to ensure the quality of the educational sessions. The group discussion followed the presentation and began with mentors sharing their experience with the topic, followed by participant discussions regarding life changes since diagnosis (e.g., physical, emotional, social, spiritual). Each group consisted of 7-9 patients and 3 leaders (2 mentors and 1 facilitator, including a clinical psychologist, nurse clinician, or social worker). The time of group discussion varied from 45-75 minutes. This was intended to foster support among group members,both in and out of sessions.
2932076|NCT03026374|No Intervention|control group|patients from both groups were provided medical, social, or psychological care if necessary, as assessed by primary oncologists. Additionally, all patients received an educational brochure about breast cancer every 1 to 2 months, and relaxation therapy was provided to both groups to prevent demoralization from random assignment.
2932077|NCT03026361||oral lichen planus (OLP)|"Histopathologically confirmed samples of OLP underwent immunohistochemical analysis of IGF2 and IGF2R expression.~Fresh-frozen samples of clinically OLP changed and adjacent healthy mucosa underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
2932078|NCT03026361||oral squamous cell carcinoma (OSCC)|"Histopathologically confirmed samples of OSCC underwent immunohistochemical analysis of IGF2 and IGF2R expression.~Fresh-frozen samples of clinically OSCC changed and adjacent healthy mucosa underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
2932079|NCT03026361||healthy mucosa|"Archival samples of healthy oral mucosa underwent immunohistochemical analysis of IGF2 and IGF2R expression.~Fresh-frozen samples of healthy mucosa taken during alveolotomy underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
2932080|NCT03026348|Active Comparator|Treatment Group A|Day 0 RSV F Vaccine 135µg/0.5mL Day 21 Phosphate Buffer
2932081|NCT03026348|Active Comparator|Treatment Group B|Day 0 Treatment / Formulation 1 Day 21 Phosphate Buffer
2932082|NCT03026348|Active Comparator|Treatment Group C|Day 0 Treatment / Formulation 1 Day 21 Treatment / Formulation 1
2932083|NCT03026348|Active Comparator|Treatment Group D|Day 0 Treatment / Formulation 2 Day 21 Phosphate Buffer
2932084|NCT03026348|Active Comparator|Treatment Group E|Day 0 Treatment / Formulation 2 Day 21 Treatment / Formulation 2
2932085|NCT03026348|Active Comparator|Treatment Group F|Day 0 Treatment / Formulation 3 Day 21 Phosphate Buffer
2932086|NCT03026348|Active Comparator|Treatment Group G|Day 0 Treatment / Formulation 3 Day 21 Treatment / Formulation 3
2932087|NCT03026348|Active Comparator|Treatment Group H|Day 0 Treatment / Formulation 4 Day 21 Phosphate Buffer
2932088|NCT03026348|Active Comparator|Treatment Group J|Day 0 Treatment / Formulation 4 Day 21 Treatment / Formulation 4
2932089|NCT03026348|Active Comparator|Treatment Group K|Day 0 Treatment / Formulation 5 Day 21 Phosphate Buffer
2932090|NCT03026348|Active Comparator|Treatment Group L|Day 0 Treatment / Formulation 5 Day 21 Treatment / Formulation 5
2932091|NCT03026348|Placebo Comparator|Treatment Group M|Day 0 Phosphate Buffer Day 21 Phosphate Buffer
2932092|NCT03026335|Experimental|Positive Action Curriculum|"A school-wide program was implemented in the experimental schools referred to as Positive Action and was integrated with the existing Health and Family Life Education curriculum."
2932093|NCT03026335|Active Comparator|Control/Comparison Group|Business as usual with students in non-intervened schools
2932094|NCT03026322|Active Comparator|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
2932095|NCT03026322|Active Comparator|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
2932096|NCT03026309||depressed|un medicated diagnosed with major depression and scheduled to start SSRI treatment.
2932097|NCT03026309||healthy|healthy volunteers.
2932200|NCT03025490|Experimental|Capnography|Patient undergoing sedation, treatment team does have capnography data available.
2932098|NCT03026296|Experimental|Participators in HLCs|Adults with high risk of non-communicable diseases (musculoskeletal disease, obesity, physical distress) about to start a 3 months structural support for lifestyle change in a Healthy Life Center (HLC) in Norway
2932099|NCT03026283|Experimental|1: HeartFlow CT-FFR Arm|All patients who consent will receive HeartFlow CT-FFR and medically acceptable care based on the study protocol, commonly accepted standards of care, and the patients condition.
2932100|NCT03026270|Other|seven layers|Volunteers will be submitted to the application of seven layers therapy paraffin surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded. .The Application will be made with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide)
2932101|NCT03026270|Other|ten layers|Volunteers will be submitted to the application of seven layers therapy paraffin surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded. .The Application will be made with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide)
2932102|NCT03026257|Experimental|AOHG|Lotrafilcon B contact lenses with added wetting agent, worn bilaterally (in both eyes) for 30 days in a daily wear modality and cared for with either a hydrogen peroxide-based contact lens solution with added wetting agent or a POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent, as randomized
2932103|NCT03026257|Active Comparator|Habitual|Habitual silicone hydrogel contact lenses worn bilaterally for 30 days in a daily wear modality and cared for with participant's habitual multi-purpose solution (MPS)
2932104|NCT03026244|Active Comparator|Nutritional intervention product|Milk protein, prebiotics, vitamin D
2932105|NCT03026244|Placebo Comparator|Placebo product|placebo product
2932106|NCT03026231|Active Comparator|PRIM-DJ2727|Subjects with PD will be randomly assigned to receive PRIM-DJ2727 in orally administered enteric-coated capsules
2932107|NCT03026231|Placebo Comparator|Placebo|Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
2932108|NCT03026218|Experimental|Group and Glucose Mama|Enrolled subjects with have GlucoseMama application and group care.
2932109|NCT03026218|Placebo Comparator|Group and No Glucose Mama|Enrolled participants will be enrolled in group care but will not have access to GlucoseMama application.
2932110|NCT03026218|Experimental|Traditional and glucoseMama|Enrolled subjects will have traditional care and glucoseMama
2932111|NCT03026218|No Intervention|Traditional and no GlucoseMama|enrolled subjects will not have access to group care or GlucoseMama.
2932112|NCT03026205|Experimental|Single Arm|ARMS-I dosage of 0.75 mg will be sprayed orally in the mouth once as a single dose of four sprays on Day 1, and then three times a day starting on Day 3 for 4 Days.
2932113|NCT03026192||no PDA|These are infants who do not have a patent ductus arteriosus (PDA) as determine by echocardiography
2932114|NCT03026192||hsPDA|These are infants who have a hemodynamically significant PDA (hsPDA) as determined by echocardiography
2932115|NCT03026179|Other|Intervention parents|Parents were asked to view 5-10 minutes of a program designed to educate about discipline.
2932116|NCT03026166|Experimental|Rovalpituzumab Tesirine and nivolumab|Rovalpituzumab tesirine 0.3 mg/kg intravenous (various dose regimens) and nivolumab intravenous (various doses and dose regimens)
2932117|NCT03026166|Experimental|Rovalpituzumab Tesirine and nivolumab plus ipilimumab 1 mg/kg|Rovalpituzumab tesirine 0.3 mg/kg intravenous (various dose regimens) and nivolumab intravenous (various doses and dose regimens) plus ipilimumab 1 mg/kg intravenous
2932118|NCT03026166|Experimental|Rovalpituzumab Tesirine and nivolumab plus ipilimumab 3 mg/kg|Rovalpituzumab tesirine 0.3 mg/kg intravenous (various dose regimens) and nivolumab intravenous (various doses and dose regimens) plus ipilimumab 3 mg/kg intravenous
2932119|NCT03026153|Other|Control group - Oral Survey 1|Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections
2932120|NCT03026153|Other|Intervention Group - Oral Survey 2|Oral Survey 2 will be administered as the intervention : patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
2932121|NCT03026140|Active Comparator|group 1|drug: ipilimumab 1 mg/kg day 1 (IV) drug: nivolumab 3 mg/kg on day 1 and day 15 (IV)
2932122|NCT03026140|Experimental|group 2|drug: ipilimumab 1 mg/kg day 1 (IV) drug: nivolumab 3 mg/kg on day 1 and day 15 (IV) drug: celecoxib 200 mg daily (oral)
2932123|NCT03026127|Experimental|CRISP|Cognitive Reappraisal Intervention for Suicide Prevention (CRISP) is a psychosocial intervention aimed to reduce suicide risk in middle-aged and older adults who have been hospitalized for suicidal ideation or suicide attempt. CRISP offers a combination of emotion regulation techniques, including changing the subject's perspective or the way he/she thinks to improve emotion reactions. Additional strategies taught include the provision of environmental adaptation tools (notes, checklists, calendars, etc), phone calls, and a tablet application called WellPATH.
2932124|NCT03026127|Active Comparator|Supportive Therapy (ST)|Supportive Therapy focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
2932125|NCT03026101|Experimental|Migraine Intervention|Subjects who will be administered 200 micrograms of nitroglycerin once into branches of their external carotid artery to determine the role of dilation of this artery to cause migraine-like pain
2932126|NCT03026088|Experimental|Bisoprolol|
2932127|NCT03026075|Experimental|Colonoscopy with MCS|Standard colonoscopy procedure with Motus Cleansing System
2932128|NCT03026062|Experimental|Sequential Group|Tremelimumab 3 mg/kg IV q4w for up to 4 doses followed by Durvalumab 1.5 g IV q4w for up to 9 doses upon progression
2932129|NCT03026062|Experimental|Combination Group|Tremelimumab 1 mg/kg IV plus Durvalumab 1.5g IV q4w for up to 4 doses followed by Durvalumab monotherapy 1.5 g IV q4w for up to 9 doses or until progression or unacceptable toxicity followed by physician directed ovarian cancer therapy upon progression
2932130|NCT03026049|Active Comparator|deep venous stent|Patients will receive deep venous stenting in the iliaco(femoral) region
2932131|NCT03026049|No Intervention|conservative managment|Conservative management of complaints
2932135|NCT03026023|Experimental|Treatment with grazoprevir + elbasvir +/- ribavirin|12 to 16 weeks of treatment with combination tablet of grazoprevir + elbasvir +/- ribavirin
2932136|NCT03025997|Active Comparator|Active yoghurt|Yoghurt snack containing encapsulated lipid
2932137|NCT03025997|Placebo Comparator|Placebo yoghurt|"Yoghurt snack containing non-encapsulated lipid~+ empty encapsulation matrix"
2932138|NCT03025984|Active Comparator|Texting|"Patients in the Texting group will receive reminders based on their individual disease treatment. A text message shall be sent one day (12 to 36 hours) before appointments to remind about the appointment and with instructions to bring glucose and food records to the appointment. If medication changes are made at the appointment, the patient will receive a text message reminder the day after her appointment to reinforce the regimen. Postpartum patients who had GDM will receive a text message reminder to complete their glucose tolerance test. A reminder will be sent at 2 weeks postpartum followed by a reminder at 6 weeks and 10 weeks postpartum if the testing is not completed."
2932139|NCT03025984|No Intervention|No texting|Patients in the contact control group will be enrolled in the text4baby program with assistance from a healthcare provider. As the study will conclude upon the patient's postpartum visit, she will be offered the option of discontinuing messages, which otherwise would continue through the infant's first year of life.
2932140|NCT03025971|Other|Single arm observational study|Intervention: J-Valve Transcatheter Aortic valve replacement. Prospective, multi-center, single arm observational study. Subjects will include patients with severe aortic valve stenosis and/or severe aortic regurgitation who require replacement of their native aortic valve.
2932141|NCT03025958|Experimental|Nimotuzumab|Elderly patients with locoregionally advanced nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent radiotherapy, weekly nimotuzumab (200 mg/week).
2932142|NCT03025945|Experimental|nepafenac 0.3%|nepafenac 0.3% ophthalmic solution dosed once daily
2932143|NCT03025945|Placebo Comparator|Saline Solution|sterile saline drops with a pH approximately of 7.0 and osmolality of 290 mOsm/kg, dosed at once daily
2932144|NCT03025932||Patient cohort|Patients who underwent laparoscopic hernia repair of giant hiatal hernia with mesh and received anterior fundoplication
2932145|NCT03025906|Experimental|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
2932146|NCT03025906|Experimental|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
2932147|NCT03025893|Experimental|Sunitinib|Patients in this experimental arm will receive sunitinib in a high-dose, intermittent schedule.
2932148|NCT03025893|Active Comparator|Lomustine|Patients in this control arm will receive lomustine, currently used as second-line treatment in the case of recurrence.
2932149|NCT03025880|Experimental|Single arm|"Eligible patients will be enrolled and treated with Pembrolizumab (P) at a dose of 200mg as an intravenous (IV) infusion on day 1 of each 21-day cycle in combination with Gemcitabine (G) at a dose of 1,250mg/m2 or 1,000mg/m2 (this dose will be explored in combination with P in the initial exploratory run-in-phase if necessary) as a IV infusion on day 1 and 8 of each 21-day cycle.~Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. An initial exploratory run-in-phase will be performed to test the safety of the combination and determine the Recommended Phase II Dose (RP2D) of G in combination with fixed doses of P."
2932150|NCT03025841|Other|Ceftaroline|Patients receive Ceftaroline 600mg BID
2932151|NCT03025828|Experimental|Acthar|Acthar will be administered subcutaneously (SC) 80 units for the first week and then 80 units twice weekly
2932152|NCT03025815|Experimental|Intervention group|Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.
2932153|NCT03025815|Sham Comparator|Control group|sham stimulation program consists of the same researcher placing her hands for 15 minutes.
2932154|NCT03025789|Experimental|Open label arm|children and adults to receive fexinidazole either as inpatients or outpatients.
2932155|NCT03025776||stroke|individuals chronic (> 6 months) post-stroke
2932156|NCT03025776||age matched health controls|age matched (double sample size anticipated) healthy controls
2932157|NCT03025763||Coronal Nonsyndromic Craniosynostosis, trios|Participants with diagnosis of coronal, nonsyndromic craniosynostosis including affected and unaffected biological parents
2932158|NCT03025763||Coronal, nonsyndromic craniosynostosis|Participants with coronal, nonsyndromic craniosynostosis when biological parents are not available
2932159|NCT03025763||Unaffected controls|Unaffected controls who may have undergone clinically indicated craniofacial surgery for trauma or conditions other than craniosynostosis or bone disease
2932160|NCT03025750|Experimental|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
2932161|NCT03025750|Active Comparator|IPV SSI|IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
2932162|NCT03025737||athletes|Healthy highly trained elite athletes, recreational athletes, young and master athletes free of known structural myocardial disease
2932163|NCT03025737||controls|Healthy volunteers without a history of competitive physical exercise
2932164|NCT03025724|No Intervention|Control|After the surgical excision, subjects will be asked to fill out a satisfaction survey. They will not receive any PDT treatment.
2932196|NCT03025516||Adults with pulmonary TB symptoms|"All patients will be tested with both the reference and index TB diagnostic tests. Index test results will not be used to inform case management.~All samples must be collected before the patient starts any form of TB treatment. Patients will be randomized to receive either the TB Breathalyser or AeonoseTM on Day 1, and will be tested with the remaining breath-test on Day 2. A follow-up evaluation will be required after 8 weeks for all patients who do not have microbiologic confirmation of TB (smear or culture). Two additional breath samples may also be collected upon follow-up."
2932165|NCT03025724|Experimental|Intervention Group|Subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours. At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals). Lastly, they will be asked to fill out a satisfaction survey.
2932166|NCT03025711||Pertuzumab|Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Pertuzumab under Spanish compassionate use or early access program
2932167|NCT03025711||Trastuzumab emtansine|Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Trastuzumab emtansine (T-DM1) under Spanish compassionate use or early access program
2932168|NCT03025698|Experimental|Cohort A (Option 1)|
2932169|NCT03025698|Experimental|Cohort A (option 2)|
2932170|NCT03025698|Experimental|Cohort B|
2932171|NCT03025685|Experimental|TRUST technique + Coronary Stenting|PCI with coronary stenting using TransRadial Ultra Support technique for support improvement
2932172|NCT03025685|Active Comparator|Anchoring technique + Coronary Stenting|PCI with coronary stenting using Wire Anchoring Pass technique for support improvement
2932173|NCT03025672||clostridium difficile|Patients that have been infected by clostridium difficile during their stay in hospital
2932174|NCT03025672||no clostridium difficile|Patients that have not been infected during their stay in hospital.
2932175|NCT03025659||Pediatric post-cardiac surgery|All immediately post-operative pediatric cardiac patients will be enrolled. Standard of care laboratory analysis will be performed based on current clinical protocols. Results for lactate, blood gases, liver enzymes, creatinine, glucose, hemoglobin, hematocrit and other direct and indirect measure of cardiac output will be collected. Investigators will also measure pyruvate levels at specific time points, which is not part of standard of care. To measure pyruvate, an additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw. The lactate/pyruvate ratio will be calculated and compared to direct and indirect measure of cardiac output described above.
2932176|NCT03025633|Other|Group A - PEARL|Group A will receive a combination of verbal and visual pre-treatment information via the use of PEARL.
2932177|NCT03025633|No Intervention|Group B - NON PEARL|Group B will receive verbal only pre-treatment information.
2932178|NCT03025620|Placebo Comparator|Sunflower arm|Participants were supplied with the usual diet of the hospital, daily enriched with 17.5g fat as follows during 42 days: 10 g of sunflower oil (with a high content in linoleic acid) were added into the dinner soup and 7.5g delivered through a 12.5g portion of margarine made with sunflower oil (60% fat) that replaced butter on the breakfast toasts.
2932179|NCT03025620|Active Comparator|Rapeseed arm|Participants were supplied with the usual diet of the hospital, daily enriched with 17.5g fat as follows during 42 days: 10 g of rapeseed oil (with a high content in alpha-linolenic acid) were added into the dinner soup and 7.5g delivered through a 12.5g portion of margarine made with rapeseed oil (60% fat) that replaced butter on the breakfast toasts.
2932180|NCT03025607|No Intervention|Control|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes as well as a list of resources for mHealth tools for monitoring diet, physical activity, and weight.
2932181|NCT03025607|Experimental|JOOL-Only|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes, a list of resources for mHealth tools to monitor diet, physical activity and weight, and will receive the JOOL Health mobile phone application.
2932182|NCT03025607|Experimental|JOOL-Plus|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes, a list of resources for mHealth tools to monitor diet, physical activity and weight, the JOOL Health mobile phone application, a digital scale, and a Fitbit.
2932183|NCT03025594|Experimental|Gonyautoxin|Gonyautoxin 40mcg
2932184|NCT03025594|Active Comparator|Control|Mix of chirocaine 0,2%, ketorolac and epinephrine..
2932185|NCT03025581|Active Comparator|Intervention group|Nipple stimulation.
2932186|NCT03025581|No Intervention|Control group|No intervention (expectant management only).
2932187|NCT03025568|Active Comparator|group 1|Patient will receive partial denture constructed from Bre_flex
2932188|NCT03025568|Experimental|group 2|Patients will receive removable partial denture constructed from PEEK
2932189|NCT03025555|Active Comparator|group 1|patients will receive partial denture constructed from breflex material.
2932190|NCT03025555|Experimental|group 2|patients will receive partial denture constructed from PEEK material.
2932191|NCT03025542|Experimental|Treatment Arm 1|Subjects randomized in this arm will receive a combination of Bimekizumab and Placebo injections.
2932192|NCT03025542|Experimental|Treatment Arm 2|Subjects randomized in this arm will receive Bimekizumab injections.
2932193|NCT03025529|Experimental|Active Cerebellar rTMS|Cerebellar rTMS will be carried out in ET subjects using a MagPro stimulator with a double cone coil at 1Hz (1 pulse every second) for 3 minutes on the left and 3 minutes on the right, at the cerebellar location indicated by resting state functional connectivity MRI analysis. Subjects with ET will undergo 5 consecutive daily sessions of cerebellar rTMS at either the connectivity map generated target or sham rTMS and then crossover to the other target after 2 weeks. Subjects will be blinded to the treatment order assignment. The intensity of the stimulation will be determined as 90% of the resting motor threshold, to be determined at the beginning of the first visit.
2932194|NCT03025529|Sham Comparator|Sham Cerebellar rTMS|In sham rTMS, the same parameters and procedures as Treatment Procedures 4-8 will be used, except that the coil will be angled 90 degrees from the scalp, resting on one wing of the coil.
2932195|NCT03025529|No Intervention|Healthy control pilot|This pilot phase is done to assess feasibility of obtaining MRI and cerebellocortical inhibition measures in healthy control subjects.
2932197|NCT03025503|Experimental|nipple stimulation|
2932198|NCT03025503|No Intervention|no intervention|
2932199|NCT03025490|No Intervention|standard of Care|Patient undergoing sedation, treatment team does not have capnography data available.
2932201|NCT03025477|Active Comparator|Control arm|"Initial or interval surgery associated with 6 cycles of chemotherapy in intravenous (IV) of carboplatin and paclitaxel.~The regimen of administration of the chemotherapy is as following:~Carboplatin AUC 6 - IV - Day (D) 1~Paclitaxel 80mg / m² - IV - D1, D8, D15~one cycle every 3 weeks"
2932202|NCT03025477|Experimental|Experimental arm|"Initial or interval surgery associated with 6 cycles of chemotherapy of cisplatin and epirubicin.~Cisplatin is administrated in intraperitoneal (IP) if no macroscopic residual tumor at the end of the intervention (initial or interval). If evidence of macroscopic residual tumor, cisplatin is administered in IV. Epirubicin is always given in IV.~Second cytoreduction surgery at mid-term of chemotherapy cycles, only in patients operable in response after 3 cycles and with persistent residual disease after initial surgery or incomplete initial staging.~The regimen of administration of the chemotherapy is as following:~Cisplatin 80mg / m² - IV or IP - D1~Epirubicin 60mg / m² - IV - D3~one Cycle every 3 weeks."
2932203|NCT03025451|Experimental|The Complete Health Improvement Program|Participants in The Complete Health Improvement Program
2932204|NCT03025425|Experimental|MPV-arm|Subjects use mouth piece ventilation (MPV) according to their will for 24 hours to alleviate dyspnea.
2932205|NCT03025412|Experimental|Endoscopic surgery|Ambulatory surgery. Postoperative rehabilitation. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
2932206|NCT03025412|Active Comparator|Conservative treatment|Physiotherapy and exercise. First physiotherapy consultation: Information, advice, instructions. Exercise regime during 12 weeks in three phases.
2932207|NCT03025399|Experimental|Tangwang Prescription|The prescription was composed five Chinese herbal medicines,every bag has 4.87g granules, take it one bag each time, two times a day.
2932208|NCT03025399|Placebo Comparator|Placebo|Placebo is a simulated drug of tangwang Prescription,every bag has 4.87g granules, take it one bag each time, two times a day.
2932209|NCT03025386|Other|Adult cochlear implant users|Evaluation of a concordance between the mismatch negativity amplitude mesured by electroencephalography and the capacity of logatoms discrimination by using a logatoms test
2932210|NCT03025373||Patients - prolonged ICU stay (> 5 days)|Controlled visual and acoustic stimulation in a virtual reality setting
2932211|NCT03025373||Heart surgery patients (< 5 days)|Controlled visual and acoustic stimulation in a virtual reality setting
2932212|NCT03025347|Experimental|Control|Experimental day where participants rest.
2932213|NCT03025347|Experimental|Exercise|Experimental day where participants complete a run.
2932214|NCT03025334|Active Comparator|Real tDCS left|Real anodal tDCS (left DLPFC)
2932215|NCT03025334|Sham Comparator|Sham tDCS|sham tDCS (30sec ramp-up and 3sec ramp-down)
2932216|NCT03025334|Active Comparator|Real tDCS right|Real anodal tDCS (right DLPFC)
2932217|NCT03025321|Experimental|transcranial direct current stimulation|This group will receive bilateral tDCS (left cathodal/right anodal) over the DLPFC. The stimulation will take place two times daily for 13 minutes with a rest interval of 20 minutes for five consecutive days.
2932218|NCT03025321|Sham Comparator|Sham tDCS|The control group receives sham, for which the stimulator will be gradually turned off after 30 seconds.
2932219|NCT03025308|Experimental|Filgotinib Dose A|Filgotinib dose A plus placebo to match (PTM) filgotinib dose B for up to 3 years
2932220|NCT03025308|Experimental|Filgotinib Dose B|Filgotinib dose B plus PTM filgotinib dose A for up to 3 years
2932221|NCT03025295|Experimental|Dexmedetomidine group|Induction dose of dexmedetomidine is 1ug/kg with 10min, maintain dose is 0.4ug/kg/h until 30 min before surgery completion.
2932222|NCT03025295|Placebo Comparator|Saline group|Control group given equal volume of saline with the dexmedetomidine group.
2932223|NCT03025282|Experimental|CD10367 3% Solution - Non-desquamated zone|
2932224|NCT03025282|Experimental|CD10367 1% Solution - Non-desquamated zone|
2932225|NCT03025282|Placebo Comparator|CD10367 solution placebo - Non-desquamated zone|CD10367 solution placebo serves as negative control.
2932226|NCT03025282|Active Comparator|Betneval ointment - Non-desquamated zone|This comparator containing Betamethasone valerate 0.1% serves as positive control.
2932227|NCT03025282|Experimental|CD10367 3% Solution - Desquamated zone|
2932228|NCT03025282|Placebo Comparator|CD10367 solution placebo - Desquamated zone|
2932229|NCT03025269||Relapsing MS patients treated with Ocrelizumab|30 patients diagnosed with relapsing forms of multiple sclerosis and newly beginning treatment with Ocrelizumab according to neurologists' orders
2932230|NCT03025256|Experimental|Nivolumab|"Dose Escalation: Participants receive intrathecal (IT) Nivolumab every 14 days. Cycle 1 consists of IT Nivolumab only, but in subsequent cycles the IT Nivolumab dose is followed by an intervenous dose of Nivolumab.~Intrathecal dose administered by accessing the Ommaya.~Dose Expansion: Maximum tolerated dose from Dose Escalation."
2932231|NCT03025243|Experimental|50 micron|surgical guide constructed with 3D printing with printing layer thickness 50 micron
2932232|NCT03025243|Active Comparator|100 micron|surgical guide constructed with 3D printing with printing layer thickness 100 micron
2932233|NCT03025230|Experimental|Experimental group|Dry needling technique and the application of a rectangular, biphasic, asymmetric analgesic electric current by selecting a frequency of 2 Hz with a pulse width 40 μs, with an intensity located at the tolerance threshold and for a time of 20 minutes.
2932234|NCT03025230|Active Comparator|Control group|Dry technique in PG.The needle will be moved in-and-out into different directions to encounter sensitive spots in PG region.
2932235|NCT03025217|Experimental|TLC Program|The TLC Program consists of one in-person visit with a licensed dietician and biweekly phone coaching sessions. During the program, the dietician will 1) identify specific nutrition goals, 2) review and tailor the education materials to the patient's needs, and 3) set up regular telephone coaching sessions of up to two sessions per month for six months for each patient. Motivational interviewing and nutrition/health coaching will be provided.
2932236|NCT03025204|Active Comparator|GAP Surgical Access (GAP + OFD, 15 patients)|Patients diagnosed with generalized aggressive periodontitis (GAP), in which the previously selected intrabony defect will receive will receive open flap debridement.
2932237|NCT03025204|Experimental|GAP Surgical Access + EMD (GAP + OFD/EMD, 15 patients)|Patients with a diagnosis of generalized aggressive periodontitis (GAP), in which the previously selected intrabony defect will receive open flap debridement and, in addition, application of the EMD in the defect.
2932238|NCT03025204|Active Comparator|GCP Surgical Access + EMD (GCP + OFD/EMD, 15 patients)|Patients with a diagnosis of generalized chronic periodontitis (GCP), in which the previously selected intrabony defect will receive open flap debridement and, in addition, application of the EMD in the defect.
2932239|NCT03025191|Experimental|Prison Connect|
2932240|NCT03025178|Experimental|Central venous catheterization|Central venous catheterization will be performed using 4Fr central venous catheter at left internal jugular vein in infant. The tip of central venous catheter will be confirmed by transthoracic echocardiography. The actual insertion depth of central venous catheter will be compared to the predicted insertion depth derived from two calculation methods using height and the distance between the anatomical landmarks.
2932241|NCT03025165|Experimental|Community Adherence Clubs|ART adherence support, symptom screening and dispensation of pre-packed medications by community health worker to a club meeting of 20-25 HIV+ patients every three months, with two clinic visits every year for clinical review and laboratory monitoring
2932242|NCT03025165|Experimental|Home-Based ART Delivery|Individuals receive ART adherence support, symptom screening and dispensation of pre-packed medications by community health worker at their household every three months, with two clinic visits every year for clinical review and laboratory monitoring
2932243|NCT03025165|Other|Standard of Care|Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
2932244|NCT03025152|Experimental|Hou Gu Mi Xi|Patients in this arm receive Hou Gu Mi Xi, with an oral dose of 10 g/day during entire follow up period (2 years).
2932245|NCT03025152|Placebo Comparator|placebo|Patients in this arm receive placebo, with an oral dose of 10 g/day during entire follow up period (2 years).
2932246|NCT03025139|Active Comparator|Arm A (MAPs)|Patients attend a mindfulness meditation class over 2 hours once weekly for 6 weeks. Patients then attend in person booster sessions that include guided meditation, questions, and discussion of how to maintain a mindfulness practice over 1 hour once monthly for 2 months.
2932247|NCT03025139|Active Comparator|Arm B (SE)|Patients attend a survivorship education class over 2 hours once weekly for 6 weeks. Patients also receive monthly electronic newsletters with tailored information about topics of interest to younger survivors, including cancer-related events in the community and tips about following through on recommendations for healthy living.
2932248|NCT03025139|Active Comparator|Arm C (USUAL CARE/DELAYED TREATMENT CONTROL GROUP)|Patients receive usual care for 9 months. Patients are then offered a choice of participating in Arm A or Arm B.
2932249|NCT03025126|Experimental|HEAD Rehabilitation|rehabilitation with IT multimedial devices
2932250|NCT03025126|Active Comparator|Usual care program|usual care program
2932251|NCT03025113|Experimental|EMS association|The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
2932252|NCT03025113|Active Comparator|Miosan®|The patient will take 2 tablets (cyclobenzaprine isolated), oral, per day, each 12h.
2932253|NCT03025100||Prospective|A sample of 120 patients aged 60 years or older admitted to General Medicine at Duke University Hospital will be enrolled in the prospective cohort study. A convenience sample will be derived from a randomized daily list of general medicine admissions; weekend admissions will be excluded as these patients will not be captured within 24 hours of hospital admission.
2932254|NCT03025087|Experimental|Phase 1|6 subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery.
2932255|NCT03025087|Experimental|Phase 2|6 subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 400 mg daily until the day of MRI imaging on postoperative day 2-5
2932256|NCT03025087|Experimental|Phase 3|6 subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 400 mg twice daily (800 mg total) until the day of MRI imaging on postoperative day 2-5.
2932257|NCT03025087|Experimental|Phase 4|6 subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 500 mg twice daily (1000 mg total) until the day of MRI imaging on postoperative day 2-5.
2932258|NCT03025087|Experimental|Phase 5|6 subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ 1-2 hours after separation from CPB or at end of noncardiac surgery followed by the highest tolerated dose from the previous 4 phases divided into 2 equal daily doses until the day of MRI imaging on postoperative day 2-5.
2932259|NCT03025061||40 children with moderate asthma|Assessment of E-nose measurements: three E-nose measurements on 40 children with moderate asthma (of both sex and 6-11 years old): first measurement, second one after 30 minutes, third one after 7 days. These children attend the outpatient clinic of Pediatric Allergology & Pulmonology (PAP) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (IBIM CNR).
2932260|NCT03025061||40 children with severe asthma|Assessment of E-nose measurements: three E-nose measurements on 40 children with severe asthma (of both sex and 6-11 years old): first measurement, second one after 30 minutes, third one 7 days. These children attend the outpatient clinic of Pediatric Allergology & Pulmonology (PAP) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (IBIM CNR).
2932261|NCT03025061||40 healthy children|"Assessment of E-nose measurements: three E-nose measurements on 40 healthy children (of both sex and 6-11 years old): first measurement, second one after 30 minutes, third one after 7 days. These children attend the primary schools involved in the municipal project Educational Pathways (Palermo)."
2932262|NCT03025035|Experimental|Pembrolizumab|This is an open-label, single-arm pilot study in 20 subjects with advanced BRCA mutation-associated breast cancer having progressed through at least a standard first line therapy.
2932263|NCT03025022|Experimental|14C-JNJ-42847922 40 miiligram (mg)|Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 on Day 1.
2932264|NCT03025009|Experimental|LY3192767 (Part A)|Escalating doses of LY3192767 administered subcutaneously (SC).
2932265|NCT03025009|Placebo Comparator|Placebo (Part A)|Placebo matching LY3192767 administered subcutaneously (SC).
2932266|NCT03025009|Experimental|LY3192767 (Part B)|LY3192767 administered as a SC injection in one of three study periods.
2932267|NCT03025009|Active Comparator|Basal Insulin Peglispro (Part B)|Basal insulin peglispro administered as a SC injection in one of three study periods.
2932268|NCT03025009|Active Comparator|Insulin Glargine (Part B)|Insulin glargine administered as a SC injection in one of three study periods.
2932497|NCT03023397|Other|Der f treated Cigarette smoker|
2932269|NCT03024996|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (q3w) for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
2932270|NCT03024996|Placebo Comparator|Placebo|Participants will receive placebo matching to atezolizumab q3w for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
2932271|NCT03024983|Active Comparator|Control|Glucose monohydrate (isoglucidic portion -50 g of available carbohydrates-)
2932272|NCT03024983|Experimental|Semolina|Semolina soup (isoglucidic portion -50 g of available carbohydrates-)
2932273|NCT03024983|Experimental|Bread|Bread (isoglucidic portion -50 g of available carbohydrates-)
2932274|NCT03024983|Experimental|Short pasta (fresh)|Fresh penne (isoglucidic portion -50 g of available carbohydrates-)
2932275|NCT03024983|Experimental|Short pasta (dry)|Short pasta (dry) (isoglucidic portion -50 g of available carbohydrates-)
2932276|NCT03024983|Experimental|Long pasta (dry)|Long pasta (dry) (isoglucidic portion -50 g of available carbohydrates-)
2932277|NCT03024957|Active Comparator|Dexmedetomidine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 5 μg of dexmedetomidine in 1 mL volume intrathecally.
2932278|NCT03024957|Active Comparator|Morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 0.5 mg morphine sulphate in 1 mL volume intrathecally.
2932279|NCT03024957|Active Comparator|Dexmedetomidine + morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 5 μg of dexmedetomidine plus 0.5 mg of morphine sulphate in 1 mL volume intrathecally.
2932280|NCT03024944|Experimental|Brain Imaging with 18F-THK-5351|This group consists of 30 adult subjects: 10 with Type 2 diabetes, 10 with pre-diabetes, and 10 with normal glucose tolerance. Each subject will receive a baseline scan and a follow-up PET scan with 18F-THK-5351.
2932281|NCT03024918||MCDA cohort|Unselected monochorionic diamniotic (MCDA) twin pregnancies, included between 11 and 14 weeks of gestation
2932282|NCT03024918||TTTS cohort|Pregnancies complicated by twin-twin transfusion syndrome (TTTS) undergoing laser treatment, included at the time of diagnosis or referral
2932283|NCT03024918||sIUGR cohort|Pregnancies complicated by selective intrauterine growth restriction (sIUGR), included at the time of diagnosis or referral. We define sIUGR as a discordance in estimated fetal weight of ≥ 20%.
2932284|NCT03024905|Experimental|Division 1|"The first division receives baseline data collection for 6 months then experiences interventions for the remainder of the trial.~Interventions are behavioural and device:~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
2932285|NCT03024905|Experimental|Division 2|"The second division receives baseline data collection for 9 months then experiences interventions for the remainder of the trial.~Interventions are behavioural and device:~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
2932286|NCT03024905|Experimental|Division 3|"The third division receives baseline data collection for 12 months then experiences interventions for the remainder of the trial.~Interventions are behavioural and device:~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
2932287|NCT03024905|Experimental|Division 4|"The fourth division receives baseline data collection for 15 months then experiences interventions for the remainder of the trial.~nterventions are behavioural and device: Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
2932288|NCT03024892|Experimental|ICG gallbladder|patients who received ICG injection via gallbladder and received fluroscence image guided surgery
2932289|NCT03024892|Experimental|ICG IV|patients who received ICG injection via peripheral vein and received fluroscence image guided surgery
2932290|NCT03024892|Sham Comparator|LC conventional|Patients received conventional laparoscopic cholecystectomy
2932291|NCT03024892|Sham Comparator|LC conventional and IOC|Patients received conventional laparoscopic cholecystectomy + intraoperative cholangiography
2932292|NCT03024879|Active Comparator|Erythromycin|40 mg of erythromycin will be administered intravenously over a period of 20 min in a saline solution of 100 ml
2932293|NCT03024879|Placebo Comparator|Placebo|a saline solution of 100 ml will be administered intravenously over a period of 20 min
2932294|NCT03024866||Electronic Brachytherapy|Previously completed treatment for non-melanoma skin cancer using Xoft eBx Electronic Brachytherapy System
2932295|NCT03024866||Mohs Surgery|Previously completed treatment for non-melanoma skin cancer using Mohs Surgery
2932296|NCT03024853|Experimental|BPS PAST|Participants write down about themselves in a past when they displayed their best self. Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.
2932297|NCT03024853|Experimental|BPS PRESENT|Participants write down about themselves in in the present, focusing on what currently makes the best version of themselves (skills, features...). Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.
2932298|NCT03024853|Experimental|BPS FUTURE|"Participants write down about themselves in the future after everything has gone as well as it possibly could. Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.~This is the original BPS exercise (already validated in other studies)."
2932299|NCT03024853|Active Comparator|CONTROL|Participants write down the activities they did during the last 24 hours. Then, they visualize (imagine) the content. They practice the visualization exercise for 7 consecutive days.
2932300|NCT03024840|Experimental|sevoflurane|Sevoflurane is inhalated with 1%-2% after anesthesia induction until end of the surgery.
2932301|NCT03024840|Experimental|propofol|Propofol is injected with 9-15 mg/kg/h after anesthesia induction until end of the surgery.
2932302|NCT03024827|Experimental|Medical Cannabis Oil|CanniMed® 1:20
2932303|NCT03024814|Experimental|acetaminophen group|Babies who took acetaminophen
2932304|NCT03024814|Experimental|Placebo group (Dextrose 5)|Babies who took placebo
2932305|NCT03024801|Experimental|autologous platelet-rich plasma group|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
2932306|NCT03024801|Experimental|normal saline group|The patients with knee cartilage injury were randomized to the normal saline group.
2932307|NCT03024775|Active Comparator|Active Comparator 1|Wheat flour with high inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.
2932308|NCT03024775|Active Comparator|Active Comparator 2|Wheat flour with low inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.
2932309|NCT03024775|Placebo Comparator|Placebo 1|Placebo (xylose) will be administered blindly versus wheat flour with high inflammatory response for 15 days in NCWS patients.
2932310|NCT03024775|Placebo Comparator|Placebo 2|Placebo (xylose) will be administered blindly versus wheat flour with low inflammatory response for 15 days in NCWS patients.
2932311|NCT03024762|Experimental|Intervention arm|The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
2932312|NCT03024762|No Intervention|Control arm|The control arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years; consulting in the hospital for any motive. These children will be recruited for HIV testing at the outpatient department (OPD) and this through their accompany parents/guardians. Care providers will be advised to propose HIV testing systematically to all children and adolescents showing up at the OPD irrespective of the chief complaint.
2932313|NCT03024723||FmCPAP|CPAP ventilation administered via face mask
2932314|NCT03024710|Experimental|Intervention cluster|"The study participants (the infant who has completed his/her 6 month of age from the date of birth along with their mother) will be enrolled from MNCH database according to criteria for the intervention group.All the mothers of the selected infants along with family member/s will receive training on standard complementary feeding practices . Refresher training will be arranged 3 months after the first training.~The CHRW will visit each infant house till the infant reaches at 12 month of age at every two month interval. During the visit CHRWs will measure weight through standard SECA digital weighing scale in nearest 100 gm (precision 20 gram) and length in nearest 0.1 cm by local made standard length board with movable foot board."
2932315|NCT03024710|No Intervention|Controlled cluster|The participants for control clusters will be (the infant who has completed his/her 6 month of age from the date of birth along with their mother) will be enrolled from MNCH database according to criteria. The mother-infant pairs from control cluster will receive the usual care.
2932316|NCT03024697|Active Comparator|PECs Block|Patients randomised to receive pectoral plane blocks and a sham local anaesthetic infusion wound catheter
2932317|NCT03024697|Active Comparator|LA Infusion|Patients randomised to receive a local anaesthetic infusion wound catheter; No sham pectoral plane block performed as patients usually under general anaesthetic at time of block.
2932318|NCT03024697|Active Comparator|PECs Block & LA Infusion|Patients randomised to receive pectoral plane blocks and a local anaesthetic infusion wound catheter.
2932319|NCT03024684|Experimental|Statin|Atorvastatin 10mg oral once daily
2932320|NCT03024684|Placebo Comparator|Placebo|Matched placebo (sugar pill) once daily
2932321|NCT03024671|Experimental|patch test|Patients with patch test of cosmetics
2932322|NCT03024658|No Intervention|Zero PEEP|This group of patients did not receive any PEEP at the time of induction of general anesthesia (n= 30)
2932323|NCT03024658|Experimental|PEEP- 10 cm of H2O|This group comprised of patients who received a PEEP of 10 cm H2O at the time of induction of general anesthesia (n= 30)
2932324|NCT03024645|Experimental|BeAMom|High-risk (HR) women will receive a web-based preventive intervention for PPD (the Be a Mom program). In addition, women will receive postpartum and and pediatric treatment as usually performed in primary care settings (TAU).
2932325|NCT03024645|Experimental|BeAMom_with_partner|High-risk (HR) women and their partners will receive a web-based preventive intervention for PPD (the Be a Mom program). The women's partners will be invited to assist the program together with the women. In addition, women will receive postpartum and pediatric treatment as usually performed in primary care settings (TAU).
2932326|NCT03024645|Active Comparator|Control|High-risk (HR) women will receive postpartum and pediatric treatment as usually performed in primary care settings (TAU). During medical appointments, health professionals may ask women and provide information about psychological problems during the postpartum period.
2932327|NCT03024632||trial of labor|Pregnant women with a history of 3 or more cesarean sections who desired a trial of labor
2932328|NCT03024632||No trial of labor|Pregnant women with a history of 3 or more cesarean sections who desired a a repeat cesarean section
2932329|NCT03024606|Active Comparator|texting group|text messages focused on smoking cessation and pregnancy
2932330|NCT03024606|No Intervention|control group|No text messages
2932331|NCT03024593|Experimental|Searching condition|To simulate participants' natural behavior they are requested to search online for personally relevant health or illness information in their usual manner. By doing so their attentional focus lies on the searching process and the information they obtain.
2932332|NCT03024593|No Intervention|Waiting condition (i.e. non- searching, no distraction)|Participants are requested to do nothing and not to distract themselves by reading or using their smartphone for instance. By doing so, it is expected that their attentional focus lies on their induced worries and symptoms.
2932333|NCT03024580|Experimental|Megestrol acetate|Megestrol acetate 160 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
2932399|NCT03024099|Experimental|Hippotherapy twice a week|hippotherapy twice a week
2932400|NCT03024086|Experimental|DWJ1252|DWJ1252 + Placebo of Gasmotin
2932334|NCT03024580|Active Comparator|Anastrozole|Anastrozole 1 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
2932335|NCT03024580|Active Comparator|Letrozole|Letrozole 2.5 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
2932336|NCT03024580|Active Comparator|Exemestane|Exemestane 25 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
2932337|NCT03024580|Active Comparator|Tamoxifen|Tamoxifen 20 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
2932338|NCT03024580|Active Comparator|Fulvestrant|Fulvestrant 500 mg intramuscularly (IM) d1, d14, d28 and q28 days until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
2932339|NCT03024567|Active Comparator|Salt|6 grams sodium chloride per day for 14 days
2932340|NCT03024567|Placebo Comparator|Placebo|6 grams gelatine per day for 14 days
2932341|NCT03024554|Experimental|treatment|aortic aneurysm involving iliac arteries treatment with the Bifurcated Multilayer Flow Modulator (BMFM)
2932342|NCT03024541||LASA study|
2932343|NCT03024541||InterRAI consortium|
2932344|NCT03024528||CAM-ICU (+)|Delirious patients.
2932345|NCT03024528||CAM-ICU (-)|Non-delirious patients
2932346|NCT03024515|Experimental|Standard Practice Arm|Standard Practice Arm with opioids titration of physicians' choice
2932347|NCT03024515|Experimental|Structured Tritration Arm|Structured titration method with predefined titration steps with the use of oxycodone immediate-release and oxycodone sustained-release preparations.
2932348|NCT03024502|Experimental|EPP-AF Gel 1%|Group of patients that will be treated with EPP-AF mucoadhesive gel 1%, during 7 day, 1x/day.
2932349|NCT03024502|Experimental|Clotrimazole cream|Group of patients that will be treated with clotrimazole cream, during 7 day, 1x/day.
2932350|NCT03024502|Experimental|EPP-AF Gel 2%|Group of patients that will be treated with EPP-AF mucoadhesive gel 2%, during 7 day, 1x/day.
2932351|NCT03024489|Experimental|Palbociclib-Cetiximab-IMRT|"IMRT will be administered 5 days on/2 days off with a total dose of 70 Gy for 33 fractions.~Cetuximab will be administered 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.~Palbociclib will be administered orally daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49) on 3 dose levels and the MTD."
2932352|NCT03024476|Experimental|Intensive management arm|"Description:~Interventions in the intensive management arm consist of 1) behavioral intensification and 2) pharmacological intensification based on olmesartan~Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups).~Regarding behavioral intensification, an automated texting and call for breakthrough visit will be sent from the main server to encourage regular measurements of BP and maintain a desirable goad of BP.~Regarding pharmacological intensification, a specific algorithm for BP-lowering medication prescription will be provided to the responsible physicians by the steering committee."
2932353|NCT03024476|Active Comparator|Control arm|"Description:~Other than a bluetooth-equipped sphygmomanometer, standard managements abiding by the most current guideline will be provided from the responsible physicians.~Participants will be given a Bluetooth-equipped sphygmomanometer, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups)."
2932354|NCT03024450||HER2 positive AGC treated with H+CT|HER2 expression was assessed by IHC first. In the cases with IHC 2+, fluorescence in situ hybridization (FISH) was used to detect HER2/neu amplification levels. Only patients with high level of HER2 expression (IHC 3+ or IHC 2+ plus FISH positive) were eligible in this study.
2932355|NCT03024437|Experimental|Phase I - Dose Escalation|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and ANY or NO prior treatments.~Three dose levels of entinostat will be tested in 3-patient cohorts according to the 3 + 3 standard design (1 mg, 3 mg and 5 mg). The starting dose level of entinostat will be 1 mg orally every 7 days. The Phase II dose will be recommended phase II dose of entinostat (i.e., the highest tested dose that is declared safe and tolerable by the Investigators and Sponsor)."
2932356|NCT03024437|Experimental|Phase II - Cohort A|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and NO prior treatments.~Patients in Cohort A will be treated with atezolizumab, bevaciuzmab, and the recommended phase II dose of entinostat. During Phase II, the study will have a run-in period with entinostat for one cycle followed by atezolizumab and bevacizumab for the second cycle, and then the combination phase (i.e., atezolizumab + bevacizumab + entinostat for all cycles thereafter)."
2932357|NCT03024437|Experimental|Phase II - Cohort B|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and at least one prior treatment with a PD1 inhibitor.~Patients in Cohort B will be treated with atezolizumab alone. If there is no response to atezolizumab, then the recommended phase II dose of entinostat will be added to the standard dose of atezolizumab. If there is a response to atezolizumab, patients will continue to be treated with atezolizumab alone."
2932358|NCT03024424|Experimental|Early disclosure|Early disclosure group receives results of genetic testing at Week 4
2932359|NCT03024424|Active Comparator|Late disclosure|Late disclosure group receives results of genetic testing at final study visit (Month 12)
2932360|NCT03024411|Experimental|Music/video games|iPod (Music/video games)
2932361|NCT03024411|No Intervention|No intervention|No intervention
2932362|NCT03024385||Mothers of healthy infants|Mothers of young infants presenting for well child visits between the ages of 0-2 years of age
2932363|NCT03024372|Active Comparator|Conventional sutures|AV fistula creation with sutures
2932364|NCT03024372|Active Comparator|Anastoclips|AV fistula creation with clips
2932401|NCT03024086|Active Comparator|Gasmotin|Gasmotin + Placebo of DWJ1252
2932402|NCT03024073||SG|Study group (patients who underwent pseudophakic presbyopic correction with bilateral bifocal lenses implantation
2932365|NCT03024359|Active Comparator|obese individuals|Individuals with BMI between 30 and 35 kg/m2 will be included in this group and will receive 4 weeks of extra virgin olive oil. Before and after the intervention period data regarding dietary intake and physical activity, brown/beige adipose tissue activity, body composition (DXA), lipid profile and inflammatory markers and hypothalamic inflammation (in a subsample of 10 obese individuals)will be collected.
2932366|NCT03024359|Active Comparator|normal weight individuals|Individuals with BMI between 18.5 and 24.99 kg/m2 will be included in this group and will receive 4 weeks of extra virgin olive oil. Before and after the intervention period data regarding dietary intake and physical activity, brown/beige adipose tissue activity, body composition (DXA), lipid profile and inflammatory markers and hypothalamic inflammation (in a subsample of 10 normal weight individuals)will be collected.
2932367|NCT03024333||Healthy subjects|"Healthy subjects are:~Between 19-60 years old~Able to sign the informed consent after the whole study is explained to them~Self-reporting no history of swallowing disorders, neurological deficits and/or cancer of the mouth, neck or brain, or head or neck surgery~Able to sit upright with or without back support of chair~No other diseases affect swallowing function"
2932368|NCT03024320|Experimental|M2M|A theory-driven eHealth platform and innovative physical activity program referred to as movement-to-music (M2M), delivered customized and for the home-based for adults with physical disability.
2932369|NCT03024320|Experimental|M2Mplus|A theory-driven eHealth platform and innovative physical activity program referred to as movement-to-music (M2M), delivered customized and for the home-based for adults with physical disability. This arm also includes a social networking platform where participants will be able to interact and encourage one another through the program.
2932370|NCT03024320|Active Comparator|Attention Control|Participants will receive phone-based coaching modeled after the Living Well with a Disability health promotion curriculum; however, physical activity will not be discussed.
2932371|NCT03024307|Experimental|Involvement of pharmacists in improving medication|Pharmacists involved care group. Tools used to improve medication adherence, (1)Patient medication guide (2)tailored Short Messaging Service (SMS) (3)Pharmaceutical follow-up
2932372|NCT03024307|No Intervention|usual care only|Patients were provided with usual care.
2932373|NCT03024294|Other|Patients undergoing VATS lobectomy or segmentectomy|Patients undergoing VATS lobectomy or segmentectomy performed by one of the surgeons in the Division of Thoracic Surgery who are then placed on this specific post-operative care pathway to determine the rate of discharge of these patients by post-operative day (POD) three.
2932374|NCT03024268|Experimental|A: interventional closure of iASD|Interventional closure of iASD (n=40) with an Figulla Flex Occluder (Occlutech)
2932375|NCT03024268|No Intervention|B: no intervention|Best medical supportive care (n=40)
2932376|NCT03024255|Experimental|BBI-4000 Concentration 1|Low Concentration
2932377|NCT03024255|Experimental|BBI-4000 Concentration 2|Medium Concentration
2932378|NCT03024255|Experimental|BBI-4000 Concentration 3|High Concentration
2932379|NCT03024255|Placebo Comparator|Vehicle|Vehicle (Placebo)
2932380|NCT03024242|Experimental|Tight vaginoscope|The vaginoscope was extracted and loaded inside a thick rubber ring before its reinsertion inside the vagina again. To avoid leakage from the center of the thick rubber ring, the vaginoscopy is inserted through a premade central cruciate incision.
2932381|NCT03024229|Other|LifePort® perfusion machine|Metabolomic analysis of the preservation fluid of the graft, donor and recipient urine by nuclear magnetic resonance spectroscopy, and if possible by liquid and gas chromatography coupled with mass spectrometry.
2932382|NCT03024216|Experimental|Arm 1|Atezolizumab1200 mg IV week 1 and week 4 followed by Sipuleucel-T administered weeks 6, 8, and 10
2932383|NCT03024216|Experimental|Arm 2|Sipuleucel-T administered week 1, 3, and 5 followed by Atezolizumab1200 mg IV weeks 7 and 10
2932384|NCT03024203|Experimental|Executive Training|Executive Training (ET) involves training on computerized cognitive exercises that have graded increases in difficulty so that the participant is always challenged. A therapist will be in the room with participants to address any difficulties with the program and facilitate generation of strategies. ET will be delivered in both individual and group settings.
2932385|NCT03024203|Experimental|Perceptual Training|Perceptual Training (PT) involves training on computerized cognitive exercises that have graded increases in difficulty so that the participant is always challenged. A therapist will be in the room with participants to address any difficulties with the program and facilitate generation of strategies. PT will be delivered in both individual and group settings.
2932386|NCT03024190|Experimental|with Kinesiotaping|"stretching exercises combined with Kinesiotaping~regular OT rehabilitation program for 3 weeks"
2932387|NCT03024190|Other|control group|"the patients will receive 15-min stretching exercises~regular OT rehabilitation program for 3 weeks"
2932388|NCT03024177|Experimental|Vapendavir 528 mg|
2932389|NCT03024177|Placebo Comparator|Placebo|
2932390|NCT03024164||Young adult stroke patients|Young adult (18-45 years old) patients with confirmed first-ever acute ischemic stroke
2932391|NCT03024151|Active Comparator|T4/T3 combination replacement|Comthyroid
2932392|NCT03024151|Active Comparator|T4 mono replacement|Synthroid
2932393|NCT03024138||Repeat CT|
2932394|NCT03024125|Experimental|High protein diet (HP)|Diet with 1.2 protein g/kg body mass/day for postmenopausal women practitioners of resistance exercise. The physical strength training will be performed equally by both groups
2932395|NCT03024125|Placebo Comparator|Normal protein diet (NP)|Diet with 0.8 protein g/kg body mass/day for postmenopausal women practitioners of resistance exercise. The physical strength training will be performed equally by both groups
2932396|NCT03024112|Experimental|Heated humidified high-flow nasal cannula (HHFNC) oxygen|The intervention group received HHFNC O2 at a set flow of 40L/min. FiO2 was titrated by respiratory therapists to maintain SpO2 ≥ 90%. The HHFNC O2 apparatus included: 1) Air-Oxygen blender - capable of delivering 21-100% FiO2 at flow rates up to 60L/min, 2) Heated Humidifier - providing active heating and humidification to the delivered air-O2 blend, 3) Nasal cannula - larger diameter, slightly elongated nasal cannula with single limb connection to humidifier
2932397|NCT03024112|Active Comparator|Standard oxygen Therapy|The standard O2 treatment group received usual nasal cannula or face mask oxygen titrated by nurses as necessary to maintain SpO2 ≥ 90%.
2932398|NCT03024099|Experimental|Hippotherapy once a week|Hippotherapy once a week;
2932404|NCT03024060|Experimental|ALA 20 mW|ALA + IBL 10J at 20 mW (8min 20 sec)
2932405|NCT03024060|Experimental|ALA 10 mW|ALA + IBL 10J at 10 mW (16 min 40 sec)
2932406|NCT03024060|Placebo Comparator|Vehicle|Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving light treatment delivered at 20 mW/cm2 OR 10 mW/cm2. Subjects receiving VEH will be considered a single treatment group
2932407|NCT03024034|Active Comparator|Cohort A|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 25 mg single dose (n = 6) or matching placebo (n = 2)
2932408|NCT03024034|Active Comparator|Cohort B|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg single dose (n = 6) or matching placebo (n = 2)
2932409|NCT03024034|Active Comparator|Cohort C|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 100 mg single dose (n = 6) or matching placebo (n = 2)
2932410|NCT03024034|Active Comparator|Cohort D|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 150 mg single dose (n = 6) or matching placebo (n = 2)
2932411|NCT03024034|Active Comparator|Cohort E|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 200 mg single dose (n = 6) or matching placebo (n = 2)
2932412|NCT03024034|Active Comparator|Cohort F|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 300 mg single dose (n = 6) or matching placebo (n = 2)
2932413|NCT03024034|Active Comparator|Cohort G|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg TP 271, cross-over to 50 mg TP 271/250 mg EDTA (n = 3); 50 mg TP 271/250 mg EDTA, cross-over to 50 mg TP 271 (n = 3); matching placebo, cross over to 250 mg EDTA (n= 1); or 250 mg EDTA, cross over to matching placebo (n = 1)
2932414|NCT03024008|Experimental|Intervention Arm|"Clinical Interventions:~Blood tests: complete blood count, full blood chemistry and biochemistry including phosphate, alkaline phosphatase, calcium, renal and liver function, and coagulation. Serology tests: HIV, Hepatitis B, Hepatitis C.~Xray~Urine Test~CT~Liposuction - harvest of 50-300ml autologous adipose tissue from the subject's abdomen~Single transplantation of Investigational Medicinal Product BonoFill-II into long bone extra-articular comminuted fracture or large bone defect/critical gap"
2932415|NCT03023995|Experimental|CAF with Platelet Rich Fibrin|In test group, preparation of PRF was carried out, after which the flap was coronally positioned over the membrane to completely cover it.
2932416|NCT03023995|Active Comparator|CAF with connective tissue graft|In control group, connective tissue graft harvesting was carried out which was followed by placement of connective tissue graft on the recipient site. The connective tissue graft was placed on the recipient site and secured in position with 5-0 vicryl sutures
2932417|NCT03023982|Experimental|Pectoralic block group|After general anesthesia, 40ml of 0.25% Bupivacaine Hydrochloride will be administered before procedure Thoracotomy. Block will be administrated between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib., in assistance of ultrasound for visualization anesthetic injection point.
2932418|NCT03023982|Active Comparator|Control group|Patients in this group will receive standard pain control with opioids and NSAIDs
2932419|NCT03023969|Active Comparator|group A|percutaneous ozone intradiscal injection group A receive 10 ml of ozone oxygen mixture 40 ug O3/ ml O2
2932420|NCT03023969|Active Comparator|group B|percutaneous ozone intradiscal injection group receive 10 ml of ozone oxygen mixture 30 ug O3/ ml O2.
2932421|NCT03023956||ANF|anatomic neck fractures of proximal humerus
2932422|NCT03023956||SNF|surgical neck fractures of proximal humerus
2932423|NCT03023943|Experimental|IASTM group|Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.
2932424|NCT03023930|Experimental|Evidenced-based Practice Dissemination|Evaluating standard dissemination practice compared with implementation facilitation
2932425|NCT03023917|Active Comparator|umbilical cord clamping immediately|"Umbilical cord was clamped immediately, or as close as possible, after delivery of the infant's shoulders. (This was standard practice in the study hospital, thus it served as the control group)."
2932426|NCT03023917|Experimental|umbilical cord milking|preterm baby were placed at or below level of the placenta and about 25cm of the umbilical cord was vigorously milked towards the umbilicus two to three times before clamping the cord. The milking speed was about 25cm/2 seconds
2932427|NCT03023904|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 2 weeks for up to 2 years (104 weeks) in the absence of disease progression or unacceptable toxicity.
2932428|NCT03023891|Experimental|Prednisone|Each participant will received a single dose of oral 60 mg of prednisone
2932429|NCT03023878|Experimental|Blinatumomab|"Blinatumomab is administered as a continuous intravenous (IV) infusion. Cycle 1 is 12 weeks (84 days) in duration with step dosing of 9 µg/day x 7 days, 28 µg/day x 7 days, and 112 µg/day until the end of week 8. This is followed by a 4 week treatment free period.~Optional Cycle 2 of Blinatumomab is 4 weeks in duration (28 days), with step dosing of 9 µg/day x 7 days, 28 µg/day x 7 days, and 112 µg/day x 14 days."
2932430|NCT03023865|Experimental|Staged stress function|A preoperative staged stress function procedure for elongation of the proximal and distal segments to achieve utilizing the native esophagus to establish esophageal continuity
2932431|NCT03023852|Experimental|Panel 1: Group 1|Participants will receive Treatment A (JNJ-63623872 600 milligram (mg) (2*300 mg) oral tablets [reference]) followed by Treatment B (JNJ- 63623872 600 mg (2*300 mg) concept oral tablet formulation 1 (test 1) and then Treatment C (JNJ-63623872 600 mg (2*300 mg) concept oral tablet formulation 2 (test 2). Each treatment period will be separated 7 days washout period.
2932432|NCT03023852|Experimental|Panel 1: Group 2|Participants in Group 2 will receive Treatment A followed by Treatment C and then Treatment B with a washout period of minimum 7 days.
2932433|NCT03023852|Experimental|Panel 1: Group 3|Participants in Group 3 will receive Treatment B followed by Treatment A and then Treatment C with a washout period of minimum 7 days.
2932434|NCT03023852|Experimental|Panel 1: Group 4|Participants in Group 4 will receive Treatment B followed by Treatment C and then Treatment A with a washout period of minimum 7 days.
2932435|NCT03023852|Experimental|Panel 1: Group 5|Participants in Group 5 will receive Treatment C followed by Treatment A and then Treatment B with a washout period of minimum 7 days.
2932436|NCT03023852|Experimental|Panel 1: Group 6|Participants in Group 6 will receive Treatment C followed by Treatment B and then Treatment A with a washout period of minimum 7 days.
2932437|NCT03023852|Experimental|Panel 2: Group 7|Participants in Group 7 will receive Treatment D [JNJ-63623872/37.5 mg Oseltamivir oral fixed dose combination (FDC) tablet concept formulation (test 3)] followed by Treatment E (JNJ-63623872 600 mg, administered as 2*300 mg and Oseltamivir 75 mg, administered as 1*75 mg). Both treatment periods will be separated with a minimum of 7 days washout period.
2932438|NCT03023852|Experimental|Panel 2: Group 8|Participants in Group 8 will receive Treatment E followed by Treatment D with a washout period of minimum 7 days.
2932439|NCT03023839||Severe trauma patients|Severe Trauma patients (ISS >15) admitted to Intensive Care Unit (ICU)
2932440|NCT03023826|Experimental|LY3202626 (R-Fasting)|Single oral dose of LY3202626 (R) under fasting conditions.
2932441|NCT03023826|Experimental|LY3202626 (T1-Fasting)|Single oral dose of LY3202626 (T1) under fasting conditions.
2932442|NCT03023826|Experimental|LY3202626 (T1-Fed)|Single oral dose of LY3202626 (T1) following a high fat breakfast.
2932443|NCT03023813|Experimental|Intervention|Individualized preventive care recommendations will be distributed to subjects.
2932444|NCT03023813|No Intervention|Control|Usual care
2932445|NCT03023800|Experimental|Buckle|Macular buckling and intraocular gas (C3F8) injection.
2932446|NCT03023800|Active Comparator|Vitrectomy|Vitrectomy, internal limiting membrane peeling, and gas tamponade (C3F8).
2932447|NCT03023787|Experimental|Hepalatide|Hepalatide 4.2mg, 6.3mg and 8.4mg
2932448|NCT03023787|Placebo Comparator|Placebo|Placebo 4.2mg, 6.3mg and 8.4mg
2932449|NCT03023774|Other|neupogen|neupogen (granulocyte colony-stimulating factor) 30 IU once intrauterine at the time of ovum pickup
2932450|NCT03023761|Active Comparator|low level laser|A single visit Endodontic retreatment was done. After biomechanical preparation, Low Level Laser was irradiated to the buccal and lingual mucosa overlying the apices of the target tooth in the experimental group
2932451|NCT03023761|Placebo Comparator|laser sham|In the control group patients received placebo laser to eliminate the probable psychological effects of laser.
2932452|NCT03023748|Experimental|intravenous paricalcitol solutions|"Intravenous paricalcitol will be administered twice or thrice weekly post-hemodialysis with a dose based on the baseline iPTH level divided by 120.~For instance, with a baseline iPTH 1200pg/mL, an induction dose of 10mcg twice or thrice weekly will be given. The maximum weekly dose allowed is 30mcg. Subsequent dose titration may be required depending on the serum PTH level. Intravenous paricalcitol will be continued up to 24 months."
2932453|NCT03023722|Experimental|All Subjects|Patients with advanced metastatic pancreatic cancer who have measurable disease
2932454|NCT03023709|Other|Pilot phase|Participants will receive the current seasonal quadrivalent, inactivated influenza vaccine (IIV4)/Fluzone® given intramuscularly to confirm the safety of administering the seasonal influenza vaccine 3-14 days prior to tonsillectomy.
2932455|NCT03023709|Other|Study phase|Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.
2932456|NCT03023696|Experimental|Foraminotomy Group|Prophylactic bilateral cervical keyhole foraminotomy will be done in addition to their decompression surgery
2932457|NCT03023696|Active Comparator|Control Group|Cervical decompression will be done without prophylactic bilateral foraminotomy
2932458|NCT03023683|Other|Group A: 2-8 yo healthy non-twins|Participants will be given seasonal live, attenuated influenza vaccine (LAIV), FluMist® . Children with no prior influenza vaccine history will receive a second dose of LAIV at least 28 days after the first study dose.
2932459|NCT03023683|Other|Group B: 18-49 yo healthy non-twins|Participants will be given seasonal LAIV, FluMist® .
2932460|NCT03023670|Active Comparator|Group A|This group will include patients with low flow of mixed oxygen / air (1:1L) during the period of cardiopulmonary bypass
2932461|NCT03023670|Active Comparator|Group B|This group will receive low rate (4\min) with low tidal volume ( 2ml/kg ) during the period of cardiopulmonary bypass.
2932462|NCT03023657|Experimental|Severe brain-damaged patient in coma awakening|For each patient, video sessions of the face will be performed during a waking period, until the spontaneous macro-EFE (Emotional Facial Expression) reappears. The video sessions will be done without stimulation or with visual, auditory or tactile stimulation. The sessions will be daily for 7 days then weekly for a maximum duration of 4 weeks.
2932463|NCT03023644|Experimental|Cogmed Working Memory Training|The group randomized to the intervention will receive Cogmed computerized training of executive function and attention skills. The standard Cogmed RM will be used for this trial arm. This is a child-friendly web-based software program. The investigators will use a version of the program that contains 12 different neurocognitive tasks. Tasks become more difficult as a function of performance on a session-by-session basis. Each training session lasts 35-40 minutes, with one session to be completed per day 5 days each week for 5 weeks, for a total of 25 sessions. The program yields individual session-by-session and task-by- task training results, including the children's responses, time spent on each task, and evolution curves.
2932464|NCT03023644|No Intervention|Standard of Care|Children randomly assigned to the control group will receive the standard of care recommended for patients with critical CHD. This includes cardiac surveillance and neurodevelopmental counseling and screening at our Cardiac Neurodevelopmental Program if needed. Once enrolled in our study, a child in the control group will not receive Cogmed intervention or any other cognitive intervention that targets executive functions or ADHD symptoms until after the 3-month follow-up neurodevelopmental evaluation is performed, i.e., 5-6 months after initial enrollment. Like children assigned to the intervention group, controls can continue on treatments that are already in place for other neurodevelopmental disabilities (e.g., speech therapy, occupational services).
2932465|NCT03023631|Experimental|GARDASIL 9|Participants receive Gardasil as 3 injections at 3 separate timepoints under the skin in the arm or thigh. Participants receive the vaccinations at about 6 months (+/- 8 weeks) after the stem cell transplant, then again about 2 months after the first injection, and then again about 4 months after the second injection.
2932466|NCT03023618|No Intervention|control group|patients before 2014, in which fluids were administered without FloTrac monitoring
2932467|NCT03023618|Active Comparator|case group|patients after 2014, after management of fluid therapy has been guided by FloTrac parameters as a standard clinical practice (NICE protocol)
2932468|NCT03023605|No Intervention|Pre-intervention PE Diagnosis|Patients visited in Emergency Department, with suspected Pulmonary Embolism, before the training intervention.
2932469|NCT03023605|Experimental|Post-intervention PE Diagnosis|"Patients visited in Emergency Department, with suspected Pulmonary Embolism, after the training intervention.~Training intervention centered on emergency department staff, regarding the application of clinical probability scores (Wells and Geneva scores) to guide the determination of D-dimer and the performance of pulmonary CT in patients with suspected pulmonary embolism."
2932470|NCT03023592|Experimental|Iguratimod|Patients are treated with Iguratimod 25 mg Twice a day for 24 weeks.
2932471|NCT03023579|Experimental|The star excursion balance test|The star excursion balance test: simple test for dynamic balance
2932472|NCT03023566||Dotarem Enhanced MRI|All pediatric patients (< 18 years) scheduled for clinically indicated contrast enhanced MRI (Brain MRI with/without contrast) will receive a single IV bolus injection of Dotarem at a dose of 0.1 mmol/kg bw at a flow rate of 1-2 mL/sec followed by saline flush (routine/ standard of care).
2932473|NCT03023553|Other|TIV Group|Healthy adult males and females, 18-30 years of age. Immunization with standard trivalent, inactivated influenza vaccine (TIV), Fluzone®.
2932474|NCT03023553|Other|LAIV Group|Healthy adult males and females, 18-30 years of age. Immunize with intranasal live, attenuated influenza vaccine (LAIV), FluMist®.
2932475|NCT03023540|Active Comparator|PXT3003 dose 1|PXT3003: Liquid oral solution, 5 mL bid (taken morning and evening with food) for 9 consecutive months
2932476|NCT03023540|Active Comparator|PXT3003 dose 2|PXT3003: Liquid oral solution, 5 mL bid (taken morning and evening with food) for 9 consecutive months
2932477|NCT03023527|Experimental|nivo-pom-dex|Nivolumab in combination with Pomalidomide and low dose dexamethasone
2932478|NCT03023527|Experimental|nivo-pom-dex-elo|Pomalidomide in combination with Nivolumab , dexamethasone and elotuzumab
2932479|NCT03023514|Experimental|ALA + P|Oral alpha-lipoic acid + vaginal Progesterone
2932480|NCT03023514|Active Comparator|P|vaginal Progesterone
2932481|NCT03023501|Experimental|Gabapentin|Gabapentin 1200mg capsule was administered orally 2 hours before surgery
2932482|NCT03023501|Placebo Comparator|Placebo|Placebo capsule was prepared by hospital pharmacy and was administered orally 2 hours before surgery.
2932483|NCT03023488|Experimental|Flexible ureteroscopy arm|the findings of patients undergoing flexible ureteroscopy + laser lithotripsy for renal stones according to EAU Guidelines Doppler Ultrasound examination has been performed in the pre-operative and post-operative periods
2932484|NCT03023475|Active Comparator|LigaSure endoscopic radial harvesting|The endoscopic vessel harvesting will be performed using the LigaSure device.
2932485|NCT03023475|Active Comparator|TLS2 endoscopic radial harvesting|The endoscopic vessel harvesting will be performed using the TLS2 device.
2932486|NCT03023462|Active Comparator|Quadratus lumborum 3 Block|"Intervention is postoperative medication with Ketobemidone Hydrochloride, Oksykodonhydroklorid, Ondansetron and Droperidol~These patients are given an Quadratus lumborum 3 Block with Ropivacaine 7,5 mg/ml"
2932487|NCT03023462|Active Comparator|TAP Block|"Intervention is postoperative medication with Ketobemidone Hydrochloride, Oksykodonhydroklorid, Ondansetron and Droperidol~These patients are given a TAP block with Ropivacaine 7,5 mg/ml"
2932488|NCT03023449|Experimental|Healthy Controls|The protocol will be a 35-minute monitoring session, during which cerebral hemodynamics will be monitored with both DCS and TCD, while blood pressure, heart rate, cardiac output, respiratory rate, end oxygen saturation, and inhaled nitric oxide concentration, are continuously monitored. 5 minutes of baseline hemodynamics will be assessed, after which the subject will breath iNO for 5 minutes, followed by 5 minutes of room air. This iNO/room air cycle will be repeated with a total of 3 different iNO concentrations. The full protocol will require 35 minutes. Subjects will be called at 24 hours after the monitoring session to determine any tolerability issues or adverse events.
2932489|NCT03023449|Experimental|Acute Ischemic Stroke|Patients will be enrolled in the study within 72 hours of stroke symptom onset. The protocol will be a 35-minute monitoring session, during which cerebral hemodynamics will be monitored with both DCS and TCD, while blood pressure, heart rate, cardiac output, respiratory rate, end oxygen saturation, and inhaled nitric oxide concentration, are continuously monitored. 5 minutes of baseline hemodynamics will be assessed, after which the subject will breath iNO for 5 minutes, followed by 5 minutes of room air. This iNO/room air cycle will be repeated with a total of 3 different iNO concentrations. The full protocol will require 35 minutes. Subjects will be undergo a final assessment at 24 hours after the monitoring session to determine any tolerability issues or adverse events.
2932490|NCT03023436|Experimental|CRS + HIPEC + Systemic Chemotherapy|"Cytoreductive surgery(CRS) followed by Hyperthermic Intraperitoneal Chemotherapy(HIPEC) and systemic chemotherapy will be performed for the treatment of patients assigned to this group.~CF regimens or other first line regimens based on Fluoropyrimidine and Cisplatin according to the National Comprehensive Cancer Network（NCCN） Guidelines （Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial."
2932491|NCT03023436|Active Comparator|Systemic Chemotherapy alone|"Systemic chemotherapy will be performed for the treatment of patients assigned to this group.~CF regimens or other first line regimens based on Fluoropyrimidine and Cisplatin according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial."
2932492|NCT03023423|Experimental|Treatment Arm A: Atezolizumab|Participants in Treatment Arm A will receive Atezolizumab 1,200 milligram (mg) intravenously (IV) on Day 1 of every 21-day cycle. Participants with confirmed disease progression based on RECIST 1.1 may cross over to Arm B and receive daratumumab and atezolizumab, provided crossover eligibility criteria are met.
2932493|NCT03023423|Experimental|Treatment Arm B: Atezolizumab and Daratumumab|Participants will receive daratumumab 16 milligram per kilogram [mg/kg] (Safety Run-in and Treatment Arm B) Intravenously (IV) weekly for 3 cycles (Day 1, 8 and 15), and Day 1 of every 21-day cycle thereafter. Atezolizumab will be administered at 1200 mg IV on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter. Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met.
2932494|NCT03023410||Partial Revision|"A partial revision will be indicated when only the tibial liner is changed or only the tibial liner with the tibial tray or only the tibial liner with the femoral component."
2932495|NCT03023410||Total Revision|"A total revision will be indicated when all components are completely removed and replaced (tibial tray, femoral component and tibial liner)."
2932496|NCT03023397|Other|Der f treated Non-smoker|
2932499|NCT03023358|Experimental|chidamide regimen|patients receive chidamide (30mg twice every week) po, cyclophosphamide (750mg/m2) iv on day 1, liposomal doxorubicin (30mg/m2) iv on day 1, vincristine (1.4mg/m2, max to 2mg) iv on day 1 and prednisone (100mg/d) po on day 1-5.
2932500|NCT03023358|Active Comparator|CDOP regimen|patients receive cyclophosphamide (750mg/m2) iv on day 1, liposomal doxorubicin (30mg/m2) iv on day 1, vincristine (1.4mg/m2, max to 2mg) iv on day 1 and prednisone (100mg/d) po on day 1-5.
2932501|NCT03023345|Experimental|Microwave|Microwave trans rectal focal treatment
2932502|NCT03023332|Experimental|Self-management need|SM-need (i.e. need for bipolar education or resourcefulness training or HRV-focused biofeedback training or no need for any)
2932503|NCT03023332|Experimental|Self-management preference|SM-preference (i.e. preference for bipolar education or resourcefulness training or HRV-focused biofeedback training or no intervention)
2932504|NCT03023332|No Intervention|Control|No intervention or treatment
2932505|NCT03023332|Active Comparator|Usual care|Bipolar education
2932506|NCT03023319|Experimental|Bosutinib and Pemetrexed|Bosutinib and pemetrexed
2932507|NCT03023306|Experimental|preemptive group|"The preemptive group will receive the anti-emetic regimen i.v. (10 mg of metoclopramide at 18 pm and 22 pm, and100 mg of dimenhydrinate at 22 pm) the day before surgery. During surgery this group will receive i.v. 0.9% NaCl in volumes equal to the volume of 10 mg of metoclopramide before anesthesia induction and 30 min after skin incision. Thirty minutes after skin incision 0.9% NaCl equal in volume with the volume of 100 mg dimenhydrinate will be given as well.~The intervention consists of the different time points of antiemetic treatment, thus the day before surgery.~Intervention: Antiemetic treatment the day before surgery"
2932508|NCT03023306|Active Comparator|intraoperative group|"The day before surgery the intraoperative group will receive i.v. 0.9% NaCl at 18 pm and 22 pm in volumes equal to the volume of 10 mg of metoclopramide; also 0.9% NaCl in volume equal to the volume of 100 mg dimenhydrinate at 22 pm will be given. During surgery the active comparator group will receive i.v. 10 mg of metoclopramide and 100 mg of dimenhydrinate instead of NaCl at the same time points as the preemptive group.~Intervention: Antiemetic treatment intraoperatively"
2932509|NCT03023293||gestational diabetes mellitus|The investigators plan to establish a prospective GDM cohort and collect n-3 PUFAs consumption and irisin information at 24-28 weeks'gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum, respectively.
2932510|NCT03023280||Patients undergoing radio frequency ablation|Patients undergoing radio frequency for large symptomatic heterotypic gastric mucosa
2932511|NCT03023267|Experimental|Interventional|Applying music therapy with kangaroo care to mothers and fathers during their NICU hospitalization
2932512|NCT03023267|Active Comparator|Control|Applying only Kangaroo care to mothers and fathers during their stay in the NICU
2932513|NCT03023254|Other|hydrotherapy group|"Subjects included in the hydrotherapy group will undergo a 3-weeks Avène hydrotherapy in addition to their usual psoriasis and/or pruritus management (treatments and/or skin care products)."
2932514|NCT03023254|No Intervention|Control group|"Subjects included in the control group will not undergo the hydrotherapy and will keep following their usual psoriasis and/or pruritus management (treatments and/or skin care products)."
2932515|NCT03023241|Experimental|all study patients|Same intervention for all subjects: anamnesis, questionnaires and biological samples (bladder biopsy, bladder washing, blood and urine) are collected at one single visit.
2932516|NCT03023228|Experimental|diabetes self-management education|Diabetes survival skills self-management education (DSME) program content was aligned with American Diabetes Association and Joint Commission suggested key areas for hospital diabetes education. Content areas were as follows: when and how to take diabetes medications; glycemic goals and self-blood glucose monitoring; definition, prevention, recognition, and treatment of hypoglycemia and hyperglycemia; what to do before you see the dietitian; sick day management; and when to call the doctor or go to the ED. Program content was created for delivery via either DVD or print format.
2932517|NCT03023215|Experimental|Guided Meditation Group (GM)|"Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB."
2932518|NCT03023215|Active Comparator|Focused Breathing Group (FB)|"Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.."
2932519|NCT03023215|Active Comparator|Standard of Care Group (SC)|"Participants listen to a 10 minute neutral-content audio clip from National Public Radio prior to stereotactic breast biopsy (SBB).~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB."
2932520|NCT03023202||PMMTB|"This study of the PMMTB will include all patients >= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor.~All standard of care functions will be performed by standard procedures."
2932521|NCT03023189|Active Comparator|Tranexamic acid|At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h
2932522|NCT03023189|Placebo Comparator|Placebo|At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h
2932523|NCT03023176|Other|Healthy 1-8 year-old twins|Healthy 1-8 yr old identical and fraternal twin pairs given trivalent, inactivated influenza (Fluzone® standard IIV3 0.5ml or Fluzone® standard IIV3 Pediatric Dose) per participant age and standard of care.
2932524|NCT03023163||Older SCI|Individuals that are between the ages of 50-75 years old, have a traumatic SCI, level of injury between C1-T12, non-ambulatory (wheelchair dependent), AIS grade A, B, or C, and injury occurred more than 1 year ago.
2932525|NCT03023163||Older Able-Bodied Controls|Individuals that are between the ages of 50-75 years old and primary language is English.
2932526|NCT03023163||Longitudinal SCI|Individuals that are between the ages of 28-54 years old and previously participated in the Impact of Age on Cardiovascular, Cerebrovascular, and Cognitive Health study in a 3-5 year span.
2932527|NCT03023163||Longitudinal Able-Bodied Controls|Individuals that are between the ages of 28-54 years old and previously participated in the Impact of Age on Cardiovascular, Cerebrovascular, and Cognitive Health study in a 3-5 year span.
2932528|NCT03023150|Experimental|Ischemic Preconditioning|Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times.
2932529|NCT03023150|Sham Comparator|Sham|Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times.
2932530|NCT03023137|Active Comparator|Walking & dietary modification (W&D)|W&D should begin when participants wish to conceive. The intervention was standardized by training of research staff. Careful instructions about walking speed and diet would be given to participants assigned to W&D at enrolment and at each consultation.
2932531|NCT03023137|No Intervention|Controls|No recommendations regarding diet or physical activity were given to controls. Antiemetics such as ondansetron would be given to controls complaining of vomiting.
2932532|NCT03023124|Experimental|Trabectedin|trabectedin: 1.5 mg/m² - 1.3 mg/m² given in 24-hour continuous infusion every 21 days for 6 cycles
2932533|NCT03023124|Experimental|Adriamycin and Dacarbazine|Adriamycin: 75 mg/m2/day, bolus, day 1 every 21 days for 6 cycles Dacarbazine: 400 mg/m2/day, days 1, 2 every 21 days for 6 cycles
2932534|NCT03023111|Active Comparator|Sbv|"Meglumine antimoniate (Glucantime):~Dosage: 20 mg / kg / day, intravenously, during 20 days."
2932535|NCT03023111|Experimental|Miltefosine plus placebo|Miltefosine (28 days / 2.5mg / Kg / day at a maximum dose of 150mg / day orally) + Topical placebo (gel cream, 2 times a day for 28 days)
2932536|NCT03023111|Experimental|Miltefosine plus GM-CSF|Miltefosine (28 days / 2.5mg / kg / day at a maximum dose of 150mg / day orally) + Topical GM-CSF (0.01% gel cream, 2 times a day for 28 days)
2932537|NCT03023098|Experimental|Drug-eluting balloon|
2932538|NCT03023098|Active Comparator|Conventional PTA|
2932539|NCT03023085|Experimental|BLI4700|BLI4700 Bowel Preparation
2932540|NCT03023072||Phase 1|Subjects will use the incontinence pad with incontinence detection notifications turned on
2932541|NCT03023072||Phase 2|Subjects will use the incontinence pad with incontinence notification turned off
2932542|NCT03023059|Experimental|Escalating dose of carbidopa-levodopa|The intervention is that patients will receive open label, commercially available Carbidopa-Levodopa 25 Mg-100 Mg oral tablet, once daily hs for one month, followed by one tablet dosed three times daily, in the morning, with supper and hs for one month, followed by two tablets dosed three times daily, in the morning, with supper and hs for one month (100-600 mg of levodopa daily). This is the equivalent of very low to moderate doses of carbidopa-levodopa in patients with Parkinson's disease (daily dose of levodopa 200-800 mg).
2932543|NCT03023046|Experimental|Treatment (chemotherapy)|Patients receive etoposide IV over 96 hours, doxorubicin IV over 96 hours, and vincristine sulfate IV over 96 hours on days 1-4. Patients also receive cyclophosphamide IV over 1 hour on day 5 and prednisone PO BID on days 1-5. Patients who are Ph+ also receive imatinib mesylate or dasatinib PO QD on days 1-14. Patients who are CD20+ also receive rituximab IV on day 1 or day 5. Courses repeat every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
2932544|NCT03023033|Experimental|Clinic group 1|Clinics using SMS health promotion and reminder messages (mhealth messaging)
2932545|NCT03023033|Experimental|Clinic group 2|Clinics using SMS health promotion and reminder messages + Clinics providing payment scaled to reflect typical transport costs to facility (transport payments)
2932546|NCT03023033|No Intervention|Clinic group 3|Services provided under the Ministry of Health standard care
2932547|NCT03023020|Other|Abbreviated antiplatelet regimen|"Dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and a single antiplatelet agent is continued until at least 11 months post randomization (i.e. 12 months post stent implantation).~In patients on oral anticoagulants, dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and either Aspirin or Clopidogrel is continued until 5 months post randomization (i.e. 6 months post stent implantation). Oral anticoagulation is continued until at least 11 months post randomization (i.e. 12 months post stent implantation)"
2932548|NCT03023020|Other|Prolonged antiplatelet regimen|"Aspirin is continued for at least 11 months post randomization (i.e. 12 months post stent implantation), the P2Y12 inhibitor being taken at the time of randomization is continued for at least 5 months and up to 11 months post randomization (i.e. 12 months post stent implantation).~In patients on oral anticoagulants, aspirin and Clopidogrel are continued for at least 2 months post randomization (i.e. 3 months post stent implantation) and up to 11 months post randomization (i.e. 12 months after stent implantation). Either aspirin or Clopidogrel is continued up to 11 months post randomization (i.e. 12 months post stent implantation)"
2932549|NCT03023007|Experimental|Loco-regional anaesthesia|Loco-regional anaesthesia Anesthesia technique used : loco-regional PECS for patients requiring Mastectomy; And/or Axillary node dissection ; And/or Reconstruction of breast by prosthesis
2932550|NCT03022994||NCWS patients|"Forty consecutive adult patients with an IBS-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients will be recruited between January 2016 and February 2017 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects will undergo upper gastrointestinal endoscopy and proctoscopy at the Gastroenterology Unit at the University Hospital of Palermo, Italy. Duodenal and rectal biopsies will be evaluated at 2 centers: the Pathology Unit at the University Hospital of Palermo, Italy, and the Institute of Pathology at the Spedali Civili of Brescia, Italy."
2932581|NCT03022812|Active Comparator|Exercises at a physiotherapy clinic|Neck-specific exercise at a physiotherapy clinic, 24 times during 12 weeks (plus an additional first visit).
2932582|NCT03022812|Experimental|Exercises with Internet support|Neck-specific exercise with Internet support combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
2932551|NCT03022994||IBS patients|"Forty sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as control group. All subjects will undergo upper gastrointestinal endoscopy and proctoscopy at the Gastroenterology Unit at the University Hospital of Palermo, Italy. Duodenal and rectal biopsies will be evaluated at 2 centers: the Pathology Unit at the University Hospital of Palermo, Italy, and the Institute of Pathology at the Spedali Civili of Brescia, Italy."
2932552|NCT03022981|Experimental|PK Lead-in Phase: Cohort 1 (12 to < 18 years old)|SOF/VEL FDC (1 x 400/100 mg tablet or 2 x 200/50 mg tablets) for 7 days
2932553|NCT03022981|Experimental|PK Lead-in Phase: Cohort 2 (6 to < 12 years old)|Pending PK and safety results from Cohort 1, participants in Cohort 2 will initiate and receive SOF/VEL FDC (age-appropriate dose) for 7 days.
2932554|NCT03022981|Experimental|PK Lead-in Phase: Cohort 3 (3 to < 6 years old)|"3 to < 6 years of age: SOF/VEL FDC 200/50 mg oral granules (4 x 50/12.5 mg packets) administered once daily, for participants who weigh ≥17 kg;~SOF/VEL FDC 150/37.5 mg oral granules (3 x 50/12.5 mg packets) administered once daily, for participants who weigh < 17 kg"
2932555|NCT03022981|Experimental|Treatment Phase: Group 1 (12 to < 18 years old)|Participants from the PK Lead-in will immediately rollover into Treatment Phase with no interruption of study drug administration until the appropriateness of the dose has been confirmed by PK and safety results from the PK Lead-in. Additional participants (12 to < 18 years of age) will be enrolled in the Treatment Phase upon confirmation of the appropriateness of the dose from the PK Lead-in Phase and will receive SOF/VEL FDC for 12 weeks.
2932556|NCT03022981|Experimental|Treatment Phase: Group 2 (3 to < 12 years old)|Participants from the PK Lead-in will immediately rollover into Treatment Phase with no interruption of study drug administration until the appropriateness of the dose has been confirmed by PK and safety results from the PK Lead-in. Additional participants (3 to < 12 years of age) will be enrolled in the Treatment Phase upon confirmation of the appropriateness of the dose from the PK Lead-in Phase and will receive SOF/VEL FDC for 12 weeks.
2932557|NCT03022968|Experimental|Alzheimer disease|[18F]T807 PET
2932558|NCT03022968|Experimental|Benson disease|[18F]T807 PET
2932559|NCT03022968|Experimental|Healthy volunteer|[18F]T807 PET
2932560|NCT03022955|Active Comparator|Dark chocolate: FDG-PET|100 g dark chocolate bar (70% cocoa solids (~500kcal, ~50% fat)) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using chocolate: fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
2932561|NCT03022955|Active Comparator|Dark chocolate: Physiological Measurement|150 g dark chocolate mousse (~500kcal, ~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.
2932562|NCT03022955|Placebo Comparator|White chocolate: FDG-PET|100 g white chocolate bar (0% cocoa solids (~500kcal, 50% fat) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using FDG-Positron Emission Tomography.
2932563|NCT03022955|Placebo Comparator|White chocolate: Physiological Measurement|150 g white chocolate mousse (~500kcal, ~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.
2932564|NCT03022942|Experimental|Costal mobilization & Diaphragm Release|Costal mobilization. Lying: two sets of ten deep respiratory cycles with one minute interval between sets. Sitting: two series with interval of one minute between them. Manual Diaphragm Release Technique: will be applied during two series of ten deep respiratory cycles, with one minute interval between sets.
2932565|NCT03022942|Active Comparator|Manual Diaphragm Release|Manual Diaphragm Release Technique: will be applied during two series of ten deep respiratory cycles, with one minute interval between sets.
2932566|NCT03022929|No Intervention|Adapted Intervention|The investigators will use GetSmart materials published by the CDC appropriate to the emergency department and urgent care settings and select and adapt brochures and other campaign messages for acute care providers.
2932567|NCT03022929|Experimental|Enhanced Intervention|"The investigators will use all of the methods of the Adapted Intervention. In addition to these methods, the investigators will add posters within exam rooms which will include modified GetSmart content and other nudges such as physician pictures with their signed public commitment to antibiotic stewardship or flair denoting commitment to stewardship. The investigators will also provide physicians with personalized monthly performance ranking with each physician receiving the designation of top performer or not a top performer based on their appropriate antibiotic prescribing practices for acute respiratory infections. This will be the Enhanced Antimicrobial Stewardship Commitment and Feedback intervention."
2932568|NCT03022916|Experimental|Jublia|Both big toes will receive application of Jublia. One big toe will not use nail polish.
2932569|NCT03022903|Other|Photodynamic Therapy (PDT)|PDT with ALA (photosensitizer) for 3 hours
2932570|NCT03022890|Experimental|Hatha yoga|12 weeks of hatha yoga classes, once per week
2932571|NCT03022890|Placebo Comparator|Health education|12 weeks of health education classes, once per week
2932572|NCT03022877|Placebo Comparator|Placebo|Placebo is given as a Bolus (instead of Bolus application of Levosimendan) over 10 min i.v., starting 10 min before recanalization.
2932573|NCT03022877|Active Comparator|Bolus Levosimendan|Levosimendan is given as Bolus (12 µg/kg over 10 min i.v.), starting 10 min before recanalization.
2932574|NCT03022877|Active Comparator|Bolus and infusion Levosimendan|Levosimendan is given as Bolus (12 µg/kg over 10 min i.v.), starting 10 min before recanalization and additionally as continuous infusion (0.1-0.2 µg/kg/min i. v. for 24 hours).
2932575|NCT03022864||Chronic pain|Follow up the patients for three months after surgery using the designed table. If the patient evaluate the pain more than 3 points according the Numerical Rating Scale, then it can be considered that the patient has chronic pain.
2932576|NCT03022864||No chronic pain|Follow up the patients for three months after surgery using the designed table. If the patient evaluate the pain no more than 3 points according the Numerical Rating Scale, then it can be considered that the patient doesn't have chronic pain.
2932577|NCT03022851|Experimental|Occlutech AFR Device|Patients who will get the AFR Device implantation
2932578|NCT03022838|Active Comparator|Caffeine|Caffeine tablets (Recip) 100 mg, 300-800 mg
2932583|NCT03022799|Experimental|KM-819|Each cohort consists of 8 subjects; 6 subjects will receive planned dose of KM-819 and 2 subjects will receive placebo.
2932584|NCT03022799|Placebo Comparator|Placebo|Each cohort consists of 8 subjects; 6 subjects will receive planned dose of KM-819 and 2 subjects will receive placebo.
2932585|NCT03022786|No Intervention|Understanding patient perspective|Patients will be interviewed who have been diagnosed with stasis dermatitis. The Principal Investigator will learn their perspective on their leg swelling, impact on quality of life, and obstacles to wearing compression stockings
2932586|NCT03022786|No Intervention|Refining tool kit|"Using in-depth interviews for our inpatients selected using the same criteria as in Phase 1 and independent focus groups of providers, The study staff will obtain feedback to refine the items in our toolkit before implementing them in January 2017.~There will be a focus group comprised of providers. This focus group will explore the perceptions of the providers and what unmet needs remain for the patients."
2932587|NCT03022786|Other|Implementation|Our patient education materials and toolkit include an order set to help providers guide patients to adhere to compression, the gold standard of care for this condition. This will also direct patients to know who to contact if itching or pain persists, what the patient can do at home, when to go to the hospital, as well as information on financial and home care assistance as it relates to managing their chronic condition.
2932588|NCT03022773|Other|Carotenoid measurements|Subjects are asked to have carotenoid levels measured in the eye, skin and/or blood.
2932589|NCT03022760|Active Comparator|Work-related measures|"One-day training for GP:s and rehabilitation coordinators~A treatment protocol which includes contact with the patient's employer~Clinical support from the Institute of Stress Medicine"
2932590|NCT03022760|No Intervention|Treatment as usual|
2932591|NCT03022747|Active Comparator|Standard maintenance therapy|Standard maintenance therapy with 6 mercaptopurine and methotrexate
2932592|NCT03022747|Experimental|Allopurinol treatment|The second 12 week phase during which allopurinol is added to oral 6-mercaptopurine and methotrexate therapy
2932593|NCT03022734|Experimental|chemotherapy with radiotherapy|Cetuximab or Bevacizumab, FOLFOX or FOLFIRI, radiotherapy
2932594|NCT03022721||Patients with diabetes|"Patients with both type 1 and type 2 Diabetes will be enrolled, Independent of Diabetes Duration, therapy etc.~No interventions are planned."
2932595|NCT03022721||Pre-Diabetics|"Patients who have either imparied fasting Glucose or impaired Glucose tolerance in the oral Glucose tolerance test.~No interventions are planned."
2932596|NCT03022721||Healthy controls|"Study participants without Diabetes or Pre-diabetes in the oral Glucose tolerance test.~no interventions are planned."
2932597|NCT03022708|Experimental|Xeltis Bioabsorbable Pulmonary Valved Conduit|"The Bioabsorbable Pulmonary Valved Conduit bio-absorbable, polymer-based medical device.~The PV conduit is used in patients for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT), in patients less than 22 years with any of the following congenital heart malformations:~Tetralogy of Fallot~Truncus Arteriosus~Pulmonary Atresia~Transposition of Great Arteries with Ventricular Septal Defect~Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes~In addition, the PV conduit can be used for the following indications:~replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits (except for mechanical valves, see exclusion criterion 3).~Patients undergoing a Ross procedure, where the PV conduit would replace the patient's own pulmonary valve which is used to replace a diseased aortic valve."
2932598|NCT03022695|Experimental|Treatment with high-intensity focused ultrasound|
2932599|NCT03022682||IDEO Cohort|IDEO is recruiting 145 lean and obese individuals from three ethnicities, covering a spectrum of obesity and T2DM risk. The cohort will include three ethnic groups; Caucasian, Hispanic/Latino, and Chinese and also include subjects slated to undergo bariatric surgery. Adipose tissue samples are collected from all subjects, including aspirational subcutaneous biopsies from nonsurgical subjects and excisional biopsies, performed intra-operatively by surgical collaborators as required. Participants also undergo anthropometric measurements, stool collection, blood sample collection for circulating blood cells, serum, and plasma. Dual-energy x-ray absorptiometry (DXA) scan for amount and distribution of body fat as well as bone density is performed. Study subjects complete validated questionnaire inventories to measure bio-behavioral issues such as depression, stress, health locus of control, and dietary habits.
2932600|NCT03022669|Experimental|Text Message Group|"The TM group will use the VA Annie text messaging program to remind patients to take antiplatelet medications. The content for the text messages will be determined through preliminary focus groups that will be conducted prior to the RCT."
2932601|NCT03022669|Experimental|Application Group|"The App group will use a mobile application to remind patients to take antiplatelet medications. The commercially available mobile app will be selected by participants through preliminary focus groups that will be conducted prior to the RCT."
2932602|NCT03022669|Experimental|Website-Control|"The Website-Control group will will be offered the American Heart Association patient education website (My Life Check - 7 Steps To Healthy Living) and will serve as an attention-control. The website will be offered to participants in all three groups. The 7 small steps to big changes are to manage blood pressure, control cholesterol, reduce blood sugar, get active, eat better, lose weight, and stop smoking."
2932603|NCT03022656|Sham Comparator|Monitor Only|A brace monitor will be embedded inside the brace to monitor compliance.
2932604|NCT03022656|Experimental|Active Brace System|An active brace device will be embedded inside the brace to dynamically control interface pressure and monitor compliance.
2932605|NCT03022643|No Intervention|Pain Patients|40 Pain Patients will be screened for social and behavioral rhythms with no treatment involved. All patients will be evaluated an Actigraph by Philips for 8-days to assess sleep and activity.
2932606|NCT03022643|No Intervention|Controls|40 Controls will be screened for social and behavioral rhythms with no treatment involved. All Controls will be evaluated an Actigraph by Philips for 8-days to assess sleep and activity.
2932607|NCT03022643|Experimental|Treatment|10 patients from the original 40 will receive Interpersonal Social Rhythms Psychotherapy and Bright Light Device therapy to improve social and behavioral rhythms.
2932608|NCT03022630|Other|Comprehensive Palliative Care services|Comprehensive Palliative Care services in addition to usual hepatic care
2932609|NCT03022630|Other|Usual hepatic care|Usual hepatic care
2932610|NCT03022617|Experimental|Study Group|Open-label drug administration group. No comparator.
2932611|NCT03022604|Experimental|C4/Generation 4|12 grams of C4/Generation 4 Extreme
2932612|NCT03022604|Active Comparator|C450X|12 grams of C4X (150% of regular dose)
2932613|NCT03022604|Placebo Comparator|Placebo|12 grams of flavored dextrose
2932614|NCT03022578|Experimental|Laser Interstitial Thermal Therapy (LITT) + Lomustine|"Participants undergo thermal ablation of tumor utilizing the LITT procedure.~14-35 days following the LITT procedure participants initiate treatment with Lomustine.~Lomustine administered by mouth at 90 mg/m2 on Day 1 for the first six week cycle. The dose of Lomustine may be increased to 110 mg/m2 starting with the second six week cycle, at the treating physician's discretion, as long as patient has not required dose modification for toxicity.~Quality of life questionnaires completed at baseline, 14 days after LITT procedure, on Day 1 of each Lomustine cycle, 6 weeks after Lomustine stopped, and every 3 months during follow up."
2932615|NCT03022565|Experimental|Vorinostat|"Vorinostat:~400 mg orally, once daily for 15 days."
2932616|NCT03022552||MINOCA|Women with myocardial infarction (MI) with demonstrated non-obstructive coronary artery disease during cardiac catheterization (less than 50% blockage in any major vessel).
2932617|NCT03022552||MI-CAD|Women with myocardial infarction (MI) with demonstrated obstructive coronary artery disease during cardiac catheterization (50% or greater blockage in any major vessel) or previous history of percutaneous coronary intervention (PCI) or or coronary artery bypass graft (CABG).
2932618|NCT03022552||CATH-NOCA|Women with stable angina that are age and race matched to women in the MINOCA arm that are clinically referred for cardiac catheterization
2932619|NCT03022526|Experimental|CSE|intrathecal bupivacaine 2.5mg + fentanyl 15mcg followed by infusion (PCEA): bupivacaine 0.083% with fentanyl 2mcg/mL: basal 8mL/hr, demand 8mL, 2 boluses per hour allowed, total maximum hourly allowance 24mL
2932620|NCT03022526|Active Comparator|Epidural|epidural bupivacaine 0.083% + fentanyl 2mcg/mL (8mL) followed by fentanyl 100mcg (2mL); follwed by infusion (PCEA): bupivacaine 0.083% with fentanyl 2mcg/mL: basal 8mL/hr, demand 8mL, 2 boluses per hour allowed, total maximum hourly allowance 24mL
2932621|NCT03022513|Active Comparator|NCWS patients|Fifty consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients will be recruited between January 2017 and January 2018 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo, Italy.
2932622|NCT03022513|No Intervention|CD patients|Fifty sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as first control group. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo, Italy.
2932623|NCT03022513|No Intervention|IBS patients|Fifty sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as second control group. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo.
2932624|NCT03022500|Experimental|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
2932625|NCT03022487||ICD Patients with Ischaemic cardiomyopathy|A standard 30-minute electrophysiological (EP) cardiac stimulation protocol will be performed at the end of the ICD implant at baseline. Participants will be followed up for 12-18 months for endpoints.
2932626|NCT03022474|Experimental|Intervention group|
2932627|NCT03022474|No Intervention|Control group|
2932628|NCT03022461||Ongoing HM3 CE Mark study patients|The study will include the ongoing HM3 CE Mark study patients that have consented to continue the long term follow-up data collection.
2932629|NCT03022448||Treatment Group|Trabectedin will be used according to the local SmPC. Modification of the treatment schedule should follow the standard medical practice at the discretion of the treating physician and is not part of this Observational Plan.
2932630|NCT03022435|Other|Group B: 18-30 yo identical twins (LAIV)|Participants to receive FluMist® LAIV by nasal spray.
2932631|NCT03022435|Other|Group B: 18-30 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
2932632|NCT03022435|Other|Group D: 40-64 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
2932633|NCT03022435|Other|Group F: 65-100 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
2932634|NCT03022435|Other|Group F: 65-100 yo identical twins (High-Dose TIV)|Participants to receive High-Dose Fluzone® standard TIV
2932635|NCT03022422|Other|Group B: 18-30 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
2932636|NCT03022422|Other|Group C: 18-30 yo fraternal twins (TIV)|Individual twins to receive Fluzone® standard TIV
2932637|NCT03022422|Other|Group D: 40-64 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
2932638|NCT03022422|Other|Group E: 40-64 yo fraternal twins (TIV)|Individual twins to receive Fluzone® standard TIV
2932639|NCT03022422|Other|Group F: 65-100 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
2932640|NCT03022422|Other|Group F: 65-100 yo identical twins (High-Dose TIV)|Individual twins to receive High-Dose Fluzone® TIV
2932641|NCT03022409|Experimental|AZD6738|AZD6738 is 100 mg or 20 mg oral tablet administered twice daily continuous dosing for a minimum of 10 days and a maximum of 21 days.
2932642|NCT03022409|Experimental|Olaparib|Olaparib is 100 mg or 150 mg oral tablet administered twice daily continuous dosing for a minimum of 10 days and a maximum of 21 days.
2932643|NCT03022396|Other|Group A: age 8-17 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
2932644|NCT03022396|Other|Group B: age 18-30 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
2932645|NCT03022396|Other|Group C: age 18-30 yo fraternal twins|Individual twins to receive Fluzone® (intramuscular)
2932646|NCT03022396|Other|Group D: age 40 - 59 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
2932647|NCT03022396|Other|Group E: age 40 - 59 yo fraternal twins|Individual twins to receive Fluzone® (intramuscular)
2932648|NCT03022396|Other|Group F: age 70 - 100 yo identical twins|Individual twins to receive Fluzone® (intramuscular) or High Dose Fluzone® (intramuscular)
2932649|NCT03022383|Experimental|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the DRI OCT Triton Plus device
2932650|NCT03022370|Experimental|Stepping Stones and Creating Futures|Participants receive the Stepping Stones and Creating Futures intervention, comprising of 21 participatory/inter-active sessions, delivered by a trained facilitators. Each session last approximately 3 hours. Sessions are delivered twice a week. Sessions are primarily single sex, with 20 participants per group.
2932651|NCT03022370|No Intervention|Wait-list control|Participants receive no intervention until after final data collection occurs, at which point they will be offered Stepping Stones and Creating Futures.
2932652|NCT03022344|Sham Comparator|Healthy|Patients in this cohort consist of 100 healthy patients
2932653|NCT03022344|Sham Comparator|Diabetes mellitus|Newly diagnosed (< 1 year) diabetes patients clinically classified as type-2 diabetes patients of both sex
2932654|NCT03022318|Experimental|once daily|carbidopa-levodopa 25-100 mg tablets once daily hs for up to 32 days
2932655|NCT03022318|Experimental|3 times daily|carbidopa-levodopa 25-100 mg tablets 3 times daily,in the morning, with supper and hs for up to 32 days
2932656|NCT03022305|Experimental|Group one - standard therapy|Standard physical therapy treatment for shoulder and hip malalignment will be administered for one week.
2932657|NCT03022305|Experimental|Group two - neuromuscular therapy|Experimental neuromuscular physical therapy treatment for shoulder and hip malalignment will be administered for one week. This therapy is exercised based.
2932658|NCT03022305|No Intervention|Group three - no treatment|No physical therapy treatment will be given to this group.
2932659|NCT03022292|Experimental|IAI Treatment|Intravitreal injection of aflibercept 2 mg/0.05 ml at baseline, week 4, week 8, week 16, week 24, week 36, and week 48. Additional injections can be administered during the remaining visits on an as needed basis per Primary Investigator (PI) discretion based on the presence of any intraretinal or subretinal fluid on OCT, heme visualized on examination, reduction of BCVA by 5 or more ETDRS letters, or evidence of either increased area, density, or activity of the brush border of the neovascularization on OCT-angiography. There will be a minimum of 21 days between subsequent injections. Each subject will therefore receive a minimum of 7 injections and up to a maximum of 13 injections throughout the study period.
2932660|NCT03022279|Active Comparator|TAP blocks|TAP block group will receive three injections performed by an Anesthesiologist trained in the procedure, prior to initiation of the surgical procedure. Bilateral posterior transversalis fascial plane blocks and a right sided subcostal transverse abdominal plane block will be placed under ultrasound guidance. Normal saline will be used to confirm proper muscle layer placement before instillation of the local anesthesia. All patients will receive 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine with maximum of 60 mL (divided equally amongst the injection sites).
2932661|NCT03022279|Active Comparator|Local Wound Infiltration|Local wound infiltration (LWI) will be performed by the operative surgeon using 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine with maximum of 60 mL divided amongst the four port sites. 40% of the total dose will be given at the umbilicus, and 20% will be given at each of the other 3 ports. The majority of the anesthetic will be administered at the peritoneal level. Laparoscopic/robotic cholecystectomy will be performed with a port at the umbilicus and three smaller ports in a standard fashion in the subxiphoid and right upper quadrant regions. If conversion to open cholecystectomy occurs, the study data will still be collected, but the patient's data will be excluded from analysis.
2932662|NCT03022266|Experimental|Intervention Arm|Participants receiving the Financial Incentive and Mobile Phone App will be given an smartphone app offering pill reminders and $50/month financial incentives for three months to upload photos of medication each day for 90 days. Medication adherence will be measured via a CleverCap(R) electronic monitoring pillbox.
2932663|NCT03022266|No Intervention|Usual Care Control Arm|Participants in the usual care control arm will receive the usual education about medications provided by hospital staff. Medication adherence will be measured via a CleverCap(R) electronic monitoring pillbox.
2932664|NCT03022253|Experimental|Liberal Platelet transfusion group|"Platelet transfusion to maintain a platelet count above 1,00,000 per microliter until one of the endpoints is met.~As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
2932665|NCT03022253|Active Comparator|Restrictive platelet transfusion group|"Platelet transfusion for standard criteria.~As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
2932666|NCT03022240|Experimental|Inhalational Technique|All patients will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction. After inhalation induction of anesthesia with sevoflurane (in 100% O2), an IV will be obtained. Anesthesia will be maintained with sevoflurane (in a mixture of air:oxygen) with a minimum alveolar concentration of 1.0-1.3, titrated to effect. No long acting opioids or nitrous oxide will be used. Airway management will be at the discretion of the anesthesiologist. Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
2932667|NCT03022240|Experimental|Total Intravenous Anesthetic Technique|All patients will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to IV insertion. Once an IV is established, patients will receive an IV bolus of propofol (2-6mg/kg). Anesthesia will be maintained with a propofol infusion starting at 250 mcg/kg/min and titrated to effect. Airway management will be at the discretion of the anesthesiologist. Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
2932668|NCT03022227|Experimental|group A start with the remote session followed by on site|
2932669|NCT03022227|Active Comparator|group B start with on site followed by telemedecine|
2932670|NCT03022214|Experimental|Placebo|5 capsules of placebo (microcrystalline cellulose) taken once in the morning with breakfast and once in the evening with dinner for two days prior to the study supervised exercise period and then one dose taken on the morning of the exercise test with the first meal
2932671|NCT03022214|Experimental|Intervention|"For presentation to volunteers, the daily capsules will be divided into two servings, one serving to be taken in the morning with breakfast, and one serving to be taken in the evening with dinner. Each serving containing 5 capsules, as follows:~EnduraCell broccoli sprout powder: 3 capsules~Bulk Powders Green tea extract: 1 capsule~Bulk Powders Cinnamon Bark Extract: 1 capsule to be taken for two days prior to the study supervised exercise period and then one dose taken on the morning of the exercise test with the first meal"
2932672|NCT03022201|Experimental|DA-9701|In this arm, the study participants will receive DA-9701 30mg + placebo domperidone tablet tid ac for 4 weeks.
2932673|NCT03022201|Active Comparator|Domperidone|(This study is a randomized, double-blinded, non-inferiority trial. Thus it is designed to have no placebo arm.) In this arm, the study participants will receive domperidone 10mg + placebo DA-9701 tablet tid ac +for 4 weeks.
2932674|NCT03022188||Observational|Observational
2932675|NCT03022175|Experimental|SPR741|"SPR741 is a novel chemical entity known as a potentiator that specifically interacts with the outer membrane of Gram-negative bacteria to increase the membrane's permeability. This increase in permeability allows Gram-positive antibiotics to enter and kill the cell.~SAD cohorts: Subjects will receive single doses of SPR741 over 60 minute IV infusion. Planned doses to be studied are 5, 15, 50, 100, 200, 400, 600 and 800 mg.~MAD cohorts: Subjects will receive SPR741 over 60 minute IV infusion three times a day (TID). Four dose groups will be studied. Doses will be determined by assessing SAD cohort data."
2932676|NCT03022175|Placebo Comparator|Placebo|"The placebo used during this study is normal saline (0.9% sodium chloride for injection).~SAD: Subjects will receive single infusions of placebo (0.9% sodium chloride for injection) over 60 minutes.~MAD: Subjects will receive TID infusions of placebo over 60 minutes for 14 days"
2932677|NCT03022149|Experimental|Doctormate® (200mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) once daily for 6 months
2932678|NCT03022149|Sham Comparator|Doctormate® (60mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (60mmHg) once daily for 6 months
2932679|NCT03022136|Experimental|Epidural Block|Epidural block for patients undergoing urological surgery
2932680|NCT03022123|Experimental|pegylated liposomal doxorubicin|PL-doxorubicin 35-40 mg/m(2) was given on day 1 in combination with standard dosage of prednisone, vincristine, cyclophosphamide (according to CHOP regimen) every 21 days for six courses;Rituximab 375 mg/m(2) was given on day 0.
2932681|NCT03022123|Active Comparator|Epirubicin|Epirubicin 70 mg/m(2) was given on day 1 in combination with standard dosage of prednisone, vincristine, cyclophosphamide (according to CHOP regimen) every 21 days for six courses;Rituximab 375 mg/m(2) was given on day 0.
2932682|NCT03022110|Active Comparator|plastic stent|Endoscopic Ultrasound-guided Drainage with plastic stent
2932683|NCT03022110|Experimental|lumen-apposing metal stent (LAMS)|Endoscopic Ultrasound-guided Drainage with lumen-apposing metal stent
2932684|NCT03022097|Experimental|Experimental 1|Aclidinium bromide 400μg/Formoterol fumarate 12 μg
2932685|NCT03022097|Experimental|Experimental 2|Aclidinium bromide 400 μg
2932686|NCT03022097|Active Comparator|Comparator|Formoterol fumarate 12 μg
2932687|NCT03022097|Placebo Comparator|Placebo|Placebo
2932688|NCT03022084|Experimental|Desyncra|This group will use the sound-therapy device, Desyncra™ for Tinnitus Therapy System.
2932689|NCT03022084|Other|Cognitive Behavioral Therapy|Standard of Care
2932690|NCT03022071|Experimental|Cognitive behavior therapy|The included patients will receive cognitive therapy for depression for 16 weeks and monthly booster sessions up to 28 weeks.
2932691|NCT03022071|Active Comparator|Psychodynamic therapy|The included patients will receive short-term psychodynamic psychotherapy for 28 weeks.
2932692|NCT03022058|Experimental|Patients with type 1 diabetes mellitus|
2932693|NCT03022045|Experimental|Risankizumab Dose 1|Risankizumab dose 1 administered by subcutaneous injection.
2932694|NCT03022045|Experimental|Risankizumab Dose 2|Risankizumab dose 2 administered by subcutaneous injection.
2932695|NCT03022032|Experimental|Comparing Steps Collected by Accelerometer|"10 patients will be enrolled in stage 1 to refine the HOPE App intervention~All participants will receive :~HOPE App~The Fitbit Zip~The Fitbit Charge 2 The amount of step collected by each device will be compared. This will allow the team to identify which wearable accelerometer to use in stage 2"
2932696|NCT03022032|Other|Usual care|"Stage 2 will consist of arm 2-5 and will enroll 100 patients randomized.~Usual care~The app will also collect passive data from the smartphone"
2932697|NCT03022032|Experimental|Wearable accelerometer|"Participants will be asked to wear the Fitbit~The Hope App will measure daily steps~The app will also collect passive data from the smartphone"
2932698|NCT03022032|Experimental|Refined smartphone app|"Participants will be prompted to answer questions about their quality of life and physical health daily~The HOPE App will present tailored advice to improve symptoms if one or more low-risk toxicities are reported. If the symptoms are determined to be high-risk, the App will prompt the patient to call their clinician.~The app will also collect passive data from the smartphone"
2932699|NCT03022032|Experimental|Refined smartphone app and accelerometer|"Participants will be prompted to answer questions about their quality of life and physical health daily~The HOPE App will present tailored advice to improve symptoms if one or more low-risk toxicities are reported. If the symptoms are determined to be high-risk, the App will prompt the patient to call their clinician.~Participants will be asked to wear the Fitbit~-The Hope App will measure daily steps The app will also collect passive data from the smartphone"
2932700|NCT03022019|No Intervention|No ReNovaCell treatment|Lesion on the same patient that receives only standard therapy, no ReNovaCell treatment.
2932701|NCT03022019|Experimental|ReNovaCell treatment|Lesion on the same patient that receives the ReNovaCell treatment
2932702|NCT03022006|Other|Dialysis patients with genotype 1 HCV infection|elbasvir/grazoprevir
2932703|NCT03021993|Experimental|Nivolumab|Nivolumab (OPDIVO) will be administered every two weeks for up to four doses prior to surgery at 3mg/kg
2932704|NCT03021980|Experimental|SuperFIT|This is the intervention group. They will receive the intervention SuperFIT.
2932705|NCT03021980|No Intervention|Control|This is the control group. Participants will receive 'care as usual' in this arm.
2932818|NCT03021226|No Intervention|Group III: No Intervention: Youth|Participants in Group III will be youth ages 16 to 19 years of age who do not receive any hours of intervention.
2932706|NCT03021954|Experimental|Platelet rich plasma|Platelet rich plasma injected intramuscularly in pelvic floor muscle immediately following labor and before perineoraphy, simultaneously with the injection of local anesthesia
2932707|NCT03021954|No Intervention|Control|No intervention given, patient will only get local anesthesia injection before perineoraphy
2932708|NCT03021941|Other|Elelyso 60 units/kg|All patients receive 60 units/kg of Elelyso.
2932709|NCT03021928|Experimental|60 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
2932710|NCT03021928|Experimental|132 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
2932711|NCT03021928|Experimental|228 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
2932712|NCT03021928|Experimental|324 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
2932713|NCT03021915|Other|OvaPrime Treatment|The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
2932714|NCT03021902|Experimental|IV amino acid + in-bed cycle ergometry|Beginning within 96 hours of initiation of mechanical ventilation, participants will receive the combined intervention that includes IV amino acids supplementation and in-bed cycle ergometry exercise
2932715|NCT03021902|No Intervention|Usual care|Participants randomized to the usual care arm will receive usual care protein and exercise.
2932716|NCT03021889|Experimental|Nutritional therapy group|The group nutritional therapy intervention was subjected to a protocol that included: nutritional counseling and weekly phone calls for 12 weeks.
2932717|NCT03021889|Other|Control group|The control group received conventional care consisting of usual medical care. The control group was followed according to the ambulatory care routine, which consists of medical follow-up by the assistant team.
2932718|NCT03021876|Placebo Comparator|ordinary group|usual intake prior to liver surgery
2932719|NCT03021876|Active Comparator|carnitine group|treatment with oral L-carnitine, 1500 mg/body per day for 2 weeks prior to liver surgery
2932720|NCT03021863|Active Comparator|Group A Reminder|Tone of reminder email (duty 14 days followed by duty for non-responders 28 days)
2932721|NCT03021863|Active Comparator|Group B Reminder|Tone of reminder email (encouragement 14 days followed by encouragement for non-responders 28 days)
2932722|NCT03021863|Active Comparator|Group C Reminder|Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)
2932723|NCT03021863|Active Comparator|Group D Reminder|Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)
2932724|NCT03021863|Active Comparator|Group E Reminder|Tone of reminder email (generic reminders at 14 days followed by generic for non-responders 28 days)
2932725|NCT03021863|Active Comparator|Group F Reminder|Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)
2932726|NCT03021863|Active Comparator|Group G Reminder|Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)
2932727|NCT03021863|Active Comparator|Group H Reminder|Tone of reminder email (duty 14 days followed by generic for non-responders 28 days)
2932728|NCT03021863|Active Comparator|Group I Reminder|Tone of reminder email (encouragement 14 days followed by generic for non-responders 28 days)
2932729|NCT03021850|Active Comparator|Stretching associated with shortwave heating|Applying deep heat through the shortwave equipment for 20 minutes, in coplanar application to the posterior part of the thigh associated with flexibility training of the hamstrings in the last 10 minutes of the session, performed by passive static stretching of the hamstring muscles in 10 repetitions of 30 seconds, with a 10 second pause between each repetition.
2932730|NCT03021850|Active Comparator|Stretching associated with cryotherapy|Cryotherapy application for 20 minutes, applied to the posterior part of the thigh associated with flexibility training of the hamstring muscles in the last 10 minutes of the session, performed by passive static stretching of the hamstring muscles, in 10 repetitions of 30 seconds , with a 10 second pause between each repetition.
2932731|NCT03021850|Other|Stretching isolated|The flexibility training of the hamstring muscles will be by passive static stretching of the hamstring muscles in 10 repetitions of 30-second , with a 10-second pause between each repetition.
2932732|NCT03021837||all patients|Patient receiving antenatal corticosteroid course for fetal lung maturity consisting of betamethasone or dexamethasone Women without known gestational diabetes and women with non-insulin requiring gestational diabetes (A1GDM)
2932733|NCT03021824||Moderate-Severe ARDS|All adults admitted to participating ICUs with study-defined moderate-to-severe ARDS.
2932734|NCT03021811|Other|LumiHeal|Treatment of chronic wounds with KLOX LumiHeal BioPhotonic System
2932735|NCT03021785|Experimental|0.5mg|In the core study, patients will receive 0.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
2932736|NCT03021785|Experimental|1.0mg|In the core study, patients will receive 1.0mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
2932875|NCT03020758|Experimental|Dried Fruit|Daily consumption of ¾ cup blend of dried plums, figs, dates and raisins (DPFDR) for 4 weeks
2932737|NCT03021785|Experimental|1.5mg|In the core study, patients will receive 1.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
2932738|NCT03021772|Active Comparator|Group N|30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
2932739|NCT03021772|Active Comparator|Group D|30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
2932740|NCT03021759|No Intervention|Control|No intervention
2932741|NCT03021759|Experimental|Active choice|Physicians will be asked to review a list of their patients eligible for statin therapy who are not yet prescribed a statin and make an active choice whether or not to prescribe a statin.
2932742|NCT03021759|Experimental|Active choice with social comparison feedback|Physicians will be asked to review a list of their patients eligible for statin therapy who are not yet prescribed a statin and make an active choice whether or not to prescribe a statin. Physicians will receive social comparison feedback informing them of how their performance compares to their peers
2932743|NCT03021746|Experimental|Parish Nurse plus Peer Leader|The focus of this approach is for Peer Leaders (PL) to provide Diabetes Self Management Support (DSMS) with the oversight of Parish Nurses (PN). The first component starts with group-based Diabetes Self Management Education (DSME) provided by Certified Diabetes Educators (CDE), co-facilitated by PN and PL and held at the church. PL will also facilitate activities including behavioral goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit, with oversight of PN. As the study progresses, PL and PN will have progressive leadership responsibilities. Following DSME, participants will be invited to attend 12 months of monthly DSMS support groups led by the PL, with oversight from the PN. This approach allows for PN to provide direct supervision to PL in areas of clinical content, educational methods, and group facilitation and communication skills.
2932744|NCT03021746|Experimental|Peer Leader Only|This approach will contain the same elements as the PN plus PL approach, except that a PN will not be used. Rather, PL will provide all aspects of DSMS, including behavioral goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit. This approach will be delivered in a group setting. DSME will be provided by CDEs and co-facilitated by a PL to ensure consistency in the DSME content. Following DSME, participants will be invited to attend 12 monthly DSMS groups led by PL. Following the group sessions, participants will transition into a period of ongoing support. During this time, participants and PL will be encouraged to foster DSMS through programs and initiatives that are meaningful to them, utilizing the existing church infrastructure. If needed, PL may contact the CDE for additional information
2932745|NCT03021746|Experimental|Parish Nurse Only|The main focus of this approach will contain all of the same elements as the PN plus PL approach, except that PL will not be used. Rather, the PN will provide all aspects of Diabetes Self Management Support (DSMS), including facilitation of goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit. Diabetes Self Management Education (DSME) will be provided by CDEs and co-facilitated by a PN to ensure consistency in the DSME content. Following DSME, participants will be invited to attend 12 months of monthly, DSMS support groups led by the PN. Following support sessions, participants will transition into a period of ongoing support, where the participants and PN will be encouraged to continue to foster DSMS through programs and initiatives that are meaningful to them, utilizing the existing church infrastructure. The PN may answer clinical questions and may contact the CDE for additional information if needed.
2932746|NCT03021733||Non-operative|Patients whom elected non-operative treatment
2932747|NCT03021733||Operative|Patients whom elected operative treatment
2932748|NCT03021720|Active Comparator|Femoral arterial access|Femoral arterial puncture for the uterine fibroid embolization procedure
2932749|NCT03021720|Experimental|Radial arterial access|Radial arterial puncture for the uterine fibroid embolization procedure
2932750|NCT03021694|Experimental|Young Males Week 1|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
2932751|NCT03021694|Experimental|Young Males Week 3|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
2932752|NCT03021694|Experimental|Young Males Week 5|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
2932753|NCT03021681|Other|COPD group(self control)|Prior treatment:20 stable COPD patients were enrolled,estimated the respiratory function and serum index Intervention:autologous bronchial basal cell transplantation After treatment:Estimate the change of respiratory function and serum index in third days , first months, third months, sixth months and first years of the follow-up after treatment respectively
2932754|NCT03021668|Experimental|Prevena Peel & Place Dressing for wound closure|In the participants randomized to this arm the surgical site will be closed using Prevena Peel & Place Dressing.
2932755|NCT03021668|Placebo Comparator|Standard closure of the wound|In the participants randomized to this arm the surgical site will be closed using the standard closure technique.
2932756|NCT03021655|Experimental|Adventure-based intervention group|Adventure-based intervention group included 1 day-camp and will be divided into 2 parts: (1) physical activity such as wall climbing, ropes course etc, (2) health education delivering about the relationship of self-efficacy, self-esteem, emotion and smoking abstinence. The training will be held before the 6-month follow-up. Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
2932817|NCT03021226|Experimental|Group II: Adults|Participants in Group II will be adults ages 20 to 24 years of age 60 hours of instruction provided over a six-week period, and address three major topic areas: Fatherhood Development, Relationship Enhancement, and Financial Literacy/Work.
2932757|NCT03021655|Experimental|WhatsApp intervention group|For WhatsApp intervention group, not more than 8 subjects with same gender will be assigned into a group. Messages about mood and stress management will be sent to the group per week and the group will last for 6 months. It aims to relieve their pressure and emotion by sharing their unhappy things with other subjects. Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
2932758|NCT03021655|Other|Control group|For the control group, the subjects will receive telephone counseling on quitting smoking at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
2932759|NCT03021642|Experimental|Sequence A: Tepotinib test then Tepotinib reference|
2932760|NCT03021642|Experimental|Sequence B: Tepotinib reference then Tepotinib test|
2932761|NCT03021629||primary open-angle glaucoma patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
2932762|NCT03021629||high myopia patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
2932763|NCT03021629||age-matched people|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
2932764|NCT03021616|Experimental|Energy drink|Two 16 oz bottles of energy drink will be consumed at baseline.
2932765|NCT03021616|Active Comparator|Moxifloxacin control|32oz of active control drink will contain 400mg moxifloxacin with inactive flavoring ingredients.
2932766|NCT03021616|Placebo Comparator|placebo control|32oz placebo control drink
2932767|NCT03021603|Experimental|Intervention Group|"This is a 4-week Brief Hope Intervention~Four sessions in total:~two face-to-face sessions (1-hour) and two telephone follow up sessions (30 mins) in between.~Homework : A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
2932768|NCT03021603|Experimental|Control Group|"Standard care:~Clinic follow up and normal hospital care. Logistic call and social communication On completion of the 4-week standard care, the 4-session brief hope intervention will be offered"
2932769|NCT03021590|Experimental|Clarithromycin :Concomitant Therapy|Amoxicillin 1000 mg Tablets, Clarithromycin 500 mg Tablets , Tinidazole 500 mg Tablets and Esomeprazole 20 mg Capsule each every 12 hours for 14 days all by mouth
2932770|NCT03021590|Active Comparator|Levofloxacin :Concomitant Therapy|Levofloxacin 500 mg Tablets Amoxicillin 1000 mg Tablets,Tinidazole 500 mg Tablets and Esomeprazole 20 mg each every 12 hours for 14 days all by mouth
2932771|NCT03021577|Active Comparator|Orbital Atherectomy System (OAS) Group|Subjects randomized to OAS. In a subset of patients (n= 20) a baseline cardiac magnetic Resonance Imaging (MRI) scan will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
2932772|NCT03021577|Active Comparator|Rotational Atherectomy (RA) Group|Subjects randomized to RA using the Rotablator Rotational Atherectomy System. In a subset of patients (n= 20) a baseline cardiac magnetic Resonance Imaging (MRI) scan will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
2932773|NCT03021538|Active Comparator|Cardiopulmonary Bypass|There will be 40 patients placed on cardiopulmonary bypass during lung transplantation.
2932774|NCT03021538|Active Comparator|Extracorporeal Membrane Oxygenation|There will be 40 patients placed on ECMO during lung transplantation.
2932775|NCT03021525|Experimental|Individualized Goal Directed Therapy (iGDT)|Patients receive fluids and catecholamines following a protocol of individualized parameters achieved by extended hemodynamic monitoring.
2932776|NCT03021525|Active Comparator|Control|Patients in the control group will be treated according to established basic treatment goals.
2932777|NCT03021512||Group 1 (BFG)|(Bifocal group). Subjects that underwent bifocal intraocular lenses implantation. (ie. Phaco with Restor intervention).
2932778|NCT03021512||Group 2 (TFG)|(Trifocal group). Subjects that underwent trifocal intraocular lenses implantation. (ie. Phaco with Panoptix intervention).
2932779|NCT03021499|Experimental|Voclosporin|oral, 23.7 mg BID
2932780|NCT03021499|Placebo Comparator|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules BID
2932781|NCT03021486|Experimental|Haloperidol Group|"All participants receive Haloperidol 2 mg by vein every 6 hours regularly and every hour as needed upon admission to acute palliative care unit (APCU). If Richmond Agitation Sedation Scale (RASS) scores reach ≥+2, participant randomized to Haloperidol 2 mg by vein every 4 hours and every hour as needed.~Symptom questionnaire completed at baseline and every 8 hours during the first 24 hours in the palliative care unit. After the first 24 hours, questionnaire completed 1 time each day until discharge."
2932782|NCT03021486|Experimental|Chlorpromazine Group|"All participants receive Haloperidol 2 mg by vein every 6 hours regularly and every hour as needed upon admission to acute palliative care unit (APCU). If Richmond Agitation Sedation Scale (RASS) scores reach ≥+2, participant randomized to Chlorpromazine 25 mg by vein every 4 hours and every hour as needed.~Symptom questionnaire completed at baseline and every 8 hours during the first 24 hours in the palliative care unit. After the first 24 hours, questionnaire completed 1 time each day until discharge."
2932783|NCT03021486|Experimental|Haloperidol and Chlorpromazine Group|"All participants receive Haloperidol 2 mg by vein every 6 hours regularly and every hour as needed upon admission to acute palliative care unit (APCU). If Richmond Agitation Sedation Scale (RASS) scores reach ≥+2, participant randomized to Haloperidol 1 mg by vein every 4 hours and every hour as needed, and Chlorpromazine 12.5 mg by vein every 4 hours and every hour as needed.~Symptom questionnaire completed at baseline and every 8 hours during the first 24 hours in the palliative care unit. After the first 24 hours, questionnaire completed 1 time each day until discharge."
2932784|NCT03021460|Experimental|Treatment (ibrutinib, pembrolizumab)|Patients receive ibrutinib PO daily on days 1-28 of course 1 and days 1-21 of course 2 and subsequent courses. Patients also receive pembrolizumab IV over 30 minutes on day 8 of course 1 and day 1 of course 2 and subsequent courses. Course 1 continues for 28 days and subsequent courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2932815|NCT03021239|Active Comparator|2) Hemodynamic-Echo Ramp Testing -|This testing is performed during a right heart catheterization procedure which provides hemodynamic measurements (pressure and blood flow) in addition to the echocardiography measurements. With this method, more echo images and measurements are taken. The final pump speed and medical treatment adjustments are made using the hemodynamic measurements as well as the information from the echo. This test will take about 1 hour and 45 minutes.
2932785|NCT03021434|Experimental|Standard Testing|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. A water sample from these households will be collected for laboratory analysis. Household-specific water quality information will be delivered to households within 72 hours, and households will be informed whether their drinking water was found to be contaminated. A study team member will review the information from the laboratory tests with the household and review information covered in the informational materials on safe water handling, storage, and use behaviours.
2932786|NCT03021434|Experimental|Test Kits|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. Data collectors will demonstrate the use of the low-cost microbiological water test kits and test household stored drinking water. A study team member will return to the household within 72 hours and review the household-specific water quality information from the initial test with household members. Households will be given 10 water test kits to use at their discretion over the 1-2 month follow up period. They will be appropriately trained in how to both perform the test and interpret the results. Households will also review information on safe water handling, storage, and use behaviours.
2932787|NCT03021434|Active Comparator|Comparison|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. A water sample from these households will be collected for laboratory analysis. Results from this analysis will be returned to the household at project endline. A study team member will return to the household within 72 hours to review the information on safe water handling, storage, and use behaviours.
2932788|NCT03021421|Sham Comparator|Group USA|(Marcain Heavy 0.5%; AstraZeneca®, London, UK) using a 25-G Quincke spinal injector (B. Braun®, Melsungen, Germany).
2932789|NCT03021421|Active Comparator|Group PCS|"(Stimupleks A; B. Braun®, Melsungen AG, Germany) to lumbar plexus in psoas muscle compartment (injected material 20 ml local anaesthetic mixture5 ml of 2% lidocaine + 15 ml of 0.5% bupivacaine)~%2 Aritmal ampul (Osel İlaç,Turkey) and Marcaine %0.5 flacon (AstraZeneca®, London, UK)"
2932790|NCT03021408|Experimental|MIRT + Treadmill|In the context of MIRT, the gait training in this group will be performed by using a treadmill without cues.
2932791|NCT03021408|Experimental|MIRT + Treadmill Plus|In the context of MIRT, the gait training in this group will be performed by using a treadmill with visual and auditory cues.
2932792|NCT03021408|Experimental|MIRT + Virtual Reality|In the context of MIRT, the gait training in this group will be performed by using Virtual Reality with enhanced perceptions (visual, auditory, and haptic inputs).
2932793|NCT03021395|Experimental|MRD-positive|MRD-positive patients receive Decitabine regimen.
2932794|NCT03021395|No Intervention|MRD-negative|MRD-negative patients receive no intervention.
2932795|NCT03021382||severity of calcification|All vessels were divided into tertile groups according to the severity of coronary calcification evaluated by the Agatston score.
2932796|NCT03021382||minimal lumen diameter (MLD) ≥1.0 mm|All lesions were divided according to an MLD ≥1.0 mm, and <1.0 mm by OCT in order to isolate the lesions which an MLD below the OCT catheter size.
2932797|NCT03021369|Active Comparator|Pleural drainage system Medela|These patients receive the digital Medela system
2932798|NCT03021369|Active Comparator|Pleural drainage system Ocean|These patients receive the analogue Maquet system
2932799|NCT03021356|Active Comparator|Trifecta aortic xenograft|The Trifecta aortic xenograft is implanted in these patients.
2932800|NCT03021356|Active Comparator|Magna Ease aortic xenograft|The Magna Ease aortic xenograft is implanted in these patients.
2932801|NCT03021343|Active Comparator|Colchicine|Colchicine 2 mg 12-24 hours prior to surgery and 1 mg 4 hours before or immediately after surgery and then continued at a dose of 0.5 mg twice daily until hospital discharge. Half the dose was given to patients weighing <70 kg or intolerant to the full dose.
2932802|NCT03021343|No Intervention|No colchicine|In this arm no active medication was administered
2932803|NCT03021330|Active Comparator|DA Regimen|Patients receive standard DA induction regimen including daunomycin and cytarabine.
2932804|NCT03021330|Experimental|Intermediate Dose of DA Regimen|Patients receive DA induction regimen including daunomycin and intermediate dose of cytarabine.
2932805|NCT03021317|Experimental|Treated Group|Open label, single arm treatment study using MRI and laboratory markers to assess efficacy of ACTHAR in MS patients who are undergoing relapses.
2932806|NCT03021304|Experimental|Mepolizumab SC 100 mg/milliliter (mL) in Safety syringe|Subjects will receive 3 doses of 100 mg mepolizumab, liquid drug product in safety syringe, subcutaneously as a single injection that is self-administered in the thigh, abdomen or administered in the upper arm (by caregiver only) at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
2932807|NCT03021291|Experimental|Gelesis100|Gelesis100 (2.25 g) twice daily
2932808|NCT03021278|Experimental|Saline Injection|In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl).
2932809|NCT03021278|Experimental|Sham Injection|In the sham injection group, a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience.
2932810|NCT03021278|No Intervention|Control Group|The control group will not receive any kind of pain or pinprick sensation.
2932811|NCT03021265||T80/A5/H12.5 FDC|Patients with hypertension
2932812|NCT03021252|Experimental|High intensity IEMT|Inspiratory and expiratory muscle training + standard swallow therapy.
2932813|NCT03021252|Sham Comparator|Sham IEMT|Sham inspiratory and expiratory muscle training + standard swallow therapy
2932814|NCT03021239|Active Comparator|1) Echo Guided Testing -|This testing uses echocardiography to create images of the heart and make measurements while gradually increasing the heart pump speed. The final pump speed and medical treatment are determined using the echo measurements. This will take about 45 minutes.
2932816|NCT03021226|Experimental|Group I: Youth|Participants in Group I will be youth ages 16 to 19 years of age who receive 60 hours of instruction provided over a six-week period, and address three major topic areas: Fatherhood Development, Relationship Enhancement, and Financial Literacy/Work.
2932909|NCT03020563|Placebo Comparator|Bupivacaine|Immediate Acting Bupivacaine
2932819|NCT03021226|No Intervention|Group IV: No Intervention: Adults|Participants in Group IV will be adults ages 20 to 24 years of age who do not receive any hours of intervention.
2932820|NCT03021200|Experimental|Indocyanine green in Conventional Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (SPY-Elite) for conventional oncological surgeries
2932821|NCT03021200|Experimental|Indocyanine green in minimally invasive Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (Pinpoint) for minimally invasive oncological surgeries
2932822|NCT03021200|Experimental|Indocyanine green in robot-assisted Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (Firefly) for robot-assisted oncological surgeries
2932823|NCT03021187|Experimental|Semaglutide 3 mg|
2932824|NCT03021187|Experimental|Semaglutide 3 mg + 7 mg|
2932825|NCT03021187|Experimental|Semaglutide 3 mg + 7 mg + 14 mg|
2932826|NCT03021187|Placebo Comparator|Placebo|
2932827|NCT03021174|Experimental|Exercise|Exercise for Cancer Patients (EXCAP©®), developed by Dr. Karen Mustian, involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
2932828|NCT03021174|Active Comparator|Nutrition Education Control|Nutrition education (control) involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
2932829|NCT03021161|Experimental|intervention group|The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019 (probiotic formula).
2932830|NCT03021161|Placebo Comparator|Placebo Oral Capsule|The control group will receive once daily similar capsules containing placebo.
2932831|NCT03021148||High-school children|"High-school children, age range from 13 to 18 years, from Liceo Classico and Liceo Artistico Tommaso Fazello of Sciacca, Agrigento, Italy"
2932832|NCT03021135|Active Comparator|Conventional Mucosal Resection|C-EMR will be made with saline injection with the indigo carmine.
2932833|NCT03021135|Experimental|Underwater Mucosal Resection|UW-EMR will be made after the complete filling of lumen with water.
2932834|NCT03021122|Experimental|Arm A (PedAMINES™ / Conventional Method)|A 2-period study where nurses will be randomized to a 15-minute CPR scenario to prepare and deliver Dopamine with the help of PedAMINES™ first, then crossover (incl. washout period) to prepare and deliver Norepinephrine with the help of a Conventional Method.
2932835|NCT03021122|Active Comparator|Arm B (Conventional Method / PedAMINES™)|A 2-period study where nurses will be randomized to a 15-minute CPR scenario to prepare and deliver Dopamine with the help of a Conventional Method first, then crossover (incl. washout period) to prepare and deliver Norepinephrine with the help of PedAMINES™.
2932836|NCT03021109|Experimental|Inferior vena cava diameteres|Measurement of inferior vena cava diameters with ultrasound
2932837|NCT03021083|Experimental|IONSYS Administration|"Patients who have elective multi-level spinal fusions under general anesthesia (who do not receive methadone) will be enrolled. In addition, all patients will receive Pepcid 20 mg, dexamethasone 10 mg, and ondansetron 4 mg.~When patients will arrive in the post anesthesia care unit (PACU), pain will initially be controlled with IV hydromorphone to achieve an NRS score of 3 or less. Once transferred to the step down unit (SDU), the IONSYS patch will be applied. IONSYS should be utilized when they have pain, but rescue analgesia will be available. If severe pain continues, the chronic pain service will be consulted, to potentially change the medications.~Patients will be assessed for pain at rest and with PT in the AM and PM of POD 1 and POD 2. The IONSYS system will be discontinued after 48 hours, and a total dose of fentanyl received per 24 hours will be recorded. PT milestones for discharge will be assessed on the afternoon of POD 1 and POD 2."
2932838|NCT03021070|Experimental|Cash transfer arm|The intervention is a conditional cash transfer payment for each health facility appointment honoured for ANC, delivery, postnatal care and childhood immunization; and referrals related to any of these visits.
2932839|NCT03021070|No Intervention|Non-cash transfer arm|The control is a mobile phone airtime transfer value of 50 Ksh. transferred through the electronic system for each health facility appointment honoured for ANC, delivery, postnatal care and childhood immunization; and referrals related to any of these visits.
2932840|NCT03021044|Other|STANDARD OF CARE|The standard of care group will be recommended about medications and a correct life style (physical activity, low salt and low fat diet, no smoking) in order to prevent cardiovascular events. In this 15-minutes talk study doctor will explain to patients and relatives the importance of aerobic physical activity (30-60 minutes daily, moderate intensity, for example speedy walking, for at least 5 days/weekly) with the aim of reducing cardiovascular risk. Patients will also receive a brochure with clear explanations. Study doctor and study coordinator will be helpful for any question and they will ensure that patients and relatives understand the importance of physical activity for cardiovascular health.
2932841|NCT03021044|Experimental|PHYSICAL ACTIVITY INTERVENTION|Besides standard of care, the experimental group will participate to a program of physical activity intervention. Following hospital discharge, participants in stable clinical conditions will be referred by their cardiologist to the exercise-based secondary prevention program. All exercise testing and training sessions will be performed without discontinuing the prescribed medications. On admission to the program, and quarterly during follow-up, each patient will perform a 1-km treadmill walk test as previously described (1k-TWT).
2932842|NCT03021018|Experimental|Brivaracetam (BRV) 100 mg|Two 5 ml vials of brivaracetam administered intravenously over a 2-minute period
2932843|NCT03021018|Experimental|Brivaracetam (BRV) 200 mg|Four 5 ml vials of brivaracetam administered intravenously over a 4-minute period
2932844|NCT03021018|Active Comparator|Lorazepam (LZP)|Lorazepam bolus is to be injected based on information from the patient leaflet/package insert. The rate of injection should not exceed 2.0 mg/min. The LZP dose will be determined according to the Investigator's clinical judgment.
2932845|NCT03021005|Experimental|Self Testing Kit|"This group will be provided a free Food and Drug Administration-approved HIV self-testing home kit (OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test). Participants in this group will also be provided 5 referral cards to give to their partners and peers in the drug, sex, and social networks for them to request a free HIV self-testing kit from the I Want The Kit website."
2932866|NCT03020797|Placebo Comparator|placebo|placebo 1 tablet QD for 2 weeks placebo 2 tablets QD for 2 weeks placebo 3 tablets QD for 2 weeks placebo 4 tablets QD for 2 weeks
2932846|NCT03021005|No Intervention|No Self Testing Kit|"This group will not receive a free Food and Drug Administration-approved HIV self-testing home kit (OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test). Participants in this group will not receive referral cards for their partners or peers for them to request a free HIV self-testing kit from the I Want The Kit website."
2932847|NCT03020992|Experimental|Certolizumab Pegol|Subjects will receive a loading dose of Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) administered at Baseline, Week 2, and Week 4 followed by CZP 200 mg sc every two Weeks
2932848|NCT03020979|Experimental|500mg apatinib|Patients will receive 500mg of apatinib tablet orally, once daily.
2932849|NCT03020966|Experimental|Oral Tylenol|Patient group receiving 1000mg of oral acetaminophen and an intravenous placebo
2932850|NCT03020966|Experimental|Intravenous Tylenol|Patient group receiving 1000mg of intravenous acetaminophen and an oral placebo
2932851|NCT03020953|Experimental|Exercise + Estrogen|Strength training 3 times a week for 12 weeks. Estrogen patches which provide 100 um pr. 24 hours.
2932852|NCT03020953|Active Comparator|Exercise + Placebo|Strength training 3 times a week for 12 weeks. Placebo patches.
2932853|NCT03020927|Active Comparator|Therapist Delivered|Children in the therapist-delivered condition will receive two, 60-minute long sessions of Reciprocal Imitation Training each week for ten consecutive weeks. These sessions will be delivered by trained graduate, undergraduate, and post-graduate research staff. Parents will be permitted to observe sessions via live video, but will not be directly involved in intervention.
2932854|NCT03020927|Experimental|Parent + Therapist Delivered|Children in the parent + therapist-delivered condition will receive one, 60-minute long session of Reciprocal Imitation Training each week for ten consecutive weeks. These sessions will be delivered by trained graduate, undergraduate, and post-graduate research staff. During the same period of time, parents/guardians of children will receive one, 60-minute long parent education session per week with graduate and post-graduate research staff, aimed at teaching parents to implement Reciprocal Imitation Training at home with the child.
2932855|NCT03020914|Experimental|Audiovisual Distraction|Patients get audiovisual distraction during surgery and in the recovery room using video goggles and headphones; patients can choose a movie from a preexisting library; with an initial dose of midazolam in preparation for the administration of the neuraxial anesthesia, additional sedation with midazolam in 1 mg increments if requested by the patient or deemed necessary by the anesthesia provider.
2932856|NCT03020914|No Intervention|Standard of care sedation|Standard of care sedation with with a initial dose of midazolam in preparation for the administration of the neuraxial anesthesia; propofol infusion titrated to effect.
2932857|NCT03020888|Experimental|Magseed and Sentimag|"Magseed marker deployed to mark a breast lesion under imaging guidance up to 30 days prior to surgery.~Marker located during surgery using the Sentimag system, and removed with the lesion."
2932858|NCT03020875|Active Comparator|PO Acetaminophen|"Preop:~Eligible patients will receive oral acetaminophen within 3 hours of OR start time.~Postop:~Eligible patients will be administered oral acetaminophen following 1 and 2 level LLIFs supplemented with instrumented posterior fusion to evaluate pain management outcomes. Dosing for the group will be the following:~• Oral Acetaminophen 1,000 mg every 6 hours for 48 hours postoperative. Medication will be given at least 6 hours following initial preoperative dose of oral acetaminophen.~Postop supplemental pain medications:~All patients will receive a standardized hydromorphone IV-PCA order set for 24 hours postoperatively. The use of tramadol and tapentadol will specifically be discouraged due to challenges in determining morphine-equivalent dosing with these specific agents. Similarly, acetaminophen containing combination products (e.g. oxycodone/acetaminophen or hydrocodone/acetaminophen) will not be allowed due to overlap with the primary study medications."
2932859|NCT03020875|Active Comparator|Intravenous Acetaminophen|"Preop:~Eligible patients will receive IV acetaminophen within 3 hours of OR start time.~Postop:~Eligible patients will be administered IV acetaminophen following 1 and 2 level LLIFs supplemented with instrumented posterior fusion to evaluate pain management outcomes. Dosing for the group will be the following:~• IV Acetaminophen 1,000 mg [100 ml] every 6 hours for 48 hours postoperative. Medication will be given at least 6 hours following initial preoperative dose of IV acetaminophen.~Postop supplemental pain medications:~All patients will receive a standardized hydromorphone IV-PCA order set for 24 hours postoperatively. The use of tramadol and tapentadol will specifically be discouraged due to challenges in determining morphine-equivalent dosing with these specific agents. Similarly, acetaminophen containing combination products (e.g. oxycodone/acetaminophen or hydrocodone/acetaminophen) will not be allowed due to overlap with the primary study medications."
2932860|NCT03020862|Experimental|Placebo ---> Dietary beetroot|"Placebo was administrated in the first period of the cross-over trial, while the intervention beverage Dietary Beetroot juice was administrated in the second period of the trial.~The placebo: was an NO3- negligble drink from James White Drinks England (Beet-it), which was otherwise similar to the dietary beetroot juice in nutrient composition, smell and appearance. Dose: 2x70 mL consumed twice a day for six days.~Intervention beverage, Dietary beetroot juice:Consumed as beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days."
2932861|NCT03020862|Experimental|Dietary beetroot juice --> Placebo|The intervention beverage Dietary beetroot juice was administrated in the first period of the cross-over trial, while placebo was administrated in the second period of the trail Intervention beverage, Dietary beetroot juice:Consumed as beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days. The placebo: was an NO3- negligble drink from James White Drinks England (Beet-it), which was otherwise similar to the dietary beetroot juice in nutrient composition, smell and appearance. Dose: 2x70 mL consumed twice a day for six days.
2932862|NCT03020836|Other|Hypertension patient referral|Referral to primary care physician for hypertension control: Patients with uncontrolled hypertension were referred to a primary care physician for treatment.
2932863|NCT03020836|Other|Smoking cessation patient referral|Referral to smoking quit line: Patients that were current smokers were referred to the Maryland smoking cessation quit line if they were willing.
2932864|NCT03020823|Experimental|SCB01A alone|intra-subject dose escalation starting from 12 mg/m2, then to18 mg/m2, and finally to 24 mg/m2 if no DLT
2932865|NCT03020797|Experimental|perampanel|perampanel 2mg QD for 2 weeks perampanel 4mg QD for 2 weeks perampanel 6mg QD for 2 weeks perampanel 8mg QD for 30 weeks
2932867|NCT03020784|Placebo Comparator|Placebo|IV placebo
2932876|NCT03020758|Experimental|Control|Daily consumption of isocaloric and macronutrient matched snack food for 4 weeks
2932877|NCT03020745|Experimental|Part 1, Cohort A : GSK3389404 30 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 30 mg or matching placebo
2932878|NCT03020745|Experimental|Part 1, Cohort B: GSK3389404 60 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 60 mg or matching placebo
2932879|NCT03020745|Experimental|Part 1, Cohort C: GSK3389404 120 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 120 mg or matching placebo
2932880|NCT03020745|Experimental|Part 1, Cohort C1 (optional): GSK3389404 120 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 120 mg or matching placebo
2932881|NCT03020745|Experimental|Part 1, Cohort D: GSK3389404 </= 240 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 <= 240 mg or matching placebo
2932882|NCT03020745|Experimental|Part 2: GSK3389404 or placebo SC|Enrolled subjects will receive different parallel dose level and regimens of GSK3389404 or placebo SC at dose determined in part 1. The treatments for Part 2 are 60 mg GSK3389404 weekly, 120 mg bi-weekly GSK3389404, 120 mg GSK3389404 weekly or placebo.
2932883|NCT03020732|Experimental|test groups|In this split mouth study, bilaterally gingival recession defects were randomly treated in test(CGF+CAF) or control(SCTG+CAF) groups.In test groups, a special centrifuge machine(Medifuge) and subjects venous blood were used to obtain Concentrated growth factor. A special compress was used to transform Concentrated growth factor membrane.
2932884|NCT03020732|Active Comparator|control groups|In this split mouth study, bilaterally gingival recession defects were randomly treated in test(CGF+CAF) or control(SCTG+CAF) groups. In control groups, subepithelial connective tissue graft was taken from the palatal canine teeth-first molar teeth area with a trap door technique according to the width of the exposed root surface and the adjacent bone margins. The graft's thickness was adjusted between 1.5 and 2 mm.
2932885|NCT03020719|Experimental|Oral Glutathione|Oral Glutathione oral powder at 65mg/kg/day
2932886|NCT03020719|Placebo Comparator|Placebo|Placebo oral powder at 65mg/kg/day
2932887|NCT03020706|Experimental|Magnesium|magnesium sulfate, injectable intravenous administration (50mg/kg diluted in 100ml normal saline) during general anesthesia
2932888|NCT03020706|No Intervention|Control|No intervention
2932889|NCT03020693|Experimental|Invasive electrostimulation combined with exercises.|Dry needling + TENS ( 4 Hz 200 microseconds during 30 minutes to therapeutic intensity) combined with exercises program.
2932890|NCT03020693|Active Comparator|Placebo electrostimulation and exercises.|Sham dry needling + TENS ( 4 Hz 200 microseconds during 30 minutes to non-therapeutic intensity) with surface electrodes combined with exercises program.
2932891|NCT03020680|Experimental|ubiquinol|It is the reduced form of coenzyme Q10
2932892|NCT03020680|Active Comparator|ubiquinone|It is the oxidized form of coenzyme Q10
2932893|NCT03020667||IQOS Users|"The criteria defining an IQOS user are listed in the section Eligibility."
2932894|NCT03020667||Cigarette (CC) Smokers|"The criteria defining a CC smoker are listed in the section Eligibility."
2932895|NCT03020654|Experimental|Treatment group|Virtual environment with fast moving objects these are graded in intensity from 1-7. Participants complete head and eye exercises within the environment using focus points such as benches and lanterns for a six week treatment program.
2932896|NCT03020654|Active Comparator|Control group|Virtual environment with no movement graded at grade 0. Participants complete head and eye exercises within the environment using focus points such as benches and lanterns for a six week treatment program.
2932897|NCT03020641|Experimental|Low pneumoperitoneum pressure.|Pneumoperitoneum pressure at 8 mmHg or lower.
2932898|NCT03020641|Active Comparator|standard pneumoperitoneum pressure|Pneumoperitoneum pressure at 12 mmHG or higher
2932899|NCT03020628|Experimental|NBP607-QIV 0.5mL|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine
2932900|NCT03020628|Active Comparator|NBP607-TIV 0.25mL|Trivalent Inactivated Cell Culture-derived Influenza Vaccine
2932901|NCT03020615|Active Comparator|Stable Dosing|In the first 8 weeks (+ 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (+ 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 1 (Stable Dosing) continues standard treatment.
2932902|NCT03020615|Experimental|Intensive Dosing|In the first 8 weeks (+ 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (+ 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 2 (Intensive Dosing) will have their HU dose increased by 5 mg/kg/day every 8 weeks up to a maximum of 35 mg/kg/day.
2932903|NCT03020602|Experimental|Treatment (BPM31510)|Patients receive ubidecarenone injectable nanosuspension IV over 72 hours twice weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2932904|NCT03020589|Experimental|CYP3A5 based tacrolimus dosing|Subjects in this treatment arm will receive initial tacrolimus based on their genotype i.e., CYP3A5*1/*1 and CYP3A5*1/*3 (Expressers) will receive the initial tacrolimus dose of 0.2 mg/kg/day, with maximum of 20 mg/day in 2 divided doses. For CYP3A5*3/*3 (Non-Expressers), the subjects will receive initial tacrolimus dose of 0.1 mg/kg/day in 2 divided doses.
2932905|NCT03020589|No Intervention|Control|Subjects in the prospective control group will receive standard tacrolimus dosing as recommended per package insert and will not be dosed based on their genotype. Similarly, subjects that underwent renal transplant after 2010 and received standard tacrolimus dosing (per package insert) will serve as historical controls.
2932906|NCT03020576|Active Comparator|Conventional Therapy|Participants randomized to this arm will receive conventional based therapy to their affected upper limb dose matched with the Robotic Therapy group. These interventions are aimed at increasing range of motion, strength and function at the shoulder, elbow, wrist and hand.
2932907|NCT03020576|Experimental|Robotic Therapy|Participants randomized to this arm will receive robotic based therapy using the Amadeo Hand Robot device to improve range of motion, strength, and coordination to the wrist and hand.
2932908|NCT03020563|Active Comparator|Liposomal Bupivacaine|Time release Bupivacaine
2932911|NCT03020537|Other|Group A: 1-2 years old|Group A: 1-2 years old, seasonal influenza vaccine-naive. Given intramuscular,inactivated influenza vaccine-trivalent (IM IIV3) - Fluzone (pediatric formulation).
2932912|NCT03020537|Other|Group B: 18-30 years old|Group B: 18-30 years old, who did not receive the 20l2-2013 seasonal influenza vaccine. Given intramuscular,inactivated influenza vaccine-trivalent (IM IIV3) - Fluzone.
2932913|NCT03020524|Experimental|Dose level 1:|Autologous CD4 T-Cells0.8-1x10^9 transduced CD4+T-cells administered IV as a single dose
2932914|NCT03020524|Active Comparator|Dose level 2|Autologous CD4 T-Cells 2.4-3x10^9 transduced CD4+ T-cells administered IV as a single dose
2932915|NCT03020524|Active Comparator|Dose level 3|Autologous CD4 T-Cells 0.8-1x10^10 transduced CD4+ T-cells administered IV as a single dose
2932916|NCT03020511|Other|Ancient wheat flours|"We prospectively will survey 30 nuns from the Congregazione delle Suore Collegine della Santa Famiglia, Palermo, Italy. The subjects will be recruited between January 2017 and June 2017 and will be examined before and after the diet period (30 days) with ancient grains, undergoing clinical evaluation and blood and feces samples collection. Ancient wheat flours will be administered in open label for 30 days"
2932917|NCT03020498|Other|Group A: 8-17 yo identical twins|Group A: 8-17 year-old identical twin pairs randomly assigned to Fluzone (trivalent, inactivated influenza vaccine (TIV)) or FluMist (live, attenuated influenza vaccine (LAIV)) within the pair
2932918|NCT03020498|Other|Group B: 8-30 yo non-twin|Group B: 8-30 years old non-twin individuals randomly assigned to Fluzone (trivalent, inactivated influenza vaccine (TIV)) or FluMist (live, attenuated influenza vaccine (LAIV))
2932919|NCT03020498|Other|Group C: 70-100 yo non-twin|Group C: 70-100 years old non-twin elderly adults given Fluzone (trivalent, inactivated influenza vaccine (TIV))
2932920|NCT03020485|Experimental|Isomaltulose|50g of isomaltulose dissolved in 250ml of water
2932921|NCT03020485|Experimental|Sucrose|50g of sucrose dissolved in 250ml of water
2932922|NCT03020472|Experimental|2008-2009 FluMist LAIV (Intranasal)|2008-2009 FluMist LAIV (Intranasal) Seasonal live, attenuated influenza vaccine
2932923|NCT03020459|Experimental|peeling-reposition|"After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany) with the help of Constellation 23-gauge vitrectomy system (Alcon Laboratories Inc, Fort Worth, TX), the intervention of peeling-reposition was used to peel and unfold the ILM. And the postoperative posture would be prone position in two weeks for all patients after the operation."
2932924|NCT03020459|Active Comparator|peeling|"After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany) with the help of Constellation 23-gauge vitrectomy system, the intervention of peeling was used to grasped ILM with end-gripping forceps. And the postoperative posture would be prone position in two weeks for all patients after the operation."
2932925|NCT03020446|Experimental|Sorbion dressing to venous leg ulcer|any venous leg ulcer will receive sorbion dressing weekly for 4 weeks than wound will be assessed
2932926|NCT03020433|Active Comparator|rTMS Contralesional M1 Inhibition|
2932927|NCT03020433|Active Comparator|rTMS Contralesional PMC facilitation|
2932928|NCT03020433|Active Comparator|rTMS Ipsilesional PMC facilitation|
2932929|NCT03020433|Sham Comparator|rTMS Sham at Ipsilesional M1|
2932930|NCT03020420|Experimental|treatment arm|receive cicatricell cream
2932931|NCT03020420|No Intervention|control arm|to treatment
2932932|NCT03020407|Experimental|IVC Ultrasound-guided|The treating physician will promptly assess the IVC diameter to obtain the collapsibility index (IVCCI) (or distensibility index, IVCDI) of an eligible patient. A previous study showed that IVCCI > 40% were strongly associated with fluid responsiveness. Accordingly, the patient will be given 10 ml/kg of bolus of 0.9% normal saline solution (NSS) each time when the IVCCI > 40% is discovered and serial measurements will be done after each intravenous bolus is achieved until the IVCCI < 40 % during our protocol. Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
2932933|NCT03020407|No Intervention|Usual care|Patients will be promptly and empirically treated by 30 ml/kg loading of NSS in this treatment arm. After the NSS bolus, treatment with either the additional intravenous fluid or a vasopressor is given depended on physicians' discretion during the 6-hour study period. Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
2932934|NCT03020394|Experimental|Noninvasive ventilation|Noninvasive positive pressure ventilation is achieved by Philips Respironics V60/Vision ventilator. Choose bilevel positive airway pressure mode, and adjust the fraction of inspire oxygen(FiO2) or oxygen flow rate to maintain patient's oxygen saturation(SpO2) between 88% to 92%. Parameter adjustment and weaning of NPPV follow the protocols used before.
2932935|NCT03020394|No Intervention|Invasive ventilation|Intubated immediately and connected to the ventilator. Parameter adjustment and weaning of IPPV follow the protocols used before.
2932936|NCT03020381||Cognitively Normal (Control Group)|Participants aged 65 and older, with absence of Dementia (by DSM IV and DSM V) criteria. Normal age-, sex-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD.
2932937|NCT03020381||Subjective Cognitive Impairment (SCI)|"Participants aged 65 and older, with absence of Dementia (by DSM IV and DSM V) criteria. Normal age-, sex-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD. Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event. Answering yes to both of the following questions: Do you feel like your memory or thinking is becoming worse? and Does this concern you?"
2932938|NCT03020381||Mild Cognitive Impairment (MCI)|Participants aged 65 and older that have self-experienced persistent decline in cognitive capacity and unrelated to an acute event. MCI is operationalized following Peterson's criteria as: i) presence of subjective memory complaints from the patient and family; ii) objective memory impairment in cognitive tests (below 1.5 SD on standardized cognitive tests adjusted by age, sex, and education-); iii) preserved activities of daily living (assessed using the Lawton-Brody scale); iv) absence of clinical dementia established using DSM-IV-TR (from 2007 to 2013) and DSM V (from 2014 and onwards)
2932939|NCT03020368|Experimental|Leeches|"One-time topical application of 2-3 leeches (medileech, Hirudo verbana) periarticularly on the painful thumb base"
2932940|NCT03020368|Active Comparator|Diclofenac|3 times daily topical application of Diclofenac gel (1 g with 10 mg diclofenac-Na) over 4 weeks
2932941|NCT03020355|Experimental|Placental Blood Drainage|Immediately after vaginal delivery, after clamping and cutting the cord—the cord will unclamped and the blood will drained until the flow ceased.
2932942|NCT03020355|Active Comparator|not Placental Blood Drainage|In the control group, the clamped cord will not released.
2932943|NCT03020329|Experimental|Paclitaxel, Cisplatin, 5-Fu,|Patients receive paclitaxel (135mg/m2 on day 1), cisplatin (70mg/m2 on day 1) and fluorouracil (700mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy(Intensive modulate radiotherapy,IMRT)and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
2932944|NCT03020316|No Intervention|Usual Care|"Subjects will be encouraged to follow-up with their primary physicians.~Subjects will be informed that they will be periodically contacted by telephone and/or email by the research team for future assessments."
2932945|NCT03020316|Active Comparator|Peer Mentor & Transcendental Meditation|"Subjects will be assigned a peer mentor (a volunteer with CAD). After initial contact, the peer mentor and subject will be encouraged to communicate at whatever frequency or medium they deem most appropriate. This may include speaking by telephone, personal email or meeting in person. Mentors (and subjects if willing) will be asked to keep a log of such contacts, which will be provided to the study staff at interval reassessments.~In addition to the peer mentor, subjects will be instructed in transcendental meditation (TM) in the standard manner by a trained TM instructor."
2932946|NCT03020316|Active Comparator|Peer Mentor|"We are no longer recruiting in this arm.~Subjects will be assigned a peer mentor (a volunteer with CAD). After initial contact, the peer mentor and subject will be encouraged to communicate at whatever frequency or medium they deem most appropriate. This may include speaking by telephone, personal email or meeting in person. Mentors (and subjects if willing) will be asked to keep a log of such contacts, which will be provided to the study staff at interval reassessments."
2932947|NCT03020303|Placebo Comparator|Placebo Oral Tablet|A tablet with no active medication that will be an exact match of the active spironolactone in taste and appearance
2932948|NCT03020303|Active Comparator|Spironolactone 25 MG Tablet|25 mg of active spironolactone in tablet form
2932949|NCT03020290||patients with femoropopliteal lesion|patients with femoropopliteal lesion - Endovascular treatment for PAD during medical care
2932950|NCT03020277|Other|ASD children families|
2932951|NCT03020264|Experimental|Patients older than 75 years|Collection of hypoglycaemia épisodes with the glycemic sensor FREESTYLE Libre
2932952|NCT03020251|Active Comparator|control group (C group)|patient will receive preoperative chest physiotherapy (standard supportive care)
2932953|NCT03020251|Experimental|rehabilitation group (R group)|patient will receive preoperative chest physiotherapy and a preoperative rehabilitation program at home (exercise training)
2932954|NCT03020238|Placebo Comparator|BiClamp group|BiClamp forcep (BiClamp® forcep, ERBE Elektromedizin, GmbH, Tuebingen, Germany) is used to dissect inferior hypogastric plexus
2932955|NCT03020238|Active Comparator|water jet group|water jet (ERBEJET®2, ERBE Elektromedizin, GmbH, Tuebingen, Germany) is used to dissect inferior hypogastric plexus
2932956|NCT03020225|Active Comparator|White cheese|Reference group- animal protein food source: White cheese (contains 30g protein), intact, plus 250ml mineral water
2932957|NCT03020225|Experimental|Green peas|Plant food source: Green peas (contains 30g protein), intact, cooked, plus 250ml mineral water
2932958|NCT03020225|Experimental|Mankai|Plant food source: Wolffia globosa (Mankai, contains 30g protein), intact, cooked, plus 250ml mineral water
2932959|NCT03020212|Active Comparator|Oxygen|Long-term oxygen therapy in patients with chronic obstructive pulmonary disease (COPD)
2932960|NCT03020212|No Intervention|Not oxygen|No intervention ( no therapy with oxygen)
2932961|NCT03020199|Experimental|A1|80 patients (65 in Arm A1a and 15 in Arm A1b) with new-onset psoriasis will receive 300 mg secukinumab by s.c. injection at baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 48 inclusive.
2932962|NCT03020199|Active Comparator|B1|80 patients (65 in Arm B1a and 15 in Arm B1b) with new-onset psoriasis will receive 1 or 2 cycles of nb-UVB of 12 weeks each with a maximum break of 28 weeks between cycles (patients with PASI 90 at Week 40 will not receive a second treatment cycle).Only during the first 4 weeks of each cycle, nb-UVB treatment should be applied in combination with topical calcipotriol 50 μg/g and betamethasone 0.5 mg/g.
2932963|NCT03020199|Experimental|A2|secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 100 inclusive (last dose administered at Week 100)
2932964|NCT03020199|Experimental|C1|secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 48 inclusive (last dose administered at Week 48)
2932965|NCT03020199|Experimental|C2|secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 100 inclusive (last dose administered at Week 100)
2932966|NCT03020186|Placebo Comparator|Physical activity|Physical activity (PA) group will receive free gym memberships and the instruction necessary to engage in moderate-intensity physical activity, ~80% of which will have an aerobic component. The participants will get basic health promoting guideline for healthy diet .
2932967|NCT03020186|Experimental|Physical activity+ MED diet|On top of the PA intervention described in Arm 1, the participants will be guided for moderate weight loss with a traditional Mediterranean (MED) diet, low in simple carbohydrates. The diet will include 1oz/day of walnuts that will be provided free of charge.
2932968|NCT03020186|Experimental|Physical activity+ green-MED diet|"On top of the PA intervention described in Arm 1, the participants will guided for moderate weight loss with a MED diet, low in simple carbohydrates that will be rich in plants and polyphenols and low in processed meat. The diet will include 1oz/day of walnuts, 3-4 cups/day of green tea and ~500cc green shake/dinner based on specific strain of duckweed [Wolffia globose, Mankai], an aquatic plant, which might serve as a plant protein source. All the above will be provided free of charge."
2932969|NCT03020173||BMI above 30|Oocytes and granulosa of infertile women with BMI above 30
2932970|NCT03020173||BMI below 30|Oocytes and granulosa of infertile women with BMI above 30
2932971|NCT03020160|Experimental|Emicizumab: Expansion Part|Participants will received SC emicizumab at a loading dose of 3 mg/kg every week for initial 4 weeks followed by a maintenance dose of 6 mg/kg every 4 weeks for a minimum of 24 weeks.
2933054|NCT03019549|Experimental|Rosuvastatin|Rosuvastatin administered once orally on Day 1
2932972|NCT03020160|Experimental|Emicizumab: PK Run-in Part|Participants will received SC emicizumab at a dose of 6 mg/kg every 4 weeks for a minimum of 24 weeks.
2932973|NCT03020147||early BCG|Children received BCG soon after their birth between 2008 and 2013.
2932974|NCT03020147||delayed BCG|Children received BCG when they are 2,5kg between 2008 and 2013.
2932975|NCT03020134|Experimental|PKGroup(Ravidasvir/Danoprevir/Ritonavir)|Ravidasvir + Danoprevir/ Ritonavir
2932976|NCT03020134|Placebo Comparator|Placebo Group|Placebo
2932977|NCT03020121|Experimental|BD HPV assay on Viper LT|"The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.~Device: BD HPV assay on Viper LT The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test. Colposcopy/biopsy will be performed on all subjects."
2932978|NCT03020108||Group 1|The group 1 will comprise of 30 patients with benign ovarian cysts such as mature teratoma or simple serous cysts on ultrasound examination.
2932979|NCT03020108||Group 2|The group 2 will comprise of 30 patients with diagnosis of stage 1-2 endometriosis in guidance with the revised American Society for Reproductive Medicine classification.
2932980|NCT03020108||Group 3|The group 3 will comprise of 30 patients with diagnosis of stage 3-4 endometriosis in guidance with the revised American Society for Reproductive Medicine classification.
2932981|NCT03020095|Experimental|Ravidasvir,Danoprevir/r,RBV|Participants will receive Ravidasvir 200mg plus Ritonavir boosted Danoprevir 200/200mg,and Ribavirin 1000/1200mg daily for 12 weeks.
2932982|NCT03020082|Experimental|Danoprevir, Ritonavir, Peg-IFN,RBV|Participants will receive Ritonavir- boosted Danoprevir 100mg/100mg BID in combination with subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and RBV administered orally 500mg (5 tablets)( body weight ＜75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg for 12 weeks.
2932983|NCT03020069|Experimental|Glucose Meter|Continuing Glucose Monitoring Device
2932984|NCT03020069|Active Comparator|No Glucose Meter|Average Blood glucose measure
2932985|NCT03020056|Placebo Comparator|waiting surgery|Cataract surgery will be performed at 1 year after enrollment.These participants will be provided with Phacolin eye drops(Zhongshan ophthalmic center, China).
2932986|NCT03020056|Experimental|expedited surgery|Cataract surgery will be performed within 4 weeks.
2932987|NCT03020030|Other|Initial Low Risk (Initial LR)|"Meets all the following criteria: B-ALL, Age 1-<15 years, WBC < 50,000/microliter, CNS-1 or CNS-2, no BCR-ABL1, no iAMP21, and no VHR characteristics.~Treated with Induction IA (vincristine, dexamethasone, pegaspargase), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
2932988|NCT03020030|Other|Initial High Risk (Initial HR)|"Meets at least one of the following criteria: Age >=15 years, WBC >=50,000/microliter, CNS-3, T-ALL, iAMP21, BCR-ABL1~And: No VHR characteristics~Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
2932989|NCT03020030|Other|Initial Very High Risk (Initial VHR)|"Any of the following are present: IKZF1 deletion, MLL (KMT2A) rearrangement, low hypodiploidy, t(17;19)~Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
2932990|NCT03020030|Other|Final Low Risk (Final LR)|"Initial Low Risk and Low MRD (<0.0001) at first time point (Day 32)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, methotrexate, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
2932991|NCT03020030|Other|Final Intermediate Risk (Final IR)|"Initial High Risk and Low MRD (<0.0001) at first time point (Day 32)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
2932992|NCT03020030|Other|Final High Risk (Final HR)|"Initial Low Risk or Initial High Risk with High MRD (>=0.0001) at first time point (Day 32) but low MRD (<0.001) at second time point (week 10-12)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
2932993|NCT03020030|Other|Final Very High Risk (Final VHR)|"Initial VHR or any patient with high MRD (>=0.001) at second time point (week 10-12)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~Consolidation IB/B-ALL (High-dose methotrexate + leucovorin, cyclophosphamide, etoposide, IT chemotherapy); Consolidation IB/T-ALL (nelararbine, cyclophosphamide, etoposide); Consolidation IC (High-dose cytarabine, etoposide, dexamethasone, pegaspargase [by direct assignment], IT chemotherapy); CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~Dasatinib administered daily during all phases to pts with ABL1-class fusions. All treatment completed 24 months from date of complete remission."
2932994|NCT03020030|Active Comparator|Fixed Dose Pegaspargase|Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks at standard fixed-dose (2500 IU/m2/dose).
2932995|NCT03020030|Experimental|Reduced Dose (PK-Adjusted) Pegaspargase|Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks beginning at a reduced dose (2000 IU/m2/dose); subsequent doses adjusted based on nadir serum asparaginase activity (NSAA) levels, with goal of maintaining NSAA between 0.4 and 1.0 IU/mL
2932996|NCT03020030|Other|Direct Assignment|All VHR patients, and any Final LR, IR, HR patients who decline randomization: Assigned to receive standard dosing of pegaspargase (15 doses of pegaspargase every 2-weeks at standard fixed-dose; 2500 IU/m2/dose).
2932997|NCT03020017|Experimental|Treatment (NU-0129)|Patients receive NU-0129 IV over 20-50 minutes and undergo standard of care tumor resection within 8-48 hours.
2932998|NCT03020004|Experimental|Danoprevir,Ritonavir, Peg-IFN,RBV|Participants will receive a combination of Ritonavir-boosted Danoprevir 100mg/100mg BID, subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and oral Ribavirin (RBV)1000/1200 mg/day (bodyweight<75/≥75 kg) for 12 weeks.
2932999|NCT03019991|Experimental|PK Group (Danoprevir,Ritonavir)|Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14;100mg BID on day 5 -day 13; Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13;
2933000|NCT03019991|Placebo Comparator|Placebo Group|ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13; Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13 for 14 days;
2933001|NCT03019965|Active Comparator|Intermittent Piperacillin/tazobactam|Piperacillin/tazobactam 300mg/kg/day, divided into 4 doses/day, diluted in 5% glucose solution, at a concentration of 50mg/ml, to be administered in 30 minutes infusion every 6 hours.
2933002|NCT03019965|Experimental|Continuous Piperacillin/tazobactam|Piperacillin/tazobactam initial doses 75mg/kg in 30 minutes infusion, immediately thereafter continue 300mg/kg/day, diluted in 5% glucose solution, at a concentration of 50mg/ml, to be administered in 24 hours infusion every 24 hours, as determined by antibiotic stability at room temperature.
2933003|NCT03019965|Active Comparator|Intermittent Imipenem|Imipenem 80mg/kg/day, divided into 4 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 60 minutes infusion every 6 hours.
2933004|NCT03019965|Experimental|Extended Imipenem|Imipenem initial doses 20mg/kg in 60 minutes infusion, immediately thereafter continue 80mg/kg/day, divided into 4 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 6 hours infusion every 6 hours, as determined by antibiotic stability at room temperature.
2933005|NCT03019965|Active Comparator|Intermittent Meropenem|Meropenem 100mg/kg/day, divided into 3 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 60 minutes every 8 hours.
2933006|NCT03019965|Experimental|Extended Meropenem|Meropenem initial doses 35mg/kg in 60 minutes infusion, immediately thereafter continue 100mg/kg/day, divided into 3 doses/day, diluted in 0.9% saline solution at a concentration of 7mg/ml, to be administered in 8 hours infusion every 8 hours, as determined by antibiotic stability at room temperature.
2933007|NCT03019939|Experimental|Isavuconazole|Dosing is identical for oral and intravenous administration of Isavuconazonium Sulfate. Isavuconazonium sulfate administered at a dose of 372 mg (i.e., 2 capsules, or 200 mg of Isavuconazole) orally every 8 hours for 6 doses (48 hours), and 372 mg (i.e., 2 capsules, or 200 mg of Isavuconazole) orally once daily thereafter. Maintenance doses should be started 12 to 24 hours after the last loading dose.
2933008|NCT03019887|Experimental|reduction group|dose reduction of antipsychotics at a rate not exceeding 50mg chlorpromazine equivalent/week
2933009|NCT03019861|Active Comparator|Ayurvedic nutritional counseling|Patients will receive three Ayurvedic nutritional counselings (according to tradition) after 1, 3 and 8 weeks after Baseline.
2933010|NCT03019861|Active Comparator|Conventional nutritional counseling|Patients will receive three conventional nutritional counselings (according to German Nutrition Society - DGE) after 1, 3 and 8 weeks after Baseline.
2933011|NCT03019848|Experimental|Curcumin|Each patient of this group will receive 1.67 grams of curcumin ( 7 capsules of 231 mg) divided in 3 doses daily for 6 months.
2933012|NCT03019848|Placebo Comparator|Placebo|The control group will receive 7-capsules/ day identical in color and size, containing placebo for 6 months.
2933013|NCT03019835|Active Comparator|GROUP 1|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 1 response of 4 in TOF mode (Train Of Four)
2933014|NCT03019835|Active Comparator|GROUP 2|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 2 response of 4 in TOF mode (Train Of Four)
2933015|NCT03019835|Active Comparator|GROUP 3|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 3 response of 4 in TOF mode (Train Of Four)
2933016|NCT03019835|Active Comparator|GROUP 4|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 4 response of 4 in TOF mode (Train Of Four)
2933017|NCT03019835|Active Comparator|CONTROL|A control group : not receiving an antagonist (spontaneous recovery)
2933018|NCT03019822|Other|Placebo, LSD, d-Amphetamine, MDMA|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, lysergic acid diethylamide (LSD), d-Amphetamine or methylenedioxymethamphetamine (MDMA) and followed by all other drugs each separated by a wash-out phase
2933019|NCT03019822|Other|LSD, d-Amphetamine, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
2933020|NCT03019822|Other|d-Amphetamine, MDMA, LSD, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
2933021|NCT03019822|Other|MDMA, LSD, Placebo, d-Amphetamine,,|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
2933022|NCT03019809|Experimental|Plerixafor/G-CSF for HSCT conditioning|Myeloablative conditioning regimen with Plerixafor and G-CSF as addition agents before stem cell transplantation in WAS patients.
2933023|NCT03019796|Placebo Comparator|NO EXERCISE TRAINING|"The participants of this arm will remain physically inactive (i.e., less than 1 day a week of exercise) during the 4 months of intervention.~The investigators will withhold their medication during 48 h to achieve 2 conditions:~no exercise, no medication.~no exercise, yes medication."
2933024|NCT03019796|Experimental|EXERCISE TRAINING|"The participants of this arm will exercise during 4 months (i.e., 3 days a week during 45-60 min) at workloads individualized by percent heart rate of either continuous or intervallic aerobic exercise, with increases in workload as exercise adaptations manifest during training.~The investigators will withhold their habitual medication during 48 h to achieve the following 2 conditions:~c) yes exercise, no medication d) yes exercise, yes medication."
2933025|NCT03019783|Placebo Comparator|Remains on baseline HIV regimen|Subjects are enrolled and either kept on their baseline regimen. This is being designated the placebo comparator.
2933026|NCT03019783|Active Comparator|Atazanavir switch|These subjects are switched to an atazanavir-based regimen.
2933027|NCT03019770|Experimental|PrEP Decision Aid|All participants in the study will go through the Decision Aid with a provider.
2933028|NCT03019757||Alzheimer's disease|Individuals with a clinical diagnosis of Alzheimer's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
2933029|NCT03019757||Lewy Body dementia|Individuals with a clinical diagnosis of Lewy Body Dementia will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
2933030|NCT03019757||Parkinson's disease|Individuals with a clinical diagnosis of Parkinson's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
2933031|NCT03019744|Experimental|MeCFES|25 daily sessions (45 minutes each) of MeCFES-assisted task-oriented upper limb rehabilitation
2933032|NCT03019744|Active Comparator|Control|25 daily sessions (45 minutes each) of usual care task-oriented upper limb rehabilitation
2933033|NCT03019731|Experimental|Children with Tourette syndrome|Eligible children, between ages 7-13 years, with the diagnosis of Tourette syndrome or chronic motor/vocal tic disorder will be recruited from the Tourette Syndrome Clinics at Johns Hopkins (Dr. Singer). The Johns Hopkins Center has been acclaimed a Center of Excellence by the Tourette Association of America. This center currently follows more than 1,000 tic patients and averages 4-6 new referrals and 4 follow up patients weekly. Children will be randomly assigned to either the Therapist-directed Behavioral Therapy group or the Home-based DVD therapy group.
2933034|NCT03019718|Experimental|GSA-Online plus|Patients receive access to the internet-based aftercare program after inpatient treatment.
2933035|NCT03019705||Participants|Individuals with pathological health anxiety
2933036|NCT03019692||enrolled babies with neonatal intracranial bleed|all babies who suffered from intra cranial or intraventricular bleed during neonatal period
2933037|NCT03019679||Study group|Patients with polycystic ovary syndrome
2933038|NCT03019679||Control group|Patients without polycyctic ovary syndrome
2933039|NCT03019666|Experimental|Multiple Myeloma|After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and elotuzumab for Multiple Myeloma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
2933040|NCT03019666|Experimental|Non-Hodgkin Lymphoma|After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and rituximab for Non-Hodgkin Lymphoma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
2933041|NCT03019653|Active Comparator|ANX-042 first, then Placebo|In the first intervention period the subjects will receive an infusion of ANX-042. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of placebo
2933042|NCT03019653|Active Comparator|Placebo first, then ANX-042|In the first intervention period the subjects will receive placebo. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of ANX-042.
2933043|NCT03019640|Experimental|CB-Derived NK Cells with HDC/Auto SCT|High dose chemotherapy (HDC) [Rituximab +BEAM + Lenalidomide] as preparative regimen + umbilical cord blood derived NK cells + autologous stem cell transplant (autosct) for treatment of lymphoma that requires a stem cell transplant (SCT)
2933044|NCT03019627|Experimental|rhNGF 20μg/mL|Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
2933045|NCT03019627|Placebo Comparator|Vehicle|vehicle eye drops six times daily
2933046|NCT03019614|Experimental|Group 1|"Volunteers in group 1 received the following interventions:~Chronocort® 30 mg given at night (~ 23:00h) as a combination of one 10mg capsule and one 20mg capsule (n=18).~Chronocort® 30mg given as one 20mg capsule at night (~ 23:00h) and as one 10mg capsule in the morning (~ 7:00h) following the initial night-time dose (n=18).~Hydrocortisone 30mg given at night (~ 23:00h) given as three 10mg tablets (n=18).~Each administration of IMP was separated by a washout period of at least 7 days."
2933047|NCT03019614|Experimental|Group 2|"Volunteers in group 2 received the following interventions:~Chronocort® 5mg given at night (~ 23:00h) as one 5mg capsule (n=12).~Chronocort® 10mg given at night (~ 23:00h) as one 10mg capsule (n=12).~Chronocort® 20mg given at night (~ 23:00h) as one 20mg capsule (n=12).~Each administration of IMP was separated by a washout period of at least 7 days."
2933048|NCT03019601|Experimental|Group education|Non pregnant HIV+ mothers were exposed to a structured educational intervention on family planning facilitated by Peer Champions.
2933049|NCT03019588|Experimental|Pembrolizumab 200 mg|Participants receive pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
2933050|NCT03019588|Active Comparator|Paclitaxel 80 mg/m^2|Participants receive paclitaxel 80 mg/m^2 IV infusion on Days 1, 8 and 15 of each 4-week cycle for up to approximately 2 years.
2933051|NCT03019575|Experimental|Corifollitropin alfa + hCG|
2933052|NCT03019562|Experimental|Oxycodone|4mg of oxycodone iv bolus
2933053|NCT03019562|Active Comparator|Fentanyl|50ug of fentanyl iv bolus
2933055|NCT03019549|Experimental|Lanabecestat + Rosuvastatin|Period 2: Lanabecestat administered orally for multiple days alone and one day in combination with rosuvastatin
2933056|NCT03019536|Experimental|LY3303560 IV|Multiple doses of LY3303560 administered intravenously (IV) for up to 48 weeks, followed by a 16 week follow-up period
2933057|NCT03019536|Experimental|Placebo IV|Multiple doses of placebo administered IV for up to 48 weeks, followed by a 16 week follow-up period
2933058|NCT03019523|Placebo Comparator|Sugar Pill|Maltodextrin (~2 grams to match weight of active treatment) placebo pre-testing (1 dose w/3 oz of water) 30 minutes following ingestion exercise and Makoto testing were completed.
2933059|NCT03019523|Active Comparator|Caffeine Blend|75 mg caffeine, 75 mg theanine, and 2g tyrosine pre-testing (1 dose w/3 oz of water) 30 minutes following ingestion exercise and Makoto testing were completed.
2933060|NCT03019510|Placebo Comparator|no exercise|Subjects will be studied from 6 pm to 7 am following 48 hr of no exercise
2933061|NCT03019510|Active Comparator|morning exercise|Subjects will be studied from 6 pm to 7 am. Subjects will have exercised at 7 am on that day.
2933062|NCT03019510|Active Comparator|evening exercise|Subjects will be studied from 6 pm to 7 am. Subjects will exercise at 8 pm following dinner on the study day.
2933063|NCT03019497|Experimental|CBT-E|CBT-E refers to Cognitive Behavioral Therapy with specific modules. In the CBT-E condition and following the identification of the needs identified during the evaluation, additional strategies will be added to the CBT strategies for PTSD to address one or more of the seven related problem types that emerged as a result of the traumatic event: 1) major depression, 2) sleep disorders, 3) pain, 4) stressors, 5) inadequate social support, 6) substance use disorder, and 7) anxiety disorder.
2933064|NCT03019497|Active Comparator|CBT-C|CBT-C refers to Cognitive Behavioral Therapy without specific modules. CBT-C participants will be offered only cognitive-behavioral intervention strategies to alleviate the symptoms of each of the PTSD diagnostic criteria.
2933065|NCT03019484|Experimental|Intervention|The intervention consisted on breastfeeding support at three stages: a) week 28-39 pregnancy: women were provided with written information and watch a breastfeeding self-efficacy enhancing video; b) during hospitalization after birth: based on their responses to the Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF) questionnaire and the observation of a whole breastfeed, nurses provided specific advice using active listening. All the relevant information was registered; c) within one week after birth: a nurse or midwife made a phone call to follow-up mothers breastfeeding behaviour, addressing issues that during the hospitalization needed reinforcement, solving any question or matter that they had and providing positive reinforcement.
2933066|NCT03019484|No Intervention|Control: Standard Care|"This group received standard antenatal and postnatal care by midwives and nurses caring for them during their regular antenatal visits and after delivery.~The professionals delivering the intervention were the same than those providing the standard care. That was the reason to first collect the data from the control group and after that organising the training of health professionals to deliver de intervention."
2933067|NCT03019471||Lung cancer|Isolate Tumor DNA from the patients blood.
2933068|NCT03019471||Breast cancer|Isolate Tumor DNA from the patients blood.
2933069|NCT03019471||Colorectal cancer|Isolate Tumor DNA from the patients blood.
2933070|NCT03019471||Glioma|Isolate Tumor DNA from the patients blood.
2933071|NCT03019458|Experimental|MINGO|MINGO is a supplement consisting of local ingredients such as moringa, rice and mung beans, which can be added to any type of edible paste, food, and liquid. The experimental group is required to take 6 sachets per day for 12 weeks in addition to their regular diet. They are required to keep a daily food diary
2933072|NCT03019458|No Intervention|Control|The control group is required to eat their normal diet. They are also required to keep a daily food diary.
2933073|NCT03019419|Experimental|Perampanel 4mg|Once daily 4mg of perampanel with dose-escalation tolerable from 2mg to 4mg for 48 weeks
2933074|NCT03019419|Experimental|Perampanel 8mg|Once daily 8mg of perampanel with dose-escalation tolerable from 2mg to 8mg for 48 weeks
2933075|NCT03019419|Placebo Comparator|Placebo|Once daily placebo for control for 48 weeks
2933076|NCT03019406|Experimental|GZ402666|administered intravenously every 2 weeks as an ascending dose cohort
2933077|NCT03019406|Active Comparator|alglucosidase alfa|administered intravenously at current stable dose (i.e. administered regularly for a minimum of 6 months immediately prior to study entry)
2933078|NCT03019393|Other|Beef|Beef topside fully cooked, 200g
2933079|NCT03019380|Experimental|Impacted cerumen|removing cerumen from external ears of patients with impacted cerumen, obscuring the canal and the tympanic membrane.
2933080|NCT03019367|Active Comparator|Umbilical cord milking UCM|Milking the umbilical cord 4 times towards the infant at a speed of 20cm/2seconds.
2933081|NCT03019367|Active Comparator|Delayed cord clamping DCC|Delayed clamping of the umbilical cord for at least 60 seconds.
2933082|NCT03019354|Experimental|high-flow nasal oxygen|high-flow nasal oxygen was used during intravenous general anesthesia
2933083|NCT03019354|Active Comparator|Oxygen mask|oxygen mask was used during intravenous general anesthesia
2933084|NCT03019341||Patients with enhanced CT scan|Patients undergo CT examination after the administration of non-ionic contrast media for clinical need.
2933085|NCT03019302|Experimental|Arrow PICC with Chloragard Technology|Arrow Peripherally- Inserted Central Catheters with Chloragard Technology. The application of Chlorag+ard® Technology uses a proprietary process whereby chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body.
2933086|NCT03019289|Experimental|pridopidine|Pridopidine (TV-7820) capsules
2933087|NCT03019276|Experimental|TQ-B3101|TQ-B3101 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2933088|NCT03019263|Experimental|Nutraceutical|Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid
2933089|NCT03019263|Active Comparator|Control|Nutritional counseling
2933090|NCT03019250|Experimental|Colostrum|Intervention patients will be received enteral formula and colostrum powder 20 g/kg/day given via nasogastric tube as boluses q 4hrs.
2933091|NCT03019250|Placebo Comparator|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
2933092|NCT03019237|Experimental|intranasal anti-IgE|Anti-IgE (Xolair) will be freshly diluted in sterile 0.9% sodium chloride solution (438 μg/ml) and will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
2933093|NCT03019237|Active Comparator|intranasal allergen|GMP produced rBet v 1 will be freshly diluted in sterile 0.9% sodium chloride solution (50 μg/ml) and will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
2933094|NCT03019237|Placebo Comparator|intranasal saline|Sterile 0.9% sodium chloride solution will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
2933095|NCT03019224|Placebo Comparator|Group 1|The use of desensitizing dentifrice [Sucralose (S) Control dentifrice)] in plastic tray.
2933096|NCT03019224|Experimental|Group 2|The use of desensitizing dentifrice [Sodium fluoride (FS) with 1450ppm of fluorine (Close up triple, Unilever)] in plastic tray.
2933097|NCT03019224|Experimental|Group 3|The use of desensitizing dentifrice [Arginine, calcium carbonate (ACC) and sodium monofluorophosphate with 1450 ppm fluorine (Colgate sensitive pro-relief, Colgate-Palmolive)] in plastic tray.
2933098|NCT03019224|Experimental|Group 4|The use of desensitizing dentifrice [Sodium fluoride based dentifrice with 1450 ppm of fluorine associated with 5% potassium nitrate] in plastic tray.
2933099|NCT03019211|Experimental|Hydrotherapy|Exercise performed in an aquatic environment. The participants will perform static/dynamic exercises (balance and resistance training) in an aquatic environment. Training volume and intensity we will increase systematically over 12 weeks.
2933100|NCT03019211|Active Comparator|Control|The participants will perform exercises (balance and resistance training) like hydrotherapy group but out of the aquatic environment, during a 12 weeks training period (3sessions/week). Training volume and intensity we will increase systematically over 12 weeks.
2933101|NCT03019198|Experimental|TXA|Performed an intravenous bolus administration of 15 mg/kg of TXA to the volunteers after the end of the anesthesia and 15 minutes prior to skin incision.
2933102|NCT03019198|Placebo Comparator|Control|This group underwent the same procedures of the TXA group, excepting the preoperative administration of the medication.
2933103|NCT03019185|Experimental|Phase 2 Cohort|Patients in the Phase 2 cohort will receive bardoxolone methyl throughout the study. Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR >300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
2933104|NCT03019185|Active Comparator|Phase 3 Bardoxolone Cohort|Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR >300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
2933105|NCT03019185|Placebo Comparator|Phase 3 Placebo Cohort|Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.
2933106|NCT03019172|Experimental|Lactobacillus reuteri|Women in experimental branch will receive two sachets. Sachet one contains a total of 5*10^8 CFU of Lactobacillus reuteri DSM 16666 & Lactobacillus reuteri DSM 17938, mixed with maltodextrin for flowability during production. Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica.
2933107|NCT03019172|Placebo Comparator|Sachet with cranberry + placebo|Women in control branch will receive two sachets. Sachet one contains only Maltodextrin and sachet two contains instant cranberry drinkcomposed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica Both sachets should be emptied in a glass and mixed with 200 ml of cold water
2933108|NCT03019159||Tele-consulting|One visit out of two takes place with teleconsulting and the other is a face-to-face consultation
2933109|NCT03019159||No tele-consulting|
2933110|NCT03019146|Experimental|High Intensity Interval Training (HIIT)|3 x 15 minute sessions per week for 6 weeks. Sessions include 5x intervals of cycling at 110% of Wmax derived from CPET, interspersed with 90s rest periods of unloaded cycling.
2933111|NCT03019146|Experimental|Isometric Handgrip (HOLD)|3x 15 minute sessions per week for 6 weeks Sessions include 4x intervals of 2minutes isometric handgrip contraction of dominant arm at 30% Maximal voluntary contraction, interspersed with 2minute rest periods
2933112|NCT03019146|Experimental|Remote Ischaemic Preconditioning (HUG)|3x 15 minute sessions per week for 6 weeks. Sessions include 3x intervals of 3 minutes of arm ischaemia (blood pressure cuff inflated to 200mmHg on dominant arm) interspersed with 3 minute rest periods.
2933113|NCT03019146|No Intervention|Control|No intervention
2933114|NCT03019133|No Intervention|Usual Care|Usual care will be provided.
2933115|NCT03019133|Active Comparator|Sound reduction|Use of noise reduction headphones. Pro For Sho safety ear muffs with a noise reduction rate of 34dB will be used.
2933116|NCT03019133|Active Comparator|Sound masking|Use of headphones and relaxing music. Sennheiser HD 280 pro headphones will be used for sound masking.
2933117|NCT03019120|Experimental|Active Comparator: Intervention group|Vitamin D supplementation for subjects with below normal levels of this vitamin.
2933118|NCT03019094|Experimental|Treatment|Implantation of the RENOVA tibial nerve stimulation system
2933146|NCT03018899|Experimental|paravertebral block|patients received ultrasound guided two-segment paravertebral block for percutaneous nephrolithotomy
2933147|NCT03018899|Active Comparator|Epidural|patients received thoracic epidural anesthesia for percutaneous nephrolithotomy
2933119|NCT03019081|Experimental|Anorexia nervosa-study drug|"Drug: Isoproterenol Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant. The isoproterenol dose will range from 0.1 micrograms to 4.0 micrograms and exposure during each visit will not exceed 25.0 micrograms. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.~Other Names: Isuprel"
2933120|NCT03019081|Placebo Comparator|Anorexia nervosa-placebo|"Drug: Normal Saline Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.~Other Names:~Saline"
2933121|NCT03019055|Experimental|CAR-20/19-T cells|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1
2933122|NCT03019042|Experimental|Hou Gu Mi Xi|Patients in this arm receive Hou Gu Mi Xi, with oral dose of 10 g/day during entire follow up period (2 years).
2933123|NCT03019042|Placebo Comparator|placebo|Patients in this arm receive placebo, with oral dose of 10 g/day during entire follow up period (2 years).
2933124|NCT03019029|Experimental|Peripheral nerve amyloidosis|Patients with pathologically-confirmed peripheral nerve amyloidosis will undergo 18-F Florbetapir PET/MR scan on a GE SIGNA PET/MR scanner.
2933125|NCT03019016||Robotic RC (IA)|Benign or malignant disease under going a right colectomy.
2933126|NCT03019016||Robotic RC (EA)|Patients with benign or malignant disease under going a right colectomy.
2933127|NCT03019016||Laparoscopic RC (IA)|Patients with benign or malignant disease under going a right colectomy.
2933128|NCT03019016||Laparoscopic RC (EA)|Patients with benign or malignant disease under going a right colectomy.
2933129|NCT03019003|Experimental|Azacitidine, Durvalumab, and Tremelimumab|Azacitidine will be administered alone in Cycle 1 and the combination of azacitidine, durvalumab, and tremelimumab therapy will be given in Cycles 2-5. Azacitidine and durvalumab will be given in Cycles 6-12.
2933130|NCT03018990|Active Comparator|Alcoholic liver fibrosis|
2933131|NCT03018990|Active Comparator|Non-alcoholic steatohepatitis|
2933132|NCT03018990|Active Comparator|Healthy control|
2933133|NCT03018977|Active Comparator|Sedative weaning protocol|We create the new sedative weaning protocol and then use the sedative weaning protocol.
2933134|NCT03018977|Placebo Comparator|Usual Care|no use sedative weaning protocol. Sedative or/and analgesic medications are adjusted base on physician
2933135|NCT03018964|Experimental|Solo-SILC|Solo surgery using a laparoscopic camera holder instead of a camera operator in SILC
2933136|NCT03018964|Active Comparator|Ca-SILC|No solo surgery, operation with a camera operator in SILC
2933137|NCT03018951||Tool Development Stage|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
2933138|NCT03018951||Pilot Test 1|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
2933139|NCT03018951||Pilot Test 2|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
2933140|NCT03018938|Experimental|Insulin Analog Mid Mixture|Insulin analog mid mixture given subcutaneously (SC).
2933141|NCT03018938|Experimental|Basal Insulin Analog|Basal insulin analog given SC.
2933142|NCT03018925||Ulcerative Colitis|"The proposed study will include 15 UC anti-TNF naïve patients . We will consider remission when patients have an endoscopic Mayo score ≤1, and activity index score, Mayo= 0 points.~Stool samples will be collected before starting Anti-TNF treatment (M0), and then every 3 months (M1, M2, M3 and M4) to complete the study.~GOLIMUMAB induction with 200mg at week 0, and 100mg at week 2. Under 70kg, the follow up treatment will be 50mg/month, and 100mg/month in patients over 70kg, as clinical practice."
2933143|NCT03018912|Experimental|Active Sleep VS|"Patients check-in for their primary care physician visit and are provided a Sleep VS survey packet. Medical assistants will review the Sleep VS, and patients that screen positive on their Sleep VS will be asked to complete an extended set of sleep questions. A triaging algorithm will be available based on answers to the extended sleep questions to assist the primary care physician with assessment and triaging care. Patients that screen negative will not be asked the extended sleep questions nor will they be brought to the attention of the primary care physician and proceed with usual care."
2933144|NCT03018912|Experimental|Non-Active Sleep VS|"Patients check-in for their primary care physician visit and are provided a Sleep VS survey packet. The packet will be collected by the receptionists and will be unavailable to medical assistants or physicians. After completing the survey packet patients will proceed with usual care. Although the sleep vital sign will not be available to the medical providers the extended sleep questionnaire and triaging algorithm can still be utilized to assist in care, if in the course of caring of the patient a potential sleep disorder is recognized."
2933145|NCT03018912|No Intervention|Usual Care|"Patients check-in for their primary care physician visit and proceed with usual care. Although the sleep vital sign will not be collected, the medical providers can still use the extended sleep questionnaire and triaging algorithm, if in the course of caring of the patient a potential sleep disorder is recognized."
2933148|NCT03018886|Other|healthy control subjects|126 healthy controls underwent the GHRH plus arginine stimulations test
2933149|NCT03018886|Experimental|patients with suspected GH deficiency|34 patients with pituitary disease and suspicion of GH deficiency underwent the GHRH plus arginine test
2933150|NCT03018873|Experimental|long-term RIPC group|"routine treatment + interventions interventions: once preoperative RIPC and once RIPC/day after PCI for one year. Once preoperative remote ischemic preconditioning （RIPC） : Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg before primary percutaneous coronary intervention(PCI).~Once RIPC/day after PCI for one year:Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg."
2933151|NCT03018873|Active Comparator|preoperative RIPC group|routine treatment + Once preoperative remote ischemic preconditioning （RIPC） : Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg before primary percutaneous coronary intervention.
2933152|NCT03018873|No Intervention|control group|routine treatment, no RIPC
2933153|NCT03018860|Experimental|"Moderate management"|Women are encouraged by physicians to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration.
2933154|NCT03018860|Active Comparator|"Intensive management"|Usual obstetrical care in France
2933155|NCT03018834|Experimental|A: ANAKINRA|ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
2933156|NCT03018834|Placebo Comparator|B: Placebo|PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
2933157|NCT03018821|Active Comparator|Standard CMF|"Standard Chinese medical formulas (CMF) for the corresponding TCM syndromes, plus an anti-virus treatment of western drugs (such as Entecavir or Tenofovir).~Yinchengao Decoction plus Ganlu Detoxification Pill for the Traditional Chinese Medicine (TCM) syndrome: Damp-heat blocking middle jiao~Chaihu Shugan San for the TCM syndrome: Liver depression and qi stagnation~Xiaoyao powder for the TCM syndrome: Stagnation of liver qi and spleen deficiency.~Yiguan Decoction for the TCM syndrome: Yin deficiency of liver and kidney~Fuzilizhong Decoction plus Jinkui Shenqi Bolus for the TCM syndrome: Yang deficiency of spleen and kidney~Ge Xia Zhu Yu Decoction for the TCM syndrome: Internal blood stasis"
2933158|NCT03018821|Experimental|Advanced CMF|"Advanced TCM formulas for corresponding TCM syndromes provided by famous TCM doctors who were national wide known in China, plus an anti-virus western drugs (such as Entecavir or Tenofovir).~Taohong Huazhuo Decoction for the Traditional Chinese Medicine (TCM) syndrome: Damp-heat blocking middle jiao~Soothe the liver and regulate qi Decoction for the TCM syndrome: Liver depression and qi stagnation~Supplemented Ganbi Decoction for the TCM syndrome: Stagnation of liver qi and spleen deficiency.~Supplemented Zimu Dan for the TCM syndrome: Yin deficiency of liver and kidney~Guifu Erxian Decoction for the TCM syndrome: Yang deficiency of spleen and kidney~Supplemented Ganji Decoction for the TCM syndrome: Internal blood stasis"
2933159|NCT03018821|Experimental|Pure Entecavir or Tenofovir|Use an anti-virus western drug alone (such as Entecavir or Tenofovir).
2933160|NCT03018808||Subjects met inclusion with at least one exclusion criteria|Subjects who meet all the inclusion criteria, but have at least one exclusion criteria or not agree to participate in the whole study will be invited to sign a special ICF in order to complete a minimal questionnaire.
2933161|NCT03018808||Subjects who satisfy all inclusion/exclusion criteria|Subjects who satisfy all inclusion/exclusion criteria and agree to sign the ICF, an interview will be conducted for information regarding medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
2933162|NCT03018808||Spirometry confirmed COPD Subjects|The spirometry confirmed COPD patients will be requested to complete the COPD Assessment Test (CAT), self-administered questionnaire related to quality of life on COPD patients.
2933163|NCT03018795|Active Comparator|Ozone Group|Decontamination of implant surfaces with saline irrigation and additional ozone therapy in combination with regenerative surgery
2933164|NCT03018795|Active Comparator|Control Group|Decontamination of implant surfaces with saline irrigation alone in combination with regenerative surgery
2933165|NCT03018782|Active Comparator|Brief Pain Inventory Short Form|Completes the Brief Pain Inventory Short Form
2933166|NCT03018782|No Intervention|No Brief Pain Inventory Short Form|Does not complete the Brief Pain Inventory Short Form
2933167|NCT03018769||chronic SCAD|
2933168|NCT03018756|Active Comparator|Fentanyl Citrate|Single dose, nebulized 100 mcg fentanyl citrate. This is a double-blind, placebo-controlled, two-period crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate to that of a placebo (0.9% saline). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and placebo at the second treatment visit, patients in the other arm will receive placebo first and fentanyl second.
2933169|NCT03018756|Placebo Comparator|Placebo|Single dose, nebulized 0.9% saline solution. This is a double-blind, placebo-controlled, two-period crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate to that of a placebo (0.9% saline). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and placebo at the second treatment visit, patients in the other arm will receive placebo first and fentanyl second.
2933170|NCT03018743||dapoxetine treatment group|Consecutive patients who seek medical treatment for PE will be enrolled in the study.
2933171|NCT03018730|Experimental|PRX-102|PRX-102 infusion every 2 weeks
2933172|NCT03018717|Other|Tele-monitoring Constant|To analyze the efficacy and cost-efficacy of incorporating tele-monitoring of bio-parameters into the shared comprehensive clinical care plan. Patients will receive in their home a kit consisting of a briefcase containing all equipment (scale, pulse-oximeter ... etc) and a logo access to devices (Tablet) through mobile communications m2m between patient and platform Management for Chronic Patients.
2933173|NCT03018717|Other|Standard clinical care|Standard clinical care plan shared between plan of attention to the patient with Pluri-pathological process and the care plan for patients with chronic diseases, based on a comprehensive clinical assistance shared between Primary Care and Hospital Care
2933174|NCT03018704|Placebo Comparator|Placebo|a placebo control arm
2933175|NCT03018704|Experimental|Topiramate|Topiramate an FDA approved anticonvulsant has been shown effective in the treatment of alcohol use disorder but there is no data supporting use in minority patients.
2933176|NCT03018691|Experimental|0.3% OPA-15406 Ointments|Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.
2933177|NCT03018691|Experimental|1% OPA-15406 Ointments|Subjects were treated with assigned 1% OPA-15406 ointment twice daily.
2933178|NCT03018691|Placebo Comparator|Placebo Ointments|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
2933179|NCT03018678||Patients with HOFH|No intervention
2933180|NCT03018665|Experimental|Exenatide and Metformin|Exenatide in Combination With Metformin
2933181|NCT03018665|Active Comparator|BIAsp30 and Metformin|BIAsp30 in Combination With Metformin
2933182|NCT03018652|Experimental|Intervention group|IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks) n=8
2933183|NCT03018652|Placebo Comparator|Control group|Normal saline (0.9% NaCl) 5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks) n=8
2933184|NCT03018639||Dialectical Behavior Therapy|The program's purpose is to help patients achieve the following therapeutic goals: (1) reduction of suicidal behaviors, (2) reduction of therapy-interfering behaviors, and (3) other risky or destabilizing behaviors. Standard DBT aims to achieve these goals by (1) conveying behavioral capabilities (skills), (2) motivation for applying these skills, (3) generalization of learned skills to the patient's natural environment, (4) structuring the treatment environment to reinforce functional behavior, and (5) conveying therapeutic resources and motivation to effectively treat patients with BPD.
2933185|NCT03018626|Active Comparator|DA-EPOCH-R|DA-EPOCH-R regimen: rituximab (375 mg/m2) given intravenously (IV) on day 0, etoposide(50 mg/m2), doxorubicin(10 mg/m2) and vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours), cyclophosphamide(750 mg/m2)/dayg IV on days 5, prednisone (60 mg/m2) given orally bid on days 1 through to 5.All patients received granulocyte colony-stimulating factor (G-CSF) beginning on day 6 and continued until the ANC was more than 5 × 109/L above the nadir level. The adjustment paradigm was based on the ANC nadir in the previous cycle as previously described(Wilson, Grossbard et al. 2002)
2933186|NCT03018626|Experimental|Modified R-ACVBP|R-ACVBP regimen: rituximab (375 mg/m2) given intravenously (IV) on day 0, doxorubicin (75 mg/m2) and cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1, vindesine (2 mg/m2) given on days 1 and 5, bleomycin (10 mg) given IV on days 1 and 5, prednisone (60 mg/m2) given orally on days 1 through to 5.
2933187|NCT03018613|Active Comparator|treatment for part 1|Fecal microbiota transplantation and traditional treatments will be used in patients with chronic functional constipation in part 1.
2933188|NCT03018613|Placebo Comparator|Placebo for part 2|The traditional treatments and normal saline will be used in patients with chronic functional constipation in part 2 according to associated guidelines.
2933189|NCT03018600||1|We included 15 inpatients admitted to the Immunology Department, Peking Union Medical College Hospital (PUMCH), Beijing, China from April 1, 2016 to September 1, 2016.Intervention including glucocorticoid: 1-2mg/kg/day prednisone-equivalent (intravenous/oral methylpredisolone or oral prednisone) to the patients every morning at 8am for at least five days.
2933190|NCT03018600||2|We included 10 inpatients admitted to the Immunology Department, Peking Union Medical College Hospital (PUMCH), Beijing, China from April 1, 2016 to September 1, 2016.Intervention including glucocorticoid: using less than 15mg/day prednisone-equivalent glucocorticoid maintenance for at least 3 months and now treating with 1-2mg/kg/day prednisone-equivalent (intravenous/oral methylpredisolone or oral prednisone) for the relapse of primary autoimmune disease for at least five days.
2933191|NCT03018587|Experimental|TruSculpt|Subject(s) will receive 1 radio frequency treatment in desired area.
2933192|NCT03018574||ADHD-patients|The whole blood sample from diagnoses of the children 6-14 years old with ADHD. Diagnoses of the children with ADHD were made in Xijing Hospital and Children's Hospital Affiliated to Soochow University according to criteria described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Children with ADHD had an IQ score above 70.
2933193|NCT03018574||Controls-healthy children|The whole blood sample from age- and gender- matched healthy 6-14 years old children
2933194|NCT03018561|Active Comparator|aged-gender matched healthy controls|Healthy subjects: with no MetS and no-documented coronary heart disease (CHD), both males and females, aged>18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living.
2933195|NCT03018561|Experimental|patients with metabolic syndrome|Patients with MetS and no-documented CHD, both males and females, aged > 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Metabolic syndrome (MetS) will be defined according to recent updated criteria (Alberti et al. 2005):presence of at least three of five criteria, namely abdominal obesity (waist circumference cut-off depending on the recently published ethnic-based variations, triglycerides > 1.70 mmol/l, decreased HDL-cholesterol (< 1.0 mmol/l in men and < 1.3 mmol/l in women), systolic blood pressure > 130 mmHg or diastolic blood pressure > 85 mmHg, and FPG > 5.6 mmol/l.
2933196|NCT03018561|Experimental|patients with coronary heart disease|CHD patients, both males and females, aged > 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Moreover, they must have documented CHD (prior myocardial infarction, prior coronary angiography or angioplasty, or documented myocardial ischemia on myocardial scintigraphy).
2933197|NCT03018561|Experimental|patients with chronic heart failure|"Patients with documented stable chronic heart failure will be recruited if they show the following inclusion criteria:~≥18 years~Left ventricular ejection fraction (LVEF) <40% (measured within 6 months of their enrolment by a multigated acquisition Scan, echo or radiological ventriculography)~NYHA functional class I-III~Optimal therapy at stable doses including a beta-blocker and an ACE inhibitor or ARA for at least 6 weeks prior to investigation (unless documented rationale for variation).~Able to perform an symptom limited exercise test.~Capacity and willingness to sign the informed consent form."
2933198|NCT03018548|Experimental|subject blood drawns|subjects will have blood drawn which will then be exposed to blast via CO2 cartridge
2933199|NCT03018535|Experimental|RITUXIMAB|1 g. IV of Rituximab on days 1 and 15
2933200|NCT03018535|Active Comparator|Corticosteroids and Cyclophosphamide|Month 1, 3 and 5: 1g IV methylprednisolone daily for 3 doses; oral methylprednisolone (0.4mg/kg/day) or prednisone (0.5/mg/kg/day); Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day)
2933201|NCT03018509|Experimental|JTE-451 Dose 1|JTE-451 dose 1 for 28 days
2933202|NCT03018509|Experimental|JTE-451 Dose 2|JTE-451 dose 2 for 28 days
2933203|NCT03018509|Experimental|JTE-451 Dose 3|JTE-451 dose 3 for 28 days
2933204|NCT03018509|Experimental|JTE-451 Dose 4|JTE-451 dose 4 for 28 days
2933205|NCT03018509|Experimental|Placebo|Placebo for 28 days
2933206|NCT03018496|Experimental|Older Men|Healthy male adults aged 18-35 Subjects will receive both HMB and placebo on separate visits in a crossover fashion
2933207|NCT03018496|Experimental|Younger Men|Healthy male adults aged 65-85 Subjects will receive both HMB and placebo on separate visits in a crossover fashion
2933208|NCT03018483|Experimental|Variable PSV|
2933209|NCT03018483|Active Comparator|Conventional PSV|
2933210|NCT03018483|Active Comparator|Automated PSV|
2933211|NCT03018470||Control cohort|Patient with COPD and home NIV admitted for planned respiratory review and without any sign of exacerbation
2933212|NCT03018470||Exacerbation cohort|Patient with COPD and home NIV admitted for acute exacerbation of COPD
2933213|NCT03018470||Outpatient exacerbation|Patient with COPD and home NIV admitted for planned respiratory review and with signs of acute exacerbation of COPD but not requiring inpatient management
2933214|NCT03018457||patients who need a dental implants|
2933215|NCT03018444|Experimental|Atorvastatin|2 weeks treatment with Atorvastatin (1st week 40 mg once daily on day, 2nd week 80 mg (2x40mg) once daily)
2933216|NCT03018444|Placebo Comparator|Placebo|2 weeks treatment with placebo tablets of comparable sizes and color to the Atorvastatin tablets (1st week one tablet once daily, 2nd week two tablets once daily)
2933217|NCT03018431||Physician routine evaluation|systematic evaluation of the probability of tracheobronchitis or pneumonia based upon clinical and biological, associated with standard radiographs, performed by the physician in chrage of the patient.
2933218|NCT03018431||independent evaluation|systematic evaluation of the probability of tracheobronchitis or pneumonia based upon early CT scan, and repeated lung ultrasonography, performed by an independent operator.
2933219|NCT03018418|Experimental|Proton Therapy and Chemotherapy|Standard chemoradiation using 5-FU, Mitomycin, with pencil beam proton radiotherapy
2933220|NCT03018405|Experimental|Hematological tumors|The dose escalation arm for hematological tumors will use a 3 +3 design to determine the maximum tolerated dose.
2933221|NCT03018405|Experimental|Solid Tumors|The dose escalation arm for solid tumors will use a 3 +3 design to determine the maximum tolerated dose.
2933222|NCT03018392|Experimental|Tritanium|TLIF with Tritanium® PL cage and pedicle screw fixation
2933223|NCT03018379||Assessment of body composition|The collection of the samples and the analyses were undertaken according to the guidelines of the International Atomic Energy Agency. In brief, after having emptied the bladder, each participant provided a predose saliva sample using a cotton ball.A 99.8 % deuterium dose of 0.5 g per kg body weight was given orally to the participant. The postdose sample was collected from 3h to 4h after the administration of the dose. The saliva samples were stored at 20°C until analysis by Fourier transform infrared spectroscopy (FTIR).
2933224|NCT03018379||Assessment of energy expenditure|"Each participant provided a predose urine sample. A dose of doubly labelled water 2.625 ml per kg body weight was given orally to the participant.~The post dose sample was collected at 3h to 4h , and on days 3, 7 and 14 after dosing. An aliquot of those samples were stored at 20°C in tightly sealed containers until analysis by isotope-ratio mass spectrometry (IRMS)."
2933225|NCT03018379||Assessment of physical activity|The participants were instructed to wear the accelerometer triaxial (GT3X+) attached to an elasticized belt around the waist, once they woke up until bed time at night for 7 consecutive days and to remove the accelerometer any time they were to perform activities that involve the use of water and when going to bed.
2933226|NCT03018366|Active Comparator|17Beta Estradiol, Progesterone|17Beta Estradiol (0.1mg/day) , Progesterone (200mg) or Medroxyprogesterone (10mg) for patient with a peanut allergy because progesterone 200mg is a peanut based product
2933227|NCT03018366|Placebo Comparator|Transdermal Placebo Patch, Placebo Pill|Placebo Transdermal Patch, Placebo Pill
2933228|NCT03018353|Other|Navigation services with sof/vel therapy|This a single group demonstration project in which, patients are treated with the FDA-approved drug, Sofosbuvir/Velpatasvir (Epclusa). If a patients is released during their treatment regimen, they will receive patient navigation services to continue their care and treatment in the community.
2933229|NCT03018340|Experimental|Pimavanserin 34 mg|Drug- pimavanserin, 34 mg, taken as two 17 mg tablets, once daily by mouth
2933230|NCT03018340|Placebo Comparator|Placebo|Placebo, taken as two tablets, once daily by mouth
2933231|NCT03018327||Case group|250 Renal Transplant Recipients; 125 women and 125 men
2933232|NCT03018327||Control group|250 healthy controls; 125 women and 125 men
2933233|NCT03018314||Group 1|The first group will comprise of 30 women with polycystic ovaries in ultrasound examination or anovulatory cycles.
2933234|NCT03018314||Group 2|The second group will comprise of 30 women with diagnosis of unexplained infertility, normal menstrual periods and without known male factor infertility.
2933235|NCT03018314||Group 3|The third group will comprise of 30 women those partners with sperm count between 5x106 -15x106 /mL, type A + type B motility <%32 and Kruger morphology <4%.
2933236|NCT03018301|Active Comparator|Ketamine group|will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.
2933237|NCT03018301|Placebo Comparator|Control group|will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
2933238|NCT03018288|Experimental|2/RT+TMZ+Pembrolizumab+HSPPC-96|tumor meets criteria randomized vaccine group
2933239|NCT03018288|Placebo Comparator|3/RT+TMZ+Pembrolizumab +Placebo|tumor meets criteria randomized placebo group
2933240|NCT03018288|Experimental|1/RT+TMZ+Pembrolizumab|tumor does not meet criteria (ancillary group)
2933241|NCT03018275|Experimental|1|"Vials of lyophilized R mucosa (103, 104, or 105 CFU)"
2934529|NCT03009799|Active Comparator|Eye drops containing Iota-Carrageenan|Eye drops 3.2mg/ml
2933242|NCT03018249|Active Comparator|Arm I (medroxyprogesterone acetate, hysterectomy)|Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24.
2933243|NCT03018249|Experimental|Arm II (medroxyprogesterone acetate, entinostat, hysterectomy)|Patients receive medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Patients undergo hysterectomy between days 21-24.
2933244|NCT03018236|Experimental|Alcohol N-acetylcysteine|600 mg N-acetylcysteine capsule by mouth, every 12 hours for 8 weeks
2933245|NCT03018236|Placebo Comparator|Alcohol Placebo|A placebo capsule matching color and smell of the active medication
2933246|NCT03018236|Experimental|Cocaine N-acetylcysteine|600 mg N-acetylcysteine capsule by mouth, every 12 hours for 8 weeks
2933247|NCT03018236|Placebo Comparator|Cocaine Placebo|A placebo capsule matching color and smell of the active medication
2933248|NCT03018223|Experimental|Conditioning/HCT/GVHD Prophylaxis|"Pre-HCT Conditioning, HCT, GVHD Prophylaxis.~Conditioning regimen: To reduce heterogeneity, two commonly used myeloablative (MAC) and reduced intensity (RIC) regimens are permitted on this trial. Myeloablative conditioning: fludarabine, busulfan. Reduced intensity conditioning: fludarabine, cyclophosphamide, total body irradiation.~Peripheral blood hematopoietic cell transplantation~Graft vs. Host Disease (GVHD) prevention treatment: cyclophosphamide, mycophenolate mofetil, sirolimus.~Growth factor support: G-CSF"
2933249|NCT03018197|Experimental|Medication Education|Patients will receive training on the use of the personal health record and health education via the personal health record.
2933250|NCT03018197|No Intervention|No Medication Education|Patients will receive the current standard of care for the personal health record. Patients will not receive training on the use of the personal health record or health education via the personal health record.
2933251|NCT03018171|Experimental|SC|this arm will receive intrathecal clonidine addiction to sufentanil during combined spinal epidural analgesia for labor
2933252|NCT03018171|Active Comparator|S|this arm will receive intrathecal sufentanil during combined spinal epidural analgesia for labor
2933253|NCT03018158|No Intervention|dentulous|MR Imaging was collected with condition at the tongue at rest position.
2933254|NCT03018158|No Intervention|edentulous without denture wear.|MR Imaging was collected without denture wear.
2933255|NCT03018158|Experimental|edentulous with denture wear.|MR Imaging was collected with denture wear.
2933256|NCT03018145|Experimental|Standard stretcher group|Use a standard stretcher car as a transporting method in the operating room
2933257|NCT03018145|Active Comparator|Wagon group|Use a wagon as a transporting method in the operating room
2933258|NCT03018132|Other|Mental Health Screening Education and Referral|Investigators will prospectively assign all 200 women to this screening, education and referral intervention, without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and a health outcome. The health-related intervention, in this case, is an educational program and related process-of-care changes.
2933259|NCT03018119|Active Comparator|Anesthesiologists|Total: 11 Intervention: Survey
2933260|NCT03018119|Active Comparator|Obstetricians|Total: 11 Intervention: Survey
2933261|NCT03018119|Active Comparator|Registered Nurses|Total: 10 Intervention: Survey
2933262|NCT03018119|Active Comparator|Surgical Technicians|Total: 6 Intervention: Survey
2933263|NCT03018106|Experimental|Ospemifene|Women randomized to this arm will receive 60mg oral ospemifene, taken daily, for 12 weeks
2933264|NCT03018106|Active Comparator|Estrogen|Women randomized to this arm will receive 0.5mg vaginal conjugated estrogens, placed vaginally twice per week, for 12 weeks
2933265|NCT03018093|Experimental|C-CAR011|In day 0, 1 and 2, CAR011 cells will be intravenous infused at the 10%, 30% and 60% ratio respectively.
2933266|NCT03018080|Experimental|Cohort A|Paclitaxel will be given as an IV infusion over 60 minutes, on days 1 and 8 every 21 (+/- 3) days during Cycles 1 and 2. No pembrolizumab will be given during Cycles 1 and 2. Starting with cycle 3 and subsequent cycles, pembrolizumab will be given as an IV infusion over 30 minutes before paclitaxel on day 1 every 21 (+/- 3) days.
2933267|NCT03018080|Experimental|Cohort B|Pembrolizumab will be given as an IV infusion on day 1 before paclitaxel every 21 (+/- 3) days. Paclitaxel will be given as an IV infusion over 60 minutes, on days 1 and 8 every 21 (+/- 3) days.
2933268|NCT03018067|Placebo Comparator|Placebo|Microcrystalline Cellulose (MCC), 2 g qd. Subjects assigned to the Placebo group will be randomly assigned in a 1:1:1 ratio to receive either one, two, or three bottles of drug per day.
2933269|NCT03018067|Experimental|10 g qd|RDX227675, 10 g qd
2933270|NCT03018067|Experimental|20 g qd|RDX227675, 20 g qd
2933271|NCT03018067|Experimental|30 g qd|RDX227675, 30 g qd
2933272|NCT03018054|Experimental|E6007 30 mg|Participants will receive E6007 30 milligrams (mg) once daily after breakfast.
2933273|NCT03018054|Experimental|E6007 60 mg|Participants will receive E6007 60 mg once daily after breakfast.
2933274|NCT03018054|Placebo Comparator|Placebo|Participants will receive matching placebo once daily after breakfast.
2933275|NCT03018041|Experimental|Marine n-3 PUFAs|3 capsules of Omacor 1000 mg daily, corresponding to a dose of 2.5 g / day of marine n-3 PUFAs (EPA plus DHA).
2933276|NCT03018041|Placebo Comparator|Placebo|Corresponding placebo oral capsules with olive oil, three capsules daily.
2933277|NCT03018028|Experimental|Oral semaglutide 3 mg|
2933278|NCT03018028|Experimental|Oral semaglutide 7 mg|
2933279|NCT03018028|Experimental|Oral semaglutide 14 mg|
2933280|NCT03018028|Placebo Comparator|Oral placebo|
2933281|NCT03018028|Active Comparator|Liraglutide 0.9 mg|
2933282|NCT03018015|Experimental|Ibuprofen 400 mg oral powder|oral fasted administration of 1 sachet of Ibuprofen 400 mg oral powder (Hermes Arzneimittel GmbH, Germany), containing 400 mg ibuprofen
2933283|NCT03018015|Active Comparator|Brufen 400 mg film-coated tablets|oral fasted administration of Brufen 400 mg film-coated tablets (Abbott Scandinavia AB, Sweden), containing 400 mg ibuprofen
2933284|NCT03018015|Active Comparator|Spalt forte 400 mg Weichkapseln|oral fasted administration of Spalt forte 400 mg Weichkapseln (Pfizer Consumer Healthcare GmbH, Germany), containing 400 mg ibuprofen
2933315|NCT03017781||Control Group|A group of offspring of bipolar parents with no impairment in psychosocial functioning will be used for comparison.
2934530|NCT03009799|Placebo Comparator|Ocular Lubricant Eye Drops|Carmellose 0.5% sterile solution
2933285|NCT03018002|No Intervention|Control group|HIV-infected participants identified from the churches randomized to CG will be referred to PEPFAR-supported HIV clinics that provide comprehensive care including counseling, laboratory testing, ART and ongoing support during treatment as the standard of care. The study team will not be involved in their care beyond data collection.
2933286|NCT03018002|Experimental|iSTAR|HIV-infected participants identified from the churches clustered within the randomized health facilities will receive interventions from the study team.
2933287|NCT03017989|Experimental|NIRF imaging|After the white light (WL) imaging, NIRF imaging will be performed. 2.5 mg of ICG will be administered i.v. up to 5 times if needed. The lesions identified in WL, are inspected in NIRF mode. The surgeon indicated whether the lesions are more easily identified in WL or the NIRF mode and scores the visibility on a 1-10 scale. Next, inspection will take place for lesions that are seen in NIRF mode but not in WL. Biopsies will be taken from the lesions and from normal tissue for reference and sent for histology. Evaluation will take place whether the lesions differ in histological characteristics
2933288|NCT03017976||Competitive swimmers|Regular and naïf competitive swimmers will be followed for a mean period of 90 days. A battery of measurements and biological samples will be collected at the baseline evaluation and 90 days after, in order to evaluate long-term changes in respiratory health biomarkers. Measurements will also be performed before and after a single regular training session in order to assess acute effects in respiratory health biomarkers.
2933289|NCT03017976||Recreational swimmers and swimming pool staff|Swimming pool physicochemical and microbiological characteristics and the association between each parameter measured as an indicator of water and air quality, contamination of surfaces will be evaluated and the association with recreational users, swimming teachers and pool attendants health parameters will be studied.
2933290|NCT03017963|Experimental|dose-escalation cohort|Patients are divided in 6 groups of 3 patients to receive the following intervention: 0 gram (g), 2.5 g, 5 g, 10 g, 12.5 g and 15 g of sodium thiosulfate pentahydrate (STS) intravenous. The first dose is given in 15 min immediately after inclusion at the cath-lab. In the absence of dose-limiting toxicity (DLT), a second gift of STS is given in 30 min, 6 hours later at the coronary care unit (CCU). When no DLT is observed in any of the patients after 2 gifts of the same dose an extra 3 subjects are enrolled into the next higher dose cohort. If 1 out of 3 patient develops DLT at a specific dose, an extra 3 subjects are enrolled into the same dose cohort. When more than 1 out of 6 patients develop DLT the trial will be terminated because the maximum tolerable dose (MTD) has been exceeded.
2933291|NCT03017950|Experimental|Part1 (A)|"Number of Subjects: 10~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: CKD-330~IPs for Period 2: CKD-330 + D086"
2933292|NCT03017950|Experimental|Part1 (B)|"Number of Subjects: 10~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: CKD-330 + D086~IPs for Period 2: CKD-330"
2933293|NCT03017950|Experimental|Part2 (A)|"Number of Subjects: 30~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: D086~IPs for Period 2: CKD-330 + D086"
2933294|NCT03017950|Experimental|Part2 (B)|"Number of Subjects: 30~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: CKD-330 + D086~IPs for Period 2: D086"
2933295|NCT03017937|Experimental|Q- collar|All subjects will wear 3 sizes of the q-collar and ultrasound images of the jugular vein will be measured with each collar. Also, each subject will wear a pressure collar and ultrasound images of the jugular vein will be captured at each pressure point (0.1-0.5)
2933296|NCT03017924|Experimental|Q collar|Subjects that will wear the Q collar during the breacher training
2933297|NCT03017924|No Intervention|No collar|Subjects that will not wear the Q collar during the breacher training
2933298|NCT03017911||Patients with PICC Lines|All patients included in this study have undergone PICC Line placement before enrollment.
2933299|NCT03017898|Experimental|Laser coagulation|Treatment of anal fistulae meeting the inclusion criteria
2933300|NCT03017885||Group A|Patients who started treatment with nintedanib & docetaxel after 23rd January, 2017 and have discontinued the drug at the time of participation in the active surveillance.
2933301|NCT03017885||Group B|Patients who started treatment with nintedanib & docetaxel after 23rd January, 2017 and are continuing the drug at the time of participation in the active surveillance .
2933302|NCT03017885||Group C|Patients who have been newly prescribed nintedanib & docetaxel at the time of participation in the active surveillance.
2933303|NCT03017872|Active Comparator|Standard of Care (SoC) arm|2 x NRTIs + darunavir/ritonavir 800mg/100mg po od
2933304|NCT03017872|Experimental|Dolutegravir arm|Dolutegravir 50mg + darunavir/ritonavir 800mg/100mg po od
2933305|NCT03017872|Experimental|Dolutegravir 2NRTI arm (D2N)|Dolutegravir 50mg + 2 x NRTIs (tenofovir plus emtricitabine or lamivudine)
2933306|NCT03017859|Experimental|High flow nasal cannula treatment|Airvo 2 device will be used to administer high flow air during the night
2933307|NCT03017846|Experimental|Cantharidin Treatment|Subjects with lesions treated with topical cantharidin every 3 weeks up to 12 weeks.
2933308|NCT03017833|Experimental|TAK-228 + Metformin|"Metformin taken by mouth daily (once to three times daily) starting on Cycle 1 Day 1 for 42 days. Cycle 1 includes an extra 2 weeks of study testing and dose adjustments (42 days).~TAK-228 taken by mouth daily starting on Cycle 1 Day 15 for 28 days.~Each cycle thereafter will be 28 days for both drugs."
2933309|NCT03017820|Experimental|Treatment (VSV-IFNbeta-NIS)|Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1, and then undergo SPECT/CT 3-5 days later.
2933310|NCT03017807|Experimental|Recombinant Anti-EGFr Antibody|Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance.
2933311|NCT03017794||Gleason score 6 or less|Prostate adenocarcinoma with Gleason score 6 or less
2933312|NCT03017794||Gleason score 7|Prostate adenocarcinoma with Gleason score 7
2933313|NCT03017794||Gleason score 8 -10|Prostate adenocarcinoma with Gleason score 8 -10
2933314|NCT03017781||Study Group|Offspring (15-25 years old) of parents with Bipolar Disorder (BD) with at least mild impairment in psychosocial functioning were observed to evaluate the relationship of impairment in psychosocial functioning with the manifestation of mood symptoms over 24 months
2933316|NCT03017768|Active Comparator|Acute tryptophan depletion|Administration of an amino acid mixture consisting of 15 amino acids, (4.1g L-alanine, 2.4g glycine, 2.4g L-histidine, 6.0g L-isoleucine, 10.1g L-leucine, 6.7g L-lysine, 4.3g L-phenylalanine, 9.2g L-proline, 5.2g L-serine, 4.3g L-threonine, 5.2g L-tyrosine, 6.7g L-valine, 3.7g L-argine, 2.0g L-cysteine, 3.0g L-methionine) lacking tryptophan to investigate the effect of tryptophan depletion on esophageal sensitivity
2933317|NCT03017768|Placebo Comparator|Placebo|Administration of an amino acid mixture consisting of 15 amino acids, (4.1g L-alanine, 2.4g glycine, 2.4g L-histidine, 6.0g L-isoleucine, 10.1g L-leucine, 6.7g L-lysine, 4.3g L-phenylalanine, 9.2g L-proline, 5.2g L-serine, 4.3g L-threonine, 5.2g L-tyrosine, 6.7g L-valine, 3.7g L-argine, 2.0g L-cysteine, 3.0g L-methionine and 3.0g L-trypyophan). Since this amino-acid mixture contains tryptophan it is used as the placebo arm of this cross-over study
2933318|NCT03017716|No Intervention|IBP patients on standard therapy|IBP patients on standard therapy.
2933319|NCT03017716|Active Comparator|IBP patients on standard therapy and GFD|IBP patients on standard therapy and GFD
2933320|NCT03017703|Experimental|Type 2 Diabetes|8 weeks of treatment with Aldosterone blocker Eplerenone
2933321|NCT03017703|Experimental|Healthy|8 weeks of treatment with Aldosterone blocker Eplerenone
2933322|NCT03017690||lanreotide group (Somatuline Depot®)|
2933323|NCT03017690||octreotide LAR group (Sandostatin LAR®)|
2933324|NCT03017677||Group|
2933325|NCT03017664||RFG|Retrospective review of enteral feeding in pediatric ICU patients for up to 5 days
2933326|NCT03017664||PFG|Pediatric ICU population to be fed a peptide-based enteral formula with higher protein and higher calories for up to 5 days
2933327|NCT03017651|Experimental|OM3-supplement 1|1 g capsule for OM3-supplement 1 given once
2933328|NCT03017651|Active Comparator|OM3-supplement 2|1 g capsule for OM3-supplement 2 given once
2933329|NCT03017638||Patients receiving QLB and questionaires|Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours and 48 hours and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
2933330|NCT03017638||Historical control|"The control subjects' data will be assessed reviewing patient records. Data will include:~Maximal PACU VAS pain score (per nursing charts)~Overall POD 24 hours and 48 hours and 4 weeks opioid consumption (overall morphine mg/kg equivalent dose)~POD 24 and 48 hours and 4 weeks Respiratory complications"
2933331|NCT03017612|Experimental|Single Arm Study|Evaluating the safety and effectiveness of the raindrop near vision inlay implanted in bilateral pseudophakic subjects
2933332|NCT03017599|Experimental|Intervention group|EUS-FNB using 20-gauge procore needle
2933333|NCT03017586|Experimental|STN|DBS target with Subthalamic Nucleus (STN).
2933334|NCT03017586|Experimental|GPi|DBS target with Globus Pallidus Internus (GPi).
2933335|NCT03017573|Experimental|Tumor and blood sampling|Patients will have a biopsy or a surgery and blood sampling at different time points.
2933336|NCT03017560|Experimental|Computerized cognitive treatment|Chosen exercises from the rehabilitation package of a commercially available, computerized, cognitive training program called Happy Neuron Pro will be used. This program was designed by a team of neurologists, neuropsychologists and cognitive psychologists, and has been successfully adapted for varying conditions of cognitive dysfunction.
2933337|NCT03017560|No Intervention|Wait list control|Participants assigned to the wait list control arm will receive no treatment while the experimental arm is participating in the computerized treatment. However, the computerized treatment program will be made available for these participants to utilize at the end of the study period.
2933338|NCT03017547|Experimental|IC14|IC14 4 mg/kg IV on Study Day 1, then IC14 2 mg/kg IV once daily on Study Days 2-4.
2933339|NCT03017547|Placebo Comparator|Placebo|Placebo IV once daily on Study Day 1-4
2933340|NCT03017534|Experimental|Gender Match, Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, wearing a labcoat and receive a detailed anatomic explanation of the technique.
2933341|NCT03017534|Experimental|Gender Match, Labcoat, No Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, wearing a labcoat, and receive a colloquial discussion of the technique.
2933342|NCT03017534|Experimental|Gender Match, No Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a detailed anatomic explanation of the technique.
2933343|NCT03017534|Experimental|Gender Match, No Labcoat, No Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a colloquial discussion of the technique.
2933344|NCT03017534|Experimental|Gender Mis-match, Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, wearing a labcoat and receive a detailed anatomic explanation of the technique.
2933345|NCT03017534|Experimental|Gender Mis-match, Labcoat, No Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, wearing a labcoat, and receive a colloquial discussion of the technique.
2933346|NCT03017534|Experimental|Gender Mis-match, No Labcoat, Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, not wearing a labcoat, and receive a detailed anatomic explanation of the technique.
2933347|NCT03017534|Experimental|Gender Mis-match, No Labcoat, No Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a colloquial discussion of the technique.
2933348|NCT03017521|Experimental|TAS-117|TAS-117, 16mg, orally, daily
2933349|NCT03017508|Experimental|BHV-0223 (Sublingual Riluzole)|Participants will be given one dose of BHV-0223 (sublingual riluzole) 35mg before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
2933350|NCT03017508|Placebo Comparator|Placebo|Participants will be given one dose of an identical looking sublingual placebo before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
2933351|NCT03017495|Experimental|Food effect and Drug-Drug interaction|Treatments will be given to all subjects in the same fixed sequence: Treatment A (Day 1, single dose of midazolam, fasted), Treatment B (Day 2, single dose of ACT-541468 followed by single dose of midazolam, fasted), Treatment C (Day 4, single dose ACT-541468, fed), Treatment D (multiple doses of ACT-541468 from Day 5 to Day 8 + single dose of midazolam on Day 8, fasted).
2933352|NCT03017469|Experimental|ARISE Intervention|Nurses who participate in the 1.5 day ARISE Intervention
2933353|NCT03017469|No Intervention|Control Group|Nurses who do not participate in the ARISE Intervention
2933354|NCT03017456|No Intervention|Usual Care (UC)|Patients in the UC arm will not receive the study intervention (behavioral) and instead will receive care according to usual practice. This usually involves a brief office visit (approximately 5-10 minutes) with pertinent history and physical examination related to surgical/radiation recovery, review of the pathology and general instructions regarding the next step in follow-up.
2933355|NCT03017456|Active Comparator|SCP-Intervention vs usual care|behavioral intervention vs control Patients in the SCP-Int arm will be asked to attend a one-time appointment with a trained oncology nurse. The SCP-Int is comprised of a 30-minute nurse-led face-to-face intervention and the provision of a tailored PC-specific SCP (PC-SCP). Persistent effects and concerns that are identified will prompt the development of a tailored management plan captured within the PC-SCP. Relevant patient education materials will be linked electronically. Nurses will use motivational interviewing techniques to effective in increase healthy behaviors and empower the PC survivor to actively self-manage persistent treatment effects and to decrease their risk of late effects by providing effective health information, support, and self-management support.
2933356|NCT03017443|Experimental|Nutrisystem My Way|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem My Way plan.
2933357|NCT03017443|Experimental|Nutrisystem Turbo 10|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem Turbo 10 plan.
2933358|NCT03017443|Experimental|Nutrisystem DASH|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem DASH plan.
2933359|NCT03017443|Active Comparator|Dieting on Your Own (DIY) - DASH|All subjects provided publically available information on the DASH diet and instructed to follow a reduced calorie DASH diet meal plan on their own.
2933360|NCT03017430|Experimental|Pregabalin|This group (N= 40) receives up to 600 mg a day of Pregabalin for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
2933361|NCT03017430|Active Comparator|Clonidine|This group (N= 40) receives up to 600 micrograms of Clonidine a day for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)..
2933362|NCT03017417|Experimental|Exercise Intervention arm|"exercise training intervention to include:~DEXA scan will collect data on via a full body scan to determine post-cranial appendicular whole body LM, whole body fat free mass (FFM) and whole body FM.~Muscle Strength assessment~Physical function assessment~Questionnaires and diet diaries"
2933363|NCT03017417|Active Comparator|standard of care arm|"standard treatment~exercise advice~Questionnaires"
2933364|NCT03017404|Experimental|treatment group:35 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
2933365|NCT03017404|Experimental|treatment group:40 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
2933366|NCT03017404|Experimental|treatment group:45 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
2933367|NCT03017404|Experimental|treatment group:50 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
2933368|NCT03017391|Active Comparator|algorithm 1 first metoclopramide|metoclopramide 10 mg tablets 3x daily orally and in those patients that cannot swallow tablets the medication will be substituted by suppositories 10 mg 3x daily rectally. In case of failure, granisetron patch 3.1mg/24 hours will be added to the treatment and a loading dose of 2 mg granisetron oral if the patient can swallow. In case of toxicity metoclopramide will be stopped. In case of failure of the combination (second step) or toxicity, an oral dose of dexamethasone 8 mg will be added daily.
2933369|NCT03017391|Active Comparator|algorithm 2 first granisetron|"granisetron patch 3.1 mg/24 hours will be offered to the patient, and a loading dose of 2 mg granisetron oral if the patient can swallow In case of failure, metoclopramide 10 mg tablets 3x daily orally will be added and in those patients that cannot swallow tablets the oral medication will be substituted with rectal suppositories 10 mg. The granisetron patch will only be withdrawn from patients that suffer from clinically relevant toxicity. Metoclopramide will then be administered.~In the case of secondary failure or toxicity, dexamethasone 8 mg orally daily will be added."
2933370|NCT03017378|Active Comparator|TB/FLU-01L (intranasal application)|Vaccine safety analysis of TB/FLU-01L at double intranasal application in healthy volunteers aged 18 to 50 years.
2933371|NCT03017378|Active Comparator|TB/FLU-01L (sublingual application)|Vaccine safety analysis of TB/FLU-01L at double sublingual application in healthy volunteers aged 18 to 50 years.
2933372|NCT03017365|Active Comparator|M-SRT|Machine-based stable resistance training. Exercising 'traditional' machine-based resistance training.
2933373|NCT03017365|Experimental|F-URT|Free weight unstable resistance training; conducted free-weight resistance training on unstable devices using dumbbells instead of exercise-machines.
2933374|NCT03017365|Experimental|M-ART|Machine-based adductor/abductor resistance training. Exercising with 'traditional' adductor/abductor machines.
2933375|NCT03017352|Experimental|Intervention|Exenatide 10 mikrogram, thrice daily, subcutaneous injection prior to main meals, 6 months.
2933376|NCT03017352|Placebo Comparator|Placebo|Placebo, thrice daily, subcutaneous injection prior to main meals, 6 months.
2933377|NCT03017339|Experimental|Laser Group|The subjects participated in a functional exercise program associated with low level laser therapy applied in the quadriceps, hamstrings and triceps sural
2933378|NCT03017339|Placebo Comparator|Placebo Group|The subjects participated in a functional exercise program associated with placebo low level laser therapy applied in the quadriceps, hamstrings and triceps sural
2933379|NCT03017326|Other|Group A Very Low Risk HB|Patients with well differentiated foetal histology will receive 2 cycles of Cisplatin (2x 100mg/m2). Patients will non-well differentiated histology will be followed up only (no intervention).
2933380|NCT03017326|Active Comparator|Group B Low Risk HB|Patients who are resected after 2 cycles of Cisplatin will be randomised to receive 4 or 6 cycles of Cisplatin overall (80mg/m2). Patients who are not resected will continue to receive up to 6 cycles of Cisplatin (80mg/m2) until resection.
2933381|NCT03017326|Active Comparator|Group C Intermediate Risk HB|Patients will be randomised to receive Cisplatin (80mg/m2), Carboplatin (500mg/m2) and Doxorubicin (60mg/m2) as SIOPEL-3HR (5 cycles), Cisplatin (100mg/m2), Doxorubicin (60mg/m2) 5-Fluorouracil (600mg/m2) and Vincristine (4.5mg/m2) as C5VD (6 cycles), or 6 cycles of high dose Cisplatin (100mg/m2)
2933382|NCT03017326|Active Comparator|Group D High Risk HB|Patients will receive SIOPEL-4 regimen (Cisplatin 70mg/m2, Doxorubicin 30mg/m2) then have surgery. Post surgery, patients with remaining metastases will be randomised to receive 6 cycles of either Carboplatin (500mg/m2) and Doxorubicin (40mg/m2) alternating with Carboplatin (800mg/m2) and Etoposide (400mg/m2), or Carboplatin (500mg/m2) and Doxorubicin (40mg/m2) alternating with Vincristine (3mg/m2) and Irinotecan (250mg/m2). Patients with no metastases will receive the standard treatment of 3 cycles of Carboplatin (500mg/m2) and Doxorubicin (40mg/m2).
2933383|NCT03017326|Other|Group E Resected HCC|Patients with an underlying predisposition to HCC through genetic, viral or metabolic conditions will be followed up (no intervention). De novo or fibrolamellar HCC patients will receive 4 cycles of PLADO regimen (Cisplatin (80mg/m2) and Doxorubicin (60mg/m2)) over 4 cycles.
2933384|NCT03017326|Active Comparator|Group F Unresected HCC|Patients will be randomised to receive up to 6 cycles of PLADO (Cisplatin 80mg/m2, Doxorubicin 60mg/m2) with Sorafenib (300mg/m2) or up to 8 cycles of PLADO with Sorafenib and GEMOX (Gemcitabine 1000mg/m2, Oxaliplatin 100mg/m2) with Sorafenib (300mg/m2)
2933385|NCT03017300|Experimental|COPD（threshold IMT training）|COPD patient use Inspiratory muscle trainer (Threshold IMT®)
2933386|NCT03017300|Experimental|COPD（resisive training）|COPD patient use Inspiratory muscle trainer (PFLEX®)
2933387|NCT03017287|Experimental|GlucoMe App|Self monitoring of glucose blood measurements using the GlucoMe glucose monitoring glucose device and App
2933388|NCT03017274||NCWS patients|Fifty consecutive adult patients with an IBS-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients was recruited between January 2015 and November 2016 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
2933389|NCT03017274||CD control patients|To compare the abdominal ultrasonographic features of NCWS patients, a control group of CD patients was randomly chosen by a computer-generated method from subjects diagnosed during the same period and age- and sex-matched with the NCWS patients. All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
2933390|NCT03017261|Experimental|TSolution One®|This group will undergo total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
2933391|NCT03017248|Active Comparator|Morphine and Placebo|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an injection of Placebos (0.9% normal saline 0.05ml/kg)
2933392|NCT03017248|Experimental|Morphine and Ketamine 0.15|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an IV bolus of Ketamine at the dose of 0.15mg/kg
2933393|NCT03017248|Experimental|Morphine and Ketamine 0.3|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an IV bolus of Ketamine at the dose of 0.3mg/kg
2933394|NCT03017235|Experimental|NaP/MC Oral Solution|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid (NaP/MC) Oral Solution
2933395|NCT03017235|Active Comparator|PREPOPIK®|
2933396|NCT03017222|Active Comparator|Ondansetron group|
2933397|NCT03017222|Experimental|Ramosetron group|
2933398|NCT03017209|Experimental|Locally-prepared bar|The bar is similar to one tested recently in a pilot study and is a locally prepared bar designed to facilitate growth and cognitive development. It will provide 300 kcal/day and will have ≈20-30% of energy from protein (of which 25-50% is from an animal protein source), 20-35% from total carbohydrate and ≈40-60% from fat. The bar will be fortified with vitamins and minerals to meet USAID recommendations for moderate malnutrition and Dietary Reference Intake recommendations for at-risk and healthy children of the ages studied, and at the same time will not exceed Upper Level nutrient recommendations for any micronutrient. Ingredients in the bar will be a combination of local products and imported shelf-stable ingredients.
2933399|NCT03017209|Active Comparator|USAID Corn Soy Blend Plus|The usual-intervention condition will be 300 kcal/day of USAID Corn Soy Blend Plus cooked in the usual manner with fortified vegetable oil (10:3 ratio) and sugar. The community health workers or other designated villagers will prepare the supplement freshly each intervention day using locally accepted standards for hygiene, and a quality control process for ratios of ingredients assigned by the research team to ensure consistent composition.
2933400|NCT03017209|Placebo Comparator|Locally-purchased rice|The placebo condition will be 300 kcal/day of locally-purchased rice cooked with a small amount of oil (10:2 ratio), which mimics the usual breakfast of children in this region. The community health workers or other designated villagers will prepare the rice freshly each intervention day using locally accepted standards for hygiene, and a quality control process for ratios of ingredients assigned by the research team to ensure consistent composition.
2933401|NCT03017196|Experimental|Intervention|Sites randomized to intervention will be expected to implement the My Life, My Healthcare Discussion Aid in their practice for at least a 6-month period.
2933402|NCT03017196|No Intervention|Control|Sites randomized to control will not be expected to implement the My Life, My Healthcare Discussion Aid in practice. They will be expected to practice chronic care as usual.
2933403|NCT03017183|Other|EBUS-TBNA - Endobrochial Forceps Biopsy|In this arm, EBUS-TBNA will be done first, followed by endobronchial forceps biopsy
2933404|NCT03017183|Other|Forceps - EBUS-TBNA|In this arm, endobronchial forceps biopsy will be done first, followed by EBUS-TBNA
2933405|NCT03017170|Experimental|Cranberry|500mg Dried Cranberry
2933406|NCT03017170|Placebo Comparator|Placebo Oral Capsule|Color Matching Placebo
2933407|NCT03017157||Anterior Myocardial Infarction|Patients who have suffered anterior myocardial infarction in our hospital
2933408|NCT03017131|Experimental|Treatment (decitabine, genetically modified T cells)|"COURSE 1: Patients receive decitabine IV daily over 1 hour on days 1-3, cyclophosphamide IV over 2 hours on days 5 and 6, and genetically engineered NY-ESO-1-specific T lymphocytes IV and IP on day 9. Patients also receive aldesleukin SC BID on days 10-23.~COURSE 2: Patients receive decitabine IV daily over 1 hour on days 31-33, genetically engineered NY-ESO-1-specific T lymphocytes IV and IP on day 37, and aldesleukin SC BID on days 38-51."
2933409|NCT03017118|Experimental|Turmeric|Subjects in this group will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
2933410|NCT03017118|Placebo Comparator|Control|Subjects in this group will receive a placebo pill 3 times per day for 6 weeks.
2933411|NCT03017105|Active Comparator|Control|Usual rehabilitation: non-operative management of the fracture; will undergo usual physiotherapy rehabilitation for the injured arm
2933412|NCT03017105|Experimental|Experimental|Cross-education of strength-training: non-operative management of the fracture; will undergo usual physiotherapy rehabilitation for the injured arm but will also undergo strength-training for the uninjured arm
2933413|NCT03017092|Experimental|tablet-guided|Study participants will be administered a brief tobacco intervention by a Salvation Army staff person who is guided by a tablet computer
2933414|NCT03017079|Experimental|semi-solidification with nutrient|"semi-solidification with nutrient:after infusion of semi-solid agent, enteral nutrition is applied less than 60 mins.~Intervention: Other: bolus Intermittent enteral feeding"
2933415|NCT03017079|Placebo Comparator|Standard enteral nutrition|"After infusion of Sterile Water for Injection,bolus Intermittent enteral feeding via the nasogastric tube is applied less than 60 mins.~Intervention: Other: Standard enteral feeding"
2933416|NCT03017066|Experimental|Infant formula|Patients were given infant formula 6 hours prior to surgery. Gastric volume was assess just after ingestion, 1 hour prior to the surgery, and before the induction of general anesthesia using ultrasound.
2933417|NCT03017066|Experimental|Carbohydrate drink|Patients were given carbohydrate drink 2 hours prior to surgery. Gastric volume was assess just after ingestion, 1 hour prior to the surgery, and before the induction of general anesthesia using ultrasound.
2933418|NCT03017053|Experimental|Radiotherapy|Primary surgery & Radiotherapy
2933419|NCT03017053|Active Comparator|Elective neck dissection|Primary surgery & Elective neck dissection
2933420|NCT03017040|Experimental|Scapholunate tear|Subjects with a full scapholunate tear will have a CT scan and fluoroscopy images taken
2933421|NCT03017040|Active Comparator|Control Wrist|Subjects will have a CT scan and fluoroscopy image taken of the contralateral wrist serve as the control.
2933422|NCT03017027|Experimental|Therapy dog visitation (TDV)|The TDV intervention consists of a one-time 10 minute TDV with the dog handler and his/her dog interacting with the patient. The therapy dog visitation program is a currently established program and each therapy dog meets obedience, temperament, and health standards required by the organization and are deemed appropriate to therapy dog visitation. For hygienic reasons, dogs are bathed before visitation and the patient is required to wash hands before and after the visit. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. The therapy dog will be leashed and controlled by the dog handler. If the participant wants the dog to be placed on the bed, a clean sheet will be placed on the bed in between the dog and patient. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Tactile and visual contact with the dog will be promoted.
2933423|NCT03017027|Other|non-TDV control|Participants randomized to the control condition will receive a new plush stuffed animal for the same 10-min timeframe without any structured activities. At the end of the session, a stuffed animal will be offered to the participant to keep.
2933424|NCT03017014||Pediatric participants receiving adalimumab|Pediatric participants receiving adalimumab for CD in real-life conditions.
2933425|NCT03017001|Experimental|CHO (carbohydrate) group|Patients received a 8h preoperative fast for solids and 2h fast with 200mL of a drink containing water plus 12.5% maltodextrin (25g) and no infusion of intraoperative w-3-PUFA
2933426|NCT03017001|Experimental|W-3 PUFA group|Patients received preoperative fast for solids but allowed to drink 200 mL of water until 2h before anesthesia, and an intravenous intraoperative dose of intravenous w-3-PUFA (0.2 mcg/kg)
2933427|NCT03017001|Experimental|CHO plus intravenous w3-PUFA group|Patients received a 8h fast for solids and 2h fast with 200mL of a drink containing water plus 12.5% maltodextrin (25g), and an intravenous intraoperative dose of intravenous w-3-PUFA (0.2 mcg/kg)
2933428|NCT03017001|No Intervention|Control|Patients received preoperative fast for solids for 8h but allowed to drink 200 mL of water until 2h before anesthesia; and no infusion of intraoperative intravenous w-3-PUFA
2933429|NCT03016988|Other|Bortezomib,Fludarabine and Cytarabine|Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11; Fludarabine(F) 25mg/m2, intravenously day 1-3; Cytarabine(A) 500mg/m2 for 3 days(day1-3).
2933430|NCT03016975|Experimental|Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System plus guideline directed medical therapy (GDMT)
2933431|NCT03016975|No Intervention|Control|Guideline directed medical therapy (GDMT)
2933432|NCT03016962|Experimental|Cap-assisted colonoscopy|cap-assisted colonoscopy
2933433|NCT03016962|Active Comparator|Standard colonoscopy|Standard colonoscopy
2933434|NCT03016949|Experimental|Group A|3 doses IPV IM at 10, 14 & 36 weeks of age incl. blood sampling at 10, 18, 36 & 40 weeks.
2933435|NCT03016949|Experimental|Group B|3 doses f-IPV ID at 10, 14 & 36 weeks of age incl. blood sampling at 10, 18, 36 & 40 weeks.
2933436|NCT03016949|Experimental|Group C|2 doses IPV IM at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
2933437|NCT03016949|Experimental|Group D|2 doses f-IPV ID at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
2933438|NCT03016949|Experimental|Group E|3 doses IPV IM at 6, 14 & 36 weeks of age incl. blood sampling at 6, 18, 36 & 40 weeks.
2933439|NCT03016949|Experimental|Group F|3 doses f-IPV ID at 6, 14 & 36 weeks of age incl. blood sampling at 6, 18, 36 & 40 weeks.
2933440|NCT03016936||Subgroup for NTproBNP Substudy|Planned subgroup analyses in patients undergoing vascular, orthopaedic, thoracic surgery, and in patients aged 65 years or older with a RCRI <2 and NSQIP- MICA <1%
2933441|NCT03016923|Experimental|FES Therapy|FES therapy will be administered over the course of 1 hour sessions that will be take place 3 times per week over 16 weeks, for a total of 48 sessions.
2933442|NCT03016910||Type 2 diabetes|This group will consist of 300 patients with type 2 diabetes mellitus without symptoms or known coronary heart disease. The group will be followed for one year and CCTA will be performed at baseline and after one year.
2933443|NCT03016910||Type 1 diabetes|This group will consist of 50-100 patients with type 1 diabetes mellitus without symptoms or known coronary heart disease. The group will be followed for one year. CCTA will be performed at baseline and after one year.
2933444|NCT03016897||Group 1|Participants enrolled solely in ALS AT HOME Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
2933445|NCT03016897||Group 2|Current participants of the Answer ALS study Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
2933446|NCT03016897||Group 3|Participants without neurological disease (controls) Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
2933447|NCT03016884|Experimental|RA patients|RA patients will be administered Zostavax vaccine once 2 weeks before initiation of bDMARD, and be monitored accordingly
2933448|NCT03016884|Experimental|Healthy Controls|healthy control patients will be administered Zostavax vaccine and be monitored accordingly
2933449|NCT03016871|Experimental|Treatment (nivolumab, etoposide, ifosfamide, carboplatin)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with CR or PR receive nivolumab for an additional 6 weeks. Patients with only SD after 6-week nivolumab treatment receive nivolumab for an additional 6 weeks or receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2 every 21 days for 6 weeks per physician/investigator's discretion. Patients with PD after 6-week nivolumab treatment or patients with PR, SD, or PD after 12-week nivolumab treatment receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2933450|NCT03016858|Experimental|NIIASV|undergoing Thoracoscopic Bullectomy Surgery under nonintubated intravenous anesthesia with spontaneous ventilation(NIIASV)
2933451|NCT03016858|Active Comparator|IASLV|undergoing Thoracoscopic Bullectomy Surgery under intubated anesthesia with single-lung mechanical ventilation(IASLV)
2933452|NCT03016832|Experimental|Huangkui|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing; HuangKui Capsule 2.5g/tid, oral dosing
2933453|NCT03016832|Active Comparator|controlled|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing; HuangKui Capsule 2.5g/tid, oral dosing irbesartan tablets 150mg /qd, oral dosing; Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
2933454|NCT03016832|Other|combined treatment|irbesartan tablets 150mg /qd, oral dosing HuangKui Capsule 2.5g/tid, oral dosing.
2933455|NCT03016819|Experimental|Indication A: ASPS AL3818 Arm|All subjects with ASPS will be assigned to the open-label AL3818 arm to receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
2933456|NCT03016819|Experimental|Indication B: LMS AL3818 Arm|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to AL3818 will receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
2933457|NCT03016819|Active Comparator|Indication B: LMS Dacarbazine Arm|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to IV dacarbazine will receive dacarbazine at a dose of 1000 mg/m^2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle.
2933458|NCT03016819|Experimental|Indication C: SS AL3818 Arm|Subjects with SS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to AL3818 will receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
2933459|NCT03016819|Active Comparator|Indication C: SS Dacarbazine Arm|Subjects with SS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to IV dacarbazine will receive dacarbazine at a dose of 1000 mg/m^2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle.
2933460|NCT03016806|Other|Full Intensity, TBI-based Conditioning|Full Intensity TBI-based Conditioning Total Body Irradiation 1200 cGy in fractions of 150 cGy days -8 or -7 to -4 Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses [to be completed 24 hours after final Cyclophosphamide dose] followed by Cord Blood Infusion Other names: TBI/Cy
2933461|NCT03016806|Other|Full Intensity, Chemo-based Conditioning|Full Intensity, Chemotherapy Conditioning Busulfan days -7 to -4 Recipients <5 years - 1 mg/kg/dose x 16 doses every 6 hours Recipients >/= 5 years - 0.8 mg/kg/dose x 16 doses every 6 hours Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses [to be completed 24 hours after final Cyclophosphamide dose] followed by Cord Blood Infusion Other names: Bu/Cy
2933462|NCT03016806|Other|Reduced Intensity Chemotherapy|Reduced Intensity Chemotherapy Fludarabine 30 mg/m2/day x 5 doses days -6 to -2 Melphalan 140 mg/m2/day x 1 dose day -2 Cord Blood Infusion Other names: Flu/Mel
2933463|NCT03016806|Other|Non-Myeloablative Conditioning|Fludarabine 40 mg/m2/day x 5 doses days -6 to -2 Cyclophosphamide 50 mg/kg/day x 1 dose day -6 Mesna 50 mg/kg/day with 20% loading dose with Cyclophosphamide dose followed by continuous infusion over 24 hours x 1 dose [to be completed 24 hours after Cyclophosphamide dose] Total Body Irradiation 200 cGy in a single fraction day -1 Cord Blood Infusion Other names: Flu/Cy/TBI
2933464|NCT03016793|Experimental|puerarin and β- tricalcium phosphate|"purabone (puerarin) is an osteoinductive bone grafts used to augment bone healing.~β- tricalcium phosphate is an osteoconductive bone graft used to augment bone healing"
2933465|NCT03016793|Active Comparator|β- tricalcium phosphate alone|β- tricalcium phosphate is an osteoconductive bone graft used to augment bone healing
2933466|NCT03016780|Active Comparator|Treatment in part 1|Fecal microbiota transplantation and traditional treatments will be used in patients with ulcerative colitis in part 1.
2933467|NCT03016780|Placebo Comparator|Placebo in part 2|The traditional treatments and normal saline will be used in patients with ulcerative colitis in part 2 according to associated guidelines.
2933468|NCT03016767|Experimental|oral stimulation|"All the subjects of the study will receive the usual medical and nursing care for premature babies. They also will receive the physiotherapeutic treatment prescribed by the rehabilitation physician, focused mainly on respiratory and musculoskeletal care.~Infants of the experimental group, in addition, will be applied a manual oral stimulation protocol designed ad hoc for this study, which consists of 12 maneuvers performed by a physiotherapist."
2933469|NCT03016767|No Intervention|non oral stimulation|All the subjects of the study will receive the usual medical and nursing care for premature babies. They also will receive the physiotherapeutic treatment prescribed by the rehabilitation physician, focused mainly on respiratory and musculoskeletal care. But this group will not be applied the oral stimulation protocol.
2933470|NCT03016741|Other|Arm I (abiraterone acetate, prednisone)|Patients receive standard of care treatment with GnRH agonist/antagonist therapy. Patients also receive abiraterone acetate PO and prednisone PO BID in the absence of disease progression or unacceptable toxicity. Patients then undergo cognitive assessment comprising of neuro-cognitive tests and assessments of overall quality of life, fatigue, pain, and symptoms at baseline, 3, 6, and 12 months. Patients also undergo MRI program for 40 minutes comprising of DTI, fMRI, ASL MRI, MPRAGE MRI, FLAIR MRI, and BOLD MRI at baseline and 3 months.
2933471|NCT03016741|Other|Arm II (enzalutamide)|Patients receive standard of care treatment with GnRH agonist/antagonist therapy. Patients also receive enzalutamide PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo cognitive assessment and MRI program as in Arm I.
2933472|NCT03016728|Experimental|Physical Activity|Participants in the experimental arm (i.e., physical activity) will be asked to complete the 12-week home-based physical activity program and to complete all study assessments.
2933473|NCT03016728|No Intervention|Wait-List Control|Participants in the no intervention arm (i.e., wait-list control) will be asked to maintain their usual lifestyle activities and to complete all study assessments. Participants in this arm will be provided with the 12-week home-based physical activity program in the exact same way as participants in the experimental arm (i.e., physical activity) at the end of the study.
2933474|NCT03016715|Experimental|Treatment|Sirolimus, 2% topical ointment will be used during randomization
2933475|NCT03016715|Placebo Comparator|Vehicle|A placebo topical ointment will be used during randomization.
2933476|NCT03016702|Experimental|High Risk Alzheimer's Disease|This group includes subjects with APOEe4 homozygotes, the genetic profile associated with the highest risk for late-onset AD and the next highest-risk group, APOE e3/e4 heterozygotes. To target the highest risk among the APOEe3/e4 heterozygotes in ADPR, the study team will consider TOMM40-'523 variant status. Although there is uncertainty about the independent role of TOMM40 in AD risk-stratification (especially across racial/ethnic groups), this study will use TOMM40-'523 to guide heterozygote selection based on findings that among e3/e4 heterozygotes, longer TOMM40-523 polyT sequences are associated with earlier age of onset for late-onset AD.
2933477|NCT03016702|Experimental|Low Risk Alzheimer Disease|This group includes e2/e2 homozygotes (rare) and e2/e3 heterozygotes. the genetic profile associated with low risk for late-onset development of Alzheimer's disease.
2933478|NCT03016676|Experimental|Spinal manipulation|Spinal manipulation -High velocity low amplitude thrust (HVLA), Dosages : 2 repetition at the same time, Duration-10-20 minutes. total 2 weeks.
2933479|NCT03016676|Experimental|Exercise therapy|Exercise Therapy(ET): Exercise therapy (ET) 3 program: self education, supervised exercise visits, and home exercise. Duration-45 minutes,Total number of visits 12 for 2 weeks.
2933480|NCT03016663||Breast Lipofilling Technique|Preliminary MRI breast were performed for volumetric measurement. Fat harvesting performed by same surgeon using water-assisted liposuction (WAL) and subsequent washing with buffered lactate in a standardized technique. Fat transfer performed using Berlin autologous lipotransplantation technique according to the BEAULI protocol .Patient were followed up monthly and MRI breast were repeated at 1st and 6th months after lipofilling. Clinical assessment and MRI Volumetric measurement performed using OsiriX (v7.0.3, 64 bit, Pixmeo c) software by same radiologist based on predefined operational procedure
2933481|NCT03016650|Active Comparator|Paracetamol|Patients will receive 100 mL of physiologic saline with 1 g IV acetaminophen (paracetamol) 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after percutaneous nephrolithotomy, respectively.
2933482|NCT03016650|Active Comparator|ibuprofen|Patients will receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after percutaneous nephrolithotomy, respectively.
2933483|NCT03016637|Experimental|EUS biopsy|EUS guided SharkCore (TM) biopsy of pancreatic lesions suspected of malignancy
2933484|NCT03016624|Active Comparator|OCT guided Magmaris implantation|Percutaneous coronary intervention with Magmaris
2933485|NCT03016624|Active Comparator|Angiography guided Magmaris implantation|Percutaneous coronary intervention with Magmaris
2933486|NCT03016611|Active Comparator|Chewing Ticagrelor|
2933487|NCT03016611|Experimental|Chewing Prasugrel|
2933488|NCT03016598|Experimental|Oxytocin|Phase 0 patients in MMT programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with cocaine use disorder and receiving MMT for co-occurring OUD to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
2933550|NCT03016221|Experimental|Perskindol Classic Gel|Intervention: Perskindol Classic Gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
2933489|NCT03016598|Placebo Comparator|Placebo|Phase 0 patients in MMT programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with cocaine use disorder and receiving MMT for co-occurring OUD to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
2933490|NCT03016585|Experimental|Tai Chi Training|Tai Chi exercises 3 times per wk for 12 weeks
2933491|NCT03016585|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 weeks.
2933492|NCT03016572|Experimental|Enhanced Treatment As Usual (E-TAU)|The patient will be referred for regular (Standard of Care) outpatient psychiatry/ psychology services or continue with the services that they were receiving prior to admission. They will be followed up by calling patient families at 3 months (post their initial appointment) and at 12 months. They will also have 1 research visit at 6 months (with Dr. Falcone), which they will schedule during their 3 month follow-up call; the Suicide Ideation Questionnaire (SIQ) will be administered. The patients assigned to this group will also be receiving 10 caring follow-up post cards at the following weeks and months (post-discharge from the inpatient unit): 2 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 5 months, 7 months, 9 months, 12 months, and on the patient's birthday.
2933493|NCT03016572|Experimental|TAU + Crisis Center (CC) Follow Up|Frontline Services will be administering (at least 9) crisis intervention phone calls to the patients; more calls will be made if they feel it is necessary for the safety and health of the patient. Follow up calls will ask the patient questions about following up in the future, whether they have had thoughts about suicide, whether they are in imminent danger of suicide by the end of the call, and whether the patient is stable. At the end of the call, the patient will be asked to rate their suicidality on a scale of 1 to 10.
2933494|NCT03016572|Experimental|TAU + CC Follow Up + Wraparound Services|This group will be linked with a care coordinator through Tapestry services. Wraparound is an intensive, individualized care coordination and treatment planning process that involves all of the important people in a child's life to work together to make the child successful in school, at home and in the community.
2933495|NCT03016559|Other|releasing muscle|The physical therapist placed thumbs on the quadratus lumborum to release muscle.
2933496|NCT03016546|Experimental|BEST-maCARE|BEST-maCARE intervention will be refined to accommodate our target population using pertinent information attained through interviews conducted with patients representative of the target group and stakeholders from the clinics where the intervention will be pilot tested.
2933497|NCT03016546|Active Comparator|time-matched attention control condition|Participants will be randomly assigned. The control group will receive an intervention that is time and attention equivalent to the experimental condition, though substantively neutral.
2933498|NCT03016533|Experimental|Dolutegravir Continued Access|All participants will receive dolutegravir film-coated tablets or film-coated dispersible tablets at appropriate doses selected as per their age and weight bands. For those participants who were previously receiving dolutegravir in study P1093 (parent study), dolutegravir will be supplied as film-coated tablets containing 10 mg, 25 mg and 50 mg of dolutegravir and 5 mg film-coated dispersible tablets of dolutegravir. Participants will receive dolutegravir until age-appropriate formulations are available to them from some other source, or until participant is no longer deriving benefit from treatment, or participant are discontinued, or until development of dolutegravir is terminated. The dose adjustment will be made if a participant's weight change requires a dose adjustment. Aging participants (those who crosses age-boundaries) who are taking the dispersible tablet formulation will be allowed to switch to the tablet formulation once daily if they are able to swallow the tablet.
2933499|NCT03016520|Experimental|Test drug|DWJ1392
2933500|NCT03016520|Experimental|Reference drug|DWC20164
2933501|NCT03016494|Experimental|Test/Reference Drug|DWJ1386 Tab. followed by co-administration of DWC20155 and DWC20156 Tab.
2933502|NCT03016494|Experimental|Reference/Test Drug|co-administration of DWC20155 and DWC20156 Tab. followed by DWJ1386 Tab.
2933503|NCT03016481|Active Comparator|the Community Health Worker -Personalized Support for Progress|Patients will work with a Community Health Worker (CHW) to complete a prioritization tool and meet as needed over the course of the next 6 months to navigate services and overcome barriers. In addition, patients will receive referrals to other professionals based on their prioritization and meet with the CHW at the time and place of their choice.
2933504|NCT03016481|Active Comparator|Care as Usual- Social Worker|Patients in the Care as Usual- Social Worker (CAU-SW) arm, will do intake with a social worker, who follows hospital procedures for intake and referrals, does a needs assessment, and offers safety planning in referral.
2933505|NCT03016468|Experimental|Parenteral Remodulin then Oral Treprostinil|
2933506|NCT03016455||DSA positive patients without cAMR|Presence of DSA w/o cAMR
2933507|NCT03016455||DSA positive patients with cAMR|Presence of DSA w/ cAMR
2933508|NCT03016455||Stable patients|No DSA No cAMR
2933509|NCT03016442|Experimental|Cook double balloon catheter|A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination İt is placed for 12 hours
2933510|NCT03016442|Active Comparator|Dinoprostone|10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
2933511|NCT03016416||chronic stroke patients|Participants for the study group will be recruited from the Clalit Health Services- Ben Yair Rehabilitation Center in Jaffa Israel.
2933512|NCT03016416||control group|The control group will be with equivalent age and lifestyle as the studt group. Participants for the control group will be recruited via solicitation adds at the Ben Yair Rehabilitation Center and at near-by clinics.
2933513|NCT03016403|Experimental|Stepped-Care Intervention|Intervention strategies are grounded in evidence-based Cognitive Behavioral Therapy (CBT), that includes stress management and relaxation treatment strategies and coping skills training. Treatment strategies have been adapted from the Transactional Model of Stress and Coping (TMSC), a theoretical model that predicts that individuals who are able to cope and adapt to the stress related to cancer treatment or caregiving will report less psychological distress than those unable to cope.
2933514|NCT03016403|Active Comparator|Enhanced Usual Care|Denver Health, St. Mary's and St. Joseph's hospitals provide supportive mental health care for patients such as printed materials, support groups, crisis counseling, and specialized care (e.g., psychiatric medication). Because the amount of usual mental health care that each patient receives varies at each site, the investigators will standardize and monitor the usual care arm across the three sites with an enhanced usual care condition.
2933515|NCT03016377|Experimental|iC9-CAR19 cells|The 3+3 design in adult subjects and an independent study using 3+3 design in pediatric subjects. The starting dose of 5 x 10^5 transduced cells/kg will enroll 3 adult subjects in the initial cohort. If there are no dose limiting toxicities w/in 4 weeks of the cell infusion in these 3 subjects, then the next cohort will evaluate 1 x10^6 transduced cells/kg in adults. If there is toxicity in 1/3 patients in the initial cohort, the cohort will be expanded to enroll up to 6 adult patients. If the dose level 1 is determined to be above the tolerated cell dose, de-escalation would occur to dose level -1 where subjects would receive 1 x 10^5 transduced cells/kg. All subjects will receive a lymphodepleting regimen of fludarabine and cyclophosphamide before administration of iC9-CAR19 T cells.
2933516|NCT03016364|Experimental|APP in dosage adjustment|Through the guidance of APP software, clinical doctors try to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain.
2933517|NCT03016351|Experimental|Aerobic Training|Participants will undergo a supervised endurance training program in accordance with established guidelines. Each session will be monitored by a physical therapist or exercise physiologist. Sessions will be carried out 3 times per week. During each session, participants will complete a 5 min warm-up followed by 30-45 min of endurance exercise using cycle ergometry. Intensity will be monitored using heart rate monitors during each exercise session, and each participant will receive an exercise prescription with a heart range equivalent to 65-85% of their heart rate max. Participants will be asked to complete 30 min of exercise during each session in week 1, 35 min in week 2 and 40-45 min weeks 3-8 with a 5 min cool down period.
2933518|NCT03016351|Experimental|Resistance Training|Participants will undergo a supervised resistance training program in accordance with established guidelines. Each session will be monitored by a physical therapist or exercise physiologist. Sessions will be carried out 3 times per week, 45 min per session. Muscle strength will be determined once before and once after resistance training by measuring ten repetition maximum (10 RM) for each exercise. Eight exercises (three sets; 8-12 repetitions) will be used on each of the large muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). In addition, workloads will be progressively increased if the patients can lift the weight more than 12 repetitions.
2933519|NCT03016338|Experimental|Niraparib|300 mg, orally (by mouth), once a day, every day of every 28 day cycle.
2933520|NCT03016325|Experimental|Part 1 Cohort 1 HNO Donor|
2933521|NCT03016325|Placebo Comparator|Placebo Part 1 Cohort 1|
2933522|NCT03016325|Experimental|Part 2 Cohort 2 HNO Donor- low dose|
2933523|NCT03016325|Experimental|Part 2 Cohort 2 HNO Donor- high dose|
2933524|NCT03016325|Placebo Comparator|Placebo Part 2 Cohort 2|
2933525|NCT03016312|Experimental|Atezolizumab + Enzalutamide|Participants will receive atezolizumab along with enzalutamide until investigator-assessed confirmed radiographic disease progression per PCWG3 criteria or unacceptable toxicity (up to approximately 42 months).
2933526|NCT03016312|Active Comparator|Enzalutamide|Participants will receive enzalutamide alone until investigator-assessed confirmed radiographic disease progression per PCWG3 criteria or unacceptable toxicity (up to approximately 42 months).
2933527|NCT03016299||Osteoarthritis hip joint|specimen of head of femur will be used- after total hip arthroplasty (due to Degenerative Osteoarthritis hip joint )
2933528|NCT03016299||Non-Osteoarthritis hip joint|specimen of head of femur will be used- after Hip Hemiarthroplasty -Partial replacment (due to traumatic fracture)
2933529|NCT03016286|Experimental|WBV group|whole-body vibration (WBV) group
2933530|NCT03016273|Experimental|Bladder flap|The bladder flap is made by superficially incising and dissecting the peritoneal lining to separate the urinary bladder from the lower uterine segment.
2933531|NCT03016273|No Intervention|Non bladder flap|
2933532|NCT03016260||Infliximab (Remicade®)|
2933533|NCT03016260||Adalimumab (Humira®)|
2933534|NCT03016260||Etanercept (Enbrel®)|
2933535|NCT03016260||Golimumab (Simponi®)|
2933536|NCT03016260||Certolizumab Pegol (Cimzia®)|
2933537|NCT03016260||Infliximab biosimilar (Remsima®/ Inflectra®)|
2933538|NCT03016260||Etanercept biosimilar (Benepali®)|
2933539|NCT03016260||Infliximab biosimilar (Flixabi®)|
2933540|NCT03016247|Active Comparator|Enhanced Usual Care|Group will receive a single visit with a Nutritionist for dietary and physical activity counseling
2933541|NCT03016247|Experimental|TRUST intervention|Group will receive parent-adolescent trust-building and weight self-management training.
2933542|NCT03016234|Active Comparator|Desflurane|inhalation anesthesia administration for maintenance of anesthesia
2933543|NCT03016234|Active Comparator|Propofol|intravenous anesthesia administration for maintenance of anesthesia
2933544|NCT03016221|Experimental|Axanova hot gel|Intervention: Axanova hot gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
2933545|NCT03016221|No Intervention|Axanova hot gel control|No product application. The contralateral lumbar back side acts as a Axanova hot gel control.
2933546|NCT03016221|Experimental|Axanova activ gel|Intervention: Axanova activ gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
2933547|NCT03016221|No Intervention|Axanova activ gel control|No product application. The contralateral lumbar back side acts as a Axanova activ gel control.
2933548|NCT03016221|Experimental|Perskindol Dolo Gel|Intervention: Perskindol Dolo Gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
2933549|NCT03016221|No Intervention|Perskindol Dolo Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Dolo Gel control.
2934531|NCT03009786||Elderly institutionalized subjects or outpatients|
2933551|NCT03016221|No Intervention|Perskindol Classic Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Classic Gel control.
2933552|NCT03016221|Experimental|Perskindol Cool Kühl-Gel|Intervention: Perskindol Cool Kühl-Gel is a topical product with a cooling effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
2933553|NCT03016221|No Intervention|Perskindol Cool Kühl-Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Cool Kühl-Gel control.
2933554|NCT03016221|Experimental|Dolor-X Hot Gel|Intervention: Dolor-X Hot Gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
2933555|NCT03016221|No Intervention|Dolor-X Hot Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Hot Gel control.
2933556|NCT03016221|Experimental|Dolor-X Classic Gel|Intervention: Dolor-X Classic Gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
2933557|NCT03016221|No Intervention|Dolor-X Classic Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Classic Gel control.
2933558|NCT03016221|Experimental|Dolor-X Cool Gel|Intervention: Dolor-X Cool Gel is a topical product with a cooling effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
2933559|NCT03016221|No Intervention|Dolor-X Cool Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Cool Gel control.
2933560|NCT03016208||Misoprostol vaginal insert for max. 24hrs|69 patients matching the inclusion criteria and received MVI for labour induction for a maximum of 24 hours
2933561|NCT03016208||Misoprostol vaginal insert for max. 10hrs|69 patients matching the inclusion criteria and received MVI for labour induction for a maximum of 10 hours
2933562|NCT03016182|Active Comparator|Remote Ischemic Preconditioning(RIPC)|3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg will be given to RIPC
2933563|NCT03016182|Placebo Comparator|Control|Control group without remote ischemic preconditioning
2933564|NCT03016169|Other|Treatment|All subjects will receive the Trifecta GT valve
2933565|NCT03016156|Experimental|Stratum I: Initial Evaluation Group|Initially, a small group of patients diagnosed with congenital or infantile cataracts, congenital glaucoma or retinoblastoma and who meet the eligibility criteria will undergo testing with CRADLE on Day 1.
2933566|NCT03016156|Experimental|Stratum II: Leukocoria Evaluation Group|A separate group of participants who are referred for evaluation of leukocoria or any other eye condition will undergo red reflex testing testing with CRADLE on Day 1.
2933567|NCT03016156|Experimental|Stratum III: Retinoblastoma Group|A separate group of participants with known retinoblastoma and who are undergoing ocular salvage treatments will be screened with red reflex testing using direct ophthalmoscopy on Day 1. They will also undergo testing with the CRADLE software application defined as the most effect in Stratum I on Day 1 then for three additional consecutive visits which typically occur every 3 to 4 weeks.
2933568|NCT03016143|Active Comparator|Group #1 (Allantoic Split Inactivated Seasonal flu Vaccine)|100 volunteers aged 18 to 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
2933569|NCT03016143|Active Comparator|Group #2 (Allantoic Split Inactivated Seasonal flu Vaccine)|100 volunteers over the age of 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
2933570|NCT03016143|Experimental|Group #3 (Vaccine VAXIGRIP)|50 volunteers aged 18 to 60 years, which introduced vaccine VAXIGRIP
2933571|NCT03016143|Experimental|Group #4 (Vaccine VAXIGRIP)|50 volunteers over the age of 60 years, which introduced vaccine VAXIGRIP
2933572|NCT03016130|Active Comparator|Liberalized Hospital Diet (Diet A)|Diet A would include fresh fruits and/or fresh vegetables in a liberalized hospital diet, and subjects will be encouraged to eat at least one daily serving of fresh fruits and/or vegetables.
2933573|NCT03016130|Active Comparator|Neutropenic Diet (Diet B)|Diet B is the hospital neutropenic diet.
2933574|NCT03016117|Experimental|Pecs II block and parasternal block|Pecs II block and parasternal block performed to provide anesthesia of breast, before of quadrantectomy with or without axillary dissection. Pecs II block performed at the 4th rib level and 20 ml of 0.5% Levobupivacaine injected, and parasternal block performed at the level of the 2nd and 4th intercostal space level, and 4 ml of 0.375% Levobupivacaine injected
2933575|NCT03016104|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
2933576|NCT03016104|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
2933577|NCT03016091|Experimental|Arm 1|IV Pembrolizumab 200mg, given every 3 weeks until disease progression or intolerable toxicity
2933578|NCT03016078|Other|Mepilex Border Post-Op Ag Dressing|A soft silicone foam dressing that absorbs wound exudate maintains a moist wound healing environment and has antimicrobial properties
2933579|NCT03016065|Experimental|Pea Fiber|Snacks fortified with 10 g of pea hull fiber will be administered for two weeks, followed by a two-week washout, and a two-week period with control snacks.
2933580|NCT03016065|Placebo Comparator|Control|Control snacks will provided for 2 weeks, followed by a two-week washout, and snacks with 10 g/d of pea fiber for 2 weeks.
2933581|NCT03016052|Experimental|ABMT|The attention bias modification treatment comprises of six computerized sessions, twice a week, in purpose of modulate biases in attention for threat stimuli.
2933582|NCT03016039|Experimental|Dietary supplementation|This group will receive Dietary supplementation
2933583|NCT03016039|No Intervention|conventional treatment|conventional Antibiotic treatment without curcumin supplementation
2933644|NCT03015597|Placebo Comparator|Contingency Management: attendance|"Contingency Management: attendance~Participants receive rewards contingent on attending the stop smoking clinic (independent of smoking status)"
2933645|NCT03015584||Septic patients admitted to the ICU|
2933646|NCT03015571|Experimental|NBI|Use of Narrow Band Imaging with regular care of cervical inlet patches detection.
2933584|NCT03016026|Experimental|ERAS|Preoperative education,breathing training and atomizing during the time of preoperative preparation.Shorten fasting time and carbohydrate load.The intravenous fluid therapy is restricted.Drainage and nasogastric tube are not placed (except the concerns of surgical safety).All patients undergo laparoscopic distal gastrectomy.An optimal management of acute postoperative pain is multimodal analgesia consists of surgical site infiltration, a nonsteroidal anti-inflammatory drug for postoperative three days (POD) and epidural analgesia.Early oral take and move.
2933585|NCT03016013|Placebo Comparator|Placebo plus MTX|Patients received placebo SC plus MTX weekly administered subcutaneously for 24 times.All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
2933586|NCT03016013|Experimental|Experimental: RC18 160 mg+MTX|Patients received the test group RC18 160mg plus MTX weekly administered subcutaneously for 24 times. All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.
2933587|NCT03016000|Experimental|Thalidomide|Thalidomide 50mg daily by mouth( increase 50mg after 2 weeks if tolerated until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if the patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/day, thalidomide discontinuation was allowed.
2933588|NCT03016000|Other|Observation|Observation
2933589|NCT03015987|Experimental|diode laser activated irrigation|Laser-activated irrigation (LAI) has been introduced as a powerful method enhancing irrigant action; The laser radiation produces transient cavitation in the liquid through optical breakdown by strong absorption of the laser energy. The high-power diode laser has been tested in several areas of dentistry such as bleaching, depigmentation and gingivectomy, with promising results in dentinal disinfection. The diode laser has proved to be a resource worth testing, because of the it's properties and its low cost and availability in comparison to most lasers used in endodontics.
2933590|NCT03015987|Active Comparator|ultrasonic activated irrigation|"ultrasonics have been developed to improve the penetration and effectiveness of irrigation in peripheral areas of the root canal space. The efficiency of sonic and ultrasonic devices is based on the creation of hydrodynamic phenomenon in well-shaped canals filled with an irrigant.~Such active root canal irrigation has been shown to facilitate the disruption of biofilms and make the cell membrane of bacteria more permeable to NaOCl."
2933591|NCT03015974||corticosteroid|pediatric IgA nephropathy treated with only corticosteroid
2933592|NCT03015974||corticosteroid and cyclophosphamide|pediatric IgA nephropathy treated with corticosteroid and cyclophosphamide
2933593|NCT03015974||corticosteroid and mycophenolate mofetil|pediatric IgA nephropathy treated with corticosteroid and mycophenolate mofetil
2933594|NCT03015961|Active Comparator|EXPAREL admixed with bupivacaine HCl|
2933595|NCT03015961|Placebo Comparator|bupivacaine HCl|
2933596|NCT03015948|Experimental|2.5mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 2.5 mg SHR4640 (n=8) or placebo (n=2)
2933597|NCT03015948|Experimental|10mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 10mg SHR4640 (n=8) or placebo (n=2) 10mg.
2933598|NCT03015948|Experimental|20mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 20mg SHR4640 (n=8) or placebo (n=2) .
2933599|NCT03015948|Experimental|Placebo|For each dose cohort, 10 subjects will be randomized in a 4:1 ratio to receive a single dose of either SHR4640 (n=8) or placebo (n=2)
2933600|NCT03015948|Experimental|5mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 5 mg SHR4640 (n=8) or placebo (n=2)
2933601|NCT03015935||Optical|visual-assisted entry
2933602|NCT03015935||Veress|Veress entry
2933603|NCT03015922|Experimental|Lenalidomide or pomalidomide, plus REOLYSIN|"Lenalidomide capsules, oral, maximum 10mg daily on days 1-21 of 28-day cycles. OR Pomalidomide capsules, oral, maximum 1mg daily on days 1-21 of 28-day cycles.~Plus (all patients):~REOLYSIN® , intravenous infusion, maximum 3x10^10 TCID50 on days 1, 8, 15 and 22 of 28-day cycles."
2933604|NCT03015909|Other|Eutropin pen inj.|
2933605|NCT03015896|Experimental|Treatment (lenalidomide, nivolumab)|Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 60 minutes on days 1 and 15 of courses 1-4 and on day 1 of courses 5-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2933606|NCT03015883|Experimental|Diffusing Alpha Radiation Emitters Therapy (DaRT)|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seed Devices
2933607|NCT03015870|Experimental|Feedback|Behavioral: Vocal exercise with real-time feedback.
2933608|NCT03015870|Active Comparator|Recording|Behavioral: Vocal exercise with recording
2933609|NCT03015857|Active Comparator|phenylephrine,|- Phenylephrine group (n=100): will receive 100 mcg phenylephrine as a single bolus just after intrathecal injection of 10 mg bupivacaine plus 20 mcg fentanyl. The dose will be diluted in 5 mL and given over seconds. A continuous infusion with placebo (normal saline) will start after the first bolus.
2933610|NCT03015857|Active Comparator|norepinephrine|- Norepinephrine group (n=100): will receive bolus of norepinephrine (10 mcg) directly after spinal block using 10 mg bupivacaine plus 20 mcg fentantanyl followed by continuous infusion of norepinephrine with a rate of 0.1 mcg/kg/min till delivery of the fetus.
2933611|NCT03015831|Active Comparator|Colchicine|Intervention by administering an active copmarator of 1 mg colchicine one day pre op and 0.5 mg daily after surgery until discharge
2933612|NCT03015831|Placebo Comparator|Placebo Oral Tablet|Identical tablet (placebo) administered in a similar way as that in the active comparator arm
2933613|NCT03015818|Experimental|18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT|
2933614|NCT03015805|Experimental|Contingency Management|This group will receive regular probation services but will also receive the Contingency Management program for substance abuse from their juvenile probation officer during regular meetings.
2933615|NCT03015805|Active Comparator|Probation as Usual|This group will receive regular services that are usually provided by juvenile probation officers.
2933647|NCT03015571|Placebo Comparator|WL|Use of High Definition White Light (WL) with regular care of cervical inlet patches detection.
2933616|NCT03015792|Experimental|Treatment (ibrutinib, lenalidomide, dexamethasone)|"PHASE I: Patients receive ibrutinib PO on days 1-28, lenalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Beginning course 25, patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 84 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive ibrutinib and dexamethasone as in phase I and lenalidomide PO on days 1-21 beginning course 2. Beginning course 25, patients receive lenalidomide and dexamethasone as in phase I."
2933617|NCT03015779|Experimental|experimental group|cultured autologous oral mucosal epithelial cell sheet
2933618|NCT03015766|Experimental|Auricular acupressure therapy|Participants in the treatment group will received AAT on five active acupoints including Acup.1. Shen Men (Spiritual Gate, TF4), Acup.2. Jiao Gan (Sympathetic autonomic, AH6a), Acup.3. Xin (Heart, CO15), Acup.4. Pi Zhi Xia (Subcortex, AT4), Acup.5. Nei Fen Mi (Endocrine, CO18)
2933619|NCT03015766|Sham Comparator|sham auricular acupressure therapy|Participants in the control group (SAA group) will receive auricular acupressure on five Helix points (HX 5-9), which were clearly remote from the inner ear area. These points have no evidence for insomnia management.
2933620|NCT03015753|Experimental|Tai Chi training|The participants in this arm will receive 12-week Tai Chi training (1 hour per day, 5 days per week).
2933621|NCT03015753|Other|Waiting list control group|Participants in this arm will be asked to maintain their usual lifestyles and exercises for 12 weeks. At the end of the trial , the participants will be offered Tai Chi training similar as Tai Chi group.
2933622|NCT03015740|Experimental|MGCD516 + Nivolumab|"Participants treated with a pre-specified daily oral dose of MGCD516 determined by the Lo-EffTox method on Day 1 of the study.~Following 2 weeks of MGCD516 monotherapy, Nivolumab additionally initiated on Day 1 of Cycles 2 and beyond.~Participants continue to receive combination therapy of MGCD516 plus Nivolumab until disease progression or unacceptable treatment-related toxicity."
2933623|NCT03015727|Experimental|IC+RT group|3 cycles of TP neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2 and cisplatin 75mg/m2. And then radiation using IMRT/TOMO without concurrent chemotherapy.
2933624|NCT03015727|Active Comparator|IC+CCRT group|3 cycles of TP neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2 and cisplatin 75mg/m2.And then chemoradiation using IMRT/TOMO with 2 cycles of cisplatin concurrent chemotherapy at 100mg/m2.
2933625|NCT03015714|Active Comparator|MIRT|Patients in this group will undergo a 4-week Multidisciplinary Intensive Rehabilitation Treatment (MIRT).
2933626|NCT03015714|Active Comparator|MIRT-AT|Patients in this group will undergo a 4-week Multidisciplinary Intensive Rehabilitation Treatment associated with Aquatic Therapy (MIRT-AT).
2933627|NCT03015701|Experimental|Arm 1|Mifepristone 200 mg orally daily for two years
2933628|NCT03015701|Placebo Comparator|Arm 2|Placebo orally daily for two years
2933629|NCT03015688||knee OA|OA diagnosis was on the basis of the diagnosis and treatment guideline of the American Academy of Orthopedic Surgeons Participants who met the following criteria were excluded：the knee OA concomitant with hip OA, suppurative and rheumatoid arthritis, gout patients, patients who underwent knee arthroscopy surgery within 6 months, bilateral or unilateral knee replacements, the knee joint trauma patients, histories of glucocorticoid and/or sterol hormones.
2933630|NCT03015688||Control|"no often have pain, aching or stiffness in your Left/right knee during last month,no Left/right knee trauma history,no histories of glucocorticoid and/or sterol hormones normal knee X-ray images,"
2933631|NCT03015675|Experimental|Ascorbic Acid with mFOLFOX6 group|"Ascorbic Acid with mFOLFOX6 Ascorbic Acid (20g/day, D1-3) every 2 weeks~mFOLOX6:~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
2933632|NCT03015675|Active Comparator|mFOLFOX6 group|"mFOLOX6:~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
2933633|NCT03015662|Experimental|Dry Needling Therapy|Active or latent MTrPs (myofascial trigger points) will be remarked in black or red, respectively. Active or latent MTrPs will be needled in the same position employed by the blinded examiner for diagnosis. All dry needling procedures will be performed by the same investigator, and the technique used will be similar to the Hong method, using sterile Ener-Qi needles (EQ 1661) for the punction of TrPs (trigger points).
2933634|NCT03015662|Active Comparator|Myofascial Release Therapy|Patients will develope a myofascial therapy protocol, administered in the following order: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
2933635|NCT03015649|Experimental|SCOUT device|"The study population consists of 25 - 35 adult surgical patient volunteers who plan to have definitive breast cancer surgery at Memorial Healthcare System (MHS) Hospitals after neoadjuvant treatment.~The investigator will identify subjects who meet inclusion/exclusion criteria, obtain patient's consent and schedule the subject for the SAVI SCOUT Surgical Guidance System procedure. All study participants will receive the same treatment assignment, i.e. lesion localization with the SCOUT device 31 - 365 days prior to surgery. Neoadjuvant treatment decisions will be determined by patient's medical oncologist."
2933636|NCT03015636|Experimental|Behavioral: Adjusted CBT-i for ADHD|Cognitive Behavioral group intervention for sleep problems in ADHD, based on Cognitive Behavioral Therapy for insomnia and behavioral treatment for Sleep Phase Disorders.
2933637|NCT03015636|Other|Treatment as Usual|Treatment as Usual. (After about ten weeks, participants in this condition are offered the experimental group treatment.)
2933638|NCT03015623|Experimental|Low dose cohort|SBI-101 device containing 250 million MSCs
2933639|NCT03015623|Experimental|High dose cohort|SBI-101 device containing 750 million MSCs
2933640|NCT03015623|Sham Comparator|Control|Sham device containing no MSCs
2933641|NCT03015610|Placebo Comparator|Placebo|participants will receive oral blinded matched placebo once daily
2933642|NCT03015610|Experimental|Genotype-guided Lansoprazole|participants will receive oral blinded commercially available lansoprazole once daily with a dose appropriate for the participant's metabolizer phenotype
2933643|NCT03015597|Experimental|Contingency Management: smoking|"Contingency Management: smoking~Participants receive rewards contingent on biochemical verification of tobacco smoking abstinence"
2933648|NCT03015571|Experimental|NBI increased care|Use of Narrow Band Imaging with increased care of cervical inlet patches detection.
2933649|NCT03015571|Placebo Comparator|WL increased care|Use of High Definition White Light (WL) with increased care of cervical inlet patches detection.
2933650|NCT03015558|Experimental|patients|
2933651|NCT03015558|Active Comparator|healthy subjects|
2933652|NCT03015545|Active Comparator|Control|This group will stand with knee flexion 60 degrees on the same vibration platform for 60 seconds for 5 times with 60-seconds rest interval, but no vibration will be given.
2933653|NCT03015545|Active Comparator|High intensity whole body vibration|This group will stand with knee flexion 30 degrees on the same vibration platform for 90 seconds. The frequency of the vibration signals will be set at 40Hz.
2933654|NCT03015532|Experimental|Cohort 1 Group 1|HTX-011 (200 mg)
2933655|NCT03015532|Placebo Comparator|Cohort 1 Group 2|Saline placebo
2933656|NCT03015532|Active Comparator|Cohort 1 Group 3|Bupivacaine HCl without epinephrine 0.25% (125 mg)
2933657|NCT03015532|Experimental|Cohort 2 Group 1|HTX-011 (400 mg)
2933658|NCT03015532|Experimental|Cohort 2 Group 2|HTX-011 (400 mg) plus ropivacaine 0.5% (50 mg)
2933659|NCT03015532|Placebo Comparator|Cohort 2 Group 3|Saline placebo
2933660|NCT03015532|Active Comparator|Cohort 2 Group 4|Bupivacaine HCl without epinephrine 0.25% (125 mg)
2933661|NCT03015519|Experimental|Albiglutide cohort 1: Part A|Approximately 12 eligible subjects, aged between 14 to 18 years, will receive a single dose of 30 mg albiglutide post-randomization.
2933662|NCT03015519|Placebo Comparator|Placebo cohort 1: Part A|Approximately 3 eligible subjects, aged between 14 to 18 years, will receive a single dose of matching placebo post-randomization.
2933663|NCT03015519|Experimental|Albiglutide cohort 2: Part A|Approximately 12 eligible subjects, aged between 10 to 14 years, will receive a single dose of 30 mg albiglutide post-randomization.
2933664|NCT03015519|Placebo Comparator|Placebo cohort 2: Part A|Approximately 3 eligible subjects, aged between 10 to 14 years, will receive a single dose of matching placebo post-randomization.
2933665|NCT03015519|Experimental|Albiglutide: Part B|Approximately 120 eligible subjects, aged between 10 to 18 years, will receive albiglutide 30 mg once weekly post-randomization.
2933666|NCT03015519|Placebo Comparator|Placebo: Part B|Approximately 60 eligible subjects, aged between 10 to 18 years, will receive matching placebo once weekly post-randomization.
2933667|NCT03015506|Active Comparator|White Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber).
2933668|NCT03015506|Experimental|Pea Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) pea flour.
2933669|NCT03015506|Experimental|Green Lentil Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) green lentil flour.
2933670|NCT03015506|Experimental|Red Lentil Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) red lentil flour.
2933671|NCT03015506|Experimental|Chickpea Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) chickpea flour.
2933672|NCT03015493|Experimental|Neural mobilization and traction|Patients in this group are treated with neural mobilization techniques combined with cervical traction
2933673|NCT03015493|Experimental|Traction group|Patients in this group are treated with cervical traction
2933674|NCT03015493|No Intervention|Control group|Patients in this group comprise the control group and are not treated with any intervention
2933675|NCT03015480|Experimental|Remote counseling|This group of people will be asked to track dietary information on MyFitnessPal and receive remote dietary counseling with a dietitian.
2933676|NCT03015467|Active Comparator|treatment for part 1|Fecal Microbiota Transplantation (FMT) and traditional treatments according to associated guidelines will be used in patients with severe acute pancreatitis(SAP) in part 1.
2933677|NCT03015467|Placebo Comparator|Placebo for part 2|The traditional treatments and normal saline (NS) according to associated guidelines will be used in patients with severe acute pancreatitis(SAP) in part 2.
2933678|NCT03015454|Experimental|With InSight|Healthcare provider receives an alert from InSight for patients trending towards severe sepsis. Healthcare provider also receives information from the severe sepsis detector in the UCSF electronic health record.
2933679|NCT03015454|Active Comparator|Without InSight|Healthcare provider does not receive any alerts from InSight. Healthcare provider receives information from the severe sepsis detector in the UCSF electronic health record.
2933680|NCT03015441|Other|Arm 1: Fermented milk product containing probiotics|
2933681|NCT03015441|Other|Arm 2: Milk-based non-fermented dairy product|
2933682|NCT03015428|Experimental|Psychoeducation|"Interventions:~Give information Teach and train strategies"
2933683|NCT03015415|Experimental|surgical|Patients undergoing surgical elbow arthrolysis. Elbow Open Arthrolyses
2933684|NCT03015415|Experimental|non-surgical|Patients submitted to a non-surgical rehabilitation protocol using splints Non-surgical intervention
2933685|NCT03015402|Experimental|Sodium Nitrite|
2933686|NCT03015402|Placebo Comparator|Placebo|
2933687|NCT03015389||Barrett's associated esophageal dysplasia|
2933688|NCT03015350||two lung ventilation of Sevoflurane|In GroupSa, 1,5 % sevoflurane will be apply continuously and blood samples will be taken at intervals of 10 minutes starting from the 40th minute.
2933689|NCT03015350||one lung ventilation of Sevoflurane|In GroupSa, 1,5 % sevoflurane will be apply continuously and first samples will taken at the 40. minutes and collection of blood samples will be continue at intervals of 10 minutes after one lung ventilation started.
2933690|NCT03015350||two lung ventilation of Desflurane|In GroupSa, 6 % desflurane will be apply continuously and blood samples will be taken at intervals of 10 minutes starting from the 40th minute.
2933691|NCT03015350||one lung ventilation of desflurane|In GroupSa, 6 % desflurane will be apply continuously and first samples will taken at the 40. minutes and collection of blood samples will be continue at intervals of 10 minutes after one lung ventilation started.
2933692|NCT03015337|Experimental|New Physical Education Instructions|
2933693|NCT03015324|Experimental|Hydroxychloroquine|Hydroxychloroquine
2933694|NCT03015311|Experimental|Intensive BP control|SBP within 110 - <130 mm Hg. Participants randomized into the Intensive BP control arm will have a goal of SBP 110 - <130 mm Hg.
2933695|NCT03015311|Active Comparator|Standard BP control|SBP within 130 - <150 mm Hg. Participants randomized into the Intensive BP control arm will have a goal of SBP 130 - <150 mm Hg.
2933696|NCT03015298||Gastric cancer|Each patient will perform a PET/MRI examination,and in the next day,a PET/CT.All the examinations are performed before the operation.
2933697|NCT03015285|Experimental|Anxiety Sensitivity Cognitive Therapy|Participants in the Cognitive Behavioural Therapy for AS condition will complete 8 weekly 50-minute therapy sessions and will be asked to continue with some parts of the intervention (i.e., interoceptive exposure) independently for the next 4 weeks, with short weekly check-ins by phone with their therapist.
2933698|NCT03015285|Active Comparator|Disorder specific Cognitive Therapy|Participants in the disorder-specific Cognitive Behavioural Therapy intervention will receive 12 weekly 50-minute therapy sessions following established, evidence-based protocols for each of the disorders included in the study.
2933699|NCT03015272|Experimental|Auditory-Motor Mapping Training (AMMT)|Auditory-Motor Mapping Training (AMMT) is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention.
2933700|NCT03015272|Active Comparator|Speech-Repetition Therapy (SRT)|Speech-Repetition-Therapy (SRT) is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT
2933701|NCT03015259|Experimental|Treatment 1|Generic Budesonide/Formoterol fumarate dihydrate (80mcg/4.5mcg) inhalation aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
2933702|NCT03015259|Active Comparator|Treatment 2|Symbicort (Budesonide/Formoterol fumarate dihydrate) inhalation aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
2933703|NCT03015259|Placebo Comparator|Treatment 3|Placebo inhalation aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
2933704|NCT03015246|Experimental|Buprenorphine-Naloxone|"Participants will be maintained on Buprenorphine-Naloxone (Zubsolv™) sublingual tablets.~Every participant will be maintained two weeks at each dosage level, in randomized order, on Buprenorphine-Naloxone (Zubsolv™) doses of 1.4/0.36 mg/day, 4.2/1.08 mg/day, and 12.8/3.16 mg/day."
2933705|NCT03015246|Other|Buprenorphine-Naloxone Stabilization|After completing the three Buprenorphine-Naloxone maintenance-dose conditions, each participant will be stabilized on a daily dose of Buprenorphine-Naloxone 4.2/1.08 mg for one week, then the daily dose will be tapered over 3 weeks to 2.8/0.72 mg (week 1), 1.4/0.36 mg (week 2) and 0/0 mg (week 3).
2933706|NCT03015220|Experimental|Oral semaglutide 3 mg|
2933707|NCT03015220|Experimental|Oral semaglutide 7 mg|
2933708|NCT03015220|Experimental|Oral semaglutide 14 mg|
2933709|NCT03015220|Active Comparator|Dulaglutide 0.75 mg|
2933710|NCT03015207|Experimental|NNC0194-0499|Injected s.c. /subcutaneously (under the skin)
2933711|NCT03015207|Placebo Comparator|Placebo|Injected s.c. /subcutaneously (under the skin)
2933712|NCT03015194|Experimental|Arm 1|The LAMPOON procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TMVR. These are all guided by fluoroscopy combined with TEE or intracardiac echocardiography.
2933713|NCT03015181|Experimental|Grp 1 and Grp 2|Group 1:1mg/kg IV on Day 0; Group 2:5mg/kg IV on Day 0
2933714|NCT03015181|Experimental|Grp 3 and Grp 6|Group 3: 5mg/kg SC on Day 0; Group 6: 5mg/kg SC on Day 0, Week 12 &amp; Week 24
2933715|NCT03015181|Experimental|Grp 4 and Grp 7|Group 4: 20mg/kg IV on Day 0; Group 7: 20mg/kg IV on Day 0, Week 12 &amp; Week 24
2933716|NCT03015181|Experimental|Grp 5|40mg/kg IV on Day 0
2933717|NCT03015168||Observational Group|Patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
2933718|NCT03015155|Experimental|Hypothermia|Infusion of Cold Saline into Local Infarction Myocardium. A standard working guide-wire, Runthrough NS (Terumo, Japan), is advanced into the distal part of the target coronary artery by using angiography. Compared to the standard PPCI after the balloon expansion, the aspirated catheter (Diver C.E. MAX, Italy) is firstly placed at the location of the distal occlusion lesion to achieve local myocardial hypothermia by infusing the cold saline (4℃, 2.5ml/min, 5min). Then we retract the aspirated catheter, following the balloon expansion and the drug eluting stent implanting. Subsequently, the infusion catheter is tautologically placed at the location of the opened occlusion, within the stent, to persistently perfuse the infarct myocardium with cold saline (4℃, 2.5ml/min, 15min).
2933719|NCT03015155|No Intervention|Standard treatment|We place a standard working guide-wire, Runthrough NS (Terumo Corporation, Japan), crossover the criminal lesion of to the distal of the target coronary artery after angiography. Then the pre-dilated balloon is placed at the occluded lesion site to expand the criminal vessel without hypothermia intervention. The operation will be completed when the flow of target coronary artery achieves TIMI class 3 after the drug eluting stent implanting.
2933720|NCT03015142||New image-guidance software|Patients in this group will undergo spine surgery with new image-guidance software application. A sample size of 240 screws will be required, therefore approximately 15-25 patients will be needed to reach the 240 screw placements.
2933721|NCT03015129|Experimental|Durvalubmab|Patients will receive intravenous infusion of durvalumab 1500mg Fixed Dose every 4 weeks until patient develops a loss of clinical benefit or experiences unacceptable toxicities.
2933722|NCT03015129|Experimental|Durvalubmab + Tremelimumab|Patients will receive 1500mg Flat Dose durvalubmab via intravenous infusion every 4 weeks for up to 4 cycles and 75mg tremelimumab via intravenous infusion every 4 weeks for up to 4 cycles, and then continue 1500mg Fixed Dose durvalumab every 4 weeks until patient develops a loss of clinical benefit or experiences unacceptable toxicities.
2933723|NCT03015116|Active Comparator|Usual Care|Participants will complete 6 weeks of stretching and cryotherapy
2933819|NCT03014505|Active Comparator|The traditional treatments|
2933724|NCT03015116|Experimental|PBM 10 Watts|Participants will complete 6 weeks of stretching and cryotherapy, plus 9 treatments of PBM (810/980 nm continuous wave, 10 Watts power) over 3 weeks
2933725|NCT03015116|Experimental|PBM 25 Watts|Participants will complete 6 weeks of stretching and cryotherapy, plus 9 treatments of PBM (810/980 nm continuous wave, 25 Watts power) over 3 weeks
2933726|NCT03015103|Experimental|Experimental group|This study is designed as a single group assignment, because the 4 dressings (3 placebos and 1 containing the product) will be applied in all volunteers. This means that the region in which the tested product will be applied will be compared with the other placebo regions in the same volunteer.
2933727|NCT03015090|Experimental|theophylline|
2933728|NCT03015077|Active Comparator|Glutamine|"intake of 5g glutamine and 10g maltodextrin. Oral glutamine is a food additive issued by food and drug government in Taiwan with number 009929.L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin.~The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy."
2933729|NCT03015077|Placebo Comparator|placebo|intake of 15g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
2933730|NCT03015064||Myocardial Infarction|Patients with first myocardial Infarction
2933731|NCT03015051|Experimental|High flow|High flow (2 L/kg/min) nasal cannula oxygen therapy
2933732|NCT03015051|Active Comparator|Low flow|Low flow (max 3 L/min) oxygen therapy
2933733|NCT03015025||Stable treatment with acenocoumarol|Patients in stable anticoagulant treatment with acenocoumarol for auricular fibrillation, venous thromboembolic disease and/or cardiac valve replacement.
2933734|NCT03015012|Active Comparator|Standard Nutrition Intervention (SNI)|Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
2933735|NCT03015012|Experimental|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
2933736|NCT03014999|Experimental|High frequency rTMS|Volunteers will be submitted to high frequency of repetitive transcranial magnetic stimulation (20Hz)
2933737|NCT03014999|Experimental|Low frequency rTMS|Volunteers will be submitted to low frequency of repetitive transcranial magnetic stimulation (1Hz)
2933738|NCT03014999|Sham Comparator|Sham rTMS|Volunteers will be submitted to sham session of repetitive transcranial magnetic stimulation
2933739|NCT03014986||Patients who receive HCV treatment|HSCT patients with HCV who are receiving (or has recently received) HCV treatment
2933740|NCT03014986||Patients who do not receive HCV treatment|HSCT patients with HCV who have not received treatment
2933741|NCT03014973|Experimental|prostate cancer patients resistant to castration|
2933742|NCT03014973|Experimental|patients naif of hormonal treatment|
2933743|NCT03014960|Experimental|Experimental Condition|Online Cognitive Behavioral Therapy for Insomnia Intervention
2933744|NCT03014960|No Intervention|Control Condition|No intervention
2933745|NCT03014947|Experimental|MSB11022|
2933746|NCT03014947|Active Comparator|US-licensed Humira|
2933747|NCT03014947|Active Comparator|EU-approved Humira|
2933748|NCT03014934||Cases: Prior Invasive Aspergillosis|History of probable or proven Invasive Aspergillosis according to EORTC 2008 criteria
2933749|NCT03014934||Controls: No prior proven Invasive Aspergillosis|Patients really negative for Invasive Aspergillosis and those with possible Invasive Aspergillosis
2933750|NCT03014921|Placebo Comparator|placebo injection group|saline solution injection as placebo
2933751|NCT03014921|Active Comparator|iron injection group|iron injection
2933752|NCT03014908||NMR-T1DM|type 1 diabetic children and adolescents
2933753|NCT03014908||NMR-C|non-diabetic children and adolescents
2933754|NCT03014895|Placebo Comparator|Cohort 1: Placebo|Intravenous placebo infusion
2933755|NCT03014895|Experimental|Cohort 1: E3112|Intravenous E3112 infusion
2933756|NCT03014895|Placebo Comparator|Cohort 2: Placebo|Intravenous placebo infusion
2933757|NCT03014895|Experimental|Cohort 2: E3112|Intravenous E3112 infusion
2933758|NCT03014895|Placebo Comparator|Cohort 3: Placebo|Intravenous placebo infusion
2933759|NCT03014895|Experimental|Cohort 3: E3112|Intravenous E3112 infusion
2933760|NCT03014895|Placebo Comparator|Cohort 4: Placebo|Intravenous placebo infusion
2933761|NCT03014895|Experimental|Cohort 4: E3112|Intravenous E3112 infusion
2933762|NCT03014895|Placebo Comparator|Cohort 5: Placebo|Intravenous placebo infusion
2933763|NCT03014895|Experimental|Cohort 5: E3112|Intravenous E3112 infusion
2933764|NCT03014882|Other|Antioxidant treatment|
2933765|NCT03014869|Experimental|High flow nasal cannula|High flow nasal cannula(OptiflowTM); Flow 25-60 L/min is set according to patients' comfort; FiO2 is adjusted to maintain peripheral capillary oxygen saturation(SpO2) 90-95%; temperature is set at 37 degree centigrade.
2933766|NCT03014869|No Intervention|Noninvasive positive ventilation|Parameters are set according to NPPV protocols
2933767|NCT03014856||OB-NMR|overweight and obese children and adolescents
2933768|NCT03014856||NMR-C|normal-weight children and adolescents
2933820|NCT03014492|Experimental|Collar Group|Soccer girls that wore the collar device
2933821|NCT03014492|No Intervention|No Collar Group|soccer girls that did not wear the collar
2933769|NCT03014843|Active Comparator|Naloxone|Administration of a centrally acting µ-opioid receptor antagonist Naloxone (20µg/kg/h intravenous infusion after 0.4mg bolus) to investigate the effect of esophageal sensitivity assessed by multimodal esophageal stimulation.
2933770|NCT03014843|Active Comparator|Methylnaltrexone bromide|Administration of a peripherally acting µ-opioid receptor antagonist Methylnaltrexone (12mg/0.6mL subcutaneous injection) to investigate the effect of esophageal sensitivity assessed by multimodal esophageal stimulation.
2933771|NCT03014843|Placebo Comparator|Placebo|Administration of placebo injection (1mL 0.9% saline IV or 0.6 IM) as a control condition to compare to the administration of naloxone or methylnaltrexone bromide in the multimodal esophageal stimulation protocol.
2933772|NCT03014830|Active Comparator|Alirocumab|Subjects will receive alirocumab for 6 weeks.
2933773|NCT03014830|Placebo Comparator|Placebos|Subjects will receive placebo for 6 weeks.
2933774|NCT03014817|Experimental|Ultrasonically activated scalpel|Dissection with ultrasonically activated scalpel. Direction of dissection undecided but by experience most naturally fundus first.
2933775|NCT03014817|Active Comparator|Electrocautery|Dissection with electrocautery. Direction of dissection undecided but by experience most naturally cystic duct first.
2933776|NCT03014804|Experimental|Group I (DCVax-L)|Patients receive autologous dendritic cells pulsed with tumor lysate antigen vaccine ID on days 0, 7, 14, and weeks 4, 6, 8, 11, 14, 17 and 20.
2933777|NCT03014804|Experimental|Group II (DCVax-L, nivolumab)|Patients receive autologous dendritic cells pulsed with tumor lysate antigen vaccine as in Group I, and nivolumab IV over 30 minutes on days 0, 14, and weeks 4, 6, 8, 11, 14, 17, and 20.
2933778|NCT03014791||Healthy Volunteers|"No IMP to be administered, only challenge agents as part of the physiological assessments.~Large artery endothelial function:~Glyceryl trinitrate 500 μg (Sublingual administration to stimulate endothelium-independent vasodilatation)~Salbutamol 2 x 200 μg (Administered by spacer device to stimulate endothelium-dependent vasodilatation)~Forearm blood flow~Acetylcholine: 7.5μg/min, 15μg/min and 30μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-dependent vasodilatation)~Sodium nitroprusside: 3μg/min, 10μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-independent vasodilatation)~LNMMA: 2μmol/min, 4μmol/min (Intra-arterial administration via brachial artery to block basal nitric oxide production)"
2933779|NCT03014791||Hypertensive Patients (Case-control)|"No IMP to be administered, only challenge agents as part of the physiological assessments.~Large artery endothelial function:~Glyceryl trinitrate 500 μg (Sublingual administration to stimulate endothelium-independent vasodilatation)~Salbutamol 2 x 200 μg (Administered by spacer device to stimulate endothelium-dependent vasodilatation)~Forearm blood flow~Acetylcholine: 7.5μg/min, 15μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-dependent vasodilatation)~Sodium nitroprusside: 3μg/min, 10μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-independent vasodilatation)~LNMMA: 2μmol/min, 4μmol/min (Intra-arterial administration via brachial artery to block basal nitric oxide production)"
2933780|NCT03014791||Hypertensive Patients (Cross-sectional)|"No IMP to be administered, only challenge agents as part of the physiological assessments.~Large artery endothelial function:~Same challenge agents as healthy volunteer and hypertensive patient (Case-control) arms~Forearm blood flow Same challenge agents as healthy volunteer and hypertensive patient (Case-control) arms~Recruited from community-based cohort studies - CLEAREST and ACCT~Equal recruitment across the following parameters:~Age: 3 groups <30, 30-60, >60 years~Gender~BMI: 3 groups <25, 25-30, >30 Kg/m2"
2933781|NCT03014778|Experimental|The Chlorhexidine gluconate arm|35 women undergoing surgery will be vaginally pre-op washed by 0.05% chlorhexidine gluconate, 50 cc for 1 minute. 3 samples will be taken for culture: before, 10 minutes and 30 minutes after the wash.
2933782|NCT03014778|Active Comparator|The Povidone iodine arm|35 women undergoing surgery will be vaginally pre-op washed by 10% Povidone iodine, 50 cc for 1 minute. 3 samples will be taken for culture: before, 10 minutes and 30 minutes after the wash.
2933783|NCT03014752|Active Comparator|Classical ketogenic diet|The classical ketogenic diet with 4:1 ketogenic ratio, each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced.
2933784|NCT03014752|Active Comparator|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
2933785|NCT03014726|Experimental|DCB Treatment|Stricture patients treated by DCB
2933786|NCT03014713|Active Comparator|Control Group|Patients in this group receive intravenous Patient-Controlled Analgesia(PCA) pump after surgery.The intravenous PCA protocol is dezocine 0.01mg/kg/h,flubiprofen 0.05mg/kg/h.
2933787|NCT03014713|Experimental|Dexmedetomidine Group|Patients in this group receive intravenous Patient-Controlled Analgesia(PCA) pump after surgery.The intravenous PCA protocol is dezocine 0.01mg/kg/h,flubiprofen 0.05mg/kg/h,dexmedetomidine 0.1μg/kg/h.
2933788|NCT03014700|Active Comparator|Cryoprecipitate Arm|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
2933789|NCT03014700|Active Comparator|Fibrinogen Concentrate Arm|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
2933790|NCT03014687|Placebo Comparator|Standard Nasal Care|One dose of preoperative intravenous (iv) antibiotic (e.g., cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg will be administered within 60 minutes of start of surgery. Repeat intraoperative dosing of antibiotics is permitted if length of surgery exceeds recommended dosing interval. IV antibiotic dosing schedules: Cefazolin 1 gm iv Q6 hr -or- Cefuroxime 1.5gm iv Q8 hr -or- Clindamycin 300 mg iv Q12 hr. Postoperative antibiotics: Study participants will receive one dose only of postoperative intravenous antibiotic (e.g., cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg [cephalosporin allergic patients]) according to the recommended dosing schedule described above. This dose of antibiotics is in addition to the preoperative dose. Placebo PO BID (twice daily) will commence on the morning of postoperative day 1 and continue for 7 days.
2933822|NCT03014479|Active Comparator|Trelagliptin|Trelagliptin 100 mg is orally administered once weekly. Trelagliptin 50 mg is orally administered once weekly in patients with moderate renal impairment.
2933823|NCT03014479|Active Comparator|Daily DPP-4 inhibitor|An inhibitor is orally administered at the dosage and administration in the package inserts for each drug
2933824|NCT03014466|Active Comparator|Tablet|Preoperative patients will utilize a video tablet for addressing pre anesthesia anxiety
2933791|NCT03014687|Experimental|Standard Nasal Care + Oral Antibiotics|One dose of preoperative iv antibiotic (cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg) will be administered within 60 minutes of start of surgery. Repeat intraoperative dosing of antibiotics is permitted if length of surgery exceeds recommended dosing interval. IV antibiotic dosing schedules: Cefazolin 1 gm iv Q6 hr -or- Cefuroxime 1.5gm iv Q8 hr -or- Clindamycin 300 mg iv Q12 hr. Participants will receive 1 dose only of postoperative iv antibiotic (cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg [cephalosporin allergic patients]) according to the recommended dosing schedule described above. This dose of antibiotics is in addition to the preoperative dose. Oral antibiotics will commence on the morning of postoperative day 1; this group will receive oral antibiotics (cefdinir [Omnicef®] 300 mg PO BID or trimethoprim/sulfamethoxazole [Bactrim DS™] PO BID for cephalosporin intolerant patients) for 7 days.
2933792|NCT03014674|Experimental|Liquid mepolizumab in safety syringe|Subjects will receive a single dose of 100 mg liquid mepolizumab administered subcutaneously using a prefilled syringe within a safety syringe according to randomization.
2933793|NCT03014674|Experimental|Liquid mepolizumab in an autoinjector|Subjects will receive a single dose of 100 mg liquid mepolizumab administered subcutaneously using a prefilled autoinjector, according to randomization.
2933794|NCT03014674|Active Comparator|Lyophilised mepolizumab from vial|Subjects will receive a single dose of 100 mg reconstituted lyophilized mepolizumab manually administered subcutaneously according to randomization
2933795|NCT03014661||Single group study|Single Group study investigating retrospectively the Quality of life of patients with pollinosis under or after specific immunotherapy with Pollinex quattro
2933796|NCT03014648|Experimental|Atezolizumab|"Atezolizumab will be given on day 1 of a 21-day cycle at 1200 mg IV over 60 (plus or minus 15) minutes for first infusion; can be decreased to 30 (plus or minus 10) minutes for subsequent cycles.~Atezolizumab will be given as long as the patient continues to experience clinical benefit in the opinion of the investigator or until unacceptable toxicity, symptomatic deterioration attributed to disease progression.~There will be no dose reduction for Atezolizumab. Patients may temporarily suspend study treatment for up to 84 days beyond the scheduled date of delayed infusion if study drug-related toxicity requiring dose suspension is experienced. If Atezolizumab is held because of adverse events for greater than 84 days beyond the scheduled date of infusion, the patient will be discontinued from Atezolizumab and will be followed for safety and efficacy."
2933797|NCT03014635|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
2933798|NCT03014635|Placebo Comparator|Placebo|Biological/Vaccine: Placebos Intramuscular injection
2933799|NCT03014622|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
2933800|NCT03014622|Placebo Comparator|Placebo|Biological/Vaccine: Placebos Intramuscular injection
2933801|NCT03014596|Experimental|Intervention|The Assert-method will be used in the counselling of adolescents with mental health problems
2933802|NCT03014596|No Intervention|Control|Treatment as usual, i.e. tha Assert-method will not be used in the counselling
2933803|NCT03014583|Experimental|HF/TCS/BURST|
2933804|NCT03014583|Experimental|HF/BURST/TCS|
2933805|NCT03014583|Experimental|BURST/HF/TCS|
2933806|NCT03014583|Experimental|BURST/TCS/HF|
2933807|NCT03014583|Experimental|TCS/BURST/HF|
2933808|NCT03014583|Experimental|TCS/HF/BURST|
2933809|NCT03014570|Active Comparator|Education-Only Control|This arm includes the education provided to all sites (this is Step 2 of the EIT-4-BPSD intervention). The sites are given the opportunity to decide how they want the education around management of behavioral symptoms to occur-face-to-face by a research staff member, via a powerpoint they can use on their own or via a webinar.
2933810|NCT03014570|Experimental|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
2933811|NCT03014557||WATCHMAN|subjects with non-valvular atrial fibrillation intended to be implanted with a WATCHMAN left atrial appendage closure device
2933812|NCT03014544||Group 1: Sequence AABB|Participants of main study with major depressive disorder (MDD) either in partial or full remission will be assigned in test sequence group AABB (Group 1) to undergo sequential cognitive performance evaluations by Test A (Computer- administered test battery) on Test Day 1 (Study Day 1) and Test Day 2 (Study Day 15 to 22) followed by Test B (Examiner-administered test battery) on Test Day 3 (Study Day 29 to 43) and Test Day 4 (Study Day 43 to 64). Each separated by a memory washout period of 14 to 21 days.
2933813|NCT03014544||Group 2: Sequence BBAA|Participants of main study with MDD either in partial or full remission will be assigned in test sequence group BBAA (Group 2) to undergo sequential cognitive performance evaluations by Test B (Examiner-administered test battery) on Test Day 1 (Study Day 1) and Test Day 2 (Study Day 15 to 22) followed by Test A (Computer- administered test battery) on Test Day 3 (Study Day 29 to 43) and Test Day 4(Study Day 43 to 64). Each separated by a memory washout period of 14 to 21 days.
2933814|NCT03014531|Experimental|almond|In this group, participants were provided with 56 g of almonds per day either as preload before meals or snack between meals. A snack was defined as an eating event that occurred between participants' regular meals, specifically two hours before and after meals. All the participants in almond group were provided daily portions of packaged almonds.
2933815|NCT03014531|Other|high-carbohydrate control food item|In this group, participants were provided with high-carbohydrate control food item that had a similar number of calories as 56 g of almonds.
2933816|NCT03014518||Suicide Attempt Study Group|Adolescents admitted to the Cleveland Clinic inpatient child and adolescent psychiatry unit after suicide attempt. Clinical assessments and blood samples; follow-up for 12 mos.
2933817|NCT03014518||Healthy Control Group|Healthy adolescents with no history of suicide attempt. Clinical assessments and blood samples; no 12mo follow-up.
2933818|NCT03014505|Experimental|FMT|Fecal Microbiota Transplantation via endoscope and/or cenema and the traditional treatments
2933825|NCT03014466|Experimental|Video Projector|Preoperative patients will utilize a video projection unit for addressing pre anesthesia anxiety
2933826|NCT03014414|Experimental|Fun First|If randomized to the 12-month Fun First program, participants will attend weekly interactive small-group sessions led by health coaches for 6 months, then receive monthly phone calls from coaches for 6 months. The first 6 months consists of a 2-month module promoting enjoyment of key maintenance skills before losing weight, followed by a 4-month behavioral weight-loss program.
2933827|NCT03014414|Active Comparator|Weight Watchers|If randomized to the 12-month Weight Watchers program, participants are provided with study-paid access to weekly ongoing Weight Watchers meetings led by peer meeting leaders for 12 months at Weight Watchers locations convenient to participants as well as study-paid access to Weight Watchers personalized online tools. [The study and investigative team have no financial relationship with Weight Watchers].
2933828|NCT03014401|Experimental|Stem Cells|Fat pad harvest with stem cell transplantation and standard arthroscopic debridement.
2933829|NCT03014401|Active Comparator|Placebo|Standard arthroscopic debridement with fat pad harvest WITHOUT stem cell transplantation
2933830|NCT03014388|Experimental|Autogenous bone graft (Gold Standard).|Patients with defective posterior maxillary alveolar ridges requiring implant insertion will have Autogenous bone graft (Gold standard) and to be used for bone augmentation with sinus lift.
2933831|NCT03014388|Experimental|Mineralized Plasmatic Matrix (MPM)|Patients with defective posterior maxillary alveolar ridges requiring implant insertion will receive bone graft using Mineralized plasmatic matrix.
2933832|NCT03014375|Experimental|Etamicastat|Single administration. 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 50 mg, hard gelatina capsules
2933833|NCT03014362|Active Comparator|TMS active|"Neuronetics NeuroStar XPLOR magnetic stimulator - Active;~Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.~Treatment Dose: ~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC (Standard of Care)."
2933834|NCT03014362|Sham Comparator|TMS sham|"Neuronetics NeuroStar XPLOR magnetic stimulator - Sham;~Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC."
2933835|NCT03014349||primary open-angle glaucoma and/or glaucoma suspects|Individuals with primary open-angle glaucoma and/or glaucoma suspects, selected from the electronic records of the VER Hospital. The following variables will be observed: gender, age, race, systemic diseases, intraocular pressure, type of glaucoma, complementary exams and degree of evolution. All patients were given a complete ophthalmologic examination, including Goldmann and pneumatic tonometry.
2933836|NCT03014336|No Intervention|Control|Patients receive standard care with a standard CO2 absorber and agree to include their data in the study.
2933837|NCT03014336|Experimental|memsorb|Patients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study.
2933838|NCT03014323|Experimental|Galantamine then Placebo, WW|4 mg (1 capsule) galantamine twice a day for 4 weeks then placebo (1 capsule) twice a day for 4 weeks in white women (WW)
2933839|NCT03014323|Placebo Comparator|Placebo then Galantamine, WW|Placebo (1 capsule) twice a day for 4 weeks then 4 mg (1 capsule) galantamine twice a day for 4 weeks in white women (WW)
2933840|NCT03014323|Experimental|Galantamine then Placebo, AAW|4 mg (1 capsule) galantamine twice a day for 4 weeks then placebo (1 capsule) twice a day for 4 weeks in African American Women (AAW)
2933841|NCT03014323|Placebo Comparator|Placebo then Galantamine, AAW|Placebo (1 capsule) twice a day for 4 weeks then 4 mg (1 capsule) galantamine twice a day for 4 weeks African American Women (AAW)
2933842|NCT03014310|Experimental|Arm 1: 3.75 mcg A/H5N8 + AS03|3.75 mcg A/H5N8 + AS03 given IM on Day 1 and 22, n=30
2933843|NCT03014310|Experimental|Arm 2: 15 mcg A/H5N8 + AS03|15 mcg A/H5N8 + AS03 given IM on Day 1 and 22, n=30
2933844|NCT03014310|Active Comparator|Arm 3: 15 mcg A/H5N8 unadjuvanted|15 mcg A/H5N8 unadjuvanted given IM on Day 1 and 22, n=15
2933845|NCT03014310|Experimental|Arm 4: 3.75 mcg A/H5N8 + MF59|3.75 mcg A/H5N8 + MF59 given IM on Day 1 and 22, n=30
2933846|NCT03014310|Experimental|Arm 5: 15 mcg A/H5N8 + MF59|15 mcg A/H5N8 + MF59 given IM on Day 1 and 22, n=30
2933847|NCT03014310|Active Comparator|Arm 6: 15 mcg A/H5N8 unadjuvanted|15 mcg A/H5N8 unadjuvanted given IM on Day and 22, n=15
2933848|NCT03014297|Experimental|everolimus + fosbretabulin|everolimus + fosbretabulin
2933849|NCT03014271|Experimental|Sources of Strength Suicide (SOS)|Receive Sources of Strength Suicide Prevention Program
2933850|NCT03014271|Active Comparator|Waitlist Control|Delayed implementation of Sources of Strength Suicide Prevention Program
2933851|NCT03014258|Active Comparator|Malaria-naïve Infectivity Control 1|1 CHMI challenge at month 8-9, n=6 immunologic malaria-naive
2933852|NCT03014258|Active Comparator|Malaria-naïve Infectivity Control 2|1 CHMI challenge at 6-12 months post-CHMI 2, n=6 immunologic malaria-naive
2933853|NCT03014258|Active Comparator|Malaria-naïve Infectivity Control 3|1 CHMI challenge at 6-12 months post-CHMI 3, n=6 immunologic malaria-naive
2933854|NCT03014258|Experimental|Repeat CHMI|1 Mock Challenge on days 1-28, followed by 4 CHMI challenges: CHMI 1 on months 2-3, CHMI 2 on months 8-9, CHMI 3 6-12 months post-CHMI 2, CHMI 4 6-12 months post-CHMI 3; N=10
2933855|NCT03014245||Pregnant|Normal pregnant women (first baby) singleton
2933856|NCT03014245||Control|Non pregnant healthy women
2933857|NCT03014232|Experimental|SLED-f with HCO dialyzer|Online sustained low-efficiency diafiltration (online SLED-f) using novel high cut-off dialyzer which had larger pore size than standard high-flux dialyzer was assigned as the new intervention to compare the efficacy of cytokine removals with the control arm.
2933858|NCT03014232|Active Comparator|SLED-f with HF dialyzer|Online sustained low-efficiency diafiltration (online SLED-f) using standard high-flux dialyzer in septic acute kidney injury patients was assigned as the control group
2933859|NCT03014219|Experimental|Only 1 arm: treatment with MSC-AFP|Single Treatment Group: Eligible patients will be treated with a Gore Bio-A Fistula Plug that has been coated with autologous mesenchymal stromal cells. This is a drug study, specifically phase 1 study of autologous mesenchymal stromal cells. Single dose of 20 million cells.
2934144|NCT03012165|Experimental|ADX-102 Ophthalmic Drops (0.5%)|ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
2933860|NCT03014180|Experimental|"In-Clinic LVAT"|All subject prior to study enrollment has been implanted with a CRT-D device. During follow-ups, under the supervision of the physician, the algorithm embeded in the device is activated with a password. The feature is deactivated at the end of each follow-up.
2933861|NCT03014167|Experimental|Community-wide deworming|Twice-yearly community-wide treatment delivered by drug distributors door to door or via community gatherings, depending upon the format of the prior LF program, for three years. All individuals above the age of 12 months will receive a single dose of albendazole.
2933862|NCT03014167|Active Comparator|Targeted deworming|Pre-school (pre-SAC) and school-age children (SAC) 12 months of age and older will receive albendazole delivered in accordance with national Ministry of Health guidelines for three years.
2933863|NCT03014154|Active Comparator|Video training Game|"Patients were submitted prior to the treadmill warming the 2kmh during 1° minutes before each session. Then held 30 minutes of aerobic interval training with video game (10 rounds of 3 minutes with 30 seconds of rest between each), followed by 5 minutes of cool-down again on the mat. The game used for training was the reflex Ridge Kinect Adventure (Xbox-360). At a higher level, it is necessary for the child to perform a greater number of jumps, squats, lateral movements and arm movements. All the activity was monitored against FC and SpO2. To determine the intensity of physical activity energy expenditure assessments were made. In which four are for the pre and post intervention evaluation and sixteen training sessions."
2933864|NCT03014154|Active Comparator|Endurance muscle training|Patients were submitted prior to the treadmill warming the 2kmh during 1° minutes before each session. Then held 30 minutes of aerobic interval training with video game (10 rounds of 3 minutes with 30 seconds of rest between each) followed by 5 minutes of cool-down again on the mat.Then the children were subjected to low intensity to endurance muscle training with 3 sets of 15 repetitions to upper limbs diagonally primitive and flexion and extension to lower lumbs. All the activity was monitored against FC and SpO2.To determine the intensity of physical activity energy expenditure assessments were made. In which four are for the pre and post intervention evaluation and sixteen training sessions.
2933865|NCT03014141|Active Comparator|Oat bran (Oatwell 28)|A beverage containing 11 gram (3 gram of oat beta-glucan) of Oat bran (Oatwell 28) will be consumed before breakfast
2933866|NCT03014141|Placebo Comparator|Maltodextrin|A beverage containing 11 gram of maltodextrin will be consumed before breakfast.
2933867|NCT03014128||Inspection and Packaging|self-descriptive
2933868|NCT03014128||Grinding, Polishing and Matting|self-descriptive
2933869|NCT03014128||All other employees at Aesculap (not in first 2 groups)|including administration and offices as well as all other mechanical workplaces
2933870|NCT03014115|Active Comparator|combination ARA+ DHA|combination 0.76% ARA+ 0.4% DHA in infant formula per day
2933871|NCT03014115|Experimental|DHA|0% ARA +0.4% DHA in infant formula per day
2933872|NCT03014102|Experimental|TPOqd|Recombinant Human Thrombopoietin 300U/kg/d ih quaque die, day-3/-2/-1 before mobilization
2933873|NCT03014102|Active Comparator|TPOqod|Recombinant Human Thrombopoietin 300U/kg/d ih qua altera die, day-3/-1/+2 before mobilization
2933874|NCT03014089|Experimental|mRNA-1325|
2933875|NCT03014089|Placebo Comparator|Placebo|0.9% sodium chloride
2933876|NCT03014076|Experimental|GP2 peptide + GM-CSF + trastuzumab|HLA-A2+/A3+ subjects receive GP2 + GM-CSF vaccine and trastzumab
2933877|NCT03014076|Active Comparator|Trastuzumab|HLA-A2-/A3- subjects followed as controls receiving trastuzumab.
2933878|NCT03014063||Hemodynamic responders|Those with a mean arterial pressure of at least 65mmHg and a decrease in catecholamine dose (in norepinephrine equivalents) from initiation of exogenous vasopressin therapy to the time of the sample collection used for analysis of plasma vasopressin concentration
2933879|NCT03014063||Hemodynamic non-responders|Those without a mean arterial pressure of at least 65mmHg and/or a decrease in catecholamine dose (in norepinephrine equivalents) from initiation of exogenous vasopressin therapy to the time of the sample collection used for analysis of plasma vasopressin concentration
2933880|NCT03014050|Experimental|EH: Stimulation of Head Point|Electrical stimulation of the head point of the hand (EH, experimental stimulation); intervention with e-Tapper TT-R1
2933881|NCT03014050|Active Comparator|CS: Control Stimulation|Electrical stimulation of the leg point of the hand (CS, control stimulation); intervention with e-Tapper TT-R1
2933882|NCT03014037|Other|Unilateral Procurement of Bone Marrow|Participants currently scheduled to undergo a bone marrow aspirate concentration (BMAC) procedure will be randomized to unilateral procurement of bone marrow.
2933883|NCT03014037|Experimental|Bilateral Bone Marrow Procurement|Participants currently scheduled to undergo a bone marrow aspirate concentration (BMAC) procedure will be randomized to bilateral procurement of bone marrow.
2933884|NCT03014024|Experimental|Low-Level Laser therapy|After inclusion in the study, patients will be treated with LLLT. The laser is a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Patient will be treated from dorsal side of the wrist on the fracture area, and distal ulna area from the palmar side. Total 20 second on each side (3 points), with 3,6 J/cm2. the light from the laser is not visible to the eye, and will not give any perceptible stimulus. The x-ray will be used to find the fracture line.
2933885|NCT03014024|Placebo Comparator|Placebo Low-Level Laser therapy|After inclusion in the study, patients will be treated with placebo LLLT. This placebo laser is identical in appearance to the other super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Patient will be treated on the same areas, and have the same procedure and time. Since the light from the laser is invisible neither the participant nor the therapist will know whether the laser is a placebo.
2933886|NCT03013998|Experimental|BAML-16-001-S1|This is an open-label Phase 1b/2 clinical study of Samalizumab given in addition to standard induction chemotherapy/consolidation, followed by Samalizumab maintenance, in newly diagnosed acute myeloid leukemia. Patients that are marker negative, as defined based on the Beat AML Master Protocol assignment or with CBF karyotype/interphase cytogenetics/molecular testing defined by presence of t(8;21)(q22;q22) or the molecular equivalent RUNX1/RUNX1T1 fusion transcript or inv(16)(p13q22) or t(16;16)(p13;q22) or the molecular equivalent CBFB/MYH11 fusion transcript based on the Beat AML will receive Samalizumab in combination with induction therapy followed by Samalizumab maintenance.
2933901|NCT03013946|Experimental|Arm A (Coaching)|Concomitant coaching (24 weeks) Pro-active TEAE (Treatment emergent adverse events) management Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15
2933887|NCT03013998|Experimental|BAML-16-001-S2|"This is an open-label Phase 1b/2 clinical study of BI 836858 given in combination with azacitidine, followed by BI 836858 plus azacitidine maintenance, in newly diagnosed acute myeloid leukemia. The target population is assigned by the Beat AML Master Protocol (the umbrella study). Eligible patients will have previously untreated acute myeloid leukemia, age greater than or equal to 60, with any 1 of the following: mutated TET2, IDH1, IDH2, or WT1, or marker negative as defined by the overall Beat AML umbrella protocol."
2933888|NCT03013998|Experimental|BAML-16-001-S3|This is a phase 2 clinical trial to assess the feasibility and efficacy of a stepwise approach to the treatment of IDH2-mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH2 inhibitor AG-221 for IDH2 R140 and R172-mutant patients. The dosing will be based on phase 1 experience of AG-221, which has established 100 mg daily as a safe and tolerated dose, with preliminary suggestion of efficacy. These will be administered continuously in 28 day cycles. Hydroxyurea will be allowed for the purposes of cytoreduction.
2933889|NCT03013998|Experimental|BAML-16-001-S4|This is a 2 cohort phase 1b/2 clinical trial to assess the feasibility and efficacy of entospletinib (ENTO) stepwise approach to the treatment of patients with balanced translocations of MLL identified cytogenetically (Cohort 1) and patients with MLL-partial tandem duplications identified molecularly (Cohort 2). All enrolled participants will be initiated on monotherapy with ENTO 400 mg PO BID. This dose will be administered continuously in 28 day cycles.
2933890|NCT03013998|Experimental|BAML-16-001-S5|This is a phase 2 clinical trial to assess the feasibility and efficacy of a stepwise approach to the treatment of patients with TP53 mutations (identified molecularly) with/without complex karyotype (Cohort A) or complex karyotype (3 or greater metaphase abnormalities without TP53) (Cohort B). All enrolled participants will be initiated on entospletinib 400 mg orally twice daily. This dose will be administered continuously in 28 day cycles.
2933891|NCT03013998|Experimental|BAML-16-001-S6|The study is an open-label phase 2 study of entospletinib in older AML patients with NPM1+/FLT3ITD- AML. It includes 2 Cohorts: patients 1) age <75 years; 2) have ECOG performance status of 0-1, and 3) are willing to receive 7 + 3 intensive chemotherapy (Cohort A); and patients who do not meet criteria for Cohort A (Cohort B). In Cohort A, entospletinib lead-in is administered on days 1-5 as a single agent (Cycle 0) and is then given daily with IV daunorubicin (days 1-3 for Cycle 1) and cytarabine (days 1-7 for Cycle 1). If a second induction is required, it is given with IV daunorubicin (days 1-2 for Cycle 2) and cytarabine (days 1-5 for Cycle 2). In Cohort B, for subjects receiving monotherapy, entospletinib is given daily for every 28 day cycle until the subject meets criteria for treatment discontinuation; for subjects receiving combination therapy, entospletinib is administered daily on days 1-28 as a single agent (Cycle 1) with azacitidine on days 1-7 of subsequent 28 day cycles
2933892|NCT03013998|Experimental|BAML-16-001-S9|This is an open-label phase 2 clinical trial of a stepwise approach to the treatment of patients with TP53 mutation AML. On day 1, all enrolled participants will be initiated on therapy with pevonedistat (20 mg/m2) day 1, 3 and 5 together with azacitidine (75 mg/m2 days 1-7 or day 1-5 then day 8, 9) every 28 days. During cycle 1, patients with rapidly progressive disease or severe organ dysfunction, not correctable by hydroxyurea cytoreduction will not be eligible to continue. Those patients who achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 4 will continue on pevonedistat and azacitidine until disease progression, unacceptable toxicity, or 12 cycles of therapy. After 12 months of combined therapy, pevonedistat will be continued until progression of disease, unacceptable toxicity, or up to 2 years of total therapy.
2933893|NCT03013998|Experimental|BAML-16-001-S16|This is an open-label phase 2 clinical study to assess the feasibility and efficacy of a combination based approach to the treatment of IDH1 mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH1 inhibitor AG-120 given daily together with azacitidine (days 1-5 and 8-9 or 7 consecutive days 1-7) in 28 day cycles for IDH1 mutant patients. Those patients who have achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 6, will continue on combination therapy for a total of 12 cycles and then patients will go onto receive monotherapy with AG-120 until disease progression or unacceptable side effects that mandate discontinuation of therapy. Patients who cannot complete 12 cycles of azacitidine may proceed onto monotherapy with AG-120.
2933894|NCT03013985|Experimental|Basal bolus insulin with glargine U300 and glulisine insulin|Subjects treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as basal bolus insulin regimen with glargine U300 once daily plus rapid-acting glulisine insulin before meals. In insulin-naïve subjects treated with oral agents, the oral antidiabetic drugs will be discontinued and the bolus insulin dose described above will be given. Half of TDD will be given as glargine U300 and half as glulisine. To prevent hypoglycemia, if a subject is not able to eat, the dose of glulisine will be held.
2933895|NCT03013985|Active Comparator|Basal bolus insulin with glargine U100 and glulisine insulin|Subjects treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as basal bolus insulin regimen with glargine U100 once daily plus rapid-acting glulisine insulin before meals. In insulin-naïve subjects treated with oral agents, the oral antidiabetic drugs will be discontinued and the bolus insulin dose as described above will be given. Half of TDD will be given as glargine U100 and half as glulisine. To prevent hypoglycemia, if a subject is not able to eat, the dose of glulisine will be held.
2933896|NCT03013972||Colorectal cancer patients|Colorectal cancer patients during adjuvant chemotherapy
2933897|NCT03013959||Resting control group|The rest group is to study the effect of the inhibition of recurrence . Patients with redness, pain, decreased visual acuity and other reaction activity in the past 30 days are observed as control group
2933898|NCT03013959||Resting test group|The rest group is to study the effect of the inhibition of recurrence . Patients with redness, pain, decreased visual acuity and other reaction activity in the past 30 days are treated with pranoprofen and observed as test group
2933899|NCT03013959||Active control group|The active control group is to study the effect of anti--inflammatory. Patients with a new redness, pain, decreased visual acuity and other reaction activity recently are observed as control group
2933900|NCT03013959||Active test group|The active test group is to study the effect of anti--inflammatory. Patients with a new redness, pain, decreased visual acuity and other reaction activity recently are treated with pranoprofen and observed as test group
2933902|NCT03013946|No Intervention|Arm B (Control)|Re-activeTEAE management (SOC) Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15
2933903|NCT03013933|Experimental|Treatment (cyclosporine, verapamil, brentuximab vedotin)|Patients receive cyclosporine PO BID on days 1-5, verapamil PO QID on days 1-5, and brentuximab vedotin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2933904|NCT03013907|Experimental|UPLIFT|Eligible participants will complete 8 weekly group sessions by phone. The intervention builds cognitive-behavioral and mindfulness skills to help reduce depressive symptoms. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment.
2933905|NCT03013907|Active Comparator|Usual Care|Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study for the UC group and outside of the study (for the intervention group) will be assessed at each time point.
2933906|NCT03013881|Experimental|UB-921 2 mg/kg (Main-study)|Intravenous infusion
2933907|NCT03013881|Experimental|UB-921 6 mg/kg (Main-study)|Intravenous infusion
2933908|NCT03013881|Experimental|UB-921 8 mg/kg (Main-study)|Intravenous infusion
2933909|NCT03013881|Experimental|UB-921 6 mg/kg (Sub-study)|Intravenous infusion
2933910|NCT03013881|Active Comparator|Herceptin 6 mg/kg (Sub-study)|Intravenous infusion
2933911|NCT03013855|Active Comparator|FIT-SOC|Fecal immunochemical test performed on spontaneously passed stool as noted in the standard instructions.
2933912|NCT03013855|Experimental|FIT-DRE|Fecal immunochemical test completed with stool collected during digital rectal exam.
2933913|NCT03013842|Experimental|Administration of Fetal Oximetry Probe|Administration of Raydiant Oximetry Sensor System on 36 weeks or greater pregnant women
2933914|NCT03013829|No Intervention|Usual Care|Incompatible potential LKDs and recipients will receive standard-of-care LD (Live Donor) and KPD education. As noted previously, potential LKDs are informed of their incompatibility during a phone call with the donor nurse coordinator. The KPD option is described and the potential LKD is provided with living donation information and a link to the UNOS KPD website, which includes a written description of KPD. This information is available in English and Spanish. For those who do not have internet access, the written educational materials are mailed. The potential LKD is advised to call the donor nurse coordinator with any questions about KPD and/or to initiate the full donation evaluation. This process occurs for the intended recipient only if their potential donor decides to initiate the full evaluation. Incompatible LKDs and recipients assigned to the UC group will be sent an email after randomization, which will include a link and a reminder to visit the UNOS website.
2933915|NCT03013829|Experimental|Video-Based KPD education|Incompatible LKDs and recipients assigned to the video-based KPD education group will receive the same living donation and KPD educational materials as those in the UC group. Also, as in the UC group, they will be encouraged by the site coordinator to review the educational materials. In addition, following randomization to this group, participants will be sent an email encouraging them to watch the embedded KPD education video. This video will be professionally designed and will highlight the operational features of KPD and address the specific barriers highlighted in our formative research. The primary goal of these sessions is to increase living donation and KPD knowledge of risks and benefits and to reduce specific concerns that are based on inaccurate information. The intent is not to persuade LKDs or recipients to pursue living donation or KPD, but to ensure that they have sufficient information to make an informed choice that is consistent with their own values and preferences.
2933916|NCT03013816|Experimental|Testimonial Messaging|There are no explicit statistics or facts about transplantation or donation in this video intervention. It is designed to appeal to those with lower motivation to process factual arguments, focusing instead on emotional appeal and peers modeling the targeted behavior, thus allowing for peripheral processing of the donation message.
2933917|NCT03013816|Experimental|Informational Messaging|This video intervention will mirror common educational campaigns and focus exclusively on factual arguments for organ donation, including the current supply-demand problem in transplantation, common reasons for/against donor designation, myths about donation, religious views of donation, the importance of communicating the donation decision to parents, and information about donor registries and how to register as a donor. This video will appeal to those with greater motivation to process factual arguments for donor designation. The video will be narrated by male and female adolescent peers. No personal testimonials will be displayed in this video.
2933918|NCT03013816|Experimental|Blended Messaging|This video intervention will comprise edited segments from the Informational Messaging and Testimonial Messaging videos.
2933919|NCT03013803|Experimental|Nutricomp Drink Plus Fibre|Nutricomp® Drink Plus Fibre (flavours vanilla, coffee, peach-apricot and chocolate)
2933920|NCT03013790|Active Comparator|Melatonin 5mg|This arm will be given 5mg tablets of Melatonin nightly for the duration of their hospital stay
2933921|NCT03013790|Active Comparator|Melatonin 3mg|This arm will be given 3mg tablets of Melatonin nightly for the duration of their hospital stay
2933922|NCT03013790|Placebo Comparator|Placebo|This arm will be given a Sucrose tablet nightly for the duration of their hospital stay
2933923|NCT03013777|Experimental|Cognitive behavioral therapy (CBT)|The patient would participate in eight forty-five minute sessions of CBT with a mental health therapist. Cognitive behavioral therapy (CBT), defined as a program of interventions that utilize education to teach relaxation, healthy coping skills, stress management, assertiveness training in order to help the individual identify and correct maladaptive beliefs in combination with education to help practice symptom reduction and improve quality of life and function.
2933924|NCT03013764|Placebo Comparator|normal protein intake|normal protein intake
2933925|NCT03013764|Experimental|high protein intake|high protein intake
2933926|NCT03013751|Experimental|Drug|Udenafil administered for 52 weeks
2933982|NCT03013348||Children (2-12)|Male or female subject between the ages of 2-12, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
2933983|NCT03013335|Experimental|Nivolumab|"The dose and schedule of nivolumab in this study will be 3 mg/kg every 2 weeks. Infusion of nivolumab will be performed in 30 minutes (± 5 minutes).~Nivolumab will be administered every 2 weeks until death, disease progression, unacceptable toxicity or withdrawal of the informed consent"
2933927|NCT03013738|Experimental|Growing Pro-Social (GPS) program|"The Growing Pro-Social (GPS) program is a cognitive-behavioral group program for offenders. GPS is based on schema therapy, which conceptualizes aggressiveness as a result of a distorted view of the self and of the others. The ultimate goal of the GPS is to promote change in dysfunctional core beliefs about the self and the others.~GPS consists of 40 sessions, each lasting about 90 minutes. Sessions must be carried out by two therapists who should be skillful in schema therapy. Sessions are grouped into five modules: (1) human communication, (2) interpersonal relationships, (3) cognitive distortions, (4) function and meaning of emotions, and (5) early maladaptive schemas.~The treatment group attended the GPS program in addition to the Treatment AsUsual (TAU) delivered at Portuguese prisons."
2933928|NCT03013738|Other|Treatment As Usual|Subjects in this group received Treatment As Usual in Portuguese prisons (supervision of school frequency, occupational and job-related tasks and sentence planning supervision over time) and did not attend the GPS program or any other structured program during the research period.
2933929|NCT03013725||The Homocysteine Study|Conducted in 1992-93, ca. 18000 participated.
2933930|NCT03013725||The Hordaland Health Study (HUSK)|Conducted in 1997-99, ca. 26000 participated.
2933931|NCT03013712|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen by infusion.
2933932|NCT03013699|Active Comparator|Usual Dietary Care|Participants receive standard educational materials that focus on healthy eating for cancer survivors and the opportunity to briefly discuss nutrition-related concerns with the Registered Dietitian weekly.
2933933|NCT03013699|Experimental|Cruciferous and Dark Leafy Green Intervention|Participants receive individual dietary counseling from a Registered Dietitian who will focus on increasing intake of cruciferous and green leafy vegetables while addressing any disease- and treatment-related eating difficulties experienced by the participant.
2933934|NCT03013686|Active Comparator|Interval Appendectomy|"The periappendicular abscess, diagnosed by a CT-scan or MRI, is initially treated conservatively with antibiotic therapy and with drainage, if necessary.~Interval appendectomy is performed at two months after the primary treatment, all patients also undergo colonoscopy prior to appendectomy."
2933935|NCT03013686|Active Comparator|Follow-up with MRI|"The periappendicular abscess, diagnosed by a CT-scan or MRI, is initially treated conservatively with antibiotic therapy and with drainage, if necessary.~The patients undergo abdominal magnetic resonance imaging at two months after the primary treatment, all patients also undergo colonoscopy right after the MRI."
2933936|NCT03013673||HIV|HIV infected individuals residing in VL-endemic areas in Northern Ethiopia
2933937|NCT03013660|No Intervention|Comparison|Participants will be provided with standard information about the benefits of STSC and breastfeeding and will be encouraged to come into the NICU every day for at least 1 hour of STSC. To facilitate increased let down of breast milk, all participants will be provided a hospital grade breast pump free of charge during the stay of their babies in the NICU and assistance will be provided to the mothers in procuring a Medicaid covered breast pump to keep when the baby leaves the NICU. The hospital grade breast pump will be provided to her as soon as she enrolls into the study and will remain with her until her baby is discharged or transferred.
2933938|NCT03013660|Experimental|Treatment: Limited Financial Support|Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment. The participants selected for the intervention arm will be asked not to discuss the payment with any other study participants (such as the members of any other families they may see at the NICU) or other health care staff at the NICU. Participants will also receive everything that the Comparison group receives.
2933939|NCT03013647|Other|Actinic Keratosis|Twenty patients with multiple thin AK on the face will be treated with Daylight Photodynamic Therapy with methyl aminolevulinate Skin biopsies before and after treatment will be performed in an AK lesion and in a field cancerization area.
2933940|NCT03013634|Experimental|Dexmedetomidine Group|Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
2933941|NCT03013634|Placebo Comparator|Normal saline Group|Equal volume normal saline substitute for dexmedetomidine
2933942|NCT03013608|Experimental|relocation of nail plate|the simple relocation of the nail plate in nailbed injuries in paediatric population
2933943|NCT03013595|Experimental|TRAM feedback|"The completion of the Transition Readiness and Appropriateness Measure (TRAM, a standardized structured assessment ) prior to the transition boundary by the child and adolescent mental health service (CAMHS) clinician, young person and parent/carer.~Feedback of TRAM findings to the CAMHS clinician to support decisions made regarding transition, communication with stakeholders and the transition process. Clinicians will be expected to communicate the findings to the young person and parent/carer, and, if a referral is made, to send the TRAM feedback to the adult clinician along with the referral letter.~The clinicians will also receive information prior to recruitment begin on the use of TRAM and the way in which it fits in with optimal transition."
2933944|NCT03013595|No Intervention|Usual care|Patients, parent/carers and clinicians in the control arm will complete the TRAM prior to the transition boundary, but the clinicians won't receive any feedback from it nor any information on the benefits of using the decision support tool.
2933945|NCT03013582|Experimental|Amnion wrapping + Tenolysis|Standard surgical tenolysis + wrapping of the released tendon with amnion.
2933946|NCT03013582|Placebo Comparator|Tenolysis control|Standard surgical tenolysis alone
2933947|NCT03013556|Active Comparator|Group A,TDF|The subjects in group A will be treated by TDF for 96 weeks
2933948|NCT03013556|Experimental|Group B,TDF+PEG|The subjects in group B will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks
2933949|NCT03013556|Experimental|Group C,TDF+PEG|The subjects in group C will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks
2933950|NCT03013543|Experimental|Setmelanotide|Setmelanotide subcutaneous injection once daily
2933951|NCT03013530||Patients with chronic disease|
2933952|NCT03013517|Experimental|Viaskin Peanut 250µg|
2934135|NCT03012243|Experimental|Gallbladder aspiration|Gallblader aspiration without drain
2935507|NCT03003117|Experimental|Intervention Program|Experimental: Intervention Program
2933953|NCT03013504|Experimental|HD201 in combination with docetaxel|"8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2-8), followed by surgery, then adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, and subsequent 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.~Neoadjuvant chemotherapy:~Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion"
2933954|NCT03013504|Active Comparator|Herceptin® in combination with docetaxel|"8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2 -8) for cycles 2-8, followed by surgery, and subsequent adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, then 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.~Neoadjuvant chemotherapy:~Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion"
2933955|NCT03013491|Experimental|CX-072|Monotherapy CX-072
2933956|NCT03013491|Experimental|CX-072 with Ipilimumab #1|Combination CX-072 + ipilimumab (Schedule 1)
2933957|NCT03013491|Experimental|CX-072 with Ipilimumab #2|Combination CX-072 + ipilimumab (Schedule 2)
2933958|NCT03013491|Experimental|CX-072 with Vemurafenib|Combination CX-072 + vemurafenib
2933959|NCT03013491|Experimental|CX-072 expansion|Monotherapy CX-072
2933960|NCT03013478|No Intervention|Standard treatment as usual (TAU)|Treatment normally offered at this primary care clinic
2933961|NCT03013478|Active Comparator|TAU plus CBT4CBT program|Treatment normally offered at this clinic PLUS 8 weeks of CBT4CBT computerized therapy.
2933962|NCT03013465|Other|Control Diet|Participants will receive a controlled diet (base diet), typical of an American diet, with 0 g/day of broccoli (control).
2933963|NCT03013465|Active Comparator|Brassica Diet|Participants will receive a controlled diet with 100 g of broccoli at both breakfast and dinner daily.
2933964|NCT03013452|Active Comparator|Autogenic drainage|Chest physiotherapy by autogenic drainage daily for 15 minutes each day, for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
2933965|NCT03013452|Active Comparator|oPEP|Chest physiotherapy with an Aerobika oPEP device daily for 15 minutes each day for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
2933966|NCT03013439|Experimental|cohort 1 iron isomaltoside|treated with first dose level of iron isomaltoside
2933967|NCT03013439|Experimental|cohort 2 iron isomaltoside|treated with second dose level of iron isomaltoside
2933968|NCT03013439|Experimental|cohort 3 iron isomaltoside|treated with third dose level of iron isomaltoside
2933969|NCT03013439|Experimental|cohort 4 iron isomaltoside|treated with fourth dose level of iron isomaltoside
2933970|NCT03013426|Experimental|NVX-508|Administration of 1, 2 or 4 doses of NVX-508 at three dose levels; 0.05ml/kg. 0.1ml/kg and 0.17ml/kg in a 3 + 3 design.
2933971|NCT03013413|Experimental|Diagnostic (elastography imaging using the Aixplorer system)|Patients undergo ultrasound-based elastography imaging using the Aixplorer system followed by standard of care ultrasound-guided prostate biopsy over approximately 25 minutes.
2933972|NCT03013400|Active Comparator|Ebselen|Three Ebselen capsules each containing 200mg taken orally twice a day for 3 weeks
2933973|NCT03013400|Placebo Comparator|Placebo|Three Placebo capsules each containing 200mg taken orally twice a day for 3 weeks
2933974|NCT03013387|Experimental|PRRT with 90Y--DOTA-tyr3-Octreotide|"The 90Y--DOTA-tyr3-Octreotide initial, Cycle 1 dose will be 50 mCi/m2 in children; 120 mCi in adults. Treatment consists of 3 cycles, 6-8 weeks apart. Cycle 1 dose is fixed. Cycles 2 and 3 doses will be determined by dosimetry-based calculation of renal doses from previous cycles; total renal dose ≤ 23Gy. 90Y-DOTA-tyr3-Octreotide will be administered with an amino acid solution to prevent radiation damage to kidneys. Amino acid infusion will begin 30 min prior to infusion of 90Y-DOTATOC and continue 3.5 hrs after infusion of study drugs.~68Ga-DOTATOC will be administered intravenously to perform the PET/CT scan. The dose will be 3-5 mCi (target 4mCi). The pediatric dose will be 0.043 mCi/kg with a minimum dose of 0.3 mCi and a maximum dose of 3 mCi in children <18 years old."
2933975|NCT03013374||Human milk fed infants|"Infants fed fortified human milk at enrollment~Any intervention is performed. Groups distinction is made according to own mother's milk availability."
2933976|NCT03013374||Preterm formula|"Infants fed preterm formula milk at enrollment.~Any intervention is performed. Groups distinction is made according to own mother's milk availability."
2933977|NCT03013361|Active Comparator|Group B (n=20)|Group B (n=20): The patients in this group were infiltrated with 3 mL of 0.5% bupivacaine.
2933978|NCT03013361|Active Comparator|Group R (n=20):|Group R (n=20): The patients in this group were infiltrated with 3 mL of 0.5% ropivacaine.
2933979|NCT03013361|Placebo Comparator|Group S (n=20, Control):|Group S (n=20, Control): The patients in this group were infiltrated with 3 mL of normal saline.
2933980|NCT03013348||Adults (22-99),|Male or female subject between the ages of 22-99, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
2933981|NCT03013348||Adolescents (13-21)|Male or female subject between the ages of 13-21, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
2934136|NCT03012230|Experimental|Treatment (pembrolizumab, ruxolitinib phosphate)|Patients receive pembrolizumab IV over 30 minutes on day 1 and ruxolitinib phosphate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2933984|NCT03013322|Active Comparator|Treatment Group|The treatment group receives an infusion of 0.04 mg/kg physostigmine salicylate with a maximum dose of 4 mg. The infusion is administered at 0.4 mg/min (= 1 mL/min = 60 mL/h). The initial dose is followed by a continuous infusion of 0.017 mg/min, i.e. 1 mg/h (= 0.042 mL/min = 2.5 mL/h) for 2-5 days, i.e. 48-120 hours (treatment phase).
2933985|NCT03013322|Placebo Comparator|Placebo Group|The placebo group is treated with 0.9% sodium chloride.
2933986|NCT03013309|Experimental|Intervention|Receives the Family Check-Up 4 Health
2933987|NCT03013309|Experimental|Control|Receives Treatment as Usual
2933988|NCT03013296|Placebo Comparator|Placebo|Saline
2933989|NCT03013296|Other|GIP-A|Infusion of GIP-A alone as study tool.
2933990|NCT03013296|Other|GLP-1 receptor antagonist Exendin[9-39]|Infusion of GLP-1 receptor antagonist Exendin[9-39] alone as study tool.
2933991|NCT03013296|Other|GIP-A + Exendin[9-39]|Infusion of GIP-A + GLP-1 receptor antagonist Exendin[9-39] together as study tools.
2933992|NCT03013270|Experimental|ARIS group|Aerobic-Resistance-Inspiratory
2933993|NCT03013270|Active Comparator|ARS group|Aerobic-Resistance
2933994|NCT03013270|Active Comparator|AIS group|Aerobic-Inspiratory
2933995|NCT03013270|Active Comparator|AT group|Aerobic Training
2933996|NCT03013257|Experimental|High Intensity Focused Ultrasound|Try to use the machine 'Echopulse' with High Intensity Focused Ultrasound to treat the relapsed Graves' disease
2933997|NCT03013257|No Intervention|Fixed-dose radioiodine-131|Using the traditional treatment, fixed-dose radioiodine-131, to treat the relapsed Graves' disease
2933998|NCT03013244|No Intervention|Waitlist Control|Participants in this condition completed assessments at baseline, 1 week, and 5 weeks.
2933999|NCT03013244|Experimental|The Body Project: More Than Muscles|Participants in this condition competed the 2-session dissonance-based eating disorder prevention protocol (2 hours per session).
2934000|NCT03013231||s/p ACLR|Patients having undergone ACL Reconstruction Surgery with goal of returning to sport. 6 months post-op, patients will complete the BRS survey as a method of evaluating resilience.
2934001|NCT03013218|Experimental|ALX148|The Part 1 Dose Escalation: ALX148 infusions will be administered weekly or every two weeks.
2934002|NCT03013218|Experimental|ALX148 + Pembrolizumab|The Part 2 Dose Escalation/Expansion: ALX148 infusions will be administered weekly or every two weeks in combination with pembrolizumab infusions administered every three weeks.
2934003|NCT03013218|Experimental|ALX148 + Trastuzumab|The Part 2 Dose Escalation/Expansion: ALX148 infusions will be administered weekly or every two weeks in combination with trastuzumab infusions administered every three weeks.
2934004|NCT03013218|Experimental|ALX148 + Rituximab|The Part 2 Dose Escalation/Expansion: ALX148 infusions will be administered weekly or every two weeks in combination with rituximab infusions administered once weekly for 4 doses followed by once monthly for 8 doses.
2934005|NCT03013205|Experimental|PT+IA+CHL|"Intraarticular triamcinolone injection~Intraarticular Xylocaine injection~Coracohumeral ligament triamcinolone injection~Physiotherapy"
2934006|NCT03013205|Active Comparator|PT+IA|"Intraarticular triamcinolone injection~Intraarticular Xylocaine injection~Physiotherapy"
2934007|NCT03013192|No Intervention|Control|No text message reminders, usual patient protocol
2934008|NCT03013192|Experimental|Intervention (text messaging)|Text message reminders for PT
2934009|NCT03013179||Black/African American Women and their 3-5 year old children|
2934010|NCT03013166||Cohort 1|IR hydrocortisone
2934011|NCT03013166||Cohort 2|IR prednisolone
2934012|NCT03013166||Cohort 3|MR hydrocortisone
2934013|NCT03013166||Cohort 4|IR to MR hydrocortisone
2934014|NCT03013153|Experimental|Low ligation with apical lymph node dissection|Left colic artery (LCA) is identified according to the CT 3D-reconstruction, tie the sigmoid artery and superior rectal artery, preserved LCA while low ligation of the inferior mesenteric artery is performed. Lymphadenectomy to the apical lymph nodes (No.253)is performed around the IMA until 2 cm from the aorta. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
2934015|NCT03013153|Active Comparator|High ligation|Open the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The IMA is ligated and divided at 2 cm from its origin. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
2934016|NCT03013140|Experimental|Goal-directed preloading|"Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until change in SV (ΔSV) <5%"
2934017|NCT03013140|Active Comparator|Preloading|"Fluid therapy: Within 30 mins before spinal anaesthesia, infuse 1000ml Ringer's injection with a pressurizer within 15 minutes."
2934018|NCT03013127|Experimental|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg i.v. every 3 weeks for up to 35 cycles
2934019|NCT03013114|Experimental|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
2934020|NCT03013101|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
2934021|NCT03013088|Experimental|CTO Crossing|With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
2934022|NCT03013075|Experimental|SPINAL PLUS GENERAL ANESTHESIA|Patient will receive the intervention SPINAL ANESTHESIA before the start of surgery using Bupivacaine heavy 40 mg and Morphine 250 micro grams comprising a total volume of 8 ml to achieve a spinal block up to T2 level followed by general anesthesia
2934023|NCT03013075|Active Comparator|ONLY GENERAL ANESTHESIA|Patient will receive only general anesthesia before the start of surgery
2934024|NCT03013062||WITH PULMONARY HYPERTENSION|It is defined as MPAP > 25 mm Hg at rest or >30 mm Hg during exercise with PVR > 3 wood units and PCWP < 15 mm Hg.
2934137|NCT03012217||Specimens that meet inclusion criteria|
2935508|NCT03003117|Active Comparator|Usual Care|Active comparator: Usual Care
2934025|NCT03013049|Active Comparator|Non cultured epidermal cell suspension|In 20 patients who have stable vitiligo with the duration of stability more than 3 months, non cultured epidermal cell suspension will be done. Patients will be divided into 2 subgroups of 10 patients each of stability duration of 3-6 months and more than 1 year respectively and non cultured epidermal cell suspension will be done.
2934026|NCT03013049|Experimental|Non cultured dermal cell suspension|In 20 patients who have stable vitiligo with the duration of stability more than 3 months, combination of non cultured epidermal cell suspension and non cultured dermal cell suspension will be done. Patients will be divided into 2 subgroups of 10 patients each of stability duration of 3-6 months and more than 1 year respectively and combination of non cultured epidermal cell suspension and non cultured dermal cell suspension will be done.
2934027|NCT03013036|Other|Group I|Patients between 1 and 2 years
2934028|NCT03013036|Other|Group II|patients between 3 and 5 years
2934029|NCT03013036|Other|Group III|patients between 6 and 8 years
2934030|NCT03013023|Placebo Comparator|Routine care|Control group
2934031|NCT03013023|Active Comparator|Behavioral-support interventions (BS)|NNS, FT, positional support, and oral sucrose feeding will be provided while infants are undergoing painful procedures
2934032|NCT03013023|Active Comparator|Parent-infant transaction program (PITP)|The PITP will be a six-session, one-on-one teaching intervention beginning on day 22 after birth, with four sessions at bedside, and two home-visit sessions within the first month after discharge.
2934033|NCT03013023|Active Comparator|BS+PITP|Behavioral-support interventions + Parent-infant transaction program
2934034|NCT03013010|Experimental|Preoperative radiochemotherapy|"1 cycle preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.~5 weeks preoperative chemoradiotherapy.~1 cycle preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.~Gastric resection. 3 cycles adjuvant chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin."
2934035|NCT03013010|Active Comparator|Preoperative chemotherapy|"3 cycles preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.~Gastric resection. 3 cycles adjuvant chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin."
2934036|NCT03012997|Active Comparator|Active Comparator: 40% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen 40% during the induction, surgery and in Postoperative care unit.
2934037|NCT03012997|Active Comparator|Active Comparator: 100% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen during 100% induction and with 60-70% ( determined according to the arterial blood gas sample results) during surgery and in Postoperative care unit.
2934038|NCT03012984|Experimental|Dexmedetomidine group|Dexmedetomidine supplemented morphine analgesia will be provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
2934039|NCT03012984|Placebo Comparator|Control group|Morphine analgesia will be provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains morphine (0.5 mg/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
2934040|NCT03012971|Experimental|Dexmedetomidine group|Dexmedetomidine supplemented morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
2934041|NCT03012971|Placebo Comparator|Control group|Morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains morphine (0.5 mg/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
2934042|NCT03012958|Active Comparator|Health control group|"Who are 18 years or older, have no history of pre-existing lung disease, and report no respiratory illness in the four weeks preceding enrollment.~This study consist of one visit: If the potential subject meets the Inclusion and exclusion then they will have the LCI testing."
2934043|NCT03012958|Experimental|Deployment-related lung disease|"Defined as the presence of unexplained chest symptoms in a deployer who, on surgical lung biopsy is found to have bronchiolitis or granulomatous pneumonitis without other known causes.~This study consist of one visit: If the potential subject meets the Inclusion and exclusion then they will have the LCI testing."
2934044|NCT03012945|Experimental|Combined Epi-GA/PCEA|Patients assigned to this group (experimental group) received combined epidural-general anesthesia (combined Epi-GA) and patient-controlled epidural analgesia (PCEA). An epidural catheter was placed before anesthesia induction. General anesthesia was induced and maintained in the same manner as in the control group, with the addition of a continuous infusion or intermittent boluses of 0.5%-0.75% ropivacaine given through the epidural catheter for anesthesia maintenance. Patient-controlled epidural analgesia was used for postoperative analgesia (0.12% ropivacaine and 0.5 ug/mL sufentanil in 250 mL normal saline, programmed to deliver a 2-mL bolus with a lockout interval of 20 minutes and a background infusion of 4 mL/hr).
2934045|NCT03012945|Active Comparator|GA/PCIA|Patients assigned to this group (control group) received general anesthesia (GA) and patient-controlled intravenous analgesia (PCIA). General anesthesia was induced with midazolam, sufentanil, propofol and rocuronium. Anesthesia was then maintained by inhalation of oxygen-nitrous oxide mixture (1:1-2) and sevoflurane, and/or continuous intravenous infusing of propofol. Sufentanil and rocuronium were given when needed. Other types of opioids and muscle relaxants were also provided when necessary. Patient-controlled intravenous analgesia was used for postoperative analgesia (50 mg morphine in 100 mL normal saline, programmed to deliver a 2-mL bolus with a 6-10 minutes lockout interval and a 1 mL/hr background infusion).
2934145|NCT03012165|Experimental|ADX-102 Ophthalmic Drops (0.1%)|ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
2934046|NCT03012932|Other|HPV Self-sampling|All participants will receive HPV self-sampling intervention. HPV self-sampling is a cervical cancer screening that can be done in private, using a device that is similar to a tampon. This intervention tests for high-risk HPV, the primary cause of cervical cancer. Each participant will complete the intervention one time only.
2934047|NCT03012919|Other|active decision support system (GDT protocol)|The active decision support system in this study is a goal directed therapy (GDT) protocol where threshold hemodynamic values are defined when to give fluid, vasopressors and inotropes. Hemodynamic values are measured with the LiDCOrapid device, which uses pulse contour analysis to continuously monitor cardiac output and respiratory variations in stroke volume (SVV).
2934048|NCT03012893|Experimental|Ultrasound transverse scan|Transvers scan by identifying the C7 transvers process using vertebral artery and absence of anterior tubercle as a landmark and then scan back following articular process, lamina and then find out the spinous process of C7
2934049|NCT03012893|Experimental|Ultrasound sagittal scan|Sagittal scan by identifying the first and second ribs and scan medially to depict the C7 transvers process.
2934050|NCT03012893|Active Comparator|Floroscopic technique|Fluoroscopy image will do on lateral view including all cervical spines and upper thoracic spines. C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
2934051|NCT03012880|Experimental|Treatment (ixazomib, lenalidomide, daratumumab, dexamethasone)|"INDUCTION PHASE: Patients receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-21. Patients receive daratumumab IV over 3-7 hours on days 1, 8, 15, and 22 of courses 1 and 2, on days 1 and 15 of courses 3, 4, and 5, and on day 1 of courses 7 and beyond. Patients also receive dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive ixazomib citrate PO on days 1, 8, and 15 and daratumumab IV over 3-7 hours on day 1. Courses repeat every 28 days for up to 36 months from registration in the absence of disease progression or unacceptable toxicity."
2934052|NCT03012867|Active Comparator|fat-based|Patients receive a fat-based enteral nutrition formula, which is routinely used as standard care in our ICU
2934053|NCT03012867|Active Comparator|glucose-based|Patients receive a glucose-based enteral nutrition formula, which is routinely used as standard care in our ICU
2934054|NCT03012854|Experimental|short-myotomy|Short-POEM for patients with esophageal achalasia
2934055|NCT03012854|Active Comparator|long-myotomy|Long-POEM for patients with esophageal achalasia
2934056|NCT03012854|Experimental|full-thickness myotomy|Full-thickness-POEM for patients with esophageal achalasia
2934057|NCT03012854|Active Comparator|circular myotomy|Circular-POEM for patients with esophageal achalasia
2934058|NCT03012841|Experimental|Treatment Arm|Subjects enrolled and treated with Arctic Front Advance Cardiac CryoAblation Catheter
2934059|NCT03012828|Experimental|Moxidectin 4mg|10 subjects will receive a single oral dose of moxidectin 4mg
2934060|NCT03012828|Experimental|Moxidectin 8mg|10 subjects will receive a single oral dose of moxidectin 8mg
2934061|NCT03012828|Experimental|Moxidectin 16mg|10 subjects will receive a single oral dose of moxidectin 16mg
2934062|NCT03012828|Experimental|Moxidectin 24mg|10 subjects will receive a single oral dose of moxidectin 24mg
2934063|NCT03012828|Experimental|Moxidectin 36mg|10 subjects will receive a single oral dose of moxidectin 36mg
2934064|NCT03012828|Placebo Comparator|Placebo|10 subjects will receive a single oral dose of placebo
2934065|NCT03012815|Experimental|Gabapentin|Patients will receive gabapentin taper over 9 days with the option to add divalproex for patients who have a history of seizures or severe withdrawal. Will still undergo CIWA-Ar scoring but will not be administered a benzodiazepine.
2934066|NCT03012815|Active Comparator|Benzodiazepine|Patients will receive a benzodiazepine if scoring greater than 9 on the CIWA-Ar scale.
2934067|NCT03012789|Other|Post Surgery|
2934068|NCT03012776|Experimental|TOPS System|Investigational surgical treatment using TOPS System
2934069|NCT03012776|Active Comparator|Transforaminal Lumbar Interbody Fusion (TLIF)|Control surgical treatment using interbody fusion and placement of posterolateral instrumentation
2934070|NCT03012763|Placebo Comparator|non-caloric water|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml non-caloric water 3 h thereafter
2934071|NCT03012763|Active Comparator|caloric drink|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml caloric drink 3 h thereafter
2934072|NCT03012763|Active Comparator|grapefruit juice|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml grapefruit juice 3 h thereafter
2934073|NCT03012750|Experimental|foot perfusion|intravenous application of indocyanine green in patients receiving tibial Bypass surgery
2934074|NCT03012737|Other|MPV arm|Subjects use mouth piece ventilation (MPV) accoring to their will to alleviate dyspnea for 24 hours.
2934075|NCT03012724|Active Comparator|H1-Coil|Device: Brainsway H1-Coil Deep TMS System. An FDA cleared deep transcranial magnetic stimulation device. The coil is designed to allow deeper brain stimulation in the lateral prefrontal cortex, including the anterior cingulated cortex without a significant increase of electric fields induced in superficial cortical regions.
2934076|NCT03012724|Experimental|H7-Coil|Device: Brainsway H7-Coil Deep TMS System. A deep transcranial magnetic stimulation device. The coil is designed to allow deeper brain stimulation in the medial prefrontal cortex, including the anterior cingulated cortex without a significant increase of electric fields induced in superficial cortical regions.
2934077|NCT03012711|Experimental|Training|Neuromuscular exercise training group will complete a 5 week NME training program
2934078|NCT03012711|No Intervention|Control|Control group will have 5 weeks with no intervention prior to being re-tested
2934079|NCT03012698|Experimental|RMS treatment|
2934138|NCT03012204|Experimental|combined rTMS at both M1|combined rTMS at both M1: sham 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / real 6 Hz rTMS on affected M1
2934139|NCT03012204|Experimental|real primed LFrTMS at unaffected M1|real primed LFrTMS at unaffected M1: real 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / sham 6 Hz rTMS on affected M1
2935593|NCT03002493|Experimental|Eribulin mesylate + Rifampicin|
2934080|NCT03012672|Experimental|Arm I (higher-dose)|"INDUCTION: Patients receive G-CSF SC on days 0-5, higher dose cladribine IV over 2 hours on days 1-5, higher dose cytarabine IV over 2 hours on days 1-5, and higher dose mitoxantrone IV over 60 minutes on days 1-3. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi with up to 2 courses of Induction receive G-CSF, cladribine, and cytarabine as in Induction. Courses repeat every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
2934081|NCT03012672|Experimental|Arm II (lower-dose)|"INDUCTION: Patients receive G-CSF SC on days 0-5, lower dose cladribine IV over 2 hours on days 1-5, lower dose cytarabine IV over 1 hour on days 1-5, and lower dose mitoxantrone IV over 60 minutes on days 1-3. Treatment repeats every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi with up to 6 courses of Induction receive G-CSF, cladribine, and cytarabine as in Induction. Courses repeat every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
2934082|NCT03012659|Experimental|Intervention Arm|Full-day contraceptive counseling training for health center staff
2934083|NCT03012659|No Intervention|Control Arm|Usual care
2934084|NCT03012646|Experimental|Active Inhaled Treprostinil|Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
2934085|NCT03012620|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV as a 30 minute infusion on Day 1 of every 21 day cycle
2934086|NCT03012607|Experimental|Perfect Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA] once daily for 6 weeks
2934087|NCT03012607|Experimental|Moderate Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA] 4 times per week (Monday, Wednesday, Friday, and Saturday) for 6 weeks
2934088|NCT03012607|Experimental|Poor Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA] 2 times per week (Monday, Thursday) for 6 weeks
2934089|NCT03012594|Experimental|Lanreotide|Open label
2934090|NCT03012581|Experimental|Nivolumab|Nivolumab 240 mg IV over 60 minutes every 14 days.
2934091|NCT03012555||Sickle Cell Disease and Vitamin D deficiency|
2934092|NCT03012542|Experimental|Diet 1|Administered for 8 weeks.
2934093|NCT03012542|Experimental|Diet 2|Administered for 8 weeks.
2934094|NCT03012529|Active Comparator|Active drug|Patients receive oral adjunctive rifampin therapy
2934095|NCT03012529|Placebo Comparator|Placebo|Patients receive oral riboflavin
2934096|NCT03012516|Experimental|PAP-treatment by physiotherapist.|Enhanced PAP-support by physiotherapist including fitness test, individualized dialogue concerning PA, prescribed PAP and a 7 times follow-up during the one year intervention..
2934097|NCT03012516|Active Comparator|Ordinary PAP-treatment at the health care centre.|Ordinary PAP-treatment at the health care centre including individualized dialogue concerning PA, prescribed PAP and an individually adjusted follow-up.
2934098|NCT03012503|Placebo Comparator|Control|Five minutes before cervical manipulation, controls received a placebo gel applied to their neck.
2934099|NCT03012503|Experimental|Treatment|Five minutes before cervical manipulation the treatment group received a menthol containing gel (Biofreeze®) applied to their neck.
2934100|NCT03012490|Active Comparator|Standard remote monitoring|Remote monitoring of CRT-P and CRT-D is activated. The physician will only receive the notifications related to technical events and ventricular arrhythmias. Therapy will be added or changed in response to these notifications and/or the symptoms and signs observed during ambulatory visits.
2934101|NCT03012490|Experimental|Comprehensive remote monitoring|Remote monitoring of CRT-P and CRT-D is activated, as well as remote assessment of symptoms and signs. In addition to notifications related to technical events and ventricular arrhythmias, the physician will receive notifications related to heart failure parameters, atrial arrhythmias, and patient's symptoms and signs. Therapy will be added or changed in response to these notifications, and/or to the symptoms and signs observed during ambulatory visits.
2934102|NCT03012477|Experimental|AZD1775|"Treatment will consist of one cycle of cisplatin monotherapy (cisplatinIV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days later.~- AZD1775 will be administered as twice daily oral dosing predetermined dosing schedule, in combination with Cisplatin predetermined dosage every 21 days.~At least 10 patients will undergo a research biopsy within 5-48 hours after beginning cisplatin (Cycle 1 Day 1) and then again within 5-8 hours after the last dose of AZD1775 in cycle 2 (Cycle 2 Day 3)."
2934103|NCT03012464||Pathologic and functional assessment|Patients of both genders, aging below 45 years with internal or external rectal prolapse
2934104|NCT03012451|Experimental|Advancing Adolescents|Received structured eight-week psychosocial sessions
2934105|NCT03012451|No Intervention|Control|Controls wait-listed for the intervention, matched for age and urban residence
2934106|NCT03012438|Experimental|NIRF imaging in thyroid surgery|"7.5 mg ICG is administered i.v. and the system will be switched to fluorescence mode. If needed, a second dose of 7.5 mg ICG can be administered. After identification of the parathyroid glands, surgery will continue until there is a desire to visualize the parathyroid glands again, another dose of ICG can be given. After complete removal of thyroid, another 7.5 mg of ICG will be given to assess the perfusion of the parathyroid gland. Directly after the procedure the researcher will ask the surgeon whether he/she thinks the technique is feasible.~After surgery, the serum calcium levels will be determined in patients after total thyroidectomy on day 1, 2 and after two weeks. TSH will be determined after 2 weeks. The thyroid specimen will be send to pathology. In the specimen, the pathologist will search for parathyroid glands. Video recordings will be analyzed, quantifying the fluorescence signal compared to the background: measuring the TBR."
2934140|NCT03012204|Active Comparator|real LFrTMS at unaffected M1|real LFrTMS at unaffected M1: sham 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / sham 6 Hz rTMS on affected M1
2934141|NCT03012204|Sham Comparator|all sham stimulation|all sham stimulation： sham 6 hertz(Hz) rTMS on unaffected M1 / sham 1 Hz rTMS on unaffected M1 /sham 6 Hz rTMS on affected M1
2934142|NCT03012191|Experimental|Gentamicin|
2934143|NCT03012178||Mitral Valve Surgery|Patients undergoing ACC/AHA guideline directed mitral valve surgery for mitral insufficiency.
2934107|NCT03012425|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Session 1- Review of initial sleep diary, formulation of impression of type/subtype of insomnia, determine modifiable factors, address immediate concerns about participation, discuss motivation & compliance. Session 2- Review of sleep diary, present 4-P model of insomnia, prescribe Sleep Restriction & Stimulus Control Therapy. Session 3- Review of sleep diary, continue with stimulus control & sleep restriction procedures, review of sleep hygiene. Session 4- Review of sleep diary, continue with stimulus control & sleep restriction procedures, introduce & practice relaxation strategies. Session 5- Review of sleep diary, continue with stimulus control & sleep restriction procedures, conduct cognitive therapy to address dysfunctional thoughts underlying insomnia. Session 6- Review of sleep diary, continue with stimulus control & sleep restriction procedures Session 7- Review of sleep diary & overall progress, discuss relapse prevention, further sleep restriction guidelines & prophylaxis.
2934108|NCT03012425|Experimental|Acupuncture|Session 1 - Detailed history and examination, introduction to acupuncture. Sessions 2 - 10 - Each session will begin with insertion and manipulation of needles, which will remain in place for 30 minutes.
2934109|NCT03012412|Experimental|Mindfulness Based Program for Infertility|"Behavioral: MBPI~The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 15 participants)."
2934110|NCT03012412|No Intervention|Treatment As Usual (TAU)|Standard infertility medical treatment provided by IVF clinics (public and private) - no psychological intervention being pursued.
2934111|NCT03012399|Experimental|Hypnosedation Group (HS)|"Hypnosedation performed from before surgery begins until after surgery is complete.~Questionnaires completed before surgery, after surgery, and 14 days after surgery."
2934112|NCT03012399|Experimental|Standard of Care Group (SC)|"Empathic conversation with the hypnotherapist, but no relaxation training before surgery.~Questionnaires completed before surgery, after surgery, and 14 days after surgery."
2934113|NCT03012386|Experimental|Sildenafil citrate|Sildenafil citrate 20 mg three times a day
2934114|NCT03012373|Experimental|Ear acupressure & Electroacupuncture (A)|Electroacupuncture plus Ear acupressure or Ear acupressure alone for four weeks followed by an one week wash-out period. Then with crossover to the othe.
2934115|NCT03012373|Experimental|Ear acupressure & Electroacupuncture (B)|Electroacupuncture plus Ear acupressure or Ear acupressure alone for four weeks followed by an one week wash-out period. Then with crossover to the othe.
2934116|NCT03012360|Placebo Comparator|no antibiotic treatment for VAT|7 days of placebo
2934117|NCT03012360|Experimental|antibiotic treatment for 3 days|"Patients randomized in one of the two experimental groups will receive 3 days of antimicrobials. Antibiotic treatment is standardized, based on the time of onset of VAT, and presence of risk factors for MDR bacteria:~patients with early-onset VAT (< 5 days of mechanical ventilation), with no risk factor for MDR will receive ceftriaxone .~patients with late-onset VAT (≥5 days of mechanical ventilation), or with at least one risk factor for multidrug resistant bacteria will receive imipenem , and ciprofloxacin as empirical treatment.~When methicillin-resistant Staphylococcus aureus (MRSA) is suspected linezolid will be added to empirical treatment.~3 days of imipenem and ciprofloxacin with optional linezolid, followed by 4 d of placebo"
2934118|NCT03012360|Experimental|antibiotic treatment for 7 days|"Patients randomized in one of the two experimental groups will receive 7 days of antimicrobials. Antibiotic treatment is standardized, based on the time of onset of VAT, and presence of risk factors for MDR bacteria:~patients with early-onset VAT (< 5 days of mechanical ventilation), with no risk factor for MDR will receive ceftriaxone.~patients with late-onset VAT (≥5 days of mechanical ventilation), or with at least one risk factor for multidrug resistant bacteria will receive imipenem, and ciprofloxacin as empirical treatment.~When methicillin-resistant Staphylococcus aureus (MRSA) is suspected, linezolid will be added to empirical treatment.~7 days of imipenem and ciprofloxacin with optional linezolid"
2934119|NCT03012347|Experimental|Sunscreen Users|Subjects will participate in a 2-Day study involving three applications of a single test article each day. The first application will be followed by an exposure of 30 minutes in a hot room.
2934120|NCT03012334|Experimental|Treatment A|Lasmiditan 50 mg, single oral tablet given once during study
2934121|NCT03012334|Experimental|Treatment B|Lasmiditan 100 mg, single oral tablet given once during study
2934122|NCT03012334|Experimental|Treatment C|Lasmiditan 200 mg, single oral tablet given once during study
2934123|NCT03012334|Active Comparator|Treatment D|Alprazolam 1 mg, single oral tablet given once during study
2934124|NCT03012334|Placebo Comparator|Treatment E|Single oral tablet given once during study
2934125|NCT03012321|Active Comparator|Arm I: Abiraterone + Prednisone|Abiraterone 1000 mg orally once daily and prednisone 5 mg orally twice daily, days 1-28 in 28 day cycles.
2934126|NCT03012321|Active Comparator|Arm II: Olaparib|Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
2934127|NCT03012321|Active Comparator|Arm III: Abiraterone + Prednisone + Olaparib|Abiraterone 1000 mg orally once daily, prednisone 5 mg orally twice daily, olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
2934128|NCT03012321|Active Comparator|Olaparib|Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
2934129|NCT03012282|Experimental|Diagnostic (CT perfusion sequence)|Patients undergo CT perfusion sequence over 30 seconds during the baseline standard of care CT scan and during follow-up CT scans at 2 and possibly 4 months after chemotherapy, at 4-6 weeks after radiation therapy, or prior to definitive surgery.
2934130|NCT03012269|Experimental|Working Memory Training|The subjects of experimental group received a series of working memory training, 30 min for 5 days per week during 6 weeks.
2934131|NCT03012269|No Intervention|Non-Working Memory Training|The subjects of control group performed traditional cognitive rehabilitation without working memory training, 30 min for 5 days per week during 6 weeks.
2934132|NCT03012256|Experimental|Cardio-respiratory management model|Additional home care management includes medication reconciliation, self-care education, advanced care planning, as well as physician communication and transfer protocols
2934133|NCT03012256|No Intervention|Control|Home care (standard of care)
2934134|NCT03012243|Active Comparator|Cholecystostomy|Percutaneous cholecystostomy, leaving drain in situ
2934146|NCT03012165|Placebo Comparator|Vehicle of ADX-102 Ophthalmic Drops|Vehicle of ADX-102 Ophthalmic Drops
2934147|NCT03012152|Active Comparator|Standard conservative group|Group A (35 patients) have standard curative conservative breast surgery without integration of plastic techniques .
2934148|NCT03012152|Active Comparator|Oncoplastic group|Group B(35 patients) have curative oncoplastic surgery in which plastic techniques integrated with oncological procedures
2934149|NCT03012139||Cancer with cachexia|Men and women (ages 35-80 years) with cancer cachexia (≥5% drop in body mass in less than 12 months)
2934150|NCT03012139||Cancer without cachexia|Men and women (ages 35-80 years) with cancer but without cachexia of similar age and sex as the group with cachexia
2934151|NCT03012139||No cancer|Men and women (ages 35-80 years) without cancer, but similar age and sex as groups with cancer.
2934152|NCT03012126|Experimental|Clinically Based: Healthy Weight Clinic|All families referred to the Healthy Weight Clinic intervention arm will be scheduled for a 30-45 minute orientation clinic visit to orient the child and family to the program. During this visit, the family will meet with the community health worker who will provide a schedule of clinic visits and dietitian contacts. The community health worker will assess the child's social and environmental context to allow treatment tailoring. For the first 6 months, each family will be asked to attend two clinic visits per month and complete weekly 20-30 minute contacts with the dietitian via telephone. The program aims to deliver approximately 30 contact hours in the 6-month period. This will be followed by monthly visits to the Healthy Weight Clinic and monthly calls with their dietitian.
2934153|NCT03012126|Experimental|Community Based: Healthy Weight & Your Child|All families referred to the Healthy Weight and Your Child intervention arm will be scheduled for a 60-minute family information session to orient the child and family to the program. During this visit, the family will receive information about the program and logistics such as program schedule and format and attendance. The program is delivered over 12 months, which includes 16 weekly sessions, followed by 4 sessions delivered every other week and concluding with 5 monthly sessions. Most sessions are 2 hours in length and include a group of about 8-15 children and their caregivers. The first hour is delivered in a classroom setting and the second hour in an additional area conducive for physical activity.
2934154|NCT03012113|Other|Short term mild cooling|Subjects will undergo a short term mild cooling protocol consisting of personalized water cooling method for approximately 2 hours.
2934155|NCT03012113|Active Comparator|Mirabegron|Subjects will receive one dosage of 200 mg Mirabegron (Astellas Pharma).
2934156|NCT03012113|Placebo Comparator|Placebo|Subjects will receive one dosage of Placebo, which is packed and labeled to mach the active compound.
2934157|NCT03012100|Experimental|Arm I (FRalpha peptide vaccine, sargramostim)|Patients receive cyclophosphamide PO BID on days 1-7 and 15-21 of course 1 only. Starting course 2, patients receive multi-epitope folate receptor alpha peptide vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for courses 2-7 and every 6 months for courses 8-14 in the absence of disease progression or unacceptable toxicity.
2934158|NCT03012100|Placebo Comparator|Arm II (placebo, sagramostim)|Patients receive cyclophosphamide as in Arm I. Starting course 2, patients receive placebo vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for courses 2-7 and every 6 months for courses 8-14 in the absence of disease progression or unacceptable toxicity.
2934159|NCT03012087|Experimental|Intervention Group|MyHealthyChoices
2934160|NCT03012087|Placebo Comparator|Control Group|Health Risk Assessment
2934161|NCT03012074|Experimental|Patients with Type II Diabetes|Patients with Type II Diabetes
2934162|NCT03012061|Placebo Comparator|Placebo|Subjects will be administered placebo once daily via the ELLIPTA® dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks. ELLIPTA is a registered trademark of the GSK group of companies.
2934163|NCT03012061|Experimental|UMEC 62.5 mcg|Subjects will be administered UMEC 62.5 mcg once daily via the ELLIPTA dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks.
2934164|NCT03012061|Experimental|UMEC 31.25 mcg|Subjects will be administered UMEC 31.25 mcg once daily via the ELLIPTA dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks.
2934165|NCT03012048|Experimental|MadiDrop (ceramic tablet)|"Households receive a MadiDrop (silver-impregnated ceramic tablet) in a safe-storage water container to use for all drinking water needs in the household. MadiDrops are replaced every 6 months over the 2-year intervention study period.~In July 2017, all households in the MadiDrop arm were crossed over to the ceramic water filter arm due to inconsistent silver release from the ceramic tablets."
2934166|NCT03012048|Active Comparator|Silver-impregnated ceramic water filter|"Households receive a silver-impregnated ceramic filter in a safe-storage water container to use for all drinking water needs in the household. Filters are replaced at the end of the 2-year intervention study period.~In December 2017, all silver-impregnated ceramic water filters were replaced with the same ceramic filters without silver due to continued inconsistencies with silver release."
2934167|NCT03012048|Active Comparator|Safe-storage water container|Households receive a safe-storage water container alone to use for all drinking water needs in the household.
2934168|NCT03012048|No Intervention|No intervention|Households are encouraged to continue their usual water treatment practices.
2934169|NCT03012035|Experimental|experimental group|Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
2934170|NCT03012035|Other|comparator group|The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
2934171|NCT03012022||Healthy Volunteers|
2934207|NCT03011866|Other|Control|"Loading dose: 10mg/kg tranexamic acid(TXA) in 100ml 0.9% NS intravenous infusion, 15-20min prior to operation initiation.~Maintenance dose: 1mg/kg/hr TXA intravenous infusion till the last suture. Bolus dose: the wound topically irrigated with 250ml 0.9% NS for 5min. Waste fluid was then removed by suction, and the wound was closed."
2934172|NCT03012009|Active Comparator|Full ablative CO2 laser + MAL PDT|The treatment starts with a full ablative CO2 laser pretreatment under local anaesthesia with injectable lidocaine hydrochloride 2% with epinephrine. This ablation is followed by photodynamic therapy: MAL is topically applied, followed by a 3 hours incubation under occlusion, whereafter 10 minutes of illumination with a LED lamp. This treatment is repeated after 14 days.
2934173|NCT03012009|Active Comparator|Fractional ablative CO2 laser+ MAL PDT|The treatment starts with a fractional ablative CO2 laser ablation under local anaesthesia with injectable lidocaine hydrochloride 2% with epinephrine. This ablation is followed by photodynamic therapy: MAL is topically applied, followed by a 3 hours incubation under occlusion, whereafter 10 minutes of illumination with LED lamp. This treatment is repeated after 14 days.
2934174|NCT03011996|Experimental|CJ-12420 100mg|CJ-12420 100mg BID for 5 days
2934175|NCT03011996|Experimental|CJ-12420 50mg + CLR 500mg + AMX 1g|coadministration of CJ-12420 50mg and CLR 500mg/AMX 1g BID for 7 days
2934176|NCT03011996|Active Comparator|Pantoprazole 40mg + CLR 500mg + AMX 1g|coadministration of Pantoprazole 40mg and CLR 500mg/AMX 1g BID for 7 days
2934177|NCT03011996|Experimental|CJ-12420 100mg + CLR 500mg + AMX 1g|coadministration of CJ-12420 100mg, CLR 500mg/AMX 1g BID for 7 days
2934178|NCT03011996|Experimental|CLR 500mg/AMX 1g|CLR 500mg/AMX 1g BID for 5 days
2934179|NCT03011996|Experimental|CJ-12420 100mg + CLR 500mg/AMX 1g|coadministration of CJ-12420 100mg and CLR 500mg/AMX 1g BID for 7 days
2934180|NCT03011983||Adolescents With Concussion|Adolescents with a concussion (n=120) will undergo neuroimaging (MEG and MRI) and neuropsychology assessments at two time points in the acute and chronic periods after injury, respectively. Brain imaging injury measures will be compared to a control normative database we will create. These brain measures will also be associated with cognitive and clinical outcomes.
2934181|NCT03011983||Adolescents Without Concussion|Age- and gender-matched healthy controls (n=160) will be recruited to establish a normative database of whole-brain slow-wave maps from MEG resting-state data as well as white-matter diffusion measures from MRI.
2934182|NCT03011970|Active Comparator|Oxytocin; 24IU, 15min|Intranasal administration, 24 international units (IU) oxytocin. Imaging starting 15min after nasal spray administration.
2934183|NCT03011970|Active Comparator|Oxytocin; 24IU, 45min|Intranasal administration, 24 IU oxytocin. Imaging starting 45min after nasal spray administration.
2934184|NCT03011970|Active Comparator|Oxytocin; 24IU, 75min|Intranasal administration, 24 IU oxytocin. Imaging starting 75min after nasal spray administration.
2934185|NCT03011970|Active Comparator|Oxytocin; 12IU, 45min|Intranasal administration, 12 IU oxytocin. Imaging starting 45min after nasal spray administration
2934186|NCT03011970|Active Comparator|Oxytocin; 48IU, 45min|Intranasal administration, 48 IU oxytocin. Imaging starting 45min after nasal spray administration
2934187|NCT03011970|Placebo Comparator|Placebo|Placebo nasal spray.
2934188|NCT03011957||Group 1|HIV positive viral load < 200 copies/ml 50-65 years old CD4 > 350 cells/ml Male or Female
2934189|NCT03011957||Group 2|HIV negative 50-65 years old CD4 > 350 cells/ml Male or Female
2934190|NCT03011944||Quality Improvement Program|This group will consist of hospitalized and SNF, at-risk/malnourished patients being discharged to home health and outpatients at-risk/malnourished patients enrolled in home health.
2934191|NCT03011944||Control|This group will consist of historical controls, concurrent controls, and matched concurrent controls across other sites within the health system.
2934192|NCT03011931|Experimental|Simvastatin|Simvastatin tablet, 20 mg, one time by mouth
2934193|NCT03011918||Observational Single Event Faller|one documented fall as an in-patient. It is hypothesized that the nutrition factors present prior to the first fall may be related to fall frequency. Data on exposure to nutrition supplementation will be collected for future analysis. Subpopulation alalysis of individuals with dementia will also be conducted
2934194|NCT03011918||Observational Multiple event faller|multiple falls documented during in-patient stay It is hypothesized that frequent fallers will demonstrate statistically greater weight decline, Hgb decline, Vitamin D deficiency and Higher C-Reactive Protein values prior to the first fall. Data on exposure to nutrition supplementation will be collected for future analysis.. Subpopulation analysis of individuals with dementia will also be conducted.
2934195|NCT03011905|Experimental|Dexamethasone|Single dose of dexamethasone (Dexagalen) 16 mg iv during operation.
2934196|NCT03011905|Placebo Comparator|Control|Single dose of NaCl, 4 ml, iv during operation.
2934197|NCT03011892|Experimental|INCB018424 cream 1.5% BID|INCB018424 cream 1.5% applied BID for 8 weeks. At Week 8, subjects who meet criteria will be offered open-label treatment with INCB018424 1.5% cream BID for 4 weeks.
2934198|NCT03011892|Experimental|INCB018424 cream 1.5% QD|INCB018424 cream 1.5% applied QD for 8 weeks. At Week 8, subjects who meet criteria will be offered open-label treatment with INCB018424 1.5% cream BID for 4 weeks.
2934199|NCT03011892|Experimental|INCB018424 cream 0.5% QD|INCB018424 cream 0.5% applied QD for 8 weeks. At Week 8, subjects who meet criteria will be offered open-label treatment with INCB018424 1.5% cream BID for 4 weeks.
2934200|NCT03011892|Experimental|INCB018424 cream 0.15% QD|INCB018424 cream 0.15% applied QD for 8 weeks. At Week 8, subjects who meet criteria will be offered open-label treatment with INCB018424 1.5% cream BID for 4 weeks.
2934201|NCT03011892|Active Comparator|Triamcinolone 0.1% cream BID|"Vehicle cream applied BID for 4 weeks after triamcinolone 0.1% cream applied BID for initial 4 weeks.~At Week 8, subjects who meet criteria will be offered open-label treatment with INCB018424 1.5% cream BID for 4 weeks."
2934202|NCT03011892|Placebo Comparator|Vehicle cream|Vehicle cream applied BID for 8 weeks. At Week 8, subjects who meet criteria will be offered open-label treatment with INCB018424 1.5% cream BID for 4 weeks.
2934203|NCT03011879||1.STEMI patients with symptom onset within 30 days|First round enrollment of STEMI patients with symptom onset within 30 days
2934204|NCT03011879||2.STEMI patients with symptom onset within 30 days|Second round enrollment of STEMI patients with symptom onset within 30 days
2934205|NCT03011879||3.STEMI patients with symptom onset within 30 days|Third round enrollment of STEMI patients with symptom onset within 30 days
2934206|NCT03011866|Experimental|Experimental|"Loading dose: 100ml 0.9% normal saline(NS) intravenous infusion, 15-20min prior to operation initiation.~Maintenance dose: 5ml/hr 0.9% NS intravenous infusion till the last suture. Bolus dose: the wound topically irrigated with 500mg TXA in 250ml 0.9% NS for 5min. Waste fluid was then removed by suction, and the wound was closed."
2934208|NCT03011840|No Intervention|Pre intervention|"In the first part planned over 2months (Jan - Feb), feedback forms will be collected from patients at the end of minor OT procedure. The number of postponement or rescheduling of cases will be noted.~Postponement or rescheduling of case is defined as an event when the patient who is called for his turn in minor OT is deferred for any amount of time in account of starvation not adequate, investigations not brought, medications not taken as prescribed."
2934209|NCT03011840|Experimental|Post Intervention|In the intervention phase, the patient information leaflet (PIL) will be handed over to all patients planned for procedure in the minor OT complex. This leaflet will be handed over by the attending doctor in the Head neck OPD. The checklist pertaining to counselling at the Head neck OPD will be ticked after they are carried out. The patient will be instructed to read leaflet carefully and carry the leaflet on the day of Minor OT procedure. In the minor OT the discharge checklist in the PIL would be carried out by all concerned including the surgical, anesthesia and nursing team. The impact of use of PIL will be assessed by noting the number of postponement or rescheduling of cases.
2934210|NCT03011827|Experimental|Prospective cohort|Fibrinogen and/or platelet administration
2934211|NCT03011814|Experimental|Arm I (durvalumab)|Patients receive durvalumab IV over 1 hour on day 1. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
2934212|NCT03011814|Experimental|Arm II (durvalumab, lenalidomide)|Patients receive durvalumab IV over 1 hour on day 1 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
2934213|NCT03011801|Experimental|Behavioral: Interpersonal Therapy|Individual psychotherapy that includes an initial engagement session and a total of 8 sessions. IPT focuses on psychoeducation and interpersonal skill building to decrease interpersonal conflict and increase interpersonal support and competence.
2934214|NCT03011801|Placebo Comparator|Enhanced Usual Care|Maternity support services (MSS) is the usual standard of care for pregnant women. A multi-disciplinary team of obstetric care providers routinely screen women for possible depression diagnosis. If a woman screens positive, she is seen by a behavioral health specialist (BHS) for further assessment and to initiate treatment, if necessary. The goals of MSS include offering services to promote healthy pregnancies and positive birth and parenting outcomes, including integrating mental health and prenatal care. Women with elevated depressive symptoms are seen by BHS throughout the pregnancy and postpartum period and then bridged to mental health treatment. BHS provides eclectic-based care but does not provide IPT.
2934215|NCT03011788|Active Comparator|Single day|Single day Golytely purge 4L purge
2934216|NCT03011788|Active Comparator|2 day colon purge|Two days of Golytely purge 8L purge
2934217|NCT03011775|Experimental|study|20 patients who received standard medical therapy complex: isosorbide dinitrate 10-20 mg 2 times a day, acetylsalicylic acid 75 mg 1 time a day, bisoprolol 2.5 mg 1 time a day, rosuvastatin 20 mg 1 time a day, ramipril 5 mg 1 time a day. Patients also received recommendations on diet and lifestyle changes. Included pioglitazone 15 mg 1 time per day in the morning for 6 months.
2934218|NCT03011775|Other|control|23 patients who received standard medical therapy complex: isosorbide dinitrate 10-20 mg 2 times a day, acetylsalicylic acid 75 mg 1 time a day, bisoprolol 2.5 mg 1 time a day, rosuvastatin 20 mg 1 time a day, ramipril 5 mg 1 time a day. Patients also received recommendations on diet and lifestyle changes.
2934219|NCT03011762|Other|Computer Controlled Mandibular Positioner|All study participants will undergo the computer controlled mandibular positioner test.
2934220|NCT03011749|Experimental|FLT PET/CT|FLT PET/CT
2934221|NCT03011736|Experimental|Supportive Care (parathyroidectomy)|Patients undergo standard minimally invasive parathyroidectomy without PTH testing during surgery.
2934222|NCT03011723|Experimental|Music therapy|10 weekly sessions of in-home music therapy for PWDs and a caregiver, including weekly practicing of the interventions with the caregiver between the sessions. The treatment is administered individually.
2934223|NCT03011710|Experimental|E-cigarette with nicotine|Nicotine level: 6 mg/ml
2934224|NCT03011710|Experimental|E-cigarette without nicotine|Nicotine level: 0 mg/ml
2934225|NCT03011710|Experimental|Conventional cigarette|Nicotine content: 0,5mg
2934226|NCT03011710|Placebo Comparator|Cigarette tip|Placebo device
2934227|NCT03011684|Experimental|ER Positive - Letrozole|
2934228|NCT03011684|Experimental|ER Positive - Tamoxifen|
2934229|NCT03011684|No Intervention|ER Negative|
2934230|NCT03011671|Experimental|Acetazolamide with Temozolomide|Subjects will receive daily ACZ together with TMZ in 28 day cycles for up to 6 cycles if they do not experience either disease worsening or unacceptable side effects.
2934231|NCT03011658|Placebo Comparator|GROUP A|5 ml of venous blood will be obtained from this group who do not have oral lichen planus and suffering from anxiety and/or depression. They will be administered a HADS standard questionnaire and their stress related issues calculated accordingly. This group has 30 patients totally
2934232|NCT03011658|Other|GROUP B|The group has 30 oral symptomatic lichen planus diagnosed patients also suffering with anxiety and/or depression. 5 ml of venous blood will be obtained from them for serum cortisol level analysis. HADS questionnaire will be administered for this group for evaluation of levels of anxiety and depression
2934233|NCT03011645|Active Comparator|Ziprasidone|Ziprasidone 60 mg tablet by mouth, once a day for one day.
2934234|NCT03011645|Active Comparator|Lorcaserin|Lorcaserin 20 mg tablet by mouth, once a day for one day.
2934235|NCT03011645|Placebo Comparator|Placebo Oral Tablet|Sugar pill (in place of ziprasidone and lorcaserin) by mouth, once a day for one day.
2934236|NCT03011632|Experimental|mometasone nasal|a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months,
2934237|NCT03011632|Placebo Comparator|placebo mometasone|a group of children without immunoglobulin E (IgE) - dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
2934238|NCT03011619|Active Comparator|Control Condition|usual standard of care during an inpatient psychiatric hospitalization; medication management, group therapy, and individual therapy.
2934497|NCT03010046|Experimental|ANX005 and IVIg Combination Therapy|ANX005 intravenous infusion in combination with intravenous immunoglobulin (IVIg)
2934239|NCT03011619|Experimental|CBT Condition|If a patient is randomly assigned to the enhanced CBT group, they will participate in manualized CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.
2934240|NCT03011606|Experimental|Robotic surgery|Single arm. All Registered patients will undergo robotic surgery
2934241|NCT03011593|Experimental|Nutrition Support Product|Participants were asked to take a nutrition support product twice per day for a period of 6 weeks.
2934242|NCT03011580|Experimental|Immediate supplementation arm|"Fultium-D3 (oral cholecalciferol or vitamin D3) will be given at a dose of 9,600 IU/day for 8 weeks (three capsules once daily as each Fulitium D-3 capsules contains 3,200 IU vitamin D3). Participants may also be given a Sensemedic dispenser each for real-time adherence monitoring and shown how to use it.~All participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day at the end of the study."
2934243|NCT03011580|Placebo Comparator|Delayed supplementation arm|Oral placebo will be given for 8 weeks at a dose of three capsules once daily. Fultium-D3 and placebo will be identical in appearance and taste. Participants may also be given a Sensemedic dispenser each for real-time adherence monitoring and shown how to use it. All participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day at the end of the study.
2934244|NCT03011567|Experimental|Severe HDP- NSAID|This arm will be assigned a postpartum analgesic regimen with ibuprofen.
2934245|NCT03011567|Experimental|Mild HDP- NSAID|This arm will be assigned a postpartum analgesic regimen with ibuprofen.
2934246|NCT03011567|Experimental|Severe HDP- No NSAID|This arm will be assigned a postpartum analgesic regimen with acetaminophen.
2934247|NCT03011567|Experimental|Mild HDP- No NSAID|This arm will be assigned a postpartum analgesic regimen with acetaminophen.
2934248|NCT03011554|Experimental|Implantable Miniature Telescope (IMT)|Intervention: Implanting the Implantable Miniature Telescope (IMT) in pseudophakic eyes of patients suffering from binocular end-stage AMD.
2934249|NCT03011541|Active Comparator|Arm 1|BMSC provided retrobulbar, subtenon and intravenous for one or both eyes
2934250|NCT03011541|Active Comparator|Arm 2|BMSC provided retrobulbar, subtenon, intravitreal and intravenous for one or both eyes
2934251|NCT03011541|Active Comparator|Arm 3|BMSC provided either intraoptic nerve or subretinal for eye with worse vision with fellow eye receiving either retrobulbar and subtenon or retrobulbar, subtenon and intravitreal; followed by intravenous.
2934252|NCT03011528|Other|VDC - IE x2 & Surgery|"Patients in Arm A receive~VDC-IE x2: Intensified induction phase:~4 cycles of VDC (Vincristine Doxorubicine Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if good response after the 4th treatment, followed by:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association~Consolidation BuMel High dose chemotherapy (Busulfan Melphalan) followed by Peripheral Blood Stem Cell Infusion~Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added~Maintenance phase~1st year : VCC (Vincristine Cyclophosphamide Celecoxib) association~2nd year : Cyclophosphamide po 25 mg/m²"
2934253|NCT03011528|Other|VDC - IE & TEMIRI & Surgery|"Patients in Arm B receive~VDC-IE & TEMIRI: Intensified induction phase:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if poor response after the 4th treatment, followed by:~4 cycles of TEMIRI (Temozolomide-Irinotecan) association~Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~Maintenance phase~1st year : VCC (Vincristine Cyclophosphamide Celecoxib) association~2nd year : Cyclophosphamide po 25 mg/m²"
2934254|NCT03011528|Other|VDC - IE x2 & Radiotherapy|"Patients in Arm C receive~VDC-IE x2: Intensified induction phase:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if good response after the 4th treatment, followed by:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~Maintenance phase~1st year : VCC (Vincristine Cyclophosphamide Celecoxib) association~2nd year : Cyclophosphamide po 25 mg/m²"
2934255|NCT03011528|Other|VDC - IE & TEMIRI & Radiotherapy|"Patients in Arm D receive~VDC-IE & TEMIRI: Intensified induction phase:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if poor response after the 4th treatment, followed by:~4 cycles of TEMIRI (Temozolomide-Irinotecan) association~Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~Maintenance phase~1st year : VCC (Vincristine Cyclophosphamide Celecoxib) association~2nd year : Cyclophosphamide po 25 mg/m²"
2934256|NCT03011515||LRTI patients|Patients with suspicion of LRTI, excluding episodes of COPD exacerbations
2934257|NCT03011515||Non-infectious patients|Afebrile patients with no apparent infectious disease
2934258|NCT03011515||LRTI patients with COPD|Patients with suspicion of LRTI in a sub-group of patients with COPD
2934259|NCT03011502|Experimental|Experimental arm|
2934260|NCT03011489|Experimental|Vacuum formed aligners group|This group will receive Vacuum formed aligners in addition to taping for 3 Months with follow-up every 1-2 weeks
2934261|NCT03011489|No Intervention|control group|This group will not receive any treatment
2934262|NCT03011476|Active Comparator|Donepezil|dosage: 5mg, 10mg frequency: once a day duration: 12 weeks
2934263|NCT03011476|Placebo Comparator|Placebos|dosage: 5mg, 10mg frequency: once a day duration: 12 weeks
2934264|NCT03011463|Active Comparator|trospium intravenous|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o.
2934265|NCT03011463|Active Comparator|trospium oral|Oral administration of 30 mg trospium chloride with 240 ml tap water
2934498|NCT03010046|Placebo Comparator|Placebo|Placebo intravenous infusion
2934266|NCT03011463|Active Comparator|trospium intravenous with ranitidine|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and oral administration of 300 mg ranitidine with 240 ml tap water
2934267|NCT03011463|Active Comparator|trospium intravenous with clarithromycin|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and oral administration of 500 mg clarithromycin with 240 ml tap water
2934268|NCT03011463|Active Comparator|trospium oral with ranitidine|Oral administration of 30 mg trospium chloride together with 300 mg ranitidine with 240 ml tap water
2934269|NCT03011463|Active Comparator|trospium oral with clarithromycin|Oral administration of 30 mg trospium chloride together with 500 mg clarithromycin with 240 ml tap water
2934270|NCT03011450|Placebo Comparator|12 Week Efficacy|K-877 or placebo comparator for 12 weeks
2934271|NCT03011450|Active Comparator|40 week extension|K-877 or fenofibrate comparator for 40 weeks
2934272|NCT03011437||cases|Patients who undergo esophagogastroduodenoscopy during 01/12/2016 and 31/12/2016 in the First People's Hospital of Kashgar Region.
2934273|NCT03011424|Experimental|Early Postoperative Extracorporal Liver Support Therapy (ELS)|Early Postoperative Extracorporal Liver Support Therapy (ELS) by using the Molecular Adsorbent Recirculating System (MARS)
2934274|NCT03011385|Experimental|Individual Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity) will be formed. Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
2934275|NCT03011385|Experimental|Dyadic Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans as well as coping plans will be formed. Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of only one person in the dyad. This target person will be selected jointly by the participants if both participants are healthy. If one participant has a chronic disease, e.g. diabetes or a cardiovascular disease, the plans are formed for the person with a disease."
2934276|NCT03011385|Experimental|Collaborative Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans and coping plans will be formed. Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of both persons within the dyad (both partners) and include some plans for joint physical activity."
2934277|NCT03011385|Active Comparator|Education|The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a partner-partner dyad and discusses individual guidelines for both dyadic partners.
2934278|NCT03011372|Experimental|Pemigatinib|
2934279|NCT03011359|Experimental|1) Conventional PCA mode|(Mode setting; total volume: 140 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 15 minutes)
2934280|NCT03011359|Active Comparator|2) Optimizing B.I PCA mode|Optimizing Basal Infusion (New) PCA mode(Mode setting; total volume: 140 ml, flow rate: changable by patients' requirement, bolus volume: 0.5 ml, and LOT: 15 minutes)
2934281|NCT03011346|Active Comparator|Symetis ACURATE neo/TF transfemoral TAVI system|Symetis ACURATE neo/TF transfemoral TAVI system: self-expandable transcatheter aortic bioprosthesis, support frame made of nitinol, supra-annular processed trileaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland)
2934282|NCT03011346|Active Comparator|Edwards Sapien 3 Transcatheter Heart Valve|Edwards SAPIEN 3 Transcatheter Heart Valve system: balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)
2934283|NCT03011333|Experimental|Group 1|HTX-011 60 mg
2934284|NCT03011333|Experimental|Group 2|HTX-011 120 mg
2934285|NCT03011333|Experimental|Group 3|HTX-011 240 mg
2934286|NCT03011333|Experimental|Group 4|HTX-011 400 mg
2934287|NCT03011333|Active Comparator|Group 5|Bupivacaine HCl 50 mg
2934288|NCT03011333|Placebo Comparator|Group 6|Saline Placebo
2934289|NCT03011320|Experimental|Cohort 1|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 4 mg/m2 EC1456 at <8 hours prior to surgery"
2934290|NCT03011320|Experimental|Cohort 2|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 4 mg/m2 EC1456 at 48±4 hours prior to surgery"
2934291|NCT03011320|Experimental|Cohort 3|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 8 mg/m2 EC1456 at <8 hours prior to surgery"
2934405|NCT03010605|Active Comparator|Standard of care physical therapy|Patients will receive 2 weeks of in-home physical therapy consisting of 3 sessions per week followed by 4 weeks of outpatient physical therapy three times weekly.
2934292|NCT03011320|Experimental|Cohort 4|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 8 mg/m2 EC1456 at 48±4 hours prior to surgery"
2934293|NCT03011307|Experimental|Oxytocin|Oxytocin 100 micrograms administered intrathecally
2934294|NCT03011307|Placebo Comparator|Placebos|Placebo injection administered intrathecally
2934295|NCT03011294|Active Comparator|CPAP (in the partner)|Positive airway pressure for treating OSA in the bed partner.
2934296|NCT03011294|Placebo Comparator|Nasal strips (in the partner)|Use od nasal dilator as a placebo for treating OSA in the bed partner.
2934297|NCT03011281||RA patients who start Tofacitinib|Korean RA patients who start Tofacitinib with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate or biologics.
2934298|NCT03011268|Experimental|Anti TNF discontinuation|Discontinuation of anti-TNF treatment (Infliximab, Adalimumab, Golimumab)
2934299|NCT03011268|Active Comparator|Anti TNF continuation|Continuation of anti-TNF treatment (Infliximab, Adalimumab, Golimumab)
2934300|NCT03011255|Experimental|peptide specific CTL arm|peptide specific CTL, radiation
2934301|NCT03011242||Psoriatic Arthritis|Individual diagnosed with Psoriatic Arthritis
2934302|NCT03011242||Healthy|Individuals that are healthy
2934303|NCT03011229|Active Comparator|Pro Core|Subject is randomized to ProCore standard needle.
2934304|NCT03011229|Experimental|Medtronic Shark Core|Subject is randomized to Medtronic Sharkcore needle
2934305|NCT03011216|Experimental|Adaptive emotional cognitive control training|"Adaptive emotional n-back task: On each trial of this task, participants are presented with an emotional facial expression. Participants have to indicate whether the emotion presented in the current trial is the same as n trials back. In order to train participants at their individual ability level, the n-level varies by trial block based on participants' performance on the previous block.~The adaptive emotional n-back task is assumed to train the ability to continuously update emotional material in working memory."
2934306|NCT03011216|Active Comparator|Placebo training|"Adaptive non-emotional feature match task: On each trial of this task, participants are presented with two panels containing 8-12 shapes each. Participants are asked to compare the two panels and decide whether or not they are identical. The panels contain a minimum of 8 shapes and a maximum of 12 shapes, depending on participants' performance on the previous block.~The adaptive non-emotional feature match task is assumed to train the speed of responding (involving processes like visual search and concentration). It does not trait working memory updating."
2934307|NCT03011203|Experimental|Ketone-ester drink|Oral intake - physical exercise
2934308|NCT03011203|Active Comparator|Carbohydrate drink|Oral intake - physical exercise
2934309|NCT03011190|Experimental|Iconic Therapy|The Iconic Therapy program consists of two parts: a) an intensive program of 10-12-week basic skills group 60-minute duration with a range of 6 to 8 face-to-face inserted sessions and b) an additional one-year program of 4 to 6 gradually less frequent face-to-face sessions. The groups are typically lead by two trainers —therapist and co-therapist- for about 8-12 outpatients. Added to these established sessions, a variable number of face-to-face individual sessions with the principal investigator will also take place. They will depend on participant´s requirements. They will consist on coaching their demands and providing human support throughout the study.
2934310|NCT03011190|Active Comparator|Support therapy|Support therapy consist of 10-12 weekly group sessions of 60-minute duration. Patients and trainers will learn and debate about different behavioral aspects of the borderline personality disorder: emotional instability and impulses control, Jacobson relaxation technique, self-image and communicational styles, mindfulness, self-esteem or social skills to name a few. The groups are typically lead by two trainers —therapist and co-therapist- for about 8-12 outpatients.Added to these established group sessions, a variable number of face-to-face individual sessions with the principal investigator will also take place. They will depend on participant´s requirements. They will consist on coaching their demands and providing human support throughout the study.
2934311|NCT03011177|Experimental|teneligliptin|teneligliptin 20mg qd
2934312|NCT03011177|Active Comparator|linagliptin|linagliptin 5mg qd
2934313|NCT03011164||WV 1|The condition of this group will be set as participants walking at 3.5km/h
2934314|NCT03011164||WV 2|The condition of this group will be set as participants walking at 4.0km/h
2934315|NCT03011164||RV 1|The condition of this group will be set as participants running at 3.5km/h
2934316|NCT03011164||RV 2|The condition of this group will be set as participants running at 4.0km/h
2934317|NCT03011138||V 1|Gait velocity will be set at 1.0km/h.
2934318|NCT03011138||V 2|Gait velocity will be set at 1.5km/h.
2934319|NCT03011138||V 3|Gait velocity will be set at 2.0km/h.
2934320|NCT03011138||V 4|Gait velocity will be set at 2.5km/h.
2934321|NCT03011138||V 5|Gait velocity will be set at 3.0km/h.
2934322|NCT03011138||V 6|Gait velocity will be set at 3.5km/h.
2934323|NCT03011138||V 7|Gait velocity will be set at 4.0km/h.
2934324|NCT03011125|Placebo Comparator|placebo|
2934325|NCT03011125|Experimental|Dexlansoprazole Injection|
2934326|NCT03011112||KL 1|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 1 according to Kellgrence/Lawrence score.
2934327|NCT03011112||KL 2|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 2 according to Kellgrence/Lawrence score.
2934328|NCT03011112||KL 3|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 3 according to Kellgrence/Lawrence score.
2934329|NCT03011112||KL 4|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 4 according to Kellgrence/Lawrence score.
2934330|NCT03011099|Experimental|Robotic exoskeleton training|During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.
2934331|NCT03011099|Active Comparator|Conventional Physical Therapy|During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
2934332|NCT03011086||oral sub mucous fibrosis|patients suffering with oral sub mucous fibrosis due to gutka/pan chewing confirmed by clinical examination
2934333|NCT03011086||control group|patients having gutka/ pan chewing habit without oral sub mucous fibrosis in oral cavity
2934334|NCT03011060|Experimental|NAC not achieving pCR|"Patients in the study group will accept neo-adjuvant chemotherapy. Among these patients, those who do not achieve pCR after neo-adjuvant chemotherapy will be treated with Capecitabine after surgery. And then they will be followed up for 5 years.~Capecitabine 1000mg/m2 tablets twice a day for 8 cycles."
2934335|NCT03011060|Experimental|NAC achieving pCR|Patients in the study group will accept neo-adjuvant chemotherapy. In these patients, those who reach to pCR after neo-adjuvant chemotherapy will be followed up for 5 years after surgery.
2934336|NCT03011060|No Intervention|Adjuvant Chemotherapy|Patients in the control group will accept surgeries and corresponding adjuvant chemotherapy.They will be followed up for 5 years after adjuvant chemotherapy.
2934337|NCT03011047|Experimental|endoscopic trans-antral approach|The maxillary sinus and prolapsed orbital contents will be visualized employing a 30-degree endoscope for the repair of orbital blow out fracture (sinus scope 4 mm, 30 degrees short one 17 cm).
2934338|NCT03011047|Active Comparator|trans-orbital surgical approach|trans-orbital surgical approach through the lower eyelid Sub-ciliary incision ( through the lower eyelid) The skin incision is made just below the eyelashes.
2934339|NCT03011034|Experimental|Talacotuzumab|Participants will receive talacotuzumab 9 milligram per kilogram (mg/kg) intravenously (IV) on Days 1 and 15 for all cycles. Each treatment cycle is of 28 days. The talacotuzumab arm of the study is closed for enrollment.
2934340|NCT03011034|Experimental|Daratumumab|Participants will receive daratumumab 16 mg/kg IV on Days 1, 8, 15, and 22 for Cycles 1 and 2; on Days 1 and 15 for Cycles 3 to 6; and on Day 1 for all subsequent cycles. Each treatment cycle is of 28 days.
2934341|NCT03011021|Experimental|UCB-Treg plus Liraglutide|Subjects will receive a single infusion of ex vivo expanded umbilical cord blood derived Treg product (2 x 10^6). Dose escalation of liraglutide up to 1.2 mg will be started 3 days after Treg infusion only if no severe side effects showed. Subjects continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as a routine therapy.
2934342|NCT03011021|Active Comparator|UCB-Treg|Subjects will receive a single infusion of ex vivo expanded Treg product (2 x 10^6). Insulin will be continued as a routine therapy.
2934343|NCT03011021|Active Comparator|Liraglutide|Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.
2934344|NCT03011021|Active Comparator|Insulin|Patients will receive insulin injection as a routine therapy.
2934345|NCT03011008|Experimental|Liraglutide + insulin|Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.
2934346|NCT03011008|Active Comparator|Insulin|Patients will receive insulin injection as a routine therapy.
2934347|NCT03010995|Active Comparator|18 mg nicotine|E-cigarette with 18 mg nicotine
2934348|NCT03010995|Active Comparator|9 mg nicotine|E-cigarette with 9 mg nicotine
2934349|NCT03010995|Placebo Comparator|0 mg nicotine|E-cigarette with 0 mg nicotine
2934350|NCT03010982|Experimental|Tazemetostat and [14C] Tazemetostat|"Tazemetostat 800 mg BID orally as tablets continuously starting on Day 1, with the exception of the morning dose on Day 16;~A single IV dose of approximately 12 µg tazemetostat that contains approximately 500 nCi of [14C] tazemetostat on Day 15;~A single oral dose of 800 mg tazemetostat as a solution containing approximately 400 µCi (14.8 MBq) of [14C] tazemetostat on Day 16."
2934351|NCT03010956||Patients with uncontrolled diabetes mellitus|Patients with uncotrolled tyre 1 or type 2 diabetes mellitus
2934352|NCT03010956||Patients with controlled diabetes mellitus|Patients with controlled type 1 or type 2 diabetes mellitus
2934353|NCT03010943|Experimental|Brain surgery with virtual reality headset|
2934354|NCT03010930|Experimental|Increased exposure to MSG|Subjects consume vegetable broth daily containing MSG
2934355|NCT03010930|Sham Comparator|No change in exposure to MSG|Subjects consume low glutamate vegetable broth daily, sodium-matched to the broth of the experimental group with NaCl
2934356|NCT03010917|Experimental|Fish Oil with ethanol and placebo ethanol infusions|Between days 30-40 subjects will participate in 2 test days at least 2 days apart and during the test day will receive an IV infusion of ethanol (placebo vs. targeted Breath Alcohol Concentration ((BrAC) of 100mg%) in a clamped fashion. Test days will be in a randomized order.
2934357|NCT03010917|Placebo Comparator|Placebo with ethanol and placebo ethanol infusions|Between days 30-40 subjects will participate in 2 test days at least 2 days apart and during the test day will receive an IV infusion of ethanol (placebo vs. targeted Breath Alcohol Concentration ((BrAC) of 100mg%) in a clamped fashion. Test days will be in a randomized order.
2934358|NCT03010904|Experimental|pasteurized milk|milk that has undergone pasteurization treatment
2934359|NCT03010904|Experimental|homogenized pasteurized milk|Milk that has undergone homogenization and pasteurization treatment
2934360|NCT03010904|Experimental|UHT milk|Milk that has undergone homogenization and ultra high temperature treatment
2934361|NCT03010891|Active Comparator|control condition|Preterm infants in the control condition will receive only usual NICU care, plus positioning and gentle touch during intrusive procedures.
2934362|NCT03010891|Experimental|experimental condition|The bundle of supportive interventions will be designed to alleviate preterm infants' stress/pain from birth to discharge from the hospital NICU.
2934527|NCT03009812|Active Comparator|Group 1|26 subjects who are planned for transverse uterine incision
2934363|NCT03010878|Experimental|Yoga Arm|Yoga administered twice a week for 8 weeks. Self-management education sessions administered once a month through the University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic (Pain Clinic). Yoga interventions were administered twice a week at the Pain Clinic.
2934364|NCT03010878|Experimental|Wait-list Control Arm|Participants received only self-management intervention, which is provided once a month through the University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic.
2934365|NCT03010865|Experimental|Sodium Butyrate|Dietary Supplement: Sodium Butyrate 4.38 gms of sodium butyrate per day for 12 weeks
2934366|NCT03010865|Placebo Comparator|Placebo Oral Capsule|Placebo Oral Capsule placebo capsules containing approximately 9 mg of sodium butyrate per day
2934367|NCT03010852|No Intervention|Standard of care incentive spirometer|Patients in the SOC cohort will not receive the preoperative education and only one postoperative visit per day to collect their self-reported use of IS, if prescribed, and respiratory symptoms but avoiding increasing their awareness of POH, O2 therapy and IS.
2934368|NCT03010852|Experimental|Focused incentive spirometer education and monitoring|One of the study investigators will meet eligible patients in the preoperative visit to the UCH Weight Loss Surgery clinic, inform and consent the patient and introduce the first education on IS therapy, highlighting its possible benefits and the importance of compliance (patient's inspiratory effort and frequency). This IS education will be repeated in the preoperative area immediately before surgery. The site will then follow the patient postoperatively. The site will directly check on the patient in the PACU and later in his/her hospital room at least 3 times a day during the first 3 days or sooner if their O2 therapy is discontinued for 2h. During these PO check ups The site will reinforce the IS use, monitor the patient's performance of IS and ask him/her about other respiratory symptoms.
2934369|NCT03010839|Active Comparator|Modified Remote Ischemic Preconditioning(mRIPC)|modified RIPC was induced at 24 h, 12 h and 1 h before surgery to reinforce the protective effects of RIPC. The single RIPC protocol was induced by three cycles of upper-limb ischemia, a standard blood-pressure cuff was placed on the ringt upper arm, then inflated the cuff to 200 mm Hg for 5 minutes, followed by 5 min of cuff deflation.
2934370|NCT03010839|Placebo Comparator|Control|Control group without remote ischemic preconditioning
2934371|NCT03010826||40 Demyelinating Disease patients|
2934372|NCT03010826||40 Non-patient participants|
2934373|NCT03010813|Experimental|Novel single port robotic system|A single port innovation designed to deliver an articulating 3D high definition camera and three fully articulating instruments through a single 25-mm cannula
2934374|NCT03010800|Experimental|With Yoni.Fit|Subjects will perform the Abbreviated Pad Test with the Yoni.Fit first, then without the Yoni.Fit.
2934375|NCT03010800|Experimental|Without Yoni.Fit|Subjects will perform the Abbreviated Pad Test without the Yoni.Fit first, then with the Yoni.Fit.
2934376|NCT03010787|Experimental|Part 1|Single ascending dose of oral V565
2934377|NCT03010787|Experimental|Part 2 - V565|Single dose level of oral V565 TID for 14 days
2934378|NCT03010787|Placebo Comparator|Part 1 and 2 - placebo|Oral placebo single dose (Part 1) or TID for 14 days (Part 2)
2934379|NCT03010787|Experimental|Part 3|Single dose of V565 in patient volunteers
2934380|NCT03010787|Experimental|Part 4|Single ascending dose of V565 in patients with Crohn's Disease
2934381|NCT03010774|Experimental|Intervention - Risk Stratification|Study participants will be risk stratified according to the eCART scoring algorithm each night. If they are stratified as low risk, they will not receive routine nighttime spot-check vital signs unless indicated by a change in patient status or monitor alarm.
2934382|NCT03010774|Active Comparator|Control - Usual Care|Study participants will be woken at night for routine nighttime spot-check vital signs regardless of patient disease severity or risk.
2934383|NCT03010761|Experimental|medication pills 1: escitalopram 10mg|10mg once daily, 8 weeks
2934384|NCT03010761|Experimental|medication pills 2: moclobemide 150mg|150mg once daily, 8 weeks
2934385|NCT03010761|Experimental|medication pills 3: Placebo - Cap|placebo once daily, 8 weeks
2934386|NCT03010748||Chinese population|Chinese population of different nation from several provinces.
2934387|NCT03010735|Active Comparator|Probiotics|The patient take two chewing tablet per day, which contain 4.0E+10 CFU of Bifidobacterium animalis A6.
2934388|NCT03010735|Placebo Comparator|Placebo|The patient take two placebo chewing tablet per day.
2934389|NCT03010722||Regorafenib|"160 mg orally (po) od for 3 weeks of every 4-week cycle~All patients will be required to have pre-treatment dynamic contrast enhance computed tomography (DECT) scan pre-treatment and at 8 weeks. Suitable patients will also be required to have dynamic contrast enhanced magnetic resonance imaging (DEC-MRI) and diffusion weighted (DW)-MRI, pre-treatment and at 2 weeks. All patients will also be required to have an Ultrasound (USS) or CT-guided biopsy of suitable metastatic lesion."
2934390|NCT03010696||Healthy subjects|Normal kidney function
2934391|NCT03010696||ESRD patients|Diagnosed as ESRD with hemodialysis
2934392|NCT03010683|Active Comparator|liraglutide|
2934393|NCT03010683|Active Comparator|Metformin|
2934394|NCT03010670|Experimental|Oxytocin (OT) spray|Syntocinon nasal spray (product code RVG 03716) will be used to intranasally administer one single dose (24 IU) of OT (3 puffs of 4 IU per nostril).
2934395|NCT03010670|Placebo Comparator|Placebo (PL) spray|Physiological water (a solution of sodium chloride (NaCl) in water) will be used to intranasally administer one single dose (24 IU) of PL (3 puffs of 4 IU per nostril).
2934396|NCT03010657|Experimental|Experimental intervention|Subjects will add certain foods to what they normally eat.
2934397|NCT03010657|No Intervention|Non-experimental intervention|Subjects will continue eating normally.
2934398|NCT03010657|No Intervention|Observational|Subjects will continue eating normally.
2934399|NCT03010644||Underserved school-aged children|Underserved school-aged children at risk for obesity
2934400|NCT03010631|Active Comparator|Cohort 1|48 mcg lubiprostone capsule once
2934401|NCT03010631|Experimental|Cohort 1- Crossover|48 mcg lubiprostone sprinkle once
2934402|NCT03010631|Experimental|Cohort 2|48 mcg lubiprostone sprinkle once
2934403|NCT03010631|Experimental|Cohort 2- Crossover|48 mcg lubiprostone sprinkle once
2934404|NCT03010618|Other|Study Group|
2934406|NCT03010605|Active Comparator|MED Device|Patients will perform 10 repetitions with the MED device 3 times daily at 8am, 2pm, and 8pm and will transmit the 10th measurement of each time point to the clinicians office.
2934407|NCT03010579|Experimental|erythropoietin group|For those lymphoma patients with hemoglobin level less than 100 g/L on day +15 after autologous hematopoietic stem cell transplantation, erythropoietin will be administered. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
2934408|NCT03010579|Active Comparator|iron supplementation|If necessary，oral ferrous succinate, vitamins B12 and folic acid will be administered.
2934409|NCT03010553|Experimental|Oropharynx|Tumors of the oropharynx T1T2N0 treated with radiotherapy
2934410|NCT03010553|Experimental|Larynx|Tumors of the T1T2N0 larynx treated by surgery, laser or robot
2934411|NCT03010540|Experimental|Morphine Plus Fentanyl|
2934412|NCT03010540|Active Comparator|Fentanyl only|
2934413|NCT03010527|Placebo Comparator|Placebo|Subjects will receive Placebo injections every four weeks (Q4W)
2934414|NCT03010527|Experimental|Bimekizumab dosing regimen 1|Subjects will receive bimekizumab injections every four weeks (Q4W)
2934415|NCT03010527|Experimental|Bimekizumab dosing regimen 2|Subjects will receive bimekizumab injections every four weeks (Q4W)
2934416|NCT03010527|Experimental|Bimekizumab dosing regimen 3|Subjects will receive bimekizumab injections every four weeks (Q4W)
2934417|NCT03010514||case|
2934418|NCT03010514||control|
2934419|NCT03010501|Experimental|100% Food Energy Density|Baseline Food Energy Density
2934420|NCT03010501|Experimental|80% Food Energy Density|Lower Food Energy Density
2934421|NCT03010501|Experimental|120% Food Energy Density|Higher Food Energy Density
2934422|NCT03010488|Experimental|Rapid Sleep Shift|Assigned Sleep Times designed to shift sleep times over several days from Baseline to desired through morning light therapy while wearing goggles.
2934423|NCT03010488|Active Comparator|Gradual Sleep Shift|Assigned Sleep Times designed gradually shift sleep from current to desired sleep times while using morning light therapy while wearing goggles.
2934424|NCT03010475|Experimental|Furosemide/Rosuvastatin/SNAC/Semaglutide|
2934425|NCT03010462|Active Comparator|Active|Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation
2934426|NCT03010462|Sham Comparator|Control|Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation
2934427|NCT03010449|Experimental|Intra-bronchial valve and blood|Bronchoscopic lung volume reduction using intra-bronchial valves combined with autologous blood instillation.
2934428|NCT03010436|Other|Open-Label|All subjects will receive the study medication- benralizumab
2934429|NCT03010423|Experimental|Nicorandil treatment group|
2934430|NCT03010423|Active Comparator|Standard treatment group|
2934431|NCT03010410||Influenza/respiratory virus pts <65 yrs|Patients with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses
2934432|NCT03010410||Influenza/respiratory virus pts ≥ 65 yrs|Patients with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses
2934433|NCT03010410||Sepsis/septic shock patients < 65 yrs|Sepsis and septic shock patients
2934434|NCT03010410||Sepsis/septic shock patients ≥ 65 yrs|sepsis and septic shock patients
2934435|NCT03010384|Active Comparator|Intervention|Consultation with a physician specialized in social medicine. The consultation lasted about one hour. Together with the patient a return-to-work (RTW) schedule was made to ascertain the need for contact to the workplace (to adjust work functions), municipality, general practitioner or short-term supportive consultations with a psychologist. If relevant, patients were offered up till 5 sessions with a psychologist.
2934436|NCT03010384|No Intervention|Control|Standard treatment from the Department of Rheumatology
2934437|NCT03010371|Experimental|Positive Psychotherapy|A group of breast cancer survivors are randomly allocated to the face-to-face version of the positive psychotherapy
2934438|NCT03010371|Experimental|Positive Online Psychotherapy|A group of breast cancer survivors are randomly allocated to the online version of the positive psychotherapy
2934439|NCT03010371|Experimental|Online support group|A group of breast cancer survivors are randomly allocated to the online support group which is the control group
2934440|NCT03010358|Experimental|Treatment (entospletinib, obinutuzumab)|Patients receive entospletinib PO either QD or BID on days -7 to -1 (run-in phase) depending on the assigned dose level. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of the first course and on day 1 of subsequent courses. Treatment with obinutuzumab repeats every 28 days for up to 6 courses and daily treatment with entospletinib continues every 28 days for up to 12 courses in the absence of disease progression or unexpected toxicity.
2934441|NCT03010345|Experimental|Osmed self inflating tissue expanders|All patients will undergo a two-stage procedure ,second stage under General endotracheal anesthesia. The first stage will be placement of the expanders. The second stage will be 21 days later, with removal of the expanders, palatal revision, and closure of the oronasal fistula
2934442|NCT03010345|Experimental|Iliac bone graft|Placement of bone graft without the use of self inflating expanders
2934443|NCT03010319|Experimental|PriMatrix|Arm will receive PriMatrix Dermal Repair Scaffold plus secondary dressings to maintain a moist wound healing environment and an appropriate off-loading device.
2934444|NCT03010319|Active Comparator|Standard of Care|Arm will receive moist wound therapy consisting of 0.9% Sodium Chloride gel plus secondary dressings and an appropriate off-loading device.
2934445|NCT03010306|No Intervention|Nutrition only|Monthly food baskets were provided to the nutrition only group. Food baskets included basic foods to sustain a family of three over one month's time, such as rice and evaporated milk. Food baskets were valued at approximately $28 US Dollars per basket.
2934494|NCT03010059|Experimental|Panel 2: Treatment EDF|Participants will receive Treatment E (test 3) in period 1, then Treatment D (reference 2) in period 2 followed by Treatment F (test 4) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2934495|NCT03010059|Experimental|Panel 2: Treatment FED|Participants will receive Treatment F (test 4) in period 1, then Treatment E (test 3) in period 2 followed by Treatment D (reference 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2934446|NCT03010306|Active Comparator|Nutrition + CASITA|The CASITA intervention was given by a community health worker (CHW) and involves individual and group modalities. HOME-CASITA took place at the dyad's place of residence, and the GROUP-CASITA at a local community center. All CASITA participants received 12 weekly sessions over 3 months. Interventions retain core elements of the SPARK approach: coaching parents on child development stimulation and providing social support and encouragement. Each session is as follows: 1) Child observation & knowledge sharing about child development; 2) Practice of reciprocal attention focusing and social interaction activities; 3) Parent encouragement on behavior and developmental interactions; and 4) Parent social support through referral assistance, reassurance, and validation of parent's concerns.
2934447|NCT03010280|Experimental|Immunonutrition|Patients receiving a preoperative balanced energy high-protein formula, enriched with Omega - 3 fatty acids (Immunonutrition formula)
2934448|NCT03010280|Active Comparator|Balanced high-protein formula|Patients receiving a preoperative balanced energy high-protein formula, without including Omega - 3 fatty acids
2934449|NCT03010267|Experimental|RT group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
2934450|NCT03010267|Experimental|TR group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
2934451|NCT03010241|Experimental|Tangbi Prescription|Based on the standard medical care, experimental group were treated with Tangbi Prescription 4.87g granules, 2 times/d, which The prescripton was composed by five Chinese herbal medicines.
2934452|NCT03010241|Placebo Comparator|Placebo|Based on the standard medical care, placebo-controlled group were treated with Placebo 4.87g granules, 2 times/d
2934453|NCT03010228|Active Comparator|VLA15 12 µg with Alum|VLA15 12 µg (microgram) with Alum has an injection volume of 100 µl (microliter). The amount of Alum per injection is 0.05 mg (milligram).
2934454|NCT03010228|Active Comparator|VLA15 12 µg w/o Alum|VLA15 12 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 100 µl (microliter).
2934455|NCT03010228|Active Comparator|VLA15 48 µg with Alum|VLA15 48 µg (microgram) with Alum (aluminum hydroxide) has an injection volume of 400 µl (microliter). The amount of Alum per injection is 0.2 mg (milligram).
2934456|NCT03010228|Active Comparator|VLA15 48 µg w/o Alum|VLA15 48 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 400 µl (microliter).
2934457|NCT03010228|Active Comparator|VLA15 90 µg with Alum|VLA15 90 µg (microgram) with Alum (aluminum hydroxide) has an injection volume of 750 µl (microliter). The amount of Alum per injection is 0.375 mg (milligram).
2934458|NCT03010228|Active Comparator|VLA15 90 µg w/o Alum|VLA15 90 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 750 µl (microliter).
2934459|NCT03010215|Other|Minimally Invasive Surgery (MIS)|Patients with plantar chronic diabetic foot ulcers will be treated by Distal Metatarsal Minimally invasive Osteotomy (DMMO).
2934460|NCT03010202|Experimental|Induction phase: Rituximab+Dexamethasone|Open-label, intravenous infusions of rituximab 1000 mg and oral dexamethasone 20 mg daily for 4 days given on day 1 and day 15.
2934461|NCT03010202|No Intervention|Induction phase: Rituximab|Open-label, intravenous infusions of rituximab 1000 mg given on day 1 and day 15.
2934462|NCT03010202|Experimental|Maintenance phase: Rituximab|Patients who respond to rituximab in the induction phase will be proceed into the maintenance phase and randomized to rituximab infusion of 500 mg in week 1 and week 24, or
2934463|NCT03010202|No Intervention|Maintenance phase: Placebo|Infusion of normal saline 0,9% in week 1 ande week 24 in second randomization.
2934464|NCT03010189|Experimental|Patient|Cluster headache patients are examined with light reflex pupillometry, two weeks actigraphy and heart-rate variability monitoring both in headache phase and remission phase.
2934465|NCT03010189|Active Comparator|Controls|Healthy controls undergo the same examinations once: light reflex pupillometry, actigraphy and heart-rate variability monitoring.
2934466|NCT03010176|Experimental|MK-1454 (cut/subcut lesions)|Participants receive escalating doses of MK-1454 via IT injection on Days 1, 8 and 15 of each 21-day cycle for Cycles 1, 2 and 3 and then receive MK-1454 via IT injection on Day 1 of each 21-day cycle for Cycle 4 and beyond for up to 35 cycles (approximately 2 years).
2934467|NCT03010176|Experimental|MK-1454+pembro (cut/subcut lesions)|Participants receive escalating doses of MK-1454 via IT injection on Days 1, 8 and 15 of each 21-day cycle for Cycles 1, 2 and 3 PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle and then receive MK-1454 via IT injection on Day 1 of each 21-day cycle for Cycle 4 and beyond PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (approximately 2 years).
2934468|NCT03010176|Experimental|MK-1454+pembro (liver metastasis/lesions)|Participants receive escalating doses of MK-1454 via IT injection on Days 1, 8 and 15 of each 21-day cycle for Cycles 1 and 2 PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle and then receive MK-1454 via IT injection on Day 1 of each 21-day cycle for Cycle 3 and beyond PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (approximately 2 years).
2934469|NCT03010163|Active Comparator|Health Fair + Pedometer|Participants will get free weight, height, waist, and blood pressure testing at health fairs stationed at NYC taxi garage bases and airport taxi holding lots. Health fair staff will follow up with participants who need to see a doctor due to a high blood pressure reading or other unusual result that needs a physician follow-up. All participants will be given a pedometer with instructions on how to use it to track their daily step counts.
2934470|NCT03010163|Experimental|Health Fair, Pedometer + Text Messaging|In addition to the health fair services with general follow-up, and giving each driver a pedometer with instructions on how to use the devise to track daily step counts, all participants in this group will receive daily healthy living advice and encouraging messages about walking through text messages sent by study staff to participants' cellular phone.
2934471|NCT03010163|Experimental|Health Fair, Pedometer, Social Network Support|Each participant in this group will receive the health fair services with general follow-up along with a pedometer with instructions on how to use the device to track daily step counts. Additionally, participants in this group will be asked to provide the names of family or friends who will form a social support network team. This team will provide encouragement and remind participants to maintain a healthy lifestyle and increase daily walking activities. Participants will be given a social network guide to train their family and/or friends on how to best motivate the participants .
2934496|NCT03010046|Experimental|ANX005 Monotherapy|ANX005 intravenous infusion
2934472|NCT03010163|Experimental|Health Fair, Pedometer, Text Msg, Social Network Support|Participants in this group will receive the health fair service with general follow-up, along with a pedometer with instructions on how to use the device to track daily step counts. Participants will also receive daily healthy living advice through encouraging text messages about walking through text messages sent by our staff to participants' cellular phones. Participants will also be asked to provide the names of family or friends who will form a social support network team. This team will provide encouragement and remind participants to maintain a healthy lifestyle and increase daily walking activities. Participants will be given tools to train their family and/or friends on how to best motivate the drivers.
2934473|NCT03010150||Head and Neck Cancer Group Adherence to Swallowing Exercises|Questionnaire completed at baseline and 6 months after radiation therapy. Blood drawn to measure the level of cytokines in blood at baseline and 6 months after radiation therapy.
2934474|NCT03010137|Placebo Comparator|Standard Closure|After surgical closure is complete, the patient receives standard of care operative incision treatment (dermabond/topical skin adhesive).
2934475|NCT03010137|Active Comparator|Incisional Negative Pressure Wound Therapy|After surgical closure is complete, an incisional negative pressure wound therapy device is applied to the incision in its entirety. This device is placed on the wound, sterilely, in the operating room, at the conclusion of the procedure. The incisional negative pressure wound therapy device is to remain in place for 7 days, and is removed in clinic after completion.
2934476|NCT03010124|Other|Patients with ovarian cancer|
2934477|NCT03010111|Other|health care workers|health care workers including doctors, nurses, technicians and orderly who were hired in 2016 at the Hanyang University Hospital
2934478|NCT03010098|Experimental|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.Take blood sample before and after surgery to measure the levels of protein S100beta and NSE.
2934479|NCT03010098|Experimental|Open-Loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.Take blood sample before and after surgery to measure the levels of protein S100beta and NSE.
2934480|NCT03010085|Active Comparator|A (Open left-sided hepatectomy)|Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
2934481|NCT03010085|Experimental|B (Laparoscopic left-sided hepatectomy)|Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
2934482|NCT03010072|Active Comparator|low-dose sucroferric oxyhydroxide|Low dose 250 mg sucroferric oxyhydroxide (PA21) per day (1x 250mg tablets/day) for 14 days.
2934483|NCT03010072|Active Comparator|high-dose sucroferric oxyhydroxide|Uniform dose 2000 mg of sucroferric oxyhydroxide (PA21) per day (4x 500mg tablets/day) for 14 days
2934484|NCT03010059|Experimental|Panel 1: Treatment ABC|Participants will receive 240 milligram (mg) JNJ-64041575 as 6.0 milliliter (mL) of a 40-milligram per milliliter (mg/mL) current oral suspension formulation (reference 1) under fasted conditions (Treatment A) in period 1, then 4.0 mL of a 60-mg/mL new concept oral suspension formulation (test 1) under fasted conditions (Treatment B) in period 2 followed by 4.0 mL of a 60-mg/mL new concept oral suspension formulation (test 2) under fed conditions (Treatment C) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2934485|NCT03010059|Experimental|Panel 1: Treatment BCA|Participants will receive Treatment B (test 1) in period 1, then Treatment C (test 2) in period 2 followed by Treatment A (reference 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2934486|NCT03010059|Experimental|Panel 1: Treatment CAB|Participants will receive Treatment C (test 2) in period 1, then Treatment A (reference 1) in period 2 followed by Treatment B (test 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2934487|NCT03010059|Experimental|Panel 1: Treatment ACB|Participants will receive Treatment A (reference 1) in period 1, then Treatment C (test 2) in period 2 followed by Treatment B (test 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2934488|NCT03010059|Experimental|Panel 1: Treatment BAC|Participants will receive Treatment B (test 1) in period 1, then Treatment A (reference 1) in period 2 followed by Treatment C (test 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2934489|NCT03010059|Experimental|Panel 1: Treatment CBA|Participants will receive Treatment C (test 2) in period 1, then Treatment B (test 1) in period 2 followed by Treatment A (reference 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2934490|NCT03010059|Experimental|Panel 2: Treatment DEF|Participants will receive JNJ-64041575 as 1 tablet of the 250-mg current oral tablet formulation (reference 2) under fasted conditions (Treatment D) in period 1, then 1 tablet of the 250-mg new concept oral tablet formulation (test 3) under fasted conditions (Treatment E) in period 2 followed by 1 tablet of the 250-mg new concept oral tablet formulation (test 4) under fed conditions (Treatment F) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2934491|NCT03010059|Experimental|Panel 2: Treatment EFD|Participants will receive Treatment E (test 3) in period 1, then Treatment F (test 4) in period 2 followed by Treatment D (reference 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2934492|NCT03010059|Experimental|Panel 2: Treatment FDE|Participants will receive Treatment F (test 4) in period 1, then Treatment D (reference 2) in period 2 followed by Treatment E (test 3) then in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2934493|NCT03010059|Experimental|Panel 2: Treatment DFE|Participants will receive Treatment D (reference 2) in period 1, then Treatment F (test 4) in period 2 followed by Treatment E (test 3) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2934528|NCT03009812|Active Comparator|Group 2|26 subjects who are planned for longitudinal uterine incision
2934499|NCT03010033|No Intervention|regular care|[Control group] preoperative treatment: smoking cession, aerosol inhalation for expectorant and antiasthmatic, anti-infection therapy if necessary and regular rehabilitation-propaganda; postoperative treatment: regular postoperative treatment (anti-infection, pain control, oxygen Inhalation aerosol inhalation for expectorant and antiasthmatic), patting back (3 times/day, 15min/time) and early ambulation unless serious patients.
2934500|NCT03010033|Experimental|pulmonary rehabilitation|[Study group] preoperative treatment: smoking cession, aerosol inhalation for expectorant and antiasthmatic, anti-infection therapy if necessary, regular rehabilitation-propaganda and interventional pulmonary rehabilitation (preoperative part); postoperative treatment: regular postoperative treatment (anti-infection, pain control, oxygen Inhalation aerosol inhalation for expectorant and antiasthmatic), patting back (3 times/day, 15min/time), early ambulation unless serious patients and interventional pulmonary rehabilitation (postoperative part).
2934501|NCT03010020|Experimental|STI-Positive: PCC|MSM diagnosed with rectal GC and/or CT infection counseled for HIV prevention using Personalized Cognitive Counseling (PCC) and treated with appropriate antibiotic therapy
2934502|NCT03010020|Placebo Comparator|STI-Positive: Traditional Counseling|MSM diagnosed with rectal GC and/or CT infection counseled for HIV prevention using traditional risk reduction counseling and treated with appropriate antibiotic therapy
2934503|NCT03010020|No Intervention|STI-Negative|MSM without rectal GC and/or CT infection
2934504|NCT03009994|Other|Exteriorization group|After delivery of the fetus and placenta, the surgeon bring uterus yet out from peritoneal cavity by manual handling of the uterus uterus from fundus and extracted out of the abdominal cavity before starting to close it. After repair of the uterus , uterus returned to abdominal cavity and repair anterior abdominal wall as following.
2934505|NCT03009994|Other|Non exteriorization group|Uterine incision will be repaired intra abdominally
2934506|NCT03009981|Active Comparator|Arm A: Degarelix Monotherapy|Patients randomized to Arm A will receive degarelix subcutaneous injections only.
2934507|NCT03009981|Experimental|Arm B: Degarelix/Apalutamide|Patients randomized to Arm B will receive degarelix and apalutamide.
2934508|NCT03009981|Experimental|Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone|Patients randomized to Arm C will receive degarelix, apalutamide at the same schedule as Arms A/C and will also take abiraterone acetate orally.
2934509|NCT03009968|No Intervention|Traditional backfill assisted voiding trial|Backfill the bladder with up to 300 ml as tolerated of normal saline or sterile water through an indwelling Foley catheter. The catheter is removed and the patient is given 15 minutes to void and the voided volume is measured. A post void residual (PVR) is measured after voiding (or attempt to void) using either an in and out catheter or a bladder scanner. The participant is considered to have passed the void trial if they have a PVR of less than 100 mL or less than half the voided volume if voided volume is greater than 200 mL.
2934510|NCT03009968|Experimental|Post-void residual free voiding trial|The post-void residual free voiding trial (intervention): Backfill the bladder with up to 300 ml as tolerated of normal saline or sterile water through an indwelling Foley catheter. The catheter is removed and the patient is given 15 minutes to void and the voided volume is measured. The participant is considered to have passed the void trial if they void more than 1/2 the instilled volume. A PVR will not be performed.
2934511|NCT03009955||Group P|patients who received primary caesarean section
2934512|NCT03009955||Group R|patients who received repeated caesarean section
2934513|NCT03009916|Other|Healthy controls|Healthy controls found according to the protocol
2934514|NCT03009916|Other|Patients with BAM|Patients with bile acid malabsorption found according to the protocol
2934515|NCT03009903||P. acne subjects|14-50 year of age, P. acne diagnosed subjects
2934516|NCT03009903||None P. acne subjects|14-50 year of age, none P. acne diagnosed subjects
2934517|NCT03009890|Experimental|Open reduction internal fixation|Surgical open reduction internal fixation (ORIF)
2934518|NCT03009890|Active Comparator|Plaster immobilization|Standard local hospital protocol for cast treatment
2934519|NCT03009877|Active Comparator|Preoxygenation with face mask|Standard preoxygenation with a mask will be performed for five minutes. Once preoxygenation is complete, patients will be induced with standard induction medications including lidocaine, midazolam, fentanyl and propofol. Once the patient is apneic, one breath will be given via facemask to confirm ventilation and then 0.6 mg/kg of rocuronium will be administered. The 5.5mm flexible intubation scope will be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope. Once the flexible intubation scope is in the trachea, the endotracheal tube (7.0 mm unless otherwise specified) will be advanced. Ventilation will not begin until the primary or secondary endpoints are reached.
2934520|NCT03009877|Experimental|Preoxygenation via hi flow nasal cannula|The high flow nasal cannula (Optiflow) will be applied as soon as the patient is in the operating room. The patient will be preoxygenated with high flow nasal cannula at 50 L/min for 5 minutes. After induction, general anesthesia will be maintained with a propofol infusion. One breath will be given via facemask to confirm ventilation and then 0.6 mg/kg of rocuronium will be administered. Upon apnea, the Optiflow™ flow will be increased to 70 L/min and jaw thrust will be performed until the patient is adequately relaxed. The video laryngoscope (C-MAC) will then be introduced into the oropharynx and the flexible intubation scope advanced into the trachea with the assistance of the C-MAC. Once the flexible intubation scope is in the trachea, the endotracheal tube will be advanced.
2934521|NCT03009864|Experimental|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
2934522|NCT03009864|Placebo Comparator|Placebo|"Treatment with placebo corresponding to each dose of Tangshen Prescription~, every bag weighs 4.87g, take it one bag each time, two times a day."
2934523|NCT03009851|Experimental|OBCHI|This small group process intervention focuses upon the cultural heritage of the residents in LTC settings measuring quality of life, activity engagement and social participation.
2934524|NCT03009851|No Intervention|Control|The control group only received the typical activities conducted in LTC facilities.
2934525|NCT03009838|Active Comparator|letrozole|letrozole 2.5 mg oral tablets will be started daily from day 3 of the menses for 5 days in a dose of 5 mg/day
2934526|NCT03009838|Active Comparator|laparoscopic drilling|laparoscopy will be performed using three-puncture technique. Each ovary will be cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using a monopolar electrosurgical needle
2934532|NCT03009773|Experimental|multitasking walking|Multitasking Group: rehabilitation multitasking walking.
2934533|NCT03009773|Active Comparator|walking simple task|Simple task group : Traditional walking rehabilitation
2934534|NCT03009760|Experimental|CJ-12420 50mg(HP-)|CJ-12420 50mg in H. pylori negative subject
2934535|NCT03009760|Experimental|CJ-12420 100mg(HP-)|CJ-12420 100mg in H. pylori negative subject
2934536|NCT03009760|Experimental|CJ-12420 50mg(HP+)|CJ-12420 50mg in H. pylori positive subject
2934537|NCT03009760|Experimental|CJ-12420 100mg(HP+)|CJ-12420 100mg in H. pylori positive subject
2934538|NCT03009747||sphincter-preserving surgery|Patients meet the inclusion criteria will be enrolled into this observing group
2934539|NCT03009734|Other|ATx201 (2% dermal formulation A) and Placebo|
2934540|NCT03009734|Other|ATx201 (2% dermal formulation B) and Placebo|
2934541|NCT03009734|Other|ATx201 (2% dermal formulation C) and Placebo|
2934542|NCT03009708|Experimental|Allograft patients|Allograft patients followed at the Institut de Cancérologie Lucien Neuwirth perform blood samples during their post graft follow up in the usual practice, weekly. With the present study, two more blood tubes will be collected with the weekly blood samples.
2934543|NCT03009695|Experimental|High frequency repetitive dTMS + Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active high frequency repetitive dTMS treatment with cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz, Duration of the train: 2 sec, Inter-train interval: 20 sec, Trains number: 80, Total pulses: 2880, Total treatment duration: 29.3 min, Cue (sight of food preferred by patient): present."
2934544|NCT03009695|Experimental|High frequency repetitive dTMS - No Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active high frequency repetitive dTMS treatment without cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz, Duration of the train: 2 sec, Inter-train interval: 20 sec, Trains number: 80, Total pulses: 2880, Total treatment duration: 29.3 min, Cue (sight of food preferred by patient): absent."
2934545|NCT03009695|Experimental|Low frequency repetitive dTMS+ Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active low frequency repetitive dTMS treatment with cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT) Frequency: 1 Hz Duration of the train: 10 min Inter-train interval: 1 min Trains number: 4 Total pulses: 2400 Total treatment duration: 43 min Cue (sight of food preferred by patient): present"
2934546|NCT03009695|Experimental|Low frequency repetitive dTMS - No Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active low frequency repetitive dTMS treatment without cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 1 Hz, Duration of the train: 10 min, Inter-train interval: 1 min, Trains number: 4, Total pulses: 2400, Total treatment duration: 43 min, Cue (sight of food preferred by patient): absent."
2934547|NCT03009695|Sham Comparator|Sham|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to sham stimulation.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz (50% of patients) and 1 Hz (50% of patients), Duration of the train: 2 sec or 10 min, Inter-train interval: 20 sec or 1 min, Trains number: 80 or 4, Total pulses: 2880 or 2400, Total treatment duration: 29.3 or 43 min, Cue (sight of food preferred by patient): present."
2934548|NCT03009682|Other|Olaparib 300 mg|Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days
2934549|NCT03009643|Experimental|iNO Group|Patients are treated with iNO at a concentration of 5-10 ppm for 3-5 days according to the clinical conditions
2934550|NCT03009643|Other|Control|Patients are treated without iNO.
2934551|NCT03009630|Experimental|RFA group|Patients with early-stage peripheral lung cancer will be performed RFA with the guidance of ENB. Post treatment response and follow up will be evaluated and carried out according to the standard procedure.
2934552|NCT03009617|Experimental|Intervention Group|The educational program and counseling Pre-test before intervention Monitoring, education, and consultation through the Web At least two reminders via e-mail or phone message a week The last test after three months The website was closed three months later.
2934553|NCT03009617|No Intervention|Control Group|Pre-test No intervention The last test after three months Opening the website to the control group
2934554|NCT03009604|Experimental|Simethicone|women take 6 tablets (2 tablets after each meal) and to fast overnight before the operation
2934555|NCT03009604|Active Comparator|Enema|women take 3 rectal Enema (8:00 pm, 12:00 am & 8:00 am) and to fast over night before the operation.
2934556|NCT03009591|Experimental|Expermiental group|All patients included in the experimental group should be on prophylactic treatment with FVIII / FIX concentrates. Likewise, the factor should be administered on the same day that they receive each of the fascial therapy treatment sessions. Each session will last approximately 50 minutes, with three physiotherapy sessions taking place over a period of 3 weeks. The treatment program includes 11 maneuvers that must be administered bilaterally:
2934557|NCT03009591|No Intervention|Control group|Subjects included in the control group will not receive physical therapy through fascial therapy and will continue with their usual routine of physical activity and exercise, and with the same pharmacological treatment regimen with FVIII / FIX. At the end of the study period the intervention will be applied under the same conditions as the experimental group, analyzing the overall sample at the end of the study.
2934558|NCT03009578|Experimental|Intravenous iron|Women will receive iron sucrose (sacrofer ampules 100 mg/5ml) A patient's total body iron deficit will be calculated using the Ganzoni formula (total iron dose = [body weight (kilogram)× (15-actual Hemoglobin)] × 2.4 + 500 mg) then the total dose will be divided on 3 settings
2934559|NCT03009578|Active Comparator|Oral ferrous bis-glycinate|Women will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets
2934560|NCT03009565||study patients|Study participants will be individuals aged 30-80 arriving to Rabin Medical Center with suspected CAD and able to provide informed consent. Participants will provide medical, lifestyle, and nutritional questionnaires. Blood pressure and heart-rate measurements will be taken during hospitalization as well as blood tests and fecal samples and/or rectal swabs. In order to evaluate and/or treat suspected atherosclerotic disease patients will undergo cardiac CT and/or cardiac catheterization in accordance with the standard of care and based upon the decision of the treating cardiologist. Diagnostics and treatment options will be based only on their medical condition and regardless of the aforementioned study protocol.
2934561|NCT03009565||control|The control group will be selected to represent an age, sex and cardiovascular risk factors -matched group without current CAD. Further exclusion criteria in the control group will be antibiotic consumption in the following 3 months, inflammatory bowel disease, or other significant chronic disease that may influence the microbiota (such as cancer, autoimmune disease, and chronic immunosuppressive treatment). The control group will undergo cardiac CT or coronary angiography according to clinical suspicion in order to rule-out CAD and irrespective of the study protocol.
2934562|NCT03009539|Experimental|eHealth Familias Unidas Primary Care|"eHealth Familias Unidas consists of 12 sessions: eight (12 - 15 minute) mock parent sessions in Spanish and four (30 - 45 minute) online family sessions delivered in either Spanish and/or English."
2934563|NCT03009539|No Intervention|Treatment as Usual|Participants in this condition will not receive an intervention.
2934564|NCT03009526|Active Comparator|Sulfadoxine-pyrimethamine|Intermittent preventive treatment with Sulfadoxine-pyrimethamine: Monthly dose of 3 co-formulated tablets containing 500 mg sulfadoxine and 25 mg pyrimethamine
2934565|NCT03009526|Experimental|dihydroartemisinin-piperaquine|"Intermittent preventive treatment with dihydroartemisinin-piperaquine: Monthly course of daily doses of co-formulated DP tablets containing 40 mg dihydroartemisinin and 320 mg piperaquine, dosed based on the woman's weight, for 3 days:~24-35.9 kg: Two tablets~36-59.9 kg: Three tablets~60-79.9 kg: Four tablets~≥80 kg: Five tablets"
2934566|NCT03009513|Experimental|single arm|
2934567|NCT03009500|Active Comparator|Local Anesthetic|Injection of 2-6 cc of LA (0.25% bupivacaine) per nerve to a maximum of 20 cc
2934568|NCT03009500|Active Comparator|Local Anesthetic with steroids|Injection of 2-6 cc of LA (0.25% bupivacaine) per nerve containing steroids (methylprednisolone (Depo-Medrol) 4 mg per cc) to a maximum of 20 cc
2934569|NCT03009500|Placebo Comparator|Saline|Injection of 2-6 cc of saline (0.9% sodium chloride) per nerve to a maximum of 20 cc
2934570|NCT03009487|Experimental|Amlodpine, Olmesartan, Rosuvastatin|co-administration of Olmesartan, Amlodipine and Rosuvastatin
2934571|NCT03009487|Placebo Comparator|Olmesartan, Rosuvastatin|co-administration of Olmesartan and Rosuvastatin
2934572|NCT03009487|Placebo Comparator|Amlodipine, Olmesartan|co-administration of Amlodipine and and Olmesartan
2934573|NCT03009474|Experimental|CJ-30060|Amlodipine 5 mg/ Valsartan 160 mg/ Rosuvastatin 10 mg
2934574|NCT03009474|Active Comparator|Exforge tab 5/160mg, Crestor tab 10mg|Amlodipine 5 mg/ Valsartan 160 mg/ Rosuvastatin 10 mg
2934575|NCT03009461|Experimental|Sor-HAIC group|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily. hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.
2934576|NCT03009461|Active Comparator|Sor group|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
2934577|NCT03009448||Late onset depression|
2934578|NCT03009435|Experimental|prophylactic manual rotation|"Only obstetricians will participate in the study. Manual rotation is performed at full dilatation.The technique employed will be at the discretion of the operator performing the procedure :~Tarnier and Chantreuil technique~or SOGC technique"
2934579|NCT03009435|No Intervention|expectative management|Expectative management . No manual rotation
2934580|NCT03009422|Experimental|Treatment|CO2 fractional laser with local application of Pentostam
2934581|NCT03009422|Active Comparator|control|Intra-lesinal Pentostam injedction
2934582|NCT03009409|Active Comparator|Ketamine Group|Participants randomized to the ketamine group will receive a 0.25 mg/kg loading dose of intravenous ketamine immediately before induction of anesthesia, followed by a continuous 5 mcg/kg/min infusion throughout maintenance of anesthesia, for approximately 45 minutes, up to a maximum cumulative dose of 100 mg. This dose is in accordance with the guidelines from the recently published Clinical Practice Guidelines for the management of post-operative pain. The attending anesthesiologist will confirm whether the use of ketamine is appropriate for each patient prior to enrolling the patient in the study.
2934583|NCT03009409|Placebo Comparator|Control Group|Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion.
2934584|NCT03009396|Experimental|Active therapy|RHB-104; a fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
2934585|NCT03009383|Experimental|A bedside portable endoscopy|
2934586|NCT03009370||Recurrent miscarriage|RM is defined as three or more pregnancy losses at< 20 weeks of gestation.
2934587|NCT03009357||thyrotoxicosis|patients with newly detected or recurrent thyrotoxicosis
2934588|NCT03009357||control|euthyroid, healthy adults
2934589|NCT03009344|Experimental|tazemetostat 800 mg|Participants will receive oral tazemetostat at a starting dose of 800 milligrams (mg) as a single dose (Cycle 0) and 800 mg twice a day as continuous dosing (Cycle 1 and later).
2934590|NCT03009331|Experimental|Prone position|Intervention: Lungrecruitment in prone position. Device: Ventilator Flow-i, Peak inspiratory pressure 40 cmH2O, PEEP 20 cm H2O during 30 s.
2934591|NCT03009331|Active Comparator|Supine position|Intervention: Lungrecruitment in supine position. Device: Ventilator Flow-i, Peak inspiratory pressure 40 cmH2O, PEEP 20 cm H2O during 30 s. Clinical routine.
2934592|NCT03009318|Other|MRS imaging and 11C-MET PET/CT|Each patient underwent both MRS and MET PET before surgery.
2934593|NCT03009305|Experimental|Lower body negative pressure|Single-arm, lower body negative pressure, continuous positive airway pressure, positive expiratory pressure.
2934594|NCT03009292|Experimental|24 mg lenvatinib|Participants will receive once daily oral dosing of lenvatinib 24 milligrams (mg)
2934595|NCT03009279||The MS group|Patients with metabolic syndrome(MS).
2934596|NCT03009279||The non-MS group|Patients without metabolic syndrome(MS).
2934597|NCT03009266|Experimental|Normal controls|Normal controls who will undergo dose-ranging studies to determine the optimal dose of phosphatidylserine-containing microbubbles that does not produce delayed myocardial opacification on myocardial contrast echocardiography (MCE).
2934598|NCT03009266|Experimental|Patients with ACS|Subjects with ACS who have undergone primary percutaneous intervention in whom MCE with phosphatidylserine-containing microbubbles will be performed to determine whether the risk area can be detected and spatially defined.
2934599|NCT03009253|Experimental|Concurrent chemoradiotherapy(CCRT) Group|Concurrent chemoradiotherapy (Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks) Followed by chemotherapy: Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles)
2934600|NCT03009253|Experimental|Chemotherapy Group|"Chemotherapy (Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles)~Followed by Concurrent chemoradiotherapy:~(Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks)"
2934601|NCT03009240|Experimental|Treatment (pevonedistat, decitabine)|Patients receive pevonedistat IV over 1 hour on days 1, 3, and 5 and decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unexpected toxicity.
2934602|NCT03009227|Active Comparator|D2 lymph node dissection|Colonic resection with D2 lymph node dissection
2934603|NCT03009227|Experimental|D3 lymph node dissection|Colonic resection with D3 lymph node dissection
2934604|NCT03009214|Experimental|AMC303|"cohorts will receive ascending doses of AMC303 as intravenous infusion~Planned doses are:~0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg, 4 mg/kg, 10 mg/kg and 20 mg/kg"
2934605|NCT03009201|Experimental|Treatment (ribociclib, doxorubicin hydrochloride)|"Patients receive ribociclib PO daily on days 1-7, and doxorubicin hydrochloride IV on day 10. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ribociclib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2934606|NCT03009188||Pedigree of the family with ARS|Nine members of the same family with ARS
2934607|NCT03009162|Experimental|Renal impaired participants|lasmiditan
2934608|NCT03009162|Experimental|Healthy participants|lasmiditan
2934609|NCT03009149|Experimental|AEROBIC EXERCISE|The effects of 12 week aerobic exercise will record
2934610|NCT03009136|Experimental|SCRT group|3g, three times a day, each taken before or between meals
2934611|NCT03009136|Placebo Comparator|placebo group|3g, three times a day, each taken before or between meals
2934612|NCT03009123||Erectile dysfunction group|Group contains men with physician-diagnosed erectile dysfunction
2934613|NCT03009123||General population men without ED|Men 50 years and older having no ED and pre-existing prostate cancer
2934614|NCT03009123||Symptomatic BPH group without ED|Men 50 years old older with symptomatic prostatic hypertrophy but with no ED nor pre-existing prostate cancer
2934615|NCT03009110|Experimental|Prophylactic NPWT|Women assigned to prophylactic NPWT will have the Prevena device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4, but longer for up to 7 days for patients who remain hospitalized.
2934616|NCT03009110|Active Comparator|Standard Dressing|Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
2934617|NCT03009097|Active Comparator|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with DFDBA
2934618|NCT03009097|Active Comparator|DFDBA with Atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with DFDBA in combination with Atorvastatin gel.
2934619|NCT03009084|Experimental|Intervention group|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
2934620|NCT03009084|No Intervention|Control group|Usual care.
2934621|NCT03009071|Experimental|Doin with Acupuncture|An acupuncture physician will administer acupuncture at 6-12 acupoints in the upper and middle trapezius area (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels). Cervical Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise (rotation) as needed.
2934622|NCT03009071|Active Comparator|Acupuncture|An acupuncture physician will administer acupuncture at 6-12 acupoints in the upper and middle trapezius area (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels).
2934623|NCT03009058|Experimental|IMM-101 + Gem panc ca|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
2934624|NCT03009058|Experimental|IMM-101+Gem/nab-paclitaxel panc ca|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
2934625|NCT03009058|Experimental|IMM-101+Gem+capecitabine panc ca|"IMM-101 will be given in combination with gemcitabine +capecitabine combination therapy.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
2934626|NCT03009058|Experimental|IMM-101 + FOLFIRINOX panc ca|"IMM-101 will be given in combination with standard FOLFIRINOX (FOLinic acid, Fluorouracil, IRINotecan and OXaliplatin) treatment.~The treatment regimen with IMM 101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
2934684|NCT03008785|Experimental|group placebo and exercise|The placebo group received 100mg containing starch of corn.
2935758|NCT03001297|Placebo Comparator|Placebo|Placebo will be administered subcutaneously (SC).
2934627|NCT03009058|Experimental|IMM-101+FOLFOX colorectal cancer|"IMM-101 will be given in combination with standard FOLFOX (FOLinic acid, Fluorouracil and OXaliplatin) treatment.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
2934628|NCT03009058|Experimental|IMM-101+FOLFIRI+CETUXIMAB CRC|"IMM-101 will be given in combination with standard FOLFIRI (FOLinic acid, Fluorouracil and IRInotecan) + cetuximab combination treatment.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
2934629|NCT03009058|Experimental|IMM-101+Gem cholangio|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
2934630|NCT03009058|Experimental|IMM-101+Gem lung ca|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter
2934631|NCT03009058|Experimental|IMM-101+Gem + nab-paclitaxel lung ca|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.~The treatment regimen with IMM 101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
2934632|NCT03009058|Experimental|IMM-101+anti-PD1 lung ca|"IMM-101 will be given in combination with standard treatment with either pembrolizumab or nivolumab.~In order to ensure that there are no increased immune-related adverse events (AEs), the first 3 patients entering the anti-PD1 (pembrolizumab or nivolumab) cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen."
2934633|NCT03009058|Experimental|IMM-101+Gem melanoma|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
2934634|NCT03009058|Experimental|IMM-101+anti-PD1 melanoma|IMM-101 will be given in combination with standard treatment with either pembrolizumab or nivolumab. The first 3 patients entering the anti-PD1 (pembrolizumab or nivolumab) cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen thereafter.
2934635|NCT03009058|Experimental|IMM-101+ anti-CTLA-4 melanoma|IMM-101 will be given in combination with standard treatment with ipilimumab. In order to ensure that there are no increased immune-related adverse events (AEs), the first 3 patients entering the ipilimumab cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen thereafter.
2934636|NCT03009058|Experimental|IMM-101+Gem breast cancer|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
2934637|NCT03009058|Experimental|IMM-101+Gem/ nab-paclitaxel breast|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
2934638|NCT03009058|Experimental|IMM-101 + Gem sarcoma|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
2934639|NCT03009058|Experimental|IMM-101+cyclophosphamide|"IMM-101 will be given in combination with low dose cyclophosphamide (300mg/m2 in patients with solid malignancies.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
2934640|NCT03009045|Experimental|Drug: 200mg oral Tedizolid|200mg oral tablet of tedizolid to be taken once daily
2934641|NCT03009032|Experimental|PMT25341|A mixture of prebiotics, probiotics, oligonutrients, essential aminoacids, omega-3 fatty acids
2934642|NCT03009032|Placebo Comparator|PLACEBO|Lactose
2934643|NCT03009019|Experimental|DFN-15 Active|DFN-15 Active
2934644|NCT03009019|Placebo Comparator|DFN-15 Placebo|DFN-15 Placebo
2934645|NCT03009006|Experimental|Calcium Hydroxide Mixed With Chlorhexidin|efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria.
2934646|NCT03009006|Experimental|Calcium Hydroxide|The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
2934647|NCT03009006|Placebo Comparator|Placebo|Mechanical preparation without intracanal medications.
2934685|NCT03008772||PCI with Commercially available DES|Patients who have undergone PCI and received a commercially available drug eluting stent
2934686|NCT03008772||Stent Types|the stent types for angina classification at follow up
2934687|NCT03008759|Placebo Comparator|Placebo|Dentifrice without fluoride
2935989|NCT02999711|Experimental|Cohort 2|REGN3500 medium dose or placebo
2934648|NCT03008993|Experimental|Post-Intervention|The HQIS comprises three phases: 1) clinician training - to improve communication-relational skills and to instruct on the project; 2) center support - 4 on site visits by experts of the project team, aimed to introduce the project and boost motivation, instruct staff on how to implement recommendations, help with context analysis and identification of solutions; assess actual implementation in the center; 3) implementation of EBM recommendations.
2934649|NCT03008993|No Intervention|Control|
2934650|NCT03008980||Community GI Group|Diagnostic Test
2934651|NCT03008980||Academic GI Group|Diagnostic Test
2934652|NCT03008980||Academic Esophageal Dysplasia and Cancer|Diagnostic Test
2934653|NCT03008980||Community Barrett's Esophagus Screening|Diagnostic Test
2934654|NCT03008980||Community Esophageal Dysplasia|Diagnostic Test
2934655|NCT03008980||Post-Ablation BE and Esophagus Dysplasia|Diagnostic Test
2934656|NCT03008980||GERD, BE, and Esophageal Dysplasia|Diagnostic Test
2934657|NCT03008967||Total Knee and Hip Arthroplasty|Rehabilitation, observational. Identification of risk factors for poor response to rehabilitation programs after TJR and use these to identify patients who are most susceptible to poor outcomes
2934658|NCT03008954|Placebo Comparator|Placebo|Microcyrstalline cellulose (Avicel): provided in 5 capsules (350 mg each), twice daily (BID) prior to lunch and dinner.
2934659|NCT03008954|Experimental|GSP3 (2.25g)|GSP3: provided in 3 capsules (750 mg each), plus 2 placebo capsules (350 mg each), twice daily (BID) prior to lunch and dinner
2934660|NCT03008954|Experimental|GSP3 (3.75g)|GSP3: provided in 5 capsules (750 mg each), twice daily (BID) prior to lunch and dinner
2934661|NCT03008941|Experimental|FMT|"Fecal microbiota capsules (provided by Openbiome).~Dosage:~Induction: 10 capsules (single dose)~Maintenance: 5 capsules, weekly, during 7 weeks."
2934662|NCT03008941|Placebo Comparator|Placebo|"Placebo capsules (provided by Openbiome).~Dosage:~Induction: 10 capsules (single dose)~Maintenance: 5 capsules, weekly, during 7 weeks."
2934663|NCT03008928|No Intervention|Control|No intervention
2934664|NCT03008928|Experimental|Alcooquizz app|Alcooquizz is a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazarzdous fashion
2934665|NCT03008915|Active Comparator|Aspirin first then placebo|Aspirin 81mg for 2 weeks followed by a washout period and then placebo for 2 weeks
2934666|NCT03008915|Placebo Comparator|Placebo first then aspirin|Placebo for 2 weeks followed by a washout period and then aspirin 81mg for 2 weeks
2934667|NCT03008902||Non-patients|Non-patients, who have not had vertebral fractures or hyperkyphosis, and have not been seen at BIDMC, will be recruited from the community as described in section B3C and B6 below. The non-patient group will consist of 16 healthy adults ages 18-40.
2934668|NCT03008902||Patients|Patients, who have been seen at BIDMC for vertebral fractures or hyperkyphosis, will be identified by review of medical records as described in B3C and B6 below. The patient group will consist of 32 adults ages 75 and older who have previously been diagnosed with a thoracic vertebral fracture at BIDMC.
2934669|NCT03008889|Experimental|Participants taking NAC|Participants randomized to the active treatment study arm will receive gradually increasing doses of N-acetylcysteine (NAC) given as a dissolving tablet in juice or water. NAC is an over-the-counter oral dietary supplement that will be used a higher than usual doses in this study.
2934670|NCT03008889|Placebo Comparator|Participants taking Placebo|Participants randomized to placebo will receive dissolving tablets identical in size and appearance to the active treatment. Placebo capsules contain inactive ingredients.
2934671|NCT03008876|Experimental|acetaminophen|Group of patients randomized to receive acetaminophen to treat their PDA
2934672|NCT03008876|Active Comparator|ibuprofen|Group of patients randomized to receive ibuprofen to treat their PDA
2934673|NCT03008863|Experimental|Education Intervention|"The investigators will use an electronic learning (E-learning) curriculum with an educational video and a user-centered checklist for anesthesia residents. This E-learning curriculum will cover how to care for geriatric patients in the preoperative, intraoperative and postoperative settings, and specific interventions that have been shown to improve postoperative outcomes in older patients.~The checklist will be user-centered. It will remind providers of what they learned in the video and online curriculum, and how to apply these lessons in real-time while they are caring for older patients."
2934674|NCT03008863|No Intervention|Control|Residents randomized to this group will receive the current, standard education provided for all Duke Anesthesiology residents.
2934675|NCT03008850|Active Comparator|Group M|2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally
2934676|NCT03008850|Active Comparator|Group P|2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally
2934677|NCT03008837|Experimental|PENFS|Veterans with fibromyalgia who meet study criteria and are randomized to the experimental group will receive standard therapy in addition to percutaneous electrical neural field stimulation (PENFS), which involves placement of small electrodes through a similar process to ear acupuncture to the ear. These electrodes are attached to a battery pack that is taped behind the ear and worn for 5-day intervals. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. Device placement (series of 4, weekly) will be performed by an Anesthesiology Pain Clinic provider. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
2934678|NCT03008837|Active Comparator|Standard Therapy|Veterans with fibromyalgia who meet study criteria and are randomized to standard therapy will receive physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
2934679|NCT03008811|Active Comparator|Cryoballoon|Pulmonary vein isolation with cryoballoon catheter.
2934680|NCT03008811|Active Comparator|Radiofrequency|Pulmonary vein isolation with radiofrequency ablation catheter.
2934681|NCT03008798|Experimental|Herbal Medicine C-117|Herbal Medicine C-117 6g granules by mouth,every 12 hours for 1 year
2934682|NCT03008798|Placebo Comparator|The Placebo of Herbal Medicine C-117|The Placebo of Herbal Medicine C-117 6g granules by mouth,every 12 hours for 1 year
2934683|NCT03008785|Experimental|group isoflavone and exercise|The isoflavone group received daily 100mg of isoflavones.
2934688|NCT03008759|Active Comparator|Dentifrice standard|Dentifrice 1100 ppm sodium fluoride (NaF). Positive control
2934689|NCT03008759|Experimental|Dentifrice 50% Nano-F|Dentifrice experimental with Fluoride being half of fluoride Nanoencapsulated and other half freeform of NaF
2934690|NCT03008759|Experimental|Dentifrice 100% Nano-F|Dentifrice experimental with fluoride 100% Nanoencapsulated
2934691|NCT03008746|Experimental|not Pseudomonas aeruginosa colonized|
2934692|NCT03008746|Experimental|Pseudomonas aeruginosa colonized|
2934693|NCT03008746|Experimental|Pseudomonas aeruginosa OprD mutant colonized|
2934694|NCT03008733|Active Comparator|NMMCB|patient with Neuropathies with Motrices Multifocal Conduction Block
2934695|NCT03008733|Active Comparator|PICD|patient with Inflammatory demyelinating polyneuropathy Chronicle
2934696|NCT03008733|Active Comparator|anti MAG|patient with neuropathy antibody Anti-MAG
2934697|NCT03008733|Placebo Comparator|healthy|healthy patient
2934698|NCT03008720|Active Comparator|tDCS active|Transcranial stimulation ( tDCS ) active will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes and intensity 2mA associated active contraction of the TA muscle.
2934699|NCT03008720|Placebo Comparator|tDCS sham|Placebo tDCS will follow the same procedures as active tDCS with active, but the tDCS device will only be switched on for 20 seconds.
2934700|NCT03008720|Active Comparator|FES active|Functional electrical stimulation (FES) active will be administered using QUARK® FES VIF 995 DUAL device. The duration of active FES will be 20 minutes, associated with active contraction of the TA muscle. The pulse width will be 250 μs, modulated at a frequency of 50 Hz, with one to two stimulation cycles (6 seconds on and 12 seconds off) and the intensity will be increased until reaching the motor threshold.
2934701|NCT03008720|Placebo Comparator|FES sham|Placebo FES will follow the same procedures as active FES , but the FES device will only be switched on for 20 seconds, following which the intensity will be gradually reduced to 0 mA.
2934702|NCT03008707||Group 1|Patients who undergo Laparoscopic Peritoneal Lavage
2934703|NCT03008707||Group 2|Patients who have a laparoscopically approached sigmoidectomy
2934704|NCT03008694|Experimental|1|PET/CT
2934705|NCT03008681|Experimental|Andresen functional removable orthodontic appliance|"All the enrolled patients was applied the Andresen Activator (a removable orthodontic appliance) 12-14 hours in a day in total.~Functional appliances helped the movement of the teeth, with the achievement of good facial muscle function. All patients in the cohort were treated with the andresen actovator appliancev for deep bite and class II malocclusion correction.~The appliances were individually manufactured of acrylic resin, with a central screw and a vestibular arch, fabricated through a wax bite registration; the patient was guided to close the mouth in mandibular protrusion with coincidence of the upper and lower midlines. The registration bite was very thin in order to obtain a minimum vertical dimension. The activator was modified every three months increasing its posterior vertical dimension in order to stimulate the mandibular ramus growth thanks to the dislocation of the mandibular condyle."
2934706|NCT03008668|Experimental|experimental group: Acupuncture|acupuncture on 5 most sensitized points/ acupoints
2934707|NCT03008668|Active Comparator|Control group: Acupuncture|acupuncture on 5 least low/non-sensitized points
2934708|NCT03008655|Active Comparator|Nd-YAG|ND-YAG only
2934709|NCT03008655|Experimental|Nd-YAG and intradermal tranexamic acid|Nd-YAG combine with intradermal tranexamic acid
2934710|NCT03008642|Experimental|CO-Rebreathing|The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.
2934711|NCT03008629|Experimental|Podofix nail brace|for mild ingrown toenails
2934712|NCT03008629|Experimental|Combiped nail brace|for Severe dystrophic ingrown toenails
2934713|NCT03008629|Experimental|Podofix and then Combiped nail brace|for Ingrown toenails with pyogenic granuloma
2934714|NCT03008616|Active Comparator|Digoxin immune fab (DigiFab)|Digoxin immune fab 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
2934715|NCT03008616|Placebo Comparator|Placebo|Normal saline, 30 minute IV infusion, every 6 hours x 4 days
2934716|NCT03008603|Experimental|Procedures with XACT Robotic System|CT-guided minimally invasive percutaneous procedures using the XACT Robotics system
2934717|NCT03008590|Other|Naltrexone first then placebo|Naltrexone for 8 weeks, then placebo for 8 weeks, blinded cross-over design
2934718|NCT03008590|Other|Placebo first then naltrexone|Placebo for 8 weeks, then naltrexone for 8 weeks, blinded cross-over design
2934719|NCT03008577|No Intervention|Ambient operating room temperature of 67°F|These patients will have an operating room temperature of 67°F for cesarean delivery, the standard of care at our institution.
2934720|NCT03008577|Active Comparator|Ambient operating room temperature of 75°F|Intervention: Ambient operating room temperature of 75°F for cesarean delivery, which is closer to World Health Organization recommendations.
2934721|NCT03008551|Experimental|Empagliflozin group|Each participant will receive empagliflozin 25mg daily for 3 months
2934722|NCT03008551|Active Comparator|Metformin group|Each participant will receive metformin 1500mg daily for 3 months
2934723|NCT03008538|Experimental|Mineralized Plasmatic Matrix|MPM(Mineralized plasmatic matrix) insertion in extraction sockets for socket preservation for later implant placement and histomorphometric analysis.
2934724|NCT03008538|Active Comparator|Autogenous Bone Graft (Gold Standards).|Socket preservation using Autogenous bone graft for later implant placement and histomorphometric analysis.
2934725|NCT03008525|Experimental|obese patients (group OB)|patients with body mass index ≥ 35 kg/m²
2934726|NCT03008525|Active Comparator|non-obese patients (group NO)|patients with body mass index < 30 kg/m²
2934727|NCT03008512|Experimental|Genexol-PM|Genexol-PM 100 mg/m2 intravenously for 1 hour on days 1, 8, and 15 of a 28-day cycle up to 8 cycles. Patients will receive study treatment until disease progression, unacceptable toxicity, or withdrawal of consent.
2934728|NCT03008499|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2934752|NCT03008356|Experimental|L-carnitine|Oral L-carnitine 1000mg twice daily
2934729|NCT03008499|No Intervention|Control|In this group, the patients will receive no special treatment. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2934730|NCT03008486|Active Comparator|DOC - real|Spastic patients with disorders of consciousness receiving the real soft splint
2934731|NCT03008486|Placebo Comparator|DOC - placebo|Spastic patients with disorders of consciousness receiving the placebo soft splint
2934732|NCT03008486|Active Comparator|Stroke - real|Spastic patients stroke receiving the real soft splint
2934733|NCT03008486|Placebo Comparator|Stroke - placebo|Spastic patients stroke receiving the placebo soft splint
2934734|NCT03008473|Experimental|video laryngoscope and chest CT iminge|First,the operator calculate the distance between the carina and the glottis by CT image and make a marker on the Uniblocker. Then the operator inserted the Uniblocker into the trachea and advanced toward the left main-stem bronchus via the video laryngoscope untill see marker just at the glottis then stopped the insertion .Second, a single lumen tube with appropriate size was intubated via video laryngoscope into the appropriate depth.Third,the Fiberoptic bronchoscopy(FOB) was inserted into single lumen tube to assess the position of the Uniblocker and the injuries of bronchi and carina
2934735|NCT03008473|Experimental|Conventional intubation of Uniblocker|First, a conventional single lumen tube (SLT) was inserted into trachea at optimal depth via video laryngoscope. Second, a Uniblocker was inserted through SLT and directed to the left main-stem bronchus. Third, an FOB was inserted into the SLT to adjust the Uniblocker to optimal position and assessed the injuries of bronchi and carina.
2934736|NCT03008460|Experimental|Eziclen®/Izinova®|
2934737|NCT03008460|Active Comparator|Klean-Prep®|
2934738|NCT03008447|Experimental|LEM5; LEM10; PBO; ZOL|Participants will receive LEM5 (one lemborexant [LEM] 5 milligram [mg] tablet and one zolpidem [ZOL]-matched placebo [PBO] tablet) in Treatment Period 1. In Treatment Period 2, participants will receive LEM10 (one LEM 10 mg tablet and one ZOL-matched PBO tablet). In Treatment Period 3, participants will receive PBO (one LEM-matched PBO tablet and one ZOL-matched PBO tablet). In Treatment Period 4, participants will receive ZOL (one LEM-matched PBO tablet and one ZOL 6.25 mg tablet).
2934739|NCT03008447|Experimental|LEM10; ZOL; LEM5; PBO|Participants will receive LEM10, ZOL, LEM5, and PBO in Treatments Periods 1, 2, 3, and 4, respectively.
2934740|NCT03008447|Experimental|ZOL; PBO; LEM10; LEM5|Participants will receive ZOL, PBO, LEM10, and LEM5 in Treatment Periods 1, 2, 3, and 4, respectively.
2934741|NCT03008447|Experimental|PBO; LEM5; ZOL; LEM10|Participants will receive PBO, LEM5, ZOL, and LEM10 in Treatment Periods 1, 2, 3, and 4, respectively.
2934742|NCT03008434|Experimental|Yoga Group|Yoga twice a week for 8 weeks focusing on balance and pain.
2934743|NCT03008421|Experimental|Study group (GBS positive w/o infection)|Treatment with study medication twice daily for 2 weeks (from study visit 1 to study visit 2)
2934744|NCT03008421|Placebo Comparator|Placebo group (GBS positive w/o infection)|Treatment with placebo twice daily for 2 weeks (from study visit 1 to study visit 2)
2934745|NCT03008408|Experimental|Phase I: Safety Lead-In - Ribociclib + Everolimus + Letrozole|"Safety lead-in of 6 patients to confirm doses of combination therapy with Ribociclib, Everolimus and Letrozole. After safety lead-in 25 more participants enrolled if there are at least 12 patients with clinical benefit.~Ribociclib 250 mg by mouth daily for 28 days. Everolimus 2.5 mg by mouth daily for 28 days. Letrozole 2.5 mg by mouth daily for 28 days."
2934746|NCT03008408|Experimental|Phase II: Ribociclib + Everolimus + Letrozole|"Phase II: 25 participants to be enrolled in this phase.~Ribociclib 250 mg (or dose determined by Safety Lead-In) by mouth daily for a 28 day cycle. Everolimus 2.5 mg (or dose determined by Safety Lead-In) by mouth daily for a 28 day cycle. Letrozole 2.5 mg (or dose determined by Safety Lead-In) by mouth daily for a 28 day cycle.~Participants may continue taking the study drugs for as long as the doctor thinks it is in their best interest."
2934747|NCT03008395|Experimental|EMMA|These participants will receive diabetes self-management education using the dialogue tools, which emphasize empowerment and use the principles of motivational communication and behaviour modification. There will be a series of four visits using the dialogue tools to guide the patient toward meaningful self-management tasks. This is not the typical approach, where providers tell the patient the behaviours they, not the patient, consider priorities. This intervention will evaluate if medical outcomes (A1c) and adherence are improved using a patient-centered not a clinician-cantered approach in individuals with poor diabetes control.
2934748|NCT03008395|Active Comparator|Treatment as Usual|The participants will receive standard diabetes education via group and individual sessions with certified diabetes educators. In this method the patient is provided structured education in which there is an emphasis on covering clinician-determined aspects of diabetes knowledge and self-management. The emphasis vis on diabetes educator recommendations.
2934749|NCT03008382|Other|Double-Blind Randomized Drug|"Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol.~This intervention aims at finding if subjects with IC/BPS have higher baseline HR compared to HCs. After 4 weeks baseline, subjects will receive a bottle with capsules containing 25 mg of metoprolol tartrate or placebo distributed in a double-blind manner by each site's investigational pharmacy. Subjects will start at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week, if HR has not decreased below 55 bpm at rest. Subjects will report daily rest HR for the first week. The subjects will then washout for 4 weeks and enter crossover in similar manner."
2934750|NCT03008382|Other|Double-Blind Randomized Placebo|"Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol.~This intervention aims at finding if subjects with IC/BPS have higher baseline HR compared to HCs. After 4 weeks baseline, subjects will receive a bottle with capsules containing 25 mg of metoprolol tartrate or placebo distributed in a double-blind manner by each site's investigational pharmacy. Subjects will start at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week, if HR has not decreased below 55 bpm at rest. Subjects will report daily rest HR for the first week. The subjects will then washout for 4 weeks and enter crossover in similar manner."
2934751|NCT03008369|Experimental|Treatment (lenvatinib)|Patients receive lenvatinib PO once daily on days 1-28. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
2934753|NCT03008356|Experimental|L-carnitine + health coaching|Oral L-carnitine 1000mg twice daily and weekly 10-15 minute health coaching calls
2934754|NCT03008356|Placebo Comparator|Placebo|Placebo capsules twice daily
2934755|NCT03008343|Experimental|Electroporation and natural killer|In this group, the patients will receive regular irreversible electroporation (IRE) treatment in combination with multiple natural killer (NK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2934756|NCT03008343|Active Comparator|Electroporation|In this group, the patients will receive regular irreversible electroporation (IRE) treatment to control the tumor growth. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2934757|NCT03008330|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2934758|NCT03008330|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2934759|NCT03008317|Active Comparator|non metallic|PEEK denture base,
2934760|NCT03008317|Placebo Comparator|metallic denture base|cobalt chromium alloy denture base
2934761|NCT03008304|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2934762|NCT03008304|No Intervention|Control group|In this group, the patients will receive no special treatment. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2934763|NCT03008291||Heart Failure Group|Patients who have left bundle branch block (LBBB), right bundle branch block (RBBB) or interventricular conduction delay (IVCD) with a QRS duration of greater than 120 ms and left ventricular ejection fraction (LVEF) ≤ 35% will be enrolled in this arm. The primary care physician will have recommended either CRT-D Implantation or CRT-P Implantation. (This is Standard of Care for this patient population; the procedures will occur even if the patient does not participate in the study.)
2934764|NCT03008291||Atrioventricular Block Group|Patients who have developed second or third degree atrioventricular block (AV block). The primary care physician will have recommended dual chamber pacemaker implantation. (This is Standard of Care for this patient population; the procedures will occur even if the patient does not participate in the study.)
2934765|NCT03008278|Experimental|Treatment (olaparib, ramucirumab)|Patients receive olaparib PO BID on days 1-14 and ramucirumab IV over 60 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2934766|NCT03008265||Colonic cancer resection|
2934767|NCT03008239|Experimental|FiberSense sensor|"Type 1, Type 2 and prediabetic subjects will wear one FiberSense sensor, randomly allocated to either the upper arm (50%) or abdomen (50%) for 28 days. In addition, these subjects will wear a Dexcom sensor on the other side of the abdomen for 7 days in one of the four study weeks.~In all 4 CAPD subjects, one FiberSense sensor will be placed in the upper arm for 28 days. No additional comparator sensor will be placed in CAPD subject."
2934768|NCT03008213|Experimental|Netupitant and Palonosetron|Subjects will be allowed to participate only once in the study. Study Day 1 will be the day of Akynzeo® dosing. Subjects will receive a single capsule of Akynzeo® (300 mg of netupitant and 0.5 mg of palonosetron) on Study 1.
2934769|NCT03008200||RDS +|postpartum RDS developed group
2934770|NCT03008200||RDS -|postpartum RDS undeveloped group
2934771|NCT03008187|Experimental|SEL24|"SEL24 will be taken orally once daily for 14 consecutive days over a 21-day treatment cycle. The cohort dose may be escalated by an increase in the daily dose level during the study based on the dose escalation rules.~Continuation of the study treatment may be discussed between the investigator and the Sponsor on a case by case basis. The DMC may also advise on the suitability of an individual patient to continue to receive study treatment.~Patients who experience a DLT will be permitted to receive further treatment with SEL24 according to the dose modification rules described in the study protocol."
2934772|NCT03008174|Experimental|Intervention|"Early one-way speaking valve (OWSV) assessment by speech language pathologist (SLP) following 12-24 hours after percutaneous tracheostomy procedure.~Second OWSV evaluation with SLP following 48-60 hours from initial percutaneous tracheostomy procedure.~Third OWSV evaluation with SLP following first tracheostomy tube change. Participants may receive additional SLP sessions between second and third sessions per standard of care."
2934773|NCT03008174|No Intervention|Control|"Standard OWSV evaluation with SLP following 48-60 hours from initial percutaneous tracheostomy procedure.~Second OWSV evaluation with SLP following first tracheostomy tube change. Participants may receive additional SLP sessions between first and second sessions per standard of care."
2934774|NCT03008161|Experimental|Cohort 1|Participants will receive monthly IV infusions of either low dose NPT088 (6 participants) or placebo (3 participants) for a total of 6 months
2934775|NCT03008161|Experimental|Cohort 2|Participants will receive monthly IV infusions of either mid-low dose NPT088 (6 participants) or placebo (3 participants) for a total of 6 months
2934776|NCT03008161|Experimental|Cohort 3|Participants will receive monthly IV infusions of either mid-high dose NPT088 (16 participants) or placebo (8 participants) for a total of 6 months
2934777|NCT03008161|Experimental|Cohort 4|Participants will receive monthly IV infusions of either high dose NPT088 (16 participants) or placebo (8 participants) for a total of 6 months
2934778|NCT03008148|Active Comparator|Radiation,Temozolomide|"CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).~Rest Phase: Rest for 4 weeks.~Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.~Maintenance Phase: No maintenance treatment until disease progression confirmed."
2934779|NCT03008148|Experimental|Radiation,Temozolomide,Siroquine(JP001)|"CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks) + Daily JP001 (2 tablets once a day for 6 weeks).~Rest Phase: Daily JP001(2 tablets/day) for 4 weeks.~Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).~Maintenance Phase: JP001(2 tablets once a day) for 48 weeks until disease progression confirmed."
2934780|NCT03008122|Experimental|Group 1|5 mcg ZPIV administered IM in a homologous prime-boost regimen on Day 1 and Day 29 , n=45 (2 sentinels, 43 non-sentinels) or placebo, n=5
2934781|NCT03008122|Experimental|Group 2|2.5 mcg ZPIV administered IM in a homologous prime-boost regimen on Day 1 and Day 29, n=35 or placebo, n=5
2934782|NCT03008109|Experimental|EGFR-TK inhibitor plus RH-endostatin|EGFR-TKI icotinib:125mg Tid RH-endostatin:15mg/m2 ,d1-7
2934783|NCT03008083|Active Comparator|3 months DAPT Intervention|After implantation of Firehawk coronary stents, all subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and thienopyridines (clopidogrel or ticagrelor)for 3 months.
2934784|NCT03008083|Active Comparator|12 months DAPT Intervention|After implantation of Firehawk coronary stents, all subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and thienopyridines (clopidogrel or ticagrelor)for 12 months.
2934785|NCT03008070|Experimental|IVA337 1200mg|IVA337 400mg, once a day (Quaque Die, QD) with food
2934786|NCT03008070|Experimental|IVA337 800mg|IVA337 400mg, once a day (Quaque Die, QD) with food
2934787|NCT03008070|Placebo Comparator|Placebo|Placebo to match, once a day (Quaque Die, QD) with food
2934788|NCT03008057|Active Comparator|vitamin D supplementation|patients with type 2 diabetes receive 1 tablet (4000 IU ) vitamin D supplementation, one time a day, for 3 months.
2934789|NCT03008057|Placebo Comparator|vitamin D placebo|patients with type 2 diabetes receive one tablet of vitamin D placebo for 3 months
2934790|NCT03008044|Experimental|Device: FiberSense system|10 subjects will wear 2 FiberSense system in abdomen and upper arm respectively and Dexcom G4 Platinum CGM sensor for 1 day.
2934791|NCT03008044|Experimental|Extension Phase|2 subjects will extend the wearing of the sensors up to 14 days (2 FiberSense systems to Day 14 and Dexcom sensor to Day 7±1) after the glucose clamp study.
2934792|NCT03008031|Experimental|arm A (40%)|Patients randomized in arm A will receive a second CESM exam with 40% of the initial dose of the contrast agent.
2934793|NCT03008031|Experimental|arm B (60%)|Patients randomized in arm A will receive a second CESM exam with 60% of the initial dose of the contrast agent.
2934794|NCT03008031|Experimental|arm C (80%)|Patients randomized in arm A will receive a second CESM exam with 80% of the initial dose of the contrast agent.
2934795|NCT03008018|Other|KA2507 (HDAC6 inhibitor)|This is a single arm dose escalating study. Patients will be treated with open label KA2507 (HDAC6 inhibitor) capsules.
2934796|NCT03008005|Placebo Comparator|Placebo Oral Capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
2934797|NCT03008005|Experimental|Dronabinol Cap 5 milligrams (MG)|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
2934798|NCT03008005|Experimental|Dronabinol Cap 10 milligrams (MG)|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
2934799|NCT03007992|Experimental|Vinorelbine Oral|Test product: Navelbine® 20 mg / 30 mg soft capsules
2934800|NCT03007979|Experimental|Palbociclib + letrozole or + fulvestrant|"Palbociclib should be taken by mouth with food on a 5 days on/2 days off schedule (meaning: on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle).~Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle.~Patients who are receiving fulvestrant will receive it as two intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.~Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- or peri-menopausal women only.~Optional research biopsy at baseline and progression~Blood for research at baseline, cycle 1 day 15, cycle 2 day 1, every 2-3 months (to coincide with imaging studies), and time of progression"
2934801|NCT03007966|Active Comparator|Ilioinguinal / Iliohypogastric Block|Patient's randomized to receive an Ilioinguinal / Iliohypogastric nerve block (IINB) for post operative analgesia following inguinal herniorrhaphy will have said block performed in a supine position in a manner consistent with the technique described by Willschke, but modified to utilize an in-plane technique rather than an out-of-plane technique for needle to ultrasound probe orientation. Either a Sonosite linear HFL38x/13-6 MHz or Sonosite curvilinear C60x/5-2 MHz probe will be utilized to visualize the pertinent ultrasound anatomy. A Pajunk 21g x 100mm Sono Plex Stim Cannula will be utilized to appropriately deposit a single local anesthetic aliquot consisting of 25cc's of bupivacaine 0.25% with epinephrine 5mcg/cc and clonidine 1.66mcg/cc.
2934802|NCT03007966|Experimental|Quadratus Lumborum Block|Patient's randomized to receive a Quadratus Lumborum block (QLB) for post operative analgesia following inguinal herniorrhaphy will have said block performed in a lateral position in a manner consistent with the technique described by Børglum. Either a Sonosite linear HFL38x/13-6 MHz or Sonosite curvilinear C60x/5-2 MHz probe will be utilized to visualize the pertinent ultrasound anatomy. A Pajunk 21g x 100mm Sono Plex Stim Cannula will be utilized to appropriately deposit a single local anesthetic aliquot consisting of 25cc's of bupivacaine 0.25% with epinephrine 5mcg/cc and clonidine 1.66mcg/cc.
2934803|NCT03007953|Experimental|Intervention|This is a nurse-led telephone-based program integrating palliative care into usual oncologic care for patients diagnosed within 2 months of any type and stage of lung cancer, who will receive therapy other than solely surgical resection. The intervention lasts for the duration of patients' primary lung cancer treatment (usually 3-4 months).
2934927|NCT03007017|Active Comparator|Arm 2|Patients selected for this arm will receive the normal standard of care operational kidney from retrieval.
2934804|NCT03007953|No Intervention|Usual Care|Subjects randomized to the usual care arm will receive medical oncology, radiation oncology, pulmonary, CT surgery, as indicated by the type and stage of cancer. At the completion of their primary lung cancer treatment, they will be disenrolled from the study.
2934805|NCT03007940|Experimental|NIATx Strategy|"The implementation intervention, NIATx, will be deployed by the first cohort of programs in a 1-year active implementation phase. Each program is assigned an expert quality improvement coach. The coach will help the staff identify ways to improve and integrate services for individuals with co-occurring substance use and mental health disorders. Supports include an in-person coach site visit, coaching including monthly coaching calls and peer to peer coaching calls and learning sessions which promote peer-to-peer sharing about specific goals and objectives and to receive guidance on how to implement organizational level changes to improve integrated treatment services. A walk-through will allow the provider to understand the co-occurring treatment process from a customer perspective."
2934806|NCT03007940|Placebo Comparator|Wait List Control|The wait-list control group will receive the NIATx strategy at the end of the twelve month implementation period for the initial cohort. During the first year of the study, they will follow a business as usual approach to the integration of co-occurring substance use and mental health services.
2934807|NCT03007927|Experimental|Bupivacaine-Dexamethasone|bupivacaine 1,5 mg/kg + dexamethasone 8 mg 2ml
2934808|NCT03007927|Active Comparator|Bupivacaine- physiological solution|bupivacaine 1,5 mg/kg + physiological solution
2934809|NCT03007914||TCM cohort|Patients continue to receive the routine TCM treatments recommended by 2011 Chinese treatment guidelines of TCM for COPD.
2934810|NCT03007914||Conventional medicine cohort|Patients continue to receive the conventional medicine recommended by 2014 GOLD and Chinese treatment guidelines for COPD.
2934811|NCT03007901|Experimental|Pilot Cohort 1|This Pilot Study will be conducted to allow us to evaluate and test the various study processes, including: consent/enrollment, run-in-trial monitoring, measurement tools, outcome assessment, educational materials, and especially the mindfulness-based climate action trainings. The pilot study does not include a control group, and data will not be used for efficacy outcome analysis.
2934812|NCT03007888|Other|Sequence 1|Treatment Period 1: ER CD-LD Capsules - 15 days; Washout Period 7-days; Treatment Period 2- IR CD-LD Tablet - 15 days
2934813|NCT03007888|Other|Sequence 2|Treatment Period 1- IR CD-LD Tablet - 15 days; Washout Period 7-days; Treatment Period 2- ER CD-LD Capsules - 15 days
2934814|NCT03007875|Experimental|High-activity natural killer|In this group, the patients will receive multiple times of high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2934815|NCT03007875|No Intervention|ControL|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2934816|NCT03007836|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2934817|NCT03007836|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2934818|NCT03007823|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2934819|NCT03007823|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2934820|NCT03007810|Experimental|Hemay005|Four subjects in cohort 1 and six subjects in each cohort (2 to 6) will receive Hemay005.
2934821|NCT03007810|Placebo Comparator|Placebo|Two subjects in each cohort (cohorts 2 to 6) will receive placebo.
2934822|NCT03007797||vaccination rate- pregnant- influenca|
2934823|NCT03007784|Experimental|2 mA anodal tDCS stimulation|Anodal tDCS stimulation at 2 mA applied to the left dorsolateral prefrontal during 20 minutes five days a week for two consecutive weeks
2934824|NCT03007784|Active Comparator|0.2 mA anodal tDCS stimulation|Anodal tDCS stimulation at 0.2 mA applied to the left dorsolateral prefrontal during 20 minutes five days a week for two consecutive weeks
2934825|NCT03007771|Experimental|MR-HIFU|"Philips 1.5T MRI scanner equipped with a Sonalleve V2 HIFU system will be used~Will be scanned in the MRI in 1 or more positions to the extremities and/or pelvis while aligned to the HIFU system. The HIFU device will then be used to apply sub-clinical levels (≤ 41°C) of heat to one or more small volumes. Regions will be heated to the desired temperature for variable short durations of time not exceeding 30 minutes.~After the session is complete, the patient will be removed from the MR-HIFU system and, following a 15-30-minute period of monitoring for any adverse events, allowed to leave.~Before the scan, after the scan and 5-10 days following the scan, participants will be asked to rate any pain, discomfort, in the area to be heated, as well as any anxiety or claustrophobia on a scale of 1-10 with 1 being minimal/none and 10 being extreme. The skin area to be treated will also be reviewed for any redness/discoloration."
2934826|NCT03007758|Active Comparator|robotic ventral hernia repair (VHR)|Robotic VHR
2934827|NCT03007758|Active Comparator|open ventral hernia repair (VHR)|Open VHR
2934828|NCT03007745|Experimental|REVAMP|Veterans randomized to this arm will have access to the Remote Veteran Apnea Management Platform (REVAMP) a personalized, interactive website that allows Veterans to be evaluated for OSA without travelling to the sleep center.
2934829|NCT03007745|Active Comparator|In-person management|Veterans randomized to this arm will receive standard in-person management of their sleep apnea in the sleep center.
2934830|NCT03007732|Experimental|Arm 1|"Patients receive ADT including leuprolide acetate IM at baseline and then every 3 months for 3 doses, prednisone PO daily for 12 months, and abiraterone acetate PO daily for 12 months in the absence of disease progression or unacceptable toxicity. Patients are then randomized into 1 of 2 arms.~Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also undergo (Stereotactic Body Radiation Therapy) SBRT QOD over 10-14 days. Treatment with pembrolizumab repeats every 21 days for up to 13 courses in the absence of disease progression or unacceptable toxicity."
2934831|NCT03007732|Experimental|Arm 2|"Patients receive ADT including leuprolide acetate IM at baseline and then every 3 months for 3 doses, prednisone PO daily for 12 months, and abiraterone acetate PO daily for 12 months in the absence of disease progression or unacceptable toxicity. Patients are then randomized into 1 of 2 arms.~Patients receive TLR9 agonist SD-101 intratumorally 1-2 weeks before Cycle 1, Day 1 and 21 days later after the first dose. Patients also receive pembrolizumab IV over 30 minutes on day 1 and undergo (Stereotactic Body Radiation Therapy) SBRT QOD over 10-14 days. Treatment with pembrolizumab repeats every 21 days for up to 13 courses in the absence of disease progression or unacceptable toxicity."
2934832|NCT03007719|Experimental|Cohort 1: Neoadjuvant|Patients with localized bladder cancer who are eligible for the UCSF phase 2 clinical trial of neoadjuvant atezolizumab before definitive surgery (NCT02451423) (Cohort 1). For the neoadjuvant cohort, study participants will undergo whole body PET/MR imaging with [18F]F-AraG within 7 days of initiating atezolizumab and within 7 days before surgery. Approximately 12 patients will be enrolled.
2934833|NCT03007719|Experimental|Cohort 2: Standard of Care (SOC)|Patients with any cancer type who are planned to initiate standard of care (SOC) anti-PD-1 or anti-PD-L1 treatment (Cohort 2). For the SOC cohort, study participants will undergo whole body PET/MR imaging with [18F]F-AraG within 7 days of initiating Cycle 1 anti-PD-1 or anti-PD-L1, and between Cycle 1 Day 15 (C1D15) and Cycle 2 Day 7 (C2D7) anti-PD-1 or anti-PD-L1. Approximately 19 patients will be enrolled.
2934834|NCT03007693|Experimental|JNJ-61393215 (Multiple Ascending Dose Phase)|Participants will receive JNJ- 61393215 once daily for 7 days. 4 sequential cohorts will be enrolled to evaluate escalating doses which will be defined, based on safety, tolerability and pharmacokinetic (PK) data from the preceding cohorts. Dose adjustment/selection (increase/decrease) for the next cohort will be based on the JNJ- 61393215 PK profile up to and including the last day of dosing (24 hours postdose) and the safety and tolerability profile of the current cohort.
2934835|NCT03007693|Placebo Comparator|Placebo (Multiple Ascending Dose Phase)|Participants will receive JNJ- 61393215 matching placebo for 7 days.
2934836|NCT03007680|Experimental|Core muscle activation|Core muscle will be activated by physical fitness using plank, crunch and leg extension.
2934837|NCT03007680|No Intervention|No core muscle activation|
2934838|NCT03007667||Colorectal cancer patients|Colorectal cancer patients
2934839|NCT03007654|Experimental|Mediclore|adhesion barrier Mediclore 5cc, to apply medical device fully around surgery area
2934840|NCT03007654|No Intervention|No treatment|standard treatment for surgery
2934841|NCT03007654|Active Comparator|Adept|adhesion barrier, Adept, to apply medical device fully around surgery area
2934842|NCT03007641|Experimental|Provider Didactic Intervention|"Phase 1 - Providers complete a needs assessment questionnaire.~Phase 2 - Providers participate in an hour long didactic session, and begin enrolling eligible metastatic breast cancer (MBC) patients. Enrolled MBC patients complete a comprehensive geriatric assessment (CGA). Providers complete a treatment plan questionnaire and a CGA utility questionnaire.~Phase 3 - Providers are administered a final questionnaire evaluating their overall view of this educational intervention."
2934843|NCT03007628|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
2934844|NCT03007628|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
2934845|NCT03007615|Experimental|Experimental group|
2934846|NCT03007602|Experimental|Treatment group: aerobic exercise|The upper extremity aerobic exercise training with an arm ergometer will be performed in the treatment group so that training intensity will be between 60% and 80% of the maximum heart rate, dyspnea perception will be 3-4 according to Modified Borg Scale and fatigue perception will be 5-6 according to Modified Borg Scale, training duration will be a 6-week.
2934847|NCT03007602|No Intervention|Control group: deep breathing exercise|Deep breathing exercises combinated with arm movements will be given as a home schedule in the control group. Training duration will be a 6-week.
2934848|NCT03007589|Other|Location|Location and Intensity of Exposure to Sunlight otc sunscreens sun protection fabrics optical filters
2934849|NCT03007589|Other|Single Duration or SPF Test|Single exposure of interventions or multiple exposures of interventions (SPF or PPD-PF tests) otc sunscreens sun protection fabrics optical filters
2934850|NCT03007576|Experimental|RegStem|Autologous MSC, 5×10^7 cells, one injection
2934851|NCT03007563|Experimental|newborn infants checked for jaundice|an experimental way of bilirubin concentration estimation from smartphone pictures is applied and compared with two standard methods: bilirubin concentration measured in standard blood samples, and bilirubin concentration measured by transcutaneous device.
2934852|NCT03007550|Experimental|Laparoscopic total gastrectomy|The surgeon will perform LTG with D1+/D2-10 lymphadenectomy for patients enrolled in this group.
2934853|NCT03007550|Other|Open total gastrectomy|The surgeon will perform OTG with D1+/D2-10 lymphadenectomy for patients enrolled in this group.
2934854|NCT03007537|Placebo Comparator|control group|0.9% sodium chloride 1ml, subcutaneous injection, once, applied 1day before cardiac surgery
2934855|NCT03007537|Experimental|Erythropoietin group|10000 IU erythropoietin, subcutaneous injection, once, applied 1day before cardiac surgery
2934856|NCT03007524|Experimental|High dose rosuvastatin|20mg/d quaque nocte(qN), at least 6 months
2934857|NCT03007524|Active Comparator|Low dose rosuvastatin|10mg/d quaque nocte（qN）, at least 6 months
2934858|NCT03007511|Experimental|Fidmi|Placement of Fidmi enhanced enteral feeding device; internal tubes replacement during follow up and device removal after 3 month from placement Fidmi enhanced enteral feeding device
2934859|NCT03007485|No Intervention|Standard of Care|Standard pulmonary rehabilitation
2934860|NCT03007485|Experimental|Intervention|Telehealth delivered pulmonary rehabilitation
2934861|NCT03007472|Experimental|CI532/N7 study group|All subjects will receive a CI532 cochlear implant (intervention) and be fit with the CP1000 sound processor
2934862|NCT03007459||Female Fitness Athletes|Psychological health and physiological health of fitness athletes
2934863|NCT03007459||Female, physically active Controls|Psychological health and physiological health of female controls
2934925|NCT03007030|Experimental|Brentuximab Vedotin|"Participants receive Brentuximab Vedotin by vein on Day 1 of every 21 Day cycle.~Participants remain on trial until unacceptable toxicity, withdrawal of consent, or disease progression."
2934864|NCT03007446|Experimental|Apatinib plus Oxaliplatin/S-1|"Apatinib :~A starting dose of apatinib was administered 500 mg daily on days 1 through 21 of each 3-week cycle.~Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle.~S-1:40mg，bid，d1-14，po，in a 21 day cycle."
2934865|NCT03007433|Experimental|healthy volunteers|60 healthy volunteers with no functional dyspepsia as defined by the Rome Questionnaire and no more than mild symptoms on maximum 1 days a week on the GSRS, that meet inclusion and exclusion criteria will be recruited. Eligible subjects will be block randomized by sex and age such that 10 men and women in each age group (<40, 41-60, >60) are recruited.
2934866|NCT03007433|Experimental|Functional dyspeptic patients|20 patients with functional dyspepsia with postprandial distress syndrome as defined by the Rome IV Questionnaire and at least moderate symptom severity on at least 3 days a week that meet the inclusion and exclusion criteria will be recruited to provide pilot data in the local patient population
2934867|NCT03007420|Experimental|Occipital Nerve Block|"After enrollment in the study, patients will be randomized (but not blinded) to receive either an occipital nerve block or a cervical medial branch block. These are injections of anti-inflammatory medications (steroids) and numbing medications (local anesthetics -lidocaine) in nerves located at the back of the head and neck. If patients exhibit a > or = 50% pain reduction on receiving the block evaluated after four weeks, then they may continue to receive blocks as needed, but not more than one every three months.~If patients exhibit < 50% pain reduction, the patient will be treated as per the clinician's judgment with the possibility of a cross over to the other treatment option."
2934868|NCT03007420|Experimental|Cervical Medial Branch Block|"After enrollment in the study, patients will be randomized (but not blinded) to receive either an occipital nerve block or a cervical medial branch block. These are injections of anti-inflammatory medications (steroids) and numbing medications (local anesthetics -lidocaine) in nerves located at the back of the head and neck. If patients exhibit a > or = 50% pain reduction on receiving the block evaluated after four weeks, then they may continue to receive blocks as needed, but not more than one every three months.~If patients exhibit < 50% pain reduction the patient will be treated as per the clinician's judgment with the possibility of a cross over to the other treatment option."
2934869|NCT03007407|Experimental|durvalumab and tremelimumab|
2934870|NCT03007394|Active Comparator|Lorcaserin|10 mg capsule by mouth, twice a day, for 13 weeks
2934871|NCT03007394|Placebo Comparator|Placebo Oral Capsule|10 mg placebo capsule, twice a day, for 13 weeks
2934872|NCT03007381|Experimental|Ketorolac tromethamine|Each patient will undergo mastectomy(ies) if immediate reconstruction is being performed, followed by uni- or bilateral abdominally based free flap harvest, microsurgical anastomoses, and flap inset. If randomized to the ketorolac intervention group, then the participant will receive 30 mg of intravenous (IV) ketorolac tromethamine. The anaesthetist will give participants their first study drug intravenously at the conclusion of surgery. The participant will then continue to receive their assigned drug every 6 hours for 72 hours, for a total of 13 doses. Patients all receive 1:1 care from nursing staff in the early postoperative period, and their nurse will administer all drugs given on the surgical ward.
2934873|NCT03007381|Sham Comparator|Normal Saline|Each patient will undergo mastectomy(ies) if immediate reconstruction is being performed, followed by uni- or bilateral abdominally based free flap harvest, microsurgical anastomoses, and flap inset. If randomized to the control group the patient will be given a sham IV medication. The sham medication will be normal saline at the same volume as ketorolac, which corresponds to 3 ccs. The anaesthetist will give participants their first study drug intravenously at the conclusion of surgery. The participant will then continue to receive their assigned drug every 6 hours for 72 hours, for a total of 13 doses. Patients all receive 1:1 care from nursing staff in the early postoperative period, and their nurse will administer all drugs given on the surgical ward.
2934874|NCT03007368|Experimental|Rice|Cooked white rice and tomato-based sauce
2934875|NCT03007368|Experimental|Potato|Cooked white peeled potato and tomato-based sauce
2934876|NCT03007368|Experimental|Pasta|Cooked macaroni product and tomato-based sauce
2934877|NCT03007368|Experimental|Sorghum thick porridge|Sorghum thick porridge and tomato-based sauce
2934878|NCT03007368|Experimental|Millet thick porridge|Millet thick porridge and tomato-based sauce
2934879|NCT03007368|Experimental|Millet couscous|Cooked millet couscous and tomato-based sauce
2934880|NCT03007368|Experimental|Millet thin porridge|Millet thin porridge
2934881|NCT03007368|Experimental|Millet thin monikuru porridge|Millet thin porridge containing cooked millet granules (monikuru)
2934882|NCT03007342|Experimental|Experimental group|Oral tablet 1000 mg of Amoxicillin/ clavulanic acid combination every 12 hours for five days.
2934883|NCT03007342|Placebo Comparator|control group|Oral tablet placebo every 12 hours for five days.
2934884|NCT03007329|Active Comparator|Dapagliflozin & Exenatide|Dapagliflozin 10mg orally once daily & Exenatide 2mg subcutaneous once weekly
2934885|NCT03007329|Placebo Comparator|Dapagliflozin & Placebo|Dapagliflozin 10mg orally once daily & Exenatide matching Placebo 2mg subcutaneous once weekly
2934886|NCT03007316|Experimental|Immediate Implants + VIP graft.|Immediate implants placed with simultaneous vascularized interpositional periosteal (VIP) connective tissue graft augmentation.
2934887|NCT03007316|No Intervention|Immediate Implants only|Immediate Implants only without soft tissue augmentation.
2934888|NCT03007303||schizophrenia|"15 patients with schizophrenia will be treated with anyone of the atypical psychotics(including olanzapine, quetiapine , ziprasidone and risperidone)or combined with MECT.~The fluctuating dosage depends on the changes of symptom according to the total scores of Positive and Negative Syndrome Scale from schizophrenia patients after treated."
2934889|NCT03007303||health controls|15 healthy individuals were collected from Dalian seventh people's hospital and were matched on age and sex to schizophrenia group
2934890|NCT03007290|Experimental|Treatment group|Group with therapeutic drug monitoring
2934891|NCT03007277|Experimental|PANJO Intervention|201 nulliparous women will be recruited within the PMI public services. Nurses/Midwives will propose to enroll in the PANJO group, which consist in receiving 6 to 12 home visits by a home visitor trained by the PANJO team The visits will consist on 45 to 90-minutes interventions aiming at supporting the family in the everyday challenges they may encounter, and to support the development of qualitative parent-child relationships.
2934926|NCT03007017|Experimental|Arm 1|Patients selected for this arm will receive the left kidney from the new method of organ retrieval.
2934892|NCT03007277|Active Comparator|Service as usual|246 nulliparous women will be recruited within several maternity wards. They will recieve the services they may request from (a) the maternities, (b) the maternal and child protection services (PMI, usually 1 or 2 home visit without any standards) or any other service available. They will be provided with the address and telephone of the closest maternity ward.
2934893|NCT03007264|Experimental|CAP treated|volar arm will be treated with cold atmospheric plasma.
2934894|NCT03007264|Experimental|CAP on bacteria|volar arm with bacteria will be treated with cold atmospheric plasma.
2934895|NCT03007264|No Intervention|no CAP on bacteria|volar arm with bacteria will not be treated with cold atmospheric plasma. Sham comparator for measurements of skin parameters TEWL, temperature and bacterial load.
2934896|NCT03007251|Experimental|"Eurythmy Therapy Movement R"|"EYT exercise R: Positioned between two steps and forearms parallel to the ground, the patient performs a rolling movement like wheels on a wagon. The movement is positioned below shoulder height and is initiated from the shoulder blade."
2934897|NCT03007251|Experimental|"Eurythmy Therapy Movement L"|"EYT exercise L: In a circular and flowing movement the patient leads his hands upwards in front of his body and down again laterally. During elevation of the arms, the patient performs a small hop onto the toes and into knock knees. Lowering his arms, he releases the legs and straightens up again."
2934898|NCT03007251|Experimental|"Eurythmy Therapy Movement B"|"EYT exercise B: The patient describes an embracing movement with both arms and the left leg while balancing on one foot. He then returns to the initial position and repeats the movement using the other leg."
2934899|NCT03007251|Active Comparator|Normal movements during walking or standing|Control exercise: Participants slowly walk across the room, their arms swinging in a natural way. This was designed to control for the most basic upright movement, shifting thermoregulation from resting conditions to exercise conditions, triggering non-thermal factors.
2934900|NCT03007238|Experimental|Supportive care (aldesleukin and ECP)|Patients receive aldesleukin SC daily for 12 weeks. Patients also undergo ECP twice weekly on weeks 1-4 and then receive 2 ECP treatments every 2 weeks on weeks 5-12. Patients responding to upfront therapy with aldesleukin and ECP have the option to continue combination therapy per the discretion of the treating physician until clinical benefit is maintained or toxicities develop.
2934901|NCT03007225|Active Comparator|group 1|Twenty-five patients underwent Chemoembolization with Drug eluting beads. using Drug eluting Doxorubicin hydrochloride (100-150 mg)
2934902|NCT03007225|Active Comparator|group 2|Twenty-five patients underwent conventional Chemoembolization (cTACE) using the standard TACE technique
2934903|NCT03007212|Experimental|HCC patients with Pranch portal vein thrombosis|Thirty HCC patients (24 male, 6 females) Child A cirrhotics with branch PVT. Follow up was done at 1, 3, 6 and 12 months after first TACE. All patients underwent laboratory investigations including liver function tests to assess deterioration in liver functions, triphasic spiral CT to assess radiological response according to mRECIST criteria. Survival analysis was performed using Kaplan-Meier estimations.
2934904|NCT03007199||AGNES Controls|AGNES controls are individuals with a first acute ST-elevation myocardial infarction but without ventricular fibrillation.
2934905|NCT03007199||AGNES cases|AGNES cases have ECG- registered ventricular fibrillation occurring before reperfusion therapy for an acute and first ST-elevation myocardial infarction.
2934906|NCT03007186||Case group|The oral glucose tolerance test that these women undergo in pregnancy between 24+0 and 28+0 showed pathological measurements.
2934907|NCT03007186||Control group|The oral glucose tolerance test of these women showed no pathological measurements.
2934908|NCT03007160|Experimental|Experimental group|Potassium Citrate Extended-release Tablets
2934909|NCT03007160|No Intervention|Blank control group|Subjects do not take the investigational product
2934910|NCT03007147|Experimental|Arm A (imatinib mesylate, EsPhALL chemotherapy)|See Detailed Description
2934911|NCT03007147|Experimental|Arm B (imatinib mesylate, COG/BFM chemotherapy)|See Detailed Description.
2934912|NCT03007147|Experimental|Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)|See Detailed Description
2934913|NCT03007121|Experimental|Morphine intrathecal|An intrathecal administration of preservative-free morphine 0.3 mg in 3 ml NS prepared in a sterile ampoules by a hospital pharmacy will be performed before induction of anaesthesia in a sitting position between L2 and L3 - L4/L5 vertebrae. Standard general anaesthesia will be performed. After surgery, the patients will have the possibility to use PCA device with morphine, bolus dose 1 mg, lock-out interval 5 min for 3 days at a surgical ICU.
2934914|NCT03007121|Active Comparator|Bupivacaine + Sufentanil epidural|An epidural catheter will be inserted before induction of anaesthesia in a sitting position between T9 and T10 - T12 and L1 vertebrae. A test dose of 4 ml 0.5 bupivacaine will be administered to rule out intravascular injection or subarachnoid or subdural block. Standard general anaesthesia will be performed. Thirty minutes before the end of the surgery, patients will be administered a bolus of a mixture of bupivacaine 0.5% (3 ml) + sufentanil 10 mcg (2 ml) + NS 5 ml followed by a continuous infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h. At the same time patients will have the possibility to use PCA device with morphine, bolus dose 1 mg, lock-out interval 5 min for 3 days at a surgical ICU.
2934915|NCT03007121|Active Comparator|Morphine intravenous|Patients will be administered standard general anaesthesia. After surgery, bolus doses of morphine 2 mg will be administered until level of pain will be < 4 (VAS 0 - 10). Analgesia will be continued by PCA device using morphine, bolus dose 1 mg, lock-out interval 5 min. for 3 days at surgical ICU.
2934916|NCT03007108|Experimental|healthy infants|
2934917|NCT03007095|Experimental|preterm children|
2934918|NCT03007095|Active Comparator|term children|
2934919|NCT03007069|Experimental|Autogenous bone graft (Gold Standard).|Patients with defective maxillary alveolar ridges requiring implant insertion will have Autogenous bone graft (Gold standard) and collagen membrane to be used for bone augmentation around exposed threads of inserted dental implants.
2934920|NCT03007069|Active Comparator|MPM Augmentation.|Mineralized plasmatic matrix (MPM) to be used without collagen membrane to augment the defect in the maxillary bone and cover the exposed threads of the dental implants.
2934921|NCT03007056||Period 1|year 2011 nCPAP
2934922|NCT03007056||Period 2|year 2014 nCPAP and high flow nasal cannula
2934923|NCT03007043||Normal responders|Normal response following IVF
2934924|NCT03007043||Suboptimal responders|Suboptimal response following IVF
2934928|NCT03007004|Experimental|Botulinum toxin group|400 units in one injection site（0.2mL） Total 2000 units（1.0mL） （For both hands total 4000 units; 2.0 mL）
2934929|NCT03007004|Sham Comparator|Physiological saline (control drug) group|"0.2mL in one injection site~Total 1.0mL (For both hands total 2.0 mL)"
2934930|NCT03006991||good efficacy|using therapeutic drug monitoring to adjust the dose of methotrexate. patients can reach effective outcome.
2934931|NCT03006991||poor efficacy|patients can not reach effective outcome.
2934932|NCT03006978|Experimental|TearCare|Subjects will receive a 12-minute treatment session with the TearCare System followed by manual expression of the meibomian glands.
2934933|NCT03006978|Active Comparator|Warm Compress|Subjects will apply a warm compress to the eyelids for 5 minutes daily for 4 weeks.
2934934|NCT03006965||Hemophilia A patients|"Group of patients in prophylactic treatment with Advate® (Octocog- Alfa), or patients using already myPKFit®.~Patients will be given a dose of Octocog- Alfa according to usual clinical practice, and two blood samples will be extracted (one sample will be extracted 3-4h postdose (+/- 30 min), and the second sample wil be extracted 24-32h postdose (+/- 1 h))."
2934935|NCT03006952|Active Comparator|pentoxifylline & losartan|pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
2934936|NCT03006952|Active Comparator|Losartan|losartan arm took 100mg losartan daily for 12 weeks.
2934937|NCT03006926|Experimental|lenvatinib 8 or 12 mg plus pembrolizumab 200 mg|Participants will receive oral lenvatinib at a starting dose of 8 or 12 milligrams (mg) once a day (QD) in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle. The starting dose of lenvatinib will be based on Baseline body weight. Participants weighing greater than or equal to 60 kilograms (kg) will receive 12 mg QD; participants weighing less than 60 kg will receive 8 mg QD.
2934938|NCT03006913|Active Comparator|Randomization to counseling: In-person|Behavioral: Comparing genetic counseling modes.
2934939|NCT03006913|Active Comparator|Randomization to counseling: By phone|Behavioral: Comparing genetic counseling modes.
2934940|NCT03006913|Active Comparator|Randomization to counseling: By video|Behavioral: Comparing genetic counseling modes.
2934941|NCT03006900|Experimental|Pilates and massage|Pilates (twice per week for 50 minutes) and massage (once per week for one hour)
2934942|NCT03006900|Active Comparator|Massage|Massage (once per week for one hour)
2934943|NCT03006887|Experimental|lenvatinib 20 mg plus pembrolizumab 200 mg|Participants will receive oral lenvatinib at a starting dose of 20 milligrams (mg) once a day (QD) in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle
2934944|NCT03006874|Experimental|CJ-12420 50mg QD|CJ-12420 50mg tablet, once daily, oral administration for up to 8 weeks.
2934945|NCT03006874|Experimental|CJ-12420 100mg QD|CJ-12420 100mg tablet, once daily, oral administration for up to 8 weeks.
2934946|NCT03006874|Active Comparator|Esomeprazole 40mg|Esomeprazole 40mg, tablet. once daily, oral administration for up to 8 weeks.
2934947|NCT03006861|Experimental|Oral creatine supplementation|21 g/d oral creatine for 7 days
2934948|NCT03006861|Placebo Comparator|Oral placebo supplementation|21 g/d oral placebo for 7 days
2934949|NCT03006848|Experimental|Avelumab|"All participants with recurrent/refractory osteosarcoma who consent to the study.~Interventions: Avelumab and quality of life questionnaires."
2934950|NCT03006835|Experimental|Domestic Clopidogrel 300mg|Domestic Clopidogrel 300mg
2934951|NCT03006835|Experimental|Domestic Clopidogrel 600mg|Domestic Clopidogrel 600mg
2934952|NCT03006835|Experimental|Imported Clopidogrel 300mg|Imported Clopidogrel 300mg
2934953|NCT03006835|Active Comparator|Imported Clopidogrel 600mg|Imported Clopidogrel 600mg
2934954|NCT03006822|Experimental|Application 90 minutes pressure release|Subjects will receive a pressure release technique for 90 seconds in the levator scapula muscle
2934955|NCT03006822|Experimental|Application 60 minutes pressure release|Subjects will receive a pressure release technique for 60 seconds in the levator scapula muscle
2934956|NCT03006822|Experimental|Application 30 minutes pressure release|Subjects will receive a pressure release technique for 30 seconds in the levator scapula muscle
2934957|NCT03006809|Experimental|1|pretreatment antibiotics + FMT delivered by colonoscopy + FMT capsules per week x 6 weeks
2934958|NCT03006809|Experimental|2|no antibiotics, FMT delivered by colonoscopy + FMT capsules per week x 6 weeks
2934959|NCT03006809|Experimental|3|pretreatment antibiotics + FMT delivered by colonoscopy + FMT delivered by enema once per week x 6 weeks
2934960|NCT03006809|Experimental|4|no antibiotics, FMT delivered by colonoscopy + FMT delivered by enema once per week x 6 weeks
2934961|NCT03006796||group 1 (AZL/C)|Group 1 - patients receiving azilsartan medoxomil/chlorthalidone 40/12.5 mg or 40/25 mg per os once a day for 6 months.
2934962|NCT03006796||group 2 (IRB/H)|Group 2 - patients receiving irbesartan/hydrochlorothiazide 150/12.5 mg or 300/25 mg per once a day for 6 months.
2934963|NCT03006783||Cross-face nerve graft treated|People treated by a solitary cross-face nerve graft or in combination with another procedure.
2934964|NCT03006783||Hypoglossal-facial treated|People treated with a solitary hypoglossal-facial anastomosis.
2934965|NCT03006770|Experimental|PLX-PAD|PLX-PAD will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.
2934966|NCT03006770|Placebo Comparator|Placebo|Placebo will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.
2934967|NCT03006757|Experimental|Column titanium dioxide|patient take titanium dioxide denture participants will receive titanium dioxide denture ( made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial.
2934968|NCT03006757|Experimental|column placebo|patient will take denture with conventional acrylic ( 20 minutes cure ) for 1 month in the initial phase
2934969|NCT03006744|Experimental|Phonological awareness training|Parents will be given specific training on how to improve phonological awareness using books provided by the investigator. Parents watch a video with examples of how to improve phonological awareness. Suggestions include placing emphasis on rhyme and alliteration, segmenting long words into syllables and talking about how words sound and what they mean.
2935030|NCT03006315||Cohort A: <65 years|Cohort A will be comprised of participants <65 years old and will accrue a total of 20 patients.
2934970|NCT03006744|Placebo Comparator|Reading enjoyment training|Parents will be given general training on how to make reading fun. Parents watch a video with examples of how they can bring books to life with funny voices, actions, and so on. The training is of a similar duration to the intervention arm.
2934971|NCT03006731|Experimental|High Intensity Training|High Intensity Interval Training patients will attend the centre 3 times/week for 24 weeks. All subjects will participate in MICE aerobic training 5 days/week in the first four weeks of the study to provide a foundation of fitness and endurance for the safe prescription of HIIT. Subsequently, the HIIT group will replace 3 MICE training days with 3 HIIT. HIIT sessions will include two 20 minute protocols; 30:60 second work:active rest ratio, and 120:180 second work:active rest ratio on a treadmill with a harness for fall protection. In addition to supervised exercise training (3 times/week), MICE will be conducted 2 times/week in the home/community, which has been shown to be both safe and effective
2934972|NCT03006731|Active Comparator|Moderate Intensity Exercise|Moderate Intensity Continuous Exercise patients will attend the centre 3 times/week for 24 weeks. Participants will be progressed to 30 to 60 minutes of continuous exercise at the heart rate that occurred at the anaerobic threshold on the exercise test. Participants will exercise on a treadmill with a harness ofr fall protection. In addition to supervised exercise training (3 times/week), MICE will be conducted 2 times/week in the home/community by both cohorts.
2934973|NCT03006718|Experimental|Patients|"Participants must have SCD (HbSS, HbSC, HbSβ0 thalassemia, HbSβ+ thalassemia, HbSOArab), within the age range of 8 - 21 years, and be admitted to the hospital for vaso-occlusive crisis (VOE)-related pain. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study.~All participants will use the PROMIS for Pain Management App over 5 consecutive weeks (starting at hospital discharge)."
2934974|NCT03006705|Experimental|Nivolumab group|"Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).~Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.~S-1 therapy(maximum 1 year):~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off~CapeOX Therapy(maximum 6 months):~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off."
2934975|NCT03006705|Placebo Comparator|Placebo group|"Placebo: Placebo solution intravenously for 30 min in every 3 weeks (maximum 1 year).~Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.~S-1 therapy(maximum 1 year):~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off~CapeOX Therapy(maximum 6 months):~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off."
2934976|NCT03006692||Take arterial blood gas|Patients with impaired consciousness are randomised into having analysed a arterial blood gas.
2934977|NCT03006692||Do not take arterial blood gas|Patients with impaired consciousness are randomised into not having analysed a arterial blood gas.
2934978|NCT03006679|Experimental|Meropenem-Vaborbactam HABP|Participants with a clinical diagnosis of HABP will be treated with meropenem 2 grams (g) and vaborbactam 2 g in 250 milliliters (mL) infused intravenously for 3 hours every 8 hours for 7 days to a maximum of 14 days.
2934979|NCT03006679|Active Comparator|Piperacillin/Tazobactam HABP|Participants with a clinical diagnosis of HABP will be treated with piperacillin 4 g and tazobactam 0.5 g in 100 mL infused intravenously for 30 minutes every 6 hours for 7 days to a maximum of 14 days.
2934980|NCT03006679|Experimental|Meropenem-Vaborbactam VABP|Participants with a clinical diagnosis of VABP will be treated with meropenem 2 g and vaborbactam 2 g in 250 mL infused intravenously for 3 hours every 8 hours for 7 days to a maximum of 14 days.
2934981|NCT03006679|Active Comparator|Piperacillin/Tazobactam VABP|Participants with a clinical diagnosis of VABP will be treated with piperacillin 4 g and tazobactam 0.5 g in 100 mL infused intravenously for 30 minutes every 6 hours for 7 days to a maximum of 14 days.
2934982|NCT03006666|Active Comparator|Control Group (Data Only)|The teams randomly allocated to the Control Group will receive monthly lists of their pre-DM patients and information on the availability of DM prevention resources. They will not have access to CHWs.
2934983|NCT03006666|Experimental|Intervention Group: (CHW Health Coaching Integrated into Team)|Teams randomly allocated to the Intervention Group will also receive regular panel data on their pre-DM patients and will have a CHW join the team, attend team meetings, and provide an outreach intervention to all prediabetic patients in the panel, as described below. CHWs and the researchers will provide regular updates to the team on these activities.
2934984|NCT03006640|Placebo Comparator|Control group|
2934985|NCT03006640|Active Comparator|NTG group|
2934986|NCT03006627|Active Comparator|Male group|All male patients scheduled for upper abdominal surgeries
2934987|NCT03006627|Active Comparator|Female group|All female patients scheduled for upper abdominal surgeries
2934988|NCT03006614|Experimental|PERS:NVB,DDP,GEM,CAP,H etc.|vinorelbine 25mg/m2 d1,d8 iv,q3w cisplatin 70mg/m2 d1，q3w gemcitabine 1000mg/m2 d1,d8,q3w capecitabine 1000mg/m2,bid,d1-14,q3w Trastuzumab
2934989|NCT03006614|Active Comparator|EPI+CTX-T+/-H|Epirubicin 90mg/m2 d1+ CTX 600mg/m2 d1 q2w, Docetaxel 75mg/m2 +/-herceptin d1,q3w
2934990|NCT03006601|Placebo Comparator|Placebo group|After enrollment, patients will be randomized into either treatment group or placebo group. Patients will receive placebo procedure which were designed to look like real vergence/accommodative therapy procedures yet not stimulate vergence, accommodation, of fine saccadic eye movement skills beyond normal daily visual activities. Office-based procedures (60 minutes per visit, one time per week, 12 weeks) and home procedures (15 minutes each time, five times per week, 12 weeks) will be provided to patients.
2934991|NCT03006601|Experimental|Treatment group|After enrollment, patients will be randomized into either treatment group or placebo group. Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 12 weeks) and home reinforcement (15 minutes each time, five times per week, 12 weeks) will be provided to patients of treatment group.
2934992|NCT03006588|Experimental|EUS-FNA for RPLN in NPC patients|Fine needle aspiration guided by EUS in retropharyngeal lymph node in suspicious recurrent naspharyngeal carcinoma.
2935029|NCT03006328|Active Comparator|Obese Subjects + Enhanced Usual Care|Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity
2934993|NCT03006575|Experimental|Consolidation chemotherapy|two cycles of consolidation chemotherapy of pemetrexed/docetaxel: pemetrexed(500mg/㎡) in non-squamous lung cancer or docetaxel(60mg/㎡) in squamous lung cancer after split-course chest radiation and concurrent chemotherapy for postoperative locoregional recurrence.
2934994|NCT03006575|Active Comparator|Observation|Observation after split-course chest radiation and concurrent chemotherapy for postoperative locoregional recurrence.
2934995|NCT03006562|Experimental|Subcutaneous Heparin|Patients randomized to the pharmacologic VTE prophylaxis arm will receive a dose of subcutaneous heparin 5,000 units prior to incision, and subcutaneous heparin 5,000 units every 8 hours after surgery until discharge.
2934996|NCT03006562|No Intervention|Control|Patients randomized to the control arm will receive routine care with intermittent pneumatic compression devices.
2934997|NCT03006549|Experimental|Emergency Manual|emergency manual present
2934998|NCT03006549|No Intervention|No Emergency|NO emergency manual present
2934999|NCT03006536|Experimental|Li-ESWT|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
2935000|NCT03006536|Sham Comparator|Sham|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
2935001|NCT03006523|Active Comparator|Intrauterine Insemination with 200 µl|The sperm sample will be concentrated by centrifugation to a volume of 200 µl
2935002|NCT03006523|Experimental|Intrauterine Insemination with 500 µl|The sperm sample will be concentrated by centrifugation to a volume of 500 µl.
2935003|NCT03006510|Active Comparator|Alert|If glucose <90 mg/dl and hypoglycemia prediction score >35, then alert with suggestion for intervention sent to treating team
2935004|NCT03006510|No Intervention|No alert|Routine standard care. If glucose <90 mg/dl and hypoglycemia prediction score >35, then report for investigators will be collected, but no active alert will be sent to teams.
2935005|NCT03006497|No Intervention|Control|The control group will not participate in any exercise program. However, at the end, home based exercises and special advice will be given to the participants.
2935006|NCT03006497|Experimental|Intervention|The intervention group will participate in an exercise program based on motor learning principles for 4 weeks/3 sessions per week, for a total of 12 sessions of 30-45 minutes each.
2935007|NCT03006471|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
2935008|NCT03006471|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
2935009|NCT03006445|Experimental|FYU-981|
2935010|NCT03006432|Active Comparator|FOLFOX|Cycles every 15 days until progression desease
2935011|NCT03006432|Experimental|TFOX|Cycles every 15 days until progression desease
2935012|NCT03006419|Active Comparator|Group A (Basiliximab group)|Basiliximab (Simulect) induction therapy: 20 mg IV at day of transplant (to be administered 2 hours prior to transplant and up to 4 hours after transplant) and second dosage (20 mg) at fourth day after kidney transplantation.
2935013|NCT03006419|Experimental|B (Low-dose Thymoglobulin group)|Thymoglobulin induction therapy (1 mg/kg rounded by 25 mg increments) at day of transplant followed by same dosage (1 mg/kg rounded by 25 mg increments) during day 1 and day 2 after transplant in order to complete 3 mg/kg accumulated dose.
2935014|NCT03006406|Active Comparator|Long term GnRH-a for 1 month|patient in this group only receive GnRH-a 3.75 for 1 month
2935015|NCT03006406|Experimental|patient in this group only receive GnRH-a 3.75 for 2 month|patient in this group only receive GnRH-a 3.75 for 2 month
2935016|NCT03006393|Experimental|Infliximab|Participants randomized to the infliximab group will receive one infusion of infliximab at 5mg/kg body weight.
2935017|NCT03006393|Placebo Comparator|Placebo|Participants randomized to the placebo group will receive one placebo infusion.
2935018|NCT03006380|Experimental|oxytocin before placental delivery|patients who will receive 10 IU of oxytocin (syntocinon®, NOVARTIS, Egypt) intramuscularly at delivery of anterior shoulder of the fetus and an identical placebo injection (normal saline, NACL 0.9%) intramuscularly following delivery of the placenta.
2935019|NCT03006380|Experimental|oxytocin after placental delivery|patients who will receive placebo injection (normal saline, NACL 0.9%) intramuscularly at delivery of anterior shoulder of the fetus and 10 IU of oxytocin (syntocinon®, NOVARTIS, Egypt) intramuscularly following delivery of the placenta.(opposite medication sequence)
2935020|NCT03006367|Experimental|NFC-1 100 mg|Single Dose of NFC-1 100 mg
2935021|NCT03006367|Experimental|NFC-1 200 mg|Single Dose of NFC-1 200 mg
2935022|NCT03006367|Experimental|NFC-1 400 mg|Single Dose of NFC-1 400 mg
2935023|NCT03006367|Experimental|NFC-1 800 mg|Single Dose of NFC-1 800 mg
2935024|NCT03006354|Experimental|nHFOV|"Ventilator-derived nHFOV will be administered using binasal prongs. Standard Device: Leoni-Plus or Leoni-2 Ventilator, Heinen Löwenstein, Germany Initial nHFOV settings are: MAP: 8cmH2O, Frequency:10 MHz, Amplitude:35 cmH2O (will be adjusted to achieve adequate chest wall vibration), I:E=1:1 and FiO2: adjusted to keep preductal sPO2 between %90-95.~Failure is defined as FiO2 requirement of >%60, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>65 cmH2O.~When nHFOV failure occurs, nasal intermittent positive pressure ventilation (nIPPV) will be applied as a rescue therapy with the following settings: Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10 L/min, FiO2:adjusted to keep preductal sPO2 between %90-95."
2935025|NCT03006354|Active Comparator|nCPAP|"Ventilator-derived nCPAP will be administered using binasal prongs. Standard Device: Leoni-Plus or Leoni-2 Ventilator, Heinen Löwenstein, Germany Initial nCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-95.~Failure is defined as FiO2 requirement of >%60, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>65 cmH2O.~When nCPAP failure occurs, nasal intermittent positive pressure ventilation (nIPPV) will be applied as a rescue therapy with the following settings: Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10 L/min, FiO2:adjusted to keep preductal sPO2 between %90-95."
2935026|NCT03006341||Dabigatran etexilate|NVAF patients initiating dabigatran etexilate
2935027|NCT03006341||Warfarin|NVAF patients initiating warfarin
2935028|NCT03006328|Experimental|Obese Subjects + GEM|Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity
2935031|NCT03006315||Cohort B: >/= 65 years|Cohort B will be comprised of participants >/= 65 years and will accrue a total of 20 patients.
2935032|NCT03006302|Experimental|Epacadostat/Pembrolizumab/CY/GVAX/CRS-207|
2935033|NCT03006302|Experimental|Epacadostat/Pembrolizumab/CRS-207|
2935034|NCT03006289||The thyroid cancer group|The postoperative pathology of thyroid is malignant
2935035|NCT03006289||The thyroid nodule group|The postoperative pathology of thyroid is benign
2935036|NCT03006276|Experimental|DFN-15 Active|DFN-15 Active
2935037|NCT03006276|Placebo Comparator|DFN-15 Placebo|DFN-15 Placebo
2935038|NCT03006263|Experimental|Totally Laparoscopic Total Gastrectomy|Totally Laparoscopic Total Gastrectomy will be performed for the treatment of patients assigned to this group.
2935039|NCT03006263|Experimental|Laparoscopy Assisted Total Gastrectomy|Laparoscopy Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
2935040|NCT03006250|Experimental|Desflurane|Desflurane group: The rule of 24 will be applied, which means that the fresh gas flow (l/ min) multiplied by volume percent of desflurane must not exceed 24. Therefore, once the patients return of spontaneous ventilation, an anesthesiologist turns on oxygen 1 l/ min, nitrous oxide 1 l/ min, and desflurane 12 vol% for 1-2 minutes. When the end-tidal desflurane reaches 3-3.5% (approximately 0.5 MAC), the anesthesiologist will decrease oxygen and nitrous oxide to each 0.5 l/ min and desflurane to 6 vol% (1 MAC). Desflurane concentration will be adjusted to maintain the end-tidal desflurane around 3-6% (0.5-1 MAC).
2935041|NCT03006250|Active Comparator|Sevoflurane|Sevoflurane group: The oxygen and nitrous oxide each 1 l/min will be turned on with sevoflurane 4 vol% for 1-2 minutes or until the end-tidal sevoflurane reach 1-1.2% (approximately 0.5 MAC). After that, the flow of oxygen and nitrous oxide is reduced to each 0.5 l/ min and concentration dial of sevoflurane is set to 2 vol% (1 MAC). During the operation, sevoflurane concentration will be adjusted to maintain the end-tidal sevoflurane around 1-2% (0.5-1 MAC)
2935042|NCT03006237|Experimental|IV IS-001 drug|IV IS-001 given during hysterectomy performed with da Vinci® Si/Xi Surgical System
2935043|NCT03006224|Active Comparator|Group S (non smoking and secondary smoking)|I want to see the effects of seconder smoking to intraoperative arterial oxygen tension during one lung ventilation for lobectomy surgery.
2935044|NCT03006224|Active Comparator|Group SS (secondary smoking)|I want to see the effects of seconder smoking to intraoperative arterial oxygen tension during one lung ventilation for lobectomy surgery.
2935045|NCT03006211|Active Comparator|corneal endothal|Evaluate the effects of nitrogen protoxide to corneal endothal and compare with oxygen.
2935046|NCT03006211|Active Comparator|Cell density|Evaluate the effects of nitrogen protoxide to Cell density and compare with oxygen.
2935047|NCT03006198||Cohort 1: Rheumatoid Arthritis|Participants with Rheumatoid arthritis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
2935048|NCT03006198||Cohort 2: Ankylosing Spondylitis|Participants with Ankylosing spondylitis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
2935049|NCT03006198||Cohort 3: Psoriatic Arthritis|Participants with Psoriatic arthritis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
2935050|NCT03006198||Cohort 4: Crohn's Disease|Participants with Crohn's disease as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
2935051|NCT03006198||Cohort 5: Ulcerative Colitis|Participants with Ulcerative colitis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
2935052|NCT03006185|Active Comparator|Test Area A|Two 50 cm2 test areas (Test Area A and B) are demarcated on the skin of each study participant. One test area is randomized to receive the intervention: Ablative Fractional Carbon Dioxide (CO2) Laser prior to standard daylight photodynamic therapy. The other test area is randomized to receive the intervention: microdermabrasion prior to standard daylight photodynamic therapy.
2935053|NCT03006185|Active Comparator|Test Area B|Two 50 cm2 test areas (Test Area A and B) are demarcated on the skin of each study participant. One test area is randomized to receive the intervention: Ablative Fractional Carbon Dioxide (CO2) Laser prior to standard daylight photodynamic therapy. The other test area is randomized to receive the intervention: microdermabrasion prior to standard daylight photodynamic therapy.
2935054|NCT03006172|Experimental|Stage I Arm A: GDC-0077 Single Agent|Participants will receive GDC-0077 in escalating dose levels with starting dose of 6 milligrams (mg). Participants will receive single dose of GDC-0077 on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
2935055|NCT03006172|Experimental|Stage I Arm B: GDC-0077 + Palbociclib + Letrozole|Participants will receive GDC-0077 in escalating dose levels (starting dose 3 mg) on Days 1-28, palbociclib on Days 1−21, and letrozole on Days 1−28 of each 28-day cycle. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
2935056|NCT03006172|Experimental|Stage I Arm C: GDC-0077 + Letrozole|Participants will receive GDC-0077 in escalating dose levels along with letrozole on Days 1−28 of each 28-day cycle. The starting dose of GDC-0077 will not exceed the starting dose in Stage I Arm A. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
2935057|NCT03006172|Experimental|Stage II Arm B: GDC-0077 + Palbociclib + Letrozole|Participants will receive GDC-0077 on Days 1-28 in combination with palbociclib on Days 1-21 and letrozole on Days 1-28 of each 28-day cycle. Dose of GDC-0077 will be decided based on the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
2935118|NCT03005743|Experimental|MR based BT|Magnetic Resonance Image based Brachytherapy
2935058|NCT03006172|Experimental|Stage II Arm C: GDC-0077 + Letrozole|Participants will receive GDC-0077 in combination with letrozole on Days 1-28 of each 28-day cycle. Dose of GDC-0077 will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
2935059|NCT03006172|Experimental|Stage II Arm D: GDC-0077 + Fulvestrant|Participants will receive GDC-0077 on Days 1-28 in combination with fulvestrant on Day 1 and 15 of Cycle 1 and then on Day 1 from Cycle 2 (cycle length: 28 days). Dose of GDC-0077 will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
2935060|NCT03006159|Experimental|Cohort 1|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 5 mg SHR0534 or matching placebo.
2935061|NCT03006159|Experimental|Cohort 2|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 10 mg SHR0534 or matching placebo.
2935062|NCT03006159|Experimental|Cohort 3|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 25 mg SHR0534 or matching placebo.
2935063|NCT03006146|Experimental|Sargramostim|Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
2935064|NCT03006120||Group 1|Conservative management
2935065|NCT03006120||Group 2|Angiografic stenting
2935066|NCT03006120||Group 3|Surgery
2935067|NCT03006107|Experimental|intraligamentary injection of piroxicam|"intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .~The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone"
2935068|NCT03006107|Active Comparator|Intraligamentary mepevacaine|mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
2935069|NCT03006081|Experimental|2mg intravitreal aflibercept injection|2mg intravitreal aflibercept (Eylea) injection at baseline, 1M, 2M, 3M, 4M, and 5M
2935070|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose A|The participants in this arm will receive Upadacitinib (ABT-494) dose A.
2935071|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose B|The participants in this arm will receive Upadacitinib (ABT-494) dose B.
2935072|NCT03006055|Experimental|MBC Group|metastatic breast cancer Age：18-75 ECOG:0-2
2935073|NCT03006055|Experimental|Control Group|benign breast tumour Age：18-75 ECOG:0-2
2935074|NCT03006029|Experimental|TAB08( Theralizumab)|TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
2935075|NCT03006016|Experimental|Omega 3|The patient will take Omega 3 before intervention 4-week course of 1.500 Mg/ day without caloric restriction
2935076|NCT03006016|Placebo Comparator|Placebo|The patient will take placebo before intervention 4-week course of 1.500 Mg/ day without caloric restriction
2935077|NCT03006003|Experimental|Raloxifene group|Raloxifene treatment
2935078|NCT03006003|Active Comparator|Comparator group|Alendronate treatment
2935079|NCT03006003|No Intervention|Control group|To refuse anti-osteoporosis treatment
2935080|NCT03005990|Experimental|Exercise training group|Exercise group will attend a supervised aerobic plus resistance exercise training class 3 times a week totally for 24 weeks.
2935081|NCT03005990|No Intervention|Control group|Control group only provide standard outpatient care program.
2935082|NCT03005977|Other|Urodynamics, pyridium pad & cough stress|"The Pelvic Floor Bother Questionnaire, a questionnaire standardized by Cleveland Clinic Florida, the Urogenital Distress Inventory (UDI-6), and the numerical analog scale are to be administered prior to and 6 weeks after the surgical intervention. (14, 15)~Prior to surgery, patients will be scheduled for a UDS performed by a qualified nurse practitioner or physician and will be given instructions in verbal and written form to undergo a 24 H pyridium pad test at least 72 hours before the UDS. Patients will be given pyridium TID and report if orange stain is noted on their pad in this period of time. A supine and a standing cough stress test will also be performed."
2935083|NCT03005964|Experimental|AM001 Cream, 7.5%|A white to off-white Cream free from any foreign particles
2935084|NCT03005964|Placebo Comparator|Vehicle Cream|A white to off-white Cream free from any foreign particles.
2935085|NCT03005951|Experimental|Lean males|This is a randomized, two-period, cross over design with the intervention of consuming breakfast versus fasting for breakfast to study the effects on hormone responses and cognitive function using CTET in lean and obese male adolescents. These two study groups will be randomized to one of two orders:: (A,B) or (B,A) where A = Yes breakfast and B=No breakfast
2935086|NCT03005951|Experimental|Obese males|This is a randomized, two-period, cross over design with the intervention of consuming breakfast versus fasting for breakfast to study the effects on hormone responses and cognitive function using CTET in lean and obese male adolescents. These two study groups will be randomized to one of two orders:: (A,B) or (B,A) where A = Yes breakfast and B=No breakfast
2935087|NCT03005938|Experimental|Spinal manipulation|Spinal manipulation
2935088|NCT03005938|Sham Comparator|Imitation of the spinal manipulation|Imitation of the spinal manipulation
2935089|NCT03005925|Experimental|connected group|remote monitoring by smartphone in the care management of patients with rheumatoid arthritis
2935090|NCT03005925|Active Comparator|control group|standard outpatient follow-up by physical consultation
2935091|NCT03005912|Placebo Comparator|Conventional acoustic telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a conventional mobile phone call with acoustic transmission of the speech signal.
2935092|NCT03005912|Active Comparator|Conventional bluetooth telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a conventional mobile phone call with direct bluetooth transmission of the speech signal to the cochlear implant or hearing aid.
2935119|NCT03005743|Other|Conventional BT|Conventional Radiograph based Brachytherapy
2935093|NCT03005912|Active Comparator|VoIP acoustic telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a VoIP mobile phone call with acoustic transmission of the speech signal.
2935094|NCT03005912|Active Comparator|VoIP bluetooth telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a VoIP mobile phone call with direct bluetooth transmission of the speech signal to the cochlear implant or hearing aid.
2935095|NCT03005899|Experimental|SyB P-1501 group|One patch of SyB P-1501 contains 10.8 mg of fentanyl hydrochloride (fentanyl 9.7 mg) and produces an electric current to deliver the drug iontophoretically after the system is activated. 40 µg fentanyl per on-demand dose, each delivered over 10 minutes for a maximum of 6 doses/hr for 24 hours or maximum of 80 doses. Each system will inactivate at 80 doses or 24 hours, whichever occurs first.
2935096|NCT03005899|Placebo Comparator|SyB P-1501 placebo group|Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
2935097|NCT03005886|Experimental|AMI+CP:|"GCF sampling,periodontal examination,phase I therapy:~Patients, who met the AMI diagnostic criteria with chronic periodontitis. Baseline periodontal examination of AMI patients and 24-48h GCF sampling was carried out in their hospital bed under sufficient illumination using artificial light. Phase I periodontal therapy including comprehensive proper plaque control program, scaling, subgingival curettage and root planning in Department of Periodontology. Mucoperiosteal flap operation was performed in cases where needed."
2935098|NCT03005886|Active Comparator|Chronic Periodontitis (CP)|"GCF sampling,periodontal examination,phase I therapy:~Systemically healthy chronic periodontitis patients.Phase I periodontal therapy including comprehensive proper plaque control program, scaling, subgingival curettage and root planning in Department of Periodontology.Mucoperiosteal flap operation was performed in cases where needed."
2935099|NCT03005886|Sham Comparator|Healthy controls|clinically healthy individuals not having any periodontal and systemic diseases history.Comprehensive medical and periodontal examination to confirm that they did not have systemic and periodontal diseases
2935100|NCT03005873|Experimental|TLC599 LD group|12 mg DSP with 100 µmol PL (1.0 mL)
2935101|NCT03005873|Experimental|TLC599 HD group|18 mg DSP with 150 µmol PL (1.5 mL)
2935102|NCT03005873|Placebo Comparator|Placebo group|1.5 mL normal saline
2935103|NCT03005860|Active Comparator|Fluoromethyl hexafluoroisopropyl ether|In Sevoflurane group, anaesthesia will be induced with Thiopental 5 - 7mg/kg, fentanyl citrate 2mcg/kg and atracurium besylate 0.5mg /kg to facilitate LMA placement. Anaesthesia will be maintained with sevoflurane 2-2.2 % to maintain a target MAC value between 0.8 & 1.0.
2935104|NCT03005860|Experimental|2,6 diisopropylphenol|In Propofol group, anesthesia will be will be induced with Propofol TCI [target controlled infusion pump - Injectomat® TIVA Agilia (Fresenius Kabi)] using Schneider model to achieve target site concentration of 4-6mcg/ml, fentanyl citrate 2mcg/kg and atracurium besylate 0.5mg /kg to facilitate LMA placement. Anaesthesia will be maintained with TCI propofol at 3 - 6 mcg/ml as effect site concentration to maintain BIS 40-60.
2935105|NCT03005847|Experimental|FPP arm|active treatment with fermented papaya preparation
2935106|NCT03005834||Atherosclerotic CVD|Atherosclerotic cardiovascular diseases (CVD) included coronary artery diseases, aortic diseases and peripheral artery diseases.
2935107|NCT03005834||Non-atherosclerotic CVD|Non-atherosclerotic cardiovascular diseases (CVD) were any CVD except atherosclerotic CVD and congenital CVD.
2935108|NCT03005821|Experimental|pediatric massage|Patients will receive Montmorillonite Powder and racecadotril granules as usual care according to different age or weight. Intravenous infusion, Oral Rehydration Salts (ORS), Zn,and antibiotics will be used if the pediatrician in charge considers necessary. Patients will receive Chinese pediatric massage once per day and for three days continuously. A cloak which can cover the child's hands and upper body will be required to put on, all the manipulations will be done under the cloak. Six acupoints will be adopted,i.e. Neibagua, Dachang,Xiaochang, Banmen, Fu, Tuishang Qijiegu. Each visit, children who are under 2 years old will receive manipulations on Neibagua for 500 times, 300 times for the other 5 acupoints each; if they are from 2-3 years old, the manipulations on Neibagua will be 700 times and 500 times for the other 5 acupoints respectively; while the manipulations on Neibagua will be 1000 times, and 800 times for the other 5 acupoints if the children are from 4-6 years old.
2935109|NCT03005821|Sham Comparator|sham massage|Patients will receive the same usual care as the experimental group. For the sham massage, the therapist will use one hand to hold the childrens' hand or just put one hand on childrens' body and the other hand will do the manipulations on the therapist's own hand instead childrens' hand or childrens' body. Patients will be required to put on the same kind of cloak as that for the the experimental group, all the manipulations will be done under the cloak. The manipulation times for each acupoints will be the same as those for experimental group in accordance with different age. The sham massage will be given once per day for 3 days continuously.
2935110|NCT03005808|No Intervention|control group|All patients had the same protocol of anesthesia and analgesia. The control group didn´t received block.
2935111|NCT03005808|Experimental|TAP 0.25 group|The TAP 0.25 group received TAP block with ropivacaine 0.25% 0.4ml/kg. All patients had the same protocol of anesthesia and analgesia.
2935112|NCT03005808|Experimental|TAP 0.5 group|The TAP 0.5 group received TAP block with ropivacaine 0.5% 0.4ml/kg. All patients had the same protocol of anesthesia and analgesia.
2935113|NCT03005795|Experimental|Music and colposcopy|Women will hear Mozarts symphony Nr. 40 during the colposcopic examination
2935114|NCT03005795|Active Comparator|Colposcopy without music|During the colposcopic examination women will not hear music
2935115|NCT03005782|Experimental|Monotherapy (REGN3767)|Group A will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition 1 tumor-specific cohort will be treated at the recommended phase 2 dose (RP2D) during dose expansion.
2935116|NCT03005782|Experimental|Combination Therapy (REGN3767+REGN2810)|Group B will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition, 9 tumor-specific cohorts will be treated at the RP2D during dose expansion
2935117|NCT03005756|Experimental|Robot-assisted Radiofrequency Ablation|CT-guided radiofrequency ablation of hepatocellular carcinoma using needle guiding robot
2935198|NCT03005288|Placebo Comparator|placebo|monthly intravenous infusion
2935120|NCT03005730|Experimental|Group 1|Submitted to a session of phototherapy with 39,27 Joules per point in muscle masseter and temporal bilateral.
2935121|NCT03005730|Placebo Comparator|Group 2|Submitted to a session of phototherapy placebo with 0,0 Joules per point in muscle masseter and temporal bilateral.
2935122|NCT03005717|Experimental|Active High|Drug: LIPO 202 (Salmeterol Xinafoate for Injection), 0.2 mcg SX/mL Total Weekly Dose: up to 3.0 mcg SX
2935123|NCT03005717|Experimental|Active Low|Drug: LIPO 202 (Salmeterol Xinafoate for Injection), 0.02 mcg SX/mL Total Weekly Dose: up to 0.3 mcg SX
2935124|NCT03005717|Placebo Comparator|Placebo|Placebo for LIPO 202 (Salmeterol Xinafoate for Injection)
2935125|NCT03005704|Experimental|Antiplatelet Treatment|Subjects will be treated with five days of ticagrelor in combination with acetylsalicylic acid.
2935126|NCT03005704|No Intervention|Control|Subjects will not receive antiplatelet treatment and their PRP will be used as the source of untreated platelets in laboratory mixing studies.
2935127|NCT03005691||Whiplash-Pain|Subjects with chronic whiplash syndrome and pain. The inclusion criteria for pain include the presence of daily pain during the previous 8 weeks. Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale. The minimum will be 2 points. Subjects will be recruited between the 4 months until 2 years after the whiplash.
2935128|NCT03005691||Whiplash-no Pain|Subjects with chronic whiplash syndrome and pain. The inclusion criteria for pain include the ausence of daily pain during the previous 8 weeks. Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale. The maximun will be 2 points. Subjects will be recruited between the 4 months until 2 years after the whiplash.
2935129|NCT03005691||Non-injured|Subjects without whiplash syndrome. The inclusion criteria are defined as a absence of previous or actual symptoms or signs of neck pain.
2935130|NCT03005678|Active Comparator|Denosumab|denosumab subcutaneous 60mg every 6 months
2935131|NCT03005678|Placebo Comparator|Alendronate|alendronate 70mg orally every week
2935132|NCT03005665|Experimental|Group A - Acetazolamide|Acetazolamide 5 mg/kg diluted in 10 ml normal saline through orogastric Ryle's Tube soon after the induction of anaesthesia followed by 10 ml normal saline flush.
2935133|NCT03005665|Placebo Comparator|Group s - Normal saline|20 ml normal saline total volume.
2935134|NCT03005652|Experimental|Mindfulness intervention|
2935135|NCT03005652|Active Comparator|Health education intervention|
2935136|NCT03005639|Experimental|Vemurafenib/Cobimetinib|Vemurafenib and cobimetinib as a combination has been approved by the United States Food and Drug Administration (FDA) for patients with more advanced melanoma. In this trial, vemurafenib and cobimetinib combination is considered to be experimental since safety of this combination prior to lymph node surgery has not been studied.
2935137|NCT03005626|Experimental|Therapeutic education|Structured therapeutic education programs
2935138|NCT03005626|Active Comparator|Control group|standard outpatient follow-up
2935139|NCT03005613|Active Comparator|sacrospinous ligament fixation group|The patients will receive sacrospinous ligament fixation operation.
2935140|NCT03005613|Experimental|ischial spine fascia fixation group|The patients will receive ischial spine fascia fixation operation.
2935141|NCT03005600||Asian Indian|"Recruitment to the Indian cohort will be carried out in urban areas of Chennai and be coordinated from Madras Diabetes Research Foundation (MDRF).~As a part of their routine care, all pregnant women will undergo regular blood tests at presentation, a dating scan if the last menstrual period is unknown and an ultrasound at 20 weeks of pregnancy for foetal anomalies.~3400 pregnant women in early pregnancy will be studied in this cohort."
2935142|NCT03005600||African|"Recruitment to the Kenyan cohort will be based and coordinated from Moi Teaching and Referral hospital (MTRH). The bulk of the recruitment will happen at MTRH with significant contribution from Usain Gisu District hospital (UGDH) and Medi-Heal.~4000 pregnant women in early pregnancy will be studied in this cohort."
2935143|NCT03005587||Cirrhotics with no previous decompensation|
2935144|NCT03005587||Cirrhotics with previous one or more than one decompensation|
2935145|NCT03005574|Experimental|TSW-HP|TSW-HP Intervention implemented by a cognitive specialist over a 6-month treatment period which includes 24 hours (1 hour per week) of facilitated cognitive exercise sessions, which will be supplemented by approximately 24 hours of home practice sessions on a tablet computer.
2935146|NCT03005574|Active Comparator|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program, which includes a one hour cognitive exercise practice session per week at Brooklyn Community Services (BCS) for 6 months. This group will not receive home based cognitive practice exercises.
2935147|NCT03005561|Experimental|Intervention|100 participants that will be participating in the Play Back meetings.
2935148|NCT03005561|No Intervention|Control|100 participants that will not be participating in the Play Back meetings.
2935149|NCT03005548|Experimental|Active tDCS|Experimental: Transcranial direct current stimulation (tDCS). Patients assigned to the active treatment group (n=31) will receive IV morphine followed by IV morphine PCA (IV morphine bolus 1 mg, lockout time 10 mins.), preceded by tDCS (20 minutes of 2 milliamperes (mA) anodal tDCS over the ipsilateral cortex for 5days/week).
2935150|NCT03005548|Sham Comparator|Sham tDCS|Sham Control Group: Patients assigned to the control group (n=31) will receive IV morphine followed by IV morphine PCA (IV morphine bolus 1 mg, lockout time 10 mins.), preceded by sham tDCS stimulation (30 sec over the ipsilateral cortex, 5 days/week).
2935151|NCT03005535|Active Comparator|Vitaminized corn oil|Vitaminized corn oil (plus B6 and E vitamins), 30 g per day, per 8 weeks, with meals (15 g per meal)
2935152|NCT03005535|Placebo Comparator|Olive oil|Olive oil (not extra-virgin), 30 g per day, per 8 weeks, with meals (15 g per meal)
2935153|NCT03005522|Placebo Comparator|placebo|dosed with placebo
2935154|NCT03005522|Active Comparator|intervention|10mg oral dexamethasone
2935155|NCT03005509|No Intervention|Pre-intervention group|"All injured patients to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority triage category will be eligible for inclusion.~The Trauma Quality Improvement Meeting (TQIM) checklist will not be introduced during this phase."
2935156|NCT03005509|Other|Post-intervention group|"All injured patients to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority triage category will be eligible for inclusion.~The Trauma Quality Improvement Meeting (TQIM) checklist will be used at all Trauma Quality Improvement Meetings (TQIMs)"
2935157|NCT03005496|Placebo Comparator|Intervention|"Nifedipin 4x10 mg oral~Dexamethasone 2x6 mg iv for 2 days~Zinc 50 mg/day~Beta-carotene 25,000 IU~Vitamin D3 50,000 IU/weekly"
2935158|NCT03005496|Active Comparator|Control|"Nifedipin 4x10 mg~Dexamethasone 2x6 mg iv for 2 days"
2935159|NCT03005483|Experimental|Gabapentin|Gabapentin 10 mg/kg in children submitted unilateral limb surgery
2935160|NCT03005483|Placebo Comparator|Placebo|Placebo in children submitted unilateral limb surgery
2935161|NCT03005470|Experimental|TELEM group|Participants in the telemonitoring home blood pressure group will receive an oscillometric monitor to measure blood pressure at home for six months. Measurements will be made for at least five days a week (including one day during the weekend). Each blood pressure measure will be sent to the center of the study coordination center through software downloaded on the participant's smartphone.
2935162|NCT03005470|Experimental|TELEMEV group|In the telemonitoring of lifestyle group, participants will receive customized standardized text messages to stimulate lifestyle changes and adherence to blood pressure lowering medication. The messages will be focused on the adoption of DASH diet, sodium restriction, increase of physical activity, weight control and adherence to drug treatment. They will be sent to the smarphones on four of the five days of the week at random times using a software developed for this study.
2935163|NCT03005470|Experimental|TELEM-TELEMEV group|Participants in the telemonitoring home blood pressure plus telemonitoring of lifestyle group (TELEM-TELEMEV) will receive both interventions as previously described.
2935164|NCT03005470|Active Comparator|Usual clinical treatment (UCT)|Participants in the control group will be under antihypertensive treatment, chosen at the discretion of the assistant physician. Participants will not receive any technological tool to stimulate blood pressure control or lifestyle modification.
2935165|NCT03005457|Experimental|Stroke|
2935166|NCT03005457|Experimental|Hemiparesis other|
2935167|NCT03005444|Experimental|Low molecular weight heparin|Nadroparin：4100IU/d subcutaneously for 2 years； Enoxaparin: 4000IU/d subcutaneously for 2 years；
2935168|NCT03005444|No Intervention|Untreated|No anticoagulants will be used.
2935169|NCT03005431|Experimental|Parent training and support|Parents will be given access to participate in an on-line support forum and a set of on-line parent training modules.
2935170|NCT03005431|No Intervention|Waitlist control group|These parents will receive regular or typical services
2935171|NCT03005418|Experimental|Limb Cohort|Patients with limb-threatening vascular trauma in an extremity will be implanted with a Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.
2935172|NCT03005418|Experimental|Torso Cohort|Patients with life-threatening vascular trauma in the torso will be implanted with a Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.
2935173|NCT03005405|Active Comparator|restoration - control|Restoration
2935174|NCT03005405|Experimental|sealant - test|Sealant
2935175|NCT03005392|Experimental|Evaluate physical fitness|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
2935176|NCT03005392|Experimental|Evaluate Cardiological changes|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
2935177|NCT03005392|Experimental|Evaluate activity physical|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
2935178|NCT03005392|No Intervention|control grup|The control group will be recommended to maintain a level of physical activity they would routinely and habitually have during the 4 months that the study will last.
2935179|NCT03005379|Active Comparator|1|Fecal Microbiota Therapy (FMT)
2935180|NCT03005379|Placebo Comparator|2|Placebo
2935181|NCT03005366|Active Comparator|Flecainide|Conventional cardioversion group using intravenous flecainide.
2935182|NCT03005366|Active Comparator|Vernakalant|Atria-preferential and atrial-specific blockade group using intravenous vernakalant.
2935183|NCT03005353|Experimental|Cumin seed extract|Group A (study group) will receive Cumin seed extract vaginal cream once daily for 7 days.
2935184|NCT03005353|Active Comparator|clotrimazole|Group B will receive conventional clotrimazole vaginal cream once daily for 7 days.
2935185|NCT03005340|Active Comparator|Group A|Period 1: Bazedoxifene 20 mg Period 2: Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg
2935186|NCT03005340|Active Comparator|Group B|Period 1: Bazedoxifene 20 mg Period 2: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 3: Cholecalciferol granule 10 mg
2935187|NCT03005340|Active Comparator|Group C|Period 1: Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg Period 3: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg
2935188|NCT03005340|Active Comparator|Group D|Period 1: Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg
2935189|NCT03005340|Active Comparator|Group E|Period 1: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 2: Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg
2935190|NCT03005340|Active Comparator|Group F|Period 1: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg Period 3: Cholecalciferol granule 10 mg
2935191|NCT03005327|Experimental|X4P-001|CXCR4 antagonist
2935192|NCT03005327|Placebo Comparator|Placebo|Matched placebo capsules
2935193|NCT03005314|Other|Surgery|Postoperative chemotherapy group
2935194|NCT03005314|Other|Chemotherapy|Preoperative chemotherapy group
2935195|NCT03005301|Experimental|Experimental group|Selected acupoints will be stimulated by the new intelligent electro-acupuncture instrument.
2935196|NCT03005301|Active Comparator|Control group|Selected acupoints will be stimulated by the Hwato electroacupuncture instrument.
2935197|NCT03005288|Experimental|bimagrumab|monthly intravenous infusion
2935199|NCT03005275|Other|IVM|"FSH injection: Day 9, 10 and 11 (can be adjusted 1-3 days before or after to avoid Ultrasound and OPU on holidays). Dose: normally 100 IU/day (maybe 75 - 150 IU/day).~Follicle and endometrium can be evaluated: on the day of final injection or one day later.~hCG 10.000 IU: one day after the final FSH injection, at 9 p.m. Can be adjusted HCG injection day (± 1-2 days) to avoid Ultrasound and OPU on vacation.~OPU: 1,5 day after hCG injection (normally 36-42 hours later).~Sperm collection: on OPU day (if mature follicle presents) or 1 day after OPU day.~Embryo transfer: 3 days after OPU.~Luteal support: progesterone gel (90 mg once daily) intra-vaginally and estradiol (4 mg/day PO, twice daily) initiated on the day of OPU or the day thereafter."
2935200|NCT03005275|Other|ICSI|"Daily SC injections with rFSH (minimum starting dose is around 150 IUI) are started on On day 2 or day 3 of the menstrual cycle (Stimulation Day 1) and continue up to and including Stimulation Day 7.~From Stimulation Day 8 onwards, subjects from ICSI treatment groups will continue with a daily SC dose of rFSH up to the day before GnRH agonist day. The maximum rFSH dose to continue treatment after the first 7 days is 300 IU but the dose could be adjusted when desired.~As soon as three follicles of 17mm are observed by USS at least, a GnRH agonist (Triptorelin 0.2 mg) will be used for final oocyte maturation at the same day. About 34-36 h thereafter, OPU followed by ICSI is performed. Two days after oocyte pick-up 2 fresh embryos will be transferred."
2935201|NCT03005249|Experimental|neural stem cells therapy group|The patients will be assigned to neural stem cells therapy group for cerebral palsy.
2935202|NCT03005249|Experimental|the control group|The patients will be assigned to the control group for cerebral palsy.
2935203|NCT03005236|Experimental|Envarsus|Basiliximab induction with maintenance therapy of Envarsus, mycophenolate mofetil and corticosteroids. Envarsus constitutes the experimental component of immunosuppression in older kidney transplant recipients.
2935204|NCT03005236|Active Comparator|Standard twice daily tacrolimus|Basiliximab induction with maintenance therapy of standard tacrolimus, mycophenolate mofetil and corticosteroids. Standard tacrolimus constitutes the control component of immunosuppression in older kidney transplant recipients.
2935205|NCT03005223|Experimental|Study effect of DWC20163 on DWC20155/DWC20156 PK|To study effect of DWC20163 on DWC20155/DWC20156 PK
2935206|NCT03005223|Experimental|Study effect of DWC20155/DWC20156 on DWC20163 PK|To study effect of DWC20155/DWC20156 on DWC20163 PK
2935207|NCT03005210|Experimental|T test|Test drug (Magicbuvir Plus)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
2935208|NCT03005210|Active Comparator|B reference (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
2935209|NCT03005210|Active Comparator|B reference (second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
2935210|NCT03005184|Experimental|S/V+Pla, S/V+I, Enal+Pla, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2935211|NCT03005184|Experimental|S/V+Pla, Enal+I, S/V+I, Enal+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2935212|NCT03005184|Experimental|S/V+Pla, Enal+Pla, Enal+I, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2935213|NCT03005184|Experimental|S/V+I, S/V+Pla, Enal+I, Enal+P|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2935214|NCT03005184|Experimental|S/V+I, Enal+Pla, S/V+Pla, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2935215|NCT03005184|Experimental|S/V+I, Enal+I, Enal+Pla, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2935216|NCT03005184|Experimental|Enal+Pla, S/V+Pla, S/V+I, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2935217|NCT03005184|Experimental|Enal+Pla, S/V+I, Enal+I, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2935218|NCT03005184|Experimental|Enal+Pla, Enal+I, S/V+Pla, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2935219|NCT03005184|Experimental|Enal+I, S/V+Pla, Enal+Pla, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2935220|NCT03005184|Experimental|Enal+I, S/V+I, S/V+Pla, Enal+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2935221|NCT03005184|Experimental|Enal+I, Enal+Pla, S/V+I, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2935222|NCT03005171|Active Comparator|Epidural|"Epidural catheters will be placed in the 9th or 10th thoracic intervertebral space prior to induction of anesthesia.Through the thoracic epidural catheter 0.125% bupivacaine at a rate of 5 mL/h will be infused.~The infusion continues for 24h"
2935223|NCT03005171|Active Comparator|Lidocaine|"Intravenous lidocaine infusion will typically start in the operating room prior to induction of anesthesia at a rate of 2 to 3 mg/min. Postoperatively, the rate will be decreased to 0.5 to 1 mg/min.~The infusion continues for 24h"
2935224|NCT03005158|Other|Validation Phase|All six hospital sites currently use the ARCHITECT STAT high- sensitive troponin I assay in the assessment of patients with suspected acute coronary syndrome and use sex-specific thresholds upper reference limits (99th centile) to rule out myocardial infarction. This validation phase of up to 10 months will provide baseline information for each site on patients with suspected acute coronary syndrome in whom myocardial infarction is ruled out.
2935225|NCT03005158|Other|Randomization Phase|Participating centres will be randomized to implement the HighSTEACS pathway (intervention). The order of implementation will be randomized, with paired participating centres implementing in steps over a 6 month period.
2935226|NCT03005158|Active Comparator|Implementation Phase|A final phase of up to 10 months after implementation of the HighSTEACS pathway will be matched by calendar month in each site to that of the validation phase, allowing each participating centre to act as its own control and to adjust for seasonal differences in the incidence of myocardial infarction and mortality.
2935227|NCT03005145|Active Comparator|Short duration (7 days)|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
2935228|NCT03005145|Active Comparator|Long duration (14 days)|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
2935229|NCT03005132||Normal brain tissue|Normal brain tissue from GBM patients
2935230|NCT03005132||GBM tissues|GBM tissues from GBM patients
2935231|NCT03005132||Metastasis tissues|Metastasis tissues from GBM patients
2935232|NCT03005119|Experimental|PTL201|Up to 30 mg/day (30 mg THC, 10 mg CBD), recommended to be administered after meals and if required before bed time. Patients will be instructed not to take more than 10 mg (two capsules) at a single dosing session.
2935233|NCT03005119|Placebo Comparator|Placebo|PTL201 and placebo capsules will be identical in appearance
2935234|NCT03005106|Experimental|StrataGraft Skin Tissue|
2935235|NCT03005093||CAREGIVERS|Caregivers of pediatric patients with swallowing disorders will be recruited.
2935236|NCT03005093||CHILDREN OF CAREGIVERS|Pediatric patients with swallowing disorders will be recruited.
2935237|NCT03005067|Experimental|Carbomer 980 (1146A)|Participants will be administered test product (nasal spray) containing carbomer 980 gel. Three actuations per nostril per dose will be applied, each actuation will be 140µL (microliters) i.e. equivalent to 140mg.
2935238|NCT03005067|Placebo Comparator|Placebo|Participants will be administered reference product (nasal spray) containing vehicle without carbomer 980. Three actuations of placebo nasal spray per nostril per dose; each actuation will be 140µL.
2935239|NCT03005054|Experimental|StrataGraft skin tissue|
2935240|NCT03005041|Experimental|Test Product 1|Participants will rinse their mouth with 15 mL of the product swishing for 30 seconds.
2935241|NCT03005041|Other|Test Product 2|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds. Participants then spit out the water.
2935242|NCT03005028||Control|
2935243|NCT03005015|Experimental|Lenvatinib|Lenvatinib 24 mg orally every day. Treatment is continued until unacceptable toxicity, progressive disease or patient withdrawal
2935244|NCT03005015|Active Comparator|Doxorubicin|Doxorubicin 60 mg/m² iv bolus every 3 weeks. Treatment is continued for a maximum of 6 cycles or until unacceptable toxicity, progressive disease or patient withdrawal.
2935245|NCT03005002|Experimental|Treatment (durvalumab, tremelimumab)|Patients receive durvalumab IV over 60 minutes and tremelimumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning at week 17, patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
2935246|NCT03004989||Programme 1|RTW group in day clinics
2935247|NCT03004989||Programme 2|RTW group in day clinics for people with fibromyalgia
2935248|NCT03004989||Programme 3|My work and I
2935249|NCT03004976|Experimental|Umbilical Cord Blood|A single intravenous infusion of umbilical cord blood within 3-10 days following stroke.
2935250|NCT03004976|Placebo Comparator|Placebo|A single intravenous infusion of diluent with the same appearance and odor as a cord blood unit within 3-10 days following stroke.
2935251|NCT03004963|Active Comparator|clinical group|evaluate the volume status just according to clinical indexes in this group.
2935252|NCT03004963|Experimental|clinical and BCM group|Both body composition monitor (BCM) and clinical indexes are used to evaluate the volume status of patients in this group.
2935253|NCT03004937|Experimental|Single-Arm, Non-Randomized, Stepped Wedge|All patients who meet the inclusion criteria will receive the same intervention.
2935254|NCT03004924|Experimental|SHP640|Instill 1 drop of SHP640 (0.6 percent (%) povidone-iodine [PVP-I] and 0.1% Dexamethasone and) ophthalmic suspension in each eye 4 times daily (QID) for 7 days.
2935255|NCT03004924|Active Comparator|PVP-I 0.6%|Instill 1 drop of 0.6% PVP-I ophthalmic solution in each eye 4 times QID for 7 days
2935256|NCT03004924|Placebo Comparator|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye 4 times QID for 7 days.
2935257|NCT03004911|Experimental|Mobile application|
2935258|NCT03004911|Active Comparator|Paper booklet|
2935259|NCT03004898|Experimental|education arm|multidisciplinary education: multidisciplinary CKD education involving case management nurse, dietitian, social worker, pharmacists.
2935260|NCT03004885|Experimental|Minimal Distension|Tidal volume 4 ml/kg PBW and PEEP based on the ARDSNet PEEP/FiO2 table (ARMA) + ECCO2R
2935261|NCT03004885|Experimental|Maximal Recruitment|Tidal volume 4 ml/kg PBW and PEEP adjusted to maintain plateau pressure between 23 - 25 cmH2O + ECCO2R
2935262|NCT03004885|Active Comparator|Standard|Tidal volume 6 ml/kg PBW and PEEP based on the ARDSNet PEEP/FiO2 table (ARMA) without ECCO2R
2935263|NCT03004859||Adults ≥ 65 with a positive test result|Adults ≥ 65 that are got a positive test result were asked to visit their general practitioner and are called for an interview two times, 8 weeks and 12 months after the screening in the pharmacy. The results of the data collection and screening in the pharmacies as well as of the two telephone interviews are compared to the results of the adults ≥ 65 with a negative test result.
2935264|NCT03004859||Adults ≥ 65 with a negative test result|Adults ≥ 65 that are got a negative test result are called for an interview 12 months after the screening in the pharmacy. The results of the data collection and screening in the pharmacy as well as of the telephone interview are compared to the results of the adults ≥ 65 with a positive test result.
2935265|NCT03004846|Experimental|Part A: GSK2981278 4%|Subjects will receive topical application of GSK2981278 4% ointment twice daily for 8 weeks. Based on new safety information, the concentration of GSK2981278 may be lowered to 2% or 0.8%.
2935266|NCT03004846|Experimental|Part B: GSK2981278 4% and vehicle|In Part B, subjects will receive topical application of GSK2981278 4 % ointment or vehicle ointment twice daily for 8 weeks. Based on new safety information, the concentration of GSK2981278 may be lowered to 2% or 0.8%.
2935267|NCT03004833|Experimental|Arm A|4 Cycles of Nivolumab plus AVD followed by IF-RT (30 Gy)
2935268|NCT03004833|Experimental|Arm B|4 Cycles of Nivolumab, followed by 2 cycles of Nivolumab plus AVD, followed by 2 Cycles of AVD followed by IF-RT (30 Gy)
2935269|NCT03004820|Experimental|Remote Ischemic Conditioning|RIC (remote ischemic conditioning) consists of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement.
2935270|NCT03004807|Experimental|Multivitamin|Centrum Silver Men's Formula Multivitamin/Multimineral Supplement: 1/day
2935271|NCT03004807|Placebo Comparator|Control|Matching tablet to active multivitamin arm: 1/day
2935272|NCT03004781|No Intervention|Waiting-list|8-week period without intervention, N=45
2935273|NCT03004781|Experimental|self-efficacy|8-week group-based parenting program on self-efficacy beliefs, N=19
2935274|NCT03004781|Experimental|self-efficacy/emotion coaching|8-week group-based parenting program on self-efficacy beliefs and emotion coaching practice, N=26
2935275|NCT03004768|Experimental|Single dose of radiolabeled BMS-986165|
2935276|NCT03004742|Experimental|Flavonoid|Flavonoid supplement
2935277|NCT03004742|Placebo Comparator|Placebo|Placebo
2935278|NCT03004729|Other|CoMiSS|Measure of CoMiSS followed by two weeks eviction Cow's milk protein diet and second CoMiSS measurement.
2935279|NCT03004703|Experimental|Active drug|Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
2935280|NCT03004703|Placebo Comparator|Placebo|Sodium chloride 0.9%; 100 ml i.v. once.
2935281|NCT03004690|Experimental|Performance temperature 22°C|Participants wearing PPE suit A or PPE suit B perform tests I -IV at 22°C.
2935282|NCT03004690|Experimental|Performance temperature 28°C|Participants wearing PPE suit A or PPE suit B perform tests I -IV at 28°C.
2935283|NCT03004677|Experimental|Continuous skin-to-skin contact|Infants assigned to SSC will rest skin-to-skin on parents' chest 24 hours a day for four days alternating between the parents.
2935284|NCT03004677|Active Comparator|Standard Care|Infants and parents will receive standard care provided in the NICU
2935285|NCT03004664||Support Empowerment Model|"The Center for Diabetes Education at the University of New Mexico Hospital (CDE) uses the Diabetes Self-Management Support Empowerment Model (DSMS). The DSMS combines a series of clinically informed group didactic sessions that use a patient self-determination approach to empower patients to take control of their own diabetes health with follow-up supports to sustain self-management gains achieved during the sessions. Patients attend a six-week group instructional session with 9 hours of class plus an individual follow-up with a certified diabetes educator. The group sessions have discussion supported by didactic conversation maps where the facilitator guides but does not control the conversation based on session thematic goals."
2935286|NCT03004664||The Chronic Care Model|One Hope Centro de Vida Diabetes Program is based on the Chronic Care Model (CCM). The CCM involves 6 synergistic domains: 1.) Improved access to care, 2.) Patient self-management support, 3.) Patient decision support, 4.) Care coordination, 5.) Integrated health information systems, and 6.) Access to community resources. To create a holistic care regime, the CCM focuses on addressing social determinants of health by meeting the medical, cultural, and linguistic needs of patients through integration of cultural norms and social relationships from the patient population into program design.
2935287|NCT03004651||Obese Patients|Power Doppler ultrasound on obese patients with PR comparating with a clinical evaluation (swollen joint count (SJC) as componant of SDAI)
2935288|NCT03004651||Non obese patients|Power Doppler ultrasound on non obese patients with PR comparating with a clinical evaluation (swollen joint count (SJC) as componant of SDAI)
2935289|NCT03004638|Experimental|MEDI6012 Cohort 1|MEDI6012 cohort 1 dose level
2935290|NCT03004638|Placebo Comparator|Placebo|Placebo
2935291|NCT03004638|Experimental|MEDI6012 Cohort 2|MEDI6012 cohort 2 dose level
2935292|NCT03004638|Experimental|MEDI6012 Cohort 3|MEDI6012 cohort 3 dose level
2935293|NCT03004638|Experimental|MEDI6012 Cohort 4|MEDI6012 cohort 4 dose level
2935294|NCT03004625|Experimental|Study Arm|HCV-1b patients without baseline NS5A resistance-associated variants receiving Daclatasvir (60mg/day) and asunaprevir (100 mg twice daily) plus weight-based ribavirin (1000-1200 mg/d) for 12 weeks. (daclatasvir, asunaprevir plus ribavirin)
2935340|NCT03004339|Experimental|SOR007 Ointment 2.0%|Topical application once daily during a 12-day treatment period (10 treatments)
2935341|NCT03004339|Experimental|SOR007 Ointment 1.0%|Topical application once daily during a 12-day treatment period (10 treatments)
2936496|NCT02996357||Cases|Patients with IAD Category 2 (red skin with skin breakdown)
2935295|NCT03004612|Experimental|Linagliptin + Metformin plus lifestyle|Patients are randomized to receive for 12 months Linagliptin 2.5mg + metformin 850mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150mg/week.
2935296|NCT03004612|Active Comparator|Metformin plus lifestyle|Patients are randomized to receive for 12 months Metformin 850mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150mg/week.
2935297|NCT03004599|Other|Transcatheter Aortic Valve Implantation (TAVI)|
2935298|NCT03004586|Experimental|EBUS-TBNA:First Using a 25-Gauge Needle Then 22-gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by first using a 25-gauge needle, followed by a 22-gauge needle.
2935299|NCT03004586|Experimental|EBUS-TBNA:First Using a 22-Gauge Needle Then 25-gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by first using a 22-gauge needle, followed by a 25-gauge needle.
2935300|NCT03004573|Experimental|Deep brain stimulation|
2935301|NCT03004560|Active Comparator|Standard Laparoscopic Approach|Minimally invasive laparoscopic procedure with 5-10 mm incisions.
2935302|NCT03004560|Active Comparator|Percutaneous Approach|Minimally invasive laparoscopic procedure with 2-3 mm incisions.
2935303|NCT03004547||Chronic Hemodialysis patients|Patients on standard in-centre 3 times a week hemodialysis
2935304|NCT03004547||Peritoneal Dialysis patients|Patients on peritoneal dialysis
2935305|NCT03004547||CKD patients|Patients with chronic kidney disease stage 4 or 5 (not dialysis dependent)
2935306|NCT03004547||Healthy Controls|Subjects without kidney disease
2935307|NCT03004534|Experimental|Presurgical Molecular Assessment|Oral 300 mg ODM-201 tablet; dose of 600 mg (2 x 300 mg tablets) b.i.d.
2935308|NCT03004521|Active Comparator|Lithium|Lithium will be prescribed to patients in this arm as an augmenter on top of a patient's existing antidepressant treatment.
2935309|NCT03004521|Experimental|Quetiapine|Quetiapine will be prescribed to patients in this arm as an augmenter on top of a patient's existing antidepressant treatment.
2935310|NCT03004508|Experimental|Gingko biloba Extract|
2935311|NCT03004508|Placebo Comparator|Placebo|
2935312|NCT03004495|Experimental|CHF5259 and CHF6001|(T): CHF6001 + CHF5259 b.i.d. for 14 days
2935313|NCT03004495|Active Comparator|CHF5259 + placebo|(R1): CHF5259 25µg b.i.d. for 14 days
2935314|NCT03004495|Active Comparator|CHF6001 + placebo|(R2): CHF6001 b.i.d. for 14 days
2935315|NCT03004469|Experimental|P-3074|finasteride 0.25% topical solution
2935316|NCT03004469|Placebo Comparator|vehicle of P-3074|vehicle topical solution
2935317|NCT03004469|Active Comparator|finasteride 1 mg|oral finasteride
2935318|NCT03004456|Experimental|Distraction|"Patients randomized to the Distraction group will be permitted to choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw."
2935319|NCT03004456|No Intervention|Standard of care|"Patients randomized to the Standard of Care group will not be provided with an iPad."
2935320|NCT03004443|Experimental|Infliximab|Participants will be randomized to receive one intravenous (IV) infusion of infliximab.
2935321|NCT03004443|Placebo Comparator|Placebo|Participants will be randomized to receive one intravenous (IV) infusion of placebo.
2935322|NCT03004430|Experimental|MAM|Mantra Meditation Group
2935323|NCT03004430|Active Comparator|PMR|Progressive Muscle Relaxation Group
2935324|NCT03004417|Experimental|CHF 6001 Dose1|CHF6001 via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
2935325|NCT03004417|Experimental|CHF 6001 Dose 2|CHF6001 via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
2935326|NCT03004417|Placebo Comparator|Placebo|Matching placebo via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
2935327|NCT03004404|Experimental|BI 730357|
2935328|NCT03004404|Placebo Comparator|Placebo|
2935329|NCT03004378|No Intervention|Control|Subjects will receive the clinic standard of care which includes individual assessment and management by: a pediatric gastroenterologist, a pediatric surgeon, a nutritionist, and a fitness instructor who are present at every visit.
2935330|NCT03004378|Other|Intervention|Receive Fitbit (activity tracking device) + subjects will receive the clinic standard of care which includes individual assessment and management by: a pediatric gastroenterologist, a pediatric surgeon, a nutritionist, and a fitness instructor who are present at every visit.
2935331|NCT03004365|Experimental|Study Arm 1|Subjects in Study Arm 1 will receive up to 1 mL of 27.2 mg C16G2 Varnish or Placebo on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
2935332|NCT03004365|Experimental|Study Arm 2|Subjects in Study Arm 2 will receive up to 1 mL of 13.6 mg C16G2 Varnish or Placebo on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
2935333|NCT03004365|Experimental|Study Arm 3|Subjects in Study Arm 3 will receive up to 1 mL of 54.4 mg C16G2 Varnish or Placebo on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
2935334|NCT03004352|Experimental|control subjects-retrograde flow|Retrograde flow was induced in control subjects.
2935335|NCT03004352|No Intervention|control subjects-control|
2935336|NCT03004352|Experimental|hypoxemic COPD-retrograde flow|Retrograde flow was induced in hypoxemic COPD patients.
2935337|NCT03004352|No Intervention|hypoxemic COPD-control|
2935338|NCT03004352|Experimental|normoxemic COPD-retrograde flow with oxygen|Retrograde flow was induced in COPD patients with normalized arterial oxygen saturation.
2935339|NCT03004352|Experimental|normoxemic COPD-control with oxygen|COPD patients with normalized arterial oxygen saturation.
2936497|NCT02996357||Controls|Patients with IAD Cat. 0 (at risk, no redness and skin intact)
2935342|NCT03004339|Experimental|SOR007 Ointment 0.3%|Topical application once daily during a 12-day treatment period (10 treatments)
2935343|NCT03004339|Experimental|SOR007 Ointment 0.15%|Topical application once daily during a 12-day treatment period (10 treatments)
2935344|NCT03004339|Placebo Comparator|SOR007 Ointment Placebo|Topical application once daily during a 12-day treatment period (10 treatments)
2935345|NCT03004339|Active Comparator|Taclonex® Ointment|Topical application once daily during a 12-day treatment period (10 treatments)
2935346|NCT03004313|Experimental|Migraine|"20 subjects experiencing 1-14 migraines per month will undergo the following:~Blood and urine samples will be collected~Complete a series of questionnaires; some of which will be completed daily~Quantitative Sensory Test (QST)will be performed~Magnetic Resonance Imaging (MRI)~PET imaging (during and outside of a migraine attack)"
2935347|NCT03004313|Active Comparator|Healthy|"20 healthy subjects will undergo the following:~Blood and urine samples will be collected~Complete a series of questionnaires; some of which will be completed daily~Quantitative Sensory Test (QST)will be performed~Magnetic Resonance Imaging (MRI)~PET imaging"
2935348|NCT03004300|Active Comparator|group 1|Patients with atresic maxilla without upper airway obstruction submitted to rapid maxillary expansion
2935349|NCT03004300|Experimental|group 2|Patients with atresic maxilla and adenotonsillar hypertrophy submitted to rapid maxillary expansion before adenotonsillectomy
2935350|NCT03004300|Experimental|group 3|Patients with atresic maxilla and adenotonsillar hypertrophy submitted to rapid maxillary expansion after adenotonsillectomy
2935351|NCT03004287|Experimental|Study Treatment|"Induction Chemotherapy: Carfilzomib, Thalidomide, Dexamethasone, Daratumumab , CisPlatin, Adriamycin, Cyclophosphamide and Etoposide (KTD-Dara-PACE).~Autologous Stem Cell Transplant (ASCT) 1: Melphalan, Dexamethasone, ASCT.~Immunological Consolidation 1: Daratumumab.~Consolidation 1: Daratumumab, Carfilzomib, Dexamethasone (Dara-KD).~ASCT 2 (optional): Melphalan, Dexamethasone, ASCT.~Immunological Consolidation 2: Daratumumab.~Maintenance: Dara-KD alternating with Daratumumab, lenalidomide, and Dexamethasone (Dara-RD) in 3-month blocks.~Bortezomib may be substituted for carfilzomib throughout the regimen at the discretion of the treating physician."
2935352|NCT03004274|Active Comparator|Running sutures|Deep layers will be closed using running sutures
2935353|NCT03004274|Experimental|Interrupted sutures|Deep layers will be closed using interrupted sutures
2935354|NCT03004261|Experimental|CMV-CTL|The donor derived CMV-CTL cells will be transfused to the patients. The patients will receive CMV-CTL cells when they are sero-positive for CMV-DNA 30 days after transplant. The CMV-DNA levels will be monitored weekly for at least 60 days after the transplant. If after the initial dose of CMV-CTL cells the patient develops a viral infection, then they may be eligible to receive one additional injection of CMV-CTLs. If the CMV levels in the blood continue to rise after the dose of T cells then the patient will receive treatment with Ganciclovir, Foscarnet.
2935355|NCT03004248|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
2935356|NCT03004222|Experimental|Local anesthetic (Bupivicaine)|The experimental arm intervention is 75 subjects will receive the study agent (20 mL of 0.5% bupivacaine) to be sprayed at the cecum after the appendix has been removed and all planned irrigation and aspiration has occurred
2935357|NCT03004222|Placebo Comparator|Placebo 20 ml|75 subjects will be treated with normal saline/placebo to be sprayed at the cecum after the appendix has been removed and all planned irrigation and aspiration has occurred
2935358|NCT03004209|Other|EPO|Erythropoietin injection: three times per a week, 100 IU/kg for each patients Trade name: epokine prefilled injection
2935359|NCT03004196|Active Comparator|Control Group|They were not given probiotic toothpaste or chlorhexidine mouthwash
2935360|NCT03004196|Experimental|Probiotic Group|"Patients were asked to brush twice daily with given G.D Probiotic Toothpaste and were asked not to eat or drink anything for half-an-hour."
2935361|NCT03004196|Experimental|Chlorhexidine Mouthwash Group|"Patients were asked to rinse daily with Dr. Reddy's Clohex chlorhexidine mouthwash of 10ml without dilution for three times a day after meals (Breakfast, Lunch Dinner) for 3-4 minutes and were asked not to eat or drink anything for half-an-hour."
2935362|NCT03004183|Experimental|Single arm|"ADV/HSV-tk (5 x 1011 virus particles) in a 2-mL total volume will be injected intratumorally on Day 0.~Valacyclovir will be orally administered at a dose of 2 g three times daily for 14 days from Day 1 to Day 15.~SBRT of 30 Gy (6 Gy X 5 fractions) will be administered over 2 weeks from Day 2 to Day 16.~Pembrolizumab (200 mg) will be administered intravenously over 30 minutes every 3 weeks starting on Day 17 and continuing until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression."
2935363|NCT03004170|Experimental|Tele-Motivational Interviewing Plus Behavioral Skills Training|The Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training (teleMI+BST) intervention comprises 5 sessions lasting approximately 45-50 minutes each. Sessions occur in weeks 3, 4, 8, and 12 post-enrollment, with a follow-up booster session in week 24. The Information-Motivation-Behavioral Skills (IMB) Model (Fisher & Fisher, 1992) provides the theoretical framework for behavior change mechanisms of teleMI+BST. The IMB posits that knowledge about condom use practices, condom use motivation, and acquisition and application of requisite condom use skills lead to engagement in condom-protected sex. The focus of this intervention is to help participants process ambivalence about engaging in condomless sex acts that risk HIV transmission.
2935364|NCT03004170|Active Comparator|Tele-Coping Effectiveness Training|The Telephone-Administered Coping Effectiveness Training (teleCET) intervention is the attention-equivalent comparator and also comprises 5 sessions lasting approximately 45-50 minutes each. The teleCET intervention is based on the Lazarus and Folkman Transactional Model of Stress and Coping (Lazarus & Folkman, 1984) and uses cognitive-behavioral principles to: (a) appraise stressor severity, (b) develop problem- and emotion-focused coping skills, (c) determine the match between coping strategies and stressor controllability, and (d) optimize coping through use of social support resources.
2935365|NCT03004157|Experimental|Two finger technique|Two finger technique TFT: the pediatric thorax is compressed with the tips of two fingers and is recommended for lone rescuer during infant CPR by international CPR guidelines
2935366|NCT03004157|Experimental|Two thumb technique|Two thumb technique TTHT: the two thumbs of the rescuer are placed over the lower third of the sternum, with the fingers encircling the torso and supporting the back. This technique is recommended for two rescuers during infant CPR by international CPR guidelines
2938386|NCT02982941|Experimental|Dose Escalation & Cohort Expansion|enoblituzumab administered IV weekly
2935367|NCT03004157|Experimental|new two-thumb technique|new two-thumb technique' (nTTT): this technique consists in using two thumbs directed at the angle of 90 degrees to the chest while closing the fingers of both hands in a fist
2935368|NCT03004144|Other|FLOAT-Support|
2935369|NCT03004131|Experimental|fixed drug combination|MP29-02 or MP-AzuFlu as fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (Dymista) plus Placebo tablet
2935370|NCT03004131|Placebo Comparator|Placebo|Nasal spray with no active dose plus Placebo tablet
2935371|NCT03004131|Active Comparator|active control|fluticasone propionate nasal spray (Flonase) plus loratadine 10 mg tablets (Claritin)
2935372|NCT03004118|Active Comparator|Ursochol|About 10.5mg/kg/day of ursochol (calculated before start study for each participant individually) (combination of ursochol 150 and 300) divided in 2 doses per day (during lunch and dinner). Oral intake. Tablets. 4 weeks.
2935373|NCT03004118|Placebo Comparator|Placebo|Same amount of pills as ursochol (calculated before start study for each participant individually) divided in 2 doses per day (during lunch and dinner). Oral intake. Tablets. 4 weeks.
2935374|NCT03004105|Experimental|Intermittent Arm - Selumetinib + Durvalumab|Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off, and Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
2935375|NCT03004105|Experimental|Safety Run In|"Short safety run-in prior to the start of randomization. Participants on the safety run-in treated with Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.~Safety run-in beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle.~During the safety run in portion of the trial, enrollment will be open to all comers, regardless of KRAS mutation status."
2935376|NCT03004105|Experimental|Continuous Arm - Selumetinib + Durvalumab|"Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in.~Participants receive Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle."
2935377|NCT03004092|Experimental|Total cohort|
2935378|NCT03004053||Volunteers will be identified by the Head and Neck Service|20 volunteers (Part I - 8 volunteers. Part II - 12 volunteers). during the course of 12 months. The volunteers will be imaged with the endoscope, and the images will be evaluated visually and with qualitative (descriptive) statistics.
2935379|NCT03004040||Case|older adult patients (over the age of 65) admitted to Health Sciences North with laboratory confirmed influenza illness (LCII)
2935380|NCT03004040||Control|matched control subjects (non-LCII)
2935381|NCT03004027|Experimental|Enhanced|self help leaflet enhanced with implementation intentions
2935382|NCT03004027|Active Comparator|Standard|self help leaflet standard (without implementation intentions)
2935383|NCT03004027|No Intervention|Waiting list control|Baseline measures administered only. self help intervention will be made available once the study has finished.
2935384|NCT03004014|No Intervention|Natural Sleep|OSA subjects referred for surgical treatment will evaluated endoscopically during natural sleep
2935385|NCT03004014|Other|Propofol Induced Sleep|"Sleep endoscopy during propofol induced sleep~OSA subjects referred for surgical treatment will be evaluated endoscopically during propofol induced sleep"
2935386|NCT03004001|Experimental|Alirocumab and atorvastatin|Alirocumab 150 mg bi-weekly and atorvastatin 20 mg/d
2935387|NCT03004001|Placebo Comparator|Alirocumab placebo and atorvastatin|Alirocumab placebo biweekly and atorvastatin 20 mg/d
2935388|NCT03003988|Experimental|Creatine monohydrate|Creatine monohydrate (6.0 g.) + dextrose (0.5 g.)
2935389|NCT03003988|Active Comparator|Creatine nitrate|Creatine nitrate (5.0 g. creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio).
2935390|NCT03003988|Placebo Comparator|Placebo|6.5 g. dextrose
2935391|NCT03003975|Active Comparator|PVI by single cryoballoon application|"A single cryoballoon application for pulmonary vein isolation will be guided by a Multipolar Recording Catheter (Achieve Mapping Catheter), passed through the inner lumen of the cryoablation catheter. A single application of 4 minutes will be used per vein guided by recording of loss of electrograms and by a defined drop of temperature within 2 minutes application. If a stable position with adequate occlusion of the vein the Achieve catheter should be located proximally for evaluation of entrance block during application, but can be advanced deeper for stability and then retracted to the ostium to evaluate vein isolation (entrance block).~If the vein then is isolated after a single application, the operator can move on to the next vein."
2935392|NCT03003975|Active Comparator|PVI by 2 cryo applications|Cryoballoon ablation with a conventional guidewire passed through the inner lumen of the catheter for stability will be used. Ablation will be performed with 2 consecutive applications for 4 minutes each in each vein guided by degree of occlusion and temperature drop at the discretion of the physician.
2935393|NCT03003962|Experimental|Arm 1: Durvalumab|Anti-PD-L1 monoclonal Antibody monotherapy
2935394|NCT03003962|Active Comparator|Arm 2: Standard of Care|Standard of Care Platinum-Based chemotherapy
2935395|NCT03003949|Placebo Comparator|Placebos|Placebo patches for 16 weeks/
2935396|NCT03003949|Active Comparator|Estradiol|Transdermal for 16 weeks
2935397|NCT03003949|Placebo Comparator|Placebo Oral Tablet|Placebo pill every day during weeks 17-18 and again at weeks 25-26
2935398|NCT03003949|Active Comparator|Progesterone|Oral progesterone (200 mg) daily during weeks 17-18 and again at weeks 25-26.
2935399|NCT03003936|Experimental|Early Dinner Timing|Test the lack of concurrence of meal timing with endogenous melatonin concentrations
2935400|NCT03003936|Experimental|Late Dinner Timing|Test the concurrence of meal timing with elevated endogenous melatonin concentrations
2935401|NCT03003923|Experimental|Taste Exposure|Children will be repeatedly offered the single vegetable which is unfamiliar to them over the 12 week period. Children will be in their natural setting at nursery and will be offered 40g of the vegetable by their usual nursery staff. The vegetable will be weighed before and after using a digital scale by the researcher.
2935402|NCT03003923|Experimental|Nutritional Education|Nursery staff will be trained by the PhunkyFoods team to deliver the nutritional education programme. Children will be taught Eat Well (learning about different food groups) and Strive for Five (learning about eating fruits and vegetables) components of the PhunkyFoods education programme by their usual nursery staff. Nurseries will be advised to deliver as much as possible of the two components over the 12 week period.
2935403|NCT03003923|Experimental|Taste Exposure and Nutritional Education|Children will be repeatedly offered a single unfamiliar vegetable over the 12 week period as well as receive the PhunkyFoods educational programme (Eat Well and Strive for Five components). Children will be in their natural setting at nursery and will be offered the vegetable and nutritional education by their usual nursery staff.
2935404|NCT03003923|No Intervention|Control|Children will be offered single unfamiliar vegetable at the beginning, end and at the follow-up. There will be no repeated taste exposure or education during the study phase or follow-up; they will be offered the nutritional education after the study has completed.
2935405|NCT03003910|Experimental|Best Possible Self|"Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.~They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero & Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously."
2935406|NCT03003910|Placebo Comparator|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts occurred in the past 24 hours.
2935407|NCT03003897||Soluble Fiber Treatment|Participants receiving soluble fiber.
2935408|NCT03003897||Placebo Treatment|Participants receiving placebo.
2935409|NCT03003884|Experimental|Remimazolam Tosilate 1|IV of Remimazolam Tosilate at 5mg for initial dose
2935410|NCT03003884|Experimental|Remimazolam Tosilate 2|IV of Remimazolam Tosilate at 7mg for initial dose
2935411|NCT03003884|Experimental|Remimazolam Tosilate 3|IV of Remimazolam Tosilate at 8mg for initial dose
2935412|NCT03003884|Experimental|Remimazolam Tosilate 4|IV of Remimazolam Tosilate at 5mg for initial dose.At the end of the endoscopy, flumazenil was injected.
2935413|NCT03003884|Active Comparator|Propofol|IV of Propofol at 1.5mg/kg for initial dose
2935414|NCT03003871|Experimental|advanced oral hygiene care programmes|participants were provided with a powered toothbrush (Oral-B® AdvancePowerTM 400 series), 0.2% chlorhexidine gluconate mouth rinse, 10 mls twice daily (CorsodylPTMP), standardized toothpaste (Colgate Maximum Cavity Protection) and oral hygiene instruction.
2935415|NCT03003871|Active Comparator|conventional oral hygiene care programme|participants were provided with a manual toothbrush (Oral-B® Pro-Health All-In-One), supply of a standardized toothpaste (Colgate Maximum Cavity Protection®) and oral hygiene instruction
2935416|NCT03003845||Interstitial Cystitis|Patients with Interstitial Cystitis will be followed with Questionnaires and blood collection at 3, 6,and 12 months
2935417|NCT03003832|Experimental|Intervention|"The intervention condition consists of a change to the electronic health record so that new opioid analgesic prescriptions automatically default to 10 pills (i.e., the quantity dispensed field is pre-populated). This value is modifiable by providers who can tailor the prescription based on clinical factors."
2935418|NCT03003832|No Intervention|Standard of care|The control condition will be the usual electronic health record interface. The default number of pills varies by medication, most medications currently have either a blank default or a default of 30 pills.
2935419|NCT03003819|Active Comparator|Control Collagen Wound Dressing|Bovine collagen sponge used to control bleeding, stabilize blood clots and protect dental wounds
2935420|NCT03003819|Active Comparator|Test Collagen Matrix|Bilayer, porcine collagen matrix for soft tissue regeneration used as a socket seal in extraction socket grafting
2935421|NCT03003806|Experimental|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
2935422|NCT03003806|Active Comparator|Control group-medical guided recommendations|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
2935423|NCT03003793||Control group|Healthy control subjects Hyperinsulinemic euglycemic clamp
2935424|NCT03003793||Atopic dermatitis/eczema group|Patients with atopic dermatitis Hyperinsulinemic euglycemic clamp
2935425|NCT03003780|Experimental|Mindful Steps|Web-based behavioral intervention
2935426|NCT03003780|No Intervention|Usual Care|
2935427|NCT03003754|Experimental|High Intensity Training (HIT) + Resistance Training (RT)|"To HIT program will be use cycle ergometers adapted for children (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) were used. Each participant performed a range of 8 to 14 cycling intervals during the intervention period. The time of each work interval cycling will be increased progressively weekly, and ranged between 40-60 s (40 s weeks 1-2; 50 s weeks 3-5; 60 s week 6), with 120 s of passive rest (over the bicycle without movement) between each interval of work.~The RT will consist in voluntary concentric/eccentric exercise during 1 minute until to get a high subjective effort perception (i.e., between 8-10 points based on the modified and subjective Borg scale of 1 to 10 points. Subjects will perform 4 exercises (biceps curl, leg-extension, shoulders press, and upper row exercise) during 6-weeks."
2935428|NCT03003754|Active Comparator|Control group|We will compare within each group (G)-1, G-2, and G-3 sub-group according to both RT and HIT intervention both pre-post changes as well as if are there some anthropometric, cardiovascular, and performance variable predicting changes in homeostasis model assessment (HOMA-IR).
2935429|NCT03003741|Experimental|Bupivacaine|Standard of care
2935430|NCT03003741|Experimental|Exparel|Extended release formula
2935431|NCT03003728|Experimental|Study Treatment|Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26; Melphalan 200 mg/m2 Ivia intravenous infusion on day -3; ASCT on day -2; ENK infusion on day 0; ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22.
2935432|NCT03003715|Experimental|Refractory Trigeminal Neurpathic Pain (TNP) Patients|All patients receive QST prior to PET scan used to obtain baseline measures, then placebo tDCS, followed by QST and Active tDCS, over the course of a 90 minute PET scan; QST is used again to take final measurements 30 minutes later.
2935505|NCT03003130|Experimental|Restylane Defyne|Single injection and optional touch up injection with Restylane Defyne in NLF
2935433|NCT03003715|Experimental|Healthy volunteers|All volunteers receive QST prior to PET scan used to obtain baseline measures, then placebo tDCS, followed by QST and Active tDCS, over the course of a 90 minute PET scan; QST is used again to take final measurements 30 minutes later.
2935434|NCT03003702|Experimental|ETH|Overnight monitoring
2935435|NCT03003702|Other|CTH|Morning monitoring
2935436|NCT03003689|Active Comparator|Scaling and Root Planing|"Hand instruments + ultrasonic scaler~PD, CAL, plaque index and gingival bleeding index will be measured at baseline, 6 weeks and 3 months. Microbial load will be measured at baseline and 3 months."
2935437|NCT03003689|Experimental|Scaling and Root Planing + Er:YAG Laser|"Er:YAG Laser, hand instruments + ultrasonic scaler~PD, CAL, plaque index and gingival bleeding index will be measured at baseline, 6 weeks and 3 months. Microbial load will be measured at baseline and 3 months."
2935438|NCT03003676|Experimental|Experimental: ONCOS-102+cyclophosphamide+pembrolizumab|Patients will receive 3 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, and 8) at 3x1011 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. They will then receive pembrolizumab i.v., 2mg/kg or 200mg flat dose, on day 22 (Week 3) and every 3 weeks thereafter until the end of treatment visit on day 169 (Week 24).
2935439|NCT03003663|Experimental|SensableCare System|Device:The interrupted time series design will alternate between the following on a monthly basis: (1) standard medical care and (2) standard medical care and the SensableCare System.
2935440|NCT03003650|Experimental|Symetis ACURATE TF™|Patient implanted with ACURATE TF™Bioprosthesis.
2935441|NCT03003637|Experimental|Nivolumab with or without Ipilimumab|First dose scheme will be 2x nivolumab 240 mg flat dose, weeks 1 and 3. When feasible and safe, the next patients will be treated with the following dose scheme: the combination of 1x ipilimumab 1 mg/kg + nivolumab 240 mg flat dose in week 1 and nivolumab mono-therapy 240 mg flat dose in week 3
2935442|NCT03003624|Experimental|Colorado microdissection needle group|In patients selected for Colorado® needle group incision was given with Colorado® needle tip ( N103 A which is 3 cm length straight, 3/32 in sleeve diameter),
2935443|NCT03003624|Experimental|Cautery group|Electrosurgery tip was used to give incisions.
2935444|NCT03003624|Active Comparator|BP Blade group|No.15 surgical blade was used to give incisions.
2935445|NCT03003611||Hypnose|the group of patient who's operated under hypnose sedation
2935446|NCT03003611||traditional anesthesia|The match is realized with a patient operated in the same period as the patient in the hypnose group and it's need a comparative type of surgery.
2935447|NCT03003598|Active Comparator|Videolaryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
2935448|NCT03003598|Active Comparator|Direct laryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
2935449|NCT03003585|Active Comparator|Fiberoptic bronchoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
2935450|NCT03003585|Active Comparator|Direct laryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
2935451|NCT03003572||patients with primary Sjögren's syndrome|Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA) in patients with primary Sjögren's syndrome according to the American-European Consensus Criteria.
2935452|NCT03003559|Experimental|High flow nasal cannula|High flow nasal cannula(OptiflowTM); Flow 25-60 L/min is set according to patients' comfort; FiO2 is adjusted to maintain peripheral capillary oxygen saturation(SpO2) 90-95%; temperature is set at 37.
2935453|NCT03003559|No Intervention|Nasal cannula|Nasal cannula;set oxygen flow to keep SpO2 90-95%
2935454|NCT03003546|Experimental|Treatment (AR160)|Patients receive nab-paclitaxel/rituximab-coated nanoparticle AR160 IV over 30-60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2935455|NCT03003533|Experimental|SPK-8011|All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8011.
2935456|NCT03003520|Experimental|Arm A: Durvalumab in combination with R-CHOP|Durvalumab 1125 mg intravenously (IV) on Day 1 of each 21-day cycle in combination with 6 to 8 cycles R-CHOP (IV rituximab, doxorubicin, vincristine, and cyclophosphamide on Day 1; daily oral/IV prednisone/prednisolone from Day 1 to 5) followed by durvalumab monotherapy for up to a total of 12 months after start of study treatment.
2935457|NCT03003520|Experimental|Arm B: Durvalumab in combination with R2-CHOP|Durvalumab 1125 mg IV on Day 1 of each 21-day cycle in combination with 6 to 8 cycles R2-CHOP (IV rituximab, doxorubicin, vincristine and cyclophosphamide on Day 1; daily oral/IV prednisone/prednisolone from Day 1 to 5; daily oral lenalidomide 15 mg from Day 1 to 14) from Cycle 2 until end of induction therapy (Cycle 6 or Cycle 8), or starting Cycle 1 if ABC subtype is identified prior to Cycle 1 Day 1 (C1D1) followed by durvalumab monotherapy for up to a total of 12 months after start of study treatment.
2935458|NCT03003507|Active Comparator|Diet 1|Low-carbohydrate Enteral Formula With Fructose
2935459|NCT03003507|Active Comparator|Diet 2|Low-carbohydrate Enteral Formula Without Fructose
2935460|NCT03003494||Spiolto® Respimat®|consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC
2935461|NCT03003468|Experimental|Arm A - Phase Ib|"Dose Escalation Cohort Cohort 1 will consist of 3-6 patients who will receive pembrolizumab 200mg IV on Day 1 of each 21 day cycle. Imprime PGG will be administered at 2mg/kg on Day 1,8, and 15 of cycles 1-4, and on Day 1 of cycles 5-16. On Day 1 of each cycle, the Imprime PGG intravenous infusion is given first followed 15-30 minutes later by the pembrolizumab.~Experimental: Arm A - Phase II Investigational Treatment The maximum safe dose of Imprime PGG in combination with pembrolizumab (as determined in the phase Ib cohort) will be given on Day 1,8, and 15 for cycles 1-4, and on Day 1 of cycles 5-16.~Cohort 2 will consist of 3-6 patients who will receive pembrolizumab 200mg IV on Day 1 and Imprime PGG at 4mg/kg on Day 1,8, and 15 for Cycles 1-4 and on Day 1 only for Cycles 5-16. On Day 1 of each cycle, the Imprime PGG intravenous infusion is given first followed 15-30 minutes later by the pembrolizumab."
2935462|NCT03003455|Active Comparator|Conventional Nasotracheal Intubation (CVT)|Blind passage of an endotracheal tube via the nare followed by videolaryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
2935506|NCT03003130|Active Comparator|Restylane|Single injection and optional touch up injection with Restylane in NLF
2935463|NCT03003455|Experimental|Nasotracheal Intubation Over a Bougie (NIB)|Nasotracheal intubation over a bougie, placed with videolaryngoscopy assistance, via a nasopharyngeal airway with or without the aid of Magill forceps
2935464|NCT03003442|Experimental|Supradyn® Energy 3RDA|Supradyn® Energy 3RDA, 1 multivitamin/mineral tablet administered by mouth daily for 28 days
2935465|NCT03003442|Placebo Comparator|Placebo|Placebo, 1 tablet administered by mouth daily for 28 days
2935466|NCT03003429|Experimental|Heart rate monitor|The intervention consist in monitoring the heart rate variability during one night by using a heart rate monitor and a Polar RS800CX
2935467|NCT03003416||OZURDEX®|Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of Diabetic Macular Edema.
2935468|NCT03003403|Experimental|Intervention Program|Balance Intervention Program: Participants randomly assigned to the 12-month digital health behavioral intervention will receive: tailored behavior change goals with interactive self-monitoring and feedback; network-connected scales to track their weight; skills training materials; and stepped coaching (via phone and/or text) from Registered Dieticians serving as health coaches within a local network of community health centers.
2935469|NCT03003403|No Intervention|Usual Care Program|Balance Usual Care Program: Participants randomly assigned to the Usual Care program will receive the standard primary care offered by their providers; health information/skills training materials to maintain a healthy weight; and automated (non-tailored) text messages with health information.
2935470|NCT03003390|Experimental|Prophylaxis with enoxaparin|A clinical nurse will administer enoxaparin subcutaneously <24 hours after insertion of the central venous catheter and then give enoxaparin subcutaneously every 12 hours until the removal of the catheter.
2935471|NCT03003390|No Intervention|Control arm|Participants randomized to the control arm will receive no 'placebo' intervention.
2935472|NCT03003377|Experimental|Device: laryngeal mask supreme|Determine the Sevoflurane concentration associate with remifentanil for the insertion of the laryngeal mask supreme
2935473|NCT03003377|Active Comparator|Device: laryngeal mask proseal|Determine the Sevoflurane concentration associate with remifentanil for insertion of the laryngeal mask ProSeal
2935474|NCT03003364|Experimental|XCEL-UMC-BETA/placebo|Ex vivo cultured human mesenchymal stem cells from Wharton jelly, in a blinded syringe (initial treatment) / Placebo (month 6)
2935475|NCT03003364|Placebo Comparator|Placebo/XCEL-UMC-BETA|Placebo in a blinded syringe (initial treatment) / XCEL-UMC-BETA (month 6)
2935476|NCT03003351||Fistula|Patients with Fistulaê that are not caused by Crohn's disease
2935477|NCT03003351||Fistula and Crohn's disease|Patients with Fistulae that are caused by underlying Crohn's disease
2935478|NCT03003338|Experimental|OBV/PTV/r with DSV followed by placebo|OBV/PTV/r in combination with DSV for 12 weeks followed by 12 weeks matching placebo.
2935479|NCT03003338|Experimental|Placebo followed by OBV/PTV/r with DSV|Matching placebo for 12 weeks followed by 12 weeks OBV/PTV/r in combination with DSV.
2935480|NCT03003325|Active Comparator|Phlebotomies + ASA|Conventional treatment based on phlebotomies and low dose (100 mg) of acetylsalicylic acid (ASA)
2935481|NCT03003325|Experimental|Phlebotomies + ASA + AOP2014|Conventional treatment based on phlebotomies, low dose (100 mg) of acetylsalicylic acid (ASA) plus the addition of 100 µg of Pegylated Proline-Interferon alpha-2b (AOP2014) once every 14 days (subcutaneously).
2935482|NCT03003299|Experimental|Failing surgical valve|Patients with a failing surgical bioprosthetic valve in the aortic position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve.
2935483|NCT03003299|Experimental|Failing transcatheter valve|Patients with a failing transcatheter bioprosthetic valve in the aortic position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve.
2935484|NCT03003286|Experimental|UOT Students and Parents|Unstuck and on Target (UOT) provided in the classroom for students at Title 1 schools
2935485|NCT03003286|Experimental|PATSS Students and Parents|Parents and Teachers Supporting Students (PATSS) provided in the classroom for students at Title 1 schools
2935486|NCT03003273|Experimental|arm (A) - stoppage of antibiotics|patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. Antibiotics will be stopped in Arm-A.
2935487|NCT03003273|Active Comparator|arm (B) - oral antibiotics till ANC ≥ 500|patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. oral antibiotics, in place of intravenous antibiotics, will be started in Arm-B.
2935488|NCT03003260|Experimental|Treatment A - Treatment B|20 patients receive first 3 weeks treatment A and after a week wash-out 3 weeks treatment B
2935489|NCT03003260|Experimental|Treatment B - Treatment A|20 patients receive first 3 weeks treatment B and after a week wash-out 3 weeks treatment A
2935490|NCT03003247|Experimental|IDP-120 Gel|IDP-120 Gel is a combination treatment
2935491|NCT03003247|Active Comparator|IDP-120 Component A Gel|IDP-120 Monad Gel of Component A
2935492|NCT03003247|Active Comparator|IDP-120 Component B Gel|IDP-120 Monad Gel of Component B
2935493|NCT03003247|Placebo Comparator|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel
2935494|NCT03003234|Other|Duodenal fluid aspiration|
2935495|NCT03003221|Active Comparator|AIR-P Dental Toolkit|Families will be provided with the Autism Intervention Research Network on Physical Health (AIR-P) Dental Toolkit.
2935496|NCT03003221|Experimental|Parent Training|Families randomized to the Parent Training condition will be provided with the AIR-P Dental Toolkit and a 10-week behavioral parent-training intervention with additional booster sessions.
2935497|NCT03003208|Other|Pulmonary rehabilitation|
2935498|NCT03003195|Experimental|Vaccination: Montanide ISA 51 VG|100mL vaccination on Weeks 1, 2, 3 and 8
2935499|NCT03003182||in clinical trials|
2935500|NCT03003182||out of clinical trials|
2935501|NCT03003169||ambulatory surgery description|
2935502|NCT03003156|Experimental|25 Hz magnetic seizure therapy|10 treatment sessions of 25 Hz MST, three times per week in the first two weeks, two times per in the following two weeks.
2935503|NCT03003156|Experimental|50 Hz magnetic seizure therapy|10 treatment sessions of 50 Hz MST, three times per week in the first two weeks, two times per in the following two weeks.
2935504|NCT03003143|Experimental|Vigabatrin treatment group|
2935509|NCT03003104|Experimental|DMT210 Topical Gel|DMT210 Topical Gel 5% applied to the face twice daily for 12 weeks
2935510|NCT03003104|Placebo Comparator|Vehicle Control|Topical Gel vehicle applied to the face twice daily for 12 weeks
2935511|NCT03003091|Experimental|Needs-based patient education|The participants received self-administered questionnaire to choose what topics they wanted to know and how much information they would like to know. After completing the questionnaire, the participants submit the questionnaire to their physicians (investigators). The surgeon then provided patient education based on participant needs.
2935512|NCT03003091|Active Comparator|Traditional patient education|The participants received all structured information
2935513|NCT03003078|Other|OncoSil™ plus SOC Chemotherapy|OncoSil™ implanted with concurrent Standard of care Chemotherapy - either FOLFIRINOX or gemcitabine + Abraxane.
2935514|NCT03003065|Other|Foscan|A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
2935515|NCT03003039|Experimental|GB241|GB241:375 mg/m2, iv, one infusion
2935516|NCT03003039|Active Comparator|Rituximab|Rituximab: 375 mg/m2, iv, one infusion
2935517|NCT03003026|Experimental|Novel task-specific program|Intervention arm - see detailed intervention group description below
2935518|NCT03003026|Active Comparator|Parent-led home-based program|Comparison arm - see detailed comparison group description below
2935519|NCT03003013|Active Comparator|Biphasic Bone Graft With Autologous Platelet-rich Fibrin|Patients will undergo complete removal of the cystic cavity with the application of SYMBIOS biphasic bone graft material in combination with PRF in the cystic cavity
2935520|NCT03003013|Active Comparator|Biphasic Bone Graft Material only|Patients will undergo complete removal of the cystic cavity with the application of SYMBIOS biphasic bone graft material without PRF in the cystic cavity
2935521|NCT03003000|Experimental|ibuprofen + caffeine|Fixed Dose Combination
2935522|NCT03003000|Active Comparator|ibuprofen|
2935523|NCT03003000|Placebo Comparator|placebo|
2935524|NCT03002987|Active Comparator|Intervention, education|Education of leaders (3 hours) in how to implement Active Pregnancy policy at their departements/workplaces
2935525|NCT03002987|No Intervention|control|as usual
2935526|NCT03002974|Experimental|Anakinra 100 mg|1 subcutaneous injection of Anakinra 100 mg once daily for 5 days, 1 subcutaneous injection of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg
2935527|NCT03002974|Experimental|Anakinra 200 mg|2 subcutaneous injections of Anakinra 100 mg (2 syringes) once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg
2935528|NCT03002974|Active Comparator|Triamcinolone 40 mg|2 subcutaneous injections of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Triamcinolone Acetonide 40 mg
2935529|NCT03002961|Experimental|Cohort 1|Subjects to receive low dose of RBP-6000 subcutaneously as a single injection
2935530|NCT03002961|Experimental|Cohort 2|Subjects to receive medium dose of RBP-6000 subcutaneously as a single injection
2935531|NCT03002961|Experimental|Cohort 3|Subjects to receive high dose of RBP-6000 subcutaneously as a single injection
2935532|NCT03002961|Experimental|Cohort 4|Subjects would receive medium dose RBP-6000 as a single injection after up to 12 mg daily dosing of sublingual (SL) suboxone tablets for 7 days
2935533|NCT03002948||Low orgasm|Female Sexual Function Index orgasm score below 3.6
2935534|NCT03002935|Experimental|BPM31510 Oral Nanosuspension 4%|Study subjects will self-administer 80 mL (4 vials of 20 mL) of oral BPM31510 (Ubidecarenone, USP; 40 mg/mL) nano-suspension 3 times daily every 4 to 6 hours for a total daily dose 9600 mg/day of BPM31510 for 14 consecutive days. The last study dose (morning dose only) is administered at the clinic on Day 15.
2935535|NCT03002922|Experimental|Healthy subjects|Subject will self-apply the test sunscreen formula to his/her face with the goal of applying 0.65 to 0.85 grams. Subject should sweat profusely.
2935536|NCT03002909|Active Comparator|epidural group|an epidural catheter will be inserted under sterile conditions through the T9- 12 interspace using the 'loss-of-resistance' technique. The catheter will be advanced 4 cm cephalad. .
2935537|NCT03002909|Active Comparator|preperitoneal group|preperitoneal catheters will be placed in the subfascial (ie, pre-peritoneal) space under direct vision.
2935538|NCT03002896|Experimental|Pep-Pal + Treatment as Usual|If the caregiver is assigned to the Pep-Pal intervention condition, the RA will provide access to the mobilized website (passcode) through an email. Caregivers will be instructed to watch each session at least once. It will be recommended that caregivers watch one to two new sessions per week so that they can have enough time to practice the skills between sessions. In addition, they will be told that they can go back and watch the sessions for review as many times as they like. Full participation will be defined as watching at least 7/9 sessions (75% of program) based on previous criteria for similar intervention completion in a prior trial with advanced cancer patients.
2935539|NCT03002896|Active Comparator|Treatment as Usual|Treatment as usual provides voluntary (at the caregiver's discretion) support services for the caregivers which is rarely used by the caregivers.
2935540|NCT03002883|Placebo Comparator|Usual Care|"Students referred to student health for tobacco cessation resources including campus Quit Kits"
2935541|NCT03002883|Active Comparator|Brief Motivational Interviewing|Students received brief motivational interviewing by a student peer educator about tobacco cessation
2935542|NCT03002883|Active Comparator|Direct referral to quitline|Students were directly referred to the state quitline for follow-up counseling
2935543|NCT03002870|Other|Endometriosis|Patients whom pathology results post surgery document endometriosis
2935544|NCT03002857|Experimental|Classical LMA|Classical LMA insertion: LMA-C insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
2935545|NCT03002857|Experimental|I-gel|I-gel LMA insertion: The I-gel LMA insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
2935622|NCT03002285|Active Comparator|Control group|Group with typical development that performed the Fitts law in a computer task
2935546|NCT03002857|Experimental|The Baska Mask®|The Baska Mask® insertion: The Baska Mask® insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
2935547|NCT03002844|Experimental|EGFR-TKI and Chemotherapy|gefitinib with pemetrexed/gemcitabine and carboplatin
2935548|NCT03002844|Experimental|EGFR-TK Inhibitor|Gefitinib
2935549|NCT03002831|Experimental|CIK combined chemotherapy|Autologous Cytokine induced killer cells combined Tegafur, Gimeracil and Oteracil Potassium Capsules. After 2 to 4 days of chemotherapy, about 5×10９autologous cytokine induced killer cells are transfused into the vein of the patients in one hour.
2935550|NCT03002831|Active Comparator|Chemotherapy|Tegafur,Gimeracil and Oteracil Potassium Capsules 40-60mg, bid, po, D1-14, Q3w
2935551|NCT03002818||HCV Genotype 1 Participants|Participants receiving paritaprevir/ritonavir/ombitasvir with dasabuvir (Viekirax®/Exviera®, 3D regimen)
2935552|NCT03002792||general anesthesia|caries treatment under general anesthesia
2935553|NCT03002792||caries treatment only|caries treatment without general anesthesia
2935554|NCT03002779|Experimental|JNJ-53718678|
2935555|NCT03002753|Experimental|DM|Group of patients receiving detached mindfulness (for details, see detailed description of the study)
2935556|NCT03002753|Active Comparator|CR|Group of patients receiving cognitive restructuring (for details, see detailed description of the study)
2935557|NCT03002753|No Intervention|WL|Waitlist control group, which, however, is again randomized after the waiting time in order to receive one of the two interventions (DM or CR).
2935558|NCT03002740||NVAF patients newly prescribed apixaban|
2935559|NCT03002740||NVAF patients newly prescribed rivaroxaban|
2935560|NCT03002740||NVAF patients newly prescribed dabigatran|
2935561|NCT03002740||NVAF patients newly prescribed VKA|
2935562|NCT03002714|Experimental|Exercise|Performance of two resistance exercise sessions
2935563|NCT03002701|No Intervention|Control - standard care|Prior to implementation of the intervention package the current standard of care will be maintained.
2935564|NCT03002701|Active Comparator|Intervention group|After implementation the intervention package will be implemented as standard care.
2935565|NCT03002688||Sequential Cataract Surgery with Survey|Subjects eligible for the study will fall into the sequential cataract surgery group and be administered brief surveys.
2935566|NCT03002675|Experimental|exenatide|Participants will receive exenatide (Bydureon, 2mg s.c. 1x/wk, AstraZeneca) during 12 weeks
2935567|NCT03002662||BMI <18.5 underweight (Group 1)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMI <18.5 underweight (Group 1)
2935568|NCT03002662||BMİ: 18.5 - 24.9 normal weight (Group 2)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ: 18.5 - 24.9 normal weight (Group 2)
2935569|NCT03002662||BMİ: 25- 29.9 overweight (Group 3)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ: 25- 29.9 overweight (Group 3)
2935570|NCT03002662||BMİ>30 obese (Group 4)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ>30 obese (Group 4)
2935571|NCT03002649|Experimental|Tofacitinib|All subjects will be provided Tofacitinib 11mg tablets for oral administration once daily. 12-week treatment period with optional 4-week treatment extension period.
2935572|NCT03002636|Experimental|Morbid Obesity group|Morbid Obesity group(n=300)
2935573|NCT03002636|Experimental|severe Obesity group|severe Obesity group (n=300)
2935574|NCT03002636|Other|non-Obesity group|non-Obesity group(n=300)
2935575|NCT03002623|Experimental|Group|CUDC-907 for thyroid cancer
2935576|NCT03002610|Active Comparator|PLS|The control group will receive PLS: text format with simple explanation of the survey topic main findings and is intended for lay audience.
2935577|NCT03002610|Experimental|Infographics|Infographics format of a Cochrane systematic review summary represents the experimental intervention in the trial, where the results are presented with text and pictures.
2935578|NCT03002610|Active Comparator|Scientific abstract|Scientific abstract is the text written for the academic population and practitioners. It is also intended for control group.
2935579|NCT03002597||Blind Children|Children between the ages of 4 and 17 who are blind (documented visual acuity of light perception or worse) in both eyes from an eye care provider.
2935580|NCT03002597||Sighted Children|Children between the ages of 4 and 17 who are sighted in both eyes.
2935581|NCT03002584||IBS & general population|"The participants will be given the IGQ questionnaire to complete as well as other self-reported questionnaires.~Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).~Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale."
2935582|NCT03002571|Experimental|IDP-124 Lotion|Lotion
2935583|NCT03002571|Active Comparator|IDP-124 Vehicle Lotion|Vehicle
2935584|NCT03002558||control (non-OSA)|Patients without sleep apnoea
2935585|NCT03002558||OSA-treated|Patients with sleep apnoea who are treated (CPAP, surgery or MAD)
2935586|NCT03002558||OSA-non treated|Patients with sleep apnoea who are not treated
2935587|NCT03002545|Placebo Comparator|Placebo|identically tasting and looking Placebo
2935588|NCT03002545|Active Comparator|Magnesium|Supplementation with 400 mg Magnesium from Magnesium citrate once daily
2935589|NCT03002532|Active Comparator|Whole-brain radiotherapy (WBRT) group|Conventional whole-brain radiotherapy for brain metastases from breast cancer with dose of 37.5 Gy in 15 fractions.
2935590|NCT03002532|Experimental|Hippocampal-sparing WBRT (HS-WBRT) group|Hippocampal-sparing whole brain radiotherapy is performed using modern intensity-modulated radiotherapy (IMRT) technique to avoid conformally the hippocampal neural stem-cell structure during WBRT. Prescription dose is 37.5 Gy in 15 fractions.
2935591|NCT03002519|Experimental|PLX-R18|Dose Escalation- first three subjects will be enrolled in the low dose cohort, 6 subjects in the intermediate-dose cohort, and 15 subjects in the high dose cohort.
2935592|NCT03002506|Experimental|ceftolozane/tazobactam|One dose of 3 grams ceftolozane/tazobactam will be administered to each study participant.
2935594|NCT03002480|Other|Severe Hemophilia A subjects w/ inhibitors|Males age 4-70 years diagnosed with severe hemophilia A with inhibitors who are currently treated with prophylaxis or on-demand treatment will be enrolled.
2935595|NCT03002467|Experimental|PESI score|treating physicians must formally calculate PESI and report in the clinical record form* each day of hospitalization on top of routine clinical practice (standard care)
2935596|NCT03002467|No Intervention|Standard care|standard care (i.e. no formally calculation of PESI on top)
2935597|NCT03002454|Experimental|99mTc MDP Injection:neutron-bombardment|Oncologic indication for which a bone scan would normally be indicated. Participant having recently had a bone scan using Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from fission-sourced 99Mo. The images of the 99mTc MDP Injection-neutron-bombardment will be compared to the previous (on file) images from the 99mTc MDP Injection-fission
2935598|NCT03002441|Active Comparator|Same-day Dilators|Participants will have Dilapan-S cervical dilators placed 4-6 hours prior to D&E and will receive 400 mcg buccal misoprostol pills 3 hours prior to D&E.
2935599|NCT03002441|Active Comparator|Overnight dilators|Participants will have Dilapan-S cervical dilators placed the day prior to their D&E procedure and will receive buccal placebo pills (vitamin B12) 3 hours prior to D&E.
2935600|NCT03002428|Experimental|Teriparatide (PF708)|PF708 20 mcg once-daily subcutaneous injection for 24 weeks
2935601|NCT03002428|Active Comparator|Teriparatide (Forteo)|Forteo 20 mcg once-daily subcutaneous injection for 24 weeks
2935602|NCT03002415|Experimental|Guided water intake|"Verbal and written guidelines will be given for the patient to ingest the daily volume of water calculated by the weight (30 ml / kg / day) for 14 days. Patients will receive an acrylic glass with a mark in 200 ml and will be instructed to take the number of glasses a day corresponding to the calculated volume (30 ml / kg). Patients will also receive a leaflet indicating how many glasses of water they will need to take. They will also be instructed to mark with an X the number of glasses of water that they actually drank daily during the fourteen days of intervention.~Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days."
2935603|NCT03002415|Placebo Comparator|Placebo - free demand water intake|Patients are instructed to drink water and other liquids on demand. Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days.
2935604|NCT03002402|Experimental|Internet-based CBT-I|"Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of cognitive-behavioral treatment for insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is allocated out over time through 6 Cores. Users obtain access to a new Core based on a time and event-based schedule (e.g., 7 days after completion of previous Core). SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a sleep restriction window)."
2935605|NCT03002389|Other|All COPD Subjects|"All subjects will be assessed with hyper polarized xenon-129 MRI, pulmonary function test, quality of life measures (BDI, TDI, SGRQ, CRQ, BODE, GOLD), and blood test.~Intervention: All subjects will received Anoro one puff once a day for 30 days first, then 3 day washout, then Arnuity 250 microgram one puff twice a day for 30 days to complete the study."
2935606|NCT03002376|Experimental|REGN2810|REGN2810 treatment
2935607|NCT03002363|Experimental|Video Modeling Intervention|The intervention group receives a video that is a behavior modeling video that walks through the entire audiological evaluation. It also includes tips for caregivers to practice with their child before the appointment.
2935608|NCT03002363|Placebo Comparator|Placebo Video|The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
2935609|NCT03002337|Experimental|Aromatherapy massage|Ten aromatherapy group received 70 minutes of aromatherapy massage once biweekly by certified aromatherapy therapist for 20 weeks.
2935610|NCT03002337|Experimental|Yoga exercise|The yoga group participated in two weekly 70-minute yoga sessions led by a midwife certified as a yoga instructor for 20 weeks
2935611|NCT03002337|No Intervention|Control|the control group received only routine prenatal care.
2935612|NCT03002324|Active Comparator|Current CDC Message Arm|Participants randomized to this arm will receive a message developed to directly follow the current message on the CDC's website.
2935613|NCT03002324|Experimental|Cervical Cancer Message Arm|Participants randomized to this arm will receive a message focused on cervical cancer risks and prevention and framed to highlight perceived susceptibility, perceived benefit, and self-efficacy.
2935614|NCT03002324|Sham Comparator|Control Message|Participants randomized to the control arm will be provided with a short message about the costs and benefits of bird feeding.
2935615|NCT03002311|Other|Control|Receiving current standard of care as designated by clinical provider or clinic's standard operating practice. Depending on the specific disease/condition studied, in addition to standard of care, participants may receive placebo version of eHealth intervention.
2935616|NCT03002311|Experimental|Epx eHealth Intervention|After providing consent, any patient who opted in will begin receiving text or phone calls regarding reminders for physician prescribed actions, or will begin receiving text or phone calls requesting clinical data (e.g. mood, weight, blood glucose level, or disease specific events) that a patient can provide on their own. The repetition rate and frequency will be differed based on disease and physician preference. The patient can then respond to these messages via numerical or binary answers (Y/N). Depending on the disease condition, these answers may trigger a prompt for the patient to call in to the provider, or where possible, an alert to the provider (delivered via page, phone call, or E-Mail) to proactively call the patient to manage their health condition.
2935617|NCT03002298|Experimental|DMD gesture task|Experimental group that made the task using a gesture in front of a webcam
2935618|NCT03002298|Experimental|DMD button-press task|Experimental group that made the task pressing the button
2935619|NCT03002298|Active Comparator|Control group gesture task|Control group that made the task using a gesture in front of a webcam
2935620|NCT03002298|Active Comparator|Control group button-press task|Control group that made the task pressing the button
2935621|NCT03002285|Experimental|Cerebral Palsy group|Group with Cerebral Palsy that performed the Fitts law in a computer task
2935623|NCT03002272||TAVR|This observational study will enroll subjects that underwent TAVR more than 3 years ago.
2935624|NCT03002272||SAVR|Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
2935625|NCT03002259|No Intervention|Control|No placebo required
2935626|NCT03002259|Active Comparator|Dexamethasone|Dexamethasone, 1 mg/kg (maximal dose 100 mg), single dose administration before cardiopulmonary bypass
2935627|NCT03002246||Average for Gestational Age|This cohort will include a sample size of 90 subjects. Fetuses will have an estimated fetal weight greater than 10th percentile and less than 90th percentile based on clinical ultrasound assessment. This cohort will receive an ultrasound examination 4-7 days before their delivery.
2935628|NCT03002246||Large for Gestational Age|This cohort will include a sample size of 30 subjects. Fetuses will have an estimated fetal weight greater than 90th percentile based on clinical ultrasound assessment.This cohort will receive an ultrasound examination 4-7 days before their delivery.
2935629|NCT03002246||Small for Gestational Age|This cohort will include a sample size of 30 subjects. Fetuses will have an estimated fetal weight less than 10th percentile based on clinical ultrasound assessment.This cohort will receive an ultrasound examination 4-7 days before their delivery.
2935630|NCT03002233|Experimental|TRK-820|PartA: 5 μg PartB: 2.5-10 μg
2935631|NCT03002220|Experimental|open-label|Patient will be treated with radium-223 at a dose of 55 kBq (after 2015 NIST implementation) per kilogram body weight, given at four-week intervals for six intravenous injections.
2935632|NCT03002207|Experimental|The defect is repaired and sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the first group,the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge and sutured.
2935633|NCT03002207|Experimental|The defect is repaired but not sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the second group, the defect of intervertebral disc is repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge but not sutured after discectomy.
2935634|NCT03002207|Experimental|The defect is sutured but not repaired|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the third group, the defect of intervertebral disc is sutured but not repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
2935635|NCT03002207|No Intervention|The defect is neither sutured nor repaired|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the four group, the defect of intervertebral disc is neither sutured nor repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
2935636|NCT03002194|Experimental|RF and PEMF therapy|Each subject is to receive 8 weekly study treatments. The study treatment consists of Glide (medical grade glycerin) being applied thoroughly to the study treatment area (face). The energy will be delivered by the Diamondpolar applicator attached to the Venus Versa, a medical device approved by health regulatory authorities, to deliver combined radiofrequency (RF) and pulsed electromagnetic field (PEMF) energies. Change in skin elasticity will be measured by Cutometer. Change in appearance will be assessed by independent reviewer using photographs.
2935637|NCT03002181|Experimental|PNE group|Pain neurophysiology education group.
2935638|NCT03002181|Experimental|Red Flag group|Red Flags education group.
2935639|NCT03002168|Active Comparator|Alpha-cyclodextrin|Two 1 gram Alpha-cyclodextrin tablets given per fat-containing meal. A total of 6 tablets (6 grams) per day for the first two consecutive days of active treatment period. Triolein radiolabeled with 100 microcuries of 3^Hydrogen and Tripalmitin radiolabeled with 20 microcuries of 14^Carbon given orally with liquid breakfast meal.
2935640|NCT03002168|Placebo Comparator|Placebo|Two Placebo Alpha-cyclodextrin tablets given per fat-containing meal. A total of 6 tablets per day for the first two consecutive days of placebo treatment period.Triolein radiolabeled with 100 microcuries of 3^Hydrogen and Tripalmitin radiolabeled with 20 microcuries of 14^Carbon given orally with liquid breakfast meal.
2935641|NCT03002155|Experimental|Exercise|EnhanceFitness exercise class, 1 hour, 3 times a week, duration of 12 weeks.
2935642|NCT03002155|No Intervention|Control|Usual care.
2935643|NCT03002142|Experimental|Patients treated with hearing aids|Patients fitted with functional hearing aids (Phonak Audéo BR)
2935644|NCT03002142|Placebo Comparator|Patients treated with placebo device|Patients fitted with non-functional hearing aids
2935645|NCT03002129|Other|fluid challenge|
2935646|NCT03002116|Active Comparator|Group N|Healthy volunteers without peripheral arterial disease according to clinical examination and Duplex ultrasound
2935647|NCT03002116|Experimental|Group DN|Patients suffering from diabetes and diabetic foot without vascular compromise according to clinical assessment continuous-wave Doppler and Duplex ultrasound
2935648|NCT03002116|Experimental|Group DC|Diabetic patients with Rutherford-Becker 5 or 6 critical limb ischemia, verified by clinical examination, abnormal continuous-wave Doppler or Duplex ultrasound and intra-arterial angiography.
2935649|NCT03002116|Experimental|Group NDC|Non diabetic patients with Rutherford-Becker 5 or 6 critical limb ischemia, verified by clinical examination, abnormal continuous-wave Doppler or Duplex ultrasound and intra-arterial angiography.
2935650|NCT03002103|Experimental|ET+P+G|
2935651|NCT03002103|Active Comparator|Control|
2935652|NCT03002090|Experimental|Iron trained|
2935653|NCT03002090|Experimental|Iron Untrained|
2935654|NCT03002090|Experimental|BZKL Trained|
2935655|NCT03002090|Experimental|BZKL Untrained|
2935656|NCT03002090|Experimental|Placebo Trained|
2935657|NCT03002090|Placebo Comparator|Placebo Untrained|
2935757|NCT03001297|Experimental|MEDI5884 Dose 1|Participants will receive single dose of MEDI5884 Dose 1 injection SC on Day 1.
2935658|NCT03002077|Experimental|Rapastinel|Rapastinel 450 milligrams (mg) intravenous (IV) open label weekly or every two weeks, based on investigator's discretion for 52 Weeks. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
2935659|NCT03002064|Experimental|DP group|Docetaxel plus cisplatin. Docetaxel: 60mg per square metre on day 1 and Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
2935660|NCT03002064|Active Comparator|PF group|Cisplatin plus 5-fluorouracil. Cisplatin: 60mg per square metre on day 1 and 5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles.
2935661|NCT03002051|Experimental|EUS guided drainage|Patients suffering from the conditions in focus would receive EUS guided drainage with the lumen apposing stent
2935662|NCT03002038|Experimental|Azathioprine|Patients in this group will receive 50 mg of azathioprine, two times each day and gradually increased to maximum dose of 3 g daily with the aim of lymphocytes count less than 1500.
2935663|NCT03002038|Experimental|Rituximab|Patients in this group will receive 1g of Rituximab in 500 cc normal saline serum through intravenous infusion with two weeks intervals (as one course) and each course of treatment is repeated every 6 months.
2935664|NCT03002025|Experimental|Cohort 1: JNJ-64304500 50 milligram (mg) or placebo|Participants (Japanese) will receive single subcutaneous (SC) dose of JNJ-64304500 50 mg or placebo on Day 1.
2935665|NCT03002025|Experimental|Cohort 2: JNJ-64304500 150 mg or placebo|Participants (Japanese) will receive single SC dose of JNJ-64304500 150 mg or placebo on Day 1.
2935666|NCT03002025|Experimental|Cohort 3: JNJ-64304500 400 mg or placebo|Participants (Japanese) will receive single SC dose of JNJ-64304500 400 mg or placebo on Day 1.
2935667|NCT03002025|Experimental|Cohort 4: JNJ-64304500 150 mg or placebo|Participants (Caucasian) will receive single subcutaneous (SC) dose of JNJ-64304500 150 mg or placebo on Day 1.
2935668|NCT03002012|Experimental|Sertraline|Fluconazole Standard of Care + Sertraline
2935669|NCT03002012|Placebo Comparator|Control|Fluconazole Standard of Care + Placebo Oral Tablet
2935670|NCT03001999|Experimental|Intervention Arm|Participants will all undergo a 16-week PP-MI health behavior intervention.
2935671|NCT03001986|Experimental|vaccine (3.0 EU)|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
2935672|NCT03001973||LN patients|Patients diagnosis as lupus nephritis
2935673|NCT03001960|Experimental|Group 1- PREloading BEFORE TAVI|"Aspirin 100 mg loading orally 6-12 hours before TAVI and~Clopidogrel 600mg loading 6-12 before TAVI followed by maintenance dose of 100mg aspirin and 75mg clopidogrel per day"
2935674|NCT03001960|Experimental|Group 2 - POSTLoading AFTER TAVI|"Aspirin 100 mg loading orally 6-12 hours after TAVI and~Clopidogrel 600mg loading 6-12 hours after TAVI followed by maintenance dose of 100mg aspirin and 75mg clopidogrel per day"
2935675|NCT03001947||IgAN patients|Biopsy-proven primary IgAN patients
2935676|NCT03001934||Nephrotic syndrome patients|Patients diagnosis as nephrotic syndrome (NS)
2935677|NCT03001921||Hemodialysis patients|End stage renal disease patients receiving hemodialysis treatment
2935678|NCT03001908|Active Comparator|control oscillation|control subjects with normal shoulders will undergo the glenohumeral mobilization-oscillation
2935679|NCT03001908|Active Comparator|control sustained|control subjects with normal shoulders will undergo the glenohumeral mobilization-sustained
2935680|NCT03001908|Experimental|stiff oscillation|subjects with stiff shoulders will undergo the glenohumeral mobilization-oscillation
2935681|NCT03001908|Experimental|stiff sustained|subjects with stiff shoulders will undergo the glenohumeral mobilization-sustained
2935682|NCT03001895|Experimental|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT Scan
2935683|NCT03001882|Experimental|Combination therapy|Nivolumab + Ipilimumab
2935684|NCT03001869|Experimental|68Ga-PSMA PET/CT|68Ga-HBED-CC-PSMA PET/CT
2935685|NCT03001856|Experimental|Oblique Intradermal Suture|OIS is very similar to conventional interrupted intradermal suture (IS), except that the suture in OIS is canted or angled relative to the vertical plane (Figure 1). To perform OIS, the needle is passed from deep to superficial dermis and canted 30°-60° from the normal vertical plane. The needle is then inserted into the opposite wound edge from superficial to deep dermis in a mirror-image fashion. The thread is tied with a square knot to finish the suture.
2935686|NCT03001856|Experimental|Intradermal Suture|Conventional interrupted intradermal suture
2935687|NCT03001843||Non-Ketamine|This group will receive intraoperative narcotics as is usually done for this surgery. This arm will not receive Ketamine.
2935688|NCT03001843||Ketamine|This group will receive an intraoperative infusion of ketamine rather than narcotics to control pain.
2935689|NCT03001830|Experimental|Treatment Arm|Treatment with AAV2/8-HLP-FVIII-V3
2935690|NCT03001817|Placebo Comparator|12 Week Efficacy|K-877 or placebo comparator twice daily for 12 weeks
2935691|NCT03001817|Active Comparator|40 Week Extension|K-877 with placebo matching fenofibrate or fenofibrate with placebo matching K-877 for 40 weeks
2935692|NCT03001804||Lenalidomide (Revlimid®) in combination with dexamethasone|Lenalidomide (Revlimid®) in combination with dexamethasone is indicated for the treatment of adult patients with untreated multiple myeloma, where stem cell transplantation cannot be performed.
2935693|NCT03001791|Experimental|Er:YAG laser|Excisional biopsy of fibrous hyperplasia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.
2935694|NCT03001791|Experimental|CO2 laser|Excisional biopsy of fibrous hyperplasia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.
2935695|NCT03001791|Experimental|Scalpel|Excisional biopsy of fibrous hyperplasia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
2935696|NCT03001778|Experimental|Usability Testing|Prototype testing
2935697|NCT03001765|Other|Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac|Intensive monitoring strategy of discharging from the Emergency Department with an external 30 day cardiac monitoring system. A negative 30 day external monitor report will be followed by an implantable cardiac monitor.
2935698|NCT03001752|Active Comparator|Open flap immediate implant|Open flap immediate implant insertion, without bone grafting
2935699|NCT03001752|Active Comparator|Open flap immediate implant and bone grafting|Open flap immediate implant insertion and bone grafting
2935700|NCT03001752|Active Comparator|Flapless immediate implant|Immediate implant insertion without opening flap of inserting bone grafting
2935701|NCT03001739|Experimental|Intensive BP control (<120mmHg)|Urapidil Hydrochloride Injection (100-400ug/min) or other antihypertensive agents to decrease the BP to < 120 mm Hg
2935702|NCT03001739|Active Comparator|Conventional BP control (120-140mmHg)|Urapidil Hydrochloride Injection (100-400ug/min) or other antihypertensive agents to decrease the BP to 120-140 mm Hg
2935703|NCT03001726|Experimental|Gastrectomy plus chemotherapy|In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
2935704|NCT03001726|Other|chemotherapy alone|Patients received chemotherapy alone.All patients received oral S1 80 mg/m2 per day (80-120 mg/day total dose depending on the patient's body surface area as follows: <1.25 m2, 80 mg; 1.25-1.5 m2, 100 mg; and >1.5 m2, 120 mg) on days 1-21 of every 3-week cycle, oxaliplatin 100 mg/m2 on day 1 of every 3-week cycle and docetaxel 40mg/m2 on day 1 of every 3-weeks cycle.
2935705|NCT03001713|Active Comparator|Arm 1: Immediate implementation|30 safety net community health centers (CHCs) will be randomized to implement the sophisticated CV Wizard clinical decision support (CDS) system at the start of study year 2. Arm 1 CHCs will receive implementation support that will be pragmatically iterated to address any barriers to adoption / sustained use of the CDS that are identified through study activities. The investigators will apply these learnings to improve adoption rates in Arm 2.
2935706|NCT03001713|Active Comparator|Arm 2: Delayed implementation|30 safety net community health centers (CHCs) will be randomized to implement the sophisticated CV Wizard clinical decision support (CDS) system 18 months later than Arm 1. The investigators will measure the intervention's impact on CVD risk factor control in CHCs.
2935707|NCT03001700|Experimental|Treatment|Subjects will be treated with the Serranator™ Alto PTA Serration Balloon Catheter device
2935708|NCT03001687|Experimental|vitamin D +|"Patients in the vitamin D group will receive enteral supplementation with vitamin D, blood collection 3mL is performed in the first 24 hours after admission and one week later for serum hepcidin measurement"
2935709|NCT03001687|Placebo Comparator|vitamin D -|"Patients in vitamin D - group do not receive enteral supplementation with vitamin D and represent the control group, blood collection 3mL is performed in the first 24 hours after admission and one week later for serum hepcidin measurement"
2935710|NCT03001674|Experimental|IABP recipient|Referred for clinically indicated right heart catheterization with intervention of IABP placement prior to LVAD surgery.
2935711|NCT03001674|Experimental|Control|Control subjects undergoing left heart catheterization with an LV ejection fraction > 50%, and without a history of heart failure symptoms who did not receive IABP therapy were enrolled.
2935712|NCT03001661|Active Comparator|Propess|Control intervention: Propess® (dinoprostone) Slow release vaginal drug delivery system (Prostaglandin E2).
2935713|NCT03001661|Experimental|Dilapan-S|Experimental intervention: DILAPAN-S® A synthetic osmotic cervical dilator for insertion into the cervical canal, using as many rods as necessary.
2935714|NCT03001648||PGS|Patients with RIF scheduled for PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridation (aCGH) underwent one or more stimulation cycles. If euploid blastocysts were available, patients underwent frozen embryo transfer/s.
2935715|NCT03001648||Standard IVF|Patients with RIF scheduled for standard IVF (In Vitro Fertilization) underwent a single stimulation cycle with the fresh embryo transfer and the subsequent frozen embryo transfers if there were surplus frozen embryos and the fresh embryo transfer was unsuccessful.
2935716|NCT03001635|Experimental|conventional treatment and oxytocin|26 patients admitted to the ICCU under a diagnosis of STEMI will receive treatment with oxytocin as an add on to the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers & ACE inhibitors). At admission, a continuance infusion with oxytocin will be initiated for a time period of 6 hours. 10 units of oxytocin will be diluted in 1 liter of 0.9% normal saline. the infusion will start at a rate of 2.5 milliunits/min. dosage will be increased at a rate of 5 milliuinits/min every 30 min if there are no side effect, up to a maximum dosage of 30 milliunits/min.
2935717|NCT03001635|Placebo Comparator|conventional treatment only|26 patients admitted to the ICCU under a diagnosis of STEMI will receive the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers & ACE inhibitors). On admission, an infusion of 0.9 normal saline will be stared as placebo.
2935718|NCT03001622|Other|IFX-1|
2935719|NCT03001609|Experimental|AC0010|each participant will be given a single dose of 14C-labeled AC0010
2935720|NCT03001596|Experimental|Neoadjuvant chemoradiotherapy|Neoadjuvant chemoradiotherapy (NCRT) is performed followed by minimally invasive esophagectomy in enrolled patients.
2935721|NCT03001596|Active Comparator|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy (NCT) is performed followed by minimally invasive esophagectomy in enrolled patients.
2935722|NCT03001583|Experimental|Education Program with cooking lessons|Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
2935723|NCT03001583|Active Comparator|Education without cooking|Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
2935753|NCT03001323|Active Comparator|Standard long-acting|Discharge on 0.3 U/kg of admission long acting insulin glargine or detemir (provided by diabetes and endocrine clinic) regardless of their home insulin regimen at the time of admission with reduction to 0.2 U/kg in CKD with GFR <30 ml/hr.
2935754|NCT03001310|Experimental|Biological-Low dose AAV - CNGB3|Subretinal administration of a single low dose of range AAV - CNGB3
2935755|NCT03001310|Experimental|Biological-medium dose AAV - CNGB3|Subretinal administration of a single medium dose of range AAV - CNGB3
2935724|NCT03001570|Experimental|Arm 1|"Radiotherapy treatment associated with concurrent Cetuximab administration.~Patients candidate to curative concurrent Cetuximab and Radiotherapy are eligible for this study. After expressing written informed consent, patients will perform CT simulation. Then an IMRT-SIB (Simultaneous Integrated Boost) treatment plan will be elaborated and deliver the following Cetuximab pharmacokinetic:~Length: 6 weeks; 1 fraction daily (From Monday to Friday) 30 Total Fractions (5 per week, 6 weeks of treatment). Cetuximab will be administered weekly from a week before starting radiotherapy until the end of treatment for 7 subsequent administration accordingly to the standard schedule (1 before and 6 during radiotherapy)."
2935725|NCT03001557|Experimental|Lemborexant 2.5 milligrams (mg)|Participants will take one lemborexant 2.5 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
2935726|NCT03001557|Experimental|Lemborexant 5 mg|Participants will take one lemborexant 5 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
2935727|NCT03001557|Experimental|Lemborexant 10 mg|Participants will take one lemborexant 10 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
2935728|NCT03001557|Experimental|Lemborexant 15 mg|Participants will take one lemborexant 5 mg tablet and one lemborexant 10 mg tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
2935729|NCT03001557|Placebo Comparator|Lemborexant-matched placebo|Participants will take two lemborexant-matched placebo tablets orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
2935730|NCT03001544|Experimental|Experimental Ascending Dose Cohort|TS23
2935731|NCT03001531|Active Comparator|HydroSun|application of ultraviolet light for 30 minutes
2935732|NCT03001531|Active Comparator|Hilotherm|application of heat (maximum of 43°C) for 30 minutes
2935733|NCT03001518||Surgery|No intervention. Patients who undergo surgical resection of their pancreatic cancer.
2935734|NCT03001505||Patients with pancreatic cancer|Patients diagnosed with pancreatic cancer evaluated at this institution.
2935735|NCT03001479|No Intervention|Standard: Liquid HMF and liquid protein|This is our standard breast milk fortification in our NICU. One packet (5 mL) of Similac Human Milk Fortifier Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. After infants reach full feedings (160 ml/kg/d), 3 ml/kg of Similac Liquid Protein Fortifier is added (0.5 g/kg protein). This is increased to 6 ml/kg (1 g/kg protein) the next day.
2935736|NCT03001479|Experimental|Intervention: HMF Hydrolyzed Protein Concentrated Liquid|One packet (5 mL) of Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. Feedings then continue to be advanced to full volume (160 ml/kg/d).
2935737|NCT03001466|Experimental|urea-loaded nanoparticles eye drops|This arm include 40 cases (67 eyes) received urea-loaded nanoparticles eye drops (one drop five times a day for 8 weeks)
2935738|NCT03001466|Placebo Comparator|Balance Salt Solution eye drops|This arm include 11 cases (22 eyes) recieved Balance Salt Solution eye drops (one drop five times a day for 8 weeks)
2935739|NCT03001453|Active Comparator|Liposomal bupivacaine|Periarticular infiltration cocktail of 20cc of liposomal bupivacaine with 20cc of normal saline and 40cc of 0.25% bupivacaine with epinephrine
2935740|NCT03001453|Active Comparator|Bupivacaine with epinephrine|Periarticular infiltration cocktail of 60cc of 0.25% bupivacaine with epinephrine
2935741|NCT03001440||ZYBAN/WELLBUTRIN users|Subjects who currently use or who have filled a prescription for ZYBAN, WELLBUTRIN, WELLBUTRIN SR, or WELLBUTRIN XL for smoking cessation within the previous 6 months will be included in the study. Subjects will be required to complete the KAB survey either online or through a telephone interview.
2935742|NCT03001427|Experimental|Structured center-based lifestyle intervention|The Structured center-based Lifestyle Intervention (C-LIFE) will include individualized plans for the DASH diet, weight management, and aerobic exercise.
2935743|NCT03001427|Experimental|Standard education and physician advice|The Medical Management with Standardized Education and Physician Advice (SEPA) will consist of encouragement to achieve an ideal body weight and engage in exercise as part of routine counseling in primary care, but no special program will be delivered to enhance the participants' ability to comply with these recommendations.
2935744|NCT03001414|Experimental|Placebo followed by Autologous EPCs transfected with eNOS|4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 1 followed by 4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 2
2935745|NCT03001414|Experimental|Autologous EPCs transfected with eNOS followed by Placebo|4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 1 followed by 4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 2
2935746|NCT03001414|Experimental|Autologous EPCs transfected with eNOS|4 monthly IV injections of Autologous EPCs transfected with human eNOS in Course 1 followed by 4 monthly injections of Autologous EPCs transfected with human eNOS in Course 2 (total of 160 million cells)
2935747|NCT03001401|Active Comparator|iDesign|Eyes will under LASIK using iDesign platform for treatment of sphere and cylinder power
2935748|NCT03001401|Active Comparator|SMILE|Eyes will under SMILE using Visumax platform for treatment of sphere and cylinder power
2935749|NCT03001375|Active Comparator|Mobilization group|Laparoscopic splenic flexure mobilization will be done.
2935750|NCT03001375|Active Comparator|Non mobilization group|No mobilization of splenic flexure.
2935751|NCT03001362|Experimental|Radical External Beam RT for Colorectal Ca|A single arm consisting of: Radical external beam RT dose of 54 Gy in 30fx with radiosensitizing chemotherapy as per institutional standard
2935752|NCT03001323|Experimental|Degludec|Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR <30 ml/hr.
2935756|NCT03001310|Experimental|Biological-high dose AAV - CNGB3|Subretinal administration of a single high dose of range AAV - CNGB3
2935759|NCT03001297|Experimental|MEDI5884 Dose 2|Participants will receive single dose of MEDI5884 Dose 2 injection SC on Day 1.
2935760|NCT03001297|Experimental|MEDI5884 Dose 3|Participants will receive single dose of MEDI5884 Dose 3 injection SC on Day 1.
2935761|NCT03001297|Experimental|MEDI5884 Dose 4|Participants will receive single dose of MEDI5884 Dose 4 injection SC on Day 1.
2935762|NCT03001284||Multiple sclerosis patients|patients with confirmed multiple sclerosis, diagnosed according to the revised McDonald's criteria
2935763|NCT03001284||Control subjects|control subjects, matched for age, gender, and presence of cardiovascular risk factors
2935764|NCT03001271|Experimental|Healthy Subjects|Placebo and Angiotensin-(1-7) acute infusion
2935765|NCT03001271|Experimental|Hypertensive Subjects|Placebo and Angiotensin-(1-7) acute infusion
2935766|NCT03001258||PO (program organizers)|"PO (program organizers): Employed by Brac as field level organizers. A two day presbyopia screening training were provided.~A total of eight POs organized eye camps in two sub districts. POs were responsible for identifying the presbyopia patients through screening and SS assisted in organizing and mobilizing the community people for the eye camps, and glass sale (on the spot). Four camps were organized per day for five days by four POs in each sub-district. Thus a total of 40 eye camps were held in two sub districts by eight POs."
2935767|NCT03001258||USS (Upgraded Shashthya Shebika)|"USS (Upgraded Shashthya Shebika): A new caddre of community health workers of Brac. A two day presbyopia screening training were provided.~In this arm, 20 USSs were assigned in two upazillas to run the two camp-day i.e. screening patients and selling glasses during the total 40 eye camps."
2935768|NCT03001258||SS (Shashthya Shebika)|"SS: Community health workers of Brac. A two day presbyopia screening training were provided.~In this arm, the SS, undertook the screening of potential presbyopia cases. A total of 27 SS organized 25 eye camps in eight days in two upazilas."
2935769|NCT03001245|Experimental|IPC|Interpersonal Counseling
2935770|NCT03001245|Active Comparator|ST|Standard treatment
2935771|NCT03001232|Experimental|Movement-oriented Dementia Care|The experimental group received movement-oriented dementia care for a period of twelve months.Movement-oriented dementia care is a multidisciplinary approach in which all involved disciplines focus on stimulating physical activity and independence as much as possible. This way physical activity is stimulated at all times for the participants.
2935772|NCT03001232|No Intervention|Care as usual|The control group received care as usual
2935773|NCT03001219|Placebo Comparator|Part 1: Placebo|Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
2935774|NCT03001219|Experimental|Part 1: RO7123520|Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
2935775|NCT03001219|Placebo Comparator|Part 2: Placebo|Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
2935776|NCT03001219|Experimental|Part 2: RO7123520|Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
2935777|NCT03001219|Placebo Comparator|Part 3: Placebo|Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
2935778|NCT03001219|Experimental|Part 3: RO7123520|Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
2935779|NCT03001206||ICCU patients|"The use of the Master Caution System (MCS) for continuous monitoring and detection of dysrhythmias and ischemic events :~For patient diagnosed with acute coronary syndrome (ACS) in the intensive cardiac care unit (ICCU) before and after planed catheterization procedure."
2935780|NCT03001206||Stress test subjects|"The use of the Master Caution System (MCS) for continuous monitoring and detection of dysrhythmias and ischemic events :~For patients referred to stress imaging with suspected ischemia."
2935781|NCT03001193|Experimental|DF01 low dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in low dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
2935782|NCT03001193|Experimental|DF01 medium dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in medium dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
2935783|NCT03001193|Experimental|DF01 high dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in high dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
2935784|NCT03001193|Placebo Comparator|PL1|The subjects will receive intravenous infusion of placebo as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
2935785|NCT03001154|Experimental|One-session VRET face-to-face|One-session Virtual Reality Exposure Therapy led by therapist (face-to-face), followed by a 4-week therapist-guided Internet-administered progressive maintenance program.
2935786|NCT03001154|Experimental|Waiting-list, then Internet-administered VRET|4-week waiting list, followed by therapist-guided, Internet-administered VRET with a 4-week progressive maintenance program.
2935787|NCT03001141||Single group - observational|
2935788|NCT03001128||Cohort A: ART initiated during chronic infection|Cohort A will include 36 participants who initiated ART during chronic infection.
2935789|NCT03001128||Cohort B: ART initiated during acute or early infection|Cohort B will include 30 participants who initiated ART during acute/early HIV infection.
2935790|NCT03001115||Participants with Hidradenitis suppurativa (HS)|Participants with HS treated with adalimumab (HUMIRA®) in routine clinical practice.
2935791|NCT03001102|Sham Comparator|Bathing with 4% Chlorhexidine gluconate|Two baths with chlorhexidine using precise methods, including to scrubb the whole body with 50mL of undiluted solution, at night before surgery and the morning of surgery.
2935792|NCT03001102|Experimental|Bathing with10% PVPI degermante|Two baths with PVPI using precise methods, including to scrubb the whole body with 50mL of undiluted solution for each bath, at night before surgery and the morning of surgery.
2935793|NCT03001102|Active Comparator|Bathing with soap without antiseptic.|Two baths with soap using precise methods, including to scrubb the whole body with 50mL of undiluted solution for each bath, at night before surgery and the morning of surgery.
2935794|NCT03001089|Active Comparator|Fludrocortisone 10 µg tablets|Oral Fludrocortisone (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
2935795|NCT03001089|Placebo Comparator|placebo oral tablet|Oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
2935796|NCT03001076|Experimental|bempedoic acid|bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
2935797|NCT03001076|Placebo Comparator|placebo|Matching placebo tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
2935798|NCT03001063|Experimental|Intervention|This arm will receive the Supported Self- Management intervention, which consists of bibliotherapy that is provided with the regular support of health or social workers for a duration of two months.
2935799|NCT03001063|Other|Control|This arm will receive enhanced treatment as usual, which consists of a leaflet with information about depression and regular care as provided by primary care centres. The control arm will receive the intervention after the intervention arm has completed the intervention period.
2935800|NCT03001050|Other|PINPOINT system|The operative intervention will proceed as current standard protocol dictates for the described procedure. No changes in the operative technique will be undertaken apart from injection of the dye and visualization with the camera. The idea would be to place the Pinpoint probe within the subacromial space, to check the vascular status of the tendon, and then take a bite of the tendon and place the pinpoint back to check if the vascularity has decreased. The Indocyanine Green dye kit will be used along with the PINPOINT system .
2935801|NCT03001037||Group A - Low Back Pain|"Group A:~Subject provides written authorization and/or consent per institution and geographical requirements~Subjects in Group A with a predominant complaint of Low back pain, with a minimum daily average VAS ≥ 30/100~Subjects in Group A are intended to be assessed with ViMove based on standard of care~Subject is willing to participate in follow-ups at 3, 6, 12 months post initial assessment~Observational study, no intervention"
2935802|NCT03001037||Group B - Without Low Back Pain|"Subject is without current low back pain~Subject does not have a history of low back pain lasting longer than 3 months in the past 12 months~Subject is willing to follow up 3 months post initial assessment~Observational study, no intervention"
2935803|NCT03001024|Experimental|Implementation of WayToServe Español|The experimental design to be employed in the trial evaluation of WayToServe Español (WTS-E) in this direct-to-Phase II project is a two-arm randomized field trial design (WTS-E vs. Usual and Customary [UC] training) with three assessment points (pretest - immediate post-test - 9 month follow-up).This constitutes a 2 (level of RBS training intervention) x 3 (level of time assessment) mixed factorial design. Spanish dominant onsite and off-site licensed alcohol premises will be the unit of analysis, stratified by type of premise (onsite vs. off-site sales) and state (New Mexico vs. Texas).
2935804|NCT03001024|Active Comparator|Usual and Customary RBS Training|The Investigators have carefully considered the over-time assessment factor in this design, and have chosen two follow-up assessments over a 9 month-period because a) our prior WayToServe® trials have shown that an immediate post-training assessment will document intervention effects when training effects are at optimum levels immediately after the training; b) the sustained effect of WTS-E needs to be demonstrated to show long-term not just short-term impact (9 months being between our previous 6-month and 1-year follow-ups). Finally, c) all follow-ups can be completed within the approximately 2-year period of a Phase II project. The immediate post-training assessment will occur for both arms of the design, one month after premises in the intervention arm are given access to WTS-E.
2935805|NCT03001011|Experimental|Renvela|oral tablets with meal, three times a day
2935806|NCT03001011|Placebo Comparator|Placebo|oral tablets with meal, three times a day
2935807|NCT03000998|Experimental|Web App Intervention Group|The BoyVac mobile web app will be evaluated in a pair-matched group-randomized pretest-posttest controlled design. In Year 2, 30 clinics in New Mexico will be pair-matched and one member of each pair will be randomized to the intervention (mobile web app) or a usual and customary (UC) HPV vaccine adoption procedures comparison group. Clinics will be paired based on similarities in patient demographic (ethnicity and % Medicaid patients) and location (urban and rural).
2935808|NCT03000998|Active Comparator|Usual Customary Care Group|Currently in pediatric clinics in New Mexico, the HPV vaccines are offered to parents and adolescents as part of annual well-child checkups. Typically for boys aged 11-13, parents initiate this checkup as part of a back-to-school activity. As part of the well-child checkup, clinic staff (physician, physician assistant and/or nurse) talk with parents and adolescents about the recommendation that their sons or daughters receive the HPV vaccination. Well-child pediatric visits to promote good health and development are recommended for all children from infancy through adolescence by the American Academy of Pediatrics.
2935809|NCT03000985|Experimental|Psychoeducation|6 session of a psychoeducation program with the family. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
2935810|NCT03000985|No Intervention|Control|Treatment as usual
2935811|NCT03000972|Active Comparator|Standard Nail|Hip fracture surgery with a PFN-A Nail (Proximal Femoral Nail Augmentation).
2935812|NCT03000972|Experimental|Augmented Nail|Hip fracture surgery with a PFN-A Nail with Cement augmentation with TraumaCemV+
2935813|NCT03000946|Experimental|Somatostatin|Continuous intravenous infusion of somatostatin-14, 6 mg per day during 6.5 days
2935814|NCT03000946|Active Comparator|Octreotide|Subcutaneous octreotide 100 μg 3 times a day for 6.5 days.
2935815|NCT03000933||Young same-sex attracted men|Same-sex attracted men aged 16 to 20
2935816|NCT03000920|No Intervention|1_Control|Classic screening invitation strategy with at least an invitation mail and then one or two reminder by mail if necessary.
2935817|NCT03000920|Experimental|2_SMS Reminder 1|Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
2935818|NCT03000920|Experimental|3_SMS before invitation|One SMS a few days before the Invitation by mail and then one or two reminder(s) by mail if necessary.
2935819|NCT03000920|Experimental|4_SMS before invitation + SMS Reminder 1|One SMS a few days before the Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
2935990|NCT02999698||Psoriasis Group|Patients with psoriasis complete the questionnaires for psychological impact.
2935820|NCT03000907|Experimental|Intervention|"diet: assessment of nutritional status and nutritional requirements and establishment of personalized nutritional plan with monthly dietetic controls.~physical exercise: a multi-component physical exercise program that will include aerobic exercise and strengthening, balance and flexibility exercises as well as a weekly group session of health education, during six months."
2935821|NCT03000907|No Intervention|Control|Clinical practise
2935822|NCT03000894|Experimental|CBT-I plus standard care|The group CBT-I will receive both CBT-I and standard care. CBT-I covers sleep-wake cycle as well as sleep hygiene education, activity scheduling, stimulus control, sleep restriction, relaxation training, and cognitive therapy. Standard care will include those treatments provided by the psychiatrists according to their clinical needs.
2935823|NCT03000894|No Intervention|Standard care|Only standard care will be provided to this group. Medications will be prescribed and referral to community nurse, social worker and psychologist will be made by the doctors according to their need.
2935824|NCT03000881|Experimental|Cohort 6|This is a sub-study testing the effect of real output applied under two adhesive strips after 8 hours.
2935825|NCT03000868|Experimental|Cold EMR group|Patients who have small colorectal polyps (<1cm) who receive endoscopic mucosal resection using snare without electrocautery.
2935826|NCT03000868|Active Comparator|Hot EMR group|Patients who have small colorectal polyps (<1cm) who receive endoscopic mucosal resection using snare with the use of electrocautery.
2935827|NCT03000855|Active Comparator|ECDS|EUS-guided choledocho-duodenostomy
2935828|NCT03000855|Active Comparator|ERCP with CSEMS|Endoscopic retrograde cholangiopancreatography with covered metallic stent
2935829|NCT03000842|Experimental|Healthy Subjects|transcutaneous vagal nerve stimulation
2935830|NCT03000842|Experimental|Hypertensive Subjects|transcutaneous vagal nerve stimulation
2935831|NCT03000829|Experimental|Tele-intensivist consultation|Standardized consultation to on-site cardiac arrest response team by off-site intensivist via two-way audiovisual link using a mobile telemedicine cart
2935832|NCT03000829|Placebo Comparator|Control|"Simulated observation by ICU physician by displaying a silent, pre-recorded, non-interactive videotape of an ICU physician. The on-site participants will be told that an intensive care physician is observing the mock code."
2935833|NCT03000816|Experimental|Experimental Arm|Patients in this arm will receive a treatment of SBRT for their oligometastatic lesions.
2935834|NCT03000803|Experimental|Early Total Caloric Intake|The Early Total Caloric Intake study group will consume the majority of their daily calories during breakfast.
2935835|NCT03000803|Active Comparator|Late Total Caloric Intake|The Late Total Caloric Intake study group will consume the majority of their daily calories during dinner.
2935836|NCT03000790|Experimental|Lingual Ring Splint|"A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.~The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior arch will make the Ring around the tongue"
2935837|NCT03000777|Experimental|Melatonin plus Zinc|Melatonin plus Zinc
2935838|NCT03000777|Placebo Comparator|Placebo|Isomaltose
2935839|NCT03000764|Experimental|Biomarkers|
2935840|NCT03000751|Active Comparator|Track A|Simple Audit Report In-Person Meeting Multi-Component Intervention
2935841|NCT03000751|Active Comparator|Track B|In-Person Meeting Simple Audit Report Multi-Component Intervention
2935842|NCT03000751|Other|Track C|Simple Audit Report Multi-Component Intervention
2935843|NCT03000738||non-hodgekin lymphoma|100 non-hodgekin lymphoma patients (age >=18y) without previous treatment would be administered, including 50 DLBCLs and 50 PTCLs.
2935844|NCT03000725|Active Comparator|UPLIFT|Project UPLIFT (Using Practice and Learning to Increase Favorable Thoughts) is a home-based intervention that teaches cognitive and mindfulness skills to people with epilepsy by phone to reduce their depression and improve quality of life (QOL).
2935845|NCT03000725|Active Comparator|USUAL CARE|Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
2935846|NCT03000712|Experimental|Autologous Adipose Tissue derived MSCs|Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml, 1 time injection(at 1week after high tibial osteotomy)
2935847|NCT03000712|No Intervention|No treatment|No treatment (after high tibial osteotomy)
2935848|NCT03000699|Experimental|Cognitive Bias Modification|64 training paragraphs, approximately 10-20 seconds each, digitally recorded and presented stereophonically through headphones, delivered over the course of one week.
2935849|NCT03000699|No Intervention|Assessment-Only Control|No training will be provided.
2935850|NCT03000686|Experimental|Treatment sequence AB|Subjects will receive GSK2586881 in period 1 and saline placebo in period 2. There will be a washout period of 3-14 days between two treatments
2935851|NCT03000686|Experimental|Treatment sequence BA|Subjects will receive saline placebo in period 1 and GSK2586881 in period 2. There will be a washout period of 3-14 days between two treatments
2935852|NCT03000673|Active Comparator|Dose Sequence 1|UFH, BMS-986177 - dose 1, BMS-986177 - dose 2, Enoxaparin
2935853|NCT03000673|Active Comparator|Dose Sequence 2|BMS-986177 - dose 1, Enoxaparin, UFH, BMS-986177 - dose 2
2935854|NCT03000673|Active Comparator|Dose Sequence 3|BMS-986177 - dose 2, UFH, Enoxaparin, BMS-986177 - dose 1
2935855|NCT03000673|Active Comparator|Dose Sequence 4|Enoxaparin, BMS-986177 - dose 2, BMS-986177 - dose 1, UFH
2935856|NCT03000660|Experimental|Venetoclax and Dexamethasone|Venetoclax will be given at one of four escalating doses (100 mg/day, 200 mg/day, 400 mg/day, or 800 mg/day) by mouth on each day of the cycle. Dexamethasone will be given at 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
2935857|NCT03000647|Active Comparator|Guided Pelvic floor exercises|Pelvic floor exercises guided by a physiotherapist
2935858|NCT03000647|Active Comparator|Non-guided pelvic floor exercises|Pelvic floor exercises not guided
2935859|NCT03000634|Experimental|Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD|Elotuzumab 10 mg day 1,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1,8,15,22 Bortezomib 1.3 mg day 1,8,15
2935860|NCT03000634|Other|VRD-bortezomib, lenalidomide, dexamethasone|Bortezomib 1.3 mg day 1, 8,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1, 8,15,22
2935861|NCT03000621||Patients with liver injury|
2935862|NCT03000621||Healthy subjects|
2935863|NCT03000608|Experimental|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
2935864|NCT03000608|Placebo Comparator|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
2935865|NCT03000595|Experimental|SAN007 Cream|A cream containing 5% East Indian sandalwood oil (EISO).
2935866|NCT03000595|Placebo Comparator|Placebo|A placebo cream containing the same components as the vehicle for the active intervention arm
2935867|NCT03000582|Experimental|Creatine monohydrate|5 gm creatine monohydrate, 1.5 gm dextrose
2935868|NCT03000582|Active Comparator|Creatine nitrate-1|1 gm creatine monohydrate, 0.5 gm nitrate, 5 gm dextrose
2935869|NCT03000582|Active Comparator|Creatine nitrate-2|2 gm creatine monohydrate, 1 gm nitrate, 3.5 gm dextrose
2935870|NCT03000582|Placebo Comparator|Placebo|6.5 gm dextrose
2935871|NCT03000569|Experimental|Combination Arm|SAGE-217 and antiparkinsonian agent(s)
2935872|NCT03000556|Experimental|experience|
2935873|NCT03000556|No Intervention|control|
2935874|NCT03000543|No Intervention|Vitamin A pool size in infants without inflammatory condition|Assessing vitamin A (VA) pool size in infants without inflammatory condition using model based compartmental analysis from the fraction of oral dose-derived 13C10-VA and 13C3-VA in plasma over time.
2935875|NCT03000543|Experimental|Vitamin A pool size in infants with inflammatory condition|Assessing vitamin A (VA) pool size in infants without inflammatory condition using model based compartmental analysis from the fraction of oral dose-derived 13C10-VA and 13C3-VA in plasma over time.
2935876|NCT03000530|Experimental|SAGE-217 dosing|SAGE-217
2935877|NCT03000530|Placebo Comparator|Placebo|Placebo
2935878|NCT03000504|Experimental|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned chest drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
2935879|NCT03000504|Active Comparator|Standard intercostal drain|Patients will have a standard 12F-16F Rocket Medical chest drain inserted as per usual clinical guidelines, using the Seldinger technique.
2935880|NCT03000478|Active Comparator|Prolonged Exposure|12 sessions of PE as per protocol
2935881|NCT03000478|Experimental|VRET|12 sessions of Virtual Reality Exposure Therapy
2935882|NCT03000465||Patients|Patients undergoing laparoscopic colorectal surgery
2935883|NCT03000452|Experimental|Administration of Daratumumab (DARA) plus Durvalumab (DURVA)|"Subjects will also receive IV DURVA at 1500 mg on Day 2 (Cycle 1) and on Day 1 (Cycles ≥ 2) of each 28-day treatment cycle.~Subjects will receive intravenous (IV) DARA at 16 mg/kg on the same dosing schedule (weekly [QW], every 2 weeks [Q2W], or every 4 weeks [Q4W] of each 28-day treatment cycle) received during their last prior therapy containing DARA at the time of DARA progression"
2935884|NCT03000439|Experimental|Tofacitinib 5 mg BID|oral, twice daily, tablet or solution.
2935885|NCT03000439|Placebo Comparator|Placebo|
2935886|NCT03000439|Experimental|Tofacitinib 10 mg BID|oral, twice daily, tablet or solution.
2935887|NCT03000426|Sham Comparator|Free gingival graft + PBM Sham|The patients allocated to the control group will receive sham irradiation. For this, black rubber protection will be placed at the tip of the laser device, which do not allow the light to reach the tissue. The applications will be performed by a different operator from the one who will measure the study parameters. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by four more applications performed every other day, with a total of 5 laser applications.
2935888|NCT03000426|Experimental|Free gingival graft + GaAlAs Laser 60|The irradiation will be performed with a GaAlAs diode laser that continuously emits a wavelength of 660 nm with a power of 30 milliwatts (mW). The patients allocated for the group 60 will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 60 Joules/cm2 and a time of 56 seconds per point (1,68 Joules/cm2 per point). During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will repeated by four more applications performed every other day, with a total of 5 laser applications. The power of the equipment will be calibrated prior to each application.
2935889|NCT03000426|Experimental|Free gingival graft + GaAlAs Laser 15|The irradiation will be performed with a GaAlAs diode laser that continuously emits a wavelength of 660 nm with a power of 30 milliwatts (mW). The patients allocated for the group 15 will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 15 Joules/cm2 and a time of 14 seconds per point (0,42 Joules/cm2 per point). During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by four more applications performed every other day, with a total of 5 laser applications. The power of the equipment will be calibrated prior to each application.
2935890|NCT03000413|Experimental|Ketamine|Intravenous ketamine infusion: bolus 2mg per kg and continuous infusion (2mg/kg/h)
2935891|NCT03000413|Active Comparator|Fentanyl|Fentanyl: bolus infusion 1μg per kg and continuous infusion (1μg/kg/h)
2935892|NCT03000400|Experimental|Intervention group|Patient and family members receiving the 8 week family centered intervention, The Traumatic Brain Injury Family System Intervention.
2935893|NCT03000400|Active Comparator|Control group|Family members attend one ongoing psycho-educational group session provided by Oslo University Hospital (OUH).
2935894|NCT03000387|Experimental|Experimental Condition|Participants unable to quit smoking after 2 weeks of treatment with 21mg nicotine patch will get 21mg nicotine patches plus additional active nicotine patches until achieving 7 consecutive days of abstinence over the next 5 weeks; maximum daily patch dose, 84mg/day
2935895|NCT03000387|Placebo Comparator|Placebo Condition|Participant unable to quit smoking after 2 weeks of treatment with 21mg nicotine patch will get 21mg nicotine patches plus placebo patches until 7 consecutive days of abstinence over the next 5 weeks; Maximun daily patch dose, 21mg active nicotine patch plus 3 placebo 21mg patches.
2935896|NCT03000387|Active Comparator|Quit condition|Participants able to quit for 7 consecutive days during the first 2 weeks of treatment with 21mg nicotine patch will continue open label 21mg active nicotine patches for the remaining 10 weeks.
2935897|NCT03000374|Experimental|Panitumumab + mFOLFOX-6|"- Modified FOLFOX-6 regimen: 5-Fluorouracil (5-FU), oxaliplatin and leucovorin will be administered intravenously once every 14 days, according to the mFOLFOX-6 regimen:~Day 1: Oxaliplatin 85 mg/m² in IV infusion of 250-500 mL and leucovorin 200 mg/m² IV, both injected over two hours, followed by 5-FU 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².~- Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.~Treatment will continue until 6 cycles have been administered, followed by surgery, 5 weeks +/- 1 week after the last dose of neoadjuvant treatment"
2935898|NCT03000361|Experimental|Motorized Spiral Colonoscopy|Motorized Spiral Colonoscopy (MSC) with the novel motorized spiral endoscope represents a new technology which offers all of the advantageous options of spiral-assisted endoscopy with a faster and less invasive approach
2935899|NCT03000348|Active Comparator|High Dose, Once per day|Patient takes one oral dose of Cysteamine (high dose) per day, in the morning. The patient takes two oral placebo doses, one at mid-day and one in the evening.
2935900|NCT03000348|Active Comparator|High Dose, Twice per day|Patient takes two oral doses of Cysteamine (high dose) per day, one in the morning and one in the evening. The patient takes one oral placebo dose, at mid-day.
2935901|NCT03000348|Active Comparator|High Dose, Three times per day|Patient takes three oral doses of Cysteamine (high dose) per day, one in the morning, one at mid-day and one in the evening.
2935902|NCT03000348|Placebo Comparator|Placebo|Patient takes three oral doses of placebo, one in the morning, one at mid-day and one in the evening.
2935903|NCT03000348|Active Comparator|Low Dose, Three times per day|Patient takes three oral doses of Cysteamine (low dose) per day, one in the morning, one at mid-day and one in the evening.
2935904|NCT03000348|Active Comparator|Mid-Range Dose, Three times per day|Patient takes three oral doses of Cysteamine (mid-range dose) per day, one in the morning, one at mid-day and one in the evening.
2935905|NCT03000335||Relapse|B-ALL patients who have succumbed to relapse
2935906|NCT03000335||Remission|B-ALL patients who are in remission
2935907|NCT03000322|Experimental|Cooling Vest|During the four-week Treatment Period, participants should use the Cooling Vest two times per day (once in the morning for one hour and once in the evening for one hour.)
2935908|NCT03000309|Other|Apremilast|Apremilast, 30 mg. tablets, two times a day for 16 weeks
2935909|NCT03000296|Experimental|Hematopoietic Stem Cell Transplantation|High doses immunosuppression Cyclophosphamide (200 mg/kg total dose for four days) and rabbit antithymocyte globulin (6.5 mg/kg total dose for four days) followed by unselected autologous hematopoietic stem cell transplantation rescue.
2935910|NCT03000283|Experimental|Conivaptan Treatment Group|All seven patients in this arm will receive conivaptan as described in Interventions.
2935911|NCT03000270|Active Comparator|Prolonged unloading prior to PPCI|Activation of Impella CP for a 30 minute duration prior to primary percutaneous coronary intervention
2935912|NCT03000270|Active Comparator|Immediate unloading prior to PPCI|Activation of Impella CP immediately prior to primary percutaneous coronary intervention
2935913|NCT03000257|Experimental|ABBV-181|"In the Monotherapy Escalation portion of the study, ABBV-181 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Based on available safety, pharmacokinetic, and pharmacodynamic data from the dose-escalation part of the study, participants will be enrolled in tumor-specific dose-expansion cohorts to further evaluate ABBV-181 at a dose level which is at or below the Maximum tolerated dose (MTD). In the Monotherapy Expansion portion of the study, ABBV-181 will be administered in 28-day dosing cycles at either 1 dose per cycle or 2 doses per cycle.~In the Combination portion of the study, ABBV-181 will be administered in combination with Rovalpituzumab Tesirine in 21-day dosing cycles. Based on available safety, PK and PD data from the single agent dose-escalation part of the study, a dose for ABBV-181 will be selected to evaluate in combination with Rovalpituzumab Tesirine."
2935914|NCT03000257|Experimental|ABBV-181 plus Rovalpituzumab Tesirine|Rovalpituzumab Tesirine will be given once every six weeks times two doses and ABBV-181 will be administered every 3 weeks.
2935915|NCT03000231||Healthy Controls|Matched by age, race, gender and BMI to adrenal insufficiency subjects
2935916|NCT03000231||Adrenal Insufficiency Patients|Eligible patients will have either primary adrenal insufficiency or secondary adrenal insufficiency and will be age 18 and older.
2935917|NCT03000218|Experimental|UDCA 8 wks|Day 1 to 56: Ursodeoxycholic acid 300mg bid
2935918|NCT03000218|Experimental|UDCA for 4wks/UDCA+metformin for 4wks|Day 1 to 28: Ursodeoxycholic acid 300mg bid Day 29 to 56: Ursodeoxycholic acid 300mg and Metformin 500mg bid
2935919|NCT03000218|Placebo Comparator|Placebo|Day 1 to 56: Placebo bid
2935920|NCT03000205|Experimental|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder spin
2935921|NCT03000205|Placebo Comparator|Normal Saline|normal saline and Lidocaine as placebo for sham group
2935922|NCT03000192||Breast cancer|Women aged <50 years
2935923|NCT03000192||Gynaecological cancers|Includes: cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer and vulval cancer
2935924|NCT03000192||Non-Hodgkin Lymphoma|Diffuse large B cell
2935925|NCT03000179|Experimental|Avelumab Monotherapy|Participants receive avelumab by IV infusion following pretreatment with H1 blockers and acetaminophen once every 2 weeks.
2935926|NCT03000166|Experimental|intervention group|Participants assigned to the intervention group will receive a 12-week physical activity intervention which includes components of education, negotiated collaboration to set individual physical activity goals during chemotherapy cycles, and tools for self-monitoring of physical activity.
2935927|NCT03000166|No Intervention|usual care group|Participants assigned to the usual care group will receive usual guidance about maintaining physical activity during chemotherapy from their oncology providers.
2935928|NCT03000153|Experimental|Completing the Goals Form|In this arm, client participants will complete the Goals Form in collaboration with their therapists at the start of every session.
2935929|NCT03000153|No Intervention|therapy as usual|In this arm, clients will have therapy as usual.
2935930|NCT03000140|Experimental|High Intensity Interval Training|Cycling on cycle ergometers (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) for 1 min at a subjective intensity of 8-10 points of the modified Borg scale of 1-10 points, and interspersed by inactive (without movement over the bicycle) of 2 minutes as recovery period.
2935931|NCT03000140|Active Comparator|Control group|Pre-hypertensive group was compared with healthy groups in the 2 manin variables systolic/diastolic blood pressure, as well as in other co-variables in pre-post changes. Thus, after the training intervention, and following the R and NR classification, we will compare the NR prevalence between both Pre-hypertensive and Healthy group.
2935932|NCT03000127|Experimental|Single arm crossover|All patients will receive testosterone gel and placebo gel during some months, but the months that they are on each treatment will be unknown to the patient
2935933|NCT03000114|Active Comparator|Percutaneous Needle Aponeurotomy|Percutaneous Needle Aponeurotomy (PNA) involves the surgeon anaesthetizing the skin over the Dupuytren's cord, then using a small gauge needle inserted percutaneously, cutting the cord with the sharp edge of the needle using a sweeping motion. This is repeated up the length of the cord to weaken it, allowing an extension force to be applied over the finger to rupture the cord.
2935934|NCT03000114|Active Comparator|Collagenase Injection|Collagenase Injection (CI) involves the injection of collagenase clostridium histolyticum (0.58 mg), directly into the Dupuytren's cord. The patient then returns to see the surgeon within one week, has local anaesthetic is administered, and an extension force is applied to the affected digit to rupture the already weakened cord.
2935935|NCT03000101|Experimental|Pomegranate juice|The pomegranate juice is 100% pomegranate juice, not from concentrate.
2935936|NCT03000101|Placebo Comparator|Placebo beverage|The placebo beverage consists in water added with sugar and citric acid.
2935937|NCT03000088||60° angle group|intubate using McGrath Videolaryngoscope with 60° angled stylet
2935938|NCT03000088||90°angle group|intubate using McGrath Videolaryngoscope with 90° angled stylet
2935939|NCT03000075|Experimental|Risankizumab high dose|
2935940|NCT03000075|Experimental|Risankizumab low dose|
2935941|NCT03000075|Placebo Comparator|Placebo|
2935942|NCT03000062|Experimental|Intervention group|"12 Family physicians in primary care will constitute the Intervention group. They will enroll 10 patients each from their ordinary practice. The physicians will be provided with a specific course on the treatment model of the study, including how to collect and register data. They will have a detailed manual indicating the content of each visit.~Following recruitment and consent, the patient will meet for the first visit in the study one week later. At this visit the patient will be provided with detailed information on the content and preparation for all meals. Data will be collected.~The manual describes a diet in accordance with official guidelines providing the patient 1600Kcal per day.~The following visits will take place after 4 weeks, 8 weeks, 4 months, 8 months and 12 months from the first visit. Data will be collected at all visits, and also at 6 and 12 months follow-up."
2935943|NCT03000062|No Intervention|Control group|"12 Family physicians in primary care will constitute the Control group. They will enroll 10 patients each from their ordinary practice. The physicians will not be provided with any information of the treatment model of the study but they will have all information about how to collect and register data.~The patients on this group will also sign consent to provide data and therefore they will know about the study but they do not get any specific information about weight loss other than the general information that their physician may tell them.~The patients in the Control Group will be asked to give data on inclusion visit and again 12 months later, and also at 6 and 12 months thereafter (i.e. 0, 12, 18 and 24 months from inclusion)."
2935944|NCT03000036|Other|Cardiovascular Magnetic Resonance|Twenty-seven female patients were imaged in a 3T magnet after consecutively enrolled in the study if they had received a breast cancer diagnosis at the Center for Integral Attention to Women's Health (University of Campinas) and had prescribed endovenous doxorubicin as part of their chemotherapy regimen.
2935945|NCT03000010|Active Comparator|Incisional Wound Vac|We will attach sponges and a suction tube to the incision after surgery. We will leave it on for 72 hours. From then on, patients will get the care that patients normally get after spinal fusion surgery.
2935946|NCT03000010|Active Comparator|Normal Gauze Bandage Group|We will cover patients incision with regular gauze bandages. These are the bandages that patients normally get after spinal fusion surgery. They will be left on for 72 hours.
2935947|NCT02999997|Experimental|Ronnie Gardiner Method (RGM)|Exercising two times/week according to the RGM program in groups of 15 participants (2 groups).
2935948|NCT02999997|No Intervention|Control group|Participants in the control group are instructed to live their ordinary life.
2935949|NCT02999984|Experimental|Treatment|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells
2935950|NCT02999971|Experimental|circuit class therapy in water|CCT on water. The intervention developed in this study will be through the realization of an exercise program in circuit (CCT). One of the groups will receive treatment in the water (intervention group), and the other on land (control group). In both groups, the intervention will be a 7-week class therapy, 3-times weekly, giving a total of 20 sessions.
2935951|NCT02999971|Experimental|circuit class therapy on land|CCT on land. The intervention developed in this study will be through the realization of an exercise program in circuit (CCT). One of the groups will receive treatment in the water (intervention group), and the other on land (control group). In both groups, the intervention will be a 7-week class therapy, 3-times weekly, giving a total of 20 sessions.
2935952|NCT02999958|No Intervention|Control|Sequential culture media without addition of antioxidants
2935953|NCT02999958|Active Comparator|Treatment|Sequential culture media with the addition of antioxidants
2935954|NCT02999945|Active Comparator|SGA-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term)
2935991|NCT02999698||Hidradenitis Suppurativa Group|Patients with hidradenitis suppurativa complete the questionnaires for psychological impact.
2935955|NCT02999945|Other|SGA-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).
2935956|NCT02999945|Active Comparator|IUGR-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
2935957|NCT02999945|Other|IUGR-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).
2935958|NCT02999932|Experimental|Low SpO2 group|SpO2 90-95%, with FiO2 as low as possible.
2935959|NCT02999932|Active Comparator|High SpO2 group|SpO2 96-100%, with FiO2 no lower than 30%.
2935960|NCT02999919|Active Comparator|BMI ≥ 30|BMI ≥ 30
2935961|NCT02999919|Active Comparator|BMI < 30|BMI <30
2935962|NCT02999906|Placebo Comparator|Placebo|Matching placebo (sugar pill)
2935963|NCT02999906|Active Comparator|Active|Oral treprostinil sustained release tablet
2935964|NCT02999893|Experimental|APR-246|"The trial regimen consists of the investigational agent APR-246, along with standard chemotherapy, Cisplatin and 5-FU. A maximum of 8 cycles of treatment will be given.~APR-246 and 5-FU must both commence on Day 1 and given on days 1 to 4 via intravenous infusion over 6 hours, whilst 5-FU must be given as a continuous infusion over 96 hours.~On Days 2-4, APR-246 must be given first via intravenous infusion over 6 hours, then commence cisplatin via intravenous infusion over one hour.~This is a dose-escalation study to determine the maximum tolerated dose (MTD) of the combination therapy. The 3 dose levels are described as follows:~Dose Level 1:~APR-246 Dose: 75mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI~Dose Level 2:~APR-246 Dose: 100mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI~Dose Level -1:~APR-246 Dose: 50mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI"
2935965|NCT02999880|Experimental|Polychromatic layering (Control):|Using and mixing different composite shades, opalescents and intensives.
2935966|NCT02999880|No Intervention|Dual-shade layering (Intervention):|Only two composite resin material shades the opaque dentin composite and enamel shade composite.
2935967|NCT02999867|Experimental|M1 triticale and mung bean|M1: triticale and mung bean as a processed food is assigned to patients at a dose of 50-100 g/d for 30-day dietary intervention.
2935968|NCT02999867|Experimental|M2 adzuki bean|M2: adzuki bean as a processed food is assigned to patients at a dose of 50-100 g/d for 30-day dietary intervention.
2935969|NCT02999854|Experimental|ATIR101|T-cell depleted HSCT from a related, haploidentical donor, followed by IV infusion with ATIR101 at a single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT
2935970|NCT02999854|Active Comparator|PTCy|T-cell replete HSCT from a related, haploidentical donor, followed by IV infusion of post-transplant cyclophosphamide (PTCy) 50 mg/kg/day at 3 and 4/5 days after the HSCT
2935971|NCT02999841|Experimental|Group A|Acarbose
2935972|NCT02999841|Active Comparator|Group B|Vildagliptin
2935973|NCT02999828|Experimental|3.0 EU in Children|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
2935974|NCT02999815|Active Comparator|Human tetanus immunoglobulin|Human tetanus immunoglobulin (Tetagam-P): Injection (prefilled syringe) 250 IU in 1 ml - Intrathecal 500 IU
2935975|NCT02999815|Sham Comparator|Intramuscular antitoxin|Human tetanus immunoglobulin (Tetagam-P): Injection (prefilled syringe) 250 IU in 1 ml - Intramuscular 3000 IU OR Equine antiserum - 21,000 units
2935976|NCT02999802|Experimental|Exercise|Determining the effect of 12 weeks of resistance training exercise on the response of muscle amino acid sensing
2935977|NCT02999789|Active Comparator|Intervention group|After an initial six week run-in period, participants will be randomized to either the intervention group or placebo group. The intervention group will have SMS reminder and audiovisual reminder functions turned on. SMS reminders will be sent twice daily to child's caregiver's cell phone reminding them to administer daily asthma medication. SmartInhaler with reminder function turned on that is attached to Inhaler medication will remind child's caregiver twice daily to administer daily asthma medication.
2935978|NCT02999789|Placebo Comparator|Placebo|After an initial six week run-in period, participants will be randomized to either the intervention group or placebo group. The placebo group will have SMS reminder and audiovisual reminder functions turned off. The SmartInhaler will only function to measure daily adherence. Once intervention group has finished their 6 week period, this group will have intervention turned on.
2935979|NCT02999776|Active Comparator|Standard of care|Daily self-administration of 1 to 5g Daivobet (Calcipotriol 50ug/g +Betamethasone, 0,5mg/g Gel) ointment, which is applied topically once per day for 8 weeks on one pre-selected randomized plaque.
2935980|NCT02999776|Experimental|Laser plus etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
2935981|NCT02999776|Active Comparator|Laser alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
2935982|NCT02999763|Experimental|Abdominal fat reduction treatment|SlimShape treatments will be administered for up to 3 sessions to the abdomen of all study participants.
2935983|NCT02999750|Other|individual therapy|individual therapy
2935984|NCT02999737|Other|Platelet Rich Plasma for 4 sessions|Autologous Platelet Rich Plasma injected in the scalp monthly x 3 then every 3 months x 1
2935985|NCT02999737|Other|Platelet rich plasma for 2 sessions|Autologous Platelet Rich Plasma injected in the scalp every 3 months
2935986|NCT02999724|Experimental|gabapentin|gabapentin 300-600 mg 1 hour preop
2935987|NCT02999724|Placebo Comparator|placebo|placebo capsule(s) 1 hour preop
2935988|NCT02999711|Experimental|Cohort 1|REGN3500 low dose or placebo
2935992|NCT02999685|Active Comparator|Home-base Pulm Rehab w/ Health Coaching|The intervention group starts with 8 weeks of Home-base Pulmonary Rehab with Health Coaching, followed by 8 weeks of observation.
2935993|NCT02999685|Active Comparator|Control/Wait|The Control/Wait group starts with 8 weeks of observation, followed by 8 weeks of intervention (Home-base Pulm Rehab w/ Health Coaching).
2935994|NCT02999672|Experimental|Cohort 1 (UBC)|First six participants with locally advanced (unresectable and not treatable with curative intent) or metastatic UBC will initially receive Regimen A (trastuzumab emtansine at a dose of 2.4 mg/kg qw). An iDMC will assess the safety among the first six participants and decide whether dose will be switched to Regimen B (trastuzumab emtansine at a dose of 3.6 mg/kg q3w).
2935995|NCT02999672|Experimental|Cohort 2 (Pancreatic cancer/cholangiocarcinoma)|First six participants with metastatic pancreatic cancer/cholangiocarcinoma will receive Regimen A (trastuzumab emtansine at a dose of 2.4 mg/kg qw). An iDMC will assess the safety among the first six participants and decide whether dose will be switched to Regimen B (trastuzumab emtansine at a dose of 3.6 mg/kg q3w).
2935996|NCT02999659||Control group|The control group implies patients with non-acute cerebral disease (e.g. cerebral aneurysm without symptoms). The pupilometer data are once collected during ambulant routine examination. The patients do not undergo any further study related examinations.
2935997|NCT02999659||Treatment group|The treatment group implies patients with an acute cerebral disease ensured by CT, MRI or spinal tap. Pupillometry measurements are done during neurological routine examinations. Generally, during the initial diagnosis examination, followed by daily routine measurements and after 3 and 6 month upon hospital discharge.
2935998|NCT02999646|Experimental|MVX-ONCO-1|MVX-ONCO-1 vaccine treatment once weekly starting on week 1 for 4 weeks followed by two additional treatments 2 weeks apart (total 6 treatments over 8 weeks). Each treatment consists of two macrocapsules containing the MVX-1 cell line and lethally irradiated autologous tumor cells.
2935999|NCT02999633|Experimental|Isatuximab|Isatuximab administration every week for 4 or 8 weeks (Induction), followed by administration every 2 weeks (Maintenance). Dexamethasone, acetaminophen, ranitidine, and diphenhydramine will be administered as premedications. - Type: Experimental
2936000|NCT02999620|Active Comparator|Alpha-cycoldextrin|All subjects randomized to receive Alpha-cycoldextrin will orally ingest two tablets containing Alpha-cyclodextrin, with their standardized liquid breakfast (100 micro Ci of [3H]triolein and 20 micro Ci of [14C]tripalmitin). The tablets will be consumed with 150 ml of still water immediately prior to consuming each meal. Subjects will be observed for a period of 48 hours as an in-patient, and then an additional 24 hours as an out-patient. During this time they will undergo a meal fatty acid metabolism study, through blood and fecal sampling, to assess meal fatty acid oxidation and storage.
2936001|NCT02999620|Placebo Comparator|Placebo|All subjects randomized to receive placebo will orally ingest two placebo tablets with their standardized liquid breakfast (100 micro Ci of [3H]triolein and 20 micro Ci of [14C]tripalmitin). The tablets will be consumed with 150 ml of still water immediately prior to consuming each meal. Subjects will be observed for a period of 48 hours as an in-patient, and then an additional 24 hours as an out-patient. During this time they will undergo a meal fatty acid metabolism study, through blood and fecal sampling, to assess meal fatty acid oxidation and storage.
2936002|NCT02999607|Experimental|active transcranial direct current stimulation|Stimulation at three different intensities during FDG-PET scan
2936003|NCT02999607|Sham Comparator|Sham tDCS|Comparator to active arm
2936004|NCT02999594|Experimental|tramadol|50mg tramadol hydrochloride will be used intramuscularly as an experimental drug for evaluating its safety and efficacy as labor analgesic
2936005|NCT02999594|Placebo Comparator|distilled water|2ml distilled water intramuscularly will be used as a placebo.
2936006|NCT02999581|Experimental|C4 Extreme|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine alpha-ketoglutarate, 250 mg vitamin C, 150 mg N-Acetyl-Tyrosine, 135 mg caffeine, 7.5 mg L-Dopa, 30 mg vitamin B3, 10 mg Bitter Orange (Citrus Aurantium) fruit standardized for 30% synephrine (Advantra Z), 0.5 mg vitamin B6, 0.25 mg vitamin B9, and 0.035 mg vitamin B12.
2936007|NCT02999581|Active Comparator|C4 Extreme (without Advantra Z)|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine alpha-ketoglutarate, 250 mg vitamin C, 150 mg N-Acetyl-Tyrosine, 135 mg caffeine, 7.5 mg L-Dopa, 30 mg vitamin B3, 0.5 mg vitamin B6, 0.25 mg vitamin B9, and 0.035 mg vitamin B12.
2936008|NCT02999581|Placebo Comparator|Placebo|One dose of flavored placebo (powder mixed with water)
2936009|NCT02999568||Experimental|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years
2936010|NCT02999568||Control group|Women who practice low level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years
2936011|NCT02999555|Experimental|Aspirated follicular fluid|Follicular fluid aspirated by follicle size and tested for the novel markers after eggs were identified and separated for the purpose of fertilization
2936012|NCT02999542|Experimental|Music|Children will receive music via headphones
2936013|NCT02999542|Experimental|No music|Children will listen to silence via headphones
2936014|NCT02999529|Experimental|Education Group|Participants offered a consent for chemotherapy treatment will watch an educational video.
2936015|NCT02999516|Experimental|Motor imaginary|Intervention with Motor imaginary with video
2936016|NCT02999516|Experimental|Non Motor imaginary|Intervention with Rest without motor imaginary
2936017|NCT02999516|Experimental|tDCS|tDCS stimulation during 20 minutes in the motor cortex.
2936018|NCT02999516|Sham Comparator|tDCS sham|tDCS stimulation during 30 seconds in the motor cortex and then 19 minutes and 30 seconds without any stimulation.
2936019|NCT02999516|Experimental|Neurofeedback|EEG monitoring in real time with positive feedback in the computer screen when participants motor cortex is activated.
2936020|NCT02999516|Sham Comparator|Neurofeedback sham|EEG monitoring in real time with randomized feedback in the computer screen despite the motor cortex activation.
2936021|NCT02999503|Experimental|Nutritional intervention|Patients subject to nutritional education by CINUSA group protocol
2936022|NCT02999503|No Intervention|No intervention|Patients not subject to nutritional education
2936023|NCT02999490|No Intervention|Controls|The controls are intravenous injected of 185 to 370 MBq 18F-FDG.Then,the controls sleep for an hour in a quiet room before scanning.
2936024|NCT02999490|Experimental|Patients|The patients are intravenous injected of 185 to 370 MBq 18F-FDG.Then,the patients sleep for an hour in a quiet room before scanning.
2936025|NCT02999477|Experimental|Nab-Paclitaxel|"2 weeks Nab-Paclitaxel Run in~Biopsy will be performed~Post mono therapy Nab-Paclitaxel administered weekly~Post mono therapy Pembrolizumab administered every 3 weeks~Agents administered for a total of 15 weeks"
2936026|NCT02999477|Experimental|Pembrolizumab|"2 weeks Pembrolizumab Run in~Biopsy will be performed~Post mono therapy Nab-Paclitaxel administered weekly~Post mono therapy Pembrolizumab administered every 3 weeks~Agents administered for a total of 14 weeks"
2936027|NCT02999464|Experimental|Qigong|Experimental group will receive a total of 50 minutes of qigong training 3 times per week and for 16 weeks.
2936028|NCT02999464|Active Comparator|Fitness Exercise|Fitness exercise group will receive home fitness exercise 3 times per week and for 16 weeks.
2936029|NCT02999451|Experimental|snare|snare-assisted POEM
2936030|NCT02999451|Other|knife|knife-assisted POEM
2936031|NCT02999438||Patients with hemodynamically significant heart disease|"Patients with either:~Single ventricle physiology s/p Fontan~Heart failure diagnosed by a cardiologist~Pulmonary hypertension diagnosed by cath"
2936032|NCT02999438||Controls|Healthy controls as defined in inclusion- exclusion criteria
2936033|NCT02999425|Experimental|Education|Educational intervention to study participants
2936034|NCT02999412|Active Comparator|Comprehensive medication review (I1)|
2936035|NCT02999412|Active Comparator|Comprehensive medication review with active follow-up (I2)|
2936036|NCT02999412|Other|Usual care (Control)|
2936037|NCT02999399|Experimental|[D10]phe and Brussels sprouts|All subjects are given 1 microgram [D10]phe before and after consuming Brussels sprouts once daily for 7 consecutive days.
2936038|NCT02999373|Experimental|CBMNC1|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 6 hours after birth ,dose is 25 million cells/kg ，the infusion speed is 4ml/kg/h， 8-12h，
2936039|NCT02999373|Experimental|CBMNC2|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 48 hours after birth ,dose is 25 million cells/kg ，the infusion speed is 4ml/kg/h， 8-12h，
2936040|NCT02999373|Placebo Comparator|Placebo1|0.9% sodium chloride infusion 6 hours after birth ,the infusion speed is 4ml/kg/h， 8-12h，
2936041|NCT02999373|Placebo Comparator|Placebo2|0.9% sodium chloride infusion 48 hours after birth ,the infusion speed is 4ml/kg/h， 8-12h，
2936042|NCT02999360|Experimental|Treatment 1|
2936043|NCT02999360|Active Comparator|Treatment 2|
2936044|NCT02999347||Cases|Women having undergone at least one pregnancy/delivery after their MUS surgery
2936045|NCT02999347||Controls|Every case will be matched with two controls. The controls will be matched with the study cases' age and year of surgery (+- 2 years of age if a perfect match is not obtainable). These controls have not undergone a subsequent pregnancy/delivery.
2936046|NCT02999334|No Intervention|Individual ANC (standard care)|Individual ANC is the standard of care. Women arrive at the clinic and and are provided ANC services on a first come, first serve basis. While waiting women who are present listen to a health lecture. Women then complete laboratory tests, including HIV testing (at the first visit), then meet individually with a midwife for a brief one-on-one physical assessment. Four ANC visits are recommended.
2936047|NCT02999334|Experimental|Group ANC (intervention)|Women in CP-based group antenatal care (intervention) arrive at clinic at the scheduled appointment time and go directly to the group space. The same group of 12 women and the midwife and co-facilitator are present at each session. Women measure and record their own vital signs and weight. Each then has a brief one-on-one assessment with the midwife in the group space room. Instead of health lectures, the group engages in facilitated and interactive discussions using activities. Four ANC visits are recommended.
2936048|NCT02999321|Experimental|0% aspartame (water)|participants will not have any aspartame, this is a control.
2936049|NCT02999321|Experimental|5 mg aspartame|participants will receive 5 mg aspartame in a beverage.
2936050|NCT02999321|Experimental|15mg aspartame|participants will receive 5 mg aspartame in a beverage, and 10mg in capsules.
2936051|NCT02999308|Experimental|single arm|
2936052|NCT02999295|Experimental|Phase 1|Ramucirumab: 8 mg/kg, every two week Nivolumab: 3.0 mg/kg or 1.0 mg/kg (optional), every two weeks
2936053|NCT02999295|Experimental|Phase 2|Ramucirumab: 8 mg/kg, every two week Nivolumab: recommended dose established in the phase 1, every two weeks
2936054|NCT02999282|Experimental|Pretreated|Asymptomatic subjects - 10 days anodal transcranial direct current stimulation
2936055|NCT02999282|Sham Comparator|Preuntreated|Asymptomatic subjects - 10 days sham transcranial direct current stimulation
2936056|NCT02999282|Experimental|FTDtreated|Symptomatic patients - 10 days anodal transcranial direct current stimulation
2936057|NCT02999282|Sham Comparator|FTDuntreated|Symptomatic patients - 10 days sham transcranial direct current stimulation
2936058|NCT02999269|Experimental|600 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
2936059|NCT02999269|Experimental|700 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
2936060|NCT02999269|Active Comparator|800 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
2936061|NCT02999256|Placebo Comparator|Placebo|"130ml serving twice daily (immediately before breakfast and dinner) for 20 days.~Placebo composition: Water (100ml), Cherry Squash Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml)."
2936062|NCT02999256|Experimental|Montmorency Tart Cherry Juice|"130ml serving twice daily (immediately before breakfast and dinner) for 20 days.~MTCJ Composition: 100ml water and 30ml Montmorency tart cherry concentrate (Cherry Active, Sunbury, UK)."
2936063|NCT02999243|Experimental|HIV self-testing|HIV self-testing kits plus harm reduction education materials will be offered to the intervention group.
2936064|NCT02999243|Placebo Comparator|Education|Harm reduction educational materials will be offered to the control group.
2936065|NCT02999230|Active Comparator|Caries Free|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Study toothpaste will be assigned.
2936066|NCT02999230|Placebo Comparator|Caries Free- Placebo|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Marketed Toothpaste will be assigned.
2936225|NCT02998190|Placebo Comparator|Multiple oral doses of placebo|Multiple ascending doses, daily for 14 days
2936067|NCT02999230|Active Comparator|Caries Active|Gums will be examined and caries assessment performed. On some visits Saliva and plaque will be collected. Study toothpaste will be assigned.
2936068|NCT02999230|Placebo Comparator|Caries Active- Placebo|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Marketed Toothpaste will be assigned.
2936069|NCT02999217|Active Comparator|Treatment|1 g of intravenous iron isomaltoside given postoperatively for patients with preoperative anaemia (Hb 90-120 g/l and plasma ferritin<100 mkg/l).
2936070|NCT02999217|Placebo Comparator|Control|The same amount of intravenous saline for patients with preoperative anaemia (Hb 90-120 g/l and plasma ferritin<100 mkg/l).
2936071|NCT02999204|Active Comparator|Vitamin D3 5,000 units per week|Patient receive a dose that is considered within the standard dosing range for Vitamin D3 for one year.
2936072|NCT02999204|Experimental|Vitamin D3 50,000 units per week|Patients receive a more aggressive Vitamin D3 dosing regimen of 50,000 units weekly for the first 3 months. At this point Vitamin D3 levels are measured. If the patient is Vitamin D3 replete (>75 nmol/L) then the dose is reduced to the equivalent of 25,000 units per week for the next 9 months. If the level is below this threshold then 50,000 units per week is continued for the next 9 months
2936073|NCT02999191|Experimental|BI 1467335 (Treatment A)|Tablet under fasted conditions
2936074|NCT02999191|Experimental|BI 1467335 (Treatment B)|Oral solution under fasted conditions
2936075|NCT02999191|Experimental|BI 1467335 (Treatment C)|Tablet under fed conditions
2936076|NCT02999178|Experimental|Nintedanib|
2936077|NCT02999178|Placebo Comparator|Placebo|
2936078|NCT02999165||CPAP group|25 infants undergoing treatment with continuous nCPAP who are making attempts at breast feeding and receiving nasogastric feeds.
2936079|NCT02999165||HHFNC group|25 infants undergoing treatment with continuous HHFNC oxygen who are making attempts at breast feeding and receiving nasogastric feeds.
2936080|NCT02999152|Experimental|Total Body Irradiation|Patient suffering from a malignant blood disease that requires a total body radiation, without (or prior to) a concomitant chemotherapy, according to the following protocol: 2x2 Gray per day, for 3 days. Blood and urines samples will be performed at days 0, 1, 2 and 3 of the treatment plan.
2936081|NCT02999152|Experimental|Partial Body Irradiation|Patient with at least one bone metastasis localized at the pelvis and requiring partial body radiation therapy without associated chemotherapy, according to the following protocol: 4 Gray per day for 5 days will perform blood and urines samples at days 0, 1, 2 and 3 after the beginning of the radiation treatment.
2936082|NCT02999139||ACL Return to Play|A specific training program, with emphasis on hamstring strengthening. There will also be a specificity on pivoting and jumping safely.
2936083|NCT02999139||Gait Retraining|Will receive training that is specific to running. Drills will help enforce a more efficient running form, as well as strengthening important muscle groups such as the hip abductors and adductors.
2936084|NCT02999139||Private Training|Participants will receive a broad training program, targeting all major muscle groups. The goal is to increase muscle strength, mobility and aerobic capacity to reduce the risk of injury.
2936085|NCT02999126|Experimental|Group 1|Patients < 65 years old Propofol 1% TCI induction using plasma concentration, Marsh model (Ke0=0.26 min-1) at 1 mcg/ml, increasing the target concentration by 0.5 mcg/ml every minute until LOC. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. CeLOC propofol concentration will be established and it will be observed for another 30 minutes. If BIS <40 or >65 propofol target concentration will be modified by 0,3 mcg/ml.
2936086|NCT02999126|Experimental|Group 2|Patients ≥ 65 years old Propofol 1% TCI induction using plasma concentration, Marsh model (Ke0=0.26 min-1) at 1 mcg/ml, increasing the target concentration by 0.5 mcg/ml every minute until LOC. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. CeLOC propofol concentration will be established and it will be observed for another 30 minutes. If BIS <40 or >65 propofol target concentration will be modified by 0,3 mcg/ml.
2936087|NCT02999100|Experimental|Group 1 -IH oxytocin|Women with an uncomplicated pregnancy in third stage of labour will be enrolled in the arm. Subjects will receive 400 micrograms (mcg) IH oxytocin. Subjects will be followed up in-person or via telephone within approximately 24 hr post dose and once between 7 days to 14 days
2936088|NCT02999100|Experimental|Group 1 -IM oxytocin|Women with an uncomplicated pregnancy in third stage of labour will be enrolled in the arm. Subjects will receive 10 I.U. IM oxytocin. Subjects will be followed up in-person or via telephone within approximately 24 hr post dose and once between 7 days to 14 days
2936089|NCT02999100|Experimental|Group 2 (IH and IV oxytocin)|Group 2 will enrol healthy, non-pregnant, non-lactating female subjects of childbearing potential, and each subject will participate in 2 dosing sessions. Group 2 will be divided into two cohorts: Cohort A will enrol women on a combined oral contraceptive, and Cohort B will enrol women who are not using a hormonal form of contraceptive. Group 2 subjects will randomized to receive IH oxytocin, and IV oxytocin in a cross fashion. Subjects will be followed up in-person once between 7 days to 21 days
2936090|NCT02999087|Active Comparator|Arm A Patient FIT|"Lead-in phase (Day-8) : no treatment~Concomitant radiotherapy phase : Radiotherapy by IMRT + cisplatin 100mg/m2~Maintenance phase : no treatment until follow-up phase"
2936091|NCT02999087|Experimental|Arm B Patient FIT|"Lead-in phase (Day-8) : Cetuximab 400mg/m2 and avelumab 10mg/kg~Concomitant radiotherapy phase : Radiotherapy by IMRT + cetuximab 250mg/m2 and avelumab 10mg/kg~Maintenance phase : avelumab 10mg/kg every 2 weeks during 12 months"
2936092|NCT02999087|Experimental|Arm C Patient UNFIT|"Lead-in phase (Day-8) : Cetuximab 400mg/m2 and avelumab 10mg/kg~Concomitant radiotherapy phase: Radiotherapy by IMRT + cetuximab 250mg/m2 and avelumab 10mg/kg~Maintenance phase : avelumab 10mg/kg every 2 weeks during 12 months"
2936093|NCT02999087|Active Comparator|Arm D Patient UNFIT|"Lead-in phase (Day-8): Cetuximab 400mg/m2~Concomitant radiotherapy phase: Radiotherapy by IMRT + cetuximab 250mg/m2~Maintenance phase : no treatment until follow-up phase"
2936094|NCT02999074|Active Comparator|Resistance exercise|
2936095|NCT02999074|Active Comparator|Aerobic exercise|
2936096|NCT02999074|Other|Waitlist control|
2936189|NCT02998450|Experimental|Cohort 4|"4 Subjects will receive a single mid dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
2936097|NCT02999048|No Intervention|control group|Patients in the control group received conventional therapy for 17 days.conventional therapy consists of: (1) dehydration therapy by 20%mannitol (Tianjin Bane Medical Drugs Ltd., Co., China.) with the dosage from 125 to 250 ml every 8 h for 7 days depending on their clinically presumed intracranial pressure, (2) therapy to deal with complications including glucose-lowering treatment for hyperglycemia, antihypertensive treatment for hypertension, anti-inflammatory treatment for infection, acid inhibitor for peptic ulcer, and (3) supportive therapy, such as physical cooling, nutritional support, fluid, and electrolyte balance, which was provided as needed.
2936098|NCT02999048|Other|intervention group|Patients in the intervention group received the same conventional therapy as in the control group for 3 days, brain CT was re-scanned at the 4th day, and was then given conventional therapy plus XUESAITONG Injection,which was mainly composed of Panax notoginseng saponins for 14 days from the 4th day.
2936099|NCT02999035||corneal sensitivity measurement|"Air jet aesthesiometry and liquid jet aesthesiometry:~All patients will receive the same intervention of corneal sensitivity measurement with air jet aesthesiometry and liquid jet aesthesiometry.~Thresholds represent the intensity of air / liquid jet that can just be perceived by the patients."
2936100|NCT02999022|Experimental|Lithium carbonate|Lithium carbonate 300mg capsule; once per day for 2 weeks.
2936101|NCT02999022|Placebo Comparator|Lactose placebo|Lactose placebo capsule; once per day for 2 weeks.
2936102|NCT02999009|Other|Trident II Tritanium Acetabular Shell|
2936103|NCT02998996|Experimental|Immunose™ FLU 1%,|15 µg haemagglutinin(HA)/strain and 1% Endocine™
2936104|NCT02998996|Experimental|Immunose™ FLU 2%,|15 µg HA/strain and 2% Endocine™
2936105|NCT02998996|Experimental|Influenza antigen,|15 µg HA/strain
2936106|NCT02998996|Placebo Comparator|Saline (NaCl),|Placebo
2936107|NCT02998996|Active Comparator|i.m. comparator,|15 µg HA/strain
2936108|NCT02998996|Active Comparator|i.n. comparator|
2936109|NCT02998983|Experimental|Racotumomab|Dosage form: intradermal injection. Dosage: 0.4 mg. Frequency: the first 5 doses: biweekly injections; the following 10 doses: monthly injections. Duration: 12 months
2936110|NCT02998970|Placebo Comparator|Placebo|The placebo group acts as a control group. This is in order to objectively isolate empagliflozin's effect on cardiac structure and function as determined by CMR imaging.
2936111|NCT02998970|Active Comparator|Empagliflozin|The study medication (Jardiance) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death. The generic name is empagliflozin and will be provided by Boehringer-Ingelheim. If the patient is randomized into the study drug group patients will receive empagliflozin 10 mg tablets once daily for a duration of 6 months.
2936112|NCT02998957|Experimental|AcuTENS|"Stimulation using a portable TENS electrostimulation device at Dingchuan point using a biphasic rectangular wave with a frequency of 2Hz and a pulse width of 200 ms. The stimulation will be achieved using the highest intensity tolerated by the patient without pain during 40 minuts.~Once a day during 5 consecutive days."
2936113|NCT02998957|Sham Comparator|Sham AcuTENS|"Stimulation using a modified portable TENS electrostimulation device at Dingchuan point with no electrical output, even though the screen will light up and display the same data as in the unmodified device during 40 minuts. Patients in this group will be informed that, due to the frequency of stimulation, it is unlikely that they will feel the electric stimulation.~Once a day during 5 consecutive days."
2936114|NCT02998931|Experimental|Glutamin|Intervention patients will be received enteral formula and glutamine 0.3 g/kg/day given via nasogastric tube as boluses q 4hrs.
2936115|NCT02998931|Placebo Comparator|maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
2936116|NCT02998918|Experimental|PolyResveratrol Supplementation|Participants take 500 mg of PolyResveratrol (100 mg curcumin phytosome, 100 mg quercetin phytosome, 100 mg green tea phytosome, 100 mg trans-resveratrol, 100 mg trans-pterostilbene; Thorne Research) twice daily for one week. Two blood Draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.
2936117|NCT02998918|Experimental|Curcumin Supplementation|Participants take 500 mg of Curcumin phytosome twice daily for one week. Two blood draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.
2936118|NCT02998905|Experimental|NOAC|Apixaban or dabigatran or edoxaban or rivaroxaban
2936119|NCT02998905|Active Comparator|Acetylsalicylic Acid|Acetylsalicylic acid
2936120|NCT02998892|Active Comparator|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 4 weeks. This intervention corresponds to the current recommendations.
2936121|NCT02998892|Experimental|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 10 hours, 5 days/week, by brisk walking for 4 weeks.
2936122|NCT02998879|Experimental|Velmanase Alfa|velmanase alfa 1mg/kg body weight infusion
2936123|NCT02998840|Active Comparator|B244 4 pumps applied to the face|4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
2936124|NCT02998840|Sham Comparator|Vehicle 4 pumps applied to the face|4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
2936125|NCT02998840|Active Comparator|B 244 8 Pumps applied to face and torso|8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
2936126|NCT02998840|Sham Comparator|Vehicle 8 pumps applied to face and torso|8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
2936127|NCT02998827|Experimental|thalidomide|use thalidomide tablet by mouth, every night for at least 6 months
2936128|NCT02998827|Active Comparator|other treatment|the treatment include infliximab, azathioprine or enteral nutrition at least 6 months
2936190|NCT02998450|Experimental|Cohort 5|"4 Subjects will receive a single mid-high dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
2936129|NCT02998814|Active Comparator|acid-etch only|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for acid-etch only will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
2936130|NCT02998814|Active Comparator|self-etch adhesive|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for self-etch adhesive will be treated with self-etch adhesive (AdperTM EasyBond, 3M ESPE) for 10 seconds followed by light curing for 20 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
2936131|NCT02998814|Active Comparator|etch-and-rinse adhesive|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch-and-rinse adhesive will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Then, etch-and-rinse adhesive (Single BondTM, 3M ESPE) will be treated with for 10 seconds followed by light curing for 20 seconds.Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
2936132|NCT02998814|Active Comparator|self-etch adhesive after acid-etch|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for acid etch + self-etch adhesive will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Then, self-etch adhesive (AdperTM EasyBond, 3M ESPE) will be treated with for 10 seconds followed by light curing for 20 seconds.Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
2936133|NCT02998801|Placebo Comparator|Watch video using IPAD|Patient will watch the educational video using an IPAD
2936134|NCT02998801|Active Comparator|Watch video using VR goggles|Patient will watch the educational video using VR goggles
2936135|NCT02998775|Other|6 participants with mild renal impairment|Renal Impairment Mild: creatinine clearance, 50 to 80 milliliters per minute (mL/min)
2936136|NCT02998775|Other|6 participants with moderate renal impairment|Renal Impairment Moderate: creatinine clearance, 30 to 49 mL/min
2936137|NCT02998775|Other|6 participants with severe renal impairment|Renal Impairment Severe: creatinine clearance, 15 to 29 mL/min
2936138|NCT02998775|Other|8 participants normal renal status|Renal status normal as defined by creatinine clearance ≥ 81 mL/min, otherwise age, gender, and smoking characteristics matching renal-impaired participants
2936139|NCT02998775|Other|6 participants with mild hepatic impairment|Hepatic impairment mild: total score on the Child-Pugh classification system between 5 and 6
2936140|NCT02998775|Other|6 participants with moderate hepatic impairment|Hepatic impairment moderate: total score on the Child-Pugh classification system between 7 and 9
2936141|NCT02998775|Other|6 participants with severe hepatic impairment|Hepatic impairment severe: total score on the Child-Pugh classification system between 10 and 15
2936142|NCT02998775|Other|8 participants normal hepatic status|Hepatic status normal, otherwise age, gender, and smoking characteristics matching hepatic-impaired participants
2936143|NCT02998736|Experimental|Intervention|"Cialis 20 mg daily by mouth for 16 day. 5 days prior to surgery, day of surgery and 10 days post surgery.~Influenza vaccine 0.5mL day of surgery"
2936144|NCT02998723|Experimental|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
2936145|NCT02998723|Active Comparator|Late booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback.
2936146|NCT02998723|No Intervention|Control group|The control group will receive no booster at all.
2936147|NCT02998697|Experimental|Treated Group|Systolic heart failure patients received Ferrous Sulfate 200 mg t.i.d for 90 days
2936148|NCT02998697|Placebo Comparator|Control Group|Systolic heart failure patients received placebo oral capsule t.i.d for 90 days
2936149|NCT02998684|Active Comparator|Active Transcranial Direct Current Stimulation|Participants will receive active Transcranial Direct Current Stimulation
2936150|NCT02998684|Sham Comparator|Sham Transcranial Direct Current Stimulation|Participants will receive sham Transcranial Direct Current Stimulation
2936151|NCT02998671|Experimental|Group 1: CJM112 high dose|CJM112 high dose in treatment period 1; CJM112 high dose in extension period 2
2936152|NCT02998671|Experimental|Group 2: CJM112 low dose|CJM112 low dose in treatment period 1; CJM112 low dose in extension period 2
2936153|NCT02998671|Placebo Comparator|Group 3: Placebo, CJM112 low dose or high dose|Placebo in treatment period 1; CJM112 low dose or CJM112 high dose in extension period 2
2936154|NCT02998658|Experimental|Vaginal cuff closure using barbed sutures|Vaginal cuff is closed with barbed sutures
2936155|NCT02998658|Active Comparator|Vaginal cuff closure using conventional sutures|Vaginal cuff is closed with conventional sutures
2936156|NCT02998645|Experimental|Eltrombopag + cyclosporine|Planned duration of treatment with eltrombopag is 6 months (for all patients); the planned duration of treatment with cyclosporine is 30 months (for responder patients).
2936157|NCT02998632|Experimental|Interventional|"Patients will receive 2 gm of amoxicillin 1 hour before surgery. Mouthwash 0.12% chlorhexidine solution for 30 seconds immediately before surgery.~Inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution.~Flap will be reflected in intraoral donor site to completely expose bone. Autogenous bone graft will be obtained and will be ground. MPM (Mineralized plasmatic matrix) will be prepared. Implant fixture/s will be inserted. Uncovered fixture threads and bone defect will be covered by MPM. Osstell will be used to measure fixture primary stability in ISQ units. Sutures will be placed. Sutures will be removed 7 days later. Immediate postoperative CBCT will be performed. Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed."
2936224|NCT02998190|Experimental|Multiple oral doses of EB8018|Multiple ascending doses, daily for 14 days
2936158|NCT02998632|Active Comparator|Comparator|"Patients will receive 2 gm of amoxicillin 1 hour before surgery. Mouthwash 0.12% chlorhexidine solution for 30 seconds immediately before surgery.~The patient will receive inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution Flap will be reflected in intraoral donor site to completely expose bone. Autogenous bone graft will be obtained and will be ground. Implant fixture/s will be inserted. Uncovered fixture threads and bone defect will be covered by autogenous bone graft and covered by titanium membrane.~Osstell instrument will be used to measure and record fixture primary stability in ISQ units.~Sutures will be placed. Sutures will be removed 7 days later. Immediate postoperative CBCT will be performed. Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed."
2936159|NCT02998619||Radiotherapy|Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes
2936160|NCT02998606|Experimental|Study Group|MOVANTIK™ (Naloxegol) 25 mg oral capsule, daily
2936161|NCT02998606|Placebo Comparator|Control Group|Placebo Oral Capsule 25 mg, daily
2936162|NCT02998593|Experimental|extracted red Bahman and white bahman|500 mg of extracted red Bahman and white bahman that is used once a day.
2936163|NCT02998593|Placebo Comparator|Placebo|500 mg of placebo once time a day
2936164|NCT02998580|Active Comparator|Convential Sequential Bilateral rTMS|"LFR followed by HFL.~1 Hz stimulation of the right DLPFC for 600 pulses followed by 10 Hz stimulation of the left DLPFC for 3000 pulses (4 seconds on 26 seconds off for 75 trains). Treatment will occur 5 times per week for 4 to 6 weeks."
2936165|NCT02998580|Experimental|Bilateral Theta Burst Stimulation|"cTBS followed by iTBS.~continuous theta burst stimulation (cTBS) of the right DLPFC for 600 pulses followed by intermittent theta burst stimulation (iTBS) of the left DLPFC for 600 pulses. Treatment will occur 5 times per week for 4 to 6 weeks."
2936166|NCT02998567|Experimental|Escalation|Fixed dose of Pembrolizumab with escalating dose of Guadecitabine to establish the phase 2 recommended dose.
2936167|NCT02998567|Experimental|Expansion|Continuation of the Guadecitabine and Pembrolizumab dose established in arm 1: expansion in the recommended patient population.
2936168|NCT02998554|Experimental|SHP640|Participants instructed to instill 1 drop of SHP640 (0.1 percent [%] Dexamethasone and 0.6% povidone-iodine [PVP-I]) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
2936169|NCT02998554|Placebo Comparator|Placebo|Participants instructed to instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
2936170|NCT02998541|Experimental|SHP640|Instill 1 drop of SHP640 (0.1 percent [%] Dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye 4 times daily (QID) for 7 days.
2936171|NCT02998541|Active Comparator|PVP-I 0.6%|Instill 1 drop of PVP-I ophthalmic solution in each eye QID for 7 days.
2936172|NCT02998541|Placebo Comparator|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
2936173|NCT02998528|Experimental|Nivolumab plus Ipilimumab|Specified dose on specified days
2936174|NCT02998528|Active Comparator|Platinum doublet chemotherapy|Specified dose on specified days
2936175|NCT02998528|Experimental|Nivolumab plus platinum doublet chemotherapy|Specified dose on specified days
2936176|NCT02998515|Experimental|ESWT order: 1.liquid oxygen, 2. concentrator|Patients will start with the endurance shuttle walk test (ESWT) by using supplemental Oxygen from a portable liquid Oxygen device (Companion) and continue on the day after with ESWT by using supplemental Oxygen from a portable concentrator.
2936177|NCT02998515|Experimental|ESWT order: 1. concentrator, 2. liquid oxygen|Patients will start with the endurance shuttle walk test (ESWT) by using supplemental Oxygen from a concentrator and continue on the day after with ESWT by using supplemental Oxygen from a portable liquid Oxygen device.
2936178|NCT02998502|Experimental|Device Group|The Freespira Breathing System (FBS) developed by Palo Alto Health Sciences, Inc, is a portable home device used for breathing biofeedback in adults with PD. FBS has now received FDA clearance for the treatment of PD adults and is currently commercially available and more than 150 therapist have provided the service nationally. However, FBS has not yet been tested for efficacy in a pediatric populations. Due to its portability, FBS may pose an advantage for use in younger age groups, compared to multiple therapy sessions required for CBT or lower acceptability for long-term medication use for adolescent PD. In this pilot intervention study, the efficacy of the FBS system in youth will be tested.
2936179|NCT02998502|No Intervention|Control Group|The device will be given to those in the control group after 8-week baseline period.
2936180|NCT02998489|Experimental|Fast milk advancement|30-40 cc/kg/d of human milk or formula milk administered by orogastric tube or by suction
2936181|NCT02998489|Active Comparator|Traditional milk advancement|20 cc/kg/d of human milk or formula milk administered by orogastric tube or by suction
2936182|NCT02998476|Experimental|Group A INCB050465 (no prior BTK inhibitor)|INCB050465 in subjects who were not previously treated with a BTK inhibitor.
2936183|NCT02998476|Experimental|Group B INCB050465 (prior BTK inhibitor)|INCB050465 in subjects who were previously treated with a BTK inhibitor.
2936184|NCT02998463|Experimental|Snuby® users|This group receives the Snuby® skin-to-skin facilitating garment to use in the first six weeks following birth with their baby. The use of the Snuby® garment is participant led, and used for as long and as often as they wish in the six week period.
2936185|NCT02998463|No Intervention|Conventional Care|This group does not receive any intervention, and collects data on the research outcomes when having conventionally facilitated skin-to-skin contact, using a towel, blanket, or clothing as preferred. Skin-to-skin contact frequency and duration is dictated by the participant.
2936186|NCT02998450|Experimental|Cohort 1|"4 Subjects will receive a single low dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
2936187|NCT02998450|Experimental|Cohort 2|"4 Subjects will receive a single low-mid dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
2936188|NCT02998450|Experimental|Cohort 3|"4 Subjects will receive a single mid-low dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
2936191|NCT02998450|Experimental|Cohort 6|"4 Subjects will receive a single high dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
2936192|NCT02998437|Experimental|Ilaprazole 10mg|"Period 1: Ilaprazole 10mg 1 tab.m one a day~Period 2: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap. twice a day, 6 days Ilaprazole 10mg, one a day at the 5 day"
2936193|NCT02998437|Active Comparator|Clarithromycin 500mg|"Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day~Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at the 5 day"
2936194|NCT02998437|Active Comparator|Amoxicillin 500mg|"Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day~Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at 5 day"
2936195|NCT02998424|Experimental|Propofol 1 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 1 µg/ml at the beginning of induction of general anesthesia for elective surgery.~Pupillary diameter measurement after 10 minutes."
2936196|NCT02998424|Experimental|Propofol 2 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 2 µg/ml at the beginning of induction of general anesthesia for elective surgery.~Pupillary diameter measurement after 10 minutes."
2936197|NCT02998424|Experimental|Propofol 3 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 3 µg/ml at the beginning of induction of general anesthesia for elective surgery.~Pupillary diameter measurement after 10 minutes."
2936198|NCT02998411||AI treatment and dosage|
2936199|NCT02998385|Active Comparator|Radiotherapy|"Arm A~Radiation therapy: 66 to 70 Gy in fractions of 2 Gy, 1 fraction/day, 5 fractions per week.~Radiation therapy will be conducted by conformational intensity modulation radiotherapy (IMRT) or protontherapy. Irradiation by 3D conformational radiotherapy can be discussed on a case by case with the Intergroup Coordinator GORTEC."
2936200|NCT02998385|Experimental|Radiotherapy + concomitant cisplatin|"Arm B Concomitant systemic treatment with cisplatin + radiotherapy~According to standard protocol of concomitant cisplatin 100 mg/m2 IV on day 1 - J22 - 43 (3 maximum cycles).~Radiation therapy: 66 to 70 Gy in fractions of 2 Gy, 1 fraction/day, 5 fractions per week.~Radiation therapy will be conducted by conformational intensity modulation radiotherapy (IMRT) or protontherapy. Irradiation by 3D conformational radiotherapy can be discussed on a case by case with the Intergroup Coordinator GORTEC"
2936201|NCT02998359|Active Comparator|Hemiarthroplasty|A cemented polished double taper stem hemiarthroplasty inserted via an anterior-lateral surgical approach (Zimmer incorporated, UK).
2936202|NCT02998359|Active Comparator|Total hip replacment|A cemented polished double taper stem arthroplasty inserted via an anterior-lateral surgical approach with a cemented acetabular cup (Zimmer incorporated, UK).
2936203|NCT02998333|Active Comparator|Open surgical ankle stabilization|These patients will receive open surgical stabilization of the ankle joint after failed conservative treatment with complaints for at least 6 months.
2936204|NCT02998333|Active Comparator|Arthroscopic surgical ankle stabilization|These patients will receive arthroscopic surgical stabilization of the ankle joint after failed conservative treatment with complaints for at least 6 months.
2936205|NCT02998320|Experimental|Genvoya|Genvoya (E/C/F/TAF) Tablet (oral use) : 150/150/200/10 mg, one tablet each day for 28 days
2936206|NCT02998307|Experimental|Monthly|Receive bedside CPR training monthly
2936207|NCT02998307|Experimental|3 months|Receive bedside CPR training every 3 months
2936208|NCT02998307|Experimental|6 months|Receive bedside CPR training every 6 months
2936209|NCT02998307|No Intervention|Control|No additional training and only performance evaluation after 1 year
2936210|NCT02998294|Experimental|Respiratory monitoring group|
2936211|NCT02998281|Active Comparator|Treatment Group|The treatment group received Inspiratory muscle training (IMT) at 40% of maximal mouth pressure (PImax) by using Threshold IMT and training loads were adjusted to maintain 40% of the PImax weekly. The PImax was measured at supervised sessions each week, and 40% of the measured value was determined as the new training work load.
2936212|NCT02998281|Sham Comparator|Control Group|The control group received sham Inspiratory muscle training (IMT) at a fixed work load, 5% of PImax by using Threshold IMT.
2936213|NCT02998268|Other|Cohort 1|"Subjects in Cohort 1 receive conventional induction chemotherapy with taxol/ carboplatin followed by weekly chemoradiation (taxol/ carboplatin) with pembrolizumab. Following surgery, pembrolizumab is administered every 3 weeks for 1 year.~Pembrolizumab dosing is 200 mg administered as a 30 minute IV infusion."
2936214|NCT02998268|Experimental|Cohort 2|"Subjects in Cohort 2 receive pembrolizumab along with induction chemotherapy with taxol/ carboplatin followed by weekly chemoradiation (taxol/ carboplatin) with pembrolizumab. Following surgery, pembrolizumab is administered every 3 weeks for 1 year.~Pembrolizumab dosing is 200 mg administered as a 30 minute IV infusion."
2936215|NCT02998255|Experimental|Single dose of 2L PEG|2 L of PEG solution was used on the day of colonoscopy.
2936216|NCT02998255|Active Comparator|Split-dose of 4L PEG|Split-dose of 4l PEG was used before and on the day of colonoscopy
2936217|NCT02998242|Active Comparator|RT alone|symptomatic bony metastatic site(s) receive SBRT less than 5 fractions
2936218|NCT02998242|Experimental|RT with apatinib|selected dose administered PO during and after SBRT
2936219|NCT02998229|Experimental|Artisse™ Intrasaccular Device|
2936220|NCT02998203|No Intervention|Conventional phase|During the conventional phase, participants are asked to maintain their usual dietary choices for 40 days.
2936221|NCT02998203|Experimental|Organic phase|During the organic phase, participants are asked to follow strictly the two 20-day organic dietary menus provided to them for 40 days. The organic dietary menus were prepared by a certified dietitian. The meals of the organic phase are prepared by a certified organic restaurant and are delivered to school every day except Sunday. For the meals of breakfast and afternoon snacks, children choose their preferred options for the week on the Friday of the previous week according to a list of organic food items and the products for these meals are delivered on Saturday along with the rest meals. Parents are responsible to pick-up the organic meals from school and ensure that the participating children have access to them.
2936222|NCT02998190|Experimental|Single oral dose of EB8018|Single ascending doses, sequential group design
2936223|NCT02998190|Placebo Comparator|Single oral dose of placebo|Single doses, matching placebo
2936226|NCT02998164|Experimental|Technology-assisted language intervention|This intervention will incorporate augmentative and alternative communication software delivered on iPads into speech-language therapy
2936227|NCT02998164|Active Comparator|usual care|This group will be usual care children are already receiving.
2936228|NCT02998151|Placebo Comparator|Placebo|Placebo pill
2936229|NCT02998151|Experimental|Acamprosate|
2936230|NCT02998151|Experimental|Lovastatin|
2936231|NCT02998151|Experimental|Minocycline|
2936232|NCT02998125||before and after total knee arthroplasty|assess the functional outcome before and 6 months after total knee arthroplasty
2936233|NCT02998112|Placebo Comparator|control|5-ASA 4g/day enema through TET for 1 week; 200ml saline infusion through TET for 3 times every other day in one week
2936234|NCT02998112|Experimental|Study group|5-ASA 4g/day enema through TET for 1 week; 200ml fecal microbiota suspension infusion through TET for 3 times every other day in one week
2936235|NCT02998099|Experimental|Aged 18-45 years|A single dose of IV rivipansel over 20 minutes.
2936236|NCT02998099|Experimental|Aged 65 and older|A single dose of IV rivipansel over 20 minutes.
2936237|NCT02998086|Experimental|Individual (1:1)|Individual, 1:1 version of the Promoting Resilience in Stress Management for Parents (PRISM-P) intervention
2936238|NCT02998086|Experimental|Group|Group-based version of the Promoting Resilience in Stress Management for Parents (PRISM-P) intervention
2936239|NCT02998086|No Intervention|Usual Care|Usual non-directed psychosocial supportive care
2936240|NCT02998073|Experimental|Conduct Disorder|Participants are justice-involved youth with conduct disorder. Participants will receive Stop, Now and Plan Youth Justice Model psychosocial intervention.
2936241|NCT02998073|No Intervention|Control|Participants are healthy teenage males. Participants receive no intervention.
2936242|NCT02998060|Active Comparator|Robot-guided|Robotic guidance (SpineAssist®or Renaissance® (Mazor Robotics Ltd. Caesarea, Israel) will be used for navigation and insertion of pedicle screws.
2936243|NCT02998060|Active Comparator|Navigated|A computer-assisted method of navigation (CT- or 3D-Fluoroscopy-based) will be used for navigation and insertion of pedicle screws.
2936244|NCT02998060|Active Comparator|Freehand|Pedicle screws will be inserted using the freehand technique under fluoroscopic control.
2936245|NCT02998047|Experimental|IV infusion of Lintuzumab AC225|Starting dose - 0.5 μCi/Kg IV infusion of Lintuzumab AC225 on Day 1 of each cycle with dose escalation 1 μCi/Kg or de-escalation to 0.25 μCi/Kg. 1 cycle = 42 days, up to 8 cycles. Re-dosing is done no sooner than 60 days.
2936246|NCT02998034|Experimental|Cemented monoblock hemiarthroplasty|The cemented monoblock hemiarthroplasty is a double tapered polished stem with a hemiarthroplasty head cemented in place (Zimmer incorporated, UK)
2936247|NCT02998034|Experimental|Hyroxyapatite coated prosthesis|the Furlong Hyroxyapatite coated prosthesis (JRI orthopaedics limited UK) is a hydroxyapatite coating uncemented a hip prosthesis with a hemiarthroplasty head. The implant is uncemented.
2936248|NCT02998021|Experimental|Resistance Training - Vibrating Dumbbell|Study participants who are randomized into the vibration exercise group will complete an in-home exercise program using a vibrating dumbbell.
2936249|NCT02998021|Active Comparator|Resistance Training - Standard Dumbbell|Study participants who are randomized into the control exercise group will complete an in-home exercise program using standard dumbbells.
2936250|NCT02998008|Other|Diabetes type 2 patients|diabetes type 2 patients whose cardiac function is tested after 4x4 high intensity interval training
2936251|NCT02998008|Other|Healthy volunteers|healthy volunteers whose cardiac function is tested after 4x4 high intensity interval training
2936252|NCT02997995|Experimental|Immune-attractant/lymphocyte activation|After the screening phase, the patient will receive immune-attractant combined with exemestane for six weeks. After three weeks (+/- 3 days), a tumor biopsy will be done. Patients who present >10% CD8+ cells in the tumor after 3 weeks and remain eligible will be included in the second part of the trial i.e. lymphocyte activation. In this second part, patients will receive durvalumab 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months. The pathological response will be checked by surgery.
2936253|NCT02997982|Experimental|Valaciclovir treatment|Valaciclovir 500Mg Tablet
2936254|NCT02997969|Active Comparator|Group 1: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in the left deltoid at months 0, 1, 3, and 6. They will receive placebo in the right deltoid at months 0 and 1, and the Protein/MF59 vaccine at months 3 and 6. All injections are via needle and syringe.
2936255|NCT02997969|Active Comparator|Group 2: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in the left deltoid at months 0, 1, and 6. They will receive placebo in both deltoids at month 3, and the Protein/MF59 vaccine at months 0, 1, and 6. All injections are via needle and syringe.
2936256|NCT02997969|Placebo Comparator|Group 3: Placebo|Participants will receive placebo in both deltoids at months 0, 1, 3, and 6. All injections are via needle and syringe.
2936257|NCT02997969|Active Comparator|Group 4: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine via Biojector in the left deltoid at months 0, 1, 3, and 6. They will receive placebo in the right deltoid at months 0 and 1, and the Protein/MF59 vaccine at months 3 and 6, via needle and syringe.
2936258|NCT02997969|Active Comparator|Group 5: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine at months 0, 1, and 6, and placebo at month 3, in the left deltoid via Biojector. They will receive placebo at month 3, and the Protein/MF59 vaccine at months 0, 1, and 6, in the right deltoid via needle and syringe.
2936259|NCT02997969|Placebo Comparator|Group 6: Placebo|Participants will receive placebo in the left deltoid via Biojector, and in the right deltoid via needle and syringe, at months 0, 1, 3, and 6.
2936260|NCT02997956|Experimental|Tocilizumab|"Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.~The first part of the trial will be Phase Ib and will enroll 18 participants. Participants will receive TACE on day 1 and Tocilizumab at dose level 1, 2, or 3 on days 1, 29 and 57. Maximum tolerated dose (MTD) of Tocilizumab will be determined.~The second part of the trial will be a Phase II and will enroll 50 subjects. Participants will receive TACE on day 1 and Tocilizumab at the MTD on days 1, 29 and 57."
2936498|NCT02996344|Active Comparator|Didactic training|Behavioral; participants will view the approximately one hour Commitment to Living: Primary Care (CTL:PC) didactic training videos.
2936261|NCT02997943|Experimental|Step 1: Optimal First Line Treatment|"Participants will first be randomized to an optimal first line treatment in order to compare APP vs. APP + coaching. Participants assigned to Step 1 treatment APP will receive a study-specific smartphone application. Participants assigned to Step 1 treatment APP + coaching will receive a study-specific smartphone application plus 12 weekly telephone coaching sessions."
2936262|NCT02997943|Experimental|Step 2: Optimal Strategy to Address Nonresponse|Beginning at week 2, participants who are identified as treatment non-responders will be re-randomized in order to compare two strategies to address non-response: a modest step-up or vigorous step-up treatment augmentation tactic. Step 2 treatment strategy: modest step-up will include provision of an additional mHealth intervention component (push notifications). Step 2 treatment strategy vigorous step-up will include provision of an additional mHealth intervention component (push notifications), plus a traditional weight loss intervention component (coaching, meal replacements). Participants will continue to receive their first line treatment.
2936263|NCT02997930|Experimental|Elderly Hip Fracture|Postoperative assess cognitive function in elderly subjects after fracture hip surgery. Measure function connectivity and DTI (diffusion tensor imaging) via: fMRI. Subjective measures will include: Montreal Cognitive Assessment (MoCA), Digital Clock Drawing Test Command and Copy, Wide Range Achievement Test reading subtest, Hopkins Verbal Learning Test (HVLT), General Depression Scale (GDS)
2936264|NCT02997917|Experimental|Education|Solutions of the five basic tastes (sweet, salty, sour, bitter and umami) and the 3 main components of the probe soup (onion, leek and carrot) will be given every 10 min with a mouthwash after each test. In the real education group, solutions at suprathreshold concentration for detection will be given with a subsequent comment on the flavor and an explanation of the components and preparation of the soup (low temperature cooking to preserve flavors).
2936265|NCT02997917|Sham Comparator|Sham|Solutions of the five basic tastes (sweet, salty, sour, bitter and umami) and the 3 main components of the probe soup (onion, leek and carrot) will be given every 10 min with a mouthwash after each test. In the sham education group solutions at subthreshold concentration for detection with no explanation will be provided.
2936266|NCT02997904|Experimental|Resultz Lice and Egg Elimination Kit|Resultz combing solution, head lice comb and instructions for use in a kit: apply liquid then comb out for 1 hour
2936267|NCT02997904|Placebo Comparator|Placebo Lice and Egg Elimination Kit|20% glycerin combing solution, comb and instructions for use in a kit: apply liquid then comb out for 1 hour
2936268|NCT02997891||intervention group|Patients with primary, unilateral hip osteoarthritis in inpatient orthopedic acute treatment, who have a medical indication of a necessary artificial hip replacement implantation.
2936269|NCT02997891||control group|Volunteers without chronic pain. As a control condition for comparing the variation in cognitive performance and everyday activity the investigators use a group of pain-free and mobility-unrestricted subjects, who do not receive or have an artificial hip.
2936270|NCT02997878|Experimental|PSC patients|Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion.
2936271|NCT02997878|Experimental|AiH patients|Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion.
2936272|NCT02997865|Experimental|Stepped Care for Depression|Participants will receive cognitive behavior therapy for depression, plus the addition of antidepressant medication if symptoms do not improve within 5-10 weeks. The study psychiatrist may choose between the following FDA-approved antidepressant medications: sertraline, escitalopram, bupropion extended release (XL), and mirtazapine. Participants will also receive individually-tailored heart failure self-care education and support
2936273|NCT02997865|No Intervention|Enhanced Usual Care|Participants will receive individually-tailored heart failure self-care education and support. With the participant's permission, his or her personal physician will be notified about the patient's depression. The participant will be asked to discuss depression treatment options with his or her personal physician.
2936274|NCT02997852|Experimental|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
2936275|NCT02997852|No Intervention|Control|Usual care in the intensive care unit.
2936276|NCT02997839|No Intervention|group 2|no intervention
2936277|NCT02997839|Other|group 1|sleep disruption
2936278|NCT02997826|Other|1 to 21-days old child|
2936279|NCT02997813||Cohort 1|All consecutive patients with complete set of data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and plerixafor
2936280|NCT02997813||Cohort 2|All consecutive patients with complete data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and cyclophosphamide
2936281|NCT02997800|Experimental|Esmolol|Esmolol infusion and 1 ml saline infusion
2936282|NCT02997800|Experimental|Labetalol|Labetalol Bolus and saline infusion
2936283|NCT02997800|Active Comparator|Fentanyl|Fentanyl Bolus and saline infusion
2936284|NCT02997787||adenomyosis|First group called adenomyosis was consisted of patients who were pathologically diagnosed pure adenomyosis after hysterectomy
2936285|NCT02997787||leiomyoma|Second group called leiomyoma was consisted of patients who were pathologically diagnosed pure leiomyoma after hysterectomy
2936286|NCT02997787||control|Third group called control group was consisted of healthy patients who were pathologically diagnosed no neoplasm after hysterectomy
2936287|NCT02997774|Active Comparator|Standard Dialysis|Patient will undergo dialysis at 36.5 degrees Celsius to assess if this affects the liver function and perfusion
2936288|NCT02997774|Experimental|Cooler Dialysis|Patient will undergo dialysis at 35 degrees Celsius to assess if this affects the liver function and perfusion
2936538|NCT02996045|Experimental|Treatment|Clinical Decision Support (CDS)
2936289|NCT02997761|Experimental|Treatment (ibrutinib, blinatumomab)|"INDUCTION THERAPY: Patients receive ibrutinib PO QD on days 1-49 of course 1 and days 1-42 of course 2, and blinatumomab IV on days 8-35 of course 1 and days 1-28 of course 2 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Patients with CR/CRi after Induction Therapy receive ibrutinib PO QD on days 1-42 and blinatumomab IV on days 1-28. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2936290|NCT02997748|No Intervention|Observational group|No intervention, standard care
2936291|NCT02997748|Sham Comparator|Sham RIPC|Three cycles of 5- min upper limb sham ischemia
2936292|NCT02997748|Experimental|RIPC-Group 1|Three cycles of 5- min upper limb ischemia
2936293|NCT02997748|Experimental|RIPC-Group 2|Three cycles of 7-min upper limb ischemia
2936294|NCT02997748|Experimental|RIPC-Group 3|Three cycles of 10-min upper limb ischemia
2936295|NCT02997748|Experimental|RIPC-Group 4|Three Cycles of 5-min upper limb ischemia. If there is no response this will be followed by 2 cycles of 10-min upper-limb ischemia
2936296|NCT02997735|Experimental|Electronic Quitline Referral|The electronic quitline referral will be embedded within the Tobacco Treatment CDS tool, a CDS system previously developed to help pediatricians provide smoking cessation counseling and treatment to parents who smoke, modeled off the CEASE intervention, an evidence-based approach for implementing smoking cessation treatment of parents in the pediatric setting. The parental tobacco treatment CDS tool prompts the pediatric clinician to ask the parent about smoking status and assess interest in quitting (at all well-child and acute visits), links to an electronic nicotine replacement therapy prescription for parents interested in quitting, and guides appropriate documentation. Electronic referral to the quitline will be made by clicking an automated link embedded in the tool that will send the parent smokers' names and telephone numbers (entered by the clinician) directly to the Pennsylvania (PA) Free Quitline.
2936297|NCT02997735|Other|Standard of Practice|All procedures implemented in the standard referral approach will be identical to those in the electronic referral approach with the exception of providing the telephone number for the Quitline to the parent (rather than electronic referral). The clinician workflow will be nearly the same, in that the clinician will use the link embedded in the tobacco treatment CDS tool to add the quitline to the patient's discharge paperwork (rather than automatically refer to the quitline).
2936298|NCT02997722|Experimental|Ketamine infusion|Patients admitted to the inpatient psychiatry unit with suicidal ideations who are randomly allocated to this arm of the study will receive ketamine 0.5 mg/kg IV infusion over the course of 45 minutes.
2936299|NCT02997722|Placebo Comparator|Normal Saline infusion|Patients admitted to the inpatient psychiatry unit with suicidal ideations who are randomly allocated to this arm of the study will receive normal saline 0.5 mg/kg IV infusion over the course of 45 minutes.
2936300|NCT02997709|Experimental|COMBINE Patients|"Blood specimen collection~Expanded Prostate Cancer Index Composite-SF-12~Memorial Anxiety Scale for Prostate Cancer patients~International Prostate Symptom Score~Multiparametric MRI (mpMRI) of the prostate~MRI-US fusion guided biopsy"
2936301|NCT02997696|Experimental|Experimental arm 1|ONO-4474 low dose every day for 4 weeks
2936302|NCT02997696|Experimental|Experimental arm 2|ONO-4474 high dose every day for 4 weeks
2936303|NCT02997696|Placebo Comparator|Placebo arm|Placebo matching ONO-4474 every day for 4 weeks
2936304|NCT02997683|Experimental|3-month home based training on whole body vibration platform|This Group will receive a training device to perform their given exercises on
2936305|NCT02997683|Placebo Comparator|3-month home based training on floor|This Group will perform their given exercises at home on the floor
2936306|NCT02997670|Experimental|Main patient cohort|Algorithmic Cardiac Resynchronisation Therapy Optimisation; Patients requiring CRT-D enrolled to receive algorithmic CRT optimisation at their device implantation. They will then be programmed to standard CRT settings for 12 weeks. Assessments will be performed and they will again undergo CRT optimisation using the specified algorithm. This time, they will be programmed to the settings giving maximal cardiac output on echocardiography, as assessed by LVOT VTI. After a further 12 weeks, they will again undergo assessment and the study will terminate.
2936307|NCT02997657|Experimental|Positive Psychotherapy for Smoking Cessation|Smoking cessation treatment that incorporates exercises and text messages derived from positive psychology interventions that are designed to boost positive moods, cognitions, and behaviors.
2936308|NCT02997657|Active Comparator|Standard smoking cessation treatment|Smoking cessation counseling that provides support and problem solving skills for avoiding smoking.
2936309|NCT02997644|Experimental|Video Education|Video education delivered on a tablet computer
2936310|NCT02997644|Placebo Comparator|Usual Care Group|Regular information about opioid usage they typically receive from their surgeon.
2936311|NCT02997631|Experimental|MEDi Distraction|The intervention will be the use of the MEDi robot. The robot will be at the child's eye level, and will be programmed to introduce itself, interact with the child, and make encouraging comments about how brave he/she was. The duration of its actions will coincide with the length of the procedure (approximately 5-8 minutes).
2936312|NCT02997631|No Intervention|Standard Care|The control group will receive standard care, which generally includes the use of topical anesthetic cream. This comparison is based on the pragmatic preferences of physicians at the Stollery Children's Hospital as well as precedent in the literature. Overall, it is felt that any new intervention (e.g., the MEDi robot) should be compared to what is currently in practice (i.e., standard care), as no single distraction therapy is consistently and routinely employed in EDs at this time.
2936313|NCT02997618|Active Comparator|Control|"1. Usual care (control)~Usual care given to patients on AAA surveillance. This includes six-monthly or annual ultrasound measurements of AAA, attendance to surveillance clinic and written (APPENDIX A) and verbal advice on managing cardiovascular risk. This advice will be based on current widely available NHS patient information15 and consists of the following information with regard to:~Smoking Exercise Weight Diet"
2936350|NCT02997332|Experimental|Patients with squamous cell carcinoma of the oral cavity,|The aim is to evaluate safety, PK and pharmacodynamics of durvalumab in adult patients with squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx previously untreated, with indication of induction chemotherapy.
2936351|NCT02997319||Night Shift-Workers|
2936314|NCT02997618|Experimental|Community Based Exercise Programme|"Community based-exercise (in addition to usual care) with the choice of either:~Home-based exercise training Participants choosing to exercise at home will follow the programmes intended for this setting, with each exercise designed to be possible without the need for specialist equipment.~Gym-based exercise training Participants will exercise at their nearest Life Leisure LTD gym, following one of the instructor designed programmes , using a combination of aerobic and resistance equipment, as well as simple floor exercises.~Duration and Frequency At least 50 minutes of exercise per day on three non-consecutive days of the week for 20 weeks."
2936315|NCT02997605|Active Comparator|Glucocorticoid (GC) tapering|"GC tapering group: patients will be asked to taper prednisone taken every morning at 8.00 AM by decreasing the daily dose by 1 mg every month as soon as they are in remission or Low Disease Activity (LDA). In addition they will receive a placebo of 20 mg/day of hydrocortisone (10 mg at 8.00 AM, 10 mg at 12.00 AM) for 3 months then 10 mg/day (at 8.00 AM) of hydrocortisone placebo for 3 months before discontinuing the hydrocortisone placebo."
2936316|NCT02997605|Active Comparator|Hydrocortisone replacer|"Hydrocortisone replacer group: patients will replace prednisone with 20 mg of hydrocortisone on a daily basis (10 mg at 8.00 AM, 10 mg at 12.00 AM) for 3 months then 10 mg daily (at 8.00 AM) for 3 months then stop as soon as they are in remission or LDA, as well as a prednisone placebo (at 8.00 AM) with a schedule to taper the prednisone placebo by 1mg/day every month until discontinuation."
2936317|NCT02997592|Experimental|SpinCare|Patients with partial thickness burns treated with the SpinCare dressing
2936318|NCT02997579|Experimental|patellar resurfacing|patellar resurfacing TKA
2936319|NCT02997579|No Intervention|patellar non-resurfacing|patellar non-resurfacing TKA
2936320|NCT02997566||Autistic Disorder|Age: 3 to 11 years-old Gender: male and female Autism Spectrum Disorder
2936321|NCT02997566||Typical|Age: 3 to 11 years-old Gender: male and female Typical
2936322|NCT02997553|Experimental|sentinel lymph node detection|"Each patient receive both injections of Technetium99 (standard care) and indocyanine green.~The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery."
2936323|NCT02997540||female breast ultrasound exam|females with at least one benign or probably benign mass, up to 2 cm in size, in one breast, detected during a standard-of-care breast ultrasound examination
2936324|NCT02997527|Experimental|Intraluminal impedance testing|"During the participant's clinical endoscopy the 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope.~The catheter (tiny tube) will be placed through the endoscope in your esophagus 1 cm above where your stomach and esophagus meet for 5 seconds.~At 2 cm above where your stomach and esophagus meet the catheter will be placed for 5 seconds~And at 3 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds.~At 4 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds.~At 5 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds."
2936325|NCT02997514|Active Comparator|Intensive Solution Focused Coaching|Participants will engage in 5 solution focused coaching sessions, each up to 60 minutes in duration
2936326|NCT02997514|Active Comparator|Solution Focused Coaching|Participants will engage in 1 solution focused coaching session up to 60 minutes in duration
2936327|NCT02997501|Experimental|AZD9291|Single arm of AZD9291, starting dose of 80mg
2936328|NCT02997488||McGrath|McGrath Videolaryngoscope
2936329|NCT02997488||Pentax|Pentax Airwayscope
2936330|NCT02997475||Women with Bulimia Nervosa|
2936331|NCT02997475||Women Healthy Controls|
2936332|NCT02997462||Heart Failure|"Heart Failure patients admitted to the ICU or Heart Failure Service.~No changes in service-directed plan of care for patients."
2936333|NCT02997462||Healthy Control|Healthy, age-matched controls.
2936334|NCT02997449||NSCLC, SABR, nodal staging|Patients with a clinical or pathological diagnosis of Non-Small Cell Lung Cancer (NSCLC), and who are medically inoperable or refuse surgery, are eligible if Stereotactic ablative radiotherapy (SABR) is recommended by a multi-disciplinary tumor board. All patients undergo complete mediastinal and hilar staging procedure (EBUS+EUS-B). Pre endoscopy imaging data will be compared with endosonography data.
2936335|NCT02997436|Experimental|PAD patients|"Patients referred for vascular ultrasound investigation for suspicion of peripheral artery disease (PAD).~Intervention is measurement of microvascular response to current application on the skin by Laser speckle flowmetry"
2936336|NCT02997410|Experimental|Ozone|Ozone application to the greatest points of pain in the related muscle, 3 times per week for 2 weeks
2936337|NCT02997410|Placebo Comparator|Placebo|Sham ozone application to the greatest points of pain in the related muscle, 3 times per week for 2 weeks
2936338|NCT02997410|Experimental|Occlusal splint|Occlusal splint use every night over a period of 4 weeks.
2936339|NCT02997397||tourniquet (+)|The cases in which the tourniquet technique is used
2936340|NCT02997397||tourniquet(-)|The cases in which the tourniquet technique is not used
2936341|NCT02997384||General practitioner|
2936342|NCT02997384||gynecologist|
2936343|NCT02997384||radiologist|
2936344|NCT02997371|Placebo Comparator|Placebo|Isotonic saline administered as an injection and infusion
2936345|NCT02997371|Experimental|1.5 g Kineret|Kineret provided as a 500 mg injection followed by a 1g infusion.
2936346|NCT02997371|Experimental|3.0 g Kineret|Kineret provided as a 500 mg injection followed by a 2.5g infusion.
2936347|NCT02997358|Active Comparator|Doxorubicin|6 cycles - 1 cycle every 3 weeks (day 1 to day 21) On day 1: Doxorubicin 75 mg/m² IV
2936348|NCT02997358|Experimental|doxorubicin + trabectedin followed by maintenance trabectedin|"Doxorubicin + trabectedin 6 cycles - 1 cycle every 3 weeks (day 1 to day 21) Doxorubicin 60 mg/m² IV D1, then Trabectedin 1.1 mg/m² per CIV 3 hours D1. Surgery for residual disease is possible after 6 cycles (in case of non evolutive disease)~In case of response or stable disease after 6 cycles 3-weeks cycle until disease progression or for a maximum of 12 months of treatment (maximum 17 cycles in maintenance therapy), whichever occurs first Trabectedin 1.1 mg/m² per CIV 3 hours"
2936349|NCT02997345||PPROM (Preterm Premature Rupture of Membranes)|PPROM / Preterm Premature Rupture of Membranes <37 weeks
2936352|NCT02997319||Day Workers|
2936539|NCT02996045|No Intervention|Control|Will not receive Clinical Decision Support (CDS)
2936353|NCT02997306|Experimental|Superior/Medial Running Sutures|In this cohort, the running sutures will be randomized to be oriented on Superior/Medial half of the scar, and the remaining half of the scar will be closed with simple interrupted sutures.
2936354|NCT02997306|Experimental|Inferior/Lateral Running Sutures|In this cohort, the running sutures will be randomized to be oriented on Inferior/Lateral half of the scar, and the remaining half of the scar will be closed with simple interrupted sutures.
2936355|NCT02997293||Enhanced Recovery|Those subjects who had major colorectal surgery at the University of Arkansas for Medical Sciences after Enhanced Recovery After Surgery implementation, between the dates of June 1, 2015 to November 30, 2016
2936356|NCT02997293||pre-Enhanced Recovery|Those subjects who had major colorectal surgery at the University of Arkansas for Medical Sciences prior to Enhanced Recovery After Surgery implementation between the dates of January 1, 2014 to December 31, 2014
2936357|NCT02997280|Experimental|Ruxolitinib treatment|Ruxolitinib 10 mg bid for adults and children with body weight > 40 kg, 0.15 mg/kg bid for children with body weight < 40 kg.
2936358|NCT02997267|Experimental|Early closure|Closure of the ileostomy 14 days after the primary operation, in which it was created.
2936359|NCT02997267|Active Comparator|Late closure|Closure of the ileostomy more than 90 days after the primary operation, in which it was created.
2936360|NCT02997241|Other|high genetic risk and high clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
2936361|NCT02997241|Active Comparator|low genetic risk but high clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method，randomized design，and chemotherapy for colorectal carcinoma
2936362|NCT02997241|Active Comparator|high genetic risk but low clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
2936363|NCT02997241|Other|low genetic risk and low clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
2936364|NCT02997228|Active Comparator|Arm I (bevacizumab, mFOLFOX6)|Patients receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of courses 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeat every 2 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity. Courses of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
2936365|NCT02997228|Experimental|Arm II (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 courses in the absence of disease progression or unacceptable toxicity.
2936366|NCT02997228|Experimental|Arm III (atezolizumab, bevacizumab, mFOLFOX6)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 courses in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 courses 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity. Courses of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
2936367|NCT02997215|Experimental|intravenous lidocaine|intravenous lidocaine 1.5mg/kg during induction then infused at 2mg/kg/h until the end of procedure.
2936368|NCT02997215|Placebo Comparator|saline placebo|same amount volume saline infusion
2936369|NCT02997202|Experimental|Gilteritinib|Participants will take gilteritinib once daily for continuous daily dosing.
2936370|NCT02997202|Placebo Comparator|Placebo|Participants will take placebo once daily for continuous daily dosing.
2936371|NCT02997189|Active Comparator|OTO-104|One of the subject's ears will receive up to three administrations of study drug prior to cisplatin-based therapy
2936372|NCT02997189|No Intervention|Control|The ear not receiving OTO-104 will receive no treatment
2936373|NCT02997176|Experimental|Group A (control, normal hepatic function)|
2936374|NCT02997176|Experimental|Group B (mild hepatic dysfunction)|
2936375|NCT02997176|Experimental|Group C (moderate hepatic dysfunction)|
2936376|NCT02997176|Experimental|Group D (severe hepatic dysfunction)|
2936377|NCT02997163|Experimental|Group A (control, normal renal function)|
2936378|NCT02997163|Experimental|Group B (mild renal impairment)|
2936379|NCT02997163|Experimental|Group C (moderate renal impairment)|
2936380|NCT02997163|Experimental|Group D (severe renal impairment)|
2936381|NCT02997150|Experimental|IL-2 low dose|
2936382|NCT02997137|Active Comparator|BOT-01|Dietary supplement: specific amino acid composition with micronutrients
2936383|NCT02997137|Placebo Comparator|Placebo|Placebo contains no amino acids and no micronutrients and is identical in appearance and solution properties
2936384|NCT02997124|Experimental|Local Infiltration with TAP block|Ultrasound guided Transversus Abdominis Plane block is administered intraoperatively using 0.2% Ropivacaine.
2936385|NCT02997124|Experimental|Local Infiltration only|Local Infiltration with 0.2% Ropivacaine.
2936386|NCT02997111|Other|Energy drink|Single group study. Platelet function analyzed with PFA-100 before and 60 minutes after ingestion of 250 ml sugar-free energy drink
2936387|NCT02997098||Patients undergoing hepatectomy|Patients undergoing hepatectomy, or liver resection, for a non-transplant indication.
2936388|NCT02997085|Experimental|Live-Action 360° Video Virtual Reality|
2936389|NCT02997085|Active Comparator|CGI 360° Video Virtual Reality|
2936390|NCT02997085|No Intervention|Waitlist|Participants randomized to the waitlist group will complete all study procedures except the VR exposure. After completion of the study visit, participants in the waitlist condition will be given the option of viewing either the Live-Action 360° 3D HD VVR or the CGI 360° 3D VVR.
2936391|NCT02997059|Experimental|Fluconazole|200mg per day for 6 months
2936392|NCT02997059|Placebo Comparator|Placebo|One capsule per day for 6 months
2936393|NCT02997046|Other|Pre-transplant assessment|"CTA abdominal and aortoiliac vasculature before transplantation~FeMRA abdominal and aortoiliac vasculature & CMR before transplantation"
2936494|NCT02996370|Active Comparator|Test group- ı shape incision|Second stage surgery was made I shape incision technique .
2936394|NCT02997046|Other|Mapping & surveillance (for fistula)|"US vascular mapping before fistula creation~6 week US fistula arm~FeMRA fistula arm/central veins & CMR before fistula creation and at 6 weeks"
2936395|NCT02997046|Other|Mapping & surveillance (for graft)|"US vascular mapping before graft creation~6 week US graft arm~FeMRA fistula arm/central veins & CMR before graft creation and at 6 weeks"
2936396|NCT02997033||Total study cohort|
2936397|NCT02997020||CRS Patients|Endoscopically-directed sinus potential difference (EDSPD) will be conducted in either the operating room or in the rhinology clinic setting to quantify CFTR activity in the sinus cavities. The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
2936398|NCT02997020||Control Patients|Endoscopically-directed sinus potential difference (EDSPD) will be conducted in either the operating room or in the rhinology clinic setting to quantify CFTR activity in the sinus cavities. The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
2936399|NCT02997007|Experimental|MCI-active|Patients will receive verum tDCS over the angular gyrus on five consecutive days.
2936400|NCT02997007|Sham Comparator|MCI-sham|Patients will receive sham tDCS over the angular gyrus on five consecutive days.
2936401|NCT02997007|Experimental|Healthy Old-active|Participants will receive verum tDCS over the angular gyrus on five consecutive days.
2936402|NCT02997007|Sham Comparator|Healthy old-sham|Participants will receive sham tDCS over the angular gyrus on five consecutive days.
2936403|NCT02996981||Cranberry group|Patients underwent pelvic floor gynecologic surgery performed by a physician at Cincinnati Urogynecology Associates, TriHealth Inc between April 2016 and September 2016 and discharged home with an indwelling urinary catheter following the surgery. This group of people had cranberry juice capsules prescribed.
2936404|NCT02996981||No cranberry group|Patients underwent pelvic floor gynecologic surgery performed by a physician at Cincinnati Urogynecology Associates, TriHealth Inc between April 2015 and September 2015. This group of people did not have cranberry juice capsules prescribed.
2936405|NCT02996968|Experimental|Self-removal group|The patients randomized to the self-removal group will be provided with a diagrammatic handout and will be instructed to remove their indwelling urinary catheter at home on the morning of Postoperative day 7.
2936406|NCT02996968|No Intervention|Office-removal group|The patients randomized to the office-removal group will visit the office for a repeat voiding trial on postoperative day 6-8 (postoperative day 7 will be encouraged). At this visit, the patients will undergo a backfill voiding trial.
2936407|NCT02996955|Experimental|SoSup group|usual care will be provided and social support and treatment of illness perceptions and activity advice and wearing the activ8
2936408|NCT02996955|Active Comparator|C group|usual care will be provided and treatment of illness perceptions and activity advice and wearing the Activ8
2936409|NCT02996942||Replacement therapy|Hemophilia A receiving replacement therapy (prophylaxis or on demand)
2936410|NCT02996929|Experimental|Study group|Subjects who are scheduled for CIED lead extraction with the LC system
2936411|NCT02996916|Active Comparator|Olmesartan|Olmesartan 10-40mg daily
2936412|NCT02996916|Active Comparator|Amlodipine|Amlodipine 2.5-10mg daily
2936413|NCT02996890|Experimental|High dose - single shot|MV-ZIKA, high dose, one vaccination, day 0
2936414|NCT02996890|Experimental|Low dose|MV-ZIKA, low dose, two vaccinations, day 0 and day 28
2936415|NCT02996890|Experimental|High dose|MV-ZIKA, high dose, two vaccinations, day 0 and day 28
2936416|NCT02996890|Placebo Comparator|Placebo|Physiological saline, two treatments
2936417|NCT02996877||Guideline Directed Medical Therapy|Patients who have an initial treatment strategy of using guideline-directed medical therapy only.
2936418|NCT02996877||Percutaneous Coronary Intervention|Patients who will have a Percutaneous Coronary Intervention as the initial treatment strategy along with guideline directed medical therapy.
2936419|NCT02996864|Experimental|Healthy Detours App|Participants will be encouraged to use the Healthy Detours app daily to track food, physical activity, and sleep.
2936420|NCT02996864|Placebo Comparator|Fat Secret App|Participants will be encouraged to use the FatSecret application daily to track food and physical activity.
2936421|NCT02996838|Experimental|TQ-B3234|TQ-B3234 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2936422|NCT02996825|Experimental|Treatment (IMGN853, gemcitabine hydrochloride)|Patients receive mirvetuximab soravtansine IV on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
2936423|NCT02996812|Active Comparator|Dose A|Subcutaneous injection of Dose A of Exendin (9-39)
2936424|NCT02996812|Active Comparator|Dose B|Subcutaneous injection of Dose B of Exendin (9-39)
2936425|NCT02996812|Active Comparator|Dose C|Subcutaneous injection of Dose C of Exendin (9-39)
2936426|NCT02996812|Active Comparator|Dose D|Subcutaneous injection of Dose D of Exendin (9-39)
2936427|NCT02996799|No Intervention|Deferred Cord Clamping|Neonate is held at the level of placenta (level of introitus (vaginal delivery ) and mother's thigh or operating table (C/S) and cord clamping is deferred for 60 seconds.
2936428|NCT02996799|Experimental|Umbilical cord milking|Manually stripping 20cm of cord segment toward the umbilicus over a period of 2-3 seconds three times before cord clamping.
2936429|NCT02996786|Experimental|Danggui Buxue Tang group|Danggui Buxue Tang group receive orally supplementation of 7.5 g/day of Danggui Buxue Tang for 10 days
2936430|NCT02996786|Placebo Comparator|Placebo group|Placebo group receive orally supplementation of 7.5 g/day of placebo for 10 days
2936431|NCT02996773|Experimental|Cyclophosphamide and Bendamustine|Several dose levels are planned to gradually decrease cyclophosphamide and replace with bendamustine on Day 4+ post-transplant.
2936432|NCT02996760|Experimental|Endometrium with less than 5mm|"Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.~Less than 5mm despite 10 days with standard doses of estrogen"
2936433|NCT02996760|No Intervention|Endometrium with more than 5mm|"Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.~More than 5mm despite 10 days with standard doses of estrogen"
2936434|NCT02996721|No Intervention|Standard of Care|Patients randomized to the standard of care arm will have a 25[OH] Vit D test performed, a sample taken and stored for future tests, and completion of a PHQ-9 depression survey at baseline and at study conclusion. No other contact is planned with the standard of care patients. Follow-up will be done by the querying of electronic records, which includes any 25[OH] Vit D testing, use of vitamin D supplementation, and outcomes.
2936435|NCT02996721|Experimental|Treatment|Patients randomized to the treatment arm will have a 25[OH] Vit D test performed, a sample taken and stored for future tests, and completion of a PHQ-9 depression survey. If at baseline a patient has a 25[OH] Vit D >40 ng/mL then follow-up testing will occur 1 year from baseline and the patient will continue current treatment strategy (no supplementation or current supplementation dosage). If baseline 25[OH] Vit D levels are <40 ng/mL then the patient will initiate or increase dose and return in 3 months (±15 days) to determine 25[OH] Vit D level. At 3 months, if 25[OH] Vit D >40 ng/mL then current dose should be kept and the patient will return in 1 year for follow-up testing. However, if 25[OH] Vit D <40 ng/mL then patients should double current dose and test again in 3 months. This should occur until 25[OH] Vit D reaches a level >40 ng/mL and once achieved, the patient will return in 1 year for follow-up 25[OH] Vit D testing.
2936436|NCT02996708||Group with teleconsultation - before period|
2936437|NCT02996708||Group without teleconsultation - before period|
2936438|NCT02996708||Group with teleconsultation - after period|
2936439|NCT02996708||Group without teleconsultation - after period|
2936440|NCT02996695|Experimental|204,800 PfSPZ of PfSPZ Challenge|204,800 PfSPZ of PfSPZ Challenge every 4 weeks x 3 doses by DVI, n=31
2936441|NCT02996695|Placebo Comparator|NaCl placebo|NaCl placebo every 4 weeks x 3 doses by DVI, n=31
2936442|NCT02996682|Experimental|SOF/VEL|SOF/VEL for 12 weeks
2936443|NCT02996682|Experimental|SOF/VEL + RBV|SOF/VEL + RBV for 12 weeks
2936444|NCT02996669||Autism Spectrum Disorder|During Screening Visits, the Autism Diagnostic Observational Schedule (ADOS) will be administered to confirm diagnosis. Criteria for group inclusion is: diagnosis of Autism Spectrum Disorder based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the Autism Diagnostic Observation Schedule (ADOS-G), and the Autism Diagnostic Interview-Revised, short form (ADI-R). Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
2936445|NCT02996669||Typical Development|Typically Developing (TD) participants from each site will be roughly matched by age and sex to the ASD group.
2936446|NCT02996656|Active Comparator|Cefazolin|During an open shoulder surgery, the Cefazolin will be administered to some patient. The Cefazolin is a first generation cephalosporin. It is a beta lactam which targets gram positive cocci and some gram negative bacilli. The INESS Antibiotic Prophylaxis in Orthopedic Guide recommends the use of Cefazolin at induction for all orthopaedic procedure with implantation of internal fixation device. The dosage is 2g intravenous if the patient weights less than 120kg or 3g if the patient weights more than 120kg. The dose should be repeated if the procedure lasts for more than three hours or if the blood loss is greater than 1500mL.
2936447|NCT02996656|Experimental|Ceftriaxone|During an open shoulder surgery, the Ceftriaxone will be administered to some patient. The Ceftriaxone is a third generation cephalosporin. It targets gram positive cocci such as staphylococcus and streptococcus, gram negative bacilli and some anaerobes, including P. acnes. The prophylactic dose is of 2g IV given a minimum of 30 minutes prior to skin incision. It is effective 12h so no other dose is needed during surgery.
2936448|NCT02996643|No Intervention|Traditional method|The traditional brace design method will be used to design a spinal brace.
2936449|NCT02996643|Active Comparator|Intervention|A custom Providence brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
2936450|NCT02996630|Other|Healthy fetuses|Pregnant patients carrying a healthy fetus. Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging and bailey test.
2936451|NCT02996630|Other|Congenital Hearth Disease|Pregnant patients carrying a fetus with a moderate-severe congenital heart disease Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging, Surgical intervention, brain monitoring and bailey test.
2936452|NCT02996617|Active Comparator|rhG-CSF regimen|Patients weren't preventive use of rhG-CSF（ruibai 100ug）.If their WBC≤1×10^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10^ 9/L for total 4 courses.
2936453|NCT02996617|Experimental|Pegylated rhG-CSF regimen|Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle for total 4 courses.
2936454|NCT02996604|Experimental|Low-He point(ST36)|Zusanli (ST36, the Low-He point of stomach) is the most important point for gastrointestinal disorder, including functional dyspepsia. Everyone in the group will be punctured at unilateral Zusanli.
2936455|NCT02996604|Experimental|Mu point(CV12)|Zhongwan (CV12, the Mu point of stomach) is also good at regulating gastric function. Everyone in the group will be punctured at Zhongwan.
2936456|NCT02996604|Active Comparator|He-Mu-point combination(ST36 and CV12)|In traditional Chinese acupuncture theory，synergistic effect can be produced by acupoints combination and the He-Mu-point combination is a classical acupoints combination formula for gastrointestinal diseases. Everyone in the group will be punctured at unilateral Zusanli and Zhongwan.
2936457|NCT02996591|Active Comparator|Spinal anesthesia with popliteal and adductor canal blocks.|Ultrasound (US) guided sciatic nerve blocks in the popliteal fossa and adductor canal block with 25 mL and 10 mL, respectively, of 0.25% bupivacaine (plus 2 mg preservative-free (PF) dexamethasone / 30 ml), performed under procedural IV sedation protocol. IV sedation protocol: midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg, + propofol as needed. Spinal protocol: 45-60 mg 1.5% mepivacaine, depending on the expected case duration (45 mg for cases with projected duration 1-2 hours, 60 mg for cases with projected duration 2-3 hours). Intraoperative sedation maintained with propofol infusion and ketamine, 10 mg/hr.
2936495|NCT02996370|Active Comparator|Control group- midcrestal incision|In the control group second stage surgery was made using the conventional method, midcrestal technique.
2936458|NCT02996591|Active Comparator|General anesthesia with popliteal and adductor canal blocks.|Ultrasound (US) guided sciatic nerve blocks in the popliteal fossa and adductor canal block with 25 mL and 10 mL, respectively, of 0.25% bupivacaine (plus 2 mg preservative-free (PF) dexamethasone / 30 ml), performed under procedural IV sedation protocol. IV sedation protocol: midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg, + propofol as needed. General anesthesia protocol: After induction with propofol and insertion of the LMA, anesthesia maintained with titrated propofol infusion, sevoflurane, ketamine 10 mg/hr.
2936459|NCT02996578|Active Comparator|Solid Matrix - Intervention|"Dietary Supplement: polyphenol rich chocolate bar~17.5g of commercially available dark chocolate will be consumed daily for 8 weeks"
2936460|NCT02996578|Active Comparator|Powder Matrix - Intervention|"Dietary Supplement: polyphenol rich cocoa powder~6g of commercially available cocoa powder (provided as 6 x 1g gelatine capsules) will be consumed daily for 8 weeks"
2936461|NCT02996578|Placebo Comparator|Solid Matrix Intervention - Placebo|"Dietary Supplement: low polyphenol chocolate~17.5g of commercially available, nutritionally similar, dark chocolate will be consumed daily for 8 weeks"
2936462|NCT02996578|Placebo Comparator|Powder Matrix - Placebo|"Dietary Supplement: nutritionally similar low polyphenol cocoa powder~6g of commercially available, nutritionally similar, cocoa powder (provided as 6 x 1g gelatine capsules) will be consumed daily for 8 weeks"
2936463|NCT02996565|Active Comparator|Best Practice Clinic-Based Care|Patients with uncontrolled hypertension who receive primary care in clinics assigned to the Best Practice Clinic-Based Care intervention.
2936464|NCT02996565|Active Comparator|Telehealth Care|Patients with uncontrolled hypertension who receive primary care in clinics assigned to the Telehealth Care intervention.
2936465|NCT02996552|Experimental|M & T Repair Group|Both mitral and tricuspid valves repair
2936466|NCT02996552|Active Comparator|Mitral-Only Group|Only mitral valve repair
2936467|NCT02996539||Type 2 diabetes|With Clinical examination and laboratory measurements
2936468|NCT02996526||Intact Vocal Cord Mobility|Patients with normal laryngeal function post thoracic surgery
2936469|NCT02996526||Vocal Cord Dysfunction|Patients with abnormal vocal cord movement of 1 or both vocal cords post thoracic surgery
2936470|NCT02996513|Experimental|Retinol Isotope dilution (RID)|A once-off dose of 0.4 mg 13C4-retinyl acetate will be administered to subjects as a capsule
2936471|NCT02996500|Experimental|Arm 1: 20 mg QD|PF-06650833 , 20 mg QD
2936472|NCT02996500|Experimental|Arm 2: 60 mg QD|PF-06650833, 60 mg QD
2936473|NCT02996500|Experimental|Arm 3: 200 mg QD|Pf-06650833, 200 mg QD
2936474|NCT02996500|Experimental|Arm 4: 400 mg QD|PF-06650833, 400 mg QD
2936475|NCT02996500|Placebo Comparator|Placebo|Placebo, 0 mg BID
2936476|NCT02996500|Active Comparator|Arm 5: Tofacitinib|Tofacitinib 5 mg BID
2936477|NCT02996487|Placebo Comparator|Placebo|Placebo every 6 hours. A placebo will look like the drug being studied, but have no active ingredients, in this case it will be fruit punch with vitamins added to mimic the taste of vancomycin.
2936478|NCT02996487|Active Comparator|vancomycin|Vancomycin 125 mg by mouth every 6 hours
2936479|NCT02996474|Experimental|Single|Up to eight cycles of pembrolizumab will be given during the initial induction phase. Each cycle is 21 days.Decitabine will ordinarily be given on days 8 through 12 and 15 through 19 on alternative cycles (ie: cycles 1, 3, 5 and 7).
2936480|NCT02996461|Experimental|Group 1|ZIKV DNA vaccine administered IM via needle and syringe at a single dosage of 4 mg on Day 0, week 4 and week 8.
2936481|NCT02996461|Experimental|Group 2|ZIKV DNA vaccine administered IM via needle and syringe as a split dose of two .5 ml injections on Day 0, week 4 and week 8.
2936482|NCT02996461|Experimental|Group 3|ZIKV DNA vaccine administered IM via needle-free injection device, PharmaJet, as a split dose of two .5 ml injections on Day 0, week 4 and week 8.
2936483|NCT02996448|Experimental|1|Participants will receive a single dose of 0.5 mL (300 micrograms of rAls3) administered via IM injection.
2936484|NCT02996435|Experimental|Mobile Adherence Platform|Participant adherence will be monitored using a mobile application and platform which provides a real-time reminder that alerts the participant to take his or her medication. The application will also send an alert to the participant when a refill is needed based on calculated medication or pill supply. The intervention will focus only on daily adherence to rivaroxaban.
2936485|NCT02996435|Other|Control: Standard of Care|Participants will receive physician- or nurse-guided standard of care for their rivaroxaban adherence.
2936486|NCT02996422|Experimental|School-based water campaign|Students who attend middle and high schools in the intervention counties will receive a school-based water campaign. A sample of students from each school will complete surveys before and after the installation of the water refilling stations to measure beverage consumption, knowledge, attitudes, and self-efficacy.
2936487|NCT02996422|No Intervention|Comparison schools|A sample of students who attend middle and high schools in the comparison county, which does not receive any intervention components, will complete surveys to measure beverage consumption, knowledge, attitudes, and self-efficacy.
2936488|NCT02996422|Experimental|Community cooking classes|Adults in the same intervention counties as the school-based water campaign will enroll in group cooking classes. They will complete a baseline and two follow-up surveys to measure changes in fruit and vegetable consumption, attitudes, and self-efficacy.
2936489|NCT02996409|Experimental|High-Volume Image-Guided Injection|HVIGI: Injection of 50 cc ( 40 cc 0,9% sodium chloride solution + 10 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.
2936490|NCT02996409|Placebo Comparator|Low-Volume Image-Guided Injection|LVIGI: Injection of 2 cc (1.6 cc 0.9% Sodium chloride solution + 0.4 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.
2936491|NCT02996396||1|Patients diagnosed with AAA who are considered candidates for Endovascular Repair and meet the study eligibility criteria and sign the Informed consent may be subsequently enrolled in the study.
2936492|NCT02996383|Active Comparator|Cemented hemiarthroplasty|Treatment of the fracture by a replacement arthroplasty with a cemented CPT hemiarthroplasty (manafactured by Zimmer company, Warsaw IN, USA) inserted via an anteriolateral approach to the hip
2936493|NCT02996383|Active Comparator|Internal fixation|Internal fixation of the fracture with a screw and plate device (Targon FN plate, Aesculap cooperation, Tuttingham, Germany)
2936499|NCT02996344|Experimental|Didactics and standardized patients|Behavioral; participants will view the approximately one hour Commitment to Living: Primary Care (CTL:PC) didactic training videos plus two practice standardized patient interactions.
2936500|NCT02996331|Active Comparator|2 hour arm|All participants in this arm are assigned a 2-hour repositioning interval.
2936501|NCT02996331|Experimental|3 hour arm|All participants in this arm are assigned a 3-hour repositioning interval.
2936502|NCT02996331|Experimental|4 hour arm|All participants in this arm are assigned a 4-hour repositioning interval.
2936503|NCT02996318|Experimental|Sirolimus coated Balloon|treatment of coronary DES-ISR with a sirolimus coated balloon
2936504|NCT02996318|Active Comparator|Paclitaxel coated balloon (SeQuent Please)|treatment of coronary DES-ISR with a paclitaxel coated balloon
2936505|NCT02996305|Experimental|OV101 regimen 1|OV101 once daily
2936506|NCT02996305|Experimental|OV101 regimen 2|OV101 twice daily
2936507|NCT02996305|Placebo Comparator|Placebo|Twice daily
2936508|NCT02996292|Experimental|Traditional brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
2936509|NCT02996292|Experimental|Active self-ligating brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using active self-ligating brackets; American orthodontics active self-ligating Empower® MBT 0.022"
2936510|NCT02996292|Experimental|Passive self-ligating brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using passive self-ligating brackets; American orthodontics passive self-ligating Empower® MBT 0.022"
2936511|NCT02996279||group 1|maternal chorioamnionitis
2936512|NCT02996279||group 2|no maternal chorioamnionitis
2936513|NCT02996266|Experimental|Fever Prevention|Fever will be prevented using a surface targeted temperature management system
2936514|NCT02996266|Active Comparator|Standard Care|Standard care in which fever may spontaneously develop
2936515|NCT02996240|Experimental|Omega-3 FFA|Patients will take 12 capsules daily with meals, divided twice daily (example, 6 with breakfast and 6 with dinner).
2936516|NCT02996227|Experimental|TAP block with Exparel|Bilateral Transversus Abdominis Plane (TAP) block procedure following injection of liposomal bupivacaine (Exparel)
2936517|NCT02996227|Active Comparator|Epidural analgesia with Bupivacaine|Epidural catheters with an infusion of Bupivacaine standard solution without additives
2936518|NCT02996214|Experimental|LP group|Liposome paclitaxel(Lipusu®) plus cisplatin. Paclitaxel liposome Sterile injection powder 175 mg/m2, given on day 1 of a 21-day cycle, for 6 cycles. Cisplatin 75 mg/m2, given on day 1 of a 21-day cycle, for 6 cycles.
2936519|NCT02996214|Active Comparator|GP group|Gemcitabine (Gemzar®) plus cisplatin. Gemcitabine hydrochloride for injection 1000 mg/m2, given on days 1 and 8 of a 21-day cycle, for 6 cycles. Cisplatin 75 mg/m2, given on day 1 of a 21-day cycle, for 6 cycles.
2936520|NCT02996201|Experimental|Electronic reporting of PRO-CTCAE items|Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
2936521|NCT02996201|No Intervention|Standard practice|
2936522|NCT02996188||Patients with refractory tense ascites|
2936523|NCT02996175|Experimental|SMART|"Treatment group targeting behavioral sleep problems for 5 weeks.~Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems~Information on healthy sleep hygiene, preventative techniques, and use of visual supports~Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking~Information on procedures for delayed sleep onset and problematic sleep associations~Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future"
2936524|NCT02996175|Active Comparator|WISE|Standard of care sleep treatment enhanced with psychoeducation. 1 Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome 2 Introduction to understanding and interpreting results from clinical evaluations 3 Introduction to educational planning, expectations, and transition planning 4 Introduction to lifespan development and advocacy and support services available 5 Feedback on current concerns and methods for obtaining services to manage concerns
2936525|NCT02996136|Experimental|Nasal Swab|Nasal Swab
2936526|NCT02996136|Experimental|Nasopharyngeal Swab|Nasopharyngeal Swab
2936527|NCT02996123|Experimental|cad/cam maxillary dentures|single maxillary dentures fabricated by cad/cam method
2936528|NCT02996123|Active Comparator|conventional dentures|heat cured single maxillary dentures
2936529|NCT02996110|Active Comparator|Nivolumab + Ipilimumab|Nivolumab + Ipilimumab
2936530|NCT02996110|Experimental|Nivolumab + Relatlimab|Nivolumab + Relatlimab
2936531|NCT02996110|Experimental|Nivolumab + BMS-986205|Nivolumab + BMS-986205
2936532|NCT02996097|Experimental|CO2 ablative laser plus intralesional triamcinolone acetonide|A topical eutectic mixture of local anesthetics (EMLA) cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
2936533|NCT02996097|Active Comparator|Intralesional triamcinolone acetonide alone|A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. The other chosen lesion would be treated with intralesional triamcinolone acetonide alone at 4 week intervals.
2936534|NCT02996071|Active Comparator|low waist to height ratio|laparoscopic sleeve gastrectomy
2936535|NCT02996071|Active Comparator|high waist to height ratio|laparoscopic sleeve gastrectomy
2936536|NCT02996058|Active Comparator|DEX I 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
2936537|NCT02996058|Active Comparator|DEX II 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale.
2936540|NCT02996032||Heart Failure|Patients admitted to the hospital with acute decompensated heart failure expected to be hospitalized for at least 72 hours
2936541|NCT02996019|Experimental|Part 1: Etrolizumab AI|Participants will receive a single dose of etrolizumab via subcutaneous (SC) injection using the AI on Day 1.
2936542|NCT02996019|Active Comparator|Part 1: Etrolizumab PFS-NSD|Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.
2936543|NCT02996019|Experimental|Part 2: Etrolizumab AI|Participants will receive a single dose of etrolizumab via SC injection using the AI on Day 1.
2936544|NCT02996019|Active Comparator|Part 2: Etrolizumab PFS-NSD|Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.
2936545|NCT02995993|Experimental|Moss-aGal|Single administration of 0.2 mg/kg recombinant human alpha-galactosidase A produced in moss (moss-aGal) as intravenous infusion
2936546|NCT02995980|Experimental|Contrast enhanced mammography|Contrast-enhanced spectral mammography for the detection breast cancer .
2936547|NCT02995980|Active Comparator|standard digital mammogram|Full field digital mammography for the detection breast cancer
2936548|NCT02995967|Active Comparator|Botulinum toxin A alone group|Intradetrusor injection of 100 units of botulinum toxin A alone
2936549|NCT02995967|Experimental|Hydrodistention group|Hydrodistention at a pressure of 80 cm H2O for 5 minutes, prior to the intradetrusor injection of 100 units of botulinum toxin A
2936550|NCT02995954|Active Comparator|Fixed|The Fixed group received one single tablet containing Perindopril/Amlodipine (Reaptan) at the appropriate dose
2936551|NCT02995954|Active Comparator|Free|The Free group, received Perindopril and Amlodipine in separate tablets at the appropriate dose
2936552|NCT02995941||Raters|No interventions will be administered. Raters will be state licensed as physical therapists working as outpatient physical therapists in the St. Luke's University Health Network.
2936553|NCT02995941||Patients|No interventions will be administered as a component of this study. Patients will be recruited from a convenience sample of consecutive patients presenting for physical therapy consultation for shoulder pain.
2936554|NCT02995928|Experimental|Decompressive craniectomy|Decompressive craniectomy and best medical treatment
2936555|NCT02995928|Active Comparator|Control|Only best medical treatment. Decompressive craniectomy is employed only if intracranial pressure >25 mm Hg for 1-12 hours to keep the patients safe.
2936556|NCT02995915|Experimental|Tele-health & Mobile CM|This arm includes a proactive tele-health intervention that combines evidence-based telephone cognitive behavioral treatment for alcohol and smoking cessation, a tele-medicine clinic for access to smoking cessation pharmacotherapy (including nicotine replacement therapy and bupropion), and mobile contingency management treatment administered via a smart-phone based application (mobile CM).
2936557|NCT02995902|Experimental|FLT-PET/MRI|
2936558|NCT02995889|Experimental|FLT-PET|
2936559|NCT02995876|No Intervention|Zirconia and E-max Press|The first design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press.
2936560|NCT02995876|Experimental|Zirconia and E-max Press and Glaze|The second design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press and the internal surface coated with a glaze layer to improve adhesion.
2936561|NCT02995876|Experimental|Zirconia and E-max Press twice|The third design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press and the internal surface coated with an E-max Press layer to improve adhesion.
2936562|NCT02995863|Experimental|Experimental Group|Rigid rocker sole footwear
2936563|NCT02995863|Active Comparator|Control Group|Therapeutic footwear
2936564|NCT02995850|Experimental|anti-cancer drug|
2936565|NCT02995837||Obstructive Sleep Apnea Syndrome (OSAS)|"The study duration is estimated at 12-14 months approximately. However, this will depend on the timing of treatment as they will undergo testing pre- and post-OSAS treatment. Participation will entail a total of 8 visits including:~Pre-treatment - neurocognitive testing, and CBF during wakefulness testing duration is one full day. The CBF nighttime testing is one full night.~Post-treatment - Six to twelve weeks after clinically indicated surgical treatment, OSAS participants will have a repeat baseline polysomnogram (one full night) to assess for residual OSA. Six and twelve months after the surgical treatment, the sleep study with the nighttime CBF testing, as well as the daytime neurocognitive testing and CBF testing will be repeated to assess for changes."
2936566|NCT02995837||Controls|The study will include 7 total visits for controls: a baseline sleep study to ensure normalcy, three full days of neurocognitive testing and CBF testing (baseline, 6 and 12 months), and three sleep studies with CBF testing (baseline, 6 and 12 months). A daytime visit and one night time visit may be scheduled during a 24-hour period if the participant and family wish so. Otherwise, they will be scheduled on separate days.
2936567|NCT02995811||Observational Cohort|"On Days 1, 3, 7 and 10 of ICU admission, patients will undergo ultrasound assessment of the diaphragm, transverse and rectus abdominis, quadriceps rectus femoris, and tibialis anterior muscles. Imaging all four muscles together requires approximately 1 hour.~Physical activity monitoring: On Days 1-10 of ICU admission patients will wear an activity monitor. These devices use several inertial motion sensors to track the movement and acceleration of the limbs in horizontal and vertical directions.~Patients will also undergo daily assessment of global peripheral skeletal muscle strength assessed by the Medical Research Council Sum-score and global function measured by the Chelsea Critical Care Physical Assessment Scale"
2936568|NCT02995798||Group A|T-score ≥-1
2936569|NCT02995798||Group B|-2.5<T-score<-1.0
2936570|NCT02995798||Group C|T-score≤-2.5
2936571|NCT02995785|Other|Experimental:simulation-based training|Experimental
2936572|NCT02995785|Other|Active comparatorr: traditional training|Traditional
2936573|NCT02995772|Active Comparator|Neoadjuvant hormonal therapy|Neoadjuvant hormonal therapy: Aromatase inhibitors (Arimidex, Femara, Aromasin), Tamoxifen, SOB and AI, SOB and Tamoxifen
2936574|NCT02995772|Active Comparator|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy: FAC 6 cycles
2936575|NCT02995759||SE before Seizure Action Plan|450 patients with status epilepticus prior to seizure action plan initiation
2936576|NCT02995759||SE after Seizure Action Plan|450 patients with status epilepticus after seizure action plan initiation
2936577|NCT02995746|Experimental|0.7mg dexamethasone intravitreal implant|Single intravitreal implantation of 0.7mg dexamethasone with a six month follow up period
2936578|NCT02995733|Active Comparator|PARTICS|addition of PARTICS strategy - Patient Activated Reliever-Triggered Inhaled CorticoSteroid (PARTICS) using QVAR . Patient will use inhaled corticosteroid at time of rescue inhaler use
2936579|NCT02995733|No Intervention|Usual Care|Provider-enhanced usual care arm; no change in asthma management
2936580|NCT02995720|Experimental|1|A fixed dose combination of Fimasartan/Amlodipine/Rosuvastatin
2936581|NCT02995720|Active Comparator|2|Co-administration of Fimasartan/Amlodipine combination drug and Rosuvastatin
2936582|NCT02995707|Experimental|thalidomide thalassemia|thalidomide:50mg/d p.o
2936583|NCT02995694|Experimental|Test|Estradiol Vaginal Cream
2936584|NCT02995694|Active Comparator|Reference.|Estrace Vaginal Cream
2936585|NCT02995694|Placebo Comparator|Placebos|Placebo with no active pharmaceutical ingredients. Topical vaginal cream
2936586|NCT02995681|Experimental|Pulmonary rehab and balance training|The intervention group will receive standard pulmonary rehab plus additional balance training.
2936587|NCT02995681|Active Comparator|Pulmonary rehab|The control group will receive pulmonary rehab only and a pulmonary rehab home program (walking and lower extremity resistance exercises) upon discharge from pulmonary. They will also receive the same monthly phone calls and three home visits at three, six and nine months to ensure proper technique and progression.
2936588|NCT02995668|No Intervention|Control|Non-active comparator
2936589|NCT02995668|Active Comparator|Strength-Function|Active comparator
2936590|NCT02995668|Experimental|Balance-Proprioception|Experimental
2936591|NCT02995655|Experimental|CX-01 + Azacitidine|"CX-01 will be administered as a 5-minute bolus infusion at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle. The dose of CX-01 should be calculated based on actual body weight (kg) as measured on Day 1 of each cycle.~Azacitidine will be administered as a 15-minute intravenous infusion at a dose of 75mg/m^2 on Days 1-7 of each 28-day cycle. Azacitidine dose should be calculated based on actual body weight and height to determine BSA. CX-01 may be administered before or after azacitidine, at the discretion of the treating physician.~Up to 6 cycles of treatment allowed"
2936592|NCT02995642|Experimental|18F-FPPRGD2|Subjects (with either carotid atherosclerosis stenosis or AAA) will receive a single intravenous injection of 10mCi of 18F-FPPRGD2 and will undergo positron emission tomography/computed tomography (PET/CT) or PET/MRI (PET/magnetic resonance imaging) imaging 45-60 minutes after injection.
2936593|NCT02995629|Experimental|green (532 nm) laser|scatter laser indirect ophthalmoscopy pan retinal photocoagulation
2936594|NCT02995629|Experimental|yellow (577 nm) laser|scatter laser indirect ophthalmoscopy pan retinal photocoagulation
2936595|NCT02995616|Experimental|Lokomat training|Patients will be tested in 3 Lokomat training sessions on 3 separate days. During the first session patients will walk in the Lokomat according to their regular therapy settings. During the second and third session patients will walk in the Lokomat with 2 different levels of guidance force (100% guidance force and 60% guidance force).
2936596|NCT02995590|Experimental|MRI of lung motion during breathing|"A medical history will be obtained defining any present and past history of respiratory illnesses, medications, and hospitalizations and the ability to have MR imaging.~A urine pregnancy test will be done for women of childbearing potential, who report the possibility that they might be pregnant.~Before and after MR imaging, a physical exam, spirometry, and a baseline %PO2 will be performed.~During the MR imaging procedure, the subject's heart rate and blood oxygen saturation will be monitored using an MR compatible pulse oximeter.~Once positioned in the MR scanner, conventional proton images of the thorax will be obtained to define the lung boundaries for subsequent image alignment. -Free breathing conventional MR imaging will be performed.~Hyperpolarized helium 3 imaging will be performed at breath hold."
2936597|NCT02995577||Feeding tolerant|Patients that are able to reach 80-100% of full enteral feeds (whether fed by mouth or through a nasogastric tube) 7 days after the initiation of feeds. Patients will be excluded from this group if they are ever diagnosed with NEC at any time during this hospitalization.
2936598|NCT02995577||Feeding intolerant|Patients with GI symptoms (vomiting, abdominal distention, diarrhea, hematemesis, and/or hematochezia) that persist for 48 hours or longer while needing to be NPO, this patient is retrospectively categorized into the feeding intolerance group. Patients with feeding intolerance may also include infants that are made NPO, placed on bowel rest, and are started on antibiotics to rule out NEC, but are never diagnosed with NEC. Exclusion criteria include patients that are continued on antibiotics for greater than 48 hours due to diagnosed bacterial sepsis or diagnosed NEC, and those that have a positive blood, urine, or sputum culture.
2936599|NCT02995577||Necrotizing enterocolitis|Any infant that is diagnosed (radiographically, by Bell's criteria) with and treated for NEC.
2936600|NCT02995564|Experimental|Social Skills Intervention|The intervention is a 16-week social skills therapy program that will consist of a 90 minute group therapy session followed by a 90 minute peer generalization session meeting once per week. Each cohort will consist of 6 adolescents with Aspergers or high-functioning autism, who will be joined by 6 typically-developing peers for the peer generalization portion. During the group therapy session young adults will discuss and watch video clips addressing social skills topics relevant to their age group. They will have a chance to practice these skills when paired with typically developing peer volunteers.
2936601|NCT02995551|Experimental|Arthroscopy|Arthroscopic meniscal repair or resection will be conducted at the discretion of the operating surgeon (this cannot be determined before the surgeon has visual confirmation about the exact knee pathology and extend of the meniscal tear by scope).
2936602|NCT02995551|Active Comparator|Exercise and Education|Patients allocated to exercise therapy and education will participate in a 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear. Furthermore, they will participate in a patient education program developed through interviews with pilot study participants, from our experiences from the Good Life with osteoArthritis in Denmark (GLA:D) program for patients with knee and hip pain. Both the exercise and education will take place in a number of private physiotherapy clinics associated with the GLA:D program, specifically trained to supervise and lead the treatment in this study.
2936661|NCT02995005|Experimental|Tenofovir Disoproxil Fumarate|Women early in pregnancy (end of first or beginning second trimester) will be treated with TDF to determine the efficacy of this strategy to bring >=95% of women to undetectable HBV DNA levels at delivery.
2936603|NCT02995538||Neurogenetic Patients|The Neurogenetics Clinic, which started in 2016, provides clinical care for undiagnosed patients with complex neurological disorders in which a genetic etiology is considered and for children with diagnosed rare neurogenetic disorders - provide pre test counseling, diagnostic services for the undiagnosed patients and long-term management of patients with a wide range of diagnosed genetic disorders of the nervous system.
2936604|NCT02995512|Experimental|Myocardial Infarction (MI) Patients|
2936605|NCT02995486|No Intervention|Control|Standard care with only an educational pamphlet.
2936606|NCT02995486|Experimental|Intervention|Post-discharge exercise group
2936607|NCT02995473|Experimental|NP000888|Pharmaceutical form: Ointment
2936608|NCT02995473|Placebo Comparator|Vehicle|Pharmaceutical form: Ointment
2936609|NCT02995460|Experimental|interval training|4x4 high intensity interval training was performed on a stationary bicycle with a supervisor twice a week and by one self-training a week.
2936610|NCT02995460|No Intervention|controls|No change in diet and training habits
2936611|NCT02995447||epilepsy patients|The group consists of patients with therapy refractory epilepsy, in which intracerebral electrodes were implanted to locate the seizure origin and to determine whether the patients are eligible for epilepsy surgery. In an observational study, differences between surface and intracerebral EEG are recorded.
2936612|NCT02995434|Experimental|Intervention Group|Participants will be randomly assigned to the intervention group (50 in total).The VR intervention will be identical for each participant and consist of a PC running the IVR application with an Virtual Reality headset 110 degrees field of view head mounted display. The VR will be a set of commercial exploratory virtual environment games designed for the HTC Vive headset. The intervention will be used for one month to enable customization to the therapy and record data over a long enough period of time to account for individual short- term changes in pain experience. Participants will be asked to use the VR therapy every day with a time exposure of 40 minutes for four consecutive weeks. There will be one rest day a week (normally a Sunday) where no therapy is given.
2936613|NCT02995434|Active Comparator|Control Group|The control group will be exposed to 2D PC equivalent versions of the same multimedia experiences but on their PC screen (without the VR headset use). These will be functionally similar to the VR experiences.
2936614|NCT02995408|Experimental|Experimental: 3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
2936615|NCT02995408|Active Comparator|Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
2936616|NCT02995395||Mucosal Impedance Balloon catheter|At the conclusion of the endoscopy, all fluids will be aspirated from the esophagus. The endoscope will then be left in place in the mid-esophagus and a custom Mucosal Impedance (MI) balloon assembly four axial arrays of 10 sensors (total of 40 sensors) will be positioned along the esophageal mucosal wall under direct visualization to directly measure MI at uniform intervals. Once in place, impedance readings will be recorded for a total of 2 minutes. At this point both the endoscope and impedance catheter will be withdrawn simultaneously.
2936617|NCT02995382|Experimental|Anterior Intramuscular Transposition|This is the only arm in our study, patients with cubital tunnel syndrome will undergo anterior intramuscular transposition, one of many surgical techniques utilized on patients with Cubital Tunnel Syndrome to alleviate symptoms.
2936618|NCT02995369|Other|Dryshield Isolation (right)|Dryshield will be used to isolate the maxillary and mandibular teeth on the right side of the mouth to place the sealants
2936619|NCT02995369|Other|Cotton Roll Isolation (right)|Cotton rolls will be used to isolate the maxillary and mandibular teeth on the right side of the mouth to place the sealants
2936620|NCT02995369|Other|Dryshield Isolation (left)|Dryshield will be used to isolate the maxillary and mandibular teeth on the left side of the mouth to place the sealants
2936621|NCT02995369|Other|Cotton Roll Isolation (left)|Cotton rolls will be used to isolate the maxillary and mandibular teeth on the left side of the mouth to place the sealants
2936622|NCT02995356||Doubt for ectopic pregnancy group|This group participants have doubt for ectopic pregnancy in terms of beta-HCG pregnancy follow-up results and ultrasonography results.
2936623|NCT02995356||Normal intrauterine pregnancy group|This groups participants have normal intrauterine pregnancy
2936624|NCT02995343|Experimental|Hypogastric and/or uterine artery ligation|Patients who had been ligated hypogastric artery and or uterine artery for ceasing uterine bleeding during c-section
2936625|NCT02995343|No Intervention|Normal postpartum women|
2936626|NCT02995330|Experimental|Bone marrow transplantation|Bone marrow transplantation followed by Cytoxan and testosterone
2936627|NCT02995317||Fall accidents|
2936628|NCT02995304|Active Comparator|Morphine and Midazolam premedication|30 children will receive 0.025 mg/kg midazolam IV followed by 0.1 mg/kg morphine 20 to 30 min before surgical incision.
2936629|NCT02995304|Active Comparator|Midazolam only premedication|30 children who will receive 0.025 mg/kg midazolam IV followed by saline 20 to 30 min before surgical incision.
2936630|NCT02995291|Placebo Comparator|Control|1.7ml saline water
2936631|NCT02995291|Experimental|OraVerse|1.7ml OraVerse
2936632|NCT02995265|Experimental|Exoskeleton Program|Exoskeleton-based walking rehabilitation until discharge (or to a maximum of 8 weeks), 3 - 5 days a week for 30-60 minutes per session. Participants will be assessed upon admission to the study, discharge, as well as at 6 months post-stroke. The exoskeleton will allow standing and walking with full weight bearing from the first sessions in rehabilitation.
2936633|NCT02995265|Active Comparator|Usual Care Program|Standard physiotherapy stroke rehabilitation which includes training for regaining walking as well as other functional tasks, 3 - 5 days a week for 30-60 minutes per session until discharge (or to a maximum of 8 weeks). Participants will be assessed upon admission to the study, discharge, as well as at 6 months post-stroke.
2936634|NCT02995252||Group 1: Hepatitis C infection|Participants with chronic hepatitis C infection; includes both hepatitis C mono infected and hepatitis C-HIV coinfected. Participants will attend study visits for research blood draws (once a year with optional additional visits), and a one-time optional knowledge questionnaire. No drugs will be given to this group.
2936635|NCT02995252||Group 2: Hepatitis B infection|"Participants with chronic hepatitis B: includes patients with hepatitis B with and without hepatitis C and/or HIV. Participants will attend study visits for research blood draws (once a year with optional additional visits), and a one-time optional knowledge questionnaire. Participants who are already taking hepatitis B treatment are eligible.~Hepatitis B treatment sub-study: In this treatment sub-study, participants with hepatitis B monoinfection will receive tenofovir alafenamide (TAF) pill once a day for 2 years with study visits every 3 months. Liver transient elastography will be reviewed or obtained. In addition, approximately 40 participants will be invited to undergo optional liver biopsies at the start, end of year 1 and end of year 2 of the sub-study."
2936636|NCT02995239|Active Comparator|CJ-12420 formulation 1|CJ-12420 formulation 1
2936637|NCT02995239|Active Comparator|CJ-12420 formulation 2|CJ-12420 formulation 2
2936638|NCT02995226|Other|Anorexia nervosa|"Patients with DSM-5 criteria of anorexia nervosa"
2936639|NCT02995226|Other|First degree relatives|First degree relatives (of patients suffering from anorexia nervosa) with no eating disorder
2936640|NCT02995226|Other|Controls (with no eating disorder)|Other
2936641|NCT02995213|Experimental|Feedback Intervention|
2936642|NCT02995200|Experimental|Group Post-Stroke|2 sessions of in-home accelerometer based feedback about paretic arm use
2936643|NCT02995200|No Intervention|Healthy Control Group|
2936644|NCT02995187|Experimental|Apatinib Mesylate tablet|Patients received oral apatinib 500 mg in tablet once daily, a treatment cycle was defined as 28 days (4 weeks).
2936645|NCT02995174|Experimental|Intervention (dichoptic video game play)|Mild amblyopic subjects will be asked to play dichoptic video game in an i-Pod touch device for 1 hour per day in 6 weeks.
2936646|NCT02995174|Placebo Comparator|Control (video game play)|Mild amblyopic subjects will be asked to play video game in an i-Pod touch device for 1 hour per day in 6 weeks.
2936647|NCT02995161|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2936648|NCT02995148|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2936649|NCT02995135|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2936650|NCT02995122|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2936651|NCT02995109|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2936652|NCT02995083|Active Comparator|Knee injection with corticosteroids|Using clinically accepted methods, subjects will undergo a palpation guided injection of corticosteroids into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
2936653|NCT02995083|Placebo Comparator|Knee injection with saline|Using clinically accepted methods, subjects will undergo a palpation guided injection of saline into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
2936654|NCT02995083|Sham Comparator|Knee injection with air|Using clinically accepted methods, subjects will undergo a palpation guided injection of air into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
2936655|NCT02995070|Experimental|CTG + LLLT|The irradiation will be performed with a GaAlAs diode laser that will continuously emits a wavelength of 660 nm with a power of 30 milliwatts. The patients allocated for the LLLT group will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 15 J/cm2 and a time of 20 seconds. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment will be calibrated prior to each application.
2936656|NCT02995070|Sham Comparator|CTG + SHAM|The patients allocated to the control group will receive sham irradiation. For this, black rubber protection will be placed at the tip of the laser device, which will not allow the light to reach the tissue. The applications will be performed by a different operator from the one who will measure the study parameters. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by seven more applications performed every other day, with a total of 8 laser applications.
2936657|NCT02995057||Nickel allergic|Participants have proven nickel allergy
2936658|NCT02995044|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2936659|NCT02995031|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2936660|NCT02995018|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2936662|NCT02994992|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2936663|NCT02994979|Experimental|Delirium-prevention group|Multicomponent delirium prevention intervention led by a Certified Nursing Assistant (CNA) adapted for the long-term care setting from the Hospital Elder Life Program.
2936664|NCT02994979|Sham Comparator|Usual care group|Usual care plus a sham visit from the intervention CNA
2936665|NCT02994966|Experimental|Surrosense|Subjects randomized to this group will receive standard care, including appropriate off-loading and footwear as well as wear SurroSense Rx® in-shoe pressure-sensing arrays, which provide visual and auditory/vibratory feedback alerts (relating to high plantar pressures) and offloading guidance to a watch display intended to assist in the recurrence of diabetic foot ulcers. They will also be advised to perform daily self-checks of their feet for redness, callous and wounds. A daily checklist will be provided to participants to evaluate compliance.
2936666|NCT02994966|Active Comparator|Standard care|Subjects randomized to this group will receive standard care, including appropriate off-loading and footwear. They will also be advised to perform daily self-checks of their feet for redness, callous and wounds. A daily checklist will be provided to participants to evaluate compliance.
2936667|NCT02994953|Experimental|Avelumab and NHS-IL12|
2936668|NCT02994953|Experimental|Avelumab (once weekly) + NHS-IL 12 (MTD)|
2936669|NCT02994953|Experimental|Avelumab (once weekly) + NHS-IL 12 (MTD) (Expansion cohort)|
2936670|NCT02994940|Experimental|Oral Acetaminophen|Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision.
2936671|NCT02994940|Experimental|Intravenous Acetaminophen|Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.
2936672|NCT02994927|Experimental|CCX168 (avacopan)|CCX168 in combination with rituximab or in combination with cyclophosphamide followed by azathioprine
2936673|NCT02994927|Active Comparator|Prednisone|Prednisone in combination with rituximab or in combination with cyclophosphamide followed by azathioprine
2936674|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation between 200 et 160|According to the score obtained with the onco geriatric evaluation, patients with a score between 200 and 160 will receive a normo fractionated radiotherapy (66 Grays in 33 fractions). This scheme of radiotherapy is already used in the clinical practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
2936675|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation between 159 et 120|According to the score obtained with the onco geriatric evaluation, patients with a score between 159 and 120 will receive an hypo fractionated radiotherapy (42,56 Grays in 16 fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
2936676|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation inferior to 119|According to the score obtained with the onco geriatric evaluation, patients with a score inferior to 119 will receive a large hypo fractionated radiotherapy (30 Grays in 5 weekly fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
2936677|NCT02994901||Group 1|Geriatric patient with Sarcopenia
2936678|NCT02994901||Group 2|Geriatric Patient without Sarcopenia
2936679|NCT02994901||Group 3|healthy control group
2936680|NCT02994888||all patients|All patients will be treated with cetuximab 500mg/m2 every 2 weeks until the time of progression
2936681|NCT02994875|Placebo Comparator|Placebo First|Placebo - Participants will receive placebo for one week. Following a two-week washout period, they will receive NAC for one week. NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications
2936682|NCT02994875|Active Comparator|NAC First|N-acetylcysteine - Participants will receive NAC for one week. Following a two-week washout period, they will receive placebo for one week. NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications
2936683|NCT02994862|Experimental|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
2936684|NCT02994862|Active Comparator|Conventional Bonding|Normal Bonding Method
2936685|NCT02994836|Active Comparator|Anti-TNF|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) or Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)
2936686|NCT02994836|Placebo Comparator|Anti-TNF discontinuation (Placebo)|Physiological saline solution (Infusion-Intravenous use) or Physiological saline solution (Injection-subcutaneous use)
2936687|NCT02994810|Experimental|Intervention group|Guidelines and review of the breastfeeding techniques.
2936688|NCT02994810|No Intervention|Control group|The control group will receive home visits only when the baby is 6 months of life, they will be re-evaluated by the researchers as the practice of exclusive breastfeeding and the technical and nursing management, and will be asked about the main difficulties encountered in maintaining breastfeeding.
2936689|NCT02994784|Experimental|Evomela|Propylene Glycol-Free Melphalan Hydrochloride (Evomela) administered intravenously at 70-100 mg/m2/day on Days -3 and -2 prior to autologous stem cell transplantation
2936690|NCT02994771|Active Comparator|Lymfactin® [1 x 10E10 vp]|Lymfactin® [1 x 10E10 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
2936691|NCT02994771|Active Comparator|Lymfactin® [1 x 10E11 vp]|Lymfactin® [1 x 10E11 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
2936692|NCT02994758|Other|Personalised medicine arm|"This is a prospective n-of-1 type of trial where every patient is his/her own control. This is a study further developing the translational use of an existing framework and infrastructure for systematic sample collection an analytics previously established in the HUB project incorporating NGS and DSRT into clinical care."
2936693|NCT02994745|Experimental|A fixed dose combination group|A fixed dose combination of Fimasartan/Atorvastatin
2936694|NCT02994745|Active Comparator|Co-administration group|Co-administration of Fimasartan and Atorvastatin
2936757|NCT02994277|Experimental|UVa and ITBA/UNLP algorithm arm|To control glycaemia in T1DM patients through UVa and ITBA/UNLP algorithm
2936695|NCT02994732|Experimental|[14C]‑BVD‑523 600mg single dose|Open-label, nonrandomized, absorption, metabolism, and excretion study of [14C]‑BVD‑523 administered as a 600 mg (approximately 200 µCi) oral dose to 6 healthy male subjects following at least an 8‑hour fast from food (not including water).
2936696|NCT02994719||Neurological Disease subjects|Parkinson's Disease and other Parkinsonian Disorders subjects. Other Parkinsonian Disorders include Atypical Parkinsonism such as Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Primary Gait Freezing Disorder, Indeterminate Parkinsonian Syndrome. During the first visit no intervention will take place. There is an optional second visit during which subjects with Parkinson's Disease are asked to come come off antiparkinson medication and if applicable, off both medication and deep brain stimulation.
2936697|NCT02994719||Healthy control subjects|The healthy control subjects will be age- and sex-matched to the Neurological Disease subjects.
2936698|NCT02994706|Experimental|Home monitoring|Home monitoring will involve participants recording their symptoms twice weekly on a modified mobile phone and recording their lung function twice weekly using a digital spirometer. This data will be automatically transmitted to the CF team and we will contact patients on the mobile phone if symptoms and/or lung function decline below a set threshold, suggesting the onset of a pulmonary exacerbation. We will contact patients within 24 hours of symptoms and/or lung function falling below this set threshold.
2936699|NCT02994706|Active Comparator|Clinical Care|Throughout the study period, participants will attend outpatient clinic visits as usual and treatment with antibiotics as clinically indicated.
2936700|NCT02994693|Experimental|OFDI capsule imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
2936701|NCT02994680|Experimental|Intervention arm|"Will receive:~Three-burner LPG stove (at enrollment)~Delivery of LPG tanks (beginning at enrollment for one year)~The study will be conducted over three years, with staggered enrollment over one year, one year of observations during the intervention period, and one year of follow-up observations after the intervention period for each participant.~Participants in the intervention arm will receive an LPG stove upon enrollment and the research team will deliver fuel twice monthly to their homes during the first year. Participants in the intervention arm will not receive fuel during the second year, but researchers will encourage these participants to continue using LPG fuel for cooking."
2936702|NCT02994680|Active Comparator|Control arm|"Will receive:~Three-burner LPG stove (one year after enrollment)~Vouchers for LPG tanks (one year after enrollment)~Participants in the control arm but will not receive an LPG stove or fuel during the first year. Instead, participants will receive an LPG stove at the end of the first year and vouchers to obtain free fuel at distribution centers during the course of the second year."
2936703|NCT02994667||Pacemaker After TAVR|The study cohort will comprise all consecutive patients who undergo permanent pacemaker placement for new conduction disturbances after TAVR at THHBP between 1/1/2015 and 12/31/2016.
2936704|NCT02994654|Experimental|ReCell|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
2936705|NCT02994654|Experimental|Control|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Control, which is the Investigator's pre-determined graft plan will be randomly allocated to either Area A or Area B
2936706|NCT02994641||Adverse discharge disposition|Patients who were discharged to a skilled nursing facility or died in the hospital
2936707|NCT02994641||No adverse discharge disposition|Patients who were not discharged to a skilled nursing facility or did not die in the hospital
2936708|NCT02994628|Active Comparator|Water|Intervention, water and no banana carbohydrate: consume 3 ml/kg water every 15 min during 75 km cycling
2936709|NCT02994628|Experimental|Mini banana|Intervention, banana carbohydrate: ingest 0.2 g carbohydrate/kg body weight from Mini banana with 3 ml/kg water every 15 minutes during 75 km cycling
2936710|NCT02994628|Experimental|Cavendish banana|Intervention, banana carbohydrate: ingest 0.2 g carbohydrate/kg body weight from Cavendish banana with 3 ml/kg water every 15 minutes during 75 km cycling
2936711|NCT02994628|Experimental|6% sugar beverage|Intervention: pure banana carbohydrate in sugar beverage; ingest 0.2 g carbohydrate/kg body weight from a 6% sugar beverage every 15 minutes during 75 km cycling (contains 60 grams sugar per liter using the same sugar profile found in Cavendish bananas)
2936712|NCT02994615||hypertrophic cardiomyopathy|
2936713|NCT02994615||Control|
2936714|NCT02994602|Experimental|Nestorone (NES) + testosterone (T) combined gel|A combination gel with Nestorone® (NES) and Testosterone (T) applied transdermally. The volume of gel to be applied will be approximately 5 mL. This gel volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day and will also contain 8.3 mg of NES that will deliver about 0.8 mg NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel) in 5 ml of combined gel.
2936715|NCT02994589|Experimental|OASIS® wound matrix|OASIS wound matrix is a biologic extracellular matrix derived from porcine small intestine submucosa. Some components of OASIS wound matrix are similar to human dermis including types of collagens, elastin, glycoproteins and proteoglycans. In addition, OASIS wound matrix retains some growth factors that have been suggested to aid in the wound healing process. It is a FDA approved wound dressing indicated for use in a variety of ulcers, abrasions and surgical wounds.
2936716|NCT02994589|Active Comparator|Tegaderm™(Absorbant, 3M)|Transparent dressing allows for wound monitoring without changing the dressing Clear design takes the guesswork out of application over the wound Novel acrylic polymer pad technology designed to handle low to moderate wound drainage. No dressing breakdown in the wound. Low friction surface minimizes potential for friction and shear. Allows for gentle removal from skin. Barrier to external contaminants, body fluids, bacteria and viruses.
2936717|NCT02994589|Active Comparator|Xeroform™|Xeroform™ Occlusive Petrolatum Gauze. 3% Bismuth Tribromophenate in a special petrolatum blend on fine mesh gauze. Non-adherent. Clings and conforms to all body contours.
2936718|NCT02994576|Experimental|Stage IB(≥ 2 cm)-IIIA non N2, resectable and untreated NSCLC|
2936719|NCT02994563|Experimental|Open arm|Thrombectomy device to be used to retrieve clot and restore blood flow.
2936720|NCT02994550|Experimental|FSH/LH 2/1|dose: 300IU FSHrec and 150IU LHrec
2936721|NCT02994550|Experimental|FSH/LH 4/1|dose: 300IU FSHrec and 75IU LHrec
2936722|NCT02994537||acute autoimmune hepatitis|Patients diagnosed autoimmune hepatitis(AIH) are divided into acute cohort or chronic cohort by biochemical results, such as liver function and coagulation, then the investigators will compare the histological results, treatment effects and prognosis between the two groups. Further more, the investigators will study the pathogenesis of different forms of autoimmune hepatitis. Even more, the investigators want to explore drug induced AIH and viral hepatitis related AIH.
2936723|NCT02994524|Other|transsphincteric perianal fistula|Rerouting technique done in patients with high transsphincteric fistula or with high internal opening.
2936724|NCT02994498|Experimental|DCB-BO1301 1 capsule|DCB-BO1301 1 capsule, tid (around 1 hour before meal) for at most 48 weeks
2936725|NCT02994498|Experimental|DCB-BO1301 2 capsules|DCB-BO1301 2 capsules, tid (around 1 hour before meal) for at most 48 weeks
2936726|NCT02994498|Experimental|DCB-BO1301 3 capsules|DCB-BO1301 3 capsules, tid (around 1 hour before meal) for at most 48 weeks
2936727|NCT02994485|Active Comparator|Simvastatin|Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks
2936728|NCT02994485|No Intervention|no treatment|no treatment
2936729|NCT02994472|Experimental|Healthy volunteers|"Each participant will have to eat scrambled egg on day 1 and porridge on day 2; both meals will contain the radioactive tracer 99mTc-DTPA.~Participants will be scanned by a trained technologist. The scans will be carried out using a General Electric, Discovery 360 Gamma Camera.The scanning process will take approximately three hours in total, however the imaging will be carried out in stages."
2936730|NCT02994459||Metabolically Normal Obese|Those with a BMI greater than or equal to 30.0 but <40.0 kg/m2; ii) fasting blood glucose: <100 mg/dl and; iii) blood glucose 2 h after an OGTT: <140 mg/dl; iv) HbA1c <5.7 %, v) < 10 uU/ml and 2h OGTT insulin <100 uU/ml
2936731|NCT02994459||Metabolically Abnormal Obese|Those with insulin resistance and high blood sugar and with a BMI greater than or equal to 30.0 but <40.0 kg/m2; ii) fasting blood glucose: <126 mg/dl; iii) blood glucose 2 h after an OGTT: & greater than or equal to 140 but <200 mg/dl.
2936732|NCT02994459||Lean|BMI greater than or equal to 18.5 but <25.0 kg/m2; ii) fasting blood glucose: <100 mg/dl; iii) blood glucose 2 h after an OGTT: <140 mg/dl; iv) HbA1c <5.7 %.
2936733|NCT02994446|Experimental|SERF Catheter Ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
2936734|NCT02994433|Experimental|Nitrous Oxide|One hour inhalation of nitrous oxide
2936735|NCT02994433|Placebo Comparator|Placebo Gas|One hour inhalation of placebo gas
2936736|NCT02994420||Lean women|BMI 18-25, weight in kg / height in m2
2936737|NCT02994420||Obese women|BMI 30-35, weight in kg / height in m2
2936738|NCT02994407|Experimental|N8-GP s.c.|
2936739|NCT02994394|Experimental|OPC41061(15 mg) disintegrating tablet with water|OPC41061 (15 mg) orally disintegrating tablet is administered with water.
2936740|NCT02994394|Experimental|OPC-41061(15 mg) disintegrating tablet without water|OPC41061 (15 mg) orally disintegrating tablet is administered without water.
2936741|NCT02994394|Experimental|OPC-41061(15 mg) conventional tablet with water|OPC-41061 (15 mg) conventional tablet is administered with water.
2936742|NCT02994394|Experimental|OPC41061(30 mg) disintegrating tablet with water|OPC41061 (30 mg) orally disintegrating tablet is administered with water.
2936743|NCT02994394|Experimental|OPC-41061(30 mg) disintegrating tablet without water|OPC41061 (30 mg) orally disintegrating tablet is administered without water.
2936744|NCT02994394|Experimental|OPC-41061(30 mg) conventional tablet with water|OPC-41061 (30 mg) conventional tablet is administered with water.
2936745|NCT02994381|Experimental|[14C]-RPC1063 Solution (0.1 g/mL)|1 mg; 10 mL [14C]-RPC1063 HCl oral dose containing NMT 1.3 MBq (37 μCi) 14C
2936746|NCT02994368||Observation|No intervention
2936747|NCT02994355|Experimental|Intervention Clinics|Clinics randomized to the intervention will be introduced to the Systems Analysis and Improvement Approach (SAIA) to understand barriers to HIV testing in family planning clinics. Sequential process flow mapping will be used to highlight areas for improvement and then specific interventions will be implemented for the clinics with the goal of increasing HIV testing rates.
2936748|NCT02994355|No Intervention|Control Clinics|Clinics randomized to the control arm of the study will continue HIV testing as per usual procedures.
2936749|NCT02994342|Active Comparator|Vaginal gel, Medical Device Class 2A|Every subject has been treated for 56 consecutive days, twice daily with a vaginal application
2936750|NCT02994342|No Intervention|Lifestyle counseling|Every subject has been observed for 56 consecutive days
2936751|NCT02994329|Active Comparator|Oral HIV self test|In this arm, community health workers conducting door-to-door HIV testing will offer oral HIV self testing (OraQuick® HIV Self-Test (Orasure Technologies, Thailand)) as an alternative to standard of care finger-prick HIV testing for individuals who are present at the time of the visit. In addition they will provide demonstration to an adult who is present at the time of the visit and leave up to 2 oral HIV self test kits to allow testing with the partner
2936752|NCT02994329|No Intervention|Standard of Care|In this arm community health workers will conduct door-to-door HIV testing using the current Zambian national HIV testing algorithm of finger-prick rapid HIV tests
2936753|NCT02994316|Experimental|children under the age of 16 diabete with ketoacidosis|"At diagnosis mellitus type 1 (measure of blood glucose level) bicarbonate levels will be measured and children will included in the arm with ketoacidosis (bicarbonate < 15mmol/L)"
2936754|NCT02994316|Sham Comparator|children under the age of 16 diabete without ketoacidosis|"At diagnosis mellitus type 1 (measure of blood glucose level) bicarbonate levels will be measured and children will included in the arm without ketoacodosis (bicarbonate> 15 mmol/L)"
2936755|NCT02994290|Experimental|receive inpatient HPV vaccine|We will select a purposive sample of postpartum women into two groups: those who receive inpatient HPV vaccine and those who decline the inpatient dose to interview until we reach thematic saturation which we anticipate to occur with about 8-10 individuals per group. Patients will be selected to include diverse representation in age, race, ethnicity, and parity.
2936756|NCT02994290|Experimental|decline the inpatient dose|We will select a purposive sample of postpartum women into two groups: those who receive inpatient HPV vaccine and those who decline the inpatient dose to interview until we reach thematic saturation which we anticipate to occur with about 8-10 individuals per group. Patients will be selected to include diverse representation in age, race, ethnicity, and parity.
2936758|NCT02994251|Experimental|All subjects|Patients must have advanced, unresectable intrahepatic cholangiocarcinoma (ICC) defined as biopsy-confirmed adenocarcinoma in the liver, with an immunohistochemical profile consistent with a pancreatico-biliary primary, not involving the common bile duct or bifurcation, and not amenable to surgical resection.
2936759|NCT02994238|Experimental|Intervention|The intervention group will have the full Remote Health Management Sensor Platform. Research staff will review uploaded sensor data on a daily basis. If participants are enrolled into the control group, they will only receive Standard Asthma Education. The Standard Asthma Education follows the National Asthma Education and Prevention Program (NAEPP) guidelines for asthma management. This will include the following topics: 1. Explanation of symptoms; 2. Asthma triggers (description and how to avoid them); 3. Using medications (how to use prescribed asthma medications, the difference between controller medications and rescue inhalers, how to use a spacer, how to use a mask); and 4. Managing asthma control (purpose of asthma control test, asthma action plan, how to use a peak flow meter).
2936760|NCT02994238|No Intervention|Control|The control group will receive only standardized education.
2936761|NCT02994225|Experimental|Study arm|"Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.~Near Infra-red images acquisition is performed during surgery"
2936762|NCT02994212|Experimental|Intervention group|115 children eligible for the outpatient treatment of SAM were provided a monthly ration of RUTF. Anthropometric measurements were taken on a weekly basis for 4 weeks to monitor treatment response.
2936763|NCT02994199|Experimental|Active video gaming|Participants will engage in active video game play.
2936764|NCT02994186||Surgical Weight Loss|Patients in this group are those that will be undergoing bariatric surgery (either Roux-en-Y gastric bypass or vertical sleeve gastrectomy).
2936765|NCT02994186||Medical Weight Loss|Patients in this group are those who are being enrolled in a supervised medical weight loss program.
2936766|NCT02994173|Active Comparator|Placebo|Oxycodone 1 mg / ml alone
2936767|NCT02994173|Active Comparator|Ketamine 0.25|Oxycodone 1 mg / ml + S-ketamine 0.25 mg / ml (ratio 1:0.25)
2936768|NCT02994173|Active Comparator|Ketamine 0.5|Oxycodone 1 mg / ml + S-ketamine 0.5 mg / ml (ratio 1:0.5)
2936769|NCT02994173|Active Comparator|Ketamine 0.75|Oxycodone 1 mg / ml + S-ketamine 0.75 mg / ml (ratio 1:0.75)
2936770|NCT02994160|Experimental|FastLIFE electrodes|Implant temporary FastLIFE electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
2936771|NCT02994147|Placebo Comparator|Placebo|"Subjects will initiate blinded study medication at a once daily (QD) regimen for 4 weeks, then titrate to twice daily (BID) for the remainder of the 24-week blinded treatment period.~At Week 24, subjects will discontinue blinded study medication and start open-label treatment with AC-201CR. All subjects will initiate open-label AC-201CR QD for 4 weeks, then titrate to BID for the remainder of the study."
2936772|NCT02994147|Experimental|AC-201CR 72mg|"Subjects will initiate blinded study medication at a once daily (QD) regimen for 4 weeks, then titrate to twice daily (BID) for the remainder of the 24-week blinded treatment period.~At Week 24, subjects will discontinue blinded study medication and start open-label treatment with AC-201CR. All subjects will initiate open-label AC-201CR QD for 4 weeks, then titrate to BID for the remainder of the study."
2936773|NCT02994134|Active Comparator|Moderate intensity exercise.|Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
2936774|NCT02994134|Experimental|High intensity exercise|High intensity aerobic exercise intervention (delivered at 65%-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
2936775|NCT02994121||People with Multiple Sclerosis or Related Disorders|Individuals must be 7 years or older, diagnosed with multiple sclerosis or related disorders, including a first central nervous system demyelinating episode with a positive MRI scan or abnormal MRI scans characteristic of MS but no clinical symptoms of the disease
2936776|NCT02994121||People without Multiple Sclerosis or Related Disorders|Control participants must be 7 years or older, have no known personal history of multiple sclerosis or related disorders, no other chronic disease, and can be a family member, unrelated household control, or control from the general population.
2936777|NCT02994108|Experimental|txt2protect|"Content will be delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants will receive 5-10 messages daily. During Phase 2 (weeks 4-36), message frequency will decrease from weekly to monthly messages. Phase 1 content will be presented in 3 modules. Module 1 will address information about HPV infection and HPV vaccine. Module 2 will address motivations to receive HPV vaccine. Module 3 will focus on behavioral skills and self-efficacy for initiating and completing the 3-dose series (e.g., talking with their doctor about the vaccine). Phase 2 booster messages will largely reinforce previous content to foster continued engagement with the program, although some new content will also be introduced."
2936778|NCT02994108|Active Comparator|Sexual Health Knowledge Control|Content will be delivered in 2 phases over 36 weeks. Phase 1 content will be presented in 3 modules; however, unlike the treatment group, content will be topic-based rather than theory-based and will focus on general sexual health. Module 1 will address basic facts about HIV and STIs, including HPV. Module 2 will address HIV/STI prevention (e.g., condom use) and will include basic facts about HPV vaccination that are currently available online. Module 3 will address healthy relationships. Phase 2 messages will reinforce Phase 1 content to maintain engagement.
2936779|NCT02994095|Experimental|Single intervention arm|Trained CHAs in Motivational Interviewing in pilot study
2936780|NCT02994082|Experimental|Tailored Intervention|The tailored behavioral intervention includes both behavioral and pharmacological components. The behavioral component will consist of six sessions of cognitive behavioral therapy and coping skills training delivered over the telephone. In addition, participants will be screened for conditions commonly associated with tobacco use (depressive symptoms, risky alcohol use, weight concerns) and offered supplementary behavioral treatment modules to address these issues. Participants will also be offered pharmacotherapy for tobacco cessation, with decisions regarding specific medication(s) based on patients' medical history, contraindications, prior experiences, and preferences.
2936822|NCT02993822|Experimental|Orvepitant 30mg|Orvepitant 30mg tablet, once daily for 12 weeks
2936823|NCT02993822|Placebo Comparator|Placebo|Placebo to match tablet, once daily for 12 weeks
2938549|NCT02981901||Patient with ovarian epithelial cancer|Ovarian epithelial cancer diagnosed in 2012
2936781|NCT02994082|Active Comparator|Facilitated tobacco quit line referral|Participants assigned to this condition will receive information about the VA telephone tobacco quit line and educational materials and encouraged to enroll in treatment. In addition, they will be given information regarding available medications for smoking cessation and encouraged to contact their primary care provider to discuss their options.
2936782|NCT02994069|Experimental|Every 3 Weeks Cisplatin + XRT|Every 3 Weeks Cisplatin + XRT
2936783|NCT02994069|Experimental|Weekly Cisplatin + XRT|Weekly Cisplatin + XRT
2936784|NCT02994056|Experimental|SOF/VEL+ RBV|SOF/VEL FDC plus RBV for 12 weeks
2936785|NCT02994043|Experimental|Mindfulness Plus Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.
2936786|NCT02994043|Active Comparator|Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.
2936787|NCT02994030||Observation|Patients at 2 months with Duchenne disease or high-grade suspicion for Duchenne disease
2936788|NCT02994017|Other|cystic fibrosis patients|
2936789|NCT02993991|Experimental|Mocetinostat and Durvalumab|"Patients will start therapy with mocetinostat within 10 days of study enrollment. Mocetinostat will be given in 2 dose levels (n = 6 evaluable patients each) of 70mg three-times weekly and 90mg three-times weekly for 2 weeks.~Durvalumab will be given as a single infusion at a dose of 1500mg, over a period of 1-hour, on day 8 of the study."
2936790|NCT02993978||Control group|Pediatric patients and their parents who were treated with radiotherapy during baseline period and enrolled in the study. Recruitment to the Control Group took Place during one year.
2936791|NCT02993978||Case group|Pediatric patients and their parents who were treated with radiotherapy during case period and enrolled in the study. Recruitment to the case group took place during one year after introduction of new methods and equipment in the in the clinic..
2936792|NCT02993965|No Intervention|Control 11-17|No additional intervention done aside from usual care for 11-17 year olds
2936793|NCT02993965|Experimental|1 R/R per Dose 11-17|Sending up to one recall notice per dose of HPV vaccine needed for 11-17 year olds
2936794|NCT02993965|Experimental|2 R/R per Dose 11-17|Sending up to two recall notices per dose of HPV vaccine needed for 11-17 year olds
2936795|NCT02993965|Experimental|3 R/R per Dose 11-17|Sending up to three recall notices per dose of HPV vaccine needed for 11-17 year olds
2936796|NCT02993965|No Intervention|Control 11-14|No additional intervention done aside from usual care for 11-14 year olds
2936797|NCT02993965|Experimental|Phone R/R 11-14|Sending up to two recall notices per dose of HPV vaccine needed via autodialer for 11-14 year olds
2936798|NCT02993965|Experimental|Mail R/R 11-14|Sending up to two recall notices per dose of HPV vaccine needed via mailed postcards for 11-14 year olds
2936799|NCT02993952|Active Comparator|Active stimulation|A constant current (anodic) of 2mA will be applied for 20 minutes on the Primary motor cortex.
2936800|NCT02993952|Sham Comparator|Sham stimulation|A constant current (sham) of 2mA will be applied, but the stimulator will be turned off after 30 seconds on the Primary motor cortex.
2936801|NCT02993939|Active Comparator|Interscalene block|Ultrasound guided Brachial plexus block injecting 20 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml, in the Interscalene groove.
2936802|NCT02993939|Experimental|Diaphragm-sparing block|Ultrasound guided combinated infraclavicular-Suprascapular block of the braquial plexus, injecting 20 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml dorsal to the axillary artery in the infraclavicular fossa plus an Ultrasound guided injection of 10 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml in the suprascapular fossa.
2936803|NCT02993926||Leuprorelin low dose group|Participants who have received leuprorelin 30 microgram per kilogram (mcg/kg) to less than (<) 90 mcg/kg per body weight, injection, subcutaneously, every 4 weeks up to at least 9 continuous months during the index period from September 1st 1998 to September 30th 2018 will be observed.
2936804|NCT02993926||Leuprorelin high dose group|Participants who have received leuprorelin 90 mcg/kg to 180 mcg/kg per body weight, injection, subcutaneously, every 4 weeks up to at least 9 continuous months during the index period from September 1st 1998 to September 30th 2018 will be observed.
2936805|NCT02993913|Experimental|Simmiparib tablet monotherapy|Drug: Simmiparib tablet oral Qd or Bid
2936806|NCT02993900|Experimental|Image-Guided Brachytherapy|Magnetic Resonance Imaging (MRI) guided brachytherapy Procedure: Image-Guided Brachytherapy
2936807|NCT02993887|Placebo Comparator|Mindfulness|Mindfulness (Decentering) only using the Stop, Breathe, Think Smart Phone application
2936808|NCT02993887|Experimental|Resourcefulness and Mindfulness|Resourcefulness Training (a cognitive behavioral intervention that teaches self-help and help-seeking skills) and Mindfulness using the Stop, Think, Breathe app.
2936809|NCT02993874|Experimental|Creatine|Creatine monohydrate (Cr) Loading - 4 doses of 5g / day for 7 days Maintenance - 1 dose of 3g / day for 49 days Clinical treatment (30-45 minutes of walking, 3 times per week)
2936810|NCT02993874|Placebo Comparator|Placebo|Dextrose Loading - 4 doses of 5g / day for 7 days Maintenance - 1 dose of 3g / day for 49 days Clinical treatment (30-45 minutes of walking, 3 times per week)
2936811|NCT02993861||Levetiracetam|Children with epilepsy who are treated with levetiracetam per local standard of care
2936812|NCT02993861||Valproic Acid|Children with epilepsy who are treated with valproic acid per local standard of care
2936813|NCT02993861||Topiramate|Children with epilepsy who are treated with topiramate per local standard of care
2936814|NCT02993861||Oxcarbazepine|Children with epilepsy who are treated with oxcarbazepine per local standard of care
2936815|NCT02993848||Operative Scapula Fracture|No intervention. Inclusion criteria and data collection is the same for both cohort.
2936816|NCT02993848||Non-Operative Scapula Fracture|No intervention. Inclusion criteria and data collection is the same for both cohort.
2936817|NCT02993835|Active Comparator|Labeled iron salt (Fe54)|Labeled iron salt (Fe54) with bouillon
2936818|NCT02993835|Active Comparator|Labeled iron salt (Fe57)|Labeled iron salt (Fe57) with bouillon
2936819|NCT02993835|Experimental|Labeled iron salt (Fe58)|Labeled iron salt (Fe58) with bouillon
2936820|NCT02993822|Experimental|Orvepitant 10mg|Orvepitant 10mg tablet, once daily for 12 weeks
2936821|NCT02993822|Experimental|Orvepitant 20mg|Orvepitant 20mg tablet, once daily for 12 weeks
2936824|NCT02993809|Experimental|BM-ECs and PRPE|Multipoint of intramuscular injections into ischemic limbs.Injections composed of bone marrow derived endothelial cells (BM-ECs) and platelet-rich plasma extract (PRPE).
2936825|NCT02993809|Active Comparator|BM-ECs|Intramuscular injection of bone marrow derived endothelial cells only.
2936826|NCT02993783|Experimental|Vedolizumab 300 milligram (mg)|Vedolizumab 300 mg, infusion, intravenously once on Days 1, 15, 43, 71 and 99.
2936827|NCT02993783|Experimental|Vedolizumab 600 mg|Vedolizumab 600 mg, infusion, intravenously once on Days 1, 15, 43, 71 and 99.
2936828|NCT02993770|Experimental|Endoscopic DCR|Endoscopic DCR will be performed by a single ophthalmic plastic surgeon expert in endoscopic surgery (F.P.) with a modified powered endonasal endoscopic technique described by Wormold.
2936829|NCT02993770|Active Comparator|External DCR|External DCR will be performed in a conventional mannervia a nasal side straight skin incision 1 cm medial to medial canthal area, 1 cm long, then orbicularis oculi muscle will be separated using blunt dissection to expose the periosteum overlying and medial to the anterior lacrimal crest
2936830|NCT02993757|Experimental|Concomitant Administration Group|Subjects will receive 3 doses of the CYD dengue vaccine and 2 doses of Gardasil® (Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant) concomitantly to the 2 first doses of CYD dengue vaccine.
2936831|NCT02993757|Experimental|Sequential Administration Group|Subjects will receive 3 doses of the CYD dengue vaccine and 2 doses of Gardasil sequentially to the 2 first doses of CYD dengue vaccine
2936832|NCT02993744||Case Group|75 woman between the age of 18 to 50 years, week of gestation 23+0 - 34+6, threatening preterm delivery, application of Betamethasone
2936833|NCT02993744||Control Group|65 woman between the age of 18 to 50 years, week of gestation 23+0 - 34+6, no threatening preterm delivery
2936834|NCT02993731|Experimental|Arm 1: Napabucasin plus Nab-paclitaxel with Gemcitabine|Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.
2936835|NCT02993731|Active Comparator|Arm 2: Nab-paclitaxel with Gemcitabine|Patients randomized to this arm will receive weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.
2936836|NCT02993718|Experimental|Dexmedetomidine|Intraoperative sedation is performed by using dexmedetomidine.
2936837|NCT02993718|Experimental|Propofol|Intraoperative sedation is performed by using propofol
2936838|NCT02993705|Experimental|Trabectedin|Trabectedin will be infused at the dose of 1.3 mg/m2 as a 3- hour iv infusion every 3 weeks via a central venous catheter.
2936839|NCT02993692|Other|fiberoptic bronchoscopy|I want to see the difference between the two group about hemodynamic and intraoculer pressure responses about fiberoptic bronchoscopy.
2936840|NCT02993692|Other|direct laryngoscopy|I want to see the difference between the two group about hemodynamic and intraoculer pressure responses about direct laryngoscopy.
2936841|NCT02993679|Other|double-bundle ACL reconstruction|surgical reconstruction of the anterior cruciate ligament
2936842|NCT02993679|Other|anterolateral ligament reconstruction|surgical reconstruction of the anterolateral ligament
2936843|NCT02993666|Experimental|upper body|warming with upper body blankets
2936844|NCT02993666|Experimental|lower body|warming with lower body blankets
2936845|NCT02993653|Experimental|Intensity-modulated radiotheapy arm|Intensity-modulated radiotheapy with stereotactic boost or intracavitary radiotherapy
2936846|NCT02993640|Experimental|vasopressin + nitro|vasopressin + nitroglycerin in simultaneous infusion
2936847|NCT02993627|Experimental|Spirulina|daily intake of spirulina tablets weight reduction diet therapy
2936848|NCT02993627|Placebo Comparator|placebo|daily intake of placebo tablets weight reduction diet therapy
2936849|NCT02993601||20 outpatients with peripheral oedema|20 outpatients with clinically detectable peripheral oedema for 1 set of measurements.
2936850|NCT02993601||20 cardiology controls|20 outpatients with heart failure without clinically detectable peripheral oedema (control group) for 1 set of measurements.
2936851|NCT02993601||10 in-patients peripheral oedema|10 in patients hospitalised as a result of heart failure and fluid congestion with peripheral oedema, those patients will have several sets of measurements taken over time to measure the reduction of peripheral oedema which is likely to show common features with the formation of peripheral oedema.
2936852|NCT02993601||30 control without cardiac conditions|less than 30 normal controls (healthy volunteers and patients without heart failure) in the age group 55 and above who agree to have images taken using the Heartfelt-1 device (not the whole set of measurements).
2936853|NCT02993588|Experimental|Melatonin|Melatonin 6 mg tablet once daily.
2936854|NCT02993588|Placebo Comparator|Placebo|Placebo tablet once daily
2936855|NCT02993562||Hypothyroid patients|Hypothyroid patients treated with Levothyroxine as part of normal treatment.
2936856|NCT02993562||Healthy volunteers|Matched on age and BMI. 18 Persons.
2936857|NCT02993523|Placebo Comparator|Placebo followed by Azacitidine|Matching Placebo for Venetoclax 400 mg orally QD on Days 1 - 28 plus Azacitidine 75 mg/m^2 SC or IV QD on Days 1 - 7 (28-day cycle)
2936858|NCT02993523|Active Comparator|Venetoclax followed by Azacitidine|Venetoclax 400 mg orally every day (QD) on Days 1 - 28 plus Azacitidine 75 mg/m^2 subcutaneously (SC) or intravenous (IV) QD on Cycle Days 1 - 7 (28-day cycle)
2936859|NCT02993510|Active Comparator|microfracture|Microfracture is an arthroscopic surgical technique involving placement of microfracture penetrations within the cartilage defect to provide stem cells and growth factors from the bone marrow to aid cartilage repair
2936860|NCT02993510|Experimental|Microfracture with Chondro-Gide sutured|Microfracture covered with a collagen membrane (Chondro-Gide®) using atraumatic sutures in a one-step mini-arthrotomy procedure
2936861|NCT02993510|Experimental|Microfracture with Chondro-Gide glued|Microfracture covered with a collagen membrane (Chondro-Gide®) using fibrin glue in a one-step mini-arthrotomy procedure
2936862|NCT02993497|Experimental|Respiratory monitoring group|
2936863|NCT02993484|Experimental|non-diabetic Sham control|Heart tissue obtained from non-diabetic patients undergoing surgery will not receive drugs or ischemia
2936864|NCT02993484|Experimental|non-diabetic Ischemia reperfusion|Heart tissue from non-diabetic patients undergoing surgery will not receive drugs but will receive ischemia
2936865|NCT02993484|Experimental|non-diabetic Ischemic preconditioning|Heart tissue from non-diabetic patients undergoing surgery will not receive drugs but will receive short periods of ischemia prior to index ischemia
2936866|NCT02993484|Experimental|non-diabetic Dimethyl malonate|Heart tissue from non-diabetic patients undergoing surgery will receive a drug (Dimethyl Malonate) prior to index ischemia
2936867|NCT02993484|Experimental|Diabetic Sham control|Heart tissue obtained from diabetic patients undergoing surgery will not receive drugs or ischemia
2936868|NCT02993484|Experimental|Diabetic Ischemia reperfusion|Heart tissue from diabetic patients undergoing surgery will not receive drugs but will receive ischemia
2936869|NCT02993484|Experimental|Diabetic Ischemic preconditioning|Heart tissue from diabetic patients undergoing surgery will not receive drugs but will receive short periods of ischemia prior to index ischemia
2936870|NCT02993484|Experimental|Diabetic Dimethyl malonate|Heart tissue from diabetic patients undergoing surgery will receive a drug (Dimethyl Malonate) prior to index ischemia
2936871|NCT02993471|Experimental|Drug Cocktail|Drug cocktail (caffeine, warfarin [plus vitamin K], omeprazole, dextromethorphan, and midazolam) administered orally once in Period 1.
2936872|NCT02993471|Experimental|Drug Cocktail + Ixekizumab|Drug cocktail (caffeine, warfarin [plus vitamin K], omeprazole, dextromethorphan, and midazolam) administered orally twice in Period 2 (day 8 and day 85). Ixekizumab administered subcutaneously (SC) on multiple occasions in Period 2.
2936873|NCT02993458|Experimental|DASH diet-Low Na diet|DASH style diet, low sodium (1500 mg/d).
2936874|NCT02993458|Active Comparator|DASH diet-High Na diet|DASH style diet, high sodium (3500 mg/d).
2936875|NCT02993458|Active Comparator|Usual diet-Low Na diet|Diet reflecting typical dietary pattern of American adolescents, low sodium (1500 mg/d).
2936876|NCT02993458|Active Comparator|Usual diet-High Na diet|Diet reflecting typical dietary pattern of American adolescents, high sodium (3500 mg/d).
2936877|NCT02993445|Experimental|Alternate Nostril Breathing|The procedure for ANB begins by bringing the right hand up to the nose; with the ring finger over the left nostril and the thumb over the right nostril, so that the nostrils may be closed by the fingers. The first step in the cycle is to hold the right nostril closed with the thumb, and exhale completely through the left nostril in a slow and controlled fashion, free from exertion and jerkiness. At the end of the exhalation, the patient will inhale slowly and completely back through the left nostril. At this point the patient will close the left nostril with the ring finger, open the right nostril by releasing the thumb, and repeat the exhale-inhale process through the right nostril, completing one cycle. Then the patient will switch back to the left nostril and begin the cycle again. This cycle will be performed for one session lasting approximately 5 minutes.
2936878|NCT02993445|Experimental|Foot Reflexology|The procedure for FR focuses on activating specific reflex areas on the foot linked with the eye and eye disease, via massage. Although in the interest of repeatable precision, we have decided to use a FR board (fig.1) to conduct the procedure. This board has two foot shaped pieces of wood mounted on a flat board with springs. On top of these wooden feet are small wooden nodes, which are organized at precise locations to activate the reflexology of the foot by stimulation certain pressure points. The patient will be instructed to rest their feet on these boards with a comfortable pressure for a period of 5 minutes.
2936879|NCT02993432|Active Comparator|Prostaglandin|Administration of the prostaglandin for cervical ripening of the clinician's choice, ie Prostin (Prostin E2 Vaginal Gel 1mg intravaginally) or Cervidil (dinoprostone, 10 mg vaginal insert)
2936880|NCT02993432|Experimental|Foley catheter filled to 80cc|Insertion of a Foley catheter through the cervix and filling to 80cc
2936881|NCT02993419|Experimental|Bacillus licheniformis Intervention|The intervention is use Bacillus licheniformis particles，The drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
2936882|NCT02993419|Placebo Comparator|placebo Intervention|The intervention is use placebo，The drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
2936883|NCT02993406|Experimental|Bempedoic Acid 180 mg|Bempedoic acid 180 mg tablet taken orally, once daily.
2936884|NCT02993406|Placebo Comparator|Placebo Comparator|Matching placebo tablet taken orally, once daily
2936885|NCT02993393||Teachers|Anesthesiologists who have involved in SBL and PBL with more than 3 years of experience in teaching
2936886|NCT02993393||Students|Students were nurse anesthetist students in the academic years of 2015
2936887|NCT02993380|Experimental|Stir-fried olive oil group|olive oil in heated under 150 degrees
2936888|NCT02993380|Experimental|Natural olive oil group|olive oil in without heated
2936889|NCT02993367|Experimental|the Butylphthalide Soft Capsules group|600mg Butylphthalide Soft Capsules/day,po tid,period of 6 months
2936890|NCT02993367|Placebo Comparator|the placebo group|60mg Butylphthalide Soft Capsules/day,po tid,period of 6 months
2936891|NCT02993354||Pregnant women|Pregnant women with singleton pregnancy with gestational age greater than or equal to 24 weeks.
2936892|NCT02993341|Experimental|Tranexamic Acid Wash|Participants in the experimental arm will receive a wash of tranexamic acid topically at the site of surgery.
2936893|NCT02993341|Placebo Comparator|Saline Wash|Participants in the control arm will receive a wash of saline topically at the site of surgery.
2936894|NCT02993328|Experimental|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
2936895|NCT02993328|Placebo Comparator|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
2936896|NCT02993315|Experimental|nDC vaccination arm|Patients in the nDC vaccination arm will receive a maximum of 3 cycles each consisting of 3 nDC injections intranodally (3-8x10^6 nDC).
2936897|NCT02993315|Placebo Comparator|placebo arm|Patients will receive a maximum of 3 cycles each consisting of 3 placebo injections intranodally.
2936898|NCT02993302|Active Comparator|PTU + Oral 1α-D3|patients were given oral 1α-D3 at dose of 1.5 mcg once daily for 8 weeks in addition to propylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis
2936899|NCT02993302|Placebo Comparator|PTU + Placebos|patients were given placebo tablets for 8 weeks in addition topropylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis
2936900|NCT02993289|Active Comparator|Detoxification and pharmacological prophylactic treatment|Group A: Two months detoxification program combined with pharmacological prophylactic treatment from start.
2936901|NCT02993289|Active Comparator|Pharmacological prophylactic treatment|Pharmacological prophylactic treatment from start without detoxification.
2936902|NCT02993289|Active Comparator|Detoxification|Two months detoxification program with postponed pharmacological prophylactic treatment after ended detoxification.
2936903|NCT02993289|No Intervention|Control group 1: Episodic migraine|
2936904|NCT02993289|No Intervention|Control group 2: Healthy volunteers|
2936905|NCT02993276||Treatment Group|All subjects receiving the Neurocap® device when surgically treated for their symptomatic peripheral end-neuroma.
2936906|NCT02993263|Other|Noncardiac surgery|VectraplexECG System with CEB® will be recorded after surgery and on day 1, 2 and 3 post operatively
2936907|NCT02993250|Experimental|Cohort 1 (Chronic Hepatitis C Without Cirrhosis)|Participants will receive 800 milligram (mg) AL-335 +odalasvir (ODV) 25 mg+simeprevir (SMV) 75 mg once daily for 8 weeks in Cohort 1.
2936908|NCT02993250|Experimental|Cohort 2 (Chronic Hepatitis C With Compensated Cirrhosis)|Participants will receive AL-335 800 milligram (mg)+ODV 25 mg+SMV 75 mg once daily for 12 weeks in Cohort 2. Dosing in cohort 2 will be started according to decision of Data Review Committee (DRC).
2936909|NCT02993237|Experimental|Group 1: DRV/COBI Placebo followed by D/C/F/TAF Placebo|Participants will receive fixed dose combination (FDC) of darunavir/cobicistat (DRV/COBI) matching placebo tablets (Intake 1) and FDC of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) matching placebo tablets (Intake 2) on Day 1. Both the intakes will be separated by at least 30 minutes.
2936910|NCT02993237|Experimental|Group 2: D/C/F/TAF Placebo followed by DRV/COBI Placebo|Participants will receive FDC of D/C/F/TAF matching placebo tablets (Intake 1) and FDC of DRV/COBI matching placebo tablets (Intake 2) on Day 1. Both the intakes will be separated by at least 30 minutes.
2936911|NCT02993224|Experimental|Deferasirox DT followed by FCT|"Deferasirox dispersable tablet (DT) will be provided for 24 weeks. At the completion of 24 weeks patients will be transitioned on Week 25 to an equivalent dose of the deferasirox film casted tablet (FCT) formulation and continue treatment to Week 48 (EOT of Core Phase).~Patients can then continue deferasirox FCT formulation as per the judgment of the investigator, through an extension phase for maximum of 12 months counting from last dose of deferasirox FCT received at the end of period 2 on Core Phase."
2936912|NCT02993211|Active Comparator|Standard resection|For patients undergoing bipolar transurethral standard resection, bladder tumour is resected in a piecemeal manner.
2936913|NCT02993211|Experimental|En bloc resection|For patients undergoing bipolar transurethral en bloc resection, bladder tumour is resected and removed in one piece.
2936914|NCT02993198|Experimental|Prophylactic Carvedilol|Carvedilol 3.125 mg by mouth every 12 hours, titrated to a max dose of 25 mg by mouth every 12 hours, depending on blood pressure and heart rate, until completion of study.
2936915|NCT02993198|No Intervention|No Therapy|Standard of care monitoring without prophylactic treatment.
2936916|NCT02993185|Experimental|Your Move|Sex education intervention
2936917|NCT02993185|Active Comparator|Eat Smart|Nutrition education intervention
2936918|NCT02993159|Experimental|Arm I (afimoxifene, placebo)|Patients apply afimoxifene gel to both breasts and receive placebo PO daily for 8±2 weeks in the absence of disease progression or unexpected toxicity.
2936919|NCT02993159|Active Comparator|Arm II (placebo, tamoxifen citrate)|Patients apply placebo gel to both breasts and receive tamoxifen citrate orally PO daily for 8±2 weeks in the absence of disease progression or unexpected toxicity.
2936920|NCT02993146|Experimental|Treatment (ropidoxuridine, WBRT)|Patients receive ropidoxuridine PO QD on days 1-28 and undergo WBRT daily for not more than 5 days per week beginning on day 8 for a total of 15 fractions.
2936921|NCT02993133|Experimental|60 patients will be used to build and validate the system|The first 30 patients will be used to build and validate the pharmacokinetic modeling of MPA in pemphigus.The 30 patients included later will provide additional data.
2936922|NCT02993120||Cohort 1|For the cohort of approximately 500 subjects taking a PCSK9i at baseline: proof consisting of a current prescription for an approved PCSK9i and subject confirmation that they have taken a PCSK9i within 30 days prior to enrollment is necessary.
2936923|NCT02993120||Cohort 2|• For the cohort of approximately 2000 subjects with LDL-C ≥ 100 mg/dL: confirmation of LDL-C ≥100 mg/dL with no change in LLT for 4 weeks.
2936924|NCT02993120||Cohort 3|For the cohort of approximately 2500 subjects with LDL-C 70-99 mg/dL: confirmation of LDL-C 70-99 mg/dL with no change in LLT for 4 weeks
2936925|NCT02993107|Other|Group 1 (Placebo Crossovers)|Subjects who complete the placebo arm of ARC003 and consent to enroll in ARC004 (Group-1) will cross over to active treatment with AR101 using the same dosing regimen used in ARC003 in open-label fashion. Group 1 subjects may also be assigned to cohorts which test the gradual lengthening of dosing intervals. Following the completion of their longest tested dosing interval, Group 1 subjects will undergo an exit double-blinded placebo-controlled food challenge (DBPCFC).
2936926|NCT02993107|Other|Group 2 (Active Rollovers)|Subjects who successfully complete the active arm of ARC003 and consent to enroll in ARC004 (Group-2) will consecutively enter treatment with AR101 in one of three cohorts which will test alternate dosing intervals. There will be a DBPCFC at the completion of the subject's longest tested dosing interval.
2936927|NCT02993094|Experimental|Ixazomib/Carboplatin|"Accelerated dose-escalation phase with a single-patient cohort per dose level until defined DLT is observed during cycle 1, or until dose level 4 is reached. At this dose level the cohort is expanded to three patients and dose escalation reverts to a conventional 3+3 escalation design.~Intervention (experimental): Ixazomib; po; 3mg escalated to 4mg; day 1, 8, 15 Intervention (backbone): AUC 1.5 escalated to AUC 2.5; day 1, 8, 15"
2936928|NCT02993068|Experimental|Arm A|Arm A: Pre- genetic testing online educational video and post- genetic testing online test results report with approximately 750 participants.
2936929|NCT02993068|Experimental|Arm B|Arm B: Pre- genetic testing online educational video and post- genetic testing online test results report with telephone genetic counseling with approximately 750 participants.
2936930|NCT02993068|Other|Arm C|Arm C: Pre- genetic testing online educational video with telephone genetic counseling and online test results report with telephone genetic counseling with approximately 750 participants.
2936931|NCT02993068|Experimental|Arm D|Arm D: Pre- genetic testing educational video with telephone genetic counseling and post- genetic testing online test results report with approximately 750 participants.
2936932|NCT02993055|Experimental|Ulimorelin|Active
2936933|NCT02993055|Placebo Comparator|Placebo|Placebo
2936934|NCT02993042|Experimental|Robot-assisted gait training|Robot-assisted gait training using an exoskeletal robot (Walkbot_S; P&S Mechanics Co. Ltd., Seoul, Korea)
2936935|NCT02993029|Experimental|99Tc-MDP|99Tc-MDP group:15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
2936936|NCT02993029|Active Comparator|celecoxib|celecoxib capsule 200mg qd by mouth.
2936937|NCT02993016|Experimental|patient-specific instruments group|procedure: PSI (patient-specific instruments) will be used as the cutting guide in total knee arthroplasty.
2936938|NCT02993016|Active Comparator|conventional instruments group|procedure: Conventional instruments will be used as the cutting guide in total knee arthroplasty.
2936939|NCT02993003|Other|Children between 7 months and 12 months|nasopharyngeal probe will be marked with indelible ink from 2-10 cm in 1-cm increments and inserted 10 cm
2936940|NCT02993003|Other|children between 1 and 5 years|nasopharyngeal probe will be marked with indelible ink from 2-15 cm in 1.5-cm increments and inserted 10 cm
2936941|NCT02993003|Other|children between 6 and 12 years|a nasopharyngeal probe will be marked with indelible ink from 2 to 20 cm at 2 cm increments from its tip, and inserted 20 cm
2936942|NCT02992990|Other|Bladder tumor biopsy|All subjects will undergo a bladder tumor biopsy followed by transurethral resection.
2936943|NCT02992977|Experimental|AutoSynVax™ vaccine|AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant
2936944|NCT02992964|Experimental|Nivolumab|"Regimen: Nivolumab will be administered every 14 days until disease progression or treatment discontinuation due to unacceptable toxicities. Treatment may extend up to 2 years in patients who show clinical and radiological benefit.~Dose: 3 mg/kg intravenously as a continuous infusion over 60 min (+/-10 min window)"
2936945|NCT02992951|Experimental|DACC-Coated Post-Operative Dressing|DACC-Coated Post-Operative Dressing
2936946|NCT02992951|No Intervention|Non-DACC coated Occlusive Post-operative Film Dressing|Non-DACC coated Occlusive Post-operative Film Dressing
2936947|NCT02992938|Experimental|Acetazolamide|250 mg VO of acetazolamide will be administered the day of the surgery 2 hours before anesthesia induction
2936948|NCT02992938|Placebo Comparator|Placebo|An oral tablet without active principle acetazolamide but with the same physical characteristics will be administered the day of the surgery 2 hours before anesthesia induction
2936949|NCT02992925|Experimental|Cohort 1: BK1310-High|
2936950|NCT02992925|Experimental|Cohort 1: BK1310-Low|
2936951|NCT02992925|Experimental|Cohort 2: BK1310-High or -Low|Either BK1310-High or -Low will be chosen based on the result of cohort 1
2936952|NCT02992925|Active Comparator|Cohort 2: ActHIB® and Tetrabik|
2936953|NCT02992912|Experimental|Patients with metastatic tumours|
2936954|NCT02992899|Experimental|Vagal Nerve Stimulation|Participants randomized to this arm will receive stimulation of the vagus nerve in conjunction with stress exposure.
2936955|NCT02992899|Sham Comparator|Sham Stimulation|Participants randomized to this arm will receive sham stimulation of the vagus nerve in conjunction with stress exposure.
2936956|NCT02992886|Experimental|preCRT+surgery|Treatment including preoperative chemoradiotherapy (preoperative radiation with concurrent chemotherapy) with Raltitrexed followed by surgery. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy or Volumetric-Modulated Arc Therapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on d1 and d22). Pelvic surgery is planned 6 weeks after completion of CRT based on the decision of MDT.
2936957|NCT02992873|Experimental|Layperson allocated to fetch an AED and start CPR|In the intervention group mobile lifesavers will be directed to fetch the nearest AED and then attach it to the victim of OHCA. At least 1 volunteer will be directed to start CPR only
2936958|NCT02992873|Active Comparator|Layperson allocated to start CPR|In the control group all mobile lifesavers will be directed to the patient to start CPR.
2936959|NCT02992860|Experimental|Treatment Arm|JNJ-56022473 will be given intravenously to all subjects at a dose of 9 mg/kg once every 14 days for an initial treatment period of 3 months (6 infusions). Responders will then receive up to 20 additional infusions whereas for non-responders the initial treatment will be followed by a up to 9 months observation period without further JNJ-56022473 treatment. Thus, the individual study duration for a subject will be approx. 1 year. A follow up visit will be performed after 3 months after last study drug administration for all patients to track pregnancy status according to IB.
2936960|NCT02992847||Dotarem|At least 5 injection with Dotarem exclusively
2936961|NCT02992847||Multihance|At least 5 injection with Multihance exclusively
2936962|NCT02992834|Active Comparator|IL-2 pre-treated CD19 cells|Initial therapy: IL-2 (interleukin,IL)stimulated, CD28-ζ-vector (cluster of differentiation 28,CD28)transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
2936963|NCT02992834|Active Comparator|IL-7/IL-15 pre-treated CD19 cells|Initial therapy: IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
2936964|NCT02992821|Experimental|Bed-side pocket-size ultrasound|All participants will be examined bed-side by pocket size ultrasound for the assessment of the carotid arteries by junior doctors. All participants will then be examined by reference imaging in specific ultrasound laboratories with conventional high end equipment and new doppler techniques and when appropriate computer tomography or magnetic resonance imaging.
2936965|NCT02992808|Active Comparator|Recombinant preparations|
2936966|NCT02992808|Active Comparator|HP-HMG|Highly purified human menopausal gonadotropin
2936996|NCT02992626|Experimental|starting with control|Participants in this arm complete the first session under control condition in the presence of a stuffed toy dog while the second session the tests are completed in the presence of a dog.
2936967|NCT02992795||Cohort Ia|Athletes in this cohort serve as control subjects participating in Division 1 Athletics at the University of Wyoming. They will be enrolled once they meet eligibility. Upon enrollment, all athletes will have an initial BrainPulse recording. Once a subject from this cohort sustains an injury, they crossover to Cohort II. Also, a matched control for every concussed subject will be selected from Cohort Ia.
2936968|NCT02992795||Cohort Ib|Athletes in this cohort are subjects currently subscribed to the Head Health Network. They will have a BrainPulse recording completed every week through the entire season. Similarly, if subjects in this cohort sustain an injury, they will crossover to Cohort II.
2936969|NCT02992795||Cohort IIa|Athletes from Cohort I will be assigned to cohort IIa once they sustain an injury other than concussion. They will have been pulled out of the game by the athletic trainer and removed from play until at least the end of the game. Once the subjects have been assigned to Cohort IIa, they will have a BrainPulse recording and a symptom evaluation within 3 days of their injury. After two weeks of recovery, subjects in this cohort will return to Cohort 1 and resume their participation in the study in their respective sub-cohort.
2936970|NCT02992795||Cohort IIb|Athletes in this cohort are injured subjects who sustain a non-penetrating head injury and are confirmed to have had a concussion according to the protocol reference standard and by their physician. All subjects enrolled in this cohort are required to have a BrainPulse recording within 3 days of their injury. Each BrainPulse recording will be accompanied by a symptoms evaluation and medical data collection documented in the case report forms. Subjects will complete 3 weeks of follow-up visits post injury.
2936971|NCT02992782|Active Comparator|Standard Care|Standard care Intervention: including a home program of therapeutic (decongestive) exercise, which will include active, non-resistive motion of the involved limb. Participants will perform the exercise once daily for about 10 minutes and will be required to wear their compression sleeve for at least 12 hours per day, each day of the week. After 24 weeks, they will be given the opportunity to take part in the decongestive progressive resistance exercise program and will be provided with an adjustable compression garment to use during exercise.
2936972|NCT02992782|Experimental|Exercise and Compression Garment|Intervention will include having participants wear a compression sleeve during exercise. They will wear the sleeve while carrying out the decongestive progressive resistance exercise program and will continue wearing their day-time compression garment for at least 12 hours per day, each day of the week. They will attend a supervised decongestive progressive resistance exercise program twice a week for 12 weeks at the Cancer Rehabilitation Clinic in Corbett Hall at the University of Alberta. Exercise session will take approximately 60-90 minutes. After 12 Weeks, participants will continue the same program twice weekly for an additional 12 weeks in a community-based fitness center or at home.
2936973|NCT02992782|Experimental|Exercise and Adjustable Compression Wrap|Intervention will include having participants will be fitted for an adjustable compression wrap. They will be required to wear the adjustable compression wrap during the decongestive progressive resistance exercise program and will continue wearing their compression sleeve at least 12 hours per day, each day of the week. They will attend a supervised decongestive progressive resistance exercise program twice a week for 12 weeks at the Cancer Rehabilitation Clinic in Corbett Hall at the University of Alberta. Exercise session will take approximately 60-90 minutes. After 12 weeks, participants will continue the same program twice weekly for an additional 12 weeks in a community-based fitness centre or at home.
2936974|NCT02992756|Experimental|PRP patients|Patients candidates to an IVF/ICSI cycle with low follicular reserve: after at least one cycle of stimulation obtaining 0-4 oocytes.
2936975|NCT02992756|No Intervention|No PRP patients|Patients candidates to an IVF/ICSI cycle with low follicular reserve: after at least one cycle of stimulation obtaining 0-4 oocytes.
2936976|NCT02992743|Experimental|Autologous genetically modified T Cells, NY-ESO-1ᶜ²⁵⁹T|
2936977|NCT02992730||Women Diagnosed with Breast Cancer|Observational - Usual Care
2936978|NCT02992717||Patients undergoing elective general anaesthesia|Male and female adult patients undergoing elective general anaesthesia.
2936979|NCT02992704|Experimental|PEG 24 weeks|peginterferon alpha 2a 180mcg for 24 weeks
2936980|NCT02992704|Experimental|PEG 48 weeks|peginterferon alpha 2a 180mcg 48 weeks
2936981|NCT02992704|No Intervention|Control|No treatment for 72 weeks
2936982|NCT02992691|Experimental|Test Product 1|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
2936983|NCT02992691|Experimental|Test Product 2|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
2936984|NCT02992691|Experimental|Test Product 3|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
2936985|NCT02992691|Active Comparator|Positive Control|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
2936986|NCT02992691|Other|Negative Control|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
2936987|NCT02992678|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
2936988|NCT02992678|Placebo Comparator|Placebo|Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
2936989|NCT02992665|Experimental|Ca ionophore|Artificial activation of the oocytes using Calcium ionophore in the cases of severe male factor infertility.
2936990|NCT02992665|Experimental|Placebo|Placebo was used to control the group of Calcium ionophore
2936991|NCT02992652|Active Comparator|Study Group|Received 600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
2936992|NCT02992652|No Intervention|Control Group|Underwent ERCP without allopurinol prophylaxis
2936993|NCT02992639|Placebo Comparator|Control group|No calorie restriction group
2936994|NCT02992639|Experimental|Weight loss group|Mild calorie restriction group (300kcal/day intake reduction)
2936995|NCT02992626|Experimental|starting with dog|Participants in this arm complete the first session in the presence of a dog. The second session is under control condition in the presence of a stuffed toy dog.
2938621|NCT02981303|Experimental|Triple Negative Breast Cancer|Imprime PGG + Pembrolizumab
2936997|NCT02992613|Experimental|Ultra-Congruent(UC) group|Ultra-Congruent(UC) insert will be used in total knee arthroplasty.
2936998|NCT02992613|Active Comparator|posterior-stabilized(PS) group|Posterior-stabilized(PS) insert will be used in total knee arthroplasty.
2936999|NCT02992600||study group|1000 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.
2937000|NCT02992600||control group|we enroll 50 healthy volunteers and do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test at 1 day (baseline), 1 week, 3 months, 1 year and 3 years without safety issue.
2937001|NCT02992574|Experimental|Post Mastectomy Radiation Therapy (PMRT)|Post mastectomy radiotherapy will be given
2937002|NCT02992574|No Intervention|Observation (No PMRT)|No adjuvant radiotherapy will be given.
2937003|NCT02992561|Active Comparator|FORNET (adapted version)|Version of FORNET including one lifeline session and 5 exposure sessions as well as 6 group sessions adapted from behavioral-therapy approaches for addiction problems.
2937004|NCT02992561|No Intervention|Waitlist control|No intervention
2937005|NCT02992548|Experimental|pravastatin group|Use of pravastatin 20mg to 40mg
2937006|NCT02992535|Experimental|Single arm|Intense pulse light therapy (E-Schwin)
2937007|NCT02992522|Experimental|Treatment (lenalidomide, venetoclax, obinutuzumab)|Patients receive lenalidomide PO on days 1-21 and venetoclax PO on days 1-28. Patients also receive obinutuzumab IV on days 1, 8, and 15 of course 1, and day 1 of courses 2-6. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2937008|NCT02992509|Other|Treatment|This pilot study group is a prospective observational study. It is not blinded and there is no control. This is a single arm study (treatment group) which will receive intravesical electrical stimulation with a total of 8 therapy sessions, each lasting 15 minutes. The sessions will be done in a serial fashion, 2 per week for 4 consecutive weeks.
2937009|NCT02992496|Active Comparator|Ketamine treatment group|Each patient will undergo six treatment sessions with 1mg/kg oral ketamine over 2 weeks.
2937010|NCT02992496|Active Comparator|Control group|Each patient will undergo six treatment sessions with 0.03mg/kg oral midazolam over 2 weeks
2937011|NCT02992483|Experimental|MIK665|
2937012|NCT02992470|Experimental|Hydrolyzed oyster extract|A 250 mg, film-coated oblong (rectangle) shaped tablet of oyster extract
2937013|NCT02992470|Placebo Comparator|Placebo|A 250 mg, film-coated oblong (rectangle) shaped tablet of maltodextrin
2937014|NCT02992457|Active Comparator|Sof-Riba|Sofosbuvir ribavirin 6 months.
2937015|NCT02992457|Active Comparator|Sof- Riba- Pegylated interferon|Sofosbuvir, Ribavirin and Pegylated-interferon alfa-2a 3 months
2937016|NCT02992457|Active Comparator|Sof- Olysio|Sofosbuvir and simeprevir for 3 months.
2937017|NCT02992457|Active Comparator|Sof- Dacla|Sofosbuvir and Daclatasvir for 3 months.
2937018|NCT02992457|Active Comparator|Harvony|Sofosbuvir and ledipasvir for 3 months
2937019|NCT02992457|Active Comparator|Ritaprevir, paritaprevir, ombetasvir|Querevo for 3 months
2937020|NCT02992457|Active Comparator|Salvage therapy|sofosbuvir, daclatasvir, simeprevir,ribavirin
2937021|NCT02992444|Experimental|Cohort 5|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin after 8 hours.~There is one visit:~Two adhesive strips (standard adhesive strip and Experimental adhesive strip)are applied on the peristomal skin and allowed to sit for 8hours before being removed."
2937022|NCT02992431|Active Comparator|Usual care|Usual care including standard disease specific follow-up with visit to general practitioner.
2937023|NCT02992431|Experimental|Participatory patient care planning|Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.
2937024|NCT02992418|Experimental|Concomitant Administration Group|Participants will be administered the first dose of CYD dengue vaccine concomitantly with a dose of Tdap vaccine
2937025|NCT02992418|Experimental|Sequential Administration Group|Participants will be administered the first dose of CYD dengue vaccine28 days after a dose of Tdap vaccine.
2937026|NCT02992405|Experimental|FOCUS Resilience Enhancement Program|Those assigned to the immediate treatment group will participate in the 10-week treatment.
2937027|NCT02992405|Experimental|Waitlist Treatment|After the 10-week immediate treatment period, wait-list control participants will be administered the treatment.
2937028|NCT02992392|Experimental|Liposic|Liposic was applied to one eye of patients in this group
2937029|NCT02992392|Experimental|Tears Naturale Forte|Tears Naturale Forte was applied to one eye of patients in this group
2937030|NCT02992379|Active Comparator|stabilizing splint|Active Comparator: stabilizing splint A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint
2937031|NCT02992379|Experimental|pivot splint|"Experimental: pivot splint A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks.~Other Names: PS"
2937097|NCT02991950|No Intervention|no treatment|Women in the control arm are administered with routine ovulation induction protocol, without the addition of parnaparin sodium.
2938654|NCT02981108|Experimental|Expansion Cohort 2|Oral Once-Daily Administration of HS-10296 260mg
2937032|NCT02992366|Experimental|socket shield (A)|"Following local anesthetic infiltration opposite to the root to be extracted the root is sectioned in a mesiodistal direction along its long axis as far apical as possible.~After sectioning the root into labial and palatal halves, the palatal half is removed with preservation of the labial root section.~The labial half is prepared to be Flushing or 1mm above the labial alveolar crest. Then thinned slightly to a concave contour in an apico-coronal and mesiodistal direction.~The implant will be inserted in place of the palatal half with the labial surface of the implant facing the labial root shield (root-implant interface)~primary closure will not be attempted as the patients will undergo immediate non-functioning provisionization."
2937033|NCT02992366|Active Comparator|conventional immediate implant (B)|"Following local anesthetic infiltration opposite to the root to be extracted non traumatic extraction of the tooth or remaining root by periotome.~The implant fixture will be inserted in the empty socket by conventional manner.~primary closure will not be attempted as the patients will undergo immediate non-functioning provisionization."
2937034|NCT02992353|Active Comparator|Three-port pulmonary resection surgery|Treated by traditional video assisted thoracoscopic three-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
2937035|NCT02992353|Active Comparator|Single-port or two-port surgery|Treated by minimally invasive video assisted thoracoscopic single-port or two-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
2937036|NCT02992340|Experimental|Phase 1B|Varlitinib (starting dose at 200 mg BID) Cisplatin Gemcitabine
2937037|NCT02992327||Cohort|Patients age ≥ 8 years of age with a GCS >13 presenting to the emergency department with a diagnosis of concussion.
2937038|NCT02992314|Experimental|Metaqil™ Oral Rinse|"In this arm the test article, Metaqil ™ oral rinse, a proprietary formulation of agents including Monk fruit extract, which can minimize the metallic taste in the mouth caused by the patient's medications.~Subjects rinse twice a day with 10 mL of the oral rinse for 30 seconds for 30 days.~They will note, in the daily oral hygiene diary, the date and time of brushing and rinsing."
2937039|NCT02992314|Placebo Comparator|Placebo Oral Rinse|This arm will use a placebo with out the active ingredients same way the experimental arm do.
2937040|NCT02992301|Experimental|Open Label|All enrolled patients will receive open label Praluent (Alirocumab).
2937041|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (5 mg)|Chronic heart failure with reduced ejection fraction
2937042|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (10 mg)|Chronic heart failure with reduced ejection fraction
2937043|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (20 mg)|Chronic heart failure with reduced ejection fraction
2937044|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (30 mg)|Chronic heart failure with reduced ejection fraction
2937045|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (40 mg)|Chronic heart failure with reduced ejection fraction
2937046|NCT02992288|Placebo Comparator|Placebo|Chronic heart failure with reduced ejection fraction
2937047|NCT02992275|Experimental|NMES + MMBI|Neuromuscular electrical stimulation applied to hip abductors along with participation in a multi-modality balance intervention
2937048|NCT02992236|Placebo Comparator|Placebo|Infusion (6 hours) of Saline
2937049|NCT02992236|Active Comparator|VAS203|Infusion (6 hours) of VAS203 (10 mg/kg)
2937050|NCT02992210|Experimental|effectiveness of 4SCAR-GD2 T cells|The 4SCAR-GD2-modified T cells can recognize and kill tumor cells through the recognize of GD2 .This study will evaluate the side effects and effective doses of 4SCAR-GD2 T cells in treating refractory and recurrent solid tumors
2937051|NCT02992197|Active Comparator|Rotarix, single dose|Rotarix 1.5 mL (standard single dose) and 1.5 mL of placebo by mouth (sterile, pharmacy-grade water) at both 6 and 10 weeks of life
2937052|NCT02992197|Experimental|Rotarix, double dose|Rotarix 3 mL by mouth (two standard doses administered simultaneously) at both 6 and 10 weeks of life
2937053|NCT02992184||HCV patients|228 HCV patients
2937054|NCT02992184||control|189 controls
2937055|NCT02992171|Experimental|care management by oncology nurses|The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
2937056|NCT02992158|Experimental|behavioral activation|The core principles of the BA model are: (1) the key to changing how people feel is helping them change what they do, (2) changes in life can lead to depression, and short-term coping strategies may keep people stuck over time, (3) the clues to figuring out what will be antidepressant for a particular client lie in what precedes and follows the client's important behaviors, (4) structure and scheduling of activities should follow a plan, not a mood, (5) change will be easier when starting small, (6) activities that are naturally reinforcing should be emphasized, (7) the therapist should act as a coach, (8) a problem-solving empirical approach should be emphasized with recognition that all results are useful, (9) patients should be encourages to not just talk, do! (10) possible and actual barriers to activation should be examined. Patients can also receive medications in this arm.
2937057|NCT02992158|Other|treatment-as-usual|Patients will receive psychotherapy (and potentially medications) as part of treatment-as-usual provided in the CMHC setting.
2937058|NCT02992145||Case group: This group will include forty (40) preeclampt|
2937059|NCT02992145||Control group: This group will include forty (40) normoten|
2937060|NCT02992132|Experimental|Pimavanserin 34 mg|Drug- pimavanserin tartrate, 34 mg, taken as two 17 mg tablets, once daily by mouth
2937061|NCT02992132|Experimental|Pimavanserin 20 mg|Drug- pimavanserin tartrate, 20 mg, taken as two 10 mg tablets, once daily by mouth
2937062|NCT02992132|Placebo Comparator|Placebo|Placebo, taken as two tablets, once daily by mouth
2937063|NCT02992119|Experimental|Group 1|RTS,S/AS01B Fractional dose
2937064|NCT02992119|Experimental|Group 2|Double RTS,S/AS01E Fractional dose
2937065|NCT02992119|Experimental|Group 3|RTS,S/AS01E Standard dose
2937066|NCT02992119|Experimental|Group 4|RTS,S/AS01E + DHA-PIP+PQ Standard dose
2937067|NCT02992119|Experimental|Group 5|RTS,S/AS01E Fractional dose
2937068|NCT02992119|Experimental|Group 6|RTS,S/AS01E + DHA-PIP+PQ Fractional dose
2937069|NCT02992119|Experimental|Group 7|RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose
2938750|NCT02980445|No Intervention|Control|
2937070|NCT02992106|Other|Normal weight during pregnancy|"Offspring of 156 women with a normal weight during their pregnancy recruited by Bogaerts et al, in 3 belgian hospitals. Results of maternal data published in 2013. Now the children will be recruited. This group wil function as a control group.~All participating children will undergo the same examinations:~Parental questionnaires~Blood sample~Urine sample~Anthropometric measurements~Abdominal ultrasound (fat mass)~EndoPAT"
2937071|NCT02992106|Other|Obese mothers without intervention|"This subgroup will be compiled of the offspring of women recruited in two different studies. First of all there is the offspring of 65 women from the cohort that was recruited by Guelinckx et al, data published in 2010. This population was recruited in the University hospital of Leuven as control group for women receiving lifestyle interventions during pregnancy. Secondly there are children of 63 women from the cohort of Bogaerts et al of 2013 that had a BMI > 29 kg/m² during their singleton pregnancy.~All participating children will undergo the same examinations:~Parental questionnaires~Blood sample~Urine sample~Anthropometric measurements~Abdominal ultrasound (fat mass)~EndoPAT"
2937072|NCT02992106|Other|Obese mothers & lifestyle intervention|"This one will also be a composition of study subjects of two different study cohorts. Firstly there are children of about 100 Belgian women that were included in the DALI cohort, a European randomized controlled trial. All of them underwent a lifestyle intervention during pregnancy, concerning diet and/ or exercise. Secondly there is the offspring of the other subgroup of the cohort recruited by Guelinckx et al. 130 women were divided into 2 groups which underwent lifestyle interventions during pregnancy.~All participating children will undergo the same examinations:~Parental questionnaires~Blood sample~Urine sample~Anthropometric measurements~Abdominal ultrasound (fat mass)~EndoPAT"
2937073|NCT02992106|Other|History of bariatric surgery|"The PABAS cohort (Pregnancy After Bariatric Surgery) provides children of 49 women who underwent bariatric surgery before their singleton pregnancy. The women were included in five Flemish hospitals before 15 weeks of pregnancy. Furthermore we will recruit the offspring of 200 women that are recruited in the ongoing AURORA cohort (bAriatric sUrgery Registration in women Of Reproductive Age). Women in this cohort are recruited from the start of their process undergoing bariatric surgery and are followed until after their pregnancy.~All participating children will undergo the same examinations:~Parental questionnaires~Blood sample~Urine sample~Anthropometric measurements~Abdominal ultrasound (fat mass)~EndoPAT"
2937074|NCT02992093||obese with PCOS|all the indicators
2937075|NCT02992093||nonobese with PCOS|all the indicators
2937076|NCT02992093||PCOS with IGT|all the indicators
2937077|NCT02992093||PCOS with T2DM|all the indicators
2937078|NCT02992093||Healthy volunteers|all the indicators
2937079|NCT02992080|Other|Cystic fibrosis Patients|
2937080|NCT02992080|Other|Patients without fibrosis cystic|
2937081|NCT02992067||Operable breast cancer|clinical stage: cTis, cI, cII, cT3N1M0
2937082|NCT02992054||Stimulating activities with the use of tactile tablet computer|Stimulating activities through the use of a tactile tablet computer. These tablets are linked to an internet-based service platform and offer a very easy and intuitive interaction for the user, even when this person is suffering from a moderate cognitive and/or physical impairment.
2937083|NCT02992054||Stimulating activities with usual stimulation activity program|No Stimulating activities through the use of a tactile tablet computer
2937084|NCT02992041|Active Comparator|Lower dose VVZ-149 Injections|At least one hour before the completion of surgical suturing subjects will receive a loading dose of VVZ-149 intravenous infusion (110 mg) over 0.5 hour. This loading dose will be followed by the maintenance dose of an intravenous VVZ-149 infusion (790 mg) over 9.5 hours.
2937085|NCT02992041|Active Comparator|Higher dose VVZ-149 Injections|At least one hour before the completion of surgical suturing subjects will receive a loading dose of VVZ-149 intravenous infusion (130 mg) over 0.5 hour. This loading dose will be followed by the maintenance dose of an intravenous VVZ-149 infusion (970 mg) over 9.5 hours.
2937086|NCT02992041|Placebo Comparator|Placebo|At least one hour before the completion of surgical suturing subjects will receive a loading dose of VVZ-149 intravenous infusion (placebo) over 0.5 hour. This loading dose will be followed by the maintenance dose of an intravenous VVZ-149 infusion (placebo) over 9.5 hours.
2937087|NCT02992028|Experimental|Intravenous vitamin C injection|During the first 30 min after beginning of the rotator cuff repair, treatment group received infusion of 3 g vitamin C (ascorbic acid) in 500 ml of Ringer.
2937088|NCT02992028|Placebo Comparator|Intravenous saline injection|During the first 30 min after beginning of the rotator cuff repair, sham group received 6 ml normal saline in 500 ml of Ringer.
2937089|NCT02992015|Experimental|Gemcitabine|The entire therapy on this study is one dose of gemcitabine. No intrapatient dose modifications are necessary. Gemcitabine will be given at 2100 mg/m2 IV over 30 minutes within 4 hours of planned surgical procedure.
2937090|NCT02991989|Experimental|Exercise Snacking Group|For 28 days, this group will be asked to perform two 'exercise snacks' a day; once in the morning and once in the evening. They will also be asked to consume 150 g of yogurt with the breakfast meal. The yogurt will be provided by the researchers.
2937091|NCT02991989|Other|Yogurt Only Group|For 28 days, this group will be asked to consume 150 g of yogurt with the breakfast meal. The yogurt will be provided by the researchers. Apart from consuming the yogurt, this group will be asked to continue their normal lifestyle.
2937092|NCT02991976|Active Comparator|35% O2|Patient receiving 35% O2 during carotid endarterectomy, Intervention - oxygen concentration
2937093|NCT02991976|Active Comparator|100% O2|Patient receiving 100% O2 during carotid endarterectomy, Intervention - oxygen concentration
2937094|NCT02991963||Case|Malaria patient defined by positive RDT or blood smear
2937095|NCT02991963||Control|Non-malaria patient defined by negative RDT or blood smear
2937096|NCT02991950|Experimental|parnaparin sodium|"Women in LMWH arm are administered with routine ovulation induction protocol and prophylactic dose of parnaparin sodium (LMWH), starting the day before the beginning of stimulation phase of the cycle until the result of the procedure is confirmed in terms of pregnancy yes or no and in case of pregnancy until the delivery or the end of pregnancy. Women in the LMWH arm will be tested for blood cell count twice in the first 10 days of therapy.~Parnaparin will be administered at the dose of 100 IU/kg/day from the day before the beginning of stimulation phase of the cycle until the result of the procedure is confirmed in terms of pregnancy yes or no and in case of pregnancy until delivery or the end of the pregnancy.~Used dosages Parnaparin 0.4 4250 UI Parnaparin 0.6 6400 UI"
2937098|NCT02991937|Active Comparator|Medical Therapy|Subjects in the medical therapy arm will be treated with piperacillin/tazobactam for at least 24 hours. Ciprofloxacin/metronidazole will be used in penicillin-allergic patients. Subjects will be maintained on nothing by mouth with intravenous fluids for at least 12 hours. Subjects will be transitioned to oral antibiotics when their WBC is normal, they have a decrease in CRP by ≥ 15%, and they have been afebrile for 24 hours on IV antibiotics.
2937099|NCT02991937|Active Comparator|Surgical Intervention|Subjects in the surgical treatment arm will receive intravenous antibiotics until the time of operation, and will be maintained on intravenous fluids and no oral intake until they undergo appendectomy as per standard of care. Appendectomy will occur within 24 hours of enrollment. Subjects in the surgical treatment arm will receive post-operative antibiotics as per standard of care.
2937100|NCT02991911|Experimental|Arm A|MEDI3726 Post-Chemo
2937101|NCT02991911|Experimental|Arm B|MEDI3726 Pre-Chemo
2937102|NCT02991911|Experimental|Arm C|MEDI3726 & Enzalutamide Combo
2937103|NCT02991898|Experimental|Treg Infusion|The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion
2937104|NCT02991885|Experimental|HAL-MPE1|HAL-MPE1 is an off-white to white liquid suspension containing modified peanut extract
2937105|NCT02991885|Placebo Comparator|HAL-MPE1 placebo|HAL-MPE1 placebo without modified peanut extract
2937106|NCT02991872|Other|V49_24E1 Group|Up to 225 subjects, who completed the full PEP rabies regimens in the parent study V49_24 (NCT01680016), will be invited to participate to this extension study.
2937107|NCT02991859|Experimental|Arm AB - FF followed by FP|Each treatment period (TP) comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or FP. In TP 1, subjects will receive evening (PM) dose of 1 puff of FF 25 microgram (mcg) (Total daily dose [TDD] = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puff of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puff of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by morning (AM) and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
2937108|NCT02991859|Experimental|Arm AC - FF followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or BUD. In TP 1, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD = 100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD = 400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD = 1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
2937109|NCT02991859|Experimental|Arm AD - FF followed by ELLIPTA Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or ELLIPTA Placebo. In TP 1, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phases followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. Washout period will be of 25-42 days.
2937110|NCT02991859|Experimental|Arm BA - FP followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or FF. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
2937111|NCT02991859|Experimental|Arm BC - FP followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or BUD. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD = 400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
2937112|NCT02991859|Experimental|Arm BE - FP followed by DISKUS Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or DISKUS Placebo. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each DISKUS Placebo in second, third and fourth phase; AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. Each TP will be followed by a washout period of 25-42 days.
2937125|NCT02991807|Placebo Comparator|Placebo|Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10.
2937113|NCT02991859|Experimental|Arm CA - BUD followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or FF. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
2937114|NCT02991859|Experimental|Arm CB - BUD followed by FP|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or FP. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD =500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
2937115|NCT02991859|Experimental|Arm CE - BUD followed by DISKUS Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or DISKUS Placebo. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each DISKUS Placebo in second, third and fourth phase; and AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. Washout period will be of 25-42 days.
2937116|NCT02991859|Experimental|Arm DA - ELLIPTA Placebo followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either ELLIPTA Placebo or FF. In TP 1, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phase followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
2937117|NCT02991859|Experimental|Arm EB - DISKUS Placebo followed by FP|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either DISKUS Placebo or FP. TP 1, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each of DISKUS Placebo in second, third and fourth phase; AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
2937118|NCT02991859|Experimental|Arm DC - ELLIPTA Placebo followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either ELLIPTA Placebo or BUD. In TP 1, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phase followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
2937119|NCT02991846||Patients with cGVHD|All consecutive patients undergoing allogenic stem cell transplant for any underlying disease who develop chronic graft-versus-host disease (cGVHD)
2937120|NCT02991833|Experimental|Of A New Incontinence Care Product|Patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 days. The visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD. Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased. To evaluate skin integrity, the perineal skin of the patients was observed every day by researcher and was recorded to the Perineal Skin Integrity Assesment Form. The number of defecation, stool consistency, and the number of care product ( the novel incontinent care product) was observed daily and was recorded to the Patient Observation Form. The main study outcomes was IAD.
2937121|NCT02991833|Active Comparator|Diaper|Patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 days. The visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD. Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased. To evaluate skin integrity, the perineal skin of the patients was observed every day by researcher and was recorded to the Perineal Skin Integrity Assesment Form. The number of defecation, stool consistency, and the number of care product (diaper ) was observed daily and was recorded to the Patient Observation Form. The main study outcomes was IAD.
2937122|NCT02991820|Experimental|Inexperienced users|Inexperienced users will include trainees (SRNAs, residents, fellows, and medical students) and nurses at NCH.
2937123|NCT02991820|Experimental|Experienced users|Experienced users will include faculty pediatric anesthesiologists CRNAs.
2937124|NCT02991807|Experimental|RAD001|RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis.
2937185|NCT02991417|Experimental|CDVAX|
2937126|NCT02991781|Experimental|COPD Patients|"C.O.P.D. patients: Presence of a post-bronchodilator forced expiratory volume at one second (FEV1) / forced vital capacity (FVC) < 0.70 with symptoms as dyspnea, chronic cough, chronic sputum production~Biofeedback and Neurofeedback Training~Varenicline use for smoking cessation~Passive Control"
2937127|NCT02991781|Experimental|Asthma Patients|"Asthma patients: Presence of 2 or more of symptoms of airflow obstruction (cough, wheezing, dyspnea). Airflow obstruction at least partially reversible demonstrated by spirometry with FEV1 increased by >12% following b2 agonist inhalation) or evidence of bronchial hyperresponsiveness by metacholine provocation test (demonstrated by provocative concentration causing a 20% fall (PC20) <8 mg or mannitol provocation test (with FEV1 decrease of 15%)~Biofeedback and Neurofeedback Training~Varenicline use for smoking cessation~Passive Control"
2937128|NCT02991781|Experimental|Smokers|"Smokers will consist of a group of patients that are under the age of 35, unemployed and healthy according to a standard clinical evaluation.~Biofeedback and Neurofeedback Training~Varenicline use for smoking cessation~Sham Neurofeedback~Passive Control"
2937129|NCT02991768|Experimental|Entocort EC|Subjects will take 6mg Entocort EC by mouth daily for 8 weeks.
2937130|NCT02991768|Placebo Comparator|Placebo|Subjects will take 6mg matching placebo pill daily for 8 weeks.
2937131|NCT02991742||Iodixanol|Iodixanol contrast media
2937132|NCT02991742||Ioxaglate|Ioxaglate contrast media
2937133|NCT02991729|Active Comparator|Routine care|These patients will receive routine care at our institution for counseling on aneuploidy screening; they will be counseled by a genetic counselor on options, and following counseling, will select their test of choice. All patients will complete a knowledge and demographics questionnaire prior to genetic counseling. Patients in this arm will then complete a knowledge and decisional conflict survey immediately following genetic counseling.
2937134|NCT02991729|Experimental|Experimental|These patients will use an iPad-based decision aid explaining options for aneuploidy screening and testing. They will then immediately be counseled by a genetic counselor on their options as is routine at our institution, and following counseling, will select their test of choice. All patients will complete a knowledge and demographics questionnaire prior to genetic counseling. Patients in this arm will then complete a knowledge and decisional conflict survey following use of the decision aid, and again immediately following genetic counseling.
2937135|NCT02991716||Recorded patients|Patients requiring Intracradiac Defibrillator (ICD) implantation, Electrophysiology (EP) study or a holter monitor recording, mainly due to suspected ventricular tachy - arrhythmias
2937136|NCT02991703|Active Comparator|SphygmoCor®|
2937137|NCT02991703|Experimental|pOpmètre®|
2937138|NCT02991690|Experimental|Hypothermia|Intravascular hypothermia will be initiated within 24 hours post-injury and 33 degrees Celsius will be maintained for 48 hours.
2937139|NCT02991690|No Intervention|Control|Standard of care medical treatment, specific to each individual.
2937140|NCT02991677|Other|control|This is an attention control group with regular contact by study staff.
2937141|NCT02991677|Experimental|aerobic exercise|Aerobic exercise intervention is for 12 weeks 3 times weekly with training on site.
2937142|NCT02991677|Experimental|resistive training|Intervention is for 12 weeks 3 times weekly with training on site.
2937143|NCT02991664|Active Comparator|Equia Forte, randomly applied|Placing glass ionomer restorations, the dentin and enamel of cavities were washed, and briefly dried. Equia Forte Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Forte Coat was applied and photocured for 20 seconds using a photo-curing light.
2937144|NCT02991664|Active Comparator|G-aenial Posterior, randomly applied|After etching procedure, the enamel and dentin were conditioned with G-aenial adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, G-aenial posterior composite resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
2937145|NCT02991651|Experimental|Dose Level 1|IRX4204 5 mg/day PO + erlotinib 100 mg/day PO
2937146|NCT02991651|Experimental|Dose Level 2|IRX4204 5 mg/day PO + erlotinib 150 mg/day PO
2937147|NCT02991651|Experimental|Dose Level 3|IRX4204 10 mg/day PO + erlotinib 150 mg/day PO
2937148|NCT02991638|Other|Ibrutinib|Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression
2937149|NCT02991625|Experimental|Placebos|Chronic Back Pain participants will enter an optional placebo trial. This phase of the study will test the clinical usefulness of the biomarkers. We will measure how expectation of starting a new treatment reduces 'clinical back pain' in each participant. Positive treatment expectations will be induced by giving them capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules twice a day and report their pain on paper forms organized as a calendar.
2937150|NCT02991625|Other|Waitlist|Chronic Back Pain participants will not be given any placebo and will be requested to report their pain on paper forms organized as a calendar.
2937151|NCT02991625|Other|Healthy Controls|Healthy control participants will complete the main part of the study, but will not be asked to take a placebo or be placed on a waitlist.
2937152|NCT02991612|Experimental|Rifaximin Treatment Group|Rifaximin 400mg bid for 2 months,
2937153|NCT02991612|No Intervention|Control Group|Receive routine endoscopic treatment without having rifaximin for 2 months
2937154|NCT02991599|Experimental|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
2937155|NCT02991599|Experimental|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
2937186|NCT02991404|Active Comparator|Continuous adductor canal block|"After successful placement of the adductor canal catheter placed in standard fashion , the patient will receive a one-time (Initial bolus) 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine followed by a continuous infusion of 0.125% bupivacaine set at 10ml/hour.~Multimodal peripheral nerve block injection."
2937156|NCT02991586|Experimental|Dialectical Behavior Therapy|Dialectical Behavior Therapy (DBT) is a cognitive behavioral treatment that was originally developed to treat chronically suicidal individuals diagnosed with borderline personality disorder (BPD) and it is now recognized as the gold standard psychological treatment for this population. In addition, research has shown that it is effective in treating a wide range of other disorders such as substance dependence, depression, post-traumatic stress disorder (PTSD), and eating disorders. In this research DBT skills will be taught to parents of adolescents with high emotional instability
2937157|NCT02991586|No Intervention|Control|"Control: The No intervention arm in this research is defined as follow:, sons and daughters are in their respective treatment but parents are nor receiving any DBT intervention"
2937158|NCT02991573|Active Comparator|existing adhesive (control)|control adhesive
2937159|NCT02991573|Experimental|new adhesive: technique 1|Prime & Bond Universal: technique 1
2937160|NCT02991573|Experimental|new adhesive: technique 2|Prime & Bond Universal: technique 2
2937161|NCT02991560|Experimental|Kinesio tape (KT)|The KT group was taped 2 days a week for 4 weeks using the muscle and fascia correction techniques
2937162|NCT02991560|Experimental|Athletic taping (AT)|An athletic tape with adhesive backing was used (38 mm wide-Muller Protape-The Netherlands).
2937163|NCT02991534|Other|Arm 1|"The investigators will use a nonrandomized stepped wedge design to evaluate the implementation in four VA Women's Practice Based Research Network (PBRN) sites. In this nonrandomized stepped wedge design, the intervention is turned on when a primary care provider (PCP) uses a CV screening template which maps to the patient CV self-screener. This design relies on sequential roll-out to participating sites over time, while using other sites as controls until they begin implementation. The investigators will use nonrandomized stepped wedges (rather than randomized) given their suitability for studying implementation. The design explicitly considers the timing of implementation spread and addresses the statistical issues introduced by lack of randomization in implementation starts and processes. The investigators will analytically compensate for the design by collecting patient-, provider-, and site-level data that may be associated with timing of the adoption of each intervention."
2937164|NCT02991521|Experimental|FAST examination after Right sided roll (FASTeR)|Subjects will have a standard FAST exam, and will then be rolled onto their right side and the FAST exam will be repeated.
2937165|NCT02991508|Placebo Comparator|Placebo|Vehicle (20 mM His/HCl pH 6.0)
2937166|NCT02991508|Active Comparator|Adrecizumab 0.5 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
2937167|NCT02991508|Active Comparator|Adrecizumab 2.0 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
2937168|NCT02991508|Active Comparator|Adrecizumab 8.0 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
2937169|NCT02991495|Active Comparator|Stamaril, Sanofi Pasteur: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
2937170|NCT02991495|Experimental|Stamaril, Sanofi Pasteur: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
2937171|NCT02991495|Active Comparator|Yellow fever vaccine, Bio-Manguinhos: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
2937172|NCT02991495|Experimental|Yellow fever vaccine, Bio-Manguinhos: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
2937173|NCT02991495|Active Comparator|Yellow fever vaccine, Institut Pasteur: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
2937174|NCT02991495|Experimental|Yellow fever vaccine, Institut Pasteur: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
2937175|NCT02991495|Active Comparator|Yellow fever vaccine, Chumakov Institute: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
2937176|NCT02991495|Experimental|Yellow fever vaccine, Chumakov Institute: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
2937177|NCT02991482|Experimental|Pembrolizumab arm|Pembrolizumab is administrated at 200 mg fixed dose i.v. on day 1 of every 3 week cycle for a maximum or 2 years (expected maximum of 36 doses), or until progression of disease determined according to RECIST 1.1 criteria or lack of tolerability, or until the patient declines further treatment.
2937178|NCT02991482|Active Comparator|Standard chemotherapy arm|"Gemcitabine (i.v. 1000 mg/m2) or vinorelbine (i.v. 30 mg/m2, or p.o 60/80 mg/m2) chemotherapy will be chosen on a per patient basis and delivered according to local standards. Chemotherapy will be administered on days 1 and 8 of every 3-week cycle. A maximum number of treatment cycles is not mandated.~Patients randomised to the control arm will be allowed to cross over to receive pembrolizumab at progression, if cross-over criteria are met. Pembrolizumab administration will follow the same schedule as for patients in the experimental arm, i.e. 200 mg fixed dose i.v. on day 1 of every 3-week cycle for a maximum of 2 years or until trial termination."
2937179|NCT02991469|Experimental|Sarilumab|Participants will receive one of two ascending doses (or an additional intermediate dose based on available data) of sarilumab by subcutaneous (SC) injection based on body weight. All the participants will receive the selected dose once the selected dose is identified. Sarilumab will be given during 12-week core treatment phase followed by a 144- week extension treatment phase.
2937180|NCT02991456|Active Comparator|Sequence A|Daily ondansetron alone for 3 weeks, followed by the use of rolapitant (one dose on day 22) plus continued daily ondansetron for 3 weeks.
2937181|NCT02991456|Active Comparator|Sequence B|Single dose of rolapitant (one dose on day 1) plus daily ondansetron for 3 weeks, followed by daily ondansetron alone for 3 weeks.
2937182|NCT02991443|Experimental|Mindfulness based stress reduction|Parents of children with IBD will undergo mindfulness based stress reduction (MBSR) intervention consisted of 8 group sessions. The effect on stress and anxiety will be assessed using 3 validated questionnaires which will be filled prior to intervention, at the end of intervention and 3 months following intervention.
2937183|NCT02991430|Active Comparator|active|active neuromodulation
2937184|NCT02991430|Placebo Comparator|placebo|placebo neuromodulation
2937187|NCT02991404|Sham Comparator|Single injection block with sham cath|Single Shot Adductor Canal Block . Patients will receive single injection adductor canal block (Initial Bolus) with bupivacaine 0.25%, epinephrine, clonidine, buprenorphine and dexamethasone. These patients will have a sham infusion catheter of inert saline placed in the same fashion as the other group.
2937188|NCT02991378|Experimental|Intervention group|"Subjects in this group will receive the Children's emotional and stress coping program which train the children the emotional self-regulation skills and stress coping skill with a standardized protocol."
2937189|NCT02991378|No Intervention|Control group|"Subjects in this group will not receive the Children's emotional and stress coping program."
2937190|NCT02991365|Active Comparator|nasal insulin|daily administration of 160 U of human insulin as nasal spray
2937191|NCT02991365|Placebo Comparator|placebo spray|daily administration of placebo solution as nasal spray
2937192|NCT02991352|Experimental|Experimental|Image guided needle placement into vascular malformations based on MRI
2937193|NCT02991339|Experimental|Dexamethasone|Dexamethasone 10 mg iv on day 1 and day 2, then 5 mg iv on day 3. For the patients the serum total bilirubin did not decrease to 1.5 ULN, then 5 mg iv on day 4.
2937194|NCT02991339|No Intervention|control|Patients are not treated with glucocorticoids.
2937195|NCT02991326|Experimental|Test Group (TG)|The Individuals who already is subject to Clinical Treatment with splints offered at the Occlusion Clinic will be subject to Osteopathic Manipulative Treatment - OMT.
2937196|NCT02991326|Sham Comparator|Control Group (CG)|The Individuals who already is subject to Clinical Treatment with splints offered at the Occlusion Clinic will be subject to sham intervention (Osteopathic Manipulative Treatment simulated).
2937197|NCT02991313|Experimental|Endocardial Ablation Procedure|ablation with Linear type catheter
2937198|NCT02991287||Chronic post-surgical pain patients|Patients scheduled for differents types of surgery (inguinal, hernia repair, abdominal hysterectomy, vaginal hysterectomy, and thoracotomy).
2937199|NCT02991274|Other|T790M mutation test|genomic testing of T790M mutation
2937200|NCT02991261|Experimental|SPARC001 type I|Treatment type I
2937201|NCT02991261|Experimental|SPARC001 type II|Treatment type II
2937202|NCT02991261|Active Comparator|Reference001 type I|Hydrocodone-Acetaminophen
2937203|NCT02991261|Active Comparator|Reference type II|Hydrocodone-Acetaminophen
2937204|NCT02991248|Experimental|robotic training & stimulation|Device: robotic treadmill training paired with active spinal cord electrical stimulation, three times a week for 6 weeks.
2937205|NCT02991248|Active Comparator|robotic training & sham|Device: robotic training paired with sham spinal cord stimulation, three time a week for 6 weeks.
2937206|NCT02991248|Placebo Comparator|treadmill only|Device: treadmill Conventional treadmill training only, three time a week for 6 weeks.
2937207|NCT02991235|Experimental|PRJ212|PRJ212 is a nutritional product with active food ingredients.
2937208|NCT02991235|Placebo Comparator|Placebo|Placebo is like PRJ212 without active food ingredients.
2937209|NCT02991222|Experimental|SPARC001 type I|Treatment type I
2937210|NCT02991222|Experimental|SPARC001 type II|Treatment type II
2937211|NCT02991222|Active Comparator|Reference001 type I|Treatment type I
2937212|NCT02991222|Active Comparator|Reference type II|Treatment type II
2937213|NCT02991209|Experimental|Tostran 2%|1 years treatment with transdermal Tostran 2%
2937214|NCT02991209|Placebo Comparator|Placebo|1 years treatment with placebo gel
2937215|NCT02991196|Experimental|DS-8273a + nivolumab|Participants will receive their treatment dose until discontinuation for any reason, or trial completion, within two years
2937216|NCT02991183|Experimental|Acceptance and Commitment Therapy|Two half day (2.5 hours) group ACT sessions delivered one week apart followed by a third session 2 weeks following the second session.
2937217|NCT02991170|Active Comparator|control group|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
2937218|NCT02991170|Experimental|interventional group|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time
2937219|NCT02991144|Experimental|Dose 1: 2.0 × 10^12 GC/kg|DTX301 (scAAV8OTC) will be administered as a single peripheral IV infusion.
2937220|NCT02991144|Experimental|Dose 2: 6.0 × 10^12 GC/kg|DTX301 (scAAV8OTC) will be administered as a single peripheral IV infusion.
2937221|NCT02991144|Experimental|• Dose 3: 1.0 × 10^13 GC/kg|DTX301 (scAAV8OTC) will be administered as a single peripheral IV infusion.
2937222|NCT02991131||Tedizolid|Hospitalized ABSSSI patients treated by tedizolid
2937223|NCT02991131||Linezolid|Hospitalized ABSSSI patients treated by linezolid
2937224|NCT02991118|Active Comparator|bempedoic acid|bempedoic acid 180 mg/day
2937225|NCT02991118|Placebo Comparator|Placebo|Placebo control
2937226|NCT02991105||Solid organ transplant recipients|"National cohort = 85,410 solid organ transplant recipients receiving their transplant between 1985 to 2015~Local cohort = approximately 3,000-4,000 solid organ transplant recipients under secondary care follow up at University Hospitals Birmingham"
2937227|NCT02991092|Experimental|the experimental group|After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h
2937228|NCT02991092|Other|the control group|"patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered."
2937229|NCT02991079|Active Comparator|Control: Lifestyle counseling|Counseling on physical activity and Mediterranean diet.
2937230|NCT02991079|Experimental|Intervention group|Add for three months a smartphone with an app (EVIDENT) to improve alimentation and physical activity, five cardio-health rides and feeding workshop.
2937231|NCT02991066||Patients|patients with de novo acute promyelocytic leukemia with hemorrhage.
2937232|NCT02991066||Control|healthy volunteers.
2937559|NCT02988895|Experimental|episcleral brachytherapy|single fraction of 24 Gy Strontium90 episcleral brachytherapy
2937233|NCT02991053|Active Comparator|block and ketamine|Transversus Abdominis Plane block after ketamine atropine induction and continued with ketamine only in anesthesia
2937234|NCT02991053|Active Comparator|block; ketamine with laryngeal mask; inhalation anesthesia|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and applied Transversus Abdominis Plane block.
2937235|NCT02991053|Active Comparator|block and ketamine ıh/ıl|Ilioinguinal / iliohypogastric block after ketamine atropine induction and continued with ketamine only in anesthesia
2937236|NCT02991053|Active Comparator|ıh/ıl block; ketamine; inhalation anesthesia|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and applied Ilioinguinal / iliohypogastric block.
2937237|NCT02991053|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
2937238|NCT02991027|Experimental|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be imaged using 2 different light sources using the DRI Triton
2937239|NCT02991014|Active Comparator|researcher-selected frequency-modulated music|
2937240|NCT02991014|Placebo Comparator|researcher-selected non-modulated music|
2937241|NCT02991014|Experimental|participant-selected non-modulated music|
2937242|NCT02991001|Experimental|Normal saline hydrodissection|Ultrasound-guided hydrodissection with normal saline between carpal tunnel and median nerve.
2937243|NCT02991001|Placebo Comparator|Normal saline|Ultrasound-guided injection with normal saline at subcutaneous layer beyond the carpal tunnel region
2937244|NCT02990988||Iron repletion|Subjects participating in the associated study under the Iron Repletion arm will also provide stool collection and answers to questionnaire and diet diary.
2937245|NCT02990988||Placebo|Subjects participating in the associated study under the Placebo arm will also provide stool collection and answers to questionnaire and diet diary.
2937246|NCT02990975|Active Comparator|block and ketamine|Transversus Abdominis Plane block after ketamine atropine induction and continued with ketamine only in anesthesia
2937247|NCT02990975|Active Comparator|ketamine atropine; laryngeal mask|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and applied Transversus Abdominis Plane block.
2937248|NCT02990975|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
2937249|NCT02990962|Experimental|Perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% Dextrose (5cc) between carpal tunnel and median nerve.
2937250|NCT02990962|Active Comparator|Perineural injection with steroid|Ultrasound-guided perineural injection with 1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and median nerve.
2937251|NCT02990949|Experimental|Testing group|Timing of trigger at end of ovarian stimulation in an IVF cycle: trigger when 2 follicles reach 18mm, OR 1 follicle reaches 18mm AND 1 follicle is between 16-18mm.
2937252|NCT02990949|No Intervention|Control group|
2937253|NCT02990936||Oropharyngeal squamous cell carcinoma|Patients with T1 to T4 oropharyngeal squamous cell carcinoma eligible for radiotherapy or concomitant chemoradiotherapy
2937254|NCT02990923|No Intervention|Control|In this group, patients will use traditional standard hemodialysis connector and receive typical disinfection management
2937255|NCT02990923|Experimental|Only High-Flow Valve|In this group, patients will use High-Flow Needleless Valve instead of traditional standard hemodialysia connector, but still receiving typical disinfection management
2937256|NCT02990923|Experimental|Both Divices|In this group, patients will receive both High-Flow Needleless Valve and DualCap Disinfection Devices in hemodialysis
2937257|NCT02990910|Other|personalized opioid analgesia|One group: positive result 10μg/kg morphine; negative result 50μg/kg morphine.Scored every 10 minutes until CHEOPS<=6 and Aldrete score>9.
2937258|NCT02990910|Other|conventional opioid analgesia|Another group: all received 25μg/kg morphine .Scored every 10 minutes until CHEOPS<=6 and Aldrete score>9.
2937259|NCT02990897|No Intervention|Control Group|Patients with Stage 3,4, or 5 CKD who are randomized to the control arm will receive standard care.
2937260|NCT02990897|Experimental|Intervention Group|Patients with Stage 3,4, or 5 CKD who are randomized to the intervention group will receive care from a physician who has been exposed to the intervention: a clinical decision support message. This clinical decision support message shows the patient's risk of kidney failure over the next 5 years.
2937261|NCT02990884|Active Comparator|block and ketamine|Ilioinguinal / iliohypogastric block after ketamine atropine induction and continued with ketamine only in anesthesia
2937262|NCT02990884|Active Comparator|ketamine atropine; laryngeal mask|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and applied Ilioinguinal / iliohypogastric block.
2937263|NCT02990884|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
2937264|NCT02990871||early rehabilitation|Patients started rehabilitative treatment during ICU hospitalization
2937265|NCT02990871||no-early rehabilitation|Patients started rehabilitative treatment after admission in Neuro-rehabilitation department
2937266|NCT02990858|Experimental|PRO 140|
2937267|NCT02990845|Experimental|Pembrolizumab/ Exemestane/ Leuprolide|Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
2937268|NCT02990832|Experimental|Exciton|Treatment of diabetic foot ulcer with Exciton Exsalt wound dressing
2937297|NCT02990650|Experimental|standard robotic guarding|A combination of nine balance training tasks where the robotic system provides guarding against loss of balance
2937332|NCT02990403|Experimental|aspirin+LMWH group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100U,hypodermic injection，qd
2937269|NCT02990819|Other|Reduced intensity regimen|Conditioning regimen is dependent on patient diagnosis and age. Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete alpha/beta T and CD19+ peripheral stem cells. Standard of care reduced intensity conditioning will include Busulfan, Fludarbine, Thiotepa followed by stem cell infusion.
2937270|NCT02990819|Other|Myeloablative regimen|"Conditioning regimen is dependent on patient diagnosis and age. Patients with chronic granulomatous disease or Wiskott-Aldrich syndrome will receive cyclophosphamide in lieu of thiotepa to ensure engraftment.~Myeloablative regimen with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete alpha/beta T and CD19+ peripheral stem cells. Standard of care myeloablative regimen will include Busulfan, Fludarbine, Thiotepa, or Cyclophosamide followed by stem cell infusion."
2937271|NCT02990819|Other|Immunotherapy|Conditioning regimen is dependent on patient diagnosis and age. Severe combined immunodeficiency (SCID) patients will be conditioned with immunotherapy only followed by stem cell transplant using the CliniMACs device to deplete alpha/beta T and CD19+ peripheral stem cells. Immunotherapy regimen will include anti-thymocyte globulin followed by stem cell infusion.
2937272|NCT02990806|Experimental|NI-071|Proposed biosimilar
2937273|NCT02990806|Active Comparator|Infliximab|Reference product
2937274|NCT02990793|Active Comparator|Active MeRT Treatment|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks.
2937275|NCT02990793|Sham Comparator|Sham MeRT Treatment|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks. Sham treatment mimicks same noise and sensation of active treatment but provides no treatment.
2937276|NCT02990780|Active Comparator|Conventionally fractionated CRT|Induction chemotherapy followed by conventionally fractionated concurrent chemo-radiotherapy,with prophylactic cranial irradiation for those who achieve a good response after combined chemoradiotherapy.
2937277|NCT02990780|Experimental|Accelerated hypofractionated CRT|Induction chemotherapy followed by accelerated hypofractionated concurrent chemo-radiotherapy,with prophylactic cranial irradiation for those who achieve a good response after combined chemoradiotherapy.
2937278|NCT02990767||observational women|collecting maternal factors, biophysical and biochemical markers at 11-13 weeks of gestation.
2937279|NCT02990754|Experimental|Intervention Group|Individuals attending one or more fearless physical activity events
2937280|NCT02990741||Usual screening group|ECG recordings at baseline plus at 1 year of follow-up; two ECG recordings in total.
2937281|NCT02990741||Intensive screening subgroup|ECG recordings at baseline plus quarterly during follow-up, at months 3, 6, 9 and 12; 5 ECG recordings in total.
2937282|NCT02990741||More intensive screening subgroup|ECG recordings at baseline plus weekly during the first month of follow-up and quarterly afterwards, at weeks 1, 2, 3 and 4 and months 3, 6, 9 and 12; 9 ECG recordings in total.
2937283|NCT02990728|Experimental|Mirena® + metformin|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
2937284|NCT02990728|Active Comparator|Mirena®|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
2937285|NCT02990715|Active Comparator|Up to 45 subjects|Subjects with known polyp lesions≥10mm which were not removed because of poor preperation or the need to perform polypectomy at hospital will ingest the C-Scan cap and then will be schduled to polypectomy. The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
2937286|NCT02990715|Experimental|Up to 25 subjects|Subjects who were reffered to screening colonoscopy as an average risk for CRC will ingest the C-Scan cap and then will be schduled to polypectomy. The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
2937287|NCT02990702|Active Comparator|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block group patients (Group R) will receive 30 cc %0.5 Bupivacaine
2937288|NCT02990702|Active Comparator|Ultrasound guided infraclavicular block|Ultrasound guided coracoid infraclavicular block group patients (Group C) will receive 30 cc %0.5 Bupivacaine
2937289|NCT02990689|Active Comparator|809M|bifocal intraocular lens (IOL)
2937290|NCT02990689|Active Comparator|839MP|trifocal intraocular lens (IOL)
2937291|NCT02990689|Active Comparator|SN6AD1|bifocal intraocular lens (IOL)
2937292|NCT02990676|Experimental|Computerised cognitive training group|Participants will be asked to complete the training programme provided using HAPPYneuron software for a minimum of 30 minutes 3 times a week for 12 weeks. The intervention will be completed in participant homes with the help of email or telephone reminders, as preferred.
2937293|NCT02990676|No Intervention|Control group|Asked to continue as normal
2937294|NCT02990663|Experimental|Bedtime BP Meds|Use of blood pressure lowering medication at bedtime
2937295|NCT02990663|Active Comparator|Morning BP Meds|Use of blood pressure lowering medication in the morning
2937296|NCT02990650|Active Comparator|Standard physical therapist|A combination of nine balance training tasks where the physical therapist provides guarding against loss of balance
2937298|NCT02990650|Experimental|challenge based robotic guarding|A combination of nine balance training tasks where the robotic system provides guarding against loss of balance while the participant works at a level greater than their current balance capability
2937299|NCT02990637|Active Comparator|OLECOL|Olive leaf extract
2937300|NCT02990637|Placebo Comparator|Placebo|Maltodextrin
2937301|NCT02990624|Active Comparator|High risk group|Patients with psoriasis and atherosclerosis will receive PUVA therapy for 36 sessions divided as 3 sessions weekly
2937302|NCT02990624|Active Comparator|Low risk group|Patients with psoriasis but no atherosclerosis detected, will receive PUVA therapy for 36 sessions divided as 3 sessions weekly
2937303|NCT02990624|No Intervention|Control group|Age-matching apparently normal individuals will receive no interventions but will perform investigational tests.
2937304|NCT02990611||Nivolumab Monotherapy patients|Patients who start treatment with nivolumab monotherapy for the first time
2937305|NCT02990611||Nivolumab/Ipilimumab Combination therapy patients|Patients who start treatment with the combination therapy of nivolumab with ipilimumab
2937306|NCT02990585|Active Comparator|One individual back school session|The 1 individual session will consist of a 60 min 1-on-1 education/exercise session with an athletic trainer. Information will be an abbreviated version of the 8-session school and fill focus on the strengthening, stretching, pain control and movement re-education most needed for the individual.
2937307|NCT02990585|Active Comparator|8 group session of back school|All sessions last 45-60 minutes. There will be up to 8 participants in each session which will be led by an athletic trainer or rehabilitation trainer. Pain management, prevention strategies, and active treatment will be covered in the 8 sessions. Active treatment includes strengthening, stretching, pain control, movement re-education, and walking.
2937308|NCT02990572||Amish and Mennonite|"Agree to allow access to past, current, and future medical records~Provide a detailed family health history~Provide contact information that may be used for future approach regarding research studies"
2937309|NCT02990559||Iron Repletion|Subjects participating in the associated study under the Iron Repletion arm will also undergo MRI (Magnetic Resonance Imaging) scan/fMRI (functional Magnetic Resonance Imaging) scan on two occasions, while performing cognitive tasks.
2937310|NCT02990559||Placebo|Subjects participating in the associated study under the Placebo arm will also undergo MRI/fMRI scans on two occasions, while performing cognitive tasks.
2937311|NCT02990546|Experimental|Intervention|In the intervention arm 10 mg of midodrine will be given orally three times daily starting at the time of stable or decreasing intravenous vasopressor support
2937312|NCT02990546|Other|Control|The control arm will receive standard of care for septic shock with IV vasopressor support as needed to maintain MAP goal > 65 mmHg
2937313|NCT02990533|Placebo Comparator|Placebo|Placebo Supplement Placebo Injection
2937314|NCT02990533|Experimental|Testosterone|Placebo Supplement Testosterone Injection
2937315|NCT02990533|Experimental|Protein Supplement|Protein Supplement Placebo Injection
2937316|NCT02990533|Experimental|Protein Supplement + Testosterone|Protein Supplement Testosterone Injection
2937317|NCT02990507|Experimental|AVEED|AVEED is composed of arm and leg cranks that can be used independently or together with a virtual exercise environment (VEE). Participants rotate arm and/or leg cranks under 4 conditions for 5 min each with a 5 min rest between: 1) Arm rotation with VEE, while sitting or standing (AVEED: Arm rotation, video display); 2) Arm rotation without VEE, while sitting or standing (AVEED: Arm rotation, without video display); 3) Leg rotation with arm-energy input to assist the legs with VEE, while sitting (AVEED: Leg rotation, arm-energy input, video display); 4) Leg rotation with arm-energy input to assist the legs without VEE, while sitting (AVEED: Leg rotation, arm-energy input, without video display). VEE controlled with voice commands, leaning, or keyboard buttons.
2937318|NCT02990494|Active Comparator|STANDARD|12-week Internet-delivered behavioral weight loss program
2937319|NCT02990494|Experimental|PREVENT|an enhanced 12-week Internet-delivered behavioral weight loss program focused on preventing future negative consequences
2937320|NCT02990494|Experimental|PROMOTE|an enhanced 12-week Internet-delivered behavioral weight loss program focused on promoting future benefits
2937321|NCT02990481|Experimental|Arm 1 - TRK-950|"Solid tumor~TRK-950 (Three dose levels will be explored during Arm 1)"
2937322|NCT02990481|Experimental|Arm 2 - TRK-950|"Colon cancer~TRK-950 (Low dose and High dose)"
2937323|NCT02990481|Experimental|Arm 3 -TRK-950|"Cholangiocarcinomas~TRK-950 (Low dose)"
2937324|NCT02990481|Experimental|Arm 4 - TRK-950|"Colon, gastric, ovarian, bladder cancers, as well as cholangiocarcinomas or hepatomas~TRK-950 (Low or High dose: dose level will be determined by the schedule of either low dose or high dose of Arm 2)"
2937325|NCT02990468|Experimental|Radiation Therapy, Cisplatin and BMX-001|In Phase 1, safety and tolerability of BMX-001 will be assessed using a Continual Reassessment Method and a maximum tolerated dose (MTD) will be determined using a single arm design. In Phase 2, the severity of radiation-induced mucositis and xerostomia will be assessed using a single arm design.
2937326|NCT02990455|Experimental|Reduced Nicotine Cigarette - Moderate|Nicotine Research Cigarette Drug Supply Program Category Codes NRC600 and NRC601 (menthol); each cigarette contains 0.8mg nicotine; participants will be instructed to smoke these cigarettes according to their usual smoking patterns
2937327|NCT02990455|Experimental|Reduced Nicotine Cigarette - Low|Nicotine Research Cigarette Drug Supply Program Category Codes NRC102 and NRC103 (menthol); each cigarette contains 0.03mg nicotine; participants will be instructed to smoke these cigarettes according to their usual smoking patterns
2937328|NCT02990442|Experimental|rTMS|treatment with repetitive transcranial magnetic stimulation for 30 days
2937329|NCT02990429|Experimental|Forced Air warmer (bair hugger)|In groups: A = 45, receiving intraoperative forced air warming( bair hugger). The forced air was delivered at the high setting of 43ºC
2937330|NCT02990429|Experimental|Intravenous Fluid Warmer(ranger warmer)|In groups:B =45, having intraoperative intravenous fluid via a fluid warmer patients received intravenous fluid via a fluid warmer after induction anesthesia. The device automatically heated fluid up to 41ºC as set point.
2937331|NCT02990416|Experimental|A-dmDT390-bisFv(UCHT1)/Radiation/Pembrolizumab|A-dmDT390-bisFv(UCHT1): 2.5 µg/kg 2x x 4 days, Ionizing Radiation: single treatment on day five of 14-24 Gy to a tumor, Pembrolizumab: 2 mg/kg IV every 3 weeks
2937560|NCT02988882|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
2937333|NCT02990403|Experimental|aspirin+LMWH+immunoglobulin group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks
2937334|NCT02990403|Experimental|aspirin+LMWH+prednisone group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + prednisone,5-10mg/day,po,qd
2937335|NCT02990403|Experimental|aspirin+LMWH+IVIG+prednisone group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks + prednisone,5-10mg/day,po,qd
2937336|NCT02990403|Other|dydrogesterone group|dydrogesterone 20-30mg/day, po, tid
2937337|NCT02990377|Experimental|RL-supported IVR intervention|Participants in the intervention group receive brief, non-tailored information related to decreasing opioid analgesic risk via pamphlets given at the ED plus the RL-supported IVR intervention.
2937338|NCT02990377|No Intervention|Enhanced Usual Care|Participants in the enhanced usual care group receive brief, non-tailored information related to decreasing opioid analgesic risk via pamphlets given at the ED.
2937339|NCT02990364|Active Comparator|Control: EMLA Topical Product|"This represents the control group and it is the traditional analgesic used for circumcisions.~EMLA cream is a eutectic mixture of 2.5% lidocaine and 2.5% prilocaine, used as a topical anaesthetic to diminish pain from cutaneous procedures. Seventy minutes prior to circumcision, the newborn will be placed in the circumcision mold with the legs restrained, and attached to a monitor. 1 gram of EMLA cream will be applied by the nurse to the penis using a syringe and then wrapped with a dressing (Tegaderm). After sixty minutes the Tegaderm and drug will be removed, and the infant will be left to settle until the circumcision."
2937340|NCT02990364|Active Comparator|EMLA + Sucrose|"There is high-quality evidence for the beneficial effect of sucrose (24%) with non-nutritive sucking (pacifier dipped in sucrose) or 0.5 mL of sucrose orally in preterm and term infants. To assess this, 10 ml of sucrose (24%) will be given to the infant during the course of the circumcision.~In combination to the EMLA cream, the infant will be given sucrose during the circumcision to test the effects of sucrose and sucking on pain management."
2937341|NCT02990364|Active Comparator|EMLA + Sucrose + Ring Block|"Ring block will be done with 1% lidocaine without epinephrine injected in a band around the penis halfway along the shaft. Ten minutes prior to circumcision, the newborn will be placed in the circumcision mold with the legs restrained, and attached to a monitor. A total of 2 mg/kg of 1% lidocaine without epinephrine will be used to perform the ring block and will be injected in a band around the penis. The block will be done by the circumciser.~In combination with the ring block, EMLA + sucrose will be given during the circumcision."
2937342|NCT02990364|Active Comparator|EMLA + Sucrose + DPNB|"Dorsal penile nerve block (DPNB) will be done with 1% lidocaine without epinephrine injected at two sites at the base of the penis (2 and 10 o'clock). Ten minutes prior to circumcision, the newborn will be placed in the circumcision mold with legs restrained, and attached to a monitor. A total of 2 mg/kg of 1% lidocaine without epinephrine will be used to perform the block, and equal aliquots in milliliters will be injected at the two sites at the base of the penis. The block will be done by the circumciser.~In combination with the DPNB, EMLA + sucrose will be given during the circumcision."
2937343|NCT02990351||HCC patients|29 HCC patients who had loco regional therapies for HCC were analyzed. Twenty patients met the Milan criteria (68.97%) & 4 (13.8%) were beyond Milan but met UCSF criteria and 5 were exceeding UCSF criteria (17.2%).All patients underwent preoperative LRTs, The protocol of bridging/down staging, methods, duration of follow up, the number of the patients who were successfully down-staged before LT and their outcomes after LT were recorded.
2937344|NCT02990338|Experimental|IPd (Isatuximab + Pomalidomide + Dexamethasone)|Isatuximab (intravenous) on Day 1, 8, 15, and 22 of 1st 28-day cycle, then on Day 1 and 15 of subsequent cycles in combination with pomalidomide per os on Day 1 to 21 + dexamethasone IV (intravenous) or per os on Day 1, 8, 15, 22 in 28-day cycles up to disease progression
2937345|NCT02990338|Active Comparator|Pd (Pomalidomide + Dexamethasone)|Pomalidomide per os on Day 1 to 21 + dexamethasone IV (intravenous) or per os on Day 1, 8, 15, 22 in 28-day cycles up to disease progression
2937346|NCT02990325|Experimental|ABX464 150mg|ABX464, 50mg per Capsule Three Capsules per day for 28 days
2937347|NCT02990325|Experimental|ABX464 50mg|ABX464, 50mg per Capsule One Capsule per day for 28 or 84 days
2937348|NCT02990312|Experimental|Sirolimus + Maraviroc|Participants will be placed on the combination of Sirolimus and Maraviroc, unless they are already on one of these medications.
2937349|NCT02990299|No Intervention|Usual Care|Participants will receive their usual care for the first year of their enrollment in the study. They will receive a referral to a diabetes educator and a clinical pharmacist, a one-page sheet of contact information for their healthcare providers, and paper-based, low-literacy diabetes information. After one year, they will crossover to the mDAS intervention arm for one year.
2937350|NCT02990299|Experimental|mHealth for Diabetes Adherence Support|Participants will receive in-person support from a health coach and a clinical pharmacist with whom they will meet with regularly via videoconference. After one year, participants who have completed the mDAS intervention will be monitored for an additional year with usual care to evaluate maintenance.
2937351|NCT02990286|Experimental|Rituximab with Mycophenolate Mofetil|
2937352|NCT02990286|Placebo Comparator|Placebo of rituximab with Mycophenolate Mofetil|
2937353|NCT02990273|Active Comparator|TEG|Blood transfusion
2937354|NCT02990273|Active Comparator|PT/INR|Blood transfusion
2937355|NCT02990260|Active Comparator|Live Saccharomyces cerevisiae|Live Saccharomyces cerevisiae. 2 capsules per day (1 g).
2937356|NCT02990260|Active Comparator|Yeast cell wall|Yeast cell wall. 2 capsules a day (700 mg).
2937357|NCT02990260|Placebo Comparator|Placebo|Maize starch and magnesium stearate. 2 capsules a day.
2937358|NCT02990247|Experimental|AMARS|Evaluation the resting ventilatory flow by applying a new technique called anharmonic morphological analysis of the respiratory signals (AMARS).
2937359|NCT02990234|Active Comparator|Capsular Repair|Capsular Repair arm. The first hip is randomized, opposite treatment on second hip. One Hip will receive the capsular repair while the other hip will not.
2937360|NCT02990234|Placebo Comparator|No Capsular Repair|Placebo arm. One hip is randomized to capsular repair while the other hip has no capsular repair.
2937361|NCT02990221|Active Comparator|Ingenol mebutate|application of ingenol mebutate for 3 consecutive days on an area of face/scalp of 25 cm2
2937362|NCT02990221|Active Comparator|cryotherapy|application of criotherapy on actinic keratosis present in an area of face/scalp of 25 cm2 different from the ingenol mebutate area
2937363|NCT02990208|Experimental|VR exposure + diaphragmatic breathing|Virtual Reality Exposure Therapy + Diaphragmatic breathing
2937364|NCT02990208|Active Comparator|VR exposure|Virtual Reality Exposure Therapy
2937365|NCT02990195|Other|Double enterostomy|
2937366|NCT02990169|Active Comparator|Goldmann Tonometer|determine if the CATS tonometer prism effectively reduces sensitivity to IOP errors produced by corneal thickness and therefore provides a more accurate IOP reading compared to the reference tonometer (Goldmann prism), based upon the correction value table for Goldmann tonometer prism
2937367|NCT02990169|Active Comparator|CATS tonometer|determine if the CATS tonometer prism effectively reduces sensitivity to IOP errors produced by corneal thickness and therefore provides a more accurate IOP reading compared to the reference tonometer (Goldmann prism), based upon the correction value table for Goldmann tonometer prism
2937368|NCT02990156|Experimental|Coil Embolization System|Coil Embolization System,or deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame,and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm.
2937369|NCT02990156|Active Comparator|Control device from Medronic|Control device from Medronic,include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils, which are manufactured by ev3 (Medtronic, Irvine, California, USA);
2937370|NCT02990143|No Intervention|Glaucoma Drainage implant no Ologen|The first group will use the routine technique for glaucoma drainage implant without placement of Ologen.
2937371|NCT02990143|Active Comparator|Glaucoma Drainage implant with Ologen|the second group will undergo the same procedure but will have the Ologen placed and secured over the plate of the AGV-FP7, under the conjunctiva, during the surgery.
2937372|NCT02990130||Study Group|This is a pilot observational study involving patients enrolled in the Seattle VA Bone Marrow Transplant Unit (BMTU) for treatment of their hematologic malignancy. Measurements of patient fitness, body composition, and inflammatory milieu will be performed at visits before HCT, and 30 days (+/- 10 days) after HCT. For patients that continue to receive care at the Seattle VA, additional visits (not exceeding 6 total) may be requested periodically for up to 2 years after HCT.
2937373|NCT02990091|Experimental|1,000mg/day n-3 HUFA|Subjects will take one capsule daily starting at study enrollment (within 24 hours of injury) for 14 consecutive days.
2937374|NCT02990091|Experimental|4,000 mg/day n-3 HUFA|Subjects will take 2 capsules twice daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
2937375|NCT02990091|Placebo Comparator|1 capsule safflower seed oil|Subjects will take 1 capsule daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
2937376|NCT02990091|Placebo Comparator|4 capsules safflower seed oil|Subjects will take 2 capsules twice daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
2937377|NCT02990078||Acute TBI|Subjects will be recruited from the neurointensive care unit within 72 hours of their injury. At the time of informed consent, the investigators will perform fNIRS testing with a hypercapnia challenge, fNIRS with hypercapnia challenge 60 minutes after a single oral dose of 50mg sildenafil citrate, outcome qustionaires and symptom checklists (including: Glasgow Outcomes Scale-Extended, Rivermead Post-Concussive Symptom Questionnaire, Brief Symptom Inventory, Alcohol Consumption Questionnaire, Patient Health Questionnaire, and Insomnia Severity Index). This will all be administered again at 14 days, 90 days, 180 days, 1 year, 2 years, 3 years, and 4 years after injury.
2937378|NCT02990078||Sub-acute/Chronic TBI|Subjects who suffered a TBI previously and have now entered a subacute or chronic phase of their TBI will be approached by the research team at their clinic visit with a TBI specialist. In those subjects, study timing will be based on the time of their original injury, therefore will start study visits at the next possible time point.
2937379|NCT02990078||Healthy Controls|"The investigators will also enroll healthy peer controls. These control subjects will be family members and friends of TBI subjects. These peer controls are likely to have similar environmental and socioeconomic exposures/support which may impact recovery after TBI and may also impact CVR. These control subjects will meet the same inclusion/exclusion criteria as TBI subjects without the requirement for an injury or acute brain imaging. These subjects will be tested in the same way as both TBI groups, but will only have one visit."
2937380|NCT02990065|Experimental|PROTEIN-FORTIFIED DIET|The protein-fortified diet consists on an energy goal based on REE measurement and a protein target based on the most recent literature recommendations (1.2-2 g/kg/die) (2). Daily caloric requirement, and subsequent protein content, of patients enrolled in the intervention group will be calculated using formulas in Table 1 (10, 12, 13). For each patient will be calculated the Resting Energy Expenditure (REE) and daily protein requirement (1.2-2g/kg/die of body weight registered at the admission) and the corresponding caloric intake (1g = 4 kcal). Finally, total daily caloric intake will be calculated by adding kcal from protein (1g = 4kcal) on kcal from non-protein (50% of REE).
2937381|NCT02990065|No Intervention|STANDARD DIET|The standard diet consists on an energy goal based on weight formula (20-25 kcal/kg/die). According to the ICU nutritional protocol, EN is started at an initial rate of 10ml/h, and increased by 20ml/h every 12 hours in the absence of significant gastric residuals (<250ml), with the aim of reaching the energy goal within 72 hours from admission. The EN formulae used are standard (1-1,5 kcal/ml, 40g/l protein). If enteral nutrition is not tolerated or is not indicated, supplemental PN is used to make up the energy shortfall. The PN formula used is standard (1000 kcal/l, 37 g/l protein).
2937382|NCT02990052|Active Comparator|Volar plating|Volar fixed-angle plating for dislocated distal radius fracture after closed reduction.
2937383|NCT02990052|Active Comparator|Conservative treatment|Primary conservative treatment (closed reduction and casting) for dislocated distal radius fracture.
2937384|NCT02990039|Experimental|Counseling letter (intervention group)|Participants of the intervention group received a brief counseling letter intervention aiming to reduce sedentary time and to increase physical activity. The intervention comprised up to three tailored letters based on separate questionnaires.
2937385|NCT02990039|No Intervention|No counseling letter (control group)|Participants of the control group did not received the brief counseling letter intervention.
2937421|NCT02989740||Group A|Patients with negative FFR (> 0.80) in the target lesion & decided on OCT (Optical Coherence Tomography) imaging findings with NO thin-cap fibroatheroma
2937386|NCT02990026|Experimental|Treatment|Specialty mental health probation - delivered by probation officers who receive specialized training and ongoing clinical consultation with a licensed mental health professional and who have reduced caseloads of exclusively mentally ill offenders.
2937387|NCT02990026|Active Comparator|Control|Standard probation - delivered by a standard probation officer - care as usual
2937388|NCT02990013|Experimental|Treatment arm|All patients will be in the treatment arm where they will be subject to skin testing with various cleansing agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
2937389|NCT02990000|No Intervention|Pragmatic Match|Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a pragmatically matched provider (control group)
2937390|NCT02990000|Experimental|Scientific Match|Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a scientifically matched provider (experimental group)
2937391|NCT02989987|Active Comparator|Narrative Exposure Therapy|According to the NET manual (one lifeline session and 7 exposure sessions; see Schauer et al. 2011).
2937392|NCT02989987|Active Comparator|Treatment-as-usual|Social support (provided on demand)
2937393|NCT02989974|Experimental|KY LEADS Survivorship Care - Survivor|The KY LEADS Survivorship Care condition involves providing a targeted and tailored psychosocial support intervention to individuals diagnosed with lung cancer (survivor).
2937394|NCT02989974|Experimental|KY LEADS Survivorship Care - Caregiver|The KY LEADS Survivorship Care condition involves providing a targeted and tailored psychosocial support intervention to caregivers of individuals diagnosed with lung cancer (caregiver)
2937395|NCT02989961|Experimental|A-Resticutis|Autologous, Activated-Platelets type of preparation.
2937396|NCT02989961|Placebo Comparator|C-Platelet-Poor Plasma PPP|Platelet-Poor Plasma type of preparation achieved by centrifugation of blood samples at high speed conditions. Resticutis is administered instead if the patient doesn't achieve full healing after 6 injections.
2937397|NCT02989948|Experimental|Physician-modified fenestrated and branched aortic endograft|Physician-modified fenestrated endografting for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
2937398|NCT02989935|Experimental|Fluticasone vilanterol bronchodilator|"Inhalation of fluticasone furoate/vilanterol trifenatate, 100 mcg/25 mcg combination, bronchodilator,using standard dry powder inhaler.~Interventions include ventilation, parasternal EMG, and phrenic magnetic stimulation."
2937399|NCT02989922|Experimental|SHR-1210 Q2W|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
2937400|NCT02989922|Experimental|SHR-1210 Q3W|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 3 weeks
2937401|NCT02989909|Active Comparator|Goldmann Tonometer|Goldmann Tonometer prism will be used as a based line comparator for tolerance assessment versus the active test comparator CATS tonometer prism
2937402|NCT02989909|Experimental|CATS tonometer|CATS tonometer prism being used as the test product to assess IOP measurement versus active comparator the Goldmann Tonometer prism
2937403|NCT02989883|Other|Peroral endoscopic myotomy (POEM)|Patients who received POEM
2937404|NCT02989870|Experimental|SBRT, Sorafenib and Bavituximab|This will be a 3+3 design with 3 dose cohorts. Following the dose escalation phase, an additional 6 patients will be enrolled as part of the dose expansion cohort.
2937405|NCT02989857|Active Comparator|AG-120 experimental study drug|AG-120, 500mg daily continuous dosing
2937406|NCT02989857|Placebo Comparator|AG-120 matched placebo|AG-120 matched placebo, daily continuous dosing. Subjects who experience disease progression and were receiving placebo, will be allowed to cross-over and receive AG-120
2937407|NCT02989844|Experimental|ALT-803|
2937408|NCT02989831|Experimental|Vibrating insoles 'on'|Duration: 30-60 seconds
2937409|NCT02989831|No Intervention|Vibrating insoles 'off'|Duration: 30-60 seconds
2937410|NCT02989818||Lesion of the Gastrointestinal tract|Investigator will collect prospective data on the Endoscopic Submucosal dissection that is used as part of the subjects standard of care to remove the Gastrointestinal lesion
2937411|NCT02989805|Active Comparator|Professional Care Manager|Each participating site will have a nurse or social worker to provide care management. Training activities will include modules for each of the key domains covered in the intervention: shared decision making, action planning; motivational interviewing; and mental health as a cornerstone of recovery, working effectively within the mental health system; and self-care and stress management.
2937412|NCT02989805|Experimental|Peer Specialist Care Manager|Each participating site will have a peer specialist to provide care management. Peer specialists will have a minimum of a high school education, a history of a mental illness, be self-described as 'in recovery,' and have reliable transportation to the study site. All certified peer specialists will receive training in a curriculum that supports identifying and pursuing goals for recovery; developing and documenting recovery-focused treatment plans; and supporting linkages with community-based services. Peers learn to help other individuals with mental health conditions to facilitate mental health dialogues; explore mental health choices and options; identify and work with a clinician; and obtain access to community health supports.
2937413|NCT02989792|Other|Unique study arm|
2937414|NCT02989779|Experimental|Active/Placebo crossover|NK1 Antagonist 7 days followed by placebo 7 days.
2937415|NCT02989779|Active Comparator|Placebo/Active Crossover|Placebo for 7 days followed by NK1 Antagonist 7 days.
2937416|NCT02989766|Active Comparator|A - Intervention|Education on Breast Feeding 3 activity sheets prenatally-study related. Complete a pre-questionnaire, a pre-delivery and a postpartum questionnaire
2937417|NCT02989766|No Intervention|B - Standard of Care|Complete a pre-questionnaire, a pre-delivery and a postpartum questionnaire
2937418|NCT02989753|Placebo Comparator|Placebo|The comparative product is a placebo with the same characteristics of appearance and packaging as studied products and in which all ingredients are replaced by maltodextrin.
2937419|NCT02989753|Experimental|VAL070-A|Studied active product n°1, named VAL070-A, is a dietary supplement in shape of capsule. VAL070-A product contains 4 active plant extracts.
2937420|NCT02989753|Experimental|VAL070-B|Studied active product n°2, named VAL070-B, is a dietary supplement in shape of capsule. VAL070-B product contains 5 active plant extracts.
2937561|NCT02988882|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
2937422|NCT02989740||Group B|Patients with negative FFR (> 0.80) in the target lesion & decided on OCT (Optical Coherence Tomography) imaging findings presence of ≥ thin-cap fibroatheroma
2937423|NCT02989740||Group C|Patients hosting FFR-positive target lesions that have been treated with PCI as per standard care and have further no TCFA lesions.
2937424|NCT02989727|Experimental|Lamotrigine - melancholic depression|Participants with melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
2937425|NCT02989727|Placebo Comparator|Placebo - melancholic depression|Participants with melancholic depression who were randomly assigned to receive a placebo comparator.
2937426|NCT02989727|Experimental|Lamotrigine - nonmelancholic depression|Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
2937427|NCT02989727|Placebo Comparator|Placebo - nonmelancholic depression|Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive a placebo comparator.
2937428|NCT02989714|Experimental|HD IL2 and Nivolumab|
2937429|NCT02989701|Experimental|Single arm|
2937430|NCT02989688|Active Comparator|modified carbohydrate drink|Dietary Supplement - renal specific slow release carbohydrate ONS (220 ml Nepro HP (Abbott Nutrition)
2937431|NCT02989688|Active Comparator|macronutrient matched drink|Dietary Supplement - 125 ml Fortisip Compact Protein (Nutricia) plus 20ml Calogen (Nutricia)
2937432|NCT02989688|Active Comparator|standard drink|Dietary Supplement - 125 ml Fortisip compact (Nutricia)
2937433|NCT02989675|Experimental|Dextrose|Children in the intervention group will immediately receive intravenous 5ml/kg 10% dextrose, Dextrose administration will continue as a maintenance infusion of intravenous 10% dextrose for 24 hours at standard maintenance rates. Capillary blood glucose monitoring will be repeated at 30 minute intervals with repeated equivalent bolus doses given until levels reach ≥5.0mmol/l. All children will be kept in the emergency department for a minimum of 60 minutes and have their vital signs checked at discharge from the emergency room to the ward.
2937434|NCT02989675|No Intervention|Control|Usual care - the care that is currently provided in the hospital - will be provided. All children in the control group will be kept in the emergency department for a minimum of 60 minutes and have their vital signs checked at discharge from the emergency room to the ward.
2937435|NCT02989662|Active Comparator|Mifepristone|Mifepristone is a high affinity antagonist of the glucocorticoid receptor (GR). It is FDA approved to treatment hyperglycemia caused by high cortisol levels in adults with endogenous Cushing's syndrome.
2937436|NCT02989662|Placebo Comparator|Placebo - Cap|This is an inactive compound which appears physically identical to active medication.
2937437|NCT02989649||Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)|Participants with type 2 diabetes mellitus (T2DM) who will receive alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) will be observed for approximately 6 months, or up to loss to follow-up or death, whichever occurs first.
2937438|NCT02989636|Experimental|Arm I (nivolumab)|Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 14 days for 8 doses, then every 28 days for a total of 2 years in the absence of disease progression or unacceptable toxicity.
2937439|NCT02989636|Experimental|Arm II (nivolumab, SRS)|Patients receive nivolumab as in Arm I. Patients undergo stereotactic radiosurgery (SRS) as per standard of care on day 8 of course 1.
2937440|NCT02989623|Experimental|Diagnostic (copper Cu 64 TP3805, PET/CT, biopsy)|Patients receive copper Cu 64 TP3805 IV over 5 minutes and 30 minutes and 2 hours later, undergo whole body Positron Emission Tomography/Computed Tomography (PET/CT) imaging over 1 hour.
2937441|NCT02989597|Experimental|Intra-operative Methadone Hydrochloride|Patient who will be given a single dose of intra-operative methadone, and having standard care otherwise
2937442|NCT02989597|Active Comparator|Control|Patients administered standard of care
2937443|NCT02989584|Experimental|Atezolizumab, Gemcitabine, Cisplatin|"This is a two phase study with a single study arm for each phase.~For Phase 1: Following enrollment participants will be treated with combination therapy on a 21 day cycle x 6 cycles. Gemcitabine (1000 mg/m2 on Day 1 and Day 8), cisplatin (70 mg/m2 on Day 1), and atezolizumab (1200 mg on Day 8) will be administered intravenously.~Phase 2: Following enrollment participants will be treated with a single dose of atezolizumab alone followed by combination therapy on a 21-day cycle x 4 cycles, followed by a single dose of atezolizumab alone. Gemcitabine 1000mg/m2, cisplatin (70 mg/m2 on Day 1), and atezolizumab (1200 mg on Day 8) will be administered intravenously."
2937444|NCT02989571|Placebo Comparator|Group 1 - Placebo Arm|Intravenous normal saline administered at 125ml/hr
2937445|NCT02989571|Active Comparator|Group 2 - Intervention Arm|Intravenous normal saline administered at 250ml/hr
2937446|NCT02989558|Active Comparator|Ticagrelor plus ASA|Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.
2937447|NCT02989558|Active Comparator|Clopidogrel plus ASA|Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
2937448|NCT02989545|No Intervention|Off treatment|2 week period without intervention
2937449|NCT02989545|Experimental|Treatment period|2 week period with intervention
2937450|NCT02989519|No Intervention|no progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation
2937451|NCT02989519|Experimental|oral progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation. All women in this arm received oral progesterone (dydrogesterone 10 mg; Duphaston™) per oral three times a day
2937452|NCT02989519|Experimental|vaginal progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation. All women in this arm received vaginal progesterone (micronized progesterone 200 mg; Utrogestan™) at bed time.
2937453|NCT02989493|Experimental|Doxazosin|Participants receive 8 weeks of doxazosin (8mg target dose).
2937454|NCT02989493|Placebo Comparator|Placebo|Participants will receive 8 weeks of matched placebo.
2937455|NCT02989480||Sarcoidosis|Patients with cardiac sarcoidosis diagnosed according to the Japanese Ministry of Health and Welfare criteria will be included. All patients will have histologically proven sarcoidosis (cardiac biopsy not mandatory) and no other potential cardiac disease. They will have no family history of cardiomyopathy.
2937456|NCT02989480||Arrhythmogenic RV cardiomyopathy|Patients with ARVC diagnosed according to the Task Force criteria with in addition either a positive family history for the condition or harbour a known pathological mutation associated with it.
2937457|NCT02989467|Active Comparator|Aprepitant|Subjects will receive one tablet daily for 5 consecutive days. On Day 1 subjects will take a 125mg tablet, on Days 2-5, subjects will take an 80 mg tablet.
2937458|NCT02989467|Placebo Comparator|Placebo|Subjects will receive one placebo tablet daily for 5 consecutive days.
2937459|NCT02989454||Tako Tsubo Cardiomyopathy patients|Any patient who has suffered from Tako Tsubo Cardiomyopathy since 2011.
2937460|NCT02989428|Experimental|Early parathyroidectomy group|Parathyroidectomy (surgery), is performed as soon as possible in the experimental group after randomization.
2937461|NCT02989428|No Intervention|Late parathyroidectomy group|Parathyroidectomy (surgery), is performed three months after study inclusion.
2937462|NCT02989415||Mechanical Ventilation|Patients undergoing mechanical ventilation during robotic surgery
2937463|NCT02989402|Experimental|Rivastigmine patch|15 cm2 patch sizes loaded with 27 mg of rivastigmine
2937464|NCT02989389|Experimental|LY3323795 (Part A)|Escalating doses of LY3323795 given orally in up to 2 of 3 periods.
2937465|NCT02989389|Placebo Comparator|Placebo (Part A)|Placebo matching LY3323795 given orally once in 1 of 3 periods.
2937466|NCT02989389|Experimental|LY3323795 (Part B)|Escalating doses of LY3323795 given orally.
2937467|NCT02989389|Placebo Comparator|Placebo (Part B)|Placebo matching LY3323795 given orally.
2937468|NCT02989389|Experimental|LY3323795 (Part C)|LY3323795 given orally in Period 1.
2937469|NCT02989389|Experimental|LY3323795 + Itraconazole (Part C)|Itraconazole given orally alone for up to 11 days in Period 2 and in combination with LY3323795 on one day in Period 2.
2937470|NCT02989376|Experimental|carotid duplex ultrasound|Single arm study. After detection of occluded vessels by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment.
2937471|NCT02989363|Experimental|O-Arm in deep brain stimulation surgeries (DBS)|Use of image surgery with technology O-Arm in deep brain stimulation surgeries (DBS)
2937472|NCT02989363|Experimental|Control group Not O-Arm in deep brain stimulation surgeries|Not use of image surgery with technology O-Arm in deep brain stimulation surgeries (DBS)
2937473|NCT02989363|Experimental|O-Arm in complex back surgeries (RAQUIS)|Use of image surgery with technology O-Arm in complex back surgeries (RAQUIS)
2937474|NCT02989363|Experimental|Control group Not O-Arm in complex back surgeries (RAQUIS)|Not use of image surgery with technology O-Arm in complex back surgeries (RAQUIS)
2937475|NCT02989350|Active Comparator|Lactobacillus reuteri DSM 17938|2 x 10(8) CFU. Both L reuteri DSM 17938 and placebo will be taken orally, twice daily 5 drops, for consecutive 5 days.
2937476|NCT02989350|Placebo Comparator|Placebo|Placebo consists of an identical formulation, except active substance.
2937477|NCT02989337||hyperemesis gravidarum with dehydration|The first group was formed of the patients diagnosed hyperemesis gravidarum with dehydration
2937478|NCT02989337||Control group|The control group was formed of the patients who were healthy pregnant women admitted to the clinic just for routine examination without any symptoms
2937479|NCT02989324|Experimental|Vaginal Misoprosto|Vaginal Misoprosto for Late Second Trimester Termination of Pregnancy With Previous Multiple Cesarean Section
2937480|NCT02989324|Active Comparator|Misoprostol Plus Foley Catheter|Misoprostol Plus Foley Catheter for Late Second Trimester Termination of Pregnancy With Previous Multiple Cesarean Sections
2937481|NCT02989311|Active Comparator|Study 1:Morning test meal+Iron+MNP|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g). Iron compound added to the morning test meal A:12 mg of iron as ferrous sulfate given as 2 mg of 57Fe and 10mg of 56Fe.~Intervention: Dietary supplement: Fortified maize porridge (MNP + Iron)"
2937482|NCT02989311|Active Comparator|Study 1:Afternoon test meal+Iron+MNP|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g). Iron compound added to the afternoon test meal B:12 mg of iron as ferrous sulfate given as 2 mg of 58Fe and 10mg of 56Fe.~Intervention: Dietary supplement: Fortified maize porridge (MNP + Iron)"
2937483|NCT02989311|Active Comparator|Study 2: Consecutive meals+Iron+MNP+GOS|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g) Iron compound added to the test meals:Test meal A will contain 12mg of ferrous sulphate given as 2mg 54Fe and 10mg 56Fe. Test meal B will contain 12mg of ferrous sulphate given as 2mg 57Fe and 10mg 56Fe.~Intervention: Dietary supplement: Fortified maize porridge (MNP+ Iron + GOS)"
2937484|NCT02989311|Active Comparator|Study 2:Alternate meal+Iron+MNP+GOS|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g) Iron compound added to the test meal C: 12mg of ferrous sulphate given as 2mg 58Fe and 10mg.~Intervention: Dietary supplement: Fortified maize porridge (MNP+ Iron + GOS)"
2937485|NCT02989298||PD patients|End stage renal disease patients receiving peritoneal dialysis treatment
2937486|NCT02989285||HIV+ cognitively impaired (HAND)|Participants will be assessed based on their performance on the neuropsychological test battery at study entry. HAND status will be diagnosed per FRASCATI research criteria and this will determine which study cohort they are allocated to. Participants will continue to receive their standard of care treatment during the study period.
2937487|NCT02989285||HIV+ cognitively normal (no-HAND)|Participants will be assessed based on their performance on the neuropsychological test battery at study entry. HAND status will be diagnosed per FRASCATI research criteria and this will determine which study cohort they are allocated to. Participants will continue to receive their standard of care treatment during the study period.
2937488|NCT02989272|Placebo Comparator|saline group|Control group (30 patients), who will receive Treatment by venous infusion of saline solution
2937489|NCT02989272|Experimental|Sulfate group|magnesium group (30 patients) who will receive pre- Venous infusion of magnesium sulphate 60 mg / kg
2937490|NCT02989259|Experimental|apatinib|apatinib 500mg p.o. qd
2937491|NCT02989246|Experimental|Intervention Arm|Ventilator management using the proposed protocol in both acute and weaning phases. Patients will be managed according the the Ventilator protocol using the esophageal catheter for the weaning phase
2937492|NCT02989233|Active Comparator|Brochure-Female-8/10|Female 8-10 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2937493|NCT02989233|Active Comparator|Brochure-Male-8/10|Male 8-10 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2937494|NCT02989233|Active Comparator|Model-Female-8/10|Female 8-10 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2937495|NCT02989233|Active Comparator|Model-Male-8/10|Male 8-10 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2937496|NCT02989233|Active Comparator|Video-Female-8/10|Female 8-10 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2937497|NCT02989233|Active Comparator|Video-Male-8/10|Male 8-10 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2937498|NCT02989233|Active Comparator|Brochure-Female-11/13|Female 11-13 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2937499|NCT02989233|Active Comparator|Brochure-Male-11/13|Male 11-13 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2937500|NCT02989233|Active Comparator|Model-Female-11/13|Female 11-13 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2937501|NCT02989233|Active Comparator|Model-Male-11/13|Male 11-13 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2937502|NCT02989233|Active Comparator|Video-Female-11/13|Female 11-13 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2937503|NCT02989233|Active Comparator|Video-Male-11/13|Male 11-13 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2937504|NCT02989220|Experimental|Intervention group|Will receive the PRCI in addition to the current recommended care pathway
2937505|NCT02989220|No Intervention|Control Group|Will follow the current recommended care pathway
2937506|NCT02989207|Active Comparator|Trabeculectomy with Mitomycin-C|The current standard surgical treatment for glaucoma remains trabeculectomy.
2937507|NCT02989207|Active Comparator|Baerveldt tube surgery with Mitomycin C|It consists of a tube, draining aqueous humour to a plate
2937508|NCT02989207|Active Comparator|Baerveldt tube surgery without Mitomycin C|It consists of a tube, draining aqueous humour to a plate
2937509|NCT02989194|Experimental|VIS410 low dose|Single intravenous fixed low dose of VIS410
2937510|NCT02989194|Experimental|VIS410 high dose|Single intravenous fixed high dose of VIS410
2937511|NCT02989194|Placebo Comparator|Placebo|Single intravenous placebo infusion
2937512|NCT02989181|Experimental|Continues Positive Airway Pressure|Use of Continues Positive Airway Pressure (CPAP) mask every night under six months period.
2937513|NCT02989181|No Intervention|Consultation of conservative measures|Study participants with DCM and OSA (no-CPAP), participants receive consultation of conservative measures such as avoiding alcohol before bedrest, sleeping on the side...
2937514|NCT02989168|Experimental|GBT440 Dose 1|Dose 1
2937515|NCT02989142|No Intervention|Control arm|No intervention
2937516|NCT02989142|Experimental|INTER-ACT arm|"Four pre-conception coaching sessions : postpartum week 6, week 8, week 12, 6 months.~Three pregnancy coaching sessions: at the time of the planned ultrasound scans."
2937517|NCT02989129|Experimental|Chemotherapy Induced Neuropathic Pain (CINP) Treatment Group|"Questionnaires completed at Baseline and at End of Study Visit.~Participants take Quercetin tablets by mouth 2 times every day for 12 weeks."
2937518|NCT02989129|Experimental|Chemotherapy Induced Neuropathic Pain (CINP) Prevention Group|"Questionnaires completed at Baseline and at End of Study Visit.~Participants take Quercetin tablets by mouth 2 times every day for 12 weeks."
2937519|NCT02989116|Experimental|Preterm Inhibition|"In children born very preterm:~Inhibition training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
2937520|NCT02989116|Experimental|Full-term Inhibition|"In children born full-term:~Inhibition training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
2937521|NCT02989116|Experimental|Full-term Working memory|"In children born full-term:~Working memory training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
2937522|NCT02989116|Experimental|Full-term Mindfulness|"In children born full-term:~Mindfulness training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
2937523|NCT02989116|Active Comparator|Full-term Active control|"In children born full-term:~Active control training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
2937524|NCT02989090|Experimental|Group A (Intervention Group)|Receive Detailed ICD Information-electronic: Receive ICD Patient Notification Summary via MyChart Patient Portal Account - Receive training to familiarize yourself with using the ePHR, MyChart Complete baseline, 3 month and 6 months survey
2937525|NCT02989090|Active Comparator|Group B (Intervention Group)|Receive Detailed ICD Information-paper: Receive ICD Patient Notification Summary via paper Receive training to familiarize yourself with using the ePHR, MyChart Complete baseline, 3 month and 6 months survey
2937526|NCT02989090|No Intervention|Group C (Control Group)|Receives Standard of Care-No Report Complete baseline, 3 month and 6 months survey
2937527|NCT02989077||Group A|Having combined coronary and cerebral ischemia.
2937528|NCT02989077||Group B|Having only coronary ischemia
2937529|NCT02989077||group C|Having only cerebral ischemia
2937530|NCT02989064|Experimental|Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells|
2937531|NCT02989051|Experimental|Restrictive fluid treatment|Restrictive fluid regimen
2937532|NCT02989051|Active Comparator|Liberal fluid treatment|This is seen as current standard clinical treatment, wherein patients will receive a more liberal fluid regimen.
2937533|NCT02989038|Experimental|NNC, INC, VLNC|Normal Nicotine Content (NNC), Intermediate Nicotine Content (INC), Very Low Nicotine Content (VLNC)
2937534|NCT02989038|Experimental|NNC, VLNC, INC|Normal Nicotine Content, Very Low Nicotine Content, Intermediate Nicotine Content
2937535|NCT02989038|Experimental|INC, VLNC, NNC|Intermediate Nicotine Content, Very Low Nicotine Content, Normal Nicotine Content
2937536|NCT02989038|Experimental|INC, NNC, VLNC|Intermediate Nicotine Content, Normal Nicotine Content, Very Low Nicotine Content
2937537|NCT02989038|Experimental|VLNC, NNC, INC|Very Low Nicotine Content, Normal Nicotine Content, Intermediate Nicotine Content
2937538|NCT02989038|Experimental|VLNC, INC, NNC|Very Low Nicotine Content, Intermediate Nicotine Content, Normal Nicotine Content
2937539|NCT02989025|Experimental|Experimental|To determine if the addition of 17 OHPC to the management of Severe PE diagnosed prior to 34 weeks gestation improves maternal and perinatal outcomes.
2937540|NCT02989012|Experimental|Drugs for experimental group|GanMaoKangNing Granules， blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous Oseltamivir Phosphate Capsules,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).
2937541|NCT02989012|Sham Comparator|Drugs for control group|Oseltamivir Phosphate Capsules ,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous GanMaoKangNing Granules, blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).
2937542|NCT02988999|Experimental|D-allulose|D-allulose 5 gm 3 times a day
2937543|NCT02988999|Active Comparator|erythritol|erythritol 5 gm 3 times a day
2937544|NCT02988986|Experimental|TAK-228 Plus Tamoxifen|"TAK-228 will be orally administered at 30 mg weekly for 16 weeks.~Tamoxifen will be orally administered at 20 mg daily for 16 weeks."
2937545|NCT02988973|Experimental|Subjects converting from rHuEPO or DA to ASP1517|ASP1517 will be administered for 52 weeks.
2937546|NCT02988973|Experimental|Subjects converting from rHuEPO or DA to DA|DA will be administered for 24 weeks.
2937547|NCT02988973|Experimental|Subjects converting from CERA to ASP1517|ASP1517 will be administered for 52 weeks.
2937548|NCT02988960|Experimental|Expansion Arm C|Additional participants with NSCLC will be enrolled in an expansion cohort that will further evaluate ABBV-927 plus ABBV-181.
2937549|NCT02988960|Experimental|Expansion Arm A|Additional participants (with squamous cell carcinoma of the head and neck [SCCHN], pancreatic adenocarcinoma, or non-small cell lung cancer [NSCLC]) will be enrolled in a dose expansion cohorts that will further evaluate ABBV-927.
2937550|NCT02988960|Experimental|Escalating Arm 2|ABBV-927 via intratumoral administration at escalating dose levels in 28-day dosing cycles (initially 2 doses per cycle).
2937551|NCT02988960|Experimental|Escalating Arm 1|ABBV-927 via intravenous administration at escalating dose levels in 28-day dosing cycles (initially 2 doses per cycle).
2937552|NCT02988960|Experimental|Expansion Arm B|Additional participants (with cutaneous melanoma or SCCHN) will be enrolled in a dose expansion cohorts that will further evaluate ABBV-927.
2937553|NCT02988960|Experimental|Escalation Arm 3|ABBV-927 via intravenous administration at escalating dose levels (initially 2 doses per cycle) in combination with ABBV-181 via intravenous administration.
2937554|NCT02988947|Experimental|Intervention Group (PNE+HyP)|Patients in this group will have 3 pre-surgical + 1 (or 2) reinforcement sessions in adition to standard TKA care. These interventions are based on Pain Neuroscience Education and Hypnosis and delivered according to standardized scripts.
2937555|NCT02988947|No Intervention|Control Group|No intervention / Standard care
2937556|NCT02988921|Experimental|Esophageal or esophagogastric cancer|
2937557|NCT02988908|Experimental|Drug: Donepezil|"Participants received Donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
2937558|NCT02988908|Placebo Comparator|Placebo (Control)|"Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
2937562|NCT02988869|Experimental|Tiotropium/Formoterol|Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
2937563|NCT02988869|Active Comparator|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
2937564|NCT02988869|Active Comparator|Tiotropium + Formoterol|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler + Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
2937565|NCT02988856|Experimental|Magnetic lid system|All participants will trial a commercially available device and an experimental magnetic device.
2937566|NCT02988843|Experimental|Brentuximab Vedotin & Bevacizumab|"Bevacizumab will be administered at a dose of 15 mg/kg IV every 21 days; over 90 minutes during 1st infusion, over 60 minutes as 2nd infusion and over 30 minutes for subsequent infusions if prior infusions well tolerated.~Brentuximab vedotin will be administered first at 1.8 mg/kg (maximum dose of 180 mg) IV over 30 minutes every 21 days."
2937567|NCT02988830|Experimental|Chronic lumbar pain|
2937568|NCT02988817|Experimental|HuMax-AXL-ADC|All arms of the trial (both in escalation and expansion phase) will be administered HuMax-AXL-ADC
2937569|NCT02988804|Active Comparator|endotracheal tube|"Procedure: Endotracheal tube~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
2937570|NCT02988804|Active Comparator|Laryngeal mask|"Procedure: Laryngeal mask~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
2937571|NCT02988791|Experimental|Probiotic (Bifidobacterium)|Active, Bifidobacterium BB12
2937572|NCT02988791|Placebo Comparator|Placebo|Placebo
2937573|NCT02988778|Experimental|Budesonid 50mcg (Noex)|"Budesonid 50mcg (Noex), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.~Treatment of 28 days."
2937574|NCT02988778|Active Comparator|Budesonid 50mcg (Busonid)|"Budesonid 50mcg (Busonid), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.~Treatment of 28 days."
2937575|NCT02988765|Experimental|Invasive vulvar cancer (IVC)|"Vulvar carcinoma (stromal infiltration > 1 mm)~Histotypes different from squamous cells carcinomas are included"
2937576|NCT02988752|Experimental|Electronic Mobile Device|Use an Electronic Low Cost Mobile Device To Determine C/D Ratio And Compare Results With Gold Standard Optical Coherence Tomography Results. The equipment needs mydriatic conditions and does not touch the patient's eye. The equipment uses a panoptik and a camera to access eye fundus.
2937577|NCT02988752|Active Comparator|Optical Coherence Tomography|Device considered as gold standard to determine c/d ratio. Needs mydriatic conditions.
2937578|NCT02988739|Experimental|Laser assisted epidermal application|"Laser pretreatment: 4 adjacent areas of 2 cm² each (14mm x 14 mm) will be pretreated with an Erbium Yttrium Aluminium Garnet laser (22,7 J/cm², 2 pulses, Density: 5%) generating micropores with a depth of approximately 91 µm.~0,1 ml of Intanza (15 µg, seasonal trivalent influenza vaccine) will be topically administered on the laser-treated area."
2937579|NCT02988739|Active Comparator|Intradermal application|0,1 ml of Intanza (15 µg, seasonal trivalent influenza vaccine) will be intradermally injected in the deltoid area.
2937580|NCT02988726|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
2937581|NCT02988700|Active Comparator|Spinal group|"Intrathecal hyperbaric bupivacaine 0.25mg/kg will be give by lumber puncture that will be made in the lateral position at the L4-5 or L5-S1 interspace with a 25 G pencil point Quincke spinal needle with a short bevel and the orifice of the spinal needle will be turned cephalad.~be given by ."
2937582|NCT02988700|Active Comparator|Caudal group|"caudal plain bupivacaine 2.5mg/kg 0.25% will be given caudally in The sacral hiatus between the sacral conru that will be palpated. While inserting the 23-G needle at 45° to the skin in the midline, a distance give or pop will be felt as the needle passes the sacral ligament into the caudal space, the needle will be tilted more toward the skin surface and inserted 2‑3mm deeper."
2937583|NCT02988674||Participants with Spondylarthritis|Participants with Spondylarthritis (ankylosing spondylitis and psoriatic arthritis) treated with adalimumab in routine clinical settings in the Russian Federation.
2937584|NCT02988661|Active Comparator|Chronic Disease Self-management Program (CDSMP)|A random sample of African American women with SLE selected from the Georgians Organized Against Lupus (GOAL) parent cohort will be used to recruit participants into the CDSMP. This group will be identified as the WELL Cohort.
2937585|NCT02988661|No Intervention|Usual Care|African American women consented into the parent Georgians Organized Against Lupus (GOAL) cohort who have not been selected to be enrolled in the intervention will comprise the usual care group. This group will continue their longitudinal assessments as part or the GOAL cohort data collection efforts.
2937586|NCT02988648|Experimental|radioiodide (I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
2937587|NCT02988635|Experimental|Early Palliative Care|Subjects receive standard of care with early palliative care.
2937588|NCT02988635|No Intervention|Standard of Care|Subjects receive standard of care.
2937589|NCT02988622|Other|Scar treated with Fraxel and CO2 laser|One half of scar is treated with Fraxel laser and the other half of scar is treated with CO2 laser.
2937590|NCT02988609|Experimental|Concussion Group|Players with a recent (<72 hours) history of concussion will be assessed 3 times. just after concussion, after disappearance of clinical symptoms and 3 months after the previous visit. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.
2937648|NCT02988154||Arm B: ''See one, do one'' cohort|Recruits to Arm B will witness an EVD placement as performed by an experienced surgeon, after which they will attempt to perform an EVD procedure on their own, using the aforementioned 3D-printed skull model. This mimics the ''see one, do one'' paradigm prevalent in surgical training.
2937591|NCT02988609|Active Comparator|Control Group|a control group with no history of concussion will be the comparator. Participants will be assessed 3 times. Visits will be the same for the control group and duration between visits in this group will be matched to the concussion group. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.
2937592|NCT02988596|Active Comparator|Enhanced Graded Exertion|At the time of the injury, participants will be given guided activity instructions regarding what activities to consider and how to observe for increases in symptoms. The focus will be on guided activity and not on restriction. Symptoms will be assessed at the end of each day. Once the patient has been asymptomatic for 24 hours or within 85% of their baseline symptom score (BSS) they will begin the enhanced graded exertion progression (Zurich protocol). This protocol will follow the Zurich guidelines, but will be enhanced to include sports and skill specific activities. Each step will be completed on a separate day. A medical professional will determine the symptom status of the athlete and when the graded exertion will begin.
2937593|NCT02988596|Experimental|Multidimensional Active Rehabilitation|At injury, participants are given instructions regarding guided activities to consider and how to observe for symptom increase. Focus is on guided activity, not restriction. The intervention consists of 5 phases designed to facilitate an active approach to concussion rehabilitation. Phases are symptom stabilization, impairment reduction, activity integration, recovery acceleration, and sport specific application. Participants complete phase specific activities under direction of a clinical professional, and progress upon meeting specific requirements. Participants are required to spend at least 2 days in Phase 1; subsequent phases are completed on separate days. Once asymptomatic for 24 hours or within 85% of their BSS they begin the enhanced graded exertion progression (Zurich protocol).
2937594|NCT02988583|Experimental|low viscosity silicone oil|Retinal detachment surgery using low viscosity silicone oil
2937595|NCT02988583|Active Comparator|high viscosity silicone oil|Retinal detachment surgery using high viscosity silicone oil
2937596|NCT02988570|Experimental|children born very preterm|A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
2937597|NCT02988557|Experimental|Treadmill|
2937598|NCT02988544|Experimental|Artificial shrinkage (AS) group|The Artificial shrinkage group where blastocoelic cavity is artificially reduced by a laser pulse prior to transfer
2937599|NCT02988544|No Intervention|Control group|No intervention on blastocoelic
2937600|NCT02988531|Experimental|PET/MR|Participants to have PET/MR scan
2937601|NCT02988518|Experimental|COGMED program|Cognitive remediation using COGMED program on bipolar euthymic patients with memory complaints
2937602|NCT02988492|Other|MRI perfusion imaging|MRI screening will be performed as per standard-of-care by the MRI technologist staff. Imaging will be performed with 1.5 T or 3 T systems (Magnetom Vision; Siemens, Erlangen, Germany) using a multisection, single shot, spin echo, echo planer imaging sequence. Diffusion gradients will be applied in each of the x, y and z directions with three b values (0, 500 and 1000 s/mm2). Imaging parameters include a TE of 94 ms, field of view of 23 cm, matrix of 128 and section thickness of 5.5 mm for the 1.5 T system and a TE of 83 ms, field of view of 23 cm, matrix of 128 and section thickness of 3 mm for the 3 T system. Conventional spin echo imaging also will be performed at each examination under T1 and T2 weighted conditions, with a fluid attenuated inversion recovery sequence and Time-of-flight MRA of the Circle-of-Willis.
2937603|NCT02988466|Experimental|Arm A: Haplo-HCT <55 years old|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients <55 years old with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≤2
2937604|NCT02988466|Experimental|Arm B: Haplo-HCT ≥55 years old|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients ≥55 years old or younger with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≥3.
2937605|NCT02988453|Experimental|MBT-CD|Mentalization-based treatment program
2937606|NCT02988453|Active Comparator|treatment as usual (TAU)|treatment as usual group
2937607|NCT02988440|Other|PDR001 + Sorafenib|
2937608|NCT02988414||Staphylococcus aureus Infection|Patients with blood culture confirmed S. aureus bloodstream infections.
2937609|NCT02988414||Gram Negative Infection|Patients with blood culture confirmed Gram Negative bloodstream infecrions
2937610|NCT02988414||Endocarditis|Patients admitted for evaluation of acute endocarditis classified using the Duke Criteria.
2937611|NCT02988401|Experimental|Intranasal insulin 20 international units|Subjects will administer 20 I.U. of insulin in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
2937612|NCT02988401|Experimental|Intranasal insulin 10 international units|Subjects will administer 10 I.U. of insulin in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
2937613|NCT02988401|Placebo Comparator|Intranasal saline|Subjects will administer a sterile diluent containing inactive ingredients in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
2937614|NCT02988388||Lung biopsy/lobectomy|Adults ages 21 or older who are undergoing lung surgery for suspected malignancy or metastases.
2937615|NCT02988375|Experimental|dCBTI|Online access to the digital CBTI program Sleepio
2937616|NCT02988375|Placebo Comparator|Sleep Education|Weekly email messages with sleep hygiene recommendations
2937617|NCT02988362|Experimental|Candesartan 16mg and Amlodipine 10mg|Candesartan 16mg and Amlodipine 10mg
2937618|NCT02988362|Experimental|HL068|HL068(combination of Candesartan 16 mg and Amlodipine 10 mg)
2937619|NCT02988349|Active Comparator|Caries-free subjects|Subjects will use Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks,.
2937620|NCT02988349|Experimental|Caries-active subjects|Subjects will use Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks,.
2937649|NCT02988115|Experimental|bempedoic acid|bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
2937650|NCT02988115|Placebo Comparator|placebo|Matching placebo tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
2937708|NCT02987686|Experimental|Topical Infliximab|Additionally to standard treatment, patients with all inclusive criteria and none exclusive criteria will be included in the therapeutic group and will receive topical infliximab QID for 4 weeks.
2937621|NCT02988323|Experimental|Cervicovestibular Physio (CV PT)|In addition to the standard protocol of rest followed by exertion, the CV PT group will participate in a combination of cervical spine and vestibular rehabilitation as per a standardized treatment algorithm based on individual assessment findings. This form of therapy combines treatment techniques for both the cervical spine and vestibular system that are commonly used in physiotherapy practice. Cervical spine treatments may include neuromotor retraining, sensorimotor retraining, manual therapy, soft tissue techniques, and range of motion exercises. Vestibular rehabilitation may include gaze stabilization, habituation, standing balance, dynamic balance and canalith repositioning maneouvers.
2937622|NCT02988323|Experimental|Low-Level Aerobic Exercise (LLAE)|Participants will exercise at 60% maximum heart rate for 15 minutes. This heart rate will be calculated by taking 220-age (in years) and multiplying by 0.6 to determine the target heart rate while performing the low level aerobic exercise. Aerobic exercises may include treadmill, walking or stationary cycling. Exercise will be performed 5-6 times per week independently at home and monitored by their parents. Individuals will be taught how to monitor their heart rate. This protocol has previously been found to be feasible and of minimal risk to participants.
2937623|NCT02988323|Other|Combination (LLAE and CV PT)|The combination group will complete a protocol that includes both the cervicovestibular physiotherapy and LLAE interventions described above. As described above, the study participants will be seen once weekly by the study physiotherapist for CV PT and also complete a protocol of LLAE at home.
2937624|NCT02988310||Individuals with below knee limb loss|Individuals with below knee limb loss will be participants of the group.
2937625|NCT02988310||Individuals with above knee limb loss|Individuals with above knee limb loss will be participants of the group.
2937626|NCT02988310||Healthy individuals|Healthy individuals will be participants of the group.
2937627|NCT02988297|Experimental|RNS60|Nebulized RNS60 will be administered by daily inhalation for 24 weeks.
2937628|NCT02988297|Placebo Comparator|Placebo|Nebulized Placebo will be administered by daily inhalation for 24 weeks.
2937629|NCT02988271|Experimental|Meditation Group|"Questionnaires completed at baseline and at end of study visit.~Participants given a device (such as a phone, tablet, or computer) that has the meditation app already installed on it. On Day 1, participants watch a pre-recorded video on the device regarding meditation. Participants to meditate at least 1 time every day for up to 2 weeks using the meditation app. Participants also complete a questionnaire about their mood before and after each meditation session using the app.~At end of study visit, participant has an interview with a member of the study staff."
2937630|NCT02988271|Other|Wait List Control Group|"Questionnaires completed at baseline and at end of study visit.~Participants will have access to their doctor as well as access to social workers, support groups, spiritual care, and other patient services for two weeks.~At the end of two weeks participants may have access to the meditation guidance recordings if requested."
2937631|NCT02988258|Experimental|Cohort 1 - 10^4 transduced cells/kg|The first 3 patients will receive a single infusion of bulk CMV-TCR transduced donor-derived T cells on first CMV reactivation post allogeneic HSCT, at a dose of 10^4 T cells/kg recipient weight
2937632|NCT02988258|Experimental|Cohort 2 - 10^5 transduced cells/kg|If no cases grade III-IV GVHD in Cohort 1 the remaining patients (N=7) each receive a single infusion of bulk CMV-TCR transduced donor-derived T cells on first CMV reactivation post allogeneic HSCT, at a dose of 10^5 T cells/kg recipient weight
2937633|NCT02988258|Experimental|Cohort 1a - 10^3 transduced cells/kg|If 1 case grade III-IV GVHD in Cohort 1, next three patients to be treated with a single infusion of bulk CMV-TCR transduced donor-derived T cells of 1 x 10^3 T cells/kg recipient weight
2937634|NCT02988245|Experimental|Genetically-Guided Treatment for BP Prescribing|Using a patient's genetic composition (specifically those of the kidney, heart, and vasculature) to guide BP prescribing for patients with hypertension.
2937635|NCT02988245|Experimental|JNC-8-Guided Treatment for BP Prescribing|Using traditional (JNC-8) guidelines for BP prescribing for patients with hypertension.
2937636|NCT02988232|Experimental|Treatment(SGHH)|Admission to Sogyeonghwalhyeol-tang granule
2937637|NCT02988232|Placebo Comparator|Placebo|admission to placebo
2937638|NCT02988219|Active Comparator|General anesthesia (G)|Holter ECG monitor General anesthesia Open kidney cancer surgery
2937639|NCT02988219|Experimental|Combined general/epidural (G/E)|Holter ECG monitor Epidural anesthesia General anesthesia Open kidney cancer surgery
2937640|NCT02988206|Other|Personalized Objects|"The item Functional Object Use was assessed by using personalized objects (e.g., cigarette, paper) and non-personalized objects, which presented in a random order.."
2937641|NCT02988206|Other|non-personalized objects|"The item Functional Object Use was assessed by using non-personalized objects"
2937642|NCT02988193|Experimental|optima4BP Medication Optimization|"optima4BP will provide a monthly medication optimization to the treating physician for review and subsequent implementation. The Treatment Recommendation will consist of:~curated blood pressure (BP) and heart rate (HR) values reported by the patient through the use of home monitoring BP arm cuff;~medication treatment recommendation;~active link to access additional analysis tools."
2937643|NCT02988193|No Intervention|Enhanced Care Management|Enhanced care management will provide monthly curated BP and HR values to the treating physician. The treating physician will not be provided with a medication optimization recommendation.
2937644|NCT02988193|No Intervention|Usual Care Management|Usual care management will follow medication treatment management according to the physician preference. The treating physician will not be provided with a medication optimization recommendation, nor with monthly curated BP and HR values.
2937645|NCT02988180|Other|intervention group|Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
2937646|NCT02988180|Other|control group|The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
2937647|NCT02988154||Arm A: Simulation training cohort|Recruits to Arm A undergo simulation training (computer simulation of the procedure, followed by simulation on a dead animal model), after which they will attempt to perform an EVD procedure on their own, on a 3D-printed skull model that we designed.
2938751|NCT02980445|Experimental|Outdoor Activity 1|40min outdoor time in total.
2937651|NCT02988089|Experimental|clarithromycin dependant group|"Patients in this group will receive 14-day bismuth-based quadruple therapies guided by the susceptibility of clarithromycin. Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI). The dose of colloidal bismuth pectin is 200 mg b.i.d.~The kinds of 2 antibiotics will be depend on the susceptibility of clarithromycin.~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen."
2937652|NCT02988089|Experimental|6 antibiotics dependant group|"Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, a bismuth and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.~Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI). The dose of colloidal bismuth pectin is 200 mg b.i.d."
2937653|NCT02988089|Other|salvage therapy for negative culture|when the results of culture are negative, patients will receive Ilaprazole 5 mg, amoxicillin 1 g, furazolidone 100 mg, Colloidal Bismuth Pectin 200 mg (IAFB regimen) or Ilaprazole 5 mg, amoxicillin 1 g, furazolidone 100 mg, tetracycline 750 mg (IAFT regimen)，all are used twice daily except tetracycline which is taken 3 times daily.
2937654|NCT02988089|Other|salvage therapy for failed eradication|If failed with AST guided eradication therapy, patients will take another therapy according to the former AST results. One susceptible antibiotics not involved in last therapy will be used as a component of 14-day bismuth-based quadruple regimen with Ilaprazole 5 mg b.i.d, amoxicillin 1 g b.i.d and Colloidal Bismuth Pectin 200 mg b.i.d.
2937655|NCT02988076|No Intervention|Control|The Control group subjects will undergo all procedures e.g. medication washout and baseline electroencephalogram, administered to the Treatment/Experimental group. A clinician treating a Control Group subject will NOT receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
2937656|NCT02988076|Active Comparator|Treatment|Intervention - Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report - Treatment group subjects will undergo all procedures e.g. medication washout and baseline electroencephalogram, administered to the Control group. A clinician treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
2937657|NCT02988063|Experimental|Compression plus PEM|Patients will receive 4-5 weeks of compression therapy, followed by treatment with 1% polidocanol endovenous microfoam (PEM) and 12 additional weeks of compression therapy. If the treating physician determines that the vein is not closed after a subjective assessment of vein patency via standard-of-care limited duplex imaging, patients will be re-treated with PEM on Day 4.
2937658|NCT02988050|Other|Conscious sedation1|Propofol-dexmedetomidine Bupivacaine; Lidocaine (local anaesthetics) Epinephrine (with local anaesthetics for skin infiltration)
2937659|NCT02988050|Other|Conscious sedation2|propofol-remifentanil Bupivacaine; Lidocaine Epinephrine (with local anaesthetics for skin infiltration)
2937660|NCT02988037|Experimental|A-DBT-A|Began Adapted Dialectical Behaviour Therapy for Adolescents
2937661|NCT02988024|Experimental|LY03005|LY03005 80 mg
2937662|NCT02988024|Active Comparator|Pristiq|Pristiq 50 mg
2937663|NCT02988011|Active Comparator|Gastric by-pass surgery|Gastric by-pass surgery without prior low-caloric diet
2937664|NCT02988011|Active Comparator|Low-caloric diet|Low-caloric diet followed by gastric by-pass surgery
2937665|NCT02987998|Experimental|Resectable Patients|Chemoradiation (Cisplatin + Etoposide + Pembrolizumab with concurrent radiation). Patients will be assessed for surgery followed by consolidation therapy
2937666|NCT02987985|Experimental|Opioid-free anesthesia|Opioid-free preoperative medications, Opioid-free pre-intubation medications, Opioid-free maintenance medication, postoperative nausea and vomiting prophylaxis
2937667|NCT02987985|Active Comparator|Opioid-sparing anesthesia|Opioid-sparing preoperative medications, Opioid sparing pre-intubation medications, Opioid-sparing maintenance medications, postoperative nausea and vomiting prophylaxis
2937668|NCT02987972|Experimental|V114 Lot 1|Infants will receive a 0.5 mL intramuscular injection of V114 Lot 1 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
2937669|NCT02987972|Experimental|V114 Lot 2|Infants will receive a 0.5 mL intramuscular injection of V114 Lot 2 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
2937670|NCT02987972|Active Comparator|Prevnar 13™|Infants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
2937671|NCT02987959|Experimental|TAK-228 treatment|Patients with complex genomic sarcomas exhibiting PI3K pathway dysregulation will be treated with TAK-228
2937672|NCT02987946|Active Comparator|Fraxiparine|Intervention: All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice. After randomization the patients in this arm will be subjected to fraxipareine 2850 IE daily. According to current guidelines in the LUMC the Fraxiparine dose is doubled to 5600 IE in patients with a weight above 100 kg.
2937673|NCT02987946|Experimental|IPD|Intervention: IPD Device: After randomization the patients in this arm will be subjected to fraxiparine 2850 IE daily and intermittent pressure devices for at least 48 hours or until mobilization. The intermittent pressure device is a leg pump delivered by Converis(R).
2937674|NCT02987933||Chronic Pain|Adults, > 6 months duration, daily pain
2937675|NCT02987933||Healthy Normals|Age and gender matched controls
2937676|NCT02987920|Active Comparator|Placebo - Concentrate|"preoperative oral medications given one time: acetaminophen 1000mg tablet, oxycodone extended release 10mg tablet, celecoxib 400mg tablet, pantoprazole 40mg tablet, and Placebo - Concentrate by mouth.~postoperative medications given for 2 days: Acetaminophen 1000mg every 6hr, Ketorolac15mg IV q6hrs x4 doses, Oxycodone 5mg po q3hrs prn moderate pain, Oxycodone10mg po q3hrs prn severe pain, Gabapentin100-300mg once at night, Dilaudid 0.2mg IV q2hrs prn severe pain"
2937677|NCT02987920|Experimental|Dextromethorphan|"preoperative oral medications given one time: acetaminophen 1000mg tablet, oxycodone extended release 10mg tablet, celecoxib 400mg tablet, pantoprazole 40mg tablet, and Dextromethorphan 60mg tablet~postoperative medications given for 2 days: Acetaminophen 1000mg every 6hr, Ketorolac15mg IV q6hrs x4 doses, Oxycodone 5mg po q3hrs prn moderate pain, Oxycodone10mg po q3hrs prn severe pain, Gabapentin100-300mg once at night, Dilaudid 0.2mg IV q2hrs prn severe pain, and dextromethorphan 60mg by mouth twice daily"
2937678|NCT02987907|Experimental|treatment group|use dexamethasone 10mg (2ml) I.A. during TACE
2937679|NCT02987907|Placebo Comparator|control group|use normal saline 2ml I.A. during TACE
2937680|NCT02987881|Experimental|Adult women with early stage localized endometrial cancer|Adult women with early stage localized endometrial cancer at least 2 months following hysterectomy
2937681|NCT02987868|Active Comparator|Supplement 1st day, placebo 2nd day|Administration of oral supplement (proprietary amino acid derivative blend). Half of the participants took the Amino acid supplement first day and half of the participants took the Amino acid supplement second day.
2937682|NCT02987868|Placebo Comparator|Placebo 1st day, supplement 2nd day|Half of the participants took the placebo first day and half of the participants took placebo second day.
2937683|NCT02987855|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe lipoaspiration harvest of subdermal fat
2937684|NCT02987855|Experimental|AD-cSVF Arm 2|ADcSVF Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction
2937685|NCT02987855|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
2937686|NCT02987842|Experimental|Experimental group|Patients in the experimental group will receive feedback using the TruScan Neurofeedback system in order to increase the power of EEG in the range of their individual upper alpha (as determined by the peak alpha frequency)
2937687|NCT02987842|Sham Comparator|Sham group|Patients in the sham group will receive feedback using the TruScan Neurofeedback system for electrical static activity of a disconnected electrode.
2937688|NCT02987829|Experimental|TRC253|Single-agent TRC253 to be administered as oral capsules once daily. The proposed TRC253 doses are 40 mg, 80 mg, 160 mg, 240 mg, 320 mg, and 400 mg.
2937689|NCT02987816|Sham Comparator|Sham tDCS|Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
2937690|NCT02987816|Experimental|Anodal tDCS|Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
2937691|NCT02987803|No Intervention|Control Group|Participants in the control group will receive the educational article with a link to additional generic information about the importance of hospital-level cesarean delivery rates. Participants will not know they are participating in a trial.
2937692|NCT02987803|Experimental|Data Group|Participants in the intervention group will receive the educational article with a link to a specific data tool with cesarean delivery rate data for their geographic location. Participants will not know they are participating in a trial.
2937693|NCT02987790|Experimental|C-reactive Protein|In this group, the attending physicians will be instructed to follow the decision flowchart based on the CRP values. Antibiotic suspension will be encouraged when levels of this marker are <35mg/L (if peak PCR below 100mg/L); or reduce 50% of the highest value (if PCR peak > 100mg/L), with a limit of seven days, if there is clinical improvement. If a given patient has persistently elevated CRP levels (> 100 mg/l or fall less than 50% relative to the time of inclusion), the investigators will encourage attending physicians to maintain antibiotics and to perform a careful search for persistent infection. In case of doubts, if the patient is well clinically and without signs of active infection, the duration of antibiotic therapy should be the same as suggested for the Best Practice group.
2937694|NCT02987790|No Intervention|Best Practice|"Patients will be initially treated according to the current protocols used in the intensive care units. Decisions about interruption or continuation of treatment will be made according to pre-established time and also according to the clinical evolution of the patients. CRP levels will not be measured and will not be considered in the decision to discontinue antimicrobials. Any decision ultimately rests with the clinical assistants. Suggestions on the suspension of antibiotics will be provided by the researchers as follows:~7 full days for most infections~10 full days for pneumonia caused by Gram negative non-fermenting bacteria or Gram negative bacteria carbapenemase producing.~14 days of treatment for necrotizing pneumonia, confirmed by chest computed tomography."
2937695|NCT02987764|Experimental|Cord Milking|The research team member will untwist the cord, and hold it in a vertical position. The cord will then be milked twice towards the abdominal insertion of the cord. The cord will be cut 1 inch above the abdominal wall. After milking for exact measurement of the cord will be obtained.
2937696|NCT02987764|No Intervention|Observational|Observational infants will receive usual care with immediate cord clamping by the delivering obstetrician. The time of cord clamping will be recorded for both groups using a timer.
2937697|NCT02987751|Experimental|Glargine + Glulisine|Insulin Glargine + Glulisine (12U/day + 4U/day) at pre-breakfast/dinner for 24 weeks
2937698|NCT02987751|Active Comparator|Premixed Analogue Insulin (70/30)|Premixed analogue Insulin (70/30) 16U/day at pre-breakfast/dinner for 24 weeks
2937699|NCT02987738|Experimental|dapagliflozin|two administrations of 10 mg dapagliflozin as tablet
2937700|NCT02987738|Placebo Comparator|Placebo Oral Tablets|two administrations identical to the experimental drug
2937701|NCT02987725|Active Comparator|Attention Control|Participants will listen to a 30-minute historical story.
2937702|NCT02987725|Experimental|Hypnosis|Participants will receive a 30-minute hypnosis session
2937703|NCT02987712|No Intervention|Survey 1|Common practice
2937704|NCT02987712|Experimental|Survey 2|Thromboelastography based protocol
2937705|NCT02987699|Experimental|Full Dosage|Full Dosage Chemotherapy regimen administered by HAI
2937706|NCT02987699|Experimental|Low Dosage of 5-Fu|Low Dose of 5-Fu Chemotherapy regimen administered by HAI
2937707|NCT02987699|Experimental|Low Dosage of oxaliplatin|Low Dose of oxaliplatin Chemotherapy regimen administered by HAI
2937793|NCT02987075|Other|Early compaction embryo group|patients have compacting embryos at 66±2 hours after ICSI
2937709|NCT02987686|No Intervention|Observational group|Patients with all inclusive criteria and one exclusive criteria will receive the standard treatment, without topical infliximab.
2937710|NCT02987673|Experimental|Mini/One anastomosis gastric bypass|Execution of a laparoscopic mini/one anastomosis gastric bypass (MGB/OAGB)
2937711|NCT02987673|Active Comparator|Laparoscopic sleeve gastrectomy|Execution of a laparoscopic sleeve gastrectomy (LSG)
2937712|NCT02987660|Experimental|LASIK with EX500|Topography Guided LASIK with WaveLight EX500 excimer laser system in bilateral surgery
2937713|NCT02987660|Active Comparator|SMILE with VisuMax|Small incision lenticular extraction (SMILE) with VisuMax laser in bilateral surgery
2937714|NCT02987647|Experimental|Hidrafemme|"The arm in question will have 14 patients who use the Hidrafemme product, encoded as group A.~Name: hidrafemme Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
2937715|NCT02987647|Active Comparator|Vagidrat|"The arm in question will have 14 patients who use the Vagidrat product, encoded as group B.~Name: vagidrat Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
2937716|NCT02987647|Active Comparator|Lubrinat|"The arm in question will have 14 patients who use the Lubrinat product, encoded as group C.~Name: lubrinat Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
2937717|NCT02987647|Active Comparator|Antrofi|"The arm in question will have 14 patients who use the Antrofi product, encoded as group D.~Name: antrofi Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
2937718|NCT02987634|Experimental|PeriActive mouthwash|patient is directed to rinse twice a day for 4 weeks. each rinse is 15 ml of Periactive
2937719|NCT02987634|Active Comparator|chlorhexidine 0.12% mouthwash|patient is directed to rinse twice a day for 4 weeks. each rinse is 10 ml of Periactive
2937720|NCT02987621|Experimental|Pre-post leg muscle strength testing|"Participants will perform leg muscle strength testing with tDCS. On a separate day they will repeat the leg muscle strength testing with Sham stimulation.~Leg strength testing will be measured by performing a series of maximal effort knee extension, knee flexion, plantar/dorsi-flexion trials. Furthermore, participants perform a 6 minute walk."
2937721|NCT02987621|Experimental|Pre-Post Fatigue testing|"Participants will perform fatigue testing with tDCS. On separate day they will repeat leg fatigue testing with Sham stimulation.~The fatigue task will be measured by time to fatigue with isometric contraction of the knee extensors."
2937722|NCT02987608|No Intervention|Control Phase (No Power Up)|60 young people will receive CAMHS treatment as usual. Measures of empowerment, activation, and symptoms will be completed by participants soon after their referral to the service. The same measures plus shared decision making questionnaires will be administered three months later.
2937723|NCT02987608|Experimental|Intervention Phase (Power Up)|60 young people use Power Up alongside CAMHS treatment as usual. Measures of empowerment, activation, and symptoms will be completed by participants soon after their referral to the service. The same measures plus shared decision making questionnaires and a Power Up feedback form will be administered three months later.
2937724|NCT02987595|Experimental|Whole-grain rye then wheat|Whole-grain rye, high lignan Whole-grain rye products for 8 weeks, then a wash-out period of 8 weeks, and then whole-grain wheat products for 8 weeks
2937725|NCT02987595|Experimental|Whole-grain wheat then rye|Whole-grain wheat, low lignan Whole-grain wheat products for 8 weeks, then a wash-out period of 8 weeks, and then whole-grain rye products for 8 weeks
2937726|NCT02987582|Experimental|Emotion-focused mindfulness group|8-week mindfulness group
2937727|NCT02987569|Experimental|Group One|Intervention
2937728|NCT02987569|Active Comparator|Group Two|Control
2937729|NCT02987556|Active Comparator|Usual System (open-loop)|In open loop, patients will be provided with an Continuous Glucose Monitoring (CGM) and an external insulin pump programmed with its usual treatment previously prescribed by its physician.
2937730|NCT02987556|Experimental|DIABELOOP System (closed-loop)|In the closed-loop, patients will be provided with the Diabeloop system consisting of insulin pump Cellnovo or Kaleido driven by remote control augmented by Diabeloop software and connected to the CGM Prescription of insulin doses proposed by a predictive algorithm.
2937731|NCT02987543|Experimental|Olaparib|Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose of 300 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions
2937732|NCT02987543|Active Comparator|Enzalutamide OR abiraterone acetate|"Enzalutamide:~Enzalutamide is available as capsules containing 40 mg of enzalutamide. Subjects will be administered study treatment orally at a dose of 160 mg once daily.~Abiraterone acetate with prednisone: Abiraterone acetate is available as tablets containing 250 mg of abiraterone acetate. Subjects will be administered study treatment orally at a dose of 1,000 mg once daily in combination with prednisone 5 mg administered twice daily orally."
2937733|NCT02987530|Experimental|Dolutegravir + Emtricitabine/Tenofovir|Patients will take Dolutegravir 50 mg (= Tivicay, 1 tablet per day) with Emtricitabine 200 mg / Ténofovir 245 mg (=Truvada, 1 tablet per day) for 48 weeks
2937734|NCT02987530|Active Comparator|Darunavir/Cobicistat + Emtricitabine/Ténofovir|Patients will take Darunavir 800 mg / Cobicistat 150 mg (=Rezolsta, 1 tablet per day) + Emtricitabine 200 mg / Ténofovir 245 mg (=Truvada, 1 tablet per day) for 48 weeks
2937735|NCT02987517|Experimental|Cadence|Runners who use an increased running cadence of 7.5 percent over preferred running cadence.
2937736|NCT02987517|Experimental|Forefoot Strike|Runners who use a forefoot strike instead of a rear foot strike
2937767|NCT02987296|Placebo Comparator|Immunonutrition without arginine|This group of patients will also receive a nutritional drink but containing no arginine for 5 days before surgery and for 5 days after surgery.
2937768|NCT02987270|Experimental|Mass screening and treatment|Each member (approximately 30,000 individuals) residing within the mass screening and treatment arm were visited three times a year and tested for malaria by rapid diagnostic test; those testing positive were treated with an appropriate antimalarial- dihydroartemisinin-piperaquine was the first-line therapy. Long-lasting insecticidal net (LLIN) coverage was topped up prior to the intervention to universal coverage (one bednet for every two household participants).
2938752|NCT02980445|Experimental|Outdoor Activity 2|80min outdoor time in total
2937737|NCT02987504|Experimental|Samalizumab 10, 15, 20 milligrams (mg)/kilogram (kg) Dose|"Participants received escalating doses of 10, 15, and 20 mg/kg of samalizumab IV every 21 days. Enrollment at each dose level and safety assessments were completed prior to enrolling at the next dose level; intra-participant dose escalation was not allowed.~3 participants were enrolled into a dose cohort: If 0/3 participants developed dose limiting toxicities (DLT) within Cycle 1, enrollment began at the next higher dose to a maximum of 20 mg/kg. If 1/3 participants developed a DLT, the dose cohort was expanded to include 3 new participants. If 0/3 new participants developed a DLT within Cycle 1, enrolment began at the next higher dose level. If ≥1 of 3 new participants developed a DLT within Cycle 1, dose-escalation was terminated, and the dose level 5 mg/kg below the current dose was considered the MTD. If ≥2 of 3 participants developed DLTs within Cycle 1, dose-escalation was terminated, and the dose level 5 mg/kg below the current dose was considered the MTD."
2937738|NCT02987491|Experimental|Exercise Metabolic Study Day|"Participants will perform a single bout of moderate intensity exercise on a cycle ergometer for 60 minutes.~A total of 3 muscle biopsies will be collected throughout the study day. Insulin sensitivity will be measured using a hyperinsulinemic-euglycemic clamp with glucose tracers."
2937739|NCT02987491|No Intervention|Resting Metabolic Study Day|"Participants will rest quietly in bed for 60 minutes and resting energy metabolism will be measured with a ventilated hood.~A total of 3 muscle biopsies will be collected throughout the study day. Insulin sensitivity will be measured using a hyperinsulinemic-euglycemic clamp with glucose tracers."
2937740|NCT02987465||Chronic Kidney Disease patients|Up to 12 patients with anaemia associated with CKD.
2937741|NCT02987465||Healthy Volunteers|Up to 12 healthy subjects will be recruited such that age and gender are similar to the CKD patients. These subjects will be recruited as negative controls for a baseline assessment of healthy physiology. These subjects will not be treated with Darbepoetin.
2937742|NCT02987452|Experimental|aerobic exercise|Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test
2937743|NCT02987452|Active Comparator|resistance exercise|resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
2937744|NCT02987452|Active Comparator|combined exercise|combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
2937745|NCT02987439|No Intervention|Standard care group|"Standard medical treatment for the exacerbation of COPD~Standard medical treatment of COPD according to GOLD~A visit by a pulmonary nurse at the patients own home 3-5 days after discharge. Lung function and smoking history is recorded. Correct use of inhaler is instructed.~Visit in the outpatient clinic within the next 2-6 months after discharge as follow-up~In the outpatient clinic they will receive an offer of pulmonary rehabilitation"
2937746|NCT02987439|Experimental|Rehabilitation group|"The group will begin pulmonary rehabilitation during hospital admission. Afterwards a rehabilitation program twice weekly for 7 weeks.~Beside rehabilitation they will receive same treatment as the standard care group"
2937747|NCT02987426|Experimental|Mindfulness-oriented intervention|Patients will get a mindfulness-oriented intervention daily for 10 minutes.
2937748|NCT02987426|No Intervention|Treatment as Usual|This group will continue receiving their normal inpatient psychiatric care and receive information (paper brochures) about health promotion.
2937749|NCT02987413|Experimental|Autologous Mesenchymal stem cells|Two escalated intrathecal infusions of autologous mesenchymal stem cell
2937750|NCT02987400|Experimental|Treatment|Obinutuzumab is given in a 21 day cycle intravenously starting at 1000 mg on day 1, 8 and 15 in cycle 1 and on day 1 of each following cycle Venetoclax is given orally at a dose of 800mg daily from day 1 of the first cycle.
2937751|NCT02987387|Experimental|TPVI|Transcatheter Pulmonary Valve Implantation with the SAPIEN XT THV
2937752|NCT02987374|Other|2011-2012 Fluzone IIV3 (IM)|Seasonal trivalent flu vaccine: NDC No 49281-011-50
2937753|NCT02987361|Experimental|treatment group 1|anodal stimulation on the lesioned primary motor cortex DC-STIMULATOR PLUS
2937754|NCT02987361|Experimental|treatment group 2|cathodal stimulation on the non-lesioned primary motor cortex DC-STIMULATOR PLUS
2937755|NCT02987361|Experimental|treatment group 3|dual stimulation such as anodal stimulation on the lesioned side and cathodal stimulation on the non-lesioned side DC-STIMULATOR PLUS
2937756|NCT02987361|Sham Comparator|sham group|sham group
2937757|NCT02987348||exenatide once weekly|type 2 diabetes patients who were first prescribed with exenatide once weekly in the index period identified from CPRD database of UK primary care
2937758|NCT02987348||basal insulin_1|type 2 diabetes patients who were first prescribed with basal insulin in the index period and matched with exenatide once weekly group identified from CPRD database of UK primary care
2937759|NCT02987348||exenatide twice daily|type 2 diabetes patients who were first prescribed with exenatide twice daily in the index period identified from CPRD database of UK primary care
2937760|NCT02987348||basal insulin_2|type 2 diabetes patients who were first prescribed with basal insulin in the index period and matched with exenatide twice daily group identified from CPRD database of UK primary care
2937761|NCT02987335||Lean Diabetes Subjects|N=20 subjects with BMI 16-22.5 kg/m2, with a history of low birth weight and malnutrition documented on at least one occasion. Will undergo pancreatic clamp.
2937762|NCT02987335||Type 2 Diabetes Mellitus Subjects|N=20 subjects with BMI 22.5-27 kg/m2. Will undergo pancreatic clamp
2937763|NCT02987335||Type 1 Diabetes Mellitus Subjects|N=20 subjects with BMI 16-22.5 kg/m2. Will undergo pancreatic clamp
2937764|NCT02987335||Nondiabetic Subjects|N=20 nondiabetic with BMI 16-22.5 kg/m2 subjects 19-45 years of age and in general good health, taking no medications, with normal glucose tolerance and no family history of diabetes. These subjects will be similar in age, ethnicity and BMI with the lean DM group, and will be recruited through various means of community outreach, including notices in shops and newspapers. Will undergo pancreatic clamp
2937765|NCT02987322|Experimental|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months for the patients in the honey group.
2937766|NCT02987296|Active Comparator|Immunonutrition with arginine|Patients will receive the nutritional supplement for 5 days prior to surgery and for 5 days after. The drink will contain arginine.
2937792|NCT02987101|Other|Standard of care|Standard wound care is given independent of this study.
2937769|NCT02987270|No Intervention|Control arm|Members of the control arm received standard of care, which includes universal (LLIN) coverage and standard malaria case management (laboratory confirmation prior to antimalarial treatment) at the study health facilities.
2937770|NCT02987257|Active Comparator|Supportive Care|Supportive care will be instituted at admission for all patients. This will include appropriate consults for ocular, systemic or genital involvement as well as: wound care (dressings, attention to erosions and ulcerations), skin barrier protection (eg. emollients or impregnated gauze), infection surveillance (eg. cultures), nutrition/fluids as appropriate, and care for mucosal involvement. A standardized supportive care protocol has been established. These patients will receive both intravenous and subcutaneous placebos to mask both the cyclosporine and etanercept arms
2937771|NCT02987257|Experimental|Cyclosporine A|In addition to supportive care as described in the respective arm, cyclosporine 1.7 mg/kg IV for 2 weeks will be started upon enrolment in the study. A single subcutaneous injection of placebo will mask the cyclosporine arm.
2937772|NCT02987257|Experimental|Etanercept|In addition to supportive care as described, 50 mg sc will be given once upon enrolment in the study. An IV placebo will mask the cyclosporine arm.
2937773|NCT02987244|Experimental|C-CHOEP|experimental arm will be treated by Chidamide combined CHOEP ( cyclophosphamide, epirubicine, vindesine, etoposide and prednisone) regimen for 6 cycles.
2937774|NCT02987231|Sham Comparator|CAF + SHAM|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. Patients randomized to the SHAM Group will receive the simulation of the electrical stimulation process.
2937775|NCT02987231|Experimental|CAF + ES|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. For electrical stimulation, a unit consisting of a signal generator, a power supply, and circuit board will be used. Conductive electrodes for electrical current application will be applied to the vestibular gingival surface on each side of the flap, at a distance of 3 mm from the relaxing incisions and an alternating current of 100 μA at 9 kHz, will be distributed in order to traverse the operated area. A single application of electrical stimulation will be given for 120 seconds, once a day for five days after surgery.
2937776|NCT02987218|Active Comparator|PROPOFOL|Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP(Intracranial pressure) Better cognitive Function preservation
2937777|NCT02987218|Active Comparator|DESFLURANE|Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
2937778|NCT02987205|Experimental|Revanesse Ultra|Revanesse Ultra in the NLF on one side of the face
2937779|NCT02987205|Active Comparator|Restylane|Restylane injection in the NLF on the other side of the face to optimal correction
2937780|NCT02987192|Experimental|traditional group|Traditional group patients will receive cutting type 22 gauge needles
2937781|NCT02987192|Experimental|minimally invasive group|minimally invasive group patients will receive pen type 27 gauge needles
2937782|NCT02987179||ESRD Patients|"The following inclusion criteria must be met for each subject.~Age ≥18 years and able to give written informed consent to the study~On chronic hemodialysis for ≥ 90 days at time of enrollment~Ability to read~Consent to have video recording taken during study visit"
2937783|NCT02987166|Experimental|Arm A: HDCRT administered with first dose of pembrolizumab|"Pembrolizumab (200 mg) plus HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) are both administered beginning on day 1.~Pembrolizumab (200 mg) will be administered on days 1, 43, 64, 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the 4 doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 1."
2937784|NCT02987166|Experimental|Arm B: HDCRT administered between doses 1& 2 of pembrolizumab|"Pembrolizumab (200 mg) begins on day 1. HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) begins on day 22.~Pembrolizumab (200 mg) will be administered on days 1, 43, 64, 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the 4 doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 22."
2937785|NCT02987166|Experimental|Arm C: HDCRT administered prior to first dose of pembrolizumab|"Pembrolizumab (200 mg) begins on day 1. HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) begins on day 1.~Pembrolizumab will be administered on days 22, 43, 64, and 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the four doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 1."
2937786|NCT02987153|Experimental|KYPHO-IORT - 10 Gy and Kyphoplasty|Intra-operative radiation therapy followed by standard kyphoplasty
2937787|NCT02987140|Experimental|PD+FoG|PD patients with FoG
2937788|NCT02987140|Active Comparator|PD-FoG|PD patients without FoG
2937789|NCT02987140|Active Comparator|Control|age-matched non-disabled adults
2937790|NCT02987114|Experimental|PLT101|PTL101 capsules (50 or 100 mg CBD per capsule) up to 25 mg/kg/day or up to 450 mg/day, the lower of the two. Twice daily (morning and evening).
2937791|NCT02987101|Experimental|Autologous SVF + Standard of care|"local injection around and under wound with autologous stromal vascular fraction.~Standard wound care is given independent of this study."
2937794|NCT02987075|Other|Cleavage stage embryo group|patients have non-compacting embryos with 7-9 cells, under 20% fragmentation. at 66±2 hours after ICSI
2937795|NCT02987062||Acenocoumarol|Patients with AF treated with acenocoumarol.
2937796|NCT02987062||Warfarin|Patients with AF treated with warfarin.
2937797|NCT02987062||Apixaban|Patients with AF treated with apixaban.
2937798|NCT02987062||Dabigatran|Patients with AF treated with dabigatran.
2937799|NCT02987062||Rivaroxaban|Patients with AF treated with rivaroxaban.
2937800|NCT02987049||ICR (Intensive Cardiac Rehab)|The Intensive Cardiac Rehabilitation (ICR) group will follow their physician-prescribed series of supervised exercise sessions and educational sessions in a cardiac rehab facility. The education component includes a series of Pritikin videos, nutrition workshops and cooking classes led by a registered dietitian, one-on-one dietary consultation with a registered dietitian, and a Pritikin notebook. The intervention for this study is comprised of 24 exercise sessions plus 24 educational sessions in 24 visits.
2937801|NCT02987049||CR (conventional Cardiac Rehab)|The conventional Cardiac Rehabilitation (CR) group will follow their physician-prescribed series of supervised exercise sessions in the same cardiac rehab facility as the ICR group. The intervention for this study is comprised of 24 exercise sessions during 24 visits.
2937802|NCT02987036|Experimental|Aerogen|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Aerogen
2937803|NCT02987036|Other|Jet Nebulizer|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet Nebulizer
2937804|NCT02987010|Experimental|Cohort A|Neoadjuvant administration of IDH305 at 550 mg BID for 6 weeks followed by surgical resection at 6 weeks. If there is no evidence of progressive disease at 6 weeks (clinical, radiographic or histopathologic exam), the patient will continue on IDH305 at 550 mg BID post-operatively for a maximum of 11 additional 28 day cycles. Subsequent assessment of disease will occur every 2 months starting in Cycle 2.
2937805|NCT02987010|Experimental|Cohort B|Patients who have inoperable tumors but measurable 2HG pre-treatment will be treated with IDH305 at 550 mg BID x 6 weeks. If there is adequate sustained knockdown of 2HG on MRS and disease is stable or improved, then the patient will continue on treatment for a maximum of 11 additional 28 day cycles.
2937806|NCT02986984||Confirmed Diabetic Nephropathy|Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who satisfy pre-specified criteria for diabetic nephropathy.
2937807|NCT02986984||Confirmed Non-diabetic Nephropathy|Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who fail pre-specified criteria for diabetic nephropathy.
2937808|NCT02986971|Experimental|New IMD|Subjects with contraceptive implants to be removed, are subjected to the novel device by personnel skilled in traditional removal.
2937809|NCT02986958|Experimental|Checklist|One-page paper-pencil agenda setting checklist involving two activities for older primary care patients and their family companion. The purpose of the checklist is to 1. clarify the role of the family companion during the visit, and 2. to discuss patient health issues to discuss with the primary care provider
2937810|NCT02986958|Placebo Comparator|Usual Care|Care as usual with their primary care provider
2937811|NCT02986945|Experimental|Immediate|"Resiliency App: Study participants randomized to the Immediate group will receive the text-messaging app, B-RESILIENT—an adaptation of a Resiliency Course for improving mood in individuals with depressive symptoms--for 4 weeks.~Wk 1: BOOST - manage unhealthy thoughts. Wk 2: BREAK - doing pleasant activities. Wk 3: BUDDY - effective communication for social support. Wk 4: Review of first 3 weeks. Each day, users will receive a daily affirmation text message, a series of approximately 5-10 text messages on the topic of the day, and a daily goal corresponding to the day's content (e.g. do a pleasant activity). At the end of the day, users will receive text messages asking them to report whether they completed the daily goal, followed by a daily mood measure."
2937812|NCT02986945|Other|Delayed|Resiliency App: The Delayed arm will receive the intervention after the Immediate Arm completes its use of the intervention.
2937813|NCT02986932|Experimental|BBB opening|ExAblate focused ultrasound under MRI-guidance delivered through the intact human skull in conjunction with timed intravenous ultrasound contrast agents (Definity®) to temporarily and focally open the BBB.
2937814|NCT02986919|Experimental|CPI-0610 Treatment|CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break.
2937815|NCT02986906|Experimental|5% dextrose|The perineural injection with 5% dextrose is a new and potential treatment for peripheral entrapment neuropathy
2937816|NCT02986906|Active Comparator|2cc 2% Xylocaine+3cc Triamcinolone (30mg)|The Ultrasound-guided injection with 2cc 2% Xylocaine+3cc Triamcinolone (30mg)
2937817|NCT02986893|Experimental|Dietary Intervention Arm|Participants will be assigned to follow a specific dietary intervention for 6 months
2937818|NCT02986893|Experimental|Non-dietary Intervention Arm|Participants will continue their usual diet and will be invited to attend monthly meetings at the MS Center for 6 months
2937819|NCT02986880|Experimental|Group D1|Patients receiving the toxin in SCM and the placebo in trapezius muscle and splenius capitis. Patients receiving the dose of 30 units (U) at injection point, totalling 120 U.
2937820|NCT02986880|Experimental|Group D2|Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 60 units (U) at injection point, totalling 240 U.
2937821|NCT02986880|Experimental|Group D3|Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 100 units (U) at injection point, totalling 400 U.
2937822|NCT02986880|Experimental|Group A1|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 30 units (U) at injection point, totalling 180 U.
2937823|NCT02986880|Experimental|Group A2|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 60 units (U) at injection point, totalling 360 U.
2937824|NCT02986880|Experimental|Group A3|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 100 units (U) at injection point, totalling 600 U.
2937825|NCT02986880|Experimental|Group F1|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 30 units (U) at injection point, totalling 300 U.
2937826|NCT02986880|Experimental|Group F2|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 60 units (U) at injection point, totalling 600 U.
2937827|NCT02986880|Experimental|Group F3|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 100 units (U) at injection point, totalling 1000 U.
2937828|NCT02986880|Placebo Comparator|Group P|Patients receiving placebo in the third muscles groups
2937829|NCT02986867|Experimental|SAbR|SAbR treatment of lesions
2937830|NCT02986854|Experimental|Menveo-Menveo Group|Approximately 300 subjects, who were vaccinated with a single dose of Menveo 4 to 6 years before, will receive one dose of MenACWY-CRM at Day 1.
2937831|NCT02986854|Experimental|Menactra-Menveo Group|Approximately 300 subjects, who were vaccinated with a single dose of Menactra 4 to 6 years before, will receive one dose of MenACWY-CRM at Day 1.
2937832|NCT02986854|Active Comparator|Naive Group|Aproximately 100 subjects, of similar age to subjects enrolled in other primed groups, who have not received any meningococcal vaccination, will receive one dose of MenACWY-CRM at Day 1.
2937833|NCT02986828|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
2937834|NCT02986828|Active Comparator|Normal saline|Normal saline for ultrasound-guided hydrodissection
2937835|NCT02986815|Experimental|[11C]Acetate Brain Imaging|[11C]Acetate will be administered The patient will have one intravenous line placed prior to [11C]Acetate administration. The patient will receive the low-dose CT portion of a PET/CT scan, after which [11C]Acetate will be administered intravenously over approximately 1 min at a dose of 0.3 mCi/kg (maximum 30 mCi) and followed by a saline flush. The injection and imaging procedure will be terminated in any patient who exhibits anaphylaxis, significant dyspnea or chest pain. The administering physician will stay with the patient for at least 15 min after injection and will remain in the Clinical PET Facility through the duration of the imaging procedure.
2937836|NCT02986802||Cohort A|Women with genital herpes receiving treatment before the 3rd trimester
2937837|NCT02986802||Cohort B|Women with genital herpes receiving treatment after the 3rd trimester
2937838|NCT02986802||Cohort C|Women with untreated genital herpes
2937839|NCT02986802||Cohort D|Women (controls) with neither genital herpes nor treatment
2937840|NCT02986776|Active Comparator|Inpatient Care + Needs Inpatient|Individuals with high alcohol involvement or low cognitive functioning receiving inpatient treatment
2937841|NCT02986776|Active Comparator|Inpatient Care + No Need for Inpatient|Individuals with low alcohol involvement or mid-high cognitive functioning receiving inpatient treatment
2937842|NCT02986776|Active Comparator|Outpatient Care + Needs Inpatient|Individuals with high alcohol involvement or low cognitive functioning receiving outpatient treatment
2937843|NCT02986776|Active Comparator|Outpatient Care + No Need for Inpatient|Individuals with low alcohol involvement and or mid-high cognitive functioning receiving outpatient treatment
2937844|NCT02986763||Professional pesticides|A specific questionnaire with professional information about pesticide uses is added for this arm Questionnaire to collect domestic pesticide use, diet, household characteristics Dust sampling Blood sampling Urine sampling Hair sampling
2937845|NCT02986763||Volunteers|Questionnaire to collect domestic pesticide use, diet, household characteristics Dust sampling Blood sampling Urine sampling Hair sampling
2937846|NCT02986750|Experimental|Experimental: Patients with dry eye syndrome 1|40 Patients with dry eye syndrome
2937847|NCT02986750|Active Comparator|Experimental: Patients with dry eye syndrome 2|40 Patients with dry eye syndrome
2937848|NCT02986750|Active Comparator|Experimental: Patients with dry eye syndrome 3|40 Patients with dry eye syndrome
2937849|NCT02986737|Experimental|ACURATE neo™ and ACURATE TA™ LP|Patients implanted with ACURATE neo™ Aortic Bioprosthesis and ACURATE TA™ LP Transapical Delivery System
2937850|NCT02986724||Vedolizumab|Bio-naïve participants with UC or CD will be treated with vedolizumab as per local prescriptions from physician in routine medical practice for up to 52 Week. Participants who fail on vedolizumab may be switched during the study to another biologic treatment as prescribed by the physician during routine medical practice for up to 52 Weeks.
2937851|NCT02986711|Experimental|Motivational Text Messages|Motivational text messages to help participants stay quit when they leave the hospital.
2937852|NCT02986711|Sham Comparator|Control|Text messages to ask about current smoking status.
2937853|NCT02986698|Experimental|in utero hematopoietic stem cell transplantation|"Perform in utero hematopoietic stem cell transplantation at the time of intrauterine transplantation in fetuses with alpha-thalassemia major. The cellular product is: Semi-allogeneic, Related, Maternal Bone Marrow-Derived, Miltenyi CliniMACS Plus enriched CD34+ hematopoietic stem cells administered in utero at a dose of 1 x 10^7-10^9 cells/kg fetal weight with equal to or less than 1% CD3+ T cells (equivalent to 10^5-10^7 T cells/kg fetal weight) in a final volume of 2-5ml suspended in 5% human serum albumin in Normosol buffer (Hospira, Inc.).~Stem cells will be administered immediately before the red blood cells intravenously via the umbilical vein during the clinically indicated IUT. All participants will receive one dose of stem cells but may receive additional transfusions as clinically indicated."
2937854|NCT02986685|Experimental|trimebutine maleate + rabeprazole|trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily
2937855|NCT02986685|Other|rabeprazole|rabeprazole 20mg once daily
2937856|NCT02986672|Active Comparator|Calanus oil|Children receiving omega-3 in form om calanus oil in capsule form
2937857|NCT02986672|Placebo Comparator|Placebo|Children receiving medical paraffin in capsule form (2 ml volume per day)
2937858|NCT02986659|Active Comparator|Metformin|Metformin dosing at 425, 850 and 1700 mg with GLUCOPHAGE® (metformin hydrochloride) Tablets. Treatment with metformin will be initiated at a dose of 425 mg (half pill) taken orally once a day at night for 7 days. After the week, the participant will be called to assess tolerance and will be asked to increase dose to one pill at night at a dose of 850 mg for one week. At the end of the second week, participants will be called again and if they tolerated the second dose, they will be asked to take two 850 mg pills, one in the morning and one at night, for a total dose of 1700 mg which is within the range of the usual effective dose of 1500 to 2000 mg/day for the remainder of the 3 months.
2937986|NCT02985840|Active Comparator|Ondansetron|Ondansetron (4 mg) followed by two 5 ml normal saline flush
2938203|NCT02984293|Active Comparator|Atorvastatin|The participants will receive atorvastatin (80 mg) orally once daily for 28 days.
2937859|NCT02986659|Placebo Comparator|Placebo|Dietary Supplement: Placebo with Methylcellulose capsules. Treatment with placebo will be initiated at a dose of a half pill taken orally once a day at night for 7 days. After the week, the participant will be called to assess tolerance and will be asked to increase dose to one pill at night for one week. At the end of the second week, participants will be called again and if they tolerated the second dose, they will be asked to take two pills, one in the morning and one at night for the remainder of the 3 months.
2937860|NCT02986646||physical therapy (PT) and rest|This group of subjects will be prescribed a physical therapy home exercise program and rest (of the injured elbow).
2937861|NCT02986646||PT and intra-tendinous steroid injection|This group of subjects will be prescribed a physical therapy home exercise program and will received an intra-tendinous corticosteroid injection into the area of the ECRB origin (of the injured elbow).
2937862|NCT02986646||PT and intra-articular steroid injection|This group of subjects will be prescribed a physical therapy home exercise program and will received an intra-articular corticosteroid injection into the elbow joint (of the injured elbow).
2937863|NCT02986633||Patients with heart failure and CRT|Heart failure with left ventricular ejection fraction less than 35 % treated with CRT
2937864|NCT02986620||AML patients|Adult AML patients with the IDH mutation test performed at diagnosis or relapse until January 31st, 2019.
2937865|NCT02986607|Experimental|Hypoparathyroidism|"Subcutaneous 24h microdialysis before PTH treatment and during continous subcutaneous PTH treatment. PTH, Natpara (parathyroid hormone 1-84) 50 µg doses with a concentration of 800 µg/ml, will be delivered by an insulin-pump (OmniPod) which delivers the infusion gear continous subcutaneously based on units (U) of insulin. 1 µg Natpara equals 0.125 U of infusion. The starting dose for pump treatment will be 0.50 µg per kilo per day and adjusted according to Calcium levels.~Controls: patients With hyperparathyroidism and healthy volunteers will perform 24h microdialysis."
2937866|NCT02986594|Experimental|aspirin group|low dose aspirin, 75-100mg, bid, after pregnancy
2937867|NCT02986594|Experimental|low molecular weight heparin group|low molecular weight heparin, 4100u, qd, after pregnancy
2937868|NCT02986594|Experimental|combination group|low molecular weight heparin, 4100u, once a day and low dose aspirin, 75-100mg, bid. After pregnancy
2937869|NCT02986568|Experimental|Ontogenetic surgery - Early cervical cacner|Cervical cancer patients, FIGO stage IB1-IIA2
2937870|NCT02986568|Experimental|Ontogenetic surgery - Advanced cervical cancer|Cervical cancer patients, FIGO stage IIB- IVA
2937871|NCT02986568|Experimental|Ontogenetic surgery - Uterine cancer|Uterine cancer patients, FIGO stage IA, grade3, IB-IVA
2937872|NCT02986568|Active Comparator|Standard treatment- Early cervical cancer|Cervical cancer patients, FIGO stage IB1-IIA2
2937873|NCT02986568|Active Comparator|Standard treatment - Advanced cervical cancer|Cervical cancer patients, FIGO stage IIB- IVA
2937874|NCT02986568|Active Comparator|Standard treatment - Uterine cancer|Uterine cancer patients, FIGO stage IA grade3, IB-IVA
2937875|NCT02986555|Placebo Comparator|Stress relief with existing biofeedback|After distressing virtual reality video and full resting time to relieve this stress, the investigators are going to give cognitive distress with serial seven, accompanied with existing biofeedback approach to relieve stress.
2937876|NCT02986555|Active Comparator|Stress relief with biofeedback and VR|After distressing virtual reality video and full resting time to relieve this stress, the investigators are going to give cognitive distress with serial seven, accompanied with biofeedback combined to virtual reality relaxation.
2937877|NCT02986542|Active Comparator|USG with the in-plane technique|Intervention: Femoral artery catheterization under USG guidance with the in-plane technique.Patients will have their femoral arterial lines inserted under the guidance of USG. The ultrasound equipment used is LOGIQ e GE medical system(China) CO.LTD
2937878|NCT02986542|Active Comparator|USG with the out-of-plane technique|Intervention: Under USG guidance femoral artery catheterization will be done with the probe placed for the out-of-plane technique. The ultrasound equipment used is LOGIQ e GE medical system(China) CO.LTD
2937879|NCT02986529|Active Comparator|GV-971 150mg/capsule|900mg, oral
2937880|NCT02986529|Experimental|GV-971 300mg/capsule|900mg, oral
2937881|NCT02986529|Experimental|GV-971 450mg/capsule|900mg, oral
2937882|NCT02986529|Placebo Comparator|Placebo|Oral
2937883|NCT02986516|Experimental|Randomized Cohort|Participants who will decided to undergo to randomization, will receive surgical treatment or definitive radiotherapy according with randomization assignment
2937884|NCT02986516|Active Comparator|Prospective Cohort|Participants who will not decide to be randomized, will received the surgical or definite radiotherapy treatment according to their choice
2937885|NCT02986503||Chemotherapy for Good responder|Doxorubicin + cisplatin + ifosfamide Pre-operative and post-operative chemotherapy for patients with good responder high grade osteosarcoma
2937886|NCT02986503||Chemotherapy for Poor responder|Doxorubicin+cisplatin+ifosfamide+methotrexate Pre-operative and post-operative chemotherapy for patients with poor responder high grade osteosarcoma
2937887|NCT02986490|Other|patient with antipsychotic/neuroleptic|Blood sample performed on patients requiring the establishment of treatment with antipsychotic / neuroleptic
2937888|NCT02986477|Other|Contrast Ultrasound|Patients with vesicoureteral reflux will receive contrast ultrasound via Foley catheter for study of vesicoureteral reflux.
2937889|NCT02986464|Active Comparator|Standard pharmacological treatment|
2937890|NCT02986464|Experimental|Virtual Reality distraction|
2937891|NCT02986451|Experimental|Intervention|All patients received clarithromycin, lenalidomide, and dexamethasone in 28-day cycles. Dexamethasone (40 mg) was given orally on days 1, 8, 15, and 22. Clarithromycin (500 mg) was given orally twice daily.Lenalidomide (25 mg) was given orally daily on days 1 to 21
2937892|NCT02986438|Active Comparator|Active rTMS frequency at 5 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive treatment stimulation in the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 5 Hz, that includes 2 sessions per day for 10 consecutive business days for 2 weeks. Then a target frequency will be determined for the remaining of the study. If this arm's target frequency is chosen, then the participants will receive the maintenance intervention of 2 sessions per week for 12 months. Each session will consist of the application of rTMS at a frequency of 5Hz, to 100% of the motor threshold.
2940415|NCT02968758|Experimental|Accuracy Testing|Comparison between GenePOC PCR and Reference Method
2937893|NCT02986438|Sham Comparator|Sham rTMS frequency at 5 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation (Sham). rTMS will be used with a coil that allows simulated stimulation (Coil AP) at a frequency of 5 Hz, with the software necessary for the operator to remain blind to the stimulation condition. This arm will only last for 2 weeks.
2937894|NCT02986438|Active Comparator|Active rTMS frequency at 10 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive treatment stimulation in the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 10 Hz, that includes 2 sessions per day for 10 consecutive business days for 2 weeks. Then a target frequency will be determined for the remaining of the study. If this arm's target frequency is chosen, then the participants will receive the maintenance intervention of 2 sessions per week for 12 months. Each session will consist of the application of rTMS at a frequency of 10 Hz, to 100% of the motor threshold.
2937895|NCT02986438|Sham Comparator|Sham rTMS frequency at 10 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation. rTMS will be used with a coil that allows simulated stimulation (Coil AP) at a frequency of 10 Hz, with the software necessary for the operator to remain blind to the stimulation condition. This arm will only last for 2 weeks.
2937896|NCT02986425|Experimental|STRIP intervention|The intervention will take place during the initial hospital admission (Index Hospitalisation) or an equivalent situation for outpatients. STRIP is a structured method to perform pharmacotherapy optimisation. The STRIP-intervention consists of 9 steps.
2937897|NCT02986425|Sham Comparator|Control|Participants in the control group will receive medication review by the prescribing physicians in accordance with usual care. If an extended drug review is in place in a ward/specialty corresponding characteristics are collected on cluster level.
2937898|NCT02986412|Experimental|CG428|Patients will self-administer the study product twice per day (morning, evening) for 6 months, for the efficacy assessment
2937899|NCT02986399||Standard care|Hip fracture patients operated at Akershus University hospital in 2012 and 2013.
2937900|NCT02986399||Fast track patient pathway|Hip fracture patients operated at Akershus University hospital in 2014 and 2015.
2937901|NCT02986386|Experimental|Intervention 1|Dental occlusion restoration by placement of dental implants and prosthesis on missing teeth.
2937902|NCT02986386|Other|Wait list control 1|Group of patients that will be evaluated until they receive the dental occlusion restoration procedure.
2937903|NCT02986386|Experimental|Intervention 2|Orthodontic treatment of malocclusion.
2937904|NCT02986386|Other|Wait list control 2|Group of patients that will be evaluated until they receive the orthodontic treatment of malocclusion.
2937905|NCT02986373|Experimental|Risankizumab|Open-label risankizumab
2937906|NCT02986360|Active Comparator|Vidscrip educational video|Patients receive Vidscrip education video discussing breast density in the context of their normal mammogram result
2937907|NCT02986360|No Intervention|Standard of care|Receive normal mammogram result and standard letter about breast density without any additional educational tools to contextualize breast density
2937908|NCT02986347|Active Comparator|Intravenous regional anesthesia (Bier)|The anesthetic technique described by Bier will be done by the anesthesiologist. The following steps were followed: 1)Placement double tourniquet on the proximal portion of the arm 2)Asepsis and antisepsis of the operative limb 3)Puncture and venous catheterization most distal in the limb 4)Elevation of limb for 1 to 2 minutes, next the limb will be spirally wrapped with Esmarch from the distal to proximal 5)The proximal cuff will be inflated 6)Withdrawal of Esmarch and injection of 40ml of lidocaine without epinephrine at 0.5% 7)Removal the canula until the distal cuff is inflated and the proximal cuff is emptied 8)Removal of the club must be done after the surgery, at least 40 minutes after the injection of the anesthetic.
2937909|NCT02986347|Active Comparator|Local anesthesia with adrenaline|Patients will be anesthetized by surgeons, who are familiar with the technique described by Lalonde. Around thirty minutes before surgery, will be infused with 20 ml of an anesthetic solution. The infiltrated solution is composed of 1% lidocaine with epinephrine in 1: 100,000. Initially 10 mL of the solution will be applied slowly in the flexion fold region of the wrist just below the skin and subfascial plane. The needle is moved slowly. The needle is then redirected to the radial side of the proximal palmar region for infiltration of another 2-3 mL of the subcutaneous solution. The remaining 7-8mL in the subdermal plane and anterior to the transverse carpal ligament.
2937910|NCT02986334|No Intervention|No Treatment Intervention|Observational Subjects randomized to this arm will be asked to discontinue their current pain medications for the length of the study. This arm is not blinded, as both study staff and participants will be aware that they are not receiving a study treatment.
2937911|NCT02986334|Active Comparator|Active Treatment Intervention|Naproxen & Omeprazole Subjects randomized to this arm will be asked to discontinue their current pain medications and take one 500mg naproxen capsule and one 40mg omeprazole capsule twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
2937912|NCT02986334|Placebo Comparator|Placebo Treatment Intervention|Subjects randomized to this arm will be asked to discontinue their current pain medications and take two placebo capsules twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment)
2937913|NCT02986321|Experimental|CHF6001 DOSE1|DOSE1
2937914|NCT02986321|Experimental|CHF6001 DOSE2|DOSE2
2937915|NCT02986321|Experimental|CHF6001 DOSE3|DOSE3
2937916|NCT02986321|Experimental|CHF6001 DOSE4|DOSE4
2937917|NCT02986321|Placebo Comparator|Matched placebo|placebo control
2937918|NCT02986321|Active Comparator|Budesonide|Budesonide DPI 800µg
2937919|NCT02986308||Intestinal Polyps|The patients who were diagnosed with Intestinal Polyps.
2937920|NCT02986308||Normal colonoscopy|People who were diagnosed by colonoscopy without intestinal polyps.
2937921|NCT02986295||BioMimeTM Stent|No intervention / Ischemic heart disease with percutaneous coronary intervention with BioMimeTM Stent
2937922|NCT02986295||Ultimaster® Stent|No intervention / Ischemic heart disease with percutaneous coronary intervention with Ultimaster® stent
2937923|NCT02986282|Other|Single arm|Interventions - repeated ankle - brachial index measurement before and after electrical cardioversion in patients with atrial fibrillation
2940416|NCT02968732|Experimental|Surgical|
2937924|NCT02986269|Experimental|Group SB|"Patient is scheduled for elective conisation or hysteroscopy under general anesthesia. The ventilation mode for this group is spontaneous breathing(SB) without pressure support ventilation (PSV) under laryngeal mask airway (LMA).~General anesthesia across LMA under SB without PSV"
2937925|NCT02986269|Active Comparator|Group PSV|General anesthesia across LMA under SB with PSV Patient is scheduled for elective conisation or hysteroscopy under general anesthesia. The ventilation mode for this group is SB with PSV under LMA.
2937926|NCT02986256|No Intervention|Conventionnal Group|No intervention for this group. Patients will be followed by a usual care.
2937927|NCT02986256|Experimental|"Telepied Group"|Patients will be followed by a nurse referring to ulcers of the diabetic foot.
2937928|NCT02986243|Experimental|Treatment|Subjects receive a diet plan and exercise regimen.
2937929|NCT02986230|Experimental|PCP-focused group|The PCP-focused group will receive a point of care clinical decision support tool called cancer prevention wizard (CP Wizard) that is integrated into the EHR. The CP Wizard provides evidenced- based recommendations to the provider and patient related to overdue cancer prevention screening services.
2937930|NCT02986230|Experimental|SDMT-focused group|The SDMT-focused group will receive a point of care clinical decision support tool called cancer prevention wizard (CP Wizard) that is integrated into the EHR. The CP Wizard provides evidenced- based recommendations to the provider and patient related to overdue cancer prevention screening services. The SDMT-focused arm also provides shared decision making tools to patient and provider at the time of the visit.
2937931|NCT02986217|No Intervention|Control Group|Participants randomized to the Control Group will submit a video of surgical performance of vaginal cuff closure during a hysterectomy. Subjects in the control group will receive traditional feedback methods as determined by each participant's training program. Subjects in the control group will repeat the process of video submission of the same procedure using the same surgical approach every 2 weeks for 2 cycles. At 6 weeks, participants will submit a final video performing vaginal cuff closure during hysterectomy.
2937932|NCT02986217|Experimental|Experimental Group|Participants randomized to the Experimental Group will submit a video of surgical performance of vaginal cuff closure during a hysterectomy. Subjects in the experimental group will then receive feedback within 5 business days of video submission and repeat the process of video submission of the same procedure using the same surgical approach every 2 weeks for 2 cycles. At 6 weeks, participants will submit a final video performing vaginal cuff closure during hysterectomy.
2937933|NCT02986204|Other|removal of ENG implant group|20 women who have an ENG implant that is difficult to feel on exam and would like to have it removed.
2937934|NCT02986204|Other|continuation of ENG implant|20 women who have are continuing to use their ENG implant.
2937935|NCT02986191|Experimental|Mucograft|One side of the mouth will be subjected to Mucograft in this split-mouth study design.
2937936|NCT02986191|Active Comparator|Connective tissue graft|The opposite side of the mouth will be subjected to a connective tissue graft.
2937937|NCT02986178|Experimental|Polio/Rhinovirus Recombinant (PVSRIPO)|Polio/Rhinovirus Recombinant (PVSRIPO)
2937938|NCT02986178|Experimental|Polio/Rhinovirus Recombinant (PVSRIPO) + Lomustine|Polio/Rhinovirus Recombinant (PVSRIPO) + Lomustine
2937939|NCT02986165|Placebo Comparator|Placebo control|100 g of flavoured water
2937940|NCT02986165|Experimental|Low dose pomace extract|1 g pomace extract powder
2937941|NCT02986165|Experimental|High dose pomace extract|2.5 g pomace extract powder
2937942|NCT02986152|Experimental|CDC Mobile App Treatment|Subjects who are randomized to the CDC mobile app treatment arm will be asked to perform the app's full suite of intervention tools such as learning about PTSD, assessment, finding support, and mind/body exercises (e.g., guided imagery, meditation, and relaxation exercises) over the entire 8-week study period.
2937943|NCT02986152|Other|CDC Mobile App Wait-List Control|Subjects who are randomized to the CDC mobile app wait-list control arm will be asked to perform only the learning about PTSD, assessment, and finding support activities for the first 4 weeks. Following completion of the Week-4 questionnaires, subjects will then be asked to additionally perform the mind/body exercises (e.g., guided imagery, meditation, and relaxation exercises) for the duration of the 8-week study period.
2937944|NCT02986139|Active Comparator|Sequence AB (Treatment A, Treatment B)|One dose of the Commercial formulation of Etanercept/Enbrel (Treatment A) followed by one dose of the New formulation Etanercept/Enbrel (Treatment B)
2937945|NCT02986139|Active Comparator|Sequence BA (Treatment B, Treatment A)|One dose of the New formulation of Etanercept/Enbrel (Treatment B) followed by one dose of the Commercial formulation Etanercept/Enbrel (Treatment A)
2937946|NCT02986126|Active Comparator|Resources for Services|Resources for Services (RS) is an evidence-based depression QI toolkit developed for primary care, but adapted for health- and community-based programs. Protocols support training licensed providers in clinical assessment, medication management, and CBT; all staff in team management; and non-clinical staff in addressing patient safety, screening, behavioral management skills (behavioral activation, problem solving) to enable education, coordination, and referral. RS is offered as an initial 1-day / 8-hour training with follow-up through 12 webinars, 3 each on team management, medication management, psychotherapy, and case management. Programs will be invited to have a staff lead per training component, with no limit on number of staff at trainings. Training experts include a psychiatrist, psychologist/CBT trainer, case manager, support staff, and patient / community advocate liaison. All enrolled study participants will be nested within programs participating in RS.
2937947|NCT02986126|Active Comparator|Resiliency Class +|"Resiliency Classes (RC) are a manualized, 7-session, CBT, psychoeducation class, lead by community health workers, that teaches skills to enhance mood. The RC manual covers: Session 1 - What Affects Your Mood and Resilience; Session 2 - Pleasant Activities Can Help Improve Your Mood and Make You Resilient; Session 3 - What Gets In The Way of Pleasant Activities: Harmful Thoughts and How to Change Them; Session 4 - How to Increase Your Resilience Through Support from Others; Session 5 - My Personal Resiliency Plan: Goal Setting; Session 6 - Celebrate Your Resiliency: Graduation Each RC will be 90-120 minutes in duration; once a week in community settings with up to 10 participants. RC will be supplemented with automated mobile text reminders about basic concepts and follow-up for care. Half of enrolled participants will be randomized to the Resiliency Class +. As of July 12, 2018, we will be offering bus tokens and $5 for completion of a satisfaction survey."
2938204|NCT02984293|Placebo Comparator|Placebo|The participants will receive matched placebo orally once daily for 28 days.
2937948|NCT02986113|Experimental|Men and Providers Preventing Suicide|Tailored interactive multimedia intervention, aimed at activating suicidal middle-aged men to disclose and discuss their suicide thoughts with and be receptive to treatment offers from a primary care provider during a linked office visit
2937949|NCT02986113|Active Comparator|Sleep hygiene video|A brief (3 minute) video regarding sleep hygiene, accompanied by introductory text summarizing research linking sleep problems with increased suicide risk.
2937950|NCT02986100|Experimental|C-14 labeled rucaparib|"Each patient will receive a single oral dose of 600 mg [14C] rucaparib (approximately 140 µCi) in the fasted state. Patients will be confined at the study site for the collection of blood samples and excreta for a maximum of 13 days, from Day -1. The patient can be discharged sooner than Day 13, if the discharge criteria are met.~After completion of Part I, patients with a deleterious BRCA mutation will have the option to participate in Part II by receiving 600 mg BID rucaparib tablets orally in 28 day cycles until disease progression, unacceptable toxicity, death, or discontinuation for other reasons"
2937951|NCT02986087|Experimental|Fetal Tracheal Occlusion|Fetuses with severe or moderate congenital diaphragmatic hernia will be offered fetal tracheal occlusion to increase lung growth.
2937952|NCT02986074|Experimental|Anatomical midline lead first|subjects in this group will receive stimulation first using an anatomical midline placed lead and subsequently using a paresthesia mapping placed lead
2937953|NCT02986074|Experimental|Paresthesia mapping lead first|subjects in this group will receive stimulation first using a paresthesia mapping placed lead and subsequently using an anatomical midline placed lead
2937954|NCT02986061|Active Comparator|Control Group|Patients with indwelling urinary catheter
2937955|NCT02986061|No Intervention|Study Group|Patients without indwelling urinary catheter
2937956|NCT02986048||Proton Beam Therapy|All patients treated with proton beam therapy at the UH Proton Therapy Center who consent to have their health information recorded, including whether the cancer was cured and if any complications occur ed due to treatment
2937957|NCT02986035|Experimental|Intervention|
2937958|NCT02986022|Experimental|Resilience|Participants will receive four sessions covering Resilience intervention content
2937959|NCT02986022|Active Comparator|Resilience+Information|Participants will receive four sessions covering Resilience intervention and Information intervention contents.
2937960|NCT02986009|Experimental|Parenting|To receive the parenting intervention
2937961|NCT02986009|Experimental|Information|To receive the information intervention
2937962|NCT02985996|No Intervention|Phase I/Pre-Drug|Ten participants will be asked to complete study phase 1. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
2937963|NCT02985996|Experimental|Phase II/Short Course|Forty participants will be asked to complete study phase 2. Participants will be randomized to receive one dose of Truvada or Genvoya. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
2937964|NCT02985996|Experimental|Phase III/Steady State|Forty participants will be asked to complete study phase 3. Participants will be randomized to receive Truvada or Genvoya to be taken once daily for ten days. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
2937965|NCT02985983|Experimental|KHK4827|KHK4827 administered SC
2937966|NCT02985983|Placebo Comparator|Placebo|Placebo administered SC
2937967|NCT02985970||ČSARIM - questionnaire|Members of Czech society of anesthesiology, resuscitation and intensive care will obtain the questionnaire
2937968|NCT02985957|Experimental|Second Generation Hormone Therapies|"Asymptomatic or minimally symptomatic subjects who have progressed after second generation hormone therapies and have not been treated with chemotherapy~Subjects will be treated with nivolumab in combination with ipilimumab followed by nivolumab monotherapy"
2937969|NCT02985957|Experimental|Cytotoxic Chemotherapy|"Subjects with progression after taxane-based chemotherapy~Subjects will be treated with nivolumab in combination with ipilimumab followed by nivolumab monotherapy"
2937970|NCT02985944||Standard scope-short time|Standard colonoscopy with unmonitored withdrawal time
2937971|NCT02985944||FUSE scope-short time|Wide-angle colonoscopy with unmonitored withdrawal time
2937972|NCT02985944||Standard scope-long time|Standard colonoscopy with monitored withdrawal time
2937973|NCT02985944||FUSE scope-long time|Wide-angle colonoscopy with monitored withdrawal time
2937974|NCT02985931||Suspected CAD subjects|
2937975|NCT02985918|Experimental|High-intensity NPPV|The patients will receive high-intensity noninvasive positive pressure ventilation.
2937976|NCT02985918|Active Comparator|Conventional-intensity NPPV|The patients will receive conventional-intensity noninvasive positive pressure ventilation.
2937977|NCT02985905|Experimental|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate,every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
2937978|NCT02985905|No Intervention|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment
2937979|NCT02985892|Experimental|SSASG|Stabilization and stretching group, 12 session, 60 minutes each. This group will perform stretching for back muscles in different positions, associated with stabilization exercises using a protocol developed by Richardson, 2005.
2937980|NCT02985892|Experimental|SSPSG|Stabilization Group, 12 session, 60 minutes each. This group will perform placebo stretching for upper limb muscles (the muscle is not stretched in it maximum extent) with stabilization exercises, using a protocol developed by Richardson, 2005.
2937981|NCT02985879|Placebo Comparator|Group 3|Placebo for ABBV-8E12
2937982|NCT02985879|Experimental|Group 1|Dose 1 ABBV-8E12
2937983|NCT02985879|Experimental|Group 2|Dose 2 ABBV-8E12
2937984|NCT02985866|Experimental|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump, study continuous glucose monitor (CGM), and a study glucometer. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
2937985|NCT02985866|Active Comparator|Sensor Augmented Therapy|Subjects will continue to use their personal insulin pump with a study continuous glucose monitor (CGM) and study glucometer.
2937987|NCT02985840|Experimental|Ondansetron plus dexamethasone|Ondansetron (4 mg), followed by dexamethasone (4 mg), followed by a single 5 ml normal saline flush
2937988|NCT02985827|Active Comparator|Rohto (r) Hydra|Menthol containing over the counter eyedrop
2937989|NCT02985827|Placebo Comparator|Systane (r) Ultra|Non-Menthol containing over the counter eyedrop
2937990|NCT02985814||patients with airway obstruction|Patients referred for pulmonary function test diagnosed with airway obstruction (FEV1/FVC < 0.7) willing to sign an informed consent.
2937991|NCT02985801|Experimental|Placebo First, then Pancrelipase|Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in first intervention period, and Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in second intervention period (after 2 week washout period).
2937992|NCT02985801|Experimental|Pancrelipase First, then Placebo|Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in first intervention period, and Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in second intervention period (after 2 week washout period).
2937993|NCT02985788||Video Instructions|Instructions on how to take a flexion/extension picture will be delivered in video format. These instructions will be followed by written instruction on how to take pictures examining pronation/supination.
2937994|NCT02985788||Written instructions|Instructions on how to take a flexion/extension picture will be delivered in a written, on paper format. These instructions will be followed by written instruction on how to take pictures examining pronation/supination.
2937995|NCT02985775|Experimental|Donor-derived CMVpp65-specific T cells|Intervention to be adminstered is about 1 million per kg CMVpp65-specific T cells infusion once acute GVHD ocurred post haploidentical transplantation.
2937996|NCT02985762|Other|EXPAREL 266 mg/20 mL|Eligible subjects, whose surgical incision must be at least 8 cm in length, will receive a single dose of EXPAREL (266 mg/20 mL) expanded in volume with 20-60 mL normal saline, depending on the size of the incision
2937997|NCT02985749|Experimental|Oxytocin|Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
2937998|NCT02985736|Experimental|open label|
2937999|NCT02985723|Experimental|939MP|AT LISA tri toric 939MP intraocular lens
2938000|NCT02985710|Other|Sudoscan only|Patients in this arm will only undergoing testing with Sudoscan.
2938001|NCT02985710|Other|Sudoscan Plus|Patients in this arm will get Sudoscan testing as well as a skin biopsy and QSART testing.
2938002|NCT02985697|Experimental|IN DEX|Group IN DEX will receive a placebo dose of flavored water followed by 3 mcg/kg intranasal dexmedetomidine in conjunction with 50/50 nitrous oxide/oxygen at a calculated flow rate. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or placebo will not be given.
2938003|NCT02985697|Experimental|MIDDEX|Group MIDDEX will receive 3 mcg/kg intranasal dexmedetomidine and 0.5 mg/kg oral midazolam and 100% oxygen at a calculated flow rate (oxygen administration to function as placebo for nitrous oxide). If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
2938004|NCT02985697|Experimental|NOMIDDEX|Group NOMIDDEX will receive 3 mcg/kg intranasal dexmedetomidine, 0.5 mg/kg oral midazolam, and 50/50 nitrous oxide/oxygen at a calculated flow rate. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
2938005|NCT02985697|Active Comparator|CTRL|The control group, Group CTRL, will receive a placebo dose of normal saline and 0.5 mg/kg oral midazolam and 50/50 nitrous oxide/oxygen at a calculated flow rate. Midazolam was chosen as the control due to its well documented history of use in pediatric procedural sedations. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
2938006|NCT02985684|Experimental|Device|Attempted implantation of GORE® CARDIOFORM ASD Occluder
2938007|NCT02985671|Experimental|orphenadrine, acetaminophen, caffeine and diclofenac sodium|"It's a tablet manufactured by Aché S.A., composed of orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg.~The experimental drug will be dispensed to 55 participants of the Group 1 in a cartridge of 1 blister with 12 tablets each. The participant shall administer 01 tablet orally three times a day, respecting the interval of 08 hours between administrations, in order to relieve the pain. If the research participant forgets to take a dose of the medication, it should be administered as soon as he remembers. Considering the schedule of this administration, the next doses should be readjusted respecting the dose interval.~The duration of treatment may be 7 days."
2938008|NCT02985671|Active Comparator|Voltaren® (diclofenac sodium 50mg)|"It's a tablet manufactured by Novartis Biociências S.A., composed of diclofenac sodium 50mg.~The active comparator will be dispensed to 55 participants of the Group 2 in a cartridge of 1 blister with 12 tablets each. The participant shall administer 01 tablet of Voltaren® orally three times a day, respecting the interval of 08 hours between administrations, in order to relieve the pain. If the research participant forgets to take a dose of the medication, it should be administered as soon as he remembers. Considering the schedule of this administration, the next doses should be readjusted respecting the dose interval.~The duration of treatment may be 7 days."
2938009|NCT02985645|Experimental|Treatment|maxillary sinus augmentation with CGF
2938010|NCT02985632|Experimental|Mild Hepatic Impairment Subjects|Subjects given an oral dose of BMS-986141.
2938011|NCT02985632|Experimental|Moderate Hepatic Impairment Subjects|Subjects given an oral dose of BMS-986141.
2938012|NCT02985632|Experimental|Healthy Subjects|Subjects given an oral dose of BMS-986141.
2938013|NCT02985619|Active Comparator|Bevacizumabe|"6 months treatment with 0.05ml (1.25mg) intravitreous injection of Bevacizumabe prn (pro re nata), monthly for central sufoveal thickness map more than 300µm by Optic Coherence Tomography."
2938014|NCT02985619|Active Comparator|Triamcinolone|6 months treatment with 0.03ml (1mg) intravitreous injection of triamcinolone each 3 months for central sufoveal thickness map more than 300µm by Optic Coherence Tomography.
2938015|NCT02985606|Active Comparator|Caffeine -60|Caffeine at 60 minutes prior to time trial
2938016|NCT02985606|Active Comparator|Caffeine -30|Caffeine at 30 minutes prior to time trial
2938017|NCT02985606|Active Comparator|Caffeine 0|Caffeine immediately prior to time trial
2938018|NCT02985606|Placebo Comparator|Placebo|Placebo drink at all time points
2938019|NCT02985593|Experimental|KHK4083|IV/SC administration
2938020|NCT02985593|Placebo Comparator|Placebo|IV/SC administration
2938021|NCT02985580|Active Comparator|Blueberry|Blueberry concentrate consumed daily for 12 weeks.
2938022|NCT02985580|Placebo Comparator|Placebo|Placebo concentrate consumed daily for 12 weeks.
2938023|NCT02985567||Intraocular pressure evaluation|Intraocular pressure evaluation using Icare tonometer 25 minutes after sedation, and then every 10 minutes until sedation is complete
2938024|NCT02985567||Safety of sedation|"Documentation of:~The need for repeat dosing of chloral hydrate.~The level of alertness of the patient at the end of sedation and the total time between induction and readiness for discharge~Interventions required for the patient including administration of oxygen, and need for intubation."
2938025|NCT02985554|Experimental|Nivolumab|Nivolumab will be administrated intravenously. Standard dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
2938026|NCT02985541|Experimental|Levonorgestrel IUS (Mirena, BAY86-5028)|Mirena, an Levonorgestrel intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg Levonorgestrel per day.
2938027|NCT02985528||TUS positive|Ultrasound detection of pleuro-pulmonary disease and further diagnostic and imaging when needed
2938028|NCT02985528||CXR positive|Radiographic detection of pleuro-pulmonary disease and further diagnostic and imaging when needed
2938029|NCT02985515|Experimental|Smell Training|Participants will first undergo a 30-day trial of budesonide nasal saline irrigation. If there is no subsequent improvement in olfaction, participants will undergo a 12-week smell training intervention.
2938030|NCT02985502||pancreatogenic diabetes|patients with pancreatogenic diabetes after pancreatectomy will be recruited
2938031|NCT02985489|Experimental|Experimental Group|Participants assigned to the experimental group will commence Olimel Parenteral Nutrition therapy delivered through central venous catheter (CVC) access within 24-48 hours of admission.
2938032|NCT02985489|No Intervention|Control Group|Participants assigned to the control group will receive standard of care (SOC) nutritional therapy. Control group patients will be assessed by the RD assigned to the medical unit to which the patient has been admitted (independent RD assessment). The unit RD will follow standard nutrition screening processes to determine nutrition risk, followed by a complete nutrition assessment in the presence of nutrition risk.
2938033|NCT02985476|Active Comparator|Interventional|Care as usual plus 8 weekly ELIJAH health reports shared with the participant and General Practitioner for 6 months i.e.: My history, My plan, My Update delivered via post or by email (dependant on participant preference) in addition to care as usual.
2938034|NCT02985476|No Intervention|Observational|Care as usual dictated by disease pathway of diagnosed inflammatory bowel disease i.e.; access to out-patient and in-patient hospital based care and community health resources via General Practitioner.
2938035|NCT02985437|Experimental|Surfactant|Alveofact® (Bovine Lung Surfactant), 0.5 mg/ml per day (solution) all two days maximal eight times
2938036|NCT02985437|Active Comparator|Saline|0.9% Sodium chloride solution (NaCl solution), 2 ml per day (solution) all two days maximal eight times
2938037|NCT02985411|Active Comparator|Immediate Gardening Intervention|Wait-listed, will receive the gardening intervention after a 1-year period
2938038|NCT02985411|Active Comparator|Delayed Gardening Intervention|Individuals in this group will serve as their own control
2938039|NCT02985398|Experimental|ALD403 (Eptinezumab) Dose Level 1|ALD403 (Eptinezumab) Dose Level 1 (IV)
2938040|NCT02985385||Abnormal Fetal Ultrasounds|"Abnormal fetal ultrasounds:~Those consistent with lethal malformations are provided with palliative management without providing respiratory support. Are given feeding and oxygen~Those compatible with life are managed by full investigation and given standard care for each case"
2938041|NCT02985385||Normal Fetal Ultrasounds|Given normal care
2938042|NCT02985372|Experimental|Acute myeloid leukemia|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
2938043|NCT02985359||Comparison district|Existing routine community health services by government
2938044|NCT02985359||Program district|In addition to existing routine community health services by the government, daily 20g Nutributter (Lipid-based Nutrient Supplement, LNS) will be provided to children 6 to 24 month of age and caregivers will participate in Social and Behavior Change Communications (SBCC) activities including the promotion of infant and young child feeding (IYCF) behaviors and water, sanitation and hygiene (WASH) behaviors will be conducted with caregivers.
2938045|NCT02985346|Experimental|BMSC group|Patients received Bone marrow mesenchymal stem cells (BMSC) plus standard treatment
2938046|NCT02985346|Active Comparator|Control group|Patients received standard treatment
2938047|NCT02985333|Experimental|Intervention|paclitaxel 175 mg/m(2) IV over 3 h d1,cyclophosphamide 200 mg/m(2) IV d1,3,5 and dexamethasone 20mg IV d1-4 in patients with relapsed or refractory MM.
2938048|NCT02985320|Experimental|Phase I Adult Group - High dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~Intervention: Single-dose regimen of high dosage investigational sIPV"
2938049|NCT02985320|Experimental|Phase I Adult Group - Medium dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~Intervention: Single-dose regimen of medium dosage investigational sIPV"
2938050|NCT02985320|Experimental|Phase I Child Group - High dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~Intervention: Single-dose regimen of high dosage investigational sIPV"
2938051|NCT02985320|Experimental|Phase I Child Group - Medium dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~Intervention: Single-dose regimen of medium dosage investigational sIPV"
2938052|NCT02985320|Experimental|Phase I Infant Group - High dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of high dosage investigational sIPV"
2938053|NCT02985320|Experimental|Phase I Infant Group - Medium dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of medium dosage investigational sIPV"
2938054|NCT02985320|Experimental|Phase I Infant Group - Low dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of low dosage investigational sIPV"
2938055|NCT02985320|Experimental|PhaseⅡExperimental Group - High dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of high dosage investigational sIPV"
2938056|NCT02985320|Experimental|PhaseⅡExperimental Group - Medium dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of medium dosage investigational sIPV"
2938057|NCT02985320|Experimental|PhaseⅡExperimental Group - Low dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of low dosage investigational sIPV"
2938058|NCT02985320|Active Comparator|PhaseⅡControl Group -commercialized sIPV|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention:Three-dose regimen of commercialized sIPV"
2938059|NCT02985320|Active Comparator|PhaseⅡ Control Group -commercialized IPV|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of commercialized IPV"
2938060|NCT02985307|Experimental|Short Message Text Service|Participants receive short messages daily via their mobile phone
2938061|NCT02985307|Active Comparator|Standard Weight Management Group|Participants attend standard group weight management sessions
2938062|NCT02985294||Cross-sectional cohort|Multiple Excitability Measures of peripheral nerves on patients with chronic peripheral neuropathic pain
2938063|NCT02985294||Longitudinal cohort|Multiple Excitability Measures of peripheral nerves on painless patients before and after potential chronic neuropathic pain-inducing interventions (chemotherapy, surgery)
2938064|NCT02985281|Active Comparator|Arm 1|"20 patients will be randomly assigned into arm 1; treated for fixed 24 duration with Gratisovir (Sofosbuvir) and Ribavirin. First intervention 'Sofosbuvir oral product' 200 mg tablet with food on daily doses based on body weight (20-29.9 kg will take one 200 mg tab daily); (30-39.9 kg will take 1.5 tab 200 mg daily); (> 40 kg will take 2 tab 200 mg daily).~Second intervention 'Ribavirin oral product' 200 mg tab on (15 mg/kg daily) doses based on body weight."
2938065|NCT02985281|Active Comparator|Arm 2|"20 patients will be randomly assigned into arm 2; treated as response guided duration; patient who show very rapid virological (undetectable HCV RNA after 2 weeks) will be treated for 16 weeks duration and reset will complete the 24 weeks duration.~Intervention 'Sofosbuvir Oral Product' 200 mg tablet with food on daily doses based on body weight (20-29.9 kg will take one 200 mg tab daily); (30-39.9 kg will take 1.5 tab 200 mg daily); (> 40 kg will take 2 tab 200 mg daily).~Second intervention 'Ribavirin oral product' 200 mg tab on (15 mg/kg daily) doses based on body weight."
2938066|NCT02985268|Active Comparator|MitraClip/Optimal Medical Therapy (OMT) and CRT ON|Patient to be implanted with both MitraClip and CRT-D. Will also receive optimal medical therapy. CRT-D will be programmed to ON
2938067|NCT02985268|Active Comparator|MitraClip/OMT and CRT OFF|Patient to be implanted with both MitraClip and CRT-D. Will also receive optimal medical therapy. CRT-D will be programmed to OFF until the 6-month follow-up visit in which the CRT will be turned ON
2938068|NCT02985268|Active Comparator|OMT and CRT ON|"Patient to be implanted with only the CRT-D and will receive optimal medical therapy.~CRT-D will be programmed to ON"
2938069|NCT02985268|Active Comparator|OMT and CRT OFF|"Patient to be implanted with only the CRT-D and will receive optimal medical therapy.~CRT-D will be programmed to OFF until the 6-month follow-up visit in which the CRT will be turned ON"
2938070|NCT02985255|Experimental|Neoadjuvant Arm|Study Subjects, eligible for NACT would undergo a pretreatment workup with Evaluation Under Anesthesia for tumor Mapping and tissue biopsy along with a PET-CT scan. They would undergo 3 cycles of NACT (weekly thrice) with injection Docetaxel, Cisplatin and 5-FU after which reassessment with PET-CT and EUA +/- biopsy would be done. Those achieving CR would undergo adjuvant CTRT while subjects with PR in PET-CT scan will be reclassified based on the biopsy report. If biopsy is negative for malignancy, they will undergo adjuvant CTRT but would undergo surgery if in the PR group. Subjects with SD or PD would undergo surgery. PET-CT and EUA +/- HPE analyses would be repeated on follow-up after 3 months of treatment completion.
2938071|NCT02985242|Experimental|Empagliflozin/glimepiride placebo|"Empagliflozin 25 mg film-coated tablet p.o. daily and glimepiride matching placebo p.o. daily~Duration of treatment: 12 months"
2938072|NCT02985242|Active Comparator|Glimepiride/empagliflozin placebo|"Glimepiride 2 mg tablet p.o. daily and empagliflozin matching placebo p.o. daily~Duration of treatment: 12 months"
2938073|NCT02985229|Experimental|All participants|All participants in the study will be given the option of home administration of 200 mg oral mifepristone and 800 μg buccal misoprostol for medical abortion.
2938074|NCT02985216|Experimental|YHD1119|YHD1119 150mg for the first 1 week, then forced titrated to YHD1119 300mg for the 1 week. And then YHD1119 150~600mg for the 2 weeks, then YHD1119 fixed dose was administrated for 8 weeks.
2938075|NCT02985216|Active Comparator|Lyrica|Lyrica 150mg for the first 1 week, then forced titrated to Lyrica 300mg for the 1 week. And then Lyrica 150~600mg for the 2 weeks, then Lyrica fixed dose was administrated for 8 weeks.
2938076|NCT02985203|Experimental|Vinorelbine oral|Oral Navelbine plus Cisplatin followed by metronomic oral vinorelbine.
2938077|NCT02985203|No Intervention|Physician's choice|Observation or maintenance therapy other than orla navelbine.
2938107|NCT02984982|Experimental|Alirocumab|Alirocumab will be given subcutaneously every 2 weeks on top of stable dose statin therapy (atorvastatin or rosuvastatin) and stable dose non-statin lipid modifying therapies (LMTs).
2940478|NCT02968316||Pregnant women|all consecutive pregnant women presenting for prenatal care
2938078|NCT02985190|Experimental|Azacitidine 75mg/m²/day|"Azacitidine 75mg/m²/j subcutaneously daily for 7 days every 4 weeks for a minimum of 6 cycles (unless overt disease progression, especially to Acute Myeloid Leukemia (AML) occure before 6 cycles) Azacitidine will be continued after 6 cycles~in patients with hematological response of myelodysplastic syndrome to azacitidine according to IWG2006 criteria by 6 cycles (Complete Response (CR), Partial Response (PR), marrow Complete Response (CRm), stable disease with Hematological Improvment (HI)), for another 6 cycles~in patients with complete or partial response of Systemic Auto-Immune Disorders (SAID) after 6 cycles of Azacitidine, even if Myelodysplastic Syndrome remains only stable per IWG2006 criteria"
2938079|NCT02985177|Active Comparator|INF + HM|The participant will receive a dose of intranasal fentanyl (1.5 mcg/kg up to a maximum of 100 mcg) AND a dose of oral hydromorphone (0.04mg/kg up to a maximum of 2 mg).
2938080|NCT02985177|Active Comparator|INF + IBU|The participant will receive a dose of intranasal (1.5 mcg/kg up to a maximum of 100 mcg) AND a dose of oral ibuprofen (10 mg/kg up to a maximum of 600 mg)
2938081|NCT02985164|Experimental|PDSa (Pocket radiation dosimeter a)|"A co-researcher reset and prepared 4 pocket dosimeters (PDS) and labelled as PDSa1, PDSa2, PDSb1 and PDSb2.~The PDSa1 and PDSa2 were placed on the outside and inside of a lead shirt respectively. The shirt-covered box was close to an anesthetic machine. This box would represent anesthetic personnel on duty and marked as position A. Position A was 160 cm. above the floor"
2938082|NCT02985164|Experimental|PDSb (Pocket radiation dosimeter b)|"The PDSb1 and PDSb2 were placed on the outside and inside of the glass shield of control room respectively. This glass shield would represent all personnel working in the operating theatre and marked as position B.~Position B was 160 cm. above the floor."
2938083|NCT02985151|Active Comparator|High Energy Treatment Group|Subjects in this group will receive at least two Syneron-Candela CO2RE laser treatments set at either the Mid mode or the Deep mode of the laser at visits three months apart. Thereafter, individuals in this group will be offered a third optional treatment at one of these settings.
2938084|NCT02985151|Placebo Comparator|Low Energy Treatment Group|Subjects in this group will receive at least two Syneron-Candela CO2RE laser treatments set at the Light mode of the laser at visits three months apart. Individuals in this group will be offered two optional high energy treatments subsequent to receiving the two light energy treatments.
2938085|NCT02985138|Experimental|Unilateral fixation|Patients undergoing TLIF and unilateral pedicle screw fixation
2938086|NCT02985138|Active Comparator|Bilateral fixation|Patients undergoing TLIF and bilateral pedicle screw fixation
2938087|NCT02985125|Experimental|Phase I - Dose Level 1|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 250mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
2938088|NCT02985125|Experimental|Phase I - Dose Level 2|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 300mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
2938089|NCT02985125|Experimental|Phase I - Dose Level -1|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 200mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
2938090|NCT02985125|Experimental|Phase I - Dose Level -2|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 150mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
2938091|NCT02985125|Experimental|Phase II - Dose|"Treatment cycles are 28 days long.~LEE011 (taken orally) - the recommended phase II dose Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
2938092|NCT02985112||Patients with FFR > 0.80|Group of patients with physiologically non-significant coronary stenoses who will not undergo coronary revascularization
2938093|NCT02985112||Patients with FFR < 0.80|Group of patients with physiologically significant coronary stenoses who will undergo coronary revascularization
2938094|NCT02985099|Active Comparator|Rosuvastatin group|Oral prophylaxis followed by 1.2% Rosuvastatin drug in gel form placed in intrabony defects
2938095|NCT02985099|Placebo Comparator|Placebo group|Oral prophylaxis followed by placebo gel placement in intrabony defects
2938096|NCT02985086|Active Comparator|Immediate induction with antibiotic prophylaxis|Immediate induction with antibiotic prophylaxis
2938097|NCT02985086|Active Comparator|Immediate induction without antibiotic prophylaxis|Immediate induction without antibiotic prophylaxis
2938098|NCT02985086|Active Comparator|Delayed induction with antibiotic prophylaxis|Delayed induction (>= 12 hours after PROM) with antibiotic prophylaxis
2938099|NCT02985073|Experimental|Veritas® mesh|Use of Veritas mesh in conjunction with immediate breast reconstruction on one side
2938100|NCT02985073|Experimental|TIGR® mesh|Use of TIGR® mesh in conjunction with immediate breast reconstruction on one side
2938101|NCT02985060|Experimental|Therapeutic hypothermia group|Therapeutic hypothermia using surface cooling device (Arctic Sun) Stroke care based on international guidelines except therapeutic hypothermia using surface cooling device (Arctic Sun)
2938102|NCT02985060|Other|Control group|Stroke care based on international guidelines
2938103|NCT02985047|Experimental|Brief Admission|Participants randomised to Brief admission (BA) will have the possibility of admitting themselves to hospital for a maximum duration of three consecutive days at a maximum frequency of three times per month. Apart from BA they have access to all psychiatric care that they would have if they had not participated in the study (including general admission to hospital).
2938104|NCT02985047|No Intervention|Control|Participants randomized to Treatment as Usual will receive no intervention from the study protocol, except the baseline assessments and repeated assessments administered on the same schedule as described above for the treatment group. They will not be given the evaluation measures that are specific to the intervention. Participants have access to all psychiatric care that they would have if they had not participated in the study (including general admission to hospital).
2938105|NCT02985021|Experimental|Treatment (docetaxel, carboplatin)|"Docetaxel 60 mg/m2 will be administered on Day 1 of each 21-day cycle. Carboplatin Area Under the Curve (AUC) 5 will be administered on Day 1 of each 21-day cycle.~Docetaxel and carboplatin should be administered over 30 minutes. Treatment will be repeated until disease progression or unacceptable toxicity."
2938106|NCT02984995|Experimental|Quizartinib|Once-daily repeated oral administration until there is no longer clinical benefit from therapy, or until unacceptable toxicity occurs.
2938205|NCT02984267|Experimental|Ultrasound Group|The interventional group that will have their spine evaluated by ultrasound prior to epidural placement
2938108|NCT02984982|Active Comparator|Standard of Care|Statin therapy (atorvastatin or rosuvastatin) will be administered with non-statin LMTs. Statin therapy and non-statin LMTs will be adjusted by physicians to achieve the LDL-C target level <100 mg/dL.
2938109|NCT02984969||Slow transit constipation|subjects met the Rome III criteria for STC
2938110|NCT02984969||Healthy subjects|Healthy controls
2938111|NCT02984943|Experimental|Hyperbaric Oxygen|Hyperbaric Oxygen
2938112|NCT02984930|Experimental|PPI + mosapride group|After diagnosis(GERD), patient of this group will be taken proton pump inhibitor (40mg) plus mosapride for 4weeks. After then, patient of this group will be undergo upper endoscopy and scintigraphy.
2938113|NCT02984930|Placebo Comparator|PPI + placebo group|After diagnosis(GERD), patient of this group will be taken proton pump inhibitor (40mg) plus placebo drug of mosapride for 4weeks. After then, patient of this group will be undergo upper endoscopy and scintigraphy.
2938114|NCT02984917|Experimental|anterior transversalis fascia approach|Patients with inguinal hernia will undergo inguinal hernia repair via the anterior transversalis fascia approach.
2938115|NCT02984917|Experimental|preperitoneal space approach|Patients with inguinal hernia will undergo inguinal hernia repair via the preperitoneal space approach.
2938116|NCT02984891||Treatment|Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) will be used in patients with coronary artery disease.
2938117|NCT02984878|Experimental|Revanesse Ultra|Revanesse Ultra open label retreatment
2938118|NCT02984865|Active Comparator|group S|Patients were attach with PCA containing 100ml combination of sulfentanyl 2.5ug/kg and flubiprofen axetil 100mg after receiving the loading dose of sulfentanyl 5 ug and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
2938119|NCT02984865|Experimental|group N1|Patients were attach with PCA containing 100ml combination of nalbuphine 1.5mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
2938120|NCT02984865|Experimental|group N2|Patients were attach with PCA containing 100ml combination of nalbuphine 2mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
2938121|NCT02984865|Experimental|group N3|Patients were attach with PCA containing 100ml combination of nalbuphine 2.5mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
2938122|NCT02984865|Other|Group ESRD|30 patients with ESRD who underwent PD catheter placement using left lateral transversus abdominis plane (TAP) block combined with rectus sheath (RS) block from our center. The TAP and RS blocks were respectively conducted with 15 ml of 0.5% ropivacaine and 10 ml of 0.5% ropivacaine. Pain intensity was evaluated by verbal rating scale (VRS), and the degree of patient and surgeon satisfaction was qualified by a categorical scale.
2938123|NCT02984852|Experimental|Treatment sequence ABC|Participants will receive a single oral tablet of darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) Treatment A (whole tablet) as reference in session 1 then Treatment B(split tablet) as test in session 2 followed by Treatment C (crushed tablet mixed in applesauce) as test in session 3 under fed conditions (standardized breakfast) on Day 1 of each treatment session. There will be a washout period of at least 7 days between consecutive drug intakes.
2938124|NCT02984852|Experimental|Treatment sequence ACB|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment A in treatment session 1, then Treatment C in session 2 followed by Treatment B in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
2938125|NCT02984852|Experimental|Treatment sequence BCA|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment B in session 1 then Treatment C in session 2 followed by Treatment A in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
2938126|NCT02984852|Experimental|Treatment sequence BAC|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment B in session 1 then Treatment A in session 2 followed by Treatment C in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
2938127|NCT02984852|Experimental|Treatment sequence CAB|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment C in session 1 then Treatment A in session 2 followed by Treatment B in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
2938128|NCT02984852|Experimental|Treatment sequence CBA|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment C in session 1 then Treatment B in session 2 followed by Treatment A in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
2938129|NCT02984839||Intra-abdominal surgery group|"The study population will include patients presenting for elective or non-elective intra-abdominal surgery requiring general anesthesia with neuromuscular blockade at OhioHealth Doctors Hospital.~Quantitative TOF will be recorded by Stimpod NMS450 in PACU."
2938130|NCT02984839||Non-intra-abdominal surgery group|"The study population will include patients presenting for elective or non-elective non intra-abdominal surgery requiring general anesthesia with neuromuscular blockade at OhioHealth Doctors Hospital.~Quantitative TOF will be recorded by Stimpod NMS450 in PACU."
2938131|NCT02984826|Active Comparator|Strength training|Intervention with specific strength training program runs for 10 weeks.
2938132|NCT02984826|Active Comparator|Ergonomic and posture|Intervention, the control group will be trained in ergonomics and posture.
2938133|NCT02984813|Experimental|GlaucoHealth|2 pills once daily in the morning for 3 months
2938134|NCT02984813|Experimental|GlaucoSelect|2 pills once daily in the morning for 3 months
2938135|NCT02984813|Placebo Comparator|Placebo|2 pills once daily in the morning for 3 months
2938136|NCT02984800|Experimental|Group I|Patients will receive one PVB injection at L1-L2 .
2938137|NCT02984800|Experimental|Group III|Patients will receive three PVB injections at T12-L1, L1-L2 and L2-L3.
2938138|NCT02984787|Experimental|3D Laparoscopic total gastrectomy|Participants including in the 3D laparoscopic total gastrectomy (3D-LTG) group will undergo 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection.
2938139|NCT02984787|Active Comparator|2D Laparoscopic total gastrectomy|Participants including in the 2D laparoscopic total gastrectomy (2D-LTG) group will undergo 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection.
2938140|NCT02984774|Experimental|Infertile endometriosis|Cystic wall segment from cystectomy material, endometrial sampling during the surgery and peripheric blood sampling during intravenous catheterization during anesthesia.
2938141|NCT02984774|Experimental|Fertile endometriosis|Cystic wall segment from cystectomy material, endometrial sampling during the surgery and peripheric blood sampling during intravenous catheterization during anesthesia.
2938142|NCT02984774|Other|Control|Ovarian tissue sampling, endometrial sampling from hysterectomy and oophorectomy pieces and peripheric blood sampling during intravenous catheterization during anesthesia.
2938143|NCT02984761|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy is an FDA approved treatment for lung cancer. However, for purposes of this study, it is being delivered to an operable population that is typically treated with surgical resection. Participants randomized to stereotactic radiotherapy will be treated according to the location of the tumor. Peripheral tumors will receive either 18 Gy x 3, 14 Gy x 4, or 11.5 Gy x 5 fractions, while central tumors will be treated with 10 Gy x 5. There will not be any elective coverage of local microscopic spread or regional lymph nodes.
2938144|NCT02984761|Active Comparator|Surgery|Participants randomized to surgery will undergo a standard lobectomy or limited anatomic pulmonary resection (segmentectomy) under general anesthesia. Non-anatomic (wedge) resections are not permitted. Pathological specimens must contain a separately divided pulmonary artery and bronchus, as well as sampled lymph nodes from mediastinal lymph node stations. Participants found to have incidental nodal involvement after surgery will be referred for adjuvant chemotherapy, with our without postoperative radiotherapy.
2938145|NCT02984748||Cochlear Implant Recipients|
2938146|NCT02984735||Evaluation of children with spastic CP|Children with a diagnosis of spastic CP aged 2 to 12 years who were referred due to chewing/swallowing problems by pediatric neurologists were included. The inclusion criteria were above the age of 24 months, and had complaints about chewing function. Children under the age of 24 months, requiring tube feeding or taking any oral nutritional supplements, and used any medicine and/or oral appliances that could affect the chewing performance, were excluded.
2938147|NCT02984722|Experimental|1|PCOS women treated with 1500 mg/die of extended-release metformin
2938148|NCT02984722|Experimental|2|PCOS women treated with 1500 mg/die of immediate-release metformin
2938149|NCT02984709|Experimental|Positive Psychology Intervention|The text message group will receive the intervention components via text message. They will be instructed to think about things that make them feel good when they are struggling with diabetes management (i.e. gratitude). Also they will be instructed to think about a positive value when they are in a situation that makes it hard to check their blood sugar (i.e. Self-Affirmation). Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths. All adolescents will be given developmentally-appropriate diabetes education material at the time of enrollment.
2938150|NCT02984709|Active Comparator|Education Group|The education group will be given developmentally-appropriate diabetes education material at the time of enrollment.
2938151|NCT02984696|Experimental|Hormonal Replace Therapy|1 mg of transdermal estradiol daily and 10mg of oral Medroxyprogesterone acetate from 16th to 24th day of therapy for six months
2938152|NCT02984683|Experimental|SAR566658 (Part 1)|SAR566658 will be given as Dose 1 (cohort 1) and Dose 2 (cohort 2) at Day 1 and Day 8 every 3 weeks intravenously
2938153|NCT02984683|Experimental|SAR566658 (Part 2)|SAR566658 (Part 2) - SAR566658 will be given as Dose 1 or Dose 2 (depending on dose level selected from part 1) at Day 1 and Day 8 every 3 weeks intravenously
2938154|NCT02984670|Experimental|Behavior Therapy|
2938155|NCT02984670|Experimental|Cognitive Therapy|
2938156|NCT02984670|Other|Waitlist|
2938157|NCT02984657||2012 patients|Surgical patients in 2012 with anesthesia and nursing staff less attuned to intraoperative RTP.
2938158|NCT02984657||2015 patients|Surgical patients in 2015 with enhanced anesthesia and nursing staff awareness and use of intraoperative RTP.
2938159|NCT02984644|Active Comparator|Dapagliflozin|32 subjects will receive dapagliflozin 10mg
2938160|NCT02984644|Placebo Comparator|Placebo|16 subjects will receive placebo
2938161|NCT02984631|Other|Preventing pulm HTN during exercise 2nd|Standard of care invasive cardiopulmonary exercise test (CPET) followed by CPET with pre-load control.
2938162|NCT02984631|Other|Preventing pulm HTN during exercise 1st|Pre-load control of invasive cardiopulmonary exercise test (CPET) followed by standard CPET.
2938163|NCT02984618|Experimental|Treatment group|Patients will receive sphenopalatine ganglion block with ropivacaine 0.375% 3ml on each side
2938164|NCT02984618|Active Comparator|Control group|Patients will receive classic epidural blood patch with 20ml of autologous blood
2938165|NCT02984605|Experimental|Interventional group|"Arm：Hypoglycemic agents + Nutrition meal replacement & exercise prescription~Hypoglycemic agents in combined with 1 times a day with bags of nutritional meal replacement and exercise"
2938166|NCT02984605|No Intervention|Control group|"Arm：Hypoglycemic agents~without take nutrition meal replacement & exercise prescription"
2938167|NCT02984592||Group 1|The participants in group 1 will state that they participate regular exercise programs in the previous 6 months
2938168|NCT02984592||Group 2|The participants in group 2 will state that they do not perform any regular exercise in previous 6 months.
2938169|NCT02984579||All Subjects|"All strains in Phase 1 and all Sputum samples in Phase 2 were tested with Hain Genotype MTBDRplus V1, Hain Genotype MTBDRplus V2, and YD REBA MTB-MDR diagnostic tests.~Investigators and Operators were blinded to all other results for a sample upon data entry."
2938170|NCT02984566|Experimental|SABR with or without KIM|All patients will receive liver SABR. Kilovoltage Intrafraction Monitoring (KIM) tracking will be trialed during mock treatment. If KIM is successful, it will be used throughout treatment. If unsuccessful, cone beam CT will be used instead.
2938197|NCT02984358|Active Comparator|High-nucleotide mycoprotein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by nucleotide-rich mycoprotein products.
2938198|NCT02984345|Active Comparator|Mycoprotein beverage|
2938171|NCT02984540|Experimental|LOW-CARBOHYDRATE DIET|The low-carbohydrate diet will consist of a meal plan of less than 20 grams of carbohydrates per day to be consumed over 6 weeks. Foods that provide high levels of healthy fats (preferably low in saturated fats) will be generously included in the diet plan. Various lean meats, fish, and nutrient rich foods that meet the requirement of less than 20 grams total carbohydrates per day will be included in the meal plans. Carbohydrates will be expected to make up less than 10% of total caloric intake. Participants in the low-carbohydrate diet group will receive a supply of extra virgin olive oil at study visits to incorporate into their individualized meal plans.
2938172|NCT02984540|Experimental|LOW-FAT DIET|The low-fat diet will consist of a low-fat, higher-carbohydrate meal plan to be consumed over 6 weeks. Participants will be encouraged to limit their amount of fat intake to less than 40 grams per day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber. Various lean meats and other sources of protein will be included in the diet plan. Carbohydrates will be expected to make up 50-60% of total caloric intake.
2938173|NCT02984527|Active Comparator|water and soap first day|Intimate hygiene performed with water and soap first day and disposable wet wipes second day
2938174|NCT02984527|Active Comparator|disposable wet wipes first day|Intimate hygiene performed with wet wipes first day and water and soap second day
2938175|NCT02984514|Experimental|Type 1 diabetes|Positron emission tomography with tracer 18F-deoxy glucose
2938176|NCT02984501|Experimental|Single Arm|Patients treated with induction chemotherapy with gemcitabine and oxaliplatin; for patients without disease progression as detected through restaging exams, chemotherapy was followed by radiochemotherapy which consisted of conformal radiation therapy and concurrent gemcitabine at the dose of 600 mg/mq weekly.
2938177|NCT02984488|Experimental|single visit endodontic treatment.|•single visit endodontic Treatment of necrotic teeth using Protaper next.
2938178|NCT02984488|Active Comparator|Two visits endodontic treatment|•Two visits endodontic Treatment of necrotic teeth using Protaper next.
2938179|NCT02984475|Active Comparator|treatment arm|30 patients receiving blood transfusion and taking iron-chelating therapy along with metformin tablets (500 mg once daily for the first week then twice daily for 6 months).
2938180|NCT02984475|No Intervention|control arm|30 patients receiving blood transfusion and taking iron-chelating therapy.
2938181|NCT02984462|Experimental|screw fixation|Surgical Percutaneous Akin osteotomy with fixation by a percutaneous cannulated screw and forefoot surgery dressing.
2938182|NCT02984462|No Intervention|No fixation|Surgical Percutaneous Akin osteotomy non-fixed, hold by forefoot surgery dressing.
2938183|NCT02984449|Experimental|Pre+postoperative Cardiac rehabilitation|receive a cardiac rehabilitation program consisting of three phases. 1) A preoperative optimization phase (3x p/wk, 4-6 weeks, before surgery), 2) a postoperative in-patient phase (15 to 18 days in rehabilitation center, weekend at home) and, 3) an outpatient patient clinical rehabilitation phase (2x p/wk, 4 weeks). During each phase, patients will visit a physical therapist (group sessions of inspiratory muscle training (IMT), strength training, aerobic cycling and breath, cough and relaxation sessions), a dietician and a psychologist to optimize general health and receive advice on lifestyle, anxiety and stress management. Two additional components are coaching to stop smoking
2938184|NCT02984449|Active Comparator|Postoperative Cardiac rehabilitation|Patients who are randomized to the POST group receive an out-patient cardiac rehabilitation program after surgery. In general, this program starts three to six weeks after discharge (phase ǀǀ) and patients always start with an exercise program, which is supervised by a physical therapist for about six weeks (twice a week). On indication support of psychological and/or dietary consult is added.
2938185|NCT02984436||ED Patients with Acute Chest Pain|Emergency Department (ED) Patients with Acute Chest Pain will have blood samples collected for High sensitivity cardiac troponin T (hs-CTnT) analysis. Results from this analysis will be integrated into the HEART Score/Pathway. It will later be seen if integration of the hs-cTnT outperforms the use of HEART Score/Pathway alone.
2938186|NCT02984410|Other|Intensity-Modulated Radiation Therapy (IMRT)|PTV prescription to tumor and high risk areas will be delivered daily for 5 days per week to a total dose of 66-70Gy in 2 Gy/fraction over 6 weeks, elective/prophylactic mucosal and nodal areas will receive a total dose of 54.25- 54.45 Gy in 33-35 fractions of 1.55-1.65 Gy over 6 weeks.
2938187|NCT02984410|Other|Trans Oral Surgery (TOS)|"The following surgical techniques are allowed:~Transoral Robotic Surgery (TORS) Transoral Microsurgery (TLM) Conventional trans-oral Surgery (CTOS)"
2938188|NCT02984397|Experimental|KF group|In each study visit, patients will receive enough pills for the next month. At the first visit, patients receiving ketotifen (KF) will receive four vials sequentially numbered (1 to 4) containing enough pills for one week each, and will be instructed by the clinician and by the pharmacist to use vial 1 for the first week (0.5 mg of KF BDI), vial 2 for the second week (1mg of KF BDI), vial 3 for the third week (2 mg of KF BDI), and vial 4 for the fourth week (3mg of KF BDI). As for weeks 4, 8 and 12 visits, patients treated with KF will receive four equal vials containing enough pills for one week each (3 mg of KF BDI)
2938189|NCT02984397|Placebo Comparator|Placebo group|Patients participating in the placebo group will also receive sequentially numbered vials at the first visit. Similarly, patients taking placebo will also receive four equal vials of pills on the next visits.
2938190|NCT02984397|Active Comparator|SOC|Standard of care - patients who refuse to participate in the study but allow us to compare their clinical data to that of participants of the study
2938191|NCT02984384|Active Comparator|Low Molecular Weight Heparin (LMWH)-Enoxaparin|Injection of 30 mg enoxaparin, twice a day via injection
2938192|NCT02984384|Active Comparator|Acetylsalicylic acid (ASA)-Aspirin|Enteral ingestion or administration of 81 mg ASA, twice a day
2938193|NCT02984371|Experimental|Group 1|Coronary artery bypass grafting + epicardial ganglionated plexi ablation
2938194|NCT02984371|Active Comparator|Group 2|Coronary artery bypass grafting
2938195|NCT02984358|Placebo Comparator|Animal protein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by animal products (meat and fish).
2938196|NCT02984358|Active Comparator|Low-nucleotide mycoprotein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by nucleotide-depleted mycoprotein products (commercial Quorn products).
2938199|NCT02984345|Placebo Comparator|Milk protein beverage|
2938206|NCT02984267|Other|Palpation Group|The control group that will have their epidural placed in the usual fashion based on palpation
2938207|NCT02984254|Experimental|functional patellofemoral neoprene brace|26 Patients will use a a functional patellofemoral neoprene brace and answer WOMAC, Lequesne questionnaires, perform Timed-up-and-go (TUG), five-times-sit-to-stand-test (FTSST) and the six-minute walk test.
2938208|NCT02984254|Experimental|neoprene sleeve brace.|26 Patients will use a neoprene sleeve brace and answer WOMAC, Lequesne questionnaires, perform Timed-up-and-go (TUG), five-times-sit-to-stand-test (FTSST) and the six-minute walk test.
2938209|NCT02984241|Active Comparator|eHealth Coping Skills Training + Coach|Access to StopSpinningMyWheels.org + Coach Support
2938210|NCT02984241|Active Comparator|eHealth Coping Skills Training Only|Access to StopSpinningMyWheels.org
2938211|NCT02984241|Active Comparator|eHealth Usual Web Care|Access to StopSpinningMyWheels.org usual care
2938212|NCT02984228|Active Comparator|PRP|
2938213|NCT02984228|Active Comparator|Hyaluronic Acid|
2938214|NCT02984202|Experimental|Safety/Efficacy|Patients will be implanted with the AMI and evaluated for safety and efficacy over a 2-year period. The placement of the AMI array into the inferior colliculus will also be evaluated.
2938215|NCT02984189|Experimental|Inspiratory Critical Pressure Group|Inspiratory Critical Pressure will be used for training and will be determined, from a progressive inspiratory threshold-loading test will start with 50%MIP followed by 10%MIP increments, every 3min until subjects reached a load that there were unable to sustain for at least 1min (PThMAX). On another day, the subjects will perform a constant inspiratory loading test against a resistance of 95%, 100% and 105%PThMAX, for as long as they could tolerate. The intensity loads will be applied according the results of block randomization. The time elapsed until task failure was defined as inspiratory muscle endurance time, and will use to set the PThC. The respiratory work done (inspiratory pressure values) will be plotted in abscissa and the time-to-exhaustion in ordinate, and a linear regression going through the 3 points will be applied using the pressure-1/t relationship. The slope of the parallel line displaced downward projecting to the origin produce the PThC value.
2938216|NCT02984189|Active Comparator|60% Maximal Inspiratory Pressure Group|60% of maximal inspiratory pressure will be used for training.
2938217|NCT02984189|Sham Comparator|Sham Group|6 cmH20 will be used for training.
2938218|NCT02984176|Active Comparator|Simethicone|Arm 1 or Group I or Simethicone 40mg. 3 tablets (one tablet after each meal) and to fast overnight the day before the operation.
2938219|NCT02984176|Placebo Comparator|placebo|Arm 2 or group 2 or placebo group. 3 tablets (one tablet after each meal) and to fast overnight the day before the operation.
2938220|NCT02984163|Experimental|Exercise Intervention|Participant exercise sessions will be conducted in groups of 10-15 under the direct supervision of the community-based exercise specialist. Sessions will be twice a week for 12-weeks. Participants will have the option to continue with the exercise program after the 12-weeks on a fee-for-service basis.
2938221|NCT02984150|Experimental|fatty acid|the nutrient that can be widely found in daily food.
2938222|NCT02984150|Sham Comparator|saline|saline
2938223|NCT02984137|Experimental|idiopathic RBD group|A group of patients diagnosed as idiopathic RBD that is confirmed by polysomnography. Interventions as testing, evaluation, samplings at baseline, then repeat at 2 years and 4 years of prospective follow-up. thereafter only clinical observations until Lewy body disease is diagnosed.
2938224|NCT02984137|Active Comparator|incident PD group|A group of patients who are newly diagnosed as Parkinson's disease, and never been treated with prolonged history of probable RBD. Interventions as testing, evaluation, sampling at baseline and then evaluations only at 3 year follow-up after anti-parkinsonian treatment.
2938225|NCT02984137|Placebo Comparator|Control|Control group includes elderly controls without neurodegerative diseases examined by neurologists. Interventions as testing, evaluation, sampling at baseline only.
2938226|NCT02984124|Experimental|Intervention|Participants (n= approximately 90 plus family members) who are randomized to the intervention arm of the study will participate in a discussion about CPR with a study doctor.
2938227|NCT02984124|Placebo Comparator|Usual Care with Attention Control|Participants (n= approximately 90 plus family members) who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
2938228|NCT02984111|Active Comparator|group A|20000 IU erythropoietin infusion during aortic cross clamp in 45-60 minutes
2938229|NCT02984111|Active Comparator|group B|20000 IU erythropoietin infusion after induction of anesthesia and before undergoing cardiopulmonary bypass pump in 45-60 minutes
2938230|NCT02984111|Placebo Comparator|control|50 ml normal saline infusion during aortic cross clamp in 45-60 minutes
2938231|NCT02984098|Experimental|Dextrose gel 40%|before heel lance, 2 ml oral dextrose gel 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
2938232|NCT02984098|Active Comparator|Dextrose gel 25%|before heel lance, 2ml oral dextrose gel 25% was administered, and pain related intensity was evaluated with premature infant pain profile scale
2938233|NCT02984085|Experimental|Genetically corrected cultured epidermal autograft|"The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate epidermal cells including stem cells. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where they will be corrected, expanded and prepared as final sheets to be implanted.~In the second surgery, genetically corrected cultured epidermal autograft (Hologene 7) will be implanted into the selected area. The specialist surgeon will either use a local or general anaesthetic for the implant operation. The treated area will be immobilized for some days after this operation. Antibiotics and anti-inflammatory drugs will be administered (if necessary) to prevent infections and to minimise swelling."
2938234|NCT02984072|Active Comparator|Menthol|5% menthol in aqueous cream (Dermacool Forte)
2938235|NCT02984072|Placebo Comparator|Placebo|Aqueous cream
2938266|NCT02983825|Experimental|Continuous positive airway pressure (CPAP) level changes|Protocol guided changes in CPAP level from clinical baseline, with responsiveness in V/Q mismatch guiding subsequent changes; limited to a range of -2 to +3 cm H2O from baseline
2938323|NCT02983383|Active Comparator|Group without TAP (Group P)|Patients in Group P will have adjuvant added to spinal anesthesia.
2938236|NCT02984059||IBD w/abdominal pain|"Patients with IBD with abdominal pain. Extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for both genomic DNA and calprotectin, and stool analyzed for microbiome. If no blood is drawn then a buccal swab done for the genomic DNA analysis and stool analyzed for calprotectin.~Pain questionnaires:~Pain Frequency-Severity-Duration Scale Pain Catastrophizing Scale-Child Version Pain Burden Interview Pediatric Quality of Life Inventory Adolescent Pediatric Pain Tool Anxiety/Depression Questionnaires Revised Children's Anxiety and Depression Scale Children's Somatization Inventory Adult Responses to Children's Symptoms"
2938237|NCT02984059||IBD w/out abdominal pain|"Patients with IBD and no abdominal pain. Colonoscopy done for standard of care, extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for genomic DNA and calprotectin and stool analyzed for microbiome. If no blood is drawn then a buccal swab for the genomic DNA analysis and stool analyzed for calprotectin.~Pain questionnaires:~Pain Frequency-Severity-Duration Scale Pain Catastrophizing Scale-Child Version Pain Burden Interview Pediatric Quality of Life Inventory Adolescent Pediatric Pain Tool Anxiety/Depression Questionnaires Revised Children's Anxiety and Depression Scale Children's Somatization Inventory Adult Responses to Children's Symptoms"
2938238|NCT02984059||Colonoscopy other reasons no abd pain|Patients who have a colonoscopy for other reasons, rectal bleeding or polyp surveillance, no abdominal pain. Extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for genomic DNA and calprotectin and stool analyzed for microbiome. If no blood is drawn then a buccal swab for the genomic DNA analysis and stool analyzed for calprotectin.
2938239|NCT02984046|Experimental|acute bronchiolitis|Prospective, monocentric, case-control and study Primary end-point: correlation between serum CC16 level and severity of the bronchiolitis, evaluated by a clinical scoring system
2938240|NCT02984033||Head and Neck patients|Patients affected by squamous cell carcinoma of head and neck (oral cavity, larynx, pharynx and hypopharynx) with no metastasis
2938241|NCT02984007|Experimental|Motivational Interviewing|Educational session based on the motivational interviewing
2938242|NCT02984007|Other|Information flyer|Information flyer on childhood vaccines
2938243|NCT02983994||Patients with asthma with an inhaled steroid|Patients with a diagnosis of asthma with indication of Treatment with an inhaled steroid (CI)
2938244|NCT02983994||Patients with asthma with an inhaled Beta agonist|Patients with a diagnosis of asthma with indication of Treatment with an inhaled Beta agonist (LABA)
2938245|NCT02983981|Experimental|open label|Topicort topical spray
2938246|NCT02983955|Other|SCI with Tetraplegia|
2938247|NCT02983942|Experimental|ketogenic diet group|Ketogenic diet is given in combination to standard HD-MTX chemotherapy to primary central nervous system lymphoma patients. Blood ketone is kept no less than 2mmol/L during the initial 4 cycles of chemotherapy. The adverse events is monitored and recorded. Tumor response is evaluated and recorded.
2938248|NCT02983942|Active Comparator|routine diet group|Standard HD-MTX chemotherapy is given with routine diet.Blood ketone is measured and recorded. The adverse events is monitored and recorded. Tumor response is evaluated and recorded.
2938249|NCT02983929||BMI <30 kg.m-2|Patients with a BMI inferior to the obesity limit defined by the World Health Organization.
2938250|NCT02983929||BMI >30 kg.m-2|Patients with a BMI superior to the obesity limit defined by the World Health Organization.
2938251|NCT02983916||Group 1: adhesiolysis|Group 1 (the operative group) consisted of all patients who underwent laparoscopy and/or laparotomy. Typically patients had positive cine-MRI. A few patients with inconclusive cine-MRI who underwent diagnostic laparoscopy are also included in this group. Patients with no adhesions found during operation remain in group 1, because analysis is performed on intention-to-treat basis.
2938252|NCT02983916||Group 2: Adhesions, conservative|Patients with evidence of adhesions based on cine-MRI who did not undergo laparoscopy or laparotomy.
2938253|NCT02983916||Group 3: No adhesions|Patients in whom no evidence of adhesions was found on cine-MRI, and who did not undergo laparoscopy or laparotomy .
2938254|NCT02983903|Experimental|Single intervention arm - transbronchial biopsy|Patients enrolled in this single arm study will have lung nodules biopsied by traditional forceps followed by transbronchial cryobiopsy
2938255|NCT02983890|Active Comparator|Arm of study1|Dicloxacillin tablets.
2938256|NCT02983890|Placebo Comparator|Arm of study 2|No treatment
2938257|NCT02983877|Active Comparator|iTAB-CV Stage 1|In the Individualized Texting for Adherence Building-CV (iTAB-CV) Stage 1, participants will receive alternating daily texts with educational and motivational content on treatment for high blood pressure and bipolar disorder, and a daily mood rating request to both monitor their mood and to determine adherence to iTAB-CV intervention.
2938258|NCT02983877|Active Comparator|iTAB-CV Stage 2|In the Individualized Texting for Adherence Building-CV (iTAB-CV) Stage 2, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from stage 1.
2938259|NCT02983864|Active Comparator|Alcohol and Relaxation|This arm will receive a brief (2-hour) alcohol intervention based on motivational interviewing termed BASICS and a brief (1.5 hour) relaxation intervention
2938260|NCT02983864|Active Comparator|Alcohol and Relationships|This arm will receive a brief (4-hour), two session, integrated alcohol and relationship intervention based on motivational interviewing designed to increase healthy alcohol use and sexual behavior. The interventions are based on an integrated BASICS and integrated Bystander protocols
2938261|NCT02983851|Experimental|Noninvasive mechanical ventilation|Patients in this group will receive Noninvasive mechanical ventilation as the initial mechanical ventilation (MV) strategy, irrespective of whether Invasive mechanical ventilation is used later during the following treatment.
2938262|NCT02983851|Active Comparator|Invasive mechanical ventilation|Patients in this group will receive Invasive mechanical ventilation as the initial MV strategy, irrespective of whether Noninvasive mechanical ventilation is used later during the following treatment.
2938263|NCT02983838||depression with cognitive impairment|depression onset after 60 years old with subjective cognitive impairment
2938264|NCT02983838||depression without cognitive impairment|depression onset after 60 years old without subjective cognitive impairment
2938265|NCT02983838||normal control|older than 65 years, free from other neurocognitive disorder
2938267|NCT02983812||Activity Monitoring - Smartphone|Patients in the activity monitoring - smartphone group will be randomly assigned to track their data using a smartphone app (which collects step counts) for 6 months. There will be no intervention for either group, both are being passively monitored.
2938268|NCT02983812||Activity Monitoring - Wearable|Patients in the activity monitoring - wearable device group will be randomly assigned to track their data using a wearable activity tracker (which collects step counts and sleep patterns/duration). There will be no intervention for either group, both are being passively monitored.
2938269|NCT02983799|Experimental|gBRCAm;|germline BRCA mutant
2938270|NCT02983799|Experimental|sBRCAm and germline BRCA wild type;|somatic BRCA mutant, germline BRCA wild type
2938271|NCT02983799|Experimental|myChoice® HRD positive and BRCAwt;|genomic instability positive and no BRCA mutation
2938272|NCT02983799|Experimental|myChoice® HRD negative and BRCAwt|genomic instability negative and no BRCA mutation
2938273|NCT02983786||Non-Invasive Monitoring|"One non-invasive optode patch will be placed adjacent to the area of invasive monitoring and the second patch will be placed contralaterally. (12 hrs. daily is chosen primarily for budgetary reasons). The information for the non-invasive technology will be compared to the invasive technology.~ICG (Indocyanine Green) will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable)."
2938274|NCT02983773|Experimental|High THC dose|1 marijuana cigarette (7.2% THC)
2938275|NCT02983773|Experimental|Low THC dose|1 marijuana cigarette (3.0% THC)
2938276|NCT02983773|Placebo Comparator|Placebo|Placebo marijuana cigarette
2938277|NCT02983760|Active Comparator|Planar V/Q-based strategy|Control arm
2938278|NCT02983760|Active Comparator|CTPA-based strategy|Control arm
2938279|NCT02983760|Experimental|V/Q SPECT-based strategy|Experimental arm
2938280|NCT02983747|Experimental|PRP Treatment(P)|PRP intra-disk injection therapy combined with NSAIDs medication (Loxoprofen Sodium tablets).
2938281|NCT02983747|Active Comparator|Medication Treatment(M)|NSAIDs medication(Loxoprofen Sodium tablets) therapy only.
2938282|NCT02983734|Active Comparator|D-cycloserine|"To compare efficacy of the novel therapeutic approach of DCS in improving cognitive functioning in GW veterans with GWI.~DCS = d-cycloserine~Dosage: 100mg~Dosage form: Pill, administered orally~Frequency: Daily for four weeks"
2938283|NCT02983734|Placebo Comparator|Placebos|To provide a control group to compare efficacy of the novel therapeutic approach of DCS in improving cognitive functioning in GW veterans with GWI.
2938284|NCT02983721|Active Comparator|Transfemoral|in case of transfemoral approach our preference was to use right femoral route. The groin was prepared and draped and the site was punctured for femoral access after anesthetizing the skin with 2-4 ml of 1% lignocaine. Once the femoral puncture was done 6F sheath of Cordis variety was introduced and 6F Judkins, catheter was introduced and it was guided under fluoroscopic guidance through the aortic route.
2938285|NCT02983721|Active Comparator|Transradial|Our preference was to use the right radial and right femoral routes as they are nearest to operator while facing cardiac monitors, in our hospital. For the radial approach, the wrist was sterilized and draped in usual fashion. Hyperextension over an arm board was done and skin over the puncture site was anesthetized with 2 - 3 ml of 1% lignocaine. A small scaled incision was performed 1 cm proximal to styloid process of radius where arterial pulse was best felt. The radial artery was punctured with a 21 G needle and 6 F sheath (Cardis, Terumo) were introduced into the artery, using Seldinger technique. All patients received verapamil (5mg) to reduce radial artery spasm. Heparin (weight adjusted) was used only in PCIs to prevent artery occlusion and not in elective diagnostic coronary studies. Long 0.038 Terumo guide wire was used under fluoroscopic guidance.
2938286|NCT02983708|Experimental|mPBMC group|G-CSF would be administered for 5 days and then mobilized peripheral blood mononuclear cells (mPBMCs) would be collected in all included patients. One month after cryopreservation of the mPBMCs (M1), patients will be randomized to receive either mPBMCs or placebo. Six months after randomization (M7), cross-over infusion of mPBMCs or placebo will be performed and the patients are observed for another 6 months. mPBMCs group would be included all patients who received mPBMCs at M1 or M7.
2938287|NCT02983708|Placebo Comparator|Placebo group|G-CSF would be administered for 5 days and then mobilized peripheral blood mononuclear cells (mPBMCs) would be collected in all included patients. One month after cryopreservation of the mPBMCs (M1), patients will be randomized to receive either mPBMCs or placebo. Six months after randomization (M7), cross-over infusion of mPBMCs or placebo will be performed and the patients are observed for another 6 months. Placebo group would be included all patients who received placebo at M1 or M7.
2938288|NCT02983695|Experimental|treatment|all participants will be in this arm and will receive study drug 'Cannabidiol-Rich whole Plant Extract (TIL-TC150) to assess dosing and tolerability according to study protocol
2938289|NCT02983682|Experimental|Lidocaine Infusion|All participants will receive intravenous lidocaine infusion of 42 mcg/kg/minute over 2 hours, for a total of 5 mg/kg. No bolus dose will be given.
2938290|NCT02983669|Experimental|Thyme|Zataria multiflora Boiss powder capsule 350 mg twice daily for 3 months
2938291|NCT02983669|Placebo Comparator|Placebo|Wheat powder capsule 350 mg twice daily for 3 months
2938292|NCT02983617|Experimental|Tirabrutinib + entospletinib|Participants will receive tirabrutinib and entospletinib for up to 104 weeks.
2938293|NCT02983617|Experimental|Tirabrutinib + entospletinib + obinutuzumab|Participants will receive obinutuzumab over 21 weeks and the combination of tirabrutinib and entospletinib for up to 104 weeks.
2938294|NCT02983604|Experimental|GS-5829 + exemestane (Phase 1b)|Participants will be sequentially enrolled at progressively higher dose levels of GS-5829 in combination with exemestane and may continue with treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
2938295|NCT02983604|Experimental|GS-5829 + fulvestrant (Phase 1b)|Participants will be sequentially enrolled at progressively higher dose levels of GS-5829 in combination with fulvestrant and may continue with treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
2938296|NCT02983604|Experimental|GS-5829 + fulvestrant (Phase 2)|Participants will receive GS-5829 (dose determined from Phase 1b) + fulvestrant until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
2938297|NCT02983604|Active Comparator|Fulvestrant (Phase 2)|Participants will receive fulvestrant alone until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
2938298|NCT02983591|Experimental|Misoprostol|Rectal misoprostol
2938299|NCT02983591|Experimental|Oxytocin|intravenous oxytocin
2938300|NCT02983578|Experimental|Advanced Non-Small Cell Lung Cancer Group|"Participants receive AZD9150 every week and MED4736 every 4 weeks.~Participants receive treatment until progression or unacceptable toxicity."
2938301|NCT02983578|Experimental|Mismatch Repair-Deficient Colorectal Cancer Group|"Participants receive AZD9150 every week and MED4736 every 4 weeks.~Participants receive treatment until progression or unacceptable toxicity."
2938302|NCT02983578|Experimental|Pancreatic Cancer Group|"Participants receive AZD9150 every week and MED4736 every 4 weeks.~Participants receive treatment until progression or unacceptable toxicity."
2938303|NCT02983565|No Intervention|Sleep study on usual long-term oxygen therapy flow rate|Participants will have a sleep study on their usual LTOT flow rate.
2938304|NCT02983565|Experimental|Sleep study on the intelligent oxygen therapy system|Participants will have a sleep study on the intelligent oxygen therapy system. This system will supply variable flow oxygen to match a pre-set oxygen saturation target of 93% during sleep.
2938305|NCT02983552|Experimental|Binocular Computer Game Treatment|Binocular computer game treatment is defined as playing a Dig Rush application on an iPad® 1 hour per day, 5 days per week for 8 weeks in addition to continued spectacle correction (if required)
2938306|NCT02983552|Active Comparator|Continued Spectacle Correction|Continued spectacle correction is defined as wearing appropriate spectacle correction (if required) for all waking hours, 7 days per week for 8 weeks.
2938307|NCT02983513|Experimental|Early Intervention|"The early intervention program is delivered during the NICU stay, according to the MITP and Premie Start Protocol, in order to train parents to: recognize signs of infant stress and alert-available behavior to promote mother-infant interaction; adopt principles of graded stimulation; optimize interactions and avoid overwhelming infants through facilitation strategies (for example, engage and support the visual attention of the newborn). The program is held in eight main sessions and one additional post-discharge session.~In addition parents are trained and invited to daily promote preterm baby massage therapy and visual attention according to a detailed protocol."
2938308|NCT02983513|No Intervention|Standard Care|Standard Care according to NICU protocols including Kangaroo Mother Care, nesting and minimal handling
2938309|NCT02983487||Index case (WP1a)|"Infant under 6 months old with clinical signs of whooping cough syndrome.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by aspiration or swabbing"
2938310|NCT02983487||Control case (WP1b)|"Contact cases of infant with a positive diagnosis for whooping cough.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by aspiration or swabbing~Blood sampling:~A blood sample collected by fingerprick"
2938311|NCT02983487||Seroepidemiological cohort (WP2)|"Children between 3 and 15 years old with complete primo-vaccination against B.Pertussis~Blood sampling:~A blood sample collected by fingerprick"
2938312|NCT02983461|Placebo Comparator|Placebo|Double Blind Placebo 3 times a day for 10 weeks.
2938313|NCT02983461|Active Comparator|Sildenafil|Double Blind Sildenafil, 20mg x 3 times a day, 10 weeks.
2938314|NCT02983448|Placebo Comparator|Sham stimulation first|"Sham stimulation delivered at the earlobe (devoid of vagal innervation) is given on first session.~Transcutaneous vagus nerve stimulation delivered at the tragus (vagal innervation) is given on second session."
2938315|NCT02983448|Active Comparator|Active stimulation first|"Transcutaneous vagus nerve stimulation delivered at the earlobe (vagal innervation) is given on first session.~Sham stimulation delivered at the tragus (devoid of vagal innervation) is given on second session."
2938316|NCT02983435|Experimental|G1 - Thrust manipulation|G1 - Thrust manipulation is an osteopathic technique. The Group 1 (G1) will receive the Thrust technique applied at the level of dysfunction. Subject in lateral decubitus, with one lower limb extended and the other in flexion, to the level of the targeted vertebra; upper trunk rotated back until the same vertebra; at the end of the range of movement will be applied the high speed and low amplitude impulse (Thrust).
2938317|NCT02983435|Active Comparator|G2 - Muscle Energy|G2 - Muscle Energy is a manual therapy technique based in muscular contraction and stretching. The Group 2 (G2) will receive the Muscle Energy technique applied at the level of dysfunction. Subject in lateral decubitus, with the upper and lower trunk flexed until the target vertebra, and upper trunk rotated back to the level of the same vertebra; lumbar in lateral flexion (using the subject's feet) until the target vertebra. Following the command the subject will perform an isometric contraction of 3-5 seconds against the therapist's hand (pushing the hand towards the floor), repeated 3 times.
2938318|NCT02983422|Active Comparator|Group aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
2938319|NCT02983422|Placebo Comparator|Group frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h，with placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
2938320|NCT02983409||Pstone|Adult Patients (> 18years) who were diagnosed as the urinary stone in the ED. All patients who visited the ED with compalin of acute pain, and urinary stone was idenfied by urinary CT in the ED.
2938321|NCT02983396|Experimental|no transmural ischemia (NTI) and transmural ischemia (TI)|"Case cross-over from no transmural ischemia (NTI) to transmural ischemia at 60 s coronary occlusion during elective coronary angioplasty (TI)~Comparison of diagnostic accuracy of standard 12-lead ECG versus Mini RELF device for detection of transmural ischemia."
2938322|NCT02983383|Active Comparator|TAP block group (Group T)|At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
2938324|NCT02983370|Experimental|Blind volunteer|Blind volunteers will be implanted with our existing vision neuroprosthetic system, which utilizes a FDA cleared microelectrode array, using a minicraniotomy. The array will be implanted near the occipital pole or in extra striate areas. The investigators will collect descriptive feedback regarding thresholds, evoked perceptions and stimulation parameters leading to recognizable patterns.
2938325|NCT02983357||Case Series Study|Subjects who received a total shoulder replacement with an anchor peg glenoid and autologous bone grafting at the department of Orthopaedic Surgery at University of Nebraska Medical Center / Nebraska Medicine and are now at least 9 years out from surgery.
2938326|NCT02983344|Active Comparator|fascia iliaca compartment block|Patient will receive 40ml of ropivacaine 0.375% at the fascia iliaca compartment under the guidance of ultrasound. It will be given 20 minutes before patient is positioned for spinal anaesthesia
2938327|NCT02983344|Active Comparator|intravenous fentanyl|Patient will receive 0.5 mcg/kg of intravenous fentanyl. It will be given 5 minutes before patient is positioned for spinal anaesthesia
2938328|NCT02983318||PET/MRI using 18[F]EPPA ligand|given experimental ligand FEPPA during MRI/PET scan to identify glutamate activity in the brain using FEPPA ligand
2938329|NCT02983305|Experimental|Retinal Dystrophy|Subjects with retinal dystrophy will have their visual field, gait and self-reported mobility tested at baseline. Subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.
2938330|NCT02983305|Experimental|Healthy Age-Matched Controls|Age-matched control subjects without eye disease will have their visual field, gait and self-reported mobility tested at baseline. Control subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.
2938331|NCT02983279|Experimental|Dietary counseling, caloric restriction diet|Patients then undergo 25% caloric intake for 3-12 weeks prior to definitive cancer surgery.
2938332|NCT02983266|Experimental|Group 1: Low Hertz|"Participants will receive 10 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
2938333|NCT02983266|Experimental|Group 1: High Hertz|"Participants will receive 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
2938334|NCT02983266|Sham Comparator|Group 1: Control|"Participants will receive 30 hertz stimulation to a non-vagally innervated region of the left ear, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
2938335|NCT02983266|Experimental|Group 2: Pre-stressor|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session prior to receiving experimental sympathetic induction.~Device: InTENsity MicroCombo"
2938336|NCT02983266|Experimental|Group 2: Post-stressor|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session after experimental sympathetic induction.~Device: InTENsity MicroCombo"
2938337|NCT02983266|Placebo Comparator|Group 2: Control|"Participants will receive 10 or 30 hertz stimulation to a non-vagally innervated region of the left ear, delivered in one 15 minute session prior to receiving experimental sympathetic induction.~Device: InTENsity MicroCombo"
2938338|NCT02983266|Experimental|Group 3: 30 Hz|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
2938339|NCT02983266|Experimental|Group 4: 30 Hz|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session. Participants will also receive stimulation on a subsequent session prior to urodynamic testing.~Device: InTENsity MicroCombo"
2938340|NCT02983266|Experimental|Group 1: Response|"Participants will receive 10-30 hertz stimulation to the left auricular branch of the vagus nerve, delivered over the course of 1 hour.~Device: InTENsity MicroCombo"
2938341|NCT02983253||Patients with HHT|blood sample of patients with HHT
2938342|NCT02983253||probands|blood sample of healthy controls
2938343|NCT02983240|Experimental|60 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 20-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
2938344|NCT02983240|Experimental|80 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 40-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
2938345|NCT02983240|Experimental|120 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 80-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
2938346|NCT02983227|Experimental|GDC-0853|Participants after completing 12 weeks of treatment with GDC-0853 in Study GA29350, will receive GDC-0853 orally BID for 52 weeks.
2938347|NCT02983214|Active Comparator|Clopidogrel|Clopidogrel 75 mg/day
2938348|NCT02983214|Active Comparator|Clopidogrel plus cilostazol|Clopidogrel 75 mg/day plus cilostazol 100 mg twice/day
2938349|NCT02983201|Active Comparator|filiform needle|Patients will receive filiform needle treatment only.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
2938385|NCT02982954|Experimental|any RCC with KPS 50%-60%|Renal Cell Carcinoma (RCC), regardless of any histology or existing non-active brain metastasis, with KPS 50%-60%
2938350|NCT02983201|Experimental|thumbtack needle+filiform needle|Thumbtack intra-dermal needle will be applied to selected acupuncture points after filiform needle treatment. The thumbtack needle will remain embedded in the patient's dermal part for 2-3 days as per instruction.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
2938351|NCT02983188|Active Comparator|Berberine|Patients will receive berberine pills in additional to current atypical antipsychotic agents
2938352|NCT02983188|Placebo Comparator|Placebo|Patients will receive placebos pills in additional to current atypical antipsychotic agents
2938353|NCT02983175|Experimental|ultrasound assessment of gastric content|
2938354|NCT02983149|Other|Double lumen tube|One lung ventilation will be achieved using a double lumen tube
2938355|NCT02983149|Other|Fuji blocker|One lung ventilation will be achieved using the Fuji blocker
2938356|NCT02983149|Other|EZ blocker|One lung ventilation will be achieved using the EZ blocker
2938357|NCT02983136|Experimental|Study site|The study arm will consist of managers and staff at at the operating department of a University hospital in western Sweden' The intervention is based on partnership, dialogue and inter-professional learning
2938358|NCT02983136|No Intervention|Control site|The Control arm will consist of managers and staff at at the operating department of a University hospital in south Sweden
2938359|NCT02983123||1 hour-troponin|1-hour troponin collected of all recruited patients in addition to the daily routine with serial troponins collected at 0- and 4/6 hours.
2938360|NCT02983110||Cohort B|Group B will be HIV Infected post-menopausal women who are not receiving hormonal therapy to provide tissue, blood, and cells
2938361|NCT02983110||Cohort C|Group C will be HIV infected transgendered women receiving hormone therapy to provide tissue and blood
2938362|NCT02983110||Cohort E|Group E will be HIV infected cisgender men
2938363|NCT02983097|Experimental|R²-DHAP|"Combination treatment with immunochemotherapy (R-DHAP) and lenalidomide~Dosage:~Rituximab 375 mg/m² day 1, i.v. Cisplatin 100 mg/m² or Carboplatin AUC5 day 2, i.v. Cytarabine 2000 mg/m², administered twice, on day 3, i.v. Dexamethasone 40 mg, days 2-5, p.o. Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o. PEG-Filgrastim 6 mg, day 6, s.c.~peripheral stem cell collection after cycle 1 or 2"
2938364|NCT02983084|Experimental|Multiforce|Variable modulus version of a current orthodontic archwire
2938365|NCT02983084|Active Comparator|CuNiTi A|".016 current orthodontic archwire"
2938366|NCT02983084|Active Comparator|CuNiTi B|"0.014 and 0.018 current orthodontic archwire sequence"
2938367|NCT02983071|Experimental|Once-Daily G1T38 Dosing|G1T38 orally (once daily) in combination with fulvestrant.
2938368|NCT02983071|Experimental|Twice-Daily G1T38 Dosing|G1T38 orally (twice daily) in combination with fulvestrant.
2938369|NCT02983058|Other|PET/SPECT and MRI scans|PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation. 30 minutes structural MRI will be obtained to permit co-registration of PET images.
2938370|NCT02983045|Experimental|Combination of NKTR-214 + nivolumab|"NKTR-214 in escalating doses, will be combined with one of the two proposed doses of nivolumab. The goal of this dose escalation Part 1 of the study is to find the RP2D.~For Part 2 of the study, enrollment into a dose expansion cohort will commence once the RP2D is established for this doublet combination.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
2938371|NCT02983045|Experimental|Combination of NKTR-214 + nivolumab + ipilimumab|"NKTR-214 will be combined with nivolumab and plus ipilimumab. The goal of theis dose escalation in Part 3 of the study is to find the RP2D and dose administration schedule.~For Part 4 of the study, enrollment into a dose expansion cohort will commence once the RP2D is established for this triplet combination.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
2938372|NCT02983032|Experimental|Brief behavioural treatment for insomnia (BBTI)|A behavioural therapy for improving symptoms of insomnia in older adults focussing on sleep-related behaviour such as napping and when a person gets up and goes to bed.
2938373|NCT02983019||Therapy with interferons' inducers|Therapy according to routine practice (including Kagocel) Groups will be splitted during the final data analysis
2938374|NCT02983019||Therapy without interferons' inducers|Therapy according to routine practice Groups will be splitted during the final data analysis
2938375|NCT02983006|Experimental|DS-8273a & Nivolumab|Patient groups (cohorts) will receive a single dose level of DS 8273a & Nivolumab; DS 8273a will be increased in subsequent cohorts.
2938376|NCT02982993||WTC responders participating in HCV infection study|Members of the World Trade Center Health Program cohort born from 1945 to 1965 who choose to participate in this research study on hepatitis C infection
2938377|NCT02982980|Experimental|Physiotherapy Guidance Mastectomy|Patients who underwent radical breast surgery, received pre and postoperative assessment and orientation.
2938378|NCT02982980|Experimental|Phys Muscle strengthening Mastectomy|Patients who underwent radical breast surgery, in addition to receiving guidance, had, weekly, physical therapy sessions with the goal to increase muscle strength in the upper limbs, between one and three months after surgery.
2938379|NCT02982980|Experimental|Physiotherapy Guidance Quadrantectomy|Patients who underwent partial breast surgery, received pre and postoperative assessment and orientation.
2938380|NCT02982980|Experimental|Phys Muscle strengthening Quadrantectomy|Patients who underwent partial breast surgery, in addition to receiving guidance, had, weekly, physical therapy sessions with the goal to increase muscle strength in the upper limbs, between one and three months after surgery.
2938381|NCT02982967|Other|Physical Activity|Single-arm study with recreational physical activity intervention by 10 weeks (Duration: 60 minutes; Intensity: 65%-85% heart rate reserve; Frequency: 4 sessions/week).
2938382|NCT02982954|Experimental|ccRCC KPS ≥ 70%|Clear-Cell Renal Cell Carcinoma (ccRCC) with Karnofsky Performance Status (KPS) ≥ 70%
2938383|NCT02982954|Experimental|Non-ccRCC, KPS ≥ 70%|Non Clear-Cell Renal Cell Carcinoma (nccRCC) with KPS ≥ 70%
2938384|NCT02982954|Experimental|RCC with non-active Brain Mets, KPS ≥70%|Renal Cell Carcinoma (RCC) with non-active Brain Metastases, with KPS ≥70%
2938387|NCT02982915|Experimental|Pilot Phase- Cohort A|Single dose of 20 million Longeveron Mesenchymal Stem Cells (LMSCs) will be delivered followed by vaccination with Fluzone High-Dose at 1 week post-infusion.
2938388|NCT02982915|Experimental|Pilot Phase Cohort B & C|Single dose of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) followed by vaccination with Fluzone High-Dose at either 1 week (Cohort B) or 4 weeks (Cohort C) post infusion.
2938389|NCT02982915|Experimental|Double-Blind,Randomized,Placebo Phase|2 cohorts to receive a single infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort A: 10 subjects) or placebo (Cohort B: 10 subjects) followed by vaccination with Fluzone High-Dose.
2938390|NCT02982902|Experimental|CMV specific adoptive t-cells|This study involves a one-time infusion of the experimental CMV specific adoptive t-cells. After this infusion, patients will be followed for 4 weeks.
2938391|NCT02982889|Experimental|LIQ865A bupivacaine formulation|Liquidia's PRINT bupivacaine free base/PLGA (poly D,L-lactic-co-glycolic acid) suspension for subcutaneous injection at doses ranging from 150mg to 600mg
2938392|NCT02982889|Experimental|LIQ865B bupivacaine formulation|Liquidia's PRINT bupivacaine free base suspension for subcutaneous injection at doses ranging from 150mg to 600mg
2938393|NCT02982889|Placebo Comparator|Diluent for LIQ865|Negative control for subcutaneous injection. Each subject will act as his own control, receiving a LIQ865 formulation subcutaneous injection in one calf, and a diluent subcutaneous injection in his other calf
2938394|NCT02982889|Active Comparator|0.5% bupivacaine hydrochoride|Positive control arm to be used with one of the LIQ865 cohorts, with each subject acting as his own positive control (i.e., one leg will receive subcutaneous injection of LIQ865A or LIQ865B, and the other leg will receive subcutaneous injection of 0.5% bupivacaine hydrochloride).
2938395|NCT02982876|No Intervention|Medical Management Group|The patients assigned to the medical management group will be placed on a scheduled institution protocol using mucolytic and expectorant therapy (nebulizer treatments using mucolytic (N-acetylcysteine) for 15 minutes BID, Guafenesin (Mucinex®) 1200 mg BID, codeine as needed and Flutter valve BID.
2938396|NCT02982876|Active Comparator|Treatment group|The patients assigned to treatment group will undergo flexible bronchoscopy with dynamic maneuvers, rigid bronchoscope , tracheobronchial wash and airway stent placement
2938397|NCT02982863||All Patients|
2938398|NCT02982850|Experimental|Dabigatran|Previous treatment of aspirin or warfarin will be changed to dabigatran treatment in patients allocated to dabigatran group.
2938399|NCT02982850|Active Comparator|Conventional Treatment|Acetylsalicylic acid or warfarin treatment will be continued in patients allocated to conventional treatment group.
2938400|NCT02982837|Experimental|PEG-IFN & NUCLEOTIDE ANALOGUES|Peginterferon alfa-2a 180 Mcg infusion per week with ongoing NUCLEOTIDE ANALOGUES for 48 weeks.
2938401|NCT02982837|Active Comparator|NUCLEOTIDE ANALOGUES|Nucleoside same dose as they started the study.
2938402|NCT02982824|Experimental|Magnesium add-on|20 children with drug resistant epilepsy will receive oral magnesium sulfate 6 ml per day which equivalent to 400 mg elemental magnesium (Yuen & Sander, 2012) for 6 months and their regular antiepileptic drugs.
2938403|NCT02982824|Placebo Comparator|Antiepileptic drugs only|20 children with drug resistant epilepsy will receive their regular antiepileptic drugs and placebo for 6 months.
2938404|NCT02982824|No Intervention|Healthy controls|To asses serum magnesium level for comparison with the intervention group.
2938405|NCT02982811|No Intervention|Control group|Therapy as usual, i.e. occupational therapy, physiotherapy, etc.
2938406|NCT02982811|Experimental|Experimental group|Therapy as usual together with 3x45min training with i-ACT system during 6 weeks.
2938407|NCT02982798|Experimental|Group I|Period I: administration of Metformin + Rosuvastatin Period II: JLP-1310
2938408|NCT02982798|Experimental|Group II|Period I: JLP-1301 Period II: administration of Metformin + Rosuvastatin
2938409|NCT02982772|Experimental|Tailored Combination Therapy|"Combination of Brief behavioral intervention Plus Nicotine replacement. The test product is a transdermal nicotine patch and Nicotine replacement gums for 12 weeks. The dosage of the test product depends on the amount of cigarettes used.~Doses will be tailored and adjust as need it"
2938410|NCT02982772|Active Comparator|Standard Care Intervention|"Brief behavioral intervention The test product is a transdermal nicotine patch plus regular flavored gums for 10 weeks. The dosage of the test product depends on the amount of cigarettes used.~Standard Flavored gums will be used as needed for 10 weeks."
2938411|NCT02982759|Other|Comparison Arm|The comparison group will receive 2 generic newsletters
2938412|NCT02982759|Experimental|Intervention Arm|The intervention arm will receive the multi-level intervention.
2938413|NCT02982746|Experimental|gPCC-G (Gothenburg Person Centred Care) Group|gPCC-G Patients randomized to the intervention group were contacted and scheduled to attend a meeting at the oncology clinic with the nurse specialist in oncology
2938414|NCT02982746|No Intervention|Control group|Control Group Patients randomized to the control group received usual care and return visits were scheduled according to the treatment procedure described under the previous heading and based on the Regional care program for patients with HNC. CG patients were recruited at the same time and in the same way as those in the intervention group
2938415|NCT02982733|Active Comparator|ABS|Ankaferd blood stopper
2938416|NCT02982733|Placebo Comparator|CS|Conventional sterile gauze
2938417|NCT02982733|Active Comparator|TR BAND|Dedicated hemostatic device
2938418|NCT02982720|Experimental|Pembrolizumab and Sylatron|Pembrolizumab will be administered intravenously at a dose of 200 mg every 3 weeks starting week 4. Sylatron will be administered at a dose of 200mcg subcutaneously weekly starting at week 1.
2938419|NCT02982707|Experimental|Mild Hepatic Subjects|Subjects are given a single dose of BMS-986177
2938420|NCT02982707|Experimental|Moderate Hepatic Subjects|Subjects are given a single dose of BMS-986177
2938421|NCT02982707|Experimental|Healthy Match Subjects|Subjects are given a single dose of BMS-986177
2938422|NCT02982694|Experimental|Atezolizumab and Bevacizumab|Atezolizumab will be administered intravenously at 1200 mg on Day 1 every 3 weeks. The dose of bevacizumab in this study is 7.5 mg/kg administered by IV infusion every 3 weeks on Day 1 of each 21 days cycle. Atezolizumab will be administered first, followed by Bevacizumab, with a minimum of 5 minutes between dosing. The interval between cycle infusions must not be < 10 days.
2941160|NCT02963649|Active Comparator|Standard angioplasty balloon|standard PTA balloon
2938423|NCT02982681|Experimental|Platelet rich Fibrin|The intrabony defects were treated with Full thickness mucoperiosteal flap was raised and thorough open flap debridement done under local anesthesia In the test site the graft was then carefully compacted from the base of the defect coronally. PRF membrane was placed in the test site secured with vicryl sutures.
2938424|NCT02982681|Active Comparator|Bioactive glass|The intrabony defects were treated with Full thickness mucoperiosteal flap was raised and thorough open flap debridement done under local anesthesia and The control site were packed with the graft alone
2938425|NCT02982668|Active Comparator|Full enteral feeding|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
2938426|NCT02982668|Experimental|Modified full enteral feeding|Consistent with full enteral feeding plan, preventively add erythromycin or mosapride everyday to improve gastrointestinal (GI) motility.
2938427|NCT02982668|Experimental|Permissive underfeeding|The caloric goal of the first day is one-third of caloric requirements, the second day is 40-60% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
2938428|NCT02982655|Experimental|Individualized BP lowering|Management policy is to lower the systolic or diastolic BP by 10-15% within 24 hours of randomization and sustained for 7 days. Sites were provided with protocols for different intravenous agents and used whichever routinely available drugs were in their hospital.
2938429|NCT02982655|Active Comparator|Guideline recommended BP lowering|Patients received management of BP based on the standard guidelines at the time, as published by the Chinese Society of Neurology (CSN) in 2014. The attending clinician may consider commencing BP treatment and sustained for 7 days if the systolic BP > 200 mmHg or diastolic BP >110 mmHg in patients with ischemic stroke, and systolic BP > 180 mmHg or diastolic BP > 110 mmHg in patients with cerebral hemorrhage.
2938430|NCT02982642|Experimental|1612 capsule|Subjects will take 1612 capsule 3 capsules per time(0.38g per capsule), 3 times per day for 52 weeks
2938431|NCT02982642|Placebo Comparator|Placebos|Subjects will take palcebo identified to 1612 capsule 3 capsules per time, 3 times per day for 52 weeks
2938432|NCT02982629|Placebo Comparator|Usual Care|Patients in this group do not receive any letters or phone calls after missing follow-up appointment.
2938433|NCT02982629|Active Comparator|Reminder Letter Intervention|Patients in this group receive letters and phone calls after missing follow-up appointment to reschedule the appointment.
2938434|NCT02982616|Experimental|positive emotion and fatty acid|positive emotion induction combine with 2.g Dodecanoic acid intragastric infusion
2938435|NCT02982616|Experimental|neutral emotion and fatty acid|neutral emotion induction combine with 2.g Dodecanoic acid intragastric infusion
2938436|NCT02982616|Experimental|positive emotion and saline|positive emotion induction combine with saline intragastric infusion
2938437|NCT02982616|Placebo Comparator|neutral emotion and saline|neutral emotion induction combine with saline intragastric infusion
2938438|NCT02982603|Experimental|Qinggongshoutao Bolus|Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761 .Qinggongshoutao bolus 70 pills every time (7g), 2 times per day and placebo identified to Ginkgo Biloba Extract 761, 2 pills per time, 2 times per day for 48 weeks.
2938439|NCT02982603|Active Comparator|Ginkgo Biloba Extract 761|Ginkgo Biloba Extract 761 and placebo identified to Qinggongshoutao bolus.The subjects will take Ginkgo Biloba Extract 761 2 times per day, 2 pills per time(80mg) ,and identified to Qinggongshoutao bolus 70 pills every time, 2 times per day for 48 weeks.
2938440|NCT02982603|Placebo Comparator|Placebos|Placebo identified to Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761.Placebo identified to Qinggongshoutao bolus 70 pills every time, 2 times per day and placebo identified to Ginkgo Biloba Extract 761, 2 pills per time, 2 times per day for 48 weeks.
2938441|NCT02982590|Active Comparator|warfarin sodium|warfarin daily, dosage according to INR monitor. Aim INR 2-3
2938442|NCT02982590|Experimental|apixaban|Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.
2938443|NCT02982577|Experimental|Pilocarpine|Spray with Pilocarpine
2938444|NCT02982577|Placebo Comparator|Placebo|Spray without Pilocarpine
2938445|NCT02982564|Experimental|Low Intensity Exercise|Participants engage in low intensity endurance exercise.
2938446|NCT02982564|Experimental|Moderate Intensity Exercise|Participants engage in moderate intensity endurance exercise.
2938447|NCT02982551|Experimental|Hyperinsulinemic Clamp|Participants will complete two MRI scans approximately one hour apart - one under baseline conditions and the second during an insulin infusion. Each scan will include data collected during rest, and a taste task. The taste task involves receiving milkshake or a tasteless solution. After the first scan, an isoglycemic-hyperinsulinemic clamp will be implemented. An IV will be placed in the antecubital vein of of arm for infusion of insulin and dextrose. HumuLIN®-R regular insulin will be infused at 40 mU/m2/min. A second IV will be inserted in the back of the hand on the opposite arm to allow for frequent sampling of blood glucose levels. Dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline value. The study team will monitor blood glucose levels and adjust dextrose infusions as necessary. Thirty minutes after starting the insulin infusion, participants will be moved back into the bore of the MRI scanner for the repeat scans.
2938448|NCT02982538|Other|Standard PE Training Condition|Providers in this condition will complete a 4-day training workshop in PE.
2938449|NCT02982538|Other|Extended PE Training Condition|Providers in this condition will complete a 4-day training workshop in PE and will receive expert PE case consultation on two PE training cases via weekly phone consultation.
2938450|NCT02982525|Experimental|No Mussels|The control group will continue to consume their normal habitual diet
2938451|NCT02982525|Experimental|One mussel portion|One 75g portion of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption.
2938452|NCT02982525|Experimental|Two mussel portions|Two 75g portions of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption
2938453|NCT02982525|Experimental|Three mussel portions|Three 75g portion of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption
2938454|NCT02982512|No Intervention|Control recording|Recording of local field potentials without drugs from the deep brain stimulator
2938455|NCT02982512|Experimental|Dexmedetomodine recording|Recording of local field potentials at different dexmedetomidine concentrations from the deep brain stimulator
2938456|NCT02982499||control group|30-45 minutes quantitative magnetic resonance image(MRI)
2938457|NCT02982499||optic neuropathy group|30-45 minutes quantitative magnetic resonance image(MRI)
2938458|NCT02982486|Experimental|Nivolumab and ipilimumab|Nivolumab 240 mg IV every 2 weeks plus Ipilimumab 1 mg/m2 IV every 6 weeks
2938459|NCT02982460|Experimental|Isoinertial + eccentric exercise|The isoinertial training will be based on 4 sets of 8 maximal repetitions using a YoYo-Squat (YoYo Technology AB, Stockholm, Sweden). This exercise device use the inertia of a spinning flywheel (moment inertia = 0.11 kg m-2), offering resistance during coupled concentric and eccentric actions, and allows for high demanding to rotator cuff exercises while offering the possibility to perform with an eccentric overload.Two initial repetitions in any set were aimed at accelerating the flywheel, before executing the subsequent 8 actions at maximal effort. Eccentric exercise will based on a set of 4 exercise implicating abduction, lateral rotation, extension and flexion of the shoulder.
2938460|NCT02982460|Active Comparator|Eccentric exercise|Eccentric exercise will based on a set of 4 exercise implicating abduction, lateral rotation, extension and flexion of the shoulder. Participants will attend three appointments per week over three weeks. They will complete three sets of 10 repetitions, with the exercises progressed in difficulty at each appointment.
2938461|NCT02982447|Active Comparator|Blue Laser Imaging colonoscopy|Insertion to cecum was performed under white light(WL) and once the cecum was reached, the Blue Laser Imaging mode was switched on during withdrawal of endoscope for complete colonic examination. Second colonoscopic examination was performed in a similar manner after the first complete withdrawal of the colonoscope. WL was used on insertion and WL was used on withdrawal
2938462|NCT02982447|Experimental|conventional white light colonoscopy|In this arm, WL was used for both insertion and withdrawal of the colonoscope during the first-pass and second-pass examinations.
2938463|NCT02982434|Experimental|Group 1|All patients underwent conventional CABG surgery. After the main stage of the surgery new pharmaceutical composition containing botulinum toxin (50 U/1 mL) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right ganglionated plexi (GP); second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior pulmonary vein (PV) and left inferior PV (between the PVs and left atrial appendage (LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
2938464|NCT02982434|Active Comparator|Group 2|All patients underwent conventional cardiac surgery. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
2938465|NCT02982421|Experimental|Research|Group Art Therapy
2938466|NCT02982421|Sham Comparator|Control|Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
2938467|NCT02982408|Experimental|Low birth weight (LBW)|25 males born at term (weeks 39-41) in 1979-1981 with LBW (BW<10th percentile)
2938468|NCT02982408|Experimental|Normal birth weight (NBW)|25 BMI- and age-matched males born at term (weeks 39-41) with normal birth weight (NBW) control individuals (BW: 50-90th percentile)
2938469|NCT02982395|Experimental|Nanoxel®M|75 mg in 100mL normal saline
2938470|NCT02982395|Active Comparator|Mitomycin|40 mg in 100mL normal saline
2938471|NCT02982382|Experimental|Manipulative Treatment|Subjects will receive Manipulative Therapy
2938472|NCT02982382|Sham Comparator|Pain Education|Subjects will receive Pain Education and manual contact over lumbar region
2938473|NCT02982369|Experimental|Spinal Manipulation|"High-velocity and low-amplitude (HVLA) manipulation techniques to the cervical and thoracic region and pain education.~The subjects will receive the treatment twice a week, for four weeks, totaling eight sessions, with an average duration of 30 minutes."
2938474|NCT02982369|Sham Comparator|Pain Education|"Pain education and a simulation of spinal manipulation (sham), involving manual contact over the cervical and thoracic region totaling 10 minutes.~The subjects will receive the treatment twice a week, for four weeks, totaling eight sessions, with an average duration of 30 minutes."
2938475|NCT02982356|Other|Fetal Selective Reduction Technology|Potassium chloride fetal heart injection in the dichorial twins with abnormal chromosome and structure
2938476|NCT02982356|No Intervention|control group|normal dichorial twins without any intervention
2938477|NCT02982343|Experimental|Falls management plus exercise training|Falls management and education session. Home proximal lower limb strength training and multi-sensory balance training.
2938478|NCT02982343|Active Comparator|Falls management only|Falls management and education session only.
2938479|NCT02982330|Experimental|Low Carbohydrate Breakfast|Breakfast composition containing <10% carbohydrate, 75% fat, 15% protein Matched calories
2938480|NCT02982330|Active Comparator|Guidelines Breakfast|Breakfast composition containing 55% carbohydrate, 30% fat, 15% protein Matched calories
2938481|NCT02982317||Study group|All patients recruited will undergo the same protocol. An anesthesiologist will perform manual palpation of the patients lumbar spine and identification of the intervertebral spaces from L1-S1. A member of the UBC Department of Engineering will perform the US scanning and level identification using the novel US technology. In addition, freehand US will be used by two practitioners to determine the participant's lumbar level locations as per gold standard.
2938482|NCT02982304|Active Comparator|Pallidal (GPi) Deep Brain Stimulation|GPi is the standard target for treating most dystonia. This setting will be the active comparator
2938483|NCT02982304|Experimental|Thalamic (Vim) Deep Brain Stimulation|Vim is the standard target to treat cerebellar dysfunction in movement disorders. It is not routinely used in secondary dystonia
2938484|NCT02982304|Experimental|GPi + Vim (Multi-Target) Deep Brain Stimulation|Combined stimulation of GPi and Vim stimulation (both electrodes ON)
2938485|NCT02982291|Active Comparator|Standard|
2938486|NCT02982291|Experimental|Individualized|
2938487|NCT02982278|Experimental|CINGS Intervention|CINGS is a 12-week nurse coordinated, Community Health Worker (CHW) intervention structure. RN developed After hospital care plan with home visits sessions will be conducted by the CHW and intermittent televideo RN interactions. After baseline assessment, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly during months two and three. follow up assessments at 3, 6, and 12-month intervals.
2938488|NCT02982278|Experimental|Control|Control group will receive usual care. Base line visit and follow up at 3, 6, and 12 months post stroke enrollment.
2938489|NCT02982252|Experimental|CoPILOT (6 weeks)|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 6 hours total training time (1 hour training sessions, 3 days per week for 2 weeks).
2938490|NCT02982252|No Intervention|Standard of Care (6 weeks)|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair consisting of 6 hours total training time (1 hour training sessions, 3 days per week for 2 weeks).
2938491|NCT02982252|Experimental|CoPILOT (12 weeks)|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 12 hours total training time (1 hour training sessions, 4 days per week for 3 weeks).
2938492|NCT02982252|No Intervention|Standard of Care (12 weeks)|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair consisting of 12 hours total training time (1 hour training sessions, 4 days per week for 3 weeks).
2938493|NCT02982239|Other|Intervention|40 students will be chosen to participate in the intervention. And 2 will be recruited as peer educators. The intervention will consist of an information session, 1-hour training session for recruited per educators,intermittent text messages that will include adherence reminders, encouraging statements, and tips for improving sleep. Messages will be randomized, with no more than 3 messages of any type per week. Messages will serve as a cue to action,and daily monitoring with sleep diaries.To ensure adherence, participants will be entered into a lottery. Adherence will be based on the event marker from a fitness/sleep tracker (Fitbit) that will be supplied to N=40 participants.
2938494|NCT02982239|Other|Intervention -Tech|Half of the participants (N=20) will be provided with blue-blocking glasses, and an LED light in addition to the information session, Fitbit, text messages, and sleep diary.
2938495|NCT02982226|Experimental|ReNu Injection|Plantar Fascia injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
2938496|NCT02982226|Active Comparator|Corticosteroid Injection|Plantar Fascia injection with Corticosteroids.
2938497|NCT02982213|No Intervention|No companion present|No companion is present during the placement of the epidural catheter.
2938498|NCT02982213|Active Comparator|Companion present|A companion will be present during the placement of the epidural catheter.
2938499|NCT02982187|Experimental|Sub-study 1 : ELLIPTA followed by DISKUS+ HANDIHALER +PQ1|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then DISKUS + HANDIHALER in period 2. At the end of Visit 1, subjects will complete version 1 of the PQ (PQ1)
2938500|NCT02982187|Experimental|Sub-study 1 : DISKUS + HANDIHALER followed by ELLIPTA+PQ2|In this sequence, subjects will be randomized to use DISKUS + HANDIHALER in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete version 2 of the PQ (PQ2)
2938501|NCT02982187|Experimental|Sub-study 1 : ELLIPTA followed by DISKUS+ HANDIHALER +PQ2|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then DISKUS + HANDIHALER in period 2. At the end of Visit 1, subjects will complete PQ2
2938502|NCT02982187|Experimental|Sub-study 1 : DISKUS + HANDIHALER followed by ELLIPTA+PQ1|In this sequence, subjects will be randomized to use DISKUS + HANDIHALER in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete PQ1
2938503|NCT02982187|Experimental|Substudy 2: ELLIPTA followed by TURBUHALER + HANDIHALER +PQ3|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then TURBUHALER + HANDIHALER in period 2. At the end of Visit 1, subjects will complete version 3 of the PQ (PQ3)
2938504|NCT02982187|Experimental|Substudy 2: TURBUHALER + HANDIHALER followed by ELLIPTA+PQ4|In this sequence, subjects will be randomized to use TURBUHALER + HANDIHALER inhaler in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete version 4 of the PQ (PQ4)
2938505|NCT02982187|Experimental|Substudy 2: ELLIPTA followed by TURBUHALER + HANDIHALER +PQ4|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then TURBUHALER + HANDIHALER in period 2. At the end of Visit 1, subjects will complete PQ4
2938506|NCT02982187|Experimental|Substudy 2: TURBUHALER + HANDIHALER followed by ELLIPTA+PQ3|In this sequence, subjects will be randomized to use TURBUHALER + HANDIHALER inhaler in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete PQ3
2938507|NCT02982174|Experimental|Normal Eyes|Subjects with no known ocular diseases will be imaged on the 3D OCT-1 Maestro and DRI OCT Triton
2938508|NCT02982161|Active Comparator|MR308 100 mg bid|Tramadol/Celecoxib 100 mg
2938509|NCT02982161|Active Comparator|MR308 150 mg bid|Tramadol/Celecoxib 150 mg
2938510|NCT02982161|Active Comparator|MR308 200 mg bid|Tramadol/Celecoxib 200 mg
2938511|NCT02982161|Active Comparator|Tramadol 100 mg qid|Tramadol IR 100 mg
2938512|NCT02982161|Placebo Comparator|Placebo|Placebo to match MR308 and Tramadol IR
2938513|NCT02982148|Experimental|methylene blue intradermal injection|For patients randomized to intradermal injection before surgery began, 0.5ml 0.4% methylene blue(1ml methylene blue mixed up with 1.5ml saline) would be injected sub-areola (12 o'clock , 3 o'clock , 6 o'clock , 9 o'clock) intradermally, 0.1ml respectively, or peritumoral depending on the tumor location, 10-15 minutes before skin incision. The breast was massaged for 5 minutes to facilitate the identification of blue lymphatic vessels and the lymph nodes.
2938550|NCT02981888||IBS-C|all patients with IBS -C will undergo an abdominal x-ray for assessment of colonic transit
2938551|NCT02981888||IBS-D|all patients with IBS-D will undergo an abdominal x-ray for assessment of colonic transit
2938514|NCT02982148|Active Comparator|methylene blue subcutaneous injection|For patients randomized to subcutaneous injection before surgery began, 0.5ml 100% methylene blue would be injected sub-areola subcutaneously(12 o'clock , 3 o'clock , 6 o'clock , 9 o'clock), 0.1ml respectively or peritumoral depending on the tumor location, 10-15 minutes before skin incision. The breast was massaged for 5 minutes to facilitate the identification of blue lymphatic vessels and the lymph nodes.
2938515|NCT02982135|Other|group 1 direct bypass|direct bypass : patients recieve direct bypass treatment
2938516|NCT02982135|Other|group 2 indirect bypass|indirect bypass: patients recieve indirect bypass treatment
2938517|NCT02982122|Experimental|CPPopt intervention group|Patients are managed according to Brain Trauma Foundation guidelines, except for CPP where the CPPopt is targeted.
2938518|NCT02982122|Active Comparator|CPP control group|"Patients are managed according to Brain Trauma Foundation guidelines with CPP between 60 and 70 mmHg.~CPPopt information is recorded but hidden for the treating clinicians."
2938519|NCT02982109||Postop pain level 1|Minor postoperative pain anticipated
2938520|NCT02982109||Postop pain level 2|Might experience postoperative pain
2938521|NCT02982109||Postop pain level 3|Moderate pain/substantial surgery performed
2938522|NCT02982109||Postop pain level 4|Severe postoperative pain expected/major surgery
2938523|NCT02982096|Active Comparator|Cellutome treatment|Cellutome Device: Use of Cellutome on burn wounds
2938524|NCT02982096|Other|Standard of Care|Standard of Care: Acellular wound management
2938525|NCT02982083|Active Comparator|Evista|20 postmenopausal women suffering from rheumatoid arthritis that take raloxifene hydrochloride 60 mg oral tablets every day for one year.
2938526|NCT02982083|Placebo Comparator|Placebo|20 postmenopausal women suffering from rheumatoid arthritis that take placebo pills every day for one year.
2938527|NCT02982070|Experimental|Mental Toughness Training|Behavioral training in goal-building, mindfulness, and the growth mindset.
2938528|NCT02982070|No Intervention|College as Usual|no training provided
2938529|NCT02982057|Active Comparator|Bioresorbable vascular scaffold(BVS)+ OMT|"hypothesis: scaffolding a non culprit coronary plaque with BVS could facilitate the stabilization process into the atherosclerotic plaque with modification of plaque morphology.~Intervention:Device"
2938530|NCT02982057|Active Comparator|OMT|"Comparator with ONLY optimal medical treatment (OMT): the aim of the study is to compare the evolution of non culprit lesions after treatment by BVS versus Optimal Medical Therapy at 2 years follow- up.~Intervention: medical treatment"
2938531|NCT02982044|Experimental|Experimental-Control|"Participants will undergo all interventions, while simultaneously serving as their own within-subject control. The left side of the body will be designated experimental, and all interventions will be applied to the left arm. The right side of the body will be designated as control, and will not receive any interventions."
2938532|NCT02982031|Sham Comparator|shamrock|shamrock: both left and right sided scan,both intertransverse and transverse process window
2938533|NCT02982031|Active Comparator|paramedian transverse scan|paramedian transverse scan (PMTS): both left and right, both intertransverse and transverse process window
2938534|NCT02982018|Experimental|Investigational Contact Lens with UV Blocker|Subjects will be dispensed the investigational contact lens with UV blocker to wear daily for a period of 12 weeks with follow-up visits occurring after 1, 2, 4, 8, and 12 weeks. Afterwards, the subjects will wear their habitual contact lenses for a period of two weeks with weekly visits.
2938535|NCT02982018|Active Comparator|Marketed Contact Lens|Subjects will be dispensed the marketed contact lens to wear daily for a period of 12 weeks with follow-up visits occurring after 1, 2, 4, 8, and 12 weeks. Afterwards, the subjects will wear their habitual contact lenses for a period of two weeks with weekly visits.
2938536|NCT02982005|Experimental|KHK4827|KHK4827 administered SC
2938537|NCT02982005|Placebo Comparator|Placebo|Placebo administered SC
2938538|NCT02981979|Active Comparator|Leflunomide group|Use Leflunomide 20mg qd po. for 24 weeks for induced remission therapy combine with the basic prednisone therapy(start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission. If the subject has not achieve clinical remission,do not change prednisone dose）. Subjects who have achieved clinical remission, with the prednisone dose reduced to 10mg within 20 weeks and maintained to the end of 24 weeks enter the maintenance therapy.The next 32 weeks for maintenance therapy use leflunomide combine with prednisone 10mg per day.
2938539|NCT02981979|Placebo Comparator|Control Group|Use Placebo for 24 weeks for induced remission therapy(24 weeks) and use leflunomide 20mg qd po. for maintenance therapy in the next 32 weeks. Prednisone is used as basic therapy during the whole trial (start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission. Then maintain 10mg per day until the end of the study). All subjects in control group enter maintenance therapy.
2938540|NCT02981966|Active Comparator|Normal Glucose Tolerance (NGT)|Individuals with normal glucose tolerance - dapagliflozin vs placebo
2938541|NCT02981966|Active Comparator|T2DM individuals|Individuals with type 2 diabetes mellitus - dapagliflozin vs placebo
2938542|NCT02981953|Other|Cardioband Tricuspid procedure|Tricuspid valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
2938543|NCT02981940|Experimental|Abemaciclib with Surgery|"Abemaciclib will be administered on a continuous twice daily dosing schedule~Patients who require re-operation will receive a short preoperative course of Abemaciclib~Tissue will be used to investigate the ability of Abemaciclib to pass through the blood brain barrier.~After recovery from surgery, participants will resume Abemaciclib. Each cycle lasts 28 days."
2938544|NCT02981940|Experimental|Abemaciclib without Surgery|"Abemaciclib will be administered on a continuous twice daily dosing schedule~Each Cycle last 28 days"
2938545|NCT02981927|No Intervention|Control|24 h habitual physical activity fed in energy balance
2938546|NCT02981927|Experimental|Bed rest matched diet|24 hour period of whole body bed-rest with a matched diet
2938547|NCT02981927|Experimental|Bed rest balanced diet|24 hour period of whole body bed-rest fed in energy balance
2938548|NCT02981914|Experimental|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks. Treatment will be administered for up to 24 months, provided that neither disease progression, nor development of a dose-limiting toxicity (DLT), has occurred.
2938552|NCT02981888||heathy control|all healthy controls will undergo an abdominal x-ray for assessment of colonic transit
2938553|NCT02981875|Experimental|experimental|oculomotor training
2938554|NCT02981875|Placebo Comparator|control|placebo vision training exercises
2938555|NCT02981862|Experimental|CaptHPV method|
2938556|NCT02981836|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~Intervention: investigational live attenuated varicella vaccine;"
2938557|NCT02981836|Sham Comparator|Control Group|"Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0;~Intervention: diluent of lyophilized vaccine;"
2938558|NCT02981823|Experimental|hip replacement|The patients undergo total hip replacement with the collum femoris preserving stem suffered from periprosthetic fractures.
2938559|NCT02981810|Active Comparator|control|tonsillectomy
2938560|NCT02981810|Experimental|coblation|coblation of the tonsills
2938561|NCT02981797||Radium 223 Standard of Care|Standard of Care and Blood Collection for Baseline Circulating Tumor Cells (CTCs) Numeration and H2AX Assay. Participants who have chosen Radium 223 treatment for their prostate cancer that has spread to the bone and causing pain. Week 1 starts with the first Radium 223 treatment and week 24 ends 4 weeks after the last or sixth Radium 223 treatment. The circulating prostate cancer cell analysis will be performed within 24 hours of blood draw. Any unused blood samples for circulating prostate cancer cell analysis will be disposed per lab protocol.
2938562|NCT02981784||Ponatinib (PACE trial)|"PACE trial : Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL), NCT01207440"
2938563|NCT02981784||Allogenis stem cell transplantation (EBMT registry)|EBMT : European Group for Blood and Marrow Transplantation
2938564|NCT02981771|Experimental|experiment|A physical activity program that is based on balance and coordination exercises
2938565|NCT02981771|Placebo Comparator|control|A physical activity program that is based on strength exercises
2938566|NCT02981758||Data Collection Phase 1|All women who had vaginal deliveries between 2010 and 2015 who had a procedure code indicative of transfusion (99.0x) or received a diagnosis suggestive of peripartum hemorrhage (e.g. diagnosis x code 666.xx, 641.x, 645.x, 646.x 674.x).
2938567|NCT02981758||Data Collection Phase 2|All women who delivered (vaginally) at HackensackUMC who had blood loss and measured quantitatively by Triton and qualitatively (i.e., EBL) by obstetrician.
2938568|NCT02981745|Experimental|CT-1530|
2938569|NCT02981732|Experimental|Shen (Kidney) yin deficiency|Shen (Kidney) yin deficiency
2938570|NCT02981732|No Intervention|the control group|the control group,there is no intervention
2938571|NCT02981719|Experimental|IRE+chemo|irreversible electroporation with chemotherapy：Gemcitabine in pancreatic cancer
2938572|NCT02981706|Active Comparator|Arteriovenous Fistula (AVF) Group|Patient will receive an arteriovenous fistula (connection between native artery and vein) as his/her dialysis access
2938573|NCT02981706|Active Comparator|Arteriovenous Graft (AVG) Group|Patient will receive an arteriovenous graft (synthetic connection between artery and vein) as his/her dialysis access
2938574|NCT02981693|Experimental|iRoot SP sealer|iRoot SP sealer was used as root canal sealer in root canal obturation.
2938575|NCT02981693|Active Comparator|AH Plus sealer|AH Plus sealer was used as a gold standard to be compared with iRoot SP sealer in root canal obturation.
2938576|NCT02981680|Experimental|RIPC|Patients in the remote ischemic preconditioning (RIPC) group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, surgery will be started. The entire pre-conditioning phase will last 30 minutes.
2938577|NCT02981680|Sham Comparator|sham-RIPC|Patients in the sham-RIPC group will have the sphygmomanometer cuff placed on their right upper arm, but the cuff will not be inflated. Similar to patients in the RIPC group, patients in the sham-RIPC group will undergo the same 30 minute delay before starting surgery.
2938578|NCT02981667||Active men and women|Healthy, active men and women ages 18-45 yr completed 1 bout of high intensity interval training and moderate intensity continuous training in a randomized, crossover design.
2938579|NCT02981654|Experimental|Femilift treatment|"The Alma Lasers Pixel carbon dioxide laser system delivers fractionated laser energy through a special lens that divides the energy into a 9 x 9 (81) matrix of 1 cm square area. The fractional laser rays cause thermal damage that reaches the vaginal sub - epithelium to stimulate the growth of new collagen.~Intervention: FemiLift vaginal handpiece is inserted into the vagina, to deliver CO2 laser energy. The vaginal epithelium is covered by rotation of vaginal handpiece in 360 degrees, releasing laser energy at 6-8 points, and than withdrawn 1 cm each time to perform the same process, to cover the the total vaginal length."
2938580|NCT02981641|Experimental|Intraoperative radiotherapy (IORT) Group|Radiotherapy (Total dose: 18~22 Gy; Single dose: 18~22 Gy; Frequency: 1) + Sequential chemotherapy
2938581|NCT02981641|Experimental|Concurrent Chemoradiotherapy (CCRT) Group|Three dimensional conformal radiation therapy (3D-CRT) (Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30) + Concurrent chemotherapy (Gemcitabine(GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d) + Sequential chemotherapy
2938582|NCT02981628|Experimental|Treatment (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 60 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2938583|NCT02981615|Experimental|treatment arm|Subjects allocated to the treatment arm of the study will be administrated Levofloxacin 500mg/d given p.o. once a day, starting on day 10 from beginning of each cycle until day 28 on an ambulatory basis. Levofloxacin will be continued in the first 4 Azacytidine cycles.
2938584|NCT02981615|Placebo Comparator|placebo|Subject allocated to the placebo arm will be treated with placebo once a day, starting on day 10 from beginning until day 28 of each of the first 4 cycles.
2938585|NCT02981602|Experimental|IONIS-HBVRx|Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
2938586|NCT02981602|Placebo Comparator|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
2938587|NCT02981576|Active Comparator|Recipient of AT-MSC|Patients who will receive Autologous Mesenchymal Stem Cells from AdiposeTissue by Intrathecal injection of stem cells that will be performed 3 times.
2938588|NCT02981576|Active Comparator|Recipient of BM-MSC|Patients who will receive Autologous Mesenchymal Stem Cells from Bone marrow by Intrathecal injection of stem cells that will be performed 3 times.
2938589|NCT02981563|Experimental|Time Together|"Time Together as described under Interventions"
2938590|NCT02981537|Experimental|two-staged|positioning endobronchial blockers to appropriate bronchus with two-staged methods
2938591|NCT02981537|Active Comparator|single-staged|positioning endobronchial blockers with traditional single-staged methods
2938592|NCT02981524|Experimental|CY/GVAX with Pembrolizumab|During each 21 day cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 followed by Pembrolizumab at 200mg, the colon cancer vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells.
2938593|NCT02981498|Experimental|Sorafenib combined with HAIC|Sorafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
2938594|NCT02981485|Experimental|Experimental|Treatment of breast cancer related lymphedema by fat grafting
2938595|NCT02981472|Experimental|Apixaban|"Children aged 3 months to < 18 years of age randomized to the apixaban arm of the study weighing less than 35 kg will get a fixed dose body weight tiered regimen using either the 0.5 mg twice daily (tablet, BID) or the 0.4 mg/ml (solution, BID).~Children aged 3 months to < 18 years of age randomized to the apixaban arm of the study weighing greater than or equal to 35 kg will be administered apixaban 5 mg BID as a tablet. Children randomized to the apixaban arm of the study weighing greater than or equal to 35 kg who cannot swallow the tablet or prefer to take the solution will receive 12.5 ml of the 0.4 mg/ml oral solution BID.~The apixaban solution (0.4 mg/mL) or tablets (0.5 or 5 mg) will be administered BID orally or by nasogastric/gastric tube at a fixed dose, with no monitoring of international normalized ratio (INR) or anti-Xa level required to adjust dose."
2938596|NCT02981472|Active Comparator|LMWH/VKA|The standard-of-care (SOC), vitamin K antagonist (VKA), or subcutaneous low molecular weight heparin (LMWH) will comprise the active comparator group. VKA or LMWH will either be commercial products labeled as per country requirements and provided by Bristol-Myers Squibb or sourced locally according to the SOC. Dose regimen and monitoring for VKA (including INR control) and LMWH will follow the American College of Chest Physicians (ACCP) 2012 guideline for thromboembolism (TE) prophylaxis.
2938597|NCT02981459|Experimental|Mirabegron 25 mg or 50 mg|
2938598|NCT02981446|Experimental|DE-117 ophthalmic solution|
2938599|NCT02981446|Active Comparator|Latanoprost ophthalmic solution 0.005%|
2938600|NCT02981420|No Intervention|Pre-intervention|Pre-intervention baseline comparison
2938601|NCT02981420|Experimental|Safety Planning|Intervention group
2938602|NCT02981420|No Intervention|Regression discontinuity|Subthreshold no intervention
2938603|NCT02981407|Active Comparator|Liberal Transfusion Strategy|Red blood cell transfusion - One unit of packed red cells is transfused following randomization followed by enough red blood cell units to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days.
2938604|NCT02981407|Active Comparator|Restrictive Transfusion Strategy|Permitted to receive a red blood cell transfusion if the blood count is below 8 g/dL and the physician believes it is in the patient's best interest. A transfusion will be strongly recommended if the blood count drops to less than 7 g/dL. If the patient has symptoms of angina (e.g., chest discomfort described as pressure or heaviness) that do not go away with medication, a blood transfusion will be ordered regardless of the blood count.
2938605|NCT02981394||BMAC Group|Intervention Group
2938606|NCT02981381|Experimental|Active sTMS (NEST-1)|"Subjects randomized to this group will receive 20 active synchronized Transcranial Magnetic Stimulation (sTMS) treatments (30 minutes each) over a period of 40 calendar days. Treatment windows will be 10 calendar days to complete 5 active sTMS sessions. Serial assessments will be completed every 5 sessions. Post-treatment (PT1) endpoint assessments will take place on the last day of active sTMS.~Participants that elect to participate in the open-label continuation phase, will receive an additional 20 sTMS treatments (using the NEST-2 device), following the same administration structure as the sham-control series.~Participants will return to complete post-treatment follow-up assessments (PT2) 1 month after their last treatment session (either PT1 or OL PT1)."
2938607|NCT02981381|Sham Comparator|Sham sTMS (SHAM)|"Subjects randomized to this group will receive 20 sham synchronized Transcranial Magnetic Stimulation (sTMS) treatments (30 minutes each) over a period of 40 calendar days. Treatment windows will be 10 calendar days to complete 5 sham sessions. Serial assessments will be completed every 5 sessions. Post-treatment (PT1) endpoint assessments will take place immediately after the final sham session.~Participants that elect to participate in the open-label continuation phase, will receive 20 sTMS treatments (using the NEST-2 device), following the same administration structure as the sham-control series.~Participants will return to complete post-treatment follow-up assessments (PT2) 1 month after their last treatment session (either PT1 or OL PT1)."
2938608|NCT02981368|Experimental|18F-DCFPyL Injection|9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
2938609|NCT02981355|Active Comparator|Microfracture treatment|Microfracture surgery of the femoral condyle
2938610|NCT02981355|Experimental|BST-CarGel plus microfracture treatment|BST-CarGel combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following an arthroscopic microfracture surgery.
2938611|NCT02981342|Experimental|Abemaciclib|Abemaciclib given orally.
2938612|NCT02981342|Experimental|Abemaciclib + LY3023414|Abemaciclib given orally and LY3023414 given orally.
2938613|NCT02981342|Experimental|Standard of Care (Gemcitabine or Capecitabine)|Gemcitabine given intravenously (IV) OR capecitabine given orally.
2938614|NCT02981329|Experimental|Group A: Hydroxyurea + Metformin|Subjects who are currently taking Hydroxyurea as part of standard of care and have sickle cell anemia.
2938615|NCT02981329|Experimental|Group B: Metformin|Subjects who are not taking Hydroxyurea as part of standard of care and have non-transfusion dependent thalassemia or sickle cell anemia.
2938616|NCT02981316|Active Comparator|RBX7455 Group A|4 days of 4 capsules twice daily RBX7455 for 10 subjects.
2938617|NCT02981316|Active Comparator|RBX7455 Group B|2 days of 4 capsules twice daily RBX7455 for 10 subjects.
2938618|NCT02981316|Active Comparator|RBX7455 Group C|2 days of 2 capsules twice daily RBX7455 for 10 subjects.
2938619|NCT02981316|Active Comparator|RBX7455 Group D|2 days of 1 capsule twice daily RBX7455 for 10 subjects.
2938620|NCT02981303|Experimental|Melanoma|Imprime PGG + Pembrolizumab
2938622|NCT02981290|Experimental|Renodapt Then Mycept Then Cellmune Then CellCept|Participants will receive Renodapt in first treatment period (each treatment period= 3 days) followed by Mycept in second treatment period then Cellmune in third treatment period and CellCept in fourth treatment period. A washout period of 7 days will be separating each treatment period.
2938623|NCT02981290|Experimental|Mycept Then CellCept Then Renodapt Then Cellmune|Participants will receive Mycept in first treatment period (each treatment period= 3 days) followed by CellCept in second treatment period then Renodapt in third treatment period and Cellmune in fourth treatment period. A washout period of 7 days will be separating each treatment period.
2938624|NCT02981290|Experimental|Cellmune Then Renodapt Then CellCept Then Mycept|Participants will receive Cellmune in first treatment period (each treatment period= 3 days) followed by Renodapt in second treatment period then CellCept in third treatment period and Mycept in fourth treatment period. A washout period of 7 days will be separating each treatment period.
2938625|NCT02981290|Experimental|CellCept Then Cellmune Then Mycept Then Renodapt|Participants will receive CellCept in first treatment period (each treatment period= 3 days) followed by Cellmune in second treatment period then Mycept in third treatment period and Renodapt in fourth treatment period. A washout period of 7 days will be separating each treatment period.
2938626|NCT02981277|Active Comparator|Transcricoid|Lignocaine delivery using transcricoid injection
2938627|NCT02981277|Active Comparator|Spray as You go|Lignocaine delivery using spray as you go method
2938628|NCT02981264|Active Comparator|Transcricoid|Lignocaine delivery using transcricoid injection
2938629|NCT02981264|Active Comparator|Spray as You go|Lignocaine delivery using spray as you go method
2938630|NCT02981251|Experimental|Intervention|Health education with support by trained female health volunteer
2938631|NCT02981251|No Intervention|Control|Extra intervention will not be provided except usual care by their physician of the participant.
2938632|NCT02981212|Experimental|Mycophenolate Mofetil|MYREPT® capsule(CKDpharm, KOREA) and corticosteroid
2938633|NCT02981212|Active Comparator|Conservative treatment|maintain conservative treatment (ACE inhibitor or ARB)
2938634|NCT02981199|Active Comparator|Micro-SCT|"patients treated with microtransplantation. [VMD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; melphalan 60mg/m2 d1; dexamethasone 20mg d1,2,4,5,8,9,11,12) + low dose allogeneic stem cell transplantation]×4cycles; [PTD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; thalidomide 100mg/d, dexamethasone 20mg d1,2,4,5,8,9,11,12)]×1cycle; then maintenance therapy with thalidomide 100mg/d.~microtransplantation = [VMD regimen chemotherapy+ low dose allogeneic stem cell transplantation]×4cycles"
2938635|NCT02981199|Active Comparator|Auto-SCT|patients treated with Auto-SCT. conditioning with Mel+Vel regimen (melphalan 200mg/m2 d-2, bortezomib 1.3mg/m2 d-6,-3,+1,+4) + autogeneic stem cell transplantation; [PTD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; thalidomide 100mg/d, dexamethasone 20mg d1,2,4,5,8,9,11,12)]×4cycle; then maintenance therapy with thalidomide 100mg/d.
2938636|NCT02981186|Experimental|IOL Implantation experimental|Implantation of POD F GF in one of the eyes of the study subject
2938637|NCT02981186|Active Comparator|IOL Implantation Comparator|Implantation of POD F in the contralateral eye of the study subject
2938638|NCT02981173|Active Comparator|Psilocybin High Dose|
2938639|NCT02981173|Active Comparator|Psilocybin Low Dose|
2938640|NCT02981173|Placebo Comparator|Placebo|
2938641|NCT02981160|No Intervention|Standard Care Group|The participants assigned to this group will follow a standard weight loss program for 12-months. This patients will be instructed by the Weight loss program registered dietitian/diet tech in clinic in terms of nutrition regimen, daily intake and calories.Patients will be followed up monthly as per clinic protocol. All visits will include physical measurements including body mass index (BMI) based on height and weight, blood pressure, and body composition (fat percentage). Body composition will be assessed during clinic visits by bio-impedance. Waist circumference (cm) will be measured at the umbilicus.
2938642|NCT02981160|Experimental|Mobile Device Assistant Group|"This group will follow the same weight loss protocol, monitoring, and clinic visits as the standard weight loss group described above, but will also use the mobile health tool (Breezing) to track REE every visit. This data will be loaded onto an accompanying electronic pad using the Breezing app and will be transmitted electronically to the study investigators who will use the information to adjust dietary and physical activity recommendations and targets. The test will be performed at initial visit, 2 weeks, 1, 3, 6 and 12 months after started."
2938643|NCT02981147|Experimental|Intervention|Phytus (Cisti, thyme and Ivy leaves) given to patients on day 1 and day 4. On 4th day, night and day cough score along with adverse event will be assessed. Sponsor will bear the treatment cost during the study time period.
2938644|NCT02981134||bioabsorbable scaffold|Patients with BVS(bioabsorbable scaffold) for coronary stenosis
2938645|NCT02981121|No Intervention|Conventional Management|A patient will receive 30 minutes of individual education from the investigator, based on the standard guidelines of the Korean Diabetes Association. And will be followed up every 6 months for 36 months.
2938646|NCT02981121|Experimental|Life style modification|"Proceed according to the Intervention Protocol developed by the Nutrition Committee of the Korean Diabetes Association. Aim to lose more than 5% of weight within 6 months, and then aim to keep weight loss constantly. After randomization, the diabetes educator team (physician / nurse / dietician) applies the intervention program for exercise therapy and diet therapy, and manages it through online education (telephone visit) and offline education (institution visit).~Exercise: Moderate or abnormal exercise for more than 150 minutes per week (moderate or abnormal exercise for 30 minutes or more per day)~Diet remedies: Train Calorie intake, nutrient intake and Monitoring."
2938647|NCT02981121|Active Comparator|Metformin|After randomization, take 250 mg once a day for 2 weeks. If there is no side effect, take 500 mg once a day for 2 weeks. If there are no side effects, the maximum dose can be increased to 1000mg.
2938648|NCT02981108|Experimental|Escalation Cohort 1|Oral Once-Daily Administration of HS-10296 55mg
2938649|NCT02981108|Experimental|Escalation Cohort 2|Oral Once-Daily Administration of HS-10296 110mg
2938650|NCT02981108|Experimental|Escalation Cohort 3|Oral Once-Daily Administration of HS-10296 220mg
2938651|NCT02981108|Experimental|Escalation Cohort 4|Oral Once-Daily Administration of HS-10296 260mg
2938652|NCT02981108|Experimental|Escalation Cohort 5|Oral Once-Daily Administration of HS-10296(MTD)
2938653|NCT02981108|Experimental|Expansion Cohort 1|Oral Once-Daily Administration of HS-10296 220mg
2938655|NCT02981108|Experimental|Expansion Cohort 3|Oral Once-Daily Administration of HS-10296 (MTD or RP2D)
2938656|NCT02981108|Experimental|Phase 2 Expansion|Oral Once-Daily Administration of HS-10296 (MTD or RP2D)
2938657|NCT02981095|Active Comparator|Bupivacaine|bupivacaine 0.5%, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
2938658|NCT02981095|Placebo Comparator|Saline|Saline solution (%0.9 sodium chloride), 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
2938659|NCT02981082|Active Comparator|Dimethyl Fumarate (DMF)|Twice daily oral doses of Dimethyl Fumarate (DMF) 120mg for the first 7 days followed by the maintenance dose of Dimethyl Fumarate (DMF) 240mg twice a day. Subjects will be dosed for 24 weeks
2938660|NCT02981082|Placebo Comparator|Placebo|Twice daily oral doses of placebo for 12 weeks
2938661|NCT02981069|Active Comparator|Byetta / Bydureon|"Exenatide:~4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc"
2938662|NCT02981069|Active Comparator|Dapagliflozin|4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg
2938663|NCT02981069|Active Comparator|Byetta/Bydureon plus Dapagliflozin|"Exenatide:~4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc PLUS~Dapagliflozin:~4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg"
2938664|NCT02981069|Placebo Comparator|Placebo|Placebo group (4 weeks and 12 weeks)
2938665|NCT02981056|Active Comparator|Wash + Lotion regimen|"Johnson's Baby Top-To-Toe Wash (Ideally 7 times a week, at least 5 times a week) + Johnson's Baby Lotion (at least once a day).~The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso."
2938666|NCT02981056|Active Comparator|Water + Lotion regimen|"Water (in lieu of bathing products) + Johnson's Baby Lotion (at least once a day).~The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso."
2938667|NCT02981056|Active Comparator|Water only|Water (in lieu of bathing products) only. The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso.
2938668|NCT02981030|Experimental|Simplified medical abortion|Women seeking medical abortion will be offered the option self-administering the medications, mifepristone and misoprostol at home.
2938669|NCT02981017|No Intervention|Control|Subjects within the control arm will undergo the Draf III/Endoscopic Modified Lothrop procedure to address their sinus disease. At the end of the procedure, no Cook Biodesign Porcine intestinal submucosal graft will be used to cover the operative site. Light nasal packing will be placed in the nasal cavity for hemostasis. No placebo will be utilized.
2938670|NCT02981017|Experimental|Cook Biodesign|Subjects within the experimental group will undergo the Draf III/Endoscopic Modified Lothrop procedure to address their sinus disease. At the end of the procedure, a small piece of Cook Biodesign porcine intestinal submucosal xenograft will be used to cover the exposed bone of the operative site along the frontal beak. It will be bolstered with light nasal packing to keep the graft in place during healing.
2938671|NCT02980991|Experimental|Neoadjuvant chemotherapy group|Two cycles of pemetrexed and cisplatin given to patients before surgery
2938672|NCT02980978|Experimental|Intervention|Individuals assigned to the intervention group will have supplemental care provided by a registered dietitian/certified diabetes educator which includes counseling on lifestyle to improve diabetes and overall health. Additionally, individuals in this group may be started on medications (or adjustments to current medications) for blood pressure, cholesterol or blood glucose to meet diabetes care goals
2938673|NCT02980978|No Intervention|Standard of Care|Individuals will be followed by their Primary Care Provider as standard of care and per usual clinical need
2938674|NCT02980965|Experimental|neoadjuvant chemo-endocrine therapy|In the experimental arm, patients received concurrent chemotherapy (fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles) with endocrine therapy (letrozole with or without leuprorelin) as a neoadjuvant treatment
2938675|NCT02980965|Active Comparator|neoadjuvant chemotherapy alone|In the control group, patients received neoadjuvant chemotherapy alone (fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles)
2938676|NCT02980952|Placebo Comparator|Eucaloric + placebo|Fed in energy balance with a placebo supplement
2938677|NCT02980952|Experimental|Eucaloric + acipimox|Fed in energy balance with an acipimox supplement
2938678|NCT02980952|Experimental|Hypercaloric + placebo|Fed in energy surplus with a placebo supplement
2938679|NCT02980952|Experimental|Hypercaloric + acipimox|Fed in energy surplus with an acipimox supplement
2938680|NCT02980939|Placebo Comparator|Euhydration - no thirst|
2938681|NCT02980939|Experimental|Dehydration - no Thirst|
2938682|NCT02980926|Experimental|Mepivacaine Spinal Anesthetic|Mepivacaine 3 mL intrathecal injection of 2% solution
2938683|NCT02980926|Active Comparator|Bupivacaine Spinal Anesthetic|Bupivacaine 12 mg of 8.25% solution
2938684|NCT02980913|Experimental|Experimental: Patients with dry eye syndrome 1|20 patients with dry eye syndrome, they will receive intervention 1 for one week and then cross over to intervention 2
2938685|NCT02980913|Experimental|Experimental: Patients with dry eye syndrome 2|20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1
2938686|NCT02980900|Placebo Comparator|Placebo|Participants will ingest an isocaloric placebo twice daily. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
2938687|NCT02980900|Experimental|Post exercise protein|Participants will ingest a protein supplement after exercise and an isocaloric placebo before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
2941505|NCT02961387|Experimental|Hydrogen generator treatment|Inhalation of hydrogen-oxygen mixed gas.
2938688|NCT02980900|Placebo Comparator|Pre bed protein|Participants will ingest an isocaloric placebo supplement after exercise and a protein supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
2938689|NCT02980887||Controls|Healthy controls No intervention as this is an observational study
2938690|NCT02980887||Pulmonary Vascular Disease|Pulmonary Vascular Disease at risk for pulmonary hypertension
2938691|NCT02980887||Pulmonary Hypertension|Those meeting WHO group classifications 1-5 of pulmonary hypertension
2938692|NCT02980874|Experimental|Active|IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections
2938693|NCT02980874|Active Comparator|Control|IVT aflibercept (2 mg/0.05 mL) + sham SC procedure
2938694|NCT02980861|Experimental|Laparoscopic total gastrectomy|Participants including in the laparoscopic total gastrectomy (LTG) group will undergo LTG with spleen-preserving splenic hilum lymph nodes dissection.
2938695|NCT02980861|Active Comparator|Open total gastrectomy|Participants who are included in the open total gastrectomy (OTG) group will OTG with spleen-preserving splenic hilum lymph nodes dissection.
2938696|NCT02980848||Screening group|Women without a history of breast cancer undergoing screening digital mammography, screening digital breast tomosynthesis, or screening breast magnetic resonance imaging.
2938697|NCT02980848||Women with breast cancer|Women diagnosed with stage 0-III breast cancer undergoing pre-operative work-up with diagnostic mammography alone or diagnostic mammography plus pre-operative breast magnetic resonance imaging.
2938698|NCT02980835|Experimental|Intervention|Patients who receive injections of A (a total of a 10 mL-solution that consists of 9 mL of ropivacaine HCl 0.5% and 1 mL of dexamethasone 4mg/mL preparation) at the beginning of surgery and second set of injections containing a mixture of B (contains 10 mL of 0.9% normal saline) and C (a total 25 mL solution that consists of 24 mL of ropivacaine HCl 0.5%, 1 mL of dexamethasone-4mg/mL preparation, and 0.125 mL of epinephrine-1:1000 preparation) prior to the closure
2938699|NCT02980835|Active Comparator|Control|Participants who receive injection of B (contains 10 mL of 0.9% normal saline) at the beginning of surgery and injectate A (a total of a 10 mL-solution that consists of 9 mL of ropivacaine HCl 0.5% and 1 mL of dexamethasone 4mg/mL preparation) and injectate C (a total 25 mL solution that consists of 24 mL of ropivacaine HCl 0.5%, 1 mL of dexamethasone-4mg/mL preparation, and 0.125 mL of epinephrine-1:1000 preparation) at the end of procedure prior to the closure (which mimics standard care) is the control group
2938700|NCT02980822||Sweden, Denmark, Norway|"Group: Degenerative lumbar disc disease patients treated in Sweden and included in the Swespine register~Group: Degenerative lumbar disc disease patients treated in Norway and included in the NORspine register~Group: Degenerative lumbar disc disease patients treated in Denmark and included in the DaneSpine register"
2938701|NCT02980809|Experimental|Apatinib and topotecan|Patients receive IV topotecan 1.5 mg/m2/d on days 1 through 5, apatinib 250mg/d, every 21 days, until disease progression.
2938702|NCT02980809|Placebo Comparator|Topotecan|Patients receive IV topotecan 1.5 mg/m2/d on days 1 through 5 every 21 days, until disease progression.
2938703|NCT02980796|Experimental|Exercise + practice|Individuals will complete 20 minutes of exercise on a recumbent bicycle before practicing a novel motor task.
2938704|NCT02980796|Active Comparator|Rest + practice|Individuals will rest for 20 minutes before practicing a novel motor task. Attention will be controlled during this time.
2938705|NCT02980783|Experimental|Juvéderm® VOLIFT®™ with Lidocaine|Juvéderm® VOLIFT®™ with Lidocaine is injected into the dynamic radial cheek line skin depressions on Day 0; volume of injection will not exceed 2mL per side. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine will be injected on Day 14; volume will not exceed 1mL per side.
2938706|NCT02980770||Obstructive Sleep Apnea (OSA)|Patients with OSA
2938707|NCT02980770||Obesity-Hypoventilation Syndrome (OHS)|Patients with OHS
2938708|NCT02980770||Normal Blood Gases|Normal Blood Gases
2938709|NCT02980757|Active Comparator|Gliclazide 120 mg MR Tablets Formula A|Single oral dose of one tablet containing 120 mg gliclazide
2938710|NCT02980757|Active Comparator|Gliclazide 120 mg MR Tablets Formula B|Single oral dose of one tablet containing 120 mg gliclazide
2938711|NCT02980757|Active Comparator|DIAMICRON MR® 60 mg x 2|Two x oral dose of one tablet containing 60 mg gliclazide
2938712|NCT02980744|Experimental|STUFFS|Participants will undergo a sedentary behaviour intervention which includes breaking up prolonged sitting by standing and walking around for 5 minutes every half-hour, standing and walking during television commercial breaks, doing 2 sets of 10 sit-to-stand transitions three times per day, and going to the kitchen to grab some drink every hour. A wrist-worn Misfit activity monitor - a motivational tool that will track adherence to the intervention will be used throughout the intervention period (i.e. 8 weeks). This device which is commercially available provides activity feedback for the user in real time.
2938713|NCT02980731|Experimental|Venetoclax|Venetoclax will be administered orally 20 mg once daily (QD) beginning with a dose-titration phase, and then escalated up to 400 mg QD.
2938714|NCT02980718|Experimental|intensive olfactory training|90 participants will undergo intensive olfactory training. They will sniff on four selected odors (10 seconds on each odor bottle in a total of 4 minutes) every morning and evening for 3 months and they will be instructed in the principles of the logbook for olfactory training.
2938715|NCT02980718|Experimental|ordinary olfactory training|90 participants will undergo ordinary olfactory training. They will sniff on four selected odors (10 seconds on each odor bottle in a total of 40 seconds) every morning and evening for 3 months and they will be instructed in the principles of the logbook for olfactory training.
2938716|NCT02980718|No Intervention|controls|20 participants represent a control group with no olfactory training
2938717|NCT02980705|Experimental|SUNPG1622 I|SUNPG1622 I dose
2938718|NCT02980705|Placebo Comparator|Placebo|Placebo dose
2938719|NCT02980692|Experimental|SUNPG1623 I|Short-term dose
2938720|NCT02980692|Experimental|SUNPG1623 II|Mid-term dose
2938721|NCT02980692|Experimental|SUNPG1623 dose III|Mid-term dose
2938722|NCT02980692|Experimental|SUNPG1623 dose IV|Mid to long-term dose
2938723|NCT02980692|Placebo Comparator|Placebo|Mid to long-term dose
2938724|NCT02980679|Experimental|CTC and G-PERT Imaging|One experimental (CTC) and one standard (G-PERT) scan, at least 48 hours apart, before thyroid surgery. The order of the scans will be randomized.
2938725|NCT02980666|Experimental|Teduglutide|Participants will receive teduglutide 0.05 milligram per kilogram per day (mg/kg/day) subcutaneous (SC) injection once daily for 24 weeks.
2938726|NCT02980653|Experimental|Megestrol|Single arm
2938727|NCT02980627|Experimental|Therapy with Mobile App Enhancement|Participants will complete initial assessments and then take part in a 3-month intervention consisting of 12 weekly individual therapy sessions with daily RR app use between sessions. At the end of the 3-month intervention period, an exit interview will be conducted and participants will complete a second assessment consisting of questionnaires and an ED diagnostic interview, a blood specimen for HbA1c, and 3-days of blinded CGM monitoring. Participants will then enter a 6-month follow-up period during which time they may continue to use the app, but will no longer attend individual sessions. Participants will be return to the clinic at 6 and 9 months for follow-up.
2938728|NCT02980614|Experimental|Participants to 4D flow imaging|"In addition to the standard clinical MR protocol, 2 added sequences:~4D MR sequence in cine mode 4D velocity mapping sequence"
2938729|NCT02980601|Experimental|Integra and a Split Thickness Skin Graft (STSG)|A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG.
2938730|NCT02980601|Active Comparator|Split Thickness Skin Graft (STSG)|reconstruction as dictated by the protocol. They will either receive 1) a 0
2938731|NCT02980588|Other|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
2938732|NCT02980575|Experimental|Exercise with music|Participants will listen to music when they exercise
2938733|NCT02980575|Active Comparator|Exercise|Participants will not listen to music when they exercise
2938734|NCT02980562|Active Comparator|2L Polyethylene glycols-Asc|1 L of PEG containing ascorbic acid (PEG A) was taken at 8:00 pm on the day before the colonoscopy, followed by an extra 500 mL of water. The second 1-L of PEG containing ascorbic acid was taken 4 h before the colonoscopy examination, with an additional 500 mL of water. Each liter of preparation and the extra 500 mL water had to be consumed within 2 h of the procedure. All colonoscopies were performed between 9 am and 1 pm.
2938735|NCT02980562|Active Comparator|1L PEG-Asc plus bisacodyl|10 mg bisacodyl at 9:00 pm on the day before the colonoscopy. Four hours before the colonoscopy examination, 1 L of PEG containing ascorbic acid was taken, followed by an additional 1 L of water. The preparation was completed 2 h before the examination. All colonoscopies were performed between 9 am and 1 pm.
2938736|NCT02980523|Experimental|PRO-157 BID (2 times per day)|"60 eyes will be evaluated with the following therapeutic regimen:~instill one drop in each eye of PRO-157 (pazufloxacin), every 12 hours per day (BID), for 7 days~instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%)every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
2938737|NCT02980523|Experimental|PRO-157 TID (3 times per day)|"60 eyes will be evaluated with the following therapeutic regimen:~instill one drop in each eye of PRO-157 (pazufloxacin), every 8 hours per day (TID), for 7 days~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
2938738|NCT02980523|Experimental|PRO-157 QID (4 times per day)|"60 eyes will be evaluated with the following therapeutic regimen:~instill one drop in each eye of PRO-157 (pazufloxacin), every 6 hours per day (QID), for 7 days~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
2938739|NCT02980523|Active Comparator|Moxifloxacin (Vigamox®)|"60 eyes will be evaluated with the following therapeutic regimen:~instill one drop in each eye of Moxifloxacin, every 8 hours per day, for 7 days.~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day for 7 days. (Can be applied 15 minutes after moxifloxacin)"
2938740|NCT02980523|Active Comparator|Gatifloxacin (Zymar®)|"60 eyes will be evaluated with the following therapeutic regimen:~instill one drop in each eye of Gatifloxacin, every 8 hours per day, for 7 days.~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day for 7 days.one drop 4 times a day for 7 days in each eye.(Can be applied 15 minutes after gatifloxacin)"
2938741|NCT02980510|Experimental|A=Experimental group|FOLFIRINOX + Panitumumab oxaliplatin 85mg/m² IV infusion over 2 hours immediately followed by folinic acid 400mg/m² given as a 2-hour IV infusion with the addition, after 30 minutes of irinotecan 150mg/m² given as a 90-minute intravenous infusion through a Y-connector immediately followed by fluorouracil 400mg/m² IV bolus then 5-FU 2400 mg/m² over 46 hours continuous infusion.
2938742|NCT02980510|Active Comparator|B=Control group|mFOLFOX6 + Panitumumab mFOLFOX6 every 2 weeks: oxaliplatin 85mg/m² IV infusion over 2 hours immediately followed by folinic acid 400mg/m² IV infusion over 2 hours followed by fluorouracil 400mg/m² IV bolus then 5-FU 2400mg/m² over 46 hours continuous infusion.
2938743|NCT02980497|Active Comparator|Listerine Zero Mouthwash (without alcohol)|Brushing twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush and rinsing with 20 ml of Listerine Zero Mouthwash (without alcohol) for 30 seconds.
2938744|NCT02980497|Active Comparator|Listerine Antiseptic Mouthwash (with alcohol)|Brushing twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush and rinsing with 20 ml of Listerine Antiseptic Mouthwash (with alcohol) for 30 seconds.
2938745|NCT02980497|No Intervention|Brush only|Brush only twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush.
2938746|NCT02980484|Experimental|Active rTMS|Subjects will receive a full course of 20 rTMS treatments over 20 consecutive weekdays as described above.
2938747|NCT02980484|Sham Comparator|Sham/crossover rTMS|Rather than receiving active treatment, subjects will receive sham treatment designed to be indistinguishable from active treatment to the patient. After completion of the sham course, patients will have the option to receive open-label active treatment at no cost.
2938748|NCT02980458|Experimental|Deferiprone 500 Lipomed film-coated tablets|Oral fasted administration of one film-coated tablet of Deferiprone 500 Lipomed film-coated tablets (Lipomed AG, Switzerland), containing 500 mg deferiprone
2938749|NCT02980458|Active Comparator|Ferriprox® film-coated tablets|Oral fasted administration of one film-coated tablet of Ferriprox® film-coated tablets (Apotex Europe B.V., Germany), containing 500 mg deferiprone
2938753|NCT02980432|Experimental|intervention arm|all participants will be assigned to the same arm. Interventions applied include presenting a visual line or a rod with or without a moving (rotating) background while being in different whole-body roll positions. Participants will be asked to adjust the line or the rod along perceived direction of gravity.
2938754|NCT02980419|Experimental|intervention arm|In each participant the investigators will assess verticality perception in whole-body upright position by use of the SVV, the SPV and the SHV after static roll-tilt at ±90deg over 5min. Measurements will be obtained on a motor-driven turntable and two different roll-tilt positions will be applied (±90°). A visual line (SVV), a rod (SHV) or the turntable itself will be adjusted to indicate perceived direction of vertical. A total of three measuring sessions, each lasting about 60 minutes are scheduled.
2938755|NCT02980406|Active Comparator|Fructans|Fructans (FODMAP) are oligosaccharides containing fructose chains. Since the human body lacks hydrolases to break down these saccharides, fructans are poorly absorbed molecules in everybody. The fructan solution used in this study has a concentration of 38g/L.
2938756|NCT02980406|Active Comparator|Fructose|Fructose can be found in the diet as free fructose, in sucrose or as polymer structure in fructans. Absorption varies and occurs more rapidly in the presence of glucose than for free fructose because glucose cotransport is involved in the uptake of fructose. Therefore, when fructose is in excess of glucose, it is regarded as a FODMAP. The fructose concentration used in this study is 100g/L.
2938757|NCT02980406|Active Comparator|FODMAP mix|The FODMAP mix consists of 20g fructans, 10g galacto-oligosaccharides (GOS), 30g fructose, 10g sorbitol and 10g mannitol in one liter of tap water.
2938758|NCT02980406|Placebo Comparator|Glucose|Glucose is a carbohydrate that is not classified as FODMAP, and is therefore used as a control in this study. The concentration of the glucose solution in this study is 100g/L.
2938759|NCT02980393|Experimental|Lifestyle intervention|Participants are guided by a fitness specialist who will help the participants to incorporate physical activity into their daily life. Based on the cardiologist assessment, an individual home-based exercise program will be developed. Participants are also guided and advised on nutrition with emphasis on low fat content and increased fiber. The nutrition counseling will focus on sustainable changes and will help participants to make healthy food choices.
2938760|NCT02980380||Complete locked-in state patients|Amyotrophic lateral sclerosis patients in complete locked-in state who have no means of communication.
2938761|NCT02980367|Experimental|ACL Rehabilitation Group|Non-surgical management [Rehabilitation] with option for later Anterior Cruciate Ligament (ACL) reconstruction, only if required.
2938762|NCT02980367|Active Comparator|ACL Reconstruction Group|Surgical Management - Anterior Cruciate Ligament (ACL) reconstruction surgery
2938763|NCT02980354||Lacunar stroke|Blood samples will be taken from 50 patients who have been diagnosed to have lacunar stroke and are 65 years of age or above.
2938764|NCT02980354||Cortical stroke|Blood samples will be taken from 50 patients who have been diagnosed to have cortical stroke and are 65 years of age or above.
2938765|NCT02980354||Elderly healthy volunteers|Blood samples will be taken from 50 healthy individuals who are 65 years of age or above.
2938766|NCT02980354||Young healthy volunteers|Blood samples will be taken from 50 healthy individuals who are between 18 and 64 years of age.
2938767|NCT02980341|Experimental|Dose Escalation Part|Participants receive U3-1402 from 1.6 mg/kg to 9.6 mg/kg, administered via intravenous (IV) solution at 3-week intervals.
2938768|NCT02980341|Experimental|Dose Finding Part|Participants receive 1 of 5 different U3-1402 dosing regimens, administered via IV solution at 2 or 3-week intervals at doses at or lower than those studied in the Dose Escalation Part.
2938769|NCT02980341|Experimental|Dose Expansion Part|Participants with HER3 high status receive 4.8 mg/kg or 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals. Participants with HER3 low status receive 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals.
2938770|NCT02980328|Experimental|LLLT group|Low-level light therapy (LLLT) was self-performed for 12 weeks, 3 times a day for 20 minutes each
2938771|NCT02980328|Placebo Comparator|Placebo-controlled group|Placebo low-level light therapy (LLLT) was self-performed for 12 weeks, 3 times a day for 20 minutes each. The placebo LLLT device was identical to the active device but did not radiate light as the hole was blocked.
2938772|NCT02980315|Experimental|CAR-T cells|the group treat with CAR-T cells
2938773|NCT02980315|No Intervention|placebo|the group treat with CAR-T cells
2938774|NCT02980302|Other|Patient|
2938775|NCT02980302|Other|Asymptomatic carrier|Father of the patient : asymptomatic carrier of the same mutation
2938776|NCT02980302|Other|Two control patients|
2938777|NCT02980289||Patients|Patients over 18 years old with advanced cancer defined as metastatic disease, no curable treatment options. The patients may not have received chemotherapy or irradiation within 4 weeks, no operations within 2 weeks and no general anesthesia within 4 days.
2938778|NCT02980276|Active Comparator|Treatment|Participants randomised to the treatment arm will receive active metformin in addition to standard care. Metformin tablets will be titrated according to a dosing schedule to achieve the pre-specified glucose targets. Tablets will be in 500mg doses and will commence at 1 tablet per day (500mg) increasing to a maximum of 5 tablets per day (2500mg).
2938779|NCT02980276|Placebo Comparator|Control|Participants randomised to the placebo arm will receive placebo in addition to standard care. Placebo will be titrated according to the dosing schedule to achieve the pre-specified glucose targets. Placebo tablets will commence at 1 tablet per day and will be increased to a maximum of 5 tablets per day over 10 days as with the treatment group.
2938780|NCT02980263|Experimental|Kawasaki patients|
2938781|NCT02980250|Experimental|low dose|The premature infant in this group will be feed with 0.2mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
2938782|NCT02980250|Experimental|normal dose|The premature infant in this group will be feed with 0.4mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
2938783|NCT02980250|Experimental|over dose|The premature infant in this group will be feed with 0.6mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
2938822|NCT02980016|Active Comparator|6H|Daily self-administered isoniazid (at a dose of 300 mg/daily) (with adjustment for participants weighing ≤24 kg) given for 26 weeks (6 months) in Study Year 1
2938784|NCT02980250|Placebo Comparator|placebo|The premature infant in this group will be feed with some vitamin which will dilute into the 5% glucose and have the same appearance and taste with the experimental team for 7 days and will be tested the residual percentage everyday.
2938785|NCT02980237|Experimental|eHealth_additional support|An e-learning education program whose audiovisual content will be implemented. The course could be access in the workplace but they will be additional support.
2938786|NCT02980237|Active Comparator|eHealth|This group will receive an e-learning education program same as the intervention group . However, the participants will not receive additional support by team.
2938787|NCT02980224|Experimental|OmegaD|OmegaD Softgels
2938788|NCT02980224|Placebo Comparator|Placebo|Placebo Softgels
2938789|NCT02980211|Experimental|Tooth Extraction and Graft Dehisced Socket|Treatment of dehiscence defects at the time of tooth extraction using a minimally-invasive GBR technique that involves the application of a particulate bone allograft and a non-resorbable PTFE membrane.
2938790|NCT02980198|Experimental|IFN-Kinoid|IFN-Kinoid + ISA 51
2938791|NCT02980198|Placebo Comparator|Placebo|Placebo + ISA 51
2938792|NCT02980185||Laparoscopic primary cytoreduction|Patients in whom primary cytoreduction was performed using a laparoscopic approach
2938793|NCT02980185||Abdominal primary cytoreduction|Patients in whom primary cytoreduction was performed using an open abdominal approach
2938794|NCT02980172||Pain triage complaint|Patients admitted at GUH ED triaged with a main complaint requiring a pain evaluation.
2938795|NCT02980159||Before triage liaison physician|All patients admitted before the introduction of the function of triage liaison physician.
2938796|NCT02980159||After triage liaison physician|All patients admitted after the introduction of the function of triage liaison physician.
2938797|NCT02980146||"Group patients with colorectal cancer"|Major patients treated surgically for colorectal cancer at Nantes University Hospital or at the Institut de Cancerologie de l'Ouest and agreeing to participate in the study
2938798|NCT02980133|Experimental|Treatment group A|Fp MDPI- Dose Regimen 1
2938799|NCT02980133|Experimental|Treatment Group B|Fp MDPI- Dose Regimen 2
2938800|NCT02980133|Experimental|Treatment Group C|FS MDPI
2938801|NCT02980133|Placebo Comparator|Treatment Group D|Matching placebo
2938802|NCT02980120||Anorexia Nervosa Group|n=50 female patients with Anorexia Nervosa (AN) who fulfill the criteria for DSM-IV, BMI z-scores will be used for age and sex specific cut-off points that are extrapolated from the adult BMI cut-off <17.5 Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
2938803|NCT02980120||Bulimia Nervosa Group|n=30 female patients with Bulimia Nervosa (BN) who have BMI z-scores from the adult range <17.5-25.0 (this reflects the lower prevalence rates of BN compared to AN) Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
2938804|NCT02980120||Healthy Control Group|n=30 healthy females who have BMI z-scores from the adult range from 19.0-25.0 and who do not fulfill diagnostic criteria for any psychiatric disorder.Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
2938805|NCT02980107|Active Comparator|PLS|The control group will receive PLS: text format with simple explanation of the survey topic main findings and is intended for lay audience.
2938806|NCT02980107|Experimental|Infographics|Infographics format of a Cochrane systematic review summary represents the experimental intervention in the trial, where the results are presented with text and pictures.
2938807|NCT02980094|Placebo Comparator|Milk Control group(C)|Using a randomized block design, 25 institutionalized elderly to receive the milk 3 times per day produced by lactating cows fed with the following diet, one of the group is control (C), without vitamin E, selenium, sunflower oil in the cow's food.
2938808|NCT02980094|Experimental|Milk Antioxidant group(A)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diet: control (C) +vitamin E+ selenium (A).
2938809|NCT02980094|Experimental|Milk Oil group(O)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).
2938810|NCT02980094|Experimental|Milk Antioxidant and oil(AO)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diets: control C+sunflower oil+vitamin E+selenium (AO) .
2938811|NCT02980081||Plain abdominal x-ray|All patients admitted to 2 EDs and with a prescription of an abdominal plain x-ray.
2938812|NCT02980068|Experimental|15N Nitrate|single 1,000mg dose of 15N nitrate with 3g of conjugated linoleic acid (CLA).
2938813|NCT02980068|Experimental|14N Sodium Nitrate|single 1,000mg dose of 14N sodium nitrate with 3g of conjugated linoleic acid (CLA)
2938814|NCT02980055|Experimental|Test: collagen matrix|Root coverage using collagen matrix
2938815|NCT02980055|Active Comparator|Control: connective tissue graft|Root coverage using connective tissue graft
2938816|NCT02980042|Experimental|Switching Group|600 mg of ocrelizumab will be administered as one 600-mg IV infusions at a scheduled interval of every 24 weeks. The first dose of ocrelizumab will be a split dose of 300 mg on day 1 and day 15 followed by 600 mg, six months later. Each ocrelizumab infusion should be given as a slow IV infusion over approximately 150 minutes (2.5 hours) for the 300-mg dose. Ocrelizumab must not be administered as an IV push or bolus. Well-adjusted infusion pumps should be used to control the infusion rate, and ocrelizumab should be infused through a dedicated line.
2938817|NCT02980042|Active Comparator|Comparator Group|Standard of care rituximab doses are 1000 mg infusion given as first dose followed by 500mg (or 1000 mg if evidence of early B cell recovery) infusion every 6 months thereafter. Rituximab must not be administered as an IV push or bolus. Well-adjusted infusion pumps should be used to control the infusion rate, and rituximab should be infused through a dedicated line
2938818|NCT02980029|Experimental|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme.
2938819|NCT02980029|Placebo Comparator|Placebo|Placebo
2938820|NCT02980016|Active Comparator|3HP (rifapentine + isoniazid)|Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), (with adjustment for participants weighing ≤50 kg) given for 12 weeks in Study Year 1
2938821|NCT02980016|Active Comparator|p3HP (rifapentine + isoniazid)|Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), (with adjustment for participants weighing ≤50 kg) given for 12 weeks in Study Years 1 and 2
2938823|NCT02980003|Active Comparator|isotonic saline|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The infusion rate will be 1 mL/kg/h in the first 5 hours they will receive isotonic saline at 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or New York Heart Association (NYHA) functional class III or IV). Then, will be infused at 3 mL/kg/h for 1 hour immediately before contrast medium injection; following this, patients will receive the same fluid at a rate of 1 mL/kg/h
2938824|NCT02980003|Active Comparator|i.v. sodium bicarbonate|in the first 5 hours patients will receive isotonic saline at 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or NYHA functional class III or IV). Then, a solution of 1.4% sodium bicarbonate (167 mEq/L; 334 milliosmol (mOsm/L)) will be infused: the initial intravenous bolus will be 3 mL/kg/h for 1 hour immediately before contrast medium injection; following this, patients will receive the same fluid at a rate of 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or NYHA functional class III or IV) during the exposure to contrast and for 6 hours after the procedure. Later, patients will resume hydration with isotonic saline for further 6 hours.
2938825|NCT02980003|Experimental|oral sodium bicarbonate:|"patients will start hydration with isotonic saline as well as Arm Hydration Alone. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water. The drug will be weighed with a precision balance with a sensitivity of ± 0.1 mg and placed in a labeled sterile plastic container. The label will report the lot number, expiry date of the sodium bicarbonate lot, the signature of the pharmacist carrying out the weighing process, a serial number to identify the sample and the patient identification number.~Documentation will be stored in the Laboratory of Galenic Preparations, Pharmacy Division, of the hospital."
2938826|NCT02979990|Placebo Comparator|Control Video|Subjects will have access to general videos on the in vitro fertilization process. They will not have access to instructional videos related to the administration of controlled ovarian stimulation.
2938827|NCT02979990|Experimental|Experimental Video|Subjects will be asked to view instructional videos related to the administration of controlled ovarian stimulation medication during their own controlled ovarian stimulation
2938828|NCT02979977|Experimental|All subjects|Advanced squamous cell carcinoma of the head and neck region, having previously been treated on a platinum based regimen or with an immune checkpoint inhibitor. Subjects will receive Afatinib dose 40 mg per day and weekly IV cetuximab.
2938829|NCT02979964|Experimental|Arm 1, Positive Framing|All metrics in the audit and feedback practice reports presented with 'positive' framing, where the proportion of patients safe from risk (i.e., appropriate/desirable prescribing behaviours) is described.
2938830|NCT02979964|Experimental|Arm 2, Negative Framing|All metrics in the audit and feedback practice reports presented with 'negative' framing, where the proportion of patients at risk (i.e., due to inappropriate/undesirable prescribing behaviours) is described.
2938831|NCT02979964|Experimental|Arm 3, Top Quartile Comparator|All metrics in the audit and feedback practice reports presented and the physician-recipient's performance is compared against the 75th percentile for performance by physicians working in nursing homes in the province for each metric.
2938832|NCT02979964|Experimental|Arm 4, Average Comparator|All metrics in the audit and feedback practice reports presented and the physician-recipient's performance is compared against the average performance by physicians working in nursing homes in the province for each metric.
2938833|NCT02979925|Experimental|Active transcutaneous magnetic stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
2938834|NCT02979925|Sham Comparator|Sham transcutaneous magnetic stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
2938835|NCT02979912|Experimental|Platelet Lysate|Autologous platelet lysate dispensed into eye droppers to be applied four times a day for a total of four weeks.
2938836|NCT02979899|Experimental|TRC105 plus votrient|weekly TRC105 i.v. in combination with standard dose votrient by mouth, once daily
2938837|NCT02979899|Active Comparator|votrient|standard dose votrient by mouth, once daily
2938838|NCT02979886|Experimental|triptorelin|GnRH-a will be given everyday to the patient undergoing IVF treatment from middle luteal phase to the day of HCG. After 14 days of injection, serum FSH/LH/E2 will be checked. Then ovarian stimulation will be started by giving daily subcutaneous injection of recombinant FSH 150~300 IU. An appropriate dose of HMG (75~150 IU) will be added when follicles are larger than 12~14mm in diameter. When one leading follicle is >18mm in diameter, or two follicles are >17mm in diameter, or three follicles are >16mm in diameter, final ovulation will be triggered by a single injection of HCG 4,000~10,000 IU or Ovidrel® 250μg (equivalent to HCG 6,500 IU)
2938839|NCT02979873|Experimental|Sirolimus|sirolimus
2938840|NCT02979860|No Intervention|Typical sleep schedule|"Children in this arm will be asked to maintain their current sleep schedule. No prescription will be provided other than to sleep how they typically would sleep."
2938841|NCT02979860|Experimental|Enhance time in bed by 90 min/night|Sleep duration - 90 minutes: Children in this arm will be asked to get into bed and to turn their lights out 90 minutes earlier than their typical bedtime. Bedtimes and wake times will remain consistent across the 4-week experimental phase of the study.
2938842|NCT02979860|Experimental|Enhance time in bed by 45 min/night|Sleep duration - 45 minutes:Children in this arm will be asked to get into bed and to turn their lights out 45 minutes earlier than their typical bedtime. Bedtimes and wake times will remain consistent across the 4-week experimental phase of the study.
2938843|NCT02979860|Experimental|Regularize sleep schedule|Sleep timing: Children in this arm will be asked to get into bed at a consistent bedtime each night and wake at a consistent time each morning such that time in bed achieved during baseline is maintained during the 4-week experimental phase; only timing of bedtimes/wake times will be manipulated in this arm.
2938844|NCT02979847|Experimental|Hybrid|hybrid catheter ablation (both epicardial and endocardial mapping and ablation)
2938845|NCT02979847|Active Comparator|Control|conventional mapping and ablation in endocardial side
2938846|NCT02979834||Early perception group|The group with early perception of fetal movement (<25th percentile)
2938847|NCT02979834||Average perception group|The group with average perception of fetal movement (>25th and <75th percentile)
2938848|NCT02979834||Late perception group|The group which late perception of fetal movement (>75 percentile)
2938849|NCT02979821|Experimental|Poziotinib|The study drug(poziotinib) will be administered orally as one 12 mg tablet once a day until disease progression or manifestation of unacceptable toxicity. The initial dose of the study drug 12 mg daily can be reduced to 8 mg once daily according to dose reduction criteria.
2938850|NCT02979808|Experimental|Navina Smart|Navina Smart will be used during 12 months for transanal irrigation (TAI).
2938851|NCT02979782||Endo-CABG, surgical group|the minimal invasive cardiac surgery group
2938852|NCT02979782||PCI, comparative surgical group|a comparative minimal invasive procedure
2938853|NCT02979782||Healthy volunteer, control group|to exclude any learning effect or natural variation in neurological testing
2938854|NCT02979769|Experimental|Palovarotene dose level 1|Adult Cohort subjects (those with at least 90% skeletal maturity) will receive 5 mg palovarotene once daily for up to 24 months; and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups.
2938855|NCT02979769|Experimental|Palovarotene dose level 2|During an eligible flare-up, Pediatric Cohort subjects (those with less than 90% skeletal maturity) will receive weight-adjusted doses of 20 mg palovarotene for 28 days, followed by 10 mg for 56 days.
2938856|NCT02979756|Experimental|Decentralized GDM screening and initial management|In this arm, the intervention consists of screening all pregnant women for GDM using the nationally recommended oral glucose tolerance test that will take place during antenatal care consultations in 10 randomly selected primary health care facilities. Overall, 80 women who are diagnosed with GDM and who consent to participate will receive initial nutritional counseling and will be closely followed up.
2938857|NCT02979756|No Intervention|Standard GDM screening and management practice|In this arm, screening for GDM will follow standard practice. 80 women diagnosed with GDM in 10 randomly selected primary health care facilities and who consent to participate will be followed up.
2938858|NCT02979743|Placebo Comparator|Occupational therapy group|The children worked with an occupational therapist for 4 hours a day for 5 days per week (totaling 40 hours) and initially concentrated on unilateral activities with the hemiplegic hand,and added bilateral activities during the second week.
2938859|NCT02979743|Active Comparator|Occupational therapy puls acupuncture and massage methods|The patients receive occupational therapy puls acupuncture and massage methods.
2938860|NCT02979730|Active Comparator|Core Lab Testing Arm|For patients with clinical concern for influenza, the usual workflow in the BMC ED is that physicians order the collection of a nasopharyngeal swab (NPS) for influenza A/B testing to be performed in the core microbiology laboratory using one of two assays. The two influenza A/B-only assays available in the core lab are a) an instrumented fluorescent immunoassay rapid antigen test, the Sofia influenza A+B FIA (Quidel Corporation) and b) an automated real-time PCR test, the Xpert Flu (Cepheid, Inc.). Which test is ordered is at the discretion of the physician. Both the Sofia and Xpert assays provide a result callout to distinguish influenza type A from type B.
2938861|NCT02979730|Experimental|ED Point of Care Testing Arm|Prior to the study the Cobas Liat Influenza A/B assay will be verified for patient care at BMC. The instrument and test kits will be available in the ED for use with study subjects randomized to this study arm. The Cobas Liat assay provides a result callout to distinguish influenza type A from type B.
2938862|NCT02979717|Experimental|high protein, high fiber|Participants receive a high protein, high fiber dietary supplement pre-load
2938863|NCT02979717|Placebo Comparator|Low protein, low fiber|Participants receive a low protein, low fiber isocaloric pre-load
2938864|NCT02979704|Active Comparator|Rosuvastatin|Intervention: Tablet Rosuvastatin (5-10) mg orally once daily dose for 08 weeks.
2938865|NCT02979704|Active Comparator|Atorvastatin|Intervention: Tablet Atorvastatin (10-20) mg orally once daily dose for 08 weeks
2938866|NCT02979691|Active Comparator|SIB-IMRT|SIB-IMRT arm receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (59.92Gy and 50.4Gy in 28 fractions) concurrently with oral S-1(40-60mg, orally twice daily, on every weekday).
2938867|NCT02979691|Experimental|S1 based SIB-IMRT|S1 based SIB-IMRT receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (59.92Gy and 50.4Gy in 28 fractions) concurrently with oral S-1(40-60mg, orally twice daily, on every weekday) followed by four cycles of S-1 (40-60mg, orally twice daily, d1-14, every 3 weeks) as an adjuvant chemotherapy.
2938868|NCT02979678|Experimental|Questionnaire|Breast cancer
2938869|NCT02979665||Ranibizumab Ophthalmic|DME consults requiring anti-VEGF treatment
2938870|NCT02979665||Control|DME consults not requiring anti-VEGF
2938871|NCT02979639|Experimental|HZ/su Group|Subjects ≥ 50 years of age who will receive two doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
2938872|NCT02979626||Moderate-to-severe Influenza|"Children 6 weeks to 8 years of age with influenza-like illness and one of the following:~Fever >39~Lower respiratory tract infection~Acute otitis media~Serious extra-pulmonary manifestations (myositis, encephalitis)"
2938873|NCT02979626||Mild Influenza|Children 6 weeks to 8 years of age with influenza-like illness (ILI) without the criteria for moderate-to-severe disease (above)
2938874|NCT02979613|Experimental|TAF|TAF + TDF placebo for 48 weeks
2938875|NCT02979613|Active Comparator|TDF|TDF + TAF placebo for 48 weeks
2938876|NCT02979613|Experimental|Open-Label Extension|Participants who complete 48 weeks of treatment are eligible for participation in the open-label extension period to receive TAF for an additional 48 weeks.
2938877|NCT02979587|Other|Harmony TPV System|Intervention Device: Harmony Transcatheter Pulmonary Valves and Delivery Systems
2938878|NCT02979574|Active Comparator|Electro-Acupuncture (EA) Procedure|Participants will receive 10 treatment of EA acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week).
2938879|NCT02979574|Active Comparator|Battle Field Acupuncture (BFA) Procedure|Participants will receive 10 treatment of BFA acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week).
2938880|NCT02979574|Active Comparator|Wait List Control (WLC) Usual Care Procedure|Subjects in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers, including analgesic medications. After the 12 week follow up period, patients in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.
2938881|NCT02979561|Experimental|group of dabigatran|
2938882|NCT02979561|Active Comparator|group of warfarin|
2938883|NCT02979548|Experimental|Group A : Aprepitant (Add on therapy)|Aprepitant group will receive aprepitant capsules 1 h prior to chemotherapy on days 1-3 in addition to 5HT3 RA (Ondansetron). The dose of aprepitant will be given based on weight groups Weight 15-40 kg : Aprepitant 80 mg on days 1-3 Weight > 41kg: Aprepitant 125 mg on day 1 followed by 80 mg on days 2-3 Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
2938884|NCT02979548|Active Comparator|Group B : 5HT3 RA (Ondansetron)|"On the day of chemotherapy, ondansetron will be administered to all patients as per our institutional practice in a dose of 0.15 mg/kg as an intravenous bolus 30 minutes before chemotherapy followed by every 8 hourly for 8 days.~Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day."
2938885|NCT02979535|Experimental|Concomitant Administration Group|Subjects will receive 3 doses of CYD dengue vaccine and 2 doses of Cervarix concomitantly with the 2 first doses of CYD dengue vaccine.
2938886|NCT02979535|Experimental|Sequential Administration Group|Subjects will receive 3 doses of CYD dengue vaccine and 2 doses of Cervarix sequentially to the 2 first doses of CYD dengue vaccine
2938887|NCT02979522|Experimental|Brentuximab vedotin 48 mg/m^2|Brentuximab vedotin 48 milligram per square meter (mg/m^2), intravenous infusion, once on Day 1 and 15 of each 28-day cycle approximately 1 hour after administration of doxorubicin 25 mg/m^2, vinblastine 6 mg/m^2, and Dacarbazine 375 mg/m^2, intravenous infusion, once on Day 1 and 15 of each 28-day cycle for up to 6 cycles. If the first 6 participants complete the dose limiting toxicity (DLT) observation period with 0 or 1 participant experiencing a DLT, 48 mg/m^2 will be established as the recommended dose for phase 2 study. If at any time more than 1 participant out of a maximum 6 DLT-evaluable participants experiences a DLT, brentuximab vedotin dose will be reduced to 36 mg/m^2. If 0 or 1 participant experiences a DLT among the 6 participants treated at 36 mg/m^2, 36 mg/m^2 will be established as recommended dose for phase 2 study. If more than 1 participant experiences a DLT in the first 6 participants treated at 36 mg/m^2, the study will be discontinued.
2938888|NCT02979509||Endoscopic ultrasound- (EUS) guided tissue sampling|All patients scheduled to undergo EUS with tissue sampling (TS) as medically indicated will be considered for the study. Patients in whom EUS-TS is considered as part of their standard medical care will be offered to participate in this study.
2938889|NCT02979496|Other|0 g pomace (control)|16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
2938890|NCT02979496|Experimental|90 g pomace|16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
2938891|NCT02979496|Experimental|180 g pomace|16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
2938892|NCT02979496|Other|Flavored water (control)|16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
2938893|NCT02979483|Other|Integrative Supportive Care|All planed procedures established during the first consultation with the investigator is successfully completed within the 14-day (+/-2 days)
2938894|NCT02979457|No Intervention|no awareness of Degree of Worry|Call handler is not made aware of caller's DOW on computer screen
2938895|NCT02979457|Experimental|awareness of Degree of Worry|Call handler is made aware of caller's DOW on computer screen alongside patient information as address etc.
2938896|NCT02979444|Experimental|Mothers and Babies Groups Home-Visitor|Women who participate in the home-visitor led arm will receive the intervention from a paraprofessional home-visitor and complete assessments at baseline, post-intervention, and 12 and 24 weeks postpartum.
2938897|NCT02979444|Experimental|Mothers and Babies Groups Clinician|Women who participate in the mental health consultant led arm will receive the intervention from a mental health consultant and complete assessments at baseline, post-intervention, and 12 and 24 weeks postpartum.
2938898|NCT02979444|No Intervention|Control|Women who participate in the control arm will not receive the intervention but will complete assessments at baseline, 8 weeks post-baseline, and 12 and 24 weeks postpartum.
2938899|NCT02979431|Experimental|ALX-0171 Dose 1|Inhalation of ALX-0171 Dose 1 once daily for 3 consecutive days
2938900|NCT02979431|Experimental|ALX-0171 Dose 2|Inhalation of ALX-0171 Dose 2 once daily for 3 consecutive days
2938901|NCT02979431|Experimental|ALX-0171 Dose 3|Inhalation of ALX-0171 Dose 3 once daily for 3 consecutive days
2938902|NCT02979431|Placebo Comparator|Placebo|Inhalation of Placebo once daily for 3 consecutive days
2938903|NCT02979405|Experimental|group 1|Phenylephrine 40 mcg/min, infusion during 5 minutes
2938904|NCT02979405|Placebo Comparator|group 2|Saline solution 21 cc, infusion during 5 minutes
2938905|NCT02979392|Experimental|Phase I|Part A, Dose escalation TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) IV once every 3 weeks (Phase I starting dose 75 mg/m2) Part B, Expansion TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) IV once every 3 weeks (RP2D dose determined in part A)
2938906|NCT02979379||Pain|Individuals with COPD who experience chronic pain (episodes of daily pain for a duration greater than three months)
2938907|NCT02979379||No Pain|Individuals with COPD who do not experience pain on a regular basis.
2938908|NCT02979366|Experimental|S64315 (also referred as MIK665)|
2938909|NCT02979353|Experimental|Shed-Meds: A Patient-Centered Deprescribing Intervention|Participants assigned to the intervention group will receive a clinical review of their prescribed medications by a research clinician (Pharmacist, Physician, and/or Nurse Practitioner) followed by a patient interview to assess their willingness to discontinue or reduce some of their medicines based on the clinical recommendations of the team. Hospital and out-patient providers also will be part of the deprescribing decision process. Deprescribing actions will be initiated in the hospital prior to discharge and continue through the skilled nursing facility stay.
2938910|NCT02979353|No Intervention|Control Group|Participants assigned to the control group will receive usual care as it is normally provided by the hospital and skilled nursing facility treatment teams. Research staff will monitor their prescribed medications in both care settings but not make any recommendations or changes, unless a safety issue is identified.
2938911|NCT02979327|Experimental|Adderall first, then Placebo|Participants will receive an Adderall capsule at the first study visit, then a Placebo capsule at the second study visit.
2938912|NCT02979327|Experimental|Placebo first, then Adderall|Participants will receive a Placebo capsule at the first study visit, then an Adderall capsule at the second study visit.
2938913|NCT02979314|Experimental|Galvanic Vestibular Stimulation|A standard placement of the electrodes will be used for GVS and sham, placed on the mastoids. Weak currents up to maximally 3 mA will be used (tested before in each participant individually, and expected mean current will be around 1.5 mA). Previous studies have used Magnetic Resonance (MR) compatible GVS without reporting any discomfort for the participants, however weak sensations of nausea could be possible and in case that they are disturbing for the participants the experiment will be aborted. Continuous stimulation for up to 30min with intensities of 1-1.5 mA is generally considered as safe and free of any considerable side effects.
2938914|NCT02979301|Experimental|Tamoxifen|Women with high background uptake on MBI take 5 mg tam per day for 30 days.
2938915|NCT02979288|Experimental|A Nugent 4 + Lactobacilli|Intermediate vaginal Flora Nugent 4 with Lactobacilli. Intervention with vaginal probiotics with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)
2938916|NCT02979288|Active Comparator|B Nugent 4 + Lactobacilli|Intermediate vaginal Flora Nugent 4 with Lactobacilli, NO Intervention
2938917|NCT02979288|Experimental|C Nugent 4 NO Lactobacilli|Intermediate vaginal Flora Nugent 4 NO Lactobacilli, Intervention with vaginal probiotics, with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)
2938918|NCT02979288|Active Comparator|D Nugent 4 NO Lactobacilli|Intermediate vaginal Flora Nugent 4 NO Lactobacilli, No Intervention
2938919|NCT02979275||BRAIN+THENAR MUSCLE INVOS|Patients undergoing open heart surgery on cardiopulmonary bypass.
2938920|NCT02979262|Experimental|Fathers for Change|Fathers for Change treatment begins with individual-focused sessions followed by co-parenting focused sessions and ending with restorative parenting sessions. The areas of focus for each of the three phases of Fathers for Change are: 1) abstinence from SA and violence; 2) co-parenting; 3) parenting/father-child relationship. Treatment begins with motivational enhancement by focusing the role of men as fathers to their young children, child development and the impact of violence and SA on parenting, and the father's own childhood experiences of SA and violence to highlight the multigenerational nature of these problems. The program then focuses on skills training in the following areas: reducing automatic hostile cognitions and increasing emotion regulation skills, 2) communication and problem solving around co-parenting, and 3) restorative parenting.
2938921|NCT02979262|Active Comparator|Parent Education (PE)|PE is an individual intervention.PE was developed to represent parent education and support that is typically available to parents with substance use problems who are at high risk for neglecting their children. Fathers enrolled in PE will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs (e.g., health care, child care, housing and education). The PE counselor will provide a choice of pamphlets on age-related parenting topics each week from a series of pamphlets designed for work with substance abusing parents. Sample pamphlet topics include routines and rituals, ages and milestones, alternatives to spanking, and nutrition and fitness.
2938922|NCT02979249|Experimental|Oral Iron|standard dose of iron pills
2938923|NCT02979236||STEMI treated with STENTYS Xposition S|Patients 18 years of age and older presenting with symptoms consistent with a ST-Elevation Myocardial Infarction (STEMI) lasting ≤12 hrs in duration, with ≥2 mm of ST-segment elevation in ≥2 contiguous leads, treated with primary stent implantation (Xposition S planned per operator's assessment).
2938924|NCT02979223|Experimental|PMC/PEG-Asc|Picolyte 1 bottle/170cc at one day before colonoscopy, 7 PM. And then, Intake Coolprep 1L at the day of colonoscopy, 5 AM
2938925|NCT02979223|Active Comparator|PEG-Asc/PMC|Intake Coolprep 1L at one day before colonoscopy, 7 PM. And then, Intake Picolyte 1 bottle/170cc at the day of colonoscopy, 5AM
2938926|NCT02979210|Other|Artificial Fecal Insult|protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline)
2938927|NCT02979197|Experimental|Amlodipine+Celecoxib|Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule qd for 14 days
2938928|NCT02979197|Active Comparator|Amlodipine+Placebo|Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule qd for 14 days
2938929|NCT02979197|Sham Comparator|Placebo+Placebo|Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule qd for 14 days
2938930|NCT02979184|Other|Intensive decongestive physiotherapy|2 weeks of intensive decongestive physiotherapy
2938931|NCT02979171|Active Comparator|LMA-Classic|airway management with LMA-Classic
2938932|NCT02979171|Active Comparator|LMA-Flexible|airway management with LMA-Flexible
2938933|NCT02979171|Active Comparator|LMA-Proseal|airway management with LMA-Proseal
2938934|NCT02979158|Experimental|CPB Low Dose|Conduct of cardiopulmonary bypass using a low heparin dose verified by the activated clotting time at 250 s
2938935|NCT02979158|Experimental|CPB High Dose|Conduct of cardiopulmonary bypass using a high heparin dose verified by the activated clotting time at 480 s
2938936|NCT02979145||Patients with CMT|Two groups of patients will be included: Group 1 (Definitive): Children with known CMT where genetic testing confirms the diagnosis, or children with a clinical diagnosis including electrophysiology confirming the presence of CMT and a corresponding family history where a first or second degree relative has a genetic diagnosis; or Group 2 (At risk): A clinical diagnosis of CMT awaiting genetic testing or confirmatory electrophysiology and evidence of a genetic diagnosis in a first or second degree relative; or individuals identified as being at risk of a CMT diagnosis (prodromal patients), without the onset of signs or symptoms.
2938937|NCT02979145||Controls|Healthy controls will be included from unaffected family members or friends accompanying patients at INC sites. Healthy controls are defined as boys and girls aged 0-≤4 years without a diagnosis of CMT or any of the other study exclusion criteria.
2938938|NCT02979132|Active Comparator|Oral Iron Supplementation|Eisensulfat LOMAPHARM 50 mg administration for 90 days
2938939|NCT02979132|Active Comparator|Intravenous Iron Supplementation|Single-dose Ferinject(R) administration
2938940|NCT02979132|Active Comparator|Food Fortification with Iron|Consumption of iron-fortified biscuits (15 mg Fe in form of FeSO4) for 90 d
2939661|NCT02974049|Experimental|ALB 400 mg x2 per year|Albendazole 400 mg given at 0, 6, 12, 18, 24 and 30 months
2938941|NCT02979119||Prospective Birth cohort|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX <1%) haemophilia A or B, born from January 1st 2000 until January 1st 2020 who have been or are to be treated with coagulation proteins in one of the participating centres
2938942|NCT02979106|Experimental|oral fructose load|test meal calculated to provide 25% of basal energy requirement containing 13C-labeled fructose (0.35 g/kg), protein (0.21 g/kg) and lipid (0.22 g/kg).
2938943|NCT02979093|Other|Addicted|The addiction group will be scanned twice using functional magnetic resonance imaging (fMRI). Subjects will be randomly assigned to receive either the active comparator (intranasal oxytocin spray) or the placebo comparator before the first scanning session. For the second scan (approximately one month later), the subject will receive the other spray which she did not receive at the time of the first scan.
2938944|NCT02979093|Other|Control|The control group will be scanned twice using functional magnetic resonance imaging (fMRI). Subjects will be randomly assigned to receive either the active comparator (intranasal oxytocin spray) or the placebo comparator before the first scanning session. For the second scan (approximately one month later), the subject will receive the other spray which she did not receive at the time of the first scan.
2938945|NCT02979080|Experimental|Oral Iron Supplementation|Eisensulfat LOMAPHARM 50 mg administration for 120 days
2938946|NCT02979067|Active Comparator|High-flow 100% oxygen|Nasal oxygen flow
2938947|NCT02979067|Active Comparator|Low-flow 100% oxygen|Nasal oxygen flow
2938948|NCT02979067|Active Comparator|High-flow 30% oxygen|Nasal oxygen flow
2938949|NCT02979054|Experimental|T4020|1 drop every other days during 5 days
2938950|NCT02979054|Placebo Comparator|Saline solution|1 drop every other days during 5 days
2938951|NCT02979041|Active Comparator|control|Patients in the control group will receive standard physiotherapy and medical care, as provided to all patients with neck pain in the aviation medicine clinic. This will reflect the standard care that has been provided to all patients.
2938952|NCT02979041|Experimental|intervention|Standard care (as provided to controls) with the addition of virtual reality training (a self-exercise program) using a VR system to address the fast, accurate head control required in flying tasks.
2938953|NCT02979028|Experimental|TEAS group|Electric stimulation was given through electrode attached to acupoints SP6 and ST36 .TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.
2938954|NCT02979028|Sham Comparator|Sham group|Non-acupoint is located 2cm inward to the specific acupoints.TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.
2938955|NCT02979028|Placebo Comparator|Control group|Control patients will receive the same treatment without electrical stimulation.
2938956|NCT02979015|Experimental|Alirocumab|Subcutaneous injection of a single dose of alirocumab, dose level according to ascending dose design
2938957|NCT02979015|Placebo Comparator|Placebo|Subcutaneous injection of a single dose of matching placebo
2938958|NCT02978989|Placebo Comparator|LC & nonsolo approach|The surgical intervention is nonsolo LC.
2938959|NCT02978989|Active Comparator|LC & solo approach|The surgical intervention is solo LC.
2938960|NCT02978976|Experimental|betamethasone|will receive two doses of 12mg betamethasone, then the pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug (betamethasone), 24 hours after the last dose, and on the day of elective Cs.
2938961|NCT02978976|Placebo Comparator|Saline|will receive saline injection placebo, then the pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug ( placebo), 24 hours after the last dose, and on the day of elective Cs.
2938962|NCT02978963|Experimental|Cognitive Behavioral Therapy|All participants will receive cognitive behavioral therapy for excessive worry. Focus in treatment will be on reducing participants' intolerance uncertainty through in vivo and imaginary exposure to uncertainty inducing situations and thoughts. Treatment will also contain psycho education about anxiety and worry, as well as planning for maintenance of treatment gains. Parents of the participants will receive support and education about worry through an internet-delivered program.
2938963|NCT02978950|Experimental|Surveillance arm|Bilateral duplex ultrasound surveillance
2938964|NCT02978950|Active Comparator|No surveillance arm|no duplex ultrasound surveillance
2938965|NCT02978937||Metabolically healthy and abnormal obese|Obese patients divided into two groups according to their metabolic profile (healthy vs unhealthy)
2938966|NCT02978924|Active Comparator|Cathodal tsDCS|20 min of active treatment
2938967|NCT02978924|Sham Comparator|Sham tsDCS|20 min of sham treatment
2938968|NCT02978911|Experimental|Skull base tumors|Patients who presented a skull base tumor that requires a surgical removal
2938969|NCT02978898||LN Lymph nodes|"Samples obtained from patients with :~LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells"
2938970|NCT02978898||PB peripheral blood|"Samples obtained from patients with :~LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells"
2938971|NCT02978885|Other|Normal preoperative lung function|Patients with normal lung function undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
2938972|NCT02978885|Other|Preoperative COPD|Patients with moderate COPD undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
2938973|NCT02978859|Experimental|MGCD516|Patients with locally advanced and unresectable or metastatic sarcoma will receive MGCD516 at the discretion of the principal investigator until disease progression, unacceptable toxicity or adverse event(s) or withdrawal of consent.
2939013|NCT02978560||control|The source population for this cohort will be 30 healthy individuals with no know cardiovascular disease or wound healing defects. Subjects will be recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once.
2938974|NCT02978846||Observational (side effects evaluation using cards)|Patients are shown two groups of cards on the last day of radiation treatment. Group A lists 48 physical side effects and group B lists 27 psychosocial side effects. The cards are shuffled and patients view one card at a time and select the side effects they attribute to their current treatment. Patients rank the selected cards from each group by order of severity. The top 5 cards from each group are then shuffled together and patients rank the remaining 10 cards in order of severity.
2938975|NCT02978833|Experimental|PRP|
2938976|NCT02978833|Active Comparator|Whole Blood|
2938977|NCT02978820|Experimental|SEAS exercise group|This group received SEAS exercises in addition to brace wearing for four months
2938978|NCT02978820|Experimental|CS exercise group|This group received core stabilization exercise training (CS) in addition to brace wearing for four months
2938979|NCT02978807||Pregnant women between 24 to 32 weeks|"Pregnant women with a singleton pregnancy who presented to care between 24 -32 weeks of their pregnancy were included in this study.~All patients enrolled in the study will receive a random point of care blood sugar, point of care and venous fasting blood sugar, point of care and venous 1 hr/2hr glucose tolerance test, and point of care and venous HbA1c."
2938980|NCT02978781|Experimental|SAGE-217 dosing|SAGE-217
2938981|NCT02978781|Placebo Comparator|Placebo|Placebo
2938982|NCT02978768|Experimental|Exercise|First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
2938983|NCT02978768|Experimental|Cognitive training|Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
2938984|NCT02978768|Experimental|Physico-Mental training|Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
2938985|NCT02978755|Experimental|GM102 escalating doses|8 successive cohorts
2938986|NCT02978755|Experimental|GM102 escalating doses + carboplatin+paclitaxel|2 successive cohorts
2938987|NCT02978755|Experimental|GM102 recommended dose|3 parallel cohorts in sex cord stromal, epithelial ovarian and cervix cancers
2938988|NCT02978742|Experimental|Coached Recovery Record App|Participants will complete the 8-week adaptive Recovery Record app program and will be linked with a healthcare professional who will provide standardized coaching, in the way of feedback and support to participants for the duration of the program.
2938989|NCT02978742|Active Comparator|Uncoached Recovery Record App|Participants will complete the 8-week adaptive Recovery Record app program on their own (i.e., without a coach providing feedback and support).
2938990|NCT02978729|Active Comparator|Telephone|Telephone telegenetic counseling: A trained Penn genetic counselor will conduct genotype disclosure visits with the participant via telephone. The participant will be in a private room at the study site. Telephone sessions will utilize a private phone line. The genetic counselor will use standardized disclosure checklist and visual aids for the disclosure session.
2938991|NCT02978729|Experimental|Videoconference|Two-way videoconferencing telegenetic counseling: A trained Penn genetic counselor will conduct genotype disclosure visits with the participant via two-way videoconferencing. The participant will be in a private room at the study site. Videoconferencing sessions will utilize tablets or laptops with web cameras and secure/confidential software for teleconferencing. The genetic counselor will use standardized disclosure checklist and visual aids for the disclosure session.
2938992|NCT02978716|Experimental|Group 1: Gemcitabine/Carboplatin|GC chemotherapy (gemcitabine 1000 mg/m2 and carboplatin AUC = 2 administered IV) on Days 1 and 8 in 21-day cycles.
2938993|NCT02978716|Experimental|Group 2: Trilaciclib (G1T28) + Gemcitabine/Carboplatin|Trilaciclib (G1T28) IV prior to GC chemotherapy (gemcitabine 1000 mg/m2 and carboplatin AUC = 2 administered IV) on Days 1 and 8 in 21-day cycles.
2938994|NCT02978716|Experimental|Group 3: Trilaciclib (G1T28) + Gemcitabine/Carboplatin|Trilaciclib (G1T28) IV on Days 1, 2, 8 and 9. GC chemotherapy (gemcitabine 1000 mg/m2 and carboplatin AUC = 2 administered IV) on Days 2 and 9 in 21-day cycles.
2938995|NCT02978690|Experimental|BI655130|
2938996|NCT02978677|Experimental|Grade II tumors (macroscopic)|Radiotherapy 68 Gy(RBE)
2938997|NCT02978677|Experimental|Grade III tumors (macroscopic)|Radiotherapy 72 Gy(RBE)
2938998|NCT02978677|Active Comparator|Grade II/III tumors (completely resected)|Radiotherapy 60 Gy(RBE)
2938999|NCT02978664|Active Comparator|Air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
2939000|NCT02978664|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy
2939001|NCT02978664|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
2939002|NCT02978651|Experimental|Pitolisant (BF2.649)|Histamine H3 receptor H3R antagonist/ inverse agonist
2939003|NCT02978651|Placebo Comparator|Placebo|Placebo
2939004|NCT02978638|Other|Finetech Vocare Bladder System|This is a pilot study of the Finetech Vocare Bladder System to improve continence in human subjects with chronic spinal cord injury. Each subject will act as their own control, comparing function with the Finetech Vocare Bladder System in use and not in use.
2939005|NCT02978625|Experimental|Treatment (talimogene laherparepvec, nivolumab)|Patients receive talimogene laherparepvec IT on day 1. Patients without response at week 12, may also receive nivolumab IV over 60 minutes on day 1. Courses repeat every 21 days for course 1 then every 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
2939006|NCT02978612|Experimental|Arm Capecitabine|Capecitabine 1000 mg/m2 bid day 1-14 q3 weeks, 8 cycles
2939007|NCT02978612|No Intervention|Arm No treatment|no chemotherapy, observation
2939008|NCT02978599|Experimental|AVL-3288 10 mg|AVL-3288 10 mg daily for 5 days
2939009|NCT02978599|Experimental|AVL-3288 30 mg|AVL-3288 30 mg daily for 5 days
2939010|NCT02978599|Placebo Comparator|Placebo|Placebo daily for 5 days
2939011|NCT02978586|Experimental|[Ga-68]PSMA PET/MR|Up to 3 experimental PET/MRI scans will be performed to determine the level of [Ga-68]PSMA tumor uptake
2939012|NCT02978573|Experimental|Cartiva|Cartiva Synthetic Cartilage Implant
2939014|NCT02978560||Wound Group|The source population will be 30 patients who present to wound care clinic with Diabetic Foot Ulcers. Candidate subjects will have had a standard wound evaluation and medical history taken as a matter of their standard of care. On the basis of the evaluation, the physician-investigators will determine if the patient meets the eligibility criteria. If so, the study will be explained to the patient at that time, and Informed Consent will be obtained. 30 healthy subjects will also be included, recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of the following inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once at the onset of their wound care.
2939015|NCT02978547|Experimental|Metformin|All patients will receive metformin 500 mg per oral twice daily with food for at least 7 days, until 2 days prior to surgery. Metformin therapy should be discontinued 2 days before surgery to reduce the risk of lactic acidosis associated with fasting.
2939016|NCT02978534||Quetiapine|Patients taking quetiapine during pregnancy are eligible to participate in the study. Their dose and plasma concentration levels of quetiapine will be monitored throughout pregnancy and up to three months postpartum.
2939017|NCT02978521|Experimental|Intervention Group|"Patients in the IG will be scheduled to receive Pulmonary Rehabilitation:~12 sessions (60 minutes approximately) over a period of 4-6 weeks (2-3 session/week). Sessions will progress as patients tolerance to exercise and will include breathing techniques, resistance training on ergometer and treadmill."
2939018|NCT02978521|No Intervention|Control Group|CG will receive information and recommendations on physical activity
2939019|NCT02978508|Experimental|Permethrin Cream, 5%|Permethrin Cream 5%, topical cream, 60g, maximum of two doses over 28 day treatment duration.
2939020|NCT02978508|Active Comparator|Elimite|"Elimite™ 60g, topical, marketed by Prestium Pharma, Inc. (Prestium), the branded subsidiary of Renaissance Pharma, maximum of two doses over 28 day treatment duration."
2939021|NCT02978495|Experimental|A- BRCA Mutation|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks."
2939022|NCT02978495|Active Comparator|B- BRCA Mutation|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~Paclitaxel 80 mg/m2 once a week, for 12 weeks."
2939023|NCT02978495|Experimental|C- BRCA wild-type|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks."
2939024|NCT02978495|Active Comparator|D- BRCA wild-type|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~Paclitaxel 80 mg/m2 once a week, for 12 weeks."
2939025|NCT02978482|Experimental|durvalumab|durvalumab alone
2939026|NCT02978482|Experimental|durvalumab+tremelimumab|durvalumab plus tremelimumab
2939027|NCT02978469|Experimental|Life style changing: reducing sedentary behavior|Meetings with social worker and physical therapist.
2939028|NCT02978469|Active Comparator|Physical exercise group|Physical therapy exercise training in group, strengthening and stretching muscles.
2939029|NCT02978456|Experimental|quantitative coronary angiography guided|
2939030|NCT02978456|Active Comparator|Intravascular ultrasound guided|
2939031|NCT02978443||Nivolumab-Ipilimumab Combination Therapy|All patients will receive nivolumab administered IV over 60 minutes at 1 mg/kg combined with ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks until progression, intolerable toxicity, or a maximum of 48 weeks, whichever comes first (Maintenance). Patients exhibiting complete response (CR) should continue nivolumab monotherapy at least 12 weeks beyond documentation of CR, if possible.
2939032|NCT02978430|Active Comparator|Standard of care|This group (started retrospectively before the first included patient of the closed-loop goal-directed fluid therapy group) consists of patients undergoing major abdominal surgery where fluid management is carried out based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output).
2939033|NCT02978430|Active Comparator|Computer-assisted GDFT|"This group consists of patients undergoing major abdominal surgery where fluid management is carried out with a closed-loop (automated) system to deliver fluid by a goal-directed fluid therapy (GDFT) standardized protocol.~Confer: Crystalloids or Colloids for Goal-directed Fluid Therapy With Closed-loop Assistance in Major Surgery (NCT02312999)"
2939034|NCT02978417|Active Comparator|Vivitrol|All drug court clients in the pilot RCT will receive standard psychosocial treatment for opioid dependence from FHR as part of their drug court program participation. Participants randomized to Vivitrol® will receive standard treatment along with monthly Vivitrol® injections administered by study staff at outpatient visits. Vivitrol® is naltrexone for extended-release injectable suspension. It is an injectable suspension containing 380 mg of naltrexone in a microsphere formulation and 4 mL diluent. The recommended dose of Vivitrol® is 380 mg delivered intramuscularly every 4 weeks or once a month. The injection should be administered by a healthcare provider as an intramuscular (IM) gluteal injection, alternating buttocks for each subsequent injection (see Links section of PRS for more information about Vivitrol).
2939035|NCT02978417|Active Comparator|Oral naltrexone|Subjects randomized to oral naltrexone in addition to standard psychosocial treatment for opioid dependence from FHR as part of their drug court program participation. Oral naltrexone is the daily tablet formulation naltrexone that carries the same risks and benefits as the long-acting injectable formulation (Vivitrol®), except it does not have any of the risks related to injection (discomfort, potential for infection). Oral naltrexone is administered and provided by FHR to interested and eligible clients as part of the range of their usual care services.
2939036|NCT02978404|Experimental|Radiosurgery and Nivolumab|"Interventions: Nivolumab (240mg IV q2week) and Radiosurgery (15-20 Gray (Gy) in 1 fraction)~Upon entering this trial, patients with metastatic brain disease(s) will receive Nivolumab (240mg IV q2week). One to 2 week after receiving the first dose of Nivolumab, radiosurgery will be delivered at doses ranging from 15 to 20 Gy in 1 fraction to the brain metastases to a maximum volume of 10 cubic centimeter."
2939037|NCT02978391|Experimental|EWD|Adhesive, synthetic biopolymer powder
2939038|NCT02978391|Active Comparator|epinephrine|Submucosal epinephrine injection
2939081|NCT02978053|Placebo Comparator|Red light|400 lux
2941506|NCT02961387|Sham Comparator|Oxygen-making machine treatment|Inhalation of oxygen.
2939039|NCT02978365|Experimental|Patients|Male patients who undergone shoulder surgery to repair chronic instability (at least 1 shoulder dislocation prior to surgery). Time since surgery will be between 26 and 28 weeks. Patients will go through filling questionnaires and isokinetic strength measurements.
2939040|NCT02978352|Experimental|face-to-face|Traditional learning group (face-to-face): 4 different sessions will be conducted to suit the participants' convenience Duration of each session is 60-90 minutes Each session comprises lecture, video demonstration of CAM-ICU assessment, discussion, volunteer participation during class demonstration
2939041|NCT02978352|Experimental|E-learning|60-90 minute online course will be accessible through intranet Wi-Fi The course encompasses types, incidence, risk factors, significance and effects of delirium, diagnostic criteria and CAM-ICU application Inclusion of video demonstration of simulated patients and CAM-ICU application, common pitfalls of healthcare providers, and practice questions
2939042|NCT02978339|Experimental|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
2939043|NCT02978326|Experimental|SAGE-217 dosing|SAGE-217
2939044|NCT02978326|Placebo Comparator|Placebo|Placebo
2939045|NCT02978313|Experimental|Cet maintenance|Cetuximab maintenance treatment following induction treatment
2939046|NCT02978313|Active Comparator|Cet+chemo continuation|Cetuximab plus continuation mFOLFOX6/FOLFIRI regimens
2939047|NCT02978300|Active Comparator|NIV/HFNC group|Continuous NIV for at least 4 hours until clinical improvement then intermittent 1-hour sessions for a minimal duration of 12 hours a day. Between NIV sessions HFNC will be delivered as in the HFNC group.
2939048|NCT02978300|Experimental|HFNC group|Continuous HFNC alone 24h/24 until weaning or intubation.
2939049|NCT02978287|No Intervention|BAVU Solution 0. hour (control)|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 0. hour
2939050|NCT02978287|Experimental|BAVU Solution 6. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 6. hour
2939051|NCT02978287|Experimental|BAVU Solution 12. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 12. hour
2939052|NCT02978287|Experimental|BAVU Solution 18. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 18. hour
2939053|NCT02978287|Experimental|BAVU Solution 24. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 24. hour
2939054|NCT02978274||MMF withdrawal by engraftment post haplo-SCT|
2939055|NCT02978274||MMF withdrawal by 2 month post haplo-SCT|
2939056|NCT02978261|Experimental|PLB1001|There are 4 dose cohorts, including 50mg BID,100mg BID, 200mg BID and 300mg BID in the dose escalation stage and PLB1001 will be administered orally to patients twice daily for each dose cohort.
2939057|NCT02978235|Experimental|TAS4464|
2939058|NCT02978222|Experimental|FRα peptide plus adjuvant (GM-CSF)|FRα peptide vaccine with GM-CSF adjuvant ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years
2939059|NCT02978222|Placebo Comparator|Adjuvant (GM-CSF) Alone|GM-CSF adjuvant alone ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years
2939060|NCT02978209|Active Comparator|5 and 7.5 %|20-30 patients with Ichthyosis Vulgaris at age 0-80 years old.
2939061|NCT02978209|Active Comparator|5 and 10 %|20-30 patients with Ichthyosis Vulgaris at age 0-80 years old.
2939062|NCT02978209|Active Comparator|7.5 and 10 %|20-30 patients with Ichthyosis Vulgaris at age 0-80 years old.
2939063|NCT02978196|Active Comparator|PD-L1 Positive|Patients tested positive for PD-L1 expression (>1%)
2939064|NCT02978196|Sham Comparator|PD-L1 Negative|Patients tested negative for PD-L1 expression (<1%)
2939065|NCT02978183|Active Comparator|Group 1|1X ST266 dosed 4 times a day for 8 days
2939066|NCT02978183|Placebo Comparator|Group 2|Placebo dosed 4 times a day for 8 days
2939067|NCT02978170|Experimental|Cone Beam Computed Tomography (CBCT)|During standard of care bronchoscopy, Cone Beam Computed Tomography (CBCT) used to ensure the biopsy instruments are in the proper location.
2939068|NCT02978157|Active Comparator|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.
2939069|NCT02978157|Experimental|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
2939070|NCT02978144|Other|Healthy volunteers|Healthy controls who never smoked (less than 100 lifetime cigarettes) with normal spirometry will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
2939071|NCT02978144|Other|Current smokers|Healthy controls who are currently smoking (> 10 pack years) with normal spirometry will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
2939072|NCT02978144|Other|Patients with moderate COPD|Patients with moderate COPD will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
2939073|NCT02978144|Other|Patients with severe COPD|Patients with severe COPD will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
2939074|NCT02978131||Patients with a clinical diagnosis of TB|Patients with a clinical diagnosis of TB. Retrospective study on biopsy samples
2939075|NCT02978118||Group A|Subjects in Group A (patients with metastatic renal cell carcinoma starting immune therapy) will have PBMC, plasma storage and analysis for immune cell profiles at baseline, 4 weeks, 12 weeks, and upon disease progression on treatment. Patients will have CTC assessment at baseline, 4 weeks, and upon disease progression.
2939076|NCT02978118||Group B|Subjects in Group B (patients with metastatic urothelial carcinoma) will have PBMC and plasma storage and analysis for immune cell profiles at baseline, 4 weeks, 12 weeks, and upon disease progression on treatment. Patients will have CTC assessment at baseline, 4 weeks, and disease progression.
2939077|NCT02978105|Experimental|Experimental|self-conditioning techniques plus standard care
2939078|NCT02978105|Active Comparator|Control|Standard care: dietary recommendations, exercise recommendations, and behavioral recommendations
2939079|NCT02978079|Experimental|Pupillometry in stroke patients|All eligible patients will undergo pupillometry test for the finding of Horner's syndrome
2939080|NCT02978053|Experimental|Bright light|10 000 lux
2939082|NCT02978040|Experimental|Cangrelor|Cangrelor bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI).
2939083|NCT02978040|Active Comparator|Tirofiban|Tirofiban bolus of 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance < 60 ml/min).
2939084|NCT02978040|Active Comparator|Prasugrel|Prasugrel oral integer or chewed at an identical loading dose of 60 mg
2939085|NCT02978027|Active Comparator|Brief Advice|The brief advice protocol was designed by removing MI-consistent elements from the NIAAA Clinician's Guide. The protocol involves screening and assessment using the NIAAA pre-screen and single-question screen and assessing for quantity and frequency. Patients exceeding recommended limits receive feedback, information, and advice to cut down drinking to recommended levels. All patients are provided with a tip sheet on strategies for cutting down and encouraged to follow-up with a behavioral health provider with any questions or concerns.
2939086|NCT02978027|Active Comparator|NIAAA Clinician's Guide|"The NIAAA brief intervention was adapted directly from the NIAAA publication Helping Patients Who Drink Too Much: A Clinician's Guide. The protocol screens using the NIAAA pre-screen and single-questions. Patients exceeding recommended limits receive feedback, information, and advice to cut down. For patients unwilling to make a change, the clinician restates their concern, encourages self reflection by asking the patient about reasons to cut down on drinking and barriers to change, and reaffirms willingness to help. For patients willing to make a change, the clinician helps the patient develop a plan to cut down within maximum limits, agree on specific steps and strategies, and provides a tip sheet on strategies for cutting down."
2939087|NCT02978027|Experimental|Motivational Interviewing (MI)|The MI intervention condition was also adapted from the NIAAA Clinician's Guide, with additional modification to include elements of MI. Clinicians normalize Screening and Brief Intervention (SBI) and ask the patient's permission before discussing alcohol use. The NIAAA pre-screen and single-question screen are administered. Assessment of quantity, frequency, and Alcohol Use Disorder symptoms is done using open questions. The ask-tell-ask technique is used to share feedback and exchange information regarding U.S adult drinking patterns. For patients low in readiness to make a change, clinicians build readiness using structured MI tools. For patients high in readiness to change, the ask-tell-ask technique is used to explore strategies for cutting down and develop an action plan.
2939088|NCT02978014|Experimental|ProSpare Arm|ProSpare (obturator) image guided IMRT (i.e. radiotherapy administered to patients with the ProSpare device inserted in the rectum)
2939089|NCT02978014|No Intervention|Non-ProSpare Arm|Standard of Care (non-obturator) image guided IMRT (i.e. radiotherapy administered to patients without the ProSpare device inserted in the rectum)
2939090|NCT02978001||Patients with Psoriasis|Patients with moderate to severe psoriasis (PASI>8)
2939091|NCT02978001||Healthy Control Subjects|Healthy subjects matching the patients with psoriasis regarding age, gender and BMI
2939092|NCT02977988|Experimental|Mindfulness Meditation|Mindfulness-Based Relapse Prevention-Women (MBRP-W)
2939093|NCT02977988|Active Comparator|Active Comparator|Brain and Recovery (B&R)
2939094|NCT02977975|Experimental|Raw sauerkraut|75 grams of raw, traditionally produced, lacto-fermented sauerkraut, each day for 6 weeks.
2939095|NCT02977975|Other|Pasteurized sauerkraut|75 grams of pasteurized sauerkraut, each day for 6 weeks.
2939096|NCT02977962|Experimental|Cognitive-Behavior Therapy|This consists of 16 weekly sessions up to 90 minutes each that helps the participant learn to cope with anxiety by facing fears, thinking more logically, and calming oneself.
2939097|NCT02977962|Placebo Comparator|Treatment as Usual|Participants randomized to this condition will wait for a period of 16 weeks before receiving treatment in the context of the study. During this time, youth may receive psychotherapy and/or initiate or change current psychiatric medication (if applicable).
2939098|NCT02977923|Active Comparator|Standard pharmacological treatment|
2939099|NCT02977923|Experimental|VR distraction via Oculus Rift|
2939100|NCT02977910|Experimental|with repair of deltoid ligament|open reduction and internal fixation with repair of deltoid ligament
2939101|NCT02977910|No Intervention|without repair of deltoid ligament|open reduction and internal fixation without repair of deltoid ligament
2939102|NCT02977897||Diarrhea on MMF|Solid organ transplant recipients on MMF who develop diarrhea while taking the drug. Fecal calprotectin will be measured in their stool and Octreotide Acetate will be used to treat their diarrhea.
2939103|NCT02977884|Experimental|The Complete Health Improvement Program|Participants in The Complete Health Improvement Program
2939104|NCT02977871|No Intervention|No Bladder Flap group|Routine uterine incision performed during cesarean section without incision and dissection of the bladder peritoneum.
2939105|NCT02977871|Active Comparator|Bladder Flap group|Routine uterine incision performed during cesarean section with an incision and a dissection of a bladder flap.
2939106|NCT02977858||Dissemination|Educational practice for HCPs,Dissemination only - Practices who will participate in education for constipation management guidelines via dissemination of webinar alone.
2939107|NCT02977858||Dissemination + ISE|Educational practice for HCPs,Spaced Education - Practices who will participate in education for constipation management guidelines via dissemination of webinar along with a web-based format referred to as Interactive Spaced Education.
2939108|NCT02977845|Experimental|Primary aim|The primary aim of this study is to assess the effect of Qigong on managing dyspnea, fatigue, and anxiety (as a cluster) in lung cancer patients.
2939109|NCT02977845|Experimental|Secondary aim|The secondary aim of this study is exploring the effect of Qigong on cough which is another common symptom linked with dyspnea, fatigue, and anxiety as a cluster, and QOL in lung cancer patients.
2939110|NCT02977832|Experimental|odyliresin|Odyliresin (Iresine celosia) 2 ml
2939111|NCT02977832|Experimental|alphalytic|alpha-antagonist (alfuzosin 10 mg)
2939112|NCT02977819|Experimental|Meditation program|Meditation courses and at-home practice
2939113|NCT02977819|Active Comparator|English learning courses|English learning courses and at-home practice
2939114|NCT02977819|No Intervention|No intervention|
2939115|NCT02977793||Non-pathologic young adults|18-28 years old
2939116|NCT02977793||Non-pathologic adults|29-80 years old
2939117|NCT02977793||Pathologic adults|29-80 years old
2941777|NCT02959775|No Intervention|Control|Receive no vaccination during the study period
2939118|NCT02977780|Active Comparator|Temozolomide|"Daily Radiation for a maximum of 49 days.~Temozolomide will be administered orally on a daily dosing schedule~Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy~Temozolomide will also be administered post radiation for up to 6 cycles (5 days/cycle)"
2939119|NCT02977780|Experimental|Abemaciclib with Temozolomide|"Daily Radiation for a maximum of 49 days.~Temozolomide will be administered orally on a daily dosing schedule during radiation~Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy~Abemaciclib will be taken post radiation at a twice daily oral pre-determined dose"
2939120|NCT02977780|Experimental|CC-115|"Twice daily oral dosing of CC-115~Daily Radiation for a maximum of 49 days~CC115 will also be taken twice daily post radiation"
2939121|NCT02977780|Experimental|Neratinib with Temozolomide|"Daily Radiation for a maximum of 49 days.~Temozolomide will be administered orally on a daily dosing schedule~Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy~Neratinib will be taken post radiation at a daily oral pre-determine dose"
2939122|NCT02977767|Experimental|Conversational hypnosis|Use of conversational hypnosis during the tracheal cannula replacement
2939123|NCT02977728||Mild Traumatic Brain Injury|The investigators will include patients who have been diagnosed with a mild traumatic brain injury (Glasgow Coma Scale 13 and above). The patients will be aged between 18 and 55 years old and admitted to the Hospital Visp in the 24 hours preceding the testing.
2939124|NCT02977728||Orthopaedic Injury|The investigators will include patients who have been diagnosed with a traumatic orthopedic injury to one of their limbs. The patients will be aged between 18 and 55 years old and admitted to the Hospital Visp in the 24 hours preceding the testing.
2939125|NCT02977715|Experimental|Intervention|Up to 1000 male and female healthcare personnel ages 18 years and older in Tshuapa Province in The Democratic Republic of Congo at risk for monkeypox will receive two doses of attenuated live virus smallpox vaccine (IMVAMUNE®) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL)
2939126|NCT02977689|Experimental|IDH305|IDH305 550 mg, oral, two times per day
2939127|NCT02977663|Other|Magnetic Resonance Imaging (MRI)|Thoracic Magnetic Resonance Imaging (MRI)
2939128|NCT02977637|Experimental|Feraheme group|All patients enrolled in the study will receive Feraheme MRI/MRA to detect vascular malformations. Ferumoxytol in its standard concentration (510 mg in 17 cc) will be administered IV at 0.15-0.21 mg/kg prior to MRI/MRA.
2939129|NCT02977624|Experimental|Hadassah Medical Organization, Jerusalem, Israel|
2939130|NCT02977611|Experimental|High Dose, Rapid Infusion Iron Sucrose|Patients will receive an infusion of 500 mg of iron sucrose over one hour and will be monitored for four hours.
2939131|NCT02977598||non-diabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
2939132|NCT02977598||prediabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
2939133|NCT02977598||diabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
2939134|NCT02977585|Active Comparator|group 1|high level support
2939135|NCT02977585|No Intervention|group 0|low level support
2939136|NCT02977572|Experimental|Non-Invasive ventilation (NIV group)|For the NIV group, a BiPAP Vision was used, by setting the Inspiratory Positive Airway Pressure (IPAP) at a level that was required to achieve a tidal volume of approximately 8-10 ml/kg. Also an Expiratory Positive Airway Pressure (EPAP) was set at a minimum of 5 cmH20 during the first hour, gradually increasing until there was a clinical improvement. Fraction inspiratory of oxygen (FiO2) was applied to maintain a transcutaneous arterial oxygen saturation (SaO2) of 92%-94%. NIV was continuously applied until there was a clinical and/or a gasometrical improvement, at which time they were replaced by a Venturi mask with FiO2 of 0.4.
2939137|NCT02977572|Placebo Comparator|Continuous Positive AirwayPressure CPAP|The CPAP was applied by using a flow generator with adjustable fractional inspired oxygen (FiO2). This was connected to the Positive End-Expiratory Pressure (PEEP) valve that was placed in the face mask. In the second instance, the CPAP system that was used was a Boussignac CPAP System Flow Jet. The Boussignac valve takes gas from a single source and splits it in order to create four high flow jets. These jets converge in the chamber creating a virtual valve. A initial level of 5cmH20 of PEEP was recommended for the first hour of ventilation, with subsequent increments (up to 15cmH20) until a clinical improvement was obtained. CPAP was continuously applied until there was a clinical and/or a gasometrical improvement, at which time it was replaced by a Venturi mask.
2939138|NCT02977559|Experimental|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable for ventilation
2939139|NCT02977559|Experimental|Laryngeal Mask Airway AuraGain|Laryngeal Mask Airway AuraGain for oxygenation and ventilation
2939140|NCT02977546||Heart Failure|Patients with chronic heart failure NYHA >= 2 based on a reduced left ventricular ejection fraction (LV-EF <= 45%). All patients receive pulmonary artery catheterization and noninvasive pulse contour Analysis.
2939141|NCT02977533|Experimental|GZ402668|Dose 1 (up to a maximum optional Dose 2) will be given as a single subcutaneous administration under fed conditions. Acyclovir will be given twice daily starting on Day 1 and continuing for 28 days after investigational medicinal product administration.
2939142|NCT02977533|Placebo Comparator|Placebo|A dose of matching placebo will be given as a single subcutaneous administration under fed conditions. Acyclovir will be given twice daily starting on Day 1 and continuing for 28 days after investigational medicinal product administration.
2939143|NCT02977520|Experimental|Interventional group|Obtain the CTA data of cerebral aneurysms and built the 3D printing models. Combined with the 3D model, the neurosurgeon can complete the discussion of preoperative prediction of aneurysms and recognize the adjacent bone, blood vessels, aneurysm directions and so on. In addition, the model can also be used to the young doctor's training, and the patient and their families can be convenient and intuitive understanding of the disease, so as to form a good communication between doctors and patients.
2939144|NCT02977520|No Intervention|general group|Obtain the CTA data of cerebral aneurysms, the neurosurgeon complete the discussion of preoperative prediction of aneurysms.
2939145|NCT02977507|Active Comparator|Lytera 2.0|Lytera 2.0 applied to the affected areas (dark patches) on one side of the face while 4% hydroquinone topical prescription cream applied to the affected areas on the other side. The test products will be applied twice a day, morning and evening, everyday for 12 weeks.
2939146|NCT02977507|Active Comparator|4% Hydroquinone Topical Cream|4% hydroquinone topical prescription cream applied to the affected areas (dark patches) on one side of the face while Lytera 2.0 applied to the affected areas on the other side. The test products will be applied twice a day, morning and evening, everyday for 12 weeks.
2939147|NCT02977494|Experimental|Daratumumab Bortezomib|
2939148|NCT02977468|Experimental|Single Arm open label|"Participants receive 'Merck 3475 Pembrolizumab' by vein two weeks before Intraoperative radiation therapy (IORT).~The Intrabeam® Photon Radiosurgery System is a miniature electron beam-driven X-ray source which provides a point source of low energy X-rays (50 kV maximum) at the tip of a 3.2 mm diameter tube. The radiation source can be inserted into the area of interest immediately after excision of the tumor and switched on for 20-35 minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and early clinical applications of this device have been well studied and this is the device which was utilized in the international TARGIT trial."
2939149|NCT02977442|Experimental|exercise|12 week exercise program, 5 days/week, 60 min/day
2939150|NCT02977442|No Intervention|standard of care|12 week standard of care recommendations
2939151|NCT02977429|Active Comparator|standard group|"The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.than collect the data of ScvO2 and Pcv-aCO2:~ScvO2≥70%，and furthermore, Pcv-aCO2 is divided into ≤6mmHg and >6mmHg"
2939152|NCT02977429|Sham Comparator|control group|"The patients with ScvO2 <70% will receive the standardized fluid therapy for 6 hours.than collect the data of ScvO2 and Pcv-aCO2:~ScvO2＜70%，and furthermore, Pcv-aCO2 is divided into ≤6mmHg and >6mmHg"
2939153|NCT02977416|Experimental|patients treated withTNF blockade|22 patients treated with TNF blockade
2939154|NCT02977416|Experimental|patients without TNF blockade|22 patients without TNF blockade
2939155|NCT02977416|Experimental|healthy subjects|22 matched healthy subjects by pubertal stage and sex
2939156|NCT02977403|Experimental|AB Retraining|Active treatment - the probe always replaces the neutral picture. There is a perfect correlation between picture type and probe location.
2939157|NCT02977403|Sham Comparator|AB Control|Control condition - the probe is equally likely to replace the food picture and the neutral picture. There is no correlation between picture type and probe location, and no training of attention should occur.
2939158|NCT02977403|Other|Booster Training other|3 months after the randomized program is completed, each subject can elect to use open-label attention bias retraining for 2 weeks
2939159|NCT02977403|Active Comparator|Booster Training|3 months after the randomized program is completed, each subject can elect to use open-label attention bias retraining for 2 weeks
2939160|NCT02977390|Other|Passive Leg Raise (PLR)|"The patient is placed in a 45 degree recumbent position. Stroke volume is measured in ml.~Intervention:The patient is placed horizontal and the legs are passively raised to 45 degrees.~Measurement:The effect of the PLR on Stroke Volume is measured. Thereafter the patient is repositioned to the initial position and Stroke Volume is measured again."
2939161|NCT02977377|Active Comparator|Whole body vibration/ Exercise|Exercise therapy and whole body vibration will be applied together for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. Whole body vibration (20-30 Hz, minimum amplitude) will be applied to cases in the form of 4 sets (1 min application and 1min rest) before exercises. After 1 week washout period, exercise program will apply for 8 weeks.
2939162|NCT02977377|Active Comparator|Exercise/ Whole body vibration|Exercise therapy will be applied for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. After 1 week washout period exercise therapy and whole body vibration will be applied together for 8 weeks.
2939163|NCT02977364|Experimental|HS-10241 100mg|HS-10241 100mg daily
2939164|NCT02977364|Experimental|HS-10241 200mg|HS-10241 200mg daily
2939165|NCT02977364|Experimental|HS-10241 400mg|HS-10241 400mg daily
2939166|NCT02977364|Experimental|HS-10241 600mg|HS-10241 600mg daily
2939167|NCT02977364|Experimental|HS-10241 800mg|HS-10241 800mg daily
2939168|NCT02977364|Experimental|HS-10241 1000mg|HS-10241 1000mg daily
2939169|NCT02977351|Experimental|Atherosclerosis|Patients with atherosclerosis and chronic periodontitis
2939170|NCT02977351|Active Comparator|Systemically healthy|Patients with Systemically healthy and chronic periodontitis.
2939171|NCT02977325||Physical activity|One group participated in therapeutic programs centered on the physical activity
2939172|NCT02977325||water cure exclusively|This group followed exclusively the water cure
2939173|NCT02977299|Experimental|Aripiprazole Augmentation|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics at their current dose throughout the 8-week trial and initiate adjunctive aripiprazole. The starting dose will be 5mg daily. The dose may be reduced to as low as 2mg for tolerability issues (this will be the lowest dose permitted for continuation in the trial). The dose may be adjusted in 2 or 5mg increments. The minimum time per increment will be 7 days. The maximum dose will be set at 15mg daily. For patients who are not on potent cytochrome 2D6 inhibitors (such as paroxetine, fluoxetine, duloxetine) or on potent cytochrome 3A4 inhibitors (such as fluvoxamine and nefazodone) and who are able to tolerate 15mg daily, the maximum dose can be raised to 20mg daily for efficacy.
2939174|NCT02977299|Experimental|rTMS Augmentation|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics at their current dose throughout the 8-week trial. We will use clinical TMS stimulators with focal figure-of-eight coils. We will start by measuring the patient´s motor threshold (MT), which is a measure of cortical excitability used to standardize the intensity of stimulation across subjects.
2939226|NCT02976974|Experimental|Manual therapy (MT)|MT: Manual Therapy. Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
2939256|NCT02976714|Other|CF patients|CF patients carry a spontaneous sputum that is made in the context of bronchial drainage sessions conducted as part of usual care.
2942054|NCT02957929|Experimental|Cohort 1a, Period C|single oral dose
2939175|NCT02977299|Experimental|Switching To Venlafaxine XR|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics throughout the 8-week trial, except for their antidepressant(s). They will be instructed to discontinue all antidepressants and initiate venlafaxine that day, as direct switch to serotonergic antidepressants is well tolerated and avoids loss of precious therapeutic time (Montgomery et al., 2014), including to switching to venlafaxine in STAR*D (Rush et al., 2006b). For patients who do not prefer a direct switch, or when clinically indicated otherwise in the opinion of the site investigator, a gradual tapering during the screening period will be permitted as long as a direct switch to venlafaxine is made on the baseline visit from the final antidepressant dose. The starting dose of venlafaxine will be 75mg daily. The dose may be reduced to as low as 37.5mg for tolerability issues (this will be the lowest dose permitted for continuation in the trial).
2939176|NCT02977286|Experimental|Naloxegol Oral Tablet|"Intervention: Naloxegol 25 mg (or 12.5 mg) tablet po (enteral) daily AND Docusate Sodium 100mg Oral Capsule twice daily AND Study laxative protocol daily [that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)] until one of the following:~Adverse event potentially attributable to the study drug.~Use of Relistor.~Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.~The participant has been administered 10 days of study medication.~The participant is discharged from the ICU.~The participant requires the initiation of a strong CYP3A4 inhibitor medication.~Other Name: Movantik"
2939177|NCT02977286|Placebo Comparator|Placebo Oral Tablet|"Intervention: Placebo tablet po (enteral) daily AND Docusate Sodium 100 mg Oral Capsule twice daily AND Study laxative protocol daily [that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)] until one of the following:~Adverse event potentially attributable to the study drug.~Use of Relistor.~Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.~The participant has been administered 10 days of study medication.~The participant is discharged from the ICU.~The participant requires the initiation of a strong CYP3A4 inhibitor medication.~Other Name: AstraZeneca provided Movantik placebo"
2939178|NCT02977273|Experimental|Test Meal 1|Thin/100% portion
2939179|NCT02977273|Experimental|Test Meal 2|Thin/150% portion
2939180|NCT02977273|Experimental|Test Meal 3|Thick/100% Portion
2939181|NCT02977273|Experimental|Test Meal 4|Thick/150% Portion
2939182|NCT02977260|Experimental|Test Meal 1|Thin/Low Energy
2939183|NCT02977260|Experimental|Test Meal 2|Thin/High Energy
2939184|NCT02977260|Experimental|Test Meal 3|Thick/Low Energy
2939185|NCT02977260|Experimental|Test Meal 4|Thick/High Energy
2939186|NCT02977247||Women undergoing routine diagnostic breast evaluation|Non-Interventional: Women presenting to enrollment sites for diagnostic examinations of symptoms or imaging findings, as recommended by a physician, and assigned BI-RADS category 4 or 5 (biopsy indicated).
2939187|NCT02977234|Experimental|Iso-Amyl 2-Cyano Acrylate|Hysteroscopic Tubal Occlusion Using Iso-Amyl 2-Cyano Acrylate (Amcrylate) in Patients With Hydrosalpinx
2939188|NCT02977221|Experimental|Piezosurgery|Piezosurgery will be performed on the anterior lower segment of the dental arch in order to accelerate the correction of mandibular anterior crowding.
2939189|NCT02977221|No Intervention|Ordinary Alignment|Treatment will be provided to the patients without any surgical interventions.
2939190|NCT02977208|Active Comparator|Homozygous for the wild type allele|"Patients with 18 years old or older with epilepsy, neuropathic pain or any chronic pain undergoing chronic treatment with gabapentin are being recruited.~Sparse blood sampling are being collected up to 4 h after administration of the drug for pharmacokinetic study. Urine sampling are being collected during the dosing interval, only in patients hospitalized at the Hospital Estadual de Américo Brasiliense (HEAB). Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms."
2939191|NCT02977208|Active Comparator|Homo- or heterozygous for rare alleles|"Patients with 18 years old or older with epilepsy, neuropathic pain or any chronic pain undergoing chronic treatment with gabapentin are being recruited.~Sparse blood sampling are being collected up to 4 h after administration of the drug for pharmacokinetic study. Urine sampling are being collected during the dosing interval, only in patients hospitalized at the Hospital Estadual de Américo Brasiliense (HEAB). Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms."
2939192|NCT02977195|Experimental|NP137|Therapeutic Class Recombinant humanized IgG1 monoclonal antibody against Netrin 1, Administered. Route of Administration is intravenous infusion over 90 min, given every 2 weeks. Seven dose-levels possible in dose escalation part: 1 mg/kg, 2 mg/kg, 4 mg/kg, 6 mg/kg, 9 mg/kg, 14 mg/kg and 20 mg/kg.
2939193|NCT02977182|No Intervention|Control Group|The control group will receive standard speech therapy treatments but not lymphedema treatment and will serve as the baseline for comparison for assessment of the effects of CDT.
2939194|NCT02977182|Experimental|Active Treatment Group|The active treatment group will receive standard speech therapy treatments in addition to complete decongestive therapy from a certified Speech Language Pathologist (CCC-SLP) trained in CDT.
2939195|NCT02977169|Experimental|Arm I (PORT)|Participants in the Arm I will receive four cycles of adjuvant chemotherapy and after that, sequential adjuvant thoracic conformal radiotherapy (50.4 Gy, 1.8 Gy once daily over 5.5 weeks) will be administered. PORT begins within 2-4 weeks after chemotherapy.
2939196|NCT02977169|Placebo Comparator|Arm II (no PORT)|Participants in the Arm II will receive four cycles of adjuvant chemotherapy and after that, do not undergo adjuvant thoracic conformal radiotherapy.
2939227|NCT02976974|Experimental|Therapeutic exercise (E)|"E: Therapeutic Exercise.~Shoulder extension: Elastic bands. Shoulder flexion: Elastic bands Shoulder external rotation: Elastic bands. Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.~Thoracic column movements: Flexion-extension"
2939228|NCT02976961|Experimental|Intervention|Implantable cardioverter defibrillator implant + usual care + supportive care given via an e-health platform. The supportive care consists of information, dialogue with a nurse or psychologist, CBT-based psychological intervention online, quizzes to increase knowledge
2939197|NCT02977156|Experimental|Combination PexaVec + Ipilimumab|"PEXA-VEC (Pexastimogene devacirepvec): Oncolytic live replicating virus, Recombinant vaccinia virus GM-GCF of Classe 1, administered by Intra-tumoral injection with fixed-dosage regimen of 1x109 pfu (9.0 Log pfu)/ injection. Up to 5 IT injections, at Week 1 Day 1, Week 3 Day 1, Week 5 Day 1 and Week 9 Day 1, and one additional IT treatment allowed in case of disease progression following a documented objective response at W12. Provided by Transgene.~IPILIMUMAB: Anti-CTLA-4 monoclonal antibody (IgG1k) produced in CHO cells by recombinant DNA technology, administered by Intra-tumoral injection. Up to 4 IT injections at Week 3 Day 1, Week 5 Day 1 and Week 9 Day 1, and one additional IT treatment allowed In case of disease progression following a documented objective response at W12. Four dose levels of ipilimumab will be tested in dose escalation step: 2.5mg, 5mg, 7.5mg, 10mg."
2939198|NCT02977143|Experimental|Fluid responsiveness test|"First, apply 10 cmH2O positive endexpiratory pressure (PEEP) and measure the increase in central venous pressure (CVP) as well as other preload indexes (central venous pressure, mean arterial pressure, stroke volume variation).~Second, measure the increase in cardiac index after administration of volulyte 300 ml.~If cardiac index increase more than 10%, fluid responsiveness is confirmed."
2939199|NCT02977130|Experimental|Map group|patients receiving general shared care for diabetes and the conversation map intervention
2939200|NCT02977130|Active Comparator|Control group|patients receiving general shared care for diabetes
2939201|NCT02977117|Experimental|Dialysate magnesium 1.0 mmol/L|Increase dialysate magnesium from 0.5 mmol/L to 1.0 mmol/L.
2939202|NCT02977117|Active Comparator|Dialysate magnesium 0.5 mmol/L|Maintain dialysate magnesium at 0.5 mmol/L.
2939203|NCT02977104|Other|Patients in afib or flutter|Maestro ECG
2939204|NCT02977104|Other|Patients in sinus rhythm|Maestro ECG
2939205|NCT02977091||GH deficiency or idiopathic short stature|growth hormone (GH) deficiency or idiopathic short stature children before they start GH treatment
2939206|NCT02977091||short stature|healthy short children
2939207|NCT02977078|Sham Comparator|Control|Inhaler use monitored by device but no feedback to participants (control); this group is unaware of the second arm receiving feedback on inhaler use.
2939208|NCT02977078|Experimental|Active|Inhaler use monitored with feedback to participants (active); participants randomized to this group sign an additional consent to receive feedback on inhaler use
2939209|NCT02977065|Active Comparator|Atorvastatin 20 mg|To administrate Atorvastatin 20 mg and 4 Placebos, PO, QD for 4weeks
2939210|NCT02977065|Experimental|Atorvastatin 20 mg + CKD-519 50 mg|To administrate Atorvastatin 20 mg, CKD-519 50 mg and 3 Placebos, PO, QD for 4weeks
2939211|NCT02977065|Experimental|Atorvastatin 20 mg + CKD-519 100 mg|To administrate Atorvastatin 20 mg, CKD-519 100 mg and 3 Placebos, PO, QD for 4weeks
2939212|NCT02977065|Experimental|Atorvastatin 20 mg + CKD-519 200 mg|To administrate Atorvastatin 20 mg, CKD-519 200 mg and 2 Placebos, PO, QD for 4weeks
2939213|NCT02977065|Active Comparator|Rosuvastatin 10 mg|To administrate Rosuvastatin 10 mg and 4 Placebos, PO, QD for 4weeks
2939214|NCT02977065|Experimental|Rosuvastatin 10 mg + CKD-519 100 mg|To administrate Rosuvastatin 10 mg, CKD-519 100 mg and 3 Placebos, PO, QD for 4weeks
2939215|NCT02977052|Experimental|Arm A: 2 courses ipi 3 + nivo 1|Patients receive 2 courses standard combination of ipilimumab 3 mg/kg + nivolumab 1 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
2939216|NCT02977052|Experimental|Arm B: 2 courses ipi 1 + nivo 3|Patients receive 2 courses ipilimumab 1 mg/kg + nivolumab 3 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
2939217|NCT02977052|Experimental|Arm C: 2 courses ipi 3 + 2 courses nivo 3|Patients receive 2 courses of ipilimumab 3 mg/kg q3wks, directly followed (> 2 hours and < 24 hours) by 2 courses nivolumab 3 mg/kg every 2 weeks prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
2939218|NCT02977039|Experimental|NDPR diet|Subjects randomized to the nutrient dense plant rich (NDPR) diet will eat foods with high micronutrient density, and favorable glycemic index. The diet is low in saturated fat, high in fiber, and rich in phytochemicals. Total caloric intake will range from 1600-2000/day based on individual needs. Foods include vegetables (30-70% of calories), fruits (15-20% of calories), Beans/Legumes (20-30% of calories), raw nuts and seeds (10-20% of calories), fish or fat-free dairy (twice weekly or less), poultry, eggs and oils (once weekly or less) and limited beef, cheese/milk, processed food and beef.
2939219|NCT02977039|Experimental|USDA diet|Subjects randomized to the healthy U.S.-Style pattern diet will eat the types and proportions of foods Americans typically consume, but in nutrient-dense forms and appropriate amounts. It is designed to meet nutrient needs while not exceeding calorie requirements and while staying within limits for overconsumed dietary components. Total caloric intake will range from 1600-2000/day based on individual needs. Foods include fruits, vegetables (dark green, red/orange, beans, and peas, starchy vegetables), grains (whole grains and refined grains), protein foods (meat, poultry, eggs, seafood, nuts, seeds and soy products), dairy, and oils.
2939220|NCT02977026|No Intervention|Control|A questionnaire that asks individuals what components of an online intervention they might find useful.
2939221|NCT02977026|Experimental|Check Your Drinking (CYD)|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to provide personalized normative feedback aimed at motivating reductions in drinking"
2939222|NCT02977026|Experimental|Alcohol Help Centre (AHC)|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding drinking."
2939223|NCT02977013||Patients with pulmonary embolism treated with enoxaparin|Anti-Xa assay correlation to the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
2939224|NCT02977000|Experimental|Propranolol|Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h. investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.
2939225|NCT02976987|Experimental|Cidofovir|Women receiving an aqueous gel containing 2% (w/w) cidofovir, administrated directly on cervix exhibiting high grade squamous intraepithelial lesion (CIN 2 and 3).
2939229|NCT02976961|No Intervention|Usual care|Implantable cardioverter defibrillator implant + usual care
2939321|NCT02976246|Placebo Comparator|RenaKvit-bone control|One tablet of non-active drug given once daily
2939230|NCT02976935||Healthy Volunteers|Subjects will receive 1L non-hyperpolarised 129Xenon to inhale. Then:Subjects will inhale the first hyperpolarised 129Xenon calibration dose (up to 1L, which may be a mix of hyperpolarised 129Xenon and N2) and hold their breath while the MRI scan is performed. Then:A further series of inhalations will be performed up to a maximum of 3 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L). Optional Study Visit #2:Identical to Study Visit 1 but with the further series of inhalations being up to a maximum of 4 (maximum total exposure to hyperpolarised 129Xenon will be 5L).Optional Study Visit #3: Identical to Study Visit 2 (maximum total exposure to hyperpolarised 129Xenon will be 5L)
2939231|NCT02976935||Chronic Obstructive Pulmonary Disease|Subjects will receive 1L bag of non-hyperpolarised 129Xenon to inhale. Then:Subjects will inhale the first hyperpolarised 129Xenon calibration dose (up to 1L, which may be a mix of hyperpolarised 129Xenon and N2) and hold their breath for required time while the MRI scan is performed.Then:A further series of inhalations will be performed up to a maximum of 3 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L). Optional Study Visit #2: Identical to Study Visit 1 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L)
2939232|NCT02976935||Idiopathic Pulmonary Fibrosis|Subjects will receive 1L bag of non-hyperpolarised 129Xenon to inhale. Then:Subjects will inhale the first hyperpolarised 129Xenon calibration dose (up to 1L, which may be a mix of hyperpolarised 129Xenon and N2) and hold their breath for required time while the MRI scan is performed.Then:A further series of inhalations will be performed up to a maximum of 3 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L). Optional Study Visit #2: Identical to Study Visit 1 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L)
2939233|NCT02976922|Active Comparator|Probiotic lozenge|Probiotic lozenge, one lozenge twice daily for 3 months. The lozenge contains Lactobacilli Reuteri (100 billions colony forming units (CFU)/tablet)
2939234|NCT02976922|Placebo Comparator|Placebo|Placebo lozenge, one lozenge twice daily for 3 months
2939235|NCT02976909|Experimental|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
2939236|NCT02976896|Experimental|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
2939237|NCT02976883|Experimental|[18F]HX4 diagnostic PET/CT scan|[18F]HX4 (370 MBq) will be administered by a single intravenous injection, after which patients will be required to wait for ≤4.0 h and undergo a PET/CT scan.
2939238|NCT02976870|Experimental|Ultrasound|Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
2939239|NCT02976857|Experimental|C-CAR011|C-CAR011 infusion In the first cell therapy 0, 1 and 2 days, respectively 10%, 30% and 60% ratio three times reinfusion.
2939240|NCT02976844||Low PEEP group|The positive end-expiratory pressure was less than 10cmH2O
2939241|NCT02976844||High PEEP group|The positive end-expiratory pressure was higher or equal to 10cmH2O.
2939242|NCT02976831|Experimental|AZD0284|"Part 1A:~Following an overnight fast of at least 10 hours, each subject will receive a single dose of AZD0284 or matching placebo in the form of an oral solution with water. The total volume that the subject will receive (IMP and water) will be 240 mL.~Part 1B (food cohort):~Subjects, will receive a single dose of AZD0284 at a dose level in the range of or slightly above the dose level anticipated to yield therapeutic exposure, currently predicted to be achieved with 28 mg AZD0284 at twice daily dosing. The total volume that the subject will receive (IMP and water) will be 240 mL.~Part 2:~In Part 2, subjects will receive 1 dose level of AZD0284 (once or twice daily) with water from Day 1 to between (including) Day 7 and Day 14. The total volume that the subject will receive (IMP with water) will be 240 mL. Subjects may be dosed in either the fasted or fed state depending on emerging data from Part 1."
2939243|NCT02976831|Active Comparator|Placebo|"Part 1A: Following an overnight fast of at least 10 hours, each subject will receive a single dose of placebo in the form of an oral solution with water. The first cohort will receive 4.0 mg AZD0284 or placebo on Day 1. The actual dose for subsequent cohorts will be determined after review of all available safety or other pertinent data from the previous dose by the SRC Part 1B (food cohort): In Part 1B, subjects, will receive a single dose of placebo at a dose level in the range of or slightly above the dose level anticipated to yield therapeutic exposure, currently predicted to be achieved with 28 mg AZD0284 at twice daily dosing.~Part 2: In Part 2, each subject will receive 1 dose level of placebo (once or twice daily) with water from Day 1 to between (including) Day 7 and Day 14. The total volume that the subject will receive (placebo with water) will be 240 mL. Subjects may be dosed in either the fasted or fed state depending on emerging data from Part 1."
2939244|NCT02976805|Experimental|Regimen A|4L PegLyte + 15 mg bisacodyl
2939245|NCT02976805|Experimental|Regimen B|6L PegLyte + 15 mg bisacodyl
2939246|NCT02976792||Renal Resistive Index/NephroCheck™test|Patients undergoing a transcatheter aortic valve implantation
2939247|NCT02976779|Experimental|OWC MGC cream|Cannabis based topical cream 3% CBD and 3% THC. The cream was designed to treat Psoriasis . The cream will be applied twice daily.
2939248|NCT02976779|Placebo Comparator|OWC Control Cream|Carrier cream. CBD and THC were taken out from the formulation. The cream will be applied twice daily.
2939249|NCT02976766|Experimental|Gypenosides|
2939250|NCT02976766|Placebo Comparator|Placebo|
2939251|NCT02976753||Elocta|Elocta will be prescribed and administered for prophylactic treatment of patients with haemophilia A according to usual clinical practice
2939252|NCT02976753||Conventional factor VIII product|Conventional factor VIII products will be prescribed and administered for prophylactic treatment of patients with haemophilia A according to usual clinical practice
2939253|NCT02976740|Experimental|SBRT+GM-CSF+Tα1|Metastasis lesion will be treated with a SBRT of 50Gy/4-10F from day 1 to day 10 . Subcutaneous injection of Immunological Agent- human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle. Subcutaneous injection of another Immunological Factors Thymosin Alpha 1(1.6mg Biw)will be executed from the fist WEEK to the 12th Weeks.
2939254|NCT02976727|Experimental|GroupA (Vit-D pretreated AFL-PDT group )|Group A was treated with topical VitD-assisted AFL-PDT
2939255|NCT02976727|Active Comparator|GroupB (Conventional AFL PDT group )|Group B was treated with conventional AFL-PDT
2939257|NCT02976701|Experimental|DLBS1033|DLBS1033 enteric-coated tablet is administered at the dose of 490 mg, one tablet three times daily, everyday for four weeks of study period
2939258|NCT02976701|Placebo Comparator|Placebo|Placebo is administered one tablet three times daily, everyday for four weeks of study period
2939259|NCT02976688|Experimental|Sodium propionate|Sodium propionate will be administered with a daily intake of 2 x 500 mg in form of capsules for 12 weeks.
2939260|NCT02976675|Experimental|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
2939261|NCT02976675|Experimental|PEG-somatropin per two weeks|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
2939262|NCT02976675|Active Comparator|Jintropin AQ|Jintropin AQ, injection, 30IU/10 mg/3ml/cartridge, 0.25mg/kg/w, once per day for 26 weeks
2939263|NCT02976662|Experimental|Artificial shrinkage|Elimination of blastocoelic fluid by creating a large hole in the zona pellucida at the cellular junction of the trophectoderm cells located far away from the inner cell mass with a laser pulse before vitrification.
2939264|NCT02976662|No Intervention|Without Artificial shrinkage|Vitrify expanded blastocysts.
2939265|NCT02976636|Active Comparator|Family-based behavioral therapy (FBT)|Family-based behavioral therapy for pediatric weight loss
2939266|NCT02976636|Experimental|Parenting training and FBT|Family-based behavioral therapy for pediatric weight loss + parenting training to enhance outcomes
2939267|NCT02976623|Other|feedback group|"this group will receive the intervention metric-based feedback training on their performance. this will be based on validated metrics and errors, a trained investigator will deliver this feedback. It will be accompanied by deliberate practice"
2939268|NCT02976623|No Intervention|control group|"this control group will receive a standard type feedback on their performance no intervention. It will be delivered by a consultant anaesthetist who will be instructed to deliver feedback as they ordinarily do during their clinical practice"
2939269|NCT02976610|No Intervention|1|This is the control group where no intervention takes place. Blood sampling carried out according to routine at the emergency department.
2939270|NCT02976610|Experimental|2|"During the blood sampling the health care professional will screen all vacuum Lithium Heparin tubes, with the Hemolysis point-of-care test (H-POCT). If the health care professional receives a negative test the bloodsample is sent to the local laboratory.~If H-POCT indicates a positive test, of free hemoglobin in plasma, the bloodsample and H-POCT will be discarded and a new sample will be collected and screened for hemolysis. This can be repeated 3 times."
2939271|NCT02976597|Active Comparator|Bupivacaine 0.25%|Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side on each side at end of the surgery.
2939272|NCT02976597|Active Comparator|Morphine 10mg|Morphine 10mg and Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side at end of the surgery.Patients will recieve 5mg morphine on each side
2939273|NCT02976597|Active Comparator|Morphine 15mg|Morphine 15mg and Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side at end of the surgery. Patients will recieve 7.5mg morphine on each side
2939274|NCT02976571|Experimental|Sub cutaneous+Intraperitoneal|Sub cutaneous Bupivacaine+ Intraperitoneal bupivacaine
2939275|NCT02976571|Active Comparator|Sub cutaneous+Placebo|Sub cutaneous Bupivacaine+ Intraperitoneal Nacl 0.9%
2939276|NCT02976571|Active Comparator|Placebo+Intraperitoneal|Sub cutaneous Nacl 0.9%+ Intraperitoneal bupivacaine
2939277|NCT02976571|Placebo Comparator|Placebo+Placebo|Sub cutaneous Nacl 0.9%+ Intraperitoneal Nacl 0.9%
2939278|NCT02976558|Experimental|Treatment Group|"Interventions:~Acupuncture, music therapy (TaKeTiNa) and Clown theatrical performance starting before allogenic stem cell transplant until three months after transplantation.~Interventions each twice a week for 4 weeks, then once a week for 4 weeks, then once every two weeks for 4 weeks"
2939279|NCT02976558|No Intervention|Control Group|control group. No interventions
2939280|NCT02976545|Other|PNES|Psychogenic Non-epileptic Seizures subjects
2939281|NCT02976545|Other|PTSD|Post Traumatic Stress Disorder
2939282|NCT02976545|Other|Healthy controls|Healthy controls
2939283|NCT02976532|Other|EMT Arm|The study is performed with a single arm, as the system is an additional tool for derotation measurement and the surgical procedure itself and its technique is not changed.
2939284|NCT02976519|Experimental|BI 443651|
2939285|NCT02976519|Placebo Comparator|Placebo|
2939286|NCT02976506|Experimental|Unsupervised exercise program|To verify the interference of an unsupervised exercise program on blood pressure, physical fitness, quality of life and safety in elderly hypertensive patients. Participants were divided into the study group or control group
2939287|NCT02976506|Experimental|Physical fitness and quality of life|To verify the interference of a walking program on physical fitness and quality of life.
2939288|NCT02976493||MM patients receiving elotuzumab|Non-Interventional Study of all patients with relapsed or refractory multiple myeloma (MM) who are beginning to receive elotuzumab at the selected sites.
2939289|NCT02976480|Active Comparator|Irrigation|The subjects randomized to this group will have their simple lacerations irrigated with a normal saline solution.
2939290|NCT02976480|Experimental|No Irrigation|The subjects randomized to this group will not have their simple lacerations directly irrigated with a normal saline solution.
2939291|NCT02976467|Experimental|Fulacimstat (BAY1142524)|30 patients with left-ventricular dysfunction after acute myocardial infarction
2939292|NCT02976467|Placebo Comparator|Placebo|30 patients with left-ventricular dysfunction after acute myocardial infarction
2939293|NCT02976454|Experimental|Guided Self-Help Obesity Treatment|Guided Self-Help obesity treatment will include 14 meetings over 6 months to mimic the structure of the proposed Medicare funding for obesity treatment for adults. These meetings will include a single one-hour meeting and 13 twenty-minute meetings that occur in the clinic. During this time, the health coach will assess patient/parent readiness to engage in behavior change, assess barriers and facilitators to behavior change, engage in behavior change and problem solving, and provide feedback and accountability.
2939322|NCT02976233||Acute Respiratory Failure in NIV|
2939323|NCT02976220|Experimental|Digital Education|1 month digital education program
2942055|NCT02957929|Experimental|Cohort 1a, Period D|single oral dose, crossover
2939294|NCT02976454|Active Comparator|Family-based behavioral obesity treatment|The active control group will receive usual care, i.e. PCP provides obesity management using decision support tools in the electronic health record and refers to a tertiary care program at the academic center. This program is the traditional family-based behavioral weight control program which consists of 20 one-hour, group-based sessions over 6 months.
2939295|NCT02976441|Experimental|Focal RT, Temozolomide, Stem Cell Collection/Reinfusion|"Autologous stem cell collection will be performed 1-4 days prior to initiating radiation therapy and temozolomide~Focal radiation therapy: standard of care dose daily for approximately 6 weeks~Temozolomide: standard of care dose by mouth daily for 6 weeks with radiation~2-7 days after the end of the radiation therapy and temozolomide the stem cells will be reinfused into the patient~Temozolomide: standard of care dose by mouth on days 1-5 every 28 days for 6 months following a 4-6 week rest period after the initial radiation and temozolomide"
2939296|NCT02976428|Active Comparator|Standard Soft Tissue Balancing|In the control group where the sensor device is not used in optimization of knee balance and alignment, definitive implants will be cemented in place and the sensor trial inserted using a thickness based on prior standard bearing insert trialing. Peak load data will be captured intraoperatively through full ROM. Custom shims will be affixed to the sensor to replicate thickness of the standard trial. The knee will then be cycled and loads recorded in the medial and lateral compartments at 10, 45 and 90 degrees of flexion. The surgeon will be blinded to the sensor output and the system will be located outside of their visual field.
2939297|NCT02976428|Experimental|Sensor Guided Soft Tissue Balancing|In the experimental group where the sensor device is used to optimize balance and alignment, the sensor trial will be inserted and tibial baseplate rotated until medial and lateral femoral contact points are parallel on the sensor output. Quantitative balance is defined as a mediolateral intercompartmental loading difference of ≤15 pounds. Flexion balance is achieved when femoral contact point position is within the midposterior third of the tibial insert and intercompartmental loads are balanced. Loads in the medial and lateral compartments are recorded at 10, 45 and 90 degrees. If compartment loads differ by >15 lbs between compartments, unbalanced, further soft tissue release/bone resection will be done to achieve a side to side compartment pressure difference of <15 lbs through ROM.
2939298|NCT02976402|Experimental|SBRT|"Postoperative RT consisting in:~31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week~32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week"
2939299|NCT02976389|Experimental|$40/month|Financial incentives: Participants will be randomized to receive $40/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
2939300|NCT02976389|Active Comparator|$20/month|Financial Incentives: Participants will be randomized to receive $20/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
2939301|NCT02976389|Active Comparator|$10/month|Financial Incentives: Participants will be randomized to receive $10/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
2939302|NCT02976376|Experimental|The Box|"After randomization, patients in the intervention group will receive a box (The Box) with all the devices described above. Instructions about the installation and usage of the devices will be given. Patients will be asked to measure their weight and blood pressure once a day. Furthermore, patients will be asked to record an ECG using the AliveCor once a day. Moreover, they are asked to record an ECG in case of any symptoms of possible cardiac origin, as judged by the patient. All data will be automatically transferred to the Leiden University Medical Center. Lastly, two of the four outpatient clinical visits will be done via a video connection. The content of the interview will be comparable to the content of a regular outpatient clinic visit."
2939303|NCT02976376|No Intervention|Control|Patients who are randomized to the control group will receive regular care.
2939304|NCT02976363||Quadrantectomy Group|The Quadrantectomy Group sample performed adjuvant radiotherapy with a linear accelerator, whose the total dosage was 5000 centigray (cGy), the daily dose 200 cGy distributed into twenty-five sessions, totaling 25 days of treatment. And data from Maximal Respiratory Pressures (MIP/MEP) were collected at two phases in the sample of Quadrantectomy Group: before the first session of radiotherapy and after the twenty-fifth session corresponding to the last day of the radiotherapy treatment.
2939305|NCT02976363||Control Group|While for the control group women with no breast cancer history were invited. Data from Maximal Respiratory Pressures (MIP/MEP) were collected at one phase in the sample of control group.
2939306|NCT02976350||Patients with HFpEF|Male patients with heart failure with preserved ejection fraction
2939307|NCT02976337|Experimental|High-dose naloxone|Naloxone 4 mg/ml i.v. infusion, total 3.25 mg/kg, target controlled infusion with three infusion rates (0.25 mg/kg; 0.75 mg/kg; 2.25 mg/kg) each of 25 min duration)
2939308|NCT02976337|Placebo Comparator|Normal saline|0.9% physiological saline, i.v. infusion, total 0.81 ml/kg, target controlled infusion with three infusion rates (0.06 ml/kg; 0.19 ml/kg; 0.56 ml/kg) each of 25 min duration.
2939309|NCT02976324|Experimental|external diaphragmatic pacemaker group|use the external diaphragmatic pacemakerI 9 counts per minute, with stimulate frequency 40 Hz
2939310|NCT02976324|No Intervention|control group|No inervention, just receive conventional therapy
2939311|NCT02976311|Active Comparator|Misgav-Ladach|cesarean section(C/S) via the modified 'Misgav-Ladach' technique
2939312|NCT02976311|Active Comparator|Pfannenstiel-Kerr|cesarean section(C/S) via the 'Pfannenstiel-Kerr' technique
2939313|NCT02976298|Sham Comparator|transcranial magnetic stimulation|sham transcranial magnetic stimulation
2939314|NCT02976298|Experimental|supplementary motor area stimulation|supplementary motor area transcranial magnetic stimulation
2939315|NCT02976298|Experimental|cerebellar stimulation|cerebellar transcranial magnetic stimulation
2939316|NCT02976272||patients with myeloma multiple|
2939317|NCT02976259|Experimental|Patient HIV primary infection|HIV primary infection Patient male receiving Dolutegravir
2939318|NCT02976246|Active Comparator|RenaKvit-vessel Active|One tablet of 360 micrograms vitamin K2 given once daily to examine the effect on vascular calcification
2939319|NCT02976246|Placebo Comparator|RenaKvit-vessel Control|One tablet of non-active drug given once daily
2939320|NCT02976246|Active Comparator|RenaKvit-bone Active|One tablet of 360 micrograms vitamin K2 given once daily to examine the effect on bone metabolism
2939324|NCT02976207||OSA diagnosed patients|patients at the age range of 18-90, male or female, who are diagnosed as suffering from OSA and are surgery candidates for their condition.
2939325|NCT02976194|Experimental|pro-re-nata|Ranibizumab 0.5mg is injected in to the vitreous cavity. An injection is given every 4 weeks three times, and then the patient will be followed up every 4 weeks. An addition injection is given as needed. Recurrence is defined as increase of exudative changes, or increase of 10% or more in central subfield macular thickness (CSMT) measured using optical coherence tomography. Aqueous humor is sampled from the anterior chamber before injection at baseline, 8 weeks and 20 weeks.
2939326|NCT02976168|No Intervention|Horizontal|Subjects will be in horizontal supine Position for 21 hours
2939327|NCT02976168|Experimental|-12° head down tilt|Subjects will be in 12° head down supine Position for 21 hours
2939328|NCT02976155|No Intervention|Pre-intervention|enteral nutrition according routine practice
2939329|NCT02976155|Experimental|Post-intervention|The intervention in this arm is the application of a standard enteral nutrition protocol
2939330|NCT02976142|Experimental|neoadjuvant chemoimmunotherapy|Patients with gastric cancer and verified free cancer cells who receive 1 course of intraperitoneal immunotherapy with interleykin-2 + 3 courses of systemic chemotherapy (Cisplatin + 5-FU). In case of downstaging (M1 -> M0) surgical treatment will be performed.
2939331|NCT02976142|No Intervention|neoadjuvant chemotherapy|Patients with gastric cancer and verified free cancer cells who receive 3 courses of systemic chemotherapy (Cisplatin + 5-FU). In case of downstaging (M1 -> M0) surgical treatment will be performed.
2939332|NCT02976129|Experimental|V565|V565 TID PO for 6 weeks
2939333|NCT02976129|Placebo Comparator|Placebo|Placebo TID PO for 6 weeks
2939334|NCT02976116|Experimental|Fruquintinib & Gefitinib|Drug: Fruquintinib and Gefitinib
2939335|NCT02976103|Other|Standard Care|-Standard Care pain medicine/management will be given
2939336|NCT02976103|Experimental|JACKI® RECOVERY JACKET + Standard Care|"Patient will be encouraged to use the Jacki Recovery Jacket at home~Patient will be taught how to tuck the drainage tubes in the jacket pocket~Patient will be taught how to un-tuck the drainage tubes from jacket pocket~Standard care pain medicine/management will be given"
2939337|NCT02976077|Experimental|RC2S+|"RC2S+~Preparation sessions (sessions 1 & 2):~Functional Outcomes Scale - Social Cognition (ERF-CS)~Psychoeducation about social cognitive impairments~Concrete objectives~Cognitive remediation (sessions 3 to 22):~Paper-and-pencil session~Simulation session~Home-based task~Transfer sessions (sessions 23 & 24):~Transfer of skills in dayly life - generalization~Assessment of the achievement of objectives"
2939338|NCT02976077|Active Comparator|Control therapy|"Control therapy~Preparation sessions (sessions 1 & 2):~Functional Outcomes Scale - Neurocognition~Psychoeducation about cognitive impairments~Concrete objectives~Cognitive remediation (sessions 3 to 24):~Paper-and-pencil session~Simulation session~Home-based task"
2939339|NCT02976064|Experimental|PreHab_Intervention|Experimental group of the prehabilitation trial
2939340|NCT02976064|No Intervention|PreHab_Control|Control group of the prehabilitation trial
2939341|NCT02976064|Experimental|Chronic patients_Intervention|Experimental group of the Rehabilitation in chronic stable patients in primary care trial
2939342|NCT02976064|No Intervention|Chronic patients_Control|Control group of the Rehabilitation in chronic stable patients in primary care trial
2939343|NCT02976064|Experimental|Citizens & mild disease_Intervention|Experimental group of the Rehabilitation in mild chronic patients and citizens at risk trial
2939344|NCT02976064|No Intervention|Citizens & mild disease_Control|Control group of the Rehabilitation in mild chronic patients and citizens at risk trial
2939345|NCT02976051|Experimental|Treatment with HART-CN|HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cisplatin and nimorazole
2939346|NCT02976038|Experimental|elamipretide|Open-label once daily subcutaneous injection of 40mg elamipretide
2939347|NCT02976025|Experimental|Longitudinal Remote Consultation|This is the active treatment arm consisting of 10 cluster randomized federally qualified health centers receiving both training in collaborative care and longitudinal remote consultation (LRC) support.
2939348|NCT02976025|Active Comparator|Collaborative Care|This comparator arm will consist of 10 cluster randomized federally qualified health centers who receive training in collaborative care.
2939349|NCT02976012|Active Comparator|IAI q8 week Group|"Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q8 week Group) where 4 additional mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up. Starting at week 20 in the q8week group eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment"
2939350|NCT02976012|Active Comparator|IAI q16 week Group|Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q16week Group) where 2 additional mandatory postoperative q4weeks IAI will be followed by mandatory q16weeks IAI for 52 weeks follow-up. Starting at week 12 in the q16 group, eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment.
2939351|NCT02975999|Experimental|Vasopressin|Vasopressin at 0.4mU/kg/min
2939352|NCT02975999|Placebo Comparator|Normal saline|Normal saline will be provided on a drip infusion to the selected group once coming off cardiopulmonary bypass following the Fontan operation.
2939353|NCT02975986|Other|Controlled metabolic diet|All study patients will be placed on an instructed controlled metabolic diet. Intervention: Uptake of radioactive isotope by the kidney Radiotracer: 123I-BMIPP, 99mTc-MAG3
2939354|NCT02975973|Experimental|2.5mA|Active stimulation group will receive 20 minutes of 2.5 mA transcranial direct current stimulation.
2939355|NCT02975973|Experimental|2.0mA|Active stimulation group will receive 20 minutes of 2.0 mA transcranial direct current stimulation.
2939356|NCT02975973|Experimental|1.5mA|Active stimulation group will receive 20 minutes of 1.5 mA transcranial direct current stimulation.
2939357|NCT02975973|Sham Comparator|0mA|This will be an active sham involving transcranial direct current stimulation, though stimulation will be brief (15 msec) and have low current (0.11 mA) pulses every 550 ms.
2939358|NCT02975960|Experimental|Stromal vascular fraction injection|Injection of autologous stromal vascular fraction on hand.
2939359|NCT02975947|Active Comparator|Control Group|Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
2939360|NCT02975947|Experimental|Study Group|The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide delivered into the open peritoneal cavity.
2939361|NCT02975934|Experimental|Rucaparib|Oral rucaparib (monotherapy).
2939362|NCT02975934|Active Comparator|Abiraterone acetate or Enzalutamide or Docetaxel|Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone).
2939363|NCT02975921|No Intervention|Malignant Effusion - Usual Care|Patients who had a pleural effusion secondary to a malignant etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had usual care during and afterwards. Usual care is the TPC only with no intrapleural medications. They would have nursing care in the recovery area afterwards and home nursing three times weekly.
2939364|NCT02975921|Experimental|Malignant Effusion with Pleurodesis|Patients who had a pleural effusion secondary to a malignant etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had intrapleural Povidone-Iodine administered at time of placement (100mL of 2% solution). They would have nursing care in the recovery area afterwards and home nursing three times weekly.
2939365|NCT02975921|No Intervention|Benign Effusion - Usual Care|Patients who had a pleural effusion secondary to a benign etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had usual care during and afterwards. Usual care is the TPC only with no intrapleural medications. They would have nursing care in the recovery area afterwards and home nursing three times weekly.
2939366|NCT02975921|Experimental|Benign Effusion with Pleurodesis|Patients who had a pleural effusion secondary to a benign etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had intrapleural Povidone-Iodine administered at time of placement (100mL of 2% solution). They would have nursing care in the recovery area afterwards and home nursing three times weekly.
2939367|NCT02975895|Other|Hydrophobic IOL: Vivinex (HOYA)|Intraocular lens with hydrophobic properties: Vivinex (HOYA).
2939368|NCT02975895|Other|Hydrophilic IOL: INCISE (Bausch+Lomb)|Intraocular lens with hydrophilic properties: INCISE (Bausch+Lomb).
2939369|NCT02975882|Experimental|Treatment (nab-rapamycin, temozolomide, irinotecan)|Patients receive nanoparticle albumin-bound rapamycin IV over 30 minutes on days 1 and 8 beginning on course 1. Patients also receive temozolomide PO and irinotecan hydrochloride PO on days 1-5 beginning on course 2. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
2939370|NCT02975869|Active Comparator|Standard Leukemia Care|Standard Leukemia care
2939371|NCT02975869|Experimental|Collaborative Palliative and Oncology Care|Collaborative care from Palliative Care and Leukemia will be given
2939372|NCT02975856|Experimental|Table Red Wine|250 ml Table Red Wine (12% ethanol)
2939373|NCT02975856|Experimental|Young Port Red Wine|150 ml Young Port Red Wine (20% ethanol)
2939374|NCT02975843|Experimental|CHF5993|99mTc Radiolabelled Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI
2939375|NCT02975830||0-2 years|Children aged from birth to 24 months Three dimensional CT based images
2939376|NCT02975830||2-4 Years|Children aged from 25-48 months Three dimensional CT based images
2939377|NCT02975830||4-6 Years|Children aged from 49-72 Three dimensional CT based images
2939378|NCT02975830||6-8 years|Children aged from 73-96 months Three dimensional CT based images
2939379|NCT02975817|Experimental|Hibler's|Insert description from protocol
2939380|NCT02975817|Active Comparator|Warm Air|Insert description from protocol
2939381|NCT02975804|Experimental|Intervention|The children in the treatment group will receive training on their trunk control using the Tymo in sitting 4 times per week for 20 minutes per session. The treatment will last for 6 weeks. All study children will continue their usual therapies at school.
2939382|NCT02975804|No Intervention|Control|Children in the control group will continue their usual therapy.
2939383|NCT02975791|Active Comparator|palpation|"Marking the cricothyroid membrane after ultrasound~The intervention is to mark the cricothyroid membrane in order to know exactly where it is in case that it should be needed fur emergency cricothyrotomy. The doctors mark the cricothyroid membrane with a pen after using palpation for identification."
2939384|NCT02975791|Active Comparator|ultrasound|"Marking of the cricothyroid membrane after Palpation~intervention is to mark the cricothyroid membrane in order to know exactly where it is in case that it should be needed fur emergency cricothyrotomy doctors mark the cricothyroid membrane with a pen after using ultrasonography for the identification"
2939385|NCT02975778|Experimental|Aged, 80 and over|
2939386|NCT02975765|Experimental|Piezosurgery|Piezosurgery-assisted corticotomy will be performed to enhance teeth alignment
2939387|NCT02975765|No Intervention|Traditional method|No intervention is going to be applied to the patients in this group.
2939388|NCT02975739|Experimental|Holmium-166 microspheres|Single session of 4 intratumoral injections consisting of 0.1-0.3 ml radioactive Holmium-166 microsphere suspension with a total activity 30 Megabecquerel, 7-12 days prior to surgical resection.
2939389|NCT02975726|Experimental|Peritoneal Dialysis Catheter Insertion|Catheters will be inserted at the bedside in a special procedure room.Argyle PD catheter kits will be used:2 cuffed curled catheters at 57cm or 62cm lengths. At time of PD catheter insertion,most patients will be drained of 5-10L of ascites or more to decrease the chance of catheter leaks.The volume removed will be at sole discretion of physician doing the procedure.Patients will be administered 25% Human Serum Albumin injection: 100cc after the 5-10L drainage,and 200cc if 10-15L is removed.Patients will undergo an initial drain and training with a specialized nurse.Patients in this arm will be instructed to drain a maximum of 2L per day after the initial drain.Monthly bloodwork will be performed.
2939390|NCT02975726|Active Comparator|Large Volume Paracentesis|Patients in this arm of the study will continue their usual practice of LVP as required. They will continue to undergo their LVP procedures through their regular means.Monthly bloodwork will be performed.
2939391|NCT02975700|Experimental|PLX3397|"Part 1: Open label, multicenter study includes a dose evaluation portion in which the safety profile of PLX3397 as a single oral agent will be evaluated~Part 2: An expansion cohort in which the efficacy and safety of PLX3397 administered at the recommended Phase 2 dose will be evaluated in patients with unresectable stage III or stage IV KIT-mutated melanoma."
2939464|NCT02975310|Active Comparator|Endoscopic Sinus Surgery (ESS)|Patients assigned to this arm will undergo endoscopic sinus surgery (ESS),
2939392|NCT02975687|Experimental|Arm A|"CD19 CAR T cells will be administered by i.v. injection as a using a split dose (total dose of 5x10^6/kg-5x10^7/kg) approach to dosing:10% on day 0, 30% on day 1 and 60% on day 2."
2939393|NCT02975674|Experimental|MT-12 dental implant|MT-12 dental implant with Morse taper implant-abutment connection
2939394|NCT02975674|Active Comparator|CON.INT dental implant|CON.INT dental implant with internal hexagon implant-abutment connection
2939395|NCT02975661||Observational 1|Huaier Granule
2939396|NCT02975661||Observational 2|Radiotherapy or chemotherapy
2939397|NCT02975661||Observational 3|treatment abandoned
2939398|NCT02975661||Observational 4|Huaier Granule & Radiotherapy or chemotherapy
2939399|NCT02975648|Active Comparator|Usual Care|Patients will receive orientations about the surgery and the rehabilitation by health professionals, especially in the discharge. Participants will have one scheduled appointment for evaluation by health professionals at six months after the Percutaneous Coronary Intervention.
2939400|NCT02975648|Experimental|Educational model + follow up|Patients will participate in the educational programme (booklets and orientation) with telephone follow up, that will be started in preoperative for six months.
2939401|NCT02975635||Oral patient information only|Patients are given oral information only (information as usual). After patients have made their decisions (repair or replacement), a questionnaire survey is conducted.
2939402|NCT02975635||Written patient education before oral patient information|Patients are given a flow chart in advance of oral information. After patients have made their decisions (repair or replacement), a questionnaire survey is conducted.
2939403|NCT02975622|Active Comparator|Subclavian|Subclavian vein will be individualized and approached by longitudinal incidence, according to previous studies. Skin puncture will be made next to the transducer, lateral to the first rib, maintaining constant visualization of the needle tip.
2939404|NCT02975622|Active Comparator|Jugular|Jugular vein will be identified by transverse or longitudinal approach, and skin puncture will be made by transverse or longitudinal incidence, according to operator's preferences. Using transverse approach, the needle will be maintained in a 45 degree angle with the skin, and the insertion site will be exactly the same as the measured distance between asking and jugular vein wall.
2939405|NCT02975609|Active Comparator|Conventional Fractionated Radiotherapy|The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response). Patients will be randomized into the control group undergoing the conventional fractionated radiotherapy to all metastatic sites and the primary tumor.
2939406|NCT02975609|Experimental|Stereotactic Body Radiation Therapy|The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response). Patients will be randomized into the experimental group undergoing SBRT to all metastatic sites and the primary tumor.
2939407|NCT02975596||Youth|Youth between the ages beteen ages 13-18 will be offered awareness, education, empowerment and accessibility intervention components.
2939408|NCT02975596||College|Age between 18-23 will be offered awareness, education, empowerment and accessibility intervention components.
2939409|NCT02975596||Adult|parents of adolescents and young adults will be offered awareness, education, and accessibility intervention components.
2939410|NCT02975583|Active Comparator|Experimental: Vorapaxar|Drug: Vorapaxar 2.08 mg orally daily for a year Other name: Zontivity
2939411|NCT02975583|Placebo Comparator|Placebo Comparator: Placebos|Medication: Matching Placebo Daily tablet
2939412|NCT02975570|Experimental|DAZZLE-24 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 24 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
2939413|NCT02975570|Experimental|DAZZLE-32 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 32 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
2939414|NCT02975570|Experimental|DAZZLE-40 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen: delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 40 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
2939415|NCT02975570|Experimental|DAZZLE-48 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 48 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
2939416|NCT02975570|Experimental|DAZZLE-56 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 56 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
2939417|NCT02975570|Active Comparator|WHO MDR-TB regimen- 9 mos or 20-24 mos|MDR-TB treatment with 9-month or 20-24 month WHO approved regimen. The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine.
2939418|NCT02975557|Active Comparator|Brimonidine 0.15%|Brimonidine 0.15% eye drops 2 times a day for 12 weeks
2939419|NCT02975557|Active Comparator|Brimonidine 0.075%|Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
2939420|NCT02975557|Placebo Comparator|Placebo|Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
2939421|NCT02975544|Experimental|Intervention group|Received CRECES programme during 5 weeks as part of the extracurricular plan
2939422|NCT02975544|No Intervention|Control group|Continued with their habitual school routine
2939465|NCT02975297|Experimental|Exenatide plus NRT plus counseling|Once weekly exenatide Injectable Product, Nicotine Replacement Therapy (NRT, Patch), smoking cessation counseling
2939423|NCT02975531|Experimental|Simulator's construction|To build the simulator was selected a volunteer (VF) as a model. This volunteer had no complaints of pain or trauma to the cervical region. This region was used to collect the displacement of the skin and cytometry neck.
2939424|NCT02975531|Experimental|Model Features|Thirty-nine volunteers (GT) were selected men and women aged over 18 years without history of trauma in the cervical region in order to determine the characteristics of the model: skin elasticity and cirtometry neck.
2939425|NCT02975531|Experimental|Parameterization technique|Five physiotherapists (GP) with at least 5 years of experience in the technique were selected to perform the technique on the simulator and complete a questionnaire in order to evaluate the texture and skin elasticity, the curvature and size of the cervical spine format. They scored these items from the Likert scale. After evaluation they used the simulator to generate a standard guide training.
2939426|NCT02975531|Experimental|Simulator training|Twenty-six volunteers (GE) were selected, men and women, aged over 18 years without prior knowledge of the technique for simulator training.
2939427|NCT02975531|Experimental|Training Evaluation|A physical therapist (VE) was selected to evaluate the volunteers (GE) before and after training in the simulator.
2939428|NCT02975518|Active Comparator|Intra-venous infusion of Flourodeoxyglucose|As a control for radio labelled cells, Flourodeoxyglucose will be administered intra-venously at an activity equal to that injected with the labelled endothelial cells.
2939429|NCT02975518|Active Comparator|Intra-Arterial infusion of Flourodeoxyglucose|As a control for radio labelled cells, Flourodeoxyglucose will be administered intra-arterially at an activity equal to that injected with the labelled endothelial cells.
2939430|NCT02975518|Experimental|Intra-venous injection of radio-labelled endothelial cells|Endothelial cells labelled with flourodeoxyglucose will be injected intra-venously with their distribution tracked using PET CT.
2939431|NCT02975518|Experimental|Intra-Arterial injection of radio-labelled endothelial cells|Endothelial cells labelled with flourodeoxyglucose will be injected intra-arterially with their distribution tracked using PET CT.
2939432|NCT02975505|Experimental|Target Systolic Blood Pressure <120 mm Hg|
2939433|NCT02975505|No Intervention|Target Systolic Blood Pressure 130-140 mm Hg|
2939434|NCT02975492|Experimental|Cholecalciferol|cholecalciferol : 100 000 Unit International (UI), sequential dose (2 mL)
2939435|NCT02975492|Experimental|Ergocalciferol|ergocalciferol : 1000 UI/mL, daily dose during 28 days (0.2 ml by day)
2939436|NCT02975479|Placebo Comparator|Intralymphatic placebo injections|ALK Diluent, ATC-code V07AB. 3 injections with 4-7 weeks interval.
2939437|NCT02975479|Active Comparator|Intralymphatic active injections|"ATC-code V01AA02. 3 injections with 4-7 weeks interval in an up-dosing protocol; 1000 SQ-U, 3000 SQ-U, 10000 SQ-U.~***IMPORTANT INFORMATION! The up-dosing protocol is changed due to an adverse event at the last injection. New regimen: 1000 SQ-U, 3000 SQ-U, 3000 SQ-U. ***"
2939438|NCT02975466|Experimental|AirQ Blocker supra-glottic airway device|Group of patients in which the Air-Q Blocker will be used and measured as an intubation conduit.
2939439|NCT02975466|Experimental|AuraGain supra-glottic airway device|Group of patients in which the AuraGain will be used and measured as an intubation conduit.
2939440|NCT02975466|Experimental|I-Gel supra-glottic airway device|Group of patients in which the I-Gel will be used and measured as an intubation conduit.
2939441|NCT02975453||Rivaroxaban|Non-valvular atrial fibrillation (NVAF) patients treated with rivaroxaban for at least 6 months prior to the study inclusion
2939442|NCT02975440|Experimental|Treatment|Treatment A (Period 1): a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam Treatment B (Period 2): 600 mg Rifampicin once daily (qd) for 7 days followed by administration of a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam followed by 600 mg Rifampicin 12 hours after Vilaprisan and Midazolam administration and continued dosing of 600 mg Rifampicin once daily for 3 days
2939443|NCT02975427||Diet group|All participants were prescribed an appropriate diet with caloric restriction and an exercise program and underwent a follow-up examination 3±1 months later.
2939444|NCT02975388|Experimental|Label: RO7079901 (Mild) (Part 1)|Participants with mild renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
2939445|NCT02975388|Experimental|RO7079901 (Moderate) (Part 1)|Participants with moderate renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
2939446|NCT02975388|Experimental|RO7079901 (Severe) (Part 1)|Participants with severe renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
2939447|NCT02975388|Active Comparator|RO7079901 (Normal) (Part 1)|Control group of participants with normal renal function will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
2939448|NCT02975388|Experimental|RO7079901 (End-stage) (Part 2)|Participants with stable end-stage renal disease undergoing hemodialysis will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
2939449|NCT02975375||Preoperative geriatric consult or assessment|Patients who have a geriatric assessment of consult billed in the 4 months before surgery
2939450|NCT02975375||No Preoperative geriatric consult or assessment|Patients who do not have a geriatric assessment of consult billed in the 4 months before surgery
2939451|NCT02975362|Experimental|Acupuncture combined rehabilitation|Acupuncture Treatment Rehabilitation Treatment
2939452|NCT02975362|Experimental|Rehabilitation|Rehabilitation Treatment
2939453|NCT02975349|Experimental|M2951 Low dose|
2939454|NCT02975349|Experimental|M2951 Mid dose|
2939455|NCT02975349|Experimental|M2951 High dose|
2939456|NCT02975349|Experimental|Placebo/M2951|
2939457|NCT02975349|Active Comparator|Tecfidera|
2939458|NCT02975336|Placebo Comparator|Placebo|
2939459|NCT02975336|Experimental|M2951 Low dose|
2939460|NCT02975336|Experimental|M2951 Mid Dose|
2939461|NCT02975336|Experimental|M2951 High dose|
2939462|NCT02975323|Experimental|Single|To administer Carvedilol 12.5 mg orally and measure Wedge pressure gradient in hepatic veins followed by change in hepatic vein wave form
2939463|NCT02975310|Experimental|Endoscopic polypectomy in clinic (EPIC)|Patients assigned to this arm of the study will undergo the In Clinic Polypectomy Performed in Clinic
2939466|NCT02975297|Placebo Comparator|plus NRT plus counseling|Once weekly placebo, Nicotine Replacement Therapy (NRT, Patch), smoking cessation counseling
2939467|NCT02975271|Experimental|Serlopitant|Dose of experimental drug Serlopitant
2939468|NCT02975271|Placebo Comparator|Placebo|Matching dose of Placebo
2939469|NCT02975245||Men receiving chemotherapy|Semen collection and analysis
2939470|NCT02975232|Experimental|Treatment|F&V economic incentive with Cooking Matters store tour
2939471|NCT02975232|No Intervention|Control|no intervention
2939472|NCT02975219|Experimental|Treatment group|4.5mg Bevacizumab-800CW intravenously
2939473|NCT02975206|Experimental|Serlopitant High Dose|serlopitant tablets - high dose
2939474|NCT02975206|Experimental|Serlopitant Low Dose|serlopitant tablets - low dose
2939475|NCT02975206|Placebo Comparator|Placebo Oral Tablet|placebo tablets
2939476|NCT02975193|Active Comparator|Control group|"Healthy adults ages 21-90 without movement disorders, psychiatric disorders, or dementia. They will complete computer games and questionnaires at one time point.~Specific interventions: Computer task assessing cognition, Impulsive-Compulsive Disorders in Parkinson's Disease, Montreal Cognitive Assessment"
2939477|NCT02975193|Experimental|Parkinson's disease group|"Parkinson's disease patients who have elected to receive DBS for treatment of their side effects of PD consent to complete computer games and questionnaires at baseline, computer games during deep brain stimulation, and computer games and questionnaires up to 2 years after surgery.~Specific interventions: Computer task assessing cognition, Impulsive-Compulsive Disorders in Parkinson's Disease, Montreal Cognitive Assessment"
2939478|NCT02975180|Experimental|FES|Unilateral and bimanual activities are performed with FES applied to the hemiparetic arm.
2939479|NCT02975180|Experimental|Conventional|Unilateral and bimanual activities are performed with no FES applied to the hemiparetic arm.
2939480|NCT02975167|Experimental|Inpatient|"Subjects randomized to this group will receive the same intervention as the outpatient group -- cervical ripening with Foley catheter -- but remain within the hospital. Subjects will be asked to complete a survey assessing their fears, opinions, anxiety, satisfaction and hours of sleep before and after the catheter is placed and removed, respectively.~The intervention: randomization to inpatient cervical ripening"
2939481|NCT02975167|Experimental|Outpatient|"Subjects randomized to this group will receive the same intervention as the inpatient group -- cervical ripening with Foley catheter -- but will be discharged home. Subjects will be asked to return to the hospital when the catheter falls out or if 24 hours has elapsed. They will be given detailed instructions and provided a 24 hour phone number to call should they have any concerns. Subjects will be asked to complete a survey assessing their fears, opinions, anxiety, satisfaction and hours of sleep before and after the catheter is placed and removed, respectively.~The intervention: randomization to outpatient cervical ripening"
2939482|NCT02975154|Active Comparator|Microcurrent therapy, type A|"Microcurrent therapy: Channel A: 100 µA; 200 Hz; Channel B: 100 µA; 300 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10.~Previous treatments will be continued."
2939483|NCT02975154|Active Comparator|Microcurrent therapy, type B|Microcurrent therapy: Channel A: 25 µA; 200 Hz; Channel B: 100 µA; 300 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10. Previous treatments will be continued.
2939484|NCT02975154|Sham Comparator|Sham Microcurrent therapy|Microcurrent therapy: Channel A: 0 µA; 0 Hz; Channel B: 0 µA; 0 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10. Previous treatments will be continued.
2939485|NCT02975154|No Intervention|No Intervention|No Intervention. Previous treatments will be continued.
2939486|NCT02975141|Experimental|Afatinib 40Mg Tab, Gemzar, Abraxane +1|Dose Level +1 Afatinib 40 mg Nab-paclitaxel 125 mg/m2 BSA Gemcitabine 1000 mg/m2 BSA
2939487|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane 0|Dose Level 0 Afatinib 30 mg Nab-paclitaxel 125 mg/m2 BSA Gemcitabine 1000 mg/m2 BSA
2939488|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane -1|Dose Level -1 Afatinib 30 mg Nab-paclitaxel 100 mg/m2 BSA Gemcitabine 800 mg/m2 BSA
2939489|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane -2|Dose Level -2 Afatinib 30 mg Nab-paclitaxel 75 mg/m2 BSA Gemcitabine 600 mg/m2 BSA
2939490|NCT02975128|Experimental|Patients|
2939491|NCT02975102|Experimental|CBL-101 Eye Drops|The test article, CBL-101 Eye Drops, is a CE-marked medical device containing 0.15% hyaluronic acid. An oxide (Oxyd®) used as mild preservative, rapidly turns into oxygen, water and ions on contact with the eye. The formula is presented in 10 mL bottles.
2939492|NCT02975102|Active Comparator|Vismed® Multi|The comparator product, Vismed® Multi ophthalmic solution (CE marked), contains 0.18% sodium hyaluronate, is unpreserved and presented in 10 mL bottles.
2939493|NCT02975089|No Intervention|Control|A leaflet of healthy diet for elderly
2939494|NCT02975089|Experimental|Nutritional Intervention 1|"Multi-nutrient supplement"
2939495|NCT02975089|Experimental|Nutritional Intervention 2|"Multi-nutrient & soy protein supplement"
2939496|NCT02975089|Experimental|Nutritional Intervention 3|Nutrition education on balanced diet & food supplement
2939497|NCT02975076|Experimental|Sanchitongshu & placebo of lopidogrel|sanchitongshu 1 capsule each time ,three times a day and Aspirin 75mg for 90 days ; placebo of clopidogrel 75mg daily for 21 days after randomization
2939498|NCT02975076|Placebo Comparator|placebo of Sanchitongshu & lopidogrel|placebo of sanchitongshu1 capsule each time ,three times a day and Aspirin 75mg for 90 days;clopidogrel 75mg per day for 21 days after randomization
2939499|NCT02975063|Experimental|A&T IYCF intervention|A&T IYCF intervention is includes comprehensive IYCF counseling which includes intensive activity that aims to deliver one-on-one counseling at home or in a health facility.
2939500|NCT02975063|No Intervention|Control|No intervention.
2939501|NCT02975050||Side location|u-Cor device will be applied on side location
2939502|NCT02975050||Front location|u-Cor device will be applied on front location
2939503|NCT02975037|Experimental|sildenafil+erythromycin|Sildenafil 25 mg PO (single dose); Erythromycin 250 mg PO (3 doses); Sildenafil 25 mg PO + Erythromycin 250 mg PO (single dose)
2939504|NCT02975037|Experimental|sildenafil+itraconazole|Sildenafil 25 mg PO (single dose); Itraconazole 100 mg PO (3 doses); Sildenafil 25 mg PO + Itraconazole 100 mg PO (single dose)
2939578|NCT02974517||Conventional Group|All embryos are cultured in our daily used incubators; embryo scores are evaluated on day 3 by embryologist.
2939505|NCT02975024||Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement and quantitative determination of VEGF after mandibular vestibuloplasty. Individuals of this pre-defined group are candidates of vestibuloplasty, where the keratinized gingiva will be enlarged by a combination of apically repositioned split thickness flap with a xenogeneic collagen matrix (Mucograft).
2939506|NCT02975024||strip gingival graft + Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement and quantitative determination of VEGF after mandibular vestibuloplasty. Individuals of this pre-defined group are candidates of vestibuloplasty, where the keratinized gingiva will be enlarged by a combination of apically repositioned split thickness flap with a strip gingival graft and a xenogeneic collagen matrix (Mucograft). The strip gingival graft is harvested from the patient's palate.
2939507|NCT02975011||Lumbar stenosis group|Lumbar stenosis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manipulation, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
2939508|NCT02974998|Experimental|Young Women's Health CoOp (YWHC)/ HTC|Participants will receive an enhanced gender-focused HTC intervention.
2939509|NCT02974998|Active Comparator|Standard HTC|Participants will receive the standard HTC available in South Africa for this population.
2939510|NCT02974985|Experimental|Women aged 40-50|"Intervention--Injections of volumizing products Restylane L and Restylane Lyft with endpoint  a dramatic result is seen that is agreed upon by both subject and injector. The number of injections will be determined (and quantified) by both the patient and the PI to achieve this endpoint."
2939511|NCT02974985|Experimental|Women aged 50-60|"Intervention--Injections of volumizing products Restylane L and Restylane Lyft with endpoint  a dramatic result is seen that is agreed upon by both subject and injector. The number of injections will be determined (and quantified) by both the patient and the PI to achieve this endpoint."
2939512|NCT02974972||Pith Moromo 2 Cohort|
2939513|NCT02974959|Experimental|gammaCore active device|Patients in this arm will be using an active device which delivers a treatment dose of current to the vagus nerve twice daily for 120 seconds
2939514|NCT02974959|Sham Comparator|gammaCore Sham device|Patients in this arm will be using a sham device which does not deliver a treatment dose of current, but will deliver enough current to cause tingling on the skin.
2939515|NCT02974946|Experimental|Study group|Patients will receive the RenalGuard system
2939516|NCT02974946|No Intervention|Control group|Standard practice will be performed with no RenalGuard system
2939517|NCT02974933|Experimental|apatinib|combined with pemetrexed
2939518|NCT02974920|Active Comparator|Aspirin 100 mg|100 mg of aspirin daily for 180 days
2939519|NCT02974920|Active Comparator|Rivaroxaban 10 mg|10 mg of Rivaroxaban daily for 180 days
2939520|NCT02974907|Experimental|RGN-259|RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
2939521|NCT02974907|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
2939522|NCT02974894|Experimental|Probiotic|Capsules containing potato starch as a filler and Lactobacillus plantarum
2939523|NCT02974894|Placebo Comparator|Placebo|Capsules containing potato starch
2939524|NCT02974881|Experimental|transcatheter mitral valve replacement|HighLife TMVR System is a novel and innovative approach developed as an alternative treatment for severe MR when medical treatment is maximal and surgical interventions not possible or at high risk. The HighLife TMVR system is composed of a Transcatheter Mitral Valve (TMV), a sub-annular implant (SAI), and their delivery systems and loading tools. The HighLife Valve is a 31 mm mitral bioprosthesis made of a self-expanding Nitinol frame covered with polyester graft and supporting bovine pericardium leaflets. The bioprosthesis is used in conjunction with the Sub-Annular Implant (SAI).
2939525|NCT02974868|Experimental|Cohort 1|PF-06651600
2939526|NCT02974868|Experimental|Cohort 2|PF-06700841
2939527|NCT02974868|Placebo Comparator|Cohort placebo|placebo
2939528|NCT02974855|Experimental|PF-06741086 (Cohort 1)|
2939529|NCT02974855|Experimental|PF-06741086 (Cohort 2)|
2939530|NCT02974855|Experimental|PF-06741086 (Cohort 3)|
2939531|NCT02974855|Experimental|PF-06741086 (Cohort 4)|
2939532|NCT02974842||Pre-Salpingo-Oophorectomy|Women with pelvic mass suspicious for malignancy or have BRCA1 or BRCA2 mutations that will undergo pre-salpingo-oophorectomy.
2939533|NCT02974829||All patients|Continuing with marketed anti-HBV or off-treatment in real-life setting
2939534|NCT02974816|No Intervention|Standard of Care|Subjects in this arm will visit their physician once every 3 months and will receive usual care.
2939535|NCT02974816|Experimental|Remote Monitoring|Subjects in this arm will visit their physician once every 3 months and will receive usual care. In addition, in between clinic visits, subjects will measure their blood glucose (BG) readings at least once a day and share their BG readings with their CDE using Glooko's mobile application. Once a week, the CDE will review the subject's BG readings on Glooko's population tracker and reach out to the subjects if he/she experienced clinical incident(s). During the conversation, the CDE will either recommend medication or lifestyle modification to address the clinical incident.
2939536|NCT02974803|Experimental|Dabrafenib and Trametinib|Dabrafenib, PO, 150mg BID Continuously Trameteinib, PO 2mg OD Continuously
2939537|NCT02974790||Circulatory failure|Patients with a circulatory failure due to a sepsis or not
2939538|NCT02974777|Active Comparator|Bleeding prevention group|Patients with reduction of standard dose DAPT due to low platelet reactivity to asprin and/or P2Y12 inhibitor
2939539|NCT02974777|Active Comparator|Ischemia prevention group|Patients with intensification of standard dose DAPT due to high platelet reactivity to asprin and/or P2Y12 inhibitor
2939540|NCT02974764||Chemotherapy Group|This cohort includes patients who will receive chemotherapy at any stage or their treatment.
2939541|NCT02974764||Radiation therapy Group|This cohort includes patients who will receive radiation therapy at any stage or their treatment.
2939542|NCT02974764||Surgical resection of the primary tumor|This cohort includes patients who will undergo resection of the primary tumor.
2939543|NCT02974738|Experimental|Part 1A|"Drug: PART 1A: PT2977 for the treatment of advanced solid tumors~PT2977 inhibits HIF-2α and is a novel approach to treatment of solid tumors."
2939579|NCT02974504|Experimental|evogliptin|evogliptin 5mg qd
2939544|NCT02974738|Experimental|Part 1B|"Drug: PART 1B: PT2977 for the treatment of advanced ccRCC~PT2977 inhibits HIF-2α and is a novel approach to treatment of ccRCC."
2939545|NCT02974738|Experimental|Part 2|"Part 2: PT2977 for the treatment of other specified solid tumors~PT2977 inhibits HIF-2α and is a novel approach to treatment of specified solid tumors."
2939546|NCT02974725|Experimental|LXH254+LTT462|
2939547|NCT02974725|Experimental|LXH254+Trametinib|
2939548|NCT02974712|Experimental|Fentanyl|After routine Induction, fentanyl was administrated.
2939549|NCT02974712|Placebo Comparator|Saline|After routine Induction, same volume saline was administrated.
2939550|NCT02974699|Experimental|Potato Starch (Bob's Red Mill)|Daily dietary supplementation with Potato Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.
2939551|NCT02974699|Placebo Comparator|Resource ThickenUp Pregelatinized Starch|Daily dietary supplementation with Pregelatinized Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.
2939552|NCT02974686|Active Comparator|Interventional (EVR)|Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus
2939553|NCT02974686|Active Comparator|Prior Agent (MPA)|Patient will have baseline data collected while on MPA for comparison with EVR
2939554|NCT02974673|Experimental|Ejaculatory test|Measures of sphincter pressures during ejaculation
2939555|NCT02974660|Active Comparator|Protamine sulfate|After obtaining optimal valve deployment patients will receive protamine sulfate (1 mg for each 100 units of UFH i.v.). Measurement of activated clotting time (ACT) will be performed (after heparin administration and after protamine sulfate administration).
2939556|NCT02974660|Placebo Comparator|0.9% NaCl|After obtaining optimal valve deployment patients will receive 0.9% saline (20 ml i.v.). Measurement of activated clotting time (ACT) will be performed (after heparin administration and after placebo administration).
2939557|NCT02974647|Experimental|rel/ref PTCLtumors are known to contain mutations associ|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
2939558|NCT02974647|Experimental|with rel/ref PTCL with functional evidence of JAK/STAT|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
2939559|NCT02974647|Experimental|with rel/ref PTCL who do not meet criteria for cohort 1 or 2.|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
2939560|NCT02974634|Other|Ostomy Self management Training|Comparing OSMT group to UC group
2939561|NCT02974634|Other|Usual care|Comparing OSMT group to UC group
2939562|NCT02974621|Experimental|Arm A (olaparib, cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO once QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2939563|NCT02974621|Experimental|Arm B (bevacizumab)|Patients receive bevacizumab IV over 90 minutes every 2 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2939564|NCT02974582|Experimental|1: Part 1 - with coupon|60 participants of high and low SES will be exposed to advertising material to inform sample size and material selection for part 2
2939565|NCT02974582|Experimental|2: Part 2 - with coupon|randomized to view direct mail marketing smoking advertising with discount coupon
2939566|NCT02974582|Experimental|3: Part 2 - no coupon|randomized to view direct mail marketing smoking advertising without discount coupon
2939567|NCT02974582|Experimental|4: Part 2 - no coupon|randomized to view direct mail marketing smoking advertising without discount coupon
2939568|NCT02974582|Experimental|5: Part 2 - control|exposure to neutral non-health related images
2939569|NCT02974569||C-SCAT|C-SCAT arm: Completes and uses Computerized Symptom Capture Tool (C-SCAT) during visit with provider for two clinic visits.
2939570|NCT02974556|Active Comparator|Standard surgical treatment group|"Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure.~Standard adjuvant systemic chemotherapy (FOLFOX or CAPOX regimens for 6 months) will be reserved in pT3 tumors with poor prognostic factors, pT4 tumor and if lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT."
2939571|NCT02974556|Experimental|Proactive management group|"Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure. Simultaneously patients will undergo infracolic omentectomy, appendectomy, exeresis of the liver round ligament and, in women, a bilateral oophorectomy. At the end of surgical procedure HIPEC will be performed with oxaliplatin 460 mg/m2 and before the beginning of HIPEC an intravenous infusion of 400 mg/m2 of 5-FU and 20 mg/m2 of leucovorin will be administered.~Standard adjuvant systemic chemotherapy (FOLFOX or CAPOX regimens for 6 months) will be reserved in pT3 tumors with poor prognostic factors, pT4 tumor and if lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT."
2939572|NCT02974543|Other|Sham 1st (Auditory only) then Active (Bimodal)|"To mitigate potential placebo effects, subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
2939573|NCT02974543|Other|Active (Bimodal) then Sham (Auditory only)|"During active treatment, the device will deliver electric somatosensory and auditory stimulation.~To mitigate potential placebo effects, subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab."
2939574|NCT02974530||Stroke population|Patient with stroke will be explored during their acute phase and in 6 months of diagnosis.
2939575|NCT02974530||Healthy population|Healthy subjects will be explored in Grenoble in research laboratory
2939576|NCT02974517||Time-lapse-Auto|All embryos are cultured in EmbryoScope®; embryo scores are evaluated on day 3 by KID Score system.
2939577|NCT02974517||Time-lapse-Manual|All embryos are cultured in EmbryoScope®; embryo scores are evaluated on day 3 by embryologist.
2939582|NCT02974478|Experimental|Orange juice with meals|Effect of orange juice consumption with three meals per day (without snacking) on glucose metabolism and antioxidative status
2939583|NCT02974478|Experimental|Orange juice between meals|Effect of orange juice consumption between three meals per day (without snacking) on glucose metabolism and antioxidative status
2939584|NCT02974478|Experimental|Sugar sweetened beverage between meals|Effect of sugar sweetened beverage consumption between three meals per day (without snacking) on glucose metabolism and antioxidative status
2939585|NCT02974465|Experimental|Experimental Group|protocol of Biofeedback Electromyography plus conventional physical therapy treatment
2939586|NCT02974465|Sham Comparator|Control Group|consisted of Sham- Biofeedback Electromyography plus conventional physical therapy treatment
2939587|NCT02974452||Group I: Older adults|healthy subjects older than 68 years old whose shoulder muscle are measured by surface electromyography
2939588|NCT02974452||Group II: Adults|healthy subjects 43 to 67 years old, whose shoulder muscle are measured by surface electromyography
2939589|NCT02974452||Group III: Young adults|healthy subjects 20 to 42 years old, whose shoulder muscle are measured by surface electromyography
2939590|NCT02974439|Experimental|LANDI-Amlodipine Besylate Tablet 5mg|During the study session, healthy subjects will be administered a single dose of LANDI-AmlodipineTablet 5mg under fasting and FED conditions.
2939591|NCT02974439|Active Comparator|Norvasc Tablets 5mg|During the study session, healthy subjects will be administered a single dose of Norvasc Tablets 5mg under fasting and FED conditions.
2939592|NCT02974426|Experimental|Arm I (PORT-first strategy)|Concurrent chemoradiotherapy + sequential chemotherapy or PORT + sequential chemotherapy: Participants in the Arm I will receive PORT at the first day of therapy. For lung adenocarcinoma, the first day of radiotherapy will be administered concurrently with chemotherapy (two cycles of chemotherapy given during radiotherapy); then continue to give two cycles of sequential chemotherapy. For squamous cell lung carcinoma, PORT will be administered first followed by subsequent four cycles of sequential chemotherapy.
2939593|NCT02974426|Active Comparator|Arm II (PORT-last strategy)|Four cycles of chemotherapy + sequential PORT: Participants in the Arm II will receive four cycles of adjuvant chemotherapy and after that, sequential PORT (50.4 Gy, 1.8 Gy once daily over 5.5 weeks) will be administered.
2939594|NCT02974413|Experimental|Intervention|The intervention to be performed will be based on the principles and steps of supported self-care, guided by Behavior Change Protocol (Behavior Change Protocol - BCP) and consists of an educational program with quarterly meetings, and individual at home, through home visits, and group in the Basic Health Unit (BHU), in addition to telephone monitoring in the interval between two meetings. This intervention will be applied together adult men with type 2 diabetes who are randomized in the intervention group (IG) for six months. Thus, these men will take part in three meetings, individual or group, and will receive four telephone calls in between the face meetings. Our objective is to draw with this intervention by the participant, an individual plan of self-care, based on concretras goals and supports you in the implementation of this plan, in order to improve their self-efficacy in self-care and therefore glycemic control.
2939595|NCT02974413|No Intervention|Control|The study will also include a Control Group (CG), and the participants of this group will participate in conversation circles at the beginning and the end of the six month follow-up.
2939596|NCT02974400|Experimental|Internet-based guided self-help|Internet-based, guided, CBT-oriented self-help treatment for persecutory ideation and auditory verbal hallucinations with access to a self-help website including regular written electronic contact with a guide and access to smartphone-based interactive worksheets (8 weeks)
2939597|NCT02974400|No Intervention|Wait-List|Wait-list control group (8 weeks)
2939598|NCT02974387|Active Comparator|Fluorometholone(FMl)|Patients will be randomized to the eye and will receive FML in one eye.
2939599|NCT02974387|Active Comparator|Loteprednol (Lotemax)|Patients will be randomized to the eye and will receive Lotemax in contralateral eye.
2939600|NCT02974374|Experimental|PF-06835919|
2939601|NCT02974374|Placebo Comparator|Placebo|
2939602|NCT02974361|Active Comparator|Part A Ibuprofen control|
2939603|NCT02974361|Experimental|Part A Ibuprofen-LDH|
2939604|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 1|
2939605|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 2|
2939606|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 3|
2939607|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 4|
2939608|NCT02974361|Active Comparator|Part A Ibuprofen Lysine|
2939609|NCT02974361|Active Comparator|Part B Ibuprofen|
2939610|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 1|
2939611|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 2|
2939612|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 3|
2939613|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 4|
2939614|NCT02974361|Active Comparator|Part C Ibuprofen|
2939615|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 1|
2939616|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 2|
2939617|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 3|
2939618|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 5|
2939619|NCT02974348|Active Comparator|arm 1: Arthemeter-lumefantrine|Arthemeter-lumefantrine (ART-LUM) is an antimalaria drug manufactured as fixed combination tablets, each containing 20 mg of artemether and 120 mg of lumefantrine. ART-LUM was administrated according to body weight as six consecutive doses: The first dose at diagnosis and the second dose eight hours later, 0- 24-48 hours
2939620|NCT02974348|Active Comparator|arm 2 : Artesunate mefloquine|Artesunate mefloquine (ASMQ) is an antimalaria drug administered as a combination of artesunate, 4 mg/kg/day, with mefloquine, 8 mg/kg/day orally once a day for 3 days or three times, at an interval of 24 hours (0 h - 24 h - 48 h).
2939621|NCT02974348|Active Comparator|arm 3 : Dihydroartemisinin piperaquine|Dihydroartemisinin piperaquine (DHA-PQ ) is an antimalaria drug administered as a combination of dihydroartemisinin, 2.5 mg per kg, with piperaquine phosphate, 20mg per kg daily for 3 days or three times, at an interval of 24 hours
2939622|NCT02974348|Other|Paracetamol|Oral paracetamol is administered at of 50mg/kg body weight per day in three divided doses for fever exceeding 37.5oC.
2939623|NCT02974348|Other|Amoxicillin|amoxicillin is an antibiotic administered at 50mg per kg body weight per day for seven days in the event of concomitant bacterial infection, absent on day 0 but present during the follow up.
2939624|NCT02974348|Other|Quinine|Quinine is an antimalarial recommended by the WHO and NMCP to be used as second line treatment for malaria. In this study, for cases of treatment failure with the artemisinin based combination therapies, quinine sulphate is administered as a second line or rescue drug at a dose of 25mg base per kg body weight per day in three divided doses for five days. The participant is then classified as ETF or LTF and excluded from the study.
2939625|NCT02974335||Identify screening and intervention approaches|Key stakeholders including: informatics/Epic leaders, medical providers, and patients from the two health systems that will be involved in the study, as well as national health information technology leaders from other large health systems.
2939626|NCT02974322|Experimental|GED-0301 1 x 160 mg once daily|GED-0301 1 x 160 mg tablet once daily (QD)
2939627|NCT02974322|Experimental|GED-0301 - 4 x 40 mg once daily|GED-0301 4 x 40 mg tablets once daily (QD)
2939628|NCT02974322|Placebo Comparator|Placebo once daily|Placebo once daily (QD)
2939629|NCT02974309|Experimental|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer.
2939630|NCT02974309|Sham Comparator|Routine|All youth in this condition are asked to follow the routine that their clinical team has established.
2939631|NCT02974296|Experimental|new target TMS|new target transcranial magnetic stimulation guided by MRI
2939632|NCT02974296|Active Comparator|standard TMS|standard transcranial magnetic stimulation
2939633|NCT02974283|Experimental|NBO group|Normobaric oxygen therapy is the delivery of high-flow oxygen (10L/min) via oxygen storage facemask. This therapy should start within 1 hours after diagnosis of ischemic stroke and last for 4hours. All participants will receive r-tPA thrombolytic therapy and a standard clinical therapy.
2939634|NCT02974283|No Intervention|Control group|The participants receive r-tPA thrombolytic therapy after diagnosed ischemic. All participants receive a standard clinical therapy.
2939635|NCT02974270|Experimental|Leuprolide acetate|
2939636|NCT02974257|Experimental|Thiamine|Intervention: Thiamine 500mg IV every 12 hours for 2 days. Oxygen consumption will be monitored with a non-invasive monitor continuously for 2 days and lactate, pyruvate dehydrogenase and other routine lab values will be checked at serial time points.
2939637|NCT02974257|Placebo Comparator|Placebo|Intervention: Placebo (100mL normal saline) IV every 12 hours for 2 days. Oxygen consumption will be monitored with a non-invasive monitor continuously for 2 days and lactate, pyruvate dehydrogenase and other routine lab values will be checked at serial time points.
2939638|NCT02974244||exenatide once weekly|type 2 diabetes who initiated exenatide once weekly treatment in the index period
2939639|NCT02974244||basal insulin|type 2 diabetes patients who initiated basal insulin treatment in the index period
2939640|NCT02974205|Active Comparator|Rehabilitation with orthosis (Jack brace)|
2939641|NCT02974205|Active Comparator|Rehabilitation without orthosis|
2939642|NCT02974205|Active Comparator|Rehabilitation with orthosis (össur brace)|
2939643|NCT02974179||Subjects who received AMG0001|Subjects from Study AG-CLI-0206 who received the study product AMG0001
2939644|NCT02974166|Active Comparator|Conventional Group|Individuals with temporomandibular disorder were used rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions during four weeks.
2939645|NCT02974166|Experimental|Osteopathic Group|Individuals with temporomandibular disorder received the same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week until the end of dental and speech therapy treatments (4 weeks).
2939646|NCT02974153|Experimental|ALD403 (Eptinezumab) Dose Level 1|ALD403 (Eptinezumab) Dose Level 1 (IV)
2939647|NCT02974153|Experimental|ALD403 (Eptinezumab) Dose Level 2|ALD403 (Eptinezumab) Dose Level 2 (IV)
2939648|NCT02974153|Placebo Comparator|Placebo|Placebo (IV)
2939649|NCT02974140|Experimental|CRS|First surgical eye randomized to Cataract Refractive Suite with second surgical eye (fellow eye) assigned to standard manual technique. Second eye surgery conducted within 7-14 days of the first eye surgery.
2939650|NCT02974140|Active Comparator|Manual|First surgical eye randomized to standard manual technique with second surgical eye (fellow eye) assigned to Cataract Refractive Suite. Second eye surgery conducted within 7-14 days of the first eye surgery.
2939651|NCT02974114|Experimental|Paracetamol and caffeine|Participants will be administered test product (containing 500 mg paracetamol and 65 mg caffeine). Two tablets will be taken orally once with 200 mL (milliliters) of water.
2939652|NCT02974114|Experimental|Paracetamol|Participants will be administered test product (containing 500 mg paracetamol). Two tablets will be taken orally once with 200 mL of water.
2939653|NCT02974114|Placebo Comparator|Placebo|Participants will be administered reference product (placebo to match Paracetamol 665mg sustained release tablets). Two tablets will be taken orally once with 200 mL of water.
2939654|NCT02974101|Experimental|spinal cord stimulation(RestoreSensor)|
2939655|NCT02974088|Experimental|Neem-based lotion plus louse comb|Neem-based conditioning lotion plus head louse detection and removal comb
2939656|NCT02974088|Experimental|Neem-based lotion plus grooming comb|Neem-based conditioning lotion plus regular grooming comb
2939657|NCT02974075|Experimental|Salvage lymph node dissection|Patients will undergo extended pelvic salvage lymph node dissection
2939658|NCT02974062|Experimental|Lumbar stabilization exercise|Lumbar stabilization exercised is a low-intensity exercise that focuses on motor control of deep abdominal and back muscles, rather than their strength or endurance. There are 3 main levels in this exercise; 1) co-contraction of deep abdominal and back muscles, 2) co-contraction with limb movement (self-perturbation), and 3) co-contraction with functional movement (i.e. walking, running, etc.)
2939659|NCT02974062|No Intervention|Healthy control|No intervention was given to this group of participants. They were asked to rest and wait for 15 minutes, then post-test was performed.
2939660|NCT02974049|Active Comparator|Standard Treatment|Albendazole 400 mg + Ivermectin 200 µg/kg body weight administered annually (at 0, 12 and 24 months)
2939662|NCT02974049|Experimental|ALB 800 mg x2 per year|Albendazole 800 mg given at 0, 6, 12, 18, 24 and 30 months
2939663|NCT02974049|Experimental|ALB 400mg + IVM 200mcg/kg + DEC 6mg/kg|Albendazole 400 mg plus Ivermectin 200 µg/kg body weight plus Diethylcarbamazine 6 mg/kg body weight given one time only
2939664|NCT02974036|Experimental|Patient education for osteoarthritis|The intervention in the education program consists of three group lessons of about 90 minutes each where information about ethiology, risk factors, treatment and coping strategies concerning OA is included. The first two lessons are held by a physiotherapist and the third by a so-called expert patient that is a person with OA who shares his or her experiences of how to live with the disease. After the intervention patients are able to choose if they want to exercise at home or in a group, supervised by a physiotherapist.
2939665|NCT02974010|Experimental|NRX-101|NRX-101 is a fixed dose combination of d-cycloserine and lurasidone
2939666|NCT02974010|Active Comparator|Lurasidone|Lurasidone will be administered in the same dosages as the lurasidone componenet of NRX-101
2939667|NCT02973997|Experimental|Treatment (lenvatinib, pembrolizumab)|Patients receive lenvatinib mesylate PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 19 courses in the absence of disease progression or unacceptable toxicity. Participants may continue treatment for up to 35 courses.
2939668|NCT02973971||Healthy subjects|
2939669|NCT02973971||Alzheimer patients|
2939670|NCT02973958|Active Comparator|No ketorolac|15 mg/kg oral dose of acetaminophen is administered prior to surgery. General anesthesia will be induced with sevoflurane via facemask. After establishing venous access, a laryngeal mask will be inserted, and anesthesia maintained with 1 minimum alveolar anesthetic concentration (MAC) of sevoflurane in oxygen/air 50/50 mixture. The DPNB nerve block is done using a 23 GA needle inserted below the Buck fascia. Once the needle tip is positioned appropriately and after a negative aspiration test, 0.2mL/kg (maximum 10mL) of 0.25% bupivacaine is injected in small aliquots, with intermittent aspiration throughout. In all patients, skin incision is performed at least 5 min after placement of the nerve block. Patients will be advised to take ibuprofen and acetaminophen post-operatively as needed.
2939671|NCT02973958|Experimental|Peri-operative ketorolac|Exactly same as the no ketorolac group except at the beginning of the circumcision, once the patient is asleep, patients in the perioperative ketorolac group will also receive a 0.5 mg/kg intravenous dose of ketorolac.
2939672|NCT02973945|Experimental|High Flow Nasal Cannula|During a 8 week Pulmonary Rehabilitation Program patients will receive oxygen through High Flow Nasal Cannula (HFNC) while they are training aerobic capacity on the treadmill.
2939673|NCT02973945|Active Comparator|The Venturi Mask|During a 8 week Pulmonary Rehabilitation Program patients will receive oxygen through The Venturi Mask (VM) while they are training aerobic capacity on the treadmill.
2939674|NCT02973932|Experimental|Internet-based psychotherapy|
2939675|NCT02973919|Experimental|Eye movements|Eye Movement Desensitization and Reprocessing Therapy + virtual reality exposure therapy
2939676|NCT02973919|Active Comparator|Control|virtual reality exposure therapy
2939677|NCT02973906|Other|ADAPT Self Directed web|ADAPT Self Directed Web. In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum)
2939678|NCT02973906|Other|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
2939679|NCT02973906|Other|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics
2939680|NCT02973893|Placebo Comparator|Placebo plus Standard Care|Placebo plus Standard Care
2939681|NCT02973893|Experimental|VF001-DP LD plus Standard Care|VF001-DP (14 micrograms per treatment) and Standard Care (low dose [LD])
2939682|NCT02973893|Experimental|VF001-DP HD plus Standard Care|VF001-DP (140 micrograms per treatment) and Standard Care (high dose [HD])
2939683|NCT02973880|Experimental|NETILDEX™ ophthalmic gel|"1 drop of NETILDEX™ (Netilmicine Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel immediately after the surgery then 1 drop twice daily (b.i.d.) from Day 1 until Day 14 after surgery + 1 drop of XANTERGEL™ ophthalmic gel twice daily (b.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
2939684|NCT02973880|Active Comparator|NETILDEX™ eye drops solution|"1 drop of NETILDEX™ (Netilmicine Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) eye drops solution immediately after the surgery then 1 drop four times a day (q.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
2939685|NCT02973867||Cohort called Elodie|Obese patients
2939686|NCT02973841|Experimental|Sono-ease group|insertion IJV catheter using sono-ease device
2939687|NCT02973828||A) Volunteer Imaging Studies|Non-patient Volunteer Imaging Studies of Normal Tissue (n = 18 - 54) In the first stage, participants will be non-patient volunteers who agree to undergo MR imaging on the MR Linac on a single or multiple occasions (up to 12) to examine the anatomic sites listed above for normal tissue visualisation.
2939688|NCT02973828||B) Patient Volunteer Imaging Studies|Patient Volunteer Imaging Studies of Normal Tissue (n = 33 - 66) In the second stage, participants will be patient volunteers, who agree to undergo MR imaging on the MR Linac on a single or multiple (up to 12) occasions to examine multiple tumour sites (n=11) for tumour/target visualisation.
2939689|NCT02973828||C) Pathway development studies|Pathway development studies (n = 66 - 110) In the third stage, participants will be patient volunteers, who agree to undergo MR imaging on the MR Linac on a single or multiple (up to 12) occasions to examine intra and inter observer variability on target and organs at risk visualisation using the exam cards from Stage B.
2939690|NCT02973815|Experimental|NU-HOME Intervention|Intervention participants will receive the NU-HOME family intervention. Families in the intervention condition will participate in group sessions with other families focused on nutrition education, cooking skills, and physical activity. In addition to the group sessions, the intervention will also include individual goal setting phone calls and online, complementary materials.
2939826|NCT02972931||Standard Reservoir Level|HIV-infected subjects who initiated cART during chronic HIV-1 infection and that show standard HIV-1 DNA levels in peripheral blood
2939691|NCT02973815|No Intervention|Delayed Intervention|Families in the delayed intervention will not receive any educational materials or training until after the final data collection. Once all data collection is completed, they will receive a version of the NU-HOME program that was offered to the intervention families.
2939692|NCT02973802|Experimental|ATX-GD-59 treatment|An upward titration over five dose levels (25, 50, 100, 400 and 800 micrograms) followed by 5 doses of 800 micrograms of ATX-GD-59 will be administered two weeks apart by intradermal injection.
2939693|NCT02973789|Experimental|NovoTTF-100L|Patients receive TTFields using the NovoTTF-100L System together with immune checkpoint inhibitors or docetaxel
2939694|NCT02973789|Active Comparator|Best Standard of Care|Patients receive best standard of care with immune checkpoint inhibitors or docetaxel
2939695|NCT02973776|Experimental|LEO 90100 aerosol foam|"LEO 90100 calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate) aerosol foam~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
2939696|NCT02973776|Active Comparator|Dermoval®/Dermovate®|"Dermoval®/Dermovate® (clobetasol propionate 0.05%) cream~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
2939697|NCT02973776|Active Comparator|Diprosone®|"Diprosone® betamethasone 0.5 mg/g (as dipropionate) ointment~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
2939698|NCT02973776|Active Comparator|Elocon®|"Elocon® mometasone furoate 0.1% cream~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
2939699|NCT02973776|Active Comparator|Locoid®|"Locoid® hydrocortisone-17-butyrate 0.1% ointment~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
2939700|NCT02973776|Placebo Comparator|LEO 90100 foam vehicle|"LEO 90100 foam vehicle~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
2939701|NCT02973763|Experimental|Alflutinib|patients take Alflutinib orally once per day at different dose
2939702|NCT02973750||Pre-Surgery Chemotherapy Patients|All participants. Patients receiving chemotherapy with carboplatin and paclitaxel before their debulking surgery, who may have more chemotherapy after surgery. Sampling procedures will include: Baseline Biopsy; Tissue Collection; Blood Draws.
2939703|NCT02973737|Experimental|arm 1|pyrotinib plus capecitabine pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
2939704|NCT02973737|Active Comparator|arm 2|placebo plus capecitabine placebo(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
2939705|NCT02973724|Experimental|Remifentanil|Extubation was performed when remifentanil was maintained a predetermined concentration throughout the emergence periods.
2939706|NCT02973711|Experimental|Nilotinib + Ruxolitinib|"The first part of the trial will be Phase I and will enroll 25 participants. Participants will receive nilotinib BID and either 10, 15 or 20 mg of ruxolitinib BID. Maximum tolerated dose (MTD) of ruxolitinib will be determined.~The second part of the trial will be a Phase II and will enroll 25 subjects. Participants will receive nilotinib and the MTD of ruxolitinib."
2939707|NCT02973698|Other|chin-down posture maneuver|The patients in received an intervention program consisting of four weekly individual sessions of 30 minutes. In these sessions, it was performed the training of Chin-down postural maneuver with saliva and water. The participants were trained to perform the maneuver twice a day, swallowing saliva, and during meals, throughout the week, at home. The participants received a form, so they recorded the number of times they performed the maneuver at home. It allowed the control of adherence, being reinforced at each session the importance of adherence to treatment. Besides, the subjects received instructions regarding feeding. All the instructions, as well as the explanation about the maneuver, were submitted to the patients through a written document.
2939708|NCT02973698|Other|Control|The participants of this group underwent evaluation of swallowing, and the same assessment was repeated after four weeks, without any intervention during that period.
2939709|NCT02973698|Other|Orientations about swallowing|The individuals participated in an intervention program which consisted of four individual sessions a week, with 30 minutes. In these sessions, the instructions about feeding were performed. The individuals received all the instructions on a written document. In the sessions, it was verified doubts about the guidelines and treatment adherence. In this group, it was not applied the Chin-down postural maneuver.
2939710|NCT02973685|Experimental|Hepatic arterial infusion chemotherapy|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: Folfox Protocol. Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
2939711|NCT02973685|Active Comparator|Transarterial chemoembolization|Procedure/Surgery: Transarterial chemoembolization Drug: TACE Drug Protocol. Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
2939712|NCT02973672|Experimental|SGM-101|
2939713|NCT02973659|Experimental|patients with palmar hyperhidrosis|oxybutynin Vs placebo
2939714|NCT02973659|Experimental|patients with plantar hyperhidrosis|oxybutynin Vs placebo
2939715|NCT02973659|Experimental|patients with axillary hyperhidrosis|oxybutynin Vs placebo
2939716|NCT02973646|Experimental|Nucleos(t)ide analogues treatment|Patients with interferon receptor level down-regulated at the 24th week. Patients of this group will receive peginterferon alfa-2b injection 80ug/d from baseline to 24th week, then nucleos(t)ide analogues (entecavir tablet 0.5mg/d or tenofovir tablet 300mg/d) from 25th to 36th week, then peginterferon alfa-2b injection 80ug/d again from 36th to 48th week.
2942056|NCT02957929|Experimental|Cohort 1b, Period E|Single oral dose under fasted conditions, crossover
2939717|NCT02973646|Active Comparator|Peginterferon treatment|Patients with interferon receptor level not down-regulated at the 24th week. Patients of this group will receive peginterferon alfa-2b injection 80ug/d from baseline to 48th week.
2939718|NCT02973633|Active Comparator|Healthy Volunteers|DTI will be performed in healthy volunteers to characterize normal fiber architecture in the heart and provide a comparison group for the patients imaged in the other arms.
2939719|NCT02973633|Active Comparator|Patients with Recent Myocardial Infarction|Patients with recent ST elevation myocardial infarcts will be recruited and imaged serially with DTI to detect changes in fiber architecture and their correlation with remodeling of the left ventricle.
2939720|NCT02973633|Active Comparator|Patients with Left Ventricular Hypertrophy|Patients with left ventricular hypertrophy and a history of heart failure will be recruited and imaged serially with DTI to detect changes in fiber architecture and their correlation with the onset and progression of heart failure.
2939721|NCT02973607||Donors|Patients who donated a kidney and took part in the original CRIB-DONOR study.
2939722|NCT02973607||Controls|Healthy subjects who took part in the original CRIB-DONOR study.
2939723|NCT02973594|Active Comparator|Ivabradine|Patients will receive ivabradine 2.5-7.5 mg PO bid in addition to baseline maximum-tolerated beta-blocker therapy.
2939724|NCT02973594|Placebo Comparator|Placebo|Patients will receive placebo bid in addition to baseline maximum-tolerated beta-blocker therapy.
2939725|NCT02973581|Experimental|metamizol|analgesic drug
2939726|NCT02973581|Experimental|acetaminophen|analgesic drug
2939727|NCT02973581|Experimental|0,5 % bupivacaine with of 2% lidocaine|a volume of 5 ml of analgesic solution for regional peribulbar block
2939728|NCT02973581|Experimental|Proxymetacaine|topical analgesia
2939729|NCT02973581|Placebo Comparator|control group|patients will receive no pre-emptive analgesia. standard doses of fentanyl will be used intraoperatively.
2939730|NCT02973555|Experimental|PRP injection|
2939731|NCT02973542|Experimental|ethosuximide|A responder will correspond to a decrease in abdominal pain score (11-points NRS pain) of at least 30% compared to the score before treatment and a score of 6 or 7 on the SGA scale. At endpoint (12-weeks treatment period), it will be compared the responder rate between the 2 treatment arms (ethosuximide vs placebo).
2939732|NCT02973542|Placebo Comparator|placebo|A responder will correspond to a decrease in abdominal pain score (11-points NRS pain) of at least 30% compared to the score before treatment and a score of 6 or 7 on the SGA scale. At endpoint (12-weeks treatment period), it will be compared the responder rate between the 2 treatment arms (ethosuximide vs placebo).
2939733|NCT02973529|Experimental|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
2939734|NCT02973529|Experimental|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
2939735|NCT02973516|Experimental|P03277 triphasic imaging|P03277 will be administered in order to acquire triphasic liver imaging
2939736|NCT02973503|Experimental|Elbasvir/Grazoprevir|evaluate the efficacy of of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
2939737|NCT02973490|Experimental|Transanal Tube Drainage|patients with transanal tube drainage after ESD
2939738|NCT02973490|No Intervention|Without Transanal Tube Drainage|patients without transanal tube drainage after ESD
2939739|NCT02973477|Experimental|Group A: Dapagliflozin/Glimepiride|Participants will take open-label dapagliflozin 5 mg daily for 4 weeks and escalate the dose gradually up to dapagliflozin 10 mg daily as needed based on their glucose monitoring for a total of 12 weeks on dapagliflozin. Patients will then begin a 2 week washout period where they are not taking any study drugs. After the washout period, participants will receive open-label glimepiride 2 mg daily for 4 weeks and escalate the dose gradually up to glimepiride 4 mg daily (no more than 4 mg daily) as needed based on their glucose monitoring for a total of 12 weeks on glimepiride.
2939740|NCT02973477|Experimental|Group B: Glimepiride/Dapagliflozin|Participants will take open-label glimepiride 2 mg daily for 4 weeks and escalate the dose gradually up to glimepiride 4 mg daily (no more than 4 mg daily) as needed based on their glucose monitoring for a total of 12 weeks on glimepiride. Patients will then begin a 2 week washout period where they are not taking any study drugs. After the washout period, participants will receive open-label dapagliflozin 5 mg daily for 4 weeks and escalate the dose gradually up to dapagliflozin 10 mg daily as needed based on their glucose monitoring for a total of 12 weeks on dapagliflozin.
2939741|NCT02973464||Valganciclovir 900mg a day|Valganciclovir 900mg tablet by mouth begin within 10 days after renal transplant，once a day till to Day 100 posttransplant.
2939742|NCT02973464||Valganciclovir 450mg a day|Valgancigclovir 450 mg tablet by mouth begin within 10 days after renal transplant，once a day till to Day 100 posttransplant.
2939743|NCT02973464||Ganciclovir|Ganciclovir 5mg/kg fluids by intravenous after renal transplant，once a day for the first 14 days；and than sequential Ganciclovir 1g tablet by mouth，third a day till to Day 100 posttransplant.
2939744|NCT02973451|Active Comparator|Laparoscopic|Laparoscopic Guided Transversus Abdominis Plane Block using Bupivacaine
2939745|NCT02973451|Active Comparator|local|Trocar Site Infiltration of Bupivacaine
2939746|NCT02973438|Experimental|Spinal Cord Injury (SCI) Intermittent Hypoxia then SHAM|This arm of individuals with SCI will receive Intermittent Hypoxia (IH) and following a 3 week washout, SHAM treatment interventions.
2939747|NCT02973438|Experimental|Control (CON) Intermittent Hypoxia then SHAM|This arm of non injured control subjects will receive Intermittent Hypoxia (IH) and following a 3 week washout, SHAM treatment interventions.
2939748|NCT02973438|Experimental|Spinal Cord Injury (SCI) SHAM then Intermittent Hypoxia|This arm of individuals with SCI will receive SHAM and following a 3 week washout, Intermittent Hypoxia (IH) treatment interventions.
2939749|NCT02973438|Experimental|Control (CON) SHAM then Intermittent Hypoxia|This arm of non injured control subjects will receive SHAM and following a 3 week washout, Intermittent Hypoxia (IH) treatment interventions.
2939824|NCT02972944|Active Comparator|Non-operative group|Patients of non-operative group will be treated conservatively with intravenous antibiotics (cefuroxime) at surgical ward. Elective cholecystectomy will not be arranged.
2939825|NCT02972931||LoViReT|HIV-infected subjects with extremely low or undetectable HIV-1 DNA levels in peripheral blood despite having initiated cART during chronic HIV-1 infection
2939750|NCT02973425|Active Comparator|NRT and mHealth assessment tool without feedback|"For the comparison group, implementation will be balanced in all variables except the Take a Break Intervention. The investigators will balance the two groups further by having the comparison (NRT-Sampling group) complete mHealth assessments (without feedback or goal-setting) as an attention control.~Participants randomized to the comparison group will only have access to a mHealth assessment tool similar to the Challenge Quizzes but without feedback."
2939751|NCT02973425|Experimental|Take a Break as an augmentation to NRT in Motivation|"The Intervention: Take a Break as an augmentation to NRT-sampling in Motivation Phase. Take a Break is an intervention in which smokers are encouraged to engage in smoking abstinence. The main element, the Break, is a two-week challenge where smokers report days they are smoke-free. The Break is preceded by a 1-week training challenge where Challenge Quizzes (ecological momentary assessments) collect information to guide the smokers during the Break. At baseline, all smokers will be provided NRT lozenges for sampling. At weeks 1 and 3 of the Marathon, our Tobacco Treatment Specialist will call all smokers, assess their experiences and collect data.Participants in the intervention will receive the full tool suite."
2939752|NCT02973399|Experimental|SNX-5422 plus ibrutinib|Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule for 2 cycles after a CR or until the cancer progresses or the subject is unable to tolerate the therapy
2939753|NCT02973386|Experimental|Concurrent chemoradiation + adjuvant chemotherapy|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
2939754|NCT02973386|Active Comparator|Concurrent chemoradiation|IMRT combine with cisplatin concurrent chemotherapy
2939755|NCT02973373|Experimental|MRI with HF-NIV|Intervention: Acquisition of MRI with High-Frequency non-invasive ventilation (HF-NIV)
2939756|NCT02973373|Active Comparator|MRI without HF-NIV|Intervention: MRI without High-Frequency non-invasive ventilation (HF-NIV)
2939757|NCT02973360|Experimental|Dose Level 1|Target dose 20 mg/kg Docosahexaenoic acid
2939758|NCT02973360|Experimental|Dose Level 2|Target dose 36 mg/kg Docosahexaenoic acid
2939759|NCT02973360|Experimental|Dose Level 3|Target dose 60 mg/kg Docosahexaenoic acid
2939760|NCT02973360|Placebo Comparator|Placebo|Soybean oil
2939761|NCT02973347|Active Comparator|Intermittent enteral feeding|Intermittent enteral feeding via the nasogastric tube is applied less than 30 mins.
2939762|NCT02973347|Active Comparator|Continuous enteral feeding|Continuous enteral feeding via the nasogastric tube using infusion pump is applied for 24 hours.
2939763|NCT02973334|Experimental|Sugar|Effects of ingestion of sugar-sweetened beverages on acute stress response
2939764|NCT02973334|Experimental|Artificial sweetener|Effects of ingestion of artificially-sweetened beverages on acute stress response
2939765|NCT02973334|Active Comparator|Water|Effects of ingestion of water on acute stress response
2939766|NCT02973321|Experimental|SAR425899 low dose|SAR425899 will be administered once daily in addition to metformin if any
2939767|NCT02973321|Experimental|SAR425899 mid dose|SAR425899 will be administered once daily in addition to metformin if any
2939768|NCT02973321|Experimental|SAR425899 high dose|SAR425899 will be administered once daily in addition to metformin if any
2939769|NCT02973321|Placebo Comparator|Placebo low dose|Placebo will be administered once daily in addition to metformin if any
2939770|NCT02973321|Placebo Comparator|Placebo mid dose|Placebo will be administered once daily in addition to metformin if any
2939771|NCT02973321|Placebo Comparator|Placebo high dose|Placebo will be administered once daily in addition to metformin if any
2939772|NCT02973321|Active Comparator|Liraglutide|Liraglutide will be administered once daily in addition to metformin if any
2939773|NCT02973308|Other|Treadmill-Test operator A|Randomised to motorised treadmill group A for inter reliability, observer A will perform both exercise tests
2939774|NCT02973308|Other|Treadmill-Test operator B|Randomised to motorised treadmill group B for intra reliability, observer A will perform one exercise test, followed by observed B
2939775|NCT02973308|Other|Cycle-Test operator A|Randomised to cycle group B for inter reliability, observer A will perform both exercise tests
2939776|NCT02973308|Other|Cycle-Test operator B|Randomised to cycle group B for intra reliability, observer A will perform one exercise test, followed by observed B
2939777|NCT02973295|Experimental|Group Silymarin|Silymarin 2x200 mg 8 weeks (2x2 caps) Silymarin 2x100 mg 16 weeks (2x1 caps)
2939778|NCT02973295|Placebo Comparator|Group Placebo|2x2 placebo caps 8 weeks 2x1 placebo caps 16 weeks
2939779|NCT02973269|Experimental|DaxibotulinumtoxinA 240 units|Botulinum Toxins, Type A Intramuscular injection
2939780|NCT02973269|Placebo Comparator|Placebo|Placebo Intramuscular injection
2939781|NCT02973243||Manual Respiration Rate Measurement|Patients with manually measured respiratory rate
2939782|NCT02973243||Automatic Respiration Rate Measurement|Patients with automatically measured respiratory rate
2939783|NCT02973217|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
2939784|NCT02973204||HCC sorafenib|HCC patients referred for Sorafenib treatment
2939785|NCT02973204||HCC curative treatment|HCC patient undergoing potential curative treatment, eg. radiofrequency ablation (RFA) or resection
2939786|NCT02973204||NET everolimus|Pancreatic NET patients referred for Everolimus treatment
2939787|NCT02973204||NET ssta|Small intestinal or unknown primary NET patients referred for treatment with somatostatin analogues, eg. lanreotide and octreotide
2939788|NCT02973191|Experimental|JCAR015 administration|Single dose of 1.0-3.0 mg/m^2 IV cyclophosphamide, JCAR015 Dose 1 1x10^6 Tcells/kg, JCAR015 Dose 2 3x10^6 Tcells/kg
2939789|NCT02973178|Other|Usability|Evaluate and validate the user-interface of the Scanadu Urine Device by the intended users for human factors and user interface of the Scanadu Urine Device.
2939790|NCT02973178|Active Comparator|Method Comparison|"Evaluate and validate the clinical performance of the Scanadu Urine Device in the hands of intended users as compared to:~The visual read of chemical test strips performed by lab technicians utilizing the Siemens Multistix® 10SG technology (K905396),~Scanadu Urine Device tests performed by lab technicians."
2939791|NCT02973178|Other|Reproducibility|Evaluate the reproducibility in the hands of the lay-users after repeated testing of samples with known test levels.
2939792|NCT02973152|Active Comparator|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
2939793|NCT02973152|Active Comparator|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
2939794|NCT02973139|Active Comparator|Thoracoscopy group|Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.
2939795|NCT02973139|Active Comparator|Fibrinolytic group|Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)
2939796|NCT02973126|Other|FFRct versus SPECT|Comparison of the diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD
2939797|NCT02973113|Experimental|EBVST Cells + Nivolumab|"PD1 inhibitor - nivolumab 3 mg/kg (max dose: 240 mg) Q 2 weeks for total 4 doses and repeat a day prior to each EBVST infusion.~EBVST- 1 x 10^8/m2 at days +1 and +15. PD1 inhibitor - nivolumab 3 mg/kg (max dose: 240 mg) Q 2 weeks for total 4 doses and repeat a day prior to each EBVST infusion.~Can receive up to 3 additional infusions of EBVSTs with a single dose of nivolumab at 6-12 week intervals starting at least 6 weeks after the second infusion if stable disease or a partial response at Week 8 evaluation"
2939798|NCT02973100|Experimental|Dulaglutide 4.5mg|4.5mg of Dulaglutide administered subcutaneously (SC)
2939799|NCT02973100|Experimental|Dulaglutide 3.0mg|3.0mg of Dulaglutide administered SC
2939800|NCT02973100|Active Comparator|Dulaglutide 1.5mg|1.5mg of Dulaglutide administered SC
2939801|NCT02973100|Placebo Comparator|Placebo|Placebo administered SC
2939802|NCT02973087|Experimental|All Study Participants|Participants with severe von Willebrand disease (VWD)
2939803|NCT02973074|Other|OLEOvital|30mg iron are being administered orally twice a day for a period of 4 Weeks it is a granulated powder which is taken orally and then solved with saliva, without taking water
2939804|NCT02973061||GH treated patients|All participants family member and teacher will fill questionnaires regarding signs of ateention deficit prior to GH treatment and after 6 and 12 months
2939805|NCT02973061||Healthy control|All participants family member and teacher will fill questionnaires regarding signs of atention deficit at baseline and after 6 and 12 months
2939806|NCT02973048|Placebo Comparator|Hyperbaric bupivacaine|Hyperbaric bupivacaine 0.5% will be administered at the dose of 10 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
2939807|NCT02973048|Active Comparator|Hyperbaric prilocaine 2%|Hyperbaric prilocaine 2% will be administered at the dose of 50 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
2939808|NCT02973035|Experimental|Amlodipine|Amlodipine 2.5mg added to antihypertensive therapy
2939809|NCT02973035|Experimental|Valsartan|Valsartan 40mg added to antihypertensive therapy
2939810|NCT02973022||Community CC&S Group|Once participants are randomized, they will be given survey 1. The intervention group in the community will be exposed to the modified CC&S educational sessions in a series of 2 one hour and 15 minute sessions on consecutive Monday nights. A free meal will be provided at both educational sessions. Childcare will be provided for community sessions. Once the final educational session is completed, all participants will be given survey 2.
2939811|NCT02973022||Community Control Group|Once participants are randomized, they will be given survey 1. The control group in the community will be exposed to a nutrition education program in a series of 2 one hour and 15 minute sessions on consecutive Monday nights. A free meal will be provided at both educational session. Childcare will be provided for community sessions. Once the final educational session is completed, all participants will be given survey 2.
2939812|NCT02973022||ACEC CC&S Group|Once participants are randomized, they will be given survey 1. The intervention group at ACEC (Adams-Columbia Electric Company) will be exposed to the modified CC&S educational sessions in a series of 6 thirty minute sessions before the work day begins over the course of several weeks. The researchers anticipate that two sessions will occur per week and therefore the delivery of the whole intervention will take 3 weeks. A free meal will be provided at all 6 educational sessions. Once the final educational session is completed, all participants will be given survey 2.
2939813|NCT02973022||ACEC Control Group|Once participants are randomized, they will be given survey 1. The control group at ACEC will be exposed to a nutrition education program in a series of 6 thirty minute sessions before the work day begins over the course of several weeks. We anticipate that two sessions will occur per week and therefore the delivery of the whole intervention will take 3 weeks. A free meal will be provided at all 6 educational sessions. Once the final educational session is completed, all participants will be given survey 2.
2939814|NCT02972996|Experimental|Blueberry|
2939815|NCT02972996|Placebo Comparator|Placebo|
2939816|NCT02972983|Placebo Comparator|Placebo|51 patients receiving a daily placebo infusion for five days on top of standard of care treatment for methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia
2939817|NCT02972983|Experimental|Daptomycin|51 patients receiving daily daptomycin infusion for five days on top of standard of care treatment for MSSA bacteremia
2939818|NCT02972970|Other|Aveera|This is a prospective, open label study to assess the scan, print and fit process to see if the Aveera will be able to be used with conventional CPAP therapy devices
2939819|NCT02972957|Experimental|LAIV-vaccinated group 1|Nasovac-S vaccination group A , blood samples days 0, 2, 21
2939820|NCT02972957|Experimental|LAIV-vaccinated group 2|Nasovac-S vaccination group B, blood samples at days 0, 7, 21
2939821|NCT02972957|No Intervention|Unvaccinated|control group C
2939822|NCT02972957|Experimental|Oral Azithromycin & vaccination|group D - a single dose of oral Azithromycin will be given 28 days prior to Nasovac-S vaccination
2939823|NCT02972944|Experimental|Cholecystectomy group|Cholecystectomy group will undergo laparoscopic cholecystectomy within 48 hrs after randomization.
2939827|NCT02972918|Other|Levosimendan|At least 12 hours before surgery: Infusion of levosimendan (0,1 mcg/kg/min). 24 hours of infusion without a bolus.
2939828|NCT02972905|Placebo Comparator|Session 1: Placebo|Subjects will receive a single dose inhalation of GSK2269557 matching placebo via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
2939829|NCT02972905|Experimental|Session 1: GSK2269557 200 mcg|Subjects will receive a single dose inhalation of GSK2269557 200 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
2939830|NCT02972905|Experimental|Session 1: GSK2269557 500 mcg|Subjects will receive a single dose inhalation of GSK2269557 500 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
2939831|NCT02972905|Experimental|Session 1: GSK2269557 700 mcg|Subjects will receive a single dose inhalation of GSK2269557 700 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
2939832|NCT02972905|Placebo Comparator|Session 2: Placebo|Subjects will receive repeated doses of GSK2269557 matching Placebo once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
2939833|NCT02972905|Experimental|Session 2: GSK2269557 200 mcg|Subjects will receive repeated doses of GSK2269577 200mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
2939834|NCT02972905|Experimental|Session 2: GSK2269557 500 mcg|Subjects will receive repeated doses of GSK2269577 500mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
2939835|NCT02972905|Experimental|Session 2: GSK2269557 700 mcg|Subjects will receive repeated doses of GSK2269577 700mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
2939836|NCT02972879|Active Comparator|Therapeutic Modalities|"Group 1: Metal orthotic, keeping 0º of the extension of the proximal interphalangeal joint, during all day, for 5 weeks, stopping the use only for bathing~Group 2: 10 LLLT sessions applications on the A1 pulley and lump formed on the flexor tendon of the the affected finger; Two sessions per week, five weeks of treatment.~Group 3: Paraffin bath 2 times a week for 20 minutes (total of 10 sessions)."
2939837|NCT02972879|Active Comparator|Corticosteroid injection|Group 4: Corticosteroid injection in the A1 pulley, 1 application.
2939838|NCT02972866|Experimental|Noex 32mcg|"Noex/Budesonide 32mcg, 2 atomizations in each nostril by the morning and during the night, total of 256 mcg per day.~Tretament of 28 days."
2939839|NCT02972866|Experimental|Budecort Aqua 32 mcg|"Budecort Aqua/Budesonide 32mcg, 2 atomizations in each nostril by the morning and during the night, total of 256 mcg per day.~Tretament of 28 days."
2939840|NCT02972853|Experimental|Mindfulness Training for Primary Care|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study. For the Mindfulness Training for Primary Care (MTPC) fMRI - arm, we acquire pre-/post-intervention neuroimaging measures from subjects enrolled in this additional pilot fMRI study."
2939841|NCT02972840|Experimental|Acalabrutinib in combination with bendamustine and rituximab|Acalabrutinib administered twice per day (BID) orally (PO) plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.
2939842|NCT02972840|Placebo Comparator|Placebo in combination with bendamustine and rituximab|Matching placebo administered BID PO plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.
2939843|NCT02972827|Experimental|NICOM/FloTrac|500-1000ml Crystalloid fluid challenge (normal saline or plasmalyte) to be given for positive passive leg raise test by either device, and also will be given at baseline, regardless of baseline PLR response.
2939844|NCT02972814||Thoracic pain|Patients presenting to the emergency room with thoracic pain probably due to a non-STEMI
2939845|NCT02972801|Experimental|Testicular tissue biopsy|Testicular biopsy
2939846|NCT02972788|Experimental|Experimental Group|Group will receive enamel matrix protein derivative treatment along with scaling and root planing.
2939847|NCT02972788|Sham Comparator|Control Group|Group will receive placebo (saline) treatment along with scaling and root planing.
2939848|NCT02972762|Active Comparator|L Group|The participants in L Group will receive Lumbar plexus and sciatic nerve block with ropivacaine before anesthesia induction.The investigator use Diprivan TCI target-controlled infusion during anesthesia induction period, target effect-site concentration is set at 4.0g / kg. After reaching the target concentration, sufentanil 0.2g / kg is administrated, Laryngeal mask will be placed into participant's mouth at 2 min after sufentanil is given. Anesthesia will be maintained with remifentanil TCI target-controlled infusion and Diprivan BIS close-loop target controlled infusion,BIS ranges from 50 to 60.The values of BP,P,PetCO2 will be controled in proper site. each participant will be given postoperative analgesia pump to release postoperative pain.
2939849|NCT02972762|Active Comparator|D Group|The participant in L Group will receive Lumbar plexus and sciatic nerve block with ropivacaine before anesthesia induction.The investigator use Diprivan TCI target-controlled infusion during anesthesia induction period, target effect-site concentration is set at 4.0g / kg. After reaching the target concentration, sufentanil 0.2g / kg is administrated, Laryngeal mask will be placed into participant's mouth at 2 min after sufentanil is given. Anesthesia will be maintained with remifentanil TCI target-controlled infusion and Diprivan BIS close-loop target controlled infusion,BIS ranges from 35 to 45.The values of BP,P,PetCO2 will be controled in proper site. The investigator use postoperative analgesia pump to control postoperative pain for each participant.
2939850|NCT02972749|Experimental|Intervention|Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
2939851|NCT02972749|No Intervention|Control|No intervention. patients are instructed to continue prescribed medical therapy.
2939852|NCT02972736||Interventional Cardiology|All procedures performed by interventional cardiologists
2939853|NCT02972736||Electrophysiology|All procedures performed by electrophysiologists
2939854|NCT02972736||Interventional Radiology|All vascular and non vascular procedures performed by interventional radiologists
2939855|NCT02972723|Experimental|Metformin therapy, single arm|Open label trial, participants will be expected to take Metformin twice a day for 2 weeks
2939856|NCT02972710|Active Comparator|Supine thoracic spine manipulation|Supine thoracic spine thrust manipulation (lying face-up on the treatment table) will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2)
2939857|NCT02972710|Active Comparator|Seated thoracic spine manipulation|Seated thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2).
2939858|NCT02972697|Experimental|11C-acetate PET|11C-acetate and FDG PET/MRI and PET/CT will be performed.
2939859|NCT02972684|No Intervention|Conventional coagulation management|management of perioperative haemorrhage following cardiac surgery using conventional blood coagulation tests.
2939860|NCT02972684|Experimental|Thrombo-elastometry POC testing|management of perioperative haemorrhage following cardiac surgery using the thrombo-elastometry point of care test.
2939861|NCT02972671|Experimental|MiStent (MT005) Coronary Artery Stent|A balloon expandable crystalline sirolimus eluting stent with an absorbable polymer coating will be implanted.
2939862|NCT02972671|Active Comparator|Xience Coronary Artery Stent|Balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating will be implanted
2939863|NCT02972658|Experimental|Lanabecestat Dose 1|Lanabecestat given orally.
2939864|NCT02972658|Experimental|Lanabecestat Dose 2|Lanabecestat given orally.
2939865|NCT02972658|Experimental|AZES Placebo Arm / AZFD Dose 1|Lanabecestat given orally.
2939866|NCT02972658|Experimental|AZES Placebo Arm / AZFD Dose 2|Lanabecestat given orally.
2939867|NCT02972645|Experimental|LY3305677|Single escalating doses of LY3305677 administered subcutaneously (SC)
2939868|NCT02972645|Placebo Comparator|Placebo|Placebo administered SC
2939869|NCT02972632|Experimental|Vortioxetine 10-20 mg|Vortioxetine 10 mg, tablets, orally, once daily followed by a dose adjustment to a maximum of 20 mg, tablets, orally, once daily up to 12 weeks. The dose may be decreased by 5 mg based on participant's response and tolerability as judged by the investigator.
2939870|NCT02972619|Experimental|Intervention|Structured multicomponent intervention (MCI)
2939871|NCT02972619|No Intervention|Usual Care|Control group receive usual care in the polyclinics
2939872|NCT02972593|Other|Liberal|Blood and blood products for transfusion. Transfusion will be done to keep Hgb >7 g/dL.
2939873|NCT02972593|Other|Conservative|Blood and blood products for transfusion. Transfusion will be done to keep Hgb > 5.5 g/dL.
2939874|NCT02972580||Cohort A|DMD/BMD Female Carriers who have/had an affected child (n=150)
2939875|NCT02972580||Cohort B|DMD/BMD Female non-carriers controls who have/had an affected child (n=50)
2939876|NCT02972580||Cohort C|Healthy Age-Matched Controls (n=50)
2939877|NCT02972580||Cohort D|DMD/BMD Female Carriers with no affected children (n=25)
2939878|NCT02972567|Experimental|Probiotic|Lactobacillus strain
2939879|NCT02972567|Placebo Comparator|Control|Maltodextrin
2939880|NCT02972554|Experimental|Propanolol Hydrochloride|This is the experimental group given the beta-blocker
2939881|NCT02972554|Placebo Comparator|Placebo|This is the control group given a placebo.
2939882|NCT02972541|Experimental|Stenting with neoadjuvant chemotherapy|After clinical success of colonic stenting, patients will receive neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 3-5 weeks after the last cycle of chemotherapy, type and extent of the surgery will be selected by the surgeon.
2939883|NCT02972541|Active Comparator|Stenting with Immediate Surgery|After clinical success of colonic stenting, patients will undergo surgery 7-14 days after inclusion. Type and extent of the elective surgery will be selected by the surgeon.
2939884|NCT02972528|Active Comparator|Platelet Lysate|Patients will receive 5ml peri-lesional injections of Platelet Lysate at weekly intervals, for 4 consecutive times (week 0,1,2,3).
2939885|NCT02972528|Placebo Comparator|Platelet Poor Plasma|Patients will receive 5ml peri-lesional injections of Platelet Poor Plasma at weekly intervals, for 4 consecutive times (week 0,1,2,3).
2939886|NCT02972515|Experimental|See Me Smoke-Free|"Participants received access to the See Me Smoke-Free mobile application (app), and were asked to use the app most days for 30 days post-enrollment. The app contained five guided imagery audio files (Introduction to Guided Imagery, Be Smoke Free, Eat Well, Get Active, and Feel Fantastic), a tracking calendar, awards, resources, reminders, and tips and techniques."
2939887|NCT02972502|Active Comparator|Metoclopramide (Reglan)|Patients will receive 10 mg of intravenous (IV) metoclopramide following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.
2939888|NCT02972502|Experimental|Haloperidol (Haldol)|Patients will receive 2.5 mg of intravenous (IV) haloperidol following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.
2939889|NCT02972489|Experimental|3D OFDI guidance arm|Bifurcation percutaneous coronary intervention (PCI) optimized by online-3D OFDI during and after procedure
2939890|NCT02972489|Active Comparator|Angio guidance arm|Bifurcation percutaneous coronary intervention (PCI) guided by angiography
2939891|NCT02972476|Active Comparator|1: Symbicort 400/12 & Eklira Genuair|Budesonide 400mcg & formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
2939892|NCT02972476|Active Comparator|2: Seretide 500/50 & Eklira Genuair|Fluticasone propionate 500mcg & salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
2939893|NCT02972476|Active Comparator|3: Seretide 250/50 & Eklira Genuair|Fluticasone propionate 250mcg & salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
2939894|NCT02972476|Active Comparator|4: Duaklir Genuair|Aclidinium bromide 340mcg & formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder for 3 months
2939895|NCT02972463|Placebo Comparator|Placebo|9 maltodextrin capsules, once daily for 12 weeks
2939896|NCT02972463|Experimental|IgY Max Low-Dose (1g IgY Max)|2 Immunoglobulin Y capsules and 7 maltodextrin capsules, once daily for 12 weeks
2939897|NCT02972463|Experimental|IgY Max Mid-Dose (2g IgY Max)|4 Immunoglobulin Y capsules and 5 maltodextrin capsules, once daily for 12 weeks
2939898|NCT02972463|Experimental|IgY Max High-Dose (4.5g IgY Max)|9 Immunoglobulin Y capsules, once daily for 12 weeks
2940044|NCT02971462|No Intervention|Control group|The participants receive a standard clinical therapy after diagnosed ischemic stroke.
2939899|NCT02972450|Experimental|Injection only: Active:placebo (3:1)|"GTU-MultiHIV B-clade + MVA HIV-B:~GTU-MultiHIV B-clade - 2 mg of DNA in 1ml encoding a multi HIV antigen (synthetic fusion protein) administered intramuscularly into the non-dominant deltoid muscle at weeks 0 and 4 and MVA HIV-B 0.5ml(1 x108 pfu/ml) MVA encoding the full-length codon-optimized sequence of Gag administered intramuscularly into the non-dominant deltoid muscle at week 12."
2939900|NCT02972450|Experimental|Infusion only: Active:placebo (3:1)|Vedolizumab will be administered in the participant's dominant arm as an intravenous infusion over 30 mins.
2939901|NCT02972450|Experimental|Injection and Infusion: Active:placebo (3:1)|GTU-MultiHIV B-clade + MVA HIV-B + Vedolizumab
2939902|NCT02972450|Placebo Comparator|Placebo|"Placebo1 for DNA: Sodium chloride for injection, 0.9% in 1ml administered intramuscularly into the non-dominant deltoid muscle at weeks 0 and 4.~Placebo 2 for MVA: S08 buffer in 0.5ml administered intramuscularly into the non-dominant deltoid muscle at week 12.~Placebo for mAb: Sodium Chloride (NaCl) for infusion, 0.9% in 250 ml infusion bags."
2939903|NCT02972424|Experimental|Teriparatide Prefilled Syringe|TPTD is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection. Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 250 mcg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4.
2939904|NCT02972424|Placebo Comparator|Placebo|Placebo is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection. Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4.
2939905|NCT02972411|Experimental|Intervention|Voluntary increase in respiration
2939906|NCT02972411|Active Comparator|Acetazolamide|Administration of Acetazolamide 125mg. since 24 hours before ascent and until 48 hours post altitude exposure, and absence of altitude sickness symptoms
2939907|NCT02972398|Experimental|NAC group|"Participants of NAC group receive 1000 mg NAC twice daily for 12 weeks as add-on to either a selective serotonin reuptake inhibitor (SSRI) or a serotonin and noradrenalin reuptake inhibitor (SNRI)"
2939908|NCT02972398|Placebo Comparator|Placebo group|"Participants of Placebo group receive placebo matched with NAC twice daily for 12 weeks as add-on to either a selective serotonin reuptake inhibitor (SSRI) or a serotonin and noradrenalin reuptake inhibitor (SNRI)"
2939909|NCT02972372|Active Comparator|CRT group|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in IMRT mode (total of 50Gy given in 25 fractions) will be given over a period 5-6 weeks.
2939910|NCT02972372|Active Comparator|Surgery group|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
2939911|NCT02972359|Experimental|Neridronic acid|Neridronic acid 100 mg administered on Day 1, Day 4, Day 7, and Day 10, resulting in a total dose of neridronic acid 400 mg.
2939912|NCT02972346|Experimental|ACTH(+)|routine treatment + ACTH
2939913|NCT02972346|No Intervention|ACTH(-)|routine treatment
2939914|NCT02972333|Experimental|AZD9291 80mg oral each day±RT|AZD9291(80mg, QD, p.o.) was provided to patients with confirmed EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI and concurrent with brain metastasis. Radiation therapy will be implemented according to investigator's clinical practice(A 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.).
2939915|NCT02972320|Experimental|temozolomide maintain therapeutic|Lobaplatin combined with etoposide for first-line treatment of extensive stage small cell lung cancer,then clinical benefit patients for temozolomide maintain therapeutic.This study have only one arm which temozolomide maintain at dose of 150mg/m2 D1-5 Q4W.
2939916|NCT02972307||caregiver|dyad of caregiver and the wheelchair user to whom they provide care
2939917|NCT02972294|Experimental|TXA + IIM|The patients randomized to this arm will have iron isomaltoside 1000 and tranexamic acid
2939918|NCT02972294|Experimental|Placebo TXA + IIM|The patients randomized to this arm will have iron isomaltoside 1000 and Placebos tranexamic acid
2939919|NCT02972294|Experimental|TXA + Placebo IIM|The patients randomized to this arm will have Placebos iron isomaltoside 1000 and tranexamic acid
2939920|NCT02972294|Experimental|Placebo TXA + Placebo IIM|The patients randomized to this arm will have Placebos iron isomaltoside 1000 and Placebos tranexamic acid
2939921|NCT02972281|Other|Patients with bacterial infections|Patients with recurrent and/or severe bacterial infections
2939922|NCT02972268|Experimental|Group I|Tamsulosin 0.2mg + Solifenacin 5mg
2939923|NCT02972268|Placebo Comparator|Group II|Tamsulosin 0.2mg + Placebo(Solifenacin)
2939924|NCT02972255|Experimental|Part I: RO7079901|Participants will be randomized in two dose cohorts to receive single dose of RO7079901 1000 and 2000 milligrams (mg) intravenous (IV) infusion on Days 1 through Day 7 every 8 hours (q8h), for a total of 19 doses, with the last dose administered on the morning of Day 7.
2939925|NCT02972255|Placebo Comparator|Part I: Placebo|Participants will be randomized in two dose cohorts to receive single dose of placebo matching to RO7079901 on Days 1 through Day 7 q8h, for a total of 19 doses, with the last dose administered on the morning of Day 7.
2939926|NCT02972255|Experimental|Part II - Single Dose and Repeat Dose: RO7079901|Participants will be randomized in two dose cohorts to receive single dose of RO7079901 IV infusion at a dose above the previously studied dose levels in Part I (greater than [>] 2000 mg) on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.
2939927|NCT02972255|Placebo Comparator|Part II - Single Dose and Repeat Dose: Placebo|Participants will be randomized in two dose cohorts to receive single dose placebo matching to RO7079901 on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.
2940283|NCT02969733|Placebo Comparator|isotonic saline serum|isotonic saline serum intravenous administration
2939928|NCT02972255|Experimental|Part III: RO7079901 + Meropenem|Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem IV infusion in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of 2000 mg meropenem IV infusion on Day 1. On Day 2, participants will receive a single dose of RO7079901 IV infusion. Participants randomized to Sequence 2 will receive a single dose of RO7079901 IV infusion on Day 1. On Day 2, participants will receive a single dose of 2000 mg meropenem IV infusion. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 in combination with meropenem IV infusion q8h, regardless of sequence. Escalation to a maximum dose of RO7079901 5000 mg q8h may be considered on the basis of safety and tolerability data from the previous cohorts.
2939929|NCT02972255|Placebo Comparator|Part III: RO7079901 Placebo + Meropenem Placebo|Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem matching placebos in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of placebo matching to meropenem on Day 1. On Day 2, participants will receive a single dose of placebo matching to RO7079901. Participants randomized to Sequence 2 will receive a single dose of placebo matching to RO7079901 on Day 1. On Day 2, participants will receive a single dose of placebo matching to meropenem. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 and meropenem matching placebos q8h, regardless of sequence.
2939930|NCT02972242|Active Comparator|Modified Field of View|In patients randomized to undergo the modified non-contrast CT scan to assess coronary calcification burden, this study will be performed by a radiologist and cardiologist as follows: axial acquisition obtained at 70% of the R-R interval using the following parameters: rotation time 0.35 sec; collimation of 64 x 0.625mm; detector coverage of 20.0 mm; axial thickness 2.5; tube voltage 80kV and tube current 250mA. The scan length will be from 1 cm below the carina to the level beneath the proximal coronary vessels defined as the greatest diameter of the apex of the right atrium.
2939931|NCT02972242|Placebo Comparator|Standard Field of View|In patients randomized to standard coronary artery calcium scoring, this scan will be performed in usual axial fashion obtained at 70% of the R-R interval using the following parameters: rotation time 0.35 sec; collimation of 64 x 0.625mm; detector coverage of 20.0 mm; axial thickness 2.5; tube voltage, 120 kV and tube current 250mA. The scan length, in accordance with current protocol, will be from 1 cm below the carina through the diaphragms.
2939932|NCT02972229|Experimental|partial body group|10x(3-5) Gy IMRT on partial vertebral body
2939933|NCT02972229|Active Comparator|whole body group|10x3 Gy IMRT on whole vertebral body
2939934|NCT02972216||Nolbaxol|For Nonsmall Cell Lung Cancer (NSCLC) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour every 3 weeks (a study medication cycle) and up to 4 study medication cycles throughout this study. For Squamous Cell Carcinoma of the Head and Neck (SCCHN) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour followed by cisplatin 60 ~ 75 mg/m2 for 1-3 hours or based on the general practice of the site every 3 weeks and up to 4 study medication cycles throughout this study.
2939935|NCT02972216||Taxotere|For Nonsmall Cell Lung Cancer (NSCLC) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour every 3 weeks (a study medication cycle) and up to 4 study medication cycles throughout this study. For Squamous Cell Carcinoma of the Head and Neck (SCCHN) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour followed by cisplatin 60 ~ 75 mg/m2 for 1-3 hours or based on the general practice of the site every 3 weeks and up to 4 study medication cycles throughout this study.
2939936|NCT02972203|Experimental|Mindfulness Training for Primary Care|• Mindfulness Training for Primary Care (MPTC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements. MTPC is a referral-based, insurance-reimbursable 8-week group psychotherapy delivered primarily by Patient-Centered Medical Home-integrated behavioral clinicians. MTPC groups are 2 hours long for 8 weeks, with a 7-hour day of silent group practice on a weekend. MTPC also emphasizes psychoeducational skills for self-regulation including a collaborative primary care provider (PCP) action-planning appointment during week 6.
2939937|NCT02972203|Active Comparator|Mindfulness Intro. +resources +waitlist|Control arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month waitlist for a Cambridge Health Alliance (CHA) mindfulness-based intervention group. All participants are scheduled to meet with their primary care provider during week 6 for a collaborative action planning visit.
2939938|NCT02972190|Experimental|Bilateral decompression with TLIF|Patients undergoing bilateral decompression with TLIF
2939939|NCT02972190|Active Comparator|laminectomy with PLIF|Patients undergoing laminectomy with PLIF
2939940|NCT02972177|Experimental|Radiofrequency ablation group|Patients with inoperable peripheral lung tumor will be performed transbronchial radiofrequency ablation with the guidance of navigation bronchoscopy.Post treatment response will be evaluated and follow up will be carried out according to the standard procedure.
2939941|NCT02972177|Experimental|Microwave ablation group|Patients with inoperable peripheral lung tumor will be performed transbronchial microwave ablation with the guidance of navigation bronchoscopy.Post treatment response will be evaluated and follow up will be carried out according to the standard procedure.
2939942|NCT02972164|No Intervention|Control|Each year, 100 school children age 9-12 who meet inclusion criteria are selected from 5 randomly chosen schools to participate in the control group. Control children are assessed for the same measures as the intervention group at the beginning and end of the intervention but receive none of the intervention modules.
2939943|NCT02972164|Experimental|Weight loss program for school children|Each year, 100 school children age 9-12 who meet inclusion criteria are selected from 5 randomly chosen schools to participate in the intervention group. The intervention children take part in the integrated approach for weight management consisting of (1) intensive weight loss camp (2) twelve weeks of after school clubs for consolidation purposes, and (3) social media and wearable sensors for support and monitoring.
2939944|NCT02972151|Experimental|Comprehensive treatment of TCM|The intervention is Comprehensive treatment of TCM,which including Oral medicine ,tradition chinese medicine enema, external treatment.
2940284|NCT02969720|Experimental|Phytosterol|Daily consumption of 2 grams (8 ml) nano-phytosterols per 180 days.
2939945|NCT02972151|Active Comparator|Expectant therapy|"Expectant treatment group patients were not treated during the observation period.~（3 months after the start of the trial and 1 months after the end of the trial.）"
2939946|NCT02972125|Experimental|Treatment A - B|Single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 100 mg tablet), followed by a Wash-Out Period of at least 7 days and a single administration of the test drug (Treatment B, a single dose of LCM 100 mg given as dry syrup).
2939947|NCT02972125|Experimental|Treatment B - A|Single administration of the test drug (Treatment B, a single dose of LCM 100 mg given as dry syrup), followed by a Wash-Out Period of at least 7 days and a single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 100 mg tablet).
2939948|NCT02972112|Active Comparator|Study group|will receive 2 sessions of 90 minutes each of a cognitive behavioral protocol for the treatment of Tokophobia administered by a CBT trained midwife.
2939949|NCT02972112|Sham Comparator|Control group|will receive 2 sessions of a delivery preparation course (practice as usual).
2939950|NCT02972099|Experimental|TcPRF Group|"According to the standard application of the device, for the PRF procedure one 5 x 13 cm skin electrode will be placed over the forehead, the other one over the posterior aspect of the neck. PRF with a duty load of 14.8 msec/sec and an average pulse frequency of 5.11 Hz will be applied for 25min. The voltage will be set to generate a current of 1 A.~Voltage and impedance will be monitored continuously during treatment and if necessary the voltage will be corrected to ensure the proper current."
2939951|NCT02972099|Placebo Comparator|Placebo Group|The setup will be made as for active treatment but no current will be delivered. The patients will not be able to feel any difference to the real treatment.
2939952|NCT02972086|Experimental|Parent|Parent of a child who is a patient at the NYU Bellevue Attention Deficit Hyperactivity Disorder (ADHD) Clinic
2939953|NCT02972073|Experimental|Exercise intervention|"There are 4 different exercise interventions (4 independent intervention studies) based on different concepts in this entire project. Interventions include:~core stabilization exercise~movement system impairment approach~neuromuscular activation using suspension~kinematic linkage imbalance"
2939954|NCT02972073|No Intervention|Healthy control|This healthy control group will be informed to maintain usual daily activities and avoid participating in activities that involve trunk muscle exercise
2939955|NCT02972060|Active Comparator|ADT|"The standard treatment for this stage of the disease is ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician."
2939956|NCT02972060|Experimental|ODM 201|"ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) bid for a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food.~Subjects who have clinical benefit at week 24 may continue to receive ODM-201 at the discretion of the investigator until disease progression, objective or clinical, or occurrence of an unacceptable toxicity. This includes those that will receive external beam radiation therapy.~Any anti-cancer therapy other than the study drug given as single agent will not be considered part of the protocol treatment."
2939957|NCT02972047|Experimental|Diaphragmatic Breathing|"Subjects randomized to the experimental intervention arm will receive instructions and rationale for Diaphragmatic Breathing in the postprandial state and receive detailed instruction in diaphragmatic breathing.~Following the office visit the patients with upright GERD and healthy persons will undergo a further 24 hours of pH impedance monitoring. This group will practice diaphragmatic breathing for 30 minutes after each meal.~During the second 24 hour period patients with GERD and healthy persons will again consume the standard pH neutral refluxogenic meal note this with an event marker~After 48 hours patients with GERD and healthy persons will present to the esophageal laboratory for probe removal"
2939958|NCT02972047|Sham Comparator|Life style counseling|"Subjects randomized to the Sham Comparator intervention arm will engage in sham therapy (listening to music/watching TV for 30 minutes after each meal)~Following the office visit the patients with upright GERD and healthy persons will undergo a further 24 hours of pH impedance monitoring. This group will will engage in sham therapy (listening to music/watching TV for 30 minutes after each meal)~During the second 24 hour period patients with GERD and healthy persons will again consume the standard pH neutral refluxogenic meal note this with an event marker~After 48 hours patients with GERD and healthy persons will present to the esophageal laboratory for probe removal"
2939959|NCT02972034|Experimental|A: MK-8353 BID Continuous+Pembro|Participants receive MK-8353 orally (PO) two times each day (BID) on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab (pembro) 200 mg intravenously (IV) on Day 1 of each 21-day cycle for up to 35 cycles.
2939960|NCT02972034|Experimental|B: MK-8353 QD Continuous+Pembro|Participants receive MK-8353 PO once each day (QD) on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
2939961|NCT02972034|Experimental|C: MK-8353 QD 1 Week On/1 Week Off+Pembro|Optional Arm: Participants receive MK-8353 PO QD on Days 1 to 7, Days 15 to 21 and Days 29 to 35 PLUS pembrolizumab 200 mg IV on Day 1 and Day 22 of each 42-day period (based on 2 cycles of 21 days) for up to 35 cycles.
2939962|NCT02972034|Experimental|D: MK-8353 QD Run-in→MK-8353 QD Continuous+Pembro|Optional Arm: Participants undergo an MK-8353 PO QD run-in period from Day -14 to Day -1 prior to Cycle 1 during which they receive MK-8353 PO QD. After the run-in period, participants receive MK-8353 PO QD on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 36 cycles.
2939963|NCT02972021|Other|control|Pure oxygen by nasal cannula group
2939964|NCT02972021|Experimental|HFNC|oxygen by High-flow nasal cannula
2939965|NCT02972008||Cerebral Lesion|Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) having at least one new cerebral ischemic lesion on postoperative cerebral MRI
2939966|NCT02972008||No Cerebral Lesion|Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) with no cerebral ischemic lesion on postoperative cerebral MRI
2939967|NCT02971995|Experimental|Prostate cancer/TEP scan|
2939968|NCT02971995|Active Comparator|Prostate cancer/mpMRI|
2939969|NCT02971982|Experimental|rituximab /Dex/CTX|rituximab /Dexamethasone/cyclophosphamide 6 cycles followed by rituximab (at least 2 cycles) rituximab:375mg/m2 d1 Dexamethasone:40mg d1-4 cyclophosphamide:750mg/m2,d1-28
2939970|NCT02971982|Experimental|Velcade/Dex/CTX|Velcade/Dexamethasone/cyclophosphamide 6 cycles followed by velcade (at least 2 cycles) Velcade:1.3mg/m2 d1,d4,d8,d11 Dexamethasone:20mg d1-2,d4-5,d8-9,d11-12 cyclophosphamide:750mg/m2,d1-28
2939971|NCT02971956|Experimental|Pembrolizumab|"Pembrolizumab administered every three weeks~Pembrolizumab will be given intravenously"
2939972|NCT02971943|Other|internal fixation for ankle fractures|The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging preoperatively and 3 months postoperatively.
2939973|NCT02971930||Prophylaxis treatment of BAY94-9027_1|2 infusions per week during the extension study
2939974|NCT02971930||Prophylaxis treatment of BAY94-9027_2|infusion every 5 days during the extension study
2939975|NCT02971930||Prophylaxis treatment of BAY94-9027_3|every 7 days during the extension study
2939976|NCT02971917|Experimental|Clinical study of TRUVIEW ART|Chest x-ray image acquisition Creation of TRUVIEW ART applied image Comparison of TRUVIEW ART image with original image
2939977|NCT02971904||Human milk collection|Lactating mothers should have enough milk to provide enough maternal milk their preterm infant(s) require plus additional collection of samples (3mL). After consenting to the study, milk from lactating mothers of preterm infants in the local ICU will be analyzed daily from the moment they express sufficient milk volume beyond their child's requirement until discharge (from 4th day of admission until 15th day of hospitalization ). Three mL of sample milk will be collected every morning and analyzed, according to hospital routine. Personal details of mothers and their infants will be collected by applying a questionnaire on the first day of analysis. The nutritional composition of the last meal before the milk sample collection and also a nutrition questionnaire intake will be evaluated.
2939978|NCT02971891|Experimental|CLS006 (Furosemide)|CLS006 (Furosemide) Topical Gel, 0.125%
2939979|NCT02971891|Placebo Comparator|Vehicle|Vehicle Topical Gel
2939980|NCT02971878|No Intervention|Control|Culture media without addition of antioxidants
2939981|NCT02971878|Active Comparator|Treatment|Culture media with the addition of antioxidants
2939982|NCT02971865|Experimental|CBT/CMT|The CBT/CMT program does not focus specifically on a particular condition such as diabetes. All treatment included patient education on nutrition content and mindfulness practice (emotions, and sensations in the present moment without trying to change them, awareness of breathing, and social economic problems) with manual therapy.
2939983|NCT02971865|Active Comparator|traditional primary care visit|Provide high quality primary care for men, women, and children of all ages. Our providers work together to ensure that you receive the most comprehensive care possible. Primary care is described as the medical setting in which patients receive most of their medical care and, therefore, is typically their first source for treatment
2939984|NCT02971839|Experimental|CTP-656, 20 mg, QD|Oral tablet dosed once-daily for 28 days
2939985|NCT02971839|Experimental|CTP-656, 100 mg, QD|Oral tablet dosed once-daily for 28 days
2939986|NCT02971839|Experimental|CTP-656, 150 mg, QD|Oral tablet dosed once-daily for 28 days
2939987|NCT02971839|Active Comparator|Kalydeco, 150 mg Tablet (open label)|150 mg, oral tablet dosed twice-daily for 28 days
2939988|NCT02971839|Placebo Comparator|Placebo, Oral Tablet, QD|Oral tablet dosed once-daily for 28 days
2939989|NCT02971826|Experimental|Thrombectomy using the REVIVETM SE device|Thrombectomy using the REVIVETM SE device in patient with an ischemic stroke
2939990|NCT02971813|Experimental|Facebook group|The Facebook group will receive peer support, education and provider support via social media.
2939991|NCT02971813|Active Comparator|Comparison group|The comparison group will receive the same educational materials as the Facebook™ group but will receive it in handout form, or via email if the patient misses cardiac rehabilitation on a particular week.
2939992|NCT02971800|Experimental|sodium fluorescein|"Once hysterectomy completed, a 10 % solution of sodium fluorescein at a 0,25 ml dose (25 mg) is injected before performing diagnostic cystoscopy for all patient.~Name: Fluorescite Injection 10%, contains sodium fluorescein (equivalent to fluorescein 10% w/v) Dosage : 25 mg Frequency: only once"
2939993|NCT02971787|Experimental|Probiotics and salt|Lactobacillus enrichment and salt increase
2939994|NCT02971774||interview|interview with patient at hospital
2939995|NCT02971774||questionnary|self administered questionnary at hospital
2939996|NCT02971761|Experimental|Treatment (pembrolizumab, enobosarm)|Patients receive pembrolizumab IV over 30 minutes on day 1 and enobosarm PO QD on days 1-21. Courses repeat every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
2939997|NCT02971748|Experimental|Pembrolizumab|200 mg on day 1 of each 3-week cycle as 30 minute intravenous (IV) infusion
2939998|NCT02971735|Experimental|interactive multimedia module|Subjects allocated to this experimental group will receive an intervention of mobile technology of e-learning (M-TEL) using the interactive multimedia (IM) module consist of integrated text, images, and small game tests (intervention) for 100 minutes. The module is a non-linearity of learning with interaction (student-based choice and pop-up feedback). This context has been adjusted to the same level to that of the PPS module.
2939999|NCT02971735|Active Comparator|Power Point show module|Subjects allocated to this experimental group will receive an intervention of mobile technology of e-learning (M-TEL) using the Power Point show (PPS) module consist of integrated text, images, and audio (intervention) for 100 minutes. The module is a linear learning without interaction. This context has been adjusted to the same level to that of the IM module.
2940000|NCT02971722|Experimental|0.3mg JY09(cohort 1)|0.3mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
2940001|NCT02971722|Experimental|1.5mg JY09(cohort 1)|1.5mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
2940002|NCT02971722|Experimental|6.0mg JY09(cohort 1)|6.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
2940003|NCT02971722|Placebo Comparator|Placebo(cohort 1)|Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
2940004|NCT02971722|Experimental|0.7mg JY09(cohort2)|0.7mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
2940005|NCT02971722|Experimental|3.0mg JY09(cohort2)|3.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
2940006|NCT02971722|Experimental|12.0mg JY09(cohort2)|12.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
2940007|NCT02971722|Placebo Comparator|Placebo(cohort 2)|Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
2940008|NCT02971709|Experimental|Shade Sail|Shade sails were constructed over passive recreation areas in public parks between pretest and posttest. Shade sails maximized available shade in the passive recreation areas from 11 am to 3 pm in the summer.
2940009|NCT02971709|No Intervention|Unshaded Control|Passive recreation areas in public parks that remained unshaded at pretest and posttest.
2940010|NCT02971696|Experimental|HCC patients (Group 1)|Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
2940011|NCT02971696|Active Comparator|HCC patients (Group 2)|Patient will take best supportive care
2940012|NCT02971683|Active Comparator|Abatacept subcutaneous + Standard Treatment|Abatacept subcutaneous weekly in addition to the subject's current standard treatment for 24 weeks followed by a 28 week open-label period of abatacept treatment plus the subject's current standard treatment.
2940013|NCT02971683|Placebo Comparator|Placebo of Abatacept subcutaneous + Standard Treatment|Placebo of Abatacept subcutaneous weekly in addition to the subject's current standard treatment for 24 weeks followed by a 28 week open-label period of abatacept treatment plus the subject's current standard treatment.
2940014|NCT02971670|Experimental|Dose Group 1|Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
2940015|NCT02971670|Experimental|Dose Group 2|Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
2940016|NCT02971670|Experimental|Dose Group 3|Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
2940017|NCT02971670|Placebo Comparator|Dose Group 0|Control: Al(OH)3 Adjuvant
2940018|NCT02971644|Experimental|cobalt alloy pedicle screw implantation|The spinal tuberculosis patients with severe kyphosis deformity who will undergo cobalt alloy pedicle screw implantation.
2940019|NCT02971631|Placebo Comparator|Placebo|Infusion of 1% human albumin in normal saline.
2940020|NCT02971631|Experimental|Exendin|Infusion of Exendin 9-39 in 1% human albumin in normal saline
2940021|NCT02971618||Total group|Patients T2D with dapagliflozin treatment
2940022|NCT02971605|Experimental|Psilocybin|Participants will be administered a 25 mg/70 kg dose of psilocybin
2940023|NCT02971592|Experimental|Experimental|
2940024|NCT02971592|Placebo Comparator|Placebo|
2940025|NCT02971566||Gastrointestinal complications|"Development of one ore more of the following gastrointestinal complications:~necrotizing enterocolitis (stage ≥2)~spontaneous intestinal perforation~feeding intolerance, defined as enteral feeding withholding ≥1 day because of suggestive clinical signs"
2940026|NCT02971566||Controls|no evidence of gastrointestinal complications during the hospitalization
2940027|NCT02971553|Experimental|Upright Resuscitator with PEEP|Ventilation with the Upright Resuscitator with PEEP
2940028|NCT02971553|Active Comparator|Upright Resuscitator|Ventilation with the Upright Resuscitator (without PEEP)
2940029|NCT02971540|Experimental|bupivacaine, LA, solution|an a local anesthetic administered for local wound infiltration in a single dose of 10 ml of 0,2% solution per segment of vertrebral columne with potential duration time of up to 8 hours according to manufacturers data
2940030|NCT02971540|Experimental|ropivacaine, LA, solution|an a local anesthetic administered for local wound infiltration in a single dose of 10 ml of 0,2% solution per segment of vertrebral columne with potential duration time of up to 8 hours according to manufacturers data
2940031|NCT02971540|Experimental|metamizol, analgesic, solution|an analgesic drug administered intravenously for pre-emptive analgesia in a initial dose of 1-1,25g with potential duration time of up to 6 hours according to manufacturers data
2940032|NCT02971540|Experimental|tramadol, analgesic, solution|a half-opioid drug administered intravenously for pre-emptive analgesia in a initial dose of 2 mg per kg of body weight with potential duration time of up to 6 hours according to manufacturers data
2940033|NCT02971540|Experimental|control group|no pre-emptive analgesia will be used.
2940034|NCT02971527|Experimental|Oste-scan 500A-SONOST3000|In this group, the investigators will measure calcaneal bone strength index of each subject by experimental device firstly and then by control device.
2940035|NCT02971527|Experimental|SONOST3000-Oste-scan 500A|In this group, the investigators will measure calcaneal bone strength index of each subject by control device firstly and then by experimental device.
2940036|NCT02971514|Experimental|Floss-Brush group|The participants flossed first followed by brushing
2940037|NCT02971514|Active Comparator|Brush-Floss group|They used dental floss after brushing
2940038|NCT02971501|Experimental|Arm I (osimertinib, bevacizumab)|Patients receive osimertinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2940039|NCT02971501|Experimental|Arm II (osimertinib)|Patients receive osimertinib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2940040|NCT02971488||Persons who inject drugs (PWID)|The study population comprises persons who visit the Cañada Real Galiana shantytown on the outskirts of Madrid, where 90% of illegal drugs in the region are sold and consumed.
2940041|NCT02971475|Experimental|ESWL alone|Patients in this group would be treated with extracorporeal shock wave lithotripsy only. Otherwise, extra endoscopic procedures will be carried out in case of continuous and aggravated pain. Analgesics will be administrated as needed and recorded.
2940042|NCT02971475|Active Comparator|ESWL combined with ERCP|People in this group would be treated with ESWL followed be endoscopic drainage of the main pancreatic duct in 48 hours. Analgesics will be administrated as needed and recorded.
2940043|NCT02971462|Experimental|RIC group|Experimental: RIC group The upper limb ischemic conditioning is composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 1 month after stroke. In addition, all participants receive a standard clinical therapy.
2940045|NCT02971449|Experimental|Tablets only|100 VHTs will receive Amazon Fire Tablets with pre-loaded instructional videos; this is the intervention arm since this involves introduction of a new technology to this realm
2940046|NCT02971449|Active Comparator|ICCM traditional training|100 VHTs will receive traditional 1 day 'in-person' training as an active comparator intervention, but participants in this arm will not receive any tablets
2940047|NCT02971436|Active Comparator|FPH Device with SensAwake On + Pressure Support A|FPH Device with SensAwake On + Pressure Support A
2940048|NCT02971436|Active Comparator|FPH Device with SensAwake Off + Pressure Support A|FPH Device with SensAwake Off + Pressure Support A
2940049|NCT02971436|Active Comparator|FPH Device with SensAwake On + Pressure Support B|FPH Device with SensAwake On + Pressure Support B
2940050|NCT02971436|Active Comparator|FPH Device with SensAwake Off + Pressure Support B|FPH Device with SensAwake Off + Pressure Support B
2940051|NCT02971436|Active Comparator|Competitor's PAP Released Device + Pressure Support A|Competitor's PAP Released Device + Pressure Support A
2940052|NCT02971436|Active Comparator|Competitor's PAP Released Device + Pressure Support B|Competitor's PAP Released Device + Pressure Support B
2940053|NCT02971423|Experimental|Part A; Cohort 1: 0.25 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a single ascending dose (SAD) of intravenous (IV) ETX2514. Participants in Cohort 1, aged 18 to 55 years, will receive 0.25 grams (g) IV ETX2514/placebo infused over 3 hours.
2940054|NCT02971423|Experimental|Part A; Cohort 2: 0.5 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 2, aged 18 to 55 years, will receive 0.5 g IV ETX2514/placebo infused over 3 hours.
2940055|NCT02971423|Experimental|Part A; Cohort 3: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 3, aged 18 to 55 years, will receive 1.0 g IV ETX2514/placebo infused over 3 hours.
2940056|NCT02971423|Experimental|Part A; Cohort 4: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 4, aged 18 to 55 years, will receive 1.0 g IV ETX2514/placebo infused over 2 hours.
2940057|NCT02971423|Experimental|Part A; Cohort 5: 2.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 5, aged 18 to 55 years, will receive 2.0 g IV ETX2514/placebo infused over 3 hours.
2940058|NCT02971423|Experimental|Part A; Cohort 6: 4.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 5, aged 18 to 55 years, will receive 4.0 g IV ETX2514/placebo infused over 3 hours.
2940059|NCT02971423|Experimental|Part A; Cohort 7: 8.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 7, aged 18 to 55 years, will receive 8.0 g IV ETX2514/placebo infused over 3 hours.
2940060|NCT02971423|Experimental|Part A; Cohort 8: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 8, aged 65 years or older, will receive 1.0 g IV ETX2514/placebo infused over 3 hours.
2940061|NCT02971423|Experimental|Part B; Cohort 9: 0.25 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of multiple ascending doses (MAD) of IV ETX2514. Participants in Cohort 9, aged 18 to 55 years, will receive 0.25 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
2940062|NCT02971423|Experimental|Part B; Cohort 10: 0.5 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 10, aged 18 to 55 years, will receive 0.5 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
2940063|NCT02971423|Experimental|Part B; Cohort 11: 1.0 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 11, aged 18 to 55 years, will receive 1.0 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
2940064|NCT02971423|Experimental|Part B; Cohort 12: 2.0 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 12, aged 18 to 55 years, will receive 2.0 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
2940065|NCT02971423|Experimental|Part C; Cohort 13: ETX2514/placebo with sulbactam|Part C of the study will explore the safety and tolerability of IV ETX2514 when administered as a single dose in combination with sulbactam (1.0 g) and/or imipenem/cilastatin (0.5 g) to healthy participants. On Day 1, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours. On Day 3, participants will receive a single dose of 1.0 g IV sulbactam infused over 3 hours. On Day 5, participants will receive a single dose of 1.0 g IV ETX2514/placebo plus 1.0 g sulbactam infused over 3 hours at the same time. The actual Day 1 and Day 5 ETX2514 dose and infusion time will be determined based on PK and safety data from Part A.
2940066|NCT02971423|Experimental|Part C; Cohort 14: ETX2514/placebo with SUL and/or IM/CIL|Part C of the study will explore the safety and tolerability of IV ETX2514 when administered as a single dose in combination with sulbactam (SUL: 1.0 g) and/or imipenem/cilastatin (IM/CIL: 0.5 g) to healthy participants. On Day 1, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours. On Day 3, participants will receive a single dose of 0.5 g IV imipenem/cilastatin infused over 30 minutes. On Day 5, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours plus 0.5 g imipenem/cilastatin infused over 30 minutes initiated at the same time as ETX2514/placebo. On Day 8, participants will receive a single dose of 1.0 g IV ETX2514/placebo plus 1.0 g sulbactam infused over 3 hours at the same time plus 0.5 g imipenem/cilastatin infused over 30 minutes initiated at the same time as ETX2514/placebo. The actual Day 1, Day 5, and Day 8 ETX2514 dose and infusion time will be determined based on PK and safety data from Part A.
2940067|NCT02971423|Experimental|Part D; Cohort 15: ETX2514/placebo with SUL and/or IM/CIL|Part D of the study will explore the safety and tolerability of multiple doses of combined IV ETX2514/sulbactam (1.0 g)/imipenem/cilastatin (0.5 g) to healthy participants. Participants in Cohort 15 will receive 1.0 g IV ETX2514/placebo and 1.0 g IV sulbactam both infused over 3 hours and 0.5 g IV imipenem/cilastatin infused over 30 minutes every 6 hours (4 times a day) for 10 days and will receive 1 dose on Day 11. The actual ETX2514 dose and infusion time will be determined based on PK and safety data from Part C.
2940068|NCT02971410|Experimental|Treatment (simvastatin)|Patients receive standard of care chemotherapy for up to 3 courses and simvastatin (PO) daily 2 days before the first dose of chemotherapy for up to 2 days after the last dose of chemotherapy. Treatment with simvastatin continues in the absence of disease progression or unacceptable toxicity.
2940069|NCT02971397|Experimental|Treatment (cytarabine, daunorubicin hydrochloride, biopsy)|"INDUCTION: Patients receive cytarabine IV continuously over 24 hours on days 1-7 and daunorubicin hydrochloride IV continuously over 24 hours on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo bone marrow aspirate and biopsy on day 14. Patients with bone marrow cellularity >= 10% and > 5% leukemic blasts, may receive a second induction of cytarabine IV continuously over 24 hours on days 1-5 and daunorubicin hydrochloride IV continuously over 24 hours on days 1-2 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients achieving remission receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with CBF AML may receive 4 courses of therapy."
2940070|NCT02971384|Experimental|Echinaforce Junior Tablets|Hydroalcoholic extract of Echinacea purpurea herb and radix
2940071|NCT02971384|Active Comparator|Vitamin C Tablets|synthetically produced ascorbic acid
2940072|NCT02971371|Experimental|Virtual Reality|This group performed 40 45-min Lokomat sessions, five times a week, by using a visual feedback showing a Virtual Reality run game where the patient had to collect or avoid objects, to motivate him/her to walk actively.
2940073|NCT02971371|Active Comparator|Only RAGT|This groups performed 40 Lokomat sessions (40-45min), five times a week, between 9am and 11am, in this case was not provided an avatar, and a smile indicating the goodness of each leg movement.
2940074|NCT02971358|Experimental|Radical prostatectomy arm|In this arm the investigators will include patients with locally advanced or metastatic prostate cancer, who will undergo cytoreductive radical prostatectomy with extended lymph node dissection.
2940075|NCT02971345|Experimental|Endovascular Brachytherapy&Stent&TACE|"Transarterial chemoembolization (TACE) is performed immediately following Iodine-125 seed strand and stent implantation.~Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE."
2940076|NCT02971345|Active Comparator|TACE alone|Only TACE is performed. Epirubicin, ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
2940077|NCT02971332||Treatment Group|Patients candidated to STARR after the failure of medical and dietary therapy and after a complete radiological and functional study.
2940078|NCT02971306|Active Comparator|Standard Medical therapy|standard medical therapy
2940079|NCT02971306|Experimental|G-CSF|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
2940080|NCT02971306|Experimental|G-CSF and NAC|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days plus NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution)
2940081|NCT02971293|Experimental|AZD8871 100 µg|The subjects will receive AZD8871 100 µg once daily, by dry powder inhaler (DPI) device. The treatment will be administered via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
2940082|NCT02971293|Placebo Comparator|Placebo|The placebo will be administered via single dose DPI that is an adaptation of the commercially available Genuair® with a smaller internal volume to enable delivery of single doses. To maintain blinding, each patient will receive one inhaled dose from placebo DPI provided to him/her on each day of the treatment period.
2940083|NCT02971293|Experimental|AZD8871 600 µg|The subjects will receive AZD8871 600 µg once daily by DPI device via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
2940084|NCT02971254|Active Comparator|Sevoflurane group|inhalation anaesthetic Sevoflurane, 1 M.A.C. during surgery
2940085|NCT02971254|Active Comparator|Desflurane group|inhalation anaesthetic Desflurane, 1 M.A.C. during surgery
2940086|NCT02971241|Experimental|Intergenerational Mobile Technology Opportunities Program|"A randomized, waitlist controlled trial with three hundred fifty older adult subjects with type 2 diabetes and 280 young adult subjects will be conducted in Taipei Tzu Chi Hospital and Hualien Tzu Chi Hospital in Taiwan. The patients who are randomized to the immediate intervention group will be assigned to the training course as soon as a course is available.~The intervention is a 12-week program which consists of 8-week training sessions followed by 4-week consultation service for technical support. Both will be provided by the young volunteers."
2940087|NCT02971241|No Intervention|Waitlist control group|The patients randomized to the waitlist control group will need to wait for four months to serve as no intervention control, and then assigned to the training course.
2940088|NCT02971228|Experimental|Part 1, Lilly glucagon or ZP4207|In Part 1, up to 10 patients will participate in 1-day treatment arms in random order (iPhone-based Bionic Pancreas using Lilly glucagon and iPhone-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
2940089|NCT02971228|Experimental|Part 1, ZP4207 or Lilly Glucagon|In Part 1, up to 10 patients will participate in 1-day treatment arms in random order (iPhone-based Bionic Pancreas using Lilly glucagon and iPhone-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
2940090|NCT02971228|Experimental|Part 2, Lilly glucagon or ZP4207|In Part 2, up to 10 new patients will participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
2940091|NCT02971228|Experimental|Part 2, ZP4207 or Lilly Glucagon|In Part 2, up to 10 new patients will participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
2940092|NCT02971215|Experimental|High-intensity laser therapy|High-intensity laser therapy application through iLux Laser device
2940093|NCT02971215|Sham Comparator|Sham device|Sham high-intensity laser therapy application through sham iLux Laser device
2940117|NCT02971020|Other|Surgical Aortic Valve Replacement|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
2940094|NCT02971202|Other|Hyperinsulinemic, euglycemic clamp: T1DM|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 milliunit (mU)/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
2940095|NCT02971202|Other|Hyperinsulinemic, euglycemic clamp:MODY2|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
2940096|NCT02971202|Other|Hyperinsulinemic euglycemic clamp:Control|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
2940097|NCT02971189|Other|Librata endometrial ablation|Librata thermal balloon endometrial ablation treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
2940098|NCT02971176|Experimental|Low-dose protocol|Patients undergo low-dose protocol computed tomography-guided lung biopsy on day 1.
2940099|NCT02971176|Active Comparator|Standard-dose protocol|Patients undergo standard-dose protocol computed tomography-guided lung biopsy on day 1.
2940100|NCT02971163|Experimental|SynDA|The research coordinator will print the appropriate version of the SynDA based on the patient's individualized risk score and the corresponding estimated probability of a serious medical event within 30 days.
2940101|NCT02971163|No Intervention|Control|Patients in the control arm will receive usual emergency care pertaining to syncope.
2940102|NCT02971150|Experimental|BBTI|Participants will receive Brief Behavioral Treatment for Insomnia (BBTI). This will be administered over the course of 4 weeks. BBTI is based on the concepts of sleep restriction and stimulus control. The first and third session are in person and the 2 and 4th session are conducted over the phone. Throughout the treatment, participants will complete daily sleep dairies. After 4 weeks of treatment, participants randomized to this group will cross over to the no intervention group and will be called once a week to assess mood and sleep symptoms.
2940103|NCT02971150|No Intervention|Control|Participants will not receive treatment. They will be contacted by phone once a week to complete assessments of mood and sleep. After 4 weeks, they will cross over to the experimental BBTI group.
2940104|NCT02971137|Experimental|Smoking Cessation plus CBI (SMK-CBI)|An intervention that includes a proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
2940105|NCT02971137|Active Comparator|Smoking Cessation Standard (SMK-STD)|A contact-equivalent control that provides standard smoking cessation telephone counseling
2940106|NCT02971124||Healthy Elderly|
2940107|NCT02971124||Mild Cognitive Impaired Elderly|
2940108|NCT02971098|Experimental|Reduced activity|participants will undergo a reduced physical activity period (75% step reduction) for two weeks.
2940109|NCT02971085||Active surveillance|This is the prospective cohort study with single group of active surveillance. We define our cohort group as the patients with following criteria: Men < 80 years, pathologically proven adenocarcinoma of the prostate by transrectal prostate biopsy ≥ 10 cores, pre-biopsy PSA ≤ 10ng/ml, PSA density < 0.15 ng/ml/ml, clinical stage T1-2a, biopsy Gleason score ≤ 6, number of positive cores ≤ 2, maximum cancer involvement in any one core ≤ 20%, and no PIRADS 5 lesion on multiparametric prostate MRI (1.5T or 3T).
2940110|NCT02971072|Experimental|Patients|Subjects with shoulder tendinopathy who will undergo both a subacromial injection and physical therapy
2940111|NCT02971059|Experimental|Adult Males >65 years|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied weekly for up to 7 levels of phenylalanine intake (7 Study periods). Each study period will include a period of 3 days. The first 2 days they will consume a liquid milkshake based diet at home. On the 3rd day they will come to the hospital for a total of 8 hours.
2940112|NCT02971059|Experimental|Adult Females >65 years|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied weekly for up to 7 levels of phenylalanine intake (7 Study periods). Each study period will include a period of 3 days. The first 2 days they will consume a liquid milkshake based diet at home. On the 3rd day they will come to the hospital for a total of 8 hours.
2940113|NCT02971046|Experimental|Protein intake|Varying protein intakes.
2940114|NCT02971033|Placebo Comparator|placebo|placebo
2940115|NCT02971033|Experimental|20mg/day ezetimibe|20mg/day ezetimibe
2940116|NCT02971033|Experimental|40mg/day exetimibe|40mg/day ezetimibe
2940285|NCT02969720|Placebo Comparator|Placebo|Daily consumption of 8 ml of a solution with Titanium Dioxide per 180 days.
2940118|NCT02971020|Other|Transcatheter Aortic Valve Replacement|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
2940119|NCT02971007|Experimental|CAMB 200 mg|200 mg CAMB (MAT2203) Oral Amphotericin B
2940120|NCT02971007|Experimental|CAMB 400 mg|400 mg CAMB (MAT2203) Oral Amphotericin B
2940121|NCT02971007|Active Comparator|Fluconazole 150 mg|Fluconazole Diflucan
2940122|NCT02970994||Preterm neonates <34 wks|Haemodynamicaly stable preterm neonates <34 weeks with in 48 hours of admission
2940123|NCT02970981|Experimental|Nivolumab and Ipilimumab|"Dosing during cycle 1 will consist of: 3 mg/kg of Nivolumab+ Ipilimumab at 1 mg/kg. Each induction treatment cycle is comprised of 4 doses of Nivolumab and 4 doses of Ipilimumab given every three weeks for a total of 12 weeks (cycle 1)~Dosing during cycles 2-5 will consist of flat dose Nivolumab at 480 mg every 4 weeks (Q4W) for 48 weeks."
2940124|NCT02970968|Experimental|Study Drug|VLY-686 (Tradipitant) oral capsule for 4 weeks.
2940125|NCT02970968|Placebo Comparator|Placebo|Placebo oral capsule for 4 weeks.
2940126|NCT02970955||Inoperable thoracic nodes metastases|Oligometastatic patients with inoperable thoracic nodes metastases from any primary
2940127|NCT02970942|Experimental|Semaglutide 0,1 mg|
2940128|NCT02970942|Experimental|Semaglutide 0,2 mg|
2940129|NCT02970942|Experimental|Semaglutide 0,4 mg|
2940130|NCT02970942|Placebo Comparator|Placebo 1|
2940131|NCT02970942|Placebo Comparator|Placebo 2|
2940132|NCT02970942|Placebo Comparator|Placebo 3|
2940133|NCT02970929|Experimental|SEP-363856|SEP-363856 capsule (25 mg, 50 mg, or 75 mg) once daily
2940134|NCT02970916|Experimental|FOLFIRI+aflibercept|
2940135|NCT02970903|Experimental|VitalPAD|Using VitalPAD prototype device
2940136|NCT02970903|Active Comparator|Control|Using traditional tools (monitors, paper records)
2940137|NCT02970890|Placebo Comparator|Placebo group|Subjects received placebo therapy. The placebo Portable Pain Away™ device was identical to the active device, displayed the same settings and emitted the same sound regardless of the comparator.
2940138|NCT02970890|Active Comparator|PBMT group|Subjects received active photobiomodulation therapy (PBMT). The active Portable Pain Away™ device was identical to the placebo device, displayed the same settings and emitted the same sound.
2940139|NCT02970877|Experimental|Allogenic treatment group|Fecal filtrate from 150 g stool from healthy lean donors
2940140|NCT02970877|Placebo Comparator|Autologous control group|Fecal filtrate from 150 g of the recipient's own stool
2940141|NCT02970864|Experimental|Polynerve|Participants found to have a nerve gap of at least 5 mm and no greater than 20mm will undergo repair with the Polynerve.
2940142|NCT02970838|Experimental|Intervention|Patients take part in a structured weight-loss program over 15 weeks including a fasting phase with formula diet over six weeks
2940143|NCT02970825|Experimental|Exercise|The experimental, intensive exercise regime will include 50-min sessions four times a week during five weeks (for a total of about 17 hours) combining aerobic exercise (20 minutes jogging and moderate to high intensity active games) and anaerobic lactic resistance exercise (power training with gymn weights).
2940144|NCT02970825|Active Comparator|Relaxation|The control activity will include 50-min sessions four times a week during five weeks (for a total of about 17 hours) combining mindfulness, stretching and low intensity active games (breath control, proprioception, walking, flexibility training).
2940145|NCT02970812|Experimental|Electrical Muscle Stimulation|EMS program was consisted of warm-up, warm-down, contraction and relaxation. It was programed to be resemble to actual muscle action of voluntary exercise. To increase energy consumption as high intensity exercise, tripled the contraction duration. EMS group used Program 3 and regulated intensity though channel from 1 to 4.
2940146|NCT02970812|Placebo Comparator|Electrical Nerve Stimulation|Transcutaneous group used Transcutaneous Electrical Nerve Stimulation (TENS) which is the use of electric current produced to stimulate the sensory nerves to block pain signal. It is programed to applied currents regularly, once a second with a frequency of 1 Hz.
2940147|NCT02970786|Experimental|68Ga-NODAGA-E(c[RGDyK])2 PET|One injection of 68Ga-NODAGA-E(c[RGDyK])2 PET (app. 200 MBq) followed by 3 PET/CT scans 10 minutes, 1 hour and 2 hours post injection
2940148|NCT02970773|Other|rivaroxaban|Rivaroxaban Oral Tablet
2940149|NCT02970747||Car/Len/Dex (KRd)|Patients treated with carfilzomib, lenalidomide and dexamethasone dosage form, dosage, frequency and duration of treatment according to current SmPC
2940150|NCT02970747||Car/Dex (Kd)|Patients treated with carfilzomib and dexamethasone dosage form, dosage, frequency and duration of treatment according to current SmPC
2940151|NCT02970734|Experimental|Breathe|6 sessions of Internet-based cognitive behavioural therapy (CBT) with limited telephone and e-mail support
2940152|NCT02970734|Active Comparator|Resource webpage|Webpage that provides general resources on anxiety
2940153|NCT02970721||Bipolar disorder-treated|Individuals in this group are taking any medication (mood stabilizer, antipsychotic, antidepressants, antianxiety) during pregnancy
2940154|NCT02970721||Bipolar Disorder-Not Treated|Individuals in this group are not taking any medications during pregnancy
2940155|NCT02970708|Experimental|EFG group|amblyopia in EFG group will receive Eyetronix Flicker Glassess treatment.
2940156|NCT02970708|Active Comparator|Patching group|amblyopia in patching group will receive patching treatment.
2940157|NCT02970695|Active Comparator|Treatment arm 1|"To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation before the application of MAT. The subjects will be asked to wear a pair of laser protective goggles so as to blind them during treatment."
2940158|NCT02970695|Active Comparator|Treatment arm 2|Subjects will receive LAT. A laser device (Pointer Pulse™) will be used in this study.
2940159|NCT02970695|Experimental|Treatment arm 3|Subjects will receive a combined approach that includes the use of LAT plus MAT. LAT will be administered prior to MAT application on the selected auricular points, and the procedures used will be similar to the procedures described for Group 1 and Group 2.
2940185|NCT02970500|Placebo Comparator|Placebo Group|"Placebo Comparator intervention:~In the double-blind randomized placebo-controlled phase, participants of the group (20) will receive 1 capsule of placebo each morning for a total of 14 days."
2940160|NCT02970682|Experimental|Aromatase Inhibitor|SFX-01 with Aromatase Inhibitor SFX-01 when used in combination with aromatase inhibitors. All patients will continue to receive their AI and, at the start of the study (D1), patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).
2940161|NCT02970682|Experimental|Fulvestrant|SFX-01 with Fulvestrant SFX-01 when used in combination with fulvestrant. All patients will continue to receive fulvestrant 500 mg IM in 28 day cycles. As patients will already have been taking this, a repeat loading dose is not necessary. Commencing on study D1 patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).
2940162|NCT02970682|Experimental|Tamoxifen|SFX-01 with Tamoxifen SFX-01 when used in combination with tamoxifen All patients will continue to receive tamoxifen and, at the start of the study (D1), patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart after food (preferably within 2 hours).
2940163|NCT02970669|Experimental|sacubitril/valsartan (LCZ696)|"Double blind treatment epoch: Patients randomized to this arm will receive 1 tablet of sacubitril/valsartan and 1 tablet of matching placebo enalapril twice daily for 8 weeks. All Patients will begin the study on Dose Level 1 (i.e. 24/26 mg sacubitril/valsartan BID). Patients may sequentially up-titrate to achieve desired dose of Dose Level 3 (i.e. 97/103 mg sacubitril/valsartan BID). Patients not tolerating dose escalation can be titrated down to next lower dose level.~Open-label treatment epoch: All patients entering this epoch (8 weeks) will be given sacubitril/valsartan 49/51 mg BID (Dose Level 2) unless they completed the double-blind treatment epoch on Dose Level 1. Instead, these patients will enter open-label epoch on Dose Level 1. Patients may sequentially up-titrate to achieve desired dose of Dose Level 3. Patients not tolerating dose escalation can be titrated down to next lower dose level."
2940164|NCT02970669|Active Comparator|enalapril|"Double blind treatment epoch: Patients randomized to this arm will receive 1 tablet of enalapril and 1 tablet of matching placebo sacubitril/valsartan twice daily for 8 weeks. All Patients will begin the study on Dose Level 1 (i.e. 2.5 mg enalapril BID). Patients may sequentially up-titrate to achieve desired dose of Dose Level 3 (i.e. 10 mg enalapril BID). Patients not tolerating dose escalation can be titrated down to next lower dose level.~Open-label treatment epoch: All patients entering this epoch (8 weeks) will be given sacubitril/valsartan 49/51 mg BID (Dose Level 2) unless they completed the double-blind treatment epoch on enalapril Dose Level 1. Instead, these patients will enter open-label epoch on Dose Level 1 of sacubitril/valsartan. Patients may sequentially up-titrate to achieve desired dose of Dose Level 3 of sacubitril/valsartan. Patients not tolerating dose escalation can be titrated down to next lower dose level."
2940165|NCT02970656|Experimental|Teens.Connect|The Teens-Connect internet-based program has two complementary components - TEENCOPE and Managing Diabetes. Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. TEENCOPE consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist.
2940166|NCT02970656|No Intervention|Control|Wait listing will serve as the control condition. Usual care at the Yale Pediatric Diabetes Center consists of quarterly visits with physicians and nurse practitioners, accessibility to nutritional and psychological consultation, and 24/7 on call service. Following completion of the 6 month data point, youth will be offered the opportunity to participate in the internet program.
2940167|NCT02970643|Experimental|Olanzapine group|Palonosetron and Olanzapine Without Dexamethasone in moderate risk chemotherapy induced nausea and vomiting group
2940168|NCT02970630|Experimental|Envarsus once a day, everolimus b.i.d.|"Tacrolimus tablets at starting dose of 0.07 mg/kg/day will be administered once daily in the morning.~Everolimus tablets at starting dose of 2 mg/day (1 mg b.i.d.) will be administered twice daily, every 12 hours."
2940169|NCT02970617|Active Comparator|Group A (no intervention)|Patients undergo standard of care radiation therapy with or without chemotherapy.
2940170|NCT02970617|Experimental|Group B (ring bell after final radiation treatment)|On the final day of standard of care radiation therapy, patients ring a bell in the clinic.
2940171|NCT02970604|Experimental|Aspirin|Non-enteric coated Aspirin 75mg once daily for 7 days
2940172|NCT02970604|No Intervention|No treatment|No treatment for 7 days
2940173|NCT02970591|Experimental|Diet B|Low carbohydrate diet
2940174|NCT02970591|Active Comparator|Medical treatment|Optimized Medical treatment
2940175|NCT02970591|Experimental|Diet A|Traditional dietary advice and low FODMAP content
2940176|NCT02970578|Experimental|3D printed module|The patients underwent 3D printed module-assisted lumbar pedicle screw placement using the Quandrant system, aiming to restore the stability of the spine.
2940177|NCT02970565|Experimental|Nutrition and Play Intervention|Mother-child dyads who are enrolled into the study will be randomly assigned to the Nutrition and Play Intervention group.
2940178|NCT02970565|Experimental|Family Nurture Intervention|Mother-child dyads who are enrolled into the study will be randomly assigned to the Family Nurture Intervention group.
2940179|NCT02970552|Active Comparator|Vaginal Progesterone|Daily self-administered vaginal progesterone
2940180|NCT02970552|Placebo Comparator|Placebo|Daily self-administered indistinguishable placebo
2940181|NCT02970539|Experimental|Oraxol +Ramucirumab|
2940182|NCT02970526||colorectal cancer survivors|
2940183|NCT02970513|Experimental|patients operated on for colorectal cancer|
2940184|NCT02970500|Experimental|Methylphenidate HCl 10Mg SR|"Methylphenidate HCl 10Mg SR Intervention In the double-blind randomized placebo-controlled phase, participants of the group (20) will receive 1 capsule of Methylphenidate HCl 10Mg SR each morning for a total of 14 days.~For the open trial phase, all the participants of the study (40) will receive 1 tablet of Methylphenidate HCl 10Mg, SR for 7 days. Depending on their response to the dose, for the following 7 days, they will receive no capsule of Methylphenidate HCl 10Mg (if they have important side effect) or 1 capsule (if they have sufficient improvement) or 2 capsules (if they don't have sufficient improvement)."
2940186|NCT02970487|Experimental|investigational device|Subjects implanted with the Precisight intraocular lens.
2940187|NCT02970474|Other|All Participants|All participants will undergo the same schedule. Each participant will be fitted with a conventional and a 3D printed bolus prior to receiving radiation therapy. Each bolus will be assessed for optimal dose distribution of the radiation to the tumor through computer stimulation. The bolus, either conventional or 3D printed, that is found to be superior will be used for the actual radiation therapy treatment.
2940188|NCT02970461|Placebo Comparator|Control Group|"Subjects will see in their Personal Health Record home page a simple text link pointing to their Bio page. Once in their Bio page, the site will display their personal information as usual with the only addition of a validate data button next to any non-validated field. The option to edit fields will also be present."
2940189|NCT02970461|Experimental|Gamified Group|"Subjects will see in their Personal Health Record home page a graphical representation of the percentage of completeness their Bio page has that when clicked acts as a link to their Bio page. Once in their Bio page, the site will display graphical elements such grayed out fields, graphical representations of the percentage of completeness for each data group and on mouse hover over any field a tooltip will inform of what percentage of completeness will be awarded if the data is validated. Also, an addition of a validate data button next to any non-validated field. The option to edit fields will also be present."
2940190|NCT02970448|Experimental|LITT with Radiation and Temozolomide|Laser interstitial thermal therapy (LITT) followed by Radiation therapy, three-dimensional conformal radiotherapy (3D-CRT) or intensity modulation radiation therapy (IMRT), 60 Gy/30 fractions. Radiation given with chemotherapy Temozolomide
2940191|NCT02970435|Experimental|Video Discharge Instructions|These videos contain the same instructions that a patient receives via the standard-of-care verbal and written discharge instructions. These instructions will be delivered by the same nursing and medical staff that also regularly provides verbal and written discharge instructions to patients. There will be no difference in the content between the standard-of-care verbal and written instructions and the video discharge instructions. Patients in this group will receive telecommunication reminders on how to access discharge videos.
2940192|NCT02970435|Active Comparator|Verbal and Written Discharge Instructions|Nursing and medical staff will provide verbal and written discharge instructions as is standard of care post surgery
2940193|NCT02970409|Active Comparator|heparin|Catheter Lock Therapy with Heparin
2940194|NCT02970409|Experimental|saline|Catheter Lock Therapy with saline
2940195|NCT02970396|Active Comparator|SMART Intervention|Participants (a total of 120 individuals) will be randomly assigned to either SMART (N=60) or the wait-list control (N= 60), in a 1:1 ratio.
2940196|NCT02970396|Active Comparator|Wait-list|Participants assigned to the wait-list will start the SMART intervention 6 months following randomization.
2940197|NCT02970383|Experimental|10 group|Initial prescription for 10 narcotic tabs
2940198|NCT02970383|Active Comparator|30 group|Initial prescription for 30 narcotic tabs
2940199|NCT02970357|Other|Enrolled patient|Every patient of the Mulhouse Hospital with a type 1 diabetes who joins the study will be followed for 10 months. They will fill in the DIAPASON questionnaire and the quality of life WHO-5 questionnaire on the day of enrollment and 10 months after enrollment, at the end of the study. Young patients followed for a type 1 diabetes at the Mulhouse Hospital usually come every two months to see the pediatric endocrinologist, so the data collected for a regular visit will also be collected for the study every two months between the enrollment and the end of study participation.
2940200|NCT02970344|Experimental|Diabetes Coping Skills training (DCST)|Twelve sessions are delivered over 6 months using a faded contact model involving 6 weekly sessions, 3 biweekly sessions and 3 monthly sessions.
2940201|NCT02970344|No Intervention|Diabetes Education|one 60 minute diabetes education session.
2940202|NCT02970331|Experimental|pefcalcitol|pefcalcitol 0.005% BID for 8 weeks
2940203|NCT02970318|Experimental|Acalabrutinib (ACP-196)|Acalabrutinib (ACP-196) Monotherapy
2940204|NCT02970318|Active Comparator|Rituximab Plus Idelalisib or Bendamustine|Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine
2940205|NCT02970305|Experimental|Pimavanserin|Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth
2940206|NCT02970305|Placebo Comparator|Placebo|Placebo, taken as two tablets, once daily by mouth
2940207|NCT02970292|Experimental|Pimavanserin|Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth
2940208|NCT02970292|Placebo Comparator|Placebo|Placebo + background antipsychotic, taken as two tablets, once daily by mouth
2940209|NCT02970279|Experimental|Enhanced Behavioural Activation Groups|"Behavioural activation group (BAG) psychotherapy delivered with two embedded treatment augmentations;~Implementation intentions~Dose-response psychoeducation"
2940210|NCT02970253|Active Comparator|Capsular resection|Capsular resection
2940211|NCT02970253|Active Comparator|Capsular retention|Capsular retention
2940212|NCT02970240||ME/CFS group|Patients with a verified diagnosis of ME/CFS according to the Canada criteria
2940213|NCT02970240||Fatigue group|Patients with fatigue, but not ME/CFS
2940214|NCT02970240||Control group|Healthy control persons
2940215|NCT02970214||Heart Failure|Patients with chronic heart failure and with/without reduced left ventricular ejection fraction (EF) at baseline (HFrEF, HFmrEF, HFpEF)
2940216|NCT02970214||Cardiometabolic risk|Patients with cardiovascular diseases and metabolic risk factors at baseline
2940217|NCT02970201|Other|Period I EpxDialysis (SMS Messaging)|SMS Messaging arm receives the intervention (EpxDialysis) first, then resumes standard of care at crossover (8 weeks).
2940218|NCT02970201|Other|Period II EpxDialysis (Control)|Control arm receives standard of care first, then receives the intervention (EpxDialysis) at crossover.
2940219|NCT02970188|No Intervention|Normal Feeding|Subjects will be instructed to eat within their normal feeding window.
2940220|NCT02970188|Experimental|Time Restricted Feeding|Subjects will be instructed to eat with an 8 hour feeding window, starting between 10:30-11:30 AM and stopping between 5:30-6:30 PM.
2940221|NCT02970175|Experimental|Bronchoscopy with terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
2940222|NCT02970175|Placebo Comparator|Bronchoscopy without terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done without terlipressin administration
2940223|NCT02970162|Experimental|amifampridine phosphate|amifampridine phosphate 10 mg (amifampridine equivalent) by mouth, 30 to 80 mg total daily dose, 3 to 4 times per day for 4 days
2940224|NCT02970162|Placebo Comparator|placebo (for amifampridine phosphate)|placebo by mouth 3 to 4 times per day for 4 days
2940225|NCT02970136|Experimental|Home Based Screening|The participant will have the option of choosing between the clinic visit or receiving home-based screening tests (OraQuick Swab, OraQuick Fingerstick, Fecal Immunochemical Test) delivered by the community health worker
2940226|NCT02970136|Active Comparator|Clinic Based Screening|The participant will meet the Community Health Worker and will be navigated to a clinic appointment for standard screening tests
2940227|NCT02970123|Experimental|SLIMM Intervention|Sit Less, Interact, Move More (SLIMM): instruction and monitoring feedback to promote decrease in sedentary activity duration, increase in casual walking duration, and increase in sedentary breaks
2940228|NCT02970123|No Intervention|Standard of Care|Subjects will receive standard of care treatment for chronic kidney disease, with no instruction or feedback to alter sedentary or casual walking durations
2940229|NCT02970097|Active Comparator|single shot IBP block|Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
2940230|NCT02970097|Active Comparator|local infiltration|Subjects will receive local infiltration into portal space and joint space with 10ml of 0.5% ropivicaine given intraoperatively to help with operative and postoperative pain
2940231|NCT02970084|Experimental|Group with K2|"The nutraceutical product (PLAK2) based on vitamin K2, will be administered once a day (a tablet 800mg) for 12 months.~All patients enrolled will continue to be treated according to the clinical standard (100 mg Cardioaspirin, cp 1 day : Acetylsalicylic acid)"
2940232|NCT02970084|No Intervention|Control group (no vitamin K2)|The control group did not take the supplement of Vitamin K2. All patients enrolled will continue to be treated according to the clinical standard (100 mg Cardioaspirin, cp 1 day : Acetylsalicylic acid)
2940233|NCT02970071||Fetal congenital heart disease cases|Gravidas with fetal congenital heart disease diagnosed by fetal echocardiography
2940234|NCT02970058|Active Comparator|Platelet-rich Plasma|30 patients will receive platelet-rich plasma post-spinal anesthesia
2940235|NCT02970058|Placebo Comparator|Control|30 patients will receive sterile saline post-spinal anesthesia
2940236|NCT02970045||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood during a regular care visit or not up to 4 times a year. Extra tissue is collected after removal during standard of care surgery and patients may undergo additional tumor sampling (needle passes) at the time of planned diagnostic biopsies. During bone marrow biopsy, the doctor may reposition the needle up to 3 times, and bone marrow for research will not be collected more than 4 times per year. Patients may undergo additional collection of other biological samples such as saliva, sputum, urine, feces, hair, and surface skin swabs for analysis. Patients also receive surveys or questionnaires to collect demographics, medical, family, and nutritional history, cancer predisposing risk factors, quality of life data, and quality of care data.
2940237|NCT02970032|Active Comparator|Standard heparin dose|The investigators will identify surgical patients placed on fixed dose heparin infusions at their attending surgeon's discretion-the proposed research will not dictate the initiation of the heparin drip intraoperatively. However, the investigators will identify patients already on heparin, evaluate steady state heparin anti-Xa levels and adjust patient's dose if necessary based on steady state anti-Xa levels. Eligible patients will be started on heparin fixed-dose intraoperatively. Steady state anti-Xa levels will be drawn at least 6 hours after initiation of heparin infusion. Goal anti-Xa levels will be 0.1-0.35 IU/mL.
2940238|NCT02970032|Experimental|Real time heparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time heparin dose adjustment and will receive follow-up steady state anti-Xa levels. Anti-Xa level monitoring will be discontinued when in range peak levels are obtained, when heparin infusions are discontinued at surgeon discretion, or when the patient is discharged.
2940239|NCT02970019|Experimental|K0706|K0706 will be administered once a day
2940240|NCT02970019|Experimental|Placebo|Placebo will be administered once a day
2940241|NCT02970006|Experimental|neurovisual stimulation|Participants in this study will be adults who have already undergone implantation of SCS for the treatment of their pain conditions. The study involves no further treatment or intervention. Subjects will be approached for participation in this study during their routine postoperative clinical visit to the Center for Neuromodulation at the Ohio State University (OSU).All eligible patients will undergo a one-day visit for the virtual reality and full body illusion intervention. This research will also investigate leg embodiment and leg analgesic effects during SCS integrated with different patterns of virtual leg illumination.
2940242|NCT02969993|Experimental|Questionnaire|Questionnaire to previously operated patients
2940243|NCT02969980|Experimental|PTCy|Patients who receive post-transplantation cyclophosphamide
2940244|NCT02969967|Experimental|SaeboFlex|Use of the SaeboFlex orthosis for a set protocol of grasp-release activities
2940245|NCT02969954|Experimental|Intervention arm|Study has one arm - who will all receive the intervention
2940246|NCT02969941|Active Comparator|Real Stimulation|Participants will receive active transcranial magnetic stimulation (TMS) daily for two weeks
2940247|NCT02969941|Placebo Comparator|Placebo Stimulation|Participants will receive sham transcranial magnetic stimulation (TMS) daily for two weeks
2940248|NCT02969928|Active Comparator|Amoxicillin and Metronidazole|In this group (n = 22), patients will take Amoxicillin 500 mg tid for 7 days and Metronidazole 400 mg tid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
2940249|NCT02969928|Experimental|Clarithromycin|In this group (n = 22), patients will take Clarithromycin 500 mg bid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
2940250|NCT02969915|Active Comparator|Integrated care centers|Participants in the active comparator arm have access to integrated care centers (ICCs)
2940251|NCT02969915|Experimental|ICC + incentives|Participants in the experimental arm have access to the ICC intervention and the incentive intervention
2940252|NCT02969902|Experimental|Buzzy® device|The Buzzy® device is applied just above the selected site of the venipuncture; an ice pack is attached under the device; the device is turned on and after 15 second the venipuncture is made.
2940253|NCT02969902|Active Comparator|Hand-held computer|Using an hand-held computer, children start to play with an age-appropriate videogame three minutes before the procedure. They continue to play during the venipuncture.
2940254|NCT02969889|Active Comparator|intubation time|handling the device till the endotracheal tube passing through the glottis
2940255|NCT02969889|Active Comparator|insertion time|handling of the device till the glottic visualization
2940256|NCT02969876|Other|Study Phase|During this phase participants receive open label vortioxetine for 6 weeks. Participants come to the Depression Clinical & Research Program at the Massachusetts General Hospital for visits once a week. During these visits the participants meet with clinicians and complete cognitive tasks.
2940257|NCT02969863|Active Comparator|Usual Care Arm - Monitored|"Subjects will manage their own diabetes and will wear a blinded Dexcom G4 CGM to record their glucose data during the week. They will be monitored for CGM connectivity and hypoglycemia.~Monitored for hypoglycemia"
2940258|NCT02969863|Active Comparator|Usual Care Arm - Unmonitored|"Subjects will manage their own diabetes and will wear a blinded Dexcom G4 CGM to record their glucose data during the week. They will be monitored only for CGM connectivity, not hypoglycemia.~Not monitored for hypoglycemia"
2940259|NCT02969863|Experimental|Bihormonal Bionic Pancreas - Monitored|"Subjects will wear the bihormonal bionic pancreas, consisting of a Dexcom G4 CGM, an insulin and glucagon pump and an iPhone running the study algorithm. They will be monitored for CGM connectivity and hypoglycemia.~Monitored for hypoglycemia"
2940260|NCT02969863|Experimental|Bihormonal Bionic Pancreas - Unmonitored|"Subjects will wear the bihormonal bionic pancreas, consisting of a Dexcom G4 CGM, an insulin and glucagon pump and an iPhone running the study algorithm. They will be monitored only for CGM connectivity, not hypoglycemia.~Not monitored for hypoglycemia"
2940261|NCT02969863|Experimental|Insulin Only Bionic Pancreas - Monitored|"Subjects will wear the insulin only bionic pancreas, consisting of a Dexcom G4 CGM, an insulin pump, and an iPhone running the study algorithm. They will be monitored for CGM connectivity and hypoglycemia.~Monitored for hypoglycemia"
2940262|NCT02969863|Experimental|Insulin Only Bionic Pancreas - Unmonitored|"Subjects will wear the insulin only bionic pancreas, consisting of a Dexcom G4 CGM, an insulin pump, and an iPhone running the study algorithm. They will be monitored only for CGM connectivity, not hypoglycemia.~Not monitored for hypoglycemia"
2940263|NCT02969850|Experimental|Vitamin D Supplementation|Participant will receive initial dose of 2400, 3600, or 4800 IU of vitamin D3, based on her serum vitamin D level. Dose will be adjusted at 3 month visit to maintain serum vitamin D level at a desirable level. If subject has insufficient dietary calcium intake, calcium supplementation will be provided in the form of one 600mg CaCO3 pill to achieve a total calcium intake of 1200mg/day.
2940264|NCT02969850|Placebo Comparator|Placebo|Participant will receive a placebo. If subject has insufficient dietary calcium intake, calcium supplementation will be provided in the form of one 600mg CaCO3 pill to achieve a total calcium intake of 1200mg/day.
2940265|NCT02969837|Experimental|E-KRd regimen|Participants will receive elotuzumab, carfilzomib, lenalidomide, and dexamethasone.
2940266|NCT02969837|Experimental|E-Rd Regimen|Participants will receive elotuzumab, lenalidomide, and dexamethasone.
2940267|NCT02969824|No Intervention|Usual Care Group|"These individuals will undergo a period of physical rest and standard care until symptoms spontaneously resolve. For the purposes of this study, rest will be defined as the avoidance of any activities beyond those of daily living, including participation in sport and physical activity. Once individuals in this group achieve asymptomatic status, they will be directed through the existing return to play guidelines."
2940268|NCT02969824|Experimental|Aerobic Exercise Group|These individuals will begin to exercise at Day 3 post-injury. These participants will be asked to complete a total of eight exercise sessions over the course of 11 days, with one day of rest after two consecutive sessions. Once individuals in this group achieve asymptomatic status, they will be directed through the existing return to play guidelines.
2940269|NCT02969798|No Intervention|(i) healthy normal glucose tolerance (NGT) subjects|Subjects (Fasting Plasma Glucose or FPG < 100 mg/dl and 2-h PG < 140 mg/dl) without FH (family history) of diabetes in a first degree relative
2940270|NCT02969798|Active Comparator|ii) healthy subjects with isolated IGT|(ii) healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive one of the following four treatments: (1) Dapagliflozin, 10 mg/day, (2) Saxagliptin, 5 mg/day (3) Pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two; (4) Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
2940271|NCT02969798|Active Comparator|(iii) healthy subjects with isolated IFG|(iii) healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive one of the following four treatments: (1) Dapagliflozin, 10 mg/day, (2) Saxagliptin, 5 mg/day (3) Pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two; (4) Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
2940272|NCT02969798|Active Comparator|(iv) healthy subjects with IGT plus IFG|(iv) healthy subjects with IGT plus IFG will receive one of the following four treatments: (1) Dapagliflozin, 10 mg/day, (2) Saxagliptin, 5 mg/day (3) Pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two; (4) Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
2940273|NCT02969785|Experimental|G1: exercises for lumbar stabilization|Specific exercises for lumbar stabilization. The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
2940274|NCT02969785|Active Comparator|G2: back strengthening exercises|Back strengthening exercises. The Group 2 (G2) will perform therapy including strengthning of back muscles on a Roman chair machine for flexion and extension of trunk with load progression from training volume for endurance and strength gains.
2940275|NCT02969772|Experimental|Assessment of upper limb variables|Assessment of clinical variables of tetraplegics reach-and-grasp pattern
2940276|NCT02969772|Experimental|Training protocol|Training with electrical stimulation of upper limb
2940277|NCT02969759|Other|Patients|ALS defined by El Escorial Criteria.
2940278|NCT02969759|Other|Controls|Asymptomatic subjects with normal examination.
2940279|NCT02969746|Experimental|Charcoal|Patients will receive a single dose (20 gram) of oral activated charcoal
2940280|NCT02969746|No Intervention|control|Standard practice
2940286|NCT02969707|Experimental|Active rTMS|The active group will receive repetitive Transcranial Magnetic Stimulation
2940287|NCT02969707|Sham Comparator|Sham rTMS|The sham repetitive Transcranial Magnetic Stimulation group will have the stimulation blocked.
2940288|NCT02969694||Patients who use psychostimulants products in sexual contexts|"Patients who come to the CSAPA at the Croix-Rousse Hospital, Lyon France following the use of psychostimulants products in sexual contexts.These patients come for an addictologique support.~The patients will answer to the G-STAT questionnaire."
2940289|NCT02969681|Experimental|Ascorbic Acid with chemotherapy group|"Ascorbic Acid with mFOLFOX6 with or without bevacizumab Ascorbic Acid (1.5g/kg/day, D1-3) every 2 weeks~mFOLFOX6:~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
2940290|NCT02969681|Active Comparator|Chemotherapy group|"mFOLFOX6:~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
2940291|NCT02969655|Experimental|Daprodustat|Subjects will receive oral daprodustat once daily and intravenous (IV) darbepoetin alfa placebo once weekly for 52 weeks
2940292|NCT02969655|Active Comparator|Darbepoetin alfa|Subjects will receive IV darbepoetin alfa once weekly and oral daprodustat placebo once daily for 52 weeks
2940293|NCT02969642|Sham Comparator|Sham|Sham low energy laser using approximately 1/1000 th energy of treatment laser.
2940294|NCT02969642|Active Comparator|Treatment|Treatment laser.
2940295|NCT02969629|Experimental|apomorphine|1.5 mg apomorphine, administered subcutaneously
2940296|NCT02969629|Placebo Comparator|Normal saline|saline, administered subcutaneously
2940297|NCT02969603|Other|Healthy volunteers- MRI|MRI scan for morphological assessment of muscle structures and anatomy
2940298|NCT02969603|Other|Healthy Volunteers- PET/MRI|The volunteers will undergo a combined [11C]acetate PET/MRI scan
2940299|NCT02969590|Active Comparator|Norethindrone/estradiol withdrawal|This arm will receive Norethindrone first then experience estradiol withdrawal.
2940300|NCT02969590|Active Comparator|Estradiol/Norethindrone|This arm will experience estradiol first and then Norethindrone.
2940301|NCT02969577|Experimental|Staying Strong & Healthy Intervention (SS&H)|Participants will take part in a 6-month exercise program and diet and nutrition coaching program. Also part of this arm is a nutritional and lifestyle counseling program to be lead by a member of the study team. Participants will also receive the usual care they would normally receive if not taking part in this study.
2940302|NCT02969577|Active Comparator|Usual Care with Attention (UCA)|Participants will receive the usual care they would normally receive if not taking part in this study.
2940303|NCT02969564||prostate cancer patient, with up to five metastases|prostate cancer patient, with up to five metastases (oligo-bone metastatic) based on scintigraphy 99mTc-MDP-SPECT/CT.
2940304|NCT02969551||Sleep apnea, Manometry and possibly DISE|Sleep apnea Patients recieved manometry measures and those who were not considered for CPAP Therapy recieved Drug induced sleep endoscopy.
2940305|NCT02969538|Other|Total etching time|Dentin etching (35% phosphoric acid) by time recommend by manufacturer (15 seconds)
2940306|NCT02969538|Experimental|Half-reduced etching time|Dentin etching (35% phosphoric acid) by 7 seconds
2940307|NCT02969525|Placebo Comparator|Placebo|Subjects will receive for 12 Weeks Placebo and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.
2940308|NCT02969525|Experimental|Bimekizumab dosage regimen 1|Subjects will receive for 12 Weeks Bimekizumab dosage regimen 1 and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.
2940309|NCT02969525|Experimental|Bimekizumab dosage regimen 2|Subjects will receive for 48 Weeks Bimekizumab dosage regimen 2.
2940310|NCT02969525|Experimental|Bimekizumab dosage regimen 3|Subjects will receive for 48 Weeks Bimekizumab dosage regimen 3.
2940311|NCT02969525|Experimental|Bimekizumab dosage regimen 4|Subjects will receive for 12 Weeks Bimekizumab dosage regimen 4 and will then be re-randomized to Bimekizumab dosage regimen 2 for 36 Weeks.
2940312|NCT02969512|Experimental|HIPPER|"The HIPPER group will receive 10 interactive online modules (~20 minutes each). HIPPER participants will receive email or phone contact (participant preference) to provide them with website portal access consisting of the web address, simple instructions to access the website using personalized encrypted login information to the site, and a personalized exercise program.~Participants in the HIPPER group will also receive an exercise program. The exercise program is created by the Trainer (using the participant's baseline data) and will be provided to the participant by email or phone when providing the web portal access. Participants will be encouraged to accumulate a minimum of 30 minutes of moderate intensity physical activity, at least 5 days per week."
2940313|NCT02969512|Active Comparator|In-Person Education|To provide a comparable level of education, participants in the In-Person Education group will receive 2 x 2-hour in-person educational small group sessions as per current practice. Each session is two hours long. There will be no tailored exercise program encouraged for participants in this group. The total participation time for this group will be four hours.
2940314|NCT02969473|Active Comparator|PF group|This is the active comparator group. All patients in this group will receive concurrent chemoradiotherapy with PF regimen (5-fluorouracil plus cisplatin).
2940315|NCT02969473|Experimental|DP group|This is the experimental group. All patients in this group will receive concurrent chemoradiotherapy with DP regimen (docetaxel plus cisplatin).
2940316|NCT02969460|Experimental|Neurotrack Virtual Cognitive Health Program|Neurotrack Virtual Cognitive Health Program participants will receive a 6 month intervention, which consists of physical exercise, nutritional guidance, cognitive training, and social engagement, supported by virtual coaches via telephone and email/text messaging.
2940317|NCT02969447|Experimental|Oxytocin administration after fetal expulsion|Administration of 10 units of intra venous oxytocin after fetal expulsion
2940318|NCT02969447|No Intervention|No additional medication after fetal expulsion|
2940319|NCT02969434|Experimental|Sleep questionnaires assessment tools|Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
2940320|NCT02969421|Active Comparator|Slow Tenaculum Placement|This group will have their tenaculum placed using the slow method
2940321|NCT02969421|Active Comparator|Cough Method|This group will have their tenaculum placed using the cough method
2940322|NCT02969408|Experimental|ABS eMDPI|Albuterol electronic multidose dry powder inhaler
2940323|NCT02969382|Experimental|SEP-363856|SEP-363856 capsule (50 mg or 75 mg) once daily
2940324|NCT02969382|Placebo Comparator|Placebo|Placebo capsule once daily
2940325|NCT02969369|Experimental|SEP-363856|SEP-363856 (25, 50, or 75mg/day), once daily
2940326|NCT02969369|Placebo Comparator|Placebo Capsule|Placebo once daily
2940327|NCT02969356|Experimental|Dysport|Each subject will undergo two intramuscular injection (treatment) cycles, receiving AbobotulinumtoxinA (Dysport®) 1500 U on Day 1 of each cycle; the two dosing occasions will be separated by at least 12 weeks (maximum 20 weeks). Subjects will also receive daily GSC therapy. The main focus of GSC will be on the primary TT limb (as determined at the Baseline Visit) and then the other limb. All muscle groups requiring active training and/or stretching should be trained. Subjects will be be given a diary to record each day whether they have performed the GSC therapy.
2940328|NCT02969343|Experimental|Intervention|Patients and providers on hospital care units where the PSLL patient safety health information technology tools are implemented, during the interventional phase of a stepped wedge randomized trial design.
2940329|NCT02969343|No Intervention|Usual Care|Patients on hospital care units where the PSLL patient safety health information technology tools have been implemented or are to be implemented, but are not during the usual care phase of a stepped wedge randomized trial design.
2940330|NCT02969330|Experimental|Glucose|Glucose ingestion
2940331|NCT02969330|Active Comparator|PES|Single session of short PES treatment before glucose ingestion.
2940332|NCT02969317|Experimental|Tiotropium + olodaterol fixed-dose combination|Fixed dose combination
2940333|NCT02969304||Off-Label|Any DMF prescription for MS patients <18 years of age, or for patients diagnosed with non-MS indications, such as psoriasis.
2940334|NCT02969304||On-Label|Prescriptions for patients who are ≥18 years of age and diagnosed with MS
2940335|NCT02969291|Other|Reduced Sedentary Time Intervention|Reduced Sedentary Time Intervention (RSTI)
2940336|NCT02969278|Experimental|Vulvar cancer patients cN0 unfit for sentinel node biopsy|"All invasive vulvar cancer patients with cN0 status:~T > 4 cm;~multicentric tumors (mono or bilateral);~primary lesion completely excised during prior diagnostic surgery~patients candidate to bilateral lymphadenectomy because of unilateral groin lymph node involvement, contralateral cN0~previous radiotherapy a/o chemotherapy (sequential or concurrent). These patients are submitted to 18FDG PET/TC and sentinel node biopsy associated with standard preoperative imaging and radical groin lymphadenectomy"
2940337|NCT02969265|Experimental|TCV-116CCB (Candesartan 8 mg Plus Amlodipine 5 mg)|"Run-in Period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 2 weeks.~Single-blind monotherapy treatment period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine 5 mg capsules, orally, once daily up to 4 weeks.~Double-blind treatment period: TCV-116CCB 8/5 mg tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 8 weeks."
2940338|NCT02969265|Experimental|Amlodipine 5 mg|"Run-in Period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 2 weeks.~Monotherapy treatment period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine 5 mg capsules, orally, once daily up to 4 weeks.~Double-blind treatment period: Amlodipine 5 mg capsules, orally, once daily along with TCV-116CCB placebo-matching tablets, orally, once daily up to 8 weeks."
2940339|NCT02969252|Other|Open label|Single and multiple dose, open label, pharmacokinetics and safety study
2940340|NCT02969239|Experimental|norepinephrine|norepinephrine 5mcg intravenously administered
2940341|NCT02969239|Active Comparator|phenylephrine|phenylephrine 100mcg intravenously administered
2940342|NCT02969226|Active Comparator|Once daily screening + PS SBTs|In this arm, RTs will screen patients between approximately 06:00 - 08:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only PS> 0 and =< 8 cm H2O with PEEP> 0 and =< 5 cm H2O.
2940343|NCT02969226|Experimental|At least twice daily screening + PS SBTs|In this arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team [RTs and physicians]. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only PS>0 and =< 8 cm H2O with PEEP>0 and =< 5 cm H2O.
2940344|NCT02969226|Active Comparator|Once daily screening + T-piece SBTs|In this arm + PS SBT' arm, RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only T-piece (off the ventilator).
2940375|NCT02969031|Experimental|Enhanced SCOPE training|Complete a baseline questionnaire, administer satisfaction surveys anonymously to a sample of their patients, audio record (using a smartphone application) eight clinic visits with eight different patients. Receive survey feedback as well as the enhanced SCOPE program that provides feedback on their audio-recorded encounters via a web-based interactive program.
2940376|NCT02969031|Active Comparator|Standard Communication training|"Complete a baseline questionnaire, administer satisfaction surveys anonymously to a sample of their patients. Receive the results of the patient surveys and be asked to conduct a quality improvement activity of their own design that responds to the feedback (the current standard communication PIM)."
2942057|NCT02957929|Experimental|Cohort 1b, Period F|Single oral dose under fed conditions, crossover
2940345|NCT02969226|Active Comparator|At least twice daily screening + T-piece SBTs|In this arm, RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently In the 'at least twice daily + PS SBT' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hrs and 13:00 - 15:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only T-piece (off the ventilator).
2940346|NCT02969213||Genetic|patients with Gene detection (+)
2940347|NCT02969213||Metabolism|patients with Metabolic disturbance
2940348|NCT02969213||Immune|patients with Immunological marker and Immunotherapy (+)
2940349|NCT02969213||infection|patients with the Infection of central nervous system
2940350|NCT02969213||structure|patients with abnormal image of brain
2940351|NCT02969213||unknown|patients not found any reason
2940352|NCT02969187|Experimental|Experimental|Patients at our Bariatric Surgery Center of Excellence fulfilling NIH criteria for bariatric surgery and planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure randomized to receive 20 ml of 1.3% Exparel + 30 ml of 0.5% Bupivacaine + 150 ml of Saline
2940353|NCT02969187|Active Comparator|Control|Patients at our Bariatric Surgery Center of Excellence fulfilling NIH criteria for bariatric surgery and planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure randomized to receive 60ml of 0.5% Bupivacaine + 140 ml of Saline.
2940354|NCT02969148|Experimental|The bursectomy and D2 lymphadenectomy|Laparoscopic bursectomy and D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.The key of this approach are that anterior lobe of transverse mesocolon and capsula pancreatis will be dissected with the D2 lymphadenectomy according to the guidelines of National Comprehensive Cancer Network(NCCN)
2940355|NCT02969148|Active Comparator|The D2 lymphadenectomy|Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.The key of this approach is that D2 lymphadenectomy is carried out according to the guidelines of National Comprehensive Cancer Network(NCCN) without dissociation of anterior lobe of transverse mesocolon and capsula pancreatis.
2940356|NCT02969135|Experimental|Progressive early passive and active movement|Active exercise starts one week after surgery.
2940357|NCT02969135|Active Comparator|Limited early passive movement|Active exercise starts six weeks after surgery.
2940358|NCT02969122|Active Comparator|Chemotherapy-first|Patients will receive hyperthermic intraperitoneal chemotherapy (HIPEC) during laparoscopic staging. Then 3 cycles of preoperative chemotherapy and clinical evaluation of chemotherapy will be performed. If the patient's disease is evaluated as progressed, the patient will receive systemic therapy. If it's stable or remission, a second time laparoscopic staging and peritoneal cytology examination will be performed. If peritoneal implant is observed, the patients will receive systemic therapy. If the peritoneal cytology is still positive, the treatment will be decided according to the suggestion of MDT discussion. If the peritoneal cytology is converted negative, standard gastrectomy with D2 lymphadenectomy and extensive intraperitoneal lavage (EIPL) will be performed. Postoperative chemotherapy will be determined according to the pathological evaluation of preoperative chemotherapy response.
2940359|NCT02969122|Experimental|Surgery-first|Patients in this arm will receive standard gastrectomy with D2 lymphadenectomy after randomization. Hyperthermic intraperitoneal chemotherapy (HIPEC) and extensive intraperitoneal lavage (EIPL) will be applied before abdominal closure. After surgery, 8 cycles of postoperative chemotherapy will be performed.
2940360|NCT02969096|Experimental|Targeted Cryoablation Therapy|liver cancer patients received targeted cryoablation therapy.
2940361|NCT02969083|Other|Radical nephro-ureterectomy (RNU)|Patients who dont fulfil inclusion criteria for chemotherapy treatment randomization (poor renal function: Glomerular Filtration Rate (GFR) <55 ml/min)
2940362|NCT02969083|Other|Gemcitabine/Cisplatin plus RNU|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) every 3 weeks before surgery
2940363|NCT02969083|Other|RNU plus Gemcitabine/Cisplatin|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) every 3 weeks after surgery
2940364|NCT02969083|Other|M-VAC protocol plus RNU|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of MVAC every 2 weeks (Methotrexate (30 mg /m²) , Vinblastine (3 mg /m²) , Adriamycin (30 mg /m²) , and Cisplatin (70 mg /m²) before surgery
2940365|NCT02969083|Other|RNU plus M-VAC protocol|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of MVAC every 2 weeks (Methotrexate (30 mg /m²) , Vinblastine (3 mg /m²) , Adriamycin (30 mg /m²) , and Cisplatin (70 mg /m²) after surgery
2940366|NCT02969070|Active Comparator|LopiGLIK™ group|4 weeks of LopiGLIK™ therapy 1 capsule/day
2940367|NCT02969070|Active Comparator|Armolipid Plus group|4 weeks of Armolipid Plus therapy 1 capsule/day
2940368|NCT02969057|No Intervention|Breakfast only|Control breakfast providing 50g carbohydrate
2940369|NCT02969057|Active Comparator|Breakfast with rice bran oil gel|Control breakfast, plus 25g rice bran oil gel (solid)
2940370|NCT02969057|Active Comparator|Breakfast with rice bran oil|Control breakfast, plus 25g rice bran oil (liquid)
2940371|NCT02969057|Active Comparator|Breakfast with palm oil gel|Control breakfast, plus 25g palm oil gel (solid)
2940372|NCT02969057|Active Comparator|Breakfast with palm oil|Control breakfast, plus 25g palm oil (liquid)
2940373|NCT02969044|Experimental|PF-06651600|Study Drug
2940374|NCT02969044|Placebo Comparator|Placebo|Placebo
2940377|NCT02969018|Experimental|PF-06700841 60 mg followed by 30 mg once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 30 mg PF-06700841 once daily
2942058|NCT02957929|Experimental|Cohort 2|Multiple oral doses
2940378|NCT02969018|Experimental|PF-06700841 60 mg followed by 10 mg once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
2940379|NCT02969018|Experimental|PF-06700841 60mg once daily followed by 100mg once weekly|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
2940380|NCT02969018|Experimental|PF-06700841 60mg once daily followed by placebo once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of placebo once daily
2940381|NCT02969018|Experimental|PF-06700841 30mg once daily|4 week induction with 30 mg PF-06700841 once daily followed by 8 week chronic administration of 30 mg PF-06700841 once daily
2940382|NCT02969018|Experimental|PF-06700841 30mg once daily followed by 10mg once daily|4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
2940383|NCT02969018|Experimental|PF-06700841 30mg once daily followed by 100mg once weekly|4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
2940384|NCT02969018|Placebo Comparator|Placebo|12 weeks once daily placebo
2940385|NCT02969005|Experimental|surgery group|The dissection was continued into the deeper layers until the bone lesion was visualized, and the bone lesion was then thoroughly resected.
2940386|NCT02968992|Experimental|rhLactoferrin|rH lactoferrin will be provided by Ventria Biosciences. Each capsule will contain 250 mg of rH lactoferrin as active ingredient. Subjects will receive 1500 mg of lactoferrin in capsule form twice a day. Dosing will be six 250 mg capsules twice a day for six months.
2940387|NCT02968992|Placebo Comparator|Placebo|Matching placebo capsule will be provided by Ventria Biosciences and six capsules twice a day will be provided to the subjects in this arm.
2940388|NCT02968966|Experimental|Therapy regime|Three medical drugs will be administered in a predefined order (1. Phenhydan® (Phenytoin), 2. Lacosamid (Vimpat®), 3. Kinidinsulfaat® (Kinidinsulfat) to investigate whether this enables an effective reduction of seizures in early onset epileptic encephalopathies..
2940389|NCT02968940|Experimental|Avelumab and hypofractionated radiation therapy(HFRT)|"Avelumab 10 mg/kg intravenously (IV) every 2 weeks.~Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions"
2940390|NCT02968927|Active Comparator|2HRbEZ/4HRb|2HRbZE
2940391|NCT02968927|Experimental|Everolimus|Everolimus 0.5 MG
2940392|NCT02968927|Experimental|Auranofin|Auranofin 6 MG
2940393|NCT02968927|Experimental|Vitamin D|Vitamin D3
2940394|NCT02968927|Experimental|CC-11050|CC-11050
2940395|NCT02968914|Active Comparator|Benralizumab by Accessorized Pre-Filled Syringe|Drug administration by Accessorized Pre-Filled Syringe. A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
2940396|NCT02968914|Other|Benralizumab by Autoinjector|Drug administration by Autoinjector A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
2940397|NCT02968901|Experimental|bitherapy|Macitentan and tadalafil
2940398|NCT02968888|Placebo Comparator|Milk|Participants performed a bout of strength training and consumed 20g of milk protein
2940399|NCT02968888|Experimental|Whey protein concentrate 80|Participants performed a bout of strength training and consumed 20g of whey protein concentrate 80
2940400|NCT02968888|Experimental|Native whey|Participants performed a bout of strength training and consumed 20g of native whey
2940401|NCT02968875|Active Comparator|Endurance Training|The first group of 40 people will do endurance training; 20 of them will perform a continuous exercise on cycle ergometer at a power equivalent to 70% of the maximal heart rate, twice a week. The other group will do Interval Training, with a four minute long base and one minute long peak, twice a week. The base workload will be equivalent to an intensity of 60% of the maximal heart rate and the peak will be equivalent to 80% of the maximal heart rate.
2940402|NCT02968875|Active Comparator|Control group|20 persons will be in the control group and they will not perform the endurance training. However, they will have 9 therapeutic education meetings.
2940403|NCT02968849|Active Comparator|ALVAC-HIV + subtype C gp120/MF59|2700 participants will receive an IM injection of ALVAC-HIV (vCP2438) at months 0 and 1, and an IM injection of ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 at months 3, 6, and 12.
2940404|NCT02968849|Placebo Comparator|Placebo|2700 participants will receive Sodium Chloride for injection, 0.9% at months 0, 1, 3, 6, and 12.
2940405|NCT02968836|Active Comparator|Active group|Blend of amino acids
2940406|NCT02968836|Placebo Comparator|Placebo group|maltodextrin only
2940407|NCT02968823|Active Comparator|Licorice|Licorice gargle
2940408|NCT02968823|Placebo Comparator|Sugar water|Sugar gargle
2940409|NCT02968810|Experimental|Group I (simvastatin)|Patients receive simvastatin PO QD. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
2940410|NCT02968810|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
2940411|NCT02968784|Experimental|ExAblate MRgFUS|"Up to 50% of the prostate gland will be treated. Treatment will include the Index lesion which is visible on MRI + tumor free margins of 3-mm; tumor free margins will not extend beyond the posterior aspect of the prostate capsule.~Urethral and bilateral neurovascular bundle preservation will be preferred whenever clinically justified.~Additional foci in the same hemisphere that are confirmed by biopsy and are < Gleason Score 7 (up to 3+4 or 4+3) or suspected to be positive for malignancy based on multi parametric-MRI) will also be included in the treated volume, providing total treatment volume does not exceed 50% of the gland."
2940412|NCT02968771||Patients with Physical Cardiac Stress|Patients with Physical Cardiac Stress
2940413|NCT02968771||Patients with Physical and Pharmacological Cardiac Stress|Patients with Physical and Pharmacological Cardiac Stress with adenosine agonist
2940414|NCT02968771||Patients with Pharmacological Cardiac Stress|Patients with Pharmacological Cardiac Stress with adenosine agonist
2940417|NCT02968719|Experimental|Donepezil TDS Version A|"Lead-in of 5 mg/day donepezil of target dose (1 x Corplex 5 mg donepezil transdermal delivery system; 7 days) followed by; Target dose of 10 mg/day donepezil (Treatment A); Corplex 10 mg donepezil transdermal delivery system.~1x patch will be worn for 7 days. A total of 4 TDS patches will be applied for 4 consecutive 7 day periods."
2940418|NCT02968719|Experimental|Donepezil TDS Version B|"Lead-in of 5 mg/day donepezil of target dose (1 x Corplex 5 mg donepezil transdermal delivery system; 7 days) followed by; Target dose of 10 mg/day donepezil (Treatment B); Corplex 10 mg donepezil delivery transdermal system.~1x patch will be worn for 7 days. A total of 4 TDS patches will be applied for 4 consecutive 7 day periods."
2940419|NCT02968719|Active Comparator|10 mg Aricept|5 mg/day oral Aricept, once daily for 7 days followed by; 10 mg/day Aricept once daily for 28 days
2940420|NCT02968719|Experimental|Donepezil TDS Version D|Target dose of 5 mg/day donepezil (Treatment D) Corplex 5 mg Donepezil TDS applied for a duration of 1 week.
2940421|NCT02968719|Experimental|Donepezil TDS Version E|Target dose of 5 mg/day donepezil (Treatment E) Corplex 5 mg Donepezil TDS applied for a duration of 1 week
2940422|NCT02968706|Experimental|High flow cannula arm|Patients in the experimental arm (the high flow nasal cannula group) will receive heated humidified high flow oxygen of 50L/min at FiO2 of 40% throughout the colonoscopy. A patient satisfaction survey will be administered after procedure.
2940423|NCT02968706|Active Comparator|Conventional cannula arm|Participants in control arm (the conventional nasal cannula group) will receive an oxygen flow of 2-5 L /min. A patient satisfaction survey will be administered after procedure.
2940424|NCT02968693||combination therapy group|antibiotic-loaded calcium sulfate and antibiotic-loaded polymethyl methacrylate (PMMA) and Vancomycin
2940425|NCT02968693||PMMA group|antibiotic-loaded polymethyl methacrylate and Vancomycin
2940426|NCT02968680|Experimental|Diagnostic (sonazoid, ultrasound imaging, SLNB)|Patients receive sonazoid ID and undergo ultrasound imaging. Patients also undergo standard of care SLNB.
2940427|NCT02968667|Experimental|Intervention|Intervention group received 6 weeks of empowerment program
2940428|NCT02968667|No Intervention|Treatment as usual|Medications
2940429|NCT02968654|Other|Restrictive Transfusion Strategy|"Blood Transfusion will be given when hemoglobin concentration will be below 7 g/dL (as suggested by current guidelines in general ICU population)"
2940430|NCT02968654|Other|Liberal Transfusion Strategy|"Blood Transfusion will be given when hemoglobin concentration will be below 9 g/dL"
2940431|NCT02968641|Active Comparator|LNF 25 mg bid and RTV 100 mg bid|Patients will take lonafarnib 25 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
2940432|NCT02968641|Active Comparator|LNF 50 mg bid and RTV 100 mg bid|Patients will take lonafarnib 50 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
2940433|NCT02968641|Active Comparator|LNF 100 mg bid|Patients will take lonafarnib 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
2940434|NCT02968628||Cases: Infants of Diabetic Mothers|"Cases: Neonates born at or over 35 weeks gestation whose mother's were recommended to receive medication for diabetes during pregnancy. This includes pre-gestational and gestational diabetics.~Interventions:~Video Electroencephalogram (EEG)~Point-of Care Blood Sugar Testing~Medical Record Data Extraction~Maternal Questionnaire"
2940435|NCT02968628||Controls|"Controls: Neonates born at or over 35 weeks gestation whose mother's had normal glycemic control testing during pregnancy.~Interventions:~Video Electroencephalogram (EEG)~Point-of Care Blood Sugar Testing~Medical Record Data Extraction~Maternal Questionnaire"
2940436|NCT02968615|Experimental|fiber & protein|A single dietary change condition that focuses exclusively on increasing fiber and protein.
2940437|NCT02968602|Experimental|Minocycline|Participants will take 50 mg minocycline capsules twice daily for 1 week, then take 100 mg capsules twice daily for 1 week.
2940438|NCT02968602|Placebo Comparator|Placebo|Participants will take capsules that match active drug, but contain no active ingredients, twice daily for week 1, and then will take capsules that match active drug, but contain no active ingredients, twice daily for week 2.
2940439|NCT02968589|Experimental|@ctiveHip intervention|"A training session for caregivers of patients with hip fracture on patient management.~The @ctiveHip tele-rehabilitation system. This system includes a 3-months occupational therapy and exercise-based program, recommendations for patients and their caregivers and the option of chats and videoconferences.~The program consists of 5 sessions/week of 50-60 minutes that patients will do at home. Each session includes videos with the prescribed activities and exercises that the patients will find in the private site of www.activehip.es."
2940440|NCT02968589|Active Comparator|Other training|"A training session for caregivers of patients with hip fracture on patient management.~The usual care for hip fracture patients at hospital discharge. In addition, patients and their families will receive a triptych with information on recommendations and exercises to do at home."
2940441|NCT02968576|Active Comparator|Truvada|Naked form Truvada (drug)
2940442|NCT02968576|Experimental|PSS-Truvada|Proteus Sensor System (PSS) (device) encapsulated Truvada (drug)
2940443|NCT02968563|Experimental|Tirabrutinib + idelalisib (Arm A)|Participants will receive tirabrutinib and idelalisib for up to 104 weeks.
2940444|NCT02968563|Experimental|Tirabrutinib + idelalisib + obinutuzumab (Arm B)|Participants will receive obinutuzumab over 21 weeks and the combination of tirabrutinib and idelalisib for up to 104 weeks.
2940445|NCT02968550||Low shunt group|patients with shunt less than 30% in one-lung ventilation at ZEEP
2940446|NCT02968550||High shunt group|Patients with shunt equal or more than 30% in one-lung ventilation at ZEEP
2940447|NCT02968537|Experimental|Alc-IT (50/50) (morning)|Alc-IT (50/50) (morning): This alcohol-specific inhibition-training (Alc-IT) training group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In the morning group, this training will be administered within the first 2 hours after awakening.
2940448|NCT02968537|Experimental|Alc-IT (75/25) (morning)|This version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In the morning group, this training will be administered within the first 2 hours after awakening.
2940449|NCT02968537|Placebo Comparator|Control-training (morning)|This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
2940450|NCT02968537|Experimental|Alc-IT (50/50) (afternoon)|"Alc-IT (50/50) (afternoon): As in the arm Alc-IT (50/50) (morning), this alcohol-specific inhibition-training (Alc-IT) group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
2940451|NCT02968537|Experimental|Alc-IT (75/25) (afternoon)|"As in the arm Alc-IT (75/25) (morning), this version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
2940452|NCT02968537|Placebo Comparator|Control-training (afternoon)|"As in the arm Control-training (morning), this group will receive an unspecific inhibition training. This training is of the same length and difficulty as the two Alc-inhibition-trainings. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
2940453|NCT02968511|Experimental|fecal microbiota transplant|250 mL of fecal transplant material by enema as treatment
2940454|NCT02968498|Active Comparator|Study arm 1|Lactulose crystals 10 g vs lactulose crystals 20 g vs oral glucose 20 g vs still water
2940455|NCT02968498|Active Comparator|Study arm 2|Lactulose liquid 10 g vs lactulose liquid 20 g vs oral glucose 20 g vs still water
2940456|NCT02968485|Experimental|SHR7390|60 subjects with advanced solid tumors were received single and then multiple oral doses of SHR7390(2 cycles,each cycle 28days).
2940457|NCT02968472|Experimental|prophylactic 4SCAR19 cells|Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.
2940458|NCT02968459|Experimental|Umbilical cord MSCs Group|1*10^7 Umbilical cord MSCs
2940459|NCT02968459|Placebo Comparator|Placebo-Controlled Group|1ml of 0.9% saline
2940460|NCT02968446|Placebo Comparator|Group 1: 4 placebo - 0 Vitamin D with Valchlor|Participants will be given 4 placebo capsules and 0 cholecalciferol (Vitamin D) capsules after being treated with Valchlor.
2940461|NCT02968446|Experimental|Group 2: 0 placebo - 4 Vitamin D with mechloroethamine|Participants will be given 0 placebo capsules and 4 cholecalciferol capsules to total 200,000 IU of cholecalciferol (Vitamin D) after being treated with Valchlor.
2940462|NCT02968433|Experimental|Infusions of Young Plasma|"All participants will undergo neuropsychological, neuropsychiatric, and kinematic assessments prior to receiving infusions of young plasma as the treatment.~Participants will receive 1 unit of young plasma, twice a week over a four week duration.~After the four weeks of plasma infusions, participants will undergo neuropsychological, neuropsychiatric and kinematic reassessments. No deception will be used."
2940463|NCT02968420|Active Comparator|Group 1|Group 1: girls who received 2 doses of Q-HPV vaccine at 0, 6 month schedule 8-10 years ago when they were between 9-13 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
2940464|NCT02968420|Active Comparator|Group 2|Group 2: girls who received 3 doses of Q-HPV vaccine at 0, 2, 6 month schedule 8-10 years ago when they were between 9-13 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
2940465|NCT02968420|Active Comparator|Group 3|Group 3: young women who received 3 doses of Q-HPV vaccine at 0, 2, 6 month schedule 8-10 years ago when they were between 16-26 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
2940466|NCT02968394|Experimental|NEVIT|Co treatment with omalizumab during another attempt of immunotherapy introduction
2940467|NCT02968381|Experimental|Imagery Intervention|Participants will receive imagery intervention which includes 6 telephone sessions, an introduction to guided imagery, setting a quit date, setting guided imagery schedule, and a description of and instructions for using the study website.
2940468|NCT02968381|Active Comparator|Control Condition|Participants will receive an attention control condition which includes 6 telephone sessions, an introduction to cognitive behavioral telephone coaching, setting a quit date, creating a quit plan, and a description of and instructions for using the Arizona Smokers' Help Line website.
2940469|NCT02968368|Experimental|Oral ferric maltol|30mg capsules BID
2940470|NCT02968368|Placebo Comparator|Oral placebo|Matching placebo capsules BID
2940471|NCT02968355||Subjects/Specimens|Subjects/Specimens that meet the eligibility criteria
2940472|NCT02968342|Experimental|Vaginal progesterone 8%|Vaginal progesterone application 8%
2940473|NCT02968342|Placebo Comparator|Placebo|Oral multivitamin supplement
2940474|NCT02968329||CVA cases|patients who experienced an ischemic CVA or TIA during the study duration and experienced a recurrence.
2940475|NCT02968329||CVA controls|patients who experienced an ischemic CVA or TIA during the study duration, but who didn't experience a recurrence.
2940476|NCT02968329||AF cases|patients who experienced an ischemic CVA or TIA during the study duration and who got diagnosed with 'new' AF
2940477|NCT02968329||AF controls|patients who experienced an ischemic CVA or TIA during the study duration but who didn't get diagnosed with 'new' AF during the study duration
2940479|NCT02968303|Experimental|Induction treatment|Induction vemurafenib and cobimetinib (6 weeks) directly followed by ipilimumab and nivolumab
2940480|NCT02968303|No Intervention|No induction treatment|Upfront ipilimumab and nivolumab without induction by vemurafenib and cobimetinib
2940481|NCT02968290|Active Comparator|Hydrofobic material-Alcon AcrySof SA60AT|Intervention- Cataract Surgery with implantation of intraocular lens. In this arm will be implantation hydrofobic material.
2940482|NCT02968290|Active Comparator|Hydrophilic material-Bausch Lomb AkreosA|Intervention- Cataract Surgery with implantation of intraocular lens. In this arm will be implantation hydrophilic material.
2940483|NCT02968277|Active Comparator|Back Pain|Individuals who experience low back pain and use a walker.
2940484|NCT02968277|Placebo Comparator|No Back Pain|Individuals who use a walker
2940485|NCT02968264||TOF participants|Tetralogy of fallot patients at any age
2940486|NCT02968251|Experimental|Hand Washing Program (HWP)|Clusters in this arm will be given a Hand Washing Program (HWP) which will consist of: integrating hand washing practice in the school health policy, setting up proper hand washing facilities in the intervention schools, training to school teachers, delivering of health talk to schoolchildren and their parents, developing reminders and posters of a simplified 5-step hand washing technique, peer briefing session, take home package (5-steps hand washing, commitment letter, poster, leaflet). The program will be delivered once every week.
2940487|NCT02968251|No Intervention|No Hand Washing Program (NHWP)|Clusters in this arm will be allowed to continue with their usual practice regarding hand washing/hygiene
2940488|NCT02968238|Active Comparator|CBT preference arm|CBT preference arm consists of participants who are randomized to the preference condition and choose to receive cognitive-behavioral therapy (CBT). CBT consists of 10 weeks of weekly treatment.
2940489|NCT02968238|Active Comparator|Yoga preference arm|Yoga preference arm consists of participants who are randomized to the preference condition and choose to receive yoga. Yoga consists of 10 weeks of bi-weekly treatment (total = 20 treatments).
2940490|NCT02968238|Active Comparator|CBT randomized arm|CBT randomized arm consists of participants who are randomized to the random condition and are randomized to receive cognitive-behavioral therapy (CBT). CBT consists of 10 weeks of weekly treatment.
2940491|NCT02968238|Active Comparator|Yoga randomized arm|Yoga randomized arm consists of participants who are randomized to the random condition and are randomized to receive yoga. Yoga consists of 10 weeks of bi-weekly treatment (total = 20 treatments).
2940492|NCT02968225|Experimental|Computer Game|"All Computer Game participants will complete:~online screening~Diagnostic and eye-tracking pre-testing~3 month intervention~Eye-tracking post-testing"
2940493|NCT02968225|No Intervention|Waitlist control|"All Treatment as usual control participants will complete:~online screening~Diagnostic and eye-tracking pre-testing~Eye-tracking post-testing"
2940494|NCT02968212|Experimental|clofazimine|Participants receive lamprene
2940495|NCT02968212|Placebo Comparator|sugar pill|Participants receive placebo
2940496|NCT02968199|Experimental|Referred women|A brief intervention based on the'5 A' model developed by the Agency for Health Care Policy and Research in the United States.
2940497|NCT02968186|Experimental|Implementation program|Health professionals will receive a training and support implementation program
2940498|NCT02968186|No Intervention|Waiting list|Health professionals will be assigned to a waiting list to receive the implementation program
2940499|NCT02968173|Experimental|Children at High Risk of severe RSV Infection|A single IM injection every 30 days beginning at Day 0 for a total of 3-5 injections determined by when in the RSV season a participant was enrolled.
2940500|NCT02968160|Experimental|Telmisartan+Rosuvastatin|"Duowell ® tablet (Telmisartan 40mg + Rosuvastatin 20mg) 1 tablet, once daily, Oral administration/ 8 weeks~* But, the increased Duowell ® tablet (Telmisartan 80mg + Rosuvastatin 20mg) will get administrated orally one tablet once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit."
2940501|NCT02968160|Active Comparator|Telmisartan/Rosuvastatin|"Telmisartan 40mg + Rosuvastatin 20mg 2 tablets, once daily, Oral administration/ 8 weeks~* But, the increased Telmisartan 80mg + Rosuvastatin 20mg will get administrated orally 2 tablets once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit."
2940502|NCT02968147|Experimental|Conventional ventilation|Catheter ablation for persistent atrial fibrillation with general anesthesia and conventional ventilation
2940503|NCT02968147|Experimental|Jet ventilation|Catheter ablation for persistent atrial fibrillation with general anesthesia and high frequency jet ventilation
2940504|NCT02968134|Other|Posaconazole|The study will enrol eight patients with presumed or confirmed systemic fungal infections, who are admitted to ICU
2940505|NCT02968121|Experimental|Part A: Single Dose Injection: Subcutaneous|Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous
2940506|NCT02968121|Experimental|Part A: Single Dose Injection: Intramuscular|Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous
2940507|NCT02968121|Experimental|Part B: Cohort 1|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
2940508|NCT02968121|Experimental|Part B: Cohort 2|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
2940509|NCT02968121|Experimental|Part B: Cohort 3|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
2940510|NCT02968108|Experimental|Group1: Ustekinumab Dose Regimen 1|Subjects will receive a single intravenous (IV) induction dose of 3 milligram per kilogram (mg/kg) for subjects less than < 40 kilogram (kg) or 130 milligram (mg) for subjects greater than or equal to >= 40 kg at Week 0 followed by subcutaneous (SC) maintenance dose of 2 mg/kg for subjects < 40 kg or 90 mg for subjects >= 40 kg at week 8.
2940511|NCT02968108|Experimental|Group2: Ustekinumab Dose Regimen 2|Subjects will receive a single Intravenous (IV) dose of 9 mg/kg for subjects <40 kg or 390 mg for subjects >= 40 kg at Week 0 followed by SC maintenance dose of 2 mg/kg for subjects <40 kg or 90 mg for subjects >= 40 kg at week 8.
2940512|NCT02968095|Experimental|Text Message Craving Program|Text messages designed to help smokers to modify their thinking styles to be more adaptive, delivered 2-3 times per day.
2940513|NCT02968095|Active Comparator|Self-Help Manual Plus Control Texts|A print, self-help manual plus general motivational text messages delivered 2-3 times per day.
2940551|NCT02967783|Experimental|ID Adaptor (Helm)|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered using a needle and syringe with an ID adaptor
2940514|NCT02968082|Placebo Comparator|Placebo group (P group)|"The group that not existed scopolamine ingredient.~dosage form: apply~dosage: 1.5 mg~frequency: 1 times (at 9 p.m. of the day before the operation day)~duration: Until the 24hr after operation.~Patients will be applied patch that not existed scopolamine ingredient."
2940515|NCT02968082|Experimental|Scopolamine group (S group)|"'Scopolamine (1.5mg) 1 patch'~The group that existed scopolamine ingredient~dosage form: apply~dosage: 1.5 mg~frequency: 1 times (at 9 p.m. of the day before the operation day)~duration: Until the 24hr after operation.~Patients will be applied patch that existed scopolamine ingredient."
2940516|NCT02968069|Experimental|Suspected gastric cancerous lesions|Magnifying endoscopy with NBI would be conducted for every patient included in our study
2940517|NCT02968056|Experimental|Hybrid group|Minimally invasive surgical radiofrequency ablation of atrial fibrillation followed by catheterized radiofrequency ablation within the same procedure
2940518|NCT02968056|Active Comparator|MIS group|Minimally invasive surgical radiofrequency ablation of atrial fibrillation only
2940519|NCT02968043|Active Comparator|control group|Control group will perform generalised physiotherapy exercises for a 60-min period for 2 or 3 times a week under the guidance of experienced physiotherapists in an outpatient clinic and for a 20-min period per day under the supervision of the parents at home. Generalised physiotherapy exercises consist of stretching and strengthening activities.
2940520|NCT02968043|Experimental|intervention group|Intervention group will perform physiotherapeutic scoliosis specific exercises for a 60-min period for 2 or 3 times a week under the guidance of experienced physiotherapists with expertise in scoliosis in an outpatient clinic and for a 20-min period per day under the supervision of the parents at home. Physiotherapeutic scoliosis specific exercises consist of patient and family education, 3D self-correction, stabilizing exercises, balance training, breathing exercises, and training in activities of daily living.
2940521|NCT02968030|Experimental|Muscle strength|Evaluate the effects of a eight weeks program of strengthening exercise on balance and functional mobility in irregular active elderly women
2940522|NCT02968017||MCA-PI|Measurement Middle cerebral artery pulsatility index
2940523|NCT02968004|Experimental|MOD-4023|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
2940524|NCT02968004|Active Comparator|Genotropin|Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)
2940525|NCT02967991|Active Comparator|19 Left|EUS-guided liver biopsy using a19-gauge liver biopsy in the left lobe
2940526|NCT02967991|Experimental|22 Left|EUS-guided liver biopsy using a 22-gauge liver biopsy in the left lobe
2940527|NCT02967991|Active Comparator|19 Right|EUS-guided liver biopsy using a 19-gauge liver biopsy in the right lobe
2940528|NCT02967991|Experimental|22 Right|EUS-guided liver biopsy using a 22-gauge liver biopsy in the right lobe
2940529|NCT02967965||Cohort|Clinical Evaluation, Coronarography, Imagery by MRI, Echocardiography and Biologial samples will be collected for each patient.
2940530|NCT02967952|Active Comparator|supraglottic airway (SGA)|Adult patients with non-trauma causes of OHCA who are resuscitated by emergency medical technician paramedic (EMTP) in the prehospital setting and received airway management of supraglottic airway (SGA).
2940531|NCT02967952|Active Comparator|endotracheal intubation (ETI)|Adult patients with non-trauma causes of OHCA who are resuscitated by emergency medical technician paramedic (EMTP) in the prehospital setting and received airway management of endotracheal intubation (ETI).
2940532|NCT02967939|Experimental|DA-2802|DA-2802 319mg tablet qd
2940533|NCT02967939|Active Comparator|Viread®|Viread® 300mg tablet qd
2940534|NCT02967926|Experimental|ERCP without Fluoroscopy|Non-fluoroscopic common bile duct stone extraction
2940535|NCT02967913|Experimental|Bladder flap performed as per routine|Bladder flap surgical step performed at time of non-urgent primary cesarean delivery as per routine
2940536|NCT02967913|No Intervention|Bladder flap is omitted|No bladder flap performed at time of non-urgent primary cesarean delivery
2940537|NCT02967887|Experimental|cisplatin and 5-fluorouracil|Enrolled patients with pre-treatment tumor biopsy will receive Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system. This treatment will be repeated every 4 weeks, up to 6 times.
2940538|NCT02967874|Experimental|Intra-articular auto-SVFs injection|"The participants will undergo a standard liposuction to harvest adipose tissue. The adipose tissue will then be processed to obtain the SVFs.~This group of subjects (n=20) will receive a single injection of auto-SVFs into affected knees (3.0 mL cell suspension/joint)."
2940539|NCT02967874|Active Comparator|Intra-articular Hyaluronic Acid|This group of subjects (n=20) will receive a single injection of Synocrom Forte 2% into affected knees (1.0 mL/joint).
2940540|NCT02967861|Active Comparator|SRP & pranayama (lifestyle modification)|30 chronic periodontitis subjects treated with SRP & pranayama for 3 months
2940541|NCT02967861|Placebo Comparator|Scaling and root planing|30 chronic periodontitis subjects treated with scaling and root planing only
2940542|NCT02967848||Patients with Cancers in Liver|Adult patients with primary liver cancer or liver metastases from any other histology who will be measured before and after Radiotherapy by '99mTc-mebrofenin hepatobiliary scintigraphy (HBS), Indocyanine Green and Liver Elasticity.
2940543|NCT02967835|Experimental|Telepsychiatry Consult|One time tele-psychiatry consultation to provide treatment recommendations for patients primary care physician.
2940544|NCT02967822||Patients with MRKH syndrome|"Biological samples for patients.~Inclusion of patients presenting MRKH syndrome, and who are followed in clinical centres participating in the study."
2940545|NCT02967822||Healthy relatives|"Biological samples for healthy relatives.~Inclusion of healthy relatives of patients included in the study (parents, brothers, sisters)"
2940546|NCT02967809||final diagnosis after portable echography|Experimental group: final diagnosis after portable cardiac echograph examination
2940547|NCT02967809||final diagnosis without portable echography|Group control: Final diagnosis for patient ( same medical condition and history) hospitalized in units without portable cardiac echograph examination avaible
2940548|NCT02967796||Supplemented group|6 capsule of Proteochoc during 4 day, from day 0 (day of delivery) to day 4
2940549|NCT02967796||Control group|no supplementation, just the same follow-up as supplemented group
2940550|NCT02967783|Active Comparator|ID Needle and Syringe|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered using a needle and syringe
2940552|NCT02967783|Experimental|ID Jet Injector (Tropis, Pharmajet)|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered by needle and syringe with a disposable syringe jet injecto
2940553|NCT02967770|Experimental|Molecularly Tailored Therapy|Patients will be treated according to their molecular profile and accordingly, the 29 evaluable patients enrolled may receive one of a dozen, or dozens of treatment regimens.
2940554|NCT02967770|Active Comparator|Physician's Discretion Standard of Care|Patients will be treated according to physician discretion standard of care regimen.
2940555|NCT02967757||liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg|
2940556|NCT02967744|Experimental|NSAID treatment|8 weeks of NSAID treatment
2940557|NCT02967731|Experimental|480 Mometasone Furoate Sinus Drug Depot|480 Mometasone Furoate Sinus Drug Depot
2940558|NCT02967718||Control group|the healthy patients
2940559|NCT02967718||Metabolic syndrome group|Include patients who are accordance with diagnostic criteria of metabolic syndrome
2940560|NCT02967718||CHD stable stage group|Include patients who are accordance with diagnostic criteria of asymptomatic angina, stable angina or stable (more than 1 month) acute coronary syndrome
2940561|NCT02967718||Acute coronary syndrome group|Include patients who are accordance with diagnostic criteria of unstable angina or non-ST-segment elevated myocardial infarction
2940562|NCT02967718||PCI or CABG group|Include the patients who will undergo percutaneous coronary intervention of coronary artery bypass grafting
2940563|NCT02967718||CHD heart failure group|Include the patients who suffered heart failure cause by CHD
2940564|NCT02967705|Experimental|Pain management group|6 + 1 meetings 2 hours each
2940565|NCT02967705|No Intervention|Treatment as usual|Waiting list - will receive treatment as usual
2940566|NCT02967692|Experimental|Investigational treatment arm|"Part 1: Safety run-in Up to 18 evaluable patients with previously untreated unresectable or metastatic BRAF V600 mutated melanoma will be enrolled and treated at different dose levels to determine the recommended Phase 3 regimen of PDR001 in combination with dabrafenib and trametinib.~Part 2: Biomarker cohort Approximately 20 patients with previously unresectable or metastatic BRAF V600 mutated melanoma will be enrolled to describe changes in the immune microenvironment and biomarker modulations~Part 3: Randomized double blind Approximately 500 patients with previously untreated unresectable and metastatic BRAF V600 mutated melanoma will be enrolled to compare the anti-tumor activity of PDR001 in combination with dabrafenib and trametinib versus placebo plus dabrafenib and trametinib."
2940567|NCT02967692|Placebo Comparator|Placebo comparator arm|Matching placebo in combination with dabrafenib and trametinib
2940568|NCT02967679|Experimental|MD1003|
2940569|NCT02967666|Experimental|FDG PET/MRI, DOTANOC PET/MRI|FDG PET/MRI and DOTANOC PET/MRI will be performed.
2940570|NCT02967653|Placebo Comparator|Placebo|Patients will be randomized to a placebo a day using simple 1:1 randomization using random.org, for 12 weeks.
2940571|NCT02967653|Experimental|Atorvastatin|Patients will be randomized to Atorvastatin 20mg/day for 12 weeks or pill placebo.
2940572|NCT02967640|Experimental|Ketalar|ketalar injection, subacromial
2940573|NCT02967640|Placebo Comparator|Placebo|physiological sodium chloride (NaCl 9%) injection, subacromial
2940574|NCT02967627|Experimental|Incisional Negative Pressure Wound Therapy (iNPWT)|Patients in the iNPWT group will have their incision covered by a single layer of Mepitel wound contact layer followed by application of a KCI V.A.C Simplace ™ Dressing composed of a strip of black foam covering the entire length of the incision followed by coverage of the incision, Mepitel, and foam with an occlusive Tegederm ™ dressing to establish an airtight seal. Negative pressure will then be applied using a SensaT.R.A.C. Pad ™ to a setting of 100 mmHg continuous suction. Dressings shall remain in place and will be removed by the surgical team on the morning of the third post-operative day and left open to air thereafter. Any loss of seal of the dressing shall be reinforced using occlusive dressings.
2940575|NCT02967627|Active Comparator|Standard Therapy|Patients in the conventional dressings group will receive a standard Mepore ™ dressing applied to cover the entire incision. This will be left in place and and removed by the surgical team on the morning of the second postoperative day and will be left open to air thereafter. Dressings may be either reinforced or changed at the discretion of the surgical team due to drainage or saturation during the first two postoperative days.
2940576|NCT02967614|Experimental|[A]→[A]+[B]|"Period 1 : At each dosing of Treatment A eye drops is administered for 8days~Period 2 : At each dosing of Treatment A + Treatment B eye drops is administered for 92days"
2940577|NCT02967614|Experimental|[B]→[A]+[B]|"Period 1 : At each dosing of Treatment B eye drops is administered for 92days~Period 2 : At each dosing of Treatment A + Treatment B eye drops is administered for 8days"
2940578|NCT02967601||Elective Cesarean Section|
2940579|NCT02967588|Experimental|Intervention|
2940580|NCT02967575||1- or 2-level cTDR|patients suffering from intractable symptomatic cervical disc disease (SCDD) requiring 1- or 2-level reconstruction of the disc from C3-C7
2940581|NCT02967562|Active Comparator|Inflation Breaths|Five 'inflation breaths' lasting two - three seconds
2940582|NCT02967562|Experimental|Sustained inflation|One fifteen second 'sustained inflation'
2940583|NCT02967549|Experimental|NAVA then PAV|Infants randomised to NAVA then PAV
2940584|NCT02967549|Experimental|PAV then NAVA|Infants randomised to PAV then NAVA
2940585|NCT02967536||Mild OSA|Untreated OSA patients. Apnoea-Hypopnoea Index (AHI) >5 events/hour and <10 events/hour with Epworth Sleepiness Score (ESS)>9.
2940586|NCT02967536||Severe OSA|Untreated OSA patients. AHI >30 events/hour, with excessive sleepiness (ESS >9).
2940587|NCT02967510|Experimental|0.005% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
2940588|NCT02967510|Experimental|0.002% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
2940589|NCT02967510|Experimental|0.0008% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
2942059|NCT02957929|Experimental|Cohort 3|Multiple oral doses
2940590|NCT02967510|Placebo Comparator|estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
2940591|NCT02967497|No Intervention|Blank|No intervention, just observation.
2940592|NCT02967497|Experimental|YQ1 group|Cisplatin-based chemotherapy + YQ1
2940593|NCT02967484|Experimental|Treatment Group|"Participants will recieve the therapy as follows: Huo Xue San Feng acupuncture method+Routine care for ischemic stroke+One type of antihypertensive medication.~Intervention:Acupuncture(choosing the bilatral acupoint: Renying(ST9),Hegu(L14), Taichong(LR3),Quchi(LI11),Zusanli(ST36))+Drugs(one type of antihypertensive medicine)"
2940594|NCT02967484|No Intervention|Control Group|"Participants recieve the therapy as follows:Routine care for ischemic stroke +One type of antihypertensive medication.~Intervention:Acupuncture(choosing the acupoint: Neiguan(PC6),Renzhong(10), Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).)+Drugs(one type of antihypertensive medicine)"
2940595|NCT02967471||ARDS group|
2940596|NCT02967471||control group|
2940597|NCT02967458|Experimental|Prostate Biopsy Patients|Fifty patients who are scheduled for a clinically indicated prostate biopsy, and who are able to undergo contrast enhanced transrectal ultrasound will be included in this single arm study. Each of the study subjects will receive in intravenous infusion of a microbubble contrast agent known as Definity™, (Perflutren Lipid Microsphere, Lantheus Medical Imaging, Inc; N. Billerica, MA). Based upon our previous experience, two vials of Perflutren Lipid Microsphere will be mixed and diluted in 50 ml of normal saline, yielding a concentration of 49.4 μl/ml. For the purpose of contrast-enhanced imaging, Perflutren Lipid Microsphere will be infused over approximately 10-12 minutes, during which time ultrasound imaging and biopsy will be performed.
2940598|NCT02967445|Experimental|Cervical pessary|Arabin Pessary
2940599|NCT02967445|Active Comparator|Cervical cerclage|McDonald Cerclage
2940600|NCT02967432|Experimental|Mupirocin|
2940601|NCT02967432|Placebo Comparator|Petroleum jelly|
2940602|NCT02967419||RIF group|People who were diagnosed as repeated implantation failure after IVF-ET
2940603|NCT02967419||Control group|People who had normal pregnancy
2940604|NCT02967406|Experimental|Lifestyle modification|4 x 4 lifestyle modification intervention, addressing four health behaviors including physical activity, diet, smoking and alcohol drinking, at four different levels, i.e. individual, household, group/ knowledge management, and community levels
2940605|NCT02967406|No Intervention|Control|No special intervention will be given. Prevention and treatment in normal practice is allowed
2940606|NCT02967393|Active Comparator|IIV4|0.5 mL intramuscular injection
2940607|NCT02967393|Active Comparator|cc IIV4|0.5 mL intramuscular injection
2940608|NCT02967380|Experimental|Diagnostic (Magnevist/Multihance, Gadavist, DCE-MRI)|Patients receive standard of care gadopentetate dimeglumine IV twice within 5 minutes or gadobenate dimeglumine IV twice within 5 minutes and then undergo DCE-MRI on day 1. Patients also receive gadobutrol IV twice within 5 minutes and then undergo DCE-MRI over approximately 30 minutes on day 3, 4, 5, 6, or 7.
2940609|NCT02967367|Experimental|Jawbone/Withings sleep trackers, Bodymedia Sensewear|2 types of Consumer sleep trackers, including Jawbone and Withings, and one research actigraph (Bodymedia Sensewear) are added to classical polysomnography in order to assess their accuracy to measure sleep parameters in obstructive sleep apnea patients
2940610|NCT02967354|Experimental|Healthy control|Healthy control
2940611|NCT02967354|Experimental|Obese with oral antidiabetic drugs|BMI>30, Type 2 diabetes treated with oral antidiabetic drugs
2940612|NCT02967354|Experimental|Obese, treated with oral antidiabetic drugs + insulin|BMI>30, Type 2 diabetes treated with oral antidiabetic drugs + insulin
2940613|NCT02967354|Experimental|Normal weight, treated with oral antidiabetic drugs|BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs
2940614|NCT02967354|Experimental|Normal weight, treated with oral antidiabetic drugs + insulin|BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs + insulin
2940615|NCT02967341|Other|Ciprofloxacin administration|Blood will be drawn, in all participants, via Port A Cath and via a peripheral draw.
2940616|NCT02967328||RP% Measurement by FCM as a Diagnostic Test for ITP|The investigators are undertaking a multi-center, prospective blind trial of 500 adults with thrombocytopenic disorders with a platelet count less than 60000/uL from 4 medical centers in China. In brief, 15 ul aliquots of anti-coagulated whole blood were incubated for 70 min with 5 ul of phycoerythrin-conjugated anti-CD42b monoclonal antibody (BD Pharmingen, Tokyo, Japan) and 1 ml of thiazole orange (Retic-COUNT; Becton-Dickinson, San Jose, CA, USA) diluted 10 times by phosphate-buffered saline. RP% was analyzed on a flow cytometer (FACScan, Becton-Dickinson) by measuring 10,000 events in the CD42b-positive fraction.
2940617|NCT02967315|Experimental|Study Group|"Procedures include:~Two Cardiac Magnetic Resonance Imaging (CMRIs) A central venous line placement, A chest X-ray Electrocardiogram (ECG) Fluid administration Blood draw Pregnancy test"
2940618|NCT02967302|Experimental|Morphine Sulfate|Morphine 3 mg intraarticular once at baseline
2940619|NCT02967302|Active Comparator|Triamcinolone|Triamcinolone 40 mg intraarticular once at baseline
2940620|NCT02967302|Placebo Comparator|Placebo|NaCl 0,9% 5 ml intraarticular at baseline
2940621|NCT02967289|Experimental|Arm A|mFOLFIRINOX Folfox Protocol + Irinotecan
2940622|NCT02967289|Active Comparator|Arm B|mFOLFOX 6 Folfox Protocol
2940623|NCT02967276|Experimental|Metformin and HDdexamethasone|"Metformin XR is initially administered at a dose of 500mg / daily by oral administration for 7 days. Patients who have a good tolerance (lack of adverse events of grade 3 or 4) may be staggered metformin dose to 2500 mg / day.~Patients in turn receiving dexamethasone pulse prescription (HDdex). A dose of dexamethasona 40 mg / day taken in a daily for four days every 8 days from 1st to 2nd cycle every 35 days and 1x per week for 4 weeks every 28 days from the 3rd to 6th cycle. The dose will be administered at 4 mg tablets, which are to be swallowed whole by 30 minutes after a meal. Patients over age 75 used 20 mg / day."
2940624|NCT02967263||Hospital-acquired AKI|Adult patients with Hospital-acquired AKI
2940625|NCT02967250|Experimental|Ursodeoxycholic acid treatment|Each subject will receive UDCA intervention for six weeks.
2940665|NCT02966951|Experimental|adipose tissue mesenchymal stem cell|Intra-articular adipose tissue derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of ATMSC in each dose
2940626|NCT02967237|Experimental|Insulin glargine (U300)|Type 2 diabetes mellitus patients uncontrolled with their current basal insulin therapy switched according to the physician decision, to insulin glargine (U300) administered subcutaneously and once daily using a pre-filled pen
2940627|NCT02967224|Experimental|Toujeo|Toujeo will be administered once daily in addition to noninsulin antidiabetic agents
2940628|NCT02967224|Active Comparator|"Standard of care commercially available basal insulin"|Lantus, Humulin Neutral Protamine Hagedorn (NPH), Levemir or Tresiba or other basal insulin, including biosimilar insulin will be administered once or twice daily according to label in addition to noninsulin antidiabetic agents
2940629|NCT02967211|Experimental|Toujeo|Toujeo will be administered once daily in addition to non-insulin antidiabetic agents
2940630|NCT02967211|Active Comparator|"Standard of care commercially available basal insulin"|Lantus, Humulin Neutral Protamine Hagedorn (NPH), Levemir, and Tresiba or other basal insulin, including biosimilar insulin will be administered once or twice daily according to label in addition to non-insulin antidiabetic agents
2940631|NCT02967198|Experimental|CT/US fusion|patients undergo routine conventional feasibility planning ultrasound, and clinical decision of percutaneous liver biopsy or RFA feasibility is made based on conventional planning ultrasound. Then additional planning ultrasound using CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging.
2940632|NCT02967185|Experimental|Brief Behavioral Therapy for Insomnia|Treatment will consist of 4 weekly, 1 hour sessions and will be conducted by a trained graduate assistant on an individual basis.
2940633|NCT02967185|No Intervention|Waitlist Control|Participants in this group will receive no intervention, but will complete the same set of assessments as those in the Experimental Group. They will be given the option of receiving the behavioral treatment program at no charge.
2940634|NCT02967172|Experimental|Peri-incisional injection|"A single, 25 cc multimodal analgesic cocktail will be injected following completion of ankle fracture fixation/instrumentation while the patient remains under general anesthesia and prior to skin closure. The injection will be administered as such:~20 mL injected into the peri-incisional soft tissues in a circumferential fashion~5mL injected into the ankle joint This cocktail includes 200 mg of 0.8% ropivacaine, 0.6 mg of epinephrine, 5 mg of morphine sulfate, and sodium chloride solution. All infiltrations will be completed with a blunt trochar to minimize the risk of intravascular injection.~Interventions:~Drug: Ropivacaine Drug: Epinephrine Drug: Morphine Drug: 0.9% sodium chloride solution Following surgery, patients in the treatment and non-treatment groups will both be provided with the same intravenous (patient-controlled analgesia) and oral pain medications scheduled per needed."
2940635|NCT02967172|No Intervention|Control|Ankle fracture fixation/instrumentation will be completed per the standard of care. No peri-incisional injection will be completed.
2940636|NCT02967159|Experimental|Treatment A (Abediterol )|Treatment A: The subjects will receive Abediterol 2.5 μg via DPI
2940637|NCT02967159|Experimental|Treatment B (AZD7594)|Treatment B: The subjects will receive AZD7594 440 μg via DPI
2940638|NCT02967159|Experimental|Treatment C (AZD7594/abediterol )|Treatment C: The subjects will receive AZD7594/ abediterol 440 μg/2.5 μg FDC via DPI
2940639|NCT02967159|Experimental|Treatment D (AZD7594 and abediterol)|Treatment D: The subjects will receive AZD7594 440 μg and abediterol 2.5 μg free combination administered via 2 separate DPIs
2940640|NCT02967146|Experimental|Mediclore|
2940641|NCT02967146|No Intervention|Not done|Standard treatment for surgery
2940642|NCT02967133|Active Comparator|Arm A|Nivolumab q 14 days until disease progression/toxicity
2940643|NCT02967133|Active Comparator|Arm B|"Nivolumab every 21 days until disease progression~Nab-paclitaxel every 21 days"
2940644|NCT02967120||p16 hydroxymethylation status|patients with p16 hydroxymethylation
2940645|NCT02967107|Active Comparator|Cold snare polypectomy|Cold snare resection, if necessary, multi-piece to resect sessile serrated adenoma (SSA) 8-20mm
2940646|NCT02967107|Active Comparator|Endoscopic mucosal resection|Endoscopic mucosal resection (EMR), if necessary, multi-piece to resect sessile serrated adenoma (SSA) 8-20mm
2940647|NCT02967094|Experimental|A - mucolytic solution|Mucolytic solution consisting of 100 ml of water, 100 mg of simethicon and 400 mg of N-acetylcystein administered 30 minutes prior to upper endoscopy.
2940648|NCT02967094|No Intervention|B - no intervention|Upper endoscopy without neither mucolytic solution nor water prior to upper endoscopy.
2940649|NCT02967094|Placebo Comparator|C - water|100 ml of water given 30 minutes prior to upper endoscopy.
2940650|NCT02967081||Pulp necrosis|
2940651|NCT02967081||Pulpitis (painless)|In this group the dentinal fluid will be sampled/collected twice: Firstly after the removal of the primary caries lesion. Subsequently the cavity will be temporized. Secondly, after removal of the temporary filling material (before final restoration).
2940652|NCT02967081||Irreversible pulpitis|
2940653|NCT02967081||Normal pulp|
2940654|NCT02967042|Other|18F-PET-TT|
2940655|NCT02967029|Active Comparator|b group|b group controlled hypotension with esmolol hydrochloride
2940656|NCT02967029|Active Comparator|r group|r group controlled hypotension with remifentanil hydrochloride
2940657|NCT02967016|Experimental|normal spontaneous vaginal delivery|Both groups will be asked to wear a fitness tracker (Actigraph GT3X+).
2940658|NCT02967016|Experimental|Cesarean Delivery|Both groups will be asked to wear a fitness tracker (Actigraph GT3X+).
2940659|NCT02966990|Other|hand orthosis patients|Patients using hand orthosis for better hand function
2940660|NCT02966977|Active Comparator|Conventional microbiological diagnostics|Conventional microbiological identification by culture plate (overnight cultures with subsequent bacterial/fungal identification).
2940661|NCT02966977|Experimental|Conventional plus mass spectrometry|Conventional microbiological identification by culture plate plus Direct mass spectrometry identification from urine sample. This additional diagnostic procedure is supplied additionally to conventional diagnostics.
2940662|NCT02966964|Experimental|Tenofovir 300mg qd + DWPUR001 500mg bid|Tenofovir 300mg qd + DWPUR001 500mg bid for up to 12 months
2940663|NCT02966964|Experimental|Tenofovir 300mg qd + DWPUR001 300mg bid|Tenofovir 300mg qd + DWPUR001 300mg bid for up to 12 months
2940664|NCT02966964|Placebo Comparator|Tenofovir 300mg qd + DWPUR001 Placebo bid|Tenofovir 300mg qd + DWPUR001 Placebo bid for up to 12 months
2940666|NCT02966938||Nut allergic patients|Allergic patient and their family with allergy to peanut or other tree nuts that are in elimination diet.
2940667|NCT02966925|Experimental|Treatment with Cellular Matrix|Patients will be treated with a combination of PRP/HA prepared with Cellular Matrix BCT-HA Kit
2940668|NCT02966912|Experimental|Magnesium|20 participants will be treated with 400 mg of Magnesium Oxide twice daily
2940669|NCT02966912|Active Comparator|Comparator|20 participants will receive no treatment
2940670|NCT02966899|Experimental|Omega-3 fatty acids|30 patients with pulmonary hypertension who are identified as having elevated myocardial triglyceride content by cardiac MRI will receive 4 grams/day of omega-3 fatty acids for six months.
2940671|NCT02966886|Active Comparator|Eccentric Reaming versus Augmented Component|"All patients will undergo treatment with shoulder arthroplasty. Patients 65 years of age or younger will be randomly assigned to one of two standard of care treatment groups:~Total Shoulder Arthroplasty with Eccentric Glenoid Reaming: Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within < 15 degrees of neutral glenoid version.~Total Shoulder Arthroplasty with Augmented Glenoid Component Implantation: Patients will undergo standard glenoid preparation and implantation of a posteriorly augmented glenoid component. The degree of posterior augment will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version."
2940672|NCT02966886|Active Comparator|Augmented Component versus Reverse Arthroplasty|"All patients will undergo treatment with shoulder arthroplasty. Patients older than age 65 will be randomly assigned to one of two standard of care treatment groups:~Total Shoulder Arthroplasty with Augmented Glenoid Component Implantation:~Patients will undergo standard glenoid preparation and implantation of a posteriorly augmented glenoid component. The degree of posterior augment will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.~Reverse Shoulder Arthroplasty:~Patient will undergo a reverse shoulder arthroplasty as per standard technique . Glenoid version will be restored to neutral with either anterior reaming and/or use of an eccentric graft."
2940673|NCT02966873|Experimental|N-Acetylcysteine (NAC) Treatment Group|"Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily, as well as weekly cognitive-behavioral therapy, medication management, and Adverse Event (AE) monitoring.~Participant will receive one week of study medication at a time from the study physician or the study coordinator. The study medication provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening."
2940674|NCT02966873|Placebo Comparator|Placebo Group|"Participant will receive 12 weeks of inactive placebo comparator daily, as well as weekly cognitive-behavioral therapy, medication management, and Adverse Event (AE) monitoring.~Participant will receive one week of study medication (placebo) at a time from the study physician or the study coordinator. The study medication (placebo) provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening."
2940675|NCT02966860|Experimental|Oxycodone and acetaminophen (OC/APAP)|Single 15 mL dose of oral solution of OC/APAP (total dose 15 mg oxycodone/975 mg acetaminophen)
2940676|NCT02966847|Experimental|CBCT Acquisition|The anesthesia and surgery will take place in the usual way. The intervention consists in the CBCT acquisition after the initiation of single-lung ventilation, after the introduction of trocars.
2940677|NCT02966834|Placebo Comparator|Placebo|Subjects will receive matching placebo
2940678|NCT02966834|Experimental|GSK2330672 20 mg once daily|Subjects will receive GSK2330672 and matching placebo to maintain blind
2940679|NCT02966834|Experimental|GSK2330672 90 mg once daily|Subjects will receive GSK2330672 and matching placebo to maintain blind
2940680|NCT02966834|Experimental|GSK2330672 180 mg once daily|Subjects will receive GSK2330672 and matching placebo to maintain blind
2940681|NCT02966834|Experimental|GSK2330672 90 mg twice daily|Subjects will receive GSK2330672 and matching placebo to maintain blind
2940682|NCT02966821|Experimental|Sulfatinib|Sulfatinib 300mg once-daily
2940683|NCT02966808||Clinical measures|multiple sclerosis patients in treatment with fampridine
2940684|NCT02966795|Experimental|Arm B: GLE/PIB for 12 weeks|Arm B: HCV GT 5 or 6 participants with compensated cirrhosis treated with GLE/PIB 300 mg/120 mg QD for 12 weeks
2940685|NCT02966795|Experimental|ARM A: GLE/PIB for 8 weeks|Arm A: Hepatitis C virus genotype 5 or 6 (HCV GT 5 or 6) non-cirrhotic participants treated with Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks
2940686|NCT02966782|Experimental|Venetoclax monotherapy (Cohort 1)|
2940687|NCT02966782|Experimental|Venetoclax + azacitidine (Cohort 2)|
2940688|NCT02966782|Experimental|Safety Expansion (Cohort 3)|
2940689|NCT02966769||Chemoradiation Group|Analyze overall survival in the group of patients treatment by Concurrent Radiotherapy (>/= 60 Gy) plus Platinum-based Chemotherapy
2940690|NCT02966769||Neoadjuvant treatment plus Surgery Group|Analyze overall survival in the group of patients treatment by Neoadjuvant Platinum-based Chemotherapy or Chemoradiation (Platinum-based plus >/= 45Gy) followed by Surgery
2940691|NCT02966756|Experimental|Venetoclax|Venetoclax will be administered orally starting with 20 mg once daily (QD); dose escalation will proceed weekly in the following progression: 50 mg QD, 100 mg QD, 200 mg QD, 400 mg QD, as tolerated.
2940692|NCT02966743|Experimental|midazolam|administration of midazolam during spinal anesthesia for target bispectral index 75-80
2940693|NCT02966743|Active Comparator|dexmedetomidine|administration of dexmedeomidine during spinal anesthesia for target bispectral index 75-80
2940694|NCT02966730|Experimental|Follicular Lymphoma|Participants will be receive Ibrutinib as an oral capsule preparation once daily for a period of 2 years. The dose will be 560mg daily. Toxicities will be recorded and graded. Response to treatment will be determined by FDG-PET imaging every 6 months, or as clinically indicated, in conjunction with clinical assessment by a physician, including physical examination, every 4 weeks from day 1 (baseline) for the first 3 months and then every 3 months until the end of treatment at 2 years.
2940715|NCT02966613|Experimental|PSCG-D|TKA performed using fully disposable Patient specific cutting guides (PSCG-D)
2940811|NCT02965950|Experimental|TP53 wt, LABC|Patients with locally advanced breast cancer, TP53 wt disease. Dose-dense cyclophosphamide
2940695|NCT02966717|Active Comparator|parallel control of conventional therapy|Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.
2940696|NCT02966717|Experimental|experimental group|Intervention of Rituximab combined with mesenchymal stem cells group: as follows, Rituximab, 100mg/time every one week, the infusion should be a total of 4 times; and then after at least 4 days interval after the first and the third infusion of the Rituximab , the dosage of mesenchymal stem cells tends to be 10^6/kg/time every 2 weeks, while the infusion should be a total of 2 times.
2940697|NCT02966704|Experimental|meal 1|mixed meal with high level of intrinsically labeled milk protein
2940698|NCT02966704|Experimental|meal 2|mixed meal with low level of intrinsically labeled milk protein
2940699|NCT02966691|Active Comparator|Patients 'sick'|"The patients of this arm have a clinical signs of bladder cancer with :~a positive result of bladder endoscopy~or an negative endoscopy and a positive result of the conventional cytology~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice .This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized"
2940700|NCT02966691|Active Comparator|Patients 'healthy'|"The patients of this arm have no suspicion of bladder cancer with negative results of their bladder endoscopy and conventional cytology.~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice . This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized."
2940701|NCT02966691|Active Comparator|Patients 'monitoring'|"The patients of this arm have a history of bladder cancer, but the results of their follow up examinations (cytologic and endoscopic) are negative (no tumor).~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice . This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized."
2940702|NCT02966678||Glaucoma|Patients with a diagnosis of glaucoma will undergo color vision test
2940703|NCT02966665|Experimental|Healthy Young Volunteers (18-30 years)|Healthy volunteers between the ages of 18 and 30 years with no diseases or conditions that would affect their participation in the study, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
2940704|NCT02966665|Experimental|Healthy Older Controls (over 65 years)|Healthy volunteers 65 years of age or older with no diseases or conditions that would affect their participation in the study, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
2940705|NCT02966665|Experimental|Coronary Angiography patients|Patients undergoing routine coronary angiography, but who do not require intracoronary procedures or have history of myocardial disease, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
2940706|NCT02966665|Experimental|Chronic Obstructive Pulmonary Disease patients|Patients diagnosed with mild to moderate COPD, but not severe COPD patients, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
2940707|NCT02966665|Experimental|Pulmonary Arterial Hypertension patients|Patients with idiopathic or heritable Group 1 pulmonary arterial hypertension, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
2940708|NCT02966665|Experimental|Heart Failure patients|Patients with Class I - III New York Heart Association symptoms of Heart Failure who are not anemic or taking medications that affect blood clotting, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
2940709|NCT02966665|Experimental|Hypertension patients|Patients with chronic high blood pressure, but with less than severe hypertension, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
2940710|NCT02966652|Active Comparator|Testosterone undecanoate|Cohort 1: single dose of 120 mg (3 x 40 mg) DITEST followed by a single dose of 80 mg (2 x 40 mg) testosterone undecanoate or a single dose of 80 mg (2 x 40 mg) testosterone undecanoate followed by single dose of 120 mg (3 x 40 mg) DITEST. The two treatments are separated by a minimum of a 7-day washout period, with both treatments given in the fed state.
2940711|NCT02966652|Experimental|DITEST|Cohort 2: single dose of 200 mg (5 x 40 mg) DITEST (fed) followed by a single dose of 200 mg DITEST (fasted) or a single dose of 200 mg DITEST (fasted) followed by single dose of 200 mg (5 x 40 mg) DITEST (fed). The two treatments are separated by a minimum of a 7-day washout period.
2940712|NCT02966639||LDS Patients|All patients with a diagnosis of single-level Lumbar Degenerative Spondylolisthesis who present to the DHMC Spine Center.
2940713|NCT02966613|Active Comparator|CI|TKA using conventional instrumentation (CI)
2940714|NCT02966613|Experimental|PSCG|TKA performed using Patient specific cutting guides (PSCG)
2940716|NCT02966600|Experimental|Progressive resistance exercise (PRE)|Progressive resistance exercise (PRE) in akinetic-rigid Parkinson's disease patients. Intervention included sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.
2940717|NCT02966600|No Intervention|Physical Activity|The control group followed its usual weekly physical activity routine
2940718|NCT02966587|Experimental|Treatment (durvalumab)|Patients receive durvalumab IV over 60 minutes on day 1. Courses repeat every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
2940719|NCT02966574|Experimental|metastatic breast cancer|
2940720|NCT02966561|Experimental|Pedometer-based activity promotion|In the context of pulmonary rehabilitation (standard care), the intervention group (IG) additionally receives a pedometer-based physical activity behaviour change intervention (BCI).
2940721|NCT02966561|Active Comparator|Short patient education and exercise|In the context of pulmonary rehabilitation (standard care), the control group (CG) additionally receives a short patient education in combination with related exercise.
2940722|NCT02966548|Experimental|Monotherapy|Relatlimab (BMS-986016) administered every 2 weeks as a single agent intravenous formulation
2940723|NCT02966548|Experimental|Combination Therapy|Relatlimab (BMS-986016) will be administered in combination with Nivolumab every 2 weeks or every 4 weeks as an intravenous formulation
2940724|NCT02966535|Experimental|1:2, 1:1 group|Inspiratory to expiratory time ratio (I:E ratio) of 1:2 during the first one hour of laparoscopy and then switched to I:E ratio of 1:1 during the rest time of laparoscopy.
2940725|NCT02966535|Active Comparator|1:1, 1:2 group|Inspiratory to expiratory time ratio (I:E ratio) of 1:1 during the first one hour of laparoscopy and then switched to I:E ratio of 1:2 during the rest time of laparoscopy.
2940726|NCT02966522|Experimental|Thalidomide|Patient with cardiac amyloidosis receive thalilomide with dexamethasone
2940727|NCT02966509|Experimental|A: Intervention Arm|All participants randomized to Arm A will receive the EPAC intervention as well as usual oncologic care.
2940728|NCT02966509|No Intervention|B: Control Group Arm|All participants randomized to Arm B will receive usual oncologic care.
2940729|NCT02966496|Experimental|the test group|The patients aged 50-80 years will be randomly assigned to implantation of Acri.LISA366D multifocal aspheric IOLs in the test group.
2940730|NCT02966496|Experimental|the control group|The patients aged 50-80 years will be randomly assigned to implantation of TecnisZ9001 multifocal aspheric IOLs in the control group.
2940731|NCT02966483|Experimental|Transanal Total Mesorectal Excision|The rectum is mobilized and resected transanally (from bottom to up) according to TME principles, via transanal platform (either rigid or flexible platform).An ideal TaTME is defined as the extraperitoneal portion of the rectum being mobilized from below.
2940732|NCT02966483|Active Comparator|Laparoscopic Total Mesorectal Excision|The traditional laparoscopic TME (LpTME) was performed via standard laparoscopic techniques, including multiple trocars and conventional laparoscopic instruments.
2940733|NCT02966470||General surgery patient|General surgery patient admitted to the Section of General Surgery, Trauma, and Surgical Critical Care who are over 60.
2940734|NCT02966457|Experimental|Selective intestinal decolonization|Drug: Decolonization with Colistimethate sodium (2 mln I.U. 4x/day PO) for 14 days
2940735|NCT02966457|No Intervention|"Wait and watch strategy"|Group without decolonization interventions
2940736|NCT02966444|Experimental|MUFA-rich HF Meal|High-fat meal rich in monounsaturated fatty acids
2940737|NCT02966444|Experimental|PUFA-rich HF Meal|High-fat meal rich in polyunsaturated fatty acids
2940738|NCT02966444|Experimental|SFA-rich HF Meal|High-fat meal rich in saturated fatty acids
2940739|NCT02966431|Experimental|Counseling|Receive counseling for 8-wks
2940740|NCT02966431|Placebo Comparator|Control|Does not receive counseling for 8-wks
2940741|NCT02966418|Active Comparator|Mild hypoxia preconditioning|Patients will be treated with mild hypoxia (Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%) before surgery.
2940742|NCT02966418|Sham Comparator|Sham preconditioning|Patients will be treated with sham preconditioning (oxygen concentration: 21％) before surgery.
2940743|NCT02966405||Healthy pregnant women|A descriptive analysis involving 300 healthy pregnant women according NACB to the establish of trimester-specific reference ranges for thyroid tests in pregnant women.
2940744|NCT02966405||Normal pregnant population|According to the selection criteria, 700 cases were selected as the normal pregnant population to establish a self-sequential longitudinal reference range. The aim of this study to monitor the change of thyroid function and antibody during the course of pregnancy in those who suffer from various thyroid disorders and normal control.
2940745|NCT02966392|Experimental|Continuous Pressure Control (CPC)|Continuous endotracheal cuff pressure control using Tracoe cuff pressure controller during their intubated stay on ICU.
2940746|NCT02966392|No Intervention|Standard Care|Intermittent cuff pressure control through manual measurement performed 3 times per day (standard care)
2940747|NCT02966379|Experimental|Cochlear implantation|Cochlear implantation with EVO electrode lead. This electrode lead has been specially designed for atraumatic surgery, in order to preserve the residual hearing of the patients included in the study. All patients are implanted with the same electrode lead.
2940748|NCT02966366|Experimental|Cochlear implantation|Evaluation of tinnitus before and after cochlear implantation
2940749|NCT02966353|Experimental|Ruxolitinib|10 mg BID (2 tablets of 5mg) will be self-administered as starting dose for all patients. This dose will be maintained for the first 12 weeks and titrated up thereafter unless they have met criteria for dose hold or dose reduction. Dose to be increased or decreased per standardized dosing paradigm and not to exceed 25 mg bid.
2940750|NCT02966340|Experimental|Prazosin 1st visit, Placebo 2nd visit|All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
2940751|NCT02966340|Experimental|Placebo 1st visit, Prazosin 2nd visit|All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
2940752|NCT02966327|Experimental|Compression Stockings-Exercise|At T2 (4-6 weeks post-operatively), 25 study participants will be randomized to the intervention group and will be prescribed compression stockings and individualized exercise. They will also receive standard education on lymphedema risk reduction.
2940753|NCT02966327|Other|Control Group|At T2 (4-6 weeks post-operatively), 25 study participants will be randomized to the control group and will receive standard education on lymphedema risk reduction.
2940754|NCT02966314|Placebo Comparator|Placebo|Placebo contains sodium chloride 0.9% and will be provided by Novartis. Placebo will be administered as a subcutaneous injection.
2940755|NCT02966314|Active Comparator|Omalizumab|Omalizumab is a sterile, white, preservative-free, lyophilized powder, contained in a single-use vial that will be reconstituted with sterile water for injection (SWFI), USP, and administered as a subcutaneous injection. Each omalizumab vial contains 202.5 mg of omalizumab, 145.5 mg sucrose, 2.8 mg L-histidine hydrochloride monohydrate, 1.8 mg L-histidine, and 0.5 mg polysorbate 20. Each vial is designed to deliver 150 mg of omalizumab in 1.2 mL after reconstitution with 1.4 mL SWFI, USP.
2940756|NCT02966301|Experimental|interventional|Single arm : Arsenic trioxide Injectable Solution
2940757|NCT02966288|Experimental|Toradol injection|3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
2940758|NCT02966288|Active Comparator|Oral NSAID|800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
2940759|NCT02966275|Experimental|Glucagon-only bionic pancreas - glucagon|"Subjects will wear the bionic pancreas that consists of a continuous glucose monitor linked to a smartphone running a hypoglycemia prevention algorithm that doses glucagon from an insulin pump through a subcutaneous infusion set.~Subjects will continue to manage any hypoglycemia that occurs according to the current recommendations of their care provider."
2940760|NCT02966275|Placebo Comparator|Glucagon-only bionic pancreas - placebo|"Subjects will wear the bionic pancreas that consists of a continuous glucose monitor linked to a smartphone running a hypoglycemia prevention algorithm that doses placebo from an insulin pump through a subcutaneous infusion set.~Subjects will continue to manage any hypoglycemia that occurs according to the current recommendations of their care provider."
2940761|NCT02966262||Optical Coherence Tomography registry group|Patients who had undergone optical coherence tomography within coronary intervention
2940762|NCT02966249|Other|Levobupivacaine intrathecally|3 ml Levobupivacaine 0,5% (15mg) given intrathecally once for anesthesia in total knee arthroplasty
2940763|NCT02966249|Active Comparator|Dexmetomidine intrathecally|5 μgr Dexmetomidine given intrathecally once for anesthesia in total knee arthroplasty
2940764|NCT02966249|Active Comparator|Dexmetomidine intravenously|Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously starting 10 min before spinal anesthesia in total knee arthroplasty
2940765|NCT02966249|Placebo Comparator|Normal Saline intrathecally|0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty
2940766|NCT02966249|Other|Normal Saline added intrathecally|Normal Saline added intrathecally up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
2940767|NCT02966249|Other|Ringer's Lactate solution intravenously|Continuous infusion of Ringer's Lactate solution given intravenously for total knee arthroplasty will start 10 minutes before spinal anesthesia to the end of the operation
2940768|NCT02966236|Experimental|Tranexamic Acid Group|Tranexamic acid 1g IV during anesthesiology induction, single dose
2940769|NCT02966236|Placebo Comparator|Placebo group|normal saline 1g IV during anesthesiology induction, single dose
2940770|NCT02966223|Experimental|MRI and HIDA scan|
2940771|NCT02966197|Experimental|Balloon group|Prophylactic Internal Iliac Artery Balloon Catheterization
2940772|NCT02966197|No Intervention|Control group|no intervention
2940773|NCT02966184|No Intervention|Benzalkonium chloride (BAC) Albuterol|This arm includes the current standard of care which patients receive at the institution. No interventions will be made within this group of patients.
2940774|NCT02966184|Experimental|Preservative Free Albuterol|This arm includes the preservative free albuterol which is being investigated. Treatment for this arm will follow current standards of care, with the only difference being the albuterol formulation.
2940775|NCT02966171|Experimental|HMPL-453|Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, untill disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 25, 50, 100, 200, 300, 400, and 500 mg/day.
2940776|NCT02966158|Experimental|AIT Group|"The AIT Group will perform usual care CR exercise for the 1st month of the program. This includes performing aerobic exercise 5 times/week and resistance training twice/week (offered 2 weeks after program start). In month two, this group will begin to perform AIT three days/week, along with two MICE and two RT sessions.~The AIT exercise protocol includes the following components:~Warm Up Period: 5-10 minutes of walking performed at an intensity that will feel fairly light. Heart rate monitors and watches will be used to gauge their effort.~Intervals: Between two to four 4-minute intervals of walking/jogging performed at an intensity that is close to participants' maximal effort, based on the exercise tests that were performed at the beginning of the program. These hard intervals will be separated by 3-minutes of active recovery performed at a very light intensity.~Cool Down Period: 5 minutes of walking performed at a fairly light intensity."
2940777|NCT02966158|No Intervention|MICE Group|"This group will perform usual care CR for 6 months, which includes both resistance and aerobic exercise (MICE) training. Aerobic exercise is prescribed in the first exercise class and performed 5 times/week, the resistance training program is offered after 2 weeks in the program and performed 2 times/week. Participants will be asked to keep a record of the exercise that they do.~Resistance/Strength Training: Patients will be performing 1-2 sets of 5 to 10 resistance training exercises using a combination of hand-held dumbbells, elastic bands of varying thicknesses, as well as their own body weight for resistance.~Aerobic Training: Patients will have their aerobic exercise prescription set at an intensity and duration that will be comfortable for them, based on the tests conducted at the beginning of the program to ensure their safety."
2940778|NCT02966145||PSP & CBD|Observational study of participants with a diagnosis of Progressive Supranuclear Palsy or Corticobasal Degeneration (also called Corticobasal Syndrome or Cortical-basal Ganglionic Degeneration).
2940779|NCT02966145||o/vPSP|Observational study of participants with a diagnosis of an oligosymptomatic or variant Progressive Supranuclear Palsy syndrome.
2940780|NCT02966145||Normal Volunteers|Observational study of participants with no known diagnosis of a neurological or neurodegenerative condition, and no known history of memory complaints.
2940781|NCT02966132|Experimental|iMD|"Participants will receive interactive Mobile Doctor (iMD) intervention in English, Chinese, Korean or Vietnamese languages that delivers video education tailored to patient's responses on a computer tablet during the clinic visit to enhance patient-provider discussion of tobacco use. The iMD intervention implements the 5As (Ask, Advice, Assess, Assist, and Arrange) recommended by the Clinical Practice Guideline for treating tobacco dependence. A summary printout including provider recommendation options, brief summary of smoking status, quit intention and concerns are provided to patients to empower them to discuss tobacco use with their providers."
2940782|NCT02966132|Active Comparator|NPA|Participants will receive a video education providing nutrition and physical activity recommendations right before before seeing their providers. A printout summarizing topics presented in the education videos will be provided to the patient
2940783|NCT02966119|Experimental|Start antiplatelet drug(s)|If the patient is randomized in this arm, an antiplatelet agent (aspirin or clopidogrel or dypyridamole), chosen by the patient's physician before the randomisation, will be prescribed to the patient during the study period
2940784|NCT02966119|No Intervention|Avoid antiplatelet drug(s)|If the patient is randomized in this arm, antiplatelet drugs will not be prescribed to the patient during the entire study period
2940785|NCT02966106|Active Comparator|Right prefrontal low frequency rTMS.|Right prefrontal low frequency rTMS (1Hz). A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
2940786|NCT02966106|Placebo Comparator|Sham-rTMS|Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
2940787|NCT02966093|Experimental|Lenvatinib|In the randomization phase, participants will receive lenvatinib until disease progression. Participants who discontinue due to confirmed disease progression will enter Extension Phase. Participants who discontinue without confirmed disease progression will be followed for tumor assessment until confirmed disease progression or initiation of anticancer therapy, at which time the participants will enter Follow-up period of Extension Phase.
2940788|NCT02966093|Experimental|Placebo|In the randomization phase, participants will receive lenvatinib matched placebo until disease progression. Participants who discontinue due to confirmed disease progression will enter Extension Phase. Participants who discontinue without confirmed disease progression will be followed for tumor assessment until confirmed disease progression or initiation of anticancer therapy, at which time the participants will enter Follow-up period of Extension Phase.
2940789|NCT02966080|Other|Adjusted-dose heparin|Patients in this arm of the study will receive intravenous unfractionated heparin at a dose adjusted to achieve an activated clotting time of 180-200 seconds.
2940790|NCT02966080|Other|Fixed low-dose heparin|Patients in this arm of the study will receive intravenous unfractionated heparin at 500 units/hour without activated clotting time monitoring.
2940791|NCT02966067|Experimental|Microneedle Device|Local Dental Anaesthetic Solution Delivery System: Microneedle device with an array of 2x3 pyramidal wet-etch silicone microneedles of 280µm height to inject anaesthetic solution.
2940792|NCT02966067|Active Comparator|30-gauge Short Hypodermic Needle|Local Dental Anaesthetic Solution Delivery System: Standard thirty-gauge short hypodermic needle to inject anaesthetic solution.
2940793|NCT02966054|Experimental|Intervention|"Patients will be provided with a booklet from the UCSF Dept. of Physical Therapy and Rehabilitation Science: Moving Through Cancer: A Guide to Exercise for Cancer Survivors. The intervention group will be given a Fitbit® Flex to wear throughout the study and will receive daily text messages to support increased physical activity."
2940794|NCT02966054|No Intervention|Control|"Patients in the control arm will be provided with a booklet at baseline from the UCSF Dept. of Physical Therapy and Rehabilitation Science: Moving Through Cancer: A Guide to Exercise for Cancer Survivors."
2940795|NCT02966041|Experimental|Ondansetron|Ondansetron 4mg IV at time of discontinuation of Propofol Infusion
2940796|NCT02966041|Placebo Comparator|Saline|2 mL IV Normal Saline at time of discontinuation of Propofol Infusion
2940797|NCT02966028|Experimental|SNF472 300 mg|Dose 1 arm (300 mg): 1 vial of physiological saline and 1 vial of active (10 mL SNF472 at 30 mg/mL)
2940798|NCT02966028|Experimental|SNF 472 600 mg|Dose 2 arm (600 mg): 2 vials of active (10 mL SNF472 at 30 mg/mL)
2940799|NCT02966028|Placebo Comparator|Matching Placebo|Placebo arm: 2 vials of physiological saline
2940800|NCT02966015|Experimental|Testing the new Coloplast Test catheter|The subjects used the new Coloplast Test catheter for 1 week
2940801|NCT02966002|Experimental|Intervention: aspirin|650 mg. Twice a day for 8 weeks
2940802|NCT02965989|Experimental|Online training of a nursing technique|Participants receives an individual online training of extraction of blood culture for 3 months (This platform aims to improve knowledge and skills), they are sent 3 homework (one per month) and are evaluated at the end of each.
2940803|NCT02965989|No Intervention|not receive online training|Participants don´t receives an individual online training of extraction of blood culture.Do their work as usual.
2940804|NCT02965976|Experimental|Arm I (botulinum toxin type A, esophagectomy)|Patients receive botulinum toxin type A injection IM while undergoing standard minimally invasive esophagectomy.
2940805|NCT02965976|Active Comparator|Arm II (esophagectomy)|Patients undergo standard minimally invasive esophagectomy.
2940806|NCT02965963|Experimental|Dopamine|Dependent variables measured with intravenous low dose dopamine infusion at rest, 60%, and 85% of VO2max
2940807|NCT02965963|Experimental|Metoclopramide|Dependent variables measured with oral metoclopramide ingestion at rest, 60%, and 85% of VO2max
2940808|NCT02965963|Experimental|Placebos|Dependent variables measured with orally ingested placebo pill and intravenous saline at rest, 60%, and 85% of VO2max
2940809|NCT02965950|Experimental|TP53 mutated, LABC|Patients with locally advanced breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide
2940810|NCT02965950|Experimental|TP53 mutated, MBC|Patients with metastatic breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide
2940812|NCT02965950|Experimental|TP53 wt, MBC|Patients with metastatic breast cancer, TP53 wt disease. Dose-dense cyclophosphamide
2940813|NCT02965937|Experimental|Story-Centred Care Intervention Program|A theory-guided approach that emphasises a health-promoting potential of nurse-person dialogue about a health challenge.Participants randomised to the IG will be made to participate in a 4-week long story-centred care intervention program conducted by a trained researcher.
2940814|NCT02965937|Active Comparator|Health consultation control condition|Participants randomised to the control group will receive a health consultation from a trained researcher once a week for 4 weeks. The health consultation will be tailored to the participants' needs. Based on a previous study, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
2940815|NCT02965924|Experimental|Phenylephrine|Subjects will receive topical phenylephrine 2.5% eye drop instilled in one eye after all baseline measurements.
2940816|NCT02965911|Active Comparator|UDCA Standard treatment|All subjects will reiceive UDCA at a dose of 13-15mg/kg/d by oral for 12 months, and UDCA will be maintained after 12 months.
2940817|NCT02965911|Experimental|Fenofibrate Combined with UDCA Treatment|All subjects will be treated with UDCA,13-15mg/kg/d, and Fenofibrate, 200mg/d by oral for 12 month,
2940818|NCT02965898|Active Comparator|Vitamin D 100ug|The highest safest dose. Expected to lower risk of chronic pancreatitis after acute pancreatitis.
2940819|NCT02965898|Placebo Comparator|Vitamin D 10ug|Placebo dose. Minimal recommended dose
2940820|NCT02965885|Experimental|TAS-116|
2940821|NCT02965872||Healthy individuals|
2940822|NCT02965859|Experimental|Metacavir Enteric-coated Capsule 80mg|"Metacavir Enteric-coated Capsules 80mg~Metacavir Enteric-coated Capsules Placebo 240mg~Adefovir Dipivoxil Capsule Placebo 10mg;"
2940823|NCT02965859|Active Comparator|Metacavir Enteric-coated Capsules 160mg|"Metacavir Enteric-coated Capsules 160mg~Metacavir Enteric-coated Capsules Placebo 160mg~Adefovir Dipivoxil Capsule Placebo 10mg;"
2940824|NCT02965859|Placebo Comparator|Metacavir Enteric-coated Capsules 320mg|"Metacavir Enteric-coated Capsules 320mg~Adefovir Dipivoxil Capsule Placebo 10mg"
2940825|NCT02965859|Active Comparator|Adefovir Dipivoxil Capsule|"Metacavir Enteric-coated Capsules Placebo 320mg~Adefovir Dipivoxil Capsule 10mg;"
2940826|NCT02965859|Placebo Comparator|Placebo|"Metacavir Enteric-coated Capsules Placebo 320mg~Adefovir Dipivoxil Capsule Placebo 10mg;"
2940827|NCT02965846|Experimental|AGN-195263|
2940828|NCT02965846|Placebo Comparator|Vehicle|
2940829|NCT02965833|Other|CCP, then HMPS|3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix contact lens solution in Period 1, followed by subject's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
2940830|NCT02965833|Other|HMPS, then CCP|Subject's habitual multi-purpose contact lens solution in Period 1, followed by 3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
2940831|NCT02965820|Other|OFPM, then HMPS|OPTI-FREE® PureMoist® multi-purpose contact lens solution in Period 1, followed by subject's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
2940832|NCT02965820|Other|HMPS, then OFPM|Subject's habitual multi-purpose contact lens solution in Period1, followed by OPTI-FREE® PureMoist® contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
2940833|NCT02965807|Experimental|Bronchial Thermoplasty|Moderate bronchial asthma patients under the Bronchial Thermoplasty.
2940834|NCT02965794||Usual care|quality of care will be measured in the participating hospitals, using a retrospective patient record analysis
2940835|NCT02965794||Care Pathway|Care pathways for colorectal cancer
2940836|NCT02965781|Active Comparator|One SADBE application|Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. Three weeks after topical sensitization dose patient will receive topical placebo applied to the patient's upper arm.
2940837|NCT02965781|Active Comparator|Two SADBE applications|Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. A 0.5% SADBE intensification dose will be applied to the patient's upper arm 3 weeks after sensitization dose.
2940838|NCT02965781|Placebo Comparator|Placebo application (DMSO only-No SADBE)|Patient will receive a topical placebo (vehicle-DMSO) dose applied to the patient's upper arm. A topical placebo (vehicle-DMSO) follow up dose will be applied to the patient's upper arm 3 weeks after the first placebo dose dose.
2940839|NCT02965768|Active Comparator|LDN arm|Naltrexone HCl 4.5mg (standard-dose) or 3.0mg (optional-dose) x24 weeks
2940840|NCT02965768|Other|Placebo/LDN arm|"Naltrexone HCl 4.5mg (standard-dose) or 3.0mg (optional-dose) Placebo~Individuals will be switched between drugs as per approved schedule during the 24 weeks."
2940841|NCT02965755|Other|Genetic profiling|All participants will undergo genetic profiling. Archival tissue will be requested to undergo routine review for possible treatment recommendations. Blood samples will be obtained to study research correlates (plasma tumor DNA, ptDNA) and tissue comparison.
2940842|NCT02965742|Experimental|The study population: first 25 patients|"The study population consists of patients referred to the Nuclear Medicine and Medical Biophysics Department of the Montpellier University Hospital for the performance of an osteodensitometric examination Intervention: Whole body exam using the Stratos Intervention: Whole body exam using the Hologic QDR 4500A Intervention: sub-regions exam using the Stratos"
2940843|NCT02965742|Experimental|The study population: last 25 patients|"The study population consists of sportsmen patients referred to the Nuclear Medicine and Medical Biophysics Department of the Montpellier University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body exam using the Stratos Intervention: Whole body exam using the Hologic QDR 4500A Intervention: sub-regions exam using the Stratos"
2940844|NCT02965729|Active Comparator|No Pedometer|Participants only participated in the family-based weight management intervention. Participants were not given a pedometer or step goals.
2941024|NCT02964598|Experimental|Sleep coaching + bright light|A combination of the two
2940845|NCT02965729|Active Comparator|Pedometer Only|In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. No step goals were provided.
2940846|NCT02965729|Active Comparator|Pedometer Plus Step Goals|In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. Participants were given individualized step goals to increase their activity by 500 steps each week (above baseline calculated as average daily steps/day during week 1).
2940847|NCT02965716|Experimental|Treatment (talimogene laherparepvec, pembrolizumab)|Patients receive talimogene laherparepvec IL and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 courses for talimogene laherparepvec and 36 courses for pembrolizumab in the absence of disease progression or unacceptable toxicity.
2940848|NCT02965703|Experimental|Arm I (aspirin)|Patients receive aspirin PO daily for 12 weeks.
2940849|NCT02965703|Experimental|Arm II (aspirin, placebo)|Patients receive aspirin PO daily at weeks 1-3 and 7-9 and placebo PO daily at weeks 4-6 and 10-12.
2940850|NCT02965703|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO daily for 12 weeks.
2940851|NCT02965690|Active Comparator|NexGen CR|Patients receive a NexGen Total Knee Replacement
2940852|NCT02965690|Active Comparator|GMK Sphere|Patients receive a GMK Total Knee Replacement
2940853|NCT02965677|Experimental|LEGFLOW OTW group|in this group subject will be treated by Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) and followed up
2940854|NCT02965677|Active Comparator|Admiral Xtreme|in this group subject will be treated by Peripheral Balloon Dilatation Catheter (Admiral Xtreme) and followed up
2940855|NCT02965664|Experimental|PresbiDrops (CSF-1)|Participants self-administer PresbiDrops (CSF-1) , with the supervision or help of the hospital staff - one drop in each eye on the day of treatment
2940856|NCT02965664|Placebo Comparator|Placebo|Participants self-administer Placebo, with the supervision or help of the hospital staff - one drop in each eye on the day of treatment
2940857|NCT02965651|Experimental|ECA System|Access to website and virtual patient advocate
2940858|NCT02965651|No Intervention|Standard of Care|Patient information sheets and meditation CD
2940859|NCT02965638|Active Comparator|Oxygen Group|The mothers will be asked to be on 4 liter of oxygen through nasal cannula up to 24 hours a day. The subjects will be blinded to their treatment.
2940860|NCT02965638|Placebo Comparator|Control Group|The mothers will be asked to be on air through nasal cannula up to 24 hours a day. The subjects will be blinded to their treatment.
2940861|NCT02965625||open elective cardiac surgery patients|Including coronary artery bypass graft and valve replacement surgery patients
2940862|NCT02965612|Experimental|ITS with Injex|For Each patient, at each monthly vaccination session and randomly in alternate mode, will be administered two vaccine doses of 0.25 ml each at 20 minutes from one another in the two arms, in an alternating manner via Injex and via subcutaneous.
2940863|NCT02965612|Active Comparator|SCIT: ITS via subcutaneous|For Each patient, at each monthly vaccination session and randomly in alternate mode, will be administered two vaccine doses of 0.25 ml each at 20 minutes from one another in the two arms, in an alternating manner via Injex and via subcutaneous.
2940864|NCT02965599|Experimental|GSK3117391|Subjects will receive GSK3117391 (Dose A) for 28 days.
2940865|NCT02965599|Placebo Comparator|Placebo|Subjects will receive placebo for 28 days.
2940866|NCT02965586|Active Comparator|intravenous dexmedetomidine group|intrathecal 2.5 ml of heavy bupivicaine 0.5% pulse 0.5 mg morphine and will receive intravenous dexmedetomidine infusion as prepared. Dexmedetomidine will be diluted to a volume of 50 ml (4 mg ml-1) and presented as coded syringes by an anesthesiologist. I.V. bolus of dexmedetomidine 1 ug kg-1 administered by a syringe pump over a 10-min period followed by an infusion of 0.4 ug kg-1h-1 dexmedetomidine during the surgery. Just after intrathecal injection, all drugs were infused intravenously. The infusions will be stopped at the end of surgery.
2940867|NCT02965586|Active Comparator|intrathecal dexmedetomidine group|intrathecal2.5 ml of heavy bupivicaine 0.5% pulse 0.5 mg morphine and dexmedetomidine (10µg) and will receive an equal volume of saline intravenously
2940868|NCT02965586|Placebo Comparator|control group|intrathecal 2.5 ml of heavy bupivicaine0.5% pulse 0.5 mg morphine and will receive an equal volume of saline intravenously
2940869|NCT02965573|Active Comparator|ARGX-113|During the Treatment period, eligible patients will be randomized at a 1:1 ratio to receive ARGX-113 or placebo
2940870|NCT02965573|Placebo Comparator|Placebo|During the Treatment period, eligible patients will be randomized at a 1:1 ratio to receive ARGX-113 or placebo
2940871|NCT02965560||HC,CHB,AD,ACLF|HC healthy controls; CHB chronic hepatitis B; AD acute decompensated cirrhosis; ACLF acute-on-chronic liver failure.
2940872|NCT02965547|Experimental|RIPC Group|RIPC was induced by 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation)
2940873|NCT02965534|Experimental|Night Spectacle Correction|Refraction for this glasses was obtained at low luminance.
2940874|NCT02965534|Active Comparator|Spectacle Correction for photopic light conditions|Refraction for this glasses was obtained at high luminance level.
2940875|NCT02965521|Experimental|Intervention|Participants will be given print material on diet for cancer survivors and access to a web-based dietary intervention with text messaging for 12 weeks.
2940876|NCT02965521|No Intervention|Control|Participants randomized to the control arm will receive print materials on diet for cancer survivors. After completion of their 12-week follow-up assessments, control participants will be given access to the web-based dietary intervention with text messaging for 12 weeks.
2940877|NCT02965508|Experimental|Home-based Primary Care Arm|Participants in this arm will be assigned a Mount Sinai Visiting Doctors primary care physician who makes a home based primary care visit.
2940878|NCT02965508|Active Comparator|Usual Care Arm|Participants in this arm will receive the usual care at office based visits
2940879|NCT02965495|Experimental|YYD302 2ml|YYD302 2ml
2940880|NCT02965495|Experimental|YYD302 3ml|YYD302 3ml
2940881|NCT02965495|Placebo Comparator|Placebo 3ml|Phosphate buffered saline 3ml
2940882|NCT02965482|Active Comparator|Aerogen Solo|Volumetric method of methacholine challenge testing performed using the Aerogen Solo nebulizer
2940883|NCT02965482|Active Comparator|Wright|Two-minute tidal breathing method of methacholine challenge testing performed using the Wright nebulizer
2940884|NCT02965469|No Intervention|Usual care|Participants randomized to this arm will have no change to their usual care
2940885|NCT02965469|Experimental|Cell phone app|"Participants randomized to this arm will use a stress reduction cell phone app called Breathe2Relax to assess feasibility and acceptability"
2940886|NCT02965456|Experimental|IDP-121 Lotion|Lotion
2940887|NCT02965456|Placebo Comparator|IDP-121 Vehicle Lotion|Vehicle
2940888|NCT02965443|Active Comparator|Verum|Dapagliflozin 10 mg + Saxagliptin 5 mg, each once daily, for 24 weeks
2940889|NCT02965443|Placebo Comparator|Placebo|Placebo 1 10 mg + Placebo 2 5 mg, each once daily, for 24 weeks
2940890|NCT02965430|Experimental|AL-SENSE diagnostic pantyliner|AL-SENSE diagnostic pantyliner of amniotic fluid compared with standard clinical diagnosis methods.
2940891|NCT02965417|Experimental|Sym004|All patients will receive a loading dose of Sym004, followed by weekly (q1w) infusions
2940892|NCT02965404|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~Intervention: investigational live attenuated varicella vaccine."
2940893|NCT02965404|Active Comparator|Positive Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;~Intervention: control live attenuated varicella vaccine."
2940894|NCT02965404|Sham Comparator|Negative Control Group|"Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0;~Intervention: diluent of lyophilized vaccine."
2940895|NCT02965378|Experimental|Arm I (AZD4547)|Patients receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2940896|NCT02965378|Experimental|Arm II (docetaxel - closed to accrual 12/18/2015)|Patients receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, patients may be eligible to re-register to Arm III.
2940897|NCT02965378|Experimental|Arm III (AZD4547 re-registration)|Patients in Arm II eligible for re-registration receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2940898|NCT02965365||TTN positive group|The group which subsequently diagnosed as TTN
2940899|NCT02965365||TTN negative group|The group which is not diagnosed as TTN
2940900|NCT02965352|Experimental|Hand strength|Volunteers without motor abnormalities. The tests were performed in a single session lasting 30 minutes, when volunteers used the door handle device, the linear switch device, and the door key device, in order to quantify the hand strength.
2940901|NCT02965326|Other|Cystic fibrosis, treated|Cystic fibrosis patients treated either by Ivacaftor or by the association Ivacaftor-Lumacaftor
2940902|NCT02965326|Other|Cystic fibrosis, non treated|Cystic fibrosis patients, non treated by a CFTR modulator
2940903|NCT02965326|Other|Non-Cystic fibrosis|Patients in whom cystic fibrosis diagnosis has been suspected, but excluded by physiological and genetic investigations
2940904|NCT02965313|Active Comparator|SSLS Procedure|
2940905|NCT02965313|Active Comparator|BSSVF-M Procedure|
2940906|NCT02965300||Primary lung cancer|patients newly diagnosed with lung cancer by tissue biopsy and did not receive any treatment aiming at the tumor, including chemotherapy and radiotherapy.
2940907|NCT02965300||Benign lung lesion|Patients diagnosed with pulmonary benign diseases.
2940908|NCT02965300||Healthy control|Patients without any pulmonary abnormal symptoms or diseases
2940909|NCT02965287||19-21 weeks' gestation|"The test validation will be performed on the 1943 serum samples of pregnant women at 19-21 weeks' gestation recruited in New Zealand for the SCOPE Study.~All the samples will be analyzed to extract and purify the whole metabolome. Metabolites will be characterized through mass spectrometric techniques. These data will be interpreted by means of a bioinformatic algorithm specifically designed for this purpose."
2940910|NCT02965287||14-16 weeks' gestation|Five hundred subjects at 14-16 weeks gestation were randomly selected from the whole cohort of patients. The serum samples collected at 14-16 weeks gestation will be used to test the diagnostic performance at this earlier gestational phase.
2940911|NCT02965274|Experimental|Test|Torrent's Fluoxetine Tablets 20 mg
2940912|NCT02965274|Active Comparator|Reference|Warner Chilcott LLC, USA
2940913|NCT02965261|Experimental|Test|Torrent's Fluoxetine Tablets 20 mg
2940914|NCT02965261|Active Comparator|Reference|Warner Chilcott LLC's Sarafem® Tablet 20 mg
2940915|NCT02965248|Active Comparator|Arm A|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months.
2940916|NCT02965248|Experimental|Arm B|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months. Patients also undergo HIPEC with raltitrexed (3mg/m2) intraperitoneally for 60 minutes during surgery or within 10 days after the operation.
2940917|NCT02965248|Experimental|Arm C|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months. Patients also undergo HIPEC comprising oxaliplatin (130mg/m2) intraperitoneally during surgery and hyperthermia for 30 minutes, following leucovorin calcium (20mg/m2 intravenously) and 5-FU (400 mg/m2 intravenously)
2940918|NCT02965235||non-POCD|Patients who don't develop POCD after surgery.
2940919|NCT02965235||POCD|Patients who develop POCD after surgery.
2940920|NCT02965222|Experimental|Intervention arm|After injecting HCG 38- 40 hours , the patient's oocytes will be taken with ICSI , then placed in the Time-Lapse. The oocytes will be IVF after 4 hours and will be stripped surrounding cumulus cell ,then will be placed in the Time-Lapse.The third day the top-grade embryo will be selected by time-lapse imaging (TLI) . The cleavage pattern and time parameters for marker embryo development were recorded daily after insemination.
2940921|NCT02965222|Experimental|Control arm|The development of the embryos at time-lapse was recorded directly and was not disturbed by temperature changes.
2940922|NCT02965209|Experimental|motorized spiral enteroscopy|Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach.
2940923|NCT02965196|Active Comparator|Dexamethasone Therapy|Three consecutive doses of IV Dexamethasone with be administered over three days. The doses will be tapered according to the following: 1st dose, 26mg., 2nd dose, 20mg., and the third dose will be 10 mg. Each dose will be administered over 24 hours in a slow drip, in a 100cc. normal saline bag (0.9%).
2940924|NCT02965196|Placebo Comparator|Placebo Therapy|Three consecutive doses of 100cc IV normal saline (0.9%), will be administered over three days. Each dose will be administered over 24 hours in a slow drip.
2940925|NCT02965183|Experimental|Temperature measurements|
2940926|NCT02965170||MS Tysabri|Patients with relapsing forms of multiple sclerosis and who are currently undergoing Tysabri® therapy at Rocky Mountain Multiple Sclerosis Research Group.
2940927|NCT02965157|Experimental|CART20|
2940928|NCT02965144||HGG patients|single-group study- long term survivors
2940929|NCT02965131|No Intervention|Non-temporary portocaval shunt|No temporary portacaval shunt is created. Full mobilization of the liver was followed by dissection of the hilar structure.
2940930|NCT02965131|Experimental|Temporary portocaval shunt|Temporary portocaval shunt is created when inadvertent massive perihepatic bleeding or technical difficulties due to untypical patients' perihepatic anatomy are encountered during total hepatectomy. Hilar dissection preceded the dissection of the retrohepatic vena cava from the native liver. Its creating prolongs the duration of the anhepatic phase.
2940931|NCT02965118|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0% will be applied to treatment area twice daily for 8 weeks.
2940932|NCT02965118|Placebo Comparator|PAC-14028 cream Vehicle|PAC-14028 cream Vehicle will be applied to treatment area twice daily for 8 weeks.
2940933|NCT02965105|Experimental|First Coloplast Test Catheter; then Speedicath|The subjects allocated to this arm first test Coloplast Test Catheter and then after cross over test the comparator Speedicath Catheter
2940934|NCT02965105|Experimental|First Speedicath; then Coloplast Test Catheter|The subjects allocated to this arm first test Speedicath Catheter and then after cross over test Coloplast Test Catheter
2940935|NCT02965092|Experimental|Second generation CAR-T cells|Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2 in the absence of disease progression or unacceptable toxicity.
2940936|NCT02965066|Experimental|First Coloplast Test catheter; then Speedicath catheter|The subjects allocated to this arm first test Coloplast Test catheter and after cross over test the comparator speedicath catheter
2940937|NCT02965066|Experimental|First Speedicath catheter; then Coloplast Test catheter|The subjects allocated to this arm first test Speedicath catheter and after cross over test the Coloplast test catheter
2940938|NCT02965053|Experimental|Period 1 Arm 1|EOS789 Dose 1 in treatment sequence 1, Placebo in treatment sequence 2
2940939|NCT02965053|Experimental|Period 1 Arm 2|Placebo in treatment sequence 1, EOS789 Dose 1 in treatment sequence 2
2940940|NCT02965053|Experimental|Period 2 Arm 1|EOS789 Dose 2 in treatment sequence 1, EOS789 Dose 2 + Sevelamer carbonate in treatment sequence 2
2940941|NCT02965053|Experimental|Period 2 Arm 2|EOS789 Dose 2 + Sevelamer carbonate in treatment sequence 1, EOS789 Dose 2 in treatment sequence 2
2940942|NCT02965040|Experimental|Roxadustat: subjects with normal renal function|Normal renal function: eGFR is equal to or greater than 90 mL/min/1.73 m^2. Single dose of roxadustat
2940943|NCT02965040|Experimental|Roxadustat: subjects with severely impaired renal function|Severely impaired renal function: eGFR is less than 30 mL/min/1.73 m^2. Single dose of roxadustat
2940944|NCT02965040|Experimental|Roxadustat: subjects with ESRD on CAPD or APD|ESRD subjects on CAPD or APD need to be on the same mode of dialysis for at least 4 months. Single dose of roxadustat
2940945|NCT02965040|Experimental|Roxadustat: subjects with ESRD on HD or HDF|ESRD subjects on HD or HDF need to be on the same mode of dialysis for at least 4 months and should have dialysis sessions three times weekly. Single dose of roxadustat, in both treatment periods
2940946|NCT02965027|Experimental|Prazosin|Prazosin capsules beginning at 1 mg orally at bedtime. Titrate over 5 weeks to maximum dose of 5 mg in the morning and 20 mg at bedtime.
2940947|NCT02965027|Placebo Comparator|Placebo|Placebo capsules
2940948|NCT02965014|Experimental|Face-to-Face Women's CoOp (WC)|Participants will engage in a two-session face-to-face Women's CoOp (WC) intervention.
2940949|NCT02965014|Experimental|mHealth Women's CoOp (WC)|Participants will receive training on the mobile health application mHealth Women's CoOp (WC) and be given tablets with the mHealth application to complete the two-session intervention.
2940950|NCT02965014|Active Comparator|HIV Counseling and Testing|Participants will receive standard HIV counseling and testing services.
2940951|NCT02965001|Experimental|68Ga-NOTA-AE105|All participants have an uPAR-PET/CT scan performed before initiation of the routine radiotherapy
2940952|NCT02964988|Experimental|uPAR PET/CT|Injection of 68Ga-NOTA-AE105 followed by PET/CT scan. Administration will be performed twice in approximately 8 weeks.
2940953|NCT02964975|Active Comparator|Optimal medical therapy|conservative treatment
2940954|NCT02964975|Active Comparator|Percutaneous coronary intervention|Percutaneous coronary intervention of chronic total occlusion
2940955|NCT02964962|Experimental|29 mm LOTUS Edge™|
2940956|NCT02964949|Experimental|Edoxaban 75 mg|Edoxaban 60 mg + edoxaban 15 mg orally, once daily, at the same time (preferably morning) for up to 12 months, with a 2-4 week follow-up period. If needed when the patient completes or discontinues the study, an open-label transition dose of 30 mg and 15 mg edoxaban tablets will be provided.
2940957|NCT02964949|Active Comparator|Edoxaban 60 mg|Edoxaban 60 mg + placebo 15 mg orally, once daily, at the same time (preferably morning) for up to 12 months, with a 2-4 week follow-up period. If needed when the patient completes or discontinues the study, an open-label transition dose of 30 mg and 15 mg edoxaban tablets will be provided.
2940958|NCT02964936|Experimental|ASP1517 Low dose group|Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.
2940959|NCT02964936|Experimental|ASP1517 High dose group|Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.
2941025|NCT02964585|Active Comparator|Active Arm|100 mg of Canagliflozin for 16 weeks
2940960|NCT02964923||Olanzapine group|Following the baseline assessment, subjects will enter an open treatment group with Olanzapine(Zyprexa) lasting 6 weeks. The subjects will start with a dose of 5-10mg/d , which would be adjusted to as low as 10 mg/d or as high as 20 mg/d, based on clinical response.And drug dose adjustments must be completed within 1 week.
2940961|NCT02964923||Risperidone group|Following the baseline assessment, subjects will enter an open treatment group with Risperidone oral solution(Risperdal) lasting 6 weeks. The subjects will start with a dose of 1ml/d , which would be adjusted to as low as 4 ml/d or as high as 6 ml/d, based on clinical response.Drug dose adjustments interval is generally not less than 2 days, and should reach a effective dose of 4~6ml/d within 1 week.
2940962|NCT02964923||Ziprasidone group|Following the baseline assessment, subjects will enter an open treatment group with Ziprasidone Hydrochloride Capsules(Zeldox) lasting 6 weeks. They started with a dose of 40mg/d , which would be adjusted to as low as 80mg/d or as high as 160/d, based on clinical response.Drug dose adjustments interval is generally not less than 2 days, and should reach a effective dose of 80~160mg/d within 10 days.
2940963|NCT02964910|Experimental|the chronic Hepatitis B patients|Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
2940964|NCT02964910|Active Comparator|the healthy volunteer|Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
2940965|NCT02964897|Experimental|Intervention Arm with Peer Support|Veterans in this arm will receive the peer-support intervention, in addition to the usual care from the Health Care for Reentry Veterans Program.
2940966|NCT02964897|Other|Comparison Arm with Usual Care|Veterans in this arm will be receiving usual care from the Health Care for Reentry Veterans program (but they will not receive the peer-support intervention). They will be selected to be frequency-matched to veterans in the intervention arm by date of release from incarceration.
2940967|NCT02964884|Active Comparator|NF1: Lovastatin + reading tutoring|"Participants (NF-1 patients) will receive 20mg of Lovastatin per day for the first two weeks, the dose will be escalated 40 mg for the remaining 11 weeks.~And one week of intensive, one-on-one reading tutoring intervention"
2940968|NCT02964884|Placebo Comparator|NF1: Placebo + reading tutoring|Participants (NF-1 patients) will receive placebo daily And one week of intensive, one-on-one reading tutoring intervention
2940969|NCT02964884|Placebo Comparator|RD: Reading tutoring|Participants (RD-only participants) will receive one week of intensive, one-on-one reading tutoring intervention
2940970|NCT02964884|Sham Comparator|RD: Other Academic (sham) tutoring|"Participants (RD-only participants) will receive one week of intensive, one-on-one tutoring intervention with an academic focus other than reading.~These participants will have the opportunity to receive reading tutoring upon finishing study participation."
2940971|NCT02964871|Active Comparator|LTCF with RIDT|Nasal swabs will be tested by nursing personnel at each intervention site using SOFIA Fluorescent Immunoassay Analyzer Influenza A+B (LTCF with RIDT). Anonymous results will be sent, via wireless transmission, for daily review by the study team and public health personnel. A positive influenza detection will trigger direct communication with LTCF personnel with advice on antiviral treatment, antiviral prophylaxis, and appropriate infection control practices. We will collect data from each site regarding the prescribing of influenza antivirals for treatment and prophylaxis, number of hospitalizations, number of deaths, and associated healthcare costs during annual, dynamic, 4-month risk windows, based on Wisconsin surveillance of influenza patterns.
2940972|NCT02964871|Placebo Comparator|LTCF Control|"Usual care.~Data will be collected from each site regarding the prescribing of influenza antivirals for treatment and prophylaxis, number of hospitalizations, number of deaths, and associated healthcare costs during annual, dynamic, 4-month risk windows, based on Wisconsin surveillance of influenza patterns."
2940973|NCT02964858|Active Comparator|Standard Arm|45 Gy in 25 fractions of 1.8 Gy per fraction over 5 weeks Involved Field radiotherapy (IFRT)/ Involved Site Radiotherapy (ISRT)
2940974|NCT02964858|Experimental|Experimental Arm|36 Gy in 20 fractions of 1.8 Gy per fraction over 4 weeks Involved Field radiotherapy (IFRT)/ Involved Site Radiotherapy (ISRT)
2940975|NCT02964845|Experimental|WISH with CHW and referral to HFM|Subjects will be assigned a CHW for intervention sessions along with receiving primary care from Highland Family Medicine. CHWs will use the SDT-based, trauma-specific motivational approach in the intervention to engage women during 6 sessions. The duration of the intervention is 3 months. Each session will last 1 hour and will take place in a community location. CHW's will also help facilitate primary care by linking subjects to primary care and will use electronic records to update and receive input from medical providers, and support treatment recommendations from Trillium Health. CHWs will empower women to convey their needs to providers for HIV risk reduction, SUD, co-morbidity (MH, IPV) treatment and will support autonomy and competence for treatment in the intervention sessions.
2940976|NCT02964845|Other|Enhanced Treatment as Usual control|eTAU participants will be given an HIV risk reduction information sheet made in cooperation with Trillium Health, HIV health providers. The sheet will include sex and drug behavioral risk reduction strategies and information on obtaining PrEP. The eTAU group is also facilitated to receive healthcare by having a cell phone, a primary care clinic which accepts patients, and bus passes.
2940977|NCT02964832|Active Comparator|PocketCPR;Grasp method|Subject grasp a smartphone in the hand and compress the chest of manikin.
2940978|NCT02964832|Active Comparator|PocketCPR;Armband-in-hand method|Grab the smartphone-contained-armband in hand when performing chest compression
2940979|NCT02964832|Active Comparator|PocketCPR;Armband-on-arm method|Fix the smartphone-contained-armband on upperarm when performing chest compression
2940980|NCT02964819|Active Comparator|exercise group|Manual cervical traction, Myofascial release of upper trapezius muscle, 3 sets of 1 minute;Sleeper's stretch, during 3 series of 30 seconds,Punch exercise, Knee push-up plus, Prone V-raise exercise (arms abducted at 120°), rotador cuff exercise (internal rotation), rotador cuff exercise (external rotation), Rotation on the wall using a ball (internal rotation), Rotation on the wall using a ball (external rotation).
2941026|NCT02964585|Placebo Comparator|Placebo Arm|Placebo for 16 weeks
2941027|NCT02964572|Active Comparator|Glimepiride|Glimepiride (anti-diabetic drug) as a comparison group
2941028|NCT02964572|Experimental|Empagliflozin|Empagliflozin (anti-diabetic drug) as a study group
2942060|NCT02957929|Experimental|Cohort 4|Multiple oral doses in presence of CYP probe substrates
2940981|NCT02964819|Experimental|exercise + Interferential current group|Addition to the exercise protocol performed in the exercise group the interferential current. Four self-adhesive electrodes (8x5 cm), two upper and two lower ones (forming a square) will be placed around the center of the shoulder. The electrodes will be positioned crosswise, following the parameters: 4KHz (carrier frequency), 1/1 second (swing pattern), 100 Hz Frequency modulation amplitude (AMF), 50 Hz (sweep frequency), automatic vector mode, With intensity at the motor threshold of sensation, with duration of 50 minutes.
2940982|NCT02964819|Placebo Comparator|exercise + US group|In addition to the exercise protocol performed in the exercise group, an ultrasound device will be used. The appliance will be used off, without any individual participant having knowledge. For this, the individual will be asked to position himself in the dorsal position on the stretcher, the therapist will perform the application of the transducer head, with gel on its surface, in the anterolateral region of the affected shoulder.
2940983|NCT02964806|Other|Ordinary Diet|Ordinary Diet
2940984|NCT02964806|Other|Modified Atkin's Diet|Modified Atkin's Diet
2940985|NCT02964806|Other|Ketogenic Diet|Ketogenic Diet
2940986|NCT02964793|Experimental|Intervention group|The intervention consists in the standardization of current practices. Clinicians in the intervention maternity units will follow a standardized protocol, and will be asked to measure SFH at each antenatal appointment, collect EFW from the 3rd trimester US, report these values on the chart, and monitor fetal growth according to the protocol guidelines
2940987|NCT02964793|No Intervention|Control group|In the control arm women will benefit from the current routine screening practice for growth failure. The management of pregnancies will remain unchanged. Consultants will be free to monitor growth according to their usual practice. In each maternity unit in the control arm, an information session will be organized on site but its content will be limited to the rational, the objectives of the trial and the study logistics.
2940988|NCT02964780||Gastric Bypass Surgery|Solid mixed meal tolerance test, MRI, CT, anthropometrics, liver biopsies, fat biopsies, muscle biopsies
2940989|NCT02964780||Conservative weight loss|Solid mixed meal tolerance test, MRI, CT, anthropometrics, liver biopsies, fat biopsies, muscle biopsies
2940990|NCT02964767||HIV mono infection|HIV Patients do not have active Mycobacterium Tuberculosis infection
2940991|NCT02964767||HIV-Tb. co infection|Patients with HIV and MycobacteriumTuberculosis co infections
2940992|NCT02964754|Experimental|the observation group|32 patients with complex long bone fractures will be randomized to undergo digital three-dimensional models will be established by CT scan for internal fixation in the observation group.
2940993|NCT02964754|Experimental|the control group|31 patients will be randomized to undergo conventional internal fixation in the control group.
2940994|NCT02964741|Active Comparator|Migraine Patients Active Group|"Episodic migraine patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 20 minute sessions, once daily for 10 days (M-F for 2 weeks).~*Active Comparator"
2940995|NCT02964741|Sham Comparator|Migraine Patients Sham Group|"Episodic migraine patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 30-second administrations at the beginning and end of each 20 minute session, once daily for 10 days (M-F for 2 weeks).~*Sham Comparator"
2940996|NCT02964741|No Intervention|Healthy Control Group|"Healthy Volunteers will be asked to undergo baseline assessments only (including imaging, but no brain stimulation).~Healthy volunteer data (n </= 10) may be used from a prior study (NINDS-K23062946 project [IRBMED #HUM00027383; Dr. Alexandre DaSilva, Principal Investigator]). Consent to use data for a future study was obtained in the informed consent document at the time of participation."
2940997|NCT02964728|Experimental|Botulinum toxin type A|Botulinum neurotoxin injections
2940998|NCT02964728|Placebo Comparator|Placebo|Normal saline solution injections
2940999|NCT02964715|Experimental|Interventional arm|Patients with NAFLD and Type 2 Diabetes prescribed 25mg empagliflozin(JARDIANCE) daily for 6 months
2941000|NCT02964702|Experimental|Thrombectomy Device(T-01)|Mechanical Thrombectomy with T-01
2941001|NCT02964689|Experimental|Combination of binimetinib, pemetrexed and cisplatin|"The trial consists of two parts:~Part 1: dose escalation based on the 3+3 design with 2 doses of binimetinib~Part 2: expansion cohort at the recommended maximum tolerated dose (MTD) level of binimetinib"
2941002|NCT02964676|Experimental|AIT group|PACG in AIT group will receive ab interno trabeculectomy with Trabectome and before AIT, Laser Peripheral Iridectomy (LPI) will be performed first.
2941003|NCT02964676|Active Comparator|Trab group|PACG in AIT group will receive trabeculectomy.
2941004|NCT02964650|No Intervention|Standard rate-response settings|Patients allocated to standard rate-response settings.
2941005|NCT02964650|Experimental|Personalised rate-response settings|Patients allocated to optimised rate-response settings.
2941006|NCT02964637||Progressive supranuclear palsy|Observational Study
2941007|NCT02964637||Corticobasal syndrome|Observational Study
2941008|NCT02964637||Behavoral variant FTD|Observational Study
2941009|NCT02964637||Semantic variant PPA|Observational Study
2941010|NCT02964637||Non-fluent variant PPA|Observational Study
2941011|NCT02964637||FTD-motor neuron disease|Observational Study
2941012|NCT02964637||Healthy controls|Observational Study
2941013|NCT02964624|Other|Rehabilitation|The rehabilitation protocol will consist of three exercise session/week for eight weeks
2941014|NCT02964611||Alzheimer's disease|Observational Study
2941015|NCT02964611||Parkinson's disease|Observational Study
2941016|NCT02964611||Frontotemporal Lobar Degeneration|Observational Study
2941017|NCT02964611||Healthy Controls|Observational Study
2941018|NCT02964598|Experimental|Control|Minimal information on sleep timing
2941019|NCT02964598|Experimental|Psychoeducation|An extensive psychoeducational platform
2941020|NCT02964598|Experimental|Bright light|Bright light treatment with 10 000 lux at max
2941021|NCT02964598|Experimental|Gamified intervention|A new gamified intervention designed for mobile phones
2941022|NCT02964598|Experimental|Bright light and gamified intervention|A combination of the two
2941023|NCT02964598|Experimental|Sleep coaching|A new intervention protocol including a personified approach to solve problems and increase motivation for better sleep behavior
2941029|NCT02964559|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
2941030|NCT02964546||Blood sample|
2941031|NCT02964533|Experimental|TFM|thunder-fire moxibustion therapy
2941032|NCT02964533|Active Comparator|MSM|common moxa-stick moxibustion therapy
2941033|NCT02964520|Experimental|A/T Neurofeedback training|10 sessions of uptraining alpha (8-11 Hz) and theta (5-7.5 Hz) frequency bands, inhibiting beta (15-30 Hz) and delta (2-4 Hz)
2941034|NCT02964520|Sham Comparator|Sham neurofeedback training|"5 sessions of (sessions 1,3,5,7,9) up-training lobeta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz).~5 sessions of (sessions 2,4,6,8,10) down-training beta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz)"
2941035|NCT02964507|Experimental|GSK525762 + Fulvestrant (Phase I)|In Phase I, all subjects will receive treatment with GSK525762 in combination with fulvestrant. Dosing will be continued until unacceptable toxicity, progression of disease, death, or withdrawal of consent.
2941036|NCT02964507|Experimental|GSK525762 + Fulvestrant (Phase II)|Subjects will receive treatment with GSK525762 in combination with fulvestrant, at a GSK525762-dose level selected from Phase I. Dosing will be continued until unacceptable toxicity, progression of disease, death, or withdrawal of consent.
2941037|NCT02964507|Placebo Comparator|Placebo + Fulvestrant (Phase II)|In Phase II, subjects will receive treatment with placebo in combination with fulvestrant. Dosing will be continued until unacceptable toxicity, progression of disease, death, or withdrawal of consent.
2941038|NCT02964481||Malignant Hyperthermia Phenotype cases|Samples from persons who identify as having the malignant hyperthermia phenotype by the North American MH Registry (NAMHR)
2941039|NCT02964481||Caffeine Halothane Contracture Test negative controls|Controls who had negative Caffeine Halothane Contracture Test (CHCT) from North American MH Registry (NAMHR)
2941040|NCT02964468|Experimental|Treatment with IMRT Dose Escalation|Dose Escalation Intensity Modulated Radiotherapy treatment
2941041|NCT02964468|Active Comparator|Treatment with 3DCRT|3DCRT treatment (sequential boost)
2941042|NCT02964455|Experimental|Docetaxel + Nedaplatin + Radiotherapy|Docetaxel and nedaplatin 5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) of each of the first six weeks during chest radiation.
2941043|NCT02964442|Experimental|Capsinoids|8 gel capsules equivalent to 12mg
2941044|NCT02964442|Experimental|Cooling Vest|Using Cooling vest (at approxiamately14 degrees Celsius) to cool the body.
2941045|NCT02964429|Experimental|Diacap Pro High-Flux|1.3/ 1.6/ 1.9 sqm
2941046|NCT02964416|Experimental|Tramadol|Injection Tramadol 100mg diluted in 10 cc syringe (10mg/ml) to be given as 1mg/kg or (1ml/10kg) via intravenous route, once, at the time of dura closure
2941047|NCT02964416|Placebo Comparator|Placebo|0.9% Normal saline in 10 cc syringe,1ml/10kg via intravenous route, once at the time of dura closure
2941048|NCT02964403|Experimental|Cox-2|Cox-2 inhibitor ParecoxibNa 40mg pre-ERCP injection
2941049|NCT02964403|Active Comparator|Indomethacin|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
2941050|NCT02964390|Experimental|Balloon Pulmonary Angioplasty|This arm includes patients qualified to BPA procedure. They have a baseline workup performed before the initiation of BPA treatment and had a follow up examination from 3 to 6 months after the last BPA session.
2941051|NCT02964377|Experimental|Open-label (+)- Epicatechin|8-weeks open-label (+)- Epicatechin at 25mg/day twice per day, 25mg/day three times per day, or 75mg/day at two times per day.
2941052|NCT02964351||High PSA (prostate-specific antigen) levels|
2941053|NCT02964338|Experimental|Fremanezumab- A|Drug Regimen 1
2941054|NCT02964338|Experimental|Fremanezumab- B|Drug Regimen 2
2941055|NCT02964338|Placebo Comparator|Placebo|Matching Placebo
2941056|NCT02964325|Experimental|Mirasol platelets (MIR PLTs)|Leukoreduced, Trima Accel® apheresis platelets stored in 100% plasma, pathogen reduced with the Mirasol® Pathogen Reduction Technology (PRT) System
2941057|NCT02964325|Active Comparator|Reference platelets (REF PLTs)|Leukoreduced, apheresis platelets stored in 100% plasma
2941058|NCT02964312|Other|Latera Implant|Nasal Implant
2941059|NCT02964299||Standard|Standard bite block
2941060|NCT02964299||Mandibular advancement bite block|Mandibular advancement by 3 mm, 6 mm or 9 mm from neutral position
2941061|NCT02964286|Experimental|Acupressure group|The intervention technique used is ''The electric vibrating massager'', ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follows the points are used to stimulate the hematopoietic function. including Hegu (LI4), Quchi (LI11), Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3), Baihui (GV20). Before the study, the trained study nurses teach patients that how to use the technique and stuck adhesive dots label on each specific acupoints.
2941062|NCT02964286|No Intervention|Control group|The patients of the control group are not admitted any acupoints press-related interventions, only take clinical treatment protocol as usual.
2941063|NCT02964273|Experimental|Active Tolvaptan|"In Phase A, subjects will be randomized in a 1:1 ratio to receive IMP (active tolvaptan or matching placebo) for 12 months.~Starting doses, if receiving active tolvaptan, are based on weight:~≥ 20 kg to < 45 kg, 15/7.5 mg tolvaptan (TLV) split-dose~≥ 45 kg to ≤ 75 kg, 30/15 mg TLV split-dose~> 75 kg, 45/15 mg TLV split-dose~After 1 week, subjects will be asked to uptitrate once from their starting dose of active tolvaptan.~≥ 20 kg to < 45 kg, 30/15 mg TLV split-dose~≥ 45 kg to ≤ 75 kg, 45/15 mg TLV split-dose~> 75 kg, 60/30 mg TLV split-dose~Qualified subjects who Complete Phase A are eligible to participate in Phase B."
2941091|NCT02964039|Experimental|Error reduction|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in error reduction mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
2942216|NCT02956811|Active Comparator|Active|Dapagliflozin 10mg once daily for 12 months
2941064|NCT02964273|Placebo Comparator|Matching Placebo|"In Phase A, subjects will be randomized in a 1:1 ratio to receive IMP (active tolvaptan or matching placebo) for 12 months.~Starting doses are based on weight:~≥ 20 kg to < 45 kg, 15/7.5 mg matching placebo split-dose~≥ 45 kg to ≤ 75 kg, 30/15 mg matching placebo split-dose~> 75 kg, 45/15 mg matching placebo split-dose~After 1 week, subjects will be asked to uptitrate once from their starting dose of matching placebo.~≥ 20 kg to < 45 kg, 30/15 mg matching placebo split-dose~≥ 45 kg to ≤ 75 kg, 45/15 mg matching placebo split-dose~> 75 kg, 60/30 mg matching placebo split-dose Qualified subjects who Complete Phase A are eligible to participate in Phase B."
2941065|NCT02964260|Experimental|TAE combined ablation simultaneously|TAE simultaneously combined with ablation.The treatment interval is 1-3 days between two procedures. TAE using embolic agents(Lipiodol/Gelatin sponge/PVA particles(300～500μm)/Blank microspheres).
2941066|NCT02964260|Other|TACE combined ablation sequentially|TACE sequentially combined thermal ablation.The treatment interval is 1 month between two procedures. TACE using chemotherapy drug(Doxorubicin/platinum agents) and embolic agents(Lipiodol/Gelatin sponge/PVA particles(300～500μm)/Blank microspheres).
2941067|NCT02964247|Experimental|liraglutide + SGLT2i ± metformin|
2941068|NCT02964247|Placebo Comparator|liraglutide placebo + SGLT2i ± metformin|
2941069|NCT02964234|Experimental|Empowerment|Behavior: Empowerment
2941070|NCT02964234|Experimental|Education|Behavior: Education
2941071|NCT02964195|Experimental|Rifaximin Group|Rifaximin 400 mg bid for 2 month,
2941072|NCT02964195|No Intervention|Control|Routine endoscopic treatment without prophylactic use of antibiotics
2941073|NCT02964182|Experimental|Usual Brand (UB) Cigarettes|"Carbon monoxide levels measured at Baseline and at Weeks 1, 2, 4, 5, and 8.~Questionnaires completed at Baseline and at Weeks 1, 2, 4, 5, and 8.~Participants answer questions and maintain a daily log every day for up to 75 days. Participants also complete electronic assessments at various points every day for up to 42 days. Participants complete an electronic survey at Weeks 1, 2, 4, 5, and 8.~Urine sample given at Baseline and at Weeks 1, 2, 4, 5, 8, and on or about Day 10 of Phases 1, 2, and 3 to bring to Weeks 5, 8, and 10 study visits.~Participants smoke their usual brand (UB) during Phase 1 (Baseline; week 1) and exclusively smoke VLNCC during Phase 2 (weeks 2-4). During phases 3 (weeks 5-7) & 4 (weeks 8-10), smokers instructed to freely use any combination of assigned VLNCC and e-cigs (VLNCC+ECIG)."
2941074|NCT02964182|Experimental|Very Low Nicotine Content Cigarettes (VLNCC)|"Carbon monoxide levels measured at Baseline and at Weeks 1, 2, 4, 5, and 8.~Questionnaires completed at Baseline and at Weeks 1, 2, 4, 5, and 8.~Participants answer questions and maintain a daily log every day for up to 75 days. Participants also complete electronic assessments at various points every day for up to 42 days. Participants complete an electronic survey at Weeks 1, 2, 4, 5, and 8.~Urine sample given at Baseline and at Weeks 1, 2, 4, 5, 8, and on or about Day 10 of Phases 1, 2, and 3 to bring to Weeks 5, 8, and 10 study visits.~Participants smoke their usual brand (UB) during Phase 1 (Baseline; week 1) and exclusively smoke VLNCC during Phase 2 (weeks 2-4). During phases 3 (weeks 5-7) & 4 (weeks 8-10), smokers instructed to freely use any combination of assigned VLNCC and e-cigs (VLNCC+ECIG)."
2941075|NCT02964182|Experimental|VLNCC + e-Cigarettes (ECIG)|"Carbon monoxide levels measured at Baseline and at Weeks 1, 2, 4, 5, and 8.~Questionnaires completed at Baseline and at Weeks 1, 2, 4, 5, and 8.~Participants answer questions and maintain a daily log every day for up to 75 days. Participants also complete electronic assessments at various points every day for up to 42 days. Participants complete an electronic survey at Weeks 1, 2, 4, 5, and 8.~Urine sample given at Baseline and at Weeks 1, 2, 4, 5, 8, and on or about Day 10 of Phases 1, 2, and 3 to bring to Weeks 5, 8, and 10 study visits.~Participants smoke their usual brand (UB) during Phase 1 (Baseline; week 1) and exclusively smoke VLNCC during Phase 2 (weeks 2-4). During phases 3 (weeks 5-7) & 4 (weeks 8-10), smokers instructed to freely use any combination of assigned VLNCC and e-cigs (VLNCC+ECIG)."
2941076|NCT02964169|Experimental|Family Planning Support|Family planning voucher and phone reminders
2941077|NCT02964169|No Intervention|No Family Planning Support|Routine care
2941078|NCT02964156|Experimental|Walking test using insoles|Supersole
2941079|NCT02964156|Experimental|Walking test not using insoles|no intervention
2941080|NCT02964143|Experimental|Experimental group|Patients from this group will be treated with a combination of platelet-rich plasma (PRP) and hyaluronic acid (HA) prepared with the Cellular Matrix / A-CP HA medical device
2941081|NCT02964143|Active Comparator|Control group 1|Patients from this group will be treated with a well-recognized hyaluronic acid named Ostenil® Plus
2941082|NCT02964143|Active Comparator|Control group 2|Patients from this group will be treated with PRP alone, prepared with RegenKit-BCT-1
2941083|NCT02964130|Other|Follow-up patient|Medical follow-up visit
2941084|NCT02964104|Experimental|Insulin 287 + placebo|Each dose group will consist of 16 subjects randomised for once-weekly s.c. (subcutaneous, under the skin) administration of insulin 287 and once daily s.c. placebo (n=12) or once-weekly s.c. placebo and once daily s.c. insulin degludec (n=4)
2941085|NCT02964104|Active Comparator|Insulin degludec + placebo|Each dose group will consist of 16 subjects randomised for once-weekly s.c. (subcutaneous, under the skin) administration of insulin 287 and once daily s.c. placebo (n=12) or once-weekly s.c. placebo and once daily s.c. insulin degludec (n=4)
2941086|NCT02964091|Other|Harvoni|sofosbuvir/ledipasvir once daily for 12 weeks
2941087|NCT02964078|Experimental|Pembrolizumab and Interleukin-2|Outpatient Intravenous (IV) infusion of Pembrolizumab and Inpatient IV infusion of Interleukin-2.
2941088|NCT02964065|Experimental|LAIV|a single dose of Live-Attenuated influenza Vaccine;Dose: 0.2 ml; Each dose contains not less than 6.9 lg EID50 of type A live attenuated influenza virus reassortants(H1N1 and H3N2), and not less than 6.4 lg EID50 of type B live attenuated influenza virus reassortants.
2941089|NCT02964065|Placebo Comparator|Placebo|a single dose of Placebo. Inactivated placebo will be identical to LAIV in appearance, ingredients and concentrations, attenuated influenza virus free.
2941090|NCT02964052||Acute ischemic stroke patients|Acute ischemic stroke patients who received intravenous (IV) thrombolysis and/or intra-arterial (IA) recanalization treatment
2941123|NCT02963870|Active Comparator|standard treatment only.|group receiving standard treatment only.
2941124|NCT02963844|Experimental|Inspiratory Muscle Training|The components of this group held the IMT load equivalent to 75% of the Pimáx. (measured weekly) for eight weeks.
2941161|NCT02963636|Experimental|Pharmacist clinical intervention|Patients exposed to the pharmacist intervention
2941092|NCT02964039|Experimental|Error augmentation|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in error augmentation mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
2941093|NCT02964039|Sham Comparator|Activity matched control|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in transparent mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
2941094|NCT02964026||Pulmonary artery catheter (PAC)|Patients received a PAC for monitoring purposes
2941095|NCT02964026||No pulmonary artery catheter (PAC)|Patients did not receive a PAC for monitoring purposes
2941096|NCT02964013|Experimental|MK-7684|During an initial dose evaluation phase, participants will receive dose A, B, C, D, or E of MK-7684 on Day 1 of each infusion cycle (for a maximum of 35 cycles) until the RPTD has been established. The RPTD will be established based on the number of dose limiting toxicities (DLTs) at each dose level. Once the RPTD is established, participants will continue receiving the RPTD of MK-7684 on Day 1 of each infusion cycle until the 35-cycle limit is reached.
2941097|NCT02964013|Experimental|MK-7684 + pembrolizumab|During an initial dose evaluation phase, participants will receive Dose A, B, C, D, or E of MK-7684 in combination with 200 mg pembrolizumab on Day 1 of each infusion cycle (for a maximum of 35 cycles) until the RPTD of MK-7684 has been established. The RPTD will be established based on the number of DLTs at each dose level. Once the RPTD of MK-7684 is established, participants will continue receiving the RPTD of MK-7684 in combination with 200 mg pembrolizumab on Day 1 of each infusion cycle until the 35-cycle limit is reached.
2941098|NCT02964013|Experimental|Advanced solid tumor cohort|Participants will receive the RPTD of MK-7684 monotherapy or the RPTD of MK-7684 in combination with 200 mg pembrolizumab on Day 1 of each infusion cycle until the 35-cycle limit is reached.
2941099|NCT02964013|Experimental|Randomized Dose 1 comparison cohort|Participants will be randomized to receive a fixed dose (Dose 1) of MK-7684 in combination with 200 mg pembrolizumab on Day 1 of each infusion cycle until the 35-cycle limit is reached.
2941100|NCT02964013|Experimental|Randomized Dose 2 comparison cohort|Participants will be randomized to receive a fixed dose (Dose 2) of MK-7684 in combination with 200 mg pembrolizumab on Day 1 of each infusion cycle until the 35-cycle limit is reached.
2941101|NCT02964000|Active Comparator|Low level 1 Watt|"The Phoenix Thera-Lase System will be on 1 watt while retaining appropriate blinding of both the operator and the patient.~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.~Each treatment session will last for 20-40 minutes."
2941102|NCT02964000|Experimental|Phoenix Thera-Lase System 42|"The Phoenix Thera-Lase System will be on 42 watts while retaining appropriate blinding of both the operator and the patient.~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.~Each treatment session will last for 20-40 minutes."
2941103|NCT02964000|Experimental|Phoenix Thera-Lase System 74|"The Phoenix Thera-Lase System will be on 74 watts while retaining appropriate blinding of both the operator and the patient.~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.~Each treatment session will last for 20-40 minutes."
2941104|NCT02963987|Experimental|100% Portion Size|100% Food and Beverage Portion Size
2941105|NCT02963987|Experimental|150% Portion Size|150% Food and Beverage Portion Size
2941106|NCT02963974|Experimental|Cochlear Implant|Pediatric patients with single sided deafness will receive a cochlear implant in the ear of loss
2941107|NCT02963961|Experimental|Cognitive Training|Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
2941108|NCT02963961|No Intervention|No Training|Patients will not undergo preoperative cognitive training. Patients will receive standard preoperative care.
2941109|NCT02963948||Medical Staff|Approximately 40 medical staff will be enrolled for the focus groups
2941110|NCT02963948||Medical staff surveyed using SAAS|Approximately 100 medical staff will be surveyed using the Substance Abuse Attitude Survey (SAAS)
2941111|NCT02963948||Wave 1 Patients|Approximately 200 patients at a Wave 1 clinic
2941112|NCT02963935|Experimental|Liraglutide|
2941113|NCT02963935|Placebo Comparator|Placebo|
2941114|NCT02963922|Experimental|liraglutide 3.0 mg|
2941115|NCT02963922|Placebo Comparator|Placebo|
2941116|NCT02963909|Experimental|ZPIV in Flavivirus-naïve Subjects|Two doses of 5.0mcg ZPIV or placebo on Days 1 and 29. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive a 5.0 mcg of ZPIV or placebo on Day 224
2941117|NCT02963909|Experimental|ZPIV in JEV (IXIARO®)|Two 0.5mL doses of IXIARO® (Valneva) Days 1 and 29 followed by two ZPIV or placebo doses will be administered on Days 112 and 140. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive it on Day 336
2941118|NCT02963909|Experimental|ZPIV in YFV (YF-VAX®)|One 0.5mL dose of YF-VAX® (Sanofi Pasteur) on Day 1 followed by two ZPIV or placebo doses on Days 84 and 112. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive it on Day 308
2941119|NCT02963896|Experimental|gentamicin|intratympanic application of gentamicin 0.5 ml
2941120|NCT02963883|Experimental|SVO2 group|After optimization of oxygenation and blood volume, concentrate transfusion (s) of red blood cells by the individual value of ScvO2, whose value must be greater than 70% after elimination of hypovolemia, hypotension or hypoxemia.
2941121|NCT02963883|Active Comparator|control group|After optimization of oxygenation and blood volume, concentrate transfusion (s) of red blood cells based on the hemoglobin values, as recommended by the National Health Authority for Anesthesiology, Surgery, Emergency (November 2014 ): transfusion threshold of <9 g / dl for patients with cardiovascular antecedents.
2941122|NCT02963870|Experimental|security plan|groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with security plan and the usual treatment
2941125|NCT02963844|Sham Comparator|Inspiratory Muscle Training Sham|This group simulate the training, conducted the training without charge for the same period the intervention group.
2941126|NCT02963831|Experimental|Dose Escalation|"During Phase 1 of the study, subjects will be evaluated for DLTs before proceeding to a subsequent cohort. Dose escalation for the determination of RCD will be performed based on the available dose levels and the respective rules for a standard 3 + 3 dose escalation study design.~For Cohort A, ONCOS-102 (1 x 10^11 VP) will be given as monotherapy the first six weeks, and then durvalumab (1500 mg) will be starting on day 71.~For Cohorts B and C, ONCOS-102 will be administered for a total of 6 weeks while durvalumab will be given for a total of 12 four-week cycles."
2941127|NCT02963831|Experimental|Cohort 1: Platinum-resistant epithelial ovarian cancer|ONCOS-102 will be administered for a total of 6 weeks, while durvalumab will be administered for a total of 12 cycles, starting on Day 15.
2941128|NCT02963831|Experimental|Cohort 2: Colorectal cancer|ONCOS-102 will be administered for a total of 6 weeks, while durvalumab will be administered for a total of 12 cycles, starting on Day 15.
2941129|NCT02963818|Experimental|Smartphone breathalyzer device & app|This is a small device that connects to a smartphone with an accompanying app that produces accurate breath alcohol readings when a user blows into a small tube attached to the device. Participants randomized to this study condition will have the opportunity to use this device and app during an alcohol drinking session in an actual bar and during a two-week field period.
2941130|NCT02963818|Experimental|BAC estimator app|This is an app that produces estimated blood alcohol content (eBAC) readings based on sex, weight, number of drinks and time taken to consume drinks. Participants randomized to this study condition will have the opportunity to use this app during an alcohol drinking session in an actual bar and during a two-week field period.
2941131|NCT02963818|Experimental|Text Messaging|A procedure whereby one sends a text message to the phone one is using after each alcoholic drink. Participants randomized to this study condition will have the opportunity to the text messaging procedure during an alcohol drinking session in an actual bar and during a two-week field period.
2941132|NCT02963805|Experimental|High intensity physical activity (HIPA)|Participants attended high intensity vigorous activity after school clubs.
2941133|NCT02963805|Experimental|Fundamental movement skill (FMS)|Participants attended fundamental movement skill based after school clubs.
2941134|NCT02963805|Experimental|Physical activity signposting (PASS)|Participants attended educational physical activity signposting sessions during school hours.
2941135|NCT02963805|No Intervention|Control|Children in the control group received British Heart Foundation leaflets that included information on heart health (given to all groups). Children participated in their usual school curriculum including two hours of physical education and school sport per week, both within and beyond the curriculum.
2941136|NCT02963792|Experimental|Structured group intervention|"Experimental: Structured group intervention a 'structured' intervention, leaning mostly on tools designed to prevent burnout and promote resilience, including predetermined exercises and topics as discussion goals in each meeting.~Fidelity will be checked and monitored at the end of each meeting, when facilitators fill out a form that summarizes the content, topics and coping skills acquired in each session."
2941137|NCT02963792|Experimental|Semi-Structured group intervention|"Experimental: Semi-Structured group intervention a 'semi-structured' intervention, based on tools for developing an emotional discourse, building a supporting team and self reflection.~The 'semi-structured' intervention offers predetermined contents that are discussed through the stories and needs presented by group members.~Fidelity will be checked and monitored at the end of each meeting, when facilitators fill out a form that summarizes the content, topics and coping skills acquired in each session."
2941138|NCT02963779|Experimental|LY2775240 (Part A)|Escalating oral doses of LY2775240 administered in healthy participants
2941139|NCT02963779|Experimental|LY2775240 (Part B)|Oral dose of LY2775240 in healthy participants
2941140|NCT02963779|Placebo Comparator|Placebo (Part A)|Placebo administered orally in healthy participants
2941141|NCT02963779|Active Comparator|Apremilast (Part B)|Oral dose of apremilast in healthy participants
2941142|NCT02963766|Experimental|Dose 1 Dulaglutide|Dulaglutide given subcutaneously (SC).
2941143|NCT02963766|Experimental|Dose 2 Dulaglutide|Dulaglutide given SC.
2941144|NCT02963766|Placebo Comparator|Placebo|Placebo given SC.
2941145|NCT02963753||hyperemesis gravidarum group|The study group consisted of women hospitalized for hyperemesis during first trimester of their pregnancy
2941146|NCT02963753||the control group|whereas the control group included all other women who delivered in the same period.
2941147|NCT02963740|Experimental|Weight Loss Intervention Group|Participants will take part in supervised exercise and home-based exercise sessions. Participants will be asked to follow a specific diet. Participants will be asked to take part in weekly behavioral group phone calls.
2941148|NCT02963727|Experimental|Wharton Jelly mesenchymal stem cell|Intra-articular Wharton Jelly derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of WJMSC in each dose
2941149|NCT02963714|Experimental|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
2941150|NCT02963714|Experimental|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
2941151|NCT02963701|Experimental|Ibuprofen+Pseudoephedrine-HCl|Fixed dose combination
2941152|NCT02963701|Active Comparator|Ibuprofen+Pseudoephedrine-HCl (RhinAdvil®)|Fixed Dose Combination
2941153|NCT02963688||KGOG 3019|Korean women with HG serous and/or endometrioid epithelial ovarian cancer
2941154|NCT02963675||Group 1|Prostate cancer patients with bone metastases (mPC)
2941155|NCT02963675||Group 2|Castration-resistant prostate cancer patients with bone metastases (mCRPC)
2941156|NCT02963662|Experimental|Roux-en-Y gastric bypass group|The patients undergo Roux-en-Y gastric bypass (RYGB group) following a comprehensive evaluation for the surgical indication
2941157|NCT02963662|Experimental|sleeve gastrectomy group|The patients undergo sleeve gastrectomy (SG group) following a comprehensive evaluation for the surgical indication
2941158|NCT02963662|No Intervention|Normal BMI group|no intervention
2941159|NCT02963649|Experimental|drug-eluting balloon IN.PACT 014|product is indicated for PTA in patients with obstructive disease of peripheral arteries with paclitaxel drug - elution.
2941162|NCT02963610|Experimental|Pembrolizumab, Lenalidomide|"Phase I The treatment will be given on a 21-day cycle, with a dose of pembrolizumab given on day1(IV) and doses of lenalidomide given on day 1-14 (orally). The dose of pembrolizumab will be fixed at 200 mg. The dose of lenalidomide will depend upon the patient cohort. Cohort 1 will receive 10mg, Cohort II will receive 15mg and cohort 3 will receive 20mg of lenalidomide.~Phase II The treatment will be given on a 21-day cycle, with a dose of pembrolizumab given on day1(IV) and doses of lenalidomide given on day 1-14 (orally). The dose of pembrolizumab will be fixed at 200 mg. Maximum Tolerated Dose (MTD) of lenalidomide as determined by the Phase I study will be given in Phase II study."
2941163|NCT02963597|Active Comparator|Group A|Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
2941164|NCT02963597|Placebo Comparator|Group B|Standard medical therapy only.
2941165|NCT02963584|Experimental|intervention group|Patients in this group will receive CTO Choice (decision aid).
2941166|NCT02963584|No Intervention|control group|Patients in this group will receive usual primary care.
2941167|NCT02963571|Experimental|screw fixation|The patients underwent minimally invasive posterior percutaneous pedicle screw internal fixation.
2941168|NCT02963558|Experimental|Intervention|The intervention group will receive in-bed cycle ergometry within 48 hours of randomization if safety criteria are met. The intervention arm will receive early physical therapy (PT). This PT will be performed according to a protocol of additional ICU and hospital-administered rehabilitation strategies that have been previously developed. Patients will receive 30 minutes of PT at least 5 times per week while conscious. If unconscious, subjects will only receive passive range of motion (PROM) for 10 repetitions per body part daily. Once conscious, subjects will progress through PT with an emphasis on ambulation. Therapy for the intervention arm patients will continue while on the floor. Outpatient therapy will be provided at the discretion of the patient's treating physicians.
2941169|NCT02963558|No Intervention|Usual Care|The control group will receive usual care physical therapy as ordered by the treating team both in the ICU and on the floor through hospital discharge. These subjects will also receive therapy as outpatients only as ordered by their regular physicians.
2941170|NCT02963545|Experimental|Patients presenting cerebral infarction|no intervention of health product administration,
2941171|NCT02963545|Other|Historical controls|no intervention of health product administration, patients characteristics, history, matched with patients for age, gender, tobacco consumption and season of inclusion, free of neurologic or psychiatric disease or psychotropic medications or medications known to impact on serotonin
2941172|NCT02963519|Experimental|VistaCare®|VistaCare® Medical device for treatment into an editable atmosphere
2941173|NCT02963519|Active Comparator|Dressings|Dressings Adapted to the case
2941174|NCT02963506|Placebo Comparator|Placebo|Subjects will receive for 12 Weeks Placebo and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
2941175|NCT02963506|Experimental|Bimekizumab Dose 1|Subjects will receive for 12 Weeks Bimekizumab Dose 1 and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
2941176|NCT02963506|Experimental|Bimekizumab Dose 2|Subjects will receive for 12 Weeks Bimekizumab Dose 2 and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
2941177|NCT02963506|Experimental|Bimekizumab Dose 3|Subjects will receive for 48 Weeks Bimekizumab Dose 3.
2941178|NCT02963506|Experimental|Bimekizumab Dose 4|Subjects will receive for 48 Weeks Bimekizumab Dose 4.
2941179|NCT02963493|Experimental|melflufen + dexamethasone|Melflufen 40 mg Day 1 and dexamethasone 40 mg (reduced dose for patients 75 years or older) on Days 1, 8, 15 and 22 of each 28-day cycle.
2941180|NCT02963480||Sepsis|Patients, who developed postoperative sepsis
2941181|NCT02963480||SIRS|Patients, who developed postoperative SIRS
2941182|NCT02963467|Other|Healthy Volunteers - non-smokers|control group: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke a dummy cigarette. Then V/Q will be measured again after 15 minutes.
2941183|NCT02963467|Other|Healthy Volunteers - occasional smokers|intervention: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke 4 conventional cigarettes. Thereafter, V/Q will be measured again after 15, 30, 45, 60 and 120 minutes.
2941184|NCT02963467|Other|Healthy Volunteers - heavy-smokers|intervention: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke 4 conventional cigarettes. Thereafter, V/Q will be measured again after 15, 30, 45, 60 and 120 minutes.
2941185|NCT02963454|Experimental|levosimendan 0.2 μg/kg/min|"Treatment with levosimendan 0.2 μg/kg/min 24h (without bolus).~Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle."
2941186|NCT02963454|Active Comparator|dobutamine 5 μg/kg/min|"Treatment with dobutamine 5 μg/kg/min. Dobutamine were administered during all the 72 hours study period.~Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle."
2941187|NCT02963428|No Intervention|Standard of Care (SOC)|Participants will receive the usual standard of care which includes written educational materials as well as counseling by their obstetric care provider.
2941188|NCT02963428|Experimental|Enhanced Care (EC)|"In addition to standard of care, the study participants will also receive:~i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy."
2941189|NCT02963415|Experimental|Virtual Reality Cognitive Training|Exergame to stimulate cognition
2941190|NCT02963402||Tocilizumab treated|
2941191|NCT02963402||Anti-TNF treated|
2941192|NCT02963389|Experimental|Tripegfilgrastim 60ug/kg, >=6 and <12-year-old patients|A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy
2941193|NCT02963389|Experimental|Tripegfilgrastim 60ug/kg, >=12 and <19-year-old patients|A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy
2941194|NCT02963389|Experimental|Tripegfilgrastim 100ug/kg, >=6 and <12-year-old patients|A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy
2941195|NCT02963389|Experimental|Tripegfilgrastim 100ug/kg, >=12 and <19-year-old patients|A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy
2941196|NCT02963376|Active Comparator|0.05 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
2941197|NCT02963376|Placebo Comparator|0.05 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
2941198|NCT02963376|Active Comparator|0.10 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
2941199|NCT02963376|Placebo Comparator|0.10 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
2941200|NCT02963376|Active Comparator|0.17 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
2941201|NCT02963376|Placebo Comparator|0.17 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
2941202|NCT02963363|Experimental|Interventional|"Home-Based Adapted Physical Activity intervention during neoadjuvant chemotherapy :~150 minutes per week of aerobic and muscle strengthening exercises during 18 weeks"
2941203|NCT02963337||remifentanil PCA|The patients in the remifentanil group will receive remifentanil hydrochloride (Ultiva, GlaxoSmithKline, Oslo, Norway) diluted in physiologic saline to a concentration of 40µg/ml and administered using PCA pump with a bolus duration of 20 sec. A stepwise bolus doses from 15 to 30 µg, maximum 40 per 2 min will be applied with no background infusion.
2941204|NCT02963337||Combined spinal-epidural analgesia PCA|A 27-gauge needle will be placed via the shaft of the epidural needle inserted at the L2-3/L3-4 inter-space by the investigator. After confirming the CSF, 2,5 mg of bupivacaine with 20 µg of fentanyl will be injected. That will be followed by the placement of a 20-gauge multi-hole catheter into the epidural space which will be connected to the PCA pump with a possibility of injecting 6-10 ml 0,1% bupivacaine with 2 µg of fentanyl/ml every 20 min with no background infusion.
2941205|NCT02963324|Experimental|Ivermectin|Single dose of ivermectin 12 mg (as 4 tablets of Stromectol (R) 3 mg) orally
2941206|NCT02963311|Experimental|ALN-PCSSC|300 milligrams (mg) administered subcutaneous (SC) on Day 1. Participants with a mean serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels not suppressed by >70% at Day 60 or Day 90, as compared to baseline, will receive a second dose at Day 90 or Day 104, respectively, based on PCSK9 levels from the previous visit. Participants also received standard of care as background therapy.
2941207|NCT02963298|Active Comparator|CRRT after cardiac arrest|Continuous renal replacement therapy (CRRT) after cardiac arrest for 72 hours for elimination of Glutamate. Repetitive testing of blood Glutamate levels.
2941208|NCT02963298|No Intervention|control|Repetitive testing of blood Glutamate levels without CRRT
2941209|NCT02963285||0 to 6 months|
2941210|NCT02963285||7 months to less than 1 year|
2941211|NCT02963285||1 to less than 2 years|
2941212|NCT02963285||2 to less than 6 years|
2941213|NCT02963285||6 to 12 years|
2941214|NCT02963272|Other|Conventional strategy|Conventional strategy to manage the patients with HF, following the international guidelines
2941215|NCT02963272|Other|ST2-guided strategy|Management of patients follow the international guidelines but are also guided by the ST2, to adapt the drugs indicated in patients with HF.
2941216|NCT02963246|Experimental|Mindfulness group|Mindfulness intervention (12 months). Mindfulness based Cognitive Therapy is an evidence-based psychological program designed to help manage depressive and stress symptoms.
2941217|NCT02963246|No Intervention|Control Group|Treatment-as-usual control
2941218|NCT02963233||Non-operative Group|Patients treated within the non-operative group will be treated with gentle reduction by the orthopaedic surgery team in the emergency department under procedural sedation. Immobilization and maintenance of reduction will be obtained through either taping of the elbow in a flexed (100-110 degree) and pronated position or through long-arm casting at 90 degrees of flexion. Immobilization type and position will be noted.
2941219|NCT02963233||Operative Group|Patients treated operatively will be largely treated with closed reduction and percutaneous pinning with 2-3 laterally-based k-wires, followed by long-arm immobilization. Immobilization type and position will be noted.
2941220|NCT02963220|Experimental|CBT-AR|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-AR. There is no control group.
2941221|NCT02963207|Experimental|Modified Sano's Classification|Modified Sano's Classification as described by Singh et al. 2013
2941222|NCT02963207|Active Comparator|NICE classification|NBI International Colorectal Endoscopic Classification as described by Hewett et al. 2012
2941223|NCT02963194|Experimental|Oxytocin|Oxytoxin nasal spray
2941224|NCT02963194|Placebo Comparator|Placebo|Placebo nasal spray
2941225|NCT02963181|Experimental|Effects of Yohimbine|Investigation into the integrity of post-ganglionic sympathetic nerves in patients with idiopathic neurogenic orthostatic hypotension
2941226|NCT02963181|Experimental|Effects of melatonin on blood pressure|Investigation into the effects of melatonin at two separate dosages (2 and 5mg) on nocturnal blood pressure in NOH patients with intact versus denervated post-ganglionic sympathetic nerves
2941227|NCT02963168|Experimental|Oradoxel|To determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered once every 3 weeks, then to determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered for two days every three weeks.
2941228|NCT02963155|Experimental|Metastatic prostate cancer blood samples|
2941338|NCT02962557|No Intervention|Control|The control group will receive no prompts by the recorded voice.
2941229|NCT02963142||SCAP requiring ECMO|"Patients diagnosed with severe respiratory failure due to community acquired pneumonia that require extra-corporeal membrane oxygenation and a routine bronchoscopy for clinical purposes.~Molecular laboratory techniques will be applied to residual respiratory tract samples including bronchoalveolar lavage and non-directed bronchoalveolar lavage. Comparisons will be made to conventional diagnostic tests used in the diagnosis of community acquired pneumonia."
2941230|NCT02963142||SCAP requiring ITU support|"Patients diagnosed with severe respiratory failure due to community acquired pneumonia that require intensive care support and undergo a routine bronchoscopy for clinical purposes.~Molecular laboratory techniques will be applied to residual respiratory tract samples including bronchoalveolar lavage and non-directed bronchoalveolar lavage. Comparisons will be made to conventional diagnostic tests used in the diagnosis of community acquired pneumonia."
2941231|NCT02963142||Healthy controls|"Healthy volunteers who undergo bronchoscopy as part of a designated research bronchoscopy list.~Molecular laboratory techniques will be applied to bronchoalveolar lavage samples."
2941232|NCT02963129|Experimental|Mupirocina|topical mupirocin nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days
2941233|NCT02963129|Placebo Comparator|Control|topical placebo nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days
2941234|NCT02963116|Experimental|Treatment A|10 mg rosuvastatin tablet alone (fasting state)
2941235|NCT02963116|Experimental|Treatment B|10 mg rosuvastatin tablet + 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)
2941236|NCT02963116|Experimental|Treatment C|200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)
2941237|NCT02963116|Experimental|Treatment D|200 mg of AZD5718 oral suspension 50 mg/mL (fasting state)
2941238|NCT02963116|Experimental|Treatment E|200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fed state)
2941239|NCT02963103|Experimental|Tacrolimus group|oral
2941240|NCT02963090|Active Comparator|Topotecan|Topotecan IV at 1265mg/m^2 Days 1-5 of every 21 day cycle
2941241|NCT02963090|Experimental|Pembrolizumab|Pembrolizumab IV 200mg infusion Day 1 of every 21 day cycle
2941242|NCT02963077|Experimental|Cohort 1 SAD - 0.1 mg A4250|Dose: 0.1 mg of A4250. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).
2941243|NCT02963077|Experimental|Cohort 2 SAD - 0.3 mg A4250|Dose: 0.3 mg of A4250.
2941244|NCT02963077|Experimental|Cohort 3 SAD - 1 mg A4250|Dose: 1 mg A4250.
2941245|NCT02963077|Experimental|Cohort 4 SAD - 3 mg A4250|Dose: 3 mg A4250.
2941246|NCT02963077|Experimental|Cohort 5 SAD - 10 mg A4250|Dose: 10 mg A4250.
2941247|NCT02963077|Placebo Comparator|Cohort 1 SAD placebo|Dose: 0.1 mg of A4250 matching placebo. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).
2941248|NCT02963077|Placebo Comparator|Cohort 2 SAD placebo|Dose: 0.3 mg A4250 matching placebo.
2941249|NCT02963077|Placebo Comparator|Cohort 3 SAD placebo|Dose: 1 mg A4250 matching placebo.
2941250|NCT02963077|Placebo Comparator|Cohort 4 SAD placebo|Dose: 3 mg A4250 matching placebo.
2941251|NCT02963077|Placebo Comparator|Cohort 5 SAD placebo|Dose: 10 mg A4250 matching placebo.
2941252|NCT02963077|Experimental|Cohort 1 MAD - 1 mg A4250 qd|Dose: 1 mg A4250 qd for 7 days.
2941253|NCT02963077|Placebo Comparator|Cohort 1 MAD placebo|Dose: 1 mg A4250 matching placebo qd for 7 days.
2941254|NCT02963077|Experimental|Cohort 2 MAD - 3 mg A4250|Dose: 3 mg A4250 qd for 7 days
2941255|NCT02963077|Placebo Comparator|Cohort 2 MAD placebo|Dose: 3 mg A4250 matching placebo qd for 7 days.
2941256|NCT02963077|Experimental|Cohort 3 MAD - 1.5 mg A4250 b.i.d for 7 days.|Dose: 1.5 mg A4250 b.i.d. for 7 days.
2941257|NCT02963077|Placebo Comparator|Cohort 3 MAD placebo|Dose: 1.5 A4250 matching placebo b.i.d for 7 days.
2941258|NCT02963077|Experimental|Cohort 4 MAD - 3 mg A4250 qd + 1 mg Questran b.i.d|Dose: 3 mg A4250 qd + 1 mg Questran b.i.d for 7 days.
2941259|NCT02963077|Active Comparator|Cohort 4 MAD A4250 placebo + 1 mg Questran b.i.d|Dose: 3 mg A4250 matching placebo + 1 mg Questran b.i.d for 7 days.
2941260|NCT02963077|Experimental|Cohort 5 MAD - 3 mg A4250 qd + 1 g CRC b.i.d|Dose: 3 mg A4250 qd + 1 g CRC b.i.d for 7 days.
2941261|NCT02963077|Placebo Comparator|Cohort 5 MAD A4250 placebo + CRC placebo|Dose: 3 mg A4250 matching placebo qd + 1 g CRC placebo b.i.d for 7 days
2941262|NCT02963077|Active Comparator|Cohort 6 MAD - 1 g CRC|Dose: 1 g CRC b.i.d
2941263|NCT02963077|Placebo Comparator|Cohort 6 MAD CRC placebo|Dose: 1 g CRC matching placebo b.i.d.
2941264|NCT02963077|Experimental|Cohort 7 MAD - 3 mg A4250 qd + 1 g CRC b.i.d|Dose: 3 mg A4250 qd + 1 g CRC b.i.d
2941265|NCT02963077|Placebo Comparator|Cohort 7 MAD A4250 placebo + CRC placebo|Dose: 3 mg A4250 matching placebo qd + 1 g CRC matching placebo b.i.d.
2941266|NCT02963064|Experimental|Blood Stem Cell Transplant w/ anti-CD117 conditioning|The study will enroll three groups based on declining age (>/=12; >2 to <12; >/=3 months newly diagnosed SCID); groups will enroll in staggered order. There are three dose levels. Patients will receive a one time dose of intravenous anti-CD117 antibody (AMG 191), followed by monitoring for antibody clearance (PK). Once the antibody has cleared below a certain level, patients will receive the blood forming stem cell graft and be monitored for immune recovery. Initially, patients will be transplanted with standard-of-care CD34+ enriched grafts. Transplants of CD34+CD90+ graft can commence when the corresponding CD34+ cohort at a given dose AMG 191 level demonstrates adequate donor cell engraftment defined by > 5% myeloid chimerism at 6 months post-HCT.
2941267|NCT02963051|Experimental|Neuroendocrine prostate cancer (NEPC)|"Subjects with neuroendocrine prostate cancer (NEPC)~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
2941268|NCT02963051|Experimental|Adenocarcinoma CRPC with non-liver/peritoneal metastases|"Subjects with adenocarcinoma CRPC with non-liver/peritoneal metastases (lymph nodes, bone, or lung)~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
2941269|NCT02963051|Experimental|Adenocarcinoma CRPC with liver and/or peritoneal mets|"Subjects with adenocarcinoma CRPC with liver and/or peritoneal metastases~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
2941270|NCT02963038|Experimental|CD19 CAR T cells|Autologous CD19-targeting CAR T cells
2941271|NCT02963025|Other|THE HIGHER PEEP LEVEL|Mechanical ventilation with VT of 5 ml/kg PBW and the level of PEEP at 10 cmH2O with lung recruitment maneuvers
2941272|NCT02963025|Other|THE LOWER PEEP LEVEL|Mechanical ventilation with VT of 5 ml/kg PBW and the level of PEEP at 5 cmH2O without lung recruitment maneuvers
2941273|NCT02962999|Experimental|Ketamine|After induction, patients will be received 1 mg/kg ketamine bolus, then will be administered 0,5 mg/kg/hour ketamine infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,25-0,5 microgram/dk/min remifentanil.
2941274|NCT02962999|Placebo Comparator|Saline|After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,25-0,5 microgram/dk/min remifentanil.
2941275|NCT02962986|Active Comparator|norepinephrine 6mcg|norepinephrine, given as 1mL IV boluses, to treat post-spinal hypotension
2941276|NCT02962986|Active Comparator|phenylephrine 100mcg|phenylephrine, given as 1mL IV boluses, to treat post-spinal hypotension
2941277|NCT02962973|Experimental|Patient implanted|
2941278|NCT02962960|Experimental|Anifrolumab - Lower dose|1ml, once every second week, one subcutaneous injection as added to stand of care, from week 0 to week 50
2941279|NCT02962960|Placebo Comparator|Placebo matching for lower dose of Anifrolumab|1ml, once every second week, one subcutaneous injection added to stand of care, from week 0 to week 50
2941280|NCT02962960|Experimental|Anifrolumab - Higher dose|2×1ml, once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
2941281|NCT02962960|Placebo Comparator|Placebo matching for higher dose of Anifrolumab|2×1ml , once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
2941282|NCT02962947|Placebo Comparator|PLACEBO|Placebo will be taken daily during the study period
2941283|NCT02962947|Active Comparator|PROPRANOLOL|Study participants in the treated group will take 80 mgR propranolol once daily .
2941284|NCT02962934||Non CRRT group|Critically ill patients receiving Ceftolozane-Tazobactam not receiving continuous renal replacement therapy
2941285|NCT02962934||CRRT group|Critically ill patients receiving Ceftolozane-Tazobactam who require continuous renal replacement therapy
2941286|NCT02962921|Experimental|Diabetic patients|"Diabetic patients were treated with insulin loads, left ventricle functional parameters were compared to those of healthy persons.~Metabolic indices of insulin effect: blood insulin levels, glucose disposal rates under insulin infusion, were compared to respective group of healthy persons, studied earlier at our institution Insulin LISPRO intravenous loading"
2941287|NCT02962908|Experimental|Group 1|(n=74): FLU-v on Day 0 and Day 21
2941288|NCT02962908|Experimental|Group 2|(n=74): adjuvanted FLU-v on Day 0, saline (0.5mL) on Day 21
2941289|NCT02962908|Placebo Comparator|Group 3|(n=37): saline solution (0.5ml) on Day 0 and Day 21
2941290|NCT02962908|Placebo Comparator|Group 4|(n=37): Adjuvanted placebo on Day 0, saline (0.5mL) on Day 21
2941291|NCT02962895|Experimental|VAY736 dose 1|VAY736 low
2941292|NCT02962895|Experimental|VAY736 dose 2|VAY736 medium
2941293|NCT02962895|Experimental|VAY736 dose 3|VAY736 high
2941294|NCT02962895|Placebo Comparator|Placebo|Placebo control
2941295|NCT02962882|Experimental|A. Mepilex Border Sacrum (Safetac)|A dressing that is a flexible, self-adherent, profylactic, absorbent pad in three layers to be used on the sacrum area at pressure points in patients in the ICU, prone to get pressure injuries (PI).
2941296|NCT02962882|Experimental|B. Mepilex Border Heel (Safetac)|A dressing that is a flexible, self-adherent, profylactic, absorbent pad in three layers to be used on the heels (on both left and right heels), in patients in the ICU, prone to get pressure injuries (PI).
2941297|NCT02962869|Experimental|BAY987517|All subjects are patched with the same product
2941298|NCT02962856|Experimental|BAY987517|All subjects are patched with the same product.
2941299|NCT02962843|Experimental|IY TCM|Incredible Year (IY) Teacher Classroom Management (TCM) training, 6 full-day workshops (42 hours)
2941300|NCT02962843|No Intervention|Comparison|No Incredible Year (IY) Teacher Classroom Management (TCM) training.
2941301|NCT02962830|Experimental|Sufentanil|
2941302|NCT02962817|Experimental|Educational intervention through a web platform|"This group will have access to our web platform where they will find information related to nonspecific chronic low back pain. This information will be presented through dynamic explanatory 3D videos made by the author.~The aim of this intervention is to change and modify wrong beliefs and attitudes about chronic low back pain of physicians and nurses working in primary care settings, using a web-based educational tool with the additional result of increasing knowledge on pain neurophysiology and reducing fear-avoidance beliefs."
2941303|NCT02962817|Active Comparator|Clinical practice guidelines on low back pain|Control group: They will have access to a video where medical staff and primary care nurses explain the content of the clinical practice guideline for addressing back pain.
2941304|NCT02962804|Experimental|Nivolumab plus radiation|Nivolumab plus radiation
2941305|NCT02962791|Experimental|Stimulation of 3 ventricular sites|Cardiac resynchronization therapy implantation wil be done as usual, except the additional stimulation lead. Standard Echocardiography will be done at one year
2941306|NCT02962791|Active Comparator|Stimulation of 2 ventricular sites|Cardiac resynchronization therapy implantation wil be done as usual. Standard Echocardiography will be done at one year
2941307|NCT02962778||treatment-resistant hypertension|patients with Treatment-resistant arterial hypertension receiving standard antihypertensive treatment with at least 3 antihypertensive agents including one diuretic
2941308|NCT02962752|Experimental|Blackadder Juice|Cold pressed Blackadder blackcurrant juice. Standardised at 500mg of polyphenols per 60kg of body weight
2941309|NCT02962752|Placebo Comparator|Placebo|Sugar, flavour and volume matched placebo control drink.
2942217|NCT02956811|Placebo Comparator|Placebo|Placebo 10mg once daily for 12 months
2941310|NCT02962739|Active Comparator|33%/67% dosing|The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).
2941311|NCT02962739|Active Comparator|33%/100% dosing|The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.
2941312|NCT02962739|Active Comparator|67%/33% dosing|The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).
2941313|NCT02962739|Active Comparator|67%/100% dosing|67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.
2941314|NCT02962739|Active Comparator|100%/33% dosing|The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.
2941315|NCT02962739|Active Comparator|100%/67% dosing|67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.
2941316|NCT02962726||Patients|100 female patients between the age of 12 and 18 years suffering from anorexia nervosa.
2941317|NCT02962726||Age matched Controls|100 females volunteers between the age of 12 and 18 years old without eating disorder.
2941318|NCT02962713|Active Comparator|ART with Equia|Occlusal-proximal restoration in primary molars using Equia (Easy/Quick/Unique/Intelligent/Aesthetic) from GC Corp, encapsulated, pre-dosed and mechanized handling.
2941319|NCT02962713|Experimental|ART with Giomer Beautifil-Bulk Restorative|Occlusal-proximal restoration in primary molars using Giomer Beautifil-Bulk Restorative (SHOFU Inc)
2941320|NCT02962700|Experimental|CVVHF|CVVHF for 48 h interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
2941321|NCT02962700|Active Comparator|IHD for 4 hours|"Intermittent haemodialysis was carried out during the first 4 h at day 1 and day 2 of the study period.~Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis."
2941322|NCT02962687|Experimental|Videoconference care management|12-week nurse care management for medically complex Veterans with CI delivered via videoconferencing
2941323|NCT02962687|Active Comparator|Telephone care management|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
2941324|NCT02962674|Other|Treatment|
2941325|NCT02962661|Experimental|Intravenous Infusion of MSCs|"Participants receive 4 weekly doses of Mesenchymal Stromal Cells (MSCs) administered intravenously at a dose of 2 x 10^6 cells/Kg.~Participants treated with routine heart failure medical therapy as prescribed by physician."
2941326|NCT02962661|Experimental|Transendocardial Injections of MSCs|"Participants receive 15 injections of 0.2 ml Mesenchymal Stromal Cells (MSCs) at a total dose of 15 x 10^7 cells during one operative procedure.~Participants treated with routine heart failure medical therapy as prescribed by physician."
2941327|NCT02962661|Active Comparator|Standard of Care|Participants treated with routine heart failure medical therapy as prescribed by physician.
2941328|NCT02962648|Experimental|Iron isomaltoside|Administered IV
2941329|NCT02962635||Hemodialysis patients|"A total of 30 patients~- measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker"
2941330|NCT02962635||Peritoneal dialysis patients|"A total of 15 patients~- measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker"
2941331|NCT02962622|Experimental|Hispanic women living with HIV|High intensity interval training (HIIT) on normally active but physically untrained HIV+ Hispanic women, one with (n=15) and other without (n=15) neuro-cognitive impairment (HAND) on antiretroviral therapy (CART) receive 2 weeks, 6 sessions of 8 x 60 seconds cycling bouts eliciting approximately 80% of maximal heart rate with 60 second rest between bouts after which they will receive 4 week, 12 sessions of 10 x 60 seconds cycling bouts eliciting approximately 90% of maximal heart rate with 60 second rest between bouts.
2941332|NCT02962622|Experimental|Hispanic women living without HIV|High intensity interval training (HIIT) on a comparison group of 15 Hispanic women without HIV receive 2 weeks, 6 sessions of 8 x 60 seconds cycling bouts eliciting approximately 80% of maximal heart rate with 60 second rest between bouts after which they will receive 4 week, 12 sessions of 10 x 60 seconds cycling bouts eliciting approximately 90% of maximal heart rate with 60 second rest between bouts.
2941333|NCT02962609|Experimental|Semielevated Side-Lying Position-ESL|Feeding Position. In the ESL position, infant's head and trunk were elevated to an angle of 45-60° with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infants were held in side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and both the head and the neck were held at the same level by the researcher, whereas the chin was held in the flexion posture mildly facing the floor.
2941334|NCT02962609|Experimental|Semielevated Supine Position-ESU|Feeding Position. In the ESU position, the head and the trunk of the infant were elevated to an angle of 45-60° with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and the infant was laid in supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas the chin was held in the flexion posture mildly facing the floor.
2941335|NCT02962583|Experimental|Probiotic|Daily probiotic consumption
2941336|NCT02962583|Placebo Comparator|Placebo|Daily placebo consumption
2941337|NCT02962570|Experimental|Only Arm|"Two minutes: Intervention: Device: On Demand Oxygen Delivery 20 sec or 3 breaths, whatever comes first: Intervention: Device: Oxygen Flow Stopped~Two minutes intervention: Device: Traditional, Always-On, Oxygen Delivery 20 sec or 3 breaths, whatever comes first: Intervention: Device: Oxygen Flow Stopped~Repeat until the end of the surgical procedure"
2941339|NCT02962557|Experimental|Experimental|The experimental group will receive playback of recorded verbal prompts to breathe with an optional shoulder shake.
2941340|NCT02962544|Active Comparator|Visumax device for FS-SMILE group|(FS-SMILE )femtosecond small incision lenticule extraction procedure using Visumax laser device as a surgical intervention for correction of myopia and myopic astigmatism will be done for 30 eyes of patients with myopia or myopic astigmatism.
2941341|NCT02962544|Active Comparator|FS 200 device for FS-LASIK group|(FS-LASIK)femtosecond assisted LASIK procedure using Fs200 laser device as a surgical intervention for correction of myopia and myopic astigmatism will be done for 30 eyes of patients with myopia or myopic astigmatism.
2941342|NCT02962531|Experimental|Treatment A|A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fasted conditions
2941343|NCT02962531|Experimental|Treatment B|A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fed conditions
2941344|NCT02962531|Experimental|Treatment C|A single 1600 mg aqueous dispersion (20 mL) oral dose of IX-01 under fasted conditions.
2941345|NCT02962518|Active Comparator|A Standard Treatment|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months."
2941346|NCT02962518|Experimental|B Pressure Device|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and are additionally treated with a non-customized pressure device."
2941347|NCT02962492|Active Comparator|Dapagliflozin Arm:|dapagliflozin 10mg (oral tablet) and exenatide (5µg acutely)/Exenatide extended release (long term) placebo (subcutaneous injection)
2941348|NCT02962492|Active Comparator|Exenatide extended release Arm:|subcutaneous injection of Exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin placebo
2941349|NCT02962492|Placebo Comparator|Placebo Arm:|dapagliflozin placebo (oral tablet) and exenatide (5µg acutely)/Exenatide extended release (long term) placebo (subcutaneous injection)
2941350|NCT02962492|Active Comparator|Exenatide extended release & dapagliflozin Arm:|Exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin 10mg
2941351|NCT02962479||TNF blocker-naïve ankylosing spondylitis patients|
2941352|NCT02962479||TNF blocker-exposed ankylosing spondylitis patients|
2941353|NCT02962479||TNF blocker-naïve nrSpA patients|
2941354|NCT02962479||TNF blocker-exposed nrSpA patients|
2941355|NCT02962479||Healthy Participants|
2941356|NCT02962466|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo).
2941357|NCT02962466|No Intervention|D3 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 3 of embryo growth (cleavage stage embryo).
2941358|NCT02962466|No Intervention|D5 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 5 of embryo growth (blastocyst stage embryo).
2941359|NCT02962453|Experimental|Morning walk|Rehabilitation using end-effector type gait robot for 5days.
2941360|NCT02962453|Active Comparator|Ground Walker|Rehabilitation using walker for 5days.
2941361|NCT02962440|Experimental|Somapacitan|
2941362|NCT02962427|Experimental|Sphenopalatine Ganglion Block|Sphenopalatine Ganglion Block: The patient is placed in the supine position. Four cc of 2% viscous lidocaine is placed to the level of the sphenopalatine ganglion with a 20 gauge angiocatheter along sterile swabs which were placed carefully into the patients nostrils bilaterally and lateral to the middle turbinate. It will be documented that the patient has no pain or paresthesia during or after the procedure. The swabs are withdrawn after 30 minutes.
2941363|NCT02962427|Active Comparator|Epidural blood patch|Epidural Blood Patch: The patient is positioned in the sitting or lateral positon. Using aseptic technique, 20mL of autologous blood is drawn by a trained practitioner. The epidural placement is performed by a trained practitioner using aseptic technique and the vertebral space accessed is at or immediately below the original neuraxial placement. After entrance into the epidural space is confirmed with loss of resistance technique to either air or saline, 15-20 milliliters of sterile autologous venous blood is injected. After the procedure the patient rests supine for at least 1 hour. Patients are instructed to avoid heavy lifting, abdominal straining, or coughing for at least 48 hours.
2941364|NCT02962414|Experimental|everolimus|everolimus, 2mg dispersible tablets
2941365|NCT02962401|Experimental|Idelalisib and Obinutuzumab|"6 cycles of Idelalisib and Obinutuzumab~Cycle 1 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. (2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15~Cycle 2 - 6 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. day 1~Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment"
2941366|NCT02962388|Active Comparator|Reference therapy arm|Best Available Therapy (BAT) in second line, after hydroxyurea. BAT restricted to anagrelide or IFNα/ PegIFNα in the study, according to the investigator decision
2941367|NCT02962388|Experimental|Investigational therapy arm|"Ruxolitinib JAKAVI® Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing paradigm.~Maximum dose 25 mg BID."
2941368|NCT02962375|Experimental|Active Treatment|100% orange juice with orange pomace fiber
2941369|NCT02962375|Placebo Comparator|Control Treatment|100% orange juice
2941370|NCT02962336|Experimental|Test|Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide (40+10+25) mg Tablets
2941371|NCT02962336|Active Comparator|Reference|Tribenzor (40+10+25) mg Tablets of Daichi Sankyo Inc, USA
2941372|NCT02962323|Experimental|Test|Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets 40 mg
2941373|NCT02962323|Active Comparator|Reference|Crestor 40 mg of AstraZeneca Pharmaceuticals LP, USA
2941374|NCT02962310|Experimental|Test|Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets 40 mg
2941375|NCT02962310|Active Comparator|Reference|Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA
2941651|NCT02960503|Active Comparator|Treatment arm (azithromycin)|Treatment arm: azithromycin 500 mg three times a week for 6 months
2941376|NCT02962297|Experimental|treatment group|Vitamin E softgel,100mg,Tid,orally, 96 weeks. All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
2941377|NCT02962297|Placebo Comparator|placebo group|A similar appearing placebo softgel , Vitamin E -Placebo, Tid, orally, 96 weeks, All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
2941378|NCT02962284|Experimental|YONSA with Methylprednisolone|Aberaterone Acetate 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
2941379|NCT02962271||Psoriatic Arthritis|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
2941380|NCT02962271||Psoriasis|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
2941381|NCT02962258|Experimental|Test|Torrent's Olmesrtan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg
2941382|NCT02962258|Active Comparator|Reference|Tribenzor of Daichi Sankyo Inc., USA
2941383|NCT02962245|Active Comparator|berberine group|regular treatment and receive oral berberine 300mg three times daily untill recurrence in one year
2941384|NCT02962245|Placebo Comparator|regular treatment group|regular treatment untill recurrence in one year
2941385|NCT02962232|Experimental|LEGFLOW OTW group|in the LEGFLOW OTW group the subject will be treated by the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW)
2941386|NCT02962232|Active Comparator|AMPHIRION DEEP group|in the AMPHIRION DEEP group the subject will be treated by PTA catheter (AMPHIRION DEEP)
2941387|NCT02962219|Experimental|Intervention|A pre-operative personalised exercise programme (my-PEP).
2941388|NCT02962219|Other|Control|Standard care
2941389|NCT02962206|Active Comparator|Standard of care|Patients will undergo standard closed fracture reduction. The sedation type, reduction method, and immobilization method will be at the discretion of the treating physician. Point-of-care ultrasound will not be used.
2941390|NCT02962206|Experimental|Experimental Group|Patients will undergo standard closed fracture reduction with the addition of point-of-care ultrasound use to assess post-reduction dorsal angulation. The sedation type, reduction method, and immobilization method will be at the discretion of the treating physician.
2941391|NCT02962180|Experimental|single arm study|Dermabrasion with dermaroller of basal cell layer suspension obtained by soft trypsinisation in vitiligo lesion.
2941392|NCT02962167|Experimental|Locally Recurrent Medulloblastoma/ATRT|Patients must have local recurrent disease (defined as negative spine MRI and negative cytology within 21 days prior to study registration) and undergo resection of local recurrence as part of their standard of care. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, directly into the tumor bed during standard of care resection.
2941393|NCT02962167|Experimental|Disseminated Recurrent MB/ATRT|Patients must have disseminated recurrent medulloblastoma (MB) or ATRT (defined as multifocal disease, positive spine MRI including leptomeningeal disease and/or positive cytology within 21 days prior to study registration) and have adequate CSF flow based on spine MRI with no evidence of bulky disease or if bulky disease is present based on a CSF flow study per institutional guidelines. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, via lumbar puncture (modified measles virus lumbar puncture).
2941394|NCT02962154||Coronary Artery Disease (CAD)|"Patients with known coronary artery disease (CAD) as defined by prior PCI, CABG, prior MI, prior abnormal stress test, or invasive coronary angiography (ICA) and who are hemodynamically stable~They will undergo the following:~Radiation: Coronary CT Angiography Other: Mood Symptom Scale Other: Anxiety Symptom Scale Other: Chronic Stress Inventories Other: Psychosocial Function Questionnaires Other: General Health and quality of life questionnaires Other: Magnetic Resonance Imaging"
2941395|NCT02962154||Major Depressive Disorder|"Patients with a diagnosis of major depressive disorder and/or a diagnosis of bipolar 1 or bipolar 2 disorder~They will undergo the following:~Radiation: Coronary CT Angiography Other: Mood Symptom Scale Other: Anxiety Symptom Scale Other: Chronic Stress Inventories Other: Psychosocial Function Questionnaires Other: General Health and quality of life questionnaires Other: Magnetic Resonance Imaging"
2941396|NCT02962141|Experimental|APERTO OTW group|in the APERTO OTW group the subject will be treated with APERTO OTW balloon (Paclitaxel Releasing Peripheral Balloon Dilatation Catheter)
2941397|NCT02962141|Active Comparator|OHICHO II group|in the OHICHO II group the subject will be treated with OHICHO II balloon (Balloon Dilatation Catheter)
2941398|NCT02962128|Experimental|High Linoleic Acid (LA) Diet|European Americans (genotypes: TT, GT & GG) and African Americans (genotypes: GT & GG) at rs173537will be randomly assigned to a high LA diet (10% energy) based on a randomized block design with 5 strata defined by race and genotype combinations.
2941399|NCT02962128|Experimental|Low Linoleic Acid (LA) Diet|European Americans (genotypes: TT, GT & GG) and African Americans (genotypes: GT & GG) at rs173537will be randomly assigned to a low LA diet (2.5% energy) based on a randomized block design with 5 strata defined by race and genotype combinations.
2941400|NCT02962115|Experimental|Decision Aid Invitation|Electronic invitation to complete a web-based lung cancer screening decision aid
2941401|NCT02962102|Experimental|Calcifediol|Calcifediol 400mcg PO/NGT/OGT x 1, followed by 200mcg PO/NGT/OGT daily x 4
2941402|NCT02962102|Experimental|Calcitriol|Calcitriol 4mcg PO/NGT/OGT daily x 5 days
2941403|NCT02962102|Placebo Comparator|Placebo|Equal volume of medium chain triglyceride (MCT) oil daily x 5 days
2941404|NCT02962089|Placebo Comparator|Placebo|Isocaloric isonitrogenous placebo for 4 months (7g, twice daily)
2941405|NCT02962089|Active Comparator|Branched chain amino acids (BCAA)|BCAA mixture for 4 months (7g, twice daily)
2941440|NCT02961829|Experimental|ART Intensification + Auranofin Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks and the gold salt auranofin for 24 weeks.
2941441|NCT02961829|Experimental|ART Intensification + DC vaccine Group|Five patients will receive antiretroviral intensification with dolutegravir and for 48 weeks, and dendritic cell vaccine.
2941504|NCT02961400|Other|No text messages|No text messages will be sent in this condition to participants in either treatment condition (i.e., TranS-C or PE).
2941406|NCT02962063|Experimental|Esophageal Cancer|Pts will get a baseline PET/CT scan prior to getting mFOLFOX6 chemo (bolus 5-fluorouracil or -FU 400 mg/m2, leucovorin 400 mg/m2, oxaliplatin 70-85 mg/m2 & infusional 5-FU 1,200 mg/m2/day ×46 hours) q14 days ×2, followed by repeat PET scan. 2 weeks after the 2nd dose of mFOLFOX6, pts get 1 dose of durvalumab 1,500 mg. 2 weeks later, all pts will start radiation (1.8 Gy/fraction ×28 fractions Monday to Friday total dose of 50.4 Gy). PET responders get concurrent chemo with oxaliplatin 70-85 mg/m2 q14 days ×3 doses with either infusional 5-FU 300 mg/m2/day ×96 hours or capecitabine 825 mg/m2 BID Monday to Friday thru the radiation period. PET non-responders get concurrent carboplatin AUC 2/paclitaxel 50 mg/m2 weekly ×5 with concurrent. All pts get a 2nd dose of durvalumab 1,500 mg q28 days after 1st dose. Pts undergo surgical resection 6-8 weeks after the end of chemoradiation. Adjuvant setting, pts who have undergone R0 resections will get durvalumab 1,500 mg every 4 weeks ×6 doses.
2941407|NCT02962050||ALS Bulbar Onset|Participants enrolled will have the following tests: Videofluoroscopic Swallowing Study (with swallowing analyses performed using the validated scales of DIGEST, Penetration Aspiration Scale, and Normalized Residue Ratio Scale) ; High Resolution Manometry, Voluntary Peak Cough Flow Testing, lingual strength and endurance trials using the Iowa Oral Performance Instrument, Lingual Electrical Impedance Myography of the tongue, reflexive cough testing using a capsaicin challenge and Pulmonary Function Testing. In addition, the patient will complete the following surveys: Eating Assessment Tool-10 (EAT-10), Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), and the The Center for Neurologic Study Bulbar Function Scale (CNS-BFS).
2941408|NCT02962050||ALS Limb Onset|Participants enrolled will have the following tests: Videofluoroscopic Swallowing Study (with swallowing analyses performed using the validated scales of DIGEST, Penetration Aspiration Scale, and Normalized Residue Ratio Scale) ; High Resolution Manometry, Voluntary Peak Cough Flow Testing, lingual strength and endurance trials using the Iowa Oral Performance Instrument, Lingual Electrical Impedance Myography of the tongue, reflexive cough testing using a capsaicin challenge and Pulmonary Function Testing. In addition, the patient will complete the following surveys: Eating Assessment Tool-10 (EAT-10), Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), and the The Center for Neurologic Study Bulbar Function Scale (CNS-BFS).
2941409|NCT02962037|No Intervention|Base line|the subject will take the tests in the morning and the evening
2941410|NCT02962037|Experimental|After treatment|the subject will take the tests in the morning and the evening
2941411|NCT02962024|Active Comparator|morphine sulphate|10mg locally morphine hydrochloride once betwwen serratus muscle and latissmus dorsi muscle
2941412|NCT02962024|Placebo Comparator|bupivacaine hydrochloride|0.25%locally bupivacaine hydrochloride once
2941413|NCT02962011|Experimental|Knotless barbed suture|
2941414|NCT02962011|Active Comparator|polyglactin 910|Vicryl
2941415|NCT02961998|Experimental|Celecoxib group|Patients were treated with sorafenib taking capsules celecoxib (Celebrex) at the same time, 200mg/day, last 6 months
2941416|NCT02961998|Active Comparator|Control group|Patients take sorafenib only.
2941417|NCT02961972|Placebo Comparator|control group|Oral ingestion of placebo pills (maltodextrin) during three weeks
2941418|NCT02961972|Experimental|creatine supplementation|Oral supplementation with 5 g of monohydrate and micronized creatine during three weeks
2941419|NCT02961959|Experimental|Surgery|Arthrodesis of SI-joint/s, physiotherapy
2941420|NCT02961959|Active Comparator|Non-surgery|Non-surgery, physiotherapy
2941421|NCT02961946|Active Comparator|Sublingual Nitroglycerin spray|Sublingual Nitroglycerin spray of 0.8 mg
2941422|NCT02961946|Active Comparator|Sublingual Nitroglycerin tablet|Sublingual Nitroglycerin tablet of 0.8 mg
2941423|NCT02961946|Active Comparator|Nitroglycerin skin patch|Nitroglycerin skin patch of 0.8 mg/h
2941424|NCT02961933|Experimental|Apneic oxygenation|
2941425|NCT02961933|Active Comparator|non-apneic oxygenation|
2941426|NCT02961920||IE ratio 1:1|Set an I(inspiration):E(expiration) ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
2941427|NCT02961920||IE ratio 1:2|Set an I(inspiration):E(expiration) ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
2941428|NCT02961907|No Intervention|Control|"The usual routine course includes :~a clinico-biological evaluation of infertility causes~a laboratory staff and decision of therapeutic strategy and decision of a therapeutic strategy~collection of blood and sperm samples"
2941429|NCT02961907|Experimental|PEPCI group|In the PEPCI group, the standardized assessment of the periconceptional profile is used to adapt the additional standardized intervention.
2941430|NCT02961894|Experimental|Revolution Treatment Arm|This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.
2941431|NCT02961881|Experimental|blinatumomab|
2941432|NCT02961868|Experimental|Prospective cohort|3 years follow-up
2941433|NCT02961855|Experimental|Clife1 gel (lidocaine plus diclofenac)|Clife1 gel (lidocaine plus diclofenac) Topical gel containing lidocaine (2%) plus diclofenac (0.5%) (15 g in total) Application of the gel bid from first day post-surgery to day 3 and once daily from day 4 to day 6
2941434|NCT02961855|Active Comparator|Clife2 gel (lidocaine)|Clife2 gel (lidocaine) Topical gel containing lidocaine (2%) (15 g in total) Application of the gel bid from first day post-surgery to day 3 and once daily from day 4 to day 6
2941435|NCT02961842|Experimental|Combination|500 mL colloid preload and 500 mL crystalloid coload. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine will be administered.
2941436|NCT02961842|Active Comparator|Coload|1000 mL crystalloid coload. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine will be administered.
2941437|NCT02961829|No Intervention|Antiretroviral Treated (ART) Group|Five patients will receive no further intervention this group (control group)
2941438|NCT02961829|Experimental|ART Intensification Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks
2941439|NCT02961829|Experimental|ART Intensification + Nicotinamide Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks.
2941442|NCT02961829|Experimental|Multi Interventional Group|Five patients will receive antiretroviral intensification with dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks, and gold salt for 24 weeks and dendritic cell vaccine.
2941443|NCT02961816|Experimental|Cohort A: Diffuse Large B-Cell Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.~Panobinostat daily from Day -9 to -2.~Gemcitabine administered on Days -8 and -3.~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.~Melphalan on Days -3 and -2.~Rituximab on Day -9 for participants with CD20+ tumors.~Dexamethasone twice a day from Day -8 AM to Day -2 PM.~Caphosol oral rinses 30 mL four times a day used from Day -8.~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.~Pyridoxine three times a day from Day -1.~Stem cells administered by vein on Day 0.~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
2941444|NCT02961816|Experimental|Cohort B: Hodgkin's Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.~Panobinostat daily from Day -9 to -2.~Gemcitabine administered on Days -8 and -3.~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.~Melphalan on Days -3 and -2.~Rituximab on Day -9 for participants with CD20+ tumors.~Dexamethasone twice a day from Day -8 AM to Day -2 PM.~Caphosol oral rinses 30 mL four times a day used from Day -8.~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.~Pyridoxine three times a day from Day -1.~Stem cells administered by vein on Day 0.~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
2941445|NCT02961816|Experimental|Cohort C: T-Cell Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.~Panobinostat daily from Day -9 to -2.~Gemcitabine administered on Days -8 and -3.~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.~Melphalan on Days -3 and -2.~Rituximab on Day -9 for participants with CD20+ tumors.~Dexamethasone twice a day from Day -8 AM to Day -2 PM.~Caphosol oral rinses 30 mL four times a day used from Day -8.~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.~Pyridoxine three times a day from Day -1.~Stem cells administered by vein on Day 0.~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
2941446|NCT02961803|Experimental|MD1003|MD1003 100mg capsules, 1 capsule tid for 24 months
2941447|NCT02961803|Placebo Comparator|Placebo|Placebo capsule, 1 capsule tid for 12 months, then switch to MD1003 100mg capsule, 1 capsule tid for 12 months
2941448|NCT02961790|Experimental|Group I (low-dose oxybutynin chloride)|Patients receive lower dose oxybutynin chloride PO BID on days 8-49 in the absence of unacceptable toxicity.
2941449|NCT02961790|Placebo Comparator|Group II (low-dose placebo)|Patients receive lower dose placebo PO BID on days 8-49 in the absence of unacceptable toxicity.
2941450|NCT02961790|Experimental|Group III (high-dose oxybutynin chloride)|Patients receive lower dose oxybutynin chloride PO BID on days 8-14 and higher dose oxybutynin chloride on days 15-49 in the absence of unacceptable toxicity.
2941451|NCT02961790|Placebo Comparator|Group IV (high-dose placebo)|Patients receive lower dose placebo PO BID on days 8-14 and higher dose placebo on days 15-49 in the absence of unacceptable toxicity.
2941452|NCT02961777||Time 1|retrospective evaluation of patient record. no intervention
2941453|NCT02961777||Time 2|retrospective evaluation of patient record. no intervention
2941454|NCT02961777||Time 3|retrospective evaluation of patient record. no intervention
2941455|NCT02961764|Active Comparator|Usual Care|Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
2941456|NCT02961764|Active Comparator|New Critical Pathway|The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
2941457|NCT02961751|Other|Ciprofloxacin|One dose of directly-observed ciprofloxacin 500 mg administered orally. N=381
2941458|NCT02961738|Active Comparator|Full-CAT|Participants in this arm receive an intervention of a full 8-session course of cognitive analytic therapy (CAT). This means that they are assessed then then receive a narrative reformulation, that then leads onto a sequential diagrammatic reformulation and then the change methods and completion.
2941459|NCT02961738|Experimental|An 8-session CAT without narrative reformulation (CAT-NR)|Participants in this arm receive an intervention of a full 8-session course of cognitive analytic therapy (as described above), but crucially with the narrative reformulation (NR) aspect removed. All other aspects of treatment remain the same.
2941460|NCT02961725|Experimental|UCMSC treatment|UCMSC: umbilical cord mesenchymal stem cells
2941461|NCT02961712|Experimental|cell therapy|NK cells and amniotic epithelial cells
2941462|NCT02961699|Experimental|Transpose ® RT System|Adipose-derived stem cells (also known as stromal vascular fraction or SVF) will be injected subcutaneously around the rim of the wound bed following standard would debridement. The standard collagen dressing material will also be saturated with SVF after placement within the would itself. Normal (standard) dressing of wound will be placed over wound.
2941463|NCT02961699|Active Comparator|debridement/dressing of wound|Wound will be debrided and collagen dressing placed within wound bed as per standard of care. Standard dressing will cover wound. No adipose-derived stem cells (SVF) will be applied to control subject wounds.
2941464|NCT02961686||Patients with prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach that comprise exclusive radiotherapy, psychological and andrologic evaluation.
2941465|NCT02961673|Experimental|HU-014 Inj(Phase 1 and 2)|HU-014 Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
2941466|NCT02961673|Active Comparator|Botox Inj(Phase 2)|Botox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
2941467|NCT02961660|Experimental|Cohort 1 (Severe Renal Impairment): Odalasvir|Participants will receive single oral dose of odalasvir 25 milligram (mg) under fed conditions (standard breakfast) on Day 1.
2941468|NCT02961660|Experimental|Cohort 2 (Normal Renal Function): Odalasvir|Participants will receive single oral dose of odalasvir 25 milligram (mg) under fed conditions (standard breakfast) on Day 1.
2941469|NCT02961647||Asymptomatic patients|Patients with asymptomatic severe mitral valve regurgitation not undergoing surgical repair of the valve.
2941470|NCT02961647||Symptomatic patients|Patients with symptomatic severe mitral valve regurgitation undergoing surgical repair of the valve.
2941471|NCT02961634|Experimental|Nailner 2 in 1 + Ciclopirox 8%|"Patients should apply Nailner 2 in 1 daily in the affected nail 2X a day, morning and night for 30 days. After 30 days passed to apply only 1x daily. No need to sand the nail before the application and the product should be applied on the entire nail, including the sides and the area affected by ringworm. Avoiding wett the nail after application and expose the nail.~They should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun."
2941472|NCT02961634|Active Comparator|Ciclopirox 8%|Patients should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun.
2941473|NCT02961621|Experimental|Stress Reduction Training Group|This group will complete a 7-week online mindfulness-based resiliency training: Stress Reduction Training for 9-1-1 Telecommunicators
2941474|NCT02961621|No Intervention|Control Group|This group is a wait-list control and will be offered the training after all data collection has been completed.
2941475|NCT02961608|Experimental|study group|
2941476|NCT02961595|No Intervention|Inactivated Polio Vaccine (IPV)|The control group received inactivated poliovirus vaccine (IPV) at the age of 6 and 12 months according to the national immunization protocol in Finland at that time.
2941477|NCT02961595|Active Comparator|Oral Polio Vaccine (OPV)|Intervention group were given doses of oral polio vaccine OPV (Polio Sabin®) at the age of 2, 3, 6 and 12 months.
2941478|NCT02961582|Experimental|Sacral Neuromodulation|
2941479|NCT02961582|Other|Personalized Conservative Treatment|
2941480|NCT02961569|Other|One open-label arm|Patients suspected of pulmonary TB will have sputum collection for acid fast bacilli by the classical strategy (Day 1, Day 2 and Day 3) and the intervention sputum collection for acid fast bacilli by the same day strategy (Hour 1, 2 and 3)
2941481|NCT02961556|Experimental|AJG555|After 2 weeks of the screening period, participants will be administered AJG555 starting on the day of the formal enrollment and continuing for 12 weeks.
2941482|NCT02961543|Experimental|Group 1.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isokinetic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
2941483|NCT02961543|Active Comparator|Group 2.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isotonic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
2941484|NCT02961530|Experimental|Group 1.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isokinetic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
2941485|NCT02961530|Active Comparator|Group 2.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isotonic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
2941486|NCT02961517||Patients|All patients with type 2 diabetes and/or cardiovascular disease who will complete the questionnaire
2941487|NCT02961504|Experimental|HLCM051 (MultiStem)|single dose of 1.2 billion HLCM051 cells
2941488|NCT02961504|Placebo Comparator|Placebo|a single dose of placebo
2941489|NCT02961478|Experimental|Iohexol plasmatic clearance|
2941490|NCT02961465||Sacral Neuromodulation (SNM)|
2941491|NCT02961452||Peanut allergic children|
2941492|NCT02961439||Patient Participants|Patient participants are adult patients in the Epworth Richmond Intensive care Unit. They are not the focus of the research but rather represent a general population of ICU patients that require echocardiography in the management of their critical illness. They will be a mix of medical and surgical patients some of whom are receiving mechanical ventilation, have movement restrictions, high BMI or other impediments to performing echocardiography.
2941493|NCT02961439||Registrar Participants|Registrar participants are doctors in training in ICU. They have completed a formal echo teaching program and completed a logbook of 30 supervised scans. They are the focus of the research and are being assessed on their diagnostic accuracy with echocardiography.
2941494|NCT02961426|Other|non cirrhotic patient|12 weeks sofosbuvir ravidasvir
2941495|NCT02961426|Other|compensated cirrhotic patient|24 weeks sofosbuvir ravidasvir
2941496|NCT02961413||cohort 1|Compound glycyrrhizin tablets / injection
2941497|NCT02961413||cohort 2|Isoglycyrrhizinate magnesium injection / diammonium glycyrrhizinate enteric-coated capsules
2941498|NCT02961413||cohort 3|Bicyclol
2941499|NCT02961413||cohort 4|Silibinin capsules
2941500|NCT02961413||cohort 5|Ursodeoxycholic acid capsules
2941501|NCT02961413||cohort 6|N- acetylcysteine
2941502|NCT02961400|Experimental|PUSH text messages|Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE).
2941503|NCT02961400|Experimental|PULL text messages|Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE). Text messages will request a response from the participant.
2941507|NCT02961374|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO once weekly. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
2941508|NCT02961361|Experimental|Group Control|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
2941509|NCT02961361|Experimental|Group Dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
2941510|NCT02961348|Active Comparator|Early start of NOAC|Day 1 to day 4 after ischemic stroke onset
2941511|NCT02961348|Active Comparator|Late start of NOAC|Day 5 to day 10 after ischemic stroke onset
2941512|NCT02961335|Experimental|Patient who need to undergo bronchoscopy|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
2941513|NCT02961322|Experimental|lobo isthmectomy|
2941514|NCT02961309|Experimental|Active THC|5.6% THC via smoked marijuana cigarette
2941515|NCT02961309|Experimental|Placebo|Placebo THC via smoked cigarette
2941516|NCT02961283|Experimental|ASN003 Dose Escalation|Multiple ascending doses of ASN003 will be administered to determine the maximum tolerated dose (MTD).
2941517|NCT02961283|Experimental|ASN003 MTD - BRAFv600 melanoma|ASN003 administered at the MTD in subjects with BRAF v600 mutated metastatic melanoma
2941518|NCT02961283|Experimental|ASN003 MTD - BRAFv600 colon or lung cancer|ASN003 administered at the MTD in subjects with BRAFv600 mutated metastatic colorectal or non-small cell lung cancer.
2941519|NCT02961283|Experimental|ASN003 MTD - PIK3 pathway mutated cancers|ASN003 administered at the MTD in subjects who have mutations in PI3 kinase or loss of PTEN.
2941520|NCT02961270|Experimental|icotinib|patients will be administered study drug (icotinib) until disease progression or unacceptable toxicity
2941521|NCT02961257|Experimental|Arm A|"Cabazitaxel 25 mg/m² intravenously over 1 hour on Day 1of a 3-week cycle, plus prednisone (or prednisolone) 10 mg orally given daily for a maximum of 10 cycles (ie 30 weeks of treatment).~Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every cycle of cabazitaxel."
2941522|NCT02961257|Experimental|Arm B|Cabazitaxel 16 mg/m2 on Day 1 and Day 15 of a 4-week cycle plus prednisone (or prednisolone) 10 mg per day up to 10 cycles (ie 40 weeks of treatment). Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every cycle of cabazitaxel.
2941523|NCT02961244|No Intervention|Control Group|Perioperative management and warming was not performed according to a standard normothermia protocol, with our clinic's traditional methods except prewarming.
2941524|NCT02961244|Active Comparator|Intervention Group|Perioperative management and warming was performed according to a standard normothermia protocol with active prewarming.
2941525|NCT02961231|Active Comparator|PCV 2p+1|PCV 2p+1 schedule: WHO recommended 2 primary at 2, 4 months and a booster dose at 12 month
2941526|NCT02961231|Active Comparator|PCV 3p+0|PCV 3p+0 schedule: WHO recommended 3 primary doses at 2, 3 and 4 months
2941527|NCT02961231|Experimental|PCV 1p+1|PCV 1p+1 schedule: one primary dose at 2 month and a booster at 12 month
2941528|NCT02961231|Experimental|PCV 0p+1|PCV 0p+1 schedule: no primary dose, only a booster at 12 month
2941529|NCT02961218|Placebo Comparator|Placebo|Matching placebo administered subcutaneously
2941530|NCT02961218|Experimental|Ilaris, Canakinumab|Randomized drug administration for 24 weeks duration (6 drug administrations each 28 days apart) followed by an additional 24-week open label phase (6 drug administrations each 28 days apart).
2941531|NCT02961205|Experimental|Oral Nutritional Supplementation|Patients randomized to the interventional arm will receive Ensure Enlive (Abbott Nutrition), a high energy, high protein oral supplement.
2941532|NCT02961205|No Intervention|Standard of care|Patients randomized to the control arm will continue their usual diet.
2941533|NCT02961192|No Intervention|Control|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts.
2941534|NCT02961192|Experimental|Supportive|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In addition to playing the game, participants will identify a family member or friend to receive updates and support them in their progress.
2941535|NCT02961192|Experimental|Competitive|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In this arm, participants will be placed into competitive groups with one or two other participants to play the game.
2941536|NCT02961192|Experimental|Collaborative|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In this arm, participants will be placed into collaborative groups with one or two other participants to play the game.
2941537|NCT02961179|Experimental|Increased dairy product|Subjects will be asked to consume a total of 3 to 5 servings per day.They will be instructed on options and variations for incorporating the dairy foods into their routine dietary pattern.
2941538|NCT02961179|Placebo Comparator|Dietary counselling|Subjects will review the standard dietary recommendation(http://www.diabetes.ca/diabetes-and-you/nutrition/meal-planning-guide/) by a registered dietitian.
2941539|NCT02961166||IgM enriched Immunoglobulins|ARDS patients with septic shock requiring ECMO therapy were treated for 3 days by IgM-enriched Immunoglobulin
2941540|NCT02961166||Control|ARDS patients with septic shock requiring ECMO therapy were NOT treated by IgM-enriched Immunoglobulin
2941541|NCT02961140|Experimental|Cardiac Output Maximization|maximize stroke volume, and maintain cardiac index and stroke volume variation during the whole operation
2941542|NCT02961140|Active Comparator|Cardiac Output Normalization|keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation
2941543|NCT02961127||group 1|no drugs were used in our study
2941544|NCT02961127||group 2|
2941545|NCT02961114|Experimental|Microcannula Harvest Adipose|Acquisition of AD-tSVF via closed syringe microcannula harvest from subdermal fat deposits
2941652|NCT02960503|Placebo Comparator|Placebo arm|Control arm: placebo three times a week for 6 months
2941546|NCT02961114|Experimental|Centricyte 1000|Autologous AD-tSVF via enzymatic isolation/concentration via Centricyte 1000 closed system to create AD-cSVF
2941547|NCT02961114|Experimental|IV Sterile Normal Saline|Re-suspension of AD-cSVF pellet in Normal Saline for deployment via IV
2941548|NCT02961101|Experimental|Anti-PD-1 antibody+decitabine|Decitabine was administrated at 10mg/d on day1 to 5, followed by Anti-PD-1 antibody 1-3mg/kg on day8 IV Q3 weeks until progression.
2941549|NCT02961075|Experimental|Cricothyroid|local surface anesthesia by Cricothyroid
2941550|NCT02961075|Experimental|Laryngeal tube|local surface anesthesia by Laryngeal tube
2941551|NCT02961062|Experimental|Treatment Sequence 1|
2941552|NCT02961062|Placebo Comparator|Treatment Sequence 2|
2941553|NCT02961049|Active Comparator|Retraction and total-etch|Gingival displacement with a gingival cord (#0, #00 or #000) prior to the restoration. Application of total-etch adhesive system: enamel and dentin etched with 35% phosphoric acid, wash, dry, two layers of primer/bond application with a brush and photoactivated for 20 seconds.
2941554|NCT02961049|Active Comparator|No retraction and total-etch|Application of total-etch adhesive system: enamel and dentin etched with 35% phosphoric acid, wash, dry, two layers of primer/bond application with a brush and photoactivated for 20 seconds.
2941555|NCT02961049|Active Comparator|Retraction and self-conditioning|Gingival displacement with a gingival cord (#0, #00 or #000) prior to the restoration. Application of self-conditioning adhesive system: selective enamel etched with 35% phosphoric acid, wash, dry, one layer of acid/pirmer on enamel and dentin with a brush, one layer of bond with a brush and photoactivated for 20 seconds.
2941556|NCT02961049|Active Comparator|No retraction and self-conditioning|Application of self-conditioning adhesive system: selective enamel etched with 35% phosphoric acid, wash, dry, one layer of acid/pirmer on enamel and dentin with a brush, one layer of bond with a brush and photoactivated for 20 seconds.
2941557|NCT02961036|Experimental|Group 1 Information|Group 1 Information about the prize draw incentive for 100% of an Amazon gift (or currency equivalent) in the invitation letter.
2941558|NCT02961036|Active Comparator|Group 2 Information|Group 2 Information about the prize draw incentive for 75% of an Amazon gift (or currency equivalent) in the invitation letter.
2941559|NCT02961036|Active Comparator|Group 3 Information|Group 3 Information about the prize draw incentive for 50% of an Amazon gift (or currency equivalent) in the invitation letter.
2941560|NCT02961036|Active Comparator|Group 4 Information|Group 4 Information about the prize draw incentive for 25% of an Amazon gift (or currency equivalent) in the invitation letter.
2941561|NCT02961036|Active Comparator|Group 5 No Information|Group 5 No Information incentive for an Amazon gift certificate (or currency equivalent) in the invitation letter.
2941562|NCT02961036|Experimental|Group A reminder|One survey reminder at 14 days
2941563|NCT02961036|Active Comparator|Group B reminders|Two survey reminders 14 days and 28 days
2941564|NCT02961023|Active Comparator|Training|15 patients are randomised to receive 15 weeks exercise therapy as per study protocol at point of study entry.
2941565|NCT02961023|Other|Control|15 patients are randomised to receive 15 weeks of standard care, acting as a control arm, followed by 15 weeks of exercise therapy.
2941566|NCT02961010|Experimental|Intervention Group|The intervention group will receive the Keeping Safe programme between 2016 and 2018. This comprises a blended package of continuing professional development training and support (plus resource materials) for teachers and school staff to enable them teach sensitive preventative education concepts through the formal statutory Personal Development curriculum, and all other informal opportunities that present in the daily life of the school. Following randomisation, intervention schools will receive the package of training and support across a 3 month period and will then implement/teach in their school across 2 school years. The intervention group will collect outcome data for the evaluation between March 2016 and June 2018.
2941567|NCT02961010|No Intervention|Wait-list Control Group|The Wait List Control group will continue with standard practice of teaching the statutory Personal Development curriculum between 2016 and 2018. They will not receive the Keeping Safe intervention until Sept 2018 following completion of the evaluation. The Waitlist control intervention group will collect outcome data for the evaluation between March 2016 and June 2018.
2941568|NCT02960997|Experimental|Treatment|Sirolimus, 2% topical ointment will be used during randomization
2941569|NCT02960997|Placebo Comparator|Vehicle|A placebo topical ointment will be used during randomization.
2941570|NCT02960984|Experimental|Neurorehabilitation|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training on an ergometer and 30' of task-oriented training focused on uppper limb rehabilitation.
2941571|NCT02960984|No Intervention|Baseline|No intervention is planned
2941572|NCT02960945|Experimental|CTP-543|Tablet, single oral dose
2941573|NCT02960945|Active Comparator|Jakafi|Tablet, single oral dose
2941574|NCT02960932|Experimental|hemiplegic cerebral child|Ultrasound scanner used to the SSI technical reproducibility.
2941575|NCT02960906|Experimental|ccRCC molecular subgroup 1: 1A|ccRCC molecular subgroup 1 -> randomisation: subjects with ccRCC1 treated with nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
2941576|NCT02960906|Experimental|ccRCC molecular subgroup 1: 1B|ccRCC molecular subgroup 1 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
2941577|NCT02960906|Experimental|ccRCC molecular subgroup 4: 4A|ccRCC molecular subgroup 4 -> randomisation: subjects with ccRCC1 treated with nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
2941578|NCT02960906|Experimental|ccRCC molecular subgroup 4: 4B|ccRCC molecular subgroup 4 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
2941579|NCT02960906|Experimental|ccRCC molecular subgroup 2: 2C|ccRCC molecular subgroup 2 -> randomisation: TKI (sunitinib 50mg daily or Pazopanib 800mg daily) according to investigator's choice until disease progression, unacceptable toxicity or other reasons specified in the protocol.
2941580|NCT02960906|Experimental|ccRCC molecular subgroup 2: 2B|ccRCC molecular subgroup 2 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
2941581|NCT02960906|Experimental|ccRCC molecular subgroup 3: 3B|ccRCC molecular subgroup 3 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
2941582|NCT02960906|Experimental|ccRCC molecular subgroup 3: 3C|ccRCC molecular subgroup 3 -> randomisation: TKI (sunitinib 50mg daily or Pazopanib 800mg daily) according to investigator's choice until disease progression, unacceptable toxicity or other reasons specified in the protocol.
2941583|NCT02960893|Experimental|BHV-4157|Participants orally receive once daily (QD) dose of BHV-4157 140 milligram (mg) provided as a loose filled capsule in the morning, without regard to meals for 8 weeks. Participants who do not tolerate their treatment switch to night time dosing if there is reason to believe that may help tolerability. In addition, the investigator may permit up to one week of every other day dosing prior to re-instituting daily dosing.
2941584|NCT02960893|Placebo Comparator|Placebo Comparator|Participants orally receive QD dose of BHV-4157 placebo-matching capsules provided as a loose filled capsule in the morning, without regard to meals for 8 weeks. Participants who do not tolerate their treatment switch to night time dosing if there is reason to believe that may help tolerability. In addition, the investigator may permit up to one week of every other day dosing prior to re-instituting daily dosing.
2941585|NCT02960880||Rivaroxaban|NVAF patients who were newly initiated on Rivaroxaban for stroke prevention
2941586|NCT02960880||Phenprocoumon|NVAF patients who were newly initiated on Phenprocoumon for stroke prevention
2941587|NCT02960854|Experimental|Nivolumab 1|Dose 1
2941588|NCT02960854|Experimental|Nivolumab 2|Dose 2
2941589|NCT02960841|Experimental|Intracavitary Manual Lymphatic Drainage|Intracavitary Manual Lymphatic Drainage technique.
2941590|NCT02960841|Active Comparator|Conventional treatment|Conventional treatment active comparator
2941591|NCT02960828|Experimental|"Intervention-Device:_Laser"|"Subthreshold focal photocoagulation~Intravitreal Anti-vascular endothelial growth factor (Anti-VEGF) injection"
2941592|NCT02960828|No Intervention|Control|Contralateral eye
2941593|NCT02960815|Active Comparator|Intramuscular vaccine|The control intervention consists in the administration of the standard intramuscular influenza vaccine (Mutagrip®), containing 15 μg of each of the three viral strains without imiquimod.
2941594|NCT02960815|Experimental|Imiquimod and intradermal vaccine|In the imiquimod and intradermal vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intradermal influenza vaccine preparations containing 15 μg of each of the three viral strains (Intanza®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.
2941595|NCT02960815|Experimental|Imiquimod and intramuscular vaccine|In the imiquimod and intramuscular vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intramuscular influenza vaccine preparations containing 15 μg of each of the three viral strains (Mutagrip®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.
2941596|NCT02960802|Active Comparator|kidney transplant patient|kidney transplantation is intervention
2941597|NCT02960802|No Intervention|healthy control|no intervention
2941598|NCT02960789|Experimental|Dehydrated Children|"Children between the ages of 2 to 18 years of age presenting to the Emergency Department at Children's Hospital Boston with complaints such as Dehydration, Gastroenteritis, Vomiting, and or Intolerance of POs be approached by study personnel for possible participation in the study.~Interventions:~Undertake and record a formalized clinical assessment of hydration status~Take a measurement of body weight on calibrated scales~RF wristband hydration status measurement~Measure capillary refill time with manual stopwatch~CRT device hydration status measurement"
2941599|NCT02960776|No Intervention|Habitual Sleep (HS)|Participants will be asked to follow a fixed bedtime routine based on the participant's regular bed- and wake-times during the habitual sleep (HS) phase.
2941600|NCT02960776|Experimental|Sleep Restriction (SR)|Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time during the sleep restriction (SR) phase.
2941601|NCT02960763|Experimental|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets), titrated from 2-15 mg daily based on symptom severity and side effects.
2941602|NCT02960763|Experimental|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, titrated from 150-300 mg daily based on symptom severity and side effects.
2941603|NCT02960763|Experimental|Switch to Bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended, titrated from 150-300 mg daily based on symptom severity and side effects.
2941604|NCT02960763|Experimental|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
2941605|NCT02960763|Experimental|Switch to Nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml.
2941606|NCT02960750|Experimental|Intervention group|Had access to the W@WS website program during 19 weeks.
2941607|NCT02960750|Active Comparator|Active comparison group|Maintained habitual behavior.
2941608|NCT02960737|Experimental|Intervention group|Intensive training with oral screen (intervention group) and traditional compensatory swallowing training under 3 months with start 6 (±2) weeks after stroke onset.
2941609|NCT02960737|No Intervention|Control group|Traditional compensatory swallowing training under 3 months with start 6 (±2) weeks after stroke onset.
2941650|NCT02960529||intraabdominal high ligation of hernia|the 150 patients were subjected trans-umbilical single-port laparoscopic intraabdominal approach repair for inguinal hernia
2941678|NCT02960347|Experimental|Active tDCS|open label active tDCS treatment
2941610|NCT02960724|Experimental|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before surgery and compared with the histological findings to evaluate uPAR PET/CT in staging of oral cancer and oropharyngeal cancer.
2941611|NCT02960711|Experimental|METFORMIN (1700MG/DAY) + LIFESTYLE|METFORMIN: 2 tablets per day, one at breakfast (or lunch) and one at dinner, of either metformin (two 850 mg tablets/day) + participation in the life-style intervention activities
2941612|NCT02960711|Placebo Comparator|PLACEBO+ LIFESTYLE|Placebo: (two identical tablets) according to the blind assignment + participation in the life-style intervention activities
2941613|NCT02960711|Experimental|METFORMIN (1700 mg/day) alone|METFORMIN: 2 tablets per day, one at breakfast (or lunch) and one at dinner, of either metformin (two 850 mg tablets/day)
2941614|NCT02960711|Placebo Comparator|PLACEBO alone|Placebo: (two identical tablets) according to the blind assignment
2941615|NCT02960698|Active Comparator|TREATED PATIENT WITH TOURETTE SYNDROME|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 40 patients
2941616|NCT02960698|Active Comparator|UNTREATED PATIENT WITH TOURETTE SYNDROME|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 40 patients
2941617|NCT02960698|Placebo Comparator|Healthy volunteers|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 80 subjects
2941618|NCT02960659|Active Comparator|2|Metformin and Liraglutide vs. Metformin Alone
2941619|NCT02960646|Experimental|Chemotherapy + Total Body Irradiation (TBI) + T Cell Infusion|"Participant's physician decides if they will receive either a high dose or low dose chemotherapy regimen. High-dose regimen includes a higher dose of melphalan than the reduced-intensity regimen.~CD20 positive lymphoma patients may receive Rituximab 375 mg/m2 by vein on Days -13, -6, +1, and +8.~Melphalan 100 mg/m2 or 140 mg/m2 by vein for one dose only on Day -6. Fludarabine 40 mg/m2 by vein daily for four doses on Days -6 to -3. Total body irradiation (TBI) at a dose of 200 cGy administered on Day -2. Modified (CD45RA depleted) PB Stem Cell Infusion on Day 0. Cyclophosphamide 50 mg/kg/day by vein on Days +3 and +4. G-CSF 5 mcg/kg/day started on Day +7."
2941620|NCT02960633|Active Comparator|THA with Collar|THA with Collar
2941621|NCT02960633|Active Comparator|THA without Collar|THA without Collar
2941622|NCT02960607|Experimental|Icotinib|250mg, tid until disease progression or unacceptable toxicities occurred
2941623|NCT02960594|Experimental|Arm 1|2 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2941624|NCT02960594|Experimental|Arm 2|8 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2941625|NCT02960594|Experimental|Arm 3|2 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2941626|NCT02960594|Experimental|Arm 4|2 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2941627|NCT02960594|Experimental|Arm 5|8 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2941628|NCT02960594|Experimental|Arm 6|8 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2941629|NCT02960594|Experimental|Arm 7|2 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2941630|NCT02960594|Experimental|Arm 8|8 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2941631|NCT02960594|Experimental|Arm 9|8 mg INO-1401 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2941632|NCT02960594|Experimental|Arm 10|8 mg INO-1401 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2941633|NCT02960581|Experimental|Group 1|HIV-uninfected participants
2941634|NCT02960581|Experimental|Group 2|HIV-uninfected participants
2941635|NCT02960581|Experimental|Group 3|HIV-uninfected participants
2941636|NCT02960581|Experimental|Group 4|HIV-infected on ART, (<50 cp/ml)
2941637|NCT02960581|Experimental|Group 5|HIV-infected on ART, (<50 cp/ml)
2941638|NCT02960581|Experimental|Group 6|HIV-infected on ART, (<50 cp/ml)
2941639|NCT02960581|Experimental|Group 7|HIV-Infected off ART (VL 2x10^3 - 1x10^5 cp/ml)
2941640|NCT02960581|Experimental|Group 8|HIV-Infected off ART (VL 2x10^3 - 1x10^5 cp/ml)
2941641|NCT02960581|Experimental|Group 9|HIV-Infected off ART (VL 2x10^3 - 1x10^5 cp/ml)
2941642|NCT02960581|Experimental|Group 10|HIV-Infected off ART (VL 1x10^2 - 2x10^3 cp/ml)
2941643|NCT02960581|Experimental|Group 11|HIV-Infected off ART (VL 1x10^2 - 2x10^3 cp/ml)
2941644|NCT02960581|Experimental|Group 12|HIV-Infected off ART (VL 1x10^2 - 2x10^3 cp/ml)
2941645|NCT02960568|Experimental|Primaquine|Poor and Intermediate Metabolizers will receive 30 mg oral primaquine (PQ) and have peripheral blood draws over a 24-hour period to measure PQ pharmacokinetics
2941646|NCT02960568|No Intervention|No primaquine|Extensive and Ultra Metabolizers will not be eligible for the pharmacokinetic portion of the study and participation will be complete after receiving genotype information
2941647|NCT02960555|Experimental|Isatuximab|"Participants receive Isatuximab 20 mg/kg as a single agent intravenous infusion every week on Days 1,8,15 and 22 during Cycle 1.~Participants receive Isatuximab 20 mg/kg as a single agent intravenous infusion every other week on Days 1 and 15 of Cycles 2 to 6.~Participants receive Isatuximab 20 mg/kg as a single agent intravenous infusion every month on Day 1 of Cycles 7 to 30.~After 30 cycles of treatment have been completed, participants come off treatment.~Methylprednisolone 100 mg intravenous once 30 minutes before Isatuximab infusion.~Diphenhydramine 25 or 50 mg by vein once 30 minutes before Isatuximab infusion. Ranitidine 50 mg by mouth once 30 minutes before Isatuximab infusion.~After last dose of study drug, participant called by a member of the study staff. Participants receive these calls at least every 6-12 months after the end of the study."
2941648|NCT02960542|Experimental|Lifestyle Weight Loss|The Behavioral: HELP Prevent Cancer Intervention is a lifestyle intervention consisting of 24-weekly group meetings led by a community health worker and 3 individual sessions with a nutritionist/diabetes educator
2941649|NCT02960529||extra-peritoneal high ligation of hernia|the 150 patients were subjected trans-umbilical single-port laparoscopic extra-peritoneal approach repair for inguinal hernia
2941653|NCT02960490|Experimental|E6011 400 mg/E6011 200 mg|In the Treatment Phase (24 weeks), participants will receive E6011 400 milligrams (mg) at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
2941654|NCT02960490|Experimental|E6011 400 mg/E6011 400 mg|In the Treatment Phase (24 weeks), participants will receive E6011 400 mg at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
2941655|NCT02960490|Experimental|Placebo/E6011 200 mg|In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
2941656|NCT02960490|Experimental|Placebo/E6011 400 mg|In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
2941657|NCT02960477|Experimental|Pain Neuroscience education|A PNE session covers the neurobiology, neurophysiology and processing of pain. Topics addressed during the educational sessions will include the characteristics of acute versus chronic pain; how pain becomes chronic (plasticity of the nervous system, modulation, modification, central sensitization, etc.); potential sustaining factors of central sensitization like emotions, stress, pain cognitions, and pain behaviour; the decision to have shoulder surgery; surgical experiences and environmental issues' effects on nerve sensitivity; recovery after shoulder surgery; scientific evidence for the PNE content; and the opportunity to reflect and write questions to ask the surgeon prior to surgery.
2941658|NCT02960477|Active Comparator|Biomedical Education|A biomedical session covers the normal course of shoulder pain; anatomy, physiology and biomechanics of the shoulder; the expected course of postoperative shoulder pain; and the importance of self-care. Also, professional and leisure time activities will be discussed. Ergonomic advices will be given: e.g. how is the best way to catch a container, how I should move my shoulder in this sport/activity, what is a good work posture? The content of the biomedical education will be biomedically-/biomechanically-focussed.
2941659|NCT02960464|Active Comparator|Active Arm|Active sessions will involve the placement of the anode over the scalp corresponding to the F3 (10-20 EEG system), and cathode over F4. Current intensity will be 2mA, and the stimulation will last for 20 minutes.
2941660|NCT02960464|Sham Comparator|Sham Arm|Sham stimulation will follow the same procedure as the Active, however after 30 seconds of stimulation, the current is turned off, mimicking the initial sensation of the tDCS session but providing no clinical or physiological effect.
2941661|NCT02960451|Experimental|PRIME care|Specialized care in the PRIME clinic
2941662|NCT02960451|Active Comparator|Usual care|Usual care in the community
2941663|NCT02960438|Experimental|E6011 100 milligrams (mg)|In the Treatment Phase, E6011 100 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
2941664|NCT02960438|Experimental|E6011 200 mg|In the Treatment Phase, E6011 200 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
2941665|NCT02960438|Experimental|E6011 400 mg|In the Treatment Phase, E6011 400 mg will be subcutaneously administered at Weeks 0, 1, 2, 4, 6, 8, and 10, and then E6011 200 mg will be subcutaneously administered every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
2941666|NCT02960438|Placebo Comparator|Placebo|In the Treatment Phase, placebo will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
2941667|NCT02960425|Experimental|HI Delivra TM Livsport preworkout cream|7 mL topical creatine cream
2941668|NCT02960425|Experimental|LO Delivra TM Livsport preworkout cream|3.5 mL topical creatine + 3.5 mL placebo cream
2941669|NCT02960412|Experimental|furosemide|furosemide 10mg (1mL) IV push for one dose
2941670|NCT02960412|Placebo Comparator|placebo|normal saline 1mL IV push for one dose
2941671|NCT02960399|Experimental|Antibody Deficient Patients|Zostavax® vaccine administered to antibody deficient patients 60 years of age and older.
2941672|NCT02960399|Active Comparator|Healthy Subjects|Zostavax® vaccine administered per standard of care to healthy adults 60 years of age and older.
2941673|NCT02960386|Other|Machine Learning Algorithm|Single group participants that will use the algorithm to be engaged in using their fitness tracker.
2941674|NCT02960373|Active Comparator|White Bread (Control)|Participants will consume a test meal containing white bread (dose: 50g available carbohydrate) at three study visits.
2941675|NCT02960373|Experimental|Dried Fruit - Glycemic Index|Participants will consume a test meal containing one variety of dried fruit (dose: 50g available carbohydrate) per visit for four visits. Varieties include raisins, sultanas, dates, and apricots.
2941676|NCT02960373|Experimental|Catalytic Fructose Dose Effect|Participants will consume a test meal containing white bread (dose: 50g available carbohydrate) and one variety of dried fruit (dose: 7g fructose) per visit for four visits. Varieties of dried fruit include: raisins, sultanas, dates, and apricots.
2941677|NCT02960373|Experimental|High GI Displacement Effect|Participants will consume a test meal containing white bread (dose: 25g available carbohydrate) and one variety of dried fruit (dose: 25g available carbohydrate) per visit for four visits. Varieties of dried fruit include: raisins, sultanas, dates, and apricots.
2941680|NCT02960321||CAG with PCI|Diagnostic coronary angiography and subsequent percutaneous coronary intervention (PCI)
2941681|NCT02960308|Experimental|Diagnostic (WNCTP scan)|Patients undergo WNCTP scan over 2-3 minutes during standard of care CT.
2941682|NCT02960295|Experimental|Virtual visit|"Pregnant women with GDM who will:~self-monitor blood glucose four times daily,~self-weigh themselves weekly,~self-check their blood pressure weekly,~check their fetus' heart rate weekly, and~alternate office visits with telephone visits with their caregivers"
2941683|NCT02960282||Ancillary-Correlative (gut microbiome analysis)|Patients undergo collection of fecal specimens at baseline, prior to start of each course of chemotherapy or immunotherapy, at the end of weeks 2, 4, 6, and 8, at the end of course 3 and courses thereafter of chemotherapy or immunotherapy, and at the time of disease progression or going off-treatment. Fecal specimens are analyzed via 16S ribosomal RNA gene sequencing, meta-transcriptomics analysis, and meta-proteomics analysis.
2941684|NCT02960269|Experimental|Telehealth team assessment|Team assessment for back pain with nurse practitioner and physical therapist via telehealth
2941685|NCT02960256||Patients admitted to an internal medicine department due to an|
2941686|NCT02960243|Sham Comparator|Bilateral Thalamic Vim OFF|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
2941687|NCT02960243|Experimental|Left Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
2941688|NCT02960243|Experimental|Right Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
2941689|NCT02960243|Experimental|Bilateral Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
2941690|NCT02960230|Experimental|Newly Diagnosed DIPG|Newly diagnosed children with diffuse intrinsic pontine glioma who are positive for HLA-A2 and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid (TT) peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks.
2941691|NCT02960230|Experimental|Newly Diagnosed Glioma (non-DIPG)|Newly diagnosed children with gliomas other than DIPG who are positive for HLA-A2 and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks.
2941692|NCT02960217|Experimental|UX007 followed by placebo|Participants will first receive UX007 for 10 weeks. After a washout period of 2 weeks, they will then receive placebo for 10 weeks
2941693|NCT02960217|Placebo Comparator|Placebo followed by UX007|Participants will first receive Placebo for 10 weeks. After a washout period of 2 weeks, they will then receive UX007 for 10 weeks
2941694|NCT02960204|Active Comparator|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (5 mg) twice a day.
2941695|NCT02960204|Active Comparator|Emricasan (25 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (25 mg) twice a day.
2941696|NCT02960204|Active Comparator|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (50 mg) twice a day.
2941697|NCT02960204|Placebo Comparator|Matching Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with a matching placebo twice a day.
2941698|NCT02960191|Other|healthy volunteers|subject with no current or past personal history of psychiatric disorders and about never having carried out suicide attempt
2941699|NCT02960191|Other|emotional witness|subject having had a personal history of unipolar or bipolar depressive disorder and who have never done in his life attempted suicide
2941700|NCT02960191|Other|patient suicide|subject having had a personal history of unipolar or bipolar depressive disorder and having realized in his life at least one suicide attempt
2941701|NCT02960178|Experimental|Perturbation-based training|Participants will practice standing and walking activities while secured in an overhead harness attached to an overhead track. While practicing these tasks, the trainer will apply pushes and pulls to the harness at unexpected times, causing a reactive step to be practiced.
2941702|NCT02960178|Active Comparator|Conventional walking training|Participants will practice standing and walking activities while secured in an overhead harness attached to an overhead track. No external perturbations will be applied.
2941703|NCT02960165|Experimental|Virtual interface group A|Older adults that started the practice on the virtual interface
2941704|NCT02960165|Experimental|Virtual interface group B|Older adults that started the practice on the virtual interface and then practiced on real task.
2941705|NCT02960165|Active Comparator|Real interface group A|Older adults that started the practice on the virtual interface
2941706|NCT02960165|Active Comparator|Real interface group B|Older adults that started the practice on the real interface and then practiced on virtual task.
2941707|NCT02960152||Anorexia Nervosa|interview and periodontal full-mouth examination
2941708|NCT02960152||Bulimia Nervosa|interview and periodontal full-mouth examination
2941709|NCT02960152||Control|interview and periodontal full-mouth examination
2941710|NCT02960139|Experimental|Test- Treatment with Sylys Surgical Sealant|Standard closure plus treatment with Sylys Surgical Sealant
2941711|NCT02960139|No Intervention|Control- Standard of Care|Control group is standard closure of anastomosis.
2941712|NCT02960126|Active Comparator|Intervention: Clopidogrel|Case management with clopidogrel 75mg once daily is provided for stroke prevention in AF patient.
2941713|NCT02960126|Experimental|Control: Aspirin|Usual care with aspirin 100mg once daily is provided for stroke prevention in AF patient.
2941714|NCT02960113|Experimental|scopolamine patch|Scopolamine patch will be placed on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery.
2941715|NCT02960113|Experimental|acupressure point P6|Acupressure point P6 stimulation will be placed on the distal right forearm just above the crest of the wrist.
2941716|NCT02960113|Experimental|scopolamine patch + acupressure point P6|Will receive both scopolamine patch and acupressure point P6 stimulation, as described above.
2941717|NCT02960100|Experimental|Arm I (mHealth HPV vaccine intervention)|Participants receive targeted HPV vaccine narrative-style video via the mobile-friendly website. Participants also receive monthly HPV vaccination reminders via email or by text message.
2941718|NCT02960100|Active Comparator|Arm II (standard HPV information and HPV VIS)|Participants receive standard information with the HPV Vaccine Information Statement via the mobile-friendly website.
2941719|NCT02960087|Active Comparator|Arm 1 LDR|Low Dose Rate (LDR) brachytherapy with I-125 to a total dose of 144 Gy
2941720|NCT02960087|Active Comparator|Arm 2 HDR|High Dose Rate brachytherapy: 19 Gy in 1 fraction with intraprostatic boost to GTV
2941721|NCT02960074|Experimental|Fecal Microbiota Capsule|The investigational agent consists of screened-donor inoculum of a biologically active human substance (FMT). We will give oral frozen FMT over 2 days.
2941722|NCT02960061|Experimental|HIPEC|After receiving neoadjuvant chemotherapy and D2 radical resection, Hyperthermic intraperitoneal perfusion chemotherapy is conducted,4 catheters are placed in 4 position in the peritoneal cavity: ① under the left diaphragm ② hepatorenal recess ③ left pelvis ④ right pelvis.catheters, all four tubes are connected to the perfusion device.Perfusion prescription: cycle 1, Paclitaxel 75mg/ m2 diluted with 3000ml normal saline heated up to a fixed temperature of 43°C circulate continuously for 60min at a speed of 400-500ml/h; cycle 2 start within 24-48 hours after cycle 1, dosage of paclitaxel adjust to 100mg/ m2, the rest of the same. A total of two cycle is administered, routine adjuvant chemotherapy using SOX (oxaliplatin plus S-1 capsule)or XELOX regimens follows within 4-6 weeks.
2941723|NCT02960061|Sham Comparator|controlled group|After receiving neoadjuvant chemotherapy and D2 radical resection, patients receive peritoneal lavage with 3000ml distilled water.Adjuvant chemotherapy using SOX or XELOX regimens is administered as routine within 4-6 weeks.
2941724|NCT02960048|Active Comparator|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
2941725|NCT02960048|Experimental|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
2941726|NCT02960035|Experimental|etanercept 50mg/week|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 will be randomised to one of three arms (period 2): this arms will receive ETN 50 mg weekly (unchanged). In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
2941727|NCT02960035|Experimental|etanercept 25mg/week|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 were randomised to one of three arms (period 2): this arms will receive ETN 25 mg weekly (half dose). In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
2941728|NCT02960035|Placebo Comparator|PLACEBO|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 were randomised to one of three arms (period 2): this arms will receive placebo weekly. In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
2941729|NCT02960022|Experimental|enzalutamide|Subjects will receive enzalutamide orally once daily at the same time each day
2941730|NCT02960022|Experimental|enzalutamide plus abiraterone acetate and prednisone|Subjects enrolling from study 9785-CL-0011 will receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide once daily
2941731|NCT02960009|Experimental|Anode HD-tDCS|The center anode is fixed on the ipsilesional primary motor cortex and the 4 surrounding cathode electrodes will be placed about 6 cm to the center.
2941732|NCT02960009|Experimental|Cathode HD-tDCS|The center cathode is fixed on the contralesional primary motor cortex and the 4 surrounding anode electrodes will be placed about 6 cm to the center.
2941733|NCT02960009|Placebo Comparator|Sham HD-tDCS|The center anode is fixed on the ipsilesional primary motor cortex and the 4 surrounding cathode electrodes will be placed about 6 cm to the center.
2941734|NCT02959996|Placebo Comparator|Placebo|Normal saline will be infiltrated
2941735|NCT02959996|Active Comparator|Intervention|Liposomal bupivacaine will be infiltrated
2941736|NCT02959983|Active Comparator|Eluxadoline|Eluxadoline 100 mg oral tablets twice daily (BID) with food for 12 weeks.
2941737|NCT02959983|Placebo Comparator|Placebo|Placebo matching eluxadoline oral tablets BID with food for 12 weeks.
2941738|NCT02959970|Experimental|ACZONE 7.5%|ACZONE (dapsone) gel 7.5% topically once daily for 12 weeks.
2941739|NCT02959957|Experimental|Temocillin|Temocillin powder for solution för injection/infusion, per day 6 g (2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.
2941740|NCT02959957|Active Comparator|Cefotaxime|Cefotaxime powder for solution för injection/infusion, per day 3-6 g (1-2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.
2941741|NCT02959944|Experimental|Ibrutinib|Ibrutinib in combination with prednisone
2941742|NCT02959944|Placebo Comparator|Placebo|Placebo in combination with prednisone
2941743|NCT02959931|Experimental|High potassium meal|In this arm individuals will be provided with a breakfast meal that provides ~2400 mg of dietary potassium.
2941744|NCT02959931|Active Comparator|Low potassium meal|In this arm individuals will be provided with a breakfast meal that provides ~540 mg of dietary potassium.
2941745|NCT02959918|Experimental|SEL-037 Pegsiticase LD(low dose) alone|
2941746|NCT02959918|Experimental|SEL-037 Pegsiticase HD(high dose) alone|
2941747|NCT02959918|Experimental|SEL-212, Pegsiticase LD & SEL-110 (1a)|
2941748|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (1b)|
2941749|NCT02959918|Experimental|SEL-212, Pegsiticase LD & SEL-110 (2a)|
2941750|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (2b)|
2941751|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (3a)|
2941752|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (3b)|
2941753|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (4a)|
2941754|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (4b)|
2941755|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (5a)|
2941756|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (5b)|
2941757|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (6a)|
2941758|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (6b)|
2941759|NCT02959905|Experimental|medium dose of preparative regimen|Patients will receive medium dose of lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by TSA-CTL.
2941760|NCT02959905|Experimental|low dose of preparative regimen|Patients will receive low dose of lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by TSA-CTL.
2941761|NCT02959905|Experimental|no preparative regimen|Patients will only receive TSA-CTL.
2941762|NCT02959892|Experimental|Fixed Combination|Amphetamine alone in Period 1; TAK-041 and amphetamine in Period 2
2941763|NCT02959879|Experimental|FOLFOX neoadjuvant chemotherapy|4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient. Curative surgery for resectable pancreatic duct adenocarcinoma will be done after neoadjuvant chemotherapy. 8 cycles of adjuvant chemotherapy are administrated following the surgery
2941764|NCT02959879|Experimental|FOLFIRINOX neoadjuvant chemotherapy|4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient. Curative surgery for resectable pancreatic duct adenocarcinoma will be done after neoadjuvant chemotherapy. 8 cycles of adjuvant chemotherapy are administrated following the surgery
2941765|NCT02959879|Active Comparator|standard adjuvant chemotherapy|"Curative surgery for resectable pancreatic duct adenocarcinoma will be done after randomization.~12 cycles of standard adjuvant chemotherapy are administrated following the surgery"
2941766|NCT02959866|Experimental|Online income tool|Patients who complete the online income tool with their health provider during the study period.
2941767|NCT02959853|Placebo Comparator|weight loss|Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
2941768|NCT02959853|Experimental|aromatase inhibitor (anastrazole) plus weight loss|Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
2941769|NCT02959840|No Intervention|Control|No anti-emetic medications and no acupuncture point P6 stimulation prior to administration of the standardized regional anesthesia
2941770|NCT02959840|Active Comparator|Metoclopramide, Ondansetron|10 mg Metoclopramide IV and 8 mg of Ondansetron IV immediately prior to administration of the standardized regional anesthesia
2941771|NCT02959840|Experimental|Acupressure Point P6 stimulator|Acupuncture point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete.
2941772|NCT02959827||Iodinated contrast agents|Children under age 4 in the Kaiser Permanente Northern California database, who had a diagnostic procedure with an iodinated contrast agent
2941773|NCT02959801|Experimental|Percutaneous Mechanical Thrombectomy|Percutaneous mechanical thrombectomy（PMT）uses a number of catheter-based mechanical devices to deliver the thrombolytic agent as well as to produce some combination of thrombus fragmentation, distribution of thrombolytic drugs throughout the thrombus, and/or thrombus aspiration.
2941774|NCT02959788||Chest pain patients|All patients who present to the ED with chest pain.
2941775|NCT02959775|Experimental|60 µg dose hepatitis B vaccine|Receive three intramuscular injections of 60 µg recombinant hepatitis B vaccine at months 0, 1 and 6
2941776|NCT02959775|Experimental|20 µg dose hepatitis B vaccine|Receive three intramuscular injections of 20 µg recombinant hepatitis B vaccine at months 0, 1 and 6
2941778|NCT02959762|Placebo Comparator|Placebo-Control|The placebo-control group will take two placebo softgel capsules every day for 8 weeks.
2941779|NCT02959762|Active Comparator|Low-Dose Vitamin K2 (45-mcg/d)|The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.
2941780|NCT02959762|Active Comparator|High-Dose Vitamin K2 (90-mcg/d)|The high-dose vitamin K2 group will take two 45-mcg vitamin K2 softgel capsules every day for 8 weeks.
2941781|NCT02959749|Active Comparator|Docetaxel, bevacizumab|docetaxel, 75mg/m2, intravenous infusion on day 1. VEGF monoclonal antibody bevacizumab, 7.5 mg/m2, intravenous infusion on day 1, every 21days a cycle，until disease progression, intolerable toxicities, or patient death.
2941782|NCT02959749|Experimental|EGFR TKI|osimertinib 80mg oral once daily，until disease progression, intolerable toxicities, or patient death.
2941783|NCT02959736||National Rehabilitation Hospital Dublin|Music Therapy (MATADOC)
2941784|NCT02959736||Spectrum|Music Therapy (MATADOC)
2941785|NCT02959736||Royal Hospital for Neuro-disability London|Music Therapy (MATADOC)
2941786|NCT02959710|Experimental|Group 1|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
2941787|NCT02959710|Experimental|Group 2|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
2941788|NCT02959710|Experimental|Group 3|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
2941789|NCT02959671|Experimental|Lower Anterior EXD-952 Self-ligating Brackets|
2941790|NCT02959658|Active Comparator|Active drug|Dimethyl fumarate, 240mg twice daily for 48 weeks
2941791|NCT02959658|Placebo Comparator|Placebo|Placebo Oral Capsules, 2 tablets twice daily for 48 weeks
2941792|NCT02959645||Cervical Dystonia|patients will have Cervical Dystonia
2941793|NCT02959645||Healthy control|Healthy Volunteers
2941794|NCT02959632|Experimental|Patients receiving AAT|"Hospitalized patients receiving Animal Assisted Therapy (AAT).~Animal Assisted Therapy (Pet Visit) will be provided to the hospitalized patients."
2941795|NCT02959619|Experimental|Ensartinib|Escalating dose of ensartinib was orally given once er day
2941796|NCT02959606|Experimental|Sarpogrelate SR 300mg + ASA|"Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.~Other Name: Anplone SR"
2941797|NCT02959606|Active Comparator|Clopidogrel + ASA|"Clopidogrel is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.~Other Name: Plavix"
2941798|NCT02959593|Experimental|Glaucoma patients|To view commercially available content through the VISIOR video goggles for thirty minutes
2941799|NCT02959593|Experimental|Healthy subjects|To view commercially available content through the VISIOR video goggles for thirty minutes.
2941800|NCT02959580|Experimental|medical|Hydrocortisone butyrate cream(0.1%) was applied to the breast by the patient twice a day on alternate days until the termination of treatment.
2941801|NCT02959580|Active Comparator|surgical|lesion extended excision
2941802|NCT02959567|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
2941803|NCT02959554|Experimental|Nivolumab (A)|Nivolumab: 240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
2941804|NCT02959554|Active Comparator|TKI (B)|Sunitinib: According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study) or Pazopanib: According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study)
2941805|NCT02959541|Other|Calciumfolinat 60 mg/m²|Intravenous infusion of Calciumfolinat 60 mg/m²given to patients with colon cancer at the time for the operation of the colon cancer.
2941806|NCT02959541|Other|Calciumfolinat 200 mg/m²|Intravenous infusion of Calciumfolinat 200 mg/m² given to patients with colon cancer at the time for the operation of the colon cancer.
2941807|NCT02959541|Other|Calciumfolinat 500 mg/ m²|Intravenous infusion of Calciumfolinat 500 mg/ m² given to patients with colon cancer at the time for the operation of the colon cancer.
2941808|NCT02959528|Active Comparator|Control|ADHD group treated with visual-perceptual training
2941809|NCT02959528|Experimental|Experiment|ADHD group treated with working memory training
2941810|NCT02959515|Active Comparator|Capnothorax|Capnothorax is obtained by the insufflation of CO2in the right pleural cavity and maintained at a preset pressure of 10 mmHg .Arterial and central venous blood gasanalyses, hemodynamic and respiratory variables will be recorded.
2941811|NCT02959515|Active Comparator|Capnothorax and CPAP|Capnothorax is obtained by the insufflation of CO2in the right pleural cavity and maintained at a preset pressure of 10 mmHg. CPAP on the non ventilated lung is set at 10 cm H2O and FiO2=1. Arterial and central venous blood gasanalyses, hemodynamic and respiratory variables will be recorded.
2941812|NCT02959502|Experimental|Receive tDCS + CR|Receive tDCS+CR: Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
2941813|NCT02959502|Experimental|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will trained to deliver tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
2942468|NCT02955368|Active Comparator|C2-R212 group|DP-R212 placebo + C1-R212 placebo + C2-R212
2941814|NCT02959489|Active Comparator|Amyloid Brain Imaging Non-Disclosure|Subjects will receive their Alzheimer's disease (AD) risk assessment based on age, gender, family history and ancestry.
2941815|NCT02959489|Experimental|Amyloid Brain Imaging Disclosure|"Subjects will receive both their elevated or not elevated amyloid neuroimaging results based on their brain scan interpretation and Alzheimer's disease (AD) risk disclosure. The AD risk assessment is based on age, gender, family history and ancestry."
2941816|NCT02959476|Experimental|Ropivacaine 0.2%|"Naropin® (ropivacaine HCl Injection, USP) bolus + Ropivacaine 0.2% Pre-Filled Dispenser infusion - Ropivacaine Infusion treatment arm"
2941817|NCT02959476|Placebo Comparator|Placebo|"Naropin® (ropivacaine HCl Injection, USP) bolus + placebo infusion (normal saline) - Placebo treatment arm"
2941818|NCT02959463|Experimental|Prior Chemotherapy + Possible Lung-Sparing Surgery|"Participants have already received at least 2 cycles of chemotherapy and possibly lung-sparing surgery.~Participants receive hemithoracic radiation therapy with intensity modulated radiation therapy (IMRT) or proton beam therapy (PBT) to a total dose of 45 Gy in 25 fractions to the entire hemithorax.~Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of each 3-week cycle after radiation therapy, for up to 2 years."
2941819|NCT02959463|Experimental|Possible Prior Chemo and No Surgery|"Participants may or may not have had prior chemotherapy or immunotherapy. Participants have not received surgery.~Participants receive palliative radiation therapy over a course of 1-3 weeks to a region that does not include the entire side of the chest, or thorax.~Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of each 3-week cycle after radiation therapy, for up to 2 years."
2941820|NCT02959450|Experimental|Modified consistency and volume diet|Modified consistency diet, with a certain viscosity and controlled volume. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP.
2941821|NCT02959450|No Intervention|Control Group|Standard treatment consisting of a modified consistency diet with adequate intake of energy and protein and general recommendations on diet prescribed by the treating physician
2941822|NCT02959437|Experimental|Treatment Group A: Azacitidine + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.
2941823|NCT02959437|Experimental|Treatment Group B: INCB057643 + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.
2941824|NCT02959437|Experimental|Treatment Group C: INCB059872 + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.
2941825|NCT02959411|Experimental|Tolvaptan|Tolvaptan 15-60 mg, once daily for 4 days or until hospital discharge
2941826|NCT02959411|Active Comparator|Standard of care diuretic therapy|Usual standard of care diuretic therapy for patients with acute decompensated heart failure
2941827|NCT02959398|Active Comparator|standard mammography|standard mammography
2941828|NCT02959398|Experimental|standard mammography and tomosynthesis|standard mammography and tomosynthesis
2941829|NCT02959385|Experimental|Definitive Radiochemotherapy|"Concurrent Radiochemotherapy:~Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day."
2941830|NCT02959385|Active Comparator|Neoadjuvant Radiochemotherapy|"Concurrent Radiochemotherapy:~Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later."
2941831|NCT02959372|Experimental|lung ultrasound group|lung ultrasound results
2941832|NCT02959372|Placebo Comparator|control group|The attending physician will not have the result of the lung ultrasound
2941833|NCT02959359|Other|DAA treatment arm|Active DAA treatment ('Ledipasvir 90mg/Sofosbuvir 400 mg plus Ribavirin' ) for HCV-HCC patients after curative resection or ablation.
2941834|NCT02959346|Sham Comparator|Sham Acupuncture|After recruitment, participants will be randomized to receive acupuncture or sham acupuncture treatment. In the sham acupuncture group, participants will receive sham acupuncture.
2941835|NCT02959346|Experimental|Acupuncture|After recruitment, participants will be randomized to receive acupuncture or sham acupuncture treatment. In the acupuncture group, participants will receive acupuncture.
2941836|NCT02959333|Experimental|hAEC treatment|hAEC: human amniotic epithelial cells 3-5*10^7 /5 ml
2941837|NCT02959320|Active Comparator|Direct Anterior Approach|All patients receiving a hip hemiarthroplasty through a Direct Anterior Approach (DAA) will have their surgeries performed with the aid of fluoroscopy on an OSI Hana table that allows the operative limb to be manipulated through range of motion and traction while keeping the pelvis stabilized. This table also has a radiolucent platform about the pelvis, enabling the surgery to be fluoroscopically assisted. The incision for the DAA will extend from a proximal point about 2 cm distal and 2 cm lateral to the ASIS to a point 8-12 cm distal and slightly lateral to this.
2941838|NCT02959320|Active Comparator|Anterolateral Approach|All patients receiving a hip hemiarthroplasty through an the Anterolateral Approach (ALA) will have their surgeries performed on a standard OR table in a contralateral lateral decubitus position. With the leg in the position of sleep, a straight 8-12 cm incision will be made, centered over the greater trochanter and femoral shaft with 1/3 of the incision extending superior to the tip of the greater trochanter.
2941839|NCT02959307|Experimental|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy and, the light energy may activate under-stimulated brain regions.
2941840|NCT02959307|Sham Comparator|Sham Transcranial Light Therapy|For the sham group, The transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy
2941841|NCT02959294|Experimental|Microcannula Harvest Adipose|Acquisition Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via close syringe microcannula harvest from subdermal fat deposits
2941842|NCT02959294|Experimental|Centricyte 1000|Autologous AD-tSVF via enzymatic isolation/concentration via Centricyte 1000 Closed System to create AD-cSVF
2941843|NCT02959294|Experimental|Sterile Normal Saline|Re-suspension of AD-cSVF pellet in Normal Saline deployment via IV
2941844|NCT02959281|Experimental|Hemodynamic data available|Providing caring physicians with hemodynamic variables measured using the NICAS system.
2941845|NCT02959281|No Intervention|Hemodynamic data not available|Hemodynamic variables measured using the NICAS system will not be provided to the caring physicians.
2941846|NCT02959268|Other|Single arm Al-Sense diagnostic|Investigator blinded to subject assessments
2941847|NCT02959255|Active Comparator|10-day concomitant PAMC|40mg esomeprazole twice daily, 500mg clarithromycin twice daily, 1gr amoxicillin twice daily, and 500mg metronidazole twice daily for 10 days
2941848|NCT02959255|Active Comparator|14-day concomitant PAMC|(40mg esomeprazole twice daily, 500mg clarithromycin twice daily, 1gr amoxicillin twice daily, and 500mg metronidazole twice daily for 14 days.
2941849|NCT02959229|Experimental|Early Lactoferrin Group|Oral Bovine Lactoferrin 100 mg/day once starting on day 1 of life and continued for 4-6 weeks.
2941850|NCT02959229|Experimental|Late Lactoferrin Group|Oral Bovine Lactoferrin 100 mg/day once starting on day 3 of life and continued for 4-6 weeks.
2941851|NCT02959229|Active Comparator|Placebo Group|placebo in form of distilled water once starting on day 1 of life and continued for 4-6 weeks.
2941852|NCT02959216|Experimental|Aerobic Exercise|Aerobic exercise participants will receive an exercise prescription based on their heart rate threshold (HRT) for symptom exacerbation during an initial treadmill test. Participants will be asked to exercise once a day at 90% of their assigned HRT for a minimum of 20 minutes. Participants will wear a heart rate monitor to track their heart rate during aerobic exercise. The treatment will continue until the participant is recovered from his/her concussion, as determined by exercise tolerance and a normal symptom count and clinical examination.
2941853|NCT02959216|Placebo Comparator|Stretching Exercise|Stretching exercise participants will receive a prescription to complete a standardized physical therapy stretching protocol once a day for approximately 20 minutes. Participants will wear a heart rate monitor to track their heart rate during the stretching exercise. The treatment will continue until the participant is recovered from his/her concussion, as determined by exercise tolerance and a normal symptom count and clinical examination.
2941854|NCT02959190|Experimental|Dose Level 1 Galcanezumab|Dose level 1 Galcanezumab given subcutaneously (SC) once a month for a year.
2941855|NCT02959190|Experimental|Dose Level 2 Galcanezumab|Dose level 2 Galcanezumab given SC once a month for a year.
2941856|NCT02959177|Experimental|Dose Level 1 Galcanezumab|Galcanezumab administered subcutaneously (SC) once a month for 6 months.
2941857|NCT02959177|Experimental|Dose Level 2 Galcanezumab|Galcanezumab administered SC once a month for 6 months.
2941858|NCT02959177|Placebo Comparator|Placebo|Placebo administered SC once a month for 6 months.
2941859|NCT02959164|Experimental|Decitabine and Gemcitabine|"Decitabine, Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.~Gemcitabine fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle."
2941860|NCT02959151|Experimental|CAR-T for liver cancer|A single dose of CART cells will be administered by vascular interventional therapy or by intra-tumor injection with a dose of （1.25~4）×107 CAR positive T cells/cm3 tumor bulk. The volume of cell products and the time of cell perfusion process lasted would depend on the ways of cell perfused. And an interventional radiologist would operate the cell infusion.
2941861|NCT02959138|Experimental|Moderate Renal Impairment (Cohort 1)|Participants with moderate renal impairment and matched healthy controls will receive a single dose of GS-9876.
2941862|NCT02959138|Experimental|Severe Renal Impairment (Adaptive Cohort 2)|Participants with severe renal impairment and matched healthy controls will receive a single dose of GS-9876
2941863|NCT02959138|Experimental|Mild Renal Impairment (Adaptive Cohort 3)|Participants with mild renal impairment and matched healthy controls will receive a single dose of GS-9876
2941864|NCT02959125|Experimental|Intervention|"Intervention~NutFish based supplementation for 60 days~Multiple micro nutrient for 60 days~Health education in pregnancy class"
2941865|NCT02959125|Active Comparator|Control|"Control~Government food supplementation for 60 days~Iron Folic acid for 60 days~Health education in pregnancy class"
2941866|NCT02959112|Active Comparator|Epinephrine sprayed on the papilla and rectal indomethacin|Epinephrine 1 mg/1 mL + 9 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
2941867|NCT02959112|Placebo Comparator|Sterile water sprayed on the papilla and rectal indomethacin|10 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
2941868|NCT02959099||Cases|Patients with acute coronary syndrome (ACS).
2941869|NCT02959099||Controls|Patients without acute coronary syndrome (ACS).
2941870|NCT02959086||1|Patients were diagnosed since January 2002.
2941871|NCT02959060|Experimental|BMS-986177 and Rifampin|
2941872|NCT02959047|Experimental|Alirocumab|Alirocumab 150mg SQ every 2 weeks
2941873|NCT02959047|Placebo Comparator|Placebo|Matched placebo
2941874|NCT02959034||BMI > 95%|No Intervention
2941875|NCT02959034||Healthy Weight Siblings|Control
2941876|NCT02959034||Healthy Weight Unrelated|Control
2941877|NCT02959021|Active Comparator|Self-directed treatment|Participants randomly assigned to this arm will receive written and pre-recorded behavioral weight loss intervention materials (i.e., DVDs, online videos), and they will be instructed to work through the materials independently at their own pace. They will have continued physician contact as needed for routine medical care.
2941878|NCT02959021|Experimental|Peer coach treatment|Participants randomly assigned to this arm will receive a combination of in-person, group-based behavioral weight loss sessions plus individual, telephone contacts. Groups and phone calls will be facilitated by a peer coach interventionist. Similar to the self-directed condition, participants will receive written and pre-recorded intervention materials (i.e., DVDs, online videos). They will also have continued contact with their physician for routine medical care.
2941879|NCT02959008||normal|Human without hypertension, diabetes, anemia, liver disease and kidney disease. The group will measure TOI and BP.
2942469|NCT02955355|Experimental|All Study Participants|
2941880|NCT02959008||hypertension|"Human only have hypertension, without diabetes, anemia, liver disease and kidney disease.~Hypertension group will measure TOI and BP."
2941881|NCT02958995||Full KPNC Cohort|Participants who were members of the KPNC registry (with or without diabetes) were followed up to 15 years (1997-2011) in this epidemiological study.
2941882|NCT02958995||Survey Responders|A subset of KPNC members who completed the Kaiser Diabetes Registry Survey in 1994-1996 and among a random sample of KPNC members who completed the Member Health Survey (MHS), in 1996, 1999, 2002, or 2005 were followed up to 15 years (1997-2011) in this epidemiological study.
2941883|NCT02958982|Experimental|RP3128|RP3128, A CRAC channel modulator
2941884|NCT02958982|Placebo Comparator|Placebo|Placebo
2941885|NCT02958969|Active Comparator|Apixaban|apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
2941886|NCT02958969|Placebo Comparator|Placebo|placebo orally twice daily for 6 months
2941887|NCT02958956||Ever User of Pioglitazone|Ever user of pioglitazone was defined as having filled 2 prescriptions for the drug within a 6-month period.
2941888|NCT02958956||Never User of Pioglitazone|Never user of pioglitazone, which included participants receiving no diabetes medications, with fewer than 2 pioglitazone prescription fills in a 6-month period, and with use of diabetes medications other than pioglitazone.
2941889|NCT02958943|Experimental|Electronic Alert|Each provider in the alert group will receive an on-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation.
2941890|NCT02958943|No Intervention|No Alert|Each provider in the non-alert group will receive no such notification.
2941891|NCT02958930|Experimental|TEMT Treatment|Patients in this arm will receive Transcranial Electromagnetic Treatment (TEMT) twice daily for a two-month treatment period utilizing the MemorEM 1000 head device.
2941892|NCT02958917|Placebo Comparator|pirfenidone 2403 mg/d|Subjects will be randomized in a 2:1 ratio to receive either pirfenidone 2403 mg/d or a placebo equivalent.
2941893|NCT02958917|Active Comparator|Placebo|The placebo will be visually similar to pirfenidone.
2941894|NCT02958878|Experimental|A|Tamsulosin 0.4mg given the night before surgery and another dose the day of surgery in the morning.
2941895|NCT02958878|Placebo Comparator|B|Placebo medication given the night before surgery and another dose the day of surgery in the morning
2941896|NCT02958865|Experimental|PF-06651600 Drug Dose Level 1|Delivered orally for 8 weeks
2941897|NCT02958865|Experimental|PF-06651600 Drug Dose Level 2|Delivered orally for 8 weeks
2941898|NCT02958865|Experimental|PF-06651600 Drug Dose Level 3|Delivered orally for 8 weeks.
2941899|NCT02958865|Placebo Comparator|PF-06651600 Placebo|Delivered orally for 8 weeks.
2941900|NCT02958865|Experimental|PF-06700841 Drug Dose Level 1|Delivered orally for 8 weeks
2941901|NCT02958865|Experimental|PF-06700841 Drug Dose Level 2|Delivered orally for 8 weeks.
2941902|NCT02958865|Experimental|PF-06700841 Drug Dose Level 3|Delivered orally for 8 weeks.
2941903|NCT02958865|Placebo Comparator|PF-06700841 Placebo|Delivered orally for 8 weeks.
2941904|NCT02958865|Experimental|PF-06651600 Drug Dose Level 4|Delivered orally for 24 weeks.
2941905|NCT02958865|Experimental|PF-06700841 Drug Dose Level 4|Delivered orally for 24 weeks.
2941906|NCT02958865|Placebo Comparator|PF-06651600 Placebo 2|Delivered orally for 24 weeks.
2941907|NCT02958865|Placebo Comparator|PF-06700841 Placebo 2|Delivered orally for 24 weeks.
2941908|NCT02958852|Active Comparator|Letrozole|Confirmed ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic endocrine treatment, in this case letrozole, 2.5 mg daily until progression of disease. Upon progression of first line, patients will receive second line treatment using fulvestrant.
2941909|NCT02958852|Experimental|Letrozole+Atorvastatin|Confirmed ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic endocrine treatment, in this case letrozole, 2.5 mg daily, with the addition of atorvastatin, 40 mg daily until progression of disease. Upon progression of first line, patients will receive second line treatment using fulvestrant.
2941910|NCT02958852|Other|Fulvestrant|Fulvestrant will be used as second line endocrine treatment upon progression on first line with letrozole +/- atorvastatin.
2941911|NCT02958839||Recurrence Group|In the case control trial, patients who have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
2941912|NCT02958839||Non-recurrence Group|In the case control trial, patients who do not have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
2941913|NCT02958813|Experimental|IMARA|IMARA blends three programs with the most relevance for AA women (SISTA) and girls (SiHLE) and families in psychiatric care (Project STYLE). Separate mother and daughter groups cover parallel content and run simultaneously, and joint activities enhance mothers' credibility as a resource for HIV/STI prevention, practice new communication skills, negotiate conflict, and strengthen the mother-daughter relationship. Activities reinforce the reciprocal impact of mothers and daughters, and enhance safe sex knowledge, attitudes, and skills. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
2941914|NCT02958813|Placebo Comparator|FUEL|FUEL Health Promotion Control combines two programs, FUEL and Project Balance Health Promotion. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. FUEL™ does not explicitly address HIV/STI prevention. Investigators will present information from Balance's session about HIV/AIDS, condoms, and other STIs. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
2941915|NCT02958800|Experimental|Intervention|The intervention consists of assigning each participant to their own single patient open label trial consisting of a 1:1 randomized sequence of two pre-determined dose reductions of atypical antipsychotics for each participant in order to determine any behavioural issues that arise from atypical antipsychotic dose alteration.
2941916|NCT02958787|Experimental|Intervention|Vessel Sparing Radiation Therapy using MRI based treatment planning to limit dose to critical erectile structures
2941917|NCT02958774|Experimental|Hypofractionated Radiation Therapy|Daily for 4 weeks
2941918|NCT02958761|Experimental|Platelet-rich plasma|Patients in the intervention group will receive three autologous PRP plus calcium gluconate (as activator) intraarticular injections at 4-week intervals. Briefly, at the Immunohaematology and Transfusion Service, on each scheduled visit 20 ml of autologous whole blood will be sampled from each patient, 2 ml ACD-A will be added directly the syringe as anticoagulant; finally the vial will be gently centrifuged at 900rpm for 7 minutes. Platelet-rich plasma was collected. The PRP vials plus activator will be immediately shipped to the rehabilitation unit, where intraarticular injection will be performed by an experienced physiatrist.
2941919|NCT02958761|Active Comparator|hyaluronic acid|Patients in the control group will receive three intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals, by the same study staff.
2941920|NCT02958748||ARDS|Patients admitted to ICU with diagnosis of ARDS,which happened in 48hours.
2941921|NCT02958748||Control|Heathy vonlunteers
2941922|NCT02958735|No Intervention|Rest|Participants randomly assigned to this arm rest quietly for thirty minutes instead of participating in the exercise challenge.
2941923|NCT02958735|Experimental|Mild Exercise|Participants randomly assigned to this arm are made to maintain a heart rate equivalent to 60% of the heart rate observed when VO2 max was achieved in the maximal stress test from the first visit.
2941924|NCT02958735|Experimental|Hard Exercise|Participants randomly assigned to this arm are made to maintain a heart rate equivalent to 80% of the heart rate observed when VO2 max was achieved in the maximal stress test from the first visit.
2941925|NCT02958722|Active Comparator|carbon dioxide|Diagnostic hysteroscopy performed with the carbon dioxide (gas)
2941926|NCT02958722|Active Comparator|physiological solution|Diagnostic hysteroscopy performed with liquid solution (physiologic solution)
2941927|NCT02958709|Experimental|high dose RIF, INH, PZA, EMB|Arm 1 participants will receive high-dose rifampicin for 8 weeks plus ethambutol at standard doses, in addition to standard doze pyrazinamide (PZA) and isoniazid.
2941928|NCT02958709|Experimental|high dose RIF, INH, PZA, LEVO|Arm 2 participants will receive high-dose rifampicin plus levofloxacin for 8 weeks, in addition to standard doze pyrazinamide and isoniazid.
2941929|NCT02958709|Active Comparator|standard dose RIF, INH, PZA, EMB|Arm 3 participants will receive standard of care dose rifampicin plus ethambutol for 8 weeks, in addition to standard doze pyrazinamide and isoniazid.
2941930|NCT02958696|Active Comparator|HTL0018318 low dose|low dose aqueous solution and/or equivalent low dose capsule
2941931|NCT02958696|Active Comparator|HTL0018318 mid dose|mid dose aqueous solution and/or equivalent mid dose capsule
2941932|NCT02958696|Active Comparator|HTL0018318 high dose|high dose aqueous solution and/or equivalent high dose capsule(s)
2941933|NCT02958683||Pectus excavatum|Patients with pectus excavatum (funnel chest) condition undergo chest wall motion analysis
2941934|NCT02958683||Pectus carinatum|Patients with pectus carinatum (pigeon chest) condition undergo chest wall motion analysis
2941935|NCT02958683||Chronic obstructive pulmonary disease|Patients affected by COPD undergo chest wall motion analysis
2941936|NCT02958683||Diaphragm abnormality|Patients with abnormal function or structure of the diaphragm. Including diaphragmatic hernia/rupture and diaphragmatic paralysis undergo chest wall motion analysis
2941937|NCT02958683||Healthy control|People who do not have any diagnosed thoracic condition and who do not have symptoms/signs suggestive of undiagnosed thoracic disease undergo chest wall motion analysis
2941938|NCT02958683||Lung cancer|Patients with suspected or confirmed lung malignancy of all histological subtypes undergo chest wall motion analysis
2941939|NCT02958683||Pleural disease|Patients with pleural thickening and/or pleural effusion, pneumothorax, empyema undergo chest wall motion analysis
2941940|NCT02958683||Asthma|Patients diagnosed with asthma clinically or upon spirometry undergo chest wall motion analysis
2941941|NCT02958683||Cystic fibrosis|Patients diagnosed with cystic fibrosis clinically or biochemically undergo chest wall motion analysis
2941942|NCT02958683||Rib or sternal disease|Patients with an abnormality in the chest wall including fractures, osteomyelitis, malignancy of all histological subtypes, chest wall resection/reconstruction undergo chest wall motion analysis
2941943|NCT02958670|Experimental|18F-AV-1451-PET|All subjects receive a Scan for assessment of TAU with the radiotracer 18-F-AV-1451
2941944|NCT02958657|Experimental|Exercise Training|Patients randomized to the training group will start the supervised regular training program 01 month after the myocardial infarction, and it will last for three months.
2941945|NCT02958657|No Intervention|Control Group|Patients in the control group will receive general instructions regarding rehabilitation post-acute myocardial infarction and will be followed for four months after the myocardial infarction.
2941946|NCT02958644|Experimental|Synbiotics|Synbiotics - 12g / day fructo-oligosaccharide and probiotics supplemented orally for 90 days.
2941947|NCT02958644|Placebo Comparator|Placebo|"Placebo - polydextrose 12g /day supplemented orally for 90 days.~The study supplements are packed in identical envelopes containing either 12g of oral powder fructo-oligosaccharide and probiotics or placebo to be diluted in water. The powder and the solution were identical in appearance, taste, and smell."
2941948|NCT02958631|Experimental|Fimasartan|Fimasartan 60mg, QD
2941949|NCT02958631|Active Comparator|Losartan|Losartan 50mg, QD
2941950|NCT02958618|Experimental|"Duration for 30 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 30 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
2941951|NCT02958618|Experimental|"Duration for 60 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 60 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
2941952|NCT02958618|Experimental|"Duration for 180 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 180 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
2941953|NCT02958605|Experimental|Smartphone|Smartphone application
2941954|NCT02958605|Experimental|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
2941955|NCT02958592||study group|patients with liver tumor intend to perform hepatectomy
2941956|NCT02958579||Obesity|Body mass index (BMI) score > 25.2 kg/m2 for women and > 27.3 kg/m2 for men or Waist circumference > 90 cm
2941957|NCT02958579||Pre-diabetics or diabetics|"if any of followings is identified the participant is regarded as diabetics and will be recruited in this arm;~Fasting Plasma glucose (FPG) level ≥ 7.0 mmol/l (126 mg/dL)~Plasma glucose ≥ 11.1 mmol/l (200 mg/dL) two hours after a 75 g oral glucose load as in a glucose tolerance test~Symptoms of hyperglycemia and casual plasma glucose ≥ 11.1 mmol/l (200 mg/dL)~Glycated hemoglobin (A1C) ≥ 6.5% if any of followings is identified the participant is regarded as pre-diabetics and will be recruited in this arm;~1- FPG levels of 100-125 mg/dl (5.6-6.9 mmol/l). 2-Two-h plasma glucose (2HPP) in the 75 g oral glucose tolerance test of 140-199 mg/dl (7.8- 11.0 mmol/l)"
2941958|NCT02958579||Hypertension|Systolic blood pressure (SBP) ≥ 130mmHgand/or diastolic blood pressure (DBP) ≥ 85mmHg or use of anti-hypertensive drugs
2941959|NCT02958579||hypertriglyceridemia|Serum triglyceride ≥150 mg/dL
2941960|NCT02958579||Low high density lipoprotein -cholesterol (HDL-c)|Serum HDL-C of <40 mg/dL for men, <50 mg/dL for women,
2941961|NCT02958566|Active Comparator|Narcotic|"Morphine, Dilaudid or Fentanyl patient controlled anesthesia (PCA) for the immediate postoperative period, in addition to Norco 5-325 mg 1-2 tabs Q4H PRN, or equivalent medication.~Post-operative day 1: PCA will be discontinued and the patients will have IV narcotics PRN: Morphine 1-2 mg Q2H PRN, fentanyl 50-75 mcg Q2H PRN or Dilaudid 0.5 mg Q2H PRN"
2941962|NCT02958566|Experimental|Non-Narcotic|Gabapentin 300 mg PO, orphenadrine 60 mg IV, acetaminophen 1000 mg PO or IV on Morning of surgery. Lidocaine 100 mg prior to incision, lidocaine 1mg/kg/hour during procedure, marcaine in all incisions. Ketamine and methadone per anesthesia. Acetaminophen 1000 mg PO or IV, gabapentin 300 mg PO, tramadol 50 mg PO in PACU. Acetaminophen 600 mg PO Q 6 hours, tramadol 50 mg PO Q 6 hours, gabapentin 300 mg PO Q 6 hours, orphenadrine 60 mg IV Q 12 hours, ketorolac 15 mg IV Q 6 hours for 48 hours post-operatively.
2941963|NCT02958553|Other|emPOWER Ankle (powered prosthesis)|The subject's own passive prosthesis will be used as a baseline and crossed over after the emPOWER has been worn 3-4 months. Then the passive foot will be crossed back to the emPOWER for a final series of tests.
2941964|NCT02958540|Experimental|SynGEM low dose|Group 1: 18 subjects receiving SynGEM low dose
2941965|NCT02958540|Experimental|SynGEM high dose|Group 2: 18 subjects receiving SynGEM high dose
2941966|NCT02958540|Placebo Comparator|placebo|12 subjects receiving placebo
2941967|NCT02958527||venlafaxine|Patients with no experience of using time Effexor(venlafaxine) who will be administered time Effexor(venlafaxine)for the first
2941968|NCT02958514|Other|traditional treatment group|Subjects in this group are treated by tobramycin and dexamethasone ophthalmic ointment qn and artificial tears qid.
2941969|NCT02958514|Experimental|IPL treatment group|Subjects in this group are treated with 3 cycles of intense pulsed light of 4 weeks interval and artificial tears qid.
2941970|NCT02958501|Active Comparator|IU/Day|This is standard dose of the drug (colecalciferol), which is not calculated in relation to patient body weight
2941971|NCT02958501|Active Comparator|IU/Kg/Day|This is dose of the drug (colecalciferol), which is based or calculated in relation to patient actual body weight
2941972|NCT02958488|Experimental|Preterm Neonates with Respiratory Distress Syndrome|34 to 36 Weeks Preterm Neonates with Respiratory Distress Syndrome
2941973|NCT02958475|Experimental|Attention Control|Participants in control arm will receive normal standard messages about infant injury prevention.
2941974|NCT02958475|Active Comparator|Breastfeeding Messages plus Social Support|Participant will receive between 5-7 text messages weekly through push notifications to their phone. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action. In addition they will be able to download the MMM app, which will store text messages received. Additionally, participants in this arm will be able to link within the app to a private Facebook page. Participants can access this page through their app or directly via Facebook where they can view, comment, and share in response to posts. The MMM app has three main elements: text messages via push notification are stored and searchable on the app, access to a breastfeeding social support group on Facebook, and access to videos and written material to facilitate knowledge acquisition and skills building.
2941975|NCT02958475|Active Comparator|Breastfeeding Messages only|Participant will receive between 5-7 text messages weekly through push notifications to their phone. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
2941976|NCT02958462|Other|Potential Premyeloid Cancer or Bone Marrow Failure Patients|Follow up provided for patients tested using Next Generation Sequencing (NGS) and other relevant functional studies
2941977|NCT02958449|Experimental|Test - Standard Closure with TissuGlu Surgical Adhesive|Standard closure plus treatment with TissuGlu
2941978|NCT02958449|No Intervention|Control - Standard Closure|Standard closure with no intervention
2941979|NCT02958436|Experimental|Cohort 1|Dose regimen 1 of REGN3500 (IV) versus placebo
2941980|NCT02958436|Experimental|Cohort 2|Dose regimen 2 of REGN3500 (IV) versus placebo
2941981|NCT02958436|Experimental|Cohort 3|Dose regimen 3 of REGN3500 (IV) versus placebo
2941982|NCT02958436|Experimental|Cohort 4|Dose regimen 4 of REGN3500 (SC) versus placebo
2941983|NCT02958436|Experimental|Cohort 5|Dose regimen 5 of REGN3500 (IV) versus placebo
2941984|NCT02958423|Experimental|Transcranial DCS Healthy Volunteers|5 HV will be treated once with transcranial direct current stimulation (2mA, anodal, 20 minutes) over right primary motor cortex with the Direct Current (DC) Stimulator (NeuroConn. Germany)
2941985|NCT02958423|Experimental|Transspinal DCS Healthy Volunteers|5 HV will be treated once with transspinal direct current stimulation (2mA, anodal, 20 minutes) over the D10 spinal process with the Direct Current (DC) Stimulator (NeuroConn. Germany)
2941986|NCT02958423|Experimental|Transcranial DCS CPP patients|5 chronic pelvic pain patients will be treated with transcranial direct current stimulation (2mA, anodal, 20 minutes) over right primary motor cortex 5 days/week for 4 weeks with the Direct Current (DC) Stimulator (NeuroConn. Germany)
2941987|NCT02958423|Experimental|Transspinal DCS CPP patients|5 chronic pelvic pain patients will be treated with transspinal direct current stimulation (2mA, anodal, 20 minutes) over the D10 spinal process 5 days/week for 4 weeks with the Direct Current (DC) Stimulator (NeuroConn. Germany)
2941988|NCT02958410|Experimental|Lymphocyte Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD30-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
2941989|NCT02958397|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with anti-CD33-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
2941990|NCT02958384|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-LeY-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
2941991|NCT02958371|Experimental|fMRI|The study consists in a fMRI experiment intended to observe the effect of the presence of choice on brain activity following consumption of a fruit-flavored drink, compared to the brain activity when the same drink is consumed without choice.
2941992|NCT02958358|Experimental|Pulmonary Hypertension|Patients with Group I pulmonary arterial hypertension to undergo CT imaging, functional PET imaging before and after 3 months of treatment with ambrisentan
2941993|NCT02958345|Active Comparator|Zostavax|Subjects will receive 0.65 mL of Zostavax subcutaneously in the deltoid region of the upper arm.
2941994|NCT02958345|Placebo Comparator|Placebo|Subjects randomized to placebo will receive an injection of 0.65 mL of sterile normal saline subcutaneously in the deltoid region of the upper arm.
2941995|NCT02958332|Experimental|video game program|Participants will play video games during 30 min , all along 5 sessions.
2941996|NCT02958319||Anti P Carb negative RA patients|RA patients negative for antibodies against the carbamylated proteins
2941997|NCT02958319||Anti P Carb positive RA patients|RA patients positive for antibodies against the carbamylated proteins
2941998|NCT02958306|Experimental|platelet rich plasma|autologous blood product
2941999|NCT02958306|No Intervention|no platelet rich plasma|control
2942000|NCT02958293||December admission|The elective surgery group of people whose admission was the end of the calendar year (December) corresponding with insurance deductible year-end.
2942001|NCT02958293||Non-December admission|The elective surgery group of people whose admission was between January and November.
2942002|NCT02958280|Other|App Development and Open Pilot|"Phase 1 (app development) will consist of: 1) development of the Fit&Sober prototype; and 2) series of usability studies with patients with AUDs.~Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the Fit&Sober app with patients with AUDs in early recovery."
2942003|NCT02958267|Experimental|BMAC injection and PRP injection|Injection of bone marrow aspirate concentrate (BMAC) withdrawn from a bone near the hip into the knee joint (intra-articular) immediately followed by an injection of platelet-rich plasma (PRP) into the knee joint.
2942004|NCT02958267|Active Comparator|Gel-One® hyaluronate injection|Gel-One® is an hyaluronate gel used in the treatment of knee osteoarthritis by injection into the knee joint (intra-articular).
2942005|NCT02958228|Experimental|Positive Mental Imagery Training (PMIT)|Computerized Positive Mental Imagery Training (PMIT), a form of mental imagery-based cognitive bias modification adapted from previous experimental (e.g. Holmes, Lang, & Shah, 2009) and clinical (e.g. Blackwell & Holmes, 2010) work. The intervention consists of 8 sessions completed over a period of 2 weeks. The training takes place alongside participants' treatment as usual (TAU) in the inpatient setting.
2942006|NCT02958228|Active Comparator|Cognitive Control Training (CCT)|An adaptive Paced Auditory Serial Addition Task (PASAT), adapted from that applied in previous studies (e.g. Siegle et al., 2007; Hoorelbeke et al., 2015). The intervention consists of 8 sessions completed over a period of 2 weeks. The training takes place alongside participants' treatment as usual (TAU) in the inpatient setting.
2942007|NCT02958228|Active Comparator|Treatment as Usual|Participants will receive their treatment as usual (TAU) within the inpatient setting, which may include group/individual psychological therapy, a range of therapeutic activities, and pharmacological treatment.
2942008|NCT02958215|Placebo Comparator|Group A|This group will include patients with orthostatic hypotension and will be managed with routine spinal anesthesia Ephedrine will be used for management of intraoperative hypotension
2942009|NCT02958215|Active Comparator|Group B|This group will include patients with orthostatic hypotension and will be managed with prophylaxis single dose of phenylephrine, 50 ug IV, will be administered immediately before the spinal block then the patients will be managed with routine spinal anesthesia Ephedrine will be used for management of intraoperative hypotension
2942010|NCT02958202|Experimental|BMN 044 IV 6 mg/kg|Weekly intravenous (IV) dosing with 6 mg/kg
2942011|NCT02958202|Experimental|BMN 044 IV 9 mg/kg|Weekly intravenous (IV) dosing with 9 mg/kg
2942012|NCT02958202|Experimental|BMN 044 SC 6 mg/kg|Weekly subcutaneous (SC) dosing with 6 mg/kg
2942013|NCT02958189|Experimental|Group 1: Tweet4Wellness+Self-monitoring|This group will receive the Tweet4Wellness intervention: daily theory-based peer-to-peer discussion prompt within the private Twitter-based support group for the entire 6 months of the study. They will also receive the Fitbit triaxial pedometer that will track their daily steps (self-monitoring component).
2942014|NCT02958189|Experimental|Group 2: Self-monitoring|This group will receive the Fitbit triaxial pedometer that will track their daily steps (self-monitoring component) for the first 3 months. For the second three months of the study, they will receive the Tweet4Wellness intervention in addition to their Fitbit self-monitoring.
2942015|NCT02958189|Active Comparator|Group 3: Control|This group will receive the address to a CDC website on physical activity and walking for the first three months. For the second three months of the study, this group will receive both the Tweet4Wellness intervention and the Fitbit triaxial pedometer.
2942016|NCT02958176|Experimental|HRV Biofeedback|At home HRV biofeedback using mobile device
2942017|NCT02958176|Experimental|HRV Biofeedback with Autogenic Training|At home HRV biofeedback using mobile device plus autogenic training recording
2942018|NCT02958176|No Intervention|Wait List|Wait list control
2942019|NCT02958163|Active Comparator|Trans-Arterial Chemo-embolization (TACE)|"Trans-arterial Embolisation will be performed with drug-eluting beads loaded with Doxorubicin. First session will be given within 4 weeks after randomization.~4-phase MRI will be performed every 2 months to assess the response. In case of insufficient response according to the MRI performed at 2 or 4 months, a second or third session of DEB-TACE will be allowed, according to the physician's choice.~Once complete response is achieved, the follow-up period will start. The date of the last session of TACE corresponds to the treatment completion date."
2942020|NCT02958163|Experimental|TACE+Stereotactic Ablative Radiotherapy|"The first part of the treatment, which is the DEB-TACE delivery, will be exactly the same than in arm A. The radiotherapy (SABR) will then start within 4 to 6 weeks after.~Afterwards, 4-phase MRI will be performed every 2 months to assess the response. In case of insufficient response according to the MRI performed at 2 or 4 months, a second or third session of DEB-TACE will be allowed, according to the physician's choice.~Once complete response is achieved, the follow-up period will start. The date of the last SABR fraction or the last session of TACE corresponds to the treatment completion date."
2942021|NCT02958150|Experimental|Dexmedetomidine|Dexmedetomidine according to the stablished protocol
2942022|NCT02958150|Active Comparator|Standard Clinical Practice|The physician in charge will decide the treatment to be administered (if deemed necessary) in accordance with the protocol established at the department
2942023|NCT02958137||Isolated CMC|Arthroscopic Resection Arthroplasty of isolated CMC joint OA. Please note, this is standard practice of Dr. Cobb's for treatment of CMC and/or STT arthritis.
2942024|NCT02958137||Pantrapezial|Arthroscopic Resection Arthroplasty of simultaneous ARA of both the CMC and the STT joints. Please note, this is standard practice of Dr. Cobb's for treatment of CMC and/or STT arthritis.
2942025|NCT02958111|Experimental|Adjuvant capecitabine|Adjuvant chemotherapy with single-agent capecitabine
2942026|NCT02958111|No Intervention|Observation|Clinical follow-up and surveillance only
2942027|NCT02958098||Myocardial infarction|Individuals with myocardial infarction before age 50 years.
2942028|NCT02958098||Stroke|Individuals with stroke before age 50 years
2942029|NCT02958098||Aortic dissection|Individuals with aortic dissection before age 50 years
2942030|NCT02958098||Systolic heart failure|Individuals with systolic heart failure/dilated cardiomyopathy before age 50 years.
2942031|NCT02958098||Atrial fibrillation|Individuals with atrial fibrillation before age 50 years
2942032|NCT02958085|Experimental|NNC0174-0833|
2942033|NCT02958085|Placebo Comparator|Placebo|
2942034|NCT02958072|Experimental|LeucoPatch|Treatment with usual ulcer care and LeucoPatch once weekly up til 24 weeks or until healing.
2942035|NCT02958072|Active Comparator|Usual care followed by LeucoPatch|Usual care weekly for 12 weeks, if the ulcer persist after the12 weeks LeucoPatch treatment will be started for up to 12 weeks or until healing.
2942036|NCT02958059|Experimental|Treatment|The intervention group
2942037|NCT02958059|Placebo Comparator|Comparator|The comparator group
2942038|NCT02958046|Experimental|Lansoprazole/Domperidone|DUOLANS 30/30 mg SR tablet per oral, one tablet daily
2942039|NCT02958033|Experimental|HF WBI-SIB breast radiation|WBI-SIB breast radiation(WBI 2.5Gy x18 and SIB 2.88Gy x18)
2942040|NCT02958033|Placebo Comparator|CF WBI-SIB breast radiation|WBI-SIB breast radiation(WBI 1.8Gy x28 and SIB 2.15Gy x28)
2942041|NCT02958007|Experimental|Peer Education on Exercise for Recovery|A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
2942042|NCT02958007|Active Comparator|Enhanced supervised fitness training|A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
2942043|NCT02957994|Experimental|TAF Arm|Tenofovir alafenamide fumarate 25mg, 1 tablet once daily for 24 weeks
2942044|NCT02957981|Experimental|Web-Based Counseling|Genetic information provided via an individually tailored website.
2942045|NCT02957981|Active Comparator|Standard Care|Participants are not provided with web-based education but can choose to pursue genetic counseling and testing.
2942046|NCT02957968|Experimental|Cohort A: Triple Negative Breast Cancer (TNBC)|Triple Negative Breast Cancer (Cohort A): Decitabine IV over 60 minutes on 4 days and pembrolizumab IV over 30 minutes on days 8 and 22. Four cycles of dose-dense doxorubicin and cyclophosphamide (AC), followed by 12 doses of weekly paclitaxel and carboplatin.
2942047|NCT02957968|Experimental|Cohort B: HER2-negative hormone receptor-positive tumors|HER2-negative hormone receptor-positive tumors (Cohort B): Decitabine IV over 60 minutes on 4 days and pembrolizumab IV over 30 minutes on days 8 and 22. Four cycles of dose-dense doxorubicin and cyclophosphamide (AC), followed by 12 doses of weekly paclitaxel.
2942048|NCT02957955|Experimental|Interventional|Group 1. Usual care + High-Intensity Interval Training, Nutritional Workshop, Stress Management Course.
2942049|NCT02957955|No Intervention|Non interventional|Group 2. Usual care. Patients are encouraged to remain physically active, although they do not participate in a regular structured exercise training program.
2942050|NCT02957942|Experimental|Spasmodic Dysphonia|1Hz repetitive transcranial magnetic stimulation (rTMS)
2942051|NCT02957942|Active Comparator|Healthy control|Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)
2942052|NCT02957929|Experimental|Cohort 1a, Period A|single intravenous dose, crossover
2942053|NCT02957929|Experimental|Cohort 1a, Period B|single oral dose, crossover
2942061|NCT02957903|Experimental|Treatment A|"Injection around the lateral femoral cutaneous nerve:~8 ml Ropivacaine 0.75 %."
2942062|NCT02957903|Placebo Comparator|Treatment B|"Injection around the lateral femoral cutaneous nerve:~8 ml isotonic Saline."
2942063|NCT02957890|Experimental|Twice-annual influenza vaccination|Twice-annual influenza vaccination: administrations of inactivated influenza vaccine (Northern hemisphere formulation, NH) prior to the northern hemisphere winter, plus inactivated influenza vaccine (Southern hemisphere formulation, SH) prior to the northern hemisphere summer.
2942064|NCT02957890|Placebo Comparator|Once-annual influenza vaccination|Administrations of inactivated influenza vaccine (Northern hemisphere formulation, NH) prior to the northern hemisphere winter, plus placebo prior to the northern hemisphere summer.
2942065|NCT02957877|Experimental|LMWH arm|8-hour hemodialysis is performed on alternate day for a week at the dialysis unit (i.e. 3 sessions) by using low-molecular weight heparin (nadroparin) as anticoagulation
2942066|NCT02957877|Active Comparator|UFH arm|8-hour hemodialysis is performed on alternate day for a week at the dialysis unit (i.e. 3 sessions) by using unfractionated heparin as anticoagulation
2942067|NCT02957864|Experimental|Switch to tenofovir alafenamide|Switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide
2942068|NCT02957864|Active Comparator|Switch to abacavir|Switch from tenofovir disoproxil fumarate (TDF) to abacavir
2942069|NCT02957851|Placebo Comparator|Oxygen/Nitrogen (22%/78%)|Medical Air
2942070|NCT02957851|Active Comparator|Nitrous Oxide/Oxygen (50%/50%)|EMONO
2942071|NCT02957838|Experimental|Non-diabetics|Non-diabetic volunteers with HbA1c < 6.5%. Subjects will be treated with C18:0 supplementation or mock.
2942072|NCT02957838|Experimental|Type 2 Diabetics|Type 2 Diabetes according to common definitions, but we exclude insulin-treated Type 2 diabetics because nutritional intervention is more difficult/risky. Subjects will be treated with C18:0 supplementation or mock.
2942073|NCT02957825|No Intervention|Control|Routine monitoring
2942074|NCT02957825|Experimental|Continuous wireless monitoring|Continuous wireless monitoring
2942075|NCT02957812|Experimental|Orthotics|Custom made orthotic provided for study
2942076|NCT02957812|No Intervention|Control|Wearing own footwear
2942077|NCT02957799|Experimental|Accountable Condition- 8 clinics|In the Accountable Condition, the intervention includes mothers who will receive home visits from government-funded CHW who will be trained once under Philani and receive ongoing monitoring and supervision.
2942078|NCT02957799|Experimental|Control Condition- 8 clinics|The Control Condition will include mothers who receive home visits from government-funded CHW who will be trained once under Philani and receive supervision and monitoring consistent with local government practices.
2942079|NCT02957786|Experimental|Cytisine plus behavioural support|"12-week course of cytisine capsules (1.5mg), with a decreasing dosing regimen (9mg/day for days 1-3, 7.5mg/day for days 4-12, 6mg/day for days 13-16, 4.5mg/day for days 17-20, 3.0mg/day from days 21-week 12).~Participants will be asked to reduce their smoking over the first four days of treatment so that they are not smoking at all by the fifth day, which will be their designated Quit date.~Participants will also withdrawal-orientated behavioural support (delivered by cessation advisors), in addition to brief cessation advice from the study-specific doctor (at the point that the prescription is provided) and community pharmacist (at the point the participant redeems their prescription)."
2942080|NCT02957786|Active Comparator|Varenicline plus behavioural support|"12-week course of Varenicline tablets (0.5mg/1mg), with an increasing dosing regimen (0.5mg/day for days 1-3, 1.0mg/day for days 4-7, 2.0mg/day for day 8-week 12).~Participants will be asked to reduce their smoking over the first four days of treatment so that they are not smoking at all by the fifth day, which will be their designated Quit date.~Participants will also receive withdrawal-orientated behavioural support (delivered by cessation advisors), in addition to brief cessation advice from the study-specific doctor (at the point that the prescription is provided) and community pharmacist (at the point the participant redeems their prescription)."
2942081|NCT02957773|Experimental|Qigong and art activities|An integrated group of Qigong and art activities for 90 minutes.
2942082|NCT02957773|Experimental|Art activities|Art activities and daily activities group for 90 minutes.
2942083|NCT02957773|Experimental|Qigong|A Qigong and daily activities group for 90 minutes
2942084|NCT02957773|Other|Daily activities|A daily activities group for 90-minutes.
2942085|NCT02957747|Experimental|Safety and Health Experiences Program|Participants in the SHE arm of the study will receive a web-based intervention utilizing motivational interviewing and education.
2942086|NCT02957747|No Intervention|Control|Participants randomized to this arm will receive referrals to VA and community resources
2942087|NCT02957734|Experimental|LAVA Ultimate restorations|For rehabilitation of the severely worn teeth, teeth are prepared (based on Minimal Invasive procedures), scanned using an intra-oral 3D-scanner (TrueDef, 3M), a digital wax-up model is made and finally restorations are milled from a pre polymerized block of resin (LAVA Ultimate). These indirect restorations are then adhesively cemented on the teeth (Relyx Ultimate, 3M). Teeth on which no indirect restoration could be made/designed a direct composite restoration was made using Filtek Supreme XTE in combination with Scotchbond Universal. Furthermore, all anterior veneer restorations are made of direct composite restorations (Filtek Supreme XTE in combination with Scotchbond Universal).
2942088|NCT02957721|Other|Behavioral self-management|Eligible patients who are registered on the practice EHR linked portal will be invited to join the study. Following informed consent, enrollment and randomization, participants in the treatment group will receive the type 2 diabetes behavioral self-management education intervention; comprised of 9 modules derived from Medline Plus.
2942089|NCT02957721|No Intervention|Usual Care|Usual care includes whatever care and services the patient's clinical provides as well as generic type 2 diabetes education built into the patient's EHR linked portal.
2942090|NCT02957708|Experimental|mCIMT + SR|modified constraint-induced movement therapy plus self regulation
2942091|NCT02957708|Active Comparator|Control|conventional occupational therapy
2942092|NCT02957695|Placebo Comparator|Control group|Control Intervention: Placebo-Neurofeedback, 20 sessions
2942093|NCT02957695|Active Comparator|Intervention group|Experimental Intervention: Active-Neurofeedback, 20 sessions
2942094|NCT02957682|Experimental|Group 1|Praluent Regimen - Administration through subcutaneous injection
2942095|NCT02957682|Experimental|Group 2|Placebo matching Praluent - Administration through subcutaneous injection
2942096|NCT02957669|Experimental|Practice Self-Regulation (PS-R)|Practice Self-Regulation (PS-R) is the treatment condition. PS-R is an in-person, individual-level, clinic-based intervention that aims to increase knowledge of sexual health and the impact of trauma on sexual decision-making.
2942097|NCT02957669|Active Comparator|Therapy Practice Group|Therapy Practice Group is the control counterfactual condition. It is an individual-level, therapy as usual in which the therapist addresses mental health concerns of the participant.
2942098|NCT02957656|Experimental|Group 1: H7N9 pLAIV + AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of approximately 10^7.0 FFU of H7N9 pLAIV at study entry (Day 0). They will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at Day 84.
2942099|NCT02957656|Experimental|Group 2: AS03-adjuvanted H7N9 pIIV + AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at study entry (Day 0) and one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at Day 84.
2942100|NCT02957656|Experimental|Group 3: AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at study entry (Day 0).
2942101|NCT02957656|Experimental|University of Rochester URMC 13-001 Participants|Participants received one dose of 10^7 FFU of H7N9 pLAIV at study entry (Day 0), one dose of 10^7 FFU of H7N9 pLAIV at Day 28, and one dose of 30 µg of unadjuvanted H7N9 pIIV at Day 84.
2942102|NCT02957656|Experimental|Johns Hopkins School of Public Health CIR293 Participants|Participants received one dose of 10^7 FFU of H7N9 pLAIV at study entry (Day 0), one dose of 10^7 FFU of H7N9 pLAIV at Day 28, and one dose of 30 µg of unadjuvanted H7N9 pIIV at Day 84.
2942103|NCT02957643|Placebo Comparator|pregnant women|iron dosage 1 per day for 3 months
2942104|NCT02957643|Experimental|pregnant women with low hemoglobin levels|iron dosage 1 per day for 6 months
2942105|NCT02957630|Experimental|15 mg E4/3 mg DRSP|15 mg estetrol/3 mg drospirenone combined oral contraceptive
2942106|NCT02957630|Active Comparator|30 mcg EE/150 mcg LNG|30 mcg ethinylestradiol/150 mcg levonorgestrel combined oral contraceptive
2942107|NCT02957630|Active Comparator|20 mcg EE/3 mg DRSP|20 mcg ethinylestradiol/3 mg drospirenone combined oral contraceptive
2942108|NCT02957617|Experimental|BIIB074|BIIB074 orally twice daily
2942109|NCT02957604||Specific Evolocumab-Exposed Cohort|Women diagnosed with hypercholesterolemia and ASCVD, or hypercholesterolemia and FH, who were exposed to evolocumab during pregnancy
2942110|NCT02957604||Comparison Group I|Women diagnosed with hypercholesterolemia and ASCVD, or hypercholesterolemia and FH, who were not exposed to evolocumab during pregnancy
2942111|NCT02957604||Comparison Group II|A general comparison group of pregnant women who have not been diagnosed with hypercholesterolemia and ASCVD, or hypercholesterolemia associated with FH, and who were not exposed to evolocumab during pregnancy
2942112|NCT02957604||General Evolocumab-Exposed Case Series|Women who were exposed to evolocumab but do not fulfill eligibility criteria for the Specific Evolocumab-Exposed Cohort
2942113|NCT02957591|Experimental|Probiotic Group|Over a period of 4 weeks, depressive patients will ingest a probiotic food supplementation (Vivomixx®) 4 times a day. Primary and secondary endpoints will be assessed before and after the intervention.
2942114|NCT02957591|Placebo Comparator|Placebo Group|Subjects in the placebo group will receive a placebo 4 times a day over 4 weeks. Primary and secondary endpoints will be assessed before and after the intervention.
2942115|NCT02957578|Experimental|Solo TTD|Placement of tympanostomy tube with Solo TTD
2942116|NCT02957565|Experimental|Video 1: No EHR - Physician A|"Participant completes 5 questionnaires during an already-scheduled office visit.~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
2942117|NCT02957565|Experimental|Video 1: No EHR - Physician B|"Participant completes 5 questionnaires during an already-scheduled office visit.~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
2942118|NCT02957565|Experimental|Video 2: With EHR - Physician A|"Participant completes 5 questionnaires during an already-scheduled office visit.~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
2942119|NCT02957565|Experimental|Video 2: With EHR - Physician B|"Participant completes 5 questionnaires during an already-scheduled office visit.~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
2942120|NCT02957552|Experimental|Treatment with Mesenchymal Stem Cells|"Two doses of 1 x 10^6 MSCs/kg body weight:~first administration intraoperatively via intraportal infusion~second infusion via intravenous infusion on postoperative day 2 (+/- 1 day)~Standard immunosuppressive treatment consisting of steroids, basiliximab and tacrolimus according to the center's pediatric liver transplantation protocol"
2942121|NCT02957539|No Intervention|No Reward|At enrollment, participants randomized to usual care will be given the MOVE! workbook that serves both as an information resource on diet and exercise, a resource for tools to achieve weight loss goals, and a log of participants' goals, motivations, and outcomes. Each participant will be given a chart with a personalized target weight for a loss of 1lb. per week for 16 weeks. Participants will be given a digital scale or wireless scale and counseled to weigh themselves daily. Participants will enter their weight weekly into an online portal. They will also complete the surveys in the portal. They will receive text message reminders to enter their weight.
2942122|NCT02957539|Experimental|Financial Reward Arm|Same as usual care, plus financial rewards that are earned in two ways: an assured and random. For the assured reward, they will receive compensation at the end of each month that they are at or below their target weight on the last day of that period. For the random portion, each week that a participant is at or below their target weight, the patient is entered in random drawing to win additional compensation. Over the first eight weeks the patient has a 1-in-8 chance of winning.Over the 17-32 week period, Veterans in this group will receive token rewards for tracking and reporting their weekly weights regardless of whether it was on target. Each week that the patient enters his/her weight into the portal, he will have a 1-in-8 chance to earn the token reward, such as a t-shirt or movie tickets. Participants will enter their weight weekly into an online portal. They will also complete the surveys in the portal. They will receive text message reminders to enter their weight.
2942123|NCT02957539|Experimental|Non-financial Reward Arm|Procedures for the non-financial rewards arm is identical to procedures for the financial reward arm, except that the Veteran will earn points rather than cash. Each week a random drawing will be for 20 points, each monthly weigh in is worth 5 points. Veterans will be given non-financial rewards associated with the number of points they earn.
2942124|NCT02957526|Experimental|App|The web-based app will be used to ask participants about their aromatase inhibitor use in the previous 7 days and ask about treatment-related adverse symptoms, or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
2942125|NCT02957526|Active Comparator|Usual Care|Participants will have access to the web-based app, but will not receive reminders. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
2942126|NCT02957513|Experimental|Text Messaging (TM)|The TM intervention will use an extensive text message library focused on 3 key behavioral areas (diet, exercise, and medication adherence). The TM intervention will incorporate supportive cognitive behavioral strategies such as goal setting, positive reinforcement, self-talk and dealing with barriers to change. Messages will encourage social interaction (social support, problem-solving, and feedback), self-monitoring of diet and exercise, diet modification, physical activity advice and prompting and basic self- regulatory skills. Messages will be tailored based on participant demographics, health literacy, and preferences.
2942127|NCT02957513|Experimental|Health Coaching (HC)|The HC intervention will place emphasis on the coach establishing rapport with the participant and assessing and establishing their initial goals using motivational interviewing, HC program goals, plans for future individual sessions. A written copy of personal health goals will be given to patients at the end of the first session. Coaches will aim to meet with participants for individual HC sessions bi-monthly the first 2-3 months followed by monthly for 8 - 9 months to provide information and support regarding health habits focusing sessions on areas related to patient-identified health goals, needs, and barriers to change. Sessions can occur in person or by phone based on patient preference.
2942128|NCT02957513|Active Comparator|Enhanced Usual Care (EC)|"All participants in all 3 study arms (TM, HC, and EC) will receive enhanced usual care. Usual care in the participating practices will be supplemented through the following key EC resources:~A. Patient-focused Resources including: 1) MODEL Program Toolkit, and 2) low literacy diabetes educational materials.~B. Availability of diabetes support services including: 1) peer group support sessions, 2) diabetes education, 3) MyDiabetesCenter.org resources, and 4) Diabetes Coalition education hub resources.~C. Practice-focused components including: 1) practice training/continuing medical education, and 2) reporting of diabetes performance measures."
2942129|NCT02957500|Experimental|Mediclore®|adhesion barrier Mediclore 5cc, to apply medical device fully around intrauterine surgery area
2942130|NCT02957500|No Intervention|No treatment|standard treatment for surgery
2942131|NCT02957474|Experimental|Treatment A = single oral dose GED 0301, fasted|Subjects will receive a single oral 160 mg dose of GED-0301 after a 10 hour overnight fast
2942132|NCT02957474|Experimental|Treatment B = single oral dose GED 0301, fed|Subjects will receive a single oral 160 mg dose of GED-0301 after a 10 hour overnight fast, and within 30 minutes of completely consuming a high fat meal.
2942133|NCT02957474|Experimental|Treatment C = single oral dose GED 0301 fasted|Subjects will receive an oral dose of 160 mg of GED-0301 given as 4 tablets of 40 mg, after a 10 hour overnight fast
2942134|NCT02957474|Experimental|Treatment D = oral omeprazole and GED-0301|Subjects will receive one oral dose of 40 mg omeprazole once a day for 6 days. On the 5th day, a single oral 160 mg dose of GED-0301 will be given together with omeprazole.
2942135|NCT02957461||Injured/Control Pool|Injured/Control Pool consisting of athletes who are injured during the season and matched control athletes.The athlete's in this pool will be tested with the study device at time of injury and 2 follow-up time points. The BrainScope Battery consists of 4 components to collect brain electrical activity, a cognitive assessment, a neurocognitive/symptom/balance assessment, and an ocular motor assessment.
2942136|NCT02957448|Experimental|BMS 986141 and Rifampin|
2942137|NCT02957435|Experimental|eplerenone|(Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
2942138|NCT02957422|Experimental|Dietary intervention|Participants will receive dietary intervention. Participants will be taking 3 servings of dairy/day.
2942139|NCT02957422|Active Comparator|Control|Participants will receive no additional intervention. Participants will continue on their regular diet, which includes ≤1.5 dairy serving/day.
2942140|NCT02957409||sacubitril/valsartan|Patients diagnosed with HFrEF being treated with sacubitril/valsartan according to the Canadian product label and treatment initiation with sacubitril/valsartan within the last 3 months. The usual recommended starting dose is one tablet of 49 mg sacubitril / 51 mg valsartan taken twice daily. The target dose is one tablet of 97 mg sacubitril / 103 mg valsartan taken twice daily. Investigator/designated will document sacubitril/valsartan treatment adherence throughout the 3 years study period
2942141|NCT02957396|Active Comparator|Adult formulation: Finerenone tablet_Fasting|Single oral dose of 20 mg intact finerenone tablet fasting
2942142|NCT02957396|Experimental|Adult formulation: Finerenone crushed tablet_Fasting|Single oral dose of 20 mg crushed and resuspended finerenone tablet fasting
2942143|NCT02957396|Experimental|Pediatric formulation: Finerenone suspension_Fasting|Single oral dose of 20 mg finerenone suspension fasting
2942144|NCT02957396|Experimental|Pediatric formulation: Finerenone suspension_Fed|Single oral dose of 20 mg finerenone suspension fed; 30 minutes after start of an American breakfast
2942145|NCT02957383|Experimental|wavelength|Wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)
2942146|NCT02957383|Experimental|intensity|Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2).
2942147|NCT02957370||Diagnosed Urinary Bladder Neoplasms|Patients who are being monitored for bladder cancer will be the experimental group to test the electro-phage and aptamer approach to following bladder cancer biomarkers
2942148|NCT02957370||Non-Urinary Bladder Neoplasms|Patients being treated for hematuria will provide a negative control to provide data from testing for biomarkers in patients being treated for other diseases.
2942149|NCT02957344||Text without context|
2942150|NCT02957344||Text with context|
2942151|NCT02957344||Map without context|
2942152|NCT02957344||Map with context|
2942153|NCT02957331|Experimental|Propranolol arm|One half of qualifying and consenting subjects will be randomized to receive propranolol. This group will receive study drug 3 times daily (every 8 hours) starting at 20 mg. The dosage may be increased by up to 60 mg/day divided over three daily doses (or an additional 20 mg/dose) as necessary until the heart rate is less than 100. Study drug will be held for hypotension (systolic <100) or bradycardia (heart rate <60 beats per minute). The maximum daily dose for the treatment of hypertension of 640 mg will not be exceeded in this study.
2942154|NCT02957331|No Intervention|Non propranolol arm|Non beta blockade arm will receive standard of care treatment and will not receive beta blockade. If a subject randomized to no Inderal develops hypertension and increased heart rate, he/she will be treated according to standard of care by the trauma team caring for the patient.
2942155|NCT02957318|Experimental|FiberBind|
2942156|NCT02957318|Experimental|RG-I fiber|
2942157|NCT02957318|Placebo Comparator|Placebo|
2942158|NCT02957305|Active Comparator|Treatment A|Misoprostol 400 µg 3 hours before intrauterine suction
2942159|NCT02957305|Experimental|Treatment B|Misoprostol 200 µg 3 hours before intrauterine suction
2942160|NCT02957292|Experimental|Levonorgestrel IUD|13,5 mg Levonorgestrel intrauterine device
2942161|NCT02957292|Active Comparator|Copper IUD|Copper (380mm2) intrauterine device
2942162|NCT02957279||Sepsis group|The patients were admitted to the Jinling Hospital, who met the diagnosis of sepsis(Sepsis 3.0).
2942163|NCT02957279||Healthy control group|Healthy volunteers.
2942164|NCT02957266|Active Comparator|Classical treatment|Classical concurrent cisplatin based chemoradiotherapy of cervical cancer. PIK3CA, KRAS, BRAF and RRM1 mutations rates.
2942165|NCT02957266|Experimental|GemInterBraVMAT|"Concurrent chemoradiotherapy of cervical cancer patients treated by VMAT (volumetric arc radiotherapy) based external beam radiotherapy, polyradiosensitization by cisplatin and gemcitabine and interstitial brachytherapy.~PIK3CA, KRAS, BRAF and RRM1 mutations rates."
2942166|NCT02957253|Experimental|Intervention (CI)|Compensated intervention (CI). Nurse-led clinic one time per year. Focus on Life style and risk factors.
2942167|NCT02957253|No Intervention|Control (CC)|Compensated Control (CC)
2942168|NCT02957253|Experimental|Intervention (DI)|Decompensated intervention (DI). Nurse-led clinic two times every month to every third month. Focus on Lifestyle, risk factors, nutrition, selfcare and psychosocial needs
2942169|NCT02957253|No Intervention|Control (DC)|Decompensated Control (DC)
2942170|NCT02957240|Active Comparator|Standard Care|Four clinic-based intervention sessions where the focus will be on home program competency and advancement and standard home program 3x daily for 15 minutes.
2942171|NCT02957240|Experimental|Standard Care and Motor Representation Techniques|4 clinic-based intervention sessions including 'standard care' intervention in addition to a 'movement representation' intervention. Home Program for Standard Care and Motor Representation 3x daily for 30 minutes.
2942172|NCT02957227||1|cohort 1: Older adults with memory impairment
2942173|NCT02957227||2|cohort 2: Age matched healthy controls
2942174|NCT02957214|Experimental|Pain education|The patient education provides a basic set of information that includes the explanation of possible pathophysiological mechanisms involved in the development of chronic pain. The main objective is to reduce pain threatening and alarmist interpretation. The patient must understand that the pain is not necessarily a sign of injury, but the consequence of a maladaptive central sensitization. One element of this therapeutic strategy is to help the patient to perform physical activities that involve a gradual exposition to stimuli associated with their pain and promote physical recovery exposure. Pain education also aims to reduce fear-avoidance behavior and the patient's disability.
2942175|NCT02957201|Other|Blood samples|Blood samples taken at baseline, day 1-2, day 3-4 and day 7-8 for Endothelial Progenitor Analysis with flow cytometer
2942176|NCT02957188||Young|Six young (18-30 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
2942177|NCT02957188||Elderly|Six older (≥ 70 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
2942178|NCT02957175||Patients that develop SIRS|Immunophenotyping of patients that develop SIRS after heart surgery
2942179|NCT02957175||Patients that develop no SIRS|Immunophenotyping of patients that develop no SIRS after heart surgery
2942180|NCT02957162|Other|Blood samples and Atorvastatin 80mg|All participants are given Atorvastatin 80mg as part of their standard care. The main study intervention is blood samples at days 1-2, 3-4 and 7-8.
2942181|NCT02957149|Experimental|Platelet Rich Plasma (PRP) Treatment|Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The Autologous Platelet-Rich Plasma is concentrated in a device (Angel Concentrated Platelet Rich Plasma System) to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
2942182|NCT02957136|Experimental|Rapid respiratory pathogen test arm|ED patients in this arm will receive a rapid respiratory pathogen nucleic acid amplification test plus usual care.
2942183|NCT02957136|No Intervention|Usual care control arm|ED patients in this arm will receive clinician-directed standard of care, which may include but is not limited to no testing, point-of-care influenza testing, or delayed testing for respiratory pathogens at off-site laboratory.
2942218|NCT02956798|Experimental|Stereotactic ablative body radiation (SABR)|Stereotactic ablative body radiation (SAbR) to all sites of measurable metastases (≤3) will be treated by SAbR. New sites of metastasis will be evaluated for continued treatment if deemed appropriate by both medical and radiation oncologists with SAbR.
2942280|NCT02956486|Experimental|elenbecestat (E2609) 50 mg|Participants will receive one 50 milligram (mg) elenbecestat (E2609) tablet orally once a day in the morning.
2942184|NCT02957123|Experimental|Intranasal auto-M2-BFs|"Intranasally-Administered Bioactive Factors, Produced by Autologous M2 Macrophage (auto-M2-BFs). M2 macrophages were generated in vitro from peripheral blood of patients during 7 days.Cell-free culture medium, containing auto-M2-BFs, was collected and aliquots of 2 mL/vial were cryopreserved.~60 patients with organic brain syndrome will receive their first doses (n=2-3) of auto-M2-BFs in clinic and wait 2 hrs to determine any short-time adverse effects of inhaled dose.~The subsequent course of intranasal inhalations (once a day up to 30 days) performed as outpatient treatment."
2942185|NCT02957097|Experimental|Medication - Gabapentin|Participants of this group will be administered either Gabapentin 900 milligram PO 2-3 hours prior to the surgical procedure.
2942186|NCT02957097|Placebo Comparator|Medication - Placebo|Participants of this group will be administered either Placebo PO 2-3 hours prior to the surgical procedure.
2942187|NCT02957058|Active Comparator|SERT 0, SCAR (low risk)|Patients with Sydney EMR Recurrence Tool (SERT scoring) score 0. These patients will be invited to return for follow up at 18 months and will have thermal ablation (SCAR technique) of the endoscopic resection defect margin.
2942188|NCT02957058|Active Comparator|SERT 1-4, SCAR (high risk)|Patients with Sydney EMR Recurrence Tool score 1-4 (SERT scoring). These patients will be invited to return for follow up at 4-6 months and will have thermal ablation (SCAR technique) of the endoscopic resection defect margin.
2942189|NCT02957045|Experimental|Cough|
2942190|NCT02957032|Experimental|F16IL2 + cytarabine|Patients will be enrolled sequentially in cohorts and treated at different dose levels of F16IL2 and a fixed dose of cytarabine.
2942191|NCT02957019|Experimental|L19-IL2 + RTX|"Phase I (Dose definition):~Cohorts of 3-6 patients will receive Rituximab on day 1 and 8 of the first 3-weeks cycle (C1D1 and C1D8, respectively) and on day 1 of the second 3-weeks cycle (C2D1). During two uninterrupted 3-weeks cycles, L19-IL2 will be administered on C1D1, C1D8, C1D15 and C2D1, C2D8, C2D15.~Phase II (Activity Evaluation):~During Phase II, 14 patients will receive Rituximab on C1D1 and C1D8 and on C2D1. Two uninterrupted 3-weeks cycles of L19-IL2 at the RD determined during Phase I will be administered on C1D1, C1D8 and C1D15 and C2D1, C2D8 and C2D15."
2942192|NCT02956993|Active Comparator|Vonapanitase|Vonapanitase administered to the distal popliteal, tibial or peroneal artery using a micro-infusion catheter.
2942193|NCT02956993|Placebo Comparator|Placebo|Placebo administered to the distal popliteal, tibial or peroneal artery using a micro-infusion catheter.
2942194|NCT02956980|Experimental|Group 1: non-pubescent children|70 non-pubescent children (25 healthy boys, 25 healthy girls, 10 boys with Klinefelter syndrome and 10 girls with Turner syndrome) Two 7 ml tubes of blood will be taken to perform the functional assays as well as the quantification of Blood Plasmacytoid dendritic cells (pDCs) absolute number in this 70 non-pubescent children.
2942195|NCT02956980|Experimental|Group 2: pubescent healthy children|50 pubescent healthy children (25 boys and 25 girls) Two 7 ml tubes of blood will be taken to perform the functional assays as well as the quantification of Blood Plasmacytoid dendritic cells (pDCs) absolute number in this 50 pubescent healthy children.
2942196|NCT02956967||Patients receiving Nivestim|
2942197|NCT02956954|Experimental|Patient treated with Enzyme replacement therapy|Magnetic Resonance Imaging will be done every 6 months for patient treated with Enzyme replacement therapy (Agalsidase alpha (Replagal®))
2942198|NCT02956954|Sham Comparator|Patient no treated with Enzyme replacement therapy|Magnetic Resonance Imaging will be done every 6 months for patient treated with Enzyme replacement therapy (Agalsidase alpha (Replagal®))
2942199|NCT02956941|Experimental|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|Intervention group will be received 12 months on nutrition behavior change communication using two modes (lecture, and posters).
2942200|NCT02956941|No Intervention|Control cluster|Control group will receive routine dietary practices.
2942201|NCT02956915||patients with severe symptomatic aortic stenosis|Stable patients with severe symptomatic aortic stenosis undergoing planned Transfemoral Transcatheter aortic valve implantation with the SAPIEN-3 prosthesis will be included. TF-TAVI will be done using a minimalist approach of local anesthesia and conscious sedation.
2942202|NCT02956902|No Intervention|Waiting list control|
2942203|NCT02956902|Experimental|Intervention|Clinician-supported smartphone application intervention
2942204|NCT02956889|Experimental|Vismodegib & Radiotherapy|"Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.~Treatment with Vismodegib will start within 4 weeks by the end of radiotherapy and will continue for 6 cycles"
2942205|NCT02956876|Experimental|Nurse practitioner consultation|standard chemotherapy for colorectal cancer
2942206|NCT02956876|Other|Standard consultation|standard chemotherapy for colorectal cancer
2942207|NCT02956863|Active Comparator|Exercises|Individuals with neck pain will receive a exercises program. Participants will receive treatments during 4 weeks, 1 treatments per week.
2942208|NCT02956863|Experimental|Osteopathic manipulative treatment|Individuals with neck pain in this group will also receive a exercises program and the participants will receive treatments during 4 weeks, 1 treatments per week associated with Osteopathic Manipulative Treatment (OMT)
2942209|NCT02956850|Experimental|Part I: SAD in Healthy Volunteers|Healthy volunteers will receive single dose of RO7020531 or matching placebo orally on Day 1 of each cohort. A planned dose-escalation sequence for SAD is 3 milligrams (mg), 10 mg, 20 mg, 40 mg, 60 mg, 100 mg, 140 mg, and 170 mg.
2942210|NCT02956850|Experimental|Part I: MAD in Healthy Volunteers|Healthy volunteers will receive RO7020531 (dose as selected based on safety, PK and PD data of SAD cohorts) or matching placebo orally every other day (QOD) from Day 1 through to Day 13.
2942211|NCT02956850|Experimental|Part II: CHB Participants|CHB participants will receive RO7020531 (dose as selected based on safety, PK and PD data of MAD cohorts) or matching placebo orally QOD from Day 1 through to Day 41.
2942212|NCT02956837|Experimental|RSV vaccine formulation 1 Group|Subjects in this group will receive a single 30µg dose injection of the investigational RSV vaccine at Day 0.
2942213|NCT02956837|Experimental|RSV vaccine formulation 2 Group|Subjects in this group will receive a single 60µg dose injection of the investigational RSV vaccine at Day 0.
2942214|NCT02956837|Experimental|RSV vaccine formulation 3 Group|Subjects in this group will receive a single 120µg dose injection of the investigational RSV vaccine at Day 0.
2942215|NCT02956837|Placebo Comparator|Control Group|Subjects in this group will receive a single placebo injection at Day 0.
2942219|NCT02956785|Active Comparator|Extension of propess+/-second propess|Women will have the initial slow-release Dinoprostone pessary left in place for six more hours (total of 30 hours in place) then removed followed by vaginal assessment 48 hours after the start of labour induction and insertion of a second slow-release pessary if required
2942220|NCT02956785|Active Comparator|Prostin|Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of quick-release Dinoprostone tablet (Prostin® 3 mg Dinoprostone vaginal tablet; Pfizer, UK) high in the posterior vaginal fornix immediately after removal of the slow-release pessary. The tablet will be left for 6 hours followed by vaginal reassessment and insertion of a second tablet if ARM is still not achievable.
2942221|NCT02956785|Active Comparator|Dilapan-S|Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of 1-5 Osmotic cervical rods (Dilapan-S® Aquacryl hydrogel rod; HPSRx Enterprises, USA) by a senior obstetrician or a midwife into the cervical canal, immediately after removal of the slow-release pessary using a vaginal speculum and a holder. The rods will be left for 12-24 hours.
2942222|NCT02956772|Experimental|TACE plus Arsenic Trioxide|Patients in this group are to receive a single dose of TACE treatment on day 1, followed by arsenic trioxide at 10 mg/day for 14 days (day 8-21). TACE treatment is repeated every 9 weeks while arsenic trioxide every 3 weeks for treatment duration of 27 weeks. At least 3 cycles of arsenic trioxide are administrated.
2942223|NCT02956772|Active Comparator|TACE|Patients in this group are to receive a single dose of TACE treatment on day 1. TACE treatment is repeated every 9 weeks for 27 weeks.
2942224|NCT02956759|Experimental|Early Intervention|pan-retinal photocoagulation laser treatment applied to the study eye within 2-4 weeks.
2942225|NCT02956759|Active Comparator|Standard Care|pan-retinal photocoagulation laser treatment deferred until the onset of any PDR.
2942226|NCT02956746|Experimental|Imovax, SYN023|Subjects will receive SYN023 and 5 doses of Imovax rabies vaccine
2942227|NCT02956746|Active Comparator|Imovax, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
2942228|NCT02956746|Experimental|RabAvert, SYN023|Subjects will receive SYN023 and 5 doses of RabAvert rabies vaccine
2942229|NCT02956746|Active Comparator|RabAvert, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
2942230|NCT02956733|Active Comparator|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
2942231|NCT02956733|Active Comparator|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 & 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
2942232|NCT02956720|Experimental|single arm|
2942233|NCT02956707||No pre-operative steroids|"This is a prospectively enrolling group of 40 subjects.~Our current clinical practice has changed. We no longer administer pre-oeprative steroids to neonates undergoing surgery with cardiopulmonary bypass. These patients still receive their post-operative steroid infusion that starts after termination from bypass. This is their standard of care and does not change due to study enrollment.~Subject's enrolled in this trial have a ACTH stimulation test performed: pre-operative, immediately post-cardiopulmonary bypass prior to the initiation of their clinical steroids, and prior to leaving the cardiac intensive care unit."
2942234|NCT02956707||Pre-operative steroids|This is a retrospective group of 40 subjects who were previously administered pre-operative steroids. These subjects also had ACTH testing performed pre-operative and immediately post-separation from cardiopulmonary bypass.
2942235|NCT02956694|Experimental|Training of clinicians + tools|Distance training program on shared decision making for clinicians (e-TUDE) + 5 Decision Boxes (DB) dealing with difficult decisions often faced by seniors with dementia and their caregivers in primary care, each designed in 2 versions, one adapted to clinicians (C-DB), and a simplified version adapted to patients/caregivers (P-DB).
2942236|NCT02956694|Other|Usual care|Clinical practice as usual and access to the training program after the end of the study data collection.
2942237|NCT02956681|Active Comparator|Delayed Intervention Group|In this arm of the randomized delayed intervention control trial, participants randomized to delayed intervention control group were sent a brochure with information on hereditary breast and ovarian cancer and the phone number to call a cancer risk program for free genetic counseling.
2942238|NCT02956681|Active Comparator|Intervention Group|In this arm of the randomized delayed intervention control trial, those randomized to the intervention group were told that because of their family history, we were able to offer them a free genetic counseling appointment.
2942239|NCT02956668|Experimental|Blindsight training associated to tDCS|"During the blindsight training (one-hour time), the patient is asked to maintain central fixation and is exposed to visual stimuli in his blind hemifield. The patient task is detection and/or discrimination of stimuli.~During each session the patient is subjected to around 700 different stimuli variously associated in space and/or time.~tDCS stimulation start at the beginning of the rehabilitation session, and continue for 30 min, during treatment.~Anode is placed over the parieto-occipital cortex. The cathode is placed in the contralateral supraorbital position."
2942240|NCT02956668|Active Comparator|Blindsight training alone|"During the blindsight training (one-hour time), the patient is asked to maintain central fixation and is exposed to visual stimuli in his blind hemifield. The patient task is detection and/or discrimination of stimuli.~During each session the patient is subjected to around 700 different stimuli variously associated in space and/or time."
2942241|NCT02956655|Experimental|Fasting therapy|Fasting therapy, lasting for 14 days, all subjects are isolated from ordinary food. However, drinking water is not limited and they are encouraged to drink more, at least 3 liters. Besides, they need to take some middle intensity exercise for at least 2 hours. They will take some prescribed medications except for hypoglycemic drugs.
2942277|NCT02956499|Experimental|Cohort 8|multiple intravenous doses
2942242|NCT02956655|Active Comparator|Insulin intensive therapy|Insulin intensive therapy, receive continuous subcutaneous insulin infusion. (Human Insulin (Novolin-R, Novo Nordisk) Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland). The insulin dose used will be adjusted everyday according to their glucose by a physician until a target blood glucose level been reached.
2942243|NCT02956642|Experimental|Blood Glucose Monitoring System|Participants in this arm will receive the Livongo Health System to manage diabetes. 150 participants will participate in this arm.
2942244|NCT02956642|Active Comparator|Standard Blood Glucose Monitoring|Participants in this arm will receive the iHealth Glucose Meter to take blood glucose measurements that will then be compared to participants from the Livongo Health System arm. 150 participants will participate in this arm.
2942245|NCT02956629|Experimental|Arm 1: HCV GT1|Male and female participants with HCV GT1a or GT1b infection take Uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
2942246|NCT02956629|Experimental|Arm 3: HCV GT2|Male and female participants with HCV GT2 infection take Uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
2942247|NCT02956629|Experimental|Arm 4: HCV GT3|Male and female participants with HCV GT3 infection take Uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
2942248|NCT02956629|Experimental|Arm 5: HCV GT4|Male and female participants with HCV GT4 infection take Uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
2942249|NCT02956629|Experimental|Arm 6: HCV GT5|Male and female participants with HCV GT5 infection take Uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
2942250|NCT02956629|Experimental|Arm 7: HCV GT6|Male and female participants with HCV GT6 infection take Uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
2942251|NCT02956616|Experimental|Enhanced Recovery|Postoperative recovery will follow the usual service protocols as if the patient were not in the study with the exception of components of the enhanced recovery protocol (detailed previously), which will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing. Additionally, participants in this group will receive intravenous ketorolac for pain control and Xylitol chewing gum for improvement of postoperative gastrointestinal function.
2942252|NCT02956616|Active Comparator|Routine Perioperative Care|Postoperative recovery will follow the usual service protocols at our institution. Participants in this group may receive intravenous ketorolac (toradol) for pain control
2942253|NCT02956603|Experimental|Neuroma Graft|In this arm, participants have already had partial muscle grafts placed on the amputated nerves to control neuroma growth. The investigators will place small electrodes percutaneously into the muscle grafts to record EMG signals and electrically stimulate the implanted nerves.
2942254|NCT02956603|Experimental|Prosthetic Control Graft|In this arm, participants will have an initial surgery to place partial muscle grafts on the amputated nerves. After a healing period, the investigators will place small electrodes percutaneously into the muscle grafts to record EMG signals and electrically stimulate the implanted nerves.
2942255|NCT02956603|Experimental|Able Bodied|The investigators will place small electrodes percutaneously into intact muscles in the arm to record EMG signals and electrically stimulate the intact nerves nearby.
2942256|NCT02956590|Active Comparator|Pitavastatin|Study Drug
2942257|NCT02956590|Placebo Comparator|Placebo|Placebo
2942258|NCT02956577||T2|Patients with type 2 diabetes without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were invited from the Outpatient Clinic of Endocrinology or The Eye Photo Clinic at Odense University Hospital (OUH) Svendborg. Diagnosis of diabetes was classified by trained endocrinologists according to international standards with relevant biochemistry. Historical data on urine- and blood samples as well as micro- and macrovascular diabetic complications have been registered consecutively in patients followed at the outpatient clinic in the regional Funen Diabetes Database (FDDB). Data on historical invasive procedures due to cardiac disease were registered in Western Denmark Heart Registry (WDHR).
2942259|NCT02956577||T1|Patients with type 1 diabetes without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were invited from the Outpatient Clinic of Endocrinology or The Eye Photo Clinic at OUH Svendborg. Diagnosis of diabetes was classified by trained endocrinologists according to international standards with relevant biochemistry. Historical data on urine- and blood samples as well as micro- and macrovascular diabetic complications have been registered consecutively in patients followed at the outpatient clinic in the regional FDDB. Data on historical invasive procedures due to cardiac disease were registered in WDHR.
2942260|NCT02956577||Non-diabetic subjects|Non-diabetic subjects without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were included from The Danish Cardiovascular Screening trial (DANCAVAS). A randomized controlled trial with the primary aim to evaluate the health benefits and costeffectiveness of using non-contrast full truncus computer tomography (CT) scans (to measure coronary artery calcification (CAC) and identify aortic/iliac aneurysms) and measurements of the ankle brachial blood pressure index (ABI) as part of a multifocal screening and intervention program for cardiovascular disease in men aged 65-74.
2942261|NCT02956564|Other|exposure group|subjects in this group are those who accept intrauterine intervention
2942262|NCT02956564|No Intervention|control group|subjects in this group are those who do not accept intrauterine intervention
2942263|NCT02956551|Experimental|cell_therapy|tumor neoantigen primed DC vaccines are administrated, 2-week interval, totally 5 times
2942264|NCT02956538|Experimental|thalidomide|thalidomide 100mg tablet by mouth, every night for 8 weeks
2942265|NCT02956538|Active Comparator|placebo|placebo (for thalidomide) 100mg tablet by mouth, every night for 8 weeks
2942266|NCT02956525|Experimental|Dexibuprofen 200 mg - Fed|Fed condition
2942267|NCT02956525|Experimental|Dexibuprofen 200 mg - Fasting|Fasting condition
2942268|NCT02956512|Experimental|Dexibuprofen 300mg - Fed|Fed condition
2942269|NCT02956512|Experimental|Dexibuprofen 300mg - Fasting|Fasting condition
2942270|NCT02956499|Experimental|Cohort 1|single intravenous dose
2942271|NCT02956499|Experimental|Cohort 2|single intravenous dose
2942272|NCT02956499|Experimental|Cohort 3|single intravenous dose
2942273|NCT02956499|Experimental|Cohort 4|single intravenous dose
2942274|NCT02956499|Experimental|Cohort 5|single intravenous dose
2942275|NCT02956499|Experimental|Cohort 6|single intravenous dose
2942276|NCT02956499|Experimental|Cohort 7|multiple intravenous doses
2942281|NCT02956486|Placebo Comparator|Placebo|Participants will receive one matching placebo tablet orally once a day in the morning.
2942282|NCT02956473|Experimental|Supine MRI|"Standard MRI will be performed~Supine MRI will be performed~Participant will receive mammography and ultrasound~Breast Radiologist will take a brief survey.~All new patients will receive Neoadjuvant Therapy~Standard of care will be performed"
2942283|NCT02956460|Active Comparator|fanfilcon A|Participants are randomized to wear fanfilcon A for two weeks during the cross over study.
2942284|NCT02956460|Active Comparator|senofilcon A|Participants are randomized to wear senofilcon A for two weeks during the cross over study.
2942285|NCT02956447|Experimental|Kisspeptin Bolus|Administration of kisspeptin 112-121 0.24 nmol/kg intravenously (IV); 10 boluses in a 10 hour period. One bolus of GnRH at hour 11. Blood sampling every 10 minutes.
2942286|NCT02956447|No Intervention|Baseline|Blood sampling every 10 minutes
2942287|NCT02956447|Experimental|Pulsatile kisspeptin|Administration of kisspeptin 112-121 0.24 nmol/kg IV every 90 minutes over 14 days using a portable pump. One-time bolus of kisspeptin 112-121 2.4 nmol/kg IV (if necessary).
2942288|NCT02956434|Experimental|Brief family intervention|Participants will receive the BFI in this arm of the study. The BFI is a 2-session intervention for family members of Veterans who are beginning PTSD treatment.
2942289|NCT02956434|No Intervention|No intervention|Participants will not receive the BFI in this arm of the study. They will be eligible for any usual support or programming for the families of Veterans.
2942290|NCT02956421|Active Comparator|RABIPUR®|Comparator vaccine RABIPUR® Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14
2942291|NCT02956421|Experimental|PIKA Rabies vaccine|PIKA Rabies vaccine with an accelerated regimen Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose)
2942292|NCT02956408|Active Comparator|Conventional|Patients in this arm will be prescribed Vitamin D3 2000 IU once a day
2942293|NCT02956408|Experimental|High Dose|Patients in this arm will be prescribed Vitamin D3 6000 IU once a day
2942294|NCT02956395|Active Comparator|Integrated care group|Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care in three healthcare sectors: Barcelona-Esquerra, Lleida and Badalona.
2942295|NCT02956395|No Intervention|Conventional care group|Patients assigned to the control group will be from other healthcare sectors in Catalonia with similar characteristics.
2942296|NCT02956382|Experimental|Phase I - Dose Level 0|"Ibrutinib (capsule) - 420mg Venetoclax (tablet) - 400mg~Each medication is taken daily. Treatment cycles are 28 days long."
2942297|NCT02956382|Experimental|Phase I - Dose Level 1|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 400mg~Each medication is taken daily. Treatment cycles are 28 days long."
2942298|NCT02956382|Experimental|Phase I - Dose Level 2|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 600mg~Each medication is taken daily. Treatment cycles are 28 days long."
2942299|NCT02956382|Experimental|Phase I - Dose Level 3|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 800mg~Each medication is taken daily. Treatment cycles are 28 days long."
2942300|NCT02956382|Experimental|Phase II Dose|The Phase II dose will be the maximum tolerated dose as determined in the Phase I portion.
2942301|NCT02956369|Placebo Comparator|Control|15 obese, non-diabetic candidates will serve as control-group. All assessments are carried out just as in the intervention groups. The control granulates consists of maize starch and long-chain fatty acids with powder.
2942302|NCT02956369|Active Comparator|SATIOSTAT|15 obese, non-diabetic candidates will ingest SATIOSTAT as meal replacement at lunch and as first course at dinner over a period of 6 weeks. The SATIOSTAT granulates consists of hydrocolloids (fibers) and long-chain fatty acids with powder.
2942303|NCT02956356|Placebo Comparator|Control treatment + oral glucose|Control treatment as preload and then an oral glucose load of 75g enriched with C13 sodium acetate (for determination of gastric emptying rates)
2942304|NCT02956356|Active Comparator|SATIOSTAT treatment + oral glucose|SATIOSTAT treatment as preload and then an oral glucose load of 75g enriched with C13 sodium acetate (for determination of gastric emptying rates)
2942305|NCT02956356|Placebo Comparator|Control treatment + meal intake|Control treatment as preload followed by a test meal
2942306|NCT02956356|Active Comparator|SATIOSTAT treatment + meal intake|SATIOSTAT treatment as preload followed by a test meal
2942307|NCT02956343||AF|Five minutes pulse wave recording in patients with atrial fibrillation at the time of recruitment
2942308|NCT02956343||SR|Five minutes pulse wave recording in patients with sinus rhythm at the time of recruitment
2942309|NCT02956330||CLS1003-201|Those subjects whose parent study primary investigator has access to their medical records, following exit from CLS1003-201.
2942310|NCT02956317|Active Comparator|STP705|Each subject will receive both active (STP705) and control (Placebo) intradermal injection twice a week for a total of 4 weeks at 20 μg/cm2/day (in Cohort A), 30 μg/cm2/day (in Cohort B) and 40 μg/cm2/day (in cohort C). The total length of linear hypertrophic scar will be divided equally for treatment with STP705 and placebo. STP705 and Placebo will be injected intradermal every 1 cm length on the hypertrophic scar.
2942311|NCT02956317|Placebo Comparator|Placebo|Each subject will receive both active (STP705) and control (Placebo) intradermal injection twice a week for a total of 4 weeks at 20 μg/cm2/day (in Cohort A), 30 μg/cm2/day (in Cohort B) and 40 μg/cm2/day (in cohort C). The total length of linear hypertrophic scar will be divided equally for treatment with STP705 and placebo. STP705 and Placebo will be injected intradermal every 1 cm length on the hypertrophic scar
2942312|NCT02956304|Other|Group iTBS-cTBS-SHAM|PMv stimulation (iTBS) at session 2, PMv inhibition (cTBS) at session 3, and control (SHAM) at session 4
2942313|NCT02956304|Other|Group iTBS-SHAM-cTBS|PMv stimulation (iTBS) at session 2, control (SHAM) at session 3, and PMv inhibition (cTBS) at session 4
2942314|NCT02956304|Other|Group cTBS-iTBS-SHAM|PMv inhibition (cTBS) at session 2, PMv stimulation (iTBS) at session 3, and control (SHAM) at session 4
2942315|NCT02956304|Other|Group cTBS-SHAM-iTBS|PMv inhibition (cTBS) at session 2, control (SHAM) at session 3, and PMv stimulation (iTBS) at session 4
2942316|NCT02956304|Other|Group SHAM-iTBS-cTBS|control (SHAM) at session 2, PMv stimulation (iTBS) at session 3, and PMv inhibition (cTBS) at session 4
2942317|NCT02956304|Other|Group SHAM-cTBS-iTBS|control (SHAM) at session 2, PMv inhibition (cTBS) at session 3, and PMv stimulation (iTBS) at session 4
2942318|NCT02956291|Experimental|Newly Diagnosed Brain Tumors|Participants with newly diagnosed brain tumors will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be performed to visualize recurrence.
2942319|NCT02956291|Experimental|Treated tumors with possible recurrence|Participants with treated brain tumors with possible recurrence will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be added to the repeat MRI studies as determined appropriate by the referring physician/primary care team.
2942320|NCT02956278|Placebo Comparator|Placebo|Subjects will take a placebo and provide blood/urine samples for 24 hours
2942321|NCT02956278|Experimental|Allopurinol|Subjects will take allopurinol for 6 days. On day 1 and 6, subjects will provide blood and urine samples for 24 hours. Subjects will provide additional blood samples on days 7 and 8.
2942322|NCT02956265|Experimental|Patients - Suffering from carcinomatous or polymorphous skin|
2942323|NCT02956252||Spinal anesthesia group|patients underwent laparoscopic cholecystectomy under spinal anesthesia
2942324|NCT02956252||General anesthesia|Patients underwent laparoscopic cholecystectomy under general anesthesia
2942325|NCT02956239|Experimental|Thermocoagulation (device)|VIA Positive women will be treated by the new device for thermocoagulation
2942326|NCT02956239|Active Comparator|Cryotherapy (device)|VIA positive women will be treated by cryotherapy
2942327|NCT02956239|Active Comparator|LEEP (device)|VIA Positive women not suitable for thermo-coagulation or cryotherapy will be treated by LEEP
2942328|NCT02956226|Experimental|Cannabinoids - 99% pure cannabinoids mix|Oral cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio] at 1 mg/kg cannabidiol per day, up-titrated until intolerance or to a maximum dose of 10 mg/kg CBD per day, divided to 3 daily doses, for 3 months.
2942329|NCT02956226|Placebo Comparator|Placebo|Oral olive oil and flavors that mimic in texture and flavor the cannabinoids' solution.
2942330|NCT02956226|Experimental|Cannabinoids - whole plant extract|Oral cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio] at 1 mg/kg cannabidiol per day, up-titrated until intolerance or to a maximum dose of 10 mg/kg CBD per day, divided to 3 daily doses, for 3 months
2942331|NCT02956213|Experimental|ARM 1 MERV17 first|"This group will receive a portable HEPA air filtering device with MERV17 air filter for the first part of the study. At cross over, this group will receive the placebo or no high-efficiency filter."
2942332|NCT02956213|Active Comparator|ARM 2 MERV17 second|This group will receive a HEPA portable air filter with no high efficiency air filter for the first part of the study. At cross over, this group will receive the high-efficiency MERV17 air filter.
2942333|NCT02956200|Experimental|fingolimod with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with fingolimod.
2942334|NCT02956200|No Intervention|standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy.
2942335|NCT02956187|Experimental|Biofeedback for constipation|Constipation will be treated by correcting functional outlet obstruction.
2942336|NCT02956187|Active Comparator|Fiber supplementation|Constipation will be treated by a fiber supplement
2942337|NCT02956174|Experimental|Co-Cr single crown|Co-Cr single crown
2942338|NCT02956174|Active Comparator|Contralateral sound tooth|Contralateral sound tooth
2942339|NCT02956161|Experimental|Up phase stimulation|Auditory stimulations are delivered in synchrony with the up phase of slow oscillations during N3 sleep stage.
2942340|NCT02956161|Experimental|Random phase stimulation|Auditory stimulations are randomly delivered during N3 sleep stage.
2942341|NCT02956161|Sham Comparator|No stimulation|The device is worn without any auditory stimulations delivered.
2942342|NCT02956148|Experimental|Radioligand [18F]MNI-659|"All subjects will receive a single intravenous dose of the radioligand [18F]MNI-659 (investigational medicinal product [IMP]) and undergo PET imaging.~The radioligand [18F]MNI-659 will be administered at a dose of less than 5 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
2942343|NCT02956122|Experimental|Study Part 1 - All Participants - GLASSIA|Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
2942344|NCT02956122|Experimental|Study Part 2 - GLASSIA|Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
2942345|NCT02956122|Placebo Comparator|Study Part 2 - Albumin (Control)|Participants to receive control (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
2942346|NCT02956109|Active Comparator|Adult formulation: Finerenone tablet_Fasting|Single oral dose of 10 mg finerenone tablet fasting
2942347|NCT02956109|Experimental|Pediatric formulation: 5X 0.25 mg Finerenone ODT_Fasting|Single oral dose of 5 x 0.25 mg finerenone oro-dispersible tablets fasting
2942348|NCT02956109|Experimental|Pediatric formulation: 1.25 mg Finerenone ODT_Fasting|Single oral dose of 1.25 mg finerenone oro-dispersible tablet fasting
2942349|NCT02956109|Experimental|Pediatric formulation: 1.25 mg Finerenone ODT_Fed|Single oral dose of 1.25 mg finerenone oro-dispersible tablet fed; 30 minutes after start of an American breakfast
2942350|NCT02956096|Active Comparator|tDCS device and Treatmill|The stimulation is accomplished with a direct current-tDCS Stimulator Plus device, via two surface electrodes sponge (non-metallic) 5-7 cm2 in saline moistened with a 2mA current during 20 minutes after hemodinamic analysis is performed for 15 minutes and then made only training treadmill for 20 minutes. Placebo tDCS will follow the same procedures, but the tDCS device will only be switched on for 20 seconds. The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve (MACKO , 2005).
2942351|NCT02956096|Sham Comparator|1- tDCS|1. Who received stimulation transcranial direct current active will receive Sham stimulation and who received the placebo stimulation receive active stimulation and then the two groups will do the workout on the treadmill
2942352|NCT02956083|Active Comparator|Lipid based artificial tears|Patients use lipid based artificial tears
2942353|NCT02956083|Active Comparator|Non-lipid based artificial tears|patients use non-lipid based artificial tears
2942354|NCT02956083|Placebo Comparator|Saline|patients use saline
2942355|NCT02956070|Experimental|Experimental|35 patients in this group will undergo the whitening procedure using the Dexamethasone acetate intervention.
2942356|NCT02956070|Placebo Comparator|Placebo|35 patients in this group will undergo the whitening procedure using the Potassium Nitrate intervention
2942357|NCT02956057|Active Comparator|PEG1D|Polyethylene glycols single dose a day before colonoscopy
2942358|NCT02956057|Active Comparator|PEG2D|Polyethylene glycols split dose
2942359|NCT02956057|Active Comparator|SPMC1D|Natrium picosulfate/ Magnesium citrate single dose day before colonoscopy
2942360|NCT02956057|Active Comparator|SPMC2D|Natrium picosulfate/ Magnesium citrate split dose
2942361|NCT02956057|Active Comparator|PEGA1D|Polyethylene glycol / Ascorbic acid single dose day before colonoscopy
2942362|NCT02956057|Active Comparator|PEGA2D|Polyethylene glycol / Ascorbic acid split dose
2942363|NCT02956044|Active Comparator|Group 1: Bexagliflozin alone|
2942364|NCT02956044|Active Comparator|Group 1: Metformin alone|
2942365|NCT02956044|Active Comparator|Group 1: Bexagliflozin + Metformin|
2942366|NCT02956044|Active Comparator|Group 2: Bexagliflozin alone|
2942367|NCT02956044|Active Comparator|Group 2: Glimepiride alone|
2942368|NCT02956044|Active Comparator|Group 2: Bexagliflozin + Glimepiride|
2942369|NCT02956044|Active Comparator|Group 3: Bexagliflozin alone|
2942370|NCT02956044|Active Comparator|Group 3: Sitagliptin alone|
2942371|NCT02956044|Active Comparator|Group 3: Bexagliflozin + Sitagliptin|
2942372|NCT02956031||HIV pos|those who serologically tested positive for HIV
2942373|NCT02956031||HIV neg|those who serologically tested negative for HIV
2942374|NCT02956031||HIV unk|those with no available serological test for HIV
2942375|NCT02956005|Other|1|Open Label
2942376|NCT02955992|No Intervention|standard of care|
2942377|NCT02955992|Experimental|Intervention|"All caregivers will receive a leaflet about the importance of end of life (EOL) communication: key elements and recommendations regarding verbal and non-verbal communication.~A local champion (opinion leader) will be designated by each team in order to help implement the strategy. These physicians will help colleagues to connect external knowledge and requirements of the study to the local context.~Development of a 3-step physician-driven support strategy starting after a decision to withhold or withdraw life-sustaining therapies is implemented:~Preparation for the death : Prepare the relative for the patient's imminent death~During the dying and death process: The physician enters the patient's room at least once to check on the relatives~After the patient's death: the physician and the nurse meet the relative"
2942378|NCT02955979||CT scan with iodinated contrast agents|Patients under 16 years old and must pass a CT scan with iodinated contrast agents. The following data will be collected in the medical record (creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern).
2942379|NCT02955966|Experimental|Patient with invasive pulmonary aspergillosis|Blood collection and imaging 18F-FDG-PET/CT
2942380|NCT02955953|Experimental|LY2963016 U-200 Formulation (Test)|LY2963016 test formulation administered as a subcutaneous (SC) injection in one of two or two of four study periods.
2942381|NCT02955953|Experimental|LY2963016 U-100 Formulation (Reference)|LY2963016 reference formulation administered as a SC injection in one of two or two of four study periods.
2942382|NCT02955940|Experimental|Ruxolitinib|
2942383|NCT02955940|Experimental|Ruxolitinib plus background cancer therapy|
2942384|NCT02955940|Experimental|Background cancer therapy alone|
2942385|NCT02955927|Experimental|ortho-k and 0.01% atropine eye drops|participants will receive treatment of ortho-k and 0.01% atropine eye drops
2942386|NCT02955927|Active Comparator|ortho-k|participants will receive treatment of ortho-k alone
2942387|NCT02955914||Optimism|Based on quality of life assessment
2942388|NCT02955914||Pessimism|Based on quality of life assessment
2942389|NCT02955901|Active Comparator|3-day low residue diet|Group A - 3 day low residue diet prior to the colonoscopy
2942390|NCT02955901|Placebo Comparator|1-day low residue diet|Group B - 1 day low residue diet prior to the colonoscopy
2942391|NCT02955888|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
2942392|NCT02955888|Placebo Comparator|Placebo|Four 200 mg capsules (total 800 mg) administered orally, once daily.
2942393|NCT02955875|Experimental|Pharmaceutical care|Participants received systematically organized pharmaceutical care services, which were provided by pharmacists, in addition to the usual care. The usual care includes traditional consultation with pharmacists as well as traditional medical services provided by physicians, nurses, and dietitian.
2942394|NCT02955875|No Intervention|Usual care|Participants received the usual care, which includes traditional consultation with pharmacists as well as traditional medical services provided by physicians, nurses, and dietitian.
2942395|NCT02955862|Other|Assigned Interventions Antifungals Patients with symptoms|"Patients with symptoms of CNS disease will be treated according to Vietnam national guidelines for HIV/AIDS management.~For CrAg-positive patients, the initial dosage of fluconazole will be 900 mg taken each day for 2 weeks. This will be followed by fluconazole 450 mg orally each day for 8 weeks. Finally, maintenance treatment with fluconazole 200mg orally each (2 tablets of 100 mg procured especially for the study) day will continue until CD4 >200 cells/µL for at least 6 months."
2942396|NCT02955849|Experimental|SLT laser group|"selective laser trabeculoplasty for 360 degrees the study eye.~Patients having 1 or 2 quadrants of angle with trabecular meshwork not visible will undergo Laser peripheral iridotomy prior to selective laser trabeculoplasty to maximize the amount of angle visible;~Cataract surgery will be offered if indicated and completed within 3 months of selective laser trabeculoplasty , if accepted by the patient.~Patients will be re-examined every 4 months and selective laser trabeculoplasty performed again according to the above protocol if intraocular pressure exceeds the target (25% reduction from the original intraocular pressure or < 21 mmHg, whichever is lower)."
2942435|NCT02955602|Experimental|MBX-8025 (10 mg)|MBX-8025 10 mg capsule once daily
2942470|NCT02955329|Experimental|Nicotine|Participants will vape tobacco leaves with nicotine out of the PAX device.
2942397|NCT02955849|No Intervention|Standard care group|"Trabeculectomy as usually performed by the operative surgeon in one eye (study eye).~Both Mitomycin and releasable sutures are permitted if indicated in the opinion of the surgeon and s/he can perform and/or has access.~Simultaneous cataract surgery is permitted if indicated in the opinion of the operating surgeon.~Patients will be re-examined every 4 months， and Timolol 0.5% added bid if intraocular pressure exceeds the target (25% reduction from the original intraocular pressure or < 21 mmHg, whichever is lower)"
2942398|NCT02955849|No Intervention|Drug treatment group|Patients not accepting the offered treatment for the study eye within 3 months will receive topical Timolol 0.5% bid at the usual price, with the prescription to be refilled per usual practice at the hospital (usually monthly).
2942399|NCT02955823|Experimental|1 arm for all patient: Ritux-Dexame-Lena|Rituximab-Dexamethasone-Lenalidomide
2942400|NCT02955810|Experimental|CyBorD-DARA|
2942401|NCT02955797|Experimental|MenACYW conjugate vaccine (Group 1)|Meningococcal vaccine-naïve participant randomized to receive MenACYW conjugate vaccine
2942402|NCT02955797|Experimental|Nimenrix® vaccine (Group 2)|Meningococcal vaccine-naïve participant randomized to receive Nimenrix® vaccine
2942403|NCT02955797|Experimental|MenACYW conjugate vaccine (Group 3)|Meningococcal C conjugate vaccine-primed participant randomized to receive MenACYW conjugate vaccine
2942404|NCT02955797|Experimental|Nimenrix® vaccine (Group 4)|Meningococcal C vaccine conjugate-primed participant randomized to receive Nimenrix® vaccine
2942405|NCT02955784|Experimental|Sinasprite Mobile App|Mobile App
2942406|NCT02955771|Experimental|PDT-Deuteporfin（6 hour）plus stenting|Deuteporfin (7.5mg/kg) was injected intravenously 6 hours before intraluminal photoactivation (wavelength,630 nm;light dose, 180 J/cm(2)). After PDT, endoscopic or percutaneous stenting will be performed.The second treatment may be given after 3 months.
2942407|NCT02955771|Experimental|PDT-Deuteporfin（9 hour）plus stenting|Deuteporfin (7.5mg/kg) was injected intravenously 9 hours before intraluminal photoactivation (wavelength,630 nm;light dose, 180 J/cm(2)). After PDT, endoscopic or percutaneous stenting will be performed.The second treatment may be given after 3 months.
2942408|NCT02955771|Other|Stenting|Endoscopic or percutaneous stenting alone will be performed.
2942409|NCT02955758|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
2942410|NCT02955732|Experimental|Intranasal dex|Dexmedetomidine 2-4 µg/kg alone
2942411|NCT02955719|Experimental|Enrolled Cases|"Integrated Care Pathway with different treatment interventions~Interventions include:~Sertraline, Venlafaxine, CBT/Psychological therapy, Psychiatric consultation, lifestyle intervention resources"
2942412|NCT02955719|No Intervention|Enrolled Controls|No intervention: Treatment as usual (TAU) will be provided by the primary care practice staff
2942413|NCT02955706|Experimental|Active|Acetyl-L-carnitine (DongA ST)
2942414|NCT02955706|Placebo Comparator|placebo|Placebo of Acetyl-L-carnitine (DongA ST)
2942415|NCT02955693|Other|Sequence A (n=8)|Fumaderm® 120 mg fed (Period 1) - LAS41008 120 mg fasting (Period 2) -Fumaderm® 120 mg fasting (Period 3) - LAS41008 120 mg fed (Period 4)
2942416|NCT02955693|Other|Sequence B (n=8)|LAS41008 120 mg fasting (Period 1) - LAS41008 120 mg fed (Period 2) - Fumaderm® 120 mg fed (Period 3) - Fumaderm® 120 mg fasting (Period 4)
2942417|NCT02955693|Other|Sequence C (n=8)|Fumaderm® 120 mg fasting (Period 1) - Fumaderm® 120 mg fed (Period 2) - LAS41008 120 mg fed (Period 3) - LAS41008 120 mg fasting (Period 4)
2942418|NCT02955693|Other|Sequence D (n=8)|LAS41008 120 mg fed (Period 1) - Fumaderm® 120 mg fasting (Period 2) - LAS41008 120 mg fasting (Period 3) - Fumaderm® 120 mg fed (Period 4)
2942419|NCT02955680|Experimental|Group M|At the end of surgery, patients were stimulated to wake up by recorded mother's voice, which was recorded before the operation.
2942420|NCT02955680|Active Comparator|Group S|At the end of surgery, patients were stimulated to wake up by recorded stranger's voice, which was recorded before the operation.
2942421|NCT02955667|Experimental|invivo microscopy group|patients receive invivo micro-colposcopy examination and do not have to receive the biopsies
2942422|NCT02955667|Other|normal group|patients receive normal colposcopy examination and the biopsy specimens are sent for pathological HE staining and analysis
2942423|NCT02955654|Experimental|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
2942424|NCT02955654|Active Comparator|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
2942425|NCT02955654|Other|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
2942426|NCT02955641|Active Comparator|NSAIDs-Placebo|Will receive Nepafenac 0.1%in the first eye, and Hydroxyethylcellulose 0.19% in the second eye
2942427|NCT02955641|Active Comparator|Placebo-NSAIDs|Will receive Hydroxyethylcellulose 0.19% in the first eye, and Nepafenac 0.1%in the second eye
2942428|NCT02955641|Active Comparator|Steroid-Placebo|Will receive Dexamethasone Disodium Phosphate 0.1% in the first eye, and Hydroxyethylcellulose 0.19% in the second eye
2942429|NCT02955641|Active Comparator|Placebo-Steroids|Will receive Hydroxyethylcellulose 0.19%in the first eye, and Dexamethasone Disodium Phosphate 0.1%in the second eye
2942430|NCT02955628|Experimental|Ibrutinib-RICE|Patients not achieving a complete remission at time of PET-2 will receive ibrutinib and proceed on to autologous transplant if at least a partial remission is achieved. After transplantation, ibrutinib will be continued for up to 1 year. Autologous transplantation will be with BEAM conditioning.
2942431|NCT02955615|Experimental|ILT-101|Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12
2942432|NCT02955615|Placebo Comparator|Placebo|Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12
2942433|NCT02955602|Experimental|MBX-8025 (2 mg)|MBX-8025 2 mg capsule once daily
2942434|NCT02955602|Experimental|MBX-8025 (5 mg)|MBX-8025 5 mg capsule once daily
2942436|NCT02955589|Experimental|HBI-8000|Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.
2942437|NCT02955576|Placebo Comparator|Control group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.
2942438|NCT02955576|Active Comparator|Patch group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.
2942439|NCT02955576|Experimental|Microneedle patch group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.
2942440|NCT02955563|Experimental|CSDM Tool|Surrogate will complete educational sessions on CSDM tool prior to each family meeting with clinical team.
2942441|NCT02955563|No Intervention|Control|Surrogates will receive augmented usual care. The augmentation is that there will be 2 family meetings scheduled during the first 10 days of enrollment.
2942442|NCT02955550|Experimental|PNK-007 and rhIL-2|Melphalan per institutional practices (within Day -5 to 01), ASCT (Day 0), PNK-007 at varying dose levels (within Day 7 to Day 14) and rhIL-2 every other day starting day of PNK-007 administration.
2942443|NCT02955537|No Intervention|Usual care|Usual care participants will be given a prescription for antihypertensive medications, printed educational materials on hypertension, and a home blood pressure monitor for daily use, but will receive no further intervention.
2942444|NCT02955537|Experimental|MI-BP|MI-BP participants will receive an antihypertensive medication prescription, and be asked to use technology-mediated devices/services linked to positive changes in target behavior/outcome including the MI-BP app, a secure, mHealth platform that will be installed on participant smartphones.
2942445|NCT02955524|Experimental|Treatment session 1a|"Topical ophthalmic anesthesia to participants (#) on each session (letter) of intra-arterial chemotherapy.~where #1 is the participant identifier and letter-a is the start session with study protocol (most candidates will receive more than 4 sessions in a 6 month period)"
2942446|NCT02955511|Active Comparator|Blade MAC size 3|"Patient will be intubated using a:~Direct Laryngoscope (DL) Mac size 3 (Sun-Med GreenLine®/D™ Macintosh)"
2942447|NCT02955511|Active Comparator|Blade MAC size 3.5|"Patient will be intubated using a:~DL-blade mac size 3.5 (Sun-Med Greenline®/D™ Macintosh)"
2942448|NCT02955511|Experimental|Inscope Blade size 3.5|"Patient will be intubated using a:~Inscope DL-blade size 3.5"
2942449|NCT02955498|Experimental|R-T|First period: administration of reference drug, Second period: administration of test drug
2942450|NCT02955498|Experimental|T-R|First period: administration of test drug, Second period: administration of reference drug
2942451|NCT02955485||Patients with chronic ankle instability|All patients that develop chronic ankle instability after an ankle sprain and reporting at the emergency department. Experiencing persisting complaints of instability for more than 6 months.
2942452|NCT02955485||Patients without chronic ankle instability|All patients that do not develop chronic ankle instability after an ankle sprain and reporting at the emergency department. Complaints resolve within 6 months.
2942453|NCT02955472|Other|Group 1|"Period 1: GLA5PR GLARS-NF1 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~wash-out period: over 7 days.~Period 2: GLA5PR GLARS-NF3 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
2942454|NCT02955472|Other|Group 2|"Period 1: GLA5PR GLARS-NF3 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~wash-out period: over 7 days.~Period 2: ComparGLA5PR GLARS-NF1 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
2942455|NCT02955459|Experimental|VNRX-5133|IV infusion
2942456|NCT02955459|Placebo Comparator|Placebo|IV infusion
2942457|NCT02955433|Experimental|Rideshare|The intervention arm will receive an appointment reminder and free transportation for one appointment to travel between the patient's home and primary care clinic using a rideshare-based transportation service.
2942458|NCT02955433|No Intervention|Control|The control arm will receive an appointment reminder, but no free transportation offer.
2942459|NCT02955420|Experimental|BC 007 (15, 50, 150, 300, 450, 750, 1350, 1200 mg)|"Part A:~BC 007 at doses of 15, 50 and 150 mg or matching placebo administered as i.v. bolus + infusion of 20 min (Cohorts 1 to 4). The sentinel pair of each cohort will be dosed without bolus.~NaCl 0.9% (matching placebo) administered as i.v. bolus + infusion of 20 min (Part A: Cohorts 1 to 4).~Part B:~BC 007 at doses of 50 and 150 mg administered (Cohort 1) or a single dose < 50 mg or 150 mg (Cohort 2) as i.v. bolus + infusion of 20 min is administered to GPCR autoantibody positive subjects. The first subject in each dosing period of Cohort 1 will be dosed without bolus.~Part C:~BC007 administered at doses of 300 mg (Cohort 1), 450 mg (Cohort 2), 750 mg (Cohort 3), 1350 mg (Cohort 4) as i.v. bolus + infusion of 40 min to GPCR autoantibody positive subjects. The first three subjects in each dosing period of Cohort 1-4 will be dosed without bolus. In Cohort 5 BC007 dose of 1200 mg will be administered as a continuous infusion of 20 min."
2942460|NCT02955407||Low back pain patients|Low back pain since more than 3 months Age: 18-65 Caucasian race
2942461|NCT02955407||Controls without low back pain|no low back ain Age: 18-65 Caucasian race
2942462|NCT02955394|Placebo Comparator|Fulvestrant Without Enzalutamide|500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
2942463|NCT02955394|Experimental|Fulvestrant With Enzalutamide|500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC), plus160mg of Enzalutamide will be given daily.
2942464|NCT02955381|Experimental|Restylane Silk, 1.0 ml|Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Restylane® Silk) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will remain blinded to the treatment administered to them during these visits.
2942465|NCT02955381|Placebo Comparator|Placebo (Saline), 1.0 ml|Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Placebo (Saline)) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will remain blinded to the treatment administered to them during these visits.
2942466|NCT02955368|Experimental|DP-R212 group|DP-R212 + C1-R212 placebo + C2-R212 placebo
2942467|NCT02955368|Active Comparator|C1-R212 group|DP-R212 placebo + C1-R212 + C2-R212 placebo
2942471|NCT02955329|Experimental|THC|Participants will vape marijuana leaves with THC (Tetrahydrocannabinol) out of the PAX device.
2942472|NCT02955329|Experimental|Nicotine/THC|Participants will vape flavorless 6% nicotine e-liquid, followed by THC (Tetrahydrocannabinol) out of the PAX device.
2942473|NCT02955303|Experimental|TECH protocol|Daily self-training using tablet apps facilitated by weekly group sessions. The self-training will take place independently at participants' home and will include mostly playing puzzle-apps to train different cognitive components. Participants will be requested to play (and log) various apps three to five times a week for 30-60 minutes each time, for a total of 15-20 training sessions. In addition they will use the tablets for a variety of everyday uses. The individual self-training will be accompanied by five weekly sessions (of 60-90 minutes) in a small group setting (5-6 participants) led by an experienced occupational therapist. For initial learning of the tablet's basic use, an individual session for each participant will take place.
2942474|NCT02955290|Experimental|Group A (CIMAvax, nivolumab)|"PHASE I: Patients receive CIMAvax IM and nivolumab IV over 60 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Within 4 weeks after the 4th dose, patients receive CIMAvax IM at the same time as the next nivolumab dose.~MAINTENANCE PHASE I: Patients receive CIMAvax IM and nivolumab IV over 60 minutes. Courses repeat every 4 weeks for CIMAvax and every 2 weeks for nivolumab in the absence of disease progression or unacceptable toxicity."
2942475|NCT02955290|Experimental|Group B (CIMAvax, nivolumab)|"PHASE I: Patients receive CIMAvax IM and nivolumab IV over 60 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Within 4 weeks after the 4th dose, patients receive CIMAvax IM at the same time as the next nivolumab dose.~MAINTENANCE PHASE I: Patients receive CIMAvax IM and nivolumab IV over 60 minutes. Courses repeat every 8 weeks for CIMAvax and every 2 weeks for nivolumab in the absence of disease progression or unacceptable toxicity."
2942476|NCT02955290|Experimental|Group C (CIMAvax, nivolumab)|"PHASE I: Patients receive CIMAvax IM and nivolumab IV over 60 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Within 4 weeks after the 4th dose, patients receive CIMAvax IM at the same time as the next nivolumab dose.~MAINTENANCE PHASE I: Patients receive CIMAvax IM and nivolumab IV over 60 minutes. Courses repeat every 12 weeks for CIMAvax and every 2 weeks for nivolumab in the absence of disease progression or unacceptable toxicity."
2942477|NCT02955277|Experimental|TECH protocol|TECH protocol - Daily self-training using tablet apps facilitated by weekly group sessions. The self-training will take place independently at participants' home and will include mostly playing puzzle-apps to train different cognitive components. Participants will be requested to play (and log) various apps three to five times a week for 30-60 minutes each time, for a total of 15-25 training sessions. In addition they will use the tablets for a variety of everyday uses. The individual self-training will be accompanied by five weekly sessions (of 60-90 minutes) in a small group setting (5-6 participants) led by an experienced occupational therapist.
2942478|NCT02955277|No Intervention|standard care|Participants will receive standard medical care with no TECH protocol.
2942479|NCT02955264|Experimental|D-Galactose|D-Galactose is an oral powdered supplement to be taken by mouth. For the first 6 weeks galactose will be given at the dose 0.5g per kg, then from weeks 7-12 at 1.0g per kg, lastly from weeks 13 to 18 at 1.5g per kg (with a maximum daily dose of 50g).
2942480|NCT02955251|Experimental|Arm 1|ABBV-428 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle).
2942481|NCT02955251|Experimental|Arm A, B, and C|Additional participants (with ovarian cancer, NSCLC, etc.) will be enrolled in a dose expansion cohorts that will further evaluate ABBV-428.
2942482|NCT02955251|Experimental|Arm D|Additional participants with NSCLC will be enrolled in an expansion cohort that will further evaluate ABBV-428 plus nivolumab.
2942483|NCT02955251|Experimental|Arm 2|ABBV-428 plus nivolumab.
2942484|NCT02955238|Experimental|Special Intervention|The Special Intervention (SI) is designed to modify multiple, modifiable CVD risk factors that affect atherosclerosis and can be measured by sonography of the carotid intimal thickness. The SI is designed to address multiple, modifiable CVD risk factors that involve medication therapy, including hypertension, diabetes, and dyslipidemia.
2942485|NCT02955238|No Intervention|Usual Care|Usual care (UC) reflects current practices by the primary care providers in the adult medicine department. Participants randomized into the UC group will continue with their regular medical visits and referrals to the health educator as they were before randomization.
2942486|NCT02955225|Experimental|Flexible shoe with Active Insole|Subjects will be trained to change the plantar pressure using a flexible walking shoe with an activated pressure-detecting shoe insole (Moticon OpenGO insole).
2942487|NCT02955225|Active Comparator|Flexible shoe with Passive Insole|A flexible walking shoe with a passive pressure-detecting shoe insole will be used for a comparator group.
2942488|NCT02955212|Placebo Comparator|Placebo (Period 1) followed by Upadacitinib (Period 2)|Placebo will be administered in Period 1, followed by upadacitinib which will be administered in Period 2.
2942489|NCT02955212|Experimental|Upadacitinib (Period 1) followed by Upadacitinib (Period 2)|Upadacitinib will be administered in Periods 1 and 2.
2942490|NCT02955199|Experimental|Mothering From the Inside Out|Mothering from the Inside Out (MIO) is a 12 session individual parenting therapy designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. MIO aims to promote their capacity for parental reflective functioning (the capacity to recognize and make sense of their own and their child's difficult emotions during challenging parenting situations).
2942491|NCT02955199|Active Comparator|Parent Education|Parent Education (PE) is a 12 session individual parent counseling intervention designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. PE provides psycho-education about child development and parenting strategies typically available at community agencies on parenting. PE is designed to control for active treatment, treatment dose, and individualized intervention approach.
2942492|NCT02955186|Experimental|125 mg saracatinib|Participants will take 125 mg of saracatinib daily for 8 days.
2942493|NCT02955186|Placebo Comparator|Placebo|Participants will take placebo daily for 8 days.
2942494|NCT02955173|Experimental|Open surgery of rectal cancer|Patients undergoing rectal cancer resection in an open approach
2942495|NCT02955173|Experimental|Laparoscopic surgery of rectal cancer|Patients undergoing rectal cancer resection in a laparoscopic approach
2942496|NCT02955173|Experimental|Open surgery of gastric cancer|Patients undergoing gastric cancer resection in an open approach
2942497|NCT02955173|Experimental|Laparoscopic surgery of gastric cancer|Patients undergoing gastric cancer resection in a laparoscopic approach
2942498|NCT02955160|Experimental|Multivalent|Pneumococcal conjugate vaccine
2942499|NCT02955160|Active Comparator|Tdap|Tetanus, diphtheria, and pertussis vaccine
2942500|NCT02955147|Experimental|Ustekinumab plus prednisone|"Ustekinumab: 90 mg of ustekinumab will be administered subcutaneously at baseline, week 4, week 12, week 20, week 28, week 36 and week 44.~Prednisone: All patients will receive a prednisone course tapered according to predefined schedules starting at either 60 mg, 40 mg or 20 mg. The initial dose of prednisone will be chosen by the investigators according to disease severity and comorbid medical conditions. The duration of the prednisone taper will be 6 months in all cases."
2942501|NCT02955134|Experimental|Chinese medicine prescription|On the basis of symptomatic treatment of Talcid® and Compound Azimtamide Entieric-coated Tablets,patients in experimental group use the traditional Chinese medicine application prescription.
2942502|NCT02955134|Placebo Comparator|placebo|On the basis of symptomatic treatment of Talcid® and Compound Azimtamide Entieric-coated Tablets,patients in placebo group use the simulate granule of traditional Chinese medicine application prescription.
2942503|NCT02955121|Active Comparator|Pharmacogenetic Testing Arm|Genotyping for CYP2C19 variants is performed. The test results are integrated into the electronic health record and alerts are displayed to the prescriber. The ultimate decision regarding antiplatelet therapy is left to the prescriber
2942504|NCT02955121|No Intervention|Control Arm|No genotyping information is performed as part of clinical care. Standard therapy is followed. Genotyping will be performed at conclusion of study in control arm, and genotyping results will not be incorporated into electronic health record.
2942505|NCT02955108|Experimental|music first then no music|
2942506|NCT02955108|Experimental|no music first then music|
2942507|NCT02955095|Experimental|Current cigarette smoker|
2942508|NCT02955082|Experimental|Carboplatin|Patients with a germline DNA repair gene mutation identified in part 1 of the study, or who are already known to have a germline mutation will undergo assessment for inclusion in part 2 of the study to receive Carboplatin treatment.
2942509|NCT02955069|Experimental|PDR001|110 patients will be administered PDR001 infusion.
2942510|NCT02955056|Experimental|Teriparatide Intervention|Will be asked to self-administer Teriparatide treatment (self-injection) once a day for 12 weeks
2942511|NCT02955056|No Intervention|Usual care|No intervention, patients will be treated as per local practice but will be followed up identically to the intervention group.
2942512|NCT02955043|Experimental|Behavioral intervention|Participants will learn behavioral techniques to improve sleep and increase daytime activity with the goal of alleviating insomnia, fatigue, and depression. The intervention will be delivered in three 45-60 minute face-to-face sessions at approximately 3-4, 8, and 12 weeks post-HSCT with brief telephone coaching calls scheduled between sessions. Participants will be encouraged to use the behavioral strategies from hospital discharge through 18 weeks post-HSCT. Participants will be asked to complete a daily checklist indicating which intervention strategies they used. Participants will also receive standard medical care following HSCT.
2942513|NCT02955043|No Intervention|Usual care|Participants will receive standard medical care following HSCT.
2942514|NCT02955030|Experimental|NSV0001(Cohort1)|15 µg of hemagglutinin [HA] antigen per strain with 150 µg of ND002 adjuvant, administration by sublingual route
2942515|NCT02955030|Experimental|NSV0001(Cohort2)|30 µg of hemagglutinin[HA] antigen per strain with 300 µg of ND002 adjuvant, administration by sublingual route
2942516|NCT02955030|Experimental|NSV0001(Cohort3)|60 µg of hemagglutinin[HA] antigen per strain with 600 µg of ND002 adjuvant, administration by sublingual route
2942517|NCT02955030|Placebo Comparator|Placebo|0 µg of hemagglutinin[HA] antigen per strain with 0 µg of ND002 adjuvant, administration by sublingual route
2942518|NCT02955030|Active Comparator|"Influenza HA vaccine Biken HA"|Seasonal quadrivalent influenza vaccine, administration by subcutaneous injection route
2942519|NCT02955017|Active Comparator|Traditional follow-up|
2942520|NCT02955017|Experimental|"Distance follow-up new technologies"|
2942521|NCT02954991|Experimental|Glesatinib and Nivolumab|Glesatinib oral tablet administered twice daily in combination with Nivolumab administered as 240 mg IV every 2 weeks
2942522|NCT02954991|Experimental|Sitravatinib and Nivolumab|Sitravatinib oral capsule administered daily in combination with nivolumab administered as 240 mg IV every 2 weeks
2942523|NCT02954991|Experimental|Mocetinostat and Nivolumab|Mocetinostat oral capsule administered three times weekly in combination with nivolumab administered as 240 mg IV every 2 weeks
2942524|NCT02954978|Placebo Comparator|Placebo|"Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 1 will receive the placebo (sugar pill) one (1) capsule by mouth once daily (taken without a meal) for 12 months and 3 months follow up."
2942525|NCT02954978|Active Comparator|Nilotinib 150mg|Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
2942526|NCT02954978|Active Comparator|Nilotinib 300mg|Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
2942527|NCT02954965|Experimental|Reward|A brief, phone-administered intervention designed to help graduate students increase the number of pleasant and rewarding activities in their daily lives.
2942528|NCT02954965|Experimental|Approach|A brief, phone-administered intervention designed to help graduate students block procrastination and avoidance and to approach important activities they are currently avoiding.
2942529|NCT02954965|No Intervention|Monitoring|Participants will monitor their current behaviors, mood, and burnout with no directed intervention to change behavior
2942530|NCT02954952|Other|Standard of care (baseline)|Subjects will receive the Sedline sensor. The anesthesiologist will be blinded to the PSI Rev 1.X score and the raw EEG data from the Masimo device. Anesthesia management will be in accordance with standard of care protocols and procedures.
2942531|NCT02954952|Experimental|PSI Rev 1.X|The anesthesiologist will be monitoring subjects using an old version of PSI (Rev 1.X).
2942532|NCT02954952|Experimental|PSI Rev 2.X|The anesthesiologist will be monitoring subjects using a new version of PSI (Rev 2.X).
2942533|NCT02954939|Active Comparator|MMF-MMF|Class III/IV+V LN patients who receive prednisolone (PRED) (0.8mg/kg/d) plus mycophenolate mofetil (MMF) (1g bd) as induction-maintenance therapy
2942534|NCT02954939|Placebo Comparator|CTX-AZA|Class III/IV+V LN patients who receive prednisolone (PRED) (0.8mg/kg/d) plus Cyclophosphamide (CTX) (1.5-2mg/kg/d) followed by Azathioprine (AZA) (1-1.5mg/kg/d) as induction-maintenance therapy
2942535|NCT02954926|Experimental|IVIG|IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
2942536|NCT02954926|No Intervention|Control|No intervention
2942537|NCT02954913|Experimental|Simultaneous Resection|Patients will undergo resection of the colon or rectum and liver in the same anesthetic setting. The type of colorectal and liver resection will be decided by the treating physician. The type of liver resection will be described according to the Couinaud classification and the Brisbane terminology of liver anatomy.
2942538|NCT02954900|Other|Decision aid|50 women at high-risk for developing breast cancer will use a decision support tool, RealRisks, when discussing breast cancer risk with their providers who will have access to the BNAV provider clinical decision support tool.
2942539|NCT02954887|Experimental|GWP42003-P|"Administered orally, up to the target dose recommended by the data safety monitoring committee.~Participants continue at the target dose, or the highest tolerated dose up to the target dose, for a total of 12 months' treatment."
2942540|NCT02954874|Experimental|Arm I (observation)|Patients receive no treatment but are monitored at standard clinical intervals during first year after randomization. Patients are examined every 12 weeks for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients may undergo radiation therapy within 12 weeks of last breast cancer operation or after treatment.
2942541|NCT02954874|Experimental|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on days 1 and 22. Courses repeat every 42 days for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may undergo radiation therapy within 12 weeks of last breast cancer operation or after treatment.
2942542|NCT02954861||Cardiac surgery|Patients who develop delirium following cardiac surgery
2942543|NCT02954848|Experimental|TAK-438 10 mg|One TAK-438 10 mg tablet will be orally administered once daily
2942544|NCT02954848|Placebo Comparator|Placebo|One TAK-438 placebo tablet will be orally administered once daily
2942545|NCT02954835|Active Comparator|Prevena|Subjects randomized to the Prevena dressing will have the dressing in place for 5 to 7 days postoperatively and removed before discharge, or at the first outpatient visit.
2942546|NCT02954835|Active Comparator|Traditional Dressing|Subjects randomized to the traditional dressing will undergo dressing changes as per the standard protocol with the first dressing change at postoperative day 2 or 3, or at the discretion of the attending surgeon.
2942547|NCT02954822|Experimental|(Group A)|Evogliptin→Evogliptin+Glimepiride→Glimepiride
2942548|NCT02954822|Experimental|(Group B)|Glimepiride→Evogliptin→Evogliptin+Glimepiride
2942549|NCT02954809|Experimental|Experimental|Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.
2942550|NCT02954809|Active Comparator|Attention Control|Exposure to dim light delivered with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.
2942551|NCT02954796|Experimental|(Dose Escalation) Cohort -1 - 6|SGN-CD352A will be given intravenously (into a vein; IV) every 28 days at increasing doses.
2942552|NCT02954783|Experimental|High Intensity Interval Training|The HIIT-group will receive usual care plus a supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes.
2942553|NCT02954783|Active Comparator|Usual Care Observational Control|Patients randomized to usual care control will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.
2942554|NCT02954770||Fitbit® challenger|The residents who participated a Fitbit® challenge study about one year ago
2942555|NCT02954757|Experimental|Treatment arm|HIFU treatment
2942556|NCT02954744|Experimental|Treatment arm|HIFU treatment
2942557|NCT02954731|Experimental|UP-CBT|"The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) is one of the most widely studied transdiagnostic manuals. Here, the investigators apply a group manual that has been modified from the published UP for individual therapy based on recommendations on group delivery from the UP Institute (personal communications) and integrations modifications necessary for the delivery in the Mental Health Service. Group UP-CBT, consist of 8 treatment modules delivered in 14 group sessions given weekly in 2 hour sessions."
2942558|NCT02954731|Active Comparator|Standard-CBT|Group CBT following Danish versions of diagnosis specific manuals (Social Anxiety Disorder (SAD) Group; Depression (DEP) Group; Agoraphobia/Panic Disorder (Ag/PD) (standard-CBT). The original elements of psychoeducation, cognitive restructuring, and exposure/activity scheduling are present in the applied manuals. Standard-CBT, consist of 8 treatment modules delivered in 14 group sessions given weekly in 2 hour sessions.
2942559|NCT02954718|Experimental|1|patient-centered task oriented activity training in real life
2942560|NCT02954718|Experimental|2|patient-centered video-based task oriented activity training
2942561|NCT02954705||Group AAV|Patients recruited from the Nantes University Hospital. 50 milliliter of blood and 10mL of urine are collected from these patients during levies in clinical visit.
2942562|NCT02954705||Group control|"People recruited from the Etablissement français du sang (French blood establishment ).~10 milliliter of blood are collected from these donors"
2942563|NCT02954692|Experimental|Insulin glargine (U300)|Insulin glargine (U300) will be administered daily through subcutaneous injection, and thereafter, dose will be titrated weekly (preferably 3-4 days) as needed. Background non-insulin anti-diabetic drugs approved for use in combination with insulin according to local labelling, will be permitted, with the exception of Thiazolidinediones (TZDs), which must be stopped at the time of basal insulin initiation.
2942564|NCT02954666|Experimental|Patients with neurally mediated syncope|Tailored radio-frequency ablation of the ARGP (CardNM).
2942565|NCT02954666|Experimental|Patients with sick sinus syndrome|Tailored radio-frequency ablation of the ARGP (CardNM).
2942566|NCT02954653|Experimental|Dose Escalation|Single agent PF-06747143 dose escalation
2942567|NCT02954653|Active Comparator|Cohort 1|PF-06747143 with standard dose cytarabine and daunorubicin.
2942568|NCT02954653|Active Comparator|Cohort 2|PF-06747143 in combination with Azacitidine or Decitabine.
2942569|NCT02954653|Experimental|Cohort 3|PF-06747143 dose expansion as a single agent.
2942570|NCT02954640|Other|Patient with PID|"For patient with clinical diagnosis of PID, an additional blood sampling will be taken.~The genetic diagnosis will be done via the method of gene-panel in the frame of the study.~A genetic confirmation will, in any case, be done via the reference method (Sanger), in order to establish a final diagnosis for these patients."
2942571|NCT02954627||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
2942572|NCT02954614|Experimental|Intervention group|Active play in after school programs (ASP). Training program for ASP staff.
2942573|NCT02954614|No Intervention|Control group|ASP as usual.
2942574|NCT02954601|Active Comparator|Placebo|Placebo (fish oil)
2942575|NCT02954601|Active Comparator|Dose1|Dose 1 ORMD-0801 (qd)
2942576|NCT02954601|Active Comparator|Dose2|Dose 2 ORMD-0801 (bid)
2942577|NCT02954601|Active Comparator|Dose 3|Dose 3 ORMD-0801 (tid)
2942578|NCT02954588|Active Comparator|Pyridoxamine (1)|Subjects will be asked to consume dietary supplements containing pyridoxamine (dosage 1), three times daily during 8 weeks.
2942579|NCT02954588|Active Comparator|Pyridoxamine (2)|Subjects will be asked to consume dietary supplements containing pyridoxamine (dosage 2), three times daily during 8 weeks
2942580|NCT02954588|Placebo Comparator|Placebo|Subjects will be asked to consume dietary supplements containing placebo (amylum solani), three times daily during 8 weeks
2942581|NCT02954575|Experimental|All patients|All patients will receive Wilate for prophylactic treatment
2942582|NCT02954562||Anxiety|"Participants enrolled in study A randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated with a Life-Threatening Illness (NCT02427568) who meet further inclusion criteria for fMRI scan"
2942583|NCT02954549|Active Comparator|Healthy control group|Subjects in this arm have a normal serum level of 25(OH)D, >30 ng/mL. Subjects submit to blood draws and biometric tests (DXA, body composition, BP) and questionnaires on 3 occasions. They do not receive vitamin D3 supplementation.
2942584|NCT02954549|Experimental|Low dose supplementation group|Subjects in this group have been identified as having a level of 25(OH)D of < 30 ng/mL and are randomized to receive vitamin D3 supplementation of 2000 IU daily for 3 months.
2942585|NCT02954549|Experimental|High dose supplementation group|Subjects in this group have been identified as having a level of 25(OH)D of <30 ng/mL and are randomized to receive vitamin D3 supplementation of 5000 IU daily for 3 months.
2942586|NCT02954536|Experimental|Pembrolizumab, trastuzumab,capecitabine/cisplatin|Pembrolizumab 200 mg IV every 3 weeks, trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) IV every 3 weeks with cisplatin IV every 3 weeks with oral capecitabine 2 weeks on/1 week off. Each cycle consists of 21 days. Treatment will be administered on an outpatient basis. In Cycle 1, patients will initiate therapy with trastuzumab 8 mg/kg IV with pembrolizumab 200 mg IV. CT/MRI scan will be performed after the initial 3 weeks (1 cycle) to determine response to pembrolizumab and trastuzumab combination. With subsequent cycles, all patients will begin systemic chemotherapy with the capecitabine/cisplatin regimen in addition to pembrolizumab 200 mg IV with trastuzumab 6 mg/kg maintenance. Patients will receive cisplatin 80 mg/m2 IV on Day 1, and capecitabine 850mg/m2 twice a day on Days 1 through 14, every 3 weeks.
2942587|NCT02954523|Experimental|Phase I and Phase II|"Osimertinib (AZD9291) will be given at a 80mg/day dose taken orally across all levels of the dose escalation schedule.~Dasatinib is taken orally and will be given at up to 4 dose levels. Level -2 (50 mg once daily), Level -1 (70 mg once daily), Level 1 (the starting dose - 50 mg twice daily), Level 2 (70 mg twice daily).~Dose escalation will only include 2 dose levels (Levels 1 and 2); in addition there will be 2 dose levels below the starting dose level if dose reductions are necessary (Levels -1 and -2).~There is no limit to the number of cycles a patient can receive.~The phase II portion of the study will use the maximum tolerated dose of dasatinib determined in the phase I portion. Osimertinib (AZD9291) will be given at the same 80mg dose as the phase I portion."
2942588|NCT02954510|Experimental|Intervention|Single arm utilizing ferumoxytol
2942589|NCT02954497|Experimental|Jarvik 2015 Device VAD|New, experimental continuous flow VAD
2942590|NCT02954484|Active Comparator|PREGABALIN|All subjects receive intravenous PCA morphine, paracetamol 1g po six hourly and etoricoxib 120mg po once daily. Subjects receive pregabalin 75mg orally preoperatively followed by 75mg at night for two days. During surgery, patients received general anaesthesia with femoral nerve block on the side of surgery.
2942591|NCT02954484|Placebo Comparator|PLACEBO|All subjects receive intravenous PCA morphine, paracetamol 1g po six hourly and etoricoxib 120mg po once daily. Subjects receive either placebo tablet (of identical appearance to pregabalin) orally preoperatively followed by 75mg at night for two days. During surgery, patients received general anaesthesia with femoral nerve block on the side of surgery.
2942592|NCT02954471||Participants With Breast Cancer|This study will retrospectively collect data from participants with breast cancer in Saudi Arabia.
2942593|NCT02954458|Experimental|Standard of care (SOC) treatment +/- teduglutide (TED)|Participants will receive 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injections once daily into 1 of the 4 quadrants of the abdomen or into either the thigh or arm as needed in addition to SOC treatment.
2942594|NCT02954445|Experimental|B Cell Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-BCMA-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
2942595|NCT02954432|Experimental|Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
2942596|NCT02954432|Sham Comparator|Sham tDCS + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
2942597|NCT02954419||IgA nephropathy group|Eligible biopsy-proven primary IgA nephropathy patients.
2942632|NCT02954185|Active Comparator|Standard Therapy|Standard care therapy for should pain
2942598|NCT02954406|Experimental|TAK-659 + Bendamustine|TAK-659 60 milligram (mg), immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 milligram per square meter (mg/m^2), infusion, intravenously, over 10 or 60 minutes (depending on formulation used) on Days 1 and 2 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 will be escalated to 100 mg once daily after safety and tolerability of 60 mg dose is determined.
2942599|NCT02954406|Experimental|TAK-659 + Bendamustine + Rituximab|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes (depending on formulation used) on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 will be escalated to 100 mg once daily after safety and tolerability of 60 mg dose is determined.
2942600|NCT02954406|Experimental|TAK-659 + Gemcitabine|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with gemcitabine 1000 mg/m^2, infusion, intravenously, over 30 minutes on Days 1 and 8 in a 21-day treatment cycle. The TAK-659 will be escalated to 100 mg once daily after safety and tolerability of 60 mg dose is determined.
2942601|NCT02954406|Experimental|TAK-659 + Lenalidomide|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 28 along with lenalidomide 25 mg, capsules orally, once daily on Days 1 to 21 in a 28-day treatment cycle. The TAK-659 will be escalated to 100 mg once daily after safety and tolerability of 60 mg dose is determined.
2942602|NCT02954406|Experimental|TAK-659 + Ibrutinib|TAK-659 60 mg, immediate-release tablet, orally, once daily along with ibrutinib 560 mg capsules, orally, once daily on Days 1 to 28 in a 28-day treatment cycle. The TAK-659 will be escalated to 100 mg once daily after safety and tolerability of 60 mg dose is determined.
2942603|NCT02954393|Placebo Comparator|Control|Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Placebos healing phase TID for 14 days.
2942604|NCT02954393|Active Comparator|Active phase|Scaling and root planing + Metronidazole active phase (400 mg/thrice a day,TID) + Amoxicillin active phase (500 mg/ TID) for 14 days and Placebos healing phase TID for 14 days.
2942605|NCT02954393|Active Comparator|Healing phase|Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Metronidazole healing phase (400 mg/TID) + Amoxicillin healing phase (500 mg/TID) for 14 days.
2942606|NCT02954380|Experimental|ZIO/ILR|THe Zio ILR arm will already have an ILR implanted for standard of care and will receive the Zio patch
2942607|NCT02954367|Experimental|PROTEIN (MEAT + WHEY)|Post workout (training days) or breakfast (non training days) 20g of meat protein (10g meat + 10g whey) mixed with 200ml of orange juice and water
2942608|NCT02954367|Placebo Comparator|CARBOHYDRATE (CHO)|Post workout (training days) or breakfast (non training days) 20g of maltodextrin mixed with 200ml orange juice and water
2942609|NCT02954354|Experimental|Adults: Baloxavir Marboxil|Participants aged 20 to 64 years will receive two or four 20-mg Baloxavir Marboxil tablets orally on Day 1 and one oseltamivir placebo capsule orally twice a day (BID) on Days 1 to 5.
2942610|NCT02954354|Active Comparator|Adults: Oseltamivir|Participants aged 20 to 64 years will receive 75 mg oseltamivir twice a day on Days 1 to 5 and two or four S 033188 placebo tablets on Day 1.
2942611|NCT02954354|Placebo Comparator|Adults: Placebo|Participants aged 20 to 64 years will receive two or four S 033188 placebo tablets on Day 1 and one oseltamivir placebo capsule orally twice a day on Days 1 to 5.
2942612|NCT02954354|Experimental|Adolescents: Baloxavir Marboxil|Participants aged 12 to 19 years will receive two or four S 033188 20-mg tablets on Day 1.
2942613|NCT02954354|Placebo Comparator|Adolescents: Placebo|Participants aged 12 to 19 years will receive two or four Baloxavir Marboxil placebo tablets on Day 1.
2942614|NCT02954328|Experimental|tDCS|"The active tDCS condition will consist of 4 visit:~During each visit, subject will receive a single 20-minute session targeting the prefrontal cortices of either real (1.5 mA) or sham tDCS. Total 4 different targets:~Sham~motor M1 area~motor M1 + Dorsolateral Prefrontal cortex~Dorsolateral Prefrontal cortex.~The tDCS condition will be randomized and double blinded"
2942615|NCT02954315|Experimental|Almond arm|The almond dose will be provided as 20% of total energy (20% E) in the diet. This dose was selected based on a previous randomized trial examining lipid parameters in response to 0, 10%, and 20% E as dietary almonds and a recent meta-analysis of intervention trials.
2942616|NCT02954315|No Intervention|Western diet Snack (Granola bar + Pretzels)|The control snack will be a typical western diet snack (see Table 1). The calorie-matched control snack will be commercially available individually wrapped food products such as a small granola bar + pretzels.
2942617|NCT02954302|Experimental|PrPD with RGA|Patients who will undergo PrPD with proximal Roux-en-y gastrojejunal anastomosis.
2942618|NCT02954302|Experimental|conventional PrPD|Patients who will undergo conventional PrPD.
2942619|NCT02954289|Other|Dietary intervention|Dietary intervention
2942620|NCT02954276|Experimental|75 mg Omexa sumatriptan sublingual tablet|
2942621|NCT02954276|Active Comparator|100 mg Imitrex oral tablet|
2942622|NCT02954263|Experimental|TD-1439|Capsule formulation
2942623|NCT02954263|Placebo Comparator|Placebo|Capsule formulation
2942624|NCT02954250|No Intervention|Control|Patients randomized to the control group will be offered literature on mental health promotion and Treatment as usual
2942625|NCT02954250|Experimental|Mindfulness Group|The intervention will consist of group, lasting 90 minutes in one session per week for 8 weeks. The exercises will be 5 minutes long alternating between 4 or 5 each session.
2942626|NCT02954224|Experimental|CPAP therapy arm|Auto-titrating Continuous Positive Airway Pressure (CPAP)) treatment will be given on postoperative days 1, 2, and 3.
2942627|NCT02954224|No Intervention|Control arm|no auto-titrating CPAP, standard care
2942628|NCT02954211|Experimental|rTMS/PT|There will be only one group. All participants will receive 10 treatments of active repetitive transcranial magnetic stimulation combined with physical therapy.
2942629|NCT02954198|Active Comparator|Tacrolimus + MMF|Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Tacrolimus Daily (5 -12ng/mL) + mycophenolate mofetil 1g BID + prednisone x 6 months
2942630|NCT02954198|Active Comparator|Envarsus + Everoliumus|Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Envarsus Daily (2-5ng/mL) + Everolimus Daily (3-8ng/mL) + prednisone x 6 months
2942631|NCT02954185|Experimental|WellClub Device|Hand held device that patients use for home therapy
2942633|NCT02954172|Experimental|Bevacizumab in combination withPaclitaxel/Carboplatin|Drug Bevacizumab 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
2942634|NCT02954172|Active Comparator|Avastin in combination with Paclitaxel/Carboplatin|Drug avastin15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
2942635|NCT02954159|Active Comparator|Treatment arm|vedolizumab at standard regimen with concomitant induction treatment of tacrolimus (starting 0.05 mg per Kg twice daily)
2942636|NCT02954159|Placebo Comparator|Placebo Arm|vedolizumab at standard regimen with placebo.
2942637|NCT02954146|Active Comparator|CBT only|Veterans will receive 12 weekly individual cognitive behavioral therapy (CBT only) sessions for anger management.
2942638|NCT02954146|Experimental|CBT + Connectd mobile health app|Veterans will receive 12 weekly individual cognitive behavioral therapy (CBT) sessions for anger management. In addition, veterans in this group will also receive instructions for using Connectd mobile health app with a family member or friend that will provide data for the CBT clinician.
2942639|NCT02954133|Experimental|I7: Control|Subjects assigned to this group receive no OrthoPulse™ treatment, and switch Invisalign aligners every 7 days.
2942640|NCT02954133|Experimental|OP7: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 7 days.
2942641|NCT02954133|Experimental|OP5: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 5 days.
2942642|NCT02954133|Experimental|OP3.5: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 3.5 days.
2942643|NCT02954120||(PCOS-CP-)|systemically and periodontally healthy participants
2942644|NCT02954120||(PCOS-CP+)|systemically healthy participants with CP
2942645|NCT02954120||(PCOS+CP-)|PCOS participants with periodontally healthy
2942646|NCT02954120||(PCOS+CP+)|PCOS participants with CP
2942647|NCT02954107||Absence epilepsy|Children aged 6-12 years of age primarily presenting with episodes of brief loss of consciousness (absences) in an otherwise normal child in the previous 2 years. With an EEG showing 3 Hz (2.5-4.5 Hz) generalized rhythmic spike-and-wave complexes with a discharge duration of at least 3 seconds on a present or former EEG.
2942648|NCT02954107||Controls|Overall healthy children aged 6-12 years of age following a regular school without major problems.
2942649|NCT02954068|Active Comparator|IV Infusion|Oxytocin 10 IU, 500 ml IV infusion within 40 minutes + intra muscular injection of placebo, 10 IU
2942650|NCT02954068|Active Comparator|IM administration|Oxytocin 10 IU via intra muscular injection + Intravenously administered placebo, 10 IU, 500ml
2942651|NCT02954055|Active Comparator|Arm A|Paclitaxel 90 mg/m2 days 1, 8, 15 q4w. Patients will continue to receive assigned treatment until progression or lack of tolerability.
2942652|NCT02954055|Experimental|Arm B|"Metronomic VEX:~Cyclophosphamide 50 mg orally once daily continuously, Capecitabine 500 mg, orally 3 times a day (1500 mg/day) continuously, Vinorelbine 40 mg orally days 1, 3, 5 each week continuously. Patients will continue to receive assigned treatment until progression or lack of tolerability."
2942653|NCT02954042|Experimental|Pelvital probe|Probe to use for incontinence-Pevital is company name of product
2942654|NCT02954042|Placebo Comparator|Placebo Probe|Placebo probe
2942655|NCT02954029|Experimental|Study group (transradial cohort)|device-assisted compression with ezClot pad
2942656|NCT02954029|Experimental|Study group (transfemoral cohort)|manual compression with ezClot pad
2942657|NCT02954029|Active Comparator|Control group (transradial cohort)|Rotary compression device
2942658|NCT02954029|Active Comparator|Control group (transfemoral cohort)|manual compression with BloodSTOP ix pad
2942659|NCT02954016|Experimental|ePass|Subjects implanted with the investigational ValenTx Endo Bypass System
2942660|NCT02954003|Experimental|Endo Bypass|Subjects implanted with the investigational ValenTx Endo Bypass System
2942661|NCT02953990|Experimental|MOMS Program|The MOMS Program involves: (1) mindfulness of symptoms and goal-setting through a nurse-participant partnership, and (2) 12 weeks of weekly community-based group prenatal yoga classes (75 minutes each) and self-directed home activity. Participants will engage in 12 weeks of weekly community-based group prenatal yoga classes (75 minutes each) and self-directed home practice.
2942662|NCT02953977|Experimental|Diabetes Intervention|Diabetes Prevention Program
2942663|NCT02953977|Other|Delayed Intervention|Diabetes Prevention Program
2942664|NCT02953964|Experimental|Behavioral: perceptual-based memory encoding training|Participants receive perceptual-based memory encoding training
2942665|NCT02953964|Experimental|Behavioral: Semantic-based memory encoding training|Participants receive semantic-based memory encoding training
2942666|NCT02953964|Active Comparator|Behavioral : control group|Participants receive cognitive stimulation intervention
2942667|NCT02953951||Stored Blood Cells|"Blood transfusion:~Stored blood cells transfused patients"
2942668|NCT02953951||Autologous Salvaged Blood|"Blood transfusion:~Autologous salvaged blood transfused patients"
2942669|NCT02953951||Control|"Blood transfusion:~No transfusion patients"
2942670|NCT02953938|Active Comparator|mono therapy|ranibizumab alone
2942671|NCT02953938|Experimental|combination therapy|ranibizumab with Grid&Direct short pulse laser photocoagulation
2942672|NCT02953925||primary health care users|Subjects with high risk of cardiovascular diseases who lived in the catchment areas of the participating PHC institutions.
2942673|NCT02953912|Experimental|Reciproc single-file.|The Reciproc is a single-file nickel-titanium systems used in reciprocating motion, made of a special nickel-titanium (NiTi) alloy called M-Wire created by innovated thermal treatment process which increases flexibility and improved resistance to cyclic fatigue .
2942674|NCT02953912|Active Comparator|One Shape single-file .|One Shape is single file made of austenite 55- NiTi alloy characterized by different cross sectional designs ,it is used in continuous clockwise rotation for a quick and safe root canal preparation due to its flexibility and minimal fatigue. with electropolished safety tip instrument for enhanced cutting efficiency and it is delivered in a sterile blister for single use.
2942704|NCT02953717|Active Comparator|Stereotactic radiosurgery (SRS)|Gamma Knife radiosurgery
2942705|NCT02953717|Active Comparator|Whole Brain Radiation Therapy (WBRT)|Whole Brain Radiation Therapy
2942675|NCT02953899|Experimental|Contingency Management|This is a treatment where participants earn points for treatment attendance and for providing evidence of gambling abstinence. These points are added to study accounts that can be redeemed for goods and services available at a variety of on-line businesses (e.g., Amazon, Walmart, etc.). Submission of evidence of gambling behaviour or non-attendance at an on-line counselling session re-sets subsequent points to the starting level. The CM procedure is implemented as part of the CBT counselling session.
2942676|NCT02953899|Active Comparator|Cognitive Behavioural Therapy|"CBT is currently considered best practice for the treatment of problem gambling, as noted in the National Health and Medical Research Council (Australia) endorsed Clinical Guidelines for problem and pathological gambling treatment (Problem Gambling Research and Treatment Centre, 2011). CBT is typically a semi-structured approach for delivering cognitive behavioural therapy addressing the participant's experiences, thoughts, and emotions relating to their gambling and substance use. Techniques include psychoeducation, behavioural interventions, and cognitive strategies. Participants are expected to attend on-line counselling sessions three times a week for approximately 12 weeks. All participants will receive individual counselling from an experienced counsellor/therapist."
2942677|NCT02953886|Experimental|Silver Diamine Fluoride (SDF)|Application of Silver Diamine Fluoride (SDF) to root or cervical carious lesions (cavities). Collection of plaque pre- and one month post-SDF application.
2942678|NCT02953873|Other|Conversion Arm|Tacrolimus Extended Release Capsule (goal 5 - 12ng/mL) + Mycophenolate Mofetil ≥500mg twice a day OR Mycophenolate Sodium ≥360mg twice a day+ prednisone ≥ 5mg Daily
2942679|NCT02953860|Experimental|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given, in conjunction with Fulvestrant, PO daily.
2942680|NCT02953847|Other|sequence 1|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
2942681|NCT02953847|Other|sequence 2|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
2942682|NCT02953847|Other|sequence 3|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
2942683|NCT02953847|Other|sequence 4|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
2942684|NCT02953847|Other|sequence 5|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
2942685|NCT02953847|Other|sequence 6|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
2942686|NCT02953834|Experimental|Kisspeptin and Insulin Resistance Test|intravenous administration of kisspeptin 112-121; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose
2942687|NCT02953834|Placebo Comparator|Placebo and Insulin Resistance Test|intravenous administration of IV fluids that contain no study drug; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose
2942688|NCT02953821|Experimental|Repository corticotropin injection|During Weeks 1 to 4, 1 mL (80 U) of repository corticotropin injection will be administered subcutaneously (SC) every other day. During Weeks 5 to 24, repository corticotropin injection 1 mL (80 U) will be administered SC 2x/week.
2942689|NCT02953821|Placebo Comparator|Placebo gel|During Weeks 1 to 4, 1 mL of Placebo gel will be administered subcutaneously (SC) every other day. During Weeks 5 to 24, Placebo gel 1 mL will be administered SC 2x/week.
2942690|NCT02953808|Experimental|Cohort 1 Group A|In dosing sessions 1, 2, and 3, subjects will receive GSK2315698 10 mg/hr, GSK2315698 20 mg/hr, and Placebo, respectively, as intravenous infusion over 1 hour.
2942691|NCT02953808|Experimental|Cohort 1 Group B|In dosing sessions 1, 2, and 3, subjects will receive GSK2315698 10 mg/hr, Placebo, and GSK2315698 40 mg/hr, respectively, as intravenous infusion over 1 hour.
2942692|NCT02953808|Experimental|Cohort 1 Group C|In dosing sessions 1, 2, and 3, subjects will receive Placebo, GSK2315698 20 mg/hr, and GSK2315698 40 mg/hr, respectively, as intravenous infusion over 1 hour.
2942693|NCT02953808|Experimental|Cohort 2 Group D|In a single dosing session, subjects will receive GSK2315698 20 mg/hr as intravenous infusion over 15 hours.
2942694|NCT02953808|Placebo Comparator|Cohort 2 Group E|In a single dosing session, subjects will receive Placebo as an intravenous infusion over 15 hours.
2942695|NCT02953782|Experimental|Phase 1b dose escalation|In Phase 1b, patients with advanced solid tumors will receive escalating doses of Hu5F9-G4 in combination with cetuximab.
2942696|NCT02953782|Experimental|Phase 2 KRAS mutant|In Phase 2, patients with advanced KRAS mutant colorectal cancer will receive Hu5F9-G4 in combination with cetuximab.
2942697|NCT02953782|Experimental|Phase 2 KRAS wild-type|In Phase 2, patients with advanced KRAS wild-type colorectal cancer will receive Hu5F9-G4 in combination with cetuximab.
2942698|NCT02953769||Arm 1|Ventral hernia repair using standard wound care.
2942699|NCT02953769||Arm 2|Ventral hernia repair, regarding wound morbidity, post-operative pain and patient comfort to ambulation, with the use of Prevena™
2942700|NCT02953756||Stereotactic radiosurgery (SRS)|Gamma Knife radiosurgery (GKRS)
2942701|NCT02953743|Experimental|Lenvatinib 12 mg|Participants weighing ≥ 60 kg will be enrolled in this arm.
2942702|NCT02953743|Experimental|Lenvatinib 8 mg|Participants weighing < 60 kg will be enrolled in this arm.
2942703|NCT02953730|Experimental|PEG-rhG-CSF|
2942706|NCT02953704||Myelofibrosis Cohort|Patients will be categorized as low-risk using Dynamic International Prognostic Scoring System (DIPSS) risk OR intermediate-1 risk by DIPSS by reason of age alone.
2942707|NCT02953704||Essential Thrombocythemia Cohort|Patients will be age ≥ 60 years OR have history of thromboembolic events OR currently receiving ET-directed therapy.
2942708|NCT02953691|Experimental|Galacto-Oligosaccharides (GOS)|Clasado Biosciences Limited will provide Bimuno Pastilles for the clinical trial. Each pastille contains 0.92g GOS and will be taken 3 times per day. Following informed consent, subjects will be issued prepackaged GOS pastilles to be taken three times daily up until the evening prior to surgery. Subjects will be randomly assigned to receive GOS prebiotics. Each subject has an equal chance of receiving GOS or placebo. GOSn will be administered in the hospital when patient reinstitutes oral intake. GOS will be issued to each subject to last until the day of their scheduled follow-up for POCD (approximately 1.5 months post surgery).
2942709|NCT02953691|Placebo Comparator|Maltodextrin (Placebo)|Clasado Biosciences Limited will provide placebo (Maltodextrin) for the clinical trial. Each pastille contains maltodextrin and will be taken 3 times per day. Following informed consent, subjects will be issued prepackaged pastilles to be taken three times daily up until the evening prior to surgery. Subjects will be randomly assigned to receive GOS prebiotics or placebo. Each subject has an equal chance of receiving GOS or placebo. Placebo will be administered in the hospital when patient reinstitutes oral intake. Placebo will be issued to each subject to last until the day of their scheduled follow-up for POCD (approximately 1.5 months post surgery).
2942710|NCT02953678|Experimental|Ruxolitinib in combination with corticosteroids|Ruxolitinib twice daily at the protocol-defined starting dose in combination with corticosteroids.
2942711|NCT02953665|Active Comparator|Liraglutide|Liraglutide 6 mg/ml (Novo Nordisk A/S) will be self-administered subcutaneously once daily at a maximum dose of 1.8 mg after a 2 week titration schedule.
2942712|NCT02953665|Placebo Comparator|Placebo|Placebo will be self-administered subcutaneously once daily according to the same schedule.
2942713|NCT02953652|Experimental|HBI-8000|Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.
2942714|NCT02953639|Experimental|Basmisanil 240 mg|Participants will receive basmisanil twice daily orally for 24 weeks.
2942715|NCT02953639|Experimental|Basmisanil 80 mg|Participants will receive basmisanil twice daily orally for 24 weeks.
2942716|NCT02953639|Placebo Comparator|Placebo|Participants will receive matching placebo to basmisanil twice daily orally for 24 weeks.
2942717|NCT02953626|Experimental|Immediate Treatment Condition (ITC)|Mother Matters Online Postpartum Support Group. Participants will be assigned to begin immediately after randomization.
2942718|NCT02953626|No Intervention|Waitlist Control Condition (WLC)|Mother Matters Online Postpartum Support Group. Participants will receive the intervention after the Immediate Treatment Condition group completes the intervention, and after follow-up data are collected from both groups.
2942719|NCT02953613|Experimental|Cardiac Catheterization with NIRS/IVUS|Cardiac cathetirization with NIRS/IVUS assessment if with blockage of indeterminate severity (greater or equal to 20% to 70%). One day to one week after invasive catheterization a CCTA will be done to correlate result, then CCTA will be repeated at 24 months
2942720|NCT02953600|Experimental|Standard Dose Spirulina Platensis|Spirulina platensis pill/500mg, 3 pills before each meal /6 pills per day
2942721|NCT02953600|Active Comparator|Zero Spirulina Platensis|Spirulina platensis pill/500mg, 6 pills before each meal /12 pills per day
2942722|NCT02953600|Active Comparator|Double Dose Spirulina Platensis|same as usual, non pill taken
2942723|NCT02953587|Experimental|Vertical Sleeve Gastrectomy (VSG) NJ/PO|Patients that are undergoing routine VSG will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed by administering glucose through a nasojejunal (NJ) feeding tube preoperatively and orally (PO) postoperatively.
2942724|NCT02953587|Experimental|Roux-en-Y Gastric Bypass (RYGB) NJ/PO|Patients that are undergoing routine RYGB will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed by administering glucose through a nasojejunal (NJ) feeding tube preoperatively and orally (PO) postoperatively.
2942725|NCT02953587|Experimental|Vertical Sleeve Gastrectomy (VSG) PO/PO|Patients that are undergoing routine VSG will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed.
2942726|NCT02953587|Experimental|Roux-en-Y Gastric Bypass (RYGB) PO/PO|Patients that are undergoing routine RYGB will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed.
2942727|NCT02953574|Experimental|daily sleep enhancement nursing protocol|"A 7 step nursing protocol. Each step is daily provided to the demented patient through a nurse by bedtime.~Step 1: serve a late snack Step 2: evening care (brush teeth, get pyjama on, go to toilette) Step 3: note and treat physical circumstances that restrain sleep (pain, obstipation,...) Step 4: ensure comfortable position abed Step 5: assist to eliminate stressful situation (calm, reorientating conversation) Step 6: turn off the light Step 7: care for a silent environment (turn off Television, radio and do not disturb-sign at the door)"
2942728|NCT02953574|No Intervention|usual nursing care|
2942729|NCT02953561|Experimental|Lead-in Phase Ib|"Avelumab (antiPDL1) and Azacytidine~5-azacytidine subcutaneously or intravenously daily for 7 days of each treatment cycle; length of the cycle will be at least 28 days to evaluate DLT."
2942764|NCT02953327|Experimental|Intervention arm|Intervention arm, these participants will receive BCG vaccination.
2942730|NCT02953561|Experimental|Phase II|"Avelumab (antiPDL1) and Azacytidine~Avelumab by vein on Day 1 & Day 14 (+/-3 days) of each 5-azacytidine cycle for first 4 cycles or until CR (whichever occurs earlier) followed by a maintenance regimen (one dose of avelumab on day 1 of each cycle of 5-azacytidine)."
2942731|NCT02953548|Experimental|GWP42003-P|Administered orally, titrating to a target dose of 40 mg/kg/day. Participants continue at the target dose, or the highest tolerated dose up to the target dose, for the remainder of the 2-week treatment period.
2942732|NCT02953535|Experimental|T test|Test drug (Magicbuvir)1 tablet contains 400 mg Sofosbuvir
2942733|NCT02953535|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
2942734|NCT02953535|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
2942735|NCT02953522|Other|191 mcg/day of Folate|Diet with 191 mcg/day of Folate
2942736|NCT02953522|Other|90 mcg/day of Folate|Diet with 90 mcg/day of Folate
2942737|NCT02953509|Experimental|Phase 1b dose escalation|In Phase 1b, patients with non-Hodgkin's lymphoma will receive escalating doses of Hu5F9-G4 in combination with ritixumab.
2942738|NCT02953509|Experimental|Phase 2 indolent lymphoma|In Phase 2, patients with indolent lymphoma will receive Hu5F9-G4 in combination with ritixumab.
2942739|NCT02953509|Experimental|Phase 2 diffuse large B-cell lymphoma|In Phase 2, patients with diffuse large B-cell lymphoma will receive Hu5F9-G4 in combination with ritixumab.
2942740|NCT02953496|Experimental|vonapanitase|
2942741|NCT02953483|Experimental|Acellular first|Lung preservative solution without red blood cells will be used for perfusion in the initial 2 hours followed by addition of red blood cells for the next two hours
2942742|NCT02953483|Experimental|Cellular first|Lung preservative solution will contain red blood cells for the first two hours followed by acellular perfusate for the next two hours
2942743|NCT02953470|Experimental|Individual tailored functional exercise|Receives general advice about physical activity with the goal to be physically active at least 30 minutes per day at 5 of 7 days per week. The intervention group, which is based on a behavioural medicine approach in physiotherapy, also receive individual tailored functional exercise with the goal to enhance the ability to perform everyday activities by reduce pain-related disability and pain-related beliefs and increase physical function. The participants receive 9 visits from a physiotherapist during the 12 weeks period. The participants will also fill in a activity diary to check the compliance to the intervention and to enhance their self-efficacy in relation to perform everyday activities, exercise and physical activity.
2942744|NCT02953470|Active Comparator|Standard care|The participants in the comparison Group will receive standard care which means that they receives one visit from physiotherapist where the participant receive general advice about physical activity with the goal to be physically active at least 30 minutes per day at 5 of 7 days per week. During intervention week 1-8 and 10 the participants receive telephone calls once a week where they will be reminded to follow the advice about physical activity.
2942745|NCT02953457|Experimental|Treatment (olaparib, tremelimumab, durvalumab)|Patients receive olaparib PO BID, and tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment with olaparib continues for up to 12 months in the absence of disease progression or unacceptable toxicity. Treatment with tremelimumab repeats every 4 weeks for up to 4 courses and treatment with durvalumab repeats every 4 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity.
2942746|NCT02953444|No Intervention|Wait List Control|Participants receive daily email surveys for two weeks before being given access to the brief-mindfulness-practice training materials.
2942747|NCT02953444|Experimental|Thirty-Second Mindfulness Practice|Participants watch a ten minute mindfulness training video then are given electronic access to an audio recording of guidance for a thirty-second mindfulness meditation practice. Participants are asked to complete this practice using the audio-recorded guidance at least three times a day for two weeks. Participants are sent daily emails that include reminders to complete the practice and a link to a brief online survey.
2942748|NCT02953444|Active Comparator|Three-Minute Mindfulness Practice|Participants watch a ten minute mindfulness training video then are given electronic access to an audio recording of guidance for a three minute mindfulness meditation practice. Participants are asked to complete this practice using the audio-recorded guidance at least three times a day for two weeks. Participants are sent daily emails that include reminders to complete the practice and a link to a brief online survey.
2942749|NCT02953431|Placebo Comparator|PEEP 0|Participants will be randomized to positive expiratory pressure (PEEP) 0
2942750|NCT02953431|Active Comparator|PEEP 10|Participants will be randomized to positive expiratory pressure (PEEP) 10
2942751|NCT02953418|Experimental|Radiofrequency ablation|Step-wise endoscopic RFA with the Barrx™ Flex Radiofrequency Ablation System using will be performed in 3 month intervals up to 12 months.
2942752|NCT02953392|Active Comparator|Arm 1|Transcrestal Sinus Floor Elevation using platform switched implant with bone graft material.
2942753|NCT02953392|Active Comparator|Arm 2|Transcrestal Sinus Floor Elevation using platform switched implant with no bone graft material.
2942754|NCT02953392|Active Comparator|Arm 3|Transcrestal Sinus Floor Elevation using platform matching implant with bone graft material.
2942755|NCT02953392|Active Comparator|Arm 4|Transcrestal Sinus Floor Elevation using platform matching implant with no bone graft material.
2942756|NCT02953379|Experimental|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
2942757|NCT02953379|Active Comparator|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
2942758|NCT02953366|Experimental|EMS Mometasone gel|The patient should administer 1 spray in each nostril once daily.
2942759|NCT02953366|Active Comparator|Mometasone spray nasal|The patient should administer 1 spray in each nostril once daily.
2942760|NCT02953353|Active Comparator|Active group|Active transcranial direct current stimulation (tDCS) and hypocaloric diet.
2942761|NCT02953353|Sham Comparator|Control group|Sham transcranial direct current stimulation (tDCS) and hypocaloric diet.
2942762|NCT02953340|Experimental|Docetaxel +Cyclophosphamide+ SPI-2012|"SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6)~Supplied in prefilled single-use syringes for subcutaneous injection~Administered on Day 2 of each cycle"
2942763|NCT02953340|Active Comparator|Docetaxel +Cyclophosphamide+ Pegfilgrastim|"Pegfilgrastim (6 mg/0.6 mL) (Neulasta®)~Single-dose subcutaneous injection on Day 2 of each cycle."
2942765|NCT02953327|Placebo Comparator|Placebo arm|The placebo arm will receive BCG solvent.
2942766|NCT02953314|Experimental|Part A: Cohort 1|VX-661 50 mg qd + IVA 75 mg q12h
2942767|NCT02953314|Experimental|Part A: Cohort 2|VX-661 50 mg qd + IVA 150 mg q12h
2942768|NCT02953314|Experimental|Part B: VX-661 + IVA|VX-661 + IVA 75 mg q 12h or IVA 150 mg q 12h
2942769|NCT02953301|Experimental|resminostat|3 x 200 mg tablets p.o., 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
2942770|NCT02953301|Placebo Comparator|Placebo|3 tablets p.o. matching verum, 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
2942771|NCT02953288||Benign thyroid nodules|Benign thyroid nodules
2942772|NCT02953288||Thyroid Carcinoma|Thyroid Carcinoma
2942773|NCT02953275|Experimental|vedolizumab plus pentoxifylline|Patients will receive standard induction and maintenance dosing of vedolizumab 300 mg intravenously as well as pentoxifylline 400 mg orally thrice daily.
2942774|NCT02953275|Placebo Comparator|vedolizumab plus placebo|Patients will receive standard induction and maintenance dosing of vedolizumab 300 mg intravenously as well as placebo orally thrice daily.
2942775|NCT02953262|Experimental|Encouragement Arm|Participants in the encouragement condition will receive a mailing to 1) emphasize the importance of setting health goals, 2) explain how MHV can help, and 3) offer participation in the intervention. The Supported Adoption intervention consists of a one-on one session (to sign up and learn how to use secure messaging), a MyHealtheVet group training session (which will emphasize the features most meaningful for diabetes management), and follow-up support after the training sessions to provide further encouragement and help.
2942776|NCT02953262|No Intervention|Comparison Arm|The Comparison condition will receive a mailing with goal setting content.
2942777|NCT02953249||Study group|The study group will include 30 subjects with type 1 diabetes mellitus who require extraction of 1 or more erupted teeth
2942778|NCT02953249||Control group|The control group will include 30 healthy subjects, without diabetes mellitus, in need of tooth extraction
2942779|NCT02953236|Experimental|Instrumented massage|
2942780|NCT02953236|Active Comparator|Manual massage|
2942781|NCT02953210|Experimental|GF general free|pre induction midazolam 50ug.kg-1, clonidine 1ug.kg induction dexter ketamine 0.2mg.kg, lidocaine 1.5mg.kg, propofol 2mg.kg,rocuronium 0.6mg.kg maintenance isoflurane 1 CAM, lidocaine 2mg.kg.h
2942782|NCT02953210|Active Comparator|GBal general balanced|pre induction with midazolam 50 ug.kg induction fentanyl 3ug.kg, propofol 2mg.kg, rocuronium 0.6mg.k maintenance isoflurane 1 CAM and fentanyl as needed
2942783|NCT02953197|Experimental|Single arm radiotherapy dose escalation|FDG-PET guided radiation dose escalation Selective dose escalation
2942784|NCT02953184|Active Comparator|conventional Doxorubicin plus C-T|AC-T regimen 8 cycles ,60mg/M2 conventional Doxorubicin will be used as active comparator. four cycles of Doxorubicin plus 600mg/m2 Cyclophosphamide every three weeks followed 4 cycles of 100mg/m2 Taxotere, every three weeks for one cycle.Dexrazoxane (DZR)will be used for protecting cardiac toxicity.Patients will undergo Modified Radical Mastectomy or Breast Conserved Surgery or Axillary Lymph Node Dissection(ALND) or Sentinel Lymph Node Biopsy（SLNB） after 8 cycles of chemotherapy
2942785|NCT02953184|Experimental|PLD plus C -T|Pegylated Liposomal Doxorubicin(PLD) plus Cyclophosphamide followed Taxotere 8 cycles.35mg/M2 PLD will be used as experimental medicine. four cycles of PLD plus 600mg/m2 Cyclophosphamide every three weeks followed 4 cycles of 100mg/m2 Taxotere , every three weeks for one cycle.Vitamin B will be used for protecting hand-foot syndrome(HFS).Patients will undergo Modified Radical Mastectomy or Breast Conserved Surgery or Axillary Lymph Node Dissection(ALND) or Sentinel Lymph Node Biopsy（SLNB） after 8 cycles of chemotherapy
2942786|NCT02953171|Experimental|Raw sauerkraut+Probiotic capsule|75 grams of raw, lacto-fermented sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.
2942787|NCT02953171|Experimental|Raw sauerkraut+placebo capsule|75 grams of raw, lacto-fermented sauerkraut + 1 placebo capsule, each day for 6 weeks.
2942788|NCT02953171|Experimental|Pasteurized sauerkraut+Probiotic capsule|75 grams of pasteurized sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.
2942789|NCT02953171|Placebo Comparator|Pasteurized sauerkraut+Placebo capsule|75 grams of pasteurized sauerkraut + 1 placebo capsule, each day for 6 weeks.
2942790|NCT02953158|Experimental|Haas Avocado|Haas Avocado commercially available Behavioral: Dietary recommendations Recommendation: a hypocaloric weight loss diet
2942791|NCT02953158|Active Comparator|Dietary Counseling|Behavioral: Dietary Counseling Recommendation: equally hypocaloric usual American diet.
2942792|NCT02953145|Experimental|Tisseel applied|In this group, the fibrin sealant Tisseel will be applied as a hemostasis agent in patients undergoing primary palatoplasty
2942793|NCT02953145|No Intervention|No fibrin sealant|In this group, no fibrin sealant will be applied intra-operatively. Standard measures, such as electrocautery, will be used for hemostasis.
2942794|NCT02953132|Experimental|Single ascending dose, MT-4129 or Placebo|
2942795|NCT02953132|Experimental|Multiple ascending dose, MT-4129 or Placebo|
2942796|NCT02953119|Experimental|Prehabilitation|"The patients will undergo an exercise test on a cycle ergometer (VO2 max), a grip strength test (Jamar dynamometer), a Time Up and Go (TUG) test and a 6 Minutes Walking Test (6-MWT), before and after prehabilitation, in the sports medicine department. The prehabilitation (intervention) involves 3 training sessions per week during 3 weeks preoperatively, according to the High Intensity Interval Training (HIIT) model, wich consists of:~5 minute warm-up (50% of Cardiopulmonary exercise testing, CPET)~Two 10 minute series of 15 sec sprint intervals (100%) interspersed by 15 sec pauses and a 4 min rest between the two series~Cool down with a 5 min active recovery period (30%)~The grip strength test (Jamar dynamometer), TUG-test and 6-MWT will be repeated between 4 and 6 weeks and 8 and 10 week postoperatively."
2942797|NCT02953119|No Intervention|Controls|The patients will also undergo an exercise test on a cycle ergometer, a grip strength test (Jamar dynamometer), a TUG-test and a 6-MWT, but only once preoperatively, and between 4 and 6 weeks and 8 and 10 week postoperatively.
2942798|NCT02953106|Active Comparator|Azelastine-Fluticasone Nasal|137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate per actuation. 1 squirt twice daily
2942799|NCT02953106|Placebo Comparator|Placebos|contains the same components as Dymista nasal spray with the exception of the active ingredients. 1 squirt twice daily.
2942800|NCT02953093|Other|Acarbose first|Participants will take acarbose three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take placebo three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks).
2942801|NCT02953093|Other|Placebo first|Participants will take placebo three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take acarbose three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks).
2942802|NCT02953080|Active Comparator|Call for Life UgandaTM|Call for Life UgandaTM Janssen Global Public Health Research and Development, in close collaboration with the Infectious Disease Institute Kampala (IDI), has developed Call for Life UgandaTM tailored to the needs of PLHIV in Uganda. Call for Life UgandaTM is based on the CONNECT FOR LIFETM technology (CFL2015.01 or higher version) and the MOTECH platform, an open source platform developed by Grameen Foundation and the University of Southern Maine with financial support from the Bill and Melinda Gates Foundation, and was released under the terms of the MOTECH open source license agreement
2942803|NCT02953080|Active Comparator|No call for life UgandaTM|No call for life UgandaTM
2942804|NCT02953067|Active Comparator|Open reduction and internal fixation|After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
2942805|NCT02953067|Active Comparator|Primary Arthrodesis|After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
2942806|NCT02953067|Active Comparator|Conservative treatment|Non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
2942807|NCT02953054|Active Comparator|DMTS|DMTS applied to the upper arm
2942808|NCT02953054|Placebo Comparator|Placebo|Placebo patches to match DMTS applied to the upper arm
2942809|NCT02953041|Experimental|LAMA Treatment|Inhalation of 50mcg glycopyrronium from Breezhaler device 1 hour prior to methacholine challenge
2942810|NCT02953041|Experimental|uLABA Treatment|Inhalation of 75mcg indacaterol from Breezhaler device 1 hour prior to methacholine challenge
2942811|NCT02953041|Experimental|Combo Treatment|Inhalation of 50mcg glycopyrronium from one Breezhaler device, and 75mcg indacaterol from a second Breezhaler device, all one hour prior to methacholine challenge
2942812|NCT02953028|Active Comparator|Continuous Positive Airway Pressure|Patients treated With an auto-CPAP-machine which is a compressor Connected to a nose- or face mask which provides increased air pressure, opening the upper Airways during an apnea or hypopnea event.
2942813|NCT02953028|Active Comparator|Mandibular Advancing Splint|Patients treated With a twin block splint (oral appliance) advancing the mandible and thereby opening the upper Airways for easier passage of air during sleep preventing apnea and hypopnea events.
2942814|NCT02953015|Experimental|Manipulative articulatory and myofascial techniques Group|Manipulative and myofascial techniques
2942815|NCT02953015|Active Comparator|Transcutaneous Electrical Nerve Stimulation Group|Electrical Nerve Stimulation
2942816|NCT02952989|Experimental|SGN-2FF|Dose escalation and dose expansion
2942817|NCT02952989|Experimental|SGN-2FF and Pembrolizumab|Dose escalation and dose expansion
2942818|NCT02952976|Active Comparator|Abthera|Patients with open abdomen submitted to treatment with the Abthera dressing
2942819|NCT02952976|Active Comparator|Barker|Patients with open abdomen submitted to treatment with the Baker dressing
2942820|NCT02952963|Experimental|Chenodeoxycholic Acid|Chenodeoxycholic Acid (1250 mg) dissolved in 200 ml water. Here after 50 ml clean water.
2942821|NCT02952963|Experimental|Chenodeoxycholic Acid and Colesevelam|Chenodeoxycholic Acid (1250 mg) and Colesevelam (3,75 g) dissolved in 200 ml water. Here after 50 ml clean water.
2942822|NCT02952950|Other|Oralstimulation|Infants whose mothers is included in the cohort is randomized to receive oral stimulation when the infant's postnatal age is at least 32 + 0 weeks, as it is the time when the infant is able to coordinate sucking and swallowing reflex
2942823|NCT02952950|No Intervention|Controlgroup|Families in the control group is not seeing the oralstimulation movie, do not receive the script or the supervision of occupational therapists and these infants do not get oral stimulation. Both groups receive instructions after usual practice i.e. guidance and elements that promote breastfeeding example, skin to skin contact and compression.
2942824|NCT02952937|Other|Group 1|"Period 1: GLA5PR GLARS-NF1 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~wash-out period: over 7 days.~Period 2: GLA5PR GLARS-NF3 tablet 300mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
2942825|NCT02952937|Other|Group 2|"Period 1: GLA5PR GLARS-NF3 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~wash-out period: over 7 days.~Period 2: GLA5PR GLARS-NF1 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
2942826|NCT02952924|Placebo Comparator|Part 1c: MAD in Healthy Volunteers (Placebo)|Participants will receive placebo matching to RO7049389 film coated tablet from Days 1 to 13 (either once a day [QD] or twice a day [BID]) and a single dose of placebo matching to RO7049389 film coated tablet in the morning of Day 14. Participants will also receive a single dose of midazolam solution (100 micrograms [mcg]) on Day -1 and Day 14.
2942827|NCT02952924|Experimental|Part 1c: MAD in Healthy Volunteers (RO7049389)|Participants will receive RO7049389 film coated tablet from Days 1 to 13 (either QD or BID; dose and regimen will be decided based on the available PK and safety data) and a single dose of RO7049389 film coated tablet in the morning of Day 14. Participants will also receive a single dose of midazolam solution (100 mcg) on Day -1 and Day 14.
2942828|NCT02952924|Placebo Comparator|Part 2: POM in Chronic HBV Participants (Placebo)|Participants will receive placebo matching to RO7049389 film coated tablet from Days 1 to 27 (either QD or BID) and a single dose of placebo matching to RO7049389 film coated tablet in the morning of Day 28.
2942829|NCT02952924|Experimental|Part 2: POM in Chronic HBV Participants (RO7049389)|Participants will receive RO7049389 film coated tablet from Days 1 to 27 (either QD or BID; dose and regimen will be decided based on the available PK and safety data) and a single dose of RO7049389 film coated tablet in the morning of Day 28.
2942970|NCT02952001||CLS1001-301|Those subjects who completed participation CLS1001-301 who have not received additional therapy
2942830|NCT02952924|Placebo Comparator|Parts 1a and 1b: SAD in Healthy Volunteers (Placebo)|In Part 1a, participants will receive a single oral dose of placebo matching to RO7049389 film coated tablet on Day 1. In Part 1b, minimum 8 participants from Part 1a will be selected and 2 of whom will receive another single dose of placebo matching to RO7049389 on Day 16 after eating the standard United States - Food and Drug Administration (US FDA)-recommended high-fat and high-calorie breakfast.
2942831|NCT02952924|Experimental|Parts 1a and 1b: SAD in Healthy Volunteers (RO7049389)|In Part 1a, participants will receive a single oral dose of RO7049389 film coated tablet on Day 1 in dose-escalation cohorts with a starting dose of 150 milligrams (mg). The doses for subsequent cohorts will be defined by an adaptive approach based on the safety and PK data in previously-dosed healthy volunteers. In Part 1b, minimum 8 participants from Part 1a will be selected and 6 of whom will receive another single dose of RO7049389 on Day 16 after eating the standard US FDA-recommended high-fat and high-calorie breakfast.
2942832|NCT02952911|Experimental|A: MS Participants|MS participants will perform various active tests (daily, weekly or bi-weekly) and passive monitoring (daily) using smartphone and smartwatch over 24 weeks.
2942833|NCT02952911|Other|B: Healthy Controls|Healthy participants will perform various active tests (daily, weekly or bi-weekly) and passive monitoring (daily) using smartphone and smartwatch over 24 weeks.
2942834|NCT02952898|Experimental|Test Drug|GDC 695 gel applied topically as directed.
2942835|NCT02952898|Active Comparator|Reference Drug|Diclofenac sodium gel, 3% applied topically as directed.
2942836|NCT02952898|Placebo Comparator|Placebo|Vehicle gel applied topically as directed.
2942837|NCT02952885|Experimental|Pegvisomant|Open-label, non-randomized single arm variable dose study of pegvisomant conducted in a real world setting.
2942838|NCT02952872|Experimental|Arm 1|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, no animated narrator, and no motivational content.
2942839|NCT02952872|Experimental|Arm 2|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, no animated narrator, and motivational content.
2942840|NCT02952872|Experimental|Arm 3|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, the presence of an animated narrator, and no motivational content.
2942841|NCT02952872|Experimental|Arm 4|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, the presence of an animated narrator, and motivational content.
2942842|NCT02952872|Experimental|Arm 5|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, no animated narrator, and no motivational content.
2942843|NCT02952872|Experimental|Arm 6|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, no animated narrator, and the presence of motivational content.
2942844|NCT02952872|Experimental|Arm 7|7. Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, an animated narrator guiding the intervention, and no motivational content.
2942845|NCT02952872|Experimental|Arm 8|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and the presence of motivational content.
2942846|NCT02952872|Experimental|Arm 9|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, no animated narrator, and no motivational content.
2942847|NCT02952872|Experimental|Arm 10|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, no animated narrator, and the presence of motivational content.
2942848|NCT02952872|Experimental|Arm 11|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, an animated narrator to guide the intervention, and no motivational content.
2942849|NCT02952872|Experimental|Arm 12|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, an animated narrator to guide the intervention, and the presence of motivational content.
2942850|NCT02952872|Experimental|Arm 13|13. Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, no animated narrator, and no motivational content.
2942851|NCT02952872|Experimental|Arm 14|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, no animated narrator, and the presence of motivational content.
2942852|NCT02952872|Experimental|Arm 15|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and no motivational content.
2942853|NCT02952872|Experimental|Arm 16|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and the presence of motivational content.
2942854|NCT02952859||historic control group|Work-up and follow-up of the historic control will be performed through similar means by contacting primary care physicians and/or medical oncologists, if information cannot be received, the patient will be directly contacted. In case the patient cannot be reached and no other information can be received on patients outcome, the death registry will be contacted.
2942855|NCT02952859||comparator group|All patients with potentially and borderline resectable pancreatic cancer are potentially candidates for IRE and will be considered for this treatment. Patient will be recruited/referred through daily clinical practice from the Inselspital Bern. Final inclusion into the study will be performed by the responsible investigators at the Inselspital Bern. Patients will be included according to the inclusion/exclusion criteria mentioned.
2942856|NCT02952846|No Intervention|Before algorithm|Observational
2942857|NCT02952846|Experimental|After algorithm|Algorithm for tapering of analgosedation
2943185|NCT02951000|Active Comparator|platysma suture|running suture of the platysma with 3/0 polyglactin
2942858|NCT02952833|Experimental|Group 1|5.0 mcg ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25 (2 Sentinel subjects will receive intervention prior to remaining 23 subjects), Placebo for 5 subjects
2942859|NCT02952833|Experimental|Group 2|2.5 mcg ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25, Placebo for 5 subjects
2942860|NCT02952833|Experimental|Group 3|10 mcg of ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25, (2 Sentinel subjects will receive intervention prior to remaining 23 subjects) Placebo for 5 subjects
2942861|NCT02952820|Experimental|lemborexant 5 milligrams (mg)|Lemborexant 5 mg will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
2942862|NCT02952820|Experimental|lemborexant 10 mg|Lemborexant 10 mg will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
2942863|NCT02952820|Placebo Comparator|Placebo matched to lemborexant|Lemborexant-matched placebo will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
2942864|NCT02952807|Active Comparator|sequential|sequential use of vaginal misoprotol Plus Foley Catheter for Induction of Labor.
2942865|NCT02952807|Active Comparator|Concurrent|Concurrent Use of Vaginal misoprostol Plus Foley Catheter for Induction of Labor.
2942866|NCT02952794||ESD|endoscopic submucosal dissection (ESD)for early cancer
2942867|NCT02952794||EMBL|endoscopic mucosal band ligation (EMBL) for early cancer
2942868|NCT02952768|Other|ultrasound training|The aims were to develop a novel, resuscitative ultrasound-circulation-airway-breathing (US-C-A-B) protocol, to implement a short curriculum for ultrasound training and to assess the feasibility.
2942869|NCT02952755|Experimental|Study effect of DWC20162 on DWC20155/DWC20156 PK|To study effect of DWC20162 on DWC20155/DWC20156 PK
2942870|NCT02952755|Experimental|Study effect of DWC20155/DWC20156 on DWC20162 PK|To study effect of DWC20155/DWC20156 on DWC20162 PK
2942871|NCT02952742|Experimental|Black Cohosh Therapy|Black Cohosh will be provided in 250mg capsules. Subjects will take 2 capsules by mouth daily for a total daily dose of 500 mg. Subject's will remain on this study arm for 8 weeks.
2942872|NCT02952742|Placebo Comparator|Placebo|Subjects will take 2 capsules, identical to the Black Cohosh capsules, by mouth each. Subject's will remain on this study arm for 8 weeks.
2942873|NCT02952729|Experimental|Dose Escalation and Confirmation|XMT-1522 treatment will administered in groups of patients who will receive doses that increase over time. Once the maximum tolerated dose or recommended Phase 2 dose is achieved, new groups of patients will receive XMT-1522 at this fixed dose.
2942874|NCT02952716|Experimental|intervention group|Human Cord Blood Mononuclear Cell will be slowly infusion three times,at one days, 30 days,at 60days.
2942875|NCT02952716|Placebo Comparator|control group|hyperbaric oxygen
2942876|NCT02952703|Active Comparator|First Breath|brief pre-natal smoking cessation counseling
2942877|NCT02952703|Experimental|Striving to Quit|Additional pre-natal counseling (in-person and telephonic); post delivery counseling (in-person and telephonic) and incentives
2942878|NCT02952690|Active Comparator|standard curve group|The style is curved in accordance with the curve of GVL blade in this group.
2942879|NCT02952690|Experimental|tip-manipulated curve group|The style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree) in this group.
2942880|NCT02952677|Experimental|Experimental|"Participants receive Remind-to-move by means of vibration emitted through sensory cueing wristwatch devices, 3 consecutive hours daily, for 4 weeks, as well as usual care during the intervention period.They are also encouraged to use their arms as much as possible and the accelerometer built-in the device record the arm movement during daily activities."
2942881|NCT02952677|Sham Comparator|Sham treatment|Participants wear sham wristwatch devices but without vibration cueing, 3 consecutive hours daily, for 4 weeks, as well as usual care during the intervention period. They are also encouraged to use their arms as much as possible and the accelerometer built-in the device record the arm movement during daily activities.
2942882|NCT02952677|Other|Control|Participants receive usual care only during the intervention period.
2942883|NCT02952664|Experimental|PUMP Monitoring|A video camera will be placed in each subject room for recording the repositioning events to correlate the monitor signals with the actual subject repositioning captured by the video.
2942884|NCT02952651|Experimental|Children with hypovolemic state|Pulse oximeter plethysmography (POP) waveforms are obtained for 90 seconds in children with hypovolemic signs including hypotension, decreased urine output and central venous pressure less than 5 mmHg. Then, intravenous crystalloid fluid 10 mL/kg is infused for 15 min. Delta POP is calculated, and diagnostic power of delta POP for fluid responsiveness will be evaluated.
2942885|NCT02952638||Healthy|BMI is between 20 and 25
2942886|NCT02952638||Overweight|BMI is between 25 and 30
2942887|NCT02952638||Obese|BMI is between 30 and 40
2942888|NCT02952625|Other|Single arm imaging study|Single arm study: all patients have 2 PET/MR scans in the radiotherapy treatment position
2942889|NCT02952599||Patients treated with Edoxaban|Patients with established acute initial or recurrent VTE treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
2942890|NCT02952586|Experimental|Avelumab + SOC Chemoradiation Therapy|"Avelumab 10 mg/kg IV: Day 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; and Q2W for 12 months during the Maintenance Phase~Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase~Intensity Modulated Radiation Therapy (IMRT) 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase"
2942891|NCT02952586|Placebo Comparator|Placebo + SOC CRT|"Placebo IV matching avelumab: Days 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; Q2W for 12 months during the Maintenance Phase~Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase~IMRT 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase"
2943040|NCT02951624|Experimental|Breaker|Participants will spend a total of 7 hours and 12 min sedentary and a total of 48 min breaking sitting time with LPA. Sedentary time will be done in bouts of 18 min with 2 min of light walking.
2943186|NCT02951000|Active Comparator|no platysma suture|no platysma suture
2942892|NCT02952573|Experimental|FGFR3 wild-type|"JNJ-42756493: For the first cycle, 8 mg orally (by mouth), once each day for 14 days of each 28-day periods called cycles. Then dose of JNJ-42756493 may then be increased to 9 mg taken orally if no significant side effects related to JNJ-42756493 are seen during the first 14 days.~Dexamethasone: 40 mg, orally, on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly).~Patients over the age of 75 will take a reduced dose of dexamethasone of 20 mg on starting cycle 1 on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly)."
2942893|NCT02952573|Experimental|FGFR3 mutated|"JNJ-42756493: For the first cycle, 8 mg orally (by mouth), once each day for 14 days of each 28-day periods called cycles. Then dose of JNJ-42756493 may then be increased to 9 mg taken orally if no significant side effects related to JNJ-42756493 are seen during the first 14 days.~Dexamethasone: 40 mg, orally, on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly).~Patients over the age of 75 will take a reduced dose of dexamethasone of 20 mg on starting cycle 1 on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly)."
2942894|NCT02952560||High resolution CT Scan of the head and neck|Patients scheduled for high resolution computerized tomography (CT scan) of the head and neck as part of their medical investigation of thyroid or laryngeal disorders will be recruited for this study.
2942895|NCT02952547|Experimental|Test / Reference Drug|DWJ1366 Tab. followed by co-administration of DWC20155 and DWC20156 Tab.
2942896|NCT02952547|Experimental|Reference / Test Drug|Co-administration of DWC20155 and DWC20156 Tab. followed by DWJ1366 Tab.
2942897|NCT02952534|Experimental|Rucaparib|Oral rucaparib (monotherapy)
2942898|NCT02952521||Epithelial ovarian cancer|"Whole blood sample collection~Up to 3 fresh tumor tissue core biopsies~Tumor tissue sample taken from tumor tissue already removed from surgery (if surgery is planned)"
2942899|NCT02952508|Experimental|CLR 131, intravenous administration|CLR 131
2942900|NCT02952495|Experimental|Online alcohol educational class|Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults.
2942901|NCT02952495|No Intervention|No intervention|Participants will NOT Participate in the online alcohol education class.
2942902|NCT02952482||newborns testing for ALD|newborns testing for ALD
2942903|NCT02952469|Experimental|(68Ga)PSMA-HBED-CC|Intervention: positron emission tomography / computed tomography (PET/CT) scan using a experimental radiotracer for imaging prostate-specific membrane antigen
2942904|NCT02952456||Bereaved families|Person who have lost a loved one from an epilepsy-related death with interview with a psychologist
2942905|NCT02952456||Patients with épilepsy|Patients with épilepsy with interview with a psychologist
2942906|NCT02952456||Relatives of patients with epilepsy|Relatives (Parents / spouse/ Husband) of patients with epilepsy with interview with a psychologist
2942907|NCT02952443||Exercise|EX group will attend multi-component exercise sessions 3 times a week at 45-60 minutes a session for 16 weeks. Each session will include aerobic, flexibility, resistance and balance training but a strong emphasis will be placed on the latter two components.
2942908|NCT02952443||Control|CON group will be asked to just maintain their normal daily living habits for the duration of the study. The same exercise program will be made available to the CON group upon completion of the study.
2942909|NCT02952430||Frail|"Patients over 65 year old having emergency laparotomy with a Frailty score (Modified Rockwood score) of greater than or equal to five.~This group will then be observed after intervention to review outcomes."
2942910|NCT02952430||Not frail|"Patients over 65 year old having emergency laparotomy with a Frailty score (Modified Rockwood score) of less than five.~This group will then be observed after intervention to review outcomes."
2942911|NCT02952417||STEMI and NSTEMI Women|Women with ST-segment elevation myocardial infarction (STEMI) and women non-STEMI (NSTEMI) who survived following acute myocardial infarction and at risk of excess mortality.
2942912|NCT02952417||STEMI and NSTEMI Men|Men with ST-segment elevation myocardial infarction (STEMI) and women non-STEMI (NSTEMI) who survived following acute myocardial infarction and at risk of excess mortality.
2942913|NCT02952404||Before workshop|October 2014 to October 2015 Cohort which is the time frame before the educational workshop
2942914|NCT02952404||After workshop|December 2015 to December 2016 Cohort which is the time after the educational workshop
2942915|NCT02952391||Parkinson's disease patients|patients with Parkinson's disease, between the ages of 45 and 65, with a disease duration of 3 - 10 years
2942916|NCT02952391||healthy control subjects|Healthy control subjects, between the ages of 45 and 65
2942917|NCT02952378|Experimental|Burn patients|Patients with burns exceeding 6-8 Total Burned Surface Area %
2942918|NCT02952378|Experimental|Healthy individuals|Healthy individuals without allergies.
2942919|NCT02952365|Other|Eyes undergoing LASIK enhancement|Eyes undergoing LASIK enhancement will have tissue sealant applied to the eye to prevent epithelial ingrowth
2942920|NCT02952352|Experimental|Diabetes Intervention|Diabetes Prevention Program
2942921|NCT02952352|Other|Delayed Intervention|Diabetes Prevention Program
2942922|NCT02952339|Experimental|RSV LID ΔM2-2 1030s vaccine|Participants will receive a single dose of the RSV LID ΔM2-2 1030s vaccine at Day 0.
2942923|NCT02952339|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine at Day 0.
2942924|NCT02952326|Experimental|XP Endo Finisher|
2942925|NCT02952326|Active Comparator|Conventional needle irrigation|
2942926|NCT02952313|Other|Latera Implant|
2942927|NCT02952300|Experimental|neolix|single full rotation file (Neolix ® Neolix ,France) the first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani Inc., Japan). is passively fit in the canal (most of the canals) , but in case of K-file (Mani Inc., Japan) size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length of the canal
2943041|NCT02951624|Experimental|Intermediate|Total duration of sedentary time and LPA time will be the same as in Breaker. Sedentary time will be done in bouts of 54 min with 6 min of LPA between each bout.
2942928|NCT02952300|Active Comparator|wave one|single reciprocating file (Wave One ® Dentsply , Switzerland) the canal preparation is done by primary file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani Inc., Japan) is passively fit in the canal ( most of canals ) , but in case of K-file (Mani Inc., Japan) size 20 loose in the canal so we choose large large file size 40 taper 8% either of them to the full working length of the canal
2942929|NCT02952287|Experimental|Study Participants|4D PC MRI acquisition
2942930|NCT02952274|Active Comparator|locater attachment|mandibular overdenture retained with single midline implant using locator attachment
2942931|NCT02952274|Active Comparator|ball attachment|mandibular overdenture retained with single midline implant using ball attachment
2942932|NCT02952261|Other|conventional localization|This group of patients received conventional localization for small pulmonary nodules.
2942933|NCT02952261|Experimental|3D printing device assisted localization|This group of patients received 3D printing device assisted localization for small pulmonary nodules.
2942934|NCT02952248|Experimental|BI 754091|
2942935|NCT02952235|Other|SPF50+|SPF 50+ assigned to Left side of face SPF 100+ assigned to Right side of face
2942936|NCT02952235|Other|SPF100+|SPF 100+ assigned to Left side of face SPF 50+ assigned to Right side of face
2942937|NCT02952222|Active Comparator|Propofol (Group P)|Propofol only
2942938|NCT02952222|Active Comparator|Propofol with Dexmedetomidine (Group DP)|Propofol with Dexmedetomidine
2942939|NCT02952209|No Intervention|No Treatment|Tooth extraction with no bone graft.
2942940|NCT02952209|Active Comparator|Alveolar Ridge Preservation Treatment|Tooth extraction followed by alveolar ridge preservation using xenograft bone graft and covered by a resorbable collagen membrane.
2942941|NCT02952196|Placebo Comparator|placebo|
2942942|NCT02952196|Experimental|cannabinoid dose 1|
2942943|NCT02952196|Experimental|cannabinoid dose 2|
2942944|NCT02952183|Experimental|PAMS I|During operation, autonomic nerve monitoring will be performed by PAMS I which is composed of two urodynamic systems.
2942945|NCT02952170|Experimental|MRI for steatosis assessment|Abdominal MRI for assessment of hepatic steatosis
2942946|NCT02952157|Sham Comparator|Control|Normal saline will be applied to the endotracheal tube.
2942947|NCT02952157|Active Comparator|Lidocaine|Lidocaine jelly will be applied to the endotracheal tube.
2942948|NCT02952144|Experimental|Lixelle® treatment|2 years of Lixelle® treatment in the patients with dialysis related amyloidosis (DRA)
2942949|NCT02952144|No Intervention|natural history|2 years of natural history in the patients with dialysis related amyloidosis (DRA)
2942950|NCT02952131|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
2942951|NCT02952131|Experimental|AD-cSVF Arm 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
2942952|NCT02952131|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
2942953|NCT02952118|Experimental|one night with the device and one night without the device.|"The study duration with each patient will be 48 hours (two nights); at the first night the sleep study will be with PAT device, with snoring recording and without the Forrest epic device. In the second night the sleep study will be with PAT device, with snoring recording and with the Forrest epic device. The order of the sleep studies (with and without the epic device) will be randomly determined by computerized ahead prepared list. The research duration for patients that did not have a sleep study over the last year, will take place for 3 nights; the sleep study will be performed in order to make sure the patient does not suffer from obstructive respiratory disorder during sleep. The sleep studies will take place in a sleep laboratory (Millennium Sleep Labs LTD, Beer Sheva) or as an ambulatory study, at home."
2942954|NCT02952105||defibrillation patients|shockable rhythm, defibrillated
2942955|NCT02952105||non defibrillation patients|non-shockable rhythm, non defibrillated
2942956|NCT02952092|Experimental|ASP1517 Group|Subjects will take the study drug at two- or three-day intervals.
2942957|NCT02952092|Experimental|Darbepoetin alfa Group|Subjects will take the study drug once a week.
2942958|NCT02952079|Active Comparator|BlephEx treatment|Treatment with the BlephEx instrument (lid margin exfoliation)
2942959|NCT02952079|Active Comparator|MiBoFlo treatment|Treatment with the MiboFlo equipment (heat therapy to eyelids)
2942960|NCT02952066|Experimental|TRP1 Density|Bronchial Biopsy: During the biopsy procedure the investigator will collect five bronchial specimens (1-2 cubic millimeters) each the major, lobar and segmental bronchi.
2942961|NCT02952053|Experimental|Dry Needling into MTrPs.|MTrP Group: Deep Dry Needing into the medial Myofascial Trigger Point of the soleus muscle.
2942962|NCT02952053|Active Comparator|Dry Needling within Taut Band|TB Group: Deep Dry Needling distal to Myofascial Trigger Point of the soleus muscle (in the same taut band; out of MTrPs).
2942963|NCT02952040|Experimental|ASP1517 alone period preceding group|Subjects will receive a single oral dose of ASP1517 alone in period 1, then subjects will receive a single oral dose of ASP1517 with lanthanum carbonate hydrate in period 2.
2942964|NCT02952040|Experimental|ASP1517+lanthanum period preceding group|Subjects will receive a single oral dose of ASP1517 with lanthanum carbonate hydrate in period 1, then subjects will receive a single oral dose of ASP1517 alone in period 2.
2942965|NCT02952027|Experimental|Bell On|Subjects in the Bell On arm will receive a timer where the alarm will sound every hour.
2942966|NCT02952027|Placebo Comparator|Bell Off|Subjects in the Bell Off arm will receive a timer where the alarm will not sound, but still record incentive spirometer usage
2942967|NCT02952014|Experimental|C4 Extreme|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 10 mg synephrine, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
2942968|NCT02952014|Active Comparator|C4 Extreme (without Advantra Z)|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
2942969|NCT02952014|Placebo Comparator|Placebo|One dose of flavored placebo (powder mixed with water)
2943125|NCT02951260|Placebo Comparator|Placebo|17 days placebo treatment
2942971|NCT02951988|Experimental|Rapastinel 450 mg Weekly|Rapastinel 450 milligrams (mg) intravenous (IV) open label once a week followed by rapastinel 450 mg IV once a week. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
2942972|NCT02951988|Experimental|Rapastinel 450 mg Every 2 Weeks|Rapastinel 450 mg IV open label once a week followed by rapastinel 450 mg IV once every 2 weeks. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
2942973|NCT02951988|Placebo Comparator|Placebo|Rapastinel 450 mg IV open label once a week followed by placebo-matching rapastinel 450 mg IV once a week. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
2942974|NCT02951975||OZURDEX®|Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of non-infectious uveitis affecting the posterior segment of the eye.
2942975|NCT02951962|Experimental|Twynsta 80/5mg|Day 1 ~ Day 9 : Twynsta 80/5mg / Day 10 ~ Day 14 : Twynsta 80/5mg + Crestor 20mg
2942976|NCT02951962|Experimental|Crestor 20mg|Day 1 ~ Day 5 : Crestor 20mg / Day 6 ~ Day 14 : Twynsta 80/5mg + Crestor 20mg
2942977|NCT02951949||Postmenopausal women|Postmenopausal women attending the outpatient service of a third level hospital for health control.
2942978|NCT02951936|Experimental|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index < 2.9 +Total Peripheral resistance Index >3000+Mean arterial pressure >70mmHG then add vasodilators.~If Heart Rate<60 consider to reduce beta blockers dose If Cardiac Index>4.2 and Mean arterial pressure 70-100mmHG and HR >100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
2942979|NCT02951936|Sham Comparator|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment
2942980|NCT02951923|Experimental|Bovine colostrum|8 weeks of Bovine colostrum power, 60g per day
2942981|NCT02951923|Active Comparator|Soy powder|8 weeks of Soy powder, 60g per day
2942982|NCT02951910|Experimental|Intervention|Patients receiving zinc-hyaluronate eye drop
2942983|NCT02951897|Active Comparator|IA-CTC-High-enhance|IA lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy plus adjuvant chemotherapy. Postoperative CTC monitoring will be conducted.
2942984|NCT02951897|Placebo Comparator|IA-CTC-High-controls|IA lung adenocarcinoma cases with high abundant CTCs prior to operation will only undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
2942985|NCT02951897|Placebo Comparator|IA-CTC-low-controls|IA lung adenocarcinoma cases with low abundant CTCs prior to operation will only undergo segmentectomy. Postoperative CTC monitoring will be conducted.
2942986|NCT02951897|Active Comparator|IB-CTC-High-enhance|IB lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy plus adjuvant chemotherapy. Postoperative CTC monitoring will be conducted.
2942987|NCT02951897|Placebo Comparator|IB-CTC-High-controls|IB lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
2942988|NCT02951897|Placebo Comparator|IB-CTC-low-controls|IB lung adenocarcinoma cases with low abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
2942989|NCT02951884|Experimental|Aspiration|Participants assigned to this arm receive aspiration of the joint alone in which a needle will be introduced into the knee joint to withdraw the blood that collects within the knee.
2942990|NCT02951884|Experimental|Aspiration with injection|Participants assigned to this arm receive aspiration of the knee joint and an injection of 20cc bupivacaine 0.5% with 1:200,000 epinephrine
2942991|NCT02951884|No Intervention|Control|Participants assigned to this arm receive no injection or aspiration therapy.
2942992|NCT02951871||LP: Lymphoma Progression|
2942993|NCT02951871||TRM: Treatment Related Mortality|
2942994|NCT02951871||NHM: Non hematologic malignancy|
2942995|NCT02951871||OC: Other Cause|
2942996|NCT02951858|Experimental|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver it and other materials about the harm of substance use.
2942997|NCT02951858|Active Comparator|Control Group|The participants only receive the materials about the harm of substance use.
2942998|NCT02951845|Experimental|Part 1: Treatment Sequence A1B1C1|Participants in Part 1 will only receive single dose of Treatment A1 oral Suspension (25 milligram [mg], Fasted) then Treatment B1 (Direct Compression Tablets, 5*5 mg Tablets, Fasted) followed by Treatment C1 (Direct Compression Tablets (5*5 mg Tablets, Fed) on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2942999|NCT02951845|Experimental|Part 1: Treatment Sequence B1C1A1|Participants in Part 1 will only receive single dose of Treatment B1 then Treatment C1 followed by Treatment A1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2943000|NCT02951845|Experimental|Part 1: Treatment Sequence C1A1B1|Participants in Part 1 will only receive single dose of Treatment C1 then Treatment A1 followed by Treatment B1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2943001|NCT02951845|Experimental|Part 1: Treatment Sequence A1C1B1|Participants in Part 1 will only receive single dose of Treatment A1 then Treatment C1 followed by Treatment B1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2943002|NCT02951845|Experimental|Part 1: Treatment Sequence B1A1C1|Participants in Part 1 will only receive single dose of Treatment B1 then Treatment A1 followed by Treatment C1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2943003|NCT02951845|Experimental|Part 1: Treatment Sequence C1B1A1|Participants in Part 1 will only receive single dose of Treatment C1 then Treatment B1 followed by Treatment A1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2943187|NCT02950987|Experimental|Whole Body MRI|"Magnetic resonance imaging will be performed on participants~Participants who are two young to tolerate the scans awake, can receive sedation/anesthesia"
2943004|NCT02951845|Experimental|Part 2: Treatment Sequence A2B2C2|Participants in Part 2 will only receive single dose of Treatment A2 oral Suspension (25 mg, Fasted) then Treatment B2 (Fluid Bed Granulation Tablets (5*5 mg Tablets, Fasted) followed by Treatment C2 (Fluid Bed Granulation Tablets, 5*5 mg Tablets, Fed) on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2943005|NCT02951845|Experimental|Part 2: Treatment Sequence B2C2A2|Participants in Part 2 will only receive single dose of Treatment B2 then Treatment C2 followed by Treatment A2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2943006|NCT02951845|Experimental|Part 2: Treatment Sequence C2A2B2|Participants in Part 2 will only receive single dose of Treatment C2 then Treatment A2 followed by Treatment B2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2943007|NCT02951845|Experimental|Part 2: Treatment Sequence A2C2B2|Participants in Part 2 will only receive single dose of Treatment A2 then Treatment C2 followed by Treatment B2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2943008|NCT02951845|Experimental|Part 2: Treatment Sequence B2A2C2|Participants in Part 2 will only receive single dose of Treatment B2 then Treatment A2 followed by Treatment C2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2943009|NCT02951845|Experimental|Part 2: Treatment Sequence C2B2A2|Participants in Part 2 will only receive single dose of Treatment C2 then Treatment B2 followed by Treatment A2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2943010|NCT02951832||observational group|Observational Study about Lymphocytes Change during Menstrual Cycle in Women of Child-bearing Age
2943011|NCT02951819|Experimental|Dara-CyBorD|Subjects will receive Daratumumab along with Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) as induction on a 28-day cycle length and Daratumab and Dexamethasone on Day 1 of each cycle for 12 cycles as maintenance therapy.
2943012|NCT02951806|Active Comparator|(R) Rapid spinal fentanyl injection|Patients will receive 25 mic fentanyl spinal ( after dilution with 2.5 ml CSF) in 15 seconds then 10 mg hyperbaric bupivacaine.
2943013|NCT02951806|Active Comparator|(S) Slow spinal fentanyl injection|Patients will receive 25 mic fentanyl spinal ( after dilution with 2.5 ml CSF) in 90 seconds then 10 mg hyperbaric bupivacaine.
2943014|NCT02951793||AUDIT-C > 4|Significant alcohol use within 1 year prior to ICU admission (AUDIT-C>4)
2943015|NCT02951793||AUDIT-C <=4|No significant alcohol use within 1 year prior to ICU admission (AUDIT-C: equal or less than 4)
2943016|NCT02951793||Smoking history positive last year|Who smoke cigarette within 1-year prior to ICU admission
2943017|NCT02951793||Smoking history negative last year|Who did not smoke cigarette within 1-year prior to ICU admission
2943018|NCT02951793||Prior psychotropic medication use - yes|Who used psychotropic medication within 1-year prior to ICU admission
2943019|NCT02951793||Prior psychotropic medication use - no|Who did not use psychotropic medication within 1-year prior to ICU admission
2943020|NCT02951780|Experimental|LY3185643|LY3185643 administered subcutaneous (SC)
2943021|NCT02951780|Experimental|rGlucagon|rGlucagon administered subcutaneous (SC)
2943022|NCT02951767|Experimental|Cohort 1: Treatment-naive Cisplatin Ineligible Participants|Participants with advanced disease who are treatment-naive for advanced urothelial carcinoma and cisplatin ineligible will receive atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
2943023|NCT02951754|Experimental|IR-MPH|Immediate-release methylphenidate (IR-MPH) 10 mg two or three times daily with doses increasing weekly until symptom control
2943024|NCT02951741||RTHRA group|patients undergoing revision total hip replacement
2943025|NCT02951728|Experimental|Decitabine plus R-CHOP|"Rituximab 375 mg/m2 IV d6; Cyclophosphamide 750mg/m2 IV d7; Doxorubicin 50mg/m2 IV d7; Vincristine 1.4 mg/m2 IV d7; Prednisone 60 mg/m2 PO d7－11;~Decitabine will be administered intravenously at dose levels as follow in Phase 1:~Dose level 1: Decitabine 10 mg/m2 days 1-5; Dose level 2: Decitabine 15 mg/m2 days 1-5; Dose level 3: Decitabine 20 mg/m2 days 1-5 and determine the maximum tolerated dose.~In phase 2, Decitabine will be administered intravenously at MTD."
2943026|NCT02951715|Experimental|Zinc|A full medical history assessment was performed, and each patient completed the NIHL questionnaire (Supplementary S1), audiogram, tympanogram, speech discrimination test, distortion product otoacoustic emissions (DPOAE) testing, pitch and loudness match of the tinnitus, Tinnitus Handicap Inventory (THI) and serum zinc level analyses. All tests were repeated after 2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day).
2943027|NCT02951702|No Intervention|Control|"This will be the historical arm that has not received oral vancomycin but match criteria for high risk"
2943028|NCT02951702|Experimental|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician Intervention type: drug, vancomycin 125 mg daily"
2943029|NCT02951689|Experimental|Probiotic|Multi-strain probiotic
2943030|NCT02951689|Placebo Comparator|Placebo|Maltodextrin placebo
2943031|NCT02951676||EA - Extraction with antibiotics|"Patients undergoing third molar extraction with antibiotic treatment.~Amoxicillin 250 mg , three times daily for five days."
2943032|NCT02951676||E - Extraction without antibiotics|Patients undergoing third molar extraction with antibiotic treatment.
2943033|NCT02951676||Control|Age and sex matched controls who are not undergoing extractions or antibiotic treatment
2943034|NCT02951663|Experimental|Protein Supplement|Ready to drink blinded protein supplement
2943035|NCT02951663|No Intervention|Control|Control group
2943036|NCT02951650|Experimental|Cyberonics VNS|Cyberonics VNS
2943037|NCT02951637|Experimental|Group A|Patient will be administrated with Pemetrexed plus carboplatin combined with gefitinib
2943038|NCT02951637|Experimental|Group B|Patient will be administrated with gefitinib
2943039|NCT02951624|Experimental|Control|Participants will spend 8 hours sedentary. Sedentary time will be spent sitting in a chair, restricted to sedentary behaviors (working on a computer, reading, watching TV, etc.) Participants will only be allowed to stand or walk to go to the toilet.
2943042|NCT02951624|Experimental|Prolonger|Total duration of sedentary time and LPA time will be the same as in Breaker. Sedentary time will be done in bouts of 108 min with 12 min of LPA between each bout.
2943043|NCT02951611|Sham Comparator|Sham stimulation|Put the electrodes on SI3, SJ6, PC6 and LI4 without stimulation.
2943044|NCT02951611|Experimental|Treatment: Acupuncture stimulation|Stimulate the SI3, SJ6, PC6 and LI4 since 30 minutes before anesthesia induction until the end of operation. Stimulate again at above acupoints at 6 and 24h after operation, for 30 minutes each time. The stimulation frequency is 2/100Hz. The stimulation current is two to three times of the lowest current that the patient can feel.
2943045|NCT02951598|Other|MCI (Amyloid Positive)|Participants with mild cognitive impairment (MCI) due to AD who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
2943046|NCT02951598|Other|Mild AD Dementia (Amyloid Positive)|Participants with mild AD dementia who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
2943047|NCT02951598|Other|MCI (Amyloid Negative)|Participants with MCI who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
2943048|NCT02951598|Other|Mild Dementia (Amyloid Negative)|Participants with mild dementia who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
2943049|NCT02951585|Experimental|KARTILAGE CROSS|Kartilage® Cross (2.2 mL, 16 mg/g of hyaluronic acid)
2943050|NCT02951585|Placebo Comparator|Placebo|Saline solution (2.2-2.5 mL, NaCl 9 mg/g)
2943051|NCT02951572|Other|Patients with RLD initiating NIV|Patients with RLD initiating NIV according to Belgian Health guidelines are followed-up before and after NIV initiation
2943052|NCT02951559|Experimental|Brushing|Patients will undergo nasal brushing as further described additionally to other gold standard practices according to the suspected aetiology (brain MRI, lumbar puncture, plasma tests, etc.)
2943053|NCT02951546|Experimental|Mediterranean diet|"Hypocaloric Mediterranean diet for a 4-month period;~Aerobic exercise training for a 4-month period;"
2943054|NCT02951546|Experimental|Low fat diet|"Hypocaloric low fat diet supplemented by branched and essential amino acids considering the total protein intake for a 4- month period;~Aerobic exercise training for a 4- month period;"
2943055|NCT02951533|Experimental|Group I: Guselkumab|Participants will receive Guselkumab 100 milligram (mg) administered as 100 milligram per milliliter (mg/mL) solution subcutaneously (SC) by single-use prefilled syringe (PFS) at weeks 0, 4, 12 and 20.
2943056|NCT02951533|Active Comparator|Group II: Fumaric Acid Esters (FAE)|Participants will receive Fumaderm initial/Fumaderm tablets by self administration at week 0. The individual FAE dose representing the optimal efficacy/tolerability ratio needs to be determined for each participant according to local prescription information. To this aim, FAE doses will be slowly increased beginning with increasing doses of Fumderm initial (containing 30 mg dimethylfumarate) over the first 3 weeks. Thereafter, participants will be switched to Fumaderm tablets (containing 120 mg dimethylfumarate) starting with 1 tablet per day. Fumaderm dose may be increased to a maximum of 3*2 tablets per day. The decision to maintain, increase or decrease the FAE dose depends on efficacy, safety and tolerability.
2943057|NCT02951520|Experimental|SOFT block|Fifty patients will form the study group (one group). All the patients will receive supine ultrasound guided (US) sciatic, obturator, femoral nerve block technique using a single skin puncture (SOFT block).
2943058|NCT02951507|Active Comparator|Conventional partial denture|Intervention will be O T unilateral attachment
2943059|NCT02951507|Active Comparator|Conventional removal partial denture|Intervention will be new design of extra coronal attachment( O T unilateral attachment)
2943060|NCT02951494|Active Comparator|AlterG Anti-gravity treadmill|cont. aerobic exercise training with lower body weight support
2943061|NCT02951494|No Intervention|Exercise without body weight support|cont. aerobic exercise training without lower body weight support
2943062|NCT02951481||Systematic evaluation by an ID expert.|Patients diagnosed with CDI during 2017 in the University Hospital 12 de Octubre will be systematically evaluated by an Infectious Disease expert to ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes. This group of patients will also receive a close follow up during the period of greatest risk of relapse (8 weeks after completion of antibiotic treatment for CDI) in order to reduce as far as possible, the number of relapses.
2943063|NCT02951481||Retrospective historic cohort.|Patients diagnosed with CDI during 2015 in the University Hospital 12 de Octubre in which a systematic intervention was not done.
2943064|NCT02951468||Nonunion group|All patients who were treated for clavicular non- or malunion with a locking compression plate and an iliac crest bone graft between January 2010 and December 2014 were included in this retrospective study.
2943065|NCT02951455|Experimental|CD-LC|Group behavioral intervention with 9 weekly sessions lasting 2 hours. Critical Dialogue (CD), Licensed Clinician (LC).
2943066|NCT02951455|Experimental|CBP- LC|Group community mobilizing intervention with 9 weekly sessions spread in 15 weeks. Capacity Building Project (CBP), Licensed Clinician (LC)
2943067|NCT02951455|Experimental|QLW- LC|Group intervention where participants learn to develop and implement personal goals that are measurable, attainable, realistic, and time bound. Intervention includes 9 sessions. Quality of Life Wheel, Licensed Clinician (LC)
2943068|NCT02951455|Experimental|CD & CBP- LC|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
2943069|NCT02951455|Experimental|CD & QLW- LC|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
2943070|NCT02951455|Experimental|QLW & Capacity Building ProjectCBP- LC|Combination of goal development and implementation with community mobilization intervention including 9 weekly sessions spread across 15 weeks. Licensed Clinician (LC)
2943071|NCT02951455|Experimental|QLW & CD & CBP-LC|Combination of group behavioral intervention, goal development and implementation, and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
2943126|NCT02951234|Experimental|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin. After fever subsides, low-dose aspirin (3-5mg/kg/day) will be prescribed until 6-8 weeks.
2943072|NCT02951455|Experimental|LC|This condition will include 3 core sessions that are not a part of the components being tested. These are support sessions to the components being tested and is hypothesized to have the smallest impact on substance use outcomes.Licensed Clinician (LC)
2943073|NCT02951455|Experimental|CD- PF|Group behavioral intervention with 9 weekly sessions lasting 2 hours. Critical Dialogue (CD), Peer Facilitator (PF)
2943074|NCT02951455|Experimental|CBP- PF|Group community mobilizing intervention with 9 weekly sessions spread in 15 weeks. Capacity Building Project (CBP), Peer Facilitator (PF)
2943075|NCT02951455|Experimental|QLW-PF|Group intervention where participants learn to develop and implement personal goals that are measurable, attainable, realistic, and time bound. Intervention includes 9 sessions. Quality of Life wheel, Peer Facilitator (PF)
2943076|NCT02951455|Experimental|CD & CBP- PF|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions. Peer Facilitator (PF)
2943077|NCT02951455|Experimental|CD & QLW- PF|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Peer Facilitator (PF)
2943078|NCT02951455|Experimental|QLW & CBP- PF|Combination of goal development and implementation with community mobilization intervention including 9 weekly sessions spread across 15 weeks.Peer Facilitator (PF)
2943079|NCT02951455|Experimental|CD & QLW & CBP- PF|Combination of group behavioral intervention, goal development and implementation, and community mobilization intervention including 15 weekly sessions.Peer Facilitator (PF)
2943080|NCT02951455|Experimental|PF|This condition will include 3 core sessions that are not a part of the components being tested. These are support sessions to the components being tested and is hypothesized to have the smallest impact on substance use outcomes. Peer Facilitator (PF)
2943081|NCT02951442|Experimental|Renal Transplant|
2943082|NCT02951429|Placebo Comparator|Pirfenidone + Placebo|Participants will receive pirfenidone along with placebo matched to sildenafil, orally, three times a day (TID) for 52 weeks.
2943083|NCT02951429|Experimental|Pirfenidone + Sildenafil|Participants will receive pirfenidone along with sildenafil, orally, TID for 52 weeks.
2943084|NCT02951416||Idiopathic Pulmonary Fibrosis (IPF)|"IPF diagnosis according to the guidelines of 2011 (AJRCCM 2011; 183:788). For patients diagnosed prior to 2011, the criteria of the consensus statement 2000 apply (AJRCCM 2000;161:646).~Patient registry (observation and biomaterial sampling)."
2943085|NCT02951416||Non-specific interstitial pneumonia|"Non-specific interstitial pneumonia (NSIP) based on the histopathological demonstration of an NSIP pattern.~Patient registry (observation and biomaterial sampling)."
2943086|NCT02951416||Cryptogenic organising pneumonia (COP)|"COP characterised histologically by an organising pneumonia with intraluminal organising fibrosis in the alveolar ducts and alveolar spaces.~Patient registry (observation and biomaterial sampling)."
2943087|NCT02951416||Acute interstitial pneumonia (AIP)|"Histological pattern of diffuse alveolar damage (DAD), characterised by hyaline membranes, alveolar oedema and a marked interstitial and alveolar inflammatory reaction.~Patient registry (observation and biomaterial sampling)."
2943088|NCT02951416||Lymphoid interstitial pneumonia (LIP)|"Histological pattern of LIP primary or secondary (e.g. rheumatoid arthritis, Sjögren's syndrome, pernicious anaemia, chronic active hepatitis, systemic lupus erythematosus (SLE), primary biliary cirrhosis, myasthenia gravis, severe immune deficiency syndromes (AIDS)).~Patient registry (observation and biomaterial sampling)."
2943089|NCT02951416||respiratory bronchiolitis-ILD (RB-ILD)|Histological pattern of RB-ILD or typical clinical and radiological findings. Patient registry (observation and biomaterial sampling).
2943090|NCT02951416||Desquamative Interstitial Pneumonia|"Histological pattern of Desquamative Interstitial Pneumonia (DIP). The picture is similar to RB-ILD, but the distribution pattern is much more homogeneous and does not even have the bronchiolocentric distribution.~Patient registry (observation and biomaterial sampling)."
2943091|NCT02951416||Hypersensitivity Pneumonitis|"Hypersensitivity Pneumonitis (HP) characterized by exposure to inhaled organic antigens and development of antibodies. Typical clinical and radiological findings, lymphocytosis in bronchoalveolar lavage (BAL) or histology showing HP granulomas.~Patient registry (observation and biomaterial sampling)."
2943092|NCT02951416||Sarcoidosis|"Histological pattern with sarcoid granulomas or typical clinical and radiological findings with a lymphocytosis in BAL.~Patient registry (observation and biomaterial sampling)."
2943093|NCT02951416||Lung Cancer|"Histological confirmation of Lung Cancer. Patients will be included as control group.~Patient registry (observation and biomaterial sampling)."
2943094|NCT02951416||Chronic Obstructive Pulmonary Disease|"Obstructive spirometry and physical history suggesting Chronic Obstructive Pulmonary Disease (COPD). Patients will be included as control group.~Patient registry (observation and biomaterial sampling)."
2943095|NCT02951416||Pulmonary Hypertension|"Pulmonary Hypertension (PH) diagnosed through right heart catheterisation. Patients will be included as control group.~Patient registry (observation and biomaterial sampling)."
2943096|NCT02951416||Sleep Apnea|"Sleep Apnea diagnosed by polysomnography. Patients will be included as control group.~Patient registry (observation and biomaterial sampling)."
2943097|NCT02951416||Asthma|"Asthma diagnosed by positive bronchoprovocation test and typical history or bronchoreversibility in the lung function measurement or through peak flow measurement. Patients will be included as control group.~Patient registry (observation and biomaterial sampling)."
2943098|NCT02951416||Control/Health Individuals|Healthy volunteers not suffering from any lung disease as control group. Patient registry (observation and biomaterial sampling).
2943099|NCT02951403|Experimental|Operative treatment|Patients to whom the elbow arthroscopy will be performed.
2943100|NCT02951403|Other|Conservative treatment|Patients to whom special physiotherapy will be advised.
2943101|NCT02951390|Active Comparator|High-definition white-light endoscopy|High-definition white-light endoscopy without indigo carmine instilation
2943102|NCT02951390|No Intervention|High-definition chromoendoscopy|High-definition indigo-carmine chromoendoscopy
2943103|NCT02951377|No Intervention|Control|Wait list control - usual care - free to pursue other treatments prescribed by the patients family physician
2943127|NCT02951234|Active Comparator|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside. After fever subsides, low-dose aspirin (3-5mg/kg/day) will be prescribed until 6-8 weeks.
2943104|NCT02951377|Experimental|MDT +/- TESI|Exercise (MDT approach) and/or Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%). Patients will further classified into centraliser (group 2a) and non-centralising pain responses (group 2b). Group 2a: will continue with exercise (MDT approach). Group 2b: Patients with a non-centralising pain response will be offered Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under fluoroscopic guidance with contrast medium (Omni Pac 240). Two weeks after completion of the MDT or TESI intervention, patients will be reassessed and treated consistent with their response: 1) resolved: advice on remaining active; 2) centralising: daily exercises based on MDT principles; 3) non-centralising but significant less pain: advice to remain active, with respect for worsening leg pain; and 4) persisting high levels of pain and/or disability: advise to remain active as tolerated and consult family physician.
2943105|NCT02951364||LDV/SOF|Adult patients with genotypes 1, 4, 5, and 6 chronic HCV infection who take LDV/SOF as part of routine clinical care at a participating clinical site.
2943106|NCT02951351|Active Comparator|Standard procedure + Culture|Patients will undergo the standard injection protocol. A conjunctival culture will then be obtained followed by the application of povidone-iodine to the eyelashes and eyelid margins. Patients will be randomized to receive 5% povidone-iodine drop to the conjunctival surface followed by conjunctival culture then re-application of 5% povidone-iodine drop to the conjunctival surface. Injection with then proceed.
2943107|NCT02951351|Experimental|Proparacaine (Extra topical anesthesia + Culture)|Patients will undergo the standard injection protocol. A conjunctival culture will then be obtained followed by the application of povidone-iodine to the eyelashes and eyelid margins. Patients will undergo application of another drop of topical anesthetic followed by conjunctival culture. After the culture, this group of patients will have 5% povidone iodine applied to the conjunctival surface. Intravitreal injection will then proceed.
2943108|NCT02951338|Active Comparator|Group aerobic exercise only|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
2943109|NCT02951338|Experimental|PROPEL program|The PROPEL program involves both group aerobic exercise (as described above) and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
2943110|NCT02951325|No Intervention|Standard|"Surgery +/- chemotherapy only~Surgery (Standard/routine care) Cysto-prostatectomy and pelvic nodal dissection as part of their standard care.~Chemotherapy All patients following cysto-prostatectomy (inclusive of those received neo-adjuvant chemotherapy) will receive upto 4 cycles of adjuvant chemotherapy if medically fit for the same. The chemotherapy regimen, doses and schedule will be as per standard institutional practice. No concomitant chemotherapy with radiotherapy is recommended.~No radiation therapy will be given."
2943111|NCT02951325|Experimental|Test|"Surgery +/- chemotherapy as per standard arm and Radiation therapy as experimental intervention~Radiation Therapy:~All patients will be treated with conformal radiotherapy technique with intensity modulated radiotherapy with or without image guidance. The radiotherapy will start within 8 weeks from the date of surgery if adjuvant chemotherapy has not been planned. The radiotherapy will start within 4 weeks from the date of last chemo cycle, in patients who will be given adjuvant chemotherapy.~Dose Prescription:~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) will be prescribed for the nodal PTV. In case of R1 and/or R2 resection dose to the pelvic nodes and tumour bed may be increased to 54-56 Gy in 28 fractions depending on the constraints achieved during planning.~Patient assessments: Clinical assessment for toxicity evaluation and disease status. QOL evaluation of the patients."
2943112|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 25mg|Glycopyrrolate Inhalation Solution 25 μg via eFlow nebulizer, once daily
2943113|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 75mg|Glycopyrrolate Inhalation Solution 75 μg via eFlow nebulizer, once daily
2943114|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 200mg|Glycopyrrolate Inhalation Solution 200 μg via eFlow nebulizer, once daily
2943115|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 200mg Jet|Glycopyrrolate Inhalation Solution 200 μg via jet nebulizer, once daily
2943116|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 500mg|Glycopyrrolate Inhalation Solution 500 μg via eFlow nebulizer, once daily
2943117|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution1000mg|Glycopyrrolate Inhalation Solution 1000 μg via eFlow nebulizer, once daily
2943118|NCT02951312|Placebo Comparator|Placebo 0.5 mL|Placebo 0.5 mL via jet nebulizer, once daily
2943119|NCT02951299|Experimental|pentoxifylline group|Received oral pentoxifylline (400 mg) three times a day for 14 days.
2943120|NCT02951299|No Intervention|no treatment group|No intervention.
2943121|NCT02951286|Experimental|high pull headgear + OBA|A modified version of the Open Bite Appliance (OBA),introduced by Erverdi and Usumez, will be applied with high pull headgear for Orthoclassic ®1300 NE Alpha Drive, McMinnville, OR 97128 USA 866.752.0065.
2943122|NCT02951286|Experimental|OBA (control group)|A modified version of the Open Bite Appliance (OBA),introduced by Erverdi and Usumez, will be applied only.
2943123|NCT02951273||Study of cerebral blood flow|Patients undergoing oesophageal- or ventricular resection (n=30)
2943124|NCT02951260|Experimental|Metformin|17 days metformin treatment
2943130|NCT02951208|Experimental|Active tDCS + Active VR|Active tDCS over the left DLPFC (30 minutes) combined with active VR motivation training (60 minutes), administered 3 times per week for 4 weeks.
2943131|NCT02951208|Sham Comparator|Sham tDCS + Sham VR|Sham tDCS over the left DLPFC (30 minutes) combined with sham VR motivation training (60 minutes), administered 3 times per week for 4 weeks.
2943132|NCT02951195|Experimental|Heterozygous F508del/MF Cohort 1A: Triple Combination (TC)|"VX-152 100 milligrams (mg) administered every 12 hours (q12h). TEZ 100 mg once daily (qd). IVA 150 mg q12h.~Morning Dose: VX-152 + TEZ/IVA~Evening Dose: VX-152 + IVA"
2943133|NCT02951195|Placebo Comparator|Heterozygous F508del/MF Cohort 1A: TC|Placebos matched to VX-152, TEZ/IVA, and IVA.
2943134|NCT02951195|Experimental|Heterozygous F508del/MF Cohort 1B: TC|"To be initiated after blinded review of Cohort 1A, if supported by safety and PK Data.~The dosage of VX-152 may be adjusted based on data from Cohort 1A.~Morning Dose: VX-152 + TEZ/IVA~Evening Dose: VX-152 + IVA"
2943135|NCT02951195|Placebo Comparator|Heterozygous F508del/MF Cohort 1B: Triple Placebo|Placebos matched to VX-152, TEZ/IVA, and IVA.
2943136|NCT02951195|Experimental|Heterozygous F508del/MF Cohort 1C: TC|"To be initiated after blinded review of Cohort 1B, if supported by safety and PK Data.~The dosage of VX-152 to be determined based on data from Cohort 1B.~Morning Dose: VX-152 + TEZ/IVA~Evening Dose: VX-152 + IVA"
2943137|NCT02951195|Placebo Comparator|Heterozygous F508del/MF Cohort 1C: Triple Placebo|Placebos matched to VX-152, TEZ/IVA, and IVA.
2943138|NCT02951195|Experimental|Homozygous F508del/F508del Cohort 2A: TC|"To be initiated after blinded review of Cohort 1A or Cohort 1B, if supported by safety and PK Data.~The dosage of VX-152 to be determined based on data from Cohort 1A (and from Cohort 1B, if applicable.)~Morning Dose: VX-152 + TEZ/IVA~Evening Dose: VX-152 + IVA~The experimental period will be preceded by a 4-week run-in period and followed by a 2-week washout period, during both of which subjects will receive:~TEZ 100 mg administered once daily (qd). IVA 150 mg q12h."
2943139|NCT02951195|Active Comparator|Homozygous F508del/F508del Cohort 2A: TEZ/IVA|"To be initiated after blinded review of Cohort 1A or Cohort 1B, if supported by safety and PK Data.~Morning Dose: Placebo + TEZ/IVA~Evening Dose: Placebo + IVA~The active comparator period will be preceded by a 4-week run-in period and followed by a 2-week washout period, during both of which subjects will receive:~TEZ 100 mg administered once daily (qd). IVA 150 mg q12h."
2943140|NCT02951195|Experimental|Homozygous F508del/F508del Cohort 2B: TC|"To be initiated after blinded review of Cohort 2A, if supported by safety and PK Data.~The dosage of VX-152 to be determined based on data from Cohorts 1A, 1B, and 2B, as applicable.~Morning Dose: VX-152 + TEZ/IVA~Evening Dose: VX-152 + IVA~The experimental period will be preceded by a 4-week run-in period and followed by a 2-week washout period, during both of which subjects will receive:~TEZ 100 mg administered once daily (qd). IVA 150 mg q12h."
2943141|NCT02951195|Active Comparator|Homozygous F508del/F508del Cohort 2B: TEZ/IVA|"To be initiated after blinded review of Cohort 1A or Cohort 1B, if supported by safety and PK Data.~Morning Dose: Placebo + TEZ/IVA Evening Dose: Placebo + IVA~The active comparator period will be preceded by a 4-week run-in period and followed by a 2-week washout period, during both of which subjects will receive:~TEZ 100 mg administered once daily (qd). IVA 150 mg q12h."
2943142|NCT02951182|Experimental|Heterozygous F508del/MF 4-week Cohort A:Triple Combination(TC)|"VX-440 200 milligram (mg) administered every 12 hours (q12h). TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.~Morning Dose: VX-440 + TEZ/IVA~Evening Dose: VX-440 + IVA"
2943143|NCT02951182|Placebo Comparator|Heterozygous F508del/MF 4-week Cohort A: Triple Placebo|Placebos matched to VX-440, TEZ/IVA, and IVA.
2943144|NCT02951182|Experimental|Heterozygous F508del/MF 4-week Cohort B TC-High|"To be initiated after blinded review of Cohort A, if supported by safety and PK Data.~The dosage of VX-440 may be adjusted based on data from Cohort A.~Morning Dose: VX-440 + TEZ + IVA~Evening Dose: VX-440 + TEZ + IVA"
2943145|NCT02951182|Experimental|Heterozygous F508del/MF 4-week Cohort B:TC-Low|"To be initiated after blinded review of Cohort A, if supported by safety and PK Data.~Placebo matched to VX-440~Morning Dose: VX-440 + TEZ + IVA~Evening Dose: VX-440 + TEZ + IVA"
2943146|NCT02951182|Placebo Comparator|Heterozygous F508del/MF 4- week Cohort B: Triple Placebo|"To be initiated after blinded review of Cohort A, if supported by safety and PK Data.~Placebos matched to VX-440, TEZ, and IVA."
2943147|NCT02951182|Experimental|Homozygous F508del/F508del 4-week Cohort: TC- High|"To be initiated after the Cohort A blinded review, if supported by safety and PK data.~The dosage of VX-440 may be adjusted based on data from Cohort A.~Placebo matched to morning TEZ/IVA.~Morning Dose: VX-440 + TEZ + IVA~Evening Dose: VX-440 + TEZ + IVA~The treatment period will be preceded by a 4-week run-in period and followed by a 4-week washout period, during both of which subjects will receive:~TEZ 100 mg administered once daily (qd). IVA 150 mg q12h."
2943148|NCT02951182|Active Comparator|Homozygous F508del/F508del 4-week Cohort: TEZ/IVA|"To be initiated after blinded review of Cohort A, if supported by safety and PK Data.~Placebos matched to VX-440, evening TEZ, and morning IVA.~TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.~Morning Dose: TEZ/IVA~Evening Dose: IVA~The treatment period will be preceded by a 4-week run-in period and followed by a 4-week washout period, during both of which subjects will receive:~TEZ 100 mg administered once daily (qd). IVA 150 mg q12h."
2943149|NCT02951182|Experimental|Heterozygous F508del/MF 12-week Cohort: TC-High|"To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.~The dosage of VX-440 will be determined based on data from Heterozygous F508del/MF 4-week Cohorts A and B.~Morning Dose: VX-440 + TEZ + IVA~Evening Dose: VX-440 + TEZ + IVA"
2943150|NCT02951182|Experimental|Heterozygous F508del/MF 12-week Cohort: TC-Low|"To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.~The dosage of VX-440 will be determined based on data from Heterozygous F508del/MF 4-week Cohorts A and B.~Placebo matched to VX-440~Morning Dose: VX-440 + TEZ + IVA~Evening Dose: VX-440 + TEZ + IVA"
2943151|NCT02951182|Experimental|Heterozygous F508del/MF 12-week Cohort: Dual IVA|"To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.~The dosage of VX-440 will be determined based on data from Heterozygous F508del/MF 4-week Cohorts A and B.~Placebo matched to TEZ.~Morning Dose: VX-440 + IVA~Evening Dose: VX-440 + IVA"
2943152|NCT02951182|Experimental|Heterozygous F508del/MF 12-week Cohort: Dual TEZ|"To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.~The dosage of VX-440 will be determined based on data from Heterozygous F508del/MF 4-week Cohorts A and B.~Placebo matched to IVA~Morning Dose: VX-440 + TEZ~Evening Dose: VX-440 + TEZ~VX-440 administered in combination with TEZ q12h and placebo matched IVA."
2943153|NCT02951182|Placebo Comparator|Heterozygous F508del/MF 12-week Cohort: Triple Placebo|"To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.~Placebos matched to VX-440, TEZ, and IVA."
2943154|NCT02951156|Experimental|Phase 1b Arm A|avelumab/utomilumab/rituximab
2943155|NCT02951156|Experimental|Phase 1b Arm B|avelumab/utomilumab/azacitidine
2943156|NCT02951156|Experimental|Phase 1b Arm C|avelumab/rituximab/bendamustine
2943157|NCT02951156|Experimental|Phase 3 Arm D (selected from Phase 1b)|Selected regimen from Phase 1b component which may be i) avelumab/utomilumab/rituximab OR ii) avelumab/rituximab/azacitidine OR iii) avelumab/rituximab/bendamustine
2943158|NCT02951156|Active Comparator|Phase 3 Arm E|Investigator's Choice of either rituximab/bendamustine or rituximab/gemcitabine/oxaliplatin
2943159|NCT02951143|Experimental|Single arm|All participants will complete the same experimental events across 6 laboratory sessions.
2943160|NCT02951143|Experimental|0.4 mg/g Concentration|Participants in this arm will experience the 0.4 mg/g Concentration
2943161|NCT02951143|Experimental|1.4 mg/g Concentration|Participants in this arm will experience the 1.4 mg/g Concentration
2943162|NCT02951143|Experimental|2.5 mg/g Concentration|Participants in this arm will experience the 2.5 mg/g Concentration
2943163|NCT02951143|Experimental|5.6 mg/g Concentration|Participants in this arm will experience the 5.6 mg/g Concentration
2943164|NCT02951143|Experimental|17.4 mg/g Concentration|Participants in this arm will experience the 17.4 mg/g Concentration
2943165|NCT02951130|Experimental|Milrinone|Milrinone infusion at 0.33µg/kg/min. The dose of the study drug will be increased to 0.66 µg/kg/min if oxygenation index (OI) remains ≥ 10 without any evidence of hypotension (as defined by the protocol) two hours after initiation of study drug. Infusion will be continued until the OI decreases to < 7. The maximum duration of study drug infusion is 72 hours.
2943166|NCT02951130|Placebo Comparator|5% dextrose (D5W)|An equivalent volume of 5% dextrose (D5W) will be used for infants randomized to the placebo arm.
2943167|NCT02951117|Experimental|Arm A Venetoclax QD + ABBV-838 Q3W + Dexamethasone|ABBV-838 administered at cohort-defined doses every 3 weeks (Q3W; starting dose 4.0 mg/kg) in combination with venetoclax (400 mg or 800 mg once daily [QD]) and dexamethasone (40 mg once weekly [Q1W]); once the maximum-tolerated-dose (MTD) and recommended phase two dose (RPTD) are determined, ABBV-838 in combination with venetoclax and dexamethasone at RPTD will be administered in a dose expansion phase of the study.
2943168|NCT02951117|Experimental|Arm B Venetoclax QD + ABBV-838 Q1W or Q2W + Dexamethasone Q1W|"Dose escalation portion will investigate either the ABBV-838 weekly (Q1W) or bi-weekly (Q2W) dosing interval in combination with venetoclax (400 or 800 mg QD) and dexamethasone (40 mg Q1W).~The dose expansion portion will investigate either the ABBV-838 weekly (Q1W) or bi-weekly (Q2W) dosing interval in combination with venetoclax and dexamethasone at the RPTD combination defined from the Dose Escalation portion."
2943169|NCT02951104|Experimental|NICOM|
2943170|NCT02951091||biomarker group|400 Her-2 (-) metastatic/recurrent gastric cancer patients will be centrally screened for druggable targets [Epstein-Barr virus, Microsatellite instability, HER2, EGFR, c-MET, and PTEN] by immunohistochemistry and in situ hybridization during first line chemotherapy. At the time of second line treatment, patients will be randomized to the biomarker vs control group as 4: 1 ratio. The biomarker group will be offered for entry into a specific protocol based on their molecular cohort and treated with specific targeted agents in combination with weekly paclitaxel; 1) EGFR cohort (EGFR 2+ or EGFR 3+) for pan-ERBB inhibitor (afatinib), 2)PTEN loss cohort (PTEN score less than 100) for PIK3CB inhibitor (GSK2636771), 3) PD-L1 positive, MSI-high, or EBV positive cases for nivolumab, 4) none for weekly paclitaxel.
2943171|NCT02951091||control group|
2943172|NCT02951078|Experimental|Thulium Laser en Bloc Resection of bladder tumor|Thulium Laser en Bloc Resection of the Non-muscle Invasive Bladder tumor with thulium laser
2943173|NCT02951078|Active Comparator|Electrical transurethral resection of bladder tumor|Electrical transurethral resection of the Non-muscle Invasive Bladder tumor
2943174|NCT02951065|Experimental|Bristle-less brush|Subjects will be assigned to use a bristle-less manual tooth brush with short, rubbery cones for one year twice daily
2943175|NCT02951065|Active Comparator|Soft bristle brush|Subjects will be assigned to use a soft, nylon-bristled tooth brush for one year twice daily
2943176|NCT02951052|Experimental|CAB LA + RPV LA every 4 weeks|Eligible participants receive Oral CAB 30 mg + RPV 25 mg once daily for four weeks, IM CAB LA 600 mg and RPV LA 900 mg for the first injection, and Week 4 onwards subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks until withdrawal.
2943177|NCT02951052|Active Comparator|Current antiretroviral regimen|Eligible participants will continue their current anti-retroviral regimen (2 NRTIs plus an INI, NNRTI, or a PI) for 52 weeks. After 52 weeks participants have the option to continue study participation by switching to CAB LA + RPV LA in the Extension Phase where they will follow the procedure of CAB LA + RPV LA arm.
2943178|NCT02951039||Edoxaban|Patients with established NVAF treated with edoxaban according to package information. Physician's prescribing behaviour will not be influenced; patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
2943179|NCT02951026||0.03mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.03mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
2943180|NCT02951026||0.07mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.07mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
2943181|NCT02951026||0.23mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.23mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
2943182|NCT02951026||Placebo (previously injected)|"Subjects in this group received a single intra-articular injection of placebo into the target knee during the parent study prior to enrolling in this observational study."
2943183|NCT02951013|Experimental|restrictive group|Patients in this group will have a transfusion when the hemoglobin concentration falls below 6g/dL, with a target hemoglobin range of 7.5-8.0g/dL.
2943184|NCT02951013|Active Comparator|liberal group|Patients in this group will have a transfusion when the hemoglobin concentration falls below 8g/dL, with a target hemoglobin range of 9.5-10.0g/dL.
2943314|NCT02950012|Experimental|OPTI-BIOME™ Bacillus subtilis MB40|
2943188|NCT02950974|Active Comparator|NSS|NSS 30 ml/kg (maximum of 2 litres) intravenous load over 1 hour
2943189|NCT02950974|Experimental|Sterofundin|Sterofundin solution 30 ml/kg (maximum of 2 litres) intravenous load over 1 hour
2943190|NCT02950961|Other|Arm 1: nonrandomized stepped wedge|"The investigators will use a nonrandomized stepped wedge design to evaluate the implementation in four VA Women's Practice Based Research Network (PBRN) sites. In the context of the nonrandomized stepped wedge design, the intervention is turned on when a primary care provider (PCP) at a site makes her/his first referral to the CCWV care manager. This design relies on sequential roll-out to participating sites over time, while using other sites as controls until they begin implementation. The investigators will use nonrandomized stepped wedges (rather than randomized) given their suitability for studying implementation. The design explicitly considers the timing of implementation spread and addresses the statistical issues introduced by lack of randomization in implementation starts and processes. The investigators will analytically compensate for the design by collecting patient-, provider-, and site-level data that may be associated with timing of the adoption of each intervention."
2943191|NCT02950948|Experimental|Progesterone|25 mg of progesterone will be administered daily by subcutaneous injection.
2943192|NCT02950948|Placebo Comparator|Placebo|25 mg of progesterone will be administered daily by subcutaneous injection.
2943193|NCT02950935|Experimental|Progesterone|25 mg of subcutaneous progesterone will be administered twice à day until the 12th week of gestation.
2943194|NCT02950935|Placebo Comparator|Placebo|placebo will be administered twice à day until the 12th week of gestation.
2943195|NCT02950922|Experimental|RVT-501 0.2% ointment|RVT-501 0.2% ointment BID x 28 days (30 adults, 20 adolescents)
2943196|NCT02950922|Experimental|RVT-501 0.5% ointment|RVT-501 0.5% ointment BID x 28 days (30 adults, 20 adolescents)
2943197|NCT02950922|Placebo Comparator|Vehicle ointment|Vehicle ointment BID x 28 days (30 adults, 20 adolescents)
2943198|NCT02950909|Experimental|Emphasized exercise group|Patients in the emphasized exercise group performed exercises emphasizing the deep cervical extensor muscles applying a resistance at the level of the vertebral arch of C4 either therapeutically with the therapist's fingers or as a home exercise with the aid of a towel or belt. These exercises were performed in sitting and standing in front of a table propped up on both forearms. In the latter position, a dynamic exercise was added moving the head from maximal flexion to maximal extension keeping the gaze fixed at an object lying between both elbows hoping to activate more the extensors in the lower cervical spine.
2943199|NCT02950909|Experimental|General exercise group|Patients in the general exercise group performed exercises targeting all cervical extensor muscles including the superficial ones applying resistance at the head pushing against a wall or the therapist's hand or as a home exercise with the aid of a towel. As in the other group, these exercises were performed in sitting and standing in front of a table propped up on both forearms. In the latter position, the same dynamic exercise was added as in the other group with the only difference that the gaze was fixed at an object lying between both hands hoping to activate all cervical extensors
2943200|NCT02950883|Experimental|Active Treatment Group|7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
2943201|NCT02950883|Active Comparator|Control Group|0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks
2943202|NCT02950870|Experimental|group treated|this group will be treated with Ombitasvir-Paritaprevir-Ritonavir (12,5 mg/75 mg/50 mg) and Dasabuvir ( 250 mg) with or without Ribavirina every day , for 12 weeks.
2943203|NCT02950870|No Intervention|group untreated|Control group
2943204|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 0.9 µg/kg|Four weekly subcutaneous injections of 0.9 µg/kg EPEG
2943205|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 1.2 µg/kg|Four weekly subcutaneous injections of 1.2 µg/kg EPEG
2943206|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 1.5 µg/kg|Four weekly subcutaneous injections of 1.5 µg/kg EPEG
2943207|NCT02950831|Experimental|Activity and sleep quality recording|Patients will receive a wrist worn accelerometer and accelerometry will be used to monitor physical activity and sleep quality during standard BurstDR Spinal Cord Stimulation clinical treatment
2943208|NCT02950818|Experimental|Take Heart self-management program|Group and telephone-based educational program to enhance self-management of heart disease and related risk factors.
2943209|NCT02950818|No Intervention|Waitlist control|Control group participants will be offered the opportunity to participate in Take Heart following the conclusion of their study involvement.
2943210|NCT02950805|Experimental|Placebo + AZD5634|Subjects were administered single dose of placebo in period 1 and AZD5634 in period 2.
2943211|NCT02950805|Experimental|AZD5634 + Placebo|Subjects were administered single dose of AZD5634 in period 1 and placebo in period 2.
2943212|NCT02950792|Experimental|ViewRay MRI-IGART|"ViewRay MRI-Image-Guided Adaptive Radiation Therapy (IGART):~Daily MRI on ViewRay 5 days per week for 4 weeks in combination with weekly standard of care chemo-radiation.~Daily MRI on ViewRay during Week 5 in combination with Stereotactic Body Radiation Therapy boost for daily for up to 1 week.~Continued standard of care consolidation chemotherapy every 21 days for 3 cycles, beginning 4 - 6 weeks after completion radiation therapy, ."
2943213|NCT02950766|Experimental|Neovax in Combination with Ipilimumab|"Patients will undergo surgery with the intent to resect the primary kidney tumor~Neovax is a combination of Poly-ICLC and Neoantigen Peptides~Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22~In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20~Ipilimumab will be injected within 1 cm of each NeoVax administration"
2943214|NCT02950753|Experimental|Lactated Ringer|Intravenous bolus of Lactated Ringer solution (30ml/kg) via 18ga IV catheter at wide open.
2943215|NCT02950753|Placebo Comparator|Normal Saline|Intravenous bolus of Normal Saline (30ml/kg) via 18ga IV catheter at wide open.
2943216|NCT02950740||Center 01 (SA)|Toddlers from Santo André Early Childhood Public School
2943217|NCT02950740||Center 02 (POA)|Toddlers from Porto Alegre Early Childhood Public School
2943218|NCT02950740||Center 03 (MG)|Toddlers from Uberaba Early Childhood Public School
2943219|NCT02950740||Center 04 (RN)|Toddlers from Natal Early Childhood Public School
2943220|NCT02950727|Experimental|3 bicortical screw|1st group:3 bicortical screws will be used to fix the sagittal split ramus osteotomy.
2943315|NCT02950012|Placebo Comparator|Placebo|
2943221|NCT02950727|Active Comparator|adjustable plate and 2 bicortical screws|adjustable plate and 2 bicortical screws will be used to fix the sagittal split ramus osteotomy.
2943222|NCT02950714|Experimental|LIN_NOW|Participants from CaNIOS centres randomized to the NOW group will be provided immediate access to the lupus interactive navigator (LIN), a web-based program developed to promote engagement and self-care in lupus.
2943223|NCT02950714|Active Comparator|LIN_WAIT|Participants from CaNIOS centres randomized to the WAIT group will have usual care for three months prior to crossing over to access to the LIN.
2943224|NCT02950688|Experimental|Group 1: Seasonal LAIV|Participants will receive 1 dose of seasonal LAIV on Day 0. They will receive 1 dose of the wild-type A/California/2009-like influenza challenge virus on Day 56.
2943225|NCT02950688|Placebo Comparator|Group 2: Placebo|Participants will receive 1 dose of placebo on Day 0. They will receive 1 dose of the wild-type A/California/2009-like influenza challenge virus on Day 56.
2943226|NCT02950675||Normal Adult|Control:Normal Adult
2943227|NCT02950675||Burn Patient|The burn patient will be identified according to the diagnoses (ICD-9-CM code: 940-949).
2943228|NCT02950662|Active Comparator|Metal housing|metal housing of ball and socket attachment the intervention will be overdenture
2943229|NCT02950662|Active Comparator|Peek housing|Peek housing of ball and socket attachment the intervention will be overdenture
2943230|NCT02950649|Experimental|Hemodynamic Monitored Guided Assesment|This group will have the non-invasive hemodynamic monitoring device placed and its data will help guide (intervention) patient's management decisions (experimental).
2943231|NCT02950649|Active Comparator|No Hemodynamic Monitored Guided Assesment|This group will have the non-invasive hemodynamic monitoring device placed but its data will NOT be factored for intervention of the patient's management decisions.
2943232|NCT02950636|Experimental|Restorative Yoga|Subjects will participate in a structured restorative yoga program. Subjects will attend a 60 minute restorative yoga class twice a week for 8 weeks in a yoga studio.
2943233|NCT02950623|Experimental|patients take titanium dioxide denture|patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial then in the later phase after one month they will receive( rapid heat cured acrylic resin)denture
2943234|NCT02950623|Placebo Comparator|patients take rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles )
2943235|NCT02950610||Healthy|Healthy volunteer: self-declared healthy individual (no known illness or medications) with Normal BMI
2943236|NCT02950610||Nonalcoholic steatohepatitis|NAFLD without cirrhosis: Metabolic syndrome with known liver disease (NAFLD, excluding other coexisting liver condition) without cirrhosis
2943237|NCT02950610||NAFLD Cirrhosis|NAFLD cirrhosis: well characterised NAFLD compensated cirrhosis (Child's A-B)
2943238|NCT02950584|Experimental|Patients take titanium dioxide denture|Participants will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) for 1 month in the initial phase of the trial then in the later phase after one month they will receive (rapid heat cured acrylic resin) denture
2943239|NCT02950584|Placebo Comparator|Patients take rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles)
2943240|NCT02950571|Active Comparator|Standard Care|Routine care is comprised of a high level of support from an interdisciplinary team with access to unit-specific and centralized programming
2943241|NCT02950571|Experimental|Digital Picture Frames|"Setup: Over 1-2, approximately 30 minute meetings pictures will be uploaded onto the device from picture files provided by the participant and/or their family or an open online source (e.g., Google Images) that are relevant and of interest to the participant.~Installation: The picture frames are secured to a surface in the participant's room (most typically a table) by facilities staff. Participants are instructed in its use.~Check in: At midpoint (2 weeks) an RA will check in with the participant to informally discuss whether or not it continues to work, is being used, and if they want more pictures uploaded. If the latter is requested step 1 will be repeated."
2943242|NCT02950558|Active Comparator|Ropivacaine|Single injection of ropivacaine immediately prior to surgery
2943243|NCT02950558|Experimental|Ropivacaine plus Nerve Block|Single injection of ropivacaine immediately prior to surgery plus 5 day ambulatory popliteal nerve block.
2943244|NCT02950545|Experimental|Contact Lens Rx|Simulated driving with 3 within-subject interventions: Placebo Lenses, Spherical Lenses, Toric Lenses
2943245|NCT02950532||Cases|Retrospective radiological evaluation in cases presenting A3 or A4 TL burst fractures (AOSpine classification) between T11 to L2 with or without suspected PLC injury
2943246|NCT02950519|Active Comparator|As needed Cuff Pressure Checks|Cuff pressure checks upon intubation and after any manipulation of ET tube
2943247|NCT02950519|Experimental|Cuff Pressure checks every 8 hrs|Cuff pressure checks upon intubation, after manipulation of ET tube, and minimum of 8 hr interval
2943248|NCT02950506|Active Comparator|Active tDCS|There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with active tDCS(transcranial direct current stimulation) andcognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
2943249|NCT02950506|Sham Comparator|Sham tDCS|There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with sham tDCS and cognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
2943250|NCT02950493|Other|Single group, one arm study group|Compare echocardiograph imaging efficacy of active Definity (perflutren lipid microsphere) with compressed Definity.
2943251|NCT02950480|Experimental|Zafirlukast|Zafirlukast
2943252|NCT02950480|Other|Standard of Care (no intervention)|Standard of Care (no intervention)
2943253|NCT02950467|Experimental|Group therapy plus psilocybin|Modified brief Supportive-Expressive Group Therapy will be administered as eight weekly sessions. Oral psilocybin will be administered once in a clinical setting.
2943254|NCT02950454|Experimental|Intervention|8 weeks of twice weekly high intensity interval training. Session protocol: 2 minute warm up at nominal resistance on cycle ergometer, 6 six intervals of 80-95% heart rate max interspersed with 6 intervals of 1.5 minute working rest. Then 3 minutes cool down.
2943255|NCT02950454|Active Comparator|control|8 weeks of twice weekly continuous moderate intensity exercise. Session protocol: 2 minutes warm up at nominal resistance on cycle ergometer, 20 minutes at 60-70% heart rate max. Then 3 minutes cool down.
2943256|NCT02950441|Experimental|Nicotinamide Riboside|1000mg (2x250mg tablets twice daily)
2943257|NCT02950441|Placebo Comparator|Placebo|Two tablets twice daily
2943258|NCT02950428|Experimental|ACURATE neo™TA Delivery System|Patients implanted with ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™ TA Transapical Delivery System
2943259|NCT02950415|Other|virtual + coaching|Parent is present virtually via an internet pad (iPad) and has received coaching about how best to verbally soothe child
2943260|NCT02950415|Other|virtual + no coaching|Parent is present virtually via an internet pad (iPad) and has not received coaching about how best to verbally soothe child
2943261|NCT02950415|Other|physical + coaching|Parent is physically present and has received coaching about how best to verbally soothe child
2943262|NCT02950415|Other|physical + no coaching|Parent is physically present and has not received coaching about how best to verbally soothe child
2943263|NCT02950402|Experimental|Two Dried Plums per day|Two Dried Plums per day is approximately 14 g.
2943264|NCT02950402|Experimental|Six Dried Plums per day|Six Dried Plums per day is approximately 42 g.
2943265|NCT02950389|Experimental|Group A|Six bicarbonate dialysis session with PMMA dialysis filter for 2 weeks, followed by 2 weeks of 6 on-line HFR session with HFR17 dialysis filter, than 6 bicarbonate dialysis session for 2 weeks with F7 dialysis filter.
2943266|NCT02950389|Experimental|Group B|Six on-line HFR session with HFR17 dialysis filter for 2 weeks, followed by 2 weeks of 6 o bicarbonate dialysis session with PMMA dialysis filter for 2 weeks, than 6 bicarbonate dialysis session for 2 weeks with F7 dialysis filter.
2943267|NCT02950376||Group1：amphetamine abusers|
2943268|NCT02950376||Group2: health control|
2943269|NCT02950376||Group3: norm of assessment system|
2943270|NCT02950350||radiation and chemotherapy|The patients will receive radiation and chemotherapy
2943271|NCT02950350||removal of pelvic lymph nodes and abdominal aorta lymph nodes|The patients will receive removal of pelvic lymph nodes and abdominal aorta lymph nodes ,and receive concurrent radiation and chemotherapy
2943272|NCT02950337|Experimental|Group 1: Peripherally Located Tumors|Peripherally Located Tumors - SBRT
2943273|NCT02950337|Experimental|Group 2: Peripherally Located Chest Wall Adjacent Tumors|Peripherally Located Chest Wall Adjacent Tumors - SBRT
2943274|NCT02950337|Experimental|Group 3: Centrally Located Tumors|Centrally Located Tumors - SBRT
2943275|NCT02950324|Experimental|Prehabilitation|Patients in this (intervention) arm of the study will be enrolled into a multimodal programme that involves 15 weeks of exercise, nutritional support and psychological prehabilitation in the form of 'Medical Coaching'.
2943276|NCT02950324|Active Comparator|Standard care|Patients in the 'standard care' arm of the study will not receive the study intervention. The patients will continue to be offered the standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care.
2943277|NCT02950311|Experimental|Intranasal xylitol spray|Two sprays each nostril, twice a day.
2943278|NCT02950311|Placebo Comparator|Intranasal saline spray|Two sprays each nostril, twice a day.
2943279|NCT02950285|Experimental|Baseline alert|For patients randomly selected for the baseline alert arm, their physicians will be alerted via email that a patient(s) under their care has atrial fibrillation, is at high risk of stroke, and is not currently anticoagulated. Physicians will also be asked to complete a survey related to anticoagulation for each patient and will be provided with educational resources and consultation services.
2943280|NCT02950285|No Intervention|3-month alert arm|For patients randomly selected for the 3-month alert arm, their physicians will not be notified during the 3-month study follow-up period. Instead, PCPs will be sent alerts after 3-months via email for these patients.
2943281|NCT02950259|Experimental|IRX-2 Regimen -Early Stage Breast Cancer|Enrolled subjects with early stage breast cancer will receive a single dose of cyclophosphamide (300 mg/m2) by IV infusion on Day 1. Also starting on Day 1 and continuing until Day 21, subjects will take daily oral indomethacin (25 mg three times each day), daily oral omeprazole (one tablet) and daily oral multivitamin containing 15-30 mg of zinc. On any 10 consecutive day period between Days 4-17, patients will receive two 1 mL subcutaneous periareolar injections of IRX-2.
2943282|NCT02950259|Experimental|IRX-2 Regimen -Triple Negative Breast Cancer|Enrolled subjects with triple negative breast cancer will receive a single dose of cyclophosphamide (300 mg/m2) by IV infusion on Day 1. Also starting on Day 1 and continuing until Day 21, subjects will take daily oral indomethacin (25 mg three times each day), daily oral omeprazole (one tablet) and daily oral multivitamin containing 15-30 mg of zinc. On any 10 consecutive day period between Days 4-17, patients will receive two 1 mL subcutaneous periareolar injections of IRX-2.
2943283|NCT02950246|Experimental|2% alcoholic chlorhexidine group|"Skin preparation Use of 10 ml of 2% alcoholic Chlorhexidine drug for disinfection in place of povidone iodine without scrubing device Wait at least 30 secondes for drying Perineural catheterization implementation Ultrasonography use"
2943284|NCT02950246|Active Comparator|povidon iodine group|"Skin preparation Use of 10 ml of povidone iodine drug for disinfection with scrubing device Wait at least 30 seondes for drying Perineural catheterization implementation Ultrasonography use"
2943285|NCT02950233|Experimental|NMDA active + Steroid placebo|"NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
2943286|NCT02950233|Experimental|Steroid active + NMDA placebo|"NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID [first week]; one capsule BID [following three weeks]).~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
2943316|NCT02949999|Experimental|0.25mg/kg voclosporin|0.25mg/kg voclosporin BID.
2943287|NCT02950233|Experimental|NMDA active + Steroid active|"NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
2943288|NCT02950233|Placebo Comparator|NMDA placebo + Steroid placebo|"NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID [first week]; one capsule BID [following three weeks]).~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
2943289|NCT02950220|Experimental|Arm 1|
2943290|NCT02950194||PPAWI|patients with multidisciplinary PPAWI approach
2943291|NCT02950181|Experimental|Specific Aim|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
2943292|NCT02950168||Edoxaban|All patients treated with edoxaban with a planned or unplanned diagnostic or interventional procedure
2943293|NCT02950155|Experimental|Rituximab|A single infusion at a dose of 500 mg of Mabthera/Rituximab.
2943294|NCT02950155|Sham Comparator|Sodium Chloride solution|A single infusion with sodium chloride solution.
2943295|NCT02950142|Experimental|CPOE with order sets|Physicians who use CPOE including order sets for large range of indications.
2943296|NCT02950142|Active Comparator|CPOE without order sets|Physicians who use CPOE without order sets.
2943297|NCT02950129|Other|measurements of gait|all subjects will undergo 6 tests to assess gait before and after SIJ; SIJ pain diagnostic tests
2943298|NCT02950116|Active Comparator|Asthma|Asthmatic patients will perform three multiple breath nitrogen washout tests (N2-MBW-test)
2943299|NCT02950116|Active Comparator|Non-CF bronchiectasis|Patients with non-CF bronchiectasis will perform three multiple breath nitrogen washout tests (N2-MBW-test)
2943300|NCT02950116|Active Comparator|Cystic fibrosis|Patients with cystic fibrosis will perform three multiple breath nitrogen washout tests (N2-MBW-test)
2943301|NCT02950103|Experimental|Synthetic phosphoethalonamine|Phosphoethanolamine PO daily
2943302|NCT02950090|Experimental|MobilWise|MobilWise will use data transmitted from an affordable accelerometer-based personal monitor (Fitbit Flex) via Fitabase to: allow a remote coach to view and collect physical activity data generated by the personal monitor, and use that data to formulate and provide tailored behavioral support, using motivational interviewing. The coach has a phone conversation weekly x 12 using motivational interviewing with participants to set goals and encourage activity. Coaches mention patient use of treatment elements (accountability) and will be positively reinforcing for adherent participants, or will include positive statements for those who are not adherent (supportive).Participants are also encouraged to use all the features of Fitbit (social networking, challenges, email reminders).
2943303|NCT02950090|Active Comparator|Fitbit Only|will use data transmitted from an affordable accelerometer-based personal monitor (Fitbit Flex) to monitor their own progress and physical activity level without coaching support. Participants are again encouraged to use all the features of Fitbit (social networking, challenges, email reminders) to achieve activity levels.
2943304|NCT02950090|No Intervention|Waitlist Control|Participants in the waitlist arm have exposure to the usual wellness supports provided by the company: Motiva is the internal corporate wellness program that is under the direction of the Chief Medical Officer. Initiated in 2000, Motiva is staffed by two full- time health professionals and two full-time healthy lifestyle professionals. Motiva provides wellness programming year round on a BCBSIL intranet web page plus an individual page called myMotiva, where self- assessment of health risks, including weight and physical activity behavior, is encouraged. Participating in myMotiva allows individuals to earn up to $200 per year in an incentive program called Wellness Rewards
2943305|NCT02950077|Experimental|All subjects|Individuals who are under the care of the Yale Liver Center with a diagnosis of autoimmune hepatitis
2943306|NCT02950064|Experimental|BTP-114|Intravenous (IV) treatment n 21-day cycles
2943307|NCT02950051|Active Comparator|Standard chemoimmunotherapy (SCIT)|"Patients up to age 65: 6 cycles (q28d) of Fludarabine + Cyclophosphamide + Rituximab (FCR)~Patients older than 65 years: 6 cycles (q28d) of Bendamustine + Rituximab (BR)"
2943308|NCT02950051|Experimental|Rituximab + Venetoclax (RVe)|6 cycles (q28d) of RVe + 6 cycles (q28d) of Venetoclax (alone)
2943309|NCT02950051|Experimental|Obinutuzumab + Venetoclax (GVe)|6 cycles (q28d) of GVe + 6 cycles (q28d) of Venetoclax (alone)
2943310|NCT02950051|Experimental|Obinutuzumab + Ibrutinib + Venetoclax (GIVe)|"6 cycles (q28d) of GIVe + 6 cycles (q28d) of Ibrutinib plus Venetoclax.~Administration of ibrutinib will be continued for a maximum of 36 months or until MRD negativity, start of new anti-CLL therapy or inacceptable toxicity, whatever occurs first."
2943311|NCT02950038|Experimental|Ibrutinib + Nivolumab|"Ibrutinib administered by mouth daily in 28 day cycles.~Nivolumab administered by vein beginning with cycle 2, and given on Days 1 and 15 of every 28 day cycle."
2943312|NCT02950025|Experimental|Arm 1: Online-Adaptive MRI-guided SBRT|"All patients will be initially planned for stereotactic body radiation therapy to a minimum dose of 50Gy in five fractions to the planning target volume (PTV)~Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site~When patients present for their first SBRT treatment session, the treating physician will evaluate their individual anatomy to determine if adaptive planning is indicated. Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day~Quality of life questionnaire baseline, 6 weeks after treatment conclusion, and 6 months after treatment conclusion"
2943313|NCT02950025|Active Comparator|Arm 2: Online non-adaptive MRI-guided SBRT|"All patients will be initially planned for stereotactic body radiation therapy to a minimum dose of 50Gy in five fractions to the planning target volume (PTV)~Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site~Quality of life questionnaire baseline, 6 weeks after treatment conclusion, and 6 months after treatment conclusion"
2943317|NCT02949999|Experimental|0.5mg/kg voclosporin|0.5mg/kg voclosporin BID
2943318|NCT02949999|Experimental|1.0mg/kg voclosporin|1.0mg/kg voclosporin BID
2943319|NCT02949999|Experimental|1.5mg/kg voclosporin|1.5mg/kg voclosporin BID
2943320|NCT02949999|Placebo Comparator|Placebo voclosporin|placebo BID
2943321|NCT02949986|Experimental|Tablet-based Fall Prevention|The exercise program will be self-administered via a tablet-based version of the fall prevention program and the exercises performed in the home.
2943322|NCT02949973|Experimental|Voclosporin|Voclosporin, oral, 23.7 mg BID
2943323|NCT02949960|Experimental|DMT210 Topical Gel|DMT210 Topical Gel 5% applied to target lesion twice daily
2943324|NCT02949960|Placebo Comparator|Vehicle Control|Topical Gel vehicle applied to target lesion twice daily
2943325|NCT02949947|Experimental|Group A - Ferric Carboxymaltose|"Participants receive a Ferric Carboxymaltose injection by vein. Dose repeated 1 week later.~Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24."
2943326|NCT02949947|Active Comparator|Group B - Iron Supplement|"Participants take iron supplements by mouth every day for up to 3 months.~Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24."
2943327|NCT02949934|Active Comparator|Tolcapone|Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days
2943328|NCT02949934|Placebo Comparator|Placebo|Placebo three times per day for eight days
2943329|NCT02949921|Experimental|"Grade 4 Hands group"|"Grade 4 Hands group will be subjects with hand grading of grade 4 (very severe loss of fatty tissue, marked visibility of veins and tendons in the dorsal hand). Grade 4 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 4 Hands group can have up to three retreatments over an 18 month period."
2943330|NCT02949921|Experimental|"Grade 2 or 3 Hands group"|"Grade 2 or 3 Hands group will be subjects with hand grading of grade 2 or grade 3 (moderate to severe loss of fatty tissue, mild to moderate visibility of veins and tendons in the dorsal hand). Grade 2 or 3 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 2 or 3 Hands group can have up to three retreatments over an 18 month period."
2943331|NCT02949908||Relapsing-Remitting Multiple Sclerosis (RRMS)|Subjects diagnosed with RRMS who have discontinued their oral or injectable first-line MS medication and have been receiving the treatment with subcutaneous Interferon beta-1a (IFNβ-1b) (Rebif)
2943332|NCT02949895|Experimental|Dose Escalation Dose 1|BMS-986012 Dose Escalation Dose 1
2943333|NCT02949895|Experimental|Dose Escalation Dose 2|BMS-986012 Dose Escalation Dose 2
2943334|NCT02949895|Experimental|Chemotherapy Combination|BMS-986012 + Cisplatin + Etoposide
2943335|NCT02949882|Experimental|Probiotic Intervention|130 Elderly participants receiving daily 65ml Yakult for 10 consecutive weeks.
2943336|NCT02949882|Active Comparator|Non-Probiotic Intervention|130 Elderly participants receiving daily 65 ml of Dairy Peach Drink (AH Basic) for 10 consecutive weeks.
2943337|NCT02949869|Experimental|Infant Lumbar Punctures|Infants will all be assigned to received two sets of skin markings and sonography exam to assess lumbar puncture landmarks and anatomy.
2943338|NCT02949856|Experimental|Tapered|Mallinckrodt, COVIDIEN
2943339|NCT02949856|Active Comparator|Cylindrical|Endotracheal tube, Unomedical
2943340|NCT02949843|Experimental|Arm I (nivolumab, pembrolizumab)|Patients receive nivolumab IV over 60 minutes every 2 weeks or pembrolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
2943341|NCT02949843|Experimental|Arm II (kinase inhibitor, chemotherapy, immunotherapy)|Patients receive tyrosine kinase inhibitor therapy PO targeting the initial oncogenic driver or other treatment for about 3 weeks.
2943342|NCT02949843|Experimental|Arm III (kinase inhibitor, targeted therapy, other treatment)|Patients receive tyrosine kinase inhibitor therapy PO targeting initial oncogenic driver, a drug targeting the secondary mutation, or other treatment for about 3 weeks.
2943343|NCT02949830|Experimental|givosiran (ALN-AS1)|
2943344|NCT02949817|Experimental|IMU sensor training group(intervention group)|video-game based rehabilitation therapy system training group
2943345|NCT02949817|Active Comparator|Conventional OT group (control group)|conventional training group (control group)
2943346|NCT02949804||Smoker|Vasovagal tendency will be compared among smokers and non smokers
2943347|NCT02949804||Non-smokers|Vasovagal tendency will be compared among smokers and non smokers
2943348|NCT02949791|Active Comparator|Low Intra abdominal pressure HIPEC|Cytoreductive surgery and HIPEC with low intra-abdominal pressure
2943349|NCT02949791|Experimental|High Intra abdominal pressure HIPEC|Cytoreductive surgery and HIPEC with high intra-abdominal pressure
2943350|NCT02949778|Active Comparator|Ropivacaine 3.75mg/mL|QL-block using 20 mL ropivacaine 3.75mg/mL
2943351|NCT02949778|Placebo Comparator|Sodium chloride 9 mg/mL|QL-block using 20 mL sterile sodium chloride 9 mg/mL
2943352|NCT02949765|Active Comparator|Iron sulfate 105 mg|Iron sulfate 105 mg: 1 pill/day is administered
2943353|NCT02949765|Experimental|Iron-rich diet|Iron-rich diet recommendations are given
2943354|NCT02949752|Experimental|Aripiprazole Adjunct|Aripiprazole 5 mg as a fixed dose as adjunct to other antipsychotics
2943355|NCT02949739|Active Comparator|Intensive lifestyle modification|"the investigators will recruit 3,600 South Asian men and women aged 40-70 years with i. central obesity (waist≥100 cm) and/or ii. prediabetes (HbA1c 6.0-6.4%) to the study (Index cases). Recruitment will be from the Indian subcontinent (India, Pakistan, Sri Lanka) and Europe (UK). Index cases will receive either i. intensive lifestyle modification (N=1,800); or ii. usual care (N=1,800).~Intensive lifestyle modification follows clinically accepted, evidence based strategies to achieve >7% reduction in weight through improved diet and increased physical activity, and is delivered as 9 face-face and 13 telephone contact sessions over 12 months.~Index cases will be followed for three years to identify new-onset T2D."
2943356|NCT02949739|No Intervention|Usual Care|"The investigators will recruit 3,600 South Asian men and women aged 40-70 years with i. central obesity (waist≥100 cm) and/or ii. prediabetes (HbA1c 6.0-6.4%) to the study.~Recruitment will be from the Indian subcontinent (India, Pakistan, Sri Lanka) and Europe (UK). Index cases will receive either i. intensive lifestyle modification (N=1,800); or ii. usual care (N=1,800).~Usual care group will comprise one diabetes prevention session and written material."
2943357|NCT02949726|Other|Cancer-treated patients receiving NIRFLI|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
2943358|NCT02949713|Experimental|Text messaging-motivational interviewing|Participants will register their phone numbers into an automated SMS software (provided by WelTel.org). Every Monday morning, a text message (SMS) will be sent to participants in the intervention group encouraging participants to continue breastfeeding, and inquire if participants have any problems breastfeeding their infants. Participants will be asked to respond within 48 hours, indicating that they either do not have a problem or they have a problem and require help. In addition to text messaging, participants will have motivational interviews post-delivery at weeks 2, 6, 10, 14, and 24. Motivational interviews will explore and support the participant's commitment to continue breastfeeding.
2943359|NCT02949713|No Intervention|Usual standard of care|Usual standard of care
2943360|NCT02949700|Experimental|Single arm, treatment|"Patients in the Phase I trial will be assigned to a single arm, experimental treatment which will test dose escalation for metformin in the context of chemo-radiation, with toxicity as the primary outcome.~Patients in the Phase II trial will be assigned to a single arm, experimental treatment consisting of metformin plus chemo-radiation."
2943361|NCT02949687|Experimental|ileal interposition sleeve sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
2943362|NCT02949674|Active Comparator|Bupivacaine|It will be used bupivacaine in surgical site prior surgery (25 mg). At least 10 minutes before skin incision.
2943363|NCT02949674|Active Comparator|Ropivacaine|It will be used ropivacaine in surgical site prior surgery (37.5 mg). At least 10 minutes before skin incision.
2943364|NCT02949661|Experimental|Superficial cervical plexus block|Patients will receive bilateral superficial cervical plexus block using levobupivacaine
2943365|NCT02949661|Active Comparator|Local wound infiltration|Patients will receive local wound infiltration with levobupivacaine after the conclusion of surgery
2943366|NCT02949648||Electronic cigarette ever user|Youth Quitline callers who reported ever use of e-cigarette at baseline.
2943367|NCT02949648||Electronic cigarette never user|Youth Quitline callers who reported never use of e-cigarette at baseline.
2943368|NCT02949622|Experimental|Multimodal intervention program|The intervention program will be in group format, with a size of 10 to 12 patients per group and with an extension of 12 sessions. The treatment program will feature sessions with psychoeducation of metabolic syndrome and treatment model, problem solving, stress management, anger management, social skills, self-efficacy and social support.
2943369|NCT02949622|Active Comparator|Lifestyle counseling|The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
2943370|NCT02949609|Experimental|Mirror Therapy (MT)|Standard therapy + 30 min/day of mirror therapy, 5 days/week, for 4 weeks, administered by experienced physical and occupational therapists.
2943371|NCT02949609|Active Comparator|Control Therapy (CT)|Standard therapy + 30 min/day of CT.
2943372|NCT02949583|Experimental|Punica granatum Linn.|The childrens used the mouthwash contain pomegranate 6,25% twice daily for 14 days.
2943373|NCT02949583|Active Comparator|chlorhexidine|The childrens used the mouthwash contain chlorhexidine 0.12% twice daily for 14 days.
2943374|NCT02949570|Experimental|Treatment|
2943375|NCT02949557|Active Comparator|Decortication +DFDBA|After phase 1 therapy patients were assigned for decortication+ DFDBA group. Mucoperiosteal flaps were reflected. After open flap debridement, decortication was performed and DFDBA graft was placed in the treatment of intrabony defects.
2943376|NCT02949557|Active Comparator|Decortication+ Xenograft (Cerabone)TM|After phase 1 therapy patients were assigned for decortication+ xenograft (Cerabone)TM group. Mucoperiosteal flaps were reflected. After open flap debridement, decortication was performed and DFDBA graft was placed in the treatment of intrabony defects.
2943377|NCT02949544|Other|water immersion|patients with heart failure will be immersed to the neck for 15 minutes
2943378|NCT02949531|Active Comparator|21% oxygen|room air will be delivered via Venturi mask during cycle ergometry
2943379|NCT02949531|Active Comparator|28% oxygen|28% oxygen will be delivered via Venturi mask during cycle ergometry
2943380|NCT02949531|Active Comparator|40% oxygen|40% oxygen will be delivered via Venturi mask during cycle ergometry
2943381|NCT02949518|Experimental|ERAS for Spine Pathway|
2943382|NCT02949518|No Intervention|Usual Care|
2943383|NCT02949505|Experimental|Intervention arm|12-week home prehabilitation program
2943384|NCT02949492|Experimental|IL-2 arm|Liver recipients <50 years old and 2-6 years after transplantation will receive IL-2 and gradually discontinue their immunosuppressive medication
2943385|NCT02949479|Other|Dissociation Investigation in Sex Offenders|The study will be proposed to the subjects after their usual clinical evaluation in the center for sexual offence, and to extend this evaluation by a specific focus on childhood abuse and neglect, trauma and dissociative history
2943386|NCT02949466|Experimental|triamcinolone and hyaluronic acid group|combined triamcinolone (Triamcinolone 10 mg 1cc) and hyaluronic acid (2 cc) injections: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined triamcinolone and hyaluronic acid injections to hyaluronic acid injections
2943387|NCT02949466|Active Comparator|hyaluronic acid group|hyaluronic acid (2cc) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined triamcinolone and hyaluronic acid injections to hyaluronic acid injections
2943388|NCT02949453|Experimental|patients after suicidal episode|Patients receiving a telephone-delivered intervention after deliberate self-harm (DSH)
2943389|NCT02949440|Experimental|the caudal-to-cranial approach|Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein（SMV）and Superior mesenteric artery（SMA）and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein（SMV）. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called caudal-to-cranial approach.
2943421|NCT02949206|Experimental|Part 1: Cohort 3 (0.3 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.3 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
2944368|NCT02942706|Experimental|Cet maintenance|Cetuximab maintenance treatment following induction treatment
2943390|NCT02949440|Active Comparator|the medial-to-lateral approach|First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein（SMV）to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
2943391|NCT02949414|Experimental|Tracheal Replacement|Each patient will receive surgery to implant the cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells and all follow-up procedures.
2943392|NCT02949388|Placebo Comparator|Placebo|Placebo Comparator: Placebo daily Two (2) placebo capsules given twice daily (AM and PM) for 84 (± 2 days
2943393|NCT02949388|Active Comparator|300 mg (150 mg BID)|Active Comparator: 300 mg of Prurisol daily One (1) capsule containing 100 mg Prurisol and one (1) capsule containing 50 mg of Prurisol given twice (AM and PM) for 84 (± 2) days
2943394|NCT02949388|Active Comparator|400 mg (200 mg BID)|Active Comparator: 400 mg of Prurisol daily Two (2) capsule each containing 100 mg Prurisol given twice daily (AM and PM) for 84 (± 2) days
2943395|NCT02949375|Placebo Comparator|Placebo Arm|Gel capsule containing Placebo to be taken once per day
2943396|NCT02949375|Active Comparator|4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken once per day
2943397|NCT02949375|Active Comparator|6mg GRI-0621|6mg GRI-0621 gel capsule to be taken once per day
2943398|NCT02949362|Experimental|Standard of Care (SOC) Treatment +/- Teduglutide|TED 0.05mg/kg subcutaneous injections once daily as needed in addition to SOC treatment
2943399|NCT02949349|Experimental|MMF 500mg|Mycophenolate mofetil 500mg, PO BID
2943400|NCT02949349|Experimental|MMF 750mg|Mycophenolate mofetil 750mg, PO BID
2943401|NCT02949349|Active Comparator|AZA|Azathioprine 1mg/kg, PO BID
2943402|NCT02949336||Group 1: Traditional UKA|Patients with a traditional Medial Unicompartmental Knee Arthroplasty, SIGMA® High Performance Partial Knee System (functional ACL and tibial posterior slope matching the native bone) will undergo observational use of fluoroscopy to analyze joint kinematics
2943403|NCT02949336||Group 2: ACL deficient UKA|Patients with the same medial UKA implant (SIGMA® High Performance Partial Knee System) in an ACL deficient knee, where the UKA was implanted at a 50% reduced tibial posterior slope relative to the native knee will undergo observational use of fluoroscopy to analyze joint kinematics.
2943404|NCT02949323||children with urinary stones|children with urinary stones
2943405|NCT02949323||children without urinary stones|children without urinary stones
2943406|NCT02949310|Placebo Comparator|Control|Placebo use instead of nefopam
2943407|NCT02949310|Experimental|Nefopam|Intraoperative use of nefopam 40 mg
2943408|NCT02949297|Other|Ovation Alto Abdominal Stent Graft System|Endovascular repair of AAA using the Ovation Alto Abdominal Stent Graft System.
2943409|NCT02949284|Experimental|Arm I (androgen receptor ARN-509, radical prostatectomy)|Patients receive androgen receptor antagonist ARN-509 PO daily for 3 months. Patients then undergo radical prostatectomy.
2943410|NCT02949284|Active Comparator|Arm II (ARN-509, abiraterone acetate, GnRH, prednisone, RP)|Patients receive GnRH agonist SC on day 1, androgen receptor antagonist ARN-509 PO daily PO for 4 times, abiraterone acetate PO daily for 4 times, and prednisone PO daily for 3 months. Patients then undergo radical prostatectomy.
2943411|NCT02949284|Active Comparator|Arm III (radical prostatectomy)|Patients undergo radical prostatectomy.
2943412|NCT02949271|Active Comparator|Programmed Intermittent Epidural Bolus|Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive either 6 mL every 45 minutes in the PIEB arm (first bolus 30 minutes after epidural initiation). All study participants will be provided with PCEA set to 8mL boluses with a 10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
2943413|NCT02949271|Active Comparator|Continuous Epidural Infusion|Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive 8mL/hr of continuous infusion beginning immediately after the loading dose for the maintenance of analgesia in the CEI arm. All study participants will be provided with PCEA set to 8mL boluses with a10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
2943414|NCT02949258|Experimental|SEEOX group|A three-cycle neoadjuvant chemotherapy will be performed in all cases. In every cycle, oxaliplatin 150 mg, etoposide 100 mg and epirubicin 50 mg will be administered from the celiac artery on day 1. Oral S-1 120 mg per day will be given for days 1-14. The second cycle will be scheduled following a 1-week rest after the first cycle.After two courses of neoadjuvant chemotherapy, patients will be reevaluated and receive curative or palliative resection or exploratory laparotomy within 14 days after completing the second course of chemotherapy.
2943415|NCT02949245||Groups/Cohorts|"Surgical treatment~This observational study is examining the outcomes of standard surgical treatments for adult spinal deformity."
2943416|NCT02949232|Experimental|Prednisolone|Prednisolone will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following treatment guidelines for Inflammatory Bowel Diseases (2008).
2943417|NCT02949232|Placebo Comparator|Placebo Oral Tablet|Placebo will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following the treatment schedule of the experimental arm
2943418|NCT02949219|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2943419|NCT02949206|Experimental|Part 1: Cohort 1 (0.03 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.03 milligram per kilogram (mg/kg) intravenous (IV) dose of JNJ-64179375 or matching placebo on Day 1.
2943420|NCT02949206|Experimental|Part 1: Cohort 2 (0.1 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.1 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
2943422|NCT02949206|Experimental|Part 1: Cohort 4 (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 1.0 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
2943423|NCT02949206|Experimental|Part 1: Cohort 5 (2.5 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 2.5 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
2943424|NCT02949206|Experimental|Part 1: Cohort 6 (5.0 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 5.0 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
2943425|NCT02949206|Experimental|Part 1: Cohort 7 (Escalation Dose of JNJ-64179375 or Placebo)|Dose escalation will proceed until the toxicology study exposure limits or a highest tolerable dose will be reached.
2943426|NCT02949206|Experimental|Part 1: Cohort 8 (Escalation Dose of JNJ-64179375 or Placebo)|Dose escalation will proceed until the toxicology study exposure limits or a highest tolerable dose will be reached.
2943427|NCT02949206|Experimental|Part 2: Reversal Cohort :(50 IU/kg of 4-factor PCC)|Participants will receive a 2.5 mg/kg of JNJ-64179375 or highest tolerable dose if lower than 2.5 mg/kg followed by administration of a single IV 50 International Unit per kilogram (IU/Kg) dose of a 4 factor prothrombin complex concentrate (PCC) or matching placebo on Day 1.
2943428|NCT02949206|Experimental|Part 3: Subcutaneous Cohort (1.0 mg/kg of JNJ-64179375)|Participants will receive a Single Subcutaneous (SC) dose of 1.0 mg.kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375 or matching placebo on Day 1.
2943429|NCT02949193|Experimental|evogliptin|evogliptin 5mg qd add-on to metformin
2943430|NCT02949193|Active Comparator|sitagliptin|sitagliptin 100mg qd add-on to metformin
2943431|NCT02949180||AF|Five minutes puls wave recording will be performed in patients in atrial fibrillation at time of recruitment
2943432|NCT02949180||SR|Five minutes puls wave recording will be performed in patients in sinus rhythm at time of recruitment
2943433|NCT02949167|Experimental|MyHealth intervention arm|Nurse-led follow-up
2943434|NCT02949167|No Intervention|MyHealth Control condition|Physician-led follow-up
2943435|NCT02949154||Metastatic melanoma patients|All patients >18 years with histologically proven metastatic melanoma (American Joint Committee on Cancer [AJCC] stage IV melanoma) treated in the UMCG between May 2014 and December 2015.
2943436|NCT02949141|Experimental|Ultrasound|All patients will initially get an ultrasound (interpreted by emergency department physician) followed by chest x-ray (read by independent radiologist) and computed tomography (read by radiologist)
2943437|NCT02949128|Experimental|ALXN1210|ALXN1210
2943438|NCT02949115|Experimental|70 mL red beetroot juice|70 mL red beetroot juice naturally containing 300 mg nitrate.
2943439|NCT02949115|Active Comparator|70 mL placebo drink plus potassium nitrate|70 mL calorie-matched placebo control drink containing 489 mg potassium nitrate to deliver 300 mg nitrate.
2943440|NCT02949115|Active Comparator|70 mL red beetroot juice without nitrate|70 mL red beetroot juice per day without nitrate.
2943441|NCT02949115|Placebo Comparator|70 mL placebo drink|70 mL calorie-matched placebo control drink devoid of nitrate, vitamins, minerals, and polyphenols.
2943442|NCT02949102|Experimental|Crave Crush|Crave Crush is a plant-based tablet that alters taste perception by affecting sweet taste receptors on the tongue.
2943443|NCT02949102|Placebo Comparator|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
2943444|NCT02949089|Experimental|ACH04|Dosage: 1 capsule, PO, 24/24h for 10 days.
2943445|NCT02949076|Experimental|Exercise|Lung cancer patients will undergo unilateral resistance exercise 3 times per week for 8 weeks during cancer treatment, while the other leg remains unexercised and will serve as a within-subject control.
2943446|NCT02949050|Experimental|Treatment Group|the treatment -patients underwent SCIT and antihistamine/nasal steroid/use.
2943447|NCT02949050|No Intervention|Control Group|Control patient group only used antihistamines/nasal steroids but no SCIT
2943448|NCT02949037|Experimental|Intervention|Use of (4) bluetooth-enabled biomedical devices (i.e. scale, blood pressure cuff, activity monitor, glucose monitor), for use in self care activities, integrated with the mobile health care environment (MHCE) system. The MHCE system will provide tailored behavioral messages triggered by clinical values and survey responses.
2943449|NCT02949037|No Intervention|Control|Use of (4) bluetooth-enabled biomedical devices (i.e. scale, blood pressure cuff, activity monitor, glucose monitor), for use in self care activities, NOT integrated with the mobile health care environment (MHCE) system.
2943450|NCT02949024|Experimental|TX Naïve Arm|Treatment in the TX Naive arm will consist of one unilateral injection of IVT aflibercept in combination with one unilateral injection of SC CLS-TA in the same eye.
2943451|NCT02949024|Experimental|Previous TX Arm|Treatment in the Previous TX arm of the study will consist of one unilateral injection of SC CLS-TA.
2943452|NCT02949011|Experimental|Baloxavir Marboxil|Participants aged ≥ 12 years will receive two or four 20-mg S 033188 tablets orally on Day 1 and one oseltamivir placebo capsule orally twice a day (BID) on Days 1 to 5.
2943453|NCT02949011|Active Comparator|Oseltamivir|Participants aged ≥ 12 years will receive 75 mg oseltamivir twice a day on Days 1 to 5 and two or four S 033188 placebo tablets on Day 1.
2943454|NCT02949011|Placebo Comparator|Placebo|Participants aged ≥ 12 years will receive two or four S 033188 placebo tablets on Day 1 and one oseltamivir placebo capsule orally twice a day on Days 1 to 5.
2943455|NCT02948998|No Intervention|control|The participants in control group do not take spironolactone.
2943456|NCT02948998|Experimental|spironolactone|The participants in spironolactone group take 10-20mg spironolactone orally and daily.
2943457|NCT02948985||RAS and B-raf wild type mCRC|patients with histologically confirmed RAS and B-raf wild type mCRC treated with FOLFIRI±cetuximab
2943458|NCT02948972|Experimental|complete surgery|Prior surgery 3 months before IVF followup 1, 6 12 and 24 month after surgery
2943459|NCT02948972|Active Comparator|In vitro fertilization without surgery|IVF without endometriosis surgery follow up 6, 12 and 24 month after inclusion.
2943460|NCT02948959|Experimental|Dupilumab|Doses of dupilumab will be administered every 2 weeks added to current controller medications
2943461|NCT02948959|Placebo Comparator|Placebo|Placebo (for dupilumab) will be administered every 2 weeks added to current controller medications
2943555|NCT02948192||Preterm Delivery|African american women who present for prenatal care who experience spontaneous preterm birth
2943462|NCT02948946||Neuroendocrine Tumor (NET) Cohort|Participants with histologically or cytologically proven diagnosis of any grade, any stage NET of gastroenteropancreatic (GEP) or lung origin; In the first stage of the study (initial 50 patients) only potential participants with stage IV, well-differentiated tumors (G1/G2) will be enrolled.
2943463|NCT02948946||Non-NET Cohort|Participants with histologically or cytologically proven diagnosis of any grade, any stage gastrointestinal (GI) malignancies.
2943464|NCT02948920|Experimental|Ephedrine|Intravenous 9 mg of ephedrine (3 ml) given at finishing local anesthetic administration for spinal anesthesia
2943465|NCT02948920|Placebo Comparator|NSS|Intravenous normal saline 3 ml given at finishing local anesthetic administration for spinal anesthesia
2943466|NCT02948907|Other|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes, endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological results obtained by EBUS-TBNA."
2943467|NCT02948894|Experimental|MAD|Mandibular advancement device. A dentist, who is otherwise not involved in HF care, will open a sealed envelope at the time of randomization and program the MAD device accordingly. Each mode will be maintained for 3 months
2943468|NCT02948894|Placebo Comparator|Sham-MAD|Mandibular advancement device (non-advanced device). A dentist, who is otherwise not involved in HF care, will open a sealed envelope at the time of randomization and program the MAD device accordingly. Each mode will be maintained for 3 months
2943469|NCT02948868|Experimental|Pilot|Contingency Management
2943470|NCT02948855||Tm group|Simple thymoma group：The patients have suffered thymoma only and have no other complications.
2943471|NCT02948855||Tm+MG group|Thymoma complicated with myasthenia gravis (MG) group: The patients have suffered thymoma and myasthenia gravis in the mean time.
2943472|NCT02948855||Tm+MG+AD group|"Thymoma complicated with myasthenia gravis and other autoimmune diseases (AD) group:~The patients have suffered thymoma, myasthenia gravis and other autoimmune diseases in the mean time."
2943473|NCT02948842|Experimental|Clostridium histolyticum collagenase|After (5-10 minutes) Urojet instillation for local anesthesia (20 mL of 2% lidocaine jelly), the patient will undergo cystoscopy, transurethral injection (via a 5 Fr flexible cystoscopic needle manufactured by Laborie, Ontario, Canada) of XIAFLEX® (0.25 mL of reconstituted XIAFLEX® that contains 0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.25 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture. The remaining 0.25 mL that remains in the injection syringe will be discarded per institutional policy for biohazard disposal.
2943474|NCT02948829|Experimental|Tetravalent Dengue Vaccine Candidate|Tetravalent Dengue Vaccine Candidate (TDV) 0.5 mL, subcutaneous injection on Day 1 and Day 90.
2943475|NCT02948816|Experimental|Facebook|Participants will spend 30 minutes interacting with a Facebook page that is made up of 20% food-related posts, and 80% non food-related posts (news, sports, etc). They will be provided with bowls of snacks, which will be weighed before and after their session.
2943476|NCT02948816|Experimental|Facebook + Food|Participants will spend 30 minutes interacting with a Facebook page that is made up of 70% food-related posts, and 30% non food-related posts (news, sports, etc). They will be provided with bowls of snacks, which will be weighed before and after their session.
2943477|NCT02948816|Active Comparator|Colouring|Participants will spend 30 minutes colouring. They will be provided with bowls of snacks, which will be weighed before and after their session.
2943478|NCT02948803|Experimental|Intervention group|smartphone based intervention with Active Coach app: participants in the intervention group will use a newly developed smartphone app in combination with a Fitbit Charge activity tracker for 9 weeks. The app aims to promote an active lifestyle.
2943479|NCT02948803|No Intervention|control group|participants in the control groups only receive a flyer with standard information about an active lifestyle
2943480|NCT02948790|Experimental|Neuristim|Electrical stimulation with the Neuristim and auditory nerve electrical response measurements (wave V).
2943481|NCT02948790|Active Comparator|Digisonic SP EVO cochlear implant|Electrical stimulation with the patient's cochlear implant and auditory nerve electrical response measurements (wave V).
2943482|NCT02948777|Experimental|Evolocumab|Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks
2943483|NCT02948764|Other|single-arm study|This project is designed as a one-armed diagnostic study. Every patient included in the study will undergo the same diagnostic test, the vacuum-assisted biopsy, after NACT and before surgery according to guidelines.
2943484|NCT02948738|Experimental|Interactive Education|Interactive asthma education
2943485|NCT02948738|Active Comparator|Standard Education|Standard asthma education
2943486|NCT02948725|Experimental|cross-education + standard rehabilitation|The cross-education group will engage in strength training of the non-paretic hand in addition to standard rehabilitation. Cross-education will be progressive in nature, beginning with 2 sets of 8 repetitions and increasing up to a maximum of 6 sets of 8 repetitions of maximal voluntary effort isometric handgrip contractions as tolerated. Grip training will be performed using standard grip trainers (Digi-Flex Grip trainers) to train both finger flexors and full hand and wrist isometric contractions. In addition, patients will perform controlled dynamic wrist flexion and extension training of the non-paretic hand using exercise tubing with the same prescription. Patients will be asked to complete exercises 3 times per week for 26 weeks, and to record adherence in a training log. An average of one session per week will be considered 'trained'.
2943487|NCT02948725|No Intervention|standard rehabilitation|Standardized rehabilitation involves several strategies tailored to the patient and remains somewhat based on clinician preference. These therapies may involve functional electrical stimulation, neuro-facilitation, strengthening, range of motion (ROM), mirror therapy, and force-use therapy (e.g., CIMT). Patients engage in therapy 5 days per week as inpatients, and 2 days per week as outpatients with additional home exercises. Specific therapies for each patient will be tracked using a therapy log.
2943488|NCT02948712|Experimental|Survivor Distress|This intervention will use the NCCN Distress Screening Thermometer to score each participant on their level of distress. Depending on the score the intervention will be tailored to the participant based on the Overview of Evaluation and Treatment Schema DIS-4 per the NCCN Distress Guidelines V1.0, 2016.
2943489|NCT02948699|Experimental|Nutrition support|Nutrison was added to regular diet while the patients can be fed through mouth. Nutrison will replace regular diet by NG or PEG while the patients can not eat for serious oral mucositis.
2943490|NCT02948699|No Intervention|Regular diet|Regular diet without other nutritional intervention.
2943491|NCT02948686|Active Comparator|SET (Self-Etching)|55 teeth will receive restorations using Self-Etching Application Strategy
2943492|NCT02948686|Experimental|SEE (Selective Enamel Etching)|55 teeth will receive restorations using Enamel Etching Application Strategy
2943493|NCT02948686|Experimental|SETT (Self-Etching, more time)|55 teeth will receive restorations using Self Etching with Extended time Application Strategy
2943494|NCT02948686|Experimental|SETL (Self-Etching, more layers)|55 teeth will receive restorations using Self Etching with Extended layers number Strategy
2943495|NCT02948673|Placebo Comparator|Control|4 placebo tablets/day (2 in the morning and 2 in the evening)
2943496|NCT02948673|Active Comparator|Glutathione|4 oral GSH tablets/day (2 in the morning and 2 in the evening)
2943497|NCT02948660|Other|acute consciousness disorders group|"Duration time of coma <= 3 weeks.~This group will receive sleep EEG monitoring, serum melatonin and orexin level testing, and Zolpidem Tartrate Tablets or melatonin treatment."
2943498|NCT02948660|Other|chronic consciousness disorders group|"Duration time of coma > 3 weeks.~This group received sleep EEG monitoring, serum melatonin and orexin testing, and Zolpidem Tartrate Tablets or melatonin treatment."
2943499|NCT02948647|No Intervention|Control Group|Will receive standard of care, which is general dietary advice
2943500|NCT02948647|Experimental|Intervention Group|Will receive standard of care as well as sugar-reduction education
2943501|NCT02948634|Sham Comparator|Sham Phoenix Laser Treatment|Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy.
2943502|NCT02948634|Active Comparator|Active Phoenix Laser Treatment|Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Participants in the laser treatment group will be treated at 42 watts for up to 60 seconds at tender spots in the spine or extremities. Total treatment time is not to exceed 30 minutes.
2943503|NCT02948621||Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.
2943504|NCT02948595|Experimental|Video feedback then verbal feedback|Video feedback followed by structured verbal feedback
2943505|NCT02948595|Experimental|Verbal feedback then video feedback|Structured verbal feedback followed by video feedback
2943506|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution12.5μg|Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
2943507|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 50μg|Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
2943508|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 100μg|Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
2943509|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 200μg|Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
2943510|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 400μg|Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
2943511|NCT02948582|Placebo Comparator|Placebo 0.5mL|Placebo 0.5mL via e-flow nebulizer, once daily
2943512|NCT02948569|Experimental|3-V Bioscience-2640|Subjects will take a singly daily dose of 3-V Bioscience-2640 before bedtime or 22:30, whichever comes first, for 10 days.
2943513|NCT02948556||Chronic fatigue syndrome|Participants with chronic fatigue syndrome
2943514|NCT02948543|Experimental|Treatment (Arm B):Intravesical BCG + MMC|"Induction (weekly x 9); and followed by Maintenance (monthly x 9) beginning 3 months after randomisation.~Dosage of Bacillus of Calmette-Guerin (BCG) dependent on preferred brand of BCG by participating institution. Either 2-8 x 10^8 CFU for OncoTICE or, 81mg for ImmuCYST and TheraCys. Prior to treatment commencement, investigators should nominate which BCG brand will be used. The same brand of BCG must be used for all treatment administered to an individual participant throughout the study.~Dosage of Mitomycin (MMC) fixed at 40mg per instillation."
2943515|NCT02948543|Other|Treatment (Arm A): Intravesical BCG|"Induction (weekly x 6); and followed by Maintenance (monthly x 10) beginning 3 months after randomisation.~Dosage of Bacillus of Calmette-Guerin (BCG) dependent on preferred brand of BCG by participating institution. Either 2-8 x 10^8 CFU for OncoTICE or, 81mg for ImmuCYST and TheraCys. Prior to treatment commencement, investigators should nominate which BCG brand will be used. The same brand of BCG must be used for all treatment administered to an individual participant throughout the study."
2943516|NCT02948517|Experimental|Time restricted feeding|Time restricted feeding
2943517|NCT02948517|No Intervention|Control|No intervention
2943518|NCT02948504||Observation|Aneurysms are left untreated based on patients and family's wishes. These patients will be included in the observation group.
2943519|NCT02948504||Coiling or Clipping|Patients are included in the coiling group if they undergo endovascular coiling, such as single coiling, stent-assisted coiling and balloon-assisted coiling. Or Patients are included in the clipping group if they undergo surgical coiling, such as aneurysm neck clipping, aneurysm isolation or trapping.
2943520|NCT02948491|Experimental|Music therapy|First. Recording of the voice of the mother singing the song to the child. (To choose this option, the song must be sung to the child during pregnancy at least 2 to 3 times per week. Second. The mother's favorite song, obtained externally. (To choose this option, the mother must bring the song that she that she listened to frequently, at least 5 times per week). Third. Pre-determined lullaby. (This option refers only to the lullaby melody or Brahms lullaby, edited to obtain stable volumes and normalization of the audio, with the effect of progressively appearing and fading for the first and last 10 seconds of the intervention with music therapy, so there are no drastic acoustic changes in the intervention. Audacity editing software will be used.)
2943556|NCT02948192||Term delivery|African american women who present for prenatal care who experience term birth
2943521|NCT02948491|No Intervention|Without sound emission|"The infant does not receive any sound emission because the baffle will be turned off.~One of the three intervention options are chosen. The parents are told that their child may be randomly assigned to either the therapeutic or control group."
2943522|NCT02948478||Precarious patients|Precarious patients - exposed - will be those identified as precarious by at least one of the three scores (EPICES, Pascal, European Deprivation Index)
2943523|NCT02948478||Non precarious patients|Non precarious patient - non exposed - will be all the patients identified as non-precarious by the three scores (EPICES, Pascal, European Deprivation Index)
2943524|NCT02948452||Anorexia|fMRI: reward task, anxiety provocation
2943525|NCT02948452||Mild anxiety comparison group|fMRI: reward task, anxiety provocation
2943526|NCT02948439|Experimental|Exercise Intervention|The aerobic exercise intervention will consist of a walking program at 50-70% of individual heart rate reserve. This will begin at 16-20 weeks gestation and continue 3-4 times per week until the end of the study (34-36 weeks). The duration of exercise will increase each week up to a maximum of 40 minutes (5 min warm up, 25 minutes exercise, 5 min cool down). Women will have at least one supervised exercise session per week. The investigators will also monitor other activity using questionnaires and accelerometry. This will occur at baseline (16-20 weeks), mid-intervention (24-26 weeks) and at the end (34-36 weeks).
2943527|NCT02948439|No Intervention|Control Group|These women will continue regular daily activities. Activity will be monitored periodically with questionnaires and accelerometry. This will occur at baseline (16-20 weeks), mid-intervention (24-26 weeks) and at the end (34-36 weeks).
2943528|NCT02948426|Experimental|ES1 Phase 1 Dose Escalation Arm|The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design.
2943529|NCT02948426|Experimental|EX1 Dose Expansion Arm|10 additional patients will be treated at the MTD
2943530|NCT02948400|Experimental|Google Cardboard virtual environment|pedestrian safety training using the Google Cardboard device and delivery of a pedestrian virtual environment by mobile smartphone. Note that children in this arm will be trained using an immersive virtual environment delivered by smartphone, which is different from the other arm that is trained using a semi-immersive virtual environment delivered in a kiosk. The intervention is pedestrian safety training for both arms.
2943531|NCT02948400|Active Comparator|semi-immersive virtual environment|pedestrian safety training using a semi-immersive virtual pedestrian environment kiosk. Note that children in this arm will be trained using a semi-immersive virtual environment delivered in a kiosk, which is different from the other arm that is trained using an immersive virtual environment delivered by smartphone. The intervention is pedestrian safety training for both arms.
2943532|NCT02948374||Delirium positive|Patients with a positive CAM-ICU test
2943533|NCT02948374||Delirium negative|Patient without delirium determined with the CAM-ICU test
2943534|NCT02948361|Experimental|QT Ultrasound breast scan|
2943535|NCT02948348|Experimental|Nivolumab|chemoradiotherapy with capecitabine+ Nivolumab + surgical therapy
2943536|NCT02948322|Experimental|OGTT, CMRI with gadolinium in patients|Patients with acromegaly will be investigated
2943537|NCT02948322|Active Comparator|OGTT, CMRI with gadolinium in volunteers|Age-, sex- and BMI-matched healthy volunteers will be investigated
2943538|NCT02948309|Experimental|Mistletoe extract (Iscador Qu)|Fermented aqueous extract of Viscum album ssp album (L.) (mistletoe) = Iscador Qu, subcutaneous use 3 injections/week; dose escalation from 0,01mg - 20mg
2943539|NCT02948309|Placebo Comparator|Placebo|isotonic saline solution, subcutaneous use 3 injections/week
2943540|NCT02948296|Experimental|medial prefrontal cortex stimulation|Participants will receive a single session of medial prefrontal cortex stimulation using continuous theta burst stimulation
2943541|NCT02948296|Experimental|dorsolateral prefrontal cortex stimulation|Participants will receive a single session of dorsolateral prefrontal cortex stimulation using 10 Hz stimulation
2943542|NCT02948296|Sham Comparator|sham|Participants will receive a single session of sham stimulation to the medial prefrontal cortex or dorsolateral prefrontal cortex
2943543|NCT02948283|Experimental|Treatment (metformin hydrochloride, ritonavir)|"SINGLE AGENT STAGE : Patients receive metformin hydrochloride PO BID on days 1-7 in the absence of disease progression or unacceptable toxicity.~COMBINATION REGIMEN STAGE: Patients receive metformin hydrochloride PO BID and ritonavir orally PO BID on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2943544|NCT02948270||Adolescents with ADHD|Adolescents who met diagnostic criteria in previous clinical/research assessment are invited to come back to SickKids to participate (ages 13-17)
2943545|NCT02948270||Adolescents without ADHD|Adolescent controls (ages 13-17) are tested through local high schools
2943546|NCT02948244|Active Comparator|Group A - Active/Placebo|Participants will receive 3 months of creatine monohydrate followed by a 6 week washout period followed by 3 months of placebo.
2943547|NCT02948244|Active Comparator|Group B - Placebo/Active|Participants will receive 3 months of placebo followed by a 6 week washout period followed by 3 months of creatine monohydrate.
2943548|NCT02948231|Experimental|Mistral|
2943549|NCT02948218|Active Comparator|Shanghai Longhua hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
2943550|NCT02948218|Active Comparator|Shanghai Guanghua hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
2943551|NCT02948218|Active Comparator|Huadong hospital of Fudan University|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
2943552|NCT02948218|Active Comparator|Shanghai Yueyang Integrated hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
2943553|NCT02948205|Experimental|3D group|infertility patient get TU-LESS by 3D Laparoscopy
2943554|NCT02948205|Other|normal group|infertility patient get normal laparoscopic surgery
2943557|NCT02948179|Experimental|Preimplantation genetic diagnosis group|ADPKD patients will complete the whole process of preimplantation genetic diagnosis with healthy baby without pathogenic gene inheritance.
2943558|NCT02948179|No Intervention|Natural pregnancy group|ADPKD patients, pathogenic mutations in PKD1, have natural pregnancy without preimplantation genetic diagnosis. The investigators will do umbilical cord blood gene detection for the baby.
2943559|NCT02948166|Active Comparator|Stenting of the femoral artery|A standard endovascular treatment of the steno-occlusive lesion in femoro-popliteal arterial segment.
2943560|NCT02948166|Experimental|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomnyh wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial bed is performed intraoperatively by X-ray angiography.
2943561|NCT02948153||asthma with bronchial hypersecretion|In a clinical study, participants are often divided into groups. Group one: they were defined as those who expectorated daily for at least three months for a minimum period of two consecutive years, without attribution to any other cause or disease.
2943562|NCT02948153||asthma without hypersecretion|In a clinical study, participants are often divided into groups. Group two: We defined asthma as a history of variable respiratory symptoms and evidence of variable expiratory airflow limitation.
2943563|NCT02948140|Experimental|Stroke|
2943564|NCT02948127|Experimental|RSV LID cp ΔM2-2 Vaccine|Participants will receive a single dose of the RSV LID cp ΔM2-2 vaccine at study entry (Day 0).
2943565|NCT02948127|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
2943566|NCT02948114|Active Comparator|Control: Cow milk-based infant formula|Cow milk-based infant formula
2943567|NCT02948114|Experimental|Experimental 1: Cow milk-based infant formula|Cow milk-based infant formula with prebiotics
2943568|NCT02948114|Experimental|Experimental 2: Cow milk-based infant formula|Cow milk-based infant formula with probiotics
2943569|NCT02948114|Experimental|Experimental 3: Cow milk-based infant formula|Cow milk-based infant formula with prebiotics and probiotics
2943570|NCT02948114|No Intervention|Human Milk Reference|Human Milk Reference
2943571|NCT02948101|Experimental|PD 0360324 + Cyclophosphamide|"Cycle 1 is 42 days. Cycles 2 and beyond are 28 days.~Participants receive PD 0360324 by vein over about 30 minutes on Days 1, 8, 15, and 22 of Cycle 1. Participants only receive 4 doses.~Starting at Cycle 2, participants take 1 Cyclophosphamide capsule by mouth at the same time every day in the morning."
2943572|NCT02948075|Experimental|Quisinostat 12 mg & Paclitaxel & Carboplatin|One 3-weeks course includes 6 doses of Quisinostat 12 mg at Days 1, 3, 5, 7, 9 and 11 and Paclitaxel 175 mg/m2 and Carboplatin (mg/ml x min) x [GFR (ml/min) + 25] on Day 7 up to 6 cycles.
2943573|NCT02948036|Experimental|Moodify|
2943574|NCT02948023|No Intervention|Standard Surgical therapy|Includes the control group that fulfills the inclusion criteria
2943575|NCT02948023|Active Comparator|Ex-vivo cultivated limbal stem cell pool|0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
2943576|NCT02948010|Active Comparator|Auto CPAP + comfort feature A|Auto CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
2943577|NCT02948010|Active Comparator|Auto CPAP with comfort feature B|Auto CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
2943578|NCT02948010|Active Comparator|Auto CPAP with no comfort feature|Auto CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
2943579|NCT02948010|Active Comparator|Auto CPAP with comfort feature A+B|Auto CPAP with comfort feature A+B using Fisher & Paykel Healthcare CPAP Device
2943580|NCT02948010|Active Comparator|CPAP with comfort feature A|CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
2943581|NCT02948010|Active Comparator|CPAP with comfort feature B|CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
2943582|NCT02948010|Active Comparator|CPAP with no comfort feature|CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
2943583|NCT02948010|Active Comparator|CPAP with comfort feature A + B|CPAP with comfort feature A + B using Fisher & Paykel Healthcare CPAP Device
2943584|NCT02948010|Active Comparator|CPAP at Sub therapeutic level|CPAP at Sub therapeutic level using Fisher & Paykel Healthcare CPAP Device
2943585|NCT02947997|Experimental|OFDI capsule imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
2943586|NCT02947984|Experimental|Standard Treatment|Standard radiation therapy: 55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week.
2943587|NCT02947984|Experimental|Higher Dose Treatment|63 CGE in 35 treatments of 1.8 CGE given once a day, for five days of each week.
2943588|NCT02947971|Experimental|OFDI Imaging|Experimental OFDI Imaging
2943589|NCT02947958|Experimental|Teleconsultation|Tele consultation (experimental) - after the randomization the patient is guided to seek primary care under teleconsultation supervision to keep his treatment. One year later the patient's symptoms are reassessed in a medical consultation.
2943590|NCT02947958|Active Comparator|Hospital|Hospital (control) - after the randomization the patient is guided to keep his treatment in the tertiary care as usual. One year later the patient's symptoms are reassessed in a medical consultation.
2943591|NCT02947945|Other|Open-Label|all subjects will receive the study medication- reslizumab.
2943592|NCT02947932|Experimental|Pre-ERCP group Oral resveratrol in in all patients.|Oral resveratrol was administrated within 1hour before ERCP in all patients.
2943593|NCT02947932|Active Comparator|Post-ERCP rectal Indomethacin in high-risk patients.|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
2943594|NCT02947919|Experimental|Intervention|Music in the perioperative period
2943595|NCT02947919|No Intervention|Control|Usual treatment
2943596|NCT02947906||Study group|Participants with multiple sclerosis who able to walk at least 30 meters independently.
2943597|NCT02947906||Control Group|Healthy participants
2943779|NCT02946749||the Xinhua hospital affiliated to Shanghai jiaotong University|
2943598|NCT02947893|Placebo Comparator|Group 1 (placebo)|Out of 42 total participants with mild to moderate AD (MMSE=17-24 inclusive) and their study partners that will be recruited and 1:1 randomized, 21 (twenty-one) will be assigned to group 1 and given 1 capsule of a placebo drug by mouth every day for the first 6 months followed by 2 capsules once daily for the subsequent 6 months, every time taken without a meal, for the total duration of the study for 12 months.
2943599|NCT02947893|Active Comparator|Group 2 (treated)|Out of 42 total participants with mild to moderate AD (MMSE=17-24 inclusive) and their study partners that will be recruited and 1:1 randomized, 21 (twenty-one) will be assigned to group 2 treated with 1 capsule (150mg Nilotinib) once a day by mouth for the first 6 months followed by dose escalation to 2 capsules (300mg Nilotinib) once daily by mouth for the subsequent 6 months, every time taken without a meal, for the total study duration of 12 months.
2943600|NCT02947880|Experimental|Bumetanide group|"During 3 months in the double blind, the patient will receive the experimental treatment. For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.~After the 3 months in the double blind trial (bumetanide versus placebo), all the patient will receive (in the open phase of the trial) the bumetanide during 3 months with the posology fitting with their weights."
2943601|NCT02947880|Placebo Comparator|Placebo group|"During 3 months in the double blind, the patient will receive the placebo. For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.~After the 3 months in the double blind trial (bumetanide versus placebo), all the patient will receive (in the open phase of the trial) the bumetanide during 3 months with the posology fitting with their weights."
2943602|NCT02947867|Experimental|"aganirsen low-dose:"|43µg daily, one drop of 0.86 mg/g emulsion (morning) + one drop of placebo (evening) daily
2943603|NCT02947867|Experimental|"aganirsen high-dose"|86µg daily, one drop of 0.86 mg/g emulsion twice daily (morning and evening)
2943604|NCT02947867|Placebo Comparator|aganirsen placebo (vehicle)|one drop of placebo emulsion (morning) + one drop of placebo emulsion (evening) daily
2943605|NCT02947854|Experimental|Photosensitizer and adjuvant|Run-in cohort for selection of fimaporfin starting dose in the main study. Single intradermal dosing of fimaporfin and adjuvant (Hiltonol [poly-ICLC]) followed by light application.
2943606|NCT02947854|Experimental|Photosensitizer, adjuvant and antigens|Main part: Intradermal dosing of fimaporfin, adjuvant (Hiltonol, poly-ICLC) and antigens (KLH and HPV E7) followed by light application.
2943607|NCT02947854|Experimental|Assessments of time between ID dosing and light|Optional part: Assessment of different time interval between intradermal dosing of fimaporfin, adjuvant/antigens and light application.
2943608|NCT02947841|Placebo Comparator|Placebo|In the placebo cohort, subjects will alternate their DBS parameters between group A and group B every week for 12 weeks, but they will be blinded to the fact that their group A and group B are equivalent.
2943609|NCT02947841|Active Comparator|Treatment|In the treatment cohort, subjects will alternate their DBS parameters between group A and group B every week for 12 weeks.
2943610|NCT02947828||T2D patients|600 type 2 diabetes (T2D) patients recruited from the DD2 cohort
2943611|NCT02947828||Gender- and age-matched healthy controls|100 healthy subjects
2943612|NCT02947815|Experimental|NABOTA|Single-dose
2943613|NCT02947815|Active Comparator|BOTOX|Single-dose
2943614|NCT02947802|Experimental|Consumer Support|Participants will be presented with three labels: a calorie label, a textual warning label and a textual warning label with corresponding graphic images and will be asked to rate their support for each label on a 1 (not at all) to 7 (a great deal) scale.
2943615|NCT02947802|Experimental|Consumer Support with Effectiveness Info|Participants will be presented with three labels: a calorie label, a textual warning label and a textual warning label with corresponding graphic images and will be asked to rate their support for each label on a 1 (not at all) to 7 (a great deal) scale. Participants will also receive effectiveness information- how each label influenced the purchasing of sugar sweetened beverages- from a recent field experiment.
2943616|NCT02947789||Postoperative mortality within 3 days|Group 1: Patients undergoing emergency surgery with postoperative mortality within 3 days Group 2: Patients undergoing emergency surgery without postoperative mortality within 3 days
2943617|NCT02947776|Active Comparator|USUAL|Usual care
2943618|NCT02947776|Experimental|PEER|Usual care + peer-befriending
2943619|NCT02947763|Active Comparator|multiple visit|multiple visit root canal treatment with triple antibiotic paste intracanal medication (a mixture of metronidazole, ciprofloxacin, and minocycline)
2943620|NCT02947763|No Intervention|single visit|single visit root canal treatment without any intra-canal medication
2943621|NCT02947750|Experimental|Exercise training + 6R-BH4|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take the study drug 6R-BH4.
2943622|NCT02947750|Active Comparator|Exercise training + placebo|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo instead of the active study drug.
2943623|NCT02947750|Active Comparator|Stretching + 6R-BH4|Participants randomized to this arm will do muscle stretching and toning for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take the study drug 6R-BH4.
2943624|NCT02947750|Placebo Comparator|Stretching + placebo|Participants randomized to this arm will do muscle stretching and toning for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo instead of the active study drug.
2943625|NCT02947737|Experimental|Amniotic membrane dressing|One donor site per study participant will be covered with an amniotic membrane dressing.
2943626|NCT02947737|Active Comparator|Gentamicin and xeroform dressing|One donor site per study participant will be covered with a gentamicin and xeroform dressing.
2943627|NCT02947724|No Intervention|drainage only|50 patients underwent laparoscopic fenestration and electrocautery of the endometrioma cyst wall
2943628|NCT02947724|No Intervention|cystectomy only|50 patients underwent laparoscopic excision of the endometrioma cyst wall
2943629|NCT02947724|Active Comparator|drainage & Surgicel|50 patients underwent laparoscopic fenestration of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the cyst cavity
2943630|NCT02947724|Active Comparator|cystectomy & Surgicel|50 patients underwent laparoscopic excision of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
2943631|NCT02947711|Experimental|E2027 100 mg alone and in combination with diltiazem ER 300 mg|E2027 100 milligrams (mg) will be administered orally on Days 1 and 12. Diltiazem extended release (ER) 300 mg will be administered alone on Days 7 to 24; however, on the morning of Day 12 it will be coadministered with E2027 100 mg.
2943632|NCT02947698||Acute kidney injury patients admitted on weekday|All patients with acute kidney injury requiring dialysis admitted on week day (Monday to Friday) between 1st April 2003 and 31st March 2015
2943633|NCT02947698||Acute kidney injury patients admitted on weekend|All patients with acute kidney injury requiring dialysis admitted on weekend (Saturday or Sunday) between 1st April 2003 and 31st March 2015
2943634|NCT02947685|Experimental|Arm A|Palbociclib 125 mg daily + AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt) until confirmed disease progression
2943635|NCT02947685|Active Comparator|Arm B|AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant) until confirmed disease progression
2943636|NCT02947672|Active Comparator|Intravenous dexamethasone|50 patients will receive intravenous dexamethasone
2943637|NCT02947672|Active Comparator|Intra peritoneal dexamethasone|50 patients will receive intraperitoneal dexamethasone
2943638|NCT02947646|Experimental|BabyGentleStick™ ON|Experimental intervention to be compared to the Active Comparator.
2943639|NCT02947646|Active Comparator|BabyGentleStick™ OFF|Active Comparator intervention to be compared to the Experimental Treatment.
2943640|NCT02947633|Experimental|Continuous sciatic PNB|If a CPI catheter is placed, the CPI catheter will be placed under ultra-sound guidance, with the tip of the catheter being placed immediately adjacent to the sciatic nerve, after the local anesthesia has been deposited. CPI catheters will only remain in-situ for 48 hours.
2943641|NCT02947633|Active Comparator|Single-injection sciatic PNB|Under ultrasound-guidance, the sciatic nerve can readily be identified in the posterior thigh. The nerve appears hyperechoic and can be traced distally to the popliteal fossa, where it divides into the tibial and common peroneal nerves. Local anesthesia is injected under real-time visualization following a negative aspiration. If a single-injection block is done, local anesthesia is deposited adjacent to the sciatic nerve within the fascial plane, but not within the epineurium. As such, single-injection sciatic PNB, which can last up to 24 hours, should provide adequate analgesia precluding the need for oral narcotic or nonsteroidal anti-inflammatory medications following ACL reconstruction with a hamstring autograft.
2943642|NCT02947620|Active Comparator|Metformin/Atorvastatin|Metformin/Atorvastatin, QD
2943643|NCT02947620|Placebo Comparator|Metformin|Metformin, QD
2943644|NCT02947620|Placebo Comparator|Atorvastatin|Atorvastatin, QD
2943645|NCT02947607||Healthy control|Patients undergoing lower GI endoscopy without any colorectal adenoma or carcinoma.
2943646|NCT02947607||Adenoma|Patients undergoing lower GI endoscopy with presence of colorectal adenoma detected.
2943647|NCT02947607||Colorectal cancer|Patients diagnosed with colorectal cancer and referred to surgical carcinoma resection.
2943648|NCT02947581|Experimental|Interventions|Albendazole and praziquantel. Albendazole: 15 mg/k/d up to 800 mg/d (days 1 to 20), followed by 15 mg/k/d up to 1200 mg/d (day 21 to 30) and prazicuantel (50 mg/k/d days 1 to 15).
2943649|NCT02947581|Active Comparator|Comparison regime|Albendazole and praziquantel placebo. Albendazole: 15 mg/k/d (days 1 to 30) and prazicuantel placebo in similar doses 50 mg/k/d (days 1 to 15).
2943650|NCT02947568||CKD|chronic kidney disease
2943651|NCT02947568||DM|diabetes mellitus
2943652|NCT02947568||CKD+DM|chronic kidney disease + diabetes mellitus
2943653|NCT02947555||DM+/AT+|Patients with type 2 diabetes mellitus and atherosclerotic event in history
2943654|NCT02947555||DM+/AT-|Patients with type 2 diabetes mellitus without atherosclerotic event in history
2943655|NCT02947555||DM-/AT+|Non-diabetic patients with atherosclerotic event in history
2943656|NCT02947555||DM-/AT-|Non-diabetic patients without atherosclerotic event in history
2943657|NCT02947542|Experimental|BLK catheter|Coronary angiography will be performed with the BLK catheter (one-catheter concept).
2943658|NCT02947542|Experimental|Tiger catheter|Coronary angiography will be performed with the Tiger catheter (one-catheter concept).
2943659|NCT02947542|Active Comparator|Judkins catheter|Coronary angiography will be performed with the Judkins catheter (standard catheter).
2943660|NCT02947529|Experimental|Hemiarthroplasty|Patients are placed into this arm based on the type of surgery performed, they are randomized to either receive tranexamic acid or a placebo
2943661|NCT02947529|Experimental|Intramedullary nail|Patients are placed into this arm based on the type of surgery performed, they are randomized to either receive tranexamic acid or a placebo
2943662|NCT02947516|Active Comparator|Percutaneous liver biopsy|Participants will be referred for liver biopsy by their hepatologist/gastroenterologist. The intervention is that these participants will undergo a percutaneous liver biopsy per standard protocol.
2943663|NCT02947516|Experimental|EUS-guided liver biopsy|Participants will be referred for liver biopsy by their hepatologist/gastroenterologist. The intervention is that these participants will undergo an endoscopic ultrasound procedure per standard protocol. The liver will be identified, and Color Doppler imaging prior to needle puncture will confirm lack of significant vascular structures within the needle path. Liver biopsies using up to 1-2 passes from the left hepatic lobe using a transgastric approach and up to 1-2 passes from the right hepatic lobe using a transduodenal bulb approach will be performed. The participant will be observed in the recovery unit for up to 60 minutes after the EUS-LB, and discharged if no pain or signs of complication.
2943664|NCT02947503|Active Comparator|Metformin on top of usual care|"Metformin HCL 850 CF (1-3 times daily) added to usual care from start of the diagnosis GDM.~Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed.~Intervention: metformin HCF 850 CF (1-3 times daily) on top of usual care."
2943665|NCT02947503|No Intervention|Usual care|"Usual care from start of the diagnosis GDM. Control group without metformin. Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed.~Intervention: usual care."
2943780|NCT02946749||The Sixth people's hospital of Shanghai|
2943666|NCT02947490|Sham Comparator|Standard BP management|Participants will continue to receive routine measurement of BP and management of treatment from their General Practitioner (GP).
2943667|NCT02947490|Placebo Comparator|Self BP measurement and standard care|Participants in this group (Se-Mo) will be taught to use a validated British Hypertension Society (BHS) approved home BP monitor (with built in memory/printer) by the study nurse along with written information on the procedure and a copy of the BHS Home BP Monitoring DVD. Participants will be contacted before each recording week & arrangements will be made to deliver and demonstrate the use of self BP monitor by the study nurse. Home BP monitoring will be performed over a 7 day period 3 times during the 6 month follow-up and on each occasion the patient will be given a copy of the BP results and asked to inform the GP of the results and the GP will decide if any alteration in therapy is needed.
2943668|NCT02947490|Active Comparator|Self BP measurement and treatment|Participants in this group will undergo exactly the same self BP monitoring training process as the Se-MO group and will undertake monitoring at the same time intervals. However they will be equipped with a validated BP monitor with a Bluetooth interface phone, BP values recorded by the patient will be transmitted automatically via mobile telephone to the trial coordinating centre. The data will be password protected and saved on a secure server and be available only to the trial team (study nurse & supervising physicians). The patient would then be contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels. This will be recorded on the CRF and the GP notified of any treatment changes.
2943669|NCT02947477|Experimental|Treatment|The EMA intervention uses twice-a-day interactive questions for emotion tracking including type of emotion, intensity of emotion, trigger to emotion and response to emotion through an Iphone app designed for the study. The study users receive individualized feedback about their daily reporting of emotions, sleep and stress.The study tracking is for 14 days.
2943670|NCT02947477|No Intervention|Control|The control arm does nothing for 14 days and then receives the 14 day emotion tracking listed above.
2943671|NCT02947464|Active Comparator|Control|Standard clinical practice
2943672|NCT02947464|Experimental|Intervention|Standard clinical practice + Rapid Maxillary Expansion
2943673|NCT02947451|Experimental|Manual therapy|In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee, in a single application.
2943674|NCT02947451|Experimental|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application.
2943675|NCT02947438|Active Comparator|Reference group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form:Injection Strength: 2000IU, 3000IU, 4000IU~Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks."
2943676|NCT02947438|Experimental|Experimental group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form: Injection Strength: 2000IU, 3000IU, 4000IU~Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks."
2943677|NCT02947412||sleeve gastrectomy|laparoscopic sleeve gastrectomy
2943678|NCT02947399|Other|I-124 in thyroid hormone withdrawal|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
2943679|NCT02947386|Experimental|Treatment (nivolumab, nimotuzumab)|Patients receive nivolumab IV over 60 minutes and nimotuzumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2943680|NCT02947373|Other|Imaging Arm|Patients will receive a one-time injection of Hyperpolarized Pyruvate prior to a single MR imaging examination that includes the acquisition of HP carbon-13 metabolic data.
2943681|NCT02947360|Experimental|FOVUS|All eligible and consenting patients will receive a focused vascular ultrasound examination of the carotid arteries
2943682|NCT02947347|Experimental|(Part 1 : Arm A) ibrutinib + rituximab|"Subjects will receive 560mg of ibrutinib and rituximab 375mg/m^2 weekly x4 with maintenance.~In Part 1, Arm A to Arm B ratio is 3:1"
2943683|NCT02947347|Placebo Comparator|(Part 1 : Arm B) placebo + rituximab|"Subjects will receive placebo and rituximab 375mg/m^2 weekly x4 with maintenance.~In Part 1, Arm A to Arm B ratio is 3:1"
2943684|NCT02947347|Experimental|(Part 2 : Arm A1) ibrutinib|"Subjects will receive 560mg of ibrutinib~Part 1 Arm A subjects will be re-randomized 1:1 into Part 1 Arm A1 or Arm A2"
2943685|NCT02947347|Placebo Comparator|(Part 2 : Arm A2) placebo|"Subjects will receive placebo~Part 1 Arm A subjects will be re-randomized 1:1 into Part 2 Arm A1 or Arm A2"
2943686|NCT02947347|Placebo Comparator|(Part 2 : Arm B) placebo|"Subjects will receive placebo~Part 1 Arm B subjects will be re-randomized into Part 2 Arm B"
2943687|NCT02947334|Experimental|Bococizumab|Bococizumab Q2wks
2943688|NCT02947334|Placebo Comparator|Placebo|Bococizumab placebo Q2wks
2943689|NCT02947321|Experimental|RFA Group|A genicular nerve RFA will be performed prior to planned total knee arthroplasty.
2943690|NCT02947321|Sham Comparator|Control Group|A sham genicular nerve RFA will be performed prior to planned total knee arthroplasty.
2943691|NCT02947308||Adolescents with NSSI|12-16 year old females who have a history of non-suicidal self-injury are included in this cohort. No interventions will be administered.
2943692|NCT02947308||Healthy Controls|12-16 year old females with no history of non-suicidal self-injury are included in this cohort.
2943693|NCT02947282|Active Comparator|Intervention|Educational Workshop
2943694|NCT02947282|No Intervention|Control|They will continue regular prenatal care as planned
2943695|NCT02947269|Experimental|Intervention group|Patients will receive an oral capsule containing 2mg Prucalopride 2-3 hours preoperatively. Study medication (2mg oral Prucalopride daily) will continue for 6 days postoperatively or until the patient has achieved the study's primary outcome.
2943696|NCT02947269|Placebo Comparator|Placebo group|Patients will receive an oral capsule containing a placebo 2-3 hours preoperatively. Study medication (placebo) will continue for 6 days preoperatively or until the patient has achieved the study's primary outcome.
2943697|NCT02947256|Active Comparator|standard laparoscopic cholecystectomy|This included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery.
2943698|NCT02947256|Experimental|RI approach|"Retroinfundibular laparoscopic cholecystectomy: This included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.~Operative procedure of by RI approach:"
2943699|NCT02947243|Active Comparator|Standard pharmacological treatment|Standard pharmacological treatment (including Morphine) according to the unit's protocol and adjusted to each participant`s age, weight and condition by the anesthetist and pain clinic nurse.
2943700|NCT02947243|Experimental|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention.
2943701|NCT02947230|Experimental|Tailored Knowledge Translation|During the 12-week KT intervention, intervention group participants will have access to the Portal and will receive mobility-focused weekly email alerts including blog posts and evidence summaries relevant to mobility and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant mobility information.
2943702|NCT02947230|No Intervention|Control group|Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored mobility intervention.
2943703|NCT02947217|Experimental|Influenza Vaccine|O.5 mL single dose influenza vaccine suspension administered intramuscularly
2943704|NCT02947217|Placebo Comparator|Saline Injection|O.5 ml of sterile Saline administered intramuscularly
2943705|NCT02947204|Active Comparator|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge.
2943706|NCT02947204|Experimental|Intermittent oxygen monitoring|Oxygen saturation will be measured intermittently, every 4 hours, through the child's hospital stay until discharge.
2943707|NCT02947191|Experimental|Collagen membrane + HUC-MSCs|
2943708|NCT02947178|Active Comparator|Bupivicaine|Bupivicaine fascial iliaca regional soft tissue infiltration blockade
2943709|NCT02947178|Active Comparator|Bupivacaine plus liposomal bupivacaine|Bupivacaine plus liposomal bupivacaine fascial iliaca regional soft tissue infiltration blockade
2943710|NCT02947165|Experimental|NIS793|
2943711|NCT02947165|Experimental|NIS793 + PDR001|
2943712|NCT02947152|Experimental|Dose escalation part|Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer) and clear cell or papillary renal cell carcinoma
2943713|NCT02947152|Experimental|Dose expansion part (RCC arm)|Includes patients with clear cell or papillary renal cell carcinoma
2943714|NCT02947152|Experimental|Dose expansion part (ovarian cancer arm)|Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer)
2943715|NCT02947139|Experimental|Study effect of DWC20161 on DWC20155/DWC20156 PK|To study effect of DWC20161 on DWC20155/DWC20156 PK
2943716|NCT02947139|Experimental|Study effect of DWC20155/DWC20156 on DWC20161 PK|To study effect of DWC20155/DWC20156 on DWC20161 PK
2943717|NCT02947126|Experimental|Cystic Fibrosis (HS, IS)|"CF subjects: ages 12 or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator. Subjects receive HS dose on first imaging day and IS dose on the second imaging day,~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml), Inhaled Hypertonic Saline (4ml)"
2943718|NCT02947126|Experimental|Cystic Fibrosis (IS, HS)|"CF subjects: ages 12 or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator. Subjects receive IS dose on first imaging day and HS dose on the second imaging day.~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml), Inhaled Hypertonic Saline (4ml)"
2943719|NCT02947126|Experimental|Parents of CF subjects|"Ages 18 and older, biological parent of a CF patient who is also enrolled in the study~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml)"
2943720|NCT02947126|Experimental|non CF controls|"Ages 18 and older with no history of lung disease~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml)."
2943721|NCT02947113|Experimental|chemotherapy combined with radiotherapy|Patients will be treated with two 3-weekly courses of cisplatin (Day 1: 75mg/m2) and pemetrexed (Day 1: 500mg/m2 for non-squamous) or etoposide (Day1-3 100mg/m2 for squamous), together with hypofractionated radiotherapy (24 daily fractions of 2.42 Gy to the involved mediastinal lymph nodes with an integrated boost of 2.75 Gy to the primary tumor).
2943722|NCT02947100|Experimental|SCD-Omegatex™|single arm
2943723|NCT02947087|Active Comparator|Prolastin-C|Subjects will be given Prolastin-C intravenously at 60mg/kg weekly for 4 weeks.
2943724|NCT02947087|Placebo Comparator|Placebo|Subjects will be given Saline weekly for 4 weeks.
2943725|NCT02947074|No Intervention|Control|Waiting list
2943726|NCT02947074|Experimental|Yoga Meditation|Previously naive to yoga and meditation, subjects will receive 2 30min yoga meditation classes for 8 weeks.
2943727|NCT02947061|Experimental|test group|S1 plus Docetaxel ：S-1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
2943728|NCT02947061|Active Comparator|control group|Capecitabine plus Docetaxel ：Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
2943729|NCT02947048|Experimental|100 mg open|open-label lead-in 100 mg L1-79 t.i.d.
2943730|NCT02947048|Experimental|100 mg blinded|blinded and randomized 100 mg L1-79 t.i.d.
2943731|NCT02947048|Experimental|200 mg open|open-label lead-in 200 mg L1-79 t.i.d.
2943732|NCT02947048|Experimental|200 mg blinded|blinded and randomized 200 mg L1-79 t.i.d.
2943733|NCT02947048|Placebo Comparator|Placebo|placebo t.i.d.
2943734|NCT02947035|Experimental|Low Risk|Molecular testing and ultrasound features will be used to predict if thyroid cancer is low risk. Intervention will be to perform thyroid lobectomy.
2943735|NCT02947035|Experimental|High Risk|Molecular testing and ultrasound features will be used to predict if thyroid cancer is high risk. Intervention will be to perform more aggressive surgery to include total thyroidectomy with CCND.
2943736|NCT02947022|Experimental|Calcium DTPA followed by Zinc DTPA|Subjects will receive IV administration of Ca-DTPA on Day 1 and Zn-DTPA on Day 2 at each of treatment time-points. Three identical treatment time-points are scheduled on Month 1, Month 2 and Month 3.
2943737|NCT02947009|Experimental|Adolescent athletes with PVFMD|"participants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report.~Any participant who declares he or she is a competitive athlete and presents to the clinic reporting atypical dyspnea during exertion and associated decrements in athletic performance for more than 2 weeks prior to presentation will be considered for the study. Participants must score at least a 10 out of 40 on the Dyspnea Index"
2943738|NCT02947009|Active Comparator|Adolescent athletes at-risk for PVFMD|"participants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report.~Participants in the at-risk group must report playing sports in a competitive environment, must report no symptoms of atypical dyspnea over the past 6 months, and must score less than 6 out of 40 on the Dyspnea Index."
2943739|NCT02946996|Experimental|Arm 1: Metformin Only|Subjects will be supplied with metformin tablets 850mg. During the ramp up phase subjects will take metformin in the morning. During weeks 2-12 the metformin tablet will be taken approximately 12 hours apart.
2943740|NCT02946996|Experimental|Arm 2: OPC only|Subjects will take one OPC capsule at the same time each morning and evening, approximately 12 hours apart during weeks 1-12.
2943741|NCT02946996|Experimental|Arm 3: Metformin plus OPC|"During week 1, subjects will take one metformin tablet in the morning and one OPC tablet in the morning and in the evening, about 12 hours apart.~During weeks 2-12 the metformin tablet will be taken approximately 12 hours apart and one OPC about 12 hours apart, in the morning and in the evening."
2943742|NCT02946983|Active Comparator|Fructose - Neutral emotion condition|Intragastric infusion of fructose with neutral emotion induction
2943743|NCT02946983|Active Comparator|Fructose - Sad emotion condition|Intragastric infusion of fructose with sad emotion induction
2943744|NCT02946983|Placebo Comparator|Placebo - Neutral emotion condition|Intragastric infusion of distilled water with neutral emotion induction
2943745|NCT02946983|Placebo Comparator|Placebo - Sad emotion condition|Intragastric infusion of distilled water with sad emotion induction
2943746|NCT02946970|Placebo Comparator|Control|Intragastric infusion
2943747|NCT02946970|Experimental|Quinine hydrochloride|Intragastric infusion
2943748|NCT02946957|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia is delivered by trained sleep therapists in six telephone sessions.
2943749|NCT02946957|Active Comparator|Education Control|Education Only Control is delivered by trained sleep therapists in six telephone sessions.
2943750|NCT02946944|Experimental|double drug therapy|
2943751|NCT02946944|Active Comparator|mono drug therapy|
2943752|NCT02946931||Prizbind|patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
2943753|NCT02946918|Experimental|Tablets|Patients in this arm will receive levothyroxine tablets (encapsulated for blinding purposes)
2943754|NCT02946918|Experimental|Gelcaps|Patients in this arm will receive levothyroxine gelcaps (encapsulated for blinding purposes)
2943755|NCT02946905||SCD participant|No intervention
2943756|NCT02946905||Non-SCD participant|No intervention
2943757|NCT02946892|Experimental|Carvedilol|Study participants will receive carvedilol for 12 weeks
2943758|NCT02946892|Experimental|Placebo|Study participants will receive placebo (sugar pill) for 12 weeks
2943759|NCT02946879||Low dose AAV OPTIRPE65|subretinal administration of a single low dose of AAV RPE65
2943760|NCT02946879||Intermediate dose AAV OPTIRPE65|subretinal administration of a single intermediate dose of AAV RPE65
2943761|NCT02946879||High dose AAV OPTIRPE65|subretinal administration of a single highdose of AAV RPE65
2943762|NCT02946866||Cerebral cavernous malformation|Patients with newly diagnosed, cerebral cavernous malformation who will visit one of the study centers during the period from June 2016 to December 2017. Patients would be eligible for enrollment if they were 18 years of age or older and had at least 1 cavernous malformation. All patients who would visit a study center during the enrollment period and meet these criteria will be asked to join the study. The cohort will consists of patients who agree to participate. Target population of this study is 228 patients.
2943763|NCT02946853|Active Comparator|CRT-D|Patients will be randomized at enrollment. Patients in this arm of the study will receive cardiac resynchronization therapy with defibrillator (CRT-D).
2943764|NCT02946853|Experimental|CRT-D and AVJ Ablation|Patients in this arm of the study will receive CRT-D and undergo atrioventricular junctional (AVJ) ablation.
2943765|NCT02946840||Solid pancreatic masses|Consecutive patients with solid pancreatic masses, submitted to FNA with 25 G Beacon needle (Medtronic, Newton, MA, USA)
2943766|NCT02946827|Experimental|Low FODMAPs /balanced gluten free diet|An expert in nutrition will give a balanced gluten free diet to patients, low in FODMAPs foods.
2943767|NCT02946827|Active Comparator|Balanced gluten free diet|An expert in nutrition will give a balanced gluten free diet to patients.
2943768|NCT02946814|Active Comparator|essential oils|a single mouthwash with 20 ml of essential oils for 30 seconds.
2943769|NCT02946814|Experimental|essential oils without mouthwash|a single mouthwash with 20 ml of essential oils without alcohol for 30 seconds.
2943770|NCT02946814|Sham Comparator|sterile water|a single mouthwash with 20 ml of sterile water for 30 seconds.
2943771|NCT02946801|Active Comparator|Essential oils mouthwash|20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1).
2943772|NCT02946801|Experimental|essential oils without mouthwash|20 mL rinses for 30 seconds with essential oils without alcohol/2 times daily (1/0/1)
2943773|NCT02946801|Sham Comparator|sterile water mouthwash|20 mL rinses for 30 seconds with sterile water/2 times daily (1/0/1)
2943774|NCT02946788|Experimental|BPX-01 1%|BPX-01 1% minocycline topical gel
2943775|NCT02946788|Experimental|BPX-01 2%|BPX-01 2% minocycline topical gel
2943776|NCT02946762|Other|Universal Test and Treat|All incarcerated individuals with HIV infection will receive antiretroviral therapy (ART) by test and treat.
2943777|NCT02946749||Shanghai First Maternity and Infant Hospital|
2943778|NCT02946749||the Putuo District Maternity and Child Health Care Hospital|
2943781|NCT02946736|Experimental|Supervisor Intervention|Supervisors in the intervention group will go through the FSSB/sleep leadership training and receive actigraphy feedback.
2943782|NCT02946736|Experimental|Employee Intervention|Employees in the intervention group will receive actigraphy feedback.
2943783|NCT02946723|Experimental|US group|lead implantation surgery for SNM using ultrasound guided technique
2943784|NCT02946723|Sham Comparator|X-ray group|lead implantation surgery for SNM using X-ray guided technique
2943785|NCT02946697|No Intervention|Enhanced care and wait-list control group|Participants in the control group will receive enhanced usual care while waiting for the JLA program. Participants will be given information booklets in Chinese developed by the American Cancer Society and cover common issues related to breast cancer, various treatments, and life after treatment. Participants will be asked to read through the booklet individually.
2943786|NCT02946697|Experimental|Social support intervention group|The intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
2943787|NCT02946684|Placebo Comparator|Lactose Monohydrate|2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH
2943788|NCT02946684|Active Comparator|Letrozole 5mg|2 tablets of 2,5mg Letrozole are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH
2943789|NCT02946671|Experimental|Cohort 1|KW-0761 (Mogamulizumab): 0.1 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
2943790|NCT02946671|Experimental|Cohort 2|KW-0761 (Mogamulizumab): 0.3 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
2943791|NCT02946671|Experimental|Cohort 3|KW-0761 (Mogamulizumab): 1.0 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
2943792|NCT02946658|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
2943793|NCT02946658|Experimental|AD-cSVF Arm 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
2943794|NCT02946658|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
2943795|NCT02946645|Active Comparator|Manual Physiotherapy|TMD patients will treat with orofacial physiotherapy by one expert operator according to literature
2943796|NCT02946645|Active Comparator|Neuromuscular Bite|TMD patients will receive an intraoral neuromuscular bite according to literature
2943797|NCT02946645|Placebo Comparator|Placebo|TMD placebo group.
2943798|NCT02946632|Experimental|Triple combination therapy group|Xigduo (metformin 1000mg + dapagliflozin 10mg), saxagliptin 5mg once daily for 104 weeks
2943799|NCT02946632|Active Comparator|Stepwise add-on therapy group|"Participants were started on metformin 1000mg once daily after screening & assignment~At each visits, FPG and HbA1c are measured. Sequential add-on therapy regimen is described"
2943800|NCT02946619|No Intervention|Control Condition|Participants in the control group were asked to write for three weeks about facts regarding their cancer and its treatment for three sessions.
2943801|NCT02946619|Experimental|Self-regulation condition|For the self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; in session two, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
2943802|NCT02946619|Experimental|Enhanced self-regulation condition|For the enhanced self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; during session two, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
2943803|NCT02946606|Experimental|Group 1: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
2943804|NCT02946606|Experimental|Group 2: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
2943805|NCT02946606|Experimental|Group 3: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
2943806|NCT02946593|Experimental|Treatment|Participants in the treatment group will attend a once a week 7-week outdoor fall prevention program that includes didactic presentations, group discussions/problem solving, practice in strategy use, and action planning for safe community mobility.
2943807|NCT02946593|Active Comparator|Control|Participants in the control group will receive written information about preventing outdoor falls.
2943808|NCT02946580|Experimental|MOVANTIK™ (naloxegol)|Subjects in the treatment group will be administered MOVANTIK™ (naloxegol) 25 mg tablet or placebo once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing). Subjects with renal impairments (creatine clearance rate of less than 60 mL/min) will receive a 12.5 mg dose tablet of naloxegol in place of the 25 mg dose as advised by FDA guidelines. For patients who are unable to swallow the tablet whole, the tablet can be crushed and given orally or administered via nasogastric tube.
2943809|NCT02946580|Placebo Comparator|Sugar pill|Matching placebo consists of an inert mixture supplied by AstraZeneca in identical-appearing tablets. Subjects in the placebo group will be administered a placebo tablet once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing).
2943810|NCT02946567|Experimental|Noisy City|Participant will play the Noisy City game developed by this project.
2943811|NCT02946567|Placebo Comparator|Control|Participant will play a generic game.
2943812|NCT02946554|Other|Low dose cohort|"Two dose regimens of HepaStem will be given, which differ in the amount of cells per infusion.~The low dose regimen will be given to the first cohort (first 6 patients included in the study)."
2943813|NCT02946554|Other|High dose cohort|The high dose regimen will be given to the second cohort after evaluation of the safety of the 1st cohort (stepwise approach)
2943814|NCT02946541|Experimental|evogliptin 5mg|evogliptin 5mg QD
2943815|NCT02946541|Placebo Comparator|placebo|Placebo QD
2943816|NCT02946528|Experimental|urgent-start peritoneal dialysis|All patients in urgent-start peritoneal dialysis arm initiate peritoneal dialysis as urgent-start dialysis modality.
2943817|NCT02946528|Active Comparator|urgent-start hemodialysis|All patients in urgent-start hemodialysis arm initiate hemodialysis as urgent-start dialysis modality.
2943818|NCT02946515|Experimental|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
2943819|NCT02946515|Experimental|Waitlist Control Group|The control group will participate in pre- and post-test assessments of their conversational skills with a trained actor. At the end of the study, the waitlist control group will be allowed to access to the simulation and the study team will provide training to participants upon request.
2943820|NCT02946502|Experimental|Handheld dynamometry (handgrip strength)|All included patients will have a blinded evaluation of handgrip strength before weaning process.
2943821|NCT02946489|Experimental|CI-581a+MET+MBRP|Administration of CI-581a during wk 2 and possibly at wk 3 or 4 at 0.71 mg/kg in the context of a 2 wk course of MET followed by a 4 wk course of MBRP
2943822|NCT02946476||HFrEF|patients with heart failure and reduced ejection fraction
2943823|NCT02946476||HFpEF|patients with heart failure and preserved ejection fraction
2943824|NCT02946463|Experimental|ALXN1210|ALXN1210
2943825|NCT02946463|Active Comparator|Eculizumab|Eculizumab
2943826|NCT02946450||Not applicable-observational study|Not applicable-observational study
2943827|NCT02946437|Experimental|Sevoflurane|"Sevoflurane postconditioning will start after the bleeding source is excluded by coiling or clipping as soon as the patient returns to the ICU and will be continued for 4 hours. 0.5-1.5vol% sevoflurane will be administrated into the ventilation circuit by a MIRUS™System.~The used dose (0.5-1.5vol%) is a lower dose as used for anaesthesia for a surgical intervention (0.5-3vol%), but high enough to provide sufficient sedation."
2943828|NCT02946437|Active Comparator|Propofol or Midazolam|Propofol or midazolam will be administrated intravenously before and after the postconditioning with sevoflurane as in the standard sedation regimen of the Neurointensive Care Unit, University Hospital Zurich (propofol 0.3-4.0mg/kg/h cont. i.v.; midazolam 0.03-0.2mg/kg/h cont. i.v.)
2943829|NCT02946437|Other|MIRUS™System|MIRUS™ is a newly developed device, considered as vaporizer system, which can be used in the setting of operating rooms or in intensive care units. The MIRUS™System is successfully in use in daily clinical practice. This type of device is similar to the well-known AnaConDa® system (AnaConDa®, Sedana Medical, Uppsala, S) with several advantages. Since 2005 the anaesthetic-conserving device AnaConDa® facilitates, from a technical viewpoint, the routine use of volatile anaesthetics in intensive care patients as part of prolonged sedation, using ICU ventilators (Soukup J et al., 2009). The MIRUS™System forms a closed loop. It measures the end-tidal concentration of the anaesthetic gas and governs the application of the anaesthetic gas according to these values and the ventilation parameters.
2943830|NCT02946424|Experimental|Simvastatin treatment|Simvastatin for one year time period
2943831|NCT02946424|Placebo Comparator|Placebo treatment|Placebo for one year time period
2943832|NCT02946411||Patients|The glucose of 48 patients will be measured during 5 days after cardiac surgery.
2943833|NCT02946398||elderly patients who visit the ED|elderly patients (65 years and older) who present to the emergency department for internal medicine or gastroenterology
2943834|NCT02946385|Experimental|ABCWY_ 0_2 Group|Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
2943835|NCT02946385|Experimental|ABCWY_0_2_6 Group|Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
2943836|NCT02946385|Experimental|B_0_2 Group|Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study
2943837|NCT02946385|Experimental|ABCWY_ 0_6 Group|Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
2943838|NCT02946385|Active Comparator|ABCWY Naive Group|Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive either 2 doses of MenABCWY in this extension study
2943839|NCT02946385|Active Comparator|rMenB+OMV Naive Group|Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive either 2 doses of rMenB+OMV in this extension study
2943840|NCT02946372|Experimental|ILMT|internal limiting membrane autologous transplantation (ILMT)
2943841|NCT02946359|Experimental|Patients with ALK translocation|Treatment-naive lung adenocarcinoma cancer patients with ALK translocation with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
2943866|NCT02946190|Experimental|Arm 1: Pertagen® aP + Td-pur®|BioNet-Asia recombinant acellular Pertussis vaccine (Pertagen®) given simultaneously with Td-pur® vaccine (Novartis/GSK) intramuscularly as a single dose on Day 0
2943842|NCT02946359|Experimental|Patients with ROS1 translocation|Treatment-naive lung adenocarcinoma cancer patients with ROS1 translocation with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
2943843|NCT02946359|Experimental|Patients with MET amplification|Treatment-naive lung adenocarcinoma cancer patients with MET amplication with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
2943844|NCT02946346|Experimental|Vaginal and blood sampling|
2943845|NCT02946333||Patient with MM who are not candidates for ASCT|Patients with newly diagnosed MM who are not candidates for ASCT and who are going to start drug treatment for the study disease and patient who is capable of understanding and filling in the study questionnaires At least 450 patients will be enrolled in a 2-year period. Patients must meet all of the inclusion criteria and none of the exclusion criteria and must have previously granted their informed consent in writing.
2943846|NCT02946320|Active Comparator|Non-compliant balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
2943847|NCT02946320|Experimental|Scoring balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
2943848|NCT02946320|Experimental|Cutting balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
2943849|NCT02946307|Experimental|small vessel cohort:Restore DEB|receiving the treatment with Restore DEB（dimeter>2.00 mm） in small vessel cohort
2943850|NCT02946307|Active Comparator|small vessel cohort:Resolute DES|receiving the treatment with Resolute DES in small vessel cohort
2943851|NCT02946307|Other|very small vessel cohort:Restore DEB|receiving the treatment with Restore DEB（dimeter:2.00 mm）in very small vessel cohort
2943852|NCT02946294|Active Comparator|modified pectoral nerves block|Modified pectoral nerves block with general anesthesia. Using the ultrasound, 10 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the pectoralis major and minor muscles. And another 20 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the pectoralis minor and the serratus anterior muscles.
2943853|NCT02946294|Active Comparator|serratus plane block|Serratus plane block with general anesthesia. Using the ultrasound, 0.4 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the serratus anterior muscle and the underlying ribs.
2943854|NCT02946281|Experimental|Intervention|
2943855|NCT02946281|No Intervention|Care as usual|
2943856|NCT02946268|Experimental|Volume of bolus|Ropivacaine 0.2% volume increased or decreased by 1ml based on previous patient experience. If pain greater than or equal to 5/10 in the previous patient, the current patient will receive an increase in volume of bolus by 1ml. If pain is less than 5/10 in the previous patient the current patient will receive a decrease in volume by 1ml.
2943857|NCT02946268|Experimental|Rate of delivery of bolus|Ropivacaine 0.2% rate increased or decreased by 50ml/hr based on previous patient experience. If pain greater than or equal to 5/10 in the previous patient at 30 minutes, the current patient will receive an increase in rate of bolus by 50ml/hr. If the pain is less than 5/10 the rate will be decreased by 50ml/hr.
2943858|NCT02946268|Experimental|Interval between bolus|Ropivacaine 0.2% interval increased or decreased by 1 hour based on previous patient experience. If the previous patient received pain score of 2/10 at 2 hours then the current patient will have an interval of three hours. If the pain is greater than 2/10, the interval will be shortened by 1 hour.
2943859|NCT02946255|Experimental|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
2943860|NCT02946255|Experimental|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions."
2943861|NCT02946255|Active Comparator|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
2943862|NCT02946242|Other|General Ultrasound Exam|Each subject may elect to participate in up to five (5) study scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan. Ophthalmic scanning will be limited to no more than 15 cumulative minutes of scan time per eye, per day.
2943863|NCT02946229|Other|MHD Population Ultrasound|Patients on Maintenance Hemodialysis (MHD) will undergo a non-invasive cardiac, pulmonary, and abdominal ultrasound scan on the commercially available GE Vivid S70 system lasting approximately 30 to 45 minutes.
2943864|NCT02946203|Active Comparator|Flavored Beverage Oral Contrast-Breeza|Pediatric patients that are undergoing awake CT and MR enterography at the Cincinnati Children's Hospital Medical Center (CCHMC) base (Burnett) campus will be randomized to either VoLumen (current standard of care oral contrast) or Breeza.
2943865|NCT02946203|Active Comparator|Barium Sulfate Oral Contrast-VoLumen|Pediatric patients that are undergoing awake CT and MR enterography at the CCHMC base (Burnett) campus will be randomized to either VoLumen (current standard of care oral contrast) or Breeza.
2943867|NCT02946190|Active Comparator|Arm 2: Boostrix® dTpa|Licensed Tetanus-diphtheria (reduced dose)-acellular Pertussis vaccine (Boostrix® dTpa; GSK) given intramuscularly as a single dose on Day 0
2943868|NCT02946177|Experimental|Influenza Vaccine|O.5 mL single dose influenza vaccine suspension administered intramuscularly
2943869|NCT02946177|Placebo Comparator|Saline Injection|O.5 ml of sterile Saline administered intramuscularly
2943870|NCT02946164|No Intervention|Comparison: Standard of Care|Standard services available to all men at AHF Wellness Centers.
2943871|NCT02946164|Active Comparator|Intervention: 'Stick To It' Intervention|Behavioral intervention.
2943872|NCT02946151|Experimental|Implantation|Intervention: Implantation of the subcutaneous electrode and connection to the external logging device
2943873|NCT02946138|Experimental|carbon-ion radiotherapy with GM-CSF|Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gray(Gy) [relative biological effectiveness (RBE)] in 5 fractions for intrahepatic cases away from gastro-intestinal (GI) tract (>1cm) with concurrent GM-CSF 125ug/m2/d, subcutaneous injection d1-28;
2943874|NCT02946125|Experimental|MDD-administered EYN-1601|EYN-1601 Ophthalmic Solution administered using the Eyenovia MDD
2943875|NCT02946125|Active Comparator|Phenylephrine 2.5% Eyedrop|Phenylephrine Hydrochloride Ophthalmic Solution 2.5% administered as an eyedrop
2943876|NCT02946125|Active Comparator|Phenylephrine 10% Eyedrop|Phenylephrine Hydrochloride Ophthalmic Solution 10% administered as an eyedrop
2943877|NCT02946112||Shoulder pain|volleyball players with shoulder pain
2943878|NCT02946112||No shoulder pain|volleyball players without shoulder pain
2943879|NCT02946099|Experimental|Reciproc file|Reciproc files in reciprocating motion
2943880|NCT02946099|Active Comparator|ProTaper Next file|ProTaper Next files in continuous rotary motion
2943881|NCT02946086|Experimental|prismatic adaptation|Including 8 hours of therapy with prismatic adaptation wearing prismatic goggles during bimanual intensive and locomotor intensive intervention (HABIT-ILE).
2943882|NCT02946086|Active Comparator|sham goggles|"Including 8 hours of therapy wearing sham goggles during bimanual intensive and locomotor intensive intervention (HABIT-ILE)."
2943883|NCT02946073|Placebo Comparator|Placebo|CAM2038 placebo injections
2943884|NCT02946073|Experimental|CAM2038|CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, 16 mg, 24 mg, or 32 mg. CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.
2943885|NCT02946060|Sham Comparator|Usual Care|Participants in this intervention will receive the minimal standard of care provided at the Cardiac Rehabilitation and Prevention Program at Toronto Rehabilitation Institute. Participants will receive an iPod with a silent track or white noise.
2943886|NCT02946060|Active Comparator|Audiobooks|Participants in this arm will receive iPods with Audiobooks based on their preferred genres.
2943887|NCT02946060|Experimental|Tempo-pace Synchronized Playlists|Participants in this arm will receive audio playlists synchronized to their exercise pace. Rhythmic enhancements will be added to the playlists during either month 2 or month 3 of the study.
2943888|NCT02946047|Experimental|Treatment group|Patients will be given at least one treatment cycle of Ixazomib.
2943889|NCT02946034|Experimental|Treatment|12 week therapy with Viekira Pak ± ribavirin
2943890|NCT02946021|Experimental|Pneumatic Compression|Head and neck lymphedema treatment with compression device.
2943891|NCT02946021|Experimental|NIRFLI with ICG|All study participants will undergo imaging using NIRFLI with Indocyanine green (ICG)
2943892|NCT02946008|Experimental|SBRT|Stereotactic Body Radiation Therapy (SBRT) will be delivered over 5 treatment sessions for approximately 1.5 weeks total.
2943893|NCT02945982|Placebo Comparator|Entecavir/Carvedilol/ Placebo|Tablet with Entrcavir and Carvedilol+ Tablet with starch
2943894|NCT02945982|Experimental|Entecavir/Carvedilol/ Fuzheng Huayu|Tablet with Entrcavir and Carvedilol+ Tablet with Fuzheng Huayu
2943895|NCT02945982|Experimental|Entecavir/Carvedilol/ Fuzheng Huayu/TCM|Tablet with Entrcavir and Carvedilol+ Tablet with Fuzheng Huayu
2943896|NCT02945969|Experimental|Low Sodium Diet|Behavioral modification to decrease dietary sodium intake to ≤2,300 mg/day for 24 weeks. The intervention program consists of two phases. An initial 12-week intensive phase will include weekly individual and group sessions. This will be followed by a 12-week maintenance phase that includes telephone counseling sessions every 2 weeks.
2943897|NCT02945969|No Intervention|Usual Diet|No dietary intervention.
2943898|NCT02945956|Placebo Comparator|Entecavir + Placebo|Tablet with Entrcavir+ Tablet with starch
2943899|NCT02945956|Experimental|Entecavir + Fuzheng Huayu|Tablet Tablet with Entrcavir+ Tablet with Fuzheng Huayu
2943900|NCT02945943|Experimental|Mobilization|High Velocity Low Amplitude mobilization group. The three joints manipulated included proximal tibiofibular, the distal tibiofibular, and talocrural joints and were mobilized the first three sessions prior to the participants performing the exercise protocol.
2943901|NCT02945943|Active Comparator|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
2943902|NCT02945891|Experimental|Study group|Each women recruited for the study belong to the study group. Intervention is performance of HPV testing on Evalyn®Brush and FloqSwab specimens compared to clinician-sampled specimen. Providing an urinary sample (Colli-PeeTM), blood, and a questionnaire data is optional.
2943903|NCT02945865|Experimental|ITreatment arm: Pain Assessment|Pain assessment by Doloplus-2 pain scale regularly and additional pain assessment in situations where pain is suspected.
2943904|NCT02945865|No Intervention|Control arm: No treatment|Treatment us usual
2943905|NCT02945852|Experimental|refractory SCLC|Patients receive apatinib 500mg/d until progressive Disease(PD).
2943906|NCT02945839|Active Comparator|Acute Treatment+ED-initiated preventive medication +PMR|All subjects will be discharged on acute migraine therapy (naproxen, triptan) unless there is a contraindication and will also be started on topiramate (25mg/night) with a plan to increase the dose every week by 25 mg up to 100 mg/night. Subjects will receive medicine along with progressive muscle relaxation therapy
2943938|NCT02945592|Experimental|Intervention|"adaptive, therapeutic cueing during reading tasks~adaptive, therapeutic cueing during visuo spatial tasks"
2943939|NCT02945592|No Intervention|Control|- unspecific neglect treatment
2944369|NCT02942706|Active Comparator|Cet+chemo continuation|Cetuximab plus continuation mFOLFOX6/FOLFIRI regimens
2943907|NCT02945839|Active Comparator|Enhanced Usual Care (EUC)|Subjects will be given a general education session consisting of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently. Any migraine treatment decisions on discharge will be left up to the ED attending. The RC will load the APP onto the subjects' smart phones but the PMR component will be blocked on the version of the APP that they receive. All subjects will be asked to track headache frequency, intensity, and acute medication use on the APP.
2943908|NCT02945826|Experimental|uPAR PET/MRI|One injection of 68Ga-NOTA-AE105 followed by PET/MRI.
2943909|NCT02945813|Experimental|Arm A: Metformin|"Metformin - 850mg PO BID; 48 weeks~Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks"
2943910|NCT02945813|Active Comparator|Arm B: Salvage Radiotherapy|- Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks
2943911|NCT02945800|Experimental|Combination Therapy|Participants will receive nab-Paclitaxel and Gemcitabine on days 1, 8, and 15 of each 28 day cycle, for up to 12 cycles.
2943912|NCT02945787|Experimental|Extended Self-help|Spanish-Language Version of the Stop Smoking for Good: The Extended Self-help condition will comprise the 11 Stop Smoking for Good booklets and 9 supportive My Story pamphlets transcreated for Spanish speaking smokers.
2943913|NCT02945787|Active Comparator|Usual Care (UC)|NCI-Produced Spanish-language Self-help Booklet: The UC control condition enhances the external validity of the study by providing a comparison to an existing, credible intervention that a smoker could receive in a medical setting or elsewhere.
2943914|NCT02945774|Experimental|(18F)-FEPPA|
2943915|NCT02945761|Active Comparator|High concentration of sugar solution|Lavage group of high-concentration sugar solution (HCSS): disinfected the Skin outside wound with conventional PVP. HCSS refers to supersaturated sugar solution made of 50% high-concentration glucose and white sugar. Prior to wound irrigation, dry cotton balls are used to wipe the wound and internal lacuna, to clean some necrotic tissues out of the wound. HCSS is applied on the wound once a day, and whether the lavaging is stopped based on the amount of exudation from the wound.
2943916|NCT02945761|Active Comparator|conventional surgical dressing change|conventional surgical dressing change:separated suture, expanded the wound, placed drainage ribbon gauze and used hydrogen peroxide or(and) PVP to wash the wound; the decision-making power of these operators is determined by a doctor. After the doctor confirms granulation cleaning in the wound, the decision-making power of suture is also determined by a doctor.
2943917|NCT02945735|Experimental|gaze-contingent|Attention modification: participants will receive gaze-contingent feedback according to their viewing patterns
2943918|NCT02945735|Placebo Comparator|non-gaze contingent|Participants will receive non-gaze-continent feedback unrelated to their viewing patterns
2943919|NCT02945722|Active Comparator|Decolonization|persistent carriers will be decolonized. Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days.
2943920|NCT02945722|Placebo Comparator|No decolonization|HD patients in which decolonization is not performed including impersistent carriers.
2943921|NCT02945709|Experimental|Personalized ACT|The personalized attention control training (ACT), comprised of six computerized sessions, in purpose of modulate biases in attention for personalized threat stimuli.
2943922|NCT02945709|Active Comparator|Non personalized ACT|The Non-personalized attention control training (ACT), comprised of six sessions, in purpose of modulate biases in attention for non-personalized threat stimuli.
2943923|NCT02945709|Placebo Comparator|Control training|Computerized control training, comprised of six sessions with a variation of the dot-probe task with neutral stimuli
2943924|NCT02945696|No Intervention|Local port site injection|
2943925|NCT02945696|No Intervention|Ultrasound-guided nerve blocks|
2943926|NCT02945696|Experimental|Laparoscopic guided nerve blocks|These patients will receive the same volume of local anesthetic as those in the ultrasound-guided arm, but the delivery of the local anesthetic will be guided by laparoscopy.
2943927|NCT02945683|Active Comparator|Reuterin D3|Patients should take 10 drops once a day during meals for 3 months
2943928|NCT02945683|Placebo Comparator|Placebo|Patients should take 10 drops once a day during meals for 3 months
2943929|NCT02945657|Experimental|MM36 1% ointment|MM36 topical ointment, 1%, applied twice daily for 28 days
2943930|NCT02945644|Placebo Comparator|Placebo|pill filled with inert material
2943931|NCT02945644|Active Comparator|Trazodone 50mg|
2943932|NCT02945644|Active Comparator|Trazodone 100mg|
2943933|NCT02945631|Experimental|Reduced Dose Radiation|All patients will receive daily radiation treatment with intensity-modulated radiotherapy (IMRT) - PTV56 and PTV50.4. Treatment will be given 5 days per week and will not routinely be delivered on Saturday, Sunday or major holidays unless a treatment is missed during the week due to technical and/or medical reasons. No more than 5 treatments should be given per week.
2943934|NCT02945618|Experimental|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
2943935|NCT02945618|Active Comparator|Conventional program with ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
2943936|NCT02945605|Experimental|Early Vestibular Rehabilitation|Participants in this group will receive a customized vestibular rehabilitation program designed and implemented by a vestibular physical therapist. The vestibular physical therapy must be initiated within 72 hours after randomization. Participants in this group will continue to receive standard of care treatment as directed by their physician.
2943937|NCT02945605|Active Comparator|Standard of Care|Participants in this group will receive standard care as directed by their physician.
2943940|NCT02945579|Experimental|Breast Cancer Surveillance|"Feasibility Phase to enroll 6 participants then Expansion Phase begins.~Image-guided biopsy of the breast performed after completing chemotherapy and before beginning radiation therapy.~Radiation therapy to the breast performed within 12 weeks after completion of chemotherapy.~Questionnaires completed at baseline and again at 6 months, 1, 3, and 5 years after post-chemotherapy biopsy."
2943941|NCT02945566|Active Comparator|Standard TME surgery|Radical total mesorectal excision
2943942|NCT02945566|Experimental|Long course concurrent chemoradiation|Capecitabine: 825 mg/m² orally, b.i.d., on radiotherapy days Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
2943943|NCT02945566|Experimental|Short course radiotherapy|A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
2943944|NCT02945553|Experimental|NMES|Neuromuscular electrical stimulation (NMES) group
2943945|NCT02945553|Active Comparator|Microstimulation|Microstimulation
2943946|NCT02945527|Active Comparator|Acetazolamide|750 mg acetazolamide p.o. divided in three dily doses, for 10 days
2943947|NCT02945527|Active Comparator|Dexamethasone|8 mg p.o. divided in three daily daily doses, for 2 days followed by gradual tapering
2943948|NCT02945527|No Intervention|No additional anti-edema treatment|No additional treatment
2943949|NCT02945501|Experimental|Subjects Who Received TES SO|Participants will sleep for approximately a two hour period and receive TES SO via the NeuroConn DC Stimulator PLUS during the second hour of that two hour sleep period. They will then experience a 46 hour period of sleep deprivation, during which cognitive performance, mood and subjective and objective aspects of sleepiness will be assessed approximately every 75 minutes beginning on the night of restricted sleep/treatment.
2943950|NCT02945501|Sham Comparator|Received SHAM (no TES SO)|Participants will sleep for approximately a two hour period and receive a SHAM (no TES SO) during the second hour of that two hour sleep period. They will then experience a 46 hour period of sleep deprivation, during which cognitive performance, mood and subjective and objective aspects of sleepiness will be assessed approximately every 75 minutes beginning on the night of restricted sleep/treatment.
2943951|NCT02945488|Experimental|Exercise and dietary plan|Combination cardiovascular and resistance training and Mediterranean dietary plan
2943952|NCT02945488|Experimental|Exercise and no dietary plan|Combination cardiovascular and resistance training and participants regular diet (control diet)
2943953|NCT02945488|Experimental|Stretching and dietary plan|Flexibility training (control exercise) and Mediterranean dietary plan
2943954|NCT02945488|Active Comparator|Stretching and no dietary plan|Flexibility training (control exercise) and participants regular diet (control diet)
2943955|NCT02945475||obese|Individuals ages 18 to 35 years of age with body mass index (BMI) 30-40 kg/m2
2943956|NCT02945475||lean|Individuals ages 18 to 35 years of age with BMI of 19-25 kg/m2; report never having been overweight and report no obese ﬁrst degree relatives
2943957|NCT02945475||obesity prone|Individuals ages 18 to 35 years of age with BMI of 20-29 kg/m2; report at least one first degree relative with a BMI >30 kg/m2; report having to put effort into not gaining weight; report previous attempts to lose weight, but not actively attempting to lose weight
2943958|NCT02945462|Experimental|autologous mesenchymal stem cells|"Intervention:~Autologous bone marrow derived stem cells will be injected twice intracavernously to enrolled erectile dysfunction patients"
2943959|NCT02945449|Experimental|Dose I|Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up.
2943960|NCT02945436|Active Comparator|SOC + SOC|Participants will receive current standard of care (SOC) for HIV counseling, testing, and referral at both visit 1 and visit 2.
2943961|NCT02945436|Experimental|SOC + SUBI|Participants will receive SOC at visit 1 and the experimental substance use brief intervention (SUBI) at visit 2.
2943962|NCT02945436|Experimental|SUBI + SUBI|Participants will receive the SUBI at both visit 1 and visit 2.
2943963|NCT02945436|Experimental|SUBI + SOC|Participants will receive the SUBI at visit 1 and SOC at visit 2.
2943964|NCT02945410|Experimental|Caloric Restriction and High Protein|Participants will be calorie restricted to 30 kcal/kg FFM/day and consume 1.7 g protein/kg BW/day.
2943965|NCT02945410|Active Comparator|Caloric Restriction and Normal Protein|Participants will be calorie restricted to 30 kcal/kg FFM/day and consume 0.8 g protein/kg BW/day.
2943966|NCT02945410|Placebo Comparator|Energy Balance|Participants will be in energy balance and consume 1.7 g protein/kg BW/day.
2943967|NCT02945397|Active Comparator|Individual activity|The individual activity consists of a 3 month membership card at a given gym. This is in addition to regular follow-up from welfare authorities.
2943968|NCT02945397|Active Comparator|Group-based activity|The group-based activity consists of a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services. This is in addition to regular follow-up from welfare authorities.
2943969|NCT02945384|Experimental|Creating Connections|Dual-generation intervention: child component delivered in classroom setting, parent component delivered in small-group setting
2943970|NCT02945384|No Intervention|Head Start as usual|Regular Head Start curriculum
2943971|NCT02945371|Experimental|IC Training|"The experimental arm (ARM1) is a person-centered inhibitory control training intervention, or PeCIC.~Between the baseline and endpoint sessions, participants come to our lab 12 times to participate in the training sessions. Each participant is randomly assigned to either the PeCIC training or an active control training. The training sessions will take place approx. every other day for 24 days.~Beginning 2-3 days after the baseline session, the experimental group (will come to our behavioral testing lab to receive the PeCIC training. At 11 sessions spaced one every other day, participants will complete one 8-min run of a modified stop-signal task. The cue on each trial (preceding the go signal arrow) will be an image of a personalized risk-cue (PRC) or a neural image."
2944013|NCT02945033|Experimental|Patient with aspirin intake|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines. Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece. If the mutation is detected, patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years. Blood intake will be done every 6 months to evaluate patient compliance to treatment
2943972|NCT02945371|Active Comparator|Control Training|Participants in the active control group (ARM2) of the PeCIC intervention will come to the behavioral testing laboratory to complete an 8-min control task every other day for 12 sessions. This control task is identical to the PeCIC except the auditory stop cues are omitted. All other procedures, settings, and schedules are identical to those in the experimental group. The only difference between the groups is that the active control does not practice IC.
2943973|NCT02945358||Prolonged ICU stay|Group 1: adult cardiac surgery with cardiopulmonary pump with prolonged ICU stay Group 2: adult cardiac surgery with cardiopulmonary pump with non-prolonged ICU stay
2943974|NCT02945332|Experimental|Required supervised walking|Device: Fitbit Flexes
2943975|NCT02945332|Active Comparator|Non-required supervised walking|Device: Fitbit Flexes
2943976|NCT02945306|Experimental|Adenotonsillectomy|Removal of tonsils and adenoids under a general anaesthetic
2943977|NCT02945306|Active Comparator|Watchful waiting with supportive care|Reassurance with active medical treatment of conditions associated with Sleep Disordered Breathing such as otitis media with effusion and allergic rhinitis
2943978|NCT02945293|Other|Study Procedures|Study procedures include a screening visit, a study day visit, and a follow-up phone call. Oxycodone is administered on the study day.
2943979|NCT02945280|Experimental|patients with acute UEDVT|Patients will receive 10 mg PO apixaban for 7 days and then 5 mg PO for 11 weeks, for a total of 12 weeks of treatment.
2943980|NCT02945267|Experimental|Nimotuzumab plus S1|Nimotuzumab Injection:400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks; S1:40 mg (Body surface area<1.5 m2) or 60mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
2943981|NCT02945267|Active Comparator|Placebo plus S1|Placebo:400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks; S1:40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
2943982|NCT02945254|Active Comparator|Background noise|Overnight sleep study with filtered white noise
2943983|NCT02945254|No Intervention|Silence|Overnight sleep study with normal environmental noise
2943984|NCT02945241|Experimental|Cystatin C-guided vancomycin dosing algorithm|Cystatin C is an endogenous cysteine proteinase inhibitor produced by all nucleated cells and a biomarker used routinely to estimate glomerular filtration rate either alone or in combination with creatinine. This new dosing algorithm includes patient weight, individualized goal trough concentration, and glomerular filtration rate (expressed with the CKD-EPI creatinine-cystatin C equation in mL/min) to determine dose and frequency.
2943985|NCT02945241|Other|Creatinine clearance guided vancomycin dosing|Historical controls for the quality improvement project had doses based on weight and interval established with the creatinine clearance using the Cockcroft-Gault equation.
2943986|NCT02945228||Chronic infection of hepatitis C virus (HCV) genotype 2|Participants with confirmed chronic HCV genotype 2, receiving paritaprevir/ritonavir/ombitasvir and ribavirin according to standard of care and in line with the current local label
2943987|NCT02945215|Experimental|IBI301|
2943988|NCT02945215|Active Comparator|Rituximab|
2943989|NCT02945202|Other|All Eyes|All eyes undergo the same interventions. These are the following examinations: Biometry, Refraction and Corneal Topography. The examinations take place 6 months after surgery
2943990|NCT02945189||Peri menopausal|Participants aged 41-55 years
2943991|NCT02945189||post menopausal|participants aged 56-65 years
2943992|NCT02945176|Experimental|ARGOS-IO system|"The ARGOS-IO system is a non-European Community (CE) marked investigational medical device composed of the implant and its accessories.~Implant: ARGOS-IO pressure sensor implant for sulcus placement or transcleral fixation~Accessories: MESOGRAPH reading device, Implant Injector"
2943993|NCT02945163|Experimental|Arm 1|Tenofovir 200mg + Lamivudine 300mg +Efavirenz 400mg PO Quaque die
2943994|NCT02945163|Active Comparator|Arm 2|Tenofovir 300mg + Lamivudine 300mg +Efavirenz 600mg PO Quaque die
2943995|NCT02945150|Experimental|Treatment with grazoprevir plus elbasvir|12 to 16 weeks of treatment with grazoprevir plus elbasvir
2943996|NCT02945124|Experimental|Normal children with K Tape|
2943997|NCT02945124|No Intervention|Normal children without K Tape|
2943998|NCT02945124|Experimental|DCD with K Tape|
2943999|NCT02945124|No Intervention|DCD without K Tape|
2944000|NCT02945111|Experimental|Real-time view|Women undergoing Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) will watch the cervical images taken throughout the examination in real-time on a digital screen. The patients' anxiety level both before and after the examination will be measured using the Spielberg's State Anxiety Inventory.
2944001|NCT02945111|Active Comparator|No visual support|Women in this arm will undergo Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) without any visual support. Their anxiety level both before and after the examination will be measured using the Spielberg's State Anxiety Inventory.
2944002|NCT02945098|No Intervention|Control group|No intervention. Remained five minutes at rest.
2944003|NCT02945098|Placebo Comparator|Placebo group|Apply Kinesio Taping without tension.
2944004|NCT02945098|Experimental|KT group|Apply Kinesio Taping application with tension.
2944005|NCT02945085|Experimental|Home Based Care Team|Primarily in-home treatment provided by team led by nurse practitioner with geriatrics and geriatric psychiatry expertise.
2944006|NCT02945085|Active Comparator|Telephone Based Care Team|Primarily telephone-based treatment provided by existing care management program offered by collaborating Medicare Advantage insurer.
2944007|NCT02945072|Active Comparator|Sevoflurane group|general anesthesia will be maintained with sevoflurane
2944008|NCT02945072|Experimental|TIVA group|general anesthesia will be maintained with total intravenous anesthesia (propofol and remifentanyl)
2944009|NCT02945059|Experimental|1|Patients will undergo reversible PVE before major hepatic resection.
2944010|NCT02945046|Experimental|Fremanezumab - A|Drug Regimen 1
2944011|NCT02945046|Experimental|Fremanezumab - B|Drug Regimen 2
2944012|NCT02945046|Placebo Comparator|Placebo|Matching Placebo
2944072|NCT02944656|Experimental|Gabapentin group|This group will receive local anesthesia per clinic protocol plus Gabapentin 600mg 1-2 hours preoperatively.
2944073|NCT02944656|Placebo Comparator|Placebo group|This group will receive local anesthesia per clinic protocol plus placebo 1-2 hours preoperatively.
2944014|NCT02945033|Placebo Comparator|Patient with placebo intake|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines. Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece. If the mutation is detected, patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years. Blood intake will be done every 6 months to evaluate patient compliance to treatment
2944015|NCT02945020|Experimental|Dabigatran etexilate mesylate+Odalasvir+Simeprevir|All participants will receive study medications in a fixed sequential order as: a single dose of dabigatran etexilate mesylate 75 milligram (mg) on Days 1, 17 and 26; Odalasvir (ODV) 25 mg once daily from Day 4 to 28; Simeprevir (SMV) 75 mg once daily from Day 20 to 28. The study drugs will be taken orally.
2944016|NCT02945007|Experimental|JNJ-53718678: PART 1|Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and B (novel concept formulation 1), and under fed condition for treatment C (novel concept formulation 1).
2944017|NCT02945007|Experimental|JNJ-53718678: PART 2|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and D (novel concept formulation 2), and under fed condition for treatment E (novel concept formulation 2).~Part 2 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
2944018|NCT02945007|Experimental|JNJ-53718678: PART 3|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and F (novel concept formulation 3), and under fed condition for treatment G (novel concept formulation 3).~Part 3 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
2944019|NCT02945007|Experimental|JNJ-53718678: PART 4|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and H (novel concept formulation 4), and under fed condition for treatment I (novel concept formulation 4).~Part 4 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
2944020|NCT02945007|Experimental|JNJ-53718678: PART 5|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and J (novel concept formulation 5), and under fed condition for treatment K (novel concept formulation 5).~Part 5 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
2944021|NCT02945007|Experimental|JNJ-53718678: PART 6|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and L (novel concept formulation 6), and under fed condition for treatment M (novel concept formulation 6).~Part 6 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
2944022|NCT02945007|Experimental|JNJ-53718678: PART 7|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and N (novel concept formulation 7), and under fed condition for treatment O (novel concept formulation 7).~Part 7 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
2944023|NCT02945007|Experimental|JNJ-53718678: PART 8|"Participants will receive a single dose of JNJ-53718678, 500 mg oral solution under fasted or fed conditions on day 1 for treatment A and P (oral concept formulation 1, 2, 3, 4, 5, 6 or 7) and under fed conditions for treatment Q (oral concept formulation 1, 2, 3, 4, 5, 6 or 7).~Part 8 of the study is optional, might be performed, depending on the interim results of prior parts. One of the concept formulations might be re-evaluated under different feeding conditions."
2944024|NCT02944994|Experimental|Unified Protocol|Unified Protocol-psychotherapy
2944025|NCT02944994|Experimental|Routine Care|Routine Care psychotherapy comparison
2944026|NCT02944981|Experimental|Gabapentin|Patient receiving oral gabapentin 600 mg preoperatively
2944027|NCT02944981|Placebo Comparator|Placebo|Patient receiving oral placebo tablet preoperatively
2944028|NCT02944968|Experimental|Treatment group|Radiofrequency ablation treatment with the THERMOCOOL SMARTTOUCH® SF-5D catheter in Paroxysmal AF population.
2944029|NCT02944955|Experimental|BLEX 404 Oral Liquid|"Part I:~Part I-1: Low Dose BLEX 404 Oral Liquid (3 mg/kg, BID) is administered in combination with 2 cycles of azacitidine.~Part I-2: High Dose BLEX 404 Oral Liquid (4.5 mg/kg, BID) is administered in combination with 2 cycles of azacitidine.~Part II:~Recommended Dose Level (RDL) of BLEX 404 Oral Liquid will be determined by results from Part I.~BLEX 404 Oral Liquid at RDL is administered in combination with 6 cycles of azacitidine."
2944030|NCT02944942||Postoperative nausea and vomiting|Group 1: Patients undergoing general anesthesia with postoperative nausea and vomiting Group 2: Patients undergoing general anesthesia without postoperative nausea and vomiting
2944031|NCT02944929|Experimental|Self-rehabilitation program|Self-rehabilitation program + standard medical care (BTI + conventional physiotherapy)
2944032|NCT02944929|No Intervention|Control arm|Arm with standard medical care ( BTI + conventional physiotherapy) without self-rehabilitation program
2944033|NCT02944916|Experimental|IryPump R Set|A new set for transanal irrigation composed by 2 parts : 1 pump and 1 rectal catheter . 1 rectal catheter used per irrigation respecting the patient usual frequency of transanal irrigation
2944034|NCT02944890|Experimental|RESTORE DEB|Conduct Drug Eluting Balloon Catheters(RESTORE DEB）
2944035|NCT02944890|Active Comparator|SeQuent® Please|Conduct Drug Eluting Balloon Catheters(SeQuent® Please）
2944036|NCT02944877|Experimental|intervention|experimental
2944037|NCT02944877|Other|control|Other
2944038|NCT02944864|Experimental|TQ-B3395|TQ-B3395 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2944039|NCT02944851||Prospective observational|The changes of IVC diameter, SpHb and vital signs of blood donors were observed after blood donation
2944074|NCT02944643|Experimental|Active group|Will get the mindfulness and support groups
2944075|NCT02944630|Experimental|Experimental:|Receiving psychotherapy and medical treatment.
2944076|NCT02944630|No Intervention|Control|Awaiting group: Receiving medical treatment.
2944077|NCT02944617|Experimental|Arm I (probiotic yogurt supplement)|Patients receive probiotic supplement Activia yogurt QD during weeks 2-13 of VEGF‐TKI treatment.
2944585|NCT02941211|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
2944040|NCT02944838|Active Comparator|Advocacy|"The Senior Change Makers Advocacy Program consists of weekly meetings, 1 hour each, for 8-weeks. The program will be led by graduate level students and will address topics such as how the environment affects walking, potential pedestrian hazards and solutions, how to conduct an audit of the walking environment, what advocates do, local examples of successful advocacy projects, creating an advocacy action plan, creating a fact sheet about the advocacy issue, writing letters to representatives, and making an advocacy presentation. The program will culminate with the presentation of the advocacy issue to a decision maker (e.g., a city planner, engineer, city council member, etc.)."
2944041|NCT02944838|Active Comparator|Physical Activity|The Senior Change Makers Physical Activity Program consists of weekly meetings, 1 hour each, for 8 weeks. The program provides participants with information about safe physical activity, strategies to increase physical activity, and guided walks. Topics will focus on walking, but we will also include information and activities relating to strength training, flexibility, and balance. Behavioral skills such as goal setting, addressing barriers, and social support will also be addressed.
2944042|NCT02944825|Active Comparator|Antibiotic|Patients randomized to the intervention arm will be provided a single oral dose of prophylactic oral antibiotic at the time of cystoscopic stent removal
2944043|NCT02944825|Active Comparator|No Antibiotic|Patients randomized to the non-intervention arm will not undergo prophylaxis at the time of cystoscopic stent removal
2944044|NCT02944812|Experimental|Chidamide|Chidamide is given to the patients, the dosage is 30mg,biw,po.
2944045|NCT02944799|Active Comparator|Alendronate|Continues treatment with alendronate, 70mgs oral tablet once every week
2944046|NCT02944799|Placebo Comparator|Placebo|Placebo tablets, one every week
2944047|NCT02944786|Experimental|HOPE-model|Four person-centred health dialogue sessions that include pain/stress management and education about stress and pain.
2944048|NCT02944786|No Intervention|Control|Standard care
2944049|NCT02944773|Experimental|facilitated tucking device (FTD)|20 infants use a FTD in the procedure of daily weight
2944050|NCT02944773|No Intervention|without FTD|20 infants use not a FTD in the procedure of daily weight
2944051|NCT02944760|Experimental|Low-Level Light Therapy Group|The patient was placed supine on a stretcher and the application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. Six points in quadriceps and four points in gastrocnemius, were irradiated, bilaterally, by 30 seconds.
2944052|NCT02944760|Placebo Comparator|Placebo Group|The patient was placed supine on a stretcher and the application of laser therapy occured with apparatus off.
2944053|NCT02944747|Experimental|Education & paper based calendar|"The participants will be counseled on importance of remembering LMP. In addition, a free calendar will be provided to the participant who will be asked to record menstrual bleeding and spotting dates in each month. The women will be asked to record no bleeding if she did not bleed for any particular month. Likewise, if anybody forgets to record, she will ask to keep a record of it in the subsequent month. Female counselors from the study team will conduct the group or individual education sessions."
2944054|NCT02944747|Experimental|Education & SMS system|Cell-phones will be provided free of cost to participants who will be asked to text the bleeding dates of their menstruation and spotting every month within 3 days of the start of the bleeding. Study team will collaborate with a mobile phone company and the charge of SMS for reporting LMP dates will be free for the user. In situations, where the participant fails to text, she will be provided with several SMS reminders after the due date.
2944055|NCT02944747|Experimental|Education & smart-phone application|Smart phones with an application and an inbuilt reminder system will be provided free of cost to participants who will be asked for recording menstruation dates. Experienced programmer from icddr,b will be involved in developing the application. Again, participants will be asked to record bleeding dates each month and will upload the data in the central server via internet. If participants fail to record the dates and upload the data, an automatic reminder will be sent.
2944056|NCT02944747|No Intervention|Comparison|The participants will not receive any of the interventions that are focused in this study.
2944057|NCT02944734|Experimental|Candesartan Cilexetil (CC) 8mg|Candesartan Cilexetil 8mg, once a day for 8 weeks
2944058|NCT02944734|Experimental|CC 16mg|Candesartan Cilexetil 16mg, once a day for 8 weeks
2944059|NCT02944734|Experimental|Amlodipine(AML) 5mg|Amlodipine 5mg, once a day for 8 weeks
2944060|NCT02944734|Experimental|AML 10mg|Amlodipine 10mg, once a day for 8 weeks
2944061|NCT02944734|Experimental|CC 8mg / AML 5mg|Candesartan 8mg and Amlodipine 5mg, once a day for 8 weeks
2944062|NCT02944734|Experimental|CC 8mg / AML 10mg|Candesartan 8mg and Amlodipine 10mg, once a day for 8 weeks
2944063|NCT02944734|Experimental|CC 16mg / AML 5mg|Candesartan 16mg and Amlodipine 5mg, once a day for 8 weeks
2944064|NCT02944734|Experimental|CC 16mg / AML 10mg|Candesartan 16mg and Amlodipine 10mg, once a day for 8 weeks
2944065|NCT02944721|Other|Transversal study|Patients who had surgery for breast cancer for 2 years or less
2944066|NCT02944721|Other|Longitudinal study|Patients that must be operated for a breast cancer
2944067|NCT02944708|Active Comparator|Conventional chemotherapy|Patients in this arm will only receive 4-8 cycles of cisplatin-based regimen. TPF ( docetaxel, cisplatin and 5-fluorouracil ), TP (docetaxel and cisplatin), GP (gemcitabine and cisplatin) and PF (cisplatin and 5-fluorouracil) regimens are preferred.
2944068|NCT02944708|Experimental|Maintenance chemotherapy 1|Patients in this arm will receive 6 cycles of oral fluoropyrimidine monotherapy as maintenance therapy, in addition to 4-8 cycles of cisplatin-based standard chemotherapy.
2944069|NCT02944708|Experimental|Maintenance chemotherapy 2|Patients in this arm will receive oral fluoropyrimidine maintenance therapy until disease progression or intolerable toxicities, after 4-8 cycles of cisplatin-based standard chemotherapy.
2944070|NCT02944682|Experimental|Liquefied petroleum gas cookstove|Participants randomized to the experimental arm will receive a liquefied petroleum gas (LPG) cookstove and 18-month supply of LPG.
2944071|NCT02944682|No Intervention|Control|Participants in the control group will not receive a liquefied petroleum gas (LPG) stove and will continue using traditional cooking methods (open fire or traditional stoves), or the cooking method of their choice. Control households will be provided equivalent LPG stoves and fuel supplies following the completion of the study.
2944779|NCT02939872|Active Comparator|Clopidogrel only|Clopidogrel monotherapy
2944078|NCT02944617|Active Comparator|Arm II (no intervention)|Patients avoid any intake of yogurt or yogurt-containing foods and refrain from taking/consuming other probiotic supplements for 3 months.
2944079|NCT02944604|Experimental|PEG-rhG-CSF|Patients with breast cancer who were treated with intensive chemotherapy received PEG-rhG-CSF.
2944080|NCT02944578|Experimental|Curcumin Arm|Participants in this arm will use 2000 mg of intravaginal curcumin daily for 12 weeks.
2944081|NCT02944578|Placebo Comparator|Placebo Arm|Participants in this arm will use 2000 mg of a placebo daily for 12 weeks.
2944082|NCT02944565|Experimental|Treatment (daratumumab)|Patients receive daratumumab IV over 1.5 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.
2944083|NCT02944552|Experimental|low dose group|Patients in the low dose group administrated bicyclol tablet 25mg orally, three times daily for 4-8 weeks.
2944084|NCT02944552|Experimental|high dose group|Patients in the high dose group administrated bicyclol tablet 50mg orally, three times daily for 4-8 weeks.
2944085|NCT02944552|Active Comparator|positive drug control group|Patients in the positive drug control group administrated polyene phosphatidylcholine capsule 456mg orally, three times daily for 4-8 weeks.
2944086|NCT02944539||Gastric cancer group|300 consecutive patients were recruited, who have diagnosed with gastric cancer by biopsy
2944087|NCT02944539||Control group|The 300 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
2944088|NCT02944526|Experimental|Ropivacaine Suprascapular Nerve Block|"Suprascapular nerve block realized in sterile conditions under live ultrasound guidance: injection of 5ml of Ropivacaine monohydrochloride 2mg/ml.~3 successive blocks are realized at 1 week interval."
2944089|NCT02944526|Placebo Comparator|Placebo Suprascapular Nerve Block|"Suprascapular nerve block realized in sterile conditions under live ultrasound guidance: injection of 5ml of physiological /isotonic saline.~3 successive blocks are realized at 1 week interval."
2944090|NCT02944513|Experimental|Experimental|Subjects will receive the Quell device
2944091|NCT02944513|No Intervention|Control|Subjects will not receive the Quell device
2944092|NCT02944500|Experimental|Liraglutide followed by placebo|Participants will receive liraglutide with dose titration over 5 weeks (0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, and 3.0mg for 1 week) followed by a minimum of 3 weeks wash-out and then return for the same dose of placebo for the same amount of time.
2944093|NCT02944500|Experimental|Placebo followed by liraglutide|Participants will receive placebo with dose titration (0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, and 3.0mg for 1 week) followed by a minimum of 3 weeks wash-out and then return for the same dose of liraglutide for the same amount of time.
2944094|NCT02944487|Experimental|Single ascending doses of lucerastat|Subjects were enrolled sequentially in 4 groups and received a single oral dose of lucerastat from 100 mg to 1000 mg in the morning of Day 1
2944095|NCT02944487|Experimental|B.i.d. Dose Group|Subjects received two doses of lucerastat (2 x 1 g) 12 hours apart on Day 1
2944096|NCT02944487|Placebo Comparator|Placebo for singe ascending doses|These subjects received matching placebo administered orally in the morning of Day 1
2944097|NCT02944487|Placebo Comparator|Placebo for b.i.d.Group|These subjects received matching placebo administered orally in the morning and in the evening of Day 1
2944098|NCT02944474|Experimental|Cohort 1 (200 mg)|Six subjects received 200 mg of lucerastat twice daily for 7 consecutive days in fasting conditions
2944099|NCT02944474|Experimental|Cohort 2 (500 mg)|Six subjects received 500 mg of lucerastat as a single dose in the morning of Day 1 in fed conditions. After a 5-day washout, they received the same dose twice daily for 7 consecutive days in fasting conditions
2944100|NCT02944474|Experimental|Cohort 3 (500 mg)|Six subjects received 500 mg of lucerastat twice daily for 7 consecutive days in fasting conditions
2944101|NCT02944474|Experimental|Cohort 4 (1000 mg)|Six subjects received 1 g of lucerastat for 7 consecutive days in fasting conditions
2944102|NCT02944474|Placebo Comparator|Placebo cohorts 1 to 4|Twelve subjects received matched placebo (3 subjects per cohort, except for Cohort 3 where 4 subjects received placebo)
2944103|NCT02944461|Experimental|Dapsone gel 7.5%|Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.
2944104|NCT02944448|Active Comparator|CR845 tablet 1 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
2944105|NCT02944448|Active Comparator|CR845 tablet 2.5 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
2944106|NCT02944448|Active Comparator|CR845 tablet 5 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
2944107|NCT02944448|Placebo Comparator|Placebo tablet|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
2944108|NCT02944435|Experimental|CB-839 Capsules|A single dose of 3 x 200-mg capsules of CB-839 will be administered orally with water approximately 5 minutes after consuming an entire meal
2944109|NCT02944435|Active Comparator|CB-839 Tablets|A single dose of 3 x 200-mg tablets of CB-839 will be administered orally with water approximately 5 minutes after consuming an entire meal
2944110|NCT02944422||Males|Primary school Egyptian boys from 7-10 years.
2944111|NCT02944422||Females|Primary school Egyptian girls from 7-10 years.
2944112|NCT02944396|Experimental|Veliparib and nivolumab with platinum doublet chemotherapy|Veliparib and nivolumab in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed)
2944113|NCT02944396|Experimental|Veliparib with platinum doublet chemotherapy|Veliparib in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed)
2944114|NCT02944383|Experimental|Gemcabene 300 mg QD|Subjects will be randomized to gemcabene 300 mg QD for 12 weeks
2944115|NCT02944383|Experimental|Gemcabene 600 mg QD|Subjects will be randomized to gemcabene 600 mg QD for 12 weeks
2944116|NCT02944383|Placebo Comparator|Placebo|Subjects will be randomized to placebo tablet QD for 12 weeks
2944236|NCT02943564|Experimental|Rapastinel 450 mg|Rapastinel 450 mg weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
2944117|NCT02944370|Experimental|PlayFit, Modified exercise games|Subjects will participate in three 60 minute game sessions each week for 12 weeks. During each game session, subjects will be divided randomly into two teams to play a modified game. Research staff will review the instructions of the game and if needed, modify the game rules during play to enhance the experience (ie. keep it fun, keep it to moderate intensity level). The length of play session between breaks increases each week.
2944118|NCT02944357|Experimental|Treatment (gemcitabine hydrochloride, cisplatin, AGS-003-BLD)|"NEOADJUVANT PHASE: Patients receive gemcitabine hydrochloride IV on days 1 and 8, AGS-003-BLD ID on day 1, and cisplatin IV on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive AGS-003-BLD ID on day 1. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo cystectomy during course 8.~ADJUVANT PHASE: Patients continue AGS-003-BLD ID on day 1 of course 9. Treatment repeats every 12 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity."
2944119|NCT02944344|Experimental|Four Conversations Intervention|Subjects in this arm will participate in Reimagine's online Four Conversations program during the initial study period of four weeks.
2944120|NCT02944344|Other|Waitlisted Control|Subjects in this arm will continue to receive standard care from their healthcare providers during the initial study period (i.e. no intervention). After four weeks, subjects will then participate in Reimagine's online Four Conversations program.
2944121|NCT02944318|Experimental|"The Movement Program"|The intervention program was structured according three main components: (1) training and activities in general curriculum and Physical Education classes; (2) active facilities in the school environment; (3) health education in school community.
2944122|NCT02944318|No Intervention|No intervention|"Schools in the control group will maintain a regular academic year with conventional activities. Thus schools have two weekly Physical Education classes which are organized by according to the perspective of their teachers. Besides that, the Program Saúde na Escola is also performed."
2944123|NCT02944305||Patient with difficult intubation|Group 1: Patient undergoing endotracheal intubation with difficult intubation Group 2: Patient undergoing endotracheal intubation without difficult intubation
2944124|NCT02944292|Experimental|All enrolled patients|"Study population:~Adult, mechanically ventilated patients with IAP between 12 and 20 mmHg in at least two consecutive measurements, spontaneous breathing activity of at least 6 breaths/minute, RASS score between 0 and -4, if no contraindications to propofol administration are present and no other immediate interventions to reduce IAP are planned~Intervention: Deepening of sedation Deepening of sedation will be achieved with a bolus of propofol followed by continuous infusion for one hour."
2944125|NCT02944279||Peking University Third Hospital|
2944126|NCT02944279||Beijing Friendship Hospital|
2944127|NCT02944279||Beijing Shijitan Hospital|
2944128|NCT02944279||Beijing Xiyuan Hospital|
2944129|NCT02944279||China-Japan Friendship Hospital|
2944130|NCT02944266||Hypovolemia group|Those patients who are said to be positive for one or more of the following TTE criteria are grouped under this , them being i.IVC diameter of less than 1 cm , ii.Caval index of > 50%, iii.Left ventricular end diastolic area of < 10 cm2 iv. VTI variation with respiration of < 12.5%, are grouped under the hypovolaemia group .
2944131|NCT02944266||Normovolaemia group|Those patients without the above said TTE findings are hypothesised to be normovolaemic and grouped in here.
2944132|NCT02944253|Experimental|Low energy diet 70g carbohydrates|isocaloric (4128 kJ/day (1000 kcal/day) for women, 5021 kJ/day (1200 kcal/day) for men)low energy diet containing 70 gram carbohydrates.
2944133|NCT02944253|Experimental|Low energy diet 100g carbohydrates|isocaloric (4128 kJ/day (1000 kcal/day) for women, 5021 kJ/day (1200 kcal/day) for men)low energy diet containing 100 gram carbohydrates
2944134|NCT02944253|Experimental|Low energy diet 130g carbohydrates|isocaloric (4128 kJ/day (1000 kcal/day) for women, 5021 kJ/day (1200 kcal/day) for men)low energy diet containing 130 gram carbohydrates
2944135|NCT02944227|Experimental|Lucentis|Lucentis fixed treatment
2944136|NCT02944214|Experimental|Febuxostat|take orally,10-80mg per day, for 1 year,start with a low dose, and adjust the dose according to the level of uric acid
2944137|NCT02944214|Experimental|Benzbromarone|take orally,12.5-100mg per day, for 1 year,start with a low dose, and adjust the dose according to the level of uric acid
2944138|NCT02944201|Experimental|Carvedilol|Carvedilol will be started at 6.25 mg by mouth twice daily. Patients will take carvedilol for 28 days prior to prostatectomy. They will be seen every 7 days and adjustments in the dose will be considered at those visits.
2944139|NCT02944188|Experimental|LRH plus ERAS|patients undergo Laparoscopic right hemicolectomy plus ERAS
2944140|NCT02944188|Active Comparator|ORH plus ERAS|patients undergo open right hemicolectomy plus ERAS
2944141|NCT02944175|Experimental|Sugammadex|Patients will receive Sugammadex to antagonise the residual effects of neuromuscular blocking drugs
2944142|NCT02944175|Active Comparator|Neostigmine|Patients will receive Neostigmine to antagonise the residual effects of neuromuscular blocking drugs
2944143|NCT02944162|Experimental|CAR-NK Cell immunotherapy|Enrolled patients will receive CAR-NK cells immunotherapy with a novel specific chimeric antigen receptor targeting CD33 antigen by infusion.
2944144|NCT02944149|Active Comparator|assistant medical officer (AMO)|Assistant medical officers (AMO) are currently allowed to provide tubal ligation by minilaparotomy, however government regulations do not allow clinical officers (COs) to provide this service.
2944145|NCT02944149|Experimental|clinical officer (CO)|Experimental: clinical officer (CO) In Tanzania, COs are mid-level providers who offer diagnosis, treatment, and minor surgeries. They are more common in rural areas than medical officers (MOs) and assistant medical officers (AMOs) and are generally considered capable of performing minor surgery. Almost all facilities in Tanzania are understaffed, but COs vastly outnumber MOs and AMOs. COs are more prevalent in poorer and/or rural areas than other higher level cadres; thus, task-shifting to COs would increase access to tubal ligation by minilaparotomy for many women who are most in need.
2944146|NCT02944136|Active Comparator|Enhanced Usual Care|Referred to a therapist and/or psychiatrist in their home town depending on the type of treatment they prefer (e.g., behavioral and/or medication)
2944275|NCT02943304||Exposed|Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV
2944147|NCT02944136|Experimental|stepped collaborative care|At least biweekly contact from a care coordinator by phone and face-to- face visits occurring approximately every 2 months during the patients outpatient visits or treatment, and 24/7 access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
2944148|NCT02944123|Other|Clopidogrel 75 mg|Clopidogrel 600 mg as loading dose and followed by 75 mg/day as maintenance dose.
2944149|NCT02944123|Experimental|Prasugrel 5 mg|Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
2944150|NCT02944123|Experimental|Ticagrelor 45 mg|Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
2944151|NCT02944110|Active Comparator|Pancreatectomised + LY2409021|During the experimental day the patient will undergo a 75gr-OGTT. On the evening before the experimental day, the patient will ingest a dose of 300mg of LY2409021.
2944152|NCT02944110|Placebo Comparator|Pancreatectomised + placebo|During the experimental day the patient will undergo a 75gr-OGTT. On the evening before the experimental day, the patient will ingest placebo tablets.
2944153|NCT02944110|Active Comparator|Healthy + LLY2409021|During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest a dose of 300mg of LY2409021.
2944154|NCT02944110|Placebo Comparator|Healthy + placebo|During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest placebo tablets.
2944155|NCT02944097|Experimental|Vineatrol30 native powder|500 mg Vineatrol30 containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin
2944156|NCT02944097|Experimental|Vineatrol30 micelles|500 mg Vineatrol30 micelles containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin
2944157|NCT02944084|Experimental|Rice bran extract|2 g of unprocessed rice bran extract
2944158|NCT02944084|Experimental|Porridge in water|35 g of porridge containing 2 g of rice bran extract mixed with 95 ml of warm water
2944159|NCT02944084|Experimental|Porridge in milk|35 g of porridge containing 2 g of rice bran extract mixed with 95 ml of warm milk (3.8% fat)
2944160|NCT02944071|Experimental|Ranger™ and Ranger™|
2944161|NCT02944058|Active Comparator|Philos plate|Intervention is surgery with Philos plate
2944162|NCT02944058|Active Comparator|Multiloc nail|Intervention is surgery with Multiloc nail
2944163|NCT02944045|Placebo Comparator|Placebo|Saline serum, same volume as in the Experimental arm.
2944164|NCT02944045|Experimental|Steroids|"Methylprednisolone intra veinous~Day 1 to 5 : 30mg twice per day~Day 6 to 10 : 30mg per day~Day 11 to 21 : 20mg per day"
2944165|NCT02944032|Experimental|Cogmed|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
2944166|NCT02944032|Active Comparator|MobyMax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
2944167|NCT02944019||Edoxaban|Patients with established Non Valvular Atrial Fibrillation (NVAF) treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
2944168|NCT02943993||Patients treated with Edoxaban|Patients with established acute initial or recurrent VTE treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
2944169|NCT02943980|Experimental|CMAC Videolaryngoscope|tracheal intubation using CMAC
2944170|NCT02943980|Experimental|Macintosh laryngoscope|tracheal intubation using Macintosh laryngoscope
2944171|NCT02943967|Active Comparator|CXL + PRK group|"Corneal cross-linking surgery is perfomed in one eye : deepithelization of the cornea and instillation of 0,1% riboflavin (ophthalmos - Brazil) for 30 minutes and UVA for irradiated for 30 minutes with ultraviolet-A of 365nm light with an irradiance of 3 mW/cm2 using Xlink (Opto - São Carlos) Photorefractive keratotomy will be perfomed in the same eye using excimer laser Ladarvision (Alcon - USA) with 0,02 % mitomicin for 30 seconds (Ophthalmos - Brasil) simultaneously with the other eye.~Both procedures will have the same post operative treatment :~gatifloxacin 0,3% 6/6h for 10 days prednisolone acetate 0,12% 6/6h por 14 days"
2944172|NCT02943967|Active Comparator|PRK group|"Photorefractive keratotomy will be perfomed in the fellow eye using excimer laser Ladarvision (Alcon - USA) with 0,02 % mitomicin for 30 seconds (Ophthalmos - Brasil) simultaneously with the other eye.~Both procedures will have the same post operative treatment :~gatifloxacin 0,3% 6/6h for 10 days prednisolone acetate 0,12% 6/6h por 14 days"
2944173|NCT02943954|Other|Angiography guided PCI|Revascularisation of non-culprit lesions guided by PCI
2944174|NCT02943954|Other|FFR guided PCI|Revascularisation of non-culprit lesions guided by FFR measurement
2944175|NCT02943928|Experimental|laryngoscope and chest CT image|First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis.
2944176|NCT02943928|Experimental|Traditional method by experience|Operator inserted the double lumen tube by experience
2944177|NCT02943915|Experimental|Group 1: Ekso GT Rehabilitation Therapy|Participants in this group receive Ekso GT (gait training) PT therapy intervention 3 times per week for 12 weeks (36 sessions). Intervention: Ekso GT Rehabilitation therapy
2944353|NCT02942719||Suzhou Municipal Hospital|
2944354|NCT02942719||Wenling Women's and Children's Hospital|
2944178|NCT02943915|Active Comparator|Group 2: Active controls - BWSTT Therapy|Participants in this group receive a matched number of sessions of standard gait training using body-weight supported treadmill training and overground training. Intervention: Body Weight Supported Treadmill Training
2944179|NCT02943915|No Intervention|Group 3: Passive controls|Participants in this group continue with normal daily activities over 12 weeks.
2944180|NCT02943902|Experimental|Group 1a (1+1, 6 weeks)|PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks and 9 months of age
2944181|NCT02943902|Experimental|Group 1b (1+1, 6 weeks)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks and 9 months of age
2944182|NCT02943902|Experimental|Group 2a (1+1, 14 weeks)|PCV10 (Synflorix 0.5ml injection) will be administered at 14 weeks and 9 months of age
2944183|NCT02943902|Experimental|Group 2b (1+1, 14 weeks)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 14 weeks and 9 months of age
2944184|NCT02943902|Active Comparator|Group 3a (2+1)|PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa
2944185|NCT02943902|Active Comparator|Group 3b (2+1)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa
2944186|NCT02943889|Experimental|Mesenchymal stem cell transplantation|This group will include 20 patients with liver cirrhosis, autologous bone marrow derived mesenchymal stem cells will be transplanted to them. Every patient will receive 2 million cells per Kg via portal vein once.
2944187|NCT02943889|No Intervention|Control group|This group will include 20 patients with liver cirrhosis as control group matching (stem cell group) in age, sex and child score. They will continue on the conventional therapy they already on and no stem cell transplantation will done for them.
2944188|NCT02943876|No Intervention|Control|Serves as a control group, receiving generic information about depression and self-help.
2944189|NCT02943876|Experimental|Intervention|Serves as an intervention group, receiving personalized depression risk information determined by the sex-specific risk calculators, and generic information about depression and self-help.
2944190|NCT02943863|Active Comparator|HFNC first|"Patients in HFNC first receive oxygen therapy using HFNC in ahead of conventional nasal cannula oxygen therapy. After 20 minutes of HFNC therapy, patients receive conventional nasal cannula oxygen therapy."
2944191|NCT02943863|Active Comparator|LFS first|"Patients in LFS first receive oxygen therapy using conventional nasal cannula in ahead of HFNC therapy. After 20 minutes of conventional nasal cannula oxygen therapy, patients receive HFNC oxygen therapy."
2944192|NCT02943850|Experimental|Stem cell implantation|Subjects meeting all Eligibility Criteria and providing Informed Consent will be enrolled in one of two sequential dosing groups (Group A and B). Subjects will be treated sequentially with a minimum of one month interval between surgeries for the first three subjects in each dosing cohort. The remaining subjects in the cohort will be treated with a minimum interval of at least one week between surgeries. There will be 9 subjects in each group. No control group is included. All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
2944193|NCT02943837|Active Comparator|EUS-FNA|Device: 22G FNA needle
2944194|NCT02943837|Experimental|EUS-FNB|Device: 20G FNB needle
2944195|NCT02943824|Experimental|Machine Learning Planning|Patients will be pre-operatively planned using a machine-learning computer program. An expert radiation oncologist will evaluate the plan prior to implantation. The prescription dose is 145 Gy for monotherapy LDR brachytherapy.
2944196|NCT02943824|Active Comparator|Radiation Therapist Planning|Patients will be pre-operatively planned manually by an expert radiation therapist (> 60 cases planned). An expert radiation oncologist will evaluate the plan prior to implantation.The prescription dose is 145 Gy for monotherapy LDR brachytherapy.
2944197|NCT02943811||MANIPULATOR|Patients who were operated for endometrial cancer by laparoscopy with the use of a uterine manipulator
2944198|NCT02943811||NO MANIPULATOR|Patients who were operated for endometrial cancer by laparoscopy without the use of a uterine manipulator
2944199|NCT02943798|Experimental|Group A|Patients will be administered with etoposide plus carboplatin as first-line treatment.
2944200|NCT02943798|Experimental|Group B|Patients will be administered with paclitaxel plus carboplatin as first-line treatment.
2944201|NCT02943785|Experimental|Edoxaban-based Regimen|Edoxaban-based regimen 60 mg and 30 mg film coated tablet for once-daily oral use, and 15 mg film coated tablet for transitioning at end of treatment. Dosing must follow the locally approved label.
2944202|NCT02943785|Active Comparator|VKA-based Regimen|VKA-based regimen oral VKA tablets as selected and provided by the site and used in accordance with the local label. The Investigator will monitor the patient and adjust the VKA dose to maintain the dose within target.
2944203|NCT02943772|Experimental|Local hypothermia|Local application of a brick cooled to -20(celsius)
2944204|NCT02943772|Sham Comparator|Control|Local application of a brick in room temperature
2944205|NCT02943759|Experimental|Neem leaf extract|Neem leaf extract (alcoholic solution) used as an anti inflammatory , antibacterial irrigant
2944206|NCT02943759|Active Comparator|Chlorhexidine gluconate|2% chlorhexidine gluconate intracanal irrigant solution used as an antibacterial chemical mean for canal irrigation
2944207|NCT02943746|Active Comparator|Control Group (Standard Protein Diet)|"Infants will receive a standard feeding regimen which consists of mother's own milk or donor human milk (DHM) with DHM derived fortifier.~Once daily, a 24 hour batch of human milk is prepared for each infant (standard practice). A 2.5 mL sample will be analyzed for calories, protein, fat, and carbohydrates. Based on the amount of protein in the milk, fortification of feeds with donor human milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day of protein. Data will be recorded for milk analysis, nutrition, and infant growth.~The diet will be continued until approximately 35 to 36 weeks postmenstrual age at which point a DXA scan will be performed.~A serum blood urea nitrogen and creatinine as well as serum calcium, phosphorus, and alkaline phosphatase when the DXA is performed.~Anthropometrics: weekly weight, length, and head circumference by trained research nurse."
2944235|NCT02943564|Experimental|Rapastinel 225 mg|Rapastinel 225 milligram (mg) weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
2944355|NCT02942719||First Affiliated Hospital of Kunming Medical University|
2944208|NCT02943746|Experimental|Intervention Group (High Protein Diet)|"The intervention group will receive the same standard feeding regimen with the addition of extra milk fortification to give a high protein diet.~Human milk will be prepared and analyzed in the same method as the control group. Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.~The diet will be continued until approximately 35 to 36 weeks PMA at which point a DXA scan will be performed.~Infants will have 3 sets of labs. A serum blood urea nitrogen and creatinine as well as serum calcium, phosphorus, and alkaline phosphatase when the DXA is performed.~Anthropometrics: weekly weight, length, and head circumference by trained research nurse."
2944209|NCT02943733|Experimental|TAS-102 and TMZ|"Part 1: dose-escalation phase to determine MTD of TAS-102 in combination with Temozolomide (TMZ). Treatment cycles are 28 days, with TAS-102 administered orally twice daily days 1-5 and 8-12, and TMZ administered orally days 8-12. No treatment medications administered days 13-28 of each cycle. Growth factor support is required during Part 1 and should be dosed per institutional standards.~Part 2: expansion phase to evaluate preliminary efficacy of MTD. Subjects treated with the recommended phase 2 drug doses determined in part 1. Treatment will continue for up to 13 cycles (approx. 12 months). Growth factor support is allowed during Part 2 and should be dosed per institutional standards."
2944210|NCT02943720|Placebo Comparator|placebo|5 SC injections in 2 months
2944211|NCT02943720|Experimental|AllerT 50 ug|5 SC injections in 2 months
2944212|NCT02943720|Experimental|AllerT 10 ug|5 SC injections in 2 months
2944213|NCT02943707|Experimental|treatment group: ABMSCi & drugs|ABMSCi: Autologous bone marrow stem cells infusion drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
2944214|NCT02943707|Active Comparator|control group: drugs|drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
2944215|NCT02943694|Experimental|TaTME with CS-Compact (GelPoint Path)|Based on newly-designed devices tailored for transanal TME, CS-Compact, GelPoint and Octoport are employed for the clinical applications.
2944216|NCT02943681|Experimental|Measles vaccine|Measles vaccine, 1 dose of 0.5 ml
2944217|NCT02943681|No Intervention|Control|Nothing
2944218|NCT02943668|Experimental|Treatment (deferasirox)|Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
2944219|NCT02943655|Active Comparator|combined oral contraceptives|oral second generation pills one tablet daily
2944220|NCT02943655|Active Comparator|medroxyprogesterone acetate|oral 5 mg daily
2944221|NCT02943655|Active Comparator|non-steroidal anti-inflammatory|oral 500 mg mefenamic acid three times per day
2944222|NCT02943642|Experimental|A-dmDT390-bisFv(UCHT1)|A-dmDT390-bisFv(UCHT1) will be administered as Total Dose µg/kg given as 1/8 Total Dose µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes.
2944223|NCT02943642|Active Comparator|Vorinostat|Subjects in the control arm will receive oral vorinostat capsules at a dose of 400 mg daily up to 12 months in duration until disease progression or uncontrolled side effects take place. Subjects in the vorinostat arm who experience progressive disease may cross over into the experimental arm after 6 months of treatment after a 2-week vorinostat washout period.
2944224|NCT02943642|Experimental|Lead-in Dosing single arm|"Dose Group 1: A-dmDT390-bisFv(UCHT1) will be administered as 5 µg/kg given as 0.625 µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes.~Dose Group 2: A-dmDT390-bisFv(UCHT1) will be administered as 10 µg/kg given as 1.25 µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes."
2944225|NCT02943629|Experimental|Non-Obese: Apneic Oxygenation: eight minute|Non-obese healthy female patients requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed and then receive 10 l/minute flow of oxygen through the P blade (apneic oxygenation) for eight minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
2944226|NCT02943629|Other|Non-Obese: Without Apneic Oxygenation|Non-obese healthy female patients requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed for eight minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
2944227|NCT02943629|Experimental|Obese: Apneic Oxygenation: five minute|Morbidly obese patients (BM I ≥ 40 kg/m2) requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed and then receive 10 l/minute flow of oxygen through the P blade (apneic oxygenation) for five minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
2944228|NCT02943629|Other|Obese: Without Apneic Oxygenation|Morbidly obese patients (BM I ≥ 40 kg/m2) requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed for five minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
2944229|NCT02943616|Experimental|Absorb BVS|Subjects receiving Absorb GT1 Bioresorbable Vascular Scaffold (BVS).
2944230|NCT02943603|Experimental|mFOLFX6 + Pembrolizumab|Subjects will receive mFOLFOX6 every 2 weeks (on Days 1, 15, 29, 43) and Pembrolizumab every 3 weeks (on Days 1, 22, 43).
2944231|NCT02943590|Placebo Comparator|Placebo|Placebo will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)
2944232|NCT02943590|Experimental|Atorvastatin|Atorvastatin will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)
2944233|NCT02943577|Experimental|Rapastinel 450 mg|Rapastinel 450 mg weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
2944234|NCT02943577|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
2944237|NCT02943564|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
2944238|NCT02943551|Other|Providers|"Physicians, pediatric nurse practitioners and physician assistants (referred to as providers from here forward) will be recruited from 20 practices, with a maximum of four providers participating from a single practice, for a maximum of 80 providers.~Providers will receive an online tutorials, interactive group webinars, simulated booster sessions as well as feedback reports."
2944239|NCT02943551|Other|Parents|"The number of parents who participate will depend on the number of providers who agree to participate at each of the 20 practices. The total could range from a minimum of 1800 parents to a maximum of 7200 parents.~Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit."
2944240|NCT02943538|Experimental|Telemedicine group|In this group, monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
2944241|NCT02943538|Experimental|Telephone support group|A telephone control of their state and evolution will be made through the nursing staff of the unit.
2944242|NCT02943538|Active Comparator|Control group|Conventional care provided in the unit to patients with IBD -high moderate complexity.
2944243|NCT02943525|Experimental|packing|Patients after laparoscopic sacrocolpopexy with a vaginal packing at the end of surgery
2944244|NCT02943525|No Intervention|no packing|Patients after laparoscopic sacrocolpopexy without a vaginal packing at the end of surgery
2944245|NCT02943512|Experimental|Discharge day of Procedure|Subjects in this arm will be discharged the same day of their cardiac device implant if deemed safe by treating physician.
2944246|NCT02943512|No Intervention|Control|Subjects in this arm will remain in the hospital overnight per standard of care and will be discharged the next day if deemed safe by treating physician.
2944247|NCT02943499|Active Comparator|Active Comparator App/Training|This is a standard smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. Subjects will be encouraged to set a quit date of 3 weeks, to allow comparison to experimental arm quit date.
2944248|NCT02943499|Experimental|Experimental App/Training|This is a 3-week smartphone-based training program that trains mindfulness for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
2944249|NCT02943486|Experimental|dac-MSCs and Fitostimoline|Intradermic application of dac-MSCs (1 mL ) in four equidistant points around the ulcer (twice: day 0 and 7) and topical application of fitostimoline every other day
2944250|NCT02943486|Active Comparator|MSCs and Fitostimoline|Intradermic application of MSCs (500,000 cells/mL) in four equidistant points around the ulcer (once: day 0 ) and topical application of fitostimoline every other day
2944251|NCT02943486|Active Comparator|Fitostimoline|Topical application of fitostimoline every other day
2944252|NCT02943473|Experimental|Ibrutinib|Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis
2944253|NCT02943460|Experimental|GS-9674 30 mg (Blinded Study Phase)|GS-9674 30 mg + placebo to match GS-9674 100 mg for 12 weeks
2944254|NCT02943460|Experimental|GS-9674 100 mg (Blinded Study Phase)|GS-9674 100 mg + placebo to match GS-9674 30 mg for 12 weeks
2944255|NCT02943460|Placebo Comparator|Placebo (Blinded Study Phase)|Placebo to match GS-9674 30 mg + placebo to match GS-9674 100 mg for 12 weeks
2944256|NCT02943460|Experimental|GS-9674 (Open Label Extension Phase)|Following the Blinded Study Phase, eligible participants may have the option to receive GS-9674 for an additional 96 weeks.
2944257|NCT02943447|Experimental|GS-9674 30 mg (Blinded Study Phase)|GS-9674 30 mg + placebo to match GS-9674 100 mg for 12 weeks
2944258|NCT02943447|Experimental|GS-9674 100 mg (Blinded Study Phase)|GS-9674 100 mg + placebo to match GS-9674 30 mg for 12 weeks
2944259|NCT02943447|Placebo Comparator|Placebo (Blinded Study Phase)|Placebo to match GS-9674 30 mg + placebo to match GS-9674 100 mg for 12 weeks
2944260|NCT02943447|Experimental|GS-9674 (Open Label Extension Phase)|Following the Blinded Study Phase, eligible participants may have the option to receive GS-9674 for an additional 96 weeks.
2944261|NCT02943434|Other|Processed Food|Changes in resting energy expenditure will be measured via indirect calorimetry after consumption of a processed foods meal to determine changes in diet-induced thermogenesis.
2944262|NCT02943434|Other|Whole Food|Changes in resting energy expenditure will be measured via indirect calorimetry after consumption of a whole foods meal to determine changes in diet-induced thermogenesis.
2944263|NCT02943408|Experimental|person-centered mental health intervention (PCMHI)|We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.
2944264|NCT02943408|Active Comparator|health and wellness|The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
2944265|NCT02943395|Experimental|dual cure amine free adhesive resin cement|resin cement that get activated by both light and chemicals
2944266|NCT02943395|Active Comparator|light cured adhesive resin cement|resin cement that only get activated by light
2944267|NCT02943382|Experimental|Fingerprick Autologous Blood (FAB)|Assigned treatment with FAB
2944268|NCT02943369|Experimental|Cangrelor|Ticagrelor will be followed by Cangrelor
2944269|NCT02943369|Active Comparator|Ticagrelor|Ticagrelor only
2944270|NCT02943356|Experimental|Tadalafil|Patients will be treated with Tadalafil for 8 weeks.
2944271|NCT02943330||Hemodialysis|Hemodialysis patients
2944272|NCT02943330||Hepatitis C|Patients receiving interferon treatment for hepatitis C
2944273|NCT02943317|Experimental|Part A: VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
2944274|NCT02943317|Experimental|Part A: Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
2944276|NCT02943304||Unexposed|Asymptomatic pregnant women with a negative RT-PCR ZIKV in serum and urine, and a negative specific serology for ZIKV at enrollment into the study and at the time of delivery
2944277|NCT02943291|Experimental|4x4 minutes interval training|4x4 minutes high intensity interval training with 4 minute intervals
2944278|NCT02943291|Experimental|10x1 minute interval training|10x1 minute high intensity interval training with 1 minute intervals
2944279|NCT02943278|Placebo Comparator|Sleep Hygiene Group|Participants assigned to the sleep hygiene group you have 1 session with a clinician to learn about different things they can do to improve their sleep.
2944280|NCT02943278|Active Comparator|Intensive Sleep Retraining Group|Participants assigned to this group will spend just over 1 day at our sleep lab, starting around your usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake the participant up after a few minutes if they fall asleep.
2944281|NCT02943265|Experimental|Complex Care Survivors|Patients eligible for the study who will receive Care Coordination Strategies.
2944282|NCT02943252|Experimental|Apatinib plus S1|Patients received oral apatinib 500 mg in tablet once daily. Patients also received oral S1 in capsule 40-60mg bid, days 1-14. A treatment cycle was defined as 21 days (3 weeks).
2944283|NCT02943239|Experimental|Panel A|REGN1033 + REGN2477 (Regimen 1) or placebo
2944284|NCT02943239|Experimental|Panel B|Panel B - REGN1033 + REGN2477 (Regimen 2) or Placebo
2944285|NCT02943239|Experimental|Panel C|Panel C - Patients will receive either REGN1033 + REGN2477 (Regimen 3) or Placebo
2944286|NCT02943239|Experimental|Panel D|Panel D - Patients will receive either REGN1033 + REGN2477 (Regimen 4), REGN1033, REGN2477 (high dose) or Placebo
2944287|NCT02943239|Experimental|Panel E|REGN2477 (Regimen 5) or placebo
2944288|NCT02943239|Experimental|Panel F|REGN2477 + REGN1033 (Regimen 6) or placebo
2944289|NCT02943226|Experimental|Becton Dickinson Nexiva Diffusics System|Intervention with the new Becton Dickinson Nexiva Diffusics System will be evaluated to see if it will improve image quality compared to the standard catheter.
2944290|NCT02943226|Active Comparator|Standard intravenous catheter|Standard catheter with one hole at the tip will be compared to novel 3 hole Becton Dickinson Nexiva Diffusics System to see which catheter provides the best image quality.
2944291|NCT02943213|Experimental|Treatment Period 1|First dosing period in which all enrolled subjects are administered a single dose of 25 mg Chlorpromazine Hydrochloride Tablet.
2944292|NCT02943213|Experimental|Treatment Period 2|Second dosing period in which all enrolled subjects are administered a single dose of 25 mg Chlorpromazine Hydrochloride Tablet.
2944293|NCT02943187|Experimental|Nutrition and Cognitive Training|The intervention includes a physician-directed diet, exercise, and nutritional supplementation regimen, combined with a 60-hour, clinician-delivered cognitive training program created by LearningRx.
2944294|NCT02943174|Experimental|MIND Programme for cancer|"MIND programme for cancer is a manualized acceptance, mindfulness and compassionate-based group intervention for cancer patients. It included 8 weekly group sessions, 2h hours each, run in small groups (ranging from 10 to 12 participants).~Participants in this group also receive cancer treatment as usually performed at the Coimbra University Hospital."
2944295|NCT02943174|Other|Treatment as Usual (TAU)|Cancer treatment as usually performed at the Coimbra University Hospital.
2944296|NCT02943161|Experimental|L-Citrulline|In this pilot study subjects with asthma that have an increased body mass index compatible with being obese, will be invited to participate in a short open-label treatment with 15g/day of L-citrulline for two weeks. Study participants will be asked to do lung function testing and donate blood before and after taking the supplement. L-citrulline is safe and well tolerated and has been used at much higher doses without significant side effects.
2944297|NCT02943135|Active Comparator|lidocaine in-situ|Self-administered gel 10 min before intrauterine device insertion
2944298|NCT02943135|Placebo Comparator|placebo|Self-administered gel 10 min before intrauterine device insertion
2944299|NCT02943109|Experimental|High tech, high touch|Patient receives the full version of MyChart Bedside. Patient receives training/intervention from technology navigator
2944300|NCT02943109|Experimental|Low tech, high touch|Patient receives the non-interactional version of MyChart Bedside. Patient receives training/intervention from technology navigator
2944301|NCT02943109|Experimental|High tech, low touch|Patient receives the full version of MyChart Bedside. Patient receives online training, only
2944302|NCT02943109|Experimental|Low tech, low touch|Patient receives the non-interactional version of MyChart Bedside. Patient receives online training, only
2944303|NCT02943096|Active Comparator|Flavanol|Blinded treatment with either CocoaVia 500mg or placebo.
2944304|NCT02943096|Placebo Comparator|Placebo|Blinded treatment with either CocoaVia 500mg or placebo.
2944305|NCT02943083|Experimental|Coached Intervention|Perform prenatal relaxation exercise in the lab with a coach and at home
2944306|NCT02943083|Active Comparator|Home Intervention|Only perform relaxation exercise at home
2944307|NCT02943083|No Intervention|Control Group|Never performs relaxation routine, attends prenatal assessment sessions
2944308|NCT02943083|No Intervention|Postpartum Only|Only attends visits postpartum, never receives prenatal assessments
2944309|NCT02943070|Experimental|Rezum Treatment|Patients received the Rezum transurethral needle ablation procedure to treat benign prostatic hyperplasia.
2944310|NCT02943057|Experimental|2% guttae Ganciclovir|2% guttae Ganciclovir 5 times a day for 6 weeks
2944311|NCT02943031|Experimental|IPTP Group|The IPTP Group will receive the Individualized Precision Therapy Programs. After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
2944312|NCT02943018||anovaginal distance variation|3 measurements
2944313|NCT02943005|Active Comparator|Rotator cuff repair with sling|Patients wear a sling during 4 weeks, they also move passively during this period. Then progressive active mobilization is done.
2944314|NCT02943005|Experimental|Rotator cuff repair without sling|Patients don't wear any sling, they move passively in all axes during 4 weeks. Then progressive active mobilization is done.
2944315|NCT02942992|No Intervention|Control|Usual Care Group
2944316|NCT02942992|Other|Intervention|Intervention Group
2944317|NCT02942979||MISSION Implementation as Usual|Passive implementation or, IU for MISSION-Vet is comprised of a two-hour webinar training, along with key information on how to access and use the MISSION-Vet Treatment Manual and Consumer Workbook. The manual is posted on the web and available inside the VA on the National Center for Homelessness Among Veterans website or at missionmode.org. This passive implementation strategy has been used in previous studies
2944318|NCT02942979||Facilitation Implementation of MISSION|Facilitation is a comprehensive approach in which implementation experts partner with local staff to support implementation planning and to tailor adoption strategies to the local context. Facilitation gives attention to addressing individual- and organizational-level factors that can influence successful implementation of an evidence based practice with good fidelity.
2944319|NCT02942966|Experimental|Tack Implant|Implantation of a Tack using the Intact Vascular Tack Endovascular System for the repair of post angioplasty dissections below the knee.
2944320|NCT02942953||Diaphragmatic Pacer|Patient that have been proposed to diaphragmatic pacer placement at our institution.
2944321|NCT02942940|Active Comparator|mobile app|
2944322|NCT02942940|Active Comparator|in-person|
2944323|NCT02942927|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:~Medication reconciliation~Identification of patient priorities for care~Identification of medications that are potentially appropriate for discontinuation/dose reduction~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~Identification of medications for trial of discontinuation/dose reduction (shared decision making)~Pause of medication and clinical monitoring"
2944324|NCT02942927|No Intervention|Control|Standard of Care as wait list control. Control group will be offered intervention as part of usual clinical care at 6 months.
2944325|NCT02942914|Experimental|LY3209590|LY3209590 administered subcutaneously (SC).
2944326|NCT02942914|Placebo Comparator|Placebo|Placebo (sterile saline) administered SC.
2944327|NCT02942914|Active Comparator|Insulin Glargine (Lantus)|Insulin Glargine administered SC.
2944328|NCT02942888|Active Comparator|Healthy control|Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10). Controls will receive sugar pills.
2944329|NCT02942888|Experimental|MCI|Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10).Controls will receive sugar pills.
2944330|NCT02942875|Experimental|Mirror therapy group|MT group subjects will attend training sessions of bilateral upper limb exercise daily in the presence of the mirror.
2944331|NCT02942875|Active Comparator|Control therapy group|Control group subjects will undergo the same training sessions of bilateral upper limb exercise daily without mirror.
2944332|NCT02942823|Experimental|Intervention|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). Additionally, the intervention group will take the game home on a tablet computer to play it with their parents in between session 1 and 2. The game equips the children and their parents with knowledge about the core areas nutrition, physical activity, and psychosocial factors.
2944333|NCT02942823|No Intervention|Control|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). The game equips the children with knowledge about the core areas nutrition, physical activity, and psychosocial factors. The parents are not involved.
2944334|NCT02942810|Experimental|WCK 5222 (Cefepime and zidebactam combination)|IV infusion over a period of 60 minutes
2944335|NCT02942797||NRS 2002 score ≥ 3|
2944336|NCT02942797||NRS 2002 score ＜ 3|
2944337|NCT02942771|Experimental|Cohort 1 - TT301/MW189|TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
2944338|NCT02942771|Experimental|Cohort 2 -TT301/MW189|TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
2944339|NCT02942771|Experimental|Cohort 3- TT301/MW189|TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
2944340|NCT02942758|Experimental|low-dose AZA / ATRA / Pioglitazone|low-dose azacitidine (75 mg/d), ATRA, pioglitazone
2944341|NCT02942758|Active Comparator|standard-dose AZA|standard-dose azacitidine (75mg/m²/d)
2944342|NCT02942745|Placebo Comparator|Control|Minimal interaction between participant and facilitator regarding cessation strategies. Participants will only be given a betel nut cessation booklet.
2944343|NCT02942745|Experimental|Experimental|Intensive 5-session intervention program over the span of 22 days, with an additional follow up session after 6 months. The sessions will utilize betel nut cessation social support groups, as well as interactive discussion on how to quit chewing.
2944344|NCT02942732|Other|normal-weight adult subjects|normal-weight adult subjects (n=30, age ≤ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
2944345|NCT02942732|Other|overweight adult subjects|overweight adult subjects (n=30, age ≤ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
2944346|NCT02942732|Other|normal-weight elderly|normal-weight elderly (n=60, age ≥ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
2944347|NCT02942732|Other|overweight elderly|overweight elderly (n=60, age ≥ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
2944348|NCT02942719||Shanghai First Maternity and Infant Hospital|
2944349|NCT02942719||Dalian Maternity and Child Health Hospital|
2944350|NCT02942719||Beijing Obstetrics and Gynecology Hospital|
2944351|NCT02942719||Shijiazhuang Obstetrics and Gynecology Hospital|
2944352|NCT02942719||The Children and Women's Healthcare of Laiwu City|
2944370|NCT02942693|Experimental|Apatinib with Particle Therapy|Participants will receive apatinib (0.5g, daily) for 6 weekly followed by particle radiotherapy (proton: 56 GyE/28 Fx, plus carbon: 15 GyE/5 Fx for boost).
2944371|NCT02942693|Experimental|Particle Therapy|Participants will receive particle radiotherapy alone (proton: 56 GyE/28 Fx, plus carbon: 15 GyE/5 Fx for boost).
2944372|NCT02942680|Experimental|Experimental|acetylsalicylic acid started for 24 hours before surgery and determination of platelet function
2944373|NCT02942680|Other|Control|acetylsalicylic acid stayed for 5 days before surgery and determination of platelet function
2944374|NCT02942667||Subjects undergoing high quality MRI Scans|
2944375|NCT02942654|Experimental|LY900014|Test formulation. LY900014 administered subcutaneously (SC) in one of two periods.
2944376|NCT02942654|Active Comparator|Insulin Lispro|Reference formulation. Lispro administered SC in one of two periods.
2944377|NCT02942641|Experimental|Indwelling urethral catheterization (Foley)|Foley catheter as the intervention.
2944378|NCT02942641|Experimental|Clean intermittent catheterization (CIC)|CIC as the intervention .
2944379|NCT02942628|Experimental|Vegetarian - Meat|4 weeks of vegetarian diet followed by 4 weeks of 'wash out' (no intervention) and 4 weeks of meat-containing diet
2944380|NCT02942628|Active Comparator|Meat - Vegetarian|4 weeks of meat-containing diet followed by 4 weeks of 'wash out' (no intervention) and 4 weeks of vegetarian diet
2944381|NCT02942615|Experimental|Heart safety management|limit heart dose more frequent follow up of cardiac function professional management of cardiac toxicity
2944382|NCT02942615|No Intervention|Control group|without any restrict heart dose limitation for RT Follow up of cardiac function Observation and without any special management of cardiac toxicity
2944383|NCT02942602|Experimental|Atorvastatin 20 mg|lipid lowering treatment
2944384|NCT02942602|Experimental|Cholestyramine 8 g|lipid lowering treatment
2944385|NCT02942602|Experimental|Omega-3 (EPA+DHA) 2 g|lipid lowering treatment
2944386|NCT02942602|Experimental|Atorvastatin 5 mg + Ezetimibe 10 mg|lipid lowering treatment
2944387|NCT02942602|Active Comparator|Life style modification for management of dyslipidemia|
2944388|NCT02942589|Experimental|100% Portions|Meal portion size: 100%
2944389|NCT02942589|Experimental|125% Portions|Meal portion size: 125%
2944390|NCT02942589|Experimental|150% Portions|Meal portion size: 150%
2944391|NCT02942589|Experimental|175% Portions|Meal portion size: 175%
2944392|NCT02942576|Experimental|Edoxaban-based regimen|Edoxaban-based regimen for 21 days pre- and 90 days post-ablation period.
2944393|NCT02942576|Active Comparator|VKA-based regimen|VKA-based regimen for 21 days pre- and 90 days post-ablation period (control regimen)
2944394|NCT02942563|Experimental|FOLFOXIRI|irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
2944395|NCT02942550|Active Comparator|Methylnaltrexone|Methylnaltrexone bromide (Relistor®). Single intravenous injection of 8 mg (0.4 ml solution) for patients weighing 38-61 kg or 12 mg (0.6 ml solution) patients weighing 62-114 kg).
2944396|NCT02942550|Placebo Comparator|Placebo|Sodium Chloride, 9mg /mL ingle intravenous injection of 0.4 mL solution for patients weighing 38-61 kg or 0.6 mL solution patients weighing 62-114 kg).
2944397|NCT02942537|Experimental|Intervention|Microwave treatment
2944398|NCT02942537|Active Comparator|Control|Uterine artery embolization
2944399|NCT02942524|Experimental|Supportive care (TEPID)|Patients complete the TEPID checklist of items during hospital stay.
2944400|NCT02942498|Experimental|Vitamin C 10 mg/Kg + Vitamin E 10 mg/Kg|Vitamin C and Vitamin E supplementation 10 mg/kg/ day
2944401|NCT02942498|Placebo Comparator|Placebo|Placebo solution
2944402|NCT02942485|Experimental|Metronidazole|Patients will be given rectal metronidazole (Flagyl) 500 mg/dose for children weighing 10-14,9 kg, 1000 mg/dose for those weighing 15-29,9 kg and 1500 mg/dose for those weighing 30-44,9 kg. Suppositories will not be halved. Patients will be given 1 dose/day for 3 days.
2944403|NCT02942485|Active Comparator|Tinidazole|Patients will be treated with a standard regimen of oral tinidazole (Fasigyn) at a single dose of 50 mg/kg, maximum 2 g/dose
2944404|NCT02942459|Experimental|Music Therapy|"25 Weekly Hours of Music Therapy adapted to the Needs of the Participants. Interventions can be Active (playing Music, singing, improvising, Song-writing) or Receptive (Listening to selected Play-lists, or to the Participants´ favored Music).~A Manual is created and trained with the Music Therapists, which distinguishes between~Unique and Essential Principles for Music Therapy with people suffering from Schizophrenia with negative Symptoms,~Essential but not Unique Principles,~Acceptable but not necessary Principles,~Not acceptable and Proscribed Principles. These Principles concern Attitude and Listening Perspectives by the Music Therapist, how to conduct the Musical Interventions and Questions of Frames for the Music Therapy Work."
2944405|NCT02942459|Active Comparator|Music Listening|"25 Weekly Hours of Being together with an unknown Care Staff Member listening to Music from selected Play-Lists. Music Therapists at the Music Therapy Research Clinic at Aalborg University Hospital, Psychiatry have developed Play-Lists in a Taxonomy from very Supportive to less Supportive Music including around 100 Hours of Music all together on the Lists.~A Manual is created and trained with the Care Staff Members. Here the Activities are much more limited (only Music Listening to the Play-Lists are allowed). No Therapeutical Conversation is allowed."
2944406|NCT02942446|Experimental|Headgear|Investigative Headgear with CPAP mask
2944407|NCT02942433|Experimental|Radio Program|Married couple participants will be asked to interact with a radio program and participate in weekly, sex-separate listening and discussion groups (LDG) that each last for between 75 and 120 minutes over the course of 9 months.
2944408|NCT02942433|Other|Control|The control group participants will be exposed to the radio program only, and will not participate in the LDGs, nor will they or their family members participate in the workshops and community activities.
2944409|NCT02942420|Experimental|Dose Group A|Bucillamine 300 mg/day
2944410|NCT02942420|Experimental|Dose Group B|Bucillamine 600 mg/day
2944411|NCT02942407|Experimental|apixaban|apixaban 5 mg twice daily (apixaban 2.5 mg twice daily for selected patients)
2944412|NCT02942407|Experimental|warfarin|warfarin daily dose adjusted to target International Normalized Ration(INR) of 2-3
2944413|NCT02942381|Active Comparator|Hydroxychloroquine Sulfate|200mg Bid (eGFR>60 ml/min/1.73m2), 100mg Tid (eGFR45-59 ml/min/1.73m2), 100mg Bid (eGFR 30-44 ml/min/1.73m2) and supportive treatment
2944414|NCT02942381|Placebo Comparator|Placebo|Placebo and supportive treatment
2944415|NCT02942368|Experimental|tDCS|Patients will receive transcranial direct current stimulation using an adaptive protocol allowing for doses of 0 to 4 mA during the course of the treatment, with twenty 20-minute sessions over the course of 4 to 6 weeks. Treatments will take place daily, 5 days per week.
2944416|NCT02942355|Experimental|Cohort A: First-line therapy|Anastrozole by mouth daily and palbociclib by mouth Days 1-21 on a 28 day cycle
2944417|NCT02942355|Experimental|Cohort B: Maintenance therapy|Anastrozole by mouth daily and palbociclib by mouth Days 1-21 on a 28 day cycle
2944418|NCT02942329|Experimental|apatinib and SHR-1210|Every patients will received apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effects.
2944419|NCT02942316|Experimental|Pupil dilation reflex measurement|Four measurements of PDR during surgery at standardized times
2944420|NCT02942303|Active Comparator|Technique 1: Lateral orbicularis injections|5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim.
2944421|NCT02942303|Active Comparator|2. Technique 2: Lateral orbicularis and Corrugator injections|5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed into the corrugator at the medial brow
2944422|NCT02942290|Experimental|Venetoclax + Azacitidine|
2944423|NCT02942277|Experimental|1a|(n=5), to receive 16 microgram Pfs25M-EPA/AS01 on D0, D28, D168 (Bamako)
2944424|NCT02942277|Experimental|1b|(n=10), to receive 47 microgram Pfs25M-EPA/AS01 on D0, D28, D168 (Bamako)
2944425|NCT02942277|Experimental|2a|(n=5), to receive 13 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168 (Bamako
2944426|NCT02942277|Experimental|2b|(n=10), to receive 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168 (Bamako
2944427|NCT02942277|Experimental|3a|(n=5), to receive 16 microgram Pfs25M-EPA/AS01 and 13 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168(Bamako)
2944428|NCT02942277|Experimental|3b|(n=10), to receive 47 microgram Pfs25M-EPA/AS01 and 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168 (Bamako)
2944429|NCT02942277|Experimental|3c|(n=60), to receive 47 microgram Pfs25M-EPA/AS01 and 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168 (Bancoumana &amp; Doneguebougou)
2944430|NCT02942277|Experimental|3d|(n=60), to receive 47 microgram Pfs25M-EPA/AS01 and 40 g Pfs230D1M-EPA/AS01 on D0, D28, then 9 microgram Pfs25M-EPA/AS01 and 8 microgram Pfs230D1M-EPA/AS01 (fractional dose) on D168 (Bancoumana &amp; Doneguebougou)
2944431|NCT02942277|Active Comparator|4a|(n=10), to receive Bexsero on D0, D28 and Fluarix on D168 (Bamako)
2944432|NCT02942277|Active Comparator|4b|(n=10), to receive Bexsero on D0, D28 and Fluarix on D168 (Bamako)
2944433|NCT02942277|Active Comparator|4c|(n=120), to receive Bexsero and normal saline on D0, D28 and Fluarix and normal saline on D168 (start study with Arm 3c and 3d in Bancoumana &amp; Doneguebougou)
2944434|NCT02942264|Experimental|Phase I Arm 1|dose dense TMZ 125 mg/m2 x 7 days on / 7days off plus TG02 dose escatlation
2944435|NCT02942264|Experimental|Phase I Arm 2|metronomic TMZ 50 mg/ m2 daily plus TG02 doseescalation
2944436|NCT02942264|Experimental|Phase II Arm 1|"MTD of TG02 from phase I plus and winner of dd vs metronomic TMZ from phase I"
2944437|NCT02942264|Active Comparator|Phase II Arm 2|"winner of dd vs metronomic TMZ from phase I alone"
2944438|NCT02942251|Experimental|Clinical features and medication|A group patients with significant high risk of clinical features and medications.
2944439|NCT02942251|Experimental|Psycho-social|A group patients with significant high risk of psycho-social problems.
2944440|NCT02942251|Experimental|immunology|A group patients with significant high risk of immune disturbance.
2944441|NCT02942251|Experimental|Laboratory abnormality|A group patients with significant high risk of Laboratory abnormalities.
2944442|NCT02942251|Experimental|Comorbidity|A group patients with physical or mental disorders comorbidities.
2944443|NCT02942251|Experimental|Treatment as usual|Control group.
2944444|NCT02942238|Experimental|Complete Mesocolic Excision|the group underwent laparoscopic right hemicolectomy with CME. In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
2944445|NCT02942238|Active Comparator|D3 lymph node dissection|the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 lymph node dissection group(D3), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue. No.6 lymph node should be dissected in this group.
2944446|NCT02942225||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
2944447|NCT02942225||TD group|Typically development controls without lifetime diagnosis with ADHD
2944448|NCT02942212|Experimental|Project HALT II: In-Depth Interviews|"Participants complete a computerized questionnaire to assess demographics and smoking history.~Participants take part in individual in-depth interviews discussing smoking history, attempts to quit, and suggestions for smoking cessation program."
2944449|NCT02942212|Active Comparator|Project HALT II: Standard Treatment (ST)|"Participants complete a computerized questionnaire to assess demographics and smoking history at baseline.~Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.~Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Participants receive brief advice to quit smoking. Participants receive phone counseling for support in quitting smoking (5 sessions over the course of 6 weeks) with a counselor at the Texas Quitline.~Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up."
2944698|NCT02940431|Experimental|High Autonomy|Children will choose active video games for use during the study.
2944450|NCT02942212|Experimental|Project HALT II: Tailored Treatment (HALT)|"Participants complete a computerized questionnaire to assess demographics and smoking history at baseline.~Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.~Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Participants receive brief advice to quit smoking. Participants scheduled to attend 5 individual, in-person smoking cessation treatment counseling sessions.~Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up."
2944451|NCT02942199|Experimental|MySafeRx Intervention|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. This arm represents MySafeRx using the MedicaSafe 3000 electronic pill dispenser.
2944452|NCT02942173|No Intervention|CD45RA-|
2944453|NCT02942173|Experimental|CD45RA+|
2944454|NCT02942160|Experimental|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
2944455|NCT02942147|Active Comparator|conventional radiofrequency therapy|In the conventional radiofrequency method applied to Group 1 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position.
2944456|NCT02942147|Active Comparator|conventional TENS|Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
2944457|NCT02942147|Active Comparator|pulse radiofrequency therapy|In the pulse radiofrequency method applied to Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position.
2944458|NCT02942121|Experimental|LST App|Participants will use the LifeScience Technologies application (LST app) before surgery, and post surgery. Participants will use the app as an educational tool to learn more about their surgery. Participants will also answer questions about themselves in the app.
2944459|NCT02942108|Active Comparator|healthy, conventional surgery|Surgical bone removal by conventional rotary burs in healthy patients during third molar surgery
2944460|NCT02942108|Experimental|healthy, piezo surgery|Surgical bone removal by piezoelectric vibrations in healthy patients during third molar surgery
2944461|NCT02942095|Experimental|Dose Escalation Group - Ixazomib + Erlotinib|"Dose Escalation Phase: Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle starting with Dose Level 1.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
2944462|NCT02942095|Experimental|Dose Expansion Group - Non Small Cell Lung Cancer|"Dose Expansion Phase : Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle at the maximum tolerated dose from Dose Escalation Phase.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
2944463|NCT02942095|Experimental|Dose Expansion Group - Pancreatic Ductal Adenocarcinoma|"Dose Expansion Phase : Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle at the maximum tolerated dose from Dose Escalation Phase.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
2944464|NCT02942082|Experimental|ACP oral care geldesensitizing agent|a desensitizing agent will be applied on tooth before and /or after bleaching.
2944465|NCT02942082|Placebo Comparator|glycrin|glycrin will be applied on tooth before and /or after bleaching.
2944466|NCT02942056|Experimental|Study Drug|Randomized to cinnamon cassia 750 mg TID for 6 months. Assess HbA1c and CV risk profile
2944467|NCT02942056|Placebo Comparator|Placebo|Randomized to placebo matching tablet TID for 6 months. Assess HbA1c and CV risk profile
2944468|NCT02942043|Experimental|Group A (low dose group)|Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
2944469|NCT02942043|Experimental|Group B (medium dose group)|Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
2944470|NCT02942043|Experimental|Group C (high dose group)|Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
2944471|NCT02942030||ADHD|Children diagnosed with ADHD after a complete psychiatric evaluation.
2944472|NCT02942030||Non-ADHD|Children diagnosed with other mental conditions after a complete psychiatric evaluation.
2944473|NCT02942017|Experimental|SAGE-547|Intravenous
2944474|NCT02942017|Placebo Comparator|Placebo|Intravenous
2944475|NCT02942004|Experimental|SAGE-547 Standard Dose|Intravenous
2944476|NCT02942004|Experimental|SAGE-547 Lower Dose|Intravenous
2944477|NCT02942004|Placebo Comparator|Placebo|Intravenous
2944478|NCT02941991||uniocular subretinal injection of hESC-RPE cells|Cohort 1. 50,000 cells transplanted; Cohort 2. 100,000 cells transplanted; Cohort 3. 150,000 cells transplanted; Cohort 4. 200,000 cells transplanted
2944479|NCT02941978|Experimental|Subject on Motivational Interview|"Motivational Interview - Baseline: At hospital discharge, patients assigned to the intervention group will be contacted in person by a study physician (MD) and will be given a leaflet that will educate them about the risk for stroke and the importance of adherence to OAC medication. The leaflet will also provide some basic information on how to take OAC medication (doses, food interactions, skipping doses, etc.) and will describe the main clinical manifestations of side effects.~Motivational Interview - Follow-up: Patients assigned to the intervention group will be contacted via telephone for a pre-specified interview at 1 week, 2 months, 6 months and 1 year after discharge. The three elements of medication adherence (initiation, implementation, and discontinuation) will be evaluated. Based on the patient's dosing history, the delegated study personnel will assess whether an intervention is required and provide specific support tailored to the needs of the patient"
2944480|NCT02941978|Active Comparator|Subject Control|Patients assigned to the control group will be contacted via telephone for a pre-specified interview at 1 year after discharge
2944481|NCT02941965|Experimental|ICSI without PGS|Selection of embryos are based on blastocyst morphology criteria on day 5. A maximum of 2 embryos will be transferred for each treatment cycle.
2944482|NCT02941965|Experimental|ICSI with PGS|"PGS will be applied to select embryos on day 5, only euploid embryos will be transferred.~A maximum of 2 embryos will be transferred for each treatment cycle."
2944483|NCT02941939|Active Comparator|Ambient pressure arm|High intensity training will be completed while the subjects are breathing normal air.
2944484|NCT02941939|Experimental|Hyperoxic-hyperbaric arm|The high intensity training program will be carried out in a hyperbaric chamber.
2944485|NCT02941926|Experimental|Ribociclib + letrozole|Ribociclib oral (3 weeks on/1 week off) in combination with oral once daily letrozole: 600 mg ribociclib QD + 2.5 mg letrozole QD
2944486|NCT02941913|Experimental|Fixed Dose Palonosetron group|patient will receive a fix dose of 75 μg of palonosetron
2944487|NCT02941913|Experimental|Bodyweight-adjusted Dose Palonosetron|patient will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron
2944488|NCT02941900||Non-melanoma skin cancers (NMSCs)|
2944489|NCT02941887||Down's Syndrome|Behavior analysis in Down's Syndrome patients
2944490|NCT02941874||Healthy volunteers IRAP measurement|
2944491|NCT02941861||recurrence rate of HCC after surgery|There were 33 for Hepatocellular carcinoma between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.
2944492|NCT02941861||recurrence rate of CCA after surgery|There were 34 patients underwent liver resection for Cholangiocarcinoma between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.
2944493|NCT02941848|Experimental|Group1|"C → A + B~A : HGP0816 B : HGP1404 C : HCP1306"
2944494|NCT02941848|Experimental|Group2|"A + B → C~A : HGP0816 B : HGP1404 C : HCP1306"
2944495|NCT02941835|Other|radiation|intervention: pre-operative breast irradiation of 21 fx of 2.2Gy and boost 2.66Gy
2944496|NCT02941822|Experimental|Arm 1|"Each patient will self-administer the study drug, ambroxol (60 mg per tablet) at 5 intra-dose escalations (DE) over the duration of 6 months that will be taken three times a day, see below:~Day 1-7, 60 mg~Day 8-14, 120 mg~Day 15-21, 180 mg~Day 22-28, 300 mg~Day 29-186, 420 mg"
2944497|NCT02941809|Experimental|Placebo Dose-Extension|Participants assigned to the placebo dose extension group will be given placebo pills, and will be asked to take one placebo pill for two weeks, immediately prior to receiving their methadone dose, starting on the first day of their methadone treatment (Day 0). At the start of day 14 and through days 28, 56, and 84, participants will be instructed to supplement this morning placebo pill dose with a second placebo pill (evening dose), taken twelve hours later at home.
2944498|NCT02941809|No Intervention|Treatment as usual|Participants assigned to TAU will receive no placebo pills, but will be asked to meet with the study team 5 times throughout the course of the study.
2944499|NCT02941796|Experimental|Sequence 1|"T → R~T : HCP1105 4cap R : HGP0918 4cap + HGP0816 4tab"
2944500|NCT02941796|Experimental|Sequence 2|"R → T~T : HCP1105 4cap R : HGP0918 4cap + HGP0816 4tab"
2944501|NCT02941783||BAY81-8973|Hemophilia A patients who require Factor VIII replacement therapy
2944502|NCT02941770|No Intervention|Control group|"Clinic standard care protocol:~Baseline evaluation session with a Pediatrician for initial screening;~Appointment with a Dietitian;~A brochure with physical activity guidelines for youth with examples of physical exercises."
2944503|NCT02941770|Experimental|Intervention group I|"Clinic standard care protocol;~Physical activity consultation (Physical activity behavior change);"
2944504|NCT02941770|Experimental|Intervention group II|"Clinic standard care protocol;~Physical activity consultation;~2 exercise sessions per week (≈60 min/session) directed by one Exercise Physiologist."
2944505|NCT02941757|Experimental|Mediterranean Diet Intervention group|"In phase I, Group 1 will receive the MDNI for 12-months. Phase II: Group 1 fire houses will cross-over to self-sustained continuation, a less intense, self-directed, maintenance phase for 12 months to examine longer-term persistence of behavior change after the active 12-month MDNI. During self-sustained continuation access to some environmental changes: such as discounted food access, peer education/support, and online learning will remain; however, the stations will not receive investigator-led educational sessions"
2944506|NCT02941757|No Intervention|Control group|"2) In phase I, Group 2 will receive usual care, consisting of existing IFD health and wellness activities, with no investigator-provided interventions. In Phase II, Group 2 fire houses will cross-over to receive the full active MDNI for 6 months. The Group 2 MDNI will test the efficacy of a shorter, but otherwise identical MDNI. It will be followed by a final 6 months of self-sustained continuation (as described above) to examine the shorter MDNI's effect on persistence of adherence."
2944507|NCT02941744|Experimental|IpNiv|low fixed dose ipilimumab plus low fixed dose nivolumab
2944508|NCT02941731|Experimental|Sequence 1|HIP1403→HGP0919
2944509|NCT02941731|Experimental|Sequence 2|HGP0919→HIP1403
2944510|NCT02941718|Experimental|Sleep Advancement Counseling|"Participants will receive a 15-week intervention targeting smoking cessation and sleep counseling intervention.~Smoking Cessation intervention components include:~6 individual smoking cessation sessions over 15 weeks (week 1, 3, 4, 7, 11, 15)~12 weeks of the quit-smoking drug chantix. The standard dosing will be used - 0.5 mg once per day for days 1-3, 0.5my twice per day for days 4-7; and 1mg twice per day from week 3 until the end of treatment.~Sleep counseling components in the form of CBT for insomnia will be given as part of the smoking cessation counseling."
2944586|NCT02941198|Active Comparator|Gynefix|The GyneFix® 200 IUD(frameless iud) is only 2 cm long. Its small surface area is 1/3 of that of the conventional T-shaped IUDs such as TCu380A
2944587|NCT02941198|Active Comparator|Cu T380a|conventional T-shaped IUDs (TCu380A)which has a frame will be placed into the uterus after placental extraction
2944511|NCT02941718|Active Comparator|General Health Intervention|"Participants will receive a 15-week intervention targeting smoking cessation and general health information.~Smoking Cessation intervention components include:~6 individual smoking cessation sessions over 15 weeks (week 1, 3, 4, 7, 11, 15)~12 weeks of the quit-smoking drug chantix. The standard dosing will be used - 0.5 mg once per day for days 1-3, 0.5my twice per day for days 4-7; and 1mg twice per day from week 3 until the end of treatment.~The general health information counseling will be given as part of the smoking cessation counseling and topics include diet, physical activity, oral health, cancer screening and skin protection."
2944512|NCT02941705|Active Comparator|RECIEVED CELLS|this arm will receive the CDCs /CAP 1002 solution
2944513|NCT02941705|Placebo Comparator|CONTROL ARM|this arm will receive a solution during randomization but will not receive the CDCs
2944514|NCT02941692|Experimental|Oxytocin|Participants randomized to this condition will receive 40 IU dose of intranasal oxytocin.
2944515|NCT02941692|Placebo Comparator|Placebo|Participants randomized to this condition will receive a matching dose of intranasal saline spray as placebo.
2944516|NCT02941679|Experimental|HCP1202|Test
2944517|NCT02941679|Active Comparator|HGP1011|Control
2944518|NCT02941679|Active Comparator|HCP0910|Control
2944519|NCT02941666||Collapse ON group|This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with post collapse osteonecrosis.
2944520|NCT02941666||Pre-collapse group|This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with pre-collapse osteonecrosis.
2944521|NCT02941666||FAI group|This control group will be selected in patients undergoing hip arthroscopy for femoral/acetabular impingement.
2944522|NCT02941653|Active Comparator|Control: Potassium Nitrate 2% gel|The patient will receive the application of potassium nitrate 2% gel on vestibular surface teeth, for 10 minutes.
2944523|NCT02941653|Experimental|Intervention: Potassium Oxalate 5% gel|The patient will receive the application of potassium oxalate 5% gel on vestibular surface teeth, for 10 minutes.
2944524|NCT02941640|Experimental|Laparoscopic appendectomy. E group.|The securing the base of appendix by Endo-loop.
2944525|NCT02941640|Experimental|Laparoscopic appendectomy. S group.|The securing the base of appendix by stapler.
2944526|NCT02941640|Experimental|Laparoscopic appendectomy. H group.|The securing the base of appendix by Hem-o-lok clip.
2944527|NCT02941640|Experimental|Laparoscopic appendectomy. DS group.|The securing the base of appendix by DS clip.
2944528|NCT02941627|Experimental|Cochlear Implant|Neuro Cochlear Implant System
2944529|NCT02941614||Distress screening|Newly diagnosed breast cancer patients will be offered a brief distress screening questionnaire, the Patient Health Questionnaire (PHQ), around the time of their breast cancer diagnosis and again at subsequent transitions in care as appropriate (e.g., the initiation of chemotherapy).
2944530|NCT02941614||No screening|Newly diagnosed breast cancer patients will experience usual care.
2944531|NCT02941601|Experimental|Cohort 1: Necitumumab + Gemcitabine and Carboplatin|Predominately European sites. Gemcitabine administered intravenously (IV) and carboplatin IV plus necitumumab IV.
2944532|NCT02941601|Experimental|Cohort 2: Necitumumab + Gemcitabine and Carboplatin|Predominately United States sites. Gemcitabine administered IV and carboplatin IV plus necitumumab IV.
2944533|NCT02941588||non-cardiac surgery after DES|The patients who underwent non-cardiac surgery after percutaneous coronary intervention with drug-eluting stent
2944534|NCT02941575|Active Comparator|Control|Implant superstructure crown: All ceramic, IPS Emax
2944535|NCT02941575|Experimental|Intervention|Implant superstructure crown: Hybrid ceramic, crystal Ultra crown
2944536|NCT02941562|Experimental|Preoperative chemotherapy with short-course radiotherapy|Preoperative treatment:4 course of FOLFOX4 therapy combined with short-course radiotherapy
2944537|NCT02941562|Active Comparator|Preoperative neo-adjuvant therapy|Preoperative treatment:neo-adjuvant therapy
2944538|NCT02941549|Placebo Comparator|Placebo|Participants in this group will receive matching placebo capsules twice daily.
2944539|NCT02941549|Experimental|500 mg DS102|Participants in this group will receive 500 mg DS102 capsules twice daily.
2944540|NCT02941549|Experimental|1000 mg DS102|Participants in this group will receive 1000 mg DS102 capsules twice daily.
2944541|NCT02941536|Other|Circulating Tumor Cells and Radiotherapy|Circulating tumor cells evaluation before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose and correlate with the local and distant brain progression free survival in patients with metastatic breast cancer
2944542|NCT02941523|Experimental|1a NOX66|"NOX66 administered daily for 14 day in a 21-day treatment cycle. NOX66 treatment given to two cohorts of patients as 1 of 2 dose regimens:~Regimen 1: 400 mg; Regimen 2: 800 mg (idronoxil)"
2944543|NCT02941523|Experimental|1b NOX66 and Carboplatin (combined)|"NOX66 administered on Days 1-7 and carboplatin IV infusion on Day 2 of each 28-day treatment cycle up to 6 cycles.~NOX66 at the same dosage received in the Run-In Arm combined with 2 carboplatin doses starting with low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6."
2944544|NCT02941523|Experimental|2a NOX66 and Carboplatin|"This arm triggered by observed meaningful clinical responses from the 1b Combination Arm in particular disease indications.~Treatment NOX66 + carboplatin administered over 6 cycles each of 28-days at observed clinical response dosage. A maximum of 2 cohorts, each comprising patients with specific tumour type."
2944545|NCT02941510|Experimental|Budesonide|Will participate in all study activities but will receive budesonide.
2944546|NCT02941510|Placebo Comparator|Placebo|Will participate in all study activities but will receive placebo.
2944547|NCT02941497|Experimental|Intensive intervention group|The intensive intervention group participates in development and implementation of the social marketing and health promotion campaign and peer-led campus activities and is assessed for their health-related behaviors. This was Wave 1 in colleges in Yr 01-02 and is being repeated as Wave 2 in colleges in Yr 03. This will also be repeated in high schools in Yr 04.
2944588|NCT02941185|Other|Devit-3 Oral Drop 400 IU|supplemented with oral Vitamin D 400 IU/day (Devit-3 Oral Drop, 50000 IU/15 ml, Deva Company, Turkey) started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
2944699|NCT02940431|Experimental|Low Autonomy|Children will be assigned active video games for use during the study.
2944548|NCT02941497|Experimental|Diffuse intervention group|The diffuse intervention group receives the social marketing and health promotion campaign and participates in the peer-led campus activities and is assessed for their health related behaviors, but is not involved in the design and delivery of the intervention materials and activities. This was Wave 1 in colleges in Yr 01-02 and is being repeated as Wave 2 in colleges in Yr 03. This will also be repeated in high schools in Yr 04.
2944549|NCT02941484|Experimental|1 early oral intake|early oral intake since postoperative day 1.
2944550|NCT02941484|Experimental|2 jejunostomy tube feeding (JTF)|jejunostomy tube feeding (JTF) was carried out after PD
2944551|NCT02941471|Experimental|Interferential Stimulation|Medical Device: Interferential stimulation. Stimulation parameters: 4 KHz of carrier stimulation, beat frequency between 80-160Hz, amplitude upto 33mA. Delivered via two 100mm x 50mm adhesive pads placed on the anterior abdominal wall
2944552|NCT02941471|Active Comparator|Standard electrical stimulation|Medical Device: Standard electrical stimulation. Parameters set to provide continuous electrical stimulation at a pulse width of 210µs and a frequency of 14Hz and an amplitude upto 33mA.
2944553|NCT02941458||Non-small cell lung cancer|patients treated for a non small cell lung cancer
2944554|NCT02941458||Small cell lung cancer|patients treated for a small cell lung cancer
2944555|NCT02941458||Mesotelioma|patients treated for a mesotelioma
2944556|NCT02941458||timic cancer|patients treated for a timic cancer
2944557|NCT02941458||carcinoid cancer|patients treated for a carcinoid cancer
2944558|NCT02941445|Experimental|COMBO (sitagliptin and metformin)|metformin 1000 mg BID and sitagliptin 50mg BID for 12 weeks
2944559|NCT02941445|Experimental|MET (metformin)|metformin 1000 mg BID
2944560|NCT02941432|Other|Black tea|Black tea compress treatment
2944561|NCT02941419|Experimental|Platelet lysate injection|Injection of platelet lysate intramuscularly in the gastrocnemius muscle
2944562|NCT02941406||Healthy subjects|"Men and Women aged 18 and older~Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant~Normal ophthalmological findings unless the investigator considers an abnormality to be clinically irrelevant"
2944563|NCT02941406||Age-related macular degeneration patients|"Men and Women aged 18 and older~Presence of a macular disease (such as dry or exudative age-related macular degeneration, diabetic maculopathy, epiretinal membrane)"
2944564|NCT02941393|Active Comparator|Intrauterine pressure catheter|Intrauterine pressure catheter is used during labor to follow up the contractions
2944565|NCT02941393|Active Comparator|External tocodynamometry|External tocodynamometry is used during labor to follow up the contractions
2944566|NCT02941380||Ischemic heart disease|Patients admitted for coronary artery bypass grafting with the use of cardiopulmonary bypass
2944567|NCT02941367|Experimental|Lyxumia|Patients will receive Lyxumia once daily as investigational medicinal product (IMP) on top of patient's previous basal insulin with/without metformin. Non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.
2944568|NCT02941367|Active Comparator|Sulfonylurea|Patients will continue the treatment with previous Sulfonylurea as IMP on top of patient's previous basal insulin with/without metformin. The IMP and non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.
2944569|NCT02941354|Experimental|Turoctocog alfa|
2944570|NCT02941328|Experimental|Pyridostigmine|(this is a cross-over trial, in which participants will receive both a placebo and pyridostigmine in different study periods. Both investigators and participants are blinded for what medication is used in what period. All patients will eventually use a placebo for 8 weeks and pyridostigmine for 8 weeks).
2944571|NCT02941328|Placebo Comparator|Placebo|(this is a cross-over trial, in which participants will receive both a placebo and pyridostigmine in different study periods. Both investigators and participants are blinded for what medication is used in what period. All patients will eventually use a placebo for 8 weeks and pyridostigmine for 8 weeks).
2944572|NCT02941315|Experimental|with CMR confirmed etiology|Participants who were identified with cardiac magnetic resonance (CMR) in etiology were treated with drug including etiologic treatment,anti-myocardial remodeling.
2944573|NCT02941315|Placebo Comparator|etiology unconfirmed WO acute HF|Participants who were not identified with cardiac magnetic resonance (CMR) in etiology and without acute hearts failure (HF) were treated with drug with anti-myocardial remodeling.
2944574|NCT02941315|Placebo Comparator|etiology unconfirmed with acute HF|Participants who were not identified with CMR in etiology but with acute hearts failure were treated with drug with anti-myocardial remodeling,anti-acute heart failure.
2944575|NCT02941315|Experimental|etiology confirmed with acute HF|Participants who were identified with CMR in etiology but with acute hearts failure were treated with drug with Etiological, anti-remodeling and symptom treatment.
2944576|NCT02941302|Experimental|determine the biological boundaries|Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
2944577|NCT02941289|Experimental|Alzheimer's patient|Probable diagnosis of Alzheimer's disease with a mild impairment (MMSE 20-26) according to DSM IV diagnosis criteria
2944578|NCT02941289|Active Comparator|Control patient|patient with MMSE score equal or > 27
2944579|NCT02941276|Experimental|Group A|Active electrostimulator device
2944580|NCT02941276|Sham Comparator|Group B|Sham electrostimulator device
2944581|NCT02941250|Experimental|treatment|patients receiving ISSD emulator
2944582|NCT02941237|Other|Healthcare worker measurement of SpO2|Measurement of SpO2 using the Lifebox pulse oximeter probe in children of different ages, stratified by age: 0-1 months, 2-11 months, 12-23 months and 24-59 months
2944583|NCT02941237|Other|Expert measurement of SpO2|Measurement of SpO2 using the Lifebox pulse oximeter probe in children of different ages, stratified by age: 0-1 months, 2-11 months, 12-23 months and 24-59 months
2944584|NCT02941224|Experimental|SELUTION DCB|The SELUTION™ DCB (coated with sirolimus) is intended for use as a Percutaneous Transluminal Angioplasty (PTA) balloon catheter to dilate de-novo or restenotic vascular lesions, for the purpose of improving limb perfusion and decreasing the incidence of restenosis.
2944589|NCT02941185|Active Comparator|Devit-3 Oral Drop 800 IU|Devit-3 Oral Drop 800 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
2944590|NCT02941185|Active Comparator|Devit-3 Oral Drop 1000 IU|Devit-3 Oral Drop1000 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
2944591|NCT02941172|Other|[18F]FMPEP-d2 in warm conditions|PET scan is performed using PET radiotracer [18F]FMPEP-d2 in standard room temperature conditions.
2944592|NCT02941172|Other|[18F]FMPEP-d2 in cold conditions|PET scan is performed using PET radiotracer [18F]FMPEP-d2 during controlled cold exposure.
2944593|NCT02941172|Other|[18F]FDG in cold conditions|PET scan is performed using PET radiotracer [18F]FDG during controlled cold exposure.
2944594|NCT02941159|Active Comparator|SF2000SD|The test product is a Sondashi Formula Spray dried extract (SF2000SD). It is derived from spray drying with water the Sondashi Formula (SF2000), which is a mixture of mixture of 4 plants. SF2000SD is packaged into capsules of 500mg and six capsules are taken twice, daily for 42 days. This drug has anti-HIV properties but in this study we are just looking at safety issues.
2944595|NCT02941159|Placebo Comparator|Placebo|The placebo arm is composed of capsule containing 500mg of inactive ingredient (Microcrystalline Cellulose PH102 -240mg; Starch - 10mg; Magnesium Stearate -10mg; and Maltodextrin Unidry 20 - 240mg).
2944596|NCT02941146|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the abdomen with a new applicator design.
2944597|NCT02941133|Experimental|Neural Mobilization Group|Patients in this group will be treated with neural mobilization techniques.
2944598|NCT02941133|Experimental|Standard Care Group|Patients in this group will be treated with standard care (ultrasound, exercise, TENS, massage)
2944599|NCT02941120||NOVOCART® Inject patients|Patients who where treated with NOVOCART® Inject autologous chondrocyte implantation in the knee joint.
2944600|NCT02941107|Experimental|Rotarix|Rotarix (RV1) vaccine, 1mL liquid suspension administered orally.
2944601|NCT02941107|Placebo Comparator|Placebo|Placebo liquid suspension manufactured to mimic Rotarix (RV1) vaccine, 1ml administered orally
2944602|NCT02941094|Active Comparator|angle 30 group|During central line insertion, After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 30-40 degree.
2944603|NCT02941094|Active Comparator|angle 50 group|During central line insertion,After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 50-60 degree
2944604|NCT02941094|Active Comparator|angle 70 group|During central line insertion,After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 60-80 degree
2944605|NCT02941081|Experimental|IHAT|IHAT arm: novel iron supplement - 1 dose/day single IMP containing IHAT (iron hydroxide adipate tartrate) powder bioequivalent to 12.5 mg elemental iron (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to ferrous sulphate)
2944606|NCT02941081|Active Comparator|ferrous sulphate|Ferrous sulphate arm: clinical standard of oral iron supplementation - 1 dose/day single IMP containing ferrous sulphate (FeSO4 ) powder equivalent to 12.5 mg elemental iron
2944607|NCT02941081|Placebo Comparator|placebo|Placebo arm: 'no iron' arm - 1 dose/day containing saccharose powder
2944608|NCT02941068|Experimental|Prophylactic group|Patients would received intravenous fluconazole (loading dose 800 mg, then 400 mg/day) or caspofungin (loading dose 70 mg, then 50 mg/day) if patients had organ failure or renal or liver dysfunction during the immediately surgery. The antifungal treatment would continue for 5 to 7 days.
2944609|NCT02941068|No Intervention|Empirical group|
2944610|NCT02941055|Experimental|Fiber diet|50% of daily intake, 5 days a week, a diet rich in fiber, fish and probiotics will be provided to study subjects
2944611|NCT02941055|Active Comparator|Protein diet|50% of daily intake, 5 days a week, a diet rich in protein, red meat and saturated fat will be provided to study subjects
2944612|NCT02941042|Experimental|NNC9204-1177|
2944613|NCT02941042|Placebo Comparator|Placebo|
2944614|NCT02941029||Evaluate toxicity biomarkers|Investigators will determine if measurement of circulating DNA from tumor and normal tissues shortly after RT provides an early and quantitative measure of risk of radiation-related complications. It will be necessary to collect blood specimens prior to and during the first week of radiation therapy.
2944615|NCT02941016|Experimental|Lipid lowering|
2944616|NCT02941003|Experimental|OCT treatment|Randomly assigned patients whose small pulmonary nodules are inflated with the diluted OCT medium (2:3) used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS (next-generation sequencing) for driver mutations.
2944617|NCT02941003|Experimental|OCT free|Randomly assigned patients whose small pulmonary nodules are uninflated with OCT used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS for driver mutations.
2944618|NCT02940990|Placebo Comparator|Group A|Participants in the Group A will receive 4-6 cycles of standard two-drug chemotherapy. After that, clinical observation or maintenance chemotherapy will be given.
2944619|NCT02940990|Experimental|Group B|Participants in the Group B will also receive 4-6 cycles of standard two-drug chemotherapy. However, they will receive an additional treatment of SBRT to primary lesions or metastatic lesions combined with GM-CSF.
2944620|NCT02940977||Prostate cancer patients|Patients diagnosed with prostate cancer, confirmed with needle biopsy, and suitable for radical prostatectomy, and have not received any treatments before.
2944621|NCT02940964|Experimental|COMSCPR first|Group A will proceed to perform one cycle (two minutes) of COMSCPR. After taking a fifteen minute rest, participants will cross over to perform one cycle of the other method of CPR.
2944622|NCT02940964|Active Comparator|Standard CPR first|Group A will proceed to perform one cycle (two minutes) of Standard CPR. After taking a fifteen minute rest, participants will cross over to perform one cycle of the other method of CPR.
2944623|NCT02940951|Other|Usual home care provided by clinicians|Usual care provided by the home health clinicians. This may or may not include use of some standardized forms of quality of life assessment that were in place prior to the study beginning.
2944624|NCT02940951|Experimental|Use of QPSS by home health clinicians|Usual home care plus the use of the Quality of Life Assessment and Practice Support System (QPSS) at point of care to document, monitor and address the quality of life concerns of patients and family caregivers.
2944625|NCT02940938|Experimental|Children under general anesthesia|During general anesthesia without surgical stimuli, pulse oximeter sensor is applied with gradually increased contact force, from 0 to maximal 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds at each contact force. Delta POP will be calculated and compared.
2944626|NCT02940925|Experimental|Drug: Taxol,cisplatin and capecitabine|"Taxol, cisplatin and capecitabine as induction chemotherapy (IC) combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy |(CCRT)."
2944627|NCT02940925|Active Comparator|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
2944628|NCT02940912|Active Comparator|Apomorphine (5 mg/ml)|Active phase is apomorphine (from 0.5 mg (0.1 ml) to maximum 5 mg (1 ml)/hour of apomorphine), delivered with a pump (subcutaneous administration), during 22 days.
2944629|NCT02940912|Placebo Comparator|Physiologic serum|Physiological serum (from 0.1 ml to maximum 1 ml/ hour), delivered with a pump (subcutaneous administration), during 22 days.
2944630|NCT02940899|Active Comparator|Intervention: Syracuse University Fir Families Program (SUFFP)|SUFFP is a randomized control trial comparing two groups of families of children with autism spectrum disorders. 20 families participated in the intervention program
2944631|NCT02940899|Active Comparator|Control: Syracuse University Fir Families Program (SUFFP)|20 families served as a wait-list control group. The control group will fill out the same pre and post measures as the intervention families (membership in the control vs. intervention group will be selected semi-randomly such that the average age of each of the two groups is equal), which will allow us to tease apart the effects of development vs. those related to the intervention.
2944632|NCT02940886|Experimental|Iron isomaltoside (Monofer)|Administered iv
2944633|NCT02940886|Active Comparator|Iron sucrose (Venofer)|Administered iv
2944634|NCT02940873|Experimental|HARPdoc courses|Hypoglycaemia Awareness Restoration Programme for adults with type 1 diabetes and problematic hypoglycaemia persisting despite optimised self-care (HARPdoc) - a combination of structured education around hypoglycaemia recognition, avoidance and treatment combined with hypoglycaemia-focussed cognitive behavioural therapy, delivered by diabetes educators, supported by a clinical psychologist, to small groups of eligible adults.
2944635|NCT02940873|Active Comparator|BGAT courses|Blood Glucose Awareness Training is an existing psycho-educational program which coaches adults with type 1 diabetes better to predict and recognise extremes of plasma glucose - hyper- and hypo-glycaemia. It has been shown to reduce severe hypoglycaemia rates.
2944636|NCT02940860|Experimental|Iron isomaltoside (Monofer)|Administered IV
2944637|NCT02940860|Active Comparator|Iron Sucrose (Venofer)|Administered IV
2944638|NCT02940847|Active Comparator|blind technique|Investigators will perform a medial brachial cutaneous nerve block and an intercostobrachial nerve block with either a blind technique or an ultrasound-guided technique to estimate the effectiveness of each technique. The blind technique consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
2944639|NCT02940847|Active Comparator|ultrasound-guided technique|Investigators will perform a medial brachial cutaneous nerve block and an intercostobrachial nerve block with either a blind technique or an ultrasound-guided technique to estimate the effectiveness of each technique. In the ultrasound-guided technique, ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
2944640|NCT02940834||patients with sodium imbalance|
2944641|NCT02940834||patients without sodium imbalance|
2944642|NCT02940821|Active Comparator|Whitening and Dentifrice|
2944643|NCT02940821|Active Comparator|Whitening Dentifrice|
2944644|NCT02940821|Active Comparator|Dentifrice|
2944645|NCT02940808|Other|Caffeine first, placebo second|"Caffeine consumption during session 1, placebo consumption during session 2 (after baseline session 0)."
2944646|NCT02940808|Other|Placebo first, caffeine second|"Placebo consumption during session 1, caffeine consumption during session 2 (after baseline session 0)."
2944647|NCT02940795|Experimental|Coke cola|Exclusively lactating mothers with infants between 4-6 weeks were investigated. Lactating mothers will be consume a 20 ounce bottle of coke cola.
2944648|NCT02940795|Experimental|Diet Rite|Exclusively lactating mothers with infants between 4-6 weeks were asked to consume a 12 ounce bottle of diet rite.
2944649|NCT02940782|Experimental|Reciproc single file system|It is a reciprocating NiTi file used for instrumentation of root canals in endodontic treatment
2944650|NCT02940782|Active Comparator|One Shape single file system|It is a rotary NiTi file used for instrumentation of root canals in endodontic treatment
2944651|NCT02940769|Experimental|light glasses|Study subjects will wear light glasses
2944652|NCT02940769|Sham Comparator|sham glasses (placebo)|Study subjects will wear sham glasses
2944653|NCT02940756|Experimental|artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
2944654|NCT02940756|Experimental|artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days."
2944697|NCT02940444|Active Comparator|control group|start heparin sodium (5000 IU,BID) from postoperative day 1, and continue until discharge
2944655|NCT02940756|Experimental|Dihydroartemisinine-piperaquine|Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to <7 kg, one tablet once daily for those weighing 7 to <13 kg, and two tablets once daily for those weighing 13 to <24 kg, for three days.
2944656|NCT02940743|Active Comparator|Education (Edu)|
2944657|NCT02940743|Active Comparator|Edu + Self-Monitoring (SM)|
2944658|NCT02940743|Active Comparator|Edu + SM + Social Cognitive Theory (SCT)|
2944659|NCT02940730|Active Comparator|Dalbavancin via IV|Dalbavancin will be administered via intravenous administration. Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
2944660|NCT02940730|Active Comparator|Dalbavancin via IP|Dalbavancin will be administered as an intraperitoneal administration. Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
2944661|NCT02940717|Experimental|Vita suprinity|Vita Suprinity is a recent material with glass ceramic enriched with zirconia (approx. 10 % by weight) that offer practices and laboratories a high-strength, zirconia-reinforced lithium silicate ceramic (ZLS).
2944662|NCT02940717|Active Comparator|Emax cad|lithium disilicate glass-ceramic which is etchable and proved to have good success rate if used for laminate venners
2944663|NCT02940704|Experimental|Reciproc|"Reciproc (VDW, Munich, Germany) is a single file reciprocating system for mechanical instrumentation of root canals.~Size: R40 (40/0.06)"
2944664|NCT02940704|Active Comparator|One Shape|"One Shape (MicroMega, Besançon Cedex, France) is a single file system that works by continuous rotation for mechanical instrumentation of root canals.~Size: 25/0.06"
2944665|NCT02940691|Experimental|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.
2944666|NCT02940665||Enhanced Recovery After Surgery (ERAS)|ERAS group followed the ERAS protocol. The protocol was implemented 13 months prior to the start of data collection.
2944667|NCT02940665||Conventional|Conventional group received conventional care.
2944668|NCT02940652||Paediatric patients undergoing MRI scanning|All paediatric patients undergoing elective MRI scanning of the brain and/or brain and cervical spine
2944669|NCT02940639||Advanced RCC patients initiating Nivo for the first time|Adult patients with advanced Renal Cell Carcinoma(RCC) initiating Nivolumab treatment for the first time.
2944670|NCT02940626|Placebo Comparator|Placebo|Placebo administered as 2 separate intravenous (IV) infusions
2944671|NCT02940626|Experimental|ASN100|ASN100 administered as 2 separate intravenous (IV) infusions
2944672|NCT02940613|Experimental|Visual feedback of symptom frequency|Participants in this arm receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
2944673|NCT02940613|No Intervention|No visual feedback of symptom frequency|Participants in this arm complete the symptom checklist as is typically done during treatment, but receive no visual feedback of their self-reported symptom frequency over the first 4 weeks of active treatment.
2944674|NCT02940600|Experimental|Normothermic machine perfusion|Patients undergoing liver transplant with grafts preserved using normothermic machine perfusion
2944675|NCT02940600|Active Comparator|Static cold storage|Patients undergoing liver transplant with statically cold preserved grafts
2944676|NCT02940587|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
2944677|NCT02940587|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
2944678|NCT02940574|Experimental|Syntocinon (Oxytocin, product code RVG 03716)|Administration via nasal spray
2944679|NCT02940574|Placebo Comparator|Placebo (Physiological water(sodium chloride (NaCl) solution))|Administration via nasal spray
2944680|NCT02940561|Experimental|Methotrexate - Amneal|Methotrexate Tablets USP, 2.5 mg, single-dose in each period
2944681|NCT02940561|Active Comparator|Methotrexate - DAVA|Methotrexate Tablets USP, 2.5 mg, single-dose in each period
2944682|NCT02940548|Active Comparator|Nifedipine GITS|Nifedipine GITS 30~60mg/day
2944683|NCT02940548|Active Comparator|Amlodipine besylate|Amlodipine besylate 5~10mg/day
2944684|NCT02940535|Experimental|Low Dose GnRHa|Diphereline 0.375mg was administered in the early-luteal-phase. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the day 28.
2944685|NCT02940535|Active Comparator|GnRHa Ultra-short Protocol|Decapeptyl 0.1mg was administered in the menstrual day 2 to 7. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the menstrual day 2.
2944686|NCT02940522|Experimental|Treatment A|Subcutaneous (SQ) injection using an autoinjector
2944687|NCT02940522|Active Comparator|Treatment B|Intramuscular injection (IM) using syringe and needle
2944688|NCT02940509|Active Comparator|Ketamine plus Magnesium sulfate|Ketamine 0.5mg/kg IV dose with 2g magnesium IV dose
2944689|NCT02940509|Placebo Comparator|Placebo|Normal Saline (NaCl 0.9%)
2944690|NCT02940496|Experimental|Pembrolizumab|"Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of each 21-day cycle.~Participants may receive Pembrolizumab for up to 35 cycles (about 2 years)."
2944691|NCT02940483|Experimental|5-Azacytidine Infusion|12 infusions (once a week) into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle.
2944692|NCT02940470|Experimental|Calorie restricted diet plus exercise|See Intervention Description
2944693|NCT02940470|Active Comparator|Weight management classes|See Intervention Description
2944694|NCT02940457|Experimental|Verum tDCS|
2944695|NCT02940457|Experimental|Sham tDCS|
2944696|NCT02940444|Experimental|case group|start heparin sodium (5000IU, BID) upon admission, and continue until discharge
2944700|NCT02940418|Active Comparator|Dose 1 mil/kg|"Adipose mesenchymal cells with bone marrow mononuclear cells.~Two doses with a 6 month interval of allogenic Adipose mesenchymal cells +1 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
2944701|NCT02940418|Active Comparator|Dose 10 mil/kg|"Adipose mesenchymal cells with bone marrow mononuclear cells.~Two doses with a 6 month interval of allogenic Adipose mesenchymal cells +10 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
2944702|NCT02940405|Experimental|ketorolac tromethamine|One tablet of Ketorolac tromethamine 10-mg one hour before endodontic treatment
2944703|NCT02940405|Placebo Comparator|placebo tablet|One tablet of a placebo one hour before endodontic treatment
2944704|NCT02940392|Experimental|Rezum Treatment|Patients will receive the Rezūm transurethral needle ablation procedure to treat benign prostatic hyperplasia.
2944705|NCT02940379|Experimental|Cohort 1|Participants will initially be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 1 of Sotagliflozin plus cocktail) after 3 days
2944706|NCT02940379|Experimental|Cohort 2|Participants will initially be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 2 of Sotagliflozin plus cocktail) after 3 days
2944707|NCT02940366|Experimental|Pitavastatin 4 mg orally daily|
2944708|NCT02940366|Placebo Comparator|Atorvastatin 20 mg orally daily|
2944709|NCT02940353|Other|Treatment with Trefoil concept|Treatment
2944710|NCT02940314|Experimental|sequence 1|HGP1103→HIP1503
2944711|NCT02940314|Experimental|Sequence 2|HIP1503→HGP1103
2944712|NCT02940301|Experimental|Treatment (ibrutinib, nivolumab)|Patients receive ibrutinib PO QD on days 1-21 and nivolumab IV continuously over 60 minutes on day 1. Treatment with nivolumab repeats every 21 days for up to 16 courses and treatment with ibrutinib continues in the absence of disease progression or unacceptable toxicity.
2944713|NCT02940288|Experimental|Intervention|Participants will be randomized to receive bilateral auricular acupuncture for postoperative pain.
2944714|NCT02940288|Sham Comparator|Control|Participants will be randomized to receive bilateral sham acupuncture.
2944715|NCT02940275||Hypertension|
2944716|NCT02940275||Diabetes mellitus|
2944717|NCT02940275||Hypertension and diabetes mellitus|
2944718|NCT02940275||End stage kidney disease|
2944719|NCT02940275||Kidney transplant recipient|
2944720|NCT02940275||Coronary artery disease|
2944721|NCT02940275||Peripheral arterial occlusive disease|
2944722|NCT02940262|Experimental|Treatment (68Ga-PSMA-11)|Patients receive gallium Ga 68-labeled PSMA-11 IV. Beginning 50-100 minutes after receiving gallium Ga 68-labeled PSMA-11, patients undergo PET imaging.
2944723|NCT02940249|Experimental|1.2 g apple polyphenols|1200 mg apple polyphenols delivered in a low sugar drink.
2944724|NCT02940249|Experimental|0.9 g apple polyphenols|900 mg apple polyphenols delivered in a low sugar drink.
2944725|NCT02940249|Experimental|0.6 g apple polyphenols|600 mg apple polyphenols delivered in a low sugar drink.
2944726|NCT02940249|Placebo Comparator|Placebo|No polyphenols delivered in a low sugar drink.
2944727|NCT02940236||Multimodal analgesia|Patients scheduled for general surgery and requiring multimodal analgesia in preoperative period.
2944728|NCT02940223|Experimental|Fish Oil + Physical Activity|"Participants take a fish oil supplement by mouth twice a day and perform physical activity for 8 weeks.~Participants complete resistance exercises and a walking program at home for 8 weeks.~Symptom questionnaire completed at Baseline and on Days 8, 21, 36, and 50.~Quality of life questionnaires completed at Baseline and on Days 15, 29, 43, 57, and at end of study visit.~Walk Test performed at Baseline and on Days 29, 57, and at end of study visit.~Chair/Stand Test performed at Baseline and on Days 29, 57, and at end of study visit.~At the end of 8 weeks participants may choose to continue receiving the fish oil supplement for an additional 4 weeks along with physical activity."
2944729|NCT02940223|Placebo Comparator|Placebo + Physical Activity|"Participants take placebo by mouth twice a day and perform physical activity for 8 weeks.~Participants complete resistance exercises and a walking program at home for 8 weeks.~Symptom questionnaire completed at Baseline and on Days 8, 21, 36, and 50.~Quality of life questionnaires completed at Baseline and on Days 15, 29, 43, 57, and at end of study visit.~Walk Test performed at Baseline and on Days 29, 57, and at end of study visit.~Chair/Stand Test performed at Baseline and on Days 29, 57, and at end of study visit.~At the end of 8 weeks participants may choose to receive the fish oil supplement for 4 weeks. Participants will also take part in physical activity for 4 weeks."
2944730|NCT02940223|Other|Placebo + Stretching Exercises|"Participants take placebo by mouth twice a day for 8 weeks, and perform only stretching exercises 3 days a week for 8 weeks.~Symptom questionnaire completed at baseline and on Days 8, 21, 36, and 50.~Quality of life questionnaires completed at baseline and on Days 15, 29, 43, 57, and at end of study visit.~Walk Test performed at Baseline and on Days 29, 57, and at end of study visit.~Chair/Stand Test performed at Baseline and on Days 29, 57, and at end of study visit.~At the end of 8 weeks participants may choose to receive the fish oil supplement for 4 weeks. Participants will also take part in physical activity for 4 weeks."
2944731|NCT02940210|Experimental|Mediclore®|adhesion barrier Mediclore 5cc, to apply medical device fully around thyroid gland following thyroidectomy
2944732|NCT02940210|No Intervention|No treatment|No treatment, standard treatment for thyroidectomy
2944733|NCT02940197|Experimental|restricted diet|Mediterrasian diet according to adjusted ideal body weight with 500 calorie restriction
2944734|NCT02940197|Experimental|Non restricted diet|Mediterrasian diet according to adjusted ideal body weight without 500 calorie restriction
2944735|NCT02940184|Experimental|Enteral fructose with DPP-4 inhibition|"Enteral fructose + DPP-4 inhibition (sitagliptin)~After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals."
2944736|NCT02940184|Experimental|Enteral fructose without DPP-4 inhibition|Enteral fructose without DPP-4 inhibition (sitagliptin) After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals.
2944737|NCT02940171||Early surgery|Early Excision of full thickness burn First excision surgery of full -thickness burn performed within 48 hours from burn injury
2944738|NCT02940171||Late surgery|Late Excision of full thickness burn First excision surgery of full -thickness burn performed after 48 hours from burn injury
2944739|NCT02940158|Other|1/2 cup|1/2 cup serving size arm
2944740|NCT02940158|Other|1/4 cup|1/4 cup serving size arm
2944741|NCT02940145|Experimental|intervention 1|"The training group performed the resistance training (RT) program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, wirh 3 sets of 10-15 repetition maximums.The RT program was performed in the following order: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl, , and seated calf raise.~Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise"
2944742|NCT02940145|No Intervention|control group|The control group did not perform any type of physical exercise during the intervention period.
2944743|NCT02940132|Experimental|SC10914|SC10914 Dose Escalation： Dose Level 1：30mg(QD) Dose Level 2：60mg(QD) Dose Level 3：120mg(QD) Dose Level 4：200mg(QD) Dose Level 5：100mg(BID) Dose Level 6：300mg(QD) Dose Level 7：150mg(BID) Dose Level 8：400mg(QD) Dose Level 9：200mg(BID) Dose Expansion： Receiving SC10914 in one of three dosage regimens(low, middle or high dose-level and QD or BID) based on the assessment of dose escalation study.
2944744|NCT02940119|Active Comparator|Active PBMT|The volunteers received active phototherapy in each session.
2944745|NCT02940119|Placebo Comparator|Placebo PBMT|The volunteers received placebo phototherapy in each session.
2944746|NCT02940106|Placebo Comparator|closed device|Standard cryopreservation system.
2944747|NCT02940106|Active Comparator|open device|New cryopreservation system.
2944748|NCT02940093||Stem cell transplant recipient|
2944749|NCT02940093||Stem cell donor|
2944750|NCT02940080|Experimental|Anthocyanins and yellow potato|168 mg of anthocyanins extracted from purple-fleshed potatoes added to 350 g of steam-cooked mashed potatoes in water
2944751|NCT02940080|Experimental|Yellow potato|350 g of steam-cooked mashed potatoes in water
2944752|NCT02940067|Experimental|MedEx|This group will receive nutritional supplementation (based on components of the MEDiterranean diet) and supervised EXercise training for four weeks - hence the trial name, MedEx.
2944753|NCT02940067|No Intervention|Standard Care|This group will follow current standard preoperative care before scheduled pancreatic resection.
2944754|NCT02940054||Patents with suspected Crohn's disease|"Adult patients showing at least one of the following symptoms, from at least 4 weeks:~diarrhea~nocturnal diarrhea~body weight loss (>5%)~abdominal pain~perianal lesions."
2944755|NCT02940028|Experimental|Expressive writing intervention|The intervention group will participate in a brief expressive writing intervention.
2944756|NCT02940028|Other|Control writing intervention|The control group will receive a control writing condition (fact based writing).
2944757|NCT02940002|Experimental|BAY1003803 0.1% lipophilic cream|BAY1003803 0.1% lipophilic cream (on plaque and healthy skin)
2944758|NCT02940002|Experimental|BAY1003803 0.1% ointment|BAY1003803 0.1% ointment (on plaque and healthy skin)
2944759|NCT02940002|Experimental|BAY1003803 0.01% lipophilic cream|BAY1003803 0.01% lipophilic cream (on plaque and healthy skin)
2944760|NCT02940002|Experimental|BAY1003803 0.01% ointment|BAY1003803 0.01% ointment (on plaque and healthy skin)
2944761|NCT02940002|Active Comparator|Clobetasol propionate|Clobetasol propionate ointment 0.05 % (on plaque and healthy skin)
2944762|NCT02940002|Active Comparator|Betamethasone/calcipotriene|Betamethasone/calcipotriene ointment 0.05 %/0.005% (on healthy skin)
2944763|NCT02939989|Experimental|ABT-493/ABT-530 + SOF + RBV for 16 weeks|ABT-493/ABT-530 (300/120 mg) QD + SOF (400 mg) QD + RBV (600 - 1200 mg) daily in two divided doses (based on baseline age and weight) for 16 weeks.
2944764|NCT02939989|Experimental|ABT-493/ABT-530 + SOF + RBV for 12 weeks|ABT-493/ABT-530 (300/120 mg) QD + SOF (400 mg) QD + RBV (600 - 1200 mg) daily in two divided doses (based on baseline age and weight) for 12 weeks.
2944765|NCT02939976|Active Comparator|Single Vessel Disease|Standard of care comparator for those subjects with single vessel coronary artery disease. Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
2944766|NCT02939976|Experimental|Multi-vessel Disease, Culprit Vessel Only|Subjects randomized to revascularization of infarct related artery only. Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
2944767|NCT02939976|Experimental|Multi-vessel Disease, Complete Revascularization|Subjects randomized to complete revascularization. Complete revascularization of all diseased arteries with Medtronic Resolute family of stents; Use of Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology to determine which arteries to stent; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
2944768|NCT02939963|Experimental|ATC then pressure support 7 cm H2O PEP 4 cm H2O|
2944769|NCT02939963|Experimental|pressure support 7 cm H2O PEP 4 cm H2O then ATC|
2944770|NCT02939950|Experimental|samfilcon A Ultra Contact Lenses|Bausch + Lomb investigational samfilcon A soft contact lenses (Test) Ultra Contact Lenses
2944771|NCT02939950|Active Comparator|PureVision contact lenses|Bausch + Lomb PureVision contact lenses
2944772|NCT02939937|Experimental|phenytoin|patients received phenytoin 100mg three time daily up to 3 months
2944773|NCT02939937|Experimental|placebo|patients received placebo 100 mg three time daily for 3 months
2944774|NCT02939924|Experimental|DCB treatment|Patient treated with Kanshas DCB
2944775|NCT02939911||Paediatric patients after NMBA administration|Paediatric patients undergoing surgery with neuromuscular blockade
2944776|NCT02939898|Placebo Comparator|Lactose Monohydrate|2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 International Units of recFSH
2944777|NCT02939898|Active Comparator|Letrozole|2 tablets of 2,5 mg Letrozole are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 International Units of recFSH
2944778|NCT02939872|Experimental|DAPT|Dual antiplatelet therapy : aspirin and clopidogrel
2944780|NCT02939859|Experimental|Microcannula Harvest Adipose|Acquisition AD-tSVF via closed syringe microcannula
2944781|NCT02939859|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via enzymatic isolation/concentration via Centricyte 1000 Closed System to create AD-cSVF
2944782|NCT02939859|Experimental|Sterile Normal Saline|Re-suspension of Autologous AD-cSVF pellet in Normal Saline deployment via IV
2944783|NCT02939846|Experimental|Trametinib|Subjects will be administrated with trametinib 2 mg once daily until disease progression.
2944784|NCT02939833|Experimental|ropivacaine|patients in this group will receive scalp nerve blocks with 0.5% ropivacaine after anesthesia induction and before skull-pin insertion
2944785|NCT02939833|Placebo Comparator|saline|patients in this group will receive scalp nerve blocks with 0.9% saline after anesthesia induction and before skull-pin insertion
2944786|NCT02939807|Experimental|advanced HCC, tumor progression with 1st line sorafenib|Patients with advanced HCC who have experienced tumor progression with 1st line single agent sorafenib will receive ABC294640.
2944787|NCT02939794|Active Comparator|ferinject|-Patients will receive 1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
2944788|NCT02939794|Placebo Comparator|placebo|Patients will receive a placebo drug intravenous approximately 24 hours before surgery
2944789|NCT02939781||Febrile critically ill children|Children above 10kg admitted to the paediatric intensive care unit at Great Ormond Street Hospital who are mechanically ventilated and have a high likelihood of developing a fever. Energy expenditure will be measured using indirect calorimetry at baseline, and continuously during fever, until fever subsides.
2944790|NCT02939768|Experimental|Exercise training protocols|Participants will be randomized in one of three groups: HIIT, ST or ST combined with HIIT (ST+HIIT). Each training protocol will last 10 weeks, being the initial two weeks designed to participants' gradual adaptations to respective training protocol, with sessions performed three times per week in non-consecutive days.
2944791|NCT02939768|No Intervention|Control period|Before interventions (exercise training protocols), all participants will participate of a control period lasting one month, where participants will be encouraged to maintain their habitual lifestyle and usual diet habits.
2944792|NCT02939755|Experimental|Stepped collaborative care intervention|The 'Stepped Collaborative Care Intervention' includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
2944793|NCT02939755|Active Comparator|Enhanced Usual Care|Patients randomized to the 'Enhanced Usual Care' arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed.
2944794|NCT02939742|Experimental|Betamethasone|Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
2944795|NCT02939742|Placebo Comparator|Saline Placebo|Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
2944796|NCT02939729|Experimental|Prehabilitation|This group will receive standard preoperative information and education and be provided with a physiotherapy prehabilitation programme. This programme will be carried out from time of consenting to participate in the study until day of admission to surgery for cardiac or thoracic surgery. The prehabilitation programme consists of: walking programme, deep breathing exercises and tidal volume measurement using the incentive spirometer.
2944797|NCT02939729|No Intervention|Standard Care|This group will receive standard preoperative information and education only.
2944798|NCT02939716|Active Comparator|Rhubarb|300g frozen rhubarb, microwaved; served with 65g lactose free cream and saccharine sweetener
2944799|NCT02939716|Active Comparator|Bread|2 slices of white bread, 40g each; served with 10g butter
2944800|NCT02939716|Experimental|Lettuce|300g lettuce; served with 30g mayonnaise
2944801|NCT02939703|Active Comparator|Control Western diet|Participants will consume a control western diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period.
2944802|NCT02939703|Experimental|Microbiome Enhancer diet|Participants will consume an experimental microbiome enhancer diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period
2944803|NCT02939690|Experimental|UVC and surface measurement formula|UVC insertion depth = Umbilicus to nipple distance minus 1cm
2944804|NCT02939690|Active Comparator|UVC and Birth weight based formula|UVC insertion depth=[(3× birth weight (Kg) + 9)/2+1)] cm
2944805|NCT02939677|Other|Targeted exercise|Targeted exercise intervention
2944806|NCT02939677|No Intervention|care as usual|home based exercises
2944807|NCT02939664|Active Comparator|Banded Gastric Bypass|The patient will have done a laparoscopic Roux-en-Y banded (with polypropylene mesh) gastric bypass at the time of the surgical procedure.
2944808|NCT02939664|Active Comparator|Gastric Bypass.|The patient will have done a Laparoscopic Roux-en-Y gastric bypass at the time of the surgical procedure
2944809|NCT02939651|Experimental|Pembrolizumab|Monotherapy with PD-1 antibody pembrolizumab
2944810|NCT02939638|Active Comparator|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
2944811|NCT02939638|Active Comparator|Control diet|Half of the participants will be asked to continue their usual diets for the 16-week study period.
2944812|NCT02939625|Active Comparator|muscle training|participants will breathing exercises for 20 min, then 40 min training with Threshold IMT therapy will be held in 7 sessions
2944813|NCT02939625|Active Comparator|bilevel positive airway pressure|participants will breathing exercises for 20 min, then 40 min bilevel (IPAP and EPAP 12 = 8 cm H2O), the therapy will be held in 7 sessions
2944814|NCT02939625|Active Comparator|Continue Positive Airway Pressure|participants will breathing exercises for 20 min, then 40 min CPAP (8 cm H2O) therapy will be held in 7 sessions
2944852|NCT02939313|Experimental|medial prefrontal|Individuals will receive medial prefrontal cortex stimulation
2944815|NCT02939612|Experimental|App for Stress management|Participants will get access to two modules per week for five weeks (total 10 modules). The app consists of stress management education, cognitive behavioral interventions and relaxation training exercises.
2944816|NCT02939612|No Intervention|Waitlist control group|Participants will get treatment as usual during the study. After the one year study follow up they will receive the stress management app.
2944817|NCT02939599|Experimental|QCC374|"placebo patients from QCC374X2201 rolled into extension study will start at 0.03mg b.i.d. or 0.06mg b.i.d. and have the opportunity to up-titrate 0.12mg~-active patients will continue at the dose they finished on the QCC374X2201 study"
2944818|NCT02939586|Active Comparator|Haemodialysis|regular convectional haemodialysis 3times/weekly
2944819|NCT02939586|Active Comparator|Haemodiafiltration|post-dilution haemodiafiltration
2944820|NCT02939573|Experimental|Stage 1|Eligible patients will be initially randomized (1:1:1) to receive one of the 3 medications under investigation (colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint is response to treatment at month 6 (stage 1).
2944821|NCT02939573|Experimental|Stage 2|If the patient has to discontinue the study drug within the (stage 1) 6 month study period or during the subsequent follow-up period (up to month 12) because of a lack of response (or failure), flare or side effect, he/she will be randomized again to receive one of the remaining two study drugs (stage 2, with a 1:1 randomization ratio, colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint in this second stage will again be the response to treatment at 6 months.
2944822|NCT02939560|Experimental|rTMS|Participants will receive rTMS sessions according to the study protocol.
2944823|NCT02939547|Active Comparator|Hydroxypropyl-best-cyclodextrin IV 1500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
2944824|NCT02939547|Active Comparator|Hydroxypropyl-best-cyclodextrin IV 2500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
2944825|NCT02939534||PD and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Parkinson's disease
2944826|NCT02939521|Experimental|Surgery|Consists of a dorsal flattening of of the bone at the distal phalanx, with a frontal lifting of the distal skin of the toe
2944827|NCT02939508|Experimental|Colon originated|A history of colon (-innervating) nerve damage, moderate or more severe edema; and without a history of colon (-innervating) nerve damage, with mild or severe edema of colonic wall on CT.
2944828|NCT02939508|Active Comparator|Non-colon originated|"NCOG met one of the two following criteria:~History of nerve damage that could affect colon movement (colon [-innervating] nerve damage), such as pelvic or retroperitoneal operation, spine injury, or cerebral lesion; and non-existing or mild edema of colonic wall on abdominal CT;~Absence of history of colon(-innervating) nerve damage, with no obvious change in the colonic wall visible on the CT scan."
2944829|NCT02939495|Experimental|Study drug|Dapoxetine/Sildenafil 30/50 mg film coated tablet
2944830|NCT02939482|Active Comparator|Group 1: 40 ml/min|Triamcinolone acetonide (80 mg)/2 ml and normal saline solution 18 ml infusion in 0.5 min
2944831|NCT02939482|Experimental|Group 2: 20 ml/min|Triamcinolone acetonide (80 mg)/2 ml and normal saline solution 18 ml infusion in 1 min
2944832|NCT02939469|Experimental|Experimental: Sympathetic nerve activity|Healthy volunteers will undergo microneurography, and non invasive sympathetic nerve activity by EKG analysis at baseline and in response to stress.
2944833|NCT02939456|Other|DIR-MRI|Participants will have Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) as well as the standard Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
2944834|NCT02939443|Other|cross-sectional study|
2944835|NCT02939430|Active Comparator|Control|Reversal of neuromuscular blockade will be performed using classic drugs (neostigmine 80 mic/kg and atropine 40 mic/kg)
2944836|NCT02939430|Experimental|Sugammadex group|Reversal of neuromuscular blockade will be performed using Sugammadex 2mg/kg
2944837|NCT02939417|Experimental|using grape seed extract|Grape seed extract as collagen cross-linking agent
2944838|NCT02939417|Active Comparator|without uing grape seed extract|
2944839|NCT02939404||Volunteers|Healthy Volunteers
2944840|NCT02939391|Experimental|KW-6356 Low Dose|Oral administration
2944841|NCT02939391|Experimental|KW-6356 High Dose|Oral administration
2944842|NCT02939391|Placebo Comparator|Placebo|Oral administration
2944843|NCT02939378|Experimental|ketogenic diet group|Ketogenic diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were kept more than 2mmol/L during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.
2944844|NCT02939378|Other|Standard diet group|Standard diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were recorded during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.
2944845|NCT02939365|Experimental|Belatacept patients|"Forty patients who are previously enrolled in belatacept based regimens with a minimum of 7 years of follow up at 4 transplant centers and who are maintained on belatacept, an antiproliferative ± steroids will be approached for enrollment.~Drug withdrawal of steroids (in patients on steroids) and of antiproliferatives (MPAs or mTor inhibitors). Patients who continue to be stable for 3 months on belatacept monotherapy will be converted from q 4 weeks to q 8 weeks belatacept administrations."
2944846|NCT02939352|Experimental|Cocaine Users|Participants will receive Real continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex. Participants will also receive Sham continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex.
2944847|NCT02939352|Experimental|Alcohol Users|Participants will receive Real continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex. Participants will also receive Sham continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex.
2944848|NCT02939339|Experimental|real treatment|continuous theta burst stimulation (real) will be delivered
2944849|NCT02939339|Sham Comparator|sham treatment|continuous theta burst stimulation (sham) will be delivered
2944850|NCT02939326|Experimental|EB-001|Injection of active drug into five (5) 0.1 mL IM injections into glabellar area.
2944851|NCT02939326|Placebo Comparator|Placebo|Injection of placebo into five (5) 0.1 mL IM injections into glabellar area.
2944853|NCT02939313|Experimental|dorsolateral prefrontal|Individuals will receive dorsolateral prefrontal cortex stimulation
2944854|NCT02939313|Sham Comparator|sham|Individuals will receive sham stimulation to the medial prefrontal and dorsolateral prefrontal cortex
2944855|NCT02939300|Experimental|Combination Of Nivolumab with Ipilimumab|"All patients will be treated with the combination regimen of Nivolumab at pre-determine dose with Ipilimumab at a pre-determine dose.This will be followed by Nivolumab Monotherapy.~Each treatment Cycle will last 6 weeks"
2944856|NCT02939287|Active Comparator|Aprepitant|aprepitant plus standard anti-emetic regimen
2944857|NCT02939287|Experimental|Olanzapine|olanzapine plus standard anti-emetic regimen
2944858|NCT02939274|Other|Open Label|Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin
2944859|NCT02939261|Active Comparator|Control|Families randomized to control will receive monthly emails containing publicly available handouts on general child health.
2944860|NCT02939261|Experimental|Intervention - 4 Home Visits|Families randomized to the intervention will receive: a) 4 home visits from a health educator, b) weekly e-mails, and c) monthly mailed behavioural supports.
2944861|NCT02939248|Active Comparator|Crushed ticagrelor followed by morphine|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously
2944862|NCT02939248|Active Comparator|Crushed ticagrelor, morphine,naloxone|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
2944863|NCT02939235|Active Comparator|Crushed ticagrelor followed by morphine|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously
2944864|NCT02939235|Active Comparator|Crushed ticagrelor, morphine,metoclopramide|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
2944865|NCT02939222|Other|Routine implant placement|No comparison needed
2944866|NCT02939209|Experimental|Hydromorphone|Patients will be given 2 mg hydromorphone (immediate release) in the post anesthetic care unit.
2944867|NCT02939209|Placebo Comparator|Placebo|Patients will be given placebo in the post anesthetic care unit.
2944868|NCT02939196||Group(A)|2.7 mm rigid hysteroscopy.
2944869|NCT02939196||Group(B)|2.9 mm rigid hysteroscopy.
2944870|NCT02939183|Experimental|Part 1 Arm 1|Oprozomib (Immediate Release) plus dexamethasone
2944871|NCT02939183|Experimental|Part 1 Arm 2|Oprozomib (Gastro-retentive) plus dexamethasone
2944872|NCT02939183|Experimental|Part 2 Arm 1|Oprozomib (Immediate release) plus pomalidomide and dexamethasone
2944873|NCT02939183|Experimental|Part 2 Arm 2|Oprozomib (Gastro-retentive) plus pomalidomide and dexamethasone
2944874|NCT02939170|Experimental|DT1 MF MM|Delefilcon A multifocal contact lenses with molded marks on back surface worn bilaterally (in both eyes) for 9 hours
2944875|NCT02939170|Active Comparator|DT1 MF|Delefilcon A multifocal contact lenses worn bilaterally for 9 hours
2944876|NCT02939144|Experimental|Liquorice|Participants of the single-arm study will ingest liquorice candy and their blood, saliva and urine samples will be collected. They will be regularly monitored for any potential side effects.
2944877|NCT02939131|Experimental|COMB-R|Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention
2944878|NCT02939131|Active Comparator|ESC|Enhanced Standard of Care (ESC)
2944879|NCT02939105|Experimental|Fat Reduction|The treatments are designed to see if the fat, on the upper arm, can be reduced.
2944880|NCT02939092|Experimental|Pomegranate peel extract|Pomegranate is antimicrobial, anti inflammatory and antioxidant
2944881|NCT02939092|Active Comparator|Chlorhexidine|Chlorhexidine mouthwash is antiplaque treatment and effective against gingivitis
2944882|NCT02939079|Experimental|Fingolimod and Fish Oil|Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year.
2944883|NCT02939079|Active Comparator|Fingolimod and Placebo|Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year.
2944884|NCT02939053||Single-arm|All subjects enrolled will undergo measurements with the SOZO device daily for 30 days.
2944885|NCT02939040|Experimental|Positive Activities Intervention|Patients will note at least one positive event each day, write it down on a slip of paper and then deposit this piece of paper in a piggy bank. After approximately 21 days, the participant reads each one the night before surgery.
2944886|NCT02939040|No Intervention|Usual Care Group|The control group will serve to show the relative benefits of the Positive Piggy Bank intervention. These participants will follow the same questionnaire completion procedures.
2944887|NCT02939027|Experimental|Group 1|For the first 20 patients, a total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days week, 3 weeks or lees at least 2 days apart each fraction.
2944888|NCT02939027|Experimental|Group 2|For the next 20 patients a total dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days week 3 weeks or lees at least 2 days apart each fraction.
2944889|NCT02939014|Experimental|Brentuximab Vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg, intravenous (IV) infusion on Day 1 of each 3-week cycle until the sooner of disease progression, unacceptable toxicity, or completion of 16 cycles.
2944890|NCT02939001|Experimental|Ophthalmic surgery group|Ophthalmic surgery group (refractive surgery, phakic Intraocular Lens implantation, and cataract surgery)
2944891|NCT02938988|Experimental|Test group|Scaling and root planning and antimicrobial photodynamic therapy with red laser (658nm; 0.1W; 2229J/cm², 10s per point) and methylene blue dye (100μg/ml). Repetition after 3, 7 and 14 days.
2944892|NCT02938988|Active Comparator|Control Group|Scaling and root planning Repetition after 3, 7 and 14 days.
2944893|NCT02938975|Placebo Comparator|Placebo|placebo group receiving untreated army combat uniform and placebo lotion. Assigned interventions: Placebo lotion - a liposome lotion with no DEET Army combat uniform - army combat uniform with no permethrin
2944929|NCT02938780|Placebo Comparator|Control|The subjects in the control group will receive placebo text messages which will be timed as the intervention group that are unrelated to the study or topics of exercise and nutrition.
2944930|NCT02938780|Experimental|Intervention|The subjects in the intervention group will receive text messages with nutrition and physical activity-related information throughout the study period on a daily basis, varying text message.
2944931|NCT02938767||peritoneal dialysis patients|37 peritoneal dialysis patients followed at the Istanbul Medical Faculty from October 1994 to October 2011
2944894|NCT02938975|Active Comparator|Combo|"Combined intervention group of receiving Permethrin treated uniform 0.52% w/w and 30% DEET liposome formula.~Ultra 30 Insect Repellent Lotion (30% Lipo DEET) One application of Lipo DEET protects for up to 12 hours. DEET is a broad spectrum insect repellent that has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors.~Permethrin Factory-Treated Army Combat Uniforms treated by the military apparel contractor Warmkraft Permethrin is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings."
2944895|NCT02938975|Active Comparator|Permethrin|"permethrin intervention group receiving Permethrin treated uniform 0.52% w/w and placebo lotion.~Permethrin Factory-Treated Army Combat Uniforms treated by the military apparel contractor Warmkraft~Placebo lotion: liposome lotion with no DEET"
2944896|NCT02938975|Active Comparator|DEET|"DEET intervention group receiving untreated army combat uniform and 30% DEET liposome formula.~Ultra 30 Insect Repellent Lotion (30% Lipo DEET) Army combat uniform with no permethrin"
2944897|NCT02938962|Active Comparator|Intravenous TXA|The IV administration group will receive a single 20mg/kg dose of TXA prior to the skin incision.
2944898|NCT02938962|Active Comparator|Topical TXA|The topical administration group will have a 100mL solution (3g TXA in 100cc of normal saline) instilled into the surgical field throughout the operative procedure; 50mL of the solution will be instilled after bony preparation of the acetabulum and/or femur and 50mL of the solution will be instilled prior to closure. The topical TXA solution will be allowed to bathe the wound for 5 minutes at each administration.
2944899|NCT02938949|Active Comparator|Alirocumab|Alirocumab (150 mg) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
2944900|NCT02938949|Placebo Comparator|placebo|Placebo (sterile saline) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
2944901|NCT02938936|Experimental|Scheduling Intervention|Pre-natal visit scheduling
2944902|NCT02938936|No Intervention|Control|
2944903|NCT02938923|Experimental|Exercise + Testosterone (EX + T)|Supervised exercise training, 2 times per week, and topical testosterone 1% gel (12.5 mg per pump depression) daily, both for six months duration.
2944904|NCT02938923|Active Comparator|Exercise + Placebo (EX + P)|Supervised exercise training, 2 times per week, and placebo gel daily, both for six months duration.
2944905|NCT02938923|Placebo Comparator|Control + Placebo (CON)|Home flexibility exercise, 2 times per week, and placebo gel daily, both for six months duration.
2944906|NCT02938910||Healthy Volunteers|Healthy volunteers with normal blood pressure
2944907|NCT02938910||Primary Hyperaldosteronism|Subjects with hypertension and high levels of seric aldosterone.
2944908|NCT02938910||Secondary Hyperaldosteronism|Patient with Gitelman syndrome, with normal blood pressure and high level of aldosterone
2944909|NCT02938910||Essential Hypertension|Patient with hypertension without secondary cause of hypertension
2944910|NCT02938897|Experimental|Telenutrition Intervention|Participants receive diet-related educational materials and self-monitoring tools PLUS registered dietitian nutritionist support.
2944911|NCT02938897|Active Comparator|Enhanced Usual Care Control|Participants receive diet-related educational materials and self-monitoring tools.
2944912|NCT02938884|Active Comparator|HidrateSpark Water Bottle|"Patients meeting the eligibility criteria who are interested in participating in the study and randomized to receive the HidrateSpark water bottle be given one at no cost. They will download the associated free software application to their smartphone and be given education in the outpatient setting regarding how to use the system.~All subjects in both cohorts will be provided the same questionnaire on two occasions, at the beginning and end of the trial, to determine their attitudes about fluids and potentially identify barriers to maintaining adequate hydration status (Appendix A). Additionally, standard information from the medical record including demographics, occupation, medical history and medications will be recorded."
2944913|NCT02938884|No Intervention|No Smart water bottle|All subjects in both cohorts will be provided the same questionnaire on two occasions, at the beginning and end of the trial, to determine their attitudes about fluids and potentially identify barriers to maintaining adequate hydration status (Appendix A). Additionally, standard information from the medical record including demographics, occupation, medical history and medications will be recorded.
2944914|NCT02938871|Active Comparator|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
2944915|NCT02938871|Placebo Comparator|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
2944916|NCT02938858||ATRA-chimio|according to usual practice center
2944917|NCT02938858||ATRA-ATO|according to usual practice center
2944918|NCT02938845|Experimental|total laparoscopic hysterectomy(TLH)|Each patient's anxiety was measured using Spielberger's State-Trait Anxiety Inventory immediately before, immediately after the operation.
2944919|NCT02938845|Experimental|total abdominal hysterectomy(TAH)|Each patient's anxiety was measured using Spielberger's State-Trait Anxiety Inventory immediately before, immediately after the operation.
2944920|NCT02938832|Active Comparator|Traditional low-fat diet advice|Advice on traditional low-fat diet by dietician
2944921|NCT02938832|Active Comparator|Mediterranean diet advice|Advice on a Mediterranean dietary regime with reduced carbohydrates
2944922|NCT02938819|Experimental|Experimental group|Patients in the experimental group received a Goal-oriented upper limb intervention.
2944923|NCT02938819|Active Comparator|Control group|Patients in the control group received a standard upper limb intervention
2944924|NCT02938806||Obese/overweight children with T1D|No intervention
2944925|NCT02938806||Normal weight children with T1D|No intervention
2944926|NCT02938806||Obese/overweight children, no diabetes|No intervention
2944927|NCT02938806||Healthy, normal weight children|No intervention
2944928|NCT02938793|Experimental|Single Arm|Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) intravenously for 13 doses and Tremelimumab 75 mg Q4W (equivalent to 1 mg/kg Q4W) intravenously for 7 doses then every 12 weeks for 2 doses.
2944932|NCT02938767||renal transplant recipients|20 renal transplant recipients followed at the Istanbul Medical Faculty from October 1994 to October 2011 setted as the control group
2944933|NCT02938754|Experimental|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
2944934|NCT02938754|Active Comparator|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
2944935|NCT02938741|Experimental|r-ATG Immunosuppressive agents|"Rabbit Anti－human Thymoglobulin (r-ATG 2.5 mg/kg×4 days) were extra used in the treatment group.~The conditioning include of Busulfex 3.2mg/kg*4d,CTX 60mg/kg *4d."
2944936|NCT02938741|Placebo Comparator|placebo|"Rabbit Anti－human Thymoglobulin (r-ATG) were not used as intervention in the treatment group.~The conditioning include of Busulfex 3.2mg/kg*4d,CTX 60mg/kg *4d."
2944937|NCT02938728||Melanoma|Advanced melanoma treated by immunotherapies
2944938|NCT02938715|Experimental|Feedback group (teledermatology)|
2944939|NCT02938715|No Intervention|Control group (phone only)|
2944940|NCT02938702||Active surveillance|Group with active surveillance of their PTC
2944941|NCT02938702||Surgery|Group who underwent surgery after diagnosis of PTC
2944942|NCT02938689|Experimental|Lumbar extension exercise|Exercise education based on Mckenzie lumbar extension exercise for 4 weeks
2944943|NCT02938689|Active Comparator|Lumbar flextion exercise|Exercise education based on Wilillams lumbar flexion exercise for 4 weeks
2944944|NCT02938663||Questionnaires and measurements|assessment of physical activity, dietary intake, psychosocial factors, weight status
2944945|NCT02938650|Other|Nitrosomonas eutropha spray|Subjects will receive nitrosmonas eutropha spray that they will apply twice a day.
2944946|NCT02938624|Experimental|cohort1|Pembrolizumab 200 mg I.V single dose
2944947|NCT02938624|Experimental|Cohort II|Pembrolizumab 200 mg I.V Twice interval 21 days
2944948|NCT02938624|Experimental|Cohort III|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
2944949|NCT02938624|Experimental|COHORT -1|Pembrolizumab 100 mg I.V single dose
2944950|NCT02938611||The study population|Persons with stage >=4 chronic kidney disease.
2944951|NCT02938598|Experimental|A|Engagement On - Problem Solving High - Motivation On
2944952|NCT02938598|Experimental|B|Engagement On - Problem Solving Low - Motivation On
2944953|NCT02938598|Experimental|C|Engagement On - Problem Solving High - Motivation Off
2944954|NCT02938598|Experimental|D|Engagement On - Problem Solving Low - Motivation Off
2944955|NCT02938598|Experimental|E|Engagement Off - Problem Solving High - Motivation On
2944956|NCT02938598|Experimental|F|Engagement Off - Problem Solving Low - Motivation On
2944957|NCT02938598|Experimental|G|Engagement Off - Problem Solving High - Motivation Off
2944958|NCT02938598|Experimental|H|Engagement Off - Problem Solving Low - Motivation Off
2944959|NCT02938585|Experimental|Prophylactic treatment|
2944960|NCT02938585|Experimental|On-demand treatment|
2944961|NCT02938572|Experimental|NNC0143-0406|
2944962|NCT02938572|Active Comparator|Insulin aspart|
2944963|NCT02938559|Experimental|Cognitive Therapy plus Memory Support|
2944964|NCT02938559|Active Comparator|Cognitive Therapy-as-usual|
2944965|NCT02938546|Active Comparator|before therapy|18F-FDG PET/CT performed before therapy
2944966|NCT02938546|Experimental|3 days after cisplatin chemotherapy and targeted therapy|18F-FDG PET/CT performed 3 days after chemotherapy and targeted therapy
2944967|NCT02938546|Experimental|longer time after cisplatin chemotherapy and targeted therapy|18F-FDG PET/CT performed before the third cycle chemotherapy and the 7th week targeted therapy
2944968|NCT02938533|No Intervention|Standard of Care|Standard HIV primary care services available at HIV care and treatment clinics in Tanzania.
2944969|NCT02938533|Experimental|Behavioral Intervention Using Social Norms and Priming|Patients in this arm may have been exposed to the behavioral intervention, which included the following components: 1) visual feedback about clinic-level retention in care through an interactive poster; 2) a self-relevant priming image that appeared on all components; and 3) a take-home item (i.e., pillbox or calendar) with the priming image.
2944970|NCT02938520|Experimental|CAB LA + RPV LA every 4 weeks|After Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will receive oral CAB 30 mg + RPV 25 mg once daily for approximately four weeks. At visit Week 4b subjects will receive an initial loading dose of CAB LA (600 mg) and RPV LA (900 mg) at Week 4b. From Week 8 onwards, subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks. until withdrawal
2944971|NCT02938520|Active Comparator|ABC / DTG / 3TC (600 mg/50mg/300mg) once daily|After the Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will continue to receive oral ABC/DTG/3TC (or DTG + two NRTIs) initiated during the Induction Phase for 100 weeks. At the end of the Maintenance Phase, eligible participants receiving ABC/DTG/3TC (or DTG + two NRTIs) have the option to continue in the study by switching to CAB LA + RPV LA in the Extension Phase. These participants will transition to LA dosing, beginning with approximately 4 weeks of oral CAB + RPV therapy initiated at Week 100, and receive the first IM CAB LA + RPV LA injections at Week 104b.
2944972|NCT02938507|Experimental|Formulation 1 solabegron|Subjects will receive formulation 1 solabegron doses in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
2944973|NCT02938507|Experimental|Formulation 2 solabegron|Subjects will receive formulation 2 in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
2944974|NCT02938494|Experimental|IDP-123 Lotion|Lotion
2944975|NCT02938494|Active Comparator|Tazorac Cream|Cream
2944976|NCT02938494|Active Comparator|Vehicle Lotion|Lotion
2944977|NCT02938494|Active Comparator|Vehicle Cream|Cream
2944978|NCT02938468|Active Comparator|Surgery|Patients in this arm will receive any form if surgical intervention (i.e. bedside burrhole craniostomy, 2 burrhole washout, craniotomy, endoscopy etc.) for treatment of their chronic subdural hematoma
2944979|NCT02938468|Experimental|Dexamethasone|Patients in this arm will receive Dexamethasone over a 21day period for treatment of their chronic subdural hematoma
2945541|NCT02934594||Group B1|motor deficit group: received palliative decompression within 48 hours after symptoms occured
2944980|NCT02938442|Active Comparator|Standard Chemotherapy|"The first or control arm will receive standard chemotherapy for triple negative breast cancer."
2944981|NCT02938442|Active Comparator|Standard Chemotherapy + Vaccine|"The second or chemo + vaccine arm will receive the same standard chemotherapy plus P10s-PADRE vaccine."
2944982|NCT02938429|Other|Participants with Fontan circulation|"Physical activity measurements: Participants will wear Actigraph GT3X+ accelerometers for 7 consecutive days and complete a physical activity log. Data from the accelerometers and physical activity log will be cross referenced.~Endothelial function measurements: Participants undergo Digital Thermal Monitoring (DTM) via Vendys (VENDYS-6000, Endothelix Inc., Houston, TX). Since DTM is not currently a validated tool and its use has not been published in a paediatric population, we will employ a second assessment of endothelial function, the Endothelial Pulse Amplitude Test (Endo-PAT, Itamar Medical).~Participants will complete a questionnaire to access factors that can affect endothelial function."
2944983|NCT02938429|Other|Age and gender matched controlled|"Physical activity measurements: Participants will wear Actigraph GT3X+ accelerometers for 7 consecutive days and complete a physical activity log. Data from the accelerometers and physical activity log will be cross referenced.~Endothelial function measurements: Participants undergo Digital Thermal Monitoring (DTM) via Vendys (VENDYS-6000, Endothelix Inc., Houston, TX). Since DTM is not currently a validated tool and its use has not been published in a paediatric population, we will employ a second assessment of endothelial function, the Endothelial Pulse Amplitude Test (Endo-PAT, Itamar Medical).~Participants will complete a questionnaire to access factors that can affect endothelial function."
2944984|NCT02938416|Experimental|Isokinetic training|Ten times, three sets of isokinetic strengthening exercise using 30 degree/sec and 120 degree/sec
2944985|NCT02938416|Active Comparator|Isotonic training|Ten times, three sets of isotonic strengthening exercise using consistent resistance of 60% of 1-repetition maximum of hip or knee
2944986|NCT02938403|Experimental|In vivo group|Those who receive in vivo counseling and Nicotine Replacement Therapy (NRT)
2944987|NCT02938403|Active Comparator|Controls|Standard smoking cessation counseling and Nicotine Replacement Therapy (NRT)
2944988|NCT02938377|Active Comparator|No dx of alcohol use disorder, panic or depre|Computerized Brief Intervention (CBI)- a video about alcohol abuse
2944989|NCT02938377|Active Comparator|Risky drinking, no dx of AUD, has panic or depression|Computerized Brief Intervention (CBI)- a video about alcohol abuse, plus 4 sessions of counseling called Motivational Enhancement Therapy
2944990|NCT02938377|Active Comparator|Dx of AUD with or without panic or depression|Computerized Brief Intervention (CBI)- a video about alcohol abuse, plus 4 sessions of counseling called Motivational Enhancement Therapy plus a recommendation for Alcohol Pharmacotherapy (APT). The drugs recommended in the APT are all standard of care drugs for alcohol treatment and are not under study in this protocol.
2944991|NCT02938364|Experimental|Earplugs|The participant will be asked to put plastic earplugs in both ears for 10 minutes and then the impression will be made while they are still on.
2944992|NCT02938364|Experimental|Acupressure|The participant will be asked to wear sea bands on P6 points of both hand wrists for 10 minutes and then the impression will be made while they are still on.
2944993|NCT02938364|Placebo Comparator|Placebo|The participant will be asked to wear non pressure bands on both hand wrists for 10 minutes and then the impression will be made while they are still on.
2944994|NCT02938351|Experimental|collaborative care|To test the efficacy of a collaborative care intervention with patients treated with dialysis to reduce depression, pain, fatigue, and improve quality of life
2944995|NCT02938338||Obese patients with BMI above 35|Bariatric surgery
2944996|NCT02938325||No intervention: General Anesthesia|"Thirty patients undergoing elective surgery under general anesthesia who will be monitored with standard ASA, BIS and EEG for comparisons. In recovery unit, at the end of the surgery, patients will be questioned for awareness under anesthesia by Modified Brice Questionnaire.~There will be no intervention. Patients will be anesthetized with general anesthesia as they were supposed to be for their elective surgery. The EEG during the anesthesia will be assessed afterwards, and patients will be asked about their memory from the surgery."
2944997|NCT02938325||No intervention: Sedation|"Thirty patients undergoing elective cardiac catheterization under conscious sedation who will be monitored with standard ASA, BIS and EEG for comparisons. In recovery unit, at the end of the procedure, patients will be questioned for awareness under sedation by Modified Brice Questionnaire.~There will be no intervention. Patients will be anesthetized with sedation as they were supposed to be for their elective cardiac catheterization. The EEG during the anesthesia will be assessed afterwards, and patients will be asked about their memory from the surgery."
2944998|NCT02938312|Active Comparator|Weight Loss Only|24- month weight loss program (year 1: weekly in-person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)
2944999|NCT02938312|Experimental|Weight Loss Plus|"Same intervention as Weight Loss Only but includes community-wide interventions to increase access to healthy affordable food and opportunities for safe and convenient physical activity"
2945000|NCT02938299|Experimental|Arm 1: neoadjuvant + surgery|"Patients in Arm 1 will receive multiple intratumoral administrations into all injectable cutaneous, subcutaneous, and nodal tumors of a mixture of L19IL2 and L19TNF once weekly for up to 4 weeks (or until all injectable tumors have disappeared, or intolerance to study treatment or in the opinion of the investigator immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first).~Newly occurring injectable melanoma lesions within the 4 weeks treatment period will also be treated as described. Surgical resection of all existing metastases will follow within 4 weeks after end of treatment. Surgery will be performed after the safety evaluation carried out at week 5 and, if indicated, may be carried out on the same day of the safety evaluation."
2945001|NCT02938299|Active Comparator|Arm 2: surgery alone|Patients in Arm 2 will receive directly surgical resection of melanoma tumor lesions within 4 weeks after randomization.
2945002|NCT02938286|Experimental|Fractional CO2 laser at 5% density|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 5% density) in a subject blinded fashion. After pretreament Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied to this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
2945003|NCT02938286|Experimental|Fractional CO2 laser at 15% density|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreament Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
2945004|NCT02938286|Experimental|Fractional Er:YAG laser at 5% density|This test region will be pretreated with a Erbium Yttrium Aluminum Garnet laser with a 225 μm spot at 5% density and a pulse energy of 9 mJ/microbeam (Fractional Er:YAG laser, 9 mJ, 5% density) in a subject blinded fashion. After pretreatment Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
2945005|NCT02938286|Experimental|Fractional Er:YAG laser at 15% density|This test region will be pretreated with a Erbium Yttrium Aluminum Garnet laser with a 225 μm spot at 15% density and a pulse energy of 9 mJ/microbeam (Fractional Er:YAG laser, 9 mJ, 15% density) in a subject blinded fashion. After pretreatment Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
2945006|NCT02938273|Experimental|Bioimmunoradiotherapy|Concurrent Radiation therapy (i.e. 5 times a week, 7 weeks, total dose 70 Gy) with cetuximab (loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7) and Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months (wk 8,10, 12, 14, 16, 18, 20, 22, 24, 26.
2945007|NCT02938260||Diltiazem|
2945008|NCT02938260||Metoprolol|
2945009|NCT02938247|Experimental|Single-arm study|High caloric, high protein ONS, three portions daily, total dose of 400 kcal/day for 7 consecutive days, oral administration
2945010|NCT02938234|Experimental|Single-arm study|High caloric, high protein ONS, single dose of 400 kcal/day for 7 consecutive days, oral administration
2945011|NCT02938221|Experimental|Telemedical video-oculography|Execution of three oculomotor tests using a telemedical video-oculography system
2945012|NCT02938208|Experimental|Jupiter Full Face Mask|Participants to use full face mask in-home for a 14 ± 3 days in-home.
2945013|NCT02938195|Experimental|experimental arm|PF regimen (cis-platinum of 25 mg/m2/d, d1-3; 5-fluorouracil of 500mg/m2/d, d1-4) every 4 weeks for 2 cycles concurrently with three-dimensional radiation therapy or intensity-modulated radiotherapy followed by surgery 4-8weeks after neoadjuvant therapy in a standard manner.
2945014|NCT02938182|Experimental|clopidogrel|clopidogrel tablet 75mg daily for three months
2945015|NCT02938169|Experimental|walking exercise group|"**walking exercise with bracing exercise~walking exercise: treadmill gait with tolerable gait speed~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this."
2945016|NCT02938169|Experimental|stabilization exercise group|"** stabilization exercise with bracing exercise~stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this."
2945017|NCT02938169|Experimental|walking and stabilization exercise group|"**walking exercise, bracing exercise with stabilization exercise~stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~walking exercise:treadmill gait with tolerable gait speed"
2945018|NCT02938169|Sham Comparator|flexibility exercise group|"**Stretching exercise(control)~Only educate the flexibility exercise(stretching exercise)~Don't educate the walking exercise method and stabilization exercise method"
2945019|NCT02938143|Experimental|4-stage criteria-based exercise protocol|a progressive 4-stage criteria-based exercise protocol within the limits of pain
2945020|NCT02938143|Active Comparator|Heavy-load eccentric exercise protocol|a 12-week painful heavy-load eccentric exercise protocol
2945021|NCT02938130|Other|Wellness Programs|Community Partners and Community LIFE programs
2945022|NCT02938117|Experimental|CON : concentric cycling exercise|Thirty adults will be randomized into 2 groups: CON or EXC. The patients of ECC group will follow habituation sessions (2weeks) to avoid the secondary muscular effects of high intensity eccentric exercise
2945023|NCT02938117|Experimental|EXC : eccentric cycling exercise|Thirty adults will be randomized into 2 groups: CON or EXC. The patients of ECC group will follow habituation sessions (2weeks) to avoid the secondary muscular effects of high intensity eccentric exercise
2945024|NCT02938104|Experimental|Prehabilitation|"Immediately after randomization, until surgery and to be continued for 8 weeks after surgery, patients in this arm will:~Receive a personalized physical exercise program~Receive nutritional counselling with whey protein isolate powder~Receive relaxation techniques"
2945025|NCT02938104|Active Comparator|Rehabilitation|Patients in this arm will receive the same personalized physical exercise program, nutritional intervention and relaxation techniques as patient in the other arm but to be started after surgery.
2945026|NCT02938091|Experimental|High-fat diet|The dietary intervention was designed as a typical Western diet (39% total fat, 14% saturated fat, 12% monounsaturated fat, 9.6% polyunsaturated fat, 42% carbohydrate, 8.8 grams fiber/1000 kcal)
2945054|NCT02937909|Experimental|Prospective Data|Use of BSN medical UK range of wound dressings and compression products for 12 weeks treatment period Training and testing of woundcare nursing competencies Quality of Life questionnaire for patients
2945164|NCT02937207|Placebo Comparator|Xuxiao control group|36 patients of remission phase of Yang deficiency of asthma will take Zhi Chuan Capsule placebo and Bu Shen Na Qi Granule placebo oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
2945027|NCT02938091|Experimental|Low-fat diet|The dietary intervention consisted of a Hispanic diet (20% total fat, 5.5% saturated fat, 9.6% monounsaturated fat, 3.7% polyunsaturated fat, 61% carbohydrate, 13.7 grams fiber/1000 kcal). The diet was comprised of typical foods and recipes resembling a traditional Caribbean Hispanic diet and differed from the Western diet in four primary ways: 1) more fruits and vegetables, 2) more beans (e.g. mixed dishes to reduce serving size of white rice while increasing legumes), 3) emphasis on reduced-fat dairy products (e.g., 1% fat milk), and 4) lower total fat and lower animal and hydrogenated fat.
2945028|NCT02938078|Experimental|Treatment Eye|One eye will be treated with Avenova; the other eye will not be treated. The investigator is masked as to which eye is receiving Avenova product.
2945029|NCT02938078|No Intervention|Non-Treatment Eye|One eye will be treated with Avenova; the other eye will not will be treated. The investigator is masked as to which eye is receiving Avenova product.
2945030|NCT02938065|Other|2% Milk|16 participants will drink 10 ounces of 2% milk Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
2945031|NCT02938065|Other|Apple Juice|16 participants will drink 10 ounces of apple juice Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
2945032|NCT02938065|Other|Ensure Clear|16 participants will drink 10 ounces of ensure clear Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
2945033|NCT02938052|Experimental|Intervention Arm|"Participants will all undergo a 10-week PP-based health behavior intervention and adherence measurements (baseline and Week 10).~The participants will receive an ActiGraph accelerometer. They will be asked to begin wearing the accelerometer after their initial visit. Participants will wear the ActiGraph for 7 days at baseline and again at 10 weeks."
2945034|NCT02938039|Active Comparator|Ambu LMA|Ambu Laryngeal Mask Airway device of different sizes for age
2945035|NCT02938039|Active Comparator|I-Gel LMA|I-Gel Laryngeal Mask Airway device of different sizes for age
2945036|NCT02938026|No Intervention|Control|Usual care
2945037|NCT02938026|Experimental|Telephone intensive lifestyle counseling|Telephone intensive lifestyle counseling
2945038|NCT02938026|Experimental|Bariatric surgery|Bariatric surgery
2945039|NCT02938013|Experimental|Group A|Non-Randomized: Monoinfected Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0-7 Paired liver biopsy at days 0 and 7. SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.
2945040|NCT02938013|Experimental|Group B|Randomized: HIV/HCV coinfected; Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0 through 7, Paired liver biopsy days 0 and 7. SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.
2945041|NCT02938013|Active Comparator|Group C|Random Assignment of arm: Co-infection Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy days 0 and 7. SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12
2945042|NCT02938000|Experimental|Theraband group|This group will be furnished with Thera-band, and link to exercise video, with plans for regular exercise as described previously, in addition to usual post stroke care.
2945043|NCT02938000|Placebo Comparator|Usual Care Group|This group will have usual post stroke care, and will be advised to get regular exercise.
2945044|NCT02937974|Experimental|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
2945045|NCT02937974|Placebo Comparator|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
2945046|NCT02937961|Experimental|Early SLED|
2945047|NCT02937961|Active Comparator|Late SLED|
2945048|NCT02937948|Experimental|Adaptative Treatment plans|A Library of treatment plans will be generated for each patient before starting radiochemotherapy (standard treatment). This Library will be created using CT-Scans with variable bladder filling (and hence different uterine positions). Each day of radiotherapy treatment, an appropriate plan is chosen based on Imaging that day.
2945049|NCT02937935|Experimental|Protocol Guided-RRT|In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
2945050|NCT02937935|Active Comparator|On Demand-RRT|In the protocol guided group patients all patients would be considered for dialysis within 6 hours of randomization After randomization patients would receive dialysis as three sessions per week of at least 4 h with a blood flow >200 mL/min and a dialysate flow >500 mL/min in intermittent group and as 20-25 mL/kg/h of effluent, by filtration and/or diffusion in continuous form until recovery of renal functions
2945051|NCT02937922|Active Comparator|AEROBIC|The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 50-60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: [(HR max - HR rest) x desired intensity] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.
2945052|NCT02937922|Active Comparator|RESISTANCE|The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 60 to 90 seconds between sets and exercises. The weight will be adjusted to 60 to 70% of a maximum repetition (1-RM) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).
2945053|NCT02937922|Active Comparator|COMBINED|The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
2946023|NCT02931565|Placebo Comparator|Placebo|Matching placebo administered orally
2945055|NCT02937909|No Intervention|Historical data|Historical data from the three months prior to the study on time needed for nurse training, number of referrals to the Tissue Viability Team, costs of dressings used, number of patients with wounds treated, types of wounds, number of wound closures and duration of treatment .
2945056|NCT02937896|Experimental|Ketorolac|30mg ketorolac administrated intravenous and 4 puffs nasal Normal Saline.
2945057|NCT02937896|Active Comparator|Desmopressin|40 microgram nasal desmopressin administrated and 1cc Normal Saline intravenous
2945058|NCT02937883|Experimental|empowerment intervention|Empowerment intervention
2945059|NCT02937883|No Intervention|regular care|Regular care, care as usual
2945060|NCT02937870|Experimental|Test Product 1|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
2945061|NCT02937870|Experimental|Test Product 2|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
2945062|NCT02937870|Active Comparator|Reference Product|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
2945063|NCT02937870|Other|Negative Control|
2945064|NCT02937857|Active Comparator|Standard treatment only|Standard treatment only such as antiasthmatic, expectorant and antipyretic
2945065|NCT02937857|Experimental|Standard treatment+Xiyanping injection|Standard Treatment such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection intravenous administration of 0.2-0.4mL/kg/day ,QD for 5 days.
2945066|NCT02937844|Experimental|Anti-PD-L1 CSR T cells|Patients will receive lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide, followed by intravenous infusion of autologous anti- PD-L1 CSR T cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of CAR T cells. The tested CAR T cell dosage ranges from 5×10^4 /kg to 1×10^7 /kg.
2945067|NCT02937831||All Study Participants|
2945068|NCT02937818|Experimental|ARM A|
2945069|NCT02937818|Experimental|ARM B|
2945070|NCT02937818|Experimental|ARM C|
2945071|NCT02937805|Experimental|Moisturizing vaginal and vulvar sea buckthorn oil cream|Moisturizing non-hormonal vaginal and vulvar cream containing sea buckthorn oil as active ingredient (medical device product in development). Administered twice or once per day for 5 weeks. Post-menopausal women n= 55 + 45. Pre-menopausal women n=15
2945072|NCT02937805|Active Comparator|Moisturizing vaginal and vulvar cream|Moisturizing non-hormonal vaginal and vulvar cream (commercial medical device cream already on the market, not containing sea buckthorn oil). Administered once - twice per day for 5 weeks. Postmenopausal women n=55
2945073|NCT02937805|No Intervention|Control|No moisturizing vaginal and vulvar cream for 5 weeks. Postmenopausal women n=55
2945074|NCT02937792|No Intervention|CONTROL|one with intrathecal 12.5 mg bupivacaine
2945075|NCT02937792|Experimental|experimental|one group with intrathecal 15 mg bupivacaine
2945076|NCT02937779|Experimental|HBs Ag positive|"tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for positive Hbe Ag women.~No treatment for negative HBe Ag women"
2945077|NCT02937766|Experimental|Treatment A|Subcutaneous (SQ) injection using an autoinjector weekly over 4 weeks (4 injections)
2945078|NCT02937766|Active Comparator|Treatment B|Intramuscular injection (IM) using syringe and needle weekly over 4 weeks (4 injections)
2945079|NCT02937740|Other|BID/TID|"NATESTO administered intranasally. Multiple-dose dispenser will be used for gel deposition into the nasal cavity. The dispenser is a finger-actuated, non-pressurized dispensing system designed to deliver 122.5mg of NATESTO (5.5mg testosterone) per actuation.~For BID administration, NATESTO 22 mg/day of testosterone. For the subset of patients that continue on TID, NATESTO 33 mg/day of testosterone."
2945080|NCT02937727|Experimental|MRI compatible and LFP recordable implantable stimulator|
2945081|NCT02937714|Experimental|School mental health training|Teachers Training workshop Workshop based on local adaptation of WHO-EMRO school mental health manual will be conducted in school. The duration of the workshop will be 3 days. Teachers can decline to participate or withdraw at any stage.
2945082|NCT02937714|No Intervention|Wait list control group|Wait list control group of teachers in same schools. Half of teachers in the same school will be the wait list control group.
2945083|NCT02937701|Experimental|ABP 710|Concentrate for solution, ABP 710 3 mg/kg infusion on day 1, at weeks 2 and 6, and every 8 weeks thereafter
2945084|NCT02937701|Active Comparator|infliximab|Concentrate for solution, infliximab 3 mg/kg infusion on day 1, at weeks 2 and 6, and every 8 weeks thereafter
2945085|NCT02937675|Experimental|eFT508 Escalation Cohort|This portion of the study will evaluate the safety and pharmacology of a range of eFT508 doses administered daily in subjects with previously treated lymphomas
2945086|NCT02937675|Experimental|eFT508 Expansion Cohort|This portion of the study provides cohort expansion to further explore the safety, pharmacology, and clinical activity of a single dose level of eFT508 monotherapy in subjects with specific previously treated lymphomas
2945087|NCT02937662|Experimental|IAC regimen|Patients receive IAC regimen including idarubicin, cytarabine and cyclophosphamide.
2945088|NCT02937662|Active Comparator|Control Group|Patients receive physician-directed regimens without cyclophosphamide including FLA±G regimen, AAG regimen, decitabine with AA regimen. Physicians can choose one of these regimens based on their experience and patients' condition.
2945089|NCT02937649|Experimental|Laparoscopic sleeve gastrectomy using 48-Fr bougie|Patients will undergo laparoscopic sleeve gastrectomy with a 48-Fr (16 mm) bougie
2945090|NCT02937649|Active Comparator|Laparoscopic sleeve gastrectomy using 36-Fr bougie|Patients will undergo laparoscopic sleeve gastrectomy with a with 36 Fr (12 mm) bougie
2945091|NCT02937636|Experimental|Test Product|Participants will apply a full strip of dentifrice to cover the head of the toothbrush provided and brush their teeth with the assigned dentifrice twice daily (morning and evening) for one timed minute following their normal routine.
2945092|NCT02937636|Active Comparator|Reference Product|Participants will apply a full strip of dentifrice to cover the head of the toothbrush provided and brush their teeth with the assigned dentifrice twice daily (morning and evening) for one timed minute following their normal routine.
2945309|NCT02936180|Active Comparator|Standard dose influenza vaccine|Patients will receive one dose of FLUZONE® Standard Dose Quadrivalent Inactivated Influenza Vaccine (SD-QIV)
2945093|NCT02937623|Experimental|Test Product: Dissolvable polymer strip containing Novamin|In this arm, participants received an experimental dissolvable polymer strip containing 15 % weight/weight (w/w) calcium sodium phosphosilicate (Novamin). One strip was applied per test tooth topically by a suitably qualified member of the site staff. Each participant received 2 strips in total (as two test tooth were assessed per participant).
2945094|NCT02937623|No Intervention|Reference Product: No treatment/product|In this arm, participants did not receive any treatment/product.
2945095|NCT02937597|Active Comparator|National e-learning programme only (HSE)|Active Comparator: National e-learning programme only (HSE) National e-learning programme only Recent successful completion of the National e-learning programme by certificate will be displayed. Students then undergo performance assessment via low fidelity simulation and complete a questionnaire.
2945096|NCT02937597|Active Comparator|eS: eScenarios|Recent successful completion of the National e-learning e-learning programme by certificate will be displayed. Students will proceed to an online learning course with 4 scenarios to work through but no requirement to meet a proficiency benchmark. Following training students undergo performance assessment via low fidelity simulation and complete a questionnaire.
2945097|NCT02937597|Experimental|ePBP: eProficiency Based Progression|Recent successful completion of the National e-learning programme by certificate will be displayed. Students will proceed to a PBP e-learning course using the same series of cases as S. PBP students will be scored according to predefined metrics and will be required to reach proficiency benchmarks for the cases within the e-learning course to allow progression through the cases. Following training students undergo performance assessment via low fidelity simulation and complete a questionnaire.
2945098|NCT02937584|Experimental|GP MDI (PT001) 14.4 μg|Glycopyrronium
2945099|NCT02937584|Experimental|FF MDI (PT005) 9.6 μg|Formoterol Fumarate
2945100|NCT02937571|Experimental|Carfilzomib, Lenalidomide, and Dexamethasone|"Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 45 or 56 mg/m2 per dose, days 8, 9, 15, and 16.~Cycles 2- up to 12: Carfilzomib 45 or 56 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16~Cycles 1- up to 12: Lenalidomide 25 mg/day, days 1-21 every 28 days~Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, and 23~Cycles 5- up to 12: Dexamethasone 10 mg/dose, days 1, 2, 8, 9, 15, 16, 22 and 23"
2945101|NCT02937558|Experimental|CSI-Glucagon|Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
2945102|NCT02937558|Placebo Comparator|Placebo|Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump.
2945103|NCT02937545|Experimental|PGx Only|Patients will receive pharmacogenetic testing. Pharmacists will make recommendations for drug/dose changes based on PGx results.
2945104|NCT02937545|Experimental|PGx + MTM|Patients will receive pharmacogenetic testing along with medication therapy management. Two MTM sessions will be conducted: one at the time testing is ordered and the testing sample is collected, and one when results are returned to the patient. Pharmacists will make recommendations for drug/dose changes based on medication action plan developed during MTM and the PGx results.
2945105|NCT02937532|Placebo Comparator|GHE + TOBT training|Subjects will receive general health education and task-oriented balance training.
2945106|NCT02937532|Active Comparator|CBT + TOBT training|Subjects will receive group-based cognitive behavioral therapy and task-oriented balance training.
2945107|NCT02937519|Experimental|Melodie group|Induction chrono-chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy
2945108|NCT02937519|Other|Routine-Chemotherapy|Induction routine-chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
2945109|NCT02937506|Experimental|Propofol|Patients in the treatment arm will be given propofol only when having a colonoscopy.
2945110|NCT02937506|Experimental|Fentanyl Plus Midazolam Only|Patients in the control arm will receive only the standard of care medications, fentanyl and midazolam when having a colonoscopy.
2945111|NCT02937493||Migration Background|Migration background was defined according to current law (MighEV §6, Sozialgesetzbuch). In detail this means that migration background is fulfilled, if (1) the person does not possesses the national citizenship, or (2) the origin of birth is outside the borders of the national country, and emigration to the national territory was after 1949, or (3) origin of birth of one of the two parents is outside the current borders of the national territory plus emigration of one of the two parents occured after 1949.
2945112|NCT02937493||Non Migration Background|If the following criteria is not fulfilled: Migration background was defined according to current law (MighEV §6, Sozialgesetzbuch). In detail this means that migration background is fulfilled, if (1) the person does not possesses the national citizenship, or (2) the origin of birth is outside the borders of the national country, and emigration to the national territory was after 1949, or (3) origin of birth of one of the two parents is outside the current borders of the national territory plus emigration of one of the two parents occured after 1949.
2945113|NCT02937480|Experimental|Experimental group|Task-specific training
2945114|NCT02937480|Sham Comparator|Control group|Global stretching, memory exercises, health care orientation
2945115|NCT02937454|Active Comparator|ferric carboxymaltose|The first dose of study treatment will be administered for all randomised subjects while the patient is still hospitalised for the Index hospitalisation. The subsequent administrations of study treatment will be done as part of the outpatient clinic visits.
2945116|NCT02937454|Placebo Comparator|normal saline 0.9%|The first dose of study treatment will be administered for all randomised subjects on the same day as randomisation.
2945117|NCT02937428|Experimental|Look away and prefer to look|Participant who is self-identified as preferring to look at the needle is randomized to look away from the needle during vaccination
2945118|NCT02937428|Active Comparator|Look at needle and prefer to look|Participant who is self-identified as preferring to look at the needle is randomized to look at the needle during vaccination
2945119|NCT02937428|Experimental|Look away and prefer to look away|Participant who is self-identified as preferring to look away from the needle is randomized to look away from the needle during vaccination
2945120|NCT02937428|Active Comparator|Look at needle and prefer to look away|Participant who is self-identified as preferring to look away from the needle is randomized to look at the needle during vaccination
2945542|NCT02934594||Group B2|motor deficit group: received palliative decompression 48 hours after symptoms occured
2945121|NCT02937415|Experimental|Waterpipe smokers group|Three waterpipe cafes located in Ankara were visited. 50 waterpipe smokers aged 18-40 years, enrolled in the study and created the working group. At the same time, there were also cigarette smokers among these people. Breath carbon monoxide, pulmonary function tests were performed both before and after smoking waterpipe and parameters of oxidative stress and antioxidant status were measured in blood samples after smoking waterpipe.
2945122|NCT02937415|Active Comparator|Control group|The control group consisted of 50 people of the same age and sex, who had never smoked neither cigarette nor waterpipe. Breath carbon monoxide, pulmonary function tests were performed and parameters of oxidative stress were measured in blood samples.
2945123|NCT02937402|Experimental|Bronchoscopy with bronchoalveolar lavage|Patients undergo bronchoscopy with bronchoalveolar lavage over 45 minutes
2945124|NCT02937376|Experimental|N-acetyl Cystein|NAC supplementation (10 mg/kg/day) for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
2945125|NCT02937376|Placebo Comparator|Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
2945126|NCT02937363|Experimental|Alpha-lipoic acid|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
2945127|NCT02937363|Placebo Comparator|Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
2945128|NCT02937350|Experimental|Study Population|D6-25-hydroxyvitamin D3
2945129|NCT02937337|Experimental|Videostylet|Laryngeal mask airway insertion using video stylet guided technique
2945130|NCT02937337|Active Comparator|Blind|Laryngeal mask insertion using standard index finger-guided technique
2945131|NCT02937324|Active Comparator|Clinical Assessment|Motor assessment will be performed by a clinician using the Unified Parkinson's Disease Rating Scale.
2945132|NCT02937324|Experimental|Smartphone assessment|CloudUPDRS smartphone software assessment will be performed.
2945133|NCT02937311|Experimental|NMES group|This group of patients received Neuromuscular Electrical Stimulation (NMES) and standardized physiotherapy and rehabilitation protocol
2945134|NCT02937311|Experimental|Kinesiotape Group|This group of patients received standardized physiotherapy and rehabilitation protocol and at the same time kinesiotape was applied to their affected shoulder
2945135|NCT02937311|Experimental|Control|This group of patients received only a standardized physiotherapy and rehabilitation protocol
2945136|NCT02937298|Experimental|Control Meal|Control meal using standard breakfast foods.
2945137|NCT02937298|Experimental|Berry Treatment|This will consist of standard breakfast foods plus a berry smoothie.
2945138|NCT02937298|Experimental|Sea Buckthorn Treatment|This will consist of standard breakfast foods plus a sea buckthorn berry smoothie.
2945139|NCT02937298|Experimental|Wild Garlic Treatment|This will consist of standard breakfast foods plus a wild garlic dip.
2945140|NCT02937285|Active Comparator|Standard care|Interferon alone
2945141|NCT02937285|Experimental|Experimental group|Mitoxantrone for 6 month followed by interferon
2945142|NCT02937272|Experimental|LY3200882 Schedule 1 Escalation|
2945143|NCT02937272|Experimental|LY3200882 Schedule 2 Escalation|
2945144|NCT02937272|Experimental|LY3200882 Schedule 1 Expansion|
2945145|NCT02937272|Experimental|LY3200882 Schedule 2 Expansion|
2945146|NCT02937272|Experimental|LY3200882 + LY3300054|
2945147|NCT02937272|Experimental|LY3200882 + Gemcitabine + nab-Paclitaxel|
2945148|NCT02937272|Experimental|LY3200882 + Cisplatin + Radiation|
2945149|NCT02937259|Experimental|Self-admission|Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
2945150|NCT02937246|Experimental|the intervention group|Partial covered double bare metal stent
2945151|NCT02937246|Active Comparator|the control group|Uncovered double bare metal stent
2945152|NCT02937233|Experimental|4 Week Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 4
2945153|NCT02937233|Experimental|2 Week Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 2
2945154|NCT02937233|Experimental|Single Vaccination Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 only
2945155|NCT02937220|Experimental|Monolithic zirconia crowns|New crown material to restore dental implants
2945156|NCT02937220|Active Comparator|metal ceramic crowns|conventional crown material for restoring dental implants
2945157|NCT02937207|Experimental|Hanxiao treatment group|36 patients of exacerbation group belongs to cold type of asthma will take Ke Chuan Liu Wei Mixture oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
2945158|NCT02937207|Placebo Comparator|Hanxiao control group|36 patients of exacerbation group belongs to cold type of asthma will take Ke Chuan Liu Wei Mixture placebo oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
2945159|NCT02937207|Experimental|Fengtanxiao treatment group|36 patients of exacerbation group belongs to wind phlegm type of asthma will take Chuan Xiong Ping Chuan Mixture and Xie Wu Capsule oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
2945160|NCT02937207|Placebo Comparator|Fengtanxiao control group|36 patients of exacerbation group belongs to wind phlegm type of asthma will take Chuan Xiong Ping Chuan Mixture placebo and Xie Wu Capsule placebo oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
2945161|NCT02937207|Experimental|Rexiao treatment group|36 patients of exacerbation group belongs to hot type of asthma will take Dan Ma Jia Tablet oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
2945162|NCT02937207|Placebo Comparator|Rexiao control group|36 patients of exacerbation group belongs to hot type of asthma will take Dan Ma Jia Tablet placebo oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
2945163|NCT02937207|Experimental|Xuxiao treatment group|36 patients of remission phase of Yang deficiency of asthma will take Zhi Chuan Capsule and Bu Shen Na Qi Granule oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
2945165|NCT02937194|Experimental|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) for the expectant mothers and their husbands together with oral health education materials on infant's tooth development and eruption, establishment of proper feeding, dietary and toothbrushing habits will be given before baby delivery. Reinforcement of OHI and demonstrations on how to clean the infant's oral cavities and perform toothbrushing will be delivered after the babies are born.
2945166|NCT02937194|Active Comparator|Pamphlets distribution|Pamphlets for adults' and pregnant women's oral health care will be distributed when recruited and information on the babies' oral health care will be distributed before baby delivery.
2945167|NCT02937181|Experimental|open fractures type II and III|Every patients will receive Ceftaroline in an open label, single arm
2945168|NCT02937168|Experimental|Reslizumab|IV treatment
2945169|NCT02937168|Placebo Comparator|Placebo|IV treatment
2945170|NCT02937155||Vaccinated|Patients who have received the HPV vaccine.
2945171|NCT02937155||Vaccine Naive|Patients who have not received the HPV vaccine.
2945172|NCT02937142|Experimental|Cognitive behavior group therapy|Cognitive behavior group therapy in weekly 1,5 hour sessions during 12 weeks, 8 participants and 2 therapists per group, in addition to education on ADHD, and ADHD medication if indicated.
2945173|NCT02937142|Other|Controls|Treatment as usual: Education on ADHD, and ADHD medication if indicated.
2945174|NCT02937116|Experimental|Phase 1a|"Participants will receive IBI308 1mg/kg, 3mg/kg or 10mg/kg intravenous every 2 weeks, or 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity.~Drug: IBI308"
2945175|NCT02937116|Experimental|Phase 1b Cohort A|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity.~Drug: IBI308"
2945176|NCT02937116|Experimental|Phase 1b Cohort B|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity.~Drug: IBI308"
2945177|NCT02937116|Experimental|Phase 1b Cohort C|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity.~Drug: IBI308"
2945178|NCT02937116|Experimental|Phase 1b Cohort D|"Participants will receive IBI308 200mg in combination with cisplatinum 75mg/m2 and pemetrexed 500/m2 intravenous every 3 weeks for utmost 4 cycles, and those haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500/m2 intravenous every 3 weeks until disease progression or unacceptable toxicity.~oDrug: IBI308 oDrug: Cisplatinum oDrug: Pemetrexed"
2945179|NCT02937103|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD123-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
2945180|NCT02937090||Polycystic Ovary Syndrome|"Premenopausal women between 18-40 years of age.~Diagnosed with PCOS using Rotterdam criteria (meet 2 of the 3):~chronic oligo- or amenorrhea (irregular periods during more than a year in combination with a cycle length longer than 35 days);~total or free T levels above the reference interval and/or excessive facial hair, acne;~transvaginal ultrasound with polycystic ovaries.~Exclusion of common medical disorders (normal thyroid function tests and serum prolactin and exclusion of 21-hydroxylase deficiency)."
2945181|NCT02937090||Control|Women matched for age and BMI.
2945182|NCT02937064||Controls|Controls
2945183|NCT02937064||ACL subjects|Subjects with anterior cruciate ligament injuries.
2945184|NCT02937064||OA1, doubtful OA|Subjects with doubtful osteoarthritis.
2945185|NCT02937064||OA2, mild OA|Subjects with mild osteoarthritis.
2945186|NCT02937064||OA3, moderate OA|Subjects with moderate osteoarthritis.
2945187|NCT02937064||OA4, severe OA|Subjects with severe osteoarthritis.
2945188|NCT02937051|Active Comparator|Own Brand Cigarette Condition|
2945189|NCT02937051|Experimental|Original-flavor Black&Mild cigar|
2945190|NCT02937051|Experimental|Apple-flavor Black&Mild cigar|
2945191|NCT02937051|Experimental|Cream-flavor Black&Mild cigar|
2945192|NCT02937051|Experimental|Wine-flavor Black&Mild cigar|
2945193|NCT02937038||Healthy Kids 3-13 y|Healthy boys and girls of 3-13 y of age
2945194|NCT02937038||Parents 20-50 y|One of their Parents 20-50 y of age
2945195|NCT02937025|Experimental|Left Atrial Appendage Closure Device Group|Device:LAmbre Left Atrial Appendage Occluder（Shanghai Push Medical Device Technology CO.td） to close the left atrial appendage
2945196|NCT02937012|Experimental|Bezafibrate & Ursodeoxycholic acid|Bezafibrate 200 mg capsule every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 12 months
2945197|NCT02937012|Placebo Comparator|Placebo & Ursodeoxycholic acid|Placebo capsule (for bezafibrate 200 mg capsule) every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 12 months
2945198|NCT02936999|Experimental|Vitamin D3|Patients will be dispensed cholecalciferol, 32 capsules/bottle of 1cap/4000 IU PO QD on Day 1 visit to take home. Bottle must be labeled with instructions on how to take the drug and the assigned patient ID number. Patients will be instructed to take 1 capsule per day, with water, for 29 days using the dispensed study bottle. They will be instructed to stop taking their daily vitamin D3 dose after 30 days of treatment. A study drug diary will be provided at Day 1 visit and patients will be instructed to complete the study drug diary daily from Day 2 to Day 30. Patient's report of vitamin-D3 intake from the diary must be reconciled against the number of capsules returned at Day 30 visit.
2945199|NCT02936973|Experimental|Real catgut implantation|Participants will receive real catgut implantation at acupoints plus lifestyle modification. Participants will receive catgut implantation treatment every two weeks to fulfill a 8-session treatment course.When the acupoints and surrounding skin are disinfected, an absorbable surgical suture of an appropriate length will be embedded into the muscular layer or subcutaneous tissue of the acupoints by the specified disposable embedding needles. The absorbable surgical suture then stimulated those points over a long period.
2945235|NCT02936713|Experimental|1=Functional Gastro-Intestinal Disorder (FGID)|1=FGID study group: 40 evaluable FGID subjects with a functional gastrointestinal disorder (FGID) complaining of excessive gas evacuation per anus (i.e excessive flatulence), aged from 18 to 75 years that will consume a 3-day specific and controlled mild flatulogenic diet twice at 25 days of interval (combined or not with a fermented milk product)
2945200|NCT02936973|Sham Comparator|sham catgut implantation|Participants will receive sham catgut implantation at acupoints and lifestyle modification every two weeks to fulfill a 8-session treatment course.The operation process will be similar to that applied in the real catgut implantation group. Empty needles without catgut will be pushed into the chosen position, to a depth equivalent to that used for catgut implantation at acupoints. The frequency and duration were the the same as the catgut embedding group.
2945201|NCT02936947|Experimental|tomotherapy (HFPV vs free breathing)|Tomotherapy: locally advanced lung cancer (Stage III) or left breast cancer. High Frequency Percussive Ventilation will be coupled to tomotherapy treatment. The alternative procedure is free breathing.
2945202|NCT02936947|Experimental|linear accelerator (HFPV vs ABC)|"Linear accelerator: breast cancer or pulmonary cancers (Stage I/II) requiring a stereotaxic radiotherapy.~High Frequency Percussive Ventilation will be coupled to linear accelerator. The alternative procedure is Active Breathing Control (ABC)."
2945203|NCT02936934|Active Comparator|Morphine|Multimodal analgesia to morphine
2945204|NCT02936934|Experimental|Oxycodone|Multimodal analgesia to oxycodone
2945205|NCT02936921||Pergravidic maternal infections|proven maternal infections: true seroconversions of profiles of recent infections
2945206|NCT02936921||Subjects free of congenital infection|children who whom all tests performed before birth, at birth and after birth confirmed the absence of congenital toxoplasmosis.
2945207|NCT02936921||Congenitally infected subjects|children for whom at least one test performed before birth, at birth or after birth demonstrated a congenital infection.
2945208|NCT02936908||Ventilatory support|Adult patients presenting a neuromuscular disease, with involvement of respiratory or bulbar muscles
2945209|NCT02936895|Experimental|Vitamin D3 (Low dose)|vitamin D at a dose of 50,000 IU per day for 2 days
2945210|NCT02936895|Placebo Comparator|Placebo|Placebo (same size and shape) for 2 days
2945211|NCT02936882|Other|Preoperative gastric ultrasonography|
2945212|NCT02936869|No Intervention|Control arm|Traditional birth attendants will receive an offer of two-weekly payouts per reported delivery they take that is verified by client.
2945213|NCT02936869|Experimental|Referral incentive arm|"Traditional birth attendants will receive an offer of two-weekly payouts per reported delivery they take that is verified by client.~Traditional birth attendants randomized to this arm will also receive an offer of two-weekly payouts per successful referral of delivery clients to postnatal care within 48 hours of delivery in a facility if verified."
2945214|NCT02936856|Experimental|After Hepatic Arteriography|
2945215|NCT02936856|Active Comparator|Before Hepatic Arteriography|
2945216|NCT02936843|Experimental|Salsalate|Salsalate, 1 gram by mouth, 3 times daily (3 grams per day) for 12 months.
2945217|NCT02936843|Placebo Comparator|Comparator|Placebo for Salsalate, 1 tablet by mouth, 3 times daily for 12 months
2945218|NCT02936830|Placebo Comparator|Control|20 individuals with dentin hypersensitivity will receive a placebo solution of glycerol diluted in water in a 1:1 concentration applied on the sensitive area by the dentist
2945219|NCT02936830|Active Comparator|Fluoride group|20 individuals with dentin hypersensitivity will receive 5% Sodium Fluoride varnish applied on the sensitive area by the dentist
2945220|NCT02936830|Experimental|Nanohydroxyapetite|20 individuals with dentin hypersensitivity will receive 15% nanohydroxyapetite paste applied on the sensitive area by the dentist
2945221|NCT02936817|Other|Aerobika® device|For a period of 15 +/- 3 days all subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily). HRCT scans wil be taken at visit 1 and visit 3.
2945222|NCT02936804|Experimental|Screening Arm|Low Dose Computed Tomography (LDCT) was performed at baseline + 2 rounds of biennial repeated LDCT. Management of positive screening test will be carried out by a pre-specified protocol.
2945223|NCT02936791||Individuals diagnosed with PKD|Individuals that have been diagnosed and meet the study's definition of early stage PKD.
2945224|NCT02936791||Individuals with a family history of PKD|Unaffected/ undiagnosed family members, preferably siblings, of participants with PKD
2945225|NCT02936791||Normal individuals for the comparison|Normal volunteers with no family history of PKD or other kidney diseases.
2945226|NCT02936778||PICU (= case group)|Children aged 2-18 years admitted to a Paediatric Intensive Care Unit in the Netherlands, with a diagnosis of acute wheeze or SAA.
2945227|NCT02936778||MC (= control group)|Children aged 2-18 years admitted to a Medium Care in the Netherlands, with a diagnosis of acute wheeze or SAA.
2945228|NCT02936765|Experimental|Elastic spine pad|Patients, who receive Elastic Spine Pad (TM) as cervical disc prosthesis after ventral discectomy.
2945229|NCT02936765|Active Comparator|Squale|Patients, who receive Squale (TM) as cervical disc prosthesis after ventral discectomy.
2945230|NCT02936752|Experimental|Treatment (entinostat, pembrolizumab)|Patients receive lower dose entinostat PO on days 1 and 8 or higher dose entinostat PO on days 1, 8, and 15, and pembrolizumab IV over 30 minutes on day 1 of course 2 and courses thereafter. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve an objective response or maintain a SD status after the first 4 courses may continue to receive entinostat and pembrolizumab for up to 1 year.
2945231|NCT02936739|Experimental|Elastic spine pad|Patients, who receive Elastic Spine Pad (TM) as cervical disc prosthesis after ventral discectomy.
2945232|NCT02936739|Active Comparator|Rotaio|Patients, who receive Rotaio (TM) as cervical disc prosthesis after ventral discectomy.
2945233|NCT02936726|Active Comparator|Exercise and Health Coaching|"Walking exercise protocol program, carried out by themselves, over 12 weeks.~Health Coach addresses various topics with participant, half-hour sessions on a weekly (12 sessions)"
2945234|NCT02936726|Experimental|Exercise, Health Coaching and Meditation|"Walking exercise protocol program, carried out by themselves, over 12 weeks.~Health Coach addresses various topics with participant, half-hour sessions on a weekly (12 sessions)~Mindfulness Meditation intervention will incorporate varied types of MBI techniques 3 times per week for 12 weeks, during work hours and/or during their time on campus (after work hours)."
2945308|NCT02936193|Active Comparator|Distal gastrectomy|Patients undergo Laparoscopic Gastrectomy procedure detailing in distal gastrectomy with D2 lymphadenectomy
2945236|NCT02936713|Experimental|2=Non-FGID|2=Non-FGID study group: 60 evaluable non-FGID subjects aged from 18 to 75 years that will consume a 3-day specific controlled high flatulogenic diet twice at 25 days of interval (combined or not with a fermented milk product)
2945237|NCT02936700|Other|Control group|Add on relaxation group
2945238|NCT02936700|Experimental|Therapy ACT|Add on ACT group
2945239|NCT02936687|Experimental|Metabolic Syndrome NOS Inhibition|Will occur over two separate study visits after screening. Eligible subjects with MetSyn will undergo NOS Inhibition during one visit and placebo infusion in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
2945240|NCT02936687|Experimental|Metabolic Syndrome ET-1 Inhibition|Will occur over two separate study visits after screening. Eligible subjects with MetSyn will undergo ET-1 Inhibition during one visit and placebo infusion in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
2945241|NCT02936687|Experimental|Control NOS Inhibition|Will occur over two separate study visits after screening. Eligible control subjects will undergo NOS Inhibition during one visit and placebo infusion in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
2945242|NCT02936687|Experimental|Control ET-1 Inhibition|Will occur over two separate study visits after screening. Eligible control subjects will undergo ET-1 Inhibition during one visit and placebo infusion in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
2945243|NCT02936674|Experimental|Light 1|Light 1 will have an altered color composition as compared with a standard LED bulb.
2945244|NCT02936674|Active Comparator|Light 2|Light 2 will be a standard LED bulb.
2945245|NCT02936661|Experimental|Tranexamic acid|Tranexamic acid 1 g（10ml） IV in 2 minutes after the baby delivered during ceasarean section
2945246|NCT02936661|Placebo Comparator|placebo|NS 10ml IV in 2 minutes after the baby delivered during ceasarean section
2945247|NCT02936648|Experimental|QI|QI Intervention
2945248|NCT02936635|Experimental|tirasemtiv|tirasemtiv 250-500 mg/day
2945249|NCT02936622|Experimental|Stent 1|Zilver® PTX Stent
2945250|NCT02936622|Experimental|Stent 2|Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating
2945251|NCT02936622|Experimental|Stent 3|Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating
2945252|NCT02936609||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
2945253|NCT02936609||Medicaid Non-Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
2945254|NCT02936596|Experimental|Ursodeoxycholic acid + immunosuppressive agents group|Ursodeoxycholic acid + immunosuppressive agents
2945255|NCT02936596|Active Comparator|Ursodeoxycholic acid group|Ursodeoxycholic acid
2945256|NCT02936583|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2945257|NCT02936570|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2945258|NCT02936557|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2945259|NCT02936544|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2945260|NCT02936531||FXTAS|Patients positive for FMR1 premutation and meet diagnostic criteria for FXTAS
2945261|NCT02936531||FMR1 premutation asymptomatic|Patients positive for FMR1 premutation and do not meet diagnostic criteria for FXTAS
2945262|NCT02936518|Experimental|Intervention|
2945263|NCT02936505|Active Comparator|Arm A:Cyclosporine|Group A: Cyclosporine A, Mycophenolate mofetil (MMF) and corticosteroids according to local practice and approved label.
2945264|NCT02936505|Experimental|Arm B:Tacrolimus|Group B: Tacrolimus (Advagraf), Mycophenolate mofetil (MMF) and corticosteroids.
2945265|NCT02936492|Experimental|BAY1003803|Topical treatment: dose escalating in 9 steps from 0.13 mg to 61.7 mg per subject
2945266|NCT02936492|Placebo Comparator|Placebo|Topical treatment using matching amount of placebo
2945267|NCT02936492|Active Comparator|Clobetasol propionate|Topical treatment using 16.5 mg of clobetasol propionate per subject
2945268|NCT02936479|Experimental|Berinert treatment|
2945269|NCT02936466|Experimental|Interventional group|Bipolife group
2945270|NCT02936466|No Intervention|Control group|No specific intervention, treatment as usual
2945271|NCT02936453|Experimental|All patients|"Patients will participate during 8-12 months, during which there will be :~Pre-implant evaluations (6-8 weeks)~Device implantation and stimulation optimization (6-8 weeks)~Overground rehabilitation training with EES (5-6 months) In the period after implantation participants need to be present at the CHUV University Hospital in Lausanne 4 days per week for testing and training (lodging can be provided). It is possible to complement the neuro-rehabilitative training at CHUV with a training outside the rehabilitation room by making use of the Home-use system.~An optional extension of the study up to 3 years is offered. During this period, the patient can continue the training with the Home-use system."
2945272|NCT02936440||critical patients with AKI|Critical patients with AKI will be followed up to 12 weeks after diagnosis
2945273|NCT02936427|No Intervention|Control|Control group will receive normal post operative care including intercostal wound catheters however will not receive dexamethasone
2945274|NCT02936427|Experimental|Dexamethasone 4mg|Participants will receive 4mg of dexamethasone into the intercostal space surrounding the intercostal nerve prior to the first incision. They will then receive routine post operative care including intercostal wound catheters.
2945275|NCT02936427|Experimental|Dexamethasone 8mg|Participants will receive 8mg of dexamethasone into the intercostal space surrounding the intercostal nerve prior to the first incision. They will then receive routine post operative care including intercostal wound catheters.
2945276|NCT02936414|Experimental|Berberine group|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
2945277|NCT02936414|Placebo Comparator|Placebo group|Accept placebo(300 mg/tid)+SGAs monotherapy.
2945278|NCT02936401|Experimental|MBSR|Participants in this arm enter the 8-week MBSR course immediately after the baseline visit.
2945279|NCT02936401|Experimental|CONTROL|Participants in the waitlist control arm will receive standard of care for 16 weeks after the baseline visit, and then will be offered an identical 8-week MBSR course.
2945280|NCT02936388|Experimental|Arm A|SIRT: Transarterial radioembolisation with Yttrium-90-bearing resin microspheres (SIR-Spheres®)
2945281|NCT02936388|Active Comparator|Arm B|DSM-TACE: Transarterial chemoembolisation with Cisplatin and EmboCept® S starch microspheres (PharmaCept GmbH)
2945282|NCT02936375|Experimental|Iguratimod|Patients will receive iguratimod over the whole follow-up, combined with steroids, as well as auxiliary treatment (such as vitamin D, gastrointestinal agents, blood pressure medications, if any)
2945283|NCT02936375|Active Comparator|Cyc+AZA|Patients will receive cyclophosphamide in the first half of study (usually to 24 weeks), followed with azathioprine till the end of follow-up. Patients will also receive steroids as combinational therapy, as well as auxiliary treatment (such as vitamin D, gastrointestinal agents, blood pressure medications, if any)
2945284|NCT02936362|Other|Sourdough bread, white bread|Consumption of sourdough bread for one week, 2 week washout, consumption of white bread for one week
2945285|NCT02936362|Other|White bread, sourdough bread|Consumption of white bread for one week, 2 week washout, consumption of sourdough bread for one week
2945286|NCT02936336|No Intervention|Control|without exercise intervention
2945287|NCT02936336|Experimental|Exercise|Subjects with circuit exercise, aerobic dance, or Tai Chi exercise intervention.
2945288|NCT02936323|Experimental|PEN-221|intravenous administration of PEN-221
2945289|NCT02936310|Experimental|mindfulness intervention|"The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.The proposed topics include: 1) mindfulness: dealing with stress in a new way, 2) mindful awareness of stress: listening to our body, 3) mindful working with thoughts, 4) mindful working with emotions, 5) mindful interactions, and 6) dealing with obstacles of mindful practices and wrap-up. Mindfulness practices embedded in the program will include mindfulness breathing meditation, sitting meditation, standing meditation, walking meditation, movement meditation (Taichi or Yoga), body scan meditation and daily life meditation.~Data will be collected at pre-intervention (one week before the first session) and post-intervention (one week after the last session) to assess stress, burnout, mindfulness, anxiety,depression,the feedback on the MLWS intervention and the feedback on the influence of MLWS intervention."
2945290|NCT02936297|Placebo Comparator|Lactose free placebo|Lactose free placebo pill
2945291|NCT02936297|Active Comparator|Low dose Gluten (0.5g)|Low dose gluten pill
2945292|NCT02936297|Active Comparator|High Dose Gluten (2.0g)|High dose gluten pill
2945293|NCT02936284|Experimental|Music Enhancement|37 weekly Music Together classes for one year, then 12 monthly Music Together classes the following year.
2945294|NCT02936284|Active Comparator|Play Date|37 weekly group Play Date sessions for one year, then 12 monthly group Play Date sessions the following year.
2945295|NCT02936271|Active Comparator|Active Vasculera (diosmiplex)|Active Vasculera will be prescribed as one (1) tablet (630 mg) twice a day.
2945296|NCT02936271|Placebo Comparator|Vasculera Placebo|Vasculera Placebo will be prescribed as one (1) tablet twice a day.
2945297|NCT02936258|Other|MRI|Men in Arm A will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI. The unbiopsied men will have a repeat MRI at 2 years.
2945298|NCT02936258|Active Comparator|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
2945299|NCT02936219||Early complementary breast feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like human milk feeding, at the study enrollment.
2945300|NCT02936219||Early complementary combined feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like combined milk feeding, at the study enrollment.
2945301|NCT02936219||Early complementary formula feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like formula feeding, at the study enrollment.
2945302|NCT02936219||Late complementary breast feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like human milk feeding, at the study enrollment.
2945303|NCT02936219||Late complementary combined feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like combined milk feeding, at the study enrollment.
2945304|NCT02936219||Late complementary formula feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like formula feeding, at the study enrollment.
2945305|NCT02936206|Experimental|Fulvestrant|750 mg injection in 3 divided doses
2945306|NCT02936206|Active Comparator|Tamoxifen|20mg orally
2945307|NCT02936193|Experimental|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy with Pylorus-preservation
2945543|NCT02934568|Experimental|LEE011|All patients in all combinations with LEE011 will be entered in one arm.
2945310|NCT02936180|Active Comparator|High dose influenza vaccine|Patients will receive one dose of FLUZONE® High Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)
2945311|NCT02936167|Experimental|Ringer Lactate|fluid
2945312|NCT02936167|Experimental|Plasmalyte|fluid
2945313|NCT02936154|Experimental|300 mg|
2945314|NCT02936154|Placebo Comparator|placebo|
2945315|NCT02936141|Experimental|Group psychotherapy|Group psychotherapy sessions includes the following: training of social skills (such as communication, social interaction and assertive behaviors), cognitive stimulation and training of activities of daily living (such as personal hygiene, hygiene of spaces and standardized mealtimes)
2945316|NCT02936128|Experimental|TruSkin®|Cryopreserved skin allograft
2945317|NCT02936128|Active Comparator|Wound Cover|Active Comparator for Venous Leg Ulcers
2945318|NCT02936115|Experimental|TruSkin®|Cryopreserved skin allograft
2945319|NCT02936115|Active Comparator|Wound Cover|Active Comparator for Diabetic Foot Ulcers
2945320|NCT02936102|Experimental|FAZ053 single agent|
2945321|NCT02936102|Experimental|FAZ053 + PDR001|
2945322|NCT02936089|Experimental|Risk Stratification-directed Therapy|AE AML patients first received IA or DA induction therapy, and then received two courses of IDAC (Ara-C 1-2 g/m2 q12 h ×6 cycles). Subsequently, different subgroups of AE AML received different treatment based on risk stratification. For low-risk AE AML, they randomly received consolidation chemotherapy (two or three courses of IDAC) or autologous HSCT. For intermediate-risk AE AML, they randomly received consolidation chemotherapy (two or three courses of IDAC) or allogeneic HSCT. High-risk AE AML all received allogeneic HSCT.
2945323|NCT02936076|Active Comparator|Exercise condition|Participants randomized to the exercise condition will participate in a 12-week exercise training program. The exercise intervention will consist of both supervised and unsupervised exercise sessions and progress to 200 minutes/week of moderate-intensity exercise. Exercise bouts will be spread across 4-6 days and be at least 20 minutes in duration. During supervised visits, heart rate will be monitored by a member of the research staff to ensure that exercise is within the prescribed intensity range and ratings of perceived exertion and feeling state will be assessed periodically. Unsupervised exercise will be verified using objective physical activity monitors.
2945324|NCT02936076|Placebo Comparator|Delayed exercise condition|Participants randomized to the delayed exercise condition will be asked not to change their exercise or eating habits over the 12-week period and will complete the same assessment measures as the exercise condition. However, following the completion of the 12-week period, participants will be given two options: 1) receive a one-on-one session with an exercise physiologist at our center and receive a written exercise program, and at this time point all study obligations will be completed, or 2) complete the identical exercise protocol as the 'exercise' condition.
2945325|NCT02936063|Experimental|Surgical staples|Skin closure with surgical staples
2945326|NCT02936063|Experimental|Sutures|Skin closure with subcuticular sutures
2945327|NCT02936050|Other|Intervention|"Experimental: Addition of diagnostic ultrasound performed by nurses at the outpatient heart failure clinic. Interpretation by specialist per telemedicine.~No Control arm"
2945328|NCT02936037|Placebo Comparator|GROUP 1|Placebo capsule, 1 capsule tid (morning,noon and evening) for 15 months at least, then switch to MD1003 100mg capsule, 1 capsule tid for up to 12 months
2945329|NCT02936037|Experimental|GROUP 2|MD1003 capsule, 1 capsule tid (morning,noon and evening) for 15 months at least (double blind period) and then for all patients in open label extension for up to 12 months
2945330|NCT02936024|Experimental|Intervention Group: Two-Stage GSLO Technique|Gubernaculum-sparing laparoscopic orchidopexy will be done in two stages
2945331|NCT02936024|Other|Control Group: One-Stage GSLO Technique|Gubernaculum-sparing laparoscopic orchidopexy will be done in a single stage
2945332|NCT02936011|Other|CTO PCI with Absorb BVS|Single arm observational after successful CTO PCI with Absorb BVS after antegrade or retrograde dissection and re-entry
2945333|NCT02935998|Experimental|ziprasidone|The injection mesylate ziprasidone used in this study have been marketed, manufactured by Pfizer and provided study drug for research purposes.Strength:Each vial contains Ziprasidone 30 mg, Sulfobutyl betadex sodium 441 mg. When reconstituted as directed the solution for injection contains the equivalent of 20 mg per mL of Ziprasidone.The initial dosage of ziprasidone injection：Most patients are suggested with 20mg i.m. Those with first-episode, lower age, emaciated body, or BARS score at 5 are suggest with 10mg i.m. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.
2945334|NCT02935985||Adults with sICH less than 8h|"Adult patients presenting in one of the study locations and being diagnosed with intracerebral hemorrhage. The onset of the conditions is establised as sonner than 8h.~Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.~Participants will be assessed (clinically or by telephone) over a period of 180 days."
2945335|NCT02935972|Active Comparator|Diazepam|received intravenous diazepam 5 mg slowly just before TRUS probe insertion
2945336|NCT02935972|Active Comparator|Local|received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
2945337|NCT02935972|Active Comparator|Combined|received intravenous diazepam 5 mg slowly just before TRUS probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
2945338|NCT02935959|Active Comparator|nebulized ketamine|patients will be premedicated with nebulized ketamine solution (2 mg/kg)
2945339|NCT02935959|Active Comparator|nebulized dexmedetomidine|patients will be premedicated with nebulized dexmedetomidine solution (2 μg/kg)
2945340|NCT02935959|Active Comparator|nebulized midazolam|patients will be premedicated with midazolam (0.2 mg/kg) nebulized solution
2945341|NCT02935946|No Intervention|Room Temperature Swallows|"Once consented, each participant underwent a video fluoroscopic swallow study (VFSS). Each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder®) with an attached Similac® Infant Nipple and Ring. The swallows were assessed in real time for any swallowing dysfunction and saved electronically. These swallows were labeled RTS for room temperature swallows. If no swallow dysfunction was observed, the participant became ineligible and the study ended. If swallow dysfunction was observed, the participant became eligible to complete the other arms of the study."
2945342|NCT02935946|Experimental|Cold Liquid Swallows- 5|"Immediately following the RTS condition, a total of 5 swallows of Cold Liquid Barium was observed under fluoroscopy from an identical bottle and nipple. Images were saved electronically and labeled CS5 for cold swallows-5."
2945343|NCT02935946|Experimental|Cold Liquid Swallows- 10|"After 10 minutes of feeding a cold liquid, a total of 10 swallows of Cold Liquid Barium was observed under fluoroscopy from an identical bottle and nipple. Images were saved electronically and labeled CS10 for cold swallows-10."
2945344|NCT02935933|Active Comparator|Paravertebral block with bupivacaine|patients received 20 ml of bupivacaine 0.25% paravertebrally in 3 levels, divided into 6-7 ml in each level
2945345|NCT02935933|Active Comparator|Paravertebral block with bupivacaine + morphine|patients received 20 ml of bupivacaine 0.25% +5 mg morphine paravertebrally in 3 levels, divided into 6-7 ml in each level.
2945346|NCT02935933|Active Comparator|Paravertebral block with bupivacaine + dexmedetomidine|patients received 20 ml of bupivacaine 0.25% + 1 μg/kg dexmedetomidine paravertebrally in 3 levels divided into 6-7 ml in each level.
2945347|NCT02935920|Experimental|Individual, tailored follow-up|Patient symptoms are evaluated by the use of PRO-data to uncover the needs of a consultation. The outcome of the questionnaire is used to customize the follow-up program to the individual patient.
2945348|NCT02935920|No Intervention|Standard follow-up|Scheduled clinical examination every six months throughout the course of adjuvant treatment. Performed by a doctor or nurse.
2945349|NCT02935907|Experimental|APG-115|APG-115 to be explored sequentially during accelerated dose escalation. This will continue until either the occurrence in Cycle 1 of one DLT or two Grade 2 toxicities (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) that are related or possibly related to APG-115. When either of these criteria is fulfilled, dose escalation will be converted to a standard 3+3 escalation scheme,
2945350|NCT02935894|Experimental|Single group|"All subjects will participate in 4 study day visits in the same order.~compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).~compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).~collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).~collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen."
2945351|NCT02935881|Active Comparator|RFA (Stretta Procedure)|Radio Frequency Ablation (RFA) using a Stretta device.
2945352|NCT02935881|Sham Comparator|Placebo Arm|Stretta device used but RFA will not be generated.
2945353|NCT02935868||Test group|Patients with Type 1 diabetes mellitus
2945354|NCT02935868||Control Group|Patients without systemic diseases
2945355|NCT02935855|Active Comparator|Nondiabetics (group 1)|Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way
2945356|NCT02935855|Active Comparator|Diabetics (group 1)|Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way
2945357|NCT02935855|Active Comparator|Nondiabetics (group 2)|Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest
2945358|NCT02935855|Active Comparator|Diabetics (group 2)|Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest
2945359|NCT02935842|Experimental|Specific SL-therapy for PD-DBS|Specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
2945360|NCT02935842|Active Comparator|Specific SL-therapy for PD non-DBS|Specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
2945361|NCT02935842|Active Comparator|rBMT for PD-DBS|Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
2945362|NCT02935842|Active Comparator|rBMT for PD non-DBS|Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
2945363|NCT02935842|No Intervention|PD-DBS; no therapy|No further recruiting necessary, as data is already at hand via previous research projects.
2945364|NCT02935842|No Intervention|Healthy Controls; no therapy|No further recruiting necessary, as data is already at hand via previous research projects.
2945365|NCT02935829|Experimental|Glucose as reference food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2945366|NCT02935829|Experimental|Carob preload|Fifty healthy subjects (male: 22, female: 28) were offered a standardized breakfast and 2h after consumed one of the two preloads (carob snack and chocolate cookie) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
2945367|NCT02935829|Experimental|White bread as reference food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2945392|NCT02935686|Placebo Comparator|Group 3: Placebo|Participants will receive a single placebo injection at Weeks 0 and 12, followed by two placebo injections at Weeks 24 and 48.
2945436|NCT02935387|Experimental|Taper methotrexate, then golimumab|Taper methotrexate 25>0mg/wk during 24 weeks, then, if still in sustained remission, taper golimumab 50>0mg/month during 24 weeks.
2945368|NCT02935829|Experimental|Carob snack as test food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2945369|NCT02935829|Experimental|Chocolate cookie snack as test food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2945370|NCT02935829|Experimental|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) were offered a standardized breakfast and 2h after consumed one of the two preloads (carob snack and chocolate cookie) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
2945371|NCT02935803|Other|Modified TVM operation|Modified Trans-vaginal Mesh operation (mTVM): polypropylene monofilament meshes produced by Aspide® fixed up to the mid urethra by a resolvable suture. 76 participants will be involved.
2945372|NCT02935803|Other|Control group|76 Participants as control group undergo a traditional Trans-vaginal Mesh operation (TVM) with polypropylene monofilament meshes produced by Aspide® . (Sergent et al.)
2945373|NCT02935790|Experimental|ACY-241 combo with Ipi and Nivo|ACY-241 in Combination with Ipilimumab and Nivolumab
2945374|NCT02935777|Experimental|Pomegranate Extract|"POMANOX® pomegranate extract capsules with water by mouth, once. Dosage: 2 capsules~Capsules weigh1.083g and contain: 210mg punicalagin, 328mg other pomegranate polyphenols (e.g. flavonoids and ellagic acid), 0.37mg anthocyanins and maltodextrin."
2945375|NCT02935777|Placebo Comparator|Placebo|Identical placebo capsules by mouth, administered once. Dosage 2 capsules. Each capsule contains maltodextrin to provide PE capsule energy equivalent i.e.6.52 kcal or 27.28kJ.
2945376|NCT02935764|Experimental|FOLFIRI|5-fluorouracil,folinate combined with irinotecan
2945377|NCT02935764|Active Comparator|IRINOTECAN|irinotecan
2945378|NCT02935738|Experimental|Prednisolone treated men / positive SPA / IVF|Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having positive SPA results (greater than five) were admitted to conventional in vitro fertilization (IVF) cycles.
2945379|NCT02935738|Experimental|Prednisolone treated men / negative SPA / ICSI|Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having negative SPA results (equal or less than five) were admitted to intracytoplasmic sperm injection (ICSI) cycles.
2945380|NCT02935738|No Intervention|Control men / positive SPA / IVF|Infertile men with anti-sperm antibodies who were not treated with prednisolone, which is an intermediate acting corticosteroid, underwent sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having positive SPA results (more than five) were then admitted to in vitro fertilization (IVF) cycle.
2945381|NCT02935738|No Intervention|Control men / negative SPA / ICSI|Infertile men with anti-sperm antibodies who were not treated with prednisolone, which is an intermediate acting corticosteroid, underwent sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having negative SPA results (equal or less than five) were then admitted to intracytoplasmic sperm injection (ICSI) cycles.
2945382|NCT02935725|Experimental|Low dose AUT00206 800 mg + Ketamine|Low dose AUT00206 (800 mg) + ketamine
2945383|NCT02935725|Experimental|High dose AUT00206 2000 mg + Ketamine|High dose AUT00206 (2000 mg) + ketamine
2945384|NCT02935725|Placebo Comparator|Placebo + Ketamine|Placebo + ketamine
2945385|NCT02935725|Placebo Comparator|Placebo + Saline|Placebo + saline
2945386|NCT02935712|Experimental|Part A|Three cohorts with 9 subjects and each cohort received 2 treatments (AZD8601+Placebo/ Placebo+Placebo)
2945387|NCT02935712|Experimental|Part B|Subjects received 2 treatments (AZD8601+Placebo)
2945388|NCT02935699|Experimental|Test Drug|JDP-205 Injection, 10 mg/mL, 1 mL
2945389|NCT02935699|Active Comparator|Control|Diphenhydramine Injection, 50 mg/mL, 1 mL
2945390|NCT02935686|Experimental|Group 1: Ad26.Mos4.HIV + Clade C gp140|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12, followed by Ad26.Mos4.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminium phosphate) at Week 24 and 48. Participants who receive all 4 vaccinations and are negative for HIV infection at Week 72 can consent to be included in a long-term extension (LTE) phase (approximately 3 years after Week 72).
2945391|NCT02935686|Experimental|Group 2: Ad26.Mos4.HIV + Clade C gp140 + Mosaic gp140|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12; followed by Ad26.Mos4.HIV vaccine + combination of 125 mcg Mosaic gp140 and 125 mcg Clade C gp140 mixed with adjuvant (aluminum phosphate) at Week 24 and 48. Participants who receive all 4 vaccinations and are negative for HIV infection at Week 72 can consent to be included in a long-term extension (LTE) phase (approximately 3 years after Week 72).
2945393|NCT02935673|Experimental|Regimen A (Placebo)|Participants of part 1 and part 2 will receive a single loading dose (LD) (Dose 1) followed by 9 maintenance doses (MDs) (Doses 2 to 10) of matching placebo, administered twice daily.
2945394|NCT02935673|Experimental|Regimen B (low-dose lumicitabine)|Participants of part 1 and part 2 will receive a single 750 mg LD (Dose 1) followed by nine 250 mg MDs (Doses 2 to 10) of lumicitabine, administered twice daily.
2945395|NCT02935673|Experimental|Regimen C (High-dose lumicitabine)|Participants of part 2 will receive a single 1000 mg LD (Dose 1) followed by nine 500 mg MDs (Doses 2 to 10) of lumicitabine, administered twice daily.
2945396|NCT02935660|Experimental|Treatment|Treatment with investigational Cutera enlighten laser for tattoo removal
2945397|NCT02935647|Experimental|Propofol|Participants will receive intravenous propofol titrated rapidly at 100-200 mcg/kg/min to reach 80% burst-suppression and then maintained there for 15 minutes, after which propofol administration will be discontinued and the participant will be allowed to awaken.
2945398|NCT02935634|Active Comparator|Nivolumab and Ipilimumab Combination|Nivolumab and Ipilimumab Combination
2945399|NCT02935634|Experimental|Nivolumab and Relatlimab Combination|Nivolumab and Relatlimab Combination
2945400|NCT02935634|Experimental|Nivolumab and BMS-986205 Combination|Nivolumab and BMS-986205 Combination
2945401|NCT02935621|Experimental|Mindfulness-Oriented Recovery Enhancement|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
2945402|NCT02935621|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
2945403|NCT02935608|Experimental|BIIB074 high dose|Administered twice daily (BID)
2945404|NCT02935608|Experimental|BIIB074 low dose|Administered BID
2945405|NCT02935608|Placebo Comparator|Placebo|Placebo administered BID
2945406|NCT02935595|Experimental|Ketamine|Slow infusions of ketamine will take place over a time period of 40 minutes.
2945407|NCT02935582||Enstilar®|Patients for whom a new treatment strategy has been decided which involves start of topical treatment with Enstilar® according to the current local labelling
2945408|NCT02935582||Other topical|Patients for whom a new treatment strategy has been decided which involves start of topical treatment not including Enstilar®
2945409|NCT02935569|Experimental|Compression Headband|a compression headband, placed only at the time of irradiation
2945410|NCT02935556||post partum pre-eclampsia|women with normal deliveries followed by post partum pre-eclampsia within 1 month of delivery.
2945411|NCT02935556||controls|women with normal deliveries and normal post part courses who match the post partum pre-eclampsia women in age, BMI, smoking status, gestational age and race/ethnicity.
2945412|NCT02935543|Experimental|CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion.
2945413|NCT02935530|Experimental|s-LMWH|2125 I.U. subcutaneous injection for 5-10 days
2945414|NCT02935530|Active Comparator|LMWH|4250 I.U. subcutaneous injection for 5-10 days
2945415|NCT02935530|Experimental|Argatroban|20mg, injection for 5-10 days
2945416|NCT02935517|Experimental|Lower dose|AGTC-402 will be administered at the lowest of three planned dose levels.
2945417|NCT02935517|Experimental|Middle dose|AGTC-402 will be administered at the middle of three planned dose levels.
2945418|NCT02935517|Experimental|Higher dose|AGTC-402 will be administered at the highest of three planned dose levels.
2945419|NCT02935517|Experimental|Maximum tolerated dose|AGTC-402 will be administered at the maximum tolerated dose identified from Groups 1, 2 and 3.
2945420|NCT02935504|Experimental|Program In Support of Moms PRISM|PRISM includes MCPAP for Moms and training, implementation support, and toolkits for Ob/Gyn practices on depression screening, assessment and treatment.
2945421|NCT02935504|Active Comparator|MCPAP for Moms|Consists of access to psychiatric consultation and resources and referrals through MCPAP for Moms - MCPAP for Moms is available free of charge to all Ob/Gyn practices in Massachusetts.
2945422|NCT02935491||Transcatheter Aortic Valve Implantation|Lyon and Paris cohorts : 900 patients will be used to test the prognostic value of aortic calcifications and to propose a risk score Clermont and Rouen cohorts (700 patients) will be used to test in an independent group, the predictive value of the risk score
2945423|NCT02935478|Experimental|HCC-Left gastric artery embolization|Embospheres Microspheres as artificial embolic agent for left gastric artery embolization
2945424|NCT02935465|Experimental|Mindfulness-Oriented Recovery Enhancement|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
2945425|NCT02935465|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
2945426|NCT02935452|Active Comparator|Genie|This group will have the Genie social tool delivered on a one to one basis at discharge points in the study.
2945427|NCT02935452|No Intervention|Normal Care|This group will have the same questionaires at discharge, but will be offered normal care
2945428|NCT02935439|Active Comparator|Cell-Phone Intervention Arm|A standard cell phone system sent web-browser messages daily to ask about their weight and symptoms of heart failure. Participants received up to 3 daily messages 15 minutes apart at a time of their choosing for 90 days. Participants were given a mobile phone for the 90 day period and a weight scale.
2945429|NCT02935439|No Intervention|Usual Care|Usual Care participants continued to receive care in the Heart Failure Clinic. All subjects were enrolled in the study for 90 days. Participants were given a weight scale.
2945430|NCT02935426|Experimental|Cyanoacrylate group|Wound closure after harvesting of connective tissue graft in the donor site will be achieved with application of cyanoacrylate tissue adhesive
2945431|NCT02935426|Active Comparator|Suture group|Wound closure after harvesting of connective tissue graft in the donor site will be achieved with polytetrafluoroethylene (PTFE) continuous interlocking sutures
2945432|NCT02935413|Active Comparator|tDCS|group receiving complete treatment of transcranial direct current stimulation
2945433|NCT02935413|Active Comparator|Standard rehabilitation|Standard rehabilitation procedures
2945434|NCT02935400||Asymptomatic|Group 1 will have had no symptoms of porphyria in the past year.
2945435|NCT02935400||Symptomatic and treated with hemin|Group 2 will have a history of symptoms within the past year.
2945471|NCT02935127|Experimental|Absorbable Group|In this group of patients absorbable sutures will be used for vascular anastomoses.
2945437|NCT02935387|Active Comparator|Taper golimumab, then methotrexate|Taper golimumab 50>0mg/month during 24 weeks, then, if still in sustained remission, taper methotrexate 25>0mg/wk during 24 weeks.
2945438|NCT02935374|Active Comparator|Amoxicillin|The children with acute otitis media will be treated with amoxicillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
2945439|NCT02935374|Active Comparator|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxicillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
2945440|NCT02935374|No Intervention|Wait and see|The children with acute otitis media will be monitored without antimicrobial treatment.
2945441|NCT02935374|Other|Macrolide|The children with acute otitis media with known allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored as a separate group, outside randomization.
2945442|NCT02935361|Experimental|Treatment (guadecitabine, atezolizumab)|Patients receive guadecitabine SC on days 1-5 and atezolizumab IV over 30-60 minutes on days 8 and 22. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
2945443|NCT02935335||Menopur® HP-hMG|Treatment according to routine clinical practice.
2945444|NCT02935322|Active Comparator|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|A mouthrinse combining chlorhexidine and NaF
2945445|NCT02935322|Active Comparator|0.2 % NaF mouthrinse|A mouthrinse containing NaF
2945446|NCT02935322|Active Comparator|0.12% chlorhexidine mouthrinse|A mouthrinse containing chlorhexidine
2945447|NCT02935322|Placebo Comparator|Placebo mouthrinse|A mouthrinse containing all basic ingredients as the other three mouth rinses compared but without chlorhexidine and fluoride
2945448|NCT02935309|Experimental|Pre-Surgery Chemotherapy/Radiotherapy|Pre-surgery chemotherapy and external radiation therapy. Dose escalation of Lenvatinib; fixed dose Capecitabine; Radiotherapy. Lenvatinib and capecitabine will be started on day 1 with radiation and will be discontinued on the last day of radiation. Surgical resection should occur between 6 - 10 weeks after the participant completes preoperative lenvatinib, capecitabine, and radiation therapy. Postoperative chemotherapy after surgery will be given at investigator's discretion.
2945449|NCT02935296|No Intervention|Control|Standard of Care
2945450|NCT02935296|Experimental|Integrated Intervention|Standard of care plus an integrated system of psychosocial counseling and systems navigation for HIV treatment and Substance Use treatment
2945451|NCT02935283||OTCD participants|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD who can undergo MRI and behavioral testing
2945452|NCT02935283||Normal controls|Healthy males or females without known medical or metabolic disorder (control group) who can undergo MRI and behavioral testing
2945453|NCT02935283||HA recovery group|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD or participants with CPS-1 who have had a recent hyperammonemic episode who can undergo MRI and behavioral testing
2945454|NCT02935283||Distal UCD|Males and females with ASSD and ASLD who can undergo MRI and behavioral testing
2945455|NCT02935270||Stroke Survivors|Individuals who have experienced a unilateral hemispheric stroke
2945456|NCT02935257|Experimental|CD19CAT-41BBZ CAR T-cells|Treatment with the ATIMP: CD19CAT-41BBZ CAR T-cells
2945457|NCT02935231|Experimental|Nicotine Replacement Therapy|This experimental group receives health warning leaflet, 1-week free nicotine replacement therapy (gum/patch), a card containing instruction and potential side effects and follow-up intervention if they have the above side effects at 3-, 7- and 10-days.
2945458|NCT02935231|Experimental|Minimal Cessation Advice & Nicotine Replacement Therapy|This experimental group receives brief smoking cessation advice using AWARD model with a health warning leaflet, 1-week free nicotine replacement therapy (gum/patch), a card containing instruction and potential side effects and follow-up intervention if they have the above side effects at 3-, 7- and 10-days.
2945459|NCT02935231|Experimental|Minimal Cessation Advice|This experimental group receives brief smoking cessation advice using AWARD model with a health warning leaflet.
2945460|NCT02935231|Active Comparator|Control|This control group receives a health warning leaflet.
2945461|NCT02935218|Other|Parenting Skills for Mothers with BPD|single-arm study
2945462|NCT02935205|Experimental|Treatment (enzalutamide, indomethacin)|Patients receive enzalutamide PO QD and indomethacin PO BID or QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2945463|NCT02935192|Experimental|intervention: Seasonal Influenza Vaccine|Seasonal trivalent split, inactivated influenza vaccine
2945464|NCT02935192|Placebo Comparator|Intervention: Phosphate Buffered Saline|Phosphate buffered saline
2945465|NCT02935179|No Intervention|Control Group|No intervention
2945466|NCT02935179|Experimental|Treatment Group|White sweet potato meal replacement formula
2945467|NCT02935166|Placebo Comparator|Uncharged|Respiratory muscle training: placebo General High Intensity Training (30 minutes in cycle ergometer) and placebo respiratory muscle training: This training group performed with the valve Orygen® uncharged (placebo effect). Performing 10 consecutive inspirations (5 series) two times a day during 3 weeks.
2945468|NCT02935166|Active Comparator|Inspiratory|Respiratory muscle training: Inspiratory General Training (30 minutes in cycle ergometer) and high intensity inspiratory muscle training: The inspiratory training was conducted with the Orygen® valve. Inspiratory training load was defined as maximum and patient tolerance that would perform 10 consecutive inspirations (5 series) two times a day, during 3 weeks.
2945469|NCT02935166|Active Comparator|Inspiratory and expiratory|Respiratory muscle training: Inspiratory and expiratory General High Intensity Training (30 minutes in cycle ergometer) and inspiratory and expiratory training: The inspiratory and expiratory training was conducted with the Orygen® valve. Loading inspiratory and expiratory training was defined as maximum and patient tolerance. This was the optimal load that would allow the patient to perform 10 consecutive inspirations (5 sessions) 2 times a day,during 3 weeks.
2945470|NCT02935153|Experimental|B Cell Malignancies|Experimental: B Cell Malignancies The trial will be conducted in a manner of simon two-stage design with Anti-CD22-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
2946278|NCT02929719|Experimental|Test Gel 5%|Topical, twice daily on the face for 84 days.
2945472|NCT02935127|Experimental|Non-Absorbable Group|In this group of patients non-absorbable sutures will be used for vascular anastomoses.
2945473|NCT02935114|Experimental|37% Carbamide Peroxide|"no Gingival dam protection (as manufacturer´s instruction)~37% Carbamide Peroxide application (2 sessions of 45 minutes)~Tooth sensitivity (Verbal and visual scale) and color evaluation"
2945474|NCT02935114|Active Comparator|35% Hydrogen Peroxide|"Gingival dam protection (as manufacturer´s instruction)~35% Hydrogen Peroxide application (2 sessions of 45 minutes)~Tooth sensitivity (Verbal and visual scale) and color evaluation"
2945475|NCT02935101|Experimental|Prednisolon|Participants will receive an oral administration of prednisolone or placebo two times daily for the first five days of opioid detoxification, starting after one day of regular detoxification as baseline. Oral prednisolone will be administered in a dose consistent with standard treatment guidelines for glucocorticoid deficiency (Oelkers, 1996).
2945476|NCT02935101|Placebo Comparator|Placebo|Identical looking capsules like the IMP containing placebo (without active component) for oral administration.
2945477|NCT02935075|Experimental|Reduced dose|Tenofovir 200mg +lamivudine 300mg +efavirenz 400mg PO q.d.
2945478|NCT02935075|Active Comparator|Standard dose|Tenofovir 300mg +lamivudine 300mg +efavirenz 600mg PO q.d.
2945479|NCT02935062|Active Comparator|Traditional Phonological Therapy|This intervention will be intermediated by the traditional model cycles. This approach has the principle of treating the suppression of operant phonological processes in child's speech, from the awareness of sound-target characteristics operating in that phonological process.
2945480|NCT02935062|Experimental|Software Phonological Therapy- SIFALA|This intervention will be intermediated by the software SIFALA. The software SIFALA, allows to select target segments using the Modelo de Estratos (second model Strata), based on the level segment of production and complexity of distinctive features, from the child's sound system analysis and planned generalizations. It also seeks the treatment of phonological disorders, by selection stimulus words in more favorable environments and playful activities with computer resource for the correct production of the target segment in the words stimulus, promoting the spread segments.
2945481|NCT02935062|Placebo Comparator|Placebo Therapy|No interventional group. This group will be the sham group. The proposed activities will be fun games on the computer, there is no relationship with speech and it will be not emphasized the correct sound production, will only play activities.
2945482|NCT02935036|Experimental|ADPS topical product|A thin layer of study medication will be applied to cover affected areas once daily for 12 weeks
2945483|NCT02935036|Placebo Comparator|Placebo Control|A thin layer of study medication will be applied to cover affected areas once daily for 12 weeks
2945484|NCT02935023|Experimental|CIRT with systemic therapy arm|Carbon ion radiotherapy combined with systemic therapy
2945485|NCT02935010|Experimental|Tailored therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole 20mg bid and two sensitive ones of amoxicillin,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.
2945486|NCT02935010|Active Comparator|Empiric therapy|give esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, amoxicillin 1000mg tid and metronidazole 400mg tid for 14 days
2945487|NCT02934997||Community-Acquired Sepsis|The Adult ED at UF JAX is a high volume, high acuity ED which treats approximately 90,000 patients per year. All CA-sepsis patients will be recruited from the UF JAX ED. Patients meeting the recently updated definition of sepsis (suspected or confirmed infection plus ≥ 2 SOFA points) OR septic shock (hypotension not responsive to 30 mL/kg IV fluids, vasopressor requirement, and lactate ≥ 2) and being treated with an institutional, evidence-based guideline (EBG) management bundle for sepsis within 24 hours presenting to the UF Health Jacksonville Emergency Department (ED) will be approached for enrollment.
2945488|NCT02934997||Hospital-Acquired Sepsis|UFH (Gainesville) is a Level 1 Trauma Center and surgical tertiary care center with 24 trauma intensive care unit (ICU) and 24 surgery ICU beds and are the primary ICUs for almost every surgical patient in the hospital and the location for recruitment for Project #1 of the Sepsis P50. Patients meeting the recently updated definition of sepsis (suspected or confirmed infection plus ≥ 2 SOFA points) OR septic shock (hypotension not responsive to 30 mL/kg IV fluids, vasopressor requirement, and lactate ≥ 2) and being treated with an institutional, evidence-based guideline (EBG) management bundle for sepsis within 24 hours in the UFH Surgical ICU will be approached for enrollment.
2945489|NCT02934971||Supervised cohort of 200 chemo-treated patients|cohort of 200 patients undergoing a chemo therapy accordingly to the inclusion criteria patients
2945490|NCT02934971||Age matched control group of 200 normal subjects|200 age matched control group of subjects from the outpatient clinic who are not chemo-treated and who fit the inclusion and exclusion criteria
2945491|NCT02934971||A:machine learning approach (N=35)|70 female patients undergoing cardiotoxic chemotherapy accordingly to the inclusion criteria will be randomized into two arms (group A and B).
2945492|NCT02934971||B: conventional echocardiographic parameters (N=35)|70 female patients undergoing cardiotoxic chemotherapy accordingly to the inclusion criteria will be randomized into two arms (group A and B).
2945493|NCT02934958|Active Comparator|FIT Positive|Referral to GI or Primary Care. Patients will be referred to MD for pre-colonoscopy vist.Standard of Care.
2945494|NCT02934958|Experimental|FIT Positive Choice|Offered Chioce of Direct referral. Patients will be given a choice to advance to directly having a colonoscopy screening.Colon Cancer Screening Navigation.
2945495|NCT02934945|Other|patients with CVA(CVA group)|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for six months
2945496|NCT02934945|Other|patients with TA(TA group)|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for six months
2945497|NCT02934932|Placebo Comparator|Brexpiprazole 2mg|Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
2945498|NCT02934932|Placebo Comparator|Brexpiprazole 4mg|Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
2945499|NCT02934932|Placebo Comparator|Placebo|Subjects will be titrated to this dose of placebo for 6 weeks.
2945500|NCT02934919|Experimental|nalmefene|
2945501|NCT02934906||Control Group|Pregnant women with anti-HPA antibody negative from the same hospital, the same race, and the same gravidity and parity, who are admitted at the same time.
2945502|NCT02934906||Experimental Group|pregnant women with anti-HPA antibody positive
2945503|NCT02934893|Experimental|Intervention Group|Patient in standard diabetes management in the Medication Management Clinic plus the use of Diabetes+Me plus connected glucometer
2945504|NCT02934893|Active Comparator|Standard Diabetes Management|Patient in standard diabetes management in the Medication Management Clinic
2945505|NCT02934893|No Intervention|Primary Care|Matched cohort managed through their primary care physician (PCP) and standard of care.
2945506|NCT02934880|Experimental|Immediate APA|intervention: 10 sessions of APA within the 5 weeks (2 sessions per week) following the randomization
2945507|NCT02934880|Active Comparator|Delayed APA|intervention: 10 sessions of APA in 5 weeks (2 sessions per week) , 3 months after randomization
2945508|NCT02934867|Experimental|CONTARM|Protocol phone advice
2945509|NCT02934867|Other|CONTHAB|Usual phone advice
2945510|NCT02934854||Observation|Patients with the Creatine Deficiency Syndromes or high-grade suspicion for the Creatine Deficiency Syndromes
2945511|NCT02934841|Experimental|Conbercept|The patients are followed on a monthly basis until 12 months. Three intravitreal injections of conbercept at a dosage of 0.5 mg are initiated at inclusion (monthly) with reinjection every month only in case of CNV activity (PRN regimen) until 12 months.
2945512|NCT02934841|Sham Comparator|sham|The patients are followed on a monthly basis until 12 months. Three intravitreal sham injections are initiated at inclusion (monthly) with reinjection every month only in case of CNV activity (PRN regimen) until 12 months.
2945513|NCT02934828|Experimental|Neoadjuvant chemotherapy|Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year. RECIST is used once every 2 cycles. Patients will finish 6 cycles preoperative chemotherapy when CR/partial response(PR)/stable disease(SD) by RECIST without serious adverse events.
2945514|NCT02934828|Active Comparator|postoperative chemotherapy|Postoperative Chemotherapy:Standard chemotherapy regiments according to risk of recurrence: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
2945515|NCT02934815|Experimental|Intervention group - SEGT|16 weekly sessions, 90 min of Supportive-expressive group therapy
2945516|NCT02934815|No Intervention|Control group|No intervention
2945517|NCT02934789|Active Comparator|Study group: surgical arm|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
2945518|NCT02934789|Active Comparator|Control group: medical arm|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids
2945519|NCT02934776|Experimental|DTI acquisition|Addition of up to 10 minutes in MRI machine purpose of acquiring additional DTI images
2945520|NCT02934763|Placebo Comparator|Placebo|Saline solution by target controlled infusion
2945521|NCT02934763|Active Comparator|Propranolol at 5ng/ml target dose|Propranolol iv by target controlled infusion, to achieve a plasmatic concentration of 5ng/ml
2945522|NCT02934763|Active Comparator|Propranolol at 15ng/ml target dose|Propranolol iv by target controlled infusion, to achieve a plasmatic concentration of 15ng/ml
2945523|NCT02934750|Experimental|Pursed lip breathing|In this arm, patients will be asked to perform a six-minute walking test while continuously using the pursed lip breathing technique.
2945524|NCT02934750|No Intervention|Usual breathing|In this control arm, patients will be asked to perform a six-minute walking test while breathing normally.
2945525|NCT02934724||Vaccinated|"Women born in 1997, resident to Norway in 2009, vaccinated by the quadrivalent HPV vaccine.~Interventions:~Self sample from vagina using Rover's Evalyn Brush~Self sample from the oral cavity using COPAN's FloqSwab~Questionnaire"
2945526|NCT02934724||Un-vaccinated|"Women born in 1997, resident to Norway in 2009, not vaccinated by the quadrivalent HPV vaccine~Interventions:~Self sample from vagina using Rover's Evalyn Brush~Self sample from the oral cavity using COPAN's FloqSwab~Questionnaire"
2945527|NCT02934698|Experimental|Ivacaftor|There is only one arm to this study. The two sisters with Cystic Fibrosis will both receive Ivacaftor for 6 months for their treatment.
2945528|NCT02934685|Experimental|hypofraction|70 Gy in 28 fractions over 5.6 weeks
2945529|NCT02934685|Active Comparator|convention|80Gy in 40 fractions over 8 weeks
2945530|NCT02934659|Experimental|Investigational|Intervention - Atlas Knee System device for medial knee osteoarthritis
2945531|NCT02934646|Experimental|Subacute stroke patients|Elbow passive/active robotic treatment provided by NEUROExos Elbow Module
2945532|NCT02934633|Experimental|Keeping Baby Safe|Keeping Baby Safe 2-DVD package, designed for parents of children from birth to 24 months. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
2945533|NCT02934633|Active Comparator|AAP TIPP Sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets that parents would typically receive from their pediatrician or general practitioner at well-baby visits.
2945534|NCT02934620|Experimental|CSD500 Condom|Receive CSD500 condoms with condom counseling to use them for sexual pleasure.
2945535|NCT02934620|Active Comparator|Standard Condom|Receive the standard condom with condom counseling to use them for pregnancy and disease prevention.
2945536|NCT02934607|Active Comparator|Treatment A|2 x 160/4.5 µg Symbicort pMDI administered with no spacer device; no activated charcoal (systemic exposure).
2945537|NCT02934607|Experimental|Treatment B|2 x 160/4.5 µg Symbicort pMDI administered through AeroChamber Plus Flow-Vu spacer device; no activated charcoal (systemic exposure).
2945538|NCT02934607|Active Comparator|Treatment C|160/4.5 µg Symbicort pMDI administered with no spacer device; with activated charcoal (lung exposure).
2945539|NCT02934607|Experimental|Treatment D|160/4.5 µg Symbicort pMDI administered through AeroChamber Plus Flow-Vu spacer device; with activated charcoal (lung exposure).
2945540|NCT02934594||Group A|Motor function intact group: received palliative decompression
2946362|NCT02929173|Active Comparator|Group 2|E-max is un allceram crown
2945544|NCT02934555|Placebo Comparator|Control|Patients in the control group will receive a liquid placebo, which is 50 mL of Ensure (a dietary supplement). This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.
2945545|NCT02934555|Experimental|Ubiquinol|Patients in the experimental group will receive 300 mg of Ubiquinol in a liquid mixture. The liquid Ubiquinol will be mixed with 50 mL of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.
2945546|NCT02934542|No Intervention|Control Group|Patients in this group will undergo an elective standard laparoscopic procedure with a designated OR staff to maneuver the laparoscopic camera. The procedures will be performed according to the hospital and OR routine procedure.
2945547|NCT02934542|Experimental|AutoLap Group|Patients in this group will undergo a laparoscopic procedure using the AutoLap system. In this group the surgeon will use the AutoLap system to hold and control the movements of the laparoscopic camera.
2945548|NCT02934529|Active Comparator|A1|"FOLFIRI plus cetuximab: one cycle (cycle duration 14 days) consists of Irinotecan, Folinic acid 5-FU, cetuximab~Administration every two weeks until progression in first-line or emergence of unacceptable toxicity.~De-escalation (e.g. to irinotecan plus cetuximab or FUFA plus cetuximab) is allowed, but cetuximab should be administered until progression if safety is adequate."
2945549|NCT02934529|Experimental|B1|"FOLFIRI plus cetuximab: one cycle (cycle duration 14 days) consists of Irinotecan, Folinic acid 5-FU, cetuximab~Administration every 2 weeks for a maximum of 12 cycles~Treatment may be de-escalated to irinotecan plus cetuximab or FUFA plus cetuximab, prior to 12 cycles, for toxicity if necessary, if the best response has been SD,~Treatment may undergo 'switchover' to a fluoropyrimidine and bevacizumab, between 8 and 12 cycles, for toxicity if necessary, if the best response has been CR or PR,"
2945550|NCT02934529|Experimental|B1 Switchover regimens|"Switchover to FUFA plus bevacizumab every three weeks (cycle duration 21 days) until progression in first-line or emergence of unacceptable toxicity.~Folinic acid, 5-FU, Bevacizumab~1st administration 90 min. in case of good safety, the second 60 min. further administration 30 min.~Or alternatively Switchover to capecitabine plus bevacizumab every three weeks (cycle duration 21 days) until progression in the first-line or emergence of unacceptable toxicity."
2945551|NCT02934529|Active Comparator|A2 (third line)|"Treatment at the treating physician's discretion depending on the patient's general condition, with the exclusion of any anti-EGFR treatment whatsoever (such as for example cetuximab, panitumumab). Recommendations include Regorafenib in line with Grothey A et al, Lancet. 2013~or alternatively another anti-EGFR-free treatment according to the investigating physician's choice~Administration until progression occurs in the third line or unacceptable toxicity"
2945552|NCT02934529|Experimental|B2 (third line)|"one cycle (cycle duration 14 days) consists of Irinotecan 125mg, Folinic acid, 5-FU, cetuximab wkly~Administration every 2 weeks until progression occurs in the third line or unacceptable toxicity~or depending on the patient's general condition and the study physician's decision~Irinotecan plus cetuximab in line with Cunningham D et al, N Engl J Med. 2004"
2945553|NCT02934516|Experimental|Disimpaction with lower uterine support|Cesarean section with support of the lower uterine segment
2945554|NCT02934516|Active Comparator|Classic push method|Cesarean section with push method
2945555|NCT02934503|Experimental|Cisplatin or carboplatin, Etoposide, Pembrolizumab & Radiation|"Cohort A: cisplatin (75 mg/m^2) + carboplatin (AUC 6) + etoposide (100mg/m^2) for four to six, 3-week cycles + pembrolizumab (200 mg) followed by radiation. Pembrolizumab will be started with first cycle of chemotherapy and continued for up to 2 years.~Cohort B: Pembrolizumab (200 mg) will be added to standard therapy with cisplatin (75 mg/m2) or carboplatin (AUC 6) and etoposide (100 mg/m2) (and radiation, if appropriate), after one 3- week cycle of standard therapy and continued for up to 2 years.~Cohort C: 200 mg IV infusion of Pembrolizumab every 3 weeks over about 30 minutes after completion of standard chemotherapy with cisplatin (75 mg/ m2) and etoposide (100 mg/m2). Treatment with pembrolizumab will continue for up to 2 years.~Cohort D: Pembrolizumab 200 mg IV infusion every 3 weeks in vein after completion of standard chemotherapy and radiation. Pembrolizumab will start within 6 weeks of completing radiation therapy and continue for up to 2 years."
2945556|NCT02934490|Experimental|Treatment group|
2945557|NCT02934477||Hematopoietic Stem Cell Transplant (HCT)|Patients undergoing alloHCT in a US transplant center and reported to the CIBMTR
2945558|NCT02934477||Non-HCT|Historical non-transplant controls collected from 14 US academic centers. Centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.
2945559|NCT02934464|Experimental|A|"RAMUCIRUMAB 8 mg/kg on Days 1 and 15 of every 28-day cycle~PACLITAXEL 80 mg/m2 on Days 1, 8, and 15 of every 28-day cycle until progressive disease, unacceptable toxicity, informed consent withdrawal or patient's death."
2945560|NCT02934464|Active Comparator|B|"FOLFOX4: Oxaliplatin 85 mg/m2 + l-Leucovorin 100 mg/m2 + 5-fluorouracil 400/600 mg/m2. Cycle length is 2 weeks +/- 3 days.~mFOLFOX6: Oxaliplatin a 85 mg/m2+ l-Leucovorin 200 mg/m2 + 5-fluorouracil 400 mg/m2 and 2400 mg/m2 46-hours continous infusion. Cycle length is 2 weeks +/- 3 days.~XELOX:Oxaliplatin130 mg/m2 + Capecitabine will be 2000 mg/m2 for 14 days. Cycle length is 3 weeks +/- 3 days."
2945561|NCT02934438|Active Comparator|Neo40 Supplement|Utilizing intellectual property developed out of the University of Texas Health Science Center in Houston, Neo40 is a GMP certified, over the counter, all natural formulation that provides a system for generating NO in an endothelium-dependent and independent manner. The NEO40™ Daily™ product ingredients list and packaging was submitted to FDA Office of Compliance by Neogenis Labs, Inc. for use as a dietary supplement. It is made up of Beet root extract, hawthorne berry, Vitamin C, L-citrulline and sodium nitrite. The lozenges utilize natural product chemistry activated by the saliva to generate authentic NO gas in the oral cavity through the one-electron reduction of nitrite. This product's formulation was designed to be a quick dissolve that melts in the mouth within four to five minutes.
2945562|NCT02934438|Placebo Comparator|Placebo|A placebo product has been manufactured that looks, tastes and feels like the Neo40 active lozenge without the active ingredients
2945563|NCT02934425|Placebo Comparator|Refined carbohydrate-rich breakfast|Refined carbohydrate-rich breakfast
2945564|NCT02934425|Experimental|High pork protein breakfast|High pork protein breakfast
2945565|NCT02934412|Experimental|SHR-1314 20mg|20mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
2945566|NCT02934412|Experimental|SHR-1314 40mg|40mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
2945567|NCT02934412|Experimental|SHR-1314 80mg|80mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
2945568|NCT02934412|Experimental|SHR-1314 160mg|160mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
2945569|NCT02934412|Experimental|SHR-1314 240mg|240mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
2945570|NCT02934399||Healthy controls (HC)|Definition of the normal circadian and ultradian profiles of pituitary and adrenal hormones in healthy subjects:Each subject (total number 200, anticipated 50 per study centre) will be sampled by the ULTRADIAN sampling device for 27 hours. Day to day hormonal variability:A subgroup of 20 subjects will be asked to undergo sampling on three occasions to assess reproducibility of hormonal levels over time. Comparison of tissue and blood concentrations of hormones: 20 subjects will be asked to participate in the study comparing hormonal tissue level and blood levels.
2945571|NCT02934399||Cushing syndrome (CS)|"Diagnosis of Cushing's syndrome by ULTRADIAN dynamic cortisol measurements The primary objective is to establish circadian and ultradian hormonal profiles of patients with Cushing's from 24 hour ambulatory sampling of subcutaneous fluid.~A secondary aim is to compare the pre and post-operative hormonal profiles of patients with Cushings and to compare these results to age/sex matched control~Study subjects: Subjects with established clinical and biochemical Cushing's syndrome (ACTH-producing pituitary adenoma or ACTH-independent adrenal source)."
2945572|NCT02934399||Adrenal insufficiency (AI)|"Monitoring of adrenal insufficiency (AI) by ULTRADIAN dynamic cortisol and ACTH measurements Aims and objectives: to compare hormonal profiles of patients with Adrenal insufficiency on conventional replacement regimes to age/sex matched controls.~Study subjects: Subjects with established primary (adrenal) AI"
2945573|NCT02934399||Congenital adrenal hyperplasia (CAH)|"Monitoring of congenital adrenal hyperplasia (CAH) by ULTRADIAN dynamic cortisol, ACTH, and androgen measurements Aims and objectives: to compare hormonal profiles of patients with CAH on conventional replacement regimes to age/sex matched controls.~Study subjects: Individuals with established CAH either salt- wasting or simple virilisation forms on glucocorticoid replacement therapy"
2945574|NCT02934399||Primary hyperaldosteronism (PHA)|"Diagnosis of primary hyperaldosteronism (PHA) by ULTRADIAN dynamic aldosterone and renin measurements Aims and objectives: The primary objective is to establish circadian and ultradian profiling of free aldosterone and renin in subcutaneous tissue.~Secondary objectives are (1) to compare pre and post-operative profiles (2) to identify profiles typical for adenoma as opposed to bilateral hyperplasia and (3) to compare profiles to age/sex matched controls.~Study subjects: Subjects with suspected PHA."
2945575|NCT02934399||Growth hormone insufficiency (GHD)|"Diagnosis of growth hormone deficiency (GHD) by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal circadian and ultradian profiles of adult GHD by analysing the growth hormone profile in the subcutaneous tissue fluid.~Study subjects: Adult subjects with established clinical and biochemical GHD."
2945576|NCT02934399||Acromegaly (A)|"Diagnosis and treatment of acromegaly by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal profiles of patients with Acromegaly A secondary objective is to compare pre and post-operative profiles and to compare these profiles to age/sex matched controls.~Study subjects: Patients with established clinical and biochemical Acromegaly by current diagnostic criteria"
2945577|NCT02934386|Experimental|WinMedical WinPack device|50 volunteers undergoing experimental protocol according to IEEE 1708:2014 standard
2945578|NCT02934373|Active Comparator|A New Sound Processor|Sound Processor is the next generation sound processor.
2945579|NCT02934373|No Intervention|Subject's own sound processor|
2945580|NCT02934360||Non-small cell Lung Cancer|Previously diagnosed stage III or higher non-small cell lung cancer subjects will provide serial plasma specimens and clinical assessment information over time
2945581|NCT02934360||Breast Cancer|Previously diagnosed stage IV breast cancer subjects will provide serial plasma specimens and clinical assessment information over time.
2945582|NCT02934347||Supine|A baseline group of adult patients who required intubation as part of their routine anaesthesia who were intubated in the standard horizontal sniffing position.
2945583|NCT02934347||Back-up|A subsequent group of similar the patients who had their anaesthesia induced and tracheas intubated in a 25 degree back-up position achieved by flexion of the operating table at the hips
2945584|NCT02934334||MDD|Major Depressive Disorder
2945585|NCT02934321|Active Comparator|Aspartame Sweetened Beverage|Volunteers will consume a low-calorie, aspartame sweetened beverage (185 mg aspartame in water) after fasting for 10 hours and abstaining from alcohol, caffeine, and strenuous exercise for 24 hours prior to the visit.
2945586|NCT02934321|Experimental|Erythritol Sweetened Beverage|Volunteers will consume an isosweet, compared to aspartame, high osmolar, low-calorie erythritol sweetened beverage (50.8 g erythritol in water, 1.66 Molar) after fasting for 10 hours and abstaining from alcohol, caffeine, and strenuous exercise for 24 hours prior to the visit.
2945587|NCT02934308|Experimental|ICU patients|
2945588|NCT02934295|Experimental|Pregnant women|
2945589|NCT02934269|Experimental|CC-90006; Dose Level 1|CC-90006 will be administered by subcutaneous injection in the abdomen
2945590|NCT02934269|Experimental|CC-90006; Dose Level 2|CC-90006 will be administered by subcutaneous injection in the abdomen
2945591|NCT02934269|Experimental|CC-90006; Dose Level 3|CC-90006 will be administered by subcutaneous injection in the abdomen
2945592|NCT02934269|Experimental|CC-90006; Dose Level 4|CC-90006 will be administered by subcutaneous injection in the abdomen
2945593|NCT02934269|Experimental|CC-90006; Dose Level 5|CC-90006 will be administered by subcutaneous injection in the abdomen
2945594|NCT02934269|Experimental|Placebo|Placebo will be administered by subcutaneous injection in the abdomen
2945595|NCT02934256|Experimental|Icotinib，treatment effect evaluation|Patients use Icotinib hydrochloride tablets during the course of treatment. The drug dosage is 125mg/m3/d. Every course of treatment lasts three months. Patients are designed to receive total four courses of treatment if there is no disease progression.
2945596|NCT02934243||easy Laryngeal Mask insertion|patients in whom the insertion of the SIM has proven easy
2945597|NCT02934243||difficult Laryngeal Mask insertion|patients in whom the insertion of the SIM has proven difficult
2945815|NCT02932852|Active Comparator|GROUP II|Lipoaspiration and transplantation of scaffold (human corneal decellularized lamina) without ADAS
2945598|NCT02934230|Experimental|Prehabilitation Group|The intervention will be a home-based total-body exercise training program (prehabilitation) based on a protocol with proven efficacy in improving the function of non-frail surgical patients in less than 4 weeks of preoperative utilization.Prehabilitation will consist of 3 components: 1) strength training; 2) aerobic exercise and 3) flexibility. Prehabilitation will be prescribed as 1-hour sessions performed a minimum of 3 times per week. Intervention group patients will also be provided with nutritional advice. In addition to paper-based materials outlining the prehabilitation program, weekly prehabilitation teaching sessions will be held at our Cancer Centre for patients randomized to the intervention group, and activity logs and weekly phone calls will be used to measure compliance and to answer questions. During the final week of the program, patients will also participate in a brief qualitative interview over the phone to explore their experience with the program.
2945599|NCT02934230|No Intervention|Control Group|Patients randomized to the control group will be provided standard perioperative care as per our institutional standards. They will receive the World Health Organization (WHO) Global Recommendations for Physical Activity for Health for people 60 years and above pamphlet, as well as Canada's Food Guide. In-hospital perioperative care, and postoperative care, will be at the discretion of each patient's surgeon and anesthesiologist.
2945600|NCT02934217|Experimental|Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg Echocardiography
2945601|NCT02934217|Placebo Comparator|Control|one single intravenous bolus injection of Placebo Echocardiography
2945602|NCT02934204|Experimental|MTX and Temozolomide|"Induction therapy:~Methotrexate 3.5g/m2 ivgtt d1 2weeks/cycle，total 8 cycles Temozolomide 150mg/m2 po d1-5 4weeks/cycle, total 4 cycles~Consolidation therapy:~PCNSL patients achieve CR,Temozolomide 150mg/m2 po d1-5 4weeks/cycle, total 12 cycles"
2945603|NCT02934191|Experimental|Acetaminophen/Oxycodone + Celecoxib|Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take celecoxib orally (dose is 6mg/kg twice a day with a maximum dose of 300mg twice a day). The first dose of celecoxib will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
2945604|NCT02934191|Active Comparator|Acetaminophen/Oxycodone + Placebo|Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take the placebo orally twice a day. The first dose of placebo will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
2945605|NCT02934178|Experimental|Cohort 1|3 oral doses of 3x10^3 cfu WRSS1 12 participants, 4 placebo
2945606|NCT02934178|Experimental|Cohort 2|3 oral doses of 3x10^4 cfu WRSS1 12 participants, 4 placebo
2945607|NCT02934178|Experimental|Cohort 3|3 oral doses of 3x10^5 cfu WRSS1 12 participants, 4 placebo
2945608|NCT02934178|Experimental|Cohort 4|3 oral doses of 3x10^6 cfu WRSS112 participants, 4 placebo
2945609|NCT02934165|Experimental|Family Safety 123|Parents viewed a website with videos on child injury prevention strategies and received emails for 30 days inviting them to view additional videos.
2945610|NCT02934165|Active Comparator|AAP TIPP sheets|Parents viewed online injury prevention materials developed by the American Academy of Pediatrics and had continuing access to these materials for 30 days.
2945611|NCT02934152|Experimental|Early eradication|Group A (H pylori eradication timing: early eradication, n=100): Initial H pylori eradication with triple therapy (rabeprazole 20 mg qd, amoxicillin 1gm bid, clarithromycin 500 mg bid) for two weeks.
2945612|NCT02934152|Experimental|Late eradication|Group B (H pylori eradication timing: late eradication, n=100): PPI with rabeprazole 20 mg qd for 4 weeks, followed by H pylori eradication with triple therapy for two weeks
2945613|NCT02934152|Active Comparator|Negative Hp|For patients with negative H. p infection documented by UBT (Group C, n=200), No H pylori eradication treatment will be given but PPI with rabeprazole 20 mg qd will be given for 8 weeks.
2945614|NCT02934139|Experimental|Cavosonstat (N91115) 400 mg|Every 12 hour oral dosing of N91115 for 7 days
2945615|NCT02934139|Experimental|Cavosonstat (N91115) 600 mg|Every 12 hour oral dosing of N91115 for 7 days
2945616|NCT02934139|Experimental|Cavosonstat (N91115) 1200 mg|Once daily oral dosing of N91115 for 7 days
2945617|NCT02934139|Experimental|Cavosonstat (N91115) 800 mg|Every 12 hour oral dosing of N91115 for 7 days
2945618|NCT02934139|Placebo Comparator|Placebo|Matched placebo. Oral dosing every 12 hour or once daily for 7 days
2945619|NCT02934126||breast cancer patients|breast cancer patients who have faced a decision on different types of radiotherapy or to leave radiotherapy out of the treatment
2945620|NCT02934113|No Intervention|Control|
2945621|NCT02934113|Experimental|iOTA and HWPP|
2945622|NCT02934113|Experimental|HWPP|
2945623|NCT02934100|Active Comparator|Group 1 - ESWT Treatment|Patients treated with Extracorporeal Shock Wave Therapy once a week for 10 weeks
2945624|NCT02934100|Active Comparator|Group 2 - Body Wave|Patients treated with electric field diathermy three times a week for 5 weeks
2945625|NCT02934100|Active Comparator|Group 3 - Ultrasound|Patients treated with ultrasound therapy three times a week for 5 weeks
2945626|NCT02934100|Sham Comparator|Group 4 - Control group|Patients treated with sham laser therapy three times a week for 5 weeks
2945627|NCT02934087|Active Comparator|Retrograde Gate Cannulation|All patients undergoing elective EVAR with a standard commercially available stent graft will be randomized after informed consent obtained; gate cannulation method will be attempted for a period of 15 minutes. If unsuccessful during this time a crossover to the alternative method (snare) will be attempted. The study will be terminated at 15 minutes in the crossover arm if still unsuccessful.
2945662|NCT02933840|Experimental|AlertWatch|Patients will receive standard monitoring and in addition the AlertWatch software will alert the intensive care physician if there is a value that meets criteria for alerting. The care team will be the orthopedic surgery team in addition to the intensive care physician being involved as a consultant if he/she receives an alert.
2945663|NCT02933840|No Intervention|No AlertWatch|Patients will receive standard monitoring without the AlertWatch software. The care team will be the orthopedic surgery team without the intensive care physician being involved as a consultant.
2945628|NCT02934087|Active Comparator|Snare Technique|"All patients undergoing elective EVAR with a standard commercially available stent graft were randomized after informed consent obtained; gate cannulation method was attempted for a period of 15 minutes. If unsuccessful during this time a crossover to the alternative method (retrograde gate cannulation) was attempted. The study will be terminated at 15 minutes in the crossover arm if still unsuccessful.~Antegrade or crossover cannulation involves passing a guidewire from the ipsilateral limb to the contralateral limb gate of the endograft, which can be accomplished with a curved catheter. The wire may be retrieved on the contralateral limb using a snare device."
2945629|NCT02934074||Unilateral Lower Limb Loss|Individuals with unilateral lower limb loss will be participants of the group.
2945630|NCT02934061|Experimental|Tizaspray®|Tizaspray® administered intranasally in patients with acute low back pain
2945631|NCT02934061|Active Comparator|Sirdalud®|Sirdalud® 2 mg tablets administered in patients with acute low back pain
2945632|NCT02934048|Experimental|7-day triple regimen|Patients in this group received a 7-day triple regimen to eradicate H. pylori. The triple therapy contains proton pump inhibitor (PPI)-clarithromycin plus a susceptible antibiotics will be involved in the study.
2945633|NCT02934048|Experimental|10-day triple regimen|Patients in this group received a 10-day triple regimen to eradicate H. pylori. The triple therapy contains PPI-clarithromycin plus a susceptible antibiotics will be involved in the study.
2945634|NCT02934048|Experimental|14-day triple regimen|Patients in this group received a 14-day triple regimen to eradicate H. pylori. The triple therapy contains PPI-clarithromycin plus a susceptible antibiotics will be involved in the study.
2945635|NCT02934035||Placebo|The placebo group includes participants in eligible clinical trials who have been assigned to placebo medication.
2945636|NCT02934035||Antidepressant|The antidepressant group includes participants in eligible clinical trials who have been assigned to antidepressant medication.
2945637|NCT02934022|Other|Maraviroc|
2945638|NCT02934009|Experimental|Dialysis patients|In this group dialysis patients are measured by NMR-Mobile Universal Surface Explorer® (NMR-Mouse) during their routine dialysis sessions. After a 5 min rest period the arm of the patients is placed onto the NMR-Mouse and measured before the beginning of dialysis. The arm examined is not the shunt arm. The area selected should not display any signs of skin disease or scars from previous surgeries. After the dialysis the same area is measured again in a second measurement.
2945639|NCT02934009|Experimental|Healthy volunteers|"In this group kidney-healthy volunteers will be examined by NMR-Mobile Universal Surface Explorer® (NMR-Mouse) at three different days. The right/left arm or leg will be used for repeated measurement. Altogether 2 measurements per day are reformed in order to evaluate the reproducibility and variability."
2945640|NCT02933996|Placebo Comparator|Non TEAS group|Patients allocated in the Non TEAS group recieve the electrode patch on the skin, connected electro-acupuncture device, with no current input.
2945641|NCT02933996|Experimental|TEAS groups|TEAS is a kind of treatment combining transcutaneous electrical nerve stimulation (TENS) with traditional Chinese acupuncture points, and inputs a specific low frequency pulse current into the body through skin.Patients allocated in the TEAS group receive standardised treatment at 2 acupuncture points (ST36 and BL23). The investigator put the electrode patch on the skin, connected electro-acupuncture device, and select the maximum current intensity patients can endure. The acupuncture treatment starts from 30min prior to operation to the end of surgery, and then four times within 48 hours post operation, 30 minutes for each time.
2945642|NCT02933996|No Intervention|Control groups|Patients allocated in the control group do not receive any intervention.
2945643|NCT02933983||Control group (healthy)|Participants who do not suffer from acute or chronic airway infections
2945644|NCT02933983||CRS patients|Patients who suffer from chronic rhinosinusitis
2945645|NCT02933970|No Intervention|Control|Referral-HCV seropositive subjects enrolled for at least 12 months in an opiate agonist treatment (OAT) program will be referred to an off-site liver specialist
2945646|NCT02933970|Other|Intervention|Telemedicine - HCV seropositive subjects enrolled for at least 12 months in an OAT program will be treated on site by a liver specialist via two-way video conferencing. (telemedicine)
2945647|NCT02933944|Experimental|TG02-treatment|"Part I: The TG02-treatment consists of an intradermal injection of GM-CSF followed by an injection of TG02. The GM-CSF is to be given 15-30 minutes before TG02. TG02-treatment will be administered on Days 1, 8, 15, 22 and 36. If surgery after week 10, TG02-treatment will also be given at week 10 (Day 64).~Part II: TG02-treatment will be given as described under Part I. In addition pembrolizumab will be administered."
2945648|NCT02933931||vaccinated with 5 x 10E7 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 5 x 10E7 pfu VSV-ZEBOV
2945649|NCT02933931||vaccinated with 10E7 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 10E7 pfu VSV-ZEBOV
2945650|NCT02933931||vaccinated with 3 x 10E5 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 3 x 10E5 pfu VSV-ZEBOV
2945651|NCT02933918|Experimental|Probiotics|
2945652|NCT02933905||Non-PVD subjects|Patients with no PVD on SD-OCT at basal visit
2945653|NCT02933905||PVD subjects|Patients with PVD on SD-OCT at basal visit
2945654|NCT02933892|Active Comparator|Transradial Access|Patients scheduled for cardiac catheterization will be randomly assigned to have the doctor insert the catheter via the arm access site (transradial access).
2945655|NCT02933892|Active Comparator|Transfemoral Access|Patients scheduled for cardiac catheterization will be randomly assigned to have the doctor insert the catheter via the inner thigh access site (transfemoral access).
2945656|NCT02933879|Experimental|NVXT topical|daily dosing for one 8-week treatment period (Treatment Group A) and two 8-week treatment periods separated by a 32-week rest period (Treatment Group B),
2945657|NCT02933879|Placebo Comparator|Placebo (Vehicle) Topical|two 8-week treatment periods separated by a 32-week rest period (Treatment Group C),
2945658|NCT02933866|Experimental|DSXS topical|applied once daily for 28 days
2945659|NCT02933866|Placebo Comparator|Vehicle topical|applied once daily for 28 days
2945660|NCT02933853|Experimental|Faster Aspart|
2945661|NCT02933853|Active Comparator|Insulin Aspart|
2945664|NCT02933827|Experimental|Low dose:|Elixcyte 8 mL (ADSC 6.4*10^7 cells in total)
2945665|NCT02933827|Experimental|Middle dose|Elixcyte 24 mL (ADSC 19.2*10^7 cells in total)
2945666|NCT02933827|Experimental|High dose|Elixcyte 40 mL (ADSC 32.0*10^7 cells in total)
2945667|NCT02933814|No Intervention|Control Group|Patients in Group 1 (Plain Bupivacaine) will be treated intra-operatively with injections of 0.25% bupivacaine, with 10 mL (25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the surgical procedure.
2945668|NCT02933814|Experimental|Experimental Group|Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
2945669|NCT02933801|Experimental|Arm A: ODM-201|600mg ODM-201 BID (twice daily) and Best Supportive Care until progression
2945670|NCT02933801|Placebo Comparator|Arm B: Placebo|Placebo BID (twice daily) and Best Supportive Care until progression
2945671|NCT02933788|Experimental|Cilostazol group|Cilostazol Cilostazol 200mg tablet by mouth, once daily for 14 days
2945672|NCT02933788|Active Comparator|Aspirin group|Acetylsalicylic acid Acetylsalicylic acid 100mg tablet by mouth, once daily for 14 days
2945673|NCT02933775|Experimental|CAR-CD19 T cells|Autologous T Cells with a CD19-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection. Lymphodepleting conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day -9 - Day -4.
2945674|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 30 milligram[mg])|Healthy elderly participants will receive single dose of 30mg JNJ-54175446.
2945675|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 100mg)|Healthy elderly participants will receive single dose of 100mg JNJ-54175446.
2945676|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 300mg)|Healthy elderly participants will receive single dose of 300mg JNJ-54175446.
2945677|NCT02933762|Experimental|Part 1: Cohort A1 (Placebo)|Healthy elderly participants will receive single dose of placebo.
2945678|NCT02933762|Experimental|Part 1: Cohort A2 (JNJ-54175446 D1 mg)|Healthy elderly participants will receive an additional dose D1 mg [less than or equal to (<=) 600 mg] of JNJ-54175446, to be determined.
2945679|NCT02933762|Experimental|Part 1: Cohort A3 (JNJ-54175446 D2 mg)|Healthy young participants will receive a single dose D2 mg (<= 600 mg) of JNJ-54175446, to be determined.
2945680|NCT02933762|Experimental|Part 1: Cohort A3 (Placebo)|Healthy young participants will receive a single dose of placebo.
2945681|NCT02933762|Experimental|Part 2: Cohort B1 (JNJ-54175446 D3 mg)|Healthy elderly participants will receive multiple dose levels D3 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
2945682|NCT02933762|Experimental|Part 2: Cohort B1 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1.
2945683|NCT02933762|Experimental|Part 2: Cohort B2 (JNJ-54175446 D4 mg)|Healthy elderly participants will receive multiple dose levels D4 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
2945684|NCT02933762|Experimental|Part 2: Cohort B2 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1
2945685|NCT02933762|Experimental|Part 2: Cohort B3 (JNJ-54175446 D5 mg)|Healthy elderly participants will receive multiple dose levels D5 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
2945686|NCT02933762|Experimental|Part 2: Cohort B3 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1
2945687|NCT02933749|Active Comparator|The sitting|The sitting position Device sCtO2 Device BIS
2945688|NCT02933749|Active Comparator|The prone|The prone position Device sCtO2 Device BIS
2945689|NCT02933736|Experimental|Administration of ribociclib|"Subjects will be administered ribociclib prior to surgical resection of their tumor. Ribociclib administration will occur at sequential time-intervals (i.e.,Cohort 1 will be filled first with 16 subjects, then Cohort 2 the same, followed by Cohort 3). All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurring at one of 3 following intervals before brain tumor resection:~Cohort 1: last ribociclib dose 2-4 hours prior to craniotomy for tumor resection~Cohort 2: last ribociclib dose 4-8 hours prior to craniotomy for tumor resection~Cohort 3: last ribociclib dose 22-26 hours prior to craniotomy for tumor resection"
2945690|NCT02933723|Experimental|Blood draw- adjuvanted TIV|individuals who received adjuvanted trivalent influenza vaccine (aTIV, Fluad) and consent to a blood draw
2945691|NCT02933723|Active Comparator|Blood draw - nonadjuvanted TIV|individuals who received nonadjuvanted trivalent influenza vaccine and consent to a blood draw
2945692|NCT02933710||IMOJEV® Vaccine Group|Participants who are 12 months and older and who are given a first dose of IMOJEV® during a routine health care visit
2945693|NCT02933697|Active Comparator|Apixaban|2.5 mg apixaban twice daily for 6 to 24 months
2945694|NCT02933697|Active Comparator|Vitamin-K antagonists (Phenprocoumon)|Phenprocoumon by INR (Target: 2.0-3.0) treatment for 6 to 24 months
2945695|NCT02933684|Experimental|DCS|Participants will receive 50mg of Seromycin (aka D-cycloserine) in conjunction with virtual reality exposure therapy once a week for 4 weeks.
2945696|NCT02933684|Placebo Comparator|Placebo|Participants will receive a placebo in conjunction with virtual reality exposure therapy once a week for 4 weeks.
2945697|NCT02933671|Experimental|Suprainguinal Fascia Iliaca (SIFI) block|A nerve block technique using a numbing medication called ropivacaine.
2945698|NCT02933671|Placebo Comparator|Sham group|The same nerve block technique as above, however using an inactive solution of salt water.
2945699|NCT02933658|Experimental|Reference1|single(Reference1) -> combination(Reference1+Reference2)
2945700|NCT02933658|Experimental|Reference2|single(Reference2) -> combination(Reference1+Reference2)
2945701|NCT02933645|Active Comparator|Insulin nasal spray|"Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain fast-acting human insulin Actrapid (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.~30 min before spray administration a hyperinsulinemic euglycemic clamp will be started and continued for 170 minutes. 40 min after spray administration [18F]-FDG PET-CT scan lasting 100 min is started."
2945816|NCT02932852|Active Comparator|GROUP III|Lipoaspiration and transplantation of ADAS cellularized on scaffold (the human corneal decellularized lamina)
2945702|NCT02933645|Placebo Comparator|Placebo nasal spray|"Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd,Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd,Denmark) over 15 min.~30 min before spray administration a hyperinsulinemic euglycemic clamp will be started and continued for 170 minutes. 40 min after spray administration [18F]-FDG PET-CT scan lasting 100 min is started."
2945703|NCT02933632|Active Comparator|Standard Assistance Protocol-SAP|Patients underwent physical therapy once a day. Patients receive intervention by Physical Therapy-SAP.
2945704|NCT02933632|Active Comparator|Accelerated Rehabilitation Protocol-ARP|Patients underwent physical therapy three times a day. Patients receive intervention by Physical Therapy-ARP.
2945705|NCT02933606|Experimental|BNC210 600 mg b.i.d.|Suspension administered orally for 12 weeks.
2945706|NCT02933606|Experimental|BNC210 300 mg b.i.d.|Suspension administered orally for 12 weeks.
2945707|NCT02933606|Experimental|BNC210 150 mg b.i.d.|Suspension administered orally for 12 weeks.
2945708|NCT02933606|Placebo Comparator|Placebo b.i.d.|Suspension administered orally for 12 weeks.
2945709|NCT02933593|Active Comparator|labetalol|labetalol
2945710|NCT02933593|Active Comparator|hydralazine|Hydralazine
2945711|NCT02933593|Active Comparator|nifedipine|nifedipine
2945712|NCT02933580|Experimental|Cohort A: JNJ-56136379 (25 mg) or Placebo|Participants will receive a single oral dose of 25 milligram (mg) of JNJ-56136379 (1*25-mg tablet) or placebo on Day 1, fasted conditions.
2945713|NCT02933580|Experimental|Cohort B: JNJ-56136379 (150 mg) or Placebo|Participants will receive a single oral dose of 150 mg of JNJ-56136379 (2* 25-mg tablet and 1*100-mg tablet) or placebo on Day 1, fasted conditions.
2945714|NCT02933580|Experimental|Cohort C: JNJ-56136379 (300 mg) or Placebo|Participants will receive a single oral dose of 300 mg of JNJ-56136379 (3*100-mg tablet) or placebo on Day 1, fasted conditions.
2945715|NCT02933580|Experimental|Cohort D: JNJ-56136379 (600 mg) or Placebo|Participants will receive a single oral dose of 600 mg of JNJ-56136379 (6*100-mg tablet) or placebo on Day 1, fasted conditions.
2945716|NCT02933567|Experimental|CSC OnDemand Pilo|Pilot Intervention
2945717|NCT02933554|Experimental|NASH- Left gastric artery embolization|Embospheres Microspheres as artificial embolic agent for left gastric artery embolization
2945718|NCT02933528|Experimental|Dsxs topical product|treatment with DSXS once daily for 28 days
2945719|NCT02933515|Experimental|Yoga and occupational therapy|twice a week for 8 weeks. one hour of group occupational therapy for fall risk factor management and one hour of yoga for balance
2945720|NCT02933502|Experimental|DSXS topical product|treatment with DSXS once daily for 28 days
2945721|NCT02933489|Experimental|Arm A (DBT, AB-MR)|Participants undergo DBT followed by AB-MR for under 10 minutes on the same day or within 24 hours at baseline and then after 1 year.
2945722|NCT02933489|Experimental|Arm B (AB-MR, DBT)|Participants undergo AB-MR for under 10 minutes followed by DBT on the same day or within 24 hours at baseline and then after 1year.
2945723|NCT02933476|Experimental|Vibrotactile Stimulation Treatment|All patients will receive the vibrotactile stimulation treatment. No deception will be used.
2945724|NCT02933463|Experimental|embrace wetbond sealant|moisture tolerant resin based, have same properties of other sealant
2945725|NCT02933463|Active Comparator|clinpro sealant|is a dental resin, with low viscosity , fluoride releasing with a unique patented color change.
2945726|NCT02933450|Active Comparator|Patiromer group|Patiromer 25.2 g dose
2945727|NCT02933450|No Intervention|Standard of Care group|Standard of Care
2945728|NCT02933437|Experimental|Healthy Volunteers|Once screened by the investigators, the participants will undergo ajmaline provocation, cardiac magnetic resonance imaging and genotype evaluation
2945729|NCT02933424|No Intervention|Control beverage with no protein powder|Standard breakfast drink with no protein powder added
2945730|NCT02933424|Experimental|Beverage with Rice protein powder 25 grams|Standard breakfast drink with 25 grams of rice protein powder.
2945731|NCT02933424|Experimental|Beverage with Pea protein powder 25 grams|Standard breakfast drink with 25 grams of pea protein powder.
2945732|NCT02933424|Experimental|Beverage with Oats protein powder 25 grams|Standard breakfast drink with 25 grams of Oats protein powder.
2945733|NCT02933411||Group A|Adolescent women with heavy menstrual bleeding and low von willebrand factor activity.
2945734|NCT02933398|Active Comparator|Laparoscopic Assisted Partial Nephrectomy|Current standard for partial nephrectomies.
2945735|NCT02933398|Active Comparator|Robotic Assisted Partial Nephrectomy|Possible new standard for partial nephrectomies.
2945736|NCT02933385|Experimental|Full lifestyle program|Participants receive all the intervention tools that aimed to enhance lifestyle profile.
2945737|NCT02933385|Experimental|High lifestyle program|Participants receive most of the intervention tools that aimed to enhance lifestyle profile.
2945738|NCT02933385|Experimental|Moderate lifestyle program|Participants receive some intervention tools that aimed to enhance lifestyle profile.
2945739|NCT02933385|Experimental|Light lifestyle program|Participants receive little intervention tools that aimed to enhance lifestyle profile.
2945740|NCT02933385|No Intervention|Control group|Participants receive none of the intervention tools that aimed to enhance lifestyle profile.
2945741|NCT02933372|Experimental|Measuring Brain Varenicline with PET Scans|The purpose of Experiment 1 is to determine the dose of varenicline suitable for chronic administration in Parkinson's Disease patients. Experiment 1 involves taking varenicline for several days and having two Positron Emission Tomography (PET) scans. The PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments of severity of Parkinson disease (PD) and cognition are performed.
2945774|NCT02933177|Experimental|4 months control condition-2 months chariot flash|200 patient, in 14 other nursing homes will be exposed 4 months in the control condition and 2 months in the experimental condition
2945817|NCT02932839|Experimental|Intervention|Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
2945742|NCT02933372|Experimental|Assessing Varenicline Effects on Gait and Balance|Experiment 2 involves taking varenicline or a placebo for several weeks and measurements of walking speed and balance, as well as cognitive testing to assess brain function. There are no PET scans done in experiment 2. Walking speed is measured by how quickly a person can walk down a corridor. Balance is measured by ability to maintain a normal standing stance. Safety monitoring with clinical assessments of severity of PD and cognition are performed.
2945743|NCT02933359||Normal Tissue|Bone fragments and their associated bone marrow will be collected from patients at the time of surgery without any additional dissection or incisions. Bone will be finely minced and then plated in tissue culture flasks as previously reported by other groups [7].
2945744|NCT02933333|Experimental|GM-CSF|Eligible patients received subcutaneous GM-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. GM-CSF is given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
2945745|NCT02933333|Experimental|G-CSF|Eligible patients received subcutaneous G-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. G-CSF is given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
2945746|NCT02933333|Experimental|G-CSF + GM-CSF|Eligible patients received subcutaneous a combination of GM-CSF 5 μg/kg per day and G-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. GM-CSF and G-CSF are given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
2945747|NCT02933320|Experimental|Part A: BI-1206 single agent dose escalation phase|BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy)
2945748|NCT02933320|Experimental|Part B: Arm 1: BI-1206 single agent expansion phase|Arm 1 will be an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A. This expansion will include a minimum of 12 chronic lymphocytic leukaemia (CLL) and six mantle cell lymphoma (MCL) patients
2945749|NCT02933320|Experimental|Part B: Arm 2: combination of BI-1206 with Rituximab|Arm 2 will be an investigation of combination treatment of BI-1206 with Rituximab. Arm 2 will involve an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts) and subsequent expansion of up to 25 patients at the identified recommended combination dose. This expansion will include a minimum of 12 CLL and six mantle cell MCL patients. CLL patients recruited to the expansion will receive one rituximab infusion, one week before commencing the four weeks of combination induction therapy.
2945750|NCT02933307|No Intervention|Control group|Patients with regular measurements by nurses only (Modified Early Warning Score (MEWS))
2945751|NCT02933307|Experimental|HealthPatch (Intervention)|Patients with HealthPatch and regular MEWS measurements
2945752|NCT02933307|Experimental|ViSi Mobile (Intervention)|Patients with ViSi Mobile and regular MEWS measurements
2945753|NCT02933294|Active Comparator|Triportal pulmonary resection surgery|Treated by traditional video assisted thoracoscopic three-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
2945754|NCT02933294|Active Comparator|Uniportal pulmonary resection surgery|Treated by minimally invasive video assisted thoracoscopic single-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
2945755|NCT02933281|Experimental|Cohort 1: MTBVAC 5 x 10^3 CFU|Quantiferon (QFT) negative, 1 dose on Day 0
2945756|NCT02933281|Experimental|Cohort 2: MTBVAC 5 x 10^4 CFU|QFT Negative, 1 dose on Day 0
2945757|NCT02933281|Experimental|Cohort 3: MTBVAC 5 x 10^5 CFU|QFT Negative, 1 dose on Day 0
2945758|NCT02933281|Experimental|Cohort 4: MTBVAC 5 x 10^6 CFU|QFT Negative, 1 dose on Day 0
2945759|NCT02933281|Experimental|Cohort 5: MTBVAC 5 x 10^3 CFU|QFT Positive, 1 dose on Day 0
2945760|NCT02933281|Experimental|Cohort 6: MTBVAC 5 x 10^4 CFU|QFT Positive, 1 dose on Day 0
2945761|NCT02933281|Experimental|Cohort 7: MTBVAC 5 x 10^5 CFU|QFT Positive, 1 dose on Day 0
2945762|NCT02933281|Experimental|Cohort 8: MTBVAC 5 x 10^6 CFU|QFT Positive, 1 dose on Day 0
2945763|NCT02933281|Active Comparator|BCG 5 x 10^5 CFU|Both QFT positive and negative, 1 dose on Day 0
2945764|NCT02933268|Active Comparator|Ad libitum water intake|Ad libitum water intake, defined as intake guided by thirst to achieve a target urine osmolality > 300 mOsmo/kg
2945765|NCT02933268|Active Comparator|High water intake|Personalised daily water intake prescription to achieve target urine osmolality < 270 mOsm/kg.
2945766|NCT02933255|Experimental|Lead-in mCRPC Cohort|PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F on 2, 4, 6 and 8 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Patients will undergo sigmoidoscopies on week 9 and restaging scans on week 11. If no PD, option to continue treatment every 3 weeks until intolerance or progression (evaluated radiographically every 12 weeks).
2945767|NCT02933255|Experimental|Neoadjuvant Cohort|PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F on 2, 4 and 8 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Patients will undergo prostatectomy on week 9.
2945768|NCT02933242|Experimental|Stereotactic arm|Stereotactic ablative radiotherapy
2945769|NCT02933229|Experimental|H. pylori eradication cohort|"H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication."
2945770|NCT02933216||VR|The CSD patients are received treatment of vaginal repair.
2945771|NCT02933216||hysteroscope + laparoscope|The CSD patients are received treatment of hysteroscopic combined with laparoscopic excision.
2945772|NCT02933190|Other|CSP；transvaginal surgery；UAE and D&C|Cesarean scar pregnancy (CSP) refers to the implantation of a gestational sac with the myometrium at the site of a previous cesarean scar
2945773|NCT02933177|Experimental|2 months control condition - 4 months chariot-flash|"200 patient , in 15 nursing homes randomly will be exposed two months in the control condition (usual intervention) and 4 months in the experimental condition (chariot-flash intervention). The experimental condition is to propose the chariot-flash in emergency during the emergence or increase of productive symptoms."
2945775|NCT02933164|Experimental|Arms|Evaluation of the effectiveness of modified Sensor designs on the longevity (up to 180 days) of the Senseonics Continuous Glucose Monitoring (CGM) System. The investigation will also evaluate safety of the Senseonics CGM System usage, while in the clinic and during home use.
2945776|NCT02933151|Other|Usual Care Protocol|Facility randomized to follow the usual care nutritional supplement protocol
2945777|NCT02933151|Other|Intensive Protocol|Facility randomized to follow the intensive nutritional supplement protocol
2945778|NCT02933138||Multifactorial Chylomicronemia|no intervention, phenotypic and genotypic study
2945779|NCT02933125|Experimental|Intervention group|The youths in the intervention group will participate in a weekly 10-session out-patient motivational enhancement psychotherapy (MEP) program. In addition to this, these youths' caregivers will be referred to simultaneously take part in a weekly 10-session out-patient parenting skill training (PST) program at Kaohsiung Chang Gung Memorial Hospital.
2945780|NCT02933125|Active Comparator|Comparison group|The comparison group consists of substance-using adolescents that receive only standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court. The protection officers provide the adolescents with moral education, as well as counseling in their work or studies.
2945781|NCT02933112|Other|AMP test group|All individuals will undergo a test using the auto-titrating mandibular positioner.
2945782|NCT02933099|Experimental|Aprepitant arm|Aprepitant+palonosetron+dexamethasone
2945783|NCT02933099|Active Comparator|Control arm|palonosetron+dexamethasone
2945784|NCT02933086|Experimental|G1: exercises for lumbar stabilization|G1, will perform therapy with specific exercises for lumbar stabilization including the Swiss ball as therapeutic resource
2945785|NCT02933086|Experimental|G2: conventional therapy|G2, will perform conventional therapy including stretching of lower limbs and trunk.
2945786|NCT02933073|Experimental|OncoImmunome/Vaccine Phase|Women with Stage III/IV Ovarian Cancer who have received the standard of care treatment (surgical debulking and chemotherapy) for their cancer and are now in clinical remission will be given the experimental drug (vaccine) called OncoImmunome, which has been produced specifically for each participant.
2945787|NCT02933060|Experimental|IV fluid bolus|Patients will receive a 1000 ml bolus of normal saline, administered over 60 minutes.
2945788|NCT02933060|Sham Comparator|Control|Patients will have an IV catheter and will be connected to an IV bag, but will receive only 10 ml of normal saline over 60 minutes.
2945789|NCT02933047|Active Comparator|Outpatient LH|Patients in the intervention group are discharged within 6 to 8 hours after total laparoscopic hysterectomy.
2945790|NCT02933047|Placebo Comparator|Inpatient LH|Patients in the control group follow regular hospitalization and are discharged within 24 hours after total laparoscopic hysterectomy.
2945791|NCT02933034|Experimental|CORONARY DISEASE SUBJECT|ALL SUBJECTS IN THIS STUDY HAVE PREVIOUSLY DOCUMENTED CORONARY ARTERY DISEASE BY ANGIOGRAPHY
2945792|NCT02933021||All participants|Nurse visit for blood sample, questionnaire and phone call
2945793|NCT02933008|Experimental|aNMT Biofeedback|A group that will receive a neuromuscular training intervention that incorporates biofeedback training
2945794|NCT02933008|Sham Comparator|Sham|a group that will receive the same neuromuscular training intervention with sham feedback training.
2945795|NCT02932995||DXR stent group|Patients who undergo coronary intervention with DXR stent
2945796|NCT02932969|Experimental|Panel 1 Arm|BMS-986231 and BMS-986231 Placebo intravenously
2945797|NCT02932969|Experimental|Panel 2 Arm|BMS-986231 and BMS-986231 Placebo intravenously
2945798|NCT02932969|Experimental|Panel 3 Arm|BMS-986231 and BMS-986231 Placebo intravenously
2945799|NCT02932956|Experimental|GAP T cells + Fludarabine and Cytoxan|GPC3-Car (GAP T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with GPC3-positive solid tumors.
2945800|NCT02932943|Experimental|Rapastinel 450 mg|Rapastinel 450 milligram (mg) weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
2945801|NCT02932943|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
2945802|NCT02932930|Active Comparator|QLB group|"Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.2% ropivacaine bilaterally.~Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Ropivacaine, 0.2 ml/kg of 0.2% ropivacaine"
2945803|NCT02932930|Placebo Comparator|Control group|"Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.9% normal saline bilaterally.~Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Normal saline, 0.2 ml/kg of 0.9 % normal saline"
2945804|NCT02932917|Experimental|MapMySmoke|All patients in the study will use the MapMySmoke app to document their smoking and craving behavior
2945805|NCT02932904|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
2945806|NCT02932904|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 1 week followed by vortioxetine 20 mg, overencapsulated tablets, orally, once daily from Week 2, up to 4 weeks.
2945807|NCT02932904|Active Comparator|Paroxetine 20 mg|Paroxetine 20 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
2945808|NCT02932904|Placebo Comparator|Placebo|Vortioxetine placebo matching-capsules, orally, once daily for up to 5 weeks.
2945809|NCT02932891|Experimental|DSXS topical|active treatment
2945810|NCT02932878|Experimental|DSXS topical|administered twice daily for 28 days
2945811|NCT02932865||MD-TESE (A)|Azoospermic men, MD-TESE operation (standard treatment). Semen sample, serum sample and physical examination with testicular ultrasound.
2945812|NCT02932865||Subfertile men (B)|Subfertile men receiving medication (standard treatment). Semen sample, serum sample and physical examination with testicular ultrasound.
2945813|NCT02932865||Control (C)|Control group, men scheduled for semen analysis. Semen sample, serum sample and physical examination with testicular ultrasound.
2945814|NCT02932852|Active Comparator|GROUP I|lipoaspiration and transplantation of ADAS alone without scaffold
2945818|NCT02932826|Experimental|Treg Treatment + Insulin|subjects will be treated with Umbilical Cord Blood Regulatory T cells Therapy and insulin according to routine clinical practice at the discretion of the treating physician
2945819|NCT02932826|Active Comparator|Insulin|subjects will be treated with insulin according to routine clinical practice at the discretion of the treating physician
2945820|NCT02932813|Experimental|Intervention Group|"THINK intervention:~The program will have activity and fitness sessions lasting two hours, three times a week for a total of nine months. Sessions will include theory, clinical laboratory activities, and physically active games to facilitate a fun environment to enhance physical and health-related fitness, improve nutrition and exercise knowledge and behaviors, and exercise enjoyment and self-confidence."
2945821|NCT02932813|No Intervention|Control Group|This group will receive the traditional YMCA SPARK after-school program. They will undergo the same pre, mid, and post testing protocol as the intervention group, but will not receive the THINK program.
2945822|NCT02932800|Active Comparator|"Ballerina associated with flap fixation"|"The catheter is anchored to the skin begins by a point U around the catheter insertion site and followed by a series of woven points around the catheter , commonly referred to as  node dancer  to pass the wires on each side of the orifices located at the catheter distal flaps and hold three consecutive nodes . Then, the clamping is carried out of the catheter to the skin by means of a simple point and hold three consecutive nodes in each lateral hole of the fastening flap while leaving, between the fastening flap and the puncture site a space 2 cm distance for viewing the ostium ."
2945823|NCT02932800|Active Comparator|the usual fixation technique|The catheter is attached to the skin with a simple point and holding three we row on each side hole fixing fin while leaving, between the fastening flap and the puncture site , an area of 2 cm away for viewing ostium . The catheter is anchored to the skin by a simple point and holding three consecutive us in each hole of the side flap in the distal region.
2945824|NCT02932787|Experimental|Height-adjustable workstation|Participants received a height-adjustable workstation for four weeks
2945825|NCT02932787|No Intervention|Control|
2945826|NCT02932774|Experimental|Cetirizine 10 mg|Cetirizine HCl 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive cetirizine HCl syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
2945827|NCT02932774|Active Comparator|loratadine 10 mg|Loratadine 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive loratadine syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
2945828|NCT02932774|Placebo Comparator|placebo|Placebo syrup once daily for 2 weeks. Both placebo syrups were received by subjects who were randomized to receive placebo. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
2945829|NCT02932761|Experimental|VR + GnRHa|CSD patients were treated with vaginal repair of CSD in combination with GnRHa (Zoladex, 3.6 mg, AstraZeneca, Macclesfield, United Kingdom) as a subcutaneous injection (abbreviated as VR + GnRHa). In the group of VR + GnRHa, 2 doses of GnRHa were administered. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure. The detailed procedure of VR has been described in our previous study (Zhou et al., 2016).
2945830|NCT02932761|Placebo Comparator|VR|CSD patients were treated with vaginal repair of CSD in combination with 0.01 ml saline as a subcutaneous injection (abbreviated as VR). In the group of VR, 2 doses of saline were administered. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure. The detailed procedure of VR has been described in our previous study (Zhou et al., 2016).
2945831|NCT02932748|Experimental|Group Phone Conference Call|Delivery: Group Phone Diet: PCMs
2945832|NCT02932748|Experimental|Individual Phone Call|Delivery: Individual Phone Call Diet: PCMs
2945833|NCT02932748|Active Comparator|Enhanced Usual Care|Delivery: Face-to-Face Diet: Conventional Diet
2945834|NCT02932722|Sham Comparator|Control|Patients in the control group will be receive remote ischemic preconditioning before anesthetic induction (before exposure to any anesthetic).
2945835|NCT02932722|Active Comparator|Propofol|Patients in the propofol groups will be receive remote ischemic preconditioning after anesthetic induction using propofol, as a main anesthetic.
2945836|NCT02932722|Active Comparator|Sevoflurane|Patients in the sevoflurane groups will be receive remote ischemic preconditioning after anesthetic induction using sevoflurane, as a main anesthetic.
2945837|NCT02932709||Patients admitted of Psychiatry|Only patients who had a suicide attempt admitted to the Department of Emergency Psychiatry.
2945838|NCT02932696|Experimental|Exercise training|"Patients in this arm were encouraged to participate in an exercise training program, and they accepted to do so.~Intervention: Cardiac training program"
2945839|NCT02932696|No Intervention|No exercise training|Patients in this arm were encouraged to participate in an exercise training program, and they refused to do so.
2945840|NCT02932683|Experimental|MedNav assisted resuscitators|MedNav will be used to perform neonatal resuscitation on a mannequin and assessed after teaching and 7 weeks after intervention, following this a small group will be used as a cross over study.
2945841|NCT02932683|No Intervention|No MedNav resuscitators|Neonatal resuscitation will be performed on a mannequin (without the use of MedNav) and assessed after teaching and 7 weeks after intervention.
2945842|NCT02932670|Active Comparator|costoclavicular inflaclavicular block|costoclavicular block with similar volume
2945843|NCT02932670|Experimental|costoclavicular block|costoclavicular block with decreasing volume
2945844|NCT02932644||Rheumatoid arthritis patients|Participants in the original, parental trial
2945845|NCT02932631|Active Comparator|CONVENTIONAL PHYSICAL THERAPY group|"physical exercises divided into three phases:~stretching, strengthening and/or mobilization;~functional training of the affected muscles;~functional training of the paretic limb."
2945846|NCT02932631|Experimental|containment therapy induced|healthy side is restricted with splinting and exercises in hemiparetic member: carry out functional tasks individually. Each task will be held for 5 minutes, totaling 60 minutes of service
2945847|NCT02932618|Experimental|On-demand Treatment|Participants will receive treatment for non-surgical bleeding episodes.
2945881|NCT02932371|Experimental|Cardiac Surgery|
2945848|NCT02932618|Experimental|Elective Surgery|12-24 hours prior to surgery and within 3 hours of surgery. Minor surgery: infuse every 12-24 hours for at least 48 hours. Oral Surgery: infuse at least once within first 8-12 hours post-surgery. Major Surgery: infuse every 12-24 hours for at least first 72 hours post-surgery.
2945849|NCT02932618|Experimental|Emergency Surgery|Within 3 hours prior to surgery. Minor surgery: infuse every 12-24 hours for at least 48 hours. Oral Surgery: infuse at least once within first 8-12 hours post-surgery. Major Surgery: infuse every 12-24 hours for at least first 72 hours post-surgery.
2945850|NCT02932605|Experimental|Cannabidiol|Patients will be treated with 600mg CBD daily for 4 weeks (28 days)
2945851|NCT02932605|Placebo Comparator|Placebo|Patients will be treated with placebo daily for 4 weeks (28 days)
2945852|NCT02932592|Experimental|Dysglycemic group|"Patients with dysglycemia (not diabetic patients) will be undergone a monitoring of blood glucose with a device till the discharge of the patient.~Then, an oral glucose tolerance test (OGTT) will be done to categorize the patient as having impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), or diabetes mellitus."
2945853|NCT02932579|Active Comparator|Standard of Care|Individuals within this group will receive standard of care for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
2945854|NCT02932579|Experimental|Pharmacogenomic Group|Individuals within this group will receive pharmacogenomic testing guided prescription of pain medication for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
2945855|NCT02932566|Active Comparator|Pirfenidone|Pirfenidone 801mg capsule by mouth, three times a day (target dose) for 12 months
2945856|NCT02932566|Placebo Comparator|Placebo|Placebo capsule by mouth, three times a day (target dose) for 12 months
2945857|NCT02932553|Experimental|BVS and OMT|Optimal medical treatment + BVS implantation
2945858|NCT02932540||Healthy controls|healthy controls subjects who have age, sex and Blood pressure matched with the acute ischaemic stroke patient
2945859|NCT02932540||AIS patient-transient arm|transient change of head position from lying flat (0 degree) to sitting up (30 degree)
2945860|NCT02932540||AIS patient - persistent lying flat|lying flat (0 degree) head position for the first 24 hours in the hospital admission
2945861|NCT02932540||AIS patient - persistent sitting up|sitting up ( 30 degree) head position for the first 24 hours in the hospital admission
2945862|NCT02932527|Experimental|infertile men exposed to cannabis|Male with isolated teratozoospermia or associated with asthenozoospermia and / or oligozoospermia and / or necrozoospermia defined according to WHO recommendations (WHO guidelines, 2010) and the David amended classification (Auger et al., 2001) with normal constitutional karyotype (46, XY) exposed to cannabis; The exposure to cannabis is not an intervention in the study but is a pre-condition for inclusion. Blood intake and semen samples collection are done. Questionnaire about cannabis consumption are assessed to patient.
2945863|NCT02932527|Other|infertile men not exposed to cannabis|Male with isolated teratozoospermia or associated with asthenozoospermia and / or oligozoospermia and / or necrozoospermia defined according to WHO recommendations (WHO guidelines, 2010) and the David amended classification (Auger et al., 2001) with normal constitutional karyotype (46, XY) not exposed to cannabis; The exposure to cannabis is not an intervention in the study but is a pre-condition for inclusion. Blood intake and semen samples collection are done. Questionnaire about cannabis consumption are assessed to patient.
2945864|NCT02932514|Experimental|Eversense (Senseonics) CGM System|
2945865|NCT02932501||MRONJ|"Patients diagnosed of medication-related osteonecrosis of the jaw (MRONJ). Treatment strategies vary depending on the stage of MRONJ and can be of different nature as:~Conservative treatment Surgical treatment Adjuvant non-surgical treatment"
2945866|NCT02932488|Experimental|Sumatriptan|"In the pilot study (an MR-only study) subjects will receive up to five doses of sumatriptan in the range of 10 ug/kg to 80 ug/kg. This allows us to establish a dose-response curve for each subject. Administration of sumatriptan in the pilot study will be spaced with approximately one week apart to avoid carry-over effects of the drug.~In the main study (a PET-MR study), the sumatriptan dose with the maximal effect size and minimum side effects will be used for all subjects."
2945867|NCT02932475|Active Comparator|Treatment|Metformin 1000 mg twice a day
2945868|NCT02932475|Sham Comparator|Placebo|Placebo, identical to Metformin
2945869|NCT02932462|Experimental|DSXS 1535|DSXS 1535 topical product
2945870|NCT02932462|Placebo Comparator|Placebo|Vehicle
2945871|NCT02932436|Experimental|Empagliflozin|10 mg Empagliflozin daily per os for 12 weeks
2945872|NCT02932436|Experimental|Placebo|amount of Placebo corresponding to empagliflozin 10 mg daily per os for 12 weeks
2945873|NCT02932423|Other|1 - Snack|Each subject will consume 6 beverages with varying sugar content at lunch (500 ml) and with a snack in the afternoon (330 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.
2945874|NCT02932423|Other|2 - No snack|Each subject will consume 6 beverages with varying sugar content only at lunch (500 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.
2945875|NCT02932410|Experimental|Macitentan|Macitentan is administered once daily via oral route
2945876|NCT02932410|Other|Standard-of-care|Standard-of-care as per site's clinical practice which may comprise treatment with PAH non-specific treatment and/or up to two PAH-specific medications excluding macitentan and i.v./s.c. prostanoids.
2945877|NCT02932397|Active Comparator|Propofol|Active drug given to patients as an intravenous dose of 0.5 mg/kg of propofol
2945878|NCT02932397|Placebo Comparator|Saline solution|Placebo drug given to patients as an intravenous dose of 0.05 mL/kg of saline solution (NaCl 0.9%)
2945879|NCT02932384|Active Comparator|Control-Passport Only|"Complete a needs assessment and develop a written Passport to Wellness, an itemized set of health promoting behaviors and services aligned with lifestyle and goals. Participants are compensated based on the items they complete, services they attend."
2945880|NCT02932384|Experimental|Intervention-Passport and Peer Mentor|"In addition to the Passport to Wellness developed with project staff, study participants will select a peer mentor trained in motivational interviewing. The peer mentor will help guide the participant to complete passport items. Part of passport development will include compensation for meeting with peer mentors to form strategies for meeting goals and addressing barriers/challenges that arise."
2945882|NCT02932358|Active Comparator|Flexible Family Visitation Model (FFVM)|In the FFVM, two or fewer family members will be allowed to visit the patient for up to 12 consecutive hours each day. In addition to family visitation, patients will be allowed to receive social visits in specific time intervals (according local ICU regulation). To have access to the FFVM, family members of ICU patients will have to attend a structured meeting at ICU in which they will receive orientations about the ICU environment, common ICU treatments, rehabilitation and basic infection control practices, multidisciplinary work at ICU and palliative treatment. Social visitors will not be required to attend the structured meeting.
2945883|NCT02932358|Active Comparator|Restrictive Family Visitation Model (RFVM)|In the RFVM, patients will be allowed to receive restricted visits according routine ICU practices, but respecting the maximum limit of 4.5 hours of visitation per day. Visitors will not be required to attend the structured meeting. The length of ICU visits will be similar to those of social visits in the FFVM.
2945884|NCT02932345||Long-term survivors group (case)|EGFR M+ aNSCLC patients who continuously received gefitinib for at least 3 years
2945885|NCT02932345||Rapid PD group (control)|EGFR M+ aNSCLC patients who had undergone PD after gefitinib treatment≤3 months
2945886|NCT02932332|Active Comparator|High-flow oxygen: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with High-flow oxygen (HFOx) is followed by 3 different breathing therapies of Low-flow oxygen (LFOx), High-flow air (HFAir), and Low-flow air (LFAir) with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
2945887|NCT02932332|Active Comparator|Low-flow oxygen: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with Low-flow oxygen (LFOx) is followed by 3 different breathing therapies of HFOx, HFAir, and LFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
2945888|NCT02932332|Sham Comparator|High-flow air: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with High-flow oxygen (LFOx) is followed by 3 different breathing therapies of HFOx, LFOx, and LFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
2945889|NCT02932332|Sham Comparator|Low-flow air: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with Low-flow air (LFAir) is followed by 3 different breathing therapies of HFOx, LFOx, and HFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
2945890|NCT02932319|Active Comparator|Foley catheter|The patient will have an induction at home after 60 mn of fetal heart rate monitoring.
2945891|NCT02932319|Sham Comparator|Expectative|The patient in this arm will have the actual care (expectative until the next day befor starting the induction)
2945892|NCT02932306|Experimental|IDP-121 Lotion|IDP-121 Lotion
2945893|NCT02932306|Active Comparator|IDP-121 Vehicle Lotion|IDP-121 Vehicle Lotion Vehicle
2945894|NCT02932293|Experimental|SOF+DCV+SMV 3-4 wks|Patients without cirrhosis will receive sofosbuvir, daclatasvir and simeprevir for (a) 3 weeks if HCV viral load on day 2 is <500 IU/ml or (b) 4 weeks if HCV viral load on day 2 is >500 IU/ml.
2945895|NCT02932293|Experimental|SOF+DCV+SMV 6-8 wks|Patients with cirrhosis and CP-A will receive sofosbuvir, daclatasvir and simeprevir (a) 6 weeks if HCV VL on day 2 is <500 IU/ml or (b) 8 weeks if HCV VL on day 2 is >500 IU/ml.
2945896|NCT02932280|Experimental|Neratinib|There are 2 parts to this study: a Phase I part and a Phase II part. The Phase I portion is known as the dose escalation phase where neratinib will be tested in groups of 3-6 patients to establish the maximum tolerated dose (MTD). The phase II portion will determine whether the MTD shows a response to the tumor.
2945897|NCT02932267|Experimental|Adapalene / BPO gel|Adapalene 0.3% / BPO 2.5% gel, once daily in the evening
2945898|NCT02932254|Active Comparator|Magnesium Sulfate|"After anaesthesia induction and calibration of neuromuscular monitoring (acceleromyography) 0,6 mg/kg of rocuronium is given intravenously.~After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) or reappearance of 2 twitches of the train of four (moderate neuromuscular block), 4 mg/kg (deep neuromuscular block) or 2 mg/kg (moderate neuromuscular block) of sugammadex are given intravenously.~INTERVENTION: After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution)."
2945899|NCT02932254|Placebo Comparator|Saline Solution|"After anaesthesia induction and calibration of neuromuscular monitoring (acceleromyography) 0,6 mg/kg of rocuronium is given intravenously.~After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) or reappearance of 2 twitches of the train of four (moderate neuromuscular block), 4 mg/kg (deep neuromuscular block) or 2 mg/kg (moderate neuromuscular block) of sugammadex are given intravenously.~INTERVENTION: After 90% of baseline T4 / T1, are injected intravenously 100 mL saline solution over 10 minutes."
2945900|NCT02932241|Experimental|Computerized DBT skills training|The Computerized Dialectical Behavior Therapy Skills Training (cDBT) intervention includes 4 mindfulness, 6 emotion regulations, 2 distress tolerance, and 4 addiction skills. cDBT will retain the essence of DBT skills by being didactically focused, having a predetermined agenda driven by skills to be taught, emphasizing modeling through video vignettes, incorporating in session practice of skills whenever feasible, reviewing homework at beginning of sessions before teaching new skills, and assigning practice between sessions.
2945901|NCT02932241|No Intervention|Waitlist|A waitlist (WL) control condition was chosen considering the pilot nature of the study, feasibility, and the overall goal of assessing treatment's promise. Participants will be assessed for drinking and suicidal urges in the same manner as in the cDBT condition. After 8 weeks, subjects will be able to enroll in the intervention.
2945902|NCT02932228|Experimental|ImPACT|Patients in ImPACT receive intensive outpatient care from the ImPACT team. The ImPACT team augments existing PACT primary care with intensive services delivered by a multidisciplinary team (including a physician, nurse practitioner, social worker, recreational therapist, and program coordinator). ImPACT program elements include a comprehensive patient assessment, identification and tracking of patients' goals and priorities, care management for medical and social service needs, co-attendance at specialty care appointments, and coordination of care with VA and non-VA providers, including during and after hospitalization.
2945978|NCT02931799|Active Comparator|Minimal Intervention|
2946021|NCT02931578|Active Comparator|Glucose42|Participants in this arm will randomly receive 42% glucose in the OGTT drink 3 out of 9 visits.
2945903|NCT02932228|No Intervention|PACT|Patients in PACT receive usual VA primary care through the VA's Patient Centered Medical Home. VA primary care is delivered by PACT teamlets that comprise a primary care provider, nurse, clinical associate, and administrative associate who are supported by social work, pharmacy, and behavioral health services.
2945904|NCT02932215|Experimental|All participants|All participants will receive open label lorcaserin
2945905|NCT02932202|Experimental|Longitudinal Nutritional Counseling|The intervention group will be contacted every 2 weeks by medical students over the phone to provide nutrition counseling and complete a verbal survey. During the phone calls, participants will be asked a series of questions regarding their dietary intake over the course of the last 2 weeks. If any deficiencies are identified, participants will be counseled on those topics
2945906|NCT02932202|Placebo Comparator|Standard Care Counseling|Participants in the control group will receive standard counseling, which includes weights at every visit, and counseling on weight gain goals as perceived necessary by the provider.
2945907|NCT02932189|No Intervention|Control|Procedure: Ventilator weaning in the conventional way with a tracheal collar.
2945908|NCT02932189|Experimental|Intervention|"Procedure: Ventilator weaning with a tracheal collar after inspiratory muscle training with an isokinetic device.~Device: K5 Power Breath"
2945909|NCT02932176||Non-invasive vascular testing|All patients undergoing non-invasive vascular testing will be eligible for this study. The official results will be used to develop the algorithm and to evaluate the accuracy of the algorithm
2945910|NCT02932150|Experimental|TAF (Cohort 1)|Participants (12 to < 18 years) weighing ≥ 35 kg will receive TAF 25 mg tablet for 24 weeks
2945911|NCT02932150|Placebo Comparator|Placebo (Cohort 1)|Participants (12 to < 18 years) weighing ≥ 35 kg will receive placebo tablet for 24 weeks
2945912|NCT02932150|Experimental|TAF (Cohort 2 Group 1)|Participants (6 to < 12 years) weighing ≥ 25 kg will receive TAF 25 mg tablet for 24 weeks
2945913|NCT02932150|Experimental|TAF (Cohort 2 Group 2)|Participants (6 to < 12 years) weighing 17 kg to < 25 kg will receive TAF 15 mg tablet for 24 weeks
2945914|NCT02932150|Experimental|TAF (Cohort 2 Group 3)|Participants (2 to < 6 years) weighing < 17 kg who are unable to swallow a tablet will receive oral granules of TAF (dose to be determined) for 24 weeks.
2945915|NCT02932150|Experimental|TAF (Cohort 2 Placebo)|Participants will receive matching placebo of TAF (tablet or oral granules) for 24 weeks.
2945916|NCT02932150|Experimental|Open-Label TAF|Following 24 weeks of blinded randomized treatment, participants will be eligible to participate in an open-label extension phase to receive TAF for an additional 216 weeks.
2945917|NCT02932137|Experimental|Interleukin-2|Interleukin-2 to treat activated SLE.
2945918|NCT02932137|No Intervention|Traditional therapy|Treat activated SLE with glucocorticoid or immunosuppressor.
2945919|NCT02932124||1|manual chest compressions
2945920|NCT02932124||2|mechanical chest compression
2945921|NCT02932111|Experimental|Osteopathic session|The osteopath put fingers on abdominal projection of the junction and sinks deeply into the abdomen until it perceives the trigger zone. Once in contact with the sphincter, it performs friction in the hourly sense, vibration, inhibitions or rebounds.
2945922|NCT02932111|Placebo Comparator|Placebo manipulative session|The Osteopath will touch the patient's limbs at the same place of osteopathic manipulative treatment, but without any intention of treatment and without any known and indexed reproduction techniques to simulate an osteopathic treatment, without its benefits.
2945923|NCT02932098|Experimental|App Notifications|The web-based app will be used to remind patients of discharge instructions, ask questions related to current prescription pain medication use, new symptoms, or changes in the severity of symptoms. Patients will receive reminders via text or email to use the app. Daily reminders will be sent in Week 1, every other day in Week 2, and once per week for Weeks 3-4. All participants will be followed for a minimum of 30 days and will be asked to complete a baseline survey at enrollment and a follow-up survey scheduled 30 days after hospital discharge.
2945924|NCT02932098|Active Comparator|Usual Care|Patients will have access to the web-based app, but will not receive reminders to use it. All participants will be followed for a minimum of 30 days and will be asked to complete a baseline survey at enrollment and a follow-up survey scheduled 30 days after hospital discharge.
2945925|NCT02932085|Active Comparator|rTMS + Wash-out period + Sham|"Five consecutive daily repetitive transcranial magnetic stimulation sessions (Neurostar TMS Therapy System, NeuroStar XPLOR System)~Two weeks wash-out period~Five consecutive daily sham stimulation sessions"
2945926|NCT02932085|Sham Comparator|Sham + Wash-out period + rTMS|"Five consecutive daily sham stimulation sessions (Neurostar TMS Therapy System, NeuroStar XPLOR System)~Two weeks wash-out period~Five consecutive daily repetitive transcranial magnetic stimulation sessions"
2945927|NCT02932059|Experimental|Adult schizophrenic patients (18-45 years)|4 groups formed by the case-control study in two age strata
2945928|NCT02932059|Experimental|Aged patients with schizophrenia (≥ 55 years)|4 groups formed by the case-control study in two age strata
2945929|NCT02932059|Experimental|Adults controls (18-45 years)|4 groups formed by the case-control study in two age strata
2945930|NCT02932059|Experimental|Aged Controls (≥ 55 years)|4 groups formed by the case-control study in two age strata
2945931|NCT02932046||Standardized noon meal|"Patients with anorexia nervosa during in-patient treatment are rating hunger and satiety on a visual analogue scale before and after a standardized and supervised meal. The meal is treatment as usual in a specialized ward. A patient may participate several times, if readmitted."
2945932|NCT02932033|Active Comparator|Tack fixation|consecutive patients with bilateral inguinal hernias will be recruited for TEP repair. Mesh fixation methods with spiral tack is randomly assigned to one side, then comparative fixation method to the contralateral side. In group of active comparator, after randomization, the target inguinal hernia side of the patient has the mesh fixed with titanium spiral tacks.
2945933|NCT02932033|Experimental|Synthetic glue fixation|The same patient, his contralateral side of inguinal hernia, has the mesh fixed with synthetic glue.
2945934|NCT02932020|Experimental|Group A|"Randomized 10 subjects~Visit 1:~1st contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine interlaminar epidural injection of (a) 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI~Visit: 6 weeks (+7days): 2nd contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine"
2946022|NCT02931565|Experimental|IW-1701|Single 5-mg dose of IW-1701 administered orally
2945935|NCT02932020|Other|Group B|"Randomized 10 subjects~Visit 1:~1st contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine interlaminar epidural injection 2mL 0.5% marcaine and 1mL and 1mL steroid (depomedrol 80mg/ml).~Visit 6 weeks (+7days): 2nd contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine"
2945936|NCT02932007|Experimental|Chloroquine Phosphate|Chloroquine Phosphate will be provided at 500 mg dosage strength for oral administration. Patient will be instructed to take 2 tablets per day on the first two days and 1 tablet each day for the next 12 days for a total of 14 days treatment.
2945937|NCT02931994|No Intervention|Group A Phase 1|50% of sample are randomly assigned to Group A and are to utilise conventional flossing technique in the first phase of 6-weeks
2945938|NCT02931994|Active Comparator|Group B Phase 1|50% of sample are randomly assigned to Group B and are to utilise knotted floss technique in the phase 1 of 6-weeks
2945939|NCT02931994|Active Comparator|Group A Phase 2|After a washout period of 2 weeks, those from Group A will use the knotted floss technique for a period of 6 weeks.
2945940|NCT02931994|No Intervention|Group B Phase 2|After a washout period of 2 weeks, those from Group B will use the conventional floss technique for a period of 6 weeks.
2945941|NCT02931968||Monolithic zirconia prosthesis|Subjects previously treated with at least one arch (maxilla/mandible) of dental implants restored with a full-arch monolithic zirconia implant supported fixed dental prosthesis will be recalled for clinical and radiographic examination.
2945942|NCT02931955||Venom Group|"The investigators plan to include 15 patients with insect venom allergy and will collect blood at four time points and stool at three time points during the first week of immunotherapy.~The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients."
2945943|NCT02931955||Pollen Group|"The investigators plan to include 15 patients with pollen allergy and will collect blood at five time points and stool at three time points during the first three months of immunotherapy.~The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients."
2945944|NCT02931942||A: Acute leukemia|Patients that will receive intensive clinical chemotherapy for acute leukemia or high risk myelodysplasia (RAEB2) Blood withdrawn 5-7 x
2945945|NCT02931942||B: Autologous transplantation|Patients that will receive high dose chemotherapy and autologous stem cell rescue for varies hematological malignancies Blood withdrawn 5-7 x
2945946|NCT02931942||C: controls|Healthy controls, found amongst family members of patients of group A and B Blood withdrawn 5-7 x
2945947|NCT02931942||D: lung cancer|Patients that will receive relatively mild immunosuppressive chemotherapy for lung cancer, that will mostly be in the outpatient setting Blood withdrawn 5-7 x
2945948|NCT02931942||E: colon cancer|Patients that will receive relatively mild immunosuppressive chemotherapy for colon cancer, that will mostly be in the outpatient setting and mostly adjuvant Blood withdrawn 5-7 x
2945949|NCT02931942||F: controls|Healthy controls, found amongst family members of patients of group D and E Blood withdrawn 5-7 x
2945950|NCT02931929|Other|68Ga-NeoBOMB1|68Ga-NeoBOMB1, 2-vial kit for radiolabelling. I.v. Administration after radiolabelling
2945951|NCT02931916||healthy group|recruited for evaluation of system reliability
2945952|NCT02931916||Chronic Ankle Instability group|recruited for evaluation of system validity
2945953|NCT02931903|Experimental|Hybrid superstructure|Vita Enamic is a hybrid ceramic, consisting of composite and ceramic. The ceramic; compatible and high aesthetics while the composite; resilient material with low modulus of elasticity which will absorb stress and therefore decrease load on bone and eventually decrease crestal bone loss
2945954|NCT02931903|Active Comparator|Ceramic superstructure|IPS Emax, is the mostly used ceramic superstructures in implant supported restorations.
2945955|NCT02931890|Active Comparator|neo-adjuvant chemotherapy followed by surgery|4 courses of 3 weekly DOC followed by surgery
2945956|NCT02931890|Active Comparator|neo-adjuvant chemo and subsequent CRT followed by surgery|2 courses of 3 weekly DOC and subsequent CRT followed by surgery
2945957|NCT02931890|Active Comparator|neo-adjuvant chemoradiotherapy followed by surgery|chemoradiotherapy followed by surgery
2945958|NCT02931877|Experimental|Sevoflurane|Maintenance of anesthesia with sevoflurane during the cardiac valvular surgery.
2945959|NCT02931877|Active Comparator|Propofol|Maintenance of anesthesia propofol during the cardiac valvular surgery.
2945960|NCT02931864|No Intervention|Usual care group|Usual care is meant the routine medical and health care services at the hospital.
2945961|NCT02931864|Experimental|Experimental group|Five weekly sessions of online symptom management + mindfulness training programme + usual care
2945962|NCT02931864|Active Comparator|Comparison group 1|Five weekly sessions of online symptom management programme + usual care
2945963|NCT02931864|Active Comparator|Comparison group 2|Five weekly sessions of online mindfulness training programme and usual care
2945964|NCT02931851|Placebo Comparator|Placebo|Standard Information
2945965|NCT02931851|Active Comparator|Intervention|Professionally developed website for relatives of ICU patients
2945966|NCT02931838|Experimental|BMS-986165 Dose 1|Specified dose of BMS-986165 on specified days.
2945967|NCT02931838|Experimental|BMS-986165 Dose 2|Specified dose of BMS-986165 on specified days.
2945968|NCT02931838|Experimental|BMS-986165 Dose 3|Specified dose of BMS-986165 on specified days.
2945969|NCT02931838|Experimental|BMS-986165 Dose 4|Specified dose of BMS-986165 on specified days.
2945970|NCT02931838|Experimental|BMS-986165 Dose 5|Specified dose of BMS-986165 on specified days.
2945971|NCT02931838|Placebo Comparator|Placebo|Specified dose of Placebo for BMS-986165 on specified days.
2945972|NCT02931825|Experimental|Reminder letter|A letter is sent for remind the importance of compliance with colonoscopy AND to encourage people to to consult their general practitioner or gastroenterologist (if they haven't done their follow-up in time).
2945973|NCT02931825|No Intervention|Control|No intervention (what is done currently)
2945974|NCT02931812||Cirrhotic subjects|15 cirrhotic patients in end-stage in waiting a graft
2945975|NCT02931812||Chronic kidney disease subjects|15 chronic kidney disease patients in end-stage in waiting a graft
2945976|NCT02931812||Healthy subjects|30 healthy subjects to compare
2945977|NCT02931799|Experimental|Nurse Follow-Up and Electronic Monitoring|
2945979|NCT02931786|Active Comparator|propofol|body core temperature was measured from tympanic membrane after 1 mg/kg propofol administration, before and after magnetic resonance imaging
2945980|NCT02931786|Active Comparator|ketofol|body core temperature was measured from tympanic membrane after 0,1 ml/kg administration of ketamine propofol mixture of 10 mg/ml both, before and after magnetic resonance imaging
2945981|NCT02931773||Control|Probands having normal fasting glucose and having a head up tilt test with Task Force® Monitor.
2945982|NCT02931773||Pre-Diabetes|Patients having normal fasting glucose and abnormal Oral Glucose tolerance test and having a head up tilt test with Task Force® Monitor.
2945983|NCT02931773||Recently diagnosed Diabetic patients|Patients being diagnosed as Diabetics type in the recent five years and having a head up tilt test with Task Force® Monitor
2945984|NCT02931760|Active Comparator|subcutaneous pacemaker|The patients who are randomized to receive a subcutaneously implanted pacemaker
2945985|NCT02931760|Active Comparator|intramuscular pacemaker|The patients who are randomized to receive an intramuscular implanted pacemaker
2945986|NCT02931747|Placebo Comparator|Placebo|Subjects are received the pill of placebo which has same color, shape and smell like the Bacopa Monnieri once daily for 16 weeks.
2945987|NCT02931747|Active Comparator|Bacopa Monnieri 300 mg/day|Subjects are received the pill of Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks
2945988|NCT02931747|Active Comparator|Bacopa Monnieri 600 mg/day|Subjects are received the pill of Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks
2945989|NCT02931734|Active Comparator|Resin modified glass ionomer (RMGI)|Resin modified glass ionomer; an application every 48 hours; 4 sessions.
2945990|NCT02931734|Active Comparator|Potassium Nitrate 2% (KF)|Potassium Nitrate and Sodium fluoride 2%; an application every 48 hours; 4 sessions.
2945991|NCT02931734|Active Comparator|Low level laser therapy - GaAlAs (LLLT)|Low level laser therapy - GaAlAs; an application every 48 hours; 4 sessions.
2945992|NCT02931734|Active Comparator|RMGI and KF|Resin modified glass ionomer and potassium nitrate and sodium fluoride 2%; an application of the two associated products, every 48 hours; 4 sessions.
2945993|NCT02931734|Active Comparator|RMGI and LLLT|Resin modified glass ionomer and Low level laser therapy - GaAlAs; an application of the two associated products, every 48 hours; 4 sessions.
2945994|NCT02931734|Active Comparator|KF and LLLT|Potassium Nitrate and Sodium fluoride 2% and Low level laser therapy - GaAlAs; an application of the two associated products, every 48 hours; 4 sessions.
2945995|NCT02931734|Active Comparator|RMGI, KF, LLLT|Resin modified glass ionomer, potassium nitrate and sodium fluoride 2% and Low level laser therapy - GaAlAs ; an application of the three associated products, every 48 hours; 4 sessions.
2945996|NCT02931721||MRI Positive|Men with sperm found in MD-TESE
2945997|NCT02931721||MRI Negative|Men with no sperm found in MD-TESE
2945998|NCT02931708|Experimental|DFES group|"Diaphragm Functional Electrical Stimulation:~Each session will last 30 minutes. The parameters selected in the stimulator will be: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance.~The patient will be positioned supine, headboard 30º, knees extended. Furthermore, the electrodes used to perform the electrical stimulation will be adhesive, disposable and hypoallergenic. These will be placed at sixth, seventh and eighth intercostal spaces, axiliar medium line and paraxiphoid both chest sides."
2945999|NCT02931695|Other|pregnant women|"Women during third trimester of pregnancy and in the first trimester of post partum~ECG~circulating sex hormones levels"
2946000|NCT02931695|Other|women in the first trimester of post partum|"Women (same in first arm) in the first trimester of post partum~ECG~circulating sex hormones levels"
2946001|NCT02931669||Adult AAC users|Will be accessed via online forums to fill in online anonymous survey link
2946002|NCT02931669||Children who use AAC|Parents at local special schools will be given the opportunity for their child to participate in a face to face symbol based interview. They will give written consent and children's assent will also be obtained.
2946003|NCT02931669||Family members|The paper version of the survey will be distributed among parents at local special schools for them to fill in at home with their families. Online groups of families will also be sent the online survey link.
2946004|NCT02931669||Teachers|Teachers at local special schools will be given the paper survey forms. Online groups of teachers will receive the online link.
2946005|NCT02931669||Health Professionals|Online groups of health professionals will receive the online link
2946006|NCT02931656|Experimental|GDM aquatic exercise|GDM Diagnosis criteria accordance with to IADPSG / WHO
2946007|NCT02931656|Active Comparator|Control Group aquatic exercise|No change in blood glucose levels Group, investigated between 24-28 weeks of gestation.
2946008|NCT02931643|Placebo Comparator|High fat challenge breakfast|High fat breakfast without mixed-spices (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
2946009|NCT02931643|Experimental|High fat challenge breakfast with mixed-spices|High fat breakfast with mixed-spices (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
2946010|NCT02931630|Experimental|HP/HF|Whey protein powder / High fiber bread
2946011|NCT02931630|Experimental|HP/LF|Whey protein powder / Low fiber bread
2946012|NCT02931630|Experimental|LP/HF|Maltodextrin powder / High fiber bread
2946013|NCT02931630|Experimental|LP/LF|Maltodextrin powder / Low fiber bread
2946014|NCT02931617|Active Comparator|Physiotherapy w/Positive end expiratory pressure training|Chest Physiotherapy w/Positive end expiratory pressure training; post therapy lung volume measurements
2946015|NCT02931617|Experimental|Physiotherapy w/Inspiratory force training|Chest Physiotherapy w/Inspiratory force training; post therapy lung volume measurements
2946016|NCT02931604|Experimental|Sinus irrigation|Sinus irrigation intervention
2946017|NCT02931591|Active Comparator|GH+Metformin|The children will be given both Growth Hormone and Metformin for 6 months
2946018|NCT02931591|Placebo Comparator|GH+Placebo|Children will be given both GH and Placebo for 6 months
2946019|NCT02931578|Active Comparator|Glucose100|Participants in this arm will randomly receive 100% glucose in the OGTT drink 3 out of 9 visits.
2946020|NCT02931578|Active Comparator|Glucose50|Participants in this arm will randomly receive 50% glucose in the OGTT drink 3 out of 9 visits.
2946024|NCT02931552|Experimental|Nuevo Amancer-II Stress Management Program|Nuevo Amanecer-II (NA-II) is a 10-week peer-delivered cognitive-behavioral stress management program. Participants receive the stress management program as soon as possible after randomization.
2946025|NCT02931552|No Intervention|Wait-list Control Group|Waits six months and at the end of the six months is offered the option of receiving the NA-II program.
2946026|NCT02931539|Experimental|Maribavir Treatment|Two 200 mg tablets will be taken by mouth twice daily
2946027|NCT02931539|Active Comparator|Investigator-Assigned Treatment|Anti-CMV agent best suited to treat the respective subject. Agents of choice include: ganciclovir, valganciclovir, foscarnet, or cidofovir
2946028|NCT02931526||Group CRRT|Patients who need to treat with tigecycline for bacterial infection, have renal insufficiency and have to treat with CRRT
2946029|NCT02931526||Group non-CRRT|Patients who need to treat with tigecycline for bacterial infection, have normal renal function in ICU and have no need to treat with CRRT
2946030|NCT02931513||PBC patients|Patients with primary biliary cholangitis
2946031|NCT02931487|Experimental|ABM +|Attentional Bias Modification
2946032|NCT02931487|Sham Comparator|ABM sham|Sham. No Attentional Bias Modification
2946033|NCT02931474|Placebo Comparator|Placebo|Salt Water Solution
2946034|NCT02931474|Experimental|Tesamorelin|Growth Hormone-Releasing
2946035|NCT02931461|Experimental|needle Procore ®|
2946036|NCT02931461|Active Comparator|needle Cook®|
2946037|NCT02931435|Active Comparator|Nerve Block with Radiofrequency Ablation|A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator activation.
2946038|NCT02931435|Sham Comparator|Nerve Block with Sham Radiofrequency Ablation|A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance.Control patients will undergo the same procedure without RF generator activation. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator sham activation.
2946039|NCT02931422|Experimental|Low Financial Incentive|Conditional cash transfer upon HIV testing
2946040|NCT02931422|Experimental|Medium Financial Incentive|Conditional cash transfer upon HIV testing
2946041|NCT02931422|Experimental|High Financial Incentive|Conditional cash transfer upon HIV testing
2946042|NCT02931409|Experimental|Optimal PEEP|Patients submitted to general anesthesia and open radical cystectomy and urinary diversion (20 subjects) will be submitted an alveolar recruitment maneuver using the sustained airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds followed by a decremental PEEP titration procedure directed by static pulmonary compliance (Cstat). During PEEP titration procedure PEEP will be decreased from 14 cmH2O by 2 cmH2O every 4 minutes, until a final PEEP of 6 cmH2O. Optimal PEEP is considered as a PEEP value resulting the highest possible Cstat measured by ventilator. After PEEP titration procedure a lung protective mechanical ventilation will be performed using optimal PEEP and low tidal volumes (6 mL/Kg IBW).
2946043|NCT02931409|Active Comparator|Standard PEEP|Patients submitted to general anesthesia and open radical cystectomy and urinary diversion (20 subjects) will be submitted an alveolar recruitment maneuver using the sustained airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds followed by a standard lung protective mechanical ventilation using a PEEP value of 6 cmH2O and low tidal volumes (6 mL/Kg).
2946044|NCT02931396|Experimental|FES intervention|Study participants who are randomized into the intervention group will be fitted with a portable commercially available surface FES device and instructed in its use by a study investigator. Participants will be directed to use the FES 30 minutes a day for the first week, one hour a day during the next week, 90 minutes a day during the third week, and then a minimum of 2 hours per day or 10 hours per week for the next three months at home.
2946045|NCT02931396|No Intervention|Control|Participants will be asked to continue their activities of daily living as usual.
2946046|NCT02931383|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg once daily (QD) and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
2946047|NCT02931383|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
2946048|NCT02931370||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
2946049|NCT02931357|Experimental|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day.
2946050|NCT02931357|Active Comparator|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
2946051|NCT02931344|Experimental|Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
2946052|NCT02931331||Observational|Patients undergoing standard of care (PET stress testing followed by mechanical revascularization) are undergoing an additional PET stress test to determine the impact of revascularization.
2946053|NCT02931318|Experimental|Nevsehir|People Living in the City Center of Nevşehir
2946054|NCT02931305|Experimental|Epimedium Prenylflavonoids Extract|Single oral doses of EP (370 mg, 740 mg and 1110 mg) capsules would be orally administered.
2946055|NCT02931305|Placebo Comparator|Placebo|Single oral doses of Placebo (370 mg, 740 mg and 1110 mg) capsules would be orally administered.
2946056|NCT02931292||Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
2946124|NCT02930733|Placebo Comparator|ultrasound guided sham block|Bilateral ultrasound guided sham block with 2 ml saline subcutaneously
2946057|NCT02931253|Experimental|Metformin Group|"Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.~Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks."
2946058|NCT02931253|No Intervention|Control Group|Standard of care - ablation only
2946059|NCT02931240|Experimental|Treatment|Treatment with the Revivent TC System
2946060|NCT02931240|No Intervention|Control Pool|Treatment with Guideline Directed Medical Therapy for Heart Failure Symptoms Only
2946061|NCT02931227|Experimental|Brain-injured group|
2946062|NCT02931227|Experimental|Hypothermia group|
2946063|NCT02931227|Experimental|Hyperthermia group|
2946064|NCT02931227|Experimental|PICCO group|
2946065|NCT02931214|Experimental|GMI-1359|Dose escalation
2946066|NCT02931214|Experimental|Placebo|Dose escalation
2946067|NCT02931201|Experimental|DLBCL patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
2946068|NCT02931188||Anacetrapib|Participants who received anacetrapib, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
2946069|NCT02931188||Placebo|Participants who received placebo, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
2946070|NCT02931175|Experimental|Group 1|Mandatory twice a week (Mondays and Thursdays) treatment with SC ACTH gel 80 U/day starting at BL until month 6. Starting at month 6, the treatment will be administered on as needed basis, based on the retreatment criteria.
2946071|NCT02931175|Experimental|Group 2|Mandatory thrice a week (Mondays, Wednesdays, and Fridays) treatment with SC ACTH gel 80 U/day starting at BL until month 6. Starting at month 6, the treatment will be administered on as needed basis, based on the retreatment criteria.
2946072|NCT02931162|Experimental|Herb-partitioned moxibustion|Drug: Herbal cake, Device: Moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Herbal cakes with moxa cones will be positioned at acupuncture points ST25 and ST37. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
2946073|NCT02931162|Sham Comparator|Sham herb-partitioned moxibustion|Drug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25 and ST37. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
2946074|NCT02931149|Experimental|Submucosal injection with PRP|All participants in the study received submucosal injection of PRP prior to endoscopic resection
2946075|NCT02931136|Active Comparator|treatment group|Huperzine A treatment.
2946076|NCT02931136|Placebo Comparator|Placebo group|The placebo in 52 weeks.
2946077|NCT02931123|No Intervention|standard|
2946078|NCT02931123|Experimental|treatment|rifaximine and lattulose plus low proteine diet
2946079|NCT02931110|Experimental|CBL0137 Dose Escalation|"Dose Level 1: 150mg/m2, IV~Dose Level 2: 180mg/m2, IV~Dose Level 3: 240mg/m2, IV~Dose Level 4: 320mg/m2, IV~Dose Level 5: 400mg/m2, IV~Dose Level 6: 540mg/m2, IV~Dose Level 7: 700mg/m2, IV~Dose Level 8: 920mg/m2, IV~Dose Level 9: 1200mg/m2, IV~Dose Level 10: 1600mg/m2, IV~Dose Level 11: 2100mg/m2, IV~Dose Level 12: 2700mg/m2, IV"
2946080|NCT02931097|Active Comparator|Pedunculopontine stimulation|Deep brain stimulation of the pedunculopontine area
2946081|NCT02931097|Active Comparator|Pontomesencephalic stimulation|Deep brain stimulation of the pontomesencephalic area
2946082|NCT02931097|Sham Comparator|Sham stimulation|No deep brain stimulation
2946083|NCT02931084||ACL injury|Patients with an acute (not more than 6 weeks old) anterior cruciate ligament (ACL) injury
2946084|NCT02931084||ACL reconstruction|Some of the patients with ACL injury will have reconstruction of the ACL. These will be followed as a new group.
2946085|NCT02931071|Experimental|plerixafor and filgrastim treatment|to assess the safety and efficacy of CD34+ cells mobilization with plerixafor and filgrastim
2946086|NCT02931058|Active Comparator|Group 2|"Two knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
2946087|NCT02931058|Active Comparator|Group 4|"Four knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
2946088|NCT02931058|Active Comparator|Group 6|"Six knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
2946089|NCT02931045|Active Comparator|Ticagrelor|Ticagrelor: oral, 180 mg once (loading dose) followed by 90 mg twice daily (maintenance dose)
2946090|NCT02931045|Active Comparator|Clopidogrel|Clopidogrel: oral, 300 mg or 600 mg once (loading dose) followed by 75 mg once daily (maintenance dose)
2946091|NCT02931032|Experimental|Patients of Student Dental clinic|"Enrolled patients of the student dental clinic in Hadassah Faculty of Dental Medicine, who came to receive scheduled dental treatment and agreed to participate in the trial.~The patients sampled will originate at the students' clinics, and the samples will be taken as part of their dental treatment, namely: removal of caries and infected dentin for future restoration, and dental calculus and plaque removal for the treatment of periodontal disease."
2946125|NCT02930707|Active Comparator|Magnesium group|patients received ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulphate 10% (200 mg), on each side of the abdominal wall.
2946363|NCT02929173|Experimental|Group 1|Bio HPP crown is a hybrid crown
2946092|NCT02931019|Experimental|neck flexion first|"With specific head posture, intubation is done under flexible fiberoscopy guide.~In this arm, at the position with neck flexion, fiberoscopy is pulled into the mouth and get the photo of laryngeal view. After then, neck position is changed to neck extension, And the laryngeal view is gotten in the same way."
2946093|NCT02931019|Experimental|neck extension first|In this arm, at the position with neck extension, fiberoscopy is pulled into the mouth and get the photo of laryngeal view. After then, neck position is changed to neck flexion, And the laryngeal view is gotten in the same way.
2946094|NCT02931006|Placebo Comparator|control|
2946095|NCT02931006|Active Comparator|experimental|
2946096|NCT02930993|Experimental|anti-mesothelin CAR T cells|"Dose escalation study aimed to assess the safety and efficacy of anti-mesothelin CAR T cells.~CAR T dosage ranging from 5×10^4 /kg to 1×10^7 /kg will be tested ."
2946097|NCT02930980|Experimental|Investigational Software|Investigational Software loaded on Micra device
2946098|NCT02930967|Experimental|CSR T cells|"A dose escalation clinical study aimed to assess the safety and efficacy of CSR T cells in patients with PD-L1 positive tumors.~CSR T dosage ranging from: 5×10^4 /kg to 1×10^7 /kg will be tested."
2946099|NCT02930954|Active Comparator|Gefitinib single agent|Advanced NSCLC patients with EGFR activating mutation (L858R, 19Del) received Gefitinib 250mg Qd orally until progression, intolerable toxicity or death.
2946100|NCT02930954|Experimental|Gefitinib combined with chemotherapy|Gefitinib 250mg Qd combined with pemetrexed or gemcitabine plus carboplatin: Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days, Gemcitabine (1000 mg/m² days 1,d8, intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days
2946101|NCT02930954|Experimental|Gefitinib combined with antiangiogenesis|Gefetinib 250mg Qd combined with bevacizumab 7.5mg/kg per 21 days
2946102|NCT02930941|Experimental|Tranexamic Acid (100 mg/mL)|TXA (100 mg/1mL) sprayed in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
2946103|NCT02930941|Placebo Comparator|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
2946104|NCT02930928||Accuracy of weight estimation|Computer based comparison of the two algorithms based on collected patient data
2946105|NCT02930902|Experimental|Pembrolizumab + Paricalcitol|2 cycles of concurrent Pembrolizumab 200 mg intravenous (IV) Day 1 + Paricalcitol 7 mcg/kg IV Days 1, 8, & 15 of each 3 week cycle. Surgical resection following last dose of Paricalcitol.
2946106|NCT02930902|Experimental|Pembrolizumab + Paricalcitol & Standard Chemo|2 cycles of concurrent Pembrolizumab Day 1 + Paricalcitol Days 1, 8, & 15 of each cycle & first cycle of concurrent treatment with Chemotherapy of Gemcitabine 1000 mg/m2 + Nab-paclitaxel 125 mg/m2 administered Days 1, 8, & 15 of cycle 1. Surgical resection following last dose of Paricalcitol.
2946107|NCT02930889|Experimental|Prostate Artery Embolization|Prostate Artery Embolization
2946108|NCT02930876|Experimental|Resistance training at home|Participants will undergo training sessions at their own homes. The exercise program will be individualized and guided by trained physiotherapists, for 3 months completion, aiming at 2-3 sessions a week (27 to 40 sessions in total), each lasting 45-60 minutes.
2946109|NCT02930876|Experimental|Resistance training at the hospital|Participants will undergo training sessions at the hospital. The exercise program will be individualized and guided by trained physiotherapists, for 3 months completion, aiming at 2-3 sessions a week (27 to 40 sessions in total), each lasting 45-60 minutes.
2946110|NCT02930876|No Intervention|Controls|Participants will be given an information leaflet with the exercise recommendations of the Portuguese national ministry of health.
2946111|NCT02930863|Active Comparator|Control Non-Automated Group|Participants assigned to this group will receive the standard of care procedures for the monitoring and treatment of hypoxemia. Complete brief post-PACU stay survey.
2946112|NCT02930863|Experimental|Automated Prompt Group|Participants assigned to this group will utilize the automated verbal prompts to enable their ability to improve their current condition by following generated commands. Complete a questionnaire focused around their experience with the pulse oximetry software and its effects on the patient's satisfaction and experience.
2946113|NCT02930837|Experimental|alteplase|
2946114|NCT02930824|Experimental|Genotype guided treatment|For patients randomized to the genotype-supported arm a CYP2C19 genotype will be provided to physicians to assist in dosing.
2946115|NCT02930824|No Intervention|Conventional treatment|For patients randomized to the genotype-supported arm a no genotype will be provided to physicians to assist in dosing.
2946116|NCT02930811|Experimental|Sildenafil|Single Sildenafil oral morning intake (100mg/day) per day for a total duration of 6 months (Sildenafil 100 mg oral morning dose)
2946117|NCT02930811|Placebo Comparator|Placebo|Single Placebo oral morning intake per day for a total duration of 6 months (Placebo oral morning dose)
2946118|NCT02930798|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2946119|NCT02930785|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2946120|NCT02930772|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2946121|NCT02930759|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2946122|NCT02930746|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2946123|NCT02930733|Active Comparator|ultrasound guided serratus plane block|Bilateral ultrasound guided serratus plane block with 30 ml %0,25 bupivacaine
2946126|NCT02930707|Placebo Comparator|control group|patients received ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
2946127|NCT02930694|Experimental|Group 1: Treatment Sequence AB|Participants will receive Treatment A [JNJ-54175446, 50 milligram (mg) capsule] on Day 1 of period 1 followed by Treatment B [JNJ-54175446, 50 mg suspension] on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
2946128|NCT02930694|Experimental|Group 1: Treatment Sequence BA|Participants will receive Treatment B on Day 1 of period 1 followed by Treatment A on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
2946129|NCT02930694|Experimental|Group 2: Treatment Sequence CD|Participants will receive Treatment C [JNJ-54175446, 100 mg capsule] on Day 1 of period 1 followed by Treatment D [JNJ-54175446, 100 mg suspension] on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
2946130|NCT02930694|Experimental|Group 2: Treatment Sequence DC|Participants will receive Treatment D on Day 1 of period 1 followed by Treatment C on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
2946131|NCT02930681|Placebo Comparator|Placebo|Four capsules of placebo to be taken 30 mins before each test meal at the investigator's site
2946132|NCT02930681|Experimental|Glucosanol 1000mg|Two capsules of placebo and two capsules of Glucosanol 500mg capsules to be taken 30 mins before each test meal at the investigator's site
2946133|NCT02930681|Experimental|Glucosanol 2000mg|Four capsules of Glucosanol 500mg to be taken 30 mins before each test meal at the investigator's site
2946134|NCT02930668|Placebo Comparator|Placebo|"The placebo is identical in shape, colour and size to the active comparator with the active ingredient replaced with microcrystalline cellulose.~Subjects will take 2 capsules three times a day, 30 mins before meals."
2946135|NCT02930668|Experimental|Low dose (Glucosanol 350mg)|"Each capsule contains Glucosanol / Phaselite 350mg~Subjects will take 2 capsules three times a day, 30 mins before meals."
2946136|NCT02930668|Experimental|High dose (Glucosanol 500mg)|"Each capsule contains Glucosanol / Phaselite 500mg~Subjects will take 2 capsules three times a day, 30 mins before meals."
2946137|NCT02930655|Experimental|Lucerastat group|Ten subjects with Fabry Disease received 1000 mg of oral lucerastat twice daily for 12 weeks in addition to their standard of care treatment (enzyme replace therapy).
2946138|NCT02930655|Experimental|Control group|Four subjects with Fabry Disease under enzyme replace therapy (ERT) as standard of care treatment were included as a control group.
2946139|NCT02930642|Experimental|Mindful Eating|Participants in this arm will receive a 50 min mindful eating training with four pieces of food. They will practice mindful eating at home with two meals for a one-week duration.
2946140|NCT02930642|Active Comparator|Nutrition Digital Video Disc (DVD)|Participants will watch a 50 min DVD on nutrition and receive four pieces of food. They will receive prompts twice a week to give one-word answers to questions about food.
2946141|NCT02930642|No Intervention|Control|Participants will receive four pieces of food. They will not receive any prompts during the one week.
2946142|NCT02930616|Experimental|group 1|Patients in Group 1 will receive probe-based confocal endomicroscopy (pCLE) at first and Wight light endoscopy (WLE) 2 months later
2946143|NCT02930616|Active Comparator|goup 2|patients in Group 2 will receive WLE at first and pCLE 2 months later.
2946144|NCT02930603||Control|Control: Healthy child
2946145|NCT02930603||Experimental|Patients with Developmental Disabilities
2946146|NCT02930590|Experimental|Low Pressure mattress|Alternating Low Pressure mattress with low air loss function (IsoAir, stryker, USA)
2946147|NCT02930590|Experimental|Reactive support surface|Gel mattress (IsoGel, stryker, USA)
2946148|NCT02930590|Active Comparator|Standard mattress|basic foam
2946149|NCT02930564|Experimental|a milk fat or gluten challenge|patients will regress to the first stage diet with either a milk fat /emulsifier or a gluten/emulsifier challenge over 7 days.
2946150|NCT02930551|Active Comparator|Lidocaine|Lidocaine 2 ml injection with 2% Adrenaline
2946151|NCT02930551|Placebo Comparator|Isotonic Saline|Isotonic Saline 2 ml Injection
2946152|NCT02930538||Children undergoing surgery|Children ages 3-18 undergoing a surgical procedure at Nationwide Children's Hosp.
2946153|NCT02930525|Active Comparator|Standard care|Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
2946154|NCT02930525|Experimental|High Flow nasal cannula|Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
2946155|NCT02930512||patients with idiopathic Parkinson's disease|
2946156|NCT02930499|Experimental|Hyaluronic Acid ECM (Hyalomatrix)|Hyalomatrix ECM will be applied to the target ulcer once weekly
2946157|NCT02930499|Active Comparator|Non-Adherent wound dressing (Mepilex)|Mepilex wound dressing will be applied to the target ulcer once weekly
2946158|NCT02930486|Active Comparator|ZipTight|ZipTight suture endobutton
2946159|NCT02930486|Active Comparator|Syndesmotic screw|Tricortical 3.5 mm syndesmotic screw
2946160|NCT02930473|Experimental|Psychotherapeutic Intervention(s) for Anxiety|"People diagnosed with Anxiety (according to ICNP/NANDA standardized nursing language) will be treated using Nursing Interventions Classification (NIC) psychotherapeutic intervention(s) for anxiety (plus psychopharmaceuticals)."
2946161|NCT02930473|Active Comparator|Treatment-as-Usual for Anxiety|"People diagnosed with Anxiety (according to ICNP/NANDA standardized nursing language) will receive treatment as usual for anxiety (psychopharmaceuticals)."
2946162|NCT02930447|Experimental|Treatment group|Autologous glue will be prepared from the patient's own blood with RegenKit®-Surgery device and applied per-operatively by spraying in the undermining region space between fascia and skin.
2946163|NCT02930447|No Intervention|Control group|Patient from the control group will undergo abdominoplasty according to an identical procedure, but without application of autologous glue or any other treatment product before wound closure.
2946164|NCT02930434|Active Comparator|Standard daily vitamin D3|Cholecalciferol 600 IU daily during one year or exit from Antarctica.
2946165|NCT02930434|Active Comparator|Higher weekly vitamin D3|Cholecalciferol 25000 IU once weekly during one year or exit from Antarctica.
2946166|NCT02930421|Experimental|Exercise training (ET)|Patients will enter an 8-week ET program of 3 days per week supervised exercise training at the Rehabilitation Physiotherapy Gymnasium. Exercise training will include high-intensity endurance training at 60-80% of baseline peak work rate and strength training of upper and lower limbs with 3 sets of 6 repetitions at 50% of one repetition maximum. Each session will be 60 min duration, 30 min dedicated to cycle exercise.
2946167|NCT02930421|No Intervention|Usual care (UC)|The UC group will receive usual outpatient care and follow-up.
2946168|NCT02930395||professional rugby players|
2946169|NCT02930382|Experimental|BAROREFLEX|
2946170|NCT02930369|Active Comparator|4PD diameter of ILM peeling in surgery|patients in this group was given 4papillary diameter (PD) diameter of internal limiting membrane (ILM) peeling in surgery
2946171|NCT02930369|Experimental|2PD diameter of ILM peeling in surgery|patients in this group was given 2PD diameter of ILM peeling in surgery
2946172|NCT02930356|Experimental|NSPT-Test group|NSPT was done after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to asses the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
2946173|NCT02930356|Experimental|Scaling and root planing-Control group|Scaling and root planing was done after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to asses the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
2946174|NCT02930343|Active Comparator|group 1- MTX+LEF+HCQ|Active Comparator: Combination of Methotrexate (up to 25 mg per week), Leflunomide (20 mg once a day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.
2946175|NCT02930343|Active Comparator|group 2- MTX+SSZ+HCQ|Combination of Methotrexate (up to 25 mg per week), Sulfasalazine (2g per day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.
2946176|NCT02930330|Experimental|Interval|"2x / week INT~2x / week CONT"
2946177|NCT02930330|Active Comparator|Continuous|4x / week CONT
2946178|NCT02930317|Experimental|Pharmacokinetic parameters|Pharmacokinetic parameters of rFVIII measured in subset of 10 participants, consisting of:18 Years to 65 Years. In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg rFVIII preceded by a 72 hours washout period.
2946179|NCT02930317|Experimental|On-demand treatment|On-demand treatment with rFVIII for 6 months age 12 Years to 65 Years. In Parts 2 of the study, subjects received repeat injections of rFVIII either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor.
2946180|NCT02930304|Experimental|first physiotherapy|cold pack, TENS, exercise
2946181|NCT02930304|Experimental|second physiotherapy|cold pack, TENS, exercise, kinesiotaping
2946182|NCT02930304|Experimental|third physiotherapy|cold pack, TENS, ESWT, exercise
2946183|NCT02930265|Active Comparator|Liraglutide intervention group|Liraglutide intervention group will accept ischemic cardiomyopathy conventional drugs and Liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
2946184|NCT02930265|No Intervention|Control group|Control group will accept ischemic cardiomyopathy conventional drugs and a placebo
2946185|NCT02930252|Experimental|Niti-S Biliary ComVi Stent|"Device:~Niti-S Biliary ComVi Stent is a hollow cylindrical stent fabricated by knitting first and second super-elastic shape memory alloy wires to make a net-like structure. A plurality of interlocked points allow each of the inside and outside stent bodies to contract and expand in the longitudinal direction and to apply a force against the longitudinal contraction. A hollow polytetrafluoroethylene (PTFE) membrane tube is closely fitted between the inside and outside stent bodies, with each of overlapped ends of the PTFE membrane tube and the inside and outside stent bodies integrated into a single structure."
2946186|NCT02930252|Active Comparator|Niti-S Stent (D-type)|"Device:~The Niti-S Stent (D-type) maintains a desired bent shape corresponding to the specific target lesion. It is comprised of a hollow cylindrical stent body fabricated by knitting first and second super-elastic shape memory alloy wires to make a net-like structure with a plurality of interlocked points capable of allowing the stent body to contract and expand in the longitudinal direction and to apply a force against the longitudinal contraction of the stent body.~The wires are made of a shape memory alloy through a process of shaping the alloy then heat-treating the wires to allow restoration of the original shape at a predetermined temperature."
2946187|NCT02930239|Experimental|Gait rehabilitation|Will perform 2 weeks of gait rehabilitation using the anti gravity treadmill. Intervention will start 2 weeks post-surgery. This rehabilitation will be performed simultaneously as the patient receives the standardized rehabilitation at Linkoping University Hospital.
2946188|NCT02930239|Active Comparator|Control group|Will only receive the standardized rehabilitation at Linkoping University Hospital.
2946189|NCT02930226|Experimental|1 unit FDP-CPD|Subjects are to have sufficient plasma withdrawn during a single WB collection visit to allow re-infusion with 1 unit of autologous FDP-CPD
2946190|NCT02930226|Experimental|Reinfusion 1 unit FDP-ACD|Subjects are to have sufficient plasma withdrawn during 1 plasmapheresis collection visit to allow re-infusion with 1 unit of autologous FDP-ACD
2946191|NCT02930226|Experimental|Reinfusion 2 units FDP-CPD|Subjects are to have sufficient plasma withdrawn during 2 separate WB collection visits to allow re-infusion with 2 units of autologous FDP-CPD
2946192|NCT02930226|Experimental|Reinfusion 2 units FDP-ACD|Subjects are to have sufficient plasma withdrawn during 1 plasmapheresis collection to allow re-infusion with 2 units of autologous FDP-ACD
2946193|NCT02930226|Active Comparator|Reinfusion 3 units FDP, 3 units FFP (1st)|Subjects plasma withdrawn during 2 or 3 plasmapheresis collections to allow re-infusion with 3 units of autologous FDP-ACD and 3 units of autologous control FFP. Subjects will receive in total 6 units over the course of 2 infusion visits. Subjects are to be randomized to treatment schedule arms that dictate the sequence for infusing FDP-ACD and FFP across the 2 infusion visits
2946194|NCT02930226|Active Comparator|Reinfusion 3 units FDP, 3 units FFP (2nd)|Subjects plasma withdrawn during 2 or 3 plasmapheresis collections to allow re-infusion with 3 units of autologous FDP-ACD and 3 units of autologous control FFP. Subjects will receive in total 6 units over the course of 2 infusion visits. Subjects are to be randomized to treatment schedule arms that dictate the sequence for infusing FDP-ACD and FFP across the 2 infusion visits
2946195|NCT02930200|Active Comparator|Treatment as Usual|Behavioral: Treatment as Usual (TAU) is the Tobacco Treatment Research Program (TTRP) which offers all components of an intensive tobacco treatment intervention including: 1) initial assessment of willingness to participate, 2) the use of multiple types of clinicians, 3) at least 4 treatment sessions, in an individual- or group-counseling format, that are greater than 10 minutes in duration, 4) counseling that includes problem-solving, skills training, and social support components, and 5) and the opportunity to use effective medications to aid in tobacco cessation.
2946196|NCT02930200|Active Comparator|NCI QuitGuide|Behavioral: The National Cancer Institute's (NCI's) QuitGuide app is a free smartphone app that is available through the Smokefree.gov website. Participants can track cravings, smoking triggers, and motivations for quitting. Participants who are randomly assigned to the QuitGuide app group will receive a smartphone that is preloaded with the QuitGuide app and a quit date scheduled for 1 week after the baseline visit.
2946197|NCT02930200|Experimental|Smart-T|"Behavioral: The Smart-Treatment (Smart-T) phone based smoking cessation intervention has multiple components (e.g., an on-demand Quit Tips function, an on-demand Medications function/button that offers information about nicotine replacement therapy (NRT), button available 24/7 that offers general smoking cessation advice, daily treatment messages, and an algorithm that uses participant's EMA responses to assess risk of lapse and automatically push relevant messages to help them avoid smoking)."
2946198|NCT02930174|Experimental|Volunteer|Testing by applying noninvasive positive pressure ventilation via two different bilevel positive airway pressure (BiPAP) devices: Respironics V-60 and Drager V-500.
2946199|NCT02930161|Experimental|Runihol 2 tablets x 2 times a day|Intake of 1 tablet of Runihol and 1 placebo tablet orally, with drinking 100 ml of water, 30 minutes before meals three times a day (morning, afternoon and evening) for 84 days (12 weeks).
2946200|NCT02930161|Experimental|Runihol 1 tablet x 3 times a day|Intake of Runihol, 2 tablets orally, with drinking 100 ml of water, 30 minutes before meals, 2 times a day (morning and evening) for 84 days (12 weeks), and 2 placebo tablets orally, with drinking 100 ml of water, 30 minutes before meals, 1 time a day (afternoon) for 84 days (12 weeks).
2946201|NCT02930161|Placebo Comparator|Placebo|Two placebo tablets orally, with drinking 100 ml of water, 30 minutes before meals three times a day (morning, afternoon and evening) for 84 days (12 weeks).
2946202|NCT02930148|Experimental|Intervention|Participants will be provided with a smart phone (android, version 5.0), two smart garments, a smart garment sensor and an activity bracelet will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The smart phones will have all apps of the PEGASO ecosystem installed.
2946203|NCT02930148|No Intervention|Comparative|Participants will be asked to continue their routine daily physical and educational activities related to leading a healthy lifestyle.
2946204|NCT02930135|Experimental|Antibacterial Bond|"Indirect pulp capping using antibacterial bond and x-tra fil composite~Local anesthesia administration~Isolation of tooth with rubber dam~Opening of the cavity and the removal of undermined enamel~Caries at the lateral walls of the cavity and at the dentin-enamel junction is completely removed~Partial removal of carious dentin on the pulp wall.~Washing the cavity and dryness~Apply antibacterial light-cure, self-etching bonding agent (Clearfil SE Protect, Kuraray America, Inc.)~Light-cured bulk fill composite (x-tra fil, VOCO) used as final tooth restoration."
2946205|NCT02930135|Active Comparator|Conventional Bond|"Indirect pulp capping using conventional bond and x-tra fil composite~Local anesthesia administration~Isolation of tooth with rubber dam~Opening of the cavity and the removal of undermined enamel~Caries at the lateral walls of the cavity and at the dentin-enamel junction is completely removed~Partial removal of carious dentin on the pulp wall.~Washing the cavity and dryness~Apply conventional light-cure, self-etching bonding agent (Clearfil SE Bond, Kuraray America, Inc.)~Light-cured bulk fill composite (x-tra fil, VOCO) used as final tooth restoration."
2946206|NCT02930122|Experimental|Arm 1|"intervention: Saline (0.9%), and anakinra(150mg) Participants will initially receive a saline placebo injection within 5-7 days after ACL injury.~This will be followed with an intraarticular injection of anakinra (150mg) at 12-14 days post injury"
2946207|NCT02930122|Experimental|Arm 2|"intervention: Anakinra(150mg), Saline (0.9%), Participants will initially receive a an intraarticular injection of anakinra (150mg) within 5-7 days after ACL injury.~This will be followed with a saline placebo injection at 12-14 days post injury"
2946208|NCT02930122|Placebo Comparator|Placebo Control|intervention: Saline (0.9%), Saline (0.9%) Participants will receive two consecutive intra-articular saline placebo injections the first at 5-7 days after ACL injury and the second at 12-14 days after ACL injury
2946209|NCT02930109|Experimental|PTX-200 and cytarabine|"PTX-200 administered intravenously over 1 hour~Phase I: 4 dose levels: 25 to 55 mg/m2 (with reduction to 15 mg/m2 if needed.~Phase II: maximum tolerated dose. given as a 1 hour infusion~Cytarabine administered by continuous infusion at a dose of 400 mg/m2/day for 4 days."
2946210|NCT02930096||pulsatility index mesured with doppler ultrasound|
2946211|NCT02930070||qSOFA(+)SOFA(+)|Infection patients who has a qSOFA>=2 and SOFA>=2 in a same day within 28 day of hospital stay.This group has the greatest priority in the competition of inclusion of groups.
2946212|NCT02930070||qSOFA(-)SOFA(+)|Infection patients who has a qSOFA<2 and SOFA>=2 in a same day within 28 day of hospital stay.This group has the secondary priority in the competition of inclusion of groups.
2946213|NCT02930070||qSOFA(+)SOFA(-)|Infection patients who has a qSOFA>=2 and SOFA<2 in a same day within 28 day of hospital stay.This group has the third priority in the competition of inclusion of groups.
2946214|NCT02930070||qSOFA(-)SOFA(-)|Infection patients who has a qSOFA<2 and SOFA<2 in a same day within 28 day of hospital stay.This group has the least priority in the competition of inclusion of groups.
2946215|NCT02930057|Experimental|Celestone|all patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed.
2946274|NCT02929745|Experimental|psoriasis group|10 HLA-Cw6+ and 10 HLA Cw6- psoriasis patients will undergo skin biopsy once.
2946216|NCT02930057|Other|Control|all patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
2946217|NCT02930044|Experimental|Early glargine dose|Subcutaneous insulin glargine will be administered within two hours of starting the IV insulin infusion.
2946218|NCT02930044|Placebo Comparator|Standard therapy|Retrospective arm that received standard insulin therapy for treatment of DKA
2946219|NCT02930031|Experimental|n-acetylcysteine|orally in three daily dosages, at 20 mg/kg/day, daily for eight days after exercise
2946220|NCT02930031|Active Comparator|Placebo|orally in three daily dosages, content: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder
2946221|NCT02930018|Placebo Comparator|Placebo|Drug vehicle only
2946222|NCT02930018|Experimental|NA-1, 2.6 mg/kg|Single intravenous infusion of NA-1 over 10 ± 1 minutes
2946223|NCT02930005|Experimental|Meclofenamic acid|150mg meclofenamic acid daily for 8 weeks
2946224|NCT02930005|Experimental|Pentosan polysulfate sodium|300mg of pentosan polysulfate sodium daily for 8 weeks
2946225|NCT02929992|Experimental|Home ART initiation|Participants who are eligible to initiate ART will start in the home and will pick up their medication refills from a mobile van.
2946226|NCT02929992|Experimental|Hybrid model|Participants will be referred to the clinic to initiate ART, once started they will pick up their medication refills from a mobile van.
2946227|NCT02929992|Active Comparator|Clinic ART initiation, monitoring and resupply|This is the standard of care arm. Participants will be given a referral to the clinic to initiate ART and will pick up their medication refills from the clinic.
2946228|NCT02929979|Experimental|Cognitive Training|Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ. BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
2946229|NCT02929979|Placebo Comparator|Placebo control|Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
2946230|NCT02929966|Placebo Comparator|standard respiratory care|"The patients will receive the usual respiratory care that included both the classical treatments with antifibrotic drugs and oxygen therapy"
2946231|NCT02929966|Experimental|standard respiratory care PLUS a palliative care program|"The patients will receive the usual respiratory care that included both the classical treatments with antifibrotic drugs and oxygen therapy PLUS a palliative care program that includes paid to assessing physical and psychosocial symptoms"
2946232|NCT02929953||Diabetes mellitus type 1|"all T1DM patients in Israel, born during 2000-2013 and diagnosed prior to January 2015.~chart review"
2946233|NCT02929953||Non-diabetic|non-diabetic general population born in Israel during 2000-2013, according to the Israeli Health Ministry's Birth Registry (IHMBR) chart review
2946234|NCT02929940||PiZZ|Observational
2946235|NCT02929940||PiMZ|Observational
2946236|NCT02929940||Other AATD variants|Observational
2946237|NCT02929940||PiMM (Control)|Observational
2946238|NCT02929927|Experimental|2% NaOCl|Rubber dam isolation，tooth disinfection ，acess to the pulp of the chamber ,microbiological sample with two sterile paper points #20,then Mechanical preparation with NITIMTWO to 25#06 ,then use the kerr files hand instrument enlarger the apical to #40,and cleaned with 5 ml of 2.0% NaOCl between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2% NaOCl ,17% ethylene diamine tetra-acetic acid (EDTA) for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer ,then take the sample again,then drying the canal ,warm vertical condensation +AH-PLUS pasta,ZOE to seal the crown cavity ,one week later ,take crown restoration .Follow up at 1,7days ,3, 6,12 and 24 months.
2946239|NCT02929927|Experimental|PDT+2% NaOCl|Rubber dam isolation，tooth disinfection ，acess to the pulp of the chamber ,microbiological sample with two sterile paper points #20,then Mechanical preparation with NITIMTWO to 25#06 ,then use the kerr files hand instrument enlarger the apical to #40,and cleaned with 5 ml of 2.0% NaOCl between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2% NaOCl ,then17%EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer ,drying the canal ,PDT,then take the sample again,then drying the canal ,warm vertical condensation +AH-PLUS pasta,ZOE to seal the crown cavity ,one week later ,take crown restoration .Follow up at 1,7days ,3, 6,12 and 24 months.
2946240|NCT02929927|Experimental|PDT+1% NaOCl|Rubber dam isolation，tooth disinfection ，acess to the pulp of the chamber ,microbiological sample with two sterile paper points #20,then Mechanical preparation with NITIMTWO to 25#06 ,then use the kerr files hand instrument enlarger the apical to #40,and cleaned with 5 ml of 1.0% NaOCl between each endodontic file, At the end of the procedure, root canals were ultrasonic irrigated with 1.0% NaOClfor 1min, then17%EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer ,drying the canal,PDT,then take the sample again,then drying the canal ,warm vertical condensation +AH-PLUS pasta,ZOE to seal the crown cavity ,one week later ,take crown restoration .Follow up at 1,7days ,3, 6,12 and 24 months.
2946241|NCT02929914|Experimental|Control|Rubber dam isolation，tooth drying，remove caries incompletely,microbiological sample with otoscope curette,dentin wash with sodium 0.9% saline,sampling again.Indirect pulp treatment with calcium hydroxide(CH).Restoration with resin(Z350,3M);Follow up at 6,12 and 24 months.
2946275|NCT02929745|Experimental|healthy control group|10 healthy patients will undergo skin biopsy once.
2946242|NCT02929914|Experimental|PDT+CH|Rubber dam isolation，tooth drying，remove caries incompletely,microbiological sample with otoscope curette,disinfect the remaining dentin with antimicrobial photodynamic therapy(DENFOTEX PADplus),sampling again.Indirect pulp treatment with calcium hydroxide(CH).Restoration with resin(Z350,3M);Follow up at 6,12 and 24 months.
2946243|NCT02929901|Active Comparator|caffeine and chlorogeinc acid|caffeine (200 mg) 1 capsule / day for 6 months plus chlorogenic acid (200 mg) 1 capsule / day for 6 months
2946244|NCT02929901|Active Comparator|caffeine|caffeine (200 mg) 1 capsule / day for 6 months plus placebo (200) mg 1 capsule / day for 6 months
2946245|NCT02929901|Active Comparator|chlorogenic acid|chlorogenic acid (200 mg) 1 capsule / day for 6 months plus placebo (200 mg) 1 capsule / day for 6 months
2946246|NCT02929901|Placebo Comparator|placebo|placebo (200 mg) 1 capsule / day for 6 months plus placebo (200 mg) 1 capsule / day for 6 months
2946247|NCT02929888|Experimental|Lysine Acetilsalicilate (LA)|Loading dose (LD) of intravenous LA 450mg plus oral prasugrel 60mg/ticagrelor 180mg in patients with ST-segment elevation myocardial infarction
2946248|NCT02929888|Active Comparator|Aspirin|Loading dose (LD) of oral aspirin 300mg plus oral prasugrel 60mg/ticagrelor 180mg in patients with ST-segment elevation myocardial infarction
2946249|NCT02929875|Experimental|Case (Educational based on TPB)|"Educational intervention delivered to subjects. The content of education includes:~Three training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions."
2946250|NCT02929875|No Intervention|Control (No intervention)|No educational intervention provided to subjects in control group
2946251|NCT02929862|Experimental|Single Agent 55716|
2946252|NCT02929849|Experimental|300mg SC|300 mg Salacia Chinensis (SC). This will be compared to placebo.
2946253|NCT02929849|Active Comparator|500mg SC|500 mg Salacia Chinensis (SC). This will be compared to placebo.
2946254|NCT02929849|Placebo Comparator|Placebo|The investigators will examine subjects before and during a 3 hour period after subjects consume a Placebo capsule and a fixed breakfast meal.
2946255|NCT02929836|Active Comparator|PVI+LA linear ablation +CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI, LA linear ablation (roof line and mitral isthmus)and CFAE ablation.
2946256|NCT02929836|Active Comparator|PVI+linear ablation +CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI,roof line and mitral isthmus,cavotricuspid isthmus abaltion and CFAE ablation.
2946257|NCT02929836|Active Comparator|PVI+CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI and CFAE ablation.
2946258|NCT02929823|Experimental|Low Dose SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0.0002% SJP-0035 ophthalmic solution in the affected eye(s) 4 times daily for 4 weeks.
2946259|NCT02929823|Experimental|High Dose SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0.001% SJP-0035 ophthalmic solution in the affected eye(s) 4 times daily for 4 weeks.
2946260|NCT02929823|Placebo Comparator|Vehicle of SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0% SJP-0035 ophthalmic solution (consisting of the vehicle for the solution) in the affected eye(s) 4 times daily for 4 weeks
2946261|NCT02929810|Experimental|sleep extension|
2946262|NCT02929810|Active Comparator|sleep maintenance|
2946263|NCT02929797|Experimental|AKT + gemcitabine|gemcitabine dose 1000mg/M^2, d1,8,15，q4w ×6 AKT 5*10^8/M^2, d16,q4w ×6 Drug: gemcitabine Biological: AKT, CD8+NKG2D+ AKT Cell
2946264|NCT02929797|Active Comparator|gemcitabine|gemcitabine hydrochloride dose 1000mg/M2 d1,8,15，q4w ×6 Drug: gemcitabine
2946265|NCT02929784|Experimental|Intervention|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: Affected hemisphere anodal stimulation of the hand area of the primary motor cortex (C3/C4), Intensity of 2 mA (milliampere) for duration of 20 minutes. A total of 10 sessions: 5 sessions a week for 2 weeks.
2946266|NCT02929784|Sham Comparator|Sham|The stimulator will be turned on for only a very short duration of time (msec) no meaningful stimulation is believed to be administered in such a way.
2946267|NCT02929784|No Intervention|no HSP|Patients hospitalized in the Loewenstein department of neurologic rehabilitation after first clinical stroke who do not have hemiplegic shoulder pain.
2946268|NCT02929771|Experimental|Intervention Group|In addition to usual care, the intervention group will receive the Samsung GearVR with head mounted display (HMD), controller, and headphones. They will situated in front of the nurse and beside/on the lap of the parent, or they may be lying supine. The VR intervention will use auditory and visual stimuli (simulating the peaceful underwater environment) to distract the child before, during, and after the SCP needle insertion. Children will be allowed to 'try-out' the VR system before the SCP access to familiarize themselves with the equipment. The entire study will be videotaped.
2946269|NCT02929771|Active Comparator|Control Group|In addition to usual care, participants in the control group will be seated with their parent and in front of the nurse, according to preference. Children will watch an age appropriate video selected by an oncology-affiliated child life specialist on an iPad, while wearing the same headphones used in the experimental condition. The RA will hold the iPad and positioned within a meter of the child so that the child can still see the iPad without the RA interfering in the clinical procedure. The entire study will be videotaped.
2946270|NCT02929758|Active Comparator|Control Initial Training Group|Healthy Controls will receive initial SOPT training and will be compared against controls in the delayed training group and the PD subjects in the initial training group
2946271|NCT02929758|Active Comparator|Control Delayed Training Group|Healthy Controls will receive delayed SOPT training and will be compared against controls in the initial training group and the PD subjects in the delayed training group
2946272|NCT02929758|Other|PD Initial Training Group|PD subjects will received initial SOPT training and will be compared against PD subjects in the delayed training group and the control subjects in the initial training group
2946273|NCT02929758|Other|PD Delayed Training Group|PD subjects will receive delayed SOPT training and will be compared against PD subjects in the initial training group and the control subjects in the delayed training group
2946276|NCT02929732|Experimental|Willis-Ekbom disease patients (CASE)|
2946279|NCT02929719|Active Comparator|ACZONE Gel 5%|Topical, twice daily on the face for 84 days
2946280|NCT02929719|Placebo Comparator|Placebo Gel|Topical, twice daily on the face for 84 days
2946281|NCT02929706|Experimental|intervention group|Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
2946282|NCT02929706|No Intervention|control group|optimize the thiopurine use by coventional strategy without konwing NUDT15 genotype
2946283|NCT02929693|Experimental|combination|YYJD plus gefitinib
2946284|NCT02929693|Placebo Comparator|controll|placebo plus gefitinib
2946285|NCT02929667|Active Comparator|Treatment|Subjects randomized to treatment arm will receive fluoxetine with titration schedule consisting of 10 mg per day for 1 week, 20 mg per day for 1 week, 40 mg per day for 2 weeks, 20 mg per day for 1 week and 10 mg per day for 1 week. Then stop.
2946286|NCT02929667|Placebo Comparator|Control|Subjects randomized to control arm will receive placebo with titration schedule consisting of 10 mg per day for 1 week, 20 mg per day for 1 week, 40 mg per day for 2 weeks, 20 mg per day for 1 week and 10 mg per day for 1 week. Then stop.
2946287|NCT02929654|Active Comparator|Control|Subject continue to use their own Blood Glucose Monitoring System ( BGMS) for 12 weeks.
2946288|NCT02929654|Experimental|OneTouch Verio®|Subjects use LifeScan provided BGMS (OneTouch Verio®) for 12 weeks
2946289|NCT02929654|Experimental|Intervention 02|Subjects use LifeScan provided BGMS (OneTouch Verio® Flex ) for 12 weeks.
2946290|NCT02929641||HDWL and OE with magnification|The polyps found will be observed by HDWL and OE with magnicication model and recorded.
2946291|NCT02929628|Experimental|Patients with Various Frequency Stimulation|Patients are in the condition of Various Frequency Stimulation
2946292|NCT02929628|Sham Comparator|Patients With Traditional Frequency Stimulation|Patients in the condition of Sham Comparator are Traditional Frequency Stimulation
2946293|NCT02929615|Experimental|Treatment group|
2946294|NCT02929589|Experimental|Opioid naïve patients-Group A|Group A: Subjects will be prescribed ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days, and 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days.
2946295|NCT02929589|Experimental|Non-Opioid naïve patients-Group C|Group C: Subjects will be prescribed ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days, in addition to their preferred opioid medication prescription.
2946296|NCT02929589|Placebo Comparator|Opioid naïve patients-Group B|Group B:Subjects will be prescribed 800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain and 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days.
2946297|NCT02929589|Experimental|Non-Opioid naïve patients-Group D|Group D: Subjects will be prescribed or advised to continue to take only their preferred current oral opioid prescription (codeine, hydrocodone, hydromorphone, morphine, methadone, oxymorphone, or transdermal fentanyl).
2946298|NCT02929576|Experimental|Double-blind enzalutamide with paclitaxel|
2946299|NCT02929576|Placebo Comparator|Double-blind placebo with paclitaxel|
2946300|NCT02929576|Experimental|Open-label enzalutamide monotherapy followed by paclitaxel|At the time of disease progression, enzalutamide treatment will be discontinued and paclitaxel will be administered if considered to be an appropriate treatment by the treating physician until second disease progression.
2946301|NCT02929563|Experimental|pantoprazole|pantoprazole 1 mg/kg (maximum 40 mg) IV once daily until the participants no longer need mechanical ventilation - to a maximum of 30 days or until Pediatric Intensive Care Unit (PICU) discharge.
2946302|NCT02929563|Placebo Comparator|placebo (for pantoprazole)|an equivalent volume of normal saline IV once daily until the participants no longer need mechanical ventilation - to a maximum of 30 days or until PICU discharge.
2946303|NCT02929537||Western medicine|Patients in this group only choose conventional medicine treatment based on the classes of medications recommended by 2015 GOLD for COPD.
2946304|NCT02929537||Traditional Chinese Medicine|Patients in this group only choose conventional medicine treatment based on the Chinese Treatment Guidelines for COPD.
2946305|NCT02929537||Integrative Medicine|Patients in this group choose western medicine and Traditional Chinese Medicine.
2946306|NCT02929524|Experimental|Ketamine group|This group was used intranasal ketamine, syringes were made with 4 ml of the drug (50mg/ml), 1 randomized per patient. The validity stability and were 7 days after drawing the solution. The drug began to take effect in 10 minutes and lasted about 40 minutes.
2946307|NCT02929524|Placebo Comparator|Placebo Group|This group was used intranasal saline, syringes were made with 4 ml of liquid 1 per patient randomized. The validity stability and were 7 days after drawing the solution.
2946308|NCT02929511|Experimental|Reciproc Blue|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit. In this group, intervention will be carried out by the Reciproc motor (VDW, Germany) and Reciproc Blue single-file system (VDW, Germany). The intervention is root canal treatment with the Reciproc Blue single-file system.
2946309|NCT02929511|Experimental|OneShape|In this group, OneShape rotational single-file system (Micro Mega, France) will be used as single-file system according to the manufacturer's instruction.
2946310|NCT02929511|Active Comparator|Protaper|As a control group, Protaper (Dentsply, Mailleffer, Switzerland) will be used according to the manufacturer's instruction.
2946311|NCT02929498|Experimental|Arm A: GSK2879552 monotherapy|Subjects will receive GSK2879552 2 milligrams (mg) once daily in each 28 day cycle.
2946312|NCT02929498|Experimental|Arm B: GSK2879552+Azacitidine combination therapy|Subjects will receive GSK2879552 starting at 1 mg once daily in each 28 day cycle and Azacitidine 75 mg/square meter (m2) from Day 1 to Day 7 of each 28 day cycle.
2946313|NCT02929485|Experimental|Experimental: Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
2946314|NCT02929485|Placebo Comparator|Comparator: Placebo|Drug: Placebo for tolcapone administered at study visit
2946315|NCT02929485|Experimental|Experimental: Bromocriptine|Drug: Bromocriptine 1.25mg (single dose) administered at study visit
2946316|NCT02929472|Experimental|Physical Exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
2946317|NCT02929472|Other|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
2946318|NCT02929459|Experimental|Riboflavin Dose 1|100 mg Riboflavin (one capsule) per day for 2 weeks
2946319|NCT02929459|Experimental|Riboflavin Dose 2|50 mg Riboflavin (one capsule) per day for 2 weeks
2946320|NCT02929459|Placebo Comparator|Placebo|100 mg starch plus 0,5% silica (one capsule) per day for 2 weeks
2946321|NCT02929446|Experimental|Mobilisation|Mobilisation to sit in an armchair as long as possible
2946322|NCT02929446|No Intervention|Control|No mobilisation until the day after surgery
2946323|NCT02929446|Experimental|Mobilisation and breathing exercises (PEP)|Mobilisation to sit in an armchair as long as possible and breathing exercises with PEP
2946324|NCT02929433|Experimental|Cycloergometer group|Training at home with the cycloergometer per 20 minutes twice a day. The protocol suggested a continous use of the cycloergometer for a period of 6 months after 2 weeks of rehabilitation as outpatient.
2946325|NCT02929433|No Intervention|Control group|Usual care after a period (2 weeks) of rehabilitation as outpatient.
2946326|NCT02929420|Experimental|Xiaoru Sanjie capsules|a new recipe of traditional chinese medicine； Xiaoru Sanjie capsules,three pills every time,three time a day,PO, last three months.
2946327|NCT02929420|Placebo Comparator|Xiao Yao pills|"a kind of traditional chinese medicine that is efficient and safe to treat hyperplasia of mammary glands.~Xiaoyao pills,three pills every time,three time a day,PO,last three months."
2946328|NCT02929407|Experimental|FE 204205|
2946329|NCT02929407|Placebo Comparator|Placebo|
2946330|NCT02929394|Active Comparator|investigational treatment|Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity.
2946331|NCT02929394|No Intervention|observation|Observation through clinical and radiological follow-up until disease progression (RECIST 1.1).
2946332|NCT02929381|Experimental|Innovative colonoscopy|Innovative colonoscopy performed using narrow band imaging and dual focus function (NBI + Dual Focus)
2946333|NCT02929381|Active Comparator|Conventional colonoscopy|Conventional colonoscopy performed without innovative techniques assessed in this study.
2946334|NCT02929368|Active Comparator|Fluoroscopy|PICC Implantation under x-ray
2946335|NCT02929368|Active Comparator|Sherlock System (BARD)|PICC Implantation with Integrated Magnetic Tracking and ECG-guided Tip Location System
2946336|NCT02929355||diabetic patients with carotid assessment|Patients with diabetes and a carotid assessment by duplex ultrasonography in 2012 in a monocentric diabetic unit
2946337|NCT02929342|Experimental|Pitolisant|Pitolisant, oral single dose administration, from Day1 to Day7.
2946338|NCT02929342|Experimental|[14C]-Pitolisant|[14C]-Pitolisant, oral single dose administration at Day8.
2946339|NCT02929329|Experimental|Active Treatment|Oral omecamtiv mecarbil twice daily for up to 208 weeks
2946340|NCT02929329|Placebo Comparator|Placebo|Oral placebo twice daily for up to 208 weeks
2946341|NCT02929316|Experimental|Vedolizumab|Vedolizumab (Entyvio) 300mg IV at week 0, 2 and 6
2946342|NCT02929290|Experimental|BPI-9016M|
2946343|NCT02929277|Other|single arm study|
2946344|NCT02929264|Experimental|ABX-1431|ABX-1431, capsules, 40 mg, single dose
2946345|NCT02929264|Placebo Comparator|Placebo|Placebo, capsules, single dose
2946346|NCT02929264|No Intervention|Control|No Intervention
2946347|NCT02929251|Active Comparator|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
2946348|NCT02929251|Experimental|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
2946349|NCT02929251|Experimental|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
2946350|NCT02929238|Experimental|Polypropylene Suture Right Side|Polypropylene suture will be placed over half the wound. There is an equal chance for the suture to be placed on the right or left through randomization. THe other half of the wound will not have the suture placed on it and will act as the control. The wound vac will be placed over entire wound.
2946351|NCT02929238|Experimental|Polypropylene Suture Left Side|Polypropylene suture will be placed over half the wound. There is an equal chance for the suture to be placed on the right or left through randomization. THe other half of the wound will not have the suture placed on it and will act as the control. The wound vac will be placed over entire wound.
2946352|NCT02929225|Experimental|Bifid Triple Viable Capsules|BIFICO(Shanghai Sine Pharmaceutical Laboratories Co.Ltd,S10950032), A biological preparation composed of triple viable microbe(Live combined Bifidobacterium, Lactobacillus and enterococcus capsules)
2946353|NCT02929225|Placebo Comparator|placebo|placebo is also manufactured by Sine Pharmaceutical Laboratories,but only contains starch.And placebo is the same as probiotics in appearance,odor,flavor and color.
2946354|NCT02929212|Other|Solid Meal Study Group A|Patients Pre and Post-GBP who are randomly assigned to receive solid meals on study days given as one, 600 kcal, meal.
2946355|NCT02929212|Other|Liquid Meal Study Group A|Patients Pre and Post-GBP who are randomly assigned to receive liquid meals on meal study days, given as one, 600 kcal, meal
2946356|NCT02929212|Other|Solid Meal Study Group B|Patients Pre and Post-GBP who are randomly assigned to receive solid meals on study days given as three, 200 kcal, meals.
2946357|NCT02929212|Other|Liquid Meal Study Group B|Patients Pre and Post-GBP who are randomly assigned to receive liquid meals on meal study days, given as three, 200 kcal, meals.
2946358|NCT02929199|Active Comparator|group A|Pressable E- max, an all ceramic crown
2946359|NCT02929199|Experimental|Group B|BIO-Hpp hybrid crown
2946360|NCT02929186|Experimental|Opt-In|Opt-In Outreach
2946361|NCT02929186|Experimental|Opt-Out|Opt-Out Outreach
2946366|NCT02929147|Experimental|Morphine 1 mg|In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
2946367|NCT02929147|Experimental|Morphine 0.5|In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours
2946368|NCT02929147|Active Comparator|Dexketoprofen & Placebo|The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
2946369|NCT02929134|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
2946370|NCT02929134|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
2946371|NCT02929121|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
2946372|NCT02929121|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
2946373|NCT02929108|No Intervention|Enhanced Usual Care|This group will receive usual hospice care which has been enhanced as the staff have been trained in shared decision making.
2946374|NCT02929108|Experimental|Facebook|This group only participates in the Facebook groups, not in the shared decision making
2946375|NCT02929108|Experimental|ACCESS|This group participates in facebook and web conferencing for shared decision making
2946376|NCT02929095|Experimental|Patients in the dexmedetomidine group|Patients in the dexmedetomidine group are given 1 μg/kg/h of dexmedetomidine for 10 minutes on initiation of the procedure and then 0.2-0.7 μg/kg/h until end of the procedure and are given 1.2-7.2 μg/kg/h of remifentanil until end of the procedure
2946377|NCT02929095|Active Comparator|Patients in the midazolam group|Patients in the midazolam group are given midazolam 0.02-0.05mg/kg bolus on initiation of the procedure and are given 1.2-7.2 μg/kg/h of remifentanil until end of the procedure
2946378|NCT02929082|Experimental|Group 1 : volunteer patient|Group 1 will be constituted of 20 volunteer patients coming for abdominal MRI with no known hepatic disease, in order to determine the feasibility of FRM . A 5-minute- additional sequence to measure FRM will be done for the volunteers.
2946379|NCT02929082|Experimental|Group 2 : patient with resectable HCC|"Group 2 will be constituted of 60 patients with resectable HCC eligible for surgery. This group will enable to evaluate the gold standard.~A 5-minute- additional sequence to measure FRM will be done while MRI sequence."
2946380|NCT02929082|Experimental|Group 3 : patient with HCC eligible for TACE|"Group 3 will be constituted of 50 patients with HCC eligible for transplant with transcatheter arterial chemoembolization (TACE) treatment as pending treatment before transplant. This groups will enable to evaluate the efficiency of TACE through the necrosis percentage in treated HCC.~A 5-minute- additional sequence to measure FRM will be done while MRI sequence"
2946381|NCT02929069|Experimental|ESTEEM|Participants in all arms will receive Voluntary Counselling and Testing (VCT). Participants randomized to this arm will receive ESTEEM. ESTEEM is a 10-session intervention based on the Unified Protocol,an individually-delivered CBT intervention with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation skills; reducing avoidance patterns; and improving motivation and self-efficacy for behavior change.
2946382|NCT02929069|Active Comparator|Community Mental Health Treatment (CMHT)|Participants in all arms will receive Voluntary Counselling and Testing (VCT). Participants randomized to this arm will receive Community Mental Health Treatment (CMHT). CMHT is the current standard of care for LGB individuals who seek mental, behavioral, or sexual health care is LGB-affirmative therapy.The practice of LGB-affirmative therapy is outlined across 21 guidelines published by the American Psychological Association.
2946383|NCT02929069|Active Comparator|Voluntary Counselling and Testing (VCT)|Participants randomized to the VCT only arm will not receive any further intervention. VCT will be based on on CDC guidelines and the control arms of large community-based RCTs (e.g., Projects RESPECT, EXPLORE, AWARE). VCT will consist of one 45-minute session given that 1-session VCT is as effective as 2-session VCT for GBM.
2946384|NCT02929056|Placebo Comparator|SOC alginate dressing|SOC absorptive alginate primary dressing in conjunction with a class II multi-layer compression wrap and standard debridement
2946385|NCT02929056|Experimental|AmnioExCel dressing|AmnioExCel dressing in conjunction with a class II multilayer compression wrap and standard debridement
2946386|NCT02929043||Dentine hypersensitivity subjects|
2946387|NCT02929030||NANO Plus SES|All patients will be treated with NANO plus sirolimus-eluting stent. Patients will be prescribed with clopidogrel and aspirin before the index procedure. The lesions will be predilted if necessary before stent implantation. There are no specific limitations on coronary lesions according the study criteria.
2946388|NCT02929017|Other|Intervention|Group will receive SUPPORT, an intervention that provides information about the disease, self-management strategies, and introduction to advanced care planning in a format with enhanced content available across multiple domains (face-to-face, printed material, and digitally (via use of a tablet) delivered by an interventionist.
2946389|NCT02929017|Other|Usual Care|Group will receive usual standard-of-care, and be provided with currently available printed material for information about their illness.
2946390|NCT02929004|Experimental|Vibrasens|"In addition of classical physiotherapist sessions for the readaptation following anterior cruciate ligament reconstruction, this group will follow a local vibration training, using small and portable vibrator device.~Training programme: vibration training 3/week from Day 1 to Day 60"
2946391|NCT02929004|No Intervention|Usual activities|Usual activities from day 1 to Day 60 during their classical physiotherapist sessions for the readaptation following anterior cruciate ligament reconstruction.
2946392|NCT02928991|Experimental|Acquired Aplastic Anemia (AA)|Patients with severe or very severe acquired aplastic anemia (AA). Patients will receive a matched related donor bone marrow transplant following reduced intensity conditioning (RIC) including thymoglobulin (ATG), fludarabine and dose-reduced cyclophosphamide.
2946393|NCT02928991|Experimental|Inherited Bone Marrow Failure Syndrome + Trilineage Aplasia|Patients with inherited bone marrow failure (iBMF) syndromes with trilineage aplasia includes those with diagnoses of Fanconi Anemia, Dyskeratosis Congenita, and related conditions. Patients will receive a matched related donor bone marrow transplant following conditioning with fludarabine, cyclophosphamide, thymoglobulin.
2946394|NCT02928991|Experimental|Inherited Bone Marrow Failure Syndrome no Trilineage Aplasia|Patients with inherited bone marrow failure (iBMF) syndromes without trilineage aplasia includes those with diagnoses of Severe Congenital Neutropenia, Diamond-Blackfan Anemia, and related conditions. Patients will receive a matched related donor bone marrow transplant following conditioning with thymoglobulin, busulfan and fludarabine.
2946395|NCT02928978|Experimental|Ruxolitinib|Participants will receive ruxolitinib 20 mg by mouth twice daily for 15 days (+/- 5 days). Ruxolitinib will be supplied as four, 5 mg tablets.
2946396|NCT02928978|Placebo Comparator|Placebo|Participants will receive a placebo (sugar pill) that is designed to mimic ruxolitinib. The placebo will be supplied as four, 5 mg tablets. Participants assigned to this arm will take four, 5 mg tablets by mouth twice daily for 15 days (+/- 5 days).
2946397|NCT02928965|Experimental|Minocycline|Participants will receive capsules containing 100mg of minocycline (modified release), two per day for the first two weeks of the trial and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.
2946398|NCT02928965|Placebo Comparator|Placebo|Participants will receive placebo capsules entirely matching minocycline, two per day for the first two weeks of the trial and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.
2946399|NCT02928952|Experimental|Diabetes Self Management Education (DSME) + Mind-STRIDE|Will receive routine diabetes self-management education + the Mind-STRIDE intervention
2946400|NCT02928952|No Intervention|DSME alone|Usual care control
2946401|NCT02928939||Multimorbid patients|
2946402|NCT02928926||Thrombolysis|Acute ischaemic stroke patients who receive intravenous thrombolysis
2946403|NCT02928926||non thrombolysis|Acute ischaemic stroke patients who admitted to the hospital within the timeframe for intravenous thrombolysis but contraindicate to receive intravenous thrombolysis
2946404|NCT02928913||Sedentary|Predominantly engage in sedentary behaviours
2946405|NCT02928913||Non-sedentary|Predominantly engage in non-sedentary behaviours
2946406|NCT02928900|Experimental|Intervention period|In this stepped-wedge trial design, the experimental arm refers to the time period when the study sites receive the clinician training intervention. The intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care providers who serve HIV-positive adolescents and youth.
2946407|NCT02928900|No Intervention|Control period|In this stepped-wedge trial design, the no intervention arm refers to the time period before the study sites receive the clinician training intervention, during which standard of care is provided.
2946408|NCT02928887|Experimental|Blue light|Exposure to high illuminance (1000 lux), blue spectrum (480nm) light for the 24 hour photoperiod prior to surgery and for the 24 hour photoperiod immediately after surgery
2946409|NCT02928887|No Intervention|Ambient light|Exposure to ambient, white fluorescent light
2946410|NCT02928874|Experimental|Caloric compensation|Twenty-five minutes before breakfast, participants will be asked to consume in full one of two oatmeal preloads that will vary in ED. The order of preload conditions will be randomized across groups of children participating in the visits.
2946411|NCT02928874|Experimental|Eating in the absence of hunger (EAH)|During both study visits, children's EAH will be assessed after lunch and again after dinner. The order of presenting the low and high ED snacks will be counterbalanced across meals.
2946412|NCT02928861|Experimental|18F-FDG PET/CT-based prognostic model|The new prognostic model is based on 18F-FDG PET/CT scans, and combined with clinical and pathological prognostic factors.
2946413|NCT02928848|Experimental|tDCS|Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
2946414|NCT02928848|Sham Comparator|Sham tDCS|Sham tDCS uses identical stimulation parameters as the active condition, however terminates after 30 seconds in order to mimic the sensation of real tDCS.
2946415|NCT02928835|Experimental|Dynasplint group|The experimental group received standardized physical therapy intervention and used the knee flexion Dynasplint orthosis six hours daily during one month, starting at day seven after total knee arthroplasty surgery.
2946416|NCT02928835|No Intervention|Control group|Control group received standardized physical therapy intervention.
2946417|NCT02928822|Experimental|Experimental Group|Virtual reality based sensorimotor aphasia therapy.
2946418|NCT02928822|Active Comparator|Control Group|Conventional aphasia therapy.
2946419|NCT02928809|No Intervention|TMD control|Patients with diagnosis of temporomandibular disorder and that are not submitted to pre-fatigue low-level laser therapy
2946420|NCT02928809|Experimental|TMD LLL|Patients with diagnosis of temporomandibular disorder and that are submitted to pre-fatigue low-level laser therapy
2946421|NCT02928809|No Intervention|Without TMD control|Patients without diagnosis of temporomandibular disorder and that are not submitted to pre-fatigue low-level laser therapy
2946422|NCT02928809|Experimental|Without TMD LLL|Patients without diagnosis of temporomandibular disorder and that are submitted to pre-fatigue low-level laser therapy
2946423|NCT02928809|Placebo Comparator|TMD placebo|Patients with diagnosis of temporomandibular disorder and that are submitted to placebo low-level laser treatment
2946424|NCT02928809|Placebo Comparator|Without TMD placebo|Patients without diagnosis of temporomandibular disorder and that are submitted to placebo low-level laser treatment
2946425|NCT02928796||Trainees|Registrar Cardiologists
2946426|NCT02928796||Trainers|Consultant Cardiologists
2946492|NCT02928315|Placebo Comparator|control|100 ml of normal saline solution infused intravenously over 4 hours once daily , for 3 days
2946427|NCT02928783|Experimental|Intervention|In interventional group, we arranged individualized rehabilitation programs including home-based cardiac rehabilitation, diet education and management of daily activity for 3 months.
2946428|NCT02928783|No Intervention|Control|We didn't arrange individualized rehabilitation programs including home-based cardiac rehabilitation, diet education and management of daily activity for 3 months.
2946429|NCT02928770|Experimental|Nastent|A baseline sleep study is obtained from the subject, without wearing the device. The individual wears the device at home for at least 7 nights, and then returns to the sleep lab for an in-laboratory sleep study while wearing the device.
2946430|NCT02928757|Experimental|Intervention Group|In addition to standard medical care, participants will be enrolled to be seen as soon as possible in a complex care clinic as part of the CCKO initiative.
2946431|NCT02928757|No Intervention|Wait-list Group|The control group will receive usual care, but will be wait-listed for 1 year to be seen in a complex care clinic as part of the CCKO initiative.
2946432|NCT02928744|Experimental|COPD|
2946433|NCT02928731||Children with cancer|"Children met the criteria below were invited to fill in the questionnaires set 1.~(1) all children should be ages 9-16 years, (2) they should be able to speak and read Chinese, (3) they should have been diagnosed with cancer for at least 2 months and be currently undergoing active treatment, and (4) they should aware of their diseases (cancer)."
2946434|NCT02928731||Healthy children|"Children met the criteria below were invited to fill in the questionnaires set 2.~(1) all children should be ages 9-16 years, (2) they should be able to speak and read Chinese, and (3) they should not have cancer or any other chronic illness."
2946435|NCT02928718||High risk patients|Patients who are at high risk of post-ERCP pancreatitis, who have at least one of the following factors: clinically suspected sphincter of Oddi dysfunction, history of post-ERCP pancreatitis, pancreatic sphincterotomy, precut sphincterotomy, difficult cannulation, balloon dilatation of intact sphincter, endoscopic ampullectomy, and 2≥minor criteria(an age of less than 50 years and female sex, a history of recurrent pancreatitis (≥2 episodes), three or more injections of contrast agent into the pancreatic duct with at least one injection to the tail of the pancreas, excessive injection of contrast agent into the pancreatic duct resulting in opacification of pancreatic acini,the acquisition of a cytologic specimen from the pancreatic duct with the use of a brush).
2946436|NCT02928705||telemedicine group|physician operated telemedical prehospital analgesia
2946437|NCT02928705||historical control group|prehospital analgesia by on-scene EMS physicians
2946438|NCT02928692|Placebo Comparator|Placebo|Placebo administered before surgery
2946439|NCT02928692|Experimental|Minocycline|Minocycline was administrated before surgery
2946440|NCT02928692|No Intervention|Volunteers|Health people for calculate the incidence of POCD
2946441|NCT02928679|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
2946442|NCT02928679|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
2946443|NCT02928666|Experimental|DSS for recommendation interactions|participants may use the DSS for mitigating interactions between recommendations to detect interactions between guideline recommendations and find sets of non-conflicting recommendations. In addition, they may look at the relevant clinical guidelines and additional medical knowledge sources regarding drug-drug relationships, indications and contraindications.
2946444|NCT02928666|No Intervention|No DSS|participants use only the relevant clinical guidelines and additional medical knowledge sources regarding drug-drug relationships, indications and contraindications to detect interactions between guideline recommendations and find sets of non-conflicting recommendations
2946445|NCT02928653|Active Comparator|Sucrose Sweetened Beverage|100-140 g sucrose/day
2946446|NCT02928653|Experimental|Aspartame Sweetened Beverage|0.541-0.757 g aspartame Sweetened Beverage/day
2946447|NCT02928653|Experimental|Saccharin Sweetened Beverage|0.300-0.455 g saccharin Sweetened Beverage/day
2946448|NCT02928653|Experimental|Sucralose Sweetened Beverage|0.167-0.233 g sucralose Sweetened Beverage/day
2946449|NCT02928653|Experimental|Rebaudioside A Sweeteened Beverage|0.250-0.350 g rebaudioside A Sweetened Beverage/day
2946450|NCT02928640|Experimental|ClariCore System|ClairCore System study designed for data collection to build the prostrate tissue classification algorithm.
2946451|NCT02928627||HCC Group|samples obtained from patients with HCC (hepatic tissue and blood)
2946452|NCT02928627||Plasma control Group (PCG)|blood samples obtained from healthy controls
2946453|NCT02928614|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
2946454|NCT02928614|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
2946455|NCT02928601|Experimental|Ondansetron|
2946456|NCT02928601|Active Comparator|Saline|
2946493|NCT02928302|Experimental|TVU CL screening|TVU CL screening: single TVU CL at 18 0/7 to 23 6/7 every week
2946494|NCT02928302|No Intervention|no screening|no TVU CL screening
2946756|NCT02926794|Experimental|No SA and No II|Control writing task and control intentions condition
2946757|NCT02926781|Experimental|osteotome technique|transcrestal sinus floor elevation using osteotomes
2946457|NCT02928575|Experimental|Sunitinib, Temozolomide and Radiation Therapy|Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
2946458|NCT02928562|No Intervention|Control|TKA patients without exercise intervention
2946459|NCT02928562|Experimental|Exercise|TKA patients with exercise intervention ( cyclic exercise, aerobic exercise and resistant training exercise )
2946460|NCT02928549||Black Women with Cancer|In this formative qualitative research study we aim to use one-on-one semi-structured interviews with Black women diagnosed with ovarian cancer to learn about their experiences and their journey to accessing care at a high-volume ovarian cancer care center (HVC).
2946461|NCT02928523|Experimental|Autologous Fecal Microbiota Transplantation|
2946462|NCT02928510|Experimental|Basic Science (biospecimen collection, idelalisib)|Patients receive a physical examination during visit 1. A stool sample, blood sample, and 6 biopsies are collected at visit 2, and patients undergo a flexible fiberoptic sigmoidoscopy. Patients receive idelalisib PO twice daily BID after visit 2. Treatment continues in the absence of disease progression or unacceptable toxicity. A third research visit occurs upon development of idelalisib-associated diarrhea/colitis symptoms. Patients with diarrhea/colitis symptoms undergo a full colonoscopy and collection of stool and blood samples. Control patients with no diarrhea/colitis symptoms undergo all needed tests and assessments including a flexible fiberoptic sigmoidoscopy and collection of stool and blood samples. All patients undergo optional biospecimen collection at the time of disease progression.
2946463|NCT02928497|Experimental|WATCHMAN (Device)|WATCHMAN LAAC Device implant including modified post-implant drug regimen.
2946464|NCT02928497|Active Comparator|Single antiplatelet therapy (Control)|Single antiplatelet therapy or no therapy at the discretion of the study physician for the duration of the trial.
2946465|NCT02928484|Active Comparator|Test product|The volunteers, that have been randomly assigned to the Test product arm of the study, will be administered one oral capsule/day of the Probiotic mix CBP-004019/C (Biopolis SL) during the intervention period (1 month). The product contains 1X10Exp9 cfu/capsule of the probiotic mix (Bifidobacterium lactis, Bifidobacterium longum, Lactobacilus casei and Lactobacillus rhamnosus) plus maltodextrin and sugar.
2946466|NCT02928484|Placebo Comparator|Placebo product|The volunteers that have been randomly assigned to this arm of the study will receive one oral capsule per day of the placebo product (Biopolis SL) during the 1 month intervention period. The product contains maltodextrin and sugar.
2946467|NCT02928471||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks.
2946468|NCT02928458|Active Comparator|Omnipaque|Arm 1
2946469|NCT02928458|Active Comparator|MD-Gastroview|Arm 2
2946470|NCT02928445|Experimental|RVT-101 35 mg|RVT-101 35 mg once daily
2946471|NCT02928445|Experimental|RVT-101 70 mg|RVT-101 70 mg once daily
2946472|NCT02928432|Experimental|Steroids switch|CRPC patients with biochemical and/or limited radiological progression after at least 12 weeks of AA + prednisone.
2946473|NCT02928419|Experimental|Arm 1 (Eltrombopag)|Arm 1 is the active treatment arm
2946474|NCT02928419|Placebo Comparator|Arm 2 (Placebo)|Arm 2 is the control arm
2946475|NCT02928406|Experimental|Atezolizumab|Participants will receive atezolizumab every 3 weeks (Q3W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
2946476|NCT02928393|Experimental|Basmisanil|Basmisanil at a dose of 240 milligrams (mg) orally twice daily for 90 days.
2946477|NCT02928393|Placebo Comparator|Placebo|Placebo matched to basmisanil orally twice daily for 90 days.
2946478|NCT02928380|Active Comparator|Reference Denture Adhesive|Participants applied reference denture adhesive as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture which were placed in the mouth.
2946479|NCT02928380|Experimental|Test Denture Adhesive|Participants applied test denture adhesive as 3 continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture, which were placed in the mouth.
2946480|NCT02928380|No Intervention|No Adhesive (Negative Control)|Participants did not apply any denture adhesive in this treatment arm.
2946481|NCT02928367||Pneumonia patients|rectal swab (4x) divided over two time points (day 0 and day 28) nasopharyngeal swab (2x) divided over two time points (day 0 and day 28) blood draw (90ml) divided over two time points (day 0 and day 28)
2946482|NCT02928367||Healthy subjects|rectal swab (2x) nasopharyngeal swab (2x) blood draw (70ml)
2946483|NCT02928354|Experimental|Treatment A - AZD7594|Treatment A - AZD7594 inhalation powder Particle size Large
2946484|NCT02928354|Experimental|Treatment B - AZD7594|Treatment B - AZD7594 inhalation powder Particle size Medium
2946485|NCT02928354|Experimental|Treatment C - AZD7594|Treatment C - AZD7594 inhalation powder Particle size Small
2946486|NCT02928341|No Intervention|No intervention|Current water supply access
2946487|NCT02928341|Experimental|Intervention|Received water supply improvement intervention designed to improve access to tap water, consisting of community managed public taps, improved tap water distribution network, refurbished tap connections and promotion of new household tap connections.
2946488|NCT02928328|Experimental|GABA oral solution|This study will test if oral administration of GABA containing solutions will reduce the pain and sensitivity induced by application of capsaicin to the tongue of healthy human subjects.
2946489|NCT02928328|Experimental|Intramuscular GABA|This study will test the hypothesis that intramuscular injection of GABA alone will not be painful, but will reduce muscle pain sensitivity in healthy human subjects.
2946490|NCT02928328|Experimental|Pain modulation|This study will test the hypothesis that intramuscular injection of GABA with glutamate will decrease the intensity of glutamate-evoked muscle pain in healthy human subjects.
2946491|NCT02928315|Active Comparator|magnesium|Five ampules of 500 mg of magnesium sulfate will be dissolved in 100 ml of normal saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
2946495|NCT02928289|Active Comparator|VISCO360 ab interno canaloplasty surgery|Subjects randomized to this arm will undergo a surgical procedure in which the VISCO360 Viscosurgical System will be used to microcatheterize and viscodilate Schlemm's canal (i.e., canaloplasty).
2946496|NCT02928289|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Subjects randomized to this arm will undergo the SLT procedure.
2946497|NCT02928276|Experimental|All patients|All eligible patients
2946498|NCT02928263||Patients treated with IV agents|Metastatic renal cell carcinoma patients treated with IV agents
2946499|NCT02928263||Patients treated with oral agents|Metastatic renal cell carcinoma patients treated with oral agents
2946500|NCT02928250|Active Comparator|Carnosine oral daily|Intervention group included pediatric patients with diabetic nephropathy receiving oral carnosine daily.
2946501|NCT02928250|Placebo Comparator|Second arm received placebo oral daily|Placebo group or control patients received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
2946502|NCT02928237|Active Comparator|Real tDCS|In the active stimulation condition a constant current of active transcranial direct current stimulation (tDCS) of 2mA intensity was applied for 30 minutes,over primary motor cortex M1. The treatment was repeated every day for 10 consecutive days.
2946503|NCT02928237|Placebo Comparator|Sham tDCS|Sham tDCS was applied using the same parameters but only for 30 seconds then the machine is deactivated.
2946504|NCT02928224|Experimental|Safety Lead-in, Triplet Arm|Encorafenib + binimetinib + cetuximab.
2946505|NCT02928224|Experimental|Doublet Arm|Encorafenib + cetuximab.
2946506|NCT02928224|Active Comparator|Control Arm|Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
2946507|NCT02928211|Experimental|Experimental|All subjects will receive the ointment and have scans with the Sapphire II device
2946508|NCT02928198|Active Comparator|Fenestration|Fenestration of the Absorb Biovascular Scaffold towards the side-branch
2946509|NCT02928198|Active Comparator|No Fenestration|No fenestration of the Absorb Biovascular Scaffold towards the side-branch
2946510|NCT02928185||HSCT patients|Individual/dyadic semi-structured interviews between Day +100 to +130
2946511|NCT02928185||HSCT care givers|Individual/dyadic semi-structured interviews between Day +100 to +130
2946512|NCT02928185||HSCT dyads|Individual/dyadic semi-structured interviews between Day +100 to +130
2946513|NCT02928185||HSCT Clinicians|Can include: MD, RN, SW, PharmD and Nutritionist. Individual semi-structured interviews after 14 days to review the Coping Together manuals
2946514|NCT02928172|Other|Depth of Anesthesia|Subjects will have the qCON-qNOX and BIS monitor
2946515|NCT02928159|Experimental|Low Pulse Amplitude Seizure Therapy|Course of Right Unilateral Ultrabrief LAP-ST using Mecta spectrum 5000Q Device.
2946516|NCT02928146|Active Comparator|Lichtenstein technique|Lichtenstein inguinal hernia repair
2946517|NCT02928146|Active Comparator|TAPP|Transabdominal preperitoneal (TAPP) approach for inguinal hernia repair
2946518|NCT02928146|Active Comparator|TEP|Totally extraperitoneal (TEP) approach for inguinal hernia repair
2946519|NCT02928120||CRC group (exploratory)|"Blood samples from approximately 210 patients diagnosed with colorectal carcinoma collected prospectively and consecutively at the Department of Surgical Gastroenterology, Aalborg University Hospital during the time period 2003-2006 will be used. The blood samples were collected at the time of diagnosis, before and after treatment (surgery and radio-chemo-therapy) and at regular intervals for a time period of two years after treatment. These blood samples were collected during a previous PhD-study: Pre- and postoperative Venous Thromboembolism in Patients with Colorectal Cancer - implications of Radiotherapy (ID-number VN 2003/102)."
2946520|NCT02928120||Control group (exploratory)|"Blood samples (8ml) from patients (n=142) who underwent work-up for lower gastrointestinal malignancy during the time period 2003-2006. Colonoscopy was performed, and no malignancy or premalignant lesions found. Blood samples were collected before/after colonoscopy. These blood samples were collected during a previous PhD-study: Pre- and postoperative Venous Thromboembolism in Patients with Colorectal Cancer - implications of Radiotherapy (ID-number VN 2003/102)."
2946521|NCT02928120||CRC group (validation)|Blood samples from 143 patients were collected prospectively and consecutively for a previous study on the effect of omega 3 fatty acids an postoperative complications after colorectal surgery. All study participants have provided written informed consent (N-VN-20050035).
2946522|NCT02928120||Control group (validation)|There will be recruited approximately 100 control subjects with a positive occult faecal blood but with a normal colonoscopy for blood sampling (28 ml).
2946523|NCT02928120||IBD group (validation)|In collaboration with The Department of Medical Gastroenterology, Aalborg University Hospital, there will be recruited approximately 120 patients with ulcerous colitis for blood sampling (28 ml).
2946524|NCT02928107|Experimental|At-Home Telephone Screening (Tele-HS)|Subjects receive printed educational materials about hearing loss and access to at-home Tele-HS.
2946525|NCT02928107|Experimental|PCP Encouragement, At-Home Tele-HS|Subjects receives encouragement from primary care provider (PCP) or hearing screening, printed materials and access to at-home Tele-HS.
2946526|NCT02928107|Experimental|PCP Encouragement, In-Office Tele-HS|Subjects receives PCP encouragement for hearing screening, printed materials and access to Tele-HS while in clinic.
2946527|NCT02928094|Experimental|A: Ad5FGF-4|Ad5FGF-4, administered one time at 6x10e9 viral particles in buffer, and maximally-tolerated medical therapy for angina.
2946528|NCT02928094|Placebo Comparator|B: Placebo|Placebo buffer, administered one time, and maximally-tolerated medical therapy for angina.
2946529|NCT02928081|Experimental|Extended lymphadenectomy|In addition to the standard lymphadenectomy, the nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1) must be dissected. Retroperitoneal lymphatic tissue, nerves and connective tissue range from the hepatic portal down to the beginning part of the inferior mesenteric artery, the right to the right renal hilus, left to the left edge of the abdominal aorta is included.
2946550|NCT02927977|Experimental|dry needling|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks. Participants will receive 4-6 treatments during 4 weeks.
2946758|NCT02926781|Active Comparator|drills|transcrestal sinus floor elevation using drills
2946530|NCT02928081|Other|Standard lymphadenectomy|Lymph node dissection includes the superior and inferior pyloric nodes (LN5, LN6), anterior and posterior nodes along the common hepatic artery (CHA) (LN8a, 8b), nodes along the common hepatic duct, common bile duct and cystic duct (LN12b1, 12b2, 12c), posterior pancreatoduodenal nodes (LN13a, 13b), nodes along the superior mesenteric artery (SMA) (LN14a, 14b), anterior pancreatoduodenal nodes (LN17a, 17b), but excluding the nerve tissues around common hepatic artery and the superior mesenteric artery.
2946531|NCT02928068|Experimental|Occupational Performance Coaching (OPC)|This group received approximately 12 sessions of the telehealth intervention. The intervention consisted of parent-therapist conversations via telehealth to increase child function and participation.
2946532|NCT02928055|Experimental|PNS (3 hr/day)|The PNS (3 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (3 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
2946533|NCT02928055|Experimental|PNS (6 hr/day)|The PNS (6 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
2946534|NCT02928055|Experimental|PNS (9 hr/day)|The PNS (9 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (9 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
2946535|NCT02928042||Lactobacillus bacteria|Pseudomonas aeruginosa, Acinetobacter baumanii, Staph aureus and Klebsiella pneumoniae will be isolated from tracheal aspiration cultures. 80 isolates associated with pneumonia will be identified and made antibiogram with VITEK. Then antimicrobial effects of Lactobacillus bacteria (LAB) (Lc. lactis subsp. lactis (IL 1403), Lc. lactis subsp. lactis (ATCC 11454), Lactobacillus plantarum (FI8595), Leuconostoc mesenterodies subsp. cremoris (DSMZ 20346), Streptococcus thermophilus (NCFB2392), Pediococcus acidophilus (ATCC 25741)) and nisin bacteriocin will be investigated on the bacteria's growth rate in the laboratory.
2946536|NCT02928029|Experimental|Phase1, arm1: Radium-223 dichloride+SOC|Phase 1: Radium-223 dichloride; 33 kiloBecquerel (kBq)/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC (standard of care) bortezomib/ dexamethasone.
2946537|NCT02928029|Experimental|Phase1, arm2: Radium-223 dichloride+SOC|Phase 1: Radium-223 dichloride; 55 kBq/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/ dexamethasone.
2946538|NCT02928029|Placebo Comparator|Phase2, arm1: Placebo+SOC|Phase 2: Matching placebo (isotonic saline) every 6 weeks for a total of 6 doses plus SOC bortezomib/dexamethasone.
2946539|NCT02928029|Experimental|Phase2, arm2: Radium-223 dichloride+SOC|Phase 2: Phase 1b-selected dose of radium-223 dichloride every 6 weeks for 6 doses plus SOC bortezomib/dexamethasone
2946540|NCT02928016|Experimental|Mixed meal 1|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
2946541|NCT02928016|Experimental|Mixed meal 2|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
2946542|NCT02928016|Experimental|Mixed meal 3|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
2946543|NCT02928016|Experimental|Mixed meal 4|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
2946544|NCT02928016|Experimental|Mixed meal 5|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
2946545|NCT02928016|Experimental|Mixed meal 6|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
2946546|NCT02928003|Experimental|Lung Surgery|
2946547|NCT02927990||Study group|Percutaneous coronary interventions with additional imaging provided by the new software package
2946548|NCT02927990||Control group|Percutaneous coronary interventions without the new software package
2946549|NCT02927977|Active Comparator|Control|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
2946551|NCT02927964|Experimental|Treatment (radiation therapy, TLR9 agonist SD-101, ibrutinib)|Patients undergo radiation therapy on days 1 and 2. Within 12 hours of the completion of radiation therapy, patients receive TLR9 agonist SD-101 IT on day 2 and on days 9, 16, 23, and 30. Patients also receive ibrutinib PO daily beginning on day 10 for 96 weeks or in the absence of disease progression or unexpected toxicity.
2946552|NCT02927951|Experimental|pregabalin at 150 mg bid|Each subject was randomized to the treatment for 6 weeks, followed by a 2 week washout period, and then completed the other arm of the study.
2946553|NCT02927951|Placebo Comparator|Placebo|Each subject was randomized to the treatment for 6 weeks, followed by a 2 week washout period, and then completed the other arm of the study.
2946554|NCT02927938|Active Comparator|LSC- favorable risk AML|Favorable risk AML patients with undetectable LSCs who receive cytarabine-based consolidation chemotherapy
2946555|NCT02927938|Experimental|LSC+ favorable risk AML - HCT|Favorable risk AML patients with detectable LSCs who are randomized to allogeneic HCT
2946556|NCT02927938|Active Comparator|LSC+ favorable risk AML - chemotherapy|Favorable risk AML patients with detectable LSCs who are randomized to cytarabine-based consolidation chemotherapy
2946557|NCT02927938|Active Comparator|LSC+ intermediate risk AML|Intermediate risk AML with detectable LSCs who are treated with allogeneic HCT
2946558|NCT02927938|Active Comparator|LSC- intermediate risk AML - HCT|Intermediate risk AML patients with undetectable LSCs who are randomized to allogeneic HCT
2946559|NCT02927938|Experimental|LSC- intermediate risk AML - chemotherapy|Intermediate risk AML patients with undetectable LSCs who are randomized to cytarabine-based consolidation chemotherapy
2946560|NCT02927938|Active Comparator|Unfavorable risk AML|Unfavorable risk AML patients
2946561|NCT02927938|Active Comparator|elderly/unfit AML - treated with HMA|Elderly/unfit AML patients treated with first line hypomethylating agent (HMA) therapy
2946562|NCT02927925|Experimental|Daratumumab|Participants will receive daratumumab 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion once weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks thereafter until study drug discontinuation due to progressive disease (PD), consent withdrawal or unacceptable toxicity.
2946563|NCT02927912|Experimental|Treatment (IOERT boost)|Patients undergo standard of care lumpectomy and then undergo 1 fraction of IOERT boost to the lumpectomy cavity. Patients then undergo standard of care oncoplastic reconstruction and whole breast radiation therapy.
2946564|NCT02927899|Experimental|Prevention (dietary intervention, survey)|Patients receive 4 tomato-soy beverages and 3 labeled arugula seed powder portions. Patients add 1 arugula seed powder portion to each of 3 tomato-soy beverages immediately prior to consumption, and they consume 1 beverage without the powder. After each beverage tasting, patients complete a survey on the sensory acceptability of the sample.
2946565|NCT02927886|Experimental|Per-oral Endoscopy Pyloromyotomy (G-POEM)|
2946566|NCT02927886|Placebo Comparator|Intrapyloric injection of botulinum toxin|
2946567|NCT02927873|Experimental|RSV LD Group|Subjects in this group will receive 2 doses of 0.5 ml of ChAd155 5x10^9 vp, one month apart of the RSV vaccine low dose (LD).
2946568|NCT02927873|Experimental|RSV MD Group|Subjects in this group will receive 2 doses of 0.15 ml of ChAd155 5x10^10 vp, one month apart of the RSV vaccine middle dose (MD).
2946569|NCT02927873|Experimental|RSV HD Group|Subjects in this group will receive 2 doses of 0.5 ml of ChAd155 5x10^10 vp, one month apart of the RSV vaccine high dose (HD).
2946570|NCT02927873|Placebo Comparator|Placebo LD group|Subjects in this group will receive 2 doses of 0.15 ml of placebo, one month apart.
2946571|NCT02927873|Placebo Comparator|Placebo MD group|Subjects in this group will receive 2 doses of 0.5 ml of placebo, one month apart.
2946572|NCT02927873|Placebo Comparator|Placebo HD group|Subjects in this group will receive 2 doses of 0.5 ml of placebo one month apart.
2946573|NCT02927847|Experimental|BA + VLNC|Participants will receive Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03), and behavioral treatment prior to quit attempt, followed by standard nicotine replacement therapy with Nicotine Patch during the quit attempt. Behavioral treatments in this condition will include standard smoking cessation counseling plus behavioral activation therapy aimed at increasing reinforcement from non-drug rewards.
2946574|NCT02927847|Active Comparator|VLNC Only|Participants will receive Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03), and behavioral treatment prior to quit attempt, followed by standard nicotine replacement therapy with Nicotine Patch during quit attempt. Behavioral treatments in this condition will include standard smoking cessation counseling plus supportive counseling and health education.
2946575|NCT02927834|Active Comparator|Antibiotic only|1. Augmentin (amoxicillin/clavulanate 875/125mg) orally (PO) twice a day for 3 weeks.
2946576|NCT02927834|Active Comparator|Augmentin with 6 day steroid|Augmentin with 6 day prednisone taper (40mg PO daily (QD) for 2 days, 20mg PO QD for 2 days, 10mg PO QD for 2 days, then stop)
2946577|NCT02927834|Active Comparator|Augmentin with 21 day steroid|Augmentin with 21 days prednisone taper (40mg PO QD for 5 days, 30mg PO QD for 5 days, 20mg PO QD for 5 days, 10mg PO QD for 5 days, then stop. )
2946578|NCT02927821|Experimental|ADS Plus|Families in settings assigned to intervention will receive Adult Day Services (ADS) as usual in addition to ADS Plus. ADS Plus has 5 key components: care management, referral/linkage; disease education; counseling/emotional support/stress reduction, and care skills managing daily challenges and behavioral disturbances. The intervention begins with 2 face-to-face sessions with the site interventionist to conduct a needs assessment to identify concerns and needs and develop an agreed upon care plan. The interventionist then meets with caregivers face-to-face at convenient times to implement the care plan, every other week for the first 3 months, and then for monthly reassessments for newly emerging care concerns thereafter. Contact occurs about a minimum of 1 hour per month over 12 months.
2946579|NCT02927821|No Intervention|ADS Usual Care|Caregivers in the 15 sites assigned to serve as the usual care control group will receive Adult Day Services (ADS) as usual. Near completion of the study (project year 05), control group sites will have the option of receiving training in ADS Plus for their setting.
2946618|NCT02927457|Experimental|Group A2- Skin Sites A/C/D (A/P/P)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving GSK2646264 1% for Area A- PV lesion, Placebo for Area C- PV lesion and Placebo for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
2946580|NCT02927808|Experimental|Intervention group - Motivational Interview|"Patients assigned to the intervention group will be given a leaflet entitled Information leaflet about LDL Cholesterol that will educate them about the risks of high LDL-C and the importance of adherence to lipid-lowering medication. Patients assigned to the intervention group will be contacted via telephone for a pre-specified interview (motivational interview again stressing the importance of adherence to lipid-lowering medication) at 1 month and 6 months after discharge, and for an in-person interview plus lipid profiling at 1 year after discharge."
2946581|NCT02927808|No Intervention|Control group|Patients assigned to the control group will be contacted for a pre-specified in-person interview plus lipid profiling at 1 year after discharge.
2946582|NCT02927795||Spiolto Respimat|QOL measurement of COPD patients taking Spiolto Respimat
2946583|NCT02927782|Active Comparator|Bed Rest|48 hours of strict bed rest after incidental durotomy during lumbar spinal surgery
2946584|NCT02927782|Experimental|Early Mobilization|Immediate Mobilization after incidental durotomy during lumbar spinal surgery
2946585|NCT02927769|Experimental|Nivolumab + brentuximab vedotin|
2946586|NCT02927769|Experimental|brentuximab vedotin + bendamustine|
2946587|NCT02927743|Active Comparator|evidence-based online feedback|During three months GPs will receive weekly feedback about evidence-based management of respiratory tract infections. In order to control that they read the material, there is a questionnaire, they have to fill in every week
2946588|NCT02927743|No Intervention|control|GPs will register data without receiving online feed-back
2946589|NCT02927730||positive retainted placenta histology|base on chorionic villi in the pathalogic sample
2946590|NCT02927730||negative retainted placenta histology|
2946591|NCT02927704||case (Aggressive periodontitis)|Single intervention has been performed for each subject. Gingival crevicular fluid sample was obtained in conjunction with clinical measurements in this intervention.
2946592|NCT02927704||control (Periodontally healthy subjects)|Single intervention has been performed for each subject. Gingival crevicular fluid sample was obtained in conjunction with clinical measurements in this intervention.
2946593|NCT02927691|Experimental|Immediate Treatment|Participants will begin treatment immediately following baseline testing.
2946594|NCT02927691|Other|Delayed Treatment|Following baseline testing, participants will receive no treatment for five weeks, then begin treatment immediately following a second baseline testing session.
2946595|NCT02927678||Diabetic patients with osteomyelitis|Patients with a clinical and radiological diagnosis of osteomyelitis were included in two diabetic centers
2946596|NCT02927665||Study Subjects|Eligible subjects receiving ReShape Integrated Dual Balloon System treatment in a commercial clinical setting
2946597|NCT02927652||Questionnaires for new patients|New patients seen at Duke Clinic for Head and Neck Surgery & Communication Sciences or Duke Raleigh Otolaryngology will be administered questionnaires (BSI-18, CG-CAHPS, and patient control scale).
2946598|NCT02927639|Experimental|Intervention|This group will receive the intervention for 6 months. The intervention will consist of daily text messages sent to the subject's personal mobile device in addition to the usual standard care. Previously developed text messages based on the ADA behavior goals will be used for this intervention.
2946599|NCT02927639|Other|Control First, then Intervention|This group will not receive the intervention in the first 3 months, just the usual standard of care. After the first 3 months, this group will also receive the intervention but for only 3 months.
2946600|NCT02927626|Experimental|Yang Yin Fu Zheng therapy|
2946601|NCT02927626|Placebo Comparator|Routine medical care|
2946602|NCT02927600|Experimental|Low GI Rice Breakfast|Intake of low GI breakfast
2946603|NCT02927600|Experimental|High GI rice Breakfast|Intake of High GI breakfast
2946604|NCT02927600|Experimental|Low GI Rice Dinner|Intake of low GI dinner
2946605|NCT02927600|Experimental|High GI Rice Dinner|Intake of High GI dinner
2946606|NCT02927587|Experimental|The induction Cet of propofol 1|The induction Cet of propofol was targeted at 1 ug/ml.
2946607|NCT02927587|Other|The induction Cet of propofol 2|The induction Cet of propofol was targeted at 2 ug/ml.
2946608|NCT02927574||DCB|Treatment with Paclitaxel drug-coated balloon angioplasty (DCB)
2946609|NCT02927574||POBA|Treatment with plain old balloon angioplasty (POBA)
2946610|NCT02927522|Placebo Comparator|Control|Placebo was administrated
2946611|NCT02927522|Experimental|Donepezil|Donepezil (5mg/ day for 7 days) was administrated
2946612|NCT02927496|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
2946613|NCT02927496|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
2946614|NCT02927483|Experimental|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
2946615|NCT02927483|Active Comparator|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
2946616|NCT02927470|Experimental|Working memory task|Simple visual stimuli (e.g., dots, colors, lines) will be presented on a computer monitor. The positions of the stimuli must be attended and remembered and decisions about the stimuli and/or their locations must be made. Memory will be probed with a button press or an eye movement towards the remembered locations.
2946617|NCT02927457|Experimental|Group A1- Skin Sites A/C/D (A/P/A)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving GSK2646264 1% (A) for Area A- PV lesion, Placebo (P) for Area C- PV lesion and GSK2646264 1% for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
2946718|NCT02927002|Active Comparator|Noninvasive brain stimulation: active|In active condition, subject will receive stimulation during all the 30-minute stimulation period
2946619|NCT02927457|Experimental|Group A3- Skin Sites A/C/D (P/A/A)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving Placebo for Area A- PV lesion, GSK2646264 1% for Area C- PV lesion and GSK2646264 1% for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
2946620|NCT02927457|Experimental|Group A4- Skin Sites A/C/D (P/A/P)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving Placebo for Area A- PV lesion, GSK2646264 1% for Area C- PV lesion and Placebo for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
2946621|NCT02927457|Experimental|Group B1- Skin Sites F/ G (A/P)|In group B, two chosen lesions will be labeled F and G based on size (F >G). Subjects will be receiving GSK2646264 1% for lesion F and Placebo for lesion G once daily for 28 days according to randomisation. Skin area H- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
2946622|NCT02927457|Experimental|Group B2- Skin Sites F/ G (P/A)|In group B, two chosen skin lesions will be labeled F and G based on size (F >G). Subjects will be receiving Placebo for lesion F and GSK2646264 1% for lesion G once daily for 28 days according to randomisation. Skin area H- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
2946623|NCT02927444|Experimental|NBP606|13-valent pneumococcal conjugate vaccine
2946624|NCT02927444|Active Comparator|Prevnar13|13-valent pneumococcal conjugate vaccine
2946625|NCT02927431|Experimental|Danirixin 15 mg FBE IV plus 75 mg oseltamivir|Subjects will receive double blind 15 mg FBE IV danirixin twice daily with open label 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
2946626|NCT02927431|Experimental|Danirixin 50 mg FBE IV plus 75 mg oseltamivir|Subjects will receive double blind 50 mg FBE IV danirixin twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
2946627|NCT02927431|Placebo Comparator|Placebo of danirixin IV plus 75 mg oseltamivir|Subjects will receive double blind IV placebo of DNX twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
2946628|NCT02927418|Experimental|Strength & Conditioning|Supervised S & C program based on the Long Term Athlete Development Model. Participants will attend 2-3 sessions per week for about one hour each session for 4 months. The comprehensive program will include strength and power training as well as plyometrics, agility and flexibility exercises.
2946629|NCT02927418|Active Comparator|Control|Athletes in the control group will continue with their usual sports and activities but will not receive any type of training.
2946630|NCT02927405|Placebo Comparator|TAP Block plus placebo|Patients will only receive a TAP block procedure and then morphine consumption will be recorded.
2946631|NCT02927405|Experimental|TAP Block plus gabapentin|Patients will receive a TAP block procedure and take pre-operative oral Gabapentin and morphine consumption will me recorded after surgery.
2946632|NCT02927392|Experimental|Pre-menopausal women|To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women. We will also explore whether suppression of ovarian hormones in pre-menopausal women (using leuprolide acetate) impairs BAT activity.
2946633|NCT02927392|No Intervention|Post-menopausal women|To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women.
2946634|NCT02927379|Active Comparator|ketamine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline +1 mg /kg ketamine (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision.
2946635|NCT02927379|Active Comparator|dexmedetomidine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline + 1µg/kg dexmedetomidine (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision.
2946636|NCT02927379|Placebo Comparator|bupivacaine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision( control group).
2946637|NCT02927366|Experimental|QCC374|
2946638|NCT02927366|Placebo Comparator|Placebo|
2946639|NCT02927353|Experimental|DMB-3113|adalimumab biosimilar
2946640|NCT02927353|Active Comparator|adalimumab|adalimumab
2946641|NCT02927340|Experimental|Lorlatinib|Lorlatinib will be administered orally once daily on a 21 day cycle Blood will be collected for biomarker studies
2946642|NCT02927327|Experimental|PET/MR ZTE MRAC|"PET/MR zero echo time (ZTE) scan for head attenuation and Q.Static . PET/MR ZTE MRAC images to be acquired for post-processing and reader assessment.~Zero Echo Time (ZTE) scan for head attenuation"
2946643|NCT02927327|Experimental|PET/MR Q Static (Q. MRAC)|"Q.Static (Q. MRAC) for respiratory motion correction. PET/MR Q Static (Q. MRAC) images to be acquired for post-processing and reader assessment.~PET/MR Q Static (Q. MRAC)"
2946644|NCT02927314|Placebo Comparator|Placebo|Placebo tablets orally q12h
2946645|NCT02927314|Active Comparator|CF102 12.5mg|CF102 tablets orally q12h
2946646|NCT02927314|Active Comparator|CF102 25mg|CF102 tablets orally q12h
2946647|NCT02927301|Experimental|Atezolizumab|Participants will first receive two cycles of atezolizumab as neoadjuvant therapy prior to surgery. Participants who demonstrate clinical benefit will be eligible to receive up to 12 months of atezolizumab.
2946648|NCT02927288||Military subjects with mTBI|mTBI/concussion only Group: Participants must have been clinically diagnosed with mTBI/concussion according to criteria outline by the World Health Organization (WHO; Holm et al., 2005) and be at least three month post-injury. Participants in the mTBI/concussion only group must not have a concurrent diagnosis of PTSD and must score below 25 on the Post-traumatic stress Check List for Civilians (PCL-C).
2946719|NCT02927002|Sham Comparator|Noninvasive brain: sham|In sham condition, subject will receive stimulation only at the beginning and at the end of 30-minute stimulation period.
2946649|NCT02927288||Military subjects with PTSD|Participants in the PTSD only group must have a clinical diagnosis of PTSD, following criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV TR). Proof of diagnosis will be obtained from participants via a request for release of pertinent medical records. Participants in this group must not have a history of mTBI or concussion.
2946650|NCT02927288||Military subjects with mTBI and PTSD|Participants in the mixed group must meet criteria for mTBI/concussion and PTSD as outlined above.
2946651|NCT02927288||Military healthy control|Participants in the military control group will meet all general requirements for participation but will not have a history of either mTBI/concussion or PTSD, as described above. Participants in this group will include service members on Active Duty and those currently serving with National Guard or Reserve forces.
2946652|NCT02927288||Civilian healthy control|Participants in the civilian control group will meet all general requirements for participation but will not have a history of either mTBI/concussion or PTSD, as described above.
2946653|NCT02927275|Experimental|Standing Modality|Performance on computerized cognitive tests while standing at a desk. Experimental: Standing Modality
2946654|NCT02927275|Experimental|Biking Modality|Performance on computerized cognitive tests while biking at user's preferred speed on stationary bicycle. Experimental: Biking Modality
2946655|NCT02927275|Experimental|Walking Modality|Performance on computerized cognitive tests while walking at 1mph. Experimental: Walking Modality
2946656|NCT02927275|Other|Seated Modality|Performance on computerized cognitive tests while sitting. No Intervention: Seated Modality
2946657|NCT02927262|Experimental|ASP2215|Subjects will be treated with ASP2215 once daily (continuously for up to 2 years).
2946658|NCT02927262|Placebo Comparator|Placebo|Subjects will be treated with matching placebo tablets once daily (continuously for up to 2 years).
2946659|NCT02927249|Experimental|Arm I (aspirin)|Patients receive aspirin PO QD for five years in the absence of disease progression or unacceptable toxicity.
2946660|NCT02927249|Placebo Comparator|Arm II (Placebo)|Patients receive placebo PO QD for five years in the absence of disease progression or unacceptable toxicity.
2946661|NCT02927236|Experimental|Pilot|P1 is designed to establish safety and tolerability criteria for administering iTBS to treatment seeking cocaine users, initially as in-patient followed by an out-patient cohort
2946662|NCT02927236|Experimental|Cocaine-Active|Designed to implement the iTBS administration parameters established from P1 with a larger sample of treatment seeking CD participants. Though the schedule may change slightly based on the outcome of the pilot, a schedule of 3 daily iTBS sessions with a 20 minute interval between administrations is planned and used throughout the design.
2946663|NCT02927236|Sham Comparator|Cocaine-Sham|To test the efficacy of iTBS.
2946664|NCT02927236|Other|Healthy Control-Main|Population comparison of acute experimental iTBS.
2946665|NCT02927223|Placebo Comparator|Baseline|Patients will undergo treadmill exercise at baseline
2946666|NCT02927223|Active Comparator|atropine|Patients will undergo treadmill exercise after IV atropine
2946667|NCT02927210|Placebo Comparator|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
2946668|NCT02927210|Experimental|Dimethandrolone Undecanoate|Single doses of DMAU administered via injection intramuscularly (IM - 80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC - 50 mg, 100 mg and 200 mg)
2946669|NCT02927197|Experimental|LearningRx Cognitive Training|The intervention is a 60-hour one-on-one cognitive training program
2946670|NCT02927197|No Intervention|Waitlist Control|The treatment-as-usual control group will begin the intervention when the experimental arm has completed the intervention.
2946671|NCT02927184|Placebo Comparator|Placebo|Placebo capsule
2946672|NCT02927184|Experimental|VK2809 (5mg)|5mg VK2809 capsule
2946673|NCT02927184|Experimental|VK2809 (10mg)|10mg VK2809 capsule
2946674|NCT02927184|Experimental|VK2809 (10mg QOD)|10mg VK2809 capsule
2946675|NCT02927171|No Intervention|Usual Care|Skilled nursing facility rehabilitation therapists provide all patients with usual standard of care.
2946676|NCT02927171|Experimental|I-STRONGER|IntenSive Therapeutic Rehabilitation for Older Skilled NursinG HomE Residents (I-STRONGER) Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities. Skilled nursing facility rehabilitation therapists will be trained in I-STRONGER intervention and will implement to all eligible patients as new standard of care.
2946677|NCT02927145|Active Comparator|Group 1-Phase Ia|The study is designed to assess a 'standard' protein-in-adjuvant vaccination regimen- 2µg RH5.1/ 0.5mL AS01- of 3 doses given four weeks apart, with dose escalation to assess the best dose in healthy adults.
2946678|NCT02927145|Active Comparator|Group 2- Phase Ia|"The dose used will be- 10µg RH5.1/ 0.5mL AS01. The total number of volunteers recruited to Groups 1 and 2 will be decided based on the immunogenicity of the vaccines at the 2 µg and 10 µg doses.~If the doses are immunogenic the groups (1 and 2) will be recruited to a total of 12 volunteers."
2946679|NCT02927145|Active Comparator|Group 3-Phase Ia|"Group 3 will receive 50µg RH5.1/ 0.5mL AS0~The ultimate aim is to assess the safety and immunogenicity of giving the 'standard' first two doses of the vaccine followed by a delayed fractional dose (10 µg)."
2946680|NCT02927145|Active Comparator|Group 4-Phase Ia|Group 3 and 4 will be recruited simultaneously. The dose of vaccine for this group is same as that of 3 (50µg RH5.1/ 0.5mL AS01)
2946681|NCT02927145|Active Comparator|Group 5-Phase IIa|The vaccination dose for Group 5 was decided following the analysis of safety and exploratory immunology assays from Groups 1, 2 and 4. The dose of vaccine for this group is the same as that of group 2 (10µg RH5.1/ 0.5mL AS01).
2946682|NCT02927145|No Intervention|Group 6-Phase IIa|"Group 6 volunteers will be infectivity controls, so will not receive any vaccinations.~Groups 5 and 6 will only be recruited once at least 6 volunteers in Group 4 have completed all vaccinations."
2946683|NCT02927145|Active Comparator|Group 7-Phase IIa|Group 7 are Group 5 volunteers who will receive a fourth dose of IMP (10µg RH5.1/ 0.5mL AS01)
2946684|NCT02927145|No Intervention|Group 8 -Phase IIa|Group 8 are infectivity controls who were originally in Group 6.
2946685|NCT02927145|No Intervention|Group 9 -Phase IIa|Group 9 are new infectivity controls
2946754|NCT02926794|Experimental|SA and No II|Self-affirmation and control intentions condition
2946755|NCT02926794|Experimental|No SA and II|Implementation intentions intervention and control writing task
2946686|NCT02927132|Experimental|Alcohol-Guilt Condition|"In this condition, participants are asked to write about an incident in which they drank heavily and experienced guilt.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
2946687|NCT02927132|Experimental|Distress-Guilt Condition|"In this condition, participants are asked to write about an upsetting incident where they experienced guilt.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
2946688|NCT02927132|Experimental|Alcohol-No Guilt Condition|"In this condition, participants are asked to write about a negative drinking incident that they had experienced.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
2946689|NCT02927132|Experimental|Distress-No Guilt Condition|"In this condition, participants are asked to write about an upsetting experience that has affected their life.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
2946690|NCT02927132|No Intervention|Neutral Control Condition|"In this condition, participants are asked to write about the laboratory room in which they are seated.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
2946691|NCT02927132|Experimental|Personalized Normative Feedback|Participants in the PNF condition will be given gender-specific personalized feedback regarding their alcohol use. Participants will be presented with the drinking estimates that they previously gave in addition to average gender-specific drinking estimates provided by 1124 students at the University of Houston. Feedback will be provided for drinking frequency (i.e., number of drinking days per week), and drinking quantity (i.e., the number of drinks consumed per week and number of drinks consumed per typical drinking occasion). Participants will also receive a printed a copy of the feedback for their records. PNF participants will receive feedback immediately after the baseline assessment. We also wanted to control for any differences that might be attributed to attention. Thus, participants will be scheduled to come in to the lab for two more sessions, during which time they will write about the laboratory room in which they are seated.
2946692|NCT02927119||Non-users|Pregnant women who had not taken dietary iodine supplement before and during pregnancy.
2946693|NCT02927119||Users|Pregnant women who had taken dietary iodine supplement before and/or during pregnancy.
2946694|NCT02927106|Experimental|Acute Myeloid Leukemia (AML)|AML samples will be collected from individuals with newly diagnosed or relapsed/refractory Acute Myeloid Leukemia (AML) as defined by World Health Organization 2016.
2946695|NCT02927093||Case|neonates with NH reaching exchange transfusion threshold
2946696|NCT02927093||Control|neonates with NH within moderate threshold of the phototherapy charts
2946697|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 1)|ACE-083 150 mg IM, once every 3 weeks for up to 5 doses.
2946698|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 2)|ACE-083 200 mg IM, once every 3 weeks for up to 5 doses.
2946699|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 3)|ACE-083 up to 250 mg IM, once every 3 weeks for up to 5 doses.
2946700|NCT02927080|Experimental|ACE-083 (Part 2, DB-PC, IM tibialis anterior muscle)|Double-Blind, Placebo-Controlled ACE-083 up to 250 mg IM (tibialis anterior muscle) or placebo, once every 3 weeks for up to 9 doses.
2946701|NCT02927080|Experimental|ACE-083 (Part 2, PL, IM tibialis anterior muscle)|Open-Label ACE-083 up to 250 mg IM (tibialis anterior muscle) once every 3 weeks for up to 8 doses.
2946702|NCT02927080|Experimental|ACE-083, (Part 2, DB-PC, IM biceps brachii muscle)|Double-Blind, Placebo-Controlled ACE-083 up to 250 mg IM (biceps brachii muscle) or placebo, once every 3 weeks for up to 9 doses.
2946703|NCT02927080|Experimental|ACE-083 (Part 2, OP, biceps brachii muscle)|Open-Label ACE-083 up to 250 mg IM (biceps brachii muscle), once every 3 weeks for up to 8 doses.
2946704|NCT02927067|Experimental|Maribavir/ Placebo|200mg tablets administered orally at 400mg (2 tablets) twice daily with food and placebo tablets (2 tablets) with the same appearance and route of administration as valganciclovir
2946705|NCT02927067|Active Comparator|Valganciclovir/ Placebo|450mg tablets administered orally at 900mg (2 tablets) twice daily with food and placebo tablets (2 tablets) with the same appearance and route of administration as maribavir
2946706|NCT02927054|Other|Internal Medicine Residents|Sepsis education provided to internal medicine residents
2946707|NCT02927054|Other|Emergency Medicine Residents|Sepsis education provided to emergency medicine residents
2946708|NCT02927054|Other|Orthopedic Residents|Sepsis education provided to orthopedic residents
2946709|NCT02927054|Other|Neurosurgery Residents|Sepsis education provided to neurosurgery residents
2946710|NCT02927054|Other|General Surgery Residents|Sepsis education provided to general surgery residents
2946711|NCT02927041||OR-Trauma|Patients presenting with hemodynamic instability with expected intubation greater than 24 hours. Hemodynamic monitoring with transesophageal echo and hemodynamic support/ interventions include volume resuscitation, vasopressors, and positive inotropes. The Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
2946712|NCT02927041||OR-Cardiovascular|Requiring non-isolated cardiac surgery for repair of thoracic aortic aneurysm. Hemodynamic monitoring with transesophageal echo and hemodynamic support/ interventions include volume resuscitation, vasopressors, and positive inotropes. The Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
2946713|NCT02927028|Other|Chewing group|50 individuals, both male and female, between the ages of 18 and 60 years old, with a BMI between 18-35 kg/m2 from any ethnic/racial background will be recruited. Participants must have natural dentition and rate the hedonic value of all study foods between 3 and 7 on a 9-point category scale.
2946714|NCT02927015|Experimental|Purple Majesty potato chips|Purple Majesty potato chips
2946715|NCT02927015|Experimental|Mountain Rose potato chips|Mountain Rose potato chips
2946716|NCT02927015|Experimental|White potato chips|White potato chips
2946717|NCT02927015|Experimental|Crackers|Crackers
2946720|NCT02926989|Experimental|Isotonic solution|Plasmalyte Glucos 50 mg/mL; total daily fluid requirements are estimated using the Holiday-Segar method plus possible dehydration (according to child's weight loss during acute illness); intravenous fluids are administered using delivery pumps programmed for an hourly infusion rate (mL/hour); intravenous fluids are administered as long as needed during hospitalization, but no longer than seven days after admission.
2946721|NCT02926989|Active Comparator|Hypotonic solution|0.45% saline in 5% dextrose; total daily fluid requirements are estimated using the Holiday-Segar method plus possible dehydration (according to child's weight loss during acute illness); intravenous fluids are administered using delivery pumps programmed for an hourly infusion rate (mL/hour); intravenous fluids are administered as long as needed during hospitalization, but no longer than seven days after admission.
2946722|NCT02926976|Active Comparator|risperidone with clozapine|risperidone, dosage form: 1 mg, dosage and frequency:3.0~6.0 mg/d; clozapine, dosage and frequency:300~600 mg/d; duration: 8 weeks
2946723|NCT02926976|Active Comparator|aripiprazole with clozapine|aripiprazole, dosage form: 5 mg, dosage and frequency:15~30 mg/day; clozapine, dosage and frequency:300~600 mg/d; duration: 8 weeks
2946724|NCT02926976|Active Comparator|sodium valproate with clozapine|sodium valproate, dosage form: 250 mg, dosage and frequency:600~1200 mg/day; clozapine, dosage and frequency:300~600 mg/d; duration: 3 months.
2946725|NCT02926976|Active Comparator|clozapine|only clozapine, dosage and frequency:300~600 mg/d;
2946726|NCT02926976|Active Comparator|Modified electroconvulsive therapy with clozapine|10 times MECT for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.
2946727|NCT02926976|Active Comparator|Magnetic seizure therapy with clozapine|10 times MST for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.
2946728|NCT02926963|Experimental|Chronic Granulomatous Disease|Sample collection were performed from patients with chronic granulomatous disease linked to X or due to Autosomal Recessive (AR) forms AR220, AR470 and AR670.
2946729|NCT02926950|Experimental|Sotagliflozin|A dose of sotagliflozin (SAR439954) will be administered as 2 tablets, once daily, before the first meal of the day. Metformin will be administered per Principal Investigator.
2946730|NCT02926950|Placebo Comparator|Placebo|A matching placebo will be administered as 2 tablets, once daily, before the first meal of the day. Metformin will be administered per Principal Investigator.
2946731|NCT02926937|Experimental|Sotagliflozin Dose 1|Sotagliflozin dose 1 will be administered as 2 tablets, once daily, before the first meal of the day
2946732|NCT02926937|Experimental|Sotagliflozin Dose 2|Sotagliflozin dose 2 will be administered as 1 tablet of sotagliflozin plus 1 placebo tablet, once daily, before the first meal of the day
2946733|NCT02926937|Placebo Comparator|Placebo|A matching placebo will be administered as 2 tablets, once daily, before the first meal of the day
2946734|NCT02926924|Active Comparator|Wound Vac|Wound vac
2946735|NCT02926924|Active Comparator|Standard Dressing|Standard Dressing
2946736|NCT02926911|Active Comparator|Guideline Concordant Care|DCIS - Surgery +/- radiation choice for endocrine therapy (MMG q 12 months x 5 years usual care for recurrent disease)
2946737|NCT02926911|Experimental|Active Surveillance|DCIS - Choice for endocrine therapy (MMG q 6 months x 5 years GCC for invasive progression)
2946738|NCT02926898|Experimental|ZX008 - 0.2 mg/kg/day - Cohort 1|"ZX008 0.2 mg/kg/day is supplied as an oral solution and will be administered twice a day (BID) in equally divided doses with food.~Product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH5"
2946739|NCT02926898|Experimental|ZX008 - 0.4 mg/kg/day - Cohort 1|"ZX008 - 0.4 mg/kg/day is supplied as an oral solution and will be administered twice a day (BID) in equally divided doses with food.~Product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH5"
2946740|NCT02926898|Experimental|ZX008 - 20 mg/day maximum - Cohort 2|"ZX008 - 20 mg/day maximum dose is supplied as an oral solution administered twice a day day (BID) in equally divided doses with food. Dose to be determined based on based on Cohort 1 .~Product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH5"
2946741|NCT02926898|Placebo Comparator|Matching Placebo - Cohort 2|Matching placebo will be administered twice a day (BID) in equally divided doses with food.
2946742|NCT02926885|Active Comparator|CONVENTIONAL LIVER RETRACTOR DEVICE|USE OF CONVENTIONAL LIVER RETRACTOR FOR THE LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
2946743|NCT02926885|Experimental|FLEXIBLE LIVER RETRACTOR DEVICE|USE OF THE FLEXIBLE LIVER RETRACTOR FOR THE LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
2946744|NCT02926872||Entire Study Population|Male or female patients who are between 2 and 16 years of age (inclusive) will be eligible for the study if they meet all components of Criterion A and/or Criterion B below, provided that these abnormalities are of unknown or unconfirmed etiology and the patient has not previously had a normal LAL enzyme activity result, has not received treatment with sebelipase alfa (Kanuma), and has no evidence of neurological dysfunction within the past year. (Note: Female patients who are of childbearing potential or are pregnant may participate in this study.)
2946745|NCT02926859|Experimental|Cannabidiol|Cannabidiol as add-on to individualized pharmacological treatment
2946746|NCT02926859|Placebo Comparator|Placebo|Placebo as add-on to individualized pharmacological treatment
2946747|NCT02926846|Experimental|Lavage arm|Intravenous vancomycin & gentamicin with adjunctive lavage
2946748|NCT02926846|Active Comparator|Standard treatment arm|Intraperitoneal vancomycin & gentamicin
2946749|NCT02926833|Experimental|Single Arm|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously followed by a limited course of atezolizumab
2946750|NCT02926820|Experimental|Cognitive training|Participants will undergo five weeks of cognitive training using the Cogmed QM program. All patients complete the same intervention.
2946751|NCT02926807||Atopic Dermatis Subjects|30 subjects with atopic dermatitis
2946752|NCT02926807||Healthy Volunteers|30 subjects without AD that matches for sex, age (± 2 years) and coronary artery disease risk factor with the AD subjects will be included as control case
2946753|NCT02926794|Experimental|SA and II|Combined self-affirmation and implementations intention arm
2946759|NCT02926768|Experimental|Daily dose of CK-101|Daily oral dose of CK-101
2946760|NCT02926755|Experimental|Angiography to Assess Vulnerable Plaque|In order to characterize plaque a repeat Coronary Angiography within 2 to 40 days will be done to assess vulnerable plaque features such as plaque tears, plaque thickness, plaque volume, and lipid content in plaque) in heart arteries in patients who have suffered a recent acute heart attack, and who have blockages >50% in one or more of the other arteries in the heart.
2946761|NCT02926729|Experimental|Experimental|Standard lumpectomy followed by nonlinear microscopy imaging of excised surgical margins. If invasive cancer or DCIS at or close to the margin is detected, additional excision may be performed.
2946762|NCT02926729|Active Comparator|Control|Standard lumpectomy without nonlinear microscopy imaging.
2946763|NCT02926703||GTCS patients|Patients with generalized tonic-clonic seizures (GTCS) and whose serum lactate and creatine kinase (CK) concentrations in blood samples had been measured within 2 hours after the event. In a subgroup of patients follow up blood samples were taken at 10 to 48 hours after the seizure to allow longitudinal the comparison of both markers
2946764|NCT02926703||Syncope patients|Patients with syncope and whose serum lactate and CK concentrations in blood samples had been measured within 2 hours after the event. In a subgroup of patients follow up blood samples were taken at 10 to 48 hours after the seizure to allow longitudinal the comparison of both markers.
2946765|NCT02926690|Experimental|OTS167PO|
2946766|NCT02926677|Experimental|Cue-Centered Treatment (CCT)|Cue-Centered Therapy provides 15 sessions of treatment. Focuses on developing skills in recognizing stress cues and coping skills. Taught to self-soothe without the active involvement of a guardian. Teaches emotional, cognitive, and physiological conditioning to deal with ongoing traumatic stress. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
2946767|NCT02926677|Experimental|Trauma-Focused CBT (TF-CBT)|Trauma-Focused CBT provides 15 sessions of treatment. Focuses on reframing subconscious thought and emotions with emotional and cognitive conditioning. Uses the active involvement and support of guardians. Addresses discrete traumatic incidents in the past. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
2946768|NCT02926677|Experimental|Treatment as Usual (TAU)|TAU is the current Standard treatment at Stanford Youth Solutions will serve as the control. The treatment is known as flexible integrated services. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
2946769|NCT02926651|Active Comparator|Conventional Oral TXA, Total Hip Arthroplasty (THA)|THA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
2946770|NCT02926651|Active Comparator|Conventional Oral TXA, Total Knee Arthroplasty (TKA)|TKA patients will be given three 650mg tablets of oral TXA (Tranexamic Acid) 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
2946771|NCT02926651|Experimental|Multi-Dose Oral TXA, Total Hip Arthroplasty (THA)|THA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
2946772|NCT02926651|Experimental|Multi-Dose Oral TXA, Total Knee Arthroplasty (TKA)|TKA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
2946773|NCT02926638|Experimental|Arm I (rilotumumab, erlotinib)|Patients receive rilotumumab IV over 60-120 minutes on day 1 and erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AND INTERVENTION 11/25/2014)
2946774|NCT02926638|Active Comparator|Arm II (erlotinib)|Patients receive erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AND INTERVENTION 11/25/2014)
2946775|NCT02926625|Active Comparator|Conditional follow-up|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, ie. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
2946776|NCT02926625|Experimental|Systematic follow-up arm|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should come back for a systematic follow-up visit after 2 days, even if the child has recovered.
2946777|NCT02926612||HCT recipients ages ≤21 years|HCT recipients ages ≤21 years for whom lower respiratory secretions are being collected for direct patient care.
2946778|NCT02926599|Experimental|Personal Optimization Training|"Personal Optimization Training such as positive reinforcement, personalized psycho-physiological relaxation and mental rehearsal (total 5 hours a few weeks before the simulation).~Having 2 min to focus on techniques they were trained, after briefing of the scenario and before the start of the scenario."
2946779|NCT02926599|No Intervention|Control|"No particular training.~Screening of normal labs results during 2 min, after briefing of the scenario and before the start of the scenario."
2946780|NCT02926586|Experimental|Fludarabine|The patients in experimental arm should receive the consolidation chemotherapy regimen with fludarabine and cytarabine. The dosage of fludarabine is 30mg/m2/d for 5 days intravenously and cytarabine is 1500mg/m2/d for 5 days intravenously.
2946781|NCT02926586|Active Comparator|high-dose cytarabine|The patients in control arm should receive the consolidation chemotherapy regimen with high-dose cytarabine. The dosage of cytarabine is 2000mg/m2/12h for 3 days (1,3,5) intravenously.
2946782|NCT02926573|Active Comparator|Gabapentin|Gabapentin liquid by mouth or Per Tube 300mg twice a day
2946783|NCT02926573|Placebo Comparator|Placebo|Placebo liquid by mouth or Per Tube twice a day
2946784|NCT02926547||CCIS|
2946785|NCT02926547||invasive breast cancer|
2946786|NCT02926534||Smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) who are currently smoking conventional cigarettes with a minimum of 10 pack-year smoking history
2946843|NCT02926131||Infants|Infants requiring serum bilirubin (SBR) measurement seen in Wang Pha clinic (WPA) clinic.
2946787|NCT02926534||Ex-smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) with a minimum of 10 pack-year smoking history who stopped smoking cigarettes between 1 and 5 years ago
2946788|NCT02926534||Never-smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) who are current non-smokers and with no history of smoking (control group)
2946789|NCT02926521|No Intervention|Dressing A|Dressing A: a nerve block catheter affixed with Pajunk anchor and covered with Tegaderm.
2946790|NCT02926521|Active Comparator|Dressing B|Dressing B: a nerve block catheter affixed with Pajunk anchor, skin treated with gum mastic liquid adhesive (Mastisol), all covered with Tegaderm
2946791|NCT02926521|Active Comparator|Dressing C|Dressing C: a nerve block catheter sealed with 2-octyl cyanoacrylate liquid adhesive (Dermabond), trailing catheter affixed with Pajunk anchor, all covered with Tegaderm
2946792|NCT02926521|Active Comparator|Dressing D|Dressing D: a nerve block catheter sealed with 2-octyl cyanoacrylate (Dermabond), trailing catheter affixed with Pajunk anchor, skin treated with gum mastic liquid adhesive (Mastisol), all covered with Tegaderm
2946793|NCT02926508|Experimental|Prebiotic (Bimuno)|Bimuno (B-GOS, Galacto-oligosaccharides, produced and provided by Clasado BioSciences Ltd)
2946794|NCT02926508|Placebo Comparator|Placebo|Maltodextrin
2946795|NCT02926495|Active Comparator|Treatment (ON)|
2946796|NCT02926495|Sham Comparator|Control (OFF)|
2946797|NCT02926482|No Intervention|Control|This arm will include 35 organizations who receive access to the Prescriber Recruitment Bundle (PRB) materials online via a secure website.
2946798|NCT02926482|Experimental|PRB: organizations implementing the PRB|This arm will include 35 organizations that will implement the intervention, the Prescriber Recruitment Bundle (PRB) using the NIATx Organizational Change Model (a model developed by our center research team).
2946799|NCT02926469|No Intervention|Standard Care|For patients presenting in labor and desiring standard care (natural childbirth without pain medications, systematic distraction, or alternative therapies) the patient will experience their contractions. Afterwards they will answer pain and anxiety questionnaires.
2946800|NCT02926469|Experimental|Virtual Reality|For patients presenting in labor and desiring standard care (natural childbirth without pain medications, systematic distraction, or alternative therapies) the patient will experience their contractions while using immersive Virtual Reality.Afterwards they will answer pain and anxiety questionnaires.
2946801|NCT02926456||Cohort 1|HIV-1-infected patients being in stable ritonavir-boosted Antiretroviral (ARV) treatment with Protease Inhibitors (PIs) (either darunavir 800 milligram [mg] each day -based or not) since at least twelve months and virologically suppressed (HIV-RNA less than [<]50 copies/milliliters) since at least six months.
2946802|NCT02926443|Active Comparator|One-on-one Usual Physiotherapy Care (Control)|The Ctl group (n =16) will receive physiotherapy usual care treatments during a 6-week period. The Ctl group will receive 2 physiotherapy treatments (30 minutes) in the clinic per week (total of 12 treatments) as well as an individualized home exercise program (HEP). Treatments will include range of motion exercises, manual therapy treatments, modalities, and strengthening exercises, as determined by the treating physiotherapist. Specific muscle group exercises and parameters will be documented by the treating physiotherapist on a provided summary sheet.
2946803|NCT02926443|Experimental|Group Program (UpEx-NTP) (Exp)|The Exp group (n =16) will partake in a 6-week group Upper Extremity Neuromuscular Training Program that consists of postural education, strength exercises, motor control exercises, and upper extremity functional tasks common for active military personnel. The UpEx-NTP program consists of 35-45 minutes of exercise, three times a week for 6 weeks (18 treatments), supervised by a physiotherapist. The program consists of 11 stations with several variations of difficulty of the same exercise per station. The exercises of each station will be performed in order of difficulty. The participant chooses one exercise to perform per station based on their current ability while respecting their pain levels at 3/10 or less.
2946804|NCT02926430|Experimental|Ad26.RSV.preF 5*10^10 vp (Day 1 and Day 365): Group 1|Participants will receive 5*10^10 viral particles (vp) Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).
2946805|NCT02926430|Experimental|Ad26.RSV.preF 5*10^10 vp (Day 1)- Placebo (Day 365): Group 2|Participants will receive 5*10^10 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).
2946806|NCT02926430|Experimental|Ad26.RSV.preF 1*10^11 vp (Day 1 and Day 365): Group 3|Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).
2946807|NCT02926430|Experimental|Ad26.RSV.preF 1*10^11 vp (Day 1)- Placebo (Day 365): Group 4|Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).
2946808|NCT02926430|Experimental|Placebo (Day 1 and Day 365): Group 5|Participants will receive placebo at Day 1 and Day 365 (10 to 13 months after first vaccination).
2946809|NCT02926404||Patient-specific rods|Patients with spinal deformities receiving osteosynthesis with patient-specific rods (UNiD Rods)
2946810|NCT02926391||Cervical|30 patients who need anterior cervical corpectomy and fusion with patient-specific implants (UNiD 3D VBR)
2946811|NCT02926391||Thoraco-lumbar|30 patients who need anterior thoracolumbar corpectomy and fusion with patient-specific implants (UNiD 3D VBR)
2946812|NCT02926378|Experimental|Acupuncture Intervention|Every participant will receive six acupuncture treatments across a three to four-week period. The treatments will last a total of about one hour, including a 10 minute initial assessment, needling, and 45 min of lying down with the needles. Two treatments a week will be performed by Dr. Siminovich-Blok, the PI of this study and a NYS licensed acupuncturist at NYU Langone Medical Center (NYULMC) Ambulatory Care Center. Each acupuncture treatment will consist of 1) a combination of a fixed set of points suggested by the literature, and 2) an individualized set of points based on the evaluation by the licensed acupuncturist. The first set of points will consist of 4 acupoints used consistently in the treatment of stroke through the literature.
2946813|NCT02926365|Experimental|ICBT|Therapist-supported internet-delivered CBT
2946814|NCT02926352|Experimental|Extinction Training with LLLT|Participants will receive one-session of fear extinction training tailored to the participant's specific fear domain. 15 minutes after fear extinction, participants will receive 8 minutes of Low-Level Laser Therapy stimulation. The laser will be directed at two areas on the forehead: bilateral frontal points Fp1 and Fp2 (on the EEG electrode placement system; to stimulate the vmPFC). Each area will be stimulated for 4 minutes. Treatment will consist of alternating between each of these points after each minute.
2946815|NCT02926352|Active Comparator|Extinction Training with Sham LLLT|Participants will receive one-session of fear extinction training tailored to the participant's specific fear. 15 minutes after fear extinction, participants will receive 8 minutes of Sham Low-Level Laser Therapy stimulation. The laser will be directed at two areas on the forehead: bilateral frontal points Fp1 and Fp2 (on the EEG electrode placement system). The procedure will consist of alternating between each of these points after each minute. However, each point will receive only a brief (5-second) treatment to the intended site on the forehead, followed by 55 seconds of no treatment, for each one-minute cycle, functioning as a placebo dose of the treatment.
2946816|NCT02926352|Experimental|LLLT alone|Participants will receive 8 minutes of Low-Level Laser Therapy stimulation. The laser will be targeted first at the left forehead point F3 and then at the right forehead point F4 (on the EEG electrode placement system). F3 corresponds with the left dorsolateral prefrontal cortex and F4 corresponds with the right dorsolateral prefrontal cortex. Each area will be stimulated for 4 minutes. Treatment will consist of alternating between each of these points after each minute.
2946817|NCT02926352|Sham Comparator|Sham LLLT alone|Participants will receive 8 minutes of Sham Low-Level Laser Therapy stimulation. The laser will be targeted first at the left forehead point F3 and then at the right forehead point F4 (on the EEG electrode placement system). The procedure will consist of alternating between each of these points after each minute. However, each point will receive only a brief (5-second) treatment to the intended site on the forehead, followed by 55 seconds of no treatment, for each one-minute cycle, functioning as a placebo dose of the treatment.
2946818|NCT02926339|Experimental|Teens Against Tobacco Use presentation|Students in the intervention group will receive anti-tobacco presentations from Teens Against Tobacco Use Members
2946819|NCT02926339|No Intervention|Control|Students in this group will receive a control presentation from their physical education teachers on a topic unrelated to tobacco.
2946820|NCT02926326|Other|Period 1 and Period 2|"Period 1 - BCT197 14mg on Day 1~Period 2 - BCT 197 14mg on Day 1 and Azithromycin 500mg on Day 1,2 and 3"
2946821|NCT02926313|No Intervention|Existing Seating conditions|This group of participants received the standard care - they continue to sit in the seating system (chair and cushion) as provided by the nursing home facility staff; selected from whatever seats the facility had available.
2946822|NCT02926313|Experimental|Individualized Seating provision|This group of participants were provided with a seating system that was specifically configured to match their individual postural care needs.
2946823|NCT02926287|Experimental|Ambulatory surgery|All the patients operated for pelvic organ prolapse during the study time will be recruited. All the patient eligible for an Ambulatory surgery will be discharged earlier.
2946824|NCT02926274||Whole Blood|Adult male trauma patients presenting with systolic blood pressure <100 will receive up to 6 units of whole blood when available.
2946825|NCT02926274||Component therapy|Adult female patients presenting with systolic blood pressure <100, as well as adult male patients with systolic blood pressure <100 during periods when whole blood is not available, will receive component therapy (1:1:1 packed red blood cells: plasma:platelets) for transfusion.
2946826|NCT02926248|Experimental|Colchicine|Manipulation under Anesthesia (MUA) will be performed prior to 12 weeks after the index TKA. Patients will be randomized to oral colchicine 0.6 mg twice daily for 6 weeks. All patients will follow a standardized post-MUA physical therapy protocol.
2946827|NCT02926248|Placebo Comparator|Placebo|Manipulation under Anesthesia (MUA) will be performed prior to 12 weeks after the index TKA. Patients will be randomized to oral placebo twice daily for 6 weeks. All patients will follow a standardized post-MUA physical therapy protocol.
2946828|NCT02926235|Experimental|Amino Acid|Patients will be asked to ingest 20g of EAA o two times a day between meals 1 week prior and 2 weeks postoperatively.
2946829|NCT02926235|Placebo Comparator|Placebo|Patients will be asked to ingest 20g of placebo two times a day between meals 1 week prior and 2 weeks postoperatively.
2946830|NCT02926222|Experimental|ARM A - Regorafenib|Patients receive REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity.
2946831|NCT02926222|Active Comparator|ARM B - Lomustine|Patients receive LOMUSTINE 110 mg/m2 orally on day 1, every 6 weeks (q6w), until disease progression or unacceptable toxicity.
2946832|NCT02926209|Active Comparator|Aer-O-Scope First|Patients in this arm will undergo colonoscopy using the Aer-O-Scope followed by colonoscopy using a conventional colonoscope
2946833|NCT02926209|Active Comparator|Conventional Colonoscope First|Patients in this arm will undergo colonoscopy using a conventional colonoscope followed by colonoscopy using the Aer-O-Scope
2946834|NCT02926196|Experimental|Arm Avelumab|Avelumab 10 mg/kg I.V. q2w for 1 year (52 weeks)
2946835|NCT02926196|No Intervention|Arm Observation|Observation as per guidelines
2946836|NCT02926183|Experimental|Gemcitabine plus nab-paclitaxel|Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel: Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
2946837|NCT02926170|Experimental|rivaroxaban|Rivaroxaban 20 mg per day
2946838|NCT02926170|Active Comparator|acenocumarol|INR adjusted dose
2946839|NCT02926157|Experimental|Life Style and Sleep Group|Participants randomized into this group will undergo a 4 week sleep hygiene course (classes 1x/week for 1.5 hours), followed by a 20 week lifestyle activation program. During the 20 week lifestyle activation program, participants wear a Fit Bit and receive a call from a fitness professional every other week for motivation and recommendations, and receive a bright light therapy program from a sleep expert based on their initial sleep results at the baseline measurement session.
2946840|NCT02926157|No Intervention|Wait-list Control|Participants randomized into this group will complete all measurement sessions. After completion of the final measurement session (6 months), participants will be offered an abbreviated version of the Life Style and Sleep Group intervention including the sleep hygiene course, consultation with sleep expert to go over individual sleep patterns and be given recommendations, along with physical activity recommendations from a fitness expert.
2946841|NCT02926144|Experimental|Laryngoscope with video|Use of the video-laryngoscope McGrath Mac with use of the video feature
2946842|NCT02926144|Active Comparator|Laryngoscope without video|Use of the video-laryngoscope McGrath Mac without use of the video feature
2946844|NCT02926118|Experimental|Low glycemic load|Low glycemic load
2946846|NCT02926105|Experimental|T&E Home-based exercise programme|Individually tailored home-based test and exercise programme
2946847|NCT02926105|Experimental|Otago|Individually tailored exercise programme
2946848|NCT02926105|Active Comparator|Helsana booklet|Helsana recommendations and exercises
2946849|NCT02926092||Arm 1|Observation of progression of disease over time.
2946850|NCT02926079||Pregnant women diagnosed with gestational diabetes|
2946851|NCT02926079||Pregnant women with normal pregnancy|
2946852|NCT02926066|Experimental|AAV2-hAADC|Dosage form: Aqueous solutionDose(s): 2.371x1011 vg/case Dosing schedule: Intracerebral infusion, single doseMechanism of action (if known): supplement a gene defect
2946853|NCT02926053|Experimental|Patient group|"All patients receive the same treatment.~Surgical removal of tumor tissue for T cell production, which takes 4-6 weeks, is performed initially.~All patients are hospitalized during treatment (one week in advance of the T cell product being ready and for approximately 3 weeks in total) and receive treatment only once.~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine on day -7 to day -1.~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 5. Interleukin-2 is administered as high-dose i.v. bolus every eight hour starting approximately 6 hours after TIL infusion and for up to 5 days (maximum of 15 doses)."
2946854|NCT02926027|Active Comparator|Active subjects|Vascepa (4 gm/day), oral dose
2946855|NCT02926027|Placebo Comparator|Placebo subject|oral dose of placebo
2946856|NCT02926014|Experimental|Lingual Tonsil Hypertrophy participants|"The research group consisted of 50 consecutive adult outpatients suffering from swallowing disorders, examined by otorhinolaryngologist at the Hospital of Lithuanian University of Health Sciences.~Lingual Tonsil Hypertrophy was diagnosed using videolaryngoscopy."
2946857|NCT02926014|Other|Control participants|The control group consisted of 50 healthy adult participants, who were examined using videolaryngoscopy and no pharyngeal pathologies were diagnosed, including lingual tonsil hypertrophy.
2946858|NCT02925988|Other|EEG monitoring|Neonates will receive their aEEG monitoring as soon as the indication for monitoring is established, and cEEG electrodes will be applied in parallel, as soon as an EEG technician is available, which should usually be within less than 16 hours, in many cases within 1-4 hours.
2946859|NCT02925975|Other|Healthy controls|Healthy volunteers are enrolled as controls to get a normal range of pressure gradient in different sites of hepatic portal system (HPS), such as portal vein, superior mesenteric vein, inferior mesenteric vein and splenic vein. All enrolled healthy subjects should undergo anatomic computed tomographic angiography (CTA) and Doppler ultrasound for only one time, to rebuild a 3D-vHPS by computer.
2946860|NCT02925975|Experimental|Treatment group guided by vPVPG|Enrolled cirrhotic patients with virtual portal vein pressure gradient (vPVPG) above 12mmHg are only treated by oral carvedilol. Once there are visible varies under the endoscopy, participants will be treated with routine endoscopic procedures.
2946861|NCT02925975|Experimental|Follow-up group guided by vPVPG|Cirrhotic patients with vPVPG lower than 12mmHg are followed-up with anatomic CTA and Doppler ultrasound every six months. Once vPVPG is higher 12mmHg or visible varies under the endoscopy, participants will be rescheduled to treatment group guided by vPVPG.
2946862|NCT02925975|Active Comparator|Follow-up group guided by endoscopy|Cirrhotic patients are followed-up by routine endoscopy. Once there are visible varies, participants will be treated according to Baveno V consensus in portal hypertension, such as oral carvedilol and routine endoscopic procedures.
2946863|NCT02925962|Experimental|Clinical Decision Support System (CDSS)|"PCPs get a notice the CKD Clinical Decision Support System (CDSS) is available.~CDSS overview:~The study MDs order CKD triple marker tests~Patients will go to the lab as per usual clinical care~Lab results are returned to PCPs clinical results folder as per usual clinical workflow with information about CKD and link to KDIGO guidelines~Results will also be sent to the Study MD's for monitoring~At the patient's next visit, if the labs are completed, the full CDSS launches for the PCP~If the labs are not completed by the next visit, a Best Practice Alert (BPA) will launch for the PCP notifying them that the labs have been ordered, but the patient hasn't done them yet"
2946864|NCT02925962|Experimental|Clinic Decision Sup System + Pharmacist|"The Clinical Decision Support System + Pharmacist follow-up call extends beyond the CDSS alone.~CDSS Plus overview:~At the visit in which the CDSS launches, the PCP will hand a study card with pharmacist information to their patient notifying them that a pharmacist will be calling to follow-up after the visit~The pharmacist will use MyChart and/or phone calls to schedule a follow-up call within two weeks of the visit~On the follow-up phone call, the pharmacist will discuss understanding of CKD, medication review and adherence assessment, home BP checks, and the importance of NSAID avoidance~A second follow-up call will only be scheduled if the patient is non-adherent with their medications and makes an active plan for adherence with the pharmacist, or if the patient requests an additional call from the pharmacist"
2946865|NCT02925962|No Intervention|Usual Care|Patients continue to receive usual care by their provider.
2946866|NCT02925949|Active Comparator|DuoPACT|A 6-session HIV medication adherence support program for couples.
2946867|NCT02925949|Active Comparator|LifeSteps|A 3-session HIV medication adherence support program for individuals.
2946868|NCT02925936|Active Comparator|Cathode|Thyroid facing the cathode end of xray machine
2946869|NCT02925936|Active Comparator|Anode|Thyroid facing the anode end of xray machine
2946870|NCT02925923|Active Comparator|Ticagrelor and bivalirudin or heparin|ticagrelor (180 mg) and bivalirudin/heparin (n=50 patients)
2946871|NCT02925923|Active Comparator|Clopidogrel, eptifibatide and heparin|clopidogrel (600 mg), eptifibatide (180 mcg/kg) and heparin (n=50 patients)
2946872|NCT02925910|Other|softwheels at second round|Begining with regular wheelchair for 2 days and then changing for shock absorbing wheelchair for 2 days
2946873|NCT02925910|Other|softwheels at first round|starting with Shock absorbing wheelchair for 2 days and then changing for regular wheelchair for 2 days
2946874|NCT02925897|Experimental|Intervention|participants will receive their usual treatment from nurses who have had some training in behaviour change and motivational interviewing.
2946875|NCT02925897|No Intervention|Control|The participants will receive their usual treatment from nurses who have had no additional training in behaviour change and motivational interviewing.
2947122|NCT02924298|Experimental|Stage 1-2 Chronic Kidney Disease|Individuals with estimated glomerular filtration rate > 60 mL/min/1.73m^2, to undergo SLIMM intervention
2946876|NCT02925884|Experimental|Gunnar OTC Glasses Condition|Intervention: Gunnar Over-The-Counter Glasses with lens (subjects will wear the glasses with lens while performing visual tasks on computers.
2946877|NCT02925884|No Intervention|Control Condition|Subjects will be wearing an identical frame without any lens while performing visual tasks on computers.
2946878|NCT02925871||transitions|current transitions from the stroke unit to the home
2946879|NCT02925858|Experimental|Intervention|Intraoperative infusion of ketamine
2946880|NCT02925858|Placebo Comparator|Control|Control group receiving a saline infusion
2946881|NCT02925845|Experimental|Neuromuscular electrostimulation|Patients assigned to the group NMS, following the visit Day Hospital, in the first two hours of each HD session will perform a program of neuromuscular electrostimulation of the limb with the RC-AVF performed in the reference position of the flexors and extensors forearm at the tip intervened in each HD session on the stage previously established in the protocol (duration according to established program).
2946882|NCT02925845|No Intervention|Isometric exercises|They will perform isometric exercises operated limb on an outpatient basis (repeated pressure rubber balls, heavy lifting 1-2 kg).
2946883|NCT02925832|Experimental|Group B|Deep Topical Fornix Nerve block anesthesia using bupivacaine and proparacaine
2946884|NCT02925832|Experimental|Group R|Deep Topical Fornix Nerve block anesthesia using ropivacaine and proparacaine
2946885|NCT02925819||SEVERE MITRAL VALVE DISEASE|All patients with symptomatic severe mitral valve disease on a native valve or due to deterioration after surgical valve repair or replacement, and not eligible for surgery according to the heart-team.
2946886|NCT02925806||ER/LA opioids included in the class REMS|
2946887|NCT02925806||IR Opioids|
2946888|NCT02925806||Celecoxib|
2946889|NCT02925806||Benzodiazepines|
2946890|NCT02925793|Experimental|1% DS107 cream|Participants in this group will receive 1% DS107 cream twice daily.
2946891|NCT02925793|Experimental|5% DS107 cream|Participants in this group will receive 5% DS107 cream twice daily.
2946892|NCT02925793|Placebo Comparator|Vehicle cream|Participants in this group will receive matching placebo cream twice daily.
2946893|NCT02925780|Experimental|Icon|"The upper front teeth of each participant once distributed to each of the two evaluation groups randomly, teeth that were designated for the infiltrative resin ICON will be subjected to a cleaning operative field with paste of pumice and water, local anesthesia to work under absolute isolation from canine to canine, next, the product application Icon ® -DMG on the buccal surfaces of the anterior superior teeth selected will take place, strictly following the manufacturer's instructions.~After placing the material, a photographic archive of the tested teeth will be elaborated; the same of which have received a set distance, lighting, and camera."
2946894|NCT02925780|Active Comparator|Microabrasion|"The labial surface of teeth selected for the microabrasion after the isolation process and precleaning receive placement microabrasive material, OPALUSTRE, strictly following the manufacturer's instructions, using a rubber cup at low speed for 5 times each for 5 seconds washing by flushing water from the syringe triple surfaces between each of the applications.~After placing the material, a photographic archive of the tested teeth will be elaborated; the same of which have received a set distance, lighting, and camera."
2946895|NCT02925767|Experimental|The 311-nm Ti:Sapphire laser treatment group|All lesions were treated twice weekly for a total of 12-week period.
2946896|NCT02925767|Active Comparator|The 308-nm excimer laser treatment group|All lesions were treated twice weekly for a total of 12-week period.
2946897|NCT02925741|Experimental|Silk-Like Linens|A traditional cluster randomized crossover design will be used with patients in five medical intensive care units. Each unit will have approximately six months on the silk-like linens. For each unit, the order of intervention will be randomized.
2946898|NCT02925741|Experimental|Standard Cotton Linens|Standard cotton bed linens will be maintained and changed per unit protocol on units randomized to standard cotton bed linens.
2946899|NCT02925728|Experimental|Nutrition with Finger-Food|Nutrition with Finger-Food
2946900|NCT02925728|Active Comparator|Nutrition without Finger-Food|Nutrition without Finger-Food
2946901|NCT02925715|Experimental|supraclavicular|ultrasound guided central venous cannulation done by supraclavicular approach
2946902|NCT02925715|Experimental|infraclavicular|ultrasound guided central venous cannulation done by infraclavicular approach
2946903|NCT02925702||Radium-223|Radium-223 55 mBq/Kg every 4 weeks
2946904|NCT02925676|Experimental|hyposafe H02|All subjects included are assigned to hyposafe H02-testing
2946905|NCT02925663|Experimental|EFI-E|10-session web-based modules to teach about executive functioning with videoconferencing with a therapist
2946906|NCT02925650|Experimental|Low Dose|The study drug Posiphen dosage of 60mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
2946907|NCT02925650|Experimental|Medium Dose|The study drug Posiphen dosage of 120mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
2946908|NCT02925650|Experimental|High Dose|The study drug Posiphen dosage of 180mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
2946909|NCT02925650|Placebo Comparator|Placebo|The Placebo comparator is to be taken orally in divided doses, three times per day for a total 23-25 days.
2946910|NCT02925637|Active Comparator|treatment group|treatment group will receive FACoT, that include one to one 10 treatment sessions. the treatment sessions will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
2946911|NCT02925637|No Intervention|control group|control group receiving standard care - cognitive and functional assesment
2946912|NCT02925611|Active Comparator|Isoflurane|Isoflurane as an inhalational anaesthetic ,titrated with BIS ( bispectral index) /entropy monitoring,from start to end of surgery.
2946913|NCT02925611|Active Comparator|Desflurane|Desflurane as an inhalational anaesthetic ,titrated with BIS ( bispectral index) /entropy monitoring,from start to end of surgery.
2946914|NCT02925598|Experimental|I-gel LMA|I-gel LMA insertion: I-gel insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
2947123|NCT02924298|Experimental|Stage 3-4 Chronic Kidney Disease|Individuals with estimated glomerular filtration rate 15 to < 60 mL/min/1.73m^2, to undergo SLIMM intervention
2946915|NCT02925598|Experimental|AuraGain LMA|AuraGain insertion:AuraGain LMA insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
2946916|NCT02925598|Experimental|Endotracheal tube (ETT)|Endotracheal tube insertion: Endotracheal tube (ETT) insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
2946917|NCT02925585||Pre/post pelvic floor surgery imaging|
2946918|NCT02925572|Experimental|Concentric cycling exercise (CON)|40 obese adolescents will be randomized into 2 groups: CON or EXC
2946919|NCT02925572|Experimental|eccentric cycling exercise (EXC)|40 obese adolescents will be randomized into 2 groups: CON or EXC
2946920|NCT02925559|Experimental|Dapagliflozin|The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
2946921|NCT02925559|Active Comparator|Gliclazide MR|As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
2946922|NCT02925546|Experimental|GSK2798745 ABCD treatment sequence|Subjects will be given 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
2946923|NCT02925546|Experimental|GSK2798745 CABD treatment sequence|Subjects will be given 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
2946924|NCT02925546|Experimental|GSK2798745 ACBD treatment sequence|Subjects will be given 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
2946925|NCT02925546|Experimental|GSK2798745 BACD treatment sequence|Subjects will be given 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
2946926|NCT02925546|Experimental|GSK2798745 BCAD treatment sequence|Subjects will be given 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
2946927|NCT02925546|Experimental|GSK2798745 CBAD treatment sequence|Subjects will be given 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
2946928|NCT02925533|Experimental|B-701 and Pembrolizumab|"B-701 will be administered every 3 weeks intravenously~Pembrolizumab will be administered every 3 weeks intravenously"
2946929|NCT02925507||Healthy Controls|Healthy patients with no neurologic impairments or disease
2946930|NCT02925507||Stroke Subjects|Patients with new onset stroke for ischemic, hemorrhagic or TIA
2946931|NCT02925494|Experimental|Elagolix plus Estradiol/Norethindrone Acetate (E2/NETA)|Participants receiving Elagolix plus E2/NETA
2946932|NCT02925494|Experimental|Elagolix|Participants receiving Elagolix
2946933|NCT02925481|Experimental|Low dose Yoga|12 week online yoga for 60 minutes per week
2946934|NCT02925481|Experimental|Moderate dose Yoga|12 week online yoga for 150 minutes per week
2946935|NCT02925481|Active Comparator|Stretch and toning|12 week online stretching, toning exercises for 60 minutes per week
2946936|NCT02925468|Experimental|Intervention group|A standard initial lateral cephalogram radiograph will be taken of all subjects, unless this is already available within the specified age range. An intra-oral scanner will be used to accurately record the occlusal relationships prior to insertion of the fixed anterior bite plane (bite turbos) (T0) and repeated immediately after placement (T1). Each subject will then be re-scanned on a six weekly basis for a period of six months (T2-T5). Conventional clinical photographs and three-dimensional stereophotogrammetry will be used to assess the vertical facial relationships at T0-T5. A further lateral cephalogram radiograph will be taken at T5.
2946937|NCT02925468|No Intervention|Control group|A control group of subjects from the treatment waiting list who meet the inclusion criteria will be used. An intra-oral scanner will record the baseline occlusal relationship (T0) and will be repeated after six months (T5). The control group will also have a standard pre-treatment lateral cephalogram radiograph taken, as well as conventional and three-dimensional stereophotogrammetry at baseline (T0) and after six months (T5). This will allow changes resulting from growth to be assessed whilst no active orthodontic treatment has taken place.
2946938|NCT02925455|Experimental|Stimulation + Video Games|Contralaterally-controlled functional electrical stimulation (CCFES) enables patients with upper extremity hemiplegia to open their paretic hand by stimulating finger and thumb extensors with surface electrodes. CCFES is used during functional task practice and hand therapy video games to link motor intent with execution. Four intuitive and engaging games were developed to provide goal-oriented motor skill training, impairment-appropriate difficulty, and performance feedback that motivates iterative play and skill improvement.
2946939|NCT02925455|Active Comparator|Video Games (no stimulation)|Participants receive duration-matched, identical hand therapy video games and task practice therapy as the experiment arm, but do not receive CCFES to assist hand opening.
2946940|NCT02925442|Experimental|Standard Thermal radiofrequency ablation|Patients randomized to t-RFA will receive standard genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty for postoperative pain management.
2946941|NCT02925442|Experimental|Cooled radiofrequency ablation|Patients randomized to C-RFA will receive cooled genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty for postoperative pain management.
2946942|NCT02925442|Sham Comparator|Control:Placebo Sham|Patients randomized to control will receive simulated genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty and receive the industry standard of care for unilateral knee arthroplasty pain management.
2946943|NCT02925416|Experimental|Two doses oritavancin|On Day 1 of the study, subjects will be administered a single 1200-mg IV dose of oritavancin in 1000 mL D5W. On Day 7, an additional 1200-mg IV dose of oritavancin in 1000 mL D5W will be administered.
2946944|NCT02925416|Other|One dose oritavancin, one dose placebo|On Day 1 of the study, subjects will be administered a single 1200-mg IV dose of oritavancin in 1000 mL D5W. On Day 7, a placebo (D5W) will be administered.
2946945|NCT02925403|Active Comparator|Group 1|10μg R21/Matrix-M1 on days 0, 28, and 56.
2946946|NCT02925403|Active Comparator|Group 2|50μg R21/Matrix-M1 on days 0, 28, and 56.
2946947|NCT02925403|Placebo Comparator|Group 3|Saline injection on days 0, 28, and 56.
2946948|NCT02925377|Experimental|Neuromuscular|Neuromuscular warm-up
2946949|NCT02925377|Active Comparator|Control|Standard warm-up
2946950|NCT02925364||No pain|patients who are enrolled in the parent study and report no chest pain at their 6 month post-cardiac surgery follow-up will undergo functional and anatomical MRI
2946951|NCT02925364||Pain|Patients who are enrolled in the parent study and report chest pain at their 6 month post-cardiac surgery follow-up will undergo functional and anatomical MRI
2946952|NCT02925351|Experimental|Imaging (fluorine F 18 clofarabine, PET/CT)|Patients receive fluorine F 18 clofarabine IV and undergo a single PET/CT scan for up to 120 minutes.
2946953|NCT02925338||Patients treated with Inflectra|
2946954|NCT02925325|Experimental|Music Therapy|Music therapy 8 weekly sessions
2946955|NCT02925325|Active Comparator|Usual Treatment|It is the usual medical treatment.
2946956|NCT02925312|Experimental|Intervention|Patients receive the full diabetes pathway intervention
2946957|NCT02925312|No Intervention|Matched controls|patients receive standard of care
2946958|NCT02925299|Experimental|24/7 closed loop insulin delivery|The study system includes (1) a CGM that measures glucose levels, (2) a computer program on a smartphone that determines how much insulin is needed, and (3) an insulin pump that delivers the insulin. The name of this closed-loop system is FlorenceM. Half of the individuals taking part in the study will use the study system for 6 months.
2946959|NCT02925299|Active Comparator|Insulin pump therapy|Half of the Subjects will continue using their own insulin pump for 6 months.
2946960|NCT02925286|Experimental|Intervention group|Five organizations will get the intervention during fall/winter 2016.
2946961|NCT02925286|No Intervention|Wait-list group|Five organizations will be on the waitlist for 12 months and then get the intervention.
2946962|NCT02925273|Other|Standard|Prospective, grasp techniques will be compared in each patient from the experimental group using a palmar grasp without dorsal stimulation and a standard palmar grasp test with dorsal stimulation on the same patient as the control group
2946963|NCT02925260||Patients with normal ileal pouches|"Inclusion Criteria~Ileal pouch reservoir in situ~Greater than three years since closure of ileostomy~Normal pouch function as defined by Orësland score of <4~Never had a diagnosis of pouchitis~Never had treatment for pouchitis~No evidence of pouchitis on rigid pouchoscopy~CRP <10"
2946964|NCT02925247|Other|patient with atrial fibrillation|
2946965|NCT02925234|Experimental|Panitumumab|Panitumumab for patients with KRAS-BRAF-NRAS wild-type tumors for whom anti-tumor activity of panitumumab might be expected.
2946966|NCT02925234|Experimental|Olaparib|Olaparib for patients with BRCA or ATM mutated tumors for whom anti-tumor activity of olaparib might be expected.
2946967|NCT02925234|Experimental|Dabrafenib|Dabrafenib for patients with BRAF mutated tumors for whom anti-tumor activity of dabrafenib might be expected.
2946968|NCT02925234|Experimental|Nilotinib|Nilotinib for patients with a molecular tumor profile that can potentially be targeted by nilotinib.
2946969|NCT02925234|Experimental|Trametinib|Trametinib for patients with a molecular tumor profile that can potentially be targeted by trametinib.
2946970|NCT02925234|Experimental|Erlotinib|Erlotinib for patients with a molecular tumor profile that can potentially be targeted by erlotinib.
2946971|NCT02925234|Experimental|Trastuzumab & Pertuzumab (combination)|Trastuzumab and Pertuzumab (combination treatment) for patients with a HER2 overexpressing, amplified or mutated tumor for whom anti-tumor activity of Trastuzumab + Pertuzumab might be expected.
2946972|NCT02925234|Experimental|Vemurafenib & Cobimetinib (combination)|Vemurafenib and Cobimetinib (combination treatment) for patients with a BRAF mutated tumor for whom anti-tumor activity of vemurafenib + cobimetinib might be expected.
2946973|NCT02925234|Experimental|Vismodegib|Vismodegib for patients with a molecular tumor profile that can potentially be targeted by vismodegib.
2946974|NCT02925234|Experimental|Regorafenib|Regorafenib for patients with a molecular tumor profile that can potentially be targeted by regorafenib.
2946975|NCT02925234|Experimental|Nivolumab|Nivolumab for patients with a molecular tumor profile that can potentially be targeted by nivolumab.
2946976|NCT02925221||ADPKD patients on tolvaptan|ADPKD patients who are newly prescribed with tolvaptan or already treated with tolvaptan will be eligible.
2946977|NCT02925208||Cochlear Implant|Patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
2946978|NCT02925195|Experimental|Active Treatment|
2946979|NCT02925195|Placebo Comparator|Placebo|Placebo
2947051|NCT02924753|Experimental|CART-19|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CART-19 cells. The CART-19 cells are to be administered on day0,day1,day2.
2947052|NCT02924740|Active Comparator|control|pelvic floor muscle training
2946980|NCT02925182|Experimental|test|Recurrent Aphthous Stomatitis were irradiated with Er,Cr:YSGG laser (Waterlase MD, Biolase, Irvine, CA, USA) on hard tissue mode with a mg6 sapphire tip (600 µm diameter, 6 mm length) using non-contact mode at an energy level of 0.25W and a repetition rate of 20 kHz and pulse duration of 140 µs, 0% water and 10% air at 5 J/cm2 energy density. The treatment time was 20 s per surface by scanning the Recurrent Aphthous Stomatitis area.
2946981|NCT02925182|Placebo Comparator|Control|In the placebo group, the same Er,Cr:YSGG laser without laser emission was used.
2946982|NCT02925156||Ghana|Participants in the Ghana cohort are located at or near the the village of Nkwantakese which is approximately 20 kilometers outside of Kwame Nkrumah University of Science and Technology in Kumasi.
2946983|NCT02925156||South Africa|Participants in the South Africa cohort are located at or near Khayelitsha, the 3rd largest township in South Africa, which is an adjacent town to the city of Cape Town. The population of Khayelitsha is about 500,000 people.
2946984|NCT02925156||Seychelles|Participants in the Seychelles cohort are located at or near The Republic of Seychelles, which is an archipelago with 81,000 inhabitants located approximately 1,500 km east of Kenya in the Indian Ocean and approximately 2,000 km north of the island of Mauritius.
2946985|NCT02925156||Jamaica|Participants in the Jamaica cohort are located at or near Spanish Town, Jamaica which is an urban area 25 km from the center of Kingston. The population of Spanish Town in 1991 was estimated at 92,000 people.
2946986|NCT02925156||United States|Participants in the United States cohort are located at or near Maywood, IL, which is an African-American working class community adjacent to the western border of Chicago, IL. The population of Maywood in 2010 was estimated at 24,090 people.
2946987|NCT02925143|Experimental|E-learning course|
2946988|NCT02925130|Experimental|Inhaled Salbutamol|Acute inhalation of 800 microgram Salbutamol
2946989|NCT02925130|Experimental|Oral Salbutamol|Acute oral intake of 4 mg Salbutamol
2946990|NCT02925130|Placebo Comparator|Placebo|Acute oral intake of a placebo
2946991|NCT02925117|Active Comparator|Participants receiving Dose A|Participants receiving Dose A once daily (QD) for 16 weeks
2946992|NCT02925117|Active Comparator|Participants receiving Dose C|Participants receiving Dose C once daily (QD) for 16 weeks
2946993|NCT02925117|Placebo Comparator|Participants receiving matching placebo|Participants receiving matching placebo for 16 weeks
2946994|NCT02925117|Active Comparator|Participants receiving Dose B|Participants receiving Dose B once daily (QD) for 16 weeks
2946995|NCT02925104|Experimental|INC280|
2946996|NCT02925078|Other|<2 mm mucosa thickness|A Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) will be placed in subjects that have <2 mm mucosa thickness.
2946997|NCT02925078|Other|≥2 mm mucosa thickness|A Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) will be placed in subjects that have ≥2 mm mucosa thickness.
2946998|NCT02925065|Experimental|Early-start guitar instruction group|A 6 week twice-weekly non-traditional group guitar instruction will be implemented in addition to usual treatment between weeks 1-6 of the study.
2946999|NCT02925065|Experimental|Delayed-start guitar instruction group|A 6 week twice-weekly non-traditional group guitar instruction will be implemented in addition to usual treatment between weeks 8-13 of the study.
2947000|NCT02925052|Experimental|GTG|Gastric tube placement using the Gastric Tube Guide
2947001|NCT02925052|Other|Conventional|Gastric tube placement using a conventional method, according to local protocol.
2947002|NCT02925039|Experimental|Experimental|Sit to stand training augmented with technology delivered movement feedback
2947003|NCT02925039|Active Comparator|Control|Sit to stand training as per normal practice
2947004|NCT02925026|Experimental|Lactoferrin+Lysozyme|lactoferrin and lysozyme in rice flour
2947005|NCT02925026|Placebo Comparator|Placebo|rice flour
2947006|NCT02925013|Experimental|Study group|Pregnant women at delivery
2947007|NCT02925013|Other|Control group|Women in fertility age not pregnant
2947008|NCT02925000|Experimental|TLC178|Liposomal Vinorelbine
2947009|NCT02924987|Other|Aflibercept injection|Not applicable. There will be no randomization nor stratification to any to study arms or groups.
2947010|NCT02924974|Sham Comparator|Control|subcutaneous lidocaïne and intravenous loading dose of morphine
2947011|NCT02924974|Experimental|Intervention|Spinal injection of 4 or 5 ml of bupivacaine/morphine 2,5 mg/ml/60mcg/ml. The reduction to 4 ml is for patients over 75 years of age
2947012|NCT02924961|Experimental|Triathlon Mobile-bearing|Primary total knee replacement with cemented Triathlon posterior stabilized mobile-bearing
2947013|NCT02924961|Active Comparator|Triathlon Fixed-bearing|Primary total knee replacement with cemented Triathlon posterior stabilized fixed-bearing
2947014|NCT02924948|No Intervention|Conventional insertion|EUS will be inserted with conventional method.
2947015|NCT02924948|Experimental|Balloon inflated insertion|EUS will be inserted with balloon inflated method
2947016|NCT02924935|Experimental|Treatment|L-Histidine in 500mg capsules taken at a dose of 50mg/kg to maintain high-normal serum histidine levels
2947017|NCT02924922|Active Comparator|Laparoscopic partial nephrectomy|"Inclusion criteria fulfilled:~Baseline Abdomen CT/MRI~Patient Age, Weight, Height, Co-Medication~Informed Consent~Baseline renal function (eGFR, renal scintigraphy, sCreatinine, creatinine clearance)~During hospitalization, one day before laparoscopic partial nephrectomy:~eGFR~sCreatinine~Hemoglobin~After surgery:~Assessment of eGFR 4 days after operation~Hb assessment every 6 H in the first 48 H~Assessment of adverse events~Histological Results~6, 12, 24 months after intervention:~Creatinine Clearance (only performed at 6 months follow-up)~Tc-99m MAG3Dynamic Scintigraphy (only performed at 6 months follow-up)~eGFR~Assessment of adverse events~Assessment of possible recurrence~Assesment of kidney volume variation"
2947053|NCT02924740|Experimental|intervention|vaginal tampon training.
2947085|NCT02924480|Active Comparator|Lidocaine Study Group|Intravenous Lidocaine for Cystectomy Procedures: During the surgery, the lidocaine infusion group will receive the lidocaine bolus (1.5mg/kg bolus followed by a 2mg/kg/h infusion) 30 minutes prior to skin incision and the infusion will continue until 60 minutes after skin closure.
2947124|NCT02924285|Active Comparator|Procedure|Radiofrequency catheter ablation
2947125|NCT02924285|Active Comparator|Antiarrhythmic Drug|Amiodarone
2947018|NCT02924922|Active Comparator|Robot assisted partial nephrectomy|"Inclusion criteria fulfilled:~Baseline Abdomen CT/MRI~Patient Age, Weight, Height, Co-Medication~Informed Consent~Baseline renal function (eGFR, renal scintigraphy, sCreatinine, creatinine clearance)~During hospitalization, one day before robot assisted partial nephrectomy:~eGFR~sCreatinine~Hemoglobin~After surgery:~Assessment of eGFR 4 days after operation~Hb assessment every 6 H in the first 48 H~Assessment of adverse events~Histological Results~6, 12, 24 months after intervention:~Creatinine Clearance (only performed at 6 months follow-up)~Tc-99m MAG3Dynamic Scintigraphy (only performed at 6 months follow-up)~eGFR~Assessment of adverse events~Assessment of possible recurrence~Assesment of kidney volume variation"
2947019|NCT02924909|Experimental|induction carboplatin paclitaxel|carboplatin AUC=6 21 day cycle for 2 cycles paclitaxel 175 mg/m2 21 day cycle for 2 cycles radiotherapy 4500 cGy in 25 fractions carboplatin AUC=2 in a week regimen during radiotherapy paclitaxel 50 mg/m2 in a week regimen during radiotherapy Minimal Invasive Surgery
2947020|NCT02924896|Other|randomization 1|Palm Olein, Interesterified Palm Olein, Soybean Oil
2947021|NCT02924896|Other|randomization 2|Palm Olein, Soybean Oil, Interesterified Palm Olein
2947022|NCT02924896|Other|randomization 3|Interesterified Palm Olein, Palm Olein, Soybean Oil
2947023|NCT02924896|Other|randomization 4|Interesterified Palm Olein, Soybean Oil, Palm Olein
2947024|NCT02924896|Other|randomization 5|Soybean Oil, Interesterified Palm Olein, Palm Olein
2947025|NCT02924896|Other|randomization 6|Soybean Oil, Palm Olein, Interesterified Palm Olein
2947026|NCT02924883|Experimental|Trastuzumab Emtansine + Atezolizumab/Placebo|Atezolizumab 1200 milligrams (mg) intravenous (IV) infusion or matching Placebo followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor (approximately 29 months)
2947027|NCT02924883|Active Comparator|Trastuzumab Emtansine + Placebo|Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor (approximately 29 months)
2947028|NCT02924870|Active Comparator|Control group|Conventional management. Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.
2947029|NCT02924870|Experimental|Intervention group|Conventional management plus health education program. In addition to conventional treatment and follow-up, the patients will be referred to a nursing consultation for perform two health education sessions, at 15 and 30 days after hospital discharge.
2947030|NCT02924857|Experimental|Test Group (Chocolate Touch)|"The diameter of the Chocolate Touch should correspond to the diameter of the vessel for treatment with a balloon to artery ratio of 1.1:1.~The Chocolate Touch must be inflated to at least nominal pressure. Maintain balloon inflation for a minimum of 2 minutes. The balloon may be inflated as long as required to achieve optimal angioplasty outcome.~If delivery is attempted and failed, a new Chocolate Touch should be used for subsequent attempts after pre-dilatation."
2947031|NCT02924857|Active Comparator|Control Group (Lutonix Drug Coated Balloon)|"Never inflate the Lutonix® Drug Coated Balloon (DCB)prior to reaching the target lesion.~The Lutonix® Catheter should be advanced to the target site as fast as possible (i.e. 30 seconds) and immediately inflated to appropriate pressure to ensure full wall apposition (balloon to artery ratio of >1:1).~If the deployment of the Lutonix® Catheter exceeds 3 minutes, the catheter requires placement with a new unit.~Maintain balloon inflation for a minimum of 2 minutes (120 seconds). The balloon may be inflated as long as required by standard of care to achieve a good angioplasty outcome."
2947032|NCT02924844||Observation period before presence of clinical pharmacist|The group of patients was observed between Janary 2013 and December 2013
2947033|NCT02924844||Period with presence of clinical pharmacist|The group of patients was observed between January 2014 and June 2015.
2947034|NCT02924831|Experimental|Moxibustion group|drug:moxa Moxibustion was to stimulate acupoints of Guanyuan(RN4)and the Zusanli(ST36) with burned moxa.
2947035|NCT02924831|Experimental|Acupuncture group|material: stainless steel needle In acupuncture treatment, needles were applied to acupoints of Guanyuan(RN4)and Zusanli(ST36),with manipulations to get Deqi sensation.
2947036|NCT02924831|Placebo Comparator|Placebo group|material: stainless steel needle Needles were applied to acupoints of Guanyuan(RN4)and Zusanli(ST36),but without any manipulations and Deqi sensation.
2947037|NCT02924831|Experimental|Zusanli（ST36)-acupuncture group|material: stainless steel needle Stimulating acupoints of Zusanli(ST36) with acupuncture.
2947038|NCT02924831|Experimental|Guanyuan(RN4)-acupuncture group|material: stainless steel needle. Stimulating acupoint of Guanyuan(RN4) with acupuncture.
2947039|NCT02924818|Experimental|Chronic Obstructive Pulmonary disease (COPD)|
2947040|NCT02924818|Experimental|Cystic Fibrosis (CF)|
2947041|NCT02924818|Experimental|bronchiectasis|
2947042|NCT02924818|Experimental|Interstitial lung disease (ILD)|
2947043|NCT02924818|Experimental|controls|
2947044|NCT02924805||Telemedicine group|Cases of hypertensive emergencies and urgencies in which the prehospital emergency care was performed by on-scene paramedics, guided by a qualified physician in a teleconsultation center.
2947045|NCT02924805||Control group|Historical cases of of hypertensive emergencies and urgencies in which the prehospital emergency care was carried out by on-scene emergency medical service physicians (conventional care).
2947046|NCT02924792||Reinfusion - Fast1|Case: Autologous reinfusion through Fast1 sternal needle. (Pyng Medical) CE marked/FDA Approved
2947047|NCT02924792||Reinfusion - T.A.L.O.N|Case: Autologous reinfusion through T.A.L.O.N sternal needle. (Vidacare) CE Marked/FDA approved
2947048|NCT02924792||Reinfusion - Intravenous line|Control: Autologous reinfusion through standard intravenous line
2947049|NCT02924779||Women during labour|Women receiving lumbar epidural anaesthesia for pain during birth
2947050|NCT02924766|Experimental|Niraparib + Apalutamide/[Abiraterone Acetate + Prednisone]|Participants will receive initial starting dose of Niraparib 200 milligram (mg) once daily in combination either with Apalutamide 240 mg (4*60 mg) once daily or Abiraterone Acetate 1000 mg (4*250 mg) plus 10 mg Prednisone (5 mg twice daily) for 28 days of cycle 1. Once a safe dose of niraparib is selected with each Andrgen Receptor (AR)-targeted therapy [Apalutamide or Abiraterone Acetate plus Prednisone], then an expansion phase (Part 2) will open to further explore safety and assess antitumor activity.
2947054|NCT02924727|Experimental|LCZ696 (sacubitril/valsartan)|"Following randomization, patients will receive LCZ696 in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).~Patients will be required to take a total of two pills, (one tablet from the LCZ696 pack and one capsule from ramipril matching placebo pack) twice a day for the duration of the study.~Patients randomized to LCZ who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization will receive a valsartan bridge for one day. These patients will receive two doses of valsartan for 1 day in a blinded manner prior to beginning double-blind LCZ696 treatment."
2947055|NCT02924727|Active Comparator|Ramipril|"Following randomization, patients will receive the Ramipril in titrated doses from level 1 up to level 3 (1.25, 2.5 and 5 mg twice daily).~Patients will be required to take a total of two pills, (one capsule from the ramipril pack and one tablet from LCZ696 matching placebo pack) twice a day for the duration of the study.~Patients randomized to ramipril who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization will immediately start on double-blind ramipril; however, to maintain double blind/double dummy of the valsartan bridge, these patients will receive two doses of matching valsartan placebo for 1 day in a blinded manner prior to beginning double-blind LCZ696 placebo."
2947056|NCT02924714|Other|Discontinuation of imatinib|Patients treated with imatinib longer than 5 years for oligo-metastatic GIST (≤ 3 metastases) and who have no longer detectable GIST lesions on CT/MRI imaging following complete surgical resection (R0/R1-resection) or RFA of the metastases are assigned to discontinue imatinib.
2947057|NCT02924701||PBC patients|Patients diagnosed with primary biliary cholangitis
2947058|NCT02924688|Experimental|FF/UMEC/VI (100/31.25/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (100/31.25/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
2947059|NCT02924688|Experimental|FF/UMEC/VI (100/62.5/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (100/62.5/25) mcg inhalation powder via DPI, once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
2947060|NCT02924688|Experimental|FF/UMEC/VI (200/31.25/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (200/31.25/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
2947061|NCT02924688|Experimental|FF/UMEC/VI (200/62.5/25) mcg closed triple therapy|Subjects may receive FF/UMEC/VI (200/62.5/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
2947062|NCT02924688|Active Comparator|FF/VI (100/25) mcg dual combination therapy|Subjects will receive FF/VI (100/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
2947063|NCT02924688|Active Comparator|FF/VI (200/25) mcg dual combination therapy|Subjects will receive FF/VI (200/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
2947064|NCT02924675|Experimental|pregabalin group|
2947065|NCT02924675|Placebo Comparator|Placebo group|
2947066|NCT02924662||Kellgren and Lawrence classification I|Grade I Kellgren and Lawrence radiographic changes.
2947067|NCT02924662||Kellgren and Lawrence classification II|Grade II Kellgren and Lawrence radiographic changes.
2947068|NCT02924662||Kellgren and Lawrence classification III|Grade III Kellgren and Lawrence radiographic changes.
2947069|NCT02924662||Kellgren and Lawrence classification IV|Grade IV Kellgren and Lawrence radiographic changes.
2947070|NCT02924649|Experimental|Early Intensive mobilisation|As early as possible the experimental group will receive mobilisation on a tilt table for up to 20 minutes 5 days a week for four weeks using an ERIGO tilt table. If orthostatic hypotension occur the patient is moved to supine until parameters are stable again. Hereafter the mobilisation will continue until the patient has completed 20 minutes of standing exercise.
2947071|NCT02924649|No Intervention|Standard care group|The standard care group will receive daily mobilisation to the seated position.
2947072|NCT02924636|Experimental|Intervention|personalized and online intervention. The intervention website will provide secure communication with dietician and lifestyle coaches. Women will receive emails and monthly newsletters with new content and reminder.
2947073|NCT02924636|No Intervention|Control|standard care with oral information about the goal of nutritional needs during pregnancy and gestational weight gain guidelines according to BMI
2947074|NCT02924597|Experimental|Robot-assisted laparoscopic RFA assisted TE|RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.
2947075|NCT02924597|Active Comparator|Robot-Assisted laparoscopic partial nephrectomy|The tumor then will be laparoscopic enucleation without hilar clamping.
2947076|NCT02924571|Experimental|Bone Marrow Aspirate Concentrate (BMAC)|
2947077|NCT02924571|Active Comparator|Recombinant Human Bone Morphogenetic Protein-2 (BMP)|
2947078|NCT02924558|Experimental|Egg protein/unsaturated fatty acid|8% higher protein energy (from egg protein) and 8% higher fat energy (from unsaturated fatty acids); approximately 42/23/35% kcal from carbohydrate/protein/fat, respectively
2947079|NCT02924558|Placebo Comparator|Control|16% higher carbohydrate energy; approximately 58/15/27% kcal from carbohydrate/protein/fat, respectively
2947080|NCT02924532||Patients with total thiroidectomy|
2947081|NCT02924506|Other|Fixed Core|Cervical arthroplasty with fixed core prothesis
2947082|NCT02924506|Other|Movable Core|Cervical arthroplasty with movable core prothesis
2947083|NCT02924493|Experimental|Low FODMAP diet|This group will follow a exclusion diet called low FODMAP diet, which is a diet with restriction of fermentable carbohydrates. The patients will be guided on how to avoid some foods and how to include others. The patients will follow the diet for four weeks.
2947084|NCT02924493|Placebo Comparator|Control diet|This group will follow a placebo diet, which is designed to imitate the low FODMAP diet by restricting specific foods. However, it is randomly selected foods that will be excluded in this diet, so that it works only as a control diet. The patients in this group will also be guided how to follow the diet for four weeks.
2947086|NCT02924480|Placebo Comparator|Placebo Study Group|Intravenous Saline for Cystectomy Procedures: During the surgery, patients will be randomized to the control group and receive a normal saline bolus 30 minutes prior to skin incision and the infusion will continue until 60 minutes after skin closure.
2947087|NCT02924467|No Intervention|No intervention: Usual Care|Patients in this group will not receive any influenza vaccine reminder notifications.
2947088|NCT02924467|Experimental|1 Notice|Patients in this group will receive one influenza vaccine reminder notification via autodialer across the 2016 influenza season.
2947089|NCT02924467|Experimental|2 Notices|Patients in this group will receive up to two influenza vaccine reminder notifications via autodialer throughout the 2016 influenza season.
2947090|NCT02924467|Experimental|3 Notices|Patients in this group will receive up to three influenza vaccine reminder notifications via autodialer throughout the 2016 influenza season.
2947091|NCT02924454|Experimental|Metoprolol-Lipid emulsion|intervention 1: metoprolol Intervention 2: intravenous lipid emulsion
2947092|NCT02924454|Experimental|Metoprolol - normal saline|intervention 1: metoprolol intervention 2: Sodium chloride 0.9% solution - lipid emulsion dummy
2947093|NCT02924454|Experimental|Normal saline-Lipid emulsion|intervention 1: Sodium chloride 0.9% solution - metoprolol dummy intervention 2: intravenous lipid emulsion
2947094|NCT02924454|Experimental|Normal saline-normal saline|intervention 1: Sodium chloride 0.9% solution - metoprolol dummy intervention 2: Sodium chloride 0.9% solution - lipid emulsion dummy
2947095|NCT02924441|Experimental|Right Breast Lidocaine and calming music|Group 1 - right breast lidocaine & calming music
2947096|NCT02924441|Experimental|Right Breast Lidocaine and no music|Group 2 - right breast lidocaine & no calming music
2947097|NCT02924441|Experimental|Left Breast Lidocaine and calming music|Group 3 - left breast lidocaine & calming music
2947098|NCT02924441|Experimental|Left Breast Lidocaine and no music|Group 4 - left breast lidocaine & no calming music
2947099|NCT02924428|Experimental|Diamondpolar applicator, AC Dual applicator|"Radio frequency (RF) and pulsed magnetic field (PEMF) treatment followed by intense pulsed light (IPL) treatment delivered to the skin using the Venus Versa system.~The RF and PEMF applicator has 4 electrodes which emit RF and PEMF simultaneously.~The IPL applicator operates a blue light (415 nm) and also red light (630 nm) simultaneously. The IPL applicator also includes a sapphire cooled light guide of 10x30mm."
2947100|NCT02924428|Active Comparator|AC Dual applicator treatment|"Intense pulsed light (IPL) treatment delivered to the skin using the Venus Versa system.~The IPL applicator operates a blue light (415 nm) and also red light (630 nm) simultaneously. The IPL applicator also includes a sapphire cooled light guide of 10x30mm."
2947101|NCT02924415|Experimental|Tele-care support|Online psychoeducation treatment using new technologies
2947102|NCT02924415|Active Comparator|Control group|Standard care
2947103|NCT02924402|Experimental|Non-CLL B Cell Malignancies (Group NHL)|XmAb13676 administered IV weekly up to 8 weeks
2947104|NCT02924402|Experimental|CLL/SLL (Group CLL)|XmAb13676 administered IV weekly up to 8 weeks
2947105|NCT02924389|Other|Anti-retroviral (ARV) Naïve Males|Males diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician. Participants will be treated with either Triumeq or Truvada and dolutegravir.
2947106|NCT02924389|Other|Anti-retroviral (ARV) Naïve Females|Females diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician. Participants will be treated with either Triumeq or Truvada and dolutegravir.
2947107|NCT02924376|Experimental|Cohort A INCB054828|INCB054828 in subjects with FGFR2 translocation with a documented fusion partner in central laboratory report
2947108|NCT02924376|Experimental|Cohort B INCB054828|INCB054828 in subjects with other FGF/FGFR alterations
2947109|NCT02924376|Experimental|Cohort C INCB054828|INCB054828 in subjects negative for FGF/FGFR alteration
2947110|NCT02924363|Experimental|Single arm (cardiac MRI & hematocrit blood sample)|Patients will undergo a pre- & post- MitraClip procedure cardiac magnetic resonance imaging (CMR) scan with an FDA cleared MRI scanner and with or without an FDA approved contrast dye. The scan and the blood draw to assess the hematocrit is research, the MitraClip procedure is standard of care for these patients.
2947111|NCT02924350|Experimental|Test dentifrice containing stannous fluoride|All the participants in the test arm applied test dentifrice on their two test teeth using their finger, followed by brushing these test teeth, followed by brushing the whole mouth using test dentifrice. Participants brushed their teeth for 3 days twice daily (morning /evening).
2947112|NCT02924350|Active Comparator|Control dentifrice containing sodium monofluorophosphate|All the participants in the control arm applied control dentifrice on their two test teeth using their finger, followed by brushing these test teeth, followed by brushing the whole mouth using control dentifrice. Participants brushed their teeth for 3 days twice daily (morning /evening).
2947113|NCT02924337|Experimental|Imeglimin therapeutic dose|Tablet, oral, single dose
2947114|NCT02924337|Experimental|Imeglimin supratherapeutic dose|Tablet, oral, single dose
2947115|NCT02924337|Placebo Comparator|Placebo|Tablet, oral, single dose
2947116|NCT02924337|Active Comparator|Moxifloxacin|Tablet, oral, single dose (400 mg)
2947117|NCT02924324|Active Comparator|propofol alone|1st Bone Marrow procedure (BM) Intervention A: propofol alone. Crossover for second BM procedure propofol & ropivacaine
2947118|NCT02924324|Experimental|propofol and ropivacaine|1st BM procedure: Intervention B: propofol & ropivacaine. Crossover for second BM procedure propofol alone
2947119|NCT02924311||Previously treated patient|Already treated with any other treatment such as an anti-VEGF agent (other than IVT aflibercept), macular laser photocoagulation (laser), intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
2947120|NCT02924311||Naïve patient|Not previously treated with an anti-VEGF agent, macular laser photocoagulation (laser) or intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
2947121|NCT02924311||Entire study population|Already treated patient with any other treatment such as an anti-VEGF agent (other than intravitreal aflibercept), macular laser photocoagulation, intravitreal steroid injection and initiating treatment with intravitreal aflibercept and not previously treated patients with an anti-VEGF agent, macular laser photocoagulation or intravitreal steroids injection and initiating treatment with intravitreal aflibercept
2947126|NCT02924272|Experimental|Ixazomib|Ixazomib capsule, orally, at same dose and schedule that participants were receiving in the parent study until disease progression, clinical deterioration in the investigator's judgment, experience an unacceptable toxicity, withdraw consent, pursue an alternative therapy, meet other study-specified reasons for discontinuation of study drug, or until ixazomib is available to the participant through commercial channels, including reimbursement for the participant's indication, whichever is sooner. Participants who were receiving a combination therapy with ixazomib and another medication(s) will continue to receive the combination regimen.
2947127|NCT02924259|Experimental|Foam Roll Group|Subjects will undergo a 2-minute video-guided foam roll intervention on the left quadriceps muscle using the GRID foam roll.
2947128|NCT02924246|Placebo Comparator|Control group|Regular cholera vaccination
2947129|NCT02924246|Active Comparator|Raw milk|Cholera vaccination - raw milk
2947130|NCT02924246|Active Comparator|Pasteurized milk|Cholera vaccination - pasteurized milk
2947131|NCT02924246|Active Comparator|UHT milk|Cholera vaccination - UHT milk
2947132|NCT02924233|Experimental|Sym004 + nivolumab|"Phase 1b, dose-escalation:~Dose Level 1: Sym004 + nivolumab (Q2W)~Dose Level 2: Sym004 + nivolumab (Q2W)~Dose Level -1: Sym004 + nivolumab, if needed"
2947133|NCT02924233|Experimental|Sym004 (RP2D) + nivolumab|"Phase 2b, dose-expansion:~Receiving Sym004 in the RP2D in combination with nivolumab (Q2W)"
2947134|NCT02924233|Active Comparator|Nivolumab|"Phase 2b, dose-expansion:~Receiving nivolumab monotherapy (Q2W)"
2947135|NCT02924220||Case patients|"Patients with culture-proven listeriosis. Case patients are classified in 3 groups :~Septicemic infections: isolation of Lm in blood cultures.~CNS infections: isolation of Lm in cerebrospinal fluid, or brain stereotaxic biopsy, or by isolation of Lm in the blood with concomitant meningitis, or radiological encephalitis, rhombencephalitis, brain abscess or meningitis.~MF infections: defined by isolation of Lm in any maternal/fetal/neonatal bacteriological sample.~All patients have given their written consent to participate in the MONALISA cohort and for the collection of a blood sample including DNA samples for DNA analyses will be included in the MONALISA GENBIO study."
2947136|NCT02924220||Control patients|"Patients without listeriosis but compatible clinical presentation. Control patients are divided in 3 groups.~Septicemic controls: febrile patient with same co-morbidities as septicemic cases.~CNS controls: patient with any neurological symptom leading to the empiric prescription of amoxicillin at meningeal dosage because of listeriosis presumption.~MF controls: febrile pregnant patient without obvious focal infection.~All patients have given their written consent to participate in the MONALISA cohort and for the collection of a blood sample including DNA samples for DNA analyses will be included in the MONALISA GENBIO study."
2947137|NCT02924207|Experimental|Intervention|Path Electronic decision support arm
2947138|NCT02924194|Experimental|nbM stimulation ON for 3 months (GPi also on)|Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation ON for a period of 3 months (GPi also on). No usual treatment is withheld. PD drug doses will be stable unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor Unified Parkinson's Disease Rating Scale (UPDRS) rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
2947139|NCT02924194|Experimental|nbM stimulation OFF for 3 months (GPi is on)|Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation OFF for a period of 3 months (GPi is on). No usual treatment is withheld. PD drug doses will be stable during blinded parts of the assessment unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor UPDRS rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
2947140|NCT02924181|Active Comparator|Lt PV CF guided/rt PV CF blinded|Fifteen patients will be allocated to this group. Left side pulmonary veins isolation will be performed with contact force information guidance. Then, right side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).
2947141|NCT02924181|Active Comparator|Lt PV CF blinded/rt PV CF guided|Fifteen patients will be allocated to this group. Left side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).Then, right side pulmonary veins isolation will be performed with contact force information guidance.
2947142|NCT02924181|Active Comparator|Rt PV CF guided/lt PV CF blinded|Fifteen patients will be allocated to this group. Right side pulmonary veins isolation will be performed with contact force information guidance. Then, left side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).
2947143|NCT02924181|Active Comparator|Rt PV CF blinded/lt PV CF guided|Fifteen patients will be allocated to this group. Right side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter). Then, left side pulmonary veins isolation will be performed with contact force information guidance.
2947144|NCT02924168|Experimental|Active Radial Shockwave|Every patient will receive 5,000 continuous pulses per treatment session, at 3.5 to 4 bar air pressure (resulting in an energy flux density [EFD] of approximately 0.07 mJ/mm2) and at 15Hz frequency. A total of 4 sessions will be performed.
2947145|NCT02924168|Sham Comparator|Sham Radial Shockwave|Every patient will receive 5,000 continuous pulses per treatment session, without air pressure (resulting in no EFD) and at 15Hz frequency. A total of 4 sessions will be performed.
2947146|NCT02924155|Experimental|SJP002|single/repeated administration
2947147|NCT02924155|Placebo Comparator|SJP002 placebo|single/repeated administration
2947148|NCT02924142|Experimental|Intervention|Mandibular removable partial denture with OT Cap attachment
2947149|NCT02924142|No Intervention|Comparator|Mandibular removable partial denture with gingival approaching clasp assembly
2947150|NCT02924129|Experimental|Evoke SCS with Feedback|closed-loop/automatic stimulation
2947151|NCT02924129|Active Comparator|Evoke SCS with Conventional|open-loop/manual stimulation
2947152|NCT02924116|Experimental|Bioboosti|Treatment with the Bioboosti device for two weeks. The device produces a pulsed micro-magnetic field. Subjects will use it once a day for about one hour, before habitual sleep time.
2947153|NCT02924103|Active Comparator|Right side|"All included participants serve as their own control. A bacterial swab (Eswab 481CE, Copan Diagnostics, Italy), will be introduced to both sides of the nose (to the middle meatus); on the RIGHT side by using the Contamination free bacterial swab introduction device.~The Contamination free bacterial swab introduction device is a prototype developed for clinical testing."
2947154|NCT02924103|Active Comparator|Left side|All included participants serve as their own control. A bacterial swab (Eswab 481CE, Copan Diagnostics, Italy) will be introduced to both sides of the nose (to the middle meatus); on the LEFT side using the present day clinical procedure (visually guided introduction).
2947155|NCT02924090|Active Comparator|ECT with Etomidate|Immediately prior to ECT study patients will be administered intravenous etomidate for anesthesia at a dose of 0.3 mg/kg given as a bolus dose.
2947156|NCT02924090|Active Comparator|ECT with Ketamine|Immediately prior to ECT study patients will be administered intravenous ketamine for anesthesia at a dose of 0.5 -1.0 mg/kg given as a bolus dose.
2947157|NCT02924090|Active Comparator|ECT with Etomidate and Hyperventilation|Immediately prior to ECT study patients will be administered intravenous etomidate for anesthesia at a dose of 0.3 mg/kg given as a bolus dose. Hyperventilation will be administered (20 breaths in 30 seconds) by face mask immediately prior to ECT.
2947158|NCT02924090|Active Comparator|ECT with Ketamine and Hyperventilation|Immediately prior to ECT study patients will be administered intravenous ketamine for anesthesia at a dose of 0.5 -1.0 mg/kg given as a bolus dose. Hyperventilation will be administered (20 breaths in 30 seconds) by face mask immediately prior to ECT.
2947159|NCT02924064|Experimental|Teneligliptin 20mg|Teneligliptin (20mg once daily) for 24 weeks in combination with metformin
2947160|NCT02924064|Placebo Comparator|Placebo|Placebo for 24 weeks in combination with metformin
2947161|NCT02924051|Active Comparator|Control|Control group received cookbooks, cooking classes, food preparation tools and prepared food dishes to take home to their families.
2947162|NCT02924051|Experimental|Intervention|Intervention group participants received cookbooks, cooking classes, food preparation tools and prepared food dishes to take home to their families, along with monthly motivational interviewing conducted by a trained registered nurse.
2947163|NCT02924038|Experimental|IMA950/poly-ICLC subQ + Varlilumab IV|IMA950 4.96mg and poly-ICLC 1.4mg administered as one formulation subcutaneously followed immediately by a Varlilumab 3mg/kg infusion (intravenously) -23±2 days (about 3 weeks) before the date of scheduled standard-of-care surgery to remove the WHO grade II glioma. Patients will continue receiving IMA950/poly-ICLC subcutaneous injections every week leading up to surgery (Days -16±2, -9±2 and 24-48 hours prior to scheduled surgery) and every 3 weeks after surgery (Weeks A1, A4, A7, A10, A13, A16, A19, A22; defining Week A1 as the first post-surgery vaccine). After surgery, patients will continue receiving a Varlilumab infusion every 6 weeks immediately following the IMA950/poly-ICLC injection (Weeks A1, A7, A13, and A19).
2947164|NCT02924038|Experimental|IMA950/poly-ICLC subQ only|IMA950 4.96mg and poly-ICLC 1.4mg administered as one formulation subcutaneously every week leading up to standard-of-care surgery to remove the WHO grade II glioma (Days -23±2, -16±2, -9±2 and 24-48 hours prior to scheduled surgery) and every three weeks after surgery (Weeks A1, A4, A7, A10, A13, A16, A19, A22; defining Week A1 as the first post-surgery vaccine). Patients will not receive Varlilumab.
2947165|NCT02924025|Experimental|Case|The women in this group will receive motivational interviews approximately once every 2 weeks for half a year.
2947166|NCT02924025|No Intervention|Control|The women in this group will have the usual guidance in weightloss with a booklet on the seven health tips from the danish government. They will not be contacted ind the half year between study onset and finish.
2947167|NCT02924012|Experimental|active video game|An active game session lasting 40 minutes
2947168|NCT02924012|Other|sedentary video game|An sedentary game session lasting 40 minutes
2947169|NCT02924012|Other|walking|An walking lasting 40 minutes
2947170|NCT02923999|Experimental|Dose cohort 1|P2G12 0.125g
2947171|NCT02923999|Experimental|Dose cohort 2|P2G12 0.25g
2947172|NCT02923999|Experimental|Dose cohort 3|P2G12 0.5g
2947173|NCT02923986|Experimental|BP1001 (varying dose) + Dasatinib|Phase 1b: BP1001 (varying dose levels) in combination with Das
2947174|NCT02923986|Experimental|BP1001 (fixed dose) + Dasatinib|Phase IIa: BP1001 (fixed dose based on Phase 1b) in combination with Das
2947175|NCT02923973|Experimental|TVU CL screening|TVU CL screening: serial TVU CL scan from 16 0/7 to 24 6/7 every week, for a total of nine scans Vaginal progesterone 200mg suppository daily from 14 0/7 to 20 6/7 weeks for the history of prior spontaneous preterm delivery
2947176|NCT02923973|No Intervention|No TVU CL screening|no screening Vaginal progesterone 200mg suppository daily from 14 0/7 to 20 6/7 weeks for the history of prior spontaneous preterm delivery
2947177|NCT02923960|Active Comparator|Standard ONS|liquid oral nutritional supplement
2947178|NCT02923960|Experimental|Diabetes specific ONS 1|liquid oral nutritional supplement with novel carbohydrate blend
2947179|NCT02923960|Active Comparator|Diabetes specific ONS 2|liquid oral nutritional supplement with novel carbohydrate blend
2947180|NCT02923947|Experimental|Normal renal function|For inclusion in the study as a patient with normal renal function, patients must have creatinine clearance ≥90 mL/min.
2947181|NCT02923947|Experimental|Severe renal impairment|For inclusion in the study as a patient with severe renal impairment, patients must have stable severe renal impairment (creatinine clearance <30 mL/min), as defined by the Cockcroft Gault equation, for at least 2 months prior to Day 1.
2947182|NCT02923934|Experimental|Ipilimumab and Nivolumab|All Subjects will be treated with: Nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg concurrently every 3 weeks for 4 doses followed by nivolumab only at 3mg/kg every 2 weeks until progression (up to 48 total doses of nivolumab)
2947183|NCT02923921|Experimental|ARM 1|AM0010 (5 μg/kg) dosed on Days 1-5 and Days 8-12 SQ plus FOLFOX (dl-LV 400 mg/m2 and oxaliplatin 85 mg/m2 followed by bolus 5-FU 400 mg/m2 and a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycles or until disease progression.
2947184|NCT02923921|Active Comparator|ARM 2|FOLFOX (dl-LV 400 mg/m2 and oxaliplatin 85 mg/m2 followed by bolus 5-FU 400 mg/m2 and a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycles or until disease progression.
2947185|NCT02923895|Experimental|Test dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will then first brush each of the qualifying test teeth for 30 seconds each followed by the whole mouth thoroughly for at least 1 timed minute twice daily.
2947186|NCT02923895|Active Comparator|Control dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will brush the whole mouth thoroughly for at least 1 minute twice daily.
2947187|NCT02923882|Experimental|Intervention group|In the intervention group, the pregnant women at 8-12 weeks of gestational age used biomass fuels for cooking in the '$100Kitchen and improved cookstove'.
2947188|NCT02923882|No Intervention|Control group|In the control group, the pregnant women at 8-12 weeks of gestational age used biomass fuels for cooking in the traditional cookstove.
2947189|NCT02923869|Active Comparator|Group L|Children will receive 0.15 ml/kg of 0.2% Levobupivacaine
2947190|NCT02923869|Active Comparator|Group B|Children will receive 0.15 ml/kg of 0.2% Bupivacaine
2947191|NCT02923856|Experimental|Clarithromycin resistance group|Patients who are resistant to clarithromycin in susceptibility test were classified into clarithromycin resistance group.
2947192|NCT02923856|Experimental|7 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 7days standardized treatment.
2947193|NCT02923856|Experimental|7 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 7days standardized treatment.
2947194|NCT02923856|Experimental|10 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 10days standardized treatment.
2947195|NCT02923856|Experimental|10 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 10days standardized treatment.
2947196|NCT02923856|Experimental|14 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 14days standardized treatment.
2947197|NCT02923856|Experimental|14 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 14days standardized treatment.
2947198|NCT02923843|Experimental|intervention|Comprehensive Geriatric Assessment
2947199|NCT02923843|No Intervention|control|Standard care
2947200|NCT02923830|Active Comparator|Control Group|Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
2947201|NCT02923830|Experimental|Intervention Group|Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.
2947202|NCT02923817|Experimental|Treatment|
2947203|NCT02923804|Experimental|Omega-3|3 capsules of 1g concentrated omega-3 taken daily for 6 months
2947204|NCT02923804|Placebo Comparator|Olive oil|3 capsules of 1g olive oil taken daily for 6 months
2947205|NCT02923791|Experimental|Filgrastim Hospira|
2947206|NCT02923791|Active Comparator|US-Approved Neupogen|
2947207|NCT02923778|Experimental|Treatment (talimogene laherparepvec, radiation therapy)|Patients receive talimogene laherparepvec IT at weeks 1, 4, 6 and 8. Beginning 8-10 days after start of talimogene laherparepvec, patients undergo radiation therapy at weeks 2-6.
2947208|NCT02923765|Active Comparator|combined training (CT)|additional aerobic training by a stepper : 35 minutes/session, 5 sessions/week and 4-5 weeks
2947209|NCT02923765|No Intervention|usual rehabilitation (UR)|Usual rehabilitation, without additional aerobic training
2947210|NCT02923765|No Intervention|healthy participant (HP)|healthy control
2947211|NCT02923739|Experimental|Part 1 - Safety Lead-In|"Participants receive 4 weeks of Paclitaxel, Bevacizumab, and Emactuzumab to check for the highest tolerable dose.~Participants receive Paclitaxel by vein on Days 1, 8, 15 and 22, Bevacizumab by vein on Days 1 and 15, and Emactuzumab by vein on Days 1 and 15."
2947212|NCT02923739|Experimental|Part 2A - Induction|"Participants receive Paclitaxel plus Bevacizumab for 8 weeks then undergo evaluation for response.~Paclitaxel given by vein Days 1, 8, 15 and 22 for up to 2 cycle, and Bevacizumab by vein on Days 1 and 15 for up to 2 cycles."
2947213|NCT02923739|Experimental|Part 2B Arm 1- Paclitaxel + Bevacizumab|"Participants with stable disease continue Paclitaxel plus Bevacizumab.~Participants receive Paclitaxel by vein on Days 1, 8, 15, and 22 of each cycle, Bevacizumab by vein on Days 1 and 15 of each cycle.~Study cycle is 28 days."
2947214|NCT02923739|Experimental|Part 2B Arm 2 - Paclitaxel + Bevacizumab + Emactuzumab|"Participants with stable disease receive Paclitaxel plus Bevacizumab plus Emactuzumab.~Participants receive Paclitaxel by vein on Days 1, 8, 15, and 22 of each cycle, and Bevacizumab and Emactuzumab by vein on Days 1 and 15 of each cycle.~Study cycle is 28 days."
2947215|NCT02923726|Active Comparator|ATP and Shock|Once tachycardia has been detected and duration met, this group would receive antitachycardia pacing prior to shock therapy.
2947216|NCT02923726|Experimental|Shock only|Once tachycardia has been detected and duration met, this group would receive shock therapy only.
2947217|NCT02923700|Experimental|Leukocyte-rich PRP group|Three weekly knee intra-articular injections of leukocyte-rich PRP
2947218|NCT02923700|Experimental|Leukocyte-poor PRP group|Three weekly knee intra-articular injections of leukocyte-poor PRP
2947219|NCT02923687|Active Comparator|Buccal infiltration of Ketorolac|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, case group will receive a supplemental buccal infiltration of 30 mg/mL of Ketorolac tromethamine (Alborz-Darou Co. Qazvin, Iran).
2947220|NCT02923687|Placebo Comparator|Buccal infiltration of Normal saline|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the control group will receive normal saline as placebo.
2947221|NCT02923674|Other|Weight loss + sitless|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.~Participants will be encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3)."
2947222|NCT02923674|Other|Weight loss + exercise|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.~Participants will be asked to perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week."
2947223|NCT02923674|Other|Weight loss + exercise + sitless|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.~Participants will be encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3).~Participants will be asked to perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week."
2947224|NCT02923661|Experimental|CM LOC attachment group|this group will receive CM LOC attachment and lower overdenture attached to it
2947225|NCT02923661|Active Comparator|Ball attachment|this group will receive Ball attachment and lower overdenture attached to it
2947226|NCT02923648||Very prematurely born with BPD|Very prematurely born (gestational age [GA]< 32 weeks) with bronchopulmonary dysplasia (BPD) as defined by Jobe and Bancalari 2001, age 18-22.
2947227|NCT02923648||Very prematurely born without BPD|Very prematurely born (GA< 32 weeks) without BPD in the neonatal period, age 18-22
2947228|NCT02923648||Asthma full-term control group|Subjects with mild atopic asthma, born at term (GA> 37 weeks), age 18-22
2947229|NCT02923648||Healthy full-term control group|Healthy participants, born at term (GA>37 weeks), age 18-22
2947230|NCT02923635|Active Comparator|Standard Wide Local Excision group|Group A (35 patients) have standard curative conservative breast surgery without integration of plastic techniques .
2947231|NCT02923635|Active Comparator|Oncoplastic group|Group B(35 patients) have curative oncoplastic surgery in which plastic techniques integrated with oncological procedures
2947232|NCT02923622||Traditional Chinese and Western medicine combined group|
2947233|NCT02923622||Traditional Chinese medicine group|
2947234|NCT02923622||Western medicine group|
2947235|NCT02923609|Active Comparator|SC Group|After enrollment, all patients will receive 5-day stem cell mobilization with G-CSF. Thereafter, patients will be randomly allocated to either active (SC Group) or control group (Controls) in a 2:1 ratio. Patients in the SC Group will undergo apheresis; CD34+ cells will be collected with immunomagnetic selection, and delivered transendocardialy in the target areas defined by electroanatomical mapping.
2947236|NCT02923609|Placebo Comparator|Control|In the Control group, no apheresis or immunomagnetic selection of CD34+ cells will be performed; the patients will receive transendocardial injections of placebo using the same electroanatomical mapping protocol as in patients from the SC Group.
2947237|NCT02923596||Patients with Ear Keloids|Records of Patients with Ear Keloids will be reviewed. Data and photographs will be analysed.
2947238|NCT02923596||Patients with Neck Keloids|Records of Patients with Neck area Keloids will be reviewed. Data and photographs will be analysed.
2947239|NCT02923596||Patients with Scalp Keloids|Records of Patients with Scalp Keloids will be reviewed. Data and photographs will be analysed.
2947240|NCT02923583|Experimental|M834|M834 (abatacept biosimilar candidate)
2947241|NCT02923583|Active Comparator|US Orencia®|US-sourced Orencia® (abatacept)
2947242|NCT02923583|Active Comparator|EU Orencia®|EU-sourced Orencia® (abatacept)
2947243|NCT02923570|Experimental|Photon intensity modulated radiation therapy (IMRT)|IMRT to standard dose of 60-66Gy
2947244|NCT02923570|Experimental|Proton beam radiotherapy (PBRT)|PBRT to standard dose of 60-66Gy
2947245|NCT02923557|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy.
2947246|NCT02923557|Experimental|Single intravesical instillation|intravesical instillation within 24 hours postoperatively
2947247|NCT02923544|Experimental|total laparoscopic or robotic-assisted hysterectomy|The YUMI manipulator will be placed at the start of each case. During the surgery, the surgeon will track any intraoperative complications. The surgeon fellow will also note the feasibility of placing the uterine manipulator.After surgery, the surgeon will complete the product evaluation form.
2947248|NCT02923531|Experimental|X4P-001 plus nivolumab|
2947249|NCT02923518||Inclusion group|Inclusion group: Those with a positive score in a questionnaire including symptoms and family history and/or high risk-score in the NORRISK-score system.
2947250|NCT02923518||Control group|Those without a positive score on the two scores listed above.
2947251|NCT02923505||SDB+COPD|Patients with sleep-disordered breathing and concomitant chronic obstructive pulmonary disease
2947252|NCT02923505||SDB+HF|Patients with sleep-disordered breathing and concomitant heart failure
2947253|NCT02923505||SDB+COPD+HF|Patients with sleep-disordered breathing and concomitant chronic obstructive pulmonary disease and heart failure
2947254|NCT02923492|Experimental|In-person Therapy by ED Staff|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care delivered by ED staff in-person.
2947255|NCT02923492|Experimental|Remote Therapy by Research Staff|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care delivered remotely (over video) by research staff.
2947256|NCT02923492|No Intervention|Comparison Group|This group will not receive an intervention, but did receive an informational pamphlet of resources in the area (enhanced usual care).
2947257|NCT02923479|Experimental|Experimental: ARBOT Group|"The patients in the ARBOT Group underwent to following interventions:~General Rehabilitation~Specific ankle rehabilitation by ARBOT device"
2947258|NCT02923479|Other|Control Group|"The patients in the Control Group underwent to following interventions:~General Rehabilitation~Specific ankle rehabilitation performed by physiotherapist~Specific ankle rehabilitation by Biodex System 3 dynamometer~Specific ankle rehabilitation by ProKin PK254 platform."
2947259|NCT02923466|Experimental|VSV-IFNβ-NIS|VSV-IFNβ-NIS will be administered intratumorally as a single dose on day 1.
2947260|NCT02923466|Experimental|VSV-IFNβ-NIS and avelumab|VSV-IFNβ-NIS will be administered intratumorally as a single dose on day 1. Avelumab will be administered intravenously every 2 weeks starting on day 1.
2947261|NCT02923453|Placebo Comparator|Placebo|1g/meal of placebo three times per day (3g/day) for 8-weeks.
2947262|NCT02923453|Active Comparator|Ginseng Extract|CNT2000 (Chai-Na- Ta Corp., Langley, BC) American ginseng extract 1g/meal of placebo three times per day (3g/day) for 8-weeks.
2947263|NCT02923440|Experimental|Congenital heart defects|
2947264|NCT02923427|Active Comparator|Laryngeal mask Supreme|"Insertion of the Laryngeal mask Supreme and evaluation of its clinical performance"
2947265|NCT02923427|Experimental|i-gel|"Insertion of the i-gel and evaluation of its clinical performance"
2947266|NCT02923414|Active Comparator|Standard escalating shocks|Patients will be randomized to a standard escalating shock protocol using the energy settings: 125, 150, 200 J. All cardioversion attempts will be performed using LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA
2947267|NCT02923414|Active Comparator|High energy shocks|Patients will be randomized to a high energy shock protocol using the energy settings: 360, 360, 360 J. All cardioversion attempts will be performed using LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA
2947268|NCT02923401|Experimental|High-Intensity Interval Training (HIIT) Group|"Participants come to the Energy Balance Center to exercise 3 times a week for 12 weeks.~Participants receive written materials and instructions on how to perform their exercises.~Participants walk uphill on a treadmill for a total of 33 minutes 3 times a week for 12 weeks.~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.~One (1) time each month, participant attends a motivational session."
2947269|NCT02923401|Experimental|Moderate-Intensity Continuous Training (MICT) Group|"Participants come to the Energy Balance Center to exercise 3 times a week for 12 weeks.~Participants receive written materials and instructions on how to perform their exercises.~Participants walk uphill on a treadmill or use a stationary bicycle continuously for 41 minutes 3 times a week for 12 weeks.~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.~One (1) time each month, participant attends a motivational session."
2947270|NCT02923401|Active Comparator|Control Group|"Participants receive written materials and counseling by an exercise physiologist.~Participants called by a member of the study staff 1 time each week for 12 weeks and asked about any exercise they have done and their weight loss goals.~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.~One (1) time each month, participant attends a motivational session."
2947271|NCT02923388|Active Comparator|Experimental|"Intervention: Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.~Intervention: Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks."
2947272|NCT02923388|Placebo Comparator|Placebo|"Intervention: Injection normal saline (1 ml) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.~Intervention: Oral placebo pill 2 tablets thrice daily for 5 weeks."
2947273|NCT02923375|Experimental|Cohort A|Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 1 million cells/kg (up to a maximum of 100 million cells) by IV infusion on two occasions (Day 0 and Day 7)
2947274|NCT02923375|Experimental|Cohort B|Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 2 million cells/kg (up to a maximum of 200 million cells) by IV infusion on two occasions (Day 0 and Day 7)
2947275|NCT02923362||Laparoscopic Fundoplication Group|This group of patients are surgical candidates based on preoperative testing results for laparoscopic fundoplication antireflux procedure and possible hiatal hernia repair.
2947276|NCT02923362||LINX Antireflux Device Group|This group of patients are surgical candidates based on preoperative testing results for the laparoscopic LINX antireflux device placement and possible hiatal hernia repair.
2947277|NCT02923349|Experimental|INCAGN01949|
2947278|NCT02923336|Other|Smart pill|Single group, before and after, the same group is going to be its own control
2947279|NCT02923323|Experimental|Group 1 T1DM aged 12-18 years.|T1DM patients. Receiving regularly insulin. Interventions: performance of continuous EEG , CGMS, MRI of brain with DTI , actigraph, neurocognitive testing
2947280|NCT02923323|Active Comparator|Group 2 Healthy aged 12-18 years.|Healthy Interventions: performance of continuous EEG , CGMS, MRI of brain with DTI , actigraph, neurocognitive testing
2947281|NCT02923310|Experimental|Osteoarthrits G II and III|Group of treatment
2947282|NCT02923310|Experimental|Osteoarthrits GIV|Group of treatment
2947283|NCT02923297|Other|Parkinson's disease patients|blood sampling
2947284|NCT02923284||Imaged renal mass cohort|Subjects undergoing surgery for an kidney tumor identified radiologically.
2947285|NCT02923284||control cohort|Subjects undergoing surgery for any kind of cancer other than kidney.
2947286|NCT02923271|Experimental|Teen-Parent Monitoring Group|"Cellcontrol DriveID device will automatically turn on when the teen or parent begins driving and will be pre-set to block all calls and text messages when the car is in motion but participants will have the ability to override the blocking. The teen-parent monitoring group involves will send email notifications to the teen when their parent unlocks their phone while driving and vice versa.~Participants (parents and teens) will self-report information on their individual driving behaviors for the three weeks prior to study enrollment, including how often they report texting while driving and self-report cellphone use. At the end of the study participants will be asked to report feedback about the use the cellphone blocking technology and their perceptions for whether their safety improved using the technology."
2947317|NCT02923089|Experimental|Small Green Lentil Chili|Chili: 25g available carbohydrate from small green lentil
2947318|NCT02923089|Experimental|Split Red Lentil Chili|Chili: 25g available carbohydrate from split red lentil
2947319|NCT02923089|Placebo Comparator|Rice Chili|Chili: 25g available carbohydrate from rice
2947320|NCT02923076|Experimental|Study treatment|Allogeneic transplantation with CCR5 delta32/delta32 hematopoietic cells from cord blood.
2947350|NCT02922868|Active Comparator|Olympus Visera Elite OTV-S190 Scope|Olympus HD Flexible Cysto-Nephro Videoscope (CYF-VH) with Olympus Visera Elite Platform, including OTV-S190 Video Processor CLV-S190 Xenon Light Source. Olympus Visera Elite OTV-S190 Scope.
2947632|NCT02920801|Active Comparator|metformin group|metformin group consumed metformin 1500mg per day for 12 week
2947287|NCT02923271|Experimental|Teen Only Monitoring Group|"Cellcontrol DriveID device will automatically turn on when the teen or parent begins driving and will be pre-set to block all calls and text messages when the car is in motion but participants will have the ability to override the blocking. The teen only group involves parental monitoring of the teen's cellphone use while driving only. The parent will receive an email notification when their teen unlocks their phone while driving. Both parents and teens will drive under the same restrictions, but only the parent is notified of teen cellphone use.~Participants (parents and teens) will self-report information on their individual driving behaviors for the three weeks prior to study enrollment, including how often they report texting while driving and self-report cellphone use. At the end of the study participants will be asked to report feedback about the use the cellphone blocking technology and their perceptions for whether their safety improved using the technology."
2947288|NCT02923258|Experimental|Experimental|Concurrent Chemoradiotherapy With Docetaxel and IMRT
2947289|NCT02923258|Active Comparator|Control|Concurrent Chemoradiotherapy With Cisplatinum and IMRT
2947290|NCT02923245|Experimental|POCUS|Patients will be given consecutive IV fluid boluses until a full bladder is visualized by the ED physician on POCUS or the patient endorses maximal bladder fullness on a 0-4 Likert Scale. The patient will then have a transabdominal pelvic ultrasound performed by a radiologist or ultrasound technician.
2947291|NCT02923245|No Intervention|Usual Care|Patients will be given consecutive IV fluid boluses until the patient endorses sensation of maximum bladder fullness on a 0-4 Likert Scale. The patient will then have a transabdominal pelvic ultrasound performed by a radiologist or ultrasound technician
2947292|NCT02923232|Experimental|Accommodative contact lens|The accommodative contact lens is composed of traditional hydrogel lens material but has an internal cavity to allow lens deformation that increases its refractive power at an downward angle.
2947293|NCT02923219|Experimental|Stem cells separation|Stem cells separation: The adipose-derived stem cells are separated from vacuumed fat obtained through liposuction of abdomen, hip, thigh and so on. It was confirmed the adipose-derived stem cells can be induced differentiation into fat cells under the special condition in the current literature.Stem cells are used to treat wrinkles and facial rejuvenation.
2947294|NCT02923206|Experimental|Phase 0 - healthy volunteers|Phase 0 is an initial safety phase where subjects will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.
2947295|NCT02923206|Experimental|Phase A - preeclampsia patients|Phase A is a safety and dose-finding phase during which pregnant women diagnosed with preeclampsia will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.
2947296|NCT02923206|Experimental|Phase B - preeclampsia patients|Phase B is a safety and efficacy phase during which pregnant women diagnosed with preeclampsia will undergo TheraSorb sFlt-1 adsorber apheresis procedures up to twice weekly.
2947297|NCT02923193|Experimental|Lithoplasty System followed by DCB|Shockwave Lithoplasty® Peripheral Lithoplasty System is a lithotripsy-enhanced, low-pressure balloon dilatation of calcified, stenotic peripheral arteries in patients who are candidates for percutaneous therapy. lithoplasty
2947298|NCT02923193|Active Comparator|Medtronic IN.PACT (DCB)|Medronic IN.PACT Drug Coated Balloon (DBS) is indicated for percutaneous transluminal angioplasty (PTA) in patients with obstructive disease of peripheral arteries, including patients with in-stent restenosis (ISR) and arteriovenous (AV) access to help maintain hemodialysis access in patients with end-stage renal disease.
2947299|NCT02923180|Experimental|Enoblituzumab|15mg/kg IV (in the vein) weekly for 6 weeks
2947300|NCT02923167|Experimental|Robotic-assisted training of the hand|Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on particpant fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
2947301|NCT02923154|Experimental|MT-3995|
2947302|NCT02923154|Placebo Comparator|Placebo|
2947303|NCT02923141|Active Comparator|Neutral Writing + Contingency Management|Participants will attend four attention-matched control sessions, consisting of face-to-face administration of psychological measures and neutral writing exercises. Participants will also take part in 36 contingency management sessions in which they provide self-collected urine for toxicology screening and receive financial incentives for each negative drug result.
2947304|NCT02923141|Active Comparator|Expressive Writing + Contingency Management|Participants will attend four expressive writing sessions focusing on traumatic or stressful events. Participants will also take part in 36 contingency management sessions in which they provide self-collected urine for toxicology screening and receive financial incentives for each negative drug result.
2947305|NCT02923128|Active Comparator|Dexmedetomidine+routine PCIA|Dexmedetomidine 150ug is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.Routine patient controlled intravenous analgesia(PCIA) formula is sufentanyl(0.06ug.kg-1.h-1),diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
2947306|NCT02923128|Sham Comparator|Routine PCIA|Routine patient controlled intravenous analgesia(PCIA) formula is sufentanyl(0.06ug.kg-1.h-1),diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
2947307|NCT02923115|Experimental|DS-1040b|9 subjects each in Cohorts 1 and 2, and 15 subjects each in Cohorts 3, 4, 5, and 6.
2947308|NCT02923115|Placebo Comparator|placebo|"9 subjects each in Cohorts 1 and 2, and 5 subjects each in Cohorts 3, 4, 5, and 6.~0.9% Sodium Chloride Injection"
2947309|NCT02923102|Active Comparator|Aloysia citriodora extract|Dietary Supplement: Aloysia citriodora extract
2947310|NCT02923102|Placebo Comparator|Placebo Formulation|Dietary Supplement: Maltodextrin (no active ingredient)
2947311|NCT02923089|Experimental|Small Green Lentil Muffin|Muffin: 25g available carbohydrate from small green lentil
2947312|NCT02923089|Experimental|Split Red Lentil Muffin|Muffin: 25g available carbohydrate from split red lentil
2947313|NCT02923089|Placebo Comparator|Wheat Muffin|Muffin: 25g available carbohydrate from wheat
2947314|NCT02923089|Experimental|Small Green Lentil Soup|Soup: 25g available carbohydrate from small green lentil
2947315|NCT02923089|Experimental|Split Red Lentil Soup|Soup: 25g available carbohydrate from split red lentil
2947316|NCT02923089|Placebo Comparator|Potato Soup|Soup: 25g available carbohydrate from potato
2947321|NCT02923063|Experimental|Combined Aerobic and Resistance Exercise|Exercise will be supervised by American College of Sports Medicine certified exercise trainers 3 days per week for 12 weeks. Subjects in the exercise intervention arms will undergo supervised low-impact aerobic intervention sessions of 30-minute duration at 60-80% of the maximal heart rate and 30 minutes of resistance exercise training target 60% of single repetition maximal lift (1RM) three times per week. Investigators will use the Balke protocol for treadmill aerobic exercise. Investigators will encourage adherence to the treadmill exercise, however, if the participant declines to use of the treadmill for the day, they will be given other aerobic exercise options (elliptical trainer, cycle, etc.) targeting the same duration and goal heart rate.
2947322|NCT02923063|No Intervention|Usual Care|"At the beginning of the intervention phase, the control group will receive a one-time counseling session on appropriate dietary and physical activity recommendations. They will receive a Go4Life Workout to go sample exercise routing created by the national institutes on aging (NIA)."
2947323|NCT02923050|No Intervention|Waitlist control|
2947324|NCT02923050|Experimental|10-week family meals program|
2947325|NCT02923037|Experimental|Supportive Care (Yoga)|Patients undergo an initial yoga evaluation for 60 minutes. Patients then undergo their first guided yoga practice session for 30-60 minutes and subsequent guided yoga sessions for 30-90 minutes 3 times a week for 4 weeks, and twice a week for an additional 4 weeks. Patients are also encouraged to complete home yoga practice for 30 to 90 minutes every day for 8 weeks. They will have tape measurement of arms and ldex measurement of arms. Quality-of-Life Assessment will also be made.
2947326|NCT02923024|No Intervention|Usual Care|This arm will be usual care and there will be no intervention.
2947327|NCT02923024|Experimental|Information|In this arm, providers will be sent patient pings after a patient experiences a trigger event. The ping will be a fax sent from Oscar to the physician alerting them of an event their patient had.This trigger event could be an emergency room visit, admission to a hospital, or a hospital discharge event. The patient ping will be sent to the patient's doctor including primary care physicians and specialists. If the patient does not have a doctor, a ping will not be sent.
2947328|NCT02923024|Experimental|Information and Financial Incentives|In this arm, providers will be sent patient pings after a patient experiences a trigger event. The ping will be a fax sent from Oscar to the physician alerting them of an event their patient had.This trigger event could be an emergency room visit, admission to a hospital, or a hospital discharge event. The patient ping will be sent to the patient's doctor including primary care physicians and specialists. If the patient does not have a doctor, a ping will not be sent. Physicians will be incentivized to see patients immediately via phone call or in office visit. Physicians receive a financial incentive for calling the member within 48 hours of trigger event and will receive a larger financial incentive for seeing the patient for an office visit within 7 days of trigger event.
2947329|NCT02923011|Active Comparator|MRgFUS|Magnetic resonance-guided focused ultrasound ablation
2947330|NCT02923011|Active Comparator|CTgRFA|Computed tomography-guided radiofrequency ablation
2947331|NCT02922985|Placebo Comparator|Placebo Control Group|Patients will receive a placebo dose of all three study medications
2947332|NCT02922985|Active Comparator|Multimodal Pain Regimen Group|Patients will receive the actual study medication for all three study medications.
2947333|NCT02922972|Experimental|Four injections of A-PRP|The first injection of A-PRP after complete resection of the keloid scar,Three additional injections were administered with a one-month interval.
2947334|NCT02922959|Active Comparator|Control|Participants in this arm will be given a NARCAN (naloxone) nasal spray kit and written information about opioid overdose and treatment.
2947335|NCT02922959|Experimental|TTIP-PRO|In addition to a NARCAN (naloxone) nasal spray kit and written information about opioid overdose and treatment, participants randomized to this arm will receive the experimental TTIP-PRO intervention.
2947336|NCT02922946|Experimental|Entinostat 5mg in 2-Way Crossover|"Treatment A: 5mg entinostat following an overnight fast and followed by a 4-hour fast.~Treatment B: 5mg entinostat 2 hours after the completion of a meal and followed by a 1-hour fast."
2947337|NCT02922946|Experimental|Entinostat 5mg in 3-Way Crossover|"Treatment C: 5mg entinostat following an overnight fast and followed by a 4-hour fast.~Treatment D: 5mg entinostat following an overnight fast and 1 hour before the start of a meal.~Treatment E: 5mg entinostat 2 hours after the completion of a meal and followed by a 4-hour fast."
2947338|NCT02922933|Active Comparator|Omeprazole|"Treatment A: 5mg entinostat on Day 1~Treatment B: 20mg omeprazole for 5 days with 5mg entinostat on Day 1"
2947339|NCT02922933|Active Comparator|Famotidine|"Treatment C: 5mg entinostat on Day 1~Treatment D: 20mg famotidine on Days -1 and 1 with 5mg entinostat on Day 1"
2947340|NCT02922933|Active Comparator|Acidic Beverage|"Treatment E: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with water~Treatment F: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with an acidic beverage"
2947341|NCT02922920|Experimental|Tart cherry juice|Participants consumed 16 fl. oz of tart cherry juice daily for 12 weeks.
2947342|NCT02922920|Placebo Comparator|Placebo juice|Participants consumed 16 fl. oz of placebo daily for 12 weeks.
2947343|NCT02922907|Experimental|Arabinoxylan Rice Bran|BRM4 two 500mg capsules thrice daily p.o. for 12 weeks
2947344|NCT02922907|Placebo Comparator|Placebo|Placebo for BRM4 two 500mg capsules thrice daily p.o. for 12 weeks
2947345|NCT02922894|Experimental|Acute episodic hypoxia|To test development of ventilatory augmentation following episodic hypoxia, defined as increased Hypoxic Ventilatory Response (HVR) from early to late hypoxic exposure episodes.
2947346|NCT02922894|Experimental|Supplemental oxygen|To use supplemental oxygen to decrease peripheral chemoreceptor activity in patients with SCI and central SDB. In addition, perform a repeat evaluation after treatment with supplemental oxygen or sham O2 for 6 weeks to determine if correction of chronic intermittent hypoxia, which mitigates sensory LTF, results in decreased propensity to central apnea.
2947347|NCT02922894|Experimental|Trazodone or placebo|examine the effect of trazodone on breathing during sleep
2947348|NCT02922881|Experimental|Ulcerative Colitis Diet|Participants will receive a structured 12-week diet with a step down phase.
2947349|NCT02922868|Experimental|EndoSheath CST-5000 Scope|Cogentix Medical CST-5000 Flexible Video Cystoscope with Slide-On® EndoSheath® Technology. EndoSheath CST-5000 Scope.
2947493|NCT02921789|Experimental|Bleselumab Regimen|Bleselumab regimen (basiliximab, methylprednisone, prednisone, bleselumab and tacrolimus).
2947351|NCT02922855|No Intervention|Contemporaneous Control|This group is our 'usual care' control group. They were not contacted for an interview and were not offered an incentive to visit their primary care physician.
2947352|NCT02922855|Active Comparator|$0 group|This group completed a baseline interview but was not offered any incentive if they visited their primary care physician.
2947353|NCT02922855|Experimental|$25 group|This group completed a baseline interview and was offered $25 they visited their primary care physician within 6 months.
2947354|NCT02922855|Experimental|$50 group|This group completed a baseline interview and was offered $50 they visited their primary care physician within 6 months.
2947355|NCT02922842|Active Comparator|Tibial Nerve|Transcutaneous electrical stimulation will be placed on the posterior tibial nerve.
2947356|NCT02922842|Active Comparator|Parasacral|Transcutaneous electrical stimulation will be placed on the lower back near the s3 foramina.
2947357|NCT02922842|Sham Comparator|Shoulder|Transcutaneous electrical stimulation will be placed on the shoulder.
2947358|NCT02922816|Placebo Comparator|Control arm|The control arm will participate in the bowel preparation and perirectal swab sampling but will not receive Fecal Microbiota Transplant (FMT) nor will they be fasting during their first study cycle (Cycle 0). Participants testing positive for a multi-drug resistant organism at the of Cycle 0 will be eligible to receive MRT for up to two cycles, as necessary (Cycles 1 and 2).
2947359|NCT02922816|Experimental|Fecal Microbiota Transplant (FMT)|The experimental arm will participate in the bowel preparation, perirectal swab sampling, and will receive Fecal Microbiota Transplant (FMT) using Allogeneic Human Stool in Glycerol 10% (AHSG) on Day 1 of each cycle (Cycles 1 and 2).
2947360|NCT02922803|Active Comparator|Vitamin D insufficient|Subjects with Vitamin D level in blood > 25 nmool/L < 50 nmol/L will be treated with 1 combination tablet of Vitamin D3/calcium per day
2947361|NCT02922803|Active Comparator|Vitamin D deficient|Subjects with Vitamin D level in blood < 25 nmol/L (25-OHD) will be treated with 2 combination tablets of Vitamin D3/calcium per day
2947362|NCT02922790|Active Comparator|Control|"Subjects will review standard health information on the health consequences of smoking.~Subjects will have blood drawn but it will not be tested for DNA damage."
2947363|NCT02922790|Active Comparator|Biomarker feedback|"Subjects will review this standardized health information, plus receive information on DNA damage along with feedback of their DNA damage.~Subjects will have blood drawn and the feedback will be presented at Visit 2."
2947364|NCT02922790|Active Comparator|Biomarker feedback plus|"Subjects will review this standardized health information, information on DNA damage along with feedback of their DNA damage, and will also will see images of their own cells with and without DNA damage.~Subjects will have blood drawn and the feedback and images will be presented at Visit 2."
2947365|NCT02922777|Experimental|BGB324 in combination with docetaxel|The dose of docetaxel will be 75 mg/m2 given IV every 21 days. The dose of BGB324 will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
2947366|NCT02922764|Experimental|Single agent RGX-104|RGX-104 is a small molecule agonist of the liver X receptor (LXR), a member of the nuclear receptor family of transcription factors.
2947367|NCT02922764|Experimental|RGX-104 in combination with nivolumab|RGX-104 is a small molecule agonist of the liver X receptor (LXR), a member of the nuclear receptor family of transcription factors. Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PDL1 and PD-L2.
2947368|NCT02922751||All Subjects|All subjects will be recruited from the Children parent studies: LOGIC (NCT00571272), BASIC (NCT00345553) and PROBE (NCT00061828) and will undergo Liver Stiffness Measurement (LSM). Subjects in these studies have one or more of the following conditions: biliary atresia (BA), Alpha1 Anti-trypsin Deficiency (A1AT) or Alagille Syndrome (ALGS).
2947369|NCT02922738|Experimental|Intervention|Providers refer to VisualDx when seeing a patient that presents with a skin problem. Patients are interviewed about the outcome of their treatment.
2947370|NCT02922738|No Intervention|Control|Providers refer to usual information source or none (standard treatment.). Patients are interviewed about the outcome of their treatment.
2947371|NCT02922725|Active Comparator|Depressed patients receiving study drug|Participants diagnosed with MDD
2947372|NCT02922725|Placebo Comparator|Depressed patients receiving placebo|Participants diagnosed with MDD
2947373|NCT02922725|No Intervention|Healthy Control|
2947374|NCT02922712|Experimental|NISE 100mg|Nise 100mg given BD for 3 weeks
2947375|NCT02922699|Experimental|Omeprazole 40mg|Omez 40mg OD
2947376|NCT02922699|Active Comparator|Omeprazole 80 mg|Omez 80mg OD
2947377|NCT02922686|Active Comparator|flucloxacillin + phenoxymethylpenicillin|Flucloxacillin 500 mg four times daily + Phenoxymethylpenicillin 500 mg four times daily for 7 days.
2947378|NCT02922686|Placebo Comparator|flucloxacillin + placebo|Flucloxacillin 500 mg four times daily + Placebo four times daily for 7 days.
2947379|NCT02922673|Experimental|Treatment group|7 day treatment with placebo - first LPS challenge - 7 day treatment with ASA 80 mg (with a loading dose of 160 mg on the first day) - second LPS challenge
2947380|NCT02922673|Active Comparator|Prophylaxis group|7 day treatment with ASA 80 mg (with a loading dose of 160 mg on the first day) - first LPS challenge - 7 day treatment with ASA (no loading dose on first day) - second LPS challenge
2947381|NCT02922673|Placebo Comparator|Placebo group|7 day treatment with placebo - first LPS challenge - 7 day treatment with placebo - second LPS challenge
2947382|NCT02922660|Experimental|Group TIVA|method of anesthesia is total intravenous anesthesia(TIVA) and maintenance with propofol Cp 2—4 μg/ml and remifentanil 2—4 ng/ml in target controlled infusion(TCI) during the procedure
2947383|NCT02922660|Experimental|Group Des|method of anesthesia is inhalation anesthesia and maintenance with desflurane ranged from 0.5~1.5 MAC during the procedure
2947384|NCT02922647|Experimental|suprapubic catheterization|Intervention:suprapubic catheterization after rectal resection with low anastomosis. Evaluate the urinary tract infection rate on the four days postoperative.
2947385|NCT02922647|Active Comparator|transurethral catheterization|Intervention:transurethral catheterization after rectal resection with low anastomosis. Evaluate the urinary tract infection rate on the four days postoperative.
2947561|NCT02921269|Experimental|Treatment (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2947386|NCT02922634||older surgical patients|older surgical patients presenting for elective thoracic surgery (specifically, thoracoscopic lung resection, lobectomy, thoracotomy, or esophagectomy) and to neurological posterior thoracolumbar spine surgery by neurosurgeons Dr. Groff, Dr. Lu and Dr. Chi
2947387|NCT02922595|Active Comparator|Intubation through ILMA®|The ILMA will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers. The Intervention will be the intubation through ILMA. We will measure the time necessary to insert it, the possibility to ventilate the patient through it and the success rate of tracheal intubation through it will be assessed.
2947388|NCT02922595|Experimental|Intubation through ILTS®|The ILTA will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers. It will be proceeded to the intubation through ILTS and the time necessary to insert it, the possibility to ventilate the patient through it and the success rate of tracheal intubation through it will be assessed.
2947389|NCT02922582|Active Comparator|IV Tranexamic acid (TXA)|1 gram IV TXA intraoperatively at the end of surgery one time
2947390|NCT02922582|Experimental|DepoTXA 800mg|800mg Intracapsular at the end of surgery one time
2947391|NCT02922582|Experimental|DepoTXA 1200mg|1200mg Intracapsular at the end of surgery one time
2947392|NCT02922569|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training and mindfulness training requiring a total maximum of 60 treatment sessions, up to 5 sessions per week, 40 minutes per session.
2947393|NCT02922569|Active Comparator|Active Comparator|Commercially available computerized training and Veterans Affairs information session requiring a total maximum of 60 treatment sessions, up to 5 sessions per week, 40 minutes per session.
2947394|NCT02922556|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training (Moodify) requiring a total maximum of 50 treatment hours, 3-5 times weekly, 30-45 minutes each session.
2947395|NCT02922556|Active Comparator|Active Comparator|Commercially available computerized training (Games) requiring a total maximum of 50 treatment hours, 3-5 times weekly, 30-45 minutes each session.
2947396|NCT02922543||Relapsed or refractory multiple myeloma (MM) patients|Relapsed or refractory MM patients in the special use-results surveillance (all-case surveillance) (hereinafter referred to as the all-case surveillance) who have received Revlimid treatment for at least 7 cycles at institutions cooperating in performing the all-case surveillance and this surveillance.
2947397|NCT02922530|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring up to a maximum of 80 treatment sessions, up to 7 sessions per week, 15-60 minutes per session
2947398|NCT02922530|Active Comparator|Active Comparator|Commercially available computerized training requiring up to a maximum of 80 treatment sessions, up to 7 sessions per week, 15-60 minutes per session.
2947399|NCT02922517||patients with obstructive HCM|patients with HCM (obstructive or no obstructive)
2947400|NCT02922517||controls|patients without HCM
2947401|NCT02922517||patients with non obstructive HCM|patients with non obstructive HCM
2947402|NCT02922504|Experimental|Music intervention group|For the patients in the Music intervention group, a adjuvant treament by a music intervention will be use.
2947403|NCT02922504|Active Comparator|Controlled group|"For the patients in the  controlled  group, the use of analgesic will be use if needed during the procedure"
2947404|NCT02922491|Experimental|Group 1|"400 mg Vitamin E of synthetic source~1 once daily during 2 months"
2947405|NCT02922491|Experimental|Group 2|"400 mg Vitamin E of natural source~1 once daily during 2 months"
2947406|NCT02922491|Placebo Comparator|Group control|"400 mg of starch~1 once daily during 2 months"
2947407|NCT02922491|No Intervention|No intervention|Without intervention
2947408|NCT02922465|Experimental|K-877 & Clopidogrel|K-877 & Clopidogrel orally
2947409|NCT02922452|Experimental|BMS-986141 and Dilitazem|
2947410|NCT02922439|Experimental|Tailored Intervention|Individuals will interact with a chronic disease self-management application that provides information tailored to age, race, language (English or Spanish) and level of health literacy.
2947411|NCT02922439|Active Comparator|Control|Individuals will interact with a chronic disease self-management application that provides the same information as the experimental intervention but is not personally tailored to level of health literacy.
2947412|NCT02922426|Experimental|ALKS 3831|Oral, bilayer tablet
2947413|NCT02922426|Active Comparator|Olanzapine|Oral, bilayer tablet
2947414|NCT02922426|Placebo Comparator|Placebo|Oral, bilayer tablet
2947415|NCT02922413|Experimental|Hemin for injection|A double blind dose single dose of Panhematin 4 mg/kg body weight reconstituted with 25% human albumin and infused over at least one hour.
2947416|NCT02922413|Placebo Comparator|Placebo|A double blind dose of saline.
2947417|NCT02922400|Experimental|Social Cognition Assessment and Training|Assessment and training program to enhance social function
2947418|NCT02922387|Experimental|Varenicline + Behavioral support|varenicline and behavioral support
2947419|NCT02922387|Active Comparator|Behavioral support|behavioral support
2947420|NCT02922374|Experimental|CS|Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
2947421|NCT02922348|Experimental|Hormone Replacement Therapy|Patient will be given hormones in the form of: transdermal estradiol patch (Climara) 100 mcg/24 hours weekly, progesterone (Prometrium) 200 mg per day for first 12 calendar days of each month (If patients insurance plan does not cover transdermal estradiol, they will be prescribed oral estradiol 2 mg daily. If patients insurance plan does not cover Prometrium, they will be prescribed medroxyprogesterone (Provera) 10 mg per day for first 12 calendar days of each month).
2947422|NCT02922348|Experimental|Combined Oral Contraceptives|Patients will be given hormones in the form of: monophasic combined oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.25 mg, 1 tablet daily (21 days of active pills and 7 days of inactive pills)
2947423|NCT02922335|Experimental|Multisystemic Therapy - Emerging Adults|Multisystemic Therapy for Emerging Adults (MST-EA) is designed to help emerging adults (ages 18-21) with mental illness who have been in trouble with the law. MST-EA is a treatment program specifically for emerging adults, to increase skills and capacities that can help them reduce their antisocial behavior and help reduce problems caused by mental health illness, and alcohol or drug use when present.
2947424|NCT02922335|Active Comparator|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU) emerging adults will get the treatments that they usually receive when they have a mental illness and have been in trouble with the law. They will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
2947425|NCT02922322|Active Comparator|Pilates Group|The Pilates Group was composed by 15 participants evaluated before and after 16 sessions of intervention with mat Pilates exercises.
2947426|NCT02922322|No Intervention|Control Group|The control group was composed by 15 participants that received no intervention
2947427|NCT02922309|Experimental|experimental|Vocal Training via Telepractice
2947428|NCT02922309|Active Comparator|control|Vocal Training via face-to-face practice
2947429|NCT02922283|Experimental|IL2-PET scan|[18F]FB-IL2 PET scan, Tumor biopsy, CT scan, Biopsy of non-target tissue
2947430|NCT02922270||Patients|Who have received PD as renal replacement therapy (RRT) over a period of 20 years.
2947431|NCT02922244|No Intervention|Standard skin care|standard skin care
2947432|NCT02922244|Placebo Comparator|Control|Moisture Cream
2947433|NCT02922244|Active Comparator|Cucumber cream|Apply Cucumber cream everyday after radiation therapy on the treatment aria skin.
2947434|NCT02922244|Active Comparator|Centella cream|Apply Centella asiatica cream everyday after radiation therapy on the treatment aria skin.
2947435|NCT02922244|Active Comparator|Thunbergia cream|Apply Thunbergia cream everyday after radiation therapy on the treatment aria skin.
2947436|NCT02922231||All Study Participants|Participants with congenital hemophilia B (FIX level ≤5%)
2947437|NCT02922218||Enzalutamide|Enzalutamide 160 mg/day c/24h
2947438|NCT02922205||RYGB surgery|Obese patients eligible for laparoscopic Roux-en-Y gastric bypass (RYGB) surgery.
2947439|NCT02922192||Rheumatoid arthritis (RA)|With exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
2947440|NCT02922192||Inflammatory bowel disease (IBD)|With exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
2947441|NCT02922192||Psoriatic conditions|Patients with a psoriasis, psoriatic arthritis, ankylosing spondylitis with exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
2947442|NCT02922179||Diabetes Type 1|Individuals diagnosed with type 1 diabetes exposed to Long- and intermediate- acting insulins
2947443|NCT02922179||Diabetes Type 2|Individuals diagnosed with type 2 diabetes exposed to Long- and intermediate- acting insulins
2947444|NCT02922166|Experimental|SRX246|SRX246 oral dosage capsules, daily dose to be taken bid, for up to 7 days
2947445|NCT02922166|Placebo Comparator|Placebo|Placebo oral dosage capsules, daily dose to be taken bid, for up to 7 days
2947446|NCT02922153|Experimental|Cryoanalgesia + SOC|Cryoanalgesia in Conjunction with Standard of Care. Up to 5 sessions of cryoanalgesia for 120 seconds per session.
2947447|NCT02922153|Active Comparator|Standard of Care|Institutional SOC for pain management will be followed. The use of local post-operative pain management techniques (i.e., intercostal, peri-vertebral, or any other acceptable method) is permitted for both treatment groups up to 24 hours post-operatively according to institutional standard of care.
2947448|NCT02922140|No Intervention|control group|will receive standard care by physician in attendance
2947449|NCT02922140|Active Comparator|intervention group|will be supplied by clinical pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.
2947450|NCT02922127|Other|Ulipristal Acetate|20 women will randomized to daily use of 10mg of ulipristal acetate
2947451|NCT02922127|Other|Combined Oral Contraceptive|20 women will be randomized to daily use of a combined oral contraceptive pill
2947452|NCT02922114|Experimental|Ultrasonography|B-mode and power Doppler Ultrasonography examination
2947453|NCT02922101|Experimental|Audit and Feedback with toolbox|Access to an online dashboard that provides insight into clinical performance on quality indicators for pain management; including a quality improvement toolbox to facilitate planning and executing actions. Participating ICUs will receive one educational outreach visit and brief monthly telephone calls.
2947454|NCT02922101|Active Comparator|Audit and Feedback without toolbox|Same intervention, but without access to the quality improvement toolbox.
2947455|NCT02922075|Placebo Comparator|CTL|No soft tissue graft was used. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
2947456|NCT02922075|Experimental|CM|Patient received a collagen matrix graft. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
2947457|NCT02922075|Experimental|CTG|Patient received a connective tissue graft. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
2947458|NCT02922062|Experimental|Low Carbohydrate Diet|Half of the participants will be randomly assigned to this diet arm. The macronutrient composition of the diet will be (PRO (protein):CHO (carbohydrate):FAT, 18:8:74). There are three diet phases within this arm that use different fats as the primary cooking oil either canola oil, palm oil or butter. Each diet phase lasts for 3 weeks. At the end of each diet phase the testing battery completed at baseline will be repeated followed by a 2 week washout where subjects revert back to their usual diets. Canola oil is the low saturated fat control diet and is administered first. Participants then randomly begin either the palm oil or canola oil diet phases.
2947459|NCT02922062|Active Comparator|High Carbohydrate Diet|Half of the participants will be randomly assigned to this diet arm. The macronutrient composition of the diet will be (PRO:CHO:FAT, 18:60:22). There are three diet phases within this arm that use different fats as the primary cooking oil either canola oil, palm oil or butter. Each diet phase lasts for 3 weeks. At the end of each diet phase the testing battery completed at baseline will be repeated followed by a 2 week washout where subjects revert back to their usual diets. Canola oil is the low saturated fat control diet and is administered first. Participants then randomly begin either the palm oil or canola oil diet phases.
2947528|NCT02921516|Experimental|N'ap Grandi|Both Adolescent and Caregiver participate in assessment and intervention groups. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
2947797|NCT02919774|Experimental|POMA 40 mg BID|40 mg BID for 10 days
2947460|NCT02922049|Other|pCLE vs. biopsies with histopathology|"The investigators will compare diagnostic accuracy and sensitivity of pCLE with standard biopsies in patients with esophageal and gastric lesions and in patients after completed endoscopic treatment of BORN.~All samples taken by biopsies will be correlated with the images taken by pCLE in the detection of lesions, intestinal metaplasia, dysplasia and buried glands."
2947461|NCT02922036|Experimental|Treatment|WiSE System therapy ON with Guideline Directed Medical Therapy
2947462|NCT02922036|Sham Comparator|Control|WiSE System therapy OFF with Guideline Directed Medical Therapy
2947463|NCT02922023|Active Comparator|Chronotherapy|Chronotherapy group automatically receives a shift in 1 anti-hypertensive medication to night-time without assessment of ambulatory blood pressure monitor results.
2947464|NCT02922023|Active Comparator|ABPM|ABPM group will have their ambulatory blood pressure monitor results reviewed prior to deciding to change regimen.
2947465|NCT02921997|Experimental|Arm 1|10 Subjects: one dose of 15 µg of A/H3N2v, at Day 1
2947466|NCT02921997|Experimental|Arm 2|10 Subjects: two doses of 3.75 µg of AH7N9 AS03,at Day 1 and at Day 29
2947467|NCT02921997|Experimental|Arm 3|10 Subjects: two doses of 3.75 µg of A/H7N9, at Day 1 and Day 29
2947468|NCT02921984|Experimental|Docetaxel arm|Concurrent chemotherapy with Docetaxel if genetic testing show that the patient should be sensitive to this drug.
2947469|NCT02921984|Experimental|Pemetrexed arm|Concurrent chemotherapy with Pemetrexed if genetic testing show that the patient should be sensitive to this drug.
2947470|NCT02921984|Experimental|Cisplatin arm|Concurrent chemotherapy with Cisplatin if genetic testing show that the patient was nor sensitive to neither Pemetrexed nor Docetaxel
2947471|NCT02921971|Experimental|SAR156597|SAR156597 will be given on a specific time period
2947472|NCT02921971|Placebo Comparator|Placebo|Placebo will be given on a specific time period
2947473|NCT02921945|Experimental|SCT800|
2947474|NCT02921932|Active Comparator|Intervention|"In the interventional arm, patients will be given:~A 'Threshold' Inspiratory Muscle Trainer~A nutritional assessment: if needed, dietary supplements prescribed (i.e Ensure, Glucerna).~Cognitive exercise in the form of the 'Memory' card game will be taught to the patients and the caregiver (if available), to be done twice a day.~Patients will be provided with a protocol activities log and a study assistant will be conducting a telephone conversation on day 1, 4 and 7 to encourage compliance to the protocol and answer any queries with regards to the research study."
2947475|NCT02921932|No Intervention|Control|In the control arm, patients will be given the standard education materials regarding surgery and carry out daily activities as usual until the admission of the surgery.
2947476|NCT02921919|Experimental|Talazoparib|
2947477|NCT02921906|Experimental|Neonatal diabetes|People with neonatal diabetes due to mutations in the KCNJ11 gene who are treated with sulphonylureas and not on insulin.
2947478|NCT02921906|Active Comparator|Non-diabetic controls|People without diabetes.
2947479|NCT02921906|Active Comparator|Controls with Type 2 Diabetes|People with Type 2 diabetes who are treated with sulphonylurea medication.
2947480|NCT02921893|Experimental|Group I (ixazomib citrate, lenalidomide, dexamethasone,ASCT)|Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients undergo standard of care ASCT after completing 3 courses of treatment.
2947481|NCT02921893|Experimental|Group II (ixazomib citrate, lenalidomide, dexamethasone)|Patients receive ixazomib citrate PO, lenalidomide PO QD, and dexamethasone PO as in Group I. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
2947482|NCT02921880|Experimental|Cardiac Rehabilitation|Patients will return to the out-patient clinic at 4 weeks post - TAVR and research consent will be re-affirmed. Patients will be randomised to receive a programme of cardiac rehabilitation or routine care at this point. Patients randomised to receive cardiac rehabilitation will meet the cardiac rehab team and undergo baseline assessment for the programme. This involves recording height, weight, blood pressure, oxygen saturation and heart rate and rhythm. An individualised programme will be established to meet the needs of each patient. The patients will undergo a 6 week programme of cardiac rehab. Patients who are not allocated to the intervention group will not receive a cardiac programme and will have access to the TAVR nurse specialist team as would be usual care.
2947483|NCT02921880|No Intervention|Standard of care|15 patients will be randomised to receive a programme of cardiac rehabilitation, and 15 patients will receive standard of care which does not include a routine rehabilitation programme.
2947484|NCT02921867|Experimental|Intervention group|Simulation-based training in nine modules with optional training times and ending with an obligatory certification test before traditional training is started. Traditional training time unaltered: six weeks.
2947485|NCT02921867|No Intervention|Traditional training|Six weeks focused stay at an ultrasound ward with day to day one-on-one supervision (current practise)
2947486|NCT02921854|Experimental|All included patients|3 times Blood withdrawal for each patient (25ml each)
2947487|NCT02921841|Experimental|DSTAR|Digital HIV Prevention intervention developed to specifically address the needs of youth in mental health treatment. Sessions introduce affect regulation and cognitive monitoring in sexual situations, and provide basic sexual health skills and education.
2947488|NCT02921841|Active Comparator|DHEALTH|Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
2947489|NCT02921828||Multiple myeloma patients who received Pomalyst|Among relapsed or refractory multiple myeloma patients, all patients who received Pomalyst will be targeted in this surveillance.
2947490|NCT02921815||Patients with myeloid leukemia|All del(5q) Myelodysplastic syndrome (MDS) patients in the all-case surveillance in whom transformation to acute myeloid leukemia has not been documented at the end of the observation period of the all-case surveillance.
2947491|NCT02921802||Patients who received Revlimid|Among relapsed or refractory multiple myeloma and Myelodysplastic syndrome (MDS) with a deletion 5q cytogenetic abnormality patients, all patients who received Revlimid will be targeted in this surveillance.
2947492|NCT02921789|Active Comparator|Standard of Care Regimen|Standard of Care regimen (basiliximab induction, tacrolimus, methylprednisone, prednisone and MMF).
2947494|NCT02921776|Experimental|Aim 1- VidaTalk post-extubation|"Aim 1 is a two group iterative design preliminary to clinical trial. Group 1 and Group 2 will each consist of five previously mechanically ventilated patients who will be recruited from the ICUs at the OSUWMC (Ohio State University Wexner Medical Center), including discharged patients.~Intervention will be Aim 1 - VidaTalk - tasks. Group 1 will use an initial android prototype of VidaTalk tablet application to be assessed for functionality (ergonomics, ease of use, ease of learning, simplicity, effectiveness and user interface) and usability on customizable communication, picture symbols, and integration with mobile communication devices.~Group 2 will use an improved alpha prototype of VidaTalk tablet application version engineered from observations made during Group 1 sessions."
2947495|NCT02921776|Experimental|Aim 2 - VidaTalk intubated|"Usability testing preliminary to Clinical Trial (Aim 3). The company will perform further iterative design assessments and engineer a Vidatalk tablet application prototype. This prototype will be used with a final group of ten (10) intubated patients receiving mechanical ventilation support to field-test the prototype for functionality (human-device interaction factors, feasibility, and usability) and acceptability.~Intervention is usability tasks with the VidaTalk app"
2947496|NCT02921776|Experimental|Aim 3 - VidaTalk tablet app|"35 intubated patients (oral endotracheal tube or tracheostomy) will be randomized to the intervention arm and will receive a protocolized instruction in the use of the VidaTalk application including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.~Intervention will be receipt of VidaTalk tablet application."
2947497|NCT02921776|Other|Aim 3 - attention-control|"35 intubated patients (oral endotracheal tube or tracheostomy) will receive the standard of care, which may include primarily writing tools (paper and pen) and, occasionally, picture or alphabet communication charts.~Patients randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk application, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.~Interventions will be Aim 3 - attention-control with non-VidaTalk tablet."
2947498|NCT02921763||Dydrogesterone|Dydrogesterone 20 mg (4 tablets) per day should be orally administered in 2 divided doses (in the morning and evening). It should be administered for 21 days; dosage starts on the 5th day of each menstrual cycle until 25th day. The administration period will be from the start of Duphaston treatment (cycle 1) to cycle 4.
2947499|NCT02921750|Experimental|Dressing Exufiber|will receive dressing Exufiber
2947500|NCT02921750|Active Comparator|Dressing Aquacel Extra|Will receive Aquacel Extra
2947501|NCT02921737|Experimental|Treatment Arm|TAS-102
2947502|NCT02921724|Experimental|Cancer patients undergoing oral therapy|At the time of therapy prescription, patients candidate for oral therapy with capecitabine or sunitinib will be provided with informations on the side-effects of therapy and on the use and functions of the mobile diary app TreC-Onco. Patients are required to manually insert data into the mobile diary app at least once a day. Patients will be visited every 6 weeks. During the visit, the clinician will compare adherence and toxicity data entered into the mobile diary app with those directly reported by the patient and by drug accountability.
2947503|NCT02921711||LVIS®|
2947504|NCT02921698||FRED®|
2947505|NCT02921685|Experimental|Monalizumab|Monalizumab treatment will be initiated 75 to 100 days after hematopoietic stem cells transplantation. Patients will receive a single dose of monalizumab by intravenous route over 1 hour.
2947506|NCT02921672|Active Comparator|Cognitively Normal|Persons who are considered to have normal cognitive function. A registered dietician will meet with each person to discuss the Mediterranean Diet.
2947507|NCT02921672|Active Comparator|Mild Cognitive Impairment|Persons diagnosed mild cognitive impairment (MCI). A registered dietician will meet with each person to discuss the Mediterranean Diet.
2947508|NCT02921672|Experimental|Mild to Moderate Alzheimer's Disease|Persons diagnosed with mild to moderate Alzheimer's disease (AD). A registered dietician will meet with each person to discuss the Mediterranean Diet.
2947509|NCT02921659|Placebo Comparator|Placebo|placebo, 500 mg, 2x/day for 6 weeks
2947510|NCT02921659|Active Comparator|Niagen™|Niagen™ (nicotinamide riboside chloride, ChromaDex, Inc.) 500mg, 2x/day for 6 weeks.
2947511|NCT02921646|Other|energetic expenditure measure|To a standard treatment by chemotherapy, energetic expenditure will be measured 5 times during the study.
2947512|NCT02921633|Experimental|Intervention letter|Centrally-sent behavioural-insight informed invitation letter.
2947513|NCT02921633|No Intervention|Control|No centrally-sent invitation letter.
2947514|NCT02921620|Experimental|PRX-102|PRX-102 infusions every 2 weeks
2947515|NCT02921620|Placebo Comparator|Placebo|Placebo infusions every 2 weeks
2947516|NCT02921607||Observational|One group - all participants will be completing questionnaires and will be followed up with three months post discharge.
2947517|NCT02921594|Active Comparator|Total knee arthroplasty with Vanguard XP|The new Vanguard XP Total knee arthroplasty system is a further development of the Vanguard TKA. The new Vanguard XP system both cruciate ligaments are preserved.
2947518|NCT02921594|Active Comparator|Total knee arthroplasty with Vanguard CR|Total knee arthroplasty system without preservation of the anterior cruciate ligament
2947519|NCT02921568|Other|All patients|All patients will be imaged on the P200TE and Spectral OCT/SLO devices.
2947520|NCT02921555|Experimental|methylprednisolone & prednisone|Intravenous bolus of methylprednisolone followed by a decreasing conventional course of oral prednisone
2947521|NCT02921555|Active Comparator|prednisone|A decreasing conventional course of oral prednisone
2947522|NCT02921542||Homogenous Lesions|
2947523|NCT02921542||Heterogenous Lesions|
2947524|NCT02921542||Calcific Lesions|
2947525|NCT02921542||Restenotic Lesions|
2947526|NCT02921529|Experimental|TEAS|Patients were given 30min of TEAS(transcutaneous electrical acupoint stimulation) before anesthesia and 1,2,3 day after surgery
2947527|NCT02921529|Sham Comparator|false stimulation|Attach electrodes without electric current
2947560|NCT02921282||Genotype cannabinoids|Genotyping will be conducted at the conclusion of the study
2947529|NCT02921516|Active Comparator|N'ap Grandi - A|Adolescents participate in assessment and intervention groups, Caregivers participate in assessment only. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
2947530|NCT02921516|Placebo Comparator|Health Promotion - A|Adolescents participate in assessment and intervention groups, Caregivers participate in assessment only. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
2947531|NCT02921503|Experimental|Topical Corticosteroids App Users|Practitioners will asked to use a novel application during their patient encounters over the next three months. This application should not modify treatment, it will only act as a vehicle to present evidence based research. Patients will not be subjects of this research, as the app is only presenting best practice which the physicians should be aware of.
2947532|NCT02921490|Experimental|PET/MR recipients|All recruited patients will undergo FDG PET/MR of the lumbar spine as the single arm of the study.
2947533|NCT02921477|Experimental|Bosutinib Treatment Arm|Subjects will be administered the initial dose of bosutinib, with dosage progressively increased over the course of the study. The initial dose of bosutinib is 100 mg tablet, once per day. The dose will be increased as tolerated up to 300 mg per day. The dose will be increased by 100 mg each month if the lower dose is tolerated without significant side effects. That is to say, the subject will take 100 mg/day every day for the first month, 200 mg/day every day for the second month, and 300 mg/day every day for the third month and for the remainder of the study, provided that adverse reactions do not prohibit continuation at this dosage. Stopping and dose reduction rules for reported adverse reactions have been taken from the package insert of bosutinib. The duration of treatment is 1 year.
2947534|NCT02921464||Group A|Group A - without known pre-existing SIHD
2947535|NCT02921464||Group B|Group B - with known pre-existing SIHD.
2947536|NCT02921451|Other|Restorelle Smartmesh|Surgical procedure for treatment of uterine prolapse will use the device, Restorelle Smartmesh.
2947537|NCT02921438||Chest pain patients presenting to the ED|All patients that present to the emergency department with chest pain and potentially other symptoms consistent with ACS and meet all eligibility criteria will undergo VitalScan Magnetocardiograph.
2947538|NCT02921425|Experimental|patient health record|The study intervention involved the provision to study participants of targeted instruction and practice on use of the Track Health function of the VA's patient health record known as My HealthyVet.
2947539|NCT02921412|No Intervention|enfilcon A (habitual)|All participants wear enfilcon A toric lens (habitual) and then refitted with fanfilcon A toric lenses.
2947540|NCT02921412|Active Comparator|fanfilcon A|All participants wear enfilcon A toric lens (habitual) and then refitted with fanfilcon A toric lenses.
2947541|NCT02921399||early eradication group|In the post-endoscopic resection period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as follows: 1) early (≤ 2 weeks), 2) late (≥ 8weeks).
2947542|NCT02921399||late eradication group|In the post-endoscopic resection period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as follows: 1) early (≤ 2 weeks), 2) late (≥ 8weeks).
2947543|NCT02921386|Other|Breakfast A - Fasting|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to Fasting at breakfast and immediately prior to dinner.
2947544|NCT02921386|Other|Breakfast B - 15 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 15 g fat breakfast and immediately prior to dinner.
2947545|NCT02921386|Other|Breakfast C - 30 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 30 g fat breakfast and immediately prior to dinner.
2947546|NCT02921386|Other|Breakfast D - 45 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 45 g fat breakfast and immediately prior to dinner.
2947547|NCT02921386|Other|Breakfast E - High Fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to high fat breakfast and immediately prior to dinner.
2947548|NCT02921373|Experimental|Prostate Cancer Patients|"Up to 6 Male prostate cancer patients with metastatic, castration resistant prostate cancer will be enrolled.~19F Cell Sense-labeled PBMC (3 million cells) will be injected intradermally into the upper thigh of each participant above the inguinal lymph node. MRI will be used to image the administration site."
2947549|NCT02921373|Experimental|Healthy Volunteers|"Up to 6 male or female healthy volunteers will be enrolled.~19F Cell Sense-labeled PBMC (3 million cells) will be injected intradermally into the upper thigh of each participant above the inguinal lymph node. MRI will be used to image the administration site."
2947550|NCT02921360|Experimental|12 hours|Non-contrast CT and CT-angiography are performed in 11 hours after thrombolysis. In case no haematoma is found, patient would receive 100 mg of acetylsalicylic acid per os daily starting from 12 hours after thrombolysis
2947551|NCT02921360|No Intervention|24 hours|Non-contrast CT and CT-angiography are performed in 23 hours after thrombolysis. In case no haematoma is found, patient would receive 100 mg of acetylsalicylic acid per os daily starting from 24 hours after thrombolysis
2947552|NCT02921347|Experimental|Intervention group|Patients in this group are received ventilator weaning by switching between invasive and noninvasive ventilation
2947553|NCT02921347|No Intervention|Control group|Patients in this group are weaned from ventilator as conventional methods.
2947554|NCT02921334|Experimental|Intervention group|Patients in this group are received ventilator weaning by switching between invasive and noninvasive ventilation.
2947555|NCT02921334|No Intervention|Control group|Patients in this group are weaned from ventilator as conventional methods.
2947556|NCT02921308||With BPD|No intervention will be administered. After informed consent is obtained, children will undergo ultra-short echo time pulmonary MRI, followed by PFT and completion of questionnaires.
2947557|NCT02921308||Without BPD|No intervention will be administered. After informed consent is obtained, children will undergo ultra-short echo time pulmonary MRI, followed by PFT and completion of questionnaires.
2947558|NCT02921295|Active Comparator|Sidekick Stubbies|"Conventional Stubby prostheses were used for baseline measures. In the sequential crossover design, articulated stubby prostheses (Sidekick manufactured by College Park Ind.) were used as intervention"
2947559|NCT02921282||Genotype dopamine|Genotyping will be conducted at the conclusion of the study
2947562|NCT02921256|Active Comparator|Arm I (mFOLFOX6, RT, capecitabine)|Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID Monday-Friday for 5 weeks in the absence of disease progression or unacceptable toxicity.
2947563|NCT02921256|Experimental|Arm II (mFOLFOX6, RT, capecitabine, veliparib)|Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID and veliparib PO BID Monday-Friday for 5 weeks in the absence of disease progression or unacceptable toxicity.
2947564|NCT02921256|Experimental|Arm III (mFOLFOX6, RT, capecitabine, pembrolizumab)|ARM III: Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID Monday-Friday for 5 weeks. They also receive pembrolizumab IV over 30 minutes every 3 weeks beginning on day 1 of RT for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2947565|NCT02921243||Stool Sample Collection|
2947566|NCT02921243||Prebiotic|
2947567|NCT02921230|Experimental|ELUVIA Stent Implantation|Peripheral stenting
2947568|NCT02921230|Active Comparator|control Bare Metal Stent Implantation|Peripheral stenting
2947569|NCT02921217|Experimental|ActivBPL1|Active Probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145)
2947570|NCT02921217|Experimental|InactivBPL1|Inactivated probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145)
2947571|NCT02921217|Placebo Comparator|Control|Control
2947572|NCT02921204||Vitamin D status|Subjects are recruited to asses Vitamin D status with no interventions
2947573|NCT02921191||Lung cancer|Lung cancer patients receiving their first cycle of Grade III and IV myelosuppressive chemotherapy regimen treated prophylactically with G-CSF.
2947574|NCT02921191||Breast cancer|Breast cancer patients receiving their first cycle of Grade III and IV myelosuppressive chemotherapy regimen treated prophylactically with G-CSF (filgrastim, TBO-filgrastim or pegfilgrastim)
2947575|NCT02921165|Active Comparator|Group 1|Non hypertensive Intervention: On analgesic mouth rinses (dissolved Aspirin)
2947576|NCT02921165|Experimental|Group 2|Hypertensive Intervention: On analgesic mouth rinses (dissolved Aspirin)
2947577|NCT02921165|Experimental|Group 3|Non Hypertensive Intervention: On normal saline rinses.
2947578|NCT02921152|Other|all|All patients with early breast cancer
2947579|NCT02921139|Experimental|Arm I|Stereotactic ablative radiotherapy (SABR)
2947580|NCT02921139|Active Comparator|Arm II|Re-transcatheter arterial chemoembolization (re-TACE)
2947581|NCT02921126||High Dose Group|Apixaban - 10 mg/day Rivaroxaban - 20 mg/day Dabigatran - 300 mg/day
2947582|NCT02921126||Low Dose Group|Apixaban - 5 mg/day Rivaroxaban - 15 mg/day Dabigatran - 220 mg/day
2947583|NCT02921126||Other Dose Group|Invalid Doses / Off-Label
2947584|NCT02921100|Other|Conventional cytology|Patients in this arm will undergo an operation of EUS-FNA . The acquired cytological samples from EUS-FNA will undergo a conventional cytology.
2947585|NCT02921100|Other|DNA ploidy test|Patients in this arm will undergo an operation of EUS-FNA . The acquired cytological samples from EUS-FNA will undergo DNA ploidy test.
2947586|NCT02921087|Other|Test followed by control|Subjects will be randomized in a 1:1 ratio based on a randomization schedule according to sequentially assigned subject numbers to the test daily disposable soft contact lenses at the first visit. Subjects will crossover to the control daily disposable soft contact lenses at the second visit.
2947587|NCT02921087|Other|Control followed by test|Subjects will be randomized in a 1:1 ratio based on a randomization schedule according to sequentially assigned subject numbers to the control daily disposable soft contact lenses at the first visit. Subjects will crossover to the test daily disposable soft contact lenses at the second visit.
2947588|NCT02921074|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 24 treatment sessions, up to 7 sessions per week, 36 minutes per session.
2947589|NCT02921074|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 24 treatment sessions, up to 7 sessions per week, 36 minutes per session.
2947590|NCT02921061|Experimental|Treatment (decitabine, G-CLAM)|"CONCURRENT: Patients receive decitabine IV over 1 hour on days 1-10. Patients also receive filgrastim SC on days 0-5, cladribine IV over 2 hours on days 1-5, cytarabine IV over 2-4 hours on days 1-5, and mitoxantrone hydrochloride IV over 60 minutes on days 1-3. Treatment repeats every 10 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Beginning 6 weeks after achieving MRDneg CR or CR/CR with incomplete count recovery (CRi), patients receive decitabine, filgrastim, cladribine, and cytarabine as in Concurrent. Treatment repeats every 10 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
2947591|NCT02921048||omega-3|individuals voluntarily taking at least 3 g/wk of EPA and DHA from dietary sources including fish oil supplements and ocean fish/shellfish consumption for a period of at least 6 months prior to enrollment in the study
2947592|NCT02921048||control|individuals who have consumed no more than 1 serving size (4-6 oz)/month of ocean fish/shellfish, or no more than 1 pill/month of fish oil supplement during the 6 month period preceding enrollment
2947593|NCT02921035||Relapsing Multiple Sclerosis (RMS) group|Subjects diagnosed with RMS who are prescribed Rebif (Interferon beta-1a)
2947594|NCT02921022|Experimental|Patients without a prior thromboembolic event (TE)|Patients without a prior TE will be treated with prophylactic dose and schedule of rivaroxaban (10 mg QD), together with standard dose and schedule of gemcitabine, nab-paclitaxel and PEGPH20.
2947630|NCT02920814|Experimental|Time Intensive CBT for SPOV|Time intensive CBT for SPOV involving 6 weekly sessions and 2 intensive days of 4 hours each (over 8 weeks in total).
2947631|NCT02920801|Experimental|saxagliptin group|saxagliptin group consumed saxagliptin 5mg per day for 12 week
2947595|NCT02921022|Experimental|Patients with a prior thromboembolic event (TE)|Patients with a prior TE will be treated with therapeutic dose and schedule of rivaroxaban (15 mg BID for 21 days for induction if indicated, then 20 mg QD for chronic treatment), together with standard dose and schedule of gemcitabine, nab-paclitaxel and PEGPH20.
2947596|NCT02921009|Experimental|Crosslinking at different fluence rates|The study will investigate the effectiveness of Transepithelial riboflavin .25% treated with Ultraviolet light at fluence rates of 9mw/cm2 and 18mw/cm2 in the treatment of diagnosed keratoconus, pellucid marginal degeneration or post-LASIK ectasia.
2947597|NCT02920996|Experimental|NSCLC (Met Exon 14 Mutation)|Merestinib at the recommended phase II dose of 120 mg by mouth daily.
2947598|NCT02920996|Experimental|Solid Tumor (NTRK1,2,3 Rearrangement)|Merestinib at the recommended phase II dose of 120 mg by mouth daily.
2947599|NCT02920983|Active Comparator|somofilcon A|Subjects are randomized to wear somofilcon A for one week during the cross over study.
2947600|NCT02920983|Active Comparator|nelfilcon A II 2|Subjects are randomized to wear nelfilcon A II 2 for one week during the cross over study.
2947601|NCT02920983|Active Comparator|omafilcon A ll 2|Subjects are randomized to wear omafilcon A ll 2 for one week during the cross over study.
2947602|NCT02920970|Active Comparator|narafilcon A|Participants are randomized to wear narafilcon A lens pair for one week during the cross over study.
2947603|NCT02920970|Active Comparator|stenfilcon A|Participants are randomized to wear stenfilcon A lens pair for one week during the cross over study.
2947604|NCT02920957|Active Comparator|comfilcon A|Participants are randomized to wear the comfilcon A lens for one month during the cross over study.
2947605|NCT02920957|Active Comparator|senofilcon C|Participants are randomized to wear the senofilcon C lens for one month during the cross over study.
2947606|NCT02920944|Experimental|EUS-FNB with 20-gauge|EUS-FNB with 20-gauge procore needle
2947607|NCT02920944|Active Comparator|EUS-FNB with 22-gauge|EUS-FNB with 22-gauge procore needle
2947608|NCT02920931|Experimental|A|"st period: Tenofovir disoproxil fumarate~nd period: Tenofovir Disoproxil"
2947609|NCT02920931|Active Comparator|B|"st period: Tenofovir disoproxil~nd period: Tenofovir Disoproxil fumarate"
2947610|NCT02920918|Active Comparator|Canagliflozin|Canagliflozin will be administered orally in pill form at 100 mg, daily for 12 weeks.
2947611|NCT02920918|Active Comparator|Sitagliptin|Sitagliptin will be administered orally in pill form at 100 mg, daily for 12 weeks.
2947612|NCT02920905|Experimental|lidocaine|• Patients in group A will receive 3 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
2947613|NCT02920905|Experimental|lidocaine & atracurium|• Patients in group B receive 3 mg/kg of lidocaine 2% + 2 mg atracurium diluted with saline to a total volume of 40 ml.
2947614|NCT02920905|Experimental|lidocaine & atracurium & Mg sulphate|• Patients in group C will receive 3 mg/kg of lidocaine 2% + 2 mg atracurium mixed with 10 mg /kg magnesium sulphate diluted with saline to a total volume of 40 ml.
2947615|NCT02920892|Experimental|AFQ056 group with language intervention|12 month treatment phase during which subjects are randomized to AFQ056. The initial dose of AFQ056 will be 25 mg BID. If the subject has no side effects the dose will be titrated (mandatory titration if no side effects) to the next level, 50 mg BID, 75 mg BID and 100 mg BID in order. A flexible dose design will mimic practice, and allow use of maximum tolerated dose (MTD) which is likely to be most effective. The dose can be adjusted weekly through week 7. After 7 weeks the dose will be fixed, and at the 2 month visit all subjects will initiate the language intervention, remaining on a stable AFQ056/placebo dose for the next 6 months.
2947616|NCT02920892|Placebo Comparator|Placebo group with language intervention|12-month treatment phase during which subjects are randomized to placebo. At the 2 month visit (language intervention baseline visit) all subjects will initiate the language intervention, remaining on placebo dose for the next 6 months.
2947617|NCT02920879|Other|0 CPAP/ 0 PEEP, driving pressure 10|Patients will be preoxygenated with a CPAP-level of 0 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
2947618|NCT02920879|Other|0 CPAP/ 0 PEEP driving pressure 20|Patients will be pre-oxygenated with a CPAP-level of 0 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 20 cmH2O./PEEP-level, driving pressure
2947619|NCT02920879|Other|10 CPAP / 10 PEEP, driving pressure 10|Patients will be pre-oxygenated with a CPAP-level of 10 cmH2O and after anesthesia induction, mask-ventilated with PEEP 10 cmH2O and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
2947620|NCT02920879|Other|10 CPAP/ 0 PEEP, driving pressure 10|Patients will be pre-oxygenated with a CPAP-level of 10 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
2947621|NCT02920866|Experimental|Functional Strength Integration (FSI)|Progressive strength training exercise, specific functional activity to improve pelvic stability and core muscle strength
2947622|NCT02920866|Active Comparator|Control Group (CON)|Usual care, continuing education on postsurgical precautions
2947623|NCT02920853|Experimental|BT-CPR|Participants will receive training in relaxation and biofeedback to develop skills in relaxation/arousal reduction, and pain reduction. Then they will practice relaxing and reducing their arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback training to provide pain relief when relaxation is achieved.
2947624|NCT02920853|Active Comparator|Biofeedback-Only|Participants will receive training in relaxation and biofeedback to develop skills in relaxation/arousal reduction, and pain reduction. Then they will practice relaxing and reducing their arousal as they view graphical arousal feedback.
2947625|NCT02920840|Active Comparator|Intermittent theta-burst stimulation|Intervention: application of 200 TMS triplet bursts (at 100 Hz, inter-burst interval 200ms) over left dorsolateral prefrontal cortex
2947626|NCT02920840|Experimental|Negative-peak-triggered-TMS|Intervention: application of 200 brain-state dependent 100 Hz TMS triplet bursts triggered at the negative peak phase of the ongoing endogenous alpha-band oscillation (as detected by surface EEG over left dlPFC)
2947627|NCT02920840|Active Comparator|Open-loop replay TMS|"Intervention: application of the same sequence of TMS pulses as in condition Negative-peak-triggered-TMS, i.e. irrespective of ongoing brain state over left dlPFC"
2947628|NCT02920827|Experimental|Dapivirine Vaginal Ring|Vaginal ring containing 25 mg dapivirine
2947629|NCT02920827|Placebo Comparator|Placebo Vaginal Ring|Placebo vaginal ring
2947633|NCT02920788|Experimental|Veteran Mild TBI Group - GOALS Intervention|Veterans ages 18+ with chronic mild TBI, to undergo GOALS cognitive training as an intervention.
2947634|NCT02920788|No Intervention|Veteran Mild TBI - Treatment as Usual|Veterans ages 18+ with chronic mild TBI, matched by demographic and clinical criteria to the GOALS group, to receive the standard clinical care.
2947635|NCT02920775||Pain|
2947636|NCT02920775||PCP|
2947637|NCT02920775||Dentist|
2947638|NCT02920775||Surgery|
2947639|NCT02920775||Emergency Medicine|
2947640|NCT02920775||Oncology|
2947641|NCT02920775||Hospice and Palliative Medicine|
2947642|NCT02920775||Anesthesiology|
2947643|NCT02920775||Neurology|
2947644|NCT02920775||Nurse Practitioners|
2947645|NCT02920775||Pediatrics|
2947646|NCT02920775||Physical Medicine & Rehabilitation|
2947647|NCT02920775||Physician Assistant|
2947648|NCT02920775||Rheumatology|
2947649|NCT02920775||All Other Specialties|
2947650|NCT02920762||Buprenorphine|
2947651|NCT02920762||Fentanyl|
2947652|NCT02920762||Hydromorphone HCl|
2947653|NCT02920762||Morphine Sulfate|
2947654|NCT02920762||Morphine Sulfate Beads|
2947655|NCT02920762||Oxycodone HCl|
2947656|NCT02920762||Oxymorphone HCl|
2947657|NCT02920762||Tapentadol|
2947658|NCT02920749|Other|Sevoflurane group A|Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture.
2947659|NCT02920749|Other|Sevoflurane group B|Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
2947660|NCT02920749|Other|Propofol group C|During anaesthesia TIVA was applied with a protocol (6 to 8 mg/kg/h propofol).
2947661|NCT02920749|Other|Propofol group D|Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
2947662|NCT02920736||sepsis with acute renal injury group|Based on definition of sepsis with Sepsis 3.0 and AKI was defined using KDIGO（Kidney Disease: Improving Global Outcomes） consensus definition of AKI.The group was the secondary AKI in sepsis patients
2947663|NCT02920736||sepsis non-acute renal injury group|The group was the non-AKI in sepsis patients
2947664|NCT02920736||control group|Approximately 110 persons(18-80years) with healthy physical examination and without liver and kidney dysfunction
2947665|NCT02920723|Experimental|Training|"For the patients who were allocated in the control group in the EXESAS study. In this group, patients will perform 3 sessions of one hour per week of the NeuroGyV training program. It is a physical activity program with one session of Nordic walking, one session of aquagym and one session of gymnastic. Program lasts 9 months."
2947666|NCT02920723|Other|Control|For the patients who were allocated in the training group in the EXESAS study. In this group, patients will receive only diets and physical activity counselling
2947667|NCT02920710|Experimental|Experimental: H.P. Achtar Gel 80 U|H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 48 weeks on therapy.
2947668|NCT02920697|Experimental|B-cell Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)|
2947669|NCT02920697|Experimental|Chronic Lymphocytic Leukaemia (CLL)|
2947670|NCT02920684|Active Comparator|Passive legs mobilisation|A physiotherapist performs passive legs movement
2947671|NCT02920684|Active Comparator|Passive cycloergometer|A motorized cycloergometer performs passive legs cycling
2947672|NCT02920684|Active Comparator|Muscular electrical stimulation|Quadriceps neuromuscular electrical stimulation
2947673|NCT02920684|Active Comparator|FES cycling|A motorised cycloergometer performs a quadriceps neuromuscular electrical stimulation during passive
2947674|NCT02920671||Mitochondrial Disease|Clinical history consistent with the diagnosis of mitochondrial disease, and molecular genetic diagnosis.
2947675|NCT02920671||Obese|BMI > 30 kg/m2. These will be matched with subjects with mitochondrial disease by age, sex, estrogen status (women), and usual self-reported physical activity.
2947676|NCT02920671||Normal Weight & Overweight|BMI 18.5 - < 30 kg/m2. These will be matched with subjects with mitochondrial disease by age, sex, estrogen status (women), and usual self-reported physical activity.
2947677|NCT02920658|Experimental|NAVS Naphthalan|NAVS oil in adhesive powder in a volume ratio 2:1, to apply on the affected mucosa three times daily during 4 weeks for OLP patients; NAVS oil in adhesive powder in a volume ratio 2:1, to apply on the affected mucosa three times daily during 5 days for RAS patients
2947678|NCT02920658|Active Comparator|0.05% Betamethasone dipropionate|0.05% Betamethasone dipropionate in adhesive powder in a volume ratio 1:1, to apply on the affected mucosa three times daily during 4 weeks for OLP patients; 0.05% Betamethasone dipropionate in adhesive powder in a volume ratio 1:1, to apply on the affected mucosa three times daily during 5 days for RAS patients
2947679|NCT02920645||AVM-related ICH patients|patients that suffered intracerebral hemorrhage (ICH) due to a ruptured artery-venous malformation (AVM)
2947680|NCT02920632|Experimental|Online cognitive training 1|Eight-week, three times a week during 45 minutes cognitive training
2947681|NCT02920632|Active Comparator|Online cognitive training 2|Eight-week, three times a week during 45 minutes cognitive activities
2947682|NCT02920606|Active Comparator|Endodontic treatment|"The patient will benefit from a conventional treatment : a root canal treatment.~The root canal treatment consists of removing the pulp tissue from all the canals, disinfecting the root canal system with sodium hypochlorite and filling the root with a root canal sealer and gutta percha."
2947683|NCT02920606|Experimental|Pulpotomy|The patient will benefit from an experimental treatment : a pulpotomy. The pulpotomy aims at removing the coronal part of the pulp (the pulp present in the pulp chamber) and filling the pulp chamber with a bioactive material.
2947684|NCT02920593|Experimental|Vitamin D Prophylaxis|Participants will be provided Vitamin D 3000 IU daily or Vitamin D 4000 IU daily with and without concurrent use of prenatal vitamins, respectively.
2947685|NCT02920593|No Intervention|No Vitamin D Prophylaxis|Participants will not receive additional Vitamin D in the pregnancy.
2947686|NCT02920580|Active Comparator|Extubation|Extubation by removal of endotracheal tube.
2947687|NCT02920580|Active Comparator|Usual care|The usual clinical practice is removal of the endotracheal tube (extubation), or insertion of tracheostomy, timed according to physicians' discretion
2947688|NCT02920567|Experimental|octreotide|After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
2947689|NCT02920567|Placebo Comparator|Placebo|After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
2947690|NCT02920554|Active Comparator|wedge resection|The extent of hepatic resection is wedge resection of gallbladder fossa
2947691|NCT02920554|Active Comparator|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy
2947692|NCT02920541|Experimental|S 055746|
2947693|NCT02920528|Placebo Comparator|Placebo|placebo controlled arm
2947694|NCT02920528|Experimental|very low dose ketamine|0.25 mg/kg of sub-dissociative ketamine as an experimental arm
2947695|NCT02920528|Experimental|low dose ketamine|0.50 mg/kg of sub-dissociative ketamine as an experimental arm
2947696|NCT02920515|Experimental|GnRHa(Triptorlin or Leuprorelin)|Triptorlin or Leuprelin 100ug/kg per 28 days
2947697|NCT02920515|Active Comparator|Traditional Chinese Medicines|Zhibo dihuang pills: 8 tablets twice a day by mouth for 6 months and Dabu ying pills: 6g twice a day by mouth for 6 months
2947698|NCT02920515|No Intervention|blank group|without therapy
2947699|NCT02920502|Placebo Comparator|Arm 1: Placebo|Normal Healthy Volunteers without any skin pathology, will receive placebo
2947700|NCT02920502|Experimental|Arm 2: cholecalciferol: 50,000 IU|Normal healthy Volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 50,000 IU.
2947701|NCT02920502|Experimental|Arm 3: cholecalciferol: 100,000 IU|Normal healthy volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 100,000 IU.
2947702|NCT02920502|Experimental|Arm 4: cholecalciferol: 200,000 IU|Normal Healthy volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 200,000 IU.
2947703|NCT02920489|Experimental|Individualized epidural analgesia|Epidural catheterization will be performed after the beginning of the first stage of labor. Epidural analgesia will begin when asked by parturients and the numeric rating scale of pain is 5 or higher. A loading dose (10 ml mixture of 0.1% ropivacaine and 0.5 ug/ml sufentanil) will be administered through the epidural catheter. After a 20-minute observation, a patient-controlled analgesia pump (containing a mixture of 0.08% ropivacaine and 0.4 ug/ml sufentanil) will be connected to the epidural catheter and programmed to deliver a 6-ml bolus with a 20-minute lockout interval and a 4 ml/h background infusion. Analgesia will be terminated at the end of the third stage of labor.
2947704|NCT02920489|Active Comparator|Routine epidural analgesia|Epidural catheterization will be performed after the beginning of the first stage of labor and the cervix is dilated to 1 cm or more. Epidural analgesia will then begin. A loading dose (10 ml mixture of 0.1% ropivacaine and 0.5 ug/ml sufentanil) will be administered through the epidural catheter. After a 20-minute period observation, a patient-controlled analgesia pump (containing a mixture of 0.08% ropivacaine and 0.4 ug/ml sufentanil) will be connected to the epidural catheter and programmed to deliver a 6-ml bolus with a 20-minute lockout interval and a 4 ml/h background infusion. Analgesia will be terminated at the end of the third stage of labor.
2947705|NCT02920476|Experimental|Treatment arm|TAS-102
2947706|NCT02920463||Critically ill patients with infection|Critically ill adult patients receiving empirical antibiotic therapy for suspected or confirmed infections at the Intensive Care Unit
2947707|NCT02920450|Experimental|Treatment arm|Gedatolisib, Paclitaxel, and Carboplatin
2947708|NCT02920437|Experimental|Intervention group|Four-week weekly intervention to reduce salt intake.
2947709|NCT02920437|Other|Control group|Usual government pamphlets.
2947710|NCT02920424|Experimental|Part A: JNJ-56022473 or Placebo (4:1)|Subjects will receive 3 subcutaneous (SC) administrations of the same dose level of JNJ-56022473 Dose 1, Dose 2, or Dose 3 or placebo every 2 weeks (in the ratio of 4:1 [4 active: 1 placebo]).
2947711|NCT02920424|Experimental|Part B: JNJ-56022473 or Placebo (5:1)|Subjects will receive 3 SC administrations of the same dose level of JNJ-56022473 or placebo every 2 weeks (in the ratio of 5:1 [5 active: 1 placebo]). The dose level(s) will be based upon an interim analysis (IA) of the Part A data.
2947712|NCT02920411|Experimental|Combined dermatological treatment|"A combined treatment of two emollient products will be applied:~Pediatopic treatment cream during acute stages of atopic dermatitis and~Pediatopic body lotion during stable stages"
2947713|NCT02920398|Experimental|N8-GP pivotal|
2947714|NCT02920398|Active Comparator|N8-GP commercial|
2947715|NCT02920385|Experimental|Levothyroxine/SNAC/Placebo/Semaglutide|
2947716|NCT02920372|Experimental|EPOETIN ALFA|
2947717|NCT02920359|Experimental|LEUPRORELIN ACETATE|
2947718|NCT02920333|Experimental|tDCS+ rehab training|tDCS will be applied 10 days, followed by conventional rehab training. Anodal stimulation will be conducted at the intensity of 2 mA and last for 20 minutes over the affected primary motor cortex of cortical representation of the tibialis anterior muscle.
2947719|NCT02920333|Experimental|rTMS+ rehab training|rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
2947720|NCT02920333|Sham Comparator|sham tDCS+ rehab training|The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
2947721|NCT02920320|Experimental|Internet-based self-help|"Internet-based self-help on the basis of the program Mindfulness-Based Compassionate Living (van den Brink & Koster, 2015). The self-help program consists of seven text-based sessions, various exercises (z.B. breathing meditations, diaries,) and tasks. Participants have the possibility for guidance to the program on request."
2947722|NCT02920320|No Intervention|Waiting control group|
2947723|NCT02920307|Experimental|TEP without fixation|Standard totally extraperitoneoscopic preperitoneal (TEP) hernia repair without mesh fixation
2947724|NCT02920307|Active Comparator|TEP with fixation|Standard totally extraperitoneoscopic preperitoneal (TEP) hernia repair
2947725|NCT02920307|Experimental|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) hernia repair without mesh fixation
2947798|NCT02919774|Experimental|POMA 160 mg BID|160 mg BID for 10 days
2947726|NCT02920307|Active Comparator|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) hernia repair
2947727|NCT02920294|Active Comparator|Probiotic 1|Fresh fermented dairy drink containing yoghurt ferments consumed as follows: one bottle (100g) OD for 14 consecutive days
2947728|NCT02920294|Active Comparator|Probiotic 2|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) OD for 14 consecutive days
2947729|NCT02920294|Placebo Comparator|Placebo|Acidified dairy drink without ferments consumed as follows: one bottle (100g) OD for 14 consecutive days
2947730|NCT02920268|Experimental|Intervention|Intervention with dance and yoga sessions, two times a week in 8 months.
2947731|NCT02920268|No Intervention|Controls|No intervention
2947732|NCT02920255||Electronic Caliper Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with electronic calipers.
2947733|NCT02920255||Conventional Caliper Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with conventional calipers.
2947734|NCT02920255||X-ray Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with x-rays.
2947735|NCT02920242|Experimental|Rifaximin|Patients will receive 1 Rifaximin 200 mg tablet 3 times per day for 3 days.
2947736|NCT02920242|Active Comparator|Xifaxan|Patients will receive 1 Xifaxan 200 mg tablet 3 times per day for 3 days.
2947737|NCT02920242|Placebo Comparator|Placebo|Patients will receive 1 placebo tablet 3 times per day for 3 days.
2947738|NCT02920229|Experimental|68Ga- PSMA PET/CT|100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
2947739|NCT02920216|Experimental|eligible patient for a salvage surgery|
2947740|NCT02920203||index cases group|unexpected sudden death cases recruited by forensic institutes or pathology departements
2947741|NCT02920203||first degree relatives group|Relatives enrolled of unexpected sudden death index cases
2947742|NCT02920190|Experimental|Liraglutide|Eligible patients will be started on Liraglutide up to 1.8 mg sc once daily, as adjunct weight loss treatment for 12 months.
2947743|NCT02920177|Experimental|platelet-rich plasma|platelet-rich plasma injection into the head-neck junction of the hip joint
2947744|NCT02920177|Active Comparator|corticosteroid|corticosteroid injection into the head-neck junction of the hip joint
2947745|NCT02920164|Active Comparator|Auricular acupuncture|Auricular acupuncture with indwelling fixed auricular acupuncture needles
2947746|NCT02920164|Placebo Comparator|Placebo acupuncture|"Placebo acupuncture with placebo fixed needles"
2947747|NCT02920164|No Intervention|Standard therapy|No intervention, just observation
2947748|NCT02920151|Experimental|BALANCE EXERCISES CIRCUIT|balance exercises circuit for three months, twice weekly, 50 minutes per day.
2947749|NCT02920151|No Intervention|CONTROL GROUP|usual routine
2947750|NCT02920138||Group 5PEEP|Administered 5 cmH2O positive end expiratory pressure group( Group 5PEEP n=30).
2947751|NCT02920138||Group ZEEP|no positive end expiratory pressure group (Group ZEEP n=30)
2947752|NCT02920125|Active Comparator|Trial: Ayurvedic SUVED, REIMMUGEN|"Ayurvedic SUVED formulation comprises of 'Ghana' extract form; Dosage :3 months, 1 BD. Content: (500mg per capsule)Terminalia Arjuna: Withania somnifera; Terminalia chebula; Cyperus rotundus; Apium graveolens; Vitis vinifera; Piper longum; Fagonia Arabica; Emblica officinalis; Terminalia belerica; Nymphaea stellata; Punica granatum; Bacopa Monnieri; and stabilizing herbs.~Reimmugen Cow-colostrum is a total natural product, used as nutritional supplement Dosage: 3months, 1 TDS Contents: IgA, IgE, IgM, IgG, IgD, PRPs, Lactoferrin, Transferrin, Interferons, Cytokines, Growth Factors (bFGF, vFGF, IGF I & II & Angiogenesis growth Factor, Endothelial growth Factor, Nerve growth factor, PDGF), natural Vitamins and Minerals."
2947753|NCT02920125|Placebo Comparator|Control: grain flour|Dummy medication in same packing to mask content given in same dose as active medication. Jowari and ragi flour used in capsules
2947754|NCT02920112|Experimental|One year post-op Tele-CBT|This group will receive Telephone based Cognitive Behavioral Therapy (Tele-CBT) one year after bariatric surgery.
2947755|NCT02920099||Nutrition Literacy|Participants will be asked to completed the Nutrition Literacy Assessment Instrument (NLAI).
2947756|NCT02920086|Experimental|Nutrition Education Program|Nutrition education for family members of an elderly critically ill patient
2947757|NCT02920086|Experimental|Decision Support Program|Decision support education for family members of an elderly critically ill patient
2947758|NCT02920086|No Intervention|Usual Care|No intervention
2947759|NCT02920060|Experimental|Levetiracetam|patient in this group will receive intravenous levetiracetam as loading dose of 30 mg/kg at a rate of 50 mg/min
2947760|NCT02920060|Active Comparator|Sodium valproate|patients in this group will receive intravenous sodium valproate 20 mg/kg as loading dose at a rate of 40 mg/min
2947761|NCT02920047|Experimental|Sequence A|"Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)~There will be a washout of 14 days between the each period."
2947762|NCT02920047|Experimental|Sequence B|"Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)~There will be a washout of 14 days between the each period."
2947763|NCT02920047|Experimental|Sequency C|"Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)~There will be a washout of 14 days between the each period."
2947764|NCT02920034|Active Comparator|Radiofrequency main renal artery|Renal sympathetic denervation of the main renal artery using the radiofrequency-based Spyral™ catheter (Medtronic, MN, USA)
2947765|NCT02920034|Experimental|Radiofrequency main and branches|Renal sympathetic denervation of the main renal artery, its branches and accessories using the radiofrequency-based Spyral™ catheter (Medtronic, MN, USA)
2947766|NCT02920034|Experimental|Ultrasound main renal artery|Renal sympathetic denervation of the main renal artery using the ultrasound-based Paradise™ catheter (ReCor, CA, USA)
2947767|NCT02920021|Experimental|ANB020|ANB020, administration of ANB020
2947768|NCT02920021|Placebo Comparator|Placebo|Placebo, administration of Placebo
2947769|NCT02920008|Experimental|guadecitabine|Guadecitabine will be given SC at a dose of 60 mg/m2 in 28-day cycles (delayed as necessary to allow blood count recovery).
2947770|NCT02920008|Active Comparator|Treatment Choice (TC)|"High intensity~Low intensity~Best supportive care (BSC)."
2947771|NCT02919995|Experimental|Higher Dose RPL554|Single dose of inhaled 6 mg RPL554
2947772|NCT02919995|Experimental|Lower dose RPL554|Single dose of inhaled 1.5 mg RPL554
2947773|NCT02919995|Placebo Comparator|Placebo|Inhaled placebo dose
2947774|NCT02919969|Experimental|Pembrolizumab|"Pembrolizumab is administered every 3 week intravenously~Dosage to be determine by physician"
2947775|NCT02919956||Group I: CBF-I Single Ventricles|The 1st group (cohort group) will be patients who were enrolled in the original NIH CBF grant. These patients will undergo a 60-90 minute Magnetic Resonance Imaging scan of the brain and heart. They will also have Neurodevelopmental Testing.
2947776|NCT02919956||Group II: Prospective Single Ventricles|The 2nd group (cross sectional group) will be prospectively recruited from SV patients after Fontan operation but were not participants in the original study and will be age matched to Group I to enrich the patient population. These patients will undergo a 60-90 minute Magnetic Resonance Imaging scan of the brain and heart. They will also have Neurodevelopmental Testing.
2947777|NCT02919956||Group III: CBF-I Normal Controls|The 3rd group (cohort group) will be normal controls who were enrolled in the original CBF grant. These patients will have Neurodevelopmental Testing. The data from these patients' MRI from CBF-I (original CBF grant) will be used.
2947778|NCT02919956||Group IV: Prospective Normal Controls|The 4th group (cross sectional group) will be prospectively recruited from patients who come to Children's Hospital of Philadelphia (CHOP) for clinically indicated MRIs and found to have structurally normal cardiac and brain anatomy. These patients will have an abbreviated research MRI, lasting 15-20 minutes, added onto their clinically-indicated MRI at CHOP. They will also have Neurodevelopmental Testing.
2947779|NCT02919956||Volunteer Group|There will also be a volunteer group of one to five volunteers that will be enrolled prior to enrollment in the other four study groups. These volunteers will be prospectively recruited from patients who come to Children's Hospital of Philadelphia (CHOP) for a clinically-indicated MRI and consent to have an additional 15-20 minutes of research MRI scanning. The purpose will be to ensure that the brain MRI sequences run correctly and produce useful information before the patient and normal control enrollment begins. The volunteers will not undergo neurodevelopmental testing.
2947780|NCT02919930|Other|Oronasal - Nasal|Patients undergo polysomnography with oronasal mask during the first night and nasal mask during the second night.
2947781|NCT02919930|Other|Nasal - Oronasal|Patients undergo polysomnography with nasal mask during the first night and oronasal mask during the second night.
2947782|NCT02919917|Experimental|Usual Care Group|"Individuals randomized to the usual care group will receive BP management according to the usual care in current practice in the SCI Rehabilitation Unit.~Will receive treatment only if they experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.).~Treatment to lessen or eliminate these symptoms of low blood pressure will be guided by the attending physician and can include physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.) and/or midodrine ."
2947783|NCT02919917|Experimental|BP Threshold Treatment Group|"Individuals assigned to the BP threshold treatment group will receive BP management, regardless of symptoms, to maintain systolic BP between 111-135 mmHg for males and 101-135 mmHg for females for the duration of their in-patient hospital stay.~This treatment will be started based on your low BP, regardless of if you experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.). Before you start on any medication you will receive physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.).~If your blood pressure remains low after using these countermeasures you will begin to take midodrine 3 times a day as described in the intervention section. The dosage will increase and be stopped once until your seated SBP is between 111-135 mmHg."
2947784|NCT02919891||Participants with Chronic Pain|Questionnaire results will allow the diagnosis of chronic pain. No intervention will be administered. The results of the IENFD will be compared to the group without chronic pain.
2947785|NCT02919891||Participants without Chronic Pain|Questionnaire results will reveal the absence of chronic pain. No intervention will be administered. The results of the IENFD will be compared to the group with chronic pain.
2947786|NCT02919878|Experimental|pre-op Gemcitabine & XRT|"Pre-op chemo: Gemcitabine will be administered as continuous infusion IV over 24 hrs (100 mg/m2) weekly for 6 wks starting on day 1 of Radiotherapy (XRT).~XRT/ Intensity modulated radiotherapy(IMRT): 1.8 Gy/fx, 5 fractions/wk will be delivered. Pelvis will receive 45 Gy/25 fractions/5 wks with a boost dose of 5.4 Gy for T3 and 9 Gy for T4 to a cone down volume. The total tumor dose= 50.4 -54 Gy.~Post-op chemo: Standard 6 cycles of adjuvant Capecitabine (1250 mg/m2) PO twice per day on days 1-14 each cycle, (every 21 days) in patients who have a complete resection of rectal cancer and negative surgical margins."
2947787|NCT02919865|Other|MRI perfusion imaging|Patients who have received chemoradiation for high grade gliomas and who subsequently developed progressive enhancing lesions on follow-up MR will be asked to participate in this study.
2947788|NCT02919852|Other|laparoscopic retrovesical colpopectinopexia|new operative technic
2947789|NCT02919826|Experimental|DBT Group|Adapted Dialectical Behaviour Therapy
2947790|NCT02919826|No Intervention|Control Arm|People in this group will receive treatment as usual
2947791|NCT02919813|Active Comparator|M-gCBT Group|Mindfulness Based Group Cognitive Behavior Therapy (M-gCBT Group) is a type of counseling that teaches women to have more control over their pain.
2947792|NCT02919813|Active Comparator|Educational Seminars|Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
2947793|NCT02919800|Experimental|MOD-5014|MOD-5014 longevity is the result of fusion of three consecutive C-terminal peptide (CTP) domains to the C-terminus of FVII. CTP technology is based on a natural peptide, the C-terminal peptide of the beta chain of human chorionic gonadotropin (hCG), which provides hCG with the required longevity to maintain pregnancy (initial half-life [t1/2] ~10 h, terminal t1/2 ~37 h). The beta chain of luteinizing hormone (LH), a gonadotropin that triggers ovulation, is almost identical to hCG but does not include the CTP. As a result, LH has a significantly shorter half-life in blood (initial t1/2 ~1 h, terminal t1/2 ~10 h) (Fares et al., 1992).
2947794|NCT02919800|Placebo Comparator|MOD-5014 Placebo|Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
2947795|NCT02919787|Active Comparator|Surgery and then postoperative adjuvant chemotherapy|Surgery and then postoperative adjuvant chemotherapy
2947796|NCT02919787|Experimental|Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy|Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy
2947804|NCT02919748|Active Comparator|Control arm|General Health Education Program and Group Activities
2947805|NCT02919735|Experimental|CG 428 cutaneous solution|Herbal Medicinal Product, topical use by spray on the scalp
2947806|NCT02919735|Placebo Comparator|Placebo cutaneous solution|Placebo, topical use by spray on the scalp
2947807|NCT02919722|Experimental|Music interventions|Live music will be provided on the patient's neglected side and patients will be encouraged to play music interactively with a focus towards that side whenever possible
2947808|NCT02919709|Experimental|thoracic or abdominal aortic aneurysm|
2947809|NCT02919696|Experimental|Abemaciclib Dose Level 1|"Cycle 1: Abemaciclib administered orally.~Cycle 2: Abemaciclib administered orally."
2947810|NCT02919696|Experimental|Abemaciclib Dose Level 2|"Cycle 1: Abemaciclib administered orally.~Cycle 2: Abemaciclib administered orally."
2947811|NCT02919683|Experimental|Nivolumab With Ipilimumab|"Nivolumab to be delivered at a pre-determine dose for two weeks~Ipilimumab to be delivered at a pre-determine dose for one week~Blood Sample Collected~Standard of Care Surgery"
2947812|NCT02919683|Experimental|Nivolumab|"Nivolumab to be delivered at a pre-determine dose for two weeks~Blood Sample Collected~Standard of Care Surgery"
2947813|NCT02919670|Experimental|Enterade and Standard Supportive Care|"Two 8 oz. bottles of Enterade will be administered daily~Enterade will be given orally from admission until day +14 or until discharge~Standard Supportive Care will be administered according to institution's practice"
2947814|NCT02919670|Placebo Comparator|Placebo and Standard Supportive Care|"Two 8 oz. bottles of Placebo will be administered daily~Placebo will be given orally from admission until day +14 or until discharge~Standard Supportive Care will be administered according to institution's practice"
2947815|NCT02919657|Active Comparator|Genepro Gen2 Protein|"1 tablespoon Serving of Genepro Gen2 Protein daily will be used in each subject.~Intervention: Weekly blood draws will determine the effect on blood protein levels."
2947816|NCT02919657|Active Comparator|Whey Protein Isolate|"30g Serving of Whey Isolate Protein will be used daily in each subject.~Intervention: Weekly blood draws will determine the effect on blood protein levels."
2947817|NCT02919644|Experimental|vaccine + Interleukin -2 (IL2)|autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1), followed by IL-2 given by subcutaneous injection daily for five days (days 3-7)
2947818|NCT02919631|Active Comparator|triheptanoin|14 days on Triheptanoin treatment including a 7 days titration period and a 7 days full dose treatment of 1mL/kg/day.
2947819|NCT02919631|Placebo Comparator|placebo oil|14 days of diet on a placebo oil including 7 days titration period and 7 days full dose treatment of 1mL/kg/day
2947820|NCT02919618|Experimental|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to a region of the heart determined by EP-guidance, using noninvasive electrical mapping combined with anatomic imaging.
2947821|NCT02919605|Experimental|Single dose of Pentacarinat®|Fifty three patients using Pentacarinat® at a dose of 7 mg/kg will be included, in a single dose.
2947822|NCT02919605|Experimental|Two doses of Pentacarinat®|Fifty three patients using Pentacarinat® at a dose of 7 mg/kg, in a weekly dose, during two weeks.
2947823|NCT02919605|Experimental|Three doses of Pentacarinat®|Fifty three patients using Pentacarinat® at a dose of 7 mg/kg, in a weekly dose, during three weeks.
2947824|NCT02919592|Experimental|Primary Breast Augmentation|Participants who meet the requirements for primary breast augmentation (have not had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
2947825|NCT02919592|Experimental|Revision Breast Augmentation|Participants who meet the requirements for revision breast augmentation (have had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast implants
2947826|NCT02919592|Experimental|Primary Breast Reconstruction|Participants who meet the requirements for primary breast reconstruction (have not had previous silicone or saline breast implants, not including tissue expanders) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
2947827|NCT02919592|Experimental|Revision Breast Reconstruction|Participants who meet the requirements for revision breast reconstruction (have had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
2947828|NCT02919592|Active Comparator|Other Aesthetic Surgery|Participants who meet the requirements for other aesthetic surgery procedures, which may not include silicone implants (breast or otherwise)
2947829|NCT02919579|Experimental|Part A: Sequence ABC (Placebo+Alcohol+Esketamine)|Participants will receive intranasal placebo on Day 1 and oral placebo on Day 2 [Treatment A] in Period 1, then intranasal placebo on Day 1 and Oral alcohol on Day 2 [Treatment B] in Period 2, followed by intranasal esketamine on Day 1 and oral placebo on Day 2 [Treatment C] in Period 3.
2947830|NCT02919579|Experimental|Part A: Sequence BCA (Placebo+Alcohol+Esketamine)|Participants will receive Treatment B in Period 1, then Treatment C in Period 2, followed by Treatment A in Period 3.
2947831|NCT02919579|Experimental|Part A: Sequence CAB (Placebo+Alcohol+Esketamine)|Participants will receive Treatment C in Period 1, then Treatment A in Period 2, followed by Treatment B in Period 3.
2947832|NCT02919579|Experimental|Part A: Sequence CBA (Placebo+Alcohol+Esketamine)|Participants will receive Treatment C in Period 1, then Treatment B in Period 2, followed by Treatment A in Period 3.
2947833|NCT02919579|Experimental|Part A: Sequence ACB (Placebo+Alcohol+Esketamine)|Participants will receive Treatment A in Period 1, then Treatment C in Period 2, followed by Treatment B in Period 3.
2947834|NCT02919579|Experimental|Part A: Sequence BAC (Placebo+Alcohol+Esketamine)|Participants will receive Treatment B in Period 1, then Treatment A in Period 2, followed by Treatment C in Period 3.
2947835|NCT02919579|Experimental|Part B: Placebo+Esketamine|Participants will receive intranasal placebo on Day 1, followed by intranasal esketamine on Days 4, 8, 11, 15, 18, 22 and 25.
2947836|NCT02919553|Experimental|modified wet-suction technique|Patients in this arm will undergo the modified wet-suction technique. Details in the study description section. After sufficient sampling of the lesion, the needle will be removed and the specimen will be collected.
2947837|NCT02919553|Active Comparator|"Capillary slow pull technique"|"Patients in this arm will undergo the Capillary slow pull technique which will include moving the needle to-and-fro into the lesion. Subsequently the needle will be removed and the specimen will be collected."
2947838|NCT02919540|Experimental|kangaroo care approach|the kangaroo care approach will be implemented for dyads who agree to participate
2947839|NCT02919540|No Intervention|control group|routine care will be implemented
2947840|NCT02919527|Experimental|Self-Myofascial-Release|Two 60 seconds bouts of Self-Myofascial-Release performed at the anterior thigh; anticipated intensity of 7/10 on a 10 point numeric rating scale (0 representing no discomfort and 10 representing maximal discomfort)
2947841|NCT02919527|Active Comparator|Stretching|Two 60 seconds bouts of static stretching performed at the anterior thigh; anticipated intensity of 7/10 on a 10 point numeric rating scale (0 representing no discomfort and 10 representing maximal discomfort)
2947842|NCT02919527|No Intervention|Control|No Intervention
2947843|NCT02919514|Sham Comparator|Firm surface group|Subject will participate in exercise training on a firm surface for 50 min/session, 3 days/week for 6 weeks in total.
2947844|NCT02919514|Experimental|Sand surface group|Subject will participate in exercise training on a sand surface for 50 min/session, 3 days/week for 6 weeks in total.
2947845|NCT02919514|Active Comparator|Soft surface group|Subject will participate in exercise training on a soft surface for 50 min/session, 3 days/week for 6 weeks in total.
2947846|NCT02919501|Experimental|IV vortioxetine|
2947847|NCT02919501|Placebo Comparator|IV placebo|
2947848|NCT02919488|Experimental|Exercise Condition|
2947849|NCT02919488|Active Comparator|Control Condition|
2947850|NCT02919475|Experimental|JTE-051 Dose 1|One dose of study drug by mouth daily for 12 weeks
2947851|NCT02919475|Experimental|JTE-051 Dose 2|One dose of study drug by mouth daily for 12 weeks
2947852|NCT02919475|Experimental|JTE-051 Dose 3|One dose of study drug by mouth daily for 12 weeks
2947853|NCT02919475|Experimental|JTE-051 Dose 4|One dose of study drug by mouth daily for 12 weeks
2947854|NCT02919475|Experimental|Placebo|One dose of study drug by mouth daily for 12 weeks
2947855|NCT02919462|Experimental|Treatment Arm A|"Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) + Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles.~Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks)."
2947856|NCT02919462|Active Comparator|Treatment Arm B|"Pemetrexed, 500 mg/m2, day 1 + Cisplatin, 75 mg/m2, day 1 every 3 weeks, for 4 cycles.~Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks).~7-10 days before treatment administration, premedication with vitamin B12 1000µg intramuscular injection (every 9 weeks) and folate 1mg every day should be commenced."
2947857|NCT02919449|Experimental|MV-NIS and Atezolizumab|MV-NIS will be administered intratumorally as a single dose on day 1. Atezolizumab will be given at day 15 and then every 3 weeks.
2947858|NCT02919436|Experimental|Tamsulosin|Subjects in this arm will receive tamsulosin 0.4 mg/day for five days prior to surgery and two days after surgery.
2947859|NCT02919436|Placebo Comparator|Placebo|Subjects in this arm will receive a placebo capsule identical in appearance to the tamsulosin capsule, for five days prior to surgery and two days after surgery.
2947860|NCT02919423|Active Comparator|active TMS nonsmokers|active TMS will be administered
2947861|NCT02919423|Active Comparator|active TMS smokers|active TMS will be administered
2947862|NCT02919423|Sham Comparator|sham TMS nonsmokers|sham TMS will be administered
2947863|NCT02919423|Sham Comparator|sham TMS smokers|sham TMS will be administered
2947864|NCT02919410|Active Comparator|Surgery performed using iodophor-impregnated adhesive drapes|
2947865|NCT02919410|Other|Surgery performed without iodophor-impregnated adhesive drapes|
2947866|NCT02919397|Experimental|Intervention|If participants are allocated to the intervention group, participants will receive the wearable technology and access to the smartphone application. Motivational messages based on diabetes prevention programme content, and biofeedback messages based on physical activity data provided via the wearable technology, will be received by participants via the application. The diabetes prevention programme educational material will be available via the application.
2947867|NCT02919397|Active Comparator|Control|If participants are allocated to the control group, participants will receive the wearable technology and will be able to access their activity data via the smartphone application. Participants will also have have access to the diabetes prevention programme educational material via the application. Participants will not receive motivational messages related to the education content or activity data.
2947868|NCT02919384|Experimental|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
2947869|NCT02919384|No Intervention|Control|Embryos in this arm will be cultured at 5% oxygen (current standard of care) from day 3 until blastocyst developmental assessment.
2947870|NCT02919371|Experimental|Sunitinib and Bevacizumab Arm|Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell carcinoma (CASA)Combined Alternating Sunitinib and Bevacizumab
2947871|NCT02919358|Experimental|Music|Exposure to music, twice per day for the study period
2947872|NCT02919358|Other|Control|No intervention; standard care.
2947873|NCT02919345|Experimental|Dapagliflozin|Dapagliflozin 10 mg in addition to Metformin 1500 mg
2947874|NCT02919345|Active Comparator|Glibenclamide|Glibenclamide 5mg in addition to Metformin 1500 mg
2947875|NCT02919332||Diagnostic (18F-FDG PET/CT)|Patients receive fludeoxyglucose F-18 IV. Patients then undergo a standard of care PET/CT scan at 60 minutes and a second PET/CT scan at 240 minutes after injection.
2947876|NCT02919319|Experimental|Dose group 1|Six subjects received 5 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.
2947877|NCT02919319|Experimental|Dose group 2|Three subjects received a single oral dose (25 mg) of ACT-541468 formulation A during Period 1 and a single oral dose (25 mg) of ACT-541468 formulation B during Period 2. Three other subjects Subjects received ACT-541468 formulation B during Period 1 and ACT-541468 formulation A during Period 2. Two additional subjects received the matching placebos in both treatment periods.
2947878|NCT02919319|Experimental|Dose group 3|Six subjects received 50 mg of ACT-541468 (formulation A) as a single oral dose in combination with a [14C]-ACT-541468 oral tracer for the mass balance and metabolism analyses. Two other subjects received the matching placebos.
2947879|NCT02919319|Experimental|Dose group 4|Six subjects received 100 mg of ACT-541468 (formulation A) as a single oral dose in combination with a [14C]-ACT-541468 intravenous tracer for the absolute bioavailability assessment. Two other subjects received the matching placebos.
2947880|NCT02919319|Experimental|Dose group 5|Six subjects received 200 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.
2947881|NCT02919306|Experimental|Ad26.Mos.HIV Vaccine or MVA mosaic Vaccine|Participants will receive adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV) 0.5 milliliter (mL) injection intramuscularly (containing 5 * 10^10 viral particles [vp]) at Weeks 0 and 12 followed by modified Vaccinia Ankara-Mosaic (MVA mosaic) 0.5 mL injection (containing 10^8 Plaque-forming unit [pfu]) at Week 24 and 48.
2947882|NCT02919306|Placebo Comparator|Placebo|0.5 mL Sodium Chloride Injection United States Pharmacopeia (USP) 0.9% will be administered by intramuscular (IM) injection.
2947883|NCT02919293|Experimental|Adjuvant-Free MenAC-Hib Conjugate Vaccine Group|Participants randomized to receive adjuvant-free MenAC-Hib conjugate vaccine.
2947884|NCT02919293|Active Comparator|Adjuvant MenAC-Hib Conjugate Vaccine Group|Participants randomized to receive adjuvant MenAC-Hib conjugate vaccine.
2947885|NCT02919280||No treatment|This is an observational study. No intervention / treatment involved.
2947886|NCT02919267|Other|Intra-pulmonary pressure determination|A pressure tubing catheter will be connected to the luerlock adaptor of the bronchial blocker (BB) or to the adaptor located on the side of the occluding system mounted at the extremity of the double lumen tube (DLT). The catheter will then be connected to a differential pressure transducer (AD Instruments, Colorado Springs, CO, USA), allowing direct visualisation of the bronchial pressures. Along with intra-bronchial pressure, esophageal pressure will also be measured to eliminate the pressure generated by the positive pressure of the ventilated lung (Adult esophageal balloon catheter, Cooper Surgical, Trumbull, CT, USA). Intra-bronchial pressures will be measured at end-inspiration and end-expiration.
2947887|NCT02919267|Other|Volume determination|A one-liter bag (Roxon, Etobicoke, ON, Canada) will be filled precisely with 300 mL of air with the use of a calibrated syringe of 3 liters (Hans Rudolph inc, Shawnee, Kansas, United States), through a three-way valve (Hans Rudolph inc, Shawnee, Kansas, United States). Following the filling of the bag, it will be connected to the non-ventilated lumen of the double lumen tube (DLT) or to the bronchial blocker (BB) through the three-way connector. At the end of the observation period, the collector bag will be connected to the calibrated syringe and will emptied from its residual volume.
2947888|NCT02919254|Active Comparator|High Dosage|Subjects will receive approximately 8 mmol of dietary nitrate per day delivered as a commercially available beetroot juice supplement for 7 days.
2947889|NCT02919254|Active Comparator|Moderate Dosage|Subjects will receive approximately 0.5 mmol of dietary nitrate per day delivered as a commercially available beetroot juice supplement for 7 days.
2947890|NCT02919254|Placebo Comparator|Placebo|Subjects will receive a placebo beverage containing negligible nitrate for 7 days.
2947891|NCT02919241|Experimental|Diagnostic interview|Intervention for this group include diagnostic interview. Oral health Impact Profile (OHIP 14) and Spielberg State and Trait Anxiety (STAI-1) questionnaires and behaviour analyses are used in diagnostic interview.
2947892|NCT02919241|Experimental|Combined interview and treatment|Intervention for this group include both the diagnostic interview and one session treatment.
2947893|NCT02919228|Experimental|Visible light exposure cognitive Red|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to red LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
2947894|NCT02919228|Experimental|Visible light exposure cognitive Orange|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to orange LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
2947895|NCT02919228|Experimental|Visible light exposure cognitive Yellow|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to yellow LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
2947896|NCT02919228|Experimental|Visible light exposure cognitive Green|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to green LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
2947897|NCT02919228|Experimental|Visible light exposure cognitive Cyan|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to cyan LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
2947898|NCT02919228|Experimental|Visible light exposure cognitive Blue|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to blue LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
2947899|NCT02919228|Experimental|Visible light exposure cognitive Violet|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to violet LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
2947900|NCT02919228|Experimental|Visible light exposure cognitive White|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to white LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
2947901|NCT02919215|Experimental|Teacher Help Intervention|The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as the online support for teachers. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
2947902|NCT02919215|No Intervention|Wait-list Control|These participants will not receive access to the Teacher Help intervention until September of the following academic year. Teachers, students, guardians, and collaborating psychologists are free to access and/or provide usual services. The psychologists will provide Teacher Help access codes to the Wait-list group in September of the following academic year:
2947903|NCT02919202|Experimental|Fluoride Varnish|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.
2947904|NCT02919202|Active Comparator|SEDBA|Self-etching Dentine Bonding Agent. Scotchbond Universal by 3M ESPE. Topical application followed by light curing for 20 seconds.
2947905|NCT02919189|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to red fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2947906|NCT02919189|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to red fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2947907|NCT02919189|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to blue fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2947908|NCT02919189|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to blue fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2947909|NCT02919189|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to green fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2947910|NCT02919189|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to green fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2947911|NCT02919189|Experimental|Visible light exposure White 30 lux|The participants will be exposed to white fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2947912|NCT02919189|Experimental|Visible light exposure White 120 lux|The participants will be exposed to white fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2947913|NCT02919176|Active Comparator|Mirabegron|Mirabegron 50 mg/day
2947914|NCT02919176|Active Comparator|Pioglitazone|Pioglitazone 30 mg/day
2947915|NCT02919176|Experimental|Mirabegron and Pioglitazone|Combination of Mirabegron 50 mg/day and Pioglitazone 30 mg/day
2947916|NCT02919163|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to incandescent light with a red color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2947917|NCT02919163|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to incandescent light with a red color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2947918|NCT02919163|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to incandescent light with a blue color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2947919|NCT02919163|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to incandescent light with a blue color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2947920|NCT02919163|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to incandescent light with a green color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2947921|NCT02919163|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to incandescent light with a green color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2947922|NCT02919163|Experimental|Visible light exposure White 30 lux|The participants will be exposed to incandescent light with no color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2947923|NCT02919163|Experimental|Visible light exposure White 120 lux|The participants will be exposed to incandescent light with no color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2947944|NCT02919033|Experimental|Self-management|"BP tele-monitor & App based self-management supports~Patient proficiency training"
2947924|NCT02919150||Myotonometric and isokinetic measurement|"Myotonometric assessment: into the site of the latent medial myofascial trigger point of the soleus muscle and distal to the lateral medial myofascial trigger point of the soleus muscle but into the same taut band.~Isokinetic assessment: triceps surae muscle tone will be quantified by measuring the passive range of motion for ankle dorsiflexion and the resistance to passive ankle dorsiflexion at slow and fast velocity."
2947925|NCT02919137|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to red LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
2947926|NCT02919137|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to red LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
2947927|NCT02919137|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to blue LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
2947928|NCT02919137|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to blue LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
2947929|NCT02919137|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to green LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
2947930|NCT02919137|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to green LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
2947931|NCT02919137|Experimental|Visible light exposure White 30 lux|The participants will be exposed to white LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
2947932|NCT02919137|Experimental|Visible light exposure White 120 lux|The participants will be exposed to white LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
2947933|NCT02919124|Experimental|Echoclip device|Ultrasonography using the echoclip device
2947934|NCT02919111|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
2947935|NCT02919098|Experimental|Intervention|Two schools (all students grades 9-12) will serve as the intervention group.Participants will complete a baseline survey that will take no longer than 30 minutes. Afterwards, a trained facilitator will delivery a game-based bystander intervention program aimed at teaching students the knowledge and skills to prevent or intervene in instances in sexual harassment and violence among peers. This will last for 4 class periods (approximately 45 minutes each period, 180 minutes total). Afterwards, participants will complete an immediate post-program survey lasting no more than 30 minutes. Three months later, students will fill out an a follow up survey lasting no more than 30 minutes. School staff and administrators will be interviewed to gather their insights on the program's feasibility and acceptability.
2947936|NCT02919098|Placebo Comparator|Delayed Control|"One school (all students grades 9-12) will serve as a delayed control group. Participants will complete a baseline survey that will take no longer than 30 minutes. Afterwards, a trained facilitator will delivery a game-based health program unrelated to sexual health, sexual violence, sexual harassment, and bystander behaviors. This will last for 4 class periods (approximately 45 minutes each period, 180 minutes total). Afterwards, participants will complete an immediate post-program survey lasting no more than 30 minutes. Three months later, students will fill out an a follow up survey lasting no more than 30 minutes.~After completing the follow-up survey, this group will follow the same procedures to deliver the bystander program and capture data outlined for the intervention group."
2947937|NCT02919085|Experimental|Mobilization|
2947938|NCT02919072|Experimental|Chloroprocaine|Chloroprocaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
2947939|NCT02919072|Active Comparator|Ropivacaine|Ropivacaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
2947940|NCT02919059|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg once daily during 24 weeks
2947941|NCT02919059|Active Comparator|Glimepiride 4 mg|Glimepiride 4 mg once daily during 24 weeks
2947942|NCT02919046|Experimental|single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days,the first day,the second day,29 days,30 days Duration:Total five times
2947943|NCT02919033|Placebo Comparator|Usual care (UC)|Patients are managed by their PCPs at the registered CHCs as usual.
2947945|NCT02919033|Experimental|PCTM intervention|"BP tele-monitor & App-based self-management supports~Patient proficiency training~PCP & cardiologist training of using Web-based analytics~Proactive and interactive care by PCPs and cardiologists"
2947946|NCT02919020|Experimental|Proprioceptive neuromuscular facilitation (PNF);|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
2947947|NCT02919020|Experimental|resistance exercise|Resistance exercise to strengthen lower limbs
2947948|NCT02919007|Experimental|Silk'h HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual. Measure includes the ability to operate the device correctly according to the user manual.
2947949|NCT02918994|Experimental|LearningRx cognitive training|The intervention is a 60-hour, clinician-delivered cognitive training program.
2947950|NCT02918981|Active Comparator|Whey protein|After resistance exercise, participants aged 50-79 years will consume 14g Whey protein dissolved in 200 mL of water
2947951|NCT02918981|Experimental|Whey + Leucine|After resistance exercise, participants aged 50-79 years will consume 6.6 g Whey protein + 1.25 g Leucine dissolved in 200 mL of water
2947952|NCT02918981|Experimental|Whey + Leucine + Whey peptides|After resistance exercise, participants aged 50-79 years will consume 4 g Whey protein + 1.25 g Leucine + 2.6 g Whey peptides dissolved in 200 mL of water
2947953|NCT02918981|Experimental|Whey + Leucine + Citrulline|After resistance exercise, participants aged 50-79 years will consume 6.6 g Whey protein + 1.25 g Leucine + 0.8 g Citrulline dissolved in 200 mL of water
2947954|NCT02918981|Sham Comparator|Water|After resistance exercise, participants aged either 20-30 or 50-79 years old will consume 200 mL water
2947955|NCT02918968|Experimental|Enzalutamide Preceding Group|Enzalutamide will be administered as the 1st line AAT. After the confirmation of PSA relapse, medication will be changed from enzalutamide to flutamide as the 2nd line AAT.
2947956|NCT02918968|Experimental|Flutamide Preceding Group|Flutamide will be administered as the 1st line AAT. After the confirmation of PSA relapse, medication will be changed from flutamide to enzalutamide as the 2nd line AAT.
2947957|NCT02918955|Active Comparator|Arm rA (randomized)|Concomitant chemo-radiotherapy with early salvage neck dissection if less than complete clinical response
2947958|NCT02918955|Experimental|Arm rB (randomized)|Up-front neck dissection followed by radiotherapy with concomitant chemotherapy based on the cT pN cM staging after surgery
2947959|NCT02918955|Active Comparator|Arm oA (non-randomized)|Concomitant chemo-radiotherapy with early salvage neck dissection if less than complete clinical response
2947960|NCT02918955|Experimental|Arm oB (non-randomized)|Up-front neck dissection followed by radiotherapy with concomitant chemotherapy based on the cT pN cM staging after surgery
2947961|NCT02918929|Experimental|EDP 305 SAD Cohorts|EDP 305 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration
2947962|NCT02918929|Experimental|EDP 305 MAD Cohorts|EDP 305 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 oral suspension, once daily for 14 days
2947963|NCT02918929|Placebo Comparator|EDP 305 SAD Placebo Cohort|Matching placebo, oral suspension, once daily in one single administration
2947964|NCT02918929|Placebo Comparator|EDP 305 MAD Placebo Cohort|Matching placebo, oral suspension, once daily for 14 days
2947965|NCT02918916|Experimental|Active phototherapy group|"Phototherapy will be applied between sprint and squat training (exactly 10 minutes before squat training).~Active phototherapy will be applied by a trained therapist using a MR4 LaserShower 50 4D emitter (Multi Radiance Medical, USA), bilaterally to six sites of the quadriceps (two centrally - rectus femoris and vastus intermedius; two laterally - vastus lateralis; two medially - vastus medially) in direct contact with the skin.~The optical power will be calibrated before irradiation in each participant using a Thorlabs thermal power meter (Model S322C, Thorlabs, Newton, New Jersey, USA)."
2947966|NCT02918916|Placebo Comparator|Placebo phototherapy group|"Placebo will be applied between sprint and squat training (exactly 10 minutes before squat training). Placebo phototherapy will be applied by a trained therapist using a MR4 LaserShower 50 4D emitter (Multi Radiance Medical, USA), bilaterally to six sites of the quadriceps (two centrally - rectus femoris and vastus intermedius; two laterally - vastus lateralis; two medially - vastus medially) in direct contact with the skin. To receive active or placebo phototherapy the participant will be placed in the supine position.~The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled."
2947967|NCT02918916|No Intervention|Control group|Passive recovery will be applied between sprint and squat training (exactly 10 minutes before squat training). During the period when the other groups are receiving recovery strategies, the control group participants will remain seated for passive recovery, supervised by an independent therapist.
2947968|NCT02918903|Experimental|Minimal caries removal|the patients in this group will be treated by minimal caries removal technique, where only caries at lateral walls of cavity is removed, stainless steel crown preparation is performed and then stainless steel crown is placed as final restoration.
2947969|NCT02918903|Active Comparator|Complete caries removal|patients in this group will be treated by complete caries removal technique, where all caries will be removed, a base of resin modified glass ionomer is placed and then stainless steel crown is placed as final restoration.
2947970|NCT02918890|Experimental|CIMT|Procedure: Constraint-Induced Movement Therapy 90 hours Other Name: CIT, CI Therapy, restraint therapy, PT, OT, rehab
2947971|NCT02918890|Experimental|HABIT|Procedure: Hand-Arm Bimanual Intensive Therapy (HABIT) 90 hours Other Name: HABIT, bimanual training, bilateral training, restraint therapy, PT, OT, rehab
2947972|NCT02918877|Experimental|Inhaled Anesthesia|Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.
2947973|NCT02918877|Active Comparator|Intravenous Anesthesia|Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.
2947974|NCT02918864|Experimental|ION-ASD|ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training).
2947975|NCT02918864|Active Comparator|Facilitated Play|The active comparison condition is a facilitated play therapy group.
2948037|NCT02918500|No Intervention|Placebo|Participants will receive 3 weeks of inactive NRT patches.
2947976|NCT02918851|Experimental|7-day old RBCs|Transfusion of 7-day stored red blood cells: Subjects will be transfused with their own 7-day old red blood cells
2947977|NCT02918851|Experimental|28-day old RBCs|Transfusion of 28-day stored red blood cells: Subjects will be transfused with their own 28-day old red blood cells
2947978|NCT02918851|Experimental|42-day old RBCs|Transfusion of 42-day stored red blood cells: Subjects will be transfused with their own 42-day old red blood cells
2947979|NCT02918838|Experimental|Own Adherence Group|Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
2947980|NCT02918838|Experimental|Fixed Adherence Group|Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
2947981|NCT02918838|Active Comparator|Control Group|Participants do not receive a lottery incentive conditional on adherence. Participants will however, continue to receive weekly messaging with airtime top-up contingent on response.
2947982|NCT02918825|Experimental|Paliperidone|Drug: Paliperidone, 75-150mg/month, once a month, 12 weeks
2947983|NCT02918825|Active Comparator|Olanzapine|Drug: Olanzapine, 20mg/day, twice a day, 12 weeks
2947984|NCT02918812|Experimental|Intracervical lidocaine|This group will comprise of patients that will receive the intracervical block. The study group will receive a total of 60 mg (6 mL) of 1% lidocaine to be injected at four points (12, 4, 6, and 8 o'clock) circumferentially into the cervix (1.5 mL at each point) 5 minutes before proceeding with the hysterosalpingogram.
2947985|NCT02918812|Active Comparator|Intramuscular Diclofenac|This group will comprise of patients that will receive intramuscular diclofenac potassium 75mg 30 minutes before proceeding with the hysterosalpingogram.
2947986|NCT02918799|Other|Community cohort|Beirut community will receive the multi-component intervention Mpowerment; the community cohort of YMSM will be used to evaluate the effects of the intervention on the community, as the cohort participants may or may not have participated in the intervention.
2947987|NCT02918786|Active Comparator|Continuous positive airway pressure|After extubation, patients will receive continuous positive airway pressure (CPAP) delivered by the variable generator WhisperFlow System (control) Intervention:Device : CPAP of 5 cmH2O delivered by the variable generator WhisperFlow System for 48 hours
2947988|NCT02918786|Active Comparator|Nasal high-flow|After extubation, patients will receive oxygen therapy through the nasal high-flow (intervention) Intervention: Device: Nasal high-flow
2947989|NCT02918773|Experimental|Smartphone otoscope|Participating clinicians randomized to the smartphone otoscope study arm will use a smartphone otoscope for all otic (ear) examinations for a 6-month period.
2947990|NCT02918773|Active Comparator|Conventional otoscope|Participating clinicians randomized to the conventional otoscope study arm will use a conventional otoscope for all otic (ear) examinations for a 6-month period.
2947991|NCT02918760|Experimental|Gabapentin|This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
2947992|NCT02918760|Placebo Comparator|Placebo|Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
2947993|NCT02918747|Experimental|P-Gemoxd|"Pegaspargase+Gemcitabine+Oxaliplatin+Dexamethasone (PEG-ASP+Gemoxd): Patients received the P-Gemoxd chemotherapy regimen every 3 weeks.~Pegaspargase 2000U/m2 im day 1, Gemcitabine 800mg/m2 ivdrip 30min day 1 and day 5, Oxaliplatin 85mg/m2 ivdrip day 1, Dexamethasone 15 mg ivdrip, QD, day 1 to day 5.~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions."
2947994|NCT02918747|Active Comparator|P-CHOP|"Pegaspargase+Cyclophosphamide+Doxorubicin+Vincristine +Prednisone (P-CHOP)：Patients received the P-CHOP chemotherapy regimen every 3 weeks. Pegaspargase 2000U/m2 im，day 1； cyclophosphamide 750 mg/m2，ivdrip day 1； doxorubicin 50mg/m 2，ivdrip day 1；vincristine 1.4 mg/m 2(≤2mg），ivdrip day 1 and prednisone (60 mg/m 2 /day) on days 1 to 5 orally.~IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50-56 grays (Gy) in 25-28 fractions."
2947995|NCT02918734|Experimental|Endobutton CL BTB|Femoral fixation of the BPTB autograft with the Endobutton CL BTB Fixation System.
2947996|NCT02918734|Active Comparator|Metal interference screw|Femoral fixation of the BPTB autograft with a metal interference screw.
2947997|NCT02918721|Experimental|Restylane Lidocaine|Restylane Lidocaine will be injected into one side nasolabial fold on Day 1
2947998|NCT02918721|Active Comparator|Restylane|Restylane will be injected into the opposite side nasolabial fold on Day 1
2947999|NCT02918708|Active Comparator|group 2 (Synflorix then Prevenar13)|PCV10 given at 2 and 4 months of age, PCV13 given at 12 months of age
2948000|NCT02918708|Active Comparator|group 1 (Prevenar13 only)|PCV13 given at 2,4 and 13 months of age
2948001|NCT02918682|Experimental|Exercise Group|The multimodal intervention protocol is described separated by day (1 to 24) and by weeks (1 to 12). Each session was built to last between 50 and 60 minutes.
2948002|NCT02918682|No Intervention|Control Group|Participants from the control group will not perform any kind of physical exercise.
2948003|NCT02918669|Experimental|coflex|Patients who received the coflex Device in the IDE Study and presented with a spinous process fracture at 24 months (identified by independent radiographic review lab). Patients will undergo a CT Scan.
2948004|NCT02918656|Experimental|Infographics|Infographic presentation of health information
2948005|NCT02918656|Active Comparator|Plain Language Summary|PLS presentation of health information
2948006|NCT02918656|Active Comparator|Scientific abstract|Scientific abstract presentation of health information
2948038|NCT02918500|Active Comparator|Active|Participants will receive 3 weeks of active NRT patches
2948007|NCT02918643|Active Comparator|Application|15 physicians will receive an application to tablet device with information about potentially inappropriate medications for elderly and access for consultation of the portal of evidence-based health
2948008|NCT02918643|Sham Comparator|Control|15 physicians will receive a tablet with internet access for consultation of the portal of evidence-based health
2948009|NCT02918630|Active Comparator|Nicotine Replacement Therapy - Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
2948010|NCT02918630|Experimental|Nicotine Replacement Therapy + E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
2948011|NCT02918617|Active Comparator|Control toothpaste containing Novamin® technology|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
2948012|NCT02918617|Placebo Comparator|Control toothpaste containing 1500 ppm fluoride as MFP|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
2948013|NCT02918617|Experimental|Test toothpaste with nano-HAP (high concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
2948014|NCT02918617|Experimental|Test toothpaste with nano-HAP (low concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
2948015|NCT02918617|Experimental|Test toothpaste with nano-HAP and potassium nitrate (KNO3)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
2948016|NCT02918617|Placebo Comparator|Control toothpaste without nano-HAP|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
2948017|NCT02918617|Experimental|Test toothpaste with nano-HAP (medium concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
2948018|NCT02918617|Experimental|Test cream with nano-HAP (higher concentration)|Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
2948019|NCT02918617|Placebo Comparator|Control cream without nano-HAP|Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
2948020|NCT02918604|Other|B : veinsite access|infrared technology vein access
2948021|NCT02918604|Active Comparator|A: control group|conventional vein access
2948022|NCT02918591|Experimental|Empagliflozine|All type 2 diabetic participant will be treated during 2 month with Empagliflozine 10 to 25 mg daily during 2 month.
2948023|NCT02918578|Experimental|"Phone group"|see intervention description
2948024|NCT02918578|Experimental|"Phone and SMS group"|see intervention description
2948025|NCT02918578|Active Comparator|"single writing group"|see intervention description
2948026|NCT02918565|Experimental|Drinking Cognition Feedback (DCF)|12 weeks of interactive text messaging focused on providing feedback related only to pre-weekend drinking cognitions (plans, desire to get drunk).
2948027|NCT02918565|Experimental|Alcohol Risk Feedback (ARF)|12 weeks of interactive text messaging focused on providing feedback related only to post-weekend alcohol consumption (max drinks consumed on any occasion over the weekend).
2948028|NCT02918565|Experimental|Adaptive Goal Support (AGS)|10 weeks of interactive text messaging focused on providing adaptive goal support (based on running average of max drinks consumed).
2948029|NCT02918565|Experimental|COMBO|12 weeks of interactive text messaging incorporating features of DCF, ARF and AGS.
2948030|NCT02918565|No Intervention|Control|12 weeks of text message assessments without any feedback
2948031|NCT02918552|Experimental|Treatment|20 or 40 mg sodium nitrite tid
2948032|NCT02918552|Placebo Comparator|Control|20 or 40 mg placebo tid
2948033|NCT02918539||RAmP Registry Patients|Patients who have a) objectively verified cognitive impairment and etiology diagnosed or suspected to be Alzheimer's disease and b) a positive amyloid scan from either an existing amyloid scan that has been interpreted as positive or a florbetapir F 18 PET scan via protocol addendum
2948034|NCT02918526|Experimental|Laryngeal Mask|laryngeal mask (LMA)
2948035|NCT02918526|Active Comparator|Oro Tracheal Intubation|oro tracheal intubation
2948036|NCT02918513|Experimental|Wellness Intervention|WILD 5 Wellness is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
2948039|NCT02918487|Experimental|Active|[Formoterol + Fluticasone] Single maintenance and reliever therapy(SMART) and Active polyherbal capsule
2948040|NCT02918487|Placebo Comparator|Placebo|[Formoterol + Fluticasone] conventional along with inert similar looking placebo capsules
2948041|NCT02918474|Experimental|Contralateral Prophylactic Breast Cancer (CPM) Group|Participant with early stage breast cancer complete a brief questionnaire before and after her surgeon shows her the clinical tool. The questionnaires will take about 20 minutes to complete. Patient's participation and completion of the questionnaires will assist researchers in learning about the acceptability of the clinical tool, and whether it helped participant make decisions and improved their knowledge on the topic.
2948042|NCT02918474|Experimental|Breast Cancer Surgeons Group|After completing the clinical tool with 5 patients, each physician will complete a survey to determine whether the tool was useful, how the information was used, how patients reacted to the information provided, what impact the tool had on the patients' decision, and identify any problems in using the tool that can be addressed before it is made available to clinicians on a broader scale.
2948043|NCT02918461|Experimental|Emerging from the Haze class|A 6-week psycho-educationally-based, cognitive behavioral program to help patients with subjective cognitive complaints after cancer treatment, titled Emerging from the Haze™ (Haze). Each series meets once a week for 2-2.5 hours for 6 weeks.
2948044|NCT02918448|Experimental|Taining group|training group that performed the resistance program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays. The RT program was performed in the following order: chest press, horizontal leg press, seated row, knee extension, preacher curl (free weights), leg curl, triceps pushdown, and seated calf raise. Participants of the TG performed 3 sets of 10-15 repetition maximums. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise
2948045|NCT02918448|No Intervention|control group|control group that did not perform any type of physical exercise
2948046|NCT02918435|No Intervention|Usual Care-Control|Participants in the usual care group will receive standard pediatric care.
2948047|NCT02918435|Experimental|On-site WE CARE implementation arm|"WE CARE will be implemented in the study site using a facilitated on-site strategy. 1. Participants will receive the WE CARE survey at health supervision visits; this survey will be used to identify unmet material needs. 2. Providers will be trained on WE CARE via an on-site team which will teach them how to review the survey and provide referrals (community resource information sheets) from a Family Resource Book located in each exam room."
2948048|NCT02918435|Experimental|Self-directed web-based WE CARE implementation arm|WE CARE will be implemented in the study site using a web-based implementation strategy. 1. Participants will receive the WE CARE survey at health supervision visits; this survey will be used to identify unmet material needs. 2. Providers will be trained on WE CARE via web-based tools (e.g., webinars) which will teach them how to review the survey and provide referrals (community resource information sheets) from a Family Resource Book located in each exam room
2948049|NCT02918422|Experimental|High Carbohydrate No Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 55% CHO, 20% PRO and 25% fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
2948050|NCT02918422|Experimental|High Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 55% CHO, 20% PRO 25% and Fat 25% with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
2948051|NCT02918422|Experimental|Mod. Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 30% CHO, 20% PRO and 50% Fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
2948052|NCT02918422|Experimental|Low Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 10% CHO, 20% PRO and 70% Fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
2948053|NCT02918409|Active Comparator|Standard colistin arm|Subjects initially receive IV colistin 2.5 mg/kg/d divided into three times daily (TID) dosing. Subjects receiving colistin will undergo a 2 day up-titration of dose to an ultimate dose of 4-5 mg/kg/day, for a total treatment of 14 days. The drug is infused over 30 minutes on a TID dosing schedule.
2948054|NCT02918409|Active Comparator|Modified colistin arm|Subjects receiving IV colistin undergo a 2 day up-titration to a maximum dose of 5 mg/kg/day, divided into twice daily (BID) dosing, for a total treatment of 14 days. The drug is infused over 30 minutes BID. Steady state plasma concentrations on day 3 of therapy (on 2nd- 3rd dose once at goal dosing) will be measured; specifically, colistin peak (30 minutes after infusion), midpoint (6 hour) and trough (30 minutes prior to next infusion).
2948055|NCT02918409|Active Comparator|Standard tobramycin arm|Subjects receive IV tobramycin 8-10 mg/kg/day with once daily dosing for 14 days. Peaks and troughs are drawn with the second dose of tobramycin, and the drug is infused over 30 minutes
2948056|NCT02918396|Active Comparator|Conventional PVI|Conventional PVI by Radio-frequency Ablation: Wide area circumferential pulmonary vein isolation (PVI) only (current standard of care) using radio-frequency ablation catheters.
2948057|NCT02918396|Experimental|PVI + Scar-based ablation|Scar-Based Radio-frequency Ablation: Pulmonary vein isolation followed by targeting, using radio-frequency ablation, of dense LGE sites on MRI, which are confirmed on bipolar mapping to have voltage <0.3 mV.
2948058|NCT02918396|Experimental|PVI + Modeling-predicted rotors ablation|Rotor Anchors Radio-frequency Ablation: Pulmonary vein isolation followed by radio-frequency ablation of rotor anchors predicted by modeling.
2948059|NCT02918383|Other|Indocyanin Green Dye (ICG)|Once the patient is in the operating room, the operative intervention will take proceed as current standard protocol dictates for the described procedure. No changes in operative technique will be undertaken apart from injection of the dye and visualization with the camera. After the articular surface of the distal femur or proximal tibia has been exposed, 2.5 mg of indocyanin green will be injected intravenously by anesthetist through a pre-existing IV line outside the sterile field. The operating surgeon will grade 6 locations on a standard scale of chondromalacia or cartilage damage.
2948089|NCT02918240|Experimental|6 week interval|Patients will be seen every 6 weeks to adjust their orthodontic braces
2948060|NCT02918370|Experimental|Aripiprazole|Aripiprazole will be given to the participant beginning at 2 mg per day(QD) then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.
2948061|NCT02918370|Placebo Comparator|Placebo|Matching placebo will be given to the participant beginning at 2mg QD then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.
2948062|NCT02918357|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
2948063|NCT02918344||Standard sagittal split osteotomy group|Patients undergoing sagittal split osteotomy without paste application
2948064|NCT02918344||Cohort/Hydroset group|Patients undergoing sagittal split osteotomy with paste application
2948065|NCT02918331|Experimental|Daratumumab with Lenalidomide and dexamethasone|"Daratumumab (16 milligram per kilogram [mg/kg]) will be administered by intravenous [IV] infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.~Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle.~Participants will receive dexamethasone 40mg weekly, at day 1, 8, 15, 22 of each cycle."
2948066|NCT02918318|Experimental|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
2948067|NCT02918318|Experimental|Esketamine 28 milligram (mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
2948068|NCT02918318|Experimental|Esketamine 56 mg|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
2948069|NCT02918318|Experimental|Esketamine 84 mg|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
2948070|NCT02918305|Sham Comparator|PRDS-001 Renal Denervation Ultrasound System|Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using PRDS-001 System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
2948071|NCT02918305|Sham Comparator|Sham Procedure|Randomization will occur following the diagnostic renal angiography. For blinded patients randomized to control, the diagnostic renal angiography will be considered the sham procedure.
2948072|NCT02918292|Experimental|Haplo Bone Marrow HSCT|Patients will be treated with a preparative regimen of Antithymocyte Globulin (ATG) (4.5 mg/kg), fludarabine (150 mg/m^2), cyclophosphamide (29 mg/kg), and low dose total body irradiation (TBI) (200 cGy) before undergoing the haplo HSCT. GVHD prophylaxis will be with post-HSCT cyclophosphamide (100 mg/kg), tacrolimus, and mycophenolate mofetil (MMF). G-CSF will be administered post-transplant.
2948073|NCT02918279|Experimental|Liraglutide|
2948074|NCT02918279|Placebo Comparator|Placebo|
2948075|NCT02918266|Experimental|Part 1: TAK-071 80 mg + Scopolamine 0.5 mg|TAK-071 80 milligram (mg), drug in capsule (DIC), orally, Day 1, followed by scopolamine 0.5 mg, injection, subcutaneously, Day 2. TAK-071 will be taken 24 hours before scopolamine injection.
2948076|NCT02918266|Experimental|Part 2: Treatment Sequence ABDEC|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period1(A); followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(C). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
2948077|NCT02918266|Experimental|Part 2: Treatment Sequence BCEAD|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period4(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(D). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
2948078|NCT02918266|Experimental|Part 2: Treatment Sequence CDABE|TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(C);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period3(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(E). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
2948090|NCT02918240|Experimental|8 week interval|Patients will be seen every 8 weeks to adjust their orthodontic braces
2948091|NCT02918240|Experimental|10 week interval|Patients will be seen every 10 weeks to adjust their orthodontic braces
2948117|NCT02918019|Experimental|MSTT1041A 210 mg|Participants will receive MSTT1041A 210 milligrams (mg), subcutaneously every 4 weeks from randomization through Week 50.
2948432|NCT02915848||PC+S group|PC+S group gets Medtronic, Activa PC+S DBS device,
2948079|NCT02918266|Experimental|Part 2: Treatment Sequence DEBCA|TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period5(A). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
2948080|NCT02918266|Experimental|Part 2: Treatment Sequence EACDB|TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period2(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(C);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(B). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
2948081|NCT02918266|Experimental|Part 2: Treatment Sequence ACBED|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period1(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(D). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
2948082|NCT02918266|Experimental|Part 2: Treatment Sequence BDCAE|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(D);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period4(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(E). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
2948083|NCT02918266|Experimental|Part 2: Treatment Sequence CEDBA|TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period5(A). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
2948084|NCT02918266|Experimental|Part 2: Treatment Sequence DAECB|TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period2(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(C); followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(B). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
2948085|NCT02918266|Experimental|Part 2: Treatment Sequence EBADC|TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period3(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(D);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(C). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
2948086|NCT02918253|Experimental|Tumour visible on MRI|Targeted focal HDR Brachytherapy to dominant lesion +/- whole-gland elective dose
2948087|NCT02918253|Active Comparator|No tumour visible on MRI|Whole-gland HDR Brachytherapy
2948088|NCT02918240|Experimental|4 week interval|Patients will be seen every 4 weeks to adjust their orthodontic braces
2948092|NCT02918227|Experimental|Search retrograde ejaculation|Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
2948093|NCT02918214||echocardiography|Each patient will be hemodynamically assessed using echocardiography: Day1 defines the first echocardiography performed within the first 12 hours (ideally within the first 6 h) following the diagnosis of septic shock, Day2 and Day3 define the examination performed 24 to 36 h and 48 to 72 h later (guidance of treatment during the acute phase), Day end defines the examination performed after vasopressors cessation (end of hemodynamic failure). In addition, echocardiography will be performed on ICU discharge and on Day28 or on hospital discharge (whatever occurs first) to document potential reversibility of LV diastolic dysfunction. Transthoracic echocardiography will always first be performed and transesophageal echocardiography will be limited to ventilated patients without adequate surface echocardiographic image quality, under sedation and during the initial phase of septic shock (D1 to D3), according to the standards of care of participating centers.
2948094|NCT02918201|Experimental|topical tranexamic acid|bandages wetted in tranexamic acid solution to be applied on one of two superficial donor wounds on each participant. Potential candidates will be consecutively identified by the trial investigators among patients admitted to the plastic surgical department at St Olav's University Hospital and the burn unit at Haukeland University Hospital.
2948095|NCT02918201|Placebo Comparator|placebo control|bandages wetted in saline solution to be applied on one of two superficial donor wounds on each participant. Potential candidates will be consecutively identified by the trial investigators among patients admitted to the plastic surgical department at St Olav's University Hospital and the burn unit at Haukeland University Hospital.
2948096|NCT02918188|Experimental|Hydrogen|Patients will receive hydrogen-rich water (4mL/kg three times one day, 0.8 ppm)
2948097|NCT02918175|Other|mHealth Intervention|Subjects in this study arm will have data on activity levels, quality of life, medication adherence, and blood samples collected. In addition, they will receive personalized feedback on activity goals based on prior week step counts and participate in coaching sessions using the Pillbox medication tool.
2948098|NCT02918175|No Intervention|No intervention|Subjects in this study arm will have data on activity levels, quality of life, medication adherence, and blood samples collected.
2948099|NCT02918162|Experimental|Pembrolizumab|"All study subjects will receive standard of care chemotherapy regimen for 3 cycles prior to and 3 cycles following surgery in combination with Pembrolizumab with an additional cycle of Pembrolizumab (4 total) in the pre-operative period. Additionally subjects will complete 12 months of maintenance Pembrolizumab (14 additional doses to complete 17 post-operative cycles) following completion of post-operative chemotherapy.~Standard of care combination chemotherapy regimen has a 21-day cycle."
2948100|NCT02918149|Other|Palpation Landmark Technique LP|Traditional landmark palpation technique will be used to perform LP
2948101|NCT02918149|Experimental|Ultrasound-Assisted Technique LP|Bedside ultrasonography exam will be used for identification of anatomic landmarks before performing LP
2948102|NCT02918136|Experimental|adipose-derived stem cell injection|ultrasound guided injection of 5cc of adipose-derived stem cells (ADSCs)
2948103|NCT02918136|Active Comparator|cortisone injection|ultrasound guided injection of cortisone
2948104|NCT02918123|Experimental|Treatment|"FURESTEM-CD Inj. 5.0x10^7 cells~FURESTEM-CD Inj. 1.0x10^7 cells~FURESTEM-CD Inj. 2.0x10^8 cells"
2948105|NCT02918110|Experimental|Cytotec|orally administrated solution of misoprostol (Cytotec®)
2948106|NCT02918110|Experimental|Misodel|vaginal slow release misoprostol (Misodel®)
2948107|NCT02918097|Experimental|Lithium|"Group Started: Lithium (900mg-1500mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Lithium (LSL 0.6-0.8). Non responsive patients: 2nd step.~Second step: Monotherapy with lithium (LSL 1.0-1.2). Non responsive patients: 3rd step.~Third step: Lithium + Sertraline (50mg-200mg). Non responsive patients: 4th step.~Fourth step: Lithium + Nortriptyline 100mg. Non responsive patients: 5th step.~Fifth step: Lithium + Nortriptyline 100mg + Sertraline (100mg-200mg). Non responsive patients: 6th step~Sixth step: Lithium + Nortriptyline 100mg + Sertraline 200mg + Risperidone (1mg-6mg)."
2948108|NCT02918084|Sham Comparator|ARM A|Adjuvant chemotherapy → Aromatase inhibitors x 5 yrs (sequential arm)
2948109|NCT02918084|Experimental|ARM B|Adjuvant chemotherapy + Aromatase inhibitors x 5 yrs (concurrent arm)
2948110|NCT02918071|Experimental|Arm Benralizumab|Benralizumab administered subcutaneously every 4 weeks
2948111|NCT02918058|Active Comparator|McGill University Health Centre|This arm is defined by the geographic cluster of all eligible participants presenting to the McGill University Health Centre (Montreal, Quebec, Canada) Montreal General Hospital or Royal Victoria Hospital during the study period. The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
2948112|NCT02918058|Active Comparator|University Health Network, Toronto|This arm is defined by the geographic cluster of all eligible participants presenting to the University Health Network (Toronto, Ontario, Canada) at the Toronto General Hospital or Toronto Western Hospital. The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
2948113|NCT02918058|Active Comparator|University of Ottawa, Ottawa|This arm is defined by the geographic cluster of all eligible participants presenting to the Ottawa Hospital (Ottawa, Ontario, Canada). The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
2948114|NCT02918045|Experimental|Hemcon Dental Dressing|The HemCon® Bandage is an FDA-cleared chitosan-based flat bandage that controls severe arterial bleeding from traumatic injuries. In comparison to traditional bandages, the HemCon® Bandage provides superior control of bleeding, wound site adhesiveness, multiple injury site usage, biocompatibility and provides a barrier to infective agents.
2948115|NCT02918045|Active Comparator|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions involves the placement of an absorbable oxidized cellulose gauze Surgicel (Ethicon, Inc, San Angelo, TX) into the extraction socket. This treatment was chosen as the study control to compare the HemCon Dental Dressing to the standard local hemostatic care for oral surgery subjects.
2948118|NCT02918019|Experimental|MSTT1041A 490 mg|Participants will receive MSTT1041A 490 mg, subcutaneously every 4 weeks from randomization through Week 50.
2948119|NCT02918019|Experimental|MSTT1041A 70 mg|Participants will receive MSTT1041A 70 mg, subcutaneously every 4 weeks from randomization through Week 50.
2948120|NCT02918019|Placebo Comparator|Placebo|Participants will receive placebo matched with MSTT1041A, subcutaneously every 4 weeks from randomization through Week 50.
2948121|NCT02918006|Experimental|Oral Vaccine (VXA-A1.1)|Oral enteric coated vaccine tablets. Placebo (saline solution) IM injection will also be administered in this arm.
2948122|NCT02918006|Active Comparator|QIV IM Injection|A commercially available QIV will be administered at the approved dose level as the active comparator. Oral placebo tablets will also be administered in this arm.
2948123|NCT02918006|Placebo Comparator|Oral and IM Placebo|Two forms or placebos (saline IM injection and oral placebo tablets) will be administered in this arm.
2948124|NCT02917993|Experimental|INCB039110 + osimertinib|
2948125|NCT02917980||surgical treatment|patients with structural heart disease received surgical treatment
2948126|NCT02917980||interventional treatment|patients with structural heart disease received interventional treatment
2948127|NCT02917980||surgical combined with interventional treatment|patients with structural heart disease received surgical combined with interventional treatment
2948128|NCT02917967|Experimental|BTX injection group|Botulinum toxin injection group
2948129|NCT02917954|No Intervention|ePRO Control (3 or 6 months)|Control participants will complete surveys at baseline, 3 months, and/or 6 months. Surveys will capture patient demographics, their assessment of quality-of-life, chronic disease management, and primary care experience. A part from completing these surveys, no change to routine care will be seen.
2948130|NCT02917954|Experimental|ePRO intervention (12 or 9 months)|"During the ePRO Tool intervention participants will complete surveys at every 3 months intervals starting month at 4 or month 7, for study duration. Surveys capture patient demographics, assessment of quality-of-life, chronic disease management, primary care experience, and Electronic Patient Reported Outcome (ePRO) Mobile Application tool usability.~Participants will also meet with their provider to setup and monitor a health goal to track during the study via the ePRO application. During the study, participants will meet with their primary care providers 4-5 times to discuss their health goal monitoring. Post-study participants will discuss their experience using the ePRO app in an interview or focus group setting."
2948131|NCT02917941|Experimental|Ixazomib 4.0 mg, lenalidomide 25 mg, dexamethasone 40 mg|Patients will receive study drug (ixazomib 4.0 mg) on Days 1, 8, and 15 plus lenalidomide (25 mg) on Days 1 through 21 and dexamethasone (40 mg) on Days 1, 8, 15, and 22 of a 28-day cycle.
2948132|NCT02917928|Active Comparator|Intervention|Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
2948133|NCT02917928|Placebo Comparator|Control|Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
2948134|NCT02917915|Experimental|New Canadian Standardized PR|"Education Content: exercise, living well with chronic lung disease, breathing management, conserving energy, pulmonary medications, inhaler devices, integrating exercise in your life, management of respiratory infections, management of aggravating environmental factors, management of stress & anxiety, nutrition, leisure & travel, getting a good night's sleep, enjoying intimacy, living in a smoke-free environment, integrating long-term oxygen into your life, keeping a healthy lifestyle.~Delivery style: During group sessions patients engage in active, participatory-based learning of program content. Workbooks are available. During one-on-one interactions motivational communication style (asking for permission before providing information, using open questions, etc.) is used."
2948135|NCT02917915|Active Comparator|Traditional PR|"Education Content: Exercise, anatomy, pulmonary diseases, healthier breathing, pulmonary medications, pulmonary devices, exercise action plan, allergies & pulmonary function tests, health and air quality, healthier eating, travel, stress management & relaxation, tips to remember/summary of content.~Delivery style: During group sessions, patients engage in passive learning of program content delivered in a lecture-style approach. Patients also receive one-on-one education regarding: dyspnea management/pacing, inhaler technique, exercise maintenance."
2948136|NCT02917902|Experimental|Immediate intervention|Intervention: Food boxes. Monthly boxes of food for 6 months, along with brief educational information from food pantry staff regarding eating healthy on a budget, starting immediately after randomization. Patients will continue to receive routine medical care at the Free Clinic.
2948137|NCT02917902|Other|Delayed intervention|Intervention: Food boxes. Monthly boxes of food for 6 months, along with brief educational information from food pantry staff regarding eating healthy on a budget, starting 3 months after randomization. Patients will continue to receive routine medical care at the Free Clinic. Participants will be given referrals to local food pantries in their neighborhoods that provide food free of charge as well as referrals for CalFresh (formerly known as food stamps) during the 3 month time frame when patients are waiting to receive food distributions on site at the clinics.
2948138|NCT02917889|Experimental|Caffeine protocol|300 mg in pills
2948139|NCT02917889|Experimental|Placebo protocol|300 mg in pills
2948140|NCT02917863|Experimental|Solid L-Thyroxine|"Patients assume L-Thyroxine (tablet, per os) according to the Summary Product Characteristics for 6 months (then switch to the other formulation).~Dosage in children with hypothyroidism:~0-6 months: 10 mcg/kg body weight/die 6-12 months: 8 mcg/kg body weight/die~1- 5 years: 6 mcg/kg body weight/die 5-10 years: 4 mcg/kg body weight/die~Dosage in adults:~initial dose of 50mcg/die; maintenance dose 100-200 (300) mcg/die (medium dose 2-2,5 mcg/kg body weight/die).~Dosage will be adjusted according to TSH level."
2948141|NCT02917863|Active Comparator|Liquid L-Thyroxine|"Patients assume L-Thyroxine (oral drops, solution) according to the Summary Product Characteristics for 6 months (then switch to the other formulation).~Dosage in children with acquired hypothyroidism:~initial dose: 12,5-50 mcg/die maintenance dose: 100-150 mcg/m2 body surface area~Dosage in adults:~initial dose: 50 mcg/die; maintenance dose: 100-200 (300) mcg/die (medium dose 2-2,5 mcg/kg body weight/die).~Dosage will be adjusted according to TSH level."
2948142|NCT02917850|Active Comparator|Isokinetic|Patients who benefit from the hip flexors isokinetic strengthening rehabilitation program
2948143|NCT02917850|Active Comparator|Control|Patients who benefit from a conventional rehabilitation program
2948247|NCT02917135||Angel® Catheter|All consecutive, hospitalized patients in whom the Angel® Catheter is placed, or there has been an attempt to place, at selected Registry sites.
2948144|NCT02917837|Active Comparator|"Report card group"|Diagnostic imaging utilization for a prior six-month period: This is the group that receives a report card detailing use of diagnostic imaging per patient compared to their peers in a prior six month period.
2948145|NCT02917837|No Intervention|"No report card group"|No report card is given to this group
2948146|NCT02917824|Experimental|Low load|30 breaths at 15% of the maximal inspiratory pressure, twice daily for 6 weeks
2948147|NCT02917824|Experimental|High load|30 breaths at 50% of the maximal inspiratory pressure, twice daily for 6 weeks
2948148|NCT02917811||ICU patients|
2948149|NCT02917798||Genetic Testing in Ovarian ,Prostate or Pancreas Cancer|This study is a prospective single-arm study to examine how an alternative clinical genetics cancer care delivery model affects ovarian, prostate or pancreas cancer patients' cognitions, emotions, and behaviors. Participants will be contacted 1 week (+/- 1 week) (Assessment #2; and 3 months (+/- 2 weeks) (Assessment #3;) following the telephone post-test counseling session to complete the follow-up assessments. These assessments will measure psychological and behavioral study constructs.
2948150|NCT02917785|Experimental|Karman curettage|after a retained product of interception is observed in ultrasound examination, the women in this arm will undergo Karman curretage.
2948151|NCT02917785|No Intervention|Control|
2948152|NCT02917772|Experimental|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab~If CR/PR: Nivolumab Maintenance Mono-Therapy~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy~If CR/PR: Nivolumab Maintenance Mono-Therapy~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy"
2948153|NCT02917759||Hepatocellular cancer|Surgical waste tissue will be collected after removal of a liver tumor. A blood sample may be collected at the time of labs related to treatment for the diagnosis. An extra sample of biopsy tissue will be collected from participants having a targeted mass biopsy.
2948154|NCT02917759||Cholangiocarcinoma|Surgical waste tissue will be collected after removal of a biliary tumor. A blood sample may be collected at the time of labs related to treatment for the diagnosis. An extra sample of biopsy tissue will be collected from participants having a targeted mass biopsy.
2948155|NCT02917746|Experimental|Imiquimod treatment arm|Treatment by vaginal imiquimod cream during 16 weeks.
2948156|NCT02917746|Active Comparator|Standard treatment arm|Treatment by large loop excision of the transformation zone.
2948157|NCT02917733|Experimental|Radiolabelled LY3039478|Single dose of radiolabelled LY3039478 administered orally.
2948158|NCT02917720|Experimental|TKI-stop, pre-treatment with nilotinib|"Treatment after unsuccessful 1st discontinuation at least two year with nilotinib (300 mg/bid). In total, retreatment with TKI for at least 3 years before entering screening for stopping phase is warranted. Clinical monitoring every 3 months during this 2 years.~Patients who re-achieved and maintained MR4 for at least 12 months and MR4.5 for at least 6 months can enter screening phase for TFR .If MR4.5 is confirmed by an validated laboratory, patient may enter stopping phase of the study. Patient not fulfilling these criteria can be screened again every 3 months until month 48. After TKI-stop hematological monitoring and quantitative PCR of BCR/ABL1 (month 1-6 after stopping: monthly; month 7-12 after stopping: every 1.5 months, thereafter once every three months, for 3 years in total.~Relapse is defined as BCR-ABL1 > 0.1% on IS at a single time point (loss of MMR) In case of relapse restart of TKI. In general, the same TKI (nilotinib) as before second stop is recommended"
2948159|NCT02917707||normal colorectal tissues (PN)|normal colorectal tissues
2948160|NCT02917707||primary colorectal carcinoma tissues|primary colorectal carcinoma tissues
2948161|NCT02917707||liver metastasis tissues|liver metastasis tissues
2948162|NCT02917681|Experimental|MSC injection|Patients will be followed for 3 months before bone marrow aspiration (BMA). Patients will receive 2 intrathecal MSC injections, 1 and 2 months after BMA. The patients will be followed for 6 months after the interventions.
2948163|NCT02917668|Active Comparator|Group A|15 patients who will receive usual care for 30 minutes and then switch to FreeO2 for another 30 minutes
2948164|NCT02917668|Active Comparator|Group B|15 patients who will be oxygenated by FreeO2 for 30 minutes and then switch to usual care for another 30 minutes
2948165|NCT02917655|Experimental|Educational Program Associated (EPA)|"45 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital on months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; on month 4 for a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).~Answer WOMAC, Lequesne, VAS, IPAQ, Tampa Scale for Kinesiophobia (TSK); perform the FTSST, TUG, six-minute test have calculated BMI and body fat percentage at baseline evaluations, 6, 12 and 24 months."
2948166|NCT02917655|Other|Educational Program Isolated (EPI)|"45 patients will participate in two days of lectures two-months apart on the subject of knee OA.~Answer WOMAC, Lequesne, VAS, IPAQ, Tampa Scale for Kinesiophobia (TSK); perform the FTSST, TUG, six-minute test have calculated BMI and body fat percentage at baseline evaluations, 6, 12 and 24 months."
2948167|NCT02917642|Experimental|Passive Ultrasonic Irrigation Protocol|ultrasonic activation of antimicrobial solutions
2948168|NCT02917642|Active Comparator|Non-Ultrasonic Irrigation Protocol|no-activation of antimicrobial solutions
2948169|NCT02917629|Experimental|Group I (ACTOplus met XR)|Patients receive ACTOplus met XR PO QD for 14-21 days in the absence of disease progression or unacceptable toxicity. Patients may continue ACTOplus met XR PO QD for a maximum of 25 days if end of treatment biopsy/surgical treatment is delayed beyond day 22.
2948170|NCT02917629|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD daily for 14-21 days.
2948171|NCT02917616|Experimental|Alkaline water|Two liters (minimum) daily of alkaline drinking-water (pH=9) for 14 days
2948172|NCT02917616|Active Comparator|Neutral Water|Two liters (minimum) daily of neutral drinking-water (pH=7) for 14 days
2948173|NCT02917603|Experimental|Intervention|These family members and residents will use web conferencing technology to attend their quarterly care conferences
2948174|NCT02917603|No Intervention|Control|These family and residents will receive usual care
2948248|NCT02917122|Placebo Comparator|sertraline + sham tDCS|Patients will take sham tDCS.
2948285|NCT02916862|Active Comparator|Soluble Corn Fiber (SCF) without calcium|This group will receive 12 g/d of soluble corn fiber (SCF) + 600 mg/d of elemental calcium carbonate, administered twice a day
2948175|NCT02917590|Experimental|Dual-task obstacle crossing training|The four obstacles in the sizes of 4cm wide, 8cm wide, 4cm high, and 8cm high are randomly placed along a 10-meter walkway in 2-meter intervals. Subjects are instructed to walk continuously over obstacles at their comfortable speed, as good as they can without contact the obstacles by their leg or device. During walk over obstacles, subjects asked to perform simultaneously with a color word stroop task which requires subjects to see and answer the color of the name of a color words in the monitor (ignore the meaning) as quickly as possible, and loudly.
2948176|NCT02917590|Sham Comparator|Single-task obstacle crossing training|The four obstacles in the sizes of 4cm wide, 8cm wide, 4cm high, and 8cm high are randomly placed along a 10-meter walkway in 2-meter intervals. Subjects are asked to walk continuously over obstacles at their comfortable speed, as good as they can without contact the obstacles by their leg or device.
2948177|NCT02917577|Active Comparator|Avaxim Pediatric®|2 doses (0.5 mL each) six months apart of Avaxim Pediatric®
2948178|NCT02917577|Active Comparator|Avaxim ® (adult)|2 doses (0.5 mL each) six months apart of Avaxim ® (adult)
2948179|NCT02917564|Sham Comparator|Control|"Patients placed in a semi supine position. A cotton-tipped applicator saturated with proparacaine 0.5% (Alcaine, Alcon Labs) is placed into the conjunctival fornix of the supero-temporal quadrant for 5 minutes following initial proparacaine drops.~After anaesthetic medication is placed, a 3 ml syringe will be placed into the superotemporal conjunctival fornix but no needle is present and no drug injected.~Topical prednisolone acetate 1% qid for 4 weeks or PRN Topical atropine 1% qid for one week or PRN"
2948180|NCT02917564|Active Comparator|Injection|"Patients placed in a semi supine position. A cotton-tipped applicator saturated with proparacaine 0.5% (Alcaine, Alcon Labs) is placed into the conjunctival fornix of the supero-temporal quadrant for 5 minutes following initial proparacaine drops.~After anaesthetic medication is placed, 1mL of a 40 mg/ml suspension of triamcinolone acetonide is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down.~Topical prednisolone acetate 1% qid for 4 weeks or PRN Topical atropine 1% qid for one week or PRN"
2948181|NCT02917551|Active Comparator|Shorter duration (7 days)|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
2948182|NCT02917551|Active Comparator|Longer duration (14 days)|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
2948183|NCT02917538|Experimental|Intervention group|In the intervention group: The operator will perform the RFA treatment guided by real-time CF parameters.
2948184|NCT02917538|Active Comparator|Control group|In the control group: The Operator will perform the RFA treatment blinded to the real-time CF parameters.
2948185|NCT02917525|Experimental|Vitamin K2|22 patients will receive 360ug Vitamin K2 daily during 18 months.
2948186|NCT02917525|Placebo Comparator|Placebo|22 patients will receive placebo during 18 months.
2948187|NCT02917512|Experimental|HU00701|"HU00701(Cyclosporine 0.01% + 3% trehalose)~1 drop b.i.d at 12 hour interval for 12 weeks"
2948188|NCT02917512|Experimental|HU007|"HU007(Cyclosporine 0.02% + 3% trehalose)~1 drop b.i.d at 12 hour interval for 12 weeks"
2948189|NCT02917512|Active Comparator|Restasis|"Restasis(Cyclosporine 0.05%)~1 drop b.i.d at 12 hour interval for 12 weeks"
2948190|NCT02917512|Placebo Comparator|Placebo(without main component)|"Placebo~1 drop b.i.d at 12 hour interval for 12 weeks"
2948191|NCT02917499|Experimental|TMS|The experimental group will be treated with transcranial magnetic stimulation for 4 weeks.
2948192|NCT02917499|No Intervention|noTMS|The control (no intervention) group will be treated as usual (with pharmacotherapy). These patients will receive TMS treatment after data collection is ended.
2948193|NCT02917486||ECMO piperacillin|patients in intensive care treated with ECMO with antiinfective therapy : piperacillin
2948194|NCT02917486||without ECMO piperacillin|patients in intensive care without ECMO with antiinfective therapy : piperacillin
2948195|NCT02917473|Other|Control|"Education and counseling as commonly delivered to the patients in clinical practice.~Brief oral counseling to the patient focusing on sun protection, self-skin examination, medical skin examination, increased risk of melanoma for their first-degree relatives, who should be informed orally by the patients to protect themselves from UV radiation, perform self-skin examination and ask their GP or dermatologist to perform annual skin examination"
2948196|NCT02917473|Experimental|Intervention group|"Education and counseling as commonly delivered to the patients in clinical practice and written advice for their first-degree relatives.~In addition to oral counseling to the patient, written advice will be provided to patients for their relatives focusing on sun protection, self-skin examination, medical skin examination, increased risk of melanoma for first-degree relatives, who should also be informed orally by the patients to protect themselves from UV radiation, perform self-skin examination and ask their GP or dermatologist to perform annual skin examinations."
2948197|NCT02917460|Experimental|Enrollees|Enrollment of healthy and affected subjects to collect samples and data for a pediatric genomic Biorepository. Data includes genomic sequencing and resultant molecular diagnostic results, if any.
2948198|NCT02917447|Experimental|DESTRESS-WV|Tailored online intervention for PTSD for women Veterans with coach support.
2948199|NCT02917447|Placebo Comparator|Phone Monitoring|Weekly check-in calls from a study coach.
2948200|NCT02917434|Active Comparator|Patients with PsA and obesity|Low Energy liquid Diet (LED)
2948201|NCT02917434|Other|Patients with obesity|Low Energy liquid Diet (LED)
2948202|NCT02917421|Experimental|Cohort 1|"(Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.~Radiation therapy : Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost."
2948284|NCT02916862|Experimental|Soluble Corn Fiber (SCF) + Calcium|This group will receive 12 g/d of soluble corn fiber (SCF) + 600 mg/d of elemental calcium carbonate, administered twice a day
2948203|NCT02917421|Experimental|Cohort 2|"In addition to receiving radiation to the original tumor bed, patients will also receive radiation to Level III axillary nodes and Supraclavicular nodes: 3D-CRT or IMRT at 2.7 Gy X 15 fraction (40.50 Gy)~Radiation Therapy : Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost."
2948204|NCT02917408||Primary biliary cholangitis during January 2001 to July 2016|
2948205|NCT02917395|Experimental|echo|"Population study- patients with obstructive hypertrophic cardiomyopathy that are treated with disopyramide.~Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide."
2948206|NCT02917382||Waiting list for liver transplant|Patients on the waiting list for liver transplant treated at ambulatory liver transplant of Hospital of Clinics of the Federal University of Minas Gerais
2948207|NCT02917382||Undergoing liver transplantation|Patients undergoing liver transplantation treated at ambulatory liver transplant of Hospital of Clinics of the Federal University of Minas Gerais
2948208|NCT02917369||Normal lung tissue|Normal lung tissue from LCLC patients
2948209|NCT02917369||LCLC tissues|LCLC tissues from LCLC patients
2948210|NCT02917369||Metastasis tissues|Metastasis tissues from LCLC patients
2948211|NCT02917356|Experimental|Spiritual laying on of hands group|"Spiritist Passe - performed by spiritual healers from the religion Spiritism (5 min, once a week, for 8 weeks)~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
2948212|NCT02917356|Active Comparator|Non-spiritual Laying on of Hands group|"Non-spiritual Laying on of Hands - performed by lay persons (5 min, once a week, for 8 weeks)~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
2948213|NCT02917356|Sham Comparator|Control Group (CG)|"Sham/ Control Group (CG) - performed by lay persons. They will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands (5 min, once a week, for 8 weeks)~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
2948214|NCT02917343|Experimental|intervention arm|participants received 4 weeks of mirror therapy and repetitive task training
2948215|NCT02917330|Experimental|Strength and stretching intervention|Treatment as usual + a strength and stretching intervention together with a physiotherapist
2948216|NCT02917330|No Intervention|Control group|Treatment as usual
2948217|NCT02917304|Experimental|GC3110A vaccine group|Participants administered a single dose of GC3110A(Quadrivalent Influenza Vaccine).
2948218|NCT02917291|Experimental|FAB117-HC (Ph 1)|Patients with acute traumatic spinal cord injury grading AIS A (6 patients)
2948219|NCT02917291|Other|Control group (Ph 2)|Patients with acute traumatic spinal cord injury grading AIS A or B (20 patients)
2948220|NCT02917291|Experimental|FAB117-HC (Ph 2)|Patients with acute traumatic spinal cord injury grading AIS A or B (20 patients)
2948221|NCT02917278|Experimental|Meals|High-protein renal-specific meals
2948222|NCT02917278|No Intervention|Control|No Meals
2948223|NCT02917252|Active Comparator|Intervention|Subjects drink 3-hydroxybuturate
2948224|NCT02917252|Placebo Comparator|Placebo|Subjects drink saline
2948225|NCT02917226|Experimental|Clinical decision support and monitoring system|
2948226|NCT02917226|No Intervention|Control Group|
2948227|NCT02917213||StudyGroup|"A cohort of 92 patients with first ST elevation acute myocardial infarction (AMI), sinus rhythm, and LV ejection fraction < 45% in the first 24-72 h after symptoms onset.~In the first 24 hours after enrollment a coagulation blood test, a Doppler echocardiogram exam, a Carotid duplex ultrasound exam, a Transcranial Doppler monitoring and a Reveal LINQ insertable cardiac monitoring system will be 1:1 randomly implanted.~A clinical examination (including neuropsiquiatric evaluation), a Doppler echocardiogram exam, a cardiac MRI and a brain MRI will be performed after a week and after 6 months after enrollment."
2948228|NCT02917200|Active Comparator|MOX + CTRL|Moxifloxacin, 400 mg/day oad, 5 days + Negative control, tid, 7 days
2948229|NCT02917200|Experimental|MOX + DAV132 7.5 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g tid, 7 days
2948230|NCT02917200|Experimental|MOX + DAV132 7.5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g bid, 7 days
2948231|NCT02917200|Experimental|MOX + DAV132 5 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g tid, 7 days
2948232|NCT02917200|Experimental|MOX + DAV132 5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g bid, 7 days
2948233|NCT02917200|Experimental|MOX + DAV132 3.3 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3.3 g tid, 7 days
2948234|NCT02917200|Experimental|MOX + DAV132 3 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3 g bid, 7 days
2948235|NCT02917200|Experimental|MOX + DAV132 2 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 2 g tid, 7 days
2948236|NCT02917200|Experimental|MOX + DAV132 1.5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1.5 g bid, 7 days
2948237|NCT02917200|Experimental|MOX + DAV132 1 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g tid, 7 days
2948238|NCT02917200|Experimental|MOX + DAV132 1 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g bid, 7 days
2948239|NCT02917200|Other|CTRL|Negative control, tid, 7 days
2948240|NCT02917187|Experimental|Randomized Group 1|After two week run-in, BIIB074 three times a day (TID) followed by placebo (TID) after two week washout period
2948241|NCT02917187|Experimental|Randomized Group 2|After two week run-in, Placebo three times a day (TID) followed by BIIB074 (TID) after two week washout period
2948242|NCT02917174|Experimental|mobile management|use mobile management to improve asthma control
2948243|NCT02917174|Other|Traditional management|use Traditional management to improve asthma control
2948244|NCT02917161|Experimental|Prostatic Artery Embolization (PAE)|PAE is performed 6weeks before RALP
2948245|NCT02917148||aGVHD|Patient who undergo allogeneic transplant with clinical and/or biopsy-proven diagnosis of aGVHD within the first 100 days post-transplant.
2948246|NCT02917148||non aGVHD|Patients who undergo allogeneic transplant but do not develop aGVHD.
2948286|NCT02916862|Placebo Comparator|Placebo|This group will receive a similar supplement without SCF or calcium
2948249|NCT02917122|Active Comparator|sertraline + active tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
2948250|NCT02917109|Experimental|LearningRx cognitive training|The intervention is a 60-hour, clinician-delivered cognitive training program.
2948251|NCT02917096|Experimental|Treatment (ruxolitinib phosphate, chemotherapy,allogeneic HCT)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV on days -9 to -5, melphalan IV over 20 minutes on day -4, and ruxolitinib phosphate PO BID on days -3 to 30 with a taper for 2-3 weeks in the absence of disease progression or unacceptable toxicity. Patients being treated with ruxolitinib phosphate prior to allogeneic HCT as standard therapy may continue receiving ruxolitinib phosphate.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously beginning on day -3 and convert to PO daily when the patient is able to tolerate and absorb oral medications. Patients also receive sirolimus PO daily beginning on day -3. Treatment continues in the absence of GVHD.~STEM CELL TRANSPLANT: Patients undergo allogeneic HCT on day 0."
2948252|NCT02917083|Experimental|CD30.CAR T Cells|"Each patient will receive one infusion of CAR modified T cells.~Unless post autologous transplant, patients will receive Cyclophosphamide and Fludarabine to induce lymphopenia.~Patients post autologous stem cell transplantation will receive T cell infusion starting at least 14 days after the date of transplant, unless there is clear evidence of relapse, then T-cell infusion can occur at any time after transplant. No lymphodepleting chemotherapy will be given to these patients."
2948253|NCT02917070||Patients|Patients who have chronic kidney diseases
2948254|NCT02917070||Healthy controls|Healthy subjects
2948255|NCT02917057||Exenatide once weekly initiators|Type 2 diabetes patients who initiated exenatide once weekly treatment during the index period
2948256|NCT02917057||Basal Insulin initiator cohort|Type 2 diabetes patients who initiated basal insulin treatment in the index period
2948257|NCT02917044|Active Comparator|Group A - Standard Care|The operator will attempt to complete the WACA lesion set using standard techniques. These include ablating any obvious gaps in the lesion set, ablating at the WACA line in a location radial to the earliest PV signal measured by the Orion catheter situated within the PV, and guided by amplitude and dV/dt of signals along the WACA lesion set measured using the mapping catheter. If this fails the operator will resort to OSA as per their usual practice.
2948258|NCT02917044|Experimental|Group B - Rhythmia mapping|The operator will form Rhythmia maps focussing on the region of the WACA line surrounding the non-isolated vein(s) whilst pacing from CS. This will be used as a means of targeting RF ablation to gaps in the WACA line (in addition to use of standard observation of signals as per group A). If this fails then the operator will resort to OSA as per their usual practice.
2948259|NCT02917031|Active Comparator|Saxagliptin|one tablet of saxagliptin 5 mg or 2.5 mg + one placebo capsule matching sitagliptin
2948260|NCT02917031|Active Comparator|Sitagliptin|one capsule of sitagliptin 100 mg or 50 mg + one placebo tablet matching saxagliptin
2948261|NCT02917031|Placebo Comparator|Placebo|one placebo tablet matching saxagliptin + one placebo capsule matching sitagliptin
2948262|NCT02917018|Active Comparator|Dexmedetomidine 1|patients will receive dexmedetomidine 1 mic/kg
2948263|NCT02917018|Active Comparator|Dexmedetomidine 0.75|patients will receive dexmedetomidine 0.75 mic/kg
2948264|NCT02917018|Active Comparator|Dexmedetomidine 0.5|patients will receive dexmedetomidine 0.5 mic/kg
2948265|NCT02917005|Experimental|Palbociclib Arm|Palbociclib (Pfizer) 125mg/day orally for 3 weeks followed by 1 week off plus Exemestane (Pfizer) 25mg/day orally continuously plus Goserelin (Astrazeneca) 3.6 mg SC given every 28 days
2948266|NCT02917005|Active Comparator|Control Arm|Exemestane (Pfizer) 25mg/day orally continuously plus Goserelin (Astrazeneca) 3.6 mg SC given every 28 days
2948267|NCT02916992|Active Comparator|Spontaneous pneumothorax patients 1|"Patients who were treated for spontaneous pneumothorax in Rijnstate hospital. Interventions: visit to out-patient clinic,CT scan of pulmones."
2948268|NCT02916992|Active Comparator|Spontaneous pneumothorax patients 2|"Patients who were treated for spontaneous pneumothorax in Rijnstate hospital. Interventions: withdrawal of blood sample for DNA analyses,"
2948269|NCT02916979|Other|Conditioning Regimen|Fludarabine, Busulfan, Rabbit ATG, Methotrexate
2948270|NCT02916966||ALS Patients in Case-Control|ALS patients enrolled by Cleveland Clinic Foundation (CCF)
2948271|NCT02916966||Non-neurodegenerative patients in case control|Non-neurodegenerative patients enrolled by CCF
2948272|NCT02916966||Non-neurodegeneration population in population control|Non-neurodegenerative general population enrolled by ABS mailing system from DHMC
2948273|NCT02916966||ALS Patients in State of OH|ALS registry of all cases in Ohio
2948274|NCT02916940|Experimental|Diprophos|Patients having had a sprain of the long fingers, within 2 weeks of consultation. This group will receive a single injection of corticoids.
2948275|NCT02916940|No Intervention|Control group|Patients having had a sprain of the long fingers (Eaton classification type I and II), within 2 weeks of consultation. This group will receive the standard of care treatment, without injection of corticoids.
2948276|NCT02916927|Experimental|Ketamine IV infusion|Ketamine 0.3 mg/kg in 100 mL normal saline minibag infused over 15 minutes. Placebo: 10 mL normal saline in syringe pushed over 1 minute. Masking: placebo normal saline minibags and placebo syringes will appear identical to the normal saline minibus and syringes with ketamine.
2948277|NCT02916927|Active Comparator|Ketamine IV push|Ketamine 0.3 mg/kg in a syringe pushed over 1 minutes. Placebo: 100 mL normal saline minibag infused over 15 minutes. Masking: placebo normal saline minibags and placebo syringes will appear identical to the normal saline minibus and syringes with ketamine.
2948278|NCT02916914|Other|Q2 feeding|feeding intervals: 2 hours
2948279|NCT02916914|No Intervention|Q3feeding|feeding intervals: 3 hours
2948280|NCT02916901|Experimental|CKD-519 200mg|CKD-519 tab(formulation II) 200mg (100mg X 2tabs)
2948281|NCT02916901|Placebo Comparator|Placebo|placebo
2948282|NCT02916888||Care provided by general pediatrician|Standard of care management of atopic dermatitis by general pediatrician. This includes an initial visit with a 2-week follow-up.
2948283|NCT02916888||Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by pediatric dermatologist. This includes an initial visit with a 2-week follow-up.
2948427|NCT02915874|No Intervention|Control|
2948287|NCT02916849|Experimental|Safe Step - Health Care Centre|Participants will be recruited informed and asked for participation in the study by health care professionals. If included in the study, and choosing the Safe Step exercise program as intervention, participants will be given a green prescription for exercise using the application Safe Step. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises in the application. During the four month intervention the participants will create weekly exercise plan, keep a digital exercise diary, and receive motivational feed-back within the system. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
2948288|NCT02916849|Active Comparator|OEP - Health Care Centre|Participants will be recruited informed and asked for participation in the study by health care professionals. If included in the study, and choosing the Otago Exercise Program as intervention in the study participants will be given a green prescription for exercise with the Otago Home Exercise Programme-booklet. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises using the booklet for guidance. During the four month intervention the participants will keep a paper-based exercise diary that will be sent to the researchers on a monthly basis. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
2948289|NCT02916849|Experimental|Safe Step - Advertising|Participants are recruited through meetings at senior citizens organisations and interviewed by telephone for background data and choice of intervention before inclusion. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises in the Safe Step application. During the four month intervention the participants will create weekly exercise plan, keep a digital exercise diary, and receive motivational feed-back within the system. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time
2948290|NCT02916849|Experimental|Safe Step mentors- Advertising|This arm is exactly the same as the Safe Step Advertising group except the participants will be invited to attend group meetings with peer mentors, once a month during the intervention. The peer mentors are older adults earlier involved in the research project . They will act as role models and encourage the participants throughout the four months of exercise.
2948291|NCT02916849|Active Comparator|OEP - Advertising|Participants are recruited through meetings at senior citizens organisations and interviewed by telephone for background data and choice of intervention before inclusion. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises using the Otago booklet for guidance. During the four month intervention the participants will keep a paper-based exercise diary that will be sent to the researchers on a monthly basis. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
2948292|NCT02916836||With TDC sheet|Use of therapeutic drug conciliation sheet (TDC) by the hospital and transmitted to the family practitioner with other usual documentation
2948293|NCT02916836||Without TDC Sheet|transmission of usual documentation only to the family practitioner
2948294|NCT02916810|Active Comparator|Active rTMS stimulation|Real active rTMS stimulation.
2948295|NCT02916810|Sham Comparator|Sham rTMS stimulation|Sham repetitive TMS stimulation.
2948296|NCT02916797|Experimental|Stepping training with feedback|Subjects stand in a step standing position with placing the affected leg on the load cells of the VWTM and the non-affected leg slightly backward outside the load cells, look forward to light bars of the displayed section which will be set at their eye level. Then subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can. Subjects repetitively practice the task for 30 minutes with a period of sufficient rest as required.
2948297|NCT02916797|No Intervention|Stepping training without feedback|Subjects will be trained and instructed the same as the experimental group but without using the displayed section, for approximately 30 minutes/day (excluding rest periods), 5 days/week, for 4 week. Then, every subject will be trained to walk overground with or without a walking device for 10 minutes in order to promote transferability of the part-task practice to the whole/target task. Subjects still receive routine treatments from other rehabilitation professionals as needed during participation in the study.
2948298|NCT02916784||Sit-to-stand: Pass|The subjects seated on a standard armless chair with their back upright at 90 degrees against the backrest of the chair, feet placement on the floor with the heels at 10 cm behind the knees and their arms on their sides. Then they were instructed to stand up from the chair without using the arms. The ability was recorded as 'pass' if the subjects could safely rise from the chair without using their arms and with no more than contact guarding assist.
2948299|NCT02916784||Sit-to-stand: Fail|The subjects seated on a standard armless chair with their back upright at 90 degrees against the backrest of the chair, feet placement on the floor with the heels at 10 cm behind the knees and their arms on their sides. Then they were instructed to stand up from the chair without using the arms. The ability was recorded as 'fail' if the subjects could not rise from the chair without using their arms and/or with more than contact guarding assist.
2948300|NCT02916771|Experimental|Ixazomib|"Cycles 1-9~Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle~Lenalidomide is administered orally on days 1-21 on a 28 days cycle~Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle~Cycle 10-24~Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle~Lenalidomide is administered orally on days 1-21 on a 28 days cycle~Supportive measures consistent with optimal patient care may be given throughout the study"
2948301|NCT02916758|Experimental|Let's Go Community Mobility Program|Participation in 4 week program
2948302|NCT02916745|Experimental|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of 2 mg/kg-porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, a laser light will be applied to the tumor.
2948303|NCT02916732||Module 1|Identification and monitoring of pregnant women who develop clinical signs of acute infection due to ZIKV (standard monitoring report)
2948304|NCT02916732||Module 2|Monitoring of pregnant women with a suspected embryofetopathy (standard monitoring report)
2948305|NCT02916732||Module 3|Trimester biological collection of all pregnant women during the outbreak of Zika (standard monitoring report)
2948306|NCT02916732||Module 4|Biological collection of maternal blood and cord blood collected during the delivery
2948307|NCT02916732||Module 5|Biological collection of maternal blood and fetal tissues of pregnant women whose pregnancies started during the outbreak of Zika , ends in an spontaneous abortion, Induced abortion or intrauterine fetal demise
2948308|NCT02916719|Experimental|Neo-adjuvant radiotherapy|Group of women having undergone a neo-adjuvant radiotherapy for early breast cancer.
2948309|NCT02916706|Experimental|Teneligliptin 20mg|Teneligliptin (20mg once daily) for 24 weeks
2948310|NCT02916706|Placebo Comparator|Placebo|Placebo for 24 weeks
2948311|NCT02916693|Experimental|Mirabegron|Participants take 25- 50mg oral Mirabegron tablets daily for 12 weeks,
2948312|NCT02916680|Experimental|Pancreatic islet transplantation|Pancreatic islet transplantation in the anterior chamber of the human eye
2948313|NCT02916667|Active Comparator|CNdiet|CNdiet includes chrono nutritional dietary guidelines
2948314|NCT02916667|Placebo Comparator|GDMdiet|GDMdiet includes regular GDM diet
2948315|NCT02916654|Active Comparator|sulphate iron|patients administered with sulphate iron
2948316|NCT02916654|Experimental|sucrosomial iron|patients administered with sucrosomial iron
2948317|NCT02916641|Experimental|Fuzhenghuayu+UDCA|Regular UDCA treatment combination with Fuzhenghuayu
2948318|NCT02916641|Active Comparator|Monotherapy|UDCA monotherapy
2948319|NCT02916628|Experimental|Group 1|auricular acupressure + group counseling
2948320|NCT02916628|Placebo Comparator|Group 2|placebo acupressure + group counseling
2948321|NCT02916628|No Intervention|Group 3|self-help smoking cessation
2948322|NCT02916628|No Intervention|Group 4|Non-smokers
2948323|NCT02916615|Active Comparator|High nitrate vegetables|During 5 weeks subjects receive 100-150 g of a leafy green vegetable (High nitrate vegetables) per day and placebo pills containing 300 mg KCl (2 x 150 mg).
2948324|NCT02916615|Placebo Comparator|Low nitrate vegetables|During 5 weeks subjects receive 100-150 g of tomatoes/sweet pepper (Low nitrate vegetables) per day and placebo pills containing 300 mg KCl (2 x 150 mg).
2948325|NCT02916615|Active Comparator|Low nitrate vegetables + nitrate|During 5 weeks subjects receive 100-150 g of tomatoes/sweet pepper (Low nitrate vegetables) per day and nitrate pills containing 300 mg KNO3 (2 x 150 mg).
2948326|NCT02916602|Experimental|Treatment|HCP1401
2948327|NCT02916602|Active Comparator|Reference|HCP0605
2948328|NCT02916589|Placebo Comparator|Baseline|The subjects will start with one week eating their normal diet.
2948329|NCT02916589|Active Comparator|Igelosa Diet|After one week the subjects will be provided the Igelosa Diet.
2948330|NCT02916576|Experimental|Blood glucose measurement|
2948331|NCT02916550|Experimental|Breathing exercise|Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
2948332|NCT02916537|Experimental|Cohort A: Pre-prostatectomy patients|Patients with prostate cancer prior to radical prostatectomy (N = 5). Single IV dose (370 MBq, or 10 mCi). Combined PET/MR imaging (prostate + whole body) will be performed following tracer injection. Patients in cohort A will undergo radical prostatectomy (plus lymph node dissection) within 12 weeks following CTT1057 PET/MR.
2948333|NCT02916537|Experimental|Cohort B: Metastatic prostate cancer|"Patients with evidence of metastatic castration-resistant prostate cancer (N = 15).~Single IV dose (370 MBq, or 10 mCi). Combined PET/MR imaging (prostate + whole body) will be performed following tracer injection. Patients in cohort B (metastatic prostate cancer) will have the option for metastatic tumor biopsy following CTT1057 PET imaging."
2948334|NCT02916524|Experimental|Model-based|Semantic Feature Analysis training will be provided in the language that was selected by the computational model.
2948335|NCT02916524|Active Comparator|Model-opposite|Semantic Feature Analysis training will be provided in the language opposite to that which was selected by the computational model.
2948336|NCT02916511|Experimental|Chemo-radiation group|"A total dose of 45Gy will be delivered in 25 fractions at 1.8Gy/fraction, 5 fractions per week in 5 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and celiac nodes.~Paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; Carboplatin AUC=2, ivgtt, d1; qw*5"
2948337|NCT02916498|Active Comparator|bipolar field shape stimulation|
2948338|NCT02916498|Experimental|alternative field shape stimulation|
2948339|NCT02916485|Experimental|Bioresorbable scaffold|Percutaneous coronary intervention (PCI) with a sirolimus-eluting resorbable coronary magnesium scaffold
2948340|NCT02916472|Experimental|CyberCycling - Aerobic Exercise|30-60 mins/week, 3 days/week supervised stationary cycling with exergaming/videogaming for 12 weeks
2948341|NCT02916472|Active Comparator|Control Stretching - Resistance Bands|2 days/week at home for 12 weeks
2948342|NCT02916459|Active Comparator|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 21G EBUS-TBNA needle
2948343|NCT02916459|Experimental|Flex 19G EBUS-TBNA|Mediastinal and hilar lymph node sampling using the flexible 19G EBUS-TBNA needle
2948344|NCT02916446|Experimental|Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, daily administration
2948345|NCT02916446|Placebo Comparator|Placebo|Placebo patch, daily administration
2948346|NCT02916433|No Intervention|Usual care|This group will continue to receive treatments that have already been initiated to manage bronchial secretions.
2948347|NCT02916433|Experimental|Octreotide|This group will continue to receive treatments that have already been initiated to manage bronchial secretions. Additionally, this group will receive parenteral octreotide.
2948348|NCT02916420|Experimental|Treatment|Pomalidomide plus low-dose Dexamethasone
2948349|NCT02916407|Active Comparator|Sevoflurane Group|The patients will maintained general anesthesia with sevoflurane.
2948350|NCT02916407|Experimental|Desflurane Group|The patients will maintained general anesthesia with desflurane.
2948351|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+++|Patients in this group had IGF-1R overexpression tumors and did not receive any treatment before this study.
2948428|NCT02915861||EXPa|Scrub typhus patients: Group A
2948429|NCT02915861||EXPb|Scrub typhus patients: Group B
2948352|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R++|Patients in this group had IGF-1R moderate expression tumors and did not receive any treatment before this study.
2948353|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+|Patients in this group had IGF-1R low expression tumors and did not receive any treatment before this study.
2948354|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：healthy volunteers|Patients in this group who are healthy volunteer.
2948355|NCT02916381|Experimental|PEC block|Ultrasound-guided PEC block after induction of general anaesthesia.
2948356|NCT02916381|Sham Comparator|Control|No ultrasound-guided PEC block; only general anaesthesia will be provided.
2948357|NCT02916368||with surgery|
2948358|NCT02916368||with chemotherapy or radiotherapy|
2948359|NCT02916355|Experimental|Normal BMI|Healthy young men, normal BMI (BMI >18 and ≤28 kg/m2) will receive interventions Anakinra and sodium Chloride (NaCl)
2948360|NCT02916355|Experimental|Overweight|Healthy young men (BMI >30 and ≤35 kg/m2) will receive interventions Anakinra and NaCl
2948361|NCT02916342|Active Comparator|Interscalene brachial plexus block|An ultrasound-guided interscalene brachial plexus block will be performed prior to surgery.
2948362|NCT02916342|Experimental|Supraclavicular-axillary nerve blocks|A dual supraclavicular-axillary nerve blocks will be performed prior to surgery.
2948363|NCT02916329|Experimental|68Ga-ZEGFR: EGFR++|Patients in this group had EGFR-activating mutant and EGFR high expression tumors and did not receive any treatment before this study.
2948364|NCT02916329|Experimental|68Ga-ZEGFR: EGFR+|Patients in this group had EGFR-activating mutant and EGFR medium expression tumors and did not receive any treatment before this study.
2948365|NCT02916329|Experimental|68Ga-ZEGFR: EGFR-|Patients in this group had no EGFR expression tumors and did not receive any treatment before this study.
2948366|NCT02916329|Experimental|68Ga-ZEGFR: EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
2948367|NCT02916329|Experimental|68Ga-ZEGFR:unknown EGFR status|Patients without the EGFR status measurement results and did not receive any treatments were classified in this group.
2948368|NCT02916329|Experimental|68Ga-ZEGFR: EGFR|Patients in this group had EGFR expression tumors and had receive some treatment before this study.
2948369|NCT02916316||Chemo immunotherapy|All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline (R-COMP; Sec. 648 DM) administered every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
2948370|NCT02916303||Patients|Patients followed up at least during 3 years at PAFIP clinic
2948371|NCT02916290|Experimental|Fuzhenghuayu+UDCA|Regular UDCA treatment combination with Fuzhenghuayu
2948372|NCT02916290|Active Comparator|Monotherapy|UDCA monotherapy
2948373|NCT02916264|Active Comparator|a scalp block|A standard scalp block ,with 0.5% bupivacaine total dose < 3 mg/kg, is performed by an anesthesiologist.
2948374|NCT02916264|No Intervention|no scalp block|An anesthesiology will pretend to perform the scalp block,
2948375|NCT02916251|Experimental|ZP4207(dasiglucagon)|Intervention: ZP4207(dasiglucagon) glucagon analogue (4 mg/mL) planned doses: 0.03, 0.08, 0.2 and 0.6 mg at euglycemic and hypoglycemic conditions.
2948376|NCT02916251|Active Comparator|Glucagon (Native glucagon)|Intervention: Glucagon (Native glucagon) 1 mg/mL as active comparator planned doses: 0.03, 0.08 and 0.2 mg at euglycemic conditions.
2948377|NCT02916238|Experimental|Measurement Based Care|Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
2948378|NCT02916238|Active Comparator|Enhanced Usual Care|Depression symptoms monitored at 3 month interval; results from PHQ-9 available to ART clinic physicians.
2948379|NCT02916225|Active Comparator|High intensity interval training|exercise protocol for high intensity/aerobic interval training as described by ESC statement (Mezzani et al.)
2948380|NCT02916225|Placebo Comparator|Moderate Continuous Training|exercise protocol for continuous aerobic training as described by ESC statement (Mezzani et al.)
2948381|NCT02916212|Experimental|Experimental|Hospital units where alarms have been optimized
2948382|NCT02916212|No Intervention|Control|Hospital units where alarms remain unchanged
2948383|NCT02916199|Experimental|Needle knife fistulotomy|"Device: Needle knife fistulotomy Disease: Common bile duct stone, Malignant biliary stricture, Benign biliary stricture, Benign pancreatic disease, biliary sphincter of Oddi dysfunction Indication: High risk of post-endoscopic retrograde cholangiopancreatography pancreatitis~- Intervention: canulation of ampulla of Vater Intervention: canulation of ampulla of Vater"
2948384|NCT02916199|Active Comparator|conventional cannulation|"Device: conventional canulation catheter Disease: Common bile duct stone, Malignant biliary stricture, Benign biliary stricture, Benign pancreatic disease, biliary sphincter of Oddi dysfunction Indication: High risk of post-endoscopic retrograde cholangiopancreatography pancreatitis~- Intervention: canulation of ampulla of Vater Intervention: canulation of ampulla of Vater"
2948385|NCT02916186|Experimental|Tunnel technique with acellular dermal matrix|the tunnel technique involves separation of the gingiva, then acellular dermal matrix interposed between the flap and the root surface.
2948386|NCT02916186|Active Comparator|subepithelial connective tissue graft|Tunnel is prepared and sub-epithelial connective tissue graft is harvested from the palate and placed under the flap.
2948387|NCT02916173|Experimental|Human chorionic gonadotrophin group|Patients will receive Human chorionic gonadotrohpin injection 5000 unit
2948388|NCT02916173|Active Comparator|Human chorionic gonadotrophin + agonist group|patients will receive both Human chorionic gonadotrophin (2500 unit) and gonadotrophin releasing hormone agonist 1mg leuprolide acetate
2948389|NCT02916160|Experimental|SACUBITRIL - VALSARTAN|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.
2948390|NCT02916147|Experimental|volatile anesthesia|Use 2-3% sevoflurane to maintain the anesthesia during OLV surgery with bispectral index (BIS) 40-60.
2948391|NCT02916147|Active Comparator|intravenous anesthesia|Anesthesia was maintained by a continuous infusion of propofol （4-6mg/kg/h）with BIS 40-60.
2948392|NCT02916134|Active Comparator|Operative Intervention|Laparoscopic +/- open appendicectomy, with antibiotics at induction and 3 further doses of intravenous antibiotics. Co-amoxiclav, or cefuroxime and metronidazole if previous rash-allergy to penicillin.
2948393|NCT02916134|Experimental|Antibiotic Treatment|Intravenous antibiotics until clinical improvement and then 5 further days of oral antibiotics. Co-amoxiclav, or if rash-allergy to penicillin, cefuroxime and metronidazole.
2948394|NCT02916121|Experimental|folic acid 5 mg/cap|folic acid 5 mg/d and vitamin B12 500 ug/d
2948395|NCT02916121|Placebo Comparator|placebo|placebo
2948396|NCT02916108||Concussion|"Study group include up to 30 children with history of concussion in the last 24 hours before admitting to emergency department.~Reading EEG."
2948397|NCT02916108||Isolated limb injury|"Cohort group include up to 30 children with history of isolated limb injury in the last 24 hours before admitting to emergency department.~Reading EEG."
2948398|NCT02916095|Experimental|Kanitinib|Subjects will be enrolled in cohorts at different dose levels in order to evaluate the safety,tolerability and determine the maximum tolerated dose and recommended phase II dose of kanitinib.
2948399|NCT02916082||Prolonged pregnancy|Pregnancies with 41 weeks or more of gestation determined by a reliable last menstrual period or early fetal ultrasound.
2948400|NCT02916069|Active Comparator|Group 1 (Multimodal brain monitoring)|Patients will be monitored with combination of brain monitoring; Nearinfrared Spectroscopy (NIRS), Transcranial Doppler (TCD), and Bispectral index (BIS). Interference will be done to optimize the medical condition based on such monitors.
2948401|NCT02916069|No Intervention|Group 2|Patients will be monitored without any interference based on such monitors
2948402|NCT02916056|Experimental|Azeliragon 5 mg|Azeliragon (TTP488) 5mg orally once daily for 2 years
2948403|NCT02916043||Cardiovascular surgery with cardiopulmonary bypass|Cardiovascular surgery with cardiopulmonary bypass
2948404|NCT02916030||Group 1 (hemorrhagic stroke)|All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.
2948405|NCT02916030||Group 2 (Ischemic stroke)|All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.
2948406|NCT02916017||Participants receiving adalimumab|Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis
2948407|NCT02916004|Other|Measurement of NFR and PDR|Diagnostic intervention: excite NFR and PDR in comparison to behavior pain scale (BPS)
2948408|NCT02915991||All patients|This is a single-arm study, so all patients enrolled will be in this arm and will undergo diagnostic catheterization procedure as per standard hospital care.
2948409|NCT02915978|Experimental|Lower Dose Fentanyl|Lower dose Fentanyl delivered via sublingual spray every 4 hours.
2948410|NCT02915978|Experimental|Higher Dose Fentanyl Sublingual Spray|Higher dose Fentanyl delivered via sublingual spray every 4 hours.
2948411|NCT02915978|Placebo Comparator|Placebo|Placebo (matching Fentanyl) delivered via sublingual spray every 4 hours.
2948412|NCT02915965|Experimental|DCX and surgery|docetaxol 60mg/m2 iv d1 and cisplatin 30mg/m2 iv d1-2 and capecitabine 850mg/m2 bid po d1-14 repeated every 21 days for 4-6 cycles, followed by surgery of Ivor Lewis Esophagectomy
2948413|NCT02915952|Active Comparator|Zip Closure Device|The Zip device is a non-invasive, single use, sterile medical device for closure of the skin layer for surgical incisions or laceration repair.
2948414|NCT02915952|Active Comparator|Conventional Sutures|Conventional subdermal (subcuticular) absorbable sutures
2948415|NCT02915939|Experimental|Treatment Group|The Residential Care Transition Module (RCTM) includes six in-person consultation sessions over a 4-month period conducted by a trained Transition Counselor (TC) with a primary family caregiver (self-identified as the person most responsible for providing on-going assistance to the care recipient in a residential long-term care setting such (RLTC) such as a nursing home or assisted living memory care unit.
2948416|NCT02915939|No Intervention|Usual Care Group|The usual care control group will adjust for the social engagement provided to the Residential Care Transition Module (RCTM )treatment condition. The Transition Counselor (TC) will provide quarterly contact calls and the research coordinator will send a bi-annual project newsletter to all participants. If caregivers in the control group initiate contact with the TC for care needs, the TC will provide information and referral support.
2948417|NCT02915926|Active Comparator|OT|standard OT
2948418|NCT02915926|Experimental|OT+OPC|occupational performance coaching
2948419|NCT02915913|Experimental|High Intensity Interval|One session for 30-60 minutes of high intensity aerobic exercise
2948420|NCT02915913|Experimental|Resistance training|One session for 30-60 minutes of resistance exercise
2948421|NCT02915913|Experimental|Plus: High Intensity Interval + Resistance Training|One session for 30-60 minutes of high intensity aerobic exercise and resistance exercise
2948422|NCT02915913|Placebo Comparator|Non-exercise|Non-exercise
2948423|NCT02915900|Experimental|Intervention|Hormone dosage is calculated by using the new method Gonadotropin removal test.
2948424|NCT02915900|Active Comparator|Routine IVF method|Hormone dosage is chosen by the clinician according to standard clinical routine.
2948425|NCT02915887|Experimental|cervical taping|Participants received treatment including elastic taping application to the neck. They were assessed 3 times: Pre taping, 20 minutes post-taping on day 1, and 7 days post-taping.
2948426|NCT02915874|Active Comparator|Acceptance and Commitment Therapy Behavioral Intervention|"Subjects randomized to the ACT Intervention group will attend a 1-day group workshop in which two broad areas will be covered:~Behavioral Change training will involve a) teaching subjects how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and those related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise;~Mindfulness and Acceptance Training will emphasize new ways of managing troubling thoughts, feelings, and physical sensations (i.e. learning how to recognize, and develop cognitive distances from unhelpful thoughts such as I can't take this anymore and learning how to willingly face experiences that cannot be changed). In-session exercises and practice will be heavily emphasized during the group intervention and handouts will be distributed for home use."
2948433|NCT02915835|Active Comparator|riociguat|Riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
2948434|NCT02915835|Placebo Comparator|Placebo|Matching placebo tablets: 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg matching placebo tablet.
2948435|NCT02915822|Experimental|Minimally Invasive Chevron/Akin osteotomy|Minimally invasive technique to surgically correct Hallux Valgus
2948436|NCT02915822|Active Comparator|Open Scarf/Akin osteotomy|Open technique to surgically correct Hallux Valgus
2948437|NCT02915809|Experimental|GC3110B Vaccine Group|Participants randomized to receive a single dose of GC3110B vaccine (Biological: GC3110B vaccine).
2948438|NCT02915809|Active Comparator|GCFLU Quadrivalent Inj.|Participants randomized to receive a single dose of GCFLU Quadrivalent Inj. vaccine (Biological: GCFLU Quadrivalent Inj. vaccine).
2948439|NCT02915796|Experimental|G-CSF + CD133(+) cells + PTA|Intramuscular injection of G-CSF along with transarterial infusion of CD133 (+) cells combined with percutaneous transluminal angioplasty
2948440|NCT02915796|Active Comparator|PTA + G-CSF|Percutaneous transluminal angioplasty along with intramuscular injection of G-CSF
2948441|NCT02915796|Placebo Comparator|Only PTA|Only Percutaneous transluminal angioplasty along with placebo infusion of sodium chloride injection
2948442|NCT02915783|Experimental|lenvatinib 18 mg/day and everolimus 5 mg/day|Participants will receive initial doses of lenvatinib 18 milligrams per day (mg/day) (one 10-mg capsule and two 4-mg capsules) and everolimus 5 mg/day (5-mg tablets). Capsules and tablets are to be taken orally in immediate succession once a day (QD), and dosing is recommended to occur at approximately the same time each morning (consistently either with or without food).
2948443|NCT02915770|Experimental|participants receive cholangiojejunostomy|participants will receive hepatectomy、cholangiojejunostomy and T-tube Drainage
2948444|NCT02915770|Active Comparator|participants receive no cholangiojejunostomy|participants will receive hepatectomy and T-tube Drainage
2948445|NCT02915757|Experimental|Depressive patients|EDOR test on depressed patients with or without personal history of suicidal behavior
2948446|NCT02915744|Experimental|NKTR-102|In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.
2948447|NCT02915744|Active Comparator|Treatment of Physician's Choice (TPC)|In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.
2948448|NCT02915718|Experimental|experimental group|protein A immunoadsorption for 5 days
2948449|NCT02915718|No Intervention|control group|non intervention
2948450|NCT02915705|Experimental|burosumab|0.8 mg/kg starting dose, administered every 2 weeks by subcutaneous injection
2948451|NCT02915705|Active Comparator|Active Control|"Multiple daily doses of oral phosphate and active vitamin D therapy, individualized for each subject at the Investigator's discretion.~In the study extension period, eligible subjects that cross-over onto burosumab will receive 0.8 mg/kg starting dose, administered every 2 weeks by subcutaneous injection."
2948452|NCT02915692||ERASE Silver Coated Foley Catheters|Subjects given silver catheters from an ERASE CAUTI Tray.
2948453|NCT02915692||Comparator Silver Coated Catheter|Comparator silver urinary catheter
2948454|NCT02915679|Other|Study participant|"All the participants performed blood sample for genetic purpose, psychiatric assessment and pain investigation:~81 depressed patients admitted after a recent suicidal act (<8 days)~81 depressed subjects with a past history of suicidal act (>1month)~80 depressed subjects without any personal history of suicidal behaviour"
2948455|NCT02915666|Experimental|Digoxin combination for Melanoma|Drugs: Dabrafenib 150mg PO 2x daily, Trametinib 2 mg PO daily, and Digoxin 0.25 mg PO daily for 8-week cycles.
2948456|NCT02915653|No Intervention|Control|Control: not receiving any intervention
2948457|NCT02915653|Experimental|Intervention 1|Receiving educational materials on a new diagnostic service
2948458|NCT02915653|Experimental|Intervention 2|Receiving educational materials on a new diagnostic service
2948459|NCT02915640|Experimental|Remote technology|Remote technology will be used for an initial patient assessment after being contacted by phone from the peripheral center to transfer an acutely ill pediatric patient as assessed by the referral centre care provider.
2948460|NCT02915640|No Intervention|Control|A Nurse Practitioner or General Practitioner from a remote site has a pediatric acute care referral and arranges a transportation. There is an initial call to obtain a patient history, to provide advice to the remote caregiver to initiate specific therapies and to mobilize the specialized team to the patient.
2948461|NCT02915627|Active Comparator|Healthy participants|Non chronic kidney disease (CKD) participants. Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
2948462|NCT02915627|Active Comparator|CKD patients not on dialysis|CKD 4/5 patients not on Dialysis- Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
2948463|NCT02915627|Active Comparator|CKD patients on Dialysis|Patients having haemodialysis treatment at least 3 times per week at a London Health Sciences Centre facility-Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
2948464|NCT02915614|Active Comparator|PiMM patients|"COPD patients with the Alpha-1 antitrypsin genetic variant PiMM (Smoking-related COPD)"
2948465|NCT02915614|Experimental|PiZZ patients|COPD patients with alpha-1 antitrypsin deficiency (genotype PiZZ)
2948466|NCT02915601|Experimental|Sodium Bicarbonate|Participants assigned to oral sodium bicarbonate will receive 0.5 mEq/kg-lean body weight (LBW)/day for the entire 12 months. Participants will take ½ the daily dose in the morning and the other ½ in the evening. The number of capsules will be rounded to the nearest whole capsule. To reduce pill burden and increase compliance the maximum number of pills per day will be six.
2948467|NCT02915601|Placebo Comparator|Placebo|Subjects randomly assigned to placebo will take the same number of capsules as if they were assigned to receive 0.5 mEq/kg-LBW/day of sodium bicarbonate. Participants will take ½ the daily dose in the morning and the other ½ in the evening. The number of capsules will be rounded to the nearest whole capsule. To reduce pill burden and increase compliance the maximum number of pills per day will be six.
2948468|NCT02915588|Active Comparator|Primary Active|Early postoperative isometric activation of the rotator cuff
2948469|NCT02915588|Active Comparator|Primary Passive|Standard postoperative passive movement rehabilitation protocol
2948470|NCT02915575|Other|Control Arm (usual care)|Participants will be discharged as per usual ward discharge protocols.
2948471|NCT02915575|Other|Risk guided follow-up|Participant will be stratified for risk of CKD in three groups: Low (<1% risk of CKD), medium (1-10 % risk of CKD) and high (≥10 % risk of CKD). Specific follow-up will be guided by risk status
2948472|NCT02915562|Active Comparator|Depressive Group|GDS 15 (Geriatric Depression Score) ≥5 at baseline
2948473|NCT02915562|Active Comparator|Non-depressive Group|GDS 15 (Geriatric Depression Score) <5 Points at baseline
2948474|NCT02915549|Experimental|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
2948475|NCT02915549|Active Comparator|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
2948476|NCT02915523|Active Comparator|Entinostat plus Avelumab|Avelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with Entinostat administration on D1 and D8 of each cycle at the Maximum tolerated Dose (MTD)/RP2D as determined in the Phase Ib (Dose Determination) part of the study.
2948477|NCT02915523|Placebo Comparator|Placebo plus Avelumab|Avelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with placebo administered on D1 and D8 of each cycle.
2948478|NCT02915510|Experimental|GMP|Single arm designed, 3 day baseline, 28day on GMP
2948479|NCT02915497|No Intervention|Treatment As Usual + Resilience-Based Supportive Therapy|Routine psychosocial management of trauma patients, including Manualized Resilience-Based Therapy.
2948480|NCT02915497|Experimental|Abbreviated Early Prolonged Exposure Therapy|AEPET, including Manualized Resilience-Based supportive Therapy.
2948481|NCT02915484|Experimental|tDCS stimulation A|Intervention: Transcranial Direct Current Stimulation (tDCS) Up to 20 minutes of tDCS applied to the prefrontal cortex.
2948482|NCT02915484|Experimental|tDCS stimulation B|Intervention: Transcranial Direct Current Stimulation (tDCS) Up to 20 minutes of tDCS applied to the prefrontal cortex.
2948483|NCT02915471|Experimental|Virtual Peer-to-Peer Support Mentoring|n addition to standard medical care, adolescents in the experimental group will receive the iP2P support program, a manualized peer-mentorship program that will provide mentoring and reinforcement by peers (young adults with cancer aged 16-25 years who have learned to function successfully with their cancer to the mentored participants).
2948484|NCT02915471|No Intervention|Wait-list Control|The control group will receive usual care but without the mentorship intervention. They will be offered the iP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
2948485|NCT02915445|Experimental|CAR-T cells recognizing EpCAM|Autologous T cells from patient are engineered to expressing a special chimeric antigen receptor to recognizing EpCAM by lentiviral vector. The engineered T cells were then endowed cytotoxicity to the tumor cells and hold the potential to inhibit the advance of tumors.
2948486|NCT02915432|Experimental|3 mg/kg anti-PD-1 mAb JS001 Q2W|Subjects will be eligible for this study after they fulfill the inclusion criteria and exclusion criteria. Subjects diagnosed as the gastric adenocarcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, or head and neck squamous cell carcinoma will receive treatment at the dose of 3 mg/kg.
2948487|NCT02915432|Experimental|360 mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
2948488|NCT02915419|Active Comparator|group A|prp revascularization
2948489|NCT02915419|Experimental|group B|treatment of affected teeth using platelet rich fibrin by applying prf in steril root canal
2948490|NCT02915393||Healthy Volunteers (BC)|Healthy Volunteers with Balanced Constitution(n=10).
2948491|NCT02915393||Healthy Volunteers(QC)|Healthy Volunteers with Qi Deficiency Constitution(n=10).
2948492|NCT02915393||Healthy Volunteers(DC)|Healthy Volunteers with Damp-heat Constitution(n=10).
2948493|NCT02915393||Superficial Gastritis(SDS)|Superficial Gastritis with Spleen-qi Deficiency Syndrome(n=10).
2948494|NCT02915393||Superficial Gastritis(DS)|Superficial Gastritis with Damp-heat Syndrome(n=10).
2948495|NCT02915393||Atrophic Gastritis(SDS)|Atrophic Gastritis with Spleen-qi Deficiency Syndrome(n=10).
2948496|NCT02915393||Atrophic Gastritis(DS)|Atrophic Gastritis with Damp-heat Syndrome(n=10).
2948497|NCT02915393||Gastric Cancer(SDS)|Gastric Cancer with Spleen-qi Deficiency Syndrome(n=10).
2948498|NCT02915393||Gastric Cancer(DS)|Gastric Cancer with Damp-heat Syndrome(n=10).
2948499|NCT02915367|Experimental|SMS Reminders|Participants will receive regular SMS reminders regarding PrEP. All participants will receive adherence monitoring through a WisePill device.
2948500|NCT02915367|No Intervention|No Reminders|Participants will not receive SMS reminders. All participants will receive adherence monitoring through a WisePill device.
2948501|NCT02915354|Experimental|Etanercept, AS|The patients were diagnosed with ankylosing spondylitis and obtained the ASAS20 response after etanercept treatment. Then they were discontinued to etanercept and received no treatment except DMARDs or NSAIDs which had used before.
2948502|NCT02915328|Experimental|Stent Roadsaver® +Filterwire EZ™|The arm assess the efficacy of the combination of the stent Roadsaver® with the Filterwire EZ™ protection
2948503|NCT02915328|Experimental|Stent Roadsaver® + MO.MA Ultra|The arm assess the efficacy of the combination of the stent Roadsaver® with the MO.MA Ultra protection
2948504|NCT02915328|Experimental|Carotid Wallstent +MO.MA Ultra|The arm assess the efficacy of the combination of the Carotid Wallstent with the MO.MA Ultra protection
2948505|NCT02915328|Experimental|Carotid Wallstent + Filterwire EZ™|The arm assess the efficacy of the combination of the Carotid Wallstent with the Filterwire EZ™ protection
2948506|NCT02915315||Baseline survey period|All subjects will continue a normal diet for 3 days in which questionnaire design and anthropometric measurements will be implemented.
2948507|NCT02915315||Low-salt diet|All subjects will be instructed to maintain a low-salt diet for 7 days (3g of salt or 51.3mmol of sodium per day).
2948508|NCT02915315||High -salt diet|After washout period, all subjects will be instructed to maintain a 18g of salt or 307.8mmol of sodium per day.
2948509|NCT02915302|Active Comparator|Fluzone Quadrivalent Vaccine, 0.25-mL|Participants received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per ACIP guidance, a second 0.25-mL dose of Fluzone Quadrivalent vaccine was administered at Day 28.
2948510|NCT02915302|Experimental|Fluzone Quadrivalent Vaccine, 0.5-mL|Participants received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per ACIP guidance, a second 0.5-mL dose of Fluzone Quadrivalent vaccine was administered at Day 28.
2948511|NCT02915289|Active Comparator|Povidone Iodine|10% povidone iodine solution will be used for vaginal cleansing prior to non-emergent cesarean section. The preparation will be applied according to the manufacture guidelines with a minimum of four completed minutes of drying time before placement of surgical drapes. The group will receive standard obstetrical care, continuous fetal monitoring, and pre-operative prophylactic antibiotics at least one hour prior to skin incision.
2948512|NCT02915289|Active Comparator|Chlorhexidine gluconate|4% chlorhexidine gluconate solution will be used for vaginal cleansing prior to non-emergent cesarean section. The preparation will be applied according to manufacture guidelines. The group will receive standard obstetrical care, continuous fetal monitoring, and pre-operative prophylactic antibiotics at least one hour prior to skin incision.
2948513|NCT02915276|Active Comparator|Blastocentisis|The blastocoelic fluid will be aspirated from the embryonic cavity on day 5 or 6 of development and will be subjected to genetic analysis
2948514|NCT02915276|Active Comparator|Trophectoderm biopsy|Throphectoderm cells will be removed from the embryo on day 5 or 6 of development and will be subjected to genetic analysis
2948515|NCT02915263|Placebo Comparator|0.9% Sodium Chloride|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The placebo will consist of 0.9% Sodium Chloride per day over 5 days. Participants who are randomized to placebo will receive the same volume as they would if they were randomized to IVIG (i.e.: as if receiving IVIG at 2gm/kg) through a peripheral IV line.
2948516|NCT02915263|Experimental|IGIV-C|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The treatment will consist of IVIG administered at 2 grams/kg divided over 5 days, with a follow up treatment 3 weeks (+/-3 days) later of IVIG 1gram/kg administered over 2 day (or placebo).
2948517|NCT02915250|Experimental|BioChaperone® Combo|Individualised single subcutaneous of BioChaperone® Combo + injection of placebo (0.9% NaCl) to ensure the double dummy
2948518|NCT02915250|Active Comparator|Humalog® Mix25|Individualised single subcutaneous of Humalog® Mix25 + injection of placebo (0.9% NaCl) to ensure the double dummy
2948519|NCT02915250|Active Comparator|Humalog® and Lantus®|Individualised simultaneous subcutaneous injections
2948520|NCT02915237|Experimental|Low Dose - Concord grape juice|Daily dietary supplementation with 4 oz. of a commercially available Concord grape juice.
2948521|NCT02915237|Experimental|Moderate Dose - Concord grape juice|Daily dietary supplementation with 8 oz. of a commercially available Concord grape juice.
2948522|NCT02915237|Experimental|High Dose - Concord grape juice|Daily dietary supplementation with 16 oz. of a commercially available Concord grape juice.
2948523|NCT02915237|Placebo Comparator|Low dose - placebo beverage|Daily dietary supplementation with 4 oz. of a placebo beverage
2948524|NCT02915237|Placebo Comparator|Moderate Dose - placebo beverage|Daily dietary supplementation with 8 oz. of a placebo beverage
2948525|NCT02915237|Placebo Comparator|High Dose - placebo beverage|Daily dietary supplementation with 16 oz. of a placebo beverage
2948526|NCT02915224||Obinutuzumab|Participants will receive obinutuzumab as per Summary of Product Characteristics in daily practice along with chlorambucil for 24 months.
2948527|NCT02915211|Experimental|Consumption of Keyo|Participants will consume their normal KD and take Keyo as advised by the lead dietitian.
2948528|NCT02915198|Experimental|Metformin|Participants are randomly assigned in a 1:1 ratio to treatment with metformin XR 500 mg or matching placebo.
2948529|NCT02915198|Placebo Comparator|Placebo|Participants are randomly assigned in a 1:1 ratio to treatment with metformin XR 500 mg or matching placebo.
2948530|NCT02915185|Experimental|strength training intervention|Strength training of the affected upper limb in chronic stroke survivors
2948531|NCT02915185|Experimental|direct-current brain stimulation (tDCS)|tDCS real of sham will be applied during each session of the strength training intervention
2948532|NCT02915172|Experimental|Lenvatinib + Capecitabine|"Phase 1 Study Escalation: Group consists of participants with various solid tumors.~Dose of Lenvatinib received depends on when joining study. First group of participants receive lowest dose level of Lenvatinib. Each new group receives a higher dose of Lenvatinib than the group before it, if no intolerable side effects were seen. This continues until highest tolerable dose of Lenvatinib found.~All participants receive the same dose of Capecitabine.~Phase 2 Study Expansion: Group consists of participants with advanced breast cancer and any solid tumors with confirmed FGFR abnormalities.~Participants receive Lenvatinib at the highest dose that was tolerated in Dose Escalation Phase.~All participants receive the same dose of Capecitabine."
2948533|NCT02915159|Experimental|Abatacept|Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months
2948534|NCT02915159|Placebo Comparator|Placebo|Placebo for Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months
2948535|NCT02915146|Active Comparator|NB-UVB monotherapy|Narrowband ultraviolet B monotherapy will be used
2948536|NCT02915146|Active Comparator|NB-UVB + UVA1|Narrowband ultraviolet B combined with ultraviolet A1 phototherapy will be used
2948537|NCT02915133||MF-MB|Consecutive participants with high myopic foveoschisis are scheduled to macular buckling (MB) surgery.
2948538|NCT02915120|Active Comparator|Real Pulsed Radiofrequency|Before needle insertion, the patient's inferomedial (IM), superomedial (SM), and superolateral (SL) GN branches will be identified under ultrasound guidance. RF needles and probes will be advanced to each of the target nerves under ultrasound guidance. A 50 Hz-frequency sensorial stimulation will be applied with a threshold of < 0.5 mA to identify the nerve position, the current intensity (mA) will be reduced at < 0,2 mA. During the sensorial stimulation, the patients will be asked if they feel tingling, pain, or discomfort inside the knee. The RF probe will be maintained in place until one of those feelings is elicited. In order to avoid inactivating motor nerves, the nerve will be tested for the absence of fasciculation in the the lower extremity on stimulation of 0,5 mA at 2 Hz.
2948539|NCT02915120|Sham Comparator|Sham Pulsed Radiofrequency|Control patients will undergo the same procedure. The sensorial and motor stimulations will be applied too. The RF electrode will be then inserted through the cannula, and RF lesions will be simulated without applying pulsed RF treatment to the IM, SM and SL, GN branches for 8 minutes each GN branch and the temperature of the electrode tip was not raised.
2948540|NCT02915107|Experimental|Biofreedom|Experimental: Biofreedom BioFreedom stent at index procedure
2948541|NCT02915107|Active Comparator|Orsiro|Active comparator: Orsiro Orsiro stent at index procedure
2948542|NCT02915081|Experimental|Blue light|Subjects will be exposed to 24 hours of bright (1700 lux) blue (peak 442 nm) spectrum light the day prior to operative intervention and for the 24 hours after the operative intervention.
2948543|NCT02915081|No Intervention|Ambient light|Subjects will be exposed preoperatively to the lighting conditions of their living environment and postoperatively to the standard, white fluorescent lighting environment of the hospital.
2948544|NCT02915068|No Intervention|Control|Physicians do not receive focused education and training on patient-centered communication with the EHR
2948545|NCT02915068|Experimental|EHR-PACE|participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
2948546|NCT02915055||Patients with pain following knee arthroscopic meniscectomy|
2948547|NCT02915042|Experimental|Experimental group|Intervention group 1: pre-operative administration of IV dexmedetomidine 1mcg/kg
2948548|NCT02915042|Placebo Comparator|Placebo group|Intervention group 2: placebo
2948549|NCT02915029|Experimental|Education and Lifestyle Coaching|"Education and life style coaching includes:~education about diabetes and kidney disease Coaching /counseling about lifestyle, nutrition and medication adherence"
2948550|NCT02915029|No Intervention|Usual care (UC) control arm|once randomize to the Usual Care control group, the participants are left alone and are suggested to contact their providers for health care. The group gets labs and other survey done at 6 and 12 months of the intervention.
2948551|NCT02915016|Experimental|Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.
2948552|NCT02915016|Experimental|Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.
2948553|NCT02915016|Experimental|Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.
2948554|NCT02915016|Experimental|Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
2948555|NCT02915016|Experimental|Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
2948556|NCT02915016|Experimental|Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
2948557|NCT02915016|Experimental|Group 7: Placebo + Protein/AS01B|Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
2948558|NCT02915016|Placebo Comparator|Group 8: Placebo|Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.
2948559|NCT02915003|Experimental|E-health website intervention|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
2948560|NCT02915003|No Intervention|Control|usual health insurance navigation, and ACA materials provided by social service agencies and clinics where individuals seek services.
2948561|NCT02914990|Experimental|BPI-15086|BPI-15086, orally administered daily
2948562|NCT02914977|Experimental|Low-dose daunorubicin (DNR)|Eligible patients will be treated with 5 days of low dose daunorubicin (DNR) for one cycle only.
2948563|NCT02914964|Experimental|Swank Diet|Individuals randomized to this arm will follow a low saturated fat diet starting at week 12.
2948564|NCT02914964|Experimental|Wahls Elimination Diet|Individuals randomized to this arm will follow a modified paleolithic diet that eliminates all grains, dairy, eggs, legumes, and nightshade vegetables/spices starting at week 12.
2948565|NCT02914951|Experimental|Cognitive-Behavioral Therapy|CBT is a behavioral intervention where children are taught various skills for coping with frustration and parents are taught various strategies for managing situations that can be anger-provoking for their child.
2948566|NCT02914938|Experimental|ME-401 Alone|This is an open-label, dose escalation study with 4 planned cohorts which may enroll up to 61 subjects.
2948567|NCT02914938|Experimental|ME-401 in Combination with Rituximab|This is an open-label study evaluating the safety, efficacy, and pharmacokinetics of ME-401 in combination with rituximab. There are two planned cohorts which may enroll up to 72 subjects.
2948568|NCT02914925|Experimental|ArmeoSpring/CIT|Group will receive ArmeoSpring and CIT therapy
2948569|NCT02914912||GALS symptomatic patients group|Patents With symptoms of chronic mesenteric ischemia shall be investigated with GALS.
2948570|NCT02914899||focus groups with drivers|The investigators will conduct a series of 4-6 focus groups with Chinese livery drivers who (currently, or in the past) smoke, and a series of 12-15 in-depth interviews with livery base management and staff, and with 12-15 primary care physicians (PCPs), clinic directors, hospital CFOs, heads of financial services and counseling, and heads of radiology facilities serving the Chinese community. Both focus group and in-depth interview methodologies have previously been used successfully to explore barriers and factors related to cancer screening among both male and female Chinese immigrants. Focus groups and in-depth interviews will be 75-90 minutes in duration.
2948571|NCT02914886|Experimental|Group 1|Daily use of insulin Apidra in insulin pump. The dosis will be according to the patient's former dosing scheme.
2948572|NCT02914886|Active Comparator|Group 2|Daily use of current insulin in insulin pump.The dosis will be according to the patient's former dosing scheme.
2948573|NCT02914873|Active Comparator|Current practice for active surveillance|In this arm, patients are monitored according to current practice for active surveillance at the trial centre. Repeat biopsies (and/or other examinations) and curative treatment are performed according to the urologist's judgement.
2948574|NCT02914873|Experimental|Standardized triggers for treatment|In this arm, patients are monitored according to a standardized active surveillance protocol with specific triggers for treatment. Repeat biopsies and curative treatment are only initiated if/when specific criteria are fulfilled.
2948575|NCT02914860|Experimental|Volunteers|Healthy volunteers
2948576|NCT02914860|Active Comparator|PAF|Patients with paroxysmal atrial fibrillation
2948577|NCT02914860|Active Comparator|Pers AF|Patients with persistent atrial fibrillation
2948578|NCT02914860|Active Comparator|L-s Pers AF|Patients with long-standing persistent atrial fibrillation
2948579|NCT02914847|Experimental|Immediate Functional Imagery Training (FIT)|Participants in this arm receive Functional Imagery training (FIT) immediately.
2948580|NCT02914847|No Intervention|Delayed Functional Imagery Training (FIT)|Participants in this arm receive Functional Imagery Training (FIT) after a 3 month delay.
2948581|NCT02914834|Experimental|Device Acupuncture|Standardized acupuncture protocol twice per week for 5 weeks for a total of 10 sessions
2948582|NCT02914834|Active Comparator|Non-pain related video health education|The attention control group will receive non-pain related video health education over 5 weeks equal to the approximate 10 hours of treatment for the acupuncture group.
2948583|NCT02914821|No Intervention|"Business as Usual (No Tax)"|Baseline data where business 'as usual' will be conducted and no price increases will be implemented on SSBs.
2948584|NCT02914821|Experimental|"General Tax (without named beneficiary)"|In the general tax condition investigators will introduce a 3 cent/ounce tax on the five SSB flavors the café offers. An example of this sign would be 'Pepsi, $2.29, includes 60 cent sugary drink surcharge.'
2948585|NCT02914821|Experimental|"Pre-K Tax"|"In the Pre-K tax condition investigators will institute a 3 cent/ounce tax but will label the tax as proceeds going to Pre-K education. An example of this sign is, Pepsi, $2.29, includes a 60 cent sugary drink surcharge to fund Pre-K education."
2948586|NCT02914821|Experimental|"Childhood Healthy Eating Tax"|"In the Childhood Healthy Eating tax condition investigators will institute a 3 cent/ounce tax but will label the tax as proceeds going to Pre-K education. An example of this sign is, Pepsi, $2.29, includes a 60 cent sugary drink surcharge to fund Childhood Healthy Eating education."
2948587|NCT02914795||non-resuscitated myocardial infarction|diagnostic analysis of platelet function of a matched historical cohort of the ATLANTIS-ACS trial
2948588|NCT02914795||resuscitated myocardial infarction|diagnostic analysis of platelet function of the patienten cohort included according to the inclusion criteria
2948589|NCT02914769|Placebo Comparator|placebo|patients receiving a passive placebo
2948590|NCT02914769|Experimental|Ayahuasca|patients receiving Ayahuasca
2948591|NCT02914756||Sepsis|Patients suffering from Severe sepsis or Septic chock at the ICU.
2948592|NCT02914756||Non-Sepsis|Patients being treated at ICU but not suffering from severe sepsis/septic chock
2948593|NCT02914743|Experimental|Dental Cleaning and MI Arm|Subjects in this arm will receive a dental cleaning by the hygienist as well as a motivational interviewing (MI) session to explore the subject's motivations to pursue oral health treatment.
2948594|NCT02914743|Experimental|MI only Arm|Subjects in this arm will not receive a dental cleaning but the hygienist will provide a motivational interviewing (MI) session to explore the subject's motivations to pursue oral health treatment.
2948595|NCT02914743|No Intervention|Control Arm|Subjects in this arm of the study will not receive any oral health intervention while hospitalized. A medical record review will be completed, and patients will be contacted via telephone at 3, 6, and 12 months post-hospitalization to assess their oral health-related quality of life and oral health care-seeking behaviors.
2948596|NCT02914704|Experimental|Patients treated with MRI-HIFU|
2948597|NCT02914691|Active Comparator|Active|Dapagliflozin 10 mg once daily tablet treatment
2948598|NCT02914691|Placebo Comparator|Placebo|Identical once daily tablet treatment
2948599|NCT02914678|No Intervention|Existing treatment|Business as usual: Ambulance personnel use existing treatment approach (a total of 2 μg/kg fentanyl per transport)
2948600|NCT02914678|Experimental|More liberal treatment|Ambulance personnel use a more liberal treatment approach (a total of 3 μg/kg fentanyl per transport)
2948601|NCT02914665|Experimental|20 mg elamipretide|20 mg elamipretide once daily for 7 consecutive days
2948602|NCT02914665|Placebo Comparator|Placebo|Placebo once daily for 7 consecutive days
2948603|NCT02914652|Experimental|Operated VSD's|Through the use of Electronic Patient Journal (EPJ), the investigators have identified a total of 182 children who underwent surgical closure of a congenital VSD at Aarhus University Hospital, Denmark between 1990 and 1995. After thorough review of all charts, 117 patients were excluded from participation. Exclusion criteria were coexistence of other congenital heart defects (n=89), associated syndromes, e.g. Down's (n=14), operation through a ventricular approach (n=7), missing chart (n=6) and documented arrhythmia requiring pacemaker (n=1). The remaining 68 patients represent a homogeneous group comparing surgeons, anaesthetists, surgical procedure and post-surgical period. A fraction of this group will be randomly selected for this trial, and receives salbutamol or norflouran, blinded.
2948604|NCT02914652|Experimental|Un-operated VSD's|Using EPJ, this project identified a total of 481 children born between 1985 and 1998 who had a small VSD, confirmed through diagnosis codes, that was not closed, neither spontaneously nor surgically. Exclusion criteria were lack of medical record, suffering from coronary disease, other congenital cardiac abnormalities than VSD, spontaneous closure of the ventricular septal defect at inclusion date, magnetic implants, pregnancy, lack of Danish language skills, suffering from lung disease requiring continuous medical treatment. The remaining patients represent a homogenous group of patients with isolated persistent ventricular septal defects. A fraction of this group will be randomly selected for this trial, and receives salbutamol or norflouran, blinded.
2948605|NCT02914652|Experimental|Healthy controls|Will function as a control group. Controls will be recruited through www.forsoegsperson.dk and www.sundhed.dk. Current group receives salbutamol or norflouran, blinded.
2948606|NCT02914639|Experimental|SF0166 low dose BID|SF0166 low dose will be instilled in study eye BID for 28 days of treatment.
2948607|NCT02914639|Experimental|SF0166 high dose BID|SF0166 high dose will be instilled in study eye BID for 28 days of treatment.
2948608|NCT02914626|Experimental|Ranibizumab|Standard of care therapy plus intravitreal ranibizumab injections
2948609|NCT02914626|Sham Comparator|Control|Standard of care therapy
2948610|NCT02914613|Experimental|SF0166 low dose BID|SF0166 low dose will be instilled in study eye BID for 28 days of treatment.
2948611|NCT02914613|Experimental|SF0166 high dose BID|SF0166 high dose will be instilled in study eye BID for 28 days of treatment.
2948612|NCT02914600|Experimental|Filgotinib Dose A (blinded dosing)|Filgotinib dose A + placebo to match filgotinib dose B for up to 144 weeks
2948613|NCT02914600|Experimental|Filgotinib Dose B (blinded dosing)|Filgotinib dose B + placebo to match filgotinib dose A for up to 144 weeks
2948614|NCT02914600|Placebo Comparator|Placebo (blinded dosing)|Placebo for up to 144 weeks
2948615|NCT02914600|Experimental|Filgotinib Dose A (open-label)|Filgotinib dose A for up to 144 weeks
2948616|NCT02914600|Experimental|Filgotinib Dose B (open-label)|Filgotinib dose B for up to 144 weeks
2948617|NCT02914587|Experimental|ARTAS System|Implantation with the ARTAS System.
2948618|NCT02914587|Active Comparator|Manual Implantation|Implantation manually.
2948619|NCT02914574|Other|healthy control|Healthy control group will attend one visit and functional performance, muscle strength and flexibility, quadriceps AMI, patellar position and posture will be measured. No intervention will be applied.
2948620|NCT02914561|Experimental|Filgotinib Dose A (Induction Study)|Filgotinib dose A + placebo to match filgotinib dose B for 10 weeks
2948621|NCT02914561|Experimental|Filgotinib Dose B (Induction Study)|Filgotinib dose B + placebo to match filgotinib dose A for 10 weeks
2948622|NCT02914561|Placebo Comparator|Placebo (Induction Study)|Placebo to match filgotinib dose A + placebo to match filgotinib dose B for 10 weeks
2948623|NCT02914561|Experimental|Maintenance Study|Participants who meet response or remission criteria at Week 10 will continue into the Maintenance Study and receive filgotinib and/or placebo for 48 weeks.
2948624|NCT02914548|Experimental|0.3% OPA-15406|Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.
2948625|NCT02914548|Experimental|1% OPA-15406|Subjects were treated with assigned 1% OPA-15406 ointment twice daily.
2948626|NCT02914548|Placebo Comparator|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
2948627|NCT02914535|Experimental|Filgotinib Dose A (blinded dosing)|Filgotinib dose A + placebo to match dose B for up to 144 weeks
2948628|NCT02914535|Experimental|Filgotinib Dose B (blinded dosing)|Filgotinib dose B + placebo to match dose A for up to 144 weeks
2948629|NCT02914535|Placebo Comparator|Placebo (blinded dosing)|Placebo for up to 144 weeks
2948630|NCT02914535|Experimental|Filgotinib Dose A (open-label)|Filgotinib dose A for up to 144 weeks
2948631|NCT02914535|Experimental|Filgotinib Dose B (open-label)|Filgotinib dose B for up to 144 weeks
2948632|NCT02914522|Experimental|Filgotinib Dose A (Induction Study)|Filgotinib dose A + placebo to match filgotinib dose B for 10 weeks
2948633|NCT02914522|Experimental|Filgotinib Dose B (Induction Study)|Filgotinib dose B + placebo to match filgotinib dose A for 10 weeks
2948634|NCT02914522|Placebo Comparator|Placebo (Induction Study)|Placebo to match dose A + placebo to match dose B for 10 weeks
2948635|NCT02914522|Experimental|Maintenance Study|Participants who meet response or remission criteria at Week 10 will continue into Maintenance Study and will receive filgotinib and/or placebo for 48 weeks.
2948636|NCT02914509|Experimental|OTX-TP|OTX-TP (sustained release travoprost) Intracanalicular Depot
2948637|NCT02914509|Placebo Comparator|PV|PV (Placebo Vehicle) Intracanalicular Depot
2948638|NCT02914496|Experimental|Diabetes in Balance|"The intervention consists of the manual-based CBT-group intervention Diabetes in Balance. It is given in a group format with six to ten participants and consists of 7 sessions. The sessions are given bi-weekly for two hours. Each session has a specific theme such as Stress and acceptance The life-compass; what is important in my life. The participants also conduct assignments related to the themes between the sessions. A licensed psychologist specialised in CBT and a diabetes specialist nurse, both trained in ACT-stress management will be leading the intervention group."
2948639|NCT02914496|No Intervention|Control|The control group receives regular care including regular visits at the out-patient clinic, 3-4 times per year.
2948640|NCT02914483|Other|Enhanced Usual Care (EUC)|
2948641|NCT02914483|Other|Stress Management|
2948642|NCT02914470|Experimental|carbo, cyclo, atezolizumab|The starting dose is carboplatin AUC 5mg/ml*min (d1), cyclophosphamide 600mg/m2(d1) and atezolizumab 840 mg (D1, 15), all administered intravenously
2948643|NCT02914457|Experimental|Active Comparator: Standard biventricular pacing|Intervention: Device: Standard biventricular pacing
2948644|NCT02914457|Experimental|Simultaneous Left Ventricular Multispot pacing|Intervention: Device: MultiSpot pacing
2948645|NCT02914457|Experimental|Sequential Left Ventricular Multispot pacing|Intervention: Device: MultiSpot pacing
2948646|NCT02914431|Experimental|3D Printing Personalized Titanium Plate|After the LeFort I osteotomy, the intraoperative repositioning and fixation of the maxilla is accomplished using 3D printing personalized titanium plates.
2948647|NCT02914431|No Intervention|CAD/CAM Surgical Splint|After the LeFort I osteotomy, the intraoperative repositioning of the maxilla is accomplished using CAD/CAM surgical splints and the fixation of the maxilla is accomplished using commercialization titanium plates.
2948648|NCT02914418|Experimental|Active iTBS|iTBS will be delivered using the 50Hz, 600 pulses protocol for 10 sessions over a period of two weeks. The hand representation of the primary motor cortex will targeted using a circular coil held over the vertex of skull. Intensity will be set to 80% of Resting Motor Threshold (RMT), which will be determined visually by the lowest percentage of stimulator output which can cause upper limb motor twitch in at least 5 out of 10 attempts.
2948649|NCT02914418|Sham Comparator|Sham iTBS|Sham iTBS will be delivered using the 50Hz, 600 pulses protocol for 10 sessions over a period of two weeks. Intensity will be set at 80% RMT. Circular coil will be held over vertex of skull but angled away to ensure no neural stimulation.
2948650|NCT02914405|Experimental|Treatment|"The dose and schedule of 131-I mIBG will be constant, and the doses of ch14.18/ CHO and Nivolumab determined by cohort:~Cohort I: 3 mg/kg Nivolumab (100% adult dose). No ch14.18/CHO. (3-6 patients)~Cohort II: 50mg/m2/cycle ch14.18/CHO (50% established Long Term Intervention (LTI) dose) and 3 mg/kg Nivolumab (100% adult dose) (3-6 patients)~Cohort III: 100mg/m2/cycle ch14.18/CHO (100% established LTI dose) and 3 mg/kg Nivolumab (100% adult dose) (initial 3-6 patients, expanded to 15 patient cohort if tolerated)"
2948651|NCT02914392||Fetal congenital heart disease cases|Gravidas with fetal congenital heart disease diagnosed by fetal echocardiography
2948652|NCT02914392||Matched Controls for fetal congenital heart disease cases|Gravidas without fetal congenital heart disease
2948653|NCT02914379|Experimental|[¹⁴C]-LY3337641|Oral dose of LY3337641 containing 120 microcuries of radioactivity.
2948654|NCT02914366|Experimental|Ambroxol high dose (1050 mg)|Participants randomized to the 1050 mg/day group will begin with a dose of 225mg (3 mg/kg/day), increasing bi-weekly by ~3mg/kg to a dose of 1050 mg/day (~l5 mg/kg/day).
2948655|NCT02914366|Experimental|Ambroxol low dose (525 mg)|Participants randomized to the 525 mg/day group will begin with a dose of 150 mg/day increasing biweekly by ~1.5mg/kg to a dose of 525 mg/day.
2948656|NCT02914366|Placebo Comparator|Placebo|Participants receive capsules visually identical to the experimental groups but without active ingredients.
2948657|NCT02914353|Experimental|Experimental - EP-7041|"Single Ascending Dose: Single IV dose for each cohort; dose range 0.01 mg/kg to 1.0 mg/kg~Multiple Ascending Dose: 0.01 mg/kg/h - 5 x 24 h continuous infusion up to 0.6 mg/kg/h - 5 x 24 h continuous infusion"
2948658|NCT02914353|Placebo Comparator|Placebo - Sterile Saline|"Single Ascending Dose: Single IV dose for each cohort;~Multiple Ascending Dose: 5 x 24 h continuous infusion for each cohort"
2948659|NCT02914340|Experimental|Treatment|The treatment algorithm is complete occlusion of one lobe of the lung by using valves to occlude all segments of the lobe. The lobe will be selected based on imaging with high resolution computed tomography (HRCT). The lobe to be treated will have severe heterogeneous emphysema based on visual exam. The selected lobe will also have an intact fissure separation with the ipsilateral lobe. An intact fissure will be estimated visually to be ≥ 90% complete after viewing the HRCT in 3 dimensions. If more than one lobe meets criteria, the investigator will determine a primary lobe to treat based on fissure completeness, heterogeneity, disease severity, and the anatomy of the airways that will be treated.
2948660|NCT02914327|Experimental|SNX-5422 plus ibrutinib|Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule until the cancer progresses or the subject is unable to tolerate the therapy
2948661|NCT02914314|Experimental|Perampanel 12 or 16 mg/day|Pediatric participants, ranging from 1 month to less than 24 months of age, will receive a target dose of perampanel 12 mg/day (non-enzyme-inducing antiepileptic drug [non-EIAED] participants) or 16 mg/day (EIAED participants) administered as an oral suspension once a day for up to 24 weeks.
2948662|NCT02914301|Active Comparator|Babyscripts Prenatal App|For patients allocated to the study group, they will be assisted in downloading the BRx app to their smartphone and set up the connected weight scale and blood pressure cuff. At time of enrollment, research assistant will also collect baseline demographic and clinical data. For patients who were allocated to the intervention arm, the clinician will told that they are in intervention group and therefore will be receiving regular app-based education and clinician will be receiving regular blood pressure and weight measurements. Following that communication, it will be the physicians' judgement to reduce in-person visits from usual care.
2948663|NCT02914301|Placebo Comparator|Placebo|For patients cared for by clinicians allocated to the usual care arm, the clinician will discuss the management options and scheduling procedures with the parent in that clinician's usual fashion. The patient will not be given access to the BRx app but will consent to the study data collection and survey administration. All potential study subjects will receive standard medical care per DoD/VA Clinical Practice Guidelines for Management of the uncomplicated pregnancy (REF) and local preference by board-certified OB/GYN physicians.
2948664|NCT02914275|Experimental|Seqirus QIV Cohort A|Seqirus Quadrivalent Inactivated Influenza Vaccine - Subjects 6 months through 35 months of age
2948665|NCT02914275|Experimental|Seqirus QIV Cohort B|Seqirus Quadrivalent Inactivated Influenza Vaccine - Subjects 36 months through 59 months of age
2948666|NCT02914275|Active Comparator|Comparator QIV Cohort A|Comparator Quadrivalent Inactivated Influenza Vaccine - Subjects 6 months through 35 months of age
2948667|NCT02914275|Active Comparator|Comparator QIV Cohort B|Comparator Quadrivalent Inactivated Influenza Vaccine - Subjects 36 months through 59 months of age
2948668|NCT02914262|Experimental|Experimental:Cohort 1-6 Experimental|Intervention AKB 4924 Six subjects per cohort will receive single doses of 20 to up to 480 mg of AKB 4924 orally in a dose escalation format
2948669|NCT02914262|Placebo Comparator|Placebo:Cohort 1-6|"Intervention Placebo:~Two subjects per cohort will receive single oral doses of placebo"
2948670|NCT02914249|Experimental|Orange juice|Orange juice: thirty-nine obese individuals were submitted to a low-caloric diet (500 kcal/d of energy restriction) plus 100% orange juice (500 mL/d) during 12 weeks.
2948671|NCT02914249|No Intervention|Control|Control: thirty-nine obese individuals were submitted to a low-caloric diet (500 kcal/d of energy restriction) during 12 weeks.
2948672|NCT02914236|Experimental|Vivaer Stylus|Intervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area
2948673|NCT02914223|Experimental|Treatment and observation period|On Day 1, subjects will receive a single oral dose of 2 mg 14C-radiolabeled cenerimod. Subjects will be followed for 21 days during which blood, urine, feces, and expired air samples will be collected
2948674|NCT02914223|Experimental|Extended observation period|In case, radioactivity recovery does not meet the stopping criteria described in the protocol, the subjects will have to come for a maximum of 7 24-h in-clinic visits during which blood, urine, feces, and expired air samples will be collected
2948675|NCT02914210|Other|Virtual physical therapy|Virtual physical therapy rehabilitation program (VERA) used in the home with care planning and remote support and monitoring by physical therapists
2948676|NCT02914210|Other|Traditional physical therapy|No intervention. Standard home health physical therapy and/or outpatient clinic physical therapy as prescribed.
2948677|NCT02914197|Experimental|Full information|"The intervention arm will receive full information on the risks and benefits of mammography through:~Decision aid~YouTube video~Group information session"
2948678|NCT02914197|No Intervention|Control|Standard information leaflet for breast screening from Cancer Care Ontario
2948679|NCT02914184|Experimental|Liq_A Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot A, at 6 and 12 weeks of age
2948680|NCT02914184|Experimental|Liq_B Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot B, at 6 and 12 weeks of age
2948681|NCT02914184|Experimental|Liq_C Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot C, at 6 and 12 weeks of age
2948682|NCT02914184|Active Comparator|Lyo Group|All subjects will receive two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age
2948683|NCT02914171|Experimental|Treatment arm|Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention using an add-on procedure delivering autologous bone marrow-derived mononuclear cells into the right ventricle.
2948684|NCT02914171|Other|Control arm|Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention without cell delivery.
2948685|NCT02914158|Experimental|Goserelin and aromatase inhibitors|"Goserelin: GnRH analogues goserelin 3.6 mg administered intravenously every 28 days, for 5 years.~AI: no restriction of specific drugs, oral by standard dose of post-menopause breast cancer, for 5 years."
2948686|NCT02914158|Active Comparator|Goserelin and tamoxifen|"Goserelin: GnRH analogues goserelin 3.6 mg administered intravenously every 28 days, for 5 years.~Tamoxifen: 20mg oral for every day, for 5 years."
2948687|NCT02914145|Other|Participants|Any individual from the study area who participates and is medicated with DHAp in the mass drug administration campaign
2948688|NCT02914132|Other|Seraph 100 Filter|Renal replacement patient with bacteremia.
2948689|NCT02914119||Eligible patients|"Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.~Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received."
2948690|NCT02914106||Control group|Sixty-90 year-old subjects were randomly selected and distributed in two experimental groups: 1) a control group, involving subjects without physical or psychiatric illness, and 2) an Acute Ischemic Stroke group (AIS group).
2948691|NCT02914106||Acute Ischemic Stroke group|Patients with diagnosis of AIS within the 24 hours of their neurovascular event.
2948692|NCT02914093|Experimental|IMT-feasibility|Single arm intervention
2948693|NCT02914067|Experimental|Cohort 1|"Prior to surgery, subjects will have a complete standard of care history and physical exam by the neurosurgeon and then undergo peri-diagnostic neurocognitive testing utilizing the NIH Toolbox Cognitive Battery computer testing software for iPad (will take 45 minutes). The peri-diagnostic period will be defined as the period from first presentation to 2 weeks post-diagnosis or two weeks post-op, whichever is later.~Participants will also undergo a rsfcMRI during their standard of care MRI imaging which will add 15 minutes to their scan time"
2948694|NCT02914067|Experimental|Cohort 2|"Patients with diagnosis of a posterior tumor will undergo neurocognitive testing utilizing the NIH Toolbox. Testing will be every 6 months for children currently receiving therapy and annually for those that have completed all therapy for a total of 2 sessions. During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of time. rsfcMRI will be obtained every 6 months for children currently receiving therapy and annually for those that have completed therapy for a total of 3 rsfcMRIs for each patient.~Patients in Cohort 1 with posterior fossa tumors will also be eligible to continue with the longitudinal assessment as just described. These participants will then undergo repeat neurocognitive testing using the NIH toolbox 6-9 months for an additional 2 testing sessions. rsfcMRI will be obtained during their follow-up imaging at 6-9 month intervals for a total of 3 additional rsfcMRIs (4 total scans)."
2948695|NCT02914054|Active Comparator|Conventional Prednisone receiving group|Patients in PDN arm received PDN
2948696|NCT02914054|Active Comparator|Dxamethasone receiving group|In HD-DXM arm, DXM was administered
2948697|NCT02914041||Kyphosis group|Subjects are community-dwelling elderly with different degrees of kyphosis, aged at least 60 years with a body mass index between 18.5-29.9 kg/m2 and OWD >0 cm.
2948698|NCT02914028|Active Comparator|intravenous analgesia (control)|subjects that only given intravenous contramal 100 mg and paracetamol 1000 mg at the end of the surgery
2948699|NCT02914028|Active Comparator|transversus abdominis plane block|patients that applied transversus abdominis plane block at the end of the surgery after given intravenous analgesia
2948700|NCT02914015|Experimental|Continuous QLB+postoperative IPCA|Single-injection of QLB (quadratus lumborum block) is given preoperatively followed with continuous infusion+ postoperative IPCA (intravenous patient control analgesia)
2948701|NCT02914015|Active Comparator|IPCA|Postoperative IPCA (intravenous patient control analgesia) is given alone
2948702|NCT02914002|Experimental|Psychoeducational intervention|Participants will be receiving a cooking lesson in their community every 2 weeks for 1 year.
2948703|NCT02914002|No Intervention|Usual Food Practices - AC|These are participants from the communities where the intervention is active but are not attending the cooking lessons.
2948704|NCT02914002|No Intervention|Usual Food Practices - NAC|These are participants from a community where the intervention is not active.
2948705|NCT02913989||Doctors from Medical Specialities|Doctors from Medical Specialities A voluntary and anonymous questionnaire was distributed to all physicians for a period of 4 months. The questions included sociodemographic data, smoking habits characterization, attitudes towards smoking, importance attribute to smoking cessation programme in the hospital and knowledge of the 2008 country law.
2948706|NCT02913989||Doctors from Surgical Specialities|Doctors from Surgical Specialities A voluntary and anonymous questionnaire was distributed to all physicians for a period of 4 months. The questions included sociodemographic data, smoking habits characterization, attitudes towards smoking, importance attribute to smoking cessation programme in the hospital and knowledge of the 2008 country law.
2948707|NCT02913976|Experimental|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
2948708|NCT02913976|Placebo Comparator|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
2948709|NCT02913963|Active Comparator|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
2948710|NCT02913963|Placebo Comparator|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
2948711|NCT02913937|Active Comparator|Needle irrigation|Endodontic irrigation will be done using an endodontic needle.
2948712|NCT02913937|Experimental|Passive ultrasonic irrigation|Endodontic passive ultrasonic irrigation will be done using an endodontic needle followed by passive ultrasonic agitation.
2948713|NCT02913924|Experimental|Clonazepam|"Clonazepam will be taken twice per day in the morning and in the evening. Clonazepam is given in a fixed flexible dose schedule with the dose titrated to 2mg per day or the maximum tolerated dose. Clonazepam will be taken for the first 8 weeks of the trial."
2948714|NCT02913924|Placebo Comparator|Placebo|Placebo will be taken twice per day in the morning and in the evening. Placebo will be taken for the first 8 weeks of the trial.
2948715|NCT02913911|Experimental|Feedback|Subjects will be trained using the sit-to-stand weight-taking machine. Prior to the training, subjects sit in a standard sitting position. Then they will be instructed to take most of their body-weight onto the legs while they standing up where the light bars will be gradually lightened from the red, yellow and green zones according to the level of LLL. Then they stand up, hold a standing position for 3-5 seconds and sit-down with always maximize their body-weight onto their legs during performing the task in which the green zone will always be lightened.
2948716|NCT02913911|Sham Comparator|No feedback|Subjects will be trained using the same instruction and protocol as the experimental group, but without the provision of external feedback.
2948717|NCT02913898|Experimental|IBLT (information bias learning task)|Computerised task in which most information is provided by positive outcomes. Completed for 10 mins per day every day for 2 weeks.
2948718|NCT02913898|Placebo Comparator|IBLT control|Computerised task in which information is provided by both positive and negative outcomes. Completed 10 mins per day every day for 2 weeks
2948719|NCT02913885|Active Comparator|Group 2|curodont repair is a biomimetic regeneration scaffold for remineralization
2948720|NCT02913885|Experimental|Group 1|fluoride varnish inhibit progression of white spot lesion
2948721|NCT02913859|Experimental|pelvic radiotherapy|long-term hormonal therapy (LHRH agonist and/or antiandrogens) plus radiotherapy to the pelvis and prostate
2948722|NCT02913859|Active Comparator|No pelvic radiotherapy|long-term hormonal therapy ( LHRH agonist and/or antiandrogens) alone
2948723|NCT02913846||Hospital revalidation units|The study will take place within the CHU Brugmann hospital (Brussels) who has 4 revalidation units (104 beds). All patients coming within these units during the study duration will be included.
2948724|NCT02913833|Experimental|Daily pain evaluation|Patients recruited in a sequential order within the chronic revalidation unit of the CHU Brugmann hospital, Queen Astrid site.
2948725|NCT02913833|No Intervention|Control|Patients recruited in a sequential order within the chronic revalidation unit of the CHU Brugmann hospital, Queen Astrid site.
2948726|NCT02913820||snowfall >5cm/d|impact of snowfall and its correlation with acute myocardial infarctions is analyzed. Other precipitation (rainfall) changes in atmospheric pressure and temperature will be variables to be corrected for.
2948727|NCT02913807|Placebo Comparator|Traditional Reconstruction|This cohort will be reconstructed using hand contoured osteotomies and reconstruction bars
2948728|NCT02913807|Experimental|Computerized Custom|This cohort will be reconstructed using customized computer-modeled titanium locking customized jigs and plates for the osteotomies.
2948729|NCT02913781|Experimental|polar body removal|polar body removal by zona drilling with laser then suction by injecting pipette then ICSI procedure is done
2948730|NCT02913768|Active Comparator|Ondansetron|Intravenous Ondansetron 4 mg diluted in 10 mL of normal saline over 1 min, 5 min before spinal anaesthesia
2948731|NCT02913768|Placebo Comparator|control|Normal Saline 10 mL over 1 min, 5 min before spinal anaesthesia
2948732|NCT02913755|Experimental|Intervention group|Repeated viewing of a short Preparatory video about ABI rehabilitation; viewed every 2-3 days over a 4 week period
2948733|NCT02913755|Active Comparator|Lagged Control Group|2 week period of treatment as usual followed by repeated viewing of a short Preparatory video about ABI rehabilitation; viewed every 2-3 days over a 4 week period
2948734|NCT02913742|Experimental|monitoring by depth electrode|Subjects will be drawn from refractory mesial temporal lobe epilepsy patients determined to be candidates for LITT. During their LITT surgery, in addition to the placement of the stereotactic LITT probe, subjects will receive a second smaller stereotactic electrode for intraoperative monitoring of epileptic discharges before and after surgery. After surgery, at regularly scheduled follow-ups, patients will receive a QOLIE-31-P questionnaire, in addition to standard post-operative care.
2948735|NCT02913729|Experimental|radiotherapy in arm 1|pre-operative accelerated partial breast irradiation
2948736|NCT02913729|Active Comparator|radiotherapy in arm 2|post-operative accelerated partial breast irradiation
2948737|NCT02913716|Experimental|Defactinib treatment|Single dose of 400 mg [14C]-defactinib, oral suspension
2948738|NCT02913703|Experimental|Healthy subjects - Preprandial AG (Acyl Ghrelin)|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG (Acyl Ghrelin) bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
2948739|NCT02913703|Experimental|Healthy subjects - Preprandial saline|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial saline bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
2948740|NCT02913703|Experimental|Healthy subjects - Prandial AG|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 5 hour fast, they will receive a prandial AG bolus over 1 minute starting at the same time as the liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
2948741|NCT02913703|Experimental|Healthy subjects - Preprandial & prandial AG|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG bolus over 1 minute. Sixty minutes later, they will receive another AG bolus over 1 minute starting at the same time as the liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
2948742|NCT02913703|Experimental|Diabetic subjects - Preprandial AG|Type 2 diabetic subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
2948743|NCT02913703|Experimental|Diabetic subjects - Preprandial Saline|Type 2 diabetic subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial saline bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
2948744|NCT02913690|Placebo Comparator|Control group|Control group will be supplemented with placebo for 12 months.
2948745|NCT02913690|Active Comparator|Intervention group|The intervention arm will be supplemented with TRF for 12 months.
2948746|NCT02913677|Active Comparator|group 1|prolonged minimal enteral nutrition
2948747|NCT02913677|Placebo Comparator|group 2|slowly advancing enteral nutrition
2948748|NCT02913664|Experimental|Aerobic Exercise (Ex)|Aerobic exercise training; blood and cholesterol management will be standard-care by participant's regular doctor.
2948749|NCT02913664|Experimental|Intensive Reduction of Vascular Risk Factors (IRVR)|Lowering SBP < 130 mmHg, administration of atorvastatin 80 mg daily, and stretching exercise.
2948750|NCT02913664|Experimental|IRVR+Ex|A combination of IRVR and aerobic exercise training.
2948751|NCT02913664|Placebo Comparator|Usual Care|Blood and cholesterol management will be standard-care by participant's regular doctor, and stretching exercise.
2948752|NCT02913651||Idiopathic hypersomnia|Drug-free patients diagnosed with idiopathic hypersomnia from 01/01/11 to 15/09/15
2948753|NCT02913651||Controls|Patients with no sleep complaints, having a 24-h ambulatory ad libitum polysomnography
2948754|NCT02913625|Experimental|Ultrasound guided retroclavicular block|Patients assigned to this group will receive an ultrasound guided retroclavicular brachial plexus block
2948755|NCT02913625|Active Comparator|Ultrasound guided infraclavicular block|Patients assigned to this group will receive an ultrasound guided infraclavicular brachial plexus block
2948756|NCT02913612|Experimental|Intervention Group|Subjects assigned to this arm will be randomized to either 0.25% Timolol or 0.5% Timolol for 180 days. If during the 180 days the subject is considered a treatment failure, the subject will be unblinded. If the subject is on 0.25% timolol they will be changed to 0.5% timolol, if on 0.5% timolol the treating physician will decide to either continue 0.5% timolol or withdraw the subject and begin alternative treatment.
2948757|NCT02913612|No Intervention|Non-Intervention Group|Subjects assigned to this group will not receive treatment. The subject will only be photographed on the same schedule as the intervention group.
2948758|NCT02913573|Experimental|GA + Pec Block|Following induction of general anesthesia, the patients in the intervention group will undergo an ultrasound-guided pectoral block. With the patient in proper position, the infraclavicular and axillary regions are prepped with chlorhexidine. An US probe is placed below the third of the clavicle over the pectoralis major muscle. After identifying the appropriate anatomical structures, a 21-gauge echogenic needle is advanced under US visualization to the tissue plane between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie and 15 mL of 0.25% bupivacaine will be deposited. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
2948759|NCT02913573|No Intervention|GA only|Patients will receive standard general anesthesia.
2948760|NCT02913547|Experimental|Treatment group|"Each subject will serve as his/her own control, while comparing results before treatment, and after 6 weeks of treatment.~Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual."
2948761|NCT02913521|Experimental|Diclofenac Sodium Gel 1%|Apply 4 g of gel to the knee four times a day
2948762|NCT02913521|Active Comparator|Voltaren Gel|Apply 4 g of gel to the knee four times a day
2948763|NCT02913521|Placebo Comparator|Placebo|Apply 4 g of gel to the knee four times a day
2948764|NCT02913508|Experimental|Vedolizumab 300 mg IV Q8W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, and then every 8 weeks (Q8W) (Weeks 6 and 14).
2948765|NCT02913508|Experimental|Vedolizumab 300 mg IV / 160 mg SC Q3W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, then vedolizumab 160 mg, subcutaneously (SC), every 3 weeks (Q3W) (Weeks 6, 9, 12, 15 and 18).
2948766|NCT02913508|Experimental|Vedolizumab 300 mg IV / 108 mg SC Q2W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, then vedolizumab 108 mg, subcutaneously, every 2 weeks (Q2W) (Weeks 6, 8, 10, 12, 14, 16, 18 and 20).
2948767|NCT02913508|Experimental|Vedolizumab 480 mg SC / 160 mg SC Q3W|Vedolizumab 480 mg, subcutaneously, at Weeks 0 and 2, then vedolizumab 160 mg, subcutaneously, every 3 weeks (Weeks 6, 9, 12, 15 and 18).
2948768|NCT02913508|Experimental|Vedolizumab 324 mg SC / 108 mg SC Q2W|Vedolizumab 324 mg, subcutaneously, at Weeks 0 and 2, then vedolizumab 108 mg, subcutaneously, every 2 weeks (Weeks 6, 8, 10, 12, 14, 16, 18 and 20).
2948769|NCT02913495|Experimental|Vaginal Progesterone|200mg micronized progesterone vaginally, to be taken daily starting at 16 0/7 - 23 6/7 weeks, and continued daily until 36 6/7 weeks' gestation or delivery
2948770|NCT02913495|Active Comparator|Intramuscular Progesterone|250mg intramuscular progesterone to be administered weekly starting at 16 0/7 - 23 6/7 weeks, and continued weekly until 36 6/7 weeks' or delivery.
2948771|NCT02913482|Experimental|Part 1 (Dose Finding): RO7034067|Participants will receive multiple ascending doses of RO7034067, administered orally once daily for 4 weeks followed by open-label extension phase.
2948772|NCT02913482|Experimental|Part 2 (Confirmatory): RO7034067|Participants will receive RO7034067, administered orally at the dose defined in Part 1 of the study. Treatments will continue maximum up to 24-months.
2948773|NCT02913469|Experimental|morphine+metoclopramide|administrated intravenous morphine 5mg and metoclopramide 10mg
2948774|NCT02913469|Active Comparator|morphine|avenous morphine 5mg and 0.9%normal saline 2ml
2948775|NCT02913469|Sham Comparator|metoclopramide|intravenous metoclopramide 10mg and 0.9%normal saline 2ml
2948776|NCT02913469|Placebo Comparator|placebo|intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml
2948777|NCT02913456||HER2-positive unresectable LA/mBC|Participants with HER2-positive unresectable LA/mBC diagnosed up to 6 months prior to enrollment will be included in the study. Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LA/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site.
2948778|NCT02913443|Experimental|Arm A - Introductory Cohort: RO7051790|To ensure participant safety, prior to the dose escalation study, an introductory cohort (Cohort 0) will be enrolled. RO7051790 will be administered to 2 participants. Once the 2 participants have completed a DLT observation period, the Sponsor will evaluate all available data and the dose escalation study will begin if it is deemed safe to start.
2948779|NCT02913443|Experimental|Arm B - Dose Escalation: RO7051790|Initial cohort dose of RO7051790 monotherapy, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
2948780|NCT02913443|Experimental|Arm C - Dose Expansion: RO7051790|Dose expansion cohort with the recommended phase 2 dose of the intra-patient dose escalation regimen.
2948781|NCT02913430|Active Comparator|Arm A|fulvestrant administered 500mg IM Q28 days
2948782|NCT02913430|Active Comparator|Arm B|Tamoxifen is administered orally, at a dose of20mg PO Qdaily
2948783|NCT02913417|Experimental|hepatic radiation followed by immunotherapy|SIR-Spheres Yttrium 90 will be given by injection into the hepatic artery in two treatments, one for each lobe. 3-5 weeks later patients receive concurrent ipilimumab 3mg/kg q 3 wk x 4 and nivolumab 1mg/kg q 3 weeks x 4, all followed by nivolumab 3mg/kg q 2 weeks until progression or 3 years
2948784|NCT02913404|Experimental|ACL Reconstruction|"Surgical Protocol~Standard single bundle anatomic ACL reconstruction will be performed for all subjects. Quadrupled hamstring tendon will be used with cortical fixation on femur and tibia."
2948785|NCT02913404|Experimental|ACL Recon. extra-articular-tenodesis|"Surgical Protocol~Standard single bundle anatomic ACL reconstruction will be performed for all subjects. Quadrupled hamstring tendon will be used with cortical fixation on femur and tibia. ACL-R+EAT will be performed as described by Marcacci with doubled hamstring tendon left attached at the pes anserinus, an anatomic tibial tunnel, staple fixation in the over the top position, routing of the graft superficial to the LCL, and staple fixation at Gerdy's tubercle. Concomitant tears to the menisci and their roots will be repaired as indicated."
2948786|NCT02913391|Experimental|recruitment group (RG)|After extubation the patient who was randomized to the Recruitment Group (RG) used noninvasive ventilation (NIV) associated with recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV until 30 minutes with pressure support for a tidal volume of 6 mL/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen (FiO2) for a peripheral oxygen saturation (SpO2) ≥ 95%.
2948787|NCT02913391|Active Comparator|control group (CG)|After extubation the patient who was randomized to the Control Group (CG) used noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, FiO2 for a SpO2 ≥ 95%.
2948788|NCT02913378|Experimental|Locking plate|Surgical treatment with open reduction and osteosynthesis with locking plate
2948789|NCT02913378|Active Comparator|Conservative|Conservative treatment with sling and rehabilitation
2948790|NCT02913365||Patients presenting with hemoptysis|Patients over 18 years of age presenting with hemoptysis at the Centre Hospitalier Universitaire de Sherbrooke (CHUS) between the periods of 2005 to 2010.
2948791|NCT02913352|Active Comparator|Latarjet procedure|Open Latarjet-Patte procedure. Surgery. Anterior glenoid bone graft from coracoid. Fixation with 2 screws.
2948792|NCT02913352|Experimental|Modified Eden-Hybinette Procedure|Surgery. Modified Eden-Hybinette surgery, with capsular repair on the iliac bone Anterior glenoid bone graft from iliac bone. Fixation with 2 screws.
2948793|NCT02913339|Experimental|Intervention|Community health workers (CHWs) will conduct screening for CVD risk using a mobile phone application to assess risk and to schedule appointments at primary care centers (PCCs). The screening process will be non-invasive and no surgical, pharmaceutical, or other testing procedures will be utilized for screening of CVD risk by CHWs. If the CHW calculates the risk of CVD to be > 10%, s/he will schedule a clinical visit with a health professional at one of the PCCs for further assessment and/or appropriate treatment. An automatic reminder messaging system will send reminder messages about upcoming appointments to the participants.
2948977|NCT02912013|Experimental|Me mini|Subjects treated with Me mini device
2948794|NCT02913339|Active Comparator|Control|"The protocol will be identical to that implemented in the intervention arm with the following difference:~If the CHW calculates the risk of CVD to be > 10%, s/he will verbally advise the study participant of her/his increased risk and recommend that s/he schedule a clinical visit with a health professional at one of the PCCs for further assessment and/or appropriate treatment."
2948795|NCT02913326|Experimental|Dabigatran etexilate|
2948796|NCT02913326|Active Comparator|Warfarin|
2948797|NCT02913313|Experimental|Part 1A- Dose Escalation- Monotherapy|Specified dose on specified days
2948798|NCT02913313|Experimental|Part 1B- Dose Escalation- Combination Therapy|Specified dose on specified days
2948799|NCT02913313|Experimental|Part 2A- Expansion- Monotherapy|Specified dose on specified days
2948800|NCT02913313|Experimental|Part 2B- Expansion- Combination Therapy|Specified dose on specified days
2948801|NCT02913300|Active Comparator|1 % Lignocaine|1 % Lignocaine administered for topical anaesthesia during EBUS-TBNA
2948802|NCT02913300|Active Comparator|2 % Lignocaine|2 % Lignocaine administered for topical anaesthesia during EBUS-TBNA
2948803|NCT02913287|Placebo Comparator|Placebo|Maltodextrin
2948804|NCT02913287|Experimental|Aquamin/Aquamin MG|Aquamin/Aquamin MG mix
2948805|NCT02913274|Experimental|"DEB arm"|dilation by a high-pressure conventional angioplasty balloon (sized to fit the reference native vein diameter) until disappearance of the stenotic obstructive area and achievement of technical success (possibility of changing balloon size or dilation pressure) then dilation by a DEB.
2948806|NCT02913274|Active Comparator|"conventional angioplasty arm"|dilation will be performed by a conventional high-pressure balloon until technical success is achieved (possibility of changing balloon size or dilation pressure), then by a sham balloon i.e a conventional low-pressure balloon (placebo)
2948807|NCT02913261|Active Comparator|Ruxolitinib|Ruxolitinib 10 mg Bis In Diem (BID)
2948808|NCT02913261|Active Comparator|Best Available Therapy (BAT)|As selected by the investigator
2948809|NCT02913248|Experimental|Conventional periodontal treatment|35 subjects diagnosed with manifest periodontitis, which will all receive standardized treatment according to protocol. In brief, this treatment includes professional tooth cleaning and thorough instruction in self-performed oral hygiene procedures. Clinical registrations and collection of microbiological samples (subgingival and saliva) will performed at baseline and 2, 6 and 12 weeks after treatment.
2948810|NCT02913235|Experimental|Oral hygiene discontinuation group|The intervention of the present study is discontinuation of regular oral hygiene procedures for a period of 10 days. Discontinuation of oral hygiene will allow undisturbed biofilm formation (supragingival dental plaque) along the gingival margin of the teeth. After 10 days all individuals will resume regular oral hygiene. Clinical registrations and collection of microbiological samples (supragingival and saliva) will be performed at baseline and 4, 7 and 10 days after discontinuation of regular oral hygiene, and will be repeated 14 days after regular oral hygiene has been resumed.
2948811|NCT02913222|Experimental|Movement Pattern Training (MPT)|Treatment: 10 sessions over 12 weeks and a home program provided by a physical therapist. Treatment includes assessment of patient goals and patient education. Movement Pattern Training (MPT) will focus on task-specific training to improve lower extremity movement patterns during basic tasks, such as sit to stand and stairs, and reported patient-specific tasks. Patient education will include instruction in abnormal movement patterns and methods to optimize movement patterns during each task. Exercises will include repeated practice of tasks using optimized movement patterns. Verbal cues and visual aids will be used to assist the participant. Difficulty of the task-specific activities will be progressed by varying repetitions performed, increasing load or changing the support surface.
2948812|NCT02913222|Active Comparator|Standard Rehabilitation|Treatment: 10 sessions over 12 weeks and a home program provided by a physical therapist. Treatment includes assessment of patient goals and patient education. For the Standard Rehabilitation, focus will be on progressive lower extremity and trunk strengthening and lower extremity flexibility. Patient education will include instruction to modify intensity, frequency or duration of patient-specific tasks. Using current clinical practice guidelines and previous reports, strengthening and flexibility exercises will be prescribed and progressed by varying the repetitions performed or increasing the load.
2948813|NCT02913209||Multiple Sclerosis Fatigue (MSF) Cohort|Participants will complete study assessments over 4 visits to the DC VAMC. Disease severity will be assessed by the EDSS, and a cognitive battery will be completed. Peak torque assessment for the knee flexors and extensors will be performed on an isokinetic dynamometer (Biodex System 4). Muscle morphology measures of the rectus femoris will be obtained using diagnostic musculoskeletal ultrasound. The sonographic measures will include muscle thickness and echogenicity. Isokinetic and isoinertial mode fatigue measures for the knee extensors will be assessed on separate visits (at least 48 hours apart). Performance-based measures of function will include an assessment of patient mobility and the 25-foot walk test. Muscle power will be estimated by the timed sit to stand test. Subjective measures of fatigue and quality of life include the MSQoL, MFIS, and Neurology Quality of Life Adult Fatigue Bank (AFB).
2948814|NCT02913196|Experimental|All patients|Apalutamide, 120 mg (cohort 1), 240 mg (cohort 2), 180 mg (cohort 3) Abiraterone Acetate 1000mg Prednisone 10mg Docetaxel 75 mg/m2
2948815|NCT02913183|Experimental|young Fresh Frozen Plasma|"Drug: young plasma will be administered as 2 unit /day over a course of 3 consecutive days after stroke onset.~Drug: young plasma exchange over a course of 3 consecutive days after stroke onset."
2948816|NCT02913183|Placebo Comparator|old Fresh Frozen Plasma|"Old plasma will be administered as 2 unit /day over a course of 3 consecutive days after stroke onset.~Old plasma exchange over a course of 3 consecutive days after stroke onset.~Patients will receive usual care and drug use in hospital."
2948817|NCT02913170|Experimental|Nattokinase group|A nattokinase group composed of 50 individuals who consumed a 300mg nattokinase capsule (100mg of nattokinase and 200mg of maltodextrin) daily after meal.
2948818|NCT02913170|Placebo Comparator|Placebo group|A placebo group composed of 50 individuals who consumed a 300mg placebo capsule (300mg of maltodextrin) daily after meal.
2948819|NCT02913157|Experimental|Hydroxychloroquine|Oral Hydroxychloroquine, 200mg BID
2948857|NCT02912923|Experimental|Start with Visual + Force|Participants will complete a set of trials while receiving Visual + Force Feedback. After finishing, participants will continue to a new set of trials while receiving Visual + Force + Game Scores Feedback.
2949286|NCT02909673|No Intervention|Control|Control: Treatment as usual (standard health class curriculum)
2948820|NCT02913131|Experimental|Part A: Feasibility Run-In|Patients with advanced solid tumor malignancies with at least one liver metastasis will be enrolled with iterative adjustment of coil design to optimize imaging parameters including spatial resolution and signal-to-noise ratio (SNR) of hyperpolarized pyruvate / lactate within the target metastatic lesion(s). The target SNR of 10 must be achieved in at least 3 patients in order to proceed to part B of the study.
2948821|NCT02913131|Experimental|Part B: Biomarker Cohort|Patients with advanced solid tumor malignancies and the presence of at least one liver metastasis amenable to hyperpolarized C-13 pyruvate metabolic MR imaging who are planning on being treated with agent targeting PI3K/mTOR pathway will be enrolled.
2948822|NCT02913118|Experimental|standard antibiotic treatment +AS injection|Andrographolid Sulfonate Injection (AS Injection) plus one of 3 antibiotics in China CAP Guideline
2948823|NCT02913118|Placebo Comparator|standard antibiotic treatment + AS placebo|AS placebo (NS injection) plus one of 3 antibiotics in China CAP Guideline
2948824|NCT02913105|Experimental|LMB763|Oral dose once daily for 12 weeks (84 days)
2948825|NCT02913105|Placebo Comparator|Placebo|Oral dose once daily for 12 weeks (84 days)
2948826|NCT02913092|Experimental|Electronic sensor and OW education|MDI sensor-generated alerts will be relayed and responded to (e.g. outreach worker contacts the participant for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide asthma education over the phone
2948827|NCT02913092|No Intervention|Usual Care|Usual care group will receive the electronic tracker but the sensor-generated alerts will not be delivered. If the usual care group rescue inhaler data reveals frequent use of rescue medication (daily use for >3 days) investigators will reach out (via app or phone call) to advise the participant to see their physician
2948828|NCT02913079|Experimental|Sit-stand desk|During this condition, participants will sit or stand as much as they like throughout a workday.
2948829|NCT02913079|Placebo Comparator|Sitting|During this condition, participants will work in the sitting position only.
2948830|NCT02913066|Experimental|Single drug|S-1 concurrent Radiotherapy
2948831|NCT02913066|Active Comparator|Double drug|S-1 plus cisplatin concurrent Radiotherapy
2948832|NCT02913053|Active Comparator|Aerobic exercise|
2948833|NCT02913053|Active Comparator|Stretching and Toning|
2948834|NCT02913053|No Intervention|Usual care: Control Group|
2948835|NCT02913040|Experimental|High Flow Nasal Cannula|Oxygen delivery through Heated Humidified High Flow Nasal Cannula
2948836|NCT02913040|Active Comparator|Low Flow Nasal Prongs|Oxygen delivery through Low Flow Nasal Prongs
2948837|NCT02913027|No Intervention|Observational|ARM: Normal Pelvic Exam Exposures: External Exam followed by speculum exam, followed by bimanual exam
2948838|NCT02913027|Active Comparator|Experimental Pelvic Exam|Arm: Changing the order of Pelvic Exam Intervention: External exam, Bimanual Exam, Speculum Exam
2948839|NCT02913014|Active Comparator|Arm 1- No AAD post Ablation|Subjects will not resume their Anti Arrhythmic Drugs after cryoballoon-ablation for paroxysmal atrial fibrillation.
2948840|NCT02913014|No Intervention|Arm 2-Resume AAD post Ablation|Subjects will resume their pre-ablation Anti Arrhythmic Drugs after cryoballoon-ablation for paroxysmal atrial fibrillation, during the 90 day blanking period following the ablation.
2948841|NCT02913001|Experimental|Low Glycemic Load Diet|Participants received a diet education to follow a low glycemic load diet and received some low glycemic load staple foods.
2948842|NCT02913001|Active Comparator|Usual Eating Plan|Participants received a diet education to continue with their usual diet.
2948843|NCT02912988|Experimental|Letrozole group|"Letrozole + standard treatment:~Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration."
2948844|NCT02912988|No Intervention|Control group|"Standard treatment:~Daily 150-300 IU HMG/FSH cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) until the day before hCG administration. GnRH antagonist 0.25 mg daily from stimulation day 5 until the day of hCG administration."
2948845|NCT02912975|Experimental|Mirror treatment|Five minutes treatment period twice a day for three weeks
2948846|NCT02912975|Active Comparator|Tactile treatment|Tactile massage twice a day for three weeks
2948847|NCT02912962|Experimental|Intervention Group|"Cognitive testing 1, 12 intervention sessions, Cognitive testing 2, Approximately a 12 week wait (no intervention), Cognitive testing 3.~The intervention is a 12 week, individualized, one-on-one self-regulation intervention where adolescents will learn to attain, change, or maintain an appropriate level of alertness ."
2948848|NCT02912962|Experimental|Waitlist|Cognitive testing 1, Approximately a 12 week wait (no intervention), Cognitive testing 2, 12 intervention sessions, Cognitive testing 3
2948849|NCT02912949|Experimental|Part 1 Dose Escalation|Cohorts receiving escalating doses of MCLA-128 until MTD or RP2D is reached. Each Cycle is 21 days. Single agent treatment.
2948850|NCT02912949|Experimental|Part 2 breast cancer|Participants will receive intravenous infusion of MCLA-128 at the recommended Phase 2 dose (RP2D) once per cycle. The duration of each treatment cycle is 21 days.
2948851|NCT02912949|Experimental|Part 2 ovarian cancer|Participants will receive intravenous infusion of MCLA-128 at the recommended Phase 2 dose (RP2D) once per cycle. The duration of each treatment cycle is 21 days.
2948852|NCT02912949|Experimental|Part 2 gastric/GE junction cancer|Participants will receive intravenous infusion of MCLA-128 at the recommended Phase 2 dose (RP2D) once per cycle. The duration of each treatment cycle is 21 days.
2948853|NCT02912949|Experimental|Part 2 endometrial cancer|Participants will receive intravenous infusion of MCLA-128 at the recommended Phase 2 dose (RP2D) once per cycle. The duration of each treatment cycle is 21 days.
2948854|NCT02912949|Experimental|Part 2 non small cell lung cancer|Participants will receive intravenous infusion of MCLA-128 at the recommended Phase 2 dose (RP2D) once per cycle. The duration of each treatment cycle is 21 days.
2948855|NCT02912936|Experimental|Ketogenic medium chain triglyceride drink|Lactose-free skim milk drink containing 25 g of MCT oil per 250 ml.
2948856|NCT02912936|Placebo Comparator|Placebo|Lactose-free skim milk drink containing high-oleic sunflower oil in the equivalent amount of energy as the active arm.
2948858|NCT02912923|Experimental|Start with Visual + Force + Game Scores|Participants will complete a set of trials while receiving Visual + Force + Game Scores Feedback. After finishing, participants will continue to a new set of trials while receiving Visual + Force Feedback.
2948859|NCT02912910||Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
2948860|NCT02912910||Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
2948861|NCT02912897|Experimental|Cellular therapy with EBV specific autologous CTL infusion|
2948862|NCT02912884||PV|Patients with a diagnosis of polycythaemia vera.
2948863|NCT02912884||ET|Patients with a diagnosis of essential thrombocythaemia.
2948864|NCT02912871|Experimental|MRIgHIFU unilateral subthalamotomy|Unilateral Subthalamotomy performed by MRI guided High intensity focused ultrasound in a single session.
2948865|NCT02912858|Experimental|geko plus R-2|neuromuscular electrostimulation
2948866|NCT02912845|Experimental|20 IU/kg KamRAB + Active Anti-Rabies Vaccine|
2948867|NCT02912832|Experimental|TBDx|"All samples were tested with TBDx and compared with smear microscopy and Xpert MTB/RIF using solid and liquid culture as gold standard.~Operators were blinded to all other results for a sample upon data entry."
2948868|NCT02912793|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 1500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
2948869|NCT02912793|Active Comparator|Hydroxy-propyl-beta-cyclodextrin IV 2000 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
2948870|NCT02912793|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 2500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
2948871|NCT02912767||SLN cohort|Patients who underwent hysterectomy only or with SLN mapping alone.
2948872|NCT02912767||LND cohort|Patients who underwent hysterectomy with standard lymphadenectomy, with or without SLN mapping.
2948873|NCT02912754|Experimental|Ibrutinib plus Ruxolitinib|Patients taking ibrutinib for relapsed CLL will add ruxolitinib twice per day at the dose identified in a preliminary phase I trial for 7 cycles (3 weeks on/2 weeks off).
2948874|NCT02912754|No Intervention|Ibrutinib alone|Patients will continue to take Ibrutinib for the equivalent period of time.
2948875|NCT02912741|Experimental|Vanish xt Extended Contact Varnish|Vanish xt Extended Contact Varnish is a resin modified glass ionomer cement and fluoride varnish used to treat white spot lesions to be more resistant to early caries progression.
2948876|NCT02912741|Active Comparator|Resin infiltration|Resin infiltration is a low viscous resin infiltrates into small pores of white spot lesions to block entrance of bacteria into dentinal tubules of the tooth and more resistant to early caries progression.
2948877|NCT02912728|Active Comparator|CGM + Family Behavioral Intervention|CGM training for CGM groups using a standard curriculum will take place at the 1, 3 and 6 week visits in addition to the training at baseline. The family behavioral intervention will be delivered by a study coordinator (separate coordinator from the CGM instruction) at the 1, 3, 6, 13 and 19 week visits and is expected to take approximately 30 minutes.
2948878|NCT02912728|Active Comparator|Standard CGM|"Each participant will be asked to use a CGM sensor on a daily basis, inserting a new sensor as needed with a maximum of 7 days of wear per sensor.~A home BGM will be used for calibration of the CGM sensor. Additional BGM glucose measurements may be performed by the participant at any time, particularly prior to making a real-time management decision based on the CGM glucose reading.~Participants will be instructed to use the CGM as per the FDA labeling."
2948879|NCT02912728|No Intervention|BGM - usual care control group|A BGM will be used for a finger stick blood glucose check with a recommendation of at least 4 times a day. BGM data will be downloaded and reviewed with the participant at each visit.
2948880|NCT02912715|Experimental|Paclitaxel releasing angioplasty balloon|Intervention treatment of balloon angioplasty with Paclitaxel releasing angioplasty balloon(Passeo-18 Lux) in new and non-stented re-stenotic lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA)
2948881|NCT02912702|Experimental|L-DEP|Pegaspargase 2000U/m2 day5; doxorubicin hydrochloride liposome injection 25 mg/m2 day 1; etoposide 100 mg/m2 was administered once on the first day of every week; methylprednisolone 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
2948882|NCT02912702|Active Comparator|HLH-94 regimen|Etoposide 150 mg/m2 twice weekly for 2 weeks and then weekly; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
2948883|NCT02912689|Experimental|Neurally adjusted ventilator assist|Neurally adjusted ventilator assist (NAVA) during NIV for exacerbation of COPD.
2948884|NCT02912689|Active Comparator|Pressure support ventilation|Pressure support ventilation (PSV) during NIV for exacerbation of COPD.
2948885|NCT02912676|Experimental|6TG/6MP/MTX|Single arm feasibility study aiming to demonstrate the applicability of combining incremental doses of oral 6-Thioguanine with oral daily 6-Mercaptopurine and oral weekly Methotrexate in order to achieve mean levels of DNA-TG above 500 fmol/mikrogram DNA.
2948886|NCT02912663|Experimental|Verapamil and Magnesium Sulfate|10mg of verapamil in 10 cc of normal saline and 1000mg of magnesium sulfate in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot to the treatment group
2948887|NCT02912663|Placebo Comparator|Placebo|Control group will receive saline only
2948888|NCT02912650|Experimental|Ibuprofen 250 mg / Acetaminophen 500 mg|2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg
2948889|NCT02912650|Active Comparator|Ibuprofen 250 mg|2 caplets of IBU 125 mg
2948890|NCT02912650|Active Comparator|Acetaminophen 650 mg|2 tablets of APAP 325 mg
2948891|NCT02912650|Active Comparator|Placebo|2 caplets of Placebo
2948892|NCT02912637||CF patients|Hyperpolarized Xenon MRI
2948893|NCT02912637||Healthy volunteers|Hyperpolarized Xenon MRI
2948894|NCT02912611|Other|Moderate and High risk for AKI|
2948895|NCT02912598|Active Comparator|Mallinckrodt™ Endobronchial Tube|Usage of a left-sided Mallinckrodt™ double-lumen tube (DLT) to achieve lung isolation and one lung ventilation.
2948896|NCT02912598|Active Comparator|Fuji Uniblocker™|Usage of a Fuji Uniblocker™ in a generic single-lumen tube to achieve lung isolation and one lung ventilation.
2948975|NCT02912026|Experimental|Intravenous|Intravenous AUC0-infinity
2948897|NCT02912598|Experimental|ETView VivaSight™-SL+EB|Usage of a ETView VivaSight™-EB endobronchial blocker in a ETView VivaSight™-SL single-lumen tube to achieve lung isolation and one lung ventilation.
2948898|NCT02912598|Active Comparator|COOK© Arndt Endobronchial Blocker|Usage of a COOK© Arndt Endobronchial Blocker in a generic single-lumen tube to achieve lung isolation and one lung ventilation.
2948899|NCT02912585|Experimental|Own mother's colostrum|Oropharyngeal administration of own mother's colostrum.
2948900|NCT02912585|Placebo Comparator|Placebo|Oropharyngeal administration of sterile water.
2948901|NCT02912585|Active Comparator|Donor human milk|Oropharyngeal administration of donor human milk.
2948902|NCT02912572|Experimental|Pole Mutated Endometrial Cancer|Participants with Pole mutated endometrial cancer Avelumab will be administered intravenously twice per cycle
2948903|NCT02912572|Experimental|MSS Endometrial Cancer|Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle
2948904|NCT02912559|Experimental|Arm I (combination chemotherapy, atezolizumab)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3. Treatment repeats every 14 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes starting on day 1 of course 1 or 2. Treatment repeats every 14 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.
2948905|NCT02912559|Active Comparator|Arm II (combination chemotherapy)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3. Treatment repeats every 14 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2948906|NCT02912546|Active Comparator|Control group|Eighteen healthy subjects and eighteen hypertensive patients (men and women) will be enrolled. A 1.5 Tesla MRI device with a large magnet bore (70 cm) will be used, allowing positions change. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and Cerebral Blood Flow (CBF) maps will be reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers). Differences in CBF values (in mL/100g/min) will be analyzed using SAS 9.3 software for Windows (SAS Institute, Cary North Carolina, USA).
2948907|NCT02912546|Active Comparator|Stroke patients|Eighteen stroke patients (men and women) will be enrolled. A 1.5 Tesla MRI device with a large magnet bore (70 cm) will be used, allowing positions change. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and Cerebral Blood Flow (CBF) maps will be reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers). Differences in CBF values (in mL/100g/min) will be analyzed using SAS 9.3 software for Windows (SAS Institute, Cary North Carolina, USA).
2948908|NCT02912533|Experimental|JR-131|
2948909|NCT02912520||Patients with antibiotic therapy|Patients with antibiotic therapy for 2 weeks.
2948910|NCT02912520||Patients without antibiotic therapy|Patients without any antibiotic therapy in the last 3 months.
2948911|NCT02912507|Experimental|Investigational Enlighten Device|Tattoo removal treatments with the investigational Cutera enlighten laser
2948912|NCT02912507|Active Comparator|Cynosure PicoSure 755 nm laser|Tattoo removal treatments with the Cynosure PicoSure 755 nm laser
2948913|NCT02912494|Experimental|JR-131|
2948914|NCT02912494|Active Comparator|Darbepoetin alfa|
2948915|NCT02912481|Experimental|Posterior tibial artery|real time ultrasound guided arterial catheterization on the posterior tibial artery
2948916|NCT02912481|Active Comparator|Radial artery|real time ultrasound guided arterial catheterization on the radial artery
2948917|NCT02912481|Active Comparator|Dorsalis pedis artery|real time ultrasound guided arterial catheterization on the dorsalis pedis artery
2948918|NCT02912468|Experimental|Dupilumab (Arm A)|A dose of dupilumab will be administered subcutaneously (SC) every 2 weeks (q2w) up to Week 24. Patients will use MFNS daily.
2948919|NCT02912468|Placebo Comparator|Placebo (Arm B)|A matching placebo will be administered subcutaneously (SC) every 2 weeks (q2w) up to Week 24. Patients will use MFNS daily.
2948920|NCT02912455|Active Comparator|Study Drug (canagliflozin)|Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
2948921|NCT02912455|Placebo Comparator|Placebo|Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
2948922|NCT02912442||Infertile women study 1|
2948923|NCT02912442||Infertile women study 2|
2948924|NCT02912442||Repeated pregnancy loss|
2948925|NCT02912429|Other|Inlay|specific technical type of patellofemoral arthroplasty
2948926|NCT02912429|Other|Onlay|specific technical type of patellofemoral arthroplasty
2948927|NCT02912416|Experimental|Probiotics|Capsule with probiotics
2948928|NCT02912416|Placebo Comparator|Placebo|Capsule with placebo
2948929|NCT02912403||Postpartum Cesarean Section|We will be including postpartum women as this study idea is pertaining to recent pregnancy
2948930|NCT02912390|Active Comparator|Cerclage|- Macdonald cerclage placed in standard fashion
2948931|NCT02912390|Active Comparator|Expectant management|- Patient is placed on activity restrictions
2948932|NCT02912377|Experimental|Arm 1; B12019 / Neulasta|2 single doses of B12019 followed by one dose of Neulasta
2948933|NCT02912377|Experimental|Arm 2; Neulasta / B12019|2 single doses of Neulasta followed by one dose B12019
2948934|NCT02912364|Experimental|Eslicarbazepine|Randomized to eslicarbazepine 800mg po bid in crossover design.
2948935|NCT02912364|Experimental|Carbamazepine|Randomized to carbamazepine 400mg po bid in crossover design.
2948936|NCT02912338|Experimental|Resistant Training Group|sandbag 2-5lb, grip ball, twice/week, Duration:12 weeks
2948937|NCT02912338|Active Comparator|Control Group|not change lifestyle
2948938|NCT02912325|Other|FaseMetS ® a food supplement|Daily administration: 2 tablets FaseMETS a day
2948976|NCT02912026|Experimental|Oral|Oral AUC0-infinity
2948939|NCT02912312|Experimental|Group 1 - Shorter Regional Nodal Irradiation (RNI)|"Participants receive about 3 weeks of radiation (15 treatments) to the entire breast or chest wall and the lymph nodes in that area.~Participants also have 5-8 additional treatments of radiation as a boost.~Questionnaires completed at baseline and at at months 3, 6, 12, 18, 24, 66, and 126 months after radiation therapy."
2948940|NCT02912312|Active Comparator|Group 2 - Standard Regional Nodal Irradiation (RNI)|"Participants receive about 5 weeks of radiation (25 treatments) to the entire breast or chest wall and the lymph nodes in that area.~Participants also have 5-8 additional treatments of radiation as a boost.~Questionnaires completed at baseline and at at months 3, 6, 12, 18, 24, 66, and 126 months after radiation therapy."
2948941|NCT02912299||Septic patients|Patients admitted to the ICU that fulfill the criteria for the systemic inflammatory response syndrome in the presence of a(n expected) new infection. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
2948942|NCT02912299||CABG patients|Patients admitted to the ICU after coronary artery bypass grafting. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
2948943|NCT02912299||Patients before hip replacement|Patients that will undergo a hip replacement because of arthrosis. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
2948944|NCT02912286|Active Comparator|conventional needle irrigation|side-vented needle used for endodontic irrigation
2948945|NCT02912286|Experimental|passive ultrasonic irrigation|IrriSafe ultrasonic tip used for irrigation agitation in endodontic treatment
2948946|NCT02912286|Experimental|sonic irrigation|Vibringe is a sonic irrigation system used to irrigate and activate the irrigant at same time
2948947|NCT02912273||Fall Risk Assessment Group|-Participants will complete baseline primarily self-administered cancer-specific geriatric assessments and measures of neuropathy and pain, an abbreviated geriatric assessment with each follow-up clinic visit (generally every 3-4 weeks in patients receiving systemic therapy) for 6-months of follow-up and a final end-of-study assessment.
2948948|NCT02912260|Experimental|MGL-3196|Study Drug
2948949|NCT02912260|Placebo Comparator|Placebo|Matching Placebo
2948950|NCT02912247|Experimental|monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection 40mg administered subcutaneously once
2948951|NCT02912247|Active Comparator|adalimumab|adalimumab 40mg administered subcutaneously once
2948952|NCT02912234|Experimental|Apixaban and Clarithromycin|
2948953|NCT02912221|No Intervention|Control|Participants will be reimbursed for participation in the study but will not receive other encouragements for meeting fitbit and step count goals
2948954|NCT02912221|Active Comparator|Incentive|An incentive will be used for this arm to encourage participants to meet their step goals
2948955|NCT02912208|Experimental|Arm 1 (Eltrombopag)|Arm 1 is the active treatment arm
2948956|NCT02912208|Placebo Comparator|Arm 2 (Placebo)|Arm 2 is the control arm
2948957|NCT02912195|Experimental|Intravenous lidocaine|"Participants will receive IV lidocaine (75 mg if <50kg, 100 mg if 50 - 100 kg, and 150 mg if >100 kg) over 10 minutes in a 100 mL normal saline minibag followed by a 50 minute IV lidocaine drip (75 mg if <50kg, 100 mg if 50 - 100 kg, and 150 mg if >100 kg) in a 100 mL normal saline minibag.~At 20 and 40 minutes, participants can elect to receive morphine 4mg IV as a rescue analgesic."
2948958|NCT02912195|Active Comparator|Morphine|"ED provider will choose an appropriate dose of intravenous morphine for the patient.~At 20 and 40 minutes, participants can elect to receive morphine 4mg IV as a rescue analgesic."
2948959|NCT02912182|Placebo Comparator|Placebo|Day 1: Intravenous sodium-chloride 2ml Day 2-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
2948960|NCT02912182|Active Comparator|Short treatment|Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-3: 10 tablets prednisolone 5 mg Day 4-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
2948961|NCT02912182|Active Comparator|Standard treatment|Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-6: 10 tablets prednisolone 5 mg Day 7: 8 tablets prednisolone 5 mg Day 8: 6 tablets prednisolone 5 mg Day 9: 4 tablets prednisolone 5 mg Day 10: 2 tablets prednisolone 5 mg Day 11: 1 tablet prednisolone 5 mg
2948962|NCT02912169|Experimental|Autologous Adipose-derived Stromal Vascular Fraction infusion|Autologous Adipose-derived Stromal Vascular Fraction (AD-SVF infusion) intravenous (IV) and Intranasal.
2948963|NCT02912156|Experimental|Vaway FC Tablets|Vaway FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing
2948964|NCT02912156|Active Comparator|VFEND FC Tablets|VFEND FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing
2948965|NCT02912143||newly diagnosed children with hemophilia|no intervention
2948966|NCT02912130|No Intervention|Control|No Intervention
2948967|NCT02912130|Experimental|Exercise|"Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise~Resistance Exercise i.e. 60 minutes per week of progressive resistance training"
2948968|NCT02912130|Experimental|Exercise+Nutrition|"Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise~Dietary Supplement i.e. Protein Supplementation 1.2-1.5g/kg/body weight per day"
2948969|NCT02912130|Experimental|Nutrition|Dietary Supplement: Protein Supplementation i.e. 1.2-1.5g/kg/body weight per day
2948970|NCT02912104|Experimental|hAECs transplantation|To clarify the safety and effectiveness of human amniotic epithelial cells transplantation for the treatment of primary ovarian insufficiency(POI) patients
2948971|NCT02912078|Experimental|Pocket-warmed epidural medication|This arm will consist of pocket-warmed epidural medications to be administered per standard protocol to patients randomized to this group; this group is the pocket-warming group.
2948972|NCT02912078|Active Comparator|Room-temperature epidural medication|This arm will consist of room-temperature epidural medications to be administered per standard protocol to patients randomized to this group. This group has no experimental intervention; standard of care labor epidural.
2948973|NCT02912052|Experimental|Peri-operative chemotherapy|Patients receive 2 cycles of chemotherapy before surgery,and contniue to receive another 4 cycles of chemotherapy 21-28 days later after surgery.
2948974|NCT02912052|Active Comparator|postoperative chemotherapy|Patients receive 6 cycles of chemotherapy 21-28 days later after surgery.
2948978|NCT02912000|Experimental|Intervention|The intervention group will receive the TEACH intervention - an electronic tablet screening in waiting room for the modifiable risk factors
2948979|NCT02912000|No Intervention|Control|Care as usual: No electronic tablet in waiting room
2948980|NCT02911987|Experimental|the 'cardio' HIT group|Group 1 receives HIT exercise, aimed only at improving cardiovascular endurance (the 'cardio' HIT group).
2948981|NCT02911987|Experimental|the 'general' HIT group|Group 2 receives HIT exercise aimed at improving both cardiovascular and general muscle condition (the 'general' HIT group ).
2948982|NCT02911987|Experimental|the 'lumbar' HIT group|Group 3 receives HIT exercise, aimed at improving both cardiovascular condition and specific trunk muscle condition (the 'lumbar' HIT group).
2948983|NCT02911987|Experimental|the 'combined' HIT group|Group 4 receives HIT exercise which is a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'combined' HIT group). These trainings will take place in the REVAL Rehabilitation Research Center on the campus of Hasselt University in Diepenbeek.
2948984|NCT02911987|Active Comparator|control group|Group 5 receives MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group)
2948985|NCT02911974|Active Comparator|Acquire EUS Biopsy Device|All patients will undergo sampling of pancreatic masses using the Acquire EUS Biopsy Device. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
2948986|NCT02911974|Active Comparator|Expect EUS Aspiration Needle|All patients will undergo sampling of pancreatic masses using the Expect EUS Aspiration Needle. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types
2948987|NCT02911961|Experimental|Acetaminophen|Subjects will take extra strength acetaminophen (4g/day) for the three days prior to the embolization procedure.
2948988|NCT02911961|No Intervention|Observational - No Acetaminophen|Subjects will take no acetaminophen containing products prior to the embolization procedure.
2948989|NCT02911948|Experimental|Insulin degludec/liraglutide|
2948990|NCT02911948|Active Comparator|Insulin degludec|
2948991|NCT02911935|Active Comparator|Oral azithromycin|Oral Azithromycin
2948992|NCT02911935|Placebo Comparator|Placebo|Oral Placebo
2948993|NCT02911922|Experimental|Endorectal balloon - Radiation therapy|"Group 1 : Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
2948994|NCT02911922|Experimental|Rectal spacer - Radiation therapy|"Group 2 : Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
2948995|NCT02911909|Active Comparator|Standard rehabilitation|Patients will receive standard post-operative ACL rehabilitation
2948996|NCT02911909|Experimental|Delfi moderated blood flow restriction|Patients will receive Delfi moderated blood flow post-operative ACL rehabilitation
2948997|NCT02911883||Normal|Not having glaucoma or retinal pathology
2948998|NCT02911883||Glaucoma|Having glaucoma.
2948999|NCT02911883||Retina|Having retinal pathology
2949000|NCT02911870|Experimental|Part A, SNAC|Single dose of 1.2mg, 2.4mg or 3.6mg increasing for each cohort of trial participants.
2949001|NCT02911870|Placebo Comparator|Part A, placebo|Single dose at corresponding dose levels.
2949002|NCT02911870|Experimental|Part B, SNAC, Placebo, Moxifloxacin|Subjects will receive 4 different treatments in random order. SNAC dose between 1.2-3.6 mg, Placebo in two different periods, moxifloxacin 400mg.
2949003|NCT02911857|Experimental|Canakinumab (ACZ885)|Participants continued the study drug based on the final dose and regimen administered at the end of the CACZ885N2301 study. All participants received 1 or 2 ACZ885 subcutaneous injections every 4 or 8 weeks.
2949004|NCT02911844|Other|Fulvestrant|500 mg administered intramuscularly (as two 5 mL injections) on days 0, 14, 28 and 56
2949005|NCT02911831|Experimental|Tranexamic Acid: Abdominal Hysterectomy|"Agent/Device: Tranexamic acid. Patients undergoing abdominal hysterectomy who consent to the study may be randomized to this arm.~· Protocol dose: 1g in solution to be given intravenously, within 1 hour prior to procedure"
2949006|NCT02911831|Placebo Comparator|Sodium chloride (placebo): Abdominal Hysterectomy|"Agent/Device: 0.9% sodium chloride solution. Patients undergoing abdominal hysterectomy who consent to the study may be randomized to this arm.~· Protocol dose: 100ml to be given intravenously, within 1 hour prior to procedure"
2949007|NCT02911818|Active Comparator|CMS-Alone|Lifestyle counseling, as currently recommended by the CMS.
2949008|NCT02911818|Active Comparator|CMS-Liraglutide|CMS lifestyle counselling plus liraglutide.
2949009|NCT02911818|Active Comparator|Multi-Component Intervention|CMS-Liraglutide plus a 1000-1200 kcal/day portion-controlled diet.
2949010|NCT02911818|Active Comparator|12-Week Extension Study: Phentermine Group|After the 1-year trial, half the participants who join the extension study will be randomized to phentermine 15.0 mg/d in a double-blind fashion, while continuing to take liraglutide. They will also continue to receive monthly lifestyle counseling.
2949011|NCT02911818|Active Comparator|12-Week Extension Study: Placebo Group|After the 1-year trial, half the participants who join the extension study will be randomized to placebo in a double-blind fashion, while continuing to take liraglutide. They will also continue to receive monthly lifestyle counseling.
2949012|NCT02911805|Active Comparator|Aerobic Exercise|Exercise 3 times a week
2949013|NCT02911805|Placebo Comparator|Balance Training|Group balance training 3 times a week
2949114|NCT02910934|No Intervention|non-IRS|This arm is comprised of village clusters that will not receive indoor residual spray
2949014|NCT02911792|Experimental|Dapagliflozin|Subjects will be randomized to dapagliflozin, 5 mg/day. After 2 weeks (Visit 5), dapagliflozin will be increased to 10 mg/day
2949015|NCT02911792|Active Comparator|Metformin|Subjects will be randomized to metformin-XR, 1000 mg/day. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).
2949016|NCT02911779|Other|change of medilateral angle line|change of medilateral angle line during crowning of the head
2949017|NCT02911766|Active Comparator|Corsodyl, 0.2% mouthrinse|"The comparator solution was Corsodyl, 0.2% Chlorhexidine mouthrinse,~Intervention Rinsing 60 sec with Comparator solution twice daily for 21 days"
2949018|NCT02911766|Experimental|FluxProKlorhexidine 0.12% mouthrinse|"The experimental solution was FluxProChlorhexidine 0.12% mouthrinse~Intervention Rinsing 60 sec with test solution twice daily for 21 days"
2949019|NCT02911766|Experimental|Corsodaily 0.06% mouthrinse|"The second experimental solution was Corsodaily, 0.06% chlorhexidine mouthrinse.~Intervention Rinsing 60 sec with test solution twice daily for 21 days"
2949020|NCT02911753|Experimental|Mediterranean Lemonade Consumption|All participants will be asked to consume 32 ounces daily of Mediterranean Lemonade. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
2949021|NCT02911753|Experimental|Green Tea Consumption|All participants will be asked to consume 32 ounces daily of Green Tea. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
2949022|NCT02911753|Placebo Comparator|Flavored Water Consumption|All participants will be asked to consume 32 ounces daily of Flavored Water. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
2949023|NCT02911740|Experimental|Urine LAM Ag test|Patients will be enrolled prospectively and tested for TB using the urine LAM Ag test
2949024|NCT02911740|No Intervention|Retrospective arm|Charts of retrospectively selected patients from the Hospital Santo Tomas database who presented within the last five years meeting inclusion criteria will be used as controls
2949025|NCT02911727|Experimental|Fast-track discharge|Intention to discharge within 28 hours after elective cesarean section including a home visit by a nurse or midwife from the postnatal ward.
2949026|NCT02911727|No Intervention|Standard discharge|Discharge at least 48 hours after elective cesarean section.
2949027|NCT02911714|Experimental|CEUS and Delayed Graft Function|On the first post-operative day after kidney transplantation, recipients enrolled in the study will undergo CEUS using Lumason to quantify microvascular perfusion within the cortical and medullary zones of the kidney allograft for comparison to the concentration of neutrophil gelatinase-associated lipocalin (NGAL, an early biomarker of acute kidney injury) measured from recipient urine simultaneously collected on the first post-operative day.
2949028|NCT02911714|Experimental|CEUS and Biopsy-Proven Acute Rejection|We will identify and enroll kidney transplant recipients in need of clinically-indicated duplex ultrasounds and possible biopsy to evaluate allograft dysfunction during hospital admissions and outpatient follow-up. Immediately after the duplex ultrasound, we will perform CEUS using Lumason for allograft perfusion measurements to determine its potential association with biopsy-proven acute rejection according to the most recent Banff criteria.
2949029|NCT02911701|Experimental|Acetaminophen|Study participants randomized to the acetaminophen group will receive 650mg of acetaminophen orally every 6 hours during their postpartum hospital stay.
2949030|NCT02911701|Active Comparator|Ibuprofen|Study participants randomized to the ibuprofen group will receive 600mg of ibuprofen orally every 6 hours during their postpartum hospital stay.
2949031|NCT02911688|Placebo Comparator|placebo|Safflower oil, taken in 2 capsules every 12 hours for a total of 4 doses
2949032|NCT02911688|Active Comparator|gamma tocopherol|gamma tocopherol 1400 mg, taken as 2 700 mg capsules every 12 hours for a total of 4 doses
2949033|NCT02911675||Standard of Care Group|Study Group 1: Standard EVD/IVC management with therapeutic CSF drainage as appropriate and hourly EVD/IVC ICP measurements per standard of care with simultaneous IPM/Camino ICP measurements collected.
2949034|NCT02911675||Experimental Group|Study Group 2: Therapeutic CSF drainage as appropriate, with EVD/IVC closure and ICP assessment approximately every 12 hours with simultaneous IPM/Camino ICP measurements collected.
2949035|NCT02911662|Experimental|3-day treatment|Three-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.
2949036|NCT02911662|Active Comparator|7-day treatment|Seven-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.
2949037|NCT02911649|Experimental|Wearable Device Only|Participants will be allowed to choose one of three wearable devices (FitBit, Garmi or Polar), for the wearable technology intervention. Once the participant has chosen their wearable device they will be oriented to their chosen device, platform to obtain information from the device, as well as a guide with ideas for reducing sedentary behaviour. Participants will be asked to wear the devices every day during waking hours.
2949038|NCT02911649|Experimental|Online Educational Workshop Only|The Online Educational Group will be asked to participate in 6 online workshops that will occur during the 12-week intervention. Adobe connect software will be used to implement these workshops which allows for interaction between participants and leader. Workshops will focus on specific aspects related to reducing sedentary behaviours and increasing PA time. Each workshop will be developed by study coordinator/author (MO) and constructed using Social Cognitive Theory (SCT), ensuring the themes such as self-efficacy, self-control and reinforcements are within each topic. EDU topics will include motivation, goal setting, and activities and ways to reduce sedentary behaviour.
2949039|NCT02911649|Experimental|Wearable Device+Online Edu Workshop|Both the wearable technology intervention and Online Educational Group intervention simultaneously.
2949040|NCT02911649|No Intervention|Control Group|Participants in this group will receive usual care
2949041|NCT02911636|Experimental|Arm 1|Pelvic SABR with intra-prostatic SABR
2949042|NCT02911623|Experimental|Lithoplasty Treatment|Patients in this group will receive treatment with the Shockwave Lithoplasty® System which uses lithotripsy-enhanced, low-pressure balloon dilation of calcified stenotic peripheral arteries.
2949043|NCT02911610|Experimental|Arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
2949044|NCT02911610|Other|volar plate|surgery of wrist fractures with volar plate
2949045|NCT02911597|Experimental|A: Ketamine + Naltrexone or placebo|"Patients will receive two infusions of Ketamine 0.5mg/kg divided into two phases Phase A and Phase B, which are separated by 30 days.~Patients will be randomly assigned to receive either Naltrexone 50 mg or a matched placebo in both Phase A and B. The Naltrexone or placebo will be given 45 min prior to the administration of ketamine 0.5 mg/kg (e.g. patient X assigned to arm X. Arm X is assigned to Ketamine 0.5mg/kg plus Naltrexone 50 mg during Phase A then when transitioning to Phase B they would receive Ketamine 0.5mg/kg plus a matched placebo). In Phase A will then be followed for 30 days with study assessments to examine the durability of Ketamine effects then once at day 30 for transition."
2949046|NCT02911597|Experimental|B: Ketamine + Naltrexone or placebo|"Patients will receive two infusions of Ketamine 0.5mg/kg divided into two phases Phase A and Phase B, which are separated by 30 days.~Patients will be randomly assigned to receive either Naltrexone 50 mg or a matched placebo in both Phase B and A. The Naltrexone or placebo will be given 45 min prior to the administration of ketamine 0.5 mg/kg (e.g. patient X assigned to arm X. Arm X is assigned to Ketamine 0.5mg/kg plus Naltrexone 50 mg during Phase A then when transitioning to Phase B they would receive Ketamine 0.5mg/kg plus a matched placebo). In Phase B will then be followed for 30 days with study assessments to examine the durability of Ketamine effects then once at day 30 for transition."
2949047|NCT02911584|Active Comparator|Sacral colpopexy|Laparoscopic procedure
2949048|NCT02911584|Active Comparator|POPS|Laparoscopic procedure: Pelvic Organs Prolapse Suspension
2949049|NCT02911571|Experimental|MMprofiler SKY92|Eligible patients will have their bone marrow biopsy sample analyzed for the prognostic MMprofiler SKY92 gene signature
2949050|NCT02911532|Experimental|Optical Coherence tomography|
2949051|NCT02911519|Experimental|Brief Group Psychoeducation|It was designed after a review of the literature on the subject; content and procedures will be written in a manual. They will be five sessions of two hours once a week. Each session will be conducted by a clinical psychologist and a general practitioner trained in group management.
2949052|NCT02911519|Active Comparator|Treatment as Usual Only|The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
2949053|NCT02911493|Experimental|Sedentary Group-Experimental|The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.
2949054|NCT02911493|Experimental|Sedentary Group-Interventional|The intervention group will use the activPAL data to see how sedentary they have been throughout a week where as the control group will not see this data until the end of the study.
2949055|NCT02911493|Active Comparator|Physical Activity Group|The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.
2949056|NCT02911480|Experimental|oxytocin intravenous 0.1 IU|single dose of 0.1 International Units (IU) intravenous (IV) oxytocin
2949057|NCT02911480|Experimental|oxytocin intravenous 1 IU|single dose of 1 IU IV oxytocin
2949058|NCT02911480|Experimental|oxytocin intravenous 10 IU|single dose of 10 IU IV oxytocin
2949059|NCT02911480|Experimental|oxytocin tablet 20 IU|single dose of 20 IU tablet oxytocin
2949060|NCT02911480|Experimental|oxytocin tablet 200 IU|single dose of 200 IU tablet oxytocin
2949061|NCT02911467|Experimental|MR imaging with hyperpolarized 13C pyruvate of men with CRPC|75 men with castration-resistant prostate cancer (CRPC) will undergo MR imaging with hyperpolarized 13C pyruvate of a pre-selected target lesion at baseline and after 1 month of treatment with an androgen signaling inhibitor. Patients with CRPC that is not primarily refractory (defined as disease progression by PCWG2 criteria within 6 months of treatment initiation) to Androgen Signaling Inhibitors (ASI) treatment will undergo a third metabolic MR scan at the time of disease progression. Patients may undergo optional MR- or CT-guided tumor biopsies at baseline and at the time of disease progression.
2949062|NCT02911454|Experimental|Healthy infants: fully or partly formula fed|
2949063|NCT02911441|Experimental|Treatment Group|Receives 8-12 weeks of one-on-one Cognitive Behavioral Therapy sessions
2949064|NCT02911441|No Intervention|Control Group|Receives no intervention during data-collection phase. Participants in this group will receive the intervention post-data collection.
2949065|NCT02911428||dosages of 0.25 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac in the dosages of 0.25 ml, during the study under Protocol 02-E-2015 in October-November 2015.
2949066|NCT02911428||dosages of 0.5 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac in the dosages of 0.5 ml, during the study under Protocol 02-E-2015 in October-November 2015.
2949067|NCT02911415||the dosage of 0.25 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac-Combi in the dosages of 0.25 ml, during the study under Protocol 01-COMBI-2015 in October-November 2015.
2949068|NCT02911415||the dosage of 0.5 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac-Combi in the dosages of 0.5 ml, during the study under Protocol 01-COMBI-2015 in October-November 2015
2949069|NCT02911389|Active Comparator|Home PT via web-based platform|unsupervised, home rehabilitation delivered by a web-based platform
2949070|NCT02911389|Active Comparator|Home PT via paper manual|unsupervised, home rehabilitation delivered by a paper manual
2949071|NCT02911389|Active Comparator|outpatient PT|outpatient physical therapy
2949072|NCT02911363|Active Comparator|Capitvator Cassette|The EMR specimen will be processed using the Captivator Cassette.
2949073|NCT02911363|Active Comparator|Standard of Care Processing|The EMR specimen will be prepared per Standard of Care.
2949115|NCT02910895|Other|single arm|single tumor biopsy
2949191|NCT02910362|Active Comparator|AMO phacoemulsification equipment|cataract surgery with the AMO phacoemulsification equipment
2949074|NCT02911350|Experimental|Hormone Suppressors, Paclitaxel & Radiation therapy|"Hormone Suppressors: Patients may take any of the following combinations for a period of 6 months:~Lupron / Flutamide~Zoladex/ Flutamide~Lupron/ Casodex~Zoladex/ Casodex~Paclitaxel: 30 mg/m2 twice a week administered as a one hour infusion either Monday & Wednesday or Tuesday & Thursday for eight consecutive weeks will be started within the first week of radiation therapy. Following the first 3 dose levels, the dose of Paclitaxel will be escalated to 35 mg/m2 (dose level IV), 40 mg/m2 (dose level V) & 45 mg/m2 (dose level VI).~Radiation Therapy: 5 days a week for 8 weeks to a total dose of 66.6 to 73.8 Gray depending on when patient enter the study."
2949075|NCT02911337|Experimental|Lifestyle modification|Lifestyle modification
2949076|NCT02911324|Experimental|Nabilone|Will receive nabilone at 1 mg daily (BID) over 4 weeks.
2949077|NCT02911324|Experimental|Nabilone and EX/RP|Will receive nabilone at 1 mg daily (BID) plus therapist-guided Exposure and Response Prevention Therapy during 4 weeks.
2949078|NCT02911311|Experimental|IVC group|intravitreal injection of conbercept (IVC) group：all study eyes randomised to receive conbercept will receive an intravitreal injection of conbercept 2 mg/ 0.05 mL at baseline and at 1 and 2 moths. Further treatment since months 3 is determined by the degree of regression of neovascularization (NV) of disc and elsewhere on clinical examination
2949079|NCT02911311|Active Comparator|PRP group|panretinal photocoagulation (PRP) group:all study eyes randomised to receive PRP will receive an fill-in PRP in 1-2 two weekly sessions as per routine clinical practice with emphasis on targeting retinal nonperfusion areas
2949080|NCT02911298|Experimental|Mucoadhesive formulation|A single dose of 100 mg Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation is administered to subject in fasted state
2949081|NCT02911298|Active Comparator|Non-mucoadhesive formulation|A single dose of 100 mg Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation is administered to subject in fasted state
2949082|NCT02911285|Experimental|NAC/CBT|Participants will receive N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT) for 8 weeks.
2949083|NCT02911285|Placebo Comparator|Placebo/CBT|Participants will receive placebo pills and CBT for 8 weeks.
2949084|NCT02911272|Active Comparator|2-hour group|Augmentation of labour at 2-hour action line on the labour partograph
2949085|NCT02911272|Experimental|4-hour group|Augmentation of labour at 4-hour action line on the labour partograph
2949086|NCT02911259|Experimental|Group 1|Post-operative suction is set to -2 cmH2O.
2949087|NCT02911259|Active Comparator|Group 2|Post-operative suction is set to -10 cmH2O (standard treatment).
2949088|NCT02911207|Experimental|Intervention arm|patients choose one creative activity (evolutive art-therapy, writing workshop, theatre, singing) and one physical activity (pilates, mindfulness meditation, shiatsu, ayurvedic massage) that they will practice during the following six months
2949089|NCT02911207|Active Comparator|control arm|patients choose one creative activity (evolutive art-therapy, writing workshop, theatre, singing) and one physical activity (pilates, mindfulness meditation, shiatsu, ayurvedic massage) that they will practice during six months but they will start 6 months later after randomization
2949090|NCT02911194|Experimental|Treatment|a2 milk intervention period
2949091|NCT02911194|Placebo Comparator|Control|a1 containing milk (normal) intervention period
2949092|NCT02911168|Active Comparator|Proximal Intercostal Block|See Intervention Section
2949093|NCT02911168|Active Comparator|Paravertebral Block|See Intervention Section
2949094|NCT02911155||US Nuclear Medicine Technologist|radiologic technologists certified in nuclear medicine
2949095|NCT02911142|Experimental|1|Patients with PEL and KSHV-associated large cell lymphoma
2949096|NCT02911116|Experimental|Ustekinumab|Subcutaneous injections of ustekinumab
2949097|NCT02911103|Experimental|Active|Single Arm Study
2949098|NCT02911064||Assessment Questionnaires|Questionnaires completed before and after inpatient rehabilitation. Questionnaires ask about daily living activity performance, expectation of how well daily living activities will be performed after completion of inpatient rehabilitation, symptoms experienced in the past 24 hours, and physical, functional, social, and emotional well-being.
2949099|NCT02911051|Experimental|Actreen Hydrolite Cath|a new hydrophilic coated catheter for Urinary Intermittent Catheterisation
2949100|NCT02911025||Patients Treated With Clobazam|Single group, patients treated with clobazam by their treating physician (no interventions from PI), followed longitudinally for 1 week after reaching effective clobazam dose.
2949101|NCT02911012||Study Group|The identified population will be assessed on VTE risk according to the risk score PADUA, CAPRINI, KHORANA, and IMPROVE for BLD risk.
2949102|NCT02910999||NSCLC patients with squamous tumor histology|
2949103|NCT02910999||NSCLC patients with non-squamous tumor histology|
2949104|NCT02910986|No Intervention|Usual Care|Breast density notification using standard language reporting for dense and non-dense breasts within the mammogram results notification letter
2949105|NCT02910986|Active Comparator|Enhanced|Usual Care plus a written educational brochure
2949106|NCT02910986|Active Comparator|Interpersonal|Usual Care plus Enhanced plus interaction with a promotora (lay health educator)
2949107|NCT02910973|Active Comparator|Vagus Nerve Stimulation|Device: Vagus nerve stimulation Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes.
2949108|NCT02910973|Sham Comparator|Sham Vagus Nerve Stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes.
2949109|NCT02910960|Active Comparator|Acquire EUS Biopsy Device|All patients will undergo sampling of pancreatic masses using the Acquire EUS Biopsy Device. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
2949110|NCT02910960|Active Comparator|SharkCore Biopsy System|All patients will undergo sampling of pancreatic masses using the SharkCore Biopsy System. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
2949111|NCT02910947|Experimental|quadratus lumborum|
2949112|NCT02910947|Experimental|TAP(Transversus abdominis plane)|
2949113|NCT02910934|Experimental|IRS|This arm is comprised of village clusters that have received indoor residual spray with Actellic CS.
2949116|NCT02910882|Experimental|Single Arm|"Cohort I (PEGPH20 Dose Escalation + Gemcitabine and Concurrent Radiotherapy), First 3 Patients:~An abbreviated sequential dose escalation schema for the first 3 patients (each subsequent patient will be accrued only after no dose limiting toxicities are found in the first 2 weeks of concurrent therapy for the previous patient).~Intravenous (IV) PEGPH20, per dose escalation guidelines for first 3 patients; Intravenous (IV) Gemcitabine (Standard Regimen); Radiotherapy (Standard Regimen);~Cohort II (PEGPH20 + Gemcitabine and Concurrent Radiotherapy), Patients 4 - 10:~IV PEGPH20, per dosing level determined in dose escalation (Cohort I); IV Gemcitabine (Standard Regimen); Radiotherapy (Standard Regimen);"
2949117|NCT02910869||Successful weight loss|Patients who have lost =>5% of their weight after completing MOVE! or TeleMOVE!
2949118|NCT02910869||Unsuccessful weight loss|Patients who have lost <5% of their weight after completing MOVE! or TeleMOVE!
2949119|NCT02910843|Experimental|Regorafenib & Capecitabine|"Regorafenib dose level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.~Regorafenib dose level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table.~Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.~External beam Radiotherapy~Surgery"
2949120|NCT02910817|Experimental|Metformin-treated group|51 overweight and obese women (BMI>24) with PCOS underwent their first fresh autologous IVF-embryo transfer cycle
2949121|NCT02910817|Placebo Comparator|Placebo|A cohort of fifty-one cross matched PCOS women
2949122|NCT02910804|Experimental|68Ga-BBN-IRDye800CW PET/NIRF|The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.
2949123|NCT02910791||atopic dermatitis|up to 40 subjects with atopic dermatitis will be enrolled into study.
2949124|NCT02910791||psoriasis|up to 20 subjects with psoriasis will be enrolled into study.
2949125|NCT02910791||people without skin conditions|Up to 40 subjects without skin conditions will be enrolled into study.
2949126|NCT02910778|Experimental|Atorvastatin|80 mg atorvastatin for 14 days with a loading dose of 180 mg ticagrelor on day 15
2949127|NCT02910778|Placebo Comparator|Placebo|Placebo for 14 days with a loading dose of 180 mg ticagrelor on day 15
2949128|NCT02910765|Active Comparator|M methylene blue and ozone|intravenous methylene blue and blood mixed with ozone ozone injection in early sepsis patients
2949129|NCT02910765|Placebo Comparator|P Placebo|saline and oxygen mixed blood injection in early sepsis patients
2949130|NCT02910752|Experimental|"CLAM|PBSC"|CLAM chemotherapy with mobilized PBSC infusion: Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
2949131|NCT02910739|Experimental|Part I: MK-8931 40 mg in Moderate HI Participants|Single oral dose of MK-8931 40 mg tablet in participants with moderate HI in fasted state (Part I)
2949132|NCT02910739|Active Comparator|Part I: MK-8931 40 mg in Healthy Participants|Single oral dose of MK-8931 40 mg tablet in healthy matched participants in fasted state (Part I)
2949133|NCT02910739|Experimental|Part II: MK-8931 40 mg in Mild HI Participants|Single oral dose of MK-8931 40 mg tablet in participants with mild HI in fasted state (Part II)
2949134|NCT02910739|Active Comparator|Part II: MK-8931 40 mg in Healthy Participants|Single oral dose of MK-8931 40 mg tablet in healthy matched participants in fasted state (Part II)
2949135|NCT02910726|Experimental|Sentinel Lymph Node Biopsy|This is a single-center clinical trial to evaluate non-inferiority of ICG-guided SLN biopsy compared with the gold standard TcL-guided SLN biopsy in pediatric patients with solid tumors. Each patient will undergo TcL, consistent with the standard of care, but the surgeon will be blinded to the results preoperatively. Intraoperatively, ICG injection and transdermal lymphography will be used to identify the draining nodal basin and the position of the sentinel nodes. ICG transdermal lymphography will be considered successful if SLNs can be visualized on near-infrared imaging. After the transdermal lymphography results have been recorded, the surgeon will be unblinded to the TcL mapping.
2949136|NCT02910700|Experimental|TRIDeNT-A: Nivolumab + Dabrafenib + Trametinib|"Group consists of metastatic melanoma patients, except those with untreated brain metastases.~Participants take Trametinib by mouth every day while on study.~Participants take Dabrafenib by mouth twice a day.~Participants receive Nivolumab by vein on Days 1 and 15 of each cycle.~Cycles are 28 days."
2949137|NCT02910700|Experimental|TRIDeNT-B: Nivolumab + Dabrafenib + Trametinib|"Group consists of metastatic melanoma patients with untreated brain metastases.~Participants take Trametinib by mouth every day while on study.~Participants take Dabrafenib by mouth twice a day.~Participants receive Nivolumab by vein on Days 1 and 15 of each cycle.~Cycles are 28 days."
2949138|NCT02910687||NSTEMI75+|Patients, 75 years old or older, with Non ST Elevation Myocardial Infarction (NSTEMI)
2949139|NCT02910661||Patients|Focus groups (n=6-8/group) will be conducted at 4 sites selected to maximize racial diversity and to ensure availability of adequate numbers in each age group (Montreal (incl. the McGill University Health Centre (MUHC), Centre Hospitalier Universitaire-Ste. Justine & CHUM ), Pittsburgh, Seattle, and St. Louis). Separate focus groups will be conducted with patients clustered by patient age to maximize homogeneity in developmental stage. Purposive sampling will be employed to ensure that each focus group includes patients with combinations of characteristics that are likely to account for variation in perspectives, including the major racial and ethnic groups, both sexes, time since transplant, and level of adherence.
2949140|NCT02910661||Parents|Focus groups (n=6-8/group) will be conducted at Pittsburgh & Seattle. Focus groups will be conducted with parents clustered by patient age (12-14 y. & 15- 17 y.)
2949141|NCT02910661||Healthcare professionals|One focus group of healthcare professionals (HCP) representing the variety of multidisciplinary transplant team members at each center will be convened. We will aim for 4-8 HCP per group; however, the number will be dictated by the composition and size of the transplant team at each site. We expect variability in the organization of care across the 7 sites, which represent 2 countries and small to large program sizes; including all sites will capture this variability.
2949188|NCT02910375|Other|Cohort A|Patients starting golimumab therapy Week 0: 200 mg Week 2: 100 mg Week 6, 10, 14, and 18: 50 mg (<80 kg) or 100mg (>80 kg body weight)
2949192|NCT02910336||Cases|Orofacial Pain patients under went to quantitative sensory test
2949142|NCT02910648|Experimental|Approach/Inhibit group|"Participants in the experimental group and control sham sound cues group will complete the Modified Go/No-Go Task.~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
2949143|NCT02910648|Sham Comparator|Sham sound cues group|"Participants in the experimental group and control sham sound cues group will complete the Modified Go/No-Go Task.~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
2949144|NCT02910648|Sham Comparator|Sham go/no-go group|"Participants in the control sham go/no-go group will complete a modified Go/No-Go Task with sham approach and inhibit items.~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
2949145|NCT02910635|Experimental|Volanesorsen, Intravenous (IV)|300 mg of volanesorsen (ISIS 304801) administered Intravenous (IV) single dose
2949146|NCT02910635|Experimental|Volanesorsen, Subcutaneous (SQ)|300 mg of volanesorsen (ISIS 304801) administered Subcutaneous (SQ) single dose
2949147|NCT02910635|Active Comparator|Moxifloxacin Hydrochloride|Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose
2949148|NCT02910635|Placebo Comparator|Placebo Intravenous (IV) single dose|Administered as normal saline (0.9% Sodium Chloride)
2949149|NCT02910635|Placebo Comparator|Placebo Subcutaneous (SC) single dose|Administered as normal saline (0.9% Sodium Chloride)
2949150|NCT02910622||Oncogramme breast|Taking a fragment of breast tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme
2949151|NCT02910622||Oncogramme ovarian|Taking a fragment of ovarian tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme
2949152|NCT02910609||Management at PN 3-7 days|Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated at 3-7 days of their life
2949153|NCT02910609||Management after PN 7 days|Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated beyond 7 days of their life
2949154|NCT02910596|Experimental|A|"Ucholine(Bethanechol chloride, 10 mg) 2 tablets oral tid, ac Start on 3rd - 5th postoperative day~In bethanechol chloride arm arm should be vital signs were monitored every 30 minute on first hour then every 4 hours on first day. Any adverse event were recorded.~Remove urethral catheter on 5thpostoperative day. Void volume and postvoid residual urine were record. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
2949155|NCT02910596|Experimental|B|"Early bladder training Start on 3rd - 5th postoperative day~Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
2949156|NCT02910596|Experimental|C|"Early bladder training and Ucholine(Bethanechol chloride, 10 mg) 2 tablets oral tid, ac Start on 3rd - 5th postoperative day~should be vital signs were monitored every 30 minute on first hour then every 4 hours on first day. Any adverse event were recorded.~Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
2949157|NCT02910596|Other|D|-Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative
2949158|NCT02910583|Experimental|MRD Cohort Randomized ibrutinib (blinded)|Subjects will receive 420 mg capsules of single-agent ibrutinib for the first 3 cycles followed by ibrunitib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization. Subjects that are MRD-negative will be randomized to receive ibrutinib 420 mg capsules orally once daily on a continuous schedule until clinical disease progression or unacceptable toxicity
2949159|NCT02910583|Placebo Comparator|MRD Cohort Randomized Placebo to match ibrutinib (blinded)|Subjects will receive 420 mg capsules of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization. Subjects that are MRD-negative will be randomized to receive matching ibrutinib placebo capsules orally once daily on a continuous schedule until MRD-positive relapse, clinical disease progression or unacceptable toxicity.
2949189|NCT02910375|Other|Cohort B|Patients already on golimumab therapy will continue their actual treatment 50 mg every 4 weeks (<80 kg) or 100mg every 4 weeks (>80 kg body weight)
2949190|NCT02910362|Experimental|Alcon phacoemulsification equipment|cataract surgery performed with the Alcon phacoemulsification equipment
2949437|NCT02908620|Active Comparator|CTY-5339-CB 1 Spray|Benzocaine only 14.0% Benzocaine, USP = 28 mg
2949160|NCT02910583|Experimental|MRD Cohort Randomized open-label ibrutinib + venetoclax|Subjects will receive 420 mg capsules of single-agent ibrutinib for the first 3 cycles followed by ibrunitib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization. Subjects that are MRD-positive will be randomized to receive ibrutinib 420 mg capsules and venetoclax 400 mg tablets orally once daily on a continuous schedule until clinical disease progression or unacceptable toxicity.
2949161|NCT02910583|Experimental|MRD Cohort Randomized open-label ibrutinib|Subjects will receive 420 mg capsules of single-agent ibrutinib for the first 3 cycles followed by ibrunitib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization. Subjects that are MRD-positive will be randomized to receive ibrutinib 420 mg capsules orally once daily on a continuous scheduled until clinical disease progression or unacceptable toxicity.
2949162|NCT02910583|Experimental|Fixed Duration Cohort - Open Label ibrutinib + venetoclax|Subjects will receive 420 mg capsules of single agent ibrutinib for first 3 cycles followed by ibrutinib plus venetoclax combination treatment for 12 cycles (a cycle is defined by 28 days) or until disease progression or unacceptable toxicity.
2949163|NCT02910570|Experimental|Liraglutide 3 mg|Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.
2949164|NCT02910570|Placebo Comparator|Liraglutide 3 mg placebo|Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
2949165|NCT02910544||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks.
2949166|NCT02910531|Experimental|ALA supplement|"Clinical data including medical history, plain KUB x-ray and renal ultrasound, routine blood work and 24-hour urine collections for all subjects will be collected as part of normal clinical care at routine clinical visit every 4 months.~Subjects in this study arm will be taking one supplement tablet containing 1200 mg of alpha lipoic acid orally once daily for three years.~At the end of the three years of study drug treatment, all subjects will undergo a low dose non-contrast CT scan to look for a silent change in stone size."
2949167|NCT02910531|Placebo Comparator|Placebo|"Clinical data including medical history, plain KUB x-ray and renal ultrasound, routine blood work and 24-hour urine collections for all subjects will be collected as part of normal clinical care at routine clinical visit every 4 months.~Subjects in this study arm will be taking one placebo tablet containing 10 mg of sucrose orally once daily for three years.~At the end of the three years of study drug treatment, all subjects will undergo a low dose non-contrast CT scan to look for a silent change in stone size."
2949168|NCT02910518|Experimental|Insulin glulisine (U300) - Test formulation|Insulin glulisine (U300) will be given as a single subcutaneous (SC) dose on Day 1 of each period under fasting conditions according to the random list and assigned sequence. Glucose, insulin aspart (IV) and heparin will be used for clamp procedure. NPH insulin (if necessary) and insulin aspart (SC) will be handed out at screening to change insulin regimen and glucagon at Day 1 to treat cases of severe hypoglycemia.
2949169|NCT02910518|Active Comparator|Insulin glulisine - Reference formulation|Insulin glulisine (U100) will be given as a single SC dose on Day 1 of each period under fasting conditions according to the random list and assigned sequence. Glucose, insulin aspart (IV) and heparin will be used for clamp procedure. NPH insulin (if necessary) and insulin aspart (SC) will be handed out at screening to change insulin regimen and glucagon at Day 1 to treat cases of severe hypoglycemia.
2949170|NCT02910505|Experimental|Treatment|Treatment with investigational Cutera enlighten laser for tattoo removal
2949171|NCT02910492|Experimental|Investigational Enlighten Device|Laser treatment for facial skin rejuvenation with the experimental enLighten Laser
2949172|NCT02910479|Experimental|temperature measurements with 4 devices|temperature measurements with e-device Celsius, esophageal probe and a rectal probe and vital sense capsule
2949173|NCT02910466|Experimental|Experimental: rhPTH(1-84)|Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection once daily for 24 months. The dose will be individualized based on Albumin-corrected Serum Calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.
2949174|NCT02910453||VATS group|Pulmonary lobectomy via VATS. VATS starts with a utility incision, approximately 4 cm in length, anterior to the latissimus dorsi muscle at the 4th intercostal space. Muscle fibers are split without cutting and a wound protector is regularly placed in site. The camera port is placed in the 6th or 7th intercostal space at the anterior axillary line and a third 10-mm access is made at the same intercostal space at the posterior axillary line. The hilum is approached anteriorly
2949175|NCT02910453||Open group|Pulmonary lobectomy via posterolateral thoracotomy (PLT). PLT consists in a standard 10-15 muscle-sparing incision at 4th intercostal space, rib divaricators are utilized and the hilum is approached posteriorly as previously described
2949176|NCT02910440|Experimental|DCL-101|
2949177|NCT02910440|Active Comparator|GoLytely|
2949178|NCT02910427|Placebo Comparator|Na salt|regular salt
2949179|NCT02910427|Active Comparator|K salt|potassium-enriched salt
2949180|NCT02910427|Active Comparator|K/Mg salt|potassium and magnesium-enriched salt
2949181|NCT02910414|Experimental|Treated with Peregrine System Kit|The experimental group will receive an infusion of Dehydrated Alcohol Injection, USP into the perivascular space of the renal arteries with the Peregrine Catheter. A total of 0.6mL of the alcohol will be delivered to the perivascular space of each renal artery. The drug will only be delivered once to each renal artery during the treatment procedure.
2949182|NCT02910414|Sham Comparator|Peregrine System Kit (Sham Procedure)|The sham control group will have a percutaneous procedure in which the Peregrine Catheter is delivered to the renal artery, but the needles will not be deployed and no alcohol will be delivered to the perivascular space of the renal arteries.
2949183|NCT02910401|Active Comparator|Asthmatic|Asthmatic subjects will be infected with Rhinovirus (GMP RV16 human (H)RV-16)
2949184|NCT02910401|Active Comparator|Allergic rhinitis|Allergic rhinitis subjects will be infected with Rhinovirus (GMP RV16 HRV-16)
2949185|NCT02910401|Active Comparator|Healthy control|Healthy controls will be infected with Rhinovirus (GMP RV16 HRV-16)
2949186|NCT02910388|Experimental|LLETZ with colposcopy|The LLETZ procedure will be performed under direct colposcopic vision
2949187|NCT02910388|Active Comparator|LLETZ without colposcopy|The LLETZ procedure will be performed without colposcopy
2949193|NCT02910336||Control|Volunteers and presented neither previous diagnostic of orofacial pain nor generalized pain, under went to quantitative sensory test
2949194|NCT02910323||Experimental group|Patients with a history of Cluster Headaches and other TACs, or Trigeminal Neuralgia.
2949195|NCT02910323||Family/Healthy Controls|Healthy volunteer controls and family members may be enrolled for identification of genetic mutations.
2949196|NCT02910310|No Intervention|Baseline period|The baseline period will involve data collection on study outcomes before uterine balloon tamponade (UBT) is introduced at study sites.
2949197|NCT02910310|Experimental|Uterine balloon tamponade|The UBT period will involve data collection on study outcomes after providers at sites are trained on UBT use and UBT is introduced into PPH management practice at study sites.
2949198|NCT02910245|Active Comparator|Mercaptopurine (Purinethol)|Mercaptopurine (Purinethol),1-1.5 mg/kg/day oral, 52 weeks & Prednisone, 40 mg/day oral, 2 weeks, followed by fixed tapering over 6 weeks OR budesonide (cortiment) 9 mg/day during 8 weeks & Mesalamine, 2 g/day oral, 52 weeks.
2949199|NCT02910245|Placebo Comparator|Placebo|Placebo, 1-1.5 mg/kg/day, 52 weeks & Prednisone, 40 mg/day oral, 2 weeks, followed by fixed tapering over 6 weeks OR budesonide (cortiment) 9 mg/day during 8 weeks & Mesalamine, 2 g/day oral, 52 weeks.
2949200|NCT02910232||1|The groups were orthopedic patients and neurosurgical patients. The samples to fill the voiding space of bone and skull same as autografts.
2949201|NCT02910219|Experimental|Treatment|Patients on the treatment arm will take one tablet of crofelemer twice a day (each tablet is 125 mg), to be swallowed whole without chewing or crushing, during cycles 1-2 of chemotherapy with THP or TCHP. Patient will be monitored off crofelemer during cycle 3 of chemotherapy.
2949202|NCT02910219|No Intervention|Control|Patients on the control arm will be on the study for cycles 1-3 of THP or TCHP. Patients on the control arm will not receive crofelemer at any time on this study.
2949203|NCT02910206|Experimental|etomidate|etomidate is given for maintenance of general anesthesia,combined with sufentanil and cisatracurium
2949204|NCT02910206|Experimental|propofol|propofol is given for maintenance of general anesthesia,combined with sufentanil and cisatracurium
2949205|NCT02910193||alcohol-dependent patients|
2949206|NCT02910193||first-degree relatives|Parents, children, siblings of alcohol-dependent patients
2949207|NCT02910193||healthy control subjects|
2949208|NCT02910180||Repository Group|The Repository Group consists of patients which have donated tissue to the repository.
2949209|NCT02910167||Men with spasmodic syndromes|Men with any type of gastrointestinal, hepato-biliary, urinary or genital spasmodic syndromes
2949210|NCT02910167||Women with spasmodic syndromes|Women with any type of gastrointestinal, hepato-biliary, urinary or genital spasmodic syndromes
2949211|NCT02910154|Experimental|Weight loss, training, medication|"The intervention program consists of a comprehensive 24-week treatment period of: 1) Body weight loss without significant loss of muscle mass, through low energy diet combined with 2) Exercise training based on interval training and resistance exercise and 3) Optimal medical treatment for hypertension and hypercholesterolemia (with statin and ACE-inhibition). Further, participants in this allocation group receive nutrition counselling.~The diet products are sponsored by Cambridge Weight Plan. No persons with interest in Cambridge Weight Plan will take part in the intervention phase, analyzing phase, data processing, or publication of data in this study."
2949212|NCT02910154|No Intervention|Control|The control group receives 24 weeks of usual care according to guidelines of Danish Cardiology Society. Treatment of angina pectoris in absence of coronary artery disease is normally provided by the patient's general practitioner and does not comprise intensive lifestyle intervention or medical treatment. If control group participants in this study need medical therapy for hypertension or hypercholesterolemia, this will be effectuated by the researcher, MD. Then, control participants will be monitored with blood pressure and LDL blood samples and receive medicine adjustments according to National Prevention Guidelines during the full study period.
2949213|NCT02910141||CSII (subcutaneous insulin infusion)|People with Type 2 diabetes treated by continuous subcutaneous insulin infusion (CSII)
2949214|NCT02910141||MDI (multiple daily insulin injections)|People with type 2 diabetes treated by multiple daily insulin injections
2949215|NCT02910128|Experimental|School intervention|chiquichefs education innovation
2949216|NCT02910128|No Intervention|control school|A primary schools will function as control schools.
2949217|NCT02910115|Other|Control Group|Following delivery of the fetus patients in the control group will have Pitocin® administered to them intravenously according to the usual protocol. The uterus may be wrapped lap sponges soaked in room-temperature saline while the uterine incision is closed per the attending obstetrician's usual practice. At the discretion of the attending obstetrician additional uterotonic medications (Pitocin®, Methergine® Cytotec® and/or Hemabate®) may be given to improve uterine contraction.
2949218|NCT02910115|Experimental|Study Group|"Following delivery of the fetus, patients in the study group also will have Pitocin® administered to them according to the usual protocol.~Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in cold laparotomy sponges saturated in sterile, iced normal saline. The skin of the abdomen will be draped to prevent contact with the cold towels. Additional uterotonic medications may be given at the discretion of the attending obstetrician."
2949219|NCT02910102|Experimental|RVT-101 35 mg|RVT-101 35 mg
2949220|NCT02910102|Placebo Comparator|Placebo|Placebo
2949221|NCT02910089|Other|Shared Decision Making/Brief Negotiated Interviewing|This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
2949222|NCT02910089|No Intervention|Control Arm|Seven hundred patients will also be identified by Horizon Analytics as a control group for analyses purposes only; these patients will not be contacted.
2949223|NCT02910076|Experimental|Healthy volunteers|
2949224|NCT02910076|Experimental|Diabetes patients|
2949225|NCT02910063|Experimental|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIVI). A single cycle of blinatumomab is continuous infusion with step dosing of 9 µg/day x 7 days, 28 µg/day x 7 days, and 112 µg/days until the end of the cycle.
2949226|NCT02910063|Active Comparator|Investigator's Choice|Standard of care (SOC) chemotherapy per investigator's decision in the second salvage setting. Examples include but not limited to R-ICE, R-DHAP, R-GDP, R-ESHAP, R-EPOCH.
2949227|NCT02910050|Experimental|bicalutamide+ Aromatase Inhibitor|ER(+)/AR(+)/HER2(+) metastatic breast cancer patients that previously treated by an aromatase inhibitor
2949228|NCT02910037|Experimental|patients enrolled for mNGS testing|Patients with meningitis and/or encephalitis will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective chart review and clinical reimbursement documents).
2949229|NCT02910024|Active Comparator|Real-rTMS|Repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex in the lesioned hemisphere using the intermittent theta-burst-stimulation protocol (iTBS; application of 3 pulses with a frequency of 50 Hz, in a theta-rhythm of 5 Hz for 2 seconds, repeated every 10 seconds, duration of one session: about 3,5 minutes) before physiotherapy for 8 days
2949230|NCT02910024|Sham Comparator|Sham-rTMS|Repetitive transcranial magnetic stimulation (rTMS) in sham position (tilted coil over parieto-occipital vertex) before physiotherapy for 8 days
2949231|NCT02910011|Experimental|Topical Administration of Study Drug|2.5 grams of Nanodox 1% (doxycycline monohydrate hydrogel) will be applied topically to an indicated lesion daily for 28 days
2949232|NCT02909985|Experimental|Visual response to IR|"15 healthy participants will describe IR light passing through narrow bandpass filters over a broad spectrum light source~10 colorblind participants will describe IR light passing through narrow bandpass filters over a broad spectrum light source~For both groups, as intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band Tungsten halogen light with narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see."
2949233|NCT02909985|Experimental|Electroretinography|"5 healthy participants will undergo an ERG with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR~A total of 15 participants, or five per retinal disease, will be recruited . Retinal diseases include retinitis pigmentosa, age related macular degeneration, congenital stationary night blindness, cataracts. Participants will undergo an ERG with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR"
2949234|NCT02909985|Experimental|Visual Evoke Potential Test|"5 healthy participants will undergo an VEP with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR~A total of 15 participants, or five per retinal disease, will be recruited . Retinal diseases include retinitis pigmentosa, age related macular degeneration, congenital stationary night blindness, cataracts. Participants will undergo an VEP with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR"
2949235|NCT02909972|Experimental|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days
2949236|NCT02909972|Experimental|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
2949237|NCT02909959|Active Comparator|Sulforaphane|"Participants will take a sulforaphane supplement 3-8 tablets daily, with dose depending upon body weight. Each tablet contains 125 mg broccoli seed powder and 50 mg broccoli sprout extract, providing approximately 15 µmol sulforaphane.~The weight-based dosing schedule is as follows:~3 tablets (approx. 46.5 µmol SF) if <100 lb; 5 tablets (approx. 77.5 µmol SF) if 100-125 lb; 6 tablets (approx. 93 µmol SF) if 126-175 lb; 7 tablets (approx. 108.5 µmol SF) if 176-199 lb; 8 tablets (approx. 124 µmol SF) if ≥ 200 lb"
2949238|NCT02909959|Placebo Comparator|Placebo|Participants in this arm will take placebo tablets that are identical in shape, size, and color to the sulforaphane tablets. The number of tablets taken per day corresponds to the weight-based schedule described for the sulforaphane arm.
2949239|NCT02909946|Active Comparator|Intervention Arm|NHs randomized to the Intervention Arm will implement a new multi-modal infection control program.
2949240|NCT02909946|No Intervention|Control Arm|NHs randomized to the Control Arm will continue their current standard infection control practices.
2949241|NCT02909933|Experimental|liraglutide|liraglutide 3 mg QD for 12 weeks
2949242|NCT02909933|Experimental|metformin and liraglutide|metformin 1000 mg BID and liraglutide 1.2 mg QD for 12 weeks
2949243|NCT02909920|Experimental|Telerehabilitation|The Telerehabilitation group receives a standardized and customized exercises through a web application that allows the Physiotherapist generate videos, images and parameters of each exercise program and send them via email for each patient. Patients are initially supervised by a physiotherapist who will conduct videoconference sessions to ensure proper execution of exercises and encourage patient adherence.
2949244|NCT02909920|Active Comparator|Traditional Physiotherapy|Traditional Physiotherapy group receives assistance in a physiotherapy center through the usual procedure of rehabilitation in Spain consisting in personalized therapy 1 to 1 with a physical therapist and exercise programs for home.
2949245|NCT02909907|Experimental|150 units of abobotulinumtoxinA|150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
2949246|NCT02909907|Experimental|75 units of abobotulinumtoxinA|75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
2949247|NCT02909894|Experimental|Prolonged Sitting|
2949248|NCT02909894|Active Comparator|Light intensity arm ergometry breaks|
2949249|NCT02909881|Experimental|Endurance trained male cyclists|8 male endurance trained male cyclist will consume varying amounts (0, 1, 1.5 and 2 g/min) of PhytoSpherix (sweet-corn derived sugar) during a 150 min . cycling exercise
2949250|NCT02909868|Experimental|RV location|All included subjects will undergo the PV loop test with 'BackBeat PHC' ON and OFF
2949251|NCT02909855||Participants|Parents of children aged 2-4 who will receive the child flu vaccine from their general practitioner (GP)
2949252|NCT02909842|Experimental|study group|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB) and 100 ml bottle of yoghurt drink, unlabelled drinking fermented milk containing probiotic, Lactobacillus paracasei (IMULUS)
2949253|NCT02909842|Placebo Comparator|control group|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB) and 100 ml bottle of placebo, unlabelled acidified milk with similar physical and sensory appearance to the experimental one
2949285|NCT02909673|Experimental|Fourth R|Fourth R: 27 lesson curriculum addressing youth risk and health promoting behaviors
2949254|NCT02909829|Experimental|Closed Loop Delivery|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm. Participants will eat breakfast and bolus, then eat lunch and not bolus.
2949255|NCT02909829|Experimental|Closed Loop Delivery with Meal Detection Module|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm with an overlying meal detection module which detects missed meals and will increase insulin infusion rates based on a predictive meal detection algorithm. Participants will eat breakfast and bolus, then eat lunch and not bolus.
2949256|NCT02909829|Active Comparator|Conventional Pump Therapy|Insulin will be delivered by subcutaneous insulin infusion pump with participants usual infusion rate. Participants will eat breakfast and bolus as per usual, then eat lunch and not bolus.
2949257|NCT02909803|Experimental|Lentil Variety|Each participant will consume a serving of one of eight lentil varieties (Greenland; Improve; Impower; Imigreen; Asterix; Redberry; Redcliff; Redbow) containing 25g available carbohydrate at separate study visits
2949258|NCT02909803|Active Comparator|White Bread|Each participant will consume a serving of white bread containing 25g available carbohydrate on two separate visits
2949259|NCT02909790|Experimental|CURVE LLLT treatment|Up to 20 subjects are randomly selected to receive Curve Low Level Laser Therapy
2949260|NCT02909790|Sham Comparator|SHAM device treatment|Up to 20 subjects assigned to the sham group will be treated with a device that is designed to have the same physical appearance as the treatment group, except that the interlock fuse (grey fuse holder back of device) will be removed prior to treatment. The laser screen will still be active and show to the subject that the treatment time will still be counting down, but will not activate lasers in the treatment paddles
2949261|NCT02909777|Experimental|CUDC-907|"CUDC-907 orally administered~CUDC-907 once daily for 5 consecutive days per week followed by two days without dosing~Dose level assigned at registration~Pre-dose pharmacokinetic blood sample will be collected~Dose escalation will follow a standard 3+3 design"
2949262|NCT02909764|No Intervention|Control Group|Children will receive regularly salted cereal to consume 4 times per week over a 2-month period.
2949263|NCT02909764|Experimental|Low Sodium Group|Intervention: Children will receive low sodium cereal to consume 4 times per week over a 2-month period.
2949264|NCT02909751|Active Comparator|Neoadjuvant chemotherapy|"HER2 negative:~Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv followed by Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv~HER2 positive:~Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv + 3-weekly trastuzumab (8 mg/kg iv saturation, then 6 mg/kg iv) and possibly pertuzumab (840 mg saturation, then 420 mg iv) followed by Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv"
2949265|NCT02909751|Experimental|Neoadjuvant chemotherapy + tocotrienol|"HER2 negative:~Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv followed by Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv.~Daily: Tocotrienol 300 mg x 3~HER2 positive:~Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv + 3-weekly trastuzumab (8 mg/kg iv saturation, then 6 mg/kg iv) and possibly pertuzumab (840 mg saturation, then 420 mg iv) followed by Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv.~Daily: Tocotrienol 300 mg x 3"
2949266|NCT02909738||Volunteers|Healthy volunteers willing to pedal a bike for 30 minutes.
2949267|NCT02909725|Experimental|Limit accumulation of sedentary time|Group 1 (SR): Participants will be asked to limit the accumulation of prolonged bouts ( >50 minutes) of sedentary time.
2949268|NCT02909725|Experimental|Walk 30 minutes most days of the week|Group 2 (WALK): Participants will be asked to walk 30 minutes per day on most days of the week.
2949269|NCT02909725|Active Comparator|Normal daily routine; Usual Care|Group 3 (UC): Participants will be asked to continue on with their normal daily routine. The usual care group will receive no form of intervention.
2949270|NCT02909712|Active Comparator|sulfadoxine-pyrimethamine (SP)|"Group 1 (50 CareStart™ RDT-positive women)~Group 2 (50 CareStart™ RDT-negative women)~These 100 women will have an ECG exam, provide blood for microscopy and molecular analysis, and receive SP on day 0. On days 7, 14, 21, and 28 women will provide blood for microscopy and molecular analysis."
2949271|NCT02909712|Experimental|dihydroartemisinin-piperaquine (DHA-PQP)|"Group 3 (50 CareStart™ RDT-positive women)~Group 4 (50 CareStart™ RDT-negative women)~These 100 women will have an ECG exam, provide blood for microscopy, molecular, and PK analysis, and receive DHA-PQP day 0. On day 1, women will receive dose 2. On day 2, women will have an ECG exam, begin Holter monitoring, provide blood for PK analysis, and receive dose 3. Blood for PK analysis will be drawn at 4, 5, and 6 hours following dose 3. An ECG exam will be conducted during this period and, again, on day 7. On days 7, 14, 21, and 28, women will provide blood for microscopy and molecular analysis."
2949272|NCT02909699||Dose 1|1,000mg of resveratrol per day (1 pill 3 times per day). This ancillary study will be observational without drug administration.
2949273|NCT02909699||Dose 2|1,500mg of resveratrol per day (1 pill 3 times per day)
2949274|NCT02909699||Placebo|Alike looking 1 pill 3 times per day
2949275|NCT02909686|Experimental|Boswellia Serrata|400-800mg in capsule form by mouth every day
2949276|NCT02909686|Experimental|Curcumin|1000-2000mg in capsule form by mouth every day
2949277|NCT02909686|Experimental|Epimedium|1000-2000mg in capsule form by mouth every day
2949278|NCT02909686|Experimental|Fisetin|200-800mg in capsule form by mouth every day
2949279|NCT02909686|Experimental|Luteolin|200-400mg in capsule form by mouth every day
2949280|NCT02909686|Experimental|Nettle|435-1305mg in capsule form by mouth every day
2949281|NCT02909686|Experimental|Pycnogenol|200-400mg in capsule form by mouth every day
2949282|NCT02909686|Experimental|Reishi Mushroom|1600-3200mg in capsule form by mouth every day
2949283|NCT02909686|Experimental|Resveratrol|200-600mg in capsule form by mouth every day
2949284|NCT02909686|Placebo Comparator|Placebo|in capsule form by mouth every day
2949287|NCT02909660|Experimental|Support-seeking intervention|Cognitive-behavioural therapy intervention that guides participants to seek support rather than reassurance; participants' significant others are asked to provide support rather than reassurance.
2949288|NCT02909660|Active Comparator|Family accommodation reduction intervention|Cognitive-behavioural therapy intervention that guides participants' significant others to withhold reassurance when it is requested; participants are asked to refrain from seeking reassurance.
2949289|NCT02909647|Active Comparator|Plan group|3D preoperative planning for the distal radius fracture was performed prior to the osteosynthesis.
2949290|NCT02909647|Active Comparator|Control group|Conventional preoperative planning for the distal radius fracture was performed prior to the osteosynthesis.
2949291|NCT02909621|Active Comparator|Group A|Group A: FLEXOFYTOL® high dosage
2949292|NCT02909621|Active Comparator|Group B|Group B: FLEXOFYTOL® low dosage
2949293|NCT02909621|Placebo Comparator|Group C|Group C: PLACEBO
2949294|NCT02909608||Controls|
2949295|NCT02909608||Children With Pulmonary Hypertension|
2949296|NCT02909595|Experimental|Balloon catheter group|Bile duct stones extraction was carried out with a balloon catheter.
2949297|NCT02909595|Active Comparator|Basket catheter group|Bile duct stones extraction was carried out with a basket catheter.
2949298|NCT02909582|No Intervention|Pfannenstiel Incision|This curved incision is approximately 10-15 cm long and 2 cm above the pubic symphysis. If a pannus is present, the pannus should be retracted up (see diagram) to allow placement of the Pfannenstiel incision.
2949299|NCT02909582|Experimental|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
2949300|NCT02909569|Experimental|INCB039110|INCN039110 400 mg QD for 20 weeks. Subjects without clinical response after four weeks will increase to 600mg QD.
2949301|NCT02909556|Experimental|ACURATE neo AS|
2949302|NCT02909530|Active Comparator|First pass EZ Shot 3Plus then EZ Shot 2|Olympus EZ Shot 3Plus will be used to puncture the mass first (Intervention EUS-FNB with EZ Shot 3Plus first), then the 19G and EZ Shot 2 will be used to puncture the pancreatic mass.
2949303|NCT02909530|Active Comparator|First pass EZ Shot 2 then EZ Shot 3Plus|Olympus EZ Shot 2 will be used to puncture the mass first (Intervention EUS-FNB with EZ Shot 2 19G first), then the EZ Shot 3Plus will be used to puncture the pancreatic mass.
2949304|NCT02909517||Choroidal nevus|Requires distinction from melanoma through diagnostic testing (low-risk features)
2949305|NCT02909517||Choroidal indeterminate melanocytic lesion|Requires diagnostic testing for identification and distinction from nevus and melanoma (high-risk features)
2949306|NCT02909517||Choroidal melanoma|Requires confirmation of diagnosis and evaluation for potential metatstases
2949307|NCT02909517||Suspected metastatic tumour|Requires identification of primary tumour (ie, primary tumour elsewhere)
2949308|NCT02909517||Locally treated ocular tumour|Requires followup to evaluate response to treatment and potential change or repeat therapy
2949309|NCT02909504|Other|Lithium|
2949310|NCT02909491||Cases|Inpatient with severe behavioural disorders
2949311|NCT02909491||Controls|Inpatients without severe behavioural disorder and taking no antipsychotics
2949312|NCT02909478|Experimental|Aprepitant arm|Aprepitant + Tropisetron
2949313|NCT02909478|Active Comparator|Control arm|Dexamethasone+ Tropisetron
2949314|NCT02909465|Placebo Comparator|placebo|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections of distilled water (one 2 ml and the other 0.05 cc/kg) 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
2949315|NCT02909465|Experimental|midazolam|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. one will be 2 ml of distilled water and the other 0.05 mg/kg midazolam, 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
2949316|NCT02909465|Experimental|haloperidol|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. One will be 0.05 cc/kg of distilled water and the other 5 mg of haloperidol (in 2 cc syringes), 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
2949317|NCT02909452|Active Comparator|ENT 1mg daily with pembro every 3 weeks|Entinostat daily in combination with pembrolizumab every three weeks
2949318|NCT02909452|Active Comparator|ENT 5mg weekly with pembro every 3 weeks|Entinostat once weekly in combination with pembrolizumab every three weeks
2949319|NCT02909452|Active Comparator|ENT 10mg bi-weekly with pembro every 3 weeks|Entinostat once every other week in combination with pembrolizumab every three weeks
2949320|NCT02909439|Active Comparator|Neostigmine|Patients in this arm will receive neostigmine for reversal of neuromuscular blockade. Neostigmine is historically the medication that has been used for this purpose.
2949321|NCT02909439|Active Comparator|Sugammadex|Patients in this arm will receive sugammadex for reversal of neuromuscular blockade. Sugammadex is a newer, FDA approved, medication for this purpose.
2949322|NCT02909426||Women aged 40-59|"Asymptomatic women aged 40-59 who participate in the National Cancer Screening Program in Korea and agreed with participating in this study will be the cohort.~The participants' digital mammography and ultrasonography will be interpreted combinedly by radiologists who perform the screening sonography and the participants' digital mammography will be interpreted independently by other radiologists who do not perform the screening sonography."
2949323|NCT02909413|Experimental|Group Desflurane|Anesthesia maintenance: After endotracheal intubation, patients will be randomized into Desﬂurane for maintenance. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
2949324|NCT02909413|Active Comparator|Group Sevoflurane|Anesthesia maintenance: After endotracheal intubation, patients will be randomized into sevoﬂurane for maintenance. The gas flow rate of Sevoflurane group is 2L/ min, include 50％O2 and 1.7-2.0% Sevoflurane.
2949325|NCT02909400|Experimental|Treatment A|Oral administration of 100 mg KH176 twice daily
2949326|NCT02909400|Placebo Comparator|Treatment B|Oral administration of matching placebo twice daily
2949549|NCT02907840|Experimental|Recruitment|Lung aeration monitored by Swisstom BB2 during PEEP steps and recruitment maneuver
2949327|NCT02909387|Experimental|Stratum A|This is the group that will first receive Project UPLIFT, a distance-delivered mindfulness-based cognitive therapy intervention. The intervention is conducted by one-hour phone call once a week for 8 weeks.
2949328|NCT02909387|Active Comparator|Stratum B|This group will also receive the Project UPLIFT intervention at crossover, after a 10 waiting period.
2949329|NCT02909374|Experimental|Balance training|"The program includes exercise with dual- and multi task performance and is progressive as the exercises can be performed at different levels (basic, moderate, and advanced). The 12-week balance training program will be performed two times per week for one hour each. The training will be lead by physiotherapists or trained leaders. After the balance training the participants will get recommendations for continued physical activity and training, i.e. Physical activity on prescription."
2949330|NCT02909361||Fulvestrant|500 mg on days 0, 14, and 28, and every 28 days thereafter
2949331|NCT02909335|Active Comparator|Tacrolimus group|Tacrolimus + mycophenolate mofetil + corticosteroids
2949332|NCT02909335|Experimental|Everolimus group|Everolimus + mycophenolate mofetil + corticosteroids
2949333|NCT02909322|Active Comparator|Continuous Epidural Analgesia|Analgesic medications will be given via epidural, the standard of care.
2949334|NCT02909322|Experimental|Paravertebral Block Analgesia|Analgesic medications will be given via the paravertebral space.
2949335|NCT02909309|Other|ALL INCLUDED PATIENTS|"A single arm for this study. All the patients benefit of both systems. The participants are their own control.~Non invasive sensors are used to monitor and record data of those two systems in a synchron way ( JAWAC / Capnoline + Spo2)."
2949336|NCT02909283||Sickle cell disease patients|Physical exams and blood analyzes
2949337|NCT02909270|Experimental|Mediclore|adhesion barrier Mediclore 5cc, to apply medical device fully around thyroid gland following thyroidectomy
2949338|NCT02909270|No Intervention|No treatment|No treatment, standard treatment for thyroidectomy
2949339|NCT02909257|Experimental|same dose|patient is exposed to the same previously successful dose
2949340|NCT02909257|Experimental|lower dose|patient is exposed to a lower concentration dose
2949341|NCT02909244||Patients with PID|Biological sampling: collection of feces. In case of blood samples availability in hospital biobank : analyzes of these samples in the frame of this research
2949342|NCT02909244||Control patients, with no PID|Biological sampling: collection of feces.
2949343|NCT02909231||Foothills Medical Centre|Patients admitted to the Foothills Medical Centre trauma service (Calgary, AB) over four months.
2949344|NCT02909231||Vancouver General Hospital|Patients admitted to the Vancouver General Hospital trauma service (Vancouver, BC) over four months.
2949345|NCT02909218|No Intervention|National HIV Treatment Guidelines|HIV-positive individuals are offered ART per Swaziland's national treatment guidelines
2949346|NCT02909218|Experimental|Early Access to ART for All|HIV-positive individuals are initiated on ART regardless of client's immunological and clinical staging
2949347|NCT02909205|Other|control|First phase : before training / sensitization / booklet delivery
2949348|NCT02909205|Other|post intervention|Second phase : after training / sensitization / booklet delivery
2949349|NCT02909192|Active Comparator|Bright light therapy|Participants will be treated twice daily with bright light therapy.
2949350|NCT02909192|Placebo Comparator|Dim-Red light therapy|Participants will be treated twice daily with dim-red light therapy.
2949351|NCT02909179|Experimental|mCARE-II|mCARE-II supported service provision through existing community health workforce.
2949352|NCT02909179|No Intervention|Comparison|Standard of care, paper-based service provision through existing community health workforce.
2949353|NCT02909166|Active Comparator|aliskiren|Aliskiren 300 once a day (q.d)
2949354|NCT02909166|Placebo Comparator|placebo|Placebo once a day (q.d)
2949355|NCT02909153|Experimental|single dose of Triferic in the peritoneal dialysis solution|The patient will receive a single dose of Triferic in the peritoneal dialysis solution (IP) during a long (12 hour) peritoneal dialysis dwell. Each Cohort will receive a different ascending IP dose ( 5 mg/L, 12.5 mg/L, 20 mg/L). Blood samples will be drawn periodically over a 12 hour period for analysis.
2949356|NCT02909153|Experimental|single IV dose of Triferic 6.6 mg over a 4 hour period|The patient will receive a single 6.6 mg intravenous (IV) dose of Triferic in the over a 4 hour period. All Cohorts will receive the same IV dose. Blood samples will be drawn periodically over a 12 hour period for analysis.
2949357|NCT02909140|Experimental|Topical Mydriasis|Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
2949358|NCT02909140|Experimental|Intracameral Mydriasis|Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
2949359|NCT02909140|Experimental|Topical + Intracameral mydriasis|Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia. Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
2949360|NCT02909127||Cerebral palsied children|The inclusion criteria are age above 18 months, fed orally, referred due to parent complaints about their child's swallowing function and not admitted a swallowing center before. Swallowing evaluation will be performed. The Functional Independence Measure and PEDI-EAT-10 will be filled.
2949361|NCT02909127||Healthy children|Healthy children above the age of 18 months with no medical history of voice, swallowing, reflux, airway, neurologic, rheumatologic, or neoplastic disorders will be included for normative data generation. The PEDI-EAT-10 will be filled.
2949362|NCT02909114|Experimental|Experimental group|SBRT for oligometastatases from colorectal cancer objectives
2949580|NCT02907593|Experimental|0.050 mg/kg Budesonide|0.050 mg/kg Budesonide in Calfactant
2949363|NCT02909101|Experimental|Active Cognitive Training (ACT)|Participants will complete computerized games designed to enhance working memory. Participants will complete 48 training sessions over 8 weeks.
2949364|NCT02909101|Sham Comparator|Control Training (CON)|Participants will complete 48 training sessions over 8 weeks. The control games are not designed to enhance memory.
2949365|NCT02909088|Experimental|Ecopipam 50mg|50mg of ecopipam at bedtime for the first two weeks. If there is deemed improvement by the investigator, the subject will remain on the same dose. If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
2949366|NCT02909088|Experimental|Ecopipam 100mg|If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
2949367|NCT02909075||PET/CT scans and MRI|Eligible patients will be enrolled onto the study, and will undergo 3 limited field of view (FOV) FDG-PET/CT scans and MRI of the chest: at baseline (within 4 weeks prior to transplantation), and approximately 3 months (+/-2 weeks) and 6 months (+/-2 weeks) after transplant. PET/CT and MR imaging can be completed on the same day. We will also offer the exams on other days if this is easier for the patient. The PET/CT and MR should be performed within 2 weeks of each other.
2949368|NCT02909062||Electronic Activity Monitoring (EAM)|This is a prospective, observational study. The study aims to examine the role of EAM as an objective, assessment of patient fitness in patients receiving chemotherapy for gastrointestinal malignancy. Physical activity level measured by EAM will be compared with standard measurement tools used by the oncology community to predict chemotherapy tolerability.
2949369|NCT02909049|Active Comparator|CONTROL|Saturation prostate biopsy under intravenous sedation MIDAZOLAM 1,5 mg per kilogram intravenous, 5 minutes prior to biopsy FENTANILE 0,05 mg per kilogram intravenous, 3 minutes prior to biopsy KETAMINE 0.5 mg per kilogram intravenous, 1 minute prior to biopsy
2949370|NCT02909049|Experimental|EXPERIMENTAL|Saturation prostate biopsy under local anesthesia MEPIVACAÍNE 2% 10 millimeters periprostatic block at base and ápex, bilaterally.
2949371|NCT02909036|Experimental|Melphalan|Test Dose CE Melphalan 10mg/m2 with PK studies Day -12 to Day-3, CE Melphalan Dose of Target AUC 13 mg/L/h infused with PK studies Day -2, 3-10 x 10^6 CD 34+ cells/kg reinfused Day 0, Pegfilgrastim 6mg injection Day +1
2949372|NCT02909023||Hepatitis B infected patients or cured|blood samples are performed to measure active T cellular immune response during a routine visit
2949373|NCT02909010|Active Comparator|BIS™ Brain Monitoring System|BIS monitoring to adjust sedation in order to maintain values between 50-60
2949374|NCT02909010|Placebo Comparator|RASS Monitorization|sedation was adjusted with the exclusive useof Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2.
2949375|NCT02908997|Experimental|5 week baseline|5 week baseline data collection followed by 6 week MindMate intervention
2949376|NCT02908997|Experimental|6 week baseline|6 week baseline data collection followed by 6 week MindMate intervention
2949377|NCT02908997|Experimental|7 week baseline|7 week baseline data collection followed by 6 week MindMate intervention
2949378|NCT02908984|Experimental|Specific neck rehabilitation|The intervention includes specific neck rehabilitation as described by Jull and Falla over a 4 period of weeks and recommendations for further training.
2949379|NCT02908984|Active Comparator|Standard primary health care|This represents individualized therapy administered by the primary physician.
2949380|NCT02908971||Soy based formula|"soy group will include children from the children who had milk allergy, and consumed a soy-based substitute formula for longer than three months and agreed to participate in this study."
2949381|NCT02908971||Healthy control|The control group will included children (at a rate of 2:1) who will be assigned randomly from the healthy population at the initial cohort, and who will agree to participate.
2949382|NCT02908958|Experimental|PEG-somatropin|Low dose group, PEG Somatropin 0.14mg/kg/week, subcutaneous use, inject once a week, the duration is 26 weeks.
2949383|NCT02908958|Experimental|PEG-Somatropin|High dose group, PEG Somatropin 0.2mg/kg/week, subcutaneous use, inject once a week, the duration is 26 weeks.
2949384|NCT02908945|Experimental|Group 1|Participants randomized to group 1 will receive a 0.5 mg/kg loading dose of racemic ketamine hydrochloride immediately before induction of anesthesia, followed by a continuous 10 mcg/kg/min infusion throughout maintenance of anesthesia, until procedure end (last suture inserted), up to a maximum cumulative dose of 200 mg. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
2949385|NCT02908945|Experimental|Group 2|Participants randomized to group 2 will receive a 0.25 mg/kg loading dose of racemic ketamine hydrochloride immediately before induction of anesthesia, followed by a continuous 5 mcg/kg/min infusion throughout maintenance of anesthesia, until procedure end (last suture inserted), up to a maximum cumulative dose of 200 mg. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
2949386|NCT02908945|Other|Group 3|Participants randomized to the control group will receive an equivalent anesthetic, without the addition of ketamine. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
2949387|NCT02908932|Experimental|Phospholipid-bound omega-3 supplement|2.3g/d omega-3 HUFAs (with the EPA to DHA ratio of approximately 2:1), delivered in 8 capsules/day in Krill oil concentrates (Aker BioMarine Antarctic AS, Norway). Participants will receive supplements for the duration of IBOLC (19 weeks) and up until entry in Ranger. Time between completion of IBOLC and entry in Ranger is variable, ranging from 1 weeks to 10 weeks (4 weeks typical). Total duration on supplement thus ranges from 20 to 30 weeks.
2949388|NCT02908932|Placebo Comparator|Placebo supplement|Matching placebo capsules, substituting macadamia nut oil and appropriate colorant for krill oil. Macadamia nut oil has not been associated with psychological, cognitive, or health benefits. Furthermore, it is not typically consumed in large quantities and is therefore useful in tracking blood serum levels to assess compliance within the placebo arm. Placebo capsules have been produced by Aker Biomarine. As with the experimental arm, participants will take 8 capsules daily for the duration of the study (20-30 weeks).
2949389|NCT02908919|Active Comparator|Fortrans pulv. sol|Polyethylene glycol solution. Used 4 l before colonoscopy. Bowel preparation interval: QD/BID or one day.
2949390|NCT02908919|Active Comparator|Picoprep pulv. sol.|Natrium picosulfate/ magnesium citrate solution. Used 2 l before colonoscopy. bowel preparation interval: QD/BID or one day.
2949391|NCT02908919|Active Comparator|Moviprep pulv. sol.|Polyethylene glycol + ascorbic acid solution. Used 2 l before colonoscopy. Bowel preparation interval: QD/BID or one day.
2949392|NCT02908906|Experimental|JNJ-63723283|In Part 1, the first cohort will receive JNJ-63723283 at a starting dose of 80 milligram (mg), intravenously (IV) every 2 weeks. JNJ-63723283 doses will be escalated following a modified Continual Reassessment Method (mCRM). Multiple doses and schedules may be explored. In Part 2, participants will receive JNJ-63723283 at the recommended Phase 2 dose (RP2D) determined in Part 1.
2949393|NCT02908893|Experimental|Salient|"Messages in the salient arm highlight the number of incentives (points) received by getting a flu shot and recording it through the wellness program app.~Additionally, messages mention that flu shots can be received at the pharmacy while picking up an Rx.~Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy."
2949394|NCT02908893|Active Comparator|NonSalient|"Messages in the non-salient arm highlight the benefits of getting vaccinated against flu, but make no mention of incentives received for getting vaccinated.~Incentives would still be earned through the wellness program if the vaccination is recorded. Messages mention that flu shots can be received at the pharmacy while picking up an Rx.~Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy"
2949395|NCT02908893|No Intervention|Control|Users in this group will not receive any message promoting flu vaccination. Incentives would still be earned through the wellness program if the vaccination is recorded.
2949396|NCT02908880|Experimental|MANTA vascular closure device|Open label, single arm study using the MANTA device, developed by Essential Medical, Inc.. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
2949397|NCT02908867||Therapeutic strategies group|To know the main therapeutic strategies used by men with spinal cord injury in sexual dysfunctions, mainly medicinal plants.
2949398|NCT02908854|Experimental|School Lunch Participants|School lunch participants will be given vegetables with and without additional spices and herbs to determine if intake will increase with the addition of spices and herbs.
2949399|NCT02908841|Other|Control|30 patients randomized to the control group and will receive standard of care. Control patients will be managed with direct compression with gauze pads or laparotomy pads for four minutes. If hemostasis is not achieved by compression after four minutes, the source and rate of bleeding will be reevaluated and management will be determined by the surgeon. If the surgeon uses SurgicelSnow to achieve hemostasis at some point after 4 minutes, the patient will be included in the control group, but the data will be and flagged for the analysis. If failure of hemostasis at 4 minutes with an estimated loss of ≥25 cc/min, patient will be managed as per judgment of surgeon. Persistent bleeding at the 10 minute observation point will be treated as per the surgeon's judgment.
2949400|NCT02908841|Other|Treatment|"30 patients randomized to the treatment group will receive Surgicel Snow. For patients with qualifying bleeding (rated on initial evaluation as at least mild) who have been randomized to receive Surgicel Snow, a single thin layer of dry Surgicel Snow will be applied over the area of bleeding and positioned firmly in direct contact to the areas of bleeding with blunt surgical instruments. Surgicel Snow will be left in the cavity to be absorbed. Dry gauze will not be placed over the material. No adjuncts will be added to the enhance hemostasis, but patients with small arteriolar bleeding will have pressure maintained on the bleeding site for 60 seconds. Hemostatic failure at 4 minutes will be reassessed for rate of blood loss and if the rate of loss is estimated at less than 25 cc per minute, additional observations will be made at 7 and 10 minutes."
2949401|NCT02908828|Experimental|Calanus oil|4 capsules of 500 mg Calanus oil once every day
2949402|NCT02908828|Placebo Comparator|Placebo|4 capsules of 500 mg dietary oil once every day
2949403|NCT02908815|Experimental|4 weeks active treatment|4 weeks of rTMS active treatment applied using an active rTMS coil.
2949404|NCT02908815|Experimental|2 weeks active treatment|2 weeks of rTMS active treatment applied using an active rTMS coil.
2949405|NCT02908815|Sham Comparator|4 weeks sham treatment|4 weeks of rTMS sham treatment applied using a modified rTMS coil which does not stimulate the brain.
2949406|NCT02908815|Sham Comparator|2 weeks sham treatment|2 weeks of rTMS sham treatment applied using a modified rTMS coil which does not stimulate the brain.
2949407|NCT02908802|Active Comparator|Probiotic|Probiotic capsules: two capsules twice a day
2949408|NCT02908802|Placebo Comparator|Placebo|Probiotic capsules without the active ingredient: two capsules twice a day
2949409|NCT02908789|Other|Antimicrobial photodynamic therapy (aPDT)|The technique consists of a basic protocol of two steps: the use of a photosensitizer and the laser application. In the first step, the cavity was dried and then 0.01% methylene blue solution (Formula & Ação, São Paulo, Brazil) was applied to the entire cavity using a carpule in order to keep in contact with all the walls. It remained in the cavity for a pre-irradiation period of 5 minutes. In the second step, the excess of 0.01% methylene blue solution was removed and the cavity was irradiated with an Indium Gallium Aluminum Phosphorus diode laser (InGaAlP) (Laser DUO®, MM Optics, São Carlos, São Paulo, Brazil) with a wavelength of 660 nm (visible red), a spot area of 3mm2, and fixed output power of 100 mW. We adopted the following parameters: energy of 9 J with 90 seconds of exposure time. The irradiation was applied in continuous mode and the laser array was positioned, in contact, directly over the central part of the cavity.
2949410|NCT02908776|Experimental|Dietary supplement - Probiotics|4 sachets of Ecoviesel (probiotics) per day for at least 2 weeks before undergoing a coronary angiography with possible ad hoc angioplasty; and 2 sachets of probiotic per day after angioplasty, if performed.
2949411|NCT02908776|Placebo Comparator|Placebo|Sachets with inactive substance indistinguishable from Ecoviesel
2949412|NCT02908763|Experimental|Pegylated interferon group|Low replicative chronic HBV infection patients with HBsAg <1000 IU/ mL and HBV DNA<2000 IU/mL are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for at most 96 weeks.
2949413|NCT02908763|No Intervention|Observing Group|Only observing and following up in this group.
2949414|NCT02908750|Experimental|osimertinib and fexofenadine|Sequential treatments of fexofenadine alone followed by osimertinib + fexofenadine, followed by osimertinib alone, followed by osimertinib + fexofenadine
2949415|NCT02908737|Experimental|Bass and Treble controls|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively.
2949416|NCT02908724||ERT receiving patients|Patients that were receiving specific treatment for FD (ERT, enzyme replacement therapy, Fabrazyme or Replagal) during the observational time (n= 47).
2949417|NCT02908724||non-ERT receiving patients|Patients that were not receiving specific treatment for FD (ERT, enzyme replacement therapy, Fabrazyme or Replagal) during the observational time (n= 19).
2949418|NCT02908711|Active Comparator|Patients receiving ACB before primary TKA|"Patients receiving adductor canal block (ACB) before primary total knee arthroplasty (TKA).~Patients randomized to this group will receive the block prior to incision after induction of general anesthesia"
2949419|NCT02908711|Active Comparator|Patients receiving ACB after primary TKA|"Patients receiving adductor canal block (ACB) immediately after primary total knee arthroplasty (TKA).~Patients randomized to this group will receive the block at the end of the surgery."
2949420|NCT02908698|Experimental|Prednisone Treatment|"Prednisone will be administered orally for 15 days at the following doses:~0.75 mg/kg of body weight for 5 days 0.5 mg/kg of body weight for 5 days 0.25 mg/kg of body weight for 5 days"
2949421|NCT02908698|Placebo Comparator|Placebo Control|Placebo will be administered orally for 15 days in a capsule identical to the experimental treatment.
2949422|NCT02908685|Experimental|Part 1 Group A: Adolescents and Adults (RO7034067)|Adolescent and adult participants aged 12-25 years will receive RO7034067 for 12 weeks. Once 12-week treatment is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be followed up in open-label extension (OLE) phase.
2949423|NCT02908685|Placebo Comparator|Part 1 Group A: Adults and Adolescents (Placebo)|Adolescent and adult participants aged 12-25 years will receive placebo matching to RO7034067 for 12 weeks. Once 12-week treatment is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be followed up in OLE phase.
2949424|NCT02908685|Placebo Comparator|Part 1 Group B: Children (Placebo)|Children aged 2-11 years will receive placebo matching to RO7034067 for 12 weeks. Once 12-week treatment is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be followed up in OLE phase.
2949425|NCT02908685|Experimental|Part 1 Group B: Children (RO7034067)|Children aged 2-11 years will receive RO7034067 for 12 weeks. Once 12-week treatment is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be followed up in OLE phase.
2949426|NCT02908685|Placebo Comparator|Part 2: Placebo|Participants aged 2-25 years will receive placebo matching to RO7034067. After 12 months of treatment with placebo, participants will be switched to RO7034067 and treatment will then continue until Month 24. After 24-month treatment, participants will be offered the opportunity to enter the OLE phase.
2949427|NCT02908685|Experimental|Part 2: RO7034067|Participants aged 2-25 years will receive RO7034067 at the dose selected based on the results from Part 1 of the study, for 24 months. After 24-month treatment, participants will be offered the opportunity to enter the OLE phase.
2949428|NCT02908672|Experimental|Atezolizumab + Cobimetinib + Vemurafenib + Vemurafenib Placebo|Run-In Period (Cycle 1=28 days): Participants will receive vemurafenib 960 mg (four, 240 mg tablets) PO BID along with cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21 followed by vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 22 to 28 and vemurafenib placebo (1 tablet) PO BID on Days 22 to 28. Triple Combination Period (Cycle 1 onwards): Participants will receive atezolizumab 840 mg IV infusion on Day 1 and 15, cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21, vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 1 to 28, and vemurafenib placebo (1 tablet) PO BID on Days 1 to 28 of each 28-day cycle. Study treatment will continue until investigator-determined disease progression, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurs first.
2949429|NCT02908672|Experimental|Atezolizumab Placebo + Cobimetinib + Vemurafenib|Run-In Period (Cycle1=28 days): Participants will receive vemurafenib 960 milligrams (mg) (four, 240 mg tablets) orally (PO) twice a day (BID) along with cobimetinib 60 mg (three, 20 mg tablets) PO once a day (QD) on Days 1 to 21 followed by vemurafenib 960 mg (four, 240 mg tablets) PO BID on Days 22 to 28. Triple Combination Period (Cycle 1 onwards): Participants will receive ATZ placebo by intravenous (IV) infusion on Day 1 and 15, cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21, and vemurafenib 960 mg (four, 240 mg tablets) PO BID on Days 1 to 28 of each 28-day cycle. Study treatment will continue until investigator-determined disease progression, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurs first.
2949430|NCT02908646|Experimental|microcoil|patients who plan for microcoil localization
2949431|NCT02908646|Placebo Comparator|hookwire|patients who plan for hookwire localization
2949432|NCT02908633|Active Comparator|canaloplasty ab externo and phacoemulsification|As soon as the two scleral flaps: deep and superficial -similar to deep sclerectomy are dissected, the phacoemulsification with PCIOL insertion is performed. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and guided for 360 degrees within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. Then a suture is tied to the distal tip and the microcatheter is withdrawn. As it appears at the other ostium of canal the microcatheter it separated from the suture.Then suture loop is tightened to tension the trabecular meshwork. The superficial flap is sutured watertight to prevent bleb formation
2949433|NCT02908633|Active Comparator|canaloplasty ab interno and phacoemulsification|This variant of canaloplasty spares conjunctival surface. First phacoemulsification and PCIOL placement is performed. The Schlemm's canal is reached through goniotomy through anterior chamber. Similarly microcatheter is inserted and viscodilatator applicated. The key difference, is that no tensioning suture is left after the catheter is withdrawn. phacoemulsification is performed.
2949434|NCT02908633|Active Comparator|minicanaloplasty and phacoemulsification|The dissected conjunctival flap is of minimal size. The scleral flaps are sized: superficial flap 3x1mm, and deep flap: 1x1 mm- with no removal of the deep flap. Afterwards phacoemulsification part is performed. The microcatheterization and viscodilatation are conducted as in the traditional procedure.The conjunctiva is closed with one suture or coagulation
2949435|NCT02908620|Experimental|CTY-5339-A 1 Spray|Benzocaine and Tetracaine 14.0% Benzocaine, USP = 28 mg 2.0% Tetracaine Hydrochloride, USP = 4 mg
2949436|NCT02908620|Experimental|CTY-5339-A 2 Sprays|Benzocaine and Tetracaine 14.0% Benzocaine, USP = 56 mg 2.0% Tetracaine Hydrochloride, USP = 8 mg
2949438|NCT02908607|Experimental|experimental|3 groups of patients will be participated: women with cancer, women with premalignant lesions and women with a normal cervix. All patients will undergo the same examination
2949439|NCT02908594|Experimental|exercise group|Using the Medical Exercise Peddler 3000, Medi-Bike, Taiwan as an exercise tool. Exercise group received routine care and 3- months exercise. The exercise was performed during the first 2 hr of each haemodialysis session (30 min per session, 3 sessions per week for 3 months).
2949440|NCT02908594|No Intervention|control group|The control group received routine care
2949441|NCT02908581|Active Comparator|Placebo|21 Patients Placebo Each tablet by mouth once daily for 12 weeks
2949442|NCT02908581|Experimental|Iron 150 mg and Folic acid 0.5 mg|21 Patients Iron 150 mg and Folic acid 0.5 mg Each tablet by mouth once daily for 12 weeks
2949443|NCT02908568|Experimental|Spring device|Brisk dilatation of fhe mouth.
2949444|NCT02908568|Sham Comparator|Mandible stimulator|Stimulation of fhe mouth.
2949445|NCT02908555||no intervention|Descriptive study without groups
2949446|NCT02908529|Placebo Comparator|Placebo|Placebo 2 hours before bedtime
2949447|NCT02908529|Active Comparator|Combination product of Atomoxetine and Oxybutynin|Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
2949448|NCT02908516|Experimental|Tranexamic acid|Study subjects randomized to receive the TXA group will receive 3 oral capsules of 650 mg each of TXA for a total of 1.95 g. One dose will be given upon diagnosis of a hip fracture in the emergency department (ED) and a second dose will be given two hours prior to surgical incision.
2949449|NCT02908516|Placebo Comparator|Placebo|Study subjects randomized to the placebo group will receive an equivalent dose of cellulose in 3 oral capsules. One dose will be given upon diagnosis of a hip fracture in the ED and a second dose will be given two hours prior to surgical incision.
2949450|NCT02908503|Other|1 x 2 inch PVA based film|1 x 2 inch polyvinyl acetate (PVA) based vaginal film
2949451|NCT02908503|Other|2 x 2 inch PVA based film|2 x 2 inch polyvinyl acetate (PVA) based vaginal film
2949452|NCT02908503|Other|1 x 2 cellulose based film|1 x 2 cellulose based vaginal film
2949453|NCT02908503|Other|2 x 2 cellulose based film|2 x 2 cellulose based vaginal film
2949454|NCT02908490|Experimental|Initial Sildenafil|Sildenafil 50 mg orally once daily for first 3 months, then after 2-week washout, Placebo orally once daily for 3 months
2949455|NCT02908490|Placebo Comparator|Initial Placebo|Placebo orally once daily for first 3 months, then after 2-week washout, Sildenafil 50 mg orally once daily for 3 months
2949456|NCT02908477|Experimental|De-escalated Adjuvant Radiation Therapy|Docetaxel 15 mg/m2 days 1, 8 + Radiation Therapy (RT) 30 Gy/1.5 Gy fractions twice daily (b.i.d.) days 1-12 only (intermediate risk) or 36 Gy/1.8 Gy b.i.d. fractions (high risk)
2949457|NCT02908477|Active Comparator|Standard of Care Treatment|RT 60 Gy/2 Gy fractions daily (qday) days 1-40. For high risk, add weekly Cisplatin 40 mg/m2 (Around days 1, 8, 15, 22, 29, 36)
2949458|NCT02908464|Experimental|Lumosity|"Patients in the Lumosity arm will be prescribed a perioperative neurocognitive training program created in collaboration with Lumos Labs, Inc. The program will contain brain games that focus on enhancing cognitive abilities in working memory, attention, and processing speed. Participants will be expected to complete at least 2, but no more than 3, 15 minute sessions of training per day. The protocol will be prescribed for 10 days preoperatively, and then for four weeks postoperatively."
2949459|NCT02908464|No Intervention|Usual Care|Patients in the usual care arm will undergo current standard of care for cardiac surgery and postoperative recovery. They will be asked to refrain from acquiring a Lumosity account.
2949460|NCT02908451|Experimental|AbGn-107|AbGn-107 will be administered every 28-days via intravenous infusion. Patients with a complete response (CR), partial response (PR), or stable disease (SD), or with evidence of clinical benefit may be treated every 28-days.
2949461|NCT02908438|Experimental|GnRHa group|Intervention: additional GnRHa for routine LPS GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
2949462|NCT02908438|No Intervention|control group|Control group receive only the routine LPS.
2949463|NCT02908425|Other|Healthy taking statin|healthy subjects currently taking cholesterol lowering statin
2949464|NCT02908412|Experimental|Digital nerve block in left hand|Patients in this group will receive DNB in left hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
2949465|NCT02908412|Experimental|Digital nerve block in right hand|Patients in this group will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
2949466|NCT02908399|Experimental|Thermal Imaging|Imaging using a thermal camera
2949467|NCT02908373||Case group|Nursing homes benefiting first the implementation of the coaching model (methodological help for professionals on the patient safety culture): just after the first measure (overview of the situation)
2949468|NCT02908373||Control group|Nursing homes benefiting the implementation of the coaching model (methodological help for professionals on the patient safety culture): after the second measure (impact of the device on case group)
2949469|NCT02908360||Patients with allergic rhinitis|Patients with rhinitis and / or allergic conjunctivitis duly diagnosed according to the ARIA criteria
2949470|NCT02908360||Patients with atopic dermatitis|The patient has moderate classified atopic dermatitis (SCORAD 25 to 50) or severe (SCORAD> 50).
2949471|NCT02908360||Patients with allergic asthma|The patient has allergic asthma diagnosed according to the criteria GINA21
2949472|NCT02908347|Experimental|MP1032|"Test Product:~100 mg MP1032 (= 2 capsules a 50mg) are provided orally twice daily for 42 days"
2949473|NCT02908347|Placebo Comparator|Placebo|"Placebo:~2 capsules of Placebo are provided orally twice daily for 42 days"
2949474|NCT02908334|No Intervention|Standard of Care|standard of care treatment for disseminated or meningeal coccidioidomycosis
2949475|NCT02908334|Experimental|Standard of Care + Sertraline|Standard of care treatment with the addition of sertraline for the treatment of disseminated or meningeal coccidioidomycosis
2949476|NCT02908321|Active Comparator|CBT|
2949477|NCT02908321|No Intervention|WL|
2949478|NCT02908308|Active Comparator|Normothermia|Standard care with early treatment of fever. Active temperature control with a device will be used if the patient develops a temperature greater than or equal 37.8°C.
2949479|NCT02908308|Experimental|Hypothermia|Targeted temperature management to 33°C for up to 28h.
2949480|NCT02908295|Experimental|A|Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
2949481|NCT02908295|Placebo Comparator|B|Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
2949482|NCT02908282|Other|PUFA (polyunsaturated fatty acids)-group|REMOGEN OMEGA: Usage according to instructions for use.
2949483|NCT02908282|Other|C (control)-group|Povidone: Usage according to instructions for use.
2949484|NCT02908269|Experimental|Fluzone Quadrivalent Vaccine Group 1: 3 to < 9 Years|Participants aged 3 to < 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per Advisory Committee on Immunization Practices (ACIP) guidance, a second dose of Fluzone Quadrivalent vaccine was administered at Day 28.
2949485|NCT02908269|Experimental|Fluzone Quadrivalent Vaccine Group 2: 18 to < 65 Years|Participants aged 18 to < 65 years received one 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
2949486|NCT02908269|Experimental|Fluzone High-Dose Vaccine Group 3: ≥ 65 Years|Participants aged ≥ 65 years received one 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
2949487|NCT02908256|Experimental|PVI group|Monitoring of the PVI during the surgical intervention
2949488|NCT02908256|Active Comparator|Delta PP group|Monitoring of the deltaPP during the surgical intervention
2949489|NCT02908243||Prophylaxis|Severe hemophilia A patients who receive factor VIII with dose of 15-25 IU/Kg, 2-3 times/week Severe hemophilia B patients who receive factor IX with dose of 30-50 IU/Kg, 1-2 times/week
2949490|NCT02908243||On-demand|Severe hemophilia A patients who receive factor VIII injection when bleeding occurs with the dose according to the criteria of World Federation of Hemophilia (WFH); Severe hemophilia B patients who receive factor IX injection when bleeding occurs with the dose according to the criteria of World Federation of Hemophilia (WFH)
2949491|NCT02908243||Collection of baseline data in all hemophilia A and B patients|All severe, moderate and mild types of hemophilia A and B patients
2949492|NCT02908230|Placebo Comparator|Active Control|Active Control: exposure to a non-nutrition, physical activity, or mental health curriculum/program
2949493|NCT02908230|Active Comparator|Standard Care|Standard Care: exposure to a nutrition and physical activity curriculum/program
2949494|NCT02908230|Experimental|Enhanced Care|Enhanced Care: exposure to a nutrition, physical activity, and mental health curriculum/program
2949495|NCT02908217|Experimental|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
2949496|NCT02908217|Placebo Comparator|Placebo|6 Intravenous infusions of placebo (sterile sodium chloride solution) every 4 weeks
2949497|NCT02908204||Endoscopic treatment|Patients underwent endoscopic treatment including Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Multiband Mucosectomy (MBM), Endoscopic Mucosal Band Ligation(EMBL) and so on.
2949498|NCT02908204||Traditional surgery|Patients underwent traditional surgery
2949499|NCT02908191|Experimental|ABI-H0731 or Matching Placebo|ABI-H0731 in varying doses of tablets by mouth for 1 day, 7 days, or 28 days
2949500|NCT02908191|Experimental|ABI-H0731 or Placebo and ETV or TDF|ABI-H0731 and entecavir or tenofovir in combination in a yet to be determined dose by mouth for 28 days
2949501|NCT02908191|Experimental|ABI-H0731 or Placebo and a Nucleos(t)ide and Pegasys|ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days
2949502|NCT02908178||Aim 1 Cohort|The Aim 1 Cohort is constructed to perform analysis to address study objective Aim 1. The cohort population include patients older than 67 years old who have received BCS as their first surgery. The time period for defining the cohort will be between January 1998 and December 2011. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.
2949503|NCT02908178||Aim 2 Cohort|The Aim 2 Cohort is constructed to perform analysis to address study objective Aim 2.The cohort population include patients older than 67 years old who have received BCS as the final treatment for their DCIS. The time period for defining the cohort will be between January 1998 and December 2012. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.
2949504|NCT02908165|Experimental|Group A- continuous schedule|Subjects with HCC randomized to group A
2949505|NCT02908165|Active Comparator|Group B- sequential schedule|Subjects with HCC randomized to group B
2949506|NCT02908152|Active Comparator|curcumin|curcumin
2949507|NCT02908152|Placebo Comparator|placebo|
2949508|NCT02908139||Patients before kidney transplantation|The study included who had been admitted to the TransplantClinic before kidney transplantation
2949509|NCT02908126|Experimental|Oxytocin intravenous|single dose of intravenous (IV) oxytocin
2949510|NCT02908126|Experimental|Oxytocin tablet|single dose of oxytocin tablet
2949511|NCT02908113|Other|preterm infants|physiological data collection, behavioral, cerebral hemodynamics, physical environmental newborns studied in response to visual stimuli / auditory or visual-auditory calibrated
2949512|NCT02908113|Other|term infants|physiological data collection, behavioral, cerebral hemodynamics, physical environmental newborns studied in response to visual stimuli / auditory or visual-auditory calibrated
2949513|NCT02908100|Experimental|GDC-0853 Low Dose|Participants will receive either GDC-0853 or matching placebo orally twice daily, every 12 hours starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
2949514|NCT02908100|Experimental|GDC-0853 High Dose|Participants will receive GDC-0853 orally, twice daily, every 12 hours starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
2949515|NCT02908100|Placebo Comparator|Placebo|Participants will receive matching placebo to GDC-0853, orally, every 12 hours starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
2949516|NCT02908087|Active Comparator|Victoza® (liraglutide)|Subjects with early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT) aged 10-30 years, and treated with insulin are treated with Victoza®
2949517|NCT02908087|Placebo Comparator|Placebo|Subjects with early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT) aged 10-30, and treated with insulin are treated with placebo
2949518|NCT02908074|Experimental|Experimental: Regimen 1|Drug: BGS649 Dose 1 weekly
2949519|NCT02908074|Experimental|Experimental: Regimen 2|Drug: BGS649 Dose 2 weekly
2949520|NCT02908074|Experimental|Experimental: Regimen 3|Drug: BGS649 Dose 3 weekly
2949521|NCT02908061|Active Comparator|Surgery (Usual approach group)|standard surgery
2949522|NCT02908061|Experimental|Surgery + Mesh Placement|prophylactic mesh at the time of standard surgery
2949523|NCT02908048||Hepatocellular Carcinoma|Blood samples will be collected at entry into the study and at varying intervals over a two to three year period.
2949524|NCT02908048||Biliary Tract Cancer|Blood samples will be collected at entry into the system and at varying intervals over a two to three year period.
2949525|NCT02908048||Cirrhosis|Blood samples will be collected during regular intervals over a three year period.
2949526|NCT02908048||Chronic Liver Disease without Cirrhosis|A single blood sample will be collected at entry into the study
2949527|NCT02908035|Active Comparator|Active Comparator: Temsirolimus Delivery High Dose|High-Dose Group: 0.4 mg/mL temsirolimus (including 20% contrast) Patients qualifying for enrollment will be randomized 2:1 for inclusion in either the treatment (low-dose or high-dose) or the control group. The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
2949528|NCT02908035|Active Comparator|Active Comparator: Temsirolimus Delivery Low Dose|Low-Dose Group: 0.1 mg/mL temsirolimus (including 20% contrast) Patients qualifying for enrollment will be randomized 2:1 for inclusion in either the treatment (low-dose or high-dose) or the control group. The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
2949529|NCT02908035|Placebo Comparator|Placebo Comparator: Saline Delivery|Control Group: Saline/contrast (80% normal saline for injection:20% non-ionic contrast) The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
2949530|NCT02908022|Experimental|Interaction|"Prior to the MRI sessions, the clinician will be introduced to the patient and do a general intake of physical examination.~During the MRI sessions, the patient will receive experimental pressure pain via the Hokanson Rapid Cuff Inflator and electroacupuncture analgesia to the leg for pain relief."
2949531|NCT02908022|Experimental|No Interaction|"The clinician and the patient will first be introduced at the MRI sessions.~During the MRI sessions, the patient will receive experimental pressure pain via the Hokanson Rapid Cuff Inflator and electroacupuncture analgesia to the leg for pain relief."
2949532|NCT02907996||Sofosbuvir|Adult Korean patients with genotype 1, 2, 3, or 4 chronic HCV infection who are initiating commercial sofosbuvir regimens
2949533|NCT02907983|Active Comparator|Bupivicaine|Stellate Ganglion Block injection with bupivicaine
2949534|NCT02907983|Sham Comparator|Saline|Saline injection
2949535|NCT02907957|Active Comparator|Caudal|Participants receiving a caudal neuraxial blockade, as clinically indicated.
2949536|NCT02907957|Sham Comparator|No Caudal|Participants not receiving a caudal neuraxial blockade, as clinically indicated.
2949537|NCT02907944|No Intervention|Usual Care- Control|We will use a stepped wedge design to evaluate the effect of the Implementation Facilitation on the outcomes. The first phase for all clinics is a control phase where clinic staff and patients engage in usual care. The time to implementation is randomly assigned. Each clinic is then followed prospectively to determine their outcome status.
2949538|NCT02907944|Experimental|Implementation Facilitation|We will use a stepped wedge design to evaluate the effect of the Implementation Facilitation on the outcomes. The time to implementation in a stepped wedge design is randomly assigned. Clinics are then followed prospectively to determine their outcome status..
2949539|NCT02907931|Experimental|Subjects|Lower Body Negative Pressure
2949540|NCT02907918|Experimental|Palbociclib + letrozole + trastuzumab +/- goserelin|"Neoadjuvant palbociclib + letrozole (plus goserelin if premenopausal) + trastuzumab for a total of 16 weeks, consisting of (4) 28-day cycles~Definitive surgery within 3-5 weeks after the end of Cycle 4. Letrozole and trastuzumab will continue until the day of surgery. Adjuvant therapy following definitive surgery will be at the discretion of the treating physician"
2949541|NCT02907905|Other|Population homeless or living in slum|Population homeless or living in slum realizing realizing a capillary sampling
2949542|NCT02907892|No Intervention|Control|Standard cesarean section surgical technique per surgeon preference
2949543|NCT02907892|Experimental|Glove Change|Cesarean section including changing of sterile surgical gloves immediately prior to abdominal closure
2949544|NCT02907879||Ultrasound perfusion imaging|Measuring methods of UPI with phase inversion harmonic imaging
2949545|NCT02907866||Patients undergoing bronchoscopy|All patients presenting for bronchoscopy (These patient are expected to have normal pleural sliding sign identified by ultrasound)
2949546|NCT02907866||Patients with pneumothorax|Patients with pneumothorax requiring chest tube(This group of patient is expected to have residual pneumothorax for identification of absence of lung sliding, B lines and lung point)
2949547|NCT02907866||Patients on mechanical ventilation|Patients with respiratory failure on mechanical ventilation(This group of patient is expected to have alveolo-interstitial findings such as B lines)
2949548|NCT02907853|Experimental|Contingency Management|In exchange for consecutive urine samples documenting methamphetamine abstinence, participants receive increasingly valuable reinforcers.
2949581|NCT02907593|Experimental|0.10 mg/kg Budesonide|0.10 mg/kg Budesonide in Calfactant
2949550|NCT02907827|Experimental|stage IV melanoma CR>3years|Stage IV: Complete remission for more than 3 years, confirmed by most recent CT or PET-CT imaging
2949551|NCT02907827|Experimental|Stage III Melanoma|AJCC Stage III: No evidence of disease on most recent CT or PET-CT imaging
2949552|NCT02907814|Experimental|Uveitis and Cataract Imaging Group|Subjects will undergo up to three optical coherence tomography scans.
2949553|NCT02907814|Experimental|Control|Control subjects will undergo a brief, non-contact eye exam and then undergo up to three optical coherence tomography scans.
2949554|NCT02907801|Experimental|Perception-Action Approach|Perception-Action Approach (P-AA) intervention components include environmental set-up for activity and participation in play, manual guidance in the form of light pressure applied to the infant's body in developmentally appropriate positions, and caregiver education in modifications to everyday activities consistent with the P-AA. All components are designed to promote spontaneous exploration of the environment by the infant by suggesting small, incremental changes in his/her perceptual-motor orientation and contact with the support surface. Intervention is progressed by gradually removing the environmental supports and therapist's hands to allow for spontaneous exploration of a newly found contact with the support surface or new body configuration.
2949555|NCT02907788||Cystic Fibrosis patients|Patient with cystic fibrosis diagnosed by Heel-prick screening
2949556|NCT02907788||non-CF patients|Children who undergo bronchoscopy for another reason, without CF: eg gastro-esophageal reflux.
2949557|NCT02907775|Active Comparator|Transcutaneous Electric Nerve Stimulus|Researcher 1 who is blind to patients' allocation group will perform the baseline assessments. The researcher 2 will determine the maximum tolerable level of stimulation. The researcher 2 will demonstrate to the participant how to apply the stimulation and will instruct the participant. The participant will revive the first intervention in the Royal Hallamshire Hospital under supervision of researcher 2. The researcher 2 will then issue the participants in Group-2 (SBS) with Shefstim and six multichannel electrodes. They will instruct each participant to change the electrode once every 3 days. On the 15th day the researcher 2 will visit them at home and issue further 6 multichannel electrodes and collect back the previous set. At the end of week 4, the patient will come to Hospital.
2949558|NCT02907775|Active Comparator|Sensory Barrage Stimulation|Researcher 1 who is blind to patients' allocation group will perform the baseline assessments. The researcher 2 will determine the maximum tolerable level of stimulation. The researcher 2 will demonstrate to the participant how to apply the stimulation and will instruct the participant. The participant will revive the first intervention in the Royal Hallamshire Hospital under supervision of researcher 2. The researcher 2 will then issue the participants in Group-2 (SBS) with Shefstim and six multichannel electrodes. They will instruct each participant to change the electrode once every 3 days. On the 15th day the researcher 2 will visit them at home and issue further 6 multichannel electrodes and collect back the previous set. At the end of week 4, the patient will come to Hospital.
2949559|NCT02907749|Experimental|Spironolactone|spironolactone starts from 40mg once daily and increase every week with a maximum dose as 100mg once daily
2949560|NCT02907749|Active Comparator|Carvedilol|carvedilol starts from 6.25mg once daily and increase to 12.5mg once daily in next week if being tolerated
2949561|NCT02907749|Active Comparator|Spironolactone and Carvedilol|spironolactone is added when carvedilol has reached the most tolerated dose
2949562|NCT02907723|Experimental|Continuous Sleep Recording|Continuous Sleep Recording in Patients
2949563|NCT02907710|Experimental|concurrent chemoradiotherapy + endostar|"Drug: Endostar~Endostar 7.5mg / m2,3 cycles of intravenous infusion for ten days, and 2 cycles of maintenance therapy after radiotherapy~Drug: DDP~DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles~Radiation: IMRT~IMRT:70-74Gy"
2949564|NCT02907710|Active Comparator|concurrent chemoradiotherapy|"Drug: DDP~DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles~Radiation: IMRT~IMRT:70-74Gy"
2949565|NCT02907697|Experimental|LifeSteps-Drug Use|The investigators expect the LifeSteps-Drug Use adaptation will be modeled after the Life Steps adherence intervention with the addition of a Drug Use module based on motivational interviewing and the FRAMES approach. The LifeSteps-Drug Use intervention is expected to include two in-person sessions and two telephone booster sessions. While anticipated preliminary adaptations have been based on the extant literature, changes to the protocol will be based on data obtained during the qualitative phase which will be sufficiently broad and open to assess for factors that we have not anticipated.
2949566|NCT02907697|Active Comparator|Health Education|The health education condition is a time-matched, active control arm. It will consist of two in-person sessions and two telephone sessions. Each session will cover a general health education topic.
2949567|NCT02907684|Experimental|Almonds|Almond snacks
2949568|NCT02907684|Placebo Comparator|Control muffins/crackers|Muffin/Cracker snacks
2949569|NCT02907671|Active Comparator|Group A|carpal tunnel corticoanesthetic injection between the flexor tendons
2949570|NCT02907671|Active Comparator|Group B|carpal tunnel corticoanesthetic injection next to the median nerve with hydrodissection
2949571|NCT02907658|Experimental|PROTECT intervention group|The PROTECT intervention group receives the preventive intervention PROTECT (4 modules in 4 subsequent weeks à 90 min). Participants are assessed at T1 (baseline), T2 (post treatment, 1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
2949572|NCT02907658|No Intervention|Assessment-only control group|The assessment-only control group is an observational condition without intervention. Participants are assessed at T1 (baseline), T2 (1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
2949573|NCT02907645|Experimental|Local educational|Adult patients in this arm receive educational information regarding influenza vaccination based on local data
2949574|NCT02907645|Experimental|National educational|Adult patients in this arm receive educational information regarding influenza vaccination based on national data
2949575|NCT02907645|No Intervention|Usual care|No educational information other than provided as usual care by health care providers
2949576|NCT02907632|Experimental|Metoclopramide|Blind and randomized allocation to the experimental treatment: Metoclopramide
2949577|NCT02907632|Placebo Comparator|Placebo|Blind and randomized allocation to placebo
2949578|NCT02907619|Experimental|PF-06252616|Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
2949579|NCT02907593|Experimental|0.025 mg/kg Budesonide|0.025 mg/kg Budesonide in Calfactant
2949582|NCT02907593|Experimental|0.15 mg/kg Budesonide|0.15 mg/kg Budesonide in Calfactant
2949583|NCT02907580|Experimental|Local educational data|Local-based educational handout
2949584|NCT02907580|Experimental|National educational data|National-based educational handout
2949585|NCT02907580|No Intervention|Usual care|No educational information other than provided as usual care by health care providers
2949586|NCT02907567|Active Comparator|Active Treatment-Low|6 subjects randomized to 280 mg (Low) CT1812
2949587|NCT02907567|Active Comparator|Active Treatment-High|6 subjects randomized to 560 mg (High) CT1812
2949588|NCT02907567|Placebo Comparator|Placebo|4 subjects randomized to matching placebo of CT1812
2949589|NCT02907554|Placebo Comparator|control group|control group receives a placebo
2949590|NCT02907554|Experimental|intervention group|the intervention group receives 2.5 mg/kg of cyclosporine
2949591|NCT02907541|Experimental|QI4U Group|Group 1 - Learners who will learn QI methods using eLearning through QI4U
2949592|NCT02907541|Active Comparator|Facilitated Learning Group|Group 2 - Learners who will learn QI methods by facilitated teaching
2949593|NCT02907541|Active Comparator|QI4U and Facilitated Learning Group|Group 3 - Learners who will learn QI methods using a combination of QI4U and facilitated teaching
2949594|NCT02907528|Placebo Comparator|BONE Group|bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
2949595|NCT02907528|Active Comparator|BONE+EMD Group|mixture of enamel matrix derivative proteins (EMD) (Emdogain® Straumann, Basel, Switzerland) and bone substitute consisting of βTCP/HA (Bone Ceramic® Straumann, Basel, Switzerland);
2949596|NCT02907528|Experimental|EMD Group|enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland)
2949597|NCT02907515|Experimental|cm-loc attachment|cm-loc attachment is a new attachment for dental implants and connect to the denture with resin matrix as housing
2949598|NCT02907515|Active Comparator|ball attachment|ball attachment is the most common attachment for dental implants and connect to the denture by nylon cap and metal housing
2949599|NCT02907502|Experimental|Experimental formula|Young-child formula with low protein content
2949600|NCT02907502|Active Comparator|Control formula|Young-child formula with protein content similar to that of cow's milk
2949601|NCT02907489|Other|Group 1|non setting calcium hydroxide intracanal medication.
2949602|NCT02907489|Other|Group 2|triple antibiotic paste with an anti-inflammatory drug
2949603|NCT02907476|Experimental|Iyengar Yoga|Twelve-week Iyengar Yoga protocol with two 90-minute classes per week and three 30-minute homework assignments. Classes consist of approximately 60-minutes of yoga postures, 10-minutes of rest and transition, and 20-minutes of Coherent Breathing at 5 breaths per minute. Homework consist of 15-minutes of yoga postures and 15-minutes of Coherent Breathing. Coherent Breathing is CD guided. Yoga classes are taught by certified Iyengar Yoga instructors.
2949604|NCT02907476|Active Comparator|Walking|Twelve-week walking intervention will consist of two 60-minute group-walking sessions per week and three 15-minute homework walking sessions at 2.5 miles per hour on flat surface. Walking classes are conducted by research staff.
2949605|NCT02907450|Experimental|Clinical evaluation of the tolerance of the orthosis|
2949606|NCT02907437|Active Comparator|Minocycline treatment|Intervention: Drug: Minocycline (200 mg/day)
2949607|NCT02907437|Placebo Comparator|Placebo treatment|Placebo Intervention: Drug: Placebo (200 mg/day)
2949608|NCT02907424|Active Comparator|BP-100|standard treatment
2949609|NCT02907424|Experimental|Num Trey|locally produced RUTF
2949610|NCT02907411|Experimental|Quadrivas Therapy|Hands on therapy to improve all aspects of fat tissue including the vessels within. Each of 7 subjects receive 12 treatments in one month time.
2949611|NCT02907398||ADHERE|This group will include 250 patients who have been implanted with the Inspire therapy system, enrolled in the ADHERE Registry, and are willing to complete a follow-up home sleep apnea test (HSAT).
2949612|NCT02907398||CONTROL|This group will include 100 patients who have been denied insurance coverage of the Inspire therapy system implant by their provider, have had no intervention (Inspire), and are willing to complete a HSAT and provide information about their OSA treatment after denial.
2949613|NCT02907385|Experimental|LifeSeal™ Kit|Stapled Anastomosis is performed according to Standard of Care (SoC) with the addition of LifeSeal™ Kit application during surgery.
2949614|NCT02907385|No Intervention|Standard of Care|Stapled Anastomosis is performed according to SoC without LifeSeal™ reinforcement.
2949615|NCT02907372|Other|cognitive tests|
2949616|NCT02907359|Experimental|Guadecitabine|Guadecitabine 60 mg/m2 given subcutaneously daily on Days 1-5 in 28-day cycles. The total amount (in mg) of guadecitabine to be administered is determined by body surface area.
2949617|NCT02907359|Active Comparator|Treatment Choice|"Best Supportive Care.~Low dose cytarabine.~Standard Intensive Chemotherapy."
2949618|NCT02907346|Experimental|Reinforcement for wearing CGM|The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
2949619|NCT02907333|Active Comparator|Intervention group|Women who are advised to use condom during the time period between diagnosis and follow-up
2949620|NCT02907333|No Intervention|Control group|Women who are not contacted with advise to use condoms
2949621|NCT02907320|Experimental|CYCLO 3 ® FORT and placebo MPFF|MPFF = Micronized Purified Flavonoid Fraction
2949622|NCT02907320|Active Comparator|MPFF and placebo CYCLO 3 ® FORT|MPFF = Micronized Purified Flavonoid Fraction
2949623|NCT02907320|Placebo Comparator|placebo|MPFF = Micronized Purified Flavonoid Fraction
2949624|NCT02907307|Experimental|LactiSal vaginal gel 1%|5g of 1%LactiSal Gel vaginal gel once daily for 6 days
2949625|NCT02907307|Experimental|LactiSal vaginal tablet 50 mg|50 mg of LactiSal vaginal tablet daily for 6 days
2949626|NCT02907307|Active Comparator|Clotrimazole vaginal tablet 100mg|100 mg Clotrimazole vaginal tablet daily for 6 days
2949627|NCT02907294|Experimental|PBF-999|
2949628|NCT02907294|Placebo Comparator|Placebo|
2949629|NCT02907281||Multiple sclerosis patients|Multiple sclerosis patients
2949630|NCT02907281||Healthy volunteers|Healthy volunteers
2950123|NCT02903784|Other|grade 2 glioma|Patient with grade 2 glioma use a neuropsychological examination and brain imaging (fMRI and tractography)
2949631|NCT02907268|Active Comparator|Treatment Arm A|The first treatment group received onabotulinumtoxinA (Botox) on the right side of their face and abobotulinumtoxinA (Dysport) on the left side of their face. Baseline treatment at Week 0 included the intradermal injection of onabotulinumtoxinA on one side of the face and abobotulinumtoxinA on the other. Patients were treated at Week 2 with traditional intramuscular injections consisting of onabotulinumtoxinA on the same side of their face as at Week 0 and abobotulinumtoxinA on the other side. Patients were treated based on individual need, and thus the treatment volumes were not controlled or standardized.
2949632|NCT02907268|Active Comparator|Treatment Arm B|The second treatment group received abobotulinumtoxinA (Dysport) on the right side of their face and onabotulinumtoxinA (Botox) on the left side of their face. Baseline treatment at Week 0 included the intradermal injection of onabotulinumtoxinA on one side of the face and abobotulinumtoxinA on the other. Patients were treated at Week 2 with traditional intramuscular injections consisting of onabotulinumtoxinA on the same side of their face as at Week 0 and abobotulinumtoxinA on the other side. Patients were treated based on individual need, and thus the treatment volumes were not controlled or standardized.
2949633|NCT02907255|Experimental|Oximetry monitor|"Standard care plus~Wireless respiratory monitoring~Covidien~Alarm triggers:~SpO2 ≤89% (heart rate) HR < 50 or > 120"
2949634|NCT02907255|No Intervention|Standard of Care|"• Standard care:~1:4 patient to nurse ratio~Vital signs every 4 hours~Respiratory rate and sedation scores every 2 hours for patients on the Acute Pain Service"
2949635|NCT02907242|No Intervention|Concealment|Cerebroplacental ratio measurement at 37 weeks of pregnancy only taken into account if estimated fetal weight <p10
2949636|NCT02907242|Other|Revealment|Cerebroplacental ratio measurement at 37weeks and labor induction in case of cerebroplacental ratio <p5
2949637|NCT02907229|Experimental|Treatment group|neuroendovascular therapy(NCVC-CS1)
2949638|NCT02907216|Experimental|Co-administration Group|Subjects in the Co-administration group will be administered the DPT-IPV vaccine according to a 3, 4, 6 month schedule and the liquid HRV vaccine according to a 2, 3 month schedule
2949639|NCT02907216|Active Comparator|Staggered Group|Subjects in the Staggered group will be administered the DPT-IPV vaccine according to a 3, 4.5, 6 month schedule and the liquid HRV vaccine according to a 2, 3.5 month schedule
2949640|NCT02907190|Experimental|Bean Type|Beans (black; cranberry; great northern; navy; pinto; red) soaked overnight and boiled. 1/2 cup serving eaten by participants at study visit
2949641|NCT02907190|Active Comparator|Starchy Foods|1/2 cup serving of rice or paste or potato or corn will be eaten by participants on different study visit
2949642|NCT02907177|Experimental|Ponesimod|Ponesimod
2949643|NCT02907177|Placebo Comparator|Placebo|Placebo
2949644|NCT02907164|Active Comparator|Group 1: Control|People receive emails encouraging them to sign up for the challenge. The email does not mention the number of people who have signed up.
2949645|NCT02907164|Experimental|Group 2: Norm|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up.
2949646|NCT02907164|Experimental|Group 3: Norm and health motive|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up AND highlights that the challenge helps people to stay fit in a fun way.
2949647|NCT02907164|Experimental|Group 4: Norm and reward motive|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up AND highlights that the challenge helps people to stay active and earn rewards.
2949648|NCT02907151||pre-consultation survey group|The group completing a pre consultation survey filled the same questionnaire in post consultation but the doctor will see the result in the consultation.
2949649|NCT02907151||Group absence of pre-consultation survey|This group will be a control group to see if there is a difference between completing a pre-consultation survey before or not.
2949650|NCT02907138|Experimental|Medical Yoga|Medical Yoga Group therapy for eight weeks, 60 minutes per week, with the guidance of a physical therapist.
2949651|NCT02907138|Active Comparator|Treatment as Usual (physical therapy)|Treatment as Usual provided by physical therapist
2949652|NCT02907125|Experimental|TSM arm|"The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
2949653|NCT02907125|Experimental|SM arm|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
2949654|NCT02907125|Active Comparator|Comparison arm Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
2949655|NCT02907112|No Intervention|Control|Participants to continue on their habitual diet for 4 weeks
2949656|NCT02907112|Experimental|Meat Reduction|Participants asked to reduce their red and processed meat intake by 50% for 12 weeks
2949657|NCT02907099|Experimental|BL-8040 + Pembrolizumab|"Patients will initially receive BL-8040 as a single agent, followed by the addition of Pembrolizumab.~Treatment based on three week cycles. In cycle 1, daily dose of BL-8040 administered subcutaneously on Days 1-5 and 8-12. No pembrolizumab administered during cycle 1.~Cycles 2 and beyond Pembrolizumab administered by vein on Day 1 of each 21 day cycle, and BL-8040, administered on Days 1, 4, 8, and 11 of each 21 day cycle.~Study staff calls to check participant's status 30 days after last dose of study drugs, and thereafter, every 12 weeks."
2949658|NCT02907086||colorectal cancer|
2949659|NCT02907086||melanoma|
2949660|NCT02907073|Experimental|Healthy Volunteers|At the study visit, healthy subjects will have an initial physical exam, urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration and blood sampling. Vital signs, and blood samples will be obtained. Subjects will receive an infusion [18F]BF4 over 1 minute and PET imaging will begin. Three (3) PET/CT scanning procedures will be performed over a period of approximately 4 hours with two rest breaks in between. Venous blood samples for clinical laboratory tests will be taken before radiotracer administration and at 1.5 hours post-administration of radiotracer. In addition, venous blood samples will be taken during the PET/CT scans to determine blood pharmacokinetics and metabolite evaluation. Physical exam will be repeated at the end of the study.
2949661|NCT02907073|Experimental|Myeloma patients|For cancer patients undergoing virus treatments, subjects will undergo [18F]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of [18F]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of [18F]BF4 in up to three myeloma patients when the site is accessible for biopsy.
2949662|NCT02907073|Experimental|Endometrial cancer patients|For cancer patients undergoing virus treatments, subjects will undergo [18F]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of [18F]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of [18F]BF4 in up to three endometrial cancer patients when the site is accessible for biopsy.
2949663|NCT02907060|Experimental|Mechanical cervical ripening|mechanical cervical ripening with a Cook® Cervical Ripening Balloon
2949664|NCT02907060|Active Comparator|Pharmacological cervical ripening|pharmacological cervical ripening with a 10mg slow releasing system of Dinoprostone (Propess®)
2949665|NCT02907047|Active Comparator|Tourniquet|These subjects will have their tourniquet inflated during key portions of the total knee arthroplasty procedure
2949666|NCT02907047|Other|No tourniquet|These subjects will not have their tourniquet inflated during key portions of the total knee arthroplasty procedure
2949667|NCT02907034|Experimental|Group 1|First,Virtual reality approach (VR), then classical narrative approach (CN)
2949668|NCT02907034|Active Comparator|Group 2|First, classical narrative approach (CN), then virtual reality approach
2949669|NCT02907021|Experimental|Heart failure|Treat the HER-2 positive breast cancer patients experiencing mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
2949670|NCT02906995|Experimental|Sublingual tablet 4 mg|The 24 study participants will be administered the sublingual 4 mg nicotine tablet on one occasion. Blood samples will be obtained for 4 hours for analysis of nicotine plasma levels.
2949671|NCT02906995|Active Comparator|Nicorette lozenge 4 mg|The 24 study participants will be administered the Nicorette lozenge containing 4 mg of nicotine on one occasion. Blood samples will be obtained for 4 hours for analysis of nicotine plasma levels.
2949672|NCT02906982|Experimental|Gum health formulation in intra-oral device|The interventional gum health formulation is applied to the participant's mouth by means of an intra-oral device for a single eight-minute application, daily. Participants instructed to brush their teeth with a toothbrush and toothpaste twice daily, morning and night.
2949673|NCT02906982|Experimental|Gum health formulation on toothbrush|The interventional gum health formulation is applied to the participant's mouth by means of a toothbrush and toothpaste, plus the gum health formulation, for two-minute applications, twice daily, morning and night.
2949674|NCT02906982|No Intervention|Control group (split-mouth design)|The control group did not receive the interventional gum health formulation. Participants instructed to brush their teeth with a toothbrush and toothpaste twice daily, morning and night. In addition, participants instructed to floss only half of their mouth daily, and the non-flossed half serves as the untreated comparative control receiving no intervention.
2949675|NCT02906969|Experimental|Colonoscopy educational Video|Brief educational video of colonoscopy to determine comprehension and quality of bowel preparation.
2949676|NCT02906969|Placebo Comparator|Control|Non-colonoscopy video as a control.
2949677|NCT02906956|Experimental|Preferred Music Playlist|All participants will have this phase twice in the protocol. See description in intervention section.
2949678|NCT02906943||Advanced cancer|Patients with advanced, incurable solid tumors receiving standard palliative treatment(s) will have archival tumor specimens requested and used for targeted next generation sequencing (NGS) testing. Blood samples and additional archival tumor specimens will be collected for banking and future research purposes.
2949679|NCT02906930|Experimental|3 mg oral semaglutide|
2949680|NCT02906930|Experimental|7 mg oral semaglutide|
2949681|NCT02906930|Experimental|14 mg oral semaglutide|
2949682|NCT02906930|Placebo Comparator|Placebo|
2949683|NCT02906917|Experimental|IDegAsp|
2949684|NCT02906917|Active Comparator|IGlar + IAsp|
2949685|NCT02906904|Experimental|CASE (adult sleepwalking patients)|
2949686|NCT02906904|Experimental|CONTROL (adult healthy volunteers)|
2949687|NCT02906891|Experimental|Usual Care Patients on MDI or CSII|Usual Care Patients on MDI or CSII Usual care patients on multiple daily injections of insulin (MDI) or insulin pumps (CSII) will be their own controls against baseline and will use the Vigilant Diabetes Management Application in conjunction with a wireless blood glucose meter for three months.
2949688|NCT02906839|Experimental|Intervention group|Just after AF ablation, nocturnal polygraphy will be performed to diagnose SAS. If present and AHI >15/h, the SAS will be treated, based on type and severity of SAS and on patient tolerance to treatment.
2949689|NCT02906839|No Intervention|Control group|No SAS screening will be performed in this group before the end of the 2 year follow up period.
2950124|NCT02903784|Other|healthy volunteers|healthy volunteers use a neuropsychological examination and brain imaging (fMRI and tractography)
2949690|NCT02906826|No Intervention|Reported adherence|During a 4 month period the investigators will measure adherence to therapy as reported in a daily diary by participants against actual adherence which will be measured by a digital manometer attached to the participants therapy device which uploads real time data to the cloud.
2949691|NCT02906826|Active Comparator|Adherence with a video game|During the second 4 month period, participants will be given a video game on a tablet which is operated through the digital manometer by their performing their therapy correctly.Actual adherence will be measure again during this time and be compared to the no intervention arm
2949692|NCT02906813|Experimental|TAK-935 300 mg (Tablets Fed+Tablets Fasted+Solution Fasted)|TAK-935 300 mg, tablets, orally, 30 minutes after a high-fat meal on Day 1 of Intervention Period 1, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, under fasted state on Day 1 of Intervention Period 2, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 3.
2949693|NCT02906813|Experimental|TAK-935 300 mg (Tablets Fasted+Solution Fasted+Tablets Fed|TAK-935 300 mg, tablets, orally under fasted state on Day 1 of intervention period 1, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 2, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg tablets, orally, 30 minutes after high-fate meal on Day 1 of intervention Period 3.
2949694|NCT02906813|Experimental|TAK-935 300 mg (Solution Fasted+Tablets Fed+Tablets Fasted)|TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 1, followed by washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, 30 minutes after a high-fat meal on Day 1 of intervention Period 2, followed by washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, under fasted state on Day 1 of Intervention Period 3.
2949695|NCT02906800|Experimental|DIGHANC|Patients meeting all inclusion /exclusion criteria, will be given 3 cycles of the following regimen: 1) digoxin (0.25 mg/day) for a 7-day period (digitalization time) from Day 1 to Day 7; 2) chemotherapy regimen TPF protocol from Day 8 to D12 (continuous perfusion of fluorouracil for 120h, Cisplatin at Day 10 and Docetaxel at Day 11) administered in combination with digoxin 0.25 mg/day from Day 8 to Day 9; 3) a 15-day period off treatment.
2949696|NCT02906787|Experimental|BAS+|Participants will attend 8 counseling sessions and receive a behavioral activation intervention to smoking cessation and to post-cessation weight gain (BAS+).
2949697|NCT02906787|Placebo Comparator|SC|Participants will attend 8 counseling sessions and receive standard smoking cessation counseling (SC).
2949698|NCT02906761|Experimental|Aspirin|Aspirin 600 mg (2 tablets of 300 mg) twice daily for 6 months
2949699|NCT02906761|Placebo Comparator|Placebo|Placebo (2 tablets) twice daily for 6 months
2949700|NCT02906748|Experimental|new site for parathyroid auto-graft|choose the site fairly close to the antecubital vein for parathyroid auto-transplantation
2949701|NCT02906748|Active Comparator|traditional parathyroid autograft|choose not intensely close to antecubital vein for parathyroid auto-transplantation
2949702|NCT02906735||Study group|Patients with knee surgery undergo plantar foot pressure measurement pre- and postoperatively
2949703|NCT02906722|Experimental|Experimental group|Patients receive simultaneously nebulized colimycin every 8 h and intravenous placebo administered once, twice or 3 times per day according to renal function
2949704|NCT02906722|Active Comparator|Control group|Patients receive simultaneously intravenous colimycin administered once, twice or 3 times per day according to function renal and nebulized placebo every 8 h
2949705|NCT02906709|Experimental|Omarigliptin 25 mg|Omarigliptin 25 mg once weekly for 52 weeks (Phase A and B)
2949706|NCT02906709|Experimental|Placebo→Omarigliptin 25 mg|Placebo to Omarigliptin once weekly for 16 weeks (Phase A) switching to Omarigliptin 25 mg once weekly for 36 weeks (Phase B)
2949707|NCT02906696|Experimental|Bosutinib|"Participants take Bosutinib tablets by mouth 1 time each day of a 28 day cycle.~Participant called by a member of the study staff every 12 weeks for up to 2 years and then every 24 weeks after that for the next 2 years. After that, participant called 4 times each year until the study ends or they withdraw from the study."
2949708|NCT02906683|Experimental|TAS-303 3mg|
2949709|NCT02906683|Experimental|TAS-303 6mg|
2949710|NCT02906683|Placebo Comparator|Placebo|
2949711|NCT02906670|Experimental|Phase 1a Dose-Escalation (Q1W)|Part 1 is a Phase 1a dose-escalation with Sym013 designed to determine the RP2D and regimen. Patients will receive increasing doses of Sym013 on a Q1W schedule.
2949712|NCT02906670|Experimental|Phase 1a Dose-Escalation (Q2W)|Part 1 is a Phase 1a dose-escalation with Sym013 designed to determine the RP2D and regimen. Patients will receive increasing doses of Sym013 on a Q2W schedule.
2949713|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort A|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
2949714|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort B|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
2949715|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort C|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
2949716|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort D|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
2949717|NCT02906657|Experimental|Medication reconciliation|Medication reconciliation involving a pharmacist using electronic pharmaceutical records
2949718|NCT02906657|No Intervention|Control|Usual Care
2950432|NCT02901496|Experimental|Resistance exercise + infusion of placebo|Resistance exercise training + monthly infusion of placebo
2949719|NCT02906644|Experimental|Lorcaserin + Patch|Participants will receive lorcaserin (10mg twice a day) and nicotine patches (21mg/24hr) for 14 weeks, at which point the nicotine patch dosage will be reduced to 14mg/24hr for 1 week, followed by 7mg/24hr for 1 week.
2949720|NCT02906644|Experimental|Patch|Participants will receive nicotine patches (21mg/24hr) and placebo lorcaserin for 2 weeks; after 2 weeks participants will begin to receive active lorcaserin (10mg twice a day) along with the nicotine patches for 12 weeks, at which point the nicotine patch dosage will be reduced to 14mg/24hr for 1 week, followed by 7mg/24hr for 1 week.
2949721|NCT02906631||patients admitted to the ICU for AE|Adult patients with all-cause encephalitis admitted to an intensive care unit.
2949722|NCT02906618|Experimental|LY3039478 - Oral|LY3039478 given once, orally
2949723|NCT02906618|Experimental|13C 15N 2H-LY3039478 - IV|13C 15N 2H-LY3039478 given once, IV
2949724|NCT02906605|Experimental|JNJ-809 plus Apalutamide (Group A)|JNJ-809 given as an infusion and Apalutamide 240 milligram (mg) daily.
2949725|NCT02906605|Experimental|Apalutamide (Group B)|Apalutamide 240 mg orally daily.
2949726|NCT02906579|Placebo Comparator|Control|Placebo taken once daily Day 1-Day 3
2949727|NCT02906579|Experimental|10 mg IW-1973|10 mg IW-1973 take once daily Day 4-Day 6
2949728|NCT02906579|Experimental|20 mg IW-1973|20 mg IW-1973 taken once daily Day 7-Day 9
2949729|NCT02906579|Experimental|30 mg IW-1973|30 mg IW-1973 taken once daily Day 10-Day 12
2949730|NCT02906579|Experimental|40 mg IW-1973|40 mg IW-1973 taken once daily Day 13-Day 15
2949731|NCT02906579|Experimental|50 mg IW-1973|50 mg IW-1973 taken once daily Day 16-Day 18
2949732|NCT02906566|Other|Older Group Ages 55-75|Active and Placebo. Participants received retinol lotion on one arm and placebo to match on the other arm.
2949733|NCT02906566|No Intervention|Young Group Ages 18-25|Participants in the group will give tissue sample only for comparison.
2949734|NCT02906553|Experimental|Glyceryl Trinitrate|Glyceryl Trinitrate, sublingual spray, 3 x 0.4mg dose, once per day for 3 days in total.
2949735|NCT02906553|Placebo Comparator|Placebo|The formulation composition of the placebo will be the same as the active spray minus the Glyceryl Trinitrate.
2949736|NCT02906540|Experimental|Transpubic symphysis reset therapy group|Transpubic symphysis reset therapy will be conducted once a day for 7 consecutive days.
2949737|NCT02906540|Experimental|Physiotherapy group|Physiotherapy and a sham reset treatment will be performed once a day for 7 consecutive days.
2949738|NCT02906527||Non-exposed group|Non-exposed group / Patients receiving VKA
2949739|NCT02906527||Exposed group|Exposed group / Patients receiving DOAC
2949740|NCT02906514|Experimental|Hydroxyethyl starch 130/0.4|
2949741|NCT02906514|Placebo Comparator|Sodium Chloride 0.9%|
2949742|NCT02906501||Group I (n=15)|Male children and adolescents diagnosed with ADHD not treated with risperidone or any other antipsychotic treatment.
2949743|NCT02906501||Group II (n=15)|Male children and adolescents diagnosed with ADHD intended to start risperidone or any other antipsychotic treatment due to behavioral problems.
2949744|NCT02906501||Group III (n=15)|Male children and adolescents diagnosed with ADHD treated with risperidone or any other antipsychotic treatment due to behavioral problems.
2949745|NCT02906488||Patients with Parkinson's Disease|
2949746|NCT02906475|Other|Intervention: standardized skin care regimen|Intervention: The milk lotion will be applied once daily on the total body including the face by the parents or care givers at home. If bathing is needed, the bathing addendum is used in addition to water.
2949747|NCT02906475|No Intervention|Control|In the control group no predetermined or standardized skin care regimen is prescribed.
2949748|NCT02906462|Other|Usual Practices|Usual Practices
2949749|NCT02906462|Other|Early consideration of vulnerability|Strategy promoting early consideration of patients' vulnerability
2949750|NCT02906449|Experimental|Mindfulness Training|Daily Mindfulness Training - both in-class lectures (weekly) and self-study (daily) over 3 weeks
2949751|NCT02906449|Active Comparator|Relaxation Meditation Training|Daily Relaxation Meditation Training - both in-class lectures (weekly) and self-study (daily) over 3 weeks
2949752|NCT02906436|Experimental|ExVivo lung reconditioning|
2949753|NCT02906423||Allina health patients|
2949754|NCT02906410|No Intervention|Control 1|Participants in this group will see a menu labeled with prices, but will not observe calorie information. Used as a comparator for numeric labeling conditions.
2949755|NCT02906410|Experimental|Numeric individual|Features Item-Level Calorie information. Numeric calorie labels will be featured on individual items, along with prices.
2949756|NCT02906410|Experimental|Numeric individual + aggregate|Features Item-Level Calorie information and Meal-Level Calorie information. Numeric calorie labels will be featured on individual items, along with prices. Additionally, an aggregated numeric calorie count for the entire meal will be dynamically updated as items are added or removed from the meal.
2949757|NCT02906410|No Intervention|Control 2|Participants in this group will see a menu labeled with prices, but will not observe calorie information. Used as a comparator for light labeling conditions.
2949758|NCT02906410|Experimental|Light individual|Features Item-Level Calorie information. Traffic light calorie labels will be featured on individual items, along with prices.
2949759|NCT02906410|Experimental|Light individual + aggregate|Features Item-Level Calorie information and Meal-Level Calorie information. Traffic light calorie labels will be featured on individual items, along with prices. Additionally, an aggregated traffic light label for the entire meal will be dynamically updated as items are added or removed from the meal.
2949760|NCT02906397|Experimental|Experimental: Galunisertib/SBRT|Galunisertib (LY2157299) 150mg by mouth twice a day on days 1-14 of 28 day cycles SBRT 18Gy, delivered in one fraction between Cycle 1 D15 and D28
2949761|NCT02906384|No Intervention|routine PCI|PTV:25Gy/10F. Radiation technique: VMAT.
2949762|NCT02906384|Experimental|HA-PCI|"PTV 25Gy/10F. Hippocampus avoidance: decrease the dose to HAZ as the following criteria: Dmin<9Gy Dmax<16Gy.~Radiation technique: VMAT."
2949794|NCT02906150|Experimental|Thymalfasin (Thymosin alpha 1, Ta1)|Arm A: 70 patients will receive Thymosin alpha 1 in 1mL SC injection five times a week (first four months); then two times a week for eight months. SoC chemotherapy and cisplatin (or carboplatin) for twelve months.
2950815|NCT02898350|Active Comparator|CO2 laser treatment|CO2 laser (3 treatment sessions) after suture removal
2949763|NCT02906371|Active Comparator|Tocilizumab high tumor burden|This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated CRS safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with high pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).
2949764|NCT02906371|Active Comparator|Tocilizumab low tumor burden|This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated CRS safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with low pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).
2949765|NCT02906358|Active Comparator|Community-based pain self-care|Community-based pain self-care: two, one hour meetings monthly for first three months (6 meetings) and one meeting per month for the last three months (total 9 meetings)
2949766|NCT02906358|Active Comparator|Clinic-based pain self-care|Clinic-based pain self-care: 30-45 minute individualized meetings once monthly for 6 months (total 6 meetings)
2949767|NCT02906345|No Intervention|Control Group|Patients with septic shock, no therapeutic plasma exchange, BMC standard treatment
2949768|NCT02906345|Active Comparator|TPE-Filtration Group|Patients with septic shock, therapeutic plasma exchange, plasma separation using a filter (Fresenius MultiFiltrate, Kit 16 MPS P2 dry), BMC standard treatment
2949769|NCT02906345|Active Comparator|TPE-Centrifugation|Patients with septic shock, therapeutic plasma exchange, plasma separation using a centrifuge (Fresenius COM-TEC, PL1 Erythrozytapherese/Plasmabeutel Set) BMC standard treatment
2949770|NCT02906332|Experimental|Pembrolizumab + lenalidomide|"This is an open label study.~Pembrolizumab 200 mg IV every 3 weeks and lenalidomide 25 mg po daily x 14 days and dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles.~This is followed by pembrolizumab 200 mg every 3 weeks and lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for a total of 4 cycles."
2949771|NCT02906306|Experimental|Individual Occupational therapy|In Individual Occupational Therapy treatment the activities included personal independence training (ADLs), sensory-motor stimulation activities, cognitive stimulation (attention, memory, language and executive function) and animal-assisted therapy (AAT).
2949772|NCT02906306|Experimental|Group Occupational therapy|In group Occupational Therapy treatment the activities included personal independence training (ADLs), sensory-motor stimulation activities, cognitive stimulation (attention, memory, language and executive function) and animal-assisted therapy (AAT) and psychosocial skills training.
2949773|NCT02906293||Healthy Participants|Potential participants will self-refer.
2949774|NCT02906280|Experimental|19 Ga EBUS-TBNA needle|needle aspiration by a flexible 19 Ga needle (Olympus)
2949775|NCT02906280|Active Comparator|22 Ga EBUS-TBNA needle|needle aspiration by a 22 Ga needle (Olympus)
2949776|NCT02906267|Other|Manual-controlled|Patient in the manual ventilation group will receive facemask ventilation to get a tidal volume of 8-10ml/kg with a respiratory rate of 15/min. The pop-off valve will be set to 20 cm H2O.
2949777|NCT02906267|Other|Volume-controlled|mechanical breath will be delivered by a Primus ventilator (Dräger, Lubeck, Germany) at a frequency of 15 breath/min. Tidal volume will be set to 8-10 ml/min.
2949778|NCT02906267|Other|Pressure-controlled|mechanical breath will be delivered by a Primus ventilator (Dräger, Lubeck, Germany) at a frequency of 15 breath/min. Pressure will be adjusted to obtain a tidal volume of 8-10 ml/min.
2949779|NCT02906254||ECIL-4 guidelines group|"For the FUO group, antibiotics were stopped based on two procedures, irrespective of the neutrophil count or expected duration of neutropenia:~- From 1st February 2014 to 30th November 2014, antibiotics were stopped when patients had been afebrile for more than 48 hours, as recommended by the ECIL-4 guidelines"
2949780|NCT02906254||short-course antibiotic therapy|"For the FUO group, antibiotics were stopped based on two procedures, irrespective of the neutrophil count or expected duration of neutropenia:~- From 1st December 2014 to 30th September 2015, antibiotics were stopped on day 5 in febrile or afebrile patients (short-course antibiotic therapy)."
2949781|NCT02906241|Experimental|Patients--Intervention|Patients are randomized to an intervention group. They participate in all aspects of the study and also receive the intervention, which consists of a booklet.
2949782|NCT02906241|No Intervention|Patients--Usual Care|Patients are randomized to the standard of care arm and participate in all aspects of the study but receive no intervention.
2949783|NCT02906241|Other|Physicians|Physicians receive the intervention approximately halfway through data collection for a within subjects, pre-post intervention comparison
2949784|NCT02906228|Experimental|GSM 900 MHz|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
2949785|NCT02906228|Experimental|TETRA 385 MHz|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
2949786|NCT02906228|Experimental|Sham Exposure|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
2949787|NCT02906215|Experimental|Care Coordination Intervention|The care coordination intervention will consist of a mobile application designed for treatment providers, an interagency communication protocol, and a series of cross-training in HIV and addiction issues.
2949788|NCT02906202|Experimental|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product (autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human βA-T87Q-globin gene)
2949789|NCT02906176|Experimental|SLCO2B1 wild type|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)
2949790|NCT02906176|Experimental|SLCO2B1 variant|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)
2949791|NCT02906163|Experimental|Thymalfasin biw plus SoC (tyrosine kinase inhibitor)|Twice weekly thymalfasin
2949792|NCT02906163|Experimental|Thymalfasin plus SoC (tyrosine kinase inhibitor)|5 times a week thymalfasin
2949793|NCT02906163|Active Comparator|SoC (tyrosine kinase inhibitor)|12 months
2949795|NCT02906150|Active Comparator|SoC (chemotherapy and platinum agent)|Arm B: 70 patients (control group) will receive SoC chemotherapy and cisplatin (or carboplatin) for twelve months.
2949796|NCT02906137|Experimental|HIV-1 infected subjects|"40 subjects will be recruited in the Department of Infectious Diseases of Toulouse University Hospital, France:~15 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling~15 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling~10 subjects will have both a gastroscopy and a coloscopy"
2949797|NCT02906137|Other|Uninfected-controls|"30 subjects will be recruited in the Department of Internal Medicine of Toulouse University Hospital, France:~10 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling~10 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling~10 subjects will have both a gastroscopy and a coloscopy"
2949798|NCT02906124||Repatha® exposed|Females with familial hypercholesterolaemia (FH) exposed to Repatha® in the 15 weeks prior to or during pregnancy or during breastfeeding
2949799|NCT02906124||Non exposed to Repatha®|Pregnant females with familial hypercholesterolaemia (FH) not exposed to Repatha® and enrolled into this study, overall and stratified by lipid lowering therapy use
2949800|NCT02906111|Active Comparator|Study Group on estriol vaginal gel|Drug: 1 g/daily of vaginal gel containing 50 μg of estriol (0.005%) for 3 weeks and then twice weekly for 9 weeks, for a complete cycle of treatment of 12 weeks
2949801|NCT02906111|Active Comparator|Control group, no estriol treatment|Procedure: vaginal surgery
2949802|NCT02906098|Experimental|Patient centered oral health education|The program is based on cognitive behavioral theory and principles. Hence, the intervention is adapted to each individual's problem, capacity and goals were the dental hygienist use motivational interviewing skills in communication and act as a guiding resource during the process of behavioral change. The program follows a specific structure including components such as formulation of personal goals, continuous self-monitoring by diary and planning of behavior. The initial intervention phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
2949803|NCT02906098|Active Comparator|Standard educational intervention|The subjects in the control group receive educational intervention by a dental hygienist in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
2949804|NCT02906085|Experimental|Endothelin-1|Intravenous infusion of pharmaceutical grade human endothelin-1
2949805|NCT02906085|Placebo Comparator|Placebo|Intravenous infusion of placebo (isotonic saline)
2949806|NCT02906072|Experimental|Low fat plant-based diet|Low fat plant-based diet with conventional meals and supplemented with plant-based meal replacements and participants attend the lectures on health effects of a low fat plant-based diet.
2949807|NCT02906072|Other|Control group|Control participants attend the lectures on health effects of a low fat plant-based diet.
2949808|NCT02906059|Experimental|AZD1775 & Irinotecan|"Group AZD1775 (study drug); Irinotecan (chemotherapy)~1) 125 mg two times a day (BID) for 3 days every 2 weeks; 180mg/m2 every 2 weeks~2A) 150 mg BID for 3 days every 2 weeks; 180mg/m2 every 2 weeks~2B) 125 mg BID for 5 days every 2 weeks; 180mg/m2 every 2 weeks~3) 150 mg BID for 5 days every 2 weeks ; 180mg/m2 every 2 weeks"
2949809|NCT02906046|Placebo Comparator|placebo Weight in Lower Limbs|placebo Weight in Lower Limbs
2949810|NCT02906046|Other|0,5 kg Weight in Lower Limbs|0,5 kg Weight in Lower Limbs
2949811|NCT02906046|Other|1,0 kg Weight in Lower Limbs|1,0 kg Weight in Lower Limbs
2949812|NCT02906033|Experimental|Intervention group|New perioperative practice model.
2949813|NCT02906033|No Intervention|Control group|Traditional practice model.
2949814|NCT02906020|Experimental|GZ/SAR402671|Part 1: Increasing dose of GZ/SAR402671 will be administered once per day. Part 2: A dose of GZ/SAR402671 (determined in Part 1) will be administered once per day.
2949815|NCT02906020|Placebo Comparator|Placebo|A matching placebo for Parts 1 and 2 will be administered once per day.
2949816|NCT02906007|Experimental|Bedaquiline (BDQ)|Participants will receive bedaquiline (BDQ) once a day for 2 weeks. For the next 22 weeks, participants will take BDQ 3 times a week.
2949817|NCT02905994|Experimental|Volasertib with chemotherapy|"Patients enrolled on this trial will receive induction chemotherapy with 7+3~Cytarabine continuous infusion days 1-7~Idarubicin IV bolus on days 1, 2, and 3.~Patients will receive Volasertib as an intravenous infusion over approximately 1 hour, according to dosing level, on day 8~Patients will receive Standard Anti Fungal and Standard Antibiotic during induction~A bone marrow biopsy will be performed according to standard practice on day 14"
2949818|NCT02905981|Experimental|Period 1: Iron Absorption Tests|During 3 consecutive weekly study visits, patients will receive Fer-In- Sol orally 3 mg Fe/kg body weight, Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Fer-In- Sol orally 3 mg Fe/kg body weight, and Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight (respectively). All oral doses will be administered by study personnel at the research center. Blood tests will be conducted following each administration in order to measure iron absorption to see if patients qualify for Period 2.
2949819|NCT02905981|Experimental|Period 2: Dose Titration|Patients who qualified as 'Triferic responders' in Period 1 will participate in Period 2. Patients will be given oral Shohl's solution and Triferic to administer at home 3 times per day, with the dose being titrated higher or lower based on lab results. The initial dose will be the same as Period 1 (Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight) but may be adjusted during Period 2 based on lab results. Period 2 will involve 5 study visits, scheduled every 4 weeks. At the end of Period 2, blood tests will be performed to determine if patients qualify for Period 3.
2949820|NCT02905981|Experimental|Period 3: Hemoglobin Maintenance|Patients who qualified as 'hemoglobin responders' in Period 2 will participate in Period 3. Patients will continue to take Shohl's solution and Triferic at their titrated dose for an additional six months to confirm that their hemoglobin can be maintained over an extended period of time. The period will be comprised of 3 study visits, scheduled every 8 weeks.
2949821|NCT02905968|Experimental|TTPLAR|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
2949822|NCT02905968|No Intervention|NORLAR|Tranditional low anterior resection without transanual tube placement or ileostomy.
2949823|NCT02905955|Other|Prevena|
2949824|NCT02905942|Experimental|PEG-rhG-CSF|Patients in PEG-rhG-CSF group received PEG-rhG-CSF day +1 after transplantation.
2949825|NCT02905942|Active Comparator|rhG-CSF|Patients in control group received rhG-CSF day +1 after transplantation.
2949826|NCT02905929|Experimental|Sitting Less group|The 'reduce sitting' intervention group will receive three in-person health coaching sessions followed by five counseling phone calls. Participants will wear a thigh worn inclinometer for the first 3 weeks of the intervention, and at the mid-point of the intervention. At each in-person health coaching session participants will receive feedback from the ActivPAL showing periods throughout the day where participants have been sitting. In addition to the three initial in-person counseling sessions using the ActivPAL feedback, participants will receive phone calls from the health educator biweekly to help overcome barriers, to work on self-monitoring and planning skills, and to prepare relapse prevention. Tools to help prompt standing, including a standing desk, will also be provided.
2949827|NCT02905929|Active Comparator|Attention Control|Participants in the attention control condition will receive a healthy aging educational intervention developed and tested by the investigators in previous studies. This group will receive one in-person coaching session followed by seven phone coaching sessions.
2949828|NCT02905916|Experimental|PEG-rhG-CSF|
2949829|NCT02905903|Other|Trichloroacetic Acid|Intervention-Apply 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study. Comparisons will be made using Investigators Global Assessment scoring of hyperpigmentation and erythema, colorimetry, photography, and biopsies
2949830|NCT02905890|Experimental|Norethisterone enanthate plus condoms|200 mg Norethisterone enanthate intramuscularly every eight weeks at enrolment, 2 and 4 months. Counseling and condoms will be provided at enrolment, 1, 2, 3 and 4 months.
2949831|NCT02905890|Active Comparator|Condoms only|Counseling and condoms will be provided at enrolment, 1, 2, 3 and 4 months.
2949832|NCT02905877||Functional neurological disorders|Initially especially patients diagnosed with a functional tremor.
2949833|NCT02905877||Organic neurological disorders.|Initially especially patients diagnosed with a an organic action tremor (e.g. essential tremor or dystonic tremor).
2949834|NCT02905877||Healthy control|Healthy age matched controls
2949835|NCT02905864|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
2949836|NCT02905864|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
2949837|NCT02905851|Placebo Comparator|Non Feedback|No feedback given to this group regarding their antibiotic use Subjects take images and answer questions during the study like the feedback group, but in this group no feedback re dosing is given.
2949838|NCT02905851|Active Comparator|Feedback group|"Feedback given to this group regarding their antibiotic use after baseline.~If the subject is in the feedback group, after this visit, a dermatologist will review all images and the survey results and give the patient information about whether they should:~Continue current dose~Reduce dose if there is at least a one point improvement in both the investigator acne global assessment AND the patient acne global assessment scores: A dose reduction will be such that the dose is halved from the previous dose. For example if the subject is on minocycline or doxycycline 100 mg twice daily, they will be reduced to minocycline or doxycycline 100 mg daily.~Increase dose if had been previously reduced, dose will not be increased beyond the initial starting dose."
2949839|NCT02905838|Active Comparator|Anatomic e.max Abutment|Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
2949840|NCT02905838|Active Comparator|CAD/CAM CARES Abutment|Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
2949841|NCT02905825|Experimental|Indication for Helicobacter pylori testing|Walk in basis: any pediatric subjects with indication for Helicobacter pylori testing will be enrolled if they meet study eligibility criteria and will perform stool test and urea breath test within a week of each other.
2949842|NCT02905812|Active Comparator|RGI & Massage|"relaxation and guided imagery with background music (RGI) (40 min, headphones)~a brief moderate pressure massage session (massage: 15 min)"
2949843|NCT02905812|No Intervention|Control|Sham intervention: Silent headphones to mask the audio component, and presence of an intervention nurse at the bedside with drawn curtains.
2949844|NCT02905799|Experimental|Oral resveratrol|Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
2949845|NCT02905799|Placebo Comparator|Oral Placebo|Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months.
2949846|NCT02905773|Other|postoperative pain|postoperative pain
2949847|NCT02905773|Other|intensity|intensity
2949848|NCT02905760|Experimental|Furosemide|Furosemide and Placebo filling (Glucose 5%).
2949849|NCT02905760|Active Comparator|Fluid expansion|"Placebo furosemide (Glucose 5%) and Vascular filling~The vascular filling is the gold standard in the treatment of acute myocardial infarction"
2949850|NCT02905747|Experimental|Medical Exercise Therapy|Medical Exercise Therapy (MET) developed by Oddvar Holten
2949851|NCT02905734|Experimental|nicotine replacement patch|Single administration of a nicotine patch (14 mg or 21 mg, according to the Heaviness of Smoking Index)
2949852|NCT02905734|Placebo Comparator|placebo patch|Single administration of a placebo patch
2949853|NCT02905721|Experimental|Spectral cardiac CT scan|All patients will undergo cardiac CT scan with spectral mode acquisition
2949854|NCT02905708|Active Comparator|Forced Air Warming Device|"Active Comparator: Forced Air Warming Device first group will have the warming devices started in the pre-operative area. You will receive a full body forced air warming. Device is non experimental and FDA approved, used within the hospital to keep patients warm.You will then have your temperature taken and documented by the staff at various prescribed times.~Warming in the operating room: You will receive the same or a similar warming device known as a Bair Hugger and warmed IV fluids once you are in the operating room. Bair Paws or Bair Hugger will also be used in the post-anesthesia care area."
2949855|NCT02905708|Active Comparator|Air-Activated heating packs|The second group will receive the study warming device which consists of a jacket, pants, gloves and socks with integrated Air-Activated heating packs. Device is supplied vacuum packed, heat packs of iron powder/activated charcoal activated by air. Device applied at least twenty minutes prior to surgery. The same device will be maintained in place throughout the surgery and the post-anesthesia period.
2949856|NCT02905695|Experimental|Group A|Chirocaine
2949857|NCT02905695|Placebo Comparator|Group B|Placebo
2949858|NCT02905682|Experimental|Desmopressin|Desmopressin ODT
2949859|NCT02905682|Placebo Comparator|Placebo|Placebo ODT
2949860|NCT02905669|Experimental|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device.
2949861|NCT02905656|Placebo Comparator|Brief Advice|Participants will receive brief advice to quit smoking, and be provided psycho-education citing health consequences and the positive impact on mortality and morbidity.
2949862|NCT02905656|Experimental|Motivational Interviewing (MI)|Motivational interviewing (MI) is a collaborative conversation style for strengthening a person's own motivation and commitment to change. MI attempts to avoid a confrontational style and, instead, guides participants toward choosing to make a change in their behavior.
2949863|NCT02905656|Experimental|Rate Reduction (RR)|Participants will be informed of the strong medical evidence of systematic reductions in smoking behavior can lead to long-term smoking cessation. This condition will receive Nicotine Replacement Therapy in the form of gum.
2949864|NCT02905656|Experimental|MI + RR|In this intervention, participants receive both the skills based rate reduction intervention and the more motivationally based MI intervention. This condition will receive Nicotine Replacement Therapy in the form of gum.
2949865|NCT02905643||Study subjects|Patients who have or might have a brain tumor which may be a glioblastoma.
2949866|NCT02905630|Experimental|Exercise training|High intensity aerobic exercise training
2949867|NCT02905630|No Intervention|No training|No exercise training, only ordinary daily life activities.
2949868|NCT02905617||Primary Augmentation|
2949869|NCT02905617||Revision Augmentation|
2949870|NCT02905604|Experimental|dmPFC iTBS|Repetitive transcranial magnet stimulation (rTMS) over the dorsomedial prefrontal cortices at 90% of the resting motor threshold of the foot flexors. The rTMS is given in 20 trains to the left and right dmPFC, respectively. Each train consists of 10 bursts at 5 Hz (theta-frequency), and each burst consists of 3 pulses at 50 Hz. The stimulation is intermittent with 2 seconds of stimulation, 8 seconds off. After a 15 minute break the whole protocol i applied again, resulting in 2400 pulses/day. Treatment is delivered daily at 10 week days.
2949871|NCT02905604|Sham Comparator|dmPFC Sham iTBS|A sham treatment protocol by using a sham coil with two identical sides where one side give active treatment as described above while on the other side the coil is insulated so very little magnetic energy is delivered. The coil has a built in positioning sensors and a software handling the randomization codes prompts the operator which side of the coil that should be directed towards the patient. Superficial transcutaneous electrical nerve stimulation (TENS) is applied over the stimulation site of the dmPFC synchronous wiht the TMS pulses to further mimic the sensation of the active stimulation.
2949872|NCT02905591|Experimental|Concurrent and consolidation therapy|"Concurrent therapy:~Radiation therapy, intravenous paclitaxel, intravenous carboplatin, intravenous ascorbic acid (pharmacological ascorbate)~Consolidation therapy:~Intravenous paclitaxel, intravenous carboplatin, intravenous ascorbate"
2949873|NCT02905578|Experimental|Ascorbate group|"Each cycle is 4 calendar weeks~Gemcitabine: 1000 mg/m2, once weekly for 3 weeks nab-paclitaxel: 125 mg/m2, once weekly for 3 weeks Pharmacological ascorbate: 75 grams, three times weekly for 4 weeks"
2949874|NCT02905578|Active Comparator|Control|"Each cycle is 4 calendar weeks~Gemcitabine: 1000 mg/m2, once weekly for 3 weeks nab-paclitaxel: 125 mg/m2, once weekly for 3 weeks Each cycle has 1 rest week"
2949875|NCT02905565|Placebo Comparator|Placebo|Interventions: Placebo (NBP placebo softgel capsules, 0 mg NBP, BID)
2949876|NCT02905565|Active Comparator|800 mg of NBP daily|Interventions: 800 mg NBP softgel capsules daily (400 mg BID)
2949877|NCT02905552||Case group|Patient developing a first episode of infection since diagnosis of high-risk MDS (index case)
2949878|NCT02905552||Control group|"Patient with no infection since diagnosis of MDS~Patient will be paired to index case by:~Hospital site~Age~Sexe Control patient is eligible if he has been seen in consultation within 15days before or after date of first infection of index case If matching fails, control patient can be found in another site and/or within 30days before or after date of first infection of index case"
2949879|NCT02905539|Experimental|Iron Isomaltoside 1000|Subjects receive Iron Isomaltoside 1000 solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.
2949880|NCT02905539|Active Comparator|Ferric Carboxymaltose|Subjects receive Ferric Carboxymaltose solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.
2949881|NCT02905526|Experimental|Intervention|App plus the contraceptive instant messages
2949882|NCT02905526|Placebo Comparator|Control|App only
2949883|NCT02905513|Experimental|Intervention|App plus the contraceptive instant messages
2949884|NCT02905513|Placebo Comparator|Control|App only
2949885|NCT02905487||GDM|Mother-child pairs from mothers with GDM diagnosis (ADA, 2012)
2949886|NCT02905487||No GDM|Mother-child pairs from mothers without GDM diagnosis (ADA, 2012)
2949887|NCT02905474|Experimental|eKidneyCare|The eKidneyCare mobile app has an active interface with the renal clinic pharmacy system to allow for updated medication profiles to be sent directly to the patient's smartphone for the renal clinic pharmacy information system.
2951140|NCT02896374|Experimental|Patients|Treated or hospitalized patients for schizophrenia.
2949888|NCT02905474|Active Comparator|My MedRec (Commercial App)|My MedRec is a commercially available mobile app which allows a user to have a personal health record along with keeping track of their medications. The My MedRec mobile app allows users to track blood pressure and medication information through manual data entry with the app. It is a stand alone mobile app which stores specified medical information on the native smartphone device and does not connect to any other servers or databases.
2949889|NCT02905461|Experimental|Intervention|Contraceptive text messages
2949890|NCT02905461|Placebo Comparator|Control|Text messages not about contraception
2949891|NCT02905448|Experimental|Low fat plant-based diet|Low fat plant-based nutrition: low fat plant-based diet supplemented with plant-based meal replacements
2949892|NCT02905435|Experimental|Biodegradable Temporizing Matrix|Biodegradable Temporizing Matrix (BTM)
2949893|NCT02905422|No Intervention|Waitlist Control Group|Six month delayed access to the H.E.A.L.T.H. II Intervention - Intensive intervention (wait-list control)
2949894|NCT02905422|Active Comparator|Active Intervention Group|Immediate access to the H.E.A.L.T.H. II Intervention - Intensive intervention
2949895|NCT02905409|Active Comparator|4PD diameter of ILM peeling in surgery|patients in this group was given 4PD (papillary diameter) diameter of ILM (internal limiting membrane) peeling in surgery
2949896|NCT02905409|Experimental|2PD diameter of ILM peeling in surgery|patients in this group was given 2PD diameter of ILM peeling in surgery
2949897|NCT02905396|Experimental|Spinal cord stimulation|implantation of spinal cord stimulator
2949898|NCT02905383|Experimental|Exercise|This group will perform a multi-component exercise program twice a week for 16 weeks. The multi-component exercise program consists of endurance training, progressive strength exercises and balance exercises. The intervention will be individualised, but performed in groups of four to ten patients. The participants are also expected to do exercises on their own, at least once weekly.
2949899|NCT02905383|No Intervention|Control|The participants in the control group will be encouraged to exercise on their own, according to the World Health Organization recommendations on physical activity for adults aged 65 and above.
2949900|NCT02905370|Experimental|Progressive Multi-Component (PMC)|High intensity strength training protocol, daily protein supplementation, functionally enhanced transitions of care
2949901|NCT02905370|Active Comparator|Usual Care (UC)|Low intensity rehabilitation protocol, standard education for nutrition, standard transitions of care
2949902|NCT02905357||MINOCA|OCT and CMR imaging
2949903|NCT02905357||MI-CAD|Screen failures with MI found to have obstructive CAD. Limited data collection for comparison to MINOCA cohort.
2949904|NCT02905344||1|Control, no anatomical model used for description
2949905|NCT02905344||2|Anatomical model used for description
2949906|NCT02905331|Experimental|Group 1 (Guselkumab: Placebo)|Participants will receive 100 milligram (mg) guselkumab administered as a 100 milligram per milliliter (mg/mL) solution in a single-use prefilled syringe (PFS) assembled in a SelfDose device at Weeks 0, 4, 12, 20, and 28; liquid placebo for guselkumab 100 mg at Week 16 to maintain the study blind.
2949907|NCT02905331|Experimental|Group 2 (Placebo: Guselkumab)|Partcipants will receive placebo at Weeks 0, 4, and 12 followed by guselkumab 100 mg at Weeks 16, 20, and 28.
2949908|NCT02905318|Experimental|Palbociclib|125mg orally days 1-21 every 28 day cycle
2949909|NCT02905305|Experimental|CA with dexamethasone base|Contour Advance electrode with controlled dose of dexamethasone base
2949910|NCT02905305|Active Comparator|Contour Advance|Standard Contour Advance electrode array
2949911|NCT02905279|Active Comparator|Biofeedback|Biofeedback Relaxation Training
2949912|NCT02905279|Active Comparator|Standard Exposure|Exposure Therapy
2949913|NCT02905279|Experimental|Exposure with Threat-Relevant OAs.|Exposure with Threat-Relevant Opposite Actions
2949914|NCT02905279|Experimental|Exposure with Threat-Irrelevant OAs|Exposure with Threat-Irrelevant Opposite Actions
2949915|NCT02905266|Experimental|Nivolumab and Ipilimumab Concomitant Administration|Followed by Nivolumab monotherapy
2949916|NCT02905266|Experimental|Nivolumab and Ipilimumab Sequential Administration|Followed by Nivolumab monotherapy
2949917|NCT02905253|Experimental|AC-084, single ascending dose (Part A)|AC-084 administered at different single dose levels in a sequential manner, and in a maximum of 7 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
2949918|NCT02905253|Placebo Comparator|Placebo,single ascending dose (Part A)|Matched placebo administered as single ascending doses in parallel to AC-084
2949919|NCT02905253|Experimental|AC-084, multiple ascending dose (Part B)|AC-084 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be between 1 and 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A. Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
2949920|NCT02905253|Placebo Comparator|Placebo,multiple ascending dose (Part B)|Matched placebo administered as multiple ascending doses in parallel to AC-084
2949921|NCT02905253|Experimental|AC-084, single dose (Part C)|Up to 6 subjects in part C will receive AC-084 administered at a single dose (foreseen to be 100 mg)
2949922|NCT02905240|Experimental|nSTRIDE APS|Autologous Protein Solution prepared using the nSTRIDE APS Kit
2949923|NCT02905240|Other|Saline|Saline control
2949924|NCT02905227|Experimental|Adult Asthmatics|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult asthmatics
2949925|NCT02905227|Experimental|Adult Smokers|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult smokers.
2949926|NCT02905227|Experimental|Adult Healthy Volunteers|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult healthy volunteers.
2949970|NCT02904954|Experimental|Arm 1 (Durvalumab monotherapy)|Durvalumab (MEDI4736) via IV infusion administered pre-operatively every 3 weeks for 2 cycles followed by surgical resection. Durvalumab monotherapy will be given for 12 months post-operatively.
2950493|NCT02901002||Patient|Patients suffering from CRPS of the lower limb Patients with sensory testing in the two hand and neuropsychological evaluation
2949927|NCT02905201||mCRPC participants|Participants will not receive any intervention as a part of this study. Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) who have adequate response to treatment (abiraterone Acetate + prednisone) will be observed to collect data for ECOG performance status, safety assessments (as described above), the collection of PROs (BPI-short form, Pain VAS, HCU questionnaire), the assessment of disease status and parameters, and the assessment of participant compliance to treatment.
2949928|NCT02905188|Experimental|GLYCAR T cells + Fludarabine and Cytoxan|GPC3-CAR (GLYCAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with hepatocellular carcinoma.
2949929|NCT02905175||Rheumatoid arthritis|blood sample specimen and synoviocytes from synovial tissue
2949930|NCT02905175||Osteoarthritis|blood sample specimen and synoviocytes from synovial tissue
2949931|NCT02905162||HIV positive individuals incarcerated at Lusaka Central Prison|Cohort of individuals scheduled for release within 30 days will be followed for 6 months post release
2949932|NCT02905149|Experimental|Serrato|Standard anesthesia+serratus plane block.
2949933|NCT02905149|Placebo Comparator|Control|Standard anesthesia
2949934|NCT02905136||Patient with confirmed diagnosis of autoimmune encephalitis by|"Patient with confirmed diagnosis of autoimmune encephalitis by French rare disease reference center on PNS with :~with detection in CSF of characterized antibodies against neuronal synaptic receptor or protein (anti-NMDAr, anti-LGI1, anti-CASPR2, Anti-AMPAr, anti-mGluR5, anti-GABAbr)~or uncharacterized antibodies"
2949935|NCT02905123|Experimental|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
2949936|NCT02905123|No Intervention|Control|No Intervention Control
2949937|NCT02905110|Experimental|Methotrexate / Etoposide Infusion|12 infusions of intraventricular Methotrexate and 15 infusions of intraventricular Etoposide into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle. Methotrexate will be infused twice weekly for 6 weeks and etoposide will be infused 5 times a week on weeks 1, 3 , and 5.
2949938|NCT02905097||Arthroplasty cohort|A cohort of patients who will undergo knee replacement surgery and will receive Triathlon Tritanium (cementless) tibial implant.
2949939|NCT02905071|Experimental|Study 1 Group 1 G1 (n =50)|filling of Serenat at baseline (T1)
2949940|NCT02905071|Experimental|Study 1 Group 2 G2 (n=50)|Serenat at baseline T1 and 3 others questionnaires
2949941|NCT02905071|Experimental|Study 1 Group 3 G3 (n =50)|filling of Serenat at baseline T1 and T2 (one week after baseline).
2949942|NCT02905071|Experimental|Study 2 Ancillary study (n=50)|filling of Serenat, HADS, STAY-Y and BDI at baseline T1
2949943|NCT02905058|Experimental|Ketoprofen|women will take one tablet 150 mg one hour before the procedure
2949944|NCT02905058|Placebo Comparator|Placebo|women will take one placebo tablet one hour before the procedure
2949945|NCT02905045|Active Comparator|Ketoprofen|women will take one tablet 150 mg one hour before the procedure
2949946|NCT02905045|Placebo Comparator|Placebo|women will take one tablet placebo one hour before the procedure
2949947|NCT02905032|No Intervention|Standard Care|Observations in clinical encounter via video, audio or observational notes.
2949948|NCT02905032|Active Comparator|Standard Care + Decision Aid|Observation of clinical encounter using the decision aid via video, audio, or observational notes.
2949949|NCT02905019|Active Comparator|Standard Dose x3 (Group 1)|R21 with Matrix-M1. Three vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0, 28 and 56.
2949950|NCT02905019|Active Comparator|High Dose (Group 2)|R21 with Matrix-M1. Two vaccinations with 50µg R21/50µg Matrix-M1 on days 0 and 28 and one vaccination with 10 µg R21/ 50 µg Matrix M1 on day 56.
2949951|NCT02905019|Active Comparator|Combination (Group 3)|R21 with Matrix-M1, ChAd63 ME-TRAP and MVA ME-TRAP. Three vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 , 28 and 56. Plus one vaccination with ChAd63 ME-TRAP on day 7 and one vaccination with MVA ME-TRAP on day 63.
2949952|NCT02905019|No Intervention|Control Group 4a|These volunteers will not be vaccinated and will serve as infectivity controls when groups 1-3 undergo challenge.
2949953|NCT02905019|No Intervention|Control Group 4b|These volunteers will not be vaccinated and will serve as infectivity controls when group 5-7 and sterilely protected volunteers from groups 1-3 undergo challenge.
2949954|NCT02905019|No Intervention|Control Group 4c|These volunteers will not be vaccinated and will serve as infectivity controls if any volunteers from groups 5 and 7 are rechallenged.
2949955|NCT02905019|Active Comparator|Fractional Dose (Group 5)|R21 with Matrix-M1. Two vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 and 28 and one vaccination with 2µg R21/ 50 µg Matrix-M1 on day 56.
2949956|NCT02905019|No Intervention|Long-term Efficacy (Group 6)|Volunteers in this group have received vaccinations in a different malaria vaccine trial. These volunteers will not receive any vaccinations in this trial, but will undergo controlled human malaria infection as part of this study.
2949957|NCT02905019|Active Comparator|Standard Dose x2 (Group 7)|R21 with Matrix-M1. Two vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 and 28.
2949958|NCT02905006|Placebo Comparator|Placebo|
2949959|NCT02905006|Experimental|Bimekizumab dosing regimen 1|
2949960|NCT02905006|Experimental|Bimekizumab dosing regimen 2|
2949961|NCT02905006|Experimental|Bimekizumab dosing regimen 3|
2949962|NCT02905006|Experimental|Bimekizumab dosing regimen 4|
2949963|NCT02905006|Experimental|Bimekizumab dosing regimen 5|
2949964|NCT02904993|Other|L2 paravertebral block|regional anesthetic nerve blocks using an L2 paravertebral block with ropivacaine
2949965|NCT02904993|Active Comparator|periarticular injection group|periarticular local injection into the periarticular soft tissues at the time of hip replacement using a combination of ropivacaine, epinephrine, ketorolac and morphine sulphate (periarticular injection group).
2949966|NCT02904980|Experimental|Technical Training Group|15 children diagnosed with DCD
2949967|NCT02904980|Experimental|Quiet Eye Training Group|15 children diagnosed with DCD
2949968|NCT02904967|Experimental|patients with recurrent VTE|
2949969|NCT02904967|Active Comparator|patients with only one episode of VTE|
2950003|NCT02904655|No Intervention|control diet|Participants were instructed to consume their usual diet.
2949971|NCT02904954|Experimental|Arm 2 (Durvalumab plus SBRT)|Durvalumab (MEDI4736) via IV infusion administered pre-operatively every 3 weeks for 2 cycles plus radiotherapy delivered in 3 daily fractions starting concurrently with the first cycle of durvalumab (MEDI4736) followed by surgical resection. Durvalumab monotherapy will be given for 12 months post-operatively.
2949972|NCT02904941|Experimental|Amniotic Membrane Dressing|Children allocated to this arm will receive skin dressings made out of human amniotic membrane. Dressings will be replaced every 72 - 96 hours.
2949973|NCT02904941|Active Comparator|Synthetic Dressing|Children allocated to this arm will receive skin dressings made out of silicone as part of their wound care. Dressings will be replaced every 72 - 96 hours.
2949974|NCT02904915|Active Comparator|Paracervical block|Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
2949975|NCT02904915|Active Comparator|No analgesia|IUD placement with no analgesia.
2949976|NCT02904902|Experimental|Patients receiving adalimumab|Subcutaneous injection of dose A at Week 0 (Baseline) and dose B at Week 2 followed by weekly dosing of dose C from Week 4
2949977|NCT02904889|Experimental|Stay Active at Home|One group of homecare professionals receives a training programme. In this training they learn to motivate their clients to be more active in daily and physical activities.
2949978|NCT02904889|Active Comparator|Usual care|Second group of homecare professionals will get no training and their clients will receive usual homecare.
2949979|NCT02904876|Experimental|Magnetic Resonance Imaging at 6 months|2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
2949980|NCT02904863|Experimental|patients with HUS|
2949981|NCT02904850||group of patients|Plasma dosage of erlotinib and OSI-420
2949982|NCT02904837|Experimental|Experimental Group (EG)|The Experimental training (ET) consists of 10 sessions with 4 blocks of MP (GMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
2949983|NCT02904837|Active Comparator|Control Group|The Control training (CT) consists of 10 sessions with 4 blocks of MP (nGMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
2949984|NCT02904824|Experimental|ADRC, adipose derived regenerative cells|Biological: Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
2949985|NCT02904824|Active Comparator|CAF, centrifuged autologous fat|Biological: Autologous fat tissue processed by centrifugation. Route of administration: Injection inside a paralyzed vocal cord.
2949986|NCT02904811|Experimental|Intervention group|"Testing for Ct infection immediately~Participants will perform self-taken vaginal samples.~The positive results for Ct will be examined and treated and their partner will also be informed to do so."
2949987|NCT02904811|Experimental|Control group|Testing for Ct infection at the end of the study
2949988|NCT02904798|Experimental|Polypodium Leucotomos Extract (PLE)|"Patient will serve as their own control and will be exposed to 4 doses of visible light on one side of their back prior to receiving PLE.~PLE 240mg will be dispensed to patient after evaluation of Pre-PLE visible light doses are evaluated to be taken by the patient for a total of 28 day followed by exposure of the opposite side of the back with the same 4 doses of visible light as above"
2949989|NCT02904785|Experimental|Extracorporeal Shock Waves|Focused shock waves delivered by an electromagnetic generator with a focus of 5.0cm deep on the affected knee in three different positions. A total of 7000 pulses will be delivered on a weekly session for four weeks.
2949990|NCT02904785|Sham Comparator|Sham Extracorporeal Shock Waves|Sham focused shock waves delivered by an electromagnetic generator on the affected knee in three different positions. A total of 7000 pulses will be delivered on a weekly session for four weeks. A foam will be placed in the probe as to stop the energy to be transmitted to the patient's knee, so no focused shockwaves will be delivered.
2949991|NCT02904772|Other|alipogene tiparvovec with IS|Patients in the Immuno+ group will receive an immunosuppressant regimen to be initiated three days prior to alipogene tiparvovec administration. The regimen is to be continued for 12 weeks: Cyclosporins (3 mg/kg/day) and mycophenolate mofetil (2 x 1 g/day). Patients will receive IV bolus of 1mg/kg of methyl Prednisolone half an hour prior to IMP administration.
2949992|NCT02904772|Other|alipogene tiparvovec without IS|Patients in the Immuno- group will not receive an immunosuppressant regimen during 12 weeks. Patients will receive IV bolus of 1mg/kg of methyl Prednisolone half an hour prior to IMP administration.
2949993|NCT02904759|Experimental|Desmopressin 25 µg|Desmopressin ODT
2949994|NCT02904759|Experimental|Desmopressin 50 µg|Desmopressin ODT
2949995|NCT02904759|Placebo Comparator|Placebo|Placebo ODT
2949996|NCT02904746|Experimental|Intervention|Participants receiving the Make It! intervention
2949997|NCT02904746|No Intervention|Control|Care as usual
2949998|NCT02904733|Experimental|mHealth platform|Stable HIV-1 infected subjects will be followed-up using an mHealth platform. The platform will provide users with web based and mobile device applications which interface securely with relevant medical data and facilitate remote access to healthcare providers. The minimum length of follow-up will be 12 months and the maximum 35 months.
2949999|NCT02904707||Questionary EQ-5D|"The EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.~Finally, a pain assessment questionnaire by Numeric Evaluation Scale before and after the skin graft pellet, will be filled by a caregiver during an interview with each patient."
2950000|NCT02904668|Experimental|Experimental group|Patients allocated to the experimental group were included in a self-administered program combining self-myofascial release using foam rollers and roller balls and active upper limb neurodynamic exercises. It consisted of three sessions of 50-60 minutes per week for 4 consecutive weeks.
2950001|NCT02904668|No Intervention|Control group|Those patients allocated to the control group received a booklet with information regarding neck pain and explaining basic exercises for active mobilization and stretching with pictures and a short text.
2950002|NCT02904655|Active Comparator|healthy diet|Participants were provided all meals and snacks for four weeks. Menus were created to target a healthy diet high in unsaturated fats.
2950004|NCT02904642|No Intervention|Control|"All enrolled caregivers will receive a congratulatory text message at enrollment which indicates who is conducting the study and which also includes a general-health related saying, The greatest wealth is health. No additional text messages or travel subsidies will be sent to caregivers randomized to the control arm."
2950005|NCT02904642|Experimental|SMS reminder|At enrollment, participants will be told to expect 2 SMS reminders for measles vaccine; first, at 3 days before and second, on the day before the scheduled measles vaccine at 9 months of age. At most, enrolled caregivers will receive three text messages (two for the measles vaccine and one for welcoming mother to the study). Text messages will be sent in English, Kiswahili or Dholuo language, according to the mother's preference. These reminders will have information about the child's scheduled immunization date.
2950006|NCT02904642|Experimental|SMS reminder + Unconditional Incentive|Participants will receive SMS reminders as described in the SMS reminder arm. Additionally, participants will be sent a 150 Kenyan Shillings (KES) incentive to the mobile phone number they provided at enrollment. The incentive will be delivered three days before the child turns nine months (i.e. sent on the same day as the first SMS reminder). Caregivers will receive the mobile-money incentive unconditionally. The intent of the incentive is to help offset the costs associated with transportation to the clinic. The transaction costs associated with mobile-money transactions will be borne by the study such that mothers will receive the full 150 KES.
2950007|NCT02904629|Experimental|RCL Intervention|"Respecting the Circle of Life (RCL) includes peer-group & youth-parent components. The peer-group component has 8 educational lessons, each lasting 90-120 minutes, delivered to self-selected same-sex peer groups of 8-10 AI teens. RCL lessons are delivered once/day during an 8-day summer basketball camp. The youth-parent component is one educational lesson lasting 90-120 minutes delivered within 3 months after camp to a teen and parent together at home. Total RCL duration is 810-1,080 minutes over 3 months. All 8 days of the camp are study days, in which RCL youth will receive one lesson each day. The investigators will evaluate RCL's impact on key sexual and reproductive health risk factors at 3-, 9-, 12-, 24-, and 36-month post-intervention follow-up time points."
2950008|NCT02904629|Other|Control|"The control program includes peer-group & youth-parent components. The peer-group component has 8 educational lessons, each lasting 90-120 minutes, delivered to self-selected same-sex peer groups of 8-10 AI teens. Control lessons are delivered once/day during an 8-day summer basketball camp. The youth-parent component is one educational lesson lasting 90-120 minutes delivered within 3 months after camp to a teen and parent together at home. Total control duration is 810-1,080 minutes over 3 months. All 8 days of the camp are study days, in which control youth will receive one lesson each day. The investigators will evaluate the control program's impact on key sexual and reproductive health risk factors at 3-, 9-, 12-, 24-, and 36-month post-intervention follow-up time points."
2950009|NCT02904616|Experimental|Healthy volunteers|"Healthy volunteers wash their hands with a traditional soap. Every healthy volunteers pose with palm of hand three times on the device in order to measure basal level of fluorescence of the skin.~Healthy volunteers repeated three times this procedure in order to assess the reproducibility of the measurement."
2950010|NCT02904590||IBD patients|Incidental patients with IBD controlled (including Crohn's disease, Ulcerative colitis and unclassified colitis)
2950011|NCT02904577||Training and validation cohort|"One cohort: from this cohort 2/3 of patients will be randomly separated after registration in training sample, to develop a prognostic model, and 1/3 in test sample, to validate the prognostic score obtained from the prognostic model.~The training cohort aims to develop a prognostic model and a resulting score, on the basis of clinical, biochemical and blood count parameters, in patients with non-follicular indolent lymphomas.~Intervention: any treatment, watch and wait policy included~The validation cohort is aims to assess the prognostic score on a collected set of data in parallel but independently of the sample training.~Intervention: any treatment, watch and wait policy included"
2950012|NCT02904564|Experimental|MMP with 5-FU infusion|MMP with 5-FU infusion using tattoo device
2950013|NCT02904564|Placebo Comparator|MMP with saline infusion|MMP with saline infusion using tattoo device
2950014|NCT02904551|Experimental|Experimental|Free gingival grafts
2950015|NCT02904551|Active Comparator|Control|Oral prophylaxis
2950016|NCT02904538|Experimental|Perineural group|1cc (4mg) of dexamethasone will be administrated in perineural injection. 2.5cc of isotonic saline solution will be administrated in systemic injection.
2950017|NCT02904538|Experimental|systemic group|1cc of isotonic saline will be administrated in perineural injection. 2.5cc (10mg) of dexamethasone will be administrated in systemic injection.
2950018|NCT02904525|Experimental|7T MRI + high resolution spectroscopy|Next to routine imaging, patients undergo an additional 7 tesla MRI for high resolution spectroscopy
2950019|NCT02904512|Active Comparator|Continuous glucose Monitoring and Point of Care blood glucose|Hospitalized patients with Diabetes Mellitus type 2 (DM2) managed with Continuous glucose monitoring (CGM) and Point of Care (POC) Finger sticks blood glucose
2950020|NCT02904512|Placebo Comparator|Point of Care (POC) blood glucose|Hospitalized Diabetes Mellitus type 2 (DM2) patients managed with Point of Care (POC) blood glucose only
2950021|NCT02904499||VKA|First Initiators of VKA for non-valvular atrial fibrilation
2950022|NCT02904499||Dabigatran|First Initiators of Dabigatran for non-valvular atrial fibrilation
2950023|NCT02904486|Experimental|change behavior|Modified Health Belief Model Based Intervention and study health topic in classroom to change behavior for Reduce Body Mass Index for Age in Overweight Junior High School Students.
2950024|NCT02904486|Experimental|lifestyle behavior|study health topic in classroom to change behavior for Reduce Body Mass Index for Age in Overweight Junior High School Students.
2950025|NCT02904473|Experimental|GROWell|GROWell incorporates 4 elements: phone coaching, goal setting, self-monitoring of behavior and skills training. These interactions take place on a study subject's cell phone, through text messaging, and phone calls with a dietician coach. At study initiation, the subject takes a short survey, after which the intervention algorithm assigns up to 4 tailored behavior change goals from the GROWell library. Goals are tailored to the subject's needs as indicated by the initial survey. Subjects self-monitor adherence weekly via text, responding to prompts from the system regarding their level of success with a given goal. Via text they receive immediate tailored feedback regarding their current adherence and long-term progress.
2950494|NCT02901002||Control|Healthy controls match by age, gender, Body Mass Index Healthy volunteers with sensory testing in the two hand and neuropsychological evaluation
2950026|NCT02904473|No Intervention|Attention Support Control (ASC)|The ASC control arm of the study involves one coaching call at baseline, regarding prenatal diet. Weekly text or IVR messages will focus on pregnancy, labor, delivery, and early infancy education.
2950027|NCT02904473|No Intervention|Usual Care (USC)|The USC will receive no intervention. They will simply complete baseline and follow-up CASI and blood draw.
2950028|NCT02904434||Voriconazole|Children (2-17 years old) will receive oral voriconazole as prescribed by their physicians as standard of care for the duration of the study.
2950029|NCT02904421||Group 1|the placebo group
2950030|NCT02904421||Group 2|the low-dose treatment group with 600mg calcium + 400IU Vit-D3/day
2950031|NCT02904421||Group 3|the high-dose treatment group with 600mg calcium + 800IU Vit-D3/day
2950032|NCT02904408|Experimental|Experimental|experimental group (receiving psychotherapy and medical/surgical treatment)
2950033|NCT02904408|No Intervention|Control|control group (awaiting group) (receiving medical/surgical treatment)
2950034|NCT02904369|Experimental|F/TAF 200/10|Emtricitabine (FTC) + Tenofovir Alafenamide (TAF) (200/10 mg)
2950035|NCT02904369|Experimental|F/TAF 200/25|Emtricitabine (FTC) + Tenofovir Alafenamide (TAF) (200/25 mg)
2950036|NCT02904369|Active Comparator|F/TDF 200/300|Emtricitabine (FTC) + Tenofovir Disoproxil Fumarate (TDF) (200/300 mg)
2950037|NCT02904356|Experimental|Brainsway H-coil for rTMS|Brainsway H-coil for repetitive transcranial magnetic stimulation: High-frequency rTMS will be administered to the medial prefrontal cortex for 3 weeks.
2950038|NCT02904343|Experimental|Group of domestic hemodialysis machine|
2950039|NCT02904343|Active Comparator|Group of imported hemodialysis machine|
2950040|NCT02904330|Experimental|Single dose|The intervention is K1-70 intramuscular. This is a single, ascending, intramuscular dose, sequential group study.
2950041|NCT02904317||Misprostol vaginal insert for labour induction|69 patients matching the inclusion criteria and received MVI for labour induction
2950042|NCT02904317||Oral misoprostol for labour induction|69 patients matching the inclusion criteria and received OM for labour induction
2950043|NCT02904304|Experimental|Desloratadine+Phenylephrine+Ibuprofen|"It's a tablet manufactured by Aché S.A., composed of desloratadine 2,5mg, Phenylephrine hydrochloride 20mg and Ibuprofen 400mg.~Tablet will be dispensed in a cartridge containing 10 tablet to 75 participants."
2950044|NCT02904304|Placebo Comparator|Placebo|"It's a tablet manufactured by Aché S.A,. composed of placebo will be dispensed in a cartridge containing 10 tablet to 75 participants. The participants shall administer the placebo tablets to enable the double-blind study.~The use of placebo comparator is important in this type of pathology because with this design will be able to evaluate the response of the pure treatment, rapid relief of symptoms, or 03 hours after the first administration of study drug."
2950045|NCT02904278|Experimental|Teen Pocket PATH® Mobile Application|"Participants in this group will receive the mobile application for improving adherence to their post-transplant medications, along with standard post-transplant care, in accordance with the CTOTC-10 Cardiac Consortium Clinical Care Guidelines.~The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken. Additionally, the mobile app. will inform the investigators, by way of automated text messaging, of treatment adherence.~Duration of participation: up to 12 months post heart transplantation."
2950046|NCT02904278|Other|Control Group: Standard of Care|"Participants in the control group will receive standard post-transplant care, in accordance with the CTOTC-10 Cardiac Consortium Clinical Care Guidelines.~Duration of participation: up to 12 months post heart transplantation."
2950047|NCT02904265|Active Comparator|Diazepam|Diazepam 0.5 mg/kg (up to maximum 20 mg) by mouth nightly. Duration of therapy is 4 weeks.
2950048|NCT02904265|Experimental|Acetazolamide|Acetazolamide 8-10 mg/kg (up to a maximum dose of 375 mg) by mouth (PO)divided twice daily X 1 week, then increased to 11-16 mg/kg (up to a maximum dose of 750 mg) by mouth divided twice daily thereafter. Duration of therapy is 4-8 weeks.
2950049|NCT02904252||Study group|Population : The participants are thalassemia patients who regularly visit Hematology Clinic, Department of Medicine, Faculty of Medicine Siriraj Hospital Clinical data, Laboratory data (Blood samples) and Transient elastography data will be collected from all participants, as previously described.
2950050|NCT02904226|Experimental|Part A (JTX-2011)|Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion
2950051|NCT02904226|Experimental|Part B (JTX-2011 + nivolumab)|Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion
2950052|NCT02904226|Experimental|Part C (JTX-2011)|Phase 2 expansion of JTX-2011 by IV infusion
2950053|NCT02904226|Experimental|Part D (JTX-2011 + nivolumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion
2950054|NCT02904226|Experimental|Part E (JTX-2011 + ipilimumab)|Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion
2950055|NCT02904226|Experimental|Part F (JTX-2011 + ipilimumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion
2950056|NCT02904226|Experimental|Part G (JTX-2011 + pembrolizumab)|Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion
2950057|NCT02904226|Experimental|Part H (JTX-2011 + pembrolizumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion
2950058|NCT02904213|Experimental|Pentavalent vaccine|3 Dose, interval for each dose is 4 weeks. The first dose will be received at 8-10 weeks of age
2950059|NCT02904200|Experimental|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
2950060|NCT02904200|Active Comparator|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
2950061|NCT02904187|Other|Profound deaf patients|Profound deaf patients with bilateral cochlear implants: Cortical brain activation pattern obtained by PET and EEG
2950062|NCT02904187|Other|Healthy volunteers|Healthy volunteers: Cortical brain activation pattern obtained by PET and EEG
2950092|NCT02903914|Experimental|Monotherapy Dose Escalation Solid Tumors|Monotherapy Part 1a: INCB001158 administered orally in patients with advanced/metastatic solid tumors. Escalating doses will be explored to determine the recommended phase 2 dose (RP2D).
2950495|NCT02900989|Other|ASQ-Fr|Adolescents undergo the ASQ-Fr questionnaire composed of 5 items.
2950063|NCT02904174|Experimental|Healthy Living Programme|6 weeks program, with 45 minutes weekly session over 6 weeks.Week 1 & 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 & 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 & 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies.
2950064|NCT02904161||first stage|For the first stage, 60 healthy volunteers, 10 patients with stage 4 breast cancer and 10 patients with other types of cancer will be recruited.
2950065|NCT02904161||second stage|For the second stage, approximately 65 breast cancer patients will be recruited.
2950066|NCT02904148|Experimental|Shoulder mobilisation|The shoulder mobilisation is performed daily by a physiotherapist for 45 days.
2950067|NCT02904135||first stage|During the first stage, the patient's baseline blood sample will be mainly used for validating and troubleshooting our instrument with clinical samples.
2950068|NCT02904135||second stage|During the second stage, 40 patients will be followed for up to three years after their baseline blood draw to obtain data on their survival status. The CTC results and follow-up data obtained from these samples will help to analyze any correlation with the patient's clinical outcome and further validate the prognosis ability of MiCareo's CTC platform for mBC patients.
2950069|NCT02904109|Experimental|Verum/Placebo|This group will start with triflusal and after washout will receive placebo.
2950070|NCT02904109|Experimental|Placebo/Verum|This group will start with placebo and will receive triflusal after washout.
2950071|NCT02904096|Experimental|"Grade 4 Hands group"|"Grade 4 Hands group will be subjects with hand grading of grade 4 (very severe loss of fatty tissue, marked visibility of veins and tendons in the dorsal hand). Grade 4 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 4 Hands group can have up to three retreatments over an 18 month period."
2950072|NCT02904096|Experimental|"Grade 2 or 3 Hands group"|"Grade 2 or 3 Hands group will be subjects with hand grading of grade 2 or grade 3 (moderate to severe loss of fatty tissue, mild to moderate visibility of veins and tendons in the dorsal hand). Grade 2 or 3 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 2 or 3 Hands group can have up to three retreatments over an 18 month period."
2950073|NCT02904083|Experimental|specific training of professionals|patients from centers where professionals have received specific training
2950074|NCT02904083|Active Comparator|control training of professionals|patients from centers where professionals have received control training
2950075|NCT02904070|Experimental|Threat of premature delivery|"Perform detection test of Placental Alpha-Microglobulin-1, fetal Fibronectin and phosphorylated Insulin-like Growth Factor Binding Protein-1ph by vaginal swabbing;~Collection of clinical data, laboratory data and treatment of obstetric care in the delivery room during childbirth for all included subjects"
2950076|NCT02904057|Experimental|Treatment Group|The treatment group will receive Radiesse (+) injectable implant up to 3.0 cc per jawline.
2950077|NCT02904057|No Intervention|Control Group|The control group is not treated. They will undergo assessments such as photographs, jaw grading and jaw function tests.
2950078|NCT02904044||Injured/Case|Secondary school pupil injured during a physical activity lesson between 2012-2014 in south of Reunion Island
2950079|NCT02904044||Control|Same age and gender than case in the same classroom and during the same physical activity lesson
2950080|NCT02904031|Experimental|FOLFOX plus panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes;~Oxaliplatin 85 mg/sqm iv over 2 hours, day 1;~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1;~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance panitumumab at the same dose used at the last cycle of the induction treatment. Panitumumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
2950081|NCT02904031|Experimental|5FU/LV plus panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes;~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1;~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance panitumumab at the same dose used at the last cycle of the induction treatment. Panitumumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
2950082|NCT02904005|Other|Depressed patients|Depressed patients with a recent suicide attempt or without any personal history of suicide attempt
2950083|NCT02903992|Other|All patients recruited|All patients who are enrolled in study with at least one Fried criteria will have a Dual-energy X-ray absorptiometry (DXA) to measure lean muscle mass adjusted for body mass index. As part of the usual care in the Frailty Clinic patients will also have a clinical examination, a standard biological sample (requiring 15 ml of blood); an evaluation of the cognitive and functional performances, of their medico-economic situation and lifestyle.
2950084|NCT02903979|Experimental|HVGIC|Restorations with only HVGIC in deep caries lesion of primary teeth.
2950085|NCT02903979|Active Comparator|Indirect pulp capping|Indirect pulp capping with calcium hydroxide cement, restored with HVGIC:
2950086|NCT02903966|Experimental|GSK2982772 in Part A double-blind phase|Subjects will receive GSK2982772 60 mg orally three times daily (approximately 8 hours apart) for 42 days (6 weeks).
2950087|NCT02903966|Placebo Comparator|Placebo in Part A double-blind phase|Subjects will receive placebo orally three times daily (approximately 8 hours apart) for 42 days (6 weeks).
2950088|NCT02903966|Experimental|GSK2982772 in Part B open label extension phase|Subjects from GSK2982772 and placebo arm who complete Part A study will move to Part B open-label extension phase. All subjects will receive GSK2982772 60 mg three times daily (approximately 8 hours apart) for 42 days (6 weeks).
2950089|NCT02903940|Experimental|CRT+NAVH|Surface ECG recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy and Negative Atrioventricular Hysteresis settings.
2950090|NCT02903927|Experimental|CT LUCIA|
2950091|NCT02903927|Active Comparator|Acrysof IQ Sn60WF|
2950093|NCT02903914|Experimental|INCB001158 as Monotherapy in NSCLC|Monotherapy Part 2a: INCB001158 administered orally at the RP2D in patients with advanced/metastatic NSCLC (EGFR and Anaplastic Lymphoma Kinase (ALK) negative) previously treated with Standard of Care (SOC).
2950094|NCT02903914|Experimental|INCB001158 as Monotherapy in CRC|Monotherapy Part 2b: INCB001158 administered orally at the RP2D in patients with advanced/metastatic CRC previously treated with SOC.
2950095|NCT02903914|Experimental|INCB001158 as Monotherapy in Solid Tumors|Monotherapy Part 2c: INCB001158 administered orally at the RP2D in patients with Bladder Cancer, Gastric or Gastroesophageal Junction (GEJ) Cancer, Renal Cell Cancer (RCC), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Urothelial Cell Cancer (UCC), or Melanoma, previously treated with SOC.
2950096|NCT02903914|Experimental|INCB001158 and anti-PD-1 in Combination Dose Escalation|Combination Part 1b: INCB001158 and Pembrolizumab administered in patients with advanced/metastatic NSCLC, Melanoma, Urothelial Cell Cancer, MSI CRC, MSS CRC, Gastric or Gastroesophageal Junction (GEJ) Cancer, SCCHN and Mesothelioma. Multiple dose levels will be explored to determine the recommended phase 2 dose (RP2D).
2950097|NCT02903914|Experimental|INCB001158 and anti-PD-1 in NSCLC|Part 3a: INCB001158 and Pembrolizumab the combination RP2D in patients with advanced/metastatic NSCLC (EGFR and ALK negative) with disease progression on anti-PD-1 therapy or prolonged stable disease on Pembrolizumab in the immediate prior line of therapy.
2950098|NCT02903914|Experimental|INCB001158 and anti-PD-1 in Melanoma|Part 3b: INCB001158 and Pembrolizumab at the combination RP2D administered in patients with advanced/metastatic Melanoma with disease progression on anti-PD-1 therapy or prolonged stable disease on Pembrolizumab in the immediate prior line of therapy.
2950099|NCT02903914|Experimental|INCB001158 and anti-PD-1 in Urothelial Carcinoma|Part 3c: INCB001158 and Pembrolizumab at the combination RP2D administered in patients with advanced/metastatic Urothelial Carcinoma with disease progression on anti-PD-1 therapy or prolonged stable disease on Pembrolizumab in the immediate prior line of therapy.
2950100|NCT02903914|Experimental|INCB001158 and anti-PD-1 in MSI CRC|Part 3d: INCB001158 and Pembrolizumab at the combination RP2D administered in patients with advanced/metastatic MSI CRC with disease progression on anti-PD-1 therapy or prolonged stable disease on Pembrolizumab in the immediate prior line of therapy.
2950101|NCT02903914|Experimental|INCB001158 and anti-PD-1 in MSS CRC|Part 3e: INCB001158 and Pembrolizumab at the combination RP2D administered in patients with advanced/metastatic MSS CRC that have received at least 1 prior 5-FU containing therapy and must not have had any prior checkpoint inhibitor therapy.
2950102|NCT02903914|Experimental|INCB001158 and anti-PD-1 in Gastric/GE Junction|Part 3f: INCB001158 and Pembrolizumab at the combination RP2D administered in patients with advanced/metastatic Gastric/GE Junction that have never received prior checkpoint inhibitor therapy.
2950103|NCT02903914|Experimental|INCB001158 and anti-PD-1 in SCCHN|Part 3g: INCB001158 and Pembrolizumab at the combination RP2D administered in patients with advanced/metastatic SCCHN that have never received prior checkpoint inhibitor therapy.
2950104|NCT02903914|Experimental|INCB001158 and anti-PD-1 in Mesothelioma|Part 3h: INCB001158 and Pembrolizumab at the combination RP2D administered in patients with advanced/metastatic mesothelioma that have received or were unable to receive standard front line standard therapy and have never received prior checkpoint inhibitor therapy.
2950105|NCT02903901|Placebo Comparator|Placebo|Individuals who are randomized to the control arm will receive liquid placebo sublingually 60-90 minutes prior to surgery.
2950106|NCT02903901|Active Comparator|Melatonin|Individuals who are randomized to the treatment arm will receive 10 mg liquid IR-SL melatonin 60-90 minutes prior to surgery
2950107|NCT02903888||BAY86-5028|Women aged 18 to 29 years that use Jaydess for contraception
2950108|NCT02903875||laryngectomised patients since 1 month|laryngectomised patients since 1 month and their close relative
2950109|NCT02903875||laryngectomised patients since 3 months|laryngectomised patients since 3 months and their close relative
2950110|NCT02903875||laryngectomised patients since 6 months|laryngectomised patients since 6 months and their close relative
2950111|NCT02903875||laryngectomised patients since 12 months|laryngectomised patients since 12 months and their close relative
2950112|NCT02903862|Experimental|Intervention Arm|Participants will receive the intervention, Mindoula plus DANA, which involves working with a case manager via an app for 12 weeks. The case manager will help the participant cope with the stresses of caregiving as well as remind them to use the DANA cognitive assessment app. This arm will also take the study's psychological surveys.
2950113|NCT02903862|Other|Waitlist Control Arm|These participants will take psychological surveys and a usability questionnaire for the first 12 weeks of participation, then, for the 12 weeks following, take the psychological surveys along with DANA and a usability questionnaire.
2950114|NCT02903849|Experimental|Control|On the 20th, 50th, and 90th day of the Challenge, Wellness Connection will email employees who participate in this survey. Employees will receive standard reminders generated by Wellness Connection.
2950115|NCT02903849|Experimental|Treatment|On the 20th, 50th, and 90th day of the Challenge, Wellness Connection will email employees who participate in this survey. Employees will see the motivating messages they wrote at the beginning of the Challenge, in addition to Wellness Connection's standard reminders.
2950116|NCT02903836|Experimental|Nafithromycin 800 mg 3 days|PO q24h for 3 days; subjects will receive matching placebo , to maintain the blind
2950117|NCT02903836|Experimental|Nafithromycin 800 mg 5 days|PO q24h for 5 days; subjects will receive matching placebo, to maintain the blind
2950118|NCT02903836|Active Comparator|Moxifloxacin 400 mg|PO q24h for 7 days;subjects will also receive two nafithromycin placebo tablets PO q24h on Days 1 through Day 7 to maintain the blind
2950119|NCT02903823|Experimental|Baclofen injection at designated spinal level|Days 2,3,4,5 a baclofen injection bolus will be given in the catheter, located at C4, T4, T10 and L2 respectively. Effect of baclofen injection (50 microgram bolus) upon rigidity will be assessed manually using the Modified Ashworth rating score for selected upper and lower extremities.
2950120|NCT02903810|Experimental|Mixed CAR-T Transfer|All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number
2950121|NCT02903797||Endometrial Hyperplasia|The first group was formed of the patients diagnosed endometrial hyperplasia histopathologically
2950122|NCT02903797||Control group|The control group was formed of the patients who were healthy women admitted to the clinic just for annual examination without any complain and symptoms
2950125|NCT02903771|Experimental|Part A and Part B|"Part A (Dose Escalation):~Part A is a Dose Escalation study to determine the Maximum Tolerated Dose of Cantrixil as a monotherapy.~The tolerance of Cantrixil in combination with standard chemotherapy agents will also be examined.~Part B (Expansion Cohort):~An expansion cohort of an additional 12 patients will be recruited at the MTD."
2950126|NCT02903719|Other|Group A|"st intervention: A single ultrasound guided perineural injection of Ropivacaine 7,5 mg/ml, 3 ml~nd intervention (approx. 15 minutes after 1st intervention): A single ultrasound guided perineural injection of isotonic saline solution 9 mg/ml, 3 ml"
2950127|NCT02903719|Other|Group B|"st Intervention: A single ultrasound guided perineural injection of isotonic saline solution 9 mg/ml, 3 ml~nd Intervention (approx. 15 minutes after 1st intervention):A single ultrasound guided perineural injection of Ropivacaine 7,5 mg/ml, 3 ml"
2950128|NCT02903680|Active Comparator|Dexamethasone group|Dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED.
2950129|NCT02903680|Placebo Comparator|Placebo group|The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.
2950130|NCT02903667|Experimental|bone grafting|The possibility of counteracting unfavourable ridge modelling after multiple tooth extractions by placing bone grafting material in the fresh extraction sites.
2950131|NCT02903667|Sham Comparator|natural healing|ridge modelling after multiple tooth extractions.
2950132|NCT02903641|No Intervention|Control|All households in the study were given general child nutrition educational messaging, immediately after the baseline survey and prior to any treatments. This messaging focused on appropriate feeding habits complemented by breastfeeding and ways to maintain proper hygiene during food preparation and consumption.
2950133|NCT02903641|Experimental|Personalized information only|Household received the personalized information about the index child's height.
2950134|NCT02903641|Experimental|Labeled cash transfer only|Household received the labeled cash transfer.
2950135|NCT02903641|Experimental|Personalized information and labeled cash transfer|The household received both the personalized information intervention and labeled cash transfer intervention.
2950136|NCT02903628|Experimental|eye health education|
2950137|NCT02903615|Experimental|Novel type 1 diet|Experimental diet to be examined: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
2950138|NCT02903615|Placebo Comparator|Standard therapy|Standard dietary therapy, as promulgated by Australian standards
2950139|NCT02903602|Experimental|CHW training method-Sharing Histories|"Experimental clusters of primary health care facilities provided training to Community Health Workers (CHW) from their communities utilizing the experimental teaching methodology, Sharing Histories.~CHW in both study groups made home visits to pregnant women and mothers of children under two years of age to teach mothers, monitor behaviors and danger signs in pregnant women, newborns, and children, and refer cases when needed for preventive and curative care."
2950140|NCT02903602|Active Comparator|CHW training method-Standard|"Control clusters of primary health care facilities provided training to Community Health Workers (CHW) from their communities utilizing a standard CHW teaching methodology.~CHW in both study groups made home visits to pregnant women and mothers of children under two years of age to teach mothers, monitor behaviors and danger signs in pregnant women, newborns, and children, and refer cases when needed for preventive and curative care."
2950141|NCT02903576|Active Comparator|injection of hESC-RPE in suspension|6 patients will receive cell suspension injections on the sub retinal space prior to the surgeries, to access safety
2950142|NCT02903576|Active Comparator|injection hESC-RPE seeded in a substrate|15 patients will receive a sub-retinal implantation of a polymeric scaffold seeded hesc- RPE in monolayer
2950143|NCT02903537|Experimental|5 * 10 ^6 tolDC-VitD3|5 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)
2950144|NCT02903537|Experimental|10 * 10 ^6 tolDC-VitD3|10 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3).
2950145|NCT02903537|Experimental|15 * 10 ^6 tolDC-VitD3|15 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3).
2950146|NCT02903537|Experimental|Interferon-beta|Additional group (patients treated with beta-interferon) will receive the selected dose of those 3 previously cohorts studied
2950147|NCT02903524|Active Comparator|control group|Pirarubicin combination with cyclophosphamide,4 cycles (each cycle is 21days) of chemotherapy
2950148|NCT02903524|Experimental|Experimental group|Doxorubicin Hydrochloride Liposome Injection combination with cyclophosphamide, 4 cycles (each cycle is 21 days) of chemotherapy
2950149|NCT02903511|Experimental|Metformin|Participants will receive metformin 500 mg tablets, starting with 1 tab twice a day. The dose will be increased by 500 mg every 2 weeks up to 1000 mg by mouth twice a day, as tolerated, for 12 months.
2950150|NCT02903511|Placebo Comparator|Placebo|Participants will receive placebo 500 mg tablets, starting with 1 tab twice a day. The dose will be increased by 500 mg every 2 weeks up to 1000 mg by mouth twice a day, as tolerated, for 12 months.
2950151|NCT02903498|Experimental|UFT treatment|Uracil and Tegafur
2950152|NCT02903498|No Intervention|comparator|no treatment, follow-up at regular time
2950153|NCT02903485|Experimental|nurses (intervention arm)|for patients without risk factors, the anesthetic team is not involved in patients' care
2950154|NCT02903485|Active Comparator|anesthetic team (control arm)|the anesthetic team is involved in every patient's care (with or without risk factors)
2950155|NCT02903472||Acute to first year after SCI|Individuals sustained SCI within a 1-year period
2950156|NCT02903472||Chronic|Individuals sustained SCI more than1 year ago
2950157|NCT02903459||Males|Evaluation of body mass index, determination of waist-to-hip ration and waist-to-height ration, using perimetry; evaluation of 7 skinfold according to the model 7-site-skinfold Equation, by Jackson and Pollock, and photogrammetry (to evaluate the lumbar lordosis degree) in males aged between 18 and 26.
2950158|NCT02903459||Young Adults|Evaluation of abdominal thickness, percentage of abdominal fat and photogrammetry (to evaluate the lumbar lordosis degree) in young adults females aged between 18-26.
2950159|NCT02903459||Adults|Evaluation of abdominal thickness, percentage of abdominal fat and photogrammetry (to evaluate the lumbar lordosis degree) in adult females aged between 40-60.
2951575|NCT02893176|Active Comparator|Active|10mg macitentan will be administered one time daily
2950160|NCT02903459||Females|Evaluation of body mass index, determination of waist-to-hip ration and waist-to-height ration using perimetry, evaluation of 7 skinfold according to the model 7-site-skinfold Equation, by Jackson and Pollock, and photogrammetry (to evaluate the lumbar lordosis degree) in females aged between 18 and 26.
2950161|NCT02903446|Active Comparator|Intervention|Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care
2950162|NCT02903446|No Intervention|Control|Standard urate lowering therapy
2950163|NCT02903433|Experimental|High Intake Group|"Throughout the entire study, this group will be provided with 14 avocados per week and will receive 12 bi-weekly home visits over a 6-month period during which they will receive specific brochures offering diet tips. This group will be given specific advice on avocado consumption. Each month throughout the study, we will provide opportunities for families to visit the study kitchen at the SYHC to observe the staff preparing recipes with avocado, participate in preparing recipes, and taste recipes."
2950164|NCT02903433|Active Comparator|Low Intake Group|"This group will receive 3 avocados per week, as well as 12 bi-weekly home visits over a 6-month period during which they will be provided with the same educational materials (i.e., Diet Tips) as those assigned to the High intake group. Participants in this group will be encouraged to improve the quality of their diets, but will not be given specific advice on avocado consumption. However, each month throughout the study, we will provide opportunities for families to visit the study kitchen at the SYHC to observe the staff preparing recipes with avocado, participate in preparing recipes, and taste recipes."
2950165|NCT02903420|Experimental|SAPIEN 3|Transcatheter Aortic Valve Implantation (TAVI) with the Edwards SAPIEN 3 Transcatheter Heart Valve and Delivery System
2950166|NCT02903407|Active Comparator|Midazolam|IV midazolam will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
2950167|NCT02903407|Active Comparator|Propofol or Dexmedetomidine|Propofol or Dexmedetomidine per physician discretion will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
2950168|NCT02903394|Experimental|mLCI imaging|mLCI device images cervical epithelium
2950169|NCT02903381|Experimental|Nivolumab, Lenalidomide, Dexamethasone|"A treatment cycle is defined as 28 consecutive days.~Participants will receive 6 cycles of induction therapy followed by 6 cycles of maintenance therapy with lower doses of lenalidomide and no dexamethasone for a total of 12 months."
2950170|NCT02903368|Experimental|Apalutamide & Abiraterone Acetate|"Eligible Participants will be randomized to receive;~Abiraterone acetate, Apalutamide, Leuprolide, Prednisone (6 months)~Radical Prostatectomy (RP)"
2950171|NCT02903368|Experimental|Abiraterone Acetate|"Eligible Participants will be randomized to receive;~Abiraterone acetate, Leuprolide, Prednisone (6 months)~RP"
2950172|NCT02903368|Other|Observation-Post RP|"Following RP, patient will be randomized~Patients will be followed and observed by the physician.~no treatment and observation only (current standard of care)"
2950173|NCT02903368|Experimental|Apalutamide & Abiraterone Acetate-Post RP|"Following RP, patient will be randomized~- 12 months of abiraterone acetate, Apalutamide, leuprolide and prednisone"
2950174|NCT02903355|Placebo Comparator|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
2950175|NCT02903355|Experimental|D-methionine, oral liquid suspension|D-methionine liquid suspension also contains sorbitol, orange flavor and purified water Intervention: Drug: D-methionine, oral liquid suspension.
2950176|NCT02903342|Experimental|Intervention|Parents will be asked to read a leaflet. They will then complete a survey and re-complete the survey via telephone two weeks later.
2950177|NCT02903342|No Intervention|Control|Parents will be asked to complete a survey and re-complete the survey via telephone two weeks later.
2950178|NCT02903329|Active Comparator|Protocol A|In program A, patients underwent detoxification without any acute medication during a two months period (complete stop of acute medication intake).
2950179|NCT02903329|Active Comparator|Protocol B|In program B, patients were allowed to take up to 2 days a week with analgesics or migraine medication during the two months detoxification period (restricted acute medication intake).
2950180|NCT02903316||Fluid Therapy|Systematisation of fluids during CABG surgery
2950181|NCT02903303|Other|Treatment|There will be only one arm for this pilot study. All participants will follow 4 hypnosis sessions, and then the facet block.
2950182|NCT02903290|Other|cerebellar ataxia|Evaluation ataxia according SARAs; measuring the quality of life through SF36 Questionnaire; quantifying the severity of fatigue perceived by FSS questionnaire quantifying the severity of physical tiredness by VAS before and after physical activity; quantified analysis of walking on walking track GAITRite® (with score calculation FAP and GVI) before and after physical activity; physical activity like walking on a treadmill (with measurement of maximal voluntary quadriceps by manual dynamometer before and after physical activity to ensure the induction of fatigue). Patients will be provided with a portable device for analyzing gas exchange FitMateMED® (COSMED, Rome, Italy) during walking analyzes GAITRite®
2950183|NCT02903264||GDM group|Gestational diabetes mellitus patients under treatment of an endocrinologist
2950184|NCT02903264||Control|Healthy non-pregnant females
2950185|NCT02903251|Experimental|oxytocin|"intranasal oxytocin spray Day 1-3: Twice daily intranasal oxytocin spray administered by health personnel.~Day 3-30: Self-administered intranasal spray as needed, max thrice daily intranasal spray without oxytocin"
2950186|NCT02903251|Placebo Comparator|Placebo|"intranasal spray without oxytocin Day 1-3: Twice daily intranasal spray without oxytocin, administered by health personnel.~Day 3-30: Self-administered intranasal spray as needed, max thrice daily"
2950187|NCT02903238|Experimental|Placebo|placebo capsule
2950188|NCT02903225|No Intervention|Usual Care|usual care and no changes in their previous physical activity
2950189|NCT02903225|Active Comparator|Cardiac Rehabilitation|Exercise Training program on a 3-days/week basis during 24 weeks (68-74 sessions). Each session started with a 10-min warm-up walking period followed by 20-min of breathing exercises and free non-resistance movements of limbs. This stage was followed by pedaling during 20-minutes at a circuit resistance training protocol using a stationary cycle-ergometer. Each session ended with a cool down period (5-minutes) including diverse stretching maneuvers of engaged muscle groups. The initial bicycle-ergometer workload (WL) was defined as 50% of the maximum achieved in the previous stress testing
2950190|NCT02903212|Experimental|Rheumatoid arthritis|Patients with rheumatoid arthritis. An injection of autologous apoptotic cells is performed on the D0.
2950191|NCT02903199|Experimental|Whey Protein|Whey protein (18g) experimental supplement
2950192|NCT02903199|Experimental|Hydrolysed Protein|Hydrolysed whey protein (19.1g) experimental supplement
2950193|NCT02903199|Placebo Comparator|Placebo|Water placebo supplement
2950194|NCT02903186|Experimental|Nutrition messages|The intervention will focus on reinforcing the WIC breastfeeding messages, preventing overfeeding (i.e. using spoon to feed baby, not adding baby food or cereal to bottle, not placing their babies to sleep with a bottle, feeding their babies without distractions, etc), delaying introduction of solid foods, and delaying and reducing baby juice consumption. Constructs in the transtheoretical model such as self-efficacy and decisional balance will be used to address key determinants of behavior change to ensure relevance to the audience, and will target individuals both at the earlier and later stages of change. The messages are written at a grade 5 level in Spanish (PR site) and English (Hawaii site) and will be sent on different days and times of the week.
2950195|NCT02903186|Active Comparator|General health messages|The control group will receive weekly SMS about general infant's health issues, such as placing the infant on his/her back to sleep, the timeline for immunizations, the proper use of car seats, asthma and other respiratory conditions common among small children, and other health information relevant to infants. The investigators will follow the same protocol (schedule, length, language, etc.) as for the intervention messages.
2950196|NCT02903173||Women who undergo cesarean delivery|
2950197|NCT02903160|Experimental|Intensive, Non-Cross Reactive Therapy|Prostate Cancer Rapidly cycling, Intensive, Non-Cross Reactive Therapy (PRINT) Rapidly cycling, consecutive treatment modules: 1. Abiraterone acetate + Radium-223; 2. Cabazitaxel + Carboplatin; 3. Enzalutamide + Radium-223
2950198|NCT02903147|Experimental|Functional Meta-Cognitive Intervention|The intervention is aimed to improve human factors of professional bus drivers
2950199|NCT02903147|Active Comparator|Control group|The control group had the employer's training - The company holds routine covert inspections, summons to conversations with the security offices and records in the drivers' personal files.
2950200|NCT02903134||Newborn from obese and nonobese pregnant|Obese (BMI>30) or normal weight (BMI<25) women at their first antenatal visit were invited to participate in the study at the moment of delivery at Sotero del Rio Hospital, Santiago. Information regarding birth outcomes, parental history, as well as environmental conditions was collected at recruitment. Follow-up questionnaires by phone were completed every 6 months. Umbilical cord blood samples were collected to measure IL-12, TNF-α, IL-10, IL-4; to evaluate metabolic status; to isolated monocytes and macrophage differentiation; and for DNA methylation status of the promoter regions of the genes coding for TNF-α, IL-12, IL-10, and IL-4Rα. Also, fasting blood samples of the mothers within 48 hours after delivery; and blood samples and skin prick test were collected.
2950201|NCT02903121|Experimental|Tamoxifen|Tamoxifen 10 mg (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
2950202|NCT02903121|Placebo Comparator|Placebo|Placebo (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
2950203|NCT02903108|Active Comparator|Boric acid group|Oral prophylaxis followed by 0.75% boric acid drug in gel form placed in intrabony defects
2950204|NCT02903108|Placebo Comparator|Placebo group|Oral prophylaxis followed by placebo gel placement in intrabony defects
2950205|NCT02903095|Experimental|TD-1439|Capsule formulation
2950206|NCT02903095|Placebo Comparator|Placebo|Capsule formulation
2950207|NCT02903082||Case|Patient hospitalized in intensive care for sepsis evolving for less than 48 hours with two criteria of systemic inflammatory response syndrome
2950208|NCT02903082||Control|10 Patients hospitalized for a hematologic pathology workup considered normal by two haematologists and 10 patients hospitalized for a preoperative workup.
2950209|NCT02903069|Experimental|Stage 1: Concomitant Treatment|"MRZ + TMZ + RT~Patients who complete Concomitant Treatment may continue on to Adjuvant Treatment."
2950210|NCT02903069|Experimental|Stage 1: Adjuvant Treatment|MRZ + TMZ
2950211|NCT02903069|Experimental|Stage 2: Dose-Expansion|"MRZ + TMZ + RT followed by MRZ + TMZ~In Stage 2 (dose-expansion): a minimum of 12 and up to approximately 18 additional evaluable patients will be enrolled in a cohort in which Concomitant Treatment (MRZ + TMZ + RT) is followed by Adjuvant Treatment (MRZ + TMZ) to confirm the MTD for each treatment regimen as determined in the Dose-Escalation (Stage 1), and to assess preliminary activity of the recommended Phase 2 dose (RP2D)."
2950212|NCT02903069|Experimental|Optune Arm|MRZ + TMZ + Optune
2950213|NCT02903056||Rett Syndrome|Rett Syndrome is a neurodevelopmental disease that primarily affects girls. Clinically, patients are normal before six months to one and half years old, and then develop progressive severe problems with communication, learning, co-ordination and neurodevelopment, with loss of motor skills around the age of two. At the same time, stereotyped hand movement typically appears.
2950214|NCT02903056||Control-normal|Healthy people
2950215|NCT02903043||COPD patients|Quadriceps biopsies will be done. No drug administration.
2950216|NCT02903043||Healthy controls|Quadriceps biopsies will be done. No drug administration.
2950217|NCT02903030|Experimental|Visbiome|The probiotic mix (VISBIOME) will be mainly Bifidobacteria and Lactobacilli, in view of the previously reported encouraging clinical studies and safety data.
2950218|NCT02903030|Placebo Comparator|Placebo|Placebo matched to probiotic.
2950219|NCT02903017|Active Comparator|Tranexamic acid 5%|Tranexamic acid 5%, 2000 mg (40 mL) in 60 mL normal saline (0.9%) solution (total 100 mL)
2950220|NCT02903017|Placebo Comparator|Placebo|0.9% normal saline solution (total 100 mL)
2950221|NCT02903004|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 d1 q 21 in 3 hours (central line)
2951848|NCT02891083|Experimental|Adjuvant radiotherapy group|Surgery followed by 50Gy adjuvant radiotherapy
2950222|NCT02903004|Other|Standard Treatment|Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Topotecan 4 mg/ m2 dd 1,8,15 q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28 Carboplatin AUC 5-6 q 21 or 28
2950223|NCT02902978|Experimental|Cohort 1 to 7|Participants will receive a single dose of E6130 or placebo, administered in a dose-ascending manner under the fasted condition.
2950224|NCT02902978|Experimental|Cohort 8|Participants will receive a single dose of E6130 (determined in Cohort 1 to 7), administered in the specified order (fed/fasted or fasted/fed) to evaluate the food effect.
2950225|NCT02902965|Experimental|Ibrutinib+ Bortezomib+ Dexamethasone|
2950226|NCT02902952|Experimental|Physical Exercise Condition|An eight week physical exercise intervention
2950227|NCT02902952|Active Comparator|Control Condition|An eight week control condition consisting of sedentary activities
2950228|NCT02902939|No Intervention|Uncomplicated cardiac surgery patients|Patients after scheduled cardiac surgery procedures
2950229|NCT02902939|Active Comparator|Complicated cardiac surgery patients|MECC systems Cytokines modulation by CytoSorb and PMMA membranes
2950230|NCT02902926|Experimental|Low FODMAPs Diet|"Instructed to low FODMAPs diet when patients signed the informed consent.~Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food."
2950231|NCT02902926|Placebo Comparator|Diet Instruction|1.Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food.
2950232|NCT02902913|Experimental|Oleocanthal-rich, D2i2|Extra virgin olive oil containing oleocanthal to oleacein in a 2:1 ratio.
2950233|NCT02902913|Experimental|Oleacein-rich, D2i0.5|Extra virgin olive oil containing oleocanthal to oleacein in a 1:2 ratio.
2950234|NCT02902913|Placebo Comparator|Oleocanthal and Oleacein-low, D2i0|Extra virgin olive oil containing low amounts of oleocanthal to oleacein, but with a similar total phenolic content as the other two oils
2950235|NCT02902913|Active Comparator|Ibuprofen, 400 mg|Positive control
2950236|NCT02902900||Imnovid|Patients relapse/ refractory multiple myeloma who initiated pomalidomide in routine clinical practice
2950237|NCT02902887|Experimental|Monitored CIAO therapy|Participants wear 3-hour CIAO therapy
2950238|NCT02902887|No Intervention|Observation|No intervention, just observation
2950239|NCT02902874|Experimental|Patients treated for anaplastic large cell lymphoma ( ALCL )|
2950240|NCT02902861|Active Comparator|methotrexate|Once weekly (every 7 days) s.c. administration of 17.5 mg MTX. If PASI50 is not reached after 8 weeks (week 8) or PASI75 is not reached after 24 weeks, the dosing will be increased to 22.5 mg MTX/week. If patients were already dosed with 22.5 mg MTX/week in week 24 and PASI50 is not reached, patients will be excluded from treatment. Primary endpoint after 16 weeks.
2950241|NCT02902861|Placebo Comparator|Placebo (NaCl-Solution)|Once weekly (every 7 days) s.c. administration of 0.35 mL placebo If PASI50 is not reached after 8 weeks (week 8), the dosing will be increased to 0.45 mL placebo/week. Primary endpoint after 16 weeks. After 16 weeks patients will receive 17.5 mg MTX / week. If PASI50 is not reached after 8 weeks of MTX treatment (week 24), uptitration to 22.5 mg MTX/ 0.45 mL Plac / week will be done. Patients, who will reach PASI75 under placebo treatment after 16 weeks, will be dosed neither with placebo nor with MTX until relapse. After relapse the patients will be dosed with a starting dose of 17.5 mg MTX / week.
2950242|NCT02902835|Active Comparator|Referral to treatment (Control)|The control group will receive a referral to buprenorphine treatment by the research staff.
2950243|NCT02902835|Experimental|BUP-FAST Intervention|Thirty-six participants will each be paired with a trained peer mentor who will provide the BUP-FAST intervention.
2950244|NCT02902822|Active Comparator|Screening|This arm includes all subjects randomized to regular dermatological follow-up visits on annual basis.
2950245|NCT02902822|Experimental|Tele-dermatology|This arm includes all subjects randomized to the use of a tele-dermatology system for the evaluation of newly onset non-widespread skin lesions.
2950246|NCT02902809|Experimental|Open-label study to evaluate safety|A fixed 300 mg dose every 2 weeks (Q2W) of tralokinumab administered subcutaneously in subjects with inadequately controlled asthma on medium to high-dose of inhaled corticosteroid plus long-acting β2-agonist.
2950247|NCT02902796|Active Comparator|Treatment group A|Group A will consist of sequence of treatment with 3 stimulation modes. They are, in order, 1000 hertz, standard, and burst stimulation. Each stimulation modes will last 3 weeks, with 4 days of wash off between them. Each group treatments will take about 3 months, and subject will cross over into the other treatment group. Burst stimulation sends packets of electrical pulses, composed of pulse and packet frequency. 1000 hertz stimulation delivers tonic, sub perception stimulation. The standard stimulation mode, which will serve as the control, will be below 100 hertz, and its pulse strength will be above threshold, where patients will feel the tingling from the electrical pulses generated by the spinal cord stimulator.
2950248|NCT02902796|Active Comparator|Treatment group B|Group B will consist of sequence of treatment with 3 stimulation modes. They are, in order, burst stimulation, standard, and 1000 hertz. Each stimulation modes will last 3 weeks, with 4 days of wash off between them. Each group treatments will take about 3 months, and subject will cross over into the other treatment group. Burst stimulation sends packets of electrical pulses, composed of pulse and packet frequency. 1000 hertz stimulation delivers tonic, sub perception stimulation. The standard stimulation mode, which will serve as the control, will be below 100 hertz, and its pulse strength will be above threshold, where patients will feel the tingling from the electrical pulses generated by the spinal cord stimulator.
2950249|NCT02902783||Consented deceased organ donors|Data will be collected on deceased donors, declared by neurological determination of death (DND) and by circulatory determination of death (DCD).
2950250|NCT02902770|Active Comparator|Lidocaine and normal saline push|1.5mg/kg IV Lidocaine Drip (given over 10 minutes) and normal saline push
2950251|NCT02902770|Active Comparator|Ketorolac and normal saline drip|IV Ketorolac Tromethamine 30mg push and 10 minute normal saline drip
2950252|NCT02902770|Active Comparator|Lidocaine and Ketorolac|IV Lidocaine Drip and IV Ketorolac Push
2950253|NCT02902757|Experimental|Treatment (FDG PET/CT)|Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.
2950254|NCT02902744|Experimental|ILUVIEN 0.19 MG|
2950255|NCT02902731|Placebo Comparator|placebo|PLACEBO + Usual use of tapering doses of oral prednisone
2950256|NCT02902731|Experimental|anakinra|"ANAKINRA : dose of anakinra is 100 mg/day by subcutaneous injection from day 1 until the end of week 16 (W16). The dose of Anakinra will be adapted to that recommand according to renal function.~Intervention Anakinra in add on Therapy."
2950257|NCT02902718|Experimental|mē device|The subjects will perform treatments with the mē device at the clinic under the supervision of the study personnel at the baseline visit, 1 week and 2 week visits, and 1 month and 2 month visits. In addition the subject will be expected to perform treatments at home according to the following schedule: daily treatments at home for 5 days a week during the first month, followed by 2 treatments a week during the 2nd month, and optionally 1 time a week during the 3rd month.
2950258|NCT02902705|Experimental|Chronic Kidney disease patients - stage V|Male adults non-diabetic and non-dialyzed CKD stage 5 patients. All the CKD patient will be recruited at the Department of Nephrology of Edouard Herriot University Hospital (Lyon, France).
2950259|NCT02902705|Other|Non Chronic Kidney Disease patients|Non CKD male adults matched for age, gender and body mass index (BMI) with CKD patients. All the non - CKD patient will recruited from Department of recruited at the Department of Urology of Edouard Herriot University Hospital (Lyon, France).
2950260|NCT02902692|Experimental|Brief Mindfulness|45 minute brief mindfulness intervention (lead by study investigator) on day 1 followed by 7 days of 30 minute mindfulness practice at home (without study investigator)
2950261|NCT02902679|Experimental|End Stage Renal Disease Subjects|Subjects given a single oral dose of BMS-986177 before (Period 1) and after (Period 2) a hemodialysis session
2950262|NCT02902666|Experimental|Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet|"A single dose of the experimental drug will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 1) or after (treatment arm 2) a wash-out interval of at least 7 days between the active comparator administration.~Test formulation will be administered as a single dose of one paracetamol 1000 mg/codeine 30 mg tablet."
2950263|NCT02902666|Active Comparator|paracetamol 500mg/codeine phosphate hemihydrate 30mg 2 tablets|A single dose of active comparator will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 2) or after (treatment arm 1) a wash-out interval of at least 7 days between the experimental drug administration. Reference formulation will be administered as a single dose of two 500 mg/30 mg tablets.
2950264|NCT02902653|Experimental|Oral misoprostol|"Administration of oral misoprostol according to a 3x1 diagram, that is,3 oral doses (1 per hour) and then 1 hour without treatment"
2950265|NCT02902653|Active Comparator|Vaginal misoprostol|vaginal misoprostol, 25 microgs every 4 hours
2950266|NCT02902653|Active Comparator|Vaginal dinoprostone|vaginal dinoprostone, 10 mg during 24 hours (maximum)
2950267|NCT02902640||Acute Bronchitis Participants|Participants with acute bronchitis for whom the treating physician has decided to initiate treatment with Balsamic Bactrim, will be observed. Administration of Balsamic Bactrim will be according to physician's recommendation under local labeling. The study protocol does not enforce any treatment.
2950268|NCT02902627|Experimental|Metastatic cancer|
2950269|NCT02902614|Experimental|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage: Blastomere collection from opposite side to the 2nd polar body or from vegetal pole.
2950270|NCT02902614|Experimental|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage: Blastomere collection from and side around the 2nd polar body and not the vegetal pole.
2950271|NCT02902601|Experimental|Group A: JNJ-54175446|Participants will receive a loading dose of JNJ-54175446, 600 milligram (mg) on Day 1 followed by JNJ-54175446, 150 mg once daily until Day 10.
2950272|NCT02902601|Experimental|Group B: Placebo + JNJ-54175446|Participants will receive placebo on Days 1 to 3 followed by a loading dose of JNJ-54175446, 600 mg on Day 4 followed by JNJ-54175446, 150 mg once daily until Day 10.
2950273|NCT02902601|Placebo Comparator|Group C: Placebo|Participants will receive placebo from Day 1 until Day 10.
2950274|NCT02902588|Experimental|ICG washout kinetics assessment|Intravenous administration of 5-10 mg indocyanine green (ICG-PULSION), once per subject
2950275|NCT02902588|Other|Pulse oximeter monitor|Monitoring of a person's oxygen saturation (SO2), peripheral oxygen saturation
2950276|NCT02902588|Experimental|Gadolinium washout kinetics assessment|20 mL of gadolinium (Gadovist, Bayer, Germany) injection at 5 mL/s, once per subject
2950277|NCT02902575|Experimental|Laparoscopic-assisted Gastrectomy|Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group
2950278|NCT02902562|Other|Study Visit|You will have a Contrast Enhanced Ultrasound (CEUS) and contrast Magnetic Resonance Imaging (MRI) which will take about 2 hours.
2950279|NCT02902536||Myasthenia Positive Antibodies|Patients with Acetyl choline receptor (AChR) or muscle-specific kinase (MuSK) Positive Myasthenia
2950280|NCT02902536||Myasthenia Double Negative|Patients without AChR or MuSK antibodies
2950281|NCT02902536||Normal Controls|Patients without myasthenia
2950282|NCT02902523|Active Comparator|Viread ® tablet 300mg|Tenofovir disoproxil fumarate
2950283|NCT02902523|Experimental|HUG116 tablet 245mg|Tenofovir disoproxil
2950284|NCT02902510|Experimental|Experimental|The experimental group is the group that received yoga. The individuals originally assigned to the WLC who completed the yoga intervention AFTER the 8 weeks WLC period also are considered part of the experimental group.
2950285|NCT02902510|No Intervention|Wait List Control|There was no intervention during the WLC.
2950286|NCT02902484|Experimental|Nintedanib Monotherapy|"One cycle of Nintedanib monotherapy followed by a total of eight cycles of both Nintedanib and the chemotherapeutic agents, or until disease progression, whichever comes first.~Nintedanib dose escalation: 150, 200 mg PO BID~Nab-paclitaxel: 125 mg/m2 day 1,8,15 every 28 days~Gemcitabine: 1000 mg /m2 day 1,8,15 every 28 days"
2950287|NCT02902471|Experimental|Group A|Patients with bronchiolitis obliterans syndrome after bone marrow transplantation
2950288|NCT02902458|Experimental|Psychological follow-up|Patients undergoing implantation of an ICD for primary prevention will have an individual interview with a qualified psychologist in addition to standard medical follow-up.
2950289|NCT02902458|No Intervention|Control|Patients undergoing implantation of an ICD for primary prevention will have standard medical follow-up.
2950496|NCT02900989|Other|SIQ-Fr|Adolescents undergo the SIQ-Fr questionnaire composed of 30 items if >=15 yo and the SIQ-Fr Junior composed of 15 items if <15 yo
2950290|NCT02902445||Case group|250 children from Nantes University Hospital and 150 children from Guyana Hospital admitted in paediatric emergency unit for diagnosed rotavirus acute gastroenteritis: rotavirus rapid screen test and oral swab for polymorphism exploration
2950291|NCT02902445||Control group|"250 children from Nantes University Hospital and 150 children from Guyana Hospital admitted in paediatric emergency unit without signs of infection and / or digestive clinical picture evocative of gastroenteritis.~Paired with a case upon ethnicity or origin if impossible to match the ethnicity of the case.~oral swab for polymorphism exploration"
2950292|NCT02902432|Placebo Comparator|SCCHN|patients with advanced squamous cell carcinoma of the head and neck.IMRT.
2950293|NCT02902432|Experimental|SCCHN-Endostar|patients with advanced squamous cell carcinoma of the head and neck.Endostar will be continuously intravenous pumped (7.5 mg/m2) for 14 days (d1-d14) during chemotherapy and for 5 days/week(d-5-d-1, d3-d7, d10-d14, d17-d21)during IMRT.
2950294|NCT02902419|Active Comparator|1|Wound dressing removal was performed between 12-30 hours postoperatively.
2950295|NCT02902419|Active Comparator|2|Wound dressing removal was performed between 30-48 hours postoperatively.
2950296|NCT02902406||normal oral mucosa|
2950297|NCT02902406||oral precancerous lesion or oral cancer|
2950298|NCT02902393||Success of revascularisation|
2950299|NCT02902380|Experimental|Dexmedetomidine Group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
2950300|NCT02902380|Placebo Comparator|Control Group|0.9% saline infusion
2950301|NCT02902367|Experimental|Intervention:|Outdoor walking and strength exercise, Three months, daily SMS.
2950302|NCT02902367|Other|Control group|Usual care; no restriction for exercise, Three months
2950303|NCT02902354|Other|Nifedipine for tocolysis|Only women receiving nifedipine (as standard of care) for tocolysis
2950304|NCT02902341|Active Comparator|Control|Standard protocol nutrition.
2950305|NCT02902341|Experimental|Nutrition Therapy|Resting energy expenditure was measured using indirect calorimetry or calculated. A dietician assessed daily caloric intake during the entire hospitalization. Caloric deficits were calculated. According to a predefined flow-chart protocol, nutritional interventions were launched on different time points. Interventions varied from nutritional modifications to oral supplementation, tube feeding, and parenteral nutrition.
2950306|NCT02902328||MRI data collection|A group of 30 subjects will be scanned on a 3 Tesla (T) and on a 7T MRI scanners. The images will be compared.
2950307|NCT02902315|Active Comparator|1ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
2950308|NCT02902315|Active Comparator|2ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
2950309|NCT02902315|Active Comparator|3ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
2950310|NCT02902315|Active Comparator|4ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
2950311|NCT02902302|Experimental|Ibuprofen 400 mg/10 mL oral suspension|Single dose of 1 ibuprofen 400 mg/10 mL stick administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
2950312|NCT02902302|Active Comparator|MOMENT 400 mg coated tablet|Single dose of 1 MOMENT 400 mg coated tablet administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
2950313|NCT02902289|Experimental|Ibuprofen 200 mg/5 mL oral suspension|Single dose of 1 ibuprofen 200 mg/5 mL stick administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
2950314|NCT02902289|Active Comparator|MOMENT 200 mg coated tablet|Single dose of 1 MOMENT 200 mg coated tablet administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
2950315|NCT02902250|Experimental|Decompression|bone marrow decompression at fractured vertebral body
2950316|NCT02902250|Active Comparator|vertebroplasty|vertebroplasty for compression fracture
2950317|NCT02902237|Experimental|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
2950318|NCT02902224|Placebo Comparator|PLACEBO|Single intragastric instillation of 300ml tap water via nasogastric tube
2950319|NCT02902224|Active Comparator|GLUCOSE|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
2950320|NCT02902224|Active Comparator|FRUCTOSE|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
2950321|NCT02902211|Experimental|Ankle foot orthosis|Patients will wear an off-the-shelf, carbon composite AFO that is adjusted for them for three months. The patients will be asked to wear the AFO at all times except when they are in bed or showering/bathing. The instructions given to the patients about walking will be to follow the instructions from their doctor regarding risk factor management and exercise.
2950322|NCT02902211|Active Comparator|Control|Patients will be asked to follow the instructions from their doctor regarding risk factor management and exercise for three months.
2950323|NCT02902198|Placebo Comparator|Placebo preoperative|Single intragastric instillation of 200ml tap water via nasogastric tube
2950324|NCT02902198|Placebo Comparator|Placebo postoperative|Single intragastric instillation of 200ml tap water via nasogastric tube
2950325|NCT02902198|Active Comparator|Glucose preoperative|Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube
2950326|NCT02902198|Active Comparator|Glucose postoperative|Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube
2950327|NCT02902198|Active Comparator|Monosodium glutamate preoperative|Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube
2950328|NCT02902198|Active Comparator|Monosodium glutamate postoperative|Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube
2950329|NCT02902198|Active Comparator|Quinine preoperative|Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube
2950330|NCT02902198|Active Comparator|Quinine postoperative|Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube
2950331|NCT02902185|Experimental|Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.
2950332|NCT02902185|Placebo Comparator|Placebo-controlled|Placebo with the same taste and appearance like Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.
2950333|NCT02902172|Other|Acetaminophen|Patients will be monitored for change in blood pressure
2950334|NCT02902172|Other|NSAID|Patients will be monitored during their postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
2950335|NCT02902159|Experimental|BWW|Free access to online peer support through BWW for 6 months
2950336|NCT02902159|Experimental|MZ|Access to NHS Moodzone Information Only
2950337|NCT02902146|Active Comparator|Bougie|On the first intubation attempt, this arm will attempt to place a bougie into the trachea, followed by an endotracheal tube.
2950338|NCT02902146|Active Comparator|No bougie (endotracheal tube first)|On the first intubation attempt, this arm will attempt to place an endotracheal tube into the trachea directly.
2950339|NCT02902133|Other|Acetazolamide|Acetazolamide 500 mg twice per day for 5 days
2950340|NCT02902120|Experimental|Pre-transplant|This arm will evaluate the treatment of patients with HCV and chronic kidney disease (GFR <50) who have not had a kidney transplant using grazoprevir and elbasvir.
2950341|NCT02902120|Experimental|Post-transplant|This arm will evaluate the treatment of patients with HCV and chronic kidney disease (GFR <50) who have had a kidney transplant using grazoprevir and elbasvir.
2950342|NCT02902107|Experimental|surgical resection and intraoperative radiation therapy (IORT)|Brachytherapy will be administered using the CivaSheet, a novel permanent LDR palladium-103 (Pd-103) planar brachytherapy device that is applied directly to the surgical resection bed.
2950343|NCT02902094|Experimental|Experimental|Drug eluting angioplasty balloons
2950344|NCT02902094|Active Comparator|Control|Non-drug eluting balloons
2950345|NCT02902081|Placebo Comparator|Placebo|Oral placebo administered once prior to subjective drug effects questionnaires and behavioral tasks.
2950346|NCT02902081|Experimental|300 mg Cannabidiol|300 mg cannabidiol administered once prior to subjective drug effects questionnaires and behavioral tasks.
2950347|NCT02902081|Experimental|600 mg Cannabidiol|600 mg cannabidiol administered once prior to subjective drug effects questionnaires and behavioral tasks.
2950348|NCT02902081|Experimental|900 mg Cannabidiol|900 mg cannabidiol administered once prior to subjective drug effects questionnaires and behavioral tasks.
2950349|NCT02902068||Parturients undergoing cesarean section|Healthy parturients, hypertensive parturients and parturients suffering from preeclampsia above 18 undergoing cesarean section deliveries .
2950350|NCT02902055|Active Comparator|Rocuronium 1 mg/kg i.v.|Neuromuscular blocking agent
2950351|NCT02902055|Active Comparator|Isotonic saline|
2950352|NCT02902042|Experimental|Arm A: Triple therapy|Encorafenib, binimetinib and pembrolizumab. Doses as determined in phase I
2950353|NCT02902042|Experimental|Arm B: Pembrolizumab alone|Pembrolizumab with a dose of 200 mg every 3 weeks.
2950354|NCT02902029|Experimental|Arm A|"After a 3 months run-in period with vemurafenib and cobimetinib [960 mg vemurafenib twice daily (BID), 28/0; 60 mg cobimetinib daily (QD), 21/7], all patients who do not show disease progression or definite treatment interruption (e.g. due to unacceptable toxicity) for more than 28 days will be randomized.~Further treatment with vemurafenib and cobimetinib (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7).~After progression of disease patients in Arm A will subsequently receive atezolizumab treatment (1200 mg/ q3w)."
2950497|NCT02900976|Experimental|Arm I (RTX)|Patients with newly diagnosed PTLD who achieve a CR receive additional rituximab as in induction.
2950573|NCT02900404||VTE/PE Patients|Adult female and male patients with venous thromboembolism/pulmonary embolism (VTE/PE) treated with rivaroxaban before and after surgery
2950355|NCT02902029|Experimental|Arm B|"After a 3 months run-in period with vemurafenib and cobimetinib (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7), all patients who do not show disease progression or definite treatment interruption (e.g. due to unacceptable toxicity) for more than 28 days will be randomized.~Further treatment with atezolizumab. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on day 1 of each 21 day-cycle.~After progression of disease patients in Arm B will cross back to vemurafenib and cobimetinib treatment (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7)."
2950356|NCT02902016|Experimental|Lactase expression induction by GED|
2950357|NCT02902003|No Intervention|Control|Not eligible for program services
2950358|NCT02902003|Active Comparator|Empowering Families|"These couples will be eligible to participate in the Empowering Families program."
2950359|NCT02901990||GMT-low-level group|low geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study
2950360|NCT02901990||GMT-high-level group|high geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study
2950361|NCT02901977|Experimental|ACE inhibitor|Ramipril tablets 10 mg od for 12 weeks
2950362|NCT02901977|Active Comparator|Alpha receptor blocker|Doxazosin tablets 8 mg od for 12 weeks
2950363|NCT02901964|Experimental|Group Hip Abductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
2950364|NCT02901964|Active Comparator|Group Hip Aductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
2950365|NCT02901951|Experimental|HBV Group|Subjects aged 40 to 60 years old who received 3 or 4 doses of Engerix-B (HBV vaccine) 20 to 30 years ago and were administered with a single challenge dose of HBV vaccine in this study at Day 0 (Visit 1).
2950366|NCT02901938|Experimental|cemented femoral stem group|The patients with avascular necrosis of the femoral head complicated by osteoporotic femoral neck fracture will be randomly assigned to undergo implantation of cemented femoral stem.
2950367|NCT02901938|Experimental|cannulated compression screws group|The patients with avascular necrosis of the femoral head complicated by osteoporotic femoral neck fracture will be randomly assigned to undergo percutaneous internal fixation with cannulated compression screws.
2950368|NCT02901925|Experimental|ABY-029|ABY-029 will be administered prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.
2950369|NCT02901912||Active|Women who perform at least 3h of physical activity per week
2950370|NCT02901912||Sedentary|Women who did not perform any kind of exercise
2950371|NCT02901899|Experimental|Treatment (guadecitabine, pembrolizumab)|Patients receive guadecitabine SC on days 1-4 and pembrolizumab IV over 30 minutes on day 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2950372|NCT02901886|Experimental|Intensive smoking cessation intervention|"The intervention includes 1) Individual motivational counseling in combination with 2) nicotine replacement therapy.~The intervention consists of five individual motivational counselling sessions, each lasting 20 to 40 minutes over a period of six weeks with a trained smoking cessation counsellor. The principles of motivational counselling are based on the trans theoretical model of change. The smoking cessation counsellor has also been trained in motivational counselling techniques specific to this intervention.~2. Nicotine replacement therapy The participants in the intervention group will be offered nicotine replacement therapy (NRT) free of charge and if accepted it will be tailored individually according to the Fagerström's Test for Nicotine Dependence.~The participants will note their tobacco and NRT consumption in a smoking diary."
2950373|NCT02901886|No Intervention|Control|The control group will receive the standard treatment and care in the rheumatology outpatient clinic. The participants will be encouraged to write a diary describing their tobacco use during the trial period. If participants in the control group express an interest in receiving smoking cessation counselling, they will be informed about municipal programs.
2950374|NCT02901873|Active Comparator|Thyroid surgery|Electrical Impedance Spectroscopy in Thyroid surgery
2950375|NCT02901873|Active Comparator|Parathyroid surgery|Electrical Impedance Spectroscopy in parathyroid surgery
2950376|NCT02901860||Traditional workers|"Individuals who work 'traditional work hours, i.e., 9a-5p."
2950377|NCT02901860||Non-traditional workers|Individuals who have work hours outside the usual daytime period
2950378|NCT02901847|Other|Intervention|PAD tailored care
2950379|NCT02901821||Control|No intervention. Collection of medical/demographic info and salivary RNA in children 5-21 years without history of mild traumatic brain injury (mTBI).
2950380|NCT02901821||Concussion|No intervention. Collection of medical/demographic info and salivary RNA in children 5-21 years with history of mild traumatic brain injury (mTBI). Collection of SCAT5 concussion assessment interview tool and ClearEdge balance/cognition testing at time of injury, 2wks post injury, and 4wks post injury.
2950381|NCT02901808||NOMI|Patients suffering from NOMI
2950382|NCT02901808||No-NOMI|Patients not suffering from NOMI
2950383|NCT02901782|Experimental|Personalized titanium plate|Ten males and two females with a mean age of 22.8 years were recruited. They all had bone tumor around the knee.
2950384|NCT02901769|Experimental|Depressed suicide attempters|20 subjects
2950385|NCT02901769|Experimental|Depressed patients with past history of|20 subjects
2950386|NCT02901769|Experimental|Depressed patients with no history of|20 subjects
2950387|NCT02901769|Placebo Comparator|Healthy controls|20 subjects
2950388|NCT02901743|Active Comparator|GroupI (Test)|20 patients with renal insufficiency chronic and chronic periodontitis underwent scaling and root planing. Clinical parameters( GI,PD,CAL) were assessed at baseline and after 3 months. 2ml blood was drawn to assess serum creatinine levels and urine analysis was done at baseline and after 3 months for urinary albumin: creatinine ratio.Pooled plaque samples were taken at baseline and after 3 months to assess the microbial activity of Treponema Denticola and Tannerella Forsythia by PCR.
2950816|NCT02898350|Active Comparator|Combined PDL and CO2 Laser treatment|Combined PDL and CO2 Laser resurfacing (3 treatment sessions) after suture removal
2950389|NCT02901743|Active Comparator|Group II- (Control)|20 patients with chronic periodontitis who underwent scaling and root planing.Clinical parameters(GI,PD,CAL)were assessed at baseline and after 3 months. 2ml blood was drawn to assess seum creatnine levels and urine analysis was done at baseline and after 3 months for serum urinary Albumin:Creatinine ratio.Pooled plaque samples were taken at baseline and after 3 months to assess the microbial activity of Treponema denticola and Tannerella Forsythia by PCR.
2950390|NCT02901730|Experimental|532nm laser group|LPI with 532nm laser.
2950391|NCT02901730|Experimental|561nm laser group|LPI with 561nm laser.
2950392|NCT02901717|Active Comparator|Standard of Care|Antibiotic lock + standard of care antibiotics. The standard of care antibiotic will be chosen by the investigator at the time of the infection.
2950393|NCT02901717|Experimental|Mino-Lok Therapy (MLT)|Standard of care plus MLT. MLT contains minocycline with EDTA and ethanol.
2950394|NCT02901717|No Intervention|Observation arm|Patients who have had their catheters removed and replaced due to CLABSI/CRBSI will be assessed for outcomes following a similar schedule as the treatment arms. This is a non-randomized arm for obtaining information only. This arm will only be used for experimental endpoints.
2950395|NCT02901704|Experimental|renal denervation|Iberis Multielectrode Renal Denervation System (AngioCare)
2950396|NCT02901704|Sham Comparator|Sham procedure|Renal anigography
2950397|NCT02901691|Experimental|Deaf children|
2950398|NCT02901691|Placebo Comparator|healthy volonteer children|
2950399|NCT02901678|Active Comparator|Intrusion by 200 g|Applying 200 g intrusive force for the maxillary posterior segment intrusion using miniscrews
2950400|NCT02901678|Experimental|Intrusion by 400 g|Applying 400 g of Intrusive force for the maxillary posterior segment intrusion using miniscrews
2950401|NCT02901665|No Intervention|Pre-FCC Intervention|Pre-intervention group. No intervention will be administered.
2950402|NCT02901665|Active Comparator|Post-FCC Intervention|Following unit-wide implementation of FCC intervention consisting of communicating to families an expectation that they spend 4 hours per day in the NICU with their infants.
2950403|NCT02901652|Active Comparator|GROUP 1|"NIPPV~This group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment."
2950404|NCT02901652|Active Comparator|GROUP 2|"BİPAP~This group receive Bi-Level Positive Airway Pressure (BIPAP) treatment."
2950405|NCT02901639|Experimental|counseling group|will receive counseling about contraceptive methods using illustrations through postpartum interview with the study
2950406|NCT02901639|No Intervention|NO counseling|will not receive any counseling about contraceptive methods
2950407|NCT02901626|Experimental|Pessary|Arabin pessary. Participants where local standard of care includes vaginal progesterone will also receive progesterone.
2950408|NCT02901626|No Intervention|No Pessary|Participants that do not receive a pessary will receive the usual standard of care, including vaginal progesterone if that is the local standard.
2950409|NCT02901613|No Intervention|Retrospective|Standard dry sterile dressing
2950410|NCT02901613|Experimental|Prospective|Negative-pressure wound therapy
2950411|NCT02901600||Patients with colorectal cancer|Fresh tissue samples from individuals with colorectal carcinoma taken from the tumor as well as from resection margins will be used for the detection of a potential marker of carcinogenesis.
2950412|NCT02901600||Patients with adenomatous polyps|Fresh tissue samples from individuals with adenomatous polyps will be used for the detection of a potential marker of carcinogenesis.
2950413|NCT02901600||Control patients|Fresh tissue samples from individuals without colorectal carcinoma will be used as control.
2950414|NCT02901587|Experimental|Lu AF35700 (10 mg/day)|Lu AF35700 10 mg/day for 6 weeks
2950415|NCT02901587|Experimental|Lu AF35700 (30 mg/day)|Lu AF35700 30 mg/day for 6 weeks
2950416|NCT02901587|Experimental|Quetiapine (Seroquel XR® 800 mg/day)|Quetiapine (Seroquel XR®) 800 mg/day for 6 weeks
2950417|NCT02901574|Active Comparator|tDCS plus computerized naming therapy|Anodal or cathodal tDCS, 2 milliamps (mA) plus computerized naming treatment for 15 sessions (20 minutes per each 45 minute treatment session) over the course of 3-5 weeks.The electrical current will be administered to the right cerebellum. The stimulation will be delivered at an intensity of 2 mA for a maximum of 20 minutes. Language therapy will be a computer delivered naming +picture matching task.
2950418|NCT02901574|Sham Comparator|Sham plus computerized naming therapy|Sham tDCS plus computerized naming treatment for 15 sessions (20 minutes per each 45 minute treatment session) over the course of 3-5 weeks. Current will be administered in the in a ramp like fashion for 15-30 seconds but then the current is gradually decreased and drop to 0 mA. Language therapy will be a computer delivered naming +picture matching task.
2950419|NCT02901561|Experimental|misoprostol 200|misoprostol 200 microgram placed into the vagina 3 hours prior to having the intrauterine device inserted
2950420|NCT02901561|Active Comparator|misoprostol 400|misoprostol 400 microgram placed into the vagina 3 hours prior to having the intrauterine device inserted
2950421|NCT02901548|Experimental|Durvalumab Plus Cystoscopy|Durvalumab: Fixed dose level IV infusion every 4 weeks for 13 study treatment cycles/infusions over 12 months/1 year. Cystoscopy with biopsy will be performed every 3 months to monitor the treatment response during this one year of treatment phase. It will be performed every 6 months during year 2 of the surveillance phase.
2950422|NCT02901535|Active Comparator|Control|Spirometry in baseline Spirometry - 20 weeks
2950423|NCT02901535|Experimental|Intervention|Spirometry in baseline Teleconsultation Telemonitoring Spirometry - 20 weeks
2950424|NCT02901522|Active Comparator|Control|Spirometry (baseline) Spirometry (20 - 22weeks)
2950425|NCT02901522|Experimental|Telemedicine|Spirometry (baseline) Telemonitoring Teleconsultation Spirometry (20 - 22weeks)
2950426|NCT02901509||CHIK +|People with chikungunya diagnosis (serodiagnosis)
2950427|NCT02901509||CHIK -|People without chikungunya diagnosis (negative serology)
2950428|NCT02901496|Experimental|Endurance exercise + infusion of Tocilizumab|Endurance exercise training + monthly infusion of Tocilizumab
2950429|NCT02901496|Experimental|Endurance exercise + infusion of placebo|Endurance exercise training + monthly infusion of placebo
2950430|NCT02901496|Experimental|No exercise + infusion of Tocilizumab|No exercise + monthly infusion of Tocilizumab
2950431|NCT02901496|Placebo Comparator|No exercise + infusion of placebo|No exercise training + monthly infusion of placebo
2950433|NCT02901483|Experimental|PEP503+Cisplatin+Radiotheraphy|"Phase 1b: There are 4 levels (5%, 10%, 15% and 22%) in this phase 1b study. Only primary tumor will receive PEP503 implementation via intratumor injection. A 3 + 3 dose escalation study design will be adopted in this phase to identify the recommended intratumor injection volumes of PEP503.~Phase 2: The recommended volume identified from phase 1b will be applied in phase 2 for both primary tumor and ≥ 3 cm lymph node lesions."
2950434|NCT02901457|Experimental|Healthy Body Image|Students receive the Healthy Body Image intervention containing 3x90 minutes of interactive workshops with the addition of related homework after each workshop.
2950435|NCT02901457|No Intervention|Control group|Students do not receive the intervention program.
2950436|NCT02901431|Placebo Comparator|Placebo|Participants will receive a matching placebo orally. Approximate treatment duration will be up to 24 weeks.
2950437|NCT02901431|Experimental|RO5285119 10 mg/d equivalent|Participants will receive age-adjusted total daily oral dose approximately equivalent to the adult dose of 10 milligrams per day (mg/d) of RO5285119. Approximate treatment duration will be up to 24 weeks.
2950438|NCT02901431|Experimental|RO5285119 4 mg/d equivalent|Participants will receive age-adjusted total daily oral dose approximately equivalent to the adult dose of 4 mg/d of RO5285119. Approximate treatment duration will be up to 24 weeks.
2950439|NCT02901418||control group|In this group,these children born in about two hours, we injected HBIG 200 iu and 10 micrograms of hepatitis b vaccine in their left and right thigh respectively, then injected 10 micrograms again in 1 and 6 months.
2950440|NCT02901418||experimental group|In this group,about 2 hours after birth, respectively injecting HBIG 200 IU and 10 micrograms of hepatitis b vaccine in the right and left thigh, and in 1 and 6 months again taking 10 micrograms of standard solution, in addition, offering the additional injection of 200 IU HBIG within 24 hours.
2950441|NCT02901405|Experimental|Negative Pressure Wound Therapy|120 hours of negative pressure wound therapy (ActiVAC, KCI) applied to a primarily closed ('acute') wound.
2950442|NCT02901405|Active Comparator|Standard dressings|Absorbant dressings applied in a standard fashion, i.e. only changed as necessary
2950443|NCT02901392||Artificial urinary sphincter AMS-800®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with AMS-800®
2950444|NCT02901392||AdVance/AdvanceXP®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with AdVance/AdvanceXP®
2950445|NCT02901392||VIRTUE®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with VIRTUE®
2950446|NCT02901392||INVANCE®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with INVANCE®
2950447|NCT02901379|Experimental|Atorvastatin 80mg|Subjects who will receive atorvastatin 80mg for two weeks
2950448|NCT02901379|Active Comparator|Atorvastatin 10mg|Subject who will receive atorvastatin 10mg
2950449|NCT02901366|Experimental|14C-FYU-981|14C-FYU-981, (Oral single dosing)
2950450|NCT02901340||Borderline isolated oligohydramnios|"Borderline idiopathic isolated oligohydramnios was defined according to the four quadrants technical with ultrasound examination and diagnosed with amniotic fluid index>5.0 and ≤8.0cm.~The borderline idiopathic isolated oligohydramnios group was formed of the patients who meets the inclusion criteria and between 34-37 weeks gestation (n:40)"
2950451|NCT02901340||Control group|The control group was formed of the patients who had normal amniotic volume and 34-37 weeks gestation who meets the inclusion criteria (n:100)
2950452|NCT02901327|Experimental|Lumbar Stabilisation Exercise|30 minute lumbar stabilization exercise, 3 times per week for 8 weeks.
2950453|NCT02901327|Active Comparator|Treadmill walk exercise|Walking exercise on a treadmill for a maximum of 30 minutes with increasing speed and inclination. 3 times/week for 8 weeks.
2950454|NCT02901314|Experimental|MyRoad|Receives usual care heart failure education before discharge AND a card at discharge that provided pre-recorded audio messages that can be played back on-demand on 4 themes: heart failure signs/symptoms assessment, medications, activity and exercise and diet and a general message about the importance of follow-up post discharge and following the plan of care.
2950455|NCT02901314|No Intervention|Usual care|Receives usual care heart failure education before discharge
2950456|NCT02901301|Experimental|4 combination|pembrolizumab 200mg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 capecitabine 1000mg/m2, PO, BID, Day 1-14 cisplatin 80mg/m2 (level 1), IV, q3weeks, Day 1
2950457|NCT02901288|Experimental|experimental group1|"The experimental group1 all oral regimen is consisted of isoniazid,rifampin, pyrazinamide, ethambutol and levofloxacin for 4.5 months.~Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg((less than 50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than 50kg,once daily) or 1000mg (more than 50kg,once daily), levofloxacin 600mg(less than 50kg,given once daily) or 800mg(more than 50kg,once daily)."
2950458|NCT02901288|Experimental|experimental group2|The experimental group2 all oral regimen consisted of isoniazid,rifampin, pyrazinamide, and ethambutol for 4.5 months. The dosage of isoniazid,rifampin, pyrazinamide, and ethambutol is as same as that of control regimen.
2950459|NCT02901288|Active Comparator|Control regimen group|"The control all oral regimen consisted of isoniazid,rifampin, pyrazinamide, and ethambutol during the intensive phase of treatment (2 months), followed by isoniazid and rifampin during the continuation phase (4 months).~Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg((less than 50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than 50kg,once daily) or 1000mg (more than 50kg,once daily)."
2950460|NCT02901275|Experimental|5 outpatient sessions|This is a within-subject study so all session procedures will be identical, however the specific medications provided as part of the double-blinded study medications may change during each session. During each session, which will last up to 8 hours a day and will be conducted on an outpatient basis, participants will be asked to complete standardized pain testing procedures, as well as questionnaires about how they are feeling and to complete cognitive tasks.
2950461|NCT02901262||qEEG patients|All the patients with continuous EEG (>24 hours) in teh two study units
2950570|NCT02900430||Patients with antifungal prophylaxis|Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2012 to 2015, all patients received antifungal (anti-aspergillosis) prophylaxis by posaconazole.
2950462|NCT02901249|Experimental|Sertraline|"Group Started: sertraline (50mg-200mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with sertraline (50-200mg). Non responsive patients: 2nd step.~Second step: Sertraline 200mg + lithium (900mg-1500mg)~Non responsive patients: 3rd step.~Third step: Nortriptyline 100mg~Non responsive patients: 4th step.~Fourth step: Nortriptyline 100mg + lithium (900mg-1500mg)~Non responsive patients : 5th step~Fifth step : Nortriptyline 100mg + sertraline 200mg Non responsive patients~sixth step: Nortriptyline 100mg + sertraline 200mg + Lithium ( 900mg- 1500mg)"
2950463|NCT02901236|Active Comparator|Mitomycin C|Standard Guarded Trabeculectomy will be performed. In this arm 0.02% of mitomycin C (Kyowa, Japan) will be applied on bare sclera under the conjunctiva for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
2950464|NCT02901236|Active Comparator|Bevacizumab|Standard Guarded Trabeculectomy will be performed. In this arm at the end of the case and after conjunctival closure 1.25mg of bevacizumab (Avastin; Genentech, San Francisco, CA) will be injected into the the anterior chamber through a paracentesis.
2950465|NCT02901223|Active Comparator|Quadrantectomy group|35 female patients with non metastatic breast cancer who had standard conservative breast surgery by general breast surgeons.
2950466|NCT02901223|Active Comparator|oncoplastic group|35 female patients with non metastatic breast cancer who had oncoplastic techniques for tumor resection by well trained oncoplastic breast surgeons.
2950467|NCT02901210|Experimental|Modified Delorme|Modified technique for delorme procedure done in mild to moderate rectal prolapse as the investigator destroy use the electrocautery to peal the mucosa with less intraoperative bleeding ,avoiding stripping of the mucosa done in classic delorme that induce major bleeding intraoperative .
2950468|NCT02901197|Active Comparator|Education and Reminder|This arm will consist of participants in a location that receive with web based training and exposure to reminder posters in the workplace.
2950469|NCT02901197|Active Comparator|Policy Change|This arm's participants will not receive an active intervention (education and reminders), however, policy change will take place in this location.
2950470|NCT02901184|Active Comparator|Spironolactone treatment|Spironolactone will be prescribed by the Investigator and filled by patient at conventional pharmacies as 25 mg tablets. The treatment will be on top of usual care. Initial dose is 25 mg/day until study end.
2950471|NCT02901184|Placebo Comparator|Standard care alone|Patients in the control arm will get the usual care alone
2950472|NCT02901171|Experimental|Combined Treatment|ACT group treatment combined with smartphone application
2950473|NCT02901171|Active Comparator|Acceptance and Commitment Therapy (ACT)|ACT group treatment
2950474|NCT02901171|Active Comparator|Behavioural Support Programme|Group based Behavioural Support Programme
2950475|NCT02901158||Critical care patients|Mechanically ventilated patients in the critical care unit
2950476|NCT02901158||OR-patients|Mechanically ventilated patients in the operating room
2950477|NCT02901145|Experimental|progressive/relapsed solid tumors|patient with progressive/relapsed solid tumors who failed first line therapy
2950478|NCT02901132||Cancer group 1|Colorectal cancer patients, under 18 years old, no inflammatory disease, weight loss greater 10% habitual body weight, sarcopenic.
2950479|NCT02901132||Control group|No cancer patients, under 18 years old, no inflammatory disease, no weight loss, no sarcopenic.
2950480|NCT02901119|Experimental|Whey protein|Patients are instructed to consume 20g of whey protein in the morning and 20g at night, during 15 days, as a supplement. Their regular usual diet is maintained.
2950481|NCT02901119|Active Comparator|Casein|Patients are instructed to consume 20g of casein in the morning and 20g at night, during 15 days, as a supplement. Their regular usual diet is maintained.
2950482|NCT02901106|Experimental|Patient with recurring-remitting MS|
2950483|NCT02901080|Experimental|Cranial electrotherapy stimulation|Alpha Stim AID cranial electrotherapy stimulation, Pregnancy test, Anxiety questionnaire, Quality of life questionnaire, Work and social questionnaire, Sleep questionnaire, Depression questionnaire, Quality of life and financial questionnaire
2950484|NCT02901067|Experimental|Experimental|Administration of 325mg Aspirin and 20mg of Rosuvastatin mixture in a single capsule daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.
2950485|NCT02901067|Placebo Comparator|Control|Administration of the placebo, which is identical-looking to the Aspirin and Rosuvastatin single capsule mixture, daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.
2950486|NCT02901054|Experimental|open label infusion ondansetron|"A single 4-mL CSF sample per subject.~Serial blood sampling at 0 (pre-infusion), 15, 30, 60, 120, and 180 min after ondansetron administration"
2950487|NCT02901041|Experimental|Zonisamide & Computerized Psychotherapy|Zonisamide capsules (with a target maintenance dose of 400 mg daily) and a seven module computerized psychotherapy for alcohol use disorders called Take Control (9 sessions) will be administered over the course of 12 weeks, followed by a two week medication taper.
2950488|NCT02901041|Active Comparator|Placebo & Computerized Psychotherapy|Placebo capsules (for zonisamide) and a seven module computerized psychotherapy for alcohol use disorders called Take Control will be administered over the course of 14 weeks.
2950489|NCT02901028|Experimental|Collar Device|The Device is a standard hockey neck guard, adapted for the purposes of this study. The Device incorporates two bulges localized over the site of the internal jugular veins bilaterally. Experiments performed with jugular Doppler ultrasound demonstrate that while wearing the Device, flows within the jugular veins are reduced, while flow within the carotid arteries and all portions of the cerebrum are preserved (JA Fisher, unpublished data). Thus, application of the Device to the subject will not cause any untoward health risks. The pressure exerted by the Device on the region of the neck superficial to the internal jugular vein is akin to the pressure felt when a person yawns or wears a snugly fitting necktie.
2950490|NCT02901028|Sham Comparator|Arm Device|the subject is wearing a sham arm device, which will be placed on the upper arm and not cause venous engorgement. The subject will undergo the same testing as when wearing the collar device (strength, Vo2, vision, blood, urine, etc)
2950491|NCT02901015|Other|Schizophrenic patients group 1|80 patients evaluated in the Fondamental Expertise Center for schizophrenia Network (8 centers in France).
2950492|NCT02901015|Other|Schizophrenic patients group 2|80 patients evaluated in the Fondamental Expertise Center for schizophrenia Network (8 centers in France).
2950498|NCT02900976|Experimental|Arm II (LMP-TC)|Patients with newly diagnosed PTLD who achieve a PR, SD, or PD response to induction receive allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes IV over 1- 2 minutes on days 0 and 7. Course continues for up to 42 days in the absence of disease progression or unacceptable toxicity. Patients with PR or SD after first course of course allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes receive an additional course.
2950499|NCT02900963|Other|Nutrition state determination|"Determination of nutritional state and inflammatory status:~weekly assessment of patient's weight biological parameters (albumin, transthyretin, orosomucoid) and weekly assessment of patient's weight"
2950500|NCT02900950|Experimental|Arm A-Multicolour inking specimen|"After performing the pancreaticoduodenectomies, the surgeon intraoperatively inked the surfaces/margins of the specimen with different colours. The surfaces/margins inked were the following:~Anterior surface of the pancreas (yellow);~Posterior surface of the pancreas (orange);~Superior mesenteric/portal vein groove (blu);~Superior mesenteric artery margin (retroperitoneal margin) (red);~Transection margin of the bile duct (green) The trans-section pancreatic and gastric margins were not inked."
2950501|NCT02900950|Other|Arm B-Monocolour inking specimen|In arm B, only the superior mesenteric artery margin and the pancreatic margin were intraoperatively indicated by the surgeon in the specimen: a single stitch to identify the transection pancreatic margin and a continuous suture to identify the superior mesenteric artery margin. Monochromatic inking of the superior mesenteric artery margin was subsequently carried out by the pathologist.
2950502|NCT02900937|Experimental|Coronary Scaffold Implantation|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold
2950503|NCT02900911|Experimental|Early rehabilitation|Early intervention consisting in standard swallow therapy and instructions to train respiratory muscles starting 2 weeks before Radiotherapy during 6 months
2950504|NCT02900911|Active Comparator|Later rehabilitation|Late intervention consists of standard swallow therapy and instructions to train respiratory muscles starting after completing Radiotherapy
2950505|NCT02900898|Experimental|Dynamic exercise and Mediterranean diet|"DE: divided in stretch: arms, hands, legs, knees, for 20 seconds (s), resting 5, warming and flexion: making small circles forward and backward for 20 s, resting 5, DE: resistance (contraction, twisting) using therapeutic leagues with 20 repetitions, resting 10 s. Aerobic part will perform in a treadmill by 20 minutes (monitoring blood pressure and heart rate) and relaxation: involved the stretching part.~MD: Individualized diet (energy expenditure) according to age, ideal weight and height. Distribution of macronutrients will be 50% carbohydrates, 30% lipids and 20% of proteins. This diet is according to the Mediterranean diet patterns and consist in five meals: breakfast, snack, principal meal, snack and dinner. All recommended meals include type of food and method of preparation."
2950506|NCT02900898|Experimental|Dynamic exercise|"DE: divided in stretch: arms, hands, legs, knees, for 20 seconds (s), resting 5, warming and flexion: making small circles forward and backward for 20 s, resting 5, DE: resistance (contraction, twisting) using therapeutic leagues with 20 repetitions, resting 10 s. Aerobic part will perform in a treadmill by 20 minutes (monitoring blood pressure and heart rate) and relaxation: involved the stretching part."
2950507|NCT02900898|Experimental|Mediterranean diet|MD: Individualized diet (energy expenditure) according to age, ideal weight and height. Distribution of macronutrients will be 50% carbohydrates, 30% lipids and 20% of proteins. This diet is according to the Mediterranean diet patterns and consist in five meals: breakfast, snack, principal meal, snack and dinner. All recommended meals include type of food and method of preparation.
2950508|NCT02900898|Active Comparator|Control|This group will not carry out interventions.
2950509|NCT02900820|Experimental|Novel intervention group|Discontinuing antibiotic therapy.
2950510|NCT02900820|Experimental|Usual intervention group|Usual strategy of continuing antibiotic treatment.
2950511|NCT02900794|Other|Contrast Arm (Microdebridement)|Typical pre-operative intervention including injectable local anesthetic into the inferior and middle turbinates followed by topical anesthetic on soaked cottonoids or pledgets placed in the nasal cavity floor, medial to the middle turbinate, behind the uncinate process will be performed. Using endoscopy, the nasal passage is located. Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.
2950512|NCT02900794|Other|Treatment Arm (Gold Laser)|Typical pre-operative intervention including injectable local anesthetic into the inferior and middle turbinates followed by topical anesthetic on soaked cottonoids or pledgets placed in the nasal cavity floor, medial to the middle turbinate, behind the uncinate process will be performed. Using endoscopy, the nasal passage is located. Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary. If the Investigator determines that the sinus is not sufficiently dilated or cannot be accessed, the need for and the type of additional treatment will be at the discretion of the Investigator.
2950513|NCT02900781|Active Comparator|Active Comparator Steprite™ Device'|steprite™ device active Comparator- The steprite™ System is a monitoring and biofeedback system for the Monitoring of rehabilitation patients Measuring pressure distribution, gait and range of motion of the lower extremities while a patient performs specified rehabilitation exercises
2950514|NCT02900781|Placebo Comparator|Control|Control outcomes with no device. Standard of care physical therapy and outcomes.
2950515|NCT02900768|Experimental|Exercise Group|Patients in the intervention group will receive supervised and unsupervised exercise program after their bone marrow transplant.
2950516|NCT02900768|No Intervention|Control Group|Patient will receive standard of care within the hospital as an inpatient and outpatient after their bone marrow transplant.
2950517|NCT02900755|Experimental|Epilepsy|Epilepsy patients (focal onset seizure with or without secondary generalization)
2950518|NCT02900742|Experimental|TCM granules plus Chemotherapy|"TCM granules: oral granules, YiQiFang or YangYinFang or YiQiYangYinFang, four packages, twice a day until progression or unacceptable toxicity; Chemotherapy: Gemcitabine® 1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days or Pemetrexed® 500 mg/㎡, ivgtt 30 min, day 1, every 21 days or Docetaxel® 75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity."
2950571|NCT02900417|Experimental|sitagliptin|All the patients will receive sitagliptin 100mg daily.
2950572|NCT02900404||NVAF Patients|Adult female and male patients with non-valvular atrial fibrillation (NVAF) treated with rivaroxaban before and after surgery
2950519|NCT02900742|Placebo Comparator|Placebo granules plus Chemotherapy|Placebo granules: oral granules, oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect, four packages, twice a day; Chemotherapy: Gemcitabine® 1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days or Pemetrexed® 500 mg/㎡, ivgtt 30 min, day 1, every 21 days or Docetaxel® 75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity.
2950520|NCT02900729|Experimental|Renal Denervation plus Medications|Renal denervation procedure after randomization plus maintenance of baseline standardised triple anti-hypertensive medications for 90 days and then medically necessary adjustment of antihypertensive medications for another 90 days
2950521|NCT02900729|Active Comparator|Medications|Maintenance of baseline standardised triple antihypertensive medications after randomization for 90 days and then medically necessary adjustment of antihypertensive medications for another 90 days, after which, subjects will be allowed to cross over to perform renal denervation if they still meet the inclusion criteria for the study.
2950522|NCT02900716|Experimental|Phase Ia|DTRMWXHS-12: oral capsules, daily x 21 days every 28 days
2950523|NCT02900716|Experimental|Phase Ib, DTRM-505|DTRMWXHS-12 oral capsules and everolimus oral tablets: daily x 21 days every 28 days
2950524|NCT02900716|Experimental|Phase Ib, DTRM-555|"DTRMWXHS-12 and pomalidomide oral capsules, everolimus oral tablets:~daily x 21 days every 28 days"
2950525|NCT02900703||PATIENT|
2950526|NCT02900690||recombinant activated factor VII (NovoSeven®)|Group using the Novoseven
2950527|NCT02900690||Standard care|without use of the Novoseven
2950528|NCT02900677|Experimental|Physical and nutrition program|6 education programs with physical enhancement and nutrition related information for 12 weeks.
2950529|NCT02900677|No Intervention|Control|usual care
2950530|NCT02900664|Experimental|PDR001+canakinumab in TNBC|
2950531|NCT02900664|Experimental|PDR001+CJM112 in TNBC|
2950532|NCT02900664|Experimental|PDR001+trametinib in TNBC|
2950533|NCT02900664|Experimental|PDR001+EGF816 in TNBC|
2950534|NCT02900664|Experimental|PDR001+canakinumab in NSCLC|
2950535|NCT02900664|Experimental|PDR001+CJM112 in NSCLC|
2950536|NCT02900664|Experimental|PDR001+ trametinib in NSCLC|
2950537|NCT02900664|Experimental|PDR001+EGF816 in NSCLC|
2950538|NCT02900664|Experimental|PDR001+canakinumab in CRC|
2950539|NCT02900664|Experimental|PDR001+ CJM112 in CRC|
2950540|NCT02900664|Experimental|PDR001+trametinib in CRC|
2950541|NCT02900664|Experimental|PDR001+ EGF816 in CRC|
2950542|NCT02900664|Experimental|canakinumab in TNBC|
2950543|NCT02900664|Experimental|canakinumab in NSCLC|
2950544|NCT02900664|Experimental|canakinumab in CRC|
2950545|NCT02900651|Experimental|Phase I - All|advanced stage (relapsed/refractory or recurrent/metastatic) malignancy limited to the following malignancies; DLBCL, nasopharyngeal carcinoma, gastric cancer, ovarian cancer, prostate cancer and sarcoma.
2950546|NCT02900638|Experimental|Intervention (Mentor/Mentee)|
2950547|NCT02900638|No Intervention|Wait list control|
2950548|NCT02900612|Experimental|WA (Water Aerobics Training)|Water aerobics training.
2950549|NCT02900612|Experimental|WR (Water Resistance Training)|Resistance aquatic training.
2950550|NCT02900612|Active Comparator|CG (Control Group)|Control Group.
2950551|NCT02900560|Active Comparator|Cohort 1|CC-486 100 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
2950552|NCT02900560|Active Comparator|Cohort 2|CC-486 100 mg twice a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
2950553|NCT02900560|Active Comparator|Cohort 3|CC-486 300 mg once a day, 14 days on and 14 days off combined with Pembrolizumab 200 mg IV every 21 days
2950554|NCT02900560|Active Comparator|Cohort 4|CC-486 300 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
2950555|NCT02900534|Experimental|Internet-based self-help|The self-help programme consists of 10 text-based sessions and one supportive E-Mail a week. The programme employs cognitive-behavioural interventions. The theoretical background is the Dual Process Model by Stroebe and Schutt (1999).
2950556|NCT02900534|No Intervention|Waiting control group|
2950557|NCT02900508|Experimental|Exergaming training|Participants in the exergaming training group received a 4-week exergaming intervention.
2950558|NCT02900508|Active Comparator|Control training|Participants in the control training group received a 4-week conventional training.
2950559|NCT02900495|Experimental|Suprapubic TENS|electrodes, 'transcutaneous electric nerve stimulation' placed onto the lower abdomen in the suprapubic region directly over the bladder
2950560|NCT02900495|Experimental|Posterior Tibial TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the posterior tibial nerve behind the medial malleolus of the ankle and another electrode on the bottom of the foot
2950561|NCT02900495|Experimental|Parasacral TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the S3 foramen on the sacrum on each side of the midline in the lower back/upper buttocks
2950562|NCT02900495|Placebo Comparator|Shoulder TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the scapula on the shoulder/back
2950563|NCT02900482||case group|Patients with a history of congenital hip dislocation
2950564|NCT02900482||control group|Patients with no history of congenital hip dislocation
2950565|NCT02900482||parents of case group|Parents of patients with a history of congenital hip dislocation
2950566|NCT02900469|Experimental|Denosumab & surgery|"denosumab: 120 mg subcutaneous injection~Surgery: 2-4 weeks after denosumab"
2950567|NCT02900443|Experimental|Mycophenolate mofetil|The intervention group will receive oral mycophenolate mofetil for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent EASL Clinical Practice Guidelines.
2950568|NCT02900443|Active Comparator|Azathioprine|. The control group will be treated with azathioprine (standard of care) for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent EASL Clinical Practice Guidelines.
2950569|NCT02900430||Patients without antifungal prophylaxis|Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2009 to 2011, any patient received antifungal (anti-aspergillosis) prophylaxis.
2950574|NCT02900378|Experimental|LCZ696 (sacubitril/valsartan)|Upon randomization, patients in this arm will receive LCZ696 (sacubitril/valsartan) 24 mg/26 mg bid (twice daily) and matching placebo of enalapril for 2 weeks. After 2 weeks the doses are up-titrated to 49 mg/51 mg LCZ696 (sacubitril/valsartan) and matching placebo of enalapril. After another 2 weeks (at week 6) all patients should have achieved the target dose of 97 mg/103 mg bid LCZ696 (sacubitril/valsartan) and matching placebo of enalapril , provided no safety and tolerability issues arise during up -titration.
2950575|NCT02900378|Active Comparator|Enalapril|Upon randomization, patients in this arm will receive enalapril 2.5 mg twice daily and matching placebo of LCZ696 (sacubitril/valsartan) for 2 weeks. After 2 weeks the doses are up-titrated to 5 mg bid of enalapril and matching placebo of LCZ696 (sacubitril/valsartan). After another 2 weeks (at week 6) all patients should have achieved the target dose of 10 mg bid enalapril and matching placebo of LCZ696 (sacubitril/valsartan) provided no safety and tolerability issues arise during up -titration.
2950576|NCT02900365|Experimental|Early cataract surgery group|"Eyes which presented with cataract and underwent surgery within 1 week were included in the early procedure group. They underwent early cataract surgery & IOL implantation"
2950577|NCT02900365|Experimental|Late cataract surgery group|"Eyes which presented with cataract and underwent surgery at least 1 month after trauma were included in the secondary procedure group.They underwent Late cataract surgery & IOL implantation."
2950578|NCT02900352|Experimental|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind (Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose). Subjects may increase their dose to 600mg daily during the target treatment period if it is thought to be beneficial.
2950579|NCT02900352|Placebo Comparator|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group)
2950580|NCT02900339|Experimental|MR parameters optimization|The study will be conducted on the MRI of the Neurinfo platform, in the radiology department of the University Hospital of Rennes.
2950581|NCT02900326|Placebo Comparator|Control patients with no intervention|group without intervention
2950582|NCT02900326|Experimental|Endurance training program (8 weeks) group|only physical training group
2950583|NCT02900326|Experimental|MBSR group (mindfulness-based-stress-reduction)|only mental training group(8 weeks)
2950584|NCT02900326|Experimental|Endurance training program combined with MBSR sessions|Endurance training program combined with MBSR sessions, during 8 weeks (mindfulness-based-stress-reduction)
2950585|NCT02900313|Other|Patients having cardiac surgery|Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
2950586|NCT02900248||Provider Determined Treatment|Participants with advanced solid or hematologic malignancy or myelodysplasia (MDS), will have their tumor or tissue tested by a standardized next generation sequencing (NGS) panel. They will be treated by physician determined treatment including FDA approved or compendia-listed biomarker directed therapy. All patients will be followed for time to progression by line of therapy, overall survival by line of therapy.
2950587|NCT02900235|Experimental|MT-3995|[14C]-MT-3995 after a single oral dose
2950588|NCT02900222|Experimental|Choroid Plexus Coagulation|Patients with communicating hydrocephalus will be treated with endoscopic choroid plexus coagulation.
2950589|NCT02900209||COPD frequent exacerbators|Aged 65-85 years with a diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease criteria (post bronchodilator FEV1/FVC ratio <0.70). Moderate to severe airflow limitation (FEV1 30-80% predicted). Patients have experienced 2 or more exacerbations requiring oral steroids/antibiotics treatment and/or hospitalisation in the previous 12 months.
2950590|NCT02900209||COPD infrequent exacerbators|Aged 65-85 years with a diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease criteria (post bronchodilator FEV1/FVC ratio <0.70). Moderate to severe airflow limitation (FEV1 30-80% predicted). Patients have experienced no more than 1 course of oral steroids/antibiotics and none exacerbations requiring hospital admission in the previous 12 months.
2950591|NCT02900209||Healthy controls|Aged 65-85 years and do not have any symptoms of lung disease and have normal spirometry.
2950592|NCT02900196|Experimental|1 - Test|
2950593|NCT02900196|Placebo Comparator|2 - Placebo|
2950594|NCT02900183|Experimental|ARC-AAT Injection|Intravenous administration of ARC-AAT Injection (4 mg/kg or 6 mg/kg) every 28 days for a total of 7 doses
2950595|NCT02900157|Experimental|MEDI9090|
2950596|NCT02900144|Experimental|Modified CBIT Treatment Arm|In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
2950597|NCT02900144|Active Comparator|Standard CBIT Treatment Arm|In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
2950598|NCT02900131|Experimental|trial group 1|Participants will receive Jaungo and placebo once a day for three weeks.
2950599|NCT02900131|Experimental|trial group 2|Participants will receive Jaungo twice a day for three weeks.
2950600|NCT02900131|Placebo Comparator|control group|Participants will receive placebo twice a day for three weeks.
2950601|NCT02900118||Group 1|Patients with breast cancer bone metastasis at the initial diagnosis.
2950602|NCT02900118||Group 2|Patients with breast cancer bone metastasis in a metastatic bone relapse.
2950603|NCT02900118||Group 3|Patients with breast cancer bone metastasis with a progression of bone metastasis.
2950604|NCT02900105|Experimental|Letrozole|Participants will be assigned to receive Letrozole 2.5 mg once a day for 4 months
2950605|NCT02900092|Experimental|CCD-1042 Treatment Arm|CCD-1042 at an oral dose of 225mg BID with uptitration to 450mg BID as tolerated for the duration of the 8 week trial.
2951849|NCT02891083|Other|Control group|Surgery alone
2950606|NCT02900079||travelers|persons intending to travel for 3 weeks or longer to South-East Asia, Sub-Saharan Africa or South-/ Central America; they will be trained to use a rapid diagnostic test for malaria antigen when febrile. Upon a positive test result they are recommended to use standby emergency treatment (SBET)
2950607|NCT02900053|Active Comparator|Arm 1|Cerebral modulation using tDCS (transcranial Direct-Current Stimulation) associated with repetitive traumatic exposure using a personal traumatic script
2950608|NCT02900053|Placebo Comparator|Arm 2|Placebo cerebral modulation using sham-tDCS associated with repetitive traumatic exposure using a personal traumatic script
2950609|NCT02900040||patients with kidney transplantations|patients with kidney transplantations
2950610|NCT02900027|Experimental|IONIS-APOC-III-LRx|Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
2950611|NCT02900027|Placebo Comparator|Placebo (Normal Saline)|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
2950612|NCT02900014|Experimental|Children with cleft|
2950613|NCT02900001|Active Comparator|Early invasive strategy|Patients undergo coronary angiography within 24 hours after admission and have percutaneous coronary intervention or coronary artery bypass grafting as soon as possible during the index hospitalization if appropriate.
2950614|NCT02900001|Experimental|Deferred invasive strategy|Patients undergo coronary angiography and appropriate revascularization after at lest 72 hours from admission in the index hospitalization.
2950615|NCT02899988|Experimental|Dose 1 Mirikizumab|Mirikizumab administered subcutaneously (SC).
2950616|NCT02899988|Experimental|Dose 2 Mirikizumab|Mirikizumab administered SC.
2950617|NCT02899988|Experimental|Dose 3 Mirikizumab|Mirikizumab administered SC.
2950618|NCT02899988|Placebo Comparator|Placebo|Placebo administered SC.
2950619|NCT02899975|Other|Validation Swiss|20 german talking elderly and the non-professional caregiver will validate a Fitness and Information software
2950620|NCT02899962|Active Comparator|LEO 90100 aerosol foam|Topical application twice weekly for 52 weeks
2950621|NCT02899962|Placebo Comparator|LEO 90100 aerosol foam vehicle|Topical application twice weekly for 52 weeks
2950622|NCT02899936|Active Comparator|2 drug dose - DA|Drug treatment with two-drug regimen diethylcarbamazine and albendazole (DA)
2950623|NCT02899936|Experimental|3 drug dose - IDA|Triple-drug regimen Ivermectin, diethylcarbamazine and albendazole (IDA)
2950624|NCT02899923||Autoimmune bullous dermatoses|Patients with autoimmune bullous dermatoses
2950625|NCT02899910|Experimental|Yoga with health education|12 week yoga program coupled to standardized health education for weight loss
2950626|NCT02899910|Active Comparator|Health education|Standardized health education for weight loss
2950627|NCT02899884||Cohort 1|Data of breakthrough cancer pain in cancer participants that is adequately controlled with opioids will be collected.
2950628|NCT02899871||Control|patients treated with anti-TNF not presenting any joint symptoms.
2950629|NCT02899871||case|aetiology of joint symptoms
2950630|NCT02899858|Experimental|IntraSpinal Micro-Stimulation|IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
2950631|NCT02899845|Experimental|elderly people with walking difficulties|subjects with proven gait disturbance and balance will be recruited from a walking speed test and a standardized geriatric assessment by a geriatrician
2950632|NCT02899845|Active Comparator|elderly people without walking difficulties|subjects with no gait disturbance and balance disorders will be recruited from a walking speed test and a standardized geriatric assessment, once the subjects with gait disturbance and balance disorders have been recruited in order to make a match on the age criterion
2950633|NCT02899832||NIRS|Near Infra Red Spectroscopy.
2950634|NCT02899819|Experimental|meconium|The meconium will be sampled in the first 2 days of life
2950635|NCT02899806|Placebo Comparator|Paper|Information about epidural analgesia by oral and paper sheep given by anesthesist in programed consultation
2950636|NCT02899806|Experimental|Video|Video information in addition to oral and written information gave by anesthesist in programed consultation
2950637|NCT02899793|Experimental|Pembrolizumab|Pembrolizumab 200 mg, Q3W, IV Infusion, Day 1 of each 3 week cycle
2950638|NCT02899780|Experimental|Ultraviolet arm|This arm will have their dialysis catheters treated with an ultraviolet light emitting optical fiber.
2950639|NCT02899754|Experimental|Intervention Group|Participants in this arm will use the lung cancer screening decision aid (LCSDecTool)
2950640|NCT02899754|Active Comparator|Control Group|Content that provides general information on disease prevention and health promotion unrelated to lung cancer. The information will be delivered on the same modality and take a similar amount of time to administer.
2950641|NCT02899741|Experimental|Omega-3|One group of this study. Omega-3 will be administered for thee months.
2950642|NCT02899728|Experimental|Arm I (chemotherapy, cediranib maleate, olaparib)|"Patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~Patients in Arm I who have stable disease, partial, or a complete response are randomized to receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to receive maintenance therapy.~MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.~NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with cediranib maleate and olaparib upon disease progression at the treating investigator's discretion."
2950643|NCT02899728|Experimental|Arm II (chemotherapy, cediranib maleate, olaparib)|"Patients receive treatment as in Arm I and also receive cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for up to 4 courses in theabsence of disease progression or unacceptable toxicity..~MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28."
2950644|NCT02899702|Experimental|IVIG|PRIVIGEN (CSL Behring) NORMAL HUMAN IMMUNOGLOBULINS L-PROLINE, Water for injection
2950772|NCT02898701|Active Comparator|No Overpractice (NoOVP)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) according to the practice schedule until they reach a performance plateau on the repeated sequence. At that time, members of the NoOVP group will cease practicing.
2950645|NCT02899702|Placebo Comparator|control|"Single administration of Albumin 4% diluted albumin (LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
2950646|NCT02899689|Active Comparator|Foley Bulb Group|Patients will have a Foley catheter inserted into the internal cervical os.
2950647|NCT02899689|Experimental|Dilapan Group|Patients will have Dilapan sticks inserted into the internal cervical os.
2950648|NCT02899676|Experimental|Healthy subjects aged 18 to 24|Subjects without neurological or psychiatric history
2950649|NCT02899676|Experimental|Healthy subjects aged 8 to 11|Subjects without neurological or psychiatric history
2950650|NCT02899676|Experimental|Healthy subjects aged 12 to 14|Subjects without neurological or psychiatric history
2950651|NCT02899650|Experimental|Young Fit|Young (18-39 yrs) people who have endurance training habit
2950652|NCT02899650|Experimental|Young Unfit|Young (18-39 yrs) people who have sedentary lifestyle.
2950653|NCT02899650|Experimental|Older Fit|Older (50-80 yrs) people who have endurance training habit
2950654|NCT02899650|Experimental|Older Unfit|Older (50-80 yrs) people who have sedentary lifestyle
2950655|NCT02899637|Experimental|Spinal Cord Injury (Active Group)|Active high-frequency Transcranial Magnetic Stimulation
2950656|NCT02899637|Sham Comparator|Spinal Cord Injury (Control group)|Sham high-frequency Transcranial Magnetic Stimulation
2950657|NCT02899624|Experimental|Bicuspid aortic valve (BAV)|patient with bicuspid aortic valve
2950658|NCT02899624|Active Comparator|healthy subjects related patients with BAV|healthy control, related to patient with bicuspid aortic valve, at the 1st, 2nd or 3rd degree
2950659|NCT02899624|Active Comparator|Tricuspid aortic valve (TAV)|patient with aortic stenosis on tricuspid valve
2950660|NCT02899611|Experimental|ICV Valproate|Patients receive a daily dose of ICV Valproate that increases from 3 mg to 60 mg (or MTD) over 8 weeks. A placebo week is randomly inserted in the dose escalation. During the placebo week, the patient receives normal saline.
2950661|NCT02899598|Experimental|Pregnant women|
2950662|NCT02899585|Experimental|Group A|Elaboration of the questionnaires
2950663|NCT02899585|Experimental|Group B|Patients taken care for more less than 6 days by the health care team palliatives EIVA and they eventual family caregiver. Score
2950664|NCT02899572|Experimental|Sexology consultation|specialized sexology consultation planned in the 15 days after inclusion. Randomisation is performed at D7 during a phone call to the patient.
2950665|NCT02899572|No Intervention|Leaflet concerning erectile disorders|leaflet explaining erectile disorders related to type 2 diabetes will be sent by post to the patients. Randomisation is performed at D7 during a phone call to the patient.
2950666|NCT02899559|Experimental|Control|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. The control group will read only summary information about the David Pottruck Health and Fitness Center.
2950667|NCT02899559|Experimental|Nudge Message|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. The nudge message encourages participants to make a plan for when they will exercise at the gym during the next week.
2950668|NCT02899559|Experimental|Boost Message|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. Those in the Boost condition will also have summary information about the Pottruck gym but will also be given information about why an implantation intention is an effective way to attain long term goals. They will also be given a prompt to form an implementation intention.
2950669|NCT02899533||FES PET/CT scan|All subjects will receive an [18F]FES PET/CT scan.
2950670|NCT02899520|Active Comparator|Group A|Reference method
2950671|NCT02899520|Experimental|Group B|CMP ® method (Knowledge and Control of Perineum)
2950672|NCT02899507|Experimental|Prophylactic antibiotic|Amoxicillin-Clavulanic acid 1.2g every 8h
2950673|NCT02899507|No Intervention|Clinically-driven antibiotics|Administration of antibiotics in clinically-driven group was at the discretion of attending intensivist. Selection of antibiotic in clinically-driven group was empirical or based on the results of bacterial cultures if already available.
2950674|NCT02899494|Other|Group A|Antenatal classes
2950675|NCT02899494|Experimental|Group B|Physical and psychic preparation
2950676|NCT02899481|Experimental|Study group|The study group will be constituted by pregnant women in whom the operative delivery will be preceded by a transabdominal and transperineal ultrasound to evaluate fetal head position and fetal head station, by means of determination of the 'angle of progression'.
2950677|NCT02899481|No Intervention|Control group|The control group will be constituted by pregnant women in whom the operative delivery will be carried out based solely on clinical criteria, namely transvaginal digital examination.
2950678|NCT02899468|Experimental|Active Treatment Group|Active treatment will consist of the BrightBrainer Virtual Reality (BBVR) Rehabilitation System therapy intervention (3 sessions per week x 6 weeks). Standard validated outcome measures which assess various domains of function, will be obtained at baseline and then at 3 and 6 weeks for those randomized to the Active Treatment group.
2950679|NCT02899468|Other|Wait-List Control Group|Subjects randomized to the Wait-List Control (WLC) group will wait 3 weeks before beginning the Active Treatment program intervention (3 sessions per week x 6 weeks) using the BrightBrainer Virtual Reality (BBVR) Rehabilitation System. For those randomized to the WLC group, outcome measures will be assessed at baseline, completion of waiting period (3 weeks), then at 3 and 6 weeks after initiating active treatment.
2950680|NCT02899455|Experimental|Experimental|HGP0904 + HGP0608 + HGP0816, once daily
2950681|NCT02899455|Active Comparator|Active Comparator1|HGP0904 placebo + HGP0608 + HGP0816, once daily
2950682|NCT02899455|Active Comparator|Active Comparator2|HGP0904 + HGP0608 + HGP0816 placebo, once daily
2950877|NCT02897921||Healthy controls|Healthy controls, investigated by blood sampling, Biodex 4 Isokinetic Dynamometer and MRI analysis.
2950683|NCT02899442|No Intervention|individual prevention|"The individual preventive advice will be delivered to the control group by occupational physicians during routine medical examinations (defined by law, each 6 months), in occupational medical centres. The type and time spent to explain this advice will be collected in case report form.~To ensure each night workers included in the control group received the same advice, a booklet was provided outlining the content under 5 main headings:~Information about health risks for night workers~Dietetic intake~Leisure physical activities~Sleep and alertness~Lifestyle behaviors (Tobacco, alcohol and psychoactive drugs consumption)~That's a current practice in France for Occupational physicians."
2950684|NCT02899442|Experimental|individual and collective prevention|In addition to this individual prevention, the night workers from the experimental group will benefit from implementation of preventive actions in the workplace (collective prevention in workplace ). These collective preventive measures will be dispensed by the occupational health team (occupational physicians and technician of occupational risks prevention).
2950685|NCT02899403|Experimental|healthy subjects|
2950686|NCT02899390|Experimental|Lifestyle Intervention|All the participants will be offered group and individual sessions to help them accomplish weight loss and also increase physical activity.
2950687|NCT02899377|Experimental|Group A: Health subjects|During Visit 1, these subjects will undergo the following: An MRI of the salivary glands with one-time intravenous (IV) bolus injection of 0.1 mmol/kg of gadoterate meglumine and receive one-time IV bolus injection of 500 megabecquerels (MBq) of 11C MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)
2950688|NCT02899377|Experimental|Group B: pSS subjects|During Visit 1, subjects with pSS will undergo the following: An MRI of the salivary glands with IV bolus injection of <=0.1 mmol/kg of gadoterate meglumine and receive one-time IV bolus injections: 500 MBq of 11C-MET (PET/CT: as for Group A) and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan)
2950689|NCT02899364|Experimental|Sodium thiosulfate|25 gram sodium thiosulfate is given intravenously in two doses of 12.5 gram in 250 cc. After arrival at the cath-lab, confirming STEMI and obtaining verbal informed consent the first dose, will be administered in 15 minutes (infusion rate 16.66 mL/min). After infusion the patient will receive primary percutaneous coronary intervention. Post-PCI they will be submitted to the cardiac control unit where they receive the second dose, 6 hours after start of the first dose. The second dose is administered in 30 minutes (infusion rate 8.33 mL/min). At 4 months infarct size is assessed by LGE cardiac magnetic resonance imaging.
2950690|NCT02899364|Placebo Comparator|Sodium Chloride|Sodium chloride is given as placebo in two doses of 250cc. After arrival at the cath-lab, confirming STEMI and obtaining oral informed consent the first dose, will be administered in 15 minutes (infusion rate 16.66ml/min). After infusion the patient will receive primary percutaneous coronary intervention. Post-PCI they will be submitted to the cardiac control unit where they receive the second dose, 6 hours after start of the first dose. The second dose is administered in 30 minutes (infusion rate 8.33 mL/min). At 4 months infarct size is assessed by LGE cardiac magnetic resonance imaging.
2950691|NCT02899351||Infants less than 12 months|intubated infants in ICU
2950692|NCT02899338|Experimental|BI695501 Autoinjector|
2950693|NCT02899338|Active Comparator|BI695501 Prefilled syringe|
2950694|NCT02899299|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
2950695|NCT02899299|Active Comparator|Pemetrexed and Cisplatin (or Carboplatin)|Specified dose on specified days
2950696|NCT02899286|Experimental|PEG-BCT-100|PEG-BCT-100 (PEGylated recombinant human arginase)
2950697|NCT02899273||Dentistry students|Dentistry students of the University of Göttingen
2950698|NCT02899273||Psychology students|Psychology students of the University of Hildesheim
2950699|NCT02899260|No Intervention|Control|Subjects who are randomized to to the control group will labor without the use of the peanut ball in labor.
2950700|NCT02899260|Experimental|Experimental/Peanut Ball|Subjects randomized to the intervention (peanut ball) arm will have the peanut ball planed between their upper legs for at least 30minutes during their labor. Time on the peanut ball will be quantified by the bedside nursing staff.
2950701|NCT02899247|Experimental|No Surface Sealant|Resin composite only
2950702|NCT02899247|Active Comparator|With surface Sealant|Resin composite with surface sealant application
2950703|NCT02899234|Active Comparator|Nicotine-free e-cigarette|Subjects will actively inhale nicotine-free vapor prior to blood samples and various non-invasive cardiopulmonary tests.
2950704|NCT02899234|Active Comparator|Nicotine e-cigarette|Subjects will actively inhale nicotine containing vapor prior to blood samples and various non-invasive cardiopulmonary tests.
2950705|NCT02899221|Experimental|Treatment (high dose rate brachytherapy, hyperthermia)|Patients undergo high dose rate brachytherapy for 15-30 minutes. Immediately after radiation therapy (no longer than 90 minutes), patients undergo interstitial hyperthermia treatment for up to 60 minutes.
2950706|NCT02899195|Experimental|Concurrent Durvalumab|Pemetrexed/cisplatin will be given for up to six 3-week cycles with the addition of concurrent durvalumab every 3 weeks. The first 6 patients who are enrolled and commence treatment will be monitored for safety of the combination. Use of carboplatin in place of cisplatin will be permitted for patients who are ineligible for cisplatin due to impaired renal function at screening. For patients that receive cisplatin, carboplatin may also be substituted after Cycle 1 for cisplatin related toxicity (e.g., grade 3 ototoxicity, grade 3 nausea) at the investigator's discretion.
2950707|NCT02899195|Experimental|Maintenance Durvalumab|After completion of Cycle 6 of concurrent therapy, patients with stable or responding disease per modified RECIST for malignant mesothelioma will continue on single agent durvalumab every 3 weeks until progression. Maximum duration of durvalumab treatment is 12 months starting from Cycle 1 of concurrent treatment (inclusive of any treatment delays or missed treatments).
2950708|NCT02899182|Placebo Comparator|conventional group|the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
2950709|NCT02899182|Experimental|Nitrous Oxide NO|The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
2950710|NCT02899169|Experimental|Oral Realgar-Indigo naturalis formula(RIF) Group|Induction therapy: ATO and ATRA, which will maintain until complete hematologic remission. Hydroxyurea should be administrated until WBC count decrease <10x109/L. Consolidation therapy: RIF（60mg/kg/d) and ATRA 4 weeks on and 2 weeks off, until the fusion gene expression is negative. Maintenance therapy: RIF and ATRA 2 weeks on and 2 weeks off for a total of 6 courses.
2950711|NCT02899169|Active Comparator|Intravenous Arsenic Trioxide(ATO) Group|Induction therapy: ATO and ATRA, which will maintain until complete hematologic remission. Hydroxyurea should be administrated until WBC count decrease <10x109/L. Consolidation therapy: ATO and ATRA 4 weeks on and 2 weeks off, until the fusion gene expression is negative. Maintenance therapy: ATO and ATRA 2 weeks on and 2 weeks off for a total of 6 courses.
2950712|NCT02899156|Active Comparator|Flumazenil Infusion|The flumazenil continuous infusion is started at an initial dose of 0.1 mg/hr., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.
2950713|NCT02899156|Placebo Comparator|Placebo Infusion|The placebo continuous infusion is started at an initial dose of 0.1 mg/hr., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.
2950714|NCT02899143|Experimental|Group 5-days|5-days targeted antibiotic therapy
2950715|NCT02899143|Other|Group 10-days|10-days targeted antibiotic therapy
2950716|NCT02899130|Experimental|Polyherbal|Combination of 3 whole herbs in a capsule
2950717|NCT02899130|Placebo Comparator|Matching placebo|Similar looking inert capsules
2950718|NCT02899117|Experimental|Yoga intervention|Patients in the yoga intervention group will have 4 yoga sessions with a certified yoga instructor while they are in the cancer clinic or on the inpatient floor.
2950719|NCT02899104||Radium-223 dichloride|Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC), at least 18 years of age, must have received at least one intravenous injection of Radium-223.
2950720|NCT02899091|Experimental|CB-AC-02|Subjects with Alzheimer's disease Intervention: CB-AC-02
2950721|NCT02899091|Placebo Comparator|Placebo|Subjects with Alzheimer's disease Intervention: Placebo
2950722|NCT02899078|Experimental|Treatment (ibrutinib, nivolumab)|Patients receive ibrutinib PO QD on days 1-28 and nivolumab intravenously IV over 60 minutes on days 1 and 15. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
2950723|NCT02899065|Experimental|Intervention|The intervention arm will receive pharmacist-led education and stewardship intervention and a procalcitonin test to aid in the decision of how to treat the patient. This intervention will include direct delivery of education from the pharmacist to the treating clinician about interpreting the Roche Cobas Liat Flu/RSV and procalcitonin test results, recommendations for antiviral-treatment for high-risk patients and information about infection control precautions for patients being hospitalized with a positive RSV or influenza test.
2950724|NCT02899065|No Intervention|Standard of care|The second arm will be usual care (i.e. Roche Cobas Liat Flu/RSV test only). Results will be delivered via standard of care.
2950725|NCT02899052|Experimental|Venetoclax + Carfilzomib + Dexamethasone|Part 1: Evaluate the safety and pharmacokinetic profiles while providing information to determine the appropriate doses of venetoclax and carfilzomib (VenKd) to be used in the VenKd combination in approximately 9-18 subjects. The dose levels are Venetoclax 400 mg or 800 mg; Carfilzomib 20/27 mg/m2, 20/70 mg/m2, and/or 20/56 mg/m2; Dexamethasone 40 mg Part 2: Further evaluate the safety and efficacy profile of the VenKd combination selected after completion of Part 1 in approximately 22 - 31 additional subjects. Participants may discontinue Kd but may continue receiving venetoclax once daily (QD) as monotherapy.
2950726|NCT02899039|Experimental|IgG4-related disease|Subjects suffering from IgG4-related disease
2950727|NCT02899039|Active Comparator|Sjögren syndrome|Subjects suffering from Sjôgren syndrome
2950728|NCT02899039|Active Comparator|Healthy controls|Healthy subjects
2950729|NCT02899026|Experimental|Part A: Sirukumab 100 mg SC + prednisone (6-week taper)|Eligible subjects will receive blinded Sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) for 52 weeks plus a 6-week oral prednisone taper regimen
2950730|NCT02899026|Experimental|Part A: Sirukumab 50 mg SC + prednisone (6-week taper)|Eligible subjects will receive blinded Sirukumab 50 mg SC q4w (with placebo SC injections q2w between sirukumab injections) for 52 weeks plus a 6-week oral prednisone taper regimen
2950731|NCT02899026|Placebo Comparator|Part A: Placebo SC + prednisone (52 week taper)|Eligible subjects will receive blinded placebo SC q2w for 52 weeks plus a blinded 52-week oral prednisone taper
2950732|NCT02899000|Experimental|Acne treatment|"Topical adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel (one application daily for 12 weeks)~Oral doxycycline hyclate, 200 mg per day (two 50-mg tablets twice daily for 12 weeks)"
2950733|NCT02898974||Regular Medical Marijuana users|People with MS that are regular Medical Marijuana users
2950734|NCT02898974||Non Users of Medical Marijuana|People with MS that are non users of Medical Marijuana
2950735|NCT02898961|Experimental|The study population|"ICU patients with severe sepsis treated with aminoglycosides were recruited.~Intervention: 30 mg/kg amikacin or 8 mg/kg gentamicin"
2950736|NCT02898922|Experimental|HCV group|Three doses of hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae (20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China) were given intramuscularly in the deltoid region to all participants at 0, 1 and 6 months respectively.
2950737|NCT02898922|Active Comparator|Healthy control group|Three doses of hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae (20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China) were given intramuscularly in the deltoid region to all participants at 0, 1 and 6 months respectively.
2950738|NCT02898909|Experimental|16 pieces fragmentation|
2950739|NCT02898909|Active Comparator|8 pieces fragmentation|
2950740|NCT02898896|Other|HIV-infected patients|HIV-infected patients >= 45 years with 2 or more CV risk factors currently on ART and HIV-RNA < 50 copies >= 12 months (one blip allowed) As part of this research, three additional tubes of blood (EDTA) will be taken from patients (21 mL) during blood tests performed as part of a scheduled consultation for the management of their pathology
2950773|NCT02898701|Experimental|Overpractice (OVP)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) according to the practice schedule until they reach a performance plateau on the repeated sequence. At that time, members of the OVP group will continue to practice as part of the overpractice phase until they have completed 100% overpractice.
2951141|NCT02896374|Experimental|Control|No schizophrenic participants, comparable to schizophrenia patients in age, gender, education level and socio premorbid verbal IQ.
2950741|NCT02898883|Experimental|Intervention group|Early intervention Program The early intervention program (EIP) will consist of 4 sessions with one parent/guardian of the injured child and a clinical psychology graduate student therapist. All sessions are one on one for one hour. The first session will be conducted in the hospital within an average of 24- 48 hours after the traumatic event. The subsequent three sessions will be conducted electronically via web-based video chat once per week. In general, the EIP will utilize psychoeducation, skills implementation, and daily monitoring to facilitate communication regarding the traumatic event, maintain daily and sleep routines, increase child's access to social support and mitigate the impact of life stress.
2950742|NCT02898883|No Intervention|Treatment as Usual (TAU)|As part of routine hospital protocol, all participants who screen positively for PTSD risk are provided with a packet of educational materials and potential referrals for behavioral healthcare.
2950743|NCT02898857||down-staging of a KRAS|Six with demonstrated down-staging of a KRAS mutant adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
2950744|NCT02898857||no down-staging of a KRAS|Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
2950745|NCT02898857||non-staging and triple negative adenocarcinoma|Six with or without non-staging and triple negative adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
2950746|NCT02898844|No Intervention|Control Condition|Neither roommate dieted.
2950747|NCT02898844|Experimental|Mixed Diet Condition|Low-calorie diet: One roommate in each pair was randomly assigned to a 1200-calorie/day diet, while the other roommate was instructed to eat normally.
2950748|NCT02898844|Experimental|Both Diet Condition|Low-calorie diet: Both roommates in each pair were randomly assigned to a 1200-calorie/day diet.
2950749|NCT02898831|No Intervention|Control/No Intervention|Standard clinical procedure with intrauterine device insertion involving no heated/cold compresses on the abdomen during insertion.
2950750|NCT02898831|Experimental|Cold Compress/Experimental|Cold compress (intervention) placed on abdomen just before IUD insertion and remains throughout insertion. Pain scale and survey completed following insertion regarding pre-procedure and intra-procedure pain.
2950751|NCT02898818||symptomless|vaginal and oral swab sample, questionnaire
2950752|NCT02898818||vaginal discharge|vaginal and oral swab sample, questionnaire
2950753|NCT02898818||atypical papa smear|vaginal and oral swab sample, questionnaire, papa smear
2950754|NCT02898818||no atypical papa smear|vaginal and oral swab sample, questionnaire, papa smear
2950755|NCT02898818||lichen planus|vaginal and oral swab sample, questionnaire, papa smear
2950756|NCT02898805|Experimental|LopiGLIK®|first two weeks: Placebo + prescribed Diet then 16 weeks LopiGLIK® a tablet/day after a meal + Diet
2950757|NCT02898805|Active Comparator|Armolipid Plus|first two weeks: Placebo + prescribed Diet then 16 weeks Armolipid Plus a tablet/day after a meal + Diet
2950758|NCT02898792|Experimental|targeted infusion of remifentanil untreated OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
2950759|NCT02898792|Experimental|targeted infusion of remifentanil CPAP treated OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
2950760|NCT02898792|Experimental|targeted infusion of remifentanil No OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
2950761|NCT02898779|Experimental|Cohort 1 ( Primaquine Low Dose)|"Interventions: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine A single center, prospective, cross-over, randomized phase 1 trial. Thirty-six participants, enrolled into a two cohort pharmacokinetic study evaluating two dose levels of primaquine isomers.~Cohort 1 (Low Dose Level)- single dose of 15 mg of S-Primaquine and 15 mg of R-Primaquine compared to 30 mg RS-Primaquine over 24 hours. Participants will cross-over after a one week wash-out period."
2950762|NCT02898779|Experimental|Cohort 2 (Primaquine High Dose)|"Interventions: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine A single center, prospective, cross-over, randomized phase 1 trial. Thirty-six participants, enrolled into a two cohort pharmacokinetic study evaluating two dose levels of primaquine isomers.~Cohort 2 (High Dose Level)-single dose of 22.5 mg of S-Primaquine and 22.5 mg of R-Primaquine compared to 45 mg RS-Primaquine over 24 hours. Participants will cross-over among the treatment arms following a one week wash-out period between each."
2950763|NCT02898766|Active Comparator|Enteral Nutrition Formula 1|Enteral Nutrition Formula
2950764|NCT02898766|Active Comparator|Enteral Nutrition Formula 2|Enteral Nutrition Formula
2950765|NCT02898753|Experimental|VAL-1221 3 mg/kg|Patients will receive VAL-1221 3 mg/kg IV (n=3) every other week or control (n=1)
2950766|NCT02898753|Experimental|VAL-1221 10 mg/kg|Patients will receive VAL-1221 10 mg/kg IV (n=3) every other week or control (n=1)
2950767|NCT02898753|Experimental|VAL-1221 30 mg/kg|Patients will receive VAL-1221 30 mg/kg IV (n=3) every other week or control (n=1)
2950768|NCT02898753|Active Comparator|RhGAA|Patients randomized to rhGAA will be maintained on their current dose and regimen of Myozyme or Lumizyme
2950769|NCT02898740|Experimental|Arm 1|Structured exercise
2950770|NCT02898740|Active Comparator|Arm 2|Health education
2950771|NCT02898727|Other|Local Therapy|"The local therapy offered will be determined by the participant's doctor in consultation with the site multidisciplinary team and will be dependent on the size and location of the brain metastases.~Neurosurgery: The surgery may be performed up to 6 weeks before participant being registered on the trial or up to 4 weeks after registration.~Sometimes stereotactic radiosurgery is required to be delivered to the cavity left after the metastasis has been removed (Cavity Boost).~Stereotactic Radiosurgery: Treatment is to commence within 4 weeks of study registration. The size, number and location of the brain metastasis will determine the dose and fractionation schedule of radiotherapy."
2950774|NCT02898701|Active Comparator|Standard of Care (SoC)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) until they have performed 144 practice trials over the course of one day. At that time, members of the SoC group will cease practicing.
2950775|NCT02898688|Other|Control Site + Control Patient|The obstetric practice site is randomized to be a control site and the patient is randomized to the control group.
2950776|NCT02898688|Experimental|Control Site + Intervention Patient|The obstetric practice site is randomized to be a control site and the patient is randomized to receive the intervention.
2950777|NCT02898688|Experimental|Intervention Site + Control Patient|The obstetric practice site is randomized to be an intervention site and the patient is randomized to the control group.
2950778|NCT02898688|Experimental|Intervention Site + Intervention Patient|The obstetric practice site is randomized to be an intervention site and the patient is randomized to receive the intervention.
2950779|NCT02898675|Experimental|Platelet Rich Fibrine|Platelet Rich Fibrine was applied with open flap debridement in test group.
2950780|NCT02898675|Active Comparator|Open Flap Debridement|Platelet Rich Fibrin was not applied to control groups. Only open flap debridement was applied to control groups.
2950781|NCT02898662|Experimental|AZD1419|Dose adaption of AZD1419, 4 mg or 8 mg or 1 mg based on occurence of AE's
2950782|NCT02898662|Placebo Comparator|Placebo|Matching placebo
2950783|NCT02898649|Experimental|IRE|The intervention group
2950784|NCT02898610|Active Comparator|Colchicine treatment|Colchicine 0.5mg/day plus usual care for 60 months
2950785|NCT02898610|No Intervention|Usual Standard of care alone|Normal standard of care remains for these patients
2950786|NCT02898597|Experimental|Video|Cognitive behavioral therapy Nicotine replacement therapy (Habitrol Patch)
2950787|NCT02898597|Active Comparator|Telephone|Cognitive behavioral therapy Nicotine replacement therapy (Habitrol Patch)
2950788|NCT02898584|Other|BP Track|The study participants will be asked to monitor their blood pressure twice daily at home for twelve weeks, and sync the data to the mobile intervention so that a clinical pharmacist can review and incorporate the data into ongoing hypertension management.
2950789|NCT02898571|Placebo Comparator|Placebo|360ml water based drink containing 50g mix of glucose and fructose plus flavouring
2950790|NCT02898571|Experimental|Vitamin C|360ml water based drink containig 60mg vitamin C and 50g mix of glucose and fructose plus flavouring
2950791|NCT02898571|Experimental|Epicatechin|360ml water based drink containig 80mg epicatechin and 50g mix of glucose and fructose plus flavouring
2950792|NCT02898558|Experimental|Magnification hand size|magnifying lenses used for 30 minutes daily for 14 days while completing a jigsaw puzzle
2950793|NCT02898545|Other|SEEQ monitor|Subjects will be monitored via use of the SEEQ monitor
2950794|NCT02898545|No Intervention|Standard of care|Subjects will not wear the SEEQ monitor or may have a pre-existing implanted device capable of detecting atrial fibrillation
2950795|NCT02898532|Active Comparator|Intervention group|The intervention is organised in collaboration between the local school, the Danish Shooting Association, and the national DGI (The Danish Gymnastics and Sporting Organization). The intervention is available geographical nationwide. The children will practise target-shooting sport in local Shooting Association once a week during school hours for a period of 6 months. Selected schools are either special schools or municipal schools with special educational programmes for children diagnosed with either ADHD or severe difficulties of hyperactivity, inattention and impulsivity. Teachers accompany the children to the Shooting Association where the instructors meet them.
2950796|NCT02898532|No Intervention|Control group|The same target group as children in the intervention group. In the control group children are not practicing target shooting sport, neither in school or free time.
2950797|NCT02898506|Active Comparator|Liraglutide|Subjects with multiple islet autoantibodies and dysglycemia and aged 10-30 years are treated with Victoza®
2950798|NCT02898506|Placebo Comparator|Placebo|Subjects with multiple islet autoantibodies and dysglycemia and aged 10-30 years are treated with placebo
2950799|NCT02898480|Experimental|Remote ischemic conditioning|
2950800|NCT02898467||diabetics|Type 2 diabetic patients exhibiting fasting glycemia value over 7 mmol/L or glycated hemoglobin value over 6.5% or type 2 diabetic patients under oral anti-diabetic treatment or type 2 diabetic patient under insulin treatment and in which diabetes has been diagnosed after the age of 45 y
2950801|NCT02898467||non-diabetics|patients without diagnosed diabetes exhibiting fasting glycemia value under 7 mmol/L
2950802|NCT02898454|Experimental|Dupilumab (Arm A)|A dose of dupilumab will be administered subcutaneously (SC) every 2 weeks (q2w) until Week 52. Patients will use MFNS daily.
2950803|NCT02898454|Experimental|Dupilumab (Arm B)|A dose of dupilumab will be administered SC every 2 weeks until Week 24, then every 4 weeks (q4w) until Week 52. Patients will use MFNS daily.
2950804|NCT02898454|Placebo Comparator|Placebo (Arm C)|A matching placebo will be administered SC every 2 weeks (q2w) until Week 52. Patients will use MFNS daily.
2950805|NCT02898441|Active Comparator|Screening Arm|LDCT was performed at baseline + 2 biennial repeated LDCT rounds
2950806|NCT02898441|No Intervention|Passive Arm|Eligible subjects were randomized to follow up in usual care
2950807|NCT02898428||New mothers|New mothers with type 1 diabetes
2950808|NCT02898428||Control group|Non-pregnant, non-breastfeeding women with type 1 diabetes matched for age and BMI
2950809|NCT02898415||Training set|Consecutive patients who underwent liver transplantation for HCC at Italian transplant centers
2950810|NCT02898389||Group 1: With cardiovascular risk factors|Patients fall within this group when they have at least one of the cardiovascular risk factors listed in the eligibility criteria section.
2950811|NCT02898389||Group 1: Without cardiovascular risk factors|Patients fall into this group when they do not have any of the cardiovascular risk factors listed in the eligibility criteria section.
2950812|NCT02898376|Experimental|combination tocopherol/pentoxifylline + spa care|pentoxifylline (400 mg bid) + tocopherol (500 mg x bid) during at least 6 months AND skin-oriented spa care (18 days)
2950813|NCT02898376|Active Comparator|combination tocopherol/pentoxifylline|pentoxifylline (400 mg bid) + tocopherol (500 mg x bid) during at least 6 months
2950814|NCT02898350|Active Comparator|Pulsed Dye Laser treatment|Pulsed Dye Laser treatment after suture removal (3 sessions)
2950817|NCT02898350|Active Comparator|Split PDL and CO2 Laser treatment|Half of the scar was not treated and served as a control, while the other half was treated with CO2 ablative fractional resurfacing immediately after surgery, in addition to the three combined PDL and CO2 treatment sessions after suture removal
2950818|NCT02898337||Methadone-induced QTc interval prolongation|
2950819|NCT02898337||Methadone-treated patients, no QT interval prolongation|
2950820|NCT02898324|Experimental|KiVa program full|The schools allocated in this arm will receive the Chilean adaptation of KiVa program with all its universal and indicated actions.
2950821|NCT02898324|Experimental|KiVa program w/o the digital component|The schools allocated in this arm will receive the Chilean adaptation of KiVa program without the digital component (online game)
2950822|NCT02898324|No Intervention|Control group|The schools allocated in this arm will not receive the KiVa program. If successful, these schools will receive the program the following academic year.
2950823|NCT02898298|Experimental|Immediate|Immediate group receives the Positive Emotion Regulation training immediately.
2950824|NCT02898298|Active Comparator|Waitlist control group|Waitlist control group receives the Positive Emotion Regulation training 4 weeks later.
2950825|NCT02898285|Active Comparator|Night out condition|"People randomized to this group will be asked to go on a night out with no kids (i.e. dinner, or a movie) once a month."
2950826|NCT02898285|Experimental|Individual sport condition|People randomized to this group will select an individual sport from a list of 5. They will be asked to participate in this individual sport for three months.
2950827|NCT02898285|Experimental|Team sport condition|People randomized to this group will select a team sport from a list of 5. They will be asked to participate in the team sport for three months (length of the team sport season).
2950828|NCT02898259|Experimental|Lenalidomide + Ixazomib + Rituximab|Ixazomib will be orally administered with a starting dose of 2.0mg. Lenalidomide will be administered orally with a starting dose of 20mg. Rituximab will be administered intravenously at the standard dose of 375mg/m2. The study will use a standard 3 + 3 design for determination of MTD during cycle 1. There will be three dose levels for escalation, followed by two expansion cohorts of 12 patients each at the MTD, one cohort with follicular lymphoma and one cohort with non-follicular low-grade lymphoma (SLL, marginal zone, lymphoplasmacytic). Patients will be treated for 12 cycles of 4 week duration.
2950829|NCT02898246||Patients with chronic heart failure|"Fear of physical activity (exposure) will be assessed in adult outpatients with diagnosed, chronic heart failure (with reduced ejection fraction or with preserved ejection fraction).~Hospitals provide medical data to assess patients' disease severity. Additional measures assessed via questionnaire include demographic characteristics, State and Trait depression and anxiety, heart failure related symptom distress, and coping dispositions relevant for coping with physical threat.~Fear of physical activity (FActS-HF 15) is reassessed after 4 weeks to evaluate the instrument's retest reliability.~After questionnaire completion, a subsample of participants will wear the MOVE III accelerometer for one week to objectively assess everyday physical activity and fill in an activity diary."
2950830|NCT02898233|Active Comparator|Deprexis and active LLLT|Participants will have access to Deprexis and will receive active low-level light therapy (4 days X 8 minutes of active LLLT)
2950831|NCT02898233|Sham Comparator|Deprexis and sham LLLT|Participants will have access to Deprexis and will receive sham low-level light therapy (4 days X 5 seconds of active LLLT and 55 seconds of sham LLLT)
2950832|NCT02898233|Other|Deprexis only|Participants will have access to Deprexis but will not receive real or sham LLLT
2950833|NCT02898207|Experimental|Treatment (olaparib and onalespib)|Patients receive olaparib PO BID on days 1-7 (course 0). Beginning in course 1, patients receive olaparib PO BID on days 1-28 and onalespib IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2950834|NCT02898181|Experimental|Tragus Stimulation|In this group patients will receive tragus stimulation for 8 hours per day during hospital stay.
2950835|NCT02898181|No Intervention|Control group|No tragus stimulation will be done
2950836|NCT02898168|Experimental|WA|
2950837|NCT02898168|Active Comparator|Control|
2950838|NCT02898142|Experimental|Isolated HTG without metabolic syndrome|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting.
2950839|NCT02898142|Experimental|HTG with metabolic syndrome|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting.
2950840|NCT02898129|Experimental|Tube houses|Tube Houses. Group of 75-100 houses, with 4 inhabitants per house. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
2950841|NCT02898129|Experimental|Apartment|Apartments. Group of 75-100 apartments, with 4 inhabitants per apartment. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
2950842|NCT02898129|Experimental|Rental Houses|Rental Houses. Group of 150-200 rental houses, with 2 inhabitants per rental house. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
2950843|NCT02898129|Experimental|Rural houses|Rural Houses. Group of 40-60 rural houses, with 5 inhabitant per rural house. Expected number of participants: 200-300. Predicted number of non-smoker chronic respiratory disease of 12-18.
2950844|NCT02898116|Experimental|Ensartinib ± Durvalumab|Subjects were to receive ensartinib monotherapy during a pre-immunotherapy Run-in Period for a single 28-day cycle, followed by combination therapy with ensartinib plus durvalumab for subjects with no DLTs during the Run-in Period.
2950845|NCT02898103|Experimental|Electrical current|electrical current will be introduced to the insulated percutaneous lead(s) for 5 minutes
2950846|NCT02898103|Placebo Comparator|Placebo|NO electrical current will be introduced to the insulated percutaneous lead(s) for 5 minutes
2951142|NCT02896361|Experimental|Stimulation order 1|"Stimulations delivered in following order:~Standard burst~Burst Microdosing 1~Burst Microdosing 2"
2950847|NCT02898077|Experimental|Ramucirumab + Paclitaxel|Ramucirumab intravenously (IV) on days 1 and 15 every 28-day cycle. Paclitaxel IV on days 1, 8, and 15 of every 28-day cycle. Participants will continue treatment until discontinuation criteria are met.
2950848|NCT02898077|Experimental|Placebo + Paclitaxel|Placebo IV on days 1 and 15 every 28-day cycle. Paclitaxel IV on days 1, 8, and 15 of every 28-day cycle. Participants will continue treatment until discontinuation criteria are met.
2950849|NCT02898064|Other|Standard care + brace|Spinal brace (thoracolumbosacral orthosis or cervico-thoraco-lumbar orthosis) to be fitted to the participant in addition to receiving standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
2950850|NCT02898064|Other|Standard care|Participant will receive standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
2950851|NCT02898051||Venous Thromboembolism and cancer|"Patients hospitalized for Venous Thromboembolism and having a cancer. Inclusion (as soon as the diagnosis of venous thromboembolism is confirmed). One tube of blood taken before the start of treatment (at the time of another blood sample) for determination of heparanase. After the start of treatment: three tubes of blood drawn for determination of anti-Xa activity.~Assays will be centrally performed, blinded from the clinical data and from the group knowledge of the group patient."
2950852|NCT02898051||Venous Thromboembolism and non cancer|"Patients hospitalized for Venous Thromboembolism and not having a cancer. Inclusion (as soon as the diagnosis of venous thromboembolism is confirmed). One tube of blood taken before the start of treatment (at the time of another blood sample) for determination of heparanase. After the start of treatment: 3 tubes of blood drawn for determination of anti-Xa activity.~Assays will be centrally performed, blinded from the clinical data and from the group knowledge of the group patient."
2950853|NCT02898038|Experimental|Experimental|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES PARIS for a period of 9 days.
2950854|NCT02898025|Active Comparator|G1 (Active IFC and Active Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G1) will receive the treatment of Active Interferential Current and Active Laser for 12 sessions.
2950855|NCT02898025|Active Comparator|G2 (Active IFC and Placebo Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G2) will receive the treatment of Active Interferential Current and Placebo Laser for 12 sessions.
2950856|NCT02898025|Active Comparator|G3 (Placebo IFC and Active Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G3) will receive Placebo Interferential Current and Active Laser for 12 sessions.
2950857|NCT02898025|Placebo Comparator|G4 (Placebo IFC and Placebo Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. The placebo group (G4) will receive Placebo Interferential Current and Placebo Laser for 12 sessions.
2950858|NCT02898012|Experimental|Temozolomide and Bevacizumab|Single experimental arm with two drugs : Temozolomide and Bevacizumab
2950859|NCT02897999|Experimental|SAD Cohort 1|Single dose of 0.05 mL QBKPN or Placebo
2950860|NCT02897999|Experimental|SAD Cohort 2|Single dose of 0.10 mL QBKPN or Placebo
2950861|NCT02897999|Experimental|SAD Cohort 3|Single dose of 0.20 mL QBKPN or Placebo
2950862|NCT02897999|Experimental|SAD Cohort 4|Single dose of 0.40 mL QBKPN or Placebo
2950863|NCT02897999|Experimental|SAD Cohort 5|Single dose of 0.80 mL QBKPN or Placebo
2950864|NCT02897999|Experimental|SAD Cohort 6|Single dose of 1.2 mL QBKPN or Placebo
2950865|NCT02897999|Experimental|MAD Cohort 1|5 doses of QBKPN or Placebo administered every other day (using one of the dose from the SAD Cohort)
2950866|NCT02897999|Experimental|MAD Cohort 2|5 doses of QBKPN or Placebo administered every other day (using one of the dose from the SAD Cohort)
2950867|NCT02897999|Experimental|MAD Cohort 3|5 doses of QBKPN or Placebo administered every day (using one of the dose from the SAD Cohort)
2950868|NCT02897999|Experimental|MAD Cohort 4|5 doses of QBKPN or Placebo administered every day (using one of the dose from the SAD Cohort)
2950869|NCT02897986|Experimental|patients with refractory/relapsing solid tumors|
2950870|NCT02897973||Transtibial lower limb amputation|unilateral amputation below knee resulting from traumatic injuries (with no upper-extremity amputations), evaluation took place at least 6 months post-injury, no assistive device use (e.g., canes, walkers, crutches), no other documented injuries, such as musculoskeletal impairments in the contralateral limb, neurologic disorder or traumatic brain injury that would affect gait and movement.
2950871|NCT02897973||Transfemoral lower limb amputation|unilateral amputation above knee resulting from traumatic injuries (with no upper-extremity amputations), evaluation took place at least 6 months post-injury, no assistive device use (e.g., canes, walkers, crutches), no other documented injuries, such as musculoskeletal impairments in the contralateral limb, neurologic disorder or traumatic brain injury that would affect gait and movement.
2950872|NCT02897973||Controls|Able-bodied individuals without amputation
2950873|NCT02897947||treated in Norway included in NORspine|patients having had surgery for lumbar spinal stenosis in Norway and are included in the national register NORspine
2950874|NCT02897947||treated in Sweden included in Swespine|patients having had surgery for lumbar spinal stenosis in Sweden and are included in the national register Swespine
2950875|NCT02897947||treated in Denmark included in Danespine|patients having had surgery for lumbar spinal stenosis in Denmark and are included in the national register DANEspine
2950876|NCT02897921||Carriers of recessive gene mutations of myopathies|"Patients with several different kinds of recessively inherited myopathy genes, such as for example Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, Limb Girdle limb girdle muscle dystrophy (LGMD) type 2A and 2L etc.~Investigated by blood sampling, Biodex 4 Isokinetic Dynamometer, MRI analysis, ECG, Holter monitoring, and echocardiography."
2951241|NCT02895646||Control|No specific clinical investigation for control subjects
2950878|NCT02897908||liver fibrosis and steatosis|measurements of liver fibrosis and steatosis will be obtained using Vibration controlled transient elastography FDA approved device- FibroScan for the purpose of building a data base of potential subjects for future research.
2950879|NCT02897895|Experimental|new strategy of immunosuppression monitoring|evaluation of calcineurin activity (CN-a) in combination with CNI blood levels
2950880|NCT02897895|Active Comparator|strategy of reference|CNI (inhibitor of Calcineurin) blood levels alone
2950881|NCT02897882|Experimental|Lung transplant|Pain evaluation
2950882|NCT02897869|Experimental|Treatment sequence 1|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, POL7080; Period 2, Amikacin; Period 3,POL7080+Amikacin. Each period is separated by a wash-out period of at least 12 days between last dose and start of next treatment.
2950883|NCT02897869|Experimental|Treatment sequence 2|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, Amikacin; Period 2, POL7080; Period 3,POL7080+Amikacin. Each period is separated by a wash-out period of at least 12 days between last dose and start of next treatment.
2950884|NCT02897856|Active Comparator|Buccal midazolam|Study subject will receive buccal midazolam and intramuscular placebo. The dose of buccal midazolam is 0.3 mg/kg
2950885|NCT02897856|Active Comparator|intramuscular midazolam|Study subject will receive intramuscular midazolam and buccal placebo. The dose of intramuscular midazolam is 0.25 mg/kg.
2950886|NCT02897843|Sham Comparator|sham tDCS|Sham tDCS sessions will last 20 minutes, but a real stimulus of 2 milliamps (mA) will be applied only during the first minute
2950887|NCT02897843|Experimental|tDCS|20 minute tDCS sessions
2950888|NCT02897830|Experimental|Study treatment|Ixazomib, Lenalidomide, Dexamethasone Induction and extended Consolidation followed by Lenalidomide Maintenance
2950889|NCT02897817||Oral to Injectable|Patients treated with oral MTX and requiring a switch to injectable MTX
2950890|NCT02897817||Injectable to Injectable|Patients treated with injectable MTX and eligible for a change in MTX injection device.
2950891|NCT02897804|Experimental|Knowledge alone|Participants will have access to the knowledge module for a period up to 3 weeks.
2950892|NCT02897804|Experimental|Self-efficacy alone|Participants will have access to the knowledge module plus the self-efficacy module for a period up to 3 weeks.
2950893|NCT02897804|Experimental|Perceived benefits alone|Participants will have access to the knowledge module plus the perceived benefits module for a period up to 3 weeks.
2950894|NCT02897804|Experimental|Benefits and self-efficacy|Participants will have access to the knowledge module plus the perceived benefits and self-efficacy modules for a period up to 3 weeks.
2950895|NCT02897804|Experimental|Injunctive norms alone|Participants will have access to the knowledge module plus the injunctive norms module for a period up to 3 weeks.
2950896|NCT02897804|Experimental|Injunctive norms and self-efficacy|Participants will have access to the knowledge module plus the injunctive norms and self-efficacy modules for a period up to 3 weeks.
2950897|NCT02897804|Experimental|Injunctive norms and perceived benefits|Participants will have access to the knowledge module plus the injunctive norms and perceived benefits modules for a period up to 3 weeks.
2950898|NCT02897804|Experimental|Injunctive norms, perceived benefits,self-efficacy|Participants will have access to the knowledge module plus the injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2950899|NCT02897804|Experimental|Descriptive norms alone|Participants will have access to the knowledge module plus the descriptive norms module for a period up to 3 weeks.
2950900|NCT02897804|Experimental|Descriptive norms and self-efficacy|Participants will have access to the knowledge module plus the descriptive norms and self-efficacy modules for a period up to 3 weeks.
2950901|NCT02897804|Experimental|Descriptive norms and perceived benefits|Participants will have access to the knowledge module plus the descriptive norms and perceived benefits modules for a period up to 3 weeks.
2950902|NCT02897804|Experimental|Descriptive norms,perceived benefits,self-efficacy|Participants will have access to the knowledge module plus the descriptive norms module for a period up to 3 weeks.
2950903|NCT02897804|Experimental|Descriptive norms and injunctive norms|Participants will have access to the knowledge module plus the descriptive norms and injunctive norms modules for a period up to 3 weeks.
2950904|NCT02897804|Experimental|Descriptive norms, injunctive norms,self-efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
2950905|NCT02897804|Experimental|Descriptive and injunctive norms, benefits|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
2950906|NCT02897804|Experimental|Descriptive and injunctive norms, benefits,efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2950907|NCT02897804|Experimental|Expectancies alone|Participants will have access to the knowledge module plus the expectancies module for a period up to 3 weeks.
2950908|NCT02897804|Experimental|Expectancies and self-efficacy|Participants will have access to the knowledge module plus the expectancies and self-efficacy modules for a period up to 3 weeks.
2950909|NCT02897804|Experimental|Expectancies and perceived benefits|Participants will have access to the knowledge module plus the expectancies and perceived benefits modules for a period up to 3 weeks.
2950910|NCT02897804|Experimental|Expectancies, perceived benefits, self-efficacy|Participants will have access to the knowledge module plus the expectancies, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2950911|NCT02897804|Experimental|Expectancies and injunctive norms|Participants will have access to the knowledge module plus the expectancies and injunctive norms modules for a period up to 3 weeks.
2950912|NCT02897804|Experimental|Expectancies, injunctive norms, and self-efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
2950913|NCT02897804|Experimental|Expectancies, injunctive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
2951242|NCT02895633|Experimental|Patients with bone or peripheral soft-tissue tumor|
2950914|NCT02897804|Experimental|Expectancies, injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2950915|NCT02897804|Experimental|Expectancies and descriptive norms|Participants will have access to the knowledge module plus the expectancies and descriptive norms modules for a period up to 3 weeks.
2950916|NCT02897804|Experimental|Expectancies, descriptive norms, and self-efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and self-efficacy modules for a period up to 3 weeks.
2950917|NCT02897804|Experimental|Expectancies, descriptive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and perceived benefits modules for a period up to 3 weeks.
2950918|NCT02897804|Experimental|Expectancies,descriptive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2950919|NCT02897804|Experimental|Expectancies, descriptive and injunctive norms|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and injunctive norms modules for a period up to 3 weeks.
2950920|NCT02897804|Experimental|Expectancies, descr& injun norms, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
2950921|NCT02897804|Experimental|Expectancies, desc & injun norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
2950922|NCT02897804|Experimental|Expectancies,desc & injun norms,benefits,efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2950923|NCT02897791|Experimental|Impaired Rt. Hemisphere patients|20 first stroke patients
2950924|NCT02897791|Experimental|control|20 healthy adults without any known damage to the right hemisphere. The two groups will be matched concerning sex, age, educational level and socio-economic status.
2950925|NCT02897778|Active Comparator|Entinostat|15 patients will be randomized to receive a single, supratherapeutic dose of entinostat
2950926|NCT02897778|Placebo Comparator|Placebo|15 patients will be randomized to receive a single dose of placebo
2950927|NCT02897765|Experimental|Drug: NEO-PV-01 + Nivolumab + Adjuvant|Nivolumab at a dose of 240 mg administered by intravenous (IV) infusion over 30 minutes every two weeks. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously (one vial of pooled peptides per injection site) in up to four distinct sites (each extremity or flanks) while continuing therapy with nivolumab.
2950928|NCT02897752|Experimental|WalkAide|
2950929|NCT02897752|Active Comparator|Usual gait Training|
2950930|NCT02897739||TTC Patients|Patients diagnosed with Tako-tsubo cardiomyopathy.
2950931|NCT02897739||Health Volunteers|Participants who have normal hearts.
2950932|NCT02897726|Experimental|NVP-1402|NVP-1402 was administered once a day for 24 hours
2950933|NCT02897726|Active Comparator|NVP-1402R|Active comparator was administered twice a day for 24 hours
2950934|NCT02897713|Experimental|intensive EN|Intensive enteral nutrition is to performed until discharge with max during of 7 days
2950935|NCT02897713|Active Comparator|routine EN|Routine enteral nutrition is to performed until discharge with max during of 7 days
2950936|NCT02897700|Experimental|Mono-chemotherapy|"A mono-chemotherapy (a single chemotherapeutic agent out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (or CDEFM) was performed 30~60 days prior to surgery for patients who had no history of receiving either local or systemic cancer-associated chemotherapy.~Interventions: cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate."
2950937|NCT02897700|Experimental|Combined chemotherapy|"Combined chemotherapy (random combination of two breast cancer chemotherapeutic agents including cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate, or CDEFM) was performed 30~60 days prior to surgery for patients who had no history of receiving either local or systemic chemotherapy for cancer.~Interventions: cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate."
2950938|NCT02897700|Placebo Comparator|Placebo treatment|No chemotherapeutic regimes using any cytotoxic agent was done for patients who have infiltrating ductal carcinoma of breast. Placebo was used instead.
2950939|NCT02897687|Experimental|Facebook Group|Social skills training within an online group.
2950940|NCT02897687|Active Comparator|Book Club Group|An in-person Book Club discussing material related to Autism Spectrum Disorder.
2950941|NCT02897674|Experimental|Normal weight|Participants will BMI 18.5-24.9 kg/m2 will consume 20% of their calories from one of the three dietary fats Intervention: palm olei Intervention: interesterified palm olein Intervention: soybean oil
2950942|NCT02897674|Experimental|Overweight|Participants will BMI 25-29.9 kg/m2 will consume 20% of their calories from one of the three dietary fats Intervention: palm olei Intervention: interesterified palm olein Intervention: soybean oil
2950943|NCT02897661|Experimental|MNZ plus Early FMT and EN|Metronidazole+EN (day-3~-1), FMT (day1), EN (day1-14)
2950944|NCT02897661|Experimental|MNZ plus late FMT and EN|Metronidazole+EN (day-3~-1), FMT (day8), EN (day1-14)
2950945|NCT02897661|Active Comparator|Early FMT plus EN|EN (day-3~-1), FMT (day1), EN (day1-14)
2950946|NCT02897635|Experimental|Integrative Medicine Intervention|Study participants will attend 14 visits with an integrative medicine clinician over the course of 6 months followed by a 6 month maintenance phase. The treatment modalities employed in the study will include nutrition and lifestyle recommendations.
2950947|NCT02897622|Other|Case management|Case management
2950948|NCT02897609||A simple questionary filled|
2950949|NCT02897596|Experimental|Genotype 1b|Grazoprevir 100 mg/d during 8 weeks. Elbasvir 50 mg/d during 8 weeks.
2950950|NCT02897596|Experimental|Genotype 1a and 4|Grazoprevir 100 mg/d during 12 weeks. Elbasvir 50 mg/d during 12 weeks.
2950984|NCT02897375|Experimental|Arm A (palbociclib, cisplatin)|Patients receive cisplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2950951|NCT02897583|Experimental|YAG vitreolysis|A Karickoff lens with goniosol will be used to perform the YAG vitreolysis. The number of shots will be determined at the discretion of the treating physician. A focus offset may be used at investigator discretion. Single shot mode will be used. The maximum energy per pulse will be 7 mJ. The endpoint of treatment is the vaporization of the Weiss ring into gas, as well as the disruption of it into smaller fragments as well as any other vitreous opacities deemed visually significant by the treating physician. Only one treatment session will be performed.
2950952|NCT02897583|Sham Comparator|Sham YAG vitreolysis|Sham laser treatment will be applied under the same procedure used for laser treatment but by turning the laser power down to 0.3 mJ and using a separate lens covered by a filter that absorbs the power, so no laser enters the eye.
2950953|NCT02897570|Active Comparator|Glucose|EEG_pre + Oral glucose tolerance test (50-g OGTT) + EEG_post
2950954|NCT02897570|Experimental|Milk + Cereals|EEG_pre + B1: milk (125ml) and cereals (30g) + EEG_post
2950955|NCT02897570|Experimental|Milk + Apple + Snack|EEG_pre + B2: milk (220ml), apple (200g) and cream chocolate filled sponge cake (30g) + EEG_post
2950956|NCT02897570|Experimental|Milk + Apple + Bread w/ cream|EEG_pre + B3: milk (125ml), apple (150g), and bread (50g) with hazelnut chocolate cream (15g) + EEG_post
2950957|NCT02897557|Experimental|Single Cohort in CRC|This study is a single-arm, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting.
2950958|NCT02897544|Experimental|Health Education Intervention|Study participants will attend Health Education sessions led by health educators over the course of 6 months. The emphasis in the sessions will be to provide engaging educational information on common survivorship issues.
2950959|NCT02897531|Active Comparator|ES anastomosis|Stapled end-to-side anastomosis
2950960|NCT02897531|Active Comparator|SS anastomosis|Stapled side-to-side anastomosis
2950961|NCT02897518|Experimental|endotracheal intubation with Imago V-blade|Patients in this arm will receive endotracheal intubation with the Imago V-Blade videolaryngoscopes.
2950962|NCT02897518|Active Comparator|endotracheal intubation with Glidescope|Patients in this arm will receive endotracheal intubation with the glidescope videolaryngoscopes.
2950963|NCT02897505|Experimental|Women enrolled in Empower Clinic|Women who are enrolled in the Empower Sanctuary will be asked to participate in a Music Workshop
2950964|NCT02897479|Experimental|Savolitinib|Pulmonary Sarcomatoid Carcinomas
2950965|NCT02897466|Experimental|Direct Antimicrobial Susceptibility Testing|"At day 0: Direct antibiotic susceptibility testing performed directly (DAST) on the respiratory sample At day 1: both results of isolated GNB identification using mass spectrometry and DAST will be given to the physician in charge in order to switch antimicrobial therapy to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems. Conventional antibiotic susceptibility testing (CAST) performed on isolated GNB.~At day 2-3: results of CAST will be given to the physician in charge in order to change antimicrobial therapy in case of differences between CAST and DAST (2nd switch to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems)"
2950966|NCT02897466|No Intervention|Conventional Antimicrobial Susceptibility Testing|"At day 1 identification of isolated GNB bacilli using mass spectrometry will be given to the physician in charge (usual care in ICU involved) to adapt antibiotic regimen. Conventional antibiotic susceptibility testing (CAST) performed on isolated GNB.~At day 2-3: results of CAST will be given to the physician in charge in order to switch antimicrobial therapy to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems."
2950967|NCT02897453|Experimental|The Spinal Tethering System group|Patients with adolescent idiopathic scoliosis that have been implanted with the Spinal Tethering System in an anterior vertebral body tethering construct.
2950968|NCT02897440||Full Repairing of soft tissue surrounding the hip|Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting
2950969|NCT02897440||Partial Repairing of soft tissue surrounding the hip|Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting
2950970|NCT02897427|Active Comparator|HPV E Antibody-Negative Group|During first study visit and then every 6 months for up to 5 years, participants screened for oropharyngeal cancer. Participants also screened for anal and penile cancer.
2950971|NCT02897427|Experimental|Pre-Screening for Human Papillomavirus (HPV)|Participants screened for human papillomavirus (HPV) .
2950972|NCT02897427|Experimental|HPV16 E Positive Group|During first study visit and then every 6 months for up to 5 years, participants screened for oropharyngeal cancer. Participants also screened for anal and penile cancer.
2950973|NCT02897414||Overall group of all ER/LA opioid excluding hydrocodone|
2950974|NCT02897414||Each type of opioid that has an ER/LA opioid formulation|
2950975|NCT02897414||Overall group that includes all prescription opioids except|
2950976|NCT02897414||Comparator Group taking benzodiazepines|
2950977|NCT02897414||Comparator Group taking IR hydrocodone|
2950978|NCT02897401|Experimental|Smocker|Cigarette consumption in the context of their habit (not related to the particiapion under study).
2950979|NCT02897401|Experimental|Electronic cigarette|Electronic cigarette consumption in the context of their habit (not related to the particiapion under study).
2950980|NCT02897401|Experimental|Nicotine replacement therapy|Nicotine replacement therapy (only patch) consumption in the context of their habit (not related to the particiapion under study).
2950981|NCT02897401|Placebo Comparator|Without nicotine|No consumption in the context of their habit (not related to the particiapion under study).
2950982|NCT02897388|No Intervention|Pre-intervention|all very low birth weight infants admitted to the NICU at Fudan University Children's Hospital from January 2015 through March 2015 (which is the period before any intervention started)who meet the enroll criteria
2950983|NCT02897388|Experimental|intervention|all very low birth weight infants admitted to the NICU at Fudan University Children's Hospital from April 2015 through June 2016 who meet the enroll criteria. A series of breast milk consume promotion interventions would implemented during this intervention period, which including build local lactation team, set breast milk feeding room, train NICU staff etc.
2951059|NCT02896868|Placebo Comparator|Placebo|Placebo administered IV once every two weeks over 6 weeks (four doses).
2950985|NCT02897375|Experimental|Arm B (palbociclib, carboplatin)|Patients receive carboplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2950986|NCT02897362||Adolescents with ADHD|Adolescents, male or female, ages 13-17, confirmed diagnosis of Attention Deficit Hyperactivity Disorder (inattentive, hyperactive/impulsive, or combined presentations), medically healthy, no comorbid psychiatric diagnosis other than ODD, intelligence within normal limits. Participants will complete 3 nights of ambulatory polysomnography at home and a neuropsychological assessment in the lab.
2950987|NCT02897362||Healthy Control Adolescents|Adolescents, male or female, ages 13-17, medically healthy, no psychiatric diagnoses, intelligence within normal limits. Participants will complete 3 nights of ambulatory polysomnography at home and a neuropsychological assessment in the lab.
2950988|NCT02897349|Experimental|linagliptin|
2950989|NCT02897349|Placebo Comparator|Placebo|
2950990|NCT02897336|Experimental|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
2950991|NCT02897336|Active Comparator|interlaminar|interlaminar epidural corticosteroid injection
2950992|NCT02897310||critically ill patients|critically ill patients with acute kidney failure requiring renal replacement therapy
2950993|NCT02897284|Experimental|Mindfulness 8 weeks|Mindfulness-based intervention with 8 weekly sessions
2950994|NCT02897284|Active Comparator|Mindfulness 2 weeks|Mindfulness-based intervention with 2 weekly sessions
2950995|NCT02897284|No Intervention|Control|waiting list
2950996|NCT02897258||Without anticoagulant/antiplatelet|
2950997|NCT02897258||Treated with antiplatelet only|
2950998|NCT02897258||Treated with anticoagulant only|
2950999|NCT02897258||With antiplatelet/anticoagulant|
2951000|NCT02897245||Patient with intentionally stop|
2951001|NCT02897232||Community Group Survey|Community members coming into the University Health Shreveport Ambulatory Care Facility.
2951002|NCT02897232||Physician Group Survey|Physicians affiliated with LSU Health Shreveport School of Medicine
2951003|NCT02897219|Experimental|Part 1 ASP1941|ASP1941 will be administered for 24 weeks under double blind conditions.
2951004|NCT02897219|Placebo Comparator|Part 1 Placebo|Placebo will be administered for 24 weeks under double blind conditions.
2951005|NCT02897219|Experimental|Part 2 ASP1941|ASP1941 will be administered for 28 weeks under open label conditions.
2951006|NCT02897206|Experimental|Imipenem group|Imipenem 3 x 500 mg i.v. daily ideally for 10 days (minimum 7 days, maximum 21 days)
2951007|NCT02897206|Placebo Comparator|Placebo group|Identical placebo administered in identical dosage, timing and duration.
2951008|NCT02897193|Active Comparator|Dental implant with bone augmentation|patients will be installed with ICE Dental implant 4.2 mm diameter with Alpha-Bio's grafts horizontal bone augmentation
2951009|NCT02897193|Experimental|narrow implant|patients will be installed with NICE Dental implant 3.2 mm diameter
2951010|NCT02897180|Placebo Comparator|Placebo|Subjects will receive a total of 14 capsules with Placebo
2951011|NCT02897180|Experimental|Nyaditum resae(R)|Subjects will receive a total of 14 capsules with Nyaditum resae(R)
2951012|NCT02897167||PAFIP patients (1)|"Individuals included in the First Episode Psychosis Clinical Program (PAFIP) between June 2011 and February 2016.~Retrospective study of frozen samples: samples at baseline and 3 months will be analyzed."
2951013|NCT02897167||PAFIP patients (2)|"Individuals included in the First Episode Psychosis Clinical Program (PAFIP) between September 2016 and September 2017.~Prospective study of fresh samples: samples at baseline and 3 months will be analyzed."
2951014|NCT02897167||Controls|Healthy subjects without psychotic disorder.
2951015|NCT02897141|Experimental|mVIP group|This group will receive targeted symptom strategies from the UCSF symptom management manual based on the symptoms that they report.
2951016|NCT02897141|Placebo Comparator|Attention Control Group|This group will have the My Fitness Pal app, an app without symptom strategies, pre-loaded on their smartphones.
2951017|NCT02897115|Experimental|Target to Treat (T2T)|Depending on their disease activity, participants' basic NSAID therapy (at full recommended dose) will be changed after 4 weeks to another NSAID at its full recommended dose. After another 4 weeks, if applicable based on their disease activity, participants will receive Adalimumab in combination with their NSAID therapy.
2951018|NCT02897115|Other|Standard of Care (SOC)|Participants will receive treatment as prescribed by their physicians.
2951019|NCT02897102|Active Comparator|Control group|The individuals in the control group chose to participate in different group activities: ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants). The activities were offered once per week in 2 hours classes for 35 weeks and were held between April and November of 2013.
2951020|NCT02897102|Experimental|Training group|was offered in one weekly class for 2 hours for 35 weeks between April and November of 2013. The first 50 minutes were spent performing exercises with the abacus, with increasing difficulty. One or two of the following activities followed the abacus training: playing games, neurobic and group dynamics.
2951021|NCT02897089|No Intervention|acid-etch|Acid etch+fissure sealant
2951022|NCT02897089|Other|All Bond universal adhesive|Acid etch+ All Bond universal adhesive agent+fissure sealant
2951023|NCT02897089|Other|All Bond universal|All Bond universal adhesive agent+fissure sealant
2951024|NCT02897089|Other|Scotchbond universal adhesive|Acid etch+ Scotchbond universal adhesive agent+fissure sealant
2951025|NCT02897089|Other|Scotchbond universal|Scotchbond universal adhesive agent+fissure sealant
2951026|NCT02897089|Other|Clearfil universal adhesive|Acid etch+ Clearfil universal adhesive agent+fissure sealant
2951027|NCT02897089|Other|Clearfil universal|Clearfil universal adhesive agent+fissure sealant
2951028|NCT02897089|Other|Total-etch Dental Adhesive|Acid etch+ Single Bond adhesive agent+fissure sealant
2951060|NCT02896855|Active Comparator|Arm A: Placebo + Trastuzumab + Docetaxel|Placebo matched to pertuzumab, trastuzumab (8-milligrams per kilogram [mg/kg] loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-milligrams per square meter [mg/m^2]), administered by intravenous (IV) infusion every 3 weeks until disease progression or unacceptable toxicity.
2951029|NCT02897076|Active Comparator|12mg betamethasone+12mg betamethasone|"A betamethasone course consists in 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg.~In the BETADOSE trial, the first injection will be unmasked in both groups. In both groups, women will received a first 12 mg injection of betamethasone according to local protocols.~Randomization will be performed after the first injection. Women will then received either a blinded placebo injection (50% reduced dose regimen, 12 mg only from the first injection) or a second blinded 12 mg betamethasone injection (standard full dose regimen, 12 mg from the first injection and 12 mg from the second injection=24 mg)."
2951030|NCT02897076|Placebo Comparator|12 mg betamethasone+ placebo|"A betamethasone course consists in 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg.~In the BETADOSE trial, the first injection will be unmasked in both groups. In both groups, women will received a first 12 mg injection of betamethasone according to local protocols.~Randomization will be performed after the first injection. Women will then received either a blinded placebo injection (50% reduced dose regimen, 12 mg only from the first injection) or a second blinded 12 mg betamethasone injection (standard full dose regimen, 12 mg from the first injection and 12 mg from the second injection=24 mg)."
2951031|NCT02897063|Experimental|Droxidopa and Placebo|Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of either droxidopa 300 mg or placebo after the first tilt table test, followed two hours later by a single oral dose of placebo.
2951032|NCT02897063|Experimental|Midodrine and Placebo|Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of placebo after the first tilt table test, followed two hours later by a single oral dose of either midodrine 10 mg or placebo.
2951033|NCT02897050|Experimental|T+mCX followed by FEC|Docetaxel 75mg/m2, iv, d1 + CTX 50 mg/d, po, d1-d21 + capecitabine 1200mg/m2/d, po, d1-d21 * 3 cycles (21 days per cycle) followed by fluorouracil 500mg/m2,iv,d1 + epirubicin 100mg/m2,iv,d1 + cyclophosphamide 500mg/m2,iv,d1 * 3 cycles (21 days per cycle)
2951034|NCT02897050|Active Comparator|T followed by FEC|Docetaxel 100mg/m2, iv, d1 * 3 cycles (21 days per cycle) followed by fluorouracil 500mg/m2,iv,d1 + epirubicin 100mg/m2,iv,d1 + cyclophosphamide 500mg/m2,iv,d1 * 3 cycles (21 days per cycle)
2951035|NCT02897037|Experimental|Bivalirudin|Bivalirudin will be started in the cath lab, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; if ACT<225s 5min after bolus, an additional dose of 0.3mg/kg bolus should be given. After procedure, a prolonged infusion (1.75mg/kg per h) will be given for at least 30 min (totally no more than 4 h) followed by a reduced dose infusion (0.2mg/kg per h) up to 20 h.
2951036|NCT02897037|Active Comparator|Heparin monotherapy|100 IU/kg intravenous bolus. If ACT <225s 5 min after bolus injection, additional dose of heparin (20U/kg) will be given.
2951037|NCT02897024|Active Comparator|Usual weekly|Usual weekly therapy is 1 hours of therapy one day per week for 40 weeks.
2951038|NCT02897024|Experimental|High intensity periodic|High intensity periodic is 2 hours of therapy 5 days a week for 2 weeks, followed by an 18 week break, followed by another bout of high intensity therapy for 2 hours of therapy every weekday for two 10-consecutive-weekdays, followed by another 18 week break from therapy.
2951039|NCT02897011|Sham Comparator|Group 1: MTX continue|Group will continue MTX after vaccination
2951040|NCT02897011|Experimental|Group 2: MTX hold|will hold MTX for 2 weeks after vaccination
2951041|NCT02896998|Other|Control group|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
2951042|NCT02896998|Experimental|Intervention|The syndesmotic screw will only be removed in case of symptomatic implants (e.g. implants causing pain or restricted range of motion)
2951043|NCT02896985||Participants with Crohn's disease|Participants who have developed LOR to adalimumab after a minimum of 16 weeks of treatment.
2951044|NCT02896972|Active Comparator|Inverted ILM flap group|Eyes underwent vitrectomy with inverted internal limiting membrane technique
2951045|NCT02896972|Active Comparator|ILM peeling group|Eyes underwent vitrectomy with internal limiting membrane peeling
2951046|NCT02896959|Experimental|25mmHg pressure|Pump pressure of 25mmHg during rotator cuff repair
2951047|NCT02896959|Experimental|45mmHg pressure|Pump pressure of 45mmHg during rotator cuff repair
2951048|NCT02896959|Experimental|65mmHg pressure|Pump pressure of 65mmHg during rotator cuff repair
2951049|NCT02896946|Experimental|diffusion-weighted nuclear magnetic resonance imaging|detection of liver metastasis on diffusion-weighted nuclear magnetic resonance imaging in patients with potentially resectable pancreatic adenocarcinoma
2951050|NCT02896933||patients with multiple sclerosis|recruited in a former study
2951051|NCT02896933||healthy control subjects|
2951052|NCT02896920||Participants receiving adalimumab/ Humira®|Participants with HS for whom a change in treatment to Humira® is made by the treating physician
2951053|NCT02896907|Experimental|Treatment (FOLFIRINOX, ascorbic acid)|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1. Patients then receive ascorbic acid IV over 2 hours on days 3, 5, 8, 10 and 12. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2951054|NCT02896894|Experimental|Immediate Treatment Group|The Immediate Treatment Group will receive access to the study intervention - the Big White Wall, immediately after consenting for a total duration of 3 months.
2951055|NCT02896894|Other|Delayed Treatment Group|The Delayed Treatment Group will have no access to the study intervention - the Big White Wall for the first 3 months, then receive access to the BWW for 3 consecutive months.
2951056|NCT02896894|Experimental|Immediate Treatment Group - Extension|Immediate Treatment Group participants who opt in to the nested study and are randomized to the The Immediate Treatment Group - Extension, will receive access to the Big White Wall for an additional 3 months (months 4-6), immediately after receiving the initial 3 months of access.
2951057|NCT02896894|No Intervention|Immediate Treatment Group - No Extension|Immediate Treatment Group participants who opt in to the nested study and are randomized to The Immediate Treatment Group - No extension, will not receive extended access to the Big White Wall.
2951058|NCT02896868|Experimental|LY3041658|LY3041658 administered intravenously (IV) once every two weeks over 6 weeks (four doses).
2951061|NCT02896855|Experimental|Arm B: Pertuzumab + Trastuzumab + Docetaxel|Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles), trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-mg/m^2), administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
2951062|NCT02896842|No Intervention|Control Arm|cohort 3: Imatinib through dosage ≥ 1000 ng/ml
2951063|NCT02896842|Active Comparator|Active comparator|Cohort 2 : Imatinib standard dose Imatinib through dosage < 1000 ng/ml
2951064|NCT02896842|Experimental|Experimental arm|Cohort 1 : dose adjustment based on trough plasmatic level value Imatinib through dosage < 1000 ng/ml
2951065|NCT02896829||Imatinib treatment ending|Interruption of the treatment by Imatinib
2951066|NCT02896816|Experimental|Parkinson's subjects|"The participants with Parkinson's disease should have symptoms only on one side of the body, and they should not be taking any dopamine replacement medication such as levodopa or dopamine agonists.~Surface EMG, MRI and PET scan will be performed at baseline."
2951067|NCT02896816|Active Comparator|Control subjects|Participants not affected by neurological disorders. Surface EMG will be performed at baseline.
2951068|NCT02896803|Experimental|Experimental|mFLOX
2951069|NCT02896790||Stage 1|Patients without therapeutic education
2951070|NCT02896790||Stage 2|Patients with therapeutic education
2951071|NCT02896777|Experimental|Transfer embryos from 7.20±0.02 pH|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.2±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
2951072|NCT02896777|Experimental|Transfer embryos from 7.27±0.02 pH|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.27±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
2951073|NCT02896777|Experimental|Transfer embryo from 7.34±0.02|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.34±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
2951074|NCT02896764|Experimental|Eligible patients for cone-beam CT|A cone-beam CT will be offered to the patient undergoing a CT scan of the middle ear
2951075|NCT02896751|Experimental|3D Printed NIV Mask|3D imaging and use of a custom mask from 3D printer
2951076|NCT02896725|Experimental|Keratin dressings|Wool-derived keratin matrix dressing applied with each change of the compression bandage until healing
2951077|NCT02896725|Active Comparator|Usual care dressings|Dressing chosen from study centres' formulary of non-medicated moist wound dressings applied with each change of the compression bandage until healing
2951078|NCT02896712|Active Comparator|ACT plus CM|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered to help decrease experiential avoidance while increasing acceptance and willingness to experience unpleasant thoughts, feelings, and physical symptoms.
2951079|NCT02896712|Active Comparator|ACT plus CM, with Placebo|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered and augmented with a placebo capsule during Phase 2 (weeks 5-12).
2951080|NCT02896712|Experimental|ACT plus CM, with Modafinil|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered and augmented with a Modafinil (300mg) capsule during Phase 2 (weeks 5-12).
2951081|NCT02896712|Active Comparator|DC plus CM|Drug Counseling and Contingency Management for cocaine use will be administered to help educate patients about important concepts in addiction recovery.
2951082|NCT02896712|Active Comparator|DC plus CM, with Placebo|Drug Counseling and Contingency Management for cocaine use will be administered and augmented with a placebo capsule during Phase 2 (weeks 5-12).
2951083|NCT02896712|Experimental|DC plus CM, with Modafinil|Drug Counseling and Contingency Management for cocaine use will be administered and augmented with a Modafinil (300mg) capsule during Phase 2 (weeks 5-12).
2951084|NCT02896699|Experimental|PrEP Intervention Group|Group training session including HIV Education, PrEP Education, Following the training session Booster phone calls HIv and syphillis testing
2951085|NCT02896699|Active Comparator|Control Group|Group HIV risk vignettes
2951086|NCT02896686|Active Comparator|Control|Abdominal wall closure will be done by continuous polydioxanone (PDS) suture following a SL:WL ratio of 4:1, and the skin will be closed using a subcutaneous purse-string closure
2951087|NCT02896686|Experimental|Reinforcement with Mesh|"Abdominal wall closure will be done by continous polydioxanone (PDS) suture following a SL:WL ratio of 4:1.~The incision is reinforced with onlay placement of a light polypropylene mesh (3 cm wide and the length corresponding to the incision), fixed to the aponeurosis with interrupted polyglactin (Vycril) suture.~The skin will be closed using a subcutaneous purse-string closure"
2951088|NCT02896673|Experimental|ventilatory conditions and measures with scanner and EIT|"The patient is installed on the scanner bed, EIT electrodes are connected to the acquisition device of the EIT signal.~Esophageal pressure signals, pressure and flow in the airways will be acquired continuously"
2951089|NCT02896660|Experimental|ActiGraph Link|Study participants will wear an actigraphy device, the ActiGraph Link, continuously for 90 days
2951090|NCT02896634||group with inflammation|Selection of samples from biobank with groups with inflammation
2951091|NCT02896634||group with denutrition|Selection of samples from biobank with groups with denutrition
2951092|NCT02896634||group with none|Selection of samples from biobank with groups with none
2951093|NCT02896634||group with both|Selection of samples from biobank with groups with both.
2951094|NCT02896621|Experimental|Chlorthalidone plus amiloride|"Chlorthalidone plus amiloride group received 25 mg of chlortalidone and amiloride, 5 mg.~A capsule with both drugs was taken once daily in the morning for eight weeks."
2951095|NCT02896621|Active Comparator|Amlodipine|Amlodipine group received 10 mg. A capsule was taken once daily in the morning for eight weeks. Capsules of amlodipine had identical presentation of that the intervention drug.
2951096|NCT02896608||Dravet syndrome - HCN1 channel mutation|early infantile epileptic encephalopathy with HCN1 channel mutation
2951097|NCT02896608||control with epilepsy|
2951099|NCT02896595|Active Comparator|General Anesthesia with endotracheal tube|Patients assigned to the ETT tube group will have ETT placed in the safest manner deemed appropriate by attending anesthesiologist. Possible ways to have ETT placed will be using direct laryngoscopy, glidescope or fiberoptic intubations. Size of ETT will be decided based on patient characteristics and discretion of attending anesthesiologist. Once placed, auscultation and capnography will be used to ensure correct placement of ETT.
2951100|NCT02896595|Active Comparator|General Anesthesia with laryngeal mask airway|Patients assigned to the LMA group will have LMA placed in a standard fashion by anesthesia provider. LMA size will be decided based on patient characteristics and at the discretion of attending anesthesiologist. LMA used will be LMA Supreme (Teleflex Medicals, Ireland). Once placed auscultation will be used to ensure correct placement of LMA.
2951101|NCT02896582|Experimental|Induction - ASCT - maintenance|Induction : 4 cycles of GA-DHAP every 21 days - Conditioning regimen and ASCT: GA-BEAM + Autologous transplantation - Maintenance : Obinutuzumab every 2 months for 3 years then every month for patients with positive MRD
2951102|NCT02896569|Experimental|Topical combination therapy|Application of human bone marrow stem cell derived growth factor and cytokines serum followed by a botanical lipid-based occlusive immediately post-radio-frequency treatment of the face
2951103|NCT02896569|No Intervention|Standard of care|No topical therapies for 24 hours post-radio-frequency treatment of the face
2951104|NCT02896556|Experimental|Resin infiltrate|This is a single-arm study. Resin infiltration technique will be performed to all patients.
2951105|NCT02896543||STEMI group|The study population consists of 30 patients with ST-elevated acute myocardial infarction (STEMI,n = 30) who are admitted within 24 hours after chest pain attacks. They will all undergo coronary angiography.The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had obvious blood system diseases,severe liver dysfunction, severe renal insufficiency,severe heart failure (NYHA class 3 and 4), acute or chronic infectious diseases, disease of immune system, asthma, malignant tumor, other advanced disease are excluded.
2951106|NCT02896543||Control group|15 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are enrolled as Control group.
2951107|NCT02896504||Chemotherapy|Breast Cancer patients undergoing conventional postsurgical adjuvant chemotherapy treatment
2951108|NCT02896504||Hormonal Therapy|Breast Cancer patients undergoing conventional postsurgical adjuvant hormonal therapy treatment (with no Chemotherapy)
2951109|NCT02896504||Healthy Control|Healthy age, height and body-mass matched healthy controls
2951110|NCT02896491|Experimental|GSM 900 MHz exposure|Radiation: Exposure with non-ionizing electromagnetic fields exposure with GSM 900 MHz (2W/kg)
2951111|NCT02896491|Experimental|TETRA 400 MHz exposure|"Radiation: Exposure with non-ionizing electromagnetic fields:~exposure with TETRA (6W/kg)"
2951112|NCT02896491|Sham Comparator|Sham exposure|Radiation: Exposure with non-ionizing electromagnetic fields: exposure with 0 W/kg
2951113|NCT02896465|Active Comparator|ORS+ZINC|Oral rehydration solution + Zinc
2951114|NCT02896465|Experimental|ORS+ZINC+HMO|Oral rehydration solution + Zinc + Human milk oligosaccharides
2951115|NCT02896465|Placebo Comparator|ORS+ZINC+Breastfeeding|Oral rehydration solution + Zinc + Breastfeeding
2951116|NCT02896452||Women diagnosed with PCOS without IIH|Women diagnosed with polycystic ovary syndrome without idiopathic intracranial hypertension
2951117|NCT02896452||Women diagnosed with PCOS and IIH|Women diagnosed with polycystic ovary syndrome and idiopathic intracranial hypertension
2951118|NCT02896452||Women diagnosed with IIH without PCOS|Women diagnosed with idiopathic intracranial hypertension without polycystic ovary syndrome
2951119|NCT02896452||Women without PCOS or IIH|Women age and body mass index match controls without polycystic ovary syndrome or intracranial hypertension
2951120|NCT02896426|Experimental|Collaborative Problem Solving|Participants will attend parent group sessions led by trained group leaders and learn the Collaborative Problem Solving approach.
2951121|NCT02896426|Active Comparator|Positive Solutions For Families|Participants will attend parent group sessions and learn the Positive Solutions for Families approach, a group that is usually offered by Head Start.
2951122|NCT02896413|Experimental|Dexmedetomidine Group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
2951123|NCT02896413|Placebo Comparator|Control Group|0.9% saline infusion
2951124|NCT02896400|Experimental|BNI+NRT+QL+Text|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
2951125|NCT02896400|Experimental|BNI+NRT+QL|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
2951126|NCT02896400|Experimental|BNI+NRT+Text|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
2951127|NCT02896400|Experimental|BNI+NRT|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
2951128|NCT02896400|Experimental|BNI+QL+Text|Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
2951129|NCT02896400|Experimental|BNI+QL|Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL)
2951130|NCT02896400|Experimental|BNI+Text|Brief Negotiated Interview (BNI) Registration in SmokefreeText (Text)
2951131|NCT02896400|Experimental|BNI only|Brief Negotiated Interview (BNI)
2951132|NCT02896400|Experimental|NRT+QL+Text|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
2951133|NCT02896400|Experimental|NRT+QL|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
2951134|NCT02896400|Experimental|NRT+Text|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
2951135|NCT02896400|Experimental|NRT only|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
2951136|NCT02896400|Experimental|QL+Text|Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
2951137|NCT02896400|Experimental|QL only|Referral to CT Smokers Quitline (QL)
2951138|NCT02896400|Experimental|Text only|Registration in SmokefreeText (Text)
2951143|NCT02896361|Experimental|Stimulation order 2|"Stimulations delivered in following order:~Burst Microdosing 1~Burst Microdosing 2~Standard burst"
2951144|NCT02896361|Experimental|Stimulation order 3|"Stimulations delivered in following order:~Burst Microdosing 2~Standard burst~Burst Microdosing 1"
2951145|NCT02896348|Experimental|SynPhNe therapy|"Subjects will be asked to participate in a program of 6 upper-extremity rehabilitation sessions of 60 minutes with SynPhNe platform under therapist supervision over two weeks at the MAL. The sessions will emphasize on the wrist and fingers movements, including functional activities.~The remaining 12 sessions will be done unsupervised at home, over approximately 4 weeks, and following exercises from SynPhNe platform."
2951146|NCT02896348|Active Comparator|Conventional therapy|"Subjects will be asked to participate in a program of 6 upper-extremity rehabilitation sessions of 60 minutes under therapist supervision over two weeks at the MAL. The sessions will emphasize on the wrist and fingers movements, including functional activities.~The remaining 12 sessions will be done unsupervised at home, over approximately 4 weeks, and following the therapist home treatment plan."
2951147|NCT02896335|Experimental|Palbociclib|"Description Patients who fulfill eligibility criteria will be entered into the trial to receive Palbociclib~After the screening procedures confirm participation in the research study:~Palbociclib- Fixed Dose, daily for 21 days per cycle.~The participant will be requested to maintain a medication diary of each dose of medication. The medication diary will be returned to clinic staff at the end of each cycle."
2951148|NCT02896322|Experimental|Cyberknife|APBI with cyberknife after breast conserving surgery in breast cancer
2951149|NCT02896309|Experimental|Sodium bicarbonate|Oral sodium bicarbonate tablets three times daily 1000mg
2951150|NCT02896309|Active Comparator|Sodium chloride|Oral sodium chloride capsules two times daily 1000mg
2951151|NCT02896309|No Intervention|No treatment|No treatment
2951152|NCT02896296|Experimental|Low Dose RBP-6000|Subjects completing EOS visit of the RB-US-13-0003 study will receive low dose RBP-6000 for up to 6 monthly injections. At each visit, safety assessments will be completed as defined above. Alternative treatment options should be assessed at least 2 months prior to EOS.
2951153|NCT02896296|Experimental|High Dose RBP-6000|Subjects completing EOS visit of the RB-US-13-0003 study will receive high dose RBP-6000 for up to 6 monthly injections. At each visit, safety assessments will be completed as defined above. Alternative treatment options should be assessed at least 2 months prior to EOS.
2951154|NCT02896283|Experimental|low-level laser therapy|Low-level laser (Diode, 66o nanometer, power:200 milli Watt (mW), Continuous wave, time of irradiation:32 seconds)is irradiated in donor site
2951155|NCT02896283|Placebo Comparator|Turned-off laser|The same protocol is applied in te donor site, unless the laser is remained off.
2951156|NCT02896270|Experimental|single arm|"Patients will start study treatment on Day1 and will be treated with a dose of 250mg twice daily of the valproic acid slow release formulation (Depakine Chrono© - Sanofi Pharma Belgium).~Control of valproic acid serum levels after 4 to 7 days. The dose will be progressively increased targeting valproic acid serum levels in the target range for use of the drug as an anti-epileptic (50-100µg/ml).~During the study, visits will be performed every month and at the end of treatment. The duration of the study is 12 months. Continuation of valproic acid after completion of the study will be at the investigators discretion."
2951157|NCT02896257|Other|Proactive patient-tailored electronic consult (E-consult)|Primary care clinicians receive patient-tailored guideline concordant treatment recommendations, including orders and rationale to discontinue inhaled corticosteroids.
2951158|NCT02896257|No Intervention|usual care|Standard practice (usual care). Primary care providers treat their patients as usual.
2951159|NCT02896231|Experimental|PLB1001|There are 5 dose cohorts, including 50mg BID, 100mg BID, 150mg BID, 200mg BID and 275mg BID in the dose escalation stage and PLB1001 will be administered orally to patients twice daily for each dose cohort.
2951160|NCT02896218||Pharmacist consulting group|When physicians make the decision that patients need to prescribe vancomycin or need dose adjustment, they will call for a pharmacist consultation. Pharmacists will provide the initial regimen based on PPK methods if applicable, otherwise give the suggestion of the initial dosage according to guidelines. Also, pharmacists will give suggestions on the time of sampling for serum concentration measurement. For dosage adjustment, pharmacists will be informed the results of serum vancomycin concentration, and then make a calculation using Bayesian estimation to determine whether there is a necessity to change the dosing regimen. Pharmacists will follow the patients until they discharge.
2951161|NCT02896218||Usual care group|Empirical use of vancomycin without pharmacists consultation.
2951162|NCT02896205|Experimental|Mycophenolate mofetil|Subjects will be started on Mycophenolate Mofetil 500mg twice a day and increased by 500mg every 2 weeks, if tolerated, to a target dose of 2gram per day.
2951163|NCT02896205|Placebo Comparator|Placebo|Subjects in this arm will be given matching placebo, made of lactulose, starting at two tablets per day and increased by one tablet every 2 weeks to a target of 4 tablets per day.
2951164|NCT02896192|Experimental|Setmelanotide|Setmelanotide subcutaneous injection once daily
2951165|NCT02896192|Placebo Comparator|Placebo|Placebo subcutaneous injection once daily
2951166|NCT02896179|Experimental|Robot-assisted gait training group+VR|The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
2951167|NCT02896179|Active Comparator|Robot-assisted gait training group|The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
2951168|NCT02896166|Experimental|microwave ablation|The procedure is performed similar to a needle biopsy of the lung, under CT guidance. Placement of the needle-electrode is similar to needle placement for CT-guided biopsy. Appropriate positioning of the microwave ablation antenna is confirmed by CT imaging.
2951169|NCT02896153||Adult population going to a pharmacy|Adult population going to a pharmacy will be asked to complete a questionnaire.
2951170|NCT02896140||Type 2 diabetes in WhyWAIT Program|Patients with type 2 diabetes who are participating in Joslin Diabetes Center's 12-week intensive diabetes weight management program (WhyWAIT).
2951171|NCT02896127|Experimental|Secukinumab|Secukinumab 150 mg s.c.
2951172|NCT02896127|Placebo Comparator|Placebo|Placebo s.c.
2951173|NCT02896101|Experimental|Pimecrolimus Cream, 1%|Pimecrolimus Cream, 1 % (Glenmark Pharmaceuticals Ltd) topical application
2951174|NCT02896101|Active Comparator|Elidel®|Elidel® (Valeant Pharmaceuticals North America LLC) topical application
2951175|NCT02896101|Placebo Comparator|Placebo|Placebo of Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) topical application
2951176|NCT02896075|Experimental|Leg with Delayed Onset Muscle Soreness|young healthy people with delayed onset muscle soreness in either the right or left leg will go through the 30 Minute Comedy Video and the 30 Minute Documentary Video.
2951177|NCT02896075|Sham Comparator|Leg w/o Delayed Onset Muscle Soreness|young healthy people with delayed onset muscle soreness with no soreness in the right or left leg will go through the 30 Minute Comedy Video and the 30 Minute Documentary Video.
2951178|NCT02896062|Experimental|Treatment group|In the treatment phase subjects receive a sleep-coaching
2951179|NCT02896062|Active Comparator|Waiting group control|The waiting group receives the treatment after a waiting period of up to 6 weeks
2951180|NCT02896049||Hyperthermia|treatment with the Celsius42 Hyperthermia System
2951181|NCT02896036|Experimental|Veress needle entry with concomitant CO2|For the group of participants who will be randomized to concomitant CO2 insufflation; the Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle. If the opening pressure is less than or equal to 10 mmHg, the process of insufflation will be allowed to continue. In case of a higher opening pressure, the veress will be withdrawn and reinserted up to 3 times. A failed entry will be called if the peritoneal cavity cannot be insufflated after 3 attempts.
2951182|NCT02896036|Active Comparator|Veress needle entry with subsequent CO2|For the other group of participants who will be randomized to subsequent CO2 insufflation; the Veress needle will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by insertion of the Veress needle. The gas insufflation will be started and the opening pressure will be noted. If the opening pressure is less than or equal to 10 mmHg, the process of insufflation will be allowed to continue. In case of a higher opening pressure, the Veress needle will be withdrawn and reinserted up to 3 times. Each time the needle is to reinserted, the CO2 insufflator will be switched off until the location of the Veress needle is felt to be adequate.
2951183|NCT02896023|Active Comparator|pregnant|women with positive pregnancy test after induction of ovulation and ICSI
2951184|NCT02896023|Active Comparator|Not pregnant|women with negative pregnancy test after induction of ovulation and ICSI
2951185|NCT02896010|Active Comparator|Sweetch App + DBWS|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app plus weight monitoring via digital body weight scale (DBWS).
2951186|NCT02896010|Active Comparator|Sweetch App Alone|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app alone.
2951187|NCT02895997|Experimental|Clinical Operations Room Staff|Clinicians and critical care nurse volunteers from the clinical operations room (COR) staff at Emory University Hospital will travel to Sydney Australia to deliver telemedicine.
2951188|NCT02895984|Experimental|Brief Motivational Intervention (BMI)|The intervention recipients in the BMI group will receive a 1-hour single-session alcohol intervention (BMI) with personalized normative feedback.
2951189|NCT02895984|No Intervention|Natural History Control (NHC)|Students in the NHC group will receive no contact.
2951190|NCT02895958|Other|Administration of Zepatier|
2951191|NCT02895945|Experimental|BAX802 in Surgery|Participants who are undergoing major or minor elective surgical, dental, or other invasive procedures.
2951192|NCT02895932|Experimental|Case|Patients with diagnosed Parkinson's disease
2951193|NCT02895932|Experimental|Control|Healthy adults
2951194|NCT02895919||Control group - blood culture bottles|Standard of care group for control - will inoculate all samples in blood culture bottles for ascitic fluid culture
2951195|NCT02895919||Study group - sample to lab for culture|Study group - will send a sample of ascitic fluid to lab for inoculation in addition to control sample
2951196|NCT02895906|Experimental|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as capsules for oral administration.
2951197|NCT02895893|Experimental|Smartphone app condition|"Men who are at risk for HIV and already prescribed and taking Truvada will be asked to use an application on their smart phones called PrEP Smart."
2951198|NCT02895880||usual care|first 25 participants will receive usual care (i.e. no risk communication tool)
2951199|NCT02895880||risk communication tool|next 25 participants, clinicians will use the risk communication tool in their discussion about statins and cardiovascular risk reduction
2951200|NCT02895867|Experimental|Full fat dairy group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietitian and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
2951201|NCT02895867|Experimental|Low fat dairy group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietitian and will be instructed to include at least ≥3 servings of low fat dairy products into their diet
2951202|NCT02895867|Other|Control group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
2951203|NCT02895854|Active Comparator|LDR-brachytherapy with I125 seeds|Low-dose rate-brachytherapy with I125 permanent seeds in prostate cancer.
2951204|NCT02895854|Active Comparator|Hypofractionated RT 5 x 7,25 Gy|Hypofractionated stereotactic radiotherapy 5 x 7,25 Gy delivered every second day in prostate cancer.
2951205|NCT02895841|No Intervention|Standard of Care|Patients will continue with their normal Standard of Care for their condition
2951243|NCT02895620|Other|NMIBC patients Xpert bladder test|Xpert bladder test of urine of patients with NMIBC treated with BCG therapy
2951244|NCT02895555|Active Comparator|Allograft group, standard treatment|Control group, standard treatment. Aprox 50 g pr level fused.
2951206|NCT02895841|Experimental|SMART app wearable device|"Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths')."
2951207|NCT02895828|Experimental|Core Stabilization Exercise (CSE)|The participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
2951208|NCT02895828|Experimental|General Strengthening Exercise (GSE)|The participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks.
2951209|NCT02895815|Experimental|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 * 10^4 cells) in 50 microliter (mcL) given by subretinal delivery system.
2951210|NCT02895815|Experimental|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 * 10^5 cells) in 50 mcL given by subretinal delivery system.
2951211|NCT02895815|No Intervention|Control Group|Participants will undergo observations without surgery.
2951212|NCT02895802|Other|Verbal instructions with picture diagram|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and a picture diagram of handwashing.
2951213|NCT02895802|Other|Verbal instructions with video of ADSC|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and a video of the adult down syndrome center
2951214|NCT02895802|Other|verbal instructions w. video of w/o DS|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and viewing an educational video depicting a person without down syndrome washing their hands.
2951215|NCT02895802|Other|verbal instructions w.video w/DS|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and watching an educational video depicting a person with down syndrome washing their hands.
2951216|NCT02895789||spinal muscular atrophy|ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with laboratory documentation of homozygous deletion of SMN1 exon 7
2951217|NCT02895789||mitochondrial myopathy|ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with genetic confirmation or evidence from muscle biopsy confirming the diagnosis
2951218|NCT02895789||control|The healthy control group will be age and gender-matched to the SMA and mitochondrial myopathy groups as best as possible.
2951219|NCT02895776||General Sedation|Case patients: Endovascular Acute Stroke Therapy scheduled to be performed under local sedation and finally performed under General anesthesia
2951220|NCT02895776||local sedation|Control patients: Endovascular Acute Stroke Therapy scheduled to be performed, and actually performed under conscious Sedation
2951221|NCT02895763||Neuro Muscular disease patients|French Patients, young adults and adults, with a diagnosed neuromuscular disease, of any known form.
2951222|NCT02895750|Experimental|normal to mild renal impairment|(12 subjects): eGFR ≥ 60 (normal renal function to mild renal impairment, CKD stages 1-2) METFORMIN
2951223|NCT02895750|Experimental|mild to moderate renal impairment|(12 subjects): eGFR 59-45 (mild to moderate renal impairment, CKD stage 3a) METFORMIN
2951224|NCT02895750|Experimental|moderate to severe renal impairment|(12 subjects): eGFR 44-30 (moderate to severe renal impairment, CKD stage 3b) METFORMIN
2951225|NCT02895737|Other|balloon-expandable TAVI without cerebral protection|Patient receives a balloon-expandable transcatheter aortic valve replacement without cerebral protection
2951226|NCT02895737|Other|balloon-expandable TAVI with cerebral protection|Patient receives a balloon-expandable transcatheter aortic valve replacement with cerebral protection
2951227|NCT02895737|Other|self-expandable TAVI without cerebral protection|Patient receives a self-expandable transcatheter aortic valve replacement without cerebral protection
2951228|NCT02895737|Other|self-expandable TAVI with cerebral protection|Patient receives a self-expandable transcatheter aortic valve replacement with cerebral protection
2951229|NCT02895724|Experimental|HBOT receivers|Participants in a post breast cancer surgery randomized controlled trial detected with lymphedema 1 year postoperatively are invited to 40 consequtive treatments of hyperbaric oxygen therapy to reduce lymphedema. The experimental drug is 100% medical oxygen given in a pressure chamber of 2,4 bar,every treatment lasting approximately 100 minutes.
2951230|NCT02895724|No Intervention|blodsample comparison|Matched Lymphedema free participants from LYCA Exercise recruited to donate blood samples for comparison on important blod biomarkers and collagen levels.
2951231|NCT02895711||Patients with urolithiasis|To record the effective radiation dose to the patient during endourologic procedures to treat urolithiasis
2951232|NCT02895698|Active Comparator|Treatment group|Dry cupping + active dorsiflexion exercise + stretching exercise
2951233|NCT02895698|Other|Control group|stretching exercise + active dorsiflexion without cupping
2951234|NCT02895685|Experimental|Dyad training|Participants randomized to train in pairs during the whole 6-week course
2951235|NCT02895685|No Intervention|Control group: individually training|If randomized to train individually, participants will be instructed to do all the training individually. Participants will be instructed not to practice with others when practising at home and will only receive feedback from the expert during the expert-guided self-training. At the training at CAMES, participants will sit at separate tables.
2951236|NCT02895672||Weekly GLP-1 therapy: exenatide|Patients receiving weekly exenatide
2951237|NCT02895672||Daily GLP-1 therapy liraglutide|Patients receiving daily liraglutide
2951238|NCT02895659|Active Comparator|Ringer lactate|Fluid resuscitation will be performed with lactated Ringers during the perioperative period. Perioperative hemodynamic management will be performed according to a specified treatment protocol.
2951239|NCT02895659|Active Comparator|Ringer acetate|Fluid resuscitation will be performed with acetated Ringers during the perioperative period. Perioperative hemodynamic management will be performed according to a specified treatment protocol.
2951240|NCT02895646||Beta-lactam antibiotic allergy|Diagnosis based on clinical symptomatology and skin test positive for allergen and negative for other drugs and substances. Skin tests are performed 6 weeks after allergic reaction.
2951245|NCT02895555|Experimental|i-FACTOR|i-FACTOR putty in the operation site. Fda approved. Aprox 5 ml pr level fused.
2951246|NCT02895542||Oral Anti-Cancer Agent|No intervention
2951247|NCT02895529|Experimental|Itraconazole|
2951248|NCT02895529|Active Comparator|Caspofungin|
2951249|NCT02895516|Other|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
2951250|NCT02895503|Experimental|Arm I (yoga)|Patients undergo traditional medical treatment, participate in yoga comprising basic postures and breathing exercises 3-4 times per week, and attend yoga class once weekly over 30-60 minutes for 12 weeks.
2951251|NCT02895503|Active Comparator|Arm II (emotional support group therapy)|Patients undergo traditional medical treatment and participate in emotional support group therapy with a chaplain to work on mind-body therapies comprising guided imagery and spirituality once weekly for 12 weeks.
2951252|NCT02895490|Experimental|Arm I (DVD)|Patients receive a DVD containing educational information about patients' legal rights in the workplace and communication skills demonstrated through four scenarios depicting a variety of employer-employee communication challenges for patients, provided by LINC group.
2951253|NCT02895490|Active Comparator|Arm II (control)|Patients receive information about the LINC group.
2951254|NCT02895477|Experimental|Intervention group|Hearing aid
2951255|NCT02895477|Experimental|Test group|Hearing aid
2951256|NCT02895464|Experimental|Exercise group|The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
2951257|NCT02895464|Other|Control group|The participants will receive ordinary preoperative information, but will also be encouraged to follow the recommendation of 150 minutes/week of moderate physical activity.
2951258|NCT02895451|Experimental|Extended behavioral intervention|Specific goal-setting, self-monitoring and feed-back
2951259|NCT02895451|No Intervention|Usual care|Hospital-based or home-based aerobic exercise 3 times a week with a duration of 30-60 minutes and an intensity of 40-80 % of Vo2max and resistance exercise 2 times a week of 1-3 sets of 10-15 repetitions. The exercise period is 16 weeks.
2951260|NCT02895438|Experimental|gluten|One group had a introduction of gluten followed by a wash-out period, then a placebo introduction, whereas the other group had the placebo first, then the wash-out and the gluten introduction.
2951261|NCT02895438|Active Comparator|Placebo|One group had a introduction of gluten followed by a wash-out period, then a placebo introduction, whereas the other group had the placebo first, then the wash-out and the gluten introduction.
2951262|NCT02895412|Experimental|Transplant Recipient|"The T cell product administration is personalized cellular therapy product, individually prepared for each participant.~Donor-derived WT1-CTL and P-CTL.~It's exact make up and effect is dependent on both donor and recipient characteristics and as such variability is expected in the response. These variations will be adjusted for by multiple samplings over time and collation and analysis of response in both individuals an the group as a whole.~One infusion of 2 x 107/m2 P-CTLs prophylactically on or after day 28 post-allogeneic peripheral blood haemopoietic stem cell transplant (HSCT), combined with up to four infusions of 2x107/m2 WT1-CTLs."
2951263|NCT02895386|Active Comparator|Treatment Group A|ROX Coupler implantation and continuing antihypertensive medications.
2951264|NCT02895386|Sham Comparator|Control Group B|Sham procedure and continuing current antihypertensive medications.
2951265|NCT02895373|Experimental|Alprostadil|heparin (dose adjusted to aptt 50-60s) + Alprostadil (=PGE1) 5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
2951266|NCT02895373|Placebo Comparator|Placebo|heparin (dose adjusted to aptt 50-60s) + 0.9% sodium chloride infusion, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
2951267|NCT02895360|Experimental|Phase 1|Fixed 3+3 dose escalation of BAL101553 in patients with advanced solid tumors
2951268|NCT02895360|Experimental|Phase 2a|BAL101553 at MTD in patients with platinum-resistant/refractory ovarian cancer or recurrent glioblastoma
2951269|NCT02895347|No Intervention|Control Group|Participants in the Control Group (CG) were asked to attend an orientation reviewing the study. Three weeks later they returned and were filmed timed completing a suturing activity on the porcine model.
2951270|NCT02895347|Experimental|Experimental Group|Participants in the Experimental Group (EG) were asked to attend an orientation reviewing the study. Then they were instructed to complete 4 activities on the dvSS ® that modeled suturing techniques in minimally invasive robotics-assisted surgery. EG participants repeated these 4 activities over a period of 2 weeks until they reached proficiency (91%) in all 4 activities. 4. Participants were asked to return where they were filmed and timed completing a suturing activity on the porcine model.
2951271|NCT02895334|Experimental|MyHeartBaby|Caregivers will complete Telehealth Psychosocial Sessions and 4 follow up assessments.
2951272|NCT02895334|No Intervention|Standard of Care|Caregivers will complete 4 follow up assessments.
2951273|NCT02895321|Experimental|Patients with dentin hypersensitivity|"Patients with evident clinical signs of dentin hypersensitivity. The following dental materials will be used following the manufacturers' instructions: Cavex Bite&White ExSense and Colgate Protection Caries and Placebo gel.~In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.~The effectiveness will be evaluated: immediately after application and after 2, 4, 8 weeks."
2951274|NCT02895308|Experimental|Online|The Online psychoeducation is presented on on a webpage.
2951275|NCT02895308|Active Comparator|Face-to-face|The face-to-face psychoeducation is provided by psychologist and psychology master students.
2951276|NCT02895295|Active Comparator|Control|Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and provided with a list of resources available in the community to help them choose a prescription drug plan.
2951277|NCT02895295|Experimental|Expert Recommendation|"Participants randomized to the Expert Recommendation arm will receive access to a decision support tool that provides personalized expert scores for particular plans based on individual's likely annual out-of-pocket spending, including plan premiums and spending on prescription drugs, and the Medicare star ratings (a measure of customer satisfaction)."
2951278|NCT02895295|Active Comparator|Individual Analysis|"Participants randomized to Individual Analysis arm will receive will receive access to a decision support tool that provides individualized cost information for each plan but not the expert scores for particular plans."
2951279|NCT02895269|Experimental|Collaborative shared care|Conventional primary health care providers (PHCP) are trained to collaborate with and support traditional and faith healers (complementary alternative providers, CAPs) in the care of patients with psychosis. The PHCP are purposively trained to deliver evidence-based treatment for psychosis and to conduct scheduled and on-request visits to the facilities of the CAPs to collaborate in the treatment of patients with psychosis through joint decision making and clinical management. The overall care of the patients remains the responsibility of the healers. The role of the PHCP is to support the healers deliver safe and acceptable care to patients, including the promotion of and respect for human rights and avoidance of harmful practices in the care of patients.
2951280|NCT02895269|Active Comparator|Usual care|Complementary alternative providers deliver intervention for patients with psychosis without active or formal collaboration with conventional primary health care providers. The primary health care providers in this arm nevertheless receive training on evidence-based treatment of psychosis.
2951281|NCT02895243|Experimental|Prehabilitation|
2951282|NCT02895230||Men with prostate cancer with androgen-deprivation therapy|Using the French Health Reimbursement Agency database and French hospital discharge database, the investigators will identify all men with prostate cancer who had either, at least one dispensation in a 1.5-year period (1st July 2010 to 31st December 2011) of an androgen-deprivation therapy or a hospitalization for orchiectomy. The French Health Insurance System covers the entire French population (65.3 million inhabitants in 2012).
2951283|NCT02895217|Experimental|Cycling exercise in water|The aim of this project is to investigate energetic response (energy expenditure and food intake) of a single bout of cycling exercise in water vs on dryland in normal weight and overweight premenopausal women.
2951284|NCT02895217|Experimental|cycling exercise on dryland|The aim of this project is to investigate energetic response (energy expenditure and food intake) of a single bout of cycling exercise in water vs on dryland in normal weight and overweight premenopausal women.
2951285|NCT02895204|Experimental|Test group (F-MRP)|Fermented Maillard reacted whey protein (F-MRP) supplementation
2951286|NCT02895204|Placebo Comparator|Placebo group|Placebo supplementation
2951287|NCT02895191|Experimental|Cohort 1|Cohort 1- Ulinastatin 4.8 million units per day
2951288|NCT02895191|Experimental|Cohort 2|Cohort 2- Ulinastatin 2.4 million units per day
2951289|NCT02895191|Experimental|Cohort 3|Cohort 3- Ulinastatin 1.2 million units per day
2951290|NCT02895191|Placebo Comparator|control group|Placebo
2951291|NCT02895178|Experimental|Exercise in breast cancer survivors|Combined aerobic and strength exercise training for 12 weeks under supervision
2951292|NCT02895178|No Intervention|No exercise in breast cancer survivors|Lifestyle counseling and standard of care follow up for 12 weeks
2951293|NCT02895178|Sham Comparator|Exercise in healthy subjects|Age-matched healthy subjects. Combined aerobic and strength exercise training for 12 weeks under supervision
2951294|NCT02895152|Experimental|Feedback|Those randomised to the feedback arm will receive weekly feedback on their activity levels and tailored advice on how to improve activity levels.
2951295|NCT02895152|No Intervention|Control|Control arm will wear the activity monitor as specified in the protocol but will not receive feedback on activity levels
2951296|NCT02895139|Experimental|Additive Manufactured Orthotic Device|Device will be produced via additive manufacture to the specification of a Health and Care Professions Council (HCPC) registered orthotist based on a digital foot scan.
2951297|NCT02895139|Other|Moulded Orthotic Device|Historic control collected using same protocol. Intervention was a moulded orthotic device produced from an impression box of the foot shape.
2951298|NCT02895139|Other|Milled Orthotic Device|Historic control collected using same protocol. Device will be produced via Computer Aided Design/Computer Aided Manufacture (CAD/CAM) milling to the specification of a HCPC registered orthotist based on a digital foot scan.
2951299|NCT02895126|Experimental|"Appui Parental program (44 cases)"|
2951300|NCT02895126|Other|Regular parental support (44 cases)|Usual intervention
2951301|NCT02895113|Experimental|Aspirin|Patients will be treated with aspirin 100 mg/day for one year
2951302|NCT02895113|Placebo Comparator|Placebo|Patients will be treated with placebo for one year
2951303|NCT02895100|Experimental|PTG-100 (150 mg QD)|Low dose
2951304|NCT02895100|Experimental|PTG-100 (300 mg QD)|Medium dose
2951305|NCT02895100|Experimental|PTG-100 (900 mg QD)|High dose
2951306|NCT02895100|Placebo Comparator|Placebo group|Placebo control
2951307|NCT02895087||Cohort 1: Diurnal Variation Group|Cohort recruitment - open to recruitment
2951308|NCT02895087||Cohort 2: External Stress Group|Cohort recruitment - closed to recruitment
2951309|NCT02895074|Experimental|femtosecond laser-assisted cataract surgery group|
2951310|NCT02895074|Experimental|conventional phacoemulsification surgery group|
2951311|NCT02895061|Experimental|A: Daily|A: oral daily alfacalcidol treatments total 6 microgram/week
2951312|NCT02895061|Experimental|B: Pulse|B: pulse (trice a week) alfacalcidol treatments total 6 microgram/week
2951313|NCT02895048||Chronic heart failure|
2951314|NCT02895048||CCM treatment|Subjects with heart failure receiving OPTIMIZER system implant
2951315|NCT02895035|Active Comparator|Epinephrine|Epinephrine is the intracameral additive during cataract surgery.
2951316|NCT02895035|Active Comparator|Omidria|Omidria is the intracameral additive during cataract surgery.
2951317|NCT02895022|Experimental|Lidocaine 2% adrénalinée|The main objective is to determine the ED95 dose of 2% lidocaine with epinephrine injected into the epidural catheter for which it does not arise from failure to surgical anesthesia for cesarean during labor.
2951474|NCT02893969|Experimental|Experimental group|Gradual reintroduction of non-contact physical activity at 72 hours post-concussion.
2951318|NCT02895009|Other|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. In control group, TR Band deflation is commenced at the 2nd hour with successive 5 mL air released at 2 hours intervals until the bladder was empty at the 6th hour, and the TR Band is removed at the 24th hour.
2951319|NCT02895009|Experimental|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. In experimental group, TR Band deflation is commenced at the 1st hour with 3 mL air released, and at the 2nd hour with 5ml, and at the 3rd hour with the remainder air in the bladder, and the TR Band is removed at the 12th hour.
2951320|NCT02894996|Other|Pediatric patient for general anesthesia|Pediatric patients for general anesthesia elected for scheduled surgery Patients weight between 8 and 30 kilograms
2951321|NCT02894983|Other|Arm 1|Conservative treatment chosen by physician on-call for dorsally displaced radius fracture.
2951322|NCT02894983|Other|Arm 2|Conservative treatment chosen by physician on-call for dorsally displaced radius fracture.
2951323|NCT02894970||Healthy adults|Healthy adults for checking feasibility of Pulmonary PPG
2951324|NCT02894970||Healthy children|Healthy children for checking feasibility of Pulmonary PPG
2951325|NCT02894970||Healthy neonates|Healthy neonates for checking feasibility of Pulmonary PPG and in order to be a control group for neonates with pulmonary hypertension.
2951326|NCT02894970||Healthy preterm neonates|Healthy preterm neonates for checking feasibility of Pulmonary PPG and in order to be a control group for premature neonates with patent ductus arteriosus (PDA).
2951327|NCT02894970||Preterm neonates with PDA|Preterm neonates with hemodynamic significant PDA. Intervention: evaluate Pulmonary PPG and oxygen saturation as compared to normal newborns.
2951328|NCT02894970||Neonates with pulmonary hypertension|Neonates with pulmonary hypertension. Intervention: evaluate Pulmonary PPG and oxygen saturation as compared to normal newborns.
2951329|NCT02894957|Experimental|Gradual smoking cessation|"Gradual cessation Patients randomized to the gradual cessation group will receive varenicline (0,5 mg once daily for 3 days, 0,5 mg twice daily for 4 days, and 1,0 mg bid thereafter) as an aid for smoking reduction. This pre-treatment phase will last 6 weeks at the end of which all participants must stop smoking altogether. After quitting, they will continue to receive varenicline 1,0 mg bid for a further 12 weeks.~Smoking reduction: Participants will be recommended to reduce their smoking by 25% in the first two weeks, 50% in weeks 3-4, and 75% in weeks 5-6; however, this will be given only as an indication and every subject will be allowed to chose his/her own goal and rate of progress."
2951330|NCT02894957|Active Comparator|Abrupt smoking cessation|Patients in this group will be asked to smoke as usual for 6 weeks after enrolment then stop altogether. However, those feeling ready will be allowed to quit as of week 4. Thereafter, they will receive the standard 12-week varenicline treatment, starting with a 1 week titration period as described above.
2951331|NCT02894944|Experimental|Theragene arm|Patients who were treated with Theragene®,Ad5-yCD/mutTKSR39rep-ADP and chemotherapy
2951332|NCT02894931|Sham Comparator|Control|Dietary Interventions: Control- water, Flavered Chilled water, will be administered once after O.N fasting.
2951333|NCT02894931|Active Comparator|Glucose|Dietary Interventions: Glucose, Monosaccharides, at the dose of 50 g, based on oral loading tests, once.
2951334|NCT02894931|Experimental|Fructose|Dietary Interventions: Fructose, Monosaccharides, at the dose of 50 g, once.
2951335|NCT02894931|Experimental|Galactose|Dietary Interventions: Monosaccharides, at the dose of 50 g, once.
2951336|NCT02894931|Experimental|Mannose|Dietary Interventions: Monosaccharides, at the dose of 50 g, once.
2951337|NCT02894931|Experimental|Maltose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
2951338|NCT02894931|Experimental|Sucrose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
2951339|NCT02894931|Experimental|Lactose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
2951340|NCT02894931|Experimental|Saccharin|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
2951341|NCT02894931|Experimental|Aspartame|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
2951342|NCT02894931|Experimental|Sucralose|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
2951343|NCT02894931|Experimental|Steviol|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
2951344|NCT02894931|Experimental|Leucine|Dietary Interventions: The dose of the different BCAAs Amino acids- 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
2951345|NCT02894931|Experimental|Isoleucine|Dietary Interventions: The dose of the different BCAAs Amino acids - 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
2951346|NCT02894931|Experimental|Valine|Dietary Interventions: The dose of the different BCAAs Amino acids- 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
2951347|NCT02894918|Experimental|Combination group|Maintain NAs treatment while add 48-week standard treatment by Peginterferon alfa 2a 180µg/week
2951348|NCT02894918|No Intervention|Mono NA group|Maintain NAs mono-therapy oral-daily for 48 weeks.
2951349|NCT02894905|Experimental|AL-335 (Cohort 1)|Participants with mild impaired renal function will receive a single oral dose of AL-335 800 milligram (mg) (given as 2*400-mg tablets).
2951350|NCT02894905|Experimental|AL-335 (Cohort 2)|Participants with moderate impaired renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
2951351|NCT02894905|Experimental|AL-335 (Cohort 3)|Participants with severe impaired renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
2951352|NCT02894905|Experimental|AL-335 (Cohort 4)|Participants with normal renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
2951353|NCT02894892|Active Comparator|(A)Bismuth|(A)Bismuth (120mg/tab) 1 dose prior 1 hr before endoscopy
2951354|NCT02894892|Active Comparator|(B)Bismuth|(B)Bismuth (120mg/tab) 1 dose in the morning and endoscopy in the afternoon
2951355|NCT02894892|Active Comparator|(C)Bismuth|(C)Bismuth (120mg/tab) q.i.d. and endoscopy the next day
2951356|NCT02894892|Active Comparator|(D)Esomeprazole and Bismuth|(D)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) 1 dose prior 1 hr before endoscopy
2951357|NCT02894892|Active Comparator|(E)Esomeprazole and Bismuth|(E)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) 1 dose in the morning and endoscopy in the afternoon
2951358|NCT02894892|Active Comparator|(F)Esomeprazole and Bismuth|(F)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) q.i.d. and endoscopy the next day
2951359|NCT02894892|Other|(G)Control|(G)These patients underwent endoscopy due to abdominal discomfort or other symptoms and did not have cancers in the digestive tract after series of workup.
2951360|NCT02894879|Experimental|Modify group|For 2 days pre-surgery and continuous post-surgery repeated for 5 sets a day. The patients in Modify group will be taught 4 modify techniques and receive cardiac rehabilitation phase 1 in postoperative period.
2951361|NCT02894879|Sham Comparator|Conventional group|For 2 days pre-surgery and continuous post-surgery repeated for 5 sets a day. The patients in Modify group will be taught 3 conventional techniques and receive cardiac rehabilitation phase 1 in postoperative period.
2951362|NCT02894866|Experimental|hyperbaric oxygen|Newborns with hypoxic ischemic encephalopathy treated with intensive care and hyperbaric oxygen
2951363|NCT02894866|No Intervention|control|Newborns with hypoxic ischemic encephalopathy treated with intensive care only
2951364|NCT02894840|Active Comparator|an inactivated influenza vaccine|20 volunteers in phase I study and 200 volunteers in phase II study will receive a single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
2951365|NCT02894840|Placebo Comparator|Placebo|20 volunteers in phase I study and 100 volunteers in phase II study will receive a single dose of placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
2951366|NCT02894827||EMS|
2951367|NCT02894827||Control|
2951368|NCT02894814|Active Comparator|Basic intervention|Elements of One-Stop Dispensing (use of own medication, placed in bedside locker, partly or self-administration of medication during hospitalization)
2951369|NCT02894814|Active Comparator|Extended intervention|Elements of One-Stop Dispensing and focused dialogue with the patients about their medication during the hospitalization.
2951370|NCT02894814|No Intervention|Observational part of the study|Data collection on patients under the traditional medication system
2951371|NCT02894788||ICU|patients postoperatively admitted to ICU
2951372|NCT02894788||no ICU|patients who didn't required ICU admission postoperatively
2951373|NCT02894775||included in a clinical trial|
2951374|NCT02894775||not included in a clinical trial|
2951375|NCT02894749|No Intervention|2D Angiography (2DA)|Standard of care - Patients benefit from a 2D completion angiogram at the end of the procedure, and from a angioCT-scan before discharge. If any technical issues is depicted on the CT-scan, a new intervention needs to be scheduled.
2951376|NCT02894749|Experimental|3D rotational angiography (3DRA)|New strategy - Patients benefit from a 3D rotational acquisition at the end of procedure, which offers CT-like reconstructions. If any technical issues is depicted on the 3DRA, it can be treated during the same operating time. A contrast-enhanced ultrasound is performed for each patient before discharge to confirm that no technical issue was missed by the 3DRA.
2951377|NCT02894736|Experimental|Active tDCS|Soterix tDCS machine is used to administer active stimulation
2951378|NCT02894723|Active Comparator|l-arginine|Patients will receive L-arginine 30 ml twice a day for 8 weeks.
2951379|NCT02894723|Placebo Comparator|syrup|Patients will receive placebo, 30 ml twice a day for 8 weeks.
2951380|NCT02894710|Experimental|Lidocaine 20mg/ml|Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).
2951381|NCT02894710|Placebo Comparator|Glucose 5% (placebo)|Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.
2951382|NCT02894697|Active Comparator|Angiography-guidance|
2951383|NCT02894697|Experimental|OCT-guidance|
2951384|NCT02894684|Experimental|AZLI then Standard Care|Upon first exacerbation this arm will receive AZLI, on their second they will receive standard care
2951385|NCT02894684|Active Comparator|Standard Care then AZLI|Upon first exacerbation this arm will receive standard care, on the second exacerbation this arm will receive AZLI
2951386|NCT02894671||male under 45y|blood exams performed on males under 45years (in a range of 20-90 years) not wearing articular devices, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
2951387|NCT02894671||male over 45y|blood exams performed on males over 45years (in a range of 20-90 years) not wearing articular devices, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
2951388|NCT02894671||fertile female|blood exams performed on fertile females (in a range of 20-90 years) not wearing articular devices, no pregnant, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
2951389|NCT02894671||infertile female|blood exams performed on infertile females (in a range of 20-90 years) not wearing articular devices, no pregnant, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
2951390|NCT02894658|Experimental|Lipiflow system|Treatment through the use of heat and pulsatile pressure.
2951391|NCT02894658|Active Comparator|Fellow eye warm compresses|Warm compresses to fellow eye and daily treatment with eyelid scrubs.
2951392|NCT02894645|Other|Standard Risk (SR)|
2951393|NCT02894645|Other|Intermediate Risk (IR)|
2951394|NCT02894645|Other|High risk (HR)|
2951395|NCT02894632|Experimental|Healthy volunteers|Volunteers without cardiac, hepatic or renal pathology
2951396|NCT02894606||Thymoglobulin Induction|Patient receiving thymoglobulin as an induction therapy for renal transplant
2951397|NCT02894606||Basiliximab Induction|Patient receiving basiliximab as an induction therapy for renal transplant
2951398|NCT02894593|Other|alcohol essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
2951399|NCT02894593|Active Comparator|0.20% chlorhexidine mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
2951400|NCT02894593|Placebo Comparator|Placebo|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
2951401|NCT02894593|Experimental|alcohol free essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
2951402|NCT02894567|Experimental|spiderSTN|It is an Intraoperative test during a deep brain stimulation surgery. The spiderSTN lead is implanted in a selected track in the brain, and is tested for stimulation and recording.
2951403|NCT02894554|Placebo Comparator|lamivudine|HBsAg (+) patients received renal transplant and under lamivudine therapy.
2951404|NCT02894554|Active Comparator|telbivudine|HBsAg (+) patients received renal transplant and under lamivudine therapy and then switch to telbivudine 6 months later.
2951405|NCT02894541|Experimental|CKD-519 tablet 100mg|CKD-519 tablet(formulation Ⅱ) 100mg(100mg X 1Tab) Period 1: CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal
2951406|NCT02894541|Experimental|CKD-519 tablet 200mg|CKD-519 tablet(formulation Ⅱ) 200mg(100mg X 2Tabs) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal
2951407|NCT02894541|Experimental|CKD-519 soft capsule 100mg|CKD-519 soft capsule(formulation Ⅲ) 100mg(100mg X 1Cap) Period 1:CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal
2951408|NCT02894541|Experimental|CKD-519 soft capsule 200mg|CKD-519 soft capsule(formulation Ⅲ) 200mg(100mg X 2Caps) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal
2951409|NCT02894528|Experimental|Ridge Preservation (Test Group)|
2951410|NCT02894528|Active Comparator|Ridge Preservation (Control Group)|
2951411|NCT02894515|Experimental|Test/Reference|Single dose of commercial tablet Treatment A (Test) in period I. Followed by single dose of clinical tablet Treatment B (Reference) in period II. First and second dose administration will be separated by a washout period of at least 7 days
2951412|NCT02894515|Experimental|Reference/Test|Single dose of clinical tablet Treatment B (Reference) in period I. Followed by single dose of commercial tablet Treatment A (Test) in period II. First and second dose administration will be separated by a washout period of at least 7 days
2951413|NCT02894502|Experimental|Motivational interviewing only for patients|In this arm the interventions will be delivered only to patients
2951414|NCT02894502|Experimental|Motivational interviewing to patients and caregivers|In this arm the interventions will be delivered both to patients and caregivers
2951415|NCT02894502|No Intervention|Control group|This Group will receive the usual care
2951416|NCT02894489|Experimental|corneal lenses|patients that wear corneal lenses ( Hiclear Rigid Gas Permeable Lenses)
2951417|NCT02894489|Experimental|large diameter lenses|patients that wear scleral lenses (Paragon Normaleyes)
2951418|NCT02894437||patients|SCI recruited Physical Medicine and Nantes University Hospital Rehabilitation. Recruitment will try to balance the number of people in four sub-groups followed and complicated (= history of pelvic pressure sores), not followed and uncomplicated, monitored and uncomplicated, not followed and complicated
2951419|NCT02894437||health professionals|those involved in the chain of care Spinal Cord concerning various professions (including medical, paramedical and administrative) decision and variable influence on the organization of the die care of spinal injuries.
2951420|NCT02894411||No ocular motility disorders|Patients without ocular motility disorders, with normal orbital and brain MRI.
2951421|NCT02894411||superior oblique muscle palsy|Clinical features compatible with unilateral paralysis of the SO muscle Atrophy of the SO muscle on the orbital MRI without other orbital or cerebral anomaly
2951422|NCT02894398|Experimental|Palbociclib+AI or Fulvestrant|Letrozole as first-line or later line, Anastrozole as first-line, Exemestane as first-line, Fulvestrant as first-line or later line after prior endocrine therapy.
2951423|NCT02894385|Experimental|Healthy subjects|Healthy subjects (Part 1)
2951424|NCT02894385|Experimental|Patients with severe renal impairment|Patients with severe renal impairment (Part 1)
2951425|NCT02894385|Experimental|Patients with moderate hepatic impairment|Patients with moderate hepatic impairment (Part 1)
2951426|NCT02894385|Experimental|Optional patients with mild hepatic impairment|Optional patients with mild hepatic impairment (Part 2)
2951427|NCT02894385|Experimental|Optional patients with moderate renal impairment|Optional patients with moderate renal impairment (Part 2)
2951428|NCT02894385|Experimental|Optional patients with mild renal impairment|Optional patients with mild renal impairment (Part 2)
2951473|NCT02893982|Experimental|brachytherapy|image-guided navigation of catheter placement for high dose rate (HDR) brachytherapy treatment of patients with primary liver lesions
2951429|NCT02894372|Experimental|Subjects with oral spray 1|Research subjects, who got oral spray 1. Spray was used 3 times a day 3 sprays a time for seven days. Spray 1 was Faringomoss or simple oily oral spray (unknown because of double blind method).
2951430|NCT02894372|Experimental|Subjects with oral spray 2|Research subjects, who got oral spray 2. Spray was used 3 times a day 3 sprays a time for seven days. Spray 2 was Faringomoss or simple oily oral spray (unknown because of double blind method).
2951431|NCT02894359||CD patients|10 patients with a cervical dystonia
2951432|NCT02894359||control subjects|10 healthy patients
2951433|NCT02894346||Teachers|Public school teachers in Denmark - across age, gender, subject, class and experience.
2951434|NCT02894333||Patients with Parkinson's disease|
2951435|NCT02894320||Parkinson's disease|
2951436|NCT02894320||Healthy subjects|gender and age matched with Parkinson's disease patients, whose data will be extracted from an existing database
2951437|NCT02894294||Intervention district|implementation of the seasonal malaria chemoprevention
2951438|NCT02894294||Control district|no implementation of the seasonal malaria chemoprevention
2951439|NCT02894281||Measure of pupillary light reflex|patients without optic neuritis
2951440|NCT02894281||patients with optic neuritis|clinical database of 22 patients (measurement of pupillary light reflex already performed for the same purpose, in a former study)
2951441|NCT02894268|Experimental|Regimen A|esomeprazole (E) 20 mg, doxycycline (D) 100mg, furazolidone (F) 100 mg, and colloidal bismuth subcitrate (B) 100 mg
2951442|NCT02894268|Active Comparator|Regimen B|two sensitivity antibiotics based on antibiotic sensitivity of helicobacter pylori culture, colloidal bismuth subcitrate (B) 100 mg, esomeprazole (E) 20 mg
2951443|NCT02894255|Experimental|PCI and CABG|
2951444|NCT02894242|Experimental|F&P Deimos Nasal Pillows Mask|Participants to use nasal pillows mask in-home for 2 weeks.
2951445|NCT02894229|No Intervention|No intervention wait-list|This arm will receive no intervention for approximately the first 4 months. At the conclusion of the 4-month period, this group will receive a 6-week cognitive-behavioral therapy (CBT) group
2951446|NCT02894229|Active Comparator|Mindfulness Based Stress Reduction(MBSR)|This arm will receive 6 weekly, 2-hour groups that focuses on mindfulness meditation for stress reduction
2951447|NCT02894229|Active Comparator|Cognitive Behavioral Therapy (CBT) Group|This are will receive 6 weekly, 2-hour groups that focus on cognitive-behavioral skills for stress
2951448|NCT02894203|Experimental|Mindfulness|
2951449|NCT02894203|Active Comparator|Hatha Yoga|
2951450|NCT02894203|No Intervention|Wait-list|
2951451|NCT02894177|Experimental|tcPCO2 measurement arm|Patients will be monitored by tcPCO2 during spontaneous breathing trials
2951452|NCT02894151|Active Comparator|LNG-IUS|"LNG IUS was hormonal containing IUD relased LNG at constant rate through out 5 year period.~It was inserted only first time entry in the study."
2951453|NCT02894151|Active Comparator|DMPA|DMPA was given in trimonthly intramuscular injection.
2951454|NCT02894138|Experimental|Alteplase|40 patients: 4-5 minutes of infusion of 10 ml of alteplase 2mg/ml in culprit vessel
2951455|NCT02894138|Placebo Comparator|Placebo|40 patients: 4-5 minutes of infusion of 10 ml of NaCl in culprit vessel
2951456|NCT02894138|No Intervention|Observational|10 patients with IMR <30 will undergo the same follow-up as the randomised patients
2951457|NCT02894125||old subject|
2951458|NCT02894112|Experimental|Oral glucose tolerance test|100 g of glucose in a fruit punch flavored 8 oz drink
2951459|NCT02894112|Experimental|High fat tolerance test|single high fat load determined by body weight.
2951460|NCT02894099|Experimental|Prolonged Sitting Time (PST)|Uninterrupted sitting time of 5 hours
2951461|NCT02894099|Experimental|PST+Light intensity Short bouts PA|Sitting prolonged interrupted with breaks of 2 minutes of light physical activity
2951462|NCT02894099|Experimental|PST+Moderate intensity Short bouts PA|Sitting prolonged interrupted with breaks of 2 minutes of moderate physical activity
2951463|NCT02894099|Experimental|PST+Moderate intensity Long bouts PA|Sitting prolonged interrupted with breaks of 10 minutes of moderate physical activity
2951464|NCT02894073|No Intervention|control group|PVC placement performed in the usual manner: visual inspection of the patient's anatomy
2951465|NCT02894073|Experimental|visualisation group|a skin transilluminator (such as the VeinViewer®Vision) is used to guide PVC placement
2951466|NCT02894060|Experimental|blood|blood tests
2951467|NCT02894021|Active Comparator|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
2951468|NCT02894021|Experimental|padding|areas of padding and stiching between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h.
2951469|NCT02894008|Experimental|ChAd63- KH|Single intramuscular dose of ChAd63-KH, 1 x10(10)vp or, following safety review, 7.5 x 10(10)vp in adults
2951470|NCT02894008|Experimental|ChAd63-KH|Single intramuscular dose of ChAd63-KH, 1x10(10)vp or, following safety review, 7.5 x 10(10)vp in adolescents
2951471|NCT02893995|Experimental|Slow Dose Titration Group of Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump. While hospitalized, initiation will begin at approximately 1.25 ng/kg/min of subcutaneous treprostinil with dose increases of approximately 1.25 ng/kg/min once every seven days for the first 4 weeks, then approximately 2.5 ng/kg/min every seven days thereafter according to clinical response and tolerability.
2951472|NCT02893995|Experimental|Rapid Dose Titration Group of Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump. While hospitalized, initiation will begin at approximately 2.0 ng/kg/min with dose increments of 1-2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate should be increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min has been achieved the dose increments can be increased up to 4 ng/kg/min with dose increments separated by at least 24 hours. The aim is to achieve a dose rate of at least 10, 20, 30 and 40 ng/kg/min by the end of Weeks 1, 4, 8 and 12, respectively.
2951475|NCT02893969|Sham Comparator|Control Group|Physical and cognitive rest post-injury until fully asymptomatic. Once asymptomatic participants can gradually reintroduce physical activity.
2951476|NCT02893956|Experimental|echocardiography with postural support then standard condition|the first echocardiography (ultrasound) is performed with a postural support then the second echocardiography is performed with standard condition
2951477|NCT02893956|Active Comparator|echocardiography with standard condition then support postural|the first echocardiography (ultrasounds) is performed with standard condition (usual) and the second echocardiography is performed with a postural support
2951478|NCT02893943|Active Comparator|Probiotics|1 capsule per day containing probiotics
2951479|NCT02893943|Placebo Comparator|Placebo|1 capsule per day without probiotics
2951480|NCT02893930|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2951481|NCT02893917|Experimental|Arm A (olaparib, cediranib)|Patients receive olaparib PO BID and cediranib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2951482|NCT02893917|Active Comparator|Arm B (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2951483|NCT02893904|Experimental|Propofol|General anesthesia by TCI Propofol and Remifentanil guided by BIS EEG monitoring intervention
2951484|NCT02893904|Experimental|Sevoflurane|General anesthesia by Sevoflurane and Remifentanil guided by BIS EEG monitoring intervention
2951485|NCT02893891|Active Comparator|Laparoscopic sleeve gastrectomy|Patients undergoing bariatric surgery procedure of laparoscopic sleeve gastrectomy.
2951486|NCT02893891|Active Comparator|Laparoscopic gastric plication|Patients undergoing bariatric surgery procedure of laparoscopic gastric plication.
2951487|NCT02893891|Active Comparator|Intragastric balloon|Patients undergoing bariatric surgery procedure with intragastric balloon implantation.
2951488|NCT02893878||Study cohort|Volunteered subjects who will receive influenza vaccination in approximately 10 volunteer practices.
2951489|NCT02893865|Experimental|Experimental|Continuous positive airway pressure Patients will receive continuous positive airway pressure during three months
2951490|NCT02893865|Sham Comparator|Sham Comparator|Sham-continuous positive airway pressure Patients will receive sham-continuous positive airway pressure during 3 months
2951491|NCT02893852|Active Comparator|standard CO-OP Approach|Task oriented and client-centred intervention with 12 sessions (10 interventional and 2 assessment sessions) with children and parents.
2951492|NCT02893852|Experimental|standard CO-OP Approach plus coaching parents|"Task oriented and client-centred intervention with 12 sessions (10 interventional and 2 assessment sessions) with children and parents with a boost of 4 group sessions of coaching for parents in groups."
2951493|NCT02893839|Other|Prick to prick|
2951494|NCT02893826|Experimental|EG-1962 Group|1 dose of intracisternal EG-1962 (nimodipine microparticles) 600 mg
2951495|NCT02893826|Active Comparator|Enteral Nimodipine Group|Up to a total of 21 days of enteral nimodipine (including nimodipine received prior to randomization)
2951496|NCT02893800|Other|Himatic locating system|Locating system watch with GPS-technology (free available) Main functions: telephone function and location upon request via smartphone
2951497|NCT02893800|Other|ReSOS locating system|Locating system watch with GPS-technology (free available) Main functions: telephone function and location upon request via smartphone
2951498|NCT02893787||Patients treated with anthracyclines in childhood|
2951499|NCT02893787||Healthy volunteers|
2951500|NCT02893774|Experimental|cancer quality of life|All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis
2951501|NCT02893748|Active Comparator|1: HyGIeaCare Prep and Colonoscopy|"Patients will receive:~HyGIeaCare Prep~Colonoscopy"
2951502|NCT02893748|Active Comparator|2: Split-dose PEG Prep and Colonoscopy|"Patients will receive:~Split-dose PEG~Colonoscopy"
2951503|NCT02893735|Active Comparator|Charisma-Diamond|Charisma Diamond was randomly applied for diastema closure.
2951504|NCT02893735|Active Comparator|Filtek-Z550|Filtek-Z550 was randomly applied for diastema closure.
2951505|NCT02893722|Experimental|atosiban|"Give drugs 30 minutes before the start of the embryo transfer. First step: give a 37.5 mg Atosiban (Ferring, Germany) to take 0.9 ml, that is, 6.75 mg, conduct intravenous injection in one minute.~Second step: for the remaining 4.1 ml, namely 30.75 mg, dilute to 41 ml, use the venous pump to adjust to 24 ml/h, infuse for 1 hour, namely 18 mg.~Third step: for the remaining 17 ml, use the venous pump to adjust to 8 ml/h, infuse 2.1 hours, namely 12.75 mg. Total administration time is 3 hours, total dose is 37.5 mg."
2951506|NCT02893722|Placebo Comparator|0.9% salain|intravenous injection of 0.9% saline in one minute before transfer. Then use the same dose of normal saline for intravenous infusion to set the same infusion rate with experimental group, complete the infusion in 3 hours.
2951507|NCT02893709|Experimental|Omeprazole|A course of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
2951508|NCT02893696|Active Comparator|Immediately Supine Position|Women placed in supine position within 30 seconds after spinal injection of local anesthetic drug.
2951509|NCT02893696|Active Comparator|Delayed Supine Position|Women placed in supine position after three minutes of seating after spinal injection of local anesthetic drug.
2951510|NCT02893670|Other|Tailored re-evaluation|"Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation:~Following enrollment each patient will undergo a structured re-evaluation and transition process which will include radiologic intervention (MRE) for Crohn's patients and endoscopic intervention (sigmoidoscopy) for UC patients"
2951511|NCT02893618|Experimental|DCCR 75 mg fasted|Administered a single 75 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
2951512|NCT02893618|Experimental|DCCR 150 mg fasted|Administered a single 150 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
2951513|NCT02893618|Experimental|DCCR 300 mg fasted|Administered a single 300 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
2951514|NCT02893618|Experimental|DCCR 450 mg fasted|Administered a single 450 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
2951515|NCT02893618|Experimental|DCCR 300 mg fed|Administered a single 300 mg dose of DCCR after a standardized meal
2951516|NCT02893605||Cases|Patients have a sporadic form of Amyotrophic Lateral Sclerosis.
2951517|NCT02893605||Controls|Controls correspond to spouses/partners of patients.
2951518|NCT02893579|Experimental|Early Intervention|Stress reduction intervention 1 time a month
2951519|NCT02893579|Experimental|Delayed Intervention|Wait list Control
2951520|NCT02893566|Experimental|Mi Band Step Challenge|
2951521|NCT02893553|Experimental|Study 1|Study 1: is a dose escalation to determine the individualized dose of each of 3 medications (midodrine, pyridostigmine, mirabegron) that increases SBP into the normal range (111-139 mmHg). The investigator will be using midodrine hydrochloride, pyridostigmine bromide and mirabegron.
2951522|NCT02893553|Experimental|Study 2|Study2: is a randomized placebo-controlled double-blinded investigation to determine the effect of the normalization of SBP on cerebral blood flow, cognitive function (memory and attention processing) and quality of life. The investigator will be using midodrine hydrochloride, pyridostigmine bromide, mirabegron and placebo.
2951523|NCT02893540|Experimental|Metronomic|accept capecitabine metronomic chemotherapy (500mg, twice per day, everyday)
2951524|NCT02893540|Active Comparator|Conventional|accept capecitabine conventional chemotherapy (1000mg/m2, twice per day for 14 days, every 21 days)
2951525|NCT02893527|Experimental|"Group intervention"|Personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
2951526|NCT02893527|No Intervention|"Group standard"|conventional support
2951527|NCT02893514|Placebo Comparator|Screening Only (SO)|
2951528|NCT02893514|Experimental|Substance Use Screening and Intervention Tool (SUSIT)|
2951529|NCT02893488|Experimental|SEQUENCE ABCDE|Participants will receive treatment A in period 1, treatment B in period 2, treatment C in period 3, treatment D in period 4 and treatment E in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with zero mineral content (ZMC) water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 milliliter (mL) stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 minutes(mins), re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
2951530|NCT02893488|Experimental|SEQUENCE BCDEA|Participants will receive treatment B in period 1, treatment C in period 2, treatment D in period 3, treatment E in period 4 and treatment A in period 5 (one treatment per period). Where A= EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
2951531|NCT02893488|Experimental|SEQUENCE CDEAB|Participants will receive treatment C in period 1, treatment D in period 2, treatment E in period 3, treatment A in period 4 and treatment B in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
2951532|NCT02893488|Experimental|SEQUENCE DEABC|Participants will receive treatment D in period 1, treatment E in period 2, treatment A in period 3, treatment B in period 4 and treatment C in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
2951533|NCT02893488|Experimental|SEQUENCE EABCD|Participants will receive treatment E in period 1, treatment A in period 2, treatment B in period 3, treatment C in period 4 and treatment D in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
2951534|NCT02893449|Other|SICRPPD group|(Specific Individual Cognitive Remediation Program in Parkinson's Disease). Group of patients profiting from a structured program of preoperative cognitive remediation
2951535|NCT02893449|Other|ICM group: Intensive Care Management|Group of patients profiting from a preoperative non structured support
2951536|NCT02893449|Other|CG group: Control Group|No supplementary support
2951537|NCT02893436||Curarized patients|
2951538|NCT02893423|Active Comparator|Group 1 - 0.5% Ropivacaine|Patients will receive 0.5% Ropivacaine for the TAP block Procedure: Ultrasound guided TAP BLOCK Drug: 0.5% ropivacaine 20ml of 0.5% ropivacaine is used to perform the TAP block Other Names: •Naropin
2951539|NCT02893423|Active Comparator|Group 2 - 0.25% Ropivacaine|Patients will receive 0.25% for the TAP block Procedure: ULTRASOUND GUIDED TAP BLOCK Drug: 0.25% ropivacaine 20ml of 0.25% ropivacaine is used to perform the TAP block Other Names: •Naropin
2951540|NCT02893423|No Intervention|Group 3 - No Tap Block|Patients will not receive a TAP BLOCK
2951541|NCT02893397|Active Comparator|Supervised exercise program|Exercise with a physical therapist at least 3 times a week throughout chemotherapy (10-12 weeks)
2951542|NCT02893397|No Intervention|No exercise program|No supervised exercise.
2951543|NCT02893384|Experimental|Local Anesthetic Injection|"The intervention involves injection of local anesthetic (0.25% bupivacaine with 1:200,000 epinephrine) under direct vision in the serratus anterior muscle plane at the end of surgery.~Local Anesthetic Injection above the serratus anterior"
2951544|NCT02893384|No Intervention|Control Arm|Retrospective control group who have not had the new injection technique.
2951545|NCT02893358|Active Comparator|Active treatment|Treatment will be started with allisartan isoproxil 80mg once daily taken in the morning during 8:00-9:00. After 2 months, to achieve the target BP (24h BP<130/80 mmHg, and daytime BP <135/85 mmHg, and nighttime BP <120/70 mmHg), allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan Isoproxil.
2951546|NCT02893358|Placebo Comparator|Placebo|Placebo tablets are identical to the active study drugs, with a similar schedule of administration.
2951547|NCT02893345|Experimental|Safe@Home Intervention Group|Participants receive: (1) computer-generated, personalized assessment of abilities, risk, and recommended next steps; (2) 2 person-family education visits to develop a shared understanding of client strengths and risks, set goals, develop better ways to work as a team, and problem-solve; (3) 8 in-home visits in which personal transition trainer/life skills coach provides training, compensatory strategies, and social/technological supports on self-selected activities. The ten visits last 90-120 minutes and ideally take place over a three month period.
2951548|NCT02893345|Active Comparator|Usual Care Group|Participants receive the computer-generated, personalized assessment of abilities, risk, and recommended next steps. Participants may seek services as usual over the 3-month period.
2951549|NCT02893332|Active Comparator|TKI without SBRT|"Newly diagnosed Patients will be placed on EGFR-TKI, ,Gefitinib 250mg po qd or Tarceva 150mg po qd for their metastatic EGFR-mutant stage IV oligometastatic disease.~The oligometastatic disease will not receive SBRT"
2951550|NCT02893332|Experimental|TKI with SBRT|"experimental: Oligometastatic Non-Small Cell Lung Cancer Newly diagnosed patients will be placed on EGFR-TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, and SBRT at the same time.~SBRT to up to 5 sites. The SBRT dose range from 5 Gy per fraction to 8 Gy per fraction. SBRT deliver within 5 fractions."
2951551|NCT02893319|No Intervention|Breastfeeding|control group
2951552|NCT02893319|Active Comparator|5 oz bottle|Subject will feed infant with 5oz medela bottle
2951553|NCT02893319|Active Comparator|8 oz bottle|Subject will feed infant with 8oz medela bottle
2951554|NCT02893306|Experimental|DMT1+MSCs|type 1 diabetic patients receiving a single dose of allogeneic ex vivo expanded mesenchymal stem cells
2951555|NCT02893293|Active Comparator|Ferumoxytol-enhanced MRI|Patients receive a ferumoxytol injection (Feraheme, AMAG, 5mg Fe/kg, single administration) prior to routine decompression surgery and autologous stem cell transplant. Follow-up imaging with magnetic resonance imaging will be conducted in regular intervals for evaluation of the response to treatment.
2951556|NCT02893293|Sham Comparator|Non-ferumoxytol enhanced MRI|Patients scheduled for routine decompression surgery and autologous stem cell transplant will receive follow-up magnetic resonance imaging in regular intervals for evaluation of the response to treatment.
2951557|NCT02893267|Experimental|PNS + PT|The PNS+PT Group will receive peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of outpatient physical therapy focused on shoulder pain over the same four week period.
2951558|NCT02893267|Active Comparator|PNS + sham-PT|The PNS + sham-PT Group will receive peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of sham outpatient physical therapy not focused on shoulder pain over the same four week period.
2951559|NCT02893267|Active Comparator|sham-PNS + PT|The sham-PNS + PT Group will receive sham peripheral nerve stimulation treatment (which will not produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of outpatient physical therapy focused on shoulder pain over the same four week period.
2951560|NCT02893254|Experimental|IBI303|IBI303 40mg administered subcutaneously every other week, 12cycles
2951561|NCT02893254|Active Comparator|Adalimumab|Adalimumab 40mg administered subcutaneously every other week
2951562|NCT02893241||Cohort A|Patients ≥ 50 years old, with pre-existing comorbidities, who receive general anaesthesia
2951563|NCT02893241||Cohort B|Patients, who undergo caesarean section under spinal anaesthesia
2951564|NCT02893228|Experimental|Group S (saline group)|In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected. This will be followed by repositioning of the needle between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.
2951565|NCT02893228|Active Comparator|Group C (control group)|In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. The needle tip will be positioned between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.
2951566|NCT02893215||Heart failure|Screening for silent AF with Zenicor thumb-ECG: Patients older than 65 years, diagnosed with heart failure, without any history of atrial fibrillation, ongoing OAC treatment, implanted device or recent stroke/TIA.
2951567|NCT02893215||Diabetes mellitus II|Screening for silent AF with Zenicor thumb-ECG: Patients older than 65 years, diagnosed with diabetes mellitus II, without any history of atrial fibrillation, ongoing OAC treatment, implanted device or recent stroke/TIA.
2951568|NCT02893202|Experimental|Ride On Center for Kids (ROCK) facility|8-week therapeutic horseback riding
2951569|NCT02893202|Experimental|Triple H Equitherapy Facility|8-week therapeutic horseback riding
2951570|NCT02893202|Experimental|Rainer Therapeutic Riding facility|8-week therapeutic horseback riding
2951571|NCT02893202|Experimental|REACH Therapeutic Riding facility|8-week therapeutic horseback riding
2951572|NCT02893202|Experimental|Courtney Cares Riding facility|8-week therapeutic horseback riding
2951573|NCT02893189|Experimental|4G7-CARD T-cells|All patient will receive modified CAR19 T-cells.
2951574|NCT02893176|Placebo Comparator|Placebo|10mg will be administered one time daily
2951576|NCT02893163|Experimental|CHANGE Intervention|The CHANGE intervention is a personalized approach to nutrition and exercise modification supported by a interdisciplinary team. The FD will recruit patients, complete baseline measurements and stabilize medication. The RD will create a diet plan tailored to the individual patient based on the intervention protocol. The ES will create an exercise plan tailored to the individual patient based on the intervention protocol. At the start, patients will meet weekly with the RD and ES in order to monitor progress, ascertain barriers and facilitators to change, and ensure adherence for the first 12 weeks of the intervention. Meetings will then occur monthly for the remaining 9 months of the intervention. Visits with the FD will occur every 3 months for the 12 month intervention to monitor progress, encourage behaviour change. A follow-up visit with the Research Coordinator will take place at 18 months.
2951577|NCT02893163|Active Comparator|Usual Care|The usual care arm of the study will involve regular care from the patients' FD. This may involve discussions regarding nutrition and exercise. The FD will still recruit patients, complete baseline measurements and stabilize medication. Visits to the FD will occur as usual care dictates. Participating PCNs randomized to usual care will still have interdisciplinary team members available but the referral arrangements are and will continue to be ad hoc. For the study, we will mandate that control patients have follow-up with the Research Coordinator at 3, 12 and 18 months for the purpose of assessing outcomes. At these time points, appointments will not be scheduled with the FD to manage their disease; rather, the purpose of the visit is to just conduct the outcome assessment.
2951578|NCT02893150|Active Comparator|TAU (treatment as usual)|The Treatment as Usual (TAU) will be considered as following: 1) In the cases of individuals presenting overweight (BMI of 25 kg/m ² to 29.9 kg/m ²), but without comorbidities, primary care teams propose the improvement of the life style (more physically active, and with a better eating behaviour) in order to return to the track of normal BMI (BMI of 18.5 kg/m ² to 24.9 kg/m ²). 2) For those who have comorbidities such as hypertension and diabetes, in addition to including individuals in group activities (psycho-education), it is evaluated the need for individual dietary prescription by a nutritionist.
2951579|NCT02893150|Active Comparator|TAU+MBHP|"The Mindfulness-based Health Promotion (MBHP) developed by our research group (generic protocol) will be adapted from the Mindfulness-based Stress Reduction program (MBSR), It is based on the original model developed by Jon Kabat-Zinn and colleagues (MBSR), and subsequently adapted by our research group in order to fit it better into the context and needs of Primary Care (PC) and national and local Health Systems], which has been applied by the Center Mente Aberta in Brazil (www.mindfulnessbrasil.com), and by the University of Zaragoza, in Spain (www.webmindfulness.com). One of the sessions (the sixth one) is developed in silence, with the goal of deepening the mindfulness practice."
2951580|NCT02893150|Experimental|TAU+MB-EAT|The Mindfulness-based Eating Awareness (MB-EAT) protocol consists in ten weekly sessions of 2,5 hour to improve compulsive eating, and to promote conscious eating.
2951581|NCT02893137|Experimental|Craniectomy and Optune|Patients will receive best physician's choice chemotherapy along with Optune therapy and craniotomy surgery. Optune therapy will be administered in the standard configuration and in accordance with current guidelines with the exception of the surgical intervention.
2951582|NCT02893124|Experimental|PEG-IFN group|HBeAg-negative CHB patients with HBsAg <1000 IU/ mL and HBV DNA<100 IU/mL are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for at most 96 weeks.
2951583|NCT02893124|No Intervention|NAs group|CHB patients do not need to change their NAs treatment.
2951584|NCT02893111|Experimental|Bortezomib (Velcade)|A proteasome inhibitor
2951585|NCT02893098|Experimental|Humia inj.|Participants with symptomatic Primary Osteoarthritis of Knee received a single injection of 3ml Humia inj.
2951586|NCT02893098|Active Comparator|High Hyal Plus inj.|Participants (Control Group) with symptomatic Primary Osteoarthritis of Knee received single injection of 2ml High Hyal Plus inj. given weekly for 3 weeks
2951587|NCT02893085||patients with malignant biliary stricture|
2951588|NCT02893085||patients with benign biliary diseases|
2951589|NCT02893072|Experimental|Individualized medical nutrition therapy|A comparison of normal lifestyle and medical nutrition therapy after intervention in the same individual
2951590|NCT02893046||Population at Risk|Population with at least one risk factor of being infected with hepatitis C; MSM population; people in precarious situations and / or attending support from addictions care structures.
2951591|NCT02893046||Prison population|"Proposal of participation to a  consultation arrivants  by the staff of medical units correctional"
2951592|NCT02893033|Experimental|Real stimulation|Real repetitive transcranial magnetic stimulation + swallowing training
2951593|NCT02893033|Sham Comparator|Sham stimulation|Sham repetitive transcranial magnetic stimulation + swallowing training
2951594|NCT02893007|Experimental|Brief family-centered care program|The Brief family-centered care (BFCC) program was developed and provided for hospitalized patients with BPD and their family caregivers.The BFCC protocol is outlined as 4 treatment sessions, specific goals, and example questions. Four 90-minute in-depth sessions for each dyad were initially held in a quiet interview room to assess family function, then to provide information about BPD, to support and empower the dyads to change communication styles and resolve conflicts, and to sustain or improve family function in the cognitive, affective, and behavioral domains.
2951595|NCT02893007|No Intervention|treatment-as-usual (TAU)|All patients were given the standard hospital-provided services: psychiatric nursing care, occupational therapy, and pharmacotherapy. All of the family caregivers were only to attend a routine 60-minute family discussion group about violence and suicide prevention without any specific patient-family dyad interview.
2951596|NCT02892994|Experimental|Ultrasound|Subjects will receive 5 minutes of ultrasound treatment at 0.4 W/cm^2 and 100% duty cycle on each masseter muscle.
2951597|NCT02892994|Placebo Comparator|Placebo|Subjects will receive 5 minutes of ultrasound treatment at zero power on each masseter muscle.
2951598|NCT02892981|Other|Pulmonary hypertension patients|All Pulmonary hypertension patients enrolled in the study underwent a cardiopulmonary exercise test and hypoxia and hypercapnia tests
2951631|NCT02892773|Active Comparator|EzPAP® Positive Airway Pressure Group|"Participant will be coached by a Respiratory Therapist to breathe through the mouthpiece of an EzPAP® device for 10 breaths, followed by a 60 second pause.~This cycle will be repeated two more times.~The Respiratory Therapist will coach participants three times per day.~Each duration of EzPAP® therapy will last about 15 minutes."
2951599|NCT02892968|Experimental|U/S Guided Regional Anesthesia|"Fascia-Iliaca Block(FIB) Femoral Nerve Block(FNB)~All participating emergency physicians (EPs) will be randomly assigned to the order they receive training in a stepped wedge design. Thus all EPs will begin the trial as control physicians. EPs will then be trained to use two approaches to ultrasound (U/S) guided regional anesthesia, the fascia iliaca and femoral nerve blocks. Which block that will be used will be randomly determined at the individual patient level"
2951600|NCT02892968|No Intervention|Current Local Standard Analgesia|"All participating emergency physicians (EPs) will be randomly assigned to the order they receive training in a stepped wedge design. Thus all EPs will begin the trial as control physicians. Physicians who are in the control group will provide current local standard of analgesic care for hip fracture patients such as the use of IV opiods with supplemental acetaminophen and non-steroidal anti-inflammatory agents until they receive training."
2951601|NCT02892955|Experimental|Experimental: HeartMate 3 LVAS (HM3 LVAS)|The study will be a single-arm, prospective, multi-center, study for continued evaluation of safety and clinical performance of the HM3 LVAS.
2951602|NCT02892942|Active Comparator|Control Group|"Background therapy which is the usual COH treatment:~Recombinant FSH (Gonal-F®, 225 to 450 IU/d; MerckSerono Pharmaceuticals) from day 2 of their menstrual cycle onward,~GnRH antagonist (Cetrotide®, MerckSerono Pharmaceuticals) 0.25 mg/day, S.C., starting on day 6 of Gonal-F®."
2951603|NCT02892942|Experimental|NATOS Group|"Background therapy which is the usual COH treatment:~Recombinant FSH (Gonal-F®, 225 to 450 IU/d; MerckSerono Pharmaceuticals) from day 2 of their menstrual cycle onward,~GnRH antagonist (Cetrotide®, MerckSerono Pharmaceuticals) 0.25 mg/day, S.C., starting on day 6 of Gonal-F®.~GnRH antagonist treatment (Cetrotide®, MerckSerono Pharmaceuticals) will be reinforced and patients will receive 1.5 mg/day (6 ampoules of 0.25 mg), S.C., starting on day 1 (S1) of Gonal-F® treatment until dhCG"
2951604|NCT02892929|Experimental|Motivational Interviewing|The motivational interview is a style of care that evokes the patient their motivations to make behavioral changes in the interests of their own health. It is a technique centered in patient to explore and resolve their ambivalence to modify unhealthy behavior.
2951605|NCT02892929|Active Comparator|Prescriptive Consultation|Prescriptive consultation is the Methodology usual consultation. In this type of consultation the health professional who plans the action plan for the patient and determines how it will be the patient's lifestyle modification.
2951606|NCT02892916|Experimental|Ketamine|Patients in this experimental group will receive a bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
2951607|NCT02892916|Placebo Comparator|Placebo|Patients in this control group will receive a bolus of an intravenous normal saline solution following induction of anaesthesia.
2951608|NCT02892903|No Intervention|Conventional angiography|Routine angiography will be performed according to local best practice
2951609|NCT02892903|Experimental|Routine Measurement of FFR|Additional investigation with the measurement of FFR in all major vessels
2951610|NCT02892890|Experimental|patients with CIDP|
2951611|NCT02892877||Complete Hydatidiform mole and Partial Hydatidiform mole|
2951612|NCT02892877||Invasive mole|
2951613|NCT02892877||Choriocarcinoma|
2951614|NCT02892877||Post-molar neoplasia|
2951615|NCT02892877||Placental Site Trophoblastic and Epithelioid Tumor|
2951616|NCT02892864|Active Comparator|Control arm|Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation.
2951617|NCT02892864|Experimental|Experimental Virtual Arm|Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.
2951618|NCT02892851|Experimental|Deep brain stimulation (DBS)|Deep brain stimulation of the subthalamic nuclei (STN-DBS)
2951619|NCT02892838|Experimental|mobile bearing knee prosthesis|use of the Scorpio mobile bearing knee system for total knee arthroplasty
2951620|NCT02892838|Active Comparator|fixed bearing|use of the Scorpio fixed bearing knee system for total knee arthoplasty
2951621|NCT02892825|Experimental|music group|music listening
2951622|NCT02892825|Active Comparator|no music group|no music listening
2951623|NCT02892812|Experimental|LBVE013|13-valent pneumococcal conjugate vaccine
2951624|NCT02892812|Experimental|LBVE014|14-valent pneumococcal conjugate vaccine
2951625|NCT02892812|Active Comparator|Prevnar13|13-valent pneumococcal conjugate vaccine
2951626|NCT02892799|Active Comparator|FACTT-lite Diuresis Protocol|"Within 2-hours of placement into this group, patients will have their blood pressure obtained, central venous pressure transduced in the supine position, and quantization of the prior hour's urinary output.~Following initial evaluation, at set times spaced every four hours apart, patients will have a central venous pressure transduced and the prior hour's urinary output will be used to determine placement in one of the FACTT-lite's protocol grid."
2951627|NCT02892799|Experimental|CVP Diuresis Protocol|Within 2-hours of placement into this group, patients will have their blood pressure obtained, central venous pressure transduced in the supine position, four point sonographic assessment of extravascular lung water, hourly urinary output, and quantization of the total input and output from the beginning of the morning shift (7-AM). This will allow placement in one of the cells of the CVP diuresis protocol grid to determine the fluid goal over the next 4-hours.
2951628|NCT02892799|Experimental|Echo Diuresis Protocol|Within 2-hours of placement into this group, patients will have their blood pressure obtained, a complete echocardiograph, four point sonographic assessment of extravascular lung water, hourly urinary output, and quantization of the total input and output from the beginning of the morning shift (7-AM). This will allow placement into one of the cells of the Echo diuresis protocol grid to determine the fluid goal over the next 4-hours. Patients will receive furosemide to achieve the goal fluid balance if needed. During this time, patients will transduction of central venous pressure and assessment of tissue perfusion for data analysis.
2951629|NCT02892786|Experimental|experimental|
2951630|NCT02892773|Other|Incentive Spirometry Group|"Participant will be asked to take 10 deep breaths through the mouthpiece of an incentive spirometer, followed by a 60 second pause.~This cycle will be repeated two more times.~A Respiratory Therapist will coach participants three times per day.~Each duration of Incentive Spirometry will last about 15 minutes."
2951632|NCT02892760|Experimental|with C-brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
2951633|NCT02892747|Experimental|Educational Program for prevention of malnutrition|In addition to the usual nutritional assessment, the patients in the experimental arm benefit of a personalized educational program for prevention of malnutrition. This program aims to monitor energy and protein intake in addition to managing sodium intake, notably by offering personalized menu ideas and recipes.
2951634|NCT02892747|No Intervention|Control|In the control arm, patients are followed-up by the cardiologist and the nutritionist, and did not benefit of the personalized educational program for prevention of malnutrition.
2951635|NCT02892734|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes Q2W and ipilimumab IV over 90 minutes Q6W in the absence of disease progression or unacceptable toxicity.
2951636|NCT02892721|No Intervention|Control group|The control group will not receive the one-day training course or access to the online educational module. Test sets will be administered in the same manner as for the intervention group, but the control group will not receive any feedback on performance during the 12 month assessment phase. Feedback on test performance will only be provided after the 12 month period has ended.
2951637|NCT02892721|Other|Training with feedback|See intervention description
2951638|NCT02892708|Active Comparator|Surgery|Surgical resection followed by radiation therapy
2951639|NCT02892708|Experimental|radiotherapy alone|radiotherapy after a brain biopsy
2951640|NCT02892695|Experimental|CAR-NK Cell immunotherapy|Enrolled patients will receive CAR-NK cell immunotherapy with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
2951641|NCT02892682|Other|Arm 1 AE-Bk|Arm of the recurring angiodeme medié by the bradykinine: blood test
2951642|NCT02892682|Other|Arm 2 AE-Mast|Superficial nettle rash group recurring angiodemes associated with superficial nettle rash: blood test
2951643|NCT02892682|Other|ARM 3 AEI|Arm recurring angiodemes isolate idiopathique not hostaminergique: blood test
2951644|NCT02892682|Other|ARM 4 US|Arm of superficial nettle rashes: blood test
2951645|NCT02892669||patients admitted to the intensive care department|
2951646|NCT02892643|Experimental|Laparoscopic proximal gastrectomy|Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
2951647|NCT02892643|Active Comparator|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
2951648|NCT02892630||Pregnant ITP women|Pregnant women more than 18 years old, with primary ITP diagnosis before pregnancy
2951649|NCT02892630||Control ITP Women (Non pregnant)|Primary ITP women more than 18 years old, at more than one year from a precedent pregnancy
2951650|NCT02892630||De novo ITP pregnant women|Pregnant women more than 18 years old, with newly diagnosed thrombocytopenia during pregnancy
2951651|NCT02892617||Group 1|Patients with low back pain lasting for more than 6 months, debilitating, with the presence of type 1 Modic disc disease on MRI at the operated disc, eligible for a disc prosthesis or arthrodesis anterior approach
2951652|NCT02892617||Group 2|Patients underwent surgery for nerve root pain by disc herniation on MRI viewable with a radio-clinical concordance with or without Modic 1 disc disease in the operated disc
2951653|NCT02892604|Experimental|insulin delivery driven by inControl|"Closed-loop insulin delivery using inControl AP system is assessed for two weeks, 24/7.~Connection of continuous glucose monitoring (CGM) system and insulin pump to inControl AP platform, all wireless and wearable, in free-life conditions Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data."
2951654|NCT02892591|Experimental|Cannabis|Medium dose THC, single administration, vaporized
2951655|NCT02892591|Active Comparator|Oxycodone|5-10 mg oxycodone hydrochloride, single administration, oral
2951656|NCT02892591|Placebo Comparator|Placebo|No active study drug
2951657|NCT02892578|Experimental|electrocardiogram|Patient will take an electrocardiogram in order to detect atrial fibrillation
2951658|NCT02892565|Experimental|Cases|Patients with SLE and/or APL and first vein thrombosis episode
2951659|NCT02892565|Other|Controls|age-matched; Patients with SLE and/or APL
2951660|NCT02892552|Experimental|Cone Beam|Patients included will have first a MultiSlice Computed tomography (MSCT) as usual and then a Cone Beam Computed Tomography (CBCT)
2951661|NCT02892526||Vital wounds|from abdominoplasty of alive persons
2951662|NCT02892526||Post-mortem wounds|from autopsy of deceased persons
2951663|NCT02892513|Experimental|Active Stimulation|Participants will have active percutaneous auricular neurostimulation for 5 days during and after elective surgery.
2951664|NCT02892513|Sham Comparator|Sham Percutaneous Neurostimulation|Participants will have inactive device worn for 5 days during and after elective surgery.
2951665|NCT02892500|Experimental|bupivacaine hydrochloride and betamethasone sodium phosphate|When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed the area will be injected with a mixture of 5 ml of 0.25 % bupivacaine hydrochloride and 2 ml of 3 mg/ml betamethasone sodium phosphate (Celestone® Soluspan®) (BTM)
2951666|NCT02892500|Active Comparator|bupivacaine hydrochloride|When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed, the area will be injected with 5ml of bupivacaine hydrochloride.
2951667|NCT02892487|Experimental|Early active swallowing therapy|
2951668|NCT02892487|No Intervention|Usual care|
2951669|NCT02892474||Hybrid Coronary Revascularization (HCR)|Patients who are scheduled to have the hybrid coronary revascularization (HCR) procedure for treatment of multi-vessel coronary artery disease. The treatment plan is determined by the patient's doctor.
2951728|NCT02892006|Experimental|Intervention|All participants in the study will participate a 6 week improv intervention.
2951670|NCT02892474||Coronary Artery Bypass Grafting (CABG)|Patients who are scheduled to have the coronary artery bypass grafting (CABG) procedure for treatment of multi-vessel coronary artery disease. The treatment plan is determined by the patient's doctor.
2951671|NCT02892461|Experimental|Umbilical cord milking|The cord will be cut at 25 cm from the umbilical stump within 30 seconds after the infant is taken out from the uterus and its blood will be milked to the infant gently and thoroughly in 30 seconds during resuscitation on the radiant warmer, and then the cord will be cut at 2 to 3 cm from the umbilical stump.
2951672|NCT02892461|No Intervention|Routine clinical treatment and care|The cord will be dealt with routine clinical method, which means it will be cut twice within 1minute after the infant is taken out from the uterus, the first cut is on the operating table, while the second cut is on the radiant warmer.
2951673|NCT02892448|Active Comparator|Unilateral Hip Resurfacing|Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
2951674|NCT02892448|Active Comparator|Bilateral Hip Resurfacing|Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
2951675|NCT02892448|Active Comparator|Non-Metal on Metal Total Hip|Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
2951676|NCT02892435|Experimental|Prevena arm|patients underwent to contaminated/dirty surgery who positioned incisional negative pressure wound therapy and kept for six days
2951677|NCT02892435|Active Comparator|Control arm|patients underwent to contaminated/dirty surgery who positioned conventional dressing
2951678|NCT02892422|Experimental|Flexible-dose of Lu AF35700|
2951679|NCT02892409|Active Comparator|Clarithromycin + Amoxicillin + Bismuth + Lansoprazole|Clarithromycin 500 milligram (mg), tablets, orally, twice daily, along with amoxicillin 1000 mg capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and lansoprazole 30 mg, capsules, orally, twice daily on Days 1 to 14.
2951680|NCT02892409|Experimental|Clarithromycin + Amoxicillin + Bismuth + TAK-438|Clarithromycin 500 mg, tablets, orally, twice daily, along with amoxicillin 1000 mg, capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and TAK-438 20 mg, tablets, orally, twice daily on Days 1 to 14.
2951681|NCT02892396||COPD patients & conventional cigarettes|COPD patients regular smokers of conventional cigarettes with no desire to quit smoking habit.
2951682|NCT02892396||COPD patients & electronic cigarettes|COPD patients who had been users of electronic cigarettes for at least 8 weeks. They will be provided with an specific type of electronic cigarette and the same dosage of inhaled nicotine.
2951683|NCT02892370|Experimental|SHR0302 fasted to fed|SHR0302 tablets (10 mg) administered on day 1 fasting, and day 7 with high fat, high calorie breakfast
2951684|NCT02892370|Experimental|SHR0302 fed to fasted|SHR0302 tablets (10 mg) administered on day 1 with high fat, high calorie breakfast, and day 7 fasting
2951685|NCT02892357|Experimental|Jianpi Qinghua Recipe|Patients in this group were administered the Jianpi Qinghua Recipe and low-dose omeprazole for 4 weeks.
2951686|NCT02892357|Active Comparator|omeprazole|Participants will orally take the placebo granules and 20mg omeprazole once a day for 4 weeks.
2951687|NCT02892344|Experimental|QMF149 150/80 μg|QMF149 150/80 microgram o.d. delivered via Concept1
2951688|NCT02892344|Active Comparator|MF 200 µg|MF 200 microgram o.d. delivered via Twisthaler®
2951689|NCT02892331|No Intervention|Control|This group does not change physical activity during the intervention period, but will receive exercise training after the study is complete
2951690|NCT02892331|Experimental|MOD-INT|The Moderate intensity exercise training (MOD-INT) group will exercise at a moderate aerobic exercise intensity for 24 weeks
2951691|NCT02892331|Experimental|HIGH-INT|High Intensity exercise training (HI-INT) group will exercise at a high aerobic intensity for 24 weeks
2951692|NCT02892318|Experimental|Cohort A1: Safety Cohort (Relapsed/refractory AML)|An initial safety evaluation of the combination will be performed in 9 participants with relapsed/refractory AML. All participants will receive atezolizumab (840 milligrams [mg] IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 milligrams per square meter [mg/m^2] subcutaneously [SC] on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit (except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
2951693|NCT02892318|Experimental|Cohort A2: Expansion Cohort (Relapsed/refractory AML)|If the combination of atezolizumab and guadecitabine is found to be safe and tolerable in Cohort A1, an expansion cohort of 11 participants with relapsed/refractory AML (Cohort A2) will be evaluated. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
2951723|NCT02892045||TOFWatch versus Mindray NMT|24 patients where Mindray NMT is monitoring one hand versus TOF-Watch Acceleromyograph on the other hand accessible in supine position, alternately right and left hands monitoring neuromuscular block of rocuronium neuromuscular blocking agent 0.6 mg/kg
2951724|NCT02892032|Experimental|Attention Modification Training|ABMT is a newly emerging intervention that trains patients to override their tendency to focus on threatening aspects of an event and to interpret events as more neutral and therefore less stressful
2951725|NCT02892032|Placebo Comparator|No Attention Modification Training|There is no disengagement of attention from a target stimulus. Attention is divided equally between two stimuli on the screen.
2951726|NCT02892019|Active Comparator|Indacaterol acetate 75 μg o.d.|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
2951694|NCT02892318|Experimental|Cohort A3: Safety Cohort (Previously Untreated AML)|If the combination of atezolizumab and guadecitabine is found to be safe and tolerable in Cohort A1, Cohort A3 will assess the safety and tolerability of the combination in 6 participants with untreated AML, who are older and unfit for induction chemotherapy. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
2951695|NCT02892318|Experimental|Cohort A4: Expansion Cohort (Previously Untreated AML)|If Cohort A3 is deemed safe and tolerable, an expansion cohort (Cohort A4) of 14 participants with untreated AML, who are older and unfit for induction chemotherapy will be evaluated. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
2951696|NCT02892305||PAC with LVLM|Patients with pancreatic cancer and low-volume liver metastasis
2951697|NCT02892279|Experimental|Diesel exhaust exposure|A single arm study in which first a baseline muscle sympathetic nerve activity (MSNA) is recorded with and without an exposure mask. When measurements have been secured exposure to dilute diesel exhaust will start.
2951698|NCT02892266||Adolescent Transplant Recipients|"Questionnaire battery at enrollment (Participants and their parents/guardians)~Clinical data from patient's chart (6 months of retrospective data & 6 months of prospective tacrolimus trough level data)"
2951699|NCT02892253|Experimental|NIR+ group|Patients who undergo conventional total thyroidectomy (TT)+/- lymph node dissection (LND) with the use of NIR (intervention group, NIR+ group)
2951700|NCT02892253|No Intervention|NIR- group|Patients who undergo conventional total thyroidectomy (TT)+/- lymph node dissection (LND) without the use of NIR - parathyroid identification was done by naked eye only (no intervention group, NIR- group)
2951701|NCT02892227|Experimental|JET ECHO|Transmitral flow estimation
2951702|NCT02892227|No Intervention|NO JET ECHO|no bedside echocardiography
2951703|NCT02892214||Hypertonic pelvic muscle dysfunction|In this subgroup, pelvic floor (PF) muscles become tight and tender. Typically, the pain is much worse at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule.
2951704|NCT02892214||Hormonally mediated PVD|The pain began while taking hormonal contraceptive or other medications that affect hormones, after removal of ovaries, breastfeeding or menopause. The entire vestibule is tender and vestibular mucosa is often dry and thin.
2951705|NCT02892214||Neuroproliferative PVD|In this condition, we speculate that women have an increased number of nociceptors in the vestibular mucosa. Pain is primary and there is tenderness of the entire vestibule.
2951706|NCT02892201|Experimental|All subjects|"for patients with squamous cell carcinoma of the head and neck who have residual disease following definitive therapy with radiation~Pembrolizumab will be given at a constant dose of 200 mg every three weeks, for four cycles. Patients with resectable disease can then go on to surgery, and patients with unresectable disease can continue on pembrolizumab until progression or for up to 1 year."
2951707|NCT02892162|Experimental|With additional LAAW linear ablation|Patients who undergo CPVI+LA roof linear ablation+/ MI linear ablation, and additional LAAW linear ablation using ThermoCool SmartTouch catheter.
2951708|NCT02892162|Active Comparator|Without additional LAAW linear ablation|Patients who undergo CPVI+LA roof +/ MI linear ablation using ThermoCool SmartTouch catheter, without LAAW linear ablation.
2951709|NCT02892149|Experimental|Vadadustat|
2951710|NCT02892149|Active Comparator|darbepoetin alfa|
2951711|NCT02892123|Experimental|ZW25 Monotherapy and ZW25 Combination Therapy|
2951712|NCT02892110|Experimental|Varenicline|2 mg daily
2951713|NCT02892110|Placebo Comparator|Placebo|2 mg daily
2951714|NCT02892097|Active Comparator|Parietal tDCS plus RTP|Single session of bilateral parietal tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP).
2951715|NCT02892097|Active Comparator|Primary motor cortex tDCS plus RTP|Single session of bilateral primary motor cortex tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP)
2951716|NCT02892097|Sham Comparator|Sham tDCS plus RTP|Single session of sham tDCS (for 30 minutes) paired with repetitive task-specific practice (RTP)
2951717|NCT02892084|Experimental|Uphill COMa training|Walking on an inclined treadmill, thus manipulating the permissive environment to elicit COMa adaptation, while receiving either tDCS or sham tDCS.
2951718|NCT02892084|Experimental|Downhill COMa training|Walking on a declined treadmill, thus manipulating the permissive environment to elicit COMa adaptation, while receiving either tDCS or sham tDCS.
2951719|NCT02892071|Active Comparator|22% TCA peel|22% trichloroacetic acid medium depth chemical peel applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek)
2951720|NCT02892071|Active Comparator|CO2 laser|CO2 ablative fractional laser resurfacing applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek)
2951721|NCT02892071|Active Comparator|Qs-NdYAG laser|Long pulsed Q-switched Nd:Yag laser will be applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek), performed at 2-week intervals for six sessions.
2951722|NCT02892045||MMG versus Mindray NMT|24 patients where Mindray NMT is monitoring one hand versus Mechanomyograph on the other hand accessible in supine position, alternately right and left hands monitoring neuromuscular block of rocuronium neuromuscular blocking agent 0.6 mg/kg.
2951727|NCT02892019|Active Comparator|Indacaterol acetate 150 μg o.d.|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
2951729|NCT02891993|Experimental|IMPROVED Intervention|"Patients randomized to IMPROVED will self-report their symptoms each day using a tablet computer.~The clinical team will view reports detailing their patients' symptom burden~Clinicians will be provided with a graphic depiction of their patients' daily symptom trajectory for that admission"
2951730|NCT02891993|Active Comparator|Usual Care|"Patients randomized to Usual Care will self-report their symptoms each day using a tablet computer~Patients will report their symptoms to their clinicians as they usually would~Clinicians will not be provided with a graphic depiction of their patients' daily symptom trajectory for that admission"
2951731|NCT02891980|Experimental|Group 2|MVA-BN®-Filo Day 1, Ad26.ZEBOV Day 29 and MVA-BN®-Filo Day 366
2951732|NCT02891980|Experimental|Group 3|Ad26.ZEBOV Day 1, MVA-BN®-Filo Day 29 and MVA-BN®-Filo Day 366
2951733|NCT02891980|Experimental|Group 4|Ad26.ZEBOV Day 1, Ad26.ZEBOV Day 29
2951734|NCT02891980|Experimental|Group1|MVA-BN®-Filo Day 1 and MVA-BN®-Filo Day 29
2951735|NCT02891967|Other|Bulk full composite (3M)|bulk fill composite in posterior class one cavities
2951736|NCT02891967|Other|Incremental packing composite resin|Nano resin composite (K Z350 xt) restoration in class one cavities
2951737|NCT02891954|Experimental|Single arm|Healthy volunteers will receive canagliflozin to assess pharmacodynamic responses to drug.
2951738|NCT02891941||Mild Traumatic Brain Injury|This cohort will have sustained a closed head injury, defined as externally inflicted trauma without skull fracture within the last month.
2951739|NCT02891928|Experimental|with rocker sole|patient were wearing the rocker soles shoes during investigation
2951740|NCT02891928|Placebo Comparator|without rocker sole|patient were wearing normal shoes during investigation
2951741|NCT02891915|Active Comparator|Short|200 subjects will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo
2951742|NCT02891915|Active Comparator|Standard|200 subjects will receive a standard course of the initially prescribed antibiotic( Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days
2951743|NCT02891863|Experimental|Acute Testing|Single-arm study - all subjects who meet the I&E criteria, sign the consent form and have inducible VT within the protocol-specified criteria may be tested for VT conversion with the LEVER Acute Study System.
2951744|NCT02891850|Experimental|BAY63-2521|PDE5i treatment will be stopped and riociguat treatment initiated following a defined washout period with a starting dose of 1 mg riociguat TID followed by an 8 weeks dose adjustment phase according to the approved riociguat dose adjustment scheme.
2951745|NCT02891850|Active Comparator|Sildenafil or Tadalafil|Patients will continue to receive PDE5i treatment as well as other standard of care treatments at the discretion of the investigator up to Week 24. Patients in the experimental and active comparator treatment arms follow the same visit schedule.
2951746|NCT02891837|Experimental|L-citrulline|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;~Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~9 mg/kg/hr continuous infusion for up to 48 hours."
2951747|NCT02891837|Placebo Comparator|Placebo|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;~Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~9 mg/kg/hr continuous infusion for up to 48 hours."
2951748|NCT02891824|Placebo Comparator|Arm A: Placebo + Avastin + platinum-based chemotherapy|"The placebo arm:~Placebo 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by placebo 1200mg q3wk until progression"
2951749|NCT02891824|Experimental|Arm B: Atezolizumab + Avastin+ platinum-based chemotherapy|"The atezolizumab arm:~Atezolizumab 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by atezolizumab 1200mg q3wk until progression"
2951750|NCT02891811|Experimental|Induction Arm A|"Carfilzomib + Thalidomide + Dexamethasone (KTd) for 9 cycles (day 1-28) Followed by second randomisation: maintenance arm with carfilzomib monotherapy versus observation only arm"
2951751|NCT02891811|Active Comparator|Induction Arm B|"Carfilzomib + Lenalidomide + Dexamethasone (KRd) for 9 cycles (day 1-28) Followed by second randomisation: maintenance arm with carfilzomib monotherapy versus observation only arm"
2951752|NCT02891798|Experimental|Bupivacaine + CBD|Patients will receive a nerve block consisting of bupivacaine plus clonidine-buprenorphine-dexamethasone (Bupivacaine-CBD)
2951753|NCT02891798|Active Comparator|Bupivacaine Only (control arm)|Patients will receive a nerve block consisting of bupivacaine only.
2951754|NCT02891785|Experimental|ANtiPain intervention|ANtiPain is a cancer pain self-management support intervention administered by nurses in an intervention session while the patient is still hospitalized and via phone calls after discharge. ANtiPain is based on three key strategies: information, skill building and nurse coaching.
2951755|NCT02891785|No Intervention|standard care|Standard care will be described as part of the study.
2951756|NCT02891772||Hypotension after anesthetic induction group|Patients with hypotension after anesthetic induction
2951757|NCT02891759|Experimental|Group A: Alloderm RTU|"Prior to the date of mastectomy, the BREAST Q patient-reported outcome survey will be administered for routine clinical care purposes. It may occur before or after enrollment.~On the day of surgery, patients will receive standardized preoperative care, a skin- or nipple-sparing mastectomy from one of two experienced surgical breast oncologists (Dr. Cyr or Dr. Margenthaler), and immediate tissue expander breast reconstruction with Dr. Myckatyn or Dr. Tenenbaum. Uniform operative techniques will be used in both treatment groups. All patients will receive a 16x8 cm (128 sq cm) ADM graft. Patients randomized to Group A will receive Alloderm RTU~A post-operative version of the Breast Q validated in patients who have received tissue expanders will be administered between 1 and 3 months after tissue expander insertion, and again prior to exchange for an implant or flap (or at time of patient-requested removal"
2951844|NCT02891135|Experimental|Intervention|Patients randomized to the intervention arm will be offered immediate treatment initiation under the intervention algorithm (SLATE).
2951845|NCT02891109||patients group|Adults patients with chronic immune thrombocytopenia
2951758|NCT02891759|Experimental|Group B: Cortiva 1mm Allograft Dermis|"Prior to the date of mastectomy, the BREAST Q patient-reported outcome survey will be administered for routine clinical care purposes. It may occur before or after enrollment.~On the day of surgery, patients will receive standardized preoperative care, a skin- or nipple-sparing mastectomy from one of two experienced surgical breast oncologists (Dr. Cyr or Dr. Margenthaler), and immediate tissue expander breast reconstruction with Dr. Myckatyn or Dr. Tenenbaum. Uniform operative techniques will be used in both treatment groups. All patients will receive a 16x8 cm (128 sq cm) ADM graft. Patients randomized to Group B will receive Cortiva 1mm Allograft Dermis~A post-operative version of the Breast Q validated in patients who have received tissue expanders will be administered between 1 and 3 months after tissue expander insertion, and again prior to exchange for an implant or flap (or at time of patient-requested removal"
2951759|NCT02891746||Premature infants|premature infants ≤ 34 weeks of gestation
2951760|NCT02891746||Term infants|neonates ≥ 37 weeks gestation
2951761|NCT02891720|Active Comparator|ARM A: Proteus Sensor System (PSS) First|ARM A will receive Proteus Sensor System (PSS) first. At 12-week intervals participants will crossover to the next condition.
2951762|NCT02891720|No Intervention|ARM B: SOC First|ARM B will 12 weeks of FTC/TDS standard of care (SOC) first. At 12-week intervals participants will crossover to the next condition.
2951763|NCT02891707|Active Comparator|Control Group|The investigators will recruit 20 healthy subjects at Walter Reed National Military Medical Center (WRNMMC) with the goal of consenting and enrolling 15 healthy subjects to assess the reliability and validity the wearable Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD) system.
2951764|NCT02891707|Active Comparator|Amputee Group|The investigators will recruit a total of 130 subjects (65 at WRNMMC and 65 at the Miami VA) with the goal of consenting and enrolling 100 subjects (50 and WRNMMC and 50 at the Miami VA) with lower limb amputation to utilize the ReLOAD system.
2951765|NCT02891694||recurrent corneal erosion|
2951766|NCT02891694||control patients (refractive surgery)|
2951767|NCT02891681|Experimental|NIR/US (Neoadjuvant Chemotherapy Cohort)|"Patients will have the NIR/US baseline scan performed before their first treatment. The desirable schedule will be >= 7 days after initial biopsy to avoid confounding effects from the biopsy related acute inflammatory response.~In addition, patients will also have NIR/US performed at end of cycle 1, end of cycle 2, end of cycle 3, end of cycle 5 (only if treatment regimen changed), and prior to surgery.~The number of NIR/US study visits may vary (5-6) depending on the patient's treatment regimen"
2951768|NCT02891681|Experimental|NIR/US (Neoadjuvant Endocrine Cohort)|"Patients will have the NIR/US baseline scan performed before their first treatment. The desirable schedule will be >= 7 days after initial biopsy to avoid confounding effects from the biopsy related acute inflammatory response.~In addition, patients will also have NIR/US performed at end of cycle 1, end of cycle 2, end of cycle 3, at time of treatment regimen change (only intended for those who have had a change in their regimen), and prior to surgery.~The number of NIR/US study visits may vary (5-6) depending on the patient's treatment regimen"
2951769|NCT02891668||Hypothyroid|Levothyroxine treatment
2951770|NCT02891668||Healthy volunteers|Matched on age and BMI 18 persons
2951771|NCT02891655||surgery for keratoconus|
2951772|NCT02891655||refractive surgery (control patients)|
2951773|NCT02891642||Malignancy, Serous effusion|Analysis of serous effusion through immunomagnetic detection device
2951774|NCT02891629|Experimental|Device use in Healthy volunteers|10 healthy volunteers will be recruited
2951775|NCT02891629|Experimental|Device use in ALS patients|5 ALS patients in early stages will be recruited
2951776|NCT02891616|Experimental|FDG-PET/CT + FLT-PET/CT + PET/MR|"-Baseline, Week 3 (between days 14-20), Week 6 (between days 35-41)~FDG-PET/CT - Patients required to fast for at least 4 hours prior to FDG administration. Roughly 60 minutes prior to PET/CT imaging, FDG will be administered via IV bolus injection. A CT will be performed immediately before PET imaging. Whole body PET imaging will be performed for a total of about 30 minutes.~FLT-PET/CT - Patients required to fast for at least 4 hours prior to FLT administration. Roughly 80 minutes prior to PET/CT imaging, FLT will be administered via IV bolus injection. A CT will be performed immediately before PET imaging. Whole body PET imaging will be performed for a total of about 30 minutes.~PET/MR - A limited whole body scan performed immediately following PET/CT imaging when possible. Should be performed at least once at each time-point. This scan will be of a more limited area and be performed for no more than 30 minutes."
2951777|NCT02891603|Experimental|Pacritinib with Sirolimus and Tacrolimus|"Pacritinib added to standard treatment with Sirolimus and Tacrolimus (PAC/SIR/TAC).~Pacritinib will begin the day of the participant's transplant (Day 0) and will continue until 70 days after the transplant.~Sirolimus will be given the day before transplant and continued daily for at least one year.~Tacrolimus will begin 3 days before transplant and will be given for at least 50 days."
2951778|NCT02891590|Experimental|DTRMWXHS-12|DTRMWXHS-12 only: oral capsules (50 mg and 150 mg strengths), successive administration, dose escalation from 50mg to 100, 200, 400, 600, 800mg daily until MTD. During successive administration, orally once a day, 28 days as a cycle.
2951779|NCT02891564|Experimental|Project:Evo|a mobile 3D video game that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms
2951780|NCT02891551||Patients receiving Azacitidine per daily clinical practice|
2951781|NCT02891538|Experimental|epigallocatechin gallate (EGCG)|Patients randomized to the EGCG arm, will start EGCG within 4-12 weeks of surgery and take EGCG 450 mg PO twice a day.
2951782|NCT02891538|No Intervention|Observation Only|Standard of care surgical resection followed by standard of care colonoscopy at year.
2951783|NCT02891525|Active Comparator|50g glucose intragastric|50g glucose dissolved in 250mL tap water given via nasogastric tube
2951784|NCT02891525|Active Comparator|25g fructose intragastric|25g glucose dissolved in 250mL tap water given via nasogastric tube
2951785|NCT02891525|Active Comparator|220mg acesulfame-K intragastric|220mg acesulfame-K dissolved in 250mL tap water given via nasogastric tube
2951786|NCT02891525|Placebo Comparator|250mL tap water intragastric|250mL tap water given via nasogastric tube
2951846|NCT02891109||control group|Adults without immune thrombocytopenia
2951847|NCT02891083|Experimental|Adjuvant chemotherapy group|Surgery followed by adjuvant chemotherapy,with Paclitaxel and Cisplatin.
2951787|NCT02891512|Experimental|ELF and Xinepa®|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues. Xinepa® is a dietary supplement containing alpha-lipoic acid, N-acetyl-L-carnitine, turmeric, vitamins B, E and C. They have an antioxidant and anti-inflammatory action on nervous system and they act on cellular energy metabolism.
2951788|NCT02891512|Placebo Comparator|ELF and Placebo Xinepa®|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues. Xinepa® without its specific activity for the condition being treated.
2951789|NCT02891499|Experimental|LLLT + immediate force|Use of Low-level laser therapy and not mediate orthodontic force application (150 gF the day of the implantation).
2951790|NCT02891499|Experimental|LLLT + mediate force|Use of Low-level laser therapy and mediate orthodontic force application (150 gF 4 weeks after the day of the implantation).
2951791|NCT02891499|No Intervention|Immediate force application|Not mediate orthodontic force application (150 gF the day of the implantation), without use of Low-level laser therapy.
2951792|NCT02891499|Experimental|Mediate force application|Mediate orthodontic force application (150 gF 4 weeks after the day of the implantation), without use of Low-level laser therapy.
2951793|NCT02891486||Incidence of surgical site infection|The number of spinal surgery patients with surgical site infections.
2951794|NCT02891473|Experimental|Mézières Method group|Sessions of exercises for the recovery of midline symmetry, diaphragmatic breathing exercises, stretching of the latissimus dorsi respecting the global elongation according to the Mézières Method.
2951795|NCT02891473|Active Comparator|Home based exercise program group|Sessions of home based exercises performed by the patients at their domicile after a training session about the exercise program made by a physiotherapy. The exercises aimed at promoting trunk control in static and dynamic position according to the specific guidelines for Parkinson's disease and proprioceptive exercises for the recovery of balance. An illustrated exercises booklet was given to the patient.
2951796|NCT02891460|Experimental|40 mg MMC in 40 mL TC-3.|TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 40 ml of TC-3 gel mixed with 40 mg MMC will be instilled using catheter.
2951797|NCT02891460|Experimental|80 mg MMC in 40 mL TC-3.|TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 40 ml of TC-3 gel mixed with 80 mg MMC will be instilled using catheter.
2951798|NCT02891447|Experimental|HIPEC|Hyperthermic intraperitoneal chemoperfusion (HIPEC) treatment during cytoreduction surgery and gastrectomy. HIPEC is a heated chemotherapy treatment delivered directly inside the abdomen over about 60 minutes containing mitomycin and cisplatin.
2951799|NCT02891434|Experimental|Acquisition on TouchScreen|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
2951800|NCT02891434|Experimental|Acquisition on Kinect|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
2951801|NCT02891434|Experimental|Acquisition on LeapMotion|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
2951802|NCT02891434|Active Comparator|Acquisition on TouchScreen Control Group|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
2951803|NCT02891434|Active Comparator|Acquisition on Kinect Control Group|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
2951804|NCT02891434|Active Comparator|Acquisition on LeapMotion Control Group|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
2951805|NCT02891421|Other|Therapeutic Horseback Riding|Therapeutic Horseback Riding: Veterans were matched to a horse by the instructor and occupational therapist for best fit and the same horse was ridden each week
2951806|NCT02891421|Other|Standard Care|Participants received standard care.
2951807|NCT02891408|Experimental|Cohort 1 (Mild Hepatic Impairment)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of 20 mg (2 x 10 mg) GS-0976 capsule (s).
2951808|NCT02891408|Experimental|Cohort 2 (Moderate Hepatic Impairment)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of 20 mg (2 x 10 mg) GS-0976 capsule (s).
2951809|NCT02891408|Experimental|Cohort 3 (Severe Hepatic Impairment)|Based on the cumulative review of safety and PK data from Cohorts 1 and 2, Cohort 3 may or may not be initiated at the discretion of the investigator and Sponsor. If Cohort 3 is initiated, participants with severe hepatic impairment and matched healthy controls will receive a single dose of 5 mg (1 x 5 mg) GS-0976 tablet (s).
2951810|NCT02891395|Experimental|open-label|"Induction phase: Imatinib mesylate - starting with 100 mg/day with increase of 100 mg/day each other week up to maximum tolerable dose or 400 mg/day whichever occurred first. For the responders and in absence of toxicity, the treatment will be maintained up to one year.~Salvage phase:~Nilotinib - starting with 200 mg/day with increase of 200 mg/day each other week up to maximum tolerable dose or 800 mg/day whichever occurred first. In absence of toxicity, the treatment will be maintained up to one year."
2951811|NCT02891382|Experimental|Individual incentives - Arm 1|This arm receives diabetes education + goal setting + individual rewards
2951812|NCT02891382|Experimental|Mixed incentives (Altruism) - Arm 2|This arm receives diabetes education + goal setting + companion support + individual rewards
2951813|NCT02891382|Experimental|Mixed Incentives (Cooperation) - Arm 3|This arm receives diabetes education + goal setting + companion support + shared rewards
2951814|NCT02891356||Anorexia patient|Dual Energy X-ray Absorptiometry (DEXA)
2951815|NCT02891343|Experimental|Healthy volunteers|
2951816|NCT02891330|Experimental|Dietary and nutritional recommendations|Postoperative personalized approach based on dietary and nutritional recommendations conducted by a nurse
2951817|NCT02891330|No Intervention|Standard of care|Postoperative standard of care
2951841|NCT02891161|Experimental|Arm B: Investigational Treatment Phase II|Subjects will receive durvalumab 1500mg Q4 weekly with RT to gross disease over 36 fractions. Durvalumab will start on Day 1. RT to start on Day 1 or 2.. Subjects will receive adjuvant durvalumab monotherapy Q4 week, up to 12 months. Adjuvant durvalumab monotherapy to start 4 weeks post completion of durvalumab and RT.
2951842|NCT02891148|Experimental|BI 690517|
2951818|NCT02891317||Cataract Surgery Only|Twenty-five participants with mild or moderate open angle glaucoma (OAG) controlled by medication with a visually significant cataract that meets clinical criteria for cataract surgery will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for cataract surgery only (Group 1) will be recruited to this group. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
2951819|NCT02891317||Cataract Surgery with iStent|Twenty-five participants with mild or moderate open angle glaucoma (OAG) that meets clinical criteria for cataract surgery with implantation of an iStent trabecular micro-bypass shunt will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for cataract surgery with iStent (Glaukos Corp., Laguna Hills, CA) implantation (Group 2) will be recruited to this group. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
2951820|NCT02891317||Glaucoma Drainage Device|Twenty-five participants with moderate or severe open angle glaucoma (OAG) that meets clinical criteria for implantation of a glaucoma drainage device (Group 3) will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for implantation of a glaucoma drainage device (Group 3) will be recruited to this group. There will be 25 participants in each of the groups. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
2951821|NCT02891304||Quarterly Feedback|In addition to each center's traditional endoscopic feedback for trainees, centers/trainees will receive objective feedback every 3-months on trainee overall performance including learning curves on ACE tool performance, performance relative to de-identified anonymous peers on each of the individual skills (e.g. fine tip control), and the global assessment for technical and cognitive skill achievement. For those skills which are not advanced/superior - trainees will additionally receive links to online didactic videos which teach these skills.
2951822|NCT02891304||Annual Feedback|In addition to each center's traditional endoscopic feedback for trainees, centers/trainees will receive learning curves at the end of each training year. Learning curves, relative to de-identified anonymous peers will be provided to program directors annually (June).
2951823|NCT02891278|Experimental|Sertraline with cytosine arabinoside|"All subjects will receive the following:~Induction phase~Sertraline, twice daily at one of the pre-defined dose levels~Cytosine arabinoside, on days 1 and 10~Consolidation phase~Patients who achieve complete remission (CR) or complete remission with incomplete count recovery (CRi) and are eligible for allogeneic stem cell transplantation will receive one of the following:~Allogeneic SCT and off study~Repeat cycle of oral sertraline and cytosine arabinoside IV infusion~Maintenance phase with sertraline for cycles of 28 days in length"
2951824|NCT02891265|No Intervention|Group A|Group A - smoking cessation with no assistance
2951825|NCT02891265|Placebo Comparator|Group B|Group B - smoking cessation with the addition of a smoking cessation patch
2951826|NCT02891252|Active Comparator|outpatient|outpatient
2951827|NCT02891252|No Intervention|inpatient|inpatient
2951828|NCT02891239|Experimental|PicoWay laser treatment|3 wavelength tattoo treatment with picosecond laser (PicoWay)
2951829|NCT02891226|Experimental|Mirikizumab Dose Level 1|"Period 1 (Weeks 0 -12) Mirikizumab dose level 1~Period 2 (Weeks 12 - 52) Mirikizumab dose level 1 or dose level 4 or dose level 3~Period 3 (Weeks 52 - 104) Mirikizumab dose level 4"
2951830|NCT02891226|Experimental|Mirikizumab Dose Level 2|"Period 1 (Weeks 0 -12) Mirikizumab dose level 2~Period 2 (Weeks 12 - 52) Mirikizumab dose level 2 or dose level 4 or dose level 3~Period 3 (Weeks 52 - 104) Mirikizumab dose level 4"
2951831|NCT02891226|Experimental|Mirikizumab Dose Level 3|"Period 1 (Weeks 0 -12) Mirikizumab dose level 3~Period 2 (Weeks 12 - 52) Mirikizumab dose level 3 or dose level 4~Period 3 (Weeks 52 - 104) Mirikizumab dose level 4"
2951832|NCT02891226|Placebo Comparator|Placebo|"Period 1 (Weeks 0 -12) Placebo~Period 2 (Weeks 12 - 52) Mirikizumab dose level 3~Period 3 (Weeks 52 - 104) Mirikizumab dose level 4"
2951833|NCT02891213||LE (Lupus Erythematosus) group|"Samples of the LE (Lupus Erythematosus) group from a specimen collection : Lupus BioBanque du Rhin Supérieur (LBBR UF 9882).~It's a historical cohort of lupic patients which samples have been collected from many centers in France and Germany and stored in a biobank Lupus BioBanque du Rhin Supérieur (project : LBBR UF 9882)."
2951834|NCT02891200|Experimental|Healthcare professional (HCP) Arm|Healthcare professional (HCP) Arm includes a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
2951835|NCT02891200|Experimental|HCP plus Peer arm|HCP plus Peer arm involves delivering of HCP support as in HCP Arm , along with adding Peer Support Program services. This program is offered to participants by especially trained 'peer mentors' with oversight from a social worker.
2951836|NCT02891187|Active Comparator|Outpatient Clinic Visits|Outpatient clinic visits for postoperative care is currently the standard of care. Patients who undergo surgery for a pelvic floor disorder will be scheduled appointments in the outpatient clinic at 1-2 weeks, 6 weeks, and 3 months where they will be evaluated by a physician.
2951837|NCT02891187|Active Comparator|Telephone Follow-up|Patients will be called instead of returning to clinic for postoperative care at 1-2 weeks, 6 weeks, and 3 months.
2951838|NCT02891174|Active Comparator|Ibuprofen followed by acetaminophen|Ibuprofen administered immediately post-partum, 600 mg (3 x 200 mg tablets) every 6 hours for 24 hours followed by acetaminophen, 650 mg (2 x 325 mg tablets) every 6 hours for 24 hours.
2951839|NCT02891174|Active Comparator|Acetaminophen followed by ibuprofen|Acetaminophen administered immediately post-partum, 650 mg (2 x 325 mg tablets) every 6 hours for 24 hours followed by ibuprofen, 600 mg (3 x 200 mg tablets) every 6 hours for 24 hours.
2951840|NCT02891161|Experimental|Arm A: Safety Run In Phase Ib|Subjects will receive durvalumab 1500mg Q4 weekly with RT to gross disease over 36 fractions. Durvalumab will start on Day 1. RT to start on Day 1 or 2. Subjects will receive adjuvant durvalumab monotherapy Q4 week, up to 12 months. Durvalumab monotherapy to start 4 weeks post completion of durvalumab and RT.
2951843|NCT02891135|No Intervention|Standard|Patients randomized to the standard arm will receive standard procedures for initiating antiretroviral therapy for HIV.
2951850|NCT02891070|Experimental|FS VH S/D 500 s-apr|FS VH S/D 500 s-apr (Tisseel), single use treatment, intraoperative
2951851|NCT02891070|Active Comparator|DuraSeal Dural Sealant|DuraSeal Dural Sealant, single use treatment, intraoperative
2951852|NCT02891057|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2951853|NCT02891044|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2951854|NCT02891031|Active Comparator|Rhus (Somagh)|500 mg twice daily after meal for 6 weeks
2951855|NCT02891031|Placebo Comparator|Placebo|500 mg twice daily after meal for 6 weeks
2951856|NCT02891018|Experimental|paclitaxel controlled release balloon catheter|Patients treated with paclitaxel controlled release balloon catheter
2951857|NCT02891018|Experimental|paclitaxel release coronary balloon catheter|Patients treated with paclitaxel release coronary balloon catheter
2951858|NCT02891005|Experimental|paclitaxel controlled release balloon catheter|Patients treated with paclitaxel controlled release balloon catheter
2951859|NCT02891005|Experimental|common balloon catheter|Patients treated with common balloon catheter
2951860|NCT02890992|Experimental|Cohort 1 - Dose 1|Alirocumab Dose 1 will be administered subcutaneously (SC). Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.
2951861|NCT02890992|Experimental|Cohort 1 - Dose 2|Alirocumab Dose 2 will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.
2951862|NCT02890992|Experimental|Cohort 2 - Dose 3|Alirocumab Dose 3 will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.
2951863|NCT02890992|Experimental|Cohort 2 - Dose 4|Experimental - Alirocumab Dose 4 will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.
2951864|NCT02890992|Experimental|Cohort 3 - Dose 5|Experimental - Alirocumab Dose 5 will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.
2951865|NCT02890992|Experimental|Cohort 3 - Dose 6|Experimental - Alirocumab Dose 6 will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.
2951866|NCT02890992|Experimental|Cohort 4 - Dose 7|Alirocumab Dose 7 will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.
2951867|NCT02890992|Experimental|Cohort 4 - Dose 8|Alirocumab Dose 8 will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.
2951868|NCT02890979|Experimental|Screening (cytology collection)|Patients undergo cytology specimen collection procedure using a swallowable sponge cell sampling device.
2951869|NCT02890966|Experimental|Cohort 1|1mg SHR4640 or placebo
2951870|NCT02890966|Experimental|Cohort 2|2.5mg SHR4640 or placebo
2951871|NCT02890966|Experimental|Cohort 3|5mg SHR4640 or placebo
2951872|NCT02890966|Experimental|Cohort 4|10mg SHR4640 or placebo
2951873|NCT02890953|Placebo Comparator|Control|Control group receives placebo medication (normal saline)
2951874|NCT02890953|Experimental|MSC group|MSC group receives mesenchymal stem cells transplantation (Pneumostem)
2951875|NCT02890940|Experimental|Pet Therapy|
2951876|NCT02890927|Experimental|Cardio-geriatric co-management|A geriatric co-management intervention will be implemented on the cardiology units of the University Hospitals Leuven. Geriatric co-management is defined as a shared responsibility and decision making between the cardiology team and the geriatric team who provides complementary medical care in the prevention and management of geriatric problems. Patients included in the co-management program will undergo a comprehensive geriatric assessment within 24 hours of hospital admission.
2951877|NCT02890927|No Intervention|Standard of care|The control group will receive the standard of care on the cardiology units. This includes multidisciplinary care with a one weekly multidisciplinary team meeting. Team members include a cardiology resident (supervised by a cardiologist), ward nurses, a physical therapist, a social worker and a dietician. A geriatric consultation team is available for consultation services if requested by the cardiology team.
2951878|NCT02890914|No Intervention|Standard Education|These residents received their standard residency education and experience.
2951879|NCT02890914|Experimental|DVD Intervention|These residents received a one-hour long DVD lecture in addition to standard residency education and experience.
2951880|NCT02890888|Experimental|Hyperbaric oxygen treatment|HBO for 1 hour at 2 ATA 10 times, administered 5 times per week over 2 consecutive weeks
2951881|NCT02890875|Active Comparator|Ethanol lock|70% ethanol
2951882|NCT02890875|Active Comparator|Heparin lock|Heparinized saline (100 U/mL)
2951883|NCT02890862||20 healthy volunteers|
2951884|NCT02890862||Dupuytren disease|10 patients dupuytren disease
2951885|NCT02890862||Tendon pathology|10 patients with tendon pathology
2951886|NCT02890862||wrist osteoarthritis|10 patients with wrist osteoarthritis
2951887|NCT02890849|Experimental|a prospective, open, self-controlled phase I clinical study|The project is planned to explore the consistency analysis of PD-L1 expression level detected in cancer tissues and pExo.We have designed to detected the expression levels of PD-L1 mRNA and protein in cancer tissue and detected the expression levels of PD-L1 mRNA in pExo.by using variance analysis of repeated measures design information.
2951888|NCT02890836||Pregnant women with pre-existing diabetes|Inclusion of 400 women is anticipated.
2951889|NCT02890836||Healthy pregnant women|Inclusion of 100 women is anticipated
2951890|NCT02890823|Experimental|EIAEDs-1000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 1000 IU once daily
2951891|NCT02890823|Experimental|EIAEDs-3000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 3000 IU once daily
2951892|NCT02890823|Experimental|EIAEDs-6000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 6000 IU once daily
2951893|NCT02890823|Active Comparator|non-EIAEDs-1000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 1000 IU once daily
2951894|NCT02890823|Active Comparator|non-EIAEDs-3000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 3000 IU once daily
2951895|NCT02890823|Active Comparator|non-EIAEDs-6000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 6000 IU once daily
2951896|NCT02890810|Experimental|Verum Electroacupuncture|Active Intervention
2951897|NCT02890810|Placebo Comparator|Placebo Electroacupuncture|Validated Control
2951898|NCT02890797|Other|Bronchiolitis children|Under two years old patient with bronchiolitis will have thoracic radiology
2951899|NCT02890784|Active Comparator|A. Standard arm|100mg dasatinib (SPRYCEL®) daily dose (QD) (7x100) (Standard therapy)
2951900|NCT02890784|Experimental|B. Study arm|100mg dasatinib (SPRYCEL®) (QD) weekdays (1-5) only (5x100+2x0) (overall dose reduction per week)
2951901|NCT02890771|Active Comparator|Tooth Brushing|Tooth brushing with dentifrice
2951902|NCT02890771|Experimental|Turmeric massaging|Tooth Brushing,massaging with whole turmeric powder
2951903|NCT02890771|Experimental|SRP with turmeric massaging|SRP with turmeric massaging on half arch
2951904|NCT02890758|Experimental|Cytokine Arm|Two infusions of Natural Killer (NK) cells and ALT803
2951905|NCT02890758|Active Comparator|No Cytokine Arm|Two infusions of Natural Killer (NK) Cells
2951906|NCT02890745|Experimental|Empagliflozin|One tablet 25 mg empagliflozin every morning for 14 days
2951907|NCT02890745|Placebo Comparator|Placebo|One tablet placebo every morning for 14 days
2951908|NCT02890732|Experimental|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
2951909|NCT02890719|Experimental|Genotype 1B|treatment 12 weeks
2951910|NCT02890719|Experimental|Genotype 1A and 4|treatment 16 weeks
2951911|NCT02890706|Other|Patients|Each patient undergo the same CT protocol. Theobservers will observe the detection of the perfusion defects in two different techniques.
2951912|NCT02890693|Experimental|interdisciplinary lifestyle/psychosocial|The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions.
2951913|NCT02890693|No Intervention|treatment as usual|Usual clinical follow-up and treatment is based on the current American Diabetes Association, the Endocrine Society guidelines, and the NICE guidelines.
2951914|NCT02890680|Experimental|Platelet-rich fibrin group|Use platelet-rich fibrin after mandibular third molar extraction
2951915|NCT02890680|Placebo Comparator|Control group|mandibular third molar extraction
2951916|NCT02890667||Beneficiaries|Incident cancer for Beneficiaries present in the EGB on January 1, 2012.
2951917|NCT02890654||Teenagers with scoliosis|"Patients will be evaluated at three times during the study :~First time measure : 1 month before the scoliosis surgery~Second time measure : 3 months after the scoliosis surgery~Third time measure : 1 year after the scoliosis surgery"
2951918|NCT02890641||Patients with Focal Cortical Dysplasia|
2951919|NCT02890628||pregnant/post-natal adolescents (<20 years)|12-24 individual with pregnant or postnatal adolescent girls (<20 years) will be interviewed.
2951920|NCT02890628||non-pregnant female adolescents (<20 years)|1 Focus group discussion of 6-10 non-pregnant female adolescents (<20 years)
2951921|NCT02890628||male adolescents (<20 year)|1 Focus group discussion of 6-10 adolescent men (<20 years)
2951922|NCT02890628||SMRU health staff of antenatal clinics (ANC)|1 Focus group discussion of 6-10 Shoklo Malaria Research Unit antenatal clinic staff
2951923|NCT02890615|Experimental|Depression Self-care Intervention (SCI)|"Intervention group participants will receive the Depression Self-Care Toolkit for Cancer Survivors and will be supported by telephone by a coach who will help to activate them, guide them through the materials, help in selecting appropriate tools, and provide positive reinforcement. Coach contacts will be made every week for 3 months followed by 3 monthly contacts, up to a maximum of 15 contacts, lasting 10-20 minutes each.~The coach uses a stepped approach (i.e. educate about depression, initiate mood monitoring, determine participant's goals with respect to reducing depressive symptoms, and help with the use of specific tools). A suggested script is provided for the coach as a framework for each call. Tailoring of the SCI to different participants will be based on problems, depressive symptoms (from the PHQ-9), or concerns a participant may raise during the call."
2951924|NCT02890615|No Intervention|Control group|"Members of both groups will continue to receive usual care for their depression. We will not interfere with usual care beyond recommending that participants discuss their depressive symptoms with their doctor. If participants consent, a short progress report will be send to their treating physician at the end of the study. At each follow-up, we will ask participants about specific treatment they have received for depression since entering the study (antidepressant medication initiation, discontinuation, change of dose, or psychotherapy) and use of community resources. The Intervention group will receive the Depression SCI. The Control group will receive only usual care for 6 months after randomization; they will be given the Toolkit with a single coaching call upon completion of the final interview, to ensure their access to depression treatment."
2951925|NCT02890602|Experimental|Darbepoietin alfa|Hemoglobin level will be checked at every cycle's day 0 or 1(1cycle is 21days) after starting Darbepoietin alfa. It will be applied to chemotherapy until increment of hemoglobin 12.0 g/dL.
2951926|NCT02890589|Experimental|SYNERGY Stent|The SYNERGY™ stent is a Device marked CE (European Conformity), platinum chromium coronary stent, currently developped by Boston Scientific™. This stent has been designed with the goal of providing optimal and rapid healing within the vessel using a bioabsorbable polymer to elute everolimus.
2951927|NCT02890589|Experimental|BVS device|The ABSORB Everolimus-eluting Bioresorbable Vascular Scaffold (BVS 1.1, Abbott Vascular, California, USA, CE approved) is Device marked CE, currently the most studied PLA (Polylactic acid) based scaffold. It consists of PLLA (Poly I-lactic acid) backbone with 1:1 PDLLA (Poly-DL Lactic Acid) drug surface coating and a total strut thickness of 156 μm.
2951971|NCT02890368|Experimental|TTI-621 + Radiation|Combination Therapy Expansion Cohort of TTI-621 plus Radiation Therapy
2951928|NCT02890576||telemedicine|Setting up of a new organization of medical monitoring (ussing telemedicine) of patient having a cochlear implant
2951929|NCT02890563|No Intervention|No Compression|Patients in this group will not receive any compression after treatment.
2951930|NCT02890563|Active Comparator|Compression|Patients in this group will use compression stockings for seven days after treatment (2 days continuously and 5 days during daytime).
2951931|NCT02890550||30 Patients Alström syndrome|
2951932|NCT02890550||60 Related patients Alström syndrome|
2951933|NCT02890537|Experimental|Core decompression/PREOB® implantation|Core decompression/autologous osteoblastic cells (PREOB®) implantation
2951934|NCT02890537|Active Comparator|Core decompression/BMC implantation|Core decompression/bone marrow concentrate (BMC) implantation
2951935|NCT02890524|Experimental|Night guard|the night guard made of EVA
2951936|NCT02890524|Placebo Comparator|Placebo night guard|Placebo night guard made of EVA
2951937|NCT02890511|Experimental|DHP107(Oral paclitaxel)|"Phase I (determining MTD) The patients diagnosed with either advanced or metastatic solid cancers were enrolled. The administered dose was escalated in a step-wise manner by an increment of 2 x 50 mg/m2 at each dose level. Three patients were treated for toxicity evaluation for each dose level.~Phase IIa (efficacy evaluation) The safety and efficacy of the corresponding dose was investigated more closely by increasing the patient number to 6 or more patients in the dose tentatively determined as recommended dose for phase IIa clinical trial."
2951938|NCT02890485|Experimental|Glute Dry Needling|Receives dry needling to their gluteal muscles in addition to standard physical therapy treatment.
2951939|NCT02890485|Experimental|Quad Dry Needling|Receives dry needling to their quadriceps muscles in addition to standard physical therapy treatment.
2951940|NCT02890485|Sham Comparator|Glute Sham Dry Needling|Receives sham dry needling to their gluteal muscles in addition to standard physical therapy treatment.
2951941|NCT02890485|Sham Comparator|Quad Sham Dry Needling|Receives sham dry needling to their quadriceps muscles in addition to standard physical therapy treatment.
2951942|NCT02890485|Active Comparator|Control|Receives only standard physical therapy treatment.
2951943|NCT02890472||prenatal diagnosis of a fetal 22q11 deletion syndrome|
2951944|NCT02890459|Active Comparator|Aim 1 - Fixed Incentive|Fixed Incentive - Prize Prize incentive - Low Prize incentive - High
2951945|NCT02890459|Experimental|Aim 1 - Loss Aversion|Loss Aversion - Prize Prize incentive - Low Prize incentive - High
2951946|NCT02890459|Experimental|Aim 1 - Lottery|Lottery - Prize Prize incentive - Low Prize incentive - High
2951947|NCT02890459|Active Comparator|Aim 2 - Standard Care|Standard care Travel voucher
2951948|NCT02890459|Experimental|Aim 2 - Enhanced Care (Intervention)|Escalating payment incentive Travel voucher
2951949|NCT02890459|Experimental|Aim 3 Pilot - Loss Aversion|Loss Aversion - Deposit
2951950|NCT02890459|Experimental|Aim 3 Pilot - Fixed Incentive|Fixed Incentive - Voucher
2951951|NCT02890459|No Intervention|Aim 3 Pilot - No incentive|Participants will be encouraged to come for repeat HIV testing, but no incentive will be offered.
2951952|NCT02890459|Experimental|Aim 3 Trial - Loss Aversion|Loss Aversion - Deposit
2951953|NCT02890459|Experimental|Aim 3 Trial - Fixed Incentive|Fixed Incentive - Voucher
2951954|NCT02890459|No Intervention|Aim 3 Trial - No incentive|Participants will be encouraged to come for repeat HIV testing, but no incentive will be offered.
2951955|NCT02890446|Experimental|External Focus (EF)|"Participants received arm training using the InMotion2 robot under external focus practice conditions and instructions. Participants practiced arm reaching by playing a simple video game.~EF instructions: Focus on moving the yellow ball on the screen in a smooth, straight line at a constant speed; Move the yellow ball toward the blinking red/orange light; and Hit the center of the target and try not to overshoot the target"
2951956|NCT02890446|Experimental|Internal Focus (IF)|"Participants received arm training using the InMotion2 robot without the video game interface. Participants were instructed to think about how they were moving their arm while completing the arm training tasks.~IF instructions:~think about how you're moving your arm; push your arm away from you; pull your arm toward you; move your arm to the right/left"
2951957|NCT02890420||Female children|Female children in third year of preschool in Thionville (north-eastern France)
2951958|NCT02890420||Male children|Male children in third year of preschool in Thionville (north-eastern France)
2951959|NCT02890394|Experimental|2 minutes Group|The group was perform the technique inhibition suboccipital two minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
2951960|NCT02890394|Experimental|4 minutes Group|The group was perform the technique inhibition suboccipital four minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
2951961|NCT02890394|Experimental|8 minutes Group|The group was perform the technique inhibition suboccipital eight minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
2951962|NCT02890394|No Intervention|not intervention Group|The not intervention group will be asked to lie supine on the table for ten minutes, collecting data by measuring with algometer and test repositioning of the head before and after laying.
2951963|NCT02890381|Experimental|RSV LID cp ΔM2-2 Vaccine|Participants received a single dose of the RSV LID cp ΔM2-2 vaccine at study entry (Day 0).
2951964|NCT02890381|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
2951965|NCT02890368|Experimental|TTI-621 Monotherapy Escalation|TTI-621 Escalation phase of single or multiple doses of TTI-621 delivered by intratumoral injections (various dose cohorts).
2951966|NCT02890368|Experimental|TTI-621 Monotherapy (Single Lesion)|TTI-621 Single Lesion Injection Expansion Cohort
2951967|NCT02890368|Experimental|TTI-621 Monotherapy (Multiple Lesions)|TTI-621 Multiple Lesion Injections Expansion Cohort
2951968|NCT02890368|Experimental|TTI-621 + PD-1/PD-L1 Inhibitor|Combination Therapy Expansion Cohort of TTI-621 plus PD-1/PD-L1 Inhibitor
2951969|NCT02890368|Experimental|TTI-621 + Pegylated Interferon-α2a|Combination Therapy Expansion Cohort of TTI-621 plus Pegylated Interferon-α2a
2951970|NCT02890368|Experimental|TTI-621 + T-Vec|Combination Therapy Expansion Cohort of TTI-621 plus T-Vec
2952010|NCT02890069|Experimental|NSCLC - PDR001+ Everolimus|Dose escalation completed, expansion arm.
2951972|NCT02890355|Experimental|Arm I (veliparib and mFOLFIRI)|Patients receive veliparib PO BID every 12 hours on days 1-7, irinotecan hydrochloride IV over 90-120 minutes on day 3, leucovorin calcium IV over 90-120 minutes on day 3, and fluorouracil IV over 46 hours on days 3-5.
2951973|NCT02890355|Active Comparator|Arm II (FOLFIRI)|Patients receive irinotecan hydrochloride IV over 90-120 minutes on day 1, leucovorin calcium IV over 90-120 minutes on day 1, and fluorouracil IV bolus over 15 minutes on days 1 and then over 46 hours on days 1-3.
2951974|NCT02890342||Propiomic Academia|Patients with Propionic Acidemia and their family members.
2951975|NCT02890329|Experimental|Arm A (decitabine, ipilimumab)|"INDUCTION PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 4 or 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
2951976|NCT02890329|Experimental|Arm B (decitabine, ipilimumab)|"INDUCTION PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 4 or 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
2951977|NCT02890316|Experimental|Radiation therapy with Homeopathy|Patients in this arm will receive the homeopathy remedy during the adjuvant radiation therapy period, from treatment number 16 until the last assessment, 3 times every day.
2951978|NCT02890316|Placebo Comparator|Radiation therapy with placebo|Patients in this arm will receive the placebo remedy during the adjuvant radiation period, from treatment number 16 until the last assessment, 3 times every day.
2951979|NCT02890303|Experimental|Zepto Capsulotomy|This study will evaluate outcome in subjects who have elected to have Zepto capsulotomies during cataract surgery. Effectiveness Rate - An effectiveness rate of 95% complete capsulotomies provides reasonable assurance that the Zepto system is effective. Primary Safety Endpoint - Posterior Capsular Rupture & Vitreous Loss (4% or less)
2951980|NCT02890290|Active Comparator|Intervention|Marine protein hydrolysate pills (3000mg)
2951981|NCT02890290|Placebo Comparator|Control|Placebo pills (gum arabicum)
2951982|NCT02890277|Experimental|Treatment group|
2951983|NCT02890238|Active Comparator|sildenafil citrate|50 women who will be given clomiphene citrate 50mg (clomid,) orally 2times/day from 2rd - 7th day of the cycle and sildenafil citrate 20mg tab from 7th-11th day of the same cycle orally 3times/day
2951984|NCT02890238|Placebo Comparator|placebo group|50 women who will be given clomiphene citrate 50mg (clomid,) orally 2times/day from 2rd- 7th day of the cycle and placebo tablets from 7th-11th day of the same cycle orally 3 times/day
2951985|NCT02890225|Other|3|Patients in 3 days
2951986|NCT02890225|Other|10|Patients in10ys
2951987|NCT02890225|Experimental|30|Patients in10ys
2951988|NCT02890212|Experimental|selenium|subjects resistant to treatment of major depression with sertraline who were randomized and ingest selenium pills (400 microgram) during six weeks
2951989|NCT02890212|Placebo Comparator|placebo|subjects resistant to treatment of major depression with sertraline who were randomized and ingest placebo pills
2951990|NCT02890199|Active Comparator|Lidocaine group|0.5% lidocaine mixed with 1:200,000 epinephrine 70 milliliters (mL) will be used for local injection at the sacrospinous ligament and for anterior / posterior colporrhaphy
2951991|NCT02890199|Experimental|Bupivacaine liposomal group|1.3% bupivacaine liposomal (20 mL) injected at the sacrospinous ligament 0.5% lidocaine mixed with 1:200,000 epinephrine 50mL for the anterior / posterior colporrhaphy
2951992|NCT02890186|Experimental|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
2951993|NCT02890186|Placebo Comparator|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
2951994|NCT02890173|Experimental|CS-3150 2.5 mg|CS-3150 2.5 mg, orally, once daily after breakfast for 12 weeks
2951995|NCT02890173|Experimental|CS-3150 5.0 mg|CS-3150 5 mg, orally, once daily after breakfast for 12 weeks
2951996|NCT02890173|Active Comparator|Eplerenone|Eplerenone 50 mg, orally, once daily after breakfast for 12 weeks
2951997|NCT02890160|Experimental|Firesorb|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）
2951998|NCT02890160|Active Comparator|XIENCE|Implantation of the XIENCE Everolimus Eluting Coronary Stent System
2951999|NCT02890108|Experimental|Sugar sweetened beverages|Subjects will receive, in 3 different ocassions, 350cc (1 can) of a sugar sweetened beverage, that contain 38,7 grams of carbs and 154 kcal, separated by at least 1 week each one
2952000|NCT02890108|Experimental|Artificially sweetened beverage|Subjects will receive, in 3 different ocassions, 350cc (1 can) of a artificially sweetened beverage, that contain 84 mg of Aspartame, 56 mg of Acesulfame K and 0,7 kcal, separated by at least 1 week each one
2952001|NCT02890095|Experimental|Arm A = Breast Cancer surgery|Arm A : women undergoing breast cancer surgery.
2952002|NCT02890095|Other|Arm B = Control (plastic surgery)|Arm B : women undergoing breast surgery for the purpose of plastic surgery
2952003|NCT02890082|Experimental|Tamoxifen stim in early follicular phase|Day cycle of the patient when ovarian stimulation begin (early follicular phase) = D1 to D3
2952004|NCT02890082|Other|Tamoxifen stim in late follicular phase|Day cycle of the patient when ovarian stimulation begin (late follicular phase) = D4 to D14
2952005|NCT02890082|Other|Tamoxifen stim in luteal phase|Day cycle of the patient when ovarian stimulation begin (luteal phase) = D15 to D28
2952006|NCT02890069|Experimental|CRC - PDR001 + LCL161|Dose escalation completed; expansion arm.
2952007|NCT02890069|Experimental|NSCLC - PDR001 + LCL161|Dose escalation completed, expansion arm.
2952008|NCT02890069|Experimental|TNBC - PDR001 + LCL161|Dose escalation completed, expansion arm.
2952009|NCT02890069|Experimental|CRC - PDR001+ Everolimus|Dose escalation completed, expansion arm.
2952011|NCT02890069|Experimental|TNBC - PDR001+ Everolimus|Dose escalation completed, expansion arm.
2952012|NCT02890069|Experimental|CRC - PDR001 + Panobinostat|Enrollment to this combination arm is closed to further enrollment.
2952013|NCT02890069|Experimental|NSCLC - PDR001 + Panobinostat|Enrollment to this combination arm is closed to further enrollment.
2952014|NCT02890069|Experimental|TNBC - PDR001 + Panobinostat|Enrollment to this combination arm is closed to further enrollment.
2952015|NCT02890069|Experimental|CRC - PDR001 + QBM076|Dose escalation.
2952016|NCT02890069|Experimental|TNBC - PDR001 + QBM076|Dose escalation.
2952017|NCT02890069|Experimental|NSCLC- PDR001 + QBM076|Dose escalation.
2952018|NCT02890069|Experimental|CRC - PDR001 + HDM201|Dose escalation.
2952019|NCT02890069|Experimental|RCC - PDR001 + HDM201|Dose escalation.
2952020|NCT02890056|Experimental|H2GO! intervention|H2GO! is a community-based behavioral intervention to reduce sugar-sweetened beverage consumption and promote water intake among school-age youth and parents.The intervention consists of 6 weekly group-based sessions (1-hour sessions twice a week) that target beverage knowledge, attitudes, and behaviors through interactive activities, youth-produced narratives, and parent-child activities. The intervention is delivered through a youth-based community setting (Boys and Girls Clubs of America) by trained Boys and Girls Club staff.
2952021|NCT02890056|No Intervention|Comparison|Usual care will take place at the comparison site (standard programming at the Boys and Girls Club comparison site).
2952022|NCT02890043|Experimental|Robot|Intervention: Surgery: robot-assisted spine surgery, device: TiRobot surgery system
2952023|NCT02890043|Active Comparator|Free-hand|Intervention: Surgery: free-hand surgery
2952024|NCT02890030||Case-Control|Patients with testicular germ cell tumor who were treated with surgery and not cisplatin-based chemotherapy
2952025|NCT02890017|Experimental|Hotel-Ambu|Outpatient surgery with a patient-hotel night
2952026|NCT02890017|Other|conventional hospitalization|conventional hospitalization
2952027|NCT02889991|Experimental|High Intensity Dry Needling|Maneuver of Input-Output with the acupuncture needle, until the disappearance of local twitch responses or patient tolerance.
2952028|NCT02889991|Experimental|Low Intensity Dry Needling|Maximum 10 input-output maneuvers with acupuncture needle or maximum 3 local twitch responses or patient tolerance.
2952029|NCT02889991|Experimental|Fascial mechanotransduction Dry needling|Maneuver of input, screwing and pulling out of the needle acupuncture.
2952030|NCT02889991|Sham Comparator|Placebo Dry Needling Technique|"Technique is performed with the Park´s Sham device."
2952031|NCT02889978||Cancer arm|Subjects with new diagnosis of cancer (multiple tumor types) from which a blood sample and contemporaneous FFPE tumor tissue will be collected.
2952032|NCT02889978||Non-cancer arm|Subjects with no known diagnosis or past history of cancer from which a blood sample will be collected.
2952033|NCT02889965||Radiologically Isolated Syndromes (RIS)|
2952034|NCT02889965||Clinically Isolated Syndromes (RIS)|
2952035|NCT02889965||Primary progressive MS (PPMS)|
2952036|NCT02889952||NIR-|All consecutive patients (n=174) who underwent conventional total thyroidectomy (TT)+/- lymph node dissection (LND) without the use of NIR - parathyroid identification was done by naked eye only- by surgeon 1, from January 2015 to January 2016 (period 1)
2952037|NCT02889952||NIR|All consecutive patients (n=63) who underwent conventional total thyroidectomy (TT)+/- lymph node dissection (LND) with intraoperative use of NIR - surgical field was examined with NIR before any thyroid dissection- by surgeon 1, from February 2016 to May 2016 (period 2)
2952038|NCT02889952||Control1|Patients (n=30) patients randomly selected among the patients who underwent TT+/- LND without the use of NIR, by another surgeon in the unit (surgeon 2), during period 1.
2952039|NCT02889952||Control2|Patients (n=30) patients randomly selected among the patients who underwent TT+/- LND without the use of NIR, by surgeon 2, during period 2.
2952040|NCT02889939|Other|UC + ETT|"An enriched comprehensive task-specific therapy (ETT) program combining intensive and task-specific therapy with the sensory-motor, social, and cognitive stimulation inherent to environmental enrichment.~The intervention was preceded by a baseline period of usual care (UC) for 3 weeks, which also served as a control."
2952041|NCT02889926|Experimental|a swab according to the method of Levine|
2952042|NCT02889926|Experimental|Bacteriological referred to biopsy|
2952043|NCT02889900|Experimental|combination of cediranib and olaparib|Open label
2952044|NCT02889887||preterm|infants who born before 37 completed weeks
2952045|NCT02889874|No Intervention|A: Radiation Therapy & endocrine therapy|Patients randomized to Arm A will receive standard radiation therapy and adjuvant endocrine therapy (standard of care).
2952046|NCT02889874|Experimental|B: No Radiation Therapy (ET only)|Patients randomized to Arm B will not receive radiation therapy (omission of radiation therapy) and receive adjuvant endocrine therapy only.
2952047|NCT02889861|Experimental|Regimen 1|IMCgp100 weekly dosing regimen (QW)
2952048|NCT02889848|Sham Comparator|Saline only|Injection of saline to assess the injection procedure
2952049|NCT02889848|Experimental|1.16 mg EN3835|Injection of maximum marketed dose of EN3835 regardless of fibroid size
2952050|NCT02889848|Experimental|Dose 1|Injection of 0.05 mg EN3835 per cm3 fibroid
2952051|NCT02889848|Experimental|Dose 2|Injection of 0.1 mg EN3835 per cm3 fibroid
2952052|NCT02889848|Experimental|Dose 3|Injection of 0.2 mg EN3835 per cm3 fibroid
2952053|NCT02889835|Active Comparator|Universal Composite|Supreme Universal Restorative
2952054|NCT02889835|Experimental|Flowable Composite|Supreme Flowable Restorative
2952055|NCT02889835|Experimental|Bulk Fill Flowable Composite|Bulk Fill Flowable Restorative
2952056|NCT02889822|Experimental|Alprostadil Liposomes for Injection|"Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd~Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days."
2952081|NCT02889640|No Intervention|Control group|These youth will receive standard mathematics instruction and support (including possibly other tutoring interventions), but not the daily, intensive, during-the-school-day math tutoring provided by SAGA.
2952158|NCT02889133|Placebo Comparator|Placebo|Subjects will donate blood donation and undergo 24-hour PTR and receive IV saline. After 5 months, subjects will donate blood again, receive IV iron-dextran and undergo 24-hour PTR.
2952057|NCT02889809|Experimental|Fluticasone furoate 50 mcg|During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled FF 50 mcg administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams [mg] for subjects who are 5 years old and 5 mg for subjects who are >= 6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol [inhalation aerosol or nebuliser]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
2952058|NCT02889809|Placebo Comparator|Placebo|During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled placebo administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams [mg] for subjects who are 5 years old and 5 mg for subjects who are >=6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol [inhalation aerosol or nebuliser]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
2952059|NCT02889796|Experimental|Filgotinib Dose A|Filgotinib dose A + placebo to match filgotinib dose B + placebo to match adalimumab in addition to a stable dose of MTX
2952060|NCT02889796|Experimental|Filgotinib Dose B|Filgotinib dose B + placebo to match filgotinib dose A + placebo to match adalimumab in addition to a stable dose of MTX
2952061|NCT02889796|Active Comparator|Adalimumab|Placebo to match filgotinib dose A + placebo to match filgotinib dose B + adalimumab in addition to a stable dose of MTX
2952062|NCT02889796|Placebo Comparator|Placebo|Placebo to match filgotinib dose A + placebo to match filgotinib dose B + placebo to match adalimumab in addition to a stable dose of MTX
2952063|NCT02889757|Experimental|NAC 1200 mg|patients with add NAC (600) 1# bid use per day during the study period
2952064|NCT02889757|Experimental|NAC 2400 mg|patients with add NAC (600) 2# bid use per day during the study period
2952065|NCT02889757|Placebo Comparator|NAC 0 mg|patients with add NAC (600) 0# (placebo) use per day during the study period
2952066|NCT02889744|Active Comparator|36-TH|Core temperature 36℃ of targeted temperature management (36-TH) for 24 hours in cardiac arrest victims using Arctic Sun.
2952067|NCT02889744|Active Comparator|33-TH|Core temperature 33℃ of targeted temperature management (36-TH) for 24 hours in cardiac arrest victims using Arctic Sun.
2952068|NCT02889718|Experimental|anaesthesia with CONCERT-CL® station|During the surgery, 3 drugs usually used for anaesthesia will be administered by the CONCERT-CL® station
2952069|NCT02889692|Experimental|TCM granules plus EGFR-TKIs|"TCM granules: oral granules, YiQiFang or YangYinFang or YiQiYangYinFang, four packages, twice a day, until progression or unacceptable toxicity; EGFR-TKIs: oral tablet, Gefitinib® 250mg daily or Erlotinib® 150mg daily or Icotinib® 125 mg three times a day，until progression or unacceptable toxicity."
2952070|NCT02889692|Placebo Comparator|Placebo granules plus EGFR-TKIs|Placebo granules: oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect, four packages, twice a day, until progression or unacceptable toxicity; EGFR-TKIs: oral tablet, Gefitinib® 250mg daily or Erlotinib® 150mg daily or Icotinib® 125 mg three times a day until progression or unacceptable toxicity.
2952071|NCT02889679|Experimental|Underwater resection|All eligible lesion identified in a patient will be resected by the underwater technique. Excluded lesions will be resected by standard polypectomy.
2952072|NCT02889679|Active Comparator|Conventional resection|All eligible lesion identified in a patient will be resected by the conventional (gas distended colon) resection techniques. Excluded lesions will be resected by standard polypectomy.
2952073|NCT02889666|Experimental|Carboplatin|Carboplatin-based chemotherapy (Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Carboplatin was done for 3 cycles with 30 days after last surgery.
2952074|NCT02889666|Experimental|Docetaxel|Docetaxel-based chemotherapy (Docetaxel 120mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Docetaxel was done for 3 cycles with 30 days after last surgery.
2952075|NCT02889666|Experimental|Gemcitabine/Cisplatin|Gemcitabine/Cisplatin-based combinational chemotherapy (Gemcitabine 200mg + Cisplatin 60mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
2952076|NCT02889666|Experimental|Cisplatin|Cisplatin-based chemotherapy (Cisplatin 60mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Cisplatin was done for 3 cycles with 30 days after last surgery.
2952077|NCT02889666|Experimental|Docetaxel/Oxaliplatin|Docetaxel/Oxaliplatin-based chemotherapy (Docetaxel 120mg + Oxaliplatin 200mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
2952078|NCT02889666|Experimental|Docetaxel/Carboplatin|Docetaxel/Carboplatin-based chemotherapy (Docetaxel 120mg + Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
2952079|NCT02889666|Experimental|Gemcitabine/Carboplatin|Gemcitabine/Carboplatin-based chemotherapy (Gemcitabine 200mg + Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
2952080|NCT02889666|Placebo Comparator|Placebo|No Adjuvant chemotherapy using CCODG was done for patients who had previous surgery to remove the primary non-small cell lung carcinoma but subject to tumor relapse. Instead, placebo was supplied to these patients as a comparator Arm.
2952159|NCT02889107|No Intervention|standard care|Patients received standard listening strategies for 10 weeks
2952082|NCT02889640|Experimental|Scale-up SAGA math tutoring|These youth will receive intensive, daily mathematics tutoring, and students will be paired with scale-up tutors. Tutors will be hired using the randomization process, and will be randomly assigned to youth.
2952083|NCT02889640|Experimental|Standard SAGA math tutoring|These youth will receive intensive, daily mathematics tutoring, and students will be paired with tutors hired via SAGA's standard process, which does not involve randomization. Tutors will be randomly assigned to youth.
2952084|NCT02889627|Experimental|FMT with microbiota suspension|Participants undergo single FMT with 200ml microbiota suspension.
2952085|NCT02889627|Placebo Comparator|FMT with saline|Participants undergo single FMT with 200ml normal saline.
2952086|NCT02889601||Fronto-temporal lobar degeneration|DAPHNE score building and internal validation through Fronto-temporal lobar degeneration patients.
2952087|NCT02889601||Control|External validation of DAPHNE score among patients with Alzheimer's disease, progressive supranuclear palsy and bipolar disorder with cognitive disorders.
2952088|NCT02889562|Active Comparator|Apixaban|"Apixaban is to be dosed at 5 mg by mouth twice daily, except in the case of the criteria listed below in dose modifications. The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination."
2952089|NCT02889562|Active Comparator|Warfarin|"While patients are hospitalized, warfarin will be dosed daily, with daily INR monitoring per hospital protocol. Daily doses may vary from 0.5mg to 15mg by mouth, as determined by patient specific factors such as patient size, hepatic function, INR, concomitant medications, diet, or other factors. Based on these factors or others not listed, there may also be days in which the patient is prescribed to not get does not receive a dose of warfarin.~After discharge from the hospital, warfarin dosing will be subsequently managed by an anticoagulation clinic, per established protocols. All patients will have a goal INR of 2-3 during the duration of the study. The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination."
2952090|NCT02889549|Experimental|Ticagrelor 22.5 mg|Ticagrelor (22.5 mg, twice daily, oral) treatment for 1 month.
2952091|NCT02889549|Experimental|Ticagrelor 45 mg|Ticagrelor (45 mg, twice daily, oral) treatment for 1 month.
2952092|NCT02889549|Experimental|Ticagrelor 90 mg|Ticagrelor (90 mg, twice daily, oral) treatment for 1 month.
2952093|NCT02889549|Active Comparator|Clopidogrel|Clopidogrel (75mg, once daily, oral) treatment for 1 month.
2952094|NCT02889536||Focus group interview, stoma clinics|Qualitative data collection. Patients attending stoma clinics in the capital region
2952095|NCT02889536||Focus group interview, referred|Qualitative data collection. Patients referred to repair surgery at a specific hospital in the capital region
2952096|NCT02889523|Experimental|Epi-RCHOP|"RCHOP + tazemetostat:~RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1):~8 cycles, every 21 days~tazemetostat: PO, doses according to dose cohorts for phase I, and at RP2D for phase II: continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID"
2952097|NCT02889510|Other|liraglutide|7-week subcutaneous liraglutide treatment once daily
2952098|NCT02889510|Other|placebo|7-week subcutaneous placebo treatment once daily.
2952099|NCT02889497|Experimental|300 subjects receive the first batch vaccine|300 subjects will be randomly received the first batch vaccine
2952100|NCT02889497|Experimental|300 subjects receive the second batch vaccine|300 subjects will be randomly received the second batch vaccine
2952101|NCT02889497|Experimental|300 subjects receive the third batch vaccine|300 subjects will be randomly received the third batch vaccine
2952102|NCT02889484||Disc hernia patients treated in Sweden|Individuals undergoing lumbar disc hernia surgery and included in the Swespine register
2952103|NCT02889484||Disc hernia patients treated in Norway|Individuals undergoing lumbar disc hernia surgery and included in the NORspine register
2952104|NCT02889484||Disc hernia patients treated in Denmark|Individuals undergoing lumbar disc hernia surgery and included in the Danespine register
2952105|NCT02889471|Experimental|ERCP with nasobiliary catheter|
2952106|NCT02889471|Active Comparator|ERCP only|
2952107|NCT02889458||Case|"Inclusion Criteria~Female~aged 18 or above~Chinese~Usually residing in Hong Kong (Definition: Having stayed in HK for at least three months during the six months before the reference time-point)~Able to speak Cantonese~Newly diagnosed with breast cancer or DCIS in 24 weeks~Exclusion Criteria~- Undergoing treatment for any non-breast cancer~Subjects will complete a structured interview with a questionnaire with research assistants' aid. Specimen of blood, normal breast tissue and tumour tissue will be collected."
2952108|NCT02889458||Control|"Inclusion Criteria~Female~aged 18 or above~Chinese~Usually residing in Hong Kong~Able to speak Cantonese~Exclusion Criteria~- History of any cancer~Subjects will complete a structured interview with a questionnaire with research assistants' aid. Specimen of blood will be collected."
2952109|NCT02889432|Experimental|Melatonin|Oral Melatonin 10mg Taken 30 minutes before bedtime for 3 weeks First dose starts the night before surgery
2952110|NCT02889432|Placebo Comparator|Placebo|Placebo tabs Taken 30 minutes before bedtime for 3 weeks First dose starts the night before surgery
2952111|NCT02889419|Experimental|Evaluation of underwear Selfia®|Every patient is his own control.
2952112|NCT02889406|Experimental|Motivational intervention|"Following the motivational interviewing schema, structured in 2 phases of treatment (motivational and intervention) and organised in 11 visits (one each month). The first and last visits will be performed in consultations of endocrinology unit from referral hospitals; the other visits will be held in paediatric primary care setting. Visits will be scheduled monthly and each one will last between 15 and 20 minutes.~In addition to individualized visits, three group workshops focused in nutrition education for families will be organized. Each workshop will last 45 minutes and will target parents/mothers and obese children, separately."
2952113|NCT02889406|No Intervention|Control group|Children who are assigned to the control group will follow the usual treatment performed in paediatrics, what is following the Clinical Practice Guideline on the prevention and treatment of child and adolescent obesity. Monthly visits will be conducted in which weight, height and waist circumference will be measured and compliance with the initial advice will be reviewed.
2952114|NCT02889393|No Intervention|Standard of care|The usual standard of care for the treatment of enterocutaneous fistulas includes meticulous wound care, optimization of nutrition (either parenteral or enteral), use of acid-suppression medications such as histamine receptor antagonists or proton-pump inhibitors, and anti-motility agents such as loperamide.
2952115|NCT02889393|Experimental|teduglutide plus standard of care|In addition to all the standard of care treatments, experimental therapy will include a daily subcutaneous injection to 0.05 mg/kg of teduglutide.
2952116|NCT02889380||Cetrotide|This study will retrospectively collect the data from the subjects who had been treated with 0.25 milligram (mg) of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available assisted reproductive technology (ART) outcome.
2952117|NCT02889367|Experimental|Treatment A|Participants will receive odalasvir 100 milligram (mg) or odalasvir matching placebo once on Day 1.
2952118|NCT02889367|Experimental|Treatment B|Participants will receive odalasvir 500 mg or odalasvir matching placebo once on Day 1.
2952119|NCT02889367|Experimental|Treatment C|Participants will receive odalasvir (dose to be determined based on pharmacokinetic data from treatment A and B but no more than 1000 mg) or odalasvir matching placebo once on Day 1.
2952120|NCT02889354|Experimental|Cognitive-behavioral therapy|
2952121|NCT02889341|Placebo Comparator|Placebo|Placebo
2952122|NCT02889341|Active Comparator|500 mg DHA/day|500 mg DHA/day
2952123|NCT02889341|Active Comparator|1g DHA/day|1g DHA/day
2952124|NCT02889341|Active Comparator|2g DHA/day|2g DHA/day
2952125|NCT02889328|Experimental|regorafenib|regorafenib 100 mg po od daily, every 4 weeks (28 day)
2952126|NCT02889302|Experimental|KPS-0373|
2952127|NCT02889302|Placebo Comparator|Placebo|
2952128|NCT02889289|Experimental|Xbox One Kinect Gaming|15 sessions of supervised physical therapy using 2 commercially available Xbox One Kinect game.
2952129|NCT02889276|Active Comparator|Control|Unsupervised activity
2952130|NCT02889276|Experimental|Functional Resistance Training (FRT)|Supervised, group-based functional resistance training
2952131|NCT02889250|Experimental|Open Label DBS|6 months of DBS
2952132|NCT02889237|No Intervention|Standard care|Start of calcium and vitamin D3 supplementation according to standard care, i.e. 12 weeks after fracture.
2952133|NCT02889237|Active Comparator|Calcium|Immediate administration of daily calcium supplementation (1000 mg calcium)
2952134|NCT02889237|Active Comparator|Calcium and low dose vitamin D|Immediate administration of daily calcium + low dose vitamin D supplementation (1000 mg calcium + 880 IU vitamin D).
2952135|NCT02889237|Active Comparator|Calcium and high dose vitamin D|Immediate administration of daily calcium + high dose vitamin D supplementation (1000 mg calcium + 1760 IU vitamin D)
2952136|NCT02889237|No Intervention|Already on treatment with Calcium or vitamin D|Patients who are already treated with Calcium or Vitamin D.
2952137|NCT02889224|Active Comparator|Obese|Subjects with BMI between 30 - 40 kg/m2 and no alteration of corticotrope axis.
2952138|NCT02889224|Experimental|Hypercortisolism|Subject with BMI between 18 - 40 kg/m2 and presenting a hypercortisolism defined by HAS (Haute Autorité de Santé).
2952139|NCT02889224|Experimental|Hydrocortisone|Subject with BMI between 18 - 30 kg/m2 and with adrenal or corticotrope failure
2952140|NCT02889224|Experimental|Control|Subject with BMI between 18 - 30 kg/m2 and with a pituitary or adrenal tumor without effect on corticotrope axis.
2952141|NCT02889211|Active Comparator|Metabolically Healthy - Non-depressed|Overweight individuals without metabolic syndrome and free of psychiatric illness
2952142|NCT02889211|Experimental|Metabolically Healthy - Depressed|Overweight individuals without metabolic syndrome and with active major depression
2952143|NCT02889211|Experimental|Insulin Resistant - Depressed|Overweight individuals with metabolic syndrome and active major depression
2952144|NCT02889211|Experimental|Insulin Resistant - Non-depressed|Overweight individuals with metabolic syndrome and free of psychiatric illness
2952145|NCT02889198|Experimental|Intervention group|Centers in this group will be granted immediate access to the Go NAP SACC website following randomization with minimal support from a local technical assistance provider. The center director will have 4 months to use Go NAPSACC tools.
2952146|NCT02889198|No Intervention|Control group|During the study, centers in this group will receive no intervention. However, they will be granted delayed access to the Go NAP SACC website and technical assistance support after post-intervention measures are collected.
2952147|NCT02889185|Experimental|Adaptative optics retinal camera|
2952148|NCT02889172|Experimental|Problem Solving Therapy|Will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City. The aim is evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
2952149|NCT02889172|No Intervention|Control|This group will receive the usual treatment , without intervention with Brief Intervention ( PST )
2952150|NCT02889159|Other|Candida albicans antigen|useful in measuring the capacity of a person to manifest a delayed-type hypersensitivity response
2952151|NCT02889159|Other|histamine phosphate|useful to assess type I IgE-mediated hypersensitivity reactions
2952152|NCT02889159|Other|imiquimod 5% cream|direct stimulator of TLR-7, a key component of the innate immune response with downstream signaling effects involving the adaptive immune response
2952153|NCT02889159|Other|tape stripping|to create alterations in key inflammatory mediators involved in both the innate and adaptive immune responses
2952154|NCT02889159|No Intervention|Control|control sample from both sun exposed and non-sun exposed skin
2952155|NCT02889146|Active Comparator|Control group|Conventional Physical Therapy: motor physical therapy delivered by the intensive care unit physical therapists, according to his own criteria, without following any protocol. Respiratory therapy.
2952156|NCT02889146|Experimental|Protocol group|Early and progressive mobilization program: motor physical therapy delivered by a trained physical therapist according to the mobilization protocol, in which patient progress according to his performance. Respiratory therapy.
2952157|NCT02889133|Active Comparator|Iron repletion|Subjects will donate blood donation and undergo 24-hour PTR and receive IV iron-dextran. After 5 months, subjects will donate blood again, receive IV saline and undergo 24-hour PTR.
2952160|NCT02889107|Experimental|intervention|Patients received an assistive listening device (personal frequency modulated systems) for 10 weeks
2952161|NCT02889094||HIV-HBV co-infected individuals|No interventions will be administered. Individuals will be undergoing routine care.
2952162|NCT02889081||infants from birth cohort with AD|maternal biological folate level and maternal biological vitamin D level and offspring's incidence of suffering from atopic dermatitis
2952163|NCT02889081||infants from birth cohort without AD|maternal biological folate level and maternal biological vitamin D level and offspring's incidence of not suffering from atopic dermatitis
2952164|NCT02889068||Intellectual disability|
2952165|NCT02889042|Experimental|Volunteers repeated drug poisoning|performing MRI and a biological assessment
2952166|NCT02889042|Other|Volunteers single drug poisoning|performing MRI and a biological assessment
2952167|NCT02889042|Other|alcoholic|performing MRI and a biological assessment
2952168|NCT02889042|Other|volunteers|performing MRI and a biological assessment
2952169|NCT02889029|Experimental|new 3D device|dedicated tailored stents wrought by 3D computer-assisted conception
2952170|NCT02889016||PANS group|500 children, 1-18 years old at onset with a strict diagnosis of PANS/PANDAS will be recruited
2952171|NCT02889016||Health Controls|100 healthy children age- and gender- matched to the PANS group will be recruited
2952172|NCT02889003|Experimental|CML patients following molecular response loss|
2952173|NCT02888990|Experimental|Treatment Arm|standard treatment + dasatinib
2952174|NCT02888964|Experimental|ACTOS treatment|Imatinib mesylate at the same daily dose and pioglitazone as add-on therapy at 30 mg/d during 2 months and then 45 mg/d in the absence of serious adverse events
2952175|NCT02888951||Diabetic Group|A group of diabetic patients who have fasted for at least 8 hours undergoing an elective surgical procedure.
2952176|NCT02888951||Non-Diabetic Group|A group of non-diabetic patients who have fasted for at least 8 hours undergoing an elective surgical procedure.
2952177|NCT02888938||Patients suspected of SpA|
2952178|NCT02888925|Other|Epilepsy|Patients do face specific tests during conventional pre-lobectomy intercritical assessment hospitalization (inclusion, day 0) and after 6 and 18 months from anterior temporal lobectomy
2952179|NCT02888925|Other|Control|Control individuals do face specific tests during inclusion visit (day 0) and after X months (X = time from day 0 and lobectomy of matched patient + 6 months)
2952180|NCT02888912|Active Comparator|EQUIA|randomly applied
2952181|NCT02888912|Active Comparator|Gradia Direct Posterior|randomly applied
2952182|NCT02888899|Experimental|Standard treatment|
2952183|NCT02888899|Experimental|PTNS in addition to standard treatment|
2952184|NCT02888886|Experimental|COPD|
2952185|NCT02888873|Active Comparator|Charisma|applied randomly
2952186|NCT02888873|Active Comparator|Charisma classic|applied randomly
2952187|NCT02888860||Group 1|Patients with candidemia
2952188|NCT02888860||Group 2|Patients without colonization during follow up
2952189|NCT02888860||Group 3|Patients without colonization at admission, with subsequent colonization during hospitalization
2952190|NCT02888860||Group|Patients colonized at admission, and during the whole hospitalization
2952191|NCT02888860||Group 5|Patients who develop colonization during hospitalization and become negative at discharge
2952192|NCT02888847|Active Comparator|Philips Zoom! White Speed whitening lamp|Philips Zoom! White Speed whitening lamp
2952193|NCT02888847|Sham Comparator|Philips Zoom! Advanced power lamp|Philips Zoom! Advanced power whitening lamp
2952194|NCT02888834||Adverse drug reaction|Patients aged over 65 years who presented a serious adverse drug reaction notified to the Regional Pharmacovigilance Center of Champagne-Ardenne between January and May 2013 were included in the study.
2952195|NCT02888821|Experimental|CLS-FUERTE|Families will receive the CLS-FUERTE intervention in the fall of the 2016-2017 school year. CLS-FUERTE includes caretaker, child and teacher components implemented during a 6 week period. All content of group sessions will be derived from the manualized CLS-FUERTE treatment protocol developed by the PI and study staff.
2952196|NCT02888821|Other|Business as Usual (BAU) Waitlist Control|Families will receive school services as usual while on a waitlist to receive CLS-FUERTE in the spring of the 2016-2017 school year.
2952197|NCT02888808||Erosive GERD|Gastroscopy examination.
2952198|NCT02888808||Control population|Gastroscopy examination.
2952199|NCT02888795|Experimental|hypertonic dextrose prolotherapy|
2952200|NCT02888782|Experimental|Pharmacist Consultation|Meet with pharmacist for consultation in addition to regular physician follow up
2952201|NCT02888782|No Intervention|Control|Receive regular physician follow up
2952202|NCT02888769|Experimental|Intervention-Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week.
2952203|NCT02888769|No Intervention|Control|Participants in the control group will receive 2 thank-you messages per month and undertake routine clinical practice.
2952204|NCT02888756|Experimental|iHIVARNA-01|Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
2952205|NCT02888756|Active Comparator|TriMix|Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
2952206|NCT02888756|Placebo Comparator|Placebo|Water for injection 3 vaccinations, two weeks interval
2952207|NCT02888743|Experimental|Arm A (tremelimumab, durvalumab)|Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses.
2952208|NCT02888743|Experimental|Arm B (tremelimumab, Durvalumab, RT)|Patients receive tremelimumab and durvalumab and as in Arm A. Beginning at week 2, patients receive high dose radiation therapy QD over 10 days for up to 3 fractions.
2952291|NCT02888106|Experimental|Arm D|Myrcludex B 2 mg for 48 weeks
2952209|NCT02888743|Experimental|Arm C (tremelimumab, durvalumab, and RT)|Patients receive tremelimumab and durvalumab and as in Arm A. Beginning at week 2, patients receive low dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.
2952210|NCT02888730|Experimental|Tobramycin nebulized nasally|Nebulized Tobramycin, one bulb (tobramycin 300 mg and sodium chloride 11.25 mg) nasally twice a day for 15 days
2952211|NCT02888730|Placebo Comparator|Physiologic serum nebulized nasally|Nebulized sodium chloride 0.9%, one bulb twice a day nasally for 15 days
2952212|NCT02888717|Experimental|OSNA stadification during surgery|The para-aortic dissection surgery is performed in the usual way. The lymph nodes are isolated from fat tissue during surgery, and will be analysis both by histological analysis and OSNA analysis
2952213|NCT02888704|Experimental|intervention: Biological: ADSTEM Inj.|"ADSTEM Inj. 1.0x10^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study.~ADSTEM Inj. 3.0x10^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study."
2952214|NCT02888691|Experimental|Low Carbohydrate Diet|< 100 grams of carbohydrate per day
2952215|NCT02888691|Experimental|High Carbohydrate Diet|> 250 grams of carbohydrate per day
2952216|NCT02888678|Experimental|ES + HIV Prevention|"Economic Strengthening + HIV prevention education combined intervention consists of 2 parts.~Impumelelo: This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.~Vhutshilo 2.2: . This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy."
2952217|NCT02888678|Experimental|ES only|Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
2952218|NCT02888678|Experimental|HIV only|HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
2952219|NCT02888678|No Intervention|No intervention (control)|The control group will not receive the ES or HIV prevention interventions. They will receive the basic package of services available to all beneficiaries of Future Families.
2952220|NCT02888665|Experimental|Treatment (pembrolizumab, doxorubicin hydrochloride)|Patients receive pembrolizumab IV over 30 minutes on day 1 and doxorubicin hydrochloride IV over 1-3 hours on day 1 of courses 2-7 only. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
2952221|NCT02888613|Other|Mini laparotomy|Patients with surgical indication to mini invasive aortic repair will be operated after randomisation with transperitoneal approach
2952222|NCT02888613|Other|Mini lumbotomy|Patients with surgical indication to mini invasive aortic repair will be operated after randomisation with retroperitoneal approach
2952223|NCT02888600|Active Comparator|Mindfulness Training|The Mindfulness Meditation Program consists of eight weekly 2- 2.5 hour group sessions, a day-long retreat in the sixth week, and daily mindfulness meditation homework.
2952224|NCT02888600|Active Comparator|Health Education|The Health Education Program also consists of eight weekly 2- 2.5 hour group sessions, a day-long retreat in the sixth week, and daily health practice homework
2952225|NCT02888587||Control group|no gastrointestinal symptoms
2952226|NCT02888587||Symptomatic group|Patients with Visceral hypersensitivity
2952227|NCT02888574|Experimental|Intranasal Oxytocin|Oxytocin nasal spray delivered bi-daily over a 14-day period at 24-IU per dose
2952228|NCT02888574|Placebo Comparator|Placebo|Placebo nasal spray containing the same ingredients as the active nasal spray minus the oxytocin and packaged in an identical bottle. To be delivered bi-daily over a 14-day period at 24-IU per dose
2952229|NCT02888548|Experimental|Arm cross over 1|botulinum toxins alone then botulinum toxins + orthos
2952230|NCT02888548|Experimental|Arm cross over 2|botulinum toxins + orthosis then botulinum toxins alone
2952231|NCT02888509||healthy control|Well mathed with patients in age, gender, education
2952232|NCT02888509||major depression disorder|patients with major depression disorder
2952233|NCT02888509||anxiety disorder|patients with anxiety disorder
2952234|NCT02888509||bipolar depression disorder|patients with bilopar depression disorder
2952235|NCT02888496||PMR patients|Patients included in the clinical trial TENOR (prospective open-labeled study of tocilizumab in treatment-naïve PMR patients)
2952236|NCT02888496||Healthy controls|Matched to PMR patients for sex and age, exclusion of any autoimmune, inflammatory, neoplastic and chronic infectious disease
2952237|NCT02888457|Other|AOM|Infants (6-30 months of age) with acute otitis media
2952238|NCT02888457|Other|DCC|Healthy infants (6-30 months of age) attending day-care centers
2952239|NCT02888444|Active Comparator|Varenicline plus behavioural support|12 weeks extended treatment with varenicline, plus relapse prevention-orientated behavioural support
2952240|NCT02888444|Placebo Comparator|Placebo plus behavioural support|12 weeks extended treatment with placebo, plus relapse prevention-orientated behavioural support
2952241|NCT02888431||Arterial blood sample|0.5 mL blood sample from arterial line which is clinically indicated
2952242|NCT02888431||peripheral venous blood sample|0.5 mL blood sample drawn simultaneously with arterial sample from clinically indicated peripheral line
2952243|NCT02888418|Experimental|One dose of HPV vaccine in women aged 18 to 30|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in women aged 18 to 30.
2952244|NCT02888418|Placebo Comparator|Placebo in women aged 18 to 30|Placebo in women aged 18 to 30.
2952245|NCT02888418|Experimental|One dose of HPV vaccine in women aged 9 to 17|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in women aged 9 to 17.
2952246|NCT02888418|Placebo Comparator|Placebo in women aged 9 to 17|Placebo in women aged 9 to 17.
2952703|NCT02884869|Experimental|Intubating laryngeal Mask|Intubating laryngeal Mask
2952247|NCT02888418|Experimental|One dose of HPV vaccine in men aged 9 to 17|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in men aged 9 to 17.
2952248|NCT02888418|Placebo Comparator|Placebo in men aged 9 to 17|Placebo in men aged 9 to 17.
2952249|NCT02888405|Experimental|High-carbohydrate diet|Single day of 9 g/kg body weight consumption of carbohydrate. Isocaloric to very low-carbohydrate condition.
2952250|NCT02888405|Experimental|Very low-carbohydrate diet|Single day of 1 - 1.5 g/kg body weight consumption of carbohydrate. Isocaloric to high-carbohydrate condition.
2952251|NCT02888392|Experimental|Kiwifruit intervention|4 week intervention treatment with 2 fresh, whole green kiwifruit per day
2952252|NCT02888392|Active Comparator|Psyllium intervention|4 week intervention treatment with psyllium, matched for fibre content of 2 green kiwifruit / day for 4 weeks
2952253|NCT02888379|Experimental|TOP1288 200 mg Rectal Solution|TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks
2952254|NCT02888379|Placebo Comparator|Placebo Rectal Solution|Placebo (for TOP1288) Rectal Solution Once Daily for 4 Weeks
2952255|NCT02888366||1|Breath samples taken, no treatment given.
2952256|NCT02888353|Experimental|Device: MRI no pre-screen|"Clinically Indicated MRI will be done in patients with cardiac devices (pacemakers and defibrillators).~Patients will not be pre-screened prior to hospital visit."
2952257|NCT02888340|Experimental|Acupuncture|One session of acupuncture prior to receiving pain medications after arriving to the emergency department with pain as a symptom.
2952258|NCT02888340|No Intervention|Usual Care|Usual care for pain, without intervention, after arriving to the emergency department with pain as a symptom.
2952259|NCT02888327|Other|Oseltamivir and AL-794|Oseltamivir alone and with AL-794 over fourteen days.
2952260|NCT02888327|Other|Digoxin, Midazolam, and AL-794|Single doses of Digoxin and Midazolam with and without AL-794 over seventeen days.
2952261|NCT02888327|Other|Pitavastatin and AL-794|Single doses of Pitavastatin with and without AL-794 over seventeen days.
2952262|NCT02888327|Other|JNJ-63623872 and AL-794|JNJ-63623872 alone and with AL-794 over fourteen days.
2952263|NCT02888301|Experimental|Basic science (18F-clofarabine biodistribution)|Patients receive 18F-clofarabine IV and undergo PET/CT scan at baseline and 2-4 weeks after completion of immunotherapy.
2952264|NCT02888288|Experimental|Mental Health Intervention|This arm was designed based on mental health needs of HIV-infected youth in Tanzania. It incorporates principles of cognitive behavioral therapy, interpersonal psychotherapy, and motivational interviewing built into 10 group sessions, approximately 90 minutes each (2 sessions with caregiver participation) and 2 individual sessions. Groups are age and gender matched and facilitated by lay counselors with a mix of lived experience and prior mental health research experience.
2952265|NCT02888288|Active Comparator|Standard of Care|This arm includes standard medical care and adherence counseling with routine education prior to the start of the HIV youth clinic from which participants are recruited.
2952266|NCT02888275|Experimental|DEX|dexmedetomidine 1mcg/kg for 10min. loading and continuous infusion during the surgery 0.5mcg/kg/hr.
2952267|NCT02888275|Active Comparator|no_DEX|Normal saline 1mcg/kg for 10min. and continuous infusion during the surgery 0.5mcg/kg/hr.
2952268|NCT02888262||Patients with bipolar disorder|Patients with newly diagnosed bipolar disorder
2952269|NCT02888262||Healthy first generation relatives|Healthy first generation relatives to the included patients
2952270|NCT02888262||Healthy individuals|Healthy individuals without a family history of psychiatric disorders
2952271|NCT02888249|Experimental|Cigarette W|"Altered composition cigarettes~moisture = 12.20 %, tar = 10.40 mg/cigarette, total particulate matter = 12.0 mg/cigarette, high sugar content"
2952272|NCT02888249|Experimental|Cigarette X|"Altered composition cigarettes~moisture = 12.10 %, tar = 8.60 mg/cigarette, total particulate matter = 9.60 mg/cigarette, low sugar content"
2952273|NCT02888249|Experimental|Cigarette Y|"Altered composition cigarettes~moisture = 13.20 %, tar = 9.10 mg/cigarette, total particulate matter = 10.10 mg/cigarette, low sugar content"
2952274|NCT02888249|Experimental|Cigarette Z|"Altered composition cigarettes~moisture = 13.60 %, tar = 8.10 mg/cigarette, total particulate matter = 9.10 mg/cigarette, low sugar content"
2952275|NCT02888236|Experimental|LEO 32731 tablet|LEO 32731 30 mg two times daily for 16 weeks
2952276|NCT02888236|Placebo Comparator|LEO 32731 Placebo tablet|LEO 32731 placebo two times daily for 16 weeks
2952277|NCT02888223|Experimental|Group A|a single dose administration of SCT800 followed by Xyntha (50 IU.kg-1, based upon the manufacturer's labeled potency)
2952278|NCT02888223|Experimental|Group B|a single dose administration of Xyntha followed by SCT800(50 IU.kg-1, based upon the manufacturer's labeled potency)
2952279|NCT02888210|Experimental|MD-15|Investigational intraocular lens
2952280|NCT02888171|Experimental|ferric citrate|Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
2952281|NCT02888171|Active Comparator|ferrous sulfate|Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
2952282|NCT02888158|Active Comparator|Pelvic Trainer without robotic assistance|"Interns randomized to this arm will have two Pelvic Trainer training sessions three months apart.~Intervention: Pelvic Trainer"
2952283|NCT02888158|Experimental|Pelvic Trainer with robotic assistance|"Interns randomized to this arm will have two Pelvic Trainer training sessions three months apart but with robotic assistance.~Intervention: Robotic assistance~Intervention: Pelvic Trainer"
2952284|NCT02888132|Experimental|Hypertrophic Obstructive Cardiomyopathy|
2952285|NCT02888119|Active Comparator|High Risk for Osteoarthritis|"High risk of developing knee OA has been defined by having knee pain but normal radiographs (Kellgren-Lawrence score 0 i.e. KL0) on both knees but at least one abnormal finding on clinical MR protocol such as overweight, prior knee injury (ligaments or menisci) or traumatic bone marrow edema lesions."
2952286|NCT02888119|Active Comparator|Mild Osteoarthritis|
2952287|NCT02888119|Active Comparator|Healthy Controls|Controls will be age/gender matched to patients within 2 years of age.
2952288|NCT02888106|Active Comparator|Arm A|PEG IFN alfa-2a 180 µg for 48 weeks
2952289|NCT02888106|Experimental|Arm B|Myrcludex B 2 mg + PEG IFN alfa-2a 180 µg for 48 weeks
2952290|NCT02888106|Experimental|Arm C|Myrcludex B 5 mg + PEG IFN alfa-2a 180 µg for 48 weeks
2952292|NCT02888106|Experimental|Arm E|Myrcludex B 10 mg (10 mg once a day) + PEG-IFN alfa-2a 180 μg during 48 weeks
2952293|NCT02888106|Experimental|Arm F|Myrcludex B 10 mg (5 mg twice a day) + Tenofovir during 48 weeks
2952294|NCT02888093|Experimental|Absorbable|Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)
2952295|NCT02888093|Experimental|Permanent|Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)
2952296|NCT02888080|Experimental|ACZ885|ACZ885 (300 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.
2952297|NCT02888080|Placebo Comparator|Placebo|Placebo (0 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.
2952298|NCT02888067|Active Comparator|Moderate neuromuscular blockade (MNB)|"The goal is to realize a moderate NMB (TOF 1-2 twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.~This represents the standard care in our institution for this type of surgery. At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the moderate neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent)."
2952299|NCT02888067|Active Comparator|Deep neuromuscular blockade (MNB)|"The goal is to realize a deep MNB (TOF zero twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.~At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the deep neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent)."
2952300|NCT02888054|Experimental|Sequence ABBA|Day 1: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 8: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 15: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 22: lesinurad/allopurinol 200/300 FDC tablet (Sequence A)
2952301|NCT02888054|Experimental|Sequence BABA|Day 1: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 8: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 15: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 22: lesinurad/allopurinol 200/300 FDC tablet (Sequence A)
2952302|NCT02888054|Experimental|Sequence ABAB|Day 1: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 8: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 15: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 22: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B)
2952303|NCT02888054|Experimental|Sequence BAAB|Day 1: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 8: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 15: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 22: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B)
2952304|NCT02888041|Experimental|Dinoprostone|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
2952305|NCT02888041|Active Comparator|Oxytocine|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
2952306|NCT02888028|Active Comparator|ICD remote monitoring|Active Comparator: ICD remote monitoring additionally to regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement
2952307|NCT02888028|Other|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
2952308|NCT02888015|Other|Upper extremity exercise|Five upper extremity exercises will be provided to each of the 10 participants to complete on a daily basis. Exercises included shoulder flexion, elbow flexion/extension, shoulder abduction, internal/external rotation
2952309|NCT02888002|Experimental|Internet-based treatment|"Guide to better alcohol habits online. An Internet-based treatment program with online counselor support."
2952310|NCT02888002|Experimental|Face-to-face treatment|"Guide to better alcohol habits F2F: Face-to-face treatment with 5 individual counselor sessions at the clinic."
2952311|NCT02887989|Experimental|Virtual Reality|Patients will be allowed to use commercially-available VR equipment in their hospital rooms for up to 20 days, as needed to manage pain as an adjunct to opioid and non-opioid pain medication.
2952312|NCT02887989|Sham Comparator|In-Room Television|Patients will be allowed to watch relaxing television content in their hospital rooms for up to 20 days, as needed to manage pain as an adjunct to opioid and non-opioid pain medication.
2952313|NCT02887976|Experimental|SoluMatrix™ Abiraterone Acetate|SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid)
2952314|NCT02887950|Active Comparator|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
2952315|NCT02887950|Experimental|Equikilon-3 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 3 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
2952316|NCT02887950|Experimental|Equikilon-6 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 6 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
2952317|NCT02887937||Breast Mass 4a-cystic|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4a-cystic breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
2952318|NCT02887937||Breast Mass 4a- non cystic|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4a-non cystic breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration..
2952319|NCT02887937||Breast Mass 4b|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4b breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
2952320|NCT02887937||Breast Mass 4c|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4c breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
2952321|NCT02887924|Active Comparator|group 1|SLI group In this group the preterm infants will receive sustained lung inflation (SLI) via short binasal prongs in the delivery room.
2952322|NCT02887924|Placebo Comparator|group 2|Preterm infants will be assisted in the delivery room without sustained lung inflation.
2952323|NCT02887911||Asthmatic, not taking inhaled steroids|Men/Women, ages 18-75 who are not currently taking corticosteroids.. No intervention; this is a prospective observational study.
2952324|NCT02887911||Asthmatic, taking inhaled steroids|Men/Women, ages 18-75 who are already taking corticosteroids prescribed by their physician. No intervention; this is a prospective observational study.
2952325|NCT02887911||Healthy, non-asthmatic without allergies|Men/Women, ages 18-75 without a current diagnosis of asthma and no allergies. No intervention; this is a prospective observational study.
2952326|NCT02887911||Healthy, atopic non-asthmatics|Men/Women, ages 18-75 with allergies but without a current diagnosis of asthma. No intervention; this is a prospective observational study.
2952327|NCT02887898|Active Comparator|Carb counting and bolus calculator|Education in carb counting and the use of an automated bolus calculator
2952328|NCT02887898|Placebo Comparator|Carb counting|Education in carb counting and manual calculation of insulin bolus
2952329|NCT02887872|Experimental|Pilot data|Four participants with chronic stroke participated in a 45-minute combined electrical stimulation-dynamic hand orthosis regimen using the affected upper extremity (UE) 5X/week for 6 weeks.
2952330|NCT02887859|Experimental|HAV Treatment|Human Acellular Vessel (HAV)
2952331|NCT02887846|Active Comparator|group 1|Heated humidified high-flow nasal cannula therapy device for post extubation
2952332|NCT02887846|Active Comparator|group 2|Nasal continuous positive airway pressure for post extubation
2952333|NCT02887833||XRT for Cancer induced bone pain|Will have community based assessment before and after radiotherapy to assess feasibility of using a clinical biomarker (thermal sensory testing) to predict treatment response
2952334|NCT02887820|Other|Pilot Arm|All subjects enrolled in the trial will be in the pilot group. These subjects will have traditional laboratory coagulation and blood transfusion tests (baseline arterial blood gas (ABG), complete blood count (CBC), fibrinogen, platelet count, aPTT, PT, anti-Xa, ACT), as well as thromboelastograph (TEG). Pertinent TEG results will include: heparinase-kaolin TEG maximum amplitude (MA) in millimeters (mm), heparinase-kaolin TEG r-time in seconds, heparinase-kaolin TEG alpha angle in degrees, and TEG functional fibrinogen (FLEV) MA in mm.
2952335|NCT02887807|Experimental|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
2952336|NCT02887807|Placebo Comparator|Control|Single intravenous bolus of placebo (2.5 mg/kg) at the onset of resuscitation
2952337|NCT02887794|Experimental|30 patients with schizophrenia|Measure the correlation between the score on the scale psychometric AHRS (Auditory Hallucination Rating Scale) to measure HAV and performance scores discrimination test psychoacoustic Tone Matching Task in subjects suffering from schizophrenia and HAV.
2952338|NCT02887768|Experimental|Treatment|Epicardial Infarct Repair with CorMatrix-ECM in addition to coronary artery bypass grafting
2952339|NCT02887755|Experimental|Amputee Group|In this study n=20 returning US military combatants between 18 and 45 years of age who have unilateral transtibial or transfemoral amputation will be asked to perform two aerobic exercise tests while we4aring the NIRS sensor. Subjects must be medically cleared and able to complete approximately 30 minutes of physical activity.
2952340|NCT02887703|Experimental|Sensory Augmentation Group 1|Each subject in Group 1 will undergo 6 weeks of balance training with sensory augmentation followed by 6 weeks of balance training without sensory augmentation.
2952341|NCT02887703|Experimental|Sensory Augmentation Group 2|Each subject in Group 2 will undergo 6 weeks of balance training without sensory augmentation followed by 6 weeks of balance training with sensory augmentation.
2952342|NCT02887690|Experimental|Modular Prosthetic Limb|The Defense Advanced Research Projects Agency's (DARPA) advanced upper limb prosthesis, the Modular Prosthetic Limb (MPL)
2952343|NCT02887677|Active Comparator|Dapagliflozin|Dapagliflozin for oral administration. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group.
2952344|NCT02887677|Placebo Comparator|Placebo|Placebo for oral administration. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group.
2952345|NCT02887664||Blood test in Mothers of SGA Infants|In mothers of Small for Gestational Age (SGA) Infants, maternal and cord blood test will be performed
2952497|NCT02886468|Experimental|ultrasound images|ultrasound images of the anterolateral aspect of the mid-right thigh
2952346|NCT02887664||Blood test in Mothers of AGA infants|In mothers of Appropriate for Gestational Age (AGA) Infants, maternal and cord blood test will be performed
2952347|NCT02887651|No Intervention|observation|patients in the observation arm receive no adjuvant local radiation therapy after complete surgical resection of a cerebral metastasis
2952348|NCT02887651|Active Comparator|cavity boost radiation therapy|patients in the intervention arm receive an adjuvant local radiation therapy (cavity boost radiation therapy: 10 x 3 Gy ad 30 Gy; clinical target volume (CTV): resection cavity plus surrounding 5 mm; planning target volume (PTV): CTV + 1mm)
2952349|NCT02887638|Experimental|headache|Patients diagnosed (neurologist - anesthesiologist - manual therapist) with tension-type and/or cervicogenic headache. During a first phase the sitting-posture, dura mater profile and pain-profile of the Headache-group will be analyzed. In a second phase, the patients will be sub-classified according to the data-analysis and receive intervention (Individual Profile Analysis +Physical therapy Intervention)
2952350|NCT02887638|No Intervention|asymptomatic controls|Asymptomatic controls, matched for gender and age. During a first phase the sitting-posture, dura mater profile and pain-profile of the control-group will be analyzed.
2952351|NCT02887625|Experimental|Combination Therapy|pioglitazone (actos) 30 mg per day and exenatide (bydureon) 2 mg per week
2952352|NCT02887625|Active Comparator|Insulin Therapy|"insulin glargine (lantus) will be started every morning and the dose will be weekly increase to achieve fasting plasma glucose (FPG) <110 mg/dl.~and Aspart insulin will be started before meals and the dose is adjusted to maintain HbA1c <7.0% and postprandial plasma glucose (PPG) <140 mg/dl"
2952353|NCT02887599|Other|Patient Group|Pancreatic cancer patients
2952354|NCT02887599|Other|Control Group|Healthy people without evidence of malignancy
2952355|NCT02887586|Experimental|Auricular Needling group|Patients will receive auricular needling for 4 weeks .
2952356|NCT02887586|No Intervention|control group|This group will receive no treatment. Subjects will be assessed at baseline and the 2th, 4th and 8th week.
2952357|NCT02887573|Experimental|Free-residue nutrients+PEG|"Diet: Free-residue nutrients Free-residue nutrient will be given when the patients are hungry before the two days of the capsule day.There are no other diet in this arm.~Drug: PEG 2L PEG are used at 05:00-07:00 the morning of the test. Drug: Mosapride citrate The patients will take 5mg mosapride citrate at 8:00. Drug:PEG 0.75L and 0.50L PEG are administered as boosters for patients. Procedure: Colon capsule endoscopy The colon capsule will be ingested at 08:30 the day of the test.The images will be reviewed by two experienced endoscopists.~Procedure: Colonoscopy On the following day of the test.All participants will undergo therapeutic colonoscopy."
2952358|NCT02887573|Experimental|Low fiber diet+PEG|"Diet: Low fiber diet Before the two days of the capsule day,when the patients hungry,low fiber diet wiil be given.~Drug: PEG 4L PEG are used at 21:00-23:00 the night before the test and 05:00-07:00 the morning of the test.~Drug: Mosapride citrate The patients will take 5mg mosapride citrate at 8:00. Drug:PEG 0.75L and 0.50L PEG are administered as boosters for patients. Procedure: Colon capsule endoscopy The colon capsule will be ingested at 08:30 the day of the test.The images will be reviewed by two experienced endoscopists.~Procedure: Colonoscopy On the following day of the test,All participants will undergo therapeutic colonoscopy."
2952359|NCT02887560|Experimental|All patient|Only one arm has been specified for the protocol. This arm included all study patient (33) for which the intervention is to be administered
2952360|NCT02887547|No Intervention|Control|Control group, with traditional orthodontic mechanics for anterior retraction. Crevicular fluid will be collected during anterior retraction mechanics to identified biomarkers in the inflammatory process
2952361|NCT02887547|Experimental|Acceleration|Group with micro-osteoperforation for accelerated tooth movement during anterior retraction, Crevicular fluid will be collected during anterior retraction mechanics to identified biomarkers in the inflammatory process
2952362|NCT02887534|Experimental|Arm 1|three times medication; SPARC1401-low dose
2952363|NCT02887534|Experimental|Arm 2|three times medication; SPARC1401-mid dose
2952364|NCT02887534|Experimental|Arm 3|three times medication; SPARC1401-high dose
2952365|NCT02887534|Active Comparator|Active comparator|Reference1401; To be administered 3 times a day
2952366|NCT02887534|Placebo Comparator|Arm 5|Placebo1401 - 3 three times a day
2952367|NCT02887521|Experimental|Intervention|Patients will receive 10 in-clinic sessions of preoperative Pulmonary Rehabilitation (PR) two weeks prior to surgery. Patients will receive a Participant Manual demonstrating and explaining the rehabilitation process. Patients will also receive a log for recording their efforts and notes for every day until the day of surgery. A video recording of the intervention from start to finish will be provided to all patients. The video recording should be played in all 10 sessions at the registering site. The PR sessions will include breathing awareness, upper and lower extremity exercise, instructions for inspiratory muscle training using the PFlex valve, practice at home and goal setting. Patients undergo surgery and will be followed until 6 months following surgery. Patients complete follow up questionnaires at 3 and 6 months after discharge.
2952368|NCT02887521|Active Comparator|Control|Patients will receive a pedometer to monitor their daily steps and a pamphlet with exercises plus the standard course of care for patients undergoing lung resection surgery. The patients will not be asked to return the pedometer. The local institutional coordinator will go over the use of the pedometer and the exercise materials with the patient. The patients will be asked to keep a log of their pre-operative steps and mail the log to the registering site. Patients undergo surgery and will be followed until 6 months following surgery. Patients complete follow up questionnaires at 3 and 6 months after discharge.
2952369|NCT02887508|Experimental|HINTS Intervention|The HINTS intervention consisted of an online four-session group intervention for 45 minutes, twice a week for two weeks. In each session, facilitators presented information, motivational skills, and behavioral skills related to a specific topic relevant to online partner seeking and transmission risk reduction, including Internet safety and communication, condom negotiation, and serostatus disclosure.
2952370|NCT02887508|Active Comparator|Healthy Living Control|The Healthy Living Control condition consisted of an online four-session group intervention for 45 minutes, twice a week for two weeks. In each session, facilitators presented information, motivational skills, and behavioral skills to address non-sexual health-related topics particularly relevant to individuals living with HIV, such as nutrition, healthy eating, portion control, exercise and staying active, and stress reduction.
2952371|NCT02887482|Experimental|Placebo|Placebo at 0 mg DNA/dose
2952372|NCT02887482|Experimental|GLS-5700|GLS 5700 at 2 mg DNA/dose. GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
2952373|NCT02887469|Active Comparator|Intermittent bolus group|"<<Within 6hr>>~Moderately Severe : 3% saline 2ml/kg over 20min *1 (unknown bwt 100ml)~Severe :3% saline 2ml/kg over 20min *2 (unknown bwt 100ml)~<additional treatment> Repeat 3% saline 2ml/kg over 20min at every sample time point (at 1/6hr) till Na 5-9 mmol/L inc from initial Na and sx relief~<<During 6-24hr>>~- Moderately Severe or Severe~: Repeat 3% saline 2ml/kg over 20min at every sample time point(at 12/18/24hr) till Na 5-9 mmol/L inc from initial Na and sx relief~<<During 24-48hr>>~Moderately Severe or Severe : Repeat 3% saline 2ml/kg over 20min at every sample time point (at 30/36/42/48hr) till Na 10-17 mmol/L inc from initial Na or Na ≥ 130mmol and sx relief"
2952374|NCT02887469|Active Comparator|slow continuous infusion group|"<<Within 24hr>>~- Moderately Severe: 3% saline 0.5ml/kg/hr (unknown bwt 25ml/hr)~- Severe: 3% saline 1ml/kg/hr (unknown bwt 50ml/hr)~Infusion protocol modification as below by Na at every sample time point (at 1/6/12/18/24 hr)~If Na 5-9 mmol/L inc from initial Na and sx relief : stop 3% saline infusion regardless of △ Na~if △ Na inc <0.5mmol/hr or △ Na inc <3mmol/6hr : add 0.25ml/kg/hr, restart 0.5ml/kg/hr if previously stopped~if △ Na inc ≥0.5mmol/hr or △ Na inc ≥ 3mmol/6hr~: maintain infusion rate~<<During 24-48hr>>~- Moderately Severe and Severe~Infusion protocol modification as below by Na at every sample time point (at 30/36/42/48hr)~If Na 10-17 mmol/L inc from initial Na or Na ≥ 130mmol and sx relief~: stop 3% saline infusion regardless of △ Na~if △ Na inc <1.5mmol/6hr~: add 0.25ml/kg/hr or restart 0.25ml/kg/hr if previously stopped~if △ Na inc ≥ 1.5mmol/6hr~: maintain infusion rate"
2952375|NCT02887456|Active Comparator|Vitapex|Endodontic treatment using Vitapex
2952376|NCT02887456|Experimental|MTA paste|Endodontic treatment using MTA paste
2952377|NCT02887430|Experimental|intervention|Participants will be received 8 sessions of foot reflexology therapy, 30 minutes each (2 sessions per week of 4 weeks) and low back pain standard care
2952378|NCT02887430|No Intervention|control|participants will be received standard care in general practice
2952379|NCT02887417||patients|glioblastoma patients
2952380|NCT02887417||controls|healthy controls
2952381|NCT02887404|Experimental|Spine surgery analgesic pathway|"Before surgery the subject will be given one time oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).~During surgery the subject will receive an infusion of ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start at incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).~After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed."
2952382|NCT02887404|Active Comparator|Usual care|"Placebo- Before surgery the subject will be given one time placebo oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).~Placebo- During surgery the subject will receive a placebo infusion of - ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start at incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).~After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed."
2952383|NCT02887391||Conventional Hemodialysis|Control group 4 hours of hemodialysis 3x per week (12 hours hemodialysis/week)
2952384|NCT02887391||In-Centre Nocturnal Hemodialysis|8 hours of hemodialysis 3x per week (24 hours hemodialysis/week)
2952385|NCT02887378|Experimental|hot clamps|reusable hot biopsy forceps
2952386|NCT02887378|Active Comparator|normal clamps|normal clamps
2952387|NCT02887365|Experimental|tegafur-uracil|tegafur-uracil treatment in patients with stage II MSI-L or MSS colon cancer
2952388|NCT02887365|No Intervention|Observation|Observation for one year
2952389|NCT02887339|Experimental|Intervention Group|Tissue requesters from participating OPOs are randomly assigned to complete additional informed consent training through an interactive online training website.
2952390|NCT02887339|Experimental|Control Group|The control group of tissue requesters receive the standard training offered by their OPO and GTEx partners.
2952391|NCT02887326||age < 20 years|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
2952392|NCT02887326||age 20-29 years|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
2952393|NCT02887326||age 30-39 year|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
2952394|NCT02887326||age 40-49 year|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
2952395|NCT02887326||age 50 - 59 years|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
2952396|NCT02887326||age 60-69 years|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
2952397|NCT02887326||age > 70 years|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
2952398|NCT02887313|Experimental|mFOLFOX6 with radiation|mFOLFOX6 with radiation:Patients receive mFOLFOX6 for 4 cycles during neoadjuvant radiotherapy, and after CRT, another 4-6 cycles of mFOLFOX6 would be given before surgery.
2952399|NCT02887300|No Intervention|Passive control group|"After randomisation, 30 consenting, eligible study participants will be allotted a place in the passive, parallel control group. Participants will work as usual in the ED. Biological and survey samples will be obtained from both groups of participants on the same days:~T1 - one week before session one T2 - one week after session 4 T3 - three months following T2"
2952400|NCT02887300|Experimental|Planned intervention - mantra meditation|"After randomisation, 30 randomly chosen, ED staff members will be taught mantra meditation by an experienced meditator. Each 4 hour session will occur once every two weeks for 8 weeks (total of 4 sessions) and consist of guided meditation as well as discussions around prescribed texts on the meaning of health care.~In addition, participants will be asked to engage in home work (20 minutes of a guided mantra meditation on a twice daily basis). Biological and survey samples will be obtained from both groups of participants on the same days:~T1 - one week before session one T2 - one week after session 4 T3 - three months following T2"
2952401|NCT02887261|Other|Power Port|patients who received power injectable port
2952402|NCT02887261|Active Comparator|Conventional Port|patients who received conventional port ( not power injectable)
2952601|NCT02885597|Experimental|Juanbi group|participants should administrate both Juanbi pill and Methotrexate
2952403|NCT02887248|Experimental|nab-paclitaxel+gemcitabine|"Induction Phase: nab-paclitaxel (125 mg/m²) and gemcitabine (1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle. Responding or stable patients will be treated with a minimum of 3 cycles and up to 6 cycles before starting the single agent maintenance therapy.~Maintenance Phase: Patients completing 3-6 cycles of induction therapy with an objective response (complete or partial response) or stable disease will continue treatment with single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment."
2952404|NCT02887235|No Intervention|Standard of Care (SOC) Meals|Patient assigned in this arm will receive standard of care nutritional services including nutrition consult, evaluation, and as needed follow-ups.
2952405|NCT02887235|Active Comparator|Medically tailored meals|Patient assigned in this arm will receive home delivered, medically tailored meals (HDMTM) in addition to the standard nutritional care.
2952406|NCT02887222|Active Comparator|PIEB volume of 7 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 7mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2952407|NCT02887222|Active Comparator|PIEB volume of 8 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 8mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2952408|NCT02887222|Active Comparator|PIEB volume of 9 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 9mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2952409|NCT02887222|Active Comparator|PIEB volume of 10 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2952410|NCT02887222|Active Comparator|PIEB volume of 11 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 11mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2952411|NCT02887222|Active Comparator|PIEB volume of 12 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 12mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2952412|NCT02887209|Experimental|CBT-I|This is a single arm study in which all participants receive the intervention (cognitive behavioural therapy for insomnia)
2952413|NCT02887183|Other|LCZ696(sacubitril/valsartan)|Subjects will receive sacubitril/valsartan (LCZ696) on Day 1. The initial dose will be determined by the investigator and per the approved indication described in the United States prescribing information/package insert (USPI). The three doses available are: 24/26 mg (Dose Level 1), 49/51mg (Dose Level 2) and 97/103mg (Dose Level 3).
2952414|NCT02887157||Specific Aim 1B|"Specific Aim 1B (implement technical innovations to improve OCT imaging in non-sedated infants in the ICN: (1B) extend imaging to the vascular-avascular junction via a wide-field lens).~Aim 1B only: 50 participants (25 healthy adult volunteers and 25 pediatric participants under going examination under anesthesia~Healthy adult volunteers will have SSOCT imaging of both eyes with the novel ultralight handpiece up to 10 times.~Pediatric participants undergoing examination under anesthesia will have SSOCT imaging of both eyes with the novel ultralight handpiece once during their EUA in the Duke Eye Center Operating Rooms (OR). These participants will be enrolled into the study at DUHS including the Duke Eye Center clinics and OR for testing the custom widefield lens."
2952415|NCT02887157||Specific Aim 2|"Specific Aim 2 (distinguish elements of retinal microanatomy that predict maldevelopment of visual pathway and poor neurodevelopment that may impact vision in preterm infants) includes 68 very preterm infants undergoing the following during evaluation for ROP.~Swept Source OCT imaging of both eyes with the novel ultralight handpiece before or after ROP examination, timed with each examination. The axial length of the eye may be measured after the ROP exam.~Non-sedated research brain Magnetic Resonance Imaging will be obtained in 68 participants prior to discharge from the nursery whenever possible (as close to term age as possible). In the case of an early infant discharge to another hospital, every effort will be made to obtain brain MRI prior to transfer or an outpatient non-sedated brain MRI at near term age.~Scavenged blood collection: Residual samples of serum/plasma in the laboratory will be collected for neuroinflammatory marker testing."
2952416|NCT02887157||Specific Aim 3|"Specific Aim 3 (delineate which elements and regions (posterior) or (peripheral) of preterm infant OCT-derived retinal microanatomy best inform us about severity of disease and visual outcomes in infants with ROP will include the same 68 participants plus an additional 42 very preterm infants undergoing evaluation for ROP and visual function but who will not be in the neurodevelopmental study and thus will not have brain MRI, 2-year Bayley Scales testing or neuroinflammatory marker testing on scavenged blood. The Specific Aim 3 subjects will undergo the following:~Swept Source OCT imaging of both eyes with the novel ultralight handpiece as described in Aim 2. The axial length of the eye may be measured after the ROP exam.~After imaging with the original lens (ultralight handpiece) both eyes will be imaged with the widefield OCT lens. before or after the ROP exam.~Ocular and systemic health data will be extracted from the study participant's medical record."
2952417|NCT02887144|Experimental|SenSura test product 1pc|"Subjects randomized to treatment sequence 1test:~SenSura test product~SenSura"
2952418|NCT02887144|Experimental|SenSura 1pc|"Subjects randomized to treatment sequence 2 test:~SenSura~SunSura test product"
2952419|NCT02887131|Experimental|Healthy volunteers|
2952420|NCT02887131|Experimental|Arthritis|
2952421|NCT02887131|Experimental|Instability|
2952422|NCT02887118||Common arm|Children with sickle cell anemia will be included. Blood samples of all the included patients will be collected during a day-hospitalization for a planned chek-up. For all these patients the number of dense erythrocytes will be evaluated
2952423|NCT02887105||Patients with cerebrovascular accident|
2952424|NCT02887066||Patients with thoracic pain and suspicion of ACS|
2952425|NCT02887053|Experimental|All subjects|All subjects will have an MRI examination
2952600|NCT02885610|Experimental|RC18 240 mg plus standard therapy|RC18 240 mg/kg SC plus standard therapy RC18 240 mg SC once weekly X 48 doses
2952426|NCT02887040|Experimental|Radiation|Study subjects receive a single daily radiation fraction of 180cGy, 5 days a week for 6 weeks overall, to a total radiation dose of 5400cGy.
2952427|NCT02887040|Experimental|Antineoplaston therapy + Radiation|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for 104 weeks. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Study subjects also receive a single daily radiation fraction of 180cGy, 5 days a week for 6 weeks overall, to a total radiation dose of 5400cGy.
2952428|NCT02887027|Experimental|Exercise Group 1|Participants assigned to this group will complete a baseline period of 8 days and an Exercise4Mood Intervention period of 21 days.
2952429|NCT02887027|Experimental|Exercise Group 2|Participants assigned to this group will complete a baseline period of 11 days and an Exercise4Mood Intervention period of 18 days.
2952430|NCT02887027|Experimental|Exercise Group 3|Participants assigned to this group will complete a baseline period of 15 days and an Exercise4Mood Intervention period of 14 days.
2952431|NCT02887014|Experimental|Group A|Participants getting SPECIFIC VERBAL INSTRUCTIONS before starting bowel preparation (Group A).
2952432|NCT02887014|No Intervention|Group B|Participants getting ordinary instructions as usual in each of the participating centers (Group B).
2952433|NCT02887001|Other|BMO|
2952434|NCT02886988|Experimental|Botulinum toxin type A|The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.100U Botulinum toxin type A(BTA) will be reconstituted with 2mL of normal saline for a concentration of 50U/mL. 0.1ml(5 units) of BTA will be injected along the wound edges. The injections will be administered within 14 days of median sternotomy with a 30G needle.
2952435|NCT02886988|Placebo Comparator|Normal Saline|The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.0.1ml normal saline will be injected along the wound edges.
2952436|NCT02886975|Experimental|low protein diet plus α-keto acid|A comparison of normal diet and low protein diet plus α-keto acid after intervention in the same individual
2952437|NCT02886962|Experimental|No anticoagulation|No oral anticoagulation, and no monitoring of the INR.
2952438|NCT02886962|Active Comparator|Oral anticoagulation with vitamin K antagonists|"VKA use as recommended in the guidelines with INR target range between 2 and 3. Daily administration or thrice weekly at the end of dialysis sessions upon Nephrologist's choice.~Antiplatelet therapy will be provided only if recent acute coronary syndrome (< 6 months) or active coronary stent. Aspirin should be preferred in dialysis patients as clopidogrel has an unpredictable reduced activity and there is no safety data on combination of VKA with prasugrel or ticagrelor in this population."
2952439|NCT02886936|Experimental|iFIT Group|This is a feasibility and effectiveness study to assess the iFIT transtibial prosthesis as a viable alternative to a traditional prosthesis. We also hope to gain information that will influence future design iterations.
2952440|NCT02886910|Experimental|Clinical observation|Asymptomatic newborns born at term to mothers with suspected chorioamnionitis. They will receive a limited evaluation (blood culture, complete blood count), and a clinical observation. Antibiotics will be started only if sepsis-related signs or symptoms are present.
2952441|NCT02886910|Active Comparator|Standard management|Asymptomatic newborns born at term to mothers with suspected chorioamnionitis. The will receive a limited evaluation (blood culture, complete blood count), a clinical observation and antibiotics at birth.
2952442|NCT02886897|Experimental|D-CIK and anti-PD-1 Immunotherapy|D-CIK was incubated with anti-PD-1 antibody before infused back into participants
2952443|NCT02886884|Experimental|20 million allogeneic hMSCs|Eight (8) subjects will be delivered via peripheral intravenous infusion of 20 million allogeneic Mesenchymal Human Stem Cells (hMSCs)
2952444|NCT02886884|Experimental|100 million hMSCs|Eight (8) subjects will be delivered via peripheral intravenous infusion of 100 million allogeneic Mesenchymal Human Stem Cells (hMSCs)
2952445|NCT02886871|Experimental|Personalized Steps Goal|Step Goal Delivery by Smartphone
2952446|NCT02886871|Active Comparator|Constant Steps Goal|Step Goal Delivery by Smartphone
2952447|NCT02886858|Experimental|tDCS|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
2952448|NCT02886858|Sham Comparator|Sham tDCS|The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
2952449|NCT02886845||Chinese Breast Cancers|Woman with breast cancer that have been diagnosed in clinic
2952450|NCT02886845||healthy controls|Woman without breast cancer
2952451|NCT02886832|Experimental|Prostate Health formulation|Prostate Health formulation
2952452|NCT02886819|Experimental|WBV group|whole-body vibration (WBV) group
2952453|NCT02886806|Experimental|high risk vascular surgery|Patients scheduled for high risk vascular surgery under automated total closed loop intravenous anesthesia and fluid management
2952454|NCT02886793|Experimental|FDG|all patients will undergo a PET scan and will receive 18F fludeoxyglucose
2952455|NCT02886780|Experimental|Concentrated Exposure Treatment (cET)|Please refer to:Havnen, A., Hansen, B., Öst, L.-G. & Kvale, G. Concentrated ERP delivered in a group setting: An effectiveness study. Journal of Obsessive Compulsive and Related Disorders 3, 319-324 (2014)
2952456|NCT02886780|Active Comparator|Self-help|"The self-help condition (SH):~Foa, E.B. & Kozak, M.J. Mastery of obsessive-compulsive disorder: Client workbook, (Graywind Publications, New York, 1997)."
2952457|NCT02886780|No Intervention|Wait list|
2952458|NCT02886767|Experimental|skin-to-skin contact (SSC)|Experimental: a daily skin-to-skin contact (SSC) at least 15 minutes in length
2952459|NCT02886767|No Intervention|Control: hospital routine care|As the hospital routine. Allow the father to visit the neonate, touching the neonate
2952526|NCT02886195|Experimental|PC plus erlotinib|pemetrexed 500mg/m2 d1 plus cisplatin 80mg/m2 d1; concurrent erlotinib 150mg/d d1-21, per 3 week, for 4-6cycles, then erlotinib 150mg/d maintain therapy
2952527|NCT02886195|Active Comparator|erlotinib|"erlotinib 150mg/d until progress disease"
2952460|NCT02886754|Active Comparator|National e-learning programme only (HSE)|National e-learning programme only Recent successful completion the National e-learning programme by certificate will be displayed. Students then complete a student satisfaction survey and proceed directly for performance assessment to the high-fidelity simulation suite.
2952461|NCT02886754|Active Comparator|Simulation (S)|Simulation Recent successful completion of the National e-learning e-learning programme by certificate will be displayed. Students will proceed to standard simulation using the same series of paper cases as PBP which prompt simulated phone calls but no requirement to meet a proficiency benchmark. 4 hours will be allotted to this training. Following training participants will complete the student satisfaction survey and will then proceed directly for performance assessment to the high-fidelity simulation suite.
2952462|NCT02886754|Experimental|Proficiency-Based Progression (PBP)|Recent successful completion of the National e-learning programme by certificate will be displayed. Students will proceed to PBP simulation using the same series of paper cases as S which prompt simulated phone calls. PBP students will be scored according to predefined metrics and will be required to reach proficiency benchmarks. Following training participants will complete the student satisfaction survey and proceed directly for performance assessment to the high-fidelity simulation suite.
2952463|NCT02886741|Other|Quality Improvement Campaign|"IHI designed and encouraged implementation of a five-component enhanced surgical site infection (SSI) prevention bundle with three relatively new evidence-based practices and two Surgical Care Improvement Program (SCIP) practices.~The campaign recruited state organizations to share information about evidence-based practices and publicize IHI activities and intervention materials (a How-to Guide, evidence reviews, a summary of the business case for interventions, and tip sheets for surgeons, other providers, patients and families). A project website and email listserv offered learning opportunities including webinar calls, faculty-led office hours, and town hall meetings."
2952464|NCT02886741|No Intervention|Comparison|Matched state pairs received no campaign intervention and experienced usual care
2952465|NCT02886728|Experimental|Filgotinib Dose A + MTX|Filgotinib dose A + placebo to match filgotinib dose B + MTX
2952466|NCT02886728|Experimental|Filgotinib Dose B + MTX|Filgotinib dose B + placebo to match filgotinib dose A + MTX
2952467|NCT02886728|Experimental|Filgotinib Dose A|Filgotinib dose A + placebo to match filgotinib dose B + placebo to match MTX
2952468|NCT02886728|Active Comparator|MTX|Placebo to match filgotinib dose A + placebo to match filgotinib dose B + MTX
2952469|NCT02886715|Experimental|Test|Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)
2952470|NCT02886715|Active Comparator|Reference|TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)
2952471|NCT02886715|Placebo Comparator|Placebo|Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)
2952472|NCT02886702|Experimental|Test|Tazarotene Cream 0.05% (Fougera Pharmaceuticals Inc.)
2952473|NCT02886702|Active Comparator|Reference|TAZORAC® (tazarotene) Cream 0.05% (Allergan, Inc.)
2952474|NCT02886702|Placebo Comparator|Placebo|Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)
2952475|NCT02886689||1|patients will be those receiving any biotherapy
2952476|NCT02886689||2|patients will be those not receiving biotherapy : non indication, refusal, contraindication.
2952477|NCT02886676|Experimental|Spirulina capsules and scaling & root planing|Patients in test group will be provided with Spirulina capsules 2gm daily, after meals for 1 month
2952478|NCT02886676|Active Comparator|Placebo capsules and scaling & root planing|Patients in test group will be provided with placebo capsules after meals for 1 month
2952479|NCT02886663|Experimental|immediate rehabilitation|
2952480|NCT02886663|Other|delayed rehabilitation|
2952481|NCT02886650|Experimental|Thermocoagulation|
2952482|NCT02886637||Acinetobacter baumannii infection|Critically ill patients infect with Acinetobacter baumannii
2952483|NCT02886624|Experimental|Grazoprevir/Elbasvir|Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
2952484|NCT02886598||Firmagon®|Treatment according to standard clinical practice.
2952485|NCT02886585|Experimental|Previously Untreated Brain Metastases-Cohort A|"- Previously Untreated Brain Metastases~Baseline Brain MRI and PET CT~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.~Brain MRI and PET/CT"
2952486|NCT02886585|Experimental|Progressive Brain Metastases-Cohort B|"- Progressive Brain Metastases~Baseline Brain MRI and PET CT~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.~Brain MRI and PET/CT"
2952487|NCT02886585|Experimental|Neoplastic Meningitis-Cohort C|"Neoplastic Meningitis~Histologically confirmed solid malignancy~Positive Cytology~Baseline Brain MRI~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.~Brain MRI and PET/CT"
2952488|NCT02886585|Experimental|1-4 Brain Metastases from Melanoma Cohort D|"1-4 Brain Metastases from Melanoma~Clinical indication for stereostatic radiosurgery~Evaluable extracranial focus~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. In Cohort D, cycle 1 and 2 of pembrolizumab will be administered 3 weeks apart and stereotactic radiosurgery will be administered between cycles. Treatment will be administered on an outpatient basis.~Brain MRI and PET CT"
2952489|NCT02886572|Experimental|Stereotactic Radiosurgery|All subjects will receive stereotactic radiosurgery(SRS) following the RTOG Stereotactic Radiotherapy Guidelines available at http://dx.doi.org/10.1016/j.prro.2011.06.014
2952490|NCT02886559|Experimental|DCCAG|Chidamide 30mg twice for one week decitabine 20mg/m^2 for 5 days
2952491|NCT02886520|Active Comparator|PVDF transobturator tape|Transobturator tension-free suburethral tape made of polyvinylidene fluoride.
2952492|NCT02886520|Active Comparator|PP transobturator tape|Transobturator tension-free suburethral tape made of polypropylene.
2952493|NCT02886507|Active Comparator|NSK-SD (nattokinase)|One capsule (100 mg) nattokinase/day for the 8-week study duration.
2952494|NCT02886507|Placebo Comparator|Placebo|One capsule placebo/day for the 8-week study duration.
2952495|NCT02886494|Active Comparator|BAC|
2952496|NCT02886494|Placebo Comparator|Matched vehicle|
2952498|NCT02886455|Experimental|Cohort 4|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin at two different time points (4 and 24 hours).~There are two visits:~Visit 1:~Two adhesive strips (standard adhesive strip and new adhesive strip)contaminated with the subjects own output are applied on the peristomal skin and allowed to sit for 4 hours before being removed~Visit 2: Two adhesive strips (standard adhesive strip and new adhesive strip)contaminated with the subjects own output are applied on the peristomal skin and allowed to sit for 24 hours before being removed"
2952499|NCT02886442|Experimental|Cohort 3|"This is a sub-study testing how the adhesion of two adhesives is influenced by exposure to real output.~There are two kinds of visits:~Visit 1:~Two adhesive strips (standard adhesive strip) are applied on the peristomal skin; one strip is exposed to real output (contained in a sleeve) and the other strip is not.~Visit 2:~Two adhesive strips (new adhesive strip) are applied on the peristomal skin; one strip is exposed to real output (contained in a sleeve) and the other strip is not.~Visit 2:"
2952500|NCT02886429|Active Comparator|Group A|Ultrasound guided paravertebral block with bupivacaine group Thirty patients will be given isobaric bupivacaine 0.5% (0.3ml/kg) via paravertebral route.
2952501|NCT02886429|Active Comparator|Group B|Ultrasound guided paravertebral block with bupivacaine and dexmedetomidine group Thirty patients will be given isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg) via paravertebral route (Bupivacaine plus Dexmedetomidine)
2952502|NCT02886403|Experimental|Cohort 02|"This is a sub-study testing how the adhesion of two adhesives is influenced by exposure to real output.~There are two visits:~The first visit:~Two adhesive strips (standard adhesive strip) are applied to the peristomal skin and one of these strips is exposed to real output (contained in a sleeve) and the other strip is not.~The second visit:~Two adhesive strips (new adhesive strip) are applied to the peristomal skin and one of these strips is exposed to real output (contained in a sleeve) and the other strip is not."
2952503|NCT02886390|Experimental|RIC group|The upper limb ischemic conditioning is composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 2 hours after r-tPA thrombolytic therapy. In addition, all participants receive a standard clinical therapy.
2952504|NCT02886390|No Intervention|Control group|The participants received r-tPA thrombolytic therapy after diagnosed ischemic stroke. In addition, all participants receive a standard clinical therapy.
2952505|NCT02886377||NMOSD-ON|NMOSD-ON included patients who met the established diagnostic criteria for NMO or NMOSD published by Wingerchuk et al,with AQP4 seropositive according to the results of the AQP4-Ab test.
2952506|NCT02886377||MS-ON|MS-ON group patients included typical acute demyelinating ON with brain lesions fulfilling the revised McDonald criteria or clinical isolate syndrome (CIS), with AQP4 seronegative according to the results of the AQP4-Ab test.
2952507|NCT02886377||Healthy controls|Age- and gender- matched healthy controls.
2952508|NCT02886364|Other|Women delivered at AAC Hospital|The intervention is only being implemented at the Ángel Albino Corzo Hospital due to limited funding. The site was selected by the Ministry of Health in Chiapas as a hospital that would benefit from improved quality of care around childbirth. There are no other arms in this study.
2952509|NCT02886351|Experimental|nitrous oxide|Administration of high concentration of nitrous oxygen in pediatric dentistry
2952510|NCT02886338|Experimental|capsule endoscopy examination|Capsule endoscopic examination for the esophagus, stomach and duodenum.
2952511|NCT02886325|Experimental|Cancer Clear and Simple|Participants in this study group will receive the Cancer Clear and Simple education session. This is a 2.5 hour educational program. Participants will complete a 15 minute survey prior to the educational program, at the end of the educational program and six months following the completion of the educational program.
2952512|NCT02886325|Placebo Comparator|Nutrition Education|Participants in this study group will receive the Nutrition Education. This is a 2.5 hour educational program. Participants will complete a 15 minute survey prior to the educational program, at the end of the educational program and six months following the completion of the educational program.
2952513|NCT02886299|Active Comparator|Fenofibrate group|Group I (30 patients): Patients receiving fenofibrate (100 mg) taken on dialysis days after the dialysis session (three times per week).
2952514|NCT02886299|Active Comparator|Simvastatin group|Group II (30 patients): Patients receiving simvastatin (20 mg) taken on dialysis days after the dialysis session (3 times per week).
2952515|NCT02886286|Experimental|Bupivacaine + Opioid|Intrathecal solution has bupivacaine with an opioid (hydromorphone, fentanyl or morphine). Patients will administer PTM bolus of bupivacaine with opioid. The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be >2 and <10. The bupivacaine dosage would range between 0.4 and 1.5 mg per bolus. The opioid dose will vary depending on the concentration of the opioid in the solution.
2952516|NCT02886286|Active Comparator|Opioid|Intrathecal solution has only an opioid (hydromorphone, fentanyl or morphine) and no bupivacaine. Patients will administer PTM bolus of opioid without bupivacaine. This opioid bolus dose would be the same as they would have received prior to enrolling in the study (with bupivacaine). The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be >2 and <10.
2952517|NCT02886273||Group 1|SCA with first MI (n = 43)
2952518|NCT02886273||Group 2|SCA with recurrent MI (n = 10)
2952519|NCT02886273||Group 3|SCA with no MI and without former heart disease (n = 3)
2952520|NCT02886273||Group 4|SCA with established heart disease and without acute MI (n = 18)
2952521|NCT02886247||participants|individuals with a personal or family history of pancreas tumors
2952522|NCT02886234|Experimental|Mindfulness training (MT)|Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
2952523|NCT02886234|Active Comparator|Health Coaching (HC)|Eight, 30-minute phone delivered HC sessions once a week for 8 weeks
2952524|NCT02886221|Other|HV patients|patients with symptomatic Hallux Valgus treated my Reverdin-Isham Osteotomy
2952525|NCT02886208|Experimental|Intervention|This study has a single arm. All participants in a summer employment program at an urban farm in Indianapolis, IN are invited to participate.
2952528|NCT02886195|Active Comparator|PC|pemetrexed 500mg/m2 d1 plus cisplatin 80mg/m2 d1 for 4-6 cycles
2952529|NCT02886182||group A|pregnants who were positivity for serum HBsAg for more than 6 months and HBeAg , HBV DNA >106IU/mL, alanine aminotransferase (ALT) below 35 IU/mL (ULN=40IU/mL) and no received nucleoside analogue antiviral therapy were enrolled into group A
2952530|NCT02886182||group B|the CHB infection pregnants with undetectable HBVDNA were enrolled into group B(control group)
2952531|NCT02886169|Experimental|High fat meal with Sacha Inchi|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar
2952532|NCT02886169|Placebo Comparator|unsupplemented group|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
2952533|NCT02886156|Experimental|CPAP plus BSC|Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center.
2952534|NCT02886156|Active Comparator|BSC intervention|Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
2952535|NCT02886143|Experimental|Active Voiding Trial (instillation of sterile saline)|Patients randomized to receive an active voiding trial will have the bladder filled with 250-400 cc of sterile saline (or until the bladder was full) via the lumen of the urinary catheter before the urinary catheter is removed. The patient will then be immediately assisted to void. Physician teams will follow a standardized algorithm for the management of urinary retention arising during the study.
2952536|NCT02886143|Active Comparator|Passive Voiding Trial|For patients randomized to receive a passive voiding trial, the urinary catheter will be removed, the bladder will fill with urine naturally, and the patient will be assisted to void when he or she reports the urge. To ensure uniformity in the intervention, all voiding trials in the study will be supervised by an experienced nurse who will ensure that the protocol is followed.
2952537|NCT02886130|Placebo Comparator|Placebo|Maltodextrin tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration
2952538|NCT02886130|Experimental|Alpha-GPC|Alpha-GPC tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration
2952539|NCT02886104|Active Comparator|CRLM resection group|Resection of both primary and secondary tumors in SCRLM and resection of MCRLM. Interventions: Simultaneous resection of both primary and secondary tumors in SCRLM and resection of MCRLM.
2952540|NCT02886104|Experimental|CRLM ablation group|"Ablation of CRLM after resection of primary tumor in SCRLM and ablation of MCRLM.~Interventions: Ablation of liver metastasis within 30 days after resection of primary tumor in SCRLM and ablation of MCRLM."
2952541|NCT02886078|Experimental|Dorsal approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.
2952542|NCT02886078|Active Comparator|Volar approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.
2952543|NCT02886065|Experimental|PVX-410 + Citarinostat|"Participants will receive:~6 biweekly doses of PVX-410~6 biweekly doses of Hiltonol~3 monthly cycles of Citarinostat"
2952544|NCT02886065|Experimental|PVX-410 + Citarinostat + Lenalidomide|"Participants will receive:~6 biweekly doses of PVX-410~6 biweekly doses of Hiltonol~3 monthly cycles of Citarinostat~3 monthly cycles of Lenalidomide"
2952545|NCT02886052|Experimental|ICBT for insomnia|Therapist guided Internet-CBT for insomnia
2952546|NCT02886052|Active Comparator|Active control|Written information on sleep, insomnia, and sleep hygiene
2952547|NCT02886039|Other|patients|Patient with cardiac arrest benefiting an electroencephalogram
2952548|NCT02886026|Active Comparator|Inpatient TUR-BT|Transurethral bladder tumor resection in operating theatre as inpatient.
2952549|NCT02886026|Experimental|laser bladder tumor destruction|Outpatient laser mediated destruction of bladder tumors (LMD-BT)
2952550|NCT02886013||Mexican adolescents|"Students without known disease, between 14 and 18 years from the Lic. Adolfo Lopez Mateos Preparatory school of the Autonomous University of the State of Mexico (UAEMex)."
2952551|NCT02885987|No Intervention|Standard Colonoscopy|AmplifEYE will not be used.
2952552|NCT02885987|Experimental|Colonoscopy with AmplifEYE|AmplifEYE accessory device will be attached to the colonoscope prior to starting the procedure
2952553|NCT02885974|Experimental|Celecoxib plus Gemcitabine/Cisplatin chemo|Celecoxib plus Gemcitabine/Cisplatin neoadjuvant chemotherapy
2952554|NCT02885961|Other|Dabigatran|"All patients will be entered into the arm, i.e. this is a single arm study. All patients will complete 2 FDG PET scans. All patients will receive dabigatran (direct thrombin inhibitor) at a dose of 110mg twice daily (oral).~The drug will be given for 24 days (+/-3 days). The variation in duration reflects that scans are completed Monday to Friday only."
2952555|NCT02885948|Experimental|Naloxone|"The naloxone arm of the study will receive naloxone at a rate of 5mcg/kg/hr which equates to 0.25ml/kg/hr. Each 1 ml ampoule of solution contains 400 micrograms (0.4mg) naloxone hydrochloride present as naloxone hydrochloride dihydrate.~Excipients: each 1ml contains 3.55mg sodium. This will be diluted to a concentration of 20mcg/ml with 0.9% NaCl. Presented as solution for injection or infusion. Clear colourless sterile solution."
2952556|NCT02885948|Placebo Comparator|Saline|The placebo arm of the study will receive an infusion of normal saline at a rate of 0.25ml/kg/hr.
2952557|NCT02885935|Experimental|Recommended protein intake|Subjects consumed diets with a macronutrient distribution of 10% protein, 55% carbohydrates, and 35% fat for 4 weeks.
2952558|NCT02885935|Experimental|Elevated protein intake|Subjects consumed diets with a macronutrient distribution of 20% protein, 45% carbohydrates and 35% fat for 4 weeks.
2952559|NCT02885909|Active Comparator|Insulin protocal with CGM|Insulin protocal with continue glucose monitor
2952560|NCT02885909|Active Comparator|Insulin protocal|Insulin protocal with convential glucose monitor
2952561|NCT02885909|No Intervention|Convential treatment|Convential insulin treatment and glucose monitor
2952598|NCT02885610|Experimental|RC18 80 mg plus standard therapy|RC18 80 mg/kg SC plus standard therapy RC18 80 mg SC once weekly X 48 doses
2952599|NCT02885610|Experimental|RC18 160 mg plus standard therapy|RC18 160 mg/kg SC plus standard therapy RC18 160 mg SC once weekly X 48 doses
2952562|NCT02885896||Experimental period (active platform)|During the experimental period, the eligible calls will be transferred to the platform by SAMU regulator doctors, and callers will be subject to health advice by specially trained nurses. The nurse conduct the call by holding the conversation guide, giving advice for a home care, answering questions from the circle (caller, family,..) and ensuring the proper understanding of these tips. An information leaflet for the theme of the call will be sent in the days following the call to the caller of the experimental group having given their consent.
2952563|NCT02885896||Control period (inactive platform)|During the control periods, the call center will not be active, eligible calls can not receive advice from nurses, but will be subject to the usual care: the regulator doctor will treat the call as its current practice.
2952564|NCT02885883|Active Comparator|a control group|
2952565|NCT02885883|Experimental|patients with paroxysmal or persistent AF|
2952566|NCT02885883|Experimental|patients with permanent AF|
2952567|NCT02885870|Experimental|Patient|"Patient with :~Spinal muscular atrophy (n=25)~X-linked spinobulbar muscular atrophy (n=25)~Amyotrophic lateral sclerosis (n=25)"
2952568|NCT02885870|Experimental|Healthy subject|Subject without any neurologic or spine affection Subject matched for sex and age with patient arm
2952569|NCT02885857|Experimental|Shenyan kangfu Tablets|Shenyan Kangfu Tablets；Each weighing 0.48g；Oral；Once five, three times a day
2952570|NCT02885844|Experimental|INVERTED VISION|inverted vision (upside down) using commercial off-the-shelf inverting prism goggles
2952571|NCT02885844|Active Comparator|NORMAL VISION|During normal vision trials, subject's field of view will be restricted by goggles without lenses (see below) in order to be equivalent to the inverted vision one.
2952572|NCT02885831||A - Abduction splintage|Treatment by abduction splintage. Sonographic, clinical and radiographic surveillance. 45 patients.
2952573|NCT02885831||B - Surveillance|No treatment by abduction splintage. Sonographic, clinical and radiographic surveillance. 45 patients
2952574|NCT02885805|Experimental|SPF evaluation + Control|Fair-skinned subjects in good health with Skin Types I, II or III.
2952575|NCT02885792|Experimental|Debuting and chronic schizophrenia|"ILLNESS HISTORY:~Existing psychiatric and somatic diagnosis and treatment~Charlson co-morbidity~MEASURE OF SOCIAL CONDITIONS~- For example Lubben Social Network Scale-6 and Brief Trauma Questionnaire.~MEASURE OF PSYCHIATRIC CONDITION::~Positive and Negative Syndrome Scale (PANSS)~Clinical Global Impression Scale (CGI)~Columbia Suicide Severity Rating Scale (C-SSRS)~Beck Cognitive Insight Scale~Birchwood Insight Scale~CARDIOVASCULAR MEASUREMENT:~CT Coronary angiography (CT-CAG)~Echocardiography~Heart rate variability (HRV)~Pulmonary function test (PFT)~Toe blood pressure (TBP)~Blood test~Body composition analysis~CT scan of upper abdomen~Cardiovascular magnetic resonance imaging (CMR)~Adipose tissue biopsy"
2952576|NCT02885792|Active Comparator|Matched controls|"CARDIOVASCULAR MEASUREMENT:~CT Coronary angiography (CT-CAG)~Echocardiography~Heart rate variability (HRV)~Pulmonary function test (PFT)~Toe blood pressure (TBP)~Blood test~Body composition analysis~CT scan of upper abdomen~Cardiovascular magnetic resonance imaging (CMR)~Adipose tissue biopsy"
2952577|NCT02885779||Patient having an operating indication of adnexa surgery|Patient having an operating indication of adnexa surgery : unilateral or bilateral adnexectomy
2952578|NCT02885766|Experimental|PF-114|"PF-114 From 50 mg up to the MTD. Dose escalation for each next cohort is conducted by increasing the dose by 20 % (or the closest lower level, which is a multiple of 25 mg) if there are Grade 3 ADRs according to NCI CTC AE v.4 without reaching а MTD. An increase of the dose by 40 % is applied if there were Grade 2 ADRs. In the absence of Grade 2 or 3 ADRs an increase of 100 % is applied.~When the dose reaches 400 mg/day, the following increase in dose can be made after discussing results of safety findings of PF-114 between the Investigators and the Sponsor.~Orally, once daily"
2952579|NCT02885753|Experimental|Experimental arm with oxaliplatin intra-arterial|Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intra-arterially Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours
2952580|NCT02885753|Active Comparator|Reference arm with oxaliplatin intravenous|Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours
2952581|NCT02885740|Experimental|Atrial fibrillation in normal heart|Patients having atrial fibrillation in normal heart
2952582|NCT02885740|Active Comparator|Control|Patients having a junctional supraventricular tachycardia in normal heart
2952583|NCT02885727|Experimental|Durvalumab + Radiation therapy|"Durvalumab (MEDI4736) 750 mg (or 10mg/kg if the patient weighs <30 kg) IV Q2W over 1 hour for all patients + Radiation therapy~First lesion to receive 25 Gy / 5 daily consecutive fractions of 5 Gy~Second lesion to receive15 Gy / 5 daily consecutive fractions"
2952584|NCT02885714|Placebo Comparator|Group I|Placebo surgery + supervised specific exercises
2952585|NCT02885714|Active Comparator|Group II|Rotator cuff repair + supervised specific exercises
2952586|NCT02885701|Experimental|No splint|
2952587|NCT02885701|Experimental|Removable Splint|
2952588|NCT02885701|Experimental|Non-removable Splint|
2952589|NCT02885688|Other|Standard-of-Care Treatment for Sepsis|Participants with diagnosis of septic shock in MD Anderson Cancer Center ICU receive standard of care treatment alone for up to 7 days.
2952590|NCT02885688|Experimental|Standard-of-Care Treatment Plus Liquid Nutrition for Sepsis|Participants with diagnosis of septic shock in MD Anderson Cancer Center ICU receive standard of care treatment plus plus liquid nutrition for up to 7 days.
2952591|NCT02885675||ARDS|
2952592|NCT02885675||Healthy control|
2952593|NCT02885662|Experimental|CS-3150|CS-3150 2.5 to 5.0 mg , orally, once daily after breakfast for 12 weeks.
2952594|NCT02885649|Experimental|Treatment (enzalutamide, nephrectomy)|Patients receive enzalutamide PO daily for 90 days in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy.
2952595|NCT02885636|Experimental|Inhaled albuterol|2.5 mg inhaled albuterol through a high efficiency nebulizer -single dose
2952596|NCT02885636|Placebo Comparator|Inhaled saline placebo|Inhaled saline through a high efficiency nebulizer -single dose
2952597|NCT02885610|Placebo Comparator|Placebo Comparator|Placebo SC plus standard therapy; placebo once weekly ,and total of 48 doses
2952602|NCT02885597|Placebo Comparator|placebo group|participants should administrate both Juanbi pill placebo and Methotrexate
2952603|NCT02885584|Experimental|Transpulmonary pressure controlled mechanical ventilation|transpulmonary pressure will be used for ventilation settings
2952604|NCT02885584|No Intervention|Conventional pressure-controlled mechanical ventilation|transpulmonary pressure will not be used for ventilation settings
2952605|NCT02885571|Active Comparator|MAD for subjective compliance|MAD for subjective compliance group wears the same SomnoDent Flex with DentiTrac to objective group, but they are subjected to be prescribed based on the subjective compliance data, which are acquired from patient's explanation. Compliance (average daily time,
2952606|NCT02885571|Experimental|MAD for objective compliance|MAD for objective compliance group wears the same SomnoDent Flex with DentiTrac to subjective group, but they are subjected to be prescribed based on the objective compliance data, which are acquired from data recorded within SomnoDent Flex with DentiTrac.
2952607|NCT02885558|Experimental|L + T-type|8 weeks treatment with efonidipine (1 week 1x20mg, 7 weeks 2x20mg)
2952608|NCT02885558|Active Comparator|L-Type|8 weeks treatment with nifedipine (1 week 1x20mg, 7 weeks 2x20mg)
2952609|NCT02885545|Experimental|Left atrial appendage occlusion|Patients receiving the Watchman device will have it placed via a percutaneous trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance. Patients will be anticoagulated for at least 45 days after the procedure.
2952610|NCT02885545|Active Comparator|Continuation of prescribed anticoagulant|Patients continuing medical therapy will continue to take their previously prescribed oral anticoagulation (vitamin K antagonist, apixiban or rivaroxaban) for the duration of the study unless a medical reason to alter therapy occurs.
2952611|NCT02885519|No Intervention|Control|Standard treatment and standard vocational rehabilitation
2952612|NCT02885519|Experimental|IBBIS MHC|IBBIS mental health care and standard vocational rehabilitation
2952613|NCT02885519|Experimental|IBBIS integrated MCH and VR|Integrated mental health care and vocational rehabilitation
2952614|NCT02885506|Placebo Comparator|Cohort 1|10 mg P218 or placebo capsule oral administration
2952615|NCT02885506|Placebo Comparator|Cohort 2|30 mg P218 or placebo capsules oral administration
2952616|NCT02885506|Placebo Comparator|Cohort 3|100 mg P218 or placebo capsules oral administration
2952617|NCT02885506|Placebo Comparator|Cohort 4|250 mg P218 or placebo capsule oral administration
2952618|NCT02885506|Placebo Comparator|Cohort 5|500 mg P218 or placebo capsules oral administration
2952619|NCT02885506|Placebo Comparator|Cohort 6|750 mg P218 or placebo capsules oral administration
2952620|NCT02885506|Placebo Comparator|Cohort 7|1000 mg P218 or placebo capsules oral administration
2952621|NCT02885506|Placebo Comparator|Cohort 8|1250 mg P218 or placebo capsules oral administration
2952622|NCT02885506|Experimental|Food effect cohort|A single oral dose of P218 under fasted or fed conditions in two different dosing periods.
2952623|NCT02885493||Falls is <or = 1 year|Patients whose number of falls is <or = 1 year
2952624|NCT02885493||falls is> 1 year|Patients whose numbers falls is> 1 year
2952625|NCT02885467|Active Comparator|Control|Standard total knee arthroplasty performed through medial parapatellar approach
2952626|NCT02885467|Experimental|Intervention|Total knee arthroplasty performed through medial parapatellar approach with identification, ligation, and burial of saphenous nerve branches
2952627|NCT02885454|Experimental|OC + AL-335 + ODV + 3-DAA combination|Participants will receive single dose of 3 milligram (mg) drospirenone/0.02 mg ethinylestradiol [OC] on Day 1, AL-335 800 mg once daily on Days 5 and 6, a single dose of AL-335 800 mg + a single dose of OC on Day 7, ODV 25 mg once daily on Days 12 to 24, followed by a single dose of ODV 25 mg and a single dose of OC on Day 25, followed by ODV 25 mg + AL-335 800 mg + simeprevir (SMV) 75 mg [3-DAA combination] once daily on Days 26 to 31, followed by a single dose of 3-DAA combination and a single dose of OC on Day 32.
2952628|NCT02885441|Experimental|Ketorolac|Tab Ketorolac,10 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.
2952629|NCT02885441|Placebo Comparator|Placebo|Tab placebo,10 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.
2952630|NCT02885402|Experimental|Osteoarthritis patient|
2952631|NCT02885402|Placebo Comparator|Healthy volunteers|
2952632|NCT02885376|Experimental|Dentoxol|Dentoxol® is a proprietary mouthrinse that has anti-inflammatory, antimicrobial and analgesic effects. Subjects will use Dentoxol® mouthrinse 5 times each day, starting on the first day of radiation therapy and ending on the last day of radiation therapy.
2952633|NCT02885376|Placebo Comparator|Placebo|The placebo rinse will be identical in color, taste and consistency as the Dentoxol rinse and will be packaged in identical bottles with the same labels. Subjects will use placebo mouthrinse 5 times each day, starting on the first day of radiation therapy and ending on the last day of radiation therapy.
2952634|NCT02885363|Experimental|Patients with newly diagnosed Left Ventricular Non Compaction|Patient newly diagnosed with Left Ventricular Non Compaction (diagnose < 6 months), confirmed by echocardiography associated or not with MRI, after centralized review
2952635|NCT02885363|Active Comparator|Patients with Idiopathic Dilated Cardiomyopathy|Patient newly diagnosed with Idiopathic Dilated Cardiomyopathy (diagnose < 6 months), confirmed by echocardiography associated or not with MRI, after centralized review
2952636|NCT02885350|Active Comparator|Spinal fentanyl|20 micrograms of intrathecally administered fentanyl in single dose. Total volume of intrathecal injection 2 ml.
2952637|NCT02885350|Experimental|Epidural fentanyl|100 micrograms of epidurally administered fentanyl in a single dose. Total volume of epidural injection 7 ml.
2952638|NCT02885350|Active Comparator|Spinal sufentanil|5 micrograms of intrathecally administered sufentanil in a single dose. Total volume of intrathecal injection 2 ml.
2952639|NCT02885350|Experimental|Epidural sufentanil|20 micrograms of epidurally administered sufentanil in a single dose. Total volume of epidural injection 7 ml.
2952698|NCT02884908|Placebo Comparator|Placebo + BBCET - NI/NI type|This group will be comprised of subjects with the NI/NI type who receive placebo and Brief Behavioral Compliance Enhancement Treatment (BBCET).
2952699|NCT02884895|Experimental|Intubating laryngeal Tube Suction|Intubating laryngeal Tube Suction
2952700|NCT02884895|Active Comparator|Direct Laryngoscopy|Direct Laryngoscopy
2952640|NCT02885337|Active Comparator|Usual Care|"Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the Kinesiologist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.~For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption."
2952641|NCT02885337|Experimental|Multi-Modal Frailty Intervention|"Exercise: A Kinesiologist will develop an individualized exercise program and schedule appointments with the patient at home including goal setting discussion. Participants will be offered free YMCA membership.~Cognitive-behavioural Change Strategy(CBCS) and education: CBCS may be an effective way to facilitate coaching strategies to increase participant exercise levels. Throughout the intervention, CBCS and education about exercise, hip or knee arthroplasty and osteoarthritis will be administered.~Protein Supplement: Participants will be provided with 1-2 daily supplements (containing 20 gram protein, 1.5 g β-Hydroxy β-Methylbutyrate /serving) to be taken with a meal or on activity days within 3-hours of exercise.~Vitamin D: All participants in the intervention arm will be provided with a supply of Vitamin D3 (1000 IU/day tablets) for the duration of the intervention period.~Medication Review: A geriatrician will review the medications for patients in the intervention arm."
2952642|NCT02885324|Experimental|Cabozantinib|Cabozantininb will be taken daily at a dose of 40 mg/m2. Drug cycles will last 28 days and be continuous for up to 12 months of therapy on study.
2952643|NCT02885311|Other|At-Risk Drinkers (AR)|AR will receive feedback about their drinking and brief advice along with follow up assessments.
2952644|NCT02885311|Other|Problem Drinkers (PD)|PD will be offered a choice of either an evidence-based behavioral intervention(Motivational Enhancement Therapy) or medication (Naltrexone) plus medication management. These participants will also receive follow up assessments.
2952645|NCT02885311|Other|AD with physiological withdrawal (AD-W)|AD-W will referred to outpatient detoxification as part of standard care, unless medically contraindicated, and will be offered medication (naltrexone) plus medication management as or an evidence-based behavioral intervention (Modified Behavioral Self-Control Therapy [MBSCT]) adapted from our two prior protocols. These participants will also receive follow up assessments.
2952646|NCT02885311|Other|AD with complex presentation (AD-CMPLX)|AD-CMPLX will receive a referral to specialty substance use disorder treatment and also receive follow up assessments.
2952647|NCT02885298||Supine intubations (0-10 degrees)|Intubations performed with patient positioned 0-10 degrees. Patient supine.
2952648|NCT02885298||Inclined (11-44 degrees)|Intubations performed with 11-44 degrees of elevation.
2952649|NCT02885298||Upright (45 degrees or greater)|intubations performed with patient elevated to 45 degrees or greater
2952650|NCT02885285|Experimental|Spinning Class|Subjects randomly selected for the spinning group will participate in spinning classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
2952651|NCT02885285|Experimental|Yoga Class|Subjects randomly selected for the yoga group will participate in yoga classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
2952652|NCT02885285|Experimental|Dance Class|Subjects randomly selected for the dance group will participate in dance classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
2952653|NCT02885285|Active Comparator|No Exercise Class|Subjects randomly selected for the no class group will not participate in the study exercise classes. Subjects will still complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
2952654|NCT02885272|Experimental|MRI + FDG PET/CT Scans|Participants undergo single paired FDG PET and MRI examinations two-weeks prior to initial maximal tumor resection. One hour after contrast drug injected, participant receives brain and whole body scan then standard-of-care MRI scan of brain, followed by two more FDG PET-CT scans at 4 - 5 hours and 7 - 8 hours after receiving contrast drug.
2952655|NCT02885259|Experimental|HyQvia|human immunoglobulin and one vial of recombinant human hyaluronidase (rHuPH20
2952656|NCT02885246||Influenza Group|All subjects who have laboratory confirmed diagnosis of influenza (laboratory confirmed case) and reported in the national influenza surveillance system from the Year 2010-2015.
2952657|NCT02885233|Active Comparator|Free From Falls|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
2952658|NCT02885233|Placebo Comparator|Waitlist|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
2952659|NCT02885220|Active Comparator|Conventional Program|The aim of our study is to determine if a goal directed program improves weight loss outcomes after sleeve gastrectomy. In the conventional weight loss program, patients will only be given their ideal weight to strive toward after surgery. Routine dietary and physiotherapy/exercise counseling are provided and patients would be educated on their ideal weights based on a BMI of 23. The target weight loss over a 12 month period would be 100% excess weight loss.
2952701|NCT02884882|Other|Emotional induction in stroke population|Six films are presented, each after a relaxation period after which the basal score is measured.
2952702|NCT02884882|Placebo Comparator|Emotional induction in healthy volunteers|Six films are presented, each after a relaxation period after which the basal score is measured.
2952660|NCT02885220|Experimental|Goal Directed Program|For the goal directed program, patients would be given an additional sheet to show expected weight loss goals to strive towards at each consultation after surgery (3, 6, 9 and 12 months post operation). Bariatric patients in this modified program will be counselled prior to laparoscopic sleeve gastrectomy (LSG) and EWL (excess weight loss) targets will be set for patients to achieve at fixed intervals post LSG. These targets are charted in a graph, with the patient's actual weight charted on the graph at each clinic consultation, providing a strong visual aid counselling and motivation.
2952661|NCT02885207|Other|Focal epilepsy of unknown cause|
2952662|NCT02885194|Other|Patients who underwent Deep Brain Stimulation (DBS)|Patients who underwent Subthalamic Nucleus (STN)-DBS at Lyon
2952663|NCT02885181|Experimental|GS-9876 Dose A|GS-9876 dose A + filgotinib placebo for 12 weeks
2952664|NCT02885181|Experimental|GS-9876 Dose B|GS-9876 dose B + filgotinib placebo for 12 weeks
2952665|NCT02885181|Experimental|Filgotinib|Filgotinib + GS-9876 placebo for 12 weeks
2952666|NCT02885181|Placebo Comparator|Placebo|GS-9876 placebo + filgotinib placebo for 12 weeks
2952667|NCT02885168|Experimental|Shock + Treatment|Patients treated with activated protein C
2952668|NCT02885168|Other|Shock|Patients not treated with activated protein C
2952669|NCT02885155||Patients with pulmonary arterial hypertension|
2952670|NCT02885142|Experimental|Transanal endoscopic microsurgery group|
2952671|NCT02885142|Active Comparator|endoscopic submucosal dissection group|
2952672|NCT02885116|Placebo Comparator|oxygen supplementation|right heart catheterization will be done in hypoxemic patients with supplemental oxygen
2952673|NCT02885116|Active Comparator|Nasal high flow (NHF) supplementation|right heart catheterization after during NHF (20 min) use with 35 l/min
2952674|NCT02885103|Placebo Comparator|inhalation with nebulizer|inhalation with an nebulizer via mouth
2952675|NCT02885103|Active Comparator|inhalation with nebulizer and NHF|inhalation with combination of nebulizer and nasal high flow (NHF) via nasal cavity
2952676|NCT02885090|Experimental|RTT patient|Blood sampling
2952677|NCT02885090|Experimental|Parents|Blood sampling. To distinguish between inherited polymorphic variants and potentially deleterious new imbalances.
2952678|NCT02885077|Experimental|High-intensity IMT + combined exercise|Participants will perform 12 weeks of IMT strength training is achieved with a device with linear load pressure with a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR). Training will progress to 80% maximal inspiratory pressure (PiMax). IMT will perform for 12 weeks with two sessions per week. The training protocol will consists of five series with ten repetitions with two minutes or according to patient feedback using the modified Borg scale.The initial charge of training will be 50% of PiMax in the first 2 weeks, with an increase of 55% of PiMax in the 3 week, 60% of PiMax in the 4 week, 65% of PiMax in the 5 week, 70% of PiMax in the 6 week, 75% of PiMax in the 7 week and 80% of PiMax in the 8 week. After the 9 and 12 week training period, the PiMax measurements will be performed weekly to keep 80% of the new PiMax.
2952679|NCT02885077|Sham Comparator|H-IMT sham + combined exercise|Participants will perform 12 weeks of IMT strength training is achieved with a device with linear load pressure with a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR). The sham group will perform for 12 weeks with two sessions per week. The protocol will consists of five series with ten repetitions with two minutes and will train at a constant inspiratory load of no more than 10% of their initial Pimax.
2952680|NCT02885051|Experimental|preterm newborn|Newborns hospitalized in the neonatal or Neonatal Resuscitation unit of Brest University Hospital and born before 36 weeks of gestation who will have recording of skin conductance and heart rate variability.
2952681|NCT02885025|Active Comparator|BSE + Nasal Fluticasone|"subjects will be randomized into 1 of 4 arms:~BSE + Nasal Fluticasone~BSE + normal saline nasal spray~Placebo Pill + Nasal Fluticasone~Placebo Pill + normal saline nasal spray"
2952682|NCT02885025|Active Comparator|BSE + normal saline nasal spray|"subjects will be randomized into 1 of 4 arms:~BSE + Nasal Fluticasone~BSE + normal saline nasal spray~Placebo Pill + Nasal Fluticasone~Placebo Pill + normal saline nasal spray"
2952683|NCT02885025|Active Comparator|Placebo Pill + Nasal Fluticasone|"subjects will be randomized into 1 of 4 arms:~BSE + Nasal Fluticasone~BSE + normal saline nasal spray~Placebo Pill + Nasal Fluticasone~Placebo Pill + normal saline nasal spray"
2952684|NCT02885025|Placebo Comparator|Placebo Pill + normal saline nasal spray|"subjects will be randomized into 1 of 4 arms:~BSE + Nasal Fluticasone~BSE + normal saline nasal spray~Placebo Pill + Nasal Fluticasone~Placebo Pill + normal saline nasal spray"
2952685|NCT02885012|Experimental|Switch to Letairis from Bosentan|Subjects will be switching treatments from Bosentan (Tracleer) to Ambrisentan (Letairis)
2952686|NCT02885012|Experimental|Switch to Letairis from Macitentan|Subjects will be switching treatments from Macitentan (Opsumit) to Ambrisentan (Letairis)
2952687|NCT02884999||severe trauma patients|Severe trauma patients admitted to the site in the first 24 hours
2952688|NCT02884986|Active Comparator|Etoricoxib|120mg of oral Etoricoxib under the brand name Arcoxia® (Merck Sharp & Dohme) one hour prior to spinal anaesthesia induction
2952689|NCT02884986|Placebo Comparator|Placebo|120mg of oral Placebo the same amount as the drug administrated one hour prior to spinal anaesthesia induction
2952690|NCT02884960|Experimental|Embozene Microspheres|Patients will undergo the uterine fibroid embolization procedure with Embozene Microspheres as the embolic agent.
2952691|NCT02884960|Active Comparator|Embosphere Microspheres|Patients will undergo the uterine fibroid embolization procedure with Embosphere Microspheres as the embolic agent.
2952692|NCT02884921|Active Comparator|Preemptive Paracetamol|Preemptive Paracetamol
2952693|NCT02884921|Active Comparator|Post surgery Paracetamol|Post surgery Paracetamol
2952694|NCT02884921|Placebo Comparator|Placebo|Placebo
2952695|NCT02884908|Experimental|Pregabalin + BBCET - NI/I/II type|This group will be comprised of subjects with the NI/I/II type who receive study medication (Pregabalin) and Brief Behavioral Compliance Enhancement Treatment (BBCET).
2952696|NCT02884908|Experimental|Pregabalin + BBCET - NI/NI type|This group will be comprised of subjects with the NI/NI type who receive study medication (Pregabalin) and Brief Behavioral Compliance Enhancement Treatment (BBCET).
2952697|NCT02884908|Placebo Comparator|Placebo + BBCET - NI/I/II type|This group will be comprised of subjects with the NI/I/II type who receive placebo and Brief Behavioral Compliance Enhancement Treatment (BBCET).
2952704|NCT02884869|Active Comparator|Direct laryngoscopy|Intubating laryngeal Mask
2952705|NCT02884856||Females observers (F)|those with female gender characteristics
2952706|NCT02884856||Male observers (M)|those with male gender characteristics
2952707|NCT02884843|Active Comparator|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction Disposable
2952708|NCT02884843|Active Comparator|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
2952709|NCT02884830|Placebo Comparator|Sham CPAP|Sham continuous positive airway pressure is a CPAP given at too low pressure to have any physiological effect on upper airways patency and on lung volumes
2952710|NCT02884830|Active Comparator|Efficace CPAP|Continuous positive airway pressure is a CPAP given at effective pressure to decrease the work of breathing in COPD patients
2952711|NCT02884817|Experimental|Listerine prof.gum.ther|"The test solution was the commercially available mouthwash product EOELA that contains essential oils and ELA in 21.6% alcohol (Listerine Professional Gum Therapy®, Johnson & Johnson,USA).~Intervention; Rinsing 30 sec with test solution twice daily for 21 days"
2952712|NCT02884817|Placebo Comparator|21.6% hydroalcoholic|"a hydro-alcohol solution made from 96% ethanol diluted with sterilized water to the final concentration of 21.6%.~Intervention: Rinsing 30 sec with placebo comparator twice daily for 21 days"
2952713|NCT02884817|Sham Comparator|Plain sterile water|"Plain sterile water.~Intervention: Rinsing 30 sec with sham comparator twice daily for 21 days"
2952714|NCT02884791|Experimental|Fasting (Healthy)|Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to10 different sweet beverages, separated by 2 weeks.
2952715|NCT02884791|Experimental|Fasting (metabolic syndrome)|Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to10 different sweet beverages, separated by 2 weeks.
2952716|NCT02884778|Experimental|NoL index in response to stimulation|"There is only one arm in this study. The intervention is not a drug, but it is the stimulus applied to the patient such as intubation and a standardized electrical stimulus applied on the forearm of the anesthetized patient. There are several stimuli that are the so-called interventions and the NoL index and the classical vital signs (heart rate, mean blood pressure, BISspectral index) are registered in response to these stimuli in an observational manner."
2952717|NCT02884765||Bicondylar Fracture|Patients presenting a bilateral condylar fracture of the mandible with or without additional symphyseal fracture. Bilateral condylar fractures will be treated non-surgical, surgical or combining both.
2952718|NCT02884739||schizophrenia|
2952719|NCT02884739||chronic psychiatric disorder other than schizophrenia|
2952720|NCT02884726|Experimental|BMS-986148 intravenous infusion|
2952721|NCT02884713|Experimental|Levofloxacin and Doxycycline and Esomeprazole|The rescue treatment was given for ten days consisting of levofloxacin 500 mg once daily, doxycycline 100 mg twice daily, and esomeprazole 20 mg twice daily
2952722|NCT02884700||Severe legionellosis cases|Patients admitted to Grenoble University Hospital for severe legionellosis between 2006 and 2011.
2952723|NCT02884674|Active Comparator|active Transcranial Magnetic Stimulation|Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, Using theta burst stimulation and using Transcranial Magnetic Stimulation navigator and robot
2952724|NCT02884674|Placebo Comparator|Placebo|Placebo comparator, using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using Transcranial Magnetic Stimulation navigator and robot
2952725|NCT02884661||Hospitalization in Cardiology department|Patients cared by the Cardiology department
2952726|NCT02884661||Hospitalization in Geriatric unit|Patients cared by the Geriatric unit
2952727|NCT02884648|Experimental|Bevacizumab|Participants receive Bevacizumab by vein on Day 1 of every 21-day study cycle, for as long as study doctor thinks it is in participant's best interest.
2952728|NCT02884635|Experimental|ASP1707|ASP1707 will be orally administered for 12 weeks.
2952729|NCT02884635|Placebo Comparator|Placebo|Placebo will be orally administered for 12 weeks.
2952730|NCT02884622|Other|CF patients|CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added and blood sampling will be collected for this study
2952731|NCT02884583|Experimental|Pulmonary function test|Patients hospitalized for Oral Food Challenge realize pulmonary function test
2952732|NCT02884557|Other|PSC + IBD group|collection of gut biopsies collection of blood samples in patients with PSC and IBD
2952733|NCT02884557|Other|IBD alone group|collection of gut biopsies collection of blood samples in patients with IBD alone
2952734|NCT02884544|Experimental|HLD100|"HLD100 (dextroamphetamine sulfate) DR/ER capsules (10mg)~HLD100 (dextroamphetamine sulfate) DR/ER capsules (20mg)~HLD100 (dextroamphetamine sulfate) DR/ER capsules (30mg)~HLD100 (dextroamphetamine sulfate) DR/ER capsules (40mg)"
2952735|NCT02884531|Experimental|Patient Education and BBAT|Patients will participate in Patient Education and Basic Body Awareness Therapy
2952736|NCT02884531|Active Comparator|Patient Education|Patients will only participate in Patient Education
2952737|NCT02884518|Experimental|patient group|The patient group recruits subjects diagnosed with first episode psychosis which occurred within 2 years and having been treated with antipsychotics for 1 year. Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity. And patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
2952738|NCT02884518|Other|healthy control group|Screening tests for healthy volunteers included physical examination, vital signs, laboratory will test (hematology, blood chemistry, and urinalysis), and a 12-lead electrocardiograms. A psychiatric interview with the Structured Clinical Interview for text revision of the Diagnostic and Statistical Manual of Mental Disorders -IV(DSM-IV-TR) Axis I disorders, Research Version, Nonpatient Edition (SCID-I/NP) (First et al. 2002) will be conducted. Subjects with any medically significant abnormality on investigations and/or psychiatric disease will be excluded. Also, healthy control group will take a PET scan at 0, 2, 4, 6, and 8 week and clinical scales at baseline.
2953197|NCT02881294|Active Comparator|Gender Effect|SUVN-G3031 tablets single dose
2952739|NCT02884505||Patients with Hypersomnolence|Patients referred for polysomnography and multiple sleep latency test
2952740|NCT02884492|Experimental|Cognitive impairment|Adults with Alzheimer's disease, preclinical Alzheimer's disease or impairment due to suspected non-Alzheimer's disease pathophysiology will receive 18F-THK- 5351 and/or lumbar puncture (optional).
2952741|NCT02884492|Active Comparator|No cognitive impairment|Normal aging adults will receive 18F-THK- 5351 and/or lumbar puncture (optional).
2952742|NCT02884479|Experimental|PT-112 + Docetaxel|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
2952743|NCT02884466|Experimental|Intervention group|The intervention group will receive a multidisciplinary rehabilitation intervention consisting of: 1) a pre-admission day, 2) two weeks of home-based activities, 3) two-week inpatient period, 4) four weeks of home-based activities, 5) 1st two-days inpatient follow-up, 6) six weeks of home-based activities and 7) 2nd two-days inpatient follow-up.
2952744|NCT02884466|Active Comparator|Usual care group|The usual care group will receive a four-week inpatient multidisciplinary rehabilitation intervention.
2952745|NCT02884453|Experimental|ibrutinib|ibrutinib delivered orally at a dose of 560mg once daily continuously on a 4 weekly cycle until disease progression or unacceptable toxicity occurs.
2952746|NCT02884440|Experimental|TAP block ropivacaine|Bilateral ultrasound guided with 15 ml ropivacaine 5mg/ml on each side under general anesthesia at the end of the intervention
2952747|NCT02884440|Placebo Comparator|TAP block placebo|Bilateral ultrasound guided with 15 ml saline on each side under general anesthesia at the end of the intervention
2952748|NCT02884427|Experimental|Cathode Stimulation|Group that is involved with the (black) negative electrode seeking the polar effect of nervous increased excitability and conductivity with the current application.
2952749|NCT02884427|Experimental|Anode Stimulation|Group that is involved with the (red) positive electrode seeking the polar effect of nervous excitability and conductivity decreased with the current application.
2952750|NCT02884427|Placebo Comparator|Control|Group that will be placed electrotherapy without operation, but only installation. Patients in this group will see the team work but it will not be delivering current.
2952751|NCT02884414|Experimental|Cutaneous Stimulation|Cutaneous stimulation and/or feedback. This stimulation and/or feedback may be visual, auditory, tactile (e.g. vibratory, temperature), or haptic and is completely external.
2952752|NCT02884401|Other|osteoporotic women with a missing tooth|Post-menopausal osteoporotic women with a missing tooth and willing to replace it with a dental implant
2952753|NCT02884388|Experimental|experimental group|Combined nerve block will be used, involving lower lumbar plexus, sciatic nerve, and paraspinal nerve L1-2.
2952754|NCT02884388|Experimental|control group|General anesthesia will be used in this group.
2952755|NCT02884375||Elderly cancer patient cohort|Patients aged 70 years or older, who had diagnosis of cancer in participating sites (including hematologic malignancies), and referred to a geriatrician for geriatric assessment (GA)
2952756|NCT02884349|Experimental|RoM assessment|All patients recruited to the study.
2952757|NCT02884323|Experimental|geko device arm|
2952758|NCT02884310|Experimental|SPI group|"Remifentanil titration before tracheal intubation and skin incision according to the SPI gradient obtained after a nociceptive test using a tetanic stimulus of 100 Hz, 60 milliamperes during 30 seconds performed at a 3 ng/ml level of the remifentanil concentration.~During surgery, the effect site remifentanil concentration was either increased or decreased by 1 ng/ml to maintain SPI below 40 or above 20, respectively."
2952759|NCT02884310|Active Comparator|Control group|"The remifentanil concentration before tracheal intubation and skin incision was fixed at 4 ng/ml.~During surgery, the remifentanil concentration was adapted according to the hemodynamic answer of the patient. It was changed by 1 ng/ml stepwise variations to maintain heart rate and mean blood pressure within 20% of the patient reference hemodynamic values."
2952760|NCT02884297|Experimental|surgical termination of pregnancy|Contrast agent: SonoVue®: Hexafluoride (SonoVue®, injectable solution to solubilisate, 8µg/mL) is injected in all patients for 2D and 3D Doppler ultrasound angiography during the termination of pregnancy. 2,4 mL are administrated per patient, divided into two injections of 1,2 mL.
2952761|NCT02884271||cardiac arrest group|patients who develop intraoperative cardiac arrest
2952762|NCT02884271||without cardiac arrest group|patients who don't develop intraoperative cardiac arrest
2952763|NCT02884258||Bariatric surgery group|Women undergoing IVF (IVF or ICSI) with a history of bariatric surgery (surgery procedures include sleeve gastrectomies and by-passes). No intervention is involved.
2952764|NCT02884258||Control Group|Women undergoing IVF with no history of bariatric surgery and matched to bariatric surgery patients for weight, parity and age.
2952765|NCT02884245|Experimental|Arm E2: With estrogens pretreatment|The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
2952766|NCT02884245|No Intervention|Arm S: without estrogens pretreatment|No estrogen pretreatment will be delivered
2952767|NCT02884232||Workers exposed to wood dust|
2952768|NCT02884219|Active Comparator|Early Treatment with cyclooxygenase inhibitors|Treatment of PDA that starts within the first 3 days of life using cyclooxygenase-inhibitors (Ibuprofen or Indomethacin)
2952769|NCT02884219|Sham Comparator|Expectative Treatment|Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
2952770|NCT02884206|Experimental|LCZ696|Patients will receive LCZ696 at 100 mg twice daily during a single-blind treatment run-in period to ensure patients tolerate this medication before they are randomized. Down-titration is not allowed during this period. Patients who are able to tolerate LCZ696 100 mg twice daily are eligible to enter the randomized treatment period. Patients randomized to receive LCZ696 will be given LCZ696 at 200 mg twice daily. Patients will receive randomized study drug for three years.
2952771|NCT02884206|Active Comparator|Valsartan|Patients will receive valsartan at 40mg and/or 80mg twice daily during a single-blind treatment run-in period. Following the run-in period, patients randomized to receive valsartan will be given valsartan at 160 mg twice daily for three years.
2952772|NCT02884193|Experimental|Brief Cooling (Quick Icing)|Group receiving the application of cold on the ventral side of the dominant forearm for 30 seconds, using the technique of ice beakers dynamically.
2952773|NCT02884193|Active Comparator|Prolonged Cold|"Group receiving the intervention of ice bag for a period of 5 and a half minutes from 1 minute, on the ventral side of the dominant forearm"
2952774|NCT02884193|Sham Comparator|Control|"Group receives a placebo application through an ice bag empty. The bag will be applied from 1 minute to 6 and a half minutes, as the group of prolonged cold"
2952775|NCT02884180|Active Comparator|Treatment A|Dexamethasone 24 mg i.v. after start of anaesthesia
2952776|NCT02884180|Placebo Comparator|Treatment B|Saline isotonic i.v. after start of anaesthesia
2952777|NCT02884167||Patients with constipation|
2952778|NCT02884167||Healthy individuals without constipation|
2952779|NCT02884154|Other|Arm who will undergo EUS-FNB|
2952780|NCT02884141||Patients|"Patients with documented fibromuscular dysplasia (see inclusion criteria).~Non-usual care added acts:~blood sampling~urine sampling~renal echography"
2952781|NCT02884128|Experimental|PEP02 + 5-FU/LV|The initial starting dose of PEP02 is 60 mg/m2, and was escalated by increments of 20 mg/m2 between dose levels. 5-FU and LV were given as 24-hour infusion via an implanted central venous catheter, with dose fixed at 2000 mg/m2 and 200 mg/m2, respectively. PEP02 was administered on Day 1; 5-FU/LV was started after the end of PEP02 infusion on Day 1 and also on Day 8.
2952782|NCT02884115|Active Comparator|Retreatment group|Serofast early syphilis cases retreated with three doses benzathine penicillin
2952783|NCT02884115|No Intervention|Control group|Absence of any retreatment
2952784|NCT02884089|Placebo Comparator|Placebo + Metformin|Single dose of placebo administered orally followed by a single dose of metformin administered orally in one of four study periods.
2952785|NCT02884089|Experimental|Abemaciclib + Metformin|Single dose of abemaciclib administered orally followed by a single dose of metformin administered orally in one of four study periods.
2952786|NCT02884089|Placebo Comparator|Placebo + Iohexol|Single dose of placebo administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
2952787|NCT02884089|Experimental|Abemaciclib + Iohexol|Single dose of abemaciclib administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
2952788|NCT02884076||Symptomatic Hemorrhoid|Consecutive patients with symptomatic hemorrhoids presenting to our clinic
2952789|NCT02884063||NGS reading for Media Free DNA|Ability to read the DNA product available in embryo culture media using NGS to have valuable diagnostic image for genetic composition of embryo before implantation.
2952790|NCT02884063||NGS reading for blastomer DNA|DNA extracted from Blastomere used for aneuploidy screening.
2952791|NCT02884050|Experimental|Topiramate|single, 100mg oral dose of topiramate
2952792|NCT02884050|Placebo Comparator|Placebo|matched inactive placebo
2952793|NCT02884037||1|Rifaxmin group
2952794|NCT02884037||2|placebo group
2952795|NCT02884024||lean|healthy subject undergoing routine screening colonoscopy, BMI< or = 25
2952796|NCT02884024||mildly obese|healthy subject undergoing routine screening colonoscopy, BMI 30-33.9
2952797|NCT02884024||moderate-to-severe obese|healthy subject undergoing routine screening colonoscopy, BMI 34+
2952798|NCT02884011||No chronic antihypertensives|not on either a chronic β-blocker or ACE-Inhibitor
2952799|NCT02884011||β-blocker|on chronic β-blocker
2952800|NCT02884011||ACE-Inhibitor|on chronic ACE-Inhibitor
2952801|NCT02884011||Both β-blocker and ACE-inhibitor|on both chronic β-blocker and ACE-inhibitor
2952802|NCT02883998|Active Comparator|Outpatient Physical Therapy Group|Once the patient is cleared for discharged from the hospital, the patient will be given a prescription for outpatient physical therapy to attend 3 times per week for 6 weeks.
2952803|NCT02883998|Experimental|Home Base Physical Therapy Group|Patients will be provided a packet of exercises and equipment to perform the home based physical therapy program. Patients will attend a single session of outpatient physical therapy prior to surgery no more than 4 weeks prior to the procedure to teach the patient how to perform the exercises.
2952804|NCT02883985|Experimental|Radiation Therapy: 6 Gy/ fraction|All patients will be treated with 6 Gy /fraction delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.
2952805|NCT02883972|Experimental|Intervention letter and reminder|Behavioural insights informed invitation letter and SMS/email reminder message
2952806|NCT02883972|Experimental|Intervention letter|Behavioural insights informed invitation letter only
2952807|NCT02883972|Experimental|Control letter and reminder|Control invitation letter and SMS/email reminder message
2952808|NCT02883972|Active Comparator|Control letter|Control invitation letter only
2952809|NCT02883959|Experimental|music therapy|Music therapy
2952810|NCT02883959|No Intervention|control arm|No music
2952811|NCT02883946||hairy-cell leukemia|Patients with hairy-cell leukemia.
2952812|NCT02883933||melanoma|Patients with melanoma.
2952813|NCT02883920||workers of Champagne vineyard|
2952814|NCT02883907||Healthy volunteers|
2952815|NCT02883907||Osteoarthritis patients|
2952816|NCT02883894||bullous pemphigoid|Patients with bullous pemphigoid.
2952817|NCT02883881||No eye rubbing|
2952818|NCT02883881||with eye rubbing|
2952819|NCT02883868||patients treated with CXL|
2952820|NCT02883842|Experimental|Intervention-Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week.
2952821|NCT02883842|No Intervention|Control|Participants in the control group will receive 2 thank-you messages per month and undertake routine clinical practice.
2952822|NCT02883829|Experimental|Peer-Based Delivery|The Peer-Based Delivery Arm will receive a brief health information intervention (delivered as video content) about diabetes self-management and alcohol use risks, measuring effects on health knowledge. For this arm, a peer will be the spokesperson delivering the intervention content.
2952861|NCT02883569|Experimental|LSS w/ instability - NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
2952823|NCT02883829|Experimental|Provider-Based Delivery|The Provider-Based Delivery Arm will receive a brief health information intervention (delivered as video content) about diabetes self-management and alcohol use risks, measuring effects on health knowledge. For this arm, a healthcare provider will be the spokesperson delivering the intervention content.
2952824|NCT02883816|Experimental|cystic fibrosis|assessment of lung function in newborns screened for cystic fibrosis
2952825|NCT02883803|Experimental|MSC|Patients hospitalized in recovery unit and having a very severe septic shock with community origin (≥ 2 organ failures other than hemodynamic) since less than 12 hours, will receive 10^6/kg heterologous mesenchymal stem cells in 250 ml albumin 4%, infused for 30 minutes in central venous line.
2952826|NCT02883803|Sham Comparator|Placebo|Patients hospitalized in recovery unit and having a very severe septic shock with community origin (≥ 2 organ failures other than hemodynamic) since less than 12 hours, will receive 250 ml albumin 4%, infused for 30 minutes in central venous line.
2952827|NCT02883790|Experimental|Somnage|Group A-Melatonin 1mg, Zinc, Magnesium Oral administration o.d.
2952828|NCT02883790|Placebo Comparator|Placebo|Oral administration o.d.
2952829|NCT02883777|Experimental|High Protein and Low Glycemic Index Diet|A protocol of a high protein and low glycemic index diet.
2952830|NCT02883777|Active Comparator|Conventional Diet|A protocol of a conventional diet.
2952831|NCT02883751|Active Comparator|Control group|Control group - gold standard: Conventional ulcer treatment with Rayon® and essential fatty acids (Dersani®). Cleaning of the surgical wound will be performed with saline solution. The wound will then be covered with a sterile polyethylene film, over which the LED plate will be positioned for placebo treatment (emission of sound, but with the device switched off). After 10 minutes, the LED plate and polyethylene film will be removed and the surgical wound will be covered with rayon moistened with essential fatty acids (following the standard protocol of the hospital), followed by the application of gauze and finalization with a crepe bandage.
2952832|NCT02883751|Experimental|LED group|LED group: Cleaning of the surgical wound will be performed with saline solution and the wound will be covered with a sterile polyethylene film, over which the LED plate will be positioned for active treatment with the device switched on. After 10 minutes, the LED plate and polyethylene film will be removed and the surgical wound will be covered with rayon moistened with essential fatty acids (following the standard protocol of the hospital), followed by the application of gauze and finalization with a crepe bandage.
2952833|NCT02883738|Experimental|upper limb tremor|
2952834|NCT02883725||Esophageal atresia|
2952835|NCT02883699|Active Comparator|Endurance Training Group 1|Standard endurance training
2952836|NCT02883699|Experimental|Endurance Training Group 2|Polarized endurance training
2952837|NCT02883699|Active Comparator|Resistance Training Group 1|Standard resistance training
2952838|NCT02883699|Experimental|Resistance Training Group 2|Daily undulating periodization resistance training
2952839|NCT02883686|Experimental|Peer-BA for Pregnant Women|Peer-delivered Behavioral Activation (BA) therapy for pregnant women
2952840|NCT02883686|Active Comparator|Care as Usual|Care as usual for depression at Kaiser Permanente (KP).
2952841|NCT02883673|Experimental|Intervention|InPress Device for Postpartum Hemorrhage will be administered to subjects who are diagnosed with postpartum hemorrhage.
2952842|NCT02883660||Cases|"patients who had empirically defined increased AEs on one of the specified antidepressants (SSRIs/ SNRIs). This group will get the Genecept Assay, which is a battery of pharmacogenetic tests relevant to psychiatry."
2952843|NCT02883660||Controls|"patients who did not have empirically defined increased AEs with an index antidepressant (one of the specified SSRIs/ SNRIs) AND were nonresponders to that antidepressant. This group will get the Genecept Assay, which is a battery of pharmacogenetic tests relevant to psychiatry."
2952844|NCT02883647||retreatment|"Patients with HBV DNA ＞ 2000 IU/ml and ALT ≥ 5×ULN;~Patients with HBV DNA ＞ 2000 IU/ml and 2×ULN ＜ ALT ≤ 5×ULN, but have clinical symptoms.~Intervention: Patients of this group will receive Entecavir 0.5mg/d or Tenofovir 300mg/d again."
2952845|NCT02883647||non-retreatment|"Patients with HBV DNA ≤ 2000 IU/ml;~Patients with HBV DNA ＞ 2000 IU/ml and ALT ≤ 2×ULN;~Patients with HBV DNA ＞ 2000 IU/ml and 2×ULN ＜ ALT ≤ 5×ULN, but have no clinical symptoms."
2952846|NCT02883634|Experimental|specific manipulation|"Participants allocated to group specific manipulation, will have their lumbar spine manipulated according to the previous clinical examination."
2952847|NCT02883634|Experimental|non-specific manipulation|"Participants allocated to group non-specific manipulation will have their upper thoracic spine manipulated (also known as global manipulation) regardless of the previous clinical examination."
2952848|NCT02883621|Active Comparator|Group A|subjects receive standard upper endoscopy
2952849|NCT02883621|Experimental|Group B|subjects receive cap assisted upper endoscopy
2952850|NCT02883608|Experimental|Initial cap assisted endoscopy|undergo initial cap assisted forward-viewing endoscope then side-viewing duodenoscope
2952851|NCT02883608|Active Comparator|Initial standard endoscopy|undergo initial side-viewing duodenoscope then cap assisted forward-viewing endoscope
2952852|NCT02883595|Experimental|thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
2952853|NCT02883595|Placebo Comparator|Placebo|Subcutaneous injections of placebo (saline) twice per day for seven days
2952854|NCT02883582|Experimental|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA)with or without ICS)+ hydrogen/ oxygen inhaled
2952855|NCT02883582|Experimental|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
2952856|NCT02883569|Active Comparator|HIVD-OP|open or endoscopic discectomy
2952857|NCT02883569|Experimental|HIVD-NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
2952858|NCT02883569|Active Comparator|LSS w/o instability -OP|decompression, instrumentation and fusion
2952859|NCT02883569|Experimental|LSS w/o instability -NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
2952860|NCT02883569|Active Comparator|LSS w/ instability - OP|decompression, instrumentation and fusion
2952862|NCT02883569|Active Comparator|No intervention group|exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
2952863|NCT02883569|Experimental|Intervention group|epidural block, epidural adhesiolysis
2952864|NCT02883556|Experimental|Pembrolizumab 200 mg|Pembrolizumab 200 mg administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
2952865|NCT02883543|Experimental|icotinib plus radiotherapy|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib plus concurrent radiotherapy.
2952866|NCT02883543|Active Comparator|icotinib|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib monotherapy.
2952867|NCT02883543|Active Comparator|chemotherapy plus radiotherapy|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive chemotherapy plus concurrent radiotherapy.
2952868|NCT02883530||Biomarker optimised patients|Optimised biomarker/Th2 low n=40
2952869|NCT02883530||non -optimised/Th2 low patients|Patients identified in clinic with FeNO <30 ppb. Those who at screening demonstrate FeNO <30 ppb and blood eosinophil count ≤0.20 x109/L will be considered to be non-optimised biomarker-low patients (Th2-low) and will proceed to bronchoscopy n=80
2952870|NCT02883530||corticosteroid-resistant biomarker|Patients identified in clinic with FeNO >45 ppb who have failed to suppress their FeNO during FeNO suppression testing. These patients are considered adherent to inhaled corticosteroids. Those who at screening also demonstrate blood eosinophils of >0.3x109/L n=40
2952871|NCT02883517||Aggressive primary cutaneous lymphomas|"Mycosis fungoides ≥ T2b~Primary cutaneous T helper follicular lymphoma ≥ T2~Primary cutaneous diffuse large B-cell lymphoma, leg type Genetic: Cytogenetic and molecular studies Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome."
2952872|NCT02883504|Experimental|Echocardiography|
2952873|NCT02883478|Active Comparator|Treatment group A|"Corneal collagen cross-linking using riboflavin with hydroxypropyl methylcellulose solution and ultraviolet-A (UVA) irradiation at 3 milliwatt/cm² (mW/cm²) for 30 minutes.~Device: UV-X 1000 irradiator (3 mW/cm²) Drug: riboflavin with hydroxypropyl methylcellulose"
2952874|NCT02883478|Active Comparator|Treatment group B|"Corneal collagen cross-linking using riboflavin with hydroxypropyl methylcellulose solution and ultraviolet-A (UVA) irradiation at 9 mW/cm² for 10 minutes.~Device: UV-X 2000 irradiator (9 mW/cm²) Drug: riboflavin with hydroxypropyl methylcellulose"
2952875|NCT02883465|Other|Single arm|
2952876|NCT02883452|Experimental|CT-P13 IV|CT-P13 IV (Infliximab)
2952877|NCT02883452|Experimental|CT-P13 SC|CT-P13 SC (Infliximab)
2952878|NCT02883439|Experimental|2|MP29-02 137 microgram, one time only 1 spray
2952879|NCT02883439|Active Comparator|1|fluticasone propionate 50 microgram, one time only 1 spray
2952880|NCT02883426|Experimental|Group 1: H3N2v Seronegative Adults: H3N2v LAIV|Participants will receive one dose of H3N2v LAIV on Day 0 (study entry). They will then receive one dose of H3N2v IIV on Day 84.
2952881|NCT02883426|Experimental|Group 2: H3N2v Seropositive Adolescents: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
2952882|NCT02883426|Placebo Comparator|Group 2: H3N2v Seropositive Adolescents: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
2952883|NCT02883426|Experimental|Group 3: H3N2v Seronegative Adolescents: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
2952884|NCT02883426|Placebo Comparator|Group 3: H3N2v Seronegative Adolescents: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
2952885|NCT02883426|Experimental|Group 4: Children: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
2952886|NCT02883426|Placebo Comparator|Group 4: Children: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
2952887|NCT02883413|Experimental|CRT +Teach the Parent|The Teach the Parent (TtP) addition to CRT is designed to increase parental understanding of their adolescents' thinking styles. We hypothesize that by doing so, parents will be more likely to challenge eating disorder behaviors and be less likely to accommodate behavioral symptoms of the eating disorder (e.g., make something low-fat for dinner because it will be easier). In this arm, adolescents will explain what they learned during CRT and walk their parents though at least 4 tasks during each TtP session. Parents and child will not be permitted to speak about the eating disorder during these sessions. TtP sessions will occur 3-4 times during hospitalization and will be guided by the adolescent.
2952888|NCT02883413|Active Comparator|CRT + Family Fun Time|In order to assess for any non-specific effects of spending non-eating disorder driven time with family, adolescents in the CRT+ Contact Control condition will be asked to spend 3-4 sessions with their parents engaging in fun activities (games, coloring, trivia). We refer to this condition as CRT + Family Fun Time (CRT+FFT). Adolescents will be asked to complete a series of fun tasks (some standardized, some are choice driven) with their parents. During these sessions, they will not be permitted to discuss CRT or the eating disorder.
2952889|NCT02883413|No Intervention|Treatment as Usual (TAU)|Adolescents in this condition will not receive any additional treatment. They will have a standard hospital stay with all normal contact with health professionals.
2952890|NCT02883400|No Intervention|SOC-Standard of care|standard of care, nontreatment
2952891|NCT02883400|Experimental|spironolactone|spironolactone
2952892|NCT02883387|Experimental|Preoperative CT Angiography|Patients will receive preoperative CT angiography to map the blood vessels potentially used for reconstruction
2952893|NCT02883387|Active Comparator|No Imaging Preoperatively|No preoperative vessel mapping will be done
2952894|NCT02883374|Experimental|Chidamide|Patients of advanced cephalic and cervical adenocystic carcinoma are given Chidamide 30mg,biw, then the efficacy and safety will be accessed.
2952895|NCT02883361|Experimental|Treatment|Receive 4 in-person motivational enhancement counseling sessions over the course of 12-months that specifically target medication adherence.
2952896|NCT02883361|Placebo Comparator|Control|Attend 4 in-person sessions to complete questionnaires and receive educational handouts.
2952897|NCT02883322||Initial|Patients answering the initial translation
2952898|NCT02883322||Committee-only|Patients answering the translation modified by an expert committee
2952899|NCT02883322||BT-only|Patients answering the translation modified with the use of a back-translation
2952900|NCT02883322||Both|Patients answering the translation modified by an expert committee with the use of a back-translation
2952901|NCT02883296|Experimental|Patients with perianal fistulizing Crohn's disease|
2952902|NCT02883283|Active Comparator|Epidural Catheter Administration|Participants will receive the 10 mL epidural loading dose in 5 mL increments via the epidural catheter following catheter placement. (Current standard practice) Epidural loading dose via epidural catheter.
2952903|NCT02883283|Experimental|Epidural Needle Administration|Participants will receive the 10 mL epidural loading dose in 5 mL increments via the epidural needle prior to catheter placement. Epidural loading dose via epidural needle.
2952904|NCT02883270|Experimental|RAGT treatment group|Robotic-assisted gait training （RAGT）is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation after some neuropathy. The investigators use LokoHelp for training, which is provided to the feet and the patient actively controls the knee and hip joints. The participants of RAGT treatment group receive 30 min conventional rehabilitation and 30 min robotic-assisted gait training daily for 8 weeks.
2952905|NCT02883270|Placebo Comparator|controls|The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
2952906|NCT02883257|Experimental|Cognitive Behavioral Therapy|"20 individual 60-minute appointments over the course of 16 weeks~Consistent with Beck, Rush, Shaw, and Emery (1979)"
2952907|NCT02883244|Experimental|Soft-Picks Advanced|Device: Curved Soft-Picks
2952908|NCT02883244|Active Comparator|Floss|Device: Waxed tape floss
2952909|NCT02883218||Comunity-acquired severe sepsis patients|Patients with new-onset community-acquired severe sepsis within 24h without confounding factors in immune status
2952910|NCT02883218||Non-severe sepsis patients|Patients between 18 and 90 years of age and be admitted to the ICU without a diagnosis of severe sepsis.
2952911|NCT02883218||Healthy controls|Heathy vonlunteers between 18 and 90 years of age.
2952912|NCT02883192|Experimental|ondansetron|ondansetron
2952913|NCT02883192|Placebo Comparator|Placebo|Placebo
2952914|NCT02883179|Active Comparator|lidocaine injection|5 mL of 2% lidocaine anhydrous solution (Depocaine) will be injected slowly along the lines of the edges of the perineal tears after delivery, with frequent aspirations to avoid intravascular injection.
2952915|NCT02883179|Experimental|lidocaine-prilocaine cream|5-g dose of Lidocaine-prilocaine cream will be applied to the intact tissue around each tear for 5 minutes before suturing
2952916|NCT02883166|Other|group 1|1000mg abiraterone fasted followed by 500 mg with breakfast
2952917|NCT02883166|Other|group 2|500 mg abiraterone with breakfast followed by 1000mg fasted
2952918|NCT02883153|Experimental|Zirconium-89 girentuximab PET/CT|A Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq).
2952919|NCT02883127||The study group|Receives lifestyle intervention with motivational interviewing focusing on following the recommended diabetes diet and gestational weight gain recommendations in addition to routine care
2952920|NCT02883127||The control group|Was given the same routine care with the same treatment goals, but without motivational interviewing.
2952921|NCT02883114|Experimental|single cohort|single dose of PF-06648671 in period 1 and 14-day dose of itraconazole plus single dose of PF-06648671 in period 2
2952922|NCT02883101|Active Comparator|Pulmonary rehabilitation group|"Participants randomised to the PR group will receive exercise training and regular instruction in self-management of ACT along with standard care. Patients will be enrolled into the pulmonary rehabilitation programme, in the Department of Pulmonary Medicine and Sleep disorders, All India Institute of Medical Sciences.~The total duration of the programme would be 8 weeks, with thrice weekly sessions of exercise training of 1 hour duration each. Of these sessions, at least 2 will be supervised while one will be at home. The patient will be asked to maintain a personal log recording the date, time, duration and type of exercise performed to ensure compliance, and these will be regularly reviewed and monitored.~The Rehabilitation Programme will include the following:~i. Patient education ii. Exercise training iii. Ventilator and breathing exercises"
2952923|NCT02883101|No Intervention|Standard care group|"Candidates randomized to the standard care group will receive standard care for bronchiectasis according to current guidelines. These participants will receive instruction and review of airway clearance therapy (ACT). Each participant will be provided with written information about bronchiectasis and education regarding self-management of the condition. Participants who have not been previously instructed in any ACT will be taught the active cycle of breathing technique. These participants will not receive any supervised exercise training."
2952924|NCT02883088||LAD-group|Subjects over 18 years who are undergoing Frequency Domain - Optical Coherence Tomography (FD-OCT) evaluation of the native left anterior descending artery during clinically indicated coronary angiography regardless of the clinical syndrome (silent ischemia, effort angina or acute coronary syndrome).
2952925|NCT02883075|Active Comparator|Study group 1|Supine position after placement of spinal anesthetic
2952926|NCT02883075|Active Comparator|Study group 2|Right lateral after placement of spinal anesthetic
2952927|NCT02883075|Active Comparator|Study group 3|Left lateral after placement of spinal anesthetic
2952928|NCT02883062|Active Comparator|Arm A (paclitaxel, carboplatin, mastectomy, lumpectomy)|Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes. Treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Within 3-6 weeks, patients undergo mastectomy or lumpectomy.
2952929|NCT02883062|Experimental|Arm B (atezolizumab, paclitaxel, carboplatin, breast surgery)|Patients receive atezolizumab IV over 30-60 minutes, paclitaxel IV over 1 hour, and carboplatin IV over 30 minutes. Treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Within 3-6 weeks, patients undergo mastectomy or lumpectomy.
2952930|NCT02883049|Experimental|DS HR B-ALL (RER)|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.~See outline for details."
2952931|NCT02883049|Experimental|DS HR B-ALL (SER)|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.~See outline for details."
2952932|NCT02883049|Experimental|Group I Arm A (HR B-ALL)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
2952933|NCT02883049|Experimental|Group I Arm B (HR B-ALL) (CLOSED 03/19/2018)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
2952934|NCT02883049|Active Comparator|Group II Arm A (VHR B-ALL - Control Arm)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
2952935|NCT02883049|Experimental|Group II Arm B (VHR B-ALL - Exp Arm1) (CLOSED 02/15/2017)|"Patients receive consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
2952936|NCT02883049|Experimental|Group II Arm C (VHR B-ALL - Exp Arm 2) (CLOSED 09/12/2014)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
2952937|NCT02883049|Experimental|Group III PH-like predicted TKI-sensitive kinase mutation|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.~See outline for details."
2952938|NCT02883036||Patients with chronic myeloid leukemia|100 adult patients(age>18 years),with chronic myeloid leukemia defined by the World Health Organization(WHO) criteria
2952939|NCT02883036||Healthy volunteers|Healthy volunteers
2952940|NCT02883023|Experimental|Electrosclerotherapy|One region of interest in the capillary malformation (approximately 1.5x1.5cm)will be treated with electrosclerotherapy
2952941|NCT02883023|Active Comparator|Intralesional bleomycin injections|One region of interest in the capillary malformation will be treated with intralesional bleomycin injections without electroporation
2952942|NCT02883023|No Intervention|No treatment|One region of interest in the capillary malformation (approximately 1.5x1.5cm)will not be treated.
2952943|NCT02883010|Experimental|PICO|Single use NPWT (PICO Softport V1.6)
2952944|NCT02883010|Other|Standard care|Gauze dressing, Film dressing, foam dressing, skin glue, no dressing
2952945|NCT02882997|Experimental|Duck Duck Punch|"Community dwelling stroke survivors: Stroke survivors will install an interactive computer game in their home. Subjects will be instructed to play the computer game as much as you want to every day for 7 days. Inpatient stroke patients: The interactive computer game will be installed at a local inpatient stroke rehabilitation hospital. Subjects will be instructed to play this game as much as you want to during non-therapy hours (evenings and weekends) over the next 7 days."
2952946|NCT02882997|Active Comparator|Standard activities|"Community dwelling stroke survivors: Subjects will receive a hard-copy handout of an arm home exercise program and given the instructions to do these exercises as many times as you can daily. Inpatient stroke patients: Subjects will be encouraged to participate in standard evening/weekend recreational activities and to remember to use the paretic arm as much as you can."
2952947|NCT02882984|Active Comparator|WBRT along with TKI|"Drug: EGFR-TKI~Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid~Other Name: Gefitinib/Tarceva/Icotinib~Radiation: whole brain radiotherapy~3750Gy/15F~Other Name: WBRT"
2952948|NCT02882984|Experimental|HFSRS with EGFR TKI|"Drug: EGFR-TKI~Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid~Other Name: Gefitinib/Tarceva/Icotinib~Radiation: whole brain radiotherapy~25 to 40 Gy/5F~Other Name: HFSRS"
2952949|NCT02882945||Group A|150 healthy blood donors without a family history of diabetes mellitus
2952950|NCT02882945||Group B|200 cases of type 2 DM without complications (group B), there were 62 males and 108 females, aged 29-53, with an average age of 42 ± 9 years
2952951|NCT02882945||Group C|120 cases of type 2 DM with macroangiopathy complication (group C), there were 70 males and 50 females, aged 40-53, with an average age of 47 ± 6 years. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD
2952952|NCT02882932|Other|Super Oxidized Solution|Procedure/Surgery: Super Oxidized Solution(SOS) in group I - SOS with normal saline solution was used
2952953|NCT02882932|Other|normal saline|"Procedure/Surgery: normal saline~In group II - patients underwent normal saline wash and bacterial load was noted."
2952954|NCT02882919|Experimental|Check Yourself v2.0|In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
2952955|NCT02882919|No Intervention|Usual care|In the usual care group, patients are asked to complete health risk screening on a computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors
2952956|NCT02882893|Experimental|DWP450|Single-dose
2952957|NCT02882893|Active Comparator|Botox|Single-dose
2952958|NCT02882880|Other|Started|Intervention: Treatment with the Luco Hybrid OSA Appliance (LHOA) Group 1, fitted with LHOA Group 2: LHOA removed for 48 hours
2952959|NCT02882880|Active Comparator|Completed|Intervention: The LUco Hybrid OSA APpliance The subjects that actually completed the study in both groups. Group 1 n = 32, in Group 2 n=19
2952960|NCT02882854|Experimental|Guanfacine|Guanfacine 1 mg capsule by mouth, one time prior to surgery.
2952961|NCT02882854|Placebo Comparator|Placebo|Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
2952962|NCT02882841|Other|Single-arm study|
2952963|NCT02882828|Experimental|DBS (dried blood spots) collection|In this study, we make a switch from Prograf® to Envarsus®. Patients will be trained to collect their blood from a finger prick on filter paper. DBS will be done at home, collected on filter paper and mailed by the patients to a centralized laboratory (Department of Pharmacology, Toxicology and Pharmacovigilance at Limoges University Hospital), where tacrolimus concentration will be determined by HPLC-MS/MS
2952964|NCT02882815|Other|IrisFIT PFO Occluder|Participating patients will have their PFO closed using the IrisFITTM PFO Occluder device.The patients will undergo a clinical examination, electrocardiogram (ECG), clinical laboratory assessment and transthoracic echocardiography (TTE). All periprocedural procedures will be performed according to site´s standard of care.. The efficacy and safety of the devices will be assessed by ECGs, vital signs, physical examination and TTE, which will be done at 1day, at 1month and at 6 months post procedure. Safety will also be assessed at 12 months by telephone visit.
2952965|NCT02882802|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format.
2952966|NCT02882802|Active Comparator|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions.
2952967|NCT02882789|Experimental|LCB01-0371 200mg|LCB01-0371 IV 200 mg
2952968|NCT02882789|Experimental|LCB01-0371 400mg|LCB01-0371 IV 400 mg
2952969|NCT02882789|Experimental|LCB01-0371 800mg|LCB01-0371 IV 800 mg
2952970|NCT02882776|Other|Ginger drink once daily|this group will receive ginger drink made by dissolving 4g ginger powder in plain water once a day for continuous 5 days.
2952971|NCT02882776|Other|Ginger drink twice daily|this group will receive ginger drink made by dissolving 4g ginger powder in plain water twice a day for continuous 5 days.
2952972|NCT02882763|Experimental|Parents As Teachers (PAT)|c.f. intervention
2952973|NCT02882763|No Intervention|control group condition|Families in the control group condition did not receive the home visiting program PAT, but were informed about support services in their community. The use of these services was permitted for ethical reasons; however, parents were regularly asked about the nature and intensity of the retrieved services. Additionally, all parents received incentives, such as greeting cards, small birthday presents, and monetary reimbursements.
2952974|NCT02882750||Surgical Patients|Early stage NSCLC patients submitted to Surgical Resection
2952975|NCT02882750||SABR Patients|Early stage NSCLC patients submitted to SABR
2952976|NCT02882737|Experimental|Exercise and glucagon before exercise|"120 minutes after breakfast; a single subcutaneous bolus of 200µg glucagon is administered by the primary investigator. However, the patient do, not know whether placebo or a glucagon injection is administered.~Exercise: Immediately thereafter, the patient will bicycle for 45 minutes at 50% of the heart rate HR reserve.~When exercise is ended a single subcutaneous bolus of 0.2 ml saline is administered and the exercise session will be suspended. Again, the patient do not know whether placebo or a glucagon is administered."
2952977|NCT02882737|Active Comparator|Exercise and glucagon after exercise|"120 minutes after breakfast; a single subcutaneous bolus of 0.2 ml saline is administered by the primary investigator. However, the patient do, not know whether placebo or a glucagon injection is administered.~Exercise: Immediately thereafter, the patient will bicycle for 45 minutes at 50% of the heart rate HR reserve.~Low-dose glucagon phase: When exercise is ended or when hypoglycemia occurs (≤3.9 mmol/l); a single subcutaneous bolus of 200μg glucagon is administered and the exercise session will be suspended. Again, the patient do not know whether placebo or a glucagon is administered."
2952978|NCT02882737|Active Comparator|Resting and glucagon after resting|"120 minutes after breakfast; a single subcutaneous bolus of 200μg placebo is administered.~Resting: After placebo injection the patient will be resting on a hospital bed for 45 minutes. The patient do not know if placebo or glucagon is administered.~Low-dose glucagon phase: After 45 minutes of resting or when hypoglycemia occurs, a single subcutaneous bolus of 200μg glucagon is administered.~Safety issues: If plasma glucose drops < 2.5 mmol/l at two consecutive measurements with 5 min interval or the patient experiences unbearable symptoms of hypoglycemia even after glucagon administration, 20 g carbohydrate is given orally. If plasma glucose drops< 2.3 mmol/l or doesn't raise sufficient after oral glucose, we will give intravenøs glucose to the patient. The study will then end and a new study day will be planned."
2952979|NCT02882724|Experimental|Exercise training|
2952980|NCT02882724|Experimental|Control|Control group did not do any exercise training.
2952981|NCT02882711|Experimental|ketamine|
2952982|NCT02882698|Experimental|Down Syndrome Group 1|Acquisition and retention phase on maze A, transfer on maze B and C.
2952983|NCT02882698|Experimental|Down Syndrome Group 2|Acquisition and retention phase on maze C, transfer on maze A and B.
2952984|NCT02882698|Active Comparator|Typical Development Group 1|Control group. Acquisition and retention phase on maze A, transfer on maze B and C.
2952985|NCT02882698|Active Comparator|Typical Development Group 2|Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
2952986|NCT02882685|Active Comparator|RYGB|Roux-en-Y gastric bypass
2952987|NCT02882685|Active Comparator|SAGB|Single anastomosis gastric bypass
2952988|NCT02882672|Experimental|Experimental|experimental group did 8 weeks exercise training
2952989|NCT02882672|Experimental|Control|Control group did not do any exercise training.
2952990|NCT02882659|Experimental|Dendritic Killer Cell (DKC)|All enrolled patients received one treatment cycle of DKC cell therapy, which consists of 5 infusion cycles approximately 23 days apart. There were 3 dose levels: 5 x 10^6, 1 x 10^7, and 5 x 10^7 cells, and the protocol followed a traditional 3+3 dose escalation design.
2952991|NCT02882646|Experimental|Stroke/CP survivors & healthy subjects|"Part A: Stroke and CP survivors greater than 18 years of age with hemiplegia and varying levels of impairment. The subject's stroke must have occurred at least 3 months prior to enrollment in the study. Healthy persons over the age of 18 with no upper limb impairment.~Part B: Low to mid functioning CP and stroke survivors greater than 18 years of age with hemiplegia. The subject's stroke must have occurred at least 3 months prior to enrollment in the study. All will be asked to use the Bi-ADLER system."
2952992|NCT02882633|Active Comparator|Lumbar Plexus Block|Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain
2952993|NCT02882633|Active Comparator|Fascia Iliac Block|Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain
2952994|NCT02882620|Experimental|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
2952995|NCT02882620|Experimental|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
2952996|NCT02882620|Experimental|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
2952997|NCT02882607|Experimental|Intervention group|Reproductive Health Peer Groups
2952998|NCT02882607|No Intervention|Control group|no intervention
2952999|NCT02882594||CIBA Study Cohort|Patients aged 1 to 13 years undergoing inhalation inductions for general anesthesia
2953000|NCT02882581|Experimental|11C-metformin|All participants allocated to the study will be included in this arm
2953001|NCT02882568|Other|investigational|Blood test for Inflammatory and immunological analysis during acute sepsis phase and one month later
2953002|NCT02882555|Experimental|Children|"12 concentrations of caspaicin are administered: - 0.6, 1.2, 2.4, 4.8, 9.8, 19.5, 39, 78.1, 156.2, 312.5, 625, 1250 μmol/l. Capsaicin concentration eliciting at least 2 coughs (C2) or 5 coughs (C5) is determined.~At least 1-hour-interval from capsaicin dose titration (in order to minimize tachyphylaxy)~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls (normal saline) in random order at baseline~At least 1-hour-interval (in order to minimize tachyphylaxy)~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls in random order during exercise, when heart rate is maximum"
2953003|NCT02882555|Active Comparator|Adults|"As reference for more precise assessment of effects of development.~12 concentrations of caspaicin are administered: 0.49, 0.98, 1.95, 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250, 500, 1000 μmol/l. Capsaicin concentration eliciting at least 2 coughs (C2) or 5 coughs (C5) is determined.~At least 1-hour-interval from capsaicin dose titration (in order to minimize tachyphylaxy)~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls (normal saline) in random order at baseline~At least 1-hour-interval (in order to minimize tachyphylaxy)~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls in random order during exercise, when heart rate is maximum"
2953004|NCT02882542|Experimental|Visible light exposure Orange 30 lux|The participants will be exposed to orange LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953005|NCT02882542|Experimental|Visible light exposure Orange 120 lux|The participants will be exposed to orange LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953006|NCT02882542|Experimental|Visible light exposure Cyan 30 lux|The participants will be exposed to cyan LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953007|NCT02882542|Experimental|Visible light exposure Cyan 120 lux|The participants will be exposed to Cyan LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953008|NCT02882542|Experimental|Visible light exposure White 30 lux|The participants will be exposed to white LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953009|NCT02882542|Experimental|Visible light exposure White 120 lux|The participants will be exposed to white LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953010|NCT02882529|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to green LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953011|NCT02882529|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to green LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953012|NCT02882529|Experimental|Visible light exposure Yellow 30 lux|The participants will be exposed to yellow LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953073|NCT02882204||Healthy Controls|Healthy controls who are not currently in treatment for any major mental illness defined using DSM-V criteria.
2953013|NCT02882529|Experimental|Visible light exposure Yellow 120 lux|The participants will be exposed to yellow LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953014|NCT02882529|Experimental|Visible light exposure Violet 30 lux|The participants will be exposed to violet LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953015|NCT02882529|Experimental|Visible light exposure Violet 120 lux|The participants will be exposed to violet LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953016|NCT02882516|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to red LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953017|NCT02882516|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to red LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953018|NCT02882516|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to blue LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953019|NCT02882516|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to blue LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953020|NCT02882516|No Intervention|darkness|The participants will not be exposed to any light but stay in darkness for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2953021|NCT02882503|Experimental|EUS-RFA|monopolar radiofrequency probe (1.2 mm Habib endoscopic ultrasound - radiofrequency ablation (EUS-RFA) catheter) and 19 or 22 gauge fine needle aspiration (FNA) needle
2953022|NCT02882490|Experimental|Parent training (PT)|The PT arm receives a 10-week therapist-guided behavioral group treatment. The treatment is based on existing literature for training parents in child behavior management skills (Barkley 1999). Parents attend weekly sessions, which last 90 minutes and are held at the Hospital Clinic of Barcelona. Parents are given homework assignments to complete between sessions.
2953023|NCT02882490|Experimental|Supportive Therapy (ST)|The ST arm receives a 10-week supportive group treatment. Parents are invited to discuss relevant problems that have occurred during the previous week. A therapist moderate the discussion but does not provide information about the behavioral techniques included in the PT group. Parents attend weekly sessions, which last 90 minutes and are held at the Hospital Clinic of Barcelona. Parents are given homework assignments to complete between sessions.
2953024|NCT02882477|Experimental|Deferiprone and Acetylcystein|PO Deferiprone 20 mg/kg divided in 2 doses PO Acetylcysteine 200 mg divided in 2 doses 5 months duration
2953025|NCT02882477|Experimental|Deferiprone and Acetylcystein with Sitagliptin and Metformin|PO Deferiprone 20 mg/kg divided in 2 doses PO Acetylcysteine 200mg divided in 2 doses PO Januet 50/500 if BW < 30kg and 50/850 if BW> 30kg *2/D 5 months duration
2953026|NCT02882464|Experimental|2PRF+CAF|"Two tubes of blood samples were centrifuged by PC-02 Centrifuged device. This centrifuged device is used with 2700 rpm and for 12 minutes( PC-02 Centrifuge, Process,France). PRF were prepared for patients in 2 layer platelet rich fibrin membrane with coronally advanced flap group (2PRF+CAF).~Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In 2PRF+CAF group: two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ and flpa is positioned coronally."
2953027|NCT02882464|Experimental|4PRF+CAF|Four tubes of blood samples were centrifuged by PC-02 Centrifuged device,four layers of PRF membranes were prepared for patients in 4 layer platelet rich fibrin membrane with coronally advanced flap.(4PRF+CAF). This centrifuged device is used with 2700 rpm and for 12 minutes( PC-02 Centrifuge, Process,France) Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In 4PRF+CAF group: four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ and flap is coronally positioned.
2953028|NCT02882464|Active Comparator|CTG+CAF|"The surgical technique in coronally advanced flap with subepithelial connective tissue graft (CTG+CAF) group was envelope technique as described by Raetzke. The papillae were dis epithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. The connective tissue graft was harvested from the palate using trap-door technique described by Edel. Epithelial layer was elevated with a horizontal and two vertical incisions. The connective tissue graft was harvested as 1 mm by using a standard caliper, then epithelial layer was sutured by resorbable suture. The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ."
2953029|NCT02882451|Experimental|pinaverium bromide|take 50 mg pinaverium bromide three times a day 1 days before and then 100 mg 1 hour before the examination orally
2953030|NCT02882451|Placebo Comparator|Vitamin C|take 50 mg Vitamin C three times a day 1 days before and then 100 mg 1 hour before the examination orally
2953031|NCT02882438|Active Comparator|Infected group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received Ginkgo Biloba in different dosage forms.
2953032|NCT02882438|Placebo Comparator|Control group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received placebo without Ginkgo Biloba.
2953033|NCT02882425|Experimental|Intravenous selexipag (Pilot phase)|Subjects received a 20-minute intravenous (i.v.) infusion of 50 µg selexipag
2953034|NCT02882425|Experimental|Sequence A-B (Main phase)|Subjects received a 80-minute i.v. infusion of 200 µg selexipag during Period 1, and 2 tablets of oral selexipag (total dose of 400 µg) as a single administration during Period 2. A washout period of 7 to 10 days separated the i.v. infusion from the oral administration.
2953035|NCT02882425|Experimental|Sequence B-A (Main phase)|Subjects received 2 tablets of oral selexipag (total dose of 400 µg) as a single administration during Period 1, and a 80-minute i.v. infusion of 200 µg selexipag during Period 2. A washout period of 7 to 10 days separated the oral administration from the i.v. infusion.
2953036|NCT02882412||patient group|
2953037|NCT02882399|Experimental|Shortystrap|
2953038|NCT02882386|Placebo Comparator|Milk 1%|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
2953039|NCT02882386|Experimental|Whey protein concentrate 80 (WPC-80)|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
2953040|NCT02882386|Experimental|Microparticulated whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
2953041|NCT02882386|Experimental|Hydrolyzed whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
2953042|NCT02882386|Experimental|Native whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
2953043|NCT02882373|Experimental|L-Arginine Group|Dose of L-Arginine given would be 200 mg/kg/day in 24 hours in four divided doses. Dose of L-Arginine escalated to 400 mg/kg/day in four divided doses after 2 weeks of start of therapy, if no response.
2953044|NCT02882373|Placebo Comparator|Placebo Group|Placebo given along with the standard of care treatment. Starting amount of placebo/liquid is an amount equivalent to the dose in group 1 in 4 divided doses. The amount of placebo/liquid doubled in four divided doses after 2 weeks of start of therapy, if no response.
2953045|NCT02882360|Experimental|Elective LSCS--Kerlix AMD|Kerlix-AMD applied to wound site pre-operatively (3 days) and post-operatively for 2 weeks
2953046|NCT02882360|Placebo Comparator|Elective LSCS--Placebo|Normal gauze applied to wound site pre-operatively for 3 days and post-operatively for 2 weeks
2953047|NCT02882360|Experimental|Labouring LSCS--Kerlix AMD|Kerlix-AMD applied to wound post-operatively for 2 weeks
2953048|NCT02882360|Placebo Comparator|Labouring LSCS--Placebo|Normal gauze applied to wound post-operatively for 2 weeks
2953049|NCT02882347|Experimental|somatostatin group|The investigators administrate somatostatin at a rate of 3.5ug/kg/hour to PHLF patients (prothrombin time < 50% and serum total bilirubin > 2.9mg/dl after liver resection) until recovery from liver failure.
2953050|NCT02882334|Experimental|Finger individuation training|Finger Force Manipulandum
2953051|NCT02882334|Active Comparator|control|conventional physiotherapy
2953052|NCT02882321|Experimental|IACS-010759|"Dose Escalation Phase: IACS-010759 administered orally daily on a 21-day schedule, with the exception that the first cycle for each subject contains a 7-day single dose lead-in. Treatment administered as an inpatient for 24 hours on day 1 and then starting on day 8 for the next 7 days for all enrolled subjects. Starting on day 8 of cycle 1, dosing is on a 21 day schedule until confirmed progressive disease (PD), initiation of alternative cancer therapy, unacceptable toxicity, or other reasons to discontinue.~Dose Expansion Phase: Subjects in the expansion phase treated at the RP2D level determined in the dose-escalation phase."
2953053|NCT02882321|Experimental|Food Effect on PK of IACS-010759|"As part of the expansion phase, the effect of a high fat meal on the PK of IACS-010759 (Food Effect) evaluated in a total of 6 subjects. After the first 6 subjects have been enrolled in the expansion cohort, the next 6 subjects enrolled in the Food Effect cohort.~Subjects in the expansion phase treated at the RP2D level determined in the dose-escalation phase."
2953054|NCT02882308|Experimental|Monotherapy with olaparib|Patients in the monotherapy arm will be treated with olaparib until the 21st -28th day depending on the day of surgery, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then have a second biopsy or be operated on the 23rd - 29th day. If surgery is delayed, olaparib will be continued until the day before surgery.
2953055|NCT02882308|Experimental|Combination of cisplatin and olaparib|Patients in the combination arm will receive treatment until the 5th day, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then will have a second biopsy or be operated on the 23rd - 29th day.
2953056|NCT02882308|No Intervention|No treatment arm|"Patients in the no treatment arm will wait to be operated or have a second biopsy on the 23rd - 29th day.Optionally, patients who have a baseline FDG-PET/CT scan may be re-examined on the 22nd -28th day by the same modality to assess metabolic response."
2953057|NCT02882295||writer's cramp|patients assessed without, then with Botulinum Neurotoxin injections
2953058|NCT02882295||control|age and gender matched
2953059|NCT02882282|Experimental|LOH Pembrolizumab Group|"Loss of Heterozygosity (LOH) positive group.~Pembrolizumab by vein on Day 1 of Cycles 1-4."
2953060|NCT02882282|No Intervention|LOH Observational Group|"Loss of Heterozygosity (LOH) positive group.~Participants only observed during course of study."
2953061|NCT02882269|Active Comparator|Postoperative chemotherapy|Patients receive 6 months of chemotherapy after surgery.
2953062|NCT02882269|Experimental|Neoadjuvant chemotherapy|Patients receive 3-4 cycles of chemotherapy before surgery. Preoperative and postoperative chemotherapy will be given for a total of 6 months.
2953063|NCT02882256|Experimental|Intervention|Patients will receive video discharge instructions in addition to standard written discharge instructions.
2953064|NCT02882256|No Intervention|Control|Patients will receive standard written discharge instructions.
2953065|NCT02882230||exposition to the drugs|patients treated with at least one of the following drugs: dolutegravir, elvitegravir and rilpivirine
2953066|NCT02882230||patients non exposed to the drugs|
2953067|NCT02882217|Active Comparator|XC8 10mg|Cohort 1: 8 subjects will be randomized in a 3:1 ratio to be treated either with 10mg XC8 (6 subjects) or placebo (2 subjects, see placebo arm)
2953068|NCT02882217|Active Comparator|XC8 50mg|Cohort 2: 8 subjects will be randomized in a 3:1 ratio to be treated either with 50mg XC8 (6 subjects) or placebo (2 subjects, see placebo arm)
2953069|NCT02882217|Active Comparator|XC8 200mg|Cohort 3: 16 subjects will be randomized in a 3:1 ratio to be treated either with 200mg XC8 (12 subjects) or placebo (4 subjects, see placebo arm)
2953070|NCT02882217|Placebo Comparator|Placebo|Placebo comparator arm consists of 2 subjects in the cohorts 1 and 2 each and 4 subjects in the cohort 3.
2953071|NCT02882204||First Episode Patients|First episode patients new to the PEPP program.
2953072|NCT02882204||Chronic Patients|Existing patients who have been enrolled in the PEPP program for >3 years
2953075|NCT02882165|Experimental|Intervention arm|Participants receive a comprehensive medical review by a Respiratory Clinical Fellow.
2953076|NCT02882165|No Intervention|Control arm|Participants receive usual care as required via their primary care practice.
2953077|NCT02882152|Experimental|femoral blockade|"femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve"
2953078|NCT02882152|Active Comparator|Morphine|intrathecal morphine
2953079|NCT02882139||Electrical storm|Documentation of 3 or more episodes of sustained ventricular arrhythmia within 24h or documentation of sustained ventricular tachycardia lasted at least 12h
2953080|NCT02882126|Experimental|Subcutaneous Treprostinil|Open-label access; The initial dose of Remodulin for this study will be the same as each subject's final dose in study CVT-CV-003. Dose modification will be based according to clinical response and tolerability.
2953081|NCT02882113|Experimental|Expressor|CYP3A5 expressor; containing CYP3A5*1 wild-type allele(*1/*1 type & *1/*3 type) intervention: Advagraf conversion
2953082|NCT02882113|Active Comparator|Non-expressor|CYP3A5 non-expressor: without CYP3A5*1 allele( *3/*3 type) intervention: Advagraf conversion
2953083|NCT02882100|Experimental|aTIV|NH facilities randomized to receive adjuvanted trivalent influenza vaccine (aTIV, FLUAD) for the residents
2953084|NCT02882100|Active Comparator|TIV|NH facilities randomized to receive standard trivalent influenza vaccine (TIV, Fluvirin) for the residents
2953085|NCT02882087|Experimental|Placebo Comparator|Placebo SC plus MTX. Patients received placebo SC weekly administered subcutaneously for 24 times.All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
2953086|NCT02882087|Experimental|Experimental: RC18 160 mg plus MTX|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times. All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.
2953087|NCT02882074|Other|Human albumin|Human albumin 5% during surgery.
2953088|NCT02882074|Other|Hydroxyethyl starch|Hydroxyethyl starch 6% (130/0.4) solution during surgery
2953089|NCT02882061|Experimental|CTDT positive|All subjects with a positive cervicothoracic differentiation test will be assigned to this arm. All subjects will then receive thoracic spinal manipulation to a level between T1 and T4.
2953090|NCT02882061|Active Comparator|CTDT negative|All subjects with a negative cervicothoracic differentiation test will be assigned to this arm. All subjects will then receive thoracic spinal manipulation to a level between T1 and T4.
2953091|NCT02882048|Experimental|Medication management & NADA Protocol|Standard of care medication management defined by opioid weaning protocol with specific, symptomatic medication regimens, and NADA protocol administered biweekly
2953092|NCT02882048|Active Comparator|Medication management|Standard of care medication management defined by opioid weaning protocol with specific, symptomatic medication regimens.
2953093|NCT02882035|Experimental|OFA (opioid free anesthesia)|"All drugs were given IV. Induction in the opioid free group began with a loading dose of clonidine (0.2 mcg kg-1), a bolus of ketamine (0.3 mg kg -1) lidocaine (1.5 mg kg -1) and a bolus of propofol (2-3 mg kg -1).~General anesthesia was maintained with sevoflurane (MAC: 1) (adapted according to hemodynamic stability).~Upon the incision, acetaminophen (1000 mg) and diclofenac (75 mg) were given in both groups. A bolus of ketamine (0.2mg kg -1) was given if necessary in the opioid free group (up to three bolus max. were permitted).~A bolus of piritramide (0.03 mg kg -1) was administered upon subcutaneous closure.~Postoperative pain was treated with IV acetaminophen (1000 mg) every 6 h for the first 24 hours and IV diclofenac (75 mg) every 12 h for the first 24 hours. Patients received a PCIA (patient-controlled intravenous analgesia) pump of piritramide."
2953094|NCT02882035|No Intervention|OA (opioid anesthesia)|"All drugs were given IV. Induction in the opioid group began with remifentanil TCI, a bolus of ketamine (0.3 mg kg -1) lidocaine (1.5 mg kg -1) and a bolus of propofol (2-3 mg kg -1).~General anesthesia was maintained with sevoflurane (MAC: 1). Upon the incision, acetaminophen (1000 mg) and diclofenac (75 mg) were given in both groups.~A bolus of piritramide (0.03 mg kg -1) was administered upon subcutaneous closure.~Postoperative pain was treated with IV acetaminophen (1000 mg) every 6 h for the first 24 hours and IV diclofenac (75 mg) every 12 h for the first 24 hours. Patients received a PCIA (patient-controlled intravenous analgesia) pump of piritramide."
2953095|NCT02882022|Experimental|CPAP|All participants will be included in this arm, and CPAP will be administered using a full face mask at incrementally increasing pressures. This will occur during a single session lasting no more than one hour.
2953096|NCT02882009|Experimental|Gantenerumab + Placebo|Participants will be randomized to receive gantenerumab HCLF and placebo solution via SC injection according to different sequences for the site of administration and different injection speeds.
2953097|NCT02881996|Experimental|IV tylenol|Post-operatively, all patients will be placed on a standard patient/nurse controlled analgesia (PCA) according to our pain service protocol which included ketorolac. A 3 hours after first dose of ketorolac, patients in the acetaminophen arm will then receive scheduled 10mg/kg of IV acetaminophen every 6hrs for a total of 3 days in between doses of ketorolac. PCA Pumps will be discontinued with the return of bowel function and transition to oral intake in all patients as per the current protocol. If a patient in the acetaminophen arm is transitioned off of PCA prior to 3 days, IV acetaminophen will be stopped at that time as well. Patients in the control group only may receive oral/rectal acetaminophen as needed for treatment of fevers.
2953098|NCT02881996|Active Comparator|No IV tylenol|Same as above without IV tylenol.
2953099|NCT02881983||STA group|Short-term alcohol abstinent patients (after 1 month of withdrawal)
2953100|NCT02881983||LTA group|Long-term alcohol abstinent patients (at least 6 months of abstinence)
2953101|NCT02881983||Control group|Healthy subjects
2953102|NCT02881970|Experimental|Neonatal hypoxic-ischaemic encephalopathy|
2953103|NCT02881957|Placebo Comparator|Control|Placebo control (simple oral syrup)
2953104|NCT02881957|Experimental|Vitamin D3|Cholecalciferol/Vitamin D3 (540,000 IU orally or by feeding tube once)
2953105|NCT02881944|Experimental|Low FODMAP (modified healthy) Diet|Low FODMAP diet for 3 weeks. Veterans will be provided a diet containing foods low in FODMAP.
2953198|NCT02881294|Active Comparator|Age Effect|SUVN-G3031 tablets single dose
2953106|NCT02881944|Experimental|High FODMAP (typical healthy) Diet|High FODMAP diet for 3 weeks. Veterans will be provided a typically healthy diet following US Dietary Guidelines, containing foods high in FODMAPs
2953107|NCT02881931||Pre-Manifest HDGEC Participant|
2953108|NCT02881931||Early-Manifest HDGEC Participant|
2953109|NCT02881931||Corresponding HDGEC participant Companion|
2953110|NCT02881918||squamous cell carcinoma|Patients affected by Head & Neck Squamous Cell Carcinoma. Blood sample at diagnosis, before any antitumor treatment
2953111|NCT02881905|Active Comparator|ball attachment|completely edentulous patients having single median mandibular implant to retain mandibular overdenture.the attachment used is the conventional ball attachment
2953112|NCT02881905|Experimental|CM LOC attachment|completely edentulous patients having single median mandibular implant to retain mandibular overdenture.the attachment used is the cm loc attachment
2953113|NCT02881879|Experimental|Allergovac depot with HDM extract|Extract of mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae (50:50) adsorbed onto aluminum hydroxide 0.33%.
2953114|NCT02881866|Active Comparator|Air Hunger|"Previous studies have shown that inhaled furosemide relieves 'air hunger'.~Each volunteer has 3 mists per visit. The mists are either in the order of Furosemide-Saline-Furosemide or Saline-Furosemide-Saline. The furosemide mist is 40mg (10mg/ml) nebulised and the saline mist is 4ml nebulised.~Induced air hunger (hypercapnia with constrained ventilation) is the active comparator and will be the type of breathlessness induced, before and after each mist inhalation on one day. ."
2953115|NCT02881866|Experimental|Work Effort|Induced sense of breathing effort (raised ventilation with external resistive load) is the 'experimental arm' and will be the type of breathlessness induced, before and after each mist inhalation on the other day. .
2953116|NCT02881853|Experimental|Part A1|XmAb7195 for IV infusion; dose level 1; 4 once-weekly doses
2953117|NCT02881853|Experimental|Part A2|XmAb7195 for SC injection; dose level 1; 4 once weekly doses
2953118|NCT02881853|Experimental|Part A3|XmAb7195 for SC injection; dose level 2; 4 once weekly doses
2953119|NCT02881853|Experimental|Part A4|XmAb7195 for SC injection; dose level 3; 4 once weekly doses
2953120|NCT02881853|Experimental|Part A5|XmAb7195 for SC injection; dose level 4; 4 once weekly doses
2953121|NCT02881853|Experimental|Part B6|XmAb7195 or placebo for SC injection; dose level 5; 4 once-weekly doses
2953122|NCT02881853|Experimental|Part B7|XmAb7195 or placebo for SC injection; dose level 6; 4 once-weekly doses
2953123|NCT02881853|Experimental|Part B8|XmAb7195 or placebo for SC injection; dose level 7; 4 once-weekly doses
2953124|NCT02881853|Experimental|Part B9|XmAb7195 or placebo for SC injection dose level 8; 4 once-weekly doses
2953125|NCT02881840|Experimental|14C-APD421|
2953126|NCT02881827|Active Comparator|Infrared Laser|Using a laser in the infrared wave spectrum (780 nm)
2953127|NCT02881827|Active Comparator|Red Laser|Using laser red wave spectrum (662 nm)
2953128|NCT02881827|Placebo Comparator|Placebo|Simulation of treatment with the device switched off
2953129|NCT02881827|Active Comparator|Control|"A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied~For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two ( statistically ) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug , which serves to prevent bias and isolating effects of such drugs."
2953130|NCT02881814|Experimental|Lung ultrasound and clinical decision|
2953131|NCT02881788||Traumatic Brain injury|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have sustained a traumatic brain injury. We are hoping to find patterns that may indicate a TBI in the data we collect.
2953132|NCT02881788||Non-Traumatic Brain injury|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have sustained a non-trauma related brain injury. We are hoping to find patterns that we may compare this data to subjects who have sustained a TBI as well as healthy controls.
2953133|NCT02881788||Control|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have not recently sustained any brain injury. We are hoping to find patterns that we may compare this data to subjects who have sustained a TBI as well as subjects who have had a non-trauma related brain injury.
2953134|NCT02881775|Experimental|rTMS and exercise|At lab visit, subjects receive repetitive transcranial magnetic stimulation (rTMS) at 10 Hz, 5 sec on, 55 sec off and quadriceps isometric exercise (5% MVIC) for 15 minutes. This is followed by a wash out period of 1 week. At the next lab visit, subjects receive sham rTMS and exercise using the same parameters.
2953135|NCT02881775|Sham Comparator|sham rTMS and exercise|"At lab visit, subjects receive sham repetitive transcranial magnetic stimulation (rTMS) at 10 Hz, 5 sec on, 55 sec off and quadriceps isometric exercise (5% MVIC) for 15 minutes. This is followed by a wash out period of 1 week. At the next lab visit, subjects receive the true rTMS and exercise using the same parameters."
2953136|NCT02881762|Active Comparator|Immediate start maraviroc|To start maraviroc immediately after randomization.
2953137|NCT02881762|Active Comparator|Delayed start maraviroc|To start maraviroc 8 weeks after enrollment.
2953138|NCT02881749|Experimental|TSEBT & mechlorethamine gel 0.016%|All subjects enrolled in the study will receive two weeks of low dose total skin electron beam therapy (TSEBT) (12 Gy total divided into 6 fractions delivered over two weeks) followed by a weekly maintenance mechlorethamine gel 0.016% regimen for one year. The initiation of the mechlorethamine gel regimen is dependent on their disease stage downgrading to IA and IB following low dose TSEBT.
2953139|NCT02881736|Experimental|Pateint with chronic stroke|
2953140|NCT02881736|Active Comparator|Healthy volunteer|
2953141|NCT02881723|Experimental|Treatment for oropharyngeal cancer by surgery|Disease-free patients treated for locally advanced oropharyngeal cancer for over 12 months by surgery
2953142|NCT02881723|Experimental|Treatment for oropharyngeal cancer by radio-chemotherapy|Disease-free patients treated for locally advanced oropharyngeal cancer for over 12 months by radio-chemotherapy
2953199|NCT02881281|Other|Education|Education program
2953143|NCT02881697||Obese insulin-resistant subjects|Adipose tissue sampling in obese volunteers (BMI > 35kg/m2) aged 18- max. 60 years, males and females; insulin-resistant, scheduled for elective bariatric surgery
2953144|NCT02881697||Lean insulin-sensitive controls|Adipose tissue sampling in normal weight patients (BMI < 27kg/m2) aged 18- max. 60 years, males and females; insulin-sensitive, scheduled for elective surgery
2953145|NCT02881684|Experimental|Treatment|"Intervention:~Device: Aspiration Therapy (AspireAssist)~- Subjects randomized to the treatment group will undergo an endoscopic procedure to have the experimental device (i.e. the A-tube) inserted. This will be followed by regular follow up visits and lifestyle therapy matched to the control group. The device will be removed at the end of one year and this group will be observed for one year more to determine if there is any legacy effect.~Behavioral: Lifestyle Therapy Lifestyle therapy is a behavioral, diet and physical activity education program Other Name: Lifestyle Behavioral Therapy"
2953146|NCT02881684|Active Comparator|Control|"Intervention:~(1) Behavioral: Lifestyle Therapy Lifestyle therapy is a behavioral, diet and physical activity education program Other Name: Lifestyle Behavioral Therapy~- Subjects randomized to the control group will receive lifestyle management matched to the treatment group in the first year. At the end of one year, they will be crossed over to treatment and the A-tube will be inserted. They will then follow up the same follow up schedule of the treatment group during the first year."
2953147|NCT02881671||Patients with congenital atrioventricular block|Patient with congenital atrioventricular block
2953148|NCT02881671||relatives with congenital atrioventricular block|Normal relatives of patients with congenital atrioventricular block
2953149|NCT02881671||Patients with progressive Cardiac Conduction Disease|Patients with progressive Cardiac Conduction Disease,
2953150|NCT02881671||relatives with progressive Cardiac Conduction disesae|Normal relatives of patients with progressive Cardiac Conduction Disease
2953151|NCT02881658|Experimental|Plant sterols-enriched soya beverage provided by Vitasoy|Daily consumption of 2g of plant sterols as provided by one pack of 250 ml of plant sterols-enriched soya beverage for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
2953152|NCT02881658|Placebo Comparator|Soya beverage provided by Vitasoy|Daily consumption of one pack of 250 ml of soya beverage (without plant sterols) for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
2953153|NCT02881645|Experimental|Best practices|Assessment of critical incidents linked to nursing with a best practices protocol
2953154|NCT02881645|No Intervention|Common practices|Assessment of critical incidents linked to nursing in common practices
2953155|NCT02881632||Healthy infants aged 0-2|Healthy infants aged 0-2 year with no respiratory diseases to provide a reference values. A structured light pattern (Structured Light Plethysmography (SLP) - Pneumscan) will be projected onto the chest and abdominal wall and the movement of this pattern as the patient breathes will be recorded for 2 min. The total period of testing per session should take approximately 30 minutes per person.
2953156|NCT02881632||Infants aged 0-1 with Bronchiolitis|Infants admitted to hospital within last 24hrs (AVB participants only). A structured light pattern (Structured Light Plethysmography (SLP) - Pneumscan) will be projected onto the chest and abdominal wall and the movement of this pattern as the patient breathes will be recorded for 2 min. The total period of testing per session should take approximately 30 minutes per person
2953157|NCT02881619|Placebo Comparator|Placebo|Placebo - (inert content)
2953158|NCT02881619|Experimental|Experimental -|400 mg of NAISE etodolac
2953159|NCT02881606|Active Comparator|Naso-alveolar molding (NAM)|Active plates and nasal stents (Grayson method)
2953160|NCT02881606|Active Comparator|Computer aided design NAM (CAD/NAM)|Computer aided design active plates and nasal stents
2953161|NCT02881567|Experimental|Daclizumab|
2953162|NCT02881554|Experimental|Diagnostic (SC SPECT/CT)|"There are 2 cohorts of patients: Those receiving radiation therapy per standard of care (Cohort A) and those undergoing surgery per standard of care (Cohort B). All patients have a total of 3 SPECT/CT imaging with 99mTc-SC. The first scan in both cohorts is routine medical care (not experimental) and takes place prior to initiation of RT or surgery. Two follow up scans are part of the protocol.~In cohort A, the first follow up scan occurs at mid-RT, and the second one at 1 month post-RT.~In cohort B, the first follow-up scan occurs 3-5 days postoperatively, and the second one at 1 month post-operatively. An additional IV contrast enhanced CT scan (70 second delay) will be obtained immediately following the SPECT/CT scan for all 3 SPECT/CT scans."
2953163|NCT02881541|Experimental|Patients having Enhanced Support|"A preoperative consultation with a nurse. This time will be dedicated to the preparation of returning home: explanation of the clinical pathway, realization of postoperative wound care, information on pain management and answer any questions the patient.~A nurse call on D + 1, the day after the operation to ensure the smooth running of returning home, assess postoperative pain, the correct performance of local care, answer questions from the patient, and provide advice to to limit pain .. A reminder to J2 / J3 will be produced at the request of the patient or on FDI initiative if particular difficulties are reported"
2953164|NCT02881541|Experimental|Patients having usual care|no intervention will be made for this group. Patients will receive usual care respecting intern procedure
2953165|NCT02881528|Experimental|Metformin Hydrochloride|"Metformin Hydrochloride Ph Eur oral solution (100mg/1ml) Starting Dose 10mg/Kg body weight once daily for 2 weeks, increasing to 10mg/Kg body weight twice daily if tolerated, increasing to target dose of 20mg/Kg body weight twice daily (max 1000mg twice daily) at Month 1 (4 weeks post randomization).~Down-titration to 10mg/kg twice daily if target dose not tolerated. Stage 1: Dosing for up to 15 months (option to extend to Stage 2: 36 months)"
2953166|NCT02881528|Placebo Comparator|Placebo|"Placebo (100mg/1ml) Starting Dose 10mg/Kg body weight once daily for 2 weeks, increasing to 10mg/Kg body weight twice daily if tolerated, increasing to target dose of 20mg/Kg body weight twice daily (max 1000mg twice daily) at Month 1 (4 weeks post randomization).~Down-titration to 10mg/kg twice daily if target dose not tolerated. Stage 1: Dosing for up to 15 months (option to extend to Stage 2: 36 months)"
2953167|NCT02881515|Experimental|Blood Pressure Reactivity|Blood Pressure Responses to a cold pressor test and acute exercise will be assessed. This will be performed while subjects are on a low sodium diet (1000 mg/daily), medium sodium diet (2300 mg/daily), and high sodium diet (7000 mg/daily).
2953200|NCT02881281|Other|Control Group|no intervention
2953201|NCT02881268||Patient with sepsis|Patient hospitalized in intensive care unit
2953168|NCT02881515|Experimental|Blood Pressure Variability|Twenty four hour blood pressure variability will be assessed. This will be performed while subjects are on a low sodium diet (1000 mg/daily), medium sodium diet (2300 mg/daily), and high sodium diet (7000 mg/daily).
2953169|NCT02881502||healthy control group|Mainly from students, family members of patients without chronic lung disease, healthy population, age 18-75 years old, the gender is not limited.
2953170|NCT02881502||mild and moderate asthma group|Patients diagnosed with asthma in the outpatient clinic, in accordance with the inclusion criteria and exclusion criteria.
2953171|NCT02881502||severe asthma group|Outpatient patients with severe asthma diagnosis, in accordance with the inclusion criteria and exclusion criteria.
2953172|NCT02881489|Experimental|Autologous BM-MSCs injection|Intervention: Biological: Cell-based therapy of autologous bone marrow-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects.
2953173|NCT02881476|Experimental|Allogeneic WJ-MSCs injection|Intervention: Biological: Cell-based therapy of allogeneic Wharton's jelly-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects.
2953174|NCT02881463|Experimental|Home Exercise Program|8- week therapeutical exercise program performing at home for women with knee joint osteoarthritis
2953175|NCT02881437|Experimental|IgHy10 (HyQvia)|"Open-label, one arm study conducted in France in subjects with PI to IgG trough level at steady state after standard SCIG dosing and after IgHy10 (HyQvia) administered every other week and every 3-4 weeks at equivalent dose. The study will have three periods:~The first period is a one-week ramp-up period. The first administration of IgHy10 (HyQvia) will be with a one-week dose~During the first three-month follow-up period, IgHy10 (HyQvia) will be administered, every other week at a dose equivalent to the dose administered with the previous treatment (standard SCIG).~At the end of this first follow-up period, the dose of IgHy10 (HyQvia) will be increased for the next infusion to reach a 3-4 week equivalent dose."
2953176|NCT02881424||alcohol-dependent patients|a group of 34 alcohol-dependent patients, currently abstinent
2953177|NCT02881424||healthy controls|a group of control subjects, without neurologic or psychiatric disease, matched for age and sex with the alcohol-dependent participants
2953178|NCT02881411|Active Comparator|Self-soft tissue therapy|Intervention group: Fibromyalgia coping skills programme plus self-soft tissue therapy (SSTT) SSTT consists of MTrP therapy on TrP sites in either the lower leg/foot or forearm/hand. MTrP therapy will be administered by the researcher for only two sessions which will include training to teach the participant how to do SSTT on themselves. All participants in the intervention group will also receive an advice booklet for SSTT.
2953179|NCT02881411|Active Comparator|Fibromyalgia coping skills programme|Control group:Fibromyalgia coping skills programme only. The FCSP is a non-pharmacological, multidisciplinary exercise and education group programme. Its main aims are to provide condition-specific, patient centred, self-management education and advice, in line with national drivers for long-term conditions and international FMS clinical guidelines.
2953180|NCT02881398|Experimental|mHealth|Each participant randomized to a mHealth assessment were evaluated with: (1) structural abnormalities with handheld-echocardiography (Vscan®, General Electric Healthcare); (2) vital signs with smartphone-connected oxymetry and blood pressure monitors (iHealthLabs®); (3) functional assessments on a 6-minute walk test with a trial-axial activity monitor (Ozeri®); (4) cardiac rhythm abnormalities with smartphone-connected- iECG (AliveCor®) and; (5)point-of-care testing with fingerstick B-type natriuretic peptide (Alere). All study participants then underwent a comprehensive transthoracic echocardiogram for anatomical assessments of the severity of rheumatic and structural heart disease prior to percutaneous valvuloplasty or a surgical valve replacement.
2953181|NCT02881398|Active Comparator|Standard-Care|Each participant randomized to a standard-assessment were evaluated with the resource available at the institution including a physical examination,12 lead-ECG, radiographic, laboratory testing as clinically required. All study participants underwent a comprehensive transthoracic echocardiogram for anatomical assessments of the severity of rheumatic and structural heart disease prior to percutaneous valvuloplasty or a surgical valve replacement.
2953182|NCT02881385||E5 Esense 10%|PSV mode using E5 ventilator with Esense 10%
2953183|NCT02881385||E5 Esense 30%|PSV mode using E5 ventilator with Esense 30%
2953184|NCT02881385||E5 Esense 50%|PSV mode using E5 ventilator with Esense 50%
2953185|NCT02881385||Servo-I Esense 10%|PSV mode using Servo-I ventilator with Esense 10%
2953186|NCT02881385||Servo-I Esense 30%|PSV mode using Servo-I ventilator with Esense 30%
2953187|NCT02881385||Servo-I Esense 50%|PSV mode using Servo-I ventilator with Esense 50%
2953188|NCT02881385||E5 Esense autocycle|PSV mode using E5 ventilator with Esense Auto cycle
2953189|NCT02881372|Experimental|Oral food desensitization|All of the children enrolled in the study will receive oral food desensitization with his or her specific EoE flare-inducing food antigen (e.g. cow's milk protein). The food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C) to stabilize and preserve the solution. This oral spray will need to be administered twice a day, every day for a total of 4 months.
2953190|NCT02881359||LifeSeal® Kit|creation of a coloanal or colorectal anastomosis
2953191|NCT02881346||Enstilar®|Patients with psoriasis vulgaris plaques on body and/or extremities will apply Enstilar® (calcipotriol /betamethasone dipropionate (50 micrograms/g + 0.5 mg/g) cutaneous foam) once daily for up to 4 weeks, according to the approved labelling of Enstilar® in Germany.
2953192|NCT02881320|Experimental|B/F/TAF|"Cohort 1 (12 to < 18 years of age ≥ 35 kg)~Part A: Participate in an Intensive PK evaluation at Week 2 or Week 4 and continue to receive B/F/TAF through Week 48.~Part B: Following confirmation of PK data from Cohort 1 Part A, participants will receive B/F/TAF through Week 48.~Cohort 2 (6 to < 12 years of age ≥ 25 kg)~Part A: Participate in an Intensive PK evaluation at Week 2 or Week 4 and continue to receive B/F/TAF through Week 48.~Part B: Following confirmation of PK data from Cohort 2 Part A, participants will receive B/F/TAF through Week 48."
2953193|NCT02881320|Experimental|Open-Label Extension|Following Week 48, participants in countries where B/F/TAF is not available may have the option to receive B/F/TAF FDC until it becomes available for use according to the participant's age and weight or the product becomes accessible to participants through an access program.
2953194|NCT02881307|Experimental|Dietary Supplement|
2953195|NCT02881307|Active Comparator|Dietary Counseling|
2953196|NCT02881294|Active Comparator|Food Effect|SUVN-G3031 tablets single dose
2953202|NCT02881268||Patient without sepsis|Patient hospitalized in intensive care unit
2953203|NCT02881255|Other|Subcutaneous ICD|Patient will receive a subcutaneous implantable cardioverter defibrillator (Boston Scientific EMBLEM)
2953204|NCT02881255|Other|Transvenous ICD|Patient will receive a single-chamber, transvenous implantable cardioverter defibrillator (from any manufacturer) which as the capability for remote monitoring.
2953205|NCT02881242|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
2953206|NCT02881229||Women in the Vulvar Specialty Clinic|Information will be collected from all patients presenting with vulvar complaints who have been seen by Dr. Schlosser in the Vulvar Mucosal Specialty Clinic at Northwestern Medical Group.
2953207|NCT02881216|Other|Common DES|Group of Patients with narrowed coronary artery disease, who were treated with an implantation of currently established drug-eluting stents (Xience Prime, Promus Element plus, Resolute Integrity).
2953208|NCT02881216|Other|Synergy Stent|Group of Patients with narrowed coronary artery disease, who were treated with Synergy stent implantation
2953209|NCT02881203|Experimental|Breathe Well + RPM|Participants will receive Breathe Well audiovisual feedback in addition to the RPM system
2953210|NCT02881203|Active Comparator|RPM|Varian's RPM system is the current standard of care at Royal North Shore Hospital where this trial is to be run.
2953211|NCT02881190|Experimental|RC48-ADC|The phase I component has several dose levels of RC48-ADC (0.1mg/kg，0.5 mg/kg, 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg, 3.0mg/kg, 3.5mg/kg and 4.0 mg/kg) and is designed as a traditional dose-escalation study.Dosing interval is once two weeks.
2953212|NCT02881177|Experimental|Oxytocin|Oxytocin 40 International Units (IU) intranasal administration prior to six Motivational Interveiwing Group Therapy (MIGT) sessions.
2953213|NCT02881177|Placebo Comparator|Placebo|Placebo 40 International Units (IU) intranasal administration prior to six Motivational Interveiwing Group Therapy (MIGT) sessions.
2953214|NCT02881164|Experimental|Low glycemic index breakfast|Low glycemic index breakfast (GI=45)
2953215|NCT02881164|Active Comparator|High glycemic index breakfast|High glycemic index breakfast (GI=80)
2953216|NCT02881151|Experimental|Treatment|Subjects will be treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that will be undertaken to assess for any possible therapeutic effect.
2953217|NCT02881138|Experimental|RC48-ADC|The phase I component has several dose levels of RC48-ADC (0.5 mg/kg, 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg, 3.0mg/kg, 3.5mg/kg, 4.0 mg/kg and 4.5 mg/kg) and is designed as a traditional dose-escalation study.Determine the recommended Phase II doses and regimens of RC48-ADC. Dosing interval is once two weeks.
2953218|NCT02881125|Experimental|Treatment (paclitaxel, nortriptyline hydrochloride)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive nortriptyline hydrochloride PO QD on days 1-7, BID on days 8-14, and TID on days 15-28 of course 1 and TID on days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2953219|NCT02881112|Experimental|Active Treatment Arm|Treatment with Provant Therapy System
2953220|NCT02881099||Recent diagnosis (P3)|Primary cohort; participants recruited if diagnosed within the last three years
2953221|NCT02881099||Early diagnosis (P50)|Participants recruited if diagnosed before the age of 50 years old
2953222|NCT02881099||Relatives (R)|Siblings of existing participants
2953223|NCT02881086|Other|Stratification I - Standard Risk (SR)/ High Risk (HR)|Induction and consolidation I therapy for standard and high risk patients, PH/BCR-ABL-negative Chemotherapy, immunotherapy, intrathecal prophylaxis, CNS irradiation according to randomisation I Drugs: Rituximab, Vincristine, Daunorubicin, Dexamethasone, Cyclophosphamide, Cytarabine, Mercaptopurine, PEG-Asparaginase, Methotrexate, Vindesine, VP16
2953224|NCT02881086|Other|Stratification I - Philadelphia (PH)+|Induction and consolidation I therapy for PH+ patients Chemotherapy, immunotherapy, intrathecal prophylaxis Drugs: Rituximab, Vincristine, Imatinib, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, VP16
2953225|NCT02881086|Active Comparator|Rand I - B-Lin + CNS Rad + i.th. MTX|Chemotherapy according to Stratification I SR/HR CNS prophylaxis: CNS irradiation 24 Gy, intrathecal Methotrexate
2953226|NCT02881086|Experimental|Rand I - B-Lin + i.th. MTX|Chemotherapy according to Stratification I SR/HR CNS prophylaxis: intrathecal Methotrexate
2953227|NCT02881086|Other|Stratification II - SR + MRD-neg|Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine, Dexamethasone
2953228|NCT02881086|Other|Stratification II - HR + MRD-neg|Chemotherapy or stem cell transplantation according to randomisation II
2953229|NCT02881086|Other|Stratification II - SR/HR/PH+ + MRD-pos|Chemotherapy or targeted therapy, followed by stem cell transplantation Drugs: Fludarabine, Idarubicin, Cytarabine, Nelarabine
2953230|NCT02881086|Active Comparator|Randomisation II - HR + MRD-neg-SCT|Stem cell transplantation
2953231|NCT02881086|Experimental|Randomisation II - HR + MRD-neg-SR-chemo|Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine
2953232|NCT02881073|No Intervention|Control|"Eligible women at participating centres prior to roll-out of PlGF testing (as per stepped wedge trial design) will be managed according to HSE/Institute of Obstetrician and Gynaecologists' National Guidelines for 'The management of hypertensive disorders during pregnancy' & The management of Pre-eclampsia or by NICE guidelines for Management of Hypertension in Pregnancy for those in Northern Ireland."
2953233|NCT02881073|Active Comparator|Maternal plasma PlGF quantification|"Women in the interventional arm will have an additional point of care test performed at the time of enrolment for immediate PlGF quantification. The PlGF measurement will be reported as the absolute value in pg/ml with the following ranges given:~PlGF <12 pg/ml: Very low~PlGF ≥12 and <100 pg/ml: Low~PlGF ≥100 pg/ml: Normal~All hospitals will follow National Guidelines for 'The management of hypertensive disorders during pregnancy' & The management of Pre-eclampsia with the additional integration of PlGF results as indicated in the algorithm."
2953234|NCT02881060|Active Comparator|Ethanol|Drinking a cocktail of ethanol (0.8 g ethanol per kg body weight), diet lemonade and water of 1:1:1 (volume distribution).
2953235|NCT02881060|Placebo Comparator|Non-ethanol|Drinking a cocktail of diet lemonade and water of 1:2 (volume distribution).
2953236|NCT02881034||Hepatitis C patients|Hepatitis C virus (HCV) infected patients with a previous non-response to pegylated-interferon/ribavirin therapy and re-treated with pegylated-interferon/ribavirin and telaprevir
2953237|NCT02881021|Experimental|Rehabilitation program and kinesiotaping.|"Each patient will attend 10 physiotherapy sessions over six. Patients from the Experimental group (KT group) will receive the same standardized rehabilitation program as control group (No-KT group) including manual therapy, movement training, stretching, muscular strengthening, and patient education.~Only KT-group (experimental) will receive therapeutic KT added to the rehabilitation program.~Kinesio® Tex Classic will be applied using a combination of techniques designed for RCTe and underlying symptoms following the instructions and principles described by Kase et al (2003).~Kinesiotaping strips will be weaned gradually, according to the individual improvements of deficits evaluated weekly by the physiotherapist treating."
2953238|NCT02881021|Active Comparator|Rehabilitation program.|"Each patient will attend 10 physiotherapy sessions over six. Patients allocated at the control group (No-KT group) will receive only the rehabilitation program, including manual therapy, movement training, stretching, muscular strengthening, and patient education.~The rehabilitation program will be exactly the same applied to the experimental group (KT group)."
2953239|NCT02881008|Experimental|Arm A|Myrcludex B 0.5 mg / day / sc / 12 weeks
2953240|NCT02881008|Experimental|Arm B|Myrcludex B 1 mg / day / sc / 12 weeks
2953241|NCT02881008|Experimental|Arm C|Myrcludex B 2 mg / day / sc / 12 weeks
2953242|NCT02881008|Active Comparator|Arm D|Entecavir 0.5 mg / day / orally / 24 weeks
2953243|NCT02881008|Experimental|Arm E|Myrcludex B 5 mg / day / sc / 12 weeks
2953244|NCT02881008|Experimental|Arm F|Myrcludex B 10 mg / day / sc / 24 weeks
2953245|NCT02880995|Experimental|patient group|"50 Drug-naïve patients with first episode psychosis (We anticipate the non-responder rate will be 30% of the patients)~Drug-naïve~Diagnosed as first episode psychosis~The total score of PANSS>70~No co-morbid psychiatric illness (including drug dependence/abuse)~They will also undergo PET scan at the baseline. And the investigators are going to determine treatment response after 6 weeks of treatment with amisulpride. Also they should complete clinical scales at 0, 2, 4, 6, and 8 week."
2953246|NCT02880995|Other|healthy control group|"12 healthy volunteers~No history of psychiatric disorder (including drug dependence/abuse)~No history of physical illness~No contra-indication to scanning~They will also undergo PET scan at the baseline"
2953247|NCT02880982|Active Comparator|Intervention|Softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3) to be taken orally once per week for 3 years
2953248|NCT02880982|Placebo Comparator|Placebo|Softgel capsule of identical taste and appearance to active comparator, but containing no cholecalciferol, to be taken orally once per week for 3 years
2953249|NCT02880969|Experimental|Patient with end stage renal disease undergoing dialysis|
2953250|NCT02880956|Experimental|Group 2|Dose 2 ABBV-8E12
2953251|NCT02880956|Experimental|Group 3|Dose 3 ABBV-8E12
2953252|NCT02880956|Experimental|Group 1|Dose 1 ABBV-8E12
2953253|NCT02880956|Placebo Comparator|Group 4|Placebo for ABBV-8E12
2953254|NCT02880943|Experimental|Group A|"Group A: patients with bone disease mainly will be treated with XOFIGO® alone.~Node and/or adrenal metastases and/or ≤5 lung metastases ≤1cm each are allowed in Group A."
2953255|NCT02880943|Experimental|Group B|Group B: patients already treated with an ongoing approved Tyrosine Kinase Inhibitor (TKI) for their visceral metastases will be treated with XOFIGO® for bone disease.
2953256|NCT02880930|Experimental|Vitamin D supplement (Cholecalciferol)|Participants will be given oral Fultium-D3 drops (Internis) contain 400 IU cholecalciferol/day for a period of 3 months. Daily vitamin D3 supplementation dose will be increased to 1,000 IU for an additional 3 months if plasma 25(OH)D still below 75 nmol/L.
2953257|NCT02880917|Active Comparator|Cognitive training + tDCs-Active|tDCs active left dorsolateral prefrontal cortex (2mA,20 min) and Cognitive training (20min) at the same time.
2953258|NCT02880917|Sham Comparator|Cognitive training+ tDCs-Sham|tDCs Sham dorsolateral prefrontal cortex ((2mA,20 min) and Cognitive training (20min) at the same time.
2953259|NCT02880891|Experimental|splinted|splinted crown
2953260|NCT02880891|No Intervention|non-splinted|single crown
2953261|NCT02880878|Experimental|Early Surgical Hematoma Evacuation|Subjects will receive early surgical hematoma evacuation using Minimally Invasive Parafascicular Surgery (MIPS).
2953262|NCT02880878|No Intervention|Medical Management|Subjects will receive standard of care medical management for ICH.
2953263|NCT02880865|Experimental|Group 1 - MMR and CD-JEV|Participants receiving one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0; Group 1 will also receive a second dose of MMR per the routine immunization schedule at D84 (12 months of age).
2953264|NCT02880865|Experimental|Group 2 - MMR then CD-JEV|Participants receiving one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Group 2 will receive a second dose of MMR per the routine immunization schedule at D84 (12 months of age).
2953265|NCT02880852|Experimental|Belimumab 10 mg/kg|In this open label study, a single dose of 10 mg/kg Belimumab will be administered intravenously in Chinese subjects with systemic lupus erythematosus.
2953266|NCT02880839|Experimental|Partial cervical lamina excision group|Patients in the cervical lamina partial excision group underwent partial cervical lamina excision and cervical pedicle screw internal fixation.
2953267|NCT02880839|Experimental|Pipeline-dredge discharge group|Patients in the pipeline-dredge discharge group underwent pipeline-dredge discharge and cervical pedicle screw internal fixation.
2953268|NCT02880839|Experimental|Digital navigation group|Patients in the digital navigation group underwent digital navigation-assisted cervical pedicle placement.
2953269|NCT02880813|Experimental|Gastric|gastric infusion
2953270|NCT02880813|Experimental|Duodenal|Duodenal infusion
2953271|NCT02880800|Experimental|Analgesia, patient controlled|Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of either morphine or hydromorphone.
2953272|NCT02880800|Active Comparator|Analgesia, as per needed|Patients will receive intravenous (IV) opioids as per needed.
2953273|NCT02880787|Other|Adult population 1|TOF-Watch SX® on nondominant arm and TOFScan® on dominant arm
2953274|NCT02880787|Other|Adult population 2|TOF-Watch SX® on dominant arm and TOFScan® on nondominant arm
2953275|NCT02880787|Other|Pediatric population 1|TOF-Watch SX® on nondominant arm and TOFScan® on dominant arm
2953276|NCT02880787|Other|Pediatric population 2|TOF-Watch SX® on dominant arm and TOFScan® on nondominant arm
2953277|NCT02880774|Experimental|Mandibular Nonspecific mobilization|GA: Mandibular Nonspecific mobilization on the region of the face with presence of TMD.
2953278|NCT02880774|Placebo Comparator|ultrasound detuned|Group B: Used ultrasound equipment detuned on the region of the face with presence of TMD.
2953279|NCT02880761|Experimental|Intervention|Patients with AVF will be followed up by a preset following-up system. Interventions would be administered according to the assessment for AVF, which including the surgery and puncture of AVF. For AVF surgery, a certain vein would be used in the operation according to the assessment results. For AVF puncture, the methods, such as 'button hole', 'rope ladder', dwelling needle, would be selected prospectively according to the assessment results.
2953280|NCT02880761|No Intervention|Control|Patients in other hemodialysis centers who are treated by routine protocal would be enrolled into control group. Their clinical data would be collected and compared with intervention group.
2953281|NCT02880748|Experimental|Water exchange (WE) method|Water exchange (WE) method was used for insertion to the cecum.
2953282|NCT02880748|Active Comparator|Air insufflation (AI) method|Air insufflation (AI) method was used for insertion to the cecum.
2953283|NCT02880735|Experimental|Non Invasive Ventilation.|"It will provide noninvasive mechanical ventilation with the following specifications:~Bilevel devices: Pressurized bilevel mode Spontaneous/Time. Interface: Facial mask Usage: During sleep Frequency: Daily Duration: Three months."
2953284|NCT02880722||IBS patients|IBS according to Rome IV criteria.
2953285|NCT02880722||Healthy control group|Healthy volunteers without abdominal complaints fulfilling Rome IV criteria for IBS.
2953286|NCT02880709|Experimental|Special diet|Special diet with taste, energy-and protein content adjusted according to previous finding
2953287|NCT02880709|No Intervention|Usual diet|Patients habitual diet
2953288|NCT02880696|Experimental|Test (Regular)|Regular stimulation sequence & DCS
2953289|NCT02880696|Active Comparator|Control (Random)|Random stimulation sequence & DCS
2953290|NCT02880683|Experimental|Single arm, transvenous cardiac autonomic nerve stimulation|
2953291|NCT02880670|Experimental|Single dose of radiolabeled BMS-986142|
2953292|NCT02880657|Experimental|SODB®-physical training|This arm receives daily two capsules of SODB® 40mg containing 560 UI of superoxide dismutase, associated with standardized physical training
2953293|NCT02880657|Experimental|Placebo-physical training|This arm receives daily two capsules of Placebo containing excipients only, associated with standardized physical training
2953294|NCT02880605||appropriate in appropriate indications|
2953295|NCT02880605||inappropriate in appropriate indications|
2953296|NCT02880605||appropriate in inappropriate indications|
2953297|NCT02880605||inappropriate in inappropriate indications|
2953298|NCT02880592|Experimental|Fresh amniotic membrane/standard of care|This group will receive the Affinity Allograft and standard of care.
2953299|NCT02880592|Active Comparator|Standard of Care|This group will receive standard of care for diabetic foot ulcers that includes offloading of the diabetic foot ulcer, debridement, and infection management using the appropriate dressings.
2953300|NCT02880566|Experimental|Treatment|Full scalp block performed with a total of 30 ml of levobupivacaine 0.33 %.
2953301|NCT02880566|Placebo Comparator|Control|Full scalp block performed with a total of 30 ml of normal saline.
2953302|NCT02880540|Active Comparator|Control Group|Fentanyl 50 micrograms IV every 15 minutes up to 3 doses in postanesthesia recovery room and Morphine 2mg IV every 2 hours for 2days on hospital floor
2953303|NCT02880540|Experimental|Dexmedetomidine Treated|Dexmedetomidine IV bolus 1.5microgram/kilogram and a continuous infusion starting at 0.1 microgram/kilogram/hour during surgery
2953304|NCT02880527||patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis will be used:~medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;~general practitioners~the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )~5) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
2953305|NCT02880514|Other|Propel Mini Sinus Implant|Placement of Propel Mini Sinus Implant after a successful in-office balloon dilation of the frontal sinus
2953306|NCT02880514|Active Comparator|In-Office Sinus Dilation|Successful in-office bilateral balloon dilation of the frontal sinus ostia (FSO) only without implant placement
2953307|NCT02880501|Experimental|proximal femoral nail antirotation|Twenty patients with intertrochanteric femoral fracture scheduled will undergo proximal femoral nail antirotation (PFNA) implantation.
2953308|NCT02880475|Experimental|OXN prolonged release tablet|The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/25mg, 20/10 mg for one time.
2953309|NCT02880462|Active Comparator|high dose sulforaphane|The goal of the study is to investigate whether adding high doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia.
2953310|NCT02880462|Active Comparator|low dose sulforaphane|The goal of the study is to investigate whether adding low doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia.
2953311|NCT02880462|Placebo Comparator|placebo|The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
2953312|NCT02880449|Experimental|Intervention|The intervention will be conducted in pre-existing older women's groups based in community centres. The intervention will consist of three educational sessions, encouragement to enlist the support of a partner or 'buddy' (e.g. a spouse, partner or friend), an information pack (containing information on the local area, walking routes, points of interest) and the option of weekly telephone contact. Participants will be given the opportunity to discuss their progress and share feedback with the rest of the group at weekly meetings.
2953313|NCT02880449|No Intervention|Control|Due to the stepped wedge design of the study, one group in each centre will not receive the intervention procedure detailed above until week seven. The control groups shall be given information about the study at baseline and informed that they will receive the intervention 6 weeks later.
2953314|NCT02880423|Other|salpingectomy group I|salpingectomy during cesarean section for sterilization
2953315|NCT02880423|Active Comparator|tubal ligation group II|tubal ligation in cesarean section
2953316|NCT02880410|Experimental|LITT Treatment w/radiation therapy and temozolomide|This is a single arm study. All eligible study subjects will undergo LITT with the NeuroBlate System in combination with radiation therapy and temozolomide
2953317|NCT02880397|Active Comparator|Garcinia Mangostana|The constituents of mangostana containing gel were prepared under the following proportions: Mangostana powder - 4gm, Gelatin - 12gm, Glycerin (wetting agent) - 0.2ml, Peppermint oil (flavouring agent) - 0.1ml, sodium saccharine (sweetening agent) - 0.1ml and purified water q.s 100ml.
2953318|NCT02880397|Placebo Comparator|Placebo gel|The placebo gel was prepared with Gelatin - 12gm, Glycerin (wetting agent) - 0.2ml, Peppermint oil (flavouring agent) - 0.1ml, sodium saccharine (sweetening agent) - 0.1ml and purified water q.s 100ml excluding the active ingredient mangostana powder - 4 mg and maintaining same physical properties such as color and taste.
2953319|NCT02880384|Experimental|FilmArray LRTI v.2.0 IUO Panel|Patients will provide sputum or sputum equivalent for FilmArray LRTI v.2.0 IUO Panel testing.
2953320|NCT02880371|Experimental|Phase 1b/Part A|Patients in Part A will receive escalating doses of single-agent ARRY-382 in combination with 2 mg/kg pembrolizumab.
2953321|NCT02880371|Experimental|Phase 2|Patients in Phase 2 will receive the MTD/RP2D dose of ARRY-382 determined during Part A in combination with 200mg pembrolizumab.
2953322|NCT02880345|Active Comparator|Cohort 1 - 8 Gy x 3 fractions|8 Gy x 3 fractions
2953323|NCT02880345|Active Comparator|Cohort 2 - 17 Gy x 1 fractions|17 Gy x 1 fraction
2953324|NCT02880332|Active Comparator|Usual care + Extra care|This group will receive usual care and one additional session; extra care.
2953325|NCT02880332|Experimental|Usual care + PNE|Next to usual care, this group will also receive pain neuroscience education.
2953326|NCT02880319|Experimental|Oligometastatic Disease|"Stereotactic Body Radiation Therapy (SBRT)to up to 3 sites of disease occurring in the bone or spine~Treatments will be delivered on a dedicated stereotactic linear accelerator that includes onboard conebeamCT imaging and orthogonal 2D/3D matching with robotic couch top.~Dosage will be determined by physician"
2953327|NCT02880319|Experimental|Metastatic Disease|"Stereotactic Body Radiation Therapy (SBRT) to site(s) of disease occurring in the bone or spine~Treatments will be delivered on a dedicated stereotactic linear accelerator that includes onboard conebeamCT imaging and orthogonal 2D/3D matching with robotic couch top.~Dosage will be determined by physician"
2953328|NCT02880306||RA cohort|RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria.
2953329|NCT02880306||Non-RA cohort|Participants who were ≥18 years of age, without a RA diagnosis
2953330|NCT02880293|Experimental|Patients will undergo donor/recipient bone marrow|All patients will undergo haploidentical, allogeneic hematopoietic cell transplantation. Conditioning will consist of fludarabine, melphalan, and thiotepa. Graft versus host disease prophylaxis will be with post-transplant cyclophosphamide in addition to standard tacrolimus and mycophenolate mofetil. Donors will undergo HLA and KIR geno- and allotyping to determine the best donor.
2953331|NCT02880280|Experimental|Human Menopausal Gonadotropin|Human menopausal gonadotropin contains follicle-stimulating hormone (FSH) and luteinizing hormone (LH)
2953332|NCT02880280|Experimental|Human Chorionic Gonadotropin|Human chorionic gonadotropin (hCG) is a hormone produced by the embryo after implantation
2953333|NCT02880254|Active Comparator|Kurbo only|use of app plus standard of care
2953334|NCT02880254|Active Comparator|Kurbo plus PHC|use of app, personal health coach and standard of care
2953335|NCT02880241|Experimental|Cohort 1A - P. vivax malaria|A single oral dose of up to 120mg MMV390048
2953336|NCT02880241|Experimental|Cohort 1B - P. falciparum malaria|A single oral dose of up to 120mg MMV390048
2953337|NCT02880241|Experimental|Cohort 2A - P. vivax malaria|A single oral dose (to be determined) of MMV390048
2953338|NCT02880241|Experimental|Cohort 2B - P. falciparum malaria|A single oral dose (to be determined) of MMV390048
2953339|NCT02880241|Experimental|Cohort 3A - P. vivax malaria|A single oral dose (to be determined) of MMV390048
2953340|NCT02880241|Experimental|Cohort 3B - P. falciparum malaria|A single oral dose (to be determined) of MMV390048
2953341|NCT02880228|Experimental|Treatment (lenalidomide, dexamethasone, pembrolizumab)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO daily on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of course 1, day 15 of course 2, and day 8 of course 3. Courses 1-3 repeat beyond 3 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo stem cell transplantation after 4 courses of treatment.
2953342|NCT02880215|Experimental|Attention Bias Modification|Behavioral intervention designed to improved negative attention bias.
2953343|NCT02880215|Experimental|Cognitive Control Training|Behavioral intervention designed to improve sustained attention.
2953344|NCT02880215|No Intervention|Assessment Only|Assessment only with no active intervention.
2953345|NCT02880202|Other|Massage Therapy|Massage therapy for hospice patients.
2953346|NCT02880189|Other|Single|All subjects will be receiving the ORBERA Intragastric Balloon and will be undergoing Endoscopic Ultrasound guided core liver biopsy.
2953347|NCT02880176|Experimental|Financial Incentive|"Financial Incentive to Increase Ambulation: A financial reward is given on a per day basis when subject meets daily step goal, 1/5 chance to win additional monetary prize if patient uploads step count data for at least 75% of study days.~Subjects will use Fitbit Zip to track step counts"
2953348|NCT02880176|No Intervention|Control (Education)|Subjects in this group will receive standard education on the benefits of post-surgery ambulation only Subjects will use Fitbit Zips to track step counts
2953349|NCT02880150|Other|Elite climbers|Elite climbers selected in a national group for their previous performances at high altitude
2953551|NCT02878525|Experimental|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
2953350|NCT02880150|Other|Sea level sportsmen|Control group with similar anthropometric, age, gender and maximal normoxic oxygen consumption that the elite climber group
2953351|NCT02880137|Experimental|RTMPE|RTMPE with Perflutren Lipid Microsphere (DEFINITY) is a safe and feasible non-invasive technique commonly used to diagnose coronary disease, and offers an attractive alternative for CAV detection.
2953352|NCT02880124|Experimental|Maple syrup|A maple syrup solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
2953353|NCT02880124|Experimental|Maple sap|A maple sap solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
2953354|NCT02880124|Active Comparator|Corn syrup|A corn syrup solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
2953355|NCT02880124|Active Comparator|Glucose|A glucose solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
2953356|NCT02880124|Active Comparator|Sport drink|A Gatorade (TM) solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
2953357|NCT02880124|Placebo Comparator|Trace|A solution containing stevia (sugar substitute) and trace amounts of glucose (3g) labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
2953358|NCT02880124|Placebo Comparator|Water|A solution containing stevia (sugar substitute) will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
2953359|NCT02880111||group 1|CF patients with Pseudomonas aeruginosa chronic colonization.
2953360|NCT02880111||group 2|CF patients without a Pseudomonas aeruginosa chronic colonization.
2953361|NCT02880072|Experimental|refeeding syndrome|6 patients with head and neck cancer and refeeding syndrome, 4 different of preparations of phosphate orally
2953362|NCT02880072|Experimental|no refeeding syndrome|6 patients with head and neck cancer without refeeding syndrome, 4 different of preparations of phosphate orally
2953363|NCT02880046||Melanoma (LyteloMel)|
2953364|NCT02880046||Lung cancer (TeloCap)|
2953365|NCT02880046||Renal carcinoma (EMIR)|
2953366|NCT02880033|Active Comparator|Parkinson's disease|ex vivo analysis of lymphocytes from 30 patients with Parkinson's disease with deferiprone and placebo treatment
2953367|NCT02880033|Active Comparator|Amyotrophic lateral sclerosis|ex vivo analysis of lymphocytes from 30 patients with Amyotrophic lateral sclerosis with deferiprone and placebo treatment
2953368|NCT02880033|Placebo Comparator|healthy age and sex matched controls|ex vivo analysis of lymphocytes from 30 healthy age and sex matched controls with deferiprone and placebo treatment
2953369|NCT02880020|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2953370|NCT02880020|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 30 minutes every 6 weeks. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2953371|NCT02880007|Experimental|ARM A|Dose Optimization in 3D Pulsed Dose Rate Brachytherapy
2953372|NCT02879994|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 35 courses in the absence of disease progression or unacceptable toxicity.
2953373|NCT02879981||Pediatric Participants With Acute Bronchitis|Pediatric participants receiving treatment for acute bronchitis with Balsamic Bactrim according to standard of care and in line with the current summary of product characteristics (SPC) / local labeling and who have no contraindication to Balsamic Bactrim as per the local label will be observed for safety.
2953374|NCT02879968||Head and Neck squamous cell carcinoma|"A single measurement of serum squamous cell carcinoma antigen level is performed in the eligible Head and Neck squamous cell carcinoma patients.~The study tool measuring serum squamous cell carcinoma antigen level is ARCHITECT SCC (Abbott).~The gross tumor volume in the cross sectional imaging obtained within 2 weeks of each patient is calculated with the typical ellipsoid formula."
2953375|NCT02879955|Experimental|10 gastric bypass operated patients|4 different carbohydrate loads ingested at separate study days will be tested against each others ability to induce GLP-1 secretion.
2953376|NCT02879955|Experimental|10 healthy control subjects|4 different carbohydrate loads ingested at separate study days will be tested against each others ability to induce GLP-1 secretion.
2953377|NCT02879942||Case cohort|Patients with pregnancies complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.
2953378|NCT02879942||Control cohort|Patients with pregnancies not complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.
2953379|NCT02879916|Placebo Comparator|Placebo|NaCl 0.9% 3ml perineural stellate ganglion injection
2953380|NCT02879916|Active Comparator|Stellate ganglion block|Levobupivacaine 3ml perineural stellate ganglion injection
2953381|NCT02879903|Experimental|biofilm tobacco effect|Group smokers - patients will receive periodontal treatment and biofilm will be collected.
2953382|NCT02879903|Experimental|biofilm non smoker effect|Group Non Smokers - patients will receive periodontal treatment and biofilm will be collected.
2953383|NCT02879877|Experimental|UCB7858 (intravenous)|Various single doses, administered to various cohorts.
2953384|NCT02879877|Placebo Comparator|Placebo (intravenous)|Single dose placebo comparator for each cohort of iv administration.
2953385|NCT02879877|Experimental|UCB7858 (subcutaneous)|Various single doses, administered to various cohorts.
2953386|NCT02879877|Placebo Comparator|Placebo (subcutaneous)|Single dose placebo comparator for each cohort of sc administration.
2953387|NCT02879864|Experimental|Light therapy|Light therapy takes place in the patient's home the day following receipt of the equipment and for at least 7 days before the start of chemotherapy and according to current recommendations: daily exposure to a high intensity light (10,000 lux) in the morning at a time to be adapted to the patient according to his chronotype), for 30 minutes. Light therapy begins immediately after receipt of the luminometer. The total duration of daily outpatient therapy program is 6 months. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at the inclusion visit and at weeks 12 and 24. They will complete the same day or the day before, and / or before any chemotherapy. A follow-up visit will be performed 1 month after the end of therapy (week 28).
2953388|NCT02879864|Active Comparator|usual care|usual care in oncology: The patient will be taken care of according to local chemotherapy in routine care and the recommendations. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24. They will complete the same day or the day before, and / or chemotherapy before . A follow-up visit will be performed 1 month after the last visit (week 28). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before
2953389|NCT02879838||Occupational Asthma|
2953390|NCT02879838||Work Aggravated Asthma|
2953391|NCT02879838||Non-Work-Related Asthma|
2953392|NCT02879825|Experimental|Group A|Mitral valve prolapse without mitral regurgitation
2953393|NCT02879825|Experimental|Group B|Mitral valve prolapse with trivial mitral regurgitation
2953394|NCT02879825|Experimental|Group C|Mitral valve prolapse with moderate or mild mitral regurgitation and asymptomatic
2953395|NCT02879825|Experimental|Group D|Mitral valve prolapse with severe mitral regurgitation or symptomatic
2953396|NCT02879812|Experimental|Multi-Component Intervention|End Stage Renal Disease (ESRD) facilities will receive feedback reports containing facility specific data, an educational webinar for dialysis facility medical directors and staff, and an educational video for patients and staff.
2953397|NCT02879812|Active Comparator|Standard Care + Pamphlet|End Stage Renal Disease (ESRD) facilities will conduct usual care and receive United Network for Organ Sharing (UNOS) educational pamphlets for staff.
2953398|NCT02879799|Experimental|Implement Family Integrated Care|Dynamic education and support intervention for families of preterm infants.
2953399|NCT02879799|No Intervention|Monitor Standard Practices|Standard nursing care of preterm infants and their families.
2953400|NCT02879786|Experimental|Phonological dyslexia|Children with phonological dyslexia
2953401|NCT02879786|Experimental|Visuo-attentional dyslexia|Children with visuo-attentional dyslexia
2953402|NCT02879786|Other|Control|Control children, age-matched
2953403|NCT02879773||Lung cancer|Patients undergoing thoracic surgery for suspected or confirmed lung cancer; including wedge resection, segmentectomy, lobectomy, bilobectomy or pneumonectomy. CTPVe will be modelled to predict postoperative lung function.
2953404|NCT02879773||Emphysema|Patients undergoing assessment of emphysema/chronic obstructive pulmonary disease (COPD) for potential surgical intervention; including lung volume reduction surgery, endobronchial valve insertion or endobronchial coil insertion. CTPVe will be modelled to predict postoperative lung function.
2953405|NCT02879773||Interstitial lung disease|Patients undergoing assessment or treatment of suspected or confirmed interstitial lung disease. CTPVe will be modelled to aid diagnosis of the subtype of interstitial lung disease confirmed by histological diagnosis.
2953406|NCT02879760|Experimental|Ad/MAGEA3, MG1-MAGEA3 and pembrolizumab|"Ad-MAGEA3 prime will be administered as a single IM dose on Day 1 at 2 x 10e11 VP.~MG1/MAGEA3 boost will be administered IV on Day 15 and Day 18 by 5 cohorts: Cohort 1: Days 15 & 18 at 1x 10e10 pfu.~Cohort 2: Days 15 & 18 at 1x 10e11 pfu. Cohort 3: Day 15 at 1 x 10e11 pfu; Day 18 at 3 x 10e11 pfu. Cohort 4: Day 15 at 1 x 10e11 pfu; Day 18 at 3 x 10e11 pfu. Cohort 5: Day 15 at 3x 10e11 pfu; Day 18 at 3 x 10e12 pfu. Pembrolizumab will be administered IV every 3 weeks starting on Day 22."
2953407|NCT02879747|Active Comparator|Interventional|Unchanged dose Genotropin
2953408|NCT02879747|Active Comparator|Interventional 2|reduced dose 50% Genotropin
2953409|NCT02879734|No Intervention|Without Omentopexy|Patients that did not undergo prophylactic omentopexy during laparoscopic insertion of peritoneal dialysis catheter
2953410|NCT02879734|Experimental|With Omentopexy|Patients that underwent prophylactic omentopexy during laparoscopic insertion of peritoneal dialysis catheter. Intervention = Prophylactic laparoscopic omentopexy
2953411|NCT02879721|No Intervention|no drug|No drug and no intervention
2953412|NCT02879721|Active Comparator|AT1R-antagonist|Angiotensin II, type 1 receptor inhibitor, (candesartan) 8 mg once daily
2953413|NCT02879721|Active Comparator|ACE-inhibitor|Angiotensin converting enzyme inhibitor, (enalapril) 5 mg once daily
2953414|NCT02879708|No Intervention|Control|40 (of 120) randomly selected villages receive no intervention
2953415|NCT02879708|Other|Information Only|"40 randomly selected villages are assigned to the information only arm where households will receive information regarding their rights and entitlements pertaining to healthcare, certain health outcomes specific to their village, as well as health-related activities happening in their village."
2953416|NCT02879708|Other|Information and Facilitation|The remaining 40 villages will receive similar information as the villages in the Information Only Arm, but will also have facilitators present that ensure the existence of the VHSNC at the village level as well as the occurrence of VHSNC monthly meetings.
2953417|NCT02879695|Experimental|Treatment (blinatumomab, nivolumab, ipilimumab)|Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 42 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 60 minutes on day 11 and then every 2 weeks for up to year. Some patients also receive ipilimumab IV over 90 minutes on day 11 and then every 6 weeks for up to 1 year.
2953418|NCT02879682|Active Comparator|nTMS|presurgical motor mapping by nTMS and fusion with intraoperative neuronavigation
2953419|NCT02879682|Sham Comparator|non-nTMS|presurgical motor mapping by nTMS without access of the surgeon to these data
2953420|NCT02879669|Experimental|ONCOS-102+cyclophosphamide+pemetrexed/cisplatin|ONCOS-102 will be administered in a priming cycle (Cycle 1) comprising injections on Days 1, 4, 8 and 36, followed by two treatment cycles at intervals of 6 weeks (Cycle 2, Day 78 and Cycle 3, Day 120). Pre-treatment with an i.v. bolus of cyclophosphamide (CPO) will be given 1 to 3 days before the first administration of ONCOS-102 (Cycle 1, Day 1) and before administration of Cycle 2 of ONCOS-102 (Day 78). Patients will also receive pemetrexed/cisplatin in 21-day cycles starting on Day 22 and continuing as applicable during the study period of 6 cycles of pemetrexed/cisplatin in combination with ONCOS-102.
2953421|NCT02879669|Active Comparator|Pemetrexed/cisplatin|Patients will be treated with pemetrexed/cisplatin in 21-day cycles starting on Day 1, and continuing as applicable during the study period of 6 cycles of chemotherapy. Patients will be monitored regularly for immunological assessment (PBMCs) including Month 9 and Month 12 (i.e., after the end of study visit), and will be followed up for survival every 3 months until end of life.
2953422|NCT02879656|Other|Cohort 1|"Early ustable fracture:~Phase 1:~After closed reduction, if satisfactory reduction is not achieved fulfilling the inclusion criteria, the patient is allocated to Cohort 1. The patient is randomized to either non-operative (=Arm 1) or operative treatment (=Arm 2). Patients allocated to non-operative treatment will undergo a standard treatment protocol. Patients allocated to operative treatment will undergo a surgery with volar locking plate with modified Henry's volar approach."
2953423|NCT02879656|Other|Cohort 2|"Early stable fracture:~Phase 1:~After closed reduction, if satisfactory position is achieved, the patient is allocated to Cohort 2 and conservative treatment is performed as usually.~Phase 2:~Patients allocated to Cohort 2, will visit orthopedic outpatient clinic in 1 week in the hospital where the treatment was initially started. If reduction is maintained the patient will undergo standard follow-up visits. If reduction is lost to fulfill the inclusion criteria for surgery the patient is asked to participate to phase 2 of this study. After the patient´s enrollment has been confirmed and informed consent is signed, the patient is randomized to either non-operative (=Arm 3N) or operative treatment (=Arm 3O). If allocated to non-operative treatment patient will undergo the same protocol as those in the Arm 1. Patients allocated to operative treatment will undergo surgery with volar locking plate with standard volar approach."
2953424|NCT02879643|Other|A multistage open label design|A multistage open label design over two Marqibo® dose levels will be used.
2953425|NCT02879630||Obese Patients|
2953426|NCT02879630||Non-obese Patients|
2953427|NCT02879617|Experimental|durvalumab|1500 mg of durvalumab will be administered intravenously (IV) on day 1 of every 28 day cycle.
2953428|NCT02879604|Experimental|Compensatory cognitive training|Compensatory cognitive training
2953429|NCT02879604|Placebo Comparator|usual treatment|usual treatment for shizophrenai
2953430|NCT02879591|Experimental|Patients with schizophrenia|Patients with schizophrenia
2953431|NCT02879591|Placebo Comparator|Healthy volunteers|Healthy volunteers
2953432|NCT02879578|Experimental|NBI-98854|NBI-98854 administered once daily for up to 24 weeks
2953433|NCT02879565|Other|qualitative and neuroimaging research|
2953434|NCT02879552||Traditional upper blepharoplasty|Patients with an odd total number of letters in their first name received traditional upper blepharoplasty.
2953435|NCT02879552||Brassiere suture with blepharoplasty|The rest of the patients received orbicularis oculi muscle fixation to periosteum (brassiere sutures)
2953436|NCT02879539|Experimental|MP3000-ACE strategy|MP3000 sound coding strategy or ACE strategy with lower stimulation rate
2953437|NCT02879526|Experimental|C-CPT|
2953438|NCT02879513|Active Comparator|Switch to CEF|Epirubicin 75 mg/m² IV push on day 1 every 3 weeks for 4 cycles. Cyclophosphamide 500 mg/m² IV push on day 1 every 3 weeks. 5-fluoruracil 500 mg/m² IV push on day 1 every 3 weeks.
2953439|NCT02879513|Experimental|Continue the neoadjuvant regimen|Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.
2953440|NCT02879513|Experimental|Pathological complete response group with chemotherapy|Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.
2953441|NCT02879513|No Intervention|Pathological complete response group with no chemotherapy|
2953442|NCT02879487|Active Comparator|Coagulation mode|Colpotomy will be performed by monopolar needle electrode using coagulation mode
2953443|NCT02879487|Active Comparator|Cut mode|Colpotomy will be performed by monopolar needle electrode using cut mode
2953444|NCT02879474||Patient with melanoma|
2953445|NCT02879461|Active Comparator|Lumbar Decompression plus Physical Therapy|First group will be submitted to lumbar decompression L3 to S1 and physical therapy with exercise Application of questionnaires Oswestry Rolland moris Sf 36 Of 6minutos walk test Likert scale Use of paracetamol
2953446|NCT02879461|Active Comparator|Physical Therapy|Second group physical therapy alone, with exercises Application of questionnaires Oswestry Rolland moris Sf 36 Of 6minutos walk test Likert scale Use of paracetamol
2953447|NCT02879448|Experimental|Amulet|Amulet left atrial appendage occluder
2953448|NCT02879448|Active Comparator|WATCHMAN (Control)|WATCHMAN left atrial appendage closure device
2953449|NCT02879435|Experimental|bupivacaine|Intervention
2953450|NCT02879435|Placebo Comparator|Placebo|Control
2953451|NCT02879422|Other|Diabetic patients with proliferative diabetic retinopathy|
2953452|NCT02879422|Other|Diabetic patients with non proliferative diabetic retinopathy|
2953453|NCT02879409|Experimental|Treatment arm 1|"75 Type 2 diabetic patients with a gender balance who will have the intervention if/when their FBG >140mg/dl~Intervention: intensify treatment until their FBG is <90mg/dl, using whatever treatment is clinically appropriate for them using different interventions (Metformin, Gliclazide, Sitagliptin, Dapagliflozin, Liraglutide, Pioglitazone, human insulin), and only intensify it further if their FPG rises to >140mg/dl again."
2953454|NCT02879409|Experimental|Treatment arm 2|"75 Type 2 diabetic patients with a gender balance who will have the intervention if/when their FBG >115mg/dl~Intervention: intensify treatment until FBG is <=115 mg/dl and intensify further if >115 mg/dl again, using what ever clinical treatment is necessary (Metformin, Gliclazide, Sitagliptin, Dapagliflozin, Liraglutide, Pioglitazone, human insulin)."
2953455|NCT02879396|Experimental|Study Participants|A maximum of 50 participants will be enrolled in the study per the inclusion and exclusion criteria. The participants will be residents of SLH who are 55 years old or older. They will have had one or more EMS calls made, ED visit or hospital admission in the past year, as determined by the incidence report at SLH. The study participants will receive PA4LE program.
2953456|NCT02879383|Experimental|DMR Procedure|Subjects randomized to the DMR procedure are followed per protocol for 48 Weeks.
2953457|NCT02879383|Sham Comparator|Sham Procedure|Unblinding to occur at 24 Weeks: Sham treatment arm to cross over to receive DMR treatment at 24 Weeks with background medications held constant from 24 - 48 Weeks of follow up.
2953458|NCT02879370|Experimental|TICRANT|Transanal Inspection and management of low ColoRectal Anastomosis
2953459|NCT02879357|Experimental|Trained Clinicians|Training in Serious Illness Communication Guide
2953460|NCT02879357|No Intervention|Untrained Clinicians|No training in Serious Illness Communication Guide
2953461|NCT02879344|Other|Patient undergoing ECMO|
2953462|NCT02879331|Active Comparator|10 coils in upper lobes|10 coils in upper lobes
2953463|NCT02879331|Experimental|15 coils in upper and lower lobes|15 coils in upper and lower lobes
2953464|NCT02879318|Active Comparator|Gemcitabine plus Nab-Paclitaxel|Gemcitabine 1000 mg/m2 IV & Nab-Paclitaxel 125 mg/m2 until unequivocal progression or unacceptable toxicity. Days 1, 7, 15 Q28 days.
2953465|NCT02879318|Experimental|Gemcitabine + Nab-Paclitaxel + Durvalumab + Tremelimumab|"Gemcitabine 1000 mg/m2 IV & Nab-Paclitaxel 125 mg/m2 until unequivocal progression or unacceptable toxicity. Day 1, 7, 15 Q28 days.~plus Durvalumab 1500mg IV day 1 only Q28 days; and Tremelimumab 75 mg IV Days 1 cycles 1, 2, 3 and 4 only until unequivocal progression or unacceptable toxicity."
2953466|NCT02879305|Experimental|Daprodustat|Participants will receive oral daprodustat once daily.
2953467|NCT02879305|Active Comparator|rhEPO|Participants on peritoneal dialysis (PD) will be administered darbepoetin alfa subcutaneously (SC) and participants on hemodialysis (HD) will be administered epoetin alfa intravenously (IV).
2953468|NCT02879279|Experimental|Robotic rehabilitation|In the robotic rehabilitation group, both the distal and the proximal parts of the patients' upper arm will be treated by means of a multi-set of robotic and technological devices, i.e, Amadeo, Pablo, Diego and Motore. The aforementioned systems can be used to perform three-dimensional movements of the shoulder, planar movements of the shoulder and elbow, prono-supination movements of the forearm, flexion-extension movements of the wrist, bimanual movements, and flexion/extension movements of the fingers. A vibratory treatment will be applied, using the Amadeo, to increase the proprioception of the hand. Motor and cognitive tasks, comprising active, passive and active-assistive, will be performed during the treatment. Visual and auditory feedback will be provided to help the patients.
2953469|NCT02879279|Active Comparator|Conventional rehabilitation|In the conventional rehabilitation group, patients will undergo a conventional treatment. The therapeutic tasks will focus on sensorimotor reprogramming, hypertonus inhibition, functional improvement, including task-oriented exercises. Specifically, patients will perform passive, active and active assisted exercises on the three upper limb joints, to improve joint function, to prevent contractures, to inhibit hypertonus and to improve trophism and motor function.
2953470|NCT02879266|Experimental|TetraVax-DV TV005|Participants will receive a subcutaneous injection of TetraVax-DV TV005 at study entry (Day 0).
2953471|NCT02879266|Placebo Comparator|Placebo|Participants will receive a subcutaneous injection of placebo at study entry (Day 0).
2953472|NCT02879240|Other|Group animated cartoon-black screen (AB)|In this group, children will be exposed to a animated cartoon during the delivery of their inhaled treatment twice a day during one week, then they will be exposed to a black screen in the same conditions for one other week.
2953509|NCT02878902||Post implementation|"Patients registered in monitoring French registry of renal patients Réseau Epidémiologie et Information en Néphrologie (REIN) from January 1, 2014 to December 31, 2015"
2953473|NCT02879240|Other|Group black screen - animated cartoon (BA)|In this group, children will be exposed to a black screen during the delivery of their inhaled treatment twice a day during one week, then they will be exposed to an animated cartoon in the same conditions for one other week.
2953474|NCT02879227|Active Comparator|Arm Cisplatin|Radiotherapy 50 Gy with cisplatin 75 mg/2 Day 1 and day 22 (2)
2953475|NCT02879227|Experimental|Arm Oxaliplatin|Radiotherapy 50Gy Oxaliplatin 85mg/m2 every 2 weeks, (6)
2953476|NCT02879214|Experimental|SIDE cervical trial|To Maximal downstage locally advanced squamous cell cervical cancer before minimal invasive surgical resection. The SIDE study is to use both RT dose escalation to the biological target defined by PET and Chemo dose escalation composited with two drugs to achieve maximal reduction of tumor burden, providing feasibility of minimal invasive surgical resection.
2953477|NCT02879201|Active Comparator|Slow efficiency dialysis|SLED is a kind of hemodialysis technique performed using Fresenius 4008B dialysis machine with FDX 120 GW (NIKKISO Japan) dialyzer. SLED sessions were 6-8 hour duration, three times per week (except Sunday), In case of severe volume overload, the session could be increased to meet clinical situation. Blood flow was maintained between 150-200 mL/hr and the dialysate flow of 300 mL/hr. Both the groups use unfractionated heparin as anticoagulant to prevent clotting of the extracorporeal circuit .the target partial thromboplastin time( PTT) was not more than twice the control level.
2953478|NCT02879201|No Intervention|Continuous renal replacement therapy|CRRT is a kind of therapy involved continuos dialysis throughout 24 hours by using Edward Delivery system (Edward Life Science) as continuous venovenous hemodiafiltration (CVVHDF) mode using Aquamax HF 12 dialyzer. Blood flow rate was kept from 100-200 mL/hr and target effluent rates of 20 mL/hr . The substitution fluid was infused at a rate of 1,000 ml/hr with ultrafiltration rate at 100-300 mL/hr.Intervention here is the different mode of dialysis
2953479|NCT02879188|Experimental|Ambulation|Patients will initiate inpatient physical therapy on the day of their surgery including attempted ambulation with an assistive device that is supervised by a physical therapist.
2953480|NCT02879188|Active Comparator|Standing|Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
2953481|NCT02879162|Experimental|Durvalumab + Tremelimumab|Durvalumab 1500 mg IV 60 min Day 1 every 4 weeks Tremelimumab 75 mg IV 60 min Day 1, cycles 1-4
2953482|NCT02879149||Group 1|Standard Rigid Fixation plus autograft
2953483|NCT02879149||Group 2|Standard rigid fixation plus AUGMENT® Bone Graft
2953484|NCT02879136|Active Comparator|Physical Therapy|Physical Therapy (PT) will consist of two weekly sessions over a 12 week period using the Mellen center protocol PT for PD.
2953485|NCT02879136|Active Comparator|Physical Therapy plus Methylphenidate|Methylphenidate 20 mg daily in combination with PT
2953486|NCT02879136|Active Comparator|Physical Therapy plus Atomoxetine|Atomoxetine 10 mg daily in combination with PT or PT alone.
2953487|NCT02879110|Experimental|Sulforaphane group|The patients will take sulforaphane for 12 weeks.
2953488|NCT02879110|Placebo Comparator|Placebo group|The patients will take placebo for 12 weeks.
2953489|NCT02879097|Experimental|CBT124 arm|CBT124 plus carboplatin and paclitaxel
2953490|NCT02879097|Active Comparator|EU Sourced Avastin® arm|EU-sourced Avastin® plus carboplatin and paclitaxel
2953491|NCT02879058|No Intervention|Without Ultrasound|Laparoscopic or robotic myomectomy will be performed without aid of intraoperative contact ultrasonography
2953492|NCT02879058|Experimental|With Ultrasound|Laparoscopic or robotic myomectomy will be performed with aid of intraoperative contact ultrasonography
2953493|NCT02879045|Experimental|elasticity Belly® oil|Volunteer's abdomen skin are divided two parts through medioventral line, half of the abdomen skin will apply the elasticity Belly® oil
2953494|NCT02879019|Sham Comparator|Stretching exercise group|Patients will receive two session per week of stretching classes.
2953495|NCT02879019|Experimental|Walking training group|Patients will perform two walking sessions per week.
2953496|NCT02879006|Active Comparator|Chinese Herbal Medication|
2953497|NCT02879006|Placebo Comparator|Placebo|
2953498|NCT02878993||Intubated infants|Recording of diaphragm EMG
2953499|NCT02878980|Experimental|Arm I (exercise intervention)|Patients undergo supervised 1-on-1 exercise sessions for 60 minutes on day 1.Treatment repeats every 3 weeks for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive a home-based exercise prescription including instructions for keeping patients' heart rate within 50-80% maximum.
2953500|NCT02878954|Other|No intervention|160 men and women with PAD will be recruited.
2953501|NCT02878954|Other|Control session|40 patients (men and women) will complete this session.
2953502|NCT02878954|Other|Exercise session|40 patients (men and women) will complete this session.
2953503|NCT02878941|Other|Elbow Fracture|Patients with an intraarticular elbow fracture and/or dislocation. Synovial fluid from the injured elbow will be obtained during the subject's emergency department encounter by one of the Chief Residents or Attending surgeon as part of standard of care procedures for pain control-related injection and aspiration. Patients with an intraarticular elbow fracture and/or dislocation receive an intraarticular elbow injection with anesthetic (i.e. lidocaine or marcaine) to provide analgesia for elbow range of motion testing and orthopaedic reduction maneveuers as the current standard of care. The patients would be asked to consent for 2 elbow joint aspirations: 1.Aspiration of the injured elbow at time of surgical fracture fixation; 2.Aspiration of the uninjured elbow at time of surgical fracture fixation.
2953504|NCT02878928|Experimental|IDgenetix Neuropsychiatric Test Panel Intervention|Medical providers for IDgenetix Neuropsychiatric Test Panel-guided group will make treatment recommendations based on test results. Patient outcomes will be measured throughout the duration of the study.
2953505|NCT02878928|No Intervention|Control Group|Medical providers for the Control Group will not receive IDgenetix Neuropsychiatric Test Panel results and will make treatment recommendations as usual. Patient outcomes will be measured throughout the duration of the study.
2953506|NCT02878915|Active Comparator|Ultrasound guided femoral puncture|
2953507|NCT02878915|No Intervention|palpation guided femoral puncture|
2953508|NCT02878902||Before implementation|"Patients registered in monitoring French registry of renal patients Réseau Epidémiologie et Information en Néphrologie (REIN) from January 1, 2012 to December 31, 2013"
2953510|NCT02878889|Experimental|Arm 1|S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
2953511|NCT02878876|Experimental|Sequence A1-A2|Dietary Supplement: Oral consumption of milk with sequence A1-A2
2953512|NCT02878876|Experimental|Sequence A2-A1|Dietary Supplement: Oral consumption of milk with sequence A2-A1
2953513|NCT02878863|Experimental|Paeoniflorin + phosphatidylcholine or silymarin|Paeoniflorin tablets(600mg, tid)combination of phosphatidylcholine or silymarin
2953514|NCT02878863|Active Comparator|Phosphatidylcholine or silymarin|Phosphatidylcholine or silymarin
2953515|NCT02878850|Experimental|Augmented Blood Pressure|Subjects will have their blood pressure kept in a higher range.
2953516|NCT02878850|No Intervention|Conventional Blood Pressure|Subjects will have their blood pressure kept in a normal range.
2953517|NCT02878837|Active Comparator|DEX|Patients undergoing surgical procedures under regional anesthesia sedated with a loading dose of 1 µg/Kg of Dexmedetomidine over 10 minutes followed by continuous infusion at 0.2 to 0.8 µg/Kg/h, along with 0.5µg/Kg bolus breakthrough doses of Fentanyl as necessary to achieve a RASS score between -3 and -1.
2953518|NCT02878837|Active Comparator|MDZ|Patients undergoing surgical procedures under regional anesthesia sedated with a 0.05mg/Kg bolus dose of Midazolam, along with 0.02 mg/Kg bolus doses of Midazolam plus 0.5µg/Kg bolus doses of Fentanyl as necessary to achieve a RASS score between -3 and -1
2953519|NCT02878824||HK-Children|This is a group of typically-developing children ages 7-12 years old who are of Chinese ethnicity, born and raised in Hong Kong (n=32).
2953520|NCT02878824||FHK-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity; either born, migrated and/or raised in Hong Kong (n=32).
2953521|NCT02878824||FU-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity, born and raised in an urban area in the Philippines (n=32).
2953522|NCT02878824||FR-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity, born and raised in a rural area in the Philippines (n=32).
2953523|NCT02878798|Placebo Comparator|Placebo|An overencapsulated placebo of identical color, shape and packaging to topiramate will be used.
2953524|NCT02878798|Experimental|Topiramate|Oral topiramate
2953525|NCT02878785|Experimental|Decitabine and Talazoparib Combo|"Phase 1:~Decitabine by IV daily for 5 days every 28 days. Talazoparib orally daily days 1-28.~The 'outer layer' of this nested dose escalation trial will escalate the dose of the two drugs by sequentially going through dose levels 1-6 in the table found in the protocol. The standard algorithm of the 3+3 design will be applied.~Phase 2:~Decitabine by IV daily for 5 days every 28 days. Talazoparib orally daily days 1-28. Phase 2 doses will be determined based on data from Phase 1."
2953526|NCT02878772|Active Comparator|vinpocetine group|Aspirin, 10mg, po and 30 mg of the vinpocetine by intravenous infusion once daily, for fourteen consecutive days
2953527|NCT02878772|Placebo Comparator|Control group|Patients will receive aspirin only.
2953528|NCT02878759|Experimental|Wristbot|WristBot will be used as diagnostic tool to evaluate the novel technology and the associated protocol for proprioception quantification during rehabilitation. The main objective is to provide clinicians with a reliable instrument able to overcome the limitations in proprioceptive measurement by current clinical methodologies.
2953529|NCT02878746|Experimental|Robotic mirror therapy|For 30 min per day for two weeks (10 sessions)
2953530|NCT02878746|Active Comparator|Conventional mirror therapy|For 30 min per day for two weeks (10 sessions)
2953531|NCT02878733||Albumin|patients that had received at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.) with any volume of 5% albumin
2953532|NCT02878733||Crystalloid Only|patients that had received at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.) without any volume of 5% albumin
2953533|NCT02878720|Experimental|Robotic therapy and real tVNS|This group receives REAL vagus nerve stimulation before robotic rehabilitation.
2953534|NCT02878720|Active Comparator|Robotic therapy and sham tVNS|This group receives SHAM VNS before robotic rehabilitation. Sham VNS is not effective. Both groups receive the same amount of robotic rehabilitation.
2953535|NCT02878707|Experimental|DEX|Intraoperative intravenous infusion of dexmedetomidine
2953536|NCT02878707|Placebo Comparator|Control|Intraoperative intravenous infusion of 0.9% saline
2953537|NCT02878694|Experimental|Myoblast autologous graft|30 million autologous myoblasts in 6 intramuscular injections
2953538|NCT02878681|Experimental|Group 1|Monthly intravitreal injections of 0.5 mg ranibizumab for six months
2953539|NCT02878681|Experimental|Group 2|Monthly intravitreal injections of 2 mg aflibercept for the initial three months followed by monthly intravitreal injections of 0.5 mg ranibizumab for the next three months.
2953540|NCT02878681|Experimental|Group 3|Monthly injections of 2 mg aflibercept for six months
2953541|NCT02878616|Experimental|LFG316 + IVIG|
2953542|NCT02878616|Experimental|LFG316 alone|
2953543|NCT02878603|Experimental|caplacizumab|Initial i.v. dose followed by daily s.c. injections for a maximum period of 6 months
2953544|NCT02878590|Experimental|BONGO DEVICE|All participants will receive the intervention of the Bongo device
2953545|NCT02878577||EEG fMRI TBI Mild/Moderate-Severe severity|patient population who suffered a brain trauma (traumatic brain injury, TBI). with a Glasgow Coma Scale between 3-15
2953546|NCT02878577||EEG fMRI Control group|healthy subjects with out a traumatic brain injury
2953547|NCT02878564|Experimental|Praziquantel treatment|Participants will be HIV-uninfected women with asymptomatic Schistosoma mansoni infection; the study will examine the impact of standard praziquantel therapy (40 mg/kg po single dose) on genital immunology and HIV susceptibility.
2953548|NCT02878551|Experimental|Prehabilitation program|Multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
2953549|NCT02878538|Active Comparator|deferiprone|Deferiprone will be administered three times a day (25mg/kg). Total dose per day will depend on participants' body weight for one, three month block.
2953550|NCT02878538|Placebo Comparator|Placebo Phase|Placebo tablets with inactive substance will be used. Total number of placebo tablets will be equivalent to the active tablets administered depending on participants' body weight for two, three month blocks.
2953552|NCT02878525|Active Comparator|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
2953553|NCT02878512|Active Comparator|PCNL under General Anesthesia|Patients were premedicated with Inj. Atropine 0.06 mg intramuscularly half an hour prior to surgery, IV ranitidine 1mg kg-1, IV ondansetron 0.08mg kg-1 IV midazolam 0.02mg kg-1 and Pentazocine 0.3 mg/kg. Anaesthesia was induced with IV Thiopentone sodium 3-5 mg kg-1 and Vecuronium 0.1mg kg-1.and then intubated. Anaesthesia was maintained on 50 %:50% nitrous oxide and oxygen, vecuronium and propofol infusion . At the end of the surgery postoperative analgesia was given with IV tarmadol and local nfiltration with 0.25% bupivacaine at the surgical site. Patients were reversed with IV glycopyrrolate 0.008mg kg-1 and IV neostigmine 0.06mg kg-1 and extubated.
2953554|NCT02878512|Experimental|PCNL under Segmental epidural Anesthesia|epidural space was located at T12 -L1 or L1-L2 space .The epidural catheter was inserted cephalad 5 cm upwards in the epidural space (tip approximately at T8 to T9). and test dose of 3 ml of 2% Adrenalized Lignocaine was administered..loading dose of 0.5% Bupivacaine, approximately 8 to 10 ml was injected epidurally with regular negative aspiration to block T6- T12 segments, if desired level was not achieved then additional dose of 1 to 1.5 ml 0.5% bupivacaine per spared segment was given to achieve the desired level.Motor blockade of the lower limbs was checked and noted before lithotomy, before prone and at the end of the surgery using Bromage scale. After two segment regression of sensory level epidural top up with 1/4th of initial dose 2 to 3 ml of 0.5% Bupivacaine was given. At the end of the surgery 8ml of 0.125% Bupivacaine was administered for postoperative analgesia and the catheter was removed.
2953555|NCT02878499|Other|ASD|
2953556|NCT02878486|Experimental|Group 1|Subjects will have clinic visits, home visits, and telephone visits. Subjects will be asked to wear a wrist monitor (Jawbone Up) for duration of the study, will meet with the study team to review Physical Activity Education and also be asked to wear the ActivPAL device to assess sitting time.
2953557|NCT02878486|Active Comparator|Group 2|Subjects will make clinic visits. At home visits, subjects will meet with the study team to review Physical Activity Education and also be asked to wear the ActivPAL device to assess sitting time.
2953558|NCT02878473|Experimental|Liver transplantation|The intervention will consist of liver transplantation
2953559|NCT02878460|Experimental|monitoring with ORI + SpO2|"Patients receive the regular monitoring with SpO2, but in this group, the ORI parameters is shown on the scope.~Lower and upper SpO2 limits are prescribed for each patient."
2953560|NCT02878460|Other|monitoring with SpO2|"Patients receive the regular monitoring; the ORI parameters is not shown (but it is recorded each time a blood gas is drown).~Lower and upper SpO2 limits are prescribed for each patient."
2953561|NCT02878447|Experimental|External Beam Radiotherapy|Patients will receive radiotherapy (3.5Gy weekly for 5 fractions to a maximum of 17G) prescribed to a central plane using mega-voltage radiation encompassing all the assessed affected lung tissue
2953562|NCT02878447|No Intervention|Control|Patients will receive best medical care.
2953563|NCT02878434||Study group|
2953564|NCT02878434||control group|
2953565|NCT02878421|Active Comparator|tobacco cigarette|Intervention: tobacco cigarettes min 15/day
2953566|NCT02878421|Active Comparator|e.cigarettes + 16mg nicotine & flavor|Intervention: One flavoured electronic cigarette 16mg nicotine/day
2953567|NCT02878421|Active Comparator|e.cigarettes + 0mg nicotine & flavour|Intervention: One electronic cigarette with flavour +0mg nicotine/day
2953568|NCT02878408|Other|acute Bipolar disorder|blood sampling and data collection Following visit at end of hospitalisation (blood sampling and data collection)
2953569|NCT02878408|Other|acute Schizophrenia|blood sampling and data collection Following visit at end of hospitalisation (blood sampling and data collection)
2953570|NCT02878408|Other|stable Bipolar disorder|blood sampling and data collection (only one visit)
2953571|NCT02878408|Other|stable Schizophrenia|blood sampling and data collection (only one visit)
2953572|NCT02878408|Other|healthy control|blood sampling and data collection (only one visit)
2953573|NCT02878395||Crohn's disease|
2953574|NCT02878382|Other|Conventional MAL-PDT|Conventional topical PDT with Methylaminolevulinate 16% in one half of the scalp with multiple AKs.
2953575|NCT02878382|Other|Calcipotriol assisted MAL-PDT|Calcipotriol ointment 50 mcg/g applied once a day for 15 consecutive days in one half of the scalp, before Conventional topical PDT
2953576|NCT02878356|Active Comparator|Regular MI-training|Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
2953577|NCT02878356|Active Comparator|Regular MI-training + supervision half|Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
2953578|NCT02878356|Active Comparator|Regular MI-training + supervision full|Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
2953579|NCT02878343|Active Comparator|Incentives|Daily lottery type incentives tied to achievement of weight loss goals
2953580|NCT02878343|Active Comparator|Environmental strategies|Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform
2953581|NCT02878343|Active Comparator|Incentive and environmental strategies|A combination of incentives and environmental strategies
2953582|NCT02878343|No Intervention|Usual care|Standard employee wellness benefits
2953583|NCT02878330|Experimental|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
2953584|NCT02878330|Placebo Comparator|Placebo|Commercially available 0.9% (w/v) saline.
2953585|NCT02878317||Malnourished participants|"Presence of malnutrition will be assessed by using the Subjective Global Assessment.~Once the identified malnourished participants have given their informed consent, they will receive intensive dietitian supervised nutritional support with the aim of improving their malnutrition. In addition, participants will receive standard dietary advice for people on dialysis based on the Nutritional Guidelines in CKD published by the Renal Association in March 2010 in the UK (Wright and Jones, 2010) and will include the following: energy (35 kcal/kg/day) and protein intake (1.2 g/kg/day), as well as potassium, phosphate and sodium restriction, according with biochemical blood parameters."
2953586|NCT02878291|Experimental|High dose Group|Received Vaccine: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine,40μg/dose
2953632|NCT02877953|Experimental|Intervention group|the prevention of complications post-TIPS
2953587|NCT02878291|Experimental|low dose Group|Received Vaccine: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine,20μg/dose
2953588|NCT02878278|Experimental|Chidamide BIW|Chidamide is given 30mg,5mg/pill,twice a week, for at least 6 weeks
2953589|NCT02878278|Experimental|Chidamide QD|Chidamide is given 10mg,5mg/pill, everyday,for at least 6 weeks.
2953590|NCT02878265|Placebo Comparator|Vitamin A|A single dose of 20,000IU Vitamin A for the whole study period
2953591|NCT02878265|Active Comparator|Vitamin A and zinc|A single dose of 20,000IU Vitamin A and 10mg of elemental zinc each day for 5 months
2953592|NCT02878265|Active Comparator|Vitamin A , Zinc and Multivitamin|A single dose of 20,000IU Vitamin A , 10mg of elemental zinc each day and 0.5ml/kg multivitamin syrup for 5 months
2953593|NCT02878239||Early OA|All patients (>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with early knee osteoarthritis because their Kellgren-Lawrence Scores were Grade I.
2953594|NCT02878239||Moderate OA|All patients (>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with moderate knee osteoarthritis because their Kellgren-Lawrence Scores were Grade II.
2953595|NCT02878239||Severe OA|All patients (>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with moderate knee osteoarthritis because their Kellgren-Lawrence Scores were Grade III/IV.
2953596|NCT02878239||Asymptomatic Participants|The asymptomatic participants（>35 years） has no history of knee pain, trauma, surgery, or obvious gait abnormalities. They are set as controls in the study.
2953597|NCT02878213|Experimental|D700 System|Patients referred to catheter-based Atrial-Fibrillation (AF) ablation procedure therapy comprising of Pulmonary Veins Isolation (PVI).
2953598|NCT02878200|Experimental|reactive treatment|Household members; defined as those sharing the same sleeping area, in the intervention villages, will be treated with a full course of dihydroartemisinin-piperaquine (DHAP)
2953599|NCT02878200|No Intervention|standard care|In control villages, no household treatment will be done
2953600|NCT02878187||placenta previa|all women managed by conservative surgical techniques during cesarean section after intraoperative hemorrhage due to placenta previa/accreta
2953601|NCT02878187||healthy controls|women delivered by Cesarean for any other indication with no intraoperative hemorrhage or any additional surgical techniques performed during Cesarean
2953602|NCT02878174|Active Comparator|conventional ultrasound (US)-guided group|internal jugular vein catheterization using conventional US-guided internal jugular vein (IJV) cannulation
2953603|NCT02878174|Experimental|rotational Prelocation group|internal jugular vein catheterization using landmark approach based on the rotation-adjusted US screen
2953604|NCT02878161|Experimental|A group|Infliximab plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
2953605|NCT02878161|Experimental|B group|Etanercept plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
2953606|NCT02878161|Experimental|C group|Adalimumab plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
2953607|NCT02878135|Experimental|fast vulsellum|rapid ratchet of the vulsellum
2953608|NCT02878135|Active Comparator|slow vulsellum|Placement of the tenaculum over 7-10 seconds and not allowing the vulsellum to ratchet audibly.
2953609|NCT02878122||Patients with epithelial ovarian cancer|Cancer treatment
2953610|NCT02878109||Hepatocellular carcinoma (HCC)|"All patients enrolled will undergo:~4D-THRIVE and 4D-FLOW sequences during magnetic resonance imaging (MRI) before and after transarterial chemoembolisation (TACE)."
2953611|NCT02878096|Experimental|[14C]-SK-1404|
2953612|NCT02878083|Experimental|VEDOLIZUMAB|300 mg IV
2953613|NCT02878070|Experimental|Peer Health Coaching|Calls from a Peer Health Coach for 6 months
2953614|NCT02878070|No Intervention|Usual Care|
2953615|NCT02878057|Experimental|Advanced Breast Cancer|Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
2953616|NCT02878044|Experimental|Implementation Arm|
2953617|NCT02878031|Experimental|Oral amoxicillin for CI pneumonia|Community management of chest indrawing pneumonia using oral amoxicillin by CHWs
2953618|NCT02878018||TCM intervention|Participants with HSPN of the Heat-Toxin type will take the Qi-Ji Shen-Kang formula. HSPN patients of the Wet-Heat type will take the Zhu-Bai formula. Those of Qi-Deficiency with Blood-Stasis type will take the Yu-Shen formula.
2953619|NCT02878018||WM conventional intervention|The WM conventional intervention, recommended by the Chinese Medical Association's (CMA) Scientific Statement, includes angiotensin-converting enzyme (ACE) inhibitor, adrenergic receptor binder (ARB), adrenal cortical hormone, Tripterygium wilfordii polyglycosidium and an immunosuppressant.
2953620|NCT02878005|Active Comparator|Intubating laryngeal Tube Suction|Intubating laryngeal Tube Suction
2953621|NCT02878005|Active Comparator|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
2953622|NCT02877992|Active Comparator|Donors|Oocyte donors without infertility problems
2953623|NCT02877992|Experimental|PCOS|Patients with Polycystic Ovary Syndrome (PCOS) according to Rotterdam criteria
2953624|NCT02877992|Experimental|Endometriosis|Patients with endometriosis (I-IV)
2953625|NCT02877992|Experimental|Age|Patients with advanced maternal age (38 years or more)
2953626|NCT02877992|Experimental|Low ovarian response|Patients with low ovarian response according to Bologna criteria
2953627|NCT02877979|Experimental|DS003 vaginal tablet|participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.
2953628|NCT02877979|Placebo Comparator|placebo|participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.
2953629|NCT02877966|Experimental|Arm A|Amixea- patented stoechiometrical mixture of EAA & AA
2953630|NCT02877966|Placebo Comparator|Arm B|Placebo
2953631|NCT02877953|No Intervention|Control group|The conventional care was performed for the patients of control group
2953633|NCT02877940|Active Comparator|ProSeal Laryngeal mask airway|ProSeal will be inserted in mechanically ventilated patients undergoing elective surgeries.
2953634|NCT02877940|Active Comparator|Laryngeal Tube Suction- Disposable|LTS-D will be inserted in mechanically ventilated patients undergoing elective surgeries.
2953635|NCT02877940|Active Comparator|Group I|i-gel will be inserted in mechanically ventilated patients undergoing elective surgeries..
2953636|NCT02877927|Experimental|Omadacycline|Omadacycline tablets
2953637|NCT02877927|Active Comparator|Linezolid|Linezolid tablets
2953638|NCT02877901|Active Comparator|tolterodine-treated group|they will receive long acting tolterodine 4 mg at bedtime for 4 weeks. After that re-evaluation. then stop medication for two weeks (washout period).
2953639|NCT02877901|Placebo Comparator|placebo-control group|they will receive placebo at bedtime for 4 weeks. After that re-evaluation. then stop for two weeks (washout period). Then re-evaluate the nocturnal incontinence status and crosed over to receive long acting tolterodine 4 mg for 4 weeks. at the end the nocturnal incontinence status will be evaluated
2953640|NCT02877888|Experimental|drug fluoride varnish /strength 22600ppm|intervention: drug :fluoride varnish 22600ppm topical application every 6 months for a total period of 2 years
2953641|NCT02877888|No Intervention|placebo comparator|placebo:use of routine dental advice
2953642|NCT02877875|Experimental|Child STEPS|Child STEPs includes (1) a treatment protocol, Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems (MATCH-ADTC;Chorpita & Weisz, 2009), and (2) a youth monitoring and feedback system (MFS).
2953643|NCT02877875|Active Comparator|Usual Care|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective, and researchers will not influence their work.
2953644|NCT02877862|Experimental|Intervention|Receive 7-day mAGIC app intervention and handout
2953645|NCT02877862|No Intervention|Control|Handout only
2953646|NCT02877849||Individuals with Alcohol Use Disorder|Individuals with Alcohol Use Disorder will be recruited from Lodging Plus treatment program (Fairview Riverside Hospital, Minneapolis, MN). All patients will have between 2-3 weeks of abstinence from alcohol use. We will collect brain imaging data, this is an observational study.
2953647|NCT02877849||Healthy Volunteers|Healthy volunteers with comparable age and gender to the patient group will be recruited through community advertisements. We will collect brain imaging data, this is an observational study.
2953648|NCT02877836|Other|Segmentary dystonia|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
2953649|NCT02877836|Other|Hemidystonia|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
2953650|NCT02877836|Other|Generalized dystonia|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
2953651|NCT02877836|Other|Healthy control subjects|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
2953652|NCT02877823|Experimental|Treatment|"Home delivery of bottled water supplying 48 oz. /day for the child and 24 oz. /day per other household members (up to 6 family members).~Child pedometer use and activity tracking to encourage child physical activity/goal setting and engage parents in monitoring their child's health behavior.~Family Navigator Services by telephone with the parent to help engage and empower parents in child healthy lifestyle changes. They will also be able to assist with resource needs for the household (food/housing services).~Healthy Lifestyle Education based on the American Academy of Pediatrics Institute for the Healthiest Childhood Weight daily guidelines which are 5 fruit and vegetable servings, two hours or less screen time, one hour or more physical activity, no sugary drinks daily and limit fruit juice to one hundred percent real fruit juice."
2953653|NCT02877823|Active Comparator|Control|Healthy Lifestyle Education based on the American Academy of Pediatrics Institute for the Healthiest Childhood Weight daily guidelines which are 5 fruit and vegetable servings, two hours or less screen time, one hour or more physical activity, no sugary drinks and limit fruit juice to one hundred percent real fruit juice.
2953654|NCT02877810|Experimental|Telemedicine|A consultation will be given for the care of a critically ill pediatric patient to a remote hospital emergency department physician by telemedicine, a live, interactive, audiovisual teleconferencing system, from a pediatric critical care physician.
2953655|NCT02877810|Active Comparator|Telephone|A consultation will be given for the care of a critically ill pediatric patient to a remote hospital emergency department physician by telephone, from a pediatric critical care physician..
2953656|NCT02877797|No Intervention|standard Esophagogastroduodenoscopy|standard Esophagogastroduodenoscopy
2953657|NCT02877797|Experimental|cap assisted Esophagogastroduodenoscopy|cap assisted Esophagogastroduodenoscopy
2953658|NCT02877784|Experimental|Screening|Participants enrolled will have the following test: Micro Mouth Pressure Meter, reflexive cough testing (with capsaicin used in blocks), lingual strength and endurance trials using the Iowa Oral Performance Instrument, Electrical Impedance Myography of the tongue, Pulmonary Function Testing, and a Videofluoroscopic Swallowing Study (VFSS). In addition, the patient will complete the following surveys: Swallowing Related Quality of Life Questionnaire (SWAL-QOL), Eating Assessment Tool-10 (EAT-10), Functional Oral Intake Scale (FOIS), Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS), and the Communicative Effectiveness Survey (CES).
2953659|NCT02877771|Experimental|t:slim insulin pump with predictive low glucose suspend|To assess the functionality of a predictive low glucose suspend (PLGS) system that uses CGM values to suspend basal insulin delivery when hypoglycemia is predicted as well as resume basal insulin delivery once Continuous Glucose Monitoring (CGM) values begin to increase.
2953660|NCT02877758|Experimental|Experimental|Tomorrowlabs cosmeceutical formulation is applied to the face of the subjects twice daily for 3 consecutive months.
2953661|NCT02877758|Sham Comparator|Control|Tomorrowlabs cosmeceutical formulation without the active ingredient is applied to the face of the subjects twice daily for 3 consecutive months.
2953662|NCT02877745||no SDB|apnea-hyponea index <15/hour
2953663|NCT02877745||SDB|apnea-hyponea index >=15/hour
2953664|NCT02877732|Experimental|Concussed Subject|EYE-SYNC eye-tracking device, Level of Alertness, SCAT-3 subtests (Symptom, Immediate memory, Balance and Orientation), Simple Reaction Time subtest of ANAM-SRT and DEM. Investigators will be collecting medical history and demographics from each subject.
2953665|NCT02877732|Active Comparator|Control Subject|EYE-SYNC eye-tracking device, Level of Alertness, SCAT-3 subtests (Symptom, Immediate memory, Balance and Orientation), Simple Reaction Time subtest of ANAM-SRT and DEM. Investigators will be collecting medical history and demographics from each subject.
2953666|NCT02877719||Children from low-income families|Children from low-income families were invited to fill in a set of questionnaires.
2953667|NCT02877719||Children from high income families|Children from high-income families were invited to fill in a set of questionnaires.
2953668|NCT02877693|Other|Thoracic MRI Scan|Subjects will be enrolled within 60 days of successful St. Jude Medical™ MR Conditional ICD System implant or within 60 days post most recent lead revision (if applicable) whichever is latter. Enrolled subjects will undergo an elective MRI scan from 60-90 days of implant or most recent lead revision (if applicable) whichever is latter. Post MRI visit all subjects will be followed up at 1-Month post MRI visit.
2953669|NCT02877680|Experimental|Intervention|Smartphone app for parents to track adolescents' strength behaviors related to living with and managing type 1 diabetes, including regular feedback to parents and training about how to recognize and reinforce positive behaviors in teens.
2953670|NCT02877680|No Intervention|Usual Care|Usual diabetes care and study-related data collection, without use of app during the study period. They will be offered an opportunity to try the app and share their feedback with the study team after completing follow-up data collection.
2953671|NCT02877667|Experimental|Open label device treatment|Up to four passes with Q-Switched laser alternating with acoustic wave device
2953672|NCT02877654|Experimental|Irritable Bowel Syndrome|
2953673|NCT02877641|Active Comparator|Control arm (multivitamin, placebo)|Patients receive a placebo and multivitamin orally each day for 52 weeks.
2953674|NCT02877641|Experimental|Supplementation arm (multivitamin, cholecalciferol)|Patients receive a multivitamin and cholecalciferol supplement orally each day for 52 weeks.
2953675|NCT02877615|Experimental|S 44819 150 mg twice a day|
2953676|NCT02877615|Experimental|S 44819 300 mg twice a day|
2953677|NCT02877615|Placebo Comparator|Placebo|
2953678|NCT02877602||Experience of liver disease|This is defined as either those who have had direct experience of liver disease as sufferers, or the carers of those who have had liver disease. Each individual receives an MRI (LiverMultiScan), with many also receiving a FibroScan.
2953679|NCT02877589||solid tumor|Patients receiving chemotherapy for solid tumors in Ambulatory Medicine Unit of the Reims University Hospital (France) between May 14, 2012 and July 31, 2013.
2953680|NCT02877576|Experimental|Epileptic patient|micro-electrode recordings interventions: Implantation of mixed intracerebral electrodes Face detection Face individualization
2953681|NCT02877563||Patients with PAD|Patients with PAD who are to undergo surgical or percutaneous revascularization.
2953682|NCT02877550|Experimental|Part A - dose escalation and part B - dose expansion|"Part A: dose escalation:~Combination therapy N= 4-18 pts Cycle 1-6 (1 cycle = 28 days) Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6 Venetoclax: p.o. once daily according to dose level (DL)~Part B - dose expansion:~Combination therapy N= up to 25 pts Cycle 1-6 (1 cycle = 28 days) Obinutuzumab: 1000 mg, i.v. infusion d1, 8, 15 C1 and d1 C2-6 Venetoclax: p.o. once daily according to MTD~Part A and part B are followed (in case of no PD) by an obinutuzumab maintenance therapy for 2 years"
2953683|NCT02877537|Experimental|Asthma child|
2953684|NCT02877537|Experimental|Control adult|
2953685|NCT02877537|Experimental|Control child|
2953686|NCT02877524|Experimental|Adaptive support ventilation|Adaptive support ventilation during NIV for acute exacerbation of COPD
2953687|NCT02877524|Active Comparator|Pressure support ventilation|Pressure support ventilation during NIV for acute exacerbation of COPD
2953688|NCT02877511|Experimental|Arm 1|2/3 of subjects testing the test article
2953689|NCT02877511|Active Comparator|Arm 2|1/3 of subjects testing the marketed control
2953690|NCT02877498|Experimental|Adaptive support ventilation|adaptive support ventilation mode during invasive mechanical ventilation
2953691|NCT02877498|Active Comparator|Volume controlled ventilation|Volume controlled ventilation during invasive mechanical ventilation
2953692|NCT02877485|Active Comparator|Triamcinolone acetonide then Ayr spray|This study arm will start with 6 weeks of therapy with the intranasal steroid, followed by 6 weeks of therapy with a placebo, with a two week washout period in between treatments.
2953693|NCT02877485|Active Comparator|Ayr spray then triamcinolone acetonide|This study arm will start with 6 weeks of placebo, followed by 6 weeks of therapy with the intranasal steroid, with a two week washout period in between treatments.
2953694|NCT02877472|Experimental|Experimental group|Patients with avascular necrosis of the femoral head after femoral neck fracture surgery will undergo core decompression and porous tantalum rod implantation (experimental group).
2953695|NCT02877472|Experimental|Control group|Patients with avascular necrosis of the femoral head after femoral neck fracture surgery will undergo core decompression (control group).
2953696|NCT02877459|Experimental|AeriSeal System|Subjects will be treated with AeriSeal Foam.
2953697|NCT02877433|Active Comparator|Roxolid short implant, 4 mm length (4)|Straumann Tissue Level Ø4.1 mm RN SLActive Roxolid Standard Plus Implants available in lengths 4mm, 10mm, 12mm and 14mm
2953698|NCT02877433|Experimental|Roxolid short implant, 4 mm length (2)|Straumann Tissue Level Ø4.1 mm RN SLActive Roxolid Standard Plus Implants available in lengths 4mm, 10mm, 12mm and 14mm
2953699|NCT02877420|Experimental|Non-Technical Skills Training Curriculum|This group will receive 4 hours of small-group and hands-on sessions and 1 hour of didactic NTS sessions. Participants will watch a video that demonstrates ideal endoscopic performance. They will use the E-NTS Checklist during the integrated scenario training. This checklist targets NTS. The group will be given 7 hours of expert-assisted instruction on the low-fidelity simulator (1 hour) and the high-fidelity VR simulator (6 hours). Six modules of increasing difficulty in colonoscopy and polypectomy will be taught with feedback from an expert endoscopist who will demonstrate techniques, answer questions and provide individualized performance feedback with a focus on NTS. The last three hours on the high fidelity simulator will be an integrated scenario (IG) featuring standardized patient (SP) and standardized nurse (SN). Feedback will be given after each IG by the instructor, SP and SN. Participants can view the E-NTS Checklist before and after each case.
2953836|NCT02876393||Cases|Persons with type 1 or type 2 DM with features of DR and or DMO ranging from extremely mild to severe.
2953700|NCT02877420|Active Comparator|Conventional Simulation Training Group|This group will receive 4 hours of small-group and hands-on sessions on colonoscopy theory from an expert endoscopist. The core curriculum is designed on the basis of the American Society for Gastrointestinal Endoscopy colonoscopy curriculum and an endoscopic training textbook. This curriculum has been shown to be effective when compared to self-regulated learning on the simulator. The sessions will be interlaced with eight hours of expert-assisted instruction on both the low-fidelity simulator (1 hour) and on the high-fidelity VR simulator (7 hours). Six modules of increasing difficulty in colonoscopy and polypectomy will be taught with feedback from an expert endoscopist. The expert will demonstrate techniques, answer questions and provide feedback on global performance. Feedback, in the form of performance metrics, will be provided by the simulator upon completion/failure of each module.
2953701|NCT02877407|Other|laparoscopic/robotic-assisted hysteropexy|patient who undergo laparoscopic/robotic-assisted hysteropexy
2953702|NCT02877407|Other|vaginal hysterectomy|patient who undergo vaginal hysterectomy
2953703|NCT02877394|Experimental|Squatting Assist Device|The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.
2953704|NCT02877394|Sham Comparator|Sham Squatting Assist Device|This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
2953705|NCT02877381|Active Comparator|Single IV Dose|• 1 gram IV TXA administered at time of prepping and draping
2953706|NCT02877381|Active Comparator|Double Dose IV|"1 gram IV TXA administered at time of prepping and draping~1 gram IV TXA administered prior to tourniquet deflation"
2953707|NCT02877381|Active Comparator|IV + Topical|"1 gram IV TXA administered at time of prepping and draping~1 gram topical TXA injected intra-articular following closure of the arthrotomy"
2953708|NCT02877381|Active Comparator|Repeated Oral Dose|• Three 650 mg tablets of TXA administered two hours prior surgery with a second dose given 6 hours postoperatively and a final dose given the morning of postoperative day 1
2953709|NCT02877368||gastrointestinal stromal tumours|Patients with advanced or high-risk resected gastrointestinal stromal tumours (GIST) .
2953710|NCT02877355|Experimental|Semaglutide|
2953711|NCT02877342||Pre-intervention|All injured patients arriving by ambulance (to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority category will be eligible for inclusion. Patients arriving without notification buy ambulance service
2953712|NCT02877342||Post-Intervention|All injured patients arriving by ambulance, and allocated to a red (1st) or yellow (2nd) priority category will be eligible for inclusion. Patients arriving with and without notification by the ambulance service using the pre-hospital notification application.
2953713|NCT02877329|Experimental|Internet-delivered ACT|Guided Internet-delivered Acceptance and commitment therapy for 8 weeks
2953714|NCT02877329|No Intervention|Wait list control|No treatment during 8 weeks
2953715|NCT02877316|Experimental|MYPLAN app|MYPLAN app (safety plan) as part of treatment
2953716|NCT02877316|Active Comparator|Safety plan on paper|Safety plan on paper as part of treatment
2953717|NCT02877303|Experimental|Hyper-CVAD + Blinatumomab|"During Cycles 1 and 3:~Cyclophosphamide 2 times each day by vein on Days 1-3. Mesna by vein non-stop to help prevent side effects on Days 1-3. Dexamethasone 1 time a day by vein on Days 1-4 and 11-14. Ofatumumab or rituximab by vein on Days 1 and 11. Methotrexate by vein on Day 2. Doxorubicin by vein non-stop for 1 day on Day 4. Vincristine by vein on Day 4 and 11. Cytarabine by vein on Day 7.~During Cycles 2 and 4:~Methotrexate by vein on Day 1. Ofatumumab or rituximab by vein on Days 1 and 8. Cytarabine by vein 2 times each day on Days 2 and 3.~After Hyper-CVAD, Blinatumomab given nonstop for Weeks 1-4 every 6 weeks of Cycles 5-8.~After 4 cycles of Blinatumomab, participants receive maintenance therapy for about 12 months.~Participants take 6-mercaptopurine by mouth 3 times every day. Methotrexate taken every week. Vincristine by vein 1 time every month. Prednisone taken by mouth on Days 1-5 of every month."
2953718|NCT02877290|Experimental|cycling test first with NIV, then without NIV|patients in this arm will perform their first constant work rate test while using NIV and the second constant work rate test without NIV
2953719|NCT02877290|Experimental|cycling test first without NIV, then with NIV|patients in this arm will perform their first constant work rate test without NIV and the second constant work rate test with NIV
2953720|NCT02877277|Experimental|Vitamin C|Oral intake of vitamin C tablet (500 mg) daily for 56 days
2953721|NCT02877277|Placebo Comparator|Placebo|Oral intake of placebo tablet daily for 56 days
2953722|NCT02877264|Experimental|Vapendavir Capsule, 264 mg|Vapendavir phosphate salt administered orally as a single dose of two 132 mg hard gelatin capsules
2953723|NCT02877264|Experimental|Vapendavir Tablets, 264 mg|Vapendavir free base tablets containing 264 mg of vapendavir
2953724|NCT02877264|Experimental|Vapendavir Oral Suspension, 264 mg|Vapendavir free base as a 24 mg/mL oral suspension
2953725|NCT02877251||Deep venous thrombosis|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with deep venous thrombosis
2953726|NCT02877251||Deep venous thrombosis and Pulmonary embolism|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with deep venous thrombosis and pulmonary embolism
2953727|NCT02877251||Pulmonary embolism|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with pulmonary embolism
2953728|NCT02877238|Active Comparator|Group A|Sevoflurane plus remote ischemic preconditioning anesthesia will be induced and maintain with sevoflurane in addition to remote ischemic preconditioning which will be done after induction and before cardiopulmonary bypass by inflating the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3 cycles
2953729|NCT02877238|Active Comparator|Group B|anesthesia will be induced and maintain with total intravenous anesthesia (propofol, midazolam plus fentanyl) during plus remote ischemic preconditioning in addition to remote ischemic preconditioning which will be done after induction and before cardiopulmonary bypass by inflating the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3 cycles
2953960|NCT02875483|Experimental|Expedited Scheduling|Group allocated to expedited scheduling practices
2953730|NCT02877225|Experimental|Treatment Sequence 1 : ABAB|Participants will receive 140 milligram (mg) of ibrutinib administered as one IMBRUVICA 140-mg oral capsule (Treatment A) in Period 1, 140 mg of ibrutinib administered as one ibrutinib 140-mg oral tablet (Treatment B) in Period 2, then Treatment A in period 3 and then followed by Treatment B in Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
2953731|NCT02877225|Experimental|Treatment Sequence 2 : BABA|Participants will receive (Treatment B) Period 1, then Treatment A in Period 2, then Treatment B in Period 3 and then followed by Treatment A in Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
2953732|NCT02877212|Experimental|Study subjects|Steroid refractory ITP patients will be given Eltrombopag to investigate the association of treatment outcome with Fc Receptor polymorphism and THPO expression in responders and non responders following comparison correlation with ITP patients treated with standard IST as control group
2953733|NCT02877199||HCV triple therapy|Cohort of HCV patients who received first-generation protease inhibitor-based triple therapy
2953734|NCT02877186|Experimental|Diet Soda|Consumption of diet soda three times daily for one week
2953735|NCT02877186|Placebo Comparator|Carbonated Water|Consumption of plain, unsweetened, carbonated water three times daily for one week
2953736|NCT02877173|Experimental|Alprostadil Liposomes for Injection|Alprostadil Liposomes for Injection at low dose:20ug,once a day,continuous administration for 3 weeks; Alprostadil Liposomes for Injection at medium dose:40ug,once a day,continuous administration for 3 weeks; Alprostadil Liposomes for Injection at high dose:60ug,once a day,continuous administration for 3 weeks;
2953737|NCT02877173|Active Comparator|Alprostadil Injection|Alprostadil Injection:10ug,once a day,continuous administration for 3 weeks;
2953738|NCT02877160|Experimental|Reference Formulation Fasted|150 mg of AL-794 study drug in suspension dosed in a fasted condition
2953739|NCT02877160|Experimental|Test Formulation Fasted|150 mg of AL-794 tablet formulation (3 x 50 mg tabs) dosed in a fasted condition
2953740|NCT02877160|Experimental|Test Formulation Fed|150 mg of AL-794 tablet formulation (3 x 50 mg tabs) dosed in a fed condition
2953741|NCT02877147|Experimental|$60 SEBTC Benefit Group|Households received $60 per summer month when school was not in session for each eligible child (Summers 2011-2013).
2953742|NCT02877147|Experimental|$30 SEBTC Benefit Group|Households received $30 per summer month when school was not in session for each eligible child (Summer 2013 only).
2953743|NCT02877147|No Intervention|No Intervention Group|Households with eligible children were not issued SEBTC benefits (Summers 2011 and 2012)
2953744|NCT02877134|Experimental|Part I : Placebo|Participants will receive placebo Subcutaneously (SC) at Weeks 0, 2, 4, 6, 8, and 10. From Week 12 Placebo-treated participants who are in clinical response at Week 12 (>=100-point reduction from baseline in Crohn's Disease Activity Index (CDAI) or CDAI <150) will continue to receive placebo SC injections every 2 weeks from Week 12 through Week 22. Placebo -treated participants who are not in clinical response at Week 12 will receive JNJ-64304500 400 mg SC at Week 12 and then JNJ-64304500 200 mg every two weeks from Week 14 through Week 22.
2953745|NCT02877134|Experimental|Part I : JNJ-64304500|Participants will receive JNJ-64304500 400 milligram (mg) SC at Week 0 then 200 mg SC every two weeks through Week 22.
2953746|NCT02877134|Experimental|Part II : Placebo|Placebo SC at Weeks 0, 2, 4, and 8. From Week 12, placebo-treated participants who are in clinical response at Week 12 (>=100-point reduction from baseline in CDAI or CDAI <150) will continue to receive placebo at Weeks 12, 14, 16, and 20. Placebo -treated participants who are not in clinical response at Week 12 will receive JNJ-64304500 150 mg SC at Week 12 and then JNJ-64304500 75 mg at Weeks 14, 16, and 20.
2953747|NCT02877134|Experimental|Part II : JNJ-64304500 High Dose|JNJ-64304500 400 mg SC at Week 0 and 200 mg SC at Weeks 2, 4, 8, 12, 16, and 20.
2953748|NCT02877134|Experimental|Part II : JNJ-64304500 Middle Dose|JNJ-64304500 150 mg SC at Week 0 and 75 mg SC at Weeks 2, 4, 8, 12, 16, and 20.
2953749|NCT02877134|Experimental|Part II : JNJ-64304500 Low Dose|JNJ-64304500 50 mg SC at Week 0 and 25 mg SC at Weeks 2, 4, 8, 12, 16, and 20.
2953750|NCT02877134|Experimental|Part II : Ustekinumab|Participants will receive tiered doses of Ustekinumab 260 mg (weight <=55 kg), Ustekinumab 390 mg (weight >55 kg and <=85 kg), Ustekinumab 520 mg (weight >85 kg) intravenously at Week 0 followed by 90 mg subcutaneously at Weeks 8 and 16.
2953751|NCT02877108||Adasuve|These patients will receive Adasuve for treatment of agitation.
2953752|NCT02877108||Haloperidol/Lorazepam|These patients will receive haloperidol/lorazepam for treatment of agitation.
2953753|NCT02877095|Experimental|Active|All subjects in the pilot study will receive the subcutaneous pump to administer a special formulation of furosemide to be delivered subcutaneously.
2953754|NCT02877082|Experimental|Tacrolimus, bortezomib, thymoglobulin|Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctor's discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.
2953755|NCT02877069|Experimental|VYC-12 Injectable Gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection on Day 0 in the face and if applicable neck areas. Participants are eligible to receive up to 3 treatments including an optional top-up and an optional second treatment.
2953756|NCT02877056||Colorectal Cancer|Participants undergo standard endoscopy before therapy. Tissue samples taken from the tumor and normal colorectal tissue.
2953757|NCT02877043||patients undergoing lung resection|
2953758|NCT02877030|Experimental|Test control group|Start the sensorimotor exercises protocol with video game immediately after the first evaluation
2953759|NCT02877030|Active Comparator|Control test group|Start of sensorimotor exercises with video game protocol after ten weeks
2953760|NCT02877030|No Intervention|comparison group|No intervention
2953761|NCT02877017|No Intervention|Pre-intervention arm|This arm is the pre-intervention arm of parents and providers before the family safety reporting bundle has been implemented.
2953762|NCT02877017|Experimental|Post-intervention arm|This arm is the post-intervention arm of parents and providers after the family safety reporting bundle has been implemented on the study units.
2953763|NCT02877004|Active Comparator|Laser for 4 weeks|3 Low-Level Laser Therapy Treatments Weekly
2953764|NCT02877004|Active Comparator|Laser for 6 weeks|2 Low-Level Laser Therapy Treatments Weekly
2953765|NCT02877004|Active Comparator|Laser for 12 weeks|1 Low-Level Laser Therapy Treatment Weekly
2953766|NCT02876991|Other|Sodium fluoride PET|"Before inclusion, patients undergo choline PET to assess an occult recurrence of prostate cancer.~After inclusion, they undergo sodium fluoride PET."
2953767|NCT02876978|Experimental|CAR-GPC3 T cells|"Intravenous infusion with escalating dose is adopted in this study.~Total dosage: 1 x 10^5 - 2 x 10^9 CAR-GPC3 T cells/kg~The next dose and interval depends on the response of the subject to previous dose.~Lymphodepletion:~Fludarabine: 30 mg/m^2/day x 4 days; Cyclophosphamide: 500 mg/m^2/day x 2 days. Adjustment is in discretion of the investigator based on individual response."
2953768|NCT02876965|Active Comparator|Physical Exercise|Aerobic physical exercise protocol of moderate intensity, for 24 weeks, 3 sessions per week, about 12 minutes. Physical activity chosen will be pedaling on a static bike.
2953769|NCT02876965|Experimental|Muscle Stretching|Stretching program at the end of the physical exercise on the main muscle groups of the body
2953770|NCT02876952|Active Comparator|Attention Control Group (AC)|Moderate to high- intensity physical activity and Mediterranean Diet recommendations
2953771|NCT02876952|Experimental|HV-HIIT|"Supervised high volume and high intensity interval training exercise group with Mediterranean Diet recommendations.~High-intensity [heart rate (HR) values up to second ventilatory threshold (VT2) to peak intensity] interval training and high-volume increasing gradually from 20 to 40 min and alternating high and moderate [HR values between first ventilatory threshold (VT1) and VT2] intensities at different protocols."
2953772|NCT02876952|Experimental|LV-HIIT|"Supervised low volume and high intensity interval training exercise group with Mediterranean Diet recommendations.~High-intensity (HR values up to VT2 to peak intensity) interval training and low-volume (20 min) alternating high and moderate (HR values between VT1 and VT2) intensities at different protocols."
2953773|NCT02876939|Experimental|HSAN III|
2953774|NCT02876939|Active Comparator|Control Subjects|
2953775|NCT02876926|Experimental|"Enhanced home-based testing"|"These participants will download a study-specific smartphone app (eTEST), and receive home-based HIV test kits in the mail every 3 months. These kits will have been fit with sensors that enable remote detection of when the kit was opened. Qualified HIV test counselors (QHTC) will then follow up with these participants within 24 hours of receiving notification that the test has been opened to conduct routine counseling, offer referrals for other services, and connect those with reactive results with follow-up care."
2953776|NCT02876926|Active Comparator|Home-based testing alone|These participants will receive a typical home-based test for HIV in the mail every 3 months, but no phone-based follow-up will be provided.
2953777|NCT02876926|Sham Comparator|Reminders for clinic-based testing|Participants in this condition will receive a letter in the mail every 3 months reminding them to be tested at a local clinic for free.
2953778|NCT02876913||Group Nasotracheal Intubation|Patients who are scheduled for nasotracheal intubation for general anesthesia
2953779|NCT02876900|Experimental|Low dose Asenapine maleate patch|Low dose asenapine maleate, transdermal patches will be compared against placebo patches.
2953780|NCT02876900|Experimental|High dose asenapine maleate patch|High dose asenapine maleate, transdermal patches will be compared against placebo patches.
2953781|NCT02876887|Active Comparator|Cocoa|Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.
2953782|NCT02876887|Placebo Comparator|Placebo|Three servings per day of placebo beverages for six months.
2953783|NCT02876874||the patients group|0.1ml, 5mg/ml indocyanine green(ICG) will be injected subcutaneously to aid visualization in NIR
2953784|NCT02876874||the health group|0.1ml, 5mg/ml indocyanine green(ICG) will be injected subcutaneously to aid visualization in NIR
2953785|NCT02876861|Active Comparator|Surgery alone|"Surgeons: the operation shall be performed by senior urologic surgeons. Try to achieve the consistency of operation quality.~Operation: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff or distal ureterectomy."
2953786|NCT02876861|Experimental|Neoadjuvant chemotherapy and Surgery|"Experimental: Neoadjuvant chemotherapy group~Neoadjuvant chemotherapy(Gemcitabine and Cisplatin):~Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.~Surgery:~2-3weeks after Neoadjuvant chemotherapy~Surgeons: the operation shall be performed by senior urologic surgeons. Try to achieve the consistency of operation quality.~Operation: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff or distal ureterectomy."
2953787|NCT02876848|Experimental|Intervention Site|"The hospital that will be the intervention site will have access to the OPTIMUM e-health tool. The intervention site cancer care team will receive the following OPTIMUM e-health alerts:~An electronic alert of increased Adjuvant Endocrine Therapy discontinuation risk.~An adherence to Adjuvant Endocrine Therapy monitor.~An electronic discontinuation occurrence alert"
2953788|NCT02876848|No Intervention|Control Site|The hospital that will be the control site will not have access to the OPTIMUM e-health tool. The cancer care team will continue to deliver care according to standard processes.
2953789|NCT02876835|Experimental|Daprodustat|Participants will receive oral daprodustat once daily.
2953790|NCT02876835|Active Comparator|Darbepoetin alfa|Participants will be administered darbepoetin alfa subcutaneously (SC).
2953791|NCT02876822|Experimental|Vitamin D|Enrolled subjects will receive one observed oral vitamin D dose (based on current vitamin D status and rounded to the nearest 5000IU) within 2 weeks prior to their HSCT.
2953792|NCT02876796|Experimental|50 mg GS-0976 (Cohort 1)|"Sequence 1:~Period 1 (2 days): 50 mg (1 x 50 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution~Sequence 2:~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 50 mg (1 x 50 mg capsule) + IV infusion 1-13C acetate and fructose solution"
2953793|NCT02876796|Experimental|200 mg GS-0976 (Cohort 2)|"Sequence 3:~Period 1 (2 days): 200 mg (1 x 200 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution~Sequence 4:~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 200 mg (1 x 200 mg capsule) + IV infusion 1-13C acetate and fructose solution"
2953837|NCT02876393||Control definition|Persons with a history of type 1 or type 2 DM without any clinical features of DR or DMO in either eye or persons without a history of DM and without retinal disease in either eye.
2953959|NCT02875483|Placebo Comparator|Standard Scheduling|Group allocated to follow standard surgical scheduling practices
2953794|NCT02876796|Experimental|20 mg GS-0976 (Cohort 3)|"Sequence 5:~Period 1 (2 days): 20 mg (2 X 10 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution~Sequence 6:~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 20 mg (2 X 10 mg capsule) + IV infusion 1-13C acetate and fructose solution"
2953795|NCT02876770|Experimental|Melatonin|
2953796|NCT02876770|Placebo Comparator|Placebo|
2953797|NCT02876757||5ARI Users|
2953798|NCT02876757||Non 5ARI users|
2953799|NCT02876731|Other|single group|PET-CT MRI
2953800|NCT02876718||Rivaroxaban, BAY59-7939|It is a single-arm study in which only patients who switched from a VKA to a NOAC treatment will be included.
2953801|NCT02876705|Experimental|Pain Patterns|In this vein, we tend to study and delineate individualized pain and discomfort patterns in exercise.
2953802|NCT02876679|Experimental|Cyclophosphamide|50mg/Kg/day cyclophosphamide (day +3 and +4)
2953803|NCT02876679|Active Comparator|Anti-Thymocyte Globulin|2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1)
2953804|NCT02876666|Experimental|Coach Intervention|
2953805|NCT02876666|No Intervention|Usual Care|
2953806|NCT02876653|Other|Severe OSA|Patients with severe OSA (AHI > 30)
2953807|NCT02876653|Other|Moderate OSA|Patients with moderate OSA (5 < AHI ≤ 30)
2953808|NCT02876653|Other|Healthy volunteers|Healthy volunteers (AHI ≤ 5)
2953809|NCT02876640|Experimental|Treatment (retinoid 9cUAB30)|Patients receive retinoid 9cUAB30 PO QD for 14 to 28 days. Patients then undergo tumor resection surgery.
2953810|NCT02876627|Experimental|breast cancer|Effect of exercise training on breast cancer patient
2953811|NCT02876601|Active Comparator|LPS|2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa
2953812|NCT02876601|Placebo Comparator|Placebo|Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa
2953813|NCT02876588|Active Comparator|Unrestricted|"Users have unrestricted access to open up to a maximum of 4 patient records at a time in the EHR"
2953814|NCT02876588|Active Comparator|Restricted|"Users have restricted access to open a maximum of 1 patient record at a time in the EHR"
2953815|NCT02876575|Other|A bipolar instrument for tonsillectomies|
2953816|NCT02876562|Experimental|root coverage with collagen matrix|evaluation of root coverage achieved by collagen matrix in conjunction with modified coronally advanced tunnel in patients with multiple gingival recession
2953817|NCT02876562|Active Comparator|root coverage with connective tissue graft|evaluation of root coverage achieved by connective tissue graft in conjunction with modified coronally advanced tunnel in patients with multiple gingival recession
2953818|NCT02876549|Experimental|G6PD Normal|
2953819|NCT02876549|Experimental|G6PD Deficient|
2953820|NCT02876536|Experimental|TNES with sending electrical impulses|The MS patients will receive electrical impulses by TENS device for 30 minutes a day, for 5 days a week and in 6 weeks
2953821|NCT02876536|Sham Comparator|TENS without sending electrical impulses|The MS patients will use the TENS device for 30 minutes a day, for 5 days a week and in 6 weeks without receiving any electrical impulses
2953822|NCT02876523||Patients with a hilar biliary stricture requiring a drainage|Drainage performed by endoscopy, echo-endoscopy or percutaneously
2953823|NCT02876510|Experimental|Treatment|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~Infusion of the IMA101 T-cell product(s)~Post-infusion administration of low-dose recombinant human interleukin-2"
2953824|NCT02876497|Experimental|Study arm|
2953825|NCT02876484|Experimental|Placebo|"Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM.~25 ml water"
2953826|NCT02876484|Experimental|Chenodeoxycholic Acid|"Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM.~Chenodeoxycholic acid (1250 mg) mixed in 25 ml yoghurt."
2953827|NCT02876484|Experimental|Colesevelam|"Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM.~Colesevelam (3,75 g) dissolved in 25 ml water and mixed in 25 ml yoghurt"
2953828|NCT02876471|No Intervention|OSA group|100 severe OSA patients without hypertension were enrolled. Primal evaluations including office blood pressure, Epworth sleepiness scale score(ESS),demographic and anthropometric data The full night polysomnogram was performed, recording nocturnal blood pressure, oximetry, beat-to-beat BPV, AHI, BP event was calculated
2953829|NCT02876471|Other|OSA with hypertension|100 severe OSA patients with hypertension were enrolled. Primal evaluations including office blood pressure, Epworth sleepiness scale score(ESS), antihypertensive medicine demographic and anthropometric data. The full night polysomnogram was performed, recording nocturnal blood pressure, oximetry, beat-to-beat BPV, AHI, BP event was calculated.Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood pressure control, the investigators would give one-night CPAP.
2953830|NCT02876458|Other|Immediate coronary angiogram|An immediate coronary angiogram will be performed
2953831|NCT02876458|Other|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 96 hours) will be performed
2953832|NCT02876445|Other|Caregiver Evaluation|ZARIT Burden Interview
2953833|NCT02876432|Experimental|Device: Electroacupuncture|"The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes"
2953834|NCT02876432|Sham Comparator|Device: Sham Electroacupuncture|In sham electroacupuncture (Sham) the investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
2953835|NCT02876432|Active Comparator|Drug: Diclofenac sodium|100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.
2953838|NCT02876380||Prospective cohort|These are women who are currently pregnant and who have a LQTS mutation. This also includes women whose partner/father of the baby has a LQTS mutation. If the father of the child has the LQTS mutation, the father will also be enrolled.
2953839|NCT02876380||Retrospective cohort|In this cohort the investigators will collect information about previous pregnancies affected by the LQTS mutation. Parents may enroll in both retrospective and prospective cohorts
2953840|NCT02876367||Acute scrub typhus (Group 1)|Participants presenting with a fever will be verbally consented for a scrub typhus RDT, using <1ml of blood that is likely to be taken as part of routine clinical assessment. If the RDT tests positive, the patient will be informed about the study and asked to give written informed consent. If they agree to join the study, participants will be asked to give a further blood sample of 10mls (2 teaspoons) for ELISA, PCR and culture testing to confirm the presence of scrub typhus.
2953841|NCT02876367||Scrub typhus serosurvey (Group 2)|Villagers who are living in an identified scrub typhus environment will be informed about the study and asked to give written informed consent. If they agree to join the study they will be asked to give a finger prick dried blood spot (DBS) test on which scrub typhus ELISA and IFA will be performed.
2953842|NCT02876354|Experimental|Menaquinone 360|All patients in the study will be assigned to receive menaquinone 360 μg /d for 4 weeks.
2953843|NCT02876341||No chronic antihypertensives|Not on either a chronic β-blocker or ACE-Inhibitor
2953844|NCT02876341||Chronic antihypertensives|On a chronic β-blocker, on chronic ACE-Inhibitor, or on both chronic β-blocker and ACE-inhibitor
2953845|NCT02876328|Experimental|Ad26.ZEBOV (rHAd26) vaccine + MVA-BN-Filo (MVA) boost|Participants will receive the Ad26.ZEBOV (rHAd26) vaccine at Day 0 followed by an MVA-BN-Filo (MVA) boost at Day 56.
2953846|NCT02876328|Placebo Comparator|Placebo (0.5 mL)|Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.
2953847|NCT02876328|Experimental|rVSVΔG-ZEBOV-GP (rVSV) vaccine + placebo boost|Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by a placebo boost at Day 56.
2953848|NCT02876328|Experimental|rVSVΔG-ZEBOV-GP (rVSV) vaccine + rVSV boost|Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by an rVSV boost at Day 56.
2953849|NCT02876328|Placebo Comparator|Placebo (1 mL)|Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.
2953850|NCT02876315|Experimental|Redoxon VI|2 film coated tablets Redoxon VI oral intake daily for 12 weeks
2953851|NCT02876315|Placebo Comparator|Placebo|2 film coated tablets placebo oral intake daily for 12 weeks
2953852|NCT02876302|Experimental|Paclitaxel (12weeks)|"Paclitaxel is administered weekly followed by standard Doxorubicin and Dyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively~16 patients will be randomized from the Run-In 7 days of Ruxolitinib~The drug will be administered at a pre-determine dosage"
2953853|NCT02876302|Experimental|Ruxolitinib with Paclitaxel (12weeks)|"Paclitaxel is administered with daily Ruxolitinib, followed by standard Doxorubicin and Cyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively~16 patients will be randomized from the Run-In 7 days of Ruxolitinib~The drug will be administered at a pre-determine dosage"
2953854|NCT02876302|Experimental|Ruxolitinib and Paclitaxel (12weeks)|"Paclitaxel is administered with daily Ruxolitinib, followed by standard Doxorubicin and Cyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively~32 patients will be randomized from the Run-In 7 days of Ruxolitinib + Paclitaxel~The drug will be administered at a pre-determine dosage"
2953855|NCT02876289||patients treated with Perampanel|
2953856|NCT02876276|Active Comparator|HA filler group|6 weeks after the initial therapy, patients were scheduled for the procedure.16 Local Anesthetic solution (2% Lignocaine HCl with adrenaline 1:80000) was administered.17 About 0.2 ml of a commercially available hyaluronic acid based gel was injected 2-3 mm coronal to the apical tip of the receded interdental papilla . Injections were performed using 23 gauge X 25mm intraoral injection needles . The concentration of HA gel used was 20 mg/ml.6 The area was gently massaged to ensure that the filler was uniformly distributed. Care was taken to fill each papilla to full correction (100% of defect). After the treatment the individual patient syringes were capped and stored in a refrigerator with patient names and details. The needle was discarded. Patients were seen three weeks after the initial treatment and if augmentation was still deemed necessary, another injection of 0.2ml was injected up to three times
2953857|NCT02876276|Placebo Comparator|saline filler group|with saline same protocol was performed as mentioned in test group
2953858|NCT02876263||Study group|Elective and emergency surgery for aneurysm or dissections of the ascending aorta, operated under extracorporeal circulation, protective deep therapeutic hypothermia and circulatory arrest.
2953859|NCT02876263||On-pump CABG Group|Elective coronary artery bypass grafting (CABG) for coronary heart disease under extracorporeal circulation
2953860|NCT02876263||OPCAB Group|Elective coronary artery bypass grafting (CABG) for coronary heart disease with a beating heart
2953861|NCT02876250|Experimental|Cyclosporine A|a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
2953862|NCT02876250|Placebo Comparator|Control|a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
2953863|NCT02876237|Experimental|geriatric assessment and quality of life|"Included patient must have a geriatric assessment before radiotherapy and 6 months later.~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later."
2953864|NCT02876224|Experimental|Cobimetinib + Bevacizumab + Atezolizumab (Stage 1: SRP)|Stage 1 Safety Run-in Phase (SRP): Approximately 12 participants will receive cobimetinib 60 milligrams (mg) orally once daily for Days 1-21 with atezolizumab 840 mg and bevacizumab 5 milligrams per kilogram (mg/kg) administered by IV infusion on Days 1 and 15 of each 28-day cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Upon determination of the safety and tolerability of the treatment regimen, the study will proceed to Stage 2: dose expansion phase. If the results from the safety run-in phase require dose reduction in cobimetinib, then an additional Stage 1 cohort will be opened. Treatment will continue until the participant has disease progression according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
2953956|NCT02875496||Early Alzheimer Disease|Subjects meeting criteria for Early Alzheimer Disease No intervention administered
2953865|NCT02876224|Experimental|Cobimetinib + Bevacizumab + Atezolizumab (Stage 2: BC)|Stage 2 Biopsy Cohort (BC): Approximately 7 evaluable participants in the biopsy cohort in expansion phase will receive bevacizumab 5 mg/kg IV on Cycle 1 Days 1 and 15 (tumor biopsy on Cycle 1 Day 8) and cobimetinib (at dose determined during safety run-in phase) orally on Cycle 1 Day 15 to Cycle 2 Day 14 (tumor biopsy on Cycle 1 Day 22). From Cycle 2 onwards, participants will follow the same treatment regimen for bevacizumab and atezolizumab (optional tumor biopsy on Cycle 2 Day 22) as those in the safety run-in phase and expansion cohort, and for cobimetinib cycles start at Day 15 and will continue 21 days to Day 7 of next cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Biopsies must be collected before the initiation of cobimetinib and atezolizumab. Treatment will continue until disease progression according to RECIST v1.1, unacceptable toxicity, death, decision to withdraw, or pregnancy, whichever occurs first.
2953866|NCT02876224|Experimental|Cobimetinib + Bevacizumab + Atezolizumab (Stage 2: EC)|Stage 2 Expansion Cohort (EC): Approximately 14 participants will receive cobimetinib (at dose determined during safety run-in phase) orally once daily for Days 1-21 with atezolizumab 840 mg and bevacizumab 5 mg/kg administered by IV infusion on Days 1 and 15 of each 28-day cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Treatment will continue until the participant has disease progression according to RECIST v1.1, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
2953867|NCT02876211|Experimental|paricalcitol plus epoetin beta|Paricalcitol 2 capsules /three times per week & epoetin
2953868|NCT02876211|Placebo Comparator|placebo plus epoetin beta|Placebo 2 capsules/three times per week & epoetin
2953869|NCT02876198||Patients treated with anti-VEGF|
2953870|NCT02876185||Patients with glaucoma|Patients presenting an open-angle glaucoma or ocular hypertension
2953871|NCT02876172|Experimental|MDMA and CBCT|Cognitive-behavioral conjoint therapy and 2 sessions of MDMA-assisted psychotherapy.
2953872|NCT02876159|Experimental|Vaccination Naïve|Participants who have received an influenza vaccine in 2 or less of the past 5 years will receive the FDA-approved 2016-2017 influenza vaccine.
2953873|NCT02876159|Experimental|Vaccination Experienced|Participants who have received an influenza vaccine at least 3 of the past 5 years will receive the FDA-approved 2016-2017 influenza vaccine.
2953874|NCT02876146|Other|Hepatic alveolar echinococcosis|"Follow-up of standardized clinical, biological, and imaging characteristics (according to the WHO-expert consensus). Albendazole treatment, 400 mg x 2/d (or mebendazole if adverse effects)~Standardized earlier withdrawal of benzimidazole :~Patients with non operable hepatic AE lesion : Withdrawal of benzimidazole treatment for patients without metastasis or neighbouring lesions (PxN0M0) after at least 4 years when viability markers became negative (PET-CT, serological markers)~Curative hepatectomy : Earlier withdrawal of benzimidazole treatment for patients without metastasis or neighbouring lesions (PxN0M0) after one year (WHO guidelines : 2 years), if viability markers became negative. Close prospective follow-up after withdrawal (PET-CT, serological markers)"
2953875|NCT02876133|Experimental|Narrow band imaging withdrawal|colonoscope withdrawal and mucosal inspection performed under narrow band imaging
2953876|NCT02876133|Placebo Comparator|white light withdrawal|colonoscope withdrawal and mucosal inspection performed under white light imaging
2953877|NCT02876120|Other|Pre- and post-implementation phases|"Pre-implementation phase: during the pre-implementation period persons with hip or knee osteoarthritis will receive usual care as it is currently delivered by physiotherapists and general practitioners.~Post-implementation phase: during the post-implementation phase the GPs and PTs will treat persons with hip or knee osteoarthritis according to the START treatment model including providing information/patient education program, supervised exercise and advice/support to loose weight and other non-surgical evidence based treatments modalities prior to being referred to an orthopaedic surgeon"
2953878|NCT02876107|Experimental|PaCT + Doxorubicin and Cyclophosphamide.|"Participants receive panitumumab, carboplatin, and paclitaxel (PaCT) followed by doxorubicin and cyclophosphamide.~Breast core biopsy performed before Day 1 of Cycle 1 for biomarker testing.~Paclitaxel given by vein on Days 1, 8, and 15 of Cycles 1-4. Carboplatin given by vein on Day 1 of Cycles 1-4. Panitumumab by vein on Day 1 of a 1-week pre-cycle. Participants then receive it on Days 1, 8, and 15 of Cycles 1-4, before paclitaxel.~Doxorubicin and cyclophosphamide given by vein on Day 1 of Cycles 5-8.~Study cycle is 21 days.~Before receiving doxorubicin and cyclophosphamide, mammogram of the involved breast and an ultrasound of the involved breast and lymph nodes performed.~Study staff checks on participant about 1 month after surgery, and once each year for at least 5 years after participant stops taking the study drugs."
2953879|NCT02876107|Experimental|CT + Adriamycin and Cyclophosphamide (AC)|"Participants receive carboplatin and paclitaxel (CT) followed by doxorubicin and cyclophosphamide (AC).~Paclitaxel given by vein on Days 1, 8, and 15 of Cycles 1-4. Carboplatin given by vein on Day 1 of Cycles 1-4.~Doxorubicin and cyclophosphamide given by vein on Day 1 of Cycles 5-8.~Study cycle is 21 days.~Before receiving doxorubicin and cyclophosphamide, mammogram of the involved breast and an ultrasound of the involved breast and lymph nodes performed.~Study staff checks on participant about 1 month after surgery, and once each year for at least 5 years after participant stops taking the study drugs."
2953880|NCT02876094|Experimental|Open-label|All patients will be treated at each dose of oral once daily celecoxib (40, 80 and 160 mcg/kg) for a period of two weeks, for a total of 6 weeks (42 days) of treatment.
2953881|NCT02876055|Active Comparator|Single shot interscalene nerve block|An interscalene nerve block will be performed under continuous live ultrasound guidance, obtaining visualization of the roots or trunks of the brachial plexus in between the anterior and middle scalene muscles. 15 to 20 mL of Bupivacaine 0.5% with 1:200,000 Epinephrine will be administered.
2953882|NCT02876055|Active Comparator|Continuous interscalene nerve block|"An interscalene nerve block and delivery of a catheter will be performed under continuous live ultrasound guidance, obtaining visualization of the roots or trunks of the brachial plexus in between the anterior and middle scalene muscles.~Initial loading bolus includes 15 to 20 mL of Bupivacaine 0.5% with 1:200,000 Epinephrine. After surgery, the continuous interscalene nerve block catheter will be loaded in the PACU with bupivacaine 0.2% 10 milliliters (mL), and then an infusion will be initiated of bupivacaine 0.2% at 8 to 10 mL per hour."
2953957|NCT02875496||Depression|Subjects meeting criteria for Depression No intervention administered
2953958|NCT02875496||MCI-Mild Cognitive Impairment|Subjects meeting criteria for MCI-Mild Cognitive Impairment No intervention administered
2953883|NCT02876055|Experimental|Local Infiltration Analgesia (LIA)|"The LIA group will utilize weight based dosing of Ropivacaine as part of a cocktail solution containing ropivacaine, epinephrine, ketorolac, and normal saline 0.9%. Patients will receive a total volume of 120 mL injected strategically in the periarticular structures by the surgeon. This is a one-time injection. This will occur after implantation of the final prostheses, but prior to closure of the fascia."
2953884|NCT02876029|Other|Reference|White wheat bread
2953885|NCT02876029|Other|Test product|Pasta
2953886|NCT02876016|Experimental|awake brain surgery|Exploration of the cortical area of the brain awake surgery
2953887|NCT02876003|Experimental|G-202 (Mipsagargin)|G-202 (Mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
2953888|NCT02875990|Experimental|patients with invasive cervical cancer|Blood sample
2953889|NCT02875977|Experimental|Educational video|A 4 minute educational video created by the division, to be viewed after being prescribed PFPT.
2953890|NCT02875977|No Intervention|Patient Handout|A 2 page patient educational handout, to be viewed after being prescribed PFPT.
2953891|NCT02875964|Experimental|registration of intracerebral activity|epileptic patient receiving implantation of intracranial electrodes
2953892|NCT02875951||ER positive, HER2 negative breast cancer patients|Postmenopausal patients with hormone receptor positive, HER2 receptor negative breast cancer
2953893|NCT02875938|Experimental|Music and reading lyrics|A single-subject adapted alternating treatment design will be used to compare two music conditions, using music with sung lyrics simultaneously with silent reading of the lyrics, and priming with music and sung lyrics followed by reading of the lyrics, with a control condition using reading materials without music.
2953894|NCT02875925|Experimental|MTM|Patients will receive MTM at an individualized frequency for 1 year.
2953895|NCT02875925|No Intervention|Control|Patients enrolled in the control group will not experience any change in their medical care.
2953896|NCT02875912|No Intervention|Usual Care|Family members are surveyed at enrollment, day 5 (if patient is still in ICU), and 90 days post ICU discharge for symptoms of PTSD, depression, and anxiety as well as for concordance of care at enrollment and ICU day 5. Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed to establish baseline data
2953897|NCT02875912|Experimental|Family Care Rituals Intervention|At enrollment, family members are given a handout/pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so. The families are then surveyed in the same way as they were during the usual care, with nursing completing the same surveys as well to compare against the baseline data
2953898|NCT02875886|Active Comparator|Diuretic treatment|Patients receive amiloride and hydrochlorothiazide
2953899|NCT02875886|Active Comparator|Low-sodium diet|Patients are put on a low-sodium diet (60 mmol/day)
2953900|NCT02875873|Experimental|Plasma-Lyte, Slow Infusion|Plasma-Lyte will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h.
2953901|NCT02875873|Experimental|Plasma-Lyte, Fast Infusion|Plasma-Lyte will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h.
2953902|NCT02875873|Experimental|Saline 0.9%, Slow Infusion|Saline 0.9% will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h.
2953903|NCT02875873|Experimental|Saline 0.9%, Fast Infusion|Saline 0.9% will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h.
2953904|NCT02875860|No Intervention|Standardized postnatal care (Expectant)|Mothers will be expectantly managed during pregnancies and babies receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website.
2953905|NCT02875860|Experimental|Prenatal Intervention (FETO)|Patients will undergo fetoscopic endoluminal tracheal occlusion and ideally prenatal reversal of the occlusion followed by standardized postnatal care as in the expectant . In this study FETO (where GoldBal2 detachable balloon and Baltaccidbpe100 Delivery Catheter are used) is to be done between 30 weeks plus 0 day and 31 weeks plus 6 days and removal of the balloon at 34 weeks plus 0 day to 34 weeks plus 6 days.
2953906|NCT02875847|Active Comparator|HMO1|Daily bolus of HMO1
2953907|NCT02875847|Active Comparator|HMO2|Daily bolus of HMO2
2953908|NCT02875847|Placebo Comparator|Dextropur|Daily bolus of dextropur
2953909|NCT02875834|Experimental|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
2953910|NCT02875834|Experimental|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
2953911|NCT02875834|Placebo Comparator|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
2953912|NCT02875821|Experimental|Group IMP|Group IMP (Ipragliflozin with Metformin with Pioglitazone)
2953913|NCT02875821|Active Comparator|Group MP|Group MP (Metformin with Pioglitazone)
2953914|NCT02875808||patients|patients with an external ventricular drainage
2953915|NCT02875795|Experimental|speech intelligibility|speech intelligibility is registered by an automatic speech processing tool
2953916|NCT02875782|Experimental|DM intervention|Subjects will receive a patient-centered motivational intervention with two components: (1) the stage-matched smoking cessation intervention and (2) the relationship between smoking and diabetic complications. All subjects will receive a self-help cessation manual with DM components and take the exhaled carbon monoxide test. The total counseling process will take about 20 minutes. Three consecutive (3-, 6- and 12-month) follow ups will be conducted. Also, the counselor will further the progress of their action plan and barriers encountered in the behavioral change process as well as engage them in the process, enhance their self-efficacy, and identify individual barriers and facilitators.
2953917|NCT02875782|Placebo Comparator|Control group|Subjects will receive usual care provided at the DM clinic. All subjects will receive a self-help cessation manual and take the exhaled carbon monoxide test. Counselor will give follow-up calls to the patients to assess their smoking status and other health-related lifestyle practices. Three consecutive (3-, 6- and 12-month) follow ups will be conducted with all participants. The total counseling process will take about 20 minutes.
2953918|NCT02875769|Experimental|Test: Mouthwash CPC+Zn+F|To rinse with pre-procedural mouthwash containing 0.075% cetylpyridinium chloride, 0.28% zinc lactate and 0.05% sodium fluoride in an Alcohol-free base (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
2953919|NCT02875769|Active Comparator|Positive control: Mouthwash CHX|To rinse with pre-procedural mouthwash containing 0.12% CHX with 10% alcohol (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
2953920|NCT02875769|Placebo Comparator|Negative control A: No rinsing|No rinsing with pre-procedural mouthwash + full mouth dental prophylaxis using ultrasonic scaler.
2953921|NCT02875769|Placebo Comparator|Negative control B: Water|To rinse with pre-procedural mouthwash containing water from a three-way syringe (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
2953922|NCT02875756|Experimental|10 revolutions|In this group, 10 revolutions will be made with the EBUS-TBNA needle
2953923|NCT02875756|Active Comparator|20 revolutions|In this group, 10 revolutions will be made with the EBUS-TBNA needle
2953924|NCT02875743|Experimental|Posaconazole|
2953925|NCT02875730|Experimental|CMRI Pulse Sequence|Patients will have late gadolinium cardiac magnetic resonance images of the individual pulmonary veins acquired with the standard and the cylindrical navigator preparatory pulse sequences for comparison.
2953926|NCT02875717||Control|
2953927|NCT02875717||Acetylsalicylic acid|Patients that were on medication with Acetylsalicylic acid on the date of shockwave lithotripsy
2953928|NCT02875717||Low Molecular weight heparin|Patients that were on medication with low molecular heparin on the date of shockwave lithotripsy
2953929|NCT02875704||Stargardt disease, AMD, DR patients|Stargardt disease, Age Related Macular Degeneration, Diabetic Retinopathy patients
2953930|NCT02875704||Controls|Patients without retinal disease who will be undergoing cataract surgery
2953931|NCT02875691|Active Comparator|green tea extract|Patients were given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules (500 mg) for three months.
2953932|NCT02875691|Placebo Comparator|Placebo|Patients in placebo group received daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
2953933|NCT02875678|Experimental|ABX-1431|ABX-1431, capsules, 40 mg, single dose
2953934|NCT02875678|Placebo Comparator|Placebo|Placebo, capsules, single dose
2953935|NCT02875665|Experimental|geko device arm|geko™ devices (acting on the posterior tibial nerve) to be used on alternate days over seven days, for an hour per day
2953936|NCT02875652|Experimental|Blood sampling|
2953937|NCT02875639|Experimental|tonifying qi group|tonifying qi group:which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng,and so on)
2953938|NCT02875639|Experimental|activating blood group|which treated by a kind of Chinese patent medicine (major components: Honghua,Taoren,Danggui，and so on)
2953939|NCT02875639|Experimental|qi and blood group|which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng，Honghua,Taoren,Danggui，and so on)
2953940|NCT02875639|Active Comparator|QISHEN YIQI DRIPPING PILLS group|which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng，and so on)
2953941|NCT02875639|Sham Comparator|placebo group|which treated by the simulation of Chinese patent medicine (major components:excipient)
2953942|NCT02875626|Experimental|Infracyanine|In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).
2953943|NCT02875613|Experimental|Avelumab|Avelumab 10mg/kg IV infusion on days 1 and 15 of 28-day cycle
2953944|NCT02875600|Experimental|Nutri drink|MRI flow measurements of mesenterial vessels and portal vein before and after stimulation with nutritional drink
2953945|NCT02875587|Active Comparator|Cabergoline group|Cabergoline is administered starting on the day of HCG administration.
2953946|NCT02875587|Experimental|Calcium gluconate infusion group|Calcium gluconate is administered starting on the day of HCG administration.
2953947|NCT02875574||All participants|
2953948|NCT02875561|Active Comparator|Sonopet Ultrasonic Aspirator|Treatment of VIN dysplasia with sonopet ultrasonic aspirator: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
2953949|NCT02875561|Experimental|CO2 Laser Ablation|Treatment of VIN dysplasia with CO2 Laser Ablation: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
2953950|NCT02875548|Experimental|Open-label Tazemetostat|Subjects will continue to receive the same tazemetostat dose and schedule as specified in their antecedent tazemetostat protocol. For subjects on combination therapy, the other therapeutic(s) must have been completed in the antecedent study or be provided by a source other than Epizyme if combination treatment is continued in this clinical rollover study.
2953951|NCT02875535|No Intervention|Usual Care|Standard school nurse care for suicide prevention.
2953952|NCT02875535|Experimental|RLAS|Through the RLAS, the investigators will train school nurses statewide. Using the Dynamic Adaptation Process, the nurses will then convene and lead Implementation Resource Teams (IRTs). With the assistance of RLAS coaches, the school nurse-led IRTs will engage in an iterative process of assessment and planning to build school capacity and implement up to six evidence-base strategies to reduce adolescent suicide.
2953953|NCT02875522|Experimental|Patients with COPD|Stable patients with COPD participated in an 8-week (24 session) individualized, non-linear aerobic exercise training program consisting of upper and lower body cycle ergometry.
2953954|NCT02875522|Active Comparator|Healthy Controls|Age, sex, BMI and activity matched controls participated in an 8-week (24 session) individualized, non-linear aerobic exercise training program consisting of upper and lower body cycle ergometry.
2953955|NCT02875496||Healthy aging|Subjects meeting criteria for healthy aging No intervention administered
2953961|NCT02875470|Experimental|Intensiv Perio Set|Root planing with diamond burs
2953962|NCT02875470|Active Comparator|Gracey curette|Root planing with Gracey curettes
2953963|NCT02875457|Experimental|Arm A|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, and apatinib 250mg/d , repeated every 21 days, a total of 6 cycles, and then continue to take apatinib 250mg/d until progressive Disease(PD).
2953964|NCT02875457|Placebo Comparator|Arm B|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, and placebo, repeated every 21 days, a total of 6 cycles, and then continue to take placebo until PD.
2953965|NCT02875444||"group abdominal aortic aneurysm"|Patients with non-operated abdominal aortic aneurysm with angio-CT realized between 01/01 2010 au 04/15/2012
2953966|NCT02875431||ACDF or cervical vertebral body replacement|
2953967|NCT02875418|Experimental|EUM and tocodynamometry|Pregnant women with gestational age 24+0/7 to 33+6/7 weeks of gestation and contractions, cramping, pelvic pressure or backache.
2953968|NCT02875405|Experimental|Received pericardiotomy|Patient will receive a posterior left pericardiotomy at the time of surgery
2953969|NCT02875405|No Intervention|No Pericardiotomy|Patient will not receive posterior left pericardiotomy.
2953970|NCT02875392|Experimental|Fucoidan use|FucoHiQ(275mg Oligo Fucoidan + 275mg HS Fucoxanthin) 550mg/capsule 6 per day(before breakfast and supper)
2953971|NCT02875392|Placebo Comparator|placebo pills|placebo capsule 6 per day (before breakfast and supper)
2953972|NCT02875379|Experimental|HME|Passive humidification with heat and moisture exchanger, Y-piece circuit.
2953973|NCT02875379|Experimental|HH33|Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
2953974|NCT02875379|Experimental|HH37|Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
2953975|NCT02875379|Experimental|NoH|Passive humidification, double tube circuit
2953976|NCT02875366|Experimental|LUM/IVA|LUM 400 mg every 12 hours (q12h)/IVA 250 mg q12h
2953977|NCT02875366|Experimental|Placebo|Placebo
2953978|NCT02875353|Other|Standard endoscopy (not experimental)|For Standard treatment group, the Doppler probe will not be used, nor will hemoclip closure of post-polypectomy ulcers be attempted. Standard published guidelines will be followed for management of blood thinners (anti-coagulants) and/or aspirin like drugs (anti-platelet drugs) before and after the colonoscopic polypectomies. This is the standard of care at the investigators' medical centers and part of written instructions that are given to the participants and their referring physicians during the scheduling process and prior to their preparation for screening or surveillance outpatient colonoscopies.
2953979|NCT02875353|Experimental|Doppler treatment (experimental)|A colon length catheter (probe) will be used to check the non-bleeding post-polypectomy ulcer with shallow and medium depth Doppler probe settings (< 4 mm deep) for arterial blood flow. If arterial flow is found, treatment through the colonoscope (either hemoclipping or multipolar electrocoagulation probe) will be used to stop the arterial flow. This will be confirmed by rechecking with Doppler probe after endoscopic treatment. Tatoos (Spot method) will be placed on two sides of the ulcer so treated.
2953980|NCT02875314|Experimental|Induction|"The 5 chemotherapy drugs used in the Induction part of treatment are vincristine, cisplatin, cyclophosphamide, etoposide and high-dose methotrexate.~Three medications are also given to help reduce the side effects of the chemotherapy drugs. Filgrastim will be given through a vein or through a tiny needle into the tissue just under the skin to help blood counts recover after the chemotherapy. Mesna will be given through a vein with cyclophosphamide to help prevent bleeding in the bladder. Leucovorin will be given through a vein after the methotrexate to protect the body from the side effects of the methotrexate."
2953981|NCT02875314|Experimental|Single Cycle Intensive Chemotherapy|"The three drugs to be used in this research study are thiotepa, etoposide and carboplatin. These drugs will be given over 6 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.~Carboplatin is given by vein over 4 hours. Thiotepa is given by vein over 3 hours. Etoposide is given by vein over 3 hours. The schedule for these drugs is as follows:~Day -8: Carboplatin Day -7: Carboplatin Day -6: Carboplatin Day -5: Thiotepa, Etoposide Day -4: Thiotepa, Etoposide Day -3: Thiotepa, Etoposide Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells"
2953982|NCT02875314|Experimental|Tandem 3 Cycle Intensive Chemotherapy|"The 2 drugs to be used in this treatment are thiotepa and carboplatin. These drugs will be given over 2 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.~Day -4: Thiotepa, Carboplatin Day -3: Thiotepa, Carboplatin Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells.~Following recovery from the first cycle of this chemotherapy, about 28 days following the Day 0 reinfusion of blood cells, the same cycle will be repeated again. A total of 3 cycles of this therapy will be administered, over the course of 12 weeks."
2953983|NCT02875301|Experimental|150 Minutes Week|Participants engage in supervised 12 month moderate intensity aerobic exercise intervention with goal of maintaining 150 minutes of exercise per week.
2953984|NCT02875301|Experimental|225 Minutes Week|Participants engage in supervised 12 month moderate intensity aerobic exercise intervention with goal of maintaining 225 minutes of exercise per week.
2953985|NCT02875301|Active Comparator|Stretch and Tone|Participants engage in supervised 12 month non-cardiorespiratory activity intervention. This group has focus on improving balance, flexibility, and strength.
2953986|NCT02875288|Experimental|Liposomal Bupivicaine arm|"Post procedure, infiltrate wounds with liposomal bupivacaine~Liposomal Bupivacaine (Brand name Exparel) 266 milligram (mg)/20 mL to be diluted to 30 mL with normal saline~10 mL of study drug to be injected at each 10-12 millimeter (mm) trocar site and 5 mL of study drug to be injected at the 5 mm trocar sites. Typically there are two 10 mm trocar sites and three 5 mm trocar sites."
2953987|NCT02875288|Active Comparator|Plain Bupivicaine|"Post procedure, infiltrate wounds with plain bupivicaine~Plain Bupivacaine 0.25%, volume of 30 mL~10 mL of study drug to be injected at each 10-12 millimeter (mm) trocar site and 5 mL of study drug to be injected at the 5 mm trocar sites. Typically there are two 10 mm trocar sites and three 5 mm trocar sites."
2953988|NCT02875275|No Intervention|Glucose Solution only|Control drink containing 50 g carbohydrate
2953989|NCT02875275|Active Comparator|Glucose with grass jelly solution|Control drink plus 3.12 g grass jelly powder
2953990|NCT02875275|Active Comparator|Glucose with grass jelly (solid)|Control drink plus 3.12 g grass jelly powder in solid form
2953991|NCT02875275|No Intervention|Porridge and juice only|Control breakfast containing 50 g carbohydrate.
2953992|NCT02875275|Active Comparator|Porridge and juice with coconut oil|Control breakfast, plus 25g coconut oil
2953993|NCT02875275|Active Comparator|Porridge and juice with coconut oil gel|Control breakfast, plus 25g coconut oil gel
2953994|NCT02875262|Experimental|Treatment|Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day. duration 3 days
2953995|NCT02875262|Placebo Comparator|placebo|NaCl 0.9% in similar dosis to treatment arm
2953996|NCT02875236|Placebo Comparator|Control|Ringer-acetat
2953997|NCT02875236|Active Comparator|Intervention|OctaplasLG®
2953998|NCT02875223|Experimental|CC-90011 Administration|CC-90011 will be administered once weekly in the morning on an empty stomach (ie, ≥ 1 hour before breakfast) with at least 240 mL of water after an overnight fast lasting ≥ 4 hours in both Parts A and B.
2953999|NCT02875210|Experimental|Patient with anterior cruciate ligament rupture|Anterior laxity of patient was measure with 4 laximeters:Telos, reference laximeter and with three other instruments called, KT-1000, GnrB and Rolimeter.
2954000|NCT02875197||Healthy Controls|"Males and females 18-50 years old~Up to 20 able-bodied sex, age, height, and weight-matched subjects"
2954001|NCT02875197||Lower Extremity Amputees|"Males & females 18-50 years old~Must have a unilateral, transtibial amputation & must have been prescribed a running-specific prosthesis~Subject with amputations resulting from trauma, congenital reasons, or cancer treatment unless cancer is in remission or treatments do not impact gait function~Physician approval to run~4 months experience using a running-specific prosthesis"
2954002|NCT02875184||Psoriatic arthritis patients treated with apremilast|Psoriatic arthritis patients who are treated with apremilast according to daily practice
2954003|NCT02875171||Anthracycline therapy|Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
2954004|NCT02875158|Active Comparator|Diode laser using conventional settings|The cyclophotocoagulation protocol is used with the conventional cyclophotocoagulation settings of 2000 mW for 2 seconds.
2954005|NCT02875158|Experimental|Diode laser using modified settings|The cyclophotocoagulation protocol is used with the modified cyclophotocoagulation settings of 1250 mW for 4 seconds.
2954006|NCT02875145||Keratoplasty with cataract surgery|Patients who underwent keratoplasty who also underwent a cataract surgery during follow up.
2954007|NCT02875145||Keratoplasty without cataract surgery|Patients who underwent keratoplasty who never underwent cataract surgery.
2954008|NCT02875132|Experimental|pembrolizumab|
2954009|NCT02875119|Experimental|Griffithsin Gel|In the randomized period, duration of treatment will be 14 days; each of the 30 subjects will self-administer Griffithsin Gel once daily for 14 consecutive days, with 5 doses administered under clinical supervision and the remaining 9 doses administered at home.
2954010|NCT02875119|Placebo Comparator|Placebo Gel|In the randomized period, duration of treatment will be 14 days; each of the 30 subjects will self-administer placebo gel once daily for 14 consecutive days, with 5 doses administered under clinical supervision and the remaining 9 doses administered at home.
2954011|NCT02875106||Atrial Fibrillation Patients|Adult female and male patients with diagnosed atrial fibrillation
2954012|NCT02875106||Sinus Rhythm Patients|Adult female and male patients with diagnosed sinus rhythm
2954013|NCT02875093|Other|ADI-PEG 20 Plus Low Dose Cytarabine|This is a phase 1, open label trial of ADI-PEG 20 (18 and 36 mg/m2) weekly in combination with low-dose cytarabine (20 mg BID [twice daily] for 10 days, every 28 days)
2954014|NCT02875080|Experimental|OPC-34712 disintegrating tablet with water|OPC-34712 (4 mg) orally disintegrating tablet is administered with water.
2954015|NCT02875080|Experimental|OPC-34712 disintegrating tablet without water|OPC-34712 (4 mg) orally disintegrating tablet is administered without water.
2954016|NCT02875080|Experimental|OPC-34712 conventional tablet with water|OPC-34712 (4 mg) conventional tablet is administered with water.
2954017|NCT02875067|Experimental|Pembrolizumab and Lenalidomide|"An intravenous infusion of 200 mg of pembrolizumab (MK3475) once every 3 weeks for a total of 4 infusions~Lenalidomide at either 15 mg, 10 mg or 20 mg (depending on which cohort patients are enrolled in) days 1-14 every 21 days"
2954018|NCT02875054|Active Comparator|Continued Casting|Participants with 24 hour cast wear (continued casting) for the entire duration of the constraint portion of camp (2 initial weeks).
2954019|NCT02875054|Active Comparator|Intermittent Casting|Participants who wear a univalve cast for 3 hours of constraint camp with home exercise program of 2 hours cast wear on the weekends (intermittent casting).
2954020|NCT02875041|Experimental|Transcranial Magnetic Stimulation (TMS) MAGSTIM Rapid2 Therapy|TMS is a non-invasive device that employs the use of a magnet on the scalp to measure and potentially modulate cortical excitability. The use of TMS for Parkinson's treatment is experimental.
2954021|NCT02875041|Active Comparator|MAGSTIM Rapid2 Therapy System|MAGSTIM Rapid2 Therapy System has been FDA cleared for the treatment of refractory depression.
2954022|NCT02875028|Experimental|Vorapaxar|subjects will be treated with 4x2,5mg vorapaxar in empty lactose-starch capsules
2954023|NCT02875028|Placebo Comparator|Placebo|subjects will be treated with 4 empty lactose-starch capsules
2954024|NCT02875015|Experimental|Liposomal Bupivacaine|20mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
2954025|NCT02875015|Active Comparator|Bupivacaine Hydrochloride and Lidocaine|Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
2954026|NCT02875002|Experimental|All subjects|Subjects have relapsed and refractory aggressive B- and T-cell lymphomas and will receive both Belinostat and Volasertib.
2954027|NCT02874989|Experimental|Dasatinib + Quercetin|
2954057|NCT02874807|Active Comparator|Empagliflozin|Treatment with empagliflozin 25mg once daily for four days
2954028|NCT02874976|Experimental|Experimental: Group A|"Active and Active Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group A, received program 1 before aerobic training, and the same program 1 after training"
2954029|NCT02874976|Experimental|Experimental: Group B|"Active and Placebo Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 1 before aerobic training, and program 2 after training."
2954030|NCT02874976|Experimental|Experimental: Group C|"Placebo and Active Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group C, received program 2 before aerobic training, and program 1 after training."
2954031|NCT02874976|Experimental|Experimental: Group D|"Placebo and Placebo Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 2 before strength training, and the same program 2 after training."
2954032|NCT02874963|Active Comparator|Surgical periodontal treatment|"Type 2 Diabetes Patients with periodontitis (without initial non-surgical periodontal therapy) at least one tooth extraction will be performed.~Non-Diabetes Patients with periodontitis (without initial non-surgical periodontal therapy) at least one tooth extraction will be performed.~Intervention:~Procedure: Surgery (Tooth Extraction)"
2954033|NCT02874963|Active Comparator|Surgical and non-surgical periodontal treatment|"Type 2 Diabetes Patients with periodontitis (with initial non-surgical periodontal therapy) at least one tooth extraction will be performed.~Non-Diabetes Patients with periodontitis (with initial non-surgical periodontal therapy) at least one tooth extraction will be performed.~Interventions:~Procedure: Surgery (Tooth Extraction)~Procedure: Non-surgical periodontal therapy-full mouth scaling and root planing (FM-SRP) with ultrasonic device and periodontal curets for mechanical debridement of the supra- and sub-gingival plaque and calculus, post operative rinsing thrice a day for 3 weeks."
2954034|NCT02874950|Experimental|Office exercise training|A package of exercise raining was defined by the researcher and one of the intervention group did it for 6 months.
2954035|NCT02874950|Experimental|Ergonomic modification|The ergonomic group, followed 6 months ergonomic modification.
2954036|NCT02874950|Experimental|Exercise and ergonomic|The mixture group, did 6 months exercise training and also followed 6 months ergonomic modification.
2954037|NCT02874950|Experimental|Control|Control group did not do any exercise and did not follow any ergonomic modification.
2954038|NCT02874937|Active Comparator|Atomoxetine|2 doses of atomoxetine 40mg PO (evening before and morning of study)
2954039|NCT02874937|Placebo Comparator|Placebo|2 doses of matching placebo 40 mg PO (evening before and morning of study)
2954040|NCT02874924|Experimental|Rapamycin|Rapamycin 1mg taken once daily for 8 weeks
2954041|NCT02874924|Placebo Comparator|Placebo|Placebo taken once daily for 8 weeks
2954042|NCT02874924|Experimental|Rapamycin Alone - Cardiovascular Effects|No placebo control; Rapamycin 1mg once daily for 8 weeks
2954043|NCT02874911|Experimental|General training|Advanced spinocerebellar disease receive 12 weeks of coordinative training based on commercially available videogames (Product names: Nintendo Wii ®, Microsoft XBOX Kinect®).
2954044|NCT02874898|Active Comparator|Heavy marijuana use|Heavy marijuana users with PTSD
2954045|NCT02874898|Active Comparator|No marijuana use|Non-marijuana users with PTSD
2954046|NCT02874885||Healthy Participants|Blood (about 2 tablespoons) drawn at 1 time point.
2954047|NCT02874885||Primary Disease w/wo Neoadjuvant Therapy|"Blood (about 2 tablespoons) drawn 1 time before participant starts treatment.~Blood also drawn:~Just before tumor surgery~1-8 weeks after surgery, or before chemotherapy begins~1-12 weeks after last dose of chemotherapy~1 year after surgery, OR 1 year after completion of treatment if no surgery~2 years after surgery, OR 2 years after completion of treatment if no surgery~If the disease gets worse during treatment, OR If disease comes back within 6 years after treatment, OR at end of 6 years follow-up."
2954048|NCT02874885||Recurrent Disease w/wo Neoadjuvant Therapy|"Blood (about 2 tablespoons) drawn 1 time before participant starts treatment.~Blood also drawn:~Just before tumor surgery~1-8 weeks after surgery, or before chemotherapy begins~1-12 weeks after last dose of chemotherapy~1 year after surgery, OR 1 year after completion of treatment if no surgery~2 years after surgery, OR 2 years after completion of treatment if no surgery~If the disease gets worse during treatment, OR If disease comes back within 6 years after treatment, OR at end of 6 years follow-up."
2954049|NCT02874885||Metastatic Disease w/wo Prior Treatment|"Blood (about 2 tablespoons) drawn 1 time before participant starts treatment.~Blood also drawn:~Just before tumor surgery~1-8 weeks after surgery, or before chemotherapy begins~1-12 weeks after last dose of chemotherapy~1 year after surgery, OR 1 year after completion of treatment if no surgery~2 years after surgery, OR 2 years after completion of treatment if no surgery~If the disease gets worse during treatment, OR If disease comes back within 6 years after treatment, OR at end of 6 years follow-up."
2954050|NCT02874872|Experimental|OASIS Collaborative|The nursing homes in this arm will receive facilitated implementation of two tools aimed at minimizing unnecessary antibiotic use. Facilitated implementation includes coaching of the nursing home staff on use of the tools. In addition, nursing home management will be coached on how to monitor implementation fidelity, antibiotic utilization, and consequences to over- and under-utilization of antibiotics as feedback on the effectiveness of the intervention. Finally, nursing home management will receive coaching on how to develop and implement a sustain plan for the OASIS intervention.
2954051|NCT02874872|No Intervention|Control|The nursing homes in this arm will continue care as usual, with no tools or facilitated implementation.
2954052|NCT02874846|Experimental|Netarsudil Ophthalmic Solution 0.02%|1 drop in each eye (OU) daily
2954053|NCT02874846|Placebo Comparator|Netarsudil Ophthalmic Solution Vehicle|1 drop in each eye (OU) daily
2954054|NCT02874833|Experimental|Exercise Group|Experimental arm type will assess whether a newly developed, supervised 8-week individualized, internet-based exercise therapy is effective in reducing depressive symptoms.
2954055|NCT02874833|No Intervention|Treatment as usual group|Treatment as usual. Other form of therapy (e.g. antidepressive medication) will not be affected.
2954056|NCT02874820|Experimental|Patient Group|Baseline PET scan followed by a blocked PET scan
2954058|NCT02874807|Placebo Comparator|Placebo|Treatment with Placebo once daily for four days
2954059|NCT02874794|Experimental|LCZ696 (sacubitril/valsartan)|minimum dose: 24/26mg, BID, oral, tablet maximum dose: 97/103mg, BID, oral, tablet All patients will begin on Dose Level 1 (24/26mg) and will be titrated every two weeks to target Dose level 3 (97/103mg). LCZ696 tablets will be provided for the 12-week open label extension.
2954060|NCT02874794|Active Comparator|Enalapril|minimum dose: 2.5mg, BID, oral, tablet maximum dose: 10 mg, BID, oral tablet All patients will begin on Dose Level 1 (2.5mg) and will be titrated every two weeks to target Dose level 3 (10mg).
2954061|NCT02874768|Experimental|dexmedetomidine|Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 ~ 0.7 mcg/kg/h)
2954062|NCT02874768|Active Comparator|Propofol|Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 ~ 1.6 mg/kg/h)
2954063|NCT02874755|Experimental|Tuberculosis Program (PPIA)|Half of the 300 participants were randomly selected to be sensitized and engaged into the program, and subsequently to receive the benefits of the PPIA intervention. Providers in the PPIA arm if networked into the program will receive the benefits of the program, including but not limited to: ability to provide presumptive TB patients and TB cases vouchers for free and/or subsidized diagnostic testing and referrals to providers for free first line anti-TB treatment (TB cases only); reimbursements for subsidized tests; training opportunities, and access to a referral network.
2954064|NCT02874755|No Intervention|No Tuberculosis Program (Non-PPIA)|The remaining half of the sample in Mumbai selected randomly will be phased into the program at least a year after the PPIA arm. However, during the year of the study, they will not be networked into the program.
2954065|NCT02874742|Experimental|Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd)|Participants will receive lenalidomide, bortezomib, dexamethasone and daratumumab.
2954066|NCT02874742|Experimental|Lenalidomide+Bortezomib+Dexamethasone (RVd)|Participants will receive lenalidomide, bortezomib and dexamethasone.
2954067|NCT02874729||Healthy donors|No interventions
2954068|NCT02874729||Cancer patients|No interventions
2954069|NCT02874716|Experimental|Tuberculosis Program (PPIA)|In Patna, 171 of the 321 participants were randomly selected to be sensitized and engaged into the program in Phase 1, and subsequently to receive the benefits of the PPIA intervention. Providers in the PPIA arm if engaged into the program will receive the benefits of the program, including but not limited to: ability to provide presumptive TB patients and TB cases vouchers for free or subsidized diagnostic testing and free first line anti-TB treatment (TB cases only); reimbursements for subsidized tests and anti-TB treatment; financial incentives to providers based on certain indicators; training opportunities, and access to a referral network.
2954070|NCT02874716|No Intervention|No Tuberculosis Program (Non-PPIA)|The remaining part of the sample in Patna selected randomly will be phased into the program at least a year after the PPIA arm in Phase 2. However, during the year of the study, they will not be engaged into the program.
2954071|NCT02874703||HIV-positive|
2954072|NCT02874703||HIV-negative|
2954073|NCT02874690|Active Comparator|Autism Spectrum (ASD) + ADHD with Methylphenidate|Autism Spectrum Disorder comorbid with Attention Deficit Hyperactivity Disorder receives methylphenidate
2954074|NCT02874690|Placebo Comparator|Autism Spectrum (ASD) + ADHD with Placebo|Autism Spectrum Disorder comorbid with Attention Deficit Hyperactivity Disorder receives a placebo
2954075|NCT02874690|No Intervention|Autism Spectrum Disorder (ASD)|Autism Spectrum Disorder without Attention Deficit Hyperactivity Disorder
2954076|NCT02874677|No Intervention|Control|Routine activities
2954077|NCT02874677|Experimental|Experimental|Effort reeducation program : 3 sessions of 20 minutes per week during 6 weeks
2954078|NCT02874664|Experimental|Rovalpituzumab Tesirine|0.3 mg/kg rovalpituzumab tesirine intravenously on Day 1 of every 6-week treatment cycle for 2 cycles omitting every third cycle
2954079|NCT02874651|Experimental|Apatinib|In the phase IIb part of this trial, patients in this arm will take oral apatinib until disease progression, intolerable toxicity, death or to a maximum of 2 years.
2954080|NCT02874651|Placebo Comparator|Placebo|In the phase IIb part of this trial, patients in this arm will take oral placebo until disease progression, intolerable toxicity, death or to a maximum of 2 years.
2954081|NCT02874638|Experimental|BASE egg protein|0.8 g/kg/d of BASE protein provided as crystalline amino acid made after egg protein.
2954082|NCT02874638|Experimental|BCAA-enriched egg protein|branched-chain amino acid-enriched egg protein
2954083|NCT02874638|Experimental|small amount of essential amino acids|small amount of essential amino acids made after egg protein, which is equivalent to the amount of essential amino acids in BASE
2954084|NCT02874638|Experimental|large amount of essential amino acids|large amount of essential amino acids made after egg protein, which is equivalent to the amount of amino acids in BCAA
2954085|NCT02874625|Active Comparator|Treatment 1|Dental restoration performed with glass-ionomer materials.
2954086|NCT02874625|Experimental|Treatment 2|Dental restoration performed with resin-based composites.
2954087|NCT02874612||Young Adults with Type 1 Diabetes Mellitus|All YA (ages 18-24) who are seen in the Cincinnati Children's Hospital Medical Center Diabetes Clinic and have recently (< 4 months) completed the Transition Readiness assessment tool as part of their standard clinical care is eligible for the study.
2954088|NCT02874599|Experimental|Patients|Patients who require multiple dental restorations. Teeth will be restored with commercial restorative composites
2954089|NCT02874586|Experimental|Plasma exchange combination of immunosuppressive regimens|Plasma exchange(once) ,with the following standard immunosuppressive regimens for the remission of auto-immune hepatitis
2954090|NCT02874573|Active Comparator|Treatment Group|Subjects in the tocilizumab group will receive a 4 mg/kg infusion at baseline, and weeks 4 and 8, as per the recommended starting dosing for rheumatoid arthritis
2954091|NCT02874573|Placebo Comparator|Control Group|Subjects in the placebo group will receive an infusion of normal saline (with the same packaging and volume as the tocilizumab group) at baseline, and weeks 4 and 8.
2954092|NCT02874560||Schizophrenia|350 patients will be included in the study. The centers selection is planned with 100 hospital-based psychiatrists, in centers for preventive medicine (CMP) or in private settings. Each investigator should consecutively enroll patients fulfilling the selection criteria to participate in the study (mean expected number of participants per center is around 10).
2954093|NCT02874547|Experimental|Intervention|Patients will receive five visits with a CHW during a 6 month period (two in-person and three by telephone). At the first visit, patients will meet the CHW who is trained in motivational interviewing techniques to deliver coaching to work on behavioral changes and introduce a 60 minute Digital Video Disc of five patient stories of individuals who have managed to control their hypertension.
2954094|NCT02874547|Other|Delayed Intervention|Patients will receive print materials at time of consent and randomization. Four to six months after randomization, DI patients will receive an invitation to schedule an in-person visit at the health center to begin receiving the intervention protocol.
2954095|NCT02874534|Experimental|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions. Session 1 provides orientation and psychoeducation on anhedonia, and activity monitoring is introduced. Sessions 2-3 include structured values assessments of 10 life areas to enhance motivation for sustained behavior change and to clarify goals. Following goals clarification, an activity hierarchy is developed, establishing a set of idiographic behavioral targets across life areas prioritized by ease of implementation to scaffold task engagement during the course of treatment.
2954096|NCT02874534|Active Comparator|Mindfulness Treatment|BATA will be compared to mindfulness based cognitive therapy (MBCT), chosen because its mechanisms of action are hypothesized to impact different brain mechanisms than BATA. Mindfulness is nonjudgmentally bringing awareness and acceptance to one's present-moment experience. MBCT will be administered in an individual format. The MBCT protocol will be modeled on the session outlines presented in Wahbeh et al., 2014. Treatment will be compromised of 15 weekly 45-minute sessions.
2954097|NCT02874521|Experimental|Intra-dialytic LF-EMS|Performed twice weekly whilst seated on a standard dialysis chair. Delivered by adhesive electrodes in a neoprene garment, applied bilaterally to the quadriceps and hamstrings. Cardiovascular stimulus via rapid, rhythmical, sub-tetanic contractions. Short bursts of four pulses repeatedly delivered by stimulator at a frequency of 4Hz. Current amplitude adjustable from 40 - 200 mA with inbuilt controller. Conducted for one hour at the maximum tolerable intensity. Five minute warm-up and cool down at a lower frequency (3 Hz).
2954098|NCT02874521|Experimental|Intra-dialytic cycle training|Semi-recumbent cycling performed twice weekly whilst seated on a standard dialysis chair. Performed for up to one hour per session, initially at a workload (Watts) equivalent to that achieved at 40-60% VO2 reserve during cardiopulmonary exercise test. Exercise intensity regulated using a combination of heart rate and rating of perceived exertion (12-14). Workload adjusted weekly and controlled with a combination of pedal resistance and cadence to provide a personalised exercise prescription. Five minute warm-up and cool down each session.
2954099|NCT02874521|No Intervention|Usual care|Continuation of dialysis treatment without the addition of an intra-dialytic exercise intervention.
2954100|NCT02874495||Healthy volunteers|22 persons.
2954101|NCT02874495||Patients with Crohn's disease|22 patients.
2954102|NCT02874482||Patients with schizophrenia|30 patients with schizophrenia (diagnosis based on the standard DSM criteria)
2954103|NCT02874482||Controls|30 healthy controls without any psychiatric or neurological diagnosis
2954104|NCT02874469|No Intervention|Control group (first period)|Patients treated as recommended with usual care in a center.
2954105|NCT02874469|Experimental|Group with diary (second period)|Intervention group = On top of usual care, an intensive care unit diary will be implemented for patients within the first 8 hours following their admission.
2954106|NCT02874456|Experimental|virus detection|detection of ZIKA virus in blood and sperm
2954107|NCT02874443|Experimental|Intervention centers|Application of a knowledge translation strategy, of new clinical practice guidelines on labor management, to physicians and nurses caring for women in labor.
2954108|NCT02874443|No Intervention|Control centers|
2954109|NCT02874430|Experimental|Treatment (metformin hydrochloride, doxycycline)|Patients receive metformin hydrochloride orally daily on days 1-3 and twice a day starting on day 4. Patients also receive doxycycline orally every 12 hours starting on day 1. Treatment repeats every 7 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2954110|NCT02874417|Experimental|Psychoeducation|The program was designed to dispel exaggerated thoughts surrounding the danger of the experience of anxiety symptoms, specifically focusing on fears regarding feelings of cognitive dyscontrol. The psychoeducation portion contains video animation and audio narration throughout, as well as some interactive features . Participants are provided with corrective information about the experience of anxiety-related sensations, with a particular focus on dispelling myths commonly held by individuals with high anxiety sensitivity cognitive concerns . Participants are taught that anxiety-related sensations are not dangerous and that they may have developed a conditioned fear to these symptoms of arousal.
2954111|NCT02874417|Placebo Comparator|Health and Wellness|The controlled condition consisted Physical Health Education Training (PHET), a computerized presentation which focuses on information on general healthy living. The PHET program contains information on nutrition, alcohol, water consumption, exercise, sexual health, hygiene, stress management, life organization, social support, positive outlook, and sleep.
2954112|NCT02874404|Experimental|Group A (PI3K delta inhibitor TGR-1202, ibrutinib)|Patients receive PI3K delta inhibitor TGR-1202 PO QD on days 1-28 and ibrutinib PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2954113|NCT02874404|Experimental|Group B (Ibrutinib, PI3K delta inhibitor TGR-1202)|Patients receive ibrutinib PO QD on days 1-28 and PI3K delta inhibitor TGR-1202 PO QD and days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2954114|NCT02874404|Experimental|Group C (PI3K delta inhibitor TGR-1202, ibrutinib)|Patients then receive PI3K delta inhibitor TGR-1202 PO QD and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2954115|NCT02874391||AV fistula group|
2954116|NCT02874391||Control group|
2954117|NCT02874378|Experimental|study group|Dexmedetomidine will be pumped at 0.3μg/kg•h during the operation till 30 minutes before the operation complete. Standard anaesthesia and standard cure are given for all patients.
2954118|NCT02874378|Placebo Comparator|control group|0.9%NaCl solution 0.1ml/kg•h during the operation till 30 minutes before the operation complete. Standard anaesthesia and standard cure are given for all patients.
2954119|NCT02874365|Experimental|Crohn disorder|arm composed by 30 patients with Crohn disorder
2954120|NCT02874365|Experimental|FAP (familial adenomatous polyposis )|arm composed by 30 patients with FAP disorder
2954121|NCT02874365|Experimental|ulcerative colitis|arm composed by 30 patients with ulcerative colitis
2954122|NCT02874365|Sham Comparator|witness|arm composed by 30 patients with no intestinal disorders
2954123|NCT02874352|Other|intensive care patients|intensive care patients with tracheostomy/ high resolution impedance manometry with Automated Impedance Manometry analysis
2954124|NCT02874352|Other|healthy volunteers|control group with healthy volunteers/ high resolution impedance manometry with Automated Impedance Manometry analysis
2954125|NCT02874339|Experimental|Optiflow Group|High flow nasal oxygen therapy
2954126|NCT02874339|Active Comparator|NIV group|
2954127|NCT02874326|Experimental|Active comparator: Octreotide LAR|Sandostatin LAR Sandostatin LAR 20 mg will be administered once every 4 weeks as a intramuscular injection
2954128|NCT02874313|Experimental|CPAP treatment|Diet and conventional pharmacological treatment with oral antidiabetic drugs or insulin plus continuous positive airway pressure (CPAP)
2954129|NCT02874313|Active Comparator|Control treatment|Diet and conventional pharmacological treatment with oral antidiabetic drugs or insulin
2954130|NCT02874300|No Intervention|Control|The control arm will comprise the offer of an assessment by a standard community falls prevention service.
2954131|NCT02874300|Other|High intensity supervision arm|high-intensity supervision
2954132|NCT02874300|Other|Moderate intensity supervision arm|Moderate intensity supervision
2954133|NCT02874287|Other|Hydroxychloroquine|Subjects are treated with hydroxychloroquine sulfate tablets.All the subjects are treated with guideline-based secondary prevention of coronary heart disease medications.
2954134|NCT02874287|Other|placebo|Subjects are treated with placebo tablets. All the subjects are treated with guideline-based secondary prevention of coronary heart disease medications.
2954135|NCT02874274|Active Comparator|100 Non-Homebound Subjects|outpatient healthcare utilization and self-reported illness.
2954136|NCT02874274|Active Comparator|60 Homebound Subjects|Will test the feasibility of offering influenza and pneumococcal vaccinations, as appropriate, to the homebound individuals in our HVP cohort
2954137|NCT02874261|Experimental|Whole Body Periodic Acceleration|"Whole-body periodic acceleration (WBPA) is a new, non-invasive, and promising therapy for a diverse and growing list of disorders including cardiovascular disease 6. During WBPA, patients lie in the supine position on a bed that is capable of translating back and forth parallel to the ground, along the head-to-foot axis of the patient. Thus, this treatment is best described as a form of passive exercise. The frequency of the translation is 120 cycles/minute; cpm) as well as a distance traveled 16 mm."
2954138|NCT02874248|Active Comparator|Group 1: 15 mg E4/3 mg DRSP (n=10)|a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
2954139|NCT02874248|Placebo Comparator|Group1: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
2954140|NCT02874248|Active Comparator|Group 2: 30 mg E4/6 mg DRSP (n=10)|a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
2954141|NCT02874248|Experimental|Group 2: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
2954142|NCT02874248|Active Comparator|Group 3: 60 mg E4/12 mg DRSP (n=10)|a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days
2954143|NCT02874248|Placebo Comparator|Group 3: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
2954144|NCT02874248|Active Comparator|Group 4: 75 mg E4/15 mg DRSP (n=9)|a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
2954145|NCT02874248|Placebo Comparator|Group 4: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
2954146|NCT02874235|Experimental|Music therapy treatment|35 patients receiving each 16 sessions of Receptive music therapy
2954147|NCT02874235|Active Comparator|Standard treatment|35 patients receiving each 16 sessions of Psychological treatment
2954148|NCT02874222||Caucasian|surveys completed by subject n=600, nationally
2954149|NCT02874222||African-American|surveys completed by subject n=200, nationally
2954150|NCT02874222||Asian|surveys completed by subject n=200, nationally
2954151|NCT02874209|Experimental|Patient with amyotrophic lateral sclerosis|ALS patients with, spinal and bulbar form, certain or probable diagnosis according to the revised El Escorial criteria will go through the MRI sodium
2954152|NCT02874209|Placebo Comparator|Healthy volunteer|Healthy Volonteer apparied for sexe and age with selected ALS patients will go through the MRI sodium
2954153|NCT02874196|Experimental|Patients with painful prosthesis|
2954154|NCT02874183|Experimental|Pharmacist intervention group|"The intervention group will receive:~A phone call 48h-72h after discharge from the hospital to ensure that the patient filled their prescriptions and started taking their medication.~A phone call five to seven days after discharge to reinforce the education using the teach back technique1. Patients will be asked about their medications, what are they for, how to use them, and what side effects to watch for, based on the education and information that was provided to them at discharge."
2954155|NCT02874183|No Intervention|usual care group|The control group will receive the usual standard care available at West Kendall Baptist Hospital.
2954156|NCT02874170|Experimental|drepanocytose affected patient|
2954157|NCT02874170|Other|Healthy volunteers|
2954158|NCT02874144|Experimental|AZ Compound|40 mg 12 weeks TID po
2954159|NCT02874144|Placebo Comparator|Placebo|40 mg 12 weeks TID po
2954212|NCT02873767|Experimental|UCB4019 Dose 2|Dose 2 calculated based on body weight
2954160|NCT02874131|Experimental|Behavioral Activation + CPT|Behavioral Activation, an evidence-based treatment for depression, is combined with Cognitive Processing Therapy (CPT), an evidence-based treatment for PTSD, to address symptoms of PTSD and comorbid MDD.
2954161|NCT02874131|Active Comparator|Cognitive Processing Therapy|CPT is an evidence-based treatment for PTSD that has also been shown to reduce depression symptoms.
2954162|NCT02874118|Experimental|HIV Patient population over 50 years old|
2954163|NCT02874105|Experimental|experimental group|Dynamic Humeral Centering
2954164|NCT02874105|Active Comparator|control group|Conventional physiotherapy
2954165|NCT02874092|Active Comparator|Rheumatoid Arthritis|-Receiving Methotrexate at stable doses of 10 to 25 mg weekly for at least 12 weeks
2954166|NCT02874092|Active Comparator|Osteoarthritis|-Diagnosis of osteoarthritis made by physician.
2954167|NCT02874079|Experimental|bullous pemphigoid|patients with bullous pemphigoid
2954168|NCT02874079|Active Comparator|no bullous pemphigoid|patients with basal cell carcinoma or squamous cell carcinoma and without inflammatory skin disease
2954169|NCT02874066|Experimental|PTV/r/OBV/DSV|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBV, 75mg/50mg/12.5mg per tablet, Viekirax): 2 tablets per os per day Dasabuvir (DSV, 250 mg per tablet, Exviera): 1 tablet per os twice per day Treatment duration: 12 weeks
2954170|NCT02874053||Healthy|Healthy Volunteers
2954171|NCT02874040|Experimental|Experimental|endoresection of the tumor scar or, when surgery is not possible, transpupillary thermotherapy on the tumor scar
2954172|NCT02874027||TBI Patients with depression|All the patients should be diagnosed by CCMD－3(evaluation of depression)
2954173|NCT02874027||TBI Patients without depression|
2954174|NCT02874014|Experimental|Hypofractionation Proton beam therapy|Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes
2954175|NCT02873988||patients with COPD|patients with COPD
2954176|NCT02873988||patients without COPD|patients without COPD
2954177|NCT02873975|Experimental|Homologous Repair (HR) Deficiency|Prexasertib (LY2606368) will be administered as an IV infusion on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
2954178|NCT02873975|Experimental|Replicative Stress|Prexasertib (LY2606368) will be administered as an IV infusion on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
2954179|NCT02873975|Experimental|CCNE1 Amplification|Prexasertib (LY2606368) will be administered as an IV infusion on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
2954180|NCT02873962|Experimental|Nivolumab with Bevacizumab|Patients will receive treatment every 14 days with Nivolumab and Bevacizumab administered on day 1 of each cycle.
2954181|NCT02873949|Other|1. Periodontitis patients|30 patients consulting at Odontology department for periodontal treatment
2954182|NCT02873949|Other|2. Control|10 patients not affected by periodontitis consulting at Odontology department for checkup of teeth state and/or scaling
2954183|NCT02873936|Experimental|Filgotinib Dose A|Filgotinib dose A + placebo to match filgotinib dose B + a stable dose of permitted csDMARD(s)
2954184|NCT02873936|Experimental|Filgotinib Dose B|Filgotinib dose B + placebo to match filgotinib dose A + a stable dose of permitted csDMARD(s)
2954185|NCT02873936|Placebo Comparator|Placebo|Placebo to match filgotinib dose A + placebo to match filgotinib dose B + a stable dose of permitted csDMARD(s)
2954186|NCT02873923||metastatic soft tissue sarcomas|No intervention : Meta-analysis of RCT conducted on patients with metastatic soft-tissue sarcoma treated with chemotherapy
2954187|NCT02873923||adjuvant breast cancer|No intervention : Meta-analysis of RCT conducted on patients with breast cancer treated with adjuvant chemotherapy
2954188|NCT02873910|Experimental|IQP-AS-119|One tablet to be taken daily with any meal, with a glass of water. They should not be chewed, but swallowed whole.
2954189|NCT02873910|Placebo Comparator|Placebo|One tablet to be taken daily with any meal, with a glass of water. They should not be chewed, but swallowed whole.
2954190|NCT02873897|Other|"Group meals on wheels at home"|
2954191|NCT02873897|Other|"Group residents of old people's homes - EHPAD"|
2954192|NCT02873884||case-management|Patients will meet the case-manager 5 times per month during 1h30 in community living
2954193|NCT02873884||traditional nursing|Patients will meet the case-manager 2 times per month during 1h00 in hospital
2954194|NCT02873871|Other|Control group|Standardized compressive dressing
2954195|NCT02873871|Experimental|Intervention group|Hemostasis with TerumoBand®
2954196|NCT02873858|Active Comparator|1.independent patients|
2954197|NCT02873858|Experimental|2. less mobile patients|
2954198|NCT02873858|Experimental|patient in a residence|
2954199|NCT02873858|Experimental|patients in a home for the elderly (EHPAD)|
2954200|NCT02873845||PATIENT|Patients with colon cancer
2954201|NCT02873845||THE SPOUSE/PARTNER|The spouse/partner of patients with colon cancer
2954202|NCT02873832||MPS|
2954203|NCT02873832||Control|
2954204|NCT02873819|Experimental|GL-0817|Subjects in active treatment will be vaccinated with GL-0817 with the adjuvants Poly-ICLC (Hiltonol®) and GM-CSF (Sargramostim, Leukine®) 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 t. Patients will receive IV Cyclophosphamide 1 day prior to the first 3 vaccinations.
2954205|NCT02873819|Placebo Comparator|Placebo|Subjects in placebo arm will receive placebo to cyclophosphamide (normal saline solution) followed by Poly-ICLC/GM-CSF/placebo vaccine injections on the same schedule as the GL-0817 cohort.
2954206|NCT02873806|Other|2 micro-bypass stents & travoprost|"Two iStent inject micro-bypass stents and topical travoprost~Intervention:~Implantation of two iStent inject micro-bypass stents~Tobramycin~Dexamethasone"
2954207|NCT02873793||7/8 cases pure seminomas|
2954208|NCT02873793||5 cases of non-seminoma|
2954209|NCT02873793||3 cases of composite tumours seminoma/non-seminoma.|
2954210|NCT02873767|Placebo Comparator|Placebo|Single dose placebo comparator for each active arm
2954211|NCT02873767|Experimental|UCB4019 Dose 1|Dose 1 calculated based on body weight
2954213|NCT02873767|Experimental|UCB4019 Dose 3|Dose 3 calculated based on body weight
2954214|NCT02873767|Experimental|UCB4019 Dose 4|Dose 4 calculated based on body weight
2954215|NCT02873754|Experimental|STEP UP|STEP UP is an intervention that combines evidence-based telephone cognitive behavioral counseling for smoking cessation, access to nicotine replacement therapy (NRT; including transdermal nicotine patch and either nicotine polacrilex or nicotine lozenge) and bupropion, and intensive mobile contingency management behavioral therapy administered via a smart-phone based application.
2954216|NCT02873741|Experimental|Validation Study|Participants will undergo a perianal and digital anorectal exam, a high resolution anoscopy, and cervical and anal swabs to determine the best method to identify women at high risk for anal cancer.
2954217|NCT02873728|Experimental|RIC|In the study group, a blood pressure cuff will be inflated to 50 mmHg above systolic blood pressure while the performing investigator examines the radial pulse to ensure complete blood flow obstruction. Ischemia will be performed for 3 cycles of 5 min each and 10 min resting between cycles.
2954218|NCT02873728|Sham Comparator|Control|In the control group, a blood pressure cuff will be inflated to 10 mmHg (Sham procedure) for 3 cycles of 5 min each and 10 min resting between cycles.
2954219|NCT02873715|Active Comparator|Usual Care (UC)|Usual Care will consist of the care typically delivered by the family's primary care provider for children with overweight or obesity. The implementations of UC may vary between providers but typically includes and assessment of the child's weight, help remove barriers to weight loss and introductions of goals for better weight management.
2954220|NCT02873715|Experimental|Family-based treatment (FBT)|Family- Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 15 to 60 minutes as frequent as weekly and no longer than monthly over the two yeart study
2954221|NCT02873702|Experimental|Healing Period: Dexlansoprazole 60 mg|Dexlansoprazole 60 milligram (mg), delayed-release capsules, orally, once daily for up to 8 weeks in the Healing Period.
2954222|NCT02873702|Experimental|Healing Period: Lansoprazole 30 mg|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks in the Healing Period.
2954223|NCT02873702|Experimental|Maintenance Period: Dexlansprazole 30 mg|Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole 30 mg, delayed-release capsules, orally, once daily for up to 6 months in the Maintenance period.
2954224|NCT02873702|Experimental|Maintenance Period: Placebo|Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 6 months in the Maintenance period.
2954225|NCT02873689|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release capsule, orally, once daily for up to 4 weeks.
2954226|NCT02873689|Experimental|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to 4 weeks.
2954227|NCT02873676|Experimental|nutritional intervention|This group received multi-dimensional intensive nutritional intervention for 3 month, which included whey (30g/d,plus three times every week ),vitamin D (1000IU) and omega-3 fatty acid (DHA 1200mg and EPA 800mg).
2954228|NCT02873676|Experimental|resistance training program|This group received resistance training program which is made up warm-up exercise, muscle strength training and relaxing.
2954229|NCT02873676|Experimental|lifestyle modification project|This group receive multi-dimensional intensive nutritional intervention and resistance training program.
2954230|NCT02873676|Placebo Comparator|control|This group receive nutritional consulting,which involve dietary pattern modification and protein intake standardization.
2954231|NCT02873663|Experimental|heavy drinkers|Plasma and head hair collection
2954232|NCT02873663|Experimental|teetotalers|Plasma and head hair collection
2954233|NCT02873650|Experimental|Group 1 - Control group|
2954234|NCT02873650|Experimental|Group 2-Moderate hepatic impairment|
2954235|NCT02873650|Experimental|Group 3-Severe hepatic impairment|
2954236|NCT02873637|Experimental|under sartorial catheter|catheter under sartorial
2954237|NCT02873637|Other|femoral catheter|femoral catheter
2954238|NCT02873611|Experimental|MRI scanning and the genicular ablation|patients undergoing both MRI scanning and the genicular ablation procedure. additional MRI testing of apprx. 0.5-1 hour
2954239|NCT02873598|Experimental|FOLFIRINOX or gemcitabine/abraxane followed by SBRT|SBRT will be administered in 3 fractions, every other day, on an outpatient basis, following chemotherapy with either FOLFIRINOX or gemcitabine/abraxane
2954240|NCT02873585|Experimental|Stationary intraoral tomosynthesis|Stationary intraoral tomosynthesis after standard conventional bitewing radiography
2954241|NCT02873572|Experimental|online poker gamblers|Recruitment by forums of online poker gamblers: an explanation of the research is sent with the dedicated link of the research.
2954242|NCT02873572|Experimental|casino gamblers|Recruitment to the casino gates: an explanation of the research is sent with the dedicated e-link of the research and they could answer directly to the questionnaire (1st step) on sites.
2954243|NCT02873572|Experimental|MMORPG gamers|Recruitment by forums of MMORPG (as guilds): an explanation of the research is sent with the dedicated link of the research.
2954244|NCT02873572|Experimental|no gamer subjects|Recruitment by poster.
2954245|NCT02873559|No Intervention|Controls|A control group, which is 20 weeks with placebo injections without training.
2954246|NCT02873559|Experimental|Testosterone|A testosterone group given 20 weeks on testosterone injections without training
2954247|NCT02873559|Experimental|Training|A Training Group, which is 20 weeks with placebo injections and 16 weeks of progressive resistance training supplemented with vitamin D and protein supplements
2954248|NCT02873559|Experimental|Testosterone and training|A combination group that is 20 weeks with testosterone injections and 16 weeks of progressive resistance training supplemented with vitamin D and protein supplements
2954249|NCT02873546|Active Comparator|anodal tDCS on left DLPFC (F3)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 minutes for 10 sessions. Anode is placed on the scalp facing on left DLPFC (F3) and cathode between Fp2-F8 EEG-repair.
2954346|NCT02872883|Active Comparator|Active management and routine vaginal examinations|Induction of labour at approximately 24hours and routine vaginal examinations
2954250|NCT02873546|Sham Comparator|sham tDCS on left DLPFC (F3)|Sham tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 minutes - 10 sessions. Anode is placed on the scalp facing on left DLPFC (F3) and cathode between Fp2-F8 EEG-repair.
2954251|NCT02873533|Other|A-Elderly patients with cancer|geriatric care and longitudinal follow up
2954252|NCT02873520|Experimental|Precision Cells combined with Chemotherapy treatment:|Precision cells combined with Chemotherapy treatment: Chemotherapy: once a week with a total of six times before 60 days prior to the start of drawing blood. Precision cells：once per 3 weeks with a total of three periods.
2954253|NCT02873520|Active Comparator|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
2954254|NCT02873507|Experimental|MRI of donor liver|MRI evaluation of graft steatosis in donor liver prior to transplantation
2954255|NCT02873494||PHYSIOFLOW PF05 Lab1TM|Impedance cardiography
2954256|NCT02873481|Experimental|Yoga (CPC+Y)|Women in Centering Pregnancy Care (CPC) will receive the intervention which is a 30 minute yoga sessions during each of the 2-hour CPC meetings (CPC+Y)
2954257|NCT02873481|No Intervention|Comparison (CPC alone)|To strengthen our ability to examine causal relationships between the intervention and outcomes, we will use longitudinal comparison group data contributed from deidentified archival data from an existing IRB-approved study (PI: Masho) which includes pregnant women who participated in the CPC model of care alone (without the yoga component) and were followed throughout their pregnancies using numerous measures identical to those in the proposed study, including weight/BMI, depressive symptoms, anxiety, and stress.
2954258|NCT02873468|Experimental|EMS Fluticasone 1|The patient will take 4,5mL, oral, BID.
2954259|NCT02873468|Experimental|EMS Fluticasone 2|The patient will take 7mL, oral, BID.
2954260|NCT02873468|Experimental|EMS Fluticasone 3|The patient will take 9mL, oral, BID.
2954261|NCT02873468|Placebo Comparator|EMS Placebo Fluticasone|The patient will take 5mL, oral, BID.
2954262|NCT02873455|Experimental|watching video|Short video clip including the circumstance of operation theater, and surgeon's interview
2954263|NCT02873442|Experimental|Precision cells combined with TACE|"Transcatheter Arterial Chemoembolization:~patients will receive MMC,EADM hepatic arterial infusion,6 cycles. Precision Cells：After accepting concurrent TACE treatment,patients will receive 3 cycles of Precision Cells treatment"
2954264|NCT02873442|Active Comparator|Transcatheter Arterial Chemoembolization|patients will receive MMC,EADM hepatic arterial infusion,6 cycles.
2954265|NCT02873429||Integrative Medicine (Complementary /Alternative)Group|Patients receiving chiropractic care, acupuncture, massage therapy, or meditation training for chronic pain
2954266|NCT02873429||Conventional Medicine Group|Patients receiving conventional medicine care (physical therapy, medication management, injections, etc.) for chronic pain.
2954267|NCT02873416|Experimental|Precision cells combined with Chemotherapy treatment:|Once a week with a total of six times before 60 days prior to the start of drawing blood. Precision cells：once per 3 weeks with a total of three periods.
2954268|NCT02873416|Active Comparator|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
2954269|NCT02873403|Experimental|KNEEMO knee brace & Popular knee brace|Patients having medial knee osteoarthritis
2954270|NCT02873403|Experimental|Popular knee brace &KNEEMO knee brace|Patients having medial knee osteoarthritis
2954271|NCT02873390|Experimental|HerinCAR-PD1 cells|Patients will receive 3 cycles of HerinCAR-PD1 cells treatment.
2954272|NCT02873377|Experimental|Enhanced Care|"Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling & Smoking Quitline Referral. Participants in the Enhanced Care intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment."
2954273|NCT02873377|Active Comparator|Standard Care|"Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The Standard Care group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment."
2954274|NCT02873364|Active Comparator|Vitamin D3 (Low dose)|Daily 600 unites of vitamin D + Cetirizine 10mg twice a day
2954275|NCT02873364|Experimental|Vitamin D3 (High dose)|Daily 4000 unites vitamin D + Cetirizine 10mg twice a day
2954276|NCT02873351|Experimental|carbidopa-levodopa 25-100 mg|Treatment with carbidopa-levodopa 25-100 mg tablets dosed once daily at bedtime for 45 +/- 5 days followed by carbidopa-levodopa 25-100 mg tablets dosed 3 times daily for 45 +/- 5 days.
2954277|NCT02873351|Placebo Comparator|Placebo for carbidopa-levodopa 25-100 mg|Treatment with placebo for carbidopa-levodopa 25-100 mg in identical tablets dosed once daily at bedtime for 45 +/- 5 days followed by placebo for carbidopa-levodopa 25-100 mg tablets dosed 3 times daily for 45 +/- 5 days.
2954278|NCT02873338|Active Comparator|Idarubicin + Cytarabine|"Induction:~Idarubicin - 12 mg/m2/day slow IV injection for 3 days;~Cytarabine - 100 mg/m2/day continuous 24-hour IV infusion for 7 days~Re-induction - same as above or:~Idarubicin - 12 mg/m2/day slow IV injection for 2 days;~Cytarabine - 100 mg/m2/day continuous 24-hour IV infusion for 5 days~Consolidation:~Cytarabine - 1.0 g/m2 IV infusion over 3 hours, q12h every other day for 3 days"
2954279|NCT02873338|Experimental|Idarubicin+Cytarabine+lower dose CX-01|"Induction:~Idarubicin - 12 mg/m2/day slow IV injection for 3 days;~Cytarabine - 100 mg/m2/day continuous 24-hour IV infusion for 7 days;~CX-01 - 4 mg/kg IV bolus followed by CX-01 0.125 mg/kg/hr as a continuous 24-hour IV infusion for 7 days~Re-induction - same as above or:~Idarubicin - 12 mg/m2/day slow IV injection for 2 days;~Cytarabine - 100 mg/m2/day continuous 24-hour IV infusion for 5 days~CX-01 - 4 mg/kg IV bolus followed by CX-01 0.125 mg/kg/hr as a continuous 24-hour IV infusion for 5 days~Consolidation:~Cytarabine - 1.0 g/m2 IV infusion over 3 hours, q12h every other day for 3 days~CX-01 - 4 mg/kg IV bolus followed by CX-01 0.125 mg/kg/hr as a continuous 24-hour IV infusion for 5 days"
2954347|NCT02872870||Control adults|lexical tests and electroencephalogram (EEG).
2954348|NCT02872870||Dyslexic patients|lexical tests
2954349|NCT02872870||Dysphasic patients|lexical tests
2954280|NCT02873338|Experimental|Idarubicin+Cytarabine+higher dose CX-01|"Induction:~Idarubicin: 12 mg/m2/day slow IV injection for 3 days;~Cytarabine: 100 mg/m2/day continuous 24-hour IV infusion for 7 days;~CX-01: 4 mg/kg IV bolus followed by CX-01 0.25 mg/kg/hr as a continuous 24-hour IV infusion for 7 days~Re-Induction - same as above or:~Idarubicin - 12 mg/m2/day slow IV injection for 2 days;~Cytarabine - 100 mg/m2/day continuous 24-hour IV infusion for 5 days;~CX-01 - 4 mg/kg IV bolus followed by CX-01 0.25 mg/kg/hr as a continuous 24-hour IV infusion for 5 days~Consolidation:~Cytarabine - 1.0 g/m2 IV infusion over 3 hours, q12h every other day for 3 days~CX-01 - 4 mg/kg IV bolus followed by CX-01 0.25 mg/kg/hr as a continuous 24-hour IV infusion for 5 days"
2954281|NCT02873312|Experimental|StimRouter Treatment|The Treatment group will receive therapeutic level StimRouter electrical stimulation. At the end of the Month 3 visit the Treatment group will continue to receive therapeutic level StimRouter electrical stimulation for an additional 3 months.
2954282|NCT02873312|Sham Comparator|StimRouter Control|The Control group will receive sham (sub-therapeutic level only) StimRouter stimulation. At the end of the Month 3 visit the Control group will be allowed to receive therapeutic level StimRouter electrical stimulation for 3 months.
2954283|NCT02873299|No Intervention|Treatment as usual|Treatment as usual, wait list control group
2954284|NCT02873299|Active Comparator|rTMS at 10Hz|10 Hz rTMS of the right dorsolateral prefrontal cortex
2954285|NCT02873299|Active Comparator|rTMS at 20Hz|20 Hz rTMS of the right dorsolateral prefrontal cortex
2954286|NCT02873286|Experimental|Group 1|First vaccination dose 1 MVA-BN-RSV, second vaccination placebo
2954287|NCT02873286|Experimental|Group 2|First vaccination dose 1 MVA-BN-RSV, second vaccination dose 1 MVA-BN-RSV
2954288|NCT02873286|Experimental|Group 3|First vaccination dose 2 MVA-BN-RSV, second vaccination placebo
2954289|NCT02873286|Experimental|Group 4|First vaccination dose 2 MVA-BN-RSV, second vaccination dose 2 MVA-BN-RSV
2954290|NCT02873286|Experimental|Group 5|First vaccination placebo, second vaccination placebo
2954291|NCT02873273|Experimental|Dexamethasone delivery system|
2954292|NCT02873260|Experimental|TetraVax-DV-TV005 + rDEN3Δ30|Participants will receive the TetraVax-DV-TV005 vaccine at Day 0 and the rDEN3Δ30 virus at Day 180.
2954293|NCT02873260|Placebo Comparator|Placebo + rDEN3Δ30|Participants will receive placebo at Day 0 and the rDEN3Δ30 virus at Day 180.
2954294|NCT02873234||Traditional Chinese Medicine|Including Zishui Qinggan Yin,Xiaoyao San, Longdan Xiegan Tang, Guipi Decoction, Ningshen Dingzhi Wan, HuangLian-EJiao decoction and Jiaotai Wan.
2954295|NCT02873234||TCM plus antidepressants|This is a integrative therapy that refers to a new treating system including TCM and antidepressants.
2954296|NCT02873234||Antidepressants|Antidepressants include Selective serotonin reuptake inhibitors (SSRIs), Norepinephrine-reuptake inhibitors and other antidepressants, such as Paroxetine, Citalopram, Venlafaxine, Sertraline, Trazodone, Maprotiline and so on.
2954297|NCT02873221|Active Comparator|Usual Care|Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of migraine attacks for up to 1 year.
2954298|NCT02873221|Experimental|Ubrogepant 50 mg|Ubrogepant 50 mg tablet orally plus placebo-matching ubrogepant tablet for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
2954299|NCT02873221|Experimental|Ubrogepant 100 mg|Ubrogepant 100 mg (two 50 mg tablets) orally for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
2954300|NCT02873208|Experimental|ALKS 3831|Oral tablet, daily dosing
2954301|NCT02873195|Experimental|Arm I (atezolizumab, bevacizumab, capecitabine)|Patients receive atezolizumab IV over 60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2954302|NCT02873195|Active Comparator|Arm II (placebo, bevacizumab, capecitabine)|Patients receive placebo IV over 60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2954303|NCT02873182|Experimental|Autonomic nervous system monitoring|During standard intraoperative neuromonitoring, additional smooth muscle free-running and stimulated EMG will be recorded from corporal tissues (corpus spongiosum) of male and female genitalia from all patients who consent to participate in the study. EMG data and additional demographics and clinical data (e.g. operative time, adverse events) will be collected for each patient.
2954304|NCT02873156|Experimental|E2027|"Four sequential cohorts of healthy participants (≥50 years and ≤85 years old) will be treated with multiple ascending doses of E2027 up to the maximum tolerated dose (MTD). A total of 6 participants per cohort will be randomized to E2027.Proposed doses of E2027 are:~Part A Cohort 1: 50 mg (1 × 50 mg capsule)~Cohort 2: 100 mg (2 × 50 mg capsules)~Cohort 3: 200 mg (4 × 50 mg capsules)~Cohort 4: 400 mg (8 × 50 mg capsules)~Cohort 6: 25 mg (5 × 5 mg capsules) Part B~Cohort 5: 400 mg (8 × 50 mg capsule)~Part C:~• Cohort 7: 50 mg (1 × 50 mg capsules)~Part D:~Cohort 8: 5 mg (1 × 5 mg capsules)~Cohort 9: 10 mg (2 × 5 mg capsules)"
2954305|NCT02873156|Placebo Comparator|Placebo|Four sequential cohorts of healthy participants (≥50 years and ≤85 years old) will be treated with multiple ascending doses of E2027 matched placebo up to the MTD. A total of 2 participants per cohort will be randomized to E2027 matched placebo.
2954306|NCT02873143||The APA2011 cohort|In September 2011, students at 4 upper secondary schools in Aalborg were invited to answer an online questionnaire and to be part of the APA2011 cohort. From 2846 potential responders, 2200 adolescents responded to the questionnaire, corresponding to a response rate of 77%. A total of 504 adolescents indicating knee pain at least monthly were successfully contacted (a response rate of 83% of those who reported their telephone numbers) and were asked standardized questions on the telephone. This forms the cohort of 504 adolescents with knee pain. In addition a random selected group of adolescents without knee pain in 2011 will be contacted and asked the same questions as those with knee pain.
2954307|NCT02873130|Experimental|Behavioral: Telepractice Global Voice Prevention Model|Participants will complete the Global Voice Prevention Model (GVPM) through West Chester University's Desire 2 Learn (D2L) software program. Synchronous and asynchronous learning opportunities are provided through D2L over a four week period. The GVPM includes vocal hygiene, vocal education, and vocal training.
2954308|NCT02873130|Experimental|Behavioral: In-person Global Voice Prevention Model|Participants will complete the Global Voice Prevention Model (GVPM) at West Chester University in-person. The GVPM will meet for 2 hours once a week for four weeks. The GVPM includes vocal hygiene, vocal education, and vocal training.
2954309|NCT02873130|Sham Comparator|Behavioral: Telepractice, Vocal Hygiene and Vocal Education|Participants will complete Vocal Hygiene and Vocal Education through West Chester University's Desire 2 Learn (D2L) software program. Asynchronous learning opportunities are provided through D2L over a one week period.
2954310|NCT02873117||5 alpha reductase inhibitor|
2954311|NCT02873117||Any other drug for benign prostate hyperplasia|
2954312|NCT02873104|Active Comparator|Treatment|truSculpt rf device, therapeutic settings
2954313|NCT02873104|Sham Comparator|Sham|truSculpt rf device, non-therapeutic settings
2954314|NCT02873091|Active Comparator|CEI|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil. The basal infusion of CEI: 10 ml/h, beginning immediately after the initial dose
2954315|NCT02873091|Active Comparator|PIEB 1|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil.The basal infusion of PIEB1: 5 ml per 30 min, beginning 30 min after the initial dose
2954316|NCT02873091|Active Comparator|PIEB 2|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil. The basal infusion of PIEB2: 10 ml per 60 min, beginning 60 min after the initial dose
2954317|NCT02873078|Experimental|Internet-delivered CBT|Children and parents will receive 10 weekly modules of cognitive behavior therapy (CBT). Parents will also receive 10 weekly modules. Main components in the children's modules are exposure for abdominal symptoms, feared stimuli and situations in which the children are afraid of having symptoms. The parental receive information on how they can support their children in the treatment and how to reinforce health y behaviors and decrease attention to pain behaviors. Therapist support is provided through written messages within the secure platform.
2954318|NCT02873078|No Intervention|Waiting list|This is a wait-list control where the children and parents are allowed to carry on with any contacts within the health-care system, exempt for psychological treatments.
2954319|NCT02873065|Experimental|Ilaprazole|Ilaprazole -based quadruple therapy for 7days：Ilaprazole -based quadruple therapy for 7days: Ilaprazole 5mg bid.
2954320|NCT02873065|Active Comparator|Esoprazole|Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid.
2954321|NCT02873026|No Intervention|Standard care|The patient will receive the standard care given to all patients that have received a vitrectomy following open globe trauma.
2954322|NCT02873026|Experimental|Triamcinolone acetonide|Triamcinolone Acetonide 4mg/0.1ml intravitreal cavity and 40mg/1ml subtenons to be injected at the time of the vitrectomy. Patients will then receive standard care following operation.
2954323|NCT02873013||Prostate Cancer|About 20,000 patients who have received a histopathological diagnosis of prostate cancer from ten countries in Asia.
2954324|NCT02873000|No Intervention|Routine Care Group|Routine Care (R): Standard of care therapy based on admitting diagnosis
2954325|NCT02873000|Experimental|Experimental Group|"Intervention 1 (E1): addition of incentive spirometry every hour while awake;~There will be a computerized protocol with specific instructions documenting:~compliance~patient position while using [sitting up vs laying flat in bed]~inspiratory volume attained~effort, motivation and compliance will subjectively be documented using a visual analogue 0-5 point scale."
2954326|NCT02872987||B-ALL/NHL|
2954327|NCT02872987||ALL/ Lymphoblastic Lymphoma (LBL)|
2954328|NCT02872974||Exposed|Offspring of woman with GDM
2954329|NCT02872974||Not exposed|Offspring of woman without GDM
2954330|NCT02872961||SIBO Positive|Positive small bowel aspirate culture and/or positive glucose breath test
2954331|NCT02872961||SIBO Negative|Negative small bowel aspirate culture and negative glucose breath test
2954332|NCT02872948||70 euploïdes foeti samples|"Patients with foetus euploïde (no sick)"
2954333|NCT02872948||30 trisomies 21 samples|"Patients with foetus reached(affected) by trisomy 21 (sick)"
2954334|NCT02872935|Placebo Comparator|Placebo: Normal Saline|1ml of Normal Saline will be given intravenously with the administering of the spinal dose
2954335|NCT02872935|Experimental|Glycopyrrolate group|1ml of Glycopyrrolate ( .2mg /ml) will be given intravenously with the administering of the spinal dose
2954336|NCT02872922|Active Comparator|Endothelial function after CWUT|Endothelial function of the all patients before and after application continuous waveform of ultrasound therapy (CWUT) measured by technique flow-mediated dilation (FMD).
2954337|NCT02872922|Active Comparator|Endothelial function after PWUT|Endothelial function of the all patients before and after application pulsed waveform of ultrasound therapy (PWUT) measured by technique flow-mediated dilation (FMD).
2954338|NCT02872922|Active Comparator|Endothelial function after PLACEBO|In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off. Endothelial function of the all patients before and after application placebo waveform of ultrasound therapy measured by technique flow-mediated dilation (FMD)
2954339|NCT02872909|Active Comparator|low irradiance LED PDT|Ambulight LED
2954340|NCT02872909|Active Comparator|conventional higher irradiance LED|Conventional LED compared with Ambulight LED
2954341|NCT02872896|Experimental|ClearSight device|Patients having orthopedic, urologic or general surgery will have blood pressure monitored by the ClearSight device second by second throughout surgery.
2954342|NCT02872896|Sham Comparator|Non-ClearSight|Patients having orthopedic, urologic or general surgery will have blood pressure monitored by the Non-ClearSight (the clinical team) every 5 minutes throughout surgery.
2954343|NCT02872883|Experimental|Expectant management and minimal vaginal examinations|Expectant management up to approximately 96hours and vaginal examinations only when necessary during active labour
2954344|NCT02872883|Experimental|Expectant management and routine vaginal examinations|Expectant management up to approximately 96hours and routine vaginal examinations during active labour
2954345|NCT02872883|Experimental|Active management and minimal vaginal examinations|Induction of labour at approximately 24hours and vaginal examinations only when necessary during active labour
2954353|NCT02872831|Active Comparator|22G SharkCore™ needle|Covidien has recently released a novel SharkCore™ Fine Needle Biopsy (FNB) system for EUS-guided tissue acquisition of solid gastrointestinal lesions. With its unique bevel design, this needle has shown promising results to acquire histologic tissue as per oral communication with physicians around the country
2954354|NCT02872831|Active Comparator|22G BNX EUS-FNA needle|The standard 22G BNX Endoscopic Ultrasound Fine needle aspiration (Beacon Endoscopic, Newton, MA) needle is routinely used for the evaluation of solid mass lesions in the pancreas and gastrointestinal tract.
2954355|NCT02872818|Active Comparator|Control group|Medicated with only 4mg/kg 17β estradiol hemihydrate for 20 days to develop endometrial hyperplasia
2954356|NCT02872818|Active Comparator|Metformin group|Having been obtained hyperplasia, the investigators continued medication with 50 mg/kg metformin in addition to 17β estradiol hemihydrate for 10 days
2954357|NCT02872818|Active Comparator|Medroxyprogesterone acetate group|Having been obtained hyperplasia, the investigators continued medication with 1mg/day medroxyprogesterone acetate in addition to 17β estradiol hemihydrate for 10 days
2954358|NCT02872805|Experimental|Educational Intervention (EI)|Prior to the initiation of the intervention an individualized transition plan will be developed to address patient needs identified in the readiness for transition assessment. The educational intervention will include handouts and other educational materials and other pertinent information needed for the transition process. The EI will be present to explain information to participants and their parents but they will not accompany participants to appointments in the adult setting.
2954359|NCT02872805|Experimental|Peer Transition Advocate (PTA)|The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.
2954360|NCT02872792|Experimental|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer in addition of Standard physiotherapy during sepsis for patient with sepsis in ICU
2954361|NCT02872792|Active Comparator|Standard physiotherapy|Standard physiotherapy during sepsis for patient with sepsis in ICU
2954362|NCT02872779|Experimental|Patients Treated for Metastatic Colorectal cancer|Blood sampling for free mutant DNA analysis for Patients Treated for Metastatic Colorectal cancer
2954363|NCT02872766|Experimental|Corneal cross linking (CXL)|Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to Ultraviolet A light with the KXL II system according to the programmed treatment pattern.
2954364|NCT02872753|Experimental|ACP GROUP|Patients will receive a single intra-op ACP injection following a procedure of arthroscopic partial meniscectomy (medial or lateral)
2954365|NCT02872753|Other|CONTROL GROUP|Patients will be treated by standard meniscectomy alone (medial or lateral)
2954366|NCT02872740|Experimental|Embolization of Left Gastric Artery|These patients will have their left gastric artery embolized
2954367|NCT02872740|Experimental|Embolization of Gastroepiploic Artery|These patients will have their gastroepiploic artery embolized
2954368|NCT02872727||Air France Company's Employees Working|Observational cohort : Air France Company's Employees Working in the Marseilles and Paris Airports having Respiratoy health, biological investigations
2954369|NCT02872714|Experimental|Cohort A-ID (Intermittent Dose) Pemigatinib|Pemigatinib in subjects with FGFR3 mutations or fusions.
2954370|NCT02872714|Experimental|Cohort A-CD (Continuous Dose) Pemigatinib|Pemigatinib in subjects with FGFR3 mutations or fusions.
2954371|NCT02872714|Experimental|Cohort B Pemigatinib|Pemigatinib in subjects with other FGF/FGFR alterations.
2954372|NCT02872701|Experimental|Patients Receiving OTL38|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
2954373|NCT02872688|Experimental|GanedenBC30|
2954374|NCT02872675|Experimental|HOST-DM059 (Prebiotic)|HOST-DM059 is the only Second Generation Prebiotic, manufactured by Clasado Biosciences/HOST Therabiomics. HOST-DM059 consists of a specific type of carbohydrate/dietary fibre (GOS), and an enzyme extracted from species of Bifidobacteria (e.g. The β-Galacotosidase Enzyme, & Bifidobacterium Bifidum). The enzyme from which HOST-DM059 is developed provides a highly selective source of energy for certain species of Bifidobacteria. HOST-DM059 encourages the growth and development of Bifidobacteria. Certain species of Bifidobacteria have been demonstrated to exert prominent immunomodulatory effects in terms of regulating systemic inflammation.
2954375|NCT02872675|Placebo Comparator|Maltodextrin|Maltodextrin will be administered as a taste/appearance-matched sugar/carbohydrate.
2954376|NCT02872649|Experimental|study medication|Dabigatran 110mg twice daily with normal renal function (glomerular filtration rate >80 ml/min) Dabigatran 75mg twice daily with impaired renal function (glomerular filtration rate between 80 and 30 ml/min)
2954377|NCT02872649|Active Comparator|control group|Phenprocoumon dosage according to INR
2954378|NCT02872636|Experimental|Treatment Group|
2954379|NCT02872623|Experimental|experimental group|patients clinically suspected of having a tumor of the small intestine
2954380|NCT02872610|Experimental|Self-help Online|6 weeks of internet-based self-help intervention
2954381|NCT02872610|No Intervention|Wait-list|Waiting list control condition
2954382|NCT02872597|Experimental|Treatment|Inhaled ipratropium bromide 250mcg given via nebulization every 6 hours for up to 5 days
2954383|NCT02872597|Placebo Comparator|Placebo|Inhaled normal saline 1.25mL given via nebulization every 6 hours for up to 5 days
2954384|NCT02872584||Prednisone|Patients with dermatological conditions requiring high dose long term glucocorticoid treatment
2954385|NCT02872571|Experimental|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
2954492|NCT02871817||Age-related macular degeneration|Patients presenting with dry AMD or neovascular (wet) AMD, when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
2954386|NCT02872558|Other|Acute Otitis Media Choice Decision Aid|"For patients whose clinician is randomized to the decision aid arm:~The study coordinator will provide the decision aid for the parent/clinician dyad.~The study coordinator will provide a color-printed copy of the decision aid to the clinician prior to the clinician having the antibiotics discussion with the parents.~The study coordinator will offer to provide the treating clinician a concise refresher of the content included in the decision aid in the context of the trial.~The clinician will then, using the decision aid as a tool to facilitate discussion regarding the natural course of AOM, pain control, antibiotics exposure and deeper infections.~The clinician will then engage the parents in a shared decision regarding the use of immediate antibiotics versus a wait and watch prescription that is consistent with both the parent's values and preferences and the clinician's level of comfort."
2954387|NCT02872558|Other|Usual Care|the clinician will discuss management options with the parent in the clinician's usual fashion.
2954388|NCT02872545|Experimental|forward tilted|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in forward tilted position
2954389|NCT02872545|Other|semi sitting|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in semi sitting
2954390|NCT02872545|Other|dorsal decubitus|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in dorsal decubitus
2954391|NCT02872532|Experimental|Testicular tissue|Children faced with a fertility threatening diagnosis or treatment plan will be offered testicular tissue cryopreservation, particularly if pre-pubescent and without other options to preserve fertility.
2954392|NCT02872519|Experimental|Experimental|Patients receive (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET scans. Patients undergo PET imaging scans during 0-45 minutes, 60-75 minutes, and 105-120 minutes after injection and within 4 weeks prior to surgery (Cohort A) or within 4 weeks of SOC imaging at diagnosis and prior to subsequent treatment (Cohort B).
2954393|NCT02872506|Active Comparator|medical treatment by Anti TNF|The medical treatment group will be chosen among patients receiving anti-TNF therapy for the first time
2954394|NCT02872506|Active Comparator|ileocecal resection|The surgical treatment group are the patients operated on for the first time by means of ileocecal resection laparoscopic or laparotomy
2954395|NCT02872493||RYGB|Roux-en-Y Gastric Bypass - these are patients that undergo a Roux-en-Y gastric bypass operation for their bariatric operation.
2954396|NCT02872493||VSG|Vertical Sleeve Gastrectomy - these are patients that undergo a vertical sleeve gastrectomy operation for their bariatric operation.
2954397|NCT02872480|Experimental|ACTIVE Training|Healthy participants will be progressed from 60-80% of their VO2max as determined by the progressive exercise test over the course of 6 30-minute training sessions. Concussed participants will begin 30-minute training sessions at 60% of the VO2 achieved at symptom exacerbation of the exercise test. Intensity will be progressed as tolerated by the participant and training sessions will continue until the participant is asymptomatic for 24 consecutive hours (total number of sessions variable based on clinical recovery).
2954398|NCT02872480|No Intervention|Control|Healthy controls will be asked to follow their normal routine for rest and physical activity. Concussed controls will be asked to follow the guidance for rest and activity as prescribed by the physicians and athletic trainers overseeing their clinical care.
2954399|NCT02872467|Experimental|Syntocinon treatment|Syntocinon spray, 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
2954400|NCT02872467|Placebo Comparator|Placebo|Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
2954401|NCT02872454|Experimental|Text Messaging|
2954402|NCT02872441|Experimental|diagnosis of disease associated with IgG4|patients suffering from organ initially compatible with a diagnosis of a disease associated with IgG4
2954403|NCT02872428|Experimental|Valproic acid (Depacon)|Valproic acid by IV infusion over one hour
2954404|NCT02872428|Placebo Comparator|Isotonic saline solution|The placebo administered by IV infusion over 1 hour
2954405|NCT02872415|Experimental|The forearm as blood puncture site|The child receives a puncture blood on the forearm
2954406|NCT02872415|Placebo Comparator|Fingers like blood puncture site|Premature receiving a puncture blood on the finger
2954407|NCT02872402|Experimental|Intervention group|"At 2-mo postpartum, women will start the 1-yr lifestyle intervention that will consist of 7 face-to-face individual sessions of 1-hr (at 2, 3, 4, 5, 6, 9, 12 mo postpartum and a follow-up at 18 mo). Metabolic and anthropometric measurements will be assessed at 2,6,12 and 18 mo postpartum. In addition, 7 individual sessions of 30 min between face-to-face sessions will be carried out on the phone.~Benefits of exclusive breastfeeding, healthy eating and physical activity will be portrayed at each visit ."
2954408|NCT02872402|Active Comparator|Active control lifestyle intervention|Women in the control group will come to the testing unit at 2, 6, 12 and 18 mo postpartum for metabolic and anthropometric measurements and at 3, 4, 5, 9 mo for weight measurements only. They will receive standard lifestyle recommendations in the form of written information at each visit.
2954409|NCT02872389|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
2954410|NCT02872389|Experimental|Desflurane|Anesthesia was maintained with desflurane.
2954411|NCT02872376||Anemic|Anemic patients
2954412|NCT02872363|No Intervention|Control|The current standard care text message reminder (SMS) that women routinely receive when being invited for their breast screening mammogram will be sent to the control group at 7 and 4 days before their timed appointment.
2954413|NCT02872363|Experimental|Intervention A - Behavioural Regulation|Intervention A will be a text message reminder (SMS) containing a behavioural regulation message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment.
2954414|NCT02872363|Experimental|Intervention B - Priority|Intervention B will be a text message reminder (SMS) containing a priority message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment.
2954415|NCT02872350|Experimental|Premature with necrotizing enterocolitis|
2954493|NCT02871817||Diabetic retinopathy|Patients presenting with Diabetic Retinopathy, when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
2954416|NCT02872337|Experimental|Experimental (Intervention): PreopPT Group|This group will undergo the group preoperative education session. Following this session (intervention) this group underwent a one-time, one-on-one preoperative PT session. They also were given access to a web-based microsite which was customized to surgeon
2954417|NCT02872337|Placebo Comparator|Control (standard of care): No PreopPT Group|This group underwent the current of standard of care at our institution. This only includes the group preoperative education session. No further preoperative education was given.
2954418|NCT02872324|Experimental|Sessions of Mindfulness Based Cognitive Therapy (MBCT)|
2954419|NCT02872311|Active Comparator|High Dose Influenza Vaccine|This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
2954420|NCT02872311|Active Comparator|Adjuvanted Influenza Vaccine|This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
2954421|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine+HD|This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study.
2954422|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine +Adj|This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
2954423|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine+Recomb|This group will be administered a standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
2954424|NCT02872298|Experimental|Treatment|Treatment: Targeted Lung Denervation (TLD)
2954425|NCT02872285|Experimental|LYC-30937-EC 25 mg PO QD|LYC-30937-EC 25 mg by mouth once daily for 12 weeks
2954426|NCT02872285|Placebo Comparator|Matching Placebo PO QD|Placebo enteric coated (EC) by mouth once daily for 12 weeks
2954427|NCT02872272|Experimental|Treatment with Amikacin|Dressing impregnated by administration of amikacin
2954428|NCT02872259|Experimental|BGB324 + pembrolizumab|"BGB324 capsules, 200 mg once daily + pembrolizumab 2 mg/kg IV every 3. week~Treatment until disease progression, or unacceptable toxicity"
2954429|NCT02872259|Experimental|BGB324 + dabrafenib and trametinib|"BGB324 capsules: Dose finding part of the study will determine if 100 mg once daily should be used for main part of the study or if 200 mg once daily once daily should be used.~Dabrafenib capsules: 150 mg twice daily Trametinib tablets: 2 mg once daily~Treatment until disease progression, or unacceptable toxicity"
2954430|NCT02872259|Active Comparator|pembrolizumab|"Pembrolizumab 2 mg/kg IV every 3. week~Treatment until disease progression, or unacceptable toxicity"
2954431|NCT02872259|Active Comparator|dabrafenib and trametinib|"Dabrafenib capsules:150 mg twice daily Trametinib tablets: 2 mg once daily~Treatment until disease progression, or unacceptable toxicity"
2954432|NCT02872246|Experimental|SPF evaluation|Subjetcs with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
2954433|NCT02872233|Experimental|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
2954434|NCT02872220|Experimental|SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104|All test products compared to that of a negative control [0.9% NaCl] were tested simultaneously on each subject.
2954435|NCT02872207|Experimental|Suncare agent 1 + control|Application of control and test product into one of the subjects two eyes.
2954436|NCT02872207|Experimental|Suncare agent 2 + control|Application of control and test product into one of the subjects two eyes.
2954437|NCT02872194|Experimental|Suncare agent A + control|Application of control and test product into one of the subjects two eyes.
2954438|NCT02872194|Experimental|Suncare agent B + control|Application of control and test product into one of the subjects two eyes.
2954439|NCT02872194|Experimental|Suncare agent C + control|Application of control and test product into one of the subjects two eyes.
2954440|NCT02872181|Experimental|BMI <30|Pregnant women undergoing C/S with BMI <30
2954441|NCT02872181|Experimental|BMI 30-40|Pregnant women undergoing C/S with BMI 30-40
2954442|NCT02872181|Experimental|BMI >40|Pregnant women undergoing C/S with BMI >40
2954443|NCT02872155|Experimental|Oral hydratation|
2954444|NCT02872155|Active Comparator|Endovenous hydratation|
2954445|NCT02872142|Experimental|Albutein 5%|Plasma exchanges with Albutein 5% as a replacement solution
2954446|NCT02872129||166 women with FM/CWP|166 women with Fibromyalgia (FM) or Chronic Widespread Pain (CWP) that participated in an Randomised Controlled Trial called GAU in western Sweden 2004-2005.
2954447|NCT02872116|Experimental|Nivolumab + Ipilimumab|"Nivolumab + Ipilimumab for 4 doses, followed by Nivolumab monotherapy~Enrollment is closed for this arm"
2954448|NCT02872116|Active Comparator|XELOX (Oxaliplatin + Capecitabine)|
2954449|NCT02872116|Active Comparator|FOLFOX (Oxaliplatin + Leucovorin + Fluorouracil)|
2954450|NCT02872116|Experimental|Nivolumab + XELOX|
2954451|NCT02872116|Experimental|Nivolumab + FOLFOX|
2954452|NCT02872103|Experimental|F-627|F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.
2954453|NCT02872103|Placebo Comparator|Placebo|Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.
2954454|NCT02872090|Experimental|Arm 1|The patients receive once a week during 4 weeks, in the order: indacaterol, tiotropium, glycopyrronium and placebo
2954455|NCT02872090|Experimental|Arm 2|The patients receive once a week during 4 weeks, in the order: tiotropium, glycopyrronium, placebo and indacaterol
2954456|NCT02872090|Experimental|Arm 3|The patients receive once a week during 4 weeks, in the order: glycopyrronium, placebo, indacaterol and tiotropium,
2954457|NCT02872090|Experimental|Arm 4|The patients receive once a week during 4 weeks, in the order: placebo, indacaterol and tiotropium and glycopyrronium
2954712|NCT02870413|No Intervention|Usual care|Participants in the control arm will receive care as usual.
2954458|NCT02872077|Active Comparator|Auricular Acupuncture|Study subjects randomized to this group will receive auricular acupuncture: the investigator will evaluate the infant using an ear point locator to determine active sites, and will place acupuncture needles in the active sites found in one ear. Acupuncture sites will be alternated every 3 days between right and left ear.
2954459|NCT02872077|No Intervention|Control|The subjects randomized to the control group will have NO interventions, and will continue to receive routine care for NAS, pharmacologic and non-pharmacologic, per NICU protocol.
2954460|NCT02872064|Experimental|Treatment with PDT|A single intravenous injection of Verteporfin (0.4mg/kg) will be administered, at least 60minutes and up to 90 minutes before laser activation. A 690nm red laser light will be delivered with a diffuser laser fibre inserted through the skin into the breast tissue, with light dose escalation after every three patients. All patients will have fixed dose of the photosensitizer but variable light dose.
2954461|NCT02872051|No Intervention|Control|Standard treatment and standard vocational rehabilitation
2954462|NCT02872051|Experimental|IBBIS MHC|IBBIS mental health care and standard vocational rehabilitation
2954463|NCT02872051|Experimental|IBBIS integrated MCH and VR|Integrated mental health care and vocational rehabilitation
2954464|NCT02872038|Experimental|Treatment|Cefepime intraperitoneal continuous dosing
2954465|NCT02872038|Active Comparator|Control|Cefazolin plus Ceftazidime intraperitoneal continuous dosing
2954466|NCT02872025|Experimental|Pembrolizumab intralesionally (IL) x 2 doses|Subjects, upon diagnosis with high risk DCIS, will be offered 2 doses of pembrolizumab injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 2nd dose. The subject will then undergo the surgical treatment as determined by the surgeon and the subject (partial mastectomy or mastectomy).
2954467|NCT02872025|No Intervention|No active treatment|The control group will proceed to surgery alone following the diagnosis of high risk DCIS.
2954468|NCT02871999|Active Comparator|Control group|This group receives normal treatment after surgery,with no acupuncture.
2954469|NCT02871999|Experimental|Experimental group|This group receives acupuncture therapy besides normal treatment after surgery. The acupuncture therapy starts after 24 hours of surgery, 1 time a day, 30 minutes every time, until the fifth day.
2954470|NCT02871986||Individuals with hypogonadism|Individuals with hypogonadism requiring pubertal induction. Participants will receive oestrogen therapy in the form of transdermal oestrogen patch, which is standard care.
2954471|NCT02871973|Experimental|SDP|Families randomized to intervention group will receive Sit Down and Play while they wait in the waiting room to be seen by their primary care provider at current and subsequent well-child visit.
2954472|NCT02871973|Active Comparator|CDC Handout|Families in the control group will receive the Center for Disease Control and Prevention (CDC) Handout at enrollment.
2954473|NCT02871960|Experimental|Robotic colectomy|Patients undergoing robotic colectomy for colorectal cancer
2954474|NCT02871960|Active Comparator|Laparoscopic colectomy|Patients undergoing laparoscopic colectomy for colorectal cancer
2954475|NCT02871934|Experimental|PGx+|Patients in the PGx+ (intervention) arm will have their SLCO1B1 results reported to their ordering provider immediately.
2954476|NCT02871934|Experimental|PGx-|Patient in the PGx- (control) arm will have their SLCO1B1 results reported to their ordering provider at the end of the study (after 12 months).
2954477|NCT02871921|Experimental|Conversational Engagement|Participants engage in 30-minute face-to-face communications with study staff through internet/webcam 4 times per week for 24 weeks (6 months), followed by sustaining dose of 2 times per week of 30 minutes session for additional 24 weeks (6 months). Conversational staff will facilitate content-standardized but naturalistic-style social engagement. Staff and participants will engage in conversation about a wide variety of topics that are culturally and personally relevant and interesting to participants. Each day, participants will be able to choose from two topics.
2954478|NCT02871921|No Intervention|Control Group|Participants will receive a phone call once per week that lasts less than 10 minutes; interviewers ask brief questions to monitor their social activities and health conditions
2954479|NCT02871908|Experimental|L reuteri DSM 17938|L reuteri DSM 17938 2 x 10^8 twice daily
2954480|NCT02871908|Placebo Comparator|Controls|Identically appearing placebo twice daily
2954481|NCT02871882|Active Comparator|Ox bile extract|Ox bile extract 500 mg tablets taken orally twice daily for 28 (+/- 4) days Gastric Emptying test, Waist and hip measurements, Mixed oral glucose tolerance test, Blood tests
2954482|NCT02871882|Placebo Comparator|Placebo|Matching placebo tablets taken orally twice daily for 28 (+/- 4) days Gastric Emptying test, Waist and hip measurements, Mixed oral glucose tolerance test, Blood tests
2954483|NCT02871869|Active Comparator|Control group A|Control group A was treated with single R-CHOP protocol[Rituximab 375mg/㎡,one day before CHOP protocol, CHOP protocol included vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
2954484|NCT02871869|Experimental|Trial group A|Trial group A was treated with Cinobufacini Tablets combined with R-CHOP protocol[Rituximab 375mg/㎡,one day before CHOP protocol, CHOP protocol included vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
2954485|NCT02871869|Active Comparator|Control group B|Control group B was treated with single CHOP protocol[vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
2954486|NCT02871869|Experimental|Trial group B|Trial group B was treated with Cinobufacini Tablets combined with CHOP protocol[vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
2954487|NCT02871856|Other|Single|Single arm only, CT screening of lung
2954488|NCT02871843|Experimental|Escalation of RRx-001 with TMZ + RT|Dose escalation of RRx-001 with fixed doses of Temozolomide and radiation followed by Temozolomide maintenance therapy
2954489|NCT02871830|Experimental|Physical activity intervention group|
2954490|NCT02871830|No Intervention|Control group|
2954491|NCT02871817||Normal Vision|Patients without significant vision deficit (20/20 vision), when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
2954494|NCT02871804|Active Comparator|separated resection of the splenic vein|separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
2954495|NCT02871804|Experimental|combined resection of the splenic vein|combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
2954496|NCT02871791|Experimental|Palbociclib, Everolimus, Exemestane|"Palbociclib will be administered orally, once daily for 21 consecutive days followed by a 7-day rest (28-day cycle)~Everolimus will be administered orally, once daily on a 28 day schedule~Exemestane will be administered orally, once daily on a 28 day schedule~Participants will be treated with increasing/decreasing doses of palbociclib and everolimus to establish MTD(s)/RP2D for both drugs in the setting of the triple combination of palbociclib, everolimus and exemestane"
2954497|NCT02871778|Experimental|VX-371 in Hypertonic Saline (HS), then HS, then HS + Ivacaftor|"Part A/ Treatment Period 1: VX-371 in Hypertonic Saline~Part A/ Treatment Period 2: Hypertonic Saline~Part B/ Treatment Period 3: Hypertonic Saline + Ivacaftor"
2954498|NCT02871778|Experimental|HS, then VX-371 in HS, then VX-371 in HS + Ivacaftor|"Part A/ Treatment Period 1: Hypertonic Saline~Part A/ Treatment Period 2: VX-371 in Hypertonic Saline~Part B/ Treatment Period 3: VX-371 in Hypertonic Saline + Ivacaftor"
2954499|NCT02871778|Experimental|VX-371, then Placebo, then Placebo + Ivacaftor|"Part A/ Treatment Period 1: VX-371~Part A/ Treatment Period 2: Placebo~Part B/ Treatment Period 3: Placebo + Ivacaftor"
2954500|NCT02871778|Experimental|Placebo, then VX-371, then VX-371 + Ivacaftor|"Part A/ Treatment Period 1: Placebo~Part A/ Treatment Period 2: VX-371~Part B/ Treatment Period 3: VX-371 + Ivacaftor"
2954501|NCT02871765|Experimental|education group|In education group, each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department by researchers. Three months later, participants in the education group received a follow-up phone call in order to clarify any questions related to the brochure. All participants completed posttest at 6-month follow-up.
2954502|NCT02871765|No Intervention|control group|The control group received the brochure only.
2954503|NCT02871752|Experimental|MBSR (Mindfulness condition)|MBSR (mindfulness-based stress reduction) is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations. Lesson activities include the following: (1) mindful meditation (e.g., awareness of breathing, body scan, sitting, walking); (2) yoga; and (3) group discussion.
2954504|NCT02871752|Active Comparator|HealthPro (Control Matched Condition)|HealthPro is a health promotion program designed by Dr. David Victorson of Northwestern University Medical Social Sciences Department and his research team to function as a matched control for the MBSR intervention in this research study. The program teaches and promotes healthy behaviors, skills, and lifestyles. Major learning themes include: (1) health behavioral change readiness and self-assessment; (2) physical activity, movement, and non-sedentary lifestyles; (3) dietary and nutritional considerations for optimal health; (4) emotional wellness and coping with difficulties; (5) social engagement, relationships intimacy, and health; (6) managing bodily pain; (7) weight management and weight loss strategies; (8) health behavior maintenance over the long-term.
2954505|NCT02871739|Experimental|DA viewing with SPI Feedback|Group 1 receives three decision aids and feedback on their standardized patient (SPI) interaction rating their shared decision making skills and highlighting opportunities for improvement.
2954506|NCT02871739|Experimental|DA viewing with no SPI Feedback|Group 2 receives three decision aids. This group does not receive any feedback from the SPI.
2954507|NCT02871739|Experimental|Webinar with SPI Feedback|Group 3 receives an online, interactive webinar that focuses on SDM skills in clinical encounters and feedback on their standardized patient (SPI) interaction rating their shared decision making skills and highlighting opportunities for improvement.
2954508|NCT02871739|Experimental|Webinar with no SPI Feedback|Group 4 receives an online, interactive webinar that focuses on SDM skills in clinical encounters. This group does not receive any feedback from the SPI.
2954509|NCT02871726|Experimental|Experimental|TRUS and TRUS-Robot will be used during prostate biopsy
2954510|NCT02871713|Active Comparator|Intrathecal morphine|Intrathecal morphine 100 mcg
2954511|NCT02871713|Experimental|Quadratus lumborum block|Bilateral QLB with 20 ml of 0.5% ropivacaine per side (maximum total dose 3 mg/kg)
2954512|NCT02871713|Experimental|Intrathecal morphine + Quadratus lumborum block|Bilateral QLB with 20 ml of 0.5% ropivacaine per side (maximum total dose 3 mg/kg) + Intrathecal morphine 100 mcg
2954513|NCT02871700|Experimental|Action observation therapy (AOT)|Action observation therapy (AOT)
2954514|NCT02871700|Experimental|Mirror therapy (MT)|Mirror therapy (MT)
2954515|NCT02871700|Active Comparator|Control group|Customary bilateral UE training
2954516|NCT02871687|Placebo Comparator|Placebo|Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital
2954517|NCT02871687|Active Comparator|Simvastatin|Subjects in the simvastatin arm will receive simvastatin 40 mg daily for the 3 month duration of the study.
2954518|NCT02871687|Active Comparator|Pravastatin|Subjects in the pravastatin arm will receive pravastatin 80 mg daily for the 3 month duration of the study.
2954519|NCT02871674|Experimental|Intervention group|Participants in the intervention group will receive behavioural training by psychologists in three sessions over three weeks
2954520|NCT02871674|No Intervention|Control group - usual care|Participants in the control group will receive usual care. They will also attend their usual appointments with the psychiatrists. They will not receive any intervention.
2954521|NCT02871661|Active Comparator|Amitriptyline|This group will be treated with medication alone (amitriptyline hydrochloride, 25 mg) for chronic vulvar pain (vulvodynia).
2954522|NCT02871661|Active Comparator|Amitriptyline plus kinesiotherapy|This group will be treated with medication (amitriptyline hydrochloride, 25 mg) plus pelvic floor exercises such as Kegel contractions and stretching of pelvic floor muscles with patients own hands.
2954713|NCT02870400|Experimental|REGN2477|Cohorts 1 - 5 will receive REGN2477
2954523|NCT02871661|Active Comparator|Amitriptyline plus IC (Quark)|This group will be treated with medication (amitriptyline hydrochloride, 25 mg) plus electrical stimulation with Interferential Current (manufacturer: Quark Medical; Model: Dualpex 961 - program number 42): two electrodes put into the perineal surface area emitting interferential current, once a week for twenty minutes each, for eight weeks long.
2954524|NCT02871648|Placebo Comparator|Placebo|Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital
2954525|NCT02871648|Active Comparator|Fludrocortisone|Subjects will receive 0.1 mg of fludrocortisone (Florinef) on one of three study days.
2954526|NCT02871648|Active Comparator|Epleronone|Subjects will receive 100 mg of epleronone on one of three study days.
2954527|NCT02871635|Experimental|BI 695501|
2954528|NCT02871635|Active Comparator|HUMIRA + BI 695501|
2954529|NCT02871609||Patients with longterm ureteral stent|
2954530|NCT02871596|Experimental|Placebo,Flavonoids,Flavonoids+Prebiotics|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
2954531|NCT02871596|Experimental|Placebo,Flavonoids+Prebiotics,Flavonoids|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
2954532|NCT02871596|Experimental|Flavonoids,Placebo,Flavonoids+Prebiotics|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
2954533|NCT02871596|Experimental|Flavonoids,Flavonoids+Prebiotics,Placebo|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
2954534|NCT02871596|Experimental|Flavonoids+Prebiotics,Placebo,Flavonoids|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
2954535|NCT02871596|Experimental|Flavonoids+Prebiotics,Flavonoids,Placebo|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
2954536|NCT02871583|Active Comparator|lichtenstein|lichtenstein procedure
2954537|NCT02871583|Active Comparator|Kugel|Kugel procedure
2954538|NCT02871583|No Intervention|control|healthy volunteers
2954539|NCT02871570|Experimental|Moderate Hepatic Impairment|A single dose of IV Rivipansel over 20 minutes
2954540|NCT02871570|Experimental|Normal Hepatic Function|A single dose of IV Rivipansel over 20 minutes
2954541|NCT02871544|Sham Comparator|Low BNP and Low NGAL Group|BNP≤100pg/ml and NGAL≤153pg/ml
2954542|NCT02871544|Active Comparator|High BNP and Low NGAL Group|BNP>100pg/ml and NGAL≤153pg/ml
2954543|NCT02871544|Active Comparator|Low BNP and High NGAL Group|BNP≤100pg/ml and NGAL>153pg/ml
2954544|NCT02871544|Active Comparator|High BNP and High NGAL Group|BNP>100pg/ml and NGAL>153pg/ml
2954545|NCT02871531|Experimental|Pneumatic retinopexy|Patients with retinal detachment allocated to pneumatic retinopexy
2954546|NCT02871531|Experimental|Vitrectomy|Patients with retinal detachment allocated to vitrectomy
2954547|NCT02871518|Experimental|Two cycle CCRT|Concurrent cisplatin(100mg/m2,D1,D22)combine with IMRT
2954548|NCT02871518|Active Comparator|Three cycle CCRT|Concurrent cisplatin(100mg/m2,D1,D22 and D43)combine with IMRT
2954549|NCT02871505|Experimental|Molecular subtyping (14d/f) of Treponema pallidum|Benzathine Penicillin G treatment
2954550|NCT02871505|Experimental|Molecular subtyping (others) of Treponema pallidum|Benzathine Penicillin G treatment
2954551|NCT02871492|Experimental|Pritelivir 5% w/w ointment|Topical treatment (20 applications), 5 times daily for 4 days
2954552|NCT02871492|Placebo Comparator|Pritelivir ointment matching placebo|Topical treatment (20 applications), 5 times daily for 4 days
2954553|NCT02871492|Active Comparator|Zovirax® cream|Topical treatment (20 applications), 5 times daily for 4 days
2954554|NCT02871479|Experimental|SAN007 5% cream|A cream containing 5% East Indian sandalwood oil (EISO).
2954555|NCT02871479|Placebo Comparator|Placebo cream|The vehicle cream
2954556|NCT02871479|Experimental|SAN007 10% cream|A cream containing 10% East Indian Sandalwood Oil (EISO).
2954557|NCT02871466|Experimental|stem cells infusion|
2954558|NCT02871453|Experimental|Acupuncture combined rehabilitation|"Scalp acupuncture treatment~Rehabilitation treatment"
2954559|NCT02871453|Experimental|Rehabilitation|Rehabilitation treatment
2954560|NCT02871440|Experimental|Eye drop 1|Omega 3
2954561|NCT02871440|Active Comparator|Eye drop 2|Optive Advanced
2954562|NCT02871440|Active Comparator|Eye drop 3|Optive
2954563|NCT02871427|Experimental|Nelotanserin|Once Daily, Oral, at 20, 40, 60, or 80 mg dose
2954564|NCT02871414|Experimental|REST - Early Group|Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
2954565|NCT02871414|Experimental|REST - Late Group|Control - No treatment for 7 weeks, then provided 7 weeks of sleep skills education provided in group and one-on-one format
2954566|NCT02871401|Experimental|Valganciclovir|Valganciclovir 450 mg, 2 pills by mouth one time per day x 12 weeks
2954567|NCT02871401|Placebo Comparator|Placebo|Placebo, 2 pills by mouth one time per day x 12 weeks
2954568|NCT02871388|Experimental|CONECT|12 week program with additional follow up at 24 weeks.
2954569|NCT02871388|No Intervention|Control|Waitlist control. No intervention for first 12 weeks. Participants given the option to participate in the program after 24 weeks.
2954570|NCT02871375|Other|DT1 MF, then Habitual|Delefilcon A multifocal contact lenses in Period 1, followed by subject's habitual multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.
2954571|NCT02871375|Other|Habitual, then DT1 MF|Subject's habitual multifocal contact lenses in Period 1, followed by delefilcon A multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.
2954572|NCT02871362|Experimental|IQP-AS-118|To be taken once daily with a glass of water. The tablets should not be chewed, but swallowed whole.
2954573|NCT02871362|Placebo Comparator|Placebo|To be taken once daily with a glass of water. The tablets should not be chewed, but swallowed whole.
2954574|NCT02871349|Experimental|Propanolol and MRI|Participants will receive propranolol via oral capsule, crushed tablet, or liquid daily. The drug dosage will be titrated slowly to ensure the drug is tolerated well. Those aged 15-24 will have an MRI before starting drug.
2954714|NCT02870400|Experimental|Placebo|Cohorts 1 - 5 will receive placebo
2954575|NCT02871349|Placebo Comparator|Placebo and MRI|Participants will receive placebo via oral capsule, crushed tablet, or liquid daily. Those aged 15-24 will have an MRI before starting drug.
2954576|NCT02871323|Experimental|Treatment (durvalumab)|Patients receive durvalumab IV over approximately 1 hour on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with SD, no new inter-current illness, and no unacceptable toxicity, may continue treatment beyond 3 courses.
2954577|NCT02871310|Experimental|IQP-AS-118|To be taken once daily dosing of 1 tablet in the morning with 250 mL of water. The tablets should not be chewed, but swallowed whole.
2954578|NCT02871310|Placebo Comparator|Placebo|To be taken once daily dosing of 1 tablet in the morning with 250 mL of water. The tablets should not be chewed, but swallowed whole.
2954579|NCT02871297|Experimental|Vortioxetine|Once daily dosing of vortioxetine (oral tablets) for 26 weeks.
2954580|NCT02871284|Experimental|Sensorimotor training (EI)|The participants of the experimental intervention arm will take part in a 45 minutes sensorimotor training class two times a week for a maximum of 24 weeks at the NCT (National Center for Tumor Diseases). Highly qualified exercise therapists will guide the class. Class size will be no bigger than 8 patients to ensure adequate individual supervision and guidance. Additionally, participants will be asked to perform one weekly 15 minutes home-based sessions without supervision. Participants who are not able to come to the NCT Heidelberg 2x/week will be offered a home-based sensorimotor program including the same exercises. At the beginning, participants will receive an appointment for an individual face-to-face counseling session at the NCT. During this appointment, the patient will receive an exercise manual for individualized home-based sensorimotor training and a practical introduction by the exercise therapist.
2954581|NCT02871284|Active Comparator|machine-based resistance training (AC)|Participants of the active control arm will receive machine-based resistance training. The supervised resistance exercise program will be undertaken twice weekly in small groups (not more than 12 people per group) of participants and will be guided by an exercise physiotherapist over a maximum of 24 weeks. All sessions will start with a warm-up and finish with a cool-down (comprising exercise on a cycle ergometer or treadmill at a relatively low intensity and stretching activities) and will take approximately 45 minutes. Additionally, participants will be asked to perform a weekly 15 minutes home-based resistance training session without supervision
2954582|NCT02871284|No Intervention|usual care|Participants will receive usual care with no additional exercise training or intervention
2954583|NCT02871271|Experimental|IQP-AS-121|To be taken once daily dosing of 1 tablet in the morning.
2954584|NCT02871258|Other|The MetaNeb® System Treatment|Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment.
2954585|NCT02871245|Active Comparator|Comparator Group|Patients received gastrointestinal neoplasms laparoscopic surgery but no acupuncture therapy.
2954586|NCT02871245|Experimental|Acupuncture Therapy Group|Patients received gastrointestinal neoplasms laparoscopic surgery and acupuncture therapy. Finish surgery up to 24 hours electricity acupuncture treatment, treatment 1 times a day, every time lasted 30 minutes, 5 days in a row
2954587|NCT02871232||Intentional exposures among adolescents and adults|
2954588|NCT02871232||Unintentional exposures among infants and children|
2954589|NCT02871219|Experimental|Obinutuzumab + Lenalidomide|"Participants receive Obinutuzumab by vein over on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of Cycles 2-6 and Cycle 8 and then every even-numbered cycle after that (Cycles 10, 12, 14, and so on) up to Cycle 30.~Participants also take Lenalidomide capsules by mouth on Days 1-21 of Cycles 1-6. After Cycle 6, participant may receive up to an additional 12 cycles of Lenalidomide based on how they are responding to Lenalidomide.~Cycle length is 28 days."
2954590|NCT02871206|Experimental|Adjuvanted Influenza Vaccine|Fluad
2954591|NCT02871206|Active Comparator|Quadrivalent Influenza Vaccine|Fluzone
2954592|NCT02871193|Sham Comparator|Group C（Control）|Group C received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml combined with general anesthesia and intravenous patient controlled analgesia pump.
2954593|NCT02871193|Experimental|Group R(Ropivacaine)|Group R received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20 ml combined with general anesthesia and intravenous patient controlled analgesia pump.
2954594|NCT02871193|Experimental|Group D(Dexamethasone)|Group D received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg combined with general anesthesia and intravenous patient controlled analgesia pump.
2954595|NCT02871180|Other|With late night snack|At 10 p.m. a late night snack (one slice of whole meal rye bread containing approximately 20 g of carbohydrate) was eaten from Type 1 diabetic patients on an intensified conventional treatment regimen.
2954596|NCT02871180|Other|Without late night snack|Not nutrients (No late night snack) were consumed at 10 p.m. from Type 1 diabetic patients on an intensified conventional treatment regimen..
2954597|NCT02871167|Experimental|Oocyte/embryo cryopreservation|"Controlled ovarian hyperstimulation (COH)~Oocyte/embryo freezing"
2954598|NCT02871154|Experimental|Delay|Delaying oocyte pick up beyond 39 hours post hCG
2954599|NCT02871141||ECT group|Patients with a major depressive episode treated with ECT. Patients will be investigated (i) prior to the 1st ECT session, (ii) after the 4th ECT session, (iii) after the 12th ECT session, and (iv) 6 months after the 1st ECT session.
2954600|NCT02871141||Antidepressant group|Patients with a major depressive episode treated with antidepressants. Patients will be investigated (i) prior to treatment, (ii) after 10 days of treatment, (iii) after 4 weeks of treatment, and (iv) after 6 months.
2954601|NCT02871128|Experimental|Natureheme-iron|Subjects receive 2 capsules per day containing either 1000 mg Fe.
2954602|NCT02871128|Placebo Comparator|Placebo|Subjects receive 2 capsules per day containing starch placebo of similar appearance.
2954603|NCT02871128|Active Comparator|supplement|Subjects receive 1 capsule per day containing either 100 mg Fe.
2954604|NCT02871115|Experimental|Pharmacy Intervention|"Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will~Perform detailed medication reconciliation~Obtain allergy and vaccination history~Evaluate and document polypharmacy (number of medications)~Document their findings in the medical record and discuss their recommendations (in-person, phone call, email) with each patient's oncology team"
2954605|NCT02871115|Active Comparator|Usual Care|"Participants receiving Usual Oncology Care will not meet with the pharmacist unless indicated as part of their routine clinical care~Study staff will obtain all patient-reported measures from the patient.~Remind participant to complete self-report measures"
2954606|NCT02871102|Experimental|Intervention Arm|
2954607|NCT02871089|Experimental|24/7 Closed loop delivery|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature until 24 months after diagnosis using 24/7 Medtronic insulin pump 640G and Android smartphone.
2954608|NCT02871089|Active Comparator|Multiple Daily Injections|Participants will apply standard insulin therapy using multiple daily injections via insulin pens during the 24 months control period
2954609|NCT02871076|Experimental|Verum Acupuncture|Patients will receive verum acupuncture twice weekly for twelve weeks.
2954610|NCT02871076|Placebo Comparator|Sham Placebo Acupuncture|Patients will receive sham placebo acupuncture twice weekly for twelve weeks.
2954611|NCT02871063||High altitude ARDS|ARDS diagnosed at altitudes greater than 1500 meters above sea level
2954612|NCT02871063||Sea level ARDS|ARDS diagnosed at altitudes below 1500 meters above sea level
2954613|NCT02871050||Castleman Disease Patients|Potential study participants may be of any age, gender, or ethnicity who have been diagnosed with Castleman disease.
2954614|NCT02871037|Experimental|Part 1_Cohort 1_Active|Single, escalating dose of PF-05221304
2954615|NCT02871037|Placebo Comparator|Part 1_Cohort 1_Placebo|Single dose of Placebo
2954616|NCT02871037|Experimental|Part 1_Cohort 2_Active|Single, escalating dose of PF-05221304
2954617|NCT02871037|Experimental|Part 1_Cohort 2_Placebo|Single dose of Placebo
2954618|NCT02871037|Experimental|Part 2_Active|Repeated, escalating doses of PF-05221304
2954619|NCT02871037|Placebo Comparator|Part 2_Placebo|Repeated doses of placebo
2954620|NCT02871037|Experimental|Part 3|Single dose of PF-05221304 with and without food
2954621|NCT02871024|Experimental|Intervention arm|Usual care with two sessions of 2-hour hemoperfusion with Toraymyxin in 24 hours apart
2954622|NCT02871011|Placebo Comparator|Control|Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
2954623|NCT02871011|Experimental|Nitric oxide|Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
2954624|NCT02870998|Experimental|Active learning|Educational strategies will be used to foster active learning.
2954625|NCT02870998|Active Comparator|Passive learning|Traditional educational strategies (lecture) will be used.
2954626|NCT02870985|Experimental|BIOTRONIK Orsiro SES|Preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted. The procedure begins once percutaneous access has been made.Following intracoronary injection of nitroglycerin or isosorbide dinitrate, a baseline angiography of the target vessel must be performed according to the QCA corelab guidelines.The subjects randomized to the experimental arm will be implanted with BIOTRONIK sirolimus eluting coronary stent(Orsiro).
2954627|NCT02870985|Active Comparator|Abbott Xience Prime™ EES|Preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted. The procedure begins once percutaneous access has been made.Following intracoronary injection of nitroglycerin or isosorbide dinitrate, a baseline angiography of the target vessel must be performed according to the QCA corelab guidelines.The subjects randomized to the comparator arm will be implanted with Abbott everolimus eluting coronary stent(Xience Prime™).
2954628|NCT02870972|Experimental|Part 1: BCX7353 350 mg once daily|BCX7353 capsules, 350 mg dose administered once per day for 28 days
2954629|NCT02870972|Experimental|Parts 2 and 3: BCX7353 250 mg once daily|BCX7353 capsules, 250 mg dose administered once per day for 28 days
2954630|NCT02870972|Experimental|Parts 2 and 3: BCX7353 125 mg once daily|BCX7353 capsules, 125 mg dose administered once per day for 28 days
2954631|NCT02870972|Placebo Comparator|Parts 1, 2 and 3: Placebo|Placebo capsules, administered once per day for 28 days
2954632|NCT02870972|Experimental|Part 3: BCX7353 62.5 mg once daily|BCX7353 capsules, 62.5 mg dose administered once per day for 28 days
2954633|NCT02870946|Experimental|Simultaneous RRT|The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced.
2954634|NCT02870946|Experimental|Standard care|The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
2954635|NCT02870933|Experimental|subject|this arm will receive Transepicardial with Transseptal CD 133+ Implantation
2954636|NCT02870933|No Intervention|control|this arm will not receive Transepicardial with Transseptal CD 133+ Implantation
2954637|NCT02870920|Active Comparator|Best Supportive Care|Best supportive care available
2954638|NCT02870920|Experimental|Durvalumab plus Tremelimumab and Best Supportive Care|Tremelimumab 75mg IV 60 minutes Day 1, cycles 1-4 Durvalumab 1500mg IV 60 minutes Day 1 every 28 days. Plus best supportive care
2954639|NCT02870907|Experimental|Low risk group|
2954640|NCT02870907|Experimental|Intermediate risk sub group 1|2 cycles (4 courses): 2 courses of etoposide and Carboplatin from D1 to D5 and Vincristin at D22 and D26- Cyclophosphamide from D22 to D26.
2954641|NCT02870907|Experimental|Intermediate risk sub group 2|2 courses of Vincristin and Carboplatin
2954642|NCT02870907|Experimental|High risk group|"Orbital irradiation~3 cycles of two different types of alternating chemotherapy courses (id 6 courses) :~Etoposide (100 mg/m²/d) and Carboplatin (160 mg/m²/d) with intrathecal Thiotepa injection.~Vincristin (1,5 mg/m²/d) - Cyclophosphamide (1000 mg/m²/d)~Cytapheresis for peripheral blood stem cells collection after the primary or the secondary courses of Vincristine- Cyclophosphamide.~High dose chemotherapy :~Carboplatin (AUC : 7/d) - etoposide (250 mg/m²/d) - Thiotepa (300 mg/m²/d)~Peripheral bood stem cell transplantation."
2954643|NCT02870868|Experimental|Slow breathing with exhale greater than inhale|
2954644|NCT02870868|Experimental|Slow breathing with exhale equal to inhale|
2954645|NCT02870855|Experimental|HCG group|intrauterine injection of HCG before blastocyst transfer
2954646|NCT02870855|No Intervention|Control group|blastocyst transfer
2954763|NCT02870075|Active Comparator|Fasted exercise|Fasted prior to exercise
2955311|NCT02866279|Experimental|Immediate Postpartum|Contraceptive Implant placed 1-3 days postpartum
2954647|NCT02870842|Placebo Comparator|Control|Perform recruitment maneuver with fraction of inspired oxygen (FiO2) of 1.0 after intubation under lung ultrasound guidance and maintain FiO2 of 0.6 during the general anesthesia.
2954648|NCT02870842|Active Comparator|Low FiO2|Perform recruitment maneuver with low FiO2 of 0.3 after intubation under lung ultrasound guidance and maintain FiO2 of 0.3 during the general anesthesia.
2954649|NCT02870829|Experimental|Vitamin K2|Vitamin K comes in various isoforms and we have elected to use the K2 isoform - menaquinone-7. We have chosen a dose of 360mcg 3x/week as previous studies using menaquinone-7 demonstrated an increasing dose efficacy relationship up to this strength. Vitamin K2 is manufactured by Nattopharma
2954650|NCT02870829|No Intervention|Standard Therapy|Subjects randomised to standard therapy will continue to receive dialysis and chronic kidney disease-metabolic bone disease (CKD-MBD) management in accordance to current best practise guidelines
2954651|NCT02870816|Active Comparator|Tissue engineered skin substitute|Application of tissue engineered skin substitute with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional application of skin substitute will be applied weekly at weeks 2-11.
2954652|NCT02870816|Experimental|Amnionic membrane graft|Application of amnionic membrane graft with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional piece of amnionic membrane graft will be applied weekly at weeks 2-11
2954653|NCT02870790|Experimental|treatment|A single open-label arm. All participants receive daily oral pill containing TDF/FTC
2954654|NCT02870777|Experimental|MRD-directed therapy|
2954655|NCT02870764|Active Comparator|Dan-shen extract|Based on the standard medical care, 200mg of Danshenduofensuanyan, added into 250ml of 0.9% saline injection, given by continuous IV infusion at 2.5ml/min within 2 hours, once a day during the patients' hospitalization. Danshen drop spill (30 pill/day) taken orally for 60 days after discharge.
2954656|NCT02870764|Placebo Comparator|Placebo|Based on the standard medical care, placebo was 200mg of glucose, added into 250ml of 0.9% saline injection, given by continuous IV infusion at 2.5ml/min within 2 hours.
2954657|NCT02870751|Experimental|ST-only ETEC strain TW11681 or TW10722|Oral inoculum of several doses of bacteria to establish range to achieve diarrhea attack rate in around 70% of volunteers.
2954658|NCT02870738|Active Comparator|Pelvic Floor Physical Therapy|One hour of pelvic floor physical therapy twice weekly for 8 weeks
2954659|NCT02870738|Active Comparator|Bladder Instillations|Bladder instillation of lidocaine, kenalog, heparin sulphate, and bicarbonate twice weekly for 8 weeks
2954660|NCT02870725|No Intervention|Control Group (Treatment As Usual)|Individuals randomized into the control condition will not receive any active treatment but will have access to customary, community-based supportive services. These individuals will complete the pre-, post- and 4-week post-intervention outcome assessment measures and will serve as a means of comparison for those in the other arm of the study.
2954661|NCT02870725|Experimental|CBT Individual Psychotherapy (Treatment)|Behavioral Intervention (Individual Psychotherapy). These individuals will complete the pre-, post- and 4-week post-intervention outcome assessment measures and will serve as a means of determining whether or not the intervention was effective compared to the control arm.
2954662|NCT02870712|Experimental|suture directed|The suture of the perineum is headed by obtaining hemostasis by digital compression 5 minutes; If hemostasis is obtained, the perineum will not be sutured. In case of failure of hemostasis, suture of the perineum will be realized.
2954663|NCT02870712|Active Comparator|systematic suture|systematic suture tears following current recommendations
2954664|NCT02870699|Experimental|ARM A|"Evonail film forming solution : 1 daily application on the left hand~Placebo excipient : 1 daily application on the right hand"
2954665|NCT02870699|Active Comparator|ARM B|"Evonail film forming solution : 1 daily application on the right hand~Placebo excipient : 1 daily application on the left hand"
2954666|NCT02870686|Active Comparator|ERCP without the use of fluoroscopy|Patients with uncomplicated bile duct stones detected by EUS was assigned to the EUS guided ERCP without fluoroscopy clear all of the bile duct stones.
2954667|NCT02870686|Active Comparator|ERCP with the use of fluoroscopy|Patients with uncomplicated bile duct stones detected by EUS was assigned to underwent ERCP with the use of fluoroscopy to clear all of the bile duct stones.
2954668|NCT02870673|Active Comparator|Injection of Shincort 0.5 ml and Xylocaine 0.5ml mixture|"In the first week of recruitment, this group will receive the local injection around the distal wrist crease with mixture of Shincort Inj(10mg/ml) 0.5 ml and xylocaine(20mg/ml) 0.5 ml only one time.~The ultrasound-guided procedure is performed by the orthopedic physician."
2954669|NCT02870673|Experimental|sham electroacupuncture|"In this group, the participants receive acupuncture treatment and only 2 minutes electrical stimulation.~Each needle insertion depth and position are confirmed by the ultrasound. The procedure makes sure that needle pin is directly placed on the median nerve and prevent nerve penetration. Then the electrical stimulator is connected to the needles as cathode and anode and is turned on to the intensity which can induce thenar muscle contraction or reach the upper limit of the participant. After 2 minutes, the stimulator will turn off spontaneously and the participant will not be informed.~The whole course will cost 20 minutes after needles are pulled out. Every participant is asked to receive 1 treatment per week in the consecutive 3 months(total 12 times)."
2954670|NCT02870673|Experimental|electroacupuncture|"In this group, the participants receive acupuncture treatment and 20 minutes electrical stimulation.~Each needle insertion depth and position are confirmed by the ultrasound. The procedure makes sure that needle pin is directly placed on the median nerve and prevent nerve penetration. Then the electrical stimulator is connected to the needles as cathode and anode and is turned on to the intensity which can induce thenar muscle contraction or reach the upper limit of the participant.~The whole course will cost 20 minutes after needles are pulled out. Every participant is asked to receive 1 treatment per week in the consecutive 3 months(total 12 times)."
2954671|NCT02870647|Other|Single arm study|only 1 arm - no comparison nor randomization in this study
2954672|NCT02870634|Experimental|Cu(II)ATSM|Cu(II)ATSM capsules, administered orally once daily
2954673|NCT02870608|Experimental|preterm labor group|Pregnant women hospitalized for preterm labor
2954674|NCT02870608|Other|control group|Pregnant women with a normal pregnancy
2955312|NCT02866279|Active Comparator|Delayed|Contraceptive Implant placed 6 or more weeks postpartum
2954675|NCT02870595|Active Comparator|Parallel lidocaine injection|Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
2954676|NCT02870595|Sham Comparator|Parallel|In the sham comparator, the device will be placed on the skin, but not turned on. Digit block anesthesia will progress in usual fashion as with active comparator, except without the vibratory device engaged.
2954677|NCT02870582|Experimental|Donafenib|Donafenib 300mg bid on 1-21 days of each 28 days cycle.
2954678|NCT02870582|Placebo Comparator|Placebo|Placebo 300mg bid on 1-21days of each 28 days cycle.
2954679|NCT02870569|Experimental|Donafenib1|This is the lower dose group. Donafenib 200mg bid
2954680|NCT02870569|Active Comparator|Donafenib2|This is the higher dose group. Donafenib 300mg bid
2954681|NCT02870556|Experimental|EP, Cervical epidural group|patients undergoing salvage laryngectomy (failed radiotherapy to treat laryngeal cancer) will receive cervical epidural analgesia in addition to the standard general anesthesia (induction with propofol 2 mg / kg, endotracheal intubation facilitated by cis-atracurium 0.3 mg / kg and 0.15 mg /kg on demand and maintained with inhalational anesthetic sevoflurane) Cervical epidural technique: epidural needle will be inserted at C 6-C7 or C7-T1 under fluoroscopy in prone position, 6 ml of 0.125% bupivacaine and fentanyl 2 mic/ ml will be administered before skin incision followed by 4 ml of the same injectate, will be infused continously for 2 days
2954682|NCT02870556|Active Comparator|GA, General anesthesia|patients undergoing salvage laryngectomy (failed radiotherapy to treat laryngeal cancer) will receive standard general anesthesia only (induction with propofol 2 mg / kg, endotracheal intubation facilitated by cis-atracurium 0.3 mg / kg and 0.15 mg /kg on demand and maintained with inhalational anesthetic sevoflurane) in addition to postoperative analgesia through patient controlled intravenous morphine analgesia (PCA), that involve 1 mg continuous infusion and 2 mg boluses with lockout interval 10 min
2954683|NCT02870543|Placebo Comparator|Placebo|Placebo
2954684|NCT02870543|Active Comparator|Phytolacca decandra|The Phytolacca decandra with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
2954685|NCT02870543|Active Comparator|Melissa officinalis|The Melissa officinalis with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
2954686|NCT02870543|Experimental|Phyt.decandra + Melissa offic.|The combination of Phytolacca decandra with Melissa offcicinalis with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
2954687|NCT02870530|Experimental|division-less gastric bypass|
2954688|NCT02870530|Active Comparator|mini-gastric bypass|
2954689|NCT02870517|Experimental|Relaxing Music|Participants will listen to relaxing music through noise-cancelling headphones during induction.
2954690|NCT02870517|Active Comparator|No Music|Participants will wear noise-cancelling headphones during induction but no music will be played through them.
2954691|NCT02870504|Experimental|corneoscleral limbus group|Laser spot locates on the corneoscleral limbus.
2954692|NCT02870504|Experimental|One spot group|Laser spot locates on one spot away from the corneoscleral limbus
2954693|NCT02870504|Experimental|Two spots group|Laser spot locates on two spots away from the corneoscleral limbus
2954694|NCT02870491|No Intervention|Control|Existing standard of care.
2954695|NCT02870491|Experimental|Free Distribute+Preemptive Delivery|Community health workers (CHWs) will deliver oral rehydration salts (ORS) and zinc for free to all households in their catchment area with a child under 5-years-old at the beginning of the study.
2954696|NCT02870491|Experimental|Cost Sharing + Preemptive Delivery|CHWs will visit all households with a child under 5-years-old at the beginning of the study and offer to sell ORS and zinc to caretakers at the time of the visit for them to store in their homes.
2954697|NCT02870491|Experimental|Free Distribution Upon Retrieval|CHWs will visit all households with a child under 5-years-old at the beginning of the study and inform caretakers that they have ORS and zinc available for free that caretakers can retrieved from the CHWs home if needed.
2954698|NCT02870478|Active Comparator|0.01% atropine daily|Nightly dosing of 0.01% atropine
2954699|NCT02870478|Experimental|0.01% atropine twice per week|Atropine dosed twice per week
2954700|NCT02870465||CRIF in operating room|Patients who present with a hand fracture amendable to closed reduction internal fixation (CRIF) who are managed in the operating room.
2954701|NCT02870465||CRIF outside of operating room|Patients who present with a hand fracture amendable to closed reduction internal fixation (CRIF) who are managed outside of the operating room (i.e.: in clinical setting, the emergency department or minor procedures area).
2954702|NCT02870452|Experimental|Hypnosis|Hypnosis for the prevention and management of pain, emotional regulation and promotion of quality of life in people with Haemophilia
2954703|NCT02870452|Experimental|Cognitive-Behavioral Therapy|Cognitive Behavioral Therapy for the prevention and management of pain, emotional regulation and promotion of quality of life in people with Haemophilia
2954704|NCT02870452|No Intervention|Control Group|No psychological intervention - standard Haemophilia care
2954705|NCT02870439|Experimental|patients with at least 20% of wounded burns body|
2954706|NCT02870439|Experimental|patients with at least 5% of wounded burns body|
2954707|NCT02870439|Experimental|patients with post-surgical wounds with skin resection|
2954708|NCT02870426||Group 1A:|Donors after brainstem death (DBDs) undergoing solid organ donation
2954709|NCT02870426||Group 1B:|Donors after brainstem death (DBDs) considered unsuitable for solid organ donation
2954710|NCT02870426||Group 2:|Neurosurgical patients undergoing anterior cranial surgery in which the olfactory nerve (ON) is cut as part of the surgical procedure. The OB of the concomitant severed ON would be donated.
2954711|NCT02870413|Experimental|Telelactation support|Participants in the experimental group will receive unlimited, free telelactation visits with lactation consultants (IBCLCs) as demanded up to 12 weeks post-partum. Services will be available through mobile phone app.
2955313|NCT02866266||All commercially insured patients in the HIRD|
2954715|NCT02870387|Active Comparator|Usual Inpatient Care|Usual Inpatient Care: High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
2954716|NCT02870387|Experimental|Comprehensive Care with Inpatient Consultation|Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.
2954717|NCT02870361|Active Comparator|Insulin nasal spray|160 Units of human insulin as nasal spray
2954718|NCT02870361|Placebo Comparator|Placebo nasal spray|Nasal spray containing placebo solution
2954719|NCT02870348|Experimental|Alpha-1 MP|Alpha-1 MP 60 mg/kg administered weekly via intravenous administration
2954720|NCT02870335|Experimental|Manual Therapy|The objective of treatment is to restore esta possible limitation of global mobility to major lower limb joints and remove any tensions from the musculature involved in a relevant way in this sport.
2954721|NCT02870335|Active Comparator|Proprioceptive neuromuscular facilitation|It is a stretching technique with the aim of increasing the ROM. It includes passive static stretching and contract-relax.
2954722|NCT02870322|Active Comparator|Fruit and Vegetable CSA Prescription|"Study participants randomized to the CSA group will be expected to pick up their weekly CSA box at University Health Services and to commit to using and consuming as much of the produce as they are able. CSA group participants will also be required to attend two cooking and food preparation classes coordinated by Slow Food UW. The classes will teach study participants how to properly clean and prepare the fruits and vegetables from a weekly CSA box, and also offer techniques and show them how to cook the foods in a healthy manner. These classes will also educate study participants on the benefits of eating fruits and vegetables and buying them from local farmers. These two classes will only exist for study participants in this fruit and veggie CSA group. Participants in the CSA group will also be required to take a field trip to the farm providing their CSA share, which will offer the opportunity for participants to gain a better understanding of from where their food comes."
2954723|NCT02870322|Active Comparator|Bikeshare Prescription|"Study participants randomized to the bikeshare group will be expected to use B-cycle bikes for transportation and/or recreation as much as is safe and appropriate. Bikeshare group participants will be required to attend one bicycle use/safety course. This course will introduce the B-cycle program, demonstrate use of the B-cycle station, provide information use of helmets and safety gear, and provide information on the basics of cycling and keeping yourself safe and comfortable while riding in traffic. The study participants in this group will also be required to attend a class on the benefits of exercise, including bicycling, among other forms of physical activity. This class will be offered by the University Health Services Wellness program. B-cycle usage, including estimated distance traveled and frequency of use, will be tracked via the B-cycle Madison website."
2954724|NCT02870322|No Intervention|Control|"Study participants in the control group will receive continued usual care from University Health Services providers, which includes educational brochures on healthy eating and exercising, plus a cash payment. Control group participants are not part of a wait-list group."
2954725|NCT02870309|Experimental|Alpha-1 MP|IV infusions of 60 mg/kg Alpha-1 MP administered weekly over 8 weeks at an infusion rate not to exceed 0.08 mL/kg/min over approximately 15 minutes
2954726|NCT02870296|No Intervention|Control|The control group will receive usual care; no interventions will be administered.
2954727|NCT02870296|Experimental|Intervention|Interventions will be administered to this group. Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
2954728|NCT02870283|Active Comparator|Lithium|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (A) Started Lithium (900mg-1500mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Lithium (900-1500mg) Non responsive patients: 2nd step.~Second step: Randomization for lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) OR lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).~Non responsive patients: 3rd step.~Third step: Crossover lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) X lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).~Non responsive patients: 4th step.~Fourth step: Association with risperidone (1-6mg)"
2954729|NCT02870283|Active Comparator|Acid Valproic|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (B) Started Valproic Acid (1000mg-1500mg).~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Valproic Acid (1000mg-1500mg) Non responsive patients: 2nd step.~Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.~Third step: Crossover: lithium (900mg-1500mg) + carbamazepine (600mg-1200mg). Non responsive patients: 4th step.~Fourth step: Association with risperidone (1-6mg)"
2954730|NCT02870283|Active Comparator|Carbamazepine|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (C) Started Carbamazepine (600mg-1200mg).~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Carbamazepine (600mg-1200mg). Non responsive patients: 2nd step.~Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.~Third step: Crossover: lithium (900mg-1500mg) + valproic acid (1000mg-1500mg). Non responsive patients: 4th step.~Fourth step: Association with risperidone (1-6mg)"
2954945|NCT02868801|Experimental|Pregabalin SR tablet 165mg/day|1pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
2954731|NCT02870270||Head and neck cancer patients|Patients with head and neck cancer who were ≥ 18 years old and had ≥ 16 teeth and no removable prosthesis or dental implants consisting of more than one teeth were included
2954732|NCT02870257|Experimental|Progressive overload strengthening group|"Strengthening protocol with progressive load~Strengthening muscle exercises for the shoulder and scapular with progressive increase of load during 10 weeks (20 sessions)"
2954733|NCT02870257|Active Comparator|Strengthening group|"Strengthening protocol without progressive load~Strengthening muscle exercises for the shoulder and scapular without increase of load (minimal load) during 10 weeks (20 sessions)"
2954734|NCT02870244|Experimental|Escalating Doses|Three patients will be treated at the first & each subsequent dose level. Patients will be observed for 30 days post T cell infusion. If there was one DLT in the first 3 patients, an additional 3 patients will be treated at that level. If no additional DLTs are observed (for a total of 1 DLT in 6 patients) then the dose will be escalated. If two patients in the first 3 patients at a dose level experience a DLT, the dose will be de-escalated to the previous level & an additional 3 patients will be enrolled at that level if 6 have not yet been treated at that level. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a DLT. If 2 or 3 patients in the first 3 patients experience a DLT at the first dose level, the study will terminate.
2954735|NCT02870231|Experimental|NNC9204-0530 / Placebo and Liraglutide 1.8|
2954736|NCT02870231|Active Comparator|NNC9204-0530 /Placebo and Liraglutide 3.0|
2954737|NCT02870218|Active Comparator|0.40mg Nicotine Cigarette w/ e-Cigarette|Participants will be assigned to smoke 0.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to 15mg/ml nicotine-containing e-cigarettes.
2954738|NCT02870218|Active Comparator|1.40mg Nicotine Cigarette w/ e-Cigarette|Participants will be assigned to smoke 1.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to 15mg/ml nicotine-containing e-cigarettes.
2954739|NCT02870218|Active Comparator|2.50mg Nicotine Cigarette w/ e-Cigarette|Participants will be assigned to smoke 2.50mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to 15mg/ml nicotine-containing e-cigarettes.
2954740|NCT02870218|Active Comparator|5.60mg Nicotine Cigarette w/ e-Cigarette|Participants will be assigned to smoke 5.60mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to 15mg/ml nicotine-containing e-cigarettes.
2954741|NCT02870218|Active Comparator|16.9mg Nicotine Cigarette w/ e-Cigarette|Participants will be assigned to smoke 16.9mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to 15mg/ml nicotine-containing e-cigarettes.
2954742|NCT02870205|Experimental|GSP 301 NS|
2954743|NCT02870205|Active Comparator|GOM-NS|
2954744|NCT02870205|Active Comparator|GMM-2 NS|
2954745|NCT02870205|Placebo Comparator|GSP 301 placebo NS|
2954746|NCT02870192|Experimental|Rectal Prolapse|Patients with rectal prolapse, who will underwent laparoscopic ventral mesh rectopexy. The implemented mesh may be synthetic or biological.
2954747|NCT02870179||Healthy volunteer|Smoker or non-smoker
2954748|NCT02870153|Experimental|SOX(oxalipaltin+S-1)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
2954749|NCT02870153|Active Comparator|XELOX (oxalipaltin+capecitabine)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
2954750|NCT02870140|Experimental|SUPRAFLEX|Percutaneous Coronary Intervention with the SUPRAFLEX Sirolimus Eluting Bioabsorbable Polymer Coronary Stent System. It is a balloon expandable sirolimus eluting stent with an bioabsorbable polymer coating.
2954751|NCT02870140|Active Comparator|XIENCE|Percutaneous Coronary Intervention with the XIENCE EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating.
2954752|NCT02870101|Active Comparator|NAAT 1 to Detect Rectal NG and CT|Performance of nucleic acid amplification test assay number 1, estimating the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis from a rectal swab.
2954753|NCT02870101|Active Comparator|NAAT 1 to Detect Pharyngeal NG and CT|Performance of nucleic acid amplification test assay number 1, estimating the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis from a pharyngeal swab.
2954754|NCT02870101|Active Comparator|NAAT 2 to Detect Rectal NG and CT|Performance of nucleic acid amplification test assay number 2, estimating the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis from a rectal swab.
2954755|NCT02870101|Active Comparator|NAAT 2 to Detect Pharyngeal NG and CT|Performance of nucleic acid amplification test assay number 2, estimating the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis from a pharyngeal swab.
2954756|NCT02870101|Active Comparator|NAAT 3 to Detect Rectal NG and CT|Performance of nucleic acid amplification test assay number 3, estimating the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis from a rectal swab.
2954757|NCT02870101|Active Comparator|NAAT 3 to Detect Pharyngeal NG and CT|Performance of nucleic acid amplification test assay number 3, estimating the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis from a pharyngeal swab.
2954758|NCT02870101|Active Comparator|NAAT 4 to Detect Rectal and Pharyngeal NG|Performance of nucleic acid amplification test assay number 4, estimating the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae from rectal and pharyngeal swabs. To be used as a tiebreaker if reference tests disagree.
2954759|NCT02870101|Active Comparator|NAAT 4 to Detect Rectal and Pharyngeal CT|Performance of nucleic acid amplification test assay number 4, estimating the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Chlamydia trachomatis from rectal and pharyngeal swabs. To be used as a tiebreaker if reference tests disagree.
2954760|NCT02870088|Active Comparator|Prolonged Sitting|Participants sat on a chair during the trial.
2954761|NCT02870088|Experimental|Breaking Sitting|Participants walked regularly during the trial.
2954762|NCT02870075|Active Comparator|Fed exercise|Fed prior to exercise
2954764|NCT02870062|Experimental|Chlorhexidine|Intervention: daily baths with chlorhexidine wipes, oral spray and shampoo. This arm will receive daily bathing with chlorhexidine wipes at 2% (CLORHEXI-WIPES ONE-STEP, G70 Antisepsis, León, México) plus an oral spray application of chlorhexidine chlorhydrate at 0.12%. For scalp washing, a chlorhexidine shampoo at 0.12% concentration will be applied.
2954765|NCT02870062|Placebo Comparator|Placebo|Intervention: daily baths with placebo wipes, oral spray and standard shampoo. This arm will receive wipes with the same components as arm #1 plus an oral spray application with the same components except chlorhexidine. For scalp, a standard shampoo will be used. These products will have the same labels and smell as the products in arm #1.
2954766|NCT02870049|Experimental|Inreach strategy|This consists of a community health worker-delivered in clinic education regrading CRC screening with a fecal immunochemical test (FIT) kit, and telephone reminders.
2954767|NCT02870049|Experimental|Outreach strategy|This consists of mailed invitations to complete screening with an enclosed fecal immunochemical test (FIT) kit and telephone reminders.
2954768|NCT02870049|Experimental|Both Inreach and Outreach strategies|This is a combination of the above two strategies: Inreach and Outreach combined.
2954769|NCT02870049|Active Comparator|Usual care|Usual care in the clinic using the fecal immunochemical test (FIT) kit.
2954770|NCT02870036|Experimental|Pharmacokinetic data investigation of Simmitecan|To further determine the pharmacokinetic (PK) characteristics of Simmitecan monotherapy in patients with advanced solid tumors
2954771|NCT02870036|Experimental|Dose escalation study of Simmitecan combined therapy|To determine the maximum tolerated dose (MTD) of Simmitecan combined with 5-fluorouracil/Leucovorin Calcium in patients with advanced solid tumor
2954772|NCT02870036|Experimental|Dose extension study of Simmitecan monotherapy|To preliminarily evaluate the anti-tumor activity of Simmitecan monotherapy in patients with advanced solid tumors, and to determine the recommended phase II dose (RP2D)
2954773|NCT02870036|Experimental|Dose extension study of Simmitecan combined Thalidomide|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with 5-fluorouracil/Leucovorin Calcium in patients with advanced/metastatic colorectal cancer (CRC), and to determine RP2D
2954774|NCT02870036|Experimental|Dose escalation&extension Simmitecan combined Thalidomide|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with thalidomide in patients with gastrointestinal tumors, and to determine RP2D and MTD
2954775|NCT02870036|Experimental|Dose extension study of Simmitecan combined therapy|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with thalidomide in patients with specific tumors
2954776|NCT02870023|Experimental|Balance training|"All sessions will start with a ten minute warm-up on either a treadmill or a cycle.~The balance intervention will be conducted in stations/domains where balance is challenged in the five different functions: standing, walking, sit to stand, stepping, and a station that exercises vestibular and gaze control.~Progression is achieved by adding exercises with increased balance requirements and by adding additional motoric and cognitive tasks to the exercises—dual-tasking.~Intensity of the exercises is defined from an error-rate where an adequate level is 20-40 percent.~The intervention is conducted according to a standardized framework that describes examples of exercises and progressions."
2954777|NCT02870023|Experimental|Strength training|"All sessions will start with a ten minute warm-up on a stationary bicycle, followed by strength training of primary muscle synergies in the lower extremities. All exercises will be performed on machines with patients sitting or lying, adequately supported. The exercises are leg press, knee extension, hip flexion, hamstring curl, and hip extension. Exercises are performed with a fast concentric phase and a slow eccentric phase..~Set, repetition, and load:~Weeks 1 and 2, 3 sets of 10 repetitions at a load of 15 repetitions maximum (RM)~Weeks 3 and 4, 3 sets of 12 repetitions at a load of 12RM~Weeks 5 and 6, 4 sets of 12 repetitions at a load of 12RM~Weeks 7 and 8, 4 sets of 10 repetitions at a load of 10RM~Weeks 9 and 10, 4 sets of 8 repetitions at a load of 8RM."
2954778|NCT02870023|No Intervention|Control group|On a waitlist. After ten weeks of waiting, and intervention that contains 50 percent strength training and 50 percent balance training begins.
2954779|NCT02870010|Experimental|non-metastatic hepatocellular carcinoma|"Radiation : Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection~Biological : blood samples (5 ml) will be taken"
2954780|NCT02869997|Experimental|Single arm|arm wherein all patients Suppression Ratio evaluated by BIS will be collected
2954781|NCT02869984|Experimental|Treatment|ramosetron treatment for 4 weeks from 1mo after anterior resection for rectal cancer
2954782|NCT02869984|No Intervention|Control|No treatment
2954783|NCT02869971|Experimental|Embolization|Prostatic Arteries Embolization
2954784|NCT02869971|Active Comparator|Combined Therapy|Combodart® : dutasteride 0.5 mg/tamsulosin 0.4 mg per day
2954785|NCT02869958|Active Comparator|1: Written action plan|Written action plan
2954786|NCT02869958|Experimental|2: Digital action plan|Written action plan + Digital action plan for asthma exacerbations Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation
2954787|NCT02869945|Other|COMT HH|COMT HH gene
2954788|NCT02869945|Other|COMT HL|COMT HL gene
2954789|NCT02869945|Other|COMT LL|COMT LL gene
2954790|NCT02869932|Other|Atypical and classic cystic fibrosis|Lung CT scan without injection
2954791|NCT02869919||Patients with AKI|critically ill patients with acute kidney injury
2954792|NCT02869919||Patients without AKI|critically ill patients without acute kidney injury
2954793|NCT02869906||FFR and iFR|The investigators compare FFR and iFR values in the acute phase of STEMI and in the subacute phase, 5-7 days after STEMI.
2954794|NCT02869893|Other|Healthy Participants|MRCP with Secretin and MR elastography will be performed on all participants.
2954795|NCT02869880|Active Comparator|Standard Pre-consent Discussion|Standard pre-consent discussion for a clinical trial.
2954869|NCT02869334|Sham Comparator|Control (computer games with sham tDCS)|Non-remediation, control computer activities (e.g. games) with sham transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
2954796|NCT02869880|Experimental|Enhanced Pre-consent Discussion|The enhanced pre-consent discussion intervention is a tool that includes both textual and graphical information regarding the trial and an interactive component designed to initiate and facilitate conversations between all parties in the decision—parent, patient, healthcare provider and research staff.
2954797|NCT02869867|No Intervention|Qutenza® without refrigerated cushion|Qutenza® without refrigerated cushion
2954798|NCT02869867|Experimental|Qutenza® with refrigerated cushion|Qutenza® with refrigerated cushion
2954799|NCT02869854|Active Comparator|PAP only|This group will follow the referral scheme for three months, and after this period they will leave new blood samples and answer surveys. They will get a new PAP with follow up after another 3 months.
2954800|NCT02869854|Active Comparator|Mindfulness only|Mindfulness. This group will receive a group course in mindfulness during 8 weeks once a week, and with 20 minutes of daily personal training. Three and six months after inclusion they will answer a new set of surveys and fasting blood samples.
2954801|NCT02869854|Experimental|Combination of the two groups|Mindfulness and physical activity prescription. This group will get a combination of the two other groups. PAP will be prescribed during the first meeting and another one after 3 months. During the first 8 weeks once a week they will participate in a mindfulness training group and also preform 20 minutes of daily training. The same surveys as the other groups and fasting blood samples
2954802|NCT02869841|Active Comparator|Continuous rectus sheath analgesia|Local anesthetic continuous infusion with infusion pumps
2954803|NCT02869841|Active Comparator|Bolus rectus sheath analgesia|Bolus administration of local anesthetic
2954804|NCT02869841|Active Comparator|Single dose rectus sheath analgesia|single dose administration of local anesthetic
2954805|NCT02869841|Placebo Comparator|Placebo|no rectus sheath analgesia
2954806|NCT02869828|Other|monitoring by arterial catheter and Spot-on|
2954807|NCT02869828|Other|monitoring by oesophagus tube and Spot-on|
2954808|NCT02869815||ICG+Methylene Blue|"ICG+Methylene Blue:~Sentinel Lymph Node (SLN) identification and resection using dual tracer technique with the sub-areolar injection of ICG+Blue dye, before surgery."
2954809|NCT02869802||Biopsy Cohort|"Participants will undergo a tumour biopsy.~Participants will undergo serial collection of plasma, serum and urine (at BC Cancer only) samples."
2954810|NCT02869802||Archival Cohort|"Genomic analyses will be performed on participants' archival tumour samples.~Participants will undergo serial collection of plasma, serum and urine (at BC Cancer only) samples."
2954811|NCT02869789|Experimental|Nivolumab in combination with Ipilimumab|Specified dose on specified days
2954812|NCT02869776|Experimental|Rapid finger stick|HIV and HCV testing through rapid finger stick. Behavioral questionnaires will also be administered.
2954813|NCT02869776|Experimental|Standard venipuncture|HIV and HCV testing through venipuncture. Behavioral questionnaires will also be administered.
2954814|NCT02869763|Experimental|10 g ethanol|"31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
2954815|NCT02869763|Experimental|20 g ethanol|"63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
2954816|NCT02869763|Placebo Comparator|Water|400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
2954817|NCT02869750||Obese PCOS|PCOS patients with BMI more than 25 kg/m2
2954818|NCT02869750||Lean PCOS|PCOS patients with BMI less than 25 kg/m2
2954819|NCT02869750||PCOS with normal HOMA2-1R|PCOS without Insuline resistance
2954820|NCT02869750||PCOS with elevated HOMA2-IR|PCOS with Insuline resistance
2954821|NCT02869724|Active Comparator|Weekly divided delivery|Hospitalized for voluntary drug intoxications.
2954822|NCT02869724|Active Comparator|Monthly divided delivery|Hospitalized for voluntary drug intoxications.
2954823|NCT02869698|Experimental|Evaluation of cognitive functions by Spectral Dynamic Imaging|Evaluation of cognitive functions by SDI will be conducted during the exploration SEEG (which usually lasts from 1 to 3 weeks), and started a few days after implantation of intracranial electrodes
2954824|NCT02869685|Other|a prospective, open,phase I clinical study|We have designed five kinds of radiation-division with bioequivalent doses, and detected the expression levels of PD-L1 in pExo after 24h, 48h of each stage of radiotherapy.
2954825|NCT02869672|Experimental|age of 18-50 years old, experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
2954826|NCT02869672|Active Comparator|age of 18-50 years old, control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
2954827|NCT02869672|Experimental|age of 7-17 years old,experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
2954828|NCT02869672|Active Comparator|age of 7-17 years old, control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
2954829|NCT02869672|Experimental|age of 2-6 years old,experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
2954830|NCT02869672|Active Comparator|age of 2-6 years old,control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
2954831|NCT02869659|Active Comparator|Control/Delayed Weight Loss Group|"Control/Delayed Weight Loss Group: (18 weeks) Participants randomized to the delayed weight loss intervention (n=100) will serve as a no-weight loss control to the weight loss group during the first 18 weeks of the study. During the control (18 weeks) phase these participants will receive a monthly phone call visit from staff to maintain contact and interest in the study. At the end of the initial 18 weeks participants will complete all follow up assessments prior to being offered the opportunity to participate in a weight loss program.~No outcome data will be collected at the end of the delayed weight loss phase."
2954904|NCT02869022|Experimental|Custodiol-N|comparison of two perfusion solutions, Custodiol-N versus Custodiol, in heart transplantation
2955314|NCT02866266||All Medicaid patients in a participating state Medicaid plan|
2954832|NCT02869659|Experimental|Weight Loss Group|"Weight Loss group: Phase 1 (18 wks): Participants assigned to this group will undergo a dietary intervention for the first 18 weeks of the study.~This level of weight loss will be achieved through the combination of a partial meal replacement (MR) program and individual and group nutrition/behavioral counseling. Participants will be provided with and asked to consume 4 Medifast® MR per day.~Phase 2 (8 wks): After completion of the active weight loss phase, participants in this group will attend bimonthly group meetings to discuss increasing their activity.~Phase 3 (26 wks): After completion of phase 2, participants will be called monthly for 26 weeks and then asked to return for a maintenance visit at the end of the 52 weeks from study start."
2954833|NCT02869646|Experimental|Verum acupuncture|Traditional Chinese Medicine (TCM) based acupuncture at prescribed sites
2954834|NCT02869646|Sham Comparator|Minimal needling|shallow and non-acupoint needles at same number of sites
2954835|NCT02869633|Experimental|Treatment (ibrutinib)|Beginning between 60-90 days post donor stem cell transplant, patients receive ibrutinib PO QD until 1 year post donor stem cell transplant in the absence of disease progression or unacceptable toxicity.
2954836|NCT02869620||Patients with thyroid cancer diagnosis|
2954837|NCT02869607||Patients with breast cancer diagnosis|
2954838|NCT02869594||Patients with prostate cancer diagnosis|
2954839|NCT02869581||Patients with diagnosis of Pancreatic neoplasms|
2954840|NCT02869568||Patients with ovarian cancer diagnosis|
2954841|NCT02869555||Patients with multiple myeloma diagnosis|
2954842|NCT02869542||Patients with lymphoma diagnosis|
2954843|NCT02869529||Chronic lymphatic leukemia diagnosis|
2954844|NCT02869516||Patient with new diagnosis of Acute Leukemia|
2954845|NCT02869503||Patients with colorectal cancer diagnosis|
2954846|NCT02869490||Patients with cervical cancer diagnosis|
2954847|NCT02869477||Patients with cardia cancer diagnosis|
2954848|NCT02869464||Patients presenting with IA|These patients will undergo an abdominal ultrasound (Imaging - Ultrasound) to test for abdominal aortic aneurysm(s). RNA, DNA testing will be planned on banked samples
2954849|NCT02869464||Patients presenting with AAA|These patients will undergo a non-contrast enhanced magnetic resonance angiogram (MRA) (Imaging - MRA) to test for intracranial aneurysm(s). RNA, DNA testing will be planned on banked samples
2954850|NCT02869451|Experimental|Treatment|Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months.
2954851|NCT02869438|Experimental|Benralizumab arm|Benralizumab administered subcutaneously
2954852|NCT02869438|Placebo Comparator|Placebo arm|Placebo administered subcutaneously
2954853|NCT02869425|Experimental|Arbaclofen ER Tablets|AERT 10 mg twice daily (BID) (20 mg/day) for 7 days, followed by AERT 15 mg BID (30 mg/day) for 7 days
2954854|NCT02869425|Placebo Comparator|Placebo for Arbaclofen ER Tablets|Matching placebo AERT 10 mg twice daily (BID) (20 mg/day) for 7 days, followed by matching placebo AERT 15 mg BID (30 mg/day) for 7 days
2954855|NCT02869412|Experimental|Group I (BCG website)|Patients use the BCG website which will collect personal information including individual health priorities/goals, demographics (i.e. age, ethnicity), health information (i.e. weight, height, cancer history, other health conditions), individual capabilities, physical activity level, and exercise preferences. Patients then receive a report with a personalized physical activity plan.
2954856|NCT02869412|Active Comparator|Group II (passive website)|Patients use a passive website (American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Survivors).
2954857|NCT02869399|Experimental|Experimental arm|The experimental arm is based on a dietary intervention in addition to standard recommendations.The diet will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences. The intervention strategy will focus on reducing inflammation and reducing glycaemia and insulinaemia while promoting nutrient-rich diet. Patients will be taught how to prepare traditional Mediterranean meals (healthy, satiating, palatable and easy to prepare).
2954858|NCT02869399|No Intervention|Control arm|Patients in the control arm will not receive specific suggestions concerning diet, but standard healthy lifestyle recommendations will be given. The recommendations, including nutritional consultation if needed by standard practice of care, will be reinforced at each clinical visit and through a leaflet according to primary cancer prevention nutritional guidelines. Patients in the control group will not receive any of the recipes or educational materials given to the intervention group and they will not have kitchen classes.
2954859|NCT02869386|Experimental|STEMO deployment|STEMO is a specialized stroke ambulance providing prehospital neurovascular expertise, a CT scanner, point-of-care testing, and telemedical support.
2954860|NCT02869386|Active Comparator|Regular care|Regular prehospital care consists of an ambulance. In suspected life-threatening cases an emergency physician is sent to the emergency scene in parallel.
2954861|NCT02869373|Experimental|Exercise|spinal stabilization exercise program was applied
2954862|NCT02869373|No Intervention|Control|
2954863|NCT02869360||Multiple Sclerosis (MS) patients|4 Secondary Progressive MS patients on no disease modifying therapy 4 Primary Progressive MS patients on no disease modifying therapy 4 Relapsing-Remitting MS patients on no disease modifying therapy 4 Relapsing-Remitting MS patients on Glatiramer Acetate 40 mg three times a week
2954864|NCT02869360||Healthy Controls|4 Healthy volunteers aged between 18-60 years of age
2954865|NCT02869347|Active Comparator|Conestat alfa|Intravenous injection of Conestat alfa, for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U (2 vials, each diluted in 14ml sterile water).
2954866|NCT02869347|Placebo Comparator|Sodium chloride 0.9%|Intravenous injection of sodium chloride 0.9%.
2954867|NCT02869334|Experimental|Auditory remediation with active tDCS|Auditory remediation program paired with active transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
2954868|NCT02869334|Experimental|Auditory remediation with sham tDCS|Auditory remediation program paired with sham transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
2954905|NCT02869022|Active Comparator|Custodiol|comparison of two perfusion solutions, Custodiol-N versus Custodiol, in heart transplantation
2954870|NCT02869321|Experimental|Fentanyl|"Administration of Morphine Sulfate Placebo and Fentanyl~Morphine Sulfate Placebo: oral solution administered through nasogastric tube, 10% of daily dose of morphine of background treatment, 1 hour before gastrostomy~Fentanyl: nasal spray solution, 100 µg pulverisation, 15 min before gastrostomy, if not efficacy second dose after 15 min during gastrostomy~Administration 1+2 if pain after 4 hours from gastrostomy"
2954871|NCT02869321|Placebo Comparator|Morphine Sulfate|"Administration of Morphine Sulfate and Fentanyl Placebo~Morphine Sulfate: oral solution administered through nasogastric tube, 10% of daily dose of morphine of background treatment, 1 hour before gastrostomy~Fentanyl Placebo: nasal spray solution, 100 µg pulverisation, 15 min before gastrostomy, if not efficacy second dose after 15 min during gastrostomy~Administration 1+2 if pain after 4 hours from gastrostomy"
2954872|NCT02869308|Other|Myocardial angioscintigraphy|
2954873|NCT02869295|Experimental|NKTR-214 Dose Escalation|This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR--214 in adult patients with locally advanced and metastatic solid tumors. The Phase 1 stage of the study is designed as an open-label dose escalation trial of NKTR--214 in participants with locally advanced or metastatic solid tumors. The goal of the dose escalation stage of the study is to find the recommended phase 2 dose, to evaluate the efficacy of NKTR--214 by assessing the objective response rate and to evaluate the safety of NKTR-214. Immunological biomarkers in plasma and tumor samples will also be measured.
2954874|NCT02869282||Prospective cohort|Levels of CXCL1, CCL5, CXCL8 and CXCL12 chemokines and of IL-6 cytokine by ELISA or Luminex technology.
2954875|NCT02869269||Early stage|patients who diagnosed as TNM stage 1 and 2
2954876|NCT02869269||Late stage|patients who diagnosed as TNM stage 3 and 4
2954877|NCT02869243|Experimental|hrBMP4|Intra-tumour and interstitial convection enhanced delivery (CED) as a continuous infusion via intracranial catheters of hrBMP4 solution and gadolinium
2954878|NCT02869230|Other|Radioguided occult lesion localization|The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
2954879|NCT02869230|Experimental|wire-guided lesion localization|wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
2954880|NCT02869217|Experimental|Dose Level -1, Dose Level 1, RP2D (expansion)|Cyclophosphamide will be given intravenously (by vein) at a fixed dose of 750mg/m2/d for 2 days
2954881|NCT02869204|Experimental|Leucocyte - Platelet rich Plasma and Dietary Supplements|"An application of an autologous platelet concentrate (20 ml). This is injected once, locally in the muscle after closure of the inner fascia and before closure of the outer fascia.~A daily dietary supplement of Vitamin C, Zinc and L-Arginine. Provided from POD2-3 until POD30"
2954882|NCT02869204|No Intervention|Treatment as usual|Patients are treated as usual.
2954883|NCT02869191||blood cultures|Admitted patients in critical care who need blood cultures
2954884|NCT02869191||blood cultures Getafe|Data collection of patients included in study
2954885|NCT02869165|Experimental|Premarin vaginal cream|The Premarin vaginal cream 1 gram will be inserted into the vaginal three times were week at nights for 3 months.
2954886|NCT02869165|Experimental|Apricot kernel oil|One teaspoonful will be applied per vagina nights for 3 months.
2954887|NCT02869152|Experimental|Intraoperative sentinel lymph node mapping|Subjects will come to the OR and undergo a flexible sigmoidoscopy after induction of anesthesia and receive separate endoscopic injections of Spot (up to 5 cc), 99mTc-sulfur colloid (up to 0.5 mCi), and Indocyanine green (ICG) (1 ml). Patient will undergo the standard transanal endoscopic surgery (TES) to remove the rectal neoplasm, exposing the lymph node basin. The sentinel node(s) will be identified using a combination of the gamma probe and fluorescence imaging endoscopically, dissected out, and removed through a transanal approach.
2954888|NCT02869139|Experimental|Package of mentholated measures|Package of mentholated measures (mentholated Ice Popsicle and lip moisturizing) Group.
2954889|NCT02869139|Active Comparator|Package of non-mentholated measures|Package of non-mentholated measures (mentholated Ice Popsicle and lip moisturizing) Group.
2954890|NCT02869126|Experimental|Patients|Patients with abnormalities of myocardial perfusion detected with stress tomoscintigraphy, undergo double isotope myocardial tomoscintigraphy using Thallium-201 and 99mTc-sestamibi and traditional myocardial tomoscintigraphy using 99mTc-sestamibi with a semiconductor camera
2954891|NCT02869113|Experimental|Sunscreen agent A + control|Application of control and test product into one of the subjects two eyes.
2954892|NCT02869113|Experimental|Sunscreen agent B + control|Application of control and test product into one of the subjects two eyes.
2954893|NCT02869113|Experimental|Sunscreen agent C + control|Application of control and test product into one of the subjects two eyes.
2954894|NCT02869100|Experimental|Spondyloarthritis Patients|
2954895|NCT02869087|Experimental|Single Group|Single Arm study, study subjects are assigned to treatment with the Akesys Prava Scaffold
2954896|NCT02869074||VWD Spanish Cohort|"Patients with previously diadnosis of VWD from approximately 38-40 different centers from Spain.~Samples from these patients will be analyzed locally, and also centrally for VWF and VWFgene"
2954897|NCT02869061|Experimental|ADRC injection|Subjects will be undergone liposuction under local anesthesia. Adipose-derived regenerative cells (ADRC) will be isolated from lipoaspirate by enzymatic digestion. Transurethral bladder neck resection followed by the injection of ADRC suspension will be performed. This is a single arm study with no control. All patients receive cell therapy.
2954898|NCT02869048||ALS patients|Patients diagnosed with ALS will be included in this group. Blood and spinal fluid samples will be stored in biobank and later analyzed. A subset of this group (20 ALS patients) will give blood and spinal fluid every 6 months during progression of the disease. A subset of 10 will donate a muscle biopsy.
2954899|NCT02869048||Control group with patients with other neurological disease|Patients referred to hospital with symptoms of acute or chronic headache.
2954900|NCT02869048||Neurologically healthy control group|Patients having orthopaedic surgery performed in spinal anaesthesia.
2954901|NCT02869035|Experimental|Treatment of MDD patients|Treatment of MDD patients with escitalopram
2954902|NCT02869035|No Intervention|Healthy controls|No treatment.
2954903|NCT02869035|Experimental|Shift of treatment for MDD patients|Treatment of MDD patients with duloxetine
2954906|NCT02869009|Experimental|clopidogrel plus aspirin group|the group will receive a 300mg loading dose of clopidogrel plus aspirin 100 mg, followed by clopidogrel 75 mg/d and aspirin 100 mg/d from day 2 to day 14, and followed by clopidogrel 75 mg/d or aspirin 100 mg/d from day 15 to day 90.
2954907|NCT02869009|Experimental|aspirin group|the group will receive 100-300 mg aspirin from day 1 to day 14, followed by aspirin 100 mg/d from day 15 to day 90.
2954908|NCT02868996|Experimental|Low dose (Part A)|Recombinant human tissue kallikrein
2954909|NCT02868996|Experimental|Medium low dose (Part A)|Recombinant human tissue kallikrein
2954910|NCT02868996|Experimental|Medium high dose (Part A)|Recombinant human tissue kallikrein
2954911|NCT02868996|Experimental|High dose (Part A)|Recombinant human tissue kallikrein
2954912|NCT02868996|Experimental|Subcutaneous (Part B)|Recombinant human tissue kallikrein
2954913|NCT02868996|Experimental|IV (Part B)|Recombinant human tissue kallikrein
2954914|NCT02868983|Experimental|Integration|"The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:~A. Identification B. Assessment C. Treatment D. Surveillance"
2954915|NCT02868983|No Intervention|Co-Location|A Behavioral Health Clinician (BHC) such as a psychologist or counselor is housed in or near the primary care practice.
2954916|NCT02868970|Other|Community (2 in NB, 2 from NS)|There are four communities involved in the study, two in New Brunswick and two in Nova Scotia. All pharmacies in each community will be allocated to one intervention. Interventions include: High-Dose TIV, Meningococcal B Vaccine, and Tdap.
2954917|NCT02868957|Active Comparator|Impression data from reference scanner|desktop scanner was used as a reference scanner. According to the data of the manufacturer, the accuracy is less than 20 µm and the scan points more than 100,000.
2954918|NCT02868957|Experimental|Trios|"Trios is a scanner with real time rendering type adopting the confocal principle, and scans the object while showing the scanned area on a screen.~Interventions: Assigned intervention to participants in this clinical study was in the form of repetitive learning of Trios intra-oral scanner."
2954919|NCT02868957|Experimental|iTero|"iTero captures teeth and periodontal soft tissue using a red laser beam and parallel confocal imaging technology. This system with a focal depth of 300 can capture up to 100,000 of laser points, and each of such laser points is separated at a 50 mm gap.~Interventions: Assigned intervention to participants in this clinical study was in the form of repetitive learning of iTero intra-oral scanner."
2954920|NCT02868944|Experimental|experimental group|sequential combined spinal epidural with local anesthetic injection associated with morphine
2954921|NCT02868944|Active Comparator|control group|sequential combined spinal epidural with local anesthetic injection alone
2954922|NCT02868931|Experimental|INPUT|INPUT consists of 12 lessons comprising all relevant information in order to treat diabetes with an insulin pump. Patients learn to effectively use the different features of their pump in order to improve not only glycemic control but also to improve the implementation of pump therapy in daily life. Psychological and motivational aspects of living with diabetes and living with an insulin pump are addressed as well.
2954923|NCT02868931|No Intervention|Waiting list|Patients are randomly assigned to the waiting list. After completion of the 6-month follow-up, these patients will also receive training with INPUT.
2954924|NCT02868918|Experimental|biodentine|bioactive dentin substitute used to act like natural dentin in insulating the pulp against external stimuli intervention
2954925|NCT02868918|Active Comparator|glass ionomer cement|high viscosity glass ionomer used as a base material comparator other name : - fuji ix
2954926|NCT02868905|Other|Control group|Control group
2954927|NCT02868905|Other|Obese group|Obese group
2954928|NCT02868905|Other|Non-obese AD group|Non-obese AD groups
2954929|NCT02868905|Other|Obese AD group|Obese AD group
2954930|NCT02868892|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 will be administered on an outpatient basis on an every three week schedule. Pemetrexed will be administered as a 10 minutes intravenous (IV) infusion in (for 500-mg vial) 100 ml of saline via peripheral vein or central line on Day 1 of each 21 day cycle.
2954931|NCT02868879||Schizophrenia|
2954932|NCT02868879||Normal controls.|
2954933|NCT02868866|Experimental|Immediate intervention|Training of church committee followed by 12 months of technical assistance phone calls.
2954934|NCT02868866|No Intervention|Delayed intervention|20 churches are followed but receive no intervention.
2954935|NCT02868853|Experimental|Photo App|Participants in this group will receive podcasts twice weekly in conjunction with using a mobile dietary tracking application(Photo App). This Photo App allows participants to track meals by taking photos.
2954936|NCT02868853|Active Comparator|Diet App|Participants in this group will receive podcasts twice weekly in conjunction with an app (Diet App) to track their diet by entering in foods and beverages consumed.
2954937|NCT02868840|Experimental|Tai Chi group|Tai Chi exercise, twice a week, one hour per session. participated in Tai Chi either while seated or standing upon their comfort level.
2954938|NCT02868840|Active Comparator|Symptom management group|manage stroke symptom through phone and text message along with other rehabilitation therapy.
2954939|NCT02868827|Experimental|Cholecalciferol|This group of patients will receive single high dose of vitamin D (Cholecalciferol) dissolved in 45 ml of fresh milk (Nestle)
2954940|NCT02868827|Placebo Comparator|Placebo|This group of patients will receive placebo - 45 ml of fresh milk (Nestle) so that the amount, color, smell, taste etc will be the same as that of experimental drug)
2954941|NCT02868814|Experimental|330mg/day|330 mg QD taken orally,1 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
2954942|NCT02868814|Experimental|495mg/day|495 mg QD taken orally,2 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
2954943|NCT02868814|Placebo Comparator|Placebo|1 or 2 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
2954944|NCT02868801|Placebo Comparator|Placebo|placebo, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
2955046|NCT02868034|Experimental|SMT Only|Patients receive 2 sessions on SMT during week 1, no additional treatment.
2954946|NCT02868801|Experimental|Pregabalin SR tablet 330mg/day|1pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
2954947|NCT02868801|Experimental|Pregabalin SR tablet 660mg/day|2pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
2954948|NCT02868788|Other|high fat high calorie|Subjects in this arm will receive high fat high calorie meal
2954949|NCT02868788|Experimental|high fat high calorie plus fiber|Subjects in this arm will receive high fat high calorie meal plus dietary fiber supplementation
2954950|NCT02868775||Interstitial cystitis/bladder pain syndrome|These are the patients that will be evaluated in this study.
2954951|NCT02868749|Experimental|Hyaluronic Acid filler 1 for deep injection|"Injection Session 1 of Hyaluronic Acid filler 1, 3 weeks to 4 months before the surgery~Injection Session 2 of Hyaluronic Acid filler 1, 5 to 9 days before the surgery"
2954952|NCT02868749|Active Comparator|Hyaluronic Acid filler 2 for deep injection|"Injection Session 1 of Hyaluronic Acid filler 2, 3 weeks to 4 months before the surgery~Injection Session 2 of Hyaluronic Acid filler 2, 5 to 9 days before the surgery"
2954953|NCT02868736||Suspected Periprosthetic Joint Infection|Individuals who are suspected of having Periprosthetic Joint Infection (PJI)
2954954|NCT02868723|No Intervention|Control; standard of care|All the subjects enrolled in this arm will receive counseling as the usual standard of care by the stroke neurologists. These will include procedures and guidelines as approved by American Heart Association (AHA), follow up and guidance as offered by Hamad General Hospital's policies.
2954955|NCT02868723|Active Comparator|Intervention; Lifestyle counselling: Behavioural|Subjects in this group will receive a more detailed guidance on rigorous management of stroke and will be provided assistance from a stroke trained nurse and pharmacist additional to the counseling offered by the Stroke Neurologist.
2954956|NCT02868710|Experimental|Individualized method|"3 days a week of exercise at the following intensity and energy expenditure:~Week 1: HR > VT1; 5.6 kcal/kg/wk Week 2: HR > VT1; 8.4 kcal/kg/wk Week 3: HR > VT1; 11.2 kcal/kg/wk Week 4: HR ≥ VT1 to <VT2; 11.2 kcal/kg/wk Week 5-6: HR ≥ VT1 to <VT2; 11.2 kcal/kg/wk Week 7: HR ≥ VT1 to <VT2; 12.6 kcal/kg/wk Week 8: HR ≥ VT1 to <VT2; 14 kcal/kg/wk Week 9-10: HR ≥ VT2; 14 kcal/kg/wk Week 11-12: HR ≥ VT2; 15.4 kcal/kg/wk"
2954957|NCT02868710|Experimental|Standardized method|"3 days a week of exercise at the following intensity and energy expenditure:~Week 1: 40-45% HRR; 5.6 kcal/kg/wk Week 2: 40-45% HRR; 8.4 kcal/kg/wk Week 3: 40-45% HRR; 11.2 kcal/kg/wk Week 4: 50-55% HRR; 11.2 kcal/kg/wk Week 5-6: 55-60% HRR; 11.2 kcal/kg/wk Week 7: 55-60% HRR; 12.6 kcal/kg/wk Week 8: 55-60% HRR; 14 kcal/kg/wk Week 9-10: 60-65% HRR; 14 kcal/kg/wk Week 11-12: 60-65% HRR; 15.4 kcal/kg/wk"
2954958|NCT02868710|No Intervention|Control|"non-exercise control group~Testing at baseline and post-program (12 weeks)"
2954959|NCT02868697|Active Comparator|A|We will lock the dialysis catheter post HD with TauroLock Hep500 at the end of of all Hemodialysis sessions and during all interdialytic periods
2954960|NCT02868697|Experimental|B|We will lock the dialysis catheter post HD with TauroLock Hep500 at the end of the first two session only per week and during first two interdialytic periods then TauroLock U 25000at the end of third session before week end, (over the week end).
2954961|NCT02868684||mild traumatic brain injury|
2954962|NCT02868684||Healthy controls|
2954963|NCT02868671|Experimental|real acupuncture|Participants will receive treatment four times a week for two weeks and three times a week for two weeks. Participants will be treated with major points: Yintang, Du20 (Bai Hui), LI4 (He Gu), LR3 (Tai Chong), RN4 (Guan Yuan), ST36 (Zusanli) (front treatment) or Du20, GB20 (Feng Chi), SP6 (Sanyinjiao), BL15 (Xin Shu), BL18 (Gan Shu), BL23 (Shen Shu) (back treatment). The position of the treatment will alternate between sessions such that the first session will be on the back, with the next session on the front. In addition to the 6 required points, acupuncturist will be allowed to choose 4 more points. The 4 supplemental points may be chosen from the following: LR2 (Xin Jian), HT7 (Shenmen), PC6 (Neiguan), GB34 (Yang Ling Quan), GB39 (Xuan Zhong), SI3 (Hou Xi), RN6 (Qi Hai), RN24 (Cheng Jiang),KI 3 (Taixi), KI 6 (Zhao Hai), ST40 (Feng Long), SP10 (Xue Hai), BL14 (Jue Yin Shu), BL17 (Ge Shu), BL19 (Dan Shu), BL20 (Pi Shu), BL60 (Kun Lun). Auricular acupuncture will be employed.
2954964|NCT02868671|Sham Comparator|sham acupuncture|Participants randomized to sham acupuncture will receive a 'placebo' acupuncture session. In the sham procedure, a needle guiding tube will be tapped on the surface of the skin near, but not on, each of the 10 acupuncture points that would have been selected for true acupuncture. The needle guiding tube will be used to create sensations that mimic needle manipulation.
2954965|NCT02868671|No Intervention|No Intervention|All participants in this study will receive usual care. For those assigned to true acupuncture and sham acupuncture, the usual care will be in addition to their acupuncture.
2954966|NCT02868658|Experimental|Health-care workers|Health-care workers recruited in the study will have blood sampling and naso-pharyngeal bottle-brush sampling
2954967|NCT02868645|Experimental|Patients with bone fibrous dysplasia|Patients with bone fibrous dysplasia will have a blood sampling to assess periostin rate in serum
2954968|NCT02868645|No Intervention|Control subjects|Control subjects will have no intervention
2954969|NCT02868632|Experimental|Cohort A: MEDI4736 + SBRT|MEDI4736 10 mg/kg IV every 2 weeks plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 10 Subjects
2954970|NCT02868632|Experimental|Cohort B:Tremelimumab + SBRT|Tremelimumab 10 mg/kg IV every 4 weeks plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 10 Subjects
2954971|NCT02868632|Experimental|Cohort C: MEDI4736 + Tremelimumab + SBRT|MEDI4736 + Tremelimumab (recommended phase 2 IV dose for combination) plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 16 Subjects
2954972|NCT02868619|Other|Healthy controls|Non obese adolescents without Binge Eating Disorder (BED)
2954973|NCT02868619|Other|Patients with BED|Obese adolescents with BED with Binge Eating Disorder (BED)
2954974|NCT02868606||Historical control group (H)|Winthrop patients with diabetes hospitalized between August 1, 2010 and March 31, 2011
2954975|NCT02868606||Intervention group (I)|Winthrop patients with diabetes hospitalized between August 1, 2011 and March 31, 2012
2954976|NCT02868606||Parallel control group (P-sub-H)|Patients with diabetes hospitalized between August 1, 2010 and March 31, 2011 at 7 control hospitals located in the New York City metropolitan region
2955047|NCT02868034|Experimental|SMT extended|2 sessions of SMT in week 1 and 6 additional sessions of SMT during weeks 2-4.
2954977|NCT02868606||Parallel control group (I-sub-H)|Patients with diabetes hospitalized between August 1, 2011 and March 31, 2012 at 7 control hospitals located in the New York City metropolitan region
2954978|NCT02868593|Experimental|Patient with clinical meningitis or meningo-encephalitis|
2954979|NCT02868580|Experimental|Single arm open label|All subjects will receive open label Triumeq following a lead-in phase. Triumeq is abacavir 600mg, lamivudine 300mg, dolutegravir 50mg
2954980|NCT02868567|Experimental|Ampyra|Ampyra open label
2954981|NCT02868554|No Intervention|Standard Invisalign Therapy|Patients receiving standard Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 14 days of compliant aligner wear.
2954982|NCT02868554|Experimental|Accelerated Invisalign|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
2954983|NCT02868554|Experimental|Accelerated Invisalign and Vibration|In addition to the accelerated Invisalign protocol described in Arm #2, patients will undergo intraoral vibration therapy using an AcceleDent Aura device for a duration of 20 minutes per day.
2954984|NCT02868541||Haaj pilgrim|Patient that are showing at the traveler hospital health center requiring the mandatory Meningococcal vaccine ACYW135
2954985|NCT02868528|Experimental|PGS group|After blastocyst culture, blastocyst embryo trophoblast biopsy will be performed and chromosome screening with NGS technology, at the same time, the blastocysts will be frozen, then the blastocysts with normal chromosome will be thawed and transferred.
2954986|NCT02868528|No Intervention|control group|After blastocyst culture, blastocysts will be transferred
2954987|NCT02868515|Experimental|Oatmeal containing beta-glucan|43 g cereal containing 3g fiber per serving
2954988|NCT02868502||Trabeculectomy|Subjects with OAG s/p Trabeculectomy. IOP measurement in different positions.
2954989|NCT02868502||Ahmed Glaucoma Valve implantation|Subjects with OAG s/p Ahmed valve implantation. IOP measurement in different positions.
2954990|NCT02868502||Cyclophotocoagulation|Subjects with OAG s/p Cyclophotocoagulation. IOP measurement in different positions.
2954991|NCT02868502||Ocular hypotensive eye drops|"Subjects with OAG treated with ocular hypotensive eye drops and no ocular surgical hypotensive treatments.~IOP measurement in different positions."
2954992|NCT02868502||Ocular Hypertension|"Subjects with no evidence of glaucomatous damage, but with IOP measurements above 21 mmHg..~IOP measurement in different positions."
2954993|NCT02868502||Control|"Subjects with healthy eyes, apart for refraction errors, post cataract surgery, strabismus or amblyopia.~IOP measurement in different positions."
2954994|NCT02868489|Experimental|Proprietary Blend - LactoWise®|After being randomized into two groups, the assigned experimental group, prior to surgery and after consenting, will be asked to complete the Gastrointestinal Quality of Life Index. In addition the experimental group will be given their supply of LactoWise®. They will be required to take 1 capsule per day (300 mg of bacillus coagulans and galactomannans at 4.5 billion live cells) at breakfast consistently for 3 months. There will be three follow up visits (Week-2, Week-6 and Month-3) where participants will be asked to complete the gastrointestinal quality of life index.
2954995|NCT02868489|Placebo Comparator|Control|For the control group, prior to surgery and after consenting to enroll in the study participants will also be asked to complete the Gastrointestinal Quality of Life Index. Participants of the control group will be administered their supply of a matching placebo. They will be required to take 1 capsule per day at breakfast consistently for 3 months. There will be three follow up visits (Week-2, Week-6 and Month-3) where participants will be asked to complete the gastrointestinal quality of life index.
2954996|NCT02868450|Experimental|Patients with HLA-DQB1 06 and/or HLA-DRB 13|
2954997|NCT02868437|Active Comparator|Group 1|The patients who are having curettage for retained product after second trimester abortion will also receive an intervention of intrauterine self-cross-linked hyaluronic acid gel after the procedure
2954998|NCT02868437|No Intervention|Group 2|The patients who are having curettage for retained product after second trimester abortion will receive no intervention
2954999|NCT02868424|Experimental|fRPE cells|Subretinal transplantation of fRPE cells in experimental eye
2955000|NCT02868411|Experimental|Patients admitted for traveller's fever|
2955001|NCT02868385|Active Comparator|Control group (A)|1x praziquantel: Children assigned to group A receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive no further treatment until the final visit (week 8).
2955002|NCT02868385|Experimental|Intervention group (B)|4x praziquantel: Children assigned to group B receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive three consecutive praziquantel treatments (40 mg/kg) in the following six weeks with 2 weeks intervals.
2955003|NCT02868372|Active Comparator|Betadine group|Subcutaneous tissues of cesarean section wounds are swabbed with10% undiluted Povidone Iodine solution without mobbing before closure of subcutaneous tissues
2955004|NCT02868372|No Intervention|No intervention group|No swabbing of subcutaneous tissue of cesarean section wounds
2955005|NCT02868359||Pregabalin / Other analgesics|Patients will be treated for 8 weeks with pregabalin in primary care: no intervention
2955006|NCT02868359||Other analgesics|Patients will be treated for 8 weeks with other analgesics in usual care: no intervention
2955007|NCT02868346|Experimental|Patients admitted for sexually transmitted infection|
2955008|NCT02868320|Experimental|Intervention group|This group received a diabetes instruction booklet in addition to daily educational SMS messages and weekly reminders
2955009|NCT02868320|Active Comparator|Control group|This group only received a diabetes instruction booklet
2955010|NCT02868307|Experimental|Patient prsenting schizophrenia|
2955011|NCT02868294|Experimental|Patient receiving the Fassier-Duval Nail|Implementation of a telescopic system intramedullary
2955012|NCT02868281|Experimental|Subjects recruited at ACT centers|For the subjects who will be recruited in the ACT centers, they will be treated based on the ACT score. If ACT score are = 25 for >=3 months then step-down the treatment; if ACT score >=20, <25 or ACT=25 for <3 months then there will be no change and if ACT score less than (<=) 19 then step-up the treatment.
2955013|NCT02868281|Active Comparator|Subjects recruited in the control centers|For subjects who will be recruited in the control centers, they will be treated based on doctor's subjective judgment.
2955014|NCT02868268||Relapsed/Refractory Neuroblastoma Pts|History of high risk neuroblastoma (NBL) according to Childrens Oncology Group (COG) risk classification with relapsed/progressive, refractory or persistent neuroblastoma. Archival or biopsied tumor specimens are provided for gene panel sequencing to subjects with potentially targetable genetic and/or immunologic biomarkers. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receiving this clinical report.
2955015|NCT02868255||Ascites|"30 inflammatory ascites of HCC patients (Collection of human samples ) Ascites will be selected only from HCC patients with an elevated protein level (ie inflammatory ascites) Puncture of ascites will be collected by paracentesis on HCC or ovarian cancer patients during their routine care These biological samples are affiliated with the biobank hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
2955016|NCT02868255||Resections|"30 HCC resections (Collection of human samples ) Fragment of resected HCC will be obtained after surgery and histological analysis will be performed by the anatomo-pathology service These biological samples are affiliated with the biobank hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
2955017|NCT02868255||blood samples|"blood samples (Collection of human samples )will be collected prospectively for complementary functional analysis of peripheral These biological samples are affiliated with the biocollection hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
2955018|NCT02868242|Experimental|LDV/SOF|Participants will receive LDV/SOF fixed dose combination (FDC) placebo to assess ability to swallow at screening up to Day 1. Based on swallowability assessment, participants will receive LDV/SOF FDC (1x 90/400 mg) or (4 x 22.5/100 mg) tablet(s) for 12 weeks.
2955019|NCT02868229|Experimental|COR-001|
2955020|NCT02868229|Placebo Comparator|Placebo|
2955021|NCT02868216|Experimental|anger management training|treatment group- Two monthly sessions will address the events triggering anger, the physiology of anger and the influence on the cardiovascular system, the dimesions of anger: cognitive, emotional and behavioral.
2955022|NCT02868216|No Intervention|Without management training|No anger management training
2955023|NCT02868203|Active Comparator|OCT at 3 months|OCT at 3 months and 12 OCT at 3 months
2955024|NCT02868203|Active Comparator|OCT at 6months|OCT at 6 months and 12 OCT at 3 months
2955025|NCT02868190|Other|Two micro-bypass stents (iStent inject)|Standalone implantation of two trabecular micro-bypass stents (iStent inject)
2955026|NCT02868177|Experimental|Totum-63|The studied active product is a food supplement formula in shape of capsule which contains Totum-63 (a patented mixture of dry extracts from 5 plants), active ingredient of Valedia
2955027|NCT02868177|Placebo Comparator|Placebo|The comparative product is a placebo with the same characteristics of appearance and packaging in which all ingredients are replaced by maltodextrin.
2955028|NCT02868164|Experimental|Fecal Microbiota Transplantation (FMT)|
2955029|NCT02868164|Active Comparator|Weight Reduction|
2955030|NCT02868151|No Intervention|GROUP A|Standard treatment followed in the regional cancer center for prevention and treatment of oral mucositis during chemo radiotherapy of cancers. 20% Benzocaine 15grms. twice daily for the entire treatment period
2955031|NCT02868151|Experimental|GROUP B|"Ascorbic acid oral supplementation 1g four times daily for the entire treatment period of 30 days and after treatment by tapering the dose of the drug to half for another month. The drug has to be started 2 days prior to initiation of treatment of cancer.~Subdivided into 2 groups , 30 patients in each : sub group 1: only radiotherapy patients, subgroup 2 includes concurrent chemo-radiotherapy patients."
2955032|NCT02868151|Experimental|GROUP C|Zinc acetate tablets 50mg orally
2955033|NCT02868112|Experimental|Transdisciplinary Intervention|"Patients randomized to the Transdisciplinary Intervention will undergo evaluation with a board-certified geriatric clinician, who will tailor their care based on the results of a brief geriatric screening tool.~-Investigators will test a two-visit Transdisciplinary Intervention with the first visit occurring within four weeks of enrollment and the second visit four weeks after the initial visit."
2955034|NCT02868112|Active Comparator|Usual Care|Participants receiving Usual Oncology Care will not meet routinely with geriatric clinicians, though they may receive a geriatrics consult at their request or at the discretion of their treating team.
2955035|NCT02868099|Placebo Comparator|Placebo|Subjects received placebo for injection treatment will be administered subcutaneously once a week
2955036|NCT02868099|Experimental|Drug|Subjects received Romiplostim for injection treatment will be administered subcutaneously once a week
2955037|NCT02868086|Experimental|Tested patients|Patients treated with anti-angiogenics for ARMD : monitoring using optical coherence tomography angiography
2955038|NCT02868086|Active Comparator|Control patients|Patients treated with anti-angiogenics for ARMD : monitoring during common practice via optical coherence tomography B scans
2955039|NCT02868073|Experimental|H1N1 (high dose) Oral Vaccine Tablet|Singe dose of orally administered VXA-G1.1-NN (high dose) Oral Vaccine Tablet. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk.
2955040|NCT02868073|Experimental|H1N1 (low dose) Oral Vaccine Tablet|Singe dose of orally administered VXA-G1.1-NN (low dose) Oral Vaccine Tablet. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk.
2955041|NCT02868073|Placebo Comparator|Placebo Tablets|Singe dose of VXA Placebo tablets. The placebo tablets are small off-white tablets that are similar in size and number to the active vaccine dose being delivered.
2955042|NCT02868060|Experimental|1 mcg/kg AMG531|The administration of Romiplostim will be performed on Day 1 and 8
2955043|NCT02868060|Experimental|3 mcg/kg AMG531|The administration of Romiplostim will be performed on Day 1 and 8
2955044|NCT02868047||Suspected Chronic Pancreatitis|Included patients will be those scheduled for an upper endoscopic ultrasound examination with suspected chronic pancreatitis
2955045|NCT02868047||NOT Suspected Chronic Pancreatitis|Included patients will be those scheduled for an upper endoscopic ultrasound examination without suspected chronic pancreatitis.
2955048|NCT02868034|Experimental|SMT with Activation Exercises|2 sessions of SMT during week 1 and 6 additional sessions of lumbar multifidus activating exercises during weeks 2-4.
2955049|NCT02868034|Experimental|SMT with Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of spinal mobilizing exercises during weeks 2-4.
2955050|NCT02868034|Experimental|SMT with Mobilizing and Activation Exercises|2 sessions of SMT during week 1; 6 sessions of lumbar multifidus activating exercises and spinal mobilizing exercises during weeks 2-4.
2955051|NCT02868034|Experimental|SMT extended with Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of SMT and spinal mobilizing exercises during weeks 2-4.
2955052|NCT02868034|Experimental|SMT extended with Activation Exercises|2 sessions of SMT during week 1; 6 sessions of SMT and lumbar multifidus activating exercises during weeks 2-4.
2955053|NCT02868034|Experimental|SMT extended with Activation and Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of SMT, multifidus activating and spinal mobilizing exercises during weeks 2-4.
2955054|NCT02868021|Placebo Comparator|NO-EX group|Subjects allocated to the No Exercise (NO-EX) group will undergo: Strength testing, Short Physical Performance Battery (SPPB), Six-minute walk (SMW), Numerical pain scale, Self-assessed function and Six-minute walk (SMW) test. Intra-op muscle biopsies.
2955055|NCT02868021|Experimental|EX-BFR group|Subjects allocated to the EX-BFR group will undergo baseline strength testing, Short Physical Performance Battery (SPPB), Numerical pain scale, Six-minute walk (SMW), Self-assessed function, and determination of 1 Repetition Maximum (1-RM). Blood flow restriction exercise, Borg Category Ratio 10 (Borg CR10) scale. Intra-op muscle biopsies.
2955056|NCT02868008|Experimental|fMRI guided AVM resection|fMRI guided microsurgical resection of brain AVMs
2955057|NCT02867995|No Intervention|Control|No glaucoma drop aid control
2955058|NCT02867995|Active Comparator|Eye Drop Aids|Participants could be placed into one of the drop aid groups (Fabrication Autodrop Eye Drop Guide,Owen Mumford OP 6100 Autosqueeze, or the Simply Touch Eye Drop Applicator)
2955059|NCT02867982|Other|Subcrestal|implants that are placed below the alveolar ridge
2955060|NCT02867982|Other|Paracrestal|implants that are placed flush to the alveolar ridge
2955061|NCT02867969|Other|Motor training|The motor training comprise of demanding coordinative exercises based on commercially available developed by Microsoft Game Console (XBOX Kinect™) exergames that specifically target ataxia dysfunctions.
2955062|NCT02867956|Experimental|Apatinib + Etoposide|"Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.~Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles."
2955063|NCT02867943||respiratory rate is 10 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
2955064|NCT02867943||respiratory rate is 12 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
2955065|NCT02867943||respiratory rate is 14 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
2955066|NCT02867943||respiratory rate is 16 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
2955067|NCT02867930|Active Comparator|Group D|Dexmedetomidine- drug used for moderate sedation prepared as 200 mic in 20 ml syringe.with intravenous loading dose at 1ml/kg/hour till required sedation is achieved and maintenance infusion of 0.05mg/kg/hour till completion of transesophageal echocardiography
2955068|NCT02867930|Active Comparator|Group KF|Ketamine+Propofol -drugs used for sedation-as ratio 1:3with 19ml of 1% propofol + 1.3ml ketamine(50mg/ml) as loading intravenous infusion dose at 1ml/kg/hour till required sedation is achieved and maintenance infusion of 0.05mg/kg/hour till completion of transesophageal echocardiography
2955069|NCT02867917|Other|Total group|Volcolon sugar free & Metamucil Orange & Psyllium Orange in a randomized order.
2955070|NCT02867904|Placebo Comparator|Group A|After arthroscopic surgery the control group (Group A) will undergo a subacromial marcaine injection (standard of care).
2955071|NCT02867904|Experimental|Group B|After arthroscopic surgery the experimental group (Group B) will undergo a subacromial corticosteroid injection+marcaine.
2955072|NCT02867891||Chemotherapy alone|The specific interventions to the subjects of the study are assigned by the individual transplant center
2955073|NCT02867891||Chemotherapy/DLI|The specific interventions to the subjects of the study are assigned by the individual transplant center
2955074|NCT02867891||Sorafenib alone|The specific interventions to the subjects of the study are assigned by the individual transplant center
2955075|NCT02867891||Sorafenib/DLI|The specific interventions to the subjects of the study are assigned by the individual transplant center
2955076|NCT02867878|Experimental|Adenosine|Patients in this arm will receive systemic infusion of adenosine at 140μg/kg/min for 3 minutes plus standard therapy according to current guidelines
2955077|NCT02867878|Placebo Comparator|Saline solution|Patients in this arm will receive systemic infusion of saline solution at 140μg/kg/min for 3 minutes plus standard therapy according to current guidelines
2955078|NCT02867865|Active Comparator|Chemotherapy arm|"Post staging laparoscopy, all patients will receive chemotherapy using Injection Gemcitabine 1000 mg/m2 delivered day 1 and 8 every 3 weeks.~In addition, Injection Cisplatin 25 mg/m2 for and 4 cycles week 1 to week 11."
2955079|NCT02867865|Experimental|Chemoradiation arm|"Post staging laparoscopy in Experimental arm The radiation dose will be 50-55 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2). Radiotherapy will be for 5 weeks which will be followed by 2 cycles of chemotherapy with Injection Gemcitabine (Gemcite,Gemzar) 1000 mg/m2 delivered day 1 and 8 every 3 weeks and cisplatin (Cisplat, Cytoplatin) 25 mg/m2from week 7 to week 11.~During week 12-13 patients will undergo repeat PETCECT scan. If the scan shows partial or good response then patients will be evaluated for surgery. Surgery if possible will be done between weeks 13-15. In case of inoperable disease patients will receive further chemotherapy"
2955080|NCT02867852|Experimental|Abiraterone acetate|Abiraterone acetate 1 g/day must be taken as four 250-mg tablets daily on an empty stomach. No food should be consumed for at least 2 hours before the dose of abiraterone acetate is taken and for at least 1 hour after the dose of abiraterone acetate is taken. Prednisone (prednisolone when prednisone is not available) 5 mg will be given orally twice a day.
2955081|NCT02867839|Experimental|A: postoperative Oxaliplatin plus S-1|"Patients in arm A will receive standard distal gastrectomy with D2 lymphadenectomy first, and 8 cycles of adjuvant Oxaliplatin plus S-1 (SOX) later.~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3W S-1: 40~60mg bid, po, d1~14, q3W (6 months)"
2955082|NCT02867839|Active Comparator|B: postoperative S-1 only|"Patients in arm B will receive standard distal gastrectomy with D2 lymphadenectomy first, and 16 cycles of adjuvant S-1 later.~S-1: 40~60mg bid, po, d1~14, q3W (12 months)"
2955083|NCT02867826|Experimental|Cap-assisted endoscopy|forward-viewing endoscope with a Cap attached at the tip
2955084|NCT02867813|Experimental|evolocumab (AMG 145)|
2955085|NCT02867800|Experimental|Standard GVHD Prophylaxis + Abatacept|"Subjects will receive~premedication (Diphenhydramine, Acetaminophen, Methylprednisolone; and Meperidine as needed)~immunosuppression (Alemtuzumab, or Thymoglobulin)~conditioning regimen (Fludarabine, Thiotepa, and Melphalan)~GVHD prophylaxis: calcineurin inhibitor (Cyclosporine,Tacrolimus, Sirolimus or Mycophenolate Mofetil with permission of the sponsor) and Methotrexate plus Abatacept on days -1, +5, +14 and +28, and a marrow infusion on day 0."
2955086|NCT02867787|Experimental|Botox arm|intramuscular injection of botulinum toxin
2955087|NCT02867774|Experimental|Intervention|This pilot study will enroll 25 women age 18-65 with greater than six months of noncyclic pelvic pain. Subjects will participate in an 8-week physical activity program specifically designed for patients with chronic pain and supervised by personal trainers and exercise physiologists in a rehab-focused, medically-based fitness center. Subjects will complete web-based assessment tools at the start of the program, immediately after completion of the 8-week program and four weeks after the conclusion of the program (at the 12-week time point).
2955088|NCT02867761|Active Comparator|Indacaterol/Glycopyrrolate|indacaterol/glycopyrrolate 27.5/15.6 mcg inhaled twice daily for 12 weeks
2955089|NCT02867761|Placebo Comparator|Placebo|Placebo 27.5/15.6 mcg inhaled twice daily for 12 weeks
2955090|NCT02867748|Experimental|1|TVT-Abbrevo
2955091|NCT02867748|Experimental|2|Serasis
2955092|NCT02867735|Experimental|LKA651|
2955093|NCT02867735|Sham Comparator|Sham Comparator|
2955094|NCT02867722|Experimental|Daylight PDT|Patients will receive daylight-PDT treatment (aminolevulinic acid)
2955095|NCT02867709|Experimental|Ubrogepant 25 mg|1 ubrogepant 25 mg tablet orally for treatment of a qualifying migraine attack. Participants may receive a second dose or placebo-matching ubrogepant orally 2 hours after initial treatment if applicable followed by 1 ubrogepant 25 mg tablet 4 days after the qualifying migraine attack for Pharmacokinetic (PK) sampling.
2955096|NCT02867709|Experimental|Ubrogepant 50 mg|1 ubrogepant 50 mg tablet orally for treatment of a qualifying migraine attack. Participants may receive a second dose or placebo-matching ubrogepant orally 2 hours after initial treatment if applicable followed by 1 ubrogepant 50 mg tablet 4 days after the qualifying migraine attack for PK sampling.
2955097|NCT02867709|Placebo Comparator|Placebo|1 ubrogepant placebo-matching tablet orally for treatment of a qualifying migraine attack. Participants may receive a second dose orally 2 hours after initial treatment if applicable followed by 1 ubrogepant placebo-matching tablet 4 days after the qualifying migraine attack for PK sampling.
2955098|NCT02867696|Active Comparator|Standard Care|Standard Care serves as the no treatment control in this project. Participants in this group will receive the typical care from their surgeon following bariatric surgery. No additional interventions will be given to participants randomized to this group.
2955099|NCT02867696|Experimental|Technology-based Intervention (TECH)|TECH is the experimental group in this project. A minimal-contact technology-based intervention for weight management will be given to this group in addition to the standard or typical care received from their surgeon following bariatric surgery.
2955100|NCT02867683|Experimental|Vibrotactile Feedback|Balance exercises completed while vibration was applied to the trunk (anterior, posterior, right, and left) if postural sway exceeded a pre-determined threshold during the exercise.
2955101|NCT02867683|No Intervention|Without Vibrotactile Feedback|Balance training without feedback
2955102|NCT02867670||Transcranial Magnetic Stimulation of Motor Cortex|All study participants will receive real TMS stimulation over the primary motor cortex in order to collect physiological measures which will later be correlated with measures of neuroplasticity. There is NO placebo stimulation.
2955103|NCT02867670||Transcranial Magnetic Stimulation of Language Cortex|All study participants will receive real TMS stimulation over the language cortex and a control site (i.e. vertex). Transient changes in speech production will be recorded and compared to measures of neuroplasticity. There is NO placebo stimulation.
2955104|NCT02867657|Experimental|Mindfulness in nature|A five day mindfulness retreat in nature
2955105|NCT02867657|Active Comparator|Mindfulness indoor|A five day mindfulness retreat indoor
2955106|NCT02867657|No Intervention|Wait list control|A wait list control group, that 6 months later is offered a two-day mindfulness retreat in nature
2955107|NCT02867644|Active Comparator|standard care|
2955108|NCT02867644|Experimental|standard care+conversational hypnosis|
2955109|NCT02867631|No Intervention|Enhanced control|Regular care as provided by the community based organization from which the convenience sample is recruited with one year of assessments only
2955110|NCT02867631|Experimental|Intervention|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
2955111|NCT02867618|Experimental|Carfilzomib + TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 and carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle.
2955112|NCT02867605||Healthy Controls ages 18-45 with BMI of 19-25 or 30-35|
2955113|NCT02867592|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2955114|NCT02867579|Other|women with denial pregnancy|women with denial pregnancy
2955115|NCT02867579|Other|women without denial pregnancy|women without denial pregnancy
2955116|NCT02867566|Experimental|IBI301|IBI301, 375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
2955117|NCT02867566|Active Comparator|Rituximab|Rituximab,375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
2955181|NCT02867098|Experimental|Cohort 3|Dose Level 3 XmAb5871 given SC Q14days X 3
2955118|NCT02867553|Experimental|Rituximab by intravenous|attack treatment (4 slow intravenous perfusions of rituximab at a dose of 375 mg / m2 on day 1, day 8, day 15 and day 22) and maintenance treatment (intravenous perfusions of rituximab at a dose of 375 mg / m2 every 2 months for 2 years).
2955119|NCT02867553|Active Comparator|multi-field radiotherapy|multi-fields radiotherapy with a dose between 20 and 30 gray and a fractionated dose over 2 at 3 weeks.
2955120|NCT02867540|Experimental|experimental group|Patient's with Crohn's disease who have had ileocolic resection
2955121|NCT02867514|Active Comparator|anodal tDCS on left DLPFC (F3)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 min for 10 sessions. Anode is placed on the scalp facing on left DLPFC and cathode on right DLPFC.
2955122|NCT02867514|Sham Comparator|sham tDCS on left DLPFC (F3)|tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 min - 10 sessions). Anode is placed on the scalp facing on left DLPFC and cathode on right DLPFC.
2955123|NCT02867514|Active Comparator|anodal tDCS on right DLPFC (F4)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 min for 10 sessions. Anode is placed on the scalp facing on right DLPFC and cathode on left DLPFC.
2955124|NCT02867514|Sham Comparator|sham tDCS on right DLPFC (F4)|tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 min - 10 sessions). Anode is placed on the scalp facing on right DLPFC and cathode on left DLPFC.
2955125|NCT02867501||Aneurysmatic disease|Patients with dilatative arteriopathy (DA) the aortic diameter must be > 3 cm or the popliteal artery diameter > 1.5 cm
2955126|NCT02867501||Peripheral arterial occlusive disease|Patients with arterial occlusive disease (PAOD) defined with an Ankle brachial index (ABI) < 0.9 and positive criteria in the Edinburgh questionnaire.
2955127|NCT02867501||Healthy|Control group of age matched persons without PAOD (ABI > 0.9) and without DA.
2955128|NCT02867475|Other|A|Physical activity motivation
2955129|NCT02867462|Other|A-Standard Care|standard care
2955130|NCT02867462|Experimental|B-manipulator consultation radiotherapy added to standard care|manipulator consultation radiotherapy added to standard care
2955131|NCT02867449|Experimental|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
2955132|NCT02867449|Experimental|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak & Foa (1997)
2955133|NCT02867436|Experimental|Gluten-free diet|Gluten-free diet
2955134|NCT02867436|No Intervention|Conventional diet|Conventional diet
2955135|NCT02867423|Other|A - CK boost radiation|CK boost radiation
2955136|NCT02867397|Other|Teysuno (S1) in combination with epirubicin and oxaliplatin|
2955137|NCT02867384|Active Comparator|Obinutuzumab|"Obinutuzumab or will be administered at a pre- determine dose, intravenously, at 3, 6, 9 and 12 months from transplantation.~Premedication with histamine blockers and acetaminophen will be provided~All subjects will undergo allogeneic stem cell transplantation according to locally approved clinical trials"
2955138|NCT02867384|Sham Comparator|Placebo|"Placebo will be administered at a pre- determine dose, intravenously, at 3, 6, 9 and 12 months from transplantation.~Premedication with histamine blockers and acetaminophen will be provided~All subjects will undergo allogeneic stem cell transplantation according to locally approved clinical trials"
2955139|NCT02867371|Experimental|-Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System
2955140|NCT02867358|Active Comparator|High dose of KT07 capsule|It will assess about 140 subjects with influenza at high dose KT07 (6 capsules each time, bid).
2955141|NCT02867358|Active Comparator|Low dose of KT07 capsule|It will assess about 140 subjects with influenza at low dose KT07 (4 capsules of KT07 + 2 capsules of placebo each time, bid).
2955142|NCT02867358|Placebo Comparator|Placebo|It will assess 140 subjects with influenza using 6 capsules of placebo each time, bid as control.
2955143|NCT02867345|Experimental|Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
2955144|NCT02867345|Placebo Comparator|Comparable group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 wild-type T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
2955145|NCT02867332|Experimental|Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
2955182|NCT02867098|Experimental|Cohort 4|Dose Level 4 XmAb5871 given IV Q14days X 3
2955183|NCT02867098|Experimental|Cohort 5|Dose Level 5 XmAb5871 given SC Q7days X 3
2955184|NCT02867085||Group 1 (MDS group)|
2955185|NCT02867085||Group 2 (control group)|
2955186|NCT02867072|Active Comparator|Open appendectomy|Subjects that underwent open surgery for appendicitis
2955146|NCT02867332|Placebo Comparator|Comparable group|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment."
2955147|NCT02867319|Experimental|age of 18-50 years old|
2955148|NCT02867319|Experimental|age of 7-17 years old|
2955149|NCT02867319|Experimental|age of 2-6 years old|
2955150|NCT02867306|Experimental|ASP1707 and methotrexate (MTX)|On day 1 patients will receive prescribed dose of MTX. On Days 3 through 8, patients will receive ASP1707 (twice daily). On Day 9, patients will receive a single dose in the morning. A single dose of MTX will be coadmistered on Day 8.
2955151|NCT02867293|Active Comparator|Preop-drainage|ascites drained over the pre-operative week through multiple ultrasound guided paracentesis
2955152|NCT02867293|Active Comparator|Op-drainage|ascetic fluid drained through an abdominal incision after anesthesia
2955153|NCT02867280|Experimental|Sorafenib|Sorafenib (Nexavar) 200mg tablet, 2 tablets oral daily for 2 years, starting within 4weeks after hepatectomy. Regular treatment combined.
2955154|NCT02867280|No Intervention|Control|No use of Sorafenib (Nexavar). Regular treatment.
2955155|NCT02867267|Experimental|thymosin alpha 1|1ml subcutaneous injection with 1.6 mg thymalfasin for 7 days, BID
2955156|NCT02867267|Placebo Comparator|Placebo|1ml subcutaneous injection with 1.6 mg placebo for 7 days , BID
2955157|NCT02867254||Groups1|15 patients with type 2 diabetes mellitus with periodontal endodontic lesions
2955158|NCT02867254||Groups 2|15 non-diabetics with periodontal endodontic lesions
2955159|NCT02867241|Experimental|Intervention|"Motivational interviews (3 visits) + supportive phone calls~Feedback of child hair nicotine levels~Feedback of home air quality (PM2.5)~New Media (Website and/or Facebook with information and parental forum)"
2955160|NCT02867241|Other|Control Regular|This group will get no intervention during the study period. Following the close of the study, participants in this group will receive a shortened version of the intervention (1 motivational interview, with feedback on child hair nicotine levels and feedback on home air quality (PM2.5))
2955161|NCT02867241|Other|Control Expanded|This group will get no intervention during the study period. However, participants will fill out a detailed questionnaire on parental perceptions of exposure and risk, as well as questions on social norms, self-efficacy, and knowledge Following the close of the study, participants in this group will receive a shortened version of the intervention (1 motivational interview, with feedback on child hair nicotine levels and feedback on home air quality (PM2.5))
2955162|NCT02867228|Other|Single Observational Group|Patients receiving mechanical ventilation and subject to the intervention: changes in ventilator settings.
2955163|NCT02867215|Active Comparator|Barley bread|Two loaves, 2 x 120 g loaf/day for 3 weeks.
2955164|NCT02867215|Active Comparator|Wheat bread|Two loaves, 2 x 120 g loaf/day for 3 weeks.
2955165|NCT02867202|Experimental|Intrauterine balloon|The heart-shaped intrauterine balloon is designed to fit into the cavity of the uterus,and removed on the 7th day after surgery. And hysteroscopy was taken out again after two menstrual cycles to evaluate the uterine adhesions.
2955166|NCT02867202|Experimental|Intrauterine contraceptive device|The IUD is inserted into the uterine after a hysteroscopic adhesiolysis and removed at the second hysteroscopy. Uterine adhesions were judged again at the second hysteroscopy.
2955167|NCT02867189|Experimental|atlas of micro-instrument|anterior chamber cell counts and visual and intraocular pressures on postoperative days 1,3,7,14 by atlas of micro-instrument training method.
2955168|NCT02867189|No Intervention|traditional training|anterior chamber cell counts and visual and intraocular pressures on postoperative days1,3,7,14 by traditional training method.
2955169|NCT02867176|Other|Corneal collagen CXL epi-off|For the epithelium-off procedure, the corneal epithelium is removed with a 10-minute soak time with isotonic riboflavin 0.1% solution and 4 minutes of exposure with 30 mw/cm2 ultraviolet-A irradiation.
2955170|NCT02867176|Other|Corneal collagen CXL epi-on|For the epithelium-on procedure, riboflavin is applied for a total soak of 4 minutes; the cornea is then completely rinsed with additional riboflavin for a total of 6 minutes. The ultraviolet-A irradiation is performed for 2 minutes and 40 seconds at 45mw/cm2.
2955171|NCT02867163||Knee replacement patients receiving TXA|Patients who receive tranexamic acid during total knee replacement surgery
2955172|NCT02867150|Experimental|Active Device|Active Device: Ward Photonics Photonica Professional Red light therapy system Intervention: Device: Ward Photonics Photonica Professional
2955173|NCT02867137||Mild TBI patients|
2955174|NCT02867124|Experimental|Vivitrol at place of residence|One injection of long-acting naltrexone (XR-NTX) in prison, followed by 6 monthly injections post-release at the participants's place of residence utilizing mobile medical treatment
2955175|NCT02867124|Active Comparator|Vivitrol at opioid treatment program|One injection of long-acting naltrexone (XR-NTX) in prison, followed by 6 monthly injections post-release at a community opioid treatment program.
2955176|NCT02867111|Other|ICSI Control|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with no intervention of the Sperm Selection Assay
2955177|NCT02867111|Placebo Comparator|ICSI + SSA placebo|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with intervention of the Sperm Selection Assay with control solution (culture medium)
2955178|NCT02867111|Experimental|ICSI + SSA Attractant substance|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with intervention of the Sperm Selection Assay with attractant solution (attractant diluted in culture medium at 10 pM)
2955179|NCT02867098|Experimental|Cohort 1|Dose Level 1 XmAb5871 given SC Q14days X 3
2955180|NCT02867098|Experimental|Cohort 2|Dose Level 2 XmAb5871 given SC Q14days X 3
2955187|NCT02867072|Active Comparator|Laparoscopic appendectomy|Subjects that underwent laparoscopic surgery for appendicitis
2955188|NCT02867059|Experimental|first dose|The dose used in the first cohort was determined on the basis of the safety and PK data generated in the FIM study (NCT02661373) currently ongoing in United States (US) and will be 150 mg.
2955189|NCT02867059|Experimental|second dose|Depending on the pharmacodynamics data (effect of SJ733 on parasitaemia) obtained from this first cohort, the dose in Cohort 2 may be adjusted but will not exceed 600 mg.
2955190|NCT02867046|Experimental|medial approach group|
2955191|NCT02867046|Active Comparator|lateral approach group|
2955192|NCT02867033|Other|Study procedure|Tumor biobank realization (biopsy...) and biobank constitution. coloscopy associated with colonic chromoscopy. Blood sampling (facultative). Pain evaluation
2955193|NCT02867020|Active Comparator|Abiraterone acetate + Prednisone + ADT (Goserelin)|"Abiraterone administered at a single 1000 mg daily oral dose (4 x 250-mg tablets)~Prednisone administered at a 5 mg twice daily oral dose~Goserelin administered as subcutaneous injections of 10.8mg every 3 months"
2955194|NCT02867020|Experimental|APALUTAMIDE monotherapy|o APALUTAMIDE administered at a single 240 mg daily oral dose (4 x 60 mg tablets)
2955195|NCT02867020|Experimental|Abiraterone acetate + Prednisone + APALUTAMIDE|"Abiraterone administered at a single 1000 mg daily oral dose (4 x 250 mg tablets)~Prednisone administered at a 5 mg twice daily oral dose~APALUTAMIDE administered at a single 240 mg daily oral dose (4 x 60 mg tablets)"
2955196|NCT02867007|Experimental|KHK2455 + Mogamulizumab|"Part 1 (Dose Escalation Part): Will identify the MTD for the KHK2455 monotherapy run-in and for the combination regimen (KHK2455 monotherapy [Cycle 0] followed by KHK2455 +mogamulizumab combination [Cycle 1]).~Part 2 (Expansion Part): Subjects with a selected tumor type will be enrolled and treated with the recommended dose of KHK2455 established in Part 1 in combination with mogamulizumab."
2955197|NCT02866994|Experimental|Project Connect Online (PCO)|Creation of personal website to share breast cancer experience with friends and family
2955198|NCT02866994|Experimental|PCO PLUS|Creation of personal website to share breast cancer experience with friends and family, as well as other women diagnosed with breast cancer
2955199|NCT02866981|Experimental|Observation|Patients that meet all inclusion and exclusion criteria are monitored every 2 months for two years or until a therapeutic intervention is warranted.
2955200|NCT02866968|Experimental|Femtosecond Laser-assisted Pterygium Surgery (FLAPS)|All patients included will undergo FLAPS in one eye.
2955201|NCT02866955|Other|GROUP E (Estramustine)|Patients with HER2-/RH+ breast cancer progressing after having already undergone a first line adjuvant treatment by estramustine
2955202|NCT02866955|Other|GROUP T (Tamoxifen)|Patients with HER2-/RH+ breast cancer progressing after having already undergone a first line adjuvant treatment by tamoxifen
2955203|NCT02866942|Experimental|Asthma: mild-moderate|LAIV administration in children with asthma receiving treatment according to British Thoracic Society step 2-3.
2955204|NCT02866942|Experimental|Asthma: moderate-severe|LAIV administration in children over 5 years with asthma receiving treatment according to British Thoracic Society step 4-5; OR in children age 2-4 years who have had at least exacerbations in the past 12 months requiring oral steroids or hospitalization.
2955205|NCT02866929|Active Comparator|Conventional orthodontic treatment|Patients that will receive conventional orthodontics
2955206|NCT02866929|Experimental|Orthodontics with decortication|Patients that will receive orthodontic treatment with selective alveolar decortication
2955207|NCT02866929|Experimental|Orthodontics decortication and Mucograft|Orthodontic treatment, selective alveolar decortication and Mucograft® on the mandibular anterior segment
2955208|NCT02866929|Experimental|Orthodontics and Mucograft®|Patients that will receive orthodontic treatment and Mucograft® on the mandibular anterior segment
2955209|NCT02866916|Experimental|Dose escalation|"The standard method 3+3 will be used for dose escalation: the first 3 patients will be treated at level 1; consecutive cohorts of 3 to 6 patients will be treated with increasing doses of SXL01.~Treatment will be administered until patient experiences unacceptable toxicity, PSA raising, progressive disease and/or treatment is discontinued at the discretion of the investigator or withdrawal of consent.~Additional patients will be included at the Recommended Phase II Dose (RP2D) in the expansion phase."
2955210|NCT02866903|Experimental|Patients with peritoneal carcinosis|Patients with peritoneal carcinosis of colorectal origin and uncertain resectability with an indication for systemic chemotherapy compatible with the FOLFIRI + bevacizumab combination.
2955211|NCT02866890|Experimental|Laryngeal Tube Suction size 1|Measurement of leak pressure
2955212|NCT02866890|Experimental|Laryngeal Tube Suction size 2|Measurement of leak pressure
2955213|NCT02866890|Experimental|Laryngeal Tube Suction size 2.5|Measurement of leak pressure
2955214|NCT02866877||Subarachnoid Hemorrhage|
2955215|NCT02866864||Subjects with animal allergy|Subjects who suffer from allergic symptom during contact with animal
2955216|NCT02866864||Subjects without animal allergy|Subjects who do not suffer from allergic symptom during contact with animal
2955217|NCT02866851|Experimental|Monitoring by Web application|Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
2955218|NCT02866838|Experimental|Tranexamic acid|Intravenous tranexamic acid: 1g loading dose given as 100 mls infusion over 10 minutes, followed by another 1g in 250 mls infused over 8 hours.
2955219|NCT02866838|Placebo Comparator|Placebo|Saline 0.9% given in identical dosage as experimental
2955220|NCT02866825|Active Comparator|IFX-1|dose escalating single i.v. administration of IFX-1 (verum)
2955221|NCT02866825|Placebo Comparator|Placebo|dose escalating mimicing single i.v. administration of placebo
2955222|NCT02866812|Experimental|patient with endovascular treatment for intracranial aneurysm|
2955223|NCT02866799|Experimental|Multi-PAP intervention|Complex intervention with general practitioners and patients
2955224|NCT02866799|Active Comparator|Usual care|Patients will receive the usual clinical care
2955225|NCT02866786|Active Comparator|OCP only arm|OCP containing 35 microgram ethinyl estradiol and 2 milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill. OCP to be taken for 6 months.
2955226|NCT02866786|Active Comparator|Metformin arm|Metformin 500mg bid in morning and evening after meals to be taken for 6 months.
2955227|NCT02866773|Experimental|PA1:Education sessions, Reminders, Whataps group|The intervention includes Physical activity knowledge enhancement session, Physical activity anti-inertia Reminders , Physical activity ambassadors' electronic communication group.
2955228|NCT02866773|Active Comparator|PA2:Education sessions, Reminders|The intervention includes Physical activity knowledge enhancement session and Physical activity anti-inertia Reminders
2955229|NCT02866773|Active Comparator|PA3:Education sessions, Whataps group|The intervention includes Physical activity knowledge enhancement session and Physical activity ambassadors' electronic communication group.
2955230|NCT02866773|Active Comparator|PA4:Education sessions|The intervention includes Physical activity knowledge enhancement session only.
2955231|NCT02866773|Experimental|HD1:Education sessions, Reminders, Whataps group|The intervention includes Health diet knowledge enhancement session, Health diet anti-inertia Reminders , Health diet ambassadors' electronic communication group.
2955232|NCT02866773|Active Comparator|HD2:Education sessions, Reminders|The intervention includes Health diet knowledge enhancement session, Health diet anti-inertia Reminders , and Health diet ambassadors' electronic communication group.
2955233|NCT02866773|Active Comparator|HD3:Education sessions, Whataps group|The intervention includes Health diet knowledge enhancement session and Health diet ambassadors' electronic communication group.
2955234|NCT02866773|Active Comparator|HD4:Education sessions|The intervention includes Health diet knowledge enhancement session only.
2955235|NCT02866747|Active Comparator|Arm A: radiation therapy alone|Hypofractionated stereotactic radiation therapy (hFSRT) 24 Gray (Gy), 8 Gy per fraction preferentially at 80% isodose (60 to 90 % accepted), 3 fractions scheduled on Day 1 of the radiotherapy (RT), Day 3 RT and Day 5 RT.
2955236|NCT02866747|Experimental|Arm B: combined treatment|"hFSRT 24 Gy, 8 Gy per fraction preferentially at 80% isodose (60 to 90 % accepted), 3 fractions scheduled on Day 1 RT, Day 3 RT and Day 5 RT, combined with Durvalumab infusion: first administration of Durvalumab* on Day 5 RT (i.e. the same day after the last fraction of radiation, corresponding to the Day 1 for Durvalumab treatment) and then administration of Durvalumab 1500 milligrams (mg) every four weeks.~* Dosing 750 mg or 1500 mg, according to the recommended combination schema determined in phase I."
2955237|NCT02866734|Active Comparator|Free screening group|Subjects in this group receive free diabetic retinopathy screening.
2955238|NCT02866734|Active Comparator|Pay screening group ($150)|Subjects in this group receiving diabetic retinopathy screening will be charged HK$150.
2955239|NCT02866734|Active Comparator|Pay screening group ($300)|Subjects in this group receiving diabetic retinopathy screening will be charged HK$300.
2955240|NCT02866721|Experimental|Human Allogeneic Mesenchymal Stem Cells|"One time IV Infusion of up to 5 x 10^6 allogeneic hMSCs/kg of body weight. A dose escalation using the 3+3 design will be employed. The three doses are 1 x 10^6, 3 x 10^6, and 5 x 10^6 hMSCs/kg. There is no placebo group. All study participants will receive stem cells."
2955241|NCT02866708|Experimental|Intermittent negative pressure (INP) therapy|"At baseline, the participants will be randomized into 2 groups: 1) INP therapy or 2) control with no INP therapy.~The 1) patients randomized to INP therapy will start with 8 weeks INP therapy two hours per day divided into timed sections (1-3 times per day or use the device as many times as practical for the individual as long as the total time is two hours). After 8 weeks of INP therapy, final measures will be performed at the Vascular lab before the participants starts their 8-week control period."
2955242|NCT02866708|No Intervention|Control|The participants randomized to control will continue their usual wound care for 8 weeks without INP therapy. The control group will start INP therapy after 8 weeks. After 8-weeks without intervention, the participants allocated to the control-group will be asked to start with INP therapy for 8 weeks before a final examination. The participants in the control group will receive vascular assesment at baseline, week 8 (end of control).
2955243|NCT02866695|Other|Open label treatment|All patients will be treated with ingenol mebutate gel 0.015%. There is no placebo or comparator for this study. The investigator will identify the patient's treatment area at Baseline, and provide a detailed application instruction sheet. The first dose will be applied in clinic under the supervision of the investigator.
2955244|NCT02866682|Other|Brand Tacrolimus Only : Prograf|Arm 1 will receive brand tacrolimus for the entire study
2955245|NCT02866682|Other|Brand Tacrolimus for 6 months then switch to Generic A|"Arm 2 will receive brand tacrolimus for the first 6 months and then receive specific generic tacrolimus for the remainder of the study.~Prograf followed by Tacrolimus."
2955246|NCT02866682|Other|Generic A Only|Arm 3 will receive specific generic tacrolimus for the entire study
2955247|NCT02866682|Other|Generic A (6 months) then switch to Generic Tacrolimus|"Arm 4 will receive specific generic for the first 6 months,then receive unspecified generic tacrolimus as per their pharmacy covered by their own health insurance~Multiple Tacrolimus."
2955248|NCT02866669|Active Comparator|Enhanced usual care|Practices in the usual enhanced care arm will receive a blood pressure medication algorithm developed using national guidelines and content experts on our study team. Practices will be provided the Joint National Committee (JNC) recommended protocol to measuring blood pressures. Practices will receive a laptop workstation that has access to the Patient Activated Learning System - an online education video system.
2955249|NCT02866669|Experimental|Practice facilitation|Practices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. Practice facilitation is a highly customized, staged approach to helping a practice to implement process and structural changes to enhance the quality of care and improve patient and staff satisfaction
2955250|NCT02866669|Experimental|Peer coach|Participants enrolled from practices that are randomized to the peer coach arm will be matched with peer advisors who will work with the participants for 12 months.
2955251|NCT02866669|Experimental|Peer coach and Practice facilitation|Practices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. The patients will also be matched with peer advisors who will work with the participants for 12 months.
2955252|NCT02866656|Experimental|control group|patients were given Conventional conservative treatment；
2955315|NCT02866253|Experimental|DHEA Group|DHEA 25mg t.i.d. for more than 12weeks
2955253|NCT02866656|Experimental|therapeutic ultrasound group|patients were given Conventional conservative treatment and low intensity ultrasonic treatment ；
2955254|NCT02866643|Experimental|Delivery Room Insertion|Participants who randomize to this arm will receive the contraceptive implant in the Labor and Delivery room (0-2 hours following delivery).
2955255|NCT02866643|Active Comparator|Postpartum Insertion|Participants who randomize to this arm will receive the contraceptive implant in the postpartum ward room before discharge (24-48 hours following delivery).
2955256|NCT02866630||Cardiopulmonary bypass (Sevoflurane)|All patients who scheduled for an elective heart surgery in University Malaya Medical Centre using a heart-lung machine and the administration of sevoflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being six additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
2955257|NCT02866630||Cardiopulmonary bypass (Desflurane)|All patients who scheduled for an elective heart surgery in University Malaya Medical Centre using a heart-lung machine and the administration of desflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being six additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
2955258|NCT02866617|Experimental|Conventional|T1-T2 : VFR constructed on conventional study model T2-T3 : VFR constructed on 3D reconstructed study model
2955259|NCT02866617|Experimental|3D|T1-T2 : VFR constructed on 3D reconstructed study model T2-T3 :VFR constructed on conventional study model
2955260|NCT02866604|Active Comparator|Strerofundin|Days of intervention: 3 days
2955261|NCT02866604|Active Comparator|0.9% saline|Days of intervention: 3 days
2955262|NCT02866591|Experimental|Arm A|Patients have a mammography performed by themselves according to auto-compression procedure. The radiologist leads the compression at a minimum threshold of 40 Newton, then leaves the control of the compression to the patient. The radiologist treats only the positioning of the breast on the sensor.
2955263|NCT02866591|Active Comparator|Arm B|Patients have a mammography performed by the radiologist according to standard procedure.
2955264|NCT02866578|Experimental|Open lung protective ventilation|"Recruitment maneuvers (30 cmH2O during 30 seconds) after intubation, after CPB initiation, before aortic declamping and at ICU arrival.~PEEP at 8 cmH2O.~Ultraprotective ventilation during CPB: PEEP 8 cmH2O, Tidal volume 3mL/kg, Respiratory rate 12 cycles per minute, FiO2 40%.~Assigned intervention - Procedure: patients are randomized and ventilated with the open lung strategy from intubation to detubation."
2955265|NCT02866578|No Intervention|Conventional strategy|No recruitment maneuvers. PEEP at 2 cmH2O. During CPB: continuous positive pressure at 2 cmH2O.
2955266|NCT02866565|Experimental|Diabetic foot ulcer|
2955267|NCT02866552|Placebo Comparator|PLACEBO|Patients will receive an injection of placebo
2955268|NCT02866552|Experimental|DRUG : Stromal Vascular Fraction|Patients will receive an injection of Stromal Vascular Fraction injection
2955269|NCT02866539|Active Comparator|Polyherbal capsule|Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.
2955270|NCT02866539|Placebo Comparator|Placebo|Placebo will contain an inert substance
2955271|NCT02866526||group1|adolescents (14-17 years old)
2955272|NCT02866526||group 2|young adults (20-29 years old)
2955273|NCT02866513|Other|Patient mechanically ventilated with APRV mode|
2955274|NCT02866500|Experimental|oral cancer|
2955275|NCT02866487||Asthmatics|"0-5 years of age: Intermittent cough, wheeze, chest symptoms AND one or more of the following: Eczema Eosinophilia Elevated total IgE Positive family history~6-17 years of age: Physician diagnosis Current treatment with one or more asthma medications Recurrent episodes of cough, wheeze, chest discomfort, pain"
2955276|NCT02866487||Age-Similar Non-asthmatic Controls|Age-similar controls will undergo diagnostic bronchoscopy for clinical indications in the absence of known asthma, including recurrent pneumonia, congenital lung anomalies, prolonged cough, suspected laryngeal abnormalities, and suspected aspiration syndromes. Inclusion in the final set to be determined post-procedure based on BAL granulocyte profiles. To be included as a control, participants must have pauci-granular BAL counts (less than 2 percent eosinophils and less than 4 percent PMN), no positive allergen sensitization, and no positive viral or bacterial studies from analysis of BAL fluid.
2955277|NCT02866474|Other|- Puteaux or Paris for elderly persons|
2955278|NCT02866474|Other|-Two EHPAD in Lyon for elderly persons living|
2955279|NCT02866461||Fibromyalgia|No treatment
2955280|NCT02866448|Placebo Comparator|Vehicle control|"Subjects will consume~4 x 250mg cellulose capsules containing 250mg cellulose, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid~1 x 75mg cellulose pill"
2955281|NCT02866448|Experimental|Isoquercetin|"Subjects will consume~4 x 250mg isoquercetin capsules containing 250mg isoquercetin, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid~1 x 75mg cellulose pill"
2955282|NCT02866448|Active Comparator|Aspirin|"Subjects will consume~1 x 75mg dispersible aspirin~4 x 250mg cellulose capsules containing 250mg cellulose, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid"
2955283|NCT02866448|Experimental|Isoquercetin plus Aspirin|"Subjects will consume~4 x 250mg isoquercetin capsules containing 250mg isoquercetin, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg folic acid~1 x 75mg dispersible aspirin"
2955284|NCT02866435|Experimental|Euglycemia pre-conditioning|Participants will undergo two euglycemia (normal blood sugar) clamps (8-10 am and 1-3 pm) on day 1, where the target glucose during the clamp will be 95 mg/dl. For each clamp, participants will be given intravenous insulin for two hours and blood glucose will be maintained at target by the infusion of 20% dextrose, the rate of which will be adjusted based on measured blood glucose values collected every 5 minutes. Potassium phosphate will also be infused during each clamp. On next day (day 2), participants will undergo MRI session during experimental hypoglycemia, i.e., while their blood sugar is clamped from normal value to low value.
2955309|NCT02866292||primigravid|Pregnant women on her first pregnancy and gestational age above 14 weeks. Pelvic floor muscle evaluation by means of vaginal palpation and vaginal squeeze pressure (perineometer), and evaluation of the sexual function by the Female Sexual Function Index (FSFI) questionnaire.
2955310|NCT02866279|Experimental|Postplacental|contraceptive implant placed within 30 minutes of placental delivery
2955285|NCT02866435|Experimental|Hypoglycemia pre-conditioning|Participants will undergo two hypoglycemia (low blood sugar) clamps (8-10 am and 1-3 pm) on day 1, where target glucose during the clamp will be 50 mg/dl. For each clamp, participants will be given intravenous insulin for two hours and blood glucose will be maintained at target by the infusion of 20% dextrose, the rate of which will be adjusted based on measured blood glucose values collected every 5 minutes. Potassium phosphate will also be infused during each clamp. On next day (day 2), participants will undergo MRI session during experimental hypoglycemia, i.e., while their blood sugar is clamped from normal value to low value.
2955286|NCT02866422||OCD|
2955287|NCT02866422||Healthy Controls|
2955288|NCT02866409|Experimental|Bupivacaine,dexmedetomidine scalp block|Bupivacaine (0.25%) and Dexmedetomedine (1 µg/kg). Maximum dose of bupivacaine kept < 2 mg /kg for scalp block
2955289|NCT02866409|Active Comparator|bupivacaine dexmedetomidine infiltration|The incision site was infiltrated with 15-20 ml bupivacaine (0.25%) and dexmedetomedine (1 µg/kg). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.
2955290|NCT02866409|Active Comparator|bupivacaine infiltration|The incision site was infiltrated with 15-20 ml of bupivacaine (0.25%). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.
2955291|NCT02866396||Pregabalin patients|Same dose of preoperative pregabalin 1h after surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration (PACU if NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
2955292|NCT02866396||Naive patients|Pregabalin 150mg PO initiated 1h before surgery and associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
2955293|NCT02866383|Experimental|Nivolumab & Radiotherapy|Patients will receive nivolumab 3 mg/kg over 60 minutes as an IV infusion on day 1 just after RT and then every 2 weeks (q2w), for a maximum of 52 weeks
2955294|NCT02866383|Experimental|Nivolumab & Ipilimumab & Radiotherapy|Patients will receive nivolumab 3 mg/kg over 60 minutes as an IV infusion on day 1 just after RT. Thirty minutes after the completion of nivolumab infusion patients will receive ipilimumab 1 mg/kg over 90 minutes IV as an IV infusion. Nivolumab will be given every 2 weeks (q2w) and ipilimumab every 6 weeks (q6w), respectively for a maximum of 52 weeks
2955295|NCT02866370|Experimental|Nintedanib|Nintedanib (BIBF1120) 200mg twice daily PO, continuously
2955296|NCT02866370|Active Comparator|Chemotherapy|"Ovarian Cancer Patients:~Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days Topotecan (4mg/m2) IV Day 1, 8, 15 every 28 days~Endometrial Cancer Patients:~Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days Doxorubicin IV (60mg/m2) every 21 days~Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
2955297|NCT02866344|Experimental|Microwave ablation|Patients will be given general anesthesia. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. Once the operating surgeon determines that the lesions as evaluated on intraoperative ultrasound remain amenable to MWA, ablations will be performed with a 2.45-gigahertz (GHz) generator with a 1.8-mm-diameter transcutaneous antenna (Acculis pMTA Accu2i; AngioDynamics Inc., Denmead, Hampshire, UK). Additional ablations will be performed sequentially. Laparoscopic core needle biopsy of lesions will be performed and submitted for permanent pathologic sectioning per current treatment standards. At the conclusion of the ablation, a collapsed titanium clip will be inserted into the microwave antenna tract as a radiographic fiducial marker. Hemostasis of the ablation track will be ensured using a combination of microwave energy, monopolar electrocautery, and/or topical hemostatics.
2955298|NCT02866344|Active Comparator|Hepatic resection|General anesthesia will be induced. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. The liver will be evaluated with intraoperative ultrasound (BK Medical A/S, Herlev, Denmark). Laparoscopic core needle biopsy of lesions will be performed. Partial hepatectomy may be carried out with parenchymal precoagulation with radiofrequency electrosurgical devices such as the LigaSure™ (Covidien, Medtronic; Minneapolis, MN), Harmonic® (Ethicon Endosurgery; Cincinnati, OH), or saline-coupled radiofrequency ablation device (Aquamantys™; Covidien/Medtronic; Minneapolis, MN); hepatic parenchymal transection can be performed as above or with the use of stapling devices to ligate and divide parenchyma. Hepatic vascular inflow occlusion will be performed at the surgeon's discretion. A topical hemostatic may be used along the transected hepatic parenchyma. Resected specimens will be preserved in formalin for pathology.
2955299|NCT02866331|Experimental|CB + G-CSF|
2955300|NCT02866331|Placebo Comparator|CB + placebo|
2955301|NCT02866331|Experimental|G-CSF|
2955302|NCT02866331|Placebo Comparator|Placebo|
2955303|NCT02866318||Novice practitioners|Residents in Emergency department who has no experiences of echocardiography prior to the study.
2955304|NCT02866305|Experimental|HRCT with bullae, treatment conservative|Patients undergo High-resolution CT scan, and significant bullae are identified (i.e. > 1 cm). Afterwards randomised to conservative treatment with conventional chest-tube drainage.
2955305|NCT02866305|Experimental|HRCT no bullae, treatment conservative|Patients undergo High-resolution CT scan, and no significant bullae are identified (i.e. > 1 cm). Afterwards randomised to conservative treatment with conventional chest-tube drainage.
2955306|NCT02866305|Experimental|HRCT with bullae, treatment VATS.|Patients undergo High-resolution CT scan, and significant bullae are identified (i.e. > 1 cm). Afterwards randomised to active treatment with VATS bullectomy and mechanical pleurodesis.
2955307|NCT02866305|Experimental|HRCT no bullae, treatment VATS.|Patients undergo High-resolution CT scan, and no significant bullae are identified (i.e. > 1 cm). Afterwards randomised to active treatment with VATS bullectomy and mechanical pleurodesis.
2955308|NCT02866292||non-pregnant nulliparous|Nulliparous without previous gestation. Pelvic floor muscle evaluation by means of vaginal palpation and vaginal squeeze pressure (perineometer), and evaluation of the sexual function by the Female Sexual Function Index (FSFI) questionnaire.
2955317|NCT02866240|Experimental|Single arm|Cathodal Transcranial Direct Current Stimulation (tDCS)
2955318|NCT02866227|Experimental|BV and/or VVC infection - Gel Treatment|Randomized 1:1 to gel nightly for 7 days. N = 40
2955319|NCT02866227|Experimental|BV and/or VVC infection - Vaginal Insert Treatment|Randomized 1:1 to insert nightly for 7 days. N = 40
2955320|NCT02866214|Experimental|Group I|This Group of Patients will receive Febuxostat Drug along with their Standard Treatment.
2955321|NCT02866214|Placebo Comparator|Group II|This Group of Patients will receive Placebo along with their standard Treatment.
2955322|NCT02866201|Experimental|Patient suffering from traveler's diarrhoea|Patient suffering form traveler's diarrhoea during a stay (up to 3 months) outside metropolitan France
2955323|NCT02866175|Experimental|edoxaban|Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects
2955324|NCT02866175|Active Comparator|vitamin k antagonist|Clopidogrel 75 mg once-daily (or in the presence of a documented clinical need prasugrel [5mg or 10 mg once-daily] or ticagrelor [90 mg twice-daily] may be used).
2955325|NCT02866162||patients with neutropenia|
2955326|NCT02866149|Experimental|"Cohort 1 - Anti checkpoint"|"Monitoring of patients with tumours treated by immune therapy.~Timing of blood sampling:~inclusion~after #8 weeks on therapy~at progression or 6 months from inclusion for patient without progressive disease~if toxicity grade 3 or 4, or grade 2 until 1 month."
2955327|NCT02866149|Experimental|"Cohort 2 - Oncoscan®"|"Monitoring of patients with HER 2+/- breast cancer and correlation with genome-wide copy number, loss of heterozygosity detection, as well as identification of frequently tested somatic mutations (Oncoscan® assays).~Timing of blood sampling:~inclusion~after 1 cycle of therapy (weeks 3-4)~up to 2 other samples, timepoints decided by the investigator"
2955328|NCT02866149|Experimental|"Cohort 3 - CirCe-PLA"|"Feasibility of Proximity-Ligation Assay (PLA) to study membrane proteins dimerisation by on isolated tumour cells in patients with HER2+/- breast cancer (HER 2+/-).~One tumor sampling.~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
2955329|NCT02866149|Experimental|"Cohort 4 - CDX PDX"|"Establishment of xenografts from tumor (PDX) and from Circulating Tumour Cell (CDX) by tumour and blood sampling.~One tumor sampling.~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
2955330|NCT02866149|Experimental|"Cohort 5 - Post-TP53"|"Follow-up of patients previously treated by neoadjuvant chemotherapy for triple negative breast cancer.~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
2955331|NCT02866149|Experimental|"Cohort 6 - Palbociclib"|"Monitoring of patients treated with palbociclib~Timing of blood sampling:~Inclusion day (2 samples)~after #2 weeks of therapy~after #4 weeks of therapy~at progression."
2955332|NCT02866149|Experimental|"Cohort 7 - CTC_PD-L1_Breast"|"Detection of PD-L1 in metastatic breast cancer patients~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
2955333|NCT02866149|Experimental|"Cohort 8 - CTC_PD-L1_Broncho-Pulmonary"|"Detection of PD-L1 in metastatic lung cancer patients~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
2955334|NCT02866149|Experimental|"Cohort 9 - NSCLC"|"Monitoring of patients with Non-Small Cell lung Cancer treated by immune therapy.~Blood sampling at 4 timepoints. Microbiota analyses."
2955335|NCT02866136|Other|(IV)Intravenous chemotherapy, laser diode|"Group 1 - Multicentric non randomised, phase II study for patients with retinoblastoma (unilateral group A,B according to age, group C according to the age and the vitreous seeding or bilateral groups A,B and C excluding the bilateral groups D or patients with bilateral macular threat).~Treatment by chemoreduction (VP16, carboplatin) followed by Carboplatin + laser day 1 (chemothermotherapy) without laser treatment at day 8 (decreasing laser sessions) combined to local treatments from third course (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan)."
2955336|NCT02866136|Other|(IA) Intraarterial Melphalan|"Group 2 - Multicentric non randomised, phase II study for the patients with bilateral very asymmetric disease (group D retinoblastoma on one of the eye, and the other amenable to a local treatment without chemotherapy) or unilateral presentation group D and groups B/C according to the age and vitreous seeding.~Treatment by Melphalan chemotherapy administered by superselective catheterization of the ophthalmic artery and combined to local treatments (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan)."
2955337|NCT02866136|Other|(IV-PM) Intravenous 3 drugs chemotherapy|Group 3 - Multicentric non randomised, phase II study for the patients with bilateral group D retinoblastoma or with a group D retinoblastoma on the only remaining eye. Treatment by 6 cycles of three drugs (VP16, carboplatin, vincristin) regimen combined to local treatments from the third cycle (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan).
2955338|NCT02866123|Experimental|patient with insertion of an NGT|
2955339|NCT02866110|Experimental|Treatment group|25 patients with BPD. In a diagnostic session, diagnostics of psychiatric disorders are conducted. For BPD diagnosis, the International Personality Disorder Examination (IPDE) is used and symptom severity is assessed with the Borderline Symptom List. The Treatment group will receive fMRI amygdala neurofeedback training (3 sessions within 2 weeks). Patients in regular psychotherapeutic treatment (treatment-as-usual) will not be excluded.
2955340|NCT02866097|Experimental|Intervention|mHealth inventory management and referrals via text messaging plus supportive supervision of CHWs via an mHealth strategy
2955341|NCT02866097|Placebo Comparator|Control|ICCM current standard of care with CHWs operating under standard conditions without enhanced inventory management or supportive supervision by mHealth
2955342|NCT02866084|Experimental|Device|Neuromodulation
2955343|NCT02866071|Active Comparator|Ketamine|50mg IN Ketamine Hydrochloride
2955344|NCT02866071|Placebo Comparator|Placebo|50mg IN placebo
2955345|NCT02866058||Cesarean|Mothers delivered by cesarean section
2955346|NCT02866058||Vaginal|Mothers delivered by vaginal delivery
2955347|NCT02866045|Active Comparator|EUS-guided Fine Needle Biopsy|EUS-FNB is performed using a 22 or 25 G SharkCore biopsy needle with a minimum of 3 passes into the lesion.
2955348|NCT02866045|Experimental|Single incision needle knife biopsy|SINK biopsy is performed under direct endoscopic visualization via EGD with a minimum of 3 biopsy samples obtained.
2955349|NCT02866032|Experimental|MOB015B|
2955350|NCT02866032|Active Comparator|Ciclopirox 80 mg/g|
2955351|NCT02866019|Experimental|CLS2702C/CLS2702D|
2955352|NCT02866006|Experimental|BVAC-C|BVAC-C IV injection at 0, 4, 8th weeks.
2955353|NCT02865993|Other|Betadine Group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
2955354|NCT02865993|Other|No Betadine Group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
2955355|NCT02865980|Experimental|inflammation|The effect of washing with betadine and clove extract on incidence of inflammation place logging shaldon catheter in the hemodialysis patients
2955356|NCT02865980|Experimental|infection|The effect of washing with betadine and clove extract on incidence of infection place logging shaldon catheter in the hemodialysis patients
2955357|NCT02865967|Experimental|Block1_Intervention|Usual care + a-GPS
2955358|NCT02865967|Other|Block1_Control|Usual Care
2955359|NCT02865967|Experimental|Block2_Intervention|Usual care + a-GPS
2955360|NCT02865967|Other|Block2_Control|Usual care
2955361|NCT02865967|Experimental|Block3_Intervention|Usual care + a-GPS
2955362|NCT02865967|Other|Block3_Control|Usual care
2955363|NCT02865954|Experimental|iball intervention|Use of iball pelvic floor training mhealth application for 16 weeks.
2955364|NCT02865954|No Intervention|Standard Care|Standard Care - control group
2955365|NCT02865941|Experimental|5 milk analysis|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed five times per week, of native breast milk batches which had been prepared for 24 hours feeding.~Routine fortifier will be added to breast milk batches.~Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
2955366|NCT02865941|Experimental|1 milk analysis|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed once per week of native breast milk batches which had been prepared for 24 hours feeding.~Routine fortifier will be added to breast milk batches.~Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
2955367|NCT02865928|Experimental|Bupivicaine HCl|Ultrasound guided serratus plane block with bupivacaine HCl.
2955368|NCT02865928|Placebo Comparator|Normal Saline|Placebo injection on operated side, same technique as experimental group.
2955369|NCT02865915|Placebo Comparator|Placebo|Plain, round, biconvex, white film-coated tablets that appear identical to MLE4901 tablets
2955370|NCT02865915|Experimental|MLE4901 40mg|Plain, round, biconvex, white film-coated tablets of 40 mg strength administered twice per day
2955371|NCT02865902|Experimental|Test Group|In Test group, the free gingival graft donor sites of each experimental group received low-level laser therapy by Ezlase; Biolase® at doses of 8.6 J/cm2.
2955372|NCT02865902|Sham Comparator|Control Group|In Control Group, the low-level laser therapy by Ezlase; Biolase® was performedin a same manner with test group at free gingival graft donor sites. However, no irradiation was occurred because of not pushing the start button.
2955373|NCT02865889||Uterine oncologic Indications for surgery|
2955374|NCT02865876|Experimental|Accelerated Corneal Cross-linking|Cross-linking in the management of microbial keratitis is an adjunctive therapy.This procedure is conducted under sterile conditions in the operating room. Tetracaine hydrochloride 0.5% (Ponti Ofteno, Sophia, Mexico) eye drops is apply for topical anesthesia. The corneal epithelium on the edge of the ulcer is cautiously removed using a microsponge. As photosensitizer, riboflavin 0.1% (Vibex, Avedro Inc, Waltham, USA) is used for 10 minutes. After impregnation, the participant´s cornea is irradiaded with UVA-light (370 nm) using 30 mW/cm2 for 3 minutes (which corresponds to a total dose of 5.4J/cm2) with accelerated cross-linking (Avedro Inc., Waltham, USA). After procedure, conventional treatment for keratitis remains unchanged.
2955375|NCT02865876|Sham Comparator|Sham Accelerated Corneal Cross-linking|"Placebo surgery. This procedure is conducted under sterile conditions in the operating room. Tetracaine hydrochloride 0.5% (Ponti Ofteno, Sophia, Mexico) eye drops is apply for topical anesthesia. Investigators do not perform removal of the corneal epithelium in edge of the ulcer. The researchers conducted the impregnation phase applying drops of saline solution for 10 minutes. After impregnation fase, a device is placed in Avedro equipment off (Avedro Inc, Waltham, USA) this device emits white light for 3 minutes. After procedure, conventional treatment for keratitis remains unchanged."
2955376|NCT02865863|Experimental|Eurycomalongifoliawater extract (Physta®) +Multivitamin|
2955377|NCT02865863|Placebo Comparator|Placebo|
2955378|NCT02865850|Experimental|Vadadustat|
2955379|NCT02865850|Active Comparator|darbepoetin alfa|
2955380|NCT02865837|Experimental|ARM 1|
2955381|NCT02865824|Active Comparator|Continue thienopyridine|Patients continue dual antiplatelet therapy (DAT) before colonoscopy and all polyps are removed by cold snare polypectomy.
2955382|NCT02865824|Experimental|Discontinue thienopyridine|Patients discontinue thienopyridines for 1 week before colonoscopy and all polyps are removed by cold snare polypectomy.
2955383|NCT02865811|Experimental|Pembrolizumab in Combination With PLD|"A safety lead in with 6 patients will be studied prior the start of the treatment.~If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced.~If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD)~Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV~Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosage"
2955384|NCT02865785|Active Comparator|Study Group|This group will include 160 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of intralipid 20% (100 mL of intralipid 20% diluted in 250 mL sterile i.v. saline administered i.v. over two hours), once between days 4 and 9 of the ovarian stimulation, and again within 7 days of a positive pregnancy test.
2955385|NCT02865785|Placebo Comparator|Placebo Group|This group will include 160 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of placebo, once between days 4 and 9 of the ovarian stimulation, and again within 7 days of a positive pregnancy test.
2955386|NCT02865772||observational|healthy newborns
2955409|NCT02865629|Experimental|N-acetyl cysteine|Following the screening and review of all laboratory studies, patients will be scheduled to receive N-acetylcysteine.
2955387|NCT02865759|Experimental|Mindfetalness|The pregnant woman will be informed about the possibility of practicing Mindfetalness verbally, in a brochure and at a website. The practice is described as spending 15 minutes every day from gestational week 28 to get to know the fetal movement pattern. The fetus must be awake when she practice Mindfetalness and the woman is suggested to lay on her left side when she observe the fetal movements. In the brochure as well at the website the woman can write down something about the nature, frequency or strength of the fetal movements. If the woman experiences decreased frequency of fetal movements or weaker movements she is instructed to seek health-care without unnecessary delay.
2955388|NCT02865759|No Intervention|Routine Care|No activities will take place in the antenatal clinics randomized to routine care.
2955389|NCT02865746|Active Comparator|Group betamethasone|Active Comparator: betamethasone disodium phosphate at a concentration of 4 mg / ml - dosage of 0.05 mg / kg
2955390|NCT02865746|Placebo Comparator|Group placebo|sterile saline solution (sodium chloride 0.9% - 1 ml ampoules) - dosage of 0.05 mg / kg
2955391|NCT02865733|Experimental|Remodulin Injection|Drug: Remodulin Injection Dosage:5 ng/kg/min-80ng/kg/min(0.15ml/hr-2.4ml/hr) Frequency: intravenous maintenance increase at a rate of 10ng/kg/min (0.3ml/hr)every 30 minutes Durations:48 hours
2955392|NCT02865733|Placebo Comparator|Distilled water group|Drug:distilled water Dosage:0.15ml/hr-2.4ml/hr Frequency:increase at a rate of 0.3ml/hr every 30 minutes Durations:48 hours
2955393|NCT02865720|Experimental|Subjects 2 to 5 years of age|500 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks
2955394|NCT02865720|Experimental|Subjects 6 years of age and older|1000 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks.
2955395|NCT02865707|Experimental|Prebiotic|Prebiotic group will take 15 grams of prebiotic product Synergy-1 per day for 6 months. Synergy-1 is chicory-derived β-fructans inulin plus FOS (1:1). During the first two weeks the patient is advised to take 7.5 g of the product at breakfast only. Starting in week 3 until the end of the treatment the participant will take 7.5 g at breakfast and 7.5 g at dinner for a total of 6 months, or until you experience a flare.
2955396|NCT02865707|Placebo Comparator|Placebo|Placebo group will take 15 grams of maltodextrin per day for 6 months. Maltodextrin is a sugar adsorbed in the small bowel with no effect on the colonic intestinal microbiota. During the first two weeks the patient is advised to take 7.5 g of the product at breakfast only. Starting in week 3 until the end of the treatment the participant will take 7.5 g at breakfast and 7.5 g at dinner for a total of 6 months, or until you experience a flare.
2955397|NCT02865681|Active Comparator|Conventional IVF|Conventional ovarian stimulation consist of ovarian stimulation with daily gonadotropins injections daily starting in the early follicular phase (cycle day 3). The final maturation of oocytes will be induced with the standard hCG trigger when at least two follicles reached 18 mm or greater. Oocyte retrieval will be performed by either local or general anesthesia depending on the ovarian response, i.e., the number of mature follicles. Retrieved oocytes will be fertilized by IVF/ICSI and subsequently cultured until the blastocyst stage. All blastocysts will be vitrified. A single thawed blastocyst will be transferred in a subsequent natural or artificially prepared cycle.
2955398|NCT02865681|Experimental|IVF protocol using nasal gonadotropins|Instead of injectable gonadotropins, nasal human menopausal gonadotropins (hMG; menopur) and oral clomiphene citrate and/or oral letrozole starting in the early follicular phase (cycle day 3). When at least two follicles reached 18 mm or greater, Synarel (Nafarelin) will be used instead of the injectable HCG trigger. Oocyte retrieval will be performed by either local or general anesthesia depending on the ovarian response, i.e., the number of mature follicles. Retrieved oocytes will be fertilized by IVF/ICSI and subsequently cultured until the blastocyst stage. All blastocysts will be vitrified. A single thawed blastocyst will be transferred in a subsequent natural or artificially prepared cycle.
2955399|NCT02865668|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 50 milligram (mg) along with one Extended Release (XR) tablet of metformin of 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 XR fixed dose combination [FDC] tablet containing canagliflozin 50 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 50 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg along with one metformin (XR) tablets of 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2955400|NCT02865668|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2955401|NCT02865668|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2955402|NCT02865668|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2955403|NCT02865655||CSD-TVU|Cesarean Section Scar Evaluation by TVU
2955404|NCT02865655||CSD-MRI|Cesarean Section Scar Evaluation by MRI
2955405|NCT02865655||CSD-MRI with saline|Cesarean Section Scar Evaluation by MRI with saline
2955406|NCT02865655||CSD-Hysteroscopic|Cesarean Section Scar Evaluation by Saline Contrast Sonohysterography During Hysteroscopy
2955407|NCT02865642|Experimental|Serotonin Uptake Inhibitors|"Treatment 1: Starting with Escitalopram 5mg/day at the baseline-visit (day 14 (+-7) post stroke) for 7 days followed by a weekly dosage increase of 5mg/day till target dose of Escitalopram 20mg/day.~Subjects will remain on Escitalopram 20mg/day until visit 3 (day 90 (+-14) post stroke) followed by dosage reduction of Escitalopram 10mg/day for one week."
2955408|NCT02865642|Placebo Comparator|Placebo|"Treatment 2: Starting with Placebo 5mg/day at the baseline-visit (day 14 (+-7) post stroke) for 7 days followed by a weekly dosage of 5mg/day till target dose of Placebo 20mg/day.~Subjects will remain on Placebo 20mg/day until visit 3 (day 90 (+-14) post stroke) followed by Placebo 10mg/day for one week."
2955496|NCT02865070||2 infants (ages 1-6mo) non-NICU setting|
2955410|NCT02865616|Experimental|MET-2 Capsules|"Patients will be on vancomycin to control symptoms up until the time of the treatment.~Initial Loading Dose: Patients will be given an initial daily loading dose of 5 g MET-2 over 2 days followed by a maintenance dose of 1.5 g over 8 days. Patients who do not experience treatment failure between Day 14 and Day 40 will be monitored until Day 130.~Second Loading Dose: Patients experiencing treatment failure after the first dose may be offered a second, higher loading dose 10 g of MET-2 in the form of 20 MET-2 capsules per day for two days, there will not be additional daily dosing beyond the first 10 days.~Colonoscopy: Patients failing the second loading dose of MET-2 may be offered 15 g of MET-2, equivalent to a 30 MET-2 capsule loading dose by weight, via colonoscopy..~All patients will be followed up for 120 days after the last treatment has been received."
2955411|NCT02865603|Experimental|PAX Good Behavior Game|The intervention is delivered by teachers within the normal school curriculum. Teachers from intervention classes completed 3-day training and were supported by the mentor, who visited their class during the 2016/17 school year and provided counseling via e-mail and phone. During the second year (2017/18) teachers could use the PAX GBG methods, but they did not receive additional support from the mentors.
2955412|NCT02865603|No Intervention|Waitlist control group|Control group continue their normal activities without intervention. After a post-test assessment in spring 2018 the control group teachers will be trained and supported to implement PAX GBG.
2955413|NCT02865590|Experimental|Lyophilized Equine Bone Allograft|Sinus Lift with Lyophilized Equine Bone Allograft
2955414|NCT02865590|Active Comparator|deproteinized bovine bone allograft|Sinus lift with deproteinized bovine bone allograft
2955415|NCT02865577||Adult asthma|"Adult asthma subjects with airflow limitation (FEV1% predicted < 80%) will be recruited for this study.~Participants will undergo following study assessments:~Clinical History~Health status and disease control questionnaires~Focused physical examination~Electrocardiogram (ECG)~Blood test~Spirometry~Echocardiogram~Cardiac magnetic resonance (CMR) imaging~CMR survey"
2955416|NCT02865577||Adult COPD|"Adult COPD subjects with airflow limitation (FEV1% predicted < 80%) will be recruited for this study.~Participants will undergo following study assessments:~Clinical History~Health status and disease control questionnaires~Focused physical examination~Electrocardiogram (ECG)~Blood test~Spirometry~Echocardiogram~Cardiac magnetic resonance (CMR) imaging~CMR survey"
2955417|NCT02865577||Healthy participants|"Healthy participants with no past history of cardiovascular or respiratory disease.~Participants will undergo following study assessments:~Clinical History~Focused physical examination~Electrocardiogram (ECG)~Blood test~Spirometry~Echocardiogram~Cardiac magnetic resonance (CMR) imaging~CMR survey"
2955418|NCT02865564|Active Comparator|Intervention group|The intervention group will receive 5 drops, a minimum of 100 million live Lactobacillus reuteri DSM 17938 a day during antibiotic treatment (empirical treatment for neonatal sepsis with ampicillin and gentamicin) and 6 consecutive weeks after finishing the antibiotic treatment.
2955419|NCT02865564|Placebo Comparator|Placebo group|Placebo group will receive 5 drops of maltodextrin in the some oil suspension a day during antibiotic treatment (empirical treatment for neonatal sepsis with ampicillin and gentamicin) and 6 consecutive weeks after finishing the antibiotic treatment.
2955420|NCT02865551|Experimental|Extended catheterization|Participants in which a foley catheter will be inserted adjacent to epidural anesthesia during labor.
2955421|NCT02865551|Experimental|Intermittent catheterization|Participants in which a short term catheter will be inserted every 4 hours during labor after epidural anesthesia until delivery.
2955422|NCT02865538|Experimental|NT-814|NT-814 to be administered as oral capsules, daily, for 14 days, up to 4 doses, 50mg, 100mg, 150mg, 200mg, ascending by cohort.
2955423|NCT02865538|Placebo Comparator|NT-814 Placebo|Placebo to match NT-814 capsules administered orally, daily. Number of placebo capsules to match active dose.
2955424|NCT02865512|Active Comparator|supine position|thoracic epidural catheterization with supine position
2955425|NCT02865512|Active Comparator|flexed lateral position|thoracic epidural catheterization with flexed lateral position
2955426|NCT02865499|Experimental|acarbose|all participants will receive acarbose
2955427|NCT02865486|Experimental|Lipid emulsion: visit 2|One of four randomly assigned lipid emulsions
2955428|NCT02865486|Experimental|Lipid emulsion: visit 3|One of four randomly assigned lipid emulsions
2955429|NCT02865486|Experimental|Lipid emulsion: visit 4|One of four randomly assigned lipid emulsions
2955430|NCT02865473|No Intervention|primary open angle glaucoma patients|
2955431|NCT02865473|No Intervention|patients with primary angle closure|
2955432|NCT02865473|No Intervention|patients with neovascular glaucoma|
2955433|NCT02865473|No Intervention|PEX glaucoma patients|
2955434|NCT02865473|No Intervention|glaucoma patients with filtering bleb|
2955435|NCT02865473|Experimental|healthy volunteers|instillation of antiglaucoma treatment in the study eye
2955436|NCT02865460|Experimental|Ubiquinol|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
2955437|NCT02865460|Placebo Comparator|Placebo|Take oral tablets as directed (2x200 mg for 2 months; 1x 200 mg for 4 months) with food each morning-upon waking
2955438|NCT02865447||PRESERVE total hip arthroplasty implant|Subjects to be prospectively implanted with the PROFEMUR PRESERVE total hip arthroplasty implant
2955439|NCT02865434|Experimental|Group 1 (RA)|Group 1 will receive 50 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m as a single IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
2955440|NCT02865434|Experimental|Group 2 (RA)|Group 2 will receive 200 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
2955441|NCT02865434|Experimental|Group 3 (RA)|Group 3 will receive 400 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
2955442|NCT02865434|Experimental|Group 4 (RA)|Group 4 will receive 50 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
2955497|NCT02865070||10 babies (full term, ages 37-42 weeks)|
2955498|NCT02865070||5 babies (premature, ages 34-37 weeks)|
2955499|NCT02865070||5 babies (premature, ages 31-34 weeks)|
2955443|NCT02865434|Experimental|Group 5 (RA)|Group 5 will receive 200 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
2955444|NCT02865434|Experimental|Group 6 (RA)|Group 6 will receive 400 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
2955445|NCT02865434|Experimental|Group 7 (RA)|Group 7 will receive 50 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
2955446|NCT02865434|Experimental|Group 8 (RA)|Group 8 will receive 200 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
2955447|NCT02865434|Experimental|Group 9 (RA)|Group 9 will receive 400 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
2955448|NCT02865434|Experimental|Group 10 (Healthy Controls)|Group 10 will receive Tc99m-tilmanocept at the MTD via IV injection, Whole body planar SPECT imaging (15 Minutes post-injection) , Whole body planar SPECT imaging (60 minutes post-injection) , Whole body planar SPECT imaging (180 minutes post-injection), and Whole body planar SPECT imaging (18-20 hours post-injection), Planar Image with both Hands in Field of View (60 minutes and 180 minutes post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after Injection) , Blood Collection for PK Testing (15 minutes post injection) , Blood Collection for PK Testing (60 minutes post injection) , Blood Collection for PK Testing (180 minutes post injection) , and Blood Collection for PK Testing (18-20 hours post injection).
2955449|NCT02865434|Experimental|Group 11 (RA)|Group 11 will receive Tc99m-tilmanocept at the MTD via IV injection, Whole body planar SPECT imaging (15 Minutes post-injection) , Whole body planar SPECT imaging (60 minutes post-injection) , Whole body planar SPECT imaging (180 minutes post-injection), and Whole body planar SPECT imaging (18-20 hours post-injection), Planar Image with both Hands in Field of View (60 minutes and 180 minutes post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after Injection) , Blood Collection for PK Testing (15 minutes post injection) , Blood Collection for PK Testing (60 minutes post injection) , Blood Collection for PK Testing (180 minutes post injection) , and Blood Collection for PK Testing (18-20 hours post injection).
2955450|NCT02865421|Experimental|Stem cells|adipose tissue derived stromal vascular fraction was used
2955451|NCT02865421|Experimental|platelet rich plasma|platelet rich plasma isolated after centrifugation from the pt was transplanted
2955452|NCT02865408|Active Comparator|Group 1: Peptamen 1.5% via enteral only|Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard EN Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d
2955453|NCT02865408|Active Comparator|Group 2: Prosol 20% IV to 1.75g/kg/day|Patients in group 2 will receive the same enteral feeding as group 1 (Peptamen 1.5) but in addition will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/d
2955454|NCT02865408|Active Comparator|Group 3: Prosol 20% IV to 2.5g/kg/day|Patients in this group will receive intravenous amino acids (Prosol 20%) in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/day.
2955455|NCT02865395|Experimental|Pre-operative Suppository|A B&O Suppository will be placed in the patient's rectum after the induction of anesthesia, but before the surgery.
2955456|NCT02865395|Active Comparator|Post-operative Suppository|A B&O Suppository will be placed in the patient's rectum while still under anesthesia, but after the surgery.
2955457|NCT02865395|Placebo Comparator|Rectal Exam|Patient's will be given a rectal exam after the procedure but while still under anesthesia to serve as a placebo.
2955458|NCT02865382|Active Comparator|Group A|white light was used for both insertion and withdrawal of the colonoscope
2955459|NCT02865382|Experimental|Group B|Insertion to cecum was performed under white light and once the cecum was reached,the OE mode was swithed on during withdrawal of endoscope for complete colonic examination
2955460|NCT02865369||Daclatasvir plus Asunaprevir treatment|Among patients taking Daclatasvir and Asunaprevir combined treatment and having advanced liver fibrosis assessed by transient elastography
2955461|NCT02865356|Experimental|Cyclosporine 5% Solution|"SP14019-F-01 Cyclosporine solution, 5%. Cyclosporine solution will be applied twice daily for four complete weeks (28 days) in all affected areas.~A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication"
2955462|NCT02865356|Placebo Comparator|Placebo|"SP14019-F-02 vehicle-control placebo solution. Vehicle-control placebo solution will be applied twice daily for four complete weeks (28 days) in all affected areas.~A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication"
2955463|NCT02865343|Active Comparator|Non-invasive Ventilation(NIV)|Subjects randomized to NIV will perform 12-weeks of FES-row training while receiving bi-level positive airway pressure ventilation applied through a full face-mask.
2955464|NCT02865343|Placebo Comparator|Sham Non-invasive ventilation(NIV)|Subjects randomized to Sham-NIV will perform 12-weeks of FES-row training while receiving sham ventilation applied through a full face-mask.
2955465|NCT02865317||Study group|Patients with obstetrical brachial plexus injury involving upper trunk (C5-6)
2955466|NCT02865304|Experimental|endostar; taxane|Endostar was administered at 7.5 mg/m2, d1-14, q21d and was continued until progressive disease, unacceptable toxicity, consent withdrawal, or completion of 24 months. In the same time,Taxane-based chemotherapy was continued until progressive disease, unacceptable toxicity, consent withdrawal, or up to 8 cycles.
2955467|NCT02865291|Experimental|ForConti device|Use the device up to 12 hours/day for 4 weeks
2955468|NCT02865278|Experimental|Polyphenol-rich drink|The participants consume the polyphenol-rich drink. After 3 hours they consume a standard meal to evaluate whether the metabolic response may be influenced by polyphenols.
2955469|NCT02865278|Placebo Comparator|Placebo drink|The participants consume the control drink.After 3 hours they consume a standard meal to evaluate the metabolic response after a placebo.
2955470|NCT02865265||Pecs II and parasternal blocks|"Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.~An ultrasound-guided ipsilateral PaB was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib."
2955471|NCT02865252|Active Comparator|MWM treatment|"Mobilization with movement (MWM) is a combination of sustained passive accessory joint mobilization with an active or functional movement.~MWM will be applied (three sets of 10 repetitions) during active knee flexion and extension range of motion (ROM). The therapist initially will apply the pain-free manual glide force on the tibia with the knee resting in a mid-range position. The glide force will be sustained while the patient performed 10 repetitions of self-active full range knee flexion and extension; overpressure was included at the end range."
2955472|NCT02865252|Sham Comparator|MWM sham|The patients will be handled similarly to MWM treatment group, except that they will not receive directional glide; instead, the physiotherapist's hands are just touch the knee skin without pressure; one hand on the tibia while the other hand on the femur. However, available active knee flexion and extension ROM will be performed (three sets of 10 repetitions).
2955473|NCT02865239|Placebo Comparator|Supine position|3.0 tesla MRI in supine position
2955474|NCT02865239|Active Comparator|Prone position|3.0 tesla MRI in prone position
2955475|NCT02865226|Experimental|experimental group|paravertebral block by the anesthetist before incision (paravertebral block guided by ultrasound)
2955476|NCT02865226|Active Comparator|control group|paravertebral block by the thoracic surgeon at chest closure (paravertebral block visual)
2955477|NCT02865213|Experimental|Miniplates + OBA|"The intrusion of posterior teeth using Miniplates + OBA will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth and miniplates.~The miniplates are for Jeil Dual top® anchor system, Jeil medical corporation, #702,kolon science valley 2nd, 811, Guro-Dong, Guro-Gu, Seoul, 152-050, Korea. Tel: 82.2.850.3500. Fax: 82.2.850.3537. homepage: www.jeilmed.co.kr/ E-mail: mktg@jeilmed.co.kr"
2955478|NCT02865213|Experimental|Miniscrews + OBA|"The intrusion of posterior teeth using Miniscrews + OBA will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth and miniscrews.~The miniscrews are for Denxy ® dental orthodontic products, Denxy technology co, limited . 404,Lihuabuilding,Furongroad, Changsha, Hunan, China. Tel: 0086-731-89717339. Fax: 0086-731-82237315. Homepage: www.denxy-orthodontic.com/email: DENXYDENTALBOSS@126.COM"
2955479|NCT02865213|Experimental|Only OBA|The intrusion of posterior teeth using OBA only will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth only.
2955480|NCT02865200|Experimental|Dry Needling Application|Dry needling was performed on active and/or latent TPs at Gluteus Medius, Quadratus Lumborum, Multifidus, Erector Spinae muscles of the subjects in the study groups without applying any local anesthetic substance. The needles were applied with a 90º angle for Multifidus, Quadratus Lumborum and Gluteus Medius muscles; while they were applied with a 45º angle for Erector Spinae muscles. Thin stainless steel needles of 0.25x0.40 mm and 0.30x0.60 mm were applied in infiltration form on the TP through many points in conformity with the injection technique. The needles were kept on the body for 20 minutes and at the 10th minute, the needle was rolled and re-stimulation was enabled. The treatment was applied twice a week, which is equal to 6 sessions in total.
2955481|NCT02865200|Experimental|Classic Physiotherapy Program|"Hot-pack was applied for 20 minutes. Burst TENS was applied on the lumbar regions of the cases of the control group paravertebrally with 4-electrode reusable silicone rubber. The dimensions of electrode is 5x5cm. Pulse width was set for 100 µsn, pulse frequency was set for 2 Hz, cycle time is set for 0.5 seconds and the amplitude was increased until visible muscle contraction was reached. If the muscle contraction is lost during the session, the amplitude was increased again. The period of treatment was 6 sessions in total with 25 minutes of each.~Ultrasound was paravertebrally applied to the lower back regions of the subjects. The treatment was applied with 1 MHz frequency, 1.5 W/cm2 power, for 6 minutes a day, for 10 sessions in total with direct contact with the patient's skin."
2955482|NCT02865187|Experimental|Vitamin D + hormonal contraception|600IU/day Vitamin D + hormonal contraception
2955483|NCT02865187|Active Comparator|Vit D + non-hormonal contraception|600IU/day Vitamin D
2955484|NCT02865174|Active Comparator|Topical tranexamic acid|Intraarticular application of tranexamic acid Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay
2955485|NCT02865174|Active Comparator|Floseal®|"Floseal® was applied on potential bleeding sites before prosthesis implantation.~Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay"
2955486|NCT02865174|Placebo Comparator|Control group|No intervention before closure of joint capsule. Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay
2955487|NCT02865161||NISELAT|Amtolmetin guacil should be taken in fasting conditions. The recommended dose is 600 mg b.i.d. Maximum daily dose - 1800 mg
2955488|NCT02865148|Experimental|Cognitive behavioral therapy (CBT) group|Participants will receive 4 sessions that lasts approximately 50 mins. The sessions will teach patients to manage their symptoms.
2955489|NCT02865148|No Intervention|Waitlist control (WLC) group|The WLC group receives standard usual care before being offered the same CBT protocol and assessment thereafter.
2955490|NCT02865135|Experimental|DPX-E7 Vaccine With Cyclophosphamide|"Subjects will 2 priming doses of DPX-E7 at a pre-determine dosage 3 weeks apart followed by a predetermine booster dose every 8 weeks until clinical progression.~Low dose metronomic oral Cyclophosphamide will start 7 days before vaccination, continue for 7 days on and then 7 days off, throughout the treatment period, until progression."
2955491|NCT02865122|Experimental|NTRA-9620-A|NTRA-9620 Dose 1 To be dosed orally for 24 weeks, 4 times/day
2955492|NCT02865122|Experimental|NTRA-9620-B|NTRA-9620 Dose 2 To be dosed orally for 24 weeks, 4 times/day
2955493|NCT02865122|Placebo Comparator|Placebo|Placebo To be dosed orally for 24 weeks, 4 times/day
2955494|NCT02865083|Active Comparator|Treatment|Subjects will receive use of the Traxi pannus retractor when undergoing cesarean section
2955495|NCT02865083|No Intervention|Standard|Patients will receive use of the standard of care option which is the montgomery straps
2955507|NCT02865044|Active Comparator|Wax Ester Marine Oil|Active: Wax ester marine oil (Calanus oil; 4 g providing 260 mg EPA and 156 mg DHA; 8 capsules)
2955508|NCT02865044|Other|Ethyl Ester Marine Oil|Control: Ethyl ester (EE) marine oil (Lovaza OM3 EE; 1 g providing 465 mg EPA and 375 mg DHA; 1 capsule)
2955509|NCT02865031|Experimental|Decorin|Intravitreal injection of 200-400 ug of Decorin.
2955510|NCT02865018|Experimental|cetirizine|10mg oral each day
2955511|NCT02865005|Active Comparator|Dapsone 5.0% Gel (Allergan)|Dapsone 5.0% Gel applied twice daily for 84 days
2955512|NCT02865005|Experimental|Dapsone 5.0% Gel (SEEGPharm)|Dapsone 5.0% Gel applied twice daily for 84 days
2955513|NCT02865005|Placebo Comparator|Placebo|Vehicle of Experimental Gel applied twice daily for 84 days
2955514|NCT02864992|Experimental|Tepotinib|
2955515|NCT02864966|Other|Other|This is a safety study where a marketed product will be placed on healthy adult skin.
2955516|NCT02864953|Experimental|BIIB093|BIIB093 administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.
2955517|NCT02864953|Placebo Comparator|Placebo|Placebo administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.
2955518|NCT02864940|Experimental|Intervention Arm|Using the cognitive exercises on Lumosity for 10 weeks
2955519|NCT02864940|Active Comparator|Control Arm|Using online crossword puzzles for 10 weeks.
2955520|NCT02864927|Experimental|Menactra Group 1|Participants aged 9 to 23 months will receive 2 doses of Menactra
2955521|NCT02864927|Experimental|Menactra Group 2|Participants aged 2 to 55 years will receive 1 dose of Menactra
2955522|NCT02864914||Empagliflozin|Patients initiating Empagliflozin treatment within the study period
2955523|NCT02864914||DPP-4 inhibitors|Patients initiating DPP-4 inhibitor treatment within the study period
2955524|NCT02864901|Experimental|KSL-W 30 mg|3 times per day over 4 treatment days
2955525|NCT02864901|Placebo Comparator|Chewing Gum Placebo|3 times per day over 4 treatment days
2955526|NCT02864888|Experimental|Radiation|Study subjects receive a single daily radiation fraction of 180cGy, 5 days a week, for the 2 weeks of the QT/QTc study and for 6 weeks overall to a total radiation dose of 1600 cGy and 5400cGy, respectively.
2955527|NCT02864888|Experimental|Antineoplaston therapy + Radiation|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 24 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.Study subjects also receive a single daily radiation fraction of 180cGy, 5 days a week, for the 2 weeks of the QT/QTc study and for 6 weeks overall to a total radiation dose of 1600 cGy and 5400cGy, respectively.
2955528|NCT02864875|No Intervention|Control|Not to receive an early replacement of fibrinogen
2955529|NCT02864875|Experimental|Intervention|Receive early replacement through fibrinogen concentrate (50mg per kg of body weight)
2955530|NCT02864862|Active Comparator|Immediate implant|Immediate implant alone
2955531|NCT02864862|Active Comparator|Immediate implant combined with SCTG|Subepithelial connective tissue graft (SCTG)
2955532|NCT02864862|Active Comparator|Immediate implant combined with ADM|Acellular dermal matrix (ADM)
2955533|NCT02864849|Experimental|TNT|"Patients with MRI defined high-risk rectal cancer will receive chemotherapy before and after chemoradiation, and will not receive adjuvant treatment. This arm is called total neoadjuvant treatment (TNT). The neoadjuvant chemotherapy regimen is designed as 3 cycles of CapeOX (Capecitabine+Oxaliplatin) over a period of approximately 8 weeks. Tumor response will be evaluated after chemotherapy. Then patients will undergo 22f-IMRT (Intensity modulated radiotherapy) with capecitabine. Patients will receive two more cycles of consolidation CapeOX if tolerable when there was no progressed disease in induction CapeOX.~Finally, patients will receive TME (Total mesorectal excision) following TNT if no metastasis occurs."
2955534|NCT02864836||Patients with head or neck cancer|Samples collection
2955535|NCT02864836||Patients with lymphoma|Samples collection
2955536|NCT02864836||Patients without tumoral pathology|Samples collection
2955537|NCT02864823|Experimental|Perichondrium|Perichondrium Autografts
2955538|NCT02864810|Experimental|[18F]GP1 PET/CT imaging|"Maximally 10 patients with deep vein thrombosis, pulmonary embolism, or arterial thromboembolism, respectively will be enrolled in the study (plus replacements for drop-outs).~Intravenous injection and PET/CT scanning of [18F]GP1"
2955539|NCT02864797|Experimental|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software.
2955540|NCT02864784|Experimental|Amorphous calcium carbonate|Subjects in this arm of the study will receive AMOR-1 tablets, containing 200 mg elemental calcium in addition to the standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab)
2955541|NCT02864784|Placebo Comparator|Placebo|Subjects in this arm of the study will receive Placebo tablets in addition to standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab)
2955542|NCT02864771||1|Derivation cohort (n=474); may be analyzed separately or combined with cohort #2 to enhance statistical power
2955543|NCT02864771||2|Validation cohort (patient #475 and after); may be combined with cohort #1 to enhance statistical power
2955544|NCT02864758||Group 1|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with rivaroxaban
2955545|NCT02864758||Group 2|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with vitamin k anatognists
2955546|NCT02864758||Group 3|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with dabigatran
2955547|NCT02864745|Experimental|Early rehabilitation arm|These patients will receive very early (<48 hours after ICU admission), protocolised, intensive rehabilitation, which will include functional electrical stimulation-assisted cycle ergometry.
2955548|NCT02864745|Active Comparator|Standard-of-care|These patients will receive standard rehabilitation delivered by non-study physiotherapist.
2955549|NCT02864732|Experimental|Stabilization exercises|The stabilization exercises program will consist of exercises for the lower back and abdomen. These exercises include various types of abdominal bracing and bridging and side bridging. The exercises will be performed in supine, sidelying, and quadruped. It involves activation of muscles, dissociation of lumbar spine movement from extremities movement and endurance.
2955550|NCT02864732|Experimental|Stabilization exercises plus electrical stimulation|The neuromuscular electrical stimulation is a hand-size unit that has four plastic adhesive electrical conductors known as electrodes. These electrodes are going to be placed on the skin covering the lower back muscles. They will deliver an electric current that will generate muscle contraction that resembles normal muscle contraction. This treatment will be given in addition to the stabilization exercise program.
2955551|NCT02864719|Experimental|Energy Conservation+Problem Solving Therapy|The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
2955552|NCT02864706|Other|EVEROLIMUS|All patients who were included in the initial core study Schedule
2955553|NCT02864693|Active Comparator|Configuration A (Kinnex)|
2955554|NCT02864693|Active Comparator|Configuration B (Pacifica LP)|
2955555|NCT02864680|Other|Cannabis users|
2955556|NCT02864680|Other|Healthy volunteers, not cannabis/tobacco users|
2955557|NCT02864680|Other|Healthy volunteers, tobacco users|
2955558|NCT02864680|Other|Schizophrenia patients|
2955559|NCT02864654|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate Adipose-derived regenerative cells (ADRC). After isolation 10 mL of autologous ADRC suspension will be injected intramuscularly, close to the site of muscle injury. 10 to 20 injections will be performed so as to infiltrate the injured muscle
2955560|NCT02864641|Experimental|TX Group: Planet K Treatment|Participants in the TX Group will receive access to Planet K. Families participating in the TX condition will be asked to attend a one-hour orientation session, during which study expectations and tasks will be explained. Families will be asked to watch a short 2-minute study overview video that summarizes study requirements and expectations. Parents and their children will then have the opportunity to provide informed consent/assent prior to their participation in the study. Adolescent and young adult participants will then receive a mobile phone preloaded with the Planet K app and a brief orientation to the app and associated website.
2955561|NCT02864641|No Intervention|CO Group: Treatment-as-usual|A national sample of CKD participants will be recruited. Because of the inability to meet with remotely located participants for orientation and distribution of phones, these participants will be assigned to the treatment-as-usual, online control (CO) condition. For recruitment of the online control group, youth and parents interested in participating will be asked to complete a brief eligibility survey. Participants in the treatment-as-usual CO condition will not receive access to the Planet K app and website but will receive email reminders to complete surveys online at each time point.
2955562|NCT02864628|Experimental|Group 1|≥55 year old healthy subjects, receiving either 5x10E7 TCID50 MVA-BN-RSV or Placebo intranasal application
2955563|NCT02864628|Experimental|Group 2|≥55 year old healthy subjects, receiving either 1x10E8 TCID50 MVA-BN-RSV or Placebo intranasal application
2955564|NCT02864628|Experimental|Group 3|≥55 year old healthy subjects, receiving either 5x10E8 TCID50 MVA-BN-RSV or Placebo intranasal application
2955565|NCT02864628|Experimental|Group 4|≥55 year old healthy subjects, receiving 5x10E8 TCID50 MVA-BN-RSV intranasal and intramuscular application
2955566|NCT02864628|Experimental|Group 5|≥55 year old healthy subjects, receiving 5x10E8 TCID50 MVA-BN-RSV intramuscular application
2955567|NCT02864615|Experimental|Stereotactic Body Radiation Therapy|Patients with stable disease on targeted or IO therapy will receive SBRT on first metastasis of clear cell renal cell carcinoma. Second metastasis will be as a control. In case of safety and 50% reduction in size of first metastasis, up to 10 metastasis will be treated with SBRT.
2955568|NCT02864602|Experimental|Dexamethasone 2mg|The experimental intervention in this arm will be an IV infusion of 2mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
2955569|NCT02864602|Experimental|Dexamethasone 4mg|The experimental intervention in this arm will be an IV infusion of 4mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
2955570|NCT02864602|Experimental|Dexamethasone 8mg|The experimental intervention in this arm will be an IV infusion of 8mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
2955571|NCT02864589|Experimental|I-HRT|Internet-delivered habit reversal training
2955572|NCT02864589|Experimental|I-ERP|Internet-delivered exposure and response prevention
2955573|NCT02864576|Experimental|Cognitive Remediation_Aerobic Exercise|"Cognitive Remediation:~12 weeks of systematic cognitive training (REHACOP), performed 3 days per week in a 90-minutes-long sessions.~Aerobic Exercise:~12 weeks of systematic aerobic exercise program, performed 3 days per week, lasting 40 minutes."
2955574|NCT02864576|Active Comparator|Cognitive Remediation_Health Promotion|"Cognitive Remediation:~12 weeks of systematic cognitive training (REHACOP), performed 3 days per week in a 90-minutes-long sessions.~Health Promotion:~12 weeks of health promotion sessions, performed 3 days per week, lasting 40 minutes each."
2955575|NCT02864563|Experimental|Prospective cohort|
2955576|NCT02864550|Experimental|Doxycycline arm|Participants in this intervention group will receive doxycycline 100mg orally daily, which is available as a 100mg capsule. This single daily dose was chosen to maximize adherence, given the common use of once-daily Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis (PrEP), as well as its efficacy as once-daily prophylaxis against malaria and its utility as dosing as infrequent as once weekly for another spirochete infection, leptospirosis.
2955577|NCT02864550|Placebo Comparator|Placebo arm|Participants in this control group will receive a placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group.
2955578|NCT02864537|No Intervention|Conventional treatment|Conventional anticoagulation treatment Before enrolment
2955579|NCT02864537|Experimental|Self-management|Trained to monitor INR and dose warfarin
2955615|NCT02864290|Experimental|Dose Expansion of AGS62P1 Schedule C|Once the MTD has been determined, an expansion cohort of up to 15 subjects may be enrolled. Subjects will receive AGS62P1 as an intravenous infusion once weekly for three weeks.
2955580|NCT02864524|Experimental|Manipulative and Massage Therapy|"Ten sessions (2/week):~High speed and low amplitude technique to lower cervical spine (C3-C4).~Dog technique flexion for high thoracic area (T1-T4).~Dog technique flexion for mid-thoracic area (T5-T8).~Dog technique flexed to low thoracic (T6-T12).~Classic Massage Therapy during 40 minutes (2 time / week):"
2955581|NCT02864524|Active Comparator|Exercise Program|Ten sessions (2 time/ week): Initial heating and continuing with aerobic and muscle stretching exercises.
2955582|NCT02864511|Experimental|Intervention group|
2955583|NCT02864498|Experimental|1g Oral DS107|1g Oral DS107 to be administered once-daily for 8 weeks.
2955584|NCT02864498|Experimental|2g Oral DS107|2g Oral DS107 to be administered once daily for 8 weeks.
2955585|NCT02864498|Placebo Comparator|Placebo|Placebo orally administered once-daily for 8 weeks.
2955586|NCT02864485|Experimental|transplantation|Live donor liver transplantation for the treatment of unresectable colorectal cancer liver metastases
2955587|NCT02864472|Other|combination Tx|combination Tx(vPDT +ranibizumab) (M0) + ranibizumab PRN (M3-6)
2955588|NCT02864472|Other|mono Tx|Ranibizumab (at 4 weeks interval) *3 (M0-2) + ranibizumab PRN (M3-6)
2955589|NCT02864459|Experimental|Muscular ultrasound|
2955590|NCT02864433||Controls for non-cholera diarrhea cases|- Community members that did not have diarrhea between date of study commencement, and time of presentation of the case
2955591|NCT02864433||Non-cholera diarrhea cases|- Cases of acute watery diarrhea that present for healthcare at the study sites, but that test negative for cholera
2955592|NCT02864433||Controls for cholera cases|- Community members that did not have diarrhea between date of study commencement, and time of presentation of the case
2955593|NCT02864433||Cholera cases|- Those with cholera-related diarrhea who present to healthcare at the study sites.
2955594|NCT02864420|Active Comparator|Inpatient hospitalization|Control / usual care arm. Patients are admitted per usual to an inpatient service. Patients' medical records will be closely monitored. Patients will wear a vitals and activity monitor whose data is used only retrospectively. On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
2955595|NCT02864420|Experimental|Home hospitalization|Intervention arm. Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
2955596|NCT02864407||Vahelva group|Korean patients with COPD who are newly prescribed with Vahelva Respimat
2955597|NCT02864394|Experimental|Pembrolizumab (MK-3475) 2mg/kg|"Participants with NSCLC receive pembrolizumab 2mg/kg intravenously (IV) over 30 minutes every 3 weeks (Q3W) for up to 35 doses (approximately 24 months).~Participants who attain a confirmed complete response (CR) per Response Criteria in Solid Tumor Version 1.1 (RECIST 1.1) or those that stop trial therapy after 35 treatment administrations for reasons other than disease progression or intolerability may be eligible for re-treatment with open-label pembrolizumab as monotherapy after they have experienced radiographic disease progression for up to 17 doses (approximately an additional 12 months)."
2955598|NCT02864394|Experimental|Docetaxel 75 mg/m^2|Participants with NSCLC receive Docetaxel 75 mg/m^2 IV over 1 hour Q3W until disease progression, toxicity, investigator's decision to discontinue or consent withdrawal
2955599|NCT02864381|Experimental|Andecaliximab+nivolumab|Andecaliximab+ nivolumab for up to 2 years
2955600|NCT02864381|Experimental|Nivolumab|Nivolumab for up to 2 years
2955601|NCT02864368|Experimental|5-day TMZ|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
2955602|NCT02864368|Experimental|21-day TMZ|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of dose-intensified TMZ (75-100 mg/m^2/day on days 1-21 of each 28 day cycle) with PEP-CMV vaccination on day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
2955603|NCT02864355|Active Comparator|Goal Directed Therapy|In this arm patient will have the FloTrac monitor and a Goal Directed Therapy algorithm will be used to manage blood pressures.
2955604|NCT02864355|No Intervention|Usual Care|Standard of care will be used to manage blood pressures.
2955605|NCT02864342|Active Comparator|BreatheMate device and application|BreatheMate Bluetooth device that attaches to Symbicort pressurized Metered Dose Inhaler (pMDI) and cell phone with application that sends medication and refill reminders and reminders to complete a COPD questionnaire
2955606|NCT02864342|Placebo Comparator|BreatheMate device without application|BreatheMate Bluetooth device that attaches to Symbicort pressurized Metered Dose Inhaler (pMDI) and cell phone without any reminders or alerts.
2955607|NCT02864316|Experimental|Radiation-Induced Metastatic Sarcoma|a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
2955608|NCT02864316|Experimental|Radiation-Induced Non-Sarcoma Metastatic Solid Tumors|a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
2955609|NCT02864303|Other|Patients with Alzheimer disease|Saliva samples were collected on this patients
2955610|NCT02864290|Experimental|Dose Escalation of AGS62P1 Schedule A|Subjects will receive AGS62P1 as an intravenous infusion once every three weeks (QW3) to determine the maximum tolerated dose (MTD)
2955611|NCT02864290|Experimental|Dose Escalation of AGS62P1 Schedule B|Subjects will receive AGS62P1 as an intravenous infusion every other week for three weeks to determine the maximum tolerated dose (MTD).
2955612|NCT02864290|Experimental|Dose Expansion of AGS62P1 Schedule A|Once the maximum tolerated dose (MTD) has been determined, an expansion cohort of up to 15 subjects may be enrolled. Subjects will receive AGS62P1 as an intravenous infusion once every three weeks (QW3).
2955613|NCT02864290|Experimental|Dose Expansion of AGS62P1 Schedule B|Once the maximum tolerated dose (MTD) has been determined, an expansion cohort of up to 15 subjects may be enrolled. Subjects will receive AGS62P1 as an intravenous infusion every other week for three weeks.
2955614|NCT02864290|Experimental|Dose Escalation of AGS62P1 Schedule C|Subjects will receive AGS62P1 as an intravenous infusion once weekly for three weeks to determine the MTD.
2955754|NCT02863237||weaning success group|Patients who pass the SBT and breathing without ventilator support within 48 hours are designated the weaning success group
2955616|NCT02864277|No Intervention|No Intervention Conventional Strategy|Perioperative Anesthetic No Intervention Management: Conventional Strategy Group 4 pages of concise directions on how to take care of the participant.
2955617|NCT02864277|Experimental|ERAS Group|ERAS (enhanced recovery after surgery)
2955618|NCT02864264|Experimental|Single Ascending Dose (SAD) - IV Panel|Single intravenous (IV) dose of BMS-986184 or placebo matching BMS-986184
2955619|NCT02864264|Experimental|Single Ascending Dose (SAD) - SC Panel|Single subcutaneous (SC) dose of BMS-986184 or placebo matching BMS-986184
2955620|NCT02864264|Experimental|Multiple Ascending Dose (MAD) - IV Panel|Multiple IV doses of BMS-986184 or placebo matching BMS-986184
2955621|NCT02864264|Experimental|Proof of Mechanism (POM) - IV Panel|Multiple IV doses of BMS-986184 or placebo matching BMS-986184
2955622|NCT02864251|Experimental|Nivolumab+Platinum doublet chemotherapy|Specified dose on specified days
2955623|NCT02864251|Experimental|Nivolumab + Ipilimumab|Specified dose on specified days
2955624|NCT02864251|Active Comparator|Platinum doublet chemotherapy|Specified dose on specified days
2955625|NCT02864238||Pre intervention|This cohort consists of patients who underwent cardiac valve surgery during calender year 2013 prior to the institution of the electronic milestone pathway
2955626|NCT02864238||post intervention|This cohort consists of patients who underwent cardiac valve surgery during calender year 2014 after the electronic milestone pathway had been instituted
2955627|NCT02864225|Experimental|Scalp electrode, fetal doppler and EUM|Once in labor, the parturient will be connected to the routine fetal doppler and EUM. When necessary according to clinical indications, the scalp electrode will be connected. Tracing will be recorded simultaneously from all three devices until delivery.
2955628|NCT02864212||Glucose monitoring|Glucose will be monitor in patients using fast-acting insulin.
2955629|NCT02864212||Depth of anesthesia monitoring|Depth of anesthesia will be monitor in patients undergoing cardiac surgery.
2955630|NCT02864212||Blood pressure monitoring|Invasive blood pressure will be monitor in patients undergoing cardiac surgery.
2955631|NCT02864199|Experimental|Group A: Moderate Renal Impairment|Participants with CrCl 30 to 50 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 micrograms (mcg) via subcutaneous (SC) injection once weekly, in combination with ribavirin, 600 milligrams (mg) orally (PO) daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
2955632|NCT02864199|Experimental|Group B: Severe Renal Impairment|Participants with CrCl <30 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 mcg via SC injection once weekly, in combination with ribavirin, 400 mg PO daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
2955633|NCT02864199|Experimental|Group C: Hemodialysis/ESRD|Participants requiring hemodialysis will receive 12 weeks of peginterferon alfa-2a, 135 mcg via SC injection once weekly, in combination with ribavirin, 200 mg PO every morning. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
2955634|NCT02864199|Experimental|Group D: Normal Renal Function|Participants with CrCl >80 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 mcg via SC injection once weekly, in combination with ribavirin, 800 to 1200 mg PO daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
2955635|NCT02864186|Active Comparator|control|Women wont use support bra for six months
2955636|NCT02864186|Active Comparator|surgical support bra|Women will use surgical support bra 24 hours a day for six months
2955637|NCT02864186|Active Comparator|common support bra|Women will use common support bra 24 hours a day for six months
2955638|NCT02864160|Experimental|Health Coaching|The health coaching intervention group (n=100) will receive written educational materials on diabetes self-management in Spanish and the diabetes self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish). In addition, patients in the intervention group will be assigned a health coach who will provide health coaching over the course of 6 months with 14 phone calls.
2955639|NCT02864160|Active Comparator|Comparison group|The comparison group (n=100) will receive the standard diabetes care that is offered at Heart of Ohio clinics including consultations with a primary care provider, a dietician, a pharmacist, and a diabetes educator. The comparison group will receive written educational materials on diabetes self-management in Spanish and diabetes self-management tools including a stretch band, a glucometer, and a diabetes cookbook in Spanish.
2955640|NCT02864147|Experimental|imiquimod + 9-valent HPV vaccine|Participants randomized to the imiquimod + 9-valent HPV vaccine group will receive instruction on imiquimod self application (16 week course) at the baseline visit. In addition, all women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
2955641|NCT02864147|Active Comparator|imiquimod only|Participants randomized to the imiquimod only group will receive instruction on imiquimod self application (16 week course) at the baseline visit.
2955642|NCT02864147|No Intervention|observation only (control)|Participants randomized to the control group will only be observed and will receive no intervention.
2955643|NCT02864121|Experimental|arm 1|all patients included in IDAHO study
2955644|NCT02864108||Those with trisomy 21|People aged 6 months to 89 years old who have some form of trisomy 21.
2955645|NCT02864108||Controls|People aged 6 months to 89 years old who do not have trisomy 21. These persons can be related to someone with some form of trisomy 21 but do not have to be related.
2955646|NCT02864095|Experimental|Intravenous epinephrine|Intravenous (IV) low dose epinephrine
2955647|NCT02864095|Experimental|Topical epinephrine|Topical epinephrine
2955648|NCT02864095|Active Comparator|Control|No epinephrine
2955649|NCT02864082|Other|Group 1|"Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side).~Part 2: Patients will apply PAT-001, 0.1% to both Treatment Areas."
2955755|NCT02863224||Healthy control|
2955756|NCT02863224||Ocular hypertension|
2955757|NCT02863224||Primary open angle glaucoma|
2955650|NCT02864082|Other|Group 2 (Part 1)|"Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side).~Part 2: Patients will apply PAT-001, 0.2% to both Treatment Areas."
2955651|NCT02864069|Experimental|Walking Intervention|
2955652|NCT02864069|Experimental|Cognitive Training Intervention|
2955653|NCT02864069|Experimental|Combined Intervention|
2955654|NCT02864056|No Intervention|Control|Usual care
2955655|NCT02864056|Experimental|Tai Chi|Completes 50 hours of Tai Chi, a combination of in-class and at-home practise.
2955656|NCT02864043|Other|NvisionVLE with Real Time Targeting|Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe
2955657|NCT02864030|Other|Single arm with Eribulin mesylate|
2955658|NCT02864017|Experimental|L-Citrulline group|Enteral nutrition 5-day L-citrulline treatment (10 grams/day)
2955659|NCT02864017|Placebo Comparator|Control group|Enteral nutrition 5-day placebo treatment
2955660|NCT02864004|Experimental|APO group|An apomorphine pump will be installed and adjusted. The target dose corresponds to the patient's individual optimized dose :maximum dose of 10 mg/hour for 16 hours
2955661|NCT02864004|Active Comparator|Control group|Patients will be optimally treated with oral dopaminergic therapy to obtain the best medical treatment (BMT) defined as the most efficient single treatment options or their combination.
2955662|NCT02863991|Experimental|ONC201|Single agent ONC201.
2955663|NCT02863978|Experimental|Digi-NewB Cohort|Multimodal signal acquisitions
2955664|NCT02863965||High definition endoscopy and optic enhancement|All the patients underwent routine preparation before the procedure. The detected lesions in high definition endoscopy were observed with optic enhancement mode. The endoscopist was required to give the real-time descriptions of surface pit patterns of the lesions, based on surface pattern classification. After that, biopsy specimens will be obtained respectively by forceps from each detected lesion recorded for histologic diagnosis.
2955665|NCT02863952|Other|EARLY POST-STRESS EF CHANGE|There is only a single arm. All patients undergoing the routine myocardial perfusion SPECT study will also have additional (earlier) image acquisition in order to assess the relation of early wall motion abnormalities to the severity of myocardial ischemia.
2955666|NCT02863939|Other|NICAS|There is only one arm - a single cohort. All patients undergoing the nuclear stress test will also have the NICAS evaluation.
2955667|NCT02863926|Experimental|Day 7|BKA performed at 7 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
2955668|NCT02863926|Experimental|Day 14|BKA performed at 14 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
2955669|NCT02863926|Experimental|Day 21|BKA performed at 21 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
2955670|NCT02863913|Experimental|Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
2955671|NCT02863913|Placebo Comparator|Comparable group|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
2955672|NCT02863900|Experimental|Experimental arm|subtypes of BC (namely luminal A and luminal B, HER2+, TN)
2955673|NCT02863887|Experimental|Weight loss intervention|Churches randomized to the intervention condition will receive the community health coach delivered church based intervention for 6 months followed by 6 months of weight maintenance.
2955674|NCT02863887|Experimental|Delayed Treatment Control Group|Churches in the delayed treatment control condition will receive information on various health topics relevant to African Americans, such as strokes, lupus, sickle cell, etc. via text message during the first six months. Participants in this group will not receive any behavioral strategies designed to alter weight, physical activity, or diet during this time. They will receive the community health coach delivered church based weight loss intervention after 6 months.
2955675|NCT02863874|Active Comparator|Vicryl®|The vaginal or and perineal tear is sutured continuously with Vicryl®. The instruments for suturing and the bedcover are clean whereas the gloves are sterile.
2955676|NCT02863874|Active Comparator|VicrylPlus®|The vaginal or and perineal tear is sutured continuously with VicrylPlus®. The instruments for suturing and bedcover are clean whereas the gloves are sterile.
2955677|NCT02863861|Experimental|Group PK|Propofol-Ketamine group: patients in this group will receive IV ketamine at a dose of 1mg.kg-1 in addition to IV propofol 1mg.kg-1 for induction with added doses of propofol 1mg.kg-1 when needed.
2955678|NCT02863861|Experimental|Group DK|Dexmedetomidine-Ketamine group: patients in this group will receive IV ketamine at a dose of 1mg.kg-1 in addition to IV dexmedetomidine 0.5 mcg.kg-1 for induction with additional doses of dexmedetomidine 0.5mcg.kg-1 when required
2955679|NCT02863848|Placebo Comparator|Placebo|Maltodextrin 2g, twice per day, 6 weeks
2955680|NCT02863848|Active Comparator|Inulin‐type fructans|Orafti inulin‐type fructans 2g, twice per day, 6 weeks
2955719|NCT02863497|Active Comparator|Mindfulness Intervention|For those randomly selected to receive mindfulness-based sex therapy, they will be asked to participate in four sessions of group therapy, over a period of 2 months. Sessions will occur in a conference room at St. Paul's Hospital. Part of the protocol of the Mindfulness - based sex therapy is that they will have a diary to be filled in. This diary will not be collected at the end of the therapy, as it is for the participant to keep. The group facilitators will be collecting session attendance.
2955681|NCT02863835|Experimental|Intervention 1|"A 1:1 randomisation will be performed to decide the order of the administration of salbutamol and CPAP. All participants will receive both interventions in a cross-over fashion. Salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure.~Each participant will then have continuous assessment of the following whilst self venting:~Spirometry - FEV1, FVC, MVV~Muscle strength measurements: MIP, MEP, SNIP~Borg scale, mMRC, Visual Analogue Scale for breathlessness~Electrical impedance tomography~EMGpara~Transcutaneous measurement of CO2 and 02 level~End-tidal CO2 monitoring~Pneumotachography"
2955682|NCT02863822|Experimental|Low FODMAP|Subjects will be given dietary education in the low FODMAP diet, which they will continue for 4 weeks. Subjects will then followup with the dietician and subjects with a symptomatic response will be given instructions for reintroduction.
2955683|NCT02863822|Active Comparator|Choose My Plate|Subjects will receive dietary counseling in the choose my plate diet as defined by choosemyplate.gov. Subjects will also receive 2 dietician visits, 4 weeks apart.
2955684|NCT02863809|Experimental|Active Treatment Arm|De-epithelialized corneas cross-linked with riboflavin 0.1% and dextran 20% solution AND ultraviolet A light (UVA Light Source).
2955685|NCT02863809|Active Comparator|Control Treatment Arm|De-epithelialized corneas will be exposed to only riboflavin 0.1% with dextran 20% solution (NO ultraviolet A light).
2955686|NCT02863783|Experimental|Fiducial Placement|EUS with Fiducial Placement into Tumor
2955687|NCT02863770|Experimental|Contrast EUS|Undergoing EUS for pancreatic indication (cyst, pancreatitis, mass)
2955688|NCT02863757||CHB Group|Patients with chronic hepatitis B
2955689|NCT02863757||CHB/NAFLD Group|Patients with chronic hepatitis B and comorbid nonalcoholic fatty liver disease
2955690|NCT02863757||NAFLD Group|Patients with nonalcoholic fatty liver disease
2955691|NCT02863744|Experimental|CAF+SCTG|
2955692|NCT02863731|Experimental|Alternating postures: first day|Alternating body postures on the first day of measurement. Sitting body posture on the second day of measurement.
2955693|NCT02863731|Experimental|Alternating postures: second day|Alternating body postures on the second day of measurement. Sitting body posture on the first day of measurement.
2955694|NCT02863731|No Intervention|Control group|Sitting body posture on both days of measurement.
2955695|NCT02863718|No Intervention|Watch & wait|Watch & wait
2955696|NCT02863718|Placebo Comparator|Placebo 420 mg/d|Placebo 420mg/d
2955697|NCT02863718|Active Comparator|Ibrutinib 420mg/d|Ibrutinib 420mg/d
2955698|NCT02863705|Experimental|COMBIGAN®|One drop of COMBIGAN® in the affected eye, administered twice daily for 12 months
2955699|NCT02863705|Experimental|COMBIGAN® + LUMIGAN® 0.01%|LUMIGAN® will be administered once daily in the evening 5 minutes after COMBIGAN® instillation in patients who require additional IOP lowering.
2955700|NCT02863679|Experimental|Tetracaine hydrochloride gel group|Patients in getracaine hydrochloride gel group were covered with a gauze with tetracaine hydrochloride gel on the cervix after hysteroscopic insertion of utrauterine balloon stent.
2955701|NCT02863679|Placebo Comparator|Control group|Patients in control group were covered with a gauze with saline on the cervix after hysteroscopic insertion of utrauterine balloon stent.
2955702|NCT02863640||Exposed patients|Patients treated for Parkinson's disease with a cumulative dose of L-DOPA above the 59th percentile of the population
2955703|NCT02863640||Non exposed patients|Patients treated for Parkinson's disease with a cumulative dose of L-DOPA below the 41th percentile of the population
2955704|NCT02863627|Experimental|Newborn Care Pathway|two telephone interviews conducted after the emergency department visit will be used to gather data to meet the objectives of this study.
2955705|NCT02863614|Experimental|Ibuprofen+Lorazepam|Oral ibuprofen (600 mg) + lorazepam (1 mg); one hour before endometrial scratching.
2955706|NCT02863614|Active Comparator|Ibuprofen|Oral ibuprofen (600 mg) + Placebo; one hour before endometrial scratching.
2955707|NCT02863614|Placebo Comparator|Placebo|Placebo + Placebo; one hour before endometrial scratching.
2955708|NCT02863588|Experimental|seropositive for Toxoplasma gondii|
2955709|NCT02863575|Experimental|Ibuprofen/Caffeine|Ibuprofen 400 mg/ Caffeine 100 mg fixed-dose combination
2955710|NCT02863575|Active Comparator|Ibuprofen|Ibuprofen 400 mg
2955711|NCT02863575|Placebo Comparator|Placebo|Placebo comparator
2955712|NCT02863562|Experimental|Group 1|"This group included 16 subjects. They received kinesio taping for both ankle joints and and performed proprioceptive exercises.~Proprioceptive exercises were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed. Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training."
2955713|NCT02863562|Experimental|Group 2|"This group received placebo kinesio taping for ankle joint (no tension) and performed proprioceptive exercises.~Proprioceptive exercises were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed. Kinesio taping technique was used on both ankles on the first day of training in the same way as before but with no tension. It was removed on the second day of training."
2955714|NCT02863562|Experimental|Group 3|This group received kinesio taping for ankle joint. Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training.
2955715|NCT02863536|Other|Polybactum®|"Polybactum® ovules are administered intravaginally on 3 cycles, 1 cycle per month.~Polybactum is a medical device Class IIa used and marketed for the recurrence of Bacterial Vaginosis."
2955716|NCT02863523|Experimental|Integrated Behavioral Intervention|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
2955717|NCT02863523|No Intervention|Usual Care|Patients receive usual care
2955718|NCT02863510|Experimental|Renal Denervation|Participation receiving renal sympathetic denervation
2955758|NCT02863224||Normal tension glaucoma|
2955720|NCT02863497|No Intervention|No Intervention|For those who are not in the intervention group they will simply be asked to fill the initial questionnaire and the 3 month post questionnaire. They will not participate in any other questionnaires.
2955721|NCT02863484|Active Comparator|Conventional surgery intra-dural|This arm will be surgically operated by direct attack of the tumour after opening the dura
2955722|NCT02863484|Experimental|Pealing surgery extra-dural|This arm the pealing of the outer layer of the lateral wall of the cavernous sinus will be done before the dura is opened. After the pealing is completed, the middle meningeal artery will be divided at the foramen spinosum. Then, the dura will be opened and the tumour attacked.
2955723|NCT02863471|Experimental|Gemcitabine|1000 milligram (mg)/ square meter (m²) body surface, intraperitoneal use, unique intraoperative application for 60 minutes
2955724|NCT02863445|Active Comparator|LNG-ECx1|Levonorgestrel 1.5 mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
2955725|NCT02863445|Experimental|LNG-ECx2|Levonorgestrel 3mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
2955726|NCT02863419|Experimental|Oral Semaglutide|
2955727|NCT02863419|Active Comparator|Liraglutide|
2955728|NCT02863419|Placebo Comparator|Placebo|
2955729|NCT02863406|Experimental|Healthy volunteers|Bronchoalveolar lavage in healthy volunteers
2955730|NCT02863406|Experimental|Patients suffering from sarcoidosis|Bronchoalveolar lavage in patients suffering from sarcoidosis
2955731|NCT02863393|Experimental|Diaphragmatic breathing exercise|The aim of this study is to ameliorate hepatic inflammation by using diaphragmatic breathing exercises instead of aerobic exercise to reduce the fat in liver inflammation.
2955732|NCT02863380|Experimental|Individualized rTMS (transcranial magnetic stimulation)|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The therapeutic protocol will be design to correct the rCBF anomaly first by defining each point where to deliver the stimulation than the stimulation protocol for each point (180% of active motor threshold, 4-second 10 Hz train duration, with 26-second intertrain interval for a total of 3000 pulses). The whole target will be homogeneously stimulated.~The active motor threshold will be assessed. The procedure will be repeated twice a day for 10 days over 2 weeks."
2955733|NCT02863380|Active Comparator|Classical rTMS (transcranial magnetic stimulation)|rTMS will be performed as usual using a figure-eight coil: Defining the active motor threshold. For each session positioning the coil on F3, stimulating at 180% of active motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session), twice a day for 10 days over 2 weeks.
2955734|NCT02863380|Active Comparator|Classical tDCS (transcranial direct current stimulation)|tDCS will be performed as usual: After controlling for skin healthiness, the anode and the cathode will be respectively placed over F3 and right shoulder. A commercial devices (MagStim), will deliver a constant current of 2 mA through 25 cm2 saline-soaked rubber sponges for 20 min per session. The procedure will be repeated twice a day for 10 days over 2 weeks.
2955735|NCT02863367|Experimental|Treatment group|Apatinib：500 mg，po，qd, d1-14, every 3 week Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
2955736|NCT02863354|Experimental|Q4WKS|Aflibercept 2 mg every 4 weeks (defined as every 28 days (+ 7 days) and at least 21 days between injections.
2955737|NCT02863354|Experimental|Q12WKS|Aflibercept 2 mg every 12-weeks. Subjects will be followed every 4 weeks through week 12, and can be treated if the pre-specified criteria are met. Starting at week 12 if NV or PDR are stable or improved (as assessed by investigator) the subject will be monitored and treated at a 12-week interval. If NV or PDR are worse per the pre-specified criteria at week 12, or at any study visit thereafter, the subject will be treated monthly through the end of the study.
2955738|NCT02863341|Experimental|naive Deprescribing arm|Team-based deprescribing practice, Deprescribing Guide
2955739|NCT02863341|No Intervention|naive Wait-list Control arm|
2955740|NCT02863341|Experimental|non-naive Deprescribing arm|Team-based deprescribing practice, Deprescribing Guide
2955741|NCT02863341|No Intervention|non-naive Wait-list Control arm|
2955742|NCT02863328|Experimental|14 mg oral semaglutide|
2955743|NCT02863328|Active Comparator|25 mg empagliflozin|
2955744|NCT02863315|Experimental|tsDCS|In the tsDCS group, anodal tsDCS will be applied for 20 minutes.
2955745|NCT02863315|Placebo Comparator|sham|In sham tsDCS group, the current of anodal tsDCS will be discontinued after 30 s while the power indicator remained on for 20 minutes.
2955746|NCT02863302|Experimental|Reflexology treatment|All patients will receive reflexology (a specialized foot therapy) from a certified reflexologist twice weekly from the beginning of chemotherapy treatment until the end of hospitalization.
2955747|NCT02863289||Children with proximal humerus fractures|Children aged from 10 to 18-year-old in NHS Tayside whom sustained proximal humerus fractures during year 2008 to 2015.
2955748|NCT02863276|Experimental|Intensified insulin group|Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving tight blood glucose control with intensified insulin therapy (blood glucose target<6 mmol*l-1) via an continuous insulin infusion.
2955749|NCT02863276|No Intervention|Control group|Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving standard blood glucose control (blood glucose target <10 mmol*l-1) via subcutaneous insulin boluses
2955750|NCT02863263|Other|Foam Dressing|Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
2955751|NCT02863263|Other|Foam Dressing with Povidone Iodine|Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
2955752|NCT02863250||Massively transfused patients|Patients (18+ years) who have had a critical bleeding event that necessitated a massive transfusion (defined as 5 or more units of red cells in any 4 hour period)
2955753|NCT02863237||weaning failure group|Patients reconnected to the ventilator within 48 hours after SBT will be designated the weaning failure group
2955759|NCT02863211||HAPPY Hearts Cohort|One-thousand women 55 years of age or older will be recruited to be screened through the HAPPY Hearts protocol. This involves the cardiovascular assessment of resting blood pressure, blood pressure response to 3-min of moderate intensity exercise and large and small arterial elasticity. The participants will be classified into risk categories based on these measures. The incidence of the following adverse cardiovascular outcomes will be assessed in the five-year period after screening in both groups: Ischemic heart disease, acute myocardial infarction, stroke, percutaneous coronary intervention, coronary bypass surgery, congestive heart failure, and hypertension.
2955760|NCT02863198|Active Comparator|endometrial injury|Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
2955761|NCT02863198|No Intervention|non endometrial injury|non endometrial injury was done only for patient of the control group
2955762|NCT02863185|Experimental|Pitavastatin group|Use of 2mg or 4mg Pitavastatin
2955763|NCT02863185|Active Comparator|Atorvastatin group|Use of 10mg or 20mg Atorvastatin
2955764|NCT02863172||Consenting Proband Group|Questionnaires completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
2955765|NCT02863172||Family Members (MDA Registered Patients) Group|Health questionnaire completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
2955766|NCT02863172||Family Members (Not MDA Registered Patients) Group|Health questionnaire completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
2955767|NCT02863159|Active Comparator|Treatment Group 1|50 qualified study patients will receive the +2.75D (ZKB00) in their dominant eye and the +3.25D (ZLB00) in their non-dominant eye.
2955768|NCT02863159|Active Comparator|Treatment Group 2|50 qualified study patients will receive the +2.75D (ZKB00) in their dominant eye and the +4.00D (ZMB00) in their non-dominant eye.
2955769|NCT02863133|Experimental|Easyx Liquid Embolic|embolization of intracranial malformations and fistulas and brain tumours with Easyx Liquid Embolic
2955770|NCT02863120|Active Comparator|Liposomal bupivacaine|Periarticular infiltration of 20cc of liposomal bupivacaine with 10cc of normal saline and 30cc of bupivacaine HCl administered prior to cementation of knee implants
2955771|NCT02863120|Active Comparator|Adductor canal and tibial nerve block|Preoperative tibial nerve block with 15cc bupivacaine HCl and adductor canal block with 20cc adductor canal block. Postoperative continuous adductor canal block with 550cc ropivacaine at 8cc per hour
2955772|NCT02863107||Colorectal Cancer|Questionnaires completed at registration in study or at baseline, and once a year for 5 years. Blood (about 2 tablespoons) collected 1 time.
2955773|NCT02863094|Active Comparator|Real Stimulation|The continuous theta burst stimulation (cTBS) protocol lasted 40 s and consisted of burst of 3 pulses delivered at 50 Hz, with bursts being repeated every 200 ms (at 5 Hz) for a total of 600 pulses. In the cTBS session, this 40s protocol was repeated for three times (1800 pulses in total) separated by two 15 min breaks (controlled by a stopwatch). MRI dataset should be acquired before the first cTBS session and after the last cTBS session.
2955774|NCT02863094|Sham Comparator|Placebo Stimulation|The procedure of this protocol was performed by a placebo coil. Each session lasted 40 s and consisted of burst of 3 pulses delivered at 50 Hz, with bursts being repeated every 200 ms (at 5 Hz) for a total of 600 pulses. No actual magnetic stimulation was applied on the head of the volunteers. MRI dataset should be acquired before the first sham TBS session and after the last sham TBS session.
2955775|NCT02863081||Healthcare providers|All healthcare providers working in the participating LTACH will be asked to complete 2 surveys and invited to participate in focus group meetings
2955776|NCT02863081||Patients|81 LTACH patients will be enrolled over the course of a 9 month period. Each patient and their LAR will be interviewed at the time of LTACH admission to garner information about their pre hospitalization physical, functional, and cognitive health status. Each day enrolled patients will undergo daily symptom assessments and medical record reviews. At the time of LTACH discharge all enrolled patients will be interviewed again to garner information about their discharge physical, functional, and cognitive health status.
2955777|NCT02863068|Placebo Comparator|control|patients will receive placebo and standard of care
2955778|NCT02863068|Experimental|topical sodium nitrite|patients will receive 2% topical sodium nitrite cream and standard of care
2955779|NCT02863055|Experimental|Nintedanib|200 mg twice a day per os
2955780|NCT02863055|Placebo Comparator|Placebo|Placebo match twice a day per os
2955781|NCT02863042|Experimental|Deltoid Tendon Repaired|Repair Deltoid Tendon
2955782|NCT02863042|Other|Ankle Fracture Without Deltoid Tendon Repair|
2955783|NCT02863029|Other|Flexible Sigmoidoscopy|Participants will undergo an unsedated Flexible Sigmoidoscopy in order to obtain 12 mucosal biopsies. Serum cholesterol, triglyceride and HBA1C levels will be determined. Plasma, serum and whole blood will be stored for future use for next generation sequencing and metabolomics to determine the effect of different genetic loci on composition and function of gut microbiota
2955784|NCT02863016||Concentrate SelectBag One|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution: first of all concentrate SelectBag One (with 3 mM of acetic acid and 0 mM of citrate)
2955785|NCT02863016||Concentrate SelectBag Citrate|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution, then with SelectBag Citrate (with 0 mM of acetic acid and 1 mM of citric acid)
2955786|NCT02862990||Pre menopausal women with breast cancer|Pre menopausal women with breast cancer prior treatment in face of infertility evoked by chemotherapy
2955787|NCT02862977|Experimental|EMS association|The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h.
2955788|NCT02862977|Active Comparator|Miosan Caf®|The patient will take 2 tablets (combination of Cyclobenzaprine and caffeine), oral, per day, each 12h.
2955789|NCT02862964||identify L4-5|Level marked as L4-5 using Accuro and palpation
2955790|NCT02862951||Term pregnancy (>37 weeks gestation)|Term pregnancy (>37 weeks gestation)
2955854|NCT02862496||Control group|control group consisting of 30 health pregnant women between 7-20 weeks of gestation with excluded hyperemesis gravidarum.
2955791|NCT02862938|Experimental|NT-501 ECT Implant|"On eligible participants that are randomized to this group, the NT-501 Investigational product will be implanted in the study eye, and participants will be followed for 24 months.~The investigational treatment, NT-501 ECT, provides intravitreal sustained release of soluble ciliary neurotrophic factor (CNTF) receptor after intraocular implantation."
2955792|NCT02862938|Sham Comparator|Sham|To maintain masking, participants randomized to this group receive sham surgery and will be followed for 12 months. Following analysis of the 6 month data, if the open label extension (OLE) is not triggered, patients in the control group will continue on the original study schedule timeline trough month 24. If OLE is triggered participants will be offered the NT-501 ECT investigational product and will followed for additional 12 months.
2955793|NCT02862925|No Intervention|Pre-Intervention|A consecutive sample of 350 patients will be collected. After informed consent, data will be abstracted from the patient's record including day and time of delivery, method of delivery, parity, gestational age, meconium presence, heart rate abnormality and induction methods. For CD, the following data will be collected: decision-to-delivery time, Partogram adherence, time of each FSST, Apgar score, date and time of delivery and Comorbidities such as: Hypertension-spectrum disorders, Malaria, Postpartum Hemorrhage, Macrosomia, History of CD, Diabetes, Sickle Cell, and HIV status.
2955794|NCT02862925|Experimental|Post-intervention|The study will take place on the labor ward at KCMC in Moshi, Tanzania. It will involve women who present to the labor ward in labor or who undergo an induction of labor. A consecutive sample of 350 patients will be collected. Study investigators will be present for 24 hours a day, 7 days a week on a rotating schedule during the enrollment period. All patients who fit inclusion and exclusion criteria will be approached if they are deemed medically stable.
2955795|NCT02862912|Experimental|Chloroprocaine (CP)|Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)
2955796|NCT02862912|Active Comparator|Bupivacaine (BUP)|Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml
2955797|NCT02862899|Experimental|Heating cable|
2955798|NCT02862886|Other|N°1|
2955799|NCT02862873|Experimental|Ondansetron|
2955800|NCT02862873|Placebo Comparator|Saline solution|
2955801|NCT02862860|Experimental|patients with type-1 diabetes|
2955802|NCT02862860|Placebo Comparator|Controls|
2955803|NCT02862847||gastroenteritis|
2955804|NCT02862847||control|
2955805|NCT02862834||patients with poikiloderma|
2955806|NCT02862821|Experimental|validation of EEfRT task|20 healthy volunteers will be recruted to validate motivation EEfRT task which is adaptated to HR-EEG
2955807|NCT02862821|Experimental|biomarkers identification|20 addict online poker gamblers and 20 non-addict online poker gamblers will be recruted : After standardized questionnaires to define the socio-demographic data, the diagnosis of gambling addiction (Diagnostic and Statistical Manual of Mental Disorder 5th edition DSM-5), screening for comorbidities addictive, the level of anxiety and impulsivity, brain acvtivity will be registred (by randomisation between the 2 tasks) with HR-EEG: during the performance of a task of motivation evaluation laboratory (EEfRT) adaptated for high-resolution electroencephalography AND during a laboratory task that assesses decision making in conditions of uncertainty (IGT) with its version for high-resolution electroencephalography has already been validated in a previous study (Giustiniani et al., 2015).
2955808|NCT02862821|Experimental|biomarkers validation|13 online poker gamblers will be recruted, independently of their dependance profile and they will realize the same task that in precedent arm (quaestionnaires and 2 tasks adaptated to HR-EEG).
2955809|NCT02862795|Other|HPV detection in anal canal samples|
2955810|NCT02862782|Experimental|hCG|Injection of hCG - Human Chorionic Gonadotropin (Ovitrelle 250 mcg mcg - Merck Serono)
2955811|NCT02862782|Experimental|hCG + GnRH agonist|Injection of hCG - Human Chorionic Gonadotropin (Ovitrelle 250 mcg mcg - Merck Serono) and GnRH agonist - Gonadotropin - releasing hormone (Decapeptyl 0.2mg - Ferring Gmgh)
2955812|NCT02862769|Experimental|Lidocaine infusion|first group (lidocaine group) will include those who receive a intraoperative lidocaine infusion (Induction bolus dose of 1.5 mg/kg body weight followed by a continous lidocaine infusion
2955813|NCT02862769|Placebo Comparator|Saline Infusion|The second group will include those who receive a intraoperative placebo i(Induction bolus dose of 1.5 mg/kg body weight of lidocaine followed by a continous saline infusion at the same rate as the lidocaine infusion.
2955814|NCT02862756|Experimental|patient with endovascular treatment|
2955815|NCT02862743|Experimental|patients with metastatic melanoma|patients with metastatic melanoma (stage III unresectable or stage IV)
2955816|NCT02862730|Experimental|Predictive Low Glucose Suspend Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient. The predictive low glucose suspend system will run through the artificial pancreas controller in predictive low glucose suspend mode and utilize the patient's optimized basal rates, correction factor, and carb ratio, but it will have the additional safety net of the pump suspending insulin when it predicts a hypoglycemic event.
2955817|NCT02862730|Experimental|Dual Hormone Closed-loop Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient using the closed-loop artificial pancreas controller in dual hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery and an increase in glucagon delivery upon detection.
2955818|NCT02862730|Experimental|Single Hormone Closed-loop Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient using the closed-loop artificial pancreas controller in single hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery upon detection.
2955819|NCT02862730|Active Comparator|Sensor Augmented Pump Therapy arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient with subject's insulin pump and glucose sensor, if he/she typically uses one. Subjects will still wear a heart rate monitor uploading to a smart phone.
2955820|NCT02862717||Hemodialysis (HD)|HD patients in MOH dialysis centres notified to NRR.
2955821|NCT02862717||Continuous ambulatory peritoneal dialysis (CAPD)|CAPD patients in MOH dialysis centres notified to NRR.
2955853|NCT02862496||hyperemesis gravidarum|hyperemesis gravidarum group consisting of 30 pregnant women between 7-20 weeks of gestation with diagnosed hyperemesis gravidarum.
2955892|NCT02862249|Placebo Comparator|Placebo|Placebo solution.
2955822|NCT02862704|Experimental|MG7-CART|A single dose of MG7-CART cells will be administered by intra-tumor injection under ultrasound guidance. The dose is 1-6x108 MG7-CAR positive T cells. The infusion will be scheduled to occur 2 days after two doses of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures. The cells perfusion process would lasts 1min to 2min, and an interventional radiologist would operate the cell infusion.
2955823|NCT02862691|Active Comparator|Oral analgesic|2 tablets of acetaminophen 325 mg/ oxycodone 5 mg orally once
2955824|NCT02862691|Experimental|Injectable local anesthetic|local injection or nerve block with bupivicaine 0.5%
2955825|NCT02862678|Experimental|Patients with head and neck squamous cell carcinoma|
2955826|NCT02862665|Experimental|IV iron|The patients will receive iron isomaltoside 1000 (Monofer®) as an i.v. infusion of 1000 mg (diluted with normal saline, 10 mg/ml) twice; 3 days before surgery and 3 days after surgery. They will receive iron isomaltoside 1000 (Monofer®) 1000 mg over 15 min.
2955827|NCT02862665|Placebo Comparator|Control|The patients will receive normal saline 100 ml as an i.v. infusion twice; 3 days before surgery and 3 days after surgery. They will receive normal saline 100 ml over 15 min.
2955828|NCT02862652|Experimental|children with acute lymphoblastic leukemia|
2955829|NCT02862639|Experimental|injection of viscosupplementation and corticosteroid|experimental group
2955830|NCT02862639|Active Comparator|injection of corticosteroid|control group
2955831|NCT02862613|Experimental|Precision Cells|"Precision Cells combined with Transcatheter Arterial Chemoembolization:~Transcatheter Arterial Chemoembolization:~patients will receive MMC,EADM hepatic arterial infusion,6 cycles. Precision Cells：After accepting concurrent TACE treatment,patients will receive 3 cycles of Precision Cells treatment"
2955832|NCT02862613|Active Comparator|Transcatheter Arterial Chemoembolization|patients will receive MMC,EADM hepatic arterial infusion,6 cycles.
2955833|NCT02862600|Experimental|Perhexiline|Perhexiline will be administered orally. Dosing will be determined based on plasma level monitoring. For the first 8 week period, the target range will be 100-300 ng/mL, for the second 8 week period, the target range will be 300-500 ng/mL.
2955834|NCT02862587|Experimental|Precision Cells|"precision cells combined with Chemotherapy treatment:~Chemotherapy:~once a week with a total of six times before 60 days prior to the start of drawing blood. precision cells：once per 3 weeks with a total of three periods."
2955835|NCT02862587|Active Comparator|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
2955836|NCT02862574|Experimental|Andecaliximab 300 mg|Andecaliximab 300 mg for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
2955837|NCT02862574|Experimental|Andecaliximab 150 mg|Andecaliximab 150 mg + placebo for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
2955838|NCT02862574|Placebo Comparator|Placebo|Placebo weekly for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
2955839|NCT02862574|Experimental|Open-Label Extension|On the Week 12 visit, eligible participants may choose to participate in the open-label portion of the study to receive open-label andecaliximab 300 mg for 52 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
2955840|NCT02862561|Experimental|Precision Cell Immunotherapy|"Precision Cells combined with Chemotherapy treatment: Chemotherapy:~once a week with a total of six times before 60 days prior to the start of drawing blood. Precision Cells：once per 3 weeks with a total of three periods."
2955841|NCT02862561|Active Comparator|Chemotherapy|"Chemotherapy:~once a week with a total of six times before 60 days prior to the start of drawing blood."
2955842|NCT02862548|Experimental|TAF|TAF for 48 weeks
2955843|NCT02862548|Active Comparator|TDF|TDF alone or in combination with other approved antivirals per local practice for 48 weeks
2955844|NCT02862548|Experimental|Optional Treatment Extension Phase|After Week 48, participants will be eligible to receive TAF for an additional 96 weeks.
2955845|NCT02862535|Experimental|Andecaliximab Monotherapy (Cohort 1)|Up to 6 participants will receive andecaliximab 800 mg until disease progression. If 2 or more participants experience dose limiting toxicities (DLT) within the first 28 days, up to 6 additional participants will be enrolled to receive andecaliximab 600 mg. If 2 additional DLTs occur at 600 mg, the study will be discontinued.
2955846|NCT02862535|Experimental|Combination Therapy Andecaliximab and SP (Cohort 2)|Up to 6 participants will receive andecaliximab 800 mg until disease progression in combination with S-1 plus cisplatin (SP) chemotherapy (dosage and regimen will be based on participant condition, investigator discretion, institutional practice and/or the in-country label). The dose of andecaliximab is based on safety data from cohort 1.
2955847|NCT02862535|Experimental|Combination Therapy Andecaliximab and SOX (Cohort 3)|Up to 10 participants will receive andecaliximab 1200 mg until disease progression in combination with 80 mg/day to 120 mg/day S-1 depending on body surface area (BSA) plus 100mg/m^2 oxaliplatin (SOX) chemotherapy. The dose of andecaliximab is based on safety data from cohort 1 and other ongoing phase 1 studies of andecaliximab.
2955848|NCT02862535|Experimental|Combination Therapy Andecaliximab and Nivolumab (Cohort 4)|Up to 10 participants will receive andecaliximab 800 mg until disease progression in combination with 3 mg/kg nivolumab chemotherapy. The dose of andecliximab is based on safety data from cohort 1.
2955849|NCT02862522||Women With CED|All subjects had blood work with included measurement of C-reactive protein, complete blood count with differential, basic chemistry panel, and uric acid level. All subjects completed a standardized questionnaire to assess baseline characteristics. All subjects underwent comprehensive coronary endothelial function assessment. Subjects completed a questionnaire of overall health several years after the index coronary angiogram and endothelial function study.
2955850|NCT02862522||Women Without CED|All subjects had blood work with included measurement of C-reactive protein, complete blood count with differential, basic chemistry panel, and uric acid level. All subjects completed a standardized questionnaire to assess baseline characteristics. All subjects underwent comprehensive coronary endothelial function assessment. Subjects completed a questionnaire of overall health several years after the index coronary angiogram and endothelial function study.
2955851|NCT02862509|Experimental|Budesonide nasal instillation|budesonide(0.5mg/2ml) 1 respule plus normal saline solution 120ml instilled in vertex to floor position daily
2955852|NCT02862509|Placebo Comparator|Normal saline nasal instillation|Normal saline solution instilled in vertex to floor position daily
2955855|NCT02862483|Experimental|Experimental|Tamsulosin 0.2mg and Tadalafil 5mg
2955856|NCT02862483|Active Comparator|Comparator|placebo for Tamsulosin 0.2mg and Tadalafil 5mg
2955857|NCT02862457|Experimental|Epacadostat (Epacad)|Cycle 1 is a dose escalation study in which participants will receive 25, 100, or 300 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 with a washout on Days 6 and 7. On Day 8 of Cycle 1 participants will receive a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25, 100, or 300 mg of epacadostat orally BID on Days 8-28. For Cycles 2 through 35 participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and receive 25, 100, or 300 mg of epacadostat orally BID on Days 1-21.
2955858|NCT02862457|Experimental|Epacad+Pembrolizumab (Pembro)|For each 21-day cycle, participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and receive 25, 100, or 300 mg of epacadostat orally BID on Days 1-21 for a maximum of 35 cycles.
2955859|NCT02862457|Experimental|Epacad+Pembro+Cisplatin+Pemetrexed|For each 21-day cycle, participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for a maximum of 35 cycles. Participants will also receive a one-time IV infusion of 75 mg/m^2 Cisplatin and 500 mg/m^2 Pemetrexed on Day 1 for the first 4 cycles.
2955860|NCT02862457|Experimental|Epacad+Pembro+Carboplatin+Pemetrexed|For each 21-day cycle, participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for a maximum of 35 cycles. Participants will also receive a one-time IV infusion of Area Under the Curve (AUC) 5 Carboplatin and 500 mg/m^2 Pemetrexed on Day 1 for the first 4 cycles.
2955861|NCT02862457|Experimental|Epacad+Pembro+Carboplatin+Paclitaxel|For each 21-day cycle, participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for a maximum of 35 cycles. Participants will also receive a one-time IV infusion of AUC6 Carboplatin and 200 mg/m^2 Paclitaxel on Day 1 for the first 4 cycles.
2955862|NCT02862444||intervention group|Culturally Appropriate Intervention
2955863|NCT02862431|Experimental|Cohort 1 (JNJ-64565111 2.5 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 2.5 Nanomole Per Kilogram (nmol/kg) JNJ-64565111 or placebo.
2955864|NCT02862431|Experimental|Cohort 2 (JNJ-64565111 3 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 3.0 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
2955865|NCT02862431|Experimental|Cohort 3 (JNJ-64565111 3.5 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 3.5 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
2955866|NCT02862431|Experimental|Cohort 4 (JNJ-64565111 Repeat or Lower Dose or Placebo)|Participants in ratio of 3:1 will receive a dose of JNJ-64565111 or placebo that would be a repeat or lower dose level previously assessed as well-tolerated.
2955867|NCT02862418||Pulmonary disease|UTE MRI
2955868|NCT02862418||Control|UTE MRI
2955869|NCT02862405||Patients with loss of central vision|Patients coming in ophthalmic consultation will be selected for the study. The diagnosis of this disease is based on clinical examination, and imaging of the retina.Patients with only loss of central vision will be selected.
2955870|NCT02862405||Patients with loss of peripheral vision|Patients coming in ophthalmic consultation will be selected for the study. Patients with loss of peripheral vision will be selected on the bases of presence of tunnel vision.
2955871|NCT02862405||Control group|Patients without loss of vision.
2955872|NCT02862379|Experimental|Elderly patients that fall|Personalized rehabilitation program for elderly patients that fall for the first time. This intervention is a home-based program combining exercises, home modifications and education on fall risk factors.
2955873|NCT02862366||Primary Myelofibrosis (PMF)|Blood sampling during routine visit
2955874|NCT02862366||Essential thrombocytosis (ET)|Blood sampling during routine visit
2955875|NCT02862366||Polycythemia vera (PV)|Blood sampling during routine visit
2955876|NCT02862353||patients with thrombocytopenia drug|
2955877|NCT02862340|Other|Autistic disorder|Children over 4 years with an autistic disorder of unknown etiology with the techniques currently available and accessible in routine diagnostics.
2955878|NCT02862327|Active Comparator|intravenous dexamethasone|intravenous injection of 8mg (2ml) of dexamethasone during regional anesthesia
2955879|NCT02862327|Placebo Comparator|intravenous placebo|intravenous injection of 2ml of NaCl 0.9% during regional anesthesia
2955880|NCT02862314|Experimental|procalcitonin group|The procalcitonin concentration is measured at inclusion.
2955881|NCT02862314|No Intervention|control group|Concentrations of procalcitonin are not measured. .
2955882|NCT02862301|Other|Control group|Healthy volunteers, free of any inflammatory disease. A blood sample is performed on the day of inclusion.
2955883|NCT02862301|Experimental|CIS group|patients with Clinically isolated syndrome. A blood sample is performed on the day of inclusion and after 3 months.
2955884|NCT02862288|Experimental|Renal tumor|Microwave ablation of renal tumor
2955885|NCT02862288|Experimental|Lung tumor|Microwave ablation of lung tumor
2955886|NCT02862288|Experimental|Bone tumor|Microwave ablation of bone tumor
2955887|NCT02862275|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 30- 60 minutes on day 1. Courses repeat every 21 days for a total of 17 doses over up to 12 months in the absence of disease progression or unacceptable toxicity.
2955888|NCT02862262||Blinded, Prospective Arm (1)|Clinical performance for the detection of B. pertussis and B. parapertussis will be evaluated in prospectively collected, de-identified, left-over, clinical specimens.
2955889|NCT02862262||Blinded, Pre-selected Arm (2)|In the event that an insufficient number of positive specimens are acquired for B. pertussis / B. parapertussis in Arm 1, clinical performance will be tested using banked, pre-selected, positive clinical specimens.
2955890|NCT02862262||Blinded, Contrived Arm (3)|Contrived specimens will be tested to evaluate detection of B. parapertussis in the event that an insufficient number of positive specimens are acquired in Arm 2.
2955891|NCT02862249|Experimental|Faecal microbiota transplantation|Faecal microbiota transplantation.
2955893|NCT02862236|Experimental|Hypericum perforatum extract (Remotiv, 250 mg)|
2955894|NCT02862236|Experimental|Hypericum perforatum extract (Remotiv, 500 mg)|
2955895|NCT02862236|Experimental|Alprazolam (Xanagis, 0.25 mg)|
2955896|NCT02862223|Experimental|Neoprinol|
2955897|NCT02862210|Experimental|Lithium carbonate|Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
2955898|NCT02862210|Placebo Comparator|Placebo|Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels provided by an unblinded study team member.
2955899|NCT02862197||study group|hemodialysis treated patients as described in the inclusion of the study
2955900|NCT02862171|Experimental|Dapivirine Vaginal Ring-004|Dapivirine Vaginal Ring, 25 mg.Each participant will engage in the screening process for up to 45 days prior to enrolment and will use the monthly Dapivirine Vaginal Ring for a period of up to 12 months. IPM will have the option to extend this trial period.
2955901|NCT02862158|Experimental|Experimental|FDT visual field will be compared to standard HVF in detecting glaucomatous visual field loss
2955902|NCT02862145|Experimental|Treatment with MRX34|Liposomal Injection of MRX34 for 5 days followed by 16 days rest with premedication of dexamethasone daily.
2955903|NCT02862132|Experimental|Vedolizumab|IV Vedolizumab 177mg/m2 Body Surface Area (BSA), max. 300mg Induction regimen: 0,2,6 and then every 8 weeks
2955904|NCT02862119|Experimental|FFR Treatment Arm|"Following PCI of the infarct related artery it is up to the PCI operator to perform FFR-guided PCI of non-infarct related lesion(s) during the index procedure or later during the index hospital admission. For stenosis grade 90-99% FFR is not mandatory (but recommended). An FFR value of ≤0.80 is to be considered significant for ischemia with a recommendation that non-culprit PCI is performed. It is up to the operator to decide whether to use intra-venous or intracoronary adenosine during FFR. An FFR of >0.80 is to be considered non-significant for ischemia with a recommendation that medical management is pursued.~Pressure wires: Only Fractional Flow Reserve pressure wires from St Jude Medical or Boston Scientific can be used in this study."
2955905|NCT02862119|Active Comparator|Conservative Treatment Arm|Only the infarct-related artery will be treated with PCI in this treatment arm during the index hospital admission. Medical therapy for angina pectoris is at the investigators discretion. Clinical follow-up of symptoms is recommended, but it is also acceptable to make a plan at hospital discharge for a later outpatient non-invasive stress-test. It is not acceptable to plan for an elective PCI in this treatment arm without signs of ischemia or symptoms.
2955906|NCT02862106|Experimental|εPA-44 900μg group-placebo|These subjects from the placebo group of protocol 71006.01 InjectεPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
2955907|NCT02862106|Experimental|εPA-44 900μg group-εPA-44 600μg|These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
2955908|NCT02862106|Experimental|εPA-44 900μg group-εPA-44 900μg|These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
2955909|NCT02862106|No Intervention|Follow-up group-placebo|These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only
2955910|NCT02862106|No Intervention|Follow-up group-εPA-44 600μg|These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only
2955911|NCT02862106|No Intervention|Follow-up group-εPA-44 900μg|These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only
2955912|NCT02862093|Active Comparator|Deep rTMS|The intervention consisted of deep rTMS of dorsolateral prefrontal cortex through the Brainsway Deep TMS System using an H-shaped coil . The motor threshold was measured by delivering a single pulse to the motor cortex. The site of stimulation was located 5.5 cm anterior to the point at which maximum stimulation of the abductor pollicis brevis muscle was reached. Each patient received a total of 12 rTMS sessions (three sessions per week): 20 trains per session at an intensity of 100% of the motor threshold, 50 pulses per train at a frequency of 10 Hertz, an inter-train interval of 15 seconds.
2955913|NCT02862093|Placebo Comparator|Placebo|The sham stimulation consisted of rTMS sessions without an effective instrument operation.
2955914|NCT02862054|Experimental|Splenectomy|Splenectomy as a treatment for patient with relapsed haemophagocytic lymphohistiocytosis of unknown etiology
2955915|NCT02862041|Active Comparator|Group Echogenic|Ultrasound guided infraclavicular brachial plexus block with Pajunk sonoplex echogenic needle
2955916|NCT02862041|Placebo Comparator|Group Nonechogenic|Non echogenic needle group, ultrasound guided infraclavicular brachial plexus block with Stimuplex Braun non echogenic needle
2955917|NCT02862028|Experimental|HerinCAR-PD1 cells|Patients will receive 3 cycles of HerinCAR-PD1 cells treatment.
2955918|NCT02862015|Experimental|Oncothermia|Patients with oncothermia treatment and palliative chemotherapy
2955919|NCT02862015|Active Comparator|Control|Patients with palliative chemotherapy only
2955920|NCT02862002|Experimental|"Therapeutic Patient Education (E.T.P)of type caratif"|Patients in arm E.T.P benefit of the nursing consultation E.T.P,
2955921|NCT02862002|Active Comparator|standard care|patients receiving standard care of cancer pain.
2955922|NCT02861989||Osteoporotic women|women over 50 years with a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
2955923|NCT02861989||At risk women|women over 50 years without a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
2955924|NCT02861989||Osteoporotic men|Men over 60 years with a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
2955925|NCT02861989||At-risk men|Men over 60 years without a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
2955926|NCT02861989||General practitioners|General practitioners from the Rhône area, France
2955927|NCT02861963|Experimental|Right ventricle outflow tract reconstruction|RVOT reconstruction used femoral allogenic vein valve conduit through ventricular fibrillation and without VSD closure
2955928|NCT02861963|Active Comparator|Systemic-to-pulmonary artery shunts|systemic-to-pulmonary artery shunts (modified Blalock-Taussig shunt or central shunts)
2955929|NCT02861950|Active Comparator|Caudal block|Patients will receive a caudal block with 0.75-1ml/kg of 0.2% ropivacaine.
2955930|NCT02861950|Active Comparator|Penile Nerve Block|Patients will receive a dorsal penile nerve block with up to 0.75ml/kg of 0.25% bupivacaine.
2955931|NCT02861937|No Intervention|healthy|
2955932|NCT02861937|Active Comparator|chronic gingivitis|Chronic gingivitis was defined as having probing depth (PD) less than or equal to 4mm, relative attachment loss (RAL) ) less than or equal to 3mm and more than to 25% sites with gingival bleeding present (BOP)
2955933|NCT02861937|Active Comparator|chronic periodontitis|Chronic periodontitis was defined as having probing depth more than or equal to 5mm, RAL more than or equal to 8mm, with more than or equal to 10% sites with BOP positive and evidence of bone loss determined radiographically.
2955934|NCT02861924|Experimental|microcirculatory responses|"Measure microcirculatory responses after localized ischemia obtained by local application of pressure (laser speckle).~A pressure is applied to the subject's arm. this causes a localized ischemia. the measures responses to this ischemia will be made by the imager speckle (LSCI) give the microvascular perfusion data."
2955935|NCT02861911|Sham Comparator|Control group|The current intensity is generally defined between the sensory and motor threshold (patients feel the power but no visible muscle contraction will be obtained).
2955936|NCT02861911|Active Comparator|Active NMES group|Tthe current intensity must always meet and exceed the motor threshold (patients feel the current and quadriceps muscle will contract a visible and quantifiable if possible).
2955937|NCT02861898|Experimental|Intra-arterial Cetuximab after BBBD|Mannitol 20% 12.5ml over two minutes for Blood Brain Barrier (BBB) disruption followed by CTX administered intra-arterially for three doses at a dose of 250mg/m2
2955938|NCT02861885||Lesion SSL|Patient cohort referred by colonoscopy screening indication, digestive syndrome or monitoring, with ascendant colon macroscopic SSL suspicion throughout white light during colonoscopy
2955939|NCT02861872||IP Patients|women, aged younger than 70 years, who will receive standard IP chemotherapy for advanced epithelial ovarian cancer, who are in an adequate physical and biochemical state to receive chemotherapy will be studied.
2955940|NCT02861859|Placebo Comparator|Placebo Comparator|"Eligible patients at high personal risk of CIVN will receive Standard of Care Regimen: Aprepitant (125 mg PO OD day 1, 80mg OD days 2-3), ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine placebo (PO OD days 1-4).~Eligible patients at low personal risk of CIVN will receive Standard of Care Regimen: Ondansetron (8mg PO, BID on Day 1 of each cycle,), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine placebo (PO OD days 1-4)."
2955941|NCT02861859|Active Comparator|Olanzapine|"Eligible patients at high personal risk of CIVN will receive Standard of Care Regimen: Aprepitant (125 mg PO, OD day 1, 80mg OD days 2-3), ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine (5 mg PO OD days 1-4).~Eligible patients at low personal risk of CIVN will receive Standard of Care Regimen: Ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine (5 mg PO OD days 1-4)."
2955942|NCT02861846|Other|Presence of biomarkers of AD in cerebrospinal fluid|Patients older than 60 years, with normal brain MRI and with normal cognitive functioning who demonstrate a profile of CSF biomarkers of AD suggestive of biological AD
2955943|NCT02861833||Patients with a cancerous wound|major patients followed in a cancer ward and holders of a cancerous wound.
2955944|NCT02861820||Substance Use Disorder (SUD)|"Participants in the SUD group will:~Complete a diagnostic screening interview at baseline.~Complete questionnaires and computer tasks at baseline, 1 month and 2 month time points.~Complete MRI brain imaging data collection at the baseline, 1 month and 2 month time points.~Complete 9 follow-up phone calls to assess for relapse."
2955945|NCT02861820||Healthy Control (HC)|"Participants in the HC group will:~Complete a diagnostic screening interview at baseline.~Complete questionnaires and computer tasks at baseline and 2 month time points.~Complete MRI brain imaging data collection at the baseline and 2 month time points."
2955946|NCT02861807|Experimental|Active stimulation with mindfulness|Brain stimulation with mindfulness-based relapse prevention. Treatment sessions will be 2 hours for 8 sessions, with the first 30 minutes consisting of transcranial direct current stimulation (tDCS) with the current set to 2.0 milliamps (mA) and guided meditation practice.
2955947|NCT02861807|Sham Comparator|Sham brain stimulation with mindfulness|Brain stimulation with mindfulness-based relapse prevention. Treatment sessions will be 2 hours for 8 sessions, with the first 30 minutes consisting of transcranial direct current stimulation (tDCS) with the current set to ramp up to 2.0 milliamps (mA) and then ramp down to 0.0 mA and guided meditation practice.
2955948|NCT02861794|Other|GMK Sphere|Patients receive a GMK Sphere Total Knee Replacement.
2955949|NCT02861781||Type 2 diabetes|Type 2 diabetes according to ADA criteria
2955950|NCT02861781||Insulin resistance non diabetes|HOMA-IR criteria ≥ 3
2955951|NCT02861781||Insulin sensitivity non diabetes|HOMA-IR criteria < 3
2955952|NCT02861768|Experimental|diagnosis of M.tuberculosis infection|
2955953|NCT02861755|Experimental|Arm 1|The MARIGOLD positive emotions course plus a blend of enhancements to include: 5-minutes of weekly facilitator contact, online discussion board, or gamification through virtual flower badges.
2955954|NCT02861755|Experimental|Arm 2|Emotion reporting control condition. Reporting daily emotions for the same duration of the online emotions course.
2955955|NCT02861742|Other|Study procedure|Delivery of questionnaires, Questionnaire T1 to fill, Questionnaire T2 to fill, Questionnaire T3 to fill, Questionnaire T4 to fill, Questionnaire T5 to fill
2955956|NCT02861729|Experimental|Suprinity|Vita Suprinity® (VITA Zahnfabrik H. Rauter GmbH & Co.KG- Germany) Zirconia reinforced lithium silicate PCRs
2955957|NCT02861729|Active Comparator|e.max|IPS-e.max® CAD (Ivoclar Vivadent AG, Schaan - Liechtenstein) lithium disilicate PCRs
2955958|NCT02861716|Experimental|fentanyl and dexmedetomidine|intrathecal bupivacaine (0.5%) 0.4mg/kg plus fentanyl and dexmedetomidine in 2ml volume will be injected slowly over 20 seconds.
2955959|NCT02861716|Active Comparator|dexmedetomidine and placebo for fentanyl|intrathecal bupivacaine (0.5%) 0.4mg/kg plus dexmedetomidine 0.2 μg/kg in 2ml volume and placebo (for fentanyl 0.2 μg/kg) it will be injected slowly over 20 seconds.
2956020|NCT02861313|Active Comparator|ball attachment|ball attachment other names metallic ball attachment
2955960|NCT02861716|Active Comparator|fentanyl and placebo for dexmedetomidine|intrathecal bupivacaine (0.5%) 0.4mg/kg plus fentanyl 0.2 μg/kg in 2ml volume and placebo (for dexmedetomidine 0.2 μg/kg) it will be injected slowly over 20 seconds.
2955961|NCT02861703|Experimental|Face-to-face lifestyle intervention|"A weekly psychosocial intervention (Face-to-face Lifestyle Intervention) delivered in a face-to-face group format, to promote positive changes in physical (eating habits, physical activity) and mental health (body image, self-esteem, self-efficacy)."
2955962|NCT02861703|Experimental|Online lifestyle intervention|"A weekly psychosocial intervention (Online Lifestyle Intervention) delivered in an online group format, to promote positive changes in physical (eating habits, physical activity) and mental health (body image, self-esteem, self-efficacy)."
2955963|NCT02861703|No Intervention|Wait-list control|Reading materials on health-promotion post-breast cancer will be provided to participants in the wait-list control, while they await active participation in one of the treatment arms.
2955964|NCT02861690|Experimental|Treatment group|patients received Liposomal Paclitaxel and Nedaplatin every 21 days until the presence of progressive disease or unacceptable toxicity
2955965|NCT02861677|No Intervention|Control group|The control group will receive the usual medical care by physicians and nurses
2955966|NCT02861677|Experimental|Intervention group|the intervention group will receive clinical pharmacy services
2955967|NCT02861664|Experimental|Test Dentifrice: Stannous fluoride (SnF2)|Participants were instructed to apply a strip of dentifrice containing 0.454% stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF) (1450 parts per million [ppm] fluoride in total) to cover the head of the toothbrush and brush their teeth for 1 timed minute, twice daily (morning and evening), following their normal routine. Participants were also permitted to rinse with tap water.
2955968|NCT02861664|Active Comparator|Negative Control Dentifrice: Sodium monofluorophosphate (SMFP)|Participants were instructed to apply a strip of dentifrice containing 1400ppm fluoride as sodium monofluorophosphate (SMFP) to cover the head of the toothbrush and brush their teeth for 1 timed minute, twice daily (morning and evening), following their normal routine. Participants were also permitted to rinse with tap water.
2955969|NCT02861638|Experimental|Experimental group|Video of the exercises and conventional physiotherapy. 30 minutes twice a day, 5 days a week for 2 weeks.
2955970|NCT02861638|Active Comparator|Control group|Video of nature scenes and conventional physiotherapy. 30 minutes twice a day, 5 days a week for 2 weeks.
2955971|NCT02861625||Group A|letter of condolence offering to the reliable person a post-death consultation with the reference physician (sent between J15 and J30 post death)
2955972|NCT02861625||Group B|no intervention, i.e without a letter of condolence proposing a consultation with the reference physician
2955973|NCT02861612||Nerve Transfer|This is an observational study that looks at function and quality of life in patients before and after nerve transfer surgery.
2955974|NCT02861599|Experimental|proprioceptive therapy|
2955975|NCT02861599|Placebo Comparator|speech therapy|
2955976|NCT02861586|Experimental|Treatment Group A; MV-CHIK low|"60 subjects will receive i.m. vaccinations with MV-CHIK low dose (5xE4 (± 0.5 log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
2955977|NCT02861586|Active Comparator|Treatment Group A/C; Priorix®|"20 subjects will receive i.m. vaccinations with Priorix® on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
2955978|NCT02861586|Experimental|Treatment Group B; MV-CHIK low|"60 subjects will receive i.m. vaccinations with placebo on study day 0. MV-CHIK low dose (5xE4 (± 0.5 log) TCID50 per 0.3 mL) on day 28 and MV-CHIK boosting dose on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
2955979|NCT02861586|Active Comparator|Treatment Group B/D; Priorix®|"20 subjects will receive i.m. vaccinations with placebo on study day 0, Priorix® on day 28 and one boosting dose with Priorix® on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
2955980|NCT02861586|Experimental|Treatment Group C; MV-CHIK high|"60 subjects will receive i.m. vaccinations with MV-CHIK high dose (5xE5 (± 0.5 log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
2955981|NCT02861586|Experimental|Treatment Group D; MV-CHIK high|"60 subjects will receive i.m. vaccinations with placebo on study day 0, MV-CHIK high dose (5xE5 (± 0.5 log) TCID50 per 0.3 mL) on study day 28 and MV-CHIK boosting dose on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
2955982|NCT02861586|Experimental|Measles Booster Group 1|"20 subjects will receive i.m. vaccinations with Priorix® on study day -28, MV-CHIK on day 0 and 28 and placebo on day 168 and 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
2955983|NCT02861586|Experimental|Measles Booster Group 2|"20 subjects will receive i.m. vaccinations with Priorix® on study day -28, placebo on day 0 and 28 and MV-CHIK on day 168 and 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
2955984|NCT02861573|Experimental|Pembrolizumab + Olaparib|Participants in Cohort A will receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week dosing cycle (Q3W) and olaparib 400 mg capsules or 300 mg tablets by mouth (PO) twice a day (BID) continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue until progression or a maximum of 35 treatment cycles (up to 2 years). Treatment with olaparib will continue until progression. Participants who must discontinue 1 of the 2 drugs in the combination due to adverse events may continue the study with the other combination drug.
2956018|NCT02861326|Other|Patients|Non-surgical periodontal treatment has performed to patients. Scaling and root planing were performed with Gracey curettes until the operator feels that root surface is clean, hard and smooth.
2956019|NCT02861313|Experimental|CM LOC attachment|CM LOC attachment other names: resin matrix attachment
2955985|NCT02861573|Experimental|Pembrolizumab + Docetaxel + Prednisone|Participants in Cohort B will receive pembrolizumab 200 mg IV on Day 1 Q3W, docetaxel 75 mg/m^2 IV on Day 1 Q3W, and prednisone 5 mg tablet PO BID continuously from Day 1 of Cycle 1. Participants will only be permitted to receive a maximum of 10 cycles of docetaxel and prednisone. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
2955986|NCT02861573|Experimental|Pembrolizumab + Enzalutamide|Participants in Cohort C will receive pembrolizumab 200 mg IV on Day 1 Q3W and enzalutamide 160 mg PO every day (QD) continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue until progression or a maximum of 35 treatment cycles (up to 2 years). Treatment with enzalutamide will continue until progression. Participants who must discontinue 1 of the 2 drugs in the combination due to adverse events may continue the study with the other combination drug.
2955987|NCT02861573|Experimental|Pembrolizumab + Abiraterone + Prednisone|Participants in Cohort D will receive pembrolizumab 200 mg IV on Day 1 Q3W, abiraterone acetate 1000 mg PO QD and prednisone 5 mg tablet PO BID continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
2955988|NCT02861560|Experimental|dHACM|Dehydrated human amnion/chorion membrane (dHACM)
2955989|NCT02861547||Traumatic brain injury|
2955990|NCT02861534|Experimental|Vericiguat|Starting dose of 2.5 mg taken orally once daily with food, on a background of standard of care. Dose will be uptitrated to 5 mg and to 10 mg.
2955991|NCT02861534|Placebo Comparator|Placebo|Starting dose of 2.5 mg taken orally once daily with food, on a background of standard of care. Dose will be uptitrated to 5 mg and to 10 mg.
2955992|NCT02861521|Experimental|Corrective shoe lift|Participants will be given an external shoe lift to correct post-operative leg length discrepancy (LLD).
2955993|NCT02861521|Sham Comparator|Sham shoe intervention|Participants will be given a sham shoe intervention that does not correct post-operative leg length discrepancy.
2955994|NCT02861508|Active Comparator|Usual care|Usual care as determined by treating team. Ultrasound may still be part of the workup per the treating team's discretion.
2955995|NCT02861508|Experimental|Early POCUS|Point-of-care ultrasound protocol will involve cardiac views (for pericardial effusion, left ventricular function, left and right ventricular equality, aortic root dilation, and inferior vena cava status), lung views (for pneumothorax, signs of alveolar interstitial syndrome), abdominal views for free fluid, and a view of the abdominal aorta for aneurysm.
2955996|NCT02861495|Experimental|humeral nail|Surgical fixation with a humeral compression/distraction nail.
2955997|NCT02861482|Experimental|Bakri Ballon|All the enrolled patients who would undergo the laying of Bakri Balloon
2955998|NCT02861469||Main carers|Individual semi-structured interviews
2955999|NCT02861469||General practitioners|Individual semi-structured interviews
2956000|NCT02861456|Active Comparator|Standard Care Group|Patient in the treatment arm will receive the Standard Model of Care as prescribed for their condition by their physician including but not limited to Advanced imaging, Rest, Bracing, Physical Therapy, and Medication.
2956001|NCT02861456|Experimental|Functional Progression Group|Patients who are randomized to the alternative model of care to guide treatment will not have advanced imaging done and will be referred directly to physical therapy care . If the patient is able to functional progress through phase I and II of physical therapy within 3 weeks and phase III within 5 weeks then they return to sport. If patient are unable to progress the are put on rest as a presumed vertebral injury (spondylolysis).
2956002|NCT02861430||Patients|
2956003|NCT02861417|Experimental|Group 1 Haploidentical Donor|Participants receive Busulfan, Cyclophosphamide, Fludarabine, Tacrolimus, Thiotepa, and Mycophenolate mofetil (MMF).
2956004|NCT02861417|Experimental|Group 2 Matched Related or Unrelated Donor|Participants receive Busulfan, Cyclophosphamide, Fludarabine, and Tacrolimus.
2956005|NCT02861417|Experimental|Group 3 Haploidentical Related Donor > 60|"Participants with a haploidentical related donor above 60 years old or comorbidity index score > 3.~Participants receive Busulfan, Cyclophosphamide, Fludarabine, Tacrolimus, Thiotepa, and Mycophenolate Mofetil (MMF)."
2956006|NCT02861417|Experimental|Group 4 Matched Related or Unrelated Donor > 60 years|"Patients with a fully matched related or unrelated donor above 60 years old or comorbidity index score > 3.~Participants receive Busulfan, Cyclophosphamide, Fludarabine, and Tacrolimus."
2956007|NCT02861417|Experimental|Group 5 Haploidentical Related Donor|"Patients receiving a haploidentical related donor transplant receive a lower dose of Thiotepa.~Participants receive Busulfan, Cyclophosphamide, Fludarabine, Tacrolimus, Thiotepa, and Mycophenolate Mofetil (MMF) and a stem transplant with cells from a haploidentical donor."
2956008|NCT02861404||Salicylate ointment|patients included in VRAIE study, treated with salicylate ointment (VRAIE study, NCT01059110)
2956009|NCT02861404||Imiquimod|patients included in VRAIE study, treated with Imiquimod (VRAIE study, NCT01059110)
2956010|NCT02861404||5-Fluoro-Uracil|patients included in VRAIE study, treated with 5-Fluoro-Uracil (VRAIE study, NCT01059110)
2956011|NCT02861404||Cryotherapy|patients included in VRAIE study, treated with cryotherapy (VRAIE study, NCT01059110)
2956012|NCT02861404||placebo|patients included in VRAIE study, receiving placebo (VRAIE study, NCT01059110)
2956013|NCT02861391|Experimental|CO2 AcuPulse Laser treatment|Subjects with USI as diagnosed in urodynamic testing intended to receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
2956014|NCT02861378|Experimental|Phentolamine mesylate|Once anesthesia is confirmed, subjects in the Phentolamine mesylate group will receive 1 injection of 1ml of a solution containing 0.24 mg of phentolamine mesylate in the same site that was previously anaesthetized (not as a part of the study).
2956015|NCT02861378|Placebo Comparator|Water|Once anaesthesia is confined, the subjects in the water group will receive 1 injection of 1 ml of sterile physiological water in the same site that was previously anaesthetized (not as a part of the study).
2956016|NCT02861352|Experimental|diet zinc|3 dietary zinc levels: 6 mg/d, 10 mg/d and 25 mg supplemental zinc/d
2956017|NCT02861339|Experimental|Keratoconus and IBD|Opthalmologic measure with DM OPD scan III (Nidek)
2956021|NCT02861300|Experimental|CB-839 + capecitabine|Patients will receive CB-839 orally twice daily for 21 days (continuous administration) and capecitabine orally twice daily for 14/21 days. In the phase I portion of the study, patients will receive escalating doses of CB-839 and capecitabine and will have day 15 blood samples drawn and archived for as needed assessment of CB-839 pharmacokinetics. In the phase II portion of the study, patients will receiving 800mg CB-839 and 1000mg/m^2 capecitabine as were determined to be safe doses during the phase I portion of the study. They will also undergo pre-treatment and post-treatment blood samples and tissue biopsies for evaluation of pharmacodynamic biomarkers.
2956022|NCT02861287||Study cohort|patients with Multiple Myeloma who underwent PBSC mobilization since December 2009 and who received plerixafor in line with inclusion criteria
2956023|NCT02861287||Historical cohort|patients with Multiple Myeloma who underwent PBSC mobilization immediately prior to marketing authorization and clinical utilization of Plerixafor which is before December 2009 (over the 2007-2009 period)
2956024|NCT02861274|Active Comparator|electrophysiological testing|Patients will receive a pacemaker.
2956025|NCT02861274|No Intervention|control group|These subjects will receive cardicor® (beta blockers).
2956026|NCT02861261|Experimental|Group A|
2956027|NCT02861261|Experimental|Group B|
2956028|NCT02861261|Experimental|Group C|
2956029|NCT02861261|Placebo Comparator|Group D|
2956030|NCT02861248|Experimental|Laser treatment|Fractional micro-plasma radiofrequency treatment given to 95 patients with non-hypertrophic burn scar.
2956031|NCT02861235|Experimental|1. stress thallium-201 tomoscintigraphy|
2956032|NCT02861235|Experimental|2. stress technetium-99m tomoscintigraphy 1|
2956033|NCT02861235|Experimental|3. stress technetium-99m tomoscintigraphy 2|
2956034|NCT02861235|Experimental|4. stress technetium-99m tomoscintigraphy 3|
2956035|NCT02861235|Experimental|5. rest thallium-201 tomoscintigraphy|
2956036|NCT02861235|Experimental|6. rest technetium-99m tomoscintigraphy|
2956037|NCT02861222|Experimental|MYOCET|2 treatments of doxorubicin are administered at 60 mg/m²/day or 75 mg/m²/day in single dose in 1-hour perfusion each 21 days. A maximum of 6 treatments/patient is administered.
2956038|NCT02861209|No Intervention|Non-care pathway|"This arm comprises patients before the implementation of the care pathway. Patients starting with an oral anticancer therapy participate in the current care process. Outcomes are assessed at start of treatment, after 1 and after 3 months.~The decision to start with an oral anticancer therapy depends solely on the treating physician."
2956039|NCT02861209|Experimental|Care Pathway|"This arm comprises patients after the implementation of the care pathway. Patients starting with an oral anticancer therapy in this arm, receive care as is described by the novel designed care pathway. Outcomes are again assessed at start of treatment, after 1 and after 3 months.~The decision to start with an oral anticancer therapy depends solely on the treating physician."
2956040|NCT02861196|Experimental|effective team|Patients who have response to neoadjuvant chemotherapy will be separated into two groups (GI cT0-1 and G2 ≥cT2). G1receive concurrent radiochemotherapy, and G2 receive partial resection of the bladder+lymphadenectomy+adjuvant radiotherapy.
2956041|NCT02861196|Experimental|ineffective or disagreed team|Patients who have no response to neoadjuvant chemotherapy or disagree to receive the sequential treatment will receive the radical resection of bladder.
2956042|NCT02861183|Experimental|OVT (Sodium Hyaluronate)|Sodium hyaluronate is supplied as a 2 mL unit dose in a 3 mL glass syringe.
2956043|NCT02861183|Placebo Comparator|Saline|0.9% sterile saline is supplied as a 2 mL unit dose in a 3 mL glass syringe.
2956044|NCT02861170|Experimental|Brief Mindfulness-Based Intervention|Participants in this arm will be provided with an educational brochure and links to videos containing strategies for coping with pain and anxiety as well as a 10-minute mindfulness-based intervention called a body scan at 3 different time-points (T1 - 1 week prior to surgery, T2 - within 4 hours before surgery, and T3 - approximately 24 hours after transfer from recovery to the orthopedic floor).
2956045|NCT02861170|No Intervention|Education|Participants in this arm will be provided with an educational brochure and links to videos containing strategies for coping with pain and anxiety.
2956046|NCT02861157|Experimental|TX Condition: Planet T1D Intervention|Families participating in the TX condition will be asked to attend a one-hour orientation session, during which study expectations and tasks will be explained. Families will be asked to watch a short 2-minute study overview video that summarizes study requirements and expectations. Parents and their children will then have the opportunity to provide informed consent/assent prior to their participation in the study. Youth participants will then receive a mobile phone preloaded with the Planet T1D app and a brief orientation to the app and associated website. Participants in the TX condition will receive immediate access to the Planet T1D application and website following the orientation session and will have four months to freely use the application. The TX group will be provided with a mobile phone for the full 2-months of the study.
2956047|NCT02861157|No Intervention|CO Condition: Treatment-As-Usual|A national sample of type 1 diabetes participants will be recruited through a partnership with Medikidz Ltd. Because of the inability to meet with remotely located participants for orientation and distribution of phones, these participants will be assigned to the treatment-as-usual, online control (CO) condition. For recruitment of the online control group, youth and parents interested in participating will be asked to complete a brief eligibility survey. Participants in the treatment-as-usual CO condition will not receive access to the Planet T1D app and website but will receive email reminders to complete surveys online at each time point.
2956048|NCT02861144|Other|Intervention|"Patient participants in the intervention arm will receive diabetes self-management program, Ma ka hana ka ̒ike which includes 5 interactive group sessions lasting 1-1/2 hours in length delivered by community peer educators once a month for 4.5 months. After 4.5 months, the patient will receive 4 monthly boosters by mail that will reinforce information from the Ma ka hana ka ̒ike program. Completion of diabetes process and glycemic outcomes will trigger the modest financial incentives.~Health care provider participants in the intervention arm will receive educational resources, Hanapū Provider Toolbox to guide their patients to optimal glycemic control.They will receive modest financial incentives when their patients complete clinical tests and achieve glycemic target."
2956119|NCT02860611||Type 2 Diabetes|Patients with type 2 diabetes
2956120|NCT02860611||Control|Healthy volunteers
2956049|NCT02861144|No Intervention|Usual Care|"Patient participants in the usual care arm will receive 5 mail-out diabetes self management education booklets endorsed by the American Diabetes Association (ADA) and the National Institute for Diabetes, Digestive and Kidney disease for 4.5 months. Patients will see their doctor according to usual care practice. After 4.5 months, the patients will receive 4 monthly boosters in mail reinforcing the previous mail-out diabetes self-management program materials.~Health care provider participants in the usual care arm will receive the latest ADA guidelines to use in their treatment plan of their patients."
2956050|NCT02861131|Experimental|Sugammadex|Sugammadex 2 mg/kg IV once at the end of surgery
2956051|NCT02861131|Active Comparator|Neostigmine|Neostigmine 0.07 mg/kg to a maximum of 5 mg (+ Glycopyrrolate 0.1-0.2 mg per 1 mg of Neostigmine administered) IV once at the end of surgery
2956052|NCT02861118||Cohort 1|Retrospective data will be collected from participants diagnosed with UC or CD that started biological treatment between June 2011 and June 2013 in Spain.
2956053|NCT02861105|Active Comparator|LMWH supplementation|40 mg of enoxaparin injected subcutaneously every 24 hours starting the day of ovum pick-up to the documentation of fetal life by ultrasound at 7 weeks of gestation
2956054|NCT02861105|Placebo Comparator|0.9% saline solution|0.9% saline injected subcutaneously every 24 hours starting the day of ovum pick-up to the documentation of fetal life by ultrasound at 7 weeks of gestation
2956055|NCT02861079|Experimental|Propess with Foley balloon catheter|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix and an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix
2956056|NCT02861079|Active Comparator|Propess vaginal ovule|10 mg PGE2 vaginal ovule will be inserted to the posterior fornix
2956057|NCT02861066|Experimental|Mindfulness-based Intervention|6 week, abbreviated group MBI treatment for depression and anxiety
2956058|NCT02861053|Experimental|chronic quiet inflammatory bowel disease patient (IBD)|Patient with chronic quiet inflammatory bowel disease patient (IBD) with regular and moderate physical activity
2956059|NCT02861053|Sham Comparator|chronic quiet inflammatory bowel disease Patient (IBD)|Patient with chronic quiet inflammatory bowel disease patient (IBD) with no regular and moderate physical activity more than usual
2956060|NCT02861040|Experimental|Treatment (volasertib, vincristine sulfate liposome)|Patients receive volasertib IV over 1 hour on day 1 and vincristine sulfate liposome IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression, development of an inter-current illness that prevents further administration of treatment, unacceptable toxicity, patient decides to withdraw or treating investigator determines that the patient should be taken off treatment for any reason.
2956061|NCT02861027|Active Comparator|PPTHA|Control Group performs the PPTHA.
2956062|NCT02861027|Experimental|FES and PPTHA|The Intervention Group performs the PPTHA associated with FES.
2956063|NCT02861014|Experimental|Ocrelizumab|Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
2956064|NCT02861001|Active Comparator|bronchoscopic guidance|optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy
2956065|NCT02861001|Experimental|tube mounted camera guidance|optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
2956066|NCT02860988|Experimental|MCCC treatment|Participants receive newly supported services to enhance fatherhood and parenting for individuals with substance use issues.
2956067|NCT02860975|Experimental|Inhaled Nitrogen|A humidified mixture of gas will be delivered by mask, nasal cannulae, and small room-sized tent. Inspiratory oxygen fraction (FiO2) will be gradually decreased to 11% over a period or five days to obtain a peripheral capillary O2 saturation (SpO2) between 80%-85% (corresponding to 40-55 mmHg of arterial partial oxygen pressure (PaO2)). Healthy volunteers will be monitored and blood and urine will be obtained at 24h and 48 hours after returning to normoxia.
2956068|NCT02860962|Active Comparator|Dextromethorphan|2 doses of Dextromethorphan 75mg oral (PO), separated by 4 hours
2956069|NCT02860962|Placebo Comparator|Placebo|2 doses of placebo (oral/PO), separated by 4 hours
2956070|NCT02860949|Experimental|LAI with PCI|Local anesthetic infiltration with posterior capsular injection (Drug inject at Anterior soft tissue, Medial gutter area, Lateral gutter area and Posterior capsular area)
2956071|NCT02860949|Active Comparator|LAI without PCI|Local anesthetic infiltration without posterior capsular injection (Drug inject at Anterior soft tissue, Medial gutter area and Lateral gutter area)
2956072|NCT02860936|Experimental|Lenvatinib|24 mg of lenvatinib will be administered daily to patients until progression of disease or intolerable toxicity or other criteria for discontinuation is met.
2956073|NCT02860923|Experimental|Exenatide|Treatment with exenatide at the initial dose of 5 µg x 2/day (subcutaneously administered) during 4 weeks, and treatment with 10 µg x 2/day during 5 months.
2956074|NCT02860923|Placebo Comparator|Placebo|Patients will be maintained on placebo (injected subcutaneously, twice a day) with the same dose and frequency than exenatide arm.
2956075|NCT02860910|Experimental|Cognitive Behavioral Group Therapy|"The six CBGT sessions are outlined in the manual entitled: Managing Hot Flushes with Group Cognitive Behaviour Therapy: An Evidenced-Based Treatment Manual for Health Care Professionals (Hunter & Smith, 2015) as follows:~Session 1: Psycho-education and the cognitive behavioural model Session 2: Stress management, improving wellbeing and identifying precipitants Session 3: Managing hot flushes using a cognitive behavioural approach Session 4: Managing night sweats and improving sleep (part one) Session 5: Managing night sweats and improving sleep (part two) Session 6: Review and maintaining changes (One alteration: Open discussion about mood disorders, anxiety and the psychological impact instead of the psychological impact of breast cancer)"
2956076|NCT02860897|Experimental|Vaginal estrogen cream|
2956077|NCT02860897|Experimental|Vaginal estrogen tablet|
2956078|NCT02860884||simple fatty liver|patients with fatty liver disease
2956079|NCT02860884||NASH|patients with nonalcoholic steatohepatitis
2956080|NCT02860858|Experimental|Aflibercept|
2956081|NCT02860845|Experimental|Boric acid and probiotics|
2956082|NCT02860845|Active Comparator|Antibiotic/Antifungal|
2956083|NCT02860819|Experimental|Gemcitabine, Carboplatin, Veliparib|Gemcitabine 800mg/m2 day 1 and 8 every 3 weeks; Carboplatin AUC = 4, day 1, every 3 weeks, Veliparib 250mg bid day continuously.
2956084|NCT02860806|Experimental|Part 1: Period 1 (JNJ‑63623872 100 mg or Placebo)|Participants will receive a single intravenous (IV) infusion of JNJ-63623872 100 milligram (mg) [3 milligram per milliliters (mg/mL) solution] (Treatment A) or matching placebo (Treatment D) over 120 minutes.
2956085|NCT02860806|Experimental|Part 1: Period 2 (JNJ‑63623872 200 mg or Placebo)|Participants will receive a single IV infusion of JNJ-63623872 200 mg (3 mg/mL solution) (Treatment B) or matching placebo (Treatment D) over 120 minutes.
2956086|NCT02860806|Experimental|Part 1: Period 3 (JNJ‑63623872 300 mg or Placebo)|Participants will receive a single IV infusion of JNJ-63623872 300 mg (3 mg/mL solution) (Treatment C) or matching placebo (Treatment D) over 120 minutes.
2956087|NCT02860806|Experimental|Part 2: Group 1 (EFG)|Participants will receive a single IV 300-mg infusion of JNJ-63623872 (3 mg/mL solution) over x minutes (Treatment E) followed by a single IV 300-mg infusion of JNJ-63623872 (3 mg/mL solution) over y minutes (Treatment F), then a single oral 600-mg dose (2* 300 mg tablets) of JNJ-63623872 under fasted conditions (Treatment G). Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
2956088|NCT02860806|Experimental|Part 2: Group 2 (FGE)|Participants will receive Treatment F, then Treatment G followed by Treatment E. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
2956089|NCT02860806|Experimental|Part 2: Group 3 (GEF)|Participants will receive Treatment G, then Treatment E followed by Treatment F. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
2956090|NCT02860806|Experimental|Part 2: Group 4 (GFE)|Participants will receive Treatment G, then Treatment F, followed by Treatment E. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
2956091|NCT02860806|Experimental|Part 2: Group 5 (FEG)|Participants will receive Treatment F, then Treatment E followed by Treatment G. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
2956092|NCT02860806|Experimental|Part 2: Group 6 (EGF)|Participants will receive Treatment E, then Treatment G followed by Treatment F. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
2956093|NCT02860806|Experimental|Part 3: JNJ-63623872 300 mg|Participants will receive multiple IV infusions of JNJ-63623872 300 mg (3 mg/mL) solution every 12 hours on Days 1 to 10, with only a morning dose on Day 10. Duration of infusion and dose will be selected after Part 2 of this study is completed.
2956094|NCT02860793|Experimental|AML patients at diagnosis|
2956095|NCT02860780|Experimental|Part A: prexasertib + ralimetinib|Prexasertib given intravenously (IV) and ralimetinib given orally.
2956096|NCT02860780|Experimental|Part B1: prexasertib + ralimetinib (colorectal cancer)|Prexasertib given IV and ralimetinib given orally.
2956097|NCT02860780|Experimental|Part B2: prexasertib + ralimetinib (NSCLC)|Prexasertib given IV and ralimetinib given orally.
2956098|NCT02860754|Other|Six-minute walk test|All patients will perform six-minute walk test before surgery, in the preoperative clinic
2956099|NCT02860741|Experimental|Intervention|Churches in the REJOICE intervention arm will provide the REJOICE intervention over an 8 week period
2956100|NCT02860741|Other|Control|Churches in the control arm will receive an educational materials about both identifying depressive symptoms and managing depressive symptoms. This is consistent with self-management interventions commonly utilized for individuals experiencing subclinical levels of depressive symptoms.
2956101|NCT02860728|Experimental|Resistance training|Patients with COPD will participate in 4 weeks (12 sessions) of individualized, non-linear, lower body resistance training.
2956102|NCT02860715|Experimental|Cohort 1|GX-I7 SC 20㎍/㎏ (8 subjects) / Placebo (2 subjects)
2956103|NCT02860715|Experimental|Cohort 2|GX-I7 SC 60㎍/㎏ (8 subjects) / Placebo (2 subjects)
2956104|NCT02860715|Experimental|Cohort 3|GX-I7 IM 60㎍/㎏ (8 subjects) / Placebo (2 subjects)
2956105|NCT02860702|Experimental|Exclusive Human Milk|All infants randomized to this arm will receive exclusive human milk diet with addition of human milk derived fortifier from birth to 30 days post initiation of feedings after initial palliative cardiac surgery
2956106|NCT02860702|Active Comparator|Human/Bovine Milk|All infants randomized to this arm will receive exclusive human milk diet prior to randomization and will use either human and/or bovine milk and fortifier per the institution's standard practice 30 days post initiation of feedings after initial palliative cardiac surgery
2956107|NCT02860676|Experimental|Cirmtuzumab|
2956108|NCT02860663|Active Comparator|Vitamin D3|10 ug/d of vitamin D3 for 6 weeks
2956109|NCT02860663|Active Comparator|Vitamin D2|10 ug/d of vitamin D2 for 6 weeks
2956110|NCT02860663|Active Comparator|25OHD|10 ug/ of 25OHD for 6 weeks
2956111|NCT02860650|Experimental|Group 1: AD26.Filo/MVA-BN-Filo or Placebo|Participants will receive Ad26.Filo or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 57.
2956112|NCT02860650|Experimental|Group 2: MVA-BN-Filo/AD26.Filo or Placebo|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.Filo or placebo on Day 57.
2956113|NCT02860650|Experimental|Group 3: MVA-BN-Filo/AD26.Filo or Placebo|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.Filo or placebo on Day 15.
2956114|NCT02860650|Experimental|Subset of Group 3: AD26.Filo or Placebo|The first 8 participants in Group 3 who are willing to enroll in the subset for third vaccination, will receive a third vaccination at Day 92. Participants who previously received placebo will receive placebo a third time and participants who previously received MVA-BN-Filo/Ad26.Filo vaccination will receive Ad26.Filo as third vaccination. After enrollment of the 8 participants, the unblinded monitor and unblinded pharmacist will assess whether 7 participants who previously received MVA-BN-Filo/Ad26.Filo vaccination have been enrolled. If less than 7 participants of the active vaccine regimen have been enrolled, 2 additional participants will be enrolled. If at least 7 participants of the active vaccine regimen have been enrolled, no further will be enrolled. The aim is to enroll 7 or 8 participants who will receive Ad26.Filo as third vaccination.
2956115|NCT02860650|Experimental|Group 4: Ad26.ZEBOV/MVA-BN-Filo or placebo|Participants will receive Ad26.ZEBOV or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 57.
2956116|NCT02860624|Experimental|10 mg ilaprazole|
2956117|NCT02860624|Active Comparator|40 mg esomeprazole|
2956118|NCT02860611||Type 1 Diabetes|Patients with type 1 diabetes
2956121|NCT02860598||Group 1|Patient with AML de novo or secondary myelodysplasia, in Complete Remission (CR) after induction and / or salvage therapy and candidate to receive a consolidation therapy
2956122|NCT02860598||Group 2|Patient with hematologic malignancies (ALL, AML, chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, myeloma, myeloproliferative syndrome (MDS)) and candidate for blood marrow or stem cell or placental blood transplantation.
2956123|NCT02860572|Experimental|follow-up without intervention|No intervention to increase the urine output within 2 hours will be done.
2956124|NCT02860572|Active Comparator|Standard group - fluid bolus|Patient will receive 500mL of balanced crystalloid intravenously over 30 minutes.
2956125|NCT02860559|Experimental|TBX-1400 treatment|Single intravenous infusion of TBX-1400
2956126|NCT02860546|Experimental|TAS-102 and Nivolumab|
2956127|NCT02860533|Experimental|Blood pressure measurement|six repetitive blood pressure measurements with iPhone and conventional oscillometric cuff device during stress testing will be performed
2956128|NCT02860507|Active Comparator|Neostigmine + Glycopyrrolate|Neostigmine 0.06 mg/kg and Glycopyrrolate 0.04mg/kg iv
2956129|NCT02860507|Experimental|sugammadex|Sugammadex 4mg/kg
2956130|NCT02860494|Experimental|Topical everolimus 0.1%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
2956131|NCT02860494|Experimental|Topical everolimus 0.5%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
2956132|NCT02860494|Experimental|Topical everolimus 1%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
2956133|NCT02860494|Placebo Comparator|Topical placebo|Topical placebo will be identical to the everolimus topical formulation. Topical placebo will be applied to the affected areas, once daily, in the evening, for 6 months by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
2956134|NCT02860481|Other|first cohort : first 100 patients|first cohort : first 100 patients 10 patients with ovarian and/or endometrial cancer 10 patients with colorectal cancer 10 patients with head and neck cancer 10 patients with uveal melanoma 40 patients with invasive breast cancer 10 patients with breast ductal carcinoma in situ 10 patients with other tumor type
2956135|NCT02860481|Other|second cohort : 100 patients|Patients with breast cancer of with ovarian and/or endometrial cancer
2956136|NCT02860468|Experimental|Cranberry juice consumption|participants in this arm will be provided cranberry juice to consume for 21 days in total
2956137|NCT02860468|Placebo Comparator|Placebo juice consumption|participants in this arm will be provided placebo juice to consume for 21 days in total
2956138|NCT02860455|Other|SpCO and COHb measurement|"SpCO measurement (Experimental) : Non invasive pulse CO-oximetry will be carried out in all patients simultaneously with venous blood sampling for standard laboratory blood gas analysis, at time of prehospital management by emergency medical services~COHb measurement (Active comparator) : Blood carboxyhemoglobin testing will be carried out in all patients"
2956139|NCT02860442|Experimental|Smartphone brief intervention (SP-BI)|
2956140|NCT02860442|Placebo Comparator|Enhanced Usual Care (EUC)|
2956141|NCT02860429|Experimental|Cinobufacini injection|"Capsule Dosage and frequency:This group receives cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.~Duration:6 chemotherapy cycles."
2956142|NCT02860429|Other|Control group|Only receive the same chemotherapy with the experimental groups.No Cinobufacini injection.And have the same adjuvant treatment with the experimental groups.
2956143|NCT02860403|Experimental|C6-C7 patients|C6-C7 patients able to recover tenodesis grasp.
2956144|NCT02860403|Experimental|C5-C6 patients|C5-C6 patients for whom surgery for rehabilitation of an upper limb is indicated with a upper limit of one year after trauma, and after complete clinical and functional evaluation
2956145|NCT02860403|No Intervention|Control group|a control group (n=6) matched on age and sex to C6-C7 without medical history or neurological disorder
2956146|NCT02860390|No Intervention|Adolescent - Control|Usual care arm of subjects aged 13-19 years old
2956147|NCT02860390|Experimental|Adolescent - SMS|Subjects aged 13-19 years and receiving Denver Health Asthma Management Program (text messaging intervention)
2956148|NCT02860390|Experimental|Adolescent - SMS plus support person|Subjects aged 13-19 years, Denver Health Asthma Management Program (text messaging intervention) sent to subjects and subjects' chosen Person of Support.
2956149|NCT02860390|No Intervention|Adult - Control|Usual care arm of subjects aged 20-40 years old.
2956150|NCT02860390|Experimental|Adult - SMS|Subjects aged 20-40 years and receiving Denver Health Asthma Management Program (text messaging intervention).
2956151|NCT02860377|Active Comparator|stranger's voice|At the end of surgery, patients were stimulated to wake up by recorded stranger's voice, which was recorded before the operation.
2956152|NCT02860377|Experimental|maternal voice|At the end of surgery, patients were stimulated to wake up by recorded maternal voice, which was recorded before the operation.
2956153|NCT02860364|Experimental|Mild Hypothermic Circulatory Arrest|During aortic hemiarch surgery, mild hypothermia (32°C) will be used during circulatory arrest.
2956154|NCT02860364|Active Comparator|Moderate Hypothermic Circulatory Arrest|During aortic hemiarch surgery, moderate hypothermia (26°C) will be used during circulatory arrest.
2956247|NCT02859597|Active Comparator|Nasal Cannula|Typical nasal cannula will be utilized to deliver oxygen to morbidly obese patients undergoing deep sedation for gastrointestinal procedures.
2956155|NCT02860338||GROUP 1- CNS Protocol|"Patients in a specialized dementia practice. Evaluated and treated for hypoxia, elevated BNP, hyperhomocysteinemia, B 12 deficiency as measured by elevated methymalonic acid, Vitamin D 25-OH deficiency, elevated CRP, and decreased IGF-1, and other metabolic abnormalities.~Treated with maximal doses of acetylcholinesterase inhibitors, memantine, methylfolate/methylB12/N-acetylcysteine, dextromethorphan/quinidine, and SSRI's; dose and duration based on protocol."
2956156|NCT02860338||GROUP 2- Community Care|Patients referred to a neuropsychology practice for cognitive evaluation and treated for MCI or dementia by their primary care clinician or non-dementia specialist according to specific provider's usual practice pattern.
2956157|NCT02860325|Experimental|NIV-NAVA|Patients allocated to non-invasive NAVA
2956158|NCT02860325|Active Comparator|Conventional|Patients allocated to nasal CPAP or non-synchronized nasal IPPV
2956159|NCT02860312|Active Comparator|Exercisers|Intradialytic exercise on stationary bicycles
2956160|NCT02860312|Placebo Comparator|Non Exercisers|No intradialytic exercise
2956161|NCT02860299|Experimental|Citrate lock|
2956162|NCT02860299|Active Comparator|Heparin lock|
2956163|NCT02860286|Experimental|Open-Label Tazemetostat|Oral Tazemetostat 800mg BID
2956164|NCT02860273|Experimental|High Flow Nasal Cannula Oxygen|"Incremental Load Treadmill Test (ILTT) using HFNCO at 21%~Constant Treadmill Load Test (CTLT) using HFNCO at 21%"
2956165|NCT02860273|Other|Control Group|"Incremental Load Treadmill Test (ILTT) at Room Air~Constant Treadmill Load Test (CTLT) at Room Air"
2956166|NCT02860260|Experimental|Patients with fibrinolysis|
2956167|NCT02860260|Placebo Comparator|Patients without fibrinolysis|
2956168|NCT02860234||Group A:Clinical complete response (cCR)|Patients who achieve cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Nonoperative Management(NOM).
2956169|NCT02860234||Group B:Near-cCR|Patients who achieve near-cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Local Excision(LE) or Nonoperative Management(NOM).
2956170|NCT02860234||Group C:Residual tumor|Patients with residual tumor when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Total Mesorectal Excision(TME).
2956171|NCT02860221|Experimental|Intravenous epinephrine|Intravenous (IV) low dose epinephrine
2956172|NCT02860221|Experimental|Topical epinephrine|Topical epinephrine
2956173|NCT02860221|Active Comparator|Control|No epinephrine
2956174|NCT02860208||3 years follow-up|all patients who received surgical treatment for peri-implantitis during a Randomized and Controlled Trial registered in ClinicalTrials.gov NCT NCT01857804
2956175|NCT02860195|Experimental|healthy volunteers|
2956176|NCT02860182||experimental|patients with acute type A dissection
2956177|NCT02860182||control|patients without any pathology of the ascending aorta, but having the same characteristics as the sick patients, in terms of age and vascular risk factors including high blood pressure
2956178|NCT02860169|Experimental|Participants with cold and flu|Eligible participants with cold and flu were instructed to answer the self administered questionnaire and participate in the assessment that included Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP
2956179|NCT02860169|Placebo Comparator|Healthy participants|Eligible healthy participants were instructed to answer the self administered questionnaire and participate in the assessment that included Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP
2956180|NCT02860156||HIV+/DD+|Subjects are HIV positive and have diastolic dysfunction
2956181|NCT02860156||HIV+/DD-|Subjects are HIV positive and do not have diastolic dysfunction
2956182|NCT02860156||HIV-/DD+|Subjects do not have HIV and have diastolic dysfunction
2956183|NCT02860143||studying ventilation during sedation|Comparing ventilation during sedation with capnography
2956184|NCT02860130|Experimental|Prismocitrate 18|
2956185|NCT02860130|Active Comparator|No Regional Anticoagulation of CRRT Circuit|
2956186|NCT02860117|Active Comparator|Ketatamine|Ketamine continuous infusion 0,2mg/kg/h
2956187|NCT02860117|Placebo Comparator|Placebo|Placebo in continuous infusion
2956188|NCT02860104|Other|microwave ablation|microwave ablation
2956189|NCT02860091||Ropivacaine infusion|Patients receiving continuous ropivacaine infusion for approximately 7 days via paravertebral nerve block catheter managed according to existing institutional protocols.
2956190|NCT02860078|Active Comparator|Ultrasound|The group I will be subjected to epidural infiltration using methylprednisolone acetate diluted in ropivacaine 0.1%. Initially the sacral hiatus is identified by palpation. After, the ultrasound device is used (USG) for the puncture, with a linear transducer of high frequency. At the end of corticosteroid administration, the placement of the needle tip will be checked with fluoroscopy and noted.
2956191|NCT02860078|Active Comparator|Radioscopy|The group II will be subjected to infiltration using methylprednisolone acetate diluted in ropivacaine 0.1% . However, only radioscopy be used to guide the puncture.
2956192|NCT02860065|Experimental|CPC-201|combination of solifenacin and high doses of donepezil
2956193|NCT02860052|Experimental|SB208 2%|
2956194|NCT02860052|Experimental|SB208 4%|
2956195|NCT02860052|Experimental|SB208 16%|
2956196|NCT02860052|Placebo Comparator|Vehicle Gel|
2956197|NCT02860039|Experimental|Group 1 - High Dose HD-TIV|Patients receive HD-TIV intramuscularly (IM) on day 0 and day 28.
2956198|NCT02860039|Active Comparator|Group 2 - Standard Dose QIV|Patients receive standard dose QIV IM on day 0 and day 28.
2956199|NCT02860026|Active Comparator|Control|Marketed cow's milk-based infant formula
2956200|NCT02860026|Experimental|Investigational|Cow's milk-based infant formula with added nutrients
2956248|NCT02859584|Other|no serious acute hepatitis|
2956249|NCT02859584|Other|Serious acute hepatitis|
2956250|NCT02859584|Other|Healthy volunteers|
2956251|NCT02859584|Other|Surrenal insufficiency|
2956360|NCT02858856|Experimental|B group|Take Sipjeondaebo-tang on 6~8 week, 9~11 week of clinical trial period, total of 4 weeks
2956201|NCT02860013|Active Comparator|Telemedicine|A tablet (a Samsung GALAXY TAB 2 (10.1)) that holds information on handling heart failure in general. The device can also collect and transmit relevant disease-specific data, which are indicative of their current state of health, via a Digital Blood Pressure Monitor (Model UA-767, plus BT-C) and a scale. The device can measure four vital signs, which are transferred wirelessly: blood pressure, pulse, and weight. The tablet can be activated and give a sound, when it is time for taking measurements again.
2956202|NCT02860013|No Intervention|Usual care|In Denmark, usual practice for treating, monitoring and caring for patients with heart failure are the responsibility of the patient's general practitioner (treatment and monitoring) and the municipalities (practical help and nursing care). Heart failure patients can make appointments with their general practitioner or practice nurse free of charge in order to get help in managing heart failure. Community based care and practical help varies. As a rule community care comes at regular intervals based on a clinically based estimate of the patients' needs, but the personnel are not necessarily certified nurses and often not fully educated in heart failure and definitely not on call
2956203|NCT02860000|Experimental|Arm I (alisertib)|Patients receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression, may cross-over to Arm II.
2956204|NCT02860000|Experimental|Arm II (alisertib, fulvestrant)|Patients receive fulvestrant IM over 1-2 minutes on days 1 and 15 of course 1 and on day 1 of all subsequent courses. Patients also receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2956205|NCT02859987|Active Comparator|Landmark Technique|Blinded method for catheter placement
2956206|NCT02859987|Experimental|Ultrasound-guided Technique|Use sonography for catheter placement
2956207|NCT02859974|Experimental|Respiratory retraining for PVFMD|Single arm study
2956208|NCT02859961|Experimental|PRO 140 SC injections|PRO 140 350 mg (175 mg/mL) SC injections per week
2956209|NCT02859948|Experimental|SKLB1028|SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
2956210|NCT02859935|No Intervention|Control group|The control group will receive standard care - 3 monthly STI screening, motivational interviewing and counselling. Both groups will get questionnaires on mental health problems: ADHD, depression, anxiety disorder, alexithymia and sex and drug addiction.
2956211|NCT02859935|Other|Intervention group|The intervention group will receive -besides standard care- additional questionnaires depending on their baseline questionnaires and in case of an indication for mental health problems, feedback and referral to relevant mental health and addiction care will be provided.
2956212|NCT02859922|Active Comparator|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
2956213|NCT02859922|Active Comparator|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
2956214|NCT02859909|Experimental|2 day treatment schedule|Patients will receive a dosage of 1 g/kg bw per day of BT595 for 2 consecutive days
2956215|NCT02859909|Experimental|5 day treatment schedule|Patients will receive a dosage of 0.4 g/kg bw per day of BT595 for 5 consecutive days
2956216|NCT02859896|Experimental|Hectorol|Hectorol (Doxercalciferol) will be administered orally two to three times weekly dependent on patient age. A dose titration scheme is used to individualize the dose to the patient's iPTH management.
2956217|NCT02859896|Active Comparator|Rocaltrol|Rocaltrol (Calcitriol) will be administered orally seven days/week. A dose titration scheme is used to individualize the dose to the patient's iPTH management.
2956218|NCT02859857|Experimental|Rising dose; safety and tolerance|Sequential cohorts of patients with advanced solid tumors and recurrent high-grade gliomas will be be treated with escalating doses of BXQ-350 until the MTD is established, or in the absence of a MAD, the highest planned DL is reached.
2956219|NCT02859857|Experimental|Solid tumor patients|Cohort of patients with advanced solid tumors administered BXQ-350 at the MTD determined in Part 1 or at the highest planned DL if the MAD is not reached.
2956220|NCT02859857|Experimental|Glioblastoma Multiforme patients|Cohort of patients with recurrent high-grade gliomas administered BXQ-350 at the MTD determined in Part 1 or at the highest planned DL if the MAD is not reached.
2956221|NCT02859844|Experimental|TTNS ON|Transcutaneous tibial nerve stimulation
2956222|NCT02859844|Sham Comparator|TTNS OFF|Sham/placebo stimulation
2956223|NCT02859831||with construction work|
2956224|NCT02859831||without construction work|
2956225|NCT02859818|Other|adolescents with type 1 diabetes|adolescents with type 1 diabetes following their participation in therapeutic education program
2956226|NCT02859792|Placebo Comparator|Placebo|
2956227|NCT02859792|Experimental|Experimental|
2956228|NCT02859779|Other|mediterranean adolescents with type 1 diabetes|
2956229|NCT02859766|Experimental|Abicipar Pegol_Repeat Dose|Treatment Group 1: Abicipar pegol 2 mg administered to the study eye by intravitreal injection, 3 injections 4 weeks apart. [Day 1, Weeks 4 and 8]
2956230|NCT02859766|Experimental|Abicipar Pegol_Single Dose|Treatment Group 2: Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1.
2956231|NCT02859753|Experimental|RFA|
2956232|NCT02859753|Active Comparator|MCT|
2956233|NCT02859740||permanent prosthesis|
2956234|NCT02859740||Temporary prosthesis|
2956235|NCT02859727|Experimental|CDZ173|140mg/day
2956236|NCT02859714||colorectal adenoma|
2956237|NCT02859701|Experimental|AK002|AK002 will be administered as an intravenous (IV) infusion in 8 cohorts of single escalating doses and two cohorts with multiple doses
2956238|NCT02859701|Placebo Comparator|Placebo|Placebo administered as anl IV infusion
2956239|NCT02859688||SRS patient|
2956240|NCT02859688||father SRS patient|
2956241|NCT02859688||control patient|
2956242|NCT02859675||triangular test|
2956243|NCT02859649|Experimental|healthy volunteers|
2956244|NCT02859610|Other|cirrhotic patients|We prospectively included 90 cirrhotic patients .
2956245|NCT02859610|Other|healthy volunteers|The pilot cohort was compared with 10 healthy volunteers.
2956246|NCT02859597|Experimental|High Flow Nasal Cannula|High flow nasal cannula will be utilized to deliver oxygen to morbidly obese patients undergoing deep sedation for gastrointestinal procedures.
2956252|NCT02859571|Active Comparator|Continuous oxytocin|oxytocin will be used at a starting dose of 1-2 mIU/min and the dose will be increased by 2 mIU/min at every 15 minutes until regular contractions will be obtained at a rate of 3-5 contractions in a 10-minute period. The maximum dose of oxytocin will 40 mIU/min and oxytocin will be administered until delivery.
2956253|NCT02859571|Experimental|intermittent oxytocin|oxytocin will be discontinued when cervical dilation will 5 cm and 2 hours after discontinuation oxytocin will be reused at a starting dose of 1-2 mIU/min and will be increased as the same protocol will be used for continuation oxytocin group.
2956254|NCT02859558|Experimental|Arm 1: Fiebig I II|Participants enrolled during Fiebig stages I-II will receive antiretroviral therapy consisting of either one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg (also known as EVG/COBI/FTC/TAF or Genvoya) by mouth daily or another medically-appropriate antiretroviral therapy
2956255|NCT02859558|Experimental|Arm 2: Fiebig III IV|Participants enrolled during Fiebig stages III-IV will receive antiretroviral therapy consisting of either one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg (also known as EVG/COBI/FTC/TAF or Genvoya) by mouth daily or another medically-appropriate antiretroviral therapy
2956256|NCT02859558|Experimental|Arm 3: Fiebig V|Participants enrolled during Fiebig stages V will receive antiretroviral therapy consisting of either one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg (also known as EVG/COBI/FTC/TAF or Genvoya) by mouth daily or another medically-appropriate antiretroviral therapy
2956257|NCT02859545|Experimental|Validation Training|In this arm, the romantic partner of the individual with chronic pain receives training on how to validate which is provided by the research assistant.
2956258|NCT02859545|Placebo Comparator|Education Training|In this arm, the romantic partner of the individual with chronic pain receives training on how to ask questions about treatments, which is provided by the research assistant.
2956259|NCT02859532|Experimental|Diagnosis of deep vein thrombosis|All subjects with proximal DVT will have quantitative elastography SWIRE, thrombin generation test and rotational thromboelastometry test.
2956260|NCT02859519|Experimental|MOB015B|
2956261|NCT02859519|Placebo Comparator|MOB015B Vehicle|
2956262|NCT02859506|Experimental|liver transplant|
2956263|NCT02859506|Active Comparator|kidney transplant|
2956264|NCT02859506|Placebo Comparator|control|
2956265|NCT02859493|Active Comparator|Saccharomyces cerevisiae|Inactivated whole yeast Saccharomyces cerevisiae presented in vaginal capsules. 1 capsule a day for 14 days.
2956266|NCT02859493|Placebo Comparator|Maize starch and magnesium stearate|Placebo presented in a vaginal capsule. 1 capsule a day for 14 days
2956267|NCT02859480|Experimental|Rosuvastatin 5mg|Patients are treated with Rosuvastatin 5mg/day for 30 months after percutaneous coronary intervention
2956268|NCT02859480|Active Comparator|Rosuvastatin 20mg|Patients are treated with Rosuvastatin 20mg/day for 30 months after percutaneous coronary intervention
2956269|NCT02859467|Experimental|Kinesio Taping and Inhibitory Treatment Techniques|"During each session participants will receive the application kinesio taping in trapezius, infraspinatus and paravertebral muscles.~Inhibitory Treatment Techniques:~Release Technique of the trapezius muscle.~Release Technique for scalene muscles.~Technique suboccipital inhibition.~Technique hands crossed for induction dorsal superficial fascia."
2956270|NCT02859467|Active Comparator|Exercise and Electrical Stimulation Therapy|Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
2956271|NCT02859454|Experimental|1|Avelumab 10 mg/kg IV every 2 weeks for up to 6 doses.
2956272|NCT02859441|Experimental|Group 1|Intravitreat injections of E10030 and Ranibizumab
2956273|NCT02859415|Experimental|Phase I|Escalating doses of MithramycinPhase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses
2956274|NCT02859415|Experimental|Phase II|Mithramycin administered at MTDPhase 2: 24 hour intravenous infusion of mithramycin given once every 14 days at MTD
2956275|NCT02859402|Experimental|Experimental Arm|Conditioning chemotherapy: Fludarabine and Busulfan followed by Allogeneic stem cell transplantation
2956276|NCT02859376|Active Comparator|sucrose24% 2 minutes before|sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE the skin breaking procedure
2956277|NCT02859376|Experimental|sucrose24% 2minutes before and during|sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE and DURING the skin breaking procedure
2956278|NCT02859363||Young stroke|Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing for the 26 common Fabry mutation types in Taiwan.
2956279|NCT02859350|Experimental|Group 1a (PfSPZ Vaccine)|18-35 years; n= 20; 3 doses of 2.7x10^6 PfSPZ Vaccine given eight weeks apart. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
2956280|NCT02859350|Placebo Comparator|Group 1a (normal saline)|18-35 years; n=6; 3 doses of normal saline given 8 weeks apart. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
2956281|NCT02859350|Experimental|Group 1b (PfSPZ CVac)|18-35 years; n=20; 3 doses of 1.0x10^5 PfSPZ Challenge given every four weeks. Group 1b will start 8 weeks after Group 1a. Volunteers in Group 1b will receive their first immunization after the loading dose of chloroquine has been administered. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
2956282|NCT02859350|Placebo Comparator|Group 1b (normal saline)|18-35 years; n=6; 3 doses of normal saline given 4 weeks apart. Group 1b will start 8 weeks after Group 1a. Volunteers in Group 1b will receive their first immunization after the loading dose of chloroquine has been administered. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
2956283|NCT02859350|Experimental|Group 2 (PfSPZ Vaccine)|36-65 years; n=12; 3 doses of 2.7x10^6 PfSPZ Vaccine given 8 weeks apart. Group 2 will start 3 weeks after Group 1a.
2956284|NCT02859350|Placebo Comparator|Group 2 (normal saline)|36-65 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 2 will start 3 weeks after Group 1a.
2956444|NCT02858362|Experimental|Open Label Treatment Arm|SMTC1100 (ezutromid) oral suspension
2956285|NCT02859350|Experimental|Group 3 (PfSPZ Vaccine)|11-17 years; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 3 will start 3 weeks after Group 1a.
2956286|NCT02859350|Placebo Comparator|Group 3 (normal saline)|11-17 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 3 will start 3 weeks after Group 1a.
2956287|NCT02859350|Experimental|Group 4 (PfSPZ Vaccine)|6-10 years; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 4 will start 4 weeks after Group 1a.
2956288|NCT02859350|Placebo Comparator|Group 4 (normal saline)|6-10 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 4 will start 4 weeks after Group 1a.
2956289|NCT02859350|Experimental|Group 5 (PfSPZ Vaccine)|1-5 years; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 5 will start 7 weeks after Group 1a.
2956290|NCT02859350|Placebo Comparator|Group 5 (normal saline)|1-5 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 5 will start 7 weeks after Group 1a.
2956291|NCT02859350|Experimental|Group 6a (PfSPZ Vaccine)|6-11 months; n=3; 1 dose of 9.0x10^5 PfSPZ Vaccine. Group 6a will start 7 weeks after Group 1a.
2956292|NCT02859350|Experimental|Group 6b (PfSPZ Vaccine)|6-11 months; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 6b will start 11 weeks after Group 1a.
2956293|NCT02859350|Placebo Comparator|Group 6b (normal saline)|6-11 months; n=4; 3 doses of normal saline given 8 weeks apart. Group 6b will start 11 weeks after Group 1a.
2956294|NCT02859337|Active Comparator|UPA-ECx1 followed by ECx2|Ulipristal acetate 30mg orally x 1 dose, washout cycle and then in the next menstrual cycle, 60mg x 1 dose. Timing of dosage depends on follicle measurements.
2956295|NCT02859337|Experimental|UPA-ECx2 followed by ECx1|Ulipristal acetate 60mg orally x 1 dose, washout cycle, and then in next menstrual cycle 30mg orally x 1 dose. Timing of dosage depends on follicle measurements.
2956296|NCT02859337|Other|UPA-ECx1 Normal BMI/weight|Ulipristal acetate 30mg orally x 1 dose. timing of dosage depends on follicle measurements. This is to obtain a normal BMI control group.
2956297|NCT02859324|Experimental|CC-122 with Nivolumab|CC-122 orally 5/7 days with nivolumab Intravenously (IV) 3mg/kg every 2 weeks. Cohorts of up to 6 subjects per dose level until Recommended Phase 2 dose (RP2D).
2956298|NCT02859311|Experimental|Withdrawal of therapy|Gradual, supervised withdrawal of medical therapy over 4-16 weeks
2956299|NCT02859311|No Intervention|Control|Continuation of usually prescribed pharmacological therapy
2956300|NCT02859298|Experimental|Suspicion of threat of premature delivery|10 consecutive patients arriving at the Brugmann maternity with suspicion of a threat of premature delivery will be encouraged to participate in this study, before the onset of any tocolytic treatment. The patient will receive an standard examination of the cervix and at the same time a polarimetric measurement.
2956301|NCT02859298|Active Comparator|Normal pregnancy|10 control patients, with the same term of pregnancy, will be benefit from the same measurements.
2956302|NCT02859285|Active Comparator|Estradiol vulvar cream|"The estradiol cream 0.5 grams will be placed on the clitoris/vestibule every night for 2 weeks, then 3 times a week thereafter on Monday, Wednesday, and Friday, for a total of 12 weeks.~In addition estradiol 10mcg tablet will be placed in the vaginal every night for 2 weeks, then 2x a week on Tuesday and Thursday, for a total of 12 weeks."
2956303|NCT02859285|Placebo Comparator|Placebo cream|"The placebo cream 0.5 grams will be placed on the clitoris/vestibule every night for 2 weeks, then 3 times a week thereafter on Monday, Wednesday, and Friday, for a total of 12 weeks.~In addition estradiol 10mcg tablet will be placed in the vaginal every night for 2 weeks, then 2x a week on Tuesday and Thursday, for a total of 12 weeks."
2956304|NCT02859259|Experimental|Treatment A: reference extended-release (ER) 1 tablet at 600mg|A single dose of BMS-663068 administered orally as specified
2956305|NCT02859259|Experimental|Treatment B: low-dose ER 4 tablets at 150mg|A single dose (4 tablets) of BMS-663068 administered orally as specified
2956306|NCT02859246|Other|Mucinex|600 mg of Mucinex 2 times a day.
2956307|NCT02859233|No Intervention|Control group|Routine advices about the interest of increase fluid after lumbar puncture to prevent PDPH will be transmitted: 2 liters will be provided to be drunk in 2 hours.
2956308|NCT02859233|Experimental|Interventional group|Lack of hyperhydration : no particular advices will be transmitted about the interest of oral hyperhydration. 500 milliliters will be provided in case of thirst, according to patient's convenience.
2956309|NCT02859220|Other|group 1|group 1 : Roche Elecsys intact PTH
2956310|NCT02859220|Other|group 2|group 2 : PTH 1-84 complete (PAC) report and CAP / PTH 7-84 (CIP), Duo PTH IRMA Scantibodies
2956311|NCT02859207|Experimental|Cohort 1|Participants with mild hepatic impairment (Child-Pugh class A).
2956312|NCT02859207|Experimental|Cohort 1C|Healthy participants (control) matched to participants in Cohort 1.
2956313|NCT02859207|Experimental|Cohort 2|Participants with moderate hepatic impairment (Child-Pugh class B)
2956314|NCT02859207|Experimental|Cohort 2C|Healthy participants (control) matched to participants in Cohort 2
2956315|NCT02859194|Experimental|Veno-veno-arterial ECMO group|
2956316|NCT02859181|Experimental|Active, Adolescent males|Subjects will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
2956317|NCT02859168|Experimental|Myofascial Induction session|Patients received a Myofascial Induction focused on the upper limb area for 30 minutes using the Pilat approach.
2956318|NCT02859168|Placebo Comparator|Placebo session|Patients received a placebo session consisted of 30 minutes of unplugged pulsed shortwave therapy.
2956319|NCT02859155|Other|Multiviceral resection colorectal cancer|Multiviceral resection surgery of 2 or more intrabdominal organs en bloc with colorectal cancer
2956320|NCT02859142|Experimental|Augmented Treatment|"Participants receive 12 weeks of Chantix along with standard smoking cessation treatment of nicotine patches and behavioral counseling visits.~Chantix (Varenicline) and NicodermCQ (Nicotine Patches): Administered according to package insert directions~Behavioral Counseling Sessions: Participants will attend one-on-one behavioral counseling sessions with a trained therapist at each of 4 study visits (pre-quit, quit date, week 2, and week 12). Behavioral sessions will involve teaching behavioral skills to assist with smoking cessation, preventing relapse, and coping with physical or emotional changes associated with cravings."
2956358|NCT02858869|Experimental|Arm C (pembrolizumab, SRS 18-21 Gy)|Patients receive pembrolizumab IV as in Arm A. Patients undergo 1 SRS fraction between days 2-3 of course 1.
2956321|NCT02859142|Active Comparator|Standard Treatment|"Participants receive 12 weeks of standard smoking cessation treatment of nicotine patches and behavioral counseling visits.~NicodermCQ (Nicotine Patches): Administered according to package insert directions~Behavioral Counseling Sessions: Participants will attend one-on-one behavioral counseling sessions with a trained therapist at each of 4 study visits (pre-quit, quit date, week 2, and week 12). Behavioral sessions will involve teaching behavioral skills to assist with smoking cessation, preventing relapse, and coping with physical or emotional changes associated with cravings."
2956322|NCT02859129|Experimental|Rosuvastatin|Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
2956323|NCT02859129|Experimental|Epanova®|Multiple oral doses of 2 g (2 x 1 g capsules) Epanova® QD for 10 consecutive days (Days 4 to 13)
2956324|NCT02859129|Experimental|Epanova® + Crestor®|Epanova® multiple oral doses of 4 g (4 x 1 g capsules) QD for 13 consecutive days (Days 14 to 26) with coadministration of single 40 mg (1 x 40 mg tablet) oral dose of rosuvastatin (Crestor®) with the 11th dose of 4 g Epanova® on Day 24
2956325|NCT02859129|Active Comparator|Vascepa®|Vascepa® multiple oral doses of 2 g (2 x 1 g capsules) every 12 hours for 20 consecutive days (Days 1 to 20).
2956326|NCT02859116||Collection of digestive tissues|Digestive tissues will be collected from participants undergoing scheduled (non-emergent) gastrointestinal surgery.
2956327|NCT02859103|Active Comparator|Treatment|Patients in this arm will receive treatment with desvenlafaxine for 8 weeks.
2956328|NCT02859103|No Intervention|Healthy Control|Patients in this arm are healthy controls and will not receive any medication.
2956329|NCT02859090|Experimental|patient|
2956330|NCT02859077|Experimental|EGFR-TKI and Chemotherapy|NSCLC patients
2956331|NCT02859064|Experimental|Lanreotide/Y-90 microspheres|"Lanreotide: 120 mg by subcutaneous injection (SQ) on Day 1 of every cycle (every 28 days) in combination with SIR-Spheres therapy.~Y-90 (Yttrium-90) microspheres [SIR-Spheres therapy]: dose and treatment day to be determined by treating radiation oncologist."
2956332|NCT02859051|No Intervention|control|No intervention
2956333|NCT02859051|Experimental|robot|Humanoid robot interacts with child, teaching breathing and coping strategies.
2956334|NCT02859038|Experimental|Upfront cytoreductive surgery|Upfront cytoreductive surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy.
2956335|NCT02859038|Active Comparator|Neoadjuvant chemotherapy|neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy.
2956336|NCT02859025|Active Comparator|A:Iiac|Treated with anterior iliac crest spongy bone to fill defects, followed by coverage with collagen membrane.
2956337|NCT02859025|Experimental|B:MSCs+LRCP|Treated with lateral ramus cortical bone plate (LRCP) to create a protected healing space by fixing it to adjacent walls of the cleft defect. BFPScs were loaded on NBBM and delivered to the defect
2956338|NCT02859025|Experimental|C:MSCs+liac|Treated with anterior iliac crest spongy bone as in Group 1, but BFP-derived mesenchymal stem cells (MSCs ) cultured over NBBM were put over the spongy bone and covered with a collagen membrane.
2956339|NCT02859012|Experimental|axitinib|Axitinib 5 mg twice (10mg) daily po medication until progression or development of unacceptable toxicity (4 weeks is considered as one cycle).
2956340|NCT02859012|Active Comparator|observation|Observation. if disease progression is detected, cross-over will be permitted.
2956341|NCT02858999|Experimental|treatment|12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD) for a total of 4 cycles PAD-VCD
2956342|NCT02858986|Experimental|3D laparoscopy|Patients will undergo laparoscopic cholecystectomy using a 3D laparoscopic system
2956343|NCT02858986|Experimental|4K laparoscopy|Patients will undergo laparoscopic cholecystectomy using a 4K laparoscopic system
2956344|NCT02858973|Experimental|Q203|Q203 tablets
2956345|NCT02858973|Placebo Comparator|Placebo|Placebo tablets
2956346|NCT02858960|Experimental|High Flow Nasal Cannula Oxygen|"Incremental Load Treadmill Test (ILTT) using HFNCO~Constant Treadmill Load Test (CTLT) using HFNCO"
2956347|NCT02858960|Active Comparator|The Venturi Mask|"Incremental Load Treadmill Test (ILTT) using venturi mask~Constant Treadmill Load Test (CTLT) using venturi mask"
2956348|NCT02858947|Active Comparator|Aelite Flo|Microhybrid flowable composite
2956349|NCT02858947|Active Comparator|x-tra base|Bulk-fill flowable composite
2956350|NCT02858934|Experimental|preoperative tomotherapy|This study is an open study investigating the effect on quality of life of a very short preoperative radiotherapy for early breast cancer, including approximately 24 women. Radiotherapy will be performed in 1 week and before the surgery in stead of following surgery.Preoperative radiotherapy has the advantage that the tumor is visible on imaging. This can result in smaller boost volumes. The surgery will follow shortly after termination of the radiotherapy, resulting in a very short treatment period.
2956351|NCT02858921|Experimental|Sequential D + T, THEN Pembrolizumab|Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day for 2 weeks, then followed by treatment with Pembrolizumab 2mg/kg delivered intravenously at weeks 2, 4, 6, and 9, then once every 3 weeks from week 12 for 50 weeks.
2956352|NCT02858921|Experimental|Concurrent D + T AND Pembrolizumab|Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day + Pembrolizumab 200mg intravenously once every 3 weeks for 52 weeks
2956353|NCT02858921|Experimental|Pembrolizumab ONLY|Pembrolizumab 200mg intravenously once every 3 weeks alone for 52 weeks.
2956354|NCT02858895|Experimental|MDNA55|"Single infusion of MDNA55 via convection enhanced delivery (CED).*~*Subjects may be eligible to receive a second administration of MDNA55."
2956355|NCT02858882||Swimmers|Screening of elite athletes
2956356|NCT02858869|Experimental|Arm A (pembrolizumab, SRS 6 Gy):|Patients receive 200 mg pembrolizumab IV over 30 minutes on day 1. Courses repeat Q3W for at least 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo 5 SRS fractions between days 2-15 of course 1.
2956357|NCT02858869|Experimental|Arm B (pembrolizumab, SRS 9 Gy)|Patients receive pembrolizumab IV as in Arm A. Patients undergo 3 SRS fractions between days 2-15 of course 1.
2956359|NCT02858856|Experimental|A group|Take Sipjeondaebo-tang on 0~2 week, 3~5 week of clinical trial period, total of 4 weeks
2956361|NCT02858843|Experimental|Lumacaftor-ivacaftor|Subjects will be monitored for glycemic changes before and after starting lumacaftor-ivacaftor.
2956362|NCT02858830|Other|Group 1: Healthy Subject|Healthy Subject (Control) will undergo assessments before and after ingesting a high fat mixed meal.
2956363|NCT02858830|Other|Group 2: FPL Subject|FPL Subject will undergo assessments before and after ingesting a high fat mixed meal.
2956364|NCT02858817|Experimental|51,200 PfSPZ|Three injections of 51,200 PfSPZ Challenge (P. falciparum strain: NF54) under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
2956365|NCT02858817|Experimental|150,000 PfSPZ|Three injections of 150,000 PfSPZ Challenge (P. falciparum strain: NF54) under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
2956366|NCT02858817|Placebo Comparator|Placebo|Three injections of NaCl 0,9% solution under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
2956367|NCT02858804|Experimental|Etoposide|50 mg/m2, IV, d1-4
2956368|NCT02858804|Experimental|Doxorubicin|10 mg/m2, IV, d1-4
2956369|NCT02858804|Experimental|Dexamethasone|30 mg/d, d1-5
2956370|NCT02858804|Experimental|Vincristine|0.4 mg/m2, IV, d1-4
2956371|NCT02858804|Experimental|Cyclophosphamide|750 mg/m2 ,d5
2956372|NCT02858804|Experimental|Cytarabine|2g/m2, q12h, d1
2956373|NCT02858804|Experimental|Cisplatin|100mg/ m2,IV, d1
2956374|NCT02858804|Experimental|Rituximab|375 mg/m2 IV, d1
2956375|NCT02858804|Experimental|Thalidomide|50-150mg/d, po, d1-28
2956376|NCT02858804|Experimental|Prednisone|0.5mg/Kg, po, qod
2956377|NCT02858791||Healthy Controls|"Subjects are made up of healthy adults~Interventions:~Venous blood drawn before and after cardiopulmonary exercise test Will have a resting 12 lead EKG Undergo pulmonary function test"
2956378|NCT02858791||Affected|"Subjects have Pulmonary Hypertension Subjects have Pulmonary hypertension with Interstitial lung disease Subjects have Interstitial lung disease~Interventions:~Venous blood drawn before and after cardiopulmonary exercise test Will have a resting 12 lead EKG Undergo pulmonary function test"
2956379|NCT02858778|Experimental|Interventional group (Ig)|The interventional group (Ig) will have an early palliative care consultation ordered during their stay in the emergency department.
2956380|NCT02858778|No Intervention|Control group (Cg)|The control group will be treated as standard of care. Palliative care consultations may or may not be ordered at the attending physician's discretion.
2956381|NCT02858765|Experimental|white polychromatic light A|
2956382|NCT02858765|Experimental|white polychromatic light B|
2956383|NCT02858765|Experimental|white polychromatic light C|
2956384|NCT02858765|Experimental|white polychromatic light D|
2956385|NCT02858752|Experimental|Healthy Children|Memory and Attention in healthy children will be assessed non-invasively through behavioral and electrophysiological measures while participants will perform passive or active computer task involving auditory and/or visual perception.
2956386|NCT02858726|Experimental|CR845 0.5mcg/kg|Part A of study: IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
2956387|NCT02858726|Experimental|CR845 1 mcg/kg|Part A of study: IV CR845 1 mcg/kg administered after each dialysis session (3 times/week)
2956388|NCT02858726|Experimental|CR845 1.5mcg/kg|Part A of study: IV CR845 1.5 mcg/kg administered after each dialysis session (3 times/week)
2956389|NCT02858726|Placebo Comparator|Placebo|Part A of study: IV Placebo administered after each dialysis session (3 times/week)
2956390|NCT02858713|Experimental|App as intervention + Enstilar©|Patients prescribed Enstilar© receive the intervention EM with app for smartphone and conventional instruction from a nurse in the consultation.
2956391|NCT02858713|Other|Conventional instructions + Enstilar©|Patients receive conventional instructions from a nurse in the consultation in how to use prescribed Enstilar© with EM.
2956392|NCT02858700|Experimental|umbilical cord blood procalcitonin|dosage of the umbilical cord blood Procalcitonin for diagnosing of IBNP
2956393|NCT02858687|Experimental|Patients with clinical diagnosis of tonsillitis|
2956394|NCT02858674|Experimental|Active Alerting Mechanism|Traditional Pop Up Alert used in Epic
2956395|NCT02858674|Active Comparator|Passive Alerting Mechanism|Noninterruptive alert that sits in the checklist
2956396|NCT02858661|Experimental|Patients diagnosed with clinical meningitis|Patients admitted in emergency rooms for clinical meningitis, for which a nasopharyngeal swab will be performed in order to confirm the etiological diagnosis of meningitis
2956397|NCT02858648|Experimental|Behavior intervention with smart phone based self-monitoring|Patients in this group were asked to attend 11 group and 1 individual session over 6 months, and received a smartphone with two downloaded applications to monitor diet, physical activity, weight, and blood glucose (connected with a blue tooth glucometer) throughout 6 months.
2956398|NCT02858648|Experimental|Behavior intervention with paper diary based self-monitoring|Patients in this group were asked to attend 11 group sessions and 1 individual session over 6 months, and received paper diaries along with a calorie counter booklet, weight scale, food scale, and pedometer to monitor diet, physical activity, weight, and blood glucose throughout 6 months.
2956399|NCT02858648|No Intervention|Usual care|Patients in this group received no intervention, they continue to receive usual diabetes care and education from the recruitment clinic.
2956400|NCT02858635|Experimental|Suicide attempters|Clinical and neuropsychological assessment. Blood and saliva samples in order to answer objectives study.
2956401|NCT02858622|Active Comparator|dual TAB group|22 patients will receive unilateral dual transversus abdominis plane (TAB) block USING bupivacaine 0.25% at a dose of 2 mg/kg
2956402|NCT02858622|Sham Comparator|control group|22 patients who will not receive dual TAB block
2956403|NCT02858609|Experimental|Patients with Diarrhoea|Patients admitted in emergency room with Diarrhoea
2956404|NCT02858596|Experimental|Semi-solid feed group|Given semi-solid feed protocol
2956405|NCT02858596|Placebo Comparator|Liquid feed group|Given liquid feed protocol
2956445|NCT02858349|Experimental|Arm 1|4-week control period with no intervention and 4-weeks of high-intensity interval training
2956446|NCT02858336|Active Comparator|Control|All participants will receive the NEA availability to act as their own control to the experimental DEA intervention.
2956571|NCT02857426|Experimental|Nivolumab for population with PTL|Specified dose on specified days
2956406|NCT02858583|Experimental|Intervention (CC+SI)|"Infants randomized into the CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression. The SI will be delivered over a period of 45 seconds. This will be followed by PEEP of 5-8 cm water to perform an assessment of the newborn's heart rate. If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 45sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI."
2956407|NCT02858583|Active Comparator|Control (3:1 C:V)|"Infants randomized into the 3:1 C:V group will receive CC at a rate of 90/min and 30 ventilations/min in a 3:1 C:V ratio as recommended by the current resuscitation guidelines."
2956408|NCT02858570|Experimental|MenCC-BIO Vaccine|Vaccine against meningococcus serogroup C conjugated to tetanus toxoid produced by Bio-Manguinhos / FIOCRUZ (MenCC-Bio). Stratum I - 11-19 years; Stratum II - 1 to 10; Stratum III - less than 1 year old)For the age groups I and II are applied 2 doses ideal interval of 6 months between them. In stratum III, are recommended 3 doses of the vaccine, at ages 3, 5 and 12 months of age, according to calendar of the National Immunization Program.
2956409|NCT02858570|Active Comparator|combined - CRM197|Adsorbed vaccine meningococcal C (combined - CRM197) produced by the Foundation Ezequiel Dias (FUNED). Stratum I - 11-19 years; Stratum II - 1 to 10; Stratum III - less than 1 year old). For the age groups I and II are applied 2 doses ideal interval of 6 months between them. In stratum III, are recommended 3 doses of the vaccine, at ages 3, 5 and 12 months of age, according to calendar of the National Immunization Program.
2956410|NCT02858557|Experimental|Group A|Patients will be allocated to 7 days of Mediterranean diet and then will cross over to 7 days of specific carbohydrate diet
2956411|NCT02858557|Experimental|Group B|Patients will be allocated to 7 days of specific carbohydrate diet and then will cross over to 7 days of Mediterranean diet
2956412|NCT02858544||Group1 - Validation Group|n=890 patients seen and evaluated for possible concussion after a motor vehicle accident. Patients with qualifying scores on the Concussion Identification Index will also complete the ImPACT.
2956413|NCT02858544||Group 2 - Cross Validation Group|n=900 patients seen and evaluated for possible concussion after a motor vehicle accident. Patients with qualifying scores on the Concussion Identification Index will also complete the ImPACT.
2956414|NCT02858531||patients < 24 months or 60 years with bronchiolitis or ARF|ARF = Acute Renal Failure
2956415|NCT02858518||patients with atrial fibrillation with anticoagulant treatment|
2956416|NCT02858505|Active Comparator|27 mg elemental iron group|received 27 mg elemental iron once daily starting at 12 weeks until 36 weeks
2956417|NCT02858505|Active Comparator|54 mg elemental iron group|received 54 mg elemental iron once daily starting at 12 weeks until 36 weeks
2956418|NCT02858492|Experimental|Subjects receiving GSK2982772 60 mg|Enrolled subjects will receive GSK2982772 60 mg thrice daily (approximately 8 hours apart) for 84 days.
2956419|NCT02858492|Experimental|Subjects receiving Placebo|Enrolled subjects will receive placebo thrice daily (approximately 8 hours apart) for 84 days.
2956420|NCT02858479|Other|patients with pain allodynic peripheral|
2956421|NCT02858479|Other|patients with pain allodynic central|
2956422|NCT02858466|Experimental|peripheric nervous lesion|MRI scan
2956423|NCT02858466|Experimental|medullar or encephalic lesion|MRI scan
2956424|NCT02858466|Other|control group|MRI scan
2956425|NCT02858453|Experimental|AQX-1125 100 mg|2 tablets, by mouth, once per day for 12 weeks; followed by a 52-week Extension Period
2956426|NCT02858453|Experimental|AQX-1125 200 mg|2 tablets, by mouth, once per day for 12 weeks; followed by a 52-week Extension Period
2956427|NCT02858453|Placebo Comparator|Placebo|2 placebo tablets, by mouth, once per day for 12 weeks; followed by randomization to 100 mg or 200 mg AQX-1125 for a 52-week Extension Period
2956428|NCT02858440|Experimental|DTPa-IPV/Hib Group|All subjects will receive three doses of primary vaccination at 3, 4.5 and 6 months of age and a single dose of booster vaccination at 18 months of age
2956429|NCT02858427|Experimental|depressed with suicide attempt (SA)|elderly depressed patients with a history of suicide attempt. interventions: eye tracking, neuropsychological assessment, psychiatric assessment and sociological interview.
2956430|NCT02858427|Experimental|depressed without a history of SA|elderly depressed patients without a history of suicide attempt. interventions: eye tracking, neuropsychological assessment, psychiatric assessment and sociological interview.
2956431|NCT02858414|Experimental|blood sample|
2956432|NCT02858401|Experimental|Vesatolimod 1 mg (Cohort 1)|Vesatolimod 1 mg for 71 days, while continuing their existing ARV regimen
2956433|NCT02858401|Experimental|Vesatolimod 2 mg (Cohort 2)|Vesatolimod 2 mg for 71 days, while continuing their existing ARV regimen
2956434|NCT02858401|Experimental|Vesatolimod 4 mg (Cohort 3)|Vesatolimod 4 mg for 71 days, while continuing their existing ARV regimen
2956435|NCT02858401|Experimental|Vesatolimod 6 mg (Cohort 4)|Vesatolimod 6 mg for 127 days, while continuing their existing ARV regimen
2956436|NCT02858401|Experimental|Vesatolimod 8 mg (Cohort 5)|Vesatolimod 8 mg for 127 days administered following overnight fasting, while continuing their existing ARV regimen
2956437|NCT02858401|Experimental|Vesatolimod 10 or 12 mg (Cohort 6)|Vesatolimod 10 or 12 mg for 127 days administered following overnight fasting, while continuing their existing ARV regimen. Participants will receive 3 administrations of 10 mg, followed by 7 administrations of 12 mg (after review of 10 mg safety data)
2956438|NCT02858401|Experimental|Vesatolimod 12 mg (Optional Cohort 7)|Vesatolimod up to 12 mg for up to 127 days for up to 10 total doses administered following overnight fasting, while continuing their existing ARV regimen
2956439|NCT02858401|Experimental|Vesatolimod 6 mg with an acidic solution (Optional Cohort 8)|Vesatolimod 6 mg for 127 days for up to 10 total doses administered with an acidic solution (cranberry juice), while continuing their existing ARV regimen
2956440|NCT02858401|Experimental|Vesatolimod up to 12 mg (Cohort 9)|Vesatolimod up to 12 mg for 127 days for up to 10 total doses administered following a moderate-fat meal, after the review of the data from the highest tolerated fasted dose cohort while continuing their existing ARV regimen
2956441|NCT02858401|Placebo Comparator|Placebo (Cohorts 1-9)|Placebo to match vesatolimod for 71 or 127 days, while continuing their existing ARV regimen
2956442|NCT02858388|Active Comparator|SN45|Sinuclean Nebules 45
2956443|NCT02858388|Placebo Comparator|Sal|Saline solution
2956447|NCT02858336|Experimental|Experimental|All participants will be in the experimental arm and received the DEA intervention.
2956448|NCT02858310|Experimental|Arm 1: Phase I|Non-myeloablative, lymphocyte depleting preparative regimen, followed by E7 TCR Cells at escalating doses, followed by aldesleukin.
2956449|NCT02858310|Experimental|Arm 2: Phase II|1 x 10 e11 E7 Cellsthat was determined in Phase I + aldesleukin
2956450|NCT02858297|Experimental|Glucosamine/Corticosteroid 4|Topical steroid (triamcinolone acetonide 0.1 %) four times per day and (glucosamine sulfate 500 mg) orally three times per day for 8 weeks
2956451|NCT02858297|Experimental|Glucosamine/Corticosteroid 2|Topical steroid (triamcinolone acetonide 0.1 %) twice per day and (glucosamine sulfate 500 mg) orally three times per day for 8 weeks
2956452|NCT02858297|Active Comparator|Corticosteroid|Topical steroid (triamcinolone acetonide 0.1 %) four times per day for 8 weeks
2956453|NCT02858284|Experimental|TUG Device|1 time external application - device powered on
2956454|NCT02858284|Sham Comparator|Sham|1 time external application - device powered off
2956455|NCT02858271|Experimental|AKB-9778|Single dose of [14C]-radiolabeled subcutaneous (SC) injection of AKB-9778 in the morning of Day 1
2956456|NCT02858258|Active Comparator|Standard Arm A|"R-CHOP/R-DHAP: Alternating 3 cycles of R-CHOP in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle~Drug: R-CHOP/R-DHAP~ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM"
2956457|NCT02858258|Experimental|Experimental Arm A+I|"R-CHOP+Ibrutinib/R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days 1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle~Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction)~ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM~2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenace)"
2956458|NCT02858258|Experimental|Experimental Arm I|"R-CHOP+Ibrutinib / R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle~Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction)~2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenance)"
2956459|NCT02858245||Commercial MitraClip® patients|Patients with Degenerative Mitral Regurgitation receiving MitraClip® Device
2956460|NCT02858232|Experimental|solid tumor|Multiple Target Antigen Stimulating Cell Therapy (MASCT-I)
2956461|NCT02858219|Experimental|Botulinum toxin|"Injection of 50 units (50U) botulinum toxin type A (powder), reconstituted in 1 mL physiologic saline solution in each perineal muscle (100 units in total).~First injection at day 1 and. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale)."
2956462|NCT02858219|Placebo Comparator|Saline solution|Injection of 1 mL physiologic saline solution in each perineal muscle. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale).
2956463|NCT02858206|Experimental|Neoadjuvant nimotuzumab|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent nimotuzumab: Patients may receive nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity.~Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
2956464|NCT02858206|Active Comparator|Neoadjuvant chemotherapy|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy: Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity.~Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
2956465|NCT02858206|Experimental|Radical nimotuzumab|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent nimotuzumab: Patients may receive nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity."
2956466|NCT02858206|Active Comparator|Radical chemotherapy|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy: Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity."
2956467|NCT02858193|Experimental|1.35 g SCMC- lys powder|1.35 g of SMC L-lysine monohydrate salt powder for solution
2956468|NCT02858193|Experimental|Fluifort® syrup|Fluifort® syrup 90 mg SCMC-lys/mL
2956469|NCT02858180|Experimental|Heart Failure Cohort|"Harvoni (sofosbuvir/ledipasvir fixed dose combination)~1 pill once daily Includes 400 mg sofosbuvir (SOF) and 90 mg ledipasvir (LDV)"
2956470|NCT02858180|Experimental|Lung Disease Cohort|"Harvoni (sofosbuvir/ledipasvir fixed dose combination)~1 pill once daily Includes 400 mg sofosbuvir and 90 mg ledipasvir"
2956471|NCT02858167|Experimental|FDG-PET|
2956472|NCT02858154|Other|Crossover HFNC and Oxygen by Cannula|All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive active comparator (oxygen by nasal cannula)
2956473|NCT02858115||one lung ventilation lung|patients requiring one lung ventilation lung resection.
2956474|NCT02858102|Active Comparator|Active treatment group|Physical activity program: 36 sessions of physical activity lasting between 30-60 minutes for 12 weeks, three days per week.
2956475|NCT02858102|No Intervention|Control group|No physical activity program
2956476|NCT02858076|Active Comparator|Intravitreous 2 mg aflibercept injections|Initial injection must be given on the day of randomization. Follow-up injections will be performed as often as every 4 weeks unless criteria for deferral are met.
2956477|NCT02858076|Active Comparator|Prompt vitrectomy plus panretinal photocoagulation|For the prompt vitrectomy + panretinal photocoagulation group, the vitrectomy must be scheduled to be performed within 2 weeks of randomization. Vitrectomy will be performed according to the investigator's usual routine, including pre-operative care, surgical procedure, and post-operative care, although anti-VEGF may not be given post-operatively unless there is recurrent hemorrhage.
2956478|NCT02858063||Pending chemotherapy +/- trastuzumab|In the 1st group (chemotherapy), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
2956479|NCT02858063||pending trastazumab +/- hormone therapy|In the 2nd group (trastazumab), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
2956480|NCT02858063||pending hormone therapy alone|In the third group (hormone therapy), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
2956481|NCT02858063||pending afercare period|In the last group (aftercare), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
2956482|NCT02858050||Portal-724 MEMs Cap Real-Time Monitoring|Group 1 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and will transmit data in real-time
2956483|NCT02858050||Portal-724 MEMs Cap Without Real-Time Monitoring|Group 2 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and data will be downloaded at each study visit while taking hepatitis C medications
2956484|NCT02858037|Experimental|HIV Open-label Prevention|Following demonstration of safety and efficacy of the dapivirine vaginal ring in MTN-020, eligible MTN-020 participants will be offered enrollment into MTN-025, a trial designed to obtain additional safety and adherence data in women
2956485|NCT02858024|Active Comparator|Cohort I|In Cohort I, eligible participants will be randomly assigned to one of two treatment sequences (ABE or BAE). During two consecutive 28-day treatment periods (treatment periods 1 and 2), separated by a washout period of 28 days, the participants will receive each of the following treatments according to their assigned treatment sequence
2956486|NCT02858024|Active Comparator|Cohort II|In Cohort II, eligible participants will be randomly assigned to one of two treatment sequences (CDE or DCE). During two consecutive 28-day treatment periods (treatment periods 1 and 2), separated by a washout period of 28 days, the participants will receive each of the following treatments according to their assigned treatment sequence
2956487|NCT02858011|Active Comparator|Control and comparison group -cash transfer program|The program is implemented during 48 months. During the first 36 months the control group does not receive any intervention. During the last 12 months eligible beneficiaries receive cash transfer and accompanying information sessions on health, child nutrition, household economics every three months (identical to experimental group).
2956488|NCT02858011|Experimental|Jigisemejiri cash transfer program|Unconditional cash is distributed every 3 months to beneficiaries of the Jigisemejiri program. During cash handouts, information sessions on health, child nutrition, households economics and education are organized by local NGOs.
2956489|NCT02858011|Experimental|Jigisemejiri - Preventive Nutrition packages|Households belonging to the experimental group who previously received Cash transfer and information sessions on health, child nutrition, households economics and education for 36 months, with children and/or pregnant/lactating women receiving rations of fortified flour (PNP) during the last 12 months of the project
2956490|NCT02858011|Active Comparator|Control and comparison group - Preventive Nutrition packages|Households belonging to the experimental group who previously received Cash transfer and information sessions on health, child nutrition, households economics and education for 36 months, with children and/or pregnant/lactating women
2956491|NCT02857998|Experimental|HMPL-523|Oral administration, at dose of 100, 200, 400, 600 and 800 mg once daily at Dose-escalation stage At Dose-expansion stage, HMPL-523 will be dose daily and the dose level will be based on result of Dose-escalation stage
2956492|NCT02857985|Experimental|Patient with Myocardial Infarction|
2956493|NCT02857972|Experimental|Wondaleaf®|This is a single arm clinical trial, all female subjects will be recruited to the arm using investigational device only.
2956494|NCT02857959|Experimental|single dose benzathine penicillin G.|single dose benzathine penicillin G.
2956495|NCT02857959|Active Comparator|three doses of benzathine penicillin G.|three doses of benzathine penicillin G.
2956496|NCT02857946|Experimental|A Test|Test drug (Prevaglip) 1 tablet contains 5 mg linagliptin
2956497|NCT02857946|Active Comparator|B Reference|Reference drug (Trajenta) 1 tablet contains 5 mg linagliptin
2956498|NCT02857933|Other|Frequency Level 1 - Daily Therapy|Level 1 daily therapy is 2 hours of one-on-one physical therapy per day for 20 straight weekdays
2956499|NCT02857933|Other|Frequency Level 2 - Intermediate Therapy|Level 2 intermediate therapy is 2 hours of therapy per day 3 days per week for 6.6 weeks
2956500|NCT02857933|Other|Frequency Level 3 - Usual Therapy|Level 3 usual weekly therapy is 2 hours of therapy one day per week for 20 weeks.
2956501|NCT02857920|Experimental|Bevacizumab and NK immunotherapy|In this group, the patients will receive regular Bevacizumab treatment in combination with multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2956534|NCT02857686|Experimental|forearm intravenous regional anesthesia|tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
2956502|NCT02857920|Active Comparator|Bevacizumab|In this group, the patients will receive regular Bevacizumab treatment to control the tumor growth. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2956503|NCT02857907||ATG group|Patients who received T cell depleting ATG therapy (blood sample one year after transplantation)
2956504|NCT02857907||anti-CD25 group|Patients who received nondepleting anti-CD25 (blood sample one year after transplantation)
2956505|NCT02857881|Experimental|Evolutive keratoconus|
2956506|NCT02857868|Experimental|ABL001|
2956507|NCT02857855|Experimental|80% fraction of inspired oxygen|80% fraction of inspired oxygen delivered either by a nonrebreathing facemask with a reservoir with oxygen flow of 14 l/min and air flow of 2 l/min or by a respirator for first 6 postoperative hours
2956508|NCT02857855|Active Comparator|28% fraction of inspired oxygen|28% fraction of inspired oxygen delivered either by a Venturi facemask or by a respirator for first 6 postoperative hours
2956509|NCT02857842|Experimental|Blood eosinophil guided prednisolone treatment|Intravenous Solu-Medrol 80 mg, followed by prednisolone tablet 37.5 mg daily (maximum of 5 days in all) if the eosinophil count in the blood ≥ 0.3 x 10E9/L. Eosinophil count in the blood <0.3 x 10E9/L results in no treatment with prednisolone. If the patient is discharged during the treatment period, given treatment from the last measured eosinophil count the remaining days.
2956510|NCT02857842|Active Comparator|Standard of care|Intravenous Solu-Medrol 80 mg on the first day followed by 37.5 mg of prednisolone tablets (1 x 25 mg plus 1 x 12.5 mg) daily for 5 days
2956511|NCT02857829|Placebo Comparator|Placebo|
2956512|NCT02857829|Active Comparator|Caffeine-alone|The effects of the combination will be compared to both placebo and caffeine-alone, to test the hypothesis that the blend of ingredients will enhance cognitive measures greater than the most commonly used cognitive enhancer, caffeine.
2956513|NCT02857829|Experimental|CAF+|
2956514|NCT02857816|Other|NURO System PTNM Therapy|Subjects will undergo 12 PTNM therapy sessions, administered weekly, utilizing the NURO system.
2956515|NCT02857803|Experimental|Virtual Reality|The Virtual Reality group will perform personalised activities of daily living in the context of a simulated city (Reh@City). The interaction with the virtual environment will be through a natural user interface.
2956516|NCT02857803|Active Comparator|Paper and Pencil|The paper and pencil group will perform a set of cognitive paper and pencil tasks personalised to their deficits and generated automatically through a Task Generator.
2956517|NCT02857803|Active Comparator|Conventional Therapy|The Conventional Therapy group will perform the activities offered by the public health system, which are motor-focused.
2956518|NCT02857777|Experimental|Cohort 1: Japanese elderly subjects (Esketamine)|Subjects will receive Treatment A (28 milligram [mg] of esketamine, administered as 1*14 mg spray of esketamine in each nostril at Time 0) in Period 1, Treatment B (56 mg of esketamine, administered as 1*14 mg spray of esketamine in each nostril at Time 0 and 5 minutes) in Period 2 and then Treatment C (84 mg of esketamine, administered as 1*14 mg spray of esketamine in each nostril at Time 0, 5, and 10 minutes) in Period 3. A washout period of 5 to 14 days will separate each intranasal esketamine treatment regimen.
2956519|NCT02857777|Active Comparator|Cohort 2: Japanese healthy subjects (Esketamine)|Subjects will receive Treatment A in Period 1, Treatment B in Period 2 and then Treatment C in Period 3. A washout period of 5 to 14 days will separate each intranasal esketamine treatment regimen.
2956520|NCT02857764||Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i) New Users|Participants will not receive any intervention as a part of this study. SGLT2i includes canagliflozin, dapagliflozin, empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
2956521|NCT02857764||Canagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of canagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 risk) and overall.
2956522|NCT02857764||Dapagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of dapagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
2956523|NCT02857764||Empagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
2956524|NCT02857764||First-time Non-SGLT2i AHA New Users|Participants will not receive any intervention as a part of this study. Non-SGLT2i AHA include dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, thiazolidinediones (TZDs), Sulfonylureas, Insulin, and other AHAs. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
2956525|NCT02857751||Surf therapy cohort 1|The first cohort of participants to enroll in the study (i.e., participants in the first 6-week program)
2956526|NCT02857751||Surf therapy cohort 2|The second cohort of participants to enroll in the study (i.e., participants in the second 6-week program)
2956527|NCT02857751||Surf therapy cohort 3|The third cohort of participants to enroll in the study (i.e., participants in the third 6-week program)
2956528|NCT02857751||Surf therapy cohort 4|The fourth cohort of participants to enroll in the study (i.e., participants in the fourth 6-week program)
2956529|NCT02857751||Surf therapy cohort 5|The fifth cohort of participants to enroll in the study (i.e., participants in the fifth 6-week program)
2956530|NCT02857738|Experimental|SPF evaluation|Subjects with Good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
2956531|NCT02857725|Experimental|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were considered for SPF testing.
2956532|NCT02857712|Experimental|Axitinib|Axitinib will be administered at 5 mg BID (starting dose); in case of no adverse events above CTCAE version 4.0 Grade 2 for a consecutive 2-week periods, the dose may be increased to 7 mg BID and further to 10 mg BID using the same criteria until tumor progression, unacceptable toxicity or other criteria for discontinuation is met.
2956533|NCT02857686|Active Comparator|arm intravenous regional anesthesia|tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
2956570|NCT02857426|Experimental|Nivolumab for population with PCNSL|Specified dose on specified days
2956535|NCT02857673|Experimental|Intervention Group|The intervention group will receive Child Abuse Prevention Problem Solving (CAPPS), a one-on-one, workbook-based intervention of six sessions, each lasting approximately 30-60 minutes. CAPPS is intended to be delivered over a period of 12 weeks, with sessions occurring every 1-2 weeks. Sessions will be delivered at the medical home by bachelor level providers, whose availability and level of training mimic those of existing medical home care coordinators.
2956536|NCT02857673|Active Comparator|Active Control Group|Parents in both study groups will receive the standard medical and social work services offered in the patient-centered medical homes where their children receive care. In addition, to account for potential surveillance bias, families in the control group will be contacted by a member of the study team six times over 12 weeks, approximating the frequency of contact that the intervention group receives from the CAPPS providers. The study team member will not be trained in CAPPS and will adhere to a case management model consistent with resources available in the medical home, checking in with control families and offering to help identify existing clinic and community resources as needed.
2956537|NCT02857660|Experimental|Whole-Body Electromyostimulation and Protein|16 weeks of whole-body intervention 1.5 x 20 min week with bipolar current up to 1.5 - 1.7 g/kg body mass/d of protein supplements up to 800 IU/d Vitamin D-Supplementation
2956538|NCT02857660|Active Comparator|Protein supplementation|up to 1.5 - 1.7 g/kg body mass/d of protein supplements up to 800 IU/d Vitamin D-Supplementation
2956539|NCT02857660|No Intervention|sedentary Control Group|No protein supplementation or WB-EMS-application, but up to 800 IU/d Vitamin D-Supplementation
2956540|NCT02857647|Experimental|The experimental group|"Participants who will assigned to the experimental group will be asked to watch an information video of 30 minutes 1-2 weeks prior to the surgery date.~n=100."
2956541|NCT02857647|No Intervention|The control group|"Participants who will assigned to the control group will receive standard care and will not asked to watch a videotaped lecture prior to the surgery.~n=100."
2956542|NCT02857634||Bladder tumor resection|
2956543|NCT02857608|Experimental|Lymphoseek - 0.5 mCi, 50 ug|A single dose of 50 µg Lymphoseek radiolabeled with 0.5 millicurie (mCi) (18.5 MBq) 99m Tc
2956544|NCT02857595|Active Comparator|Online Weight Loss Program|
2956545|NCT02857595|Experimental|Online Weight Loss Program + Nomogram|
2956546|NCT02857595|Experimental|Online Weight Loss Program + Nomogram + Bite Counter|
2956547|NCT02857582|Active Comparator|Vancomycin|Secondary treatment for relapse of Clostridium difficile infection.
2956548|NCT02857582|Experimental|Cultured human intestinal microbiota1|Cultured intestinal microbiota is experimental treatment for relapse of Clostridium difficile infection.
2956549|NCT02857582|Experimental|Cultured human intestinal microbiota2|Cultured intestinal microbiota is thirdly experimental treatment for second relapse of Clostridium difficile infection.
2956550|NCT02857569|Experimental|Experimental IT Arm|"ipilimumab: 0.3mg/kg IT injection every 3 weeks until complete response, eradication of all injectable sites, disease progression or toxicity, for a maximum of 4 doses (to compare back to back to IV standard of care and marketing authorization).~nivolumab: 1mg/kg, IV injection every 3 weeks during IT ipilimumab treatment period and 3mg/kg, IV injection every 2 weeks after IT ipilimumab treatment interruption. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient for a maximum of 12 months."
2956551|NCT02857569|Active Comparator|Standard Arm|"ipilimumab: 3mg/kg, IV injection every 3 weeks for a maximum of 4 doses as per standard of care and marketing authorization.~nivolumab: 1mg/kg, IV injection every 3 weeks during IV ipilimumab treatment period and 3mg/kg, IV injection every 2 weeks after IV ipilimumab treatment interruption. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient for a maximum of 12 months."
2956552|NCT02857556|Other|group with stage 3 kidney failure (diabetic or not)|
2956553|NCT02857556|Other|group with stage 5 kidney failure (diabetic or not)|
2956554|NCT02857543|Active Comparator|plant-based diet|Plant-based diet with as few added oils and fats as possible
2956555|NCT02857543|Active Comparator|American Heart Association|Diet encourages fruits, vegetables, whole grains, and low sodium intake but permits non-whole grains, low-fat dairy, selected plant oils, and lean meat and fish in moderation.
2956556|NCT02857543|Active Comparator|Mediterranean|Diet encourages fruits, vegetables, whole grains, and low sodium intake but permits non-whole grains, low-fat dairy, selected plant oils, with more emphasis on fish and extra virgin olive oil and/or nuts.
2956557|NCT02857530|Experimental|rhTPO|rhTPO injection
2956558|NCT02857530|Placebo Comparator|control|without rhTPO injection
2956559|NCT02857517|Experimental|intravitreal 0.05ml conbercept for ICNV|0.05ml conbercept ,1 injection with PRN
2956560|NCT02857504|Other|double lumen tube with a hook|The tube with the hook (after passing the bronchial cuff trough the vocal cords) was rotated for 180 degrees to the left and removed the stylet and when the hook passed the vocal cords, the tube was rotated for 90 degrees back to the right and push it into the bronchus. Following formula was used for the right depth (height (cm)/10 + 12 (cm)) of the tube without the hook. The tube with hook was inserted into the bronchus so that hook was placed on the carina and stopped.
2956561|NCT02857504|Other|double lumen tube without a hook|Tube without the hook was inserted with the following technique: after the bronchial cuff was passed the vocal cords, the stylet was removed and the tube was rotated 90 st towards left.
2956562|NCT02857491|Experimental|ranibizumab|Intravitreal Injection of 0.5 mg ranibizumabone week before vitrectomy.
2956563|NCT02857491|Sham Comparator|control|Sham intravitreal injection one week before vitrectomy.
2956564|NCT02857478|Experimental|Safety of a Sunscreen product|Sunscreen product safety evaluation under supervised out-door conditions on sport users.
2956565|NCT02857465|Experimental|Epidural analgesia + DEXAMETHASONE|Single epidural injection of Dexamethasone Mylan (8 mg) concomitant to epidural analgesia (ropivacaine+ sufentanil)
2956566|NCT02857465|Placebo Comparator|Epidural analgesia + PLACEBO|Single epidural injection of sodium chloride (0.9%) Lavoisier concomitant to epidural analgesia (ropivacaine + sufentanil)
2956567|NCT02857452||Lupus|
2956568|NCT02857439|Other|MD as first examiner|Patients will be examined according to a standardized physical examination item list
2956569|NCT02857439|Other|Triage nurse as first examiner|Patients will be examined according to a standardized physical examination item list
2956575|NCT02857374|Experimental|Diagnostic (intravital microscopy)|Patients receive indocyanine green and fluorescein sodium injection IV and then undergo intravital microscopic observation over 15-20 minutes during standard of care sentinel node biopsy.
2956576|NCT02857361|Experimental|Treatment A: Simultaneous Administration|Sublingual ketamine 50mg (2 x 25mg wafers) administered simultaneously at T=0 minute.
2956577|NCT02857361|Experimental|Treatment B: Sequential Administration|Sublingual ketamine 50mg (2 x 25mg wafers) administered sequentially, one 25 mg wafer at T=0 minute and one 25 mg wafer at T=3 minutes.
2956578|NCT02857348|Experimental|Adventure video game|Physicians in this arm of the trial will be asked to play Night Shift, an adventure video game, for one hour.
2956579|NCT02857348|Active Comparator|Educational Module|Physicians in this arm of the trial will be asked to use myATLS, an app designed by the American College of Surgeons to serve as an adjunct to the ATLS course, and Trauma Life Support MCQ Review, an app designed to help students prepare for the ATLS exam. They will be asked to spend at least one hour on the combined tasks.
2956580|NCT02857335|Other|study group|patients with benign intracranial hypertension ages 8-16 years
2956581|NCT02857322|Other|subjects with documented psychiatric pathology|
2956582|NCT02857309|Other|Device implant|Patients randomized to the treatment group will receive optimal medical therapy for heart failure. and implantation of the OPTIMIZER System.
2956583|NCT02857309|Active Comparator|Optimal medical therapy|Patients randomized to the control group will receive optimal medical therapy for heart failure.
2956584|NCT02857283|Placebo Comparator|Filtered Air|filtered clean air
2956585|NCT02857283|Active Comparator|Ozone|The ozone concentration will be varied from 0.06 to 0.08
2956586|NCT02857270|Experimental|LY3214996 Dose Escalation|LY3214996 given orally once a day (or twice a day) for 21 days.
2956587|NCT02857270|Experimental|LY3214996 + Midazolam|"(Preliminary Drug-Drug Interactions [DDI])~LY3214996 given orally (dose timing will be determined) and midazolam given orally on cycle 1 day 1 and cycle 1 day 16 (21 day cycles except cycle 1 only = 22 days)."
2956588|NCT02857270|Experimental|LY3214996 Monotherapy|LY3214996 given orally (dose timing will be determined) during each 21 day cycle.
2956589|NCT02857270|Experimental|LY3214996 + Abemaciclib|Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and abemaciclib given orally (single dose given during lead in period) twice a day every 12 hours during 21 day cycle.
2956590|NCT02857270|Experimental|LY3214996 + Nab-Paclitaxel + Gemcitabine|Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and nab-paclitaxel given intravenously (IV) on day 1, 8, and 15 and gemcitabine IV on day 1, 8, and 15 during each 28 day cycle.
2956591|NCT02857257|Experimental|Treatment arm|Only one treatment arm. Patients are allocated under disease condition and later treated with ACHIM. The post-treatment disease progression is monitored.
2956592|NCT02857244|Other|Open-Label Treatment Arm|"Each patient will take Duloxetine 30mg for 1 week, followed by 60mg qam for 1 week, 90mg qam for 1 week, and 120mg qam for 1 week, if tolerated. The patient will be taking Duloxetine for a total of 4 weeks. The dose of Duloxetine will be reduced if the patient cannot tolerate. Donepezil will then be added to Duloxetine 120mg qam (or the highest dose the patient can tolerate) by 5mg qd for 1 week, followed by 10mg qd for 1 week.~After a 4-week washout period, each patient will take Modafinil 100mg qam for one week, followed by 200mg qam for 1 week.~Patients will come into the medical center on 5 occasions, 1 for screening/baseline, 1 after completion of duloxetine, 1 after completion of duloxetine+donepezil, 1 after four-week washout, 1 after completion of modafinil."
2956593|NCT02857218|Experimental|Diagnostic (ferumoxytol, MRI)|Patients receive ferumoxytol IV over 15 minutes and then undergo ferumoxytol-enhanced MRI (Magnetic Resonance Imaging) after 24-36 hours and before surgery at week 12.
2956594|NCT02857205|Other|Fecal samples|High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
2956595|NCT02857192|Experimental|Horton|
2956596|NCT02857192|Placebo Comparator|control|
2956597|NCT02857166|Experimental|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
2956598|NCT02857153|Experimental|Low-level MAP|According to grouping, MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.
2956599|NCT02857153|Experimental|High-level MAP|According to grouping, MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
2956600|NCT02857127|Experimental|Intervention Group|A group of people who participated in the walking program during a six month period. This group also received an educational material and attended meetings for behavioral change strategies.
2956601|NCT02857127|No Intervention|Control Group|A group of people who did not receive the educational material and did not participated in any of the activities offered by the research team, such as walking classes and meetings for behavioral change.
2956602|NCT02857114|Other|massage|
2956603|NCT02857088|Experimental|depressed patients|patient with a current unipolar major depressive disorder intervention: olfactory assessment, image visualization and psychophysiological assessment
2956604|NCT02857088|Experimental|non depressed subject|subject without a current unipolar major depressive disorder intervention: olfactory assessment, image visualization and psychophysiological assessment
2956605|NCT02857075||Rhesus positive individuals|Red cell concentrates from RH1 individuals from each ABO group is used for the study. Red cell concentrates derived from blood donation.
2956606|NCT02857075||Rhesus negative individuals|red cell concentrates from RH-1 individuals from each ABO group is used for the study. Red cell concentrates derived from blood donation.
2956607|NCT02857062|Experimental|E45 Eczema Repair Emollient|Open label, single arm study to evaluate the skin tolerance of E45 Eczema Repair Emollient in babies and children
2956608|NCT02857049|Experimental|Geriatric patients administered with ONS|Oral nutritional supplements (ONS) degustation
2956609|NCT02857036|Experimental|responder|responder to antidepressant treatment
2956610|NCT02857036|Experimental|non responder|non responder to antidepressant treatment
2956611|NCT02857023|Experimental|Cogmed intervention|Cogmed RM Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed)
2956612|NCT02857023|Experimental|Cogmed-waitlist control|Cogmed RM Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed)
2956613|NCT02857010|Experimental|Allogenic Mesenchymal stem cells|Intravenous allogenic bone marrow derived mesenchymal stem cells: 4 doses of 2 x 106/kg administered on days 1, 4, 11 and 18
2956614|NCT02857010|Placebo Comparator|Placebo|Solution without cells on days 1, 4, 11 and 18
2956615|NCT02856997|Experimental|Chidamide with ICE regimen|"Drugs:Chidamide and ICE regimen (ifosfamide, Mesna,Carboplatin and etoposide): Chidamide 20mg on d1,4,8,11;ifosfamide 1.2g/ m2，d1-4,ivg during 4 hours; Mesna 0.4g, 0,4,8 hours during Ifosfamide transfusion, ivg, d1-4; Carboplatin AUC=4, d2,ivg; etoposide 65mg/m 2, d1-4, ivg. 3 weeks as 1 course, for 6 courses.~if the effect is PR or better than PR, go to auto-stem cell transplantation, no further treatment with Chidamide is needed.~If the effect is PR or better than PR and no auto-stem cell transplantation available,Chidamide 20mg orally, twice every week, till the end of the trial."
2956616|NCT02856984||ZIKV infected women|The study will prospectively enroll pregnant women up to 17 weeks and 6 days gestation and follow them through their pregnancy for clinical evidence of acute ZIKV infection while controlling for potential confounders. All pregnant women will be followed throughout the pregnancy, delivery, and 6 weeks postpartum. Outcomes in women, the developing fetus, and infants will be assessed.
2956617|NCT02856984||Control (uninfected women)|The women who remain uninfected will serve as the internal comparison group. The infants who remain uninfected at delivery and throughout the follow-up period will serve as the internal comparison group.
2956618|NCT02856958|Experimental|Operative|Peroneal nerve decompression
2956619|NCT02856958|Active Comparator|Non-operative|Physical therapy
2956620|NCT02856932|Experimental|Glass Ionomer with Glass Hybrid technology|Intervention
2956621|NCT02856932|Active Comparator|Conventional high viscosity Glass Ionomer|Comparator
2956622|NCT02856919|Other|Mirvaso® gel|Mirvaso® gel (5 mg/g brimonidine tartrate)
2956623|NCT02856906|Experimental|Occlusal adjustment group|Patients in this group will receive treatment of occlusal adjustment based on the clinical and lab examination results.
2956624|NCT02856893|Experimental|Osimertinib till progression|Osimertinib until PD according to RECIST 1.1
2956625|NCT02856893|Experimental|Gefitinib till + blood test/progression than Osimertinib|"Gefitinib until emergence of positive T790M status (cfDNA T790M positive progression) followed by Osimertinib until second PD according to RECIST 1.1"
2956626|NCT02856893|Active Comparator|Gefitinib till progression than Osimertinib|Gefitinib until PD according to RECIST 1.1 followed by Osimertinib until PD according to RECIST 1.1
2956627|NCT02856880|Experimental|Test zinc-IPMP toothpaste|Rinse with preprepared slurry of toothpaste in 10 milliliter (mL) water for 60 seconds(s) followed by rinse with 10mL water
2956628|NCT02856880|Experimental|Test zinc non- IPMP toothpaste|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
2956629|NCT02856880|Active Comparator|Positive control Toothpaste|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
2956630|NCT02856880|Active Comparator|SLS Negative Control|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
2956631|NCT02856880|Active Comparator|non-SLS negative control|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
2956632|NCT02856867|Active Comparator|mFOLFOX6 + Nintedanib|"Patients will receive nintedanib in combination with mFOLFOX6 (5-Fluorouracil 400 mg/m2 bolus on day 1, 5-Fluorouracil 2400 mg/m2 continuous infusion over 46 hours starting on day 1, Leucovorin 400 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1) via IV infusions every 2 weeks (14 days).~Dose modification of nintedanib and mFOLFOX6 is allowed. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression."
2956633|NCT02856867|Placebo Comparator|mFOLFOX6 + Placebo|"Patients will receive placebo in combination with mFOLFOX6 (5-Fluorouracil 400 mg/m2 bolus on day 1, 5-Fluorouracil 2400 mg/m2 continuous infusion over 46 hours starting on day 1, Leucovorin 400 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1) via IV infusions every 2 weeks (14 days).~Dose modification of placebo and mFOLFOX6 is allowed. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression."
2956634|NCT02856854|Experimental|EMB-001 (oral)|EMB-001 will be orally administered for 7 consecutive days, twice daily for 6 days followed on the last day by one EMB-001 oral dose (QD) in the morning. Three hours later Cocaine IV or Saline IV will be administered followed 2 hours by the other (saline or cocaine).
2956635|NCT02856854|Placebo Comparator|Placebo (oral)|PLB-to-match EMB-001 will be orally administered for 7 consecutive days, BID for 6 days, followed on the last day by one PLB oral dose in the morning. Three hours later Cocaine IV or Saline IV will be administered followed 2 hours by the other (saline or cocaine).
2956636|NCT02856841||optimum cytoreduction|without any gross tumor residue after surgery
2956637|NCT02856841||Suboptimum cytoreduction|with any gross tumor residue after surgery
2956638|NCT02856828|Experimental|Digital Image Enhancement (DIE) Group|A novel digital image enhancement technology will be used intraoperatively
2956639|NCT02856828|No Intervention|Control Group|Standard intraoperative imaging will be used intraoperatively
2956640|NCT02856815|Experimental|Immuncell-LC group|Adjuvant adoptive immune therapy using a CIK cell agent(Immuncell-LC) 12 times(5 treatments at a frequency of once per week, followed by 5 treatments every 2 weeks, and finally 2 treatments every 4 weeks.
2956641|NCT02856815|No Intervention|Non-treatment group|Non-treatment
2956642|NCT02856802|Experimental|DFN-02|DFN-02 Active
2956643|NCT02856802|Other|Placebo|DFN-02 Placebo
2956644|NCT02856789||Healthy volunteers (HV)|"HV without any known treatment, without any coagulation trouble and with normal hemostasis results.~FS and TEG will be processed to define the most relevant parameters for normal range and the correlation between both assays.~Tests performed on HV :~Routine hemostasis tests~Fibrin structure (FS)~Thromboelastography (TEG)~Specialized hemostasis tests"
2956690|NCT02856503|Experimental|Phase 2 - VD|Weekly oral dose of 50,000 IU Vitamin D3 (VD) therapy for the duration selected from the phase I part of the study.
2956645|NCT02856789||Patients without coagulation disorder|"Hospitalized patients without coagulation disorder or abnormal hemostasis and hematological results and witout ongoing treatment (mainly anticoagulant treatment). FS and TEG will be processed to determine the most relevant parameters to discriminate patients from normal range and the correlation between assays.~Tests performed on patients :~Routine hemostasis tests~Fibrin structure (FS)~Thromboelastography (TEG)"
2956646|NCT02856789||Patients with coagulation disorders|"Hospitalized patients with coagulation disorders, mainly trauma patients or abnormal hemostasis and hematological results, mainly decreased fibrinogen level . FS and TEG will be processed to determine the most relevant parameters to discriminate patients from normal range and the correlation between assays.~Tests performed on patients :~Routine hemostasis tests~Fibrin structure (FS)~Thromboelastography (TEG)"
2956647|NCT02856776|Experimental|Arm 1: 600 IU vitamin D|Subject will receive 600 IUs of vitamin D3/day for 24 weeks.
2956648|NCT02856776|Experimental|Arm 2: 4,000 IU vitamin D|Subject will receive 4,000 IUs of vitamin D3/day for 24 weeks
2956649|NCT02856776|Experimental|Arm 3: 10,000 IU vitamin D|Subjet will receive 10,000 IUs of vitamin D3/day for 24 weeks
2956650|NCT02856776|Experimental|Arm 4: Mixed vitamin D dosages|Subject will receive 600 IUs of vitamin D3/day for the first 8 weeks, 4,000 IUs of vitamin D3/day for the next 8 weeks, and 10,000 IUs of vitamin D3/day for the final 8 weeks.
2956651|NCT02856750|Experimental|gabapentin|gabapentin 300 mg three times daily x 30 d
2956652|NCT02856750|No Intervention|placebo|no gabapentin administered to this arm.
2956653|NCT02856737|Experimental|Earplugs and eye masks (to be used concurrently)|Group will include patients consented to the use of earplugs and eye masks. Patients will participate in the intervention nightly
2956654|NCT02856724|Experimental|Early amniotomy and PGE2|10 mg PGE2 vaginal ovul(Propess) Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
2956655|NCT02856724|Active Comparator|PGE2|10 mg PGE2 vaginal ovul(Propess)
2956656|NCT02856711|Experimental|Trauma-informed group|These groups will use the enhanced Centering Pregnancy curriculum.
2956657|NCT02856711|No Intervention|Control group|These groups will use the standard CenteringPregnancy curriculum.
2956658|NCT02856698|Experimental|midazolam|The dose of midazolam intravenously will be of 1 mg which may be repeated until a total dose of 3 mg.
2956659|NCT02856698|Active Comparator|morphine|The dose of morphine intravenously is of 2-4 mg which may be repeated until a total dose of 8 mg if the patient continue suffering from severe anxiety or distress caused by APE
2956660|NCT02856685|Experimental|PLM60|Mitoxantrone Hydrochloride Liposome
2956661|NCT02856672|Active Comparator|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
2956662|NCT02856672|Active Comparator|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
2956663|NCT02856646||Population with Condition|Community Sample
2956664|NCT02856633||Vitaliti System|
2956665|NCT02856620||Moderate AS with HF|
2956666|NCT02856620||Severe AS with HF|
2956667|NCT02856620||Moderate AS without HF|
2956668|NCT02856620||Severe AS without HF|
2956669|NCT02856620||HFpEF without AS|
2956670|NCT02856620||Normal age-matched controls|
2956671|NCT02856607||Group I|patient for whom diagnosis and medical care are realized in a referent center with cardiac surgery
2956672|NCT02856607||Group II|patients secondary addressed to a referent center with cardiac surgery
2956673|NCT02856607||Group III|patients for which the totality medical care are performed in non-referent health center
2956674|NCT02856594|Experimental|Dexmedetomidine-induced sleep|Precedex (Dexmedetomidine) intervention: Intravenous administration of 1mcg/kg over 40 minutes.
2956675|NCT02856594|Placebo Comparator|Placebo|Placebo of normal saline: Intravenous administration of normal saline over 40 minutes.
2956676|NCT02856581|Experimental|Intervention group (varenicline and behavioral intervention)|Patients receive varenicline PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult.
2956677|NCT02856581|Placebo Comparator|Control group (placebo and behavioral intervention)|Patients receive placebo PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult.
2956678|NCT02856568|Experimental|Treatment (cisplatin, gemcitabine hydrochloride, ricolinostat)|Patients receive cisplatin IV followed by gemcitabine hydrochloride IV on days 1 and 8, and ricolinostat PO on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2956679|NCT02856555|Experimental|GS-0976 5 mg|GS-0976 5 mg + placebo for 12 weeks
2956680|NCT02856555|Experimental|GS-0976 20 mg|GS-0976 20 mg + placebo for 12 weeks
2956681|NCT02856555|Experimental|Placebo|Placebo for 12 weeks
2956682|NCT02856529|Experimental|Intervention|A BICSL certified trainer conduct the intervention. It includes hand on training session standardized in a scientific way. The participants trained on hand hygiene and use of PPE. Also, it includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator.
2956683|NCT02856529|Active Comparator|Control|A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
2956684|NCT02856516|Experimental|Boost Glucose Control (A)|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption in people with Diabetes.
2956685|NCT02856516|Experimental|Boost Glucose Control (B)|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption in people with Diabetes.
2956686|NCT02856516|Active Comparator|Boost Original|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption.
2956687|NCT02856503|Experimental|Phase 1 - Group A - VD 3 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 3 weeks.
2956688|NCT02856503|Active Comparator|Phase 1 - Group B - VD 4 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 4 weeks
2956689|NCT02856503|Active Comparator|Phase 1 - Group C - VD 5 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 5 weeks.
2956691|NCT02856477|Experimental|adapted treatment|the treatment dose is adapted to the metabolic capacity of the patient. intervention: urine analysis
2956692|NCT02856477|Experimental|non-adaptated treatment|the treatment dose is adapted to the metabolic capacity of the patient. intervention: urine analysis
2956693|NCT02856464|Experimental|Experimental|
2956694|NCT02856464|Other|Control|
2956695|NCT02856451||Patients Treated with Nivolumab followed by Encephalitis Event|Case series reported to the sponsor from various health care facilities
2956696|NCT02856425|Experimental|NSCLC of adenocarcinoma tumor hist|
2956697|NCT02856425|Experimental|NSCLC of squamous cell tumor histo|
2956698|NCT02856425|Experimental|Urothelial cancer|
2956699|NCT02856425|Experimental|Renal Cell cancer (RCC)|
2956700|NCT02856425|Experimental|Colo Rectal Cancer|
2956701|NCT02856425|Experimental|Ovarian cancer (OC)|
2956702|NCT02856425|Experimental|Hepatocellular (HCC)|
2956703|NCT02856425|Experimental|Mesothelioma (MPM)|
2956704|NCT02856412|Experimental|Veterans Group Exercise|Exercise 3 times weekly (for 12 weeks), with each total workout lasting approximately 60 minutes. Integrative Exercise incorporates elements of strength training, flexibility, cardiovascular training, and controlled breathing exercises.
2956705|NCT02856412|Active Comparator|Illness Management and Recovery|Attend 3 health education classes weekly (for 12 weeks), with each class lasting approximately 60 minutes. Illness Management and Recovery is an educational program focused on helping individuals more effectively manage their illnesses to pursue their personal recovery goals. The classes include the following topic areas which have been adapted for use in PTSD: recovery, practical facts about PTSD, stress-vulnerability, building social support, medications for PTSD, drug and alcohol use, reducing relapse, coping with stress, coping with persistent symptoms, getting needs met in the VA healthcare system, and living a healthy lifestyle.
2956706|NCT02856386|Experimental|polyphenol supplement|Dietary supplement administered 8 mL once daily
2956707|NCT02856373|Other|CPVT|catecholaminergic polymorphic ventricular tachycardia (CPVT) patients
2956708|NCT02856373|Other|long QT syndrome|long QT syndrome patients
2956709|NCT02856373|Other|ARVC|arrhythmogenic right ventricular cardiomyopathy (ARVC) patients
2956710|NCT02856373|Other|HCM|hypertrophic cardiomyopathy (HCM) patients
2956711|NCT02856373|Other|DCM|dilated non-ischemic cardiomyopathy (DCM) patients
2956712|NCT02856373|Other|ICM|ischemic cardiomyopathy (ICM) patients
2956713|NCT02856360|Experimental|Moderate Stiffness|Shoe condition that has moderate stiffness
2956714|NCT02856360|Active Comparator|High Stiffness|Shoe condition that has high stiffness
2956715|NCT02856347|Other|PET 18-FDOPA|"18F-DOPA will be administered with an activity of 1.5-4 MBq/kg (MegaBecquerel) in the IV (Intra venous) tubing to decrease the extravasation risk and tracer lymphatic migration. The injection site will be distant from pathologic area (forearm).~PET CT exam will start 10 min after tracer injection and will cover the whole body (10 to 30 min).~Other series of images will be done 50 min after tracer injection. Images will be interpreted."
2956716|NCT02856334||Chronic pelvic pain|Women with chronic pelvic pain
2956717|NCT02856334||Control group|Healthy women
2956718|NCT02856308|Experimental|Hairstetics hair implant device|Subjects will undergo the Hairstetics prosthetic hair implantation starting with a test of up to 100 fibers and up to 2 additional implantation sessions with up to 1500 fibers overall per subject. The implantation will be carried out according to the device IFU.
2956719|NCT02856295|Active Comparator|clexane according to weight group|clexane dose adjusted for woman's weight according to: weight < 90 kg - 40mg, 91-130kg - 60 mg, 131-170kg - 80mg, >170kg-100mg.
2956720|NCT02856295|Active Comparator|clexane mg per kg|clexane dose of 1mg/kg up to 120 mg
2956721|NCT02856282||Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Two sprays into each nostril once a day, preferably in the morning. Once symptoms are under control ,a maintenance dose of one spray may be used accordingly
2956722|NCT02856269|Active Comparator|45 mg daily|Participants in this arm will take a daily 45 mg dose of zinc gluconate.
2956723|NCT02856269|Active Comparator|90 mg daily|Participants in this arm will take a daily 90 mg dose of zinc gluconate.
2956724|NCT02856256|Experimental|RedBull® energy drink|
2956725|NCT02856230|Experimental|Ranger SL DEB angioplasty|patients filling general and angiographic inclusion/exclusion criteria will have an BTK angioplasty using one or several Ranger SL drug-eluting balloons
2956726|NCT02856217|Other|Group 1, tunneling group|Placement of mesh between vaginal apex and sacrum is retroperitoneally: creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum.
2956727|NCT02856217|Other|Group 2, non-tunneling group|Placement of mesh between vaginal apex and sacrum is retroperitoneally: incised and sutured peritoneum between vaginal apex and sacrum
2956728|NCT02856204||Diagnostic (collection of blood samples)|Patients undergo collection of blood samples before and during the episode of febrile neutropenia for up to 6 weeks.
2956729|NCT02856191|Other|Septic shock|
2956730|NCT02856178|Experimental|F901318 + Caspofungin|"Patients will receive F901318 intravenously, starting 24 - 72 h after last chemotherapy infusion:~Day 1: 4.0 mg/kg i.v. b.i.d.~Day 2 until resolution of neutropenia (max. until day 14): 2.0 mg/kg i.v. b.i.d.~Day after last i.v. application: 2.0 mg/kg oral q.d.~Concomitant medication:~For Candida prophylaxis, concomitant caspofungin will be administered from the 4th day of chemotherapy until end of neutropenia:~Chemo day 4: Caspofungin 70 mg i.v. q.d.~Chemo day 5 until resolution of neutropenia or until end of F901318 treatment (day 15): Caspofungin 50 mg i.v. q.d.~All patients will undergo chemotherapy for acute leukaemia according to local clinical standard."
2956731|NCT02856165|Experimental|High-flow nasal canula oxygen therapy|High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (Fisher&Paykel (F&P), NZ)
2956732|NCT02856165|Active Comparator|Low-flow oxygen therapy|Low-flow oxygen therapy with standard nasal canula
2956760|NCT02855996|No Intervention|Control|"Fathers waitlisted for participation in the Fathers in Action/Padres Activos (FA/PA) program."
2956809|NCT02855658|Experimental|SS-1|SS-1 is composed of the powder of Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. Patients take 6 gram of experiment medicine three times per day.
2957297|NCT02852356|Experimental|MIRI-TL Timelapse Incubator|Timelapse incubator
2956733|NCT02856152|Experimental|Treatment A Then B Then D Then C|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment A on Day 1 of first intervention period, followed by Treatment B on Day 1 of second intervention period, followed by Treatment D on Day 1 of third intervention period, and then Treatment C on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
2956734|NCT02856152|Experimental|Treatment B, Then C, Then A, Then D|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment B on Day 1 of first intervention period, followed by Treatment C on Day 1 of second intervention period, followed by Treatment A on Day 1 of third intervention period, and then Treatment D on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
2956735|NCT02856152|Experimental|Treatment C, Then D, Then B, Then A|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment C on Day 1 of first intervention period, followed by Treatment D on Day 1 of second intervention period, followed by Treatment B on Day 1 of third intervention period, and then Treatment A on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
2956736|NCT02856152|Experimental|Treatment D, Then A, Then C, Then B|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment D on Day 1 of first intervention period, followed by Treatment A on Day 1 of second intervention period, followed by Treatment C on Day 1 of third intervention period, and then Treatment B on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
2956737|NCT02856139||1 (MB- and VL-)|without mottled fluorescent band (MB) and vascular leakage (VL)
2956738|NCT02856139||2 (MB+ and VL-)|with mottled fluorescent band (MB), without vascular leakage (VL)
2956739|NCT02856139||3 (MB-/+ and VL+)|with or without mottled fluorescent band (MB), with vascular leakage (VL)
2956740|NCT02856126|Experimental|HAIC plus sorafenib|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: HAIC Regimen Drug: Oral Sorafenib
2956741|NCT02856126|Active Comparator|TACE plus sorafenib|Procedure/Surgery: Transarterial chemoembolization Drug: TACE regimen Drug: Oral Sorafenib
2956742|NCT02856113|Experimental|Alogliptin 25 mg|Alogliptin benzoate 25 mg tablets, orally, once daily for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period.
2956743|NCT02856113|Placebo Comparator|Placebo|Alogliptin benzoate placebo-matching tablets, orally, once daily for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period.
2956744|NCT02856100||Patients with CRPC, evidence of metastases, planned treatment|
2956745|NCT02856087|Placebo Comparator|group LR|low dose remifentanil (1 ng/ml of Ce) with normal saline infusion
2956746|NCT02856087|Active Comparator|group HR|High dose remifentanil infusion (4ng/ml of Ce) with normal saline infusion
2956747|NCT02856087|Experimental|group HR-N|remifentanil infusion at 4ng/ml of Ce with naloxone infusion
2956748|NCT02856074|Experimental|Ischemic stroke patients|
2956749|NCT02856061|Other|PRT|Children with ASD who are currently receiving PRT treatment.
2956750|NCT02856061|No Intervention|Wait List / Non-Treatment Control|Children with ASD who are not currently receiving PRT treatment.
2956751|NCT02856061|No Intervention|Typically Developing|Children without ASD or developmental delay.
2956752|NCT02856048|Experimental|Triptorelin (GnRHa) + Chemotherapy|Triptorelin LP 3 mg (DECAPEPTYL LP 3 mg, IPSEN) 3 mg every 28±3 days, intramuscular during chemotherapy
2956753|NCT02856048|No Intervention|Chemotherapy alone|Patient having a chemotherapy without drug injection for fertility preservation
2956754|NCT02856035|No Intervention|Healthy Group|"The healthy adult participants will only participate in the preparation phase during which they will participate in testing data collection activity only, using fMRI and fNIRS, and rtfMRI and fNIRS + FES."
2956755|NCT02856035|Experimental|Stroke Group|"Intervention: Stroke subjects will receive neural feedback plus FES and motor learning intervention that spans 3 phases and up to a total of 60 sessions.~Phase I: real-time fMRI neural feedback training; Phase II: rtfNIRS-based neural feedback learning (built upon self-regulation strategies learned in Phase I and also assisted by neurally-triggered, peripherally-directed FES motor practice of wrist and finger extension); Phase III: motor learning minus neural feedback for an additional 46 sessions; Phase IV: follow-up testing at 3 months after-treatment ends"
2956756|NCT02856022|Experimental|Electrical ilioinguinal nerve stimulation|
2956757|NCT02856022|Active Comparator|Intravesical Irrigation|
2956758|NCT02856009|Experimental|patient|
2956759|NCT02855996|Experimental|Intervention|"Fathers will be randomly assigned to participate in the Fathers in Action/Padres Activos (FA/PA) intervention program to support fathers' healthy relationships with their children and support their co-parenting skills."
2956806|NCT02855671||Healthy volunteers|
2956761|NCT02855983|Experimental|A (Fat grafting initially)|"A PATHWAY -~Intervention: autologous fat grafting to the foot, occur first~Fat graft study intervention procedure to occur first, next post-operative follow up visits (V1-V4). The Subject will after Month 6 (V4) crossover to Pathway B to complete Observation visits V1 (Month 2) and V2 (Month 6). After completion of V2 (Month 6), the subject will have completed study participation."
2956762|NCT02855983|Other|B (Standard of care initially)|"B PATHWAY -~Intervention: standard of care (observation) for the first year, followed by autologous fat grafting to the foot~Observation visit will occur first, next the subject will have two Observation visits V1 (Month 2) and V2 (Month 6). The subject will then crossover to Pathway A. The subject will be assessed by the PI his/her for continued study eligibility. Once the continued eligibility has been determined, the subject will have the interventional fat graft procedure and subsequent post-operative follow up visits (V1-V4). After completion of Post-op V4 (Month 6), the subject will have completed study participation."
2956763|NCT02855970|Experimental|patient|
2956764|NCT02855957|Other|Blood sample|A blood collection is carry out in the three populations of patients during the day of their enrolment.
2956765|NCT02855944|Experimental|Rucaparib|"Drug: Oral rucaparib~600 mg BID Other Names: •CO-338~PF 01367338~AG 14699~Rubraca"
2956766|NCT02855944|Active Comparator|Chemotherapy|"Monotherapy platinum (cisplatin or carboplatin) or platinum-based doublet chemotherapy (carboplatin/paclitaxel, carboplatin/gemcitabine, or cisplatin/gemcitabine administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.~Single agent paclitaxel will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision."
2956767|NCT02855931|Experimental|Middle turbinate resection|Resection of one middle turbinate
2956768|NCT02855931|No Intervention|Middle turbinate preservation|Preservation of one middle turbinate
2956769|NCT02855918|Other|Blood sample for genetic purpose|"All the participants performed the same evaluations and blood analysis.~The study is composed of 3 groups :~depressed patients with an history of suicide attempt~depressed patients without any history of suicide attempt~healthy controls without any history of psychopathology"
2956770|NCT02855905|Experimental|Coronary artery disease patients|Coronary artery disease patients are exposed to brief cold exposure (-15 C for 30 min) mainly subjected to facial region during which their cardiovascular responses are registered. Exposure was repeated 4 times: rest and exercise in 22 C and rest and exercise in -15 C.
2956771|NCT02855892|Placebo Comparator|Control Group|- Placebo, two-week interval, intradermal administration
2956772|NCT02855892|Experimental|Study Group 1|- GV1001 0.4 mg, two-week interval, intradermal administration
2956773|NCT02855892|Experimental|Study Group 2|- GV1001 0.56 mg, two-week interval, intradermal administration
2956774|NCT02855892|Experimental|Study Group 3|"- GV1001 0.56 mg, four-week interval, intradermal administration~: Should be visited every two weeks (GV1001 0.56 mg or placebo is administered alternately at every visit.)"
2956775|NCT02855879||CAD patients|
2956776|NCT02855866|Experimental|cryotherapy|
2956777|NCT02855866|Active Comparator|Cortisone aerosol|
2956778|NCT02855866|Placebo Comparator|Management|
2956779|NCT02855853|Experimental|serious game|
2956780|NCT02855853|Placebo Comparator|control|
2956781|NCT02855840||systemic lupus erythematous|
2956782|NCT02855840||systemic sclerosis|
2956783|NCT02855840||inflammatory myopathy|
2956784|NCT02855801|Experimental|constant exercise without cryotherapy|constant exercise without cryotherapy
2956785|NCT02855801|Experimental|constant exercise with cryotherapy|constant exercise with cryotherapy
2956786|NCT02855801|Experimental|intermittent exercise, no cryotherapy|intermittent exercise without cryotherapy
2956787|NCT02855801|Experimental|intermittent exercise and cryotherapy|intermittent exercise with cryotherapy
2956788|NCT02855788|Experimental|POLF regimen|Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly
2956789|NCT02855775|Experimental|Bevacizumab|Bevacizumab in monotherapy or in association to other anticancer agents pharmacokinetic assessment with blood sample with additional blood sample
2956790|NCT02855775|Experimental|Trastuzumab|Trastuzumab in monotherapy or in association to other anticancer agents pharmacokinetic assessment with blood sample with additional blood sample
2956791|NCT02855762|Other|Dietary Intervention Group|Subject will be guided to eat a high polyunsaturated fatty acid diet.
2956792|NCT02855749|No Intervention|landmark group|percutaneous tracheostomy with traditional landmark technique
2956793|NCT02855749|Active Comparator|ultrasound-guided long axis group|percutaneous tracheostomy will be implemented In the real-time ultrasound-guided in plane technique
2956794|NCT02855749|Active Comparator|ultrasound-guided short axis group|percutaneous tracheostomy will be implemented In the real-time ultrasound-guided out of plane technique
2956795|NCT02855736|Experimental|Intervention group|Positive Psychology (gratitude journal)
2956796|NCT02855736|Placebo Comparator|Control group|Alimentary list
2956797|NCT02855723|Active Comparator|GS strategy|sentinel node biopsy
2956798|NCT02855723|Other|Classic strategy|systematic lymphadenectomy
2956799|NCT02855710|Other|No training|Parkinsonian Patients with no Rhythm Workers training perceptive timing and senrorimotor timing
2956800|NCT02855710|Other|Perceptive timing training|Parkinsonian Patients with Rhythm Workers training perceptive timing
2956801|NCT02855710|Other|Sensorimotor timing training|Parkinsonian Patients with Rhythm Workers training sensorimotor timing
2956802|NCT02855710|Other|Healthy volunteers|Healthy people with Rhythm Workers training perceptive timing
2956803|NCT02855697|Experimental|Olaparib +/- cediranib|Patients are administered two courses of maintenance olaparib following chemotherapy. It is possible for patients to take cediranib during the second course of olaparib if recommended as per the protocol.
2956804|NCT02855684|Experimental|Toujeo - insulin glargine (U300)|Toujeo - Insulin glargine (U300) will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks
2956805|NCT02855684|Active Comparator|Lantus - insulin glargine|Lantus - Insulin glargine will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks
2956810|NCT02855658|Placebo Comparator|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
2956811|NCT02855645|Experimental|Trichosanthes root|Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
2956812|NCT02855645|Placebo Comparator|Placebo|Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
2956813|NCT02855632|Experimental|G-CSF|G-CSF(1.8ml) will be injected into the uterine cavity by insemination catheter 7 days after first hysteroscopic adhesiolysis.
2956814|NCT02855632|Placebo Comparator|Normal saline|equal volume of normal saline(1.8ml) will be injected into the uterine cavity by insemination catheter 7 days after first hysteroscopic adhesiolysis.
2956815|NCT02855619|Active Comparator|Martin|A threshold-based IMT is performed like used by Martin in a randomized trial in 2011, in a view of inspiratory strength increase.
2956816|NCT02855619|Active Comparator|Cader|A threshold-based IMT is performed like used by Cader in a randomized trial in 2012, in a view of inspiratory endurance increase.
2956817|NCT02855619|Experimental|EDRIC|A new threshold-based IMT is performed, in a view of both inspiratory strength and endurance increase.
2956818|NCT02855593||Physicians|Physicians who perform acupuncture
2956819|NCT02855593||Patients|Patients who have received acupuncture treatment in the past
2956820|NCT02855580||PGX Testing Based Treatment|Treatment will be administered based on the results that are obtained from the pharmacogenomics testing. Results from testing will be provided two weeks after specimen collection.
2956821|NCT02855580||Standard of Care Treatment|Treatment will be based off of the standard of care. Results from pharmacogenomics testing will be provided at the end of the study.
2956822|NCT02855567|Active Comparator|Acupuncture|Receives acupuncture during gynecological surgery at 5 known points for pain control. Needles will be placed prior to the start of surgery by an anesthesiologist trained in acupuncture after induction of anesthesia and while the patient is prepped for surgery. They will be in place for 15 minutes.
2956823|NCT02855567|Sham Comparator|Sham acupuncture|Receives acupuncture during gynecological surgery at sham points not associated with pain control. Needles will be placed by the gynecologic surgeon who is not trained in acupuncture after induction of anesthesia and prior to the start of the surgery. The needles will be removed immediately after placement.
2956824|NCT02855541|Experimental|Cycling intervention|Participants will use a small cycling device (DeskCycle) at their workstation for 15 minutes every hour that they are at work.
2956825|NCT02855528|Experimental|Reduction of radiation dose and diagnostic accuracy|Reduction of radiation dose during coronary artery calcium scoring with the use of a tin filter system.
2956826|NCT02855515|Experimental|Short-time diagnostic anaesthesia|The study population will consist of patients with obstructive sleep apnoea, which will be classified as mild, moderate, severe (patients who failed or refused primary CPAP treatment). The patients will undergo a short-time general anaesthesia in order to diagnose OSA when relaxed.
2956827|NCT02855502|Active Comparator|Prednisolone|dose: 15 mg per day(divided 5 mg TDS) dosage form: tablet duration administration: 30 days
2956828|NCT02855502|Placebo Comparator|Placebo|placebo given to patient: 3 tablet (divided TDS) dosage form: tablet duration administration: 30 days
2956829|NCT02855489|Experimental|Attitudes Only|The attitudes condition targeted cognitive and affective attitudes by pairing attitudinal messages with pictures, and included an evaluative conditioning task.
2956830|NCT02855489|Experimental|Norms Only|The norms condition utilized a group-affirmation exercise, personalized feedback, and group norms in an attempt to greater condom use norms.
2956831|NCT02855489|Experimental|Perceived Behavioral Control Only|The PBC condition included a condom application video, lubrication instructions, condom negotiation videos, and a detailed description regarding purchasing condoms.
2956832|NCT02855489|Experimental|Intentions Only|The intentions condition utilized implementation intentions in order to create condom use intentions.
2956833|NCT02855489|Experimental|Three Constructs|A three construct condition, which included attitudes, norms, and perceived behavioral control represented the core components of the TPB that are thought to work through intentions to result in behavior change.
2956834|NCT02855489|Experimental|Four Constructs|"A four construct condition (i.e., attitudes, norms, PBC, and intentions) was designed to represent the full TPB model intervention which we expected would be more successful than either the three-construct intervention or any of the single construct interventions."
2956835|NCT02855489|No Intervention|No-Treatment, Control|A no-treatment control condition, which solely consisted of pretest and posttest assessments, was included. This allowed us to obtain important information about how the theoretical constructs in the TPB change over time (or do not) in the absence of an experimental manipulation.
2956836|NCT02855476||Early Pre-manifest HD|Huntington's disease gene expansion carriers who not have clinical diagnostic motor features of HD
2956837|NCT02855476||Late Pre-manifest HD|Huntington's disease gene expansion carriers who not have clinical diagnostic motor features of HD, but who have a higher burden of disease compared to the Early Pre-manifest HD cohort
2956838|NCT02855476||Early Manifest HD|Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage I or Stage II HD
2956839|NCT02855476||Moderate Manifest HD|Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage III HD
2956840|NCT02855476||Late Manifest HD|Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage IV-V HD
2956841|NCT02855476||Controls|Have no known family history of HD; or have known family history of HD but have been tested for the huntingtin gene glutamine codon (CAG) expansion and are not at genetic risk for HD.
2956842|NCT02855450|Experimental|rhNGF|rhNGF (Recombinant Human Nerve Growth Factor) 180 μg/ml eye drops solution
2956843|NCT02855450|Placebo Comparator|Vehicle|Ophthalmic Placebo solution
2956844|NCT02855437|Active Comparator|Interactive Voice Response|The interactive voice response system (IVR) is an automated telephone system that is used to contact study participants. At enrollment the study coordinator will explain how the IVR works, planned survey schedule, and that participant -initiated calls to IVR are allowed.
2956944|NCT02854774|Active Comparator|Hip muscle activation/strengthening|4 weeks of exercises focused on activation and strengthening of hip extensor muscles.
2956845|NCT02855437|Active Comparator|RheumPro Smartphone Application|RheumPro is a UAB developed smartphone application to capture patient reported outcomes. At enrollment the study coordinator will explain how RheumPro works, planned survey schedule, and that participant -initiated surveys in RheumPro are allowed.
2956846|NCT02855424|No Intervention|control|traditional rehabilitation merely, no ergocycling training
2956847|NCT02855424|Experimental|the low-intensity exercise group|traditional rehabilitation plus the low-intensity ergocycling exercise training
2956848|NCT02855424|Experimental|the moderate-intensity exercise group|traditional rehabilitation plus the moderate-intensity ergocycling exercise training
2956849|NCT02855411|Experimental|0.15 mg PF-04958242|
2956850|NCT02855411|Experimental|0.5 mg PF-04958242|
2956851|NCT02855411|Placebo Comparator|Placebo|
2956852|NCT02855385||Patient group|This are patients who have current or previous history of rectal bleeding
2956853|NCT02855385||General Practitioner group|This are General practitioner who are in public or private hospitals who treat patients with rectal bleeding
2956854|NCT02855372||Lung transplanted patients|
2956855|NCT02855359|Experimental|denintuzumab mafodotin + RCHOP|Part A: denintuzumab mafodotin (SGN-CD19A) + RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
2956856|NCT02855359|Experimental|denintuzumab mafodotin + RCHP|Part A: denintuzumab mafodotin (SGN-CD19A) + RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone)
2956857|NCT02855359|Experimental|denintuzumab mafodotin + RCHOP or RCHP|Part B: denintuzumab mafodotin (SGN-CD19A) + RCHOP or RCHP
2956858|NCT02855359|Active Comparator|RCHOP|Part B: RCHOP alone: (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
2956859|NCT02855346|Experimental|200 mg of DPV|Each participant will receive a VR containing either 200 mg DPV or 200 mg DPV + 320 mg LNG. Participants will be randomized in a 1:1 ratio. The VR should be worn for approximately 14 consecutive days +/-1 day. The ring will be removed by the participant (or clinician/designee, if necessary) at the Product Use End Visit (PUEV)/Early Termination Visit. The participant will be followed for approximately 2 days following VR removal
2956860|NCT02855346|Experimental|200 mg of DPV + 320 mg LNG|Each participant will receive a VR containing either 200 mg DPV or 200 mg DPV + 320 mg LNG. Participants will be randomized in a 1:1 ratio. The VR should be worn for approximately 14 consecutive days +/-1 day. The ring will be removed by the participant (or clinician/designee, if necessary) at the Product Use End Visit (PUEV)/Early Termination Visit. The participant will be followed for approximately 2 days following VR removal
2956861|NCT02855333||Merendino Group (MER)|Patients who underwent merendino procedure for benign or early malignant lesions of the distal esophagus/gastroesophageal junction Perioperative data and EORTC and QLQ-C30 / QLQ-OES24 questionnaire
2956862|NCT02855333||Control Group (CON)|Patients who underwent alternative surgery for benign or early malignant lesions of the distal esophagus/gastroesophageal junction Perioperative data and EORTC and QLQ-C30 / QLQ-OES24 questionnaire
2956863|NCT02855320|Experimental|PE (patient education)|Nurse-led self-management education intervention : The intervention group will benefit from the nurse intervention in addition to usual care : follow up by their rheumatologist in hospital or private care according to usual management of biologics treatment.
2956864|NCT02855320|No Intervention|Standard|The control group will be followed up by their rheumatologist in hospital or private care according to usual management of biologics treatment.
2956865|NCT02855307|Active Comparator|Unannounced exercise|The target blood glucose of the algorithm will be as usual. A pre-meal full insulin bolus will be given.
2956866|NCT02855307|Active Comparator|Announced exercise with pre-meal full bolus|The target blood glucose of the algorithm will be increased and a pre-meal full bolus will be given
2956867|NCT02855307|Active Comparator|Announced exercise with reduced insulin bolus|The target blood glucose of the algorithm will be increased and the pre-meal insulin bolus will be reduced by 33%.
2956868|NCT02855294|Active Comparator|Oral contraceptive pills users|The participants received treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of ring/pill treatment followed by a 1-week pill-free period. The women were randomized in a 1:1 ratio to receive the COC containing 30 μg of EE and 3mg of drospirenone (Yasmin; Schering AG, Berlin, Germany)
2956869|NCT02855294|No Intervention|control|no drugs
2956870|NCT02855281||NSCLC with pleural effusion|The population for selection of potential study participants is comprised of clinical routine patients presenting with (suspected malignant) pleural effusion. These patients must have an indication for pleural puncture. The cause and nature of the pleural effusion at this time point will be unknown in many cases. To establish this, further diagnostic procedures are required. Only patients with confirmed diagnosis of non-small cell lung cancer will be included in the data analysis.
2956871|NCT02855268|Experimental|RG-012|1.5 mg/kg subcutaneous injection
2956872|NCT02855268|Placebo Comparator|Placebo|
2956873|NCT02855255|Active Comparator|NHS smoking cessation|NHS 1-1 smoking cessation programme. One thirty minute session followed by five shorter sessions (approx.10/15minutes) comprising Cognitive behavioural therapy/motivational interviewing to assist with smoking cessation.
2956874|NCT02855255|Active Comparator|Allen Carr's Easyway smoking cessation|Group smoking cessation programme. One 5/6 hour group session (plus one or two 3 hour booster sessions over the following 3 months for those who require them) comprising of Allen Carr's Easyway method being delivered in a spoken form.
2956875|NCT02855242|Other|Intervention Program Group|Lifestyle Counseling
2956876|NCT02855242|Active Comparator|Controls Group|No lifestyle counseling
2956877|NCT02855229||Phase 1 Participants [No Study Drug]|Phase 1 participants are not being assigned to any study drug.
2956878|NCT02855229||Phase 2 Participants [Placebo]|Phase 2 participants that are randomly assigned to the placebo.
2956879|NCT02855229||Phase 2 Participants [Amisulpride]|Phase 2 participants that are randomly assigned to take amisulpride.
2956880|NCT02855229||Phase 2 Participants [Vortioxetine]|Phase 2 participants that are randomly assigned to take vortioxetine.
2956881|NCT02855229||Phase 2 Participants [Modafinil]|Phase 2 participants that are randomly assigned to take modafinil.
2956945|NCT02854761|Experimental|SC administration|Subcutaneous (SC) administration of 500 ng of EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly, for 6 months
2957298|NCT02852356|Experimental|Culture Coin Dish|Culture Coin dish for embryo culture
2956882|NCT02855216|Experimental|Manual technique of sub-occipital inhibition|"The technique applied to Manual Group was performed with the patient supine position. Physiotherapist in a sitting position at the head of the subject with forearms resting on the table . Suboccipital region was located , and flexing the metacarpophalangeal joints 90º a pressure was made ventrally , relaxing the rest of the head in the heel of the hand.~The technique was performed for 5 minutes"
2956883|NCT02855216|Experimental|Self-treatment by way of Occipivot®|The technique applied to the Instrumental Group was performed with the patient supine in the same position as the Manual Group . It was previously instructed the subject how to proceed with the cushion Occipivot® , indicating the installation location and method of affixing , correcting him if the application was inadequate. The subject placed the cushion Occipivot® under the suboccipital region and told him he had to stay in that position for 5 minutes. A physiotherapist warned the patient at the end of the application time so that the subject had to be aware not to control it.
2956884|NCT02855203|Experimental|SABR + Pembrolizumab|SABR treatment (18Gy-20Gy/1#) followed by 200mg pembrolizumab IV once every 3 weeks for a total of 8 cycles
2956885|NCT02855190|Experimental|68Ga-citrate and 18F-FDG PET scans|The recruited subject with surgery/pathology proved periprosthetic joint infection will undergo total four PET scans at two different stages. At first stage, subsequent FDG PET/CT and Ga68 citrate PET/CT scans on different two days will be arranged before infective prosthesis is removed. Eight to twelve weeks after the 1st stage operation, patient will receive two subsequent PET/MR scans using Ga-68 Citrate and FDG on different two days, respectively. For the subject without surgery/pathology proved infection, PET/MR scans will NOT be applied.
2956886|NCT02855177|Placebo Comparator|Placebo|Placebo will be administered as an extemporaneously prepared suspension every 8 hours for 14 days
2956887|NCT02855177|Experimental|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared suspension every 8 hours for 14 days
2956888|NCT02855164|Experimental|Part A - Arm A|Tropifexor (LJN452)- - dose 1
2956889|NCT02855164|Experimental|Part A - Arm B|Tropifexor (LJN452)- - dose 2
2956890|NCT02855164|Experimental|Part A - Arm C|Tropifezor (LJN452)- - dose 3
2956891|NCT02855164|Experimental|Part A - Arm D|Tropifexor (LJN452)- - dose 4
2956892|NCT02855164|Placebo Comparator|Part A - Arm E|Placebo
2956893|NCT02855164|Experimental|Part B - Arm F|Tropifexor (LJN452)- - dose to be determined
2956894|NCT02855164|Experimental|Part B - Arm G|Tropifexor (LJN452)- - dose to be determined
2956895|NCT02855164|Placebo Comparator|Part B - Arm H|Placebo
2956896|NCT02855164|Experimental|Part C- Arm I|Tropifexor (LJN452)- dose 9
2956897|NCT02855164|Experimental|Part C- Arm J|Tropifexor (LJN452)- dose 10
2956898|NCT02855164|Placebo Comparator|Part C- Arm K|Placebo
2956899|NCT02855138|Active Comparator|study group|The study group consisted of 40 volunteers women with PCOS (aged 18- 40 years, BMI, 18-44kg/m2) who attended the obstetrics and gynecology clinic for the treatment of menstrual irregularities and hirsutism.The patients were treated with 0.6-0.8 mg/kg oral isotretinoin up to a total dose of 120-150 mg/kg. Treatment was started at 20 mg/day and gradually increased to the maximum of 40 mg/day. The patients were monitored monthly during isotretinoin treatment.
2956900|NCT02855138|No Intervention|control group|The control group of this study was pretreatment period of the same volunteer patients.
2956901|NCT02855125|Active Comparator|Combination Therapy (TAS-114/S-1) versus Monotherapy (S-1).|Treatment cycle of the experimental arm (TAS-114/S-1) and control arm (S-1 alone) will be 21 days: 14 days of treatment and 7 days recovery.
2956902|NCT02855125|Active Comparator|Monotherapy (S-1)|Treatment cycle of the active control arm (S-1) be 21 days: 14 days of treatment and 7 days recovery
2956903|NCT02855112|No Intervention|Control|A group of 10 patients only will be subjected to electro-myogram test every 3 month and then follow up for their survival time without any cell therapy intervention.
2956904|NCT02855112|Experimental|Adipose derived Mesenchymal Stem cell|A group of 10 patients will be take stem cells intra-thecally Dose: 1 million cells/kg for three times Intervals: Every 3 weeks.
2956905|NCT02855099|Active Comparator|CR group|patients will be referred to our rehabilitation centre at the following week after the procedure, and assigned to a personalized rehabilitation program for duration of 3 month.
2956906|NCT02855099|No Intervention|conservative group|No intervention
2956907|NCT02855086|Experimental|50 mg cetuximab-IRDye 800|"Patients receive cetuximab IV over 30 minutes and a lower dose of cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.~All patients undergo standard of care surgical resection of tumor on days 2 to 5."
2956908|NCT02855086|Experimental|100 mg cetuximab-IRDye 800|"Patients receive cetuximab IV over 30 minutes and a higher dose of cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.~All patients undergo standard of care surgical resection of tumor on days 2 to 5."
2956909|NCT02855073|Experimental|ReJoinTM Group|Subjects in this Group will receive ReJoinTM injections on day 1 and day 22, and Sodium Hyaluronate injection on day 8 and day 15.
2956910|NCT02855073|Active Comparator|Sodium Hyaluronate Group|subjects in this group will receive Sodium Hyaluronate injections on day 1, 8, 15, 22.
2956911|NCT02855060|Experimental|Pelvic Binder|Commercially available device used to stabilize the pelvis
2956912|NCT02855060|No Intervention|No Binder|Standard of care
2956913|NCT02855034|Other|Blood sample|All the patients performed the same blood samples for dosage: copeptine and protein S100B
2956914|NCT02855021|Other|Parkinson disease|Patients with a Parkinson disease with clinical diagnosis made for at least 5 years
2956915|NCT02855008|Experimental|STEPS|Experimental: Individuals with ID and residential staff in group homes receive 6 one-hour STEPS sessions over 12 weeks and a booster in week 18 following a standardized manual. Sessions include interactive games to build group cohesiveness, along with interactive discussion and practice. Participants are given session materials and 1-2 worksheets to practice learned skills and are asked to return the worksheets at the next session. Residential staff are given additional materials with tips on how to help residents practice social problem-solving skills between sessions. Highlights of each session using a standardized format are brought to the following session to help with engagement and provide cues for retention of materials.
2956946|NCT02854761|Experimental|IM administration|Intramuscular (IM) adminstration of 500 ng EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly for 6 months
2957413|NCT02851446||no DS|
2956916|NCT02855008|Active Comparator|Food for Life|Active Comparator: Individuals with ID and residential staff in group homes receive 6 one-hour Food for Life sessions over 12 weeks and a booster in week 18 following a standardized manual. Sessions include interactive games regarding food and nutrition followed, along with interactive discussion and practice. Participants are given session materials and 1-2 worksheets to practice learned skills and are asked to return the worksheets at the next session. Residential staff are given additional materials with tips on how to help residents practice Food for Life skills between sessions. Highlights of each session using a standardized format are brought to the following session to help with engagement and provide cues for retention of materials.
2956917|NCT02854995|Other|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce.
2956918|NCT02854995|Other|preputioplasty with intralesional injection of triamcinolone|(ii) preputioplasty with intralesional injection of triamcinolone: longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile.
2956919|NCT02854982||Prostate Cancer|Group drawn of the case group of the case control study, entitled EPICAP
2956920|NCT02854982||No Prostate Cancer|Group drawn of the control group of the case control study, entitled EPICAP
2956921|NCT02854969|No Intervention|epinephrine auto-injector|3 months using the epinephrine auto-injector alone, and after that 3 more months using the epinephrine auto-injector + medical device
2956922|NCT02854969|Experimental|epinephrine auto-injector + medical device|"Device: Anapphylaxis is a medical device with a case for an epinephrine autoinjector that connects via Bluetooth to a mobile application~3 months using the epinephrine auto-injector + medical device , and after that 3 more months using the epinephrine auto-injector alone"
2956923|NCT02854956|Other|X-linked Mental retardation|This is an observational study which will allow to precisely describe the phenotype associated to each X-linked mental retardation gene.
2956924|NCT02854956|Other|Control Group|This group will be compared to X-linked mental retardation group in order to obtain a baseline on some cognitive tests.
2956925|NCT02854943||Critically ill patients|Male and female critically ill patients admitted to the Charité - University Medicine Berlin during 2000 and 2016.
2956926|NCT02854917||Memantine Alone|"10 subjects who previously participated in the Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial study will be enrolled in this cohort. These subjects received memantine for a period of 28 weeks."
2956927|NCT02854917||Memantine plus Individualized Management of AD|"10 subjects who previously participated in the Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial study will be enrolled in this cohort. These subjects received memantine plus individualized management of AD for a period of 28 weeks."
2956928|NCT02854904|Experimental|Dexmedetomidine intervention|Dexmedetomidine (1 ug/kg/hr) during anesthesia.
2956929|NCT02854904|Placebo Comparator|Placebo|Infusion of normal saline during anesthesia.
2956930|NCT02854878|Experimental|treatment|
2956931|NCT02854865||Echocardiography|assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
2956932|NCT02854852||Patients undergoing general anesthesia|Patients ASA 1-3, undergoing different types of general anesthesia, in supine position, with standard or advanced hemodynamic monitoring.
2956933|NCT02854839|No Intervention|The Control Group|Patients will be randomized 1:1 to the control group and the treatment group. Patients who had allocated control group will not receive adjuvant treatment.
2956934|NCT02854839|Experimental|The Treatment Group (MG4101)|Patients will be randomized 1:1 to the control group and the treatment group. The treatment group will receive 6 times of MG4101(allogeneic natural killer cells) on week 0, 1, 2, 5, 6, 7.
2956935|NCT02854826||UCLA Ronald Reagan Medical Center|"Site 1 (UCLA Regan Medical Center): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research/Evidence Based Practice Council will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
2956936|NCT02854826||Huntington Hospital|"Site 2 (Huntington Hospital): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research Council/ Evidence Based Practice will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
2956937|NCT02854826||Torrance Memorial Hospital|"Site 3 (Torrance Memorial Hospital): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research/ Evidence Based Practice Council will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
2956938|NCT02854813||Group 1|Patients with a OAB-V8 score ≥8
2956939|NCT02854813||Group 2|Patients with a OAB-V8 score <8
2956940|NCT02854800|Experimental|Varenicline|12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
2956941|NCT02854787|Active Comparator|Phenylephrine|A bolus of 100 mcg
2956942|NCT02854787|Active Comparator|Norepinephrine|A bolus of 0,2 mcg/kg
2956943|NCT02854774|Active Comparator|Knee muscle activation/strengthening|4 weeks of exercises focused on activation and strengthening of knee extensor muscles.
2956947|NCT02854748|Experimental|Empagliflozin / Lobeglitazone / Empa.+Lobe.|Period 1: Empagliflozin 25 mg QD for 5 days Period 2: Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days
2956948|NCT02854748|Experimental|Empagliflozin / Empa.+Lobe. / Lobeglitazone|Period 1: Empagliflozin 25 mg QD for 5 days Period 2: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 3: Lobeglitazone 0.5 mg QD for 5 days
2956949|NCT02854748|Experimental|Lobeglitazone / Empagliflozin / Empa.+Lobe.|Period 1: Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg QD for 5 days Period 3: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days
2956950|NCT02854748|Experimental|Lobeglitazone / Empa.+Lobe. / Empagliflozin|Period 1: Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg QD for 5 days
2956951|NCT02854748|Experimental|Empa.+Lobe. / Empagliflozin / Lobeglitazone|Period 1: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg QD for 5 days Period 3: Lobeglitazone 0.5 mg QD for 5 days
2956952|NCT02854748|Experimental|Empa.+Lobe. / Lobeglitazone / Empagliflozin|Period 1: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 2: Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg QD for 5 days
2956953|NCT02854735||Head and neck neoplasm|Patients with stage III-IV head and neck cancer (squamous cell carcinoma) patient undergoing CCRT
2956954|NCT02854722|Experimental|Deferasirox and calcium-vitamin D3|"Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.~Calcium 500 mg and Vitamin D3 800 IU should also be taken daily as a basic therapy."
2956955|NCT02854722|Placebo Comparator|Calcium-vitamin D3|Calcium 500 mg and Vitamin D3 800 IU are taken daily as a basic therapy.
2956956|NCT02854709|No Intervention|Control|Continue with habitual sleep duration
2956957|NCT02854709|Experimental|Intervention|Sleep extension
2956958|NCT02854696|Experimental|Islet graft|Patients who receive islet graft Intervention : Procedure/Surgery
2956959|NCT02854696|Active Comparator|Best medical care|Patients who continue their optimal medical treatment (insulin pump therapy coupled with real time continuous glucose monitoring) Intervention : insulin treatment
2956960|NCT02854683|Experimental|Normal Saline|Subjects will receive 1 liter of intravenous normal saline over 1 hour and on an alternate day Subjects will drink ORS solution 1 liter total by mouth over 20 minutes.
2956961|NCT02854683|Experimental|Oral rehydration solution|Subjects will receive 1 liter of intravenous normal saline over 1 hour and on an alternate day Subjects will drink ORS solution 1 liter total by mouth over 20 minutes.
2956962|NCT02854670|Experimental|Capsaicin patch|Cuttable capsaicin patch. 2 patches of 4 cm² (2 x 2cm), for a total of 2.5 mg of capsaicin.
2956963|NCT02854657|Experimental|skin self-examination|"Participants from the treatment arms of the original RCT. It is anticipated that 228 participant dyads that are 18-70 years old from the original study will be invited to continue in the ongoing study. These subjects received Skin Self- examination structured training.~The subject are being followed for an additional period of time after receiving an educational intervention."
2956964|NCT02854657|Experimental|Skin Self- examination:Distance learning|Participants receive the Skin Self- examination structured training with partner assistance educational intervention accessed via the web while under the customary care of their own dermatologists. It is anticipated that 50 new participant dyads will be recruited and randomized to this group.
2956965|NCT02854657|Active Comparator|Active control|"Participants from the control arm of the original RCT. It is anticipated that 100 participant dyads that are 18-70 years old from the original study will be invited to continue in the ongoing study.~These subjects are controls and do not receive the structured training in skin self-examination with partner assistance at the beginning of the study. After completing the 18 month online survey, the subjects may request the Skin Self- examination structured training with partner assistance."
2956966|NCT02854657|Placebo Comparator|Assessment-only control|"Participants who receive customary care from their own dermatologists. It is anticipated that 150 new participant dyads will be recruited and randomized to this group.~These subjects are controls and do not receive the structured training in skin self-examination with partner assistance at the beginning of the study. After completing the 18 month online survey, the subjects may request the structured training in skin self-examination with partner assistance."
2956967|NCT02854644|Experimental|glioma|1 additional blood sample for patients with glioma and without treatment
2956968|NCT02854644|Experimental|breast cancer|2 additional blood samples for patients with localized brest cancer, metastatic breast cancer in 1st line of treatment and breast cancer in second line of treatment.
2956969|NCT02854644|Experimental|breast cancer HER2+|1 additional blood sample for patients with metastatic breast cancer with HER2 surexpression
2956970|NCT02854644|Experimental|Breast Cancer HER 2+ or HER2 triple -|1 additional blood sample for patients with breast cancer HER2 + or HER2 triple negative treated by neo adjuvant
2956971|NCT02854631|Experimental|Selonsertib + Prednisolone|Selonsertib + prednisolone for 28 days
2956972|NCT02854631|Placebo Comparator|Prednisolone|Selonsertib placebo + prednisolone for 28 days
2956973|NCT02854618|Experimental|Everolimus treatment|
2956974|NCT02854605|Experimental|GS-9674 30 mg|GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
2956975|NCT02854605|Experimental|GS-9674 100 mg|GS-9674 100 mg + placebo to match GS-9674 30 mg for 24 weeks
2956976|NCT02854605|Placebo Comparator|Placebo|Placebo to match GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
2956977|NCT02854592||rtPA|Intravenous rt-PA thrombolysis shall be administered within 4.5 h after symptom onset, at a dose of 0.9 mg/kg body weight (maximum, 90 mg), with 10% of the dose given as a bolus over 1 min and the remaining 90% infused over 60 min.
2956978|NCT02854592||urokinase|1,000,000-1,500,000 units of urokinase intravenous infused over 30 minutes within 4.5 h of stroke onset .
2956979|NCT02854579|Experimental|Neural progenitor cell|Three doses of Neural progenitor cell (4*10^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy
2956980|NCT02854579|Experimental|Paracrine factors|Three doses of concentrated paracrine factors of human mesenchymal stem cell （0.5ml） intrathecally at 12h,24h,48h after birth.+routine therapy
2957088|NCT02853825|No Intervention|Wait List Control Group|No interventions given, this is a wait list control group.
2956981|NCT02854579|Experimental|Progenitor cell and paracrine factors|Three doses of concentrated paracrine factors 0.5ml intrathecally at 12h,24h,48h after birth.And three doses of neural progenitor cell (4*10^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy
2956982|NCT02854579|No Intervention|Routine therapy|neonates only receive routine therapy
2956983|NCT02854566||periprosthetic fractures of the femur|periprosthetic fractures of the femur treated by osteosynthesis
2956984|NCT02854553|Experimental|TAP|Transversus abdominis plane block
2956985|NCT02854553|Experimental|TAP and rectus sheath block|Transversus abdominis plane block with rectus sheath block
2956986|NCT02854553|No Intervention|control|no truncal blocks, conventional analgesia
2956987|NCT02854540|Other|Hand A (iontophoresis) vs. Hand B (no treatment)|Hand A will be treated with hydrogel electrode-based iontophoresis. Hand B will not receive treatment.
2956988|NCT02854527|Experimental|R1 (Reference 1) Digoxin|1 tablet (0.25 mg) digoxin as single dose
2956989|NCT02854527|Experimental|R2 Furosemide|0.1 mL (1 mg) furosemide oral solution as single dose
2956990|NCT02854527|Experimental|R3 Metformin hydrochloride|0.1 mL (10 mg) metformin oral solution as single dose
2956991|NCT02854527|Experimental|R4 Rosuvastatin|1 tablet (10 mg) rosuvastatin as single dose
2956992|NCT02854527|Experimental|T (Test)|1 tablet (0.25 mg) digoxin, 0.1 mL (1 mg) furosemide oral solution, 0.1 mL (10 mg) metformin oral solution, and 1 tablet (10 mg) rosuvastatin, all together as a single dose ('cocktail')
2956993|NCT02854514||aspiration of endometrial secretion|intra uterine flushing of the endometrial cavity by five millilitre of saline through embryo transfer catheter then aspirated with endometrial secretion then centrifuged then analyzed for detection of concentration of tumor necrosis factor a and interleukin 1 b
2956994|NCT02854501||Uncomplicated pregnancies|
2956995|NCT02854501||Preeclampsia|
2956996|NCT02854501||Isolated IUGR|
2956997|NCT02854501||Any complication|
2956998|NCT02854488||Women Exposed to Yervoy (ipilimumab) During Pregnancy|Women Exposed to Yervoy (ipilimumab) During Pregnancy and the Children from These Pregnancies
2956999|NCT02854475|Experimental|Proband group|Raman spectroscopy and venous blood collection
2957000|NCT02854462|Experimental|Language comprehension intervention|The intervention will run for 4 weeks. Caregivers will be provided with storybooks (e.g., Percy the Park Keeper) that have been amended to include inference-eliciting questions. Caregivers will be trained (with a video) to ask these questions and respond to their children's answers during shared reading sessions. They will be asked to read one book per day. Caregivers will keep a reading diary.
2957001|NCT02854462|Active Comparator|Counting intervention|The intervention will run for 4 weeks. Caregivers will be provided with a book 'At home with counting' that is made up of age appropriate maths exercises. Caregivers will trained (with a video) to work through one page of the book per day. This should take the same amount of time as the activity in the language intervention condition. Caregivers will keep a counting diary.
2957002|NCT02854436|Experimental|Niraparib|Participants will receive 300 milligram (mg) niraparib (3 capsules*100 mg) orally once daily.
2957003|NCT02854423||biodegradable polymer|
2957004|NCT02854423||durable-polymer|
2957005|NCT02854410|Experimental|Sodium nitrate supplementation|Patients will receive Sodium nitrate supplementation from 7 days before radiotherapy to one month after the end of radiotherapy
2957006|NCT02854410|Placebo Comparator|Placebo Comparator(sodium chloride)|Patients will receive placebo from 7 days before radiotherapy to one month after the end of radiotherapy
2957007|NCT02854397||patients with hereditary angioedema|A blood sample will be performed in crisis and 7 days after the crisis.
2957008|NCT02854397||patients with angioedema resulting of mast cell activation|A blood sample will be performed in crisis and 7 days after the crisis.
2957009|NCT02854397||healthy patients, without angioedema|A quantity of additional blood was taken from eligible patients who had a scheduled blood sample.
2957010|NCT02854384||Epilepsy Patients|males and females whose age more than 18 years, diagnosed with epilepsy, regardless of whether symptomatic,idiopathic ,focal or generalized
2957011|NCT02854384||Healthy Control|males and females whose age more than 18 years
2957012|NCT02854371|Experimental|CLD and LC|Patients with underlying chronic liver disease. Gadoxetic acid enhanced liver MRI and ICG R15 are performed in this group.
2957013|NCT02854358|Active Comparator|control|In the control group, patients received Hypozalix (artificial saliva)spray three times per day for a period of four weeks.
2957014|NCT02854358|Experimental|intervention|Patients in intervention group received sachets containing 4 grams of mixed powder of A. digitata and M. sylvestris (in a proportion of 1:1), three times per day for a period of four weeks
2957015|NCT02854345|Experimental|Tomoscintigraphic parathyroid imaging on a CZT camera|Tomoscintigraphic parathyroid imaging on a CZT camera
2957016|NCT02854332|Active Comparator|MRI by rTMS|Patients which received an MRI study of cortical plasticity by rTMS.
2957017|NCT02854332|Active Comparator|MRI by tDCS|Patients which received an MRI study of cortical plasticity by tDCS.
2957018|NCT02854319|Experimental|LOTUS Edge Valve System|Transcatheter aortic valve implantation (TAVI) with the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set
2957019|NCT02854306|Active Comparator|Surgery|Obese patient without mindfulness program in parallel.
2957020|NCT02854306|Active Comparator|Surgery with mindfulness program|Obese patient following a mindfulness program in parallel.
2957021|NCT02854293||Booklet-Question List (BQL) group|76 patients
2957022|NCT02854293||control group|"Conventional palliative management~76 patients"
2957023|NCT02854280|Active Comparator|Chronic Obstructive Pulmonary Disease (COPD)|18 patients
2957024|NCT02854280|Active Comparator|Sleep Apnea Obstructive (OSA)|18 patients
2957025|NCT02854280|Active Comparator|Healthy Volunteers|36 control patients
2957026|NCT02854267||group without guide, before guide's diffusion|For this group, only the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database; The group without guide is made up by all registered situations of brain death patients on the database (nationwide) minus the situations occuring in the group with guide (22 intensive care units forming the 'RESEAU NORD FRANCILIEN' network). The period before the diffusion of the guide is from 1st of july 2012 to 30th of june 2014
2957027|NCT02854267||group without guide, after guide's diffusion|For this group, only the primary objective (refusal rate) will be assessed, using the French Biomedicine Agency database; The group without guide is made up by all the registered situations of brain death patients on the database minus the situations occuring in the group with guide ('RESEAU NORD FRANCILIEN'). The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018
2957028|NCT02854267||Group with guide, before guide's diffusion|For this group, only the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database; The group with guide is made up by all the registered situations of brain death patients on the database occuring in the 22 intensive care unit forming the 'RESEAU NORD FRANCILIEN' network. The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018.
2957029|NCT02854267||Group with guide, after guide's diffusion|For this group, the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database. The secondary endpoints (level of anxiety of the caregivers before the meeting with the next of kins as measured by the french short version of Spielberger test and compliance to the guide) will be assessed by the datasheet prospectively filled by the caregivers. The group with guide is made up by all the registered situations of brain death patients on the database occuring in the 22 intensive care unit forming the 'RESEAU NORD FRANCILIEN' network. The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018
2957030|NCT02854254|Experimental|PICC|peripherally inserted central catheter
2957031|NCT02854254|Other|Control|peripherally venous access
2957032|NCT02854241|Experimental|LC group|LC group under surveillance of biannual ultrasonography and annual noncontrast liver MRI. Six month after the last MRI, contrast enhanced liver CT is performed to investigate presence of HCC.
2957033|NCT02854215|Other|Ovarian cancer|Patient undergoing primary surgery for a newly diagnosed ovarian, tubal or peritoneal malignancies; Stage IIIc or IVa with extrapelvic carcinomatosis according to the International Federation of Gynecology and Obstetrics classification 2014
2957034|NCT02854202|Experimental|Arm 1-Whey protein|In the Arm 1-Whey protein Breakfast the participant will consume 42 g protein at breakfast mainly from whey
2957035|NCT02854202|Active Comparator|Arm 2 Breakfast- other proteins|In the Arm 2 Breakfast- other proteins sources (No Whey) the participants will consume 42 g protein from other sources (no Whey) at breakfast
2957036|NCT02854202|Placebo Comparator|Arm 3 Breakfast- low protein|In the Arm 3: breakfast with low proteins content, the participant will consume 22 g protein at breakfast
2957037|NCT02854189|Other|patients with genu recurvatum|The medial osteoarthritis knees with genu recurvatum were included in this study. Patients had been treated with cemented minimally invasive surgery Oxford unicompartmental knee arthroplasty and had had a minimum of 24 months of follow-up.The incidence of postoperative genu recurvatum, postoperative hyperextension angle, and the knee society score were recorded.
2957038|NCT02854189|Other|patients without genu recurvatum|The medial osteoarthritis knees without genu recurvatum were included in this study. Patients had been treated with cemented minimally invasive surgery Oxford unicompartmental knee arthroplasty and had had a minimum of 24 months of follow-up.The incidence of postoperative genu recurvatum, postoperative hyperextension angle, and the knee society score were recorded.
2957039|NCT02854176|Experimental|Somatosensory electrical stimulation|
2957040|NCT02854176|Sham Comparator|Control|
2957041|NCT02854163|Experimental|Secukinumab|"Secukinumab will be given to all 20 patients registered (Secukinumab group). All doses will be given subcutaneously using the following schedule: 4 weekly injections of 150 or 300 mg subcutaneous injections depending the severity of skin involvement, followed by 11 monthly subcutaneous injections of 150mg.~Patients will continue to use their normal DMARDs treatment."
2957042|NCT02854137|Experimental|Sunscreen / Arm 1|Subjects will be escorted to a separate room for instillation of the test materials. Test materials will be instilled in immediate succession and with a randomized order of presentation. A trained technician will use the thumb and forefinger of one hand to retract the lower eyelid from the eyes of the subject forming sacs in the conjuntival tissue, apply one test product to one eye.
2957043|NCT02854137|Other|Control|A trained technician will use the thumb and forefinger of one hand to retract the lower eyelid from the other eyes of the subject forming sacs in the conjuntival tissue, apply control materials to this eye, follow the same procedure, using a new pipet tip or sterilized dropper.
2957044|NCT02854124||Patients with stage Ib and II melanoma|Melanoma and peritumoral skin excision
2957045|NCT02854111|Active Comparator|oral glucose tolerance test|75-g glucose A blood sample will be collected when the participants arrive. This is a fasting blood glucose value. Then the participants will be asked to drink a sweet liquid containing 75 g-glucose. Blood samples will be collected at timed intervals of 1 and 2 hours after you drink the glucose. This is a standard method for diagnosis of diabetes mellitus that called oral glucose tolerance test or OGTT.
2957046|NCT02854111|Experimental|ice cream|A blood sample will be collected when the participants arrive. This is a fasting blood glucose value. Then the participants will be asked to drink ice cream that contained carbohydrate 73.9 g. Blood samples will be collected at timed intervals of 1 and 2 hours after you eat the ice cream.
2957047|NCT02854098||with functional constipation|n = 200 patients with functional constipation examined for BHJS age 3 -18 years meet inclusion criteria, do not fulfill exclusion criteria
2957048|NCT02854098||without functional constipation|n = 200 patient with functional constipation examined for BHJS age 3 -18 years meet inclusion criteria, do not fulfill exclusion criteria
2957049|NCT02854085|Experimental|Art Therapy|Art Therapy, 24 sessions
2957050|NCT02854085|Experimental|Music Reminiscence Activity|Music Reminiscence Activity, 24 sessions
2957051|NCT02854085|No Intervention|Control|Participants will not participate in either of the interventions and will continue life as usual.
2957052|NCT02854072|Experimental|GV1001 + gemcitabine/capecitabine|
2957053|NCT02854072|Active Comparator|gemcitabine/capecitabine|
2957054|NCT02854059|Experimental|Treatment HMed-IdeS|IdeS intravenous infusion 0.25 mg/kg BW intravenous infusion
2957055|NCT02854046||Calciphylaxis Cases|Adult patients with advanced chronic kidney disease (DFG estimation < 30 ml/min/1.73m² - beyond 3B stage) with/without substitute therapy who has presented a case of calciphylaxis (Calcific Uremic Arteriolopathy) between 2006 and 2016 in the Regions of Pays de la Loire, Centre Val de Loire, Bretagne and Poitou-Charentes
2957056|NCT02854046||Witness cases|"Selected anonymously in French national register REIN. Matched to Calciphylaxis Cases according to gender, age, treatment by extrarenal purification at the timepoint onset of the lesions and REIN regions belonging"
2957057|NCT02854033||Cognitively Normal (CN)|"135-500 newly enrolled participants with no apparent memory problems, and 295-300 cognitively normal participants followed from the ADNI2 study.~Currently recruiting non-Caucasian participants only for the normal cognition group."
2957058|NCT02854033||Mild Cognitive Impairment (MCI)|150 - 515 newly enrolled participants with mild cognitive impairment (MCI), and 275-320 MCI participants followed from the ADNI2 study.
2957059|NCT02854033||Mild Alzheimer's Disease (AD) dementia|85 - 85 newly enrolled participants with mild Alzheimer's disease (AD) dementia, and 130 - 150 mild AD participants followed from the ADNI2 study.
2957060|NCT02854020||An asian airline|
2957061|NCT02854007||Coronary stenosis treated with Absorb|Patients with ischemic heart disease who have undergone percutaneous coronary revascularization with Absorb according to standard clinical practice. One thousand revascularized patients will be recruited at 40 siteS.
2957062|NCT02853981|Active Comparator|Harmonic scalpel group|group of donors whom will undergo liver transection using harmonic scalpel.
2957063|NCT02853981|Active Comparator|clamp-crush group|group of donors whom will undergo liver transection using Kelly clamp.
2957064|NCT02853968||Castleman's Patients|Castleman's patients with HHV8 negative multicentric MCD
2957065|NCT02853968||Related Disease Controls|Controls with inflammatory diseases similar to idiopathic multicentric Castleman's: i.e. HHV8+ MCD, HLH, Hodgkin disease
2957066|NCT02853942|Experimental|Stem cell therapy group|Using the international standard 14G (diameter 1.54mm) needle inject autologous adipose derived mesenchymal stem cells 2ml to facial nerve, the effective release of the concentration is 100 million stem cells / ml.
2957067|NCT02853942|Experimental|Neurotrophic drugs treatment group|Patients were treated with routine drug therapy，do not inject stem cell to the facial nerve of patient
2957068|NCT02853929|Experimental|dTpa Group|This group will consist of infants born to mothers belonging to the dTpa Group in study 116945 [DTPA (BOOSTRIX)-047], i.e. mothers who received a single dose of Boostrix during pregnancy and a dose of placebo immediately post-delivery and infants who received the full primary vaccination series as per protocol requirement in the primary vaccination course in the study 201330 [DTPA (BOOSTRIX)-048 PRI]. All infants in this group will receive a booster dose of Infanrix hexa co-administered with Prevenar 13.
2957069|NCT02853929|Active Comparator|Control Group|This group will consist of infants born to mothers belonging to the Control group in study 116945 [DTPA (BOOSTRIX)-047], i.e. mothers who received a single dose of placebo during pregnancy and a dose of Boostrix immediately post-delivery and infants who received the full primary vaccination series as per protocol requirement in the primary vaccination course in the study 201330 [DTPA (BOOSTRIX)-048 PRI]. All infants in this group will receive a booster dose of Infanrix hexa co-administered with Prevenar 13.
2957070|NCT02853916|Active Comparator|500 mg InSea2®|
2957071|NCT02853916|Active Comparator|250 mg InSea2®|
2957072|NCT02853916|Placebo Comparator|Placebo|
2957073|NCT02853903|Experimental|Allogenic NK immunotherapy|In this group, the patients will receive more than 4 times of allogenic NK immunotherapies in 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2957074|NCT02853903|Active Comparator|Autogenic NK immunotherapy|In this group, the patients will receive more than 4 times of autogenic NK immunotherapies in 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2957075|NCT02853890||pregnant woman|
2957076|NCT02853877|Experimental|Weekly Incentive|Participants in the Weekly Incentive arm will be asked to weigh in each week during a 12 week intervention period. They will receive tailored messages and have an opportunity to win a financial reward each week they meet their weight loss goal. Participants will be asked to complete a final weight measurement at week 24.
2957077|NCT02853877|No Intervention|Weekly Weigh-In|Participants in the Weekly Weigh-In arm will be asked to weigh in each week during a 12 week intervention period. Participants will be asked to complete a final weight measurement at week 24.
2957078|NCT02853864|Placebo Comparator|Propofol and 0.0 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.0ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
2957079|NCT02853864|Experimental|Propofol and 0.4 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.4ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
2957080|NCT02853864|Experimental|Propofol and 0.6 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.6ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
2957081|NCT02853864|Experimental|Propofol and 0.8 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.8ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
2957082|NCT02853851||France|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
2957083|NCT02853851||Italy|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
2957084|NCT02853851||spain|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
2957085|NCT02853851||montreal|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
2957086|NCT02853838|Experimental|Prolonged slow expiration+provoked coughing+ST|Prolonged slow expiration+provoked coughing+Standard Therapy
2957087|NCT02853838|Active Comparator|Manual chest wall vibration+ST|Manual chest wall vibration+Standard Therapy
2957089|NCT02853825|Experimental|Intervention Group|Receive relationship skill enhancement classes with access to parenting, employment services, and financial services.
2957090|NCT02853812|Other|single sided tinnitus|patients with single sided tinnitus on which functional brain MRI is assessed
2957091|NCT02853799|Other|Continuous Enteral Feeding|"Crossover Study:~Randomized to continuous enteral feeding first then crossed over to receive versus intermittent enteral feeding next."
2957092|NCT02853799|Other|intermittent enteral feeding|"Crossover Study:~Randomized to intermittent enteral feeding first then crossed over to receive versus continuous enteral feeding next."
2957093|NCT02853786|Experimental|LENA and advices|With the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development
2957094|NCT02853786|Active Comparator|LENA without advices|Regular speech therapy follow blindly the results of LENA
2957095|NCT02853773|Experimental|Artificial sweetener|Effects of co-ingestion of artificially sweetened beverage on the response to a test meal
2957096|NCT02853773|Active Comparator|Sugar|Effects of co-ingestion of sugar-sweetened beverage on the response to a test meal
2957097|NCT02853773|Active Comparator|Water|Effects of co-ingestion of water on the response to a test meal
2957098|NCT02853760|Experimental|Outdoor mountain hiking (M)|"First part of the intervention: an uphill walking phase on single trails and forest roads in a sparse forest with view on the mountainous region around Innsbruck for 6 km in around 1.5 hours together with the test leader. Regarding the walking intensity, the participants were instructed to choose a brisk without overspending pace (average speed: 4 km/h).~In the second part of the intervention, the participants were walking downhill on the same track for around 70 minutes back to the starting point to respond to the post-test (average speed: 5.2 km/h)."
2957099|NCT02853760|Active Comparator|Indoor treadmill walking (T)|"To ensure that all physical parameters were simultaneous to the outdoor mountain hiking condition, the distance, the difference in height, the average inclination of the track, and the time needed for the outdoor mountain hiking situation were measured in a pilot study.~First part: uphill walking, inclination: 10%, time: 1.5 hours, and speed: 4 km/h (resulting in 600 m difference in height). In accordance to possible differences in outdoor speed, the participants were allowed to change the treadmill's speed in a small range (3.8 to 4.2 km/h) to adapt to the wording brisk without overspending. Second part of the intervention contained 70 minutes of level walking on the same treadmills (5.2 km/h, 6km)."
2957100|NCT02853760|No Intervention|Sedentary control condition (C)|The sedentary control situation was located in a quiet room at the university with access to computers. The participants were allowed to use the computers, to read, and to talk, but had to remain in a sedentary position. To control for possible differences in affective response due to the daytime, the sedentary control condition contained the same timing of the measurements than the intervention condition. Sociodemographic data were collected for 5 to 10 minutes in this condition using a web-based questionnaire.
2957101|NCT02853734|Experimental|SEVERE PERIODONTITIS|Periodontal examination Biological samples collection: periodontal, saliva, blood, fecal, visceral adipose tissue
2957102|NCT02853734|Other|NO PERIODONTITIS|Periodontal examination Biological samples collection: periodontal, saliva, blood, fecal, visceral adipose tissue
2957103|NCT02853721|Experimental|Experimental group|iPTH at 6 hours after surgery
2957104|NCT02853721|Other|Control group|no dosage of iPTH
2957105|NCT02853682||presence of a vascular dysfunction|plasma
2957106|NCT02853682||absence of vascular dysfunction|plasma
2957107|NCT02853669|Experimental|group (A) lumber plexus block|Ultrasound-guided Lumber plexus Block (30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation.
2957108|NCT02853669|Experimental|Group (B) adductor canal block|ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
2957109|NCT02853643|Experimental|25 mg Dose|Single dose of 25 mg ASN002
2957110|NCT02853643|Experimental|50 mg Dose|Single dose of 50 mg ASN002
2957111|NCT02853643|Experimental|100 mg Food effect cross over|100 mg single dose under both fasted and fed conditions in a cross over fashion
2957112|NCT02853630|Active Comparator|Metformin|Tablet Metformin 1000 - 2500 mg/day for 96 weeks
2957113|NCT02853630|Experimental|Vildagliptin|Tablet Vildagliptin 100mg/day for 96 weeks
2957114|NCT02853617|Experimental|AV0328 - Cohort 1|Cohort 1 will receive 15 µg to be given as an IM injection
2957115|NCT02853617|Experimental|AV0328 - Cohort 2|Cohorts 2 will receive 30 µg to be given as an IM injection
2957116|NCT02853617|Experimental|AV0328 - Cohort 3|Cohorts 3 will receive 75 µg to be given as an IM injection
2957117|NCT02853617|Experimental|AV0328 - Cohort 4|Cohorts 4 will receive 150 µg to be given as an IM injection
2957118|NCT02853604|Placebo Comparator|Reference Treatment Group (Arm A)|Placebo Arm A
2957119|NCT02853604|Experimental|Experimental Treatment Group (Arm B)|"ADXS11-001~1:2 Arm A to Arm B"
2957120|NCT02853591|Active Comparator|Standard High Pressure (15mmHg)|Pneumoinsufflator mode and setting: standard at 15mmHg
2957121|NCT02853591|Experimental|AirSeal High Pressure (15mmHg)|Pneumoinsufflator mode and setting: pressure-barrier at 15mmHg
2957122|NCT02853591|Experimental|Standard Low Pressure (9mmHg)|Pneumoinsufflator mode and setting: standard at 9mmHg
2957123|NCT02853591|Experimental|AirSeal Low Pressure (9mmHg)|Pneumoinsufflator mode and setting: pressure-barrier at 9 mmHg
2957124|NCT02853578|Experimental|Busonid (budesonide 200mcg and 400mcg)|"It´s a capsule with inhalatoin powder composed of budesonide 200mcg or 400mcg. The experimental drug will be dispensed in a cartridge containing 60 capsules of 200 mcg or 400 mcg and an inhaler. It should be stored at room temperature (between 15 and 30°C) and protected from moisture.~Regarding the dosage, the 80 study participants will perform an inhalation 200mcg every 12 hours (400 mcg / day). During follow-up visits (V1 and V2) the attending physician will assess the need for increased PSI dose to 400 mcg every 12 hours (800mcg / day). Study participants should rinse the mouth with water and / or brush your teeth immediately after use of the drug.~The duration of treatment may be 12 weeks."
2957125|NCT02853565|Experimental|CAN008|CAN008 administered as a 30 min intravenous infusion once a week until disease progression or unacceptable toxicity.
2957126|NCT02853539|Experimental|Denosumab|One per 6 months subcutaneous injection of Denosumab (2 doses in total)
2957127|NCT02853539|No Intervention|No Denosumab|No intervention, just observation of HPN patients
2957128|NCT02853526|Experimental|TIPS arm|Transjugular intrahepatic portosystemic shunt(TIPS) is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein. It is used to treat portal hypertension.TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (also called p-TIPS or modified TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.
2957129|NCT02853526|Active Comparator|conservative treatment arm|Conservative treatment including endoscopic therapy，non-selective beta blockers (propranolol)and anticoagulation therapy (warfarin).
2957130|NCT02853500|Experimental|TACE Procedure With Surefire|"Patients will receive a single administration of intra-arterial chemotherapy (Doxorubicin) during the TACE procedure via Surefire.~Patients will undergo structural follow-up for a timeframe of one year post treatment~Post-procedural, contrast-enhanced Magnetic Resonance Imaging (MRI) will be performed one month after trial entry, and at regular intervals thereafter for a total of one year to assess tumor response"
2957131|NCT02853500|Active Comparator|TACE Procedure Traditional Delivery|"Patients will receive a single administration of intra-arterial chemotherapy (Doxorubicin) during the TACE procedure via Traditional Delivery.~Patients will undergo structural follow-up for a timeframe of one year post treatment~Post-procedural, contrast-enhanced Magnetic Resonance Imaging (MRI) will be performed one month after trial entry, and at regular intervals thereafter for a total of one year to assess tumor response"
2957132|NCT02853487||Cluster headache patients|Episodic cluster headache patients in- and outside of bout will wear an actigraph and fill out a diary for 2 weeks.
2957133|NCT02853487||Control group|Healthy, headache-free controls will wear an actigraph and fill out a diary for 2 weeks.
2957134|NCT02853474|Sham Comparator|Arm A: Chemotherapy (CT) alone|"The medical oncologists (or gastro enterologist physician) are in charge of the patient for CT administration, and for the management of symptoms related to the disease and/or the treatment, in accordance with professional practices. If needed (any time), a PC (Palliative consultation) visit could be performed.~Interventions are :~EORTC-QLQ-C30 questionnaire for the assessment of quality of life~HADS score for anxiety and depression assessment"
2957135|NCT02853474|Experimental|Arm B: CT + Early Palliative care(EPC)|"Standard oncology care as for arm A plus early PC visits.~Interventions are :~EORTC-QLQ-C30 questionnaire for the assessment of quality of life~HADS score for anxiety and depression assessment~Early palliative care visits"
2957136|NCT02853448|Experimental|Novel Device|Every Subject will be assigned to the same arm. This arm calls for blood to be drawn using an original blood drawing apparatus as well as using the novel blood drawing apparatus.
2957137|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence A-capsules, B-RC, C-HSWG|Subjects will be receive treatment sequence (ABC) which is a single dose of gepotidacin 1500 mg (three tablets of 500 mg) reference capsule (Treatment A) in Period 1, 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in Period 2 or 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 3, according to randomization. There will be a washout period of at least 3 days between doses.
2957138|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence C-HSWG, A-capsules, B-RC)|Subjects will receive treatment sequence (CAB) to receive a single dose of gepotidacin 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 1, 1500 mg (three tablets of 500 mg) reference capsule (Treatment A) in Period 2 or 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in Period 3 according to randomization. There will be a washout period of at least 3 days between doses.
2957139|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence B-RC, C-HSWG, A-capsules)|Subjects will receive treatment sequence (BCA) to receive a single dose of gepotidacin 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in period 1, 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 2, or 1500 mg (three tablets of 500 mg) (Treatment A) in Period 3 reference capsule according to randomization.. There will be a washout period of at least 3 days between doses.
2957140|NCT02853435|Experimental|Part1b: Gepotidacin 1500 mg-Sequence DE-fasted followed by fed|Subjects will receive treatment sequence (DE) according to randomization which is a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a under fasted condition (Treatment D) in Period 1 followed by fed conditions (Treatment E) in period 2. There will be a washout period of at least 3 days between doses.
2957141|NCT02853435|Experimental|Part1b: Gepotidacin 1500 mg-Sequence ED-fed followed by fasted|Subjects will be receive treatment sequence (ED) according to randomization which is single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a under fed condition (Treatment E) in period 1 followed by fasted conditions (Treatment D) in Period 2. There will be a washout period of at least 3 days between doses.
2957142|NCT02853435|Experimental|Part 2a: Gepotidacin 1500 mg (RC or HSWG)- Japanese subjects|Japanese subjects will receive a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a.
2957143|NCT02853435|Experimental|Part 2b: Gepotidacin 1500 mg (RC or HSWG)- Chinese subjects|Chinese subjects will receive a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a.
2957144|NCT02853396|Experimental|Cognitive behavioural therapy|Cognitive behaviour therapy
2957145|NCT02853396|Active Comparator|Psychoeducation|psychoeducation
2957146|NCT02853370|Experimental|Bendamustine and Rituximab|"Induction Phase (Cycle 1 to Cycle 3 ):~Bendamustine 90 mg/sqm i.v. d1 & d2* Rituximab 375 mg/m2 i.v. d1**~Extended Phase (Cycle 4 to Cycle 6):~Bendamustine 90 mg/sqm i.v. d1 & d2* Rituximab 375 mg/m2 i.v. d1~From Cycle 4 to Cycle 6, every 4 weeks, depending on the response after the first 3 Cycles~*Or days 2-3 according to institutional/patient/physician preference~**Administration of Rituximab during cycle 1 and cycle 2 can be postponed to day 8 or 14 in case of risk of tumor lysis syndrome (TLS)"
2957147|NCT02853357|Sham Comparator|Control|The control group includes randomized participants that will receive a sham manipulation. Participants will also complete the standard set of core strengthening exercises.
2957148|NCT02853357|Experimental|Manipulation|The manipulation group includes randomized participants that will receive a thoracic spine thrust manipulation. Participants will also complete the standard set of core strengthening exercises.
2957149|NCT02853344|Experimental|Cohort A: Clear Cell RCC|Participants with clear cell RCC receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to 35 doses (approximately 24 months).
2957414|NCT02851433|Experimental|Sevoflurane Group|
2957150|NCT02853344|Experimental|Cohort B: Non-clear Cell RCC|Participants with non-clear cell RCC receive pembrolizumab 200 mg IV Q3W for up to 35 doses (approximately 24 months).
2957151|NCT02853331|Experimental|Pembrolizumag+Axitinib Combination Therapy|Participants receive pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.
2957152|NCT02853331|Active Comparator|Sunitinib Monotherapy|Participants receive sunitinib 50 mg orally once daily for 4 weeks and then are off treatment for 2 weeks.
2957153|NCT02853318|Experimental|Treatment (pembrolizumab, bevacizumab, cyclophosphamide)|Patients receive pembrolizumab IV over 30 minutes and bevacizumab IV over 30-90 minutes on day 1 and cyclophosphamide PO QD on days 1-21. Treatment repeats every 3 weeks for up to 17 courses in the absence of disease progression or unacceptable toxicity. Patients without evidence of disease progression may continue treatment in the absence of disease progression or unacceptable toxicity.
2957154|NCT02853305|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for a maximum of 35 doses.
2957155|NCT02853305|Experimental|Pembrolizumab+Chemotherapy|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for a maximum of 35 doses PLUS EITHER cisplatin 70 mg/m^2 IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine IV infusion 1,000 mg/m^2 on Day 1 and Day 8 of each 3-week cycle, OR carboplatin area under the curve 5 (AUC 5) (or AUC 4.5 if required per local guidelines) IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine 1,000 mg/m^2 IV on Day 1 and Day 8 of each 3-week cycle.
2957156|NCT02853305|Active Comparator|Chemotherapy|Participants receive EITHER cisplatin 70 mg/m^2 IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine IV infusion 1,000 mg/m^2 on Day 1 and Day 8 of each 3-week cycle OR carboplatin AUC 5 (or AUC 4.5 if required per local guidelines) IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine 1,000 mg/m^2 IV on Day 1 and Day 8 of each 3-week cycle.
2957157|NCT02853292||amoxicillin crystalluria|
2957158|NCT02853279|Experimental|Interval exercise training|Supervised exercise training undertaking interval exercise twice per week for 30 min each visit over 12 weeks.
2957159|NCT02853279|Active Comparator|Continuous exercise training|Supervised exercise training undertaking continuous exercise twice per week for 30 min each visit over 12 weeks.
2957160|NCT02853266||patients KD|adults with a history of KD in childhood
2957161|NCT02853266||control group|healthy adults volunteers
2957162|NCT02853253|Experimental|SMOF|parenteral nutrition using SMOFlipid® (FreseniusKabi France, Sèvres, France)
2957163|NCT02853253|Active Comparator|Medialipide®|parenteral nutrition using Medialipide® 20% (B Braun Medical, Boulogne, France)
2957164|NCT02853240|Experimental|Children with spastic CP receiving toxin injections|Children with spastic cerebral palsy receiving toxin injections
2957165|NCT02853227||BCS|Photographs og consecutive group of 346 patients operated with breast conserving surgery were used to investigate cosmetic outcomes.
2957166|NCT02853227||DIEP|Photographs og consecutive group of 30 patients operated with DIEP-flap were used to assess cosmetic results
2957167|NCT02853214|Experimental|Identification of genetic factors in dysglobulinemia cases|
2957168|NCT02853188|Experimental|cancer of lung|
2957169|NCT02853175||Patients with both CF and ABPA|"Patients with both cystic fibrosis and allergic broncho-pulmonary aspergillosis (ABPA).~The diagnosis of ABPA (Gold Standard) rely on routine dosage of total immunoglobulin E (IgE), specific to Aspergillus IgE, specific to aspergillus Immunoglobulin G, eosinophilia on blood cell count, and imaging (infiltrate, mucoid impaction, central bronchiectasis)"
2957170|NCT02853175||Patients with CF and no ABPA|"Patients with both cystic fibrosis and no allergic broncho-pulmonary aspergillosis (ABPA).~The diagnosis of ABPA (Gold Standard) rely on routine dosage of total immunoglobulin E (IgE), specific to Aspergillus IgE, specific to aspergillus Immunoglobulin G, eosinophilia on blood cell count, and imaging (infiltrate, mucoid impaction, central bronchiectasis)"
2957171|NCT02853162|Experimental|ARREST-study|SBRT renal cell carcinoma 5 times 7Gy
2957172|NCT02853149|Experimental|Spinal Cord Injury (SCI)|Experimental: Lifestyle Intervention This arm will examine whether a twelve month treatment program (one year) for Spinal Cord injury individuals enrolled with their caregivers, can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life using a 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
2957173|NCT02853149|Active Comparator|Caregiver Intervention(CCC)|Lifestyle Intervention This arm will examine whether a twelve month treatment program (one year) enrolled with their Care-receivers( SCI individuals) can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life using a 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
2957174|NCT02853149|Placebo Comparator|Caregiver Control (CC)|Placebo: This arm will examine whether a twelve month treatment program (one year) enrolled with their Care-receivers( SCI individuals) can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life. The control group intervention will test benefits of exercise alone while controlling for investigator contact.
2957175|NCT02853136|Experimental|Reference Treatment (pilot phase)|BI 409306 low dose
2957176|NCT02853136|Experimental|Test Treatment (pilot phase)|Fluvoxamin and low dose of BI 409306
2957177|NCT02853136|Experimental|Reference Treatment (main phase)|BI 409306 medium or high dose
2957178|NCT02853136|Experimental|Test Treatment (main phase)|Fluvoxamin and medium or high dose of BI 40930
2957179|NCT02853123|Experimental|Tiotropium + Olodaterol|Patients will receive tiotropium 5mcg + olodaterol 5mcg in a fixed dose combination once daily.
2957180|NCT02853123|Active Comparator|Tiotropium|
2957181|NCT02853110|Experimental|Hypo-FLAME|External beam radiotherapy, 5 additional MRI scans, blood sampling
2957182|NCT02853097||Ancillary-Correlative (blood collection)|Patients undergo blood collection every 4-12 weeks during ADT, abiraterone, enzalutamide, or docetaxel treatment. Patients switched from ADT to either abiraterone or enzalutamide during the study will undergo phlebotomy every 6-12 weeks. Samples are analyzed for cfRNA, and cfDNA, AR-V7, and other AR-Vs via quantitative RT-PCR.
2957183|NCT02853084|Experimental|HL2351|
2957184|NCT02853071|Experimental|Estramustine|560 mg per day
2957185|NCT02853071|Active Comparator|Standard practice center|"Standard treatment center choice.~Excepted: anthracyclines, taxanes, capecitabine and eribulin"
2957186|NCT02853058|Active Comparator|normal PI|Uterine artery PI expresserd in MoM is <95e percentile
2957187|NCT02853058|Active Comparator|pathological PI|Uterine artery PI expressed in Multiple of Mediane (MoM) is >=95e percentile
2957188|NCT02853045|Experimental|period with drug (trade name) then period with generic|Period of 6 weeks.
2957189|NCT02853045|Experimental|period with generic then period with drug (trade name)|Period of 6 weeks.
2957190|NCT02853032|Active Comparator|Active rTMS to the right DLPFC|Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, active rTMS will be delivered at 20 Hz in 2 sec trains with 28 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.
2957191|NCT02853032|Placebo Comparator|Sham rTMS to the right DLPFC|Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, sham rTMS will be delivered at 20 Hz in 2 sec trains with 28 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.
2957192|NCT02853019|Sham Comparator|Healthy volunteers|Healthy volunteers
2957193|NCT02853019|Experimental|Patients with schizophrenia|Patients with schizophrenia
2957194|NCT02853006|Other|Group 1 lung cancer in stage 1-2|Group 1 : patient with lung cancer in stage 1-2, lung cancer of all histology kind eligible for surgery
2957195|NCT02853006|Other|Group 2 lung cancer in stage 3-4|Group 2 : patient with lung cancer in stage 3-4 (no adenocarcinoma or squamous) receiving classical or targeted chemotherapy on genetic anomalies.
2957196|NCT02853006|Other|Group 3 : control patients|Group 3 control patients : carriers of non-cancerous radiological anomalies : benign nodules, cicatricial lesions, infectious or inflammatory, paired with the two other groups by age, sex or tobacco.
2957197|NCT02852993||Transfused patients|A cohort of patients receiving erythrocyte transfusion for the first time at the CHU Besançon or CHU Dijon during the study period.
2957198|NCT02852980||gestational diabetes women|Women who had childbirth in the Hospital center Rene Dubos and who had gestational diabetes.
2957199|NCT02852967|Experimental|KD025 200 mg QD (Once Daily)|200 mg KD025 QD (subjects will receive one KD025 200 mg and one matching placebo tablet in the morning and a matching placebo in the evening).
2957200|NCT02852967|Experimental|KD025 200 mg BID (Twice Daily)|200 mg KD025 BID (subjects will receive one KD025 200 mg and one matching placebo tablet in the morning and KD025 200 mg in the evening).
2957201|NCT02852967|Experimental|KD025 400 mg QD (Once Daily)|400 mg KD025 QD (subjects will receive two KD025 200 mg tablets in the morning and a matching placebo in the evening).
2957202|NCT02852967|Experimental|KD025 600mg/day|600 mg/day KD025 (subjects will receive two KD025 200 mg tablets in the morning and one KD025 200 mg tablet in the evening).
2957203|NCT02852967|Placebo Comparator|Placebo|Placebo (subjects will receive two matching placebo tablets in the morning and one matching placebo tablet in the evening).
2957204|NCT02852954||study group1|20 paraffin embedded blocks which was diagnosed endometrial cancer
2957205|NCT02852954||control group|20 paraffin embedded blocks of healthy women
2957206|NCT02852954||study group2|20 paraffin embedded blocks which was diagnosed endometrial hyperplasia
2957207|NCT02852941||Patients after kidney transplantation|The study included who had been admitted to a nephrology-transplantation outpatient clinic 0.5 to 30 years after kidney transplantation.
2957208|NCT02852941||Healthy subjects|Medical staff: medical doctors, nurses
2957209|NCT02852915|Experimental|Laparoscopic surgery for T4 colon cancers|Laparoscopic surgery for T4 colon cancers
2957210|NCT02852915|No Intervention|Conventional open surgery for T4 colon cancers|Conventional open surgery for T4 colon cancers
2957211|NCT02852889||fluid responders|Patients whose stroke volume index increase by >10% in response to a 500-ml fluid bolus was defined as fluid responders.
2957212|NCT02852889||fluid non-responders|Patients whose stroke volume index increase by <10% in response to a 500-ml fluid bolus was defined as fluid non-responders.
2957213|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group A (Fasting)|Participants will receive single dose of ASP2151 assigned to Group A on day 1
2957214|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group B (Fasting)|Participants will receive single dose of ASP2151 assigned to Group B on day 1
2957215|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group C (Fasting)|Participants will receive single dose of ASP2151 assigned to Group C on day 1
2957216|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group D (Fasting)|Participants will receive single dose of ASP2151 assigned to Group D on day 1
2957217|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group E (Fasting)|Participants will receive single dose of ASP2151 assigned to Group E on day 1
2957218|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group F (Fasting)|Participants will receive single dose of ASP2151 assigned to Group F on day 1
2957219|NCT02852876|Placebo Comparator|Part 1: Placebo Single Ascending Dose (Fasting)|Participants will receive single dose of matching placebo on day 1
2957220|NCT02852876|Experimental|Part 2: ASP2151 (Fasting)|Participants will receive a single dose of ASP2151 under fasted conditions on day 1 in the first treatment period (period 1). Following a wash-out period of at least five days, the treatment will be repeated in the reverse orientation (period 2)
2957221|NCT02852876|Experimental|Part 2: ASP2151 (Fed)|Participants will receive a single dose of ASP2151 under fed conditions on day 1 in the first treatment period (period 1). Following a wash-out period of at least five days, the treatment will be repeated in the reverse orientation (period 2)
2957222|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group G (Fasting)|Participants will receive single dose of ASP2151 assigned to Group G on day 1
2957223|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group H (Fasting)|Participants will receive single dose of ASP2151 assigned to Group H on day 1
2957255|NCT02852668|Experimental|Power Training Group|Physical exercises. Strength training performed quickly
2957256|NCT02852668|Experimental|Strength Training Group|Physical exercises. Strength training performed in moderate speed
2957224|NCT02852863|Experimental|Ultrasound (case only)|Subjects will fast for a minimum of 8 hours. Ultrasound assessment of gastric volume and content will determine basal conditions. Next, subjects will chew gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
2957225|NCT02852850||Molecular Imaging With IFX-FITC|Endoscopic examination with the fluorescent antibody (IFX-FITC) was performed in patients with active ulcerative colitis before infliximab therapy was initiated. Labeled infliximab was applied topically via a standard spray catheter onto the most inflamed region of the bowel during colonoscopy, followed by CLE. In vivo imaging of inflamed areas of the intestinal mucosa showed a specific fluorescence signal of mTNF+ cells after topical application of labeled adalimumab. These specific fluorescence signals were recorded.
2957226|NCT02852837|Experimental|Part 1: Dose Escalation Part|Participants will receive single dose of daratumumab from Week 1 till Week 3 (Period 1 - single dosing period) followed by 6 weekly doses of daratumumab until Week 9 (Period 2 - weekly dosing period) and every 2 weeks for 8 infusions and then once every 4 weeks from Week 26 until disease progression, intolerability, or other reasons for treatment discontinuation (Period 3 - less intense dosing period). A dose of 8 milligram per kilogram (mg/kg) will be chosen as the starting dose and will be escalated to 16 mg/kg if the 8 mg/kg is determined safe and tolerated by study evaluation team (SET).
2957227|NCT02852837|Experimental|Part 2: Pharmacokinetic (PK) Expansion Part|Participants will receive daratumumab at 16 mg/kg in 3 periods as given in the Part 1.
2957228|NCT02852837|Experimental|Part 3: Safety Expansion Part|Participants will receive daratumumab 16 mg/kg every week for 8 weeks followed by every 2 weeks for an additional 16 weeks, and then every 4 weeks thereafter. Participants will be treated with daratumumab until disease progression, intolerability, or any other reasons for treatment discontinuation.
2957229|NCT02852824|Experimental|BI 655130|
2957230|NCT02852824|Placebo Comparator|Placebo|
2957231|NCT02852811|Other|group education|To measure improvement of menopause symptoms and depression all participating women answered a baseline questionnaire and a follow-up questionnaire four month later. The questionnaires who were used: The Menopause Rating Scale (MRS) and The Montgomery-Asberg Depression Rating Scale (MADRS). MRS were used for reflecting menopause symptom and MADRS for depression symptoms.
2957232|NCT02852811|No Intervention|control group|The control group did not obtain any group education or any other intervention. Women answered at baseline questionnaire and four month later. The questionnaires who were used: The Menopause Rating Scale (MRS) and The Montgomery-Asberg Depression Rating Scale (MADRS). MRS were used for reflecting menopause symptom and MADRS for depression symptoms.
2957233|NCT02852785||Asymptomatic volleyball attackers|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and no signs of postural and movement impairments of the upper body quadrant
2957234|NCT02852785||Asymptomatic bilateral overhead athletes|Asymptomatic swimmers involved in competitive events ≥ 2 years and no signs of postural and movement impairments of the upper body quadrant
2957235|NCT02852785||Asymptomatic non-athletes|Asymptomatic persons not regularly involved in sports activities or occupational overhead tasks (e.g. construction workers),
2957236|NCT02852785||Asympt. athletes / scapula dyskinesis|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
2957237|NCT02852785||Symptom. athletes / scapula dyskinesis|Volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis and complaints of shoulder pain and disability
2957238|NCT02852772||PLHIV with microalbuminuria|Patient infected with HIV and well controlled by treatments, with microalbuminuria for at least 5 years
2957239|NCT02852772||PLHIV without microalbuminuria (control)|Patient infected with HIV and well controlled by treatments, without microalbuminuria, matched for age +/- 5 years
2957240|NCT02852759|Experimental|intervention group|Add Selective Cold and Electroacupuncture treatment to the existing treatment for patients with insulin resistance.
2957241|NCT02852759|No Intervention|Intensive Care group|continue the existing management of insulin resistance in these patients. They will receive the same follow up, examinations etc as intervention group.
2957242|NCT02852746||Asympt. athletes / scapular dyskinesis|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
2957243|NCT02852746||Symptom. athletes / scapular dyskinesis|Symptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
2957244|NCT02852733||Residents in end-of-life situation|"Residents in end-of-life situation the day of the survey, as determined by the physician coordinator of nursing homes (we will use the definition of terminal condition contained in the guide of the CNSA (coding PATHOS - April 2011))."
2957245|NCT02852733||dead residents|dead residents in the quarter preceding the date of the survey
2957246|NCT02852720|Experimental|Pharmacokinetics|A bilateral TAP block will be performed with 20 ml levobupivacaine 0,25% and epinephrine (5ug/ml). After the blockade, venous blood samples will be taken on predefined times.
2957247|NCT02852707||Unilateral overhead throwing athletes|Volleyball attackers involved in competitive events ≥ 2 years, ≥18 years of age
2957248|NCT02852707||Bilateral overhead athletes|Swimmers involved in competitive events ≥ 2 years, ≥18 years of age
2957249|NCT02852707||Non-athletes|Persons not regularly involved in sports activities or occupational overhead tasks (e.g. construction workers), ≥18 years of age
2957250|NCT02852694|Active Comparator|High Risk Group|subcutaneous methotrexate versus subcutaneous adalimumab
2957251|NCT02852694|Active Comparator|Low risk group|subcutaneous methotrexate versus oral dose of azathioprine / 6 mercaptopurine
2957252|NCT02852694|Other|Ancillary|the ancillary study is planned to analyse of Adalimumab treated patients from inclusion (TOP-Down) versus patients switched to Adalimumab due to failure of immunomodulator therapy (STEP-Up).
2957253|NCT02852681|Other|15 mg E4/3 mg DRSP without food|Treatment A (Reference): a single 15 mg E4/3 mg DRSP tablet without food (fasted).
2957254|NCT02852681|Other|15 mg E4l/3 mg DRSP with food|Treatment B (Test): a single 15 mg E4/3 mg DRSP tablet with food (fed)
2957257|NCT02852668|No Intervention|Control Group|This group maintained the same physical activity level during the intervention period.
2957258|NCT02852655|Experimental|Pre-surgery MK-3475|"-After a screening phase of 14 days, eligible subjects will be randomized into two groups.~Pembrolizumab (MK3475) pre-surgery at pre-determine dosage followed by Pembrolizumab at pre-determine dosage every 3 weeks post surgery.~MK-3475 will be administered intravenously"
2957259|NCT02852655|Active Comparator|No MK-3475 at Pre-Surgery|"-After a screening phase of 14 days, eligible subjects will be randomized into two groups.~Pembrolizumab (MK-3475) at pre-determine dosage every 3 weeks post surgery.~MK-3475 will be administered intravenously"
2957260|NCT02852642|Experimental|Exercise|Power training model based in the potentiation of the stretch-shortening cycle.
2957261|NCT02852642|No Intervention|Control|Maintaining daily activities
2957262|NCT02852616|Active Comparator|Narrative Exposure Therapy|Participants with a PTSD diagnosis
2957263|NCT02852616|No Intervention|no / standard treatment|Participants with a PTSD diagnosis / other mental health problems / no mental health problems
2957264|NCT02852603||thoracic aortic aneurysm and dissection|Patients with thoracic aortic aneurysm and/or dissection are recruited in the study.
2957265|NCT02852577|Active Comparator|Clonazepam|Treatment with clonazepam
2957266|NCT02852577|Active Comparator|Paroxetine|Treatment with paroxetine
2957267|NCT02852564|Experimental|Enrolled Participants|Administration of a single, 50 mg oral dose of ethacrynic acid prior to bladder tumor removal surgery (Transurethral Resection of Bladder Tumor [TURBT])
2957268|NCT02852551|Experimental|PAT-1251 Single Dose|Oral solution of PAT-1251, 150 - 4000 mg administered once
2957269|NCT02852551|Placebo Comparator|Placebo Single Dose|Matching placebo solution administered once
2957270|NCT02852551|Experimental|PAT-1251 Multiple Dose|Oral tablet(s) of PAT-1251 up to 2000 mg administered daily for 7 days
2957271|NCT02852551|Experimental|Placebo Multiple Dose|Matching placebo tablets administered daily for 7 days
2957272|NCT02852538|Experimental|NEW FED TR for Anorexia|NEW FED TR
2957273|NCT02852525|Other|Confocal laser endomicroscopy (pCLE)|Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction. Photographs will be taken and digitally stored. Biopsies (which are part of the routine diagnosis and surveillance of Barrett's) will be targeted based on the microscopic images. The histologic findings on the biopsy specimens will be compared to the microscopic images to determine the accuracy of the probe-based microscopy in predicting pathology.
2957274|NCT02852512|Active Comparator|Laparoscopic sacrocolpopexy|The surgical technique will be the same between the two approaches, in this arm the approach will be laparoscopic
2957275|NCT02852512|Active Comparator|Robotic assisted Sacrocolpopexy|The surgical technique will be the same between the two approaches, in this arm the approach will be robotic assisted
2957276|NCT02852499||Mothers|Pregnant women.
2957277|NCT02852499||Fathers|Futur fathers.
2957278|NCT02852499||Children|Children after childbirth.
2957279|NCT02852486|Experimental|Pioglitazone|Pioglitazone will be given 30 mg/day, orally, for 3 months, before imatinib discontinuation
2957280|NCT02852473|Experimental|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure (CPAP) will be administered using FDA-approved equipment.
2957281|NCT02852460|Experimental|Experimental group|rapid recovery
2957282|NCT02852460|No Intervention|Controlled group|non-rapid recovery
2957283|NCT02852434|Experimental|Self-administered Gel|Patient-administered, vaginal lidocaine gel (2%)--inserted 15 minutes prior to cervical preparation procedure
2957284|NCT02852434|Active Comparator|Paracervical Block|Provider-administered lidocaine (1%) paracervical injection--administered immediately prior to tenaculum placement
2957285|NCT02852421|Active Comparator|Multiple injection paravertebral blocks|"Patients in this group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level."
2957286|NCT02852421|Experimental|Single injection paravertebral block|"Patients in single injection group will receive single injection paravertebral blocks at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections."
2957287|NCT02852408||Study|liver cauterized during laparoscopic cholecystectomy.
2957288|NCT02852408||Control|liver not-cauterized during laparoscopic cholecystectomy.
2957289|NCT02852395|Experimental|Part 1 Single Dose|Part 1 single daytime oral dose of JNJ-48816274 or placebo. Doses of JNJ-48816274 will start at 5 milligram (mg) and increase sequentially to a maximum dose of 250 mg.
2957290|NCT02852395|Experimental|Part 2 Crossover Sleep Study|Part 2 single nighttime oral dose of JNJ-48816274 or placebo administered during each of 3 or 4 crossover periods separated by 7-9 days. The doses of JNJ-48816274 will be selected based on data from Part 1 (not to exceed 250 mg).
2957291|NCT02852395|Experimental|Part 3 Repeated Dose (Optional)|Part 3 daytime oral dose of JNJ-48816274 or placebo administered once daily for 7 consecutive days. Doses will be determined based on data from Part 1, and may increase sequentially (not to exceed 250 mg/day).
2957292|NCT02852382|Active Comparator|scalp block|In this arm, after general anesthesia, before surgery and head pin placement, scalp block will be applied. Scalp block will be performed with bupivacaine (Marcaine 5 mg/mL, 0,5% bupivacaine); nervus supraorbitalis, nervus supratrochlearis, n. auriculotemporalis, nervus zygomaticotemporalis, nervus occipitalis majoris and minoris will be bilaterally blocked with 2-3 ml bupivacaine.
2957293|NCT02852382|Active Comparator|local infiltration|In this arm, after general anesthesia, before surgery, 20 ml 0,5% bupivacaine (Marcaine 5 mg/ml, 0,5% bupivacaine) will be infiltrated to head pin points and skin incision area.
2957294|NCT02852382|Placebo Comparator|control|In this arm, neither scalp block, nor local infiltration will be performed.
2957295|NCT02852369|Experimental|Task Oriented Training|"The intervention administered during each of the training sessions was modeled after the protocol outlined in Winstein et al. (2013) however implementation was in the participant's home setting and involved tasks in the participant's real world.~The manual entitled, Upper-Extremity Task-Specific Training After Stroke or Disability by Lang and Birkenmeier (2014) was also utilized to give a general overview of task specific training for the upper extremity and to help guide each activity the participant chose to work on."
2957299|NCT02852356|No Intervention|Control dish|Control Dish for embryo culture
2957300|NCT02852330|Experimental|Voltage tomography|Voltage tomography measurements will be made with the SA16 research software and CS19 (1.6.2) software during and/or immediately after electrode insertion during cochlear implantation and at scheduled post-operative clinical visits.
2957301|NCT02852317||Spina bifida patient|
2957302|NCT02852317||Patients with multiple sclerosis|
2957303|NCT02852317||Patients with spinal cord injury|
2957304|NCT02852317||Patients with overactive bladder|
2957305|NCT02852291|Experimental|Parents Make the Difference|Parents Make the Difference (Caregivers attend 10 group parent training sessions)
2957306|NCT02852291|Experimental|Parents Make the Difference Plus|Parents Make the Difference Plus (Caregivers attend 10 group parent training sessions and receive 3 home visits)
2957307|NCT02852291|No Intervention|Waitlist Control|No parenting intervention until the end of the study period
2957308|NCT02852265|Experimental|COC users or new starts|Subjects will have a etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users. Women starting a COC or recently started a COC within the past month will be considered new starts.
2957309|NCT02852239|Experimental|Group 1 - Normal renal function|Subjects with normal renal function defined as GFR ≥ 90 mL/min at baseline and matching to the renal impaired subject based on gender, race, age, and weight can be enrolled in this group.
2957310|NCT02852239|Experimental|Group 2 - Severe renal function|Subjects with severe renal impairment defined as GFR of 15-29 mL/min at baseline can be enrolled in this group
2957311|NCT02852239|Experimental|Group 3 - End stage renal disease (ESRD)|Subjects with end stage renal disease (ESRD), defined as GFR of <15 mL/min at baseline can be enrolled in this group
2957312|NCT02852226|Experimental|Study Intervention|Assess PrEP among women in the study. Assess the characteristics of women who enroll in the PrEP study. Assess the referral sources of women who enroll in the PrEP study
2957313|NCT02852213|Experimental|Single treatment arm|"Single-stage dose-escalation, open-label safety study of AAV2-hAADC delivered by image-guided convection-enhanced delivery bilaterally into the substantia nigra pars compacta and the ventral tegmental area of pediatric patients with AADC deficiency.~6 subjects will be divided in 2 groups of 3. Primary aim is to determine the dose for future studies based on safety, biomarkers of pharmacological activity of AADC and clinical outcomes.~Subjects will be enrolled into 2 dose groups. Group 1 of 3 subjects will receive a single low dose of AAV2 hAADC. The total AAV2-hAADC dose will be infused via MR guided infusion into 4 sites in both the left and right SNc and VTA. Dosing intervals will be 90 days between the first 3 subjects. Group 2 dosing level will be determined by Group 1 results."
2957314|NCT02852200||SEGAm|Elderly community-dwelling people
2957315|NCT02852187|Active Comparator|MOBIS PEEK|Transforaminal Lumbar Interbody Fusion (TLIF) with the SIGNUS MOBIS PEEK Cage
2957316|NCT02852187|Active Comparator|MOBIS II ST|Transforaminal Lumbar Interbody Fusion (TLIF) with the SIGNUS MOBIS II ST Cage
2957317|NCT02852174|Experimental|Mindfulness group|The treatment groups will participate in a mindfulness intervention training that will meet for 2 hours once a week for eight weeks. The 8-week program provides participants with 2-hour weekly instruction designed to teach specific skills and how to apply them during stressful situations (e.g., when caring for or advocating for the veteran).Mindfulness training also requires that participants engage in daily home practice for 30 to 40 minutes. Participants will be required to record the duration of the meditation in log sheets.
2957318|NCT02852174|No Intervention|Control|Participants in the control may receive the mindfulness training after the wait period ends at which point they may receive the treatment as described above.
2957319|NCT02852161|Experimental|MACE|MACE procedure
2957320|NCT02852161|Active Comparator|OGD|Clinically indicated gastroscopy
2957321|NCT02852148|Experimental|ACTICOAT|ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
2957322|NCT02852135|Experimental|LMA Proseal group|The patients were randomly allocated to two groups by using computer-generated numbers.In LMA Prosealgroup,LMA Proseal was inserted into each patient after anesthesia induction.
2957323|NCT02852135|Experimental|LMA Supreme group|The patients were randomly allocated to two groups by using computer-generated numbers.In LMA Supreme group,LMA Supreme was inserted into each patient after anesthesia induction.
2957324|NCT02852122|Experimental|C-11 choline|
2957325|NCT02852109||experimental group|patients who was firstly diagnosed as diffuse axonal injury
2957326|NCT02852109||control group|patients negative for magnetic resonance examination with no trauma
2957327|NCT02852096|Experimental|Dual or Multiple Paraffin Blocks|Assessing Her2/neu Expression in Gastric Cancer with Dual or Multiple Tumor Tissue Paraffin Blocks
2957328|NCT02852096|Active Comparator|One Paraffin Blocks|Assessing Her2/neu Expression in Gastric Cancer with One Tumor Tissue Paraffin Blocks
2957329|NCT02852083|Experimental|A: Biomodulatory treatment|treosulfan 250 mg p.o. twice daily, pioglitazone 45 mg p.o. once daily, clarithromycin 250 mg p.o. twice daily until progression or no clinical benefit observed, whichever comes first.
2957330|NCT02852083|Active Comparator|B: Standard Treatment|Nivolumab, 3 mg per kilogram of body weight every 2 weeks until disease progression according to RECIST 1.1 or unacceptable toxicity
2957331|NCT02852070|Active Comparator|control group|Bronchoscopy examination with 120ml sterile saline solution for bronchoalveolar lavage
2957332|NCT02852070|Experimental|observation group|Bronchoscopy examination with 60ml sterile saline solution for bronchoalveolar lavage
2957333|NCT02852057|Experimental|Subjects Receiving Lenses|All subjects who meet inclusion criteria will receive lenses loaded with timolol maleate and dorzolamide hydrochloride.
2957334|NCT02852044|Active Comparator|Rest|Remain rested prior to the oral glucose tolerance test
2957335|NCT02852044|Experimental|Exercise|Complete exercise prior to the oral glucose tolerance test
2957336|NCT02852031||HLHS|Infants diagnosed with HLHS
2957337|NCT02852018||Appropriate treatment|Patients who have a rhythmic event (before or after inclusion) appropriately treated either by administering an electric shock or by antiarrhythmic stimulation
2957415|NCT02851433|Active Comparator|Propofol Group|
2957338|NCT02852018||No event|Patients who have never received treatment or electrical antiarrhythmic stimulation and with a minimum follow-up of three years before inclusion and did not receive appropriate treatment during the follow up period of the study.
2957339|NCT02852005|Experimental|Group 1: MVA/HIV62B + Placebo|Participants will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive placebo in their right deltoid at Months 0 and 4.
2957340|NCT02852005|Experimental|Group 2: MVA/HIV62B + AIDSVAX B/E|Participants will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
2957341|NCT02852005|Experimental|Group 3: MVA/HIV62B + Placebo|Participants will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive placebo in their right deltoid at Months 0 and 4.
2957342|NCT02852005|Experimental|Group 4: MVA/HIV62B + AIDSVAX B/E|Participants will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
2957343|NCT02852005|Experimental|Group 5: Placebo + AIDSVAX B/E|Participants will receive placebo in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
2957344|NCT02851992|Other|GTS cementless stem|Total Hip arthroplasty with GTS cementless stem (standard and lateralized) with different cup and bearing options (metal-on-polyethylene or ceramic-on-polyethylene)
2957345|NCT02851979|Experimental|S0 - S1 - S2|S0 = no stimulation; washout; S1 = vehicle; washout; S2 = olfactory stimulation
2957346|NCT02851979|Experimental|S0 - S2 - S1|S0 = no stimulation; washout; S2 = olfactory stimulation; washout; S1 = vehicle
2957347|NCT02851979|Experimental|S1 - S0 - S2|S1 = vehicle; washout; S0 = no stimulation; washout; S2 = olfactory stimulation
2957348|NCT02851979|Experimental|S1 - S2 -S0|S1 = vehicle; washout; S2 = olfactory stimulation; washout; S0 = no stimulation
2957349|NCT02851979|Experimental|S2 - S0 - S1|S2 = olfactory stimulation; washout; S0 = no stimulation; washout; S1 = vehicle
2957350|NCT02851979|Experimental|S2 - S1 - S0|S2 = olfactory stimulation; washout; S1 = vehicle; washout S0 = no stimulation
2957351|NCT02851966|Other|TEX101|This is a single arm study. All patients will be asked to provide multiple semen samples and all samples will be tested with TEX101 ELISA assay. Timing of mTESE maybe changed according to the assay results.
2957352|NCT02851953|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
2957353|NCT02851940|Experimental|A (Rubber Band Ligation)|15 patients
2957354|NCT02851940|Experimental|B (Hypertonic Saline Infusion)|15 patients
2957355|NCT02851927|Experimental|Mini Thoracoscopy|Thoracoscopy procedure shall be performed using the Rigid Mini Thoracoscope
2957356|NCT02851927|Active Comparator|Semirigid Thoracoscopy|Thoracoscopy procedure shall be performed using the SemiRigid Thoracoscope
2957357|NCT02851914|Active Comparator|Arm 1 - TCA|"The Tricyclic Antidepressant (TCA) group will receive medication for 12 weeks. Patients will be evaluated every 4 weeks and phone call will be made in between visits to assess the effectiveness and side effects of the medication. Questionnaires will be repeated in the clinic visits and will be used in the data analysis to look for improvements and to compare the two classes of medication in this study."
2957358|NCT02851914|Active Comparator|Arm 2 - SSRI|"The Selective Serotonin Reuptake Inhibitor (SSRI) group will receive medication for 12 weeks. Patients will be evaluated every 4 weeks and phone call will be made in between visits to assess the effectiveness and side effects of the medication. Questionnaires will be repeated in the clinic visits and will be used in the data analysis to look for improvements and to compare the two classes of medication in this study."
2957359|NCT02851901|Placebo Comparator|standard varenicline treatment|(12-weeks active + 12-weeks placebo)
2957360|NCT02851901|Placebo Comparator|extended varenicline treatment|(24-weeks active)
2957361|NCT02851888|Experimental|Iliac Fascia Block (Ropivacaine)|These patients will receive a preoperative iliac fascia block performed as a single shot in the standard fashion prior to hip arthroscopy with general anesthesia.
2957362|NCT02851888|Sham Comparator|Control (Normal Saline Sham Injection)|These patients will receive a preoperative sham block of normal saline in the same fashion as a standard singl shot iliac fascia block prior to hip arthroscopy with general anesthesia.
2957363|NCT02851862||Late Onset GM2 Gangliosidosis|10-15 subjects with Late Onset GM2 Gangliosidosis
2957364|NCT02851849|Active Comparator|LGD-6972-5 mg|5 mg LGD-6972 QD
2957365|NCT02851849|Active Comparator|LGD-6972-10 mg|10 mg LGD-6972 QD
2957366|NCT02851849|Active Comparator|LGD-6972-15 mg|15 mg LGD-6972 QD
2957367|NCT02851849|Placebo Comparator|Placebo|Placebo QD
2957368|NCT02851823|Active Comparator|Control Group|Mechanical periodontal treatment: Scaling and root planing were performed with periodontal curettes until the operator feels that root surface is clean, hard and smooth.
2957369|NCT02851823|Experimental|Test Group|Combined laser therapy: An Er:YAG laser (160 mj/pulse, 10 Hz) (AT Fidelis Fotona, Ljubljana, Slovenia) with water irrigation was first used to remove subgingival calculus and infected cementum.The Er:YAG laser beam was delivered into the periodontal pockets using a chisel-shaped quartz tip in contact mode under water irrigation, from a coronal to an apical direction with the tip inclined at 10o to 15o to the root surfaces. After Er:YAG laser application, Nd:YAG laser treatment (AT Fidelis Fotona, Ljubljana, Slovenia) was performed at an energy level of 100 mJ/pulse, and 20 Hz for removing pocket epithelium and detoxiﬁcation purpose. Irradiation was accomplished with a 320 μm fiber optic delivery system. The fiber was inserted into the periodontal pocket base in parallel alignment with the root surface, and the fiber was slowly moved from apical to coronal in a sweeping motion during the laser light emission.
2957370|NCT02851797|Active Comparator|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
2957371|NCT02851797|Placebo Comparator|placebo|Placebo oral suspension (10 mg/mL) twice daily in a fed state
2957372|NCT02851784|Active Comparator|MWA only|The HCC patients will be treated only by MWA.No adoptive immunotherapy will be used.
2957373|NCT02851784|Experimental|MWA combined with immunotherapy|The HCC patients will be treated firstly by MWA, and then treated by courses of adoptive immunotherapy.
2957374|NCT02851771|Experimental|Pneumonia Patients|Patient admitted at hospital with pneumonia, who need a microbiological diagnosis
2957416|NCT02851420|Placebo Comparator|control|
2957375|NCT02851758|Experimental|Autologous mitochondria injection|All subjects will have autologous mitochondria injected into ischemic areas of the myocardium (via injection or infusion).
2957376|NCT02851745|Experimental|Linagliptin|Linagliptin 5 mg daily for 48 weeks
2957377|NCT02851745|Placebo Comparator|Placebo|Placebo 5 mg daily for 48 weeks
2957378|NCT02851732|No Intervention|Control|"Clusters randomized to the control group will keep their usual practice standards. Patient screening will be performed at the outpatient clinics and primary care centers. Both groups must complete the following forms: Admission, 06 months, and 12 months. Data collection will be performed from medical records by an independent professional not involved in patient care. Furthermore, study coordinator and data collectors from the sites, when asked, must provide appropriate documents for adjudication purposes."
2957379|NCT02851732|Experimental|Intervention|Educational multifaceted intervention can increase the evidence based prescriptions. If this is the case, this tool package may be offered as a quality improvement intervention for all hospitals. Health care professionals from each institution one being a physician (acting as a local leader) and the other being a research nurse (acting as a case manager) must attend the training course for high cardiovascular risk patients that will take place at HCor.
2957380|NCT02851719|Experimental|BF group|24 outpatient sessions of the PFMT (twice a week) using manometric-based BF equipment and daily home PFMT exercises.
2957381|NCT02851719|Active Comparator|PFMT group|24 outpatient sessions (twice a week) of PFMT without BF and daily home PFMT exercises.
2957382|NCT02851706||1-Patients with CNS Tumors|Patients with CNS tumors (or a history) including those with undiagnosed imaging abnormalities in the CNS; and patients with known genetic syndromes at high risk of developing CNS Cancers.
2957383|NCT02851693|Experimental|Optical Coherence Tomography (OCT)|
2957384|NCT02851680|Experimental|Fongitell test|
2957385|NCT02851680|Active Comparator|serum galactomannan|
2957386|NCT02851667|Experimental|Training group|Resident training programs such as talks, day camp and thematic activities were delivered in training group.
2957387|NCT02851654||Dry eye syndrome|Meibomian gland dysfunction responsible of moderate to severe dry eye syndrome
2957388|NCT02851641||Nasolacrimal duct obstruction|
2957389|NCT02851628|Experimental|Alternative sizing model trial mask|In this arm participants who are randomized to the alternative sizing model based mask will be given the alternative sizing model based mask to use in home for the duration of this arm.
2957390|NCT02851628|Active Comparator|Prototype Full Face Mask (PFFM)|In this arm, participants who are randomized to the PFFM will be given the PFFM to use in-home for the duration of this arm.
2957391|NCT02851615|Other|SCThrive|SCThrive Intervention for Adolescents with SCD - 6 week self-management group
2957392|NCT02851615|No Intervention|Attention Control|6 weekly 15-20 minute individual phone calls on educational topics. No interventions are included in this arm.
2957393|NCT02851602|Experimental|Obese|
2957394|NCT02851602|Placebo Comparator|control|
2957395|NCT02851589|Experimental|PCAR-019|Enrolled patients will receive PCAR-019 with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
2957396|NCT02851576|Experimental|Infusion of ADV specific T cells|This one arm study consists in ADV-specific T cell infusion after HSCT from a (M)MUD or, for the first time, from a haploidentical donor for patients having undergone previous UCB transplantation, in the event of refractory ADV infection or disease. Specific anti-ADV immune reconstitution was observed in all patients, and viral load clearance in all but one.
2957397|NCT02851524|Experimental|posturography|
2957398|NCT02851511|Experimental|Cognitive Training + Active Stimulation|This arm receives cognitive training combined with active tDCS.
2957399|NCT02851511|Experimental|Cognitive Training + Sham Stimulation|This arm receives cognitive training combined with sham tDCS.
2957400|NCT02851511|Experimental|Educational Training + Active Stimulation|This arm receives educational training combined with active tDCS.
2957401|NCT02851511|Experimental|Educational Training + Sham Stimulation|This arm receives educational training combined with sham tDCS.
2957402|NCT02851498|Experimental|Novel high-protein pasta and cereal|High-protein pasta (orzo and fusilli) enriched with gluten and egg white protein (%energy: 27/30/43 for protein/fat/carbohydrate) and high-protein flaked breakfast cereal enriched with gluten (%energy: 30/35/35 for protein/fat/carbohydrate) were manufactured by Zone Inc.(Boston, MA). The study foods provided an average of 945 kcal/day (one aliquot of cereal and two pasta dishes daily). Pasta meals were prepared in a metabolic kitchen and were identical in appearance and basic taste as control meals.
2957403|NCT02851498|Sham Comparator|Control pasta and cereal|Commercial gluten-free pasta (Barcilla orzo and fusilli; %energy: 13/24/63 for protein/fat/carbohydrate) and commercial flaked cereal (Post Honey Bunches of Oats; %energy: 6/18/76 for protein/fat/carbohydrate) were used as the control foods. The study foods provided an average of 945 kcal/day (one aliquot of cereal and two pasta dishes daily). Pasta meals were prepared in a metabolic kitchen and were identical in appearance and basic taste as experimental foods.
2957404|NCT02851485|Experimental|GLPG1972 600 mg oral solution fasted|600 mg GLPG1972 administered as oral solution after overnight fasting
2957405|NCT02851485|Experimental|GLPG1972 600 mg oral tablet fasted|600 mg GLPG1972 administered as oral tablet after overnight fasting
2957406|NCT02851485|Experimental|GLPG1972 600 mg oral tablet fed|600 mg GLPG1972 administered as oral tablet after a high-fat high-calorie breakfast
2957407|NCT02851472|Experimental|Inhaled Nitric Oxide|iNO will be given at 20 ppm, continuous, via inhalation before (1 hour), during (3 hours) and after (2 hours) elective blood transfusion and NIRS monitoring
2957408|NCT02851472|Active Comparator|Placebo|Placebo gas (nitrogen) will be given continuous, via inhalation at the same ppm, before (1 hour), during (3 hours) and after (2 hours) elective blood transfusion and NIRS monitoring
2957409|NCT02851459|Experimental|Morally Congruent Message|Participants randomized to this arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations.
2957410|NCT02851459|Experimental|Morally Non-Congruent Message|Participants randomized to this arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations.
2957411|NCT02851459|Sham Comparator|Control Message|Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
2957412|NCT02851446||DS|
2957418|NCT02851407|Experimental|Defibrotide|Defibrotide is administered intravenously at a dose of 25 mg/kg/day in addition to best supportive care on the day before the first day of the conditioning regimen and will continue (for those patients without a VOD diagnosis) for a recommended minimum of 21 days and end no later than Day +30 post HSCT
2957419|NCT02851407|Other|Best Supportive Care|Best supportive care alone (without the addition of defibrotide) according to institutional guidelines and patient need, is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner, or diagnosis of VOD, if applicable
2957420|NCT02851394|Active Comparator|Levobupivacaine group|
2957421|NCT02851394|Experimental|Levobupivacaine + tramadol group|
2957422|NCT02851381|Other|FG-3019|Treatment of Pancreatic Cancer with FG-3019
2957423|NCT02851368|Other|Near Infrared Fluorescence Imaging with Indocyanine Green|Patients will receive an injection of indocyanine green (ICG) 1 day prior to surgery. Near infrared fluorescence imaging (NIFI) will be used to identify pulmonary nodules during the surgical biopsy and/or resection procedure.
2957424|NCT02851342||MS|patients with multiple sclerosis
2957425|NCT02851342||CO|matched control subjects
2957426|NCT02851316|Experimental|Whole Body Vibration|The WBV intervention consists of 6 bouts of 60 seconds vibration with 2 minutes of rest in between (30Hz, 2g acceleration) while participants stand on a vibrating platform with their knees bent.
2957427|NCT02851316|No Intervention|Control|The control intervention consists of 6 bouts of 60 seconds with 2 minutes of rest in between while participants stand with their knees bent (no vibration applied).
2957428|NCT02851303|Active Comparator|Morphine|"Dose given q 3 - 4 hrs with feeds; do not exceed 4 hrs between doses Morphine (0.04mg/0.1ml)~Score Dose For Initiation 0-8 0 None 9-12 0.04 mg/dose 13-16 0.08 mg/dose 17-20 0.12 mg/dose 21-24 0.16 mg/dose 25 or above 0.20mg/dose~Morphine Maintenance/Escalation~Maintain dose if score 0-8~Increase dose by 0.02 if score is 9-12 (rescore before dosing) • Increase dose by 0.04 if score 13-16~Increase score by 0.06 if score 17-20~Weaning Instructions:~Maintain on dose 48 hrs before starting weaning~Wean 0.02 mg morphine every day for a score is 0-8 • Defer wean for score 9-12~Re-escalation~If neonate scores 9-12 re-score as described for initiation,~If second score is in 9-12 increase morphine 0.01 mg q3-4 hrs • If 2 consecutive scores 13-16, increase 0.02 mg q3-4 hrs~If 2 consecutive scores in 17-20, increase 0.04 mg q3-4 hrs etc"
2957429|NCT02851303|Active Comparator|Methadone|Step 1: 0.7 mgs/Kg/24 hrs. divided by into six doses (q 4 hrs) is starting dose Step 2: Decrease dose by half, which is 50% of starting dose, EVERY 4 hours. Step 3: Same dose which is 50% of starting dose EVERY 6 hours. Step 4: Same dose which is 50% of starting dose EVERY 8 hours. Step 5: Same dose which is 50% of starting dose EVERY 12 hours. Step 6: Decrease dose by half, which is 25% of starting dose EVERY 12 hours. Step 7: Same dose which is 25% of starting dose q 24 hours
2957430|NCT02851290|Experimental|Caudal block|Local anesthetic will be administered into the caudal space
2957431|NCT02851290|Active Comparator|Dorsal penile nerve block|Local anesthetic will be administered around the dorsal penile nerve
2957432|NCT02851277|Experimental|Low dose ASP0892 Intradermal|Participants will receive study drug once every 2 weeks for a total of 4 doses. After participants complete the Low dose arms, the Dose Escalation Committee (DEC) will determine if the study can progress to the parallel higher dose arms.
2957433|NCT02851277|Experimental|High dose ASP0892 Intradermal|Participants will receive study drug once every 2 weeks for a total of 4 doses.
2957434|NCT02851277|Placebo Comparator|Placebo Intradermal|Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.
2957435|NCT02851277|Experimental|High dose ASP0892 Intramuscular|Participants will receive study drug once every 2 weeks for a total of 4 doses.
2957436|NCT02851277|Placebo Comparator|Placebo Intramuscular|Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.
2957437|NCT02851264||Optical enhancement technology examination|After routine examination by white-light endoscopy,the imaging mode will be switched to optical enhancement.Suspicious area will be recorded in detail. Then all enrolled patients will have their esophagus sprayed with iodine solution. Suspicious area will be also recorded in detail.After that biopsy specimens will be obtained respectively by forceps from each suspicious lesion recorded for histologic diagnosis.
2957438|NCT02851238|No Intervention|Protective Ventilation|The control arm receives existing conventional protective ventilation with tidal volume of 6mL/kg of ideal body weight and positive end expiratory ventilation of 5cmH2O during one-lung ventilation
2957439|NCT02851238|Experimental|Driving Pressure Limited Ventilation|The intervention arm receives driving pressure limited ventilation during one-lung ventilation
2957440|NCT02851225|Experimental|telemedicine transmission|telemedicine transmission of biological results in the treatment of transfusion supportive care
2957441|NCT02851225|No Intervention|without telemedicine transmission|no telemedicine transmission of biological results in treatment in the treatment of transfusion supportive care
2957442|NCT02851212|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 100 milligram (mg) and 1 canagliflozin tablet 50 mg along with two Extended Release (XR) tablets of metformin of each 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 Extended Release (XR) fixed dose combination [FDC] tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg and metformin XR two tablets of each 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2957443|NCT02851212|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2957444|NCT02851212|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2957593|NCT02850055|Active Comparator|Multimodal Group|Conventional Physiotherapy, six one hour treatment sessions. An hour for week.
2957445|NCT02851212|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2957446|NCT02851199|Active Comparator|study group 1|1. A group of 15 children who will undergoe an electroencephlaography recording with 3 minutes of hyperventilation in the prone position, followed by 5 minutes of rest, then after another 5-10 minutes of recording with normal breathing. Finally the participants will performed additional 3 minutes of hyperventilation in the sitting position
2957447|NCT02851199|Active Comparator|study group 2|2. A group of 15 children who will undergoe an electroencephlaography recording with 3 minutes of hyperventilation in the sitting position, followed by 5 minutes of rest, then after another 5-10 minutes of recording with normal breathing. . Finally the participants will performed additional 3 minutes of hyperventilation in the
2957448|NCT02851186|Experimental|Electroacupuncture (EA) and Auricular Acupuncture (AA)|Subjects in the treatment group will receive EA combined with AA two hours before operation, immediately post-operation and once a day for the subsequent 5 days.
2957449|NCT02851186|Sham Comparator|Sham acupuncture|Subjects in the control group will receive non-invasive sham procedure in the same schedule as the treatment group.
2957450|NCT02851173|Experimental|LLLT|Six weekly sessions of LLLT. The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). Each laser stimulation session will consist of total 8 min, with eight 1 min/cycle treatments alternating between two locations on the right forehead.
2957451|NCT02851173|Active Comparator|Placebo|The control group will undergo the same procedure as the treatment group, but will receive brief (5-s) stimulation to the intended site on the forehead, followed by 55 s of no stimulation, for each 1-min cycle. Thus the control group will receive approximately 1/12th of the cumulative energy density as the treatment group. This is sufficient to provide a brief sensation of slight heat (as active placebo) at the onset of each one-minute cycle, using a fraction of the energy received by the experimental group.
2957452|NCT02851160||Patients requiring lung cancer chemotherapy|30 major Patients with lung cancer requiring chemotherapy either as palliative or adjuvant as surgical treatment having a semi-structured interview conducted by a clinical psychologist
2957453|NCT02851160||Family of lung cancer patients receiving chemotherapy|30 Family of lung cancer patients receiving chemotherapy having a semi-structured interview conducted by a clinical psychologist
2957454|NCT02851160||doctors caring for lung cancer patients receiving chemotherapy|15 doctors caring for lung cancer patients receiving chemotherapy 15 have a semi-structured interview conducted by a psychiatrist specialized in psycho-oncology
2957455|NCT02851147||Any Willing and Able Person for Ocular Imaging|Any Willing and Able Person for Ocular Imaging
2957456|NCT02851134||Crohn disease subject|Crohn disease affected subject
2957457|NCT02851134||family control subject|family control unaffected subject
2957458|NCT02851121|Other|Healthy volunteers|
2957459|NCT02851108|Experimental|AS-AQ-MB|Once daily a fixed dose artesunate-amodiaquine formulation combined with once daily methylene blue (15 mg/kg) over a three days period.
2957460|NCT02851108|Active Comparator|AS-AQ-PQ|Once daily a fixed dose artesunate-amodiaquine over three days combined with a single dose of primaquine on day 2 (0.25 mg/kg).
2957461|NCT02851095|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 50 milligram (mg) along with two Extended Release (XR) tablet of metformin of each 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D of (1 XR fixed dose combination [FDC] tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 50 mg and 1 metformin 1000 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg along with 2 metformin (XR) tablets of each 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2957462|NCT02851095|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2957463|NCT02851095|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2957464|NCT02851095|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2957465|NCT02851082|Experimental|Haemophilia A patients|Patients will perform endurance training program on 6 consecutive weeks
2957466|NCT02851069||HCV Genotype 1 participants|Participants receiving Paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV)
2957467|NCT02851056|Experimental|Survivin Vaccine and Autologous HCT|Dendritic Cell Survivin Vaccine (DC:AdmS) and Autologous Hematopoietic Cell Transplantation (HCT). Participants will receive 1 pre-transplant survivin vaccine, 7-30 days prior to stem cell apheresis collection. After the first survivin vaccination, participants will be mobilized with Granulocyte-colony Stimulating Factor (G-CSF). A second survivin vaccine will be administered on day +21 (between day+20 and +34) after HCT. All participants will be co-immunized with Prevnar 13 at each time they receive the survivin vaccine.
2957468|NCT02851043|Experimental|pneuRIP(breathing with resistance)|Testing the subjects breathing with resistance
2957469|NCT02851043|No Intervention|Respitrace system (Carefusion) (breathing without resistance)|Testing subjects breathing without resistance
2957470|NCT02851030|Experimental|Move, Play, Learn! Intervention|This arm will receive the 10-week Move, Play, Learn! intervention immediately.
2957471|NCT02851030|No Intervention|Waitlist Control|This arm will receive the 10-week intervention once follow-up measures on the primary outcome have been collected for both groups.
2957472|NCT02851017|Experimental|Exergaming group (XBOX Kinect|Kinect™ exercise group performed sessions on three non-consecutive days per week for 4 weeks (12 sessions in total).
2957473|NCT02851017|Experimental|Traditional gym based exercise group|Traditional gym based (TGB) exercise group performed sessions on three non-consecutive days per week for 4 weeks (12 sessions in total). Those in the TGB group performed exercises that were matched for sequence, intensity, duration and mode of exercise by adopting open and closed kinetic chain movements, in the same range and loading as required in the Kinect™ group.
2957474|NCT02851004|Experimental|BBI608 + Pembrolizumab|BBI608 and Pembrolizumab
2957475|NCT02850991|Experimental|High-dose|"concurrent chemoradiotherapy High-dose RT:59.4 Gy in 33 fractions, 1.8 Gy per fraction, 5days/week; CT: Paclitaxel 50 mg/m2 D1+carboplatin AUC (area under curve) =2 D1, weekly for 6 weeks.~After that, patients receive consolidative platinum-based 3-week chemotherapy for 2 cycles."
2957476|NCT02850991|Active Comparator|Standard-dose|"concurrent chemoradiotherapy Standard-dose RT:50.4 Gy in 28 fractions, 1.8Gy per fraction, 5days/week; CT: Paclitaxel 50 mg/m2 D1+carboplatin AUC (area under curve) =2 D1, weekly for 6 weeks.~After that, patients receive consolidative platinum-based 3-week chemotherapy for 2 cycles."
2957477|NCT02850978||Spiolto|Patient with COPD to received Spiloto
2957478|NCT02850965|Experimental|BI 695501|
2957479|NCT02850965|Active Comparator|Humira|
2957480|NCT02850952|Experimental|Rehab MATRIX|Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
2957481|NCT02850939|Experimental|Mobile phone app + patient navigation|Patients assigned to the intervention group (60) will: 1) use the personalized mobile phone app in their preferred language for a duration of 6 months; and 2) receive assistance from a patient navigator. They will also continue to receive the usual EHT care provided at the CTRC's breast clinic.
2957482|NCT02850939|No Intervention|Usual care|Patients assigned to the control (usual care) group (60) will receive the usual EHT care and materials offered at the CTRC's breast clinic.
2957483|NCT02850926|Experimental|Soccer head gear|Subjects who are wearing soccer head gear during the practices and games during the soccer season.
2957484|NCT02850926|No Intervention|Control|Subjects who are not wearing soccer head gear during the practices and games during the soccer season.
2957485|NCT02850913|Active Comparator|Doxycycline|"115 participants will be randomized to oral Doxycycline 100 mg daily for six weeks.~Each capsule contains doxycycline hyclate equivalent to 100 mg of doxycycline base.~Treatment will be initiated in hospital but will be continued at home.~Scheduled study clinic and home visits will be conducted at 6, 12, 24 months and at 2, 4 and 6 weeks respectively for adherence monitoring and assessment of safety."
2957486|NCT02850913|Placebo Comparator|Placebo|"115 participants will be randomized to the placebo arm for matching capsules containing no active ingredients daily for six weeks.~Placebo will be initiated in hospital but will be continued at home.~Scheduled study clinic and home visits will be conducted at 6, 12, 24 months and at 2, 4 and 6 weeks respectively for adherence monitoring and assessment of safety."
2957487|NCT02850900|Experimental|Internet Survey|Subject will receive an electronic survey weekly to complete
2957488|NCT02850900|No Intervention|No Survey|No intervention
2957489|NCT02850887|Active Comparator|general endotracheal anesthesia|an inhalation anesthetic (substance that blocks pain) technique in which anesthetic and respiratory gases pass through a tube placed in the trachea (throat) via the mouth or nose
2957490|NCT02850887|Active Comparator|deep sedation without endotracheal intubation|local anesthesia together with sedation (drug that produces sleep) and analgesia (drug that treats pain) only.
2957491|NCT02850874|Experimental|HIPEC|Immediately following laparoscopy for diagnosis and staging of disease, closed neoadjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) will be performed using the anatomical site of the laparoscopic procedure in the same operative encounter. Perfusion will be initiated with 4-6 L of 1.5% dextrose at a 500 mL/min flow rate with manual agitation of the abdominal wall. Once the temperature in the abdomen becomes stable above 40°C, perfusate volume will be reduced to 1.5 L/m sq, and gemcitabine (GEMZAR®) will be instilled into the abdomen (1000 mg/m sq) for 90 min. Neoadjuvant chemotherapy with gemcitabine will be administered prior to open pancreaticoduodenectomy by the standard Whipple or pylorus-preserving approach. Adjuvant systemic chemotherapy with gemcitabine will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional protocol.
2957492|NCT02850874|Other|Historical Control|Case-matched historical controls will have received neoadjuvant chemotherapy with gemcitabine prior to open pancreaticoduodenectomy (PD) by the standard Whipple or pylorus-preserving approach. Adjuvant systemic chemotherapy (SCT) with gemcitabine will be administered for 6 mo (including period of neoadjuvant therapy) according to established institutional protocol.
2957493|NCT02850861|Experimental|The experimental group|In this group, the condylar reductor was applied in the surgical treatment of mandibular condylar fractures.
2957494|NCT02850861|No Intervention|The control group|In this group, traditional surgical instruments were applied in the surgical treatment of mandibular condylar fractures.
2957495|NCT02850848|Experimental|Entigin Film Coated Tablet 0.5mg|Entigin Film Coated Tablet 0.5mg Dosing Regimen: Single dosing of two tablets
2957496|NCT02850848|Active Comparator|Baraclude 0.5mg Tablets|Baraclude 0.5mg Tablets Dosing Regimen: Single dosing of two tablets
2957497|NCT02850835|Experimental|Video Decision Aid|This group will be shown a video decision aid along with their standard of care.
2957498|NCT02850835|No Intervention|Standard Care|This group will not see the video decision aid and will only receive standard of care.
2957499|NCT02850822||Therapy pre-transplantation|Chemotherapy regimen and/or demethylation drugs(such as decitabine) were given pre-transplantation for patients with RAEB-1, REAB-2 and AML Secondary to MDS (bone marrow blast cells less than 50%).
2957500|NCT02850822||No Therapy pre-transplantation|No therapy (chemotherapy or demethylation drugs) was given pre-transplantation for patients with RAEB-1, REAB-2 and AML Secondary to MDS (bone marrow blast cells less than 50%).
2957501|NCT02850809||patients|Treated by percutaneous image-guided radiofrequency for renal tumor
2957502|NCT02850796|Experimental|Kg-Free|Kg-free is a manualized acceptance, mindfulness & compassionate-based group intervention for women struggling with their weight. It comprises 10 weekly group sessions plus 2 booster fortnightly sessions (31/2months) 2h30 hours each, run in small groups (ranging from 10 to 12 participants).
2957503|NCT02850796|Other|Treatment as Usual (TAU)|nutritional treatment for weight loss in primary care units and Hospitals from Coimbra's district that includes dietary and physical activity support
2957504|NCT02850783|Experimental|SLN identification with 89-zirconium-nanocoll|Submucosal injection of 2.5 mBq, 0.4 ml 89-Zirconium-Nanocoll and subsequently SLN identification
2957505|NCT02850770|Other|Control|Pedometers and walking logs
2957506|NCT02850770|Experimental|Phone Messaging|Phone Messaging
2957507|NCT02850770|Experimental|Phone Messaging + Family/Friend Support|Phone Messaging + Family/Friend Support
2957508|NCT02850757|Experimental|U shaped Guedl's airway|
2957509|NCT02850757|Experimental|Modified William's airway(Fekry airway )|
2957510|NCT02850744|Other|Single-arm|Open label, single arm including patients with progressive glioblastoma during or after temozolomide chemotherapy obtaining PQR309 80mg capsules.
2957511|NCT02850731|Experimental|plate-forme Hu360®|the innovative technology (plate-forme Hu360®) will be used in the experimental arm
2957512|NCT02850731|No Intervention|supervision by a therapist|an adapted physical activity program under supervision of a therapist
2957513|NCT02850718|Experimental|Period 1: Sublingual wafer|Subjects receive receive a single dose of 50 mg sublingual sildenafil followed by plasma sampling for 14 hours.
2957514|NCT02850718|Active Comparator|Period 2: Oral comparator|Subjects receive a single dose of 50 mg oral sildenafil (Viagra) followed by plasma sampling for 14 hours.
2957515|NCT02850692|Experimental|Mucoviscidose with portal hypertension|Mucoviscidosis with portal hypertension
2957516|NCT02850692|Experimental|Muco without portal hypertension|Mucoviscidosis without portal hypertension
2957517|NCT02850692|Experimental|Portal hypertension without muco|Portal hypertension without Mucoviscidosis
2957518|NCT02850692|Experimental|Healthy volunteers|Healthy volunteers
2957519|NCT02850666|Experimental|Interdisciplinary Process drama|Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
2957520|NCT02850653|Other|Endophthalmitis sufferers|Patients hospitalized for diagnostic and therapeutic evaluation of a post-operative acute endophthalmitis.
2957521|NCT02850653|Other|Healthy control patient|Patients hospitalized in the context of a scheduled surgery with sampling of aqueous humour.
2957522|NCT02850627|Experimental|Tongguan capsule|Tongguan capsule (0.5 g tid. for 6 months)
2957523|NCT02850627|Placebo Comparator|placebo capsule|same volume/day of placebo capsule (0.5 g tid. for 6 months)
2957524|NCT02850614|Active Comparator|Control|Fifty participants in the control condition will each receive a FitBit to track their physical activity. Instead of interfacing with a gaming app on their Chromebooks to track physical activity, control condition participants will interface with a minimalist activity tracker showing them only how many minutes of MVPA they've done over the course of the day. It is expected that after several weeks of baseline use, control condition participants will no longer find the FitBit novel. In order to encourage control condition participants to wear their FitBits at school daily, they will receive one entry into a weekly lottery for each day they wear the FitBit that week.
2957525|NCT02850614|Experimental|Intervention|Fifty participants will be randomized to the intervention condition, which will use a gaming application to encourage physical activity, as physical activity goal achievement will translate into rewards in the game. Physical activity will be tracked using a FitBit activity monitor and in order to encourage intervention condition participants to wear their FitBits at school daily, they will receive one entry into a weekly lottery for each day they wear the FitBit that week.
2957526|NCT02850601|Experimental|Dexamethasone solution|Dexamethasone 0.5 mg/mL, 5ml TID for 4 weeks
2957527|NCT02850601|Active Comparator|Dexamethasone solution in Mucolox™|Compounded dexamethasone 0.5 mg/mL in Mucolox™, 5ml TID for 4 weeks
2957528|NCT02850588||TCAR treatment|All high risk surgical patients undergoing transcarotid revascularization with a carotid stent during carotid artery flow reversal in hospitals that participate in the Carotid Artery Stent Registry of the Society for Vascular Surgery Patient Safety Organization
2957529|NCT02850588||CEA treatment|All patients undergoing carotid endarterectomy in hospitals that participate in the Carotid Endarterectomy Registry of the Society for Vascular Surgery Patient Safety Organization
2957530|NCT02850562|Active Comparator|Walking|The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.
2957531|NCT02850562|Experimental|Walking + Exercise|The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
2957532|NCT02850549|Other|physical therapy|Physical Therapy intervention provided by therapists in phase one without training in following a neck classification system and in phase two after being trained to follow a neck pain classification system.
2957533|NCT02850536|Experimental|anti-CEA CAR-T cells|Three infusions of gene-modified anti-CEA T cells over the course of 3 weeks into the hepatic artery via a percutaneous approach along with low dose IL-2.
2957534|NCT02850523|Experimental|Experimental|After an initial assessment, the experimental group will receive 6 weekly sessions (2 hours long) of group Cognitive Behavioural Therapy for Perinatal Anxiety (n=6 per group) for perinatal anxiety. They will then be re-assessed at post-treatment and 3 months post-treatment to determine the effectiveness of the treatment and whether these effects are maintained 3 months after treatment.
2957535|NCT02850523|No Intervention|Waitlist Control|After an initial assessment, the wait-list control group will not receive any treatment for 6 weeks. They will then be re-assessed after 6 weeks and this data will be used to compare this group to the experimental group to determine the effectiveness of the treatment. After this re-assessment they will be offered the same treatment as the experimental group: 6 weekly sessions (2 hours long) of group Cognitive Behavioural Therapy for Perinatal Anxiety
2957536|NCT02850510|Experimental|Brief Incredible Years parent training|Parent training
2957537|NCT02850510|No Intervention|No parent training|No parent training
2957538|NCT02850497|Active Comparator|CRE8 stent|Treatment with CRE8 stent implantation and evaluated with optical coherence tomography at 6 months
2957539|NCT02850497|Active Comparator|Biomatrix stent|Treatment with Biomatrix stent implantation and evaluated with optical coherence tomography at 6 months
2957540|NCT02850497|Active Comparator|patients treated with Xience stent|Treatment with Xience stent implantation and evaluated with optical coherence tomography at 6 months
2957541|NCT02850484|Active Comparator|Reference 1 Symbicort Inhaler 160/4.5μg|Reference 1: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
2957542|NCT02850484|Experimental|SYN010 HFA Inhaler|SYN010 HFA (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
2957543|NCT02850484|Active Comparator|Reference 2 Symbicort Inhaler 160/4.5μg|Reference 2: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
2957544|NCT02850471|Experimental|TEAS group|Before anesthesia, patients in this group treated with Transcutaneous Electric Acupoint Stimulation (TEAS) which is an electroacupuncture on Feishu, Hegu, Chize half an hour before the surgery, using the device Hua Tuo SDZ-II Acupoint Stimulator. The stimulus parameters set as 2/100Hz, 2V, 30min.
2957545|NCT02850471|No Intervention|controlled group|Patients in controlled group treated without TEAS or other placebo.
2957546|NCT02850458||implant retained-overdentures with the attachment of bar|patients treated with implant-retained overdentures,and the attachment is bar
2957547|NCT02850458||implant retained-overdentures with the attachment of magnet|patients treated with implant-retained overdentures,and the attachment is magnet
2957548|NCT02850445|Experimental|Integrated Treatment|
2957549|NCT02850445|Active Comparator|antipsychotic medication alone treatment|
2957550|NCT02850432|Active Comparator|Invasive treatment|Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol
2957551|NCT02850432|Active Comparator|Conservative treatment|rehabilitation with medical therapy
2957552|NCT02850419|Experimental|ThermoDox (40mg/m2)+hyperthermia+RT|Treatment will consist of up to six cycles of LTLD combined with hyperthermia every 21 days with the first day of each cycle being Day 1. ThermoDox will be administered at a dose of 40 mg/m2. Thermal dose is a one-hour treatment at a temperature between 40 and 43°C at the target site. At Cycle 1, radiotherapy will begin and will be combined with hyperthermia. A total of 40 Gy in 20 fractions of 2 Gy per fraction will be administered. Up to 66 Gy of radiation therapy can be administered however institutional guidelines should be followed.
2957553|NCT02850406|Experimental|GBT440|Subjects to receive daily oral dosing of GBT440 for 1 day (single dose) or up to 24 weeks (multiple dose)
2957554|NCT02850393|Experimental|patients with obsessive compulsive disorder|Functional magnetic resonance imaging behavioral measures physiological measurements
2957555|NCT02850393|Experimental|healthy participants|Functional magnetic resonance imaging behavioral measures physiological measurements
2957556|NCT02850380|Other|spatial orientation in weightlessness|"subjects will be asked to flip a series of switches into the off position. On Earth, the off position corresponds to down in all three reference frames: the visual allocentric, the non-visual allocentric as well as the egocentric frames. We expect that flip direction will be dominated by visual allocentric cues when those are available, will be delayed and more variable when confirmatory gravitational cues are absent, and will be biased towards the egocentric reference when tactile cues are added"
2957557|NCT02850367|Active Comparator|Acute intake|Evaluation after acute intake of the food supplement.
2957558|NCT02850367|Active Comparator|Chronic intake|Evaluation before and after chronic intake of the food supplement.
2957559|NCT02850354|Experimental|anti-g maneuvers|"Before the first parabola, pulmonary function will be evaluated. Then during each weightlessness period the subject will be instructed either to stay at rest (control condition) or to perform anti-g maneuvers (4 times each): intermittent exhalation on exertion, lower limbs and abdomen muscular contraction, combined maneuver ('intermittent exhalation on exertion' + 'muscle contraction'). Before, the exhalation on exertion, the subject will close the airway after the mouthpiece by pushing on a button actuating a pneumatic valve.~Each subject will be tested during 15 parabola where the anti-g maneuvers will be performed in randomized order. After the 15th parabola, pulmonary function will be again evaluated."
2957560|NCT02850341|Experimental|Intervention group|Patients receive a pedometer and instructions how to raise their physical activity
2957561|NCT02850341|No Intervention|Control group|Patients receive treatment-as-usual
2957562|NCT02850328|Other|high-load resistance training for long term space flights|"Short duration electrical will be delivered and the resulting EMG will be recorded. Intensity of electrical stimulation will be progressively increased until we observed a maximal EMG response.~Finally an ultrasound probe (similar to that used for prenatal diagnostic imaging) will be fixed behind your calf in order to visualize muscle."
2957563|NCT02850302|Other|FDG PET + exome analysis before treatment and after|Participants will performed one PET with FDG an tumor exome analysis before treatment is started.After 6 cycles of chemotherapy a second PET with FDG and a second tumor exome analysis will be performed
2957564|NCT02850289||Pegylated Interferon (PEG-IFN) alfa-2a and Ribavirin|Participants with hepatitis C who were to be treated with combination of pegylated interferon (PEG-IFN) alfa-2a and ribavirin, within 7 days of baseline, with ongoing management at investigator's discretion.
2957565|NCT02850276|Experimental|Pyridostigmine|30mg PO three times a day
2957566|NCT02850263||Cohort 1 / Anti-VEGF treatment naïve patients|Anti-VEGF treatment of naïve patients (who have not received any previous anti-VEGF treatment) with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the United Kingdom.
2957567|NCT02850263||Cohort 2 / Anti-VEGF treatment non-naïve patients|Anti-VEGF treatment of non-naïve patients (who have received previous anti-VEGF treatment) with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the UK.
2957568|NCT02850263||Cohort 3 / Total study population|Anti-VEGF treatment naïve patients and anti-VEGF treatment non-naïve patients with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the UK.
2957625|NCT02849743|Experimental|Placebo, then Syntocinon (= Oxytocin)|"Intranasal placebo, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)~Intranasal oxytocin, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)"
2957749|NCT02848898|Experimental|Equistasi Group|arm treated with application of devices
2957569|NCT02850224|Experimental|Motivational interviewing to elicit PCO in pediatrics|"Providers will be randomized into a patient-centered outcomes (PCO) education course or standard of care. The PCO education course will educate and test providers on patient-centered outcomes of interest and appropriate methods to deliver PCO care.~Providers randomized into the intervention arm will be required to take a brief, one-hour, webinar describing the background, problem, results from focus groups we conducted, and a training program on motivational interviewing. After completing the course, providers will be required to complete an evaluation."
2957570|NCT02850224|No Intervention|No Intervention|Standard care
2957571|NCT02850211|Experimental|Celecoxib|1 capsule of 200mg Celebrex twice a day for 14 days
2957572|NCT02850211|Active Comparator|Traditional NSAIDs|1 tablet of 385mg Ibuprofen twice a day for 14 days
2957573|NCT02850211|Active Comparator|Opioid drug|1 tablet of 50mg Tramadol twice a day for 14 days
2957574|NCT02850198|Experimental|Scalp electroacupuncture group|Select a 1.5 cun long disposable sterile filiform needle NO.30.Divide the Anterior oblique line of the vertex-temporal in ipsilesional into three equal parts to accept acupuncture.Insert the needle subcutaneously at a 30°angle to the scalp.The depth of insertion is 1 cun.The needle is twirled continuously at a frequency of about 170 times per minute.When the acupuncture sensation is obtained,connect the positive and negative outputs of the electroacupuncture to the handle of the needle in the Anterior oblique line of upper 1/3 and the middle 1/3. Select an sparse-dense wave .Use the low frequency electroacupuncture which the frequency is 2Hz. Every session lasts for 30 min per day.The treatment must be given once daily and 5 sessions constitute one therapeutic course.There is 2 days for relaxation between the two therapeutic courses.The participants must be treated for 4 weeks.
2957575|NCT02850198|Sham Comparator|Sham scalp electroacupuncture group|Select a 1.5 cun long disposable sterile filiform needle NO.30.Divide the Anterior oblique line of the vertex-temporal in ipsilesional into three equal parts to accept acupuncture.Insert the needle subcutaneously at a 30°angle to the scalp.The depth of insertion is 1 cun.The needle is twirled continuously at a frequency of about 170 times per minute.When the acupuncture sensation is obtained,connect the positive and negative outputs of the electroacupuncture to the handle of the needle in the Anterior oblique line of upper 1/3 and the middle 1/3. with shame electroacupuncture. Select an sparse-dense wave .Use the low frequency electroacupuncture which the frequency is 2Hz. Every session lasts for 30 min per day.The treatment must be given once daily and 5 sessions constitute one therapeutic course.There is 2 days for relaxation between the two therapeutic courses.The participants must be treated for 4 weeks.
2957576|NCT02850185|Experimental|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ hydrogen/ oxygen inhaled
2957577|NCT02850185|Experimental|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
2957578|NCT02850172|Experimental|Walk, eat, & breathe group|"Participants in the experimental group will receive Walk, Eat, & Breathe at initiation of CCRT and ends before curative surgery."
2957579|NCT02850172|No Intervention|Control group|Participants in the control group received usual care.
2957580|NCT02850159|Experimental|dual-mode group|the dual-mode NIBS with high-frequency rTMS and tDCS simultaneously
2957581|NCT02850159|Active Comparator|rTMS group|high-frequency rTMS and sham tDCS
2957582|NCT02850146|Experimental|18F-AV-1451|50 individuals who are cognitively normal, older, Aβ not elevated and enrolled in the LEARN study will undergo 18F-AV-1451 imaging procedures at 3 time points over a 3 year period (start, middle and end of study)
2957583|NCT02850133|Experimental|Spinal cord injury|Cardio-pulmonary exercise testing and aerobic exercise training
2957584|NCT02850120||Unconfounded|"All hospital admissions including Tension-free Vaginal Tape (TVT), Trans-obturator tape (TOT) or suprapubic sling (SS) procedures with:~no concomitant procedures,~any concomitant procedures which were considered unlikely to have an effect on outcomes from their mesh insertion, or~only other concomitant procedures which were considered likely to be rescue procedures treating complications caused by the mesh insertion procedure itself."
2957585|NCT02850120||Confounded|All hospital admissions for insertion of Tension-free Vaginal Tape (TVT), Trans-obturator tape (TOT) or suprapubic sling (SS) procedures with concomitant procedures likely to affect outcomes.
2957586|NCT02850107|Other|Non-randomized|"Directional Atherectomy + Drug Coated Balloon: DA followed by DCB will be performed in all enrolled subjects.~DA includes the use of Intervention 'Medtronic HawkOne® or TurboHawk™.~Medtronic Spider™ Distal Protection Device (DPD) is recommended for use according to IFU.~Medtronic IN.PACT® Admiral® DCB will be used after DA.~Volcano Visions® PV .014 IVUS catheter required to assess lesion in each procedure.~Nitinol Stent Placement: Only FDA approved nitinol stents can be used if provisional stenting is required."
2957587|NCT02850094|Experimental|Financial Bonuses|For two weeks following enrollment, subjects are monitored via their FitBit accelerometer to monitor their pre-intervention physical activity levels. For a twenty-four week period following the observational period, participants are eligible for financial bonuses based on their increased activity. Participants enroll as teams and are eligible for additional financial bonuses based on their team's performance.
2957588|NCT02850081|No Intervention|Observational - Maximal Dose - ARM 1|Patients on a pre-existing maximal dose of either Simvastatin (40mg) with/without currently taking amlodipine (Norvasc) and those on Simvastatin 20mg while currently on amlodipine; Atorvastatin (80mg), or Rosuvastatin (20mg) regimen will be observed for ~2 weeks before their CEA.
2957589|NCT02850081|Experimental|Less Than Maximal Dose - ARM 2|Patients on a pre-existing statin regimen at a lower dose (less than maximal) of Simvastatin <40mg without amlodipine and <20mg with amlodipine; Atorvastatin (<80mg) or Rosuvastatin (<20mg) will be randomized to maintain their current dose plus placebo or be increased to the maximal dose of their current statin for ~2 weeks before their CEA.
2957590|NCT02850081|Experimental|Statin Naive - ARM 3|Patients on no pre-existing statin regimen will be randomized to Atorvastatin 10 mg or Atorvastatin 80 mg for ~2 weeks before their CEA
2957591|NCT02850068|Experimental|Geniculate Artery Embolization|Patients in this study will receive the geniculate artery embolization (GAE) procedure. The primary aims will be to determine if geniculate artery embolization (GAE) will reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA).
2957592|NCT02850055|Experimental|Specific Manual Therapy Group|Conventional Physiotherapy and Specific manual therapy, six one hour treatment sessions. An hour for week.
2957850|NCT02848157|Placebo Comparator|PR|0.25% ropivacaine 0.3ml/kg
2957594|NCT02850042|Experimental|Occupation-based practice|Occupation-based intervention (OBP) is a form of activity-based therapy consisting of client-directed occupations that match client-identified goals. OBP group will participate in activities such as wood working, scrap booking, higher level dressing (don/doffing a bra, zipping coat), hair care, opening doors, using bathroom stalls, typing, cooking, tying shoes, washing dishes, carrying dirty dish carts, clearing dirty dishes and raking. Repetition of the tasks are not the focus in the OBP group. Each session lasted 55-minute and it was delivered twice a week for 4 weeks (8 sessions).
2957595|NCT02850042|Active Comparator|Modified-constraint induced therapy|Modified-constraint induced therapy (m-CIT) group will target functional goals (eg, activities of daily living) or goal subcomponents (eg, pinching, grasp/release, or functional reach patterns). Tasks were repeated at rate of approximately 10 to 50 repetitions each session according to the demands of the task. No physical constraint of the less-affected UE will be applied, but training compelled highly repetitive use of the more-affected upper extremity. Subjects will attempt tasks with progressive difficulty. Each session lasted 55-minute and it was delivered twice a week for 4 weeks (8 sessions).
2957596|NCT02850029||critically ill patients|Critically ill patients admitted in intensive care units and receiving one of the following aminoglycosides: gentamicin, tobramycin and amikacin as part of their usual care.
2957597|NCT02850016|Experimental|Group A|Two treatment cycles each consisting of 3BNC117 infusions (30mg/kg) + three romidepsin infusions (5mg/m2). 3BNC117 will be administered on Days 0 and 56. Romidepsin will be administered on days 2, 9, 16, 58, 65, and 72 .
2957598|NCT02850016|Experimental|Group B|Two treatment cycles each consisting of three romidepsin infusions (5mg/m2). Romidepsin will be administered on days 0, 7, 14, 56, 63, and 70 .
2957599|NCT02850003|Experimental|IDP-120 Gel|Gel
2957600|NCT02849990|Experimental|Treatment (neoadjuvant chemotherapy)|Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
2957601|NCT02849964||First time renal replacement therapy|Patients beginning renal replacement therapy by renal dialysis or preemptive kidney transplant.
2957602|NCT02849951|Experimental|LT-02|1.6 g PC in LT-02 BID
2957603|NCT02849951|Placebo Comparator|LT-02 Placebo|0 g PC in LT-02 Placebo BID
2957604|NCT02849938|No Intervention|Control Group|Usual care
2957605|NCT02849938|Experimental|Telemedicine Group|TytoCare Device
2957606|NCT02849925|Experimental|Glass Ionomer Sealant|Sealants to arrest microcavitated caries. 75 microcavitated ICDAS 3 lesions will be sealed by the use of Glass ionomer sealant, EQUIA (GC) in first permanent molars.
2957607|NCT02849925|Active Comparator|Resin Sealant|Sealants to arrest microcavitated caries. 75 microcavitated ICDAS 3 lesions will be sealed by the use of resin sealant, Clinpro (3M-ESPE) in first permanent molars
2957608|NCT02849899|Active Comparator|Vildagliptin|Group 1 will be treated with Vildagliptin 50 or 100 mg/day for 2 months, then 25 or 50 mg/d for 1 month depending on their creatinine assay.
2957609|NCT02849899|Placebo Comparator|Placebo|Group 2 will be treated with placebo according to the same dosage.
2957610|NCT02849886|Experimental|LT icasp9 ΔCD19 (cohort1)|Injection T lymphocytes iCASP9 ΔCD19 (2.10e6, 5.10e6 and 10.10e6 Gene Modified Cells (GMC)/kg).
2957611|NCT02849886|Experimental|LT iCASP9 ΔCD19 & GvHD (cohort2)|Injection T lymphocytes iCASP9 ΔCD19 (2.10e6, 5.10e6 and 10.10e6 GMC/kg). Patients who develop GVHD after administration of Gene Modified Cells (GMC) will be treated with dimerizer drug (AP1903)
2957612|NCT02849873|Experimental|IDp-123 Lotion|Lotion
2957613|NCT02849873|Active Comparator|Tazorac Cream|Cream
2957614|NCT02849860|Experimental|IDP-121 Lotion|Lotion
2957615|NCT02849834|Active Comparator|healthy volunteers|
2957616|NCT02849834|Experimental|Patients with resistant pain|
2957617|NCT02849821|Other|hypobaric pressure chamber|The healthy volunteers and IBD patients will have a 3-hour exposure to hypoxic conditions simulating an altitude of 4,000 meters above sea level (m.a.s.l.) in a hypobaric pressure chamber. Before and after the pressure chamber sigmoidoscopy will be performed. During stay in the pressure chamber repetitive measurements of bladder volume will be performed by sonography.
2957618|NCT02849808||Keratoplasty patients|All patients who underwent one or more keratoplasties since january 1983.
2957619|NCT02849795|Experimental|Psoriasis and arthritic psoriasis|additional blood sample for biological analyses bone densitometry questionnaires
2957620|NCT02849782|Experimental|Fampridine responder|"Persons who have been diagnosed as Multiple Sclerosis according to Mc Donald Criteria : person with Multiple Sclerosis (PwMS).~Fampridine was prescribed according to the guidelines issued by the French National Security Agency of Medicines and Health Products (ANSM) at the dose of 10 mg twice a day. According to official ANSM guidelines, the prescription is initially limited to 2 weeks of therapy, at which point a new assessment is performed by the medical practitioner to evaluate the clinical benefits. Fampridine responder is a PwMS with an improvement in the judgment of the practitioner."
2957621|NCT02849782|Active Comparator|Fampridine non responder|"Persons who have been diagnosed as Multiple Sclerosis according to Mc Donald Criteria : person with Multiple Sclerosis (PwMS).~Fampridine was prescribed according to the guidelines issued by the French National Security Agency of Medicines and Health Products (ANSM) at the dose of 10 mg twice a day. According to official ANSM guidelines, the prescription is initially limited to 2 weeks of therapy, at which point a new assessment is performed by the medical practitioner to evaluate the clinical benefits. Fampridine non responder is a PwMS without any improvement in the judgment of the practitioner."
2957622|NCT02849769||Patients implanted with an MR-conditional Tachy device system|Patients implanted with an MR-conditional Tachy device system in the routine care
2957623|NCT02849756||older in intensive care unit|older (age superior at 85 years) hospitalized in intensive care unit. A follow-up until 6 months after hospitalization will determine the evolution of the quality of life and others secondary outcomes.
2957624|NCT02849743|Experimental|Syntocinon (= Oxytocin), then Placebo|"Intranasal oxytocin, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)~Intranasal placebo, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks) *Dose Escalation, as appropriate, at 2 Weeks"
2957626|NCT02849730||Young adults|Patients aged 20 to 39 who had used fentanyl/ropivacaine based Epi-PCA for postoperative pain.
2957627|NCT02849730||Elderly patients|Patients aged 70 and over who had used fentanyl/ropivacaine based Epi-PCA for postoperative pain.
2957628|NCT02849717|No Intervention|Standard Care|Subjects are advised to maintain their normal level of activity
2957629|NCT02849717|Active Comparator|Home-Based Exercise|Progressive walking and resistance exercise treatment
2957630|NCT02849704|Experimental|Chronic Pancreatitis (CP) Subjects|"CP subjects will fast for 12 hours prior to the malabsorption blood test (MBT) testing, consume the MBT breakfast meal following this fast, have blood drawn (MBT, vitamins A, D, E and K, zinc, selenium, and prealbumin) prior to MBT breakfast consumption and each hour for 8 hours after consumption, consume a low-fat study lunch, eat a moderate fat diet for 4 days during home diet and stool collection, maintain a 3-day food record, collect stool over 72 hours, have body size and composition assessment, complete quality of life questionnaires, home environment and health questionnaires, and adverse events diary.~Subjects will take Creon36™ for 9 days.~Subjects will have two study visits, one before and one after treatment initiation with Creon36™. Both visits will be identical with the exception of completion of questionnaires and fecal elastase assessment (only Visit 1)."
2957631|NCT02849704|No Intervention|Healthy Controls|Healthy controls will fast for 12 hours prior to the malabsorption blood test (MBT) testing, consume the MBT breakfast meal following this fast, have blood drawn (MBT, vitamins A, D, E and K, zinc, selenium, and prealbumin) prior to MBT breakfast consumption and each hour for 8 hours after consumption, consume a low-fat study lunch, eat a moderate fat diet for 4 days during home diet and stool collection, maintain a 3-day food record, collect stool over 72 hours, have body size and composition assessment, complete quality of life questionnaires, home environment and health questionnaires, and adverse events diary. Controls will only have 1 study visit and receive no intervention.
2957632|NCT02849691||Quartile 1|Quartile 1 of plasma DPP4 activity
2957633|NCT02849691||Quartile 2|Quartile 2 of plasma DPP4 activity
2957634|NCT02849691||Quartile 3|Quartile 3 of plasma DPP4 activity
2957635|NCT02849691||Quartile 4|Quartile 4 of plasma DPP4 activity
2957636|NCT02849678|Active Comparator|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia.Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
2957637|NCT02849678|Active Comparator|Ropivacaine|"Ropivacaine is a local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.~Ropivacaine has been safely used in the paravertebral nerve blocks at our institution for several years."
2957638|NCT02849665|Experimental|Kangaroo Position|The newborn remains in a vertical position, with limbs flexed, dressed in light clothes, maintaining skin-to-skin contact and the face on the adult's thorax.
2957639|NCT02849665|No Intervention|Not Kangaroo Position|The newborns will be not placed in the position Kangaroo.
2957640|NCT02849652|Experimental|ATTOC|Addressing Tobacco Through Organizational Change is a multi-phase organizational intervention to promote the treatment of tobacco dependence
2957641|NCT02849652|Other|UC|Usual Care is the typical guideline based smoking cessation intervention
2957642|NCT02849639|Placebo Comparator|Placebo|"Participants enrolled into this arm will only receive educational materials, but will not receive specific recommendations to make changes to the medications they are taking.~Cognitive testing at the beginning and the end of the study will be done with and without a scopolamine patch to reveal cognitive reserve."
2957643|NCT02849639|Active Comparator|Medication Therapy Management (MTM)|"Participants enrolled into this arm will receive educational materials and will have their medications assessed; recommendations for changes in the medications taken will be made when appropriate.~Cognitive testing at the beginning and the end of the study will be done with and without a scopolamine patch to reveal cognitive reserve."
2957644|NCT02849626|Experimental|Perampanel|Perampanel 0.5 milligrams per milliliter (mg/mL) oral suspension
2957645|NCT02849613|Experimental|Adipose derived Stem Cells ADSC|ADSC, single IV, 1.106 cells/kg
2957646|NCT02849613|Sham Comparator|Vehicle media|IV infusion of cell excipients, 1ml/kg
2957647|NCT02849587|Placebo Comparator|Placebo Cannabis|Subjects will receive cannabis with placebo THC
2957648|NCT02849587|Experimental|Cannabis with 5.9% THC|Subjects will receive cannabis with 5.9% THC
2957649|NCT02849587|Experimental|Cannabis with 13.4% THC|Subjects will receive cannabis with 13.4% THC
2957650|NCT02849561|Active Comparator|Favourable neurological evolution after cardiac arrest|MGOS 4-5
2957651|NCT02849561|Active Comparator|Unfavourable neurological evolution after cardiac arrest|MGOS 1-3
2957652|NCT02849548|Experimental|suvorexant|10 to 20 mg to be administered after an evening written trauma narrative exposure session.
2957653|NCT02849548|Placebo Comparator|Placebo pill|A pill without active ingredients
2957654|NCT02849535|Experimental|PRISM care program|PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
2957655|NCT02849535|No Intervention|Standard of care|In the group with standard of care, patients will have interviews with a hospital pharmacist only dedicated to the record of data for outcomes assessment. These sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion , and at the end at month 6 after the final physical session.
2957656|NCT02849522||PAE patients|Men who have undergone PAE and are in the UK ROPE Register
2957657|NCT02849522||Comparator treatment patients|Men who have undergone TURP, Open Prostatectomy or laser ablation/enuclation of the prostate, and are on the UK ROPE Register.
2957658|NCT02849509||Switch Patients / A|Patients with non-valvular atrial fibirillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
2957659|NCT02849509||New Patients / B|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
2957660|NCT02849496|Experimental|Arm I (olaparib)|Patients receive olaparib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to Arm II.
2957661|NCT02849496|Experimental|Arm II (olaparib, atezolizumab)|Patients receive olaparib as Arm I and atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2957662|NCT02849483|Experimental|Ramosetron|2 ml of normal saline iv before induction, ramosetron 0.3 mg iv at the end of surgery, ramosetron 0.6 mg added to the iv PCA(Patient-Controlled Analgesia)
2957663|NCT02849483|Placebo Comparator|Control|dexamethasone 10 mg iv before induction, 2 ml of normal saline iv at the end of surgery, 4 ml of normal saline added to the iv PCA
2957664|NCT02849470|Active Comparator|ARM 1|Control: 1) HD-PRP + Matristem Matrix (ACell) (Current Standard of Care); 2) Intradermal injections of hair loss 3) Platelet Rich Plasma 4) Matristem Matrix (ACell)
2957665|NCT02849470|Active Comparator|ARM 2|"Experimental: HD-PRP + Emulsified AD-tSVF;~Intervention:~Platelet Rich Plasma~Adipose Derived Stem/Stromal Cells~Intradermal injections of hair loss"
2957666|NCT02849470|Experimental|ARM 3|"Experimental: HD- PRP + Emulsified AD-tSVF + Emulsified AD-cSVF; Intervention: Intradermal injections of hair loss~Platelet Rich Plasma~Adipose Derived Stem/Stromal Cells~Stem/Stromal Cell Isolation~Intradermal injections of hair loss"
2957667|NCT02849457|Placebo Comparator|Vigabatrin or Placebo|Vigabatrin or Placebo is given for administration, the entire content of one sachet (500 mg active drug) is dissolved in 10 ml water for oral administration that is dosed according to body weight 50-150 mg/kg/day divided BID. Dosing will follow established recommended guidelines (50 mg/kg/day and increased as needed by 50 mg/kg/day every 3 days up to a maximum dose of 150 mg/kg/day, divided BID).
2957668|NCT02849457|Other|Vigabatrin|Vigabatrin open label is given for administration, the entire content of one sachet (500 mg active drug) is dissolved in 10 ml water for oral administration that is dosed according to body weight 50-150 mg/kg/day divided BID. Dosing will follow established recommended guidelines (50 mg/kg/day and increased as needed by 50 mg/kg/day every 3 days up to a maximum dose of 150 mg/kg/day, divided BID).
2957669|NCT02849457|No Intervention|Control Group|Enrolled subjects who never develop EEG abnormalities or clinical seizures
2957670|NCT02849444||Moderate kidney failure|30 ≤ CrCl < 50 mL/min/1.73 m2
2957671|NCT02849444||Severe kidney failure|CrCl < 30 mL/min/1.73 m2
2957672|NCT02849431|Experimental|Mindfulness-based intervention|
2957673|NCT02849418|Experimental|GSK1358820 Injection 200 U|Subjects will receive a single treatment with 200 U GSK1358820 injection (30 mL of study drug will be administered as 30 injections, each of 1.0 mL) in the detrusor of bladder, using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents. If the criteria for re-treatment between 12 to 36 weeks after first treatment are met, subjects will receive a second treatment with GSK1358820. Following this, subjects could receive another re-treatment up to 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.
2957674|NCT02849418|Placebo Comparator|Placebo Injection|Subjects will receive a single treatment with placebo (30 injections, each of 1 mL) in the detrusor of bladder, using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents. If the criteria for re-treatment between 12 to 36 weeks after first treatment are met, subjects will receive treatment with GSK1358820. Following this, subjects could receive another re-treatment up to 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment
2957675|NCT02849405|Other|Arteriosclerosis|Hyperspectral camera for arteriosclerosis Diagnostic
2957676|NCT02849405|Other|Healthy controls|Hyperspectral camera for healthy control Diagnostic
2957677|NCT02849392|Experimental|Pistachio|Pistachio added 20% of kcals to diet
2957678|NCT02849392|No Intervention|No Pistachio|No pistachios in diet (control)
2957679|NCT02849379|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2957680|NCT02849379|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2957681|NCT02849366|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2957682|NCT02849366|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2957683|NCT02849353|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2957684|NCT02849353|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2957685|NCT02849340|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2957686|NCT02849340|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2957687|NCT02849327|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2957688|NCT02849327|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2957689|NCT02849314|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2957690|NCT02849314|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2957691|NCT02849301|Experimental|Cervical pessary|Arabin cervical pessary
2957692|NCT02849301|No Intervention|Standard care|No treatment
2957693|NCT02849288|Experimental|Intervention|Use of the Investigational Bigfoot Type 1 Diabetes Management System (T1DMS)
2957694|NCT02849275|Placebo Comparator|Lactose free 1% milk|Diet will be recorded with a 7-day diet record and participants will include an isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.
2957695|NCT02849275|Experimental|Probiotic treatment|Diet will be recorded with a 7-day diet record and participants will include an isocaloric fermented milk (probiotic), consumed once daily, over 4-5 weeks.
2957696|NCT02849262|Experimental|Omiganan (CLS001)|CLS001 Topical Gel, 2.5%
2957697|NCT02849262|Placebo Comparator|Vehicle|Vehicle Topical Gel
2957698|NCT02849249|Active Comparator|One day schedule|Allergovac polimerized with a mixture of 2 pollen extracts (100:100): Olea europea and Phleum pratense, administered in one day schedule. The maintenance dose (0.5 mL) is reached in one day.
2957699|NCT02849249|Active Comparator|Rapid schedule|Allergovac polimerized with a mixture of 2 pollen extracts (100:100): Olea europea and Phleum pratense, administered in a rapid Schedule.The initation phase includes 3 weekly increasing doses till the maintenance dose of 0.5 mL is reached.
2957700|NCT02849236|Placebo Comparator|Control group|PECS block performed with Saline solution instead of local anesthetic
2957701|NCT02849236|Experimental|PECS group|PECS block performed with Ropivacaine 3.75mg/mL
2957702|NCT02849223|Experimental|Transcranial Direct Current Stimulation|Participants will receive 24 sessions (3 times a week) of anodal transcranial direct current stimulation concurrent with working memory training. Stimulation will be administered at 2 milliamps (mA) for 20 minutes over the left dorsal lateral prefrontal cortex.
2957703|NCT02849223|Sham Comparator|Sham|Participants will receive 24 sessions of working memory training. The experience of transcranial direct current stimulation will be simulated by administering 30 seconds of stimulation at the beginning of the session.
2957704|NCT02849210|Experimental|Allergovac depot|Allergovac depot with Olea europaea pollen extract
2957705|NCT02849197||Primary Closure|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.~Technique: primary closure. Technical details: An elliptical incision was made, and the excision included sinus openings at the median line and extended down to the pre-sacral fascia. One suction drain was placed in the wound cavity. Subcutaneous tissue was approximated with interrupted 2-0 absorbable suture, and skin was closed with interrupted 2-0 silk suture."
2957706|NCT02849197||Limberg Flap Technique|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.~Technique: Limberg Flap Technique. Technical details: A rhomboid incision was made as to include all sinus openings, and an excision was made down to the pre-sacral fascia. A bisector drawn in the rhombohedron was extended laterally to a length similar to that of a corner of the rhombohedron. Then, the flap was prepared by removing gluteal muscle with its fascia. One suction drain was placed at the wound cavity. The base of the flap was approximated with the presacral fascia at the excised area with interrupted 2-0 absorbable sutures. Subcutaneous tissue was approximated with interrupted 2-0 absorbable sutures, and the skin was closed with interrupted 3-0 prolene suture."
2957707|NCT02849197||Modified Limberg Technique|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.~Technique: Modified Limberg Flap Technique. Technical details: As in Limberg flap technique, a rhomboid incision was made. Upper and lower corners of the excision were lateralized 2 cm away from the midline in order to keep the suturing line at the inferior from overlapping the midline. An excision was made down to the pre-sacral fascia. One suction drain was placed at the wound cavity, and the base of the flap was approximated with the pre-sacral fascia at the excised area with interrupted 2-0 absorbable sutures. Subcutaneous tissue was approximated with interrupted 2-0 absorbable suture, and the skin was closed with 3-0 prolene."
2957708|NCT02849184|Experimental|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
2957709|NCT02849184|Placebo Comparator|placebo|Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
2957710|NCT02849171|Experimental|high-grade glioma|Eligible patients must have undergone standard radiation (typically 60Gy in 30 fractions), with or without concurrent drug therapy, and have MRI findings consistent with tumor progression and/or pseudoprogression within 24 weeks after completion of radiation. Eligible patients will undergo an 11C-CH PET study within 2 weeks of the standard of care MRI that shows changes concerning for tumor progression vs. pseudoprogression. All patients will then be followed with surveillance brain MRI with and without contrast as per standard of care for a period of 11 months, to assess further progression or stabilization of the lesion. Initial MRI changes are considered to represent pseudoprogression/treatment related changes if the lesion stabilizes or becomes smaller without a change in tumor-related therapy. Otherwise, it will be considered a recurrence should there be progessive radiographic changes.
2957711|NCT02849158|Experimental|Biopsy|Patients will have new biopsy before starting RT-CT and samples will be taken on rectum surgery at the level of the tumor and away from the rectum.
2957712|NCT02849145|Experimental|Biological/Vaccine|
2957713|NCT02849132|Experimental|Treatment group|entecavir oral，0.5mg daily for 5 years
2957714|NCT02849119|Experimental|Transperitoneal approach|Laparoscopic or Robotic Partial Nephrectomy through transperitoneal approach
2957715|NCT02849119|Experimental|Retroperitoneal approach|Laparoscopic or Robotic Partial Nephrectomy through retroperitoneal approach
2957716|NCT02849106|Experimental|biopsy to obtain a chemogram|
2957748|NCT02848911|Experimental|AFM11|IV (intravenous) infusion, dose escalation
2957717|NCT02849093||Dry Eye Syndrome Patients|Patients who have been diagnosed clinically with Sjögren's will have an OCT image of their lacrimal glands and buccal mucosa taken. Imaging from patients found to have Sjögren's clinically diagnosed following examination of buccal mucosa under the microscope will be compared with images from patients without dry eye syndrome to see of any obvious differences can be identified.
2957718|NCT02849093||Epiphora Patients|Pre and post-operative OCT images of patients undergoing punctoplasty or conjunctivoplasty will be compared to images of the same structures in people without watery eyes.
2957719|NCT02849093||Asymptomatic Patients|OCT images will be captured of the cornea, conjunctiva, lacrimal gland and buccal mucosa to establish normal appearance in asymptomatic patients.
2957720|NCT02849080|Experimental|Semaglutide flexible dosing (3, 7 or 14 mg)|
2957721|NCT02849080|Active Comparator|Sitagliptin 100 mg|
2957722|NCT02849067|Experimental|Group Treatment|Patients in this group will watch a comedy show that will will not exceed 30 minutes. This group will have until five patients.
2957723|NCT02849067|Other|Group Control|patients in this group will watch a documentary that will not exceed 30 minutes. This will have until five patients
2957724|NCT02849054|Experimental|4, 5, 6ml/kg targetted tidal volume|Randomised to receive TTV at 4ml/kg, 5ml/kg, 6ml/kg. Measurement of PTPdi
2957725|NCT02849054|Experimental|4, 6, 5ml/kg targetted tidal volume|Randomised to receive TTV at 4ml/kg, 6ml/kg, 5ml/kg. Measurement of PTPdi
2957726|NCT02849054|Experimental|5, 4, 6ml/kg targetted tidal volume|Randomised to receive TTV at 5ml/kg, 4ml/kg, 6ml/kg. Measurement of PTPdi
2957727|NCT02849054|Experimental|5, 6, 4ml/kg targetted tidal volume|Randomised to receive TTV at 5ml/kg, 6ml/kg,4ml/kg. Measurement of PTPdi
2957728|NCT02849054|Experimental|6, 5, 4ml/kg targetted tidal volume|Randomised to receive TTV at 6ml/kg, 5ml/kg, 4ml/kg. Measurement of PTPdi
2957729|NCT02849054|Experimental|6, 4, 5ml/kg targetted tidal volume|Randomised to receive TTV at 6ml/kg, 4ml/kg, 5ml/kg. Measurement of PTPdi
2957730|NCT02849041|Experimental|Screening program|Who consults or is hospitalized in a medical services or vascular surgery 'Paris Saint Joseph Hospital Group' (GHPSJ) or 'the European Hospital Georges Pompidou' (HEGP) for occlusive arterial disease or aneurysm the abdominal aorta. This population should accept to have a medical imaging Low-dose CT-scanner and an Identification of Circulating Tumor Cells on their blood. 30 first patients will be proposing to particpate to the psychologic sub-study by answering to a Psychological Questionnaires
2957731|NCT02849028||TBI Patients with sleep disorder|All the patients should be diagnosed by polysomnographic (PSG)
2957732|NCT02849028||health people|The people have a normal sleep
2957733|NCT02849015|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive liver cryosurgery first to destroy big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2957734|NCT02849015|Active Comparator|Cryosurgery|In this group, the patients will receive liver cryosurgery to destroy big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2957735|NCT02849002|Experimental|Interventional Device|"The BrainPulse is used on a patient's head to non-invasively detect, amplify and capture the brain motion caused by pulsatile blood flow from the cardiac cycle.~The BrainPulse consists of a reusable headset that contains the accelerometers used to measure motion caused by pulsatile blood flow. The system is powered by rechargeable battery pack. The headset is placed on the subject's head and outputs data to a data collector that forwards the data to the computer. Each accelerometer has an attached tip that makes contact with the subject's head through hair. The headset also includes a photoplethysmograph (PPG) that simultaneously captures the subject's heart-rate information. There is no energy delivered to the brain or subject by these highly sensitive sensors."
2957736|NCT02848989|Experimental|Qigong Mind-Body Exercise (QMBE)|"After the screening procedures confirm that you are eligible to participate in the research study:~Breast cancer survivors with persistent post-surgical pain (PPSP) into a 12-week program of Qigong mind-body exercise (QMBE).~Outcome assessments related to pain, function, and quality of life"
2957737|NCT02848976||IA group|EDSS (Expanded Disability Status Scale) below 6 with RE
2957738|NCT02848976||IB group|EDSS (Expanded Disability Status Scale) below 6 with no RE
2957739|NCT02848976||IIA group|EDSS (Expanded Disability Status Scale) betwin 6 and 8 with RE
2957740|NCT02848976||IIB group|EDSS (Expanded Disability Status Scale) below 6 with RE
2957741|NCT02848963|Active Comparator|ketamine-propofol mixture 5/1|Ketamine-propofol mixture will be compare for every groups.
2957742|NCT02848963|Active Comparator|ketamine-propofol mixture 10/1|Ketamine-propofol mixture will be compare for every groups.
2957743|NCT02848963|Active Comparator|Ketamine-propofol mixture 6,7/1|Ketamine-propofol mixture will be compare for every groups
2957744|NCT02848950|Active Comparator|treatment|drug: metformin
2957745|NCT02848950|No Intervention|control|without metformin
2957746|NCT02848937||Bath with citrate|"Each patient will participate in two phases of the study. The first phase has the aim to identify the concentration of calcium in the bath with citrate which allows the equivalence of mass balance (Ca_eq) compared to the concentrate with 3 mM acetate and 1.5 mM of calcium (4 weeks). Each week, the concentration of calcium in the bath with citrate is increased from 1.5-, to 1.65, to 1.75 mM.~•Concentrate SelectBag One (with 3 mM acetic acid) and SelectBag Citrate (with 1 mM of citric acid). The potassium in the bath will be chosen on the basis of the needs of the patient (2 to 3.5 mM) and will be maintained in all concentrates.•All treatment parameters (Qb, time of treatment, weight loss and anticoagulant dose) should be overlapped at all stages of the study"
2957747|NCT02848937||Bath with citrate and Ca_eq|"Each patient will participate in two phases of the study. In the second phase will evaluate the effectiveness of the purification concentrate with 1 mM citrate and Ca_eq compared to the concentrate with 3 mM acetate and 1.5 mM calcium. For each of the sessions will be used the following materials:~Filter high permeability (Kuf> 20ml/mmHg);~Concentrate SelectBag One (with 3 mM acetic acid) and SelectBag Citrate (with 1 mM of citric acid). The potassium in the bath will be chosen on the basis of the needs of the patient (2 to 3.5 mM) and will be maintained in all concentrates.~All treatment parameters (Qb, time of treatment, weight loss and anticoagulant dose) should be overlapped at all stages of the study."
2957750|NCT02848898|Placebo Comparator|Placebo Group|arm treated with application of inactivated devices
2957751|NCT02848885|Experimental|Active TDCS|Participants who are randomly assigned to this arm will receive dual hemisphere parietal (P3 cathodal, P4 anodal) stimulation daily for 10 days. Each participant will have two MRI scans and their degree of illness awareness assessed at baseline and after 10 days of tDCS. Illness awareness will be assessed weekly thereafter for 4 weeks.
2957752|NCT02848885|Experimental|Sham TDCS|Participants who are randomly assigned to this arm will receive dual hemisphere sham stimulation with electrodes placed on the parietal lobes (P3 and P4) daily for 10 days. Each participant will have two MRI scans and their degree of illness awareness assessed at baseline and after 10 days of tDCS. Illness awareness will be assessed weekly thereafter for 4 weeks.
2957753|NCT02848872||NSCLC patients|Resected patients
2957754|NCT02848859|Active Comparator|Intervention: Go! to Sleep|We are using a web-based cognitive behavioral therapy program called Go! to Sleep. Go! to Sleep is an interactive online program developed by specialists in Cleveland Clinic's Wellness Institute and Sleep Disorders Center. The program is a 6 week self-help program that uses cognitive behavioral therapy techniques that have been proven to be effective in decreasing symptoms of insomnia.
2957755|NCT02848859|Placebo Comparator|General Sleep Hygiene Education|General Sleep Hygiene Education is the first step in the treatment of any sleep disorder. Both arms will have access to a Harvard sleep education web site that provides general information about sleep as well as sleep hygiene.
2957756|NCT02848846|Experimental|Robotic Hand|The two patient enrolled will perform the task requiring the use of the robotic hand.
2957757|NCT02848833||JARDIANCE|T2DM with JARDIANCE
2957758|NCT02848820|Experimental|Augmentin + Gentamicin|"Initial non-operative treatment strategy reserving an appendectomy for those not responding or with recurrent disease. It consist of:~Clinical observation for 48 hours with administration of Intravenous administration of amoxicillin/clavulanic acid 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) and gentamicin 7mg/kg once daily for 48 hours. If after 48 hours the patient fulfils the predefined discharge criteria, the antibiotics will be switched to oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days and discharge. An appendectomy is reserved for those patients with clinical deterioration, non-improvement after 72 hours or recurrent appendicitis.~Pain medication according to national protocol."
2957759|NCT02848820|Active Comparator|Operative treatment strategy|Clinical observation and semi-urgent appendectomy. Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics. Discharge if the patient fulfils the predefined discharge criteria. Pain medication according to national protocol.
2957760|NCT02848807|Active Comparator|NUTRIDRINK Compact Protein|NUTRIDRINK Compact Protein Oral nutritional supplement Dietary advice
2957761|NCT02848807|No Intervention|without oral nutritional supplements|Dietary advice alone
2957762|NCT02848794|Experimental|Apatinib+Irinotecan|Apatinib and irinotecan in treating patients with recurrent high-grade glioma,who have progressed on temozolomide, or radiotherapy alone, or combined with chemotherapy within 3 months after surgery .
2957763|NCT02848781|Experimental|ICD with Ablation|Patient will receive an implantable cardioverter defibrillator (ICD) with catheter ablation and standard medical management.
2957764|NCT02848781|Active Comparator|ICD Only|Patient will receive an implantable cardioverter defibrillator (ICD) and standard medical management.
2957765|NCT02848781|Active Comparator|Ablation Only (Registry)|The registry will enroll patients who refuse an implantable cardioverter defibrillator (ICD) and are thus not randomized. This arm will assess the efficacy of catheter ablation in the absence of background ICD therapy.
2957766|NCT02848742|Experimental|Treatment with cryotherapy device|To include subjects with one or more benign pigmented lesions who are willing to have the pigmented skin exposed to cooling with the Dermal Cooling System.
2957767|NCT02848729|Experimental|Oral acetaminophen|Four doses of 1,000 mg oral APAP (2 tablets, 500 mg/tablet), Q6h, Dose 2 and 3 are co-administered with IV morphine
2957768|NCT02848729|Experimental|IV acetaminophen|Four doses of IV APAP (1000 mg/100 mL), Q6h, Dose 2 and 3 are co-administered with IV morphine
2957769|NCT02848716|Active Comparator|Standard of care arm|Standard chemoradiation based on FluoroDeoxyGlucose-Positon Emission Tomography (FDG-PET) imaging status of the pelvic nodes
2957770|NCT02848716|Experimental|Experimental arm|Pretherapeutic paraaortic lymphadenectomy followed by tailored chemoradiation. Pretherapeutic lymphadenectomy will be performed via the laparoscopic extraperitoneal or transperitoneal approach
2957771|NCT02848703|Experimental|healthy volunteers|
2957772|NCT02848690|Experimental|Educational Intervention Group|Participants assigned to the educational intervention group will have dietitian consultation to receive a dietary planning based on diet rich of fruits, vegetables, low fat, low processed foods and high nonfat dairy. During six months they will have monthly dietitian appointments including educational sessions to stimulate sodium restriction and enhance to follow the dietary planning. Each 15 days they will be contacted by phone to reinforce adherence to sodium restriction diet.
2957773|NCT02848690|Sham Comparator|Usual Care Intervention Group|Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
2957774|NCT02848677|Active Comparator|intervention group|Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.
2957775|NCT02848677|Sham Comparator|control group|usual care of hypertensive patients.
2957776|NCT02848664|Experimental|Laryngeal vibrotactile stimulation|Participants with dysphagia received external laryngeal vibrotactile stimulation to trigger swallowing for swallowing retraining. Participants received training on the device and were then given a device to take home for 3 months.
2957777|NCT02848651|Experimental|Atezolizumab|Participants will receive 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression or loss of clinical benefit (up to approximately 3 years).
2958183|NCT02845830||Participants without dementia|Subjects without dementia with MMSE score 26-30 points
2957778|NCT02848625|Experimental|Group A|Patients randomized to 12 weeks of twice weekly yoga sessions. The yoga exercises have been designed specifically for patients with IPF.
2957779|NCT02848625|No Intervention|Group B|Patients who are not randomized to yoga sessions will continue with their usual care and usual activities
2957780|NCT02848599|Active Comparator|morphine|The patient-controlled intravenous analgesia with morphine (basal flow of 0.5-2 mg / h, bolus dose of 0.5 mg, lockout interval of 20 minutes, hour limit of 3 doses), which will be carried out 72 hours after the surgery
2957781|NCT02848599|Active Comparator|levobupivacaine|Upon completion of the operation for a period of 72 hours will be implemented continuous epidural local anesthetic through the Patient Controlled Analgesia (PCA) pump (Levobupivacaine 0.125%, basal flow of 6 ml / hour, a bolus dose of 2 ml, lockout interval of 20 minutes, hour limit of 3 doses).
2957782|NCT02848586|Active Comparator|ECIGS|Subjects will receive e-cigarettes for a total of 4 weeks. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. After 4 weeks, subjects will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks. Respiratory assessments will occur at study arm assignment (Visit 1) to establish baseline measures of lung function, oxidative stress, and systemic inflammation, repeated again 4 weeks after transition to ECIG (Visit 4) and again 2 weeks after stopping ECIG (Visit 5). Neuro-cognitive and behavioral assessments will occur at Visits 2, 3, 4 and 5.
2957783|NCT02848586|Active Comparator|Usual brand|Subjects will receive their usual brand of combustible cigarettes for a total of 4 weeks. A mobile contingency management mCM procedure will be used. Respiratory assessments will occur at study arm assignment (Visit 1) to establish baseline measures of lung function, oxidative stress, and systemic inflammation, repeated again 4 weeks later (Visit 4) and again 2 weeks later (Visit 5). Neuro-cognitive and behavioral assessments will occur at Visits 2, 3, 4 and 5.
2957784|NCT02848560||Treatment|Observation of lung changes over time by hyperpolarized xenon MRI on CF patients homozygous for F508del CFTR mutation as they age into the FDA approved treatment window for the CFTR modulator orkambi. Subjects will be observed at 2 time points before starting clinically prescribed treatment (orkambi) and 2 time points while on orkambi.
2957785|NCT02848560||Control|Observation of lung changes over time by hyperpolarized xenon MRI on CF patients heterozygous for F508del CFTR mutation at similar timepoints to treatment group. Control subjects are not be eligible to be clinically prescribed orkambi based on FDA approval.
2957786|NCT02848547||Intervention - SMS|Participants in the intervention group received periodic text messages on healthy lifestyle throughout the study period.
2957787|NCT02848547||Control - Standard Care|Participants in the control group received standard one time advice at entry in the study.
2957788|NCT02848508|Experimental|moderate impairment, CKD stage 3a|(12 subjects): GFR 59-45 (moderate impairment, CKD stage 3a) Metformin : 1500mg/day
2957789|NCT02848508|Experimental|moderate impairment, CKD stage 3a)|(12subjects): GFR 44-30 (moderate impairment, CKD stage 3b) Metformin : 1000mg/day
2957790|NCT02848508|Experimental|severe impairment|(12 subjects): GFR 29-15 (severe impairment, CKD stage 4) Metformin : 500mg/day
2957791|NCT02848482|Active Comparator|Control group|Plastic curette will be used to perform the mechanical debridement. Then, irrigation (2% chlorhexidine) will be performed at contaminated sites.
2957792|NCT02848482|Experimental|Test group|Plastic curette will be used to perform the mechanical debridement. Then, the addition photodynamic therapy (PDT) will be performed. This will be performed with a set-up for PDT (HELBO Photodynamic Systems, German).
2957793|NCT02848469|Active Comparator|Omega-3 fatty acids|Subjects will receive food supplements in the form of 200ml juice drinks, containing either the active component, 1000mg of eicosapentaenoic acid and 1000mg docosahexaenoic acid, or matching placebo for a duration of six months. Neither the active nor the placebo food supplements taste of fish, so the subject will be blind to whether he/she is receiving the active intervention or placebo.
2957794|NCT02848469|Placebo Comparator|placebo 200ml juice drinks|200ml juice drinks
2957795|NCT02848456|Active Comparator|Spinal Manipulation SM|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
2957796|NCT02848456|Active Comparator|Max Voluntary Isometric Contraction MVIC|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
2957797|NCT02848456|Active Comparator|SM+MVIC|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
2957798|NCT02848443|Experimental|S 95005 + oxaliplatin (+/- bevacizumab or nivolumab)|
2957799|NCT02848430|Experimental|Humulus lupulus|Spent hop extract; 2 gelatin capsules (59.5 mg extract) per day for 14 days
2957800|NCT02848417|Experimental|Curcumin|12 weeks 400mg orally twice a day
2957801|NCT02848417|Experimental|Liposomal Glutathione|12 weeks 630mg orally twice a day
2957802|NCT02848417|Experimental|Placebo Liquid or Capsules|"Placebo liquid for Glutathione 120 ml per/ bottle 420 mg/5 ml~Placebo capsules for Curcumin 60 capsules per bottle 400 mg /cap"
2957803|NCT02848404|Experimental|Categorical Language Fluency Smartphone Application|Smartphone game application specifically aimed at training categorical language fluency
2957804|NCT02848391|Experimental|healthy subjects|three hour flight simulation
2957805|NCT02848391|Experimental|COPD normocapnic|three hour flight simulation
2957806|NCT02848391|Experimental|COPD hypercapnic|three hour flight simulation
2957807|NCT02848378||Chronic periodontitis group|Subjects who have moderate to severe alveolar bone loss and clinical attachment level (CAL) ≥5 mm and probing depth (PD) ≥6mm in multiple sites of all four quadrants of the mouth but with no evidence of rapid progression
2957808|NCT02848378||Gingivitis group|Subjects who show gingival inflammation that is based on the presence of bleeding on probing (BOP) at >50% of sites in the whole mouth, no clinical and radiographic signs of periodontitis
2958184|NCT02845817|Other|Qualitative research|Semi-structured interviews
2957809|NCT02848378||Periodontally healthy group|Subjects who have no sites with PD >3mm and CAL >0 mm, a BOP score of <15% at the examination and no alveolar bone loss.
2957810|NCT02848365|Active Comparator|Glidescope|
2957811|NCT02848365|Active Comparator|Macintosh laryngoscope|
2957812|NCT02848365|Active Comparator|Bonfill's rigid scope|
2957813|NCT02848365|Active Comparator|Air traq|
2957814|NCT02848365|Active Comparator|C -Mac scope|
2957815|NCT02848365|Active Comparator|flexible fiberoptic scope|
2957816|NCT02848352|Experimental|Positive placebo group|Participants receive a nasal spray that is a placebo. However, they are told that it protects from experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
2957817|NCT02848352|Experimental|Negative placebo group|Participants receive a nasal spray that is a placebo. However, they are told that it sensitizes for experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
2957818|NCT02848352|Placebo Comparator|Placebo control group|Participants receive a nasal spray that is a placebo and are told that it is a placebo. Participants watch a film sequence that is supposed to induce sadness.
2957819|NCT02848352|Other|No-treatment control group|Participants do not receive the nasal spray. Participants watch a film sequence that is supposed to induce sadness.
2957820|NCT02848326|Placebo Comparator|Placebo|AGN-241689 placebo-matching capsule orally twice daily; in the morning and in the evening for 12 weeks.
2957821|NCT02848326|Experimental|AGN-241689 10 mg QD|AGN-241689 10 mg capsule orally once daily (QD) in the morning and one AGN-24689 placebo-matching capsule orally once daily in the evening for 12 weeks.
2957822|NCT02848326|Experimental|AGN-241689 30 mg QD|AGN-241689 30 mg capsule orally once daily in the morning and one AGN-24689 placebo-matching capsule orally once daily in the evening for 12 weeks.
2957823|NCT02848326|Experimental|AGN-241689 30 mg BID|AGN-241689 30 mg capsule orally twice daily (BID); 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
2957824|NCT02848326|Experimental|AGN-241689 60 mg QD|AGN-241689 60 mg capsule orally once daily in the morning and one AGN-24689 placebo-matching capsule orally in the evening for 12 weeks.
2957825|NCT02848326|Experimental|AGN-241689 60 mg BID|AGN-241689 60 mg capsule orally twice daily; 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
2957826|NCT02848313|Experimental|Elamipretide|40 mg dose of elamipretide administered once daily as a 1.0mL SC injection
2957827|NCT02848300|Experimental|All Participants|Bimatoprost 1% Formulation A solution applied to the left side of the scalp and trunk area and Bimatoprost 1% Formulation B solution applied to the right side of the scalp and trunk area once daily for 14 days.
2957828|NCT02848287|Placebo Comparator|Normal Saline|1*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.
2957829|NCT02848287|Experimental|Ropivacaine|1*2 gauze is soaked with 5 cc of 0.75% ropivacaine, applied in tonsillar fossae for 3 min, then removed.
2957830|NCT02848261|Experimental|Developmental Demands|Provide education on using diabetes technology in various settings and formats in this age group, and increase ability for real-time problem-solving.
2957831|NCT02848261|Experimental|Distress Reduction|Identify and reduce parent distress symptoms and worries. Provide strategies for obtaining social support.
2957832|NCT02848261|Experimental|Remote Monitoring|Optimize the use of remote monitoring by focusing on situational demands and problem solving.
2957833|NCT02848261|Experimental|Fear of Hypoglycemia|Decrease fear of hypoglycemia, particularly focusing on overnight glycemic control.
2957834|NCT02848261|Placebo Comparator|No Intervention|Serves as the control group comparator. No intervention provided.
2957835|NCT02848248|Experimental|SGN-CD123A|SGN-CD123A every 3 weeks
2957836|NCT02848235|No Intervention|Group 1 (Standard of Care)|Participants in group 1 will receive the standard of care for the Prevention of Mother to Child Transmission (PMCTC) of HIV from the clinic's Mentor Mothers.
2957837|NCT02848235|Experimental|Group 2 (Standard of Care + EMMA)|Participants in group 2 will receive the standard of care for Prevention of Mother to Child Transmission (PMCTC) of HIV plus study-specific enhanced care interventions from the clinic's Mentor Mothers.
2957838|NCT02848222|Experimental|Twice Daily Application of Bruder compress|Ten minute application of the Bruder Moist Heat Compress in the morning prior to contact lens insertion and ten minute application in the evening after lens removal
2957839|NCT02848222|Experimental|Once Daily Application of Bruder compress|Ten minute application of the Bruder Moist Heat Compress in the evening after lens removal
2957840|NCT02848222|Sham Comparator|Twice Daily Application of warm washcloth|Ten minute application of a hot-water warmed washcloth in the morning prior to contact lens insertion and ten minute application in the evening after lens removal
2957841|NCT02848209|No Intervention|Control|No peeling applied on the skin flap
2957842|NCT02848209|Experimental|Drug: TCA 20% Peeling|Trichloroacetic acid 20% applied on the skin flap until even frosting for 2-4 minutes.
2957843|NCT02848209|Experimental|Drug: TCA 40% Peeling|Trichloroacetic acid 40% applied on the skin flap until even frosting for 2-4 minutes.
2957844|NCT02848209|Experimental|Drug: Phenol/croton oil Peeling|Phenol/croton oil applied on the skin flap occluded with silicone tape for 24 hours and not neutralized.
2957845|NCT02848196|Experimental|Stereotactic body radiation therapy|Oligometastatic patients with adrenal gland metastases are treated with high dose of Stereotactic Body Radiation Therapy delivered with VMAT/Rapid Arc technique.
2957846|NCT02848183|Experimental|Pediatric de novo acute myeloid leukemia|"I. Chemotherapy Induction-1: Cytarabine + idarubicin Induction-2: High dose (HD) cytarabine + mitoxantrone Consolidation-1: Cytarabine + idarubicin Consolidation-2: HD cytarabine + etoposide Consolidation-3: HD cytarabine + mitoxantrone Consolidation-4: HD cytarabine + etoposide~II. Allogeneic hematopoietic stem cell transplantation (HSCT) Favorable prognosis group: chemotherapy only Intermediate prognosis group: chemotherapy or HSCT with reduced intensity conditioning Poor prognosis group: HSCT with myeloablative conditioning"
2957847|NCT02848170|Experimental|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast for 12 weeks
2957848|NCT02848170|Active Comparator|olmesartan medoxomil|olmesartan medoxomil 10 to 20 mg, orally, once daily after breakfast for 12 weeks
2957849|NCT02848157|Experimental|DR|dexmedetomidine 0.3mcg/kg and 0.25% ropivacaine 0.3ml/kg
2957851|NCT02848144|Other|Children with infectious shock|Children aged from 1 month to <18 years. In 3 stratified groups : <2 years, 2-8 years, and >8 years. About one third of the patients are expected in each age-group.
2957852|NCT02848144|Other|Control group: healthy children|Healthy children aged-matched to cases (same stratification group, about 20 per age group); They will be hospitalized for an elective surgery (dental, ENT, maxillofacial, urologic, hernia surgery, neurosurgery without massive hemorrhage) and without any infection.
2957853|NCT02848131|No Intervention|Group 1: Observational|Observational Only
2957854|NCT02848131|Active Comparator|Group 2: Dasatinib & Quercetin|The drugs dasatinib and quercetin will be used in this arm
2957855|NCT02848118|Experimental|A nasal-oral cannula of capnography|Start bronchoscopy when the nasal-oral capnography shows hypoventilation during bronchoscopic sedation.
2957856|NCT02848118|Active Comparator|Sedation scale|Start bronchoscopy when Observer Assessment of Alertness and Sedation scale (OAAS)=3~2 during bronchoscopic sedation.
2957857|NCT02848105|Experimental|VPA+Methyl|VPA added to standard methylpredisonlone treatment for aGVHD
2957858|NCT02848092|Experimental|FOCAL+Training|
2957859|NCT02848092|Sham Comparator|Rules of the Road Training|
2957860|NCT02848079|Experimental|combined TAS-102 and oxaliplatin|Combination treatment with TAS-102 and oxaliplatin
2957861|NCT02848066||Gastric Cancer patients|This arm is composed of the gastric cancer patients. It is perfomed a blood sampling to them after the research registration.
2957862|NCT02848066||Cancer-free healthy volunteers|This arm is composed of the cancer-free healthy volunteers. It is perfomed a blood sampling to them after the research registration.
2957863|NCT02848053||Tianqi group|used Tianqi Capsule in the REDUCES study
2957864|NCT02848053||Placebo group|used placebo in the REDUCES study
2957865|NCT02848040|Experimental|Single Arm|All patients will receive the same interventions. Single are only
2957866|NCT02848027|Experimental|Regenexx-SD procedure|Measure components of knee synovial fluid collected 2-4 days before and after Regenexx SD procedure
2957867|NCT02848014|Experimental|Expectation|Participants are asked to think and write about ways how they can positively influence/control the stress during stress induction. They also can think of strategies they used in their past. The purpose of this arm is to improve participants' personal control expectations.
2957868|NCT02848014|Experimental|Emotion|Participants in this group are asked to write a gratitude-letter to a person they want to thank. The purpose of this arm is to foster positive emotions.
2957869|NCT02848014|Active Comparator|Control|Participants in this group are asked to do a neutral writing task. The task is to write a protocol of yesterday's to-dos.
2957870|NCT02848001|Experimental|CC-90009 - Part A|Will be administered intravenously per dosing schedule in a 28-day cycle.
2957871|NCT02848001|Experimental|CC-90009 - Part B - AML and MDS patients|Relapsed or refractory AML and MDS subjects. IP will be administered intravenously per dosing schedule determined in Part A
2957872|NCT02847988|Active Comparator|Neuro-muscular electrical stimulation|"Intervention:Neuromuscular electrical stimulation (NMES)~NMES stimulation will be applied to lower extremity muscle groups up to 5 days a week until discharge. Standard physical therapy will also be administered by a therapist distinct from the therapist administering NMES"
2957873|NCT02847988|Sham Comparator|Sham stimulation|"Intervention: sham stimulation~Sham stimulation will be applied to lower extremity muscle groups up to 5 days a week until discharge. Standard physical therapy will also be administered by a therapist distinct from the therapist administering sham-NMES"
2957874|NCT02847975|Experimental|Sodium nitrate|Sodium nitrate will be administered orally and functional sympatholysis assessed before and after treatment
2957875|NCT02847962|No Intervention|Control (No FBF)|FBF provided after the intervention period
2957876|NCT02847962|Active Comparator|Corn Soy Blend Plus (CSB+)|Consumed Corn Soy Blend Plus (CSB+)
2957877|NCT02847962|Experimental|Corn Soy Blend 14 (CSB14)|Consumed Corn Soy Blend 14 (CSB14)
2957878|NCT02847962|Experimental|White Sorghum Cowpea Blend Variety 1|Consumed White Sorghum Cowpea Blend Variety 1
2957879|NCT02847962|Experimental|White Sorghum Cowpea Blend Variety 2|Consumed White Sorghum Cowpea Blend Variety 2
2957880|NCT02847962|Experimental|Red Sorghum Cowpea Blend|Consumed Red Sorghum Cowpea Blend
2957881|NCT02847962|Experimental|White Sorghum Soy Blend|Consumed White Sorghum Soy Blend
2957882|NCT02847949|Experimental|Extension arm|IGN002 study drug will initially be administered at the same dose level and schedule that the subject was receiving at the conclusion of the other Valor IGN002 study.
2957883|NCT02847936|Active Comparator|VICRYL PLUS|triclosan-coated sutures
2957884|NCT02847936|Active Comparator|VICRYL|non antibacterial coated sutures
2957885|NCT02847923|Experimental|Group Experimental|All the volunteers will use the software and then answer the questionnaire. They will be familiar with the software interface, performs an initial test to learn how to use the software, run a test script and answer the questionnaire.
2957886|NCT02847910|Experimental|experimental group|device： High-tech disposable tissue suction set for uterine cavity tissue is produced by Xi'an Mejiajia Medical Equipment Company ; The participants will be use the disposable tissue suction set during the induced abortion procedure.
2957887|NCT02847910|Experimental|control group|device： Traditional metal instruments for induced abortion procedure; The participants will be use traditional metal instruments during induced abortion procedure.
2957888|NCT02847897|Experimental|CO2 AcuPulse Laser treatment|Subjects with vulvovaginal atrophy intended to receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
2957889|NCT02847871|Other|Multimodal Intervention|The multimodal intervention on mobility will consist of the implementation of a care pathway dedicated in primary care. It will include awareness and training of general practitioners for easy identification, a care associating a dedicated geriatric consultation to rule out underlying pathology, teaching exercises by MAPA (+/- taken care in the presence of MAPA) and nutritional counseling by a dietician. Close collaboration between general practitioners, geriatrician, MAPA and dietician will be established.
2957890|NCT02847871|No Intervention|Non interventional|Patients received treatment as part of their standard care: at the discretion of the general practitioner patients
2957891|NCT02847858|Experimental|Health-E You App Participants|
2957892|NCT02847858|No Intervention|Control Group|
2957893|NCT02847845|Experimental|Red ginseng powder capsule|People in this group take a red ginseng powder capsule.
2957894|NCT02847845|Placebo Comparator|Placebo powder capsule|People in this group take a placebo powder capsule.
2957895|NCT02847819||Vocal cords movement assessment by airway USG.|Preoperatively patients undergoing thyroid surgery will be scanned by airway ultrasound and graded for vocal cord movement, the same group of patients will be again scanned and graded by airway ultrasound at 4th post operative hours.
2957896|NCT02847806|Experimental|Estradiol|dosage used in the study: 1 patch / 3-4 days dosed at 25, 37.5 or 50 mg / 24h titration according to the plasma level, with the objective of a physiological level of estradiol (25-40 pg / ml ) - During 4 weeks
2957897|NCT02847806|Experimental|Testosterone|dosage used : from 25 to 75 mg / day of testosterone (ie 2.5 to 7.5 g / day transdermal gel) according to the plasma level, with the goal of a physiological level of testosterone (5-8 ng / ml) - During 4 weeks
2957898|NCT02847806|Experimental|Testosterone + Estradiol|Testosterone + Estradiol During 4 weeks
2957899|NCT02847793|Active Comparator|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial
2957900|NCT02847793|Placebo Comparator|Placebo intervention|Using a matching procedure (i.e., yoked control group), participants are required to maintain their gaze in a given picture (e.g., a happy face), for the same average time that their counterparts in the Gaze training group (i.e. Experimental group)
2957901|NCT02847780|Active Comparator|C-Mac video laryngoscope.|Active Comparator: C-Mac Videolaryngoscope for vocal cord movement assessment.
2957902|NCT02847780|Experimental|Airway Ultrasound|Experimental: Airway Ultrasound for vocal cord movement assessment.
2957903|NCT02847767|Experimental|Perfusion Imaging|IV contrast perfusion CT will be performed at baseline and at 1 week after completing treatment. Perfusion imaging is similar to a diagnostic CT except a smaller region is serially imaged post contrast injection with multiple data acquisitions and high temporal resolution.
2957904|NCT02847754|Experimental|A|A patients in arm A carry out daily physical Training consisting of three different isometric exercises under the guidance and supervision of a physiotherapist. Training starts day one (first radiotherapy session), 10 daily units of 30 min each are scheduled during radiotherapy. Patients are expected to continue training until 12 weeks post completion of radiotherapy at home. exercise tailored isometric physical exercise
2957905|NCT02847754|No Intervention|B|Patients in arm B (control group) receive 10 daily sessions of 15 min progressive muscle relaxation starting from day one of radiotherapy.
2957906|NCT02847741|Other|Major depressive episode|Depressive patients will be assessed by interview (psychiatrists), questionnaires and blood sampling, as the inpatients's routine care
2957907|NCT02847728||Single Arm Design|The study encompasses a single arm design with 400 adults treated with nivolumab for histologically or cytologically confirmed melanoma and 800 adults treated with nivolumab for histologically or cytologically confirmed lung cancer.
2957908|NCT02847715|No Intervention|Usual care (before-phase)|In the before-phase of the before-and-after study, a group of 84 patients will be recruited and followed over a 12 month period. Data will be collected on clinical and patient outcomes in an audit in order to be able to compare to the intervention (after-phase) group.
2957909|NCT02847715|Experimental|Intervention (after-phase)|In the after-phase of the before-and-after study, a group of 84 patients will be recruited and followed over a 12 month period. Patients in this group will be assigned to the new remote monitoring follow-up pathway (ePRIME), whereby instead of attending routine outpatient appointments they are monitored remoted via a online symptom monitoring questionnaire and related clinical tests undertaken remotely. All information is collated in the patient's electronic patient record, and clinicians will review/respond to the data as necessary.
2957910|NCT02847702|Experimental|VM902A 200 mg|VM902A 200-mg Capsules
2957911|NCT02847702|Experimental|VM902A 400 mg|VM902A 400-mg Capsules (2 x 200-mg capsules)
2957912|NCT02847702|Active Comparator|Naproxen|Naproxen 500-mg Capsules
2957913|NCT02847702|Placebo Comparator|Placebo|Placebo
2957914|NCT02847689|Experimental|Language Treatment Arm|An infant participant randomized to the language treatment arm will be played recordings of his/her mother's voice 2-3 hours daily in the intermediate care nursery until discharge.
2957915|NCT02847689|Sham Comparator|Control Treatment Arm|An infant participant randomized to the control treatment arm will receive standard of care. Standard of care does not include being played recordings of his/her mother's voice while admitted to the intermediate care nursery. However, an infant randomized to the control treatment will have the same auditory equipment placed in his/her isolette or crib as an infant randomized to the Language Treatment Arm.
2957916|NCT02847676||No previous surgery, adhesions present.|Patients have had no previous abdominal surgery. Inspection shows peritoneal adhesions.
2957917|NCT02847676||No previous surgery, no adhesions present.|Patients have had no previous abdominal surgery. Inspection shows no peritoneal adhesions.
2957918|NCT02847676||Previous surgery, adhesions present.|Patients have had previous abdominal surgery. Inspection shows peritoneal adhesions.
2957919|NCT02847676||Previous surgery, no adhesions present.|Patients have had previous abdominal surgery. Inspection shows no peritoneal adhesions.
2957920|NCT02847663|Experimental|Whole-body cryotherapy|The effects of whole-body cryotherapy (-135°C for 2 minutes) are investigated after a muscle damage protocol.
2957921|NCT02847663|Other|Cold-water immersion|The effects of cold-water immersion (10°C for 15 minutes) are investigated after a muscle damage protocol.
2957922|NCT02847650|Placebo Comparator|Placebo|
2957923|NCT02847650|Experimental|PF-06649751|
2957924|NCT02847637|Experimental|Emicizumab 1.5 mg/kg/week|Participants who received episodic treatment with FVIII prior to study entry will receive emicizumab prophylaxis at a dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously for 4 weeks, followed by 1.5 mg/kg/week emicizumab subcutaneously until the end of study (maximum up to 2 years).
2957925|NCT02847637|Experimental|Emicizumab 3 mg/kg/2 weeks|Participants who received episodic treatment with FVIII prior to study entry will receive emicizumab prophylaxis at a dose of 3 mg/kg/week subcutaneously for 4 weeks, followed by 3 mg/kg/2 weeks emicizumab subcutaneously until the end of study (maximum up to 2 years).
2957961|NCT02847377|Experimental|[18F]-ODS2004436|Two TEP will be performed with the radiotracer [18F]-ODS2004436
2957926|NCT02847637|Active Comparator|No Prophylaxis|Participants who received episodic treatment with FVIII prior to study entry will be randomized to continue episodic FVIII treatment when they start the trial; they will have the opportunity to switch to emicizumab prophylaxis after 24 weeks on-study.
2957927|NCT02847637|Experimental|Emicizumab (Pre-study FVIII Prophylaxis)|Participants who received FVIII prophylaxis prior to study entry will receive emicizumab prophylaxis at a dose of 3 mg/kg/week subcutaneously for 4 weeks, followed by 1.5 mg/kg/week emicizumab subcutaneously until the end of study (maximum up to 2 years).
2957928|NCT02847624||ADPKD|
2957929|NCT02847611|Experimental|Jamar then Labin|"The order of the using of the dynamometers Jamar then Labin or Labin then Jamar is chosen by randomization"
2957930|NCT02847611|Experimental|Labin then Jamar|"The order of the using of the dynamometers Jamar then Labin or Labin then Jamar is chosen by randomization"
2957931|NCT02847598|Experimental|Part A: BIIB059 450 mg|BIIB059 450 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional dose at Week 2 for a total of 7 doses (Weeks 0, 2, 4, 8, 12, 16, and 20) in participants with systemic lupus erythematosus [SLE] with active skin manifestations and joint involvement.
2957932|NCT02847598|Placebo Comparator|Part A: Placebo|BIIB059 matching placebo administered subcutaneously (SC) every 4 weeks (Q4W) with an additional dose at Week 2 for a total of 7 doses (Weeks 0, 2, 4, 8, 12, 16, and 20) in participants with [SLE] with active skin manifestations and joint involvement.
2957933|NCT02847598|Experimental|Part B: BIIB059 50 mg|BIIB059 50 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active cutaneous lupus erythematosus [CLE] with or without systemic manifestations.
2957934|NCT02847598|Experimental|Part B: BIIB059 150 mg|BIIB059 150 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active [CLE] with or without systemic manifestations.
2957935|NCT02847598|Experimental|Part B: BIIB059 450 mg|BIIB059 450 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active [CLE] with or without systemic manifestations.
2957936|NCT02847598|Placebo Comparator|Part B: Placebo|BIIB059 matching placebo administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active [CLE] with or without systemic manifestations.
2957937|NCT02847585|Experimental|Open label|water-soluble ubiquinol
2957938|NCT02847572|Other|Surgery Patient|All patients to be implanted bilaterally with a Tecnis Extended Range Lens in the Dominant eye and a Low Add Multifocal in the non dominant
2957939|NCT02847559|Experimental|Treatment (bevacizumab, electric field therapy)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 of courses 1-4. Beginning on day 1 of course 5, patients may choose to receive bevacizumab IV every 3 weeks or remain on the every 2-week schedule. Patients also undergo electric field therapy using Optune (formerly NovoTTF-100A System) daily over 18 hours. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2957940|NCT02847533|Other|resistant depression|patients suffering from resistant unipolar depression (at least 2 failed antidepressant treatments for the current episode)
2957941|NCT02847533|Other|non resistant depression|patients in remission from unipolar depressive disorder
2957942|NCT02847494|Active Comparator|Control|Metoclopramide 10mg IV+ dexamethasone 10mg IM
2957943|NCT02847494|Active Comparator|Experimental|Metoclopramide 10mg IV + methylprednisolone acetate 160mg IM
2957944|NCT02847481|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
2957945|NCT02847481|Placebo Comparator|placebo fecal microbiota transplantation|placebo fecal microbiota transplantation
2957946|NCT02847481|Experimental|FMT after antibiotic pretreatment v1|fecal microbiota transplantation after antibiotic pretreatment
2957947|NCT02847481|Experimental|FMT after antibiotic pretreatment v2|fecal microbiota transplantation after antibiotic pretreatment
2957948|NCT02847468|Experimental|FDG and FCH PET|Patients will performed a TEP with 2 different radiotracer before treatment is started and 1 month after treatment has been started.
2957949|NCT02847455|Experimental|5 mg ilaprazole|
2957950|NCT02847455|Experimental|10 mg ilaprazole|
2957951|NCT02847455|Active Comparator|10mg Rabeprazole|
2957952|NCT02847442|Experimental|Opicapone (BIA 9-1067) 50 mg|Total duration of trial participation and treatment: three months. All subjects will start treatment with 50 mg opicapone (OPC) once daily for a 3-month period in addition to their current treatment with levodopa/dopa decarboxylase inhibitor (L-dopa/DDCI)
2957953|NCT02847429|Experimental|Crenolanib Arm|Investigational product (crenolanib)
2957954|NCT02847429|Placebo Comparator|Placebo Arm|Matching placebo
2957955|NCT02847416|Experimental|Inspiratory group|the subjects will be instructed to inspire as deeply as possible with steady flow rate for 3 seconds with end-inspiratory pause for 2-3 seconds through the inspiratory circuit and follow by passive exhalation
2957956|NCT02847416|Experimental|expiratory group|the subjects will be instructed to inspire as deeply as possible through the nose with end-inspiratory pause for 2-3 seconds and partially forced exhalation with reach to 1/3 of expiratory reserve volume (ERV) for at least 3 seconds through expiratory circuit
2957957|NCT02847403|Experimental|exenatide|long-acting exenatide 2 mg subcutaneously once-weekly
2957958|NCT02847403|Placebo Comparator|placebo|no drug assigned
2957959|NCT02847390||Pre-implementation group|"The investigators will develop and deliver a diabetes physician and nursing inpatient diabetes education intervention to our staff over a 6-month time frame from August 2016-January 2017. The investigators will use a before and after study design to assess the impact of the educational intervention on hospital-wide hypoglycemia and hyperglycemia.~Adult (>18 years), non-obstetrical patients admitted to the medical services where housestaff and hospitalist superusers have been trained, with Type 1 diabetes, Type 2 diabetes, or individuals with hospital-related hyperglycemia who do not carry a prior diabetes diagnosis (4/1/16 to 6/30/16)."
2957960|NCT02847390||Post-implementation group|Adult (>18 years), non-obstetrical patients admitted to the medical services where housestaff and hospitalist superusers have been trained, with Type 1 diabetes, Type 2 diabetes, or individuals with hospital-related hyperglycemia who do not carry a prior diabetes diagnosis (4/1/17 to 6/30/17).
2957962|NCT02847364|Experimental|Chewing gum group|The patients will be asked to chew on a regular chewing gum starting morning of post-operative day 1 until the first bowel movement.
2957963|NCT02847364|No Intervention|Control group|These patients will not be offered any food/beverage orally. Patients will be asked not to eat or chew anything till the first bowel movement.
2957964|NCT02847351|Placebo Comparator|Control Diet (CD)|Period 1(the first 4 weeks): 10 subjects were randomly assigned to Control Diet: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with a normal white grain flour. After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with Arabinoxylan-enriched flour.
2957965|NCT02847351|Experimental|Arabinoxylan Diet (AXD)|Period 1(the first 4 weeks): 9 subjects were randomly assigned to Arabinoxylan-Diet: they replaced for 4 weeks all the carbohydrates consumed in day with crackers baked with an Arabinoxylan-enriched flour. After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day with crackers produced with a normal white grain flour
2957966|NCT02847338|Experimental|Mono-therapy group|"The monotherapy group will be treated with the following treatments:~A) 1 to 2 weeks of Amlodipine 5mg followed by 6 to 7 weeks of Amlodipine 10mg B) 1 to 2 weeks of Lisinopril 10mg followed by 6 to 7 weeks of Lisinopril 20mg C) Approximately 8 weeks of 25mg Chlortalidone~Participants will be randomly allocated to one of six possible sequences of treatments of the three-treatment-three period Williams design: ABC, ACB, BAC, BCA, CAB, and CBA."
2957967|NCT02847338|Experimental|Dual-therapy arm|"The dual-therapy group will be treated with the following treatments:~A) Approximately 8 weeks of Amlodipine 5mg and Lisinopril 20mg B) Approximately 8 weeks of Amlodipine 5mg and Chlortalidone 25mg C) Approximately 8 weeks of Lisinopril 20mg and Chlortalidone 25mg D) Approximately 8 weeks of Amiloride 10mg and Chlortalidone 25mg~Participants will be randomly allocated to one of four possible sequences of treatments of the four-treatment four-period Williams design: ABDC, BCAD, CDBA, and DACB."
2957968|NCT02847325|Experimental|AC0058TA|Drug: 50 mg AC0058TA Drug: 100 mg AC0058TA Drug: 200 mg AC0058TA Drug: 400 mg AC0058TA
2957969|NCT02847325|Placebo Comparator|Placebo capsules|Drug: Placebo capsules
2957970|NCT02847312|Active Comparator|High avenanthramide, phenolic acid|66.8g Pepsico Oatmeal + 60g Oat cake
2957971|NCT02847312|Active Comparator|Low avenanthramide, medium phenolic acid|17g Oatwell + 63.6g Cream of Rice + 60g Melba Toast
2957972|NCT02847312|Placebo Comparator|Control|69.8g Cream of Rice + 8.1g Cellulose + 4.8g Pectin + 60g Melba Toast
2957973|NCT02847299|Experimental|Astral ventilator|instrumental increase of cough peak flow with air stacking
2957974|NCT02847299|Experimental|Astral ventilator - mode kiné|instrumental increase of cough peak flow with hyperinsufflation
2957975|NCT02847286|Active Comparator|Treatment A|Dapivirine Ring-004 for 28 days
2957976|NCT02847286|Active Comparator|Treatment B|Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
2957977|NCT02847286|Active Comparator|Treatment C|Clotrimazole, 5 g per day for 7 days
2957978|NCT02847260|Experimental|Remodulin|Remodulin will be initiated, whilst subjects are hospitalized (minimum of 72 hours) and under medical supervision, at approximately 2 ng/kg/min as a continuous SC infusion with dose increments of 1-2 ng/kg/min applied approximately every 12 hours according to clinical response and tolerability. Following discharge, dose rate increments are permitted at 1-2 ng/kg/min with a minimum of 24 hours between each dose up-titration. Once a dose rate of 20 ng/kg/min is achieved, the dose increments can be increased up to 4 ng/kg/min with dose increments separated by at least 24 hours. The aim is to achieve a target dose of 10, 20, and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively.
2957979|NCT02847247|Experimental|CCRE|20,000 EU of CCRE (Clinical Center Reference Endotoxin)
2957980|NCT02847208||cystic fibrosis women|It was a cohort of 155 CF women attending the Lyon adult centre. Women attending the CF adult centre in 2014 completed a written questionnaire about their contraceptive choices, frequency of gynaecological follow-up and cervical screening. Other clinical data were collected from the CF adult centre registry.
2957981|NCT02847195|Experimental|pediatric intensive care|"When aspiration is planned, pain assessment will be performed thrice :~3-5 minutes before aspiration, during aspiration, and 3-5 minutes after aspiration.~Pain assessment will be performed with both methods:~COMFORT B scale (routinely performed by nurses, and lasts less than one minute)~Simultaneously pupillometry is assessed using the device (Neurolight) (one measurement per eye, this also lasts less than one minute) These measurements can occur at any time during stay in ICU, and can be repeated."
2957982|NCT02847182|Experimental|Cord Blood Infusion (best source)|Subjects will be randomized to receive a cord blood infusion at the baseline or 6 month visit. The cord blood will be autologous (if available) or unrelated cord blood.
2957983|NCT02847182|Placebo Comparator|Placebo Infusion|Subjects will be randomized to receive a cord blood infusion at the baseline or 6 month visit or placebo. The cord blood will be autologous (if available) or unrelated cord blood. The placebo is an acellular media product similar in both appearance and odor.
2957984|NCT02847169|Active Comparator|filcon IV1 toric lens|Participants are randomized to wear filcon IV1 toric lens pair for 1 week during the cross over study.
2957985|NCT02847169|Active Comparator|ocufilcon D toric lens|Participants are randomized to wear ocufilcon D toric lens pair for 1 week during the cross over study.
2957986|NCT02847156|Other|cystic fibrosis infants|1 year follow-up in CF infants
2957987|NCT02847143|Experimental|secure|healthy adult male with secure attachement
2957988|NCT02847143|Experimental|avoidant|healthy adult male with avoidant attachement
2957989|NCT02847143|Experimental|enmeshed/fearfull|healthy adult male with enmeshed/fearfull attachement
2957990|NCT02847143|Experimental|dual style|healthy adult male with dual attachement style
2958040|NCT02846779|Experimental|Moderate intensity|Participants will receive all intervention components as in the low-intensity arm but will receive more frequent pharmacist follow-up and the option of enrolling in a text-messaging program. The pharmacist will also provide limited follow-up with the participant's provider. Only 60% of participants randomized will be targeted to receive the intervention based on adherence risk score.
2958185|NCT02845804||Alpine|The patients who received percutaneous coronary intervention with Xience Xpedition™/Alpine™
2957991|NCT02847130||Observational (chart review, focus group, interviews)|"AIM 1 (CHART REVIEW): Patients are separated for each CPG evaluated (fever and neutropenia [FN], chemotherapy induced nausea and vomiting [CINV], fertility preservation [FP]) and are randomly selected for medical chart review. Patients with eligible episodes of FN, CINV or FP within the health records are selected and have the data from their records abstracted and reviewed by COG for adherence to COG endorsed CPGs.~AIM 2 (FOCUS GROUPS): Health care providers who provide direct care to pediatric oncology patients are identified and separated to participate in three types of focus groups: physician-only, non-physician, and mixed.~AIM 3 (INTERVIEWS): Health care providers undergo one-on-one interviews consisting of think aloud technique (TAL) of cognitive interviewing."
2957992|NCT02847117|Other|Mastiha|
2957993|NCT02847104||dynamic insulin protocol|patients received intravenous insulin infusion according to a dynamic insulin protocol
2957994|NCT02847104||static insulin protocol|patients received intravenous insulin infusion according to a static insulin protocol
2957995|NCT02847091|Experimental|Ipragliflozin Group|Ipragliflozin will be administered orally for 24 weeks.
2957996|NCT02847078|Experimental|Smart phone app|The app contains education materials for secondary prevention of coronary artery disease. So patients can access them very easily. The app pushes heath management recommendation information on the timeline after percutaneous coronary intervention, and also provides health care lecture to help patients to improve their secondary prevention. And online or telephone consultation ways are integrated into the App to provide convenience for patients to communicate with health care professionals.
2957997|NCT02847078|Other|Control group|Participants allocated to the control group will receive a booklet with general advice on secondary prevention of coronary artery disease.
2957998|NCT02847039||Early repolarization syndrome|Patients with an aspect of early repolarization syndrome or belonging to a family in which the diagnosis of early repolarization was identified.
2957999|NCT02847026|Active Comparator|IPV at 14 and 22 weeks of age, Rotarix|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a full dose IPV booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
2958000|NCT02847026|Active Comparator|IPV at 14 and 22 weeks of age, RotaTeq|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a full dose IPV booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
2958001|NCT02847026|Active Comparator|IPV at 14 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
2958002|NCT02847026|Active Comparator|IPV at 14 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
2958003|NCT02847026|Active Comparator|IPV at 6 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of IPV at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
2958004|NCT02847026|Active Comparator|IPV at 6 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of IPV at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
2958005|NCT02847026|Active Comparator|fIPV at 6-14-22 weeks of age, Rotarix|Participants in this arm will receive fractional doses of IPV (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
2958006|NCT02847026|Active Comparator|fIPV at 6-14-22 weeks of age, RotaTeq|Participants in this arm will receive fractional doses of IPV (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
2958007|NCT02847013|Placebo Comparator|Placebo- Tap block w normal saline|After completion of surgery with closer of skin incision a TAP block will be performed. On confirmation of entering the fascial plane, 20cc of Normal saline will be injected after negative aspiration. That will complete the intervention. 20 patients will be in this arm
2958008|NCT02847013|Experimental|Intervention-Tap block w Liposomal bupivacaine|After completion of surgery w closure of skin incision a TAP block will be performed. On confirmation of entering the fascial plane, Liposomal bupivacaine 0.33% (10 ml diluted to 20 ml using sterile normal saline) will be injected after negative aspiration. That will complete the intervention. 20 patients will be in this arm
2958009|NCT02847000|Experimental|Decitabine + Tetrahydrouridine|Tetrahydrouridine (THU) is supplied as 250 mg/capsule, Decitabine (Dec) as 5 mg/capsule.
2958010|NCT02846987|Experimental|Abemaciclib (LY2835219)|Patients will be treated with abemaciclib 200 mg bid.
2958011|NCT02846974||Calibration cohort|In this cohort, approximately 30 subjects will be put through a controlled desaturation study with controlled hypoxia until they arrive at approximately SpO2 = 70%. Measurements will be taken via arterial catheterization to resolve proper values to calibrate the device
2958012|NCT02846974||Validation cohort|In this cohort, approximately 250 patients will have a single pulse oximetry reading taken using the novel device and a gold standard device to ensure accurate validation.
2958013|NCT02846961||Crohn's disease|Patients with moderate to severe Crohn's disease who need to get a biosimilar CT-P13
2958014|NCT02846961||Ulcerative colitis|Patients with moderate to severe ulcerative colitis who need to get a biosimilar CT-P13
2958015|NCT02846948|No Intervention|Non-echo group|Patients get the standard monitoring and treatment based on Good medical practice. Extended monitoring by focused echocardiography is not applied for this group.
2958016|NCT02846948|Experimental|Focussed echocardiography group|The extended cardiac monitoring by focused assessed echocardiography is applied.
2958017|NCT02846935|Experimental|Decitabine + Tetrahydrouridine|"oral THU dosed by weight, followed by oral decitabine dosed by weight for 60 minutes (± 10 minutes) after the THU, twice weekly on consecutive days.~Treatment on protocol monitoring continues for 52 weeks."
2958018|NCT02846922||catheter ablation group|atrial fibrillation patients with heart failure who received catheter ablation for rhythm control
2958019|NCT02846922||rate control group|atrial fibrillation patients with heart failure who received pharmacological approaches for rate control
2958020|NCT02846909|Active Comparator|Vaginal progesterone group|Will receive progesterone pessaries 400 mg once daily vaginally
2958021|NCT02846909|No Intervention|No progesterone group|Will receive nothing
2958022|NCT02846883|Active Comparator|Intravenous infusion of 1 million allogenic MSC's/Kg|In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered. The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.
2958023|NCT02846883|Active Comparator|Intravenous infusion of 3 million allogeneic MSCs/kg|In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered.The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.
2958024|NCT02846883|Placebo Comparator|Intravenous infusion of Plasmalyte A (placebo)|In a randomized fashion, the Plasmalyte A will be shipped to the performance site where it will be thawed and administered. The Plasmalyte A will be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry as will be performed on active groups in order to protect the blinding of this study. Patients will be pre-medicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.
2958025|NCT02846870|Active Comparator|Standard Education|Patients receive standard-of-care prostate cancer radiation oncology consultation.
2958026|NCT02846870|Experimental|Visually Enhanced Education|Patients receive a visually enhanced prostate cancer educational Powerpoint presentation including prostate anatomy, pathologic results, surgical options, radiation therapy, and prognosis with pictographs during radiation oncology consultation.
2958027|NCT02846857|Active Comparator|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
2958028|NCT02846857|Active Comparator|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
2958029|NCT02846857|Active Comparator|Dual-hormone closed-loop strategy|Variable subcutaneous insulin and glucagon mini-boluses will be infused using two separate subcutaneous infusion pumps to regulate glucose levels (MiniMed® Paradigm® Veo™, Medtronic). Participant's usual fast-acting insulin analog and Glucagon (Eli Lilly) will be used. Every 10 minutes, the glucose level as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. Newly reconstituted glucagon will be used every 24 hours.
2958030|NCT02846844||Group A|"Whole body vibration training~manuelle therapy~exercises for power and coordination~performance training as needed"
2958031|NCT02846844||Group B|"manuelle therapy~Exercises for power and coordination~Performance training as needed"
2958032|NCT02846831|Active Comparator|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
2958033|NCT02846831|Active Comparator|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
2958034|NCT02846818|Experimental|Low mean arterial perfusion pressure|5 patients undergoing primary, elective coronary artery bypass grafting were randomized to usual range MAP (40 to 60 mmHg) during CPB. Microdialysis catheters were positioned in a retrograde direction in the internal jugular vein.
2958035|NCT02846818|Experimental|High mean arterial perfusion pressure|5 patients undergoing primary, elective coronary artery bypass grafting were blindly randomized to intervention group MAP (60 to 80 mmHg) during CPB. Microdialysis catheters were positioned in a retrograde direction in the internal jugular vein.
2958036|NCT02846805|No Intervention|complete dentures|complete dentures will be provided for all subjects according to the standardized treatment protocol
2958037|NCT02846805|Experimental|implant-retained overdentures|subjects will receive two-implant-retained overdentures in the mandible ,and continue wearing their complete denture in the maxilla
2958038|NCT02846792|Experimental|Treatment (plinabulin, nivolumab)|Patients receive plinabulin IV over 30 minutes and nivolumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2958039|NCT02846779|Active Comparator|Low intensity|All participants randomized to this arm will receive quarterly educational mailings and limited telephonic outreach delivered by a pharmacist focused on insulin adherence and glycemic control.
2958122|NCT02846207|Experimental|Huoxue group|Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
2958041|NCT02846779|Experimental|High intensity|Participants will receive all intervention components as in the moderate-intensity arm but will receive more frequent pharmacist follow-up. The pharmacist will also provide more follow-up with the participant's provider and/or pharmacist. Only 40% of participants randomized will be targeted to receive the intervention based on adherence risk score and baseline disease control.
2958042|NCT02846766|Experimental|Lenvatinib|The starting dose of lenvatinib will be 24 mg orally per day. The duration of one cycle is defined as 28 days (4 weeks). Subjects will be treated for 2 cycles (8 weeks) and then restaged. Subjects will continue study drug until progression or unacceptable toxicity occurs.
2958043|NCT02846753|Experimental|Implantation of Venus P-Valve™|Implantation of the Venus P-Valve™ in the pulmonic position in patients with native outflow tracts; trans catheter heart valve replacement.
2958044|NCT02846740|Experimental|Adjunctive CES|CES 100µA for one hour daily, five to seven days per week. Rating scales will be administered at baseline (i.e., pre-treatment), twice a week and at the end of the study.
2958045|NCT02846740|Sham Comparator|Sham control CES|For the sham group the Alpha-Stim® will not emit electricity. All other procedures will be the same for both the sham group and the active CES group. The current intensity will be preset and locked by the manufacturer. The sham devices will appear identical to the active device.
2958046|NCT02846727||Sepsis Group|This group will consist of surgical intensive care patients with diagnosis of sepsis, severe sepsis, or septic shock.
2958047|NCT02846727||Control Group|This group will consist of patients that serve as controls who do not have diagnosis of sepsis, severe sepsis, or septic shock.
2958048|NCT02846714|Experimental|FLARE intervention|
2958049|NCT02846701|Other|patient treated by duloxetine|
2958050|NCT02846675|Experimental|SVF treatment (random knee)|A random knee (left or right) of subjects will be treated with autologous SVF.
2958051|NCT02846675|Placebo Comparator|placebo treatment (the other knee)|The other knee of subjects will be treated with placebo.
2958052|NCT02846662|Experimental|CONEMO|"Participants will be offered a behavioral activation-based intervention delivered by an applicative for smartphones (CONEMO), which encourages them to be more active and to incorporate more activities in their everyday life.~Primary care nurses will train participants to use the CONEMO app, monitor patients' adherence to CONEMO, calling patients when they are non-adherent, and give technical support when necessary. They will be supervised by clinical psychologists.~Primary care teams are informed of participants' depression level and deliver usual care according to clinical protocols, including the assessment for the need of antidepressant medication."
2958053|NCT02846662|No Intervention|ENHANCED USUAL CARE|The primary care teams are informed of the participants' depression level and can deliver usual care according to clinical protocols, including the assessment for the need of antidepressant medication. This is considered enhanced usual care because the teams are notified about participants' level of depressive symptomatology, which otherwise might go undetected, and then decide about the best way to handle with patients' needs related to their depressive symptomatology.
2958054|NCT02846649|Experimental|PIER Intervention|The program will help participants learn to recognize the presence of craving and how it can be reduced through environmental, self-regulatory and mood management. Each day, the PIER1 program sends (1) a morning reflection focused on positive thinking, (2) two random prompts assessing severity of craving, (3) feedback specific to managing withdrawal symptoms, mood management, and environmental triggers that are affecting craving, (4) evening assessments of drug use with feedback, (5) goal commitment prompt with feedback, and (6) user-triggered craving assessments with feedback
2958055|NCT02846623|Experimental|CLL - Refractory/ Relapsed After - One Prior Therapy|"Participants receive Obinutuzumab by vein over about 4-6 hours on Days 1, 2, 8, and 15 of Cycle 1 and then Day 1 of Cycles 2 - 9.~Participants receive Atezolizumab by vein on Days 1 and 15 of Cycles 2 - 9."
2958056|NCT02846623|Experimental|CLL - Untreated Patients with High-Risk Molecular Features|"Participants with CLL with high-risk molecular features (del(17p), mutated TP53, del(11q), unmutated IGHV gene, or are >65 years of age) requiring first-line therapy.~Participants receive Obinutuzumab by vein over about 4-6 hours on Days 1, 2, 8, and 15 of Cycle 1 and then Day 1 of Cycles 2 - 9.~Participants receive Atezolizumab by vein on Days 1 and 15 of Cycles 2 - 9."
2958057|NCT02846623|Experimental|CLL - On Ibrutinib for at Least 12 Months-Partial Response|"Participants receive Obinutuzumab by vein over about 4-6 hours on Days 1, 2, 8, and 15 of Cycle 1 and then Day 1 of Cycles 2 - 9.~Participants receive Atezolizumab by vein on Days 1 and 15 of Cycles 2 - 9.~If participant is taking Ibrutinib as part of standard care, they continue to take it at the current dose and schedule assigned by regular doctor."
2958058|NCT02846610||regional anesthesia|surgical patients (age: 0-100 years) having regional anesthesia along with the procedure and postoperative course
2958059|NCT02846610||systemic analgesia|surgical patients (age: 0-100 years) having systemic analgesia along with the procedure and post procedure course
2958060|NCT02846597|No Intervention|Control|Infants in this group will not receive sustained lung inflation in the delivery room and will be put immediately on CPAP at a pressure of 5 cm H2O.
2958061|NCT02846597|Active Comparator|High pressure for long duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 20 cm H2O for a duration of 20 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
2958062|NCT02846597|Active Comparator|High pressure for short duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 20 cm H2O for a duration of 10 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
2958063|NCT02846597|Active Comparator|Low pressure for long duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 15 cm H2O for a duration of 20 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
2958064|NCT02846597|Active Comparator|Low pressure for short duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 15 cm H2O for a duration of 10 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
2958065|NCT02846584|Experimental|CD19 or CD20 CAR T cells briging HSCT|lentiviral transfection and transfuse anti-CD19 or anti-CD20 CAR T cells into patients. Six months later, select appropriate patients to transplant hemopoietic stem cells.
2958066|NCT02846571|Other|Human Pancreatic Islet Transplantation|Islet transplantation into the anterior chamber of the eye single arm
2958288|NCT02845115|Other|control|standard care : usual technique for implanting
2958067|NCT02846558|Experimental|Calorie Restriction - Frequent Patient Communication|MS patients receiving monthly natalizumab infusions will use the LoseIt! smartphone application to log daily food consumption. Data from the app will be collected at follow-up visits. Patients will receive initial training in using the app, and then receive weekly supportive messages encouraging them to adhere to the calorie restriction diet between 3- and 6-month followup visits. Results will be compared primarily to those collected from the Standard of Care arm.
2958068|NCT02846558|Experimental|Timing Restriction|MS patients receiving monthly natalizumab infusions who are ineligible for the calorie restriction portion of the study (the Frequent Patient Activation and Standard of Care arms) will be offered the option to enroll in the second part of the study, assessing differences in outcomes between daily 16-hour fasting periods and no dietary changes. Patients in the second part of the study randomized to this arm will consume their normal daily food intake, but restrict eating to an 8-hour period during the day. Results will be compared to patients who do not make any changes to their diet, the No Change arm.
2958069|NCT02846558|Placebo Comparator|Calorie Restriction - Communication Standard of Care|MS patients receiving monthly natalizumab infusions will use the LoseIt! smartphone application to log daily food consumption. Data from the app will be collected at follow-up visits. Besides initial training with the application and 3- and 6-month follow up exams, participants will not receive additional support or interaction from the study team.Results will be compared with those collected from the Frequent Patient Interaction arm.
2958070|NCT02846558|No Intervention|No Diet Change|MS patients receiving natalizumab infusions who were ineligible for the calorie restriction portion of the study (e.g. body mass index < 25 kg/m^2) or did not wish to participate in calorie restriction, may elect to be part of the second portion of the study. If so, they may be randomized to this arm, in which no changes are made to amount or timing of daily food intake. Results will be compared with the experimental Timing arm
2958071|NCT02846545|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab intermittently for 52 weeks, where doses will be based on weight and/or body surface area.
2958072|NCT02846545|Placebo Comparator|Group 2: Placebo|Participants will receive a matching placebo to golimumab.
2958073|NCT02846532|Experimental|Rivaroxaban|
2958074|NCT02846532|Experimental|Acetylsalicylic Acid|
2958075|NCT02846519|Experimental|Esketamine|Participants in Cohort 1 (Han Chinese participants), Cohort 2 (Korean participants) and Cohort 3 (Japanese participants ) will receive 100-microliter (mcL) spray of 14 percent (%) esketamine solution (14 milligram [mg]) into each nostril at Time 0 and 5 minutes later for a total dose of 56 milligram (mg) in Period 1.
2958076|NCT02846519|Experimental|Esketamine+Rifampin|Participants in Cohort 4 (Caucasian participants) will receive a 56-mg intranasal esketamine dose regimen on Day 1 in treatment period 1 followed by rifampin from Day -6 to Day -1 of treatment Period 2 and followed by 56-mg intranasal esketamine dose regimen on Day 1 in treatment period 2.
2958077|NCT02846506|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 100 milligram (mg) and 1 canagliflozin tablet 50 mg along with 1 Extended Release (XR) tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 XR fixed dose combination [FDC] tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg and metformin (XR) 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2958078|NCT02846506|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2958079|NCT02846506|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2958080|NCT02846506|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2958081|NCT02846493|Active Comparator|bromocriptine group|Rectal bromocriptine (2.5 mg, qd) for 7 days
2958082|NCT02846493|Experimental|dexamethasone group|Oral take dexamethasone(3mg,qd)for 7 days
2958083|NCT02846480|Experimental|surgical treatment+behavior therapy+physical therapy|Including POP surgical treatment, and pre- post physical therapy to aim the posture, PFM awareness and the strengthening. They will be also informed and instructed on hygienic and behavioral education to prevent POP and urinary incontinence (behavior therapy).
2958084|NCT02846480|Experimental|surgical treatment+behavior therapy|Including POP surgical treatment, and information and instruction about hygienic and behavioral education to prevent POP and urinary incontinence (behavior therapy).
2958085|NCT02846467|Experimental|Portable video media|Patients who receive informed consent trough portable video media around 10 minutes
2958086|NCT02846467|Active Comparator|Traditional IC|Patients who receive traditional IC (written consent) during 10 to 15 minutes
2958087|NCT02846454|Experimental|inulin|Investigating the satiating effects of consuming 4g/d inulin (Fruitafit IQ by CHIMAB)
2958088|NCT02846454|No Intervention|non inulin and arabinoxylan|investigating the satiating effects of a control drink (2.6g/d maltodextrin)
2958089|NCT02846454|Experimental|arabinoxylan|Investigating the satiating effects of consuming 4g/d arabinoxylan (Medium Chain Naxus, BioActor b.v)
2958090|NCT02846428|Active Comparator|5-Fluorouracil + Epirubicin + Cyclophosphamide|Neoadjuvant treatment (Period 1): Participants will receive 4 cycles (cycle length = 21 days) of 5-FU + epirubicin + cyclophosphamide. Surgery will be performed 5 (+/- 1) weeks after the last cycle. Adjuvant treatment (Period 2): Participants will receive 4 cycles (cycle length = 21 days) of docetaxel.
2958123|NCT02846207|Placebo Comparator|placebo group|dextrin, Oral administration, twice one day, for 12weeks.
2958289|NCT02845115|Experimental|laser velocimetry|optimized implantation of laser velocimetry
2958091|NCT02846428|Experimental|Capecitabine + Epirubicin + Cyclophosphamide|Neoadjuvant treatment (Period 1): Participants will receive 4 cycles (cycle length = 21 days) of capecitabine + epirubicin + cyclophosphamide. Surgery will be performed 5 (+/- 1) weeks after the last cycle. Adjuvant treatment (Period 2): Participants will receive 4 cycles (cycle length = 21 days) of docetaxel.
2958092|NCT02846415|Experimental|PID group|Experimental group receiving the Play Intervention for Dementia
2958093|NCT02846415|No Intervention|Wait-list control group|Participants will receive usual care offered by the day care centre, including health and social services, and meals, etc.
2958094|NCT02846402|Experimental|Direct Distribution|The direct distribution arm consists of peer educators directly distributing HIV self-test kits to participants. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
2958095|NCT02846402|Experimental|Fixed Distribution|The fixed distribution arm consists of peer educators distributing coupons to participants. The participants can then use the coupon to collect an HIV self-test kit at a participating distribution point, including drug stores, pharmacies, and health posts. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
2958096|NCT02846402|No Intervention|Referral to Existing Services|Peer educators will not provide HIV self-tests to participants. Peer educators will only provide referral to existing services for HIV testing.
2958097|NCT02846389|Experimental|Moderate Exercise|Moderate exercise - 15 minutes a day using a pedal box before or after radiation at the hospital (75 minutes a week).
2958098|NCT02846389|No Intervention|Control Group|No exercise
2958099|NCT02846376|Experimental|Group A - Nivolumab|"Nivolumab for 12 doses, on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34~Dose level 1: 1 mg/kg~Dose level 2: 3 mg/kg"
2958100|NCT02846376|Experimental|Group B - Ipilimumab|"Ipilimumab for 6 doses on day 1 of weeks 1, 4, 7, 10, 13, 16~Dose level 1: 0.3 mg/kg~Dose level 2: 1.0 mg/kg~Dose level 3: 3.0 mg/kg"
2958101|NCT02846376|Experimental|Group C - Nivolumab + Ipilimumab|"Nivolumab 3 mg/kg for 12 doses, on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34~Ipilimumab for 6 doses on day 1 of weeks 1, 4, 7, 10, 13, 16~Dose level 1: 0.3 mg/kg~Dose level 2: 0.6 mg/kg~Dose level 3: 1.0 mg/kg"
2958102|NCT02846363||Patients included in the Rhône region from France|public awareness campaign
2958103|NCT02846363||Patients included in the control region (Isère, France)|
2958104|NCT02846350|Active Comparator|Experimental condition|The proposed intervention training utilizes a structured, sustainable MI training and supervision program designed to improve retention, adherence and persistence in challenging patients.
2958105|NCT02846350|No Intervention|Standard of Care (SOC)|Physicians providing SOC will attend 3 time-matched video presentations over 2 years on research on optimizing entry into and retention in care and adherence, from materials available at the International Association for Providers of AIDS Care
2958106|NCT02846337|Experimental|ULTRAFILTRATION|The ultrafiltration sodium-overload extraction will be chosen by the patient nephrologist and the patient himself (according to his comorbidities) among the following one: peritoneal dialysis (at least a daily contact), hemodialysis (>1 session per week) or isolated ultrafiltration (>1 session per week). Ultrafiltration technique could change throughout the care
2958107|NCT02846337|Other|ENHANCED MEDICAL TREATMENT|"The control group called enhanced medical treatment will not benefit of ultrafiltration (except refractory pulmonary edema, or terminal kidney failure requiring extra renal depuration). These situations will not be considered as protocol violation, because they are scientifically indicated for extra renal depuration."
2958108|NCT02846324|Experimental|GBT440 Dose 1|Dose 1
2958109|NCT02846324|Experimental|GBT440 Dose 2|Dose 2
2958110|NCT02846324|Placebo Comparator|Placebo|Placebo
2958111|NCT02846311||Group with support that will be usually performed|"During the first phase (before), the assumption will be that usually achieved.~The doctor continues to support according to information it has and according to good practice and service protocols."
2958112|NCT02846311||Group with a flu test|"During the second phase (after), a flu test is routinely performed within the home emergency department by the doctor who supports the patient.~The doctor continues to support according to information it has and according to good practice and service protocols."
2958113|NCT02846272|Experimental|Observational cohort|Observing MRI changes in subjects.
2958114|NCT02846246|Experimental|Intervention|The experimental group will be introduced to a person-centred care model that involves shared decision making where the person with home care service and family together with contact nurse prioritise care content and make rearrangements to make sure the provided home care service maximises health.
2958115|NCT02846246|Sham Comparator|Control|A usual care paradigm will guide the control units, i.e. a continuation with practice as usual.
2958116|NCT02846233|Active Comparator|Treatment group|Interventions: All prandial insulin injections, usually 3 times daily before meals, will be discontinued. Basal insulin, usually once daily at bed time, will be continued at 80 % of the home dose. Albiglutide OR Dulaglutide AND Empagliflozin will be added to metformin and a basal insulin.
2958117|NCT02846233|No Intervention|Control group|Interventions: There will not be any change in insulin therapy, and they will continue to have the usual and standard care through the primary care provider. They should not receive SGLT2i and GLP1 RA during the study period.
2958118|NCT02846220|Experimental|Health coaching|"Two-hour in-person group counseling session led by health coach, involving development of personalized immunity maps that lay out adherence goal, behaviors that distract from goal, hidden motives that compete with achieving goal, and underlying assumptions~Eight 50-minute individual telephone counseling sessions every three weeks with a health coach, focusing on uncovering hidden motives and challenging assumptions with the goal of overturning nonadherence mindsets"
2958119|NCT02846220|No Intervention|Usual care|
2958120|NCT02846207|Experimental|Yiqi huoxue group|Buyang Huanwu decoction , which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
2958121|NCT02846207|Experimental|Yiqi group|Astragalus 60g. Oral administration, twice one day, for 12weeks.
2958124|NCT02846194|Experimental|brief guided imagery|The study group of our research will go through six Brief Guided Imagery sessions. These sessions will be completed within two months and will last one hour each.
2958125|NCT02846194|No Intervention|control group|
2958126|NCT02846181|Experimental|Healthy|
2958127|NCT02846155|Placebo Comparator|clear water group|the patients only drink 1000ml clear water before checking
2958128|NCT02846155|Experimental|simethicone group|the patients drink 950ml clear water and 15ml simethicone before checking
2958129|NCT02846155|Experimental|simethicone combined with pronase group|the patients drink 900ml clear water and 15ml simethicone and 20，000iu pronase before checking
2958130|NCT02846142|Active Comparator|SAD PTI-428|The safety, tolerability, and pharmacokinetic profile of PTI-428 will be evaluated following a single dose of PTI-428. Three cohorts are planned for evaluation where subjects will be randomized to PTI-428 or placebo.The subjects will be followed for 7 days post dose.
2958131|NCT02846142|Placebo Comparator|SAD placebo|The safety, tolerability, and pharmacokinetic profile of PTI-428 will be evaluated following a single dose of PTI-428. Three cohorts are planned for evaluation where subjects will be randomized to PTI-428 or placebo.The subjects will be followed for 7 days post dose.
2958132|NCT02846142|Active Comparator|MAD PTI-428|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult female subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 12 and 14.
2958133|NCT02846142|Placebo Comparator|MAD placebo|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult female subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 12 and 14.
2958134|NCT02846142|Experimental|OC (ethinyl estradiol and levonorgestrel) DDI Period A|Treatment period A will consist of once daily oral contraceptive (OC) for 28-days (21-day hormonal active + 7 days off).
2958135|NCT02846142|Active Comparator|OC (ethinyl estradiol and levonorgestrel) DDI Period B|Treatment period B will randomize subjects to PTI-428 or placebo in combination with once daily OC daily for 28 days (21-day hormonal active + 7 days off).
2958136|NCT02846142|Placebo Comparator|OC (ethinyl estradiol and levonorgestrel) DDI|Treatment period B will randomize subjects 4:1 to PTI-428 or placebo in combination with once daily OC daily for 28 days (21-day hormonal active + 7 days off).
2958137|NCT02846116|Active Comparator|lithium disilicate|The intervention will be: Prosthetic crown
2958138|NCT02846116|Active Comparator|Vita suprinity|The intervention will be: Prosthetic crown
2958139|NCT02846103|Experimental|Biological samples|"Blood samples will be collected at baseline, after the first-line therapy and at 12 months.~Tumor tissues will be collected if available."
2958140|NCT02846090|Experimental|D50 Dexmedetomidine 50 micrograms group|peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
2958141|NCT02846090|Experimental|D25 Dexmedetomidine 25 micrograms group|peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine + 4.5 ml of 2% lidocaine +0.5ml of 25 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
2958142|NCT02846090|Placebo Comparator|control|peribulbar block was given using 10 ml of a mixture of local anesthetics without Dexmedetomidine. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml with 150 IU hyaluronidase.
2958143|NCT02846077||College students|College students will be monitored and will complete online surveys, install apps on their mobile phones, wear physiological sensors and provide saliva samples for later assay.
2958144|NCT02846064|Other|Ovarian tissue cryopreservation|
2958145|NCT02846051|Other|intensive sport practice|"intensive sport practice~the subject must practice for more than six months a drive of at least 8 hours / week, intense, above the ventilatory threshold, or 60-70% of maximum consumption oxygen or 70-80% of maximum heart rate, ie beyond a moderate slowdown. If stopping the intensive sport practice, the duration of the stop at the time of the study should be less practice time.~volunteers,~from 18 to 80 years,~free to consent.~covered by social security.~reported in the national register of healthy volunteers.~The intervention is a lower limb venous examination = venous mapping"
2958146|NCT02846051|Other|control group|"&) Volunteers who do not have intensive sport practice as it is defined in the group intensive sport practice 2) from 18 to 80 years, 3) free to consent. 4) covered by social security. 5) reported in the national register of healthy volunteers.~The intervention is a lower limb venous examination = venous mapping"
2958147|NCT02846038||Patient|Patients at St. Jude Children's Research Hospital who meet the eligibility criteria and consent to participate.
2958148|NCT02846038||Primary oncologist|Primary pediatric oncologists who meet the eligibility criteria and consent to participate.
2958149|NCT02846038||Parents of patient|Parents of the enrolled patient who meet eligibility criteria and consent to participate.
2958150|NCT02846025|Other|Folate|diet rich in folate
2958151|NCT02846025|Other|placebo|placebo
2958152|NCT02846025|Other|diet antioxidant|diet antioxidant
2958153|NCT02846025|Other|Hazelnut Oil|hazelnut oil capsule
2958154|NCT02846012|No Intervention|CSCM Control|Control medium
2958155|NCT02846012|Experimental|CSCM2|New Formulation medium
2958156|NCT02845999|Experimental|Allogenic NK cells transfer|Patients will be treated with a conditioning chemotherapy including 60 mg/kg intravenous cyclophosphamide, 25 mg/m2 intravenous fludarabine for 5 consecutive days and cetuximab. A lymphapheresis from an haploidentical related donor will be performed and T cells will be depleted . Allogenic NK cells will then be adoptively transferred by hepatic intraarterial infusion according to a dose escalation protocol (three doses with at least three patients per cohort)to define the dose-limiting toxicity (DLT). T
2958157|NCT02845986|Experimental|No.10 lymph node dissections|Patients with locally advanced upper third gastric carcinoma will performed laparoscopic spleen-preserving No.10 lymph node dissections.After the surgery the patients will be treated with oxaliplatin or platinum-based chemotherapy.
2958158|NCT02845973||Retrospective cohort|cohort includes patients with and without colorectal neoplasia from 2011.6 through 2016.1 who are over 40 years old and have a valid CEA(carcino embryonic antigen) and OB(occult blood) test results, as well as a valid coloscopy. The constitution of gut microbiota for each group will be studied and compared to establish a new diagnosis model for colorectal cancer.
2958159|NCT02845973||Prospective cohort|cohort includes patients with and without colorectal neoplasia from 2016.2 through 2016.9 who are over 40 years old and have a valid CEA(carcino embryonic antigen) and OB(occult blood) test results. The constitution of gut microbiota for each group will be studied and compared following by a coloscopy to verify the diagnosis model.
2958160|NCT02845960||Experimental group|rapid recovery
2958161|NCT02845960||Controlled group|no rapid recovery
2958162|NCT02845947|Experimental|Music Therapy|Music Therapy to be provided for pediatric patients undergoing extubation readiness trial
2958163|NCT02845947|No Intervention|Control|Patients undergoing standard extubation readiness trial
2958164|NCT02845934|Experimental|Mucormycosis|blood sample
2958165|NCT02845921|Placebo Comparator|Group C Control|Patient will be shifted to operation theatre. Electrocardiography (ECG), pulse oximeter and non-invasive blood pressure (NIBP) monitors will be attached. Baseline vitals will be noted. Intravenous access will be secured and crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl 2µg/kg body weight. Lower limbs will be neither elevated or wrapped. Vitals will be recorded again. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol 2mg/kg body weight injected over 30 seconds. Muscle relaxation will be achieved by inj. vecuronium 0.1mg/kg body weight. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube.
2958166|NCT02845921|Experimental|Group E Leg elevation|Patient will be shifted to operation theatre. Crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl 2µg/kg body weight. Lower limbs are elevated and supported on a stand making an angle of 30 degree to the horizontal. Vitals will be recorded again. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol 2mg/kg body weight injected over 30 seconds. Muscle relaxation will be achieved by inj. vecuronium 0.1mg/kg body weight. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube. Stand will be removed and legs will be brought to horizontal position 10 minutes after intubation.
2958167|NCT02845921|Experimental|Group W Leg wrapping|Patient will be shifted to operation theatre. Crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl. Each lower limb will be elevated alternately and wrapped from toe to mid-thigh with Esmarch bandage. Care will be taken to avoid compressing the legs to greater than arterial pressure by confirming the presence of pulse using a saturation probe. Following wrapping, the lower limbs will be brought to horizontal position. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol injected over 30 seconds. Muscle relaxation by inj. vecuronium. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube. Esmarch bandage will be removed 10 minutes after intubation.
2958168|NCT02845908|Experimental|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. The combined chemotheraphy will be treated for 9 circle. then，the capetabine was allowed
2958169|NCT02845908|Experimental|FOLFOX plus PAC(ip)|The regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2) plus paclitaxel (80 mg/m2) intra-peritoneally.Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
2958170|NCT02845908|Active Comparator|FOLFOX|The FOLFOX regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
2958171|NCT02845895||Neuroscience pole|Patient hospitalized in the department of medicine-surgery-obstetric of the neuroscience pole department
2958172|NCT02845895||Respiratory tracts pole|Patient hospitalized in the department of medicine-surgery-obstetric of the respiratory tracts pole department
2958173|NCT02845882|Other|Low risk group|Stage I or II: Induction I followed by extracompartmental Protocol M, and maintenance therapy for up to a total therapy duration of 96 weeks. Twenty triple intrathecal injections.
2958174|NCT02845882|Other|Intermediate risk group|Stage III or IV or receiving steroids within one week prior to the diagnosis: Induction protocol I followed by the extracompartmental protocol M, reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.
2958175|NCT02845882|Other|High risk group|Failure to qualify a PR, or >5% BM blasts, or with CNS disease on d33 of induction: Induction protocol I followed by 6 intensive polychemotherapy blocks (HR1'-HR2'-HR3'-HR1'-HR2'-HR3'), reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.
2958176|NCT02845869|Experimental|Light Therapy|Subjects from this group will receive 8 biweekly physiotherapy treatment and in addition Light Therapy treatment with the THOR laser LX2 system.
2958177|NCT02845869|Sham Comparator|Sham Therapy|Subjects from this group will receive 8 biweekly physiotherapy treatment and in addition Sham Therapy.
2958178|NCT02845856|Experimental|Cetuximab and NK immunotherapy|In this group, the patients who have EGFR mutation of lung cancer will receive regular Cetuximab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2958179|NCT02845856|Active Comparator|Cetuximab|In this group, the patients who have EGFR mutation of lung cancer will receive regular Cetuximab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2958180|NCT02845843|Experimental|Combination of Lopinavir /Ritonavir and IntErferon Beta 1B|Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days
2958181|NCT02845843|Placebo Comparator|Placebo|Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
2958182|NCT02845830||Participants in early stage of dementia|Subjects with any type of dementia at an early phase diagnosed in the last 12 months with MMSE score 20-25 points
2958186|NCT02845791|No Intervention|Control|The control participants will not receive the educational intervention but will be provided with a detailed advice leaflet for themselves and their parents/guardians.
2958187|NCT02845791|Other|Intervention|The educational intervention participants will receive the eight 90 minute sessions of an interactive family based lifestyle programme.
2958188|NCT02845778|Experimental|melatonin niosomes oral gel 2.5 mg|apply onto oral mucosa as single use
2958189|NCT02845778|Experimental|melatonin niosomes oral gel 5 mg|apply onto oral mucosa as single use
2958190|NCT02845778|Experimental|melatonin niosomes oral gel 10 mg|apply onto oral mucosa as single use
2958191|NCT02845765||Patients with erectile dysfunction|Patients with erectile dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual activity. Patients will be examined with Dynamic Vessel Analyzer (DVA) at baseline and 6 months after therapy with Phosphodiesterase type 5 Inhibitor (PDE5I).
2958192|NCT02845765||Subject healthy volunteers|Patients without erectile dysfunction or ocular disease. Patients will be examined with Dynamic Vessel Analyzer (DVA) at baseline
2958193|NCT02845752|Active Comparator|Stiolto Respimat|Two actuations of Stiolto Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
2958194|NCT02845752|Placebo Comparator|Placebo Respimat|Two actuations of Placebo Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
2958195|NCT02845739|Experimental|kidney transplanted patient|
2958196|NCT02845726||Patients with temporary ureteral stent|Assessment of patients transiently undergoing ureteral stenting.
2958197|NCT02845713|Active Comparator|Single IDA dose W. bancrofti positive|Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) W. bancrofti infections positive
2958198|NCT02845713|Active Comparator|Single IDA dose W. bancrofti negative|Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) in 40 individuals who are free of W. bancrofti infection.
2958199|NCT02845700|Active Comparator|Sensory Retraining Treatment (SRT)|"The retraining portion (SRT) will also involve the systematic presentation of diluted malodors. For each individual, vials on either side of their initial ideographic detection threshold established in the bias assessment phase will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor).~The retraining process will involve multiple ratings cycled through the malodors as well as other positive and neutral smells. Each training session will consist of 4 training blocks."
2958200|NCT02845700|Placebo Comparator|Sham Neutral Training (SNT)|Approximately half of the participants will be randomized to the SNT condition designed to control for the effects of time and learning. In the SNT condition, participants will complete the same assessments (including the olfactory bias assessment), as well as a sham training consisting of neutral/neutral odor pairing dilutions, rather than the combat/neutral odor pairings as in the SRT. Following the one-month assessment, they will be given the option to complete the SRT.
2958201|NCT02845687||Participants|All participants are patients within the Quit at Duke Smoking Cessation Program. This is an observational study with no interventions.
2958202|NCT02845674|Experimental|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
2958203|NCT02845661|Experimental|group 1|patients in group 1, aged 20~60, were accepted an initial dose of 0.9μg/kg dexmedetomidine over 15 min.
2958204|NCT02845661|Experimental|group 2|patients in group 2, aged 20~60, were accepted an initial dose of 1.0μg/kg dexmedetomidine over 15 min.
2958205|NCT02845661|Experimental|group 3|patients in group 3, aged 20~60, were accepted an initial dose of 1.1μg/kg dexmedetomidine over 15 min.
2958206|NCT02845635||Relapsing Remitting Multiple Sclerosis|Those who document during the study on-boarding process that they suffer from relapsing-remitting multiple sclerosis.
2958207|NCT02845635||Primary Progressive Multiple Sclerosis|This who document during the on-boarding process that they suffer from primary progressive multiple sclerosis.
2958208|NCT02845635||Secondary Progressive Multiple Sclerosis|This who document during the on-boarding process that they suffer from secondary progressive multiple sclerosis.
2958209|NCT02845635||Control|This who document during the on-boarding process that they do not suffer from multiple sclerosis.
2958210|NCT02845622|Experimental|30g peeled hazelnuts cream|Every person in this group will receive a 30 g peeled hazelnuts cream as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
2958211|NCT02845622|Experimental|30g unpeeled hazelnuts cream|Every person in this group will receive a 30 g unpeeled hazelnuts cream as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
2958212|NCT02845622|Experimental|snack w/ 30g peeled hazelnuts|Every person in this group will receive a snack with 30 g peeled hazelnuts as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
2958213|NCT02845622|Experimental|snack w/ 2.5g cocoa powder|Every person in this group will receive a snack with 2.5 g cocoa powder as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
2958214|NCT02845622|Experimental|snack w/ 30g peeled hazelnuts+2.5g cocoa|Every person in this group will receive a snack with 30 g peeled hazelnuts and 2.5 g cocoa powder as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
2958215|NCT02845622|Placebo Comparator|empty snack|Every person in this group will receive an empty snack as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
2958216|NCT02845609|Experimental|Intervention|Sialic acid-Extended release 2000 mg, three times per day (TID) for 3 months
2958217|NCT02845596|Active Comparator|Immunosuppressive Therapy|Patient will receive standard immunosuppressive therapy combination of drugs: horse anti-thymocyte globulin (ATG) and cyclosporine.
2958248|NCT02845375|Other|NEOSTIGMINE|intravenous neostigmine will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
2958218|NCT02845596|Active Comparator|Matched Unrelated Stem Cell Transplant|Patient will under go matched unrelated donor transplant of hematopoietic stem cells as their therapy using fludarabine, cyclophosphamide, rabbit anti-thymocyte globulin (ATG), and low-dose total body irradiation (TBI) as preparative regimen and cyclosporine and methotrexate for graft versus host disease (GVHD) prevention.
2958219|NCT02845583||Retrospective cohort|150 oncologic patients belonging to major complexity DRGs
2958220|NCT02845583||Perspective cohort|150 oncologic patients belonging to major complexity DRGs
2958221|NCT02845570|Experimental|68Ga-DOTANOC PET/MRI|Comparison between 68Ga-DOTANOC PET/MRI and 18F-FDG PET/MRI scans
2958222|NCT02845557||Control subjects without diabetes|"(i) 2-hour 75g OGTT with sampling of glucose, insulin, C-peptide and GLP-1 hormone, with sampling at fasting (time zero) and 30, 60, 90, 120 min after the glucose load.~(ii) 1-hour IVGTT, with sampling at time 10 and 1 min, after which glucose (300 mg/kg body weight) infused in a contralateral vein within 30 s, starting at time zero. Blood further sampled for glucose, insulin and C-Peptide with sampling schedule: 3, 5, 6, 8, 10, 15, 20, 25,30 ,40 ,50 ,60 min;~(iii) computed tomography scan, (CT) for abdominal subcutaneous and visceral fat quantification."
2958223|NCT02845557||Subjects with type 2 diabetes|"(i) 2-hour 75g OGTT with sampling of glucose, insulin, C-peptide and GLP-1 hormone, with sampling at fasting (time zero) and 30, 60, 90, 120 min after the glucose load.~(ii) 1-hour IVGTT, with sampling at time 10 and 1 min, after which glucose (300 mg/kg body weight) infused in a contralateral vein within 30 s, starting at time zero. Blood further sampled for glucose, insulin and C-Peptide with sampling schedule: 3, 5, 6, 8, 10, 15, 20, 25,30 ,40 ,50 ,60 min;~(iii) computed tomography scan, (CT) for abdominal subcutaneous and visceral fat quantification."
2958224|NCT02845544|Experimental|Experimental group - Pilates|A Pilates-based exercises program of 6 weeks' duration
2958225|NCT02845544|No Intervention|Control group - no exercises|
2958226|NCT02845531|Experimental|ICD implantation and optimal medical therapy|
2958227|NCT02845531|Active Comparator|optimal medical therapy|
2958228|NCT02845518|Experimental|cMRI AND RHC|Cardiac Magnetic Resonance Imaging (cMRI) and Right Heart Catheterization (RHC) (the latter being recommended in the current guidelines) in all patients at the baseline visit, at 4-6 months of follow up, at 24 months of follow up and in case of clinical worsening from the baseline visit to 24-month of follow up
2958229|NCT02845505||IVUS-CAMS|patients who undergo coronary computed tomography angiography, invasive coronary angiography and IVUS
2958230|NCT02845492|Experimental|Qigong intervention|Qigong meditative exercise intervention meets three times a week for 10 weeks. The qigong group (n=30) will meet at the Women's Medicine Collaborative, Miriam Hospital (146 W. River St., Providence, RI) for Qigong classes. The lesson will be taught by a validated Qi Gong master with over forty years of experience and the interventional protocol will be validated. Two and a half hours of weekly outside personal practice will also be required of participants.
2958231|NCT02845492|Active Comparator|CHIP healthy wellness-exercise class|The Complete Health Improvement Program is a validated set of weekly classes designed to promote gentle exercise and wellness related activities in a supportive group setting led by an experienced trainer.
2958232|NCT02845479|Experimental|Integrative Care Intervention|Broad-based, multi-agent integrative care program delivered by naturopathic doctors (ND) in conjunction with standard surgical and oncologic care.
2958233|NCT02845466|Experimental|Becaplermin/Promagran Dressing|Topical Becaplermin with a protease inhibitor wound dressing.
2958234|NCT02845466|Active Comparator|Becaplermin/Placebo Dressing|Topical Becaplermin with a placebo wound dressing.
2958235|NCT02845453|Experimental|Quetiapine|Quetiapine
2958236|NCT02845453|Placebo Comparator|Placebo|Placebo
2958237|NCT02845440|Active Comparator|Treatment as Usual (TAU)|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services. Participants in this arm will receive no other study-related intervention.
2958238|NCT02845440|Experimental|AD + CHW|"Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. The aim of AD is to help clinicians understand and adopt targeted evidence-based practices.~Community Health Worker (CHW) will offer to support patients and prescribers to implement smoking cessation treatments that may be requested by patients and/or recommended by prescribers."
2958239|NCT02845440|Experimental|AD Alone|Participants who are randomized to this condition will only not be offered additional Community Health Worker services; however, the participant's primary care clinic will receive Academic Detailing as described above.
2958240|NCT02845427|Active Comparator|A(drain group)|patients of primary THA will have closed suction drain introduced intraoperative at surgical site
2958241|NCT02845427|Placebo Comparator|B(No drain group)|patients of primary THA will have the surgical wound be closed with no suction drain
2958242|NCT02845414|Experimental|Intravenous Infusion of dCD133KDEL|
2958243|NCT02845401|Experimental|HBeAg-CHB patients who stop NA Therapy|"Patients with early antigen negative form of disease (HBeAg-CHB) who are already taking standard oral HBV antiviral therapy for at least 192 weeks that stop treatment.~Intervention: Cases will stop antiviral therapy"
2958244|NCT02845401|No Intervention|HBeAg-CHB patients continue NA Therapy|"Patients with early antigen negative form of disease (HBeAg-CHB) who are already taking standard oral HBV antiviral therapy for at least 192 weeks that continue to stay on treatment.~Intervention: None. Controls will continue antiviral therapy."
2958245|NCT02845388|Active Comparator|estradiol valerate|estradiol valerate 2mg every 12 hours orally starting from the second day of the menstrual cycle till reaching trilaminar endometrial pattern and endometrial thickness 8 mm or more
2958246|NCT02845388|Active Comparator|Sildenafil citrate and estradiol valerate|Sildenafil citrate 25 mg every 6 hours orally in combination with estradiol valerate 2mg every 12 hours orally starting from the second day of the menstrual cycle till reaching trilaminar endometrial pattern and endometrial thickness 8 mm or more
2958247|NCT02845375|Placebo Comparator|PLACEBO|Placebo (normal saline) will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
2958287|NCT02845128||HFNC success|not requiring intubation nor invasive mechanical ventilation
2958249|NCT02845375|Experimental|SUGAMMADEX|intravenous sugammade will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
2958250|NCT02845362|Experimental|Dysphagia assessment|
2958251|NCT02845349|Experimental|Drug-Vortioxetine|The treatment group will receive vortioxetine 10 mg per day, which will be increased to 20 mg or decreased to 5 mg, if deemed clinically necessary, at week 4 or 8.
2958252|NCT02845349|Placebo Comparator|Placebo|Matching placebo will be used.
2958253|NCT02845336|Experimental|Celecoxib|Patients who are randomized to treatment with celecoxib 100mg pills by mouth twice a day for 3 months, in addition to standard of care treatment as described under the Control arm
2958254|NCT02845336|Active Comparator|Control|Patients who are randomized to standard treatment (requiring no prescription medication, but standard recommendations such as artificial tears, avoiding cigarette smoke)
2958255|NCT02845323|Experimental|Nivolumab in combination with Urelumab|"Nivolumab and Urelumab combination:~Nivolumab 240 mg will be administered by 1 hour intravenous infusion on day 1 and day 15 for two cycles~Urelumab 8mg will be administered by 1 hour intravenous infusion on day 1 for two cycles"
2958256|NCT02845323|Active Comparator|Nivolumab monotherapy|Nivolumab 240 mg will be administered by 1 hour intravenous infusion on day 1 and day 15 for two cycles
2958257|NCT02845310|Experimental|Restricted fluid therapy group|Patients will receive restricted fluid management guided by concomitant SVV monitoring. GDT protocol
2958258|NCT02845310|Placebo Comparator|Control group|Patients will receive standard fluid management.
2958259|NCT02845297|Experimental|Safety Run In Phase (only Cohort 1):|The treatment of relapsed and refractory AML patients.
2958260|NCT02845297|Experimental|Cohort 2|The treatment of newly diagnosed AML patients (≥ 65 years) who are not candidates for intensive induction chemotherapy.
2958261|NCT02845284|No Intervention|Routine Care|Group education/counseling from Antenatal clinic midwives, routine PMTCT, HIV C&T and family planning C&T services on request.
2958262|NCT02845284|Experimental|Routine Care plus group support|Routine Care plus enhanced group support
2958263|NCT02845284|Experimental|Routine Care plus individual support|Routine Care plus enhanced individual support
2958264|NCT02845271|Experimental|GZ389988|Single intraarticular injection of GZ389988 in the knee joint
2958265|NCT02845271|Placebo Comparator|Placebo|Single intraarticular injection of placebo for GZ389988 in the knee joint
2958266|NCT02845245|Active Comparator|Standard of Care|Standard of care imaging techniques (3D CT scan and plain film radiographs) will be obtained for the surgeon to pre-operatively plan the surgery.
2958267|NCT02845245|Experimental|Intervention|A 3D printed plastic model prototype will be developed for the surgeon to use, in addition to the standard of care imaging techniques (3D CT scan and plain film radiographs), to pre-operatively plan the surgery.
2958268|NCT02845232||Intensive chemotherapy|First group: 68 patients receiving a combination of intermediate-dose cytarabine and an anthracycline. One patient with acute promyelocytic leukaemia (APL) also received all-trans retinoic acid (ATRA).
2958269|NCT02845232||Lower-intensity treatments|The second study group comprised 70 patients who were treated on frontline by lower-intensity treatments [LD-AraC(39 patients), azacitidine (16 patients), decitabine (11 patients),tipifarnib (3 patients), or ATRA (1 patient)]. Patients received LD-AraC 20 mg once or twice daily (according to physician'schoice) by subcutaneous injection for 10 consecutive days. Azacitidine was given at the dose of 75 mg/m2/day for 7 consecutive days by sc injection. Decitabine was administered by intravenous route once daily at 20 mg/m2 for 5 consecutive days. Tipifarnib was given at 600 mg administered orally twice daily for 21 consecutive days in 4-week cycles. ATRA was given at 45 mg/m2until CR achievement followed by maintenance combining 6-mercaptopurine with methotrexate.
2958270|NCT02845232||Best Supportive Care|The last study group comprises 76 patients: 31 patients received supportive care, while 36 patients also received hydroxyurea and 9 patients received 6-mercaptopurine.
2958271|NCT02845219|Experimental|Oral contraceptive/SNAC/Oral Trial drug|
2958272|NCT02845206|Experimental|Patient Specific Cutting Blocks|For the bespoke individualised cutting blocks to be manufactured, the patients will undergo a preoperative CT scan under a set protocol. The CT radiation dose will be considerably less than a conventional diagnostic CT scan.
2958273|NCT02845206|Active Comparator|Conventional Cutting Blocks|The patients in this arm will be operated on using conventional instruments.
2958274|NCT02845193|Experimental|Modified Nasoalveolar molding group|This group will receive nasoalveolar molding appliance in addition to taping for 3 Months with follow-up every 2 weeks.
2958275|NCT02845193|Experimental|Taping group|Tape will be used alone in this group on the upper lip segments for 3 months with follow-up every 2 weeks.
2958276|NCT02845193|No Intervention|Control group|This group will not receive any treatment.
2958277|NCT02845193|Experimental|CAD/NAM group|Computer Aided Designed Nasoalveolar molding and 3D printed.
2958278|NCT02845180|Experimental|3 Mo. Post AAM Injection|Injection. Adipose Allograft Extracellular Matrix (AAM). Panniculectomy post injection, 3 months.
2958279|NCT02845180|Experimental|6 Month Post AAM Injection|Injection. Adipose Allograft Extracellular Matrix (AAM). Panniculectomy post injection, 6 months.
2958280|NCT02845167|No Intervention|Usual-care only|Patients will receive usual-care only during the preoperative period.
2958281|NCT02845167|Experimental|Preoperative exercise|Patients will perform 3 consecutive days of 60 min submaximal cycling exercise at a moderate exercise intensity. During the 60 min of exercise, patients will be provided with three equally spaced 3min rest periods.
2958282|NCT02845154|Active Comparator|Control (bolus purge)|The portal vein clamp will be totally released after end of portal vein anastomosis and all graft and portal blood contents are allowed free and complete access to the systemic circulation via the inferior vena cave
2958283|NCT02845154|Experimental|Intermittent Purge|The portal clamp will be released in situ for 5 seconds to allow purge of the graft and portal contents into the systemic circulation, followed by 30 seconds of portal clamping again. This will be followed by another two cycles of 5 seconds declamping and 30 seconds clamping , then, the portal clamp will be completely released.
2958284|NCT02845141|Experimental|Actifuse|Actifuse to fill bone tunnel
2958285|NCT02845141|Active Comparator|bone graft|bone graft to fill bone tunnel
2958286|NCT02845128||HFNC failure|requiring intubation and invasive mechanical ventilation
2958290|NCT02845102|Experimental|Pre-Post Feasibility Testing|The pre-post feasibility testing/ intervention includes the use of tablet technology and cognitive behavioral therapy (CBT) for depression and self-management education for patients with chronic illness and/or chronic pain and depression. The pre-post feasibility testing phase will include 25 subjects. The total duration of pre-post feasibility testing will be 6 weeks upon the retrieval of the RA-CBT tablet and the inclusion of follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview.
2958291|NCT02845089||Advanced/Metastatic NSCLC patients from UAE and KSA|A random sample of patients diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) from select oncology centers in Kingdom of Saudi Arabia (KSA) and United Arab Emirates (UAE)
2958292|NCT02845076|Active Comparator|Decrease in duration|Weaning will be started with the liberation of patient from NIV during day-time and then nighttime support will be gradually reduced. From day 2 the daytime NIV will be gradually decreased in steps of at least 2 hours/day at the attending discretion. At day 2, nighttime discontinuation will be considered. When a patient reaches without the presence of any reinstitution criteria, the duration of NIV use as 4 hours per 16 hours during daytime, it will be liberated definitively from NIV.
2958293|NCT02845076|Active Comparator|Decrease in pressure and duration|Weaning will be started with the liberation of patient from NIV during day-time and then nighttime support will be gradually reduced. The level of pressure support will be decreased by 2-4 cmH2O per 4 hours during daytime in patients with good tolerance, with no change at night time. From day 2 the daytime NIV will be gradually decreased in steps of at least 2 hours/day at the attending discretion. At day 2, nighttime discontinuation will be considered, based on the vitals and ABGs recorded at 8 pm (see above), with gradual decrease of at least 2 hrs/night. When a patient reaches without the presence of any reinstitution criteria, the level of PS of 8 cmH20, it will be liberated definitively from NIV.
2958294|NCT02845076|Active Comparator|Abrupt discontinuation of NIV|Patients will be disconnected from NIV and oxygenated with a nasal cannula. Oxygen flow will be limited to a maximum of 5L/min.
2958295|NCT02845063|Experimental|concentric cardiovascular rehabilitation|Heart patients under ACE inhibitor intake will be enrolled in the intervention 'concentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
2958296|NCT02845063|Experimental|eccentric cardiovascular rehabilitation|Heart patients under ACE inhibitor intake will be enrolled in the intervention 'eccentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
2958297|NCT02845063|Active Comparator|concentric cardiovascular training|Healthy subjects will be enrolled in the intervention 'concentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
2958298|NCT02845063|Active Comparator|eccentric cardiovascular training|Healthy subjects will be enrolled in the intervention 'eccentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
2958299|NCT02845050|Experimental|Vinflunine+Cisplatin+radical cystectomy|neoadjuvant combination of Vinflunine+Cisplatin before radical cystectomy as proof of principle (one arm only!)
2958300|NCT02845037|Experimental|2 mg or placebo|BIA 5-453 or placebo
2958301|NCT02845037|Experimental|10 mg or placebo|BIA 5-453 or placebo
2958302|NCT02845037|Experimental|20 mg or placebo|BIA 5-453 or placebo
2958303|NCT02845037|Experimental|50 mg or placebo|BIA 5-453 or placebo
2958304|NCT02845037|Experimental|100 mg or placebo|BIA 5-453 or placebo
2958305|NCT02845037|Experimental|200 mg or placebo|BIA 5-453 or placebo
2958306|NCT02845037|Experimental|400 mg or placebo|BIA 5-453 or placebo
2958307|NCT02845037|Experimental|600 mg or placebo|BIA 5-453 or placebo
2958308|NCT02845037|Experimental|900 mg or placebo|BIA 5-453 or placebo
2958309|NCT02845037|Experimental|1200 mg or placebo|BIA 5-453 or placebo
2958310|NCT02845024|Active Comparator|oral doxycycline|Oral capsules of doxycycline 100 mg were used
2958311|NCT02845024|Placebo Comparator|oral placebo capsule|oral placebo capsule were used
2958312|NCT02845011|Experimental|Audiovisual compression feedback|Cardiopulmonary resuscitation according to international guidelines with chest compressions performed with real-time audiovisual feedback using the Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) device.
2958313|NCT02845011|Active Comparator|Standard chest compression|Cardiopulmonary resuscitation according to international guidelines with standard manual chest compression
2958314|NCT02844998|Active Comparator|Dapoxetine 30 mg|Patients who have sedentary life style will treat with Dapoxetine 30 mg (on demand)
2958315|NCT02844998|Experimental|Moderate Running|Patients who have sedentary life style will be advised moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week. (Minimally active category)
2958316|NCT02844998|Sham Comparator|Sham-controlled|Patients who have sedentary life style will be advised those to walk (not running )at most 30 minutes for 5 days in a week. (Inactive category)
2958317|NCT02844985||Addict Group|In-patient and out-patient adult men and women who meet diagnostic criteria for sexual addiction.
2958318|NCT02844985||Control Group|Individuals from the general community and college student populations who have no history of identifiable psychopathology.
2958319|NCT02844946|Experimental|ACT on Life|One day workshop aimed at providing Veterans with new tools and skills needed to pursue valued goals and directions in the face of life?s challenges. Mindfulness, acceptance, values clarification, and goal-setting will be taught.
2958320|NCT02844946|No Intervention|Treatment as Usual|Veterans will continue receiving care as usual.
2958321|NCT02844933|Experimental|Cannabidiol|Cannabidiol oral solution (40 mg/kg/day) divided into two daily doses with a standard meal
2958322|NCT02844933|Placebo Comparator|Placebo|Matching placebo solution divided into two daily doses with a standard meal
2958323|NCT02844920||Fibroid Treatment|Intrauterine ultrasound guided radio-frequency ablation
2958324|NCT02844907|Experimental|Hyperglycemic clamp|During the 2-hour procedure, a variable infusion of 20% dextrose and blood glucose will be clamped at basal + 3mM.
2958325|NCT02844907|Experimental|Hyperglycemic clamp + Exendin (9-39)|During the 2-hour procedure, a variable infusion of 20% dextrose and blood glucose will be clamped at basal + 3mM. Participants will receive an infusion of the GLP-1 receptor antagonist Exendin (9-39) between the 60-120 minute time-points of the clamp. The amount of Ex-9 infused will be 750 pmol/kg/min for 60 minutes.
2958326|NCT02844907|Experimental|Dexamethasone|Subjects will be asked to take 4 mg once daily between Visit-2 and Visit-3.
2958327|NCT02844894|Experimental|dexmedetomidine|0.5 mcg/kg dexmedetomidine in 20 ml normal saline will be infused in 5 minutes before intubation
2958328|NCT02844894|Experimental|Esmolol|0.5 mg/kg esmolol in 20 ml normal saline will be infused in 5 minutes before intubation
2958329|NCT02844894|Placebo Comparator|Placebo|20 ml normal saline infused in 5 minutes before intubation
2958330|NCT02844881|Experimental|Apatinib+MASCT|Apatinib+Multiple Antigens Specific Cellular Therapy(MASCT) in patients with advanced solid tumors,excluding T cell lymphoma
2958331|NCT02844868|Experimental|Active tDCS|During the first 20 min of training program, patient will have active tCDS (2 mA )
2958332|NCT02844868|Sham Comparator|sham tDCS|During the first 20 min of training program, patient will have sham tCDS
2958333|NCT02844855|Active Comparator|patients with Alzheimer disease|Behavioral: Cognitive tests Only patients with Alzheimer disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
2958334|NCT02844855|Active Comparator|patients with Parkinson disease|Behavioral: Cognitive tests Only patients with Parkinson disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
2958335|NCT02844855|Sham Comparator|healthy controls|Behavioral: Cognitive tests Only patients with healthy controls will be included in this arm. Controls will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
2958336|NCT02844842||1 day initiation schedule|The initiation Schedule consists in administering 0.2 mL and 0.3 mL with 30 minutes of interval in the same day. Thus, the patient will reach the maintenance dose of 0.5 mL in one day.
2958337|NCT02844842||Rapid initiation schedule|The patient will receive 3 increasing doses (0.1 mL + 0.3mL + 0.5 mL) weekly doses till the maintenance dose (0.5 mL) is reached.
2958338|NCT02844829|Other|MRI and biomarkers|Prostate MRI. Blood and urine biomarkers. Both prior to biopsy. Tissue samples during prostatectomy.
2958339|NCT02844816|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 17 courses (51 weeks) in the absence of disease progression or unacceptable toxicity.
2958340|NCT02844803|Other|Active drug-> Placebo|Metformin + S. Baicalensis --> Metformin + Placebo
2958341|NCT02844803|Other|Placebo -> Active drug|Metformin + Placebo --> Metformin + S. Baicalensis
2958342|NCT02844790|Experimental|IDegAsp|
2958343|NCT02844777|Placebo Comparator|Placebo|
2958344|NCT02844777|Experimental|5% VDA-1102|
2958345|NCT02844777|Experimental|10% VDA-1102|
2958346|NCT02844764|Experimental|StroMed + Platelet Rich plasma [PRP]|Because no enzymes or drugs are added with this mechanical process, the resulting (StroMed) cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Additional treatments with Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product by direct injection to affected joints.
2958347|NCT02844751|Experimental|Cohort 1|Interventions assigned by Principal Investigator
2958348|NCT02844751|Experimental|Cohort 2|Interventions assigned by Principal Investigator
2958349|NCT02844738|Experimental|StroMed + platelet rich plasma (PRP)|Because no enzymes or drugs are added with this mechanical process, the resulting (StroMed) cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to affected joint.
2958350|NCT02844725|Experimental|VVZ-149 injection|VVZ-149 injections will be mixed with saline, then intravenous infusion for 10hr. The drug product will be administrated with a loading dose of 1.8 mg/kg for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h for 9.5 hours.
2958351|NCT02844725|Placebo Comparator|Placebo|Placebo group will receive an water for injection the same volume and period of experimental group.
2958352|NCT02844712|Other|Evaluation of reexposure to a negatively tested betalactam|
2958353|NCT02844699|Experimental|Mobilan (M-VM3) on both Day 1 and on Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Investigational Drug Product (Mobilan (M-VM3)) administered 2 weeks apart. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
2958354|NCT02844699|Experimental|Placebo on Day 1 and Mobilan (M-VM3) on Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Placebo (Glucose 5%) first on Day 1 and Investigational Drug Product (Mobilan (M-VM3)) in two weeks on Day 15. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
2958355|NCT02844699|Placebo Comparator|Placebo on both Day 1 and Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Placebo (Glucose 5%) administered 2 weeks apart. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
2958356|NCT02844686|Experimental|Cardiac Dynamic SPECT|
2958357|NCT02844673|Active Comparator|Standard monitoring (SM) arm|Participants will receive fixed dose hydroxyurea therapy (15 mg/Kg/day) with standard monitoring. Standard monitoring is defined as a follow-up visit two weeks after initiation of therapy and monthly follow-ups thereafter
2958358|NCT02844673|Experimental|mDOT arm|Participants will receive fixed dose hydroxyurea therapy (15 mg/Kg/day) and Mobile Directly Observed Therapy (mDOT) consisting of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Participants will receive alerts on their cell phone at pre-arranged times to remind them to take their medications. Participants will be followed-up at two weeks after initiation of therapy and monthly thereafter.
2958359|NCT02844660|Experimental|EpiCord|Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
2958360|NCT02844660|Active Comparator|Standard of Care|Weekly application of moist wound therapy and offloading
2958361|NCT02844647|Experimental|MRI w/ Hyperpolarized Pyruvate (13C)|"Hyperpolarization of low natural abundance species such as 13C, when injected offers the potential of extracting metabolic information by real-time MR imaging of biochemical reactions within the body. The biochemical reactions, including lactate production, will be measured using MRI."
2958362|NCT02844634|Experimental|Immediate doxycycline 100mg PO daily|"Individuals will receive tenofovir/emtricitabine one tablet daily in an open-label fashion.~Subjects are randomized to immediate (12 months duration) doxycycline 100mg PO daily."
2958363|NCT02844634|Active Comparator|Deferred doxycycline 100mg PO daily|Individuals will receive daily tenofovir/emtricitabine one tablet daily and will begin doxycycline 100mg PO daily after 6 months for a total duration of 6 months
2958364|NCT02844621|Experimental|Healthy subjects|
2958365|NCT02844608|Other|Quality of Life|Administration of Quality of Life questionnaires
2958366|NCT02844595|Active Comparator|Standard cognitive-behavioural smoking cessation treatment|
2958367|NCT02844595|Active Comparator|Standard smoking cessation treatment and behavioral activation|
2958368|NCT02844595|No Intervention|Control group|It will be a delayed treatment control group for a period of 3 months.
2958369|NCT02844582|Experimental|Treatment (cabazitaxel, prednisone)|Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2958370|NCT02844569|Experimental|Test|Extraction treated with xenograft bone substitute (BioOss Collagen®) + 3D-collagen matrix (Mucograft Seal®).
2958371|NCT02844569|Active Comparator|Control|Extraction treated with xenograft bone substitute (BioOss Collagen®) + collagen dressing (HeliPlug®).
2958372|NCT02844556|Other|SMILE surgery|Small incision lenticule extraction (SMILE) has become a novel and effective method for the correction of myopia and myopic astigmatism. It is a micro-invasive and flapless refractive procedure that has been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
2958373|NCT02844556|Other|FS-LASIK surgery|FS-LASIK surgery is femtosecond laser assisted- conventional refractive surgery and has also been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
2958374|NCT02844543|Experimental|Athletes|Participants will be evaluated using the EYE-SYNC eye-tracking device, Desktop Eye-Tracker, and Sport Concussion Assessment Tool (SCAT-3) tool.
2958375|NCT02844530|Experimental|RIT|The experimental treatment will consist on 2 injections of 370 MBq/m2 of 90Y-epratuzumab tetraxetan fractionated RIT at day 1 and day 8. The first infusion of 90Y-epratuzumab tetraxetan will be co-injected for the six first patients in Nantes with 111In-epratuzumab tetraxetan for dosimetry purpose.
2958376|NCT02844530|Active Comparator|chemotherapy/ immunotherapy|"chemotherapy/ immunotherapy regimen will be assigned per investigator's choice to one of the following chemotherapy/ immunotherapy regimens:~FLAG +- anthracycline based regimen For subject's >60 years : idarubicin 5 mg/m2 day 1,3, fludarabine 20 mg/m2 days 1-5, cytarabine 1 g/m2 days 1-5.~Clofarabine or clofarabine based regimens. Clofarabine use as a single agent should follow the recommended prescribing information. Clofarabine combination based regimens should use >=20mg/m2/day for up to 5 days.~Hyper-C-VAd regimen: hyperfractionated cyclophosphamide 300 mg/m2 intravenously(i.v.) every 12 hours for 6 doses Days 1 to 3 + vincristine 2 mg i.v.Days 4 and 11; doxorubicin 50 mg/m2 i.v. over 24 hours via central venous catheter Day 4; and dexa-methasone 40 mg daily Days 1 to 4 and 11 to 14.~Blinatumomab (Blincyto®) : 28-day continuous infusion (9µg/d for days 1-7; 28µg/d thereafter, followed by 2 weeks of rest for up to 2 cycles."
2958377|NCT02844517|Experimental|Artificial Pancreas|The primary outcome is a qualitative assessment of the system's suitability for use in a large-scale in-home clinical trial based on the results of the Technology Acceptance questionnaire and feedback from clinical staff.
2958378|NCT02844504|Experimental|Low Intensity Exercise Training 1|Cancer survivors will receive low intensity handgrip exercise training.
2958379|NCT02844504|Experimental|Low Intensity Exercise Training 2|Cancer survivors will receive low intensity handgrip exercise training different than other arm.
2958380|NCT02844504|No Intervention|Control|This group will receive no training.
2958381|NCT02844491||Cohort A|"In Cohort A, patients will be included either in the group sustainable responseor in the short / refractory response group.~- sustainable response group : patient with NHL diffuse large B cells, and persistent complete response for at least 6 months after first-line treatment with Rituximab OR patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstrom's disease in complete response or partial stable response for at least 1 year after first line treatment with Rituximab~short / refractory response group : patient with NHL diffuse large B cells, refractory or relapsed in less than 6 months after at least one line of treatment with Rituximab OR patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstrom's disease refractory or relapsed / progression within less than 1 year after at least one line of treatment with Rituximab"
2958382|NCT02844491||Cohort B|"For Cohort B patients will be included either in the group B hematologic therapeutic abstention or in the group any blood disease not treated with anti-CD20 antibodies.~B hematologic therapeutic abstention group : patient with hematological malignancy whatever the initial expansion stage~any blood disease not treated with anti-CD20 antibodies group : patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstorm disease without treatment criteria at diagnosis and with stable disease for at least 6 months"
2958383|NCT02844478|Active Comparator|SBP ENGLISH|Caregivers will complete the 9 -week Stress-Busting Program for Family Caregivers in English
2958384|NCT02844478|Experimental|SBP SPANISH|Caregivers will complete the 9 -week Stress-Busting Program for Family Caregivers in Spanish
2958385|NCT02844465|Experimental|Treatment|Visualase MRI-guided laser ablation procedure
2958386|NCT02844452|Experimental|Verum Acupuncture 1|The participants with atopic dermatitis in the acupuncture group 1 will attend twelve acupuncture sessions over 4 weeks: 3 days a week. Once the 4-week treatment period was ended, the additional follow-up period will be conducted. The subjects will stand a final visit 4 weeks from the end of treatment period. Any other intervention will not be allowed during this study period.
2958387|NCT02844452|Experimental|Verum Acupuncture 2|The participants with atopic dermatitis in the acupuncture group 2 will attend eight acupuncture sessions over 4 weeks: 2 days a week. Once the 4-week treatment period was ended, the additional follow-up period will be conducted. The subjects will stand a final visit 4 weeks from the end of treatment period. Any other intervention will not be allowed during this study period.
2958388|NCT02844452|Sham Comparator|Sham Acupuncture|The participants in the sham acupuncture group will visit eight acupuncture sessions over 4 weeks. The acupuncture treatment will be conducted on six control points. The acupressure will be applied with ring-sham press tack needles on three control points. Unlike the acupuncture group 2, partially-individualized manual acupuncture according to the patient's symptoms will not be given but the questions about symptoms will be questioned to patients.
2958389|NCT02844452|No Intervention|Healthy Control|The participants will go through the screening test. The included subjects will complete questionnaires and their blood sample will be obtained.
2958390|NCT02844439|Experimental|Glioblastoma|The single arm design assessing PFS-6 in the overall population with the ability to detect a rate of 25% is appropriate as a preliminary test of activity in patients with glioblastoma, based on PFS-6 rates seen in randomized studies with bevacizumab [Weathers 2015; Taal 2014; Galanis 2015]. The sample size of this study is also designed to permit the comparison of results with EGFR amplified and non-amplified tumors, as well as EGFRvIII mutated versus wild-type. The sample size is adequate to characterize the safety profile in patients with glioblastoma.
2958391|NCT02844426|Placebo Comparator|Placebo|patients allowed to take maltodextrin by the experienced doctor.
2958392|NCT02844426|Experimental|synbiotic|patients are allowed to take synbiotic (BIFICOPEC) contained 0.63g bifid triple viable capsule (BIFICO) and 8g soluble dietary fiber (Pectin) .
2958393|NCT02844413|Experimental|study group|implementation of aerobic interval training
2958394|NCT02844413|No Intervention|control group|control group
2958395|NCT02844400||Adjuvant and Curative Chemotherapy|30 participants. Primarily older (60+ years in age) cancer patients receiving cytotoxic chemotherapy with adjuvant or curative intent. Will undergo both the Physical Performance Testing and Biometric Devices interventions.
2958396|NCT02844400||Palliative Chemoteraphy|30 participants. Primarily older (60+ years in age) cancer patients receiving cytotoxic chemotherapy with palliative intent. Will undergo both the Physical Performance Testing and Biometric Devices interventions.
2958397|NCT02844387|Experimental|Arginine|In the Arginine arm patients will receive 10 mg of L-arginine hydrochloride solution oral supplementation (in 200 ml of flavoured drinking water solution) administered twice a day prior to the radiation therapy fraction
2958398|NCT02844387|Placebo Comparator|Placebo|In the Placebo arm patients will receive 200 ml of flavoured drinking water oral solution administered twice a day prior to the radiation therapy fraction
2958399|NCT02844374|Other|Partial Epilepsy Drug Resistant|Patients with partial Epilepsy Drug Resistant , justifying a SEEG exploration.
2958400|NCT02844361|Experimental|autologous stem cell transplantation|Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
2958401|NCT02844361|Active Comparator|conventional chemotherapy|Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
2958402|NCT02844348|No Intervention|Standard pain control|Classical pain assessment and drug treatment at each dialysis session.
2958403|NCT02844348|Experimental|Hypnosis|Besides the classical pain assessment and drug treatment, hypnosis sessions during 2 periods of one week of dialysis sessions.
2958404|NCT02844335|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
2958405|NCT02844335|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
2958406|NCT02844322|Experimental|Bortezomib|Patients in this group will receive bortezomib+ cyclophosphamide+ dexamethasone as introduction chemotherapy regimen. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better response achieves, addition 3 cycles will be given. If not, patients will cross to RCD group for another 3 cycles. If a PR or better response comes out, addition 3 cycles will be given, otherwise, the patient will quit this study.
2958407|NCT02844322|Experimental|rituximab|Patients in this group will receive rituximab+cyclophosphamide+ dexamethasone as introduction chemotherapy regimen. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better response achieves, addition 3 cycles will be given. If not, patients will cross to BCD group for another 3 cycles. If a PR or better response comes out, addition 3 cycles will be given, otherwise, the patient will quit this study.
2958408|NCT02844309|Experimental|Thalidomide|thalidomide 50-150mg per night
2958409|NCT02844296|Experimental|exercise group|"A free handgrip (strength 15 kg) will be given to the subject and some short-bout exercise will be introduced to the subjects for reliving the cravings for smoking through a short video. After the video, the counselor will install a smartphone application which is about exercise in the subject's mobile phone to set up exercise reminder schedule for 4 weeks. 20-30 reminders on exercise and quitting tips via the App for 4 weeks. Subjects will be requested o record a daily diary on smoking.~A leaflet with exercise instruction and motivation messages based on the Health Action Process Approach (HAPA) will be given to the participant. 2-month, 6 -month and 12-month telephone interview will be conducted. Biochemical validation will be conducted at 6-month follow up. And hand grip strength will be measured the next time when the participant comes back to CISI."
2958508|NCT02843451|Experimental|Silymarin (Milk Thistle)|Each subject will have a 4 week treatment phase with milk thistle.
2958410|NCT02844296|Experimental|diet group|"Subjects will view a short video on healthy diet only. After the video, the counselor will also install another smartphone application which is about healthy diet in the subject's mobile phone to set up healthy die reminder schedule for 4 weeks.~A leaflet on healthy diet will be given to the subjects, and 20-30 reminders on healthy diet and quitting tips via the App for 4 weeks.2-,6- and 12-month telephone interview will be conducted. Biochemical validation will be conducted at 6-month follow up. And hand grip strength will be measured the next time when the participant comes back to CISI."
2958411|NCT02844283|Experimental|treatment group|Single dose of Ad-HGF given by investigator via intracoronary injection into infarct-related artery
2958412|NCT02844283|Sham Comparator|control group|0.9% sodium chloride (NaCl) injection of same volume given by investigator via intracoronary injection into infarct-related artery
2958413|NCT02844270|Experimental|Galaxy stent|The galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System will be implanted in all subjects.
2958414|NCT02844244|Experimental|training group|Two two-hour training sessions for the participants. It aimed to train lay resident leaders to be peer health promoters. The peer health promoters were taught either to independently implement or to assist social workers to conduct a series of community-based family well-being activities.
2958415|NCT02844231|Other|Sleepwalker, SW episode|Sleepwalker patients undergo single-photon emission computed tomography during a sleepwalking episode.
2958416|NCT02844231|Other|Sleepwalkers, slow wave sleep|Sleepwalker patients undergo single-photon emission computed tomography during slow-wave sleep.
2958417|NCT02844231|Other|Control group|Control subjects undergo single-photon emission computed tomography during slow-wave sleep.
2958418|NCT02844218||Intensive chemotherapy group|Group 1: Patients' age ≥ 70 years treated from 1985 to 1999 with intensive induction chemotherapy.
2958419|NCT02844218||Lower intensity treatment group|Group 2: patients treated from 2000 to 2006 with intensive chemotherapy plus improved supportive care and a follow-up protocol systematically performed at the university hospital.
2958420|NCT02844218||personalized treatment group|"Group 3: patients who had received, starting in 2007, more personalized treatment with either intensive chemotherapy or lower-intensity therapy determined by the clinical judgment of the treating physician."
2958421|NCT02844179|Experimental|dose escalation|Single dose administration of (+)-alpha-Dihydrotetrabenazine (HTBZ), escalating dosage amounts 7.5 - 30 mg orally
2958422|NCT02844166|Experimental|viscoelastic group|viscoelastic surface support
2958423|NCT02844166|Active Comparator|pyramidal foam group|pyramidal foam surface support
2958424|NCT02844153||6 groups, for each CKD stage (1, 2, 3a, 3b, 4, 5)|All patients with type 2 diabetes seen for the first time by a nephrologist.
2958425|NCT02844140|Experimental|Scans|Patients included in the trial will receive DE-CT in stead of SE-CT's.
2958426|NCT02844127|Other|Apex First|Patients born in odd-numbered years will receive an implantable cardioverter defibrillator (ICD). Defibrillation threshold determined with the right ventricular lead placed first in the apex and then in the septum. Final lead position will be determined at the discretion of the implanting physician.
2958427|NCT02844127|Other|Septum First|Patients born in even-numbered years will receive an implantable cardioverter defibrillator (ICD). Defibrillation threshold determined with the right ventricular lead placed first in the septum and then in the apex. Final lead position will be determined at the discretion of the implanting physician
2958428|NCT02844114|Experimental|Ganoderma lucidum spore & Chemotherapy|Ganoderma lucidum spore 1500mg tablet by mouth, every 8 hours for 7 days; Gemcitabine 1000mg intravenously on days 1 and 8 every 3 weeks(iv.over 30 minutes) or cisplatin 75mg intravenously on days 2 and 3 every 3 weeks (iv.15-30 minutes).
2958429|NCT02844114|Placebo Comparator|Placebo & Chemotherapy|Placebo tablet by mouth, every 8 hours for 7 days; Gemcitabine 1000mg intravenously on days 1 and 8 every 3 weeks(iv.over 30 minutes) or cisplatin 75mg intravenously on days 2 and 3 every 3 weeks (iv.15-30 minutes).
2958430|NCT02844101|Other|non-blinded group|The non-blinded subjects will be informed that the accelerometer device (GT3X Actigraph accelerometer) is an accelerometer that assessed physical activity levels and patterns
2958431|NCT02844101|Other|blinded group|The blinded subjects will be informed that they will test the reliability of a new device for body posture assessment and these youngsters will not receive any information with regards to physical activity.
2958432|NCT02844088|Experimental|vaccinated group|evaluation of immunity's level against meningococcus C among people vaccinated in 2002 in Puy-de-Dôme
2958433|NCT02844088|Other|unvaccinate group|Duration of vaccinal immunity, compare vaccinal immunity to possible natural immunity among unvaccinated people
2958434|NCT02844075|Experimental|pembrolizumab|
2958435|NCT02844062|Experimental|anti-EGFRvIII CAR T cells|Patients will receive lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide, followed by intravenous infusion of autologous anti-EGFRvIII CAR T cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of CAR T cells. The tested CAR T cell dosage ranges from 5×10^4 /kg to 1×10^7 /kg
2958436|NCT02844049|Active Comparator|Deep Brain Stimulation|DBS surgical procedure scheduled and realized
2958437|NCT02844049|No Intervention|Control group|medical treatment (psycho- and pharmaco-therapy) will continue to be given and optimized according to the defined BMT strategies and criteria
2958438|NCT02844036|Experimental|Patients with a pulmonary hypertension|Pulmonary hypertension group 4 of Dana point, chronic thromboses lesions, thromboembolic.
2958439|NCT02844023|Other|Patient with giant gells arteritis|50 patients with giant gells arteritis
2958440|NCT02844023|Other|Control patients|50 control patients : blood from French national blood service (EFS)
2958441|NCT02844010||patients with pneumonia|
2958442|NCT02843997|Other|Healthy volunteers|Members of a family
2958443|NCT02843984|No Intervention|A - untreated|The patients will be not treated with vaginal lactoferrin
2958444|NCT02843984|Active Comparator|B - 4 hrs treatment|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 4 hours prior to mid-trimester genetic amniocentesis.
2958445|NCT02843984|Active Comparator|C - 12 hrs treatment|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 12 hours prior to mid-trimester genetic amniocentesis.
2958446|NCT02843971|Experimental|Healthy volunteers|
2958447|NCT02843958|Other|Healthy volunteers and patients under Vitamin K antagonist|
2958448|NCT02843945|Experimental|Directional Brachytherapy Source Implant|Patients undergoing a whipple procedure for pancreatic cancer will receive an implant at the time of surgery of the new CivaSheet directional brachytherapy device. The directonal nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.
2958449|NCT02843932|Experimental|Psychogenic disorders|Psychogenic movement disorders and seizures
2958450|NCT02843919|Other|Healthy volunteers|Adults healthy volunteers
2958451|NCT02843906|Active Comparator|BD/CD +|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
2958452|NCT02843906|Active Comparator|BD/CD -|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
2958453|NCT02843906|Active Comparator|a-MCI|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
2958454|NCT02843893|Other|Intubated and Mechanically Ventilated Patients|Intubated and Mechanically Ventilated Patients receiving by continuous intravenous an hypnotic sedation (midazolam or propofol) associate with a morphine type drug (fentanyl, sufentanil, rémifentanil, or morphine) since at least 6 hours and for a predictable duration over 24 hours.
2958455|NCT02843880||Septic shock patients|Septic shock patients staying over 3 days mechanically ventilated in the ICU
2958456|NCT02843841|Other|ATG group|"Renal transplant Patients from Nephrology department of the University Hospital of Besancon receiving induction immunosuppressive therapy of polyclonal antilymphocyte globulin (ATG-Fresenius®) as recommended.~Intervention = blood and fecal sample"
2958457|NCT02843841|Other|Anti-CD25 group|"PRenal transplant Patients from Nephrology department of the University Hospital of Besancon receiving induction immunosuppressive therapy of anti-CD25 monoclonal antibodies (basiliximab SIMULECT®) as recommended.~Intervention = blood and fecal sample"
2958458|NCT02843828|Experimental|Samsung Hip Assist v1|gait rehabilitation with Samsung Hip Assist v1 10 sessions (5sessions - treadmill gait training / 5sessions - overground gait training), 30 min per session
2958459|NCT02843828|Active Comparator|Conventional gait training|gait rehabilitation without Samsung Hip Assist v1 10 sessions (5sessions - treadmill gait training / 5sessions - overground gait training), 30 min per session
2958460|NCT02843815|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
2958461|NCT02843815|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
2958462|NCT02843802|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
2958463|NCT02843802|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
2958464|NCT02843789|Experimental|Adiponectin evaluation|Patients evaluated for serum adiponectin level and for body composition before each infusion of Tocilizumab
2958465|NCT02843763|Other|Renal transplant with 1rst cancer|Renal transplant patients with first cancer (all cancer excepting skin cancer). Intervention : blood sample
2958466|NCT02843763|Other|Renal transplant patients without cancer|"Renal transplant patients without cancer matched for age, transplantation duration and CMV/EBV status.~Intervention : blood sample"
2958467|NCT02843763|No Intervention|Patient with cancer|Patient with cancer from oncology departement matched for cancer type and stade and CMV/EBV status.
2958468|NCT02843763|Other|Renal transplant with first skin cancer|Renal transplant patients with first epidermoid skin cancer. Intervention : blood sample
2958469|NCT02843763|Other|RT with several skin cancer|Renal transplant patients with several epidermoid skin cancer. Intervention : blood sample
2958470|NCT02843750|Experimental|Inspiratory Muscle Training-Rehabilitation|Patients will start the IMT-R, following their consent and within 2 weeks of their scheduled surgery: 10 sessions lasting about 90 minutes. Participants who completed their initial IMT greater than 2 weeks prior to surgery will have an additional visit prior to surgery. Participants will receive a Participant Manual demonstrating and explaining the rehabilitation process. Participants will also receive a log for recording their efforts and notes. A DVD of the rehabilitation is available to the participant. Participants will complete questionnaires at baseline and 3 months.
2958471|NCT02843724|Active Comparator|Control (Conventional) Arm|Treatment of Type 2 Diabetes according to the Canadian Diabetes Association guidelines. Participants' other health concerns to be addressed as per usual care by practitioners at Wise-Elephant Family Health Team.
2958472|NCT02843724|Active Comparator|Integrative (Naturopathic + Conventional) Arm|In addition to conventional care, participants will receive free naturopathic care at Brampton Naturopathic Teaching Clinic (located within the Brampton Civic Hospital). Senior student clinicians will provide care under the direct supervision of licensed naturopathic doctors. A naturopathic menu of treatment options have been designed to reflect naturopathic practice and vetted by 3 licensed naturopathic doctors and experts in the field. Participants' other health concerns will be addressed as per naturopathic doctors' discretion.
2958473|NCT02843711||Adenocarcinoma|Tumour samples coming from patients harboring a lung adenocarcinoma diagnosed at the Hospices Civils de Lyon. Tumour samples are coming from lung surgery.
2958474|NCT02843698|Experimental|Dexmedetomidine group|Patients will receive either, Dexmedetomidine (Precedex, Hospira, Lake forest, IL, USA) in a dose of (1ug/Kg LBW) bolus followed by 0.5ug/Kg continuous infusion for one hour
2958475|NCT02843698|Placebo Comparator|Control group|Patients will receive normal saline
2958476|NCT02843672|Active Comparator|TWO|"Patients with metatarsalgia and without response to non-operative treatment after six months, needing surgical treatment for relief of their symptoms.~Triple´s Weil osteotomy is performed."
2958578|NCT02842983|No Intervention|Control|Patients received conventional management of septic shock
2958477|NCT02843672|Active Comparator|DMMO|"Patients with metatarsalgia and without response to non-operative treatment after six months, needing surgical treatment for relief of their symptoms.~Distal metatarsal minimally invasive osteotomy is performed."
2958478|NCT02843659|Experimental|BMS-931699|Subcutaneous weekly injection + daily oral placebo tablets
2958479|NCT02843659|Experimental|BMS-986142|Daily oral tablets + subcutaneous placebo (weekly) injection
2958480|NCT02843659|Placebo Comparator|Placebo|Weekly subcutaneous placebo injection +daily oral placebo tablets
2958481|NCT02843646|Experimental|Walk Aide training|This group of children will receive six weeks of Walk Aide training. During training, children will wear the Walk Aide. This device triggers ankle dorsiflexion, and controls the timing and duration of personal nerve stimulation during the swing phase of gait. The duration of the stimulus is gradually increased along with the wearing of the Walkaide. Subjects will begin by wearing the prosthesis for 30 minutes. The wearing time will be increased to waking hours of the subject, depending on their age. The electrodes will be placed on the client before the session is to begin, and taken off immediately after WalkAide usage. The skin will be checked before and after WalkAide electrode usage. The skin will be cleaned with an alcohol wipe before the electrodes are applied.
2958482|NCT02843646|Placebo Comparator|Delayed Walk Aide training|This group of children will not receive Walk Aide training during the first six weeks of enrollment. This group will serve as a comparator group to Arm 1. After six weeks, children in this group will be given the option to complete the 6-week Walk Aide training protocol that is given in Arm 1.
2958483|NCT02843633|Experimental|BioFreedom™ Drug Coated Stent|
2958484|NCT02843620|Placebo Comparator|Placebo|The placebo arm will take a pill each day containing only excipients
2958485|NCT02843620|Experimental|b-2Cool|The b-2Cool arm will take a pill each day containing 40 mg of b-2Cool and excipients
2958486|NCT02843607|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
2958487|NCT02843607|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
2958488|NCT02843594|Active Comparator|LEEP Intervention C1|Cataract surgery with micro-interventional LEEP technology lens fragmentation (non-randomized cohort 1)
2958489|NCT02843594|Active Comparator|LEEP Intervention C2|Cataract surgery with micro-interventional LEEP technology lens fragmentation (randomized cohort 2)
2958490|NCT02843594|Placebo Comparator|Control Phaco C2|Cataract surgery with conventional phaco-assisted lens fragmentation (randomized cohort 2)
2958491|NCT02843581|Experimental|Cryosurgery and NK immunotherapy|We use comprehensive cryosurgery to destroy big tumors, and use multiple (more than 6 times) NK immunotherapy to destroy small tumors
2958492|NCT02843581|Active Comparator|Cryosurgery|We use comprehensive cryosurgery to destroy big tumors
2958493|NCT02843568|Active Comparator|Standard of Care|"Subjects undergo four-dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning. Subjects undergo laboratory biomarker analysis, including spirometry, diffusion capacity (DLCO), and lung volumes (FEV, FEV1). Subjects complete a self-assessment, RTOG defined acute evaluation toxicity evaluation, RTOG late toxicity evaluation, and constitutional assessment.~Radiation doses between 60-66 Gy using standard fractionation (1.8-2.0 Gy/fx) and 40-60 Gy stereotactic body radiation therapy (SBRT) hypofractionation schemes are utilized. Treatment volumes are at the discretion of the treating radiation oncologist and should follow standard of care."
2958494|NCT02843568|Experimental|Pulmonary Function Damage Reduction|All criteria and specifications in the standard of care arm are applicable for this arm, including the same 4DCT scans, and laboratory biomarker analysis. Subjects randomized to this arm of the trial will have the same prescribed radiation dose to the tumor volume and held to the same radiation dose criteria as the subjects in the standard of care arm (60-66 Gy using standard fractionation (1.8-2.0 Gy/fx) and 40-60 Gy stereotactic body radiation therapy (SBRT) hypofractionation). The fundamental difference will be radiation doses for these subjects will be redistributed away from regions predicted to cause the greatest reduction in pulmonary function if damaged.
2958495|NCT02843555||Leukodystrophy of unknown etiology|Subjects who may have an undiagnosed form of leukodystrophy
2958496|NCT02843542|Other|Control Group|primary hyperthyroidism patients that will be refered to the routine exams (PET-CT)
2958497|NCT02843542|Other|Study group|primary hyperthyroidism patients that will be refered to the routine exams (PET-CT) and in addition will also undergo the PET-MR
2958498|NCT02843529|Experimental|Altoida biomarkers, EEG and CSF|"Altoida: neuropsychological, EEG and CSF biomarkers~Participants will undergo at baseline and every 6 months a neurological examination and a neuropsychological assessment. Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
2958499|NCT02843516||patients with stroke|patients with stroke
2958500|NCT02843516||patients without stroke|patients without stroke
2958501|NCT02843503|Experimental|Arterialized-venous reference YSI|CGM monitoring performance per arterialized venous reference measurement (YSI)
2958502|NCT02843503|Experimental|Venous reference samples YSI|CGM monitoring performance per venous reference measurement (YSI)
2958503|NCT02843490|Experimental|Ranibizumab treatment of nAMD patients|nAMD patients will be treated with Ranibizumab (0.5 mg injection) 3 times within three months followed by individual therapy interval based on the clinical progress (PRN) up to 7 times. Analysis of specific biomarker.
2958504|NCT02843490|No Intervention|healthy subjects|Analysis of specific biomarker.
2958505|NCT02843477||Fluid loading group|Spontaneously breathing patients before induction of general anesthesia who receive fluid loading
2958506|NCT02843464|Experimental|long-term RIPC group|routine treatment + once RIPC/day for a year. Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
2958507|NCT02843464|No Intervention|control group|routine treatment.
2958509|NCT02843451|Placebo Comparator|Placebo|4 week placebo phase before or after milk thistle phase depending on randomization.
2958510|NCT02843438|Other|Subjects suspected of toxoplasmosis chorioretinitis infection|Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection
2958511|NCT02843425|Experimental|Regular Diet + Beans, Then Regular Diet - Beans|
2958512|NCT02843425|Active Comparator|Regular Diet - Beans, Then Regular Diet + Beans|
2958513|NCT02843412||group 1|choose one tumor tissue paraffin blocks
2958514|NCT02843412||group 2|choose two tumor tissue paraffin blocks
2958515|NCT02843399||Exenatide once weekly (EQW)|EQW cohort includes patients with one or more outpatient prescription claims for EQW between 2012 and 2015.
2958516|NCT02843399||Insulin Glargine (IG)|IG cohort includes patients with one or more outpatient prescription claims for IG between 2012 and 2015
2958517|NCT02843386|Experimental|A : Chemotherapy|Adjuvant chemotherapy by Fotemustin 100mg/m²
2958518|NCT02843386|Other|B : Surveillance|Intensive surveillance
2958519|NCT02843373||rTMS|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered to the left DLPFC as assessed by either the 5cm rule or F3 site. Daily treatment regiments will last 36.5 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
2958520|NCT02843347||Biorepository substudy participants|Participants from the main study who give consent for the genetic testing substudy.
2958521|NCT02843334||Population of adult patients undergoing chronic renal dialysis|Population of adult patients undergoing chronic renal dialysis for end stage kidney disease in 5 French areas (Rhône-Alpes-Auvergne, Ile de France, Aquitaine, Picardie and department of Gard)
2958522|NCT02843321|Experimental|T-cell infusion|Infusion of donor-derived T cells. Non randomised, prevention study arm
2958523|NCT02843308|Experimental|Immediate Treatment|Facilitated group therapy with behavioral practice; 18 weeks
2958524|NCT02843308|Experimental|Delayed Treatment|Facilitated group therapy with behavioral practice; 18 weeks (after a 18-20 week delay)
2958525|NCT02843308|No Intervention|Healthy Control|This group is matched to the immediate treatment group on age and gender. They do not receive an active treatment.
2958526|NCT02843295|Experimental|Population of the study|3 stratification groups: Group 1: High immunologic risk Patients receiving a ≥ 2nd graft and/or Panel Reactive Antibody ≥ 30% and/or Human Leukocyte Antigen (HLA) mismatches ≥ 4 Group 2: High non-immunologic risk Donors over 60 years of age and/or Donor between 50 to 59 years of age who have died of stroke, or had a history of high blood pressure, or at the time of death had a creatininemia ≥ 135 µmol/L Group 3: Low risk Patients not included in Groups 1 or 2
2958527|NCT02843282|Experimental|Cognitive training|Advanced reasoning training
2958528|NCT02843269|Active Comparator|Multi-component lifestyle intervention 1|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
2958529|NCT02843269|Active Comparator|Multi-component lifestyle intervention 2|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
2958530|NCT02843269|Active Comparator|Multi-component lifestyle intervention 3|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
2958531|NCT02843256||Patients receiving intravenous nutrition|Patients will blow into a bag that will capture 500 mL of their exhaled air daily for 7 days or the length of the parenteral nutrition, whichever is shorter. The Isomark Canary will analyze the air to generate a breath delta value.
2958532|NCT02843230||Avastin Combine with MRI, DSC and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin treatment (baseline scan).~Subsequently, patients will receive their follow-up MRI exams every 8 weeks as standard of care.~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
2958533|NCT02843230||Avastin and Temozolomide Combine with DSC, MRI and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin and Temozolomide treatment (baseline scan).~Subsequently, patients will receive their follow-up MRI exams every 8 weeks as standard of care.~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
2958534|NCT02843230||Avastin and Lomustine Combine with MRI, DSC, and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin and Lomustine treatment (baseline scan).~Subsequently, patients will receive their follow-up MRI exams every 6 weeks as standard of care.~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
2958535|NCT02843217|Experimental|Text Messaging|
2958536|NCT02843204|Experimental|Nivolumab and NK immunotherapy|In this group, the patients will receive multiple NK immunotherapies first to repair the damaged immunocytes; then regular Nivolumab procedures will be used to control tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2958537|NCT02843204|Active Comparator|Nivolumab|In this group, the patients will receive regular Nivolumab1 procedures to control tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2958538|NCT02843191|Active Comparator|Adjuvant chemotherapy|After neoadjuvant chemoradiotherapy, patients will receive surgery followed by eight cycles of chemotherapy.
2958539|NCT02843191|Experimental|Consolidation chemotherapy|After neoadjuvant chemoradiotherapy, patients will receive three cycles of chemotherapy. Thereafter, they will receive surgery followed by five cycles of chemotherapy.
2958540|NCT02843178|Experimental|1: distributed, targeted vouchers|Participants receive four $5 vouchers each valid for a subsequent week of the month (i.e., one voucher valid for week 1 only, a second for week 2 only, a third for week 3 only, and a fourth for week 4 only), starting in month 1 and continuing every month through month 6. The voucher is restricted to pay for fruits and vegetables.
2958541|NCT02843178|Active Comparator|2: lump sum, targeted vouchers|Participants receive four $5 vouchers each valid for an entire month, starting in month 1 and continuing every month through month 6. The voucher is restricted to pay for fruits and vegetables.
2958646|NCT02842541|Experimental|Repeat dose arm|Subjects will receive an intravitreal dose of EBI-031 monthly for 3 months
2958542|NCT02843178|Active Comparator|3: distributed, untargeted vouchers|Participants receive four $5 vouchers each valid for a subsequent week of the month (i.e., one voucher valid for week 1 only, a second for week 2 only, a third for week 3 only, and a fourth for week 4 only), starting in month 1 and continuing every month through month 6. The voucher can pay for any food but not tobacco, alcohol or prepared foods.
2958543|NCT02843178|Active Comparator|4: lump sum, untargeted vouchers|Participants receive four $5 vouchers each valid for an entire month, starting in month 1 and continuing every month through month 6. The voucher can pay for any food but not tobacco, alcohol or prepared foods.
2958544|NCT02843165|Experimental|CBI plus SBRT|Checkpoint blockade immunotherapy (CBI) plus stereotactic body radiation therapy (SBRT)
2958545|NCT02843165|Active Comparator|CBI|Checkpoint blockade immunotherapy (CBI)
2958546|NCT02843139||Children group|Children recruiters were categorized into three groups: obesity, overweight and normal control based on World Health Organization child growth standards.
2958547|NCT02843139||Adults group|Adults with type 2 diabetes were defined if the individual had a fasting plasma glucose (FPG) level ≥ 7.0 mmol/L.
2958548|NCT02843126|Experimental|Trastuzumab and NK immunotherapy|In this group, the patients who have tumor of Her-2 positive will receive regular Trastuzumab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2958549|NCT02843126|Active Comparator|Trastuzumab|In this group, the patients who have tumor of Her-2 positive will receive regular Trastuzumab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2958550|NCT02843113|Experimental|4 Your Child Program|Program integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
2958551|NCT02843113|Experimental|4 Your Child + Case Management|Participants assigned to treatment group that includes case management will receive an initial assessment to determine their strengths and needs. The participant will then work collaboratively with their case manager to connect to community resources to meet his needs. To do so, the case manager will meet with the participant using the following schedule: Months 1-2: intervention in the form of weekly face-to-face meeting with a case manager, plus a weekly phone call from a case manager; Months 3-4: intervention in the form of face-to-face meeting every other week, plus a weekly phone call; Months 5-6: intervention in the form of face-to-face meeting once a month, plus a weekly phone call.
2958552|NCT02843113|No Intervention|Waiting list control|Individuals who are randomly assigned to this condition will receive no treatment for a period of months in parallel with the experimental intervention conditions. Data will be gathered from them, and they will be randomly assigned to a treatment condition when possible.
2958553|NCT02843100|Experimental|Group 1|Modified Exclusive Enteral Nutrition including two weeks of Exclusive Enteral Nutrition (EEN) using Modulen followed by Partial Enteral Nutrition (PEN) along with the Crohn's Disease Exclusion Diet (CDED) for 12 weeks
2958554|NCT02843100|Active Comparator|Group 2|Standard Exclusive Enteral Nutrition for 8 weeks using Modulen, followed by free diet with gradual reduction of Modulen to 25% of energy needs by week 12.
2958555|NCT02843087||NW vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
2958556|NCT02843087||NW C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
2958557|NCT02843087||Ob vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
2958558|NCT02843087||Ob C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
2958559|NCT02843087||GDM vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
2958560|NCT02843087||GDM C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
2958561|NCT02843087||T2D vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
2958562|NCT02843087||T2D C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
2958563|NCT02843087||T1D vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
2958564|NCT02843087||T1D C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
2958565|NCT02843074|Experimental|ERd Therapy|"INDUCTION:~Cycles 1-2: elotuzumab 10mg/kg IV days 1, 8, 15, 22; lenalidomide (len) 25mg orally (PO), once daily (QD) on days 1-21; dexamethasone (dex) 28 mg PO (3-24 hrs before elotuzumab IV) and 8mg IV (45-90 minutes before elotuzumab) days 1, 8, 15, 22.~Cycles 3-4: elotuzumab 10mg/kg IV days 1 and 15; len 25mg PO QD days 1-21; dex 8mg PO (3-24 hrs before elotuzumab IV) and 8mg IV (45-90 minutes before elotuzumab) days 1 and 15; dex 40mg PO days 8 and 22.~CONSOLIDATION:~Four 28-day cycles: elotuzumab 10mg/kg IV days 1 and 15; len 15mg PO QD days 1-21; dex 28mg PO (3-24 hrs before elotuzumab) and 8mg IV (45-90 minutes before elotuzumab) days 1 and 15; dex 40mg PO days 8 and 22.~MAINTENANCE:~After completing consolidation therapy patients without progressive disease will receive, for up to 24 months, 28-day cycles of elotuzumab 20mg/kg IV day 1; len 10mg +/- 5mg PO QD days 1-21; dex 28mg PO (3-24 hrs before elotuzumab) and 8mg IV (45-90 minutes prior to elotuzumab) day 1."
2958566|NCT02843061|Experimental|Rituximab and NK immunotherapy|In this group, the patients will receive regular Rituximab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2958567|NCT02843061|Active Comparator|Rituximab|In this group, the patients will receive regular Rituximab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2958568|NCT02843048|Experimental|Exercise training|Exercise training plus standard medical follow-up care
2958569|NCT02843048|Active Comparator|Standard medical care|Standard medical follow-up care only
2958570|NCT02843035|Experimental|GZ/SAR402671|GZ/SAR402671 - Administered once a day, orally for 52 weeks. Patients will continue their usual dose of Cerezyme throughout study.
2958571|NCT02843022|Active Comparator|Usual care|Participant will receive the usual care provided by the nursing staff at Catholic Medical Center. A lactation consultant or childbirth educator attempts to call each patient within 2-3 weeks prior to discharge. Only one call is made, and a message left if the patient would like to call back.
2958572|NCT02843022|Experimental|Message Only|Participant will receive the usual care, and in addition, will receive four standardized electronic messages weekly for six months postpartum. These will be one-way messages without the option to respond.
2958573|NCT02843022|Experimental|Message and Nurse|"Participant will receive the usual care as well as the four standardized electronic messages/week for 6 months. Two of these weekly messages will be two-way, providing the option for the participant to respond yes to an offer to have a nurse call them. A nurse phone call if requested will be provided with a week."
2958574|NCT02843009|Placebo Comparator|Safflower Oil plus Resistance Exercise Training|3.0g of safflower oil taken daily alongside twice weekly resistance exercise training sessions for 18 weeks
2958575|NCT02843009|Active Comparator|Fish Oil plus Resistance Exercise Training|3.0g of fish oil taken daily alongside twice weekly resistance exercise training sessions for 18 weeks
2958576|NCT02842996||Patient and carer study group|Patients having undergone hip fracture surgery and their care givers.
2958577|NCT02842983|Experimental|Esmolol|After, at least six hours of hemodynamic optimization, patients with a hyperdynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 10% reduction in heart rate. This infusion is maintained for 72 hours.
2958579|NCT02842957|Experimental|Lifestyle intervention|Behavioral: The Lifestyle arm is the experimental group that will be exposed to an intensive, individualized approach aimed at assisting these CKD patients to adhere to lifestyle changes that are expected to be beneficial to their health and wellbeing. Patients will receive direction to implement a plant based diet, along with more physical activity in their lives. They will be assisted with the optimal use of their prescribed medications by pharmacy professionals and they will receive behavioral counseling by experts in that area.
2958580|NCT02842957|No Intervention|Usual Care|The Usual Care arm will continue to receive the current standard of care involving all the services provided at a contemporary nephrology practice in Western Massachusetts
2958581|NCT02842944|Experimental|open loop weaning group (Beacon)|mechanical ventilation following advice from the Beacon Caresystem
2958582|NCT02842944|Active Comparator|Routine care|"Connect and start Beacon with advice disabled~Standardized routine care"
2958583|NCT02842931|Active Comparator|R-DA-EPOCH-21|Protocol involves 6 cycles.
2958584|NCT02842931|Active Comparator|R-DA-EPOCH-21 + auto-SCT|Protocol involves 6 cycles. Patients with complete remission undergo auto-SCT after 6 cycles and patients with partial remission after 6 cycles undergo auto-SCT after 2 cycles of R-DHAP
2958585|NCT02842931|Active Comparator|R-mNHL-BFM-90|"Course A:~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1000 mg/m2 12 h IV 1 day, Ifosfamide 800 mg/m2/day 1 h IV 1 - 5 days, Etoposide 100 mg/m2/day IV 4, 5 days, Doxorubicin 25 mg/m2/day IV 1, 2 days, Vincristine 2 mg IV 1 day, Cytarabine 100 mg/m2/day IV 1 h 4, 5 days.~Course B:~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Cyclophosphamide 200 mg/m2/day IV 1 h 1 - 5 days, Methotrexate 1000 mg/m2 12 h IV 1 day, Doxorubicin 25 mg/m2/day IV 4, 5 days, Vincristine 2 mg IV 1 day. Protocol involves 6 cycles : A-B-A-B-A-B. One cycle continues 21 days."
2958586|NCT02842931|Active Comparator|R-mNHL-BFM-90 + auto-SCT|Protocol involves 6 cycles R-mNHL-BFM-90: A-B-A-B-A-B. Patients with complete remission undergo auto-SCT after 6 cycles and patients with partial remission after 6 cycles undergo auto-SCT after 2 cycles of R-DHAP
2958587|NCT02842918|Active Comparator|Spinal Manual Therapy|Supine thoracic spine manipulation located between the levels of T4-T7
2958588|NCT02842918|Sham Comparator|Spinal Range of Motion|Supine thoracic spine sham manipulation located between the levels of T4-T7; identical procedure as the active treatment intervention but without the delivery of high velocity low amplitude thrust
2958589|NCT02842905|Active Comparator|Control Group|Fitting Audiologist completion of the Client Outcome Scale of Improvement at a post fitting follow up visit.
2958590|NCT02842905|Experimental|Test Group|Participant's physician completion of the Client Outcome Scale of Improvement at a post fitting follow up visit.
2958591|NCT02842892|Other|Squat Jump|
2958592|NCT02842892|Other|Drop Jump|
2958593|NCT02842892|Other|Countermovement Jump|
2958594|NCT02842879|Experimental|Outpatient Foley cervix priming|Patients randomized to outpatient cervix priming will have the insertion of the catheter in the same conditions defined by the Department protocol for inpatient cervix priming. They will be discharged after a reassuring cardiotocogram following the introduction of the Foley catheter. When discharged, the patients will be instructed to apply manual traction to the catheter every 6 hours and they will be given a written document with all the information that should bring them back to hospital.
2958595|NCT02842879|No Intervention|Inpatient Foley cervix priming|The introduction of a deflated catheter (Foley catheter nº 16F) through the outer cervix orifice is preceded by iodine disinfection of the cervix. The intracervical catheter is distended with 40mL of a saline solution. The end of the catheter is taped to the medial portion of the thigh and manual traction is applied to the catheter every 6 hours. If it is not spontaneously extruded it is removed after 24h. Cervix priming occurs in an inpatient setting.
2958596|NCT02842866|Experimental|MenACYW Conjugate Vaccine Group|Participants randomized to receive a dose of MenACYW conjugate vaccine
2958597|NCT02842866|Active Comparator|Menomune® A/C/Y/W135 Vaccine Group|Participants randomized to receive a dose of Menomune® A/C/Y/W135 Vaccine
2958598|NCT02842853|Experimental|MenACYW conjugate vaccine Lot 1|Participants randomized to receive a dose of MenACYW conjugate vaccine from Lot 1
2958599|NCT02842853|Experimental|MenACYW conjugate vaccine Lot 2|Participants randomized to receive a dose of MenACYW conjugate vaccine from Lot 2
2958600|NCT02842853|Experimental|MenACYW conjugate vaccine Lot 3|Participants randomized to receive a dose of MenACYW conjugate vaccine from Lot 3
2958601|NCT02842853|Active Comparator|Licensed MCV4 vaccine|Participants randomized to receive a dose of licensed MCV4 vaccine
2958602|NCT02842840|Experimental|Patients based intervention|A multifaceted intervention program will use to improve adherence and clinical outcomes in Stroke patients. This intervention focus on behavioral treatment in the patients.
2958603|NCT02842840|Experimental|Family based intervention|Patients and their families will receive a series of educational/motivational interventions.
2958604|NCT02842840|Active Comparator|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 30 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
2958605|NCT02842827|Experimental|Multiple ascending dose|MAD Cohorts using IMG-7289 alone
2958606|NCT02842827|Experimental|Combination Therapy|IMG-7289 in combination with all-trans retinoic acid (ATRA)
2958607|NCT02842827|Experimental|Ascending duration|Treatment duration extension Cohorts using IMG-7289 alone
2958608|NCT02842814|Experimental|Full withdrawal|Intervention: 'Drug free'.
2958609|NCT02842814|Experimental|GC withdrawal|Intervention: 'HCQ' .
2958610|NCT02842814|Experimental|No withdrawal|Intervention: 'GC+HCQ' .
2958611|NCT02842801|Other|Hip Manipulation|Hip manipulation: high velocity low amplitude thrust mobilization
2958647|NCT02842528|Experimental|Alcohol-dependent patients|
2958648|NCT02842528|Active Comparator|First-degree relatives of alcohol-dependent probands|
2958649|NCT02842528|Active Comparator|Healthy Controls|
2958650|NCT02842515||Patients requiring dental avulsion|Patients requiring dental avulsion
2958694|NCT02842164|Other|Foley Catheter Balloon without tension group|The Foley catheter balloon will be just supported by simple taping to the thigh.
2958612|NCT02842788||ARDS patients receiving invasive mechanical ventilation in ICU|"ARDS criteria (Berlin definition) fulfilled the day of the study, whatever the ARDS stage. The onset of ARDS could have been established at any time between ICU admission and study day but ARDS criteria must be still present the day of the study. The ARDS criteria are listed below~Within 1 week of a known clinical insult or new or worsening respiratory symptoms~Bilateral opacities—not fully explained by effusions, lobar/lung collapse, or nodules~Respiratory failure not fully explained by cardiac failure or fluid overload. Need objective assessment (eg, echocardiography) to exclude hydrostatic edema if no risk factor present~PaO2/FIO2 ≤ 300 with Positive end-expiratory pressure (PEEP) ≥ 5 cmH2O~Age ≥ 18 years~Intubated or tracheotomized and mechanically ventilated"
2958613|NCT02842775|Experimental|Dynamic balance exercise group|balance perturbation training
2958614|NCT02842775|No Intervention|Control group|No intervention
2958615|NCT02842762|Sham Comparator|Non-paced|"cardiac surgery~3D TEE measurements of systolic dyssynchrony~right ventricular epicardial pacemaker lead (off)"
2958616|NCT02842762|Experimental|Paced|"The patient is randomized to the order of measurements taken, and serves as his own control.~cardiac surgery~3D TEE measurements of systolic dyssynchrony~right ventricular epicardial pacemaker lead (on)"
2958617|NCT02842749|Experimental|everolimus (single arm)|Everolimus is taken at a starting dose of 10 mg orally once daily.Patients will be provided with adequate supply of study treatment for self-administration at home until at least their next scheduled study visit.All patients will be followed for adverse events and serious adverse events for 30 days following the last dose of study drug. Beyond these 30 days, any serious adverse events that are suspected to be related to the study drug will also be collected
2958618|NCT02842736|Experimental|Endometrial Cryoablation|
2958619|NCT02842723|Experimental|Protontherapy|
2958620|NCT02842710|Experimental|GeneXpert®|Detection is carried out after a sample within the patient's nasal cavity. The swab containing the sample is placed in the PLC GeneXpert® Cepheid . The analysis takes one hour . The results leave automatically.
2958621|NCT02842697|Experimental|Single arm study|"Patients will receive CTA, Doppler ultrasound, HVPG measurement, and vHVPG per protocol.~Intervention: Procedure: HVPG measurement"
2958622|NCT02842684|Experimental|Traumacad software|Preoperative planning of hip prothesis is practiced by layer on radiographs whose scaling is imprecise . The recent TraumaCad system ( Brainlab® ) allows adjustment of the scales for each patient and the virtual positioning of implants to simulate the response to the return of geometric hip parameters
2958623|NCT02842684|No Intervention|without digital planning|Preoperative planning of hip prothesis is practiced by layer on radiographs whose scaling is imprecise
2958624|NCT02842671|Experimental|Assigned Ambassador (Intervention Group)|Patients who were consented, completed the accommodations survey, and for whom a medical student was available during the time of the the procedure will serve as our intervention group. The participants will be assigned an Ambassador throughout the procedure and will complete a patient satisfaction survey afterwards. The investigators hope to enroll 25 controls.
2958625|NCT02842671|No Intervention|Control Group|Patients who were consented, completed the accommodations survey, but for whom a medical student was not available during the time of the patient's procedure will serve as our control group. The controls will fill out both an accommodations survey before and a patient satisfaction survey after the procedure. No ambassador will be assigned for the procedure day. The investigators hope to enroll 25 controls.
2958626|NCT02842658|Active Comparator|A high-intensity interval exercise group|Supervised exercise training with be carried out at the Mayo Clinic Cardiac rehabilitation center on cycle ergometers using EKG telemetry. Treatment will begin one week prior to chemotherapy and is tailored around 8 weeks.
2958627|NCT02842658|Other|An attention-control group|Patients will receive counseling regarding physical activity during chemotherapy. Patients will receive a weekly phone call to maintain physical activity during chemotherapy and compliance will be verified using physical activity diaries and pedometers.
2958628|NCT02842645||Control|Children born at term and not exposed to drugs during pregnancy
2958629|NCT02842645||Case|Case = Children exposed to drugs during pregnancy
2958630|NCT02842632|Other|A virtual teaching|Group A will be introduced to the virtual TEE online (http://pie.med.utoronto.ca/TEE/)
2958631|NCT02842632|Other|B simulator|Group B will be introduced to the simulator (CAE Vimedix Simulator)
2958632|NCT02842632|Other|C hands on OR|group C will be introduced to the TEE training in the operation room.
2958633|NCT02842619|Experimental|Intervention Arm|"Four clinical interventions:~Blood tests - CBC, biochemistry, coagulation, Human immunodeficiency virus (HIV), Hepatitis B, C.~Liposuction - harvest of 50-300ml autologous adipose tissue from the abdomin~Single transplantation of Investigational Medicinal Product (IMP) BonoFill-II in maxillofacial deficient bone~Biopsy - will be performed only upon the placement of dental implants"
2958634|NCT02842606|Experimental|Fiber-enriched pasta|The participants consume whole wheat pasta with added fiber (fiber 12 g fiber/100 g).
2958635|NCT02842606|Active Comparator|Control pasta|The participants consume pasta made from durum wheat semolina (fiber 2.7g/100g).
2958636|NCT02842593|Experimental|Resistance exercise training|Whole-body resistance exercise training 4x/week for 12 weeks. Either 'lower-repetition, heavier-load' or 'higher-repetition, lighter-load' intervention.
2958637|NCT02842593|No Intervention|Non-exercising control|Continue habitual physical activity for 12 weeks.
2958638|NCT02842580|Active Comparator|Standard arm (escalation strategy - arm A)|LV5FU2 (5 FLUOROURACYL)+avastin. After progression: FOLFIRI + avastin. after the 2nd progression:FOLFOX4 (eloxatine)+ avastin.
2958639|NCT02842580|Experimental|Experimental arm (de-escalation strategy -arm B)|(4 cycles of FOLFOXIRI (campto) + avastin and 4 cycles of FOLFIRI + avastin) is followed by maintenance with capecitabine
2958640|NCT02842567|Experimental|TREATED GROUP|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks.
2958641|NCT02842567|Placebo Comparator|PLACEBO GROUP|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
2958642|NCT02842554|Other|DPA|Drug Placebo Administration
2958643|NCT02842554|Other|C|Control
2958644|NCT02842554|Other|EPT|Evoked Pain Training
2958645|NCT02842541|Experimental|Single dose arm|Subjects will receive a single intravitreal dose of EBI-031
2958651|NCT02842502|Experimental|Skin graft pellet|This group concerns patients who are recruited for skin graft procedure leading to the collection of supernumerary biopsies.
2958652|NCT02842489|Experimental|left lateral tilt-down position|patients will be positioned on left lateral tilt-down position during colonoscopy until sigmoid-descending junction were examined, and then patients will be positioned on the left lateral horizontal position during colonoscopy
2958653|NCT02842489|Active Comparator|left lateral horizontal body position|patients will be positioned on the left lateral horizontal position during colonoscopy insertion
2958654|NCT02842476||Disposable Sensor|Adhesive based Pulse Oximeter Probes, Model S0136J
2958655|NCT02842476||Reusable Sensor|Reusable Pulse Oximeter Probes, Model S0080D
2958656|NCT02842476||Control Pulse Oximetry|Reference CO-Oximeters ABL80 Flex OSM (Radiometer), # 302125, 307205 IL682 (Instrumentation Laboratories), # 012511B (ILH), #012511A (ILG)
2958657|NCT02842463||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join rehabilitation program.~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test."
2958658|NCT02842450||training with typical definitions established + photos|A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.
2958659|NCT02842450||Training only with definitions|Interns will receive typical definitions of LAP stages
2958660|NCT02842437|Experimental|Dexmedetomidine|25 patients receive a loading infusion of dexmedetomidine (1ug/kg) for 10min follow by a maintenance infusion (0.5ug/kg·h) continued until the end of the surgery
2958661|NCT02842437|Placebo Comparator|Placebo|25 patients receive matching placebo （normal saline）
2958662|NCT02842424|Experimental|Ramipril Treatment|6 months treatment with the medication Ramipril
2958663|NCT02842411||chronic constipation|patients with chronic constipation based on Rome Ⅳ
2958664|NCT02842398|Experimental|Balance Master Training|Children receive one weekly Balance Master training session, in addition to their weekly physical therapy sessions. During Balance Master training, children practice balance on a Balance Master device that simulates crossing a city street.
2958665|NCT02842398|Active Comparator|Customary Care|Children received their customary scheduled physical therapy sessions, without Balance Master training
2958666|NCT02842385|Active Comparator|Nonsubmerged thick group|Nonsubmerged type of implants placed with thick (>3 mm) soft tissue
2958667|NCT02842385|Active Comparator|Nonsubmerged thin group|Nonsubmerged type of implants placed with thin (<3 mm) soft tissue
2958668|NCT02842385|Active Comparator|Submerged thick group|Submerged type of implants placed with thick (>3 mm) soft tissue
2958669|NCT02842385|Active Comparator|Submerged thin group|Submerged type of implants placed with thin (<3 mm) soft tissue
2958670|NCT02842372||Ectoin Dermatitis Cream 7%|Cream for symptomatic treatment and relief of skin redness and itching experienced with various types of inflammatory dermatoses.
2958671|NCT02842359|Experimental|Rovelito|Fixed-dose combination of irbesartan/atorvastatin will be given orally daily for 28 days
2958672|NCT02842359|Active Comparator|Irbesartan|Irbesartan will be given orally daily for 28 days
2958673|NCT02842359|Active Comparator|Atorvastatin|Atorvastatin will be given orally daily for 28 days
2958674|NCT02842333|Experimental|Additional biological samples|"Blood samples will be realized at inclusion and 6 months after inclusion (optional).~Peripheral Blood Mononuclear Cells (PBMC) will be collected."
2958675|NCT02842320|Experimental|Additional biological samples|Bone marrow sample and blood collected at J0 (screening visit), and at 3, 6, 12, 18 and 24 months and at each additional consultations (relapse ...)
2958676|NCT02842307|Active Comparator|A(senior acupuncturists)|Manual acupuncture implemented by senior acupuncturists (clinical experience >15 years)
2958677|NCT02842307|Active Comparator|B(junior acupuncturists)|Manual acupuncture implemented by junior acupuncturists (clinical experience <5 years)
2958678|NCT02842307|Active Comparator|C(P6 points)|Manual acupuncture on P6 points by junior acupuncturists (clinical experience <5 years)
2958679|NCT02842307|No Intervention|D(no acupuncture)|No acupuncture treatment
2958680|NCT02842294||irinotecan based chemotherapy|patients having a 1st line doublet chemotherapy including irinotecan
2958681|NCT02842294||oxaliplatin based chemotherapy|patients having a 1st line doublet chemotherapy including oxaliplatin
2958682|NCT02842294||triplet chemotherapy|patient having a 1st line triplet chemotherapy including oxaliplatin / irinotecan this cohort was added while primary objective was to compare doublet chemotherapy
2958683|NCT02842281|Active Comparator|Fructan|Fructans will be provided for 72 hours.
2958684|NCT02842281|Placebo Comparator|Maltodextrin|Maltodextrin will be provided for 72 hours.
2958685|NCT02842268|Experimental|BAY987517|Subject will self-apply the test sunscreen formula to his/her face with the goal of applying 0.65 to 0.85 grams.Subject should sweat profusely.
2958686|NCT02842255|Experimental|Healthy volunteers|
2958687|NCT02842242|Experimental|Open Label|MYK-461
2958688|NCT02842229||Patients with Haematologic Neoplasms|"Patients with Myelodysplastic Syndromes (MDS), any IPSS (International Prognostic Scoring System) risk, or Acute Myeloid Leukemia (AML) who participated in the Geriatric Assessment in Haematology (GAH) study(CEL-GAH-2011-01).~Patients with Multiple Myeloma (MM), symptomatic or asymptomatic who participated in the Geriatric Assessment in Haematology (GAH) study (CEL-GAH-2011-01).~Patients with Chronic Lymphocytic Leukemia who participated in the Geriatric Assessment in Haematology (GAH) study (CEL-GAH-2011-01)."
2958689|NCT02842190|Active Comparator|NIPPV|NIPPV after ekstubation
2958690|NCT02842190|No Intervention|BIPAP after ekstubation|BIPAP after ekstubation
2958691|NCT02842177|Active Comparator|Group I (classic method)|
2958692|NCT02842177|Active Comparator|uterine sound sparing group|
2958693|NCT02842164|Other|Foley Catheter Balloon with Tension group|a 16 French transcervical Foley catheter balloon will be advanced to or past the internal os and the balloon will be filled. Then catheter will be placed on gentle traction by taping the distal tip to the medial thigh for maximum 24 hours. To maintain gentle traction, periodic repositioning of the distal tip on the thigh will be necessary.
2958695|NCT02842151|Other|Manifest refraction|Manifest refraction performed by autorefraction (automated) and manual procedures (standard). Participant implanted with ACRYSOF® IQ Monofocal IOL Model SN60WF. Autorefraction performed by Topcon® KR-1W Wave-Front Analyzer.
2958696|NCT02842138|Experimental|CD19 CAR T cells|A standard 3+3 dose escalation approach aimed to assess the safety and efficacy of autologous anti-CD19 CAR T cells will be applied. Five CAR T dosage will be tested in this study: 5×10^4 /kg ， 1×10^5 /kg ，1×10^6 /kg，3×10^6/Kg, and 6×10^6/Kg.
2958697|NCT02842125|Experimental|Ad-p53 with Xeloda 33.3% of patients|Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and daily metronomic Xeloda (capecetabine), at a dose of 625 mg/m2 BID continuously.
2958698|NCT02842125|Experimental|Ad-p53 with Keytruda 33.3% of patients|Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and infusions of pembrolizumab every 3 weeks.
2958699|NCT02842125|Experimental|Ad-p53 with Opdivo 33.3% of patients|Up to 12 patients treated with intra-tumoral Ad-P53 3 times week 1 of each cycle, dose determined by tumor size, in combination with IV nivolumab (Opdivo) 480 mg, every 4 weeks.
2958700|NCT02842112||CD34+ CD38-|A first cell population, which expressed the CD34 antigen and lacked CD38 (CD34+ CD38-), and often contained very few events requiring to be tightly clustered in a forward light scatter /side light scatter (FSC/ SSC) and CD45/SSC plot;
2958701|NCT02842112||CD34+ CD38low|A second population characterized by expression of the CD34 antigen and by a low density of CD38 antigen (CD34+ CD38low)
2958702|NCT02842112||CD34+ CD38+|A third population characterized by a large density of CD38 and CD34 antigens (CD34+ CD38+). Antigens were expressed as percent positively stained cells as well as intensity of the fluorescence signal quantified as mean fluorescence intensity (MFI) from CD34+ gated cells and from CD45low/SSC total immature cells
2958703|NCT02842099|Experimental|TA or TAC plus X|Standard chemotherapy (TA or TAC) followed by capecitabine 2.5g, po, qd for one year.
2958704|NCT02842099|Active Comparator|TA or TAC|Standard chemotherapy (TA or TAC) followed by no more chemotherapy
2958705|NCT02842086|Experimental|F/TAF|F/TAF+ F/TDF placebo for at least 96 weeks
2958706|NCT02842086|Experimental|F/TDF|F/TDF+ F/TAF placebo for at least 96 weeks
2958707|NCT02842086|Experimental|Open-label Extension|Once all participants have been on blinded treatment for at least 96 weeks, the study will be unblinded and participants will be offered the option to continue on open-label F/TAF treatment in the open-label extension for 48 weeks.
2958708|NCT02842073|Experimental|Medication Naltrexone and Buproprion|Investigators will use standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) and naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
2958709|NCT02842060|Experimental|myDEx Intervention|The proposed intervention will consist of a 6-session web-based program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, YMSM will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help YMSM consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
2958710|NCT02842060|Active Comparator|Non-tailored HIV Prevention|The investigators will create a 6-session web-based attention-control comparison to match myDEx in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites.
2958711|NCT02842047|Experimental|End of Life Care with Meditation|The intervention has two content components: end of life planning education (using end of life planning videos) and strategies and kindness based meditation (using the Stop, Breathe & Think™ app). The activities comprising these components work together to improve both analytic neural processing (e.g. improving knowledge about goal setting and EOL planning, learning self-monitoring of EOL values and goals of care, and self-regulation skills of monitoring symptoms of distress and anxiety) and emotional neural processing (e.g. teaching participants to experience the moment non-judgmentally and directing thoughts to think positive thoughts and feel positive feelings like kindness and compassion.
2958712|NCT02842047|Active Comparator|Meditation Only|This arm has the single content component of kindness based meditation delivered by using the Stop, Breathe & Think™ application. This group will also be instructed to view 3 caregiver wellness videos.
2958713|NCT02842034|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 120% of the resting motor threshold (RMT). Stimulation will be delivered at 10 Hz with 60 stimulation trains of 50 stimuli each (i.e., 3000 stimuli) and an intertrain interval of 10 sec. Treatment will be applied in sequential order to the dorsomedial prefrontal cortices (DMPFC).
2958714|NCT02842034|Sham Comparator|Sham rTMS|Sham stimulation will be delivered using the same stimulation parameters and at the same site of active treatment, but the coil will be reversed. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
2958715|NCT02842021|Active Comparator|S2G6T-1|Topical cream
2958716|NCT02842021|Active Comparator|S2G6T-2|Topical Cream
2958717|NCT02842021|Active Comparator|S2G6T-3|Topical Cream
2958718|NCT02842021|Placebo Comparator|S2G6T-4|Topical Cream
2958719|NCT02842008|Experimental|Exercise group|Wheelchair basketball players participating in home therapeutic exercise program that use the protocol of postural hygiene.
2958720|NCT02842008|No Intervention|Control group|Wheelchair basketball players that not participate in home therapeutic exercise program and use a protocol of postural hygiene provided.
2958721|NCT02841995|Experimental|KD025 200 mg QD|Two 100 mg capsules (200 mg) of KD025 once daily. Subjects should take 2 capsules with their morning meal or within 5 minutes of completing a meal.
2958722|NCT02841995|Experimental|KD025 200 mg BID|Two 100 mg capsules (200 mg) of KD025 twice daily. Subjects should take 2 capsules with their morning meal or within 5 minutes of completing a meal and 2 capsules with their evening meal or within 5 minutes of completing a meal.
2958935|NCT02840461|Active Comparator|SoolantraTM (ivermectin) Cream, 1%|reference product, manufactured by Galderma Laboratories, L.P.
2958723|NCT02841995|Experimental|KD025 400 mg QD|Four 100 mg capsules (400 mg) of KD025 once daily. Subjects should take 4 capsules with their morning meal or within 5 minutes of completing a meal.
2958724|NCT02841982|Experimental|single-injection QLB(quadratus lumborum block)|Single-injection of QLB is given preoperatively + postoperative IPCA(intravenous patient controlled analgesia)
2958725|NCT02841982|Active Comparator|IPCA|postoperative IPCA is given alone
2958726|NCT02841969|Active Comparator|Normal care - Prontosan|Patient wounds will be irrigated using the in-use product (Prontosan)
2958727|NCT02841969|Experimental|Investigational arm - Electrolysed water|Patient wounds will be irrigated using electrolysed water
2958728|NCT02841956|Experimental|Electronic Screen + Education (Phase 1)|Electronic screening of participants and targeted education of providers according to standard EDAPT model.
2958729|NCT02841956|Active Comparator|Targeted Provider Education (Phase 1)|Targeted education of providers according to standard EDAPT model.
2958730|NCT02841956|Experimental|Community Mobile Engagement (Phase 2)|Clinical intake interviews take place via videoconference at a location in the community convenient for the participant.
2958731|NCT02841956|Active Comparator|Clinic based Engagement (Phase 2)|Clinical intake interviews take place at the EDAPT clinic.
2958732|NCT02841930|Experimental|Member|"The member group will be able to join ActionHealth NYC program, where they are assigned a primary care physician and have a standardized fee scale for services obtained in network. Laboratory, diagnostic, and specialty services can be obtained at network H+H locations. They will be offered recommended USPSTF A+B tests/screenings, HIV and TB screening (if indicated), and care coordination. If they are deemed high risk, enhanced care coordination services will be offered."
2958733|NCT02841930|No Intervention|Study|The study group will be counseled on their options to access health care, including at public hospitals and community health centers. They will receive no additional services from the study.
2958734|NCT02841917||Transcatheter Aortic Valve Replacement|ROS Post TAVR
2958735|NCT02841917||Surgical Aortic Valve Replacement|ROS Post SAVR
2958736|NCT02841904|Other|CLE|CLE assessed by the pathologist
2958737|NCT02841904|Active Comparator|Biopsy|Histology assessed by the pathologist
2958738|NCT02841891|Experimental|Test|Test group will receive Sylys® Surgical Sealant as an adjunct to standard closure of stapled anastomosis in colectomy procedure.
2958739|NCT02841891|Active Comparator|Control|Control group will receive standard of care closure of stapled anastomosis in colectomy procedure without Sylys® Surgical Sealant.
2958740|NCT02841878|Other|analysis on colorectal biopsy|"Proteases activity (cystein and serin proteases)~Proteases inhibitors genes expression (Serpins A1 / E1)~Colonic biopsies permeabilityTight junctions genes expression~Cytokines genes expression (TNFalpha, interleukines)~Cellularity on histologic sections"
2958741|NCT02841839|Experimental|2-step system|Subjects are to brush with 2-step system for 4 weeks; stannous fluoride
2958742|NCT02841826|Other|Group I: IUD without uterine sound group|Transvaginal ultrasound before to intrauterine contraceptive device insertion without uterine sounding.
2958743|NCT02841826|Other|Group II: IUD with uterine sound|Intrauterine contraceptive device inserted by classic method
2958744|NCT02841813||The normal mothers group|No intervention
2958745|NCT02841813||The normal full-term infants group|No intervention
2958746|NCT02841813||The preterm mothers group|No intervention
2958747|NCT02841813||The preterms group|No intervention
2958748|NCT02841800|Experimental|Intra-luminal radiofrequency ablation|Intra-luminal radiofrequency ablation Admission for endoscopic retrograde cholangiopancreatography (ERCP) and stent placement after radiofrequency ablation. ERCP should be performed for 2 times with an interval of two months.
2958749|NCT02841787|Experimental|Social Network|iCBT for late life depression with social network included
2958750|NCT02841787|Experimental|Without Social Network|iCBT for late life depression without social network included
2958751|NCT02841787|No Intervention|Wait List Control|Waiting period, no intervention administered. Receive iCBT for late life depression after waiting period.
2958752|NCT02841774|Active Comparator|Moderate Intensity Group|pravastatin 40mg daily for 12 weeks
2958753|NCT02841774|Experimental|High Intensity Group|rosuvastatin 20 - 40 mg daily for 12 weeks
2958754|NCT02841761|Experimental|Treatment A (Midazolam)|Single dose of Midazolam 8 mg on Day 1
2958755|NCT02841761|Experimental|Treatment B1 (ACT-132577)|Single dose of ACT-132577 150 mg on Day 2; single dose of ACT-132577 50 mg on Day 3, Day 4, and Day 5.
2958756|NCT02841761|Experimental|Treatment B2 (Midazolam + ACT-132577)|Single dose of Midazolam 8 mg and single dose of ACT-132577 50 mg on Day 6
2958757|NCT02841748|Experimental|Pembrolizumab|200mg, every three weeks, iv, x 1 year
2958758|NCT02841748|Experimental|Placebo|iv, every 3 weeks, x 1 year
2958759|NCT02841735||Smartphone breathalyzer device & app|This is a small device that attaches to a smartphone with an accompanying app that produces accurate breath alcohol readings when a user blows into a small tube attached to the device. Participants randomized to this study condition will have the opportunity to use this device and app during an alcohol drinking session in a simulated laboratory.
2958760|NCT02841735||BAC estimator app|This is an app that produces estimated blood alcohol content (eBAC) readings based on sex, weight, number of drinks and time taken to consume drinks. Participants randomized to this study condition will have the opportunity to use this app during an alcohol drinking session in a simulated laboratory.
2958761|NCT02841735||Text Messaging|A procedure whereby one sends a text message to the phone one is using after each alcoholic drink. Participants randomized to this study condition will have the opportunity to the text messaging procedure during an alcohol drinking session in a simulated laboratory.
2958762|NCT02841722|Other|Biological samples|Only one arm in this pilot study. All patient will have a follow up and treatment as per standard care for this pathology. Specifically for the study all patients will have 8 additional blood samples to be drawn during the first 2 cycles of treatment (1 cycles is 21 days).
2958763|NCT02841709|Experimental|Sequence 1|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D4, D2, D3, D1 and P, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12- day washout.
2958764|NCT02841709|Experimental|Sequence 2|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D2, P, D4, D3 and D1, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12- day washout.
2958765|NCT02841709|Experimental|Sequence 3|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D3, D1, D2, P and D4, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12- day washout.
2958766|NCT02841709|Experimental|Sequence 4|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: P, D4, D1, D2, D3, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12- day washout.
2958767|NCT02841709|Experimental|Sequence 5|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D1, D3, P, D4 and D2 with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12- day washout.
2958768|NCT02841696||Hypertensive people|Hypertensive people recruited 10 years ago before any anti-hypertensive treatment
2958769|NCT02841683|Active Comparator|Lifestyle counseling|A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
2958770|NCT02841683|No Intervention|Current practices|Current practices of smoking cessation in France
2958771|NCT02841644||Traumatic Arthrotomy|Patient diagnosed with traumatic arthrotomy.
2958772|NCT02841631||Post-Tonsillectomy|Subjects undergoing tonsillectomy for non-cancer reasons including operations for: recurrent tonsillitis, asymmetric tonsils, snoring surgery or obstructive sleep apnoea.
2958773|NCT02841618|Experimental|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (10g grapeseed oil) 1 per day for 2 weeks
2958774|NCT02841618|Placebo Comparator|High Oleic Acid Healthy Cookies|High Oleic Acid Healthy Cookies (10g safflower oil) 1 per day for 2 weeks
2958775|NCT02841605|Other|AD group|AD group: rectosigmoidospcopy with biopsies of colon
2958776|NCT02841605|Other|PD group|PD group: rectosigmoidospcopy with biopsies of colon
2958777|NCT02841605|Other|PSP group|PSP group: rectosigmoidospcopy with biopsies of colon
2958778|NCT02841605|Other|Patient eligible for colorectal cancer screening|Patient eligible for colorectal cancer screening: colonoscopy with biopsies of colon
2958779|NCT02841592|Active Comparator|Non-rebreather|This group will have a non-rebreather mask applied to the face and they will receive the flush rate oxygen intervention
2958780|NCT02841592|Active Comparator|Bag-valve-mask|With each inspiration from the subject, the ventilation bag will be gently squeezed to provide positive pressure and augment the amount of oxygen that is received by the subject for each breath. This group will receive the flush rate oxygen with assist intervention.
2958781|NCT02841579|Experimental|Osimertinib|The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.
2958782|NCT02841566||Problem glambers|The group of problem gamblers will consist of patients already included in the cohort EVALADD [favorable opinion of GNEDS 06/09/2012; CNIL authorization No. 912631 of 10.09.2013], and the data will be extracted directly from the database EVALADD
2958783|NCT02841566||Non-problem gamblers|The subjects of this group will be matched on sex, age and education level with the group problem gamblers. They will be recruited over the Internet and using the volunteer base [normal declaration with the CNIL: No. 1761543 of 21/05/2014].
2958784|NCT02841540|Experimental|H3B-8800 (escalation and expansion)|H3B-8800 Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes/ Low Risk Myelodysplastic Syndromes/ Chronic Myelomonocytic Leukemia.
2958785|NCT02841527|Active Comparator|Gastric Band|The procedure will involve an operation in which a gastric Band and port will be fitted using a laparoscopic technique.
2958786|NCT02841527|Active Comparator|Gastric Bypass|The procedure will involve a laparoscopic operation in which a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.
2958787|NCT02841527|Active Comparator|Sleeve Gastrectomy|The procedure involves an operation which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach using a laparoscopic technique.
2958788|NCT02841514|Experimental|treatment group|the operator will administer the Y10 whitening toothpaste in to the attachable mouthpiece and place it in the subject's mouth and turn on the device RF. After treating the patients for 30 minutes the operator will turn off the device and retrieve the mouthpiece from the mouth.
2958789|NCT02841514|Placebo Comparator|placebo group|the operator will administer an off the shelf regular toothpaste in to the attachable mouthpiece and place it in the subject's mouth. At this point the operator will switch on the device but the RF will not be activated. After 30 minutes the operator will turn off the device and retrieve the mouthpiece from the mouth.
2958790|NCT02841501||Candidemia patients|These patients are included in the study after the reception of a positive blood culture for Candida sp.
2958791|NCT02841501||Control patients|"These patients are matched on case patients on the following criteria:~Age+/-5 years~length of hospitalisation~type of ward~type of surgery for surgical patients~IGS2 for intensive care patients"
2958792|NCT02841488|Active Comparator|Continuous nerve block|Continuous peripheral sciatic nerve block through popliteal perineural catheter with ropivacaine
2958793|NCT02841488|Active Comparator|Systemic analgesia|Intravenous fentanyl patient controlled analgesia device
2958794|NCT02841462|Experimental|Bursitis|Intra-bursal thermal ablation
2958795|NCT02841449|Experimental|Hypohydrated|After being dehydrated in the heat tent, participants in this trial arm will be given 3 mL/kg lean body mass to consume over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass would consume 191 mL water [63.75 kg * 3 mL])
2958936|NCT02840461|Placebo Comparator|Placebo/Vehicle cream|Placebo, manufactured by Actavis Laboratories UT, Inc.
2958796|NCT02841449|Experimental|Rehydrated|After being dehydrated in the heat tent, participants in this trial arm will be given 40 mL/kg lean body mass plus 150 % of their water losses (from the heat tent procedure) over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass and lost 1 % of their body mass in the heat tent (0.75 kg) would consume 2550 mL [63.75 kg * 40 mL] + 1125 mL [750 g * 1.5], totalling 3675 mL).
2958797|NCT02841436|Experimental|irreversible electroporation (IRE)|IRE (AngioDynamics, NY) To use 2 to 6 unipolar electrodes in a predetermined grid pattern. 90 pulses of 2,000 - 3,000 V were applied with a pulse generator (AngioDynamics, NY) across the gap between the electrodes for 100 microseconds (0.1 msec) per each ablation.
2958798|NCT02841423|Experimental|INTRAVENOUS ANESTHESIA|neuropsychological test battery
2958799|NCT02841423|Experimental|CLOSED LOOP ANESTHESIA|neuropsychological test battery
2958800|NCT02841410|Other|Healthy Volunteer|
2958801|NCT02841384|Other|Group taping McConnell|Taping patellar McConnell: Lateralization correction of the patella with self-adhesive rigid bandage Johnson® positioned lateral border of the patella to the medial condyle of the femur, allowing the lifting of the medial border of the patella and stretching of the knee lateral structures.
2958802|NCT02841384|Other|Group placebo taping|Placebo taping through vertical application of patellar rigid taping, with the knee in flexion without medialization of the patella.
2958803|NCT02841371||chronic kidney disease (CKD)|chronic kidney disease (CKD) is defined as abnormalities of kidney structure (markers of kidney damage) or function (decreased GFR by 99mTc-DTPA renal clearance and/or eGFR), present for more than 3 months.
2958804|NCT02841371||no CKD|Suspected chronic kidney disease but no chronic kidney disease after screening by abnormalities of kidney structure (markers of kidney damage) or function (decreased GFR by 99mTc-DTPA renal clearance and/or eGFR), present for less than 3 months, or no abnormalities of kidney structure or function.
2958805|NCT02841358|Other|Psychiatric adults patients presenting psychologic disorders|
2958806|NCT02841345|Other|Bipolar|bipolar patients type I or II (DSM-IV TR), euthymic phase
2958807|NCT02841345|Other|Schizophrenic|schizophrenic loss or paranoid or undifferentiated patients
2958808|NCT02841345|Other|Control|control group (paired in age and sex for patients)
2958809|NCT02841332|Experimental|Patients with glioblastoma|"Patient with histologically proved glioblastoma diagnostic will receive the following interventions :~Cerebral magnetic resonance imagery~Tomography emission positron with F-MISO~Bevacizumab administration~Clinical examination"
2958810|NCT02841319|Experimental|Intervention|Virtual reality exercises using Hand Tutor for 8 weeks
2958811|NCT02841319|No Intervention|Control|Home exercises for 8 weeks
2958812|NCT02841306|Active Comparator|3-5 hours|Duration between oral UDCA intake and surgery of 3-5 hours.
2958813|NCT02841306|Active Comparator|6-8 hours|Duration between oral UDCA intake and surgery of 6-8 hours.
2958814|NCT02841306|Active Comparator|9-12 hours|Duration between oral UDCA intake and surgery of 9-12 hours.
2958815|NCT02841306|Active Comparator|> 12 hours|Duration between oral UDCA intake and surgery of >12 hours.
2958816|NCT02841306|No Intervention|Control|No medication
2958817|NCT02841293||Group with biologic mesh|"Data about Pelvic reconstruction using biologic mesh, cut to fit the patients perineal defect.~Clinical and medical parameters~Utility Cost evaluation"
2958818|NCT02841293||Group with primary perineal closure|"Data about subcutaneous tissue approximation. Then skin closure with absorbable interrupted sutures~Clinical and medical parameters~Utility Cost evaluation"
2958819|NCT02841280|Experimental|Chlorthalidone|Subjects with stage 4 chronic kidney disease (CKD) and poorly controlled hypertension confirmed by 24 hour ambulatory blood pressure monitoring will be randomized into two groups, one receiving placebo and one receiving a diuretic called chlorthalidone (12.5 mg at randomization). Doubling of the dose of the diuretic (up to 50 mg) or placebo will occur every 4 weeks if required by home blood pressure (BP) results.
2958820|NCT02841280|Placebo Comparator|Placebo|Subjects with stage 4 CKD and poorly controlled hypertension confirmed by 24 hour ambulatory blood pressure monitoring will be randomized into two groups, one receiving placebo and one receiving a diuretic called chlorthalidone (12.5 mg at randomization). Doubling of the dose of the diuretic (up to 50 mg) or placebo will occur every 4 weeks if required by home BP results.
2958821|NCT02841267|Active Comparator|Low Dose, Cohort 1|4 subjects will be enrolled in cohort 1 and will receive an initial dose of 5mg/kg PF 06252616 IV every 4 weeks. Following 32 weeks of treatment and a safety review, if no stopping rules have been met, subjects will be receive an additional 32 weeks of treatment with 40 mg/kg PF 06252616 IV every 4 weeks.
2958822|NCT02841267|Active Comparator|Middle dose, Cohort 2|8 subjects will be enrolled in cohort 2 and receive 20 mg/kg of PF 06252616 IV every 4 weeks for 32 weeks.
2958823|NCT02841267|Active Comparator|High dose, Cohort 3|8 subjects will be enrolled in cohort 3 and receive 40 mg/kg of PF06252616 IV every 4 weeks for 32 weeks.
2958824|NCT02841241|Experimental|Esmolol|Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
2958825|NCT02841228|Experimental|IMRT + SIB + Chemotherapy|For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction, SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
2958826|NCT02841215|Experimental|Oral ivermectin 400 µg/kg|Oral ivermectin 400 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)
2958827|NCT02841215|Active Comparator|Oral ivermectin 200 µg/kg|Oral ivermectin 200 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)
2958828|NCT02841202|Active Comparator|oral contraceptive pills group|healthy women using oral contraceptive pills for only contraception for more than one year was called OCP group
2958829|NCT02841202|No Intervention|control group|The second group was called control group consisting 20 healthy women and using no drug
2958830|NCT02841189|Other|Video laryngoscope intubation|The King Vision Video Laryngoscope will be used for intubation
2958831|NCT02841176|Experimental|Experimental|Thermography and Golimumab (solution for subcutaneous injection, 50 or 100 mg, monthly)
2959483|NCT02836587|No Intervention|control|Control group will have no assigned intervention.
2958832|NCT02841163||Lumbar/cervical disc herniation group|Lumbar and cervical intervertebral disc herniation patients are administered integrative Korean medicine treatment consisting of herbal medicine, acupuncture, pharmacopuncture, bee venom pharmacopuncture, and Chuna manipulation.
2958833|NCT02841150|Experimental|Treatment Sequence 1|Participants will receive treatment A, on Day 1 of Intervention Period 1 followed by treatment B , on Day 1 of Intervention Period 2 followed by treatment A, Day 1 of Intervention Period 3 and then followed by treatment B, on Day 1 of Intervention Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
2958834|NCT02841150|Experimental|Treatment Sequence 2|Participants will receive treatment B, on Day 1 of Intervention Period 1 followed by treatment A, on Day 1 of Intervention Period 2 followed by treatment B, Day 1 of Intervention Period 3 and then followed by treatment A, on Day 1 of Intervention Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
2958835|NCT02841137|Experimental|progesterone 5 mg|progesterone 5 mg tablet
2958836|NCT02841137|Experimental|progesterone 10 mg|progesterone 10 mg tablet
2958837|NCT02841137|Experimental|progesterone 20 mg|progesterone 20 mg tablet
2958838|NCT02841137|Active Comparator|progesterone 100 mg|progesterone 100 mg capsule
2958839|NCT02841124|Other|Qualitative research|Semi-structured interviews
2958840|NCT02841098|Experimental|Carotid endarterectomy combined with optimal medical therapy|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)
2958841|NCT02841098|Active Comparator|Optimal medical therapy (OMT)|Optimal medical therapy (OMT)
2958842|NCT02841085||Genetic sample|Blood sample or saliva collection to genetic research
2958843|NCT02841059||Laparoscopic subtotal hysterectomy|women with benign gynecology disease and decided to receive laparoscopic subtotal hysterectomy (LSH) after discussion with her surgeon.
2958844|NCT02841059||Laparoscopic CLSH|women with benign gynecology disease and decided to receive laparoscopic cervical ligament sparing hysterectomy (CLSH) after discussion with her surgeon.
2958845|NCT02841059||Laparoscopic AVH|women with benign gynecology disease and decided to receive laparoscopic assisted vaginal hysterectomy (LAVH) after discussion with her surgeon.
2958846|NCT02841046|Other|group cardiac index|the treatment scheme of goal-directed fluid therapy(GDFT) use cardiac index（CI） as the primary judgment in group cardiac index,Patients in group cardiac index received a therapy with the goal of CI was no less than 2.5L•min-1•m-2 .
2958847|NCT02841046|Experimental|group Stroke Volume Variation|the treatment scheme of goal-directed fluid therapy(GDFT) use Stroke Volume Variation（SVV）and cardiac index（CI）as the primary judgment in group Stroke Volume Variation,Patients in group Stroke Volume Variation received a therapy with SVV was less than 12% and CI was no less than 2.5L•min-1•m-2 .
2958848|NCT02841033|Experimental|Daratumumab|Daratumumab, 16mg/kg body weight in 500mL once weekly for two months, then every 2 weeks for four months, then once each month. (first dose is 8mg/kg body weight in 500mL)
2958849|NCT02841020|No Intervention|Control SOC|Standard of care is followed
2958850|NCT02841020|Experimental|Experimental additional biopsy|Additional biopsy
2958851|NCT02841007|Experimental|geko device arm|Patients consenting to take part will receive the geko device prior to surgery to internally fixate their fractured ankle, to reduce and prevent oedema
2958852|NCT02840994|Experimental|CV301 + Pembrolizumab|CV301 + Pembrolizumab (Phase 2 portion of the trial)
2958853|NCT02840994|Active Comparator|Pembrolizumab|Pembrolizumab (Phase 2 portion of the trial)
2958854|NCT02840955|Active Comparator|Staphefekt SA.100|Staphefekt SA.100 cream, twice daily on (lesional) skin during 12 weeks
2958855|NCT02840955|Placebo Comparator|Placebo|Placebo (Gladskin cream without the Staphefekt protein), twice daily on (lesional) skin during 12 weeks
2958856|NCT02840942|No Intervention|Non-robot|Patients will interact with Child Life as per usual routine, no robot condition
2958857|NCT02840942|Experimental|Coping Robot|Robot will play coping game with children. Robot will speak and child will respond by touching tablet. Child life still present.
2958858|NCT02840942|Experimental|Non-coping Robot|Robot will play distraction only game, in addition to Child Life and routine cares
2958859|NCT02840929|Experimental|Second-look OGD group|"Second-look OGD within 16 to 24 hours after primary OGD, in addition to standard care (esomeprazole infusion for three days, followed by oral esomeprazole.~OGD will be offered if signs of rebleeding present)"
2958860|NCT02840929|Active Comparator|Standard care group|Esomeprazole infusion for three days, followed by oral esomeprazole. OGD will be offered if signs of rebleeding present
2958861|NCT02840916|Experimental|verum laser acupuncture|verum laser acupuncture
2958862|NCT02840916|Sham Comparator|sham laser acupuncture|sham laser acupuncture (no laser output)
2958863|NCT02840903||Setting 1 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
2958864|NCT02840903||Setting 2 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.65 ml/kg BW, tube voltage = 80 kvp
2958865|NCT02840903||Setting 3 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
2958866|NCT02840903||Setting 4 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 100 kvp
2958867|NCT02840903||Setting 5 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
2958868|NCT02840903||Setting 6 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.65 ml/kg BW, tube voltage = 80 kvp
2958869|NCT02840903||Setting 7 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
2958870|NCT02840903||Setting 8 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 100 kvp
2958871|NCT02840890|Experimental|experimental|Patients will have a visceral osteopathic technique perform with continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
2958872|NCT02840890|Placebo Comparator|Placebo|patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
2958873|NCT02840877|Other|DOT Adherence Monitoring|Daily adherence monitoring by study-employed directly observed therapy (DOT) worker on weekdays throughout the course of TB therapy
2958874|NCT02840864|Experimental|Arm 1|Sonographically assisted breast surgery
2958875|NCT02840864|Active Comparator|Arm 2|Conventional breast surgery
2958876|NCT02840851||Healthy young women|Healthy young women between the age of 20-34 years.
2958877|NCT02840851||Healthy young men|Healthy young men between the age of 20-34 years.
2958878|NCT02840851||Healthy older women|Healthy older women between the age of 50-64 years.
2958879|NCT02840851||Healthy older men|Healthy older men between the age of 50-64 years.
2958880|NCT02840812|Experimental|Renal function impaired|Subject with Severe Impaired Renal Function. Nemonoxacin Malate Capsules 500mg single dose oral
2958881|NCT02840812|Experimental|Healthy Subjects|Healthy volunteers. Nemonoxacin Malate Capsules 500mg single dose oral.
2958882|NCT02840799|Experimental|Potassium Nitrate (KNO3)|Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.
2958883|NCT02840799|Placebo Comparator|Potassium Chloride (KCl)|"Potassium Chloride (KCl) is the placebo (control drug) in this trial.~Potassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks."
2958884|NCT02840786|Active Comparator|Intervention: Stents|Stents group
2958885|NCT02840786|Active Comparator|Intervention: Atherectomy|Direct Atherectomy group
2958886|NCT02840773|Active Comparator|Test group-baseline|Press-fit implant connection was monitored at baseline
2958887|NCT02840773|Active Comparator|Test group-12 month|Press-fit implant connection was monitored at 12 month after prosthesis delivered.
2958888|NCT02840773|Active Comparator|Control group-baseline|Screw-retained connection was monitored at baseline
2958889|NCT02840773|Active Comparator|Control group-12 month|Screw-retained connection was monitored at 12 month after prosthesis delivered.
2958890|NCT02840760|Active Comparator|tardive dyskinesia group|tardive dyskinesia group will be delivered at an intensity that is 80% of the resting motor threshold (RMT). Stimulation will be delivered at 10 Hz with 60 stimulation trains of 30 stimuli each (i.e., 1800 stimuli) and an intertrain interval of 12 sec in primary motor cortex（M1）.
2958891|NCT02840760|No Intervention|Healthy control group|
2958892|NCT02840747||Patients with CTCL|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with CTCL (according to World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) criteria).
2958893|NCT02840747||Patients with benign dermatoses|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with benign dermatoses, including but not limited to conditions such as eczema, psoriasis, and dermatitis.
2958894|NCT02840747||Healthy Controls|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from healthy volunteers.
2958895|NCT02840734|Experimental|Kinesio taping|All subjects wore an eye mask and the taped leg was covered by clothes for preventing subjects and researchers from identifying different tapings due to double-blinding. Subjects layed down on the mat in a supine position with the hip flexed 30º and the knee flexed 60º. Y type tape was applied from a point 10 cm below the anterior superior iliac spine, bisected at the junction between quadriceps femoris tendon and the patella, ending at its inferior side. And another Y type tape was applied from the tibial tuberosity, bisected at the junction between patella tendon and the patella, ending at its superior side. The first 5 cm tape was not stretched and acted as the anchor. I type tapes were applied downward and inward to the superior and inferior meniscus of the patella respectively.
2958896|NCT02840734|Placebo Comparator|Placebo taping|Placebo tapes (3M tape) were applied with same method with Kinesio taping.
2958897|NCT02840734|No Intervention|No taping|In case of the no taping condition, the subject was treated along the same procedure which was closed subject's eyes with eye mask and covered the legs with clothes although applied anything on their legs. It might be able to minimize the error, because the researchers did not realize which condition the subject had.
2958898|NCT02840721|Experimental|PF-06480605|PF-06480605 500 mg IV Q2W X 7 doses
2958899|NCT02840708|Active Comparator|125mcg|SK-1401 125mcg single inhalation
2958900|NCT02840708|Active Comparator|250mcg|SK-1401 250mcg single inhalation
2958901|NCT02840708|Active Comparator|500mcg|SK-1401 500mcg single inhalation
2958902|NCT02840695||AS patients|Patients registered in the Swedish Patient Registry with active AS treated with or without biological DMARD according to the Swedish Prescribed Drugs Registry, with or without spinal fractures
2958903|NCT02840669|Other|Friedreich's Ataxia|
2958904|NCT02840669|Other|Healthy Volunteers (Controls)|
2958905|NCT02840656||healthy adult subject|oropharyngeal and rectal swabbing to collect Gram-negative bacilli
2958906|NCT02840643|Experimental|Constraint Therapy and Bimanual Therapy|Children in this arm will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Hand Therapy (constraint therapy), followed by 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Bimanual Hand Therapy (bimanual therapy). During constraint therapy, children will wear a mitt over their less-impaired hand and actively use their more-impaired hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements. During bimanual therapy, children will actively use both hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements.
2958937|NCT02840435|Active Comparator|North Carolina Quit Line: Quit for Life|Participants will be connected to the 'Quit for Life' program offered through the North Carolina Quit Line.
2958938|NCT02840435|Experimental|Sit to Quit|Participants will be connected to the 'Sit to Quit' program offered through the Duke Smoking Cessation Program.
2958939|NCT02840409|Active Comparator|Arm A|68 weeks of single agent Vinblastine administered once weekly IV
2958907|NCT02840643|Experimental|Bimanual Therapy and Constraint Therapy|Children in this arm will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Bimanual Hand Therapy (bimanual therapy), followed by 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Hand Therapy (constraint therapy). During bimanual therapy, children will actively use both hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements. During constraint therapy, children will wear a mitt over their less-impaired hand and actively use their more-impaired hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements.
2958908|NCT02840630|No Intervention|Non-diabetic group|Non-diabetic volunteers will be recruited for baseline data. They will only be required to provide dried blood samples (DBS) samples and information at week 0. They have to collect finger prick DBS, weigh themselves and fill in food frequency questionnaire only at one time point.
2958909|NCT02840630|No Intervention|Diabetic control intervention group|The diabetic control group will provide finger prick DBS at week 0, 8 and 16, fill in food frequency questionnaire at week 0 and 16 and weekly weighing from week 0 until 16. This group will not be receiving tinned mackerel and will be asked to continue with their habitual diet and lifestyle.
2958910|NCT02840630|Active Comparator|Diabetic fish intervention group|This intervention group will receive two 125 g portion of tinned mackerel fish (containing 7.8 g n-3 LCPUFA) per week from week 0 until 16 and a mackerel recipe book each. They will be required to provide finger prick DBS at week 0, 8 and 16, fill in food frequency questionnaire at week 0 and 16 and weekly weighing from week 0 until 16.
2958911|NCT02840617|Experimental|ICG injection group|ICG will be intravenously administered over a 10 second period immediately after the patient was anesthetized. The fluorescence will be performed during and after the surgery, respectively.
2958912|NCT02840604||patient with all types of solid malignant tumors not treatable|In the treatment or assessment of metastatic solid tumor malignancies not curable it can be offered to patients to establish the profile of their tumor by next generation sequencing (NGS). This technique permits the sequencing of millions of fragments in parallel in a short time and allows to identify rapidly somatic or constitutional mutations known or yet unknown. The establishment of the genetic profile of the tumor coupled to the available clinical data can help clinicians to predict patient outcome in terms of survival or progression to disease, but may also provide key clues to adapt the management and patient treatment.
2958913|NCT02840591|Experimental|Drug Treatment|"First 5 consecutive subjects: Ramelteon 8 mg daily at 8 pm for 5 days~Next 5 consecutive subjects: Citicoline 250 mg daily at 8 pm for 2 days, followed by citicoline 500 mg daily at 8 pm for 3 days~All subjects: Standard medical care"
2958914|NCT02840591|No Intervention|Observation-Only|Standard medical care
2958915|NCT02840565|Experimental|BIA 5-453 25 mg or placebo|Multiple oral doses of BIA 5-453 25 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
2958916|NCT02840565|Experimental|BIA 5-453 50 mg or placebo|Multiple oral doses of BIA 5-453 50 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
2958917|NCT02840565|Experimental|BIA 5-453 100 mg or placebo|Multiple oral doses of BIA 5-453 100 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
2958918|NCT02840565|Experimental|BIA 5-453 200 mg or placebo|Multiple oral doses of BIA 5-453 200 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
2958919|NCT02840565|Experimental|BIA 5-453 400 mg or placebo|Multiple oral doses of BIA 5-453 400 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
2958920|NCT02840565|Experimental|BIA 5-453 600 mg or placebo|Multiple oral doses of BIA 5-453 600 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
2958921|NCT02840552|Experimental|FCH-PET/CT|18F-Fluoromethylcholine (18F-FCH) PET/CT
2958922|NCT02840539|Experimental|Experimental|Bortezomib, Cytarabine, Dexamethasone, Pegteograstim
2958923|NCT02840526|Experimental|PVB group|Thoracic paravertebral blockade PVB (preoperatively) Bupivacaine WZF Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi
2958924|NCT02840526|Other|GEN group|Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi
2958925|NCT02840513|Experimental|Smartphone app/CO self-monitoring|The app offers a coaching function where users receive personalized messages to encourage smoking cessation and advice for behavioural changes. For the first 4 weeks of the intervention, individuals will also be asked to blow daily into a breath carbon monoxide monitor before going to sleep. Depending on the results of the breath test, individualized messages will be delivered by the Smokelyzer feedback app to either enhance maintenance of abstinence or increase the motivation to quit. After the first 4 weeks, participants will use the breath carbon monoxide monitor at least twice a week until the end of the 6-month study. The app will react with positive feedback in individuals doing well with smoking cessation and messages to encourage individuals with difficulties quitting to smoke.
2958926|NCT02840513|No Intervention|Control|Participants in the control group will be managed according to usual care as regularly provided by their SHCS physicians. Physicians will motivate patients to quit, emphasise the advantage of quitting, and provide patients with an information card that contains short advices how to quit and addresses of stop smoking clinics. The Swiss HIV Cohort Study study nurse will enter past or current use as well as of nicotine replacement therapy or use of other pharmaceutical support to quit smoking in the online study form
2958927|NCT02840500||Breakthrough Cancer Pain|No intervention (Non-interventional study)
2958928|NCT02840487|Experimental|Group 1|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0 and Week 8.
2958929|NCT02840487|Experimental|Group 2|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0 and Week 12.
2958930|NCT02840487|Experimental|Group 3|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0, Week 4 and Week 8.
2958931|NCT02840487|Experimental|Group 4|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0,Week 4 and Week 20.
2958932|NCT02840474|Experimental|1|This study will assess VRC01LS or VRC07 523LS administered at 40 mg/kg IV in HIV infected viremic participants.
2958933|NCT02840474|Experimental|2|This study will assess VRC01LS or VRC07 523LS administered at 40 mg/kg IV in HIV infected viremic participants.
2958934|NCT02840461|Experimental|Ivermectin Cream, 1%|test product, manufactured by Actavis Laboratories UT, Inc.
2958940|NCT02840409|Experimental|Arm B|68 weeks of Vinblastine administered weekly IV with the addition of 12 doses of Bevacizumab administered every two weeks IV for the initial 24 weeks.
2958941|NCT02840396|Experimental|rTMS|
2958942|NCT02840396|Sham Comparator|Sham rTMS|
2958943|NCT02840383|Active Comparator|Delayed Intervention|Schools not receiving intervention until two years after implementation.
2958944|NCT02840383|Experimental|Intervention|Schools receiving intervention at the beginning of study.
2958945|NCT02840370|Experimental|transcranial direct current stimulation|tDCS
2958946|NCT02840370|Sham Comparator|Sham tDCS|S-tDCS
2958947|NCT02840357|Experimental|Treatment Group|Purple Wheat Convenience Bars The treatment group will consume 4 servings /day of bran-enriched purple wheat convenience bars (40g/ serving)
2958948|NCT02840357|Placebo Comparator|Control Group|Control Wheat Convenience Bars The control group will consume 4 servings /day of bran-enriched ordinary wheat convenience basr (40g/ serving)
2958949|NCT02840344|Experimental|Couples MBSR|"Young breast cancer survivors and their partners take part in an 8-week Couples Mindfulness-Based Stress reduction (C-MBSR) intervention. The course will be taught through recorded videos of a trained MBSR instructor. The young breast cancer survivor and partner will be asked to watch a video module, together, each week for a total of 8 weeks. The C-MBSR course consists of practicing mindful stress reduction techniques and filling out handouts.~Both members of the couple will be asked to complete surveys assessing primary and secondary outcome measures administered at baseline and after final session. Participants will be asked to provide a Salivary Cortisol sample at baseline and after the 8th session. Follow up Surveys will be administered at one and three months after intervention."
2958950|NCT02840344|Active Comparator|Individual MBSR|"Young breast cancer survivors take part in an 8-week Individual Mindfulness-Based Stress reduction (I-MBSR) intervention. The course will be taught through recorded videos of a trained MBSR instructor. The young breast cancer survivor will be asked to watch a video module each week for 8 weeks in a row. The I-MBSR course consists of practicing mindful stress reduction techniques and filling out handouts.~Both members of the couple will be asked to complete surveys assessing primary and secondary outcome measures administered at baseline and after final session. Participants will be asked to provide a Salivary Cortisol sample at baseline and after the 8th session. Follow up Surveys will be administered at one and three months after intervention."
2958951|NCT02840331|Experimental|St. John's Wort & PDD, PDT|St. John's Wort 900 milligram once oral preoperative & intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes
2958952|NCT02840318|Experimental|Compassion Intervention|Coordinated by the ICL who co-ordinates key activities at each site to address the two core components of the Intervention. Component 1 activities include: (a) person-centred assessment of residents, focussing on their physical, psychological, emotional and social needs, (b) meetings of the core care team (General practitioner, care home nurse and/or manager and ICL) and (c) meetings of the wider multidisciplinary care teams (including care home staff, ICL, and external healthcare professionals such as geriatrician, palliative care, mental health etc). Activities to facilitate component 2 include: (d) staff training sessions, education and support for staff and family carers. Training sessions are run by the ICL and logistics of training is planned at core meetings.
2958953|NCT02840305|Other|Expérience 1|Brain bases of spatial frequencies treatment 30 young adults, 20 old adults 20 children between 4 and 6 years, 20 children between 6 and 12 years and 20 young adults
2958954|NCT02840305|Other|Expérience 2|Brain bases of Computer to Film (CtF) analysis 30 young adults, 20 old adults
2958955|NCT02840305|Other|Expérience 3|Part of parahippocampal gyrus in Computer to Film (CtF) analysis 30 young adults, 20 old adults.
2958956|NCT02840292||Cases|Late preterm neonates (>34weeks but <37weeks of gestation) with maternal hemoglobin < 11gm/dl
2958957|NCT02840292||Controls|Late preterm neonates (>34weeks but <37weeks of gestation) with maternal haemoglobin ≥ 11gm/dl
2958958|NCT02840279|Experimental|BPN14770|An oral dose of BPN14770
2958959|NCT02840279|Placebo Comparator|Placebo|An oral dose of placebo matching BPN14770
2958960|NCT02840253|Experimental|NIRS|Non-invasive near infrared spectroscopy to assess changes in tissue and cerebral oxygenation.
2958961|NCT02840240|Experimental|Gabapentin enacarbil|Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive Gabapentin enacarbil for 5 days
2958962|NCT02840240|Placebo Comparator|Placebo|Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive placebo for 5 days
2958963|NCT02840227|Experimental|Combined general/epidural anesthesia|Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
2958964|NCT02840227|Experimental|General anesthesia with opioid analgesia|General anesthesia with routine drugs and intravenous PCA opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
2958965|NCT02840214|Active Comparator|tDCS rescue group|Subjects assigned to this arm will receive transcranial direct current stimulation (tDCS) that delivers a constant, small current (2 milliAmp) across specific regions of the brain through electrodes placed on the scalp half-way through the 3-hour fatigue task.
2958966|NCT02840214|Placebo Comparator|Sham Treatment Group|Subjects assigned to this arm will initially receive current of the same intensity for a period of 30 seconds and then gradually turned off.
2958967|NCT02840214|Active Comparator|tDCS prevent group|Subjects assigned to this arm will receive transcranial direct current stimulation (tDCS) that delivers a constant, small current (2 milliAmp) across specific regions of the brain through electrodes placed on the scalp at the beginning of the task.
2958968|NCT02840188||Radius tilt angle|Children 0-16 years of age positive for distal forearm fracture and positive history of goalkeeper's fracture (to catch a ball).
2958969|NCT02840188||Normal control group|Children 0-16 years of age without radius fracture and no history of catching a ball.
2958970|NCT02840175|Experimental|Experimental|"Day 0 at Weeks 24 : Increase the interval between 2 doses of the biological agent (etanercept, adalimumab, tocilizumab, abatacept)~Weeks 24 at Weeks 72: Stop the biological agent if inactive disease is maintained."
2959556|NCT02836054|Other|Patients with cognitive disorders|lumbar punction + brain MRI
2958971|NCT02840175|Active Comparator|Control|"Day 0 at Weeks 24: Maintain the biological agent (etanercept, adalimumab, tocilizumab, abatacept) at the same dose.~Weeks 24 at Weeks 48 : Increase the interval between 2 doses of the biological agent.~Weeks 48 at Weeks 72: Stop the biological agent if inactive disease is maintained."
2958972|NCT02840162|Active Comparator|Celecoxib|Treated patients will receive 4 weeks of celecoxib at 400 mg twice daily by mouth
2958973|NCT02840162|Placebo Comparator|Placebo|Control patients will receive a suitable placebo for 4 weeks, twice daily by mouth
2958974|NCT02840149|Other|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan performed on Neuro-endocrine tumor patients
2958975|NCT02840136|Experimental|Standard of care|Sputum is collected from patients receiving standard of care therapy with IV piperacillin-tazobactam, ceftazidime or meropenem
2958976|NCT02840123|Experimental|Autologous dendritic cells|
2958977|NCT02840110||Post-ACTR087|
2958978|NCT02840097|Experimental|Tranexamic acid dose A|Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.
2958979|NCT02840097|Experimental|Tranexamic acid dose B|Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.
2958980|NCT02840097|Placebo Comparator|Placebo|Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.
2958981|NCT02840084|Experimental|Treatment Patients|In stage I, 10 women aged 22 years or older who have received saline breast implants for subglandular breast augmentation, and who subsequently developed Baker Grade III capsular contracture, will be invited to participate. In Stage II, the study group will be expanded to include an additional 50 patients who have received saline or silicone gel implants, placed in either the subglandular or submuscular position, with Grade III capsular contracture of the breast. The intervention will be treatment with the Aspen(TM) Ultrasound System.
2958982|NCT02840071|Experimental|Intervention|Psychological therapy.
2958983|NCT02840058|Experimental|Biological samples|"Blood samples will be realized specifically to the study at inclusion (baseline before starting anti PD1/PDL1 treatment), and then 1 month, 3 months and 12 months after initiation of anti-PD1/PDL1 treatment.~Peripheral blood mononuclear cells (PBMC) and plasma will be collected.~Available tumor tissues will be collected."
2958984|NCT02840045|Experimental|Alzheimer patients|Cerebral measurements from high-density electroencephalography are recorded in Alzheimer patients. The same protocol is applied in the 3 arms
2958985|NCT02840045|Experimental|patients with a depressive disorder|Cerebral measurements from high-density electroencephalography are recorded in patients with a depressive disorder. The same protocol is applied in the 3 arms
2958986|NCT02840045|Active Comparator|Healthy controls|Cerebral measurements from high-density electroencephalography are recorded in healthy controls
2958987|NCT02840019|Experimental|60 minute research full MRI scan|"Pregnant women who are able to have an MRI are eligible for the 60 minute research full MRI scan. Pregnant women may have a healthy pregnancy, a concern for fetal/placental abnormalities with a clinical fetal MRI ordered by their doctor, or a concern for fetal/placental abnormalities without a clinical fetal MRI ordered by their doctor.~The investigational MRI coil designed for pregnant women and research MRI sequences will be tested during the 60 minute research scan."
2958988|NCT02840019|Experimental|15 minute research add-on MRI scan|"Pregnant women with a concern for fetal/placental abnormalities with a clinical fetal MRI at Boston Children's Hospital are eligible for the 15 minute research add-on MRI scan.~The research MRI sequences will also be tested during the add-on research MRI scan."
2958989|NCT02840006|Active Comparator|General anesthesia only|Anesthetic induction with etomidate 0,3 a 0,4 mg.kg-1, citrate fentanyl 5 mcg.kg-1 and atracurium 0,5.kg-1
2958990|NCT02840006|Active Comparator|General anesthesia associated spinal anesthesia|spinal anesthesia using bupivacaine 0,5% hyperbaric 20 mg, morphine 200 mcg, set trendeleburg for 10 minutes, sensitive test in T1. Anesthetic induction with etomidate 0,3 a 0,4 mg.kg-1, citrate fentanyl 5 mcg.kg-1 and atracurium 0,5.kg-1.
2958991|NCT02839993|Experimental|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
2958992|NCT02839993|Sham Comparator|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
2958993|NCT02839980||orthopedics (gr1) surgery|parient admitted to the orthopedics (gr1) surgery ward for an elective or semi-emergent surgical procedure.
2958994|NCT02839980||thoracic (gr2) surgery|parient admitted to the thoracic (gr2) surgery ward for an elective or semi-emergent surgical procedure.
2958995|NCT02839980||abdominal (gr3) surgery|parient admitted to the abdominal (gr3) surgery ward for an elective or semi-emergent surgical procedure.
2958996|NCT02839980||ICU (gr4)|patients admitted to the ICU with an antcipated length of stay of 3 days or more
2958997|NCT02839967|Experimental|Photobiomodulation group|For the purposes of photobiomodulation is used a portable cluster 9 PainAway ® diodes manufactured by Multi Radiance Medical ® (Solon, OH-USA), and 1 905 nm diode LASER, 4 875 nm LED diodes and 4 670 nm diodes LED, 4 cm2 beam, emitting an energy of 39.27 J.
2958998|NCT02839967|Placebo Comparator|Photobiomodulation placebo group|"To provide the blinding of the participants of the study we will use two identical photobiomodulation equipment supplied by the manufacturer, being an active and another a placebo, but both have identical light and sound device (do not send energy and heat, non-coherent light without biological effect). The devices are named in X and Y for a researcher who does not participate in treatment and assessments."
2958999|NCT02839954|Experimental|CAR-pNK Cell immunotherapy|Enrolled patients will receive CAR-pNK cell immunotherapy with a novel specific chimeric antigen receptor targeting MUC1 antigen by infusion.
2959000|NCT02839941|Experimental|experiment|
2959001|NCT02839941|Sham Comparator|Control|
2959002|NCT02839928|Experimental|Treatment|The experimental arm consists of children given intranasal Ketamine 1 mg/kg, once
2959054|NCT02839525|Placebo Comparator|Omega 3|"3000mg of olive oil~Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
2959055|NCT02839525|Placebo Comparator|Isolate whey protein|"23g of maltodextrin~Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
2959003|NCT02839915|Experimental|Folinic Acid|Subjects randomized to receive Folinic Acid will take one capsule, twice a day. Once in the morning and once in the evening (Exception: children in the lowest weight group ( ≥ 15 - < 20 kg) will start with 10 mg capsule once a day for Days1-13). Dosing will start at 10-20 mg/day, based on subject's weight, and increase to 30-50 mg/day over four weeks. Primary caregiver will be contacted by telephone on Weeks 2, 6 and 10. Follow up visits at Weeks 4, 8 and 12 (end of Double-blind phase). After 12 weeks, the blind will not be broken and subjects will be offered treatment for a 12-week open-label extension phase.
2959004|NCT02839915|Placebo Comparator|Placebo Control|Subjects randomized to receive placebo will take one capsule, twice a day (Exception: children in the lowest weight group ( ≥ 15 - < 20 kg) will start with capsule once a day for Days1-13). The pattern of dose escalation will be the same as the active compound. Primary caregiver will be contacted by telephone on Weeks 2, 6 and 10. Follow up visits at Weeks 4, 8 and 12 (end of Double-blind phase). After 12 weeks, the blind will not be broken and subjects will be offered treatment for a 12-week open-label extension phase.
2959005|NCT02839902|Experimental|Group treated with TAK-085 2g|A dose of 2 g of omega-3-acid ethyl esters (TAK-085) is orally administered immediately after meal twice a daily.
2959006|NCT02839902|Experimental|Group not treated with TAK-085|HMG-CoA reductase inhibitor will be continued at the same dose regimen as at the time of informed consent.
2959007|NCT02839889|Placebo Comparator|Placebo|Placebo once daily for two weeks
2959008|NCT02839889|Active Comparator|Naloxegol|Naloxegol 25mg tablets once daily for two weeks
2959009|NCT02839876|Experimental|Intravenous acetaminophen|Subjects receive 1000 mg acetaminophen IV immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an oral placebo.
2959010|NCT02839876|Active Comparator|Oral acetaminophen|Subjects receive 1000 mg acetaminophen PO immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an intravenous placebo.
2959011|NCT02839850|Experimental|ATTUNE Cementless RP TKA|Subjects will receive a cementless, rotating platform total knee arthroplasty
2959012|NCT02839837|Experimental|Depressed and non-depressed controls|All participants will participate in three different conditions: Low intensity aerobic exercise and paired associative stimulation, high intensity aerobic exercise and paired associative stimulation, no exercise control and paired associative stimulation. The order of conditions will be randomized.
2959013|NCT02839811|Experimental|immediate hypersensitivity to BLC|immediate hypersensitivity to BLC by In vitro diagnosis
2959014|NCT02839798|Experimental|sTMS active|Treatment with the NEST Device
2959015|NCT02839785|Experimental|Ibuprofen|Active ibuprofen
2959016|NCT02839785|Placebo Comparator|Placebo|Placebo of ibuprofen
2959017|NCT02839772|Active Comparator|Current skin care regimen|Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 6 litres of water with added sodium hypochlorite (0.0125%), air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
2959018|NCT02839772|Experimental|Current skin regimen plus 2% glycerine|Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 1 litre of water with added sodium hypochlorite (0.0125%) and 2% glycerine, air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
2959019|NCT02839759|Experimental|TELLYHealth Group|Subjects will receive the standard of care in hearing aid education and the TELLYHealth intervention for use over a 12-week period.
2959020|NCT02839759|No Intervention|Standard of Care Group|Subjects will receive the standard of care in hearing aid education and will be followed for 123 weeks.
2959021|NCT02839746||Dabigatran|Patients switched from vitamin K antagonist (VKA) to dabigatran
2959022|NCT02839720|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients who experience a volume decrease in the target cutaneous neurofibromas may continue treatment for 12 additional courses.
2959023|NCT02839707|Experimental|Arm I (PLD, atezolizumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and atezolizumab IV over 30-60 minutes on days 1 and 15.
2959024|NCT02839707|Experimental|Arm II (PLD, bevacizumab, atezolizumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and atezolizumab IV over 30-60 minutes on days 1 and 15.
2959025|NCT02839707|Active Comparator|Arm III (PLD, bevacizumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15.
2959026|NCT02839694|Experimental|Dose escalation cohort|dose escalation cohort
2959027|NCT02839694|Experimental|Expansion cohort|expansion cohort at MTD
2959028|NCT02839694|Active Comparator|expansion cohort with celecoxib|expansion cohort at MTD with celecoxib
2959029|NCT02839681|Experimental|1/Safety Run-in Arm|Subjects will be dosed with the higher of the 2 possible anetumab ravtansine doses (dose level 1) evaluated on the study
2959030|NCT02839681|Experimental|2/Phase 2 Arm|Subjects will be dosed with anetumab ravtansineat the recommended phase 2 dose (dose level1 if no more than 1 DLT occurred in the safety runin arm, or at dose level -1 otherwise)
2959031|NCT02839668|Experimental|Sevoflurane|The patients enrolled in this arm will receive general anesthesia in which the hypnosis will be maintained with Sevoflurane. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.
2959032|NCT02839668|Active Comparator|Sevoflurane+Lidocaine|The patients enrolled in this group will receive general anesthesia in which the hypnosis will be maintained with Sevoflurane. At the induction of anesthesia the patients will receive a bolus of lidocaine 1% 1.5 mg/kg. A continuous infusion of lidocaine 1% of 1 mg/kg/h will be associated throughout the surgical procedure and until 24 h postoperative. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.
2959194|NCT02838602|Experimental|Carbon ions therapy|Radical and exclusive carbon ions radiotherapy
2959033|NCT02839668|Experimental|TIVA-TCI|The patients enrolled in this group will receive total intravenous anesthesia with propofol using a target controlled infusion technique for the maintenance of hypnosis throughout the surgery. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine. The bispectral index- BIS will be monitored throughout the anesthesia.
2959034|NCT02839668|Active Comparator|TIVA-TCI+lidocaine|The patients enrolled in this group will receive total intravenous anesthesia with propofol using a target controlled infusion technique for the maintenance of hypnosis throughout the surgery. At the induction of anesthesia the patients will receive a bolus of lidocaine 1% 1.5 mg/kg. A continuous infusion of lidocaine 1% of 1 mg/kg will be associated throughout the surgical procedure and until 24 h postoperative. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia.
2959035|NCT02839655|Experimental|Da Vinci Xi|
2959036|NCT02839642|Active Comparator|Rivastigmine|"Subject will receive a treatment of Rivastigmine twice daily during 24 weeks of treatment.~Study drug will be administered orally. Sufficient test drug will be dispensed to subjects or their caregivers at each study visit to allow twice daily dosing until the next scheduled study visit"
2959037|NCT02839642|Placebo Comparator|Placebo|Subject will receive a placebo twice daily during 24 weeks of treatment. Study drug will be administered orally. Sufficient test drug will be dispensed to subjects or their caregivers at each study visit to allow twice daily dosing until the next scheduled study visit
2959038|NCT02839629||Cohort 1: National patient cohorts in Scandinavia|Scandinavian countries: Denmark, Norway and Sweden Cohort 1 will include all patients with a diagnosis of NSCLC between 2005 and 2013
2959039|NCT02839629||Cohort 2: Electronic Medical Records based cohort (Sweden)|Patient as data is available (~2010) to 2013
2959040|NCT02839590||HiFu (ultrasound)|Manufacturer Name Eyehope Principle intended use Surgical treatment of uncontrolled glaucoma and OHT The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study.
2959041|NCT02839590||Baerveldt implant|"Manufacturer Name Abbott Medical Optics Inc., Abbott Laboratories Inc., Abbott Park, Illinois, USA.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
2959042|NCT02839590||Ahmed Implant|"Manufacturer Name New World Medical, Inc., 10763 Edison Court, Rancho Cucamonga, CA 91730, USA.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
2959043|NCT02839590||STARflo|"Manufacturer Name iSTAR Medical SA, Parc Créalys, Rue Phocas Lejeune, Bâtiment Regain 25/3, 5032 Isnes, Belgium.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
2959044|NCT02839590||Hydrus Microstent implant|"Manufacturer Name Ivantis, Inc., 38 Discovery, Suite 150, Irvine, CA 92618, USA.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
2959045|NCT02839590||iStent implant|"Manufacturer Name Glaukos Corporation, 26051 Merit Circle, Suite 103, Laguna Hills, CA 92653, USA.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
2959046|NCT02839590||Kahook Dual Blade|Manufacturer: New World Medical. Inc. Single use, ophthalmic blade Utilizes ab interno approach through a clear cornea micro incision Dual blades positioned for precise parallel incisions of the trabecular meshwork with minimal residual leaflets Maintains natural physiologic outflow pathways
2959047|NCT02839577|Active Comparator|High Volume injection (HVI) with corticosteroid|"10 mls 0.5% bupivacaine hydrochloride~20 mg of Depomedrol (40 mg/ml methylprednisolonacetat)~40 mls saline (NaCl)~HVI with corticosteroid is injected one time at baseline and compared to HVI without corticosteroid."
2959048|NCT02839577|Active Comparator|High Volume injection (HVI) without corticosteroid|"10 mls 0.5% bupivacaine hydrochloride~40 mls saline (NaCl)~HVI with corticosteroid is injected one time at baseline and compared to HVI with corticosteroid."
2959049|NCT02839564|Experimental|Adhesiolysis group|Patients underwent laparoscopic adhesiolysis
2959050|NCT02839564|Placebo Comparator|Placebo group|Patients underwent diagnostic laparoscopy alone
2959051|NCT02839551|Experimental|Simplified drug provocation test|Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
2959052|NCT02839538|Active Comparator|local Infiltration|"Induction of General Anesthesia with Propofol(2mg/Kg) and Atracurium(0,5mg/Kg) . Pulmonary ventilation with laryngeal mask and Propofol infusion ( 100mcg/Kg/min.) After , Infiltration of 0.75% ropivacaine (10 ml) each side block injection of local anesthetic at perianal.~If necessary, fentanyl endovenous injection (50 mcg)."
2959053|NCT02839538|Other|Subarachnoidal block|"Sedation with midazolam 2 mg. After , Spinal block with 10 mg of hyperbaric 0.5% bupivacaine. Injection of anesthetic at subarachnoidal space with Quincke needle 27G.~If pain, local infiltration with lidocaine 1% (5 ml) in wound."
2959195|NCT02838602|Active Comparator|Conventional radiotherapy|Radical radiotherapy by Xrays and / or protons
2959056|NCT02839525|Placebo Comparator|Omega 3 and Isolate whey protein|"3000mg of olive oil and 23g of maltodextrin~Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
2959057|NCT02839512|Experimental|Jejunal to Ileal Diversion|All subjects who receive jejunal to ileal diversion endoscopic procedure
2959058|NCT02839499|Experimental|mixed food|experimental group with RU sleeping®, autonomy scale (ADL and AGGIR) and various activity scale (IADL)
2959059|NCT02839499|Other|normal texture food|control group with RU sleeping®, autonomy scale (ADL and AGGIR) and various activity scale (IADL)
2959060|NCT02839486||vancomycin and cefoxitin pharmacokinetics|This is surgical prophylaxis and cefoxitin/vancomycin have to be administered to each patient of the study, before surgery
2959061|NCT02839473|Experimental|Hydrosorb® arm|Hydrogel Hydrosorb®
2959062|NCT02839473|Placebo Comparator|Placebo arm|Castalie water spray
2959063|NCT02839460||subjects with sarcopenia|"Screening Procedures (Physical Exam, Height & Weight, Vitals, Medical History, CHAMPS, DXA Scan, Physical Performance Testing, Muscle Strength Testing, Blood Collection)~Day 1 (target +/- 2 days) Outpatient Muscle Biopsy (Vitals, Blood Collection, Muscle Biopsy, update Concomitant Therapy and Procedure-Related AEs/SAEs)~Day 14 (target +/- 2 days) Safety Follow-up Visit (Vitals, Blood Collection, update Concomitant Therapy and Procedure-Related AEs/SAEs)"
2959064|NCT02839460||healthy, physically-active controls|"Screening Procedures (Physical Exam, Height & Weight, Vitals, Medical History, CHAMPS, DXA Scan, Physical Performance Testing, Muscle Strength Testing, Blood Collection)~Day 1 (target +/- 2 days) Outpatient Muscle Biopsy (Vitals, Blood Collection, Muscle Biopsy, update Concomitant Therapy and Procedure-Related AEs/SAEs)~Day 14 (target +/- 2 days) Safety Follow-up Visit (Vitals, Blood Collection, update Concomitant Therapy and Procedure-Related AEs/SAEs)"
2959065|NCT02839447||Normal Semen|"Semen that meet the criteria for normal on sperm number, motility, and morphology as described by the current WHO manual."
2959066|NCT02839447||Abnormal Semen|"Semen that fail to achieve one or more of the criteria for normal on sperm number, motility, and morphology as described by the current WHO manual."
2959067|NCT02839434||Treated with oral anticoagulants|Ex vivo study using blood samples from patients treated with oral anticoagulant (direct oral anticoagulants or AVK) at curative dose, taken in the usual cardiac monitoring.
2959068|NCT02839421|Experimental|Scaling and Root Planing plus moxifloxacin|The interventions are Scaling and Root Planing (SRP) combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days.The experimental treatment group consist of SRP combined with systemically administered MOX at the dosage of 400 mg once daily for 7 days.One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The adjunctive agent will start at the SRP visit. Subjects in the MOX group will be extensively informed about the intake of the prescribed medication.
2959069|NCT02839421|Active Comparator|Scaling and Root Planing plus amox-metro|"The active comparator are Scaling and Root Planing (SRP) combined with systemically administered Amoxicillin (amox) + Metronidazole (metro) 500 mg each one for 7 days.The active comparator group consist of SRP combined with systemically administered Amoxicillin (amox) + Metronidazole (metro) 500 mg each one for 7 days.~One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The adjunctive agent will start at the SRP visit. Subjects in the amox-metro group will be extensively informed about the intake of the prescribed medication."
2959070|NCT02839421|Placebo Comparator|Scaling and Root Planing plus placebo|Scaling and Root Planing (SRP) + placebo once daily for 7 days. The placebo comparator group consist of SRP combined with systemically administered placebo once daily for 7 days. One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The placebo agent will start at the SRP visit. Subjects in the placebo group will be extensively informed about the intake of the prescribed medication.
2959071|NCT02839408|Placebo Comparator|Periodontal treatment, talc powder tab|Periodontal treatment (scaling and root planning) and one tablet containing talc powder per day during 3 months
2959072|NCT02839408|Experimental|Periodontal treatment, Probitic|Periodontal treatment (scaling and root planning) and one sachet containing Lactobacillus rhamnosus SP1 per day during 3 months.
2959073|NCT02839408|Experimental|Periodontal treatment, Antibiotic|Periodontal treatment (scaling and root planning) and one tablet containing 500mg Azithromycin
2959074|NCT02839395|Active Comparator|base line|First night is the base line- no exposure to computer screen illumination.
2959075|NCT02839395|Experimental|Acute|Second night is the acute exposure to computer screen illumination.
2959076|NCT02839395|Experimental|Chronic|Chronic is the effect after five nights of exposure to computer screen light illumination.
2959077|NCT02839382|Active Comparator|Coaching|External facilitation by a practice coach for 15 months
2959078|NCT02839382|Active Comparator|Educational Outreach|Academic detailing phone calls to support implementation of a cardiovascular risk calculator/estimator in each clinic
2959079|NCT02839382|Active Comparator|Site Visit|"Site visits made by practices to 'exemplar practices to learn innovative approaches to quality improvement"
2959080|NCT02839382|Active Comparator|Educational Outreach and Site Visit|In this arm of the study, practices will be offered both educational outreach and an opportunity for a site visit
2959081|NCT02839369||children|post Traumatic Brain Injury With Cerebral Palsy Typically developed
2959082|NCT02839356|Experimental|Drug: epinephrine|20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
2959083|NCT02839356|Placebo Comparator|Drug: normal saline|20-mL irrigation with physiological saline over the entire papilla
2959084|NCT02839343|Experimental|mFOLFIRINOX + surgery + FOLFOX|Patients receive 8 cycles of mFOLFIRINOX. One cycle is 14 days. mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU. Patients undergo surgery and receive 4 cycles of FOLFOX 4-12 weeks after surgery. FOLFOX consists of oxaliplatin, leucovorin and 5-FU.
2959347|NCT02837575|Experimental|VCL-HB01, 1-mL dose|VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 4 doses
2959085|NCT02839343|Experimental|mFOLFIRINOX + radiation + surgery + FOLFOX|Patients receive 7 cycles of mFOLFIRINOX. One cycle is 14 days. mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU. Patients receive radiation therapy then undergo surgery and receive 4 cycles of FOLFOX 4-12 weeks after surgery. FOLFOX consists of oxaliplatin, leucovorin and 5-FU.
2959086|NCT02839330|Experimental|Group A|aH5N1c lot #1; receive 2 doses (on Day 1 and Day 22)
2959087|NCT02839330|Experimental|Group B|aH5N1c lot #2; receive 2 doses (on Day 1 and Day 22)
2959088|NCT02839330|Experimental|Group C|aH5N1c lot #3; receive 2 doses (on Day 1 and Day 22)
2959089|NCT02839330|Placebo Comparator|Group D|Placebo; receive 2 doses (on Day 1 and Day 22)
2959090|NCT02839317||Biological in pediatric CD|75 pediatric-onset CD Biological
2959091|NCT02839317||Biological in pediatric controls|75 pediatric controls matched on gender, age and area of residence Biological
2959092|NCT02839317||Biological in elderly CD|75 elderly-onset CD Biological
2959093|NCT02839317||Biological in elderly controls|75 elderly controls matched on gender, age and area of residence Biological
2959094|NCT02839304|Experimental|Catheter Ablation Treatment|Cryoablation System: Atrial Fibrillation Ablation
2959095|NCT02839291|Experimental|quality of life questionaries|Patients should complete 3 quality of life questionaries (EORTC-QLQ C30 ; EORTC QLQ-BM22 and Euroqol EQ-5D) at many time points : at inclusion, every 3 months and at the end of study visit (2 years after inclusion)
2959096|NCT02839278|Experimental|Immune-mediated inflammatory disease|Patients with an immune-mediated inflammatory disease. A blood sample is achieved at T0 (no follow-up).
2959097|NCT02839265|Experimental|SBRT + FLT3 Ligand Immunotherapy|"Patients will be treated with stereotactic body radiotherapy (SBRT) to a single pulmonary lesion as well as FLT3 immunotherapy.~FLT3 Ligand Therapy (CDX-301)~Daily subcutaneous injections of CDX-301 (75 ug/kg) will be administered for 5 days, beginning on the first day of SBRT.~Additional cycles of SBRT (to distinct lesions) and CDX-301 may be administered every 2-4 months to subjects who demonstrate evidence of clinical benefit (lack of treatment-related toxicity and no disease progression).~Study therapy will be discontinued in cases of treatment-related toxicity or disease progression."
2959098|NCT02839252|Experimental|Intervention Group|After the baseline tools have been completed, the child will be given the Iggy Comic Book and trading cards. Parents and their children will then watch a 12-minute Iggy Video. At the completion of the video and prior to going home, the child and parent will complete the same 2 measures on asthma knowledge and self-efficacy. At 1-month after this clinic visit, the parent will be sent an email with a link to a Qualtrics survey that will contain a few supplemental questions to assess use of the intervention and the same 2 measures that the parent and the child completed at the initial visit.
2959099|NCT02839252|No Intervention|Control Group|After the baseline tools have been completed, the parent and child will go home. At 1-month after the initial study clinic visit, the parent will be sent an email with a link to a Qualtrics survey that will contain a few supplemental questions to assess use of the intervention and the same 2 measures that the parent and the child completed at the initial visit.
2959100|NCT02839239|Experimental|Drops with lactobacilli and vitamin D3|Exclusive breast feeding plus L. rhamnosus 19070-2 and L. reuteri DSM 12246 in a dose of 125 x 106 CFU (both strains) with 1,667 mg fructooligosaccharides and 2,5 mcg (100 IU) vitamin D3 (in sunflower oil) per 6 drops. One dose (6 drops) in the first morning (from 6 AM) breastfeeding, and one dose (6 drops) in one of the evening (6 PM-12 PM) breast feedings for 28 days.
2959101|NCT02839239|Placebo Comparator|Drops with vitamin D3|Exclusive breast feeding plus 2.5 mcg (100 IU) vitamin D3 (in sunflower oil) per 6 drops. One dose (6 drops) in the first morning (from 6 AM) breastfeeding, and one dose (6 drops) in one of the evening (6 PM-12 PM) breast feedings for 28 days.
2959102|NCT02839226|Active Comparator|AR/101|AR/101 will be administered topically once daily for up to 28 days concomitantly with standard of care as advised by treating physician. After randomization, patients will be treated for up-to 28 days, or until granulation tissue formation has reached maximal score on the granulation scale, or until the wound is ready for skin grafting, whichever occurs first.
2959103|NCT02839226|Placebo Comparator|Placebo|placebo will be administered topically once daily for up to 28 days concomitantly with standard of care as advised by treating physician. After randomization, patients will be treated for up-to 14 days or until granulation tissue formation has reached maximal score on the granulation scale, or until the wound is ready for skin grafting, whichever occurs first.
2959104|NCT02839213|Active Comparator|group A (Hyoscine Butyl bromide group)|The women will be given Hyoscine Butyl bromide
2959105|NCT02839213|Active Comparator|group B (Saline group)|The women will be given saline
2959106|NCT02839200|Experimental|ACT-541468 5 mg|Each subject receives one 5-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks
2959107|NCT02839200|Experimental|ACT-541468 10 mg|Each subject receives one 10-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks
2959108|NCT02839200|Experimental|ACT-541468 25 mg|Each subject receives one 25-mg ACT-541468 capsule (+ one placebo capsule), once daily in the evening) for 4 weeks
2959109|NCT02839200|Experimental|ACT-541468 50 mg|Each subject receives two 25-mg ACT-541468 capsules, once daily in the evening for 4 weeks
2959110|NCT02839200|Active Comparator|Zolpidem|Each subject receives one 10-mg zolpidem capsule (+ one placebo capusle), once daily in the evening for 4 weeks
2959111|NCT02839200|Placebo Comparator|Placebo|Each subject receives two placebo capsules, once daily in the evening for 4 weeks
2959112|NCT02839187|Experimental|Patients with Alzheimer Disease|Patients will have Neuroimaging by Florbetapir (AV-45)-positron emission tomography
2959113|NCT02839187|Active Comparator|Controls patients|Controls will have neuroimaging by AV45-positron emission tomography
2959114|NCT02839161|Experimental|Low-dose (0,2,4 months)|10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
2959115|NCT02839161|Experimental|Low-dose (0,2,6 months)|10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
2959116|NCT02839161|Experimental|Medium-dose (0,2,4 months)|30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
2959117|NCT02839161|Experimental|Medium-dose (0,2,6 months)|30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
2959118|NCT02839161|Experimental|High-dose (0,2,4 months)|100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
2959119|NCT02839161|Experimental|High-dose (0,2,6 months)|100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
2959120|NCT02839161|Active Comparator|Comparator (0,2,4 months)|Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 4 months.
2959121|NCT02839161|Active Comparator|Comparator (0,2,6 months)|Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 6 months.
2959122|NCT02839148|Experimental|Dietary supplementation|In case of dietary supplementation, we will provide milk and egg 6 days a week for 3 months to stunted children.
2959123|NCT02839148|Experimental|psychosocial stimulation|In case of psychosocial stimulation, we well provide PS weekly for first month, fortnightly for 2nd and 3rd months and then monthly for next 3 months. The total number of visits will be 11 over a period of 6 months.
2959124|NCT02839135|Experimental|Reformulated scopolamine patch|Participants will receive reformulated scopolamine Transdermal Delivery System (TDS) patch 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.
2959125|NCT02839135|Active Comparator|Marketed scopolamine patch|Participants will receive currently marketed scopolamine TDS patch 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area, with delivery of approximately 1.0 mg over 72 hours.
2959126|NCT02839122|Experimental|Dutasteride, Tadalafil|
2959127|NCT02839122|Experimental|Tadalafil, Dutasteride|
2959128|NCT02839096|Other|Once Daily Dosing|Randomized to 325mg of ferrous sulfate in the morning and placebo in the evening
2959129|NCT02839096|Other|Twice Daily Dosing|Randomized to 325mg of ferrous sulfate in the morning and 325mg of ferrous sulfate in the evening
2959130|NCT02839083|Placebo Comparator|Thoracic Paravertebral group|Ultrasound guided thoracic paravertebral block
2959131|NCT02839083|Active Comparator|Pecs II group|Ultrasound guided Pecs II block
2959132|NCT02839070|Experimental|Regular Schedule|Participant will be on a regular sleep/wake schedule
2959133|NCT02839070|Experimental|Irregular Schedule|Participant will be on an irregular sleep/wake schedule
2959134|NCT02839057||Surgical treatment|Patients ≥70 years with C2 fracture coded in patient registry (ICD-10: S12.1) treated with surgical fracture stabilisation
2959135|NCT02839057||Non-surgical treatment|Patients ≥70 years with C2 fracture coded in patient registry (ICD-10: S12.1) treated non-surgically
2959136|NCT02839044|Experimental|Vitamin K|One group receives tablets of 360 microgram menaquinone-7 daily
2959137|NCT02839044|Placebo Comparator|Placebo|One group receives placebo tablets daily
2959138|NCT02839031|Experimental|"CBT group"|
2959139|NCT02839031|Sham Comparator|Control group|
2959140|NCT02839018||Central nervous system (CNS) group|n=50 patients with presumed low prevalence of ICU-AW
2959141|NCT02839018||Severe sepsis/shock group|n=50 patients with presumed high prevalence of ICU-AW
2959142|NCT02839005|Active Comparator|suture with polyglecaprone 25|
2959143|NCT02839005|Active Comparator|suture with polyamide (nylon)|
2959144|NCT02838992|Experimental|ATG, Cy and cord blood transfusion group|"ATG 3mg/kg/d for 5 days Cy 50mg/kg/d for 2 days CSA Started from 5mg/kg/d and adjusted to maintain trough serum concentration of 200-400ng/ml One unit of cord blood having no more than 3 HLA-A,B and DRB1 mismatches is transfused 24h after last dose of ATG administration.~Intervention:~Drug: Rabbit ATG, Thymoglobuline (Genzyme) plus Cyclophosphamide plus CSA Biological: Cord blood transfusion"
2959145|NCT02838992|Active Comparator|ATG and CSA group|ATG 3mg/kg/d for 5 days CSA started from 5mg/kg/d and adjusted to maintain trough serum concentration of 200-400ng/ml Intervention: Drug: Rabbit ATG, Thymoglobuline (Genzyme) plus CSA
2959146|NCT02838979|Experimental|Oral L-Glutamine (0.4mg/kg/day)|Subjects will receive 0.4 g/kg/day of L-glutamine (Nutrestore, EMMAUS Life Sciences, Inc Torrance, CA) in three divided daily doses. Duration 2 weeks
2959147|NCT02838979|Placebo Comparator|Maltodextrin|Identical appearing maltodextrin powder.
2959148|NCT02838966|Active Comparator|Nestle IMPACT Advanced Recovery 1|1 can per day for 5 days prior to surgery
2959149|NCT02838966|Active Comparator|Nestle IMPACT Advanced Recovery 2|2 cans per day for 5 days prior to surgery
2959150|NCT02838966|Active Comparator|Nestle IMPACT Advanced Recovery 3|3 cans per day for 5 days prior to surgery
2959151|NCT02838966|Active Comparator|Nestle Boost High Protein Drink - Control Arm|4 cans per day for 5 days prior to surgery
2959152|NCT02838953|Experimental|COPD patients|COPD patients submitted to Pulmonary Rehabilitation according to the ATS/ERS statement.
2959153|NCT02838953|No Intervention|Control|"Healthy individuals who will undergo the same COPD's evaluation protocol. As healthy individuals they will not participate to the Pulmonary Rehabilitation."
2959154|NCT02838940|Experimental|cesarean in different indications|Women that are about to undergo an elective cesarean in different indications.
2959155|NCT02838927||Hypoparathyroidism|No intervention.
2959156|NCT02838914|Experimental|patients with AF|Before radiofrequency ablation (RFCA)
2959157|NCT02838914|Experimental|Assigned Comparisons|After radiofrequency ablation (RFCA)
2959158|NCT02838901|Experimental|Beet It Beetroot Juice|70 cc (3.8 millimoles nitrate) Beet It organic beetroot juice once a day for 30 days. Vitamin C 500 mg (tablets) will be given along with each dose of the juice.
2959159|NCT02838901|Placebo Comparator|Beet It Beetroot Juice Placebo|70 cc Beet It organic beetroot juice (placebo) once a day for 30 days. The placebo beet juice is identical in appearance and taste with nitrate removed. Vitamin C 500 mg (tablets) will be given along with each dose of the juice.Beet It Placebo Beetroot juice.
2959160|NCT02838888||Routine colonoscopy Cohort|Patients receiving routine colonoscopy at the study site
2959557|NCT02836054|Other|Patients without cognitive disorders|lumbar punction + brain MRI
2959161|NCT02838875|Experimental|Pregnant women at risk population|women who arrived to the delivery room at Lis hospital and which the newborn is about to undergo glucose levels follow-up after birth regardless the study, because of their affiliation to the at-risk population.
2959162|NCT02838862||Response to Therapy|
2959163|NCT02838862||No therapy response|
2959164|NCT02838849|Sham Comparator|Fiber|Participants were treated with 2 sachets of fiber orally a day for 14 days, after baseline characterization of bowel habit and stool features.
2959165|NCT02838849|Active Comparator|Fiber and Water|Participants were treated with 2 sachets of fiber orally a day and ingested 2 liters of water a day for 14 days, after baseline characterization of bowel habit and stool features.
2959166|NCT02838836||Study sample collection|Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery
2959167|NCT02838823|Experimental|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
2959168|NCT02838810|Experimental|Experimental|CHB patients with low level HBsAg.Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg <1000 IU/mL and Hepatitis B virus DNA <100 IU/mL, are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week. The longest course of treatment is 96 weeks. After treatment, patients will be followed up for 24 weeks. During the 96 weeks course of treatment, HBsAg level will be monitored. When HBsAg level is less than 0.05 IU/mL, peginterferon treatment will be stopped and patients will receive 24 weeks follow up.
2959169|NCT02838810|Other|Control|Patients do not need to change their NAs treatment.
2959170|NCT02838797|Placebo Comparator|Placebo|"For the single ascending dose study, subjects will receive a single dose of oral acetate buffer on a single day.~For the multiple ascending dose study, subjects will receive a single daily dose of oral acetate buffer each day for 14 days."
2959171|NCT02838797|Experimental|RQ-00000010|"For the single ascending dose study, subjects will receive a single dose of either:~2 micrograms, 50 micrograms or 200 micrograms of RQ-00000010 on a single day.~For the multiple ascending dose study, subjects will receive single daily doses of either 10 micrograms, 50 micrograms or 100 vs. 200 micrograms of RQ-00000010 each day for 14 days."
2959172|NCT02838784|Experimental|Artacent Human Amniotic Membrane|Patients randomized to the Artacent group will receive standard of care (off-loading with a removable cast walker and non-adherent dressings in addition to debridement and use of moisture retentive dressing) and the application of the Artacent amniotic allograft once every two weeks for up to 5 applications or until the ulcer has healed.
2959173|NCT02838784|Active Comparator|Lower Extremity Ulcer Standard of Care|Patients randomized to standard of care will receive off-loading with a removable cast walker and non-adherent dressings (e.g. Adaptic) in addition to debridement and use of moisture retentive dressings. An outer dressing will also be applied.
2959174|NCT02838771|Experimental|Research group participants|"Research group consisted of 171 elderly nursing home residents and 82 outpatients of the Hospital of Lithuanian University of Health Sciences.~The participants were given the dysphagia screening questionnaire, consisted of 16 questions and the several sips of water to drink (clinical water drinking test for dysphagia screening)."
2959175|NCT02838771|Other|Control group participants|Community-dwelling elderly healthy individuals. The participants were given the dysphagia screening questionnaire, consisted of 16 questions and the several sips of water to drink (clinical water drinking test for dysphagia screening).
2959176|NCT02838758|Experimental|Cryoablation|Ultrasound guided perineural cryoablation. The mechanism of therapeutic cryoablation involves using short and repeated cycles of freezing and thawing to cause axonal degeneration and disrupt neuronal activity without damage to epineurium and perineurium.
2959177|NCT02838758|Active Comparator|Lidocaine|Ultrasound guided perineural lidocaine injection. Under ultrasound guidance, roughly 3cc of 2% lidocaine will be injected near the neuroma.
2959178|NCT02838758|Placebo Comparator|Saline|Ultrasound guided perineural normal saline injection. Under ultrasound guidance, roughly 3cc of normal saline will be injected near the neuroma.
2959179|NCT02838745|Experimental|Pemetrexed and Cisplatin|• Pemetrexed and cisplatin will be admixed together in 1 liter of normal saline. The admixture of pemetrexed/cisplatin is stable for 4 hours and should be prepared and delivered immediately before use in the OR. The length of the pemetrexed/cisplatin lavage will be 1 hour.
2959180|NCT02838732|Experimental|vegetarian|oral L-carnitine for one month
2959181|NCT02838732|Sham Comparator|omnivore|oral L-carnitine for one month
2959182|NCT02838719|Experimental|Perineural group|Group 1: perineural dexamethasone acetate added to bilateral transverse abdominis plane block with levobupivacaine
2959183|NCT02838719|Active Comparator|Intravenous group|Group 2: Intravenous dexamethasone acetate added with bilateral transverse abdominal plane block with levobupivacaine
2959184|NCT02838706||Elderly with hip fracture|The subjects are patients age ≥ 65 years requiring surgery for a hip fracture
2959185|NCT02838693||APT-2D (Normoglycemic)|800 Normoglycemic
2959186|NCT02838693||APT-2D (Pre-Diabetic)|1,500 Pre-Diabetic
2959187|NCT02838680|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
2959188|NCT02838667|No Intervention|Standard of Care|If participants are randomized into the non-intervention group, the participants' information during the study period will be collected. Participants will be managed by a care provider as per the standard of care. Participants may receive nephrology consultation as indicated clinically.
2959189|NCT02838667|Experimental|Standard of Care plus Nephrology Care|If participants are randomized into the intervention group, participants' information will be checked by the study investigators daily for 7 days (2 days pre-op and 5 days post-op). When appropriate, investigators may give suggestions to minimize the participants' risk(s) for AKI. Participant's primary care providers may take the suggestions into consideration. Participants' primary care providers are not obligated to carry out the suggestions that are given.
2959190|NCT02838654||cervical epidural injection group|cervical epidural injection group
2959191|NCT02838628|Experimental|KX2-391 Ointment|
2959192|NCT02838615|Active Comparator|epidural steroid injection|TF epidural steroid (dexamethasone) injection
2959193|NCT02838615|Active Comparator|IL epidural steroid injection|PS interlaminar epidural steroid(dexamethasone) injection
2959196|NCT02838589|Active Comparator|Byetta|"Pre- and post treatment investigations:~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)~Endothelial function/response by the methods:~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)~EndoPAT2000~Ankle-brachial index"
2959197|NCT02838589|Placebo Comparator|Isotonic saline|"Pre- and post treatment investigations:~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)~Endothelial function/response by the methods:~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)~EndoPAT2000~Ankle-brachial index"
2959198|NCT02838576|Experimental|Conjugated Equine Estrogen|"Thirty-six healthy postmenopausal women aged between 45 and 55 years will receive 0,625 mg/day conjugated equine estrogen (CEE) for 12 weeks. These 1 active pill containing conjugated equine estrogen, 0,625 mg will be provided by a laboratory with no trademark identification.~The bottles will be numbered in code by a pharmaceutist not involved directly in study and they will donated to volunteers.~During the intervening period, use of conjugated equine estrogen, there will be blinding. After this phase, blinding will be interrupted in order to identify volunteers who used the active drug."
2959199|NCT02838576|Placebo Comparator|Placebo|"Thirty-six healthy postmenopausal women aged between 45 and 55 years will receive placebo pills, identical in size, shape and color to the active drug, via oral administration, for 12 weeks.~The bottles, without trademark identification, will be numbered in code by a pharmaceutist not involved directly in study and they will donated to volunteers.~During the intervening period, use of placebo, there will be blinding. After this phase, blinding will be interrupted in order to identify volunteers who used the active drug and placebo."
2959200|NCT02838563||Patient living in nursing home|Patient with an Alzheimer Disease or related disorder living in nursing home.
2959201|NCT02838550|Experimental|MOI and PEDOMETER|Accessing to a motivational online intervention and wearing an unblinded pedometer (in order to receive feedback of the steps taken).
2959202|NCT02838550|Experimental|MOI (without PEDOMETER)|Accessing to a motivational online intervention and wearing a blinded pedometer (in order to not receive feedback of the steps taken).
2959203|NCT02838550|No Intervention|CONTROL|Wearing a blinded pedometer (in order to not receive feedback of the steps taken).
2959204|NCT02838537||Triptan Arm|"Users of triptan defined as at least one recorded dispensing of any drug during the follow up, with no recorded of any of these drugs during the previous 6 months (new or incident users)"
2959205|NCT02838537||Ergot Arm|"Users of ergot derivative defined as at least one recorded dispensing of any drug during the follow up, with no recorded of any of these drugs during the previous 6 months (new or incident users)"
2959206|NCT02838511||Non-cardiac surgery|Hopkins Frailty Score (HFS) or Modified Frailty Index (MFI) will be obtained during during pre anesthesia evaluation
2959207|NCT02838498|Experimental|Intensive EMS training group|"Device: ERCP mechanical simulator training EMS group was coached (by JWL) on how to use the EMS, and then practiced with supervision by a senior surgeon biliary endoscopist (WBM). Trainees practiced for a total of 20 hours performing basic maneuvers including scope insertion 2 hours, scope positioning 6 hours, selective guide wire cannulation of common bile duct (CBD) stricture or pancreatic duct (PD) 10 hours and placement of a biliary stent 2 hours.~All trainees received hands-on supervised clinical ERCP practice on patients. Time taken to perform ERCP procedures was documented. Trainees received verbal instructions, hands-on assistance from the trainer in performing the clinical procedure. If the trainee still failed after 20 minutes, the trainer took over."
2959208|NCT02838498|No Intervention|Routine ERCP training group|Other: Routine ERCP training group All trainees received hands-on supervised clinical ERCP practice on patients. Time taken to perform ERCP procedures was documented. Trainees received verbal instructions, hands-on assistance from the trainer in performing the clinical procedure. If the trainee still failed after 20 minutes, the trainer took over.
2959209|NCT02838485|Experimental|Amputees|The subjects will receive both mirror and imagery treatments in a cross-over design.
2959210|NCT02838446|Experimental|Cognitive Therapy|Graded motor imagery program was applied in only intervention group for 8 weeks.
2959211|NCT02838446|Active Comparator|Control|Rehabilitation program applied in both groups for 8 weeks. Frequency of the treatment was 2 days in per week and its duration was approximately one hour in one session.
2959212|NCT02838433|Experimental|Biological samples|"Blood samples will be collected :~at baseline,~6 months after the first-line therapy or at disease progression (if occurs first).~In particular case of patient with immunotherapy or targeted therapy, 3 blood samples will be collected :~at baseline~3 months after the initiation of immunotherapy or targeted therapy~at disease progression Tumor tissues will be collected if available."
2959213|NCT02838420|Experimental|Alectinib|Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death.
2959214|NCT02838420|Active Comparator|Crizotinib|Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death.
2959215|NCT02838407|Other|Total group|Enrolled subjects who visited the hospital with suspected chronic LRTIs and for whom BAL fluid and/or nasopharyngeal swab samples have been collected.
2959216|NCT02838394|Experimental|Dry Needling|Trigger points found in the gluteal region of one side (e.g. right) will be dry needled; presence of muscle twitching (which would signify appropriate needle insertion) will be documented.
2959217|NCT02838394|Sham Comparator|Sham Dry Needling|Trigger points found in the gluteal region of one side (e.g. right) will be SHAM dry needled with blunted needles, no actual penetration through the skin will occur.
2959218|NCT02838381|Other|Additional biological samples|"Additional blood samples will be realized at the inclusion of patients. Two optional blood samples could be realized if necessary with at least 3 months apart.~Peripheral Blood Mononuclear Cells (PBMC) will be collected. Tissue tumor will be collected if available."
2959219|NCT02838355|Active Comparator|Standard Respiration Monitoring|Participants scheduled for mechanical circulatory support device (MCSD) implant or who have been readmitted to an intensive care unit (ICU) with a continuous flow left ventricular assist device (CF-LVAD) will receive standard respiratory monitoring throughout their stay in the ICU.
2959348|NCT02837575|Placebo Comparator|Phosphate-buffered saline, 1-mL dose|PBS, 1-mL dose by intramuscular injection once every 28 days for 4 doses
2959220|NCT02838355|Experimental|Standard Respiration Monitoring + Continuous ETCO2-NC|Participants scheduled for mechanical circulatory support device (MCSD) implant or who have been readmitted to an intensive care unit (ICU) with a continuous flow left ventricular assist device (CF-LVAD) will receive standard respiratory monitoring and continuous end-tidal capnography monitoring via nasal cannula (ETCO2-NC) throughout their stay in the ICU.
2959221|NCT02838342|Experimental|Metronomic cyclophosphamide and interferon-alpha|
2959222|NCT02838329|Active Comparator|room temperature - RT|Ropivacaine used for Epidural top-up administered at room temperature
2959223|NCT02838329|Experimental|body temperature BT|Ropivacaine used for Epidural top-up administered warmed to body temperature
2959224|NCT02838316|Experimental|150 x 106 dosage|10 subjects will be receiving a dosage of 150 x 106 AMDC-GIR
2959225|NCT02838316|Experimental|300 x 106 dosage|10 subjects will be receiving a dosage of 300 x 106 AMDC-GIR
2959226|NCT02838303|Other|Group A|Initial spray session: organophosphate. Crossover spray session: placebo
2959227|NCT02838303|Other|Group B|Initial spray session: placebo. Crossover spray session: organophosphate
2959228|NCT02838290|Experimental|Induction|
2959229|NCT02838290|Other|Control group|
2959230|NCT02838277||Lipedema|Women with all stages of lipedema
2959231|NCT02838277||Dercum's disease|Men and women with nodular, mixed and diffuse Dercum's disease
2959232|NCT02838277||Control|Sex, age and BMI matched controls.
2959233|NCT02838277||Familial Multiple Lipomatosis|Women and men with multiple lipomas and/or angiolipomas
2959234|NCT02838277||Madelung's disease|Men and women with different types of Madelung's disease.
2959235|NCT02838264|Experimental|Cohort 1|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
2959236|NCT02838264|Experimental|Cohort 2|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
2959237|NCT02838264|Experimental|Cohort 3|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
2959238|NCT02838264|Experimental|Cohort 4|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive the highest safe dose (mg) of PF-06463922 as a single-dose Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
2959239|NCT02838238|Experimental|X|Capecitabine 1250mg/m², bid, po, d1-14, every 3 weeks for 6 cycles
2959240|NCT02838238|Placebo Comparator|Placebo|Placebo, bid, po, d1-14, every 3 weeks for 6 cycles
2959241|NCT02838225|Experimental|DA|docetaxel 75 mg/m², iv, day 1, doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1, every 3 weeks for 6 cycles
2959242|NCT02838225|Active Comparator|DAC|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
2959243|NCT02838212||Drug-related deaths|fatal adverse drug reactions
2959244|NCT02838212||non drug-related deaths|deaths for other causes different as drugs
2959245|NCT02838199|Experimental|TAVR|Transcatheter aortic valve replacement with SAPIEN 3
2959246|NCT02838199|Active Comparator|SAVR|Surgical aortic valve replacement
2959247|NCT02838186|Active Comparator|right colon in retroflexion|"polyp/adenoma detection~feasibility"
2959248|NCT02838186|Active Comparator|right colon in forward view|polyp/adenoma detection
2959249|NCT02838173|Experimental|SPB|Serratus Plane Bloc with Ropivacaine 2mg/ml (0,3ml/kg) and tissue infiltration with placebo made once, by the anesthetist in the operating theater before surgical incision
2959250|NCT02838173|Active Comparator|tissue infiltration|tissue infiltration with Ropivacaine 2mg/ml (0,3ml/kg) and Serratus Plane Bloc with placebo made once, by the anesthetist in the operating theater before surgical incision
2959251|NCT02838160|Experimental|booklet Group|
2959252|NCT02838160|Experimental|Oral presentations group|
2959253|NCT02838160|Experimental|Clinical teaching in bedside Group|
2959254|NCT02838147|Experimental|Normal OGTT (Oral Glucose Tolerance Test)|Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.
2959255|NCT02838147|Experimental|Pathological OGTT - 1 abnormal value|Patients will pathological OGTT (either one or more abnormal values) will be randomly allocated to the antenatal care plus FreeStyle group or the SMBG group by a computer generated random number table
2959256|NCT02838147|Experimental|Pathological OGTT - 2 abnormal value|Patients will pathological OGTT (either one or more abnormal values) will be randomly allocated to the antenatal care plus FreeStyle group or the SMBG group by a computer generated random number table
2959257|NCT02838134|Experimental|Group A: Deep Neuromuscular blockade|An extra bolus of rocuronium after intubation followed by infusion
2959258|NCT02838134|Sham Comparator|Group B: Moderate neuromuscular Blockade|Moderate neuromuscular Blockade No additional rocuronium after intubation.
2959259|NCT02838121|Experimental|Aclasta|Aclasta IV once annual for 2 years
2959260|NCT02838121|Placebo Comparator|Placebo|Placebo group
2959261|NCT02838108||patients with COPD|
2959262|NCT02838095|No Intervention|No nap|After each night with a 5-hour sleep opportunity, participants did not have a daytime nap opportunity, but instead watched documentaries.
2959263|NCT02838095|Experimental|Nap|After each night with a 5-hour sleep opportunity, participants had the chance to take a daytime nap from 14:00 to 15:00.
2959264|NCT02838082|Experimental|Sleep Hygiene Protocol|Participants in this arm will undergo a 4 week sleep hygiene protocol
2959265|NCT02838082|Active Comparator|Standard of Care Protocol|Participants will undergo 4 weeks of current inpatient standard of care procedures in a rehabilitation facility
2959266|NCT02838069|Experimental|2x106 ASC intra-articular injection|Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
2959377|NCT02837367|Other|Adults genetic assessment|Establishing a genetic signature model in the 1-carbon and omega-6/3 fatty acids metabolic pathways, with high predictive value for dyslipidemia and insulin resistance classification in adult people with obesity.
2959267|NCT02838069|Experimental|10x106 ASC intra-articular injection|Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
2959268|NCT02838069|Placebo Comparator|Placebo|0.5% glucose in saline with 4.5% albumin
2959269|NCT02838056|Experimental|epidural injection|epidural injection of 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
2959270|NCT02838043|Experimental|Participant|All participants will be experimental and receive Probio'Stick.
2959271|NCT02838030|Experimental|acetylsalicylic acid and L-arginine|acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and L-arginine 3 gr every 8 hours from the 20th week of pregnancy to pregnancy termination
2959272|NCT02838030|Placebo Comparator|acetylsalicylic acid and placebo|acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and placebo 3 gr every 8 hours from the 20th week of pregnancy to pregnancy termination
2959273|NCT02838017|Experimental|Tissue Adhesive|Tissue Adhesive will be placed over subcuticular suture closure.
2959274|NCT02838017|Active Comparator|Steri-Strips|Sterile strips will be placed over subcuticular suture closure.
2959275|NCT02838004|Other|Heidelberg University|IOL MINI WELL READY implant
2959276|NCT02837991|Experimental|CDX-014|"During the treatment phase of the study, patients will receive CDX-014 treatment every 3 weeks (RCC or OCCC) or every 2 weeks (RCC) as long as they remain eligible. Patients may be discontinued from CDX-014 treatment based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~The planned dose of CDX-014 depends on the cohort assigned at enrollment."
2959277|NCT02837978|Experimental|Tacrolimus group|RA patients treated with tacrolimus, without MTX
2959278|NCT02837978|Active Comparator|Tacrolimus + MTX group|RA patients treated with tacrolimus and MTX
2959279|NCT02837965||diagnosed bullous pemphigoid|
2959280|NCT02837952|Active Comparator|Fixed Dose Combination(FDC) IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
2959281|NCT02837952|Placebo Comparator|Placebo|Placebo
2959282|NCT02837939|Experimental|Active|Drug: Human derived Transfer factor applied by subcutaneous injection in specified time points.
2959283|NCT02837939|Placebo Comparator|Control|Aqua pro injectione 4 mL ampules for subcutaneous administration in the same time points as in the active arm
2959284|NCT02837926|Experimental|women attending for cervical cancer screening|
2959285|NCT02837913|Experimental|Underbody warmer on|Underbody warmer will be underneath the patient and turned on.
2959286|NCT02837913|Placebo Comparator|Underbody warmer off|Underbody warmer will be underneath the patient but not turned on.
2959287|NCT02837900|Placebo Comparator|Previous LT TX knee and right placebo|Previous left treated knee will have placebo treatment in this protocol.
2959288|NCT02837900|Placebo Comparator|Previous RT TX knee and left placebo|Previous right treated knee will have placebo treatment in this protocol.
2959289|NCT02837900|Active Comparator|Both TX with Active|Both knees with receive Active
2959290|NCT02837887|Experimental|Group I (immediate treatment)|Patients undergo computerized cognitive behavior therapy consisting of 45-60 minute sessions once per week for 8 weeks. Patients also complete the PHQ-9 and GAD7 at weeks 1, 3, 5, 7 and 8 and complete other questionnaires for 15-30 minutes each that assess psychosocial and physical symptoms.
2959291|NCT02837887|Experimental|Group II (wait-list)|Patients are placed on an 8-week wait-list and then undergo computerized cognitive behavior therapy and receive questionnaires as in Group I.
2959292|NCT02837874|Active Comparator|Isoperistaltic|Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
2959293|NCT02837874|Experimental|Antiperistaltic|Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
2959294|NCT02837861|Experimental|Experimental Group|Routine Nutritional Support plus supplemental IV amino acids, to begin within 24h of injury. (Target 1.5-2g protein/kg/day)
2959295|NCT02837861|Active Comparator|Control Group|Routine Nutritional Support (i.e. enteral nutrition as tolerated, to begin as early as medically feasible)
2959296|NCT02837848|Experimental|Coactivation strengthening|Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
2959297|NCT02837848|Active Comparator|Regular strengthening|Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
2959298|NCT02837835|Experimental|continuous administration of ceftazidime|
2959299|NCT02837835|Experimental|intermittent administration of ceftazidime|
2959300|NCT02837822|Active Comparator|Stimulation Off|"Patients receiving the intervention implantation with a spinal cord stimulator. The system is turn Off during the experiment."
2959301|NCT02837822|Active Comparator|Stimulation On|"Patients receiving the intervention implantation with a spinal cord stimulator. The system is turn On during the experiment."
2959302|NCT02837809|Experimental|Intervention|Low Dose CT, annual or biennial, associated with primary prevention and pulmonary function test evaluation.
2959303|NCT02837809|No Intervention|Control|Program of primary prevention with pulmonary function test evaluation
2959304|NCT02837796|Active Comparator|inside-outside group|inside-out transobturator tape approach
2959305|NCT02837796|Active Comparator|outside-inside group|outside-in transobturator tape approach
2959306|NCT02837783|Experimental|290 μg linaclotide|Linaclotide Oral, once daily
2959307|NCT02837783|Placebo Comparator|Matching Placebo|Matching Placebo Oral, once daily
2959308|NCT02837770|Active Comparator|Pacebo pill and Diclofenac Eye Drops|Pacebo pill will be administered 4 hours before the IVI and one drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
2959309|NCT02837770|Active Comparator|Oral Diclofenac and Diclofenac Eye Drops|One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI and one drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
2959310|NCT02837770|Placebo Comparator|Pacebo pill and Artificial Tears|Pacebo pill will be administered 4 hours before the IVI and one drop Artificial Tears will be instilled 45' prior to the IVI.
2959311|NCT02837757|Experimental|Biological samples|"Blood samples will be realized specifically to the study at inclusion (baseline before starting everolimus treatment), and then 3 months and 9 months (or at disease progression if occurs first) after initiation of everolimus treatment Peripheral blood mononuclear cell (PBMC) and serum will be collected.~Available tumor tissues samples will be collected."
2959312|NCT02837744|Experimental|Axiostat®|Size: 3.5 cm X 3.5 cm
2959313|NCT02837744|Active Comparator|Standard Institutional Care Product|Radial band: Size - 24 cm X 4 cm; Cotton Gauze: Size - 5 x 5 cm
2959314|NCT02837731|Experimental|Treatment Starling SV monitor|A dynamic assessment of fluid responsiveness using the Starling SV monitor will be performed at every clinical decision point for the first 72 hours of study enrollment. Examples of a clinical decision point include a mean arterial pressure (MAP) of < 65, the decision to give additional fluid volume, and the decision to either escalate or wean vasopressors. Fluid responsiveness will be assessed using a passive leg raise (PLR) to guide corresponding treatment.
2959315|NCT02837731|No Intervention|Control|No required therapeutic protocol will be used for patient treatment, and is determined per the discretion of the physician and hospital standards.
2959316|NCT02837718|Other|21 mL bupivocain|As for local anesthetic 21 mL bupivocain used for axillary brachial plexus blocade
2959317|NCT02837718|Other|19,5 mL bupivocain|As for local anesthetic 19,5 mL bupivocain used for axillary brachial plexus blocade
2959318|NCT02837718|Other|18 mL bupivocain|As for local anesthetic 18 mL bupivocain used for axillary brachial plexus blocade
2959319|NCT02837718|Other|16,5 mL bupivocain|As for local anesthetic 16,5 mL bupivocain used for axillary brachial plexus blocade
2959320|NCT02837718|Other|15 mL bupivocain|As for local anesthetic 15 mL bupivocain used for axillary brachial plexus blocade
2959321|NCT02837718|Other|13,5 mL bupivocain|As for local anesthetic 13,5 mL bupivocain used for axillary brachial plexus blocade
2959322|NCT02837718|Other|12 mL bupivocain|As for local anesthetic 12 mL bupivocain used for axillary brachial plexus blocade
2959323|NCT02837718|Other|10,5 mL bupivocain|As for local anesthetic 10,5 mL bupivocain used for axillary brachial plexus blocade
2959324|NCT02837718|Other|9 mL bupivocain|As for local anesthetic 9 mL bupivocain used for axillary brachial plexus blocade
2959325|NCT02837718|Other|7,5 mL bupivocain|As for local anesthetic 7,5 mL bupivocain used for axillary brachial plexus blocade
2959326|NCT02837718|Other|6 mL bupivocain|As for local anesthetic 6 mL bupivocain used for axillary brachial plexus blocade
2959327|NCT02837705||carriers of a mutation in the Prion gene|Carriers of a mutation in the Prion gene who are either symptomatic or pre-symptomatic and who do either know or not know their mutation status.
2959328|NCT02837705||family members of carriers of a mutation in the Prion gene|Relatives of confirmed PrP mutation carriers who carry two wild type alleles.
2959329|NCT02837692|Experimental|Cohort 1|Participants assigned to Cohort 1 group A (elderly non-Asian), group B (young healthy non-Asian) and group C (healthy Japanese) will receive JNJ-42847922 10 mg, 3 hours after completing dinner.
2959330|NCT02837692|Experimental|Cohort 2|Participants assigned to Cohort 2 group A, group B and group C will receive JNJ-42847922 20 mg, 3 hours after completing dinner.
2959331|NCT02837692|Experimental|Cohort 3|Participants assigned to Cohort 3 group A and group C will receive JNJ-42847922 40 mg, 3 hours after completing dinner. Participants in group B will receive JNJ-42847922 40 mg, 3 hours after completing dinner in Period 1, followed by at least 7 days washout period, further followed by JNJ-42847922 40 mg, immediately after completing dinner.
2959332|NCT02837692|Experimental|Cohort 4|Participants assigned to Cohort 4 group B will receive JNJ-42847922 60 or 80 mg, 3 hours after completing dinner.
2959333|NCT02837679|Experimental|Intervention|Geriatric follow up
2959334|NCT02837679|No Intervention|Control|Usual care
2959335|NCT02837666|Active Comparator|Exercise group and supplementation|Supplementation with Spirulina maxima Supplementation with placebo Group with exercise program and supplementation with Spirulina maxima or placebo (4.5 g/d) in capsules during 6 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 6 more weeks. During the 14 weeks of study duration every participant will have a personal isoenergetic diet.
2959336|NCT02837666|Active Comparator|No exercise group and supplementation|Supplementation with Spirulina maxima Supplementation with placebo Group without exercise program and supplementation with Spirulina maxima or placebo (4.5 g/d) in capsules during 6 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 6 more weeks. During the 14 weeks of study duration every participant will have a personal isoenergetic diet.
2959337|NCT02837653|Experimental|Experimental|Usual Care in Primary Health Care in Low back pain patients, consisting in Therapeutic Exercise and Superficial Thermotherapy at home, and a personalized Physical Activity Counseling based on the Cardiovascular Risk of Each Patient
2959338|NCT02837653|Active Comparator|Control|Usual Care in Primary Health Care in Low back pain patients, consisting in Therapeutic Exercise and Superficial Thermotherapy at home.
2959339|NCT02837640|Experimental|Treatment|"This is a single armed study. All patients included will receive treatment. Control will happen with data from the same patients before they received treatment.~patients will receive sinemet 200/50 1/2 tablet (levodopa-carbidopa 100/25) b.i.d for two days and then will be increased to t.i.d. for 6 months."
2959340|NCT02837614|Active Comparator|Group A (intramuscular dexamethasone)|In Group A patients, 1 ml of dexamethasone (4mg) administered in the deltoid muscle before commencement of surgical procedure
2959341|NCT02837614|Experimental|Group B (submucosal dexamethasone)|In Group B patients, 1 ml of dexamethasone was administered in submucosa after local anesthesia
2959342|NCT02837614|Placebo Comparator|Group C (control)|Group C patients continued without receiving any preoperative medication.
2959343|NCT02837601|Other|LOW AIS Pressure AirSeal®|AIS with an insufflation pressure target of 9mmHg ±1mmHg
2959344|NCT02837601|Other|HIGH AIS Pressure AirSeal®|AIS with an insufflation pressure target of 15mmHg ±1mm
2959345|NCT02837588|Active Comparator|Hyperthermy treatment with MJS electrode|30 patients who are diagnosed with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points
2959346|NCT02837588|No Intervention|CONTROL|No intervention with radiofrequency treatment, only evaluation to usual drug treatment
2960044|NCT02832713|Active Comparator|Intra-articular injection of hyaluronic acid|
2959349|NCT02837562||Interventional Cardiology/Cath Lab Staff|"This is considered to be the case or group under study. These are Interventional Cardiology/ Cardiac Cath lab staff that are exposed to radiation as a result of their role as Cardiac Cath lab staff.~Intervention: Slit lamp eye examination"
2959350|NCT02837562||Non-Interventional Cardiology/ Controls|"This is considered to be the control or comparison group. These are non-interventional cardiology/ non-cardiac cath lab staff that are not exposed to radiation as they do no operate/ work in the Cardiac Cath Lab.~Intervention: Slit lamp eye examination"
2959351|NCT02837549|Experimental|Occupational therapy treatment|"Participants will undergo the following as appropriate:~Thermal Modalities Hot packs, focused on areas with limitations Paraffin, focused on digital limitations~Application of the Physiotouch (a low-intensity negative pressure device)~Passive Range of Motion~Active Range of Motion~Functional Activities"
2959352|NCT02837536|Active Comparator|Horizontal iCare|In the horizontal iCare arm, these patients were randomized to have their IOP measured with the iCare tonometer held in the horizontal position first and then their IOP measured with the iCare tonometer held in the vertical position.
2959353|NCT02837536|Active Comparator|Vertical iCare|In the vertical iCare arm, these patients were randomized to have their IOP measured with the iCare tonometer held in the vertical position first and then their IOP measured with the iCare tonometer held in the horizontal position.
2959354|NCT02837523||Observation|Patients with a Cystinosis disease or high-grade suspicion for Cystinosis disease
2959355|NCT02837510|Other|Standard smoking cessation counseling|Participants will receive a standard treatment program consisting of smoking cessation counseling.
2959356|NCT02837497|No Intervention|Control|Standard ICU resuscitation practices
2959357|NCT02837497|Experimental|ICU-RESUS CPR Improvement Bundle|ICU-RESUS bundle implementation: 1) point-of-care bedside CPR training; and 2) post-cardiac arrest debriefings.
2959358|NCT02837484|Other|NuTech Affinity™ Membrane|Sharp dissection of the defect will be performed being careful not to violate the subchondral bone sparing the calcified cartilage layer. After hemostasis is reached, the defect will be treated with an Affinity™ patch stabilized with fibrin glue.
2959359|NCT02837471|Experimental|Intervention group, PiezoRx device|Participants will use the PiezoRx pedometer at leisure for 12 weeks, and receive the standard care of the FrancoForme cardiac prevention and rehabilitation program.
2959360|NCT02837471|No Intervention|Control group, Standard care|Participants will receive the standard care of the FrancoForme Cardiovascular disease prevention and rehabilitation program.
2959361|NCT02837458|Experimental|High-Frequency|"Transcutaneous application of high frequency electrical current over the arm for a 30 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
2959362|NCT02837458|Sham Comparator|Sham Stimulation|Electrodes are placed over the arm for a 30 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
2959363|NCT02837445|Active Comparator|Treatment|Eligible patients randomized after optimization phase to PHC ON for 3 months Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
2959364|NCT02837445|Placebo Comparator|Control|Eligible patients randomized after optimization phase to pacemaker only (PHC OFF) for 3 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
2959365|NCT02837432|Other|Healthy|Healthy individuals will receive both the placebo and hydrocortisone interventions in a randomized order
2959366|NCT02837432|Other|Depression|Individuals with depression will receive both the placebo and hydrocortisone interventions in a randomized order
2959367|NCT02837406||Doctors|specialists and general practitioners by ich territory
2959368|NCT02837406||Health professionals|"pharmacists~nurses~physiotherapists~Medical and social professionals: social workers, psychologists, educators ..."
2959369|NCT02837406||Medical-social institutes|"Hospital,~Healthcare structure,~Local Centre of Information and Gerontological Coordination ..."
2959370|NCT02837393||History of Kidney Stones|Participants with a history of kidney stones who will be undergoing kidney surgery.
2959371|NCT02837393||No History of Kidney Stones|Participants without a history of kidney stones who will be undergoing kidney surgery.
2959372|NCT02837380|Experimental|FF/UMEC/VI|Subjects will receive single combination dose of FF/UMEC/VI 100/62.5/25 mcg via a DPI in the morning for 7 days.
2959373|NCT02837367|Experimental|Adult intervention|"The intervention will consist of the administration of nutrients (as capsules) containing: 2 g betaine, 800 ug (micrograms) 5-MTHF (L-5-methyltetrahydrofolate) + 1000 ug (micrograms) Vitamin B12, 500 mg choline bitartrate, 1 g ALA (alfa-linolenic acid), 700 mg EPA (eicosapentaenoic acid), 280 mg DHA (docosahexaenoic acid).~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
2959374|NCT02837367|Placebo Comparator|Adult placebo|"The intervention will consist of the administration of nutrients (as capsules) containing inactive ingredients with low glycemic index (usually starch-based), and one capsule containing corn oil (1 g).~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
2959375|NCT02837367|Experimental|Children intervention|"The intervention will consist of the administration of nutrients (as capsules) containing: 1 g betaine, 400 ug (micrograms) 5-MTHF (L-5-methyltetrahydrofolate) + 500 ug (micrograms) Vitamin B12, 250 mg choline bitartrate, 0.5 g ALA (alfa-linolenic acid), 700 mg EPA (eicosapentaenoic acid), 140 mg DHA (docosahexaenoic acid).~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
2959376|NCT02837367|Placebo Comparator|Children Placebo|"The intervention will consist of the administration of nutrients (as capsules) containing inactive ingredients with low glycemic index (usually starch-based), and one capsule containing corn oil (1 g).~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
2959378|NCT02837367|Other|Children genetic assessment|Establishing a genetic signature model in the 1-carbon and omega-6/3 fatty acids metabolic pathways, with high predictive value for dyslipidemia and insulin resistance classification in children with obesity.
2959379|NCT02837341|Other|Volunteers|Monitoring of respiratory rates via camera-based System Monitoring of respiratory rate by Philips®Vital Sign Device - Camera-based system (Prototype) and capnography simultaneously.
2959380|NCT02837328|Experimental|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
2959381|NCT02837328|Placebo Comparator|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
2959382|NCT02837315|Experimental|BMI + SFAS|"Participants first receive a 50-minute standard brief motivational intervention designed to reduce marijuana use. A week later, they will receive the SFAS (Substance-free Activity Session., a 50-minute counseling session designed to increase the salience of the student's academic and career goals, draw attention to the potentially negative relationship between substance use and goal accomplishment, and increase engagement in substance-free alternative activities. The SFAS was described to participants as the College Adjustment Session and the session was conducted using an MI plus personalized feedback approach."
2959383|NCT02837315|Active Comparator|BMI + Relaxation Session|Participants first receive a 50-minute standard brief motivational intervention designed to reduce marijuana use. A week later, they will receive a relaxation training session. In the relaxation training session, the clinician leads the student through a diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, students were asked about their reaction to the relaxation techniques and were provided with relaxation training handouts.
2959384|NCT02837315|No Intervention|Assessment|Participants fill out a battery of measures and receive no intervention.
2959385|NCT02837302|Active Comparator|Livact|Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
2959386|NCT02837302|No Intervention|General nutritional support|General nutritional support
2959387|NCT02837289|Other|Treatment|Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.
2959388|NCT02837289|Other|Placebo|Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
2959389|NCT02837263|Experimental|SBRT + Pembrolizumab|Subjects will receive stereotactic body radiotherapy (SBRT) within 4 weeks of enrollment. Following SBRT, subjects will receive one cycle of pre-operative pembrolizumab given as an IV over approximately 30 minutes. Surgical management to remove all known sites of metastatic disease should occur 2 weeks post pembrolizumab treatment. Approximately 4-8 weeks after surgery subjects will being the second phase of pembrolizumab treatment. They will receive this treatment every 3 weeks (cycle) for 8 more cycles after surgery. Prior to the 5th cycle of pembrolizumab subjects will also have tumor imaging (CT or MRI).
2959390|NCT02837250|Experimental|Pos4Health|Pos4Health is a 6 Core Internet intervention focusing on improving adherence to ART among nonadherent substance users living with HIV in non urban areas. Pos4Health Cores each present a topic, show videos of HIV+ peers discussing that topic, and how they have coped with it, and use interactions to teach about the topic and to develop knowledge and skills. Each core ends with tips to try that include tips mentioned by peers or from expert material. Content is personalized to the user and users receive tailored feedback. Cores are metered out weekly after each Core is completed.
2959391|NCT02837250|Active Comparator|Patient Education|Patient Education is a static (unchanging) website that presents accurate information about the same topics in Pos4Health, but without personalization, peer videos, or interactivity.
2959392|NCT02837237|Experimental|KBP-5074|Single oral dose
2959393|NCT02837224||Preimplementation: Situate Locate System|Subjects/surgeries performed before implementation of the Situate Detection System.
2959394|NCT02837224||Implementation|Subjects/surgeries performed after implementation of the Situate Detection System.
2959395|NCT02837211|Experimental|Tapered Diet|
2959396|NCT02837211|Active Comparator|Traditional Low Calorie Diet|
2959397|NCT02837198|Experimental|Uric acid-overproduction Type|FYU-981
2959398|NCT02837198|Experimental|Uric acid- underexcretion Type|FYU-981
2959399|NCT02837198|Experimental|Uric acid-overproduction Type (combination)|FYU-981 , Topiroxostat
2959400|NCT02837198|Experimental|Uric acid- underexcretion Type2|FYU-981
2959401|NCT02837185|Experimental|Cervical Dystonia|'Botulinum Toxin injection' will be done and 'physiological measures' will then be collected.
2959402|NCT02837185|Other|Healthy controls|No Botulinum toxin is injected, 'physiological measures' will be collected as a healthy comparator.
2959403|NCT02837172||Parkinson's disease from UAB|MDS-UPDRS,Montreal Cognitive Assessment, PDQ-39, Diffusion Weighted Imaging (DWI), and neurological examination.
2959404|NCT02837172||Parkinson's disease from PPMI dataset|Obtain retrospective and prospective de-identified data from the The Parkinson's Progression Markers Initiative (PPMI) dataset on Parkinson's disease (PD) subjects that have the following characteristics: within 2 years of diagnosis, positive DaTscan, and not (at study entry) on any PD related medication.
2959405|NCT02837172||Controls from PPMI dataset|Obtain retrospective and prospective de-identified DTI imaging and data from the PPMI dataset
2959406|NCT02837159|Experimental|mHealth application|The assessment of the end points will be made at three moments: at baseline, at 8 weeks (at the end of the program) and at 12 months of follow-up. The intervention will consist in: 1)Feedback daily or weekly of physical exercise and diet through the application (notice) according to the records of diet and exercise and following recommendations of International Organizations 2) Participation in three sessions of seminars (1 hour each every 15 days) on habits of life healthy and cancer and the self-regulation through measurements performed by the application 3) Calls weekly to the patients of way individual to comment possible errors or doubts about the application, of 10 min of duration (8 calls).
2959407|NCT02837159|No Intervention|Usual care|Usual care
2959408|NCT02837146|Experimental|Tocilizumab (TCZ) + Methotrexate (MTX)|"Induction phase:~From week 0 to week 24, all subjects will receive TCZ and MTX~Maintenance phase:~From week 24 to week 54, all subjects will receive MTX"
2959409|NCT02837133|Experimental|other techniques group|theory and practice of pair massage with tapping, stretching of the ankle and neck, and autogenic training
2960525|NCT02829190|Experimental|Patients treated by radiotherapy|Magnetic Resonance Imaging (MRI)
2959410|NCT02837107|Active Comparator|Supplement|The supplement (Mind Master) were custom prepared and donated by LR Healthy and Beauty Systems LTD. The supplement contained per 80ml, aloe barbadensis miller gel (USA/Mexico 36%), grape juice, Polygonum cuspidatum extract (that contain 10% resveratrol), green tea extract, 1.1 mg vitamin B1 (100% RDA), 2.5 µg vitamin B12 (100% RDA), 12 mg vitamin E (α - ΤΕ) (100% RDA), coenzyme Q10, 200 µg folic acid (100% RDA), ascorbic acid, 27.5 µg selenium (100% RDA), 4.2 mg iron (100% RDA).
2959411|NCT02837107|Placebo Comparator|Placebo|A look-alike placebo were prepared and donated by LR Healthy and Beauty Systems LTD. The placebo contained Aloe barbadensis Miller Gel (USA/Mexico 3.6%), ascorbic acid, and some excipients.
2959412|NCT02837094|Experimental|C19-A3 GNP (Gold Nanoparticles)|C19A3 GNP intradermal microinjectable solution of human C19A3 proinsulin peptide coupled to gold. Solution For Injection The dose given will be equivalent to 10ug of C19A3 peptide at 3 dispensing visits, which are 4 weeks apart. Total 30ug.
2959413|NCT02837081|Active Comparator|Preauthorization group|Strategy 1 of antimicrobial stewardship: Prescriptions of antimicrobial agents are done real-time by infectious diseases physician consultant. Use restricted without real-time authorization.
2959414|NCT02837081|Experimental|Prospective audit|Strategy 2 of antimicrobial stewardship: Prescription of antimicrobial agents are audited 48-72 hours later by infectious diseases physician consultant. Use allowed without authorization for 72 hours.
2959415|NCT02837068|Experimental|Wheelchair handrail compensator|When a patient sitting on the wheelchair, the physiotherapist put the paralysis upper limb on the handrail compensator and keep the limb in normal position for at least 60 minutes one day.
2959416|NCT02837068|Active Comparator|Ordinary wheelchair|When a patient sitting on the wheelchair, the paralysis upper limb was put on the ordinary handrail for at least 60 minutes one day.
2959417|NCT02837055|Experimental|VivaSight intubation|Patients are intubated with the VivaSight-SL endotracheal tube
2959418|NCT02837055|Active Comparator|conventional intubation|Patients are intubated with a conventional endotracheal tube
2959419|NCT02837042|Experimental|Pembrolizumab 200 mg|Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks.
2959420|NCT02837029|Experimental|Treatment (yttrium Y 90 glass microspheres, nivolumab)|Patients receive yttrium Y 90 glass microspheres IA. Approximately 4 weeks after yttrium Y 90 glass microspheres treatment, patients receive nivolumab IV over 30-60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2959421|NCT02837016|Experimental|Experimental 1|Wearable biofeedback device + Relaxation Training
2959422|NCT02837016|Active Comparator|Experimental 2|Relaxation Training only
2959423|NCT02837003||Experimental: Aspirin|Aspirin treatment for 3 months after the Ultimaster sirolimus-eluting stent implantation.
2959424|NCT02837003||Experimental: Thienopyridine|Thienopyridine treatment for 3 months after the Ultimaster sirolimus-eluting Stent implantation.
2959425|NCT02836990|Active Comparator|Prevena|Prevena Incision Management System for vascular surgical groin wounds
2959426|NCT02836990|Active Comparator|Dermabond|Dermabond for vascular surgical groin wounds
2959427|NCT02836977|Experimental|maintenance therapy|Patients will receive oral tegafur-uracil 400mg/day (100mg/Cap., 2 capsules each time, twice a day), combined with oral folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day), and continue for one year.
2959428|NCT02836977|Active Comparator|observation arm|Patients will be observed following adjuvant oxaliplatin-based regimen.
2959429|NCT02836964|Active Comparator|Loading of Dental Implants after 4 weeks|"A total of 12 titanium implants with a modified SLA surface (BLT SLActive®, Institute Straumann AG, Basel, Switzerland) will be placed in the mandibular first molar. for this group.~After 4 weeks definitive crown will be placed."
2959430|NCT02836964|Active Comparator|Loading of Dental Implants after 3 months|A total of 12 titanium implants with a modified SLA surface (BLT SLActive®, Institute Straumann AG, Basel, Switzerland) will be placed in the mandibular first molar for this group. After 3 months definitive crown will be placed
2959431|NCT02836951||Patient|This group consists of patients that are hospitalized due to a head injury. Samples of blood, urine and plasma will taken from these subjects and the fluids will be analyzed for novel biomarkers using a biochemical assay. Cerebrospinal fluid (CSF) will be drawn in cases when sampling is justified for treatment, not for study purpose solely.
2959432|NCT02836951||Healthy controls|This group consists of healthy volunteers. Samples of blood, urine and plasma will taken from these subjects and the fluids will be analyzed for novel biomarkers using a biochemical assay. Cerebrospinal fluid (CSF) will be drawn only upon person's own consent.
2959433|NCT02836938||Severe|Severe chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 3
2959434|NCT02836938||Mild|Mild chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 1-2
2959435|NCT02836938||Control|Bronchiolitis obliterans syndrome (BOS), stage 0
2959436|NCT02836925|Experimental|Ledipasvir+Sofosbuvir,Sofosbuvir+Velpatasvir|The study includes an antiviral treatment with interferon-free regimen followed by lymphoma restaging; following the end of antiviral treatment patients will be evaluated for sustained virological response and safety parameters every 3 months for 1 year and then every 6 months for 2 years. ORR and vital status will be also evaluated
2959437|NCT02836912|No Intervention|Regular education|Regular education for COPD, including percussion and posture drainage.
2959438|NCT02836912|Experimental|Exercise|Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group.
2959439|NCT02836899|Placebo Comparator|Control|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours.
2959481|NCT02836600|Experimental|LY3039478|LY3039478 given orally TIW (3 times per week) in 28 day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or any other discontinuation criteria are met.
2959482|NCT02836587|Experimental|interventional|Experimental group will undergo balance training for 8 weeks.
2959440|NCT02836899|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
2959441|NCT02836886||Sézary syndrome|Patients diagnosed with Sézary syndrome diagnosed according to the WHO-EORTC criteria.
2959442|NCT02836873|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study.
2959443|NCT02836873|Placebo Comparator|Placebo tablets|Each subject will receive a placebo (inactive) tablet once daily for the duration of the study.
2959444|NCT02836860|Other|Healthy Controls|Effects of tactile stimulation on lumbar multifidus activation in healthy adults without LBP.
2959445|NCT02836860|Other|Low Back Pain|Effects of tactile stimulation on lumbar multifidus activation in adults with LBP.
2959446|NCT02836847|Experimental|target therapy|The patients wil receive conventional chemotherapy(GEMOX) combined with target agents according to the result of genomic and proteomic profiling of tumor tissue.
2959447|NCT02836847|Other|GEMOX|The patients wil receive conventional chemotherapy(GEMOX).
2959448|NCT02836834|Experimental|Dose Escalation Cohort|JS001
2959449|NCT02836834|Experimental|Expanded cohort 1|The subjects of expanded cohort 1 will use repeated doses every 2 weeks like multiple dose cohorts
2959450|NCT02836834|Experimental|Expanded cohort 2|The subjects of expanded cohort 2 will use repeated doses every 2 weeks like multiple dose cohorts
2959451|NCT02836821|Experimental|Apatinib|subjects receiving a single 750 mg oral dose of apatinib mesylate tablets and wash-out for 3 days,then rifampicin capsules 600 mg/day orally for 10 days with a single 750 mg oral dose of apatinib mesylate tablets co-administered on day 8 . apatinib mesylate tablets was administered in the morning after an overnight fast of at least 10 h
2959452|NCT02836808|No Intervention|Control|Patients attended with the standard model of care for diabetes, as out-patients in the Internal Medicine area
2959453|NCT02836808|Experimental|CAIPaDi|Patients attended in the Center of Comprehensive Care for the Patient with Diabetes, where they receive attention from 9 specialists in 1 day
2959454|NCT02836795|Experimental|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
2959455|NCT02836782||Naive patients|Patients who begin their first antiretroviral regimen. Blood sample withdrawal
2959456|NCT02836782||Experienced patients|"Patients with a history of antiretroviral treatment, switching to a new regimen.~Blood sample withdrawal"
2959457|NCT02836769|Experimental|Rehabilitation Consult (RC)|Pilot testing: single group pre-post design
2959458|NCT02836743|Experimental|Circadin 2mg|low-dose (2mg) slow-release melatonin for 1 month.
2959459|NCT02836743|Experimental|Circadin 6mg|high-dose (6mg) slow-release melatonin for 1 month.
2959460|NCT02836743|Placebo Comparator|Placebo|Administer placebo pills with identical morphology
2959461|NCT02836730||Lumbar disc herniation|Patients with surgery for lumbar disc herniation;
2959462|NCT02836730||Spinal stenosis|Patients with surgery for lumbar spinal stenosis
2959463|NCT02836730||No surgery|Patients with no surgery for lumbar disc herniation; patients with no surgery for lumbar spinal stenosis;
2959464|NCT02836704|Active Comparator|Standard initial dose of insulin glargine|Dose 1 of insulin glargine will be administered subcutaneously once a day at the same time every day. Previous non-sulfonylurea OADs (eg, metformin, acarbose) are background treatment and will be continued at the same dosage and dosing frequency as before.
2959465|NCT02836704|Experimental|Higher initial dose of insulin glargine|Dose 2 of insulin glargine will be administered subcutaneously once a day at the same time every day. Previous non-sulfonylurea OADs (eg, metformin, acarbose) are background treatment and will be continued at the same dosage and dosing frequency as before.
2959466|NCT02836691|Active Comparator|EKG to Control subjects|healthy controls without asthma or other respiratory disease.
2959467|NCT02836691|Active Comparator|EKG monitoring Mild asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
2959468|NCT02836691|Active Comparator|EKG monitoring severe control asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
2959469|NCT02836691|Active Comparator|EKG monitoring severe uncontrolled asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
2959470|NCT02836678|Active Comparator|Control group|Ridge splitting, immediate implantand PRF.
2959471|NCT02836678|Experimental|Test group|Ridge splitting, immediate implant, Nanobone with PRF.
2959472|NCT02836665|No Intervention|A: Control group|Patients of group A wait routinely until the dermatological investigator in charge arrives at the emergency room. Once the dermatological investigator is on site, he gives a diagnosis and proposes a therapy.
2959473|NCT02836665|Experimental|B: Telemedicine for dermatological emergency patients|"For Patients of group B study-related photographs of the skin lesion and anamnesis data are uploaded to the hospital information system medico. Those data can directly be processed by the dermatological investigator in charge who enters his diagnosis and his therapy proposal."
2959474|NCT02836652|Experimental|Treatment Arm|Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + placebo (1 pill/day) post HeartMate II implant
2959475|NCT02836652|Active Comparator|Control Arm|Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + acetylsalicylic acid (ASA) therapy (81mg/day) post HeartMate II implant
2959476|NCT02836639|Experimental|Busulfan, Etoposide, Bendamustine|All patients will receive the conditioning regimen followed by autologous stem cell transplantation.
2959477|NCT02836626|Experimental|Deep Fascial Mobilization|
2959478|NCT02836626|Experimental|Superficial Fascial Mobilization|
2959479|NCT02836613|Active Comparator|Galcanezumab Reference|Single dose of galcanezumab administered subcutaneously (SC) by manual prefilled syringe.
2959480|NCT02836613|Experimental|Galcanezumab Test|Single dose of galcanezumab administered SC by autoinjector.
2959484|NCT02836574|Experimental|Immediate Treatment|Neo-Kidney Augment (NKA) immediate treatment - Patients who are randomized to receive their first treatment of 2 injections of NKA as soon as NKA product is made available.
2959485|NCT02836574|Active Comparator|Delayed Treatment|Neo-Kidney Augment (NKA) delayed treatment - Patients who are randomized to receive standard of care treatment for the first 12-18 months after NKA product is made available before receiving 2 injections of NKA.
2959486|NCT02836561|Experimental|Intervention Message|Participants who are randomized to the intervention message will receive contraception information in advance of their appointment that may be helpful in their decision-making.
2959487|NCT02836561|No Intervention|Control Message|Participants who are randomized to the control message will receive appointment logistic information that may be a helpful reminder.
2959488|NCT02836548|Experimental|vorinostat|Vorinostat 360 mg once daily
2959489|NCT02836535||patients with complications|Each subject will participate in an audio-recorded interview, either in-person or by telephone, expected to last 30 to 60 minutes. Subjects' responses to the interview questions and basic demographic data will remain confidential. The interview will examine the impact of complications utilizing a semi-structured script specific to each group
2959490|NCT02836535||patients without Complications (control group)|Each subject will participate in an audio-recorded interview, either in-person or by telephone, expected to last 30 to 60 minutes. Subjects' responses to the interview questions and basic demographic data will remain confidential.
2959491|NCT02836509|Experimental|paracetamol group|First Group: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes. (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
2959492|NCT02836509|Experimental|Ibuprofen group|Second Group: 800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
2959493|NCT02836496|Experimental|Mepolizumab|Enrolled subjects will receive either mepolizumab 300 mg or placebo subcutaneous (SC) every 4 weeks while continuing their HES therapy.
2959494|NCT02836496|Placebo Comparator|Placebo|Enrolled subjects will receive either mepolizumab 300 mg or placebo SC every 4 weeks while continuing their HES therapy.
2959495|NCT02836483|Experimental|Group 1|LCB01-0371 800mg, QD
2959496|NCT02836483|Experimental|Group 2|LCB01-0371 400mg, BID
2959497|NCT02836483|Experimental|Group 3|LCB01-0371 800mg, BID
2959498|NCT02836483|Active Comparator|Group 4|Tubes 3~5Tablet, QD
2959499|NCT02836483|Active Comparator|Group 5|Zyvox 600mg, BID
2959500|NCT02836470|Experimental|LB1148|Active
2959501|NCT02836470|Placebo Comparator|Placebo|Placebo
2959502|NCT02836457||Population with Exposure to ELIQUIS (APIXABAN)|
2959503|NCT02836431|Experimental|DEX 1 mcg/kg Intranasal|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
2959504|NCT02836431|Experimental|DEX 2 mcg/kg Intranasal|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
2959505|NCT02836431|Experimental|DEX 1 mcg/kg Intravenous|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
2959506|NCT02836418|Experimental|ATYR1940|All patients will receive ATYR1940 at the highest tolerated dose received in the parent study for 12-weeks. After 12 weeks, if the patient is demonstrating good tolerability, theATYR1940 dose may be increased on a patient-specific basis at the Investigator's discretion, in consultation with the Sponsor and Medical Monitor. ATYR1940 dose increases to >3.0 mg/kg are not permissible.
2959507|NCT02836405||Autism Spectrum Disorder (ASD)|Individuals diagnosed with an Autism Spectrum Disorder (ASD) will receive transcranial magnetic stimulation (TMS) to measure brain plasticity.
2959508|NCT02836405||Intellectual Disability|Individuals diagnosed with an intellectual disability will receive transcranial magnetic stimulation (TMS) to measure brain plasticity.
2959509|NCT02836405||Healthy Control|Typically developing individuals without a history of autism will receive transcranial magnetic stimulation (TMS) to measure brain plasticity.
2959510|NCT02836379||Breakthrough Cancer Pain|No intervention (Non-interventional study)
2959511|NCT02836353|No Intervention|Observational only|Oral glucose tolerance test, neurocognitive questionnaire tasks only.
2959512|NCT02836353|Experimental|Somatostatin|Oral glucose tolerance test after 100mcg Somatostatin
2959513|NCT02836353|Experimental|Antibiotics|Oral glucose tolerance test after treatment of small intestinal bacterial overgrowth
2959514|NCT02836340|Experimental|2-Iminobiotin|Increasing dosage of study drug
2959515|NCT02836327||Multiple sclerosis|Multiple sclerosis patients confirmed by neurologist according to the 2010 revised Mcdonald criteria without other nervous system diseases.All patients performed magnetic resonance imaging.
2959516|NCT02836327||Neuromyelitis optica spectrum disorders|Neuromyelitis optica spectrum disorders confirmed by neurologist according to the 2015 revised diagnostic criteria without other nervous system diseases.All patients performed magnetic resonance imaging.
2959517|NCT02836327||Health control|Health control is defined as no other nervous system diseases such as ischemic stroke, alzheimer disease and so on. The baseline data(age,education background etc.) is similar to multiple sclerosis and neuromyelitis optica spectrum disorders patients.All participants performed magnetic resonance imaging.
2959518|NCT02836314|Experimental|PRF and ABBM|Intervention: Anorganic Bovine Bone Mineral and Platelet Rich fibrin is applied to the periodontal intrabony defects
2959519|NCT02836314|Active Comparator|Anorganic Bovine Bone Mineral|Intervention: Anorganic Bovine Bone Mineral is applied to the periodontal intrabony defects
2959520|NCT02836301|Active Comparator|Testimonials-Uplifting|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
2959555|NCT02836067|Other|Non-Smokers|"HIV-positive non-smokers will be enrolled as a comparison group to HIV-positive smokers and will have the following procedures:~Questionnaires Blood Draw Bronchoscopy"
2959521|NCT02836301|Active Comparator|Testimonials-Negative|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
2959522|NCT02836301|Active Comparator|Testimonials-Unresolved|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
2959523|NCT02836301|Experimental|Documentary-Uplifting|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
2959524|NCT02836301|Experimental|Documentary-Negative|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
2959525|NCT02836301|Experimental|Documentary-Unresolved|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
2959526|NCT02836288|Experimental|Ketamine|Oral ketamine 1.0 mg/kg mixed with syrup
2959527|NCT02836288|Placebo Comparator|Placebo|Oral placebo (syrup)
2959528|NCT02836288|Experimental|Ketamine after placebo|Optional oral Ketamine 1.0 mg/kg mixed with syrup for patients on placebo arm after 12 week treatment is completed.
2959529|NCT02836275|Experimental|Perfusion and diffusion-weighted MRI|
2959530|NCT02836262|Experimental|HIT Hip Replacement System (HRS)|Single group assignment with historical controls.
2959531|NCT02836249|Experimental|TAF|TAF + TDF placebo for up to 144 weeks
2959532|NCT02836249|Active Comparator|TDF|TDF + TAF placebo for up to 144 weeks
2959533|NCT02836249|Experimental|Open-label TAF|All participants who complete the double-blind period will be eligible to receive open-label TAF until Week 384 of the study.
2959534|NCT02836236|Experimental|TAF|TAF + TDF placebo for up to 144 weeks
2959535|NCT02836236|Active Comparator|TDF|TDF + TAF placebo for up to 144 weeks
2959536|NCT02836236|Experimental|Open-label TAF|All participants who complete the double-blind period will be eligible to receive open-label TAF until Week 384 of the study.
2959537|NCT02836223|Experimental|Interdental device|Water Flosser
2959538|NCT02836223|Other|Toothbrush|Control
2959539|NCT02836210|Active Comparator|Angled incision|Patients in this arm will undergo 27-gauge vitrectomy wound construction using angled (tunnel-like) incisions for trocar entry.
2959540|NCT02836210|Active Comparator|Straight Incision|Patients in this arm undergo 27-gauge vitrectomy wound construction using straight (perpendicular) incisions for trocar entry.
2959541|NCT02836197|Experimental|Experimental group|This group of 30 physicians will immediately attend the intervention communication skills training program (experimental group).For this experimental group, the first assessment will take place before the first training session and the second recording after the last session. This assessment involves the analyses of communicational, physiological and psychological variables recorded in the context of an encounter with a simulated advanced stage cancer patient.
2959542|NCT02836197|No Intervention|Waiting-list group|This group of 30 physicians will attend the intervention communication skills training in a delayed manner (control group). For this control group, the first and the second recording will take place with a four-month interval. This assessment involves the analyses of communicational, physiological and psychological variables recorded in the context of an encounter with a simulated advanced stage cancer patient.
2959543|NCT02836184|Active Comparator|control group|Group treated with calcium carbonate for 6 weeks first,then switch to nicotinic acids treatment after 2 week of wash-out.
2959544|NCT02836184|Experimental|nicotinic acids group|Group treated with nicotinic acids for 6 weeks first,then switch to calcium carbonate treatment after 2 week of wash-out.
2959545|NCT02836171|Experimental|Treatment|subjects receiving a single 250 mg oral dose of apatinib mesylate tablets and wash-out for 3 days,then Itraconazole capsules 100 mg/day orally for 6 days with a single 250 mg oral dose of apatinib mesylate tablets co-administered on day 4 . apatinib mesylate tablets was administered in the morning after an overnight fast of at least 10 h
2959546|NCT02836158|Experimental|R-IDARAM plus intrathecal chemotherapy|Patients will be treated with systemic R-IDARAM plus intrathecal immunochemotherapy
2959547|NCT02836132|Active Comparator|Weight Watchers Online|Participants will receive 6 months of no-cost access to the Weight Watchers Online platform.
2959548|NCT02836132|Experimental|Weight Watchers Online + Experience Success|Participants will receive 6 months of no-cost access to the Weight Watchers Online platform. They will also receive 6 months of no-cost access to the Experience Success online platform, with 4 virtual reality scenarios for training in behavioral weight loss skills.
2959549|NCT02836106|Experimental|Healthy|Lean subjects (BMI<25) with a waist circumference of <94 cm for men and<80 cm for women. Subjects will be randomly assigned to eat butter, cheese, whipped cream and sour cream in a cross-over design.
2959550|NCT02836106|Experimental|Obese|Overweight and obese subjects (BMI≥25) with a waist circumference of ≥94 cm for men and ≥80 cm for women. Subjects will be randomly assigned to eat butter, cheese, whipped cream and sour cream in a cross-over design.
2959551|NCT02836093||evaluations/assessments|
2959552|NCT02836080|Experimental|Integrated Collaborative Care Team|Integrated Collaborative Care Team (ICCTs) are housed in the local community to improve youth access, in three neighborhoods across Toronto (East Metro Youth Services [EMYS]-Scarborough, EMYS-Southeast Toronto, and Delisle Youth Services-Central Toronto). Each ICCT will include a variety of service providers and coordinated patient care delivering evidence-informed interventions in a stepped-care model.
2959553|NCT02836080|Active Comparator|Treatment as Usual (TAU)|"The comparator arm consists of out-patient TAU in a hospital setting and will occur at one of four outpatient hospital sites across Toronto.~Partners include the following four hospitals: Hospital for Sick Children (SickKids), the Centre for Addiction and Mental Health (CAMH), Michael Garron Hospital (formerly the Toronto East General Hospital), and Sunnybrook Hospital."
2959554|NCT02836067|Other|Smokers|"HIV-positive smokers will be enrolled in a smoking cessation program including the following procedures:~Counseling Smoking cessation drugs Questionnaires Blood Draw Bronchoscopy"
2959558|NCT02836041||Pediatrics cancer patients|Eligible patients will be approached for enrollment after their first night in the hospital (i.e.: not on day of admission). Patient/parent will be asked to complete a brief questionnaire describing the child's general sleep habits prior to admission. The parent and/or child will then be asked to complete a questionnaire describing sleep while in the hospital; this in-hospital sleep questionnaire will be obtained for 3 consecutive nights after enrollment, or until discharge, whichever is soonest. A subgroup of patients (between the ages of 5 and 18) will be invited to participate in an additional aspect of the study, where they wear an actigraph (a small device that looks like a watch) for up to 72 hours. This device reliably measures sleep by monitoring the child's motion. This will be used to relate sleep perception to more objective measures of sleep as provided by actigraphy.
2959559|NCT02836028|Experimental|talazoparib|Cohorts 1A (PARP inhibitor naïve), 2A (PARP inhibitor sensitive), and 3A (PARP inhibitor refractory)
2959560|NCT02836028|Active Comparator|talazoparib + temozolomide|Cohorts 1B (PARP inhibitor naïve), 2B (PARP inhibitor sensitive), and 3B (PARP inhibitor refractory)
2959561|NCT02836015|Experimental|Shared Medical Visit Groups|All patients will be enrolled in the experimental group and will be involved in shared medical visits.
2959562|NCT02836002|Experimental|Group 1 - SP low/SP high|"Group 1 will be treated with a course of subcurative sulfadoxine-pyrimethamine (SP) (SP low, 500mg/25mg) as treatment 1.~As treatment 2 (SP high) volunteers will receive a treatment with sulfadoxine-pyrimethamine (1000mg/50mg).~Group 1 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
2959563|NCT02836002|Experimental|Group 2 - SP low/Pip high|"Group 2 will be treated with a course of subcurative sulfadoxine-pyrimethamine (SP) (SP low, 500mg/25mg) as treatment 1.~As treatment 2 (Pip high) volunteers will receive a treatment with piperaquine (960mg).~Group 2 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
2959564|NCT02836002|Experimental|Group 3 - Pip low/Pip high|"Group 3 will receive piperaquine (Pip) in a low-dose (Pip low, 480 mg) as treatment 1.~As treatment 2 (Pip high) volunteers will receive a treatment with piperaquine (960mg).~Group 3 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
2959565|NCT02836002|Experimental|Group 4 - Pip low/SP high|"Group 4 will receive piperaquine (Pip) in a low-dose (Pip low, 480 mg) as treatment 1.~As treatment 2 (SP high) volunteers will receive a treatment with sulfadoxine-pyrimethamine (1000mg/50mg).~Group 4 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
2959566|NCT02835989|Experimental|CP@Home Intervention|"The experimental group will receive the CP@Home program. The main elements of this program include BP assessment, diabetes risk assessment, falls risk assessment, heart failure risk assessment, neurologic assessment, psychiatric assessment, depression screening, health-related quality of life analysis (including pain, mobility, anxiety/depression, ADLs), social isolation screening, and food and income security. The program is targeted at referrals to appropriate community resources, identification and referral of high-risk patients to their family physician (FP), as well as regular communication of participants' health information to their physician.~The intervention will be implemented by community paramedics from the local paramedic service who have undergone a structured training program (4 hours of online, interactive training modules, including case studies and the observation of an intervention visits led by another paramedic) to assure intervention fidelity."
2959567|NCT02835989|No Intervention|Control|Usual Care
2959568|NCT02835976|Experimental|Olesoxime|Participants will receive a single dose of liquid suspension of 14C-labeled olesoxime containing an equivalent of 600 milligrams (mg) of the compound. The total amount of administered radiocarbon will be 93 microcuries (mcCi), or 3.447 megabecquerels (MBq).
2959569|NCT02835950|Experimental|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
2959570|NCT02835937|No Intervention|Transfuse|Patients will receive a transfusion under standard care
2959571|NCT02835937|Experimental|No-Transfuse|Patients will not receive a transfusion
2959572|NCT02835924|Active Comparator|Arm A|160 mg/day 3w on/1w off
2959573|NCT02835924|Experimental|Arm B|120 mg/day 3w on/1w off 1st cycle; 160 mg/day 3w on/1w off 2nd cycle on
2959574|NCT02835924|Experimental|Arm C|160 mg/day 1w on/1w off 1st cycle; 160 mg/day 3w on/1w off 2nd cycle on
2959575|NCT02835911||Lymphoma|Suspected lymphoma with confirmed hematologic malignancies treated under local conditions
2959576|NCT02835898||Test Group|Patients with periodontal disease that need conventional periodontal treatment
2959577|NCT02835898||Control Group|Periodontally-healthy individuals.
2959578|NCT02835885|Experimental|Active tVNS Stimulation|Stimulating electrode will be placed on left tragus of subject. Current will be held constant (200% perceptual threshold) while pulse width and frequency are varied.The intervention used to keep current constant is Digitmer High Voltage Stimulator model DS7A TENS unit. Each stimulation period (9 randomized stimulation parameters varying in pulse width and frequency) will last 1 minute with a 3 minute break between each parameter. Physiological data (O2 saturation, blood pressure, breathing rate, and Electrocardiogram (EKG) to measure heart rate ) will be collected continuously.
2959579|NCT02835885|Sham Comparator|Sham tVNS Stimulation|Stimulating electrode will be placed on left ear lobe of subject for sham tVNS stimulation condition. Current will be held constant (200% perceptual threshold) while pulse width and frequency are varied. The intervention used to keep current constant is Digitmer High Voltage Stimulator model DS7A TENS unit. Each stimulation period (9 randomized stimulation parameters varying in pulse width and frequency) will last 1 minute with a 3 minute break between each parameter. Physiological data (O2 saturation, blood pressure, breathing rate, and Electrocardiogram (EKG) to measure heart rate ) will be collected continuously.
2959580|NCT02835872|Placebo Comparator|Cellulose control|3 g Insoluble Fiber (Cellulose)/d contained within drinks and crackers
2959581|NCT02835872|Active Comparator|Soluble fiber treatment|3 g soluble dietary fiber test ingredient contained within drinks and crackers
2960526|NCT02829190|Experimental|Patients treated by embolization|Magnetic Resonance Imaging (MRI)
2959582|NCT02835859|Experimental|Group 1- Oral solution|Participants will be randomly assigned to drink two oral solutions made of different combinations of saccharin, lactisole, acetaminophen, 3-O-methyl glucose, or glucose.
2959583|NCT02835846|Experimental|Estrogen Arm|The intervention for this study is an estrogen cream (i.e., Premarin Cream®). Women in this study will receive this estrogen cream and apply it to their vagina twice weekly for 12 weeks
2959584|NCT02835833|Experimental|Nintedanib 150 mg + Bevacizumab 15 mg/kg|"The first three patients on study will be treated with 150 mg orally of Nintedanib two times daily plus 15 mg/kg of Bevacizumab administered intravenously on day one of each three week cycle.~If one dose limiting toxicity occurs in the first cohort, then three more patients will be treated at that same starting dose and assessed for toxicity after cycle two. If two or more patients have dose limiting toxicity, then dose escalation will end and the maximum tolerated dose will be reached."
2959585|NCT02835833|Experimental|Nintedanib 200 mg + Bevacizumab 15 mg/kg|If no patients experience dose limiting toxicity, then three additional patients will be treated with 200 mg orally of Nintedanib two times daily plus 15 mg/kg of Bevacizumab administered intravenously on day one of each three week cycle.
2959586|NCT02835820|Experimental|Ketogenic Diet Group|Ketogenic meals (3 meals/day, 7 days/week x 12 weeks) prepared and delivered to participants.
2959587|NCT02835820|No Intervention|Patient Choice Diet|Control.
2959588|NCT02835807|Experimental|Health Chat including Indoor Tanning|Facebook group, Health Chat, which provides information via posts within the private group about a wide variety of health topics (e.g. tobacco use, body image) with 25% of all of the content being about indoor tanning. Indoor tanning-related content was developed by the investigators and a social media marketing expert using information from published literature on IT risk factors, evidence-based intervention content from published trials targeting IT reduction, public health campaigns from major non-profit organizations (e.g., CDC, Skin Cancer Foundation, etc.), and investigator-developed video-recorded interviews of local mothers and professionals about the risks of indoor tanning, experiences with skin cancer, and mother-daughter communication role modeling.
2959589|NCT02835807|Active Comparator|Health Chat excluding Indoor Tanning|Facebook group, Health Chat, which provides information via posts within the private group about a wide variety of health topics (e.g. tobacco use, body image), but does not include any content about indoor tanning. The designated number of posts (25%) assigned to the indoor tanning content in the intervention group will be assigned to prescription drug use in the control arm. In order to keep number and frequency of posts standardized between the two groups, prescription drug use was selected to replace the indoor tanning content for the control arm.
2959590|NCT02835794|Experimental|Arm 1|Omacetaxine - escalating doses subcutaneous twice daily on Days 1-5 and 8-12 Azacitidine 50 mg/m2 subcutaneous/intravenous daily on Days 8-12 G-CSF 5mcg/kg subcutaneous daily on Days 15-19 and 22-26
2959591|NCT02835781||Acellular dermal matrix arm|The females undergoing breast reconstruction surgery after breast removal because of breast cancer. The breast reconstruction will be performed using acellular dermal matrix implantation.
2959592|NCT02835768|Experimental|Intervention|Each participant will be provided an information package - the parenting booklet from Maternal and Child Health Centres (MCHCs) about domestic safety tips. Participants will be given an additional leaflet about the domestic safety website with address link and brief introductory information.
2959593|NCT02835768|No Intervention|Control|Each participant will be provided an information package - the parenting booklet from Maternal and Child Health Centres (MCHCs) about domestic safety tips. Only this booklet serves as the anticipatory guidance to mothers about domestic safety.
2959594|NCT02835755|Active Comparator|Group I (Control)|Patients receive standard information about HPV and HPV vaccine, such as the VIS, on a mobile-friendly website study portal.
2959595|NCT02835755|Experimental|Group II (mHealth HPV vaccine)|Patients receive the mHealth HPV vaccine intervention consisting of content about HPV and HPV vaccine on the study portal for 15 minutes and vaccination reminders sent by the portal via text or e-mail.
2959596|NCT02835742|Active Comparator|Group1|Treatments for Group 1 include GM-CSF inhalation with 250 mcg/day/body of sargramostim (125 mcg BID on Days 1-7, none on Days 8-14) for twelve 2-week cycles.
2959597|NCT02835742|Placebo Comparator|Group2|Treatments for Group 2 include placebo inhalation (Placebo BID on Days 1-7, none on Days 8-14) for twelve 2-week cycles.
2959598|NCT02835729|Experimental|Phase 1a|Patients enrolled in this arm will receive standard induction and consolidation chemotherapy (7+3) with Indoximod (freebase formulation). These patients will additionally receive maintenance therapy with indoximod for 6 months after consolidation therapy. The indoximod dose will be studied in up to 4 dose levels.
2959599|NCT02835729|Experimental|Phase 1b|Patients enrolled in this arm will receive standard induction and consolidation chemotherapy (7+3) with Indoximod (HCL formulation). These patients will receive maintenance therapy with indoximod for 6 months after consolidation therapy. The indoximod dose will be studied in up to 4 dose levels.
2959600|NCT02835703|Active Comparator|Deep hypothermic arrest|Surgical repair of coarctation of aorta under deep hypothermic circulatory arrest
2959601|NCT02835703|Active Comparator|Selective antegrade cerebral perfusion|Surgical repair of coarctation of aorta using selective antegrade cerebral perfusion
2959602|NCT02835703|Active Comparator|Double arterial cannulation|Surgical repair of coarctation of aorta using cerebral antegrade perfusion with descending aortic cannulation
2959603|NCT02835690|Experimental|Pembrolizumab 2 mg/kg|Participants receive pembrolizumab 2 mg/kg administered intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations. Cycle 1 is 28 days instead of 21 days.
2959604|NCT02835690|Experimental|Pembrolizumab 10 mg/kg|Participants receive pembrolizumab 10 mg/kg administered IV Q3W for up to 35 administrations. Cycle 1 is 28 days instead of 21 days.
2959605|NCT02835690|Experimental|Pembrolizumab 200 mg Fixed Dose|Participants receive pembrolizumab 200 mg fixed dose administered IV Q3W for up to 35 administrations. Cycle 1 is 28 days instead of 21 days.
2959606|NCT02835677|Experimental|Intervention|Behavioral intervention with caregivers to reduce stress and management of patient concerns, particularly ambulation
2959607|NCT02835664|Experimental|Nicotinamide Riboside|Supplementation of Nicotinamide Riboside (Niagen) of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.
2959731|NCT02834754|Placebo Comparator|placebo|Placebo infusions at weeks 0, 2, and 6 weeks, then every 8 weeks for 52 weeks
2959608|NCT02835664|Placebo Comparator|Placebo|Supplementation of Placebo of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.
2959609|NCT02835651|Experimental|Palmitic acid|Diet rich in palmitic acid
2959610|NCT02835651|Experimental|Stearic acid|Diet rich in stearic acid
2959611|NCT02835625|Active Comparator|Digital Breast Tomosynthesis|"Synthetic Mammography (SM) + Digital Breast Tomosynthesis (DBT)~The SM+DBT will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.~Women selected for further assessment (positive screening exam) will be recalled."
2959612|NCT02835625|Active Comparator|Digital mammography|The digital mammograms will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.
2959613|NCT02835612|Experimental|Early stimulation|skin-to skin care by mother (kangaroo care) plus massage therapy by mothers.
2959614|NCT02835612|Active Comparator|Conventional care|skin-to skin care by mother (kangaroo care).
2959615|NCT02835586|Experimental|paclitaxel delivery in femoropopliteal artery|
2959616|NCT02835573||Sepsis-induced myocardial injury group|Patients admitted to the hospital with the diagnosis of Sepsis-induced myocardial injury
2959617|NCT02835573||Blank control group|Patients admitted to the hospital without the diagnosis of Sepsis-induced myocardial injury
2959618|NCT02835560|Experimental|Experimental|Ilaprazole-based quadruple therapy for 14 days: Ilaprazole 5mg bid
2959619|NCT02835560|Active Comparator|Active Comparator|"Esoprazole~Esoprazole-based quadruple therapy for 14 days: Esoprazole 20mg bid"
2959620|NCT02835547||Systemic lupus erythematosus|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
2959621|NCT02835547||Rheumatoid arthritis|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
2959622|NCT02835547||Psoriasis|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
2959623|NCT02835547||Scleroderma|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
2959624|NCT02835547||Hematopoietic stem cells transplants|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
2959625|NCT02835547||Kidney transplants|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
2959626|NCT02835534|Experimental|rhTNK-tPA|rhTNK-tPA; Dose:16mg; Mode of admin: Single bolus Dose:50mg; Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
2959627|NCT02835534|Active Comparator|rt-PA|Drug:alteplase;Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
2959628|NCT02835521|Experimental|Intervention Group|Patients will receive the reception treatment before the joint injection
2959629|NCT02835521|Active Comparator|Control Group|patient will receive a joint injection
2959630|NCT02835508|Experimental|Treatment A|Participants will receive a single dose of 1 tablet of JNJ-56021927, 60 milligram (mg) on Day 1.
2959631|NCT02835508|Experimental|Treatment B|Participants will receive a single dose of JNJ-56021927, 120 mg (2 tablets*60 mg) on Day 1.
2959632|NCT02835508|Experimental|Treatment C|Participants will receive a single dose of JNJ-56021927, 240 mg (4 tablets*60 mg) on Day 1.
2959633|NCT02835495|Experimental|Lifestyle Weight Loss|"Behavioral: HELP Vets Intervention~Lifestyle intervention consisting of 24 weekly group meetings led by a Veteran community health worker and 3 individual sessions with a nutritionist/diabetes educator"
2959634|NCT02835495|Active Comparator|Enhanced Usual Care|"Behavioral: Individual Education Program~Standard care consisting of 2 individual sessions with a nutritionist/diabetes educator and a monthly newsletter"
2959635|NCT02835482|Experimental|Patient with glaucoma|Patient eligible for bilateral cataract surgery, with glaucoma. Each patient is his own control. The patient is treated with femtolaser surgery for one eye and with phacoemulsification for the other eye.
2959636|NCT02835482|Other|Patient without glaucoma|Patient eligible for bilateral cataract surgery, without glaucoma. Each patient is his own control. The patient is treated with femtolaser surgery for one eye and with the phacoemulsification for the other eye.
2959637|NCT02835469||Menopur® Multidose|Treatment according to routine clinical practice.
2959638|NCT02835456|Active Comparator|Group A: Sharklet Catheter|Patient requiring indwelling urinary catheter will be randomised into Group A or Group B
2959639|NCT02835456|Active Comparator|Group B: Silicone Foley Catheter|Patient requiring indwelling urinary catheter will be randomised into Group A or Group B
2959640|NCT02835443|Experimental|Electrical Stimulation|This is a single arm study and all subjects will receive electrical stimulation.
2959641|NCT02835430|Experimental|Coronally advanced flap and PRF with DFDBA|Coronally advanced flap and platelet-rich fibrin membrane with demineralized freeze-dried bone allograft.
2959642|NCT02835430|Active Comparator|Coronally advanced flap and PRF without DFDBA|Coronally advanced flap and Platelet-rich fibrin membrane without demineralized freeze-dried bone allograft.
2959643|NCT02835404|Experimental|Concurrent radiochemotherapy Group|Concurrent radiochemotherapy with Nedaplatin Pelvic External Radiotherapy: patients received 20 Gy2.0/f, for 25-27f with 8mv-X rays (SSD) 252-Cf Neutron Intracavitary Brachytherapy: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations; Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle
2959644|NCT02835404|Active Comparator|Radiotherapy Group|patients received Radiotherapy only Pelvic External Radiotherapy: patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X Linear Accelerator SSD 252-Cf Neutron Intracavitary Brachytherapy: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations.
2959645|NCT02835391|Active Comparator|PerClot|PerClot® Polysaccharide Hemostatic System (PerClot) is a medical device composed of absorbable polysaccharide particles (AMPs) and delivery applicators. Investigators will have the option to choose 3g or 5g dependent on the requirements of the patient
2959646|NCT02835391|Active Comparator|Usual Care|Usual care will consist of any other haemostat the Investigator would normally use in the control of bleeding i.e arista, Floseal, surgical, surgiflo. If the Investigator would not normally use a haemostat to control bleeding then electrocautery or diathermy may be used in this arm
2959647|NCT02835378||Bilateral upper limb amputation|Bilateral upper limb amputees, with amputation from the short transverse hand (hand completely non-functional) to complete arm, whatever their age
2959648|NCT02835365||patients treated with baclofen|Patients treated with baclofen to diminish their alcohol consumption in the ANGH centers will be enrolled
2959649|NCT02835352|Experimental|Essential oils then oil massages|Essential oils massages will be done as needed during a period of 7 days, then oïl massages as needed will be done during a follow-up period of 7 days
2959650|NCT02835352|Experimental|Oil then essential oils massages|Oil massages will be done as needed during a period of 7 days, then essential oïl massages as needed will be done during a follow-up period of 7 days
2959651|NCT02835339|Active Comparator|MgSO4 4g load, 1g/hr infusion|Once their obstetrician prescribes magnesium sulfate, participant will be assigned by 50/50 chance to one of two treatment regimens. Participant will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete.
2959652|NCT02835339|Experimental|MgSO4 6g load, 2g/hr infusion|Once their obstetrician prescribes magnesium sulfate, participant will be assigned by 50/50 chance to one of two treatment regimens. Participant will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete.
2959653|NCT02835326|Experimental|Exercise and Dietary Weight Loss|For the first 6 months, participants will meet at a community center for 3 group-based sessions and 1 individual session each month. Sessions include a 45 minute exercise component and a 45 minute dietary weight loss component. Exercise will consist of progressive aerobic and strength training. The dietary component will focus on decreasing caloric intake, while being nutritionally safe. All diets will be monitored by a Registered Dietitian. During months 7-12, participants will meet for 1 group session and 1 individual session per month. The final 12-24 months, bimonthly phone calls are provided to the participants to aid in retention efforts.
2959654|NCT02835326|Active Comparator|Walk with Ease|The Arthritis Foundation's (AF) WWE is a self-management program for symptoms of arthritis (pain, fatigue, stiffness,etc.) through exercise. It is a 6 week program involving 3 sessions per week each lasting about 60 minutes. The WWE sessions are comprised of walking, stretching and strengthening exercises, and health education lectures. These group classes will be lead by an AF instructor. Each participant will complete 2 consecutive WWE classes for a total of 12 weeks in the program. During the final week of the program, participants will be trained and transitioin to the self-directed version of WWE for maintenance of exercise. To aid in retention efforts, phone contacts are provided to participants on a monthly basis from 4-12 months and bi-monthly from 12 to 24 months
2959655|NCT02835313|Experimental|FAST+SAM|Subjects participate in fast walking training in combination with a step activity monitoring program
2959656|NCT02835313|Active Comparator|FAST|Subjects participate in fast walking training
2959657|NCT02835313|Active Comparator|SAM|Subjects participate in a step activity monitoring program
2959658|NCT02835300|Experimental|CampAir Intervention|Adolescents assigned to receive ASMA 2.0 will receive all seven modules over the two month trial, completing one module per week. Adolescents will be assigned one module per week, but will have free access to all completed modules for the duration of the two-month trial. Each module is expected to take between 30-40 minutes to complete, although adolescents will be able to engage with the software for as long as desired.
2959659|NCT02835300|Active Comparator|Information and Referral Control|Adolescents assigned to the information-and-referral control condition will be provided access to existing generic asthma education websites. They will also be referred to their medical providers for asthma. After the completion of the trial, all participants will receive access to CampAir.
2959660|NCT02835287|Active Comparator|Intervention|The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
2959661|NCT02835287|No Intervention|Control|Usual care
2959662|NCT02835274|Active Comparator|Ring Mode Stimulation|omni-directional stimulation
2959663|NCT02835274|Experimental|Unrestricted Mode Stimulation|Clinician can use any type of stimulation that they deem best for the patient
2959664|NCT02835261|No Intervention|Habitual Sleep (HS)|During the HS phase, participants will be asked to follow a fixed bedtime routine based on their screening sleep schedule.
2959665|NCT02835261|Experimental|Sleep Restriction (SR)|During the SR phase, participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 h in total sleep time. A delay in bedtimes was chosen rather than advancing wakeup time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
2959666|NCT02835248||Primary|Older adult study participants will be recruited from the cohort of participants in the STRIDE Study at the Boston trial site (http://www.stride-study.org/).
2959667|NCT02835235|Experimental|NNC9204-0530|Dose-escalation within the cohort before reaching final dose
2959668|NCT02835235|Placebo Comparator|Placebo|
2959669|NCT02835222|Experimental|cytarabine, daunorubicin, selinexor|"INDUCTION: Cytarabine IV on days 1-7, daunorubicin hydrochloride IV on days 1-3, and selinexor PO twice weekly from day 1. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~RE-INDUCTION: Patients whose disease has not responded receive cytarabine IV on days 1-5, daunorubicin hydrochloride IV on days 1-2, and selinexor PO twice weekly. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients in remission receive cytarabine IV every 12 hours on days 1, 3 and 6, and selinexor PO twice weekly from day 1. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients who have had a response and have not gone on to transplant receive selinexor PO twice weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity."
2959670|NCT02835209||Work of breathing during SBT|Ventilated premature infants born 24 to 34+6 weeks gestational age.
2959671|NCT02835183|Experimental|Insulin pump followed by iDECIDE|Participants will be randomly assigned to 4 weeks of using their insulin pump to decide insulin boluses and then 4 weeks of using iDECIDE to receive recommendations for insulin dosing.
2959672|NCT02835183|Experimental|iDECIDE followed by insulin pump|Participants will be randomly assigned to 4 weeks of using iDECIDE to receive recommendations for insulin dosing and then 4 weeks of using their insulin pump to decide insulin boluses.
2959673|NCT02835170|Experimental|Autologous immunoglobulin|Intramuscular injection of autologous immunoglobulin (IgG)
2959674|NCT02835170|Placebo Comparator|Placebo|Intramuscular injection of normal saline
2959675|NCT02835157|Experimental|Balanced salt solution or study group|After enrollment, a fluid bolus comprising of 'balanced saline' solution at a dose of 20 ml/kg over 15-20 minutes with careful monitoring for features of fluid overload would be administered to each child. Fluid resuscitation will be targeted at achieving the therapeutic end points as given in study definitions. A second bolus would be repeated with the same fluid at 20 ml/kg over 15-20 minutes in case therapeutic end points are not reached. After this the management protocol will be as per recommendations of the surviving sepsis campaign guidelines for septic shock in children.
2959676|NCT02835157|Active Comparator|Normal saline or control group|After enrollment, a fluid bolus comprising of 'normal saline' solution at a dose of 20 ml/kg over 15-20 minutes with careful monitoring for features of fluid overload would be administered to each child. Fluid resuscitation will be targeted at achieving the therapeutic end points as given in study definitions. A second bolus would be repeated with the same fluid at 20 ml/kg over 15-20 minutes in case therapeutic end points are not reached. After this the management protocol will be as per recommendations of the surviving sepsis campaign guidelines for septic shock in children.
2959677|NCT02835144|Experimental|TIQAAM_therapy|Individuals in this group will receive units from the TIQAAM treatment program
2959678|NCT02835144|Active Comparator|active_control|Individuals in this group will receive units of psychoeducation
2959679|NCT02835118|Experimental|Surotomycin 0.5 g|Two oral doses of 0.25 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
2959680|NCT02835118|Experimental|Surotomycin 1 g|Two oral doses of 0.5 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
2959681|NCT02835118|Experimental|Surotomycin 2 g|Two oral doses of 1 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
2959682|NCT02835118|Placebo Comparator|Placebo|Two oral doses of placebo for surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
2959683|NCT02835105|Experimental|Surotomycin 0.5 g|A single oral dose of 0.5 g surotomycin in hard gelatin capsules
2959684|NCT02835105|Experimental|Surotomycin 1 g|A single oral dose of 1 g surotomycin in hard gelatin capsules
2959685|NCT02835105|Experimental|Surotomycin 2 g|A single oral dose of 2 g surotomycin in hard gelatin capsules
2959686|NCT02835105|Experimental|Surotomycin 4 g|A single oral dose of 4 g surotomycin in hard gelatin capsules
2959687|NCT02835105|Placebo Comparator|Placebo|A single oral dose of placebo for surotomycin in hard gelatin capsules
2959688|NCT02835092|Active Comparator|Self-directed Control|
2959689|NCT02835092|Experimental|Take Shape For Life Program|
2959690|NCT02835092|Experimental|Medifast Direct Program|
2959691|NCT02835079|Other|open label study|one arm open label study
2959692|NCT02835066||Ancillary-Correlative (HRQOL, fitness and psychosocial health)|Patients scheduled for surgery, radiation therapy, or chemotherapy complete the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-core 30 (C30) and QLQ-Lung Cancer 13 (LC13) in addition to psychosocial health and smoking status questions from baseline up to 2 weeks prior to the start of treatment, 5-6 weeks after treatment begins, and 5-6 months from the start of treatment. During the same time points, patients also undergo function/fitness assessments including standard health measurements, short physical performance battery (SPPB), 6 minute walk test (6MWT), and a grip strength test.
2959693|NCT02835053||Emergency General Surgery|All patients having emergency general surgery procedures as defined by Scott et al (JAMA Surgery 2016)
2959694|NCT02835040|Experimental|CAP Service|
2959695|NCT02835040|Active Comparator|Usual care|
2959696|NCT02835014||Adolescents with T1DM|Adolescents with type I Diabetes Mellitus diagnosed for at least one year will be screened for mental health symptoms with the PHQ9, SCARED and UCLA PTSD. Self-efficacy regarding self-care and diabetes management will be assessed by using the SEDM. Parenting styles will be assessed by administering the Parenting Styles and Dimensions Questionnaire (PSDQ).
2959697|NCT02835001|Other|Patient with severe emphysema|Patients with severe emphysema, stable, symptomatic, not controlled despite of international recommendations treatments will have bronchoscopy
2959698|NCT02834988|Experimental|Sentinel Lymph Node Dissection|Patients will undergo surgical staging for EC (sentinel lymph node dissection (SLND) via laparotomy, laparoscopy or robotic surgery, ±hysterectomy, ±bilateral salpingo-oophorectomy (BSO)).
2959699|NCT02834975|Experimental|Pembrolizumab, Paclitaxel + Carboplatin|"Neoadjuvant chemotherapy (NACT) will be administered with pembrolizumab, paclitaxel, and carboplatin, on day 1 every 21 days.~This regimen will be followed by interval debulking surgery (IDS).~Adjuvant chemotherapy (ACT) will consist of 3 to 4 more cycles of paclitaxel with carboplatin plus pembrolizumab"
2959700|NCT02834962|Experimental|single bundle ACLR|patients undergo single bundle ACL reconstruction
2959701|NCT02834962|Active Comparator|double bundle ACLR|patients undergo double bundle ACL reconstruction
2959702|NCT02834949|Experimental|BMI + SFAS|"Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive the SFAS (Substance-free Activity Session., a 50-minute counseling session designed to increase the salience of the student's academic and career goals, draw attention to the potentially negative relationship between substance use and goal accomplishment, and increase engagement in substance-free alternative activities. The SFAS will be described to participants as the College Adjustment Session and the session will be conducted using an MI plus personalized feedback approach."
2959769|NCT02834520||control subjects|30 individuals age, gender and periodontal status matched with oral lichen planus patients and not suffering from any oral mucosal lesions or periodontal disease.
2960045|NCT02832700|Active Comparator|Casein glycomacropeptide (CGMP)|During 4 weeks a daily oral intake of CGMP-protein-shake.
2959703|NCT02834949|Active Comparator|BMI + Relaxation Session|Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive a relaxation training session. In the relaxation training session, the clinician leads the student through a diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, participants will be asked about their reaction to the relaxation techniques and provided with relaxation training handouts.
2959704|NCT02834949|No Intervention|Assessment|Participants will fill out a battery of measures and receive no intervention.
2959705|NCT02834936|Experimental|pyrotinib treatment|
2959706|NCT02834923|Active Comparator|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change. CTH utilizes web-based interactive behavior change technology, based on a logic model of behavior and maintenance that is informed by social-cognitive and social ecological theories. Prior to diabetes visits with a clinician, health educator, or care manager, patients complete a pre-visit CTH assessment at their practice through a tablet computer or computer kiosk. CTH assesses multiple diabetes management behaviors (diet, physical activity, medication adherence, alcohol and tobacco use, stress, mood) using brief assessment measures, each with cut-points highlighting areas of deficit. Action planning plays a central role, through a web-based platform that allows the patient and health care team to select and set goals collaboratively.
2959707|NCT02834923|Experimental|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH seamlessly integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol specifically designed to enhance patient engagement in SMS activities. Key components of MI have been incorporated into a practical and systematic engagement protocol that includes: (1) acknowledging the patient's point of view; (2) identifying and labeling the patient's ambivalence (both the good reasons for making the change and the good reasons for not making the change); (3) evaluating whether change is really worth the effort; (4) identifying, reflecting and labeling accompanying feelings and concerns about change; and (5) establishing a small and meaningful goal by the end of the encounter.
2959708|NCT02834910||Case group|patients with Extended-Spectrum Beta-lactamase producing Enterobacteriaceae carrying a qnr gene isolate
2959709|NCT02834910||control-group|patients with Enterobacteriaceae isolate without qnr gene
2959710|NCT02834897|Experimental|EOS and CT Exam|EOS and CT Examen for pregnant women in the 8th month of pregnancy
2959711|NCT02834884||all tumor types|Pathologically confirmed selected tumor types, including rare tumors. The SPECTA Steering Committee will decide on project basis which tumor types and stages to include at any particular time during the study.
2959712|NCT02834871|Other|patients with cervical dystonia|Computerized assessment of the cervical muscular force and with electromyogram in patients with cervical dystonia
2959713|NCT02834871|Other|patients without cervical dystonia|Computerized assessment of the cervical muscular force and with electromyogram in patients without cervical dystonia
2959714|NCT02834858|Experimental|Umbilical Cord Mesenchymal Stem Cells|Umbilical Cord Mesenchymal Stem Cells Infusion.
2959715|NCT02834858|Placebo Comparator|saline|saline injection
2959716|NCT02834845|Experimental|Sevoflurane|
2959717|NCT02834845|Experimental|Desflurane|
2959718|NCT02834832||Control|The patients will be given removable dentures with no coatings. These dentures are part of the standard of care to treat their edentulism.
2959719|NCT02834832||PECVD Coatings|The patients will be given removable partial dentures with PECVD coatings on both the tissue surface of the dentures and the acrylic denture teeth.
2959720|NCT02834819|Experimental|Hypertonic Saline|Patients randomized to the hypertonic saline group will be administered one nebulized treatment of 3% hypertonic saline. They will also receive what is considered standard of care, which includes suctioning and supportive care as needed.
2959721|NCT02834819|No Intervention|No treatment|"Patients in the No treatment arm will receive no additional treatment other than standard of care, which includes suctioning and supportive care as needed."
2959722|NCT02834806|Experimental|BioNIR drug eluting stent system|BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
2959723|NCT02834793|Experimental|Perampanel 8 mg/day|During the Randomization Phase, participants will receive perampanel at a starting dose of 2 milligrams per day (mg/day). Thereafter, the dose will be increased up to a maximum target dose of 8 mg/day according to individual tolerability and efficacy for up to 22 weeks. During the Extension Phase, participants will continue to receive perampanel at the dose last received during randomization phase. Participants can be titrated up to 12 mg/day (at 2 week intervals) per the investigator's discretion.
2959724|NCT02834793|Placebo Comparator|Matching placebo|During the Randomization Phase, participants will receive matching placebo for up to 22 weeks. During the Extension Phase, participants who will begin treatment with perampanel in a blinded manner, starting at 2 mg/day and will then be up-titrated to the optimal dose per the investigator's discretion. After the double-blind Conversion Period, participants can be titrated up to 12 mg/day (at 2 week intervals) per the investigator's discretion.
2959725|NCT02834780|Experimental|H3B-6527 (escalation and expansion)|Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
2959726|NCT02834767|Experimental|Group 1 Primary Snoring Treatment|Intervention: Eight weeks of supervised use of the genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
2959727|NCT02834767|Placebo Comparator|Group 2 Primary Snoring Placebo|Intervention: Eight weeks of supervised use of the placebo genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
2959728|NCT02834767|Experimental|Group 3 Primary OSA Treatment|Intervention: Eight weeks of supervised use of the genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
2959729|NCT02834767|Placebo Comparator|Group 4 Primary OSA Placebo|Intervention: Eight weeks of supervised use of the placebo genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
2959730|NCT02834754|Experimental|Vedolizumab|Vedolizumab infusions at weeks 0, 2, and 6 weeks, then every 8 weeks for 52 weeks
2959732|NCT02834741|Placebo Comparator|SAD Phase|"Up to 36 subjects: 50 - 1200 mg NYX-2925, Up to 12 subjects: placebo~6 additional subjects will receive a fed dose of NYX-2925, 2 additional subjects will receive a fed dose of placebo (Food Effect Cohort)~6 additional subjects will receive 1 dose of 50 mg NYX-2925 followed by a lumbar puncture at 1 and 4 (3 subjects) or 2 and 8 (3 subjects) hours post dose"
2959733|NCT02834741|Placebo Comparator|MAD Phase|"Up to 24 subjects : 150 - 600 mg NYX-2925 daily for 7 days, up to 6 subjects : placebo daily for 7 days~6 additional subjects will receive 300 mg NYX-2925 daily for 7 days and undergo lumbar puncture on Day 6 in order to have two CSF samples taken (CSF Cohort)."
2959734|NCT02834728||Frail elderly people|A group of elderly people hospitalised in medical wards via emergency department
2959735|NCT02834715|Experimental|Stevia|Once-daily oral intake of 240 mg of Stevia liquid extract for 30 days as food supplement.
2959736|NCT02834715|No Intervention|Control|No intervention, similar follow up as experimental arm to control for trial effect
2959737|NCT02834702|Experimental|Sinew acupuncture|Sinew acupuncture
2959738|NCT02834702|Sham Comparator|Sham acupuncture|Sham acupuncture
2959739|NCT02834689|Experimental|Walking|Walking on a treadmill at 3.5 metabolic equivalents (METS) for 50 minutes
2959740|NCT02834689|Experimental|Seated Control|Sitting for 50 minutes
2959741|NCT02834676||Chemonucleolysis by Gelified Ethanol|Patients visiting the pain clinic of the hospital who had cervical discogenic or radicular pain that did not resolve after the use of conventional therapy and ozone-oxygen therapy. Written informed consent was obtained from all participants.
2959742|NCT02834663|Experimental|Lucentis|
2959743|NCT02834650|Experimental|Group 1a|Group 1a comprises healthy volunteers who will complete a Cardiac MRI without contrast. A subset of healthy volunteers will have a repeat MRI at Children's Hospital of Orange County.
2959744|NCT02834650|Experimental|Group 1b|"Group 1b comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test.~A subset of boys with DMD will have a repeat MRI with contrast at Children's Hospital of Orange County."
2959745|NCT02834650|Experimental|Group 2|Group 2 comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test and a repeat MRI scan with contrast at 6 Months.
2959746|NCT02834650|Experimental|Group 3|Group 3 comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test and a genetic testing.
2959747|NCT02834637|Active Comparator|3 doses 2valent|3 doses of bivalent HPV vaccine (Cervarix) given at M0, M1 and M6
2959748|NCT02834637|Active Comparator|2 doses 2valent|2 doses of bivalent HPV vaccine (Cervarix) given at M0 and M6
2959749|NCT02834637|Active Comparator|1 dose 2valent|1 dose of bivalent HPV vaccine (Cervarix) given at M0
2959750|NCT02834637|Active Comparator|3 doses 9valent|3 doses of nonavalent HPV vaccine (Gardasil9) given at M0, M2 and M6
2959751|NCT02834637|Active Comparator|2 doses 9valent|2 doses of nonavalent HPV vaccine (Gardasil9) given at M0 and M6
2959752|NCT02834637|Active Comparator|1 dose 9valent|1 dose of nonavalent HPV vaccine (Gardasil9) given at M0
2959753|NCT02834624|Active Comparator|Calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
2959754|NCT02834624|Active Comparator|Poractant Alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
2959755|NCT02834611|Experimental|Ceramide NanoLiposome|Dose escalation of Ceramide NanoLiposome
2959756|NCT02834598|Experimental|Rocking movement|Participant is lying in a hammock with a rocking motion. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
2959757|NCT02834598|Active Comparator|Lying position|Participant is lying in a hammock with no rocking motion. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
2959758|NCT02834598|Active Comparator|Seated position|Participant is sitting on a chair. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
2959759|NCT02834585||Ultrasound|Patients undergoing Ultrasound
2959760|NCT02834585||Magnetic Resonance Imaging|Patients undergoing Magnetic Resonance Imaging
2959761|NCT02834572|Experimental|All About Me|assessment and algorithm to provide participants with a tailored recommendation of their optimal HIV testing approach
2959762|NCT02834572|Active Comparator|Control|HIV testing information
2959763|NCT02834559|Active Comparator|Adjuvant therapy with 5-FU and LMWH|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).
2959764|NCT02834559|Placebo Comparator|Standard of care|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).
2959765|NCT02834546||Patients with HCC treated with sorafenib|
2959766|NCT02834533|Active Comparator|column heading in tables.|The group 1 (G1, n=20) underwent Lokomat-Nanos training. Each patient underwent 40 1h-training sessions (for 3 times a week). Both the study groups were treated by Lokomat (Hocoma Inc., Zurich, Switzerland), which includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . The overall duration of Lokomat therapy, including the time to get on and off, was 60min, while the robotic gait training lasted around 40min.
2959767|NCT02834533|Active Comparator|row and column in table|The group 2 (G2, n=20) underwent Lokomat-Pro training, with the same G1 sessions. The Pro device offers instead a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
2959768|NCT02834520||oral lichen planus|30 patients suffering from reticular, erosive and atrophic oral lichen planus
2959855|NCT02833948|Active Comparator|ASA + Clopidogrel|ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
2959770|NCT02834507|Placebo Comparator|Placebo|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
2959771|NCT02834507|Experimental|Nebicapone 75 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
2959772|NCT02834507|Experimental|Nebicapone 150 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
2959773|NCT02834507|Active Comparator|Entacapone 200 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
2959774|NCT02834494|Other|3D Shear Wave Elastography (SWE)|
2959775|NCT02834481|Other|: ventilated children|ventilated children admitted in PICU postoperative of cardiac surgery with extracorporeal circulation with ANI/NIPE
2959776|NCT02834468|Experimental|Treatment group|DEX Combined With RTX, CSA and IVIG All patients are assigned to receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.
2959777|NCT02834455|Active Comparator|CE-CT scanning|Contrast-enhanced CT scan of the thorax and abdomen.
2959778|NCT02834455|Active Comparator|PET-CT scanning|Positron-emission-CT scanning (low dose without contrast) of the thorax and abdomen.
2959779|NCT02834442|Experimental|Single ascending dose, MT-7117 or Placebo|
2959780|NCT02834442|Experimental|Multiple ascending dose, MT-7117 or Placebo|
2959781|NCT02834429||endoscopy patients|We will recruit patients (n=1000) from the endoscopy department at the Royal Hallamshire Hospital, Sheffield, United Kingdom (UK).
2959782|NCT02834416|Experimental|Group-Supervised|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
2959783|NCT02834416|Experimental|Home-Based|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as the supervised group). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
2959784|NCT02834403|Experimental|Experimental|"Phase Ib: L-NMMA and docetaxel will be given for 6 21-day cycles. L-NMMA at doses of 5, 7.5 (starting dose), 10, 12.5, 15, 17.5, and 20 mg/kg will be administered IV on Days 1-5. For the 5, 7.5, 10, 12.5, and 15 mg/kg L-NMMA doses, docetaxel will be administered at 75 mg/m2. For the 17.5 and 20 mg/kg L-NMMA doses, docetaxel will be administered at 100 mg/m2. Docetaxel will be administered IV 15 min after the Day 1 L-NMMA infusion. Amlodipine (10 mg) will be orally administered daily for 6 days starting 24 hours before the first L-NMMA dose. Pegfilgrastim (6 mg) will be administered subcutaneously 24 h after docetaxel.~Phase II: L-NMMA starting dose will be the RP2D determined in the Phase Ib portion of the study."
2959785|NCT02834390|Experimental|Arm 1|"Quizartinib and Cytarabine to be used in both the Induction period and the Consolidation period.~And either Idarubicin or Daunorubicin to be used in the Induction period."
2959786|NCT02834377|Experimental|Treatment algorithm|Patients allocated to the study group will be connected to a cardiac output monitor. An initial haemodynamic assessment will be performed at the beginning of surgery and at regular time intervals (every 15 minutes) during surgery. The personal cardiac output value is targeted.
2959787|NCT02834377|No Intervention|Standard of Care|Patients allocated to the control group will receive the standard care of the hospital.
2959788|NCT02834364|Experimental|single arm|Encorafenib 450 mg. p.o.once daily and Binimetinib 45 mg p.o. twice daily until disease progression or toxicity requiring discontinuation of treatment. 1 cycle is defined as 28 days.
2959789|NCT02834351|Active Comparator|Peripheral artery diseased group|pad Patients referred for femoro popliteal bypass Muscle biopsy during surgery
2959790|NCT02834351|Sham Comparator|Cardiac group|Patients referred for saphenous withdrawal for coronary bypass Muscle biopsy during surgery
2959791|NCT02834338|No Intervention|Laparoscopic surgery, control|The control group is wearing an activity tracker wristband with covered display, so that the step count can't be read out.
2959792|NCT02834338|Active Comparator|Laparoscopic surgery, intervention|activity tracking for autofeedback
2959793|NCT02834338|No Intervention|Open surgery, control|The control group is wearing an activity tracker wristband with covered display, so that the step count can't be read out.
2959794|NCT02834338|Active Comparator|Open surgery, intervention|activity tracking for autofeedback
2959795|NCT02834325||exit|HFNC with no need for mechanical ventilation
2959796|NCT02834325||failure|HFNC with need for mechanical ventilation
2959797|NCT02834312|Experimental|2.5 mg estetrol|
2959798|NCT02834312|Experimental|5 mg estetrol|
2959799|NCT02834312|Experimental|10 mg estetrol|
2959800|NCT02834312|Experimental|15 mg estetrol|
2959801|NCT02834312|Placebo Comparator|placebo|
2959802|NCT02834299|Experimental|DBT Guided Self-Help|"Participants will be provided with the DBT self-help manual Dialectical Behavior Therapy for Binge Eating: A Self-Help Program by Safer, Adler & Masson (2016) and receive six brief therapy sessions via video-calling."
2959803|NCT02834299|Experimental|DBT Unguided Self-Help|"Participants will be provided with the DBT self-help manual Dialectical Behavior Therapy for Binge Eating: A Self-Help Program by Safer, Adler & Masson (2016) and asked to follow the manual on their own."
2959804|NCT02834299|Active Comparator|Self-Esteem-Focused Unguided Self-Help|"Participants will be provided with the self-help manual Self-Esteem by McKay & Fanning (2016) as asked to follow the manual on their own."
2959805|NCT02834286|Experimental|Rituximab, eltrombopag and dexamethasone|Each patient will receive Rituximab 100 mg weekly days 1, 7, 14, 21 Eltrombopag 50 mg PO days 1-28 Dexamethasone 40 mg IV/PO days 1-4
2959806|NCT02834273|Experimental|Therapeutic Workshop|Therapeutic Workshop (patients following therapeutic education workshops during their hospitalization)
2959807|NCT02834273|No Intervention|Usual care|
2959808|NCT02834260|Experimental|ozurdex group|Subconjunctival injection of the absorbable implant of Dexamethasone immediately at the end of penetrating keratoplasty. The injection is made at the 12 O'Clock position is a bubble created by subconjunctival injection of balanced salt solution.
2959809|NCT02834247|Experimental|Part 1: Advanced Solid Tumors|TAK-659 60 milligram (mg), tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 milligram per kilogram (mg/kg), infusion over 60 minutes, intravenously (IV), on Days 1 and 15 in each 28 day treatment cycle until PD or unacceptable toxicity. Dose escalation of TAK-659 to 100 mg may be done using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or RP2D.
2959810|NCT02834247|Experimental|Nivolumab Fixed Dose Cohort|After RP2D of TAK-659 has been identified, based on evaluation of combination with weight-based dose of nivolumab (3 mg/kg), RP2D may be evaluated in combination with a fixed dose of 240 mg IV nivolumab after discussion between investigator and sponsor for all types of advanced solid tumors. For single-agent nivolumab, fixed dose is expected to have equal exposure, safety, and efficacy as weight-based (3 mg/kg) dose. If nivolumab fixed dose is evaluated with TAK-659 RP2D, 3 participants will be initially enrolled into cohort. Following evaluation of safety, efficacy, and any available PK data, along with discussions between investigator and sponsor, 3 additional participants may be enrolled into cohort for a total of 3 to 6 participants. If >=1 out of 6 participants experiences dose-limiting toxicity (DLT) in Cycle 1, or significant safety issues are seen in Cycle 2 and beyond, re-evaluation of TAK-659 RP2D when administered with a fixed dose of nivolumab is permitted.
2959811|NCT02834247|Experimental|Part 2: Metastatic Triple-negative Breast Cancer (TNBC)|Participants with metastatic TNBC will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
2959812|NCT02834247|Experimental|Part 2: Metastatic Non-small Cell Lung Cancer (NSCLC)|Participants with metastatic NSCLC will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1.disease or unacceptable toxicity. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
2959813|NCT02834247|Experimental|Part 2: Metastatic HNSCC|Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
2959814|NCT02834234||Peritoneal mesothelioma specimens|"The group harbors only patients who received the diagnosis of peritoneal mesothelioma after surgery. All patients are included in this group.~The CGH arrays will be realized on frozen samples (for the comparative genomic analysis)."
2959815|NCT02834221|Experimental|Real-time ultrasound-guided puncture|Cannulate each femoral veins with two wires with real-time ultrasound-guided method.
2959816|NCT02834221|Other|Anatomical landmark guided puncture|Cannulate each femoral veins with two wires with the anatomical landmark guided method.
2959817|NCT02834208|Experimental|Schizophrenia subjects|35 patients suffering from schizophrenia
2959818|NCT02834208|Other|Healthy siblings|35 healthy siblings of the patients suffering from schizophrenia
2959819|NCT02834208|Other|Healthy controls|"35 healthy controls patients"
2959820|NCT02834182|Experimental|Bipolar Disorder patients and Schizophrenic patients|
2959821|NCT02834182|Active Comparator|Healthy Controls|
2959822|NCT02834169||pseudomyxoma peritonei|Data from pseudomyxoma peritonei cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
2959823|NCT02834169||peritoneal mesothelioma|Data from peritoneal mesothelioma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
2959856|NCT02833948|Experimental|Rivaroxaban + ASA|Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
2959824|NCT02834169||desmoplastic small round cell tumor|Data from desmoplastic small round cell tumor cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
2959825|NCT02834169||psammocarcinoma|Data from primary peritoneal serous carcinoma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
2959826|NCT02834169||primary peritoneal serous carcinoma|Data from primary peritoneal serous carcinoma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
2959827|NCT02834169||diffuse peritoneal leiomyomatosis|Data from diffuse peritoneal leiomyomatosis cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
2959828|NCT02834169||appendiceal mucinous neoplasms|Data from appendiceal mucinous neoplasms cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
2959829|NCT02834156|Other|LP in a seated position then LP in a lying position|Patients will have first a lumbar puncture (LP) in a seated position then a LP in a lying position
2959830|NCT02834156|Other|LP in a lying position then LP in a seated position|Patients will have first a lumbar puncture (LP) in a lying position then a LP in a seated position
2959831|NCT02834130|Other|children from 2 to 10 years with haemophilia or allied HBD, wh|
2959832|NCT02834117|Other|Natural cycle|Ovulation is not induced by drugs
2959833|NCT02834117|Experimental|Moderate ovarian stimulation|Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
2959834|NCT02834104|Experimental|Myocardial fibrosis|
2959835|NCT02834078|Experimental|BGG|Dose: 01 tablet three times daily just before all major meals (breakfast, lunch and dinner)
2959836|NCT02834078|Placebo Comparator|Placebo|Matching placebo capsules [for BGG tablet] composed of micro crystalline cellulose and added colors and odors. Dose: 01 tablet three times daily just before all major meals (breakfast, lunch and dinner)
2959837|NCT02834065|Active Comparator|Deep Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature ≤20 degrees Celsius
2959838|NCT02834065|Active Comparator|Low Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature 20.1 - 24.0 degrees Celsius
2959839|NCT02834065|Active Comparator|Moderate Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature 24.1 - 28 degrees Celsius
2959840|NCT02834052|Experimental|Phase 1|"This Run In phase is aimed to determine if poly-ICLC can be safely combined with standard dosages of pembrolizumab:~i. Pembrolizumab will be administered 200 mg intravenously (IV) every 3 weeks (q3w)~ii. Poly-ICLC will be administered intramuscularly (IM) twice weekly at one of two dose levels: 1 mg or 2 mg~Each dose level will enroll 3-6 participants, up to 12 participants total, depending on the occurrence of dose limiting toxicities (DLT) at each dosing level.~Participants may receive treatment for 1 year (~17 cycles)."
2959841|NCT02834052|Experimental|Phase 2|"In Phase 2, all participants will receive the standard pembrolizumab dose (200 mg IV q3w) in addition to the maximum tolerated dose of poly-ICLC (either 1 mg or 2 mg), as determined by the Phase 1 arm.~Up to 30 participants will be treated in Phase 2. Participants may receive treatment for 1 year (~17 cycles)."
2959842|NCT02834039|Active Comparator|Tidal volume 6 ml/kgBW|Tidal volume 6 ml/kgBW was given to patients after endotracheal tube was inserted properly
2959843|NCT02834039|Active Comparator|Tidal volume 10 ml/kgBW|Tidal volume 10 ml/kgBW was given to patients after endotracheal tube was inserted properly.
2959844|NCT02834026|Experimental|Intervention|The intervention group held two months of training in hemodialysis a physical therapy protocol with cycle ergometer
2959845|NCT02834026|Experimental|Control|The control group was reassessed after two months of the initial evaluation
2959846|NCT02834013|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 60 minutes on day 1. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
2959847|NCT02834000|No Intervention|Standard Care|We will compare the standard monitored group of patients with the LiDCO rapid™ monitored group. The control group will compose of patients supervised in a standard way.
2959848|NCT02834000|Experimental|LiDCO rapid™ CNAP monitoring|Young, healthy adult patients (ASA I and II) undergoing elective orthopaedic surgery under general anaesthesia will be included in to this study. We will compare the standard monitored group of patients with the LiDCO rapid™ monitored group. We will use in the LiDCO rapid™ CNAP monitoring group, the continuous real time haemodynamic monitoring through non-invasive arterial pressure waveform. The monitor LiDCO rapid™ CNAP permits, through analysis the arterial blood pressure trace, to acquire information about CO, SVR, HR variability, SV and BIS.
2959849|NCT02833987||Treated with direct oral anticoagulants (DOACs)|Patients who received a new prescription for a DOAC (apixaban, dabigatran, or rivaroxaban) in the 30 days following the date of an incident VTE diagnosis, and did not have a previous prescription for a DOAC or warfarin in the year prior to the date of the new prescription.
2959850|NCT02833987||Treated with warfarin|Patients who received a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis, and did not have a previous prescription for a DOAC or warfarin in the year prior to the date of the new prescription.
2959851|NCT02833974|Experimental|GSK2245035 20 ng|Participants will receive 20 ng of GSK2245035 Nasal spray solution (1 spray=10 ng GSK2245035 per actuation per nostril) every week for the duration of 8 weeks administered using a metered Valois VP7 pump
2959852|NCT02833974|Placebo Comparator|Placebo|Participants will receive placebo Nasal spray solution (1 spray per nostril) every week for the duration of 8 weeks administered using a metered Valois VP7 pump
2959853|NCT02833961|Experimental|ISCHEMIC STROKE|ischemic stroke admitted in the Pitié Salpêtrière Stroke unit in Paris
2959854|NCT02833961|Active Comparator|HEALTHY SUBJECTS|Age and gender-matched healthy volunteers
2959857|NCT02833935|Experimental|Physical Activity Intervention Group|Participants will complete a baseline questionnaire (week 1) about their demographic information, self-determination theory variables, their current physical activity, and other psychological indicators. They will complete the same questionnaire at two additional time points. First, about halfway through the intervention (week 6), and then at the end (week 10). Participants in the physical activity intervention group will also receive 8 1-hour physical activity sessions over 2 months (1/week) with a trained physical activity counselor through a video-based internet platform.
2959858|NCT02833935|No Intervention|Control Group|Control Group: For participants assigned to the control group, they will be asked to continue with their regular routine for the next two months. Otherwise, the participants in this group will be asked to complete the follow-up baseline questionnaires at 6 and 10 weeks post-baseline. They will be contacted by a physical activity counsellor at the end of the 10-week period.
2959859|NCT02833922||Women using Dot to avoid pregnancy|Women living in the United States, ages 18-39 who have not used hormonal birth control or been pregnant in the last three months, who are in a relationship with a male sexual partner, and who wish to use the Dot app to avoid pregnancy for at least one year.
2959860|NCT02833909|Experimental|HS|
2959861|NCT02833909|Experimental|Controls|
2959862|NCT02833896||endometrial cancer|
2959863|NCT02833896||Control|
2959864|NCT02833883|Experimental|Enzalutamide plus CC-115|The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. The doses will continue to increase for every group of study participants until the maximum tolerated dose is identified. Participants at each site will participate in the dose escalation phase of the study. During the dose escalation phase, study participants will be assigned sequentially to three dose levels in groups (cohorts) of 3 to 6 subjects per dose level: Cohort 1: CC-115 at 5 mg dose twice a day & enzalutamide at 160 mg once a day. Cohort 2: CC-115 at 10 mg dose twice a day & enzalutamide at 160 mg once a day. The protocol has been amended to accrue an additional 17-30 patients in the expansion phase treated at 7.5 mg BID.
2959865|NCT02833870|Experimental|Musical intervention|
2959866|NCT02833870|Experimental|Non-musical (cooking) intervention|
2959867|NCT02833870|Active Comparator|Control with no intervention|
2959868|NCT02833857|Experimental|Single dose of study drug|AMG 416
2959869|NCT02833844|Experimental|24-week Double Blind Period Repatha (Evolocumab)|Repatha (Evolocumab) subcutaneous injection every 4 weeks (QM)
2959870|NCT02833844|Placebo Comparator|24-week Double Blind Period Repatha (Evolocumab) Placebo|Repatha (Evolocumab) Matching Placebo subcutaneous injection every 4 weeks (QM)
2959871|NCT02833844|Experimental|24-week Open Label Period Repatha (Evolocumab)|Repatha (Evolocumab) subcutaneous injection every 4 weeks (QM)
2959872|NCT02833831|Experimental|Part 1: Group 1|Participants will receive Treatment A (a single dose of ALS-008176 1,500 mg) or Treatment B (a single dose of placebo) under fasted conditions.
2959873|NCT02833831|Experimental|Part 1: Group 2|Participants will receive Treatment C (a single dose of ALS-008176 2,500 mg) or Treatment D (a single dose of placebo) under fasted conditions.
2959874|NCT02833831|Experimental|Part 1: Group 3|Participants will receive Treatment E (a single dose of ALS-008176 3,000 mg) or Treatment F (a single dose of placebo) under fasted conditions.
2959875|NCT02833831|Experimental|Part 2: Sequence GHI|Participants will receive Treatment G (a single dose of ALS-008176 3,000 mg + a single dose of moxifloxacin placebo under fasted conditions) then Treatment H (a single dose of ALS-008176 placebo + a single dose of moxifloxacin 400 mg under fasted conditions) then Treatment I (a single dose of ALS-008176 placebo + a single dose of moxifloxacin placebo under fasted conditions). There will be a washout period of at least 14 days between subsequent treatments.
2959876|NCT02833831|Experimental|Part 2: Sequence HIG|Participants will receive Treatment H then Treatment I and then Treatment G. There will be a washout period of at least 14 days between subsequent treatments.
2959877|NCT02833831|Experimental|Part 2: Sequence IGH|Participants will receive Treatment I then Treatment G and then Treatment H. There will be a washout period of at least 14 days between subsequent treatments.
2959878|NCT02833831|Experimental|Part 2: Sequence IHG|Participants will receive Treatment I then Treatment H and then Treatment G. There will be a washout period of at least 14 days between subsequent treatments.
2959879|NCT02833831|Experimental|Part 2: Sequence HGI|Participants will receive Treatment H then Treatment G and then Treatment I. There will be a washout period of at least 14 days between subsequent treatments.
2959880|NCT02833831|Experimental|Part 2: Sequence GIH|Participants will receive Treatment G then Treatment I and then Treatment H. There will be a washout period of at least 14 days between subsequent treatments.
2959881|NCT02833818|Experimental|CAKE-intervention|Increased nutrition and dietary consultations. Growth rate followed by clinical nutritionists that supply high protein and energy if growth rate deviates from 17g/kg/day
2959882|NCT02833818|Active Comparator|CAKE-control|nutrition according to established procedures in the neonatal intensive care unit (NICU)
2959883|NCT02833805|Experimental|Bone marrow transplant|Non-myeloablative bone marrow transplant with a Thymoglobulin (ATG), fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.
2959884|NCT02833792|Experimental|Stem Cells|Stem cells
2959885|NCT02833792|Placebo Comparator|Placebo|Lactated Ringer's Solution
2959886|NCT02833779|Active Comparator|Group Therapy Exercises|Patients will be taught exercises in groups of six persons, on a daily basis for twelve sessions.
2959887|NCT02833779|Active Comparator|Individual Manual Therapy Exercises|Patients will be taught the same exercises as in a Group 1, individually, and will receive manual therapy consisting of muscular and joint re-centering
2959888|NCT02833766|Experimental|anti-EGFR-IL-dox|Metastatic, non resectable, EGFR positive TNBC patients treated in first-line
2959889|NCT02833753|Experimental|Dose Escalation|"Single arm dose finding for intraperitoneal Oxaliplatin. All patients will receive experimental treatment.~The first cohort of 3 patients will receive dose level 1. The second cohort of 3 patients will receive dose level 2. The Third cohort of 3 patients with receive dose level 3."
2960009|NCT02832921|Experimental|VR cognitive tasks + treadmill|This is the primary group of interest, in which the investigators hypothesize the greatest cognitive gains since motor activity will augment cognitive activity.
2959890|NCT02833740|Other|Click-MUAC & regular MUAC tape screening|"Each child will have nutritional status classified 11 times:~3 times with each of the 3 Click-MUAC prototypes by the mother/caregiver~1 time with a regular MUAC tape by the mother/caregiver~3 times with each of the 3 Click-MUAC prototypes by the case-finding/programme staff~1 time with a regular MUAC tape by the case-finding/programme staff~3 times with a regular MUAC tape by the data collection team (gold standard)"
2959891|NCT02833727||Asthmatic smokers (AS)|"Asthmatics will fulfill the following definition of asthma: reversible airflow obstruction and/or a provocative concentration of methacholine inducing a 20% fall in FEV1 (PC20) < 8 mg/ml with a diagnosis of asthma made by a respirologist.~Smokers or ex smokers will be defined by a smoking history of ≥ 10 pack/year."
2959892|NCT02833727||Asthmatic non-smokers (ANS)|"Asthmatics will fulfill the following definition of asthma: reversible airflow obstruction and/or a PC20 < 8 mg/ml with a diagnosis of asthma made by a respirologist.~Never smokers will have a life-long history without smoking."
2959893|NCT02833701|Experimental|Treatment (bevacizumab and ascorbic acid)|Patients receive ascorbic acid IV over 90-120 minutes three times per week (at least 24 hours apart) and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2959894|NCT02833688|Experimental|dexmedetomidine|dexmedetomidine 2mg is diluted in 0.9% sodium chloride with the concentration of 4 ug ml-1 is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
2959895|NCT02833688|Placebo Comparator|0.9% sodium chloride|0.9% sodium chloride is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
2959896|NCT02833675||bradykinin angioedema|Hereditary angioedema with or without C1Inhibitor Drug induced angiodema
2959897|NCT02833675||Histaminergic angioedema|Allergic and non allergic angioedema
2959898|NCT02833675||Control group|Patients with abdominal pain
2959899|NCT02833662|Other|Patients suspected to present a Sleep Apnea Syndrom|"Record nocturnal respiratory and cardiac parameters before and after surgery :~Severity of sleep respiratory disorders and relationship with cardiac rhythm abnormalities will be assessed in patients suspected to present Sleep Apnea, before and after surgery under general anesthesia."
2959900|NCT02833649|Experimental|Toric Implantable contact Lens|The Visian implantable collamer lens (Staar Surgical AG, Nidau, Switzerland), is a monoblock single-piece plate haptic lens made of collamer (an extremely hydrophilic and highly biocompatible flexible collagen copolymer with a refractive index of 1.452 that is permeable to oxygen and nutrients
2959901|NCT02833636||Successful CTO-PCI group|low ACEF score <1.215 (n = 79), intermediate ACEF score from 1.215 to 1.493 (n=70), and high ACEF score≥1.493 (n=72)
2959902|NCT02833636||Failed/non-attempted CTO-PCI group|low ACEF score<1.215 (n=45), intermediate ACEF score from 1.215 to 1.493 (n=57), and high ACEF score≥1.493 (n=54).
2959903|NCT02833623|Experimental|Short-message-based Re-education group|"Patients receive oral and written education before H. pylori eradication therapy at first, then they receive short message re-education twice per day during therapy.~Both the content of the oral and written education and the short message re-education are same."
2959904|NCT02833623|Active Comparator|conventional education group|Patients only receive oral and written education before H. pylori eradication therapy.
2959905|NCT02833610|Experimental|Denosumab Injection|Patients will be administered Denosumab Q4W at a pre-determine dose for 12 cycles. Denosumab Q4W is administered by subcutaneous injection.
2959906|NCT02833584|Experimental|Paracetamol|Eligible patients will be randomised to receive Paracetamol prn for fever at maximum dosage of 500 mg PO q 4 hr (3 gm/day)
2959907|NCT02833584|Placebo Comparator|Placebo|Eligible patients will be randomised to receive Placebo prn for fever at maximum dosage of 500 mg PO q 4 hr (3 gm/day)
2959908|NCT02833558|Experimental|PuraStat®|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to stop bleeding during ESD.
2959909|NCT02833558|Other|Standard Electrocautery|Control arm where standard electrocautery delivered via the endoscopic knife tip or coag grasper is used to achieve haemostasis during ESD
2959910|NCT02833545|Experimental|OZONE|injection of ozone gas
2959911|NCT02833532|Experimental|Volus|Maxium: 22ml
2959912|NCT02833532|Active Comparator|Powerfill|Maxium: 22ml
2959913|NCT02833519|No Intervention|control group|Standard care, mentally vulnerable women
2959914|NCT02833519|Active Comparator|group exercise|Supervised Group training
2959915|NCT02833506|Active Comparator|Cohort I (NY-ESO-1 protein with MIS416)|Patients receive NY-ESO-1 protein with MIS416 vaccine SC on days 1, 15, 29, 57, 85, and 113 in the absence of disease progression or toxicity.
2959916|NCT02833506|Experimental|Cohort II (NY-ESO-1 protein with MIS416, sirolimus)|Patients receive NY-ESO-1 protein with MIS416 vaccine as in Cohort I. Patients also receive sirolimus PO daily for 2 weeks followed by 2 weeks off starting on days 1, 29, 57, and 85.
2959917|NCT02833480|Experimental|Fluticasone group|Advair (fluticasone) 250 mcg to be administered twice daily via Diskus for 12 weeks
2959918|NCT02833480|Experimental|Budesonide group|Symbicort (budesonide) 400 mcg to be administered twice daily via Turbuhaler for 12 weeks
2959919|NCT02833480|Active Comparator|Formoterol group|Oxeze (formoterol) 12 microg to be administered twice daily via Turbuhaler for 12 weeks
2959920|NCT02833454|Active Comparator|direct insertion single bundle ACLR|Patients with ACL rupture undergo direct insertion anterior cruciate ligament reconstruction using single bundle technique.
2959921|NCT02833454|Experimental|anatomical double bundle ACLR|Patients with ACL rupture undergo double bundle anterior cruciate ligament reconstruction.
2959922|NCT02833454|Experimental|anatomical single bundle ACLR|Patients with ACL rupture undergo single bundle anterior cruciate ligament reconstruction.
2959923|NCT02833454|Active Comparator|direct insertion double bundle ACLR|Patients with ACL rupture undergo direct insertion anterior cruciate ligament reconstruction using double bundle technique.
2959965|NCT02833207|Experimental|EDD Lean|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible lean subjects will undergo Drug Trial 1 (EDD) (described in Intervention section).
2959924|NCT02833441|Experimental|Peer Support Intervention|Adolescents/young adults in the Peer Support Intervention arm will be referred to a Peer Support Intervention support group within their own or nearby community. This support group will meet monthly and will be facilitated by a professional HIV counsellor together with a Peer Support Intervention counselor. The Peer Support Intervention counsellors will provide regular counselling to their allocated participants through home visits and SMS messages. Each participant will be visited once a week in their home. Whatsapp messages will be delivered daily to each participant by the Community Adolescent Treatment Supporters. The agreed messages will briefly enquire about the participant's well-being without specifically making reference to HIV or ARVs. In addition, participants' caregivers will be invited to a 3-session intervention to build knowledge, skills and confidence to better support their adolescents.
2959925|NCT02833441|No Intervention|Standard of Care Practice|"Participants in the standard of care group will receive adherence evaluations and counseling at the clinic as per the current standard of care. Current procedures involve a group counseling session given on Monday morning during which topics are discussed that are relevant to adolescents. In general children aged between 13-19 years attend these sessions. After the group counseling, adolescents also receive an individual counseling session before being evaluated by the clinic doctor. Youth are also encouraged to complete a self reported adherence questionnaire and may periodically undergo pill counts by the clinic counselors.~The adolescents may belong to peer support groups in their communities, however these activities are not part of the clinic program. No interventions are typically targeted at their caregivers."
2959926|NCT02833428|Experimental|patients with acute spinal cord injury|The study will be performed on patients with acute spinal cord injury between the cord next to the C2 vertebra and marrow next to the T12 vertebra. This is usually hospitalized patients in an emergency situation, brought by EMS (emergency medical services) and taken care of immediately in the recovery room by intensivists. Patients who accepted to participate to this study will got the installation bedside biomedical equipment for the project (Eclipse Nim, Medtronic®). The aim of this work is to analyze using an artificial intelligence engine (IA, Biomedical equipment (Eclipse Nim, Medtronic®)) the influence of the physiopathological environment (set of parametric data monitoring, imaging, biology etc.) of the traumatized spinal cord on spinal pain.
2959927|NCT02833415|Experimental|High Visceral Fat - Empagliflozin|Empagliflozin 10 mg by mouth daily for 3 months.
2959928|NCT02833415|Placebo Comparator|High Visceral Fat - Placebo|Placebo one tablet daily for 3 months
2959929|NCT02833415|Experimental|Low Visceral Fat - Empagliflozin|Empagliflozin 10 mg by mouth daily for 3 months.
2959930|NCT02833415|Placebo Comparator|Low Visceral Fat - Placebo|Placebo one tablet daily for 3 months
2959931|NCT02833402||UUI patients undergoing SNM|Urine specimens, questionnaire, and medical data will be collected from subjects that have UUI and are undergoing InterStim placement (SNM).
2959932|NCT02833389|Experimental|Cohort A - UTTR1147A, 0.8-6.0 cm^2, No Infection - Dose 1|Participants with 0.8-6.0 centimeters square (cm^2) index ulcer area at screening and no infection in index ulcer will receive UTTR1147A SC at Dose Level 1 for 12 weeks (a total of 4 doses).
2959933|NCT02833389|Experimental|Cohort B - UTTR1147A, 0.8-6.0 cm^2, No Infection - Dose 2|Participants with 0.8-6.0 cm^2 index ulcer area at screening and no infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
2959934|NCT02833389|Experimental|Cohort C - UTTR1147A, 0.8-6.0 cm^2, Mild Infection - Dose 2|Participants with 0.8-6.0 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
2959935|NCT02833389|Experimental|Cohort D - UTTR1147A, 1.5-6.0 cm^2, Mild Infection - Dose 2|Participants with 1.5-6.0 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
2959936|NCT02833389|Experimental|Cohort E - UTTR1147A, 0.8-6.0 cm^2, No infection - Dose 3|Participants with 0.8-6.0 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 3 for 12 weeks (a total of 4 doses).
2959937|NCT02833389|Placebo Comparator|Placebo|Participants will receive UTTR1147A matching placebo SC in each cohort for 12 weeks (a total of 4 doses).
2959938|NCT02833376|Experimental|Alcohol group|Patients allocated to this group will receive skin antisepsis with alcohol 70% prior spinal anesthesia
2959939|NCT02833376|Experimental|Chlorhexidine group|Patients allocated to this group will receive skin antisepsis with alcoholic solution of chlorhexidine 0.5% prior spinal anesthesia
2959940|NCT02833363||patients with non-atrophic gastritis|
2959941|NCT02833363||Patients with gastritis|
2959942|NCT02833363||Patients with intestinal metaplasia|
2959943|NCT02833363||Patients with intrepithelial neoplasia|
2959944|NCT02833363||Patients with non-cardia gastric cancer|
2959945|NCT02833350|Experimental|Cohort 1: GDC-0853 High Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
2959946|NCT02833350|Experimental|Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
2959966|NCT02833207|Experimental|ROV Obese|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible obese subjects will undergo Drug Trial 2 (ROV) (described in Intervention section).
2960043|NCT02832713|Experimental|Intra-articular injection of botulinum toxin A|
2959947|NCT02833350|Experimental|Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
2959948|NCT02833350|Active Comparator|Cohort 1: GDC-0853 Placebo + Adalimumab|Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
2959949|NCT02833350|Placebo Comparator|Cohort 1: GDC-0853 Placebo + Adalimumab Placebo|Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
2959950|NCT02833350|Experimental|Cohort 2: GDC-0853 High Dose|Participants of Cohort 2 will receive GDC-0853 high dose, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
2959951|NCT02833350|Placebo Comparator|Cohort 2: GDC-0853 Placebo|Participants of Cohort 2 will receive placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
2959952|NCT02833324|Experimental|Fitbit with ambulation reminder alarms|Study participants who are postoperative for colorectal surgery will wear a Fitbit (a wireless activity tracking device) to count steps taken during their postoperative hospitalization. In addition to being educated on the importance of postoperative ambulation, this arm will have 5 alarms every day reminding them to ambulate.
2959953|NCT02833324|Active Comparator|Fitbit without ambulation reminder alarms|Study participants who are postoperative for colorectal surgery will wear a Fitbit (a wireless activity tracking device) to count steps taken during their postoperative hospitalization. Participants will be educated on the importance of postoperative ambulation but will not have ambulation reminder alarms.
2959954|NCT02833311|Active Comparator|Computer Tablet Group|A computer tablet application to set goals,self-monitor healthy behaviors, record condition-related symptom impact, and self-manage a problematic symptom.
2959955|NCT02833311|Active Comparator|Paper and Pencil Group|Use of paper and pencil diaries and worksheets to set goals, record condition-related symptom impact, and self-monitor behaviors.
2959956|NCT02833311|Active Comparator|Standard Treatment Control Group|Participants are prescribed an exercise program and given information on healthy eating.
2959957|NCT02833298|Experimental|Automated reminders|Patient will be contacted for automated reminders within one month before the six-month interval indicating they are due for HCC screening.
2959958|NCT02833298|Experimental|Patient navigation|The patient navigator will coordinate with the provider and subject to schedule the appropriate office visit and imaging for HCC screening as needed within one month before the test is due.
2959959|NCT02833272|Experimental|EMPOWER Educational Brochure|This is the only arm of the study. All participants will undergo the intervention, which is an educational brochure (EMPOWER educational brochure) to explain the possible harms of benzodiazepine and non-benzodiazepine sedative drugs.
2959960|NCT02833246|Experimental|SMS/MMS text messaging|Patients will be able to tailor their SMS/MMS reminders with respect to when (i.e., what time of day) they wish to receive the reminders, as well as how often the messages are sent (e.g., morning and evening).
2959961|NCT02833246|Active Comparator|usual care|This includes physician and nursing assessment and intervention for any identified AEs. Of note, there is not currently standard follow-up that patients receive from nursing or physician staff while on an OAM treatment. Patients are encouraged to call their physician's office with any questions or changes in their medical status but are not called routinely by MSK staff.
2959962|NCT02833233|Experimental|Cryoablation and Immune Therapy|Patients will undergo breast biopsy with cryoablation 7-10 days prior to the planned surgery, and ipilimumab with nivolumab administration 1-5 days before cryoablation. All patients will undergo surgery at the pre-determined day defined at the initial surgical consultation. Women will receive ipilimumab and nivolumab 1-5 days prior to US or MRI-guided core biopsy and cryoablation date. Intravenous ipilimumab will be administered as a single 1 mg/kg dose to be infused intravenously over 90 minutes. Intravenous nivolumab will be administered as a single 3 mg/kg dose to be infused intravenously over 60 minutes.
2959963|NCT02833220||Healthy volunteers|"Healthy adults between the ages of 18-65 are eligible.~Participants will receive non-invasive brain stimulation by way of single-pulse transcranial magnetic stimulation to the motor cortex"
2959964|NCT02833207|Experimental|EDD Obese|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible obese subjects will undergo Drug Trial 1 (EDD) (described in Intervention section).
2959967|NCT02833207|Experimental|ROV Lean|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible lean subjects will undergo Drug Trial 2 (ROV) (described in Intervention section).
2959968|NCT02833194||Leiden Group|Women with an isolated F5 rs6025 polymorphism or an isolated F2 rs1799963 polymorphism.
2959969|NCT02833194||aP1Ab-positive|"Inclusion in the aP1Ab Group:~Initially positive for aP1Ab~Second positive aP1Ab test six months later"
2959970|NCT02833194||Thrombophilia-negative|Women with completely negative thombophilia screening results.
2959971|NCT02833181||Awake patients|Awake patients
2959972|NCT02833181||Sedated patients|
2959973|NCT02833181||Sedated and curarized patients|
2959974|NCT02833168||1|Patients with proven neuromuscular disorders known to be potentially associated with significant diaphragmatic weakness, e. g. ALS, myotonic dystrophy type 1, limb-girdle muscular dystrophy, Duchenne and Becker muscular dystrophy. Patients already receiving home ventilatory support will not be included in the study.
2959975|NCT02833168||2|Patient with proven obstructive sleep apnea syndrome prior to CPAP initiation.
2959976|NCT02833168||3|Patients with sleep disorders other than sleep-related breathing disorders, e. g. narcolepsy, hypersomnia, parasomnia or sleep-related movement disorders.
2959977|NCT02833155|Experimental|Entinostat and Exemestane|"Patients receive entinostat PO on days 1, 8, 15, and 22. Entinostat in combination with exemestane will be repeatedly administered every 28 days in the absence of disease progression or unacceptable toxicity.~Exemestane wil be orally administered once daily for up to six months."
2959978|NCT02833142|Experimental|BIIB033-A|Staggered single dosing schema
2959979|NCT02833142|Experimental|BIIB033-B|Staggered single dosing schema
2959980|NCT02833116|Experimental|Group Betamethasone|One ampule containing 12 mg of betamethasone in a syringe of 10 ml
2959981|NCT02833116|Active Comparator|Group Dexamethasone|One ampule containing 4 mg of dexamethasone in a syringe os 10 ml
2959982|NCT02833103|Experimental|Pinaverium Bromide group|Able to improve the spasms of SO; literature showed that it treated biliary disorders effectively.
2959983|NCT02833103|Active Comparator|Danshu group|Contains the active pharmaceutical ingredient (API) and has the effects of fighting infection, alleviating pain, promoting bile secretion and lifting muscle spasms; literature showed that Danshu Capsules effectively improved the symptoms of biliary disorders, such as pain, nausea and abdominal distension.
2959984|NCT02833090|Other|Group 1|Control group had biomarkers.
2959985|NCT02833090|Experimental|Group 2|Biomarkers
2959986|NCT02833090|Experimental|Group 3|Biomarkers
2959987|NCT02833090|Experimental|Group 4|Biomarkers
2959988|NCT02833064||Acute Liver Failure|"biological sampling~MRI scanning for patients with paracetamol induced acute liver failure"
2959989|NCT02833064||Acute Liver Injury|- biological sampling
2959990|NCT02833064||Acute on Chronic Hepatic Injury|- biological sampling
2959991|NCT02833064||Stable Cirrhotics|- biological sampling
2959992|NCT02833064||Non-cirrhotic liver disease|- biological sampling
2959993|NCT02833038|Experimental|Magnesium group|Intravenous administration of Magnesium Sulfate
2959994|NCT02833038|Placebo Comparator|Control group|Intravenous administration of normal saline
2959995|NCT02833012|Experimental|Group 1|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
2959996|NCT02833012|Experimental|Group 2|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
2959997|NCT02833012|Experimental|Group 3|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
2959998|NCT02833012|Experimental|Group 4|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
2959999|NCT02832999|Experimental|sub cutaneous liraglutide|once daily add-on subcutaneous injection of Liraglutide at 0.6mg/day for 1 week increased to 1.2mg the second week
2960000|NCT02832999|Active Comparator|Oral Vildagliptin|Once daily oral 100mg of Vildagliptine for two weeks
2960001|NCT02832986||Patients in frailty consultation|Patients consulting in frailty consultation, at this occasion they will complete a medical questionary for the collection of study data
2960002|NCT02832973|Experimental|Spironolactone, Furosemide Amiloride|Spironolactone 25 mg qd, Furosemide 20 mg qd, Furosemide 40 mg qd, Amiloride 5 mg qd
2960003|NCT02832973|Active Comparator|Ramipril, Bisoprolol|Ramipril 5 mg qd, Ramipril 10 mg qd, Bisoprolol 5 mg qd, Bisoprolol 10 mg qd
2960004|NCT02832960|Experimental|1|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
2960005|NCT02832960|Placebo Comparator|2|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
2960006|NCT02832947|Other|Rivaroxaban Arm|
2960007|NCT02832934|Experimental|1|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
2960008|NCT02832934|Placebo Comparator|2|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
2960010|NCT02832921|Active Comparator|VR cognitive tasks - treadmill|This group will be an active control, receiving the VR cognitive training without treadmill walking, to examine whether the motor component augments the effect of the VR in the experimental group.
2960011|NCT02832921|Sham Comparator|scientific TV documentary + treadmill|This group will watch a scientific TV documentary while walking on the treadmill. This control group will permit examination of whether the VR cognitive training, which requires an especially active cognitive effort while walking on the treadmill, is more advantageous than passively watching a scientific TV documentary while performing the same motor task as the experimental group.
2960012|NCT02832921|No Intervention|Passive control|This group of participants will not receive any intervention but will be assessed with the same battery of assessments as the other three groups, permitting comparisons of the cognitive and neurobiological outcomes of the intervention groups to that of the natural course of decline/deterioration of these at-risk individuals.
2960013|NCT02832908|Other|Patients + parents|Patients with severe head trauma
2960014|NCT02832895|Experimental|Transcranial Doppler examination|Transcranial Doppler examination
2960015|NCT02832882|Experimental|No-touch RFA arm|No-touch RFA arm indicates RFA procedure using Octopus electrode and no touch technique.
2960016|NCT02832882|Active Comparator|Conventional tumor puncture RFA arm|Conventional tumor puncture RFA arm indicates RFA procedure using Octopus electrode and conventional tumor puncture technique.
2960017|NCT02832869|Experimental|short message service|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
2960018|NCT02832869|Experimental|Wechat|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as Wechat based re-education by one investigator on the day before colonoscopy.
2960019|NCT02832869|No Intervention|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
2960020|NCT02832856|Placebo Comparator|Control|"Control group members will receive a job readiness curriculum entitled Beginning to Work it Out (BWIO) that assists at-risk youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills."
2960021|NCT02832856|Experimental|Full Relationship Smarts Curriculum|This group receives the behavioral intervention of the healthy relationship education in the form of the full, 12-lesson RS+ curriculum over approximately 12 weeks. The B
2960022|NCT02832856|Experimental|Abridged Relationship Smarts Curriculum|"This group receives the behavioral intervention of the healthy relationship education in the form of the summary 8-lesson version of the RS+ curriculum - as well as four lessons on career planning and job readiness over approximately 12 weeks."
2960023|NCT02832843||NTM lung disease|Patients with NTM lung disease satisfying American Thoracic Society guidelines
2960024|NCT02832843||Healthy control|The age-, sex-matched control subjects without pulmonary diseases
2960025|NCT02832830|Experimental|A|intensity modulated radiotherapy (IMRT) 10 x 3 Gy
2960026|NCT02832830|Active Comparator|B|fractionated conventional external beam RT 10×3 Gy
2960027|NCT02832804|Experimental|anodal stimulation|10 person The patients treated by anodal stimulation (2mA) for 20 minutes
2960028|NCT02832804|Active Comparator|cathodal stimulation|10 person The patients treated by cathodal stimulation (1-2mA) for 20 minutes
2960029|NCT02832804|Sham Comparator|sham stimulation|10 person The patients treated by anodal stimulation (1-2mA) for 15 seconds
2960030|NCT02832791|Active Comparator|QUADRICEPS TENDON|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION USING QUADRICEPS TENDON
2960031|NCT02832791|Active Comparator|HAMSTRING TENDON|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION USING HAMSTRING TENDON
2960032|NCT02832778|Experimental|Stage 1 London|"Stage 1, London:~Phase 1 (2 weeks): tenofovir/emtricitabine or tenofovir/lamivudine or zidovudine/lamivudine plus efavirenz (Sustiva/Stocrin) 400 mg once daily~Phase 2 (12 weeks): tenofovir/emtricitabine or tenofovir /lamivudine or zidovudine/lamivudine) plus efavirenz (Sustiva/Stocrin) 400 mg once daily plus Rifinah or local generics once daily (rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if <50kg.)"
2960033|NCT02832778|Experimental|Stage 2 Kampala|Tenofovir/emtricitabine or lamivudine or zidovudine/lamivudine plus efavirenz (Sustiva/Stocrin) 400 mg once daily plus Rifinah or local generics once daily (rifampicin 600 mg and isoniazid 300 mg if ≥ 50 kg or rifampicin 450 mg and isoniazid 300 mg if <50kg).
2960034|NCT02832765|Experimental|A|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions
2960035|NCT02832765|Experimental|B|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis
2960036|NCT02832765|Experimental|C|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions
2960037|NCT02832765|Experimental|D|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis
2960038|NCT02832752|Active Comparator|ECPR Region|The ECPR region has incorporated ECPR therapy into the out-of-hospital cardiac arrest algorithm. Within the ECPR Protocol, full standard advanced cardiac life support treatments will continue up until the time of ECMO initiation. The anticipated enrolment in this group is 70 patients. All eligible patients in the region will be enrolled, regardless of whether the ECPR protocol is activated or whether the patient is actually treated with ECPR.
2960039|NCT02832752|No Intervention|Control Region|"The control region will continue usual care as per current protocols which include standard advanced cardiac life support. Patients will be enrolled in the control region group at the same juncture of study eligibility. The anticipated enrolment in this group is 350 patients.~Within BCEHS practice, transport to hospital without prior return of spontaneous circulation is rare. Termination of resuscitation must be approved by an on-call physician and cannot occur prior to 30 minutes of resuscitation efforts."
2960040|NCT02832739|Experimental|SENACA - self-management support system|Use of enhanced SENACA - ICT based self-management support system prototype by study participants at home for 75-100 days
2960041|NCT02832726|Active Comparator|cyano-hydroxo B12|Absorption of 3 doses of 9 ug cyano-B12 and 9 ug hydroxo-B12 for two days (the CobaSorb test). No drugs given.
2960042|NCT02832726|Active Comparator|Cyano-B12 doses|Absorption of 3 doses of 3 ug, 6 ug, and 9 ug cyano-B12 for two days (the CobaSorb test). No drugs given.
2960046|NCT02832700|Placebo Comparator|Placebo|During 4 weeks a daily oral intake of placebo-shake consisting of milk powder.
2960047|NCT02832687|Active Comparator|normal saline|Patients will receive 100 milliliters of normal saline with the first dose given preoperatively in the holding area followed by re-dosing every four hours from that point up to a maximum of 4 doses in 24 hours. Blinded medication will be prepared by research pharmacist.
2960048|NCT02832687|Experimental|acetaminophen|Patients 50kg or more will receive either 1000mg IV acetaminophen with the first dose given preoperatively in the holding area followed by re-dosing every four hours from that point up to a maximum of 4 doses or 4000mg in 24 hours. Patients <50 kg will receive 12.5mg/kg to a maximum of 75 mg /per kg/per day as per the label dose with repeat dosing Q4 hours. Blinded medication will be prepared by research pharmacist in 100mL of normal saline
2960049|NCT02832674|Experimental|Single Treatment|All enrolled subjects will receive a Percutaneous Radiofrequency Single Treatment'
2960050|NCT02832648|Experimental|selenase 200mcg|selenium as selenase 200mcg once daily, oral
2960051|NCT02832648|Experimental|selenase 50mcg|selenium as selenase 50mcg once daily, oral
2960052|NCT02832648|Placebo Comparator|placebo|matched placebo, once daily, oral
2960053|NCT02832635|Experimental|WBRT|Patients with brain metastases (＞3 lesions) ; Whole-brain radiotherapy without avoidance of hippocampus applied.
2960054|NCT02832635|Experimental|WBRT with avoidance of hippocampus|Patients with brain metastases (＞3 lesions) ; Whole-brain radiotherapy with avoidance of hippocampus applied.
2960055|NCT02832635|Experimental|WBRT with TMZ|Patients with brain metastases (＞3 lesions) ; Whole-brain radiotherapy with concurrent TMZ chemotherapy applied.
2960056|NCT02832635|Experimental|WBRT with avoidance of hippocampus and TMZ|Patients with brain metastases (＞3 lesions) ; Whole-brain radiotherapy with avoidance of hippocampus and concurrent TMZ chemotherapy applied.
2960057|NCT02832622||MPP Group|MPP ON within 1 month post implant and then continuously programmed ON until 12 months (i.e., MPP ON for months 1-12 continuously)
2960058|NCT02832622||Treatment Strategy (BiV/MPP) Group|MPP ON at the 12-month study visit and for at least 3 continuous months prior to 12-month assessment (i.e., Biventricular (BiV) pacing ON at some point in months 1-9 and MPP ON for months 10-12)
2960059|NCT02832622||BiV Group|MPP OFF at the 12-month study visit and for at least three continuous months prior to 12-month assessment (i.e., BiV pacing ON for months 10-12)
2960060|NCT02832622||Other Pacing Group|Other pacing schemes not covered above (Retrospective categorization implemented based on the usage of MPP or BiV pacing for 12 months)
2960061|NCT02832609|No Intervention|sitting position|measurement in the sitting position
2960062|NCT02832609|Active Comparator|supine position|measurement in the sitting position
2960063|NCT02832596|No Intervention|Control|Ordinary anesthesia, mean arterial pressure allowed to decrease to 60 mmHg. If it is lower the patients will receive a norepinephrine infusion in order to raise the mean arterial pressure to 60 mmHg.
2960064|NCT02832596|Active Comparator|Maintained blood pressure|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
2960065|NCT02832583|Experimental|Mesotherapy of PRP-HA into the cheeks|Three sessions of PRP-HA prepared with RegenKit BCT-HA Cellular Matrix into each cheek separated by 1 month interval.
2960066|NCT02832570|Experimental|Sildenafil|Single sildenafil oral intake (100 mg) approximately 2 hours before the treadmill test.
2960067|NCT02832570|Placebo Comparator|Placebo|Single placebo intake approximately 2 hours before the treadmill test.
2960068|NCT02832557||Autism Spectrum Disorder (ASD)|Children with autism spectrum disorder (ASD), diagnosed using DSM-5 criteria and confirmed with ADOS or another semi-structured evaluation measure. ASD should not be attributable to an underlying genetic abnormality, and participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy.
2960069|NCT02832557||Controls|Children from 2 to 6 years of age with normal developmental milestones.
2960070|NCT02832544|Experimental|Rivaroxaban (20 mg)|Rivaroxaban 20 mg od (n ~ 2250); 15 mg od (once daily) in patients with creatinine clearance (CrCl) 15-49 ml/min
2960071|NCT02832544|Active Comparator|Vitamin K antagonists (VKA)|Any approved VKA in the participating country (n ~ 2250); VKA titrated to achieve an INR of 2.0-3.0
2960072|NCT02832531|Experimental|Rivaroxaban (15 mg)|Rivaroxaban 15 mg od (n ~ 1000)
2960073|NCT02832531|Active Comparator|Aspirin (ASA)|Aspirin 100 mg od (n~1000)
2960074|NCT02832518||patients under hemodialysis|
2960075|NCT02832505||Non-CKD (Control)|"Patients without CKD (eGFR ≥ 60 ml/min/1.73 mm2) (non-CKD controls).~No intervention but only observational."
2960076|NCT02832505||CKD (chronic kidney disease)|"Patients with Patients with moderate to severe CKD (eGFR ranging from 26 to 44 ml/min/1.73 mm2).~No intervention but only observational."
2960077|NCT02832505||ESRD (end-stage renal disease)|"Patients with advanced CKD (eGFR < 15 ml/min/1.73 mm2), preparing for or undergoing the standard thrice-weekly HD or standard PD treatment (end-stage renal disease (ESRD) patients).~No intervention but only observational."
2960078|NCT02832492||PNR+|Patients who will show pupil near response during PNR assessment.
2960079|NCT02832492||PNR-|Patients who will not show pupil near response during PNR assessment.
2960080|NCT02832453|Other|Lifestyle counseling|This group will receive lifestyle counselling but not supervised exercise training sessions
2960081|NCT02832453|Experimental|Aerobic interval training|This group will receive lifestyle counselling plus supervised high intensity (80%VO2max) interval exercise training sessions
2960082|NCT02832453|Active Comparator|Traditional continous training|This group will receive lifestyle counselling plus supervised moderate intensity (60%VO2max) continous exercise training sessions
2960083|NCT02832440|Other|Intradialytic exercise|Exercise during hemodialysis
2960084|NCT02832440|Other|Home-based exercise|Exercise at home
2960085|NCT02832414|No Intervention|Regular program|
2960086|NCT02832414|Active Comparator|Intensive weight loss program|
2960087|NCT02832401|Active Comparator|Caffeine|200 mg of caffeine powder administered in capsules
2960088|NCT02832401|Placebo Comparator|Placebo|Cellulose powder administered in capsules
2960296|NCT02831049|Active Comparator|3|alcohol retrieval/soft-drink extinction
2960527|NCT02829190|Experimental|Patient operated on with free flap|Magnetic Resonance Imaging (MRI)
2960089|NCT02832388||PA-patients for MRI|A subgroup of PA-patients perform a coronary MRI, including stress-testing with adenosine, and are compared to a sex- and age-matched group of healthy Controls who perform the same MRI-procedure
2960090|NCT02832388||Healthy controls|Healthy Controls that are age-and sex-matched to the subgroup of PA-patients performing coronary MRI, perform MRI including adenosine as stress-test during MRI
2960091|NCT02832388||PA-patients diagnosed from 2013 onwards|All PA-patients diagnosed at Haukeland University from 2013 onwards are asked for inclusion in the main observational PA-study.
2960092|NCT02832375|Experimental|Experimental: stannous fluoride|Participants will be instructed to dose a dry toothbrush containing 0.454% w/w of stannous fluoride (1000 parts per million [ppm] fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
2960093|NCT02832375|Active Comparator|Standard: sodium monofluorophosphate|Participants will be instructed to dose a dry toothbrush containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
2960094|NCT02832362|Experimental|Carbomer 980|Participants will be administered test product (nasal spray) containing 0.5% carbomer 980, 4 times per day (i.e. 3 actuations per nostril per dose; each actuation will be 140 mcL, equivalent to 140 mg).
2960095|NCT02832362|Placebo Comparator|Placebo|Participants will be administered reference product (nasal spray) containing vehicle without carbomer 980, 4 times per day (i.e. 3 actuations per nostril per dose; each actuation will be 140 mcL, equivalent to 140 mg).
2960096|NCT02832349|Experimental|EA group (Educational Actions)|Epileptic patients participating to the educational actions program
2960097|NCT02832349|No Intervention|Control group|Epileptic patients with standard follow-up
2960098|NCT02832336|Experimental|Caffeine|"Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakefulness state.~Generic name :Vivarin(1,3,7-trimethylxanthine), 200 mg/day for one week, Form of Administration:Oral in veg white capsule form (size 1) Drug Class:Central nervous system (CNS) stimulants."
2960099|NCT02832336|Placebo Comparator|Fiber|Fiber powder will be used as placebo, Form of Administration:Oral in veg white capsule form (size 1)
2960100|NCT02832323|Other|Reticera|A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) and 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.
2960101|NCT02832297|Other|Vectra DA (Arm A)|Treatment intensification with non-biologic DMARDS guided by Vectra DA
2960102|NCT02832297|Other|Usual care (Arm B)|Treatment intensification by usual care without using Vectra DA
2960103|NCT02832271|Active Comparator|green tea group|green tea extract SUNPHENON EGCg for women with ultrasound confirmed endometriosis
2960104|NCT02832271|Placebo Comparator|placebo group|placebo fro women with ultrasound confirmed endometriosis
2960105|NCT02832258||Children with urinary tract infection due to E-ESBL|In this prospective observational study between March 2013 and March 2017, children (0 to 18 years) with E-ESBL UTI (febrile UTI or cystitis) were enrolled in 24 pediatric departments in France. Clinical and biological characteristics, risk factors of infection of E-ESBL, first and second lines of antibiotic therapies were analyzed. We used the Kaplan-Meier method to estimate the time to apyrexia and length of hospital stay, and Log-rank test to assess equality of survivor functions. We also analyzed the resistance patterns and molecular characterization of ESBL types in the isolates.
2960106|NCT02832232|Experimental|Mobilization Group|translational dorsal glide mobilization technique grade III and Protocolized Physiotherapy
2960107|NCT02832232|Experimental|Maintained pressure Group|pressure maintained suboccipital inhibition technique and Protocolized Physiotherapy
2960108|NCT02832232|Other|Control Group|Protocolized Physiotherapy
2960109|NCT02832219|Experimental|Molecular hydrogen|Molecular hydrogen, tablet, 2 g/day, 4 weeks
2960110|NCT02832219|Placebo Comparator|Placebo|Cellulose, tablet, 2 g/day, 4 weeks
2960111|NCT02832206||hybrid ablation|60 patients with stand-alone, persistent or long-standing persistent atrial fibrillation
2960112|NCT02832193||Study group|"POCD data of study patients of the following studies:~Phydelio - Eudract.-No.: 2008-007237-47 - 08/0618 ZS EK11 Neuprodex - Eudract-No.: 2013 -000823-15 - 13/0491 ZSEK11 BioCog - EA2/092/14 Cognitive Outcome after two stage liver operation - EA1/296/12 ReCosa - EA1/056/13 Hypnoc - EA1/273/11 Sudoco - EA1/242/08 Peratecs - EA1/241/08 Hipster - Eudract.-No.: 2009-016043-19 100/10 ZS EK15 Pain-Long-EA2/041/17 PCI - EA2/024/18 Further studies from the Department of Anesthesiology and Operative Intensive Care Medince (CCM/CVK), Charité - Universitätsmedizin Berlin"
2960113|NCT02832193||Control group I|"POCD data of prospective control subjects/patients (ASA I+II+III) and POCD data of control subjects/patients of the following studies:~Neuprodex - Eudract-No.: 2013 -000823-15 - 13/0491 ZSEK11 Phydeliostudie - Eudract.-No.: 2008-007237-47 - 08/0618 ZS EK11 BioCog - EA2/092/14 Cognitive Outcome after two stage liver operation - EA1/296/12 Hypnoc - EA1/273/11 Sudoco - EA1/242/08 Peratecs - EA1/241/08 Hipster - Eudract.-No.: 2009-016043-19 100/10 ZS EK15 BioCog-Studie - EA2/092/14 REACT-Studie - EA2/091/15 PAINLONG-Studie - EA2/041/17 PCI - EA2/024/18 Further studies from the Department of Anesthesiology and Operative Intensive Care Medince (CCM/CVK), Charité - Universitätsmedizin Berlin"
2960114|NCT02832180|Experimental|Daily single dose of OC containing EE and NET|Daily single dose of OC Containing EE and NET alone.
2960115|NCT02832180|Experimental|Daily single dose of OC in combination with BMS-986142|Daily single dose of OC containing EE and NET in combination with BMS-986142.
2960116|NCT02832167|Experimental|Nivolumab|
2960117|NCT02832154|Experimental|Supportive Care|Patients complete an initial online questionnaire lasting about 25-30 minutes. Patients complete an internet-delivered PA program during weeks 3-8. Each week consists of didactic material and 20-30 minutes of daily online exercises.
2960118|NCT02832141||Group A|Group A: immediate effects: T0, Grade 3-4 central thoracic mobilization from posterior-to-anterior on all thoracic vertebrae, immediate (T1), after 2 (T2), 4 (T3), 6 (T4), 8 (T5) and 10 (T6) minutes, 1 days wash-out period; T7, a grade 3-4 central thoracic mobilization from anterior-to-posterior on all thoracic vertebrae, immediate T8, after 2 (T9), 4 (T10), 6 (T11), 8 (T12) and 10 (T13) minutes.
2960367|NCT02830399|Placebo Comparator|sham rTMS-ECT|5 sham rTMS before 5 bilateral ECT
2960119|NCT02832141||Group B|Group B: immediate effects: T0, 3-4 central thoracic mobilization from anterior-to-posterior on all thoracic vertebrae, immediate (T1), after 2 (T2), 4 (T3), 6 (T4), 8 (T5) and 10 (T6) minutes, 1 days wash-out period; T7, a grade 3-4 central thoracic mobilization from posterior-to-anterior on all thoracic vertebrae, immediate T8, after 2 (T9), 4 (T10), 6 (T11), 8 (T12) and 10 (T13) minutes.
2960120|NCT02832128|Experimental|AUT00063 - Placebo|AUT00063 (800 mg/day) for 28 days, followed by a 2 to 4 week washout period before commencing the second 28-day dosing period with placebo
2960121|NCT02832128|Experimental|Placebo - AUT00063|Placebo for 28 days, followed by a 2 to 4 week washout period before commencing the second 28-day dosing period with AUT00063 (800 mg/day)
2960122|NCT02832115|Experimental|Study|40 mg of topical lidocaine and 30 mg of topical nitroglycerine is applied to the wrist overlying radial pulse (centered approximately 1 inch proximal to the radial styloid process) at least 60 minutes before arterial puncture. Immediately prior to sterile preparation of access site, transdermal preparation will be removed in the cath lab.
2960123|NCT02832115|Placebo Comparator|Control|40 mg of topical lidocaine and placebo is applied to the wrist overlying radial pulse (centered approximately 1 inch proximal to the radial styloid process) at least 60 minutes before arterial puncture. Immediately prior to sterile preparation of access site, transdermal preparation will be removed in the cath lab.
2960124|NCT02832102||Retrospective cohort|"A total of 1000 SCCHN patients will be enrolled in a retrospective observational study treated in the period 2008-2014.~Standard treatment of SCCHN patients The patients will be managed as foreseen by best clinical practice and international guidelines for SCCHN."
2960125|NCT02832102||Prospective cohort|"A total of 450 SCCHN patients will be enrolled in a study. Each participating Center will select consecutive patients according to the selection criteria (inclusion/exclusion criteria) for one year and will be followed up for two years or more.~Standard treatment of SCCHN patients: patients will be administered current best clinical practice treatments."
2960126|NCT02832089|Experimental|active arm|single arm study with one group given oral carvedilol.
2960127|NCT02832076|Experimental|group a|This arm will receive subcutaneous negative suction drain for the midline wound for 10 days.
2960128|NCT02832076|Active Comparator|group b|This arm will receive closure of the midline wound without a subcutaneous drain.
2960129|NCT02832063|Active Comparator|B244 arm|B244 dose administered in a 1:1 (active vs placebo) ratio
2960130|NCT02832063|Placebo Comparator|Placebo arm|Placebo dose administered in a 1:1 (active vs placebo) ratio
2960131|NCT02832050|Experimental|Intervention|"The play therapy intervention consists of a standard of care delivered by a play specialist. The play specialist delivers interventions aimed in assisting the child through the process of undergoing procedures. The intervention is semi-structured in order to facilitate a systematic approach which remains individualised and child-centred.~The intervention requires patients to be classified as 'high risk' or 'low risk' for procedure-related anxiety. This is assessed for all patients at baseline based on parent and clinician opinion. The play specialist may re-classify patients at the initial assessment or at any point whilst working with the child. If this occurs, clear documentation of the rationale for this will be recorded. Patients classified as high risk receive additional preparation sessions as detailed in the standard of care."
2960132|NCT02832050|Placebo Comparator|Comparator|The comparator group will receive standard care of patients having blood tests within the Trust, which does not include the specific intervention of a play therapist routinely. As part of standard care if a child becomes particularly distressed a clinician may make a decision to refer the child for play therapy. If this occurs during the study period the child will be referred to the play specialist delivering the intervention for the study. The child will then receive play therapy as in the described intervention. They will be excluded from the main analysis but data will still be collected and analysed descriptively.
2960133|NCT02832037|Experimental|BI 425809 dose 1|
2960134|NCT02832037|Experimental|BI 425809 dose 2|
2960135|NCT02832037|Experimental|BI 425809 dose 3|
2960136|NCT02832037|Experimental|BI 425809 dose 4|
2960137|NCT02832037|Placebo Comparator|Placebo|
2960138|NCT02832024|Active Comparator|Intervention: Stents|Stents group
2960139|NCT02832024|Active Comparator|Intervention: Atherectomy|Direct Atherectomy group
2960140|NCT02832024|Active Comparator|Intervention: Balloon|Balloon group
2960141|NCT02832011|Active Comparator|olive oil|After randomization, Investigators will give human milk fortiﬁed with olive oil
2960142|NCT02832011|Active Comparator|Eoprotin|After randomization, Human milk fortiﬁed with Eoprotin according to the recommendations of the manufacturer (1g per 30ml milk)
2960143|NCT02831998|Experimental|ZP (70% IPA)|Isopropyl alcohol (IPA) 70%
2960144|NCT02831998|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
2960145|NCT02831998|Placebo Comparator|ZP Vehicle|ZP without IPA
2960146|NCT02831985|Experimental|general practice follow-up|post-surgery follow-up by general practitioner
2960147|NCT02831985|Active Comparator|ENT specialist follow-up|post-surgery follow-up by ear-nose-throat (ENT) specialist
2960148|NCT02831972|Experimental|Period 1|A single oral dose of AG-120 will be administered at Hour 0 followed by PK sampling for 504 hours (21 days).
2960149|NCT02831972|Experimental|Period 2|In Period 2, multiple oral doses of itraconazole will be administered once daily (QD) for 18 consecutive days (Days -4 to 14) with a single oral dose of AG-120 coadministered at Hour 0 on Day 1. PK sampling for AG-120 will be taken for 504 hours (21 days) following AG-120 dosing on Day 1. PK sampling will also be collected for itraconazole and its metabolite, hydroxy-itraconazole, from Day -2 up to Day 13.
2960150|NCT02831959|Experimental|NovoTTF-100M device|Patients undergo SRS followed by continuous TTFields treatment using the NovoTTF-100M device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
2960151|NCT02831959|Active Comparator|Best Standard of Care|Patients will undergo SRS alone and be treated with the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain.
2960152|NCT02831946|Experimental|MODIFIED VICRYL PLUS|The intra-cuticular layer will closed with with VICRYL PLUS suture
2960153|NCT02831946|Experimental|DERMABOND GLUE|The intra-cuticular layer will closed with with DERMABOND GLUE
2960528|NCT02829177|Active Comparator|Allopurinol|400 mg once daily, tablet treatment
2960154|NCT02831933|Experimental|Experimental|"ADV/HSV-tk (5 x 1011 viral particles) in a 2-mL total volume will be injected intratumorally on day 0 of the study.~Valacyclovir will be orally administered at a dose of 2 g three times daily for 14 days. Valacyclovir treatment will be administered 24 hours after the gene vector injection from day 1 to day 15 of the study.~SBRT of 30 gray (Gy; 6 Gy X 5 fractions) will be administered over 2 weeks from day 2 to day 16 of the study.~Nivolumab (480 mg) will be administered intravenously over 30 minutes every 4 weeks starting on day 17 of the study and continuing until disease progression, unacceptable toxicity, or up to 12 months in patients without disease progression."
2960155|NCT02831920|Experimental|Single Arm|every patient undergoes mpMRI and targeted biopsies, CEUS and targeted biopsies and systematic biopsies. Every patient is therefore its own control.
2960156|NCT02831907||Cardiac surgery patients|Adult patients having a cardiac surgery at the Montreal Heart Institute
2960157|NCT02831894|Sham Comparator|0% Hypnotic Medication Taper|In this condition patients will be maintained on their baseline hypnotic medication dosage throughout a 20-week double-blinded tapering period.
2960158|NCT02831894|Active Comparator|25% Hypnotic Medication Taper|In this condition patients will have their current hypnotic medication dosage reduced by 25% every 2 weeks throughout a 20-week double-blinded tapering period.
2960159|NCT02831894|Active Comparator|10% Hypnotic Medication Taper|In this condition patients will have their current hypnotic medication dosage reduced by 10% every 2 weeks throughout a 20-week double-blinded tapering period.
2960160|NCT02831868|Experimental|EXP|Implantation of a HAVAI device to correct HVA without osteotomy
2960161|NCT02831855|Experimental|CP-690,550 and methotrexate|Open-label tofacitinib tablet and blinded methotrexate capsule
2960162|NCT02831855|Placebo Comparator|CP-690,550 and placebo|open-label tofacitinib tablet and blinded matching placebo for methotrexate capsule
2960163|NCT02831842||mCRC Participants|Data of mCRC participants who received first-line treatment with bevacizumab-containing regimen or with chemotherapy alone and had KRAS-mutant status and mCRC participants who received first-line treatment with bevacizumab-containing regimen or an anti-epidermal growth factor receptor (EGFR)-containing regimen and had KRAS wild type status, will be collected retrospectively.
2960164|NCT02831829|Active Comparator|Water-based exercise training group|"Intervention: Patients randomized to the water-based exercise training group will undergo water-based exercise training. The immersed exercise will include two session of aerobic (water-based) and calisthenic exercise per day, six days of a week, each lasting 30 minutes."
2960165|NCT02831829|Active Comparator|Land-based exercise training group|"Patients randomized to the land-based exercise training group will undergo exercise training which will include two aerobic and calisthenic exercise session per day, six days of a week, lasting 30 minutes"
2960166|NCT02831829|No Intervention|Control group (usual care)|Control group: patients randomized in control group will have usual care with no exercise
2960167|NCT02831816|Experimental|ZP (70% IPA)|Isopropyl alcohol (IPA) 70%
2960168|NCT02831816|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
2960169|NCT02831816|Placebo Comparator|ZP Vehicle|ZP without IPA
2960170|NCT02831803|Experimental|Intervention|All participants will receive an 8-week supply of walnuts and Extra Virgin Olive Oil (EVOO). Study supplements will consist of 28 gm of walnuts and 32 gm of EVOO per day. Participants will be instructed how to consume the proper amount of walnuts and EVOO and to report their consumption using a compliance diary. The walnuts are pre-packaged in daily servings (one 28 g packet per day) and measuring spoons will be provided with the olive oil to assist participants in consuming it appropriately. Participants will also receive recipes and other written information that will assist them in incorporating both the nuts and olive oil into their existing dietary patterns.
2960171|NCT02831790|Experimental|Educational Intervention|Participants in the intervention group will have access to the 3 teaching videos, ~3:30-5:00 minutes in duration each, beginning several weeks prior to the preadmission clinic (as soon as written consent is obtained).
2960172|NCT02831790|No Intervention|Usual Care|Participants in the usual care will not be offered an intervention and will not be made aware of the existence of the teaching videos.
2960173|NCT02831764|Experimental|DTG + 3TC (50 mg+300 mg|Eligible subjects will receive one 50 mg tablet of DTG plus one overencapsulated 300 mg 3TC tablet orally once daily upto 96 weeks; thereafter will receive DTG plus 3TC tablet upto Week 148 and will continue to receive this schedule until (i) DTG and 3TC are both locally approved for use as part of a dual regimen, and the single entities of DTG and 3TC are available to patients (e.g. through public health services), or (ii) the DTG/3TC FDC tablet, if required by local regulations, is available, , or (iii) the subject no longer derives clinical benefit, or (iv) the subject meets a protocol defined reason for discontinuation, or (v) development of the DTG plus 3TC dual regimen is terminated.
2960174|NCT02831764|Active Comparator|DTG + TDF/FTC FDC (50 mg+300/200 mg)|Eligible subjects will receive one 50 mg tablet of DTG plus one overencapsulated TDF/ FTC FDC (300/200 mg) tablet orally once daily upto 96 weeks; thereafter will receive DTG plus TDF/FTC FDC tablets upto Week 148 (open-label randomised phase).
2960175|NCT02831751|Experimental|30 µg/strain of Quadrivalent VLP Vaccine|
2960176|NCT02831751|Experimental|60 µg/strain of Quadrivalent VLP Vaccine|
2960177|NCT02831751|Active Comparator|FluLaval® Tetra (15 µg/strain)|
2960178|NCT02831751|Active Comparator|Fluzone® High-Dose (60 µg/strain)|
2960179|NCT02831738|Experimental|Active Treatment|Polydextrose 12 g
2960180|NCT02831738|Placebo Comparator|Control Treatment|No polydextrose
2960181|NCT02831712|Other|Iron supplement|Ferrous Fumarate tablet 200 mg
2960182|NCT02831699||Febrile Rash|
2960183|NCT02831699||Household|
2960184|NCT02831699||Guillain-Barré prospective|
2960185|NCT02831699||Prior Guillain-Barré|
2960186|NCT02831686|Experimental|Selinexor (KPT-330), Ixazomib, and Dexamethasone|"Patients with relapsed and/or refractory MM will be treated with ixazomib, selinexor, and dexamethasone, all of which will be administered orally.Ixazomib will be given on Days 1, 8, and 15 on a 28 day cycle.~Selinexor will be given twice weekly for three weeks, then there will be 1 week off (Days 1,3, 8,10, 15, 17) This study will follow a 3-by-3 dose escalation design.~Dexamethasone will be given on all days of Selinexor but will also be given on the week off from Selinexor (Days 1, 3, 8, 10,15, 17, 22, 24)."
2960462|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 30 mL|Perineural injection of ropivacaine 0.2 %, 30 mL
2960187|NCT02831673|Experimental|DTG + 3TC (50 mg+300 mg)|Eligible subjects will receive one 50 mg tablet of DTG plus one overencapsulated 300 mg 3TC tablet orally once daily upto 96 weeks; thereafter will receive DTG plus 3TC tablet upto Week 148 and will continue to receive this schedule until (i) DTG and 3TC are both locally approved for use as part of a dual regimen, and the single entities of DTG and 3TC are available to patients (e.g. through public health services), or (ii) the DTG/3TC FDC tablet, if required by local regulations, is available, , or (iii) the subject no longer derives clinical benefit, or (iv) the subject meets a protocol defined reason for discontinuation, or (v) development of the DTG plus 3TC dual regimen is terminated.
2960188|NCT02831673|Active Comparator|DTG + TDF/FTC FDC (50 mg+300/200 mg)|Eligible subjects will receive one 50 mg tablet of DTG plus one overencapsulated TDF/ FTC FDC (300/200 mg) tablet orally once daily upto 96 weeks; thereafter will receive DTG plus TDF/FTC FDC tablets upto Week 148 (open-label randomised phase).
2960189|NCT02831660|Experimental|idarucizumab|
2960190|NCT02831647|Experimental|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES PRAGUE for a period of 9 days.
2960191|NCT02831634|Other|Blood sampling|
2960192|NCT02831621|Active Comparator|diet (usual care)|All participants will receive a hypocaloric diet based on the individual resting metabolic rate. Resting metabolic rate (RMR) will be estimated using the WHO formula or measured using indirect calorimetry. Total energy expenditure will be calculated by multiplying RMR with a physical activity level (PAL). The used physical activity level will be 1.3. A hypocaloric diet with an energy deficit of 500 kcal/day will be prescribed. Participants will see a skilled dietician two-weekly the first month and on a monthly basis the next five months to discuss problems and solutions or coping strategies. The first consultation will have a duration of 60 minutes, the next consultations will have a duration of approximately 30 minutes. Each visit, nutritional compliance will be recorded on a 0 to 10 numeric rating scale. The usual care group will be asked to continue with their normal physical activity during the six-month intervention period.
2960193|NCT02831621|Experimental|diet+exercise|"For participants of this group, usual care will be supplemented with a prescribed exercise program. For this exercise program the participants will be referred to a local fitness club near home, free of charge. Aerobic training will be done at an intensity of 90-95% of the heart rate achieved at the RCP. Aerobic training will have a duration of 30 to 45 minutes, according to the training stage. Cardio training will be performed on different cardio devices and strength training will be done on isotonic strength training devices. Each training day, core stability training will be completed with four strength exercises for large muscle groups. Each exercise will be done in two sets of 15 repetitions with the goal to achieve better muscular strength endurance.~This combined training will be done individually during six months, three times/week.~In this study, an effort is made to reach a uniform manner of guidance to the physical activity program."
2960194|NCT02831608|Experimental|Drug: influenza vaccine|Standard influenza vaccine administered as a deep subcutaneous injection at one occasion per subject.
2960195|NCT02831608|Placebo Comparator|Drug: placebo|Saline administered as a deep subcutaneous injection at one occasion per subject.
2960196|NCT02831595||Patients undergoing unilateral TKA|
2960197|NCT02831582|Active Comparator|Arm I (omega-3 fatty acid)|Patients receive omega-3 fatty acid supplementation PO QD for 6 months.
2960198|NCT02831582|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months.
2960199|NCT02831569|Experimental|Loxoprofen sodium/methocarbamol FDC|fixed dose combination (FDC) tablets
2960200|NCT02831556||Emergency Department Subjects|Subjects that present to the Emergency Department with complaints necessitating abdominal or pelvic imaging.
2960201|NCT02831556||Non-patient volunteers|Duke employees that will voluntarily have an abdominal or pelvic ultrasound for with the sole purpose being for the study.
2960202|NCT02831543|Experimental|Motireb 5/100 mg t.i.d|Motireb 5/100 mg t.i.d + Placebo of Mosapride citrate t.i.d
2960203|NCT02831543|Active Comparator|Mosapride citrate t.i.d|Placebo of Motireb 5/100 mg t.i.d + Mosapride citrate t.i.d
2960204|NCT02831543|Placebo Comparator|Placebo t.i.d|Placebo of Motireb 5/100 mg t.i.d + Placebo of Mosapride citrate t.i.d
2960205|NCT02831530|Experimental|Abemaciclib|Patients randomized to the treatment arm will start treatment from 15 days before the surgery (day 1 of the study) to receive the last dose of treatment the day before the surgical procedure (day 14 of the study). Abemaciclib will be taken orally at a dose of 150 mg/ twice a day (Every 12h +/- 2h) on day 1 to day 14. The treatment should be taken in the morning and evening with a big glass of water (250ml) at approximately the same time.
2960206|NCT02831530|No Intervention|No treatment|
2960207|NCT02831517|Experimental|Part 1|48 participants: Cohorts 1,2 and 3 (Single Ascending Dose of BIIB074 or placebo) in a 6:2 ratio
2960208|NCT02831517|Experimental|Part 2|16 participants: Multiple Ascending Dosing of BIIB074 or placebo in a 6:2 ratio; 3 times daily [TID] in cohort 4 for 6 days and one time (QD) for 1 day and 2 times daily [BID] in cohort 5 for 6 days and QD for 1 day
2960209|NCT02831504||Myotonic Dystrophy type 1 (DM1) patients|Natural History Study
2960210|NCT02831491|Experimental|Ramucirumab + Docetaxel|Ramucirumab given intravenously (IV) on day 1 every 3 weeks followed by weekly IV infusion of docetaxel on days 1, 8, and 15 every 4 weeks.
2960211|NCT02831478|Experimental|BAY987517|2/3 of subjects testing the test article
2960212|NCT02831478|Active Comparator|Sunscreen Lotion|1/3 of subjects testing the marketed control
2960213|NCT02831465|Experimental|healthy subjects|Subjects with normal lung function between 40 and 70 years old.
2960214|NCT02831452||non-pregnant nulliparous|nulliparous without previous gestation. Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer.
2960215|NCT02831452||primigravid on 1º trimester|"nulliparous women on her first pregnancy and gestational age until 13 weeks and 6 days.~Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer."
2960216|NCT02831452||primigravid on 2º trimester|"nulliparous women on her first pregnancy and gestational age between 14 weeks and 27 weeks.~Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer."
2960217|NCT02831452||primigravid on 3º trimester|nulliparous women on her first pregnancy and gestational age above 28 weeks. Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer.
2960218|NCT02831439|Experimental|Intervention|Participating health systems in Wisconsin. Interventions include: Basic public reporting and the enhanced intervention (app)
2960219|NCT02831439|Other|Control|Health systems in comparison states. Control includes: Cost savings comparison
2960220|NCT02831426|Active Comparator|ADM two-stage reconstruction|Two-stage with Acellular Dermal Matrix (CELLIS® Breast). Tissue Expander A, Pre-pectoral, subcutaneous, two-stage reconstruction by means of TE supported by ADM
2960221|NCT02831426|Experimental|TCPM two-stage reconstruction|Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra). Tissue Expander B, Pre-pectoral, subcutaneous, two-stage reconstruction by means of TE supported by TCPM
2960222|NCT02831413|Placebo Comparator|Control|Control group members will receive an alternate curriculum that is not related to relationship education. Family Bridges has identified a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
2960223|NCT02831413|Experimental|RS+|The RS+ curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.
2960224|NCT02831413|Experimental|RS+ with enhanced facilitator support|The RS+ curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making. Affiliates assigned to this enhanced treatment group will participate in enhanced facilitator training and support activities.
2960225|NCT02831400|Experimental|IFABP assessment (1 study group)|30 elderly volunteers
2960226|NCT02831387|Experimental|0.017% P-321 Ophthalmic Solution|0.017% P-321 Ophthalmic Solution TID for 28 days.
2960227|NCT02831387|Placebo Comparator|Placebo|P-321 Ophthalmic Solution Placebo TID for 28 days.
2960228|NCT02831374|Experimental|Use of platelet rich plasma (Group A)'|Local anesthesia, surgical extraction of impacted third molar, Preparation of PRP gel, Placing platelet Rich plasma and suturing, Postoperative medication
2960229|NCT02831374|Placebo Comparator|surgical extraction (Group B)|Local anesthesia, surgical extraction of impacted third molar, Suturing, Postoperative medication
2960230|NCT02831361|Experimental|Gemigliptin 50mg|the subjects should visit a study site at an interval of 6 weeks during the treatment period for 24 weeks in total
2960231|NCT02831361|Placebo Comparator|Gemigliptin 50mg placebo|the subjects should visit a study site at an interval of 6 weeks during the treatment period for 24 weeks in total
2960232|NCT02831348||Uncontrolled asthma|Indicated by an asthma control test (ACT) score of <20 and asthma symptoms of cough, wheeze, or chest tightness for more than 2 days in the prior 2 weeks, OR current asthma exacerbation indicated by the prescription of a short course (3-5 days) of systemic corticosteroids by treating provider at the time of visit.
2960233|NCT02831348||Controlled asthma|Indicated by an ACT score of >19, or spirometry results within 10% of year's best value (based on FEV1).
2960234|NCT02831348||Pneumonia|Indicated by an admission diagnosis of pneumonia with chest X-ray consistent with the diagnosis, based on attending radiologist's interpretation.
2960235|NCT02831348||Controlled allergic rhinitis|Indicated by a rhinitis control assessment test (RCAT) score of >= 21.
2960236|NCT02831348||Uncontrolled allergic rhinitis|Indicated by an RCAT score of <21.
2960237|NCT02831348||Cystic fibrosis (exacerbated)|Indicated by treating physician's assessment of cystic fibrosis respiratory exacerbation within 24 hours of initial antibiotic therapy.
2960238|NCT02831348||Cystic fibrosis (stable)|Indicated by diagnosis of cystic fibrosis with baseline symptoms and with spirometry results (based on FEV1) within 5% of year's best value.
2960239|NCT02831348||Control|Indicated by a negative history of any of the conditions characterizing the other groups.
2960240|NCT02831335||Group 1|normal 21-35 years old participants
2960241|NCT02831335||Group 2|normal 36-50 years old participants
2960242|NCT02831335||Group 3|normal 51-65 years old participants
2960243|NCT02831335||Group 4|normal 66- 80 years old participants
2960244|NCT02831322|Experimental|radial artery occlusion|Radial artery occlusion was the absence of a flow signal by Doppler ultrasound examination.
2960245|NCT02831322|Other|radial artery normal|Radial artery normal was blood flow signal by Doppler ultrasound
2960246|NCT02831309|Sham Comparator|Sedentary Condition|Forty minutes of screen time. Standardized meals provided.
2960247|NCT02831309|Active Comparator|Light-Intensity Condition|Forty minutes of light-intensity activity. Standardized meals provided.
2960248|NCT02831309|Active Comparator|Moderate-Intensity Condition|Forty minutes of moderate-intensity activity. Standardized meals provided.
2960249|NCT02831309|Active Comparator|High-Intensity Condition|Forty minutes of high-intensity activity. Standardized meals provided.
2960250|NCT02831296||Affected Subjects <36 Mos. of Age|"Infants and children 36 months of age and younger at time of enrollment who have been genetically diagnosed with Spinal Muscular Atrophy (SMA)~The affected cohort will receive coordinated, multidisciplinary care including dietary intervention, respiratory monitoring, physical therapy, and genetic counseling. They will also undergo assessment of motor function, muscle action potential measurement, and body composition, as well as blood sample collection for DNA and biomarkers, and optional research skin biopsy."
2960251|NCT02831296||Unaffected Subjects <36 Mos. of Age|"Infants and children 36 months of age and younger who are not affected with SMA~The unaffected group will undergo the same assessments as the affected group."
2960252|NCT02831296||Unaffected Family Members|"Parents and siblings of any age, without genetic diagnosis of SMA, who have family members enrolled in either of the Affected Infants/Children/Adults cohorts.~The unaffected siblings will undergo the same assessments as the affected group, where age-appropriate. Unaffected parents' participation will be limited to blood sample collection and optional research skin biopsy."
2960368|NCT02830386||LVIS stents group|The patients with ruptured intracranial saccular aneurysm wil be treated with a LVIS stent without coils.
2960253|NCT02831296||Affected Subjects >36 Mos. of Age|"Children and adults >36 months at time of enrollment who have been genetically diagnosed with Spinal Muscular Atrophy.~The older affected cohort will receive coordinated, multidisciplinary care including dietary intervention, respiratory monitoring, physical therapy, and genetic counseling. They will also undergo assessment of motor function, muscle action potential measurement, and body composition, as well as blood sample collection for DNA and biomarkers, and optional research skin biopsy. Where applicable, these participants will be considered Affected Control Subjects."
2960254|NCT02831283|Experimental|Cognitive impairment|Alzheimer's disease, Preclinical Alzheimer's disease or Impairment due to suspected non-Alzheimer's disease pathophysiology
2960255|NCT02831283|Active Comparator|No cognitive impairment|Normal aging
2960256|NCT02831270||Control Group|Patients undergoing cardiac surgery supposed not to get acute normovolemic hemodilution (ANH) before CPB
2960257|NCT02831270||Active Comparator: Acute normovolemic hemodilution group|Patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB
2960258|NCT02831257|Experimental|AZD2014|"18 patients will be enrolled in this study in a single stage.~AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.~One cycle will consist of 28 days (1 cycle = 28 days)."
2960259|NCT02831244|Other|Agili-CTM|Intervention
2960260|NCT02831231|Active Comparator|Xanomeline plus placebo|Drug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Placebo, TID
2960261|NCT02831231|Experimental|Xanomeline plus trospium|Drug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Drug: Trospium chloride 20 mg BID, for a 40 mg total daily dose
2960262|NCT02831218|Experimental|QCA and Aspirin alone|
2960263|NCT02831218|Experimental|QCA and Clopidogrel alone|
2960264|NCT02831218|Active Comparator|Imaging guided and Aspirin alone|
2960265|NCT02831218|Active Comparator|Imaging guided and Clopidogrel alone|
2960266|NCT02831205|Experimental|ABSORB BVS|
2960267|NCT02831205|Active Comparator|XIENCE EES|
2960268|NCT02831192|Experimental|MST（microtransplantation）|
2960269|NCT02831179|Experimental|Treatment (capecitabine, temozolomide, veliparib)|Capecitabine PO BID on days 1-14, temozolomide PO BID on days 10-14 and veliparib PO BID on days 10-14.
2960270|NCT02831166|Active Comparator|Transradial approach|Transradial approach primary percutaneous coronary intervention using the TR Band device to obtain hemostasis (n=120).
2960271|NCT02831166|Active Comparator|Transfemoral approach|Transfemoral approach primary percutaneous coronary intervention using a vascular closure device to obtain hemostasis (n=120).
2960272|NCT02831153|Active Comparator|normal coronary anatomy|coronary angiography will be performed by transfemoral or transradial route.
2960273|NCT02831153|Active Comparator|coronary artery ectasia|coronary angiography will be performed by transfemoral or transradial route.
2960274|NCT02831153|Active Comparator|slow coronary flow|coronary angiography will be performed by transfemoral or transradial route.
2960275|NCT02831153|Active Comparator|nonobstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
2960276|NCT02831153|Active Comparator|obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
2960277|NCT02831140|Other|Common arm : for both groups :|"In preoperative phase~In peroperative phase~In postoperative phase"
2960278|NCT02831140|Experimental|FTR protocol group (A)|"A. Experimental : FTR protocol group :~Early exercises after a thoracic surgery : removing urinary probe and all catheters as well as alimenting ."
2960279|NCT02831140|No Intervention|Control group (B)|Traditional, conventional care group with first get up and alimentation permission in 24 hours at the postoperative.
2960280|NCT02831127|Experimental|short message service group|Patients in this arm received conventional instructions plus short message reminder.
2960281|NCT02831127|Active Comparator|conventional group|Patients in this arm just received conventional instructions.
2960282|NCT02831114|Experimental|Intervention|The nine participants in the intervention arm will receive 18 acupuncture treatments over the course of 12 weeks (2 treatments per week for 6 weeks and 1 treatment per week for 6 weeks). They will undergo assessments at baseline, 6 weeks, and 12 weeks through the use of questionnaires and blood tests. The participants will also be allowed to continue their conventional therapy for TIPN.
2960283|NCT02831114|No Intervention|Control|The nine participants in this arm will undergo the same assessments as the intervention arm at baseline, 6 weeks, and 12 weeks. They will not receive any acupuncture treatments during this time, but will be allowed to continue their conventional therapy. The control arm will be offered the same 18 acupuncture treatments after a wait of at least 12 weeks.
2960284|NCT02831101|Experimental|Sufentanil|Sufentanil intravenously, continuously with effect-site concentration of 0.3 ng/ml until the end of the study
2960285|NCT02831101|Other|Placebo|Saline intravenously, continuously with the same effect-site concentration as sufentanil (recorded on administration device) until the end of the study
2960286|NCT02831101|No Intervention|Propofol|Open administration using a separate target controlled infusion system and the PK/PD model by Schnider. Initial effect-site concentration 0.5 mcg/ml increased by 0.5 mcg/ml until LOC
2960287|NCT02831088|Experimental|Neu2000KWL High-dose group|
2960288|NCT02831088|Experimental|Neu2000KWL Low-dose group|
2960289|NCT02831088|Placebo Comparator|Placebo|
2960290|NCT02831075|Experimental|Adipose-derived stem cell|Mesenchymal stem cells derived from adipocyte transplantation
2960291|NCT02831075|Placebo Comparator|saline|saline injections
2960292|NCT02831062|No Intervention|ad lib diet|Patients who have an episode of Stage 2/3 AKI and are followed in a focused post-AKI clinic. Patients will be asked to continue on their regular diet and the protein and caloric ingestion will be recorded at each visit.
2960293|NCT02831062|Experimental|Low Protein Diet + Ketosteril|Patients who have an episode of Stage 2/3 AKI and are followed in a focused post-AKI clinic. Patients in this arm will be prescribed a low protein diet (LPD) and +Ketosteril supplementation, containing 0.6 g protein/kg per day, phosphorus 5-10 mg/kg/day, Ketosteril 1 capsule per 5 kg body weight/day divided over three doses (max 8 capsules per dose). Protein and caloric ingestion will be recorded.
2960294|NCT02831049|Experimental|1|alcohol retrieval/alcohol extinction
2960295|NCT02831049|Active Comparator|2|soft-drink retrieval/alcohol extinction
2960297|NCT02831036|Experimental|trial group|subjects in trial group will be following the experimental protocol (VO2max tests and spatial orientation tests) while performing a training program during the trial (3 months).
2960298|NCT02831036|Other|control group|following the experimental protocol (VO2max tests and spatial orientation tests)without performing additional exercise.
2960299|NCT02831023|Active Comparator|SP-AQ only|Subjects will receive sulphadoxine-pyrimethamine (SP) as single dose and administered in combination with amodiaquine (AQ), which will be given once daily for 3 days.
2960300|NCT02831023|Experimental|SP-AQ plus PQ|Participants in this arm will receive SP-AQ in combination with a single low dose of primaquine at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
2960301|NCT02831023|Active Comparator|DP only|Participants in this arm will be treated with dihydroartemisinin-piperaquine (DP), which will be administered once a day for three days.
2960302|NCT02831023|Experimental|DP plus MB|Study participants in this arm will receive DP as described above combined with once-daily methylene blue (MB) for 3 days, at 15 mg/kg/day (45 mg/kg total over 3 days).
2960303|NCT02831010||encephalopathy of prematurity|infants with encephalopathy of prematurity showed on MRI at term-equivalent age
2960304|NCT02831010||no encephalopathy of prematurity|infants with no encephalopathy of prematurity showed on MRI at term-equivalent age
2960305|NCT02830997||Conventional guidance|The conventional guidance will undergo TKA surgery with use of the Investigator's usual precision guided technique based on conventional instrumentation (mechanical and simple computer-assisted guidance techniques). For participants of the conventional guidance arm, the Investigator will employ the established technique he currently employs for all routine TKA procedures and would employ if the patient were not a participant in the study.
2960306|NCT02830997||Stereotactic guidance|The stereotactic guidance group will undergo their TKA surgery with use of a stereotactic guidance system.
2960307|NCT02830984|Experimental|EST+LBD+ENBD group|Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
2960308|NCT02830984|Active Comparator|EST+LBD group|Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
2960309|NCT02830971|Other|Clinical specific education|Providing clinical skills conditions
2960310|NCT02830958|Experimental|Kinesiotaping Group|applied next to the lymphatic system from the validated methods Kinesiotaping®.
2960311|NCT02830958|Placebo Comparator|Ordinary tape Group|Installation of an ordinary tape (not having the characteristics of Curetape®).
2960312|NCT02830945|Other|Control Brochure Arm|Control Arm households receive a culturally tailored Stroke and CVD brochure for prevention.
2960313|NCT02830945|Experimental|Motivational Interviewing Intervention Arm|The MI intervention households receive three aspects of the intervention: digital stories, motivational interviewing talking circle and the option to receive text messages to adhere to the action plan.
2960314|NCT02830932|Experimental|VXA-RSV-f Tablets (high dose)|Singe dose of orally administered VXA-RSV-f Tablets (high dose). VXA-RSV-f is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of respiratory illness caused by RSV. The vaccine vector encodes for a full-length F protein gene from RSV.
2960315|NCT02830932|Experimental|VXA-RSV-f Tablets (low dose)|Singe dose of VXA-RSV-f Tablets (low dose).VXA-RSV-f is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of respiratory illness caused by RSV. The vaccine vector encodes for a full-length F protein gene from RSV.
2960316|NCT02830932|Placebo Comparator|VXA Placebo Tablets|Singe dose of matching placebo tablets. The placebo tablets are small off-white tablets that are similar in size and number to the active vaccine dose being delivered.
2960317|NCT02830919|Experimental|Glucosamine and chondroitin sulfate combination (Eurofarma)|Glucosamine sulfate 1500mg plus chondroitin sulfate 1200mg combination, manufactured by Eurofarma Laboratórios S.A., administered once a day for 24 weeks.
2960318|NCT02830919|Active Comparator|Glucosamine and chondroitin sulfate combination (Zodiac)|Glucosamine sulfate 1500mg plus chondroitin sulfate 1200mg combination, manufactured by Zodiac Produtos Farmacêuticos S.A. (Condroflex®), administered once a day for 24 weeks.
2960319|NCT02830906|Experimental|ramosetron group|Patients received 0.3 mg of intravenous ramosetron before spinal anesthesia and intrathecal morphine
2960320|NCT02830906|Active Comparator|ondansetron group|Patients received 8 mg of intravenous ondansetron before spinal anesthesia and intrathecal morphine
2960321|NCT02830893|Experimental|The LARA Therapy|The LARA arm of this study will use the LARA system while study participants are staying at the acute rehabilitation unit of UC Irvine Douglas Hospital. LARA is a system that facilitates patients to perform high amounts of arm movement with the affected upper extremity. Study participants are able to actively propel themselves in the unit.
2960322|NCT02830893|Active Comparator|The Standard Therapy|The control arm of this study will use a standard wheelchair while study participants are staying at the acute rehabilitation unit of UC Irvine Douglas Hospital. Study participants will have no exposure to LARA and they will use a standard wheelchair. They will use their unaffected upper and lower extremities to propel themselves in the unit.
2960323|NCT02830880|Experimental|FACBC|Participants with biopsy-proven primary or recurrent castration-resistant prostate carcinoma with skeletal and/or nodal involvement will undergo an FACBC PET-CT scan.
2960324|NCT02830854|Experimental|Molecular Hydrogen|Molecular hydrogen: 20 min per day of 3% H2 during 4 weeks
2960325|NCT02830841|Experimental|DR-RIPC (donor and recipient RIPC group)|Both donors and recipients receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right upper arm(donor) or right lower limb(recipient) and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
2960326|NCT02830841|Sham Comparator|S-RIPC (sham RIPC)|Patients had a deflated cuff placed on the right upper arm or right lower limb for 30 min
2960327|NCT02830841|Experimental|R-RIPC (recipient RIPC group)|Recipients receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right lower limb and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
2960458|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 5 mL|Perineural injection of ropivacaine 0.2 %, 5 mL
2960328|NCT02830841|Experimental|D-RIPC (donor RIPC group)|Donors receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
2960329|NCT02830828||Patients|Patients fulfilling inclusion/exclusion criteria referred to the PI with suspected carpal tunnel syndrome.
2960330|NCT02830828||Controls|"Healthy volunteers fulfilling inclusion/exclusion criteria with no symptoms of carpal tunnel syndrome.~Mid-study, it was elected to also match patients to their own contralateral disease-free hand to act as a control."
2960331|NCT02830802|Experimental|Group A|Active Agent
2960332|NCT02830802|Placebo Comparator|Group B|Placebo
2960333|NCT02830789|Experimental|Calcium Carbonate|1 tablet Unikalk Forte + 1 placebo tablet by mouth three times daily equal to 1200 mg elementary calcium and 57 µg Vitamin D3
2960334|NCT02830789|Experimental|Calcium Citrate|2 tablets Unikalk Citrat by mouth three times daily equal to 1200 mg elementary calcium and 60 µg Vitamin D3
2960335|NCT02830776|Experimental|Treatment group|This is a single-arm open label proof of concept pilot study evaluating use of Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping).
2960336|NCT02830763|Experimental|Medium-chain Fatty Acid (CNT-02)|
2960337|NCT02830737|Active Comparator|Traditional RFA|Using Traditional RFA for the treatment of small hepatocellular carcinoma
2960338|NCT02830737|Experimental|No-touch RFA|Using No-touch RFA for the treatment of small hepatocellular carcinoma
2960339|NCT02830724|Experimental|Single Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + anti-hCD70 CAR transduced PBL + high-dose aldesleukin
2960340|NCT02830685|Active Comparator|Direct-To-Implant A|DTI with Acellular Dermal Matrix (CELLIS® Breast), pre-pectoral, subcutaneous direct-to-implant breast reconstruction with the aid of an Acelluar Dermal Matrix (ADM)
2960341|NCT02830685|Experimental|Direct-To-Implant B|DTI with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra), pre-pectoral, subcutaneous direct-to-implant breast reconstruction with the aid of a titanium coated polypropylene mesh
2960342|NCT02830672|Active Comparator|Open surgical release A1 Pulley|
2960343|NCT02830672|Active Comparator|Ultrasound guided close release A1 pulley|
2960344|NCT02830646|Other|DFG mesure|Measure the effect of gastric bypass on the report DFG / VEC
2960345|NCT02830633|Experimental|LNTME|Laparoscopy-assisted nerve-preserved TME (LNTME) is conducted in rectal cancer patients
2960346|NCT02830633|Active Comparator|OTME|Open TME (OTME) is conducted in rectal cancer patients
2960347|NCT02830620|Other|groupe1|cancer of the pancreas WITH syndrome of anorexia-cachexie Dosage of chimiokines
2960348|NCT02830620|Other|groupe2|cancer of the pancreas WITHOUT syndrome of anorexia-cachexie Dosage of chimiokines
2960349|NCT02830620|Other|groupe3|pure food limitation typifies restrictive anorexia nervosa Dosage of chimiokines
2960350|NCT02830620|Other|groupe4|unhurt individual of any appetite-suppressing evolutionary disease and cachectisante Dosage of chimiokines
2960351|NCT02830607|Experimental|Xiaomi Mi Band|participants will wear Xiaomi Mi Band .the device measures their daily steps number before and after epidural steroid injection for treatment of low back pain.
2960352|NCT02830594|Experimental|Treatment (pembrolizumab, RT)|"INITIAL TREATMENT: Patients undergo palliative external beam RT daily. On day 1, patients undergo the first RT fraction and then receive pembrolizumab intravenously (IV) over 30 minutes. Courses repeat every 3 weeks for up to 35 courses in the absence of disease progression or unacceptable toxicity.~SECOND PHASE: Patients who achieve a complete response, stop study treatment, and then experience radiographic disease progression may be eligible for the second phase at the discretion of the investigator if no cancer treatment was administered since the last dose of pembrolizumab and trial eligibility safety parameters are met. Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 17 courses in the absence of disease progression or unacceptable toxicity."
2960353|NCT02830568||couples kidney living donor - receiver|"Three groups for each technique of taking of kidney :~open donor nephrectomy~standard and hand-assisted laparoscopic donor nephrectomy~laparoscopic robotic-assisted nephrectomy"
2960354|NCT02830542|Experimental|SER-262|SER-262 [Single dose: 10(4), 10(5), 10(6), 10(7) or 10(8) SCFUs; Multiple dose 10(6), 10(7), or 10(8) SCFUs]
2960355|NCT02830542|Placebo Comparator|Placebo|Placebo
2960356|NCT02830529|Experimental|MAD DASH|Mindfulness based stress reduction and diet education delivered in 8 sessions lasting 2.5 hours each. Mindfulness conducted by a certified trainer. Participants were given homework and meditation CD. Dietitian delivered diet education and conducted interactive food demonstrations. Participants were given option complete weekly diet diary for the dietitian to provide feedback.
2960357|NCT02830529|Experimental|DASH diet education|Dietary approaches to stop hypertension sessions were delivered by a registered dietitian in 8 sessions lasting 1 hour each. Dietitian delivered diet education and conducted interactive food demonstrations. Participants were given option complete weekly diet diary for the dietitian to provide feedback.
2960358|NCT02830529|No Intervention|Usual Care-DASH Pamphlet Only|Dietary approaches to stop hypertension pamphlet was mailed to each participant. They continued receiving usual care from their health care provider.
2960359|NCT02830516||Lung elastance - transpulmonary pressure|Lung elastance and transpulmonary pressure measured by tidal esophageal pressure variations and by performing a PEEP step
2960360|NCT02830503|Experimental|Intervention|Feeding tube daily replacement
2960361|NCT02830503|No Intervention|Control|Feeding tubes replaced as normal practice in the department (normally once a week).
2960362|NCT02830477||BAY81-8973|Previously treated patients receiving IV infusion of KOVALTRY for routine prophylaxis
2960363|NCT02830438|Experimental|Shear wave elastography group|Patients referred for kidney biopsy will then undergo shear wave elastography measurements.
2960364|NCT02830412|Experimental|PONV Reminder|After patient has non-cardiac surgery, the subject will have Post-Operative Nausea and Vomiting Reminder display
2960365|NCT02830412|No Intervention|No PONV Reminder|After patient has non-cardiac surgery, the subject will not have Post-Operative Nausea and Vomiting Reminder display
2960366|NCT02830399|Active Comparator|active rTMS-ECT|5 active high frequency rTMS before 5 bilateral ECT
2960369|NCT02830373||LVIS stents group|patients with unruptured intracranial saccular aneurysms which located in the internal carotid artery or vertebra-basilar artery will be treated with a LVIS stent with coils
2960370|NCT02830360|Active Comparator|VT catheter ablation|Catheter ablation of ventricular tachycardia
2960371|NCT02830360|Active Comparator|Antiarrhythmic Drug Therapy|Patients will be prescribed either oral amiodarone or sotalol daily (dosage and frequency to be determined based on patient's clinical presentation at the time of the qualifying arrhythmia).
2960372|NCT02830347||Amoxicillin|No randomization is performed. Patients who are prescribed antibiotics by the clinician performing the tooth extraction ( based on case complexity and intra operative judgement) are recruited into this group.The principal investigator is not involved in the decision to prescribe antibiotics or not.
2960373|NCT02830347||No Amoxicillin|Patients who do not receive antibiotics after extractions are recruited into this group.
2960374|NCT02830321||case|"Pregnant women who suffered from hyperemesis gravidarum and admitted in the hospital~Age: 18-40 years old~Gestational age: less than 16 weeks confirmed by pelvic u/s~Excessive pregnancy - related nausea and /or vomiting that prevent adequate intake of food and fluids.~All pregnant (case and control) were asked to bring a stool sample in a clean container. Collected samples were tested in a laboratory (Ain Shams Univerisity hospital).~Stool samples were be tested by using one step H.pylori stool antigen test (CER TEST BIOTEC) for the detection of H. pylori antigen."
2960375|NCT02830321||control|Control patients which are selected from pregnant women presenting to the outpatient clinics for routine antenatal care of the same gestational age, same age range and same socioeconomic standard as cases.
2960376|NCT02830295|Experimental|Basic Body Awareness Therapy|The Basic Body Awareness Therapy is usual therapy of physiotherapy in health mental in nord of europe. BBAT is based in twelve movements and massage that improve the movement quality of patient, also BBAT improves others movement qualities like biomechanical, physiologic, socio-cultural and existential.
2960377|NCT02830295|No Intervention|control|the patients which below receive the treatment as usual, according the clinic guidelines of Health government
2960378|NCT02830243|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
2960379|NCT02830243|Experimental|Desflurane|Anesthesia was maintained with desflurane.
2960380|NCT02830230|Experimental|Intervention group/Case|"women with clinical cervicitis or cervicovaginitis as per NACO Guidelines will be enrolled in intervention group.~women with clinical cervicitis or cervicovaginitis as per NACO Guidelines will be enrolled in intervention group.A cervico-vaginal swab shall be taken for Lab diagnosis of RTIs along with HPVDNA test on day 1.Women shall be treated with Tab Azithromycin 1gm and Tab Cefixime 400mg stat along with barrier contraception advised.The women will be followed up after 7-14 days .A repeat cervicovaginal swab and HPVDNA shall be repeated."
2960381|NCT02830230|No Intervention|Control group|Women without signs and symptoms of cervicitis or cervico-vaginitis.No intervention will be done in this group
2960382|NCT02830217||STEMI patients having primary PCI|Patients with STEMI receiving primary PCI in Wuhan Aisa Heart Hospital are included in this study. All patients are the first time to have STEMI, and primary PCIs are performed according to 2013 ACCF/AHA guideline for the management of STEMI. Patients with previous stroke, pneumonia, cirrhosis, autoimmune diseases are excluded from this study.
2960383|NCT02830204|Experimental|Mitral Valve Replacement with Sapien3|subjects with surgical MVR with Sapien3
2960384|NCT02830178||Any Paracetamol|Participants with age 18 and over who received a first prescription of single-ingredient paracetamol or ibuprofen in 2012 will be enrolled. Their status with respect to prior gastrointestinal bleeding, myocardial infarction, stroke, or kidney disease will be assessed based on the presence or absence of a diagnosis in the 2 years prior to the index date. This observational study will evaluate whether new users of paracetamol have a higher prevalence of certain conditions (gastrointestinal bleeding, myocardial infarction, stroke or kidney disease) in their history when compared to new users of ibuprofen, propensity scores and outcome models.
2960385|NCT02830178||Ibuprofen|Participants with age 18 and over who received a first prescription of single-ingredient ibuprofen in 2012 will be enrolled. Their status with respect to prior gastrointestinal bleeding, myocardial infarction, stroke, or kidney disease will be assessed based on the presence or absence of a diagnosis in the 2 years prior to the index date. This observational study will evaluate whether new users of paracetamol have a higher prevalence of certain conditions (gastrointestinal bleeding, myocardial infarction, stroke or kidney disease) in their history when compared to new users of ibuprofen, propensity scores and outcome models.
2960386|NCT02830165|Experimental|Treatment (SBRT)|Patients undergo 3 fractions of SBRT over 1-2 weeks, 2-4 weeks prior to radical prostatectomy.
2960387|NCT02830152|Experimental|Left Atrial Appendage Occlusion (LAAO)|The intervention is implantation of Amplatzer Amulet LAAO device within two months after randomization. Device implantation comprises a catheterization procedure using venous access and a transseptal puncture to obtain access to the left atrium (LA). Procedural imaging guidance is left to the physician's discretion and may include several techniques such as angiography/fluoroscopy, transesophageal echocardiography (TEE) and/or intracardiac echocardiography (ICE). Recommended post-implant antithrombotic therapy includes ASA therapy for at least 6 months, which may be combined with clopidogrel for the first 45 days after implantation.
2960388|NCT02830152|Active Comparator|Medical Therapy|The optimal medical therapy of stroke prevention in non-valvular atrial fibrillation (NVAF) after intracerebral hemorrhage (ICH) is not known. Therefore, it will be left to the discretion of the treating physician to decide if, when, and which pharmacological therapy will be prescribed. Available options include anticoagulation with oral anticoagulation (OAC) or novel oral anticoagulants (NOAC), antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
2960389|NCT02830139|Sham Comparator|Radical colorectal resection without HIPEC|Patients will be treated with a radical colorectal resection for locally advanced colorectal cancer and postoperative chemotherapy (XELOX)
2960390|NCT02830139|Experimental|Radical colorectal resection with HIPEC|Patients will be treated with a radical colorectal resection for locally advanced colorectal cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (XELOX)
2960391|NCT02830126|No Intervention|Anesthesiology Control Tower Control|Patients managed by anesthesia teams without feedback alerts from the ACT
2960392|NCT02830126|Experimental|Anesthesiology Control Tower Feedback|Patients managed by anesthesia teams with feedback alerts from the ACT
2960393|NCT02830113|Experimental|non-surgical periodontal treatment|One session of non-surgical periodontal treatment consisting of a complete scaling, polishing, root planning, and the irrigation of periodontal pockets with a 10% povidone iodine solution.
2960394|NCT02830100|Other|Healthy volunteers|
2960395|NCT02830087|Active Comparator|220 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 220 mmHg.
2960396|NCT02830087|Active Comparator|250 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 250 mmHg
2960397|NCT02830087|Active Comparator|275 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 275 mmHg
2960398|NCT02830087|Active Comparator|300 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 300 mmHg
2960399|NCT02830087|Active Comparator|325 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 325 mmHg
2960400|NCT02830087|Active Comparator|350 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 350 mmHg
2960401|NCT02830074|Experimental|The BEST Program|a combined sleep and PAP adherence program, called the ?BEST? program (Best practices PAP + patient Education + ongoing Support and Training)
2960402|NCT02830074|Active Comparator|Sleep Education and standard SDB treatment|This program includes non-directive sleep education plus standard treatment of SDB.
2960403|NCT02830061||TYAC|Teenagers and young adults who have received a cancer diagnosis which puts them at moderate-to-high risk of fertility impairment. Semi-structured interviews will take place with each individual participant.
2960404|NCT02830048|Experimental|Glibenclamide dose titration|Increasing doses of glibenclamide oral suspension from 0.3mg/day to 6mg/day.
2960405|NCT02830035|Active Comparator|Anatomical Landmark Technique|Traditional anatomical landmark technique based paramedian spinal anesthesia
2960406|NCT02830035|Active Comparator|Real-time Ultrasound-guided Technique|Ultrasound-guided paramedian spinal anesthesia Intervention: Ultrasound-guided Technique
2960407|NCT02830022|Experimental|Patients|Children from 8 to 18 years with autism without without intellectual disabilities (IQ > 70), verbals and responding to classification CIM 10-DSM IV.
2960408|NCT02830022|Experimental|Healthy volunteers|Paired for age, gender, IQ and and the practice of a physical activity strictly within the school context.
2960409|NCT02830009|Other|Primary Hyperoxaluria patient|
2960410|NCT02830009|Other|Primary Hyperoxaluria patient's siblings|
2960411|NCT02830009|Other|Idiopathic hypercalciuria patients|
2960412|NCT02830009|Other|Healthy volunteers|
2960413|NCT02829996|Experimental|trabodenoson 6.0% /latanoprost 0.005% QD|trabodenoson 6.0% / latanoprost 0.005% QD FDC
2960414|NCT02829996|Experimental|trabodenoson 3.0% /latanoprost 0.005% QD|trabodenoson 3.0% / latanoprost 0.005% QD FDC
2960415|NCT02829996|Experimental|trabodenoson 6.0% /latanoprost 0.0025%QD|trabodenoson 6.0% /latanoprost 0.0025% QD FDC
2960416|NCT02829996|Active Comparator|latanoprost 0.005% QD|latanoprost 0.005% ophthalmic solution QD
2960417|NCT02829996|Active Comparator|latanoprost 0.0025% QD|latanoprost 0.0025% ophthalmic solution QD
2960418|NCT02829983|Active Comparator|clarithromycin group|20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg - 12/12 hours) for 3 days.
2960419|NCT02829983|Placebo Comparator|placebo group|20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
2960420|NCT02829970|Experimental|SUCCEEDS Program|Participants will meet individually with a research team member for three weekly sessions, two bi-weekly sessions, and complete 1-month and 3-month post treatment follow-ups. Participants will be engaged about personalized alcohol feedback and identify life values and specific activities important to those values.
2960421|NCT02829970|Active Comparator|Living a Healthy College Lifestyle|Participants will meet individually with a research team member for three weekly sessions, two bi-weekly sessions, and complete 1-month and 3-month post treatment follow-ups. Participants will engage in discussion focused on experiences as an emerging adult.
2960422|NCT02829957|Active Comparator|Rivaroxaban|
2960423|NCT02829957|Active Comparator|Apixaban|
2960424|NCT02829944|Experimental|Ropivacaine|Subjects will receive 440 mg ropivacaine and 30 mg ketorolac. Infusion of study medication will start after the skin is sutured and will continue for 48 hours after cesarean delivery.
2960425|NCT02829944|Placebo Comparator|Placebo|Subjects will receive saline placebo. Infusion of study medication will start after the skin is sutured and will continue for 48 hours after cesarean delivery.
2960426|NCT02829931|Experimental|Combination Therapy|"Safety Cohort: The first 6 participants will receive Nivolumab only to start.~Dose Expansion Cohort: All 26 participants will be treated with Hypofractionated Stereotactic Irradiation (HFSRT), followed by Nivolumab."
2960427|NCT02829918|Experimental|Nivolumab Treatment|This is a single arm study with two stage design using nivolumab in advanced biliary tract cancer (BTC), for participants who have failed or are intolerant to at least one line of therapy and no more than 2 lines of therapy. In the first stage, 18 participants will be accrued. If there is at least one response (or several participants with stable disease based on the study team's discretion), an additional 34 patients will be accrued for a total of 52 patients.
2960428|NCT02829892|Other|Light therapy|Innovative ambient lighting
2960429|NCT02829879|Experimental|arginine|25 volunteers with dentin sensitivity
2960430|NCT02829879|Active Comparator|potassium nitrate|25 volunteers with dentin sensitivity
2960431|NCT02829853||sporadic cases (SP)|Sporadic cases are defined as patients diagnosed for sarcoidosis, for which the familial history did not reveal any other cases, whatever the relative degree is: 1, 2, 3 or 4. The clinical follow-up and the genetic studies performed in the frame of this project are the same as for the familial group. During the regular follow-up, patients are regularly questioned about the putative occurrence of the disease in their family, and if such a situation occurred, the patient (and his relative) may change from the SP to the familial (FAM) group. In blood samples, genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING will be done.
2960459|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 10 mL|Perineural injection of ropivacaine 0.2 %, 10 mL
2960460|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 15 mL|Perineural injection of ropivacaine 0.2 %, 15 mL
2960461|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 20 mL|Perineural injection of ropivacaine 0.2 %, 20 mL
2960432|NCT02829853||familial cases (FAM)|Familial cases are defined as patients diagnosed for sarcoidosis with a first and/or second degree relative parent also affected by a well-proven sarcoidosis syndrome. More than 70% of SARCFAM families included two first-degree affected individuals, with both a vertical or horizontal transmission. The Mendelian trait seems to be autosomal dominant. 20 to 30% of the families consists of 3, 4 or more cases, with a subset of families including more than 5 cases. Patients are managed as for the sporadic one, and in such families, an informed consent was also provided with a clear explanation on the complexity of the genetic background of the disease. In blood samples, genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING will be done.
2960433|NCT02829840|Experimental|Cohort #1|"Cohort #1: Participants with no previous leukemia therapy (including no previous FLT3 inhibitor therapy) for either: a) front-line treatment of elderly (age 65 and greater) FLT3-mutated AML patients, or b) patients unable or unwilling to receive standard intensive therapy.~Part 1: Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant continues on to Part 2 of study.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
2960434|NCT02829840|Experimental|Cohort #2|"Cohort #2: Participants with relapsed/refractory FLT3-mutated AML that have not received prior FLT3 inhibitor therapy.~Part 1: Participants receive Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant continues on to Part 2 of study.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
2960435|NCT02829840|Experimental|Cohort #3|"Cohort #3: Participants with relapsed/refractory FLT3-mutated AML, that have received previous FLT3 inhibitor therapy (including, but not limited to, quizartinib, crenolanib, sorafenib, other FLT3 inhibitors).~Part 1: Participants receive Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant will continue on to Part 2 of study.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
2960436|NCT02829827|Experimental|Radiprodil|Each subject will enter an individualized dose titration schedule.
2960437|NCT02829814|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 12 weeks
2960438|NCT02829814|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks
2960439|NCT02829801|Experimental|AAT arm|AAT and cognitive stimulation and rehabilitation of social tie.
2960440|NCT02829801|Other|control group|Cognitive stimulation and rehabilitation of social tie.
2960441|NCT02829788||Digestive peritoneal carcinomatosis staging|All patients underwent laparoscopic followed by laparotomic surgical staging.
2960442|NCT02829775|Experimental|Interferon Alfa-2A in Cancer Participants|Participants who responded to interferon alfa-2A (either pegylated interferon alfa-2A or recombinant interferon alfa 2A) treatment during the parent study will continue to receive the same treatment in this study. Pegylated interferon alfa-2A will be administered subcutaneously once weekly and recombinant interferon alfa 2A will be administered subcutaneously once daily, until disease progression, withdrawal, or death whichever occurs first (up to approximately 3 years).
2960443|NCT02829762|Experimental|Interventional arm PS-DR|The interventional arm (PS-DR) will include the implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance (in connection with a call center 24h/24).
2960444|NCT02829762|No Intervention|Reference Arm|In the reference arm, patients will have a conventional oncological care, social support measures will be left to the discretion of the clinician and the paramedical team.
2960445|NCT02829749|Experimental|NeoChord DS1000 Artificial Chordae Delivery System|Subjects randomized to the experimental group will undergo the NeoChord implantation
2960446|NCT02829749|Other|Control|traditional mitral valve repair performed under cardiac arrest
2960447|NCT02829736|Active Comparator|Chest tube group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with a standard post-operative chest tube.
2960448|NCT02829736|Experimental|No chest tube group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with intraoperative chest tube removal.
2960449|NCT02829723|Experimental|BLZ945 single agent|
2960450|NCT02829723|Experimental|BLZ945 + PDR001|
2960451|NCT02829710||group 1 : pre implementation group|"All children aged less than 18 years, requiring mechanical ventilation for at least 24 hours and admitted in PICU between January 2013 and December 2013.~Prior to implementation of the protocol, analgesia and sedation were managed by the attending physician's order."
2960452|NCT02829710||group 2 : post implementation group|"All children aged less than 18 years, requiring mechanical ventilation for at least 24 hours and admitted in PICU between May 2014 and March 2015.~Nurses managed analgesia and sedation following an algorithm, including COMFORT-B scale."
2960453|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 2.5 mL|Perineural injection of ropivacaine 0.2 %, 2,5 mL
2960454|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 5 mL|Perineural injection of ropivacaine 0.2 %, 5 mL
2960455|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 10 mL|Perineural injection of ropivacaine 0.2 %, 10 mL
2960456|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 15 mL|Perineural injection of ropivacaine 0.2 %, 15 mL
2960457|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 20 mL|Perineural injection of ropivacaine 0.2 %, 20 mL
2960464|NCT02829658||Psychiatric patients group|Patient groups were composed with: BPD, other PD and assessed Psychologic test
2960465|NCT02829658||Control group|Matched controls (age, sex) composed the 3rd and 4th group (BPD control and other PD control). They were randomly chosen in the health database insurance previously used. They had no intervention.
2960466|NCT02829645|Other|Eating disorders|
2960467|NCT02829632|Experimental|Experimental: Group Sessions|Participants will be asked to attend 3 group meetings over a 12 week period. Groups will meet for approximately 1 hour on weeks 2, 4 and 8. At each of the group meetings, the participant will be weighed and a group leader will present information on topics related to eating and exercise.
2960468|NCT02829632|Experimental|Active Comparator: Self-Monitoring|Active Comparator: Self-monitoring Participants will record diet, activity and weight as described above in the participant's smartphone app to assist the participant in losing weight.
2960469|NCT02829632|Experimental|Experimental: Feedback|"Participants will be sent via the participant's smartphone between~1 and 4 feedback messages a day about whether the participant has been self monitoring, or the amount of calories, fat or sugar the participant has consumed."
2960470|NCT02829606|Active Comparator|small scotoma using Head Mounted Display No re-mapping|patients with scotoma smaller than 5 degrees NO re-mapping PLUS re-mapping
2960471|NCT02829606|Active Comparator|Large scotoma using Head Mounted Display PLUS re-mapping|patients with scotoma larger than 5 degrees NO re-mapping PLUS re-mapping
2960472|NCT02829593|Experimental|type 1 diabetes|type 1 diabetes >5 years duration
2960473|NCT02829593|Placebo Comparator|healthy controls|
2960474|NCT02829580|Experimental|Sickle group|Children with major sickle cell syndrome will have an usual Echocardiography
2960475|NCT02829580|Active Comparator|Control group|Children recruited in a previous study and who had an usual Echocardiography
2960476|NCT02829567|Experimental|Oral hygiene counseling and motivational interviewing|This group will receive a session of oral hygiene counseling and a single session of motivational interviewing to increase the readiness of change.
2960477|NCT02829567|No Intervention|Oral hygiene counseling|
2960478|NCT02829541|Experimental|Cohorts 1|6 participants randomized (4:2) to receive a single-ascending dose (SAD) administered orally in tablet
2960479|NCT02829541|Experimental|Cohort 2|6 participants randomized (4:2) to receive a SAD administered orally in tablet(s)
2960480|NCT02829541|Experimental|Cohort 3|8 participants randomized (6:2) to receive a SAD administered orally in tablet(s)
2960481|NCT02829541|Experimental|Cohort 4|8 participants randomized (6:2) to receive a SAD administered orally in tablet
2960482|NCT02829541|Experimental|Cohort 5|8 participants randomized (6:2) to receive a SAD administered orally in tablet(s)
2960483|NCT02829541|Experimental|Cohort 6|14 participants (all active) to receive a SAD administered orally in tablet(s)
2960484|NCT02829528|Experimental|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a New York based organization dedicated to making the tools of yoga and mindfulness available to all children and teens. Their Teacher Training Program focuses on the physical, mental emotional, and social wellbeing of students. Teachers are trained to use the five elements format (connect, breathe, move, focus, relax). Implementation of the Little Flower Yoga for Kids curriculum will be manualized prior to the start of the study with Ms. Love, and will be presented as a series of activities (e.g., poses) throughout the school year. The emphasis in these yoga and mindfulness activities is exploration not competition, which allows the child to learn and develop at her own pace with the support of Ms. Love. The children participate in the Little Flower Yoga for Kids intervention at school for 40 minutes per class, 3 to 5 times per week, for the entire academic school year (9 months).
2960485|NCT02829502|Active Comparator|Byetta|"Pre- and post treatment investigations:~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)~Endothelial function/response by the methods:~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)~EndoPAT2000~Ankle-brachial index"
2960486|NCT02829502|Placebo Comparator|Normosaline|"Pre- and post treatment investigations:~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)~Endothelial function/response by the methods:~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)~EndoPAT2000~Ankle-brachial index"
2960487|NCT02829476|Experimental|patients with AIS|Patients will have 'Osteoblast sample'
2960488|NCT02829476|Experimental|control patients|
2960489|NCT02829463||osteoarthritis patients|3.0 Tesla Magnetic resonance imaging was analyzed. It's the documentation from the outpatients and inpatients with osteoarthritis. It's not the intervention the study applied, but the subjects' disease demands.
2960490|NCT02829463||healthy controls|3.0 Tesla Magnetic resonance imaging was analyzed. It's the documentation from the outpatients and inpatients without osteoarthritis. It's not the intervention the study applied, but the subjects' non-osteoarthritis knee symptom demands.
2960491|NCT02829450||PD|"Patients with CHF and chronic renal disease which started the treatment with peritoneal ultrafiltration.~The patients will be follow up every 3 months for assesment of symptoms, QOL questionary, routine blood and urine tests and also for assesment of residual renal function and peritoneal membrane function: monitoring of clinical symptoms of fluid overload, hospital admissions, UF rate, peritoneal membrane damage parameters (cell-free DNA in peritoneal effluent, peritoneal equilibration test) and residual renal function markers (eGFR creatinine or cystatin C based , KT/V, urinary markers) at the start of the treatment, each 3 months during the treatment and at each change of prescription. Complications of all kinds will be recorded."
2960492|NCT02829450||Control|Patients with CHF and chronic renal disease which preferred to continue their regular treatment or choose other then peritoneal ultrafiltration type of renal replacement therapy (data from medical records): clinical symptoms of fluid overload, hospital admissions, urine volume,residual renal function markers (eGFR creatinine)
2960493|NCT02829437||Retrospective Observational Group|Patients who received treatment for EST Patients with EST diagnosis prior August 2016
2960494|NCT02829437||Prospective Observational Group|Patients who will receive treatment for EST Patients with EST diagnosis after August 2016
2960529|NCT02829177|Placebo Comparator|Placebo|Identical tablet treatment
2960530|NCT02829151|Experimental|Triple antiplatelet therapy group|Patient group with triple antiplatelet therapy using aspirin, clopidogrel, and cilostazol
2960495|NCT02829424|Active Comparator|Experimental group|Use of low dose methotrexate (MTX) in psoriasis patients receiving an anti TNF alpha agent according to the approved indication: etanercept- Enbrel®, adalimumab- Humira ®, infliximab -Remicade ®, infliximab's biosimilar- Inflectra®, Remsima®, or any other biosimilar or branded biological agent All anti TNF alpha agents will have to be prescribed in the same administration modality and dosing regimen than in the control group and according to the Summary of Product Characteritics (SmPC) MTX: 15 mg a week orally: on a fixed day of the week defined for each patient In patients receiving an anti TNF alpha according to the SmPC, MTX will be initiated within 7 days after the start of the anti TNF alpha agent
2960496|NCT02829424|Placebo Comparator|Control group|"Use of placebo- MTX in psoriasis patients receiving anti TNF alpha agent according to the approved indication: etanercept- Enbrel®, adalimumab- Humira ®, infliximab -Remicade ®, infliximab's biosimilar- Inflectra®, Remsima®, or any other biosimilar or branded biological agent~All anti TNF alpha agents will have to be prescribed in the same administration modality and dosing regimen than in the experimental group and according to the SmPC Placebo-MTX orally: on a fixed day of the week defined for each patient In patients receiving an anti TNF alpha according to the SmPC, MTX-placebo will be initiated within 7 days after the start of the anti TNF alpha agent"
2960497|NCT02829411|Active Comparator|Employment Services only|'Workforce Readiness Program'. job readiness workshop, organized into ten daily sessions over two weeks. The main content of these sessions will be a program-developed workforce readiness training, developed with funding from a DOL Career Pathways Bridge grant.
2960498|NCT02829411|Experimental|Employment Services with HMRE content|'Workforce Readiness Program supplemented with Relationship Education': job readiness workshop, organized into ten daily sessions over two weeks. Program will add approximately 17 hours of content from the Within My Reach relationship education curriculum to the two-week job readiness workshop - and add up to eight additional one-hour relationship skills education sessions that customers can attend in the five weeks after completing the initial two-week job readiness workshop
2960499|NCT02829398|Experimental|Patients with subarachnoid hemorrhage|Patients with subarachnoid hemorrhage will have CerebroSpinal fluid and plasma sample.
2960500|NCT02829398|Active Comparator|Control subjects|healthy controls from a previous study with a CerebroSpinal fluid and plasma sample
2960501|NCT02829385|Experimental|Apatinib combined treatment group|"Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs."
2960502|NCT02829372|Experimental|GBR 1302|Dose escalation
2960503|NCT02829359|Experimental|Entecavir therapy|Patients who received entecavir (zhengda Tianqing Co., Ltd, Lianyungang, Jiangsu Province, China; 0.5 mg/d) were submitted to antiviral group. Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month. No immunological therapy in perioperative period will be submitted to any included patients.
2960504|NCT02829359|No Intervention|No antiviral therapy|Patients who did not receive any antiviral therapies were submitted as non-antiviral group. Patients in the non-antiviral group who underwent HBV reactivation will receive entecavir therapy. No immunological therapy in perioperative period will be submitted to any included patients.
2960505|NCT02829346|Experimental|Peri-articular group|Patients received 750 mg of peri-articular Tranexamic acid (Transamin®; OLIC Thailand Ltd, Bangkok, Thailand; 250 mg/5 mL, 15 cc total volume) injection into the soft tissue around medial capsule (5 ml), lateral capsule (5 ml) and around the quadriceps muscle (5 ml), 10 minutes prior to deflating the tourniquet and wound closure.
2960506|NCT02829346|Active Comparator|Intravenous group|Patients received 750 mg of intravenous tranexamic acid(250 mg/5 ml, 15 cc total volume, keeping within the therapeutic range of 10-15 mg/kg/dose), 10 minutes prior to deflating the tourniquet and wound closure.
2960507|NCT02829333|Other|Group GA|22 patients receive general anesthesia and patient controlled intravenous analgesia
2960508|NCT02829333|Other|Group SA|22 patients receive spinal anesthesia and continuous postoperative epidural analgesia
2960509|NCT02829320|Experimental|GSK1278863|Subjects will receive GSK1278863 once daily orally at a starting dose of 4 milligrams (mg) on Day 1, and continued until the day of Week 4. From Weeks 4 to 24, interruption of treatment or dose adjustments will be made within the maintenance dose range of 1 mg to 24 mg according to the dose adjustment algorithm to achieve and/or maintain Hgb within the target range (10.0 to 12.0 g/dL) based on the Hgb value measured every 4 weeks. Dose changes will be made every 4 weeks. Iron replacement therapy will be given according to the standard starting criteria.
2960510|NCT02829307|Experimental|89Zr-GSK3128349|Subjects will receive a single dose of 89Zr-GSK3128349 as an intravenous (IV) infusion over 20 minutes to deliver a dose of 1 mg
2960511|NCT02829294|Experimental|Treatment|E002 - cerumen removal aid will be placed into the ear canal of enrolled subjects for 15 to 30 minutes
2960512|NCT02829281|Experimental|Botulinum toxin group|Patients will receive a intervention with joint injection of 100 units of botulinum toxin
2960513|NCT02829281|Active Comparator|Corticosteroid group|Patients will receive a intervention with joint injection of 40mg of triamcinolone hexacetonide (corticosteroid)
2960514|NCT02829281|Placebo Comparator|Saline Group|Patients will receive a joint injection of 2ml of normal saline
2960515|NCT02829268|Experimental|Pediatric|Pediatric patients treated with dantrolene sodium
2960516|NCT02829268|Experimental|Adult|Adult patients treated with dantrolene sodium
2960517|NCT02829255|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
2960518|NCT02829242||Prostatic Surgery|Patient scheduled for a robotic assisted laparoscopic prostatic surgery.
2960519|NCT02829242||Colorectal Surgery|Patient scheduled for a robotic assisted laparoscopic colorectal surgery.
2960520|NCT02829229|No Intervention|Usual care (UC)|Usual postpartum WIC care
2960521|NCT02829229|Experimental|Community-based obesity treatment (PP)|The PP arm includes expanded obesogenic behavior change goals, tailored skills training materials, interactive self-monitoring text messages, video testimonials, and interpersonal counseling support through health coach calls and Facebook.
2960522|NCT02829203||No-Frailty|Patients without frailty score submitted to a cardiac surgery
2960523|NCT02829203||Pre-Frailty|Patients with pre-frailty score submitted to a cardiac surgery
2960524|NCT02829190|Experimental|Healthy volunteers|Magnetic Resonance Imaging (MRI)
2960531|NCT02829151|Active Comparator|DAP (Dual antiplatelet therapy) A|Patient group with dual antiplatelet therapy using aspirin and clopidogrel
2960532|NCT02829151|Active Comparator|DAP (Dual antiplatelet therapy) B|Patient group with angioplasty using aspirin and cilostazol
2960533|NCT02829138|Placebo Comparator|Non-genetic Group|General Nutrition related to Omega-3 fats: Individuals in this group will be provided with only general nutrition information related to omega-3 fats and health.
2960534|NCT02829138|Experimental|Genetic Group|Genetic information and Omega-3 fat intake: Individuals in this group will be provided with general nutrition information related to omega-3 fats and health, as well as their personal genetic information for a common gene variant related to omega-3 fatty acid metabolism.
2960535|NCT02829099|Experimental|JNJ-64457107|In Part 1, the first cohort will receive JNJ-64457107 at a starting dose of 75 microgram per kilogram (mcg/kg). The proposed treatment schedule is intravenous (IV) dosing every 14 days. JNJ-64457107 doses will be escalated following a modified Continual Reassessment Method (mCRM); the JNJ-64457107 dose will be increased by not more than half-logarithmical (3.2-fold) dose increments. Dose escalation will continue until the maximum tolerated dose (MTD) and/or RP2D of JNJ-64457107 are defined or the maximum-administered dose (MAD) has been reached. In Part 2, subjects will receive JNJ-64457107 at the RP2D and regimen determined in Part 1.
2960536|NCT02829086|Experimental|Group I|Participants in Group I will receive the following interventions: Intro to Relationship Enhancement (8 hours), Family Stress and Conflict Management (8 hours), and case management
2960537|NCT02829086|Experimental|Group II|Participants in Group II will receive the following interventions: Intro to Relationship Enhancement (8 hours), RE & Financial Management (8 hours), and case management
2960538|NCT02829086|No Intervention|Group III|Participants in Group III will receive the the standard care of all participants, case management ONLY
2960539|NCT02829073|Experimental|Oasis™ device|Treatment using the Neuromonics Tinnitus Treatment Program and the Neuromonics Oasis™ treatment device.
2960540|NCT02829073|Placebo Comparator|Placebo device|Treatment using the Neuromonics Tinnitus Treatment Program and an identical-appearing placebo device.
2960541|NCT02829060|Active Comparator|1a: Indwelling drains (48 hr)|"This group has indwelling urinary tubes/drains and a negative urine culture~Nitrofurantoin (Macrobid) 100 mg oral bid for 48 hours prior to surgery~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
2960542|NCT02829060|Active Comparator|1b: Indwelling drains (7d)|"This group has indwelling urinary tubes/drains and a negative urine culture~Nitrofurantoin (Macrobid) 100 mg oral bid for 7 days prior to surgery~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
2960543|NCT02829060|Active Comparator|2a: +UCx with Oral Options (48hr)|"This group has a positive pre-operative urine culture with oral antibiotic options~Nitrofurantoin (Macrobid) 100 mg oral bid for 48 hours prior to surgery~If patient has previous allergies to Macrobid and/or sensitivity profile indicates Macrobid resistance, then one antibiotic will be provided in the following order: nitrofurantoin > sulfamethoxazole-trimethoprim > doxycycline> ciprofloxacin > cephalexin > cefpodoxime.~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
2960544|NCT02829060|Active Comparator|2b: +UCx with Oral Options (7d)|"This group has a positive pre-operative urine culture with oral antibiotic options~Nitrofurantoin (Macrobid) 100 mg oral bid for 7 days prior to surgery~If patient has previous allergies to Macrobid and/or sensitivity profile indicates Macrobid resistance, then one antibiotic will be provided in the following order: nitrofurantoin > sulfamethoxazole-trimethoprim > doxycycline> ciprofloxacin > cephalexin > cefpodoxime.~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
2960545|NCT02829060|Active Comparator|3a: +UCx No Oral options (48hr)|"This group has a positive pre-operative urine culture with no oral antibiotic options based on culture sensitivities~48 hour course of an IV/Intramuscular (IM) antibiotic (proven effective on sensitivity profile)~Gentamicin (80 mg) preferred if sensitive~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
2960546|NCT02829060|Active Comparator|3b: +UCx No Oral options (7d)|"This group has a positive pre-operative urine culture with no oral antibiotic options based on culture sensitivities~7 day course of an IV/Intramuscular (IM) antibiotic (proven effective on sensitivity profile)~Gentamicin (80 mg) preferred if sensitive~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
2960547|NCT02829047|Other|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (14 capsules in 3 weeks)
2960548|NCT02829034|Active Comparator|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increase to 1000mg by mouth twice per day
2960549|NCT02829034|Placebo Comparator|Placebo|Placebo by mouth twice per day
2960550|NCT02829021|Other|Thermography and mammography|"All participants will be examined with~Dynamic infrared thermography (FLIR ThermaCAM P-65)~Mammography, clinical examination and if necessary breast tissue biopsy to diagnose breast cancer."
2960551|NCT02829008|Experimental|low-dose-bevacizumab/Pemetrexed|Low-dose-bevacizumab is given at a dose of 2 mg/kg once weekly by intravenous transfusion, which is on day 1, 8 and 15, and every three weeks are a treatment cycle .Pemetrexed is given at a dose of 500mg/m2 once on the first day by intravenous transfusion, and repeated every three weeks, too. The pretreatment of pemetrexed should be conducted within the study.
2960552|NCT02829008|Active Comparator|Treatment of physician' choice|Treatment of physician's choice can be any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. It can be drugs like taxanes,capecitabine, gemcitabine, cisplatin, everolimus or even nutrient solution,et al.
2960553|NCT02828995||Comprehensive Diabetes Stigma Survey|Participants in the END STIGMA study will be adult patients who have been receiving diabetes-related medical care for a minimum of 12 months in the Vanderbilt University Medical Center Diabetes Clinic and who take at least 1 medication to manage their diabetes.
2960554|NCT02828982|Experimental|Powered Ankle Prosthesis|In this condition, the participant is fitted with a powered prosthetic ankle by a certified prosthetist. The ankle is the BiOM which is manufactured by Bionx (which used to be named iWalk). This device was given 510(K) Exempt status by the FDA under (regulation number: 890.3500). Participants will wear the device for 2 weeks.
2960621|NCT02828436|Experimental|Spinal Cord Stimulation|Boston Scientific Precision Spectra System
2960555|NCT02828982|Sham Comparator|Dynamic Response Foot|In this arm, participants will wear their clinically prescribed dynamic response foot. This period is 2 weeks long.
2960556|NCT02828969|Other|Children and adolescents with conduct disorders|Girls and boys having less than 18 years old and admitted to emergency room for aggressiveness, violence, fugue or theft.
2960557|NCT02828943|Active Comparator|IMT with Low Resistance EMT|The pressure loads can be adjusted at 2 cm H2O intervals for the Threshold IMT, up to 41 cm H2O, and 1 cm H2O intervals for the Threshold PEP, up to 20 cm H2O. For the comparator group, EMT will be set to 5 cm H2O, the lowest setting on the device. IMT training loads will be set to 30% of maximal inspiratory pressure for both groups. The patient will be blinded to the valve titration. Each training session will include one set of 10 repetitions with IMT followed by one set of 10 repetitions with low resistance EMT. Patients will be instructed to maintain a respiratory rate of 15-20 breaths/min without rest between repetitions. Participants will be monitored daily by phone and by self-reported log for completion of each training.
2960558|NCT02828943|Experimental|IMT with High Resistance EMT|The pressure loads can be adjusted at 2 cm H2O intervals for the Threshold IMT, up to 41 cm H2O, and 1 cm H2O intervals for the Threshold PEP, up to 20 cm H2O. EMT training loads in the experimental group will be set to 30% of maximal expiratory pressure. IMT training loads will be set to 30% of maximal inspiratory pressure for both groups. The patient will be blinded to the valve titration. Each training session will include one set of 10 repetitions with IMT followed by one set of 10 repetitions with high resistance EMT. Patients will be instructed to maintain a respiratory rate of 15-20 breaths/min without rest between repetitions. Participants will be monitored daily by phone and by self-reported log for completion of each training. At two weeks, participants will have a follow-up office visit to monitor progress and those that have completed 80% of their training sessions will increase their training to 40% of maximum inspiratory and expiratory pressures as tolerated.
2960559|NCT02828930|Experimental|Idasanutlin|On Day 1, 300 milligram (mg) idasanutlin tablet orally and 100 mg [14C]-radiolabeled idasanutlin capsule orally (2, 50 mg capsules containing approximately 100 microcurie of radioactivity). After 5 hours and 45 minutes of the oral dose, 100 microgram (mcg) of [13C]-radiolabeled idasanutlin will be administered over a 15-minute intravenous (IV) infusion. On Day 11, idasanutlin matching placebo aqueous dispersion orally and approximately after 1 hour, 400 mg idasanutlin tablet will be administered orally in the form of an aqueous dispersion. On Day 19, 400 mg idasanutlin tablet will be administered orally in the form of an aqueous dispersion. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days, and no treatment during 23 days of 28-day cycle, until the development of progressive disease, unacceptable toxicity, consent withdrawal or any other criteria for removal.
2960560|NCT02828917|Experimental|MedJ-01 drug eluting stent|MedJ-01 Ridaforolimus eluting coronary stent system
2960561|NCT02828904||Primary Cases|"Primary cases are women~aged 15 to 49 years~with a new VTE diagnosis within the study period~current user of CMA 2mg / EE 30µg or LNG 0.15 mg / EE 30µg categorized as new-starter or incident user"
2960562|NCT02828904||Secondary Cases|"Secondary cases are women~aged 15 to 49 years~with a new VTE diagnosis within the study period~using any HC other than CMA 2mg / EE 30µg or LNG 0.15 mg / EE 30µg, or not using any HC at all"
2960563|NCT02828904||Primary Controls|"Primary controls are women~aged 15 to 49 years~matched to a primary case by age (+/- 1 year) and region of residence~current or recent past user of CMA 2mg / EE 30µg or LNG 0.15 mg / EE 30µg categorized as new-starter or incident user"
2960564|NCT02828904||Secondary Controls|"Secondary controls are women~aged 15 to 49 years~matched to a primary case by age (+/- 1year) and region of residence~current or recent past user of other COCs (not containing CMA 2mg / EE 30µg or LNG 0.15 mg / EE 30µg)"
2960565|NCT02828891|Experimental|Experimental|Intervention: transcranial Doppler device will be utilized to measure CSF pressure.
2960566|NCT02828878|Experimental|ApoGraft|ApoGraft is a mobilized peripheral blood cell (MPBC) product derived from peripheral blood. There will be 4 cohorts, each differ in the amount of apoptotic mediator Fas Ligand (APO010) to which the graft is exposed during incubation prior to ApoGraft transplant, ranging from 10 ng/ml APO010 in Cohort 1, 25 ng/ml APO010 in Cohort 2, 50 ng/ml APO010 in Cohort 3, and 100 ng/ml APO010 in Cohort 4
2960567|NCT02828865|Experimental|irreversible electroporation (IRE)|irreversible electroporation (IRE) (AngioDynamics, NY) To use 2 to 6 unipolar electrodes of IRE in a predetermined grid pattern. 90 pulses of 2,000 - 3,000 V were applied with a pulse generator (AngioDynamics, NY) across the gap between the electrodes for 100 microseconds (0.1 msec) per each ablation.
2960568|NCT02828852|Experimental|Pregnancy|Blood sample
2960569|NCT02828852|Experimental|No pregnancy|Blood sample
2960570|NCT02828839|Experimental|Treatment Arm|Subjects will receive standard of care prostate biopsies through the use of a trans-rectal ultrasound probe for needle placement and guidance. The intervention for all patients receiving a prostate biopsy will include the use of an investigational single use, disposable stainless steel access needle and a single use, disposable polymeric needle guide.
2960571|NCT02828826|Experimental|telephone coaching|"Patients randomized to the experimental group will benefit from the telephone coaching , with 5 phone calls programmed by the physiotherapist according to the most convenient times for the patient, due to appointments per month.~The telephone coaching conducted by the physiotherapist with patients is to assess the number of exercises performed, the number of falls may have occurred, assess the fear of falling and overall assessment of the patient's general condition and a self-assessment of their physical ability (one leg balance, fear of falling, FTSST). With this information, the therapist may encourage patients to practice more diligently exercises can even strengthen the practice of some based on its evaluation.~Data from the telephone coaching will be recorded in the eCRF."
2960572|NCT02828826|No Intervention|Without telephone coaching|
2960573|NCT02828813||Normal|healthy subjects
2960574|NCT02828813||CogImpair|persons with cognitive impairments
2960575|NCT02828813||MotorDeficits|persons with motor deficits
2960576|NCT02828787|Experimental|Urticaria|15 patients with urticaria
2960577|NCT02828787|Experimental|Psoriasis|15 patients with psoriasis
2960578|NCT02828787|Other|healthy|15 healthy control subjects
2960579|NCT02828761|Experimental|Coronary Calcium Scoring|Coronary calcium scoring by multidetector row computed tomography (MDCT).
2960580|NCT02828761|Active Comparator|Standard Care|Standard evaluation of chest pain patient which often includes immediate non-invasive imaging.
2960581|NCT02828748|Experimental|active UC|patients with clinically active ulcerative colitis undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
2960582|NCT02828748|Experimental|remission UC|patients with clinically non active ulcerative colitis undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
2960583|NCT02828748|Experimental|active CD|patients with clinically active crohns disease undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
2960584|NCT02828748|Experimental|remission CD|patients with clinically non active crohns disease undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
2960585|NCT02828735|Other|Respiration assessment|
2960586|NCT02828722|Experimental|Controlled light, noise and nutrition|Simultaneously with the standard treatment performed at the clinical trial site environmental simulation of night time and daytime alternation as well as the nutrition protocol corresponding to the daily rhythm will be applied.
2960587|NCT02828722|Experimental|Controlled light and noise|Simultaneously with the standard treatment performed at the clinical trial site environmental simulation of night time and daytime alternation as well as the continuous nutrition (in accordance with the clinical trial site's standard practice) will be applied.
2960588|NCT02828722|No Intervention|Control|The treatment of the study subject will be performed based on the clinical trial site's standard practice without environmental simulation or changes in the nutrition protocol.
2960589|NCT02828709|Experimental|Irreversible electroporation (IRE)|"IRE is based on high current electric pulses, transferred between two or more placed needle electrodes. Charging the cell membrane causes holes in the cell membrane called nanopores, resulting in increased permeability of the cell and subsequent cell death."
2960590|NCT02828696|Other|No prep|"No prep treatment of worn dentition with CAD-CAM composite (PICN)"
2960591|NCT02828683|Experimental|Ultimaster, Drug Eluting Stent|Primary PCI in patients with ST segment elevation myocardial infarction with a new Drug Eluting Stent, Ultimaster
2960592|NCT02828683|Active Comparator|Kaname, Bare metal stent|Primary PCI in patients with ST segment elevation myocardial infarction with a Bare Metal Stent - Kaname
2960593|NCT02828670||patient|
2960594|NCT02828670||control|
2960595|NCT02828644|Active Comparator|EVO Multitasking|EVO Multitasking is a digital intervention that requires subjects to navigate a character through a game-like space, while collecting objects, in a fixed period of time. The intervention was administered to the subjects during the parent study (Akili-001R)
2960596|NCT02828644|Active Comparator|EVO Words|EVO Words is a digital intervention that requires subjects to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time. The intervention was administered to the subjects during the parent study (Akili-001R)
2960597|NCT02828631|Active Comparator|Macintosh laryngoscope|Nasotracheal intubation by Macintosh laryngoscope
2960598|NCT02828631|Experimental|McGrath videolaryngoscope|Nasotracheal intubation by McGrath videolaryngoscope
2960599|NCT02828631|Experimental|Pentax videolaryngoscope|Nasotracheal intubation by Pentax videolaryngoscope
2960600|NCT02828618|Active Comparator|Arm I PDS and chemotherapy|PDS with maximum effort to achieve the goal of complete gross resection then followed by 6 cycles of standard chemotherapy
2960601|NCT02828618|Experimental|Arm II Timing of surgery after 3 cycles of SOC CTX|3 cycles of standard NACT followed by IDS with maximum effort to achieve the goal of complete gross resection followed by 3 more cycles (for a total of 6) of standard chemotherapy
2960602|NCT02828605|No Intervention|Control Group|Only receive surveys.
2960603|NCT02828605|Experimental|Experimental Group|Receive VIP Transplant App and surveys.
2960604|NCT02828592|Experimental|Flu/Cy/TBI|Fludarabine, Cyclophosphamide, TBI followed by bone marrow transplantation. Post-transplant Cyclophosphamide will be on Days 3 & 4.
2960605|NCT02828579||Group 1|Patient with morbid obesity defined as a BMI above 40kg/m2 or 35kg/m2 with comorbidities who are qualified for bariatric surgery.
2960606|NCT02828566|Experimental|IN ketamine and IV saline|Ketamine, single dose, 10 mg/kg (0.1 mL/kg) of 100 mg/mL solution delivered intranasally using an atomizer and divided to both nares to a maximum of 800 mg (8 mL) AND 0.9% normal saline (NS) 0.02 to 0.03 mL/kg delivered intravenously to a maximum of 2.4 mL
2960607|NCT02828566|Active Comparator|IV ketamine and IN saline|Ketamine, single dose, 1 to 1.5 mg/kg (0.02 to 0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 120 mg (2.4 mL) AND 0.9% normal saline (NS) 0.1 mL/kg delivered intranasally using an atomizer and divided to both nares, to a maximum of 8 mL
2960608|NCT02828553||Control Group - Usual Care|At the start of the study, subjects will be enrolled in usual care when admitted to the heart failure unit following standard protocols.
2960609|NCT02828553||Intervention Group - Aggressive Ambulation|After a washout period and transition to a new aggressive ambulation protocol, subjects will be enrolled to usual care + aggressive planned ambulation with a trained mobility aide.
2960610|NCT02828540|Experimental|HT047 High-dose group|three times a day dosing schedule 3 tablets per dose
2960611|NCT02828540|Experimental|HT047 Low-dose group|three times a day dosing schedule 3 tablets per dose
2960612|NCT02828540|Placebo Comparator|Placebo|three times a day dosing schedule 3 tablets per dose
2960613|NCT02828501|Experimental|Lumbar manipulation group|Spinal Manipulation
2960614|NCT02828501|Experimental|Cervical manipulation group|Spinal Manipulation
2960615|NCT02828501|No Intervention|Control group|This group will receive a 2 minute supine rest between measurements
2960616|NCT02828475||CALYPSO-augmented|Patients' postoperative care will be augmented with the CALYPSO platform.
2960617|NCT02828475||Historical Control|Patients' postoperative care was performed using standard practice, before adopting the CALYPSO platform
2960618|NCT02828462||Experimental|Patients using the device
2960619|NCT02828462||Control|Patients not using the device
2960620|NCT02828449|Experimental|therapeutic education program|therapeutic education program which aims is to improve the adherence to the treatment and management of adverse effects of this treatment in patients taking an oral chemotherapy for active cancer
2960622|NCT02828436|Other|Exercise Intervention|If subject cannot tolerate Spinal Cord stimulation they will be assigned this arm
2960623|NCT02828423|Active Comparator|Control group|Regeneration therapy of non-contained intrabony defects with enamel matrix derivate (EMD) alone
2960624|NCT02828423|Experimental|Test group|Regeneration therapy of non-contained intrabony defects with enamel matrix derivate (EMD) and Biphasic Calcium phosphate (BC)
2960625|NCT02828410|Experimental|SBI|Serum bovine immunoglobulin protein isolate (SBI)
2960626|NCT02828397|Experimental|Reference Drug|REGN2222 Reference Formulation
2960627|NCT02828397|Experimental|Test Drug|REGN2222 Test Formulation
2960628|NCT02828384|Active Comparator|low fodmap diet|Subjects receive formalized teaching in low fodmap diet by a dietician
2960629|NCT02828384|Active Comparator|psyllium|subjects receive 7.1 g of psyllium daily
2960630|NCT02828371|Experimental|Erigo|Single daily sessions of verticalization, using a tilt table with an integrated robotic stepping device (Erigo. Hocoma AG, Switzerland) located in the ICU room. Sessions were performed five times per week (Monday-Friday) for three consecutive weeks (a total of 15 sessions per patient). On the same days the patients received conventional physiotherapy for 30 minutes a day. Before the verticalization period the experimental group received conventional in-bed physiotherapy for 60 minutes a day.
2960631|NCT02828371|Active Comparator|Conventional|treated with conventional in-bed physiotherapy for 60 minutes a day, from Monday to Friday, throughout the ICU stay.
2960632|NCT02828358|Experimental|Treatment (azacitidine, combination chemotherapy)|See Detailed Description
2960633|NCT02828332|Other|Patient with autism disorder|Interview with a psychologist who do Vineland II (VABS -II) and evaluate Quality of life and comorbidities
2960634|NCT02828319|Experimental|Z-213|
2960635|NCT02828306||Patients with skull defects|Patients with skull defects after craniotomy for example tumor resection, head trauma, stroke which need a Patient Specific Implant.
2960636|NCT02828293||GMK Sphere|Patients who underwent total knee replacement using GMK Sphere implants. Patients underwent surgery before the inclusion in the study.
2960637|NCT02828293||GMK PS Fixed Bearing|Patients who underwent total knee replacement using GMK PS Fixed Bearing implants. Patients underwent surgery before the inclusion in the study.
2960638|NCT02828293||GMK UC Fixed Bearing|Patients who underwent total knee replacement using GMK UC Fixed Bearing implants. Patients underwent surgery before the inclusion in the study.
2960639|NCT02828280||NuMask|Pt's randomized to Numask first will be ventilated for 10 breaths with the NuMask device first, followed by 10 breaths with the traditional face mask
2960640|NCT02828280||Traditional mask|patients randomized to traditional mask first will receive 10 breaths by traditional mask, followed by 10 breaths with NuMask
2960641|NCT02828267|No Intervention|Usual Care|In the Usual Care arm, patients will have standard discharge information and instructions without any further health or wellness instruction
2960642|NCT02828267|Experimental|BNI|In the BNI arm, patients will receive a 5-10 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions.
2960643|NCT02828241|Experimental|DFD-04 Ointment|DFD-04 (Itraconazole) Ointment
2960644|NCT02828241|Placebo Comparator|Placebo Ointment|Placebo Ointment
2960645|NCT02828228|Experimental|Vitamin D 1200 IU|Supplementation with vitamin D (1200 IU) once a day for 26 weeks
2960646|NCT02828228|Placebo Comparator|Placebo|Placebo once a day for 26 weeks
2960647|NCT02828189|Active Comparator|Physical Exercise|"The protocol consists in:~Physical Exercise according to their preferences.~Therapeutic Education related to Health Habits and Physical Exercise."
2960648|NCT02828189|Experimental|Therapeutic Exercise-Physiotherapy|"The protocol consists in:~15 minutes of Exercise in Step.~Force-Resistance Exercises of the principals muscle groups of the lower limbs, upper limbs and trunk.~Muscle Stretches.~Therapeutic Education related to Health Habits and Physical Exercise."
2960649|NCT02828163|Experimental|Autologous Platelet rich plasma|Autologous platelet-rich plasma (PRP) is autologous plasma that has platelet concentration above the baseline. 1 millilitre of autologous platelet-rich plasma will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
2960650|NCT02828163|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide is an effective treatment for oral erosions of pemphigus vulgaris patients. 10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
2960651|NCT02828150|Experimental|Parenteral nutrition|Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements
2960652|NCT02828137||Low NLR group|Neutrophil-to-Lymphocyte (NLR) Ratio < 1.78
2960653|NCT02828137||Intermediate NLR group|1.78 < Neutrophil-to-Lymphocyte (NLR) Ratio < 3.90
2960654|NCT02828137||High NLR group|Neutrophil-to-Lymphocyte (NLR) Ratio > 3.90
2960655|NCT02828124|Experimental|Dose Escalation Monotherapy|
2960656|NCT02828124|Experimental|Dose Expansion Monotherapy|
2960657|NCT02828124|Experimental|Dose Escalation Combination Therapy|
2960658|NCT02828124|Experimental|Dose Expansion Combination Therapy|
2960659|NCT02828111|Experimental|patidegib gel 2% - cohort 1|Patient will be randomized to either patidegib gel 2% or vehicle once daily for 12 weeks in Cohort 1.
2960660|NCT02828111|Experimental|patidegib gel 4% - cohort 2|Patient will be randomized to either patidegib gel 4% or vehicle once daily for 12 weeks in Cohort 2.
2960661|NCT02828111|Placebo Comparator|vehicle - cohort 1|Cohorts 1: patient will be randomized to either patidegib gel or vehicle once daily for 12 weeks.
2960662|NCT02828111|Experimental|patidegib gel 2% - cohort 3|Patient will be randomized to either patidegib gel 2% or vehicle twice daily for 12 weeks in Cohort 3.
2960663|NCT02828111|Experimental|patidegib gel 4% - cohort 4|Patient will be randomized to either patidegib gel 4% or vehicle twice daily for 12 weeks in Cohort 4.
2960664|NCT02828111|Placebo Comparator|vehicle - cohort 2|Cohorts 2: patient will be randomized to either patidegib gel or vehicle once daily for 12 weeks.
2960665|NCT02828111|Placebo Comparator|vehicle - cohort 3|Cohorts 3: patient will be randomized to either patidegib gel or vehicle twice daily for 12 weeks.
2960666|NCT02828111|Placebo Comparator|vehicle - cohort 4|Cohorts 4: patient will be randomized to either patidegib gel or vehicle twice daily for 12 weeks.
2960667|NCT02828098|Experimental|Part 1: BO-112 IT|BO-112 dose 1 (starting dose) intratumoral injection. BO-112 dose 2, 3 and 4 are expected to be tested, upon confirmation of the safety profile of the starting dose.
2960668|NCT02828098|Experimental|Part 2: BO-112 IT|"Combination treatment of BO-112 intratumoral injections with standard of care nivolumab intravenous treatment~Or Combination treatment of BO-112 intratumoral injections with standard of care pembrolizumab intravenous treatment"
2960669|NCT02828085|Other|Infective Pericarditis|In patient prescribed with a pericardite kit for an etiological diagnosis of a pericardial syndrome, an additional nasal swab will be performed in order to perform a specific diagnosis with PCR technique.
2960670|NCT02828072|Experimental|Sky|Sky treatment foe 15 days
2960671|NCT02828072|Sham Comparator|control|standard medical therapy
2960672|NCT02828046|Placebo Comparator|Placebo|Placebo
2960673|NCT02828046|Experimental|M281|M281
2960674|NCT02828033|Experimental|Rilonacept|A loading dose of 320 mg the first dose then be a once-weekly injection of 160 mg for 24 weeks
2960675|NCT02828020|Experimental|Ubrogepant 50 mg|1 ubrogepant 50 mg tablet and 1 placebo-matching ubrogepant tablet orally for treatment of a qualifying migraine attack. Participants may receive a second dose 2 hours after initial treatment if applicable.
2960676|NCT02828020|Experimental|Ubrogepant 100 mg|2 ubrogepant 50 mg tablets orally for treatment of a qualifying migraine attack. Participants may receive a second dose 2 hours after initial treatment if applicable.
2960677|NCT02828020|Placebo Comparator|Placebo|2 placebo-matching ubrogepant tablets orally for treatment of a qualifying migraine attack. Participants may receive a second dose 2 hours after initial treatment if applicable.
2960678|NCT02828007|Experimental|Treatment/Intervention|Each patient will be using Non Invasive Ventilation (NIV) and will use it on each possible ventilation mode in a random order with a 10 minutes washout period between modes.
2960679|NCT02827994|Experimental|Education and exercise|The intervention included neurophysiology of pain education and exercises.
2960680|NCT02827994|No Intervention|No intervention|This group received no intervention as participants were students that were not seeking treatment for their pain.
2960681|NCT02827968|Experimental|KN035|Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1, 2.5, 5 and 10 mg/kg weekly.
2960682|NCT02827955|Experimental|bilateral thalamotomy radiosurgery|Gamma Knife radiosurgery bilateral
2960683|NCT02827942|Experimental|Dual therapy|Patients assigned to this group are treated with dual therapy with vonoprazan 20 mg bid and amoxicillin 500 mg tid for 1 week. The eradication rate attained with this regimen is measured.
2960684|NCT02827942|Active Comparator|Triple therapy|Patients assigned to this group are treated with the triple therapy with vonoprazan 20 mg bid, clarithromycin 200 mg bid and amoxicillin 750 mg bid for 1 week as the first line therapy or the triple therapy with vonoprazan 20 mg bid, metronidazole 250 mg bid and amoxicillin 750 mg bid for 1 week as the second line therapy. The eradication rates attained with these regimens are measured.
2960685|NCT02827929|Experimental|educated group|Subjects who is diagnosed as COPD or asthma by their physicians were recruited from 43 primary clinic and had been visiting each primary clinic over one year or more will be provided education of 3 times for one months about disease, inhaler use technics and action plans about exacerbation
2960686|NCT02827916|Experimental|All patients|Measure of painful neuropathy for al patients with thermotest and sudoscan Devices and Neuropathic Pain Symptom Inventory.
2960687|NCT02827903|Experimental|Group I|Metformin + Rosuvastatin, Dosing to Type II DM with Dyslipidemia
2960688|NCT02827903|Active Comparator|Group II|Metformin + placebo, Dosing to Type II DM with Dyslipidemia
2960689|NCT02827903|Active Comparator|Group III|Placebo + Rosuvastatin, Dosing to Type II DM with Dyslipidemia
2960690|NCT02827890|Experimental|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Januvia Tab. 100mg)*1T/day for 5 days, QD, PO.~Period 2: Treatment B(Januvia Tab. 100mg + Duvie Tab. 0.5mg)*1T/day for 5 dyas, QD, PO.~Each treatment period was separated by a washout period of at least 10 dyas."
2960691|NCT02827890|Experimental|Group 2(Treatment B/Treatment A)|"Period 1: Treatment B(Januvia Tab. 100mg + Duvie Tab. 0.5mg)*1T/day for 5 dyas, QD, PO.~Period 2: Treatment A(Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO.~Each treatment period was separated by a washout period of at least 10 dyas."
2960692|NCT02827877|Experimental|Treatment (trastuzumab, copper Cu 64-DOTA-trastuzumab PET)|Patients receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV on day 0. Patients undergo PET scans at 18-24 and 42-48 hours, on day 1 and day 2. Within 4 days after completion of PET scans, patients receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks and pertuzumab IV over 30-60 minutes. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after 6 courses of trastuzumab and pertuzumab.
2960693|NCT02827864|Experimental|sequentially apply tDCS and MT|The participants in the SEQ group will first receive a-tDCS applied over M1 lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.
2960694|NCT02827864|Experimental|apply tDCS concurrently|"For the participants in the CON group, sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS.~Similar to the SEQ group, the participants will also practice functional tasks for 30 minutes after MT."
2960695|NCT02827864|Sham Comparator|MT with sham tDCS|For the SHAM group, the training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
2960696|NCT02827851|Experimental|SVF injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate stromal vascular fraction of cells (SVF). After SVF isolation autologous cells suspension will be injected intraarticularly into knee joint.
2960697|NCT02827838|Experimental|Treatment (durvalumab, surgery)|Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.
2960698|NCT02827812|Experimental|Participants Telemedicine Care (PTE)|"A. Comprehensive evaluation at baseline (T0) and at the end of the study (T1).~B. Physical Intervention at home for 60 minutes 3 days/week for three months~C. Home-Based telemedicine program:"
2960699|NCT02827812|Active Comparator|Participants Usual Care (PUC)|"A. Comprehensive evaluation at baseline (T0) and at the end of the study (T1).~B. Physical Intervention at home for 60 minutes 3 days/week for three months"
2960700|NCT02827799|Placebo Comparator|Heart Failure Self-Management Education|This treatment includes participation in 4 one hour biweekly face-face sessions of education on heart failure self-management, as well as a 15 minute telephone call on intervening weeks. The total intervention is 8 weeks.
2960701|NCT02827799|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This treatment includes participation in 4 one hour biweekly face-face sessions of cognitive behavioral therapy for insomnia, as well as a 15 minute telephone call on intervening weeks. The total intervention is 8 weeks.
2960702|NCT02827786|Experimental|Electromagnetic Acoustic Imaging|
2960703|NCT02827773|Experimental|Received Talking Pill Bottles|Patients received anti-hypertensives over 90 day period in Talking Pill Bottle which contained summary of pharmacy counselling session.
2960704|NCT02827773|No Intervention|Usual Care|Patients received oral summary of pharmacy counselling session.
2960705|NCT02827760|Placebo Comparator|Maltodextrin DE19|Placebo
2960706|NCT02827760|Active Comparator|Prebiotic Synergy1|Effective prebiotic
2960707|NCT02827747|Placebo Comparator|Placebo with Dietary Sources of Vitamins|Persons assigned to placebo, who obtain Vitamins A, C, E and Glutathione from dietary sources alone, and have not been on oral RDA supplementation, in the 1 month leading up the time of enrollment and throughout the study period.
2960708|NCT02827747|Active Comparator|Antioxidants(Vitamins A,C,E) plus GSH, plus Centrum|Persons assigned to the study medication, and are continuing the take an oral RDA supplementation, in the form of Centrum.
2960709|NCT02827747|Active Comparator|Antioxidants (Vitamins A,C, E) plus GSH|Persons assigned to the study medication alone, without oral RDA supplementation in the 1 month leading up the time of enrollment and throughout the study period.
2960710|NCT02827747|Active Comparator|Placebo plus Centrum|Persons assigned to placebo, who have been on oral RDA supplementation, who would continue to do so throughout the study.
2960711|NCT02827734||interstitial lung disease|patients with known or suspected ILD such as idiopathic pulmonary fibrosis, non-specific interstitial pneumonia, sarcoidosis, granulomatosis with polyangiitis
2960712|NCT02827734||pulmonary healthy controls|patients without known or suspected pulmonary disease
2960713|NCT02827721||COPD|Patients with known or suspected COPD Patients with known or suspected obstructive ventilation disorder
2960714|NCT02827721||pulmonary healthy controls|Patients without known or suspected pulmonary disease
2960715|NCT02827708|Experimental|Semaglutide|
2960716|NCT02827708|Placebo Comparator|Placebo|
2960717|NCT02827695|Experimental|SMASK|Subjects will receive electronic pill tray with reminder functions activated and Bluetooth blood pressure monitor and phone app.
2960718|NCT02827695|Other|EnhancedSC|Subjects will receive daily attention control texts with healthy lifestyle information and continue to use the pill tray without reminder functions.
2960719|NCT02827682|Experimental|study group|Using Angel-6000D Multiparameter Anesthesia Monitor to maintain the Hemodynamic stability during surgery. Keep IoC1 40 to 60 while IoC2 30-50.Target concentration of propofol was decreased by 0.5 μg/ml per adjustment when IoC1<40, with a maintenance value between 40 and 60. The target concentration of remifentanil was increased by 1 ng/ml per adjustment when IoC2>50 but was decreased by 1 ng/ml per adjustment when IoC2<30, with the maintenance value between 30 and 50.
2960720|NCT02827682|Placebo Comparator|control group|Using BIS VISTA Monitor to maintain the Hemodynamic stability during surgery. Keep BIS 40 to 60.The doses of propofol and remifentanil were adjusted by the anesthetists according to BIS. Target concentration of propofol was decreased by 0.5 μg/ml per adjustment when BIS<40, with a maintenance value between 40 and 60. The target concentration of remifentanil was increased by 1 ng/ml per adjustment when BIS>60 but was decreased by 1 ng/ml per adjustment when BIS<40, with the maintenance value between 40 and 60.
2960721|NCT02827669|Experimental|One Drop Experts Program|Participants will be able to use the One Drop mobile app and One Drop Experts program on their smartphones. The One Drop mobile app is a diabetes management platform that allows users to track and log their blood glucose levels, medications, food, and activities. One Drop Experts is a diabetes education and coaching program delivered entirely through the One Drop mobile application.
2960722|NCT02827669|Experimental|One Drop Experts Program + Apple Watch|An Apple Watch will be provided to study participants in this arm. In addition to using the One Drop mobile app and One Drop Experts program on their smartphones, participants will also be able to engage with the app and program on their Apple Watch.
2960723|NCT02827656|Experimental|Decapeptyl support|S.C single luteal Decapeptyl 0.1 mg on days 3, 6,9 post ovulation triggering
2960724|NCT02827656|Active Comparator|hCG luteal support|S.C single luteal S.C recombinant hCG 50 micrograms on days 3 ovulation triggering
2960725|NCT02827643|Active Comparator|TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement|Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study
2960726|NCT02827643|Other|TDF/3TC or FTC/EFV|the subjects in this arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.
2960727|NCT02827630|Active Comparator|DH-4|Subjects will use Proteus Discover, the digital health offering (DH) for 4 weeks
2960728|NCT02827630|Active Comparator|DH-12|Subjects will use Proteus Discover, the digital health offering (DH) for 12 weeks
2960729|NCT02827630|Other|Usual Care|Subjects received usual medical care including all normal interventions such as medication titration, adherence counseling, lifestyle coaching, and additional clinic visits per their providers' discretion.
2960730|NCT02827617||TP53 mutated CLL|
2960731|NCT02827578|Experimental|Tamsulosin + Solifenacin|Tamsulosin and Solifenacin
2960732|NCT02827578|Active Comparator|Tamsulosin + Solifenacin Placebo|Tamsulosin and Solifenacin placebo
2960733|NCT02827565|Experimental|CircuLOR-1|KRAS (exons 2, 3 et 4), NRAS (exons 2, 3 et 4) and BRAF (exon 15) mutations
2960735|NCT02827539|Other|Research|If the patient is randomized to the Research Arm, the physician will begin the procedure utilizing LessRay enhanced fluoroscopic images.
2960736|NCT02827539|Other|Control|For patients in the control arm standard fluoroscopy will be used with the C-arm set to the conventional full dose setting
2960737|NCT02827526|Active Comparator|Ketamine|Patients in the ketamine arm will receive an intraoperative and postoperative infusion of ketamine
2960738|NCT02827526|Placebo Comparator|Control|Patients in the control arm will receive an intraoperative and postoperative infusion of dextrose
2960739|NCT02827513|Experimental|Arm 1|Participants will receive sustained release (SR) Tablet Formulation 1 (SR1) containing 100 mg of Centanafadine (CTN) (2 x 100 mg tablets taken orally by mouth [PO] in the morning at starting at approximately 7 am and 2 x 100 mg tablets PO 5 hours later) for a total daily dose (TTD) of 400 mg on Days 1, 4, 7, and 10.
2960740|NCT02827513|Experimental|Arm 2|Participants will receive extended release (XR) Tablet Formulation 1 (XR1) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
2960741|NCT02827513|Experimental|Arm 3|Participants will receive XR Tablet Formulation 2 (XR2) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
2960742|NCT02827513|Experimental|Arm 4|Participants will receive XR Tablet Formulation 3 (XR3) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
2960743|NCT02827500|Active Comparator|ivabradine|Active Comparator: ivabradine
2960744|NCT02827500|Placebo Comparator|usual care|Placebo Comparator: usual care
2960745|NCT02827487|Active Comparator|Tramadol|Women will receive oral Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) and an oral placebo similar to Celecoxib 2 hours before IUD insertion.
2960746|NCT02827487|Active Comparator|Celecoxib|Women will receive oral Celecoxib 200mg (Celebrex® 200, Pfizer, USA) and an oral placebo similar to Tramadol 2 hours before IUD insertion.
2960747|NCT02827487|Placebo Comparator|Placebo 1|Women will receive a placebo similar to Tramadol and a placebo similar to Celecoxib orally 2 hours before IUD insertion.
2960748|NCT02827474||Patient Participants|Patient participants will participate in two patient interviews.
2960749|NCT02827474||Physician Participants|Provider participants will participate in one provider interview.
2960750|NCT02827461||MZ|Monozygotic twins
2960751|NCT02827461||DZ|Dizygotic twins
2960752|NCT02827435|Experimental|Rocuronium bolus|rocuronium bromide 1st bolus 0.1mg/kg, rocuronium bromide 2nd bolus 0.4mg/kg
2960753|NCT02827409|Active Comparator|Short Delay Cord Clamping|Subject will have umbilical cord clamped and cut by 1 minute of life.
2960754|NCT02827409|Active Comparator|Extended Delay Cord Clamping|Subject will have umbilical cord clamped and cut after at least 5 minutes of delayed cord clamping. Duration of cord clamping after 5 minutes will depend on if the subject is breathing and/or if the cord has stopped pulsating
2960755|NCT02827396|Experimental|Psycho-social intervention|Experimental group: The intervention group will get Psycho social Training Intervention which will be developed during the third phase of the study.
2960756|NCT02827396|No Intervention|TAU intervention|Wait-list (controlled) group: The waiting list (control) group will continue getting the general health education (TAU) that is done at disability clinics in the existing sites.
2960757|NCT02827383|Experimental|Stair Climbing 4x/day|Participants use the stair climber 4 times per day, for 4 minutes at a time. Total dose = 16 minutes.
2960758|NCT02827383|Experimental|Stair Climbing 8x/day|Participants use the stair climber 8 times per day, for 2 minutes at a time. Total dose = 16 minutes.
2960759|NCT02827370|Experimental|Precision Nutrition (dietary intervention)|During chemotherapy, patients will receive dietary counseling based on the molecular pathways driving their specific breast cancers found through genetic testing. Nutritional recommendations will seek to down-regulate the dominant molecular drivers of an individual's breast cancer while they are receiving standard chemotherapy as outlined by their treating medical oncologist.
2960760|NCT02827344||Stage IV non-small cell lung cancer|"Intervention to be done are :~- Blood sample collection for CTC and MDSC analysis"
2960761|NCT02827331||Patients exposed to benzodiazepines|"Data to be collected are :~Administrative and medical data~Exposition to hypnotics or anxiolytics benzodiazepines"
2960762|NCT02827331||Patients not exposed to benzodiazepines|"Data to be collected are :~Administrative and medical data~Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics"
2960763|NCT02827331||Control group|"Data to be collected are :~Administrative and medical data~Medical consultation without prescription of interest"
2960764|NCT02827318|Active Comparator|75g glucose|75g of glucose dissolved in 500ml provided in a clear plastic tumbler.
2960765|NCT02827318|Experimental|75g isomaltulose|75g of isomaltulose dissolved in 500ml provided in a clear plastic tumbler.
2960766|NCT02827318|Placebo Comparator|Sweetened water|500ml water sweetened with sucralose provided in a clear plastic tumbler.
2960767|NCT02827305|Experimental|group 1|scaling and Gotukola mouthwash intervention- 1.Scaling 2.Gotukola mouthwash , 10ml twice daily to be rinsed for 60 seconds
2960768|NCT02827305|Active Comparator|group 2|Scaling
2960769|NCT02827305|Active Comparator|group 3|Intervention- Gotukola mouthwash only is advised to be used two times a day, each time 10ml rinsed for 60 seconds (morning and evening ) after the food.
2960770|NCT02827292|Experimental|Laparoscopic Surgery without music|Intervention: Headphones without music (Silent). A headphone will be applied peroperatively but no music will be played. Blood samples to assess the biomolecular inflammatory response and the post operative monitoring will be done as per the protocol.
2960771|NCT02827292|Experimental|Laparoscopic Surgery with music|Intervention: peroperative music via head phones. A headphone will be applied peroperatively and music will be played for the entire duration of the surgical procedure. Blood samples to assess the biomolecular inflammatory response and the post operative monitoring will be done as per the protocol.
2960772|NCT02827279|Other|Patients|Mesure of emotional induction by eye tracking on Patient with Pervasive Developmental Disorders (PDD)
2960773|NCT02827279|Other|Healthy volunteers|Mesure of emotional induction by eye tracking on People without disorders
2960774|NCT02827266|Experimental|Epoetin beta|Participants will receive epoetin beta over an 8-week correction phase and a 4-week extension or continuation phase, for a total exposure of up to 12 weeks.
2960775|NCT02827253||Predialysis|Patients with CKD (4 and 5 stages by KDOQI guidelines) underwent MRI to obtain in vivo images of brain anatomy that were subsequently analyzed by the data processing package FreeSurfer (version 5.3). A MRI 6 months after starting haemodialysis will be performed to analyze changes in gray and white matter of the brain.
2960776|NCT02827253||Haemodialysis|Patients with end stage of renal disease (ESRD) in haemodialysis underwent MRI to obtain in vivo images of brain anatomy that were subsequently analyzed by the data processing package FreeSurfer (version 5.3). A one year follow up MRI will be performed to analyze the changes in gray and white matter of the brain.
2960777|NCT02827240|Experimental|Direct Distribution|The direct distribution arm consists of peer educators directly distributing HIV self-test kits to participants. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
2960778|NCT02827240|Experimental|Fixed Distribution|The fixed distribution arm consists of peer educators distributing coupons to participants. The participants can then use the coupon to collect an HIV self-test kit at a participating distribution point, including drug stores, pharmacies, and health posts. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
2960779|NCT02827240|No Intervention|Referral to Existing Services|Peer educators will not provide HIV self-tests to participants. Peer educators will only provide referral to existing services for HIV testing.
2960780|NCT02827227||Primary HIV- Infected patients|Primary HIV- Infected patients with a minimum of 2 years of effective cART.
2960781|NCT02827214||Surgical treatment|"Several surgical treatments exist to treat the fractures included in the study. The following section describes the different surgical treatment modalities in more detail~Approaches:~Open short segment surgical fixation (1 level above and below the fracture level) with or without posterior decompression~Open long segment posterior fixation (2 or more levels above, 2 or more levels below) with or without posterior decompression~Posterior short or long fixation with posterolateral corpectomy and reconstruction~Anterior alone instrumentation~Combined Anterior Posterior (AP) instrumentation~Percutaneous posterior fixation combined with anterior instrumentation~Percutaneous posterior fixation with or without vertebroplasty"
2960782|NCT02827214||Non-surgical treatment|"Non-surgical treatment is defined as bed rest followed by immobilization with:~Custom-molded or prefabricated total body contact thoracolumbosacral orthosis (TLSO)~Thermoplastic removable brace~Jewett hyperextension braces~Anterior hyperextension brace (ASH)~Taylor-Knight brace~Plaster of Paris (POP)"
2960783|NCT02827201|Experimental|nab-paclitaxel + gemcitabine/FOLFIRI.3|"Alternance of :~2 months with nab-paclitaxel (125 g/m² - 30 min in IV) + gemcitabine (1000 mg/m², 30 min in IV, 3 injections follow by 1 week free)~follow by 2 months with FOLFIRI.3 (irinotecan: 90 mg/m² at D1, acid folinic 400 mg/m², 5Fu continus: 2000 mg/m² IV 46 hours, and irinotecan at D3, 90 mg/m²) This alternance continus until progression"
2960784|NCT02827201|Active Comparator|nab-paclitaxel + gemcitabine|nab-paclitaxel (125 g/m² - 30 min in IV) + gemcitabine (1000 mg/m² - 30 min in IV) 3 injections follow by 1 week free, until progression
2960785|NCT02827188|Experimental|Treatment group|Subjects randomly assigned to this arm will train on the Mega Team game.
2960786|NCT02827188|No Intervention|Control-waitlist group|Subjects randomly assigned to this arm will be the wait-list group. They are allowed to play the video games that they usually play.
2960787|NCT02827175|Experimental|fevers of the travelers|
2960788|NCT02827162||Case D1|Subject having experienced a Virologically confirmed dengue infection, from the first injection until the end of the active phase, excluding Case D3 subjects
2960789|NCT02827162||Case D3|Subject having experienced a Virologically confirmed dengue infection, from 28 days after the third injection until the end of the Active Phase of the proof of concept (PoC) efficacy study
2960790|NCT02827162||Control I|Subject having not experienced a Virologically confirmed dengue infection in the Active Phase of the PoC efficacy study, and belonging to the PoC efficacy study immunogenicity subset
2960791|NCT02827162||Control E|Subject having not experienced a Virologically confirmed dengue infection in the Active Phase of the PoC efficacy study, and not belonging to the PoC efficacy study immunogenicity subset
2960792|NCT02827136|Experimental|Patch group|Lidocaine patch and Hypafix
2960793|NCT02827136|Placebo Comparator|Control group|Just Hypafix
2960794|NCT02827123|Experimental|Mcgrath group|Orotracheal intubation with McGrath MAC videolaryngoscopy
2960795|NCT02827123|Placebo Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscopy
2960796|NCT02827110|Active Comparator|fiberoptic bronchoscope|Tracheal intubation in patients with semi-rigid collar immobilization of the cervical spine using fiberoptic bronchoscope
2960797|NCT02827110|Experimental|fiberoptic bronchoscope with pentax-AWS|Tracheal intubation in patients with semi-rigid collar immobilization of the cervical spine using fiberoptic bronchoscope with pentax-AWS
2960798|NCT02827097|Experimental|Rectus sheath block group|"administration of denogan~rectus sheath block with 0.375% ropivacaine"
2960799|NCT02827097|Placebo Comparator|Control group|just administration of denogan
2960800|NCT02827084|Experimental|Kinesio Taping|Apply the Kinesio Taping with tension in the vatus mediallis
2960801|NCT02827084|Placebo Comparator|Placebo|Apply the Kinesio Taping without tension in the vatus mediallis
2960802|NCT02827084|No Intervention|Control|It will not apply Kinesio.
2960803|NCT02827071||Retina abnormalities|Subjects with various retina vascular disorders
2960804|NCT02827058|Experimental|G25 pencil point needle|healthy pregnant women who at (vaginal or cesarean section) delivery get spinal anesthesia administered with use of a 25 gauge pencil point needle
2960805|NCT02827058|Active Comparator|G27 pencil point needle|healthy pregnant women who at (vaginal or cesarean section) delivery get spinal anesthesia administered with use of a 27 gauge pencil point needle
2960806|NCT02827045||Depressive phase|Vestibular test
2960807|NCT02827045||Maniac phase|Vestibular test
2960808|NCT02827045||Euthimic phase|Vestibular test
2960809|NCT02827045||Healthy subject|Vestibular test
2960810|NCT02827032|Experimental|MobiusHD™|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
2960811|NCT02827006|Active Comparator|Bone graft|Bone graft from iliac crest as gapfiller
2960812|NCT02827006|Experimental|Calcium phosphate bone cement|CaP bone cement as gapfiller
2960813|NCT02826993|Experimental|CCE in incomplete Colonoscopies|Patients in which colonoscopy is not possible are invited for CT colonography and those patients are examined by Camera Capsule Endoscopy the day before the CT colonography and the two different examinations are compared.
2960814|NCT02826967|Experimental|Colonic Irrigation|A designated health professional will administer to the patient the colonic irrigation procedure -using the Hydro-San Plus colon therapy system, an FDA approved and ISO certified device for colonic irrigation and cleansing before endoscopic procedures (FDA #2027347).
2960815|NCT02826954||COPD patients|"Self administered questionnaires regarding sinonasal and lung symptoms, quality of life as well as symptoms of depression and anxiety.~Lower airway assessment using Spirometry with reversibility Upper airway assessment using Acoustic Rhinometry, Rhinomanometry and Peak nasal Inspiratory Flow Nasal biopsy using a nasal brush Nasal endoscopy Allergic prick-test"
2960816|NCT02826954||Healthy subjects|"Self administered questionnaires regarding sinonasal and lung symptoms, quality of life as well as symptoms of depression and anxiety.~Lower airway assessment using Spirometry with reversibility Upper airway assessment using Acoustic Rhinometry, Rhinomanometry and Peak nasal Inspiratory Flow Nasal biopsy using a nasal brush Nasal endoscopy Allergic prick-test"
2960817|NCT02826941|Experimental|Hypothermia|If randomized to hypothermia, plastic bags filled with ice wrapped in a washcloth were applied to the head and body for approximately 2 hours, then the infant was placed on an adult-size, water-circulating, cooling blanket (Cincinnati Sub-Zero Blanketrol II®, Cincinnati, OH), servo-controlled to rectal temperature to 33 ± 0.5 °C for 48 hours at the participating tertiary care center. Rewarming by 0.5°C per hour was begun after 48 hours of hypothermia.
2960818|NCT02826941|Placebo Comparator|Normothermia|If randomized to normothermia, rectal temperatures were maintained at 37 ± 0.5 °C per standard neonatal intensive care unit practice, using adult-size, water-circulating, cooling blanket (Cincinnati Sub-Zero Blanketrol II®, Cincinnati, OH), servo-controlled to rectal temperature of 37 ± 0.5 if baby was febrile.
2960819|NCT02826928|Experimental|patients with small-intestine neuroendocrine tumors|
2960820|NCT02826928|Experimental|control subjects with irritable bowel syndrome|
2960821|NCT02826902|Active Comparator|TIVA group|
2960822|NCT02826902|Active Comparator|Inhalation anesthesia group|
2960823|NCT02826889|Experimental|Fluid loading group|
2960824|NCT02826876|Placebo Comparator|Ropivacaine|Topical use of Ropivacaine
2960825|NCT02826876|Placebo Comparator|Placebo|Topical use of placebo
2960826|NCT02826863|Experimental|Experimental: ZX008 - 0.8 mg/kg/day|ZX008 is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
2960827|NCT02826863|Experimental|Experimental: ZX008 - 0.2 mg/kg/day|ZX008 is supplied as an oral solution in concentrations of 0.2 mg/kg/day ZX008 will be administered twice a day (BID) in equally divided doses with food.
2960828|NCT02826863|Placebo Comparator|Placebo Comparator: Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses with food.
2960829|NCT02826850|Sham Comparator|Genicular nerves|Neurotomy by radiofrequency of genicular nerves knee guided by fluoroscopy
2960830|NCT02826850|Active Comparator|Saphenous Nerve|Neurotomy of saphenous nerve by radiofrequency on the distal third of the thigh, guided by ultrasound
2960831|NCT02826837|Experimental|LEAC-102 and FOLFOX+Bevacizumab/Cetuximab|"The subjects will be administered folinic acid (Leucovorin; LV), Fluorouracil (5-FU) and Oxaliplatin (FOLFOX) + Bevacizumab/Cetuximab by intravenous infusion.~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)"
2960832|NCT02826798|Experimental|VBI-1501A: 0.5µg with adjuvant|
2960833|NCT02826798|Experimental|VBI-1501A: 1.0µg with adjuvant|
2960834|NCT02826798|Experimental|VBI-1501A: 2.0 µg with adjuvant|
2960835|NCT02826798|Experimental|VBI-1501: 1.0µg without adjuvant|
2960836|NCT02826798|Placebo Comparator|Placebo|Buffer/sucrose used for VBI-1501 suspension
2960837|NCT02826785|Experimental|Cognitive strategy training|The cognitive strategy training intervention consists of 6 weekly ~1 hour sessions. It is delivered in an individual, face-to-face format in the client's home. It is a behavioral intervention that teaches people metacognitive, problem-solving and other compensatory strategies to address self-identified cognitive performance problems, and it uses practice and homework to promote strategy learning, retention and transfer.
2960838|NCT02826772|Experimental|Phase 1 GT0918 level 1|generic name: not applicable dosage form: tablet dosage: oral dosage to be determined dosage frequency: daily dosage duration: 6 months
2960839|NCT02826772|Experimental|Phase 2 GT0918 level 1|generic name: not applicable dosage form: tablet dosage: oral dosage to be determined dosage frequency: daily dosage duration: 6 months
2960840|NCT02826759||serum sphingolipid metabolites in healthy subjects|Healthy subjects are classified according to BMI into three subgroups: healthy normal weight subjects, healthy overweight subjects and healthy subjects with obesity. Age and sex are matched among three subgroups. serum sphingolipid metabolites including sphingosine-1-phosphate will be compared.
2960841|NCT02826759||serum sphingolipid metabolites in diabetic subjects|Diagnosed diabetic patients are divided into three subgroups: diabetic patients with normal weight, overweight and obesity. age and sex are matched.
2960842|NCT02826759||serum sphingolipid metabolites in the progression of diabetes|serum sphingolipid metabolites are compared among three age-, sex- and body mass index-matched subgroups: healthy subjects, subjects with pre-diabetes, subjects with diabetes
2960843|NCT02826759||serum sphingolipid metabolites and HbA1c|diabetic subjects are divided by HbA1c level. the cut-offs are 7% and 9%. serum sphingolipid metabolites will be tested among diabetic patients with HbA1c <7%, 7%-9% and >9%
2960844|NCT02826759||serum sphingolipid metabolites in insulin-resistant subjects|comparison of serum sphingolipid metabolites in newly diagnosed insulin-resistant subjects and age-, sex- and BMI-matched healthy controls.
2960845|NCT02826746|Experimental|Magnesium group|intravenous administration of Magnesium Sulfate
2960846|NCT02826746|Placebo Comparator|Control group|intravenous administration of normal saline
2960847|NCT02826733||Normal|"Every child meet the age criteria and without ductus arteriosus persistence ultrasound or detectable neurological disorders after clinical, neurophysiological and radiological (ETF , Scanner, MRI).~EEG NIRS MRI"
2960848|NCT02826733||cerebral neurological disease|"Group of children meeting the criteria of age and having a detectable neurological disease after clinical, neurophysiological and radiological (ETF , Scanner, MRI) The children present either convulsions or a cerebrovascular accident or a neurological pain . Each condition being verified by a pathological electroencephalogram .~EEG NIRS MRI"
2960849|NCT02826720||HP+|Subjects with plasma Triglyceride or Total cholesterol levels > 200 mg/dl and low density lipoprotein-cholesterol levels > 130 mg/dl were included in the hyperlipidemic group and having periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
2960850|NCT02826720||HP-|Subjects with plasma Triglyceride or Total cholesterol levels > 200 mg/dl and low density lipoprotein-cholesterol levels > 130 mg/dl were included in the hyperlipidemic group and do not have periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
2960851|NCT02826720||NP+|Subjects with plasma Triglyceride or Total cholesterol levels < 200 mg/dl and low density lipoprotein-cholesterol levels < 130 mg/dl were included in the normolipidemic group and having periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
2960852|NCT02826720||NP-|Subjects with plasma Triglyceride or Total cholesterol levels < 200 mg/dl and low density lipoprotein-cholesterol levels < 130 mg/dl were included in the normolipidemic group and do not have periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
2960853|NCT02826707|Experimental|SPPAC intervention|Smartphone-delivered peer-led physical activity counselling
2960854|NCT02826707|No Intervention|Control group|Pragmatic no-contact control group
2960855|NCT02826694|Other|Well infant, whole exome sequencing|Healthy infants and their parents enrolled in the study prenatally will participate. After the infant is born saliva sample will be collected for DNA extraction and whole exome sequencing will be done.
2960856|NCT02826694|Other|Diagnosed, whole exome sequencing|Infants and children with diagnosed conditions whose parents enroll in the study and consent to having their child sequenced will have saliva samples obtained and whole exome sequencing will be done on extracted DNA.
2960857|NCT02826681|Active Comparator|Injectafer|750 mg undiluted slow IVpush (100 mg/minute) of Injectafer® (Ferric Carboxymaltose - FCM)
2960858|NCT02826681|Placebo Comparator|Normal Saline|Placebo (15 ml of Normal Saline [NS]) IV push at 2 ml/minute on Day 0 and 7.
2960859|NCT02826668|No Intervention|Control|Baseline ultrasound only, with no markings placed. No ultrasound prior to epidural placement.
2960860|NCT02826668|Experimental|Ultrasound|Baseline and pre-puncture ultrasound with markings placed.
2960861|NCT02826655|Active Comparator|Healthy Controls|Study participants will undergo imaging of both eyes with the WF-AO-OCT unit, per standard operating protocol. Imaging is noncontact. Study participants will undergo only a single imaging session on a single day.
2960862|NCT02826655|Experimental|Subjects with diabetic retinopathy|Study participants will undergo imaging of both eyes with the WF-AO-OCT unit, per standard operating protocol. Imaging is noncontact. Study participants will undergo only a single imaging session on a single day.
2960863|NCT02826642|Experimental|Arm 1: Medically fit for induction|IDH305 + Standard of care for patients that are medically fit for induction.
2960864|NCT02826642|Experimental|Arm 2 Medically unfit for induction|IDH305 + Standard of care for patients that are medically unfit for induction.
2960865|NCT02826629|Other|Schizophrenia|40 patients with diagnosis of schizophrenia (25 medicated - 15 non-medicated)
2960866|NCT02826629|Other|Healthy sibling|25 healthy siblings
2960867|NCT02826629|Other|Ultra high risk for developing Schizophrenia|15 patients with ultra high risk for developing Schizophrenia
2960868|NCT02826629|Other|Controls|-25 age and gender-matched healthy controls
2960869|NCT02826616|Experimental|Trimetazidine group|Trimetazidine 60 mg 30 min before PCI and 20 mg for 12 months after surgery
2960870|NCT02826616|No Intervention|The control group|placebo 60 mg 30 min before PCI and 20 mg for 12 months after surgery
2960871|NCT02826603|Experimental|Secukinumab|Secukinumab
2960872|NCT02826603|Active Comparator|Ustekinumab|Ustekinumab
2960873|NCT02826590|Experimental|Neck passive mobilizations|Neck passive mobilizations
2960874|NCT02826590|Placebo Comparator|Manual contact|Manual contact
2960875|NCT02826577|Active Comparator|Pregnenolone 175mg|- Single dose of 175mg
2960876|NCT02826577|Active Comparator|Pregnenolone 400mg|- Single dose of 400mg
2960877|NCT02826577|Placebo Comparator|Placebo|- Single dose of placebo
2960878|NCT02826577|No Intervention|Matched healthy controls|- No intervention
2960879|NCT02826564|Experimental|Sequential|Stereotactic body radiotherapy prior to pembrolizumab treatment
2960880|NCT02826564|Experimental|Concurrent|Stereotactic body radiotherapy concurrent with pembrolizumab treatment
2960881|NCT02826551|Placebo Comparator|No Injection|"These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction and will NOT be receiving a posterior capsular knee injection of Marcaine 0.5%.~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the INJECTION Arm of the study."
2960882|NCT02826551|Experimental|Injection|"These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction but will additionally be receiving a one-time posterior capsular knee injection of Marcaine 0.5% (20cc) during the surgery.~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the NO injection Arm of the study."
2960883|NCT02826538|Experimental|patient specific guides|fracture fixation with 3D planning and use of patient-specific instruments
2960884|NCT02826538|Active Comparator|standard procedure|standard procedure of fracture Fixation without 3D planning and without use of patient-specific instruments
2960885|NCT02826525|Experimental|Treatment|Subjects in this arm will receive AZD4076
2960886|NCT02826525|Placebo Comparator|Control|Subjects in this arm will receive placebo
2960887|NCT02826512|Experimental|Niraparib|niraparib 300 mg QD continuously
2960888|NCT02826499|Active Comparator|Fluoroscopy|Vertebral instrumentation with pedicular screwing, performed under fluoroscopy.
2960889|NCT02826499|Experimental|Fluoroscopy and Pediguard|Vertebral instrumentation with pedicular screwing, performed under fluoroscopy, with the Pediguard system.
2960890|NCT02826486|Experimental|BL-8040 plus pembrolizumab (Keytruda®)|"BL-8040 monotherapy 1.25 mg/kg subcutaneous(SC) injections daily on days 1-5 of week 1 of treatment.~Combination therapy period begins following monotherapy treatment and consists of repeated 3 week long cycles of 200 mg pembrolizumab administered by intravenous infusion (IV) on day 1 of each cycle plus SC injections of BL-8040 1.25 mg/kg three times a week on non-consecutive days."
2960891|NCT02826473|Experimental|Intervention-Group|
2960892|NCT02826473|No Intervention|Control-Group|
2960893|NCT02826460||Liver Transplant Recipients|
2960894|NCT02826447||Patients|500 patients who are going to be hospitalized for at least 24 hours at Ain Shams University Teaching Hospital in the following departments: surgery, internal medicine, gynecology/obstetrics and toxicology.
2960895|NCT02826447||Healthcare workers|50 healthcare workers working at Ain Shams University Teaching Hospital in the following departments: surgery, internal medicine, gynecology/obstetrics and toxicology.
2960896|NCT02826434|Experimental|PVX-410 and Durvalumab|"Each patient will receive 6 PVX-410 vaccine injections and 2 infusions of Durvalumab.~The injection of PVX-410 will be co-administered with Hiltonol every 2 weeks for 6 injections.~The infusion of Durvalumab will be given on the day of the 4th and 6th PVX-410 injection, for a total of 2 infusions."
2960897|NCT02826421|Experimental|UltraSert Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
2960898|NCT02826421|Active Comparator|iTec Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
2960899|NCT02826421|Active Comparator|iSert Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
2960900|NCT02826421|Active Comparator|Monarch III D Manual IOL Delivery System|Manually loaded IOL delivered via a 2.4 mm clear corneal incision during cataract surgery
2960901|NCT02826408|Active Comparator|Active group|Will receive Rabeprazole sodium (Proton pump inhibitor 20 mg once daily)
2960902|NCT02826408|Placebo Comparator|Placebo group|Will receive Folic acid 5 mg once daily
2960903|NCT02826382|Experimental|Dynamic imaging group|Dynamic imaging of suspected bone metastases with the investigation drug [68Ga]P15-041
2960904|NCT02826382|Experimental|Whole body dosimetry group|Determination of human dosimetry of the investigation drug [68Ga]P15-041
2960905|NCT02826369|Experimental|3.0 Tesla in Magnetic Resonance Imaging|
2960906|NCT02826343|Other|COPD Advair|"Subjects will undergo hyperpolarized xenon MRI with perfusion imaging, before and after a 90 day course of Adair.~All subjects belong to one arm and will receive same treatment. Then they are compared at baseline and 3 month post intervention (described below) for within same-subject changes.~Subjects will be administered with~Hyperpolarized Xenon129 inhalation during MRI twice (at baseline and post 3 month Advair)~Gadolinium intravenous contrast during MRI twice (at baseline and post 3 month Advair)~Advair diskus: strength 250mcg/50mcg, one puff twice a day for 3 months."
2960907|NCT02826330||case Crohn disease|60 cases with Crohn's Disease
2960908|NCT02826330||first relative healthy|2 healthy relatives per CD case (total 120)
2960909|NCT02826330||controls|60 controls matched on gender and age with CD cases
2960910|NCT02826304|Active Comparator|VH|Vaginal Hysterectomy for uteri larger than 280gm
2960911|NCT02826304|Active Comparator|LAVH|Laparoscopic assisted vaginal hysterectomy for uteri larger than 280gm
2960912|NCT02826291||RD-100i, OSNA|SLNM and OSNA assessment of sentinel lymph nodes compared to ultrastaging
2960913|NCT02826278||Healthy female newborns|Healthy female newborns 24 to 41 weeks of pregnancy without sexual development disturbances
2960914|NCT02826265||pulmonary disease|patients with known or suspected pulmonary disease
2960915|NCT02826252||Ventavis|The study will be conducted in patients who are enrolled in the German Ventavis patient support program Ventaplus.
2960916|NCT02826239||pulmonary healthy controls|patients without known pulmonary disease
2960917|NCT02826239||pulmonary disease|patients with known or suspected pulmonary disease
2960918|NCT02826226||obstructive ventilation disorder|patients with known or suspected obstructive ventilation disorder and clinical indication for bronchodilator testing
2960919|NCT02826213||Kidney : perfusion device lifeport|Each donor (n=140) will provide one kidney for pulsatile perfusion.
2960920|NCT02826213||Kidney : perfusion device waves|Each donor (n=140) will provide one kidney for continuous perfusion.
2960921|NCT02826200|Experimental|Group 1 (SOC+OAT)|Patients with reduced leaflet motion or with prosthetic heart valve thrombosis receiving single antiplatelet therapy plus oral anticoagulant therapy.
2960922|NCT02826200|Active Comparator|Group 2 (SOC)|Patients with reduced leaflet motion or with prosthetic heart valve thrombosis receiving standard of care therapy.
2960923|NCT02826187||Patients with acetabular implant|"Data to be collected are :~Early complications data related to implant or procedure of implantation~Late stage complications data~Efficacity of treatment with HIP score~Patient satisfaction~Radiographic evaluation during standard follow-up"
2960924|NCT02826174|Experimental|closed PKP under topical anesthesia|a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
2960925|NCT02826174|Active Comparator|open-sky PKP under retrobulbar anesthesia|an open-sky corneal transplantation under retrobulbar anesthesia
2960926|NCT02826174|Other|Anti-Rejection Agents|Anti-Rejection Agents for both groups
2960927|NCT02826174|Other|Anti-Inflammatory Agents|Anti-Inflammatory Agents for both groups
2960928|NCT02826161|Experimental|Napabucasin plus Weekly Paclitaxel|Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with paclitaxel administered intravenously, once weekly, on 3 of every 4 weeks.
2960929|NCT02826161|Active Comparator|Weekly Paclitaxel|Patients randomized to this arm will receive weekly paclitaxel alone administered intravenously, once weekly, on 3 of every 4 weeks.
2960930|NCT02826148|Other|Patients with autism disorder|The RAADS-R scale is a self-administered questionnaire completed by the patient himself assisted by a clinician
2960931|NCT02826135|Experimental|Pediatric patients with hypovolemic state|Right upper abdominal compression is performed in patients with hypovolemic signs including hypotension, decreased urine output and central venous pressure less than 5 mmHg. Changes of blood pressure during abdominal compression is continuously recorded.
2960932|NCT02826122|Active Comparator|FitBit APP|FitBit Zip APP registers and give feed-back on number of steps per day, distance and calories burned.
2960933|NCT02826122|Experimental|Pai APP|Mio Pai APP registers duration and intensity of the Activity and give feed back as activity Points.
2960934|NCT02826109|Experimental|Interventional: Cyanoacrylate Application|Application of cyanoacrylate adhesive to one quadrant of mouth
2960935|NCT02826109|No Intervention|Control: Absence of Cyanoacrylate Application|No application of cyanoacrylate adhesive to the other quadrant of mouth
2960936|NCT02826096|Experimental|biofeedback group|biofeedback therapy
2960937|NCT02826096|No Intervention|medication group|only medication treament
2960938|NCT02826083|Experimental|XXS|
2960939|NCT02826083|Placebo Comparator|Placebo|
2960940|NCT02826070|Other|Off-treatment|Patients who had stopped treatment during EFFORT extension study could receive 2-year off-treatment follow-up. All the patients in Part I will be followed up at the interval of 12 weeks. For these patients, if they have hepatitis flare during follow-up, they will be re-treated with telbivudine combined with adefovir for the left study period ( the total study period is 2 years) and followed up at the interval of 12 weeks. Hepatitis flare is defined as HBV DNA>4 Log10 copies/mL with either ALT≥5 times upper limit of normal (ULN) or TBIL≥2×ULN，or 2 ≤ALT ≤5 ×ULN (at two consecutive visits at least 2 weeks apart) and total bilirubin (TBIL) <2×ULN.
2960941|NCT02826070|Other|On-treatment|Patients with continuous treatment during EFFORT extension study will continue treatment, without off-treatment rule in the further extension study. The treatment strategy is depended on the HBV DNA level of each individual, that is, for patients with negative HBV DNA level (defined as HBV DNA <20 IU/mL) will continue their previous treatment strategy; and for patients with positive HBV DNA level (defined as HBV DNA>=20 IU/mL) will receive the combination therapy of telbivudine and adefovir, irrespective of their previous treatment strategy. All the patients in Part II will be followed up at the interval of 24 weeks until they complete the 2-year on-treatment follow-up. Patients will be conducted liver biopsy at the sixth year of treatment. All the patients with telbivudine monotherapy will be switched to telbivudine plus adefovir once confirmed HBV DNA breakthrough developed.
2960942|NCT02826057|Active Comparator|24 hour of targeted temperature management|Patients resuscitated after cardiac arrest and treated with 24 hours of targeted temperature management (33 degree Celsius)
2960943|NCT02826057|Experimental|48 hour of targeted temperature management|Patients resuscitated after cardiac arrest and treated with 48 hours of targeted temperature management (33 degree Celsius)
2960944|NCT02826044|Experimental|SP2086 50mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
2960945|NCT02826044|Experimental|SP2086 100mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
2960946|NCT02826044|Experimental|SP2086 200mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
2960947|NCT02826031|Experimental|Sodium Hyaluronate Injection + DICL-SR|"Each syringe (2.5mL) contains 25mg of sodium hyaluronate, and one Artz® will be administered via intra-articular injection into the target knee at the baseline and Weeks 1, 2, 3 and 4 respectively for the combination group.~From the run-in period to the end of study, both groups will receive DICL-SR 75mg, which is administered on demand for treatment of knee pain. If the knee pain is relieved or has disappeared, DICL-SR may be withdrawn. However, if the pain occurs again and requires treatment, the drug may be resumed. If a dose of 75mg daily fails to control the knee pain, it may be increased to the maximum dose 150mg daily upon the approval of the investigator, that is, 75mg bis in die（BID） daily"
2960948|NCT02826031|Active Comparator|DICL-SR|From the run-in period to the end of study, both groups will receive Diclofenac Sodium Sustained-release Tablets(DICL-SR) 75mg, which is administered on demand for treatment of knee pain. If the knee pain is relieved or has disappeared, DICL-SR may be withdrawn. However, if the pain occurs again and requires treatment, the drug may be resumed. If a dose of 75mg daily fails to control the knee pain, it may be increased to the maximum dose 150mg daily upon the approval of the investigator, that is, 75mg bis in die（BID daily）. A subject is allowed to withdraw from this study prematurely if unable to tolerate the adverse effects.
2960949|NCT02826018|Active Comparator|ALN-HBV|
2960950|NCT02826018|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
2960951|NCT02826005|Experimental|cirrhotic patients|if positive for 3 bio-markers- will be followed by MRI for HCC diagnosis
2960952|NCT02826005|No Intervention|non cirrhotic patients|control group - 3 bio-markers will be measured only
2960953|NCT02825992|Other|AcQMap System|Use of the AcQMap System for imaging and mapping of atrial chambers during AF ablation
2960954|NCT02825979|Active Comparator|Cryoballoon-based PVI|"Sinus rhythm control via a pulmonary vein isolation (PVI) (first-line) procedure utilizing the the Arctic Front Cryoballoon Procedure."
2960955|NCT02825979|Active Comparator|Anti-Arrhythmic Drug Therapy|"Sinus rhythm control via the use of anti-arrhythmic drug (AAD) therapy (first-line) based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF."
2960956|NCT02825966|Other|LifeVest|Assigned to wear the LifeVest overnight
2960957|NCT02825953|Active Comparator|Nebulized surfactant|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV), and than premature babies with RDS breathing spontaneously will be administered surfactant by nebulizer.
2961057|NCT02825316|Experimental|Group B|Patients with active Crohn's disease that will be allocated to the low residue diet group.
2960958|NCT02825953|Active Comparator|Endotracheal bolus application|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The investigators will administer surfactant via fundamental method.
2960959|NCT02825953|Active Comparator|Minimally invasive surfactant therapy|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). After randomisation, the investigators will administer surfactant via minimally invasive surfactant therapy (MIST) method which is recently very popular method
2960960|NCT02825940|Experimental|Atezolizumab Monotherapy: PK and Extension Phases|Participants during the PK and extension phases of the study will receive atezolizumab alone at a dose of 1200 milligrams (mg) IV every 3 weeks (q3w) (in 21-day cycles) continuously until loss of clinical benefit, disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death. Study treatment may continue beyond disease progression based on the investigator's discretion.
2960961|NCT02825940|Experimental|Atezolizumab and Chemotherapy: Extension Phase|Participants during the extension phase of the study will receive atezolizumab at a dose of 1200 mg IV on Day 1 in combination with gemcitabine at a dose of 1250 milligrams per square meter (mg/m^2) on Days 1 and 8 and cisplatin at a dose of 75 mg/m^2 on Day 1 (four or six 21-day cycles at the discretion of the investigator), followed by atezolizumab as a single agent at a dose of 1200 mg IV q3w on Day 1 of a 21-day cycle) as maintenance treatment continuously until loss of clinical benefit, disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death. Study treatment may continue beyond disease progression based on the investigator's discretion.
2960962|NCT02825927|Experimental|Intervention group|Intensive training with oral screen for 5 weeks.
2960963|NCT02825927|No Intervention|Control group|The control group is not offered any intervention.
2960964|NCT02825914|Active Comparator|Casein glycomacropeptide (CGMP)|As add-on to the standard medical treatment of active ulcerative colitis the patients will receive a daily oral intake of CGMP-protein-shake during 12 weeks.
2960965|NCT02825914|Placebo Comparator|Placebo|As add-on to the standard medical treatment of active ulcerative colitis the patients will receive a daily oral intake of placebo-shake consisting of milk powder during 12 weeks.
2960966|NCT02825901|Active Comparator|Djulis-Buckwheat & Placebo|Ingest Djulis-Buckwheat or placebo drink 100ml/day for 8 weeks
2960967|NCT02825901|Active Comparator|Buckwheat & Placebo|Ingest Buckwheat or placebo drink 100ml/day for 8 weeks
2960968|NCT02825901|Experimental|Djulis-Buckwheat & Buckwheat|Ingest Djulis-Buckwheat or Buckwheat drink 100ml/day for 8 weeks
2960969|NCT02825888||Non-obese|Body Mass index less than 30 kg/m2
2960970|NCT02825888||Obese|Body Mass index more than 30 kg/m2
2960971|NCT02825875||adenocarcinoma of the prostate|
2960972|NCT02825862|No Intervention|Replication group|Replication group - this group will complete the entire questionnaire, in order to replicate the findings of O'Carroll et al (2011)
2960973|NCT02825862|Active Comparator|Omit affective attitudes|Omitting affective attitudes The intervention is the omission of all questions on affective attitudes. This group will complete a similar questionnaire to the replication group, with the same number of questionnaire items, but affective attitudes will be omitted. Dummy questions (e.g. about politics) will be substituted for these deleted questions.
2960974|NCT02825862|Active Comparator|Omit negatively-worded items|Omitting negatively-worded affective attitudes. This intervention is the omission of a subset of negatively-worded affective attitudinal items. This group will complete a similar questionnaire to the replication group, with the same number of items, but all negatively-worded affective attitudes will be omitted. Dummy questions (e.g. about politics) will be substituted for these deleted questions.
2960975|NCT02825849|Experimental|PRP intrauterine infusion|Intrauterine infusion of platelet rich plasma in combination with standard treatment, in patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles
2960976|NCT02825849|No Intervention|Control group with standard treatment only|Patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles undergoing standard treatment protocols
2960977|NCT02825836|Experimental|M7538 (Part 1): Dose escalation|
2960978|NCT02825836|Experimental|M7538 (Part 2): Dose expansion|
2960979|NCT02825823|Experimental|Ketone Salts|Acute dose of beta-hydroxybutyrate potassium/sodium salt (0.2g beta-hydroxybutyrate/kg, 0.01g Potassium/kg, 0.01g Sodium/kg with 1 g Steviol Glycoside and 30 ml of lemon juice per dose)
2960980|NCT02825823|Placebo Comparator|Placebo|Acute dose of taste-matched placebo (0.01g Potassium/kg, 0.01g Sodium/kg with 1 g Steviol Glycoside and 30 ml of lemon juice per dose)
2960981|NCT02825810|Experimental|Cervical motor control group|
2960982|NCT02825810|No Intervention|Control group|
2960983|NCT02825797|Experimental|Group 1A|HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074), each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.
2960984|NCT02825797|Experimental|Group 1B|HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion 10-1074, each dosed at 30 mg/kg, OR placebo (sterile saline), on day 0.
2960985|NCT02825797|Experimental|Group 1C|HIV-infected individuals, off ART will be administered one infusion of 3BNC117 and one infusion 10-1074, each dosed at 30 mg/kg, on day 0.
2960986|NCT02825797|Experimental|Group 2|HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg, on days 0, 21 and 42. Participants enrolled in Group 2 will undergo an analytical treatment interruption and they will discontinue their antiretroviral (ART) regimen on day 2.
2960987|NCT02825797|Experimental|Group 3|HIV-infected individuals, off ART who will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg on days 0, 14 and 28.
2961012|NCT02825615|Experimental|Ultrasound guided method (USG)|Radial artery cannulation is done with ultrasound guidance for this group of patients. Cannulation failure with this technique were tried with Conventional technique secondarily.
2961120|NCT02824835||cancer group|Patients with colorectal cancer. Biopsies are taken before surgical resection.
2960988|NCT02825784|Experimental|Renastart|"Compared to cows' milk and/or standard pediatric enteral feeds, Renastart has the following additional nutritional features that are beneficial in children with CKD: lower phosphorus, calcium and vitamin A. The powder presentation allows flexibility with dilutions to facilitate the provision of adequate energy and protein to support growth in children with CKD.~For each subject, the recommended daily intake of Renastart is determined by the dietitian in collaboration with the local PI and primary nephrologist based on individual nutritional requirements, specifically dietary intake of potassium and serum potassium levels.~Renastart is to be given by the clinician and based on clinical and nutritional needs. Standard preparation guidelines can be found on the Renastart label."
2960989|NCT02825771|Experimental|Usual Care + Caring Contacts via Text|Usual care services plus caring contacts via text message
2960990|NCT02825771|Active Comparator|Usual Care|Usual care services provided in that community following identification of suicidal ideation or behavior.
2960991|NCT02825758|Experimental|ZestiVits|"Supplement for use in ketogenic and restricted therapeutic diets, from the age of 11.~Daily use for 7 days. Daily intake level for each subject will be determined and prescribed by a dietitian."
2960992|NCT02825745|Other|Betashot|"Children:will take Betashot as a proportion of their daily energy requirements calculated from the dietary information obtained during Visit A for up to 12 weeks.~Adults:will introduce Betashot and increase the amount taken in ml incrementally for up to 12 weeks."
2960993|NCT02825719|Experimental|Ulipristal|Patients will be prescribed Ulipristal acetate 5mg daily for 12 weeks before operation. If the patients have anaemia with haemoglobin less than 10g/dL, ferrous sulphate 300mg three times a day will be prescribed as well. Tranexamic Acid 500mg four times a day will be prescribed on request basis.
2960994|NCT02825719|Placebo Comparator|Placebo|Patients will be prescribed placebo pills daily for 12 weeks before operation. If the patients have anaemia with haemoglobin less than 10g/dL, ferrous sulphate 300mg three times a day will be prescribed as well. Tranexamic Acid 500mg four times a day will be prescribed on request basis.
2960995|NCT02825706|Experimental|Experimental group|The patients in experimental group received 60-minute educational sessions every two weeks about the pathophysiology of hemophilia, clinical manifestations, postural advice and prevention advice to avoid recurrent bleeding. Likewise, doubts on the clinical progress of hemophilic arthropathy, functional limitations and management of joint pain were resolved. In parallel with the educational sessions, patients followed a 15-week home exercise program performed once a day, 6 days a week. The program included muscle stretching exercises; isometric exercises; proprioceptive exercises on one leg with visual support; and a 20-minute walk. Low-intensity exercises with 20-25 repetitions were included.
2960996|NCT02825706|No Intervention|Control group|The patients in the control group did not receive any educational sessions and did no exercise at all at home.
2960997|NCT02825693|Active Comparator|Femtosecond laser cataract surgery|Cataract surgery with femtosecond laser treatment for corneal incisions, astigmatic keratotomies, capsulotomy and nuclear fragmentation
2960998|NCT02825693|Active Comparator|Conventional phacoemulsification surgery|Conventional phacoemulsification surgery
2960999|NCT02825680|Active Comparator|Enhanced NCP Support|Teams at facilities who expressed interest in being in the trial but who are not randomly assigned to the experimental arm will be in the active comparator arm. These facilities will receive enhanced support from NCP.
2961000|NCT02825680|Experimental|LEAP Intervention|Cohorts of 6 facilities, who expressed interest in being in the trial, will be randomly selected each quarter, as guided by the stepped-wedge trial design protocol, to participate in LEAP. These facilities will also receive the same enhanced NCP support as received by the active comparator arm.
2961001|NCT02825667|Experimental|Experimental group|"Patients included in this group will receive treatment over a period of three weeks, receiving 3 physiotherapy sessions lasting approximately 30 minutes each.~The treatment program includes 8 maneuvers that must be administered bilaterally: maneuver longitudinal sliding on the fascial surface plant, maneuver induction of the plantar fascia, maneuver longitudinal surface sliding on the anterolateral compartment of the leg, induction maneuver ankle anterior compartment, maneuver pressure and sliding on the posterior region of the leg, technical release of the popliteal fascia, maneuver induction sural triceps, and lower extremity telescopic technique."
2961002|NCT02825667|No Intervention|Control group|Patients included in this group will not receive any physiotherapy treatment. However, will be evaluated under the same conditions that patients in the experimental group (pretreatment evaluation, post-treatment and follow-up).
2961003|NCT02825654||Post-9/11 Gulf War Era Veterans|Military personnel who deployed to Central Asia, Southwest Asia, and Africa during the Post-9/11 Gulf War Era
2961004|NCT02825641|Active Comparator|Expectant Management-Dinoprostone|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).~Labor induction will be initiated with Dinoprostone after 24 hours of waiting depending on obstetric history and cervical conditions."
2961005|NCT02825641|Active Comparator|Expectant Management-Oxytocin|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).~Labor induction will be initiated with oxytocin after 24 hours of waiting depending on obstetric history and cervical conditions."
2961006|NCT02825641|Experimental|Active Management-Dinoprostone|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).~Labor induction will be initiated with Dinoprostone on presentation depending on obstetric history and cervical conditions."
2961007|NCT02825641|Experimental|Active Management-Oxytocin|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).~Labor induction will be initiated with oxytocin on presentation depending on obstetric history and cervical conditions."
2961008|NCT02825628|Experimental|Osteodex 3.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
2961009|NCT02825628|Experimental|Osteodex 6.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
2961010|NCT02825628|Experimental|Osteodex 9.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
2961011|NCT02825615|Active Comparator|Conventional method (CM)|Radial artery cannulation has been done using the conventional method. Cannulation failure with this technique were tried with USG technique secondarily.
2961056|NCT02825316|Experimental|Group A|Patients with active Crohn's disease that will be allocated to the Mediterranean diet group.
2961013|NCT02825602||Vietnam War Theater Veterans|Vietnam War Theater Veterans are defined for this protocol as those who served in the U.S. Armed Forces on the ground, in the air, or on the inland waters of Vietnam, Cambodia, and/or Laos between February 28, 1961 and May 7, 1975, inclusive. The investigators based this definition on legal dates of service set forth in 38 Code of Federal Regulations (CFR) 3.2 - Periods of war, but broadened the definition of sites of military service that constituted war zones based on written historical accounts and input from Vietnam Veterans.
2961014|NCT02825602||Blue Water Navy Vietnam Veterans|Blue Water Navy Veterans are defined as Veterans who served aboard deep-water naval vessels in waters offshore North or South Vietnam between February 28, 1961 and May 7, 1975 and who never served ashore or on inland waterways of Vietnam.
2961015|NCT02825602||Vietnam era Veterans|Vietnam era Veterans served in locations around the world OTHER than on the ground, in the air, or on the inland waters of Vietnam, Cambodia, and/or Laos or aboard deep-water naval vessels in waters offshore North or South Vietnam between February 28, 1961 and May 7, 1975.
2961016|NCT02825602||Non-military U.S. public|Non-military U.S. public are individuals who were born before 1958, never served in the U.S. military, and are age- and gender-matched (by the study investigators) to Vietnam War Theater Veterans.
2961017|NCT02825589|Experimental|BIA-guided|Assessment of target dry weight guided by using bioelectrical impedance analysis (BIA).
2961018|NCT02825589|No Intervention|Standard clinical guided|Assessment of target dry weight guided by clinical evaluation eg. jugular venous pressure, blood pressure, edema etc.
2961019|NCT02825576|Active Comparator|Sugammadex group|Sugammadex 2mg/kg intravenously at completion of surgery.
2961020|NCT02825576|Active Comparator|Neostigmine/Glycopyrrolate group|Neostigmine 50mcg/kg plus Glycopyrrolate 10mcg/kg intravenously at completion of surgery.
2961021|NCT02825563|Experimental|Anlotinib(In the fasting state)|In the fasting state, Anlotinib po only once and after 14 days it could be continued by Qd po.until disease progression or intolerable toxicity or patients withdrawal of consent
2961022|NCT02825563|Experimental|Anlotinib(In the high fat diet state)|In the high fat diet state, Anlotinib po only once and after 14 days it could be continued by Qd po.until disease progression or intolerable toxicity or patients withdrawal of consent
2961023|NCT02825550|Experimental|Hepatoma treated using Taiwan ACE Beads|The use of Taiwan ACE Beads (T-ACE) microspheres embolization as a treatment for patients with hepatoma.
2961024|NCT02825537|Experimental|With use of compression stocking|Use of compression stocking during 3 consecutives days
2961025|NCT02825537|Other|Without use of compression stocking|No use of compression stocking during 3 consecutives days
2961026|NCT02825524|Experimental|Endobiliary radiofrequency|
2961027|NCT02825511||A cohort of basal cell carcinoma|A cohort of surgically treated BCC, primitive clinically suspected or previously biopsied on a 4-month period, an expected number of 3 200 cases. The management of the BCC will be consistent with current recommendations. BCC recurrence and those who received prior medical treatment will be excluded.
2961028|NCT02825498|Experimental|Operator guided by contact force|Operator has full access to contact force parameters including force time integral (FTI).
2961029|NCT02825498|No Intervention|Operator blinded to contact force|Operator is blinded to contact force with ablation guided by standard markers of effective ablation.
2961030|NCT02825485|Other|Control Group|The control patients will be the patients with antenatal hydronephrosis who get a routine VCUG to evaluate for vesicoureteral reflux, as part of routine care.
2961031|NCT02825485|No Intervention|Observation Group|Receives no intervention
2961032|NCT02825472|Active Comparator|Exercise training program|Six-months sports participation, three times per week for 30 minutes in the target heart rate zone
2961033|NCT02825472|No Intervention|No exercise training program|no exercise training program, usual care
2961034|NCT02825459|Experimental|Abstinence from e-cigarettes|Participants abstain from e-cigarettes and other nicotine/tobacco products for 6 days
2961035|NCT02825459|No Intervention|E-cigarette use|Participants use e-cigarettes and continue to abstain from tobacco/nicotine products as they normally would.
2961036|NCT02825446|Active Comparator|angioplasty tibial arteries|
2961037|NCT02825446|Experimental|radio frequency denervation popliteal artery by the use|"radio frequency denervation popliteal artery Vessix Renal Denervation System Balloon"
2961038|NCT02825433||Patients receiving procedural sedation|The investigators collected ventilation data for each breath (respiratory rate, tidal volume, and end-tidal CO2) for all patients receiving procedural sedation for endoscopy.
2961039|NCT02825407|Experimental|main study|
2961040|NCT02825394||apixaban initiation|N=20
2961041|NCT02825394||apixaban on-treatment|N=20
2961042|NCT02825394||dabigatran initiation|N=20
2961043|NCT02825394||dabigatran on-treatment|N=20
2961044|NCT02825394||rivaroxaban initiation|N=20
2961045|NCT02825394||rivaroxaban on-treatment|N=20
2961046|NCT02825394||edoxaban initiation|N=20
2961047|NCT02825394||edoxaban on-treatment|N=20
2961048|NCT02825368|Experimental|Homeopathic vaccine group|"Diphtheria (Diphtherinum®), pertussis (Pertussinum®), tetanus (Tetanotxicum®), measles (Morbilinum®) and mumps (Ourlianum®) nosodes.~Two sterile saline injections (0.5ml each, intramuscular and subcutaneous) as placebo."
2961049|NCT02825368|Active Comparator|Conventional vaccine group|"One intramuscular dose of Tdap (tetanus, diphtheria, acellular pertussis)~One subcutaneous dose of MMR (measles, mumps, rubella)~Sugar pellets as placebo."
2961050|NCT02825368|Placebo Comparator|Control group|"Sugar pellets oral dose~Two sterile saline injections (0.5 ml each, intramuscular and subcutaneous) as placebo"
2961051|NCT02825355|No Intervention|Control|The control group will receive conventional treatment, radical pelvic lymphadenectomy.
2961052|NCT02825355|Experimental|Intervention|The intervention group will receive sentinel lymph node mapping.
2961053|NCT02825342|No Intervention|GERD with PPI's therapy|Patients will abnormal distal acid esophageal exposure will receive PPI twice daily for 8 weeks .
2961054|NCT02825342|Active Comparator|PPI's and SSRI's therapy|Patients with positive symptom index for chest pain will receive citalopram 20 mg once daily and PPI once daily for 8 weeks.
2961055|NCT02825342|Active Comparator|SSRI's therapy|Patients with a negative symptom index for chest pain will receive citalopram 20mg once daily for 8 weeks
2961058|NCT02825303|Experimental|Novel workplace - first half|Intervention: A novel two-desk sit-to-stand workstation for 23 weeks; provided within the first half of the study. Traditional workstation within the second half of the study.
2961059|NCT02825303|Experimental|Novel workplace - second half|Intervention: A novel two-desk sit-to-stand workstation for 23 weeks; provided within the second half of the study. Traditional workstation within the frist half of the study.
2961060|NCT02825303|No Intervention|Control group|Control group subjects did not encounter any changes in their regular office environments. Traditional workstation for both halves of the study.
2961061|NCT02825290|Experimental|Study group|hCG (Choriogonadotropin alfa; Ovitrelle 250 mcg) on day of embryo transfer & GnRH-agonist (Triptorelin acetate; Decapeptyl 0.1 mg) after 4 days In addition to the usual progesterone luteal support.
2961062|NCT02825290|No Intervention|Control group|The usual progesterone only luteal phase support.
2961063|NCT02825277|Other|pathological group|pregnant women with preeclampsia and/or IUGR pregnancy with a planned or semi-urgent caesarean section or vaginal delivery will be recruited into this study.
2961064|NCT02825277|Other|physiological group|pregnant women with normal pregnancy with a planned caesarean section or vaginal delivery will be recruited into this study
2961065|NCT02825264||STARflo|Patients who have been implanted with STARflo implant
2961066|NCT02825251|Experimental|Faster-acting insulin aspart CSII|
2961067|NCT02825251|Active Comparator|NovoRapid® CSII|
2961068|NCT02825238|No Intervention|Control|Control group, did not undergo intervention.
2961069|NCT02825238|Experimental|Exercise group|Experimental, exercise group, underwent intervention
2961070|NCT02825225|Experimental|20 core-biopsy fragments|Patients submitted to experimental intervention (extended sextant biopsy with 20 cores) compared to current standard biopsy protocol (extended sextant biopsy with 12 cores) guided by transrectal ultrasound.
2961071|NCT02825225|Experimental|Base and apex local anesthesia|Patients submitted to experimental intervention in prostate-biopsy anesthetic protocol (prostate base and prostate apex bilateral local anesthetic injection) compared to participants submitted to current standard anesthetic protocol in institution (prostate base bilateral local anesthesia) guided by transrectal ultrasound. guided by transrectal ultrasound.
2961072|NCT02825212|Experimental|Harvoni|90mg/400 mg FDC once daily. Subjects will take 1 tablet daily with or without food.
2961073|NCT02825199|Experimental|Caffeine group|All participants underwent otoscopy and tympanometry, responded to the Profile of Mood State (POMS), submitted to the cVEMP, oVEMP and caloric tests in that order. After that they received caffeine capsule (300mg). After 45 minutes they again responded to the POMS, repeated the cVEMP, oVEMP and caloric test.
2961074|NCT02825199|Placebo Comparator|Non caffeine group|All participants underwent otoscopy and tympanometry, responded to the Profile of Mood State (POMS), submitted to the cVEMP, oVEMP and caloric tests in that order. After that they received placebo capsule (maize starch). After 45 minutes they again responded to the POMS, repeated the cVEMP, oVEMP and caloric test.
2961075|NCT02825186|Experimental|Loteprendol|Topical Loteprendol used after strabismus surgery
2961076|NCT02825186|Experimental|Dexamethasone|Topical Dexamethasone used after strabismus surgery
2961077|NCT02825173|Experimental|Seal-G|A surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.
2961078|NCT02825160||Ventavis|Ventavis treatment group
2961079|NCT02825147|Experimental|MESA|stage I/II: methotrexate 1000mg/m2,d1 dexamethasone 40mg,d2-d4 etoposide 100mg,d2-d4 pegaspargase 2500U/m2,d5 a cycle of every 21 days with totally 4 cycles Radiotherapy at least 50Gy in dose for the involved local focus is sandwiched after 2 cycles.
2961080|NCT02825134|Experimental|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
2961081|NCT02825134|Active Comparator|Surgical aortic valve replacement|Surgical aortic valve replacement
2961082|NCT02825121|Experimental|Monitoring Neuromuscular Blockade|Monitoring Neuromuscular Blockade the Flexor Hallucis and adductor of the thumb.
2961083|NCT02825108|Experimental|experimental group|The patients who receive 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
2961084|NCT02825108|Placebo Comparator|placebo group|The patients who receive only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
2961085|NCT02825108|Other|control group|The patients for whom the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups
2961086|NCT02825095|Active Comparator|Talc Pleurodesis|"For patients in this group, chest tube type PIGTAIL 10 - 14 Fr will be inserted by by chest ultrasound guided and under local anesthesia, allowing good draining of the hemithorax, in case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed, chest tube will be removed 24 - 48 hours later on. the patient will be admitted in the hospital during the whole procedure course.~If the patient developed non expanded - trapped lung post chest tube insertion, or if he had persistence high chest tube output for more than 10 days, then the patient will remain with the PIGTAIL as an Indwelling Pleural Catheter."
2961087|NCT02825095|Active Comparator|Indwelling Pleural Catheter|"All patients from this group will have Indwelling Pleural Catheter insertion type PLEURAX inserted by ultrasound guided and under local anesthesia.~the patient and his/her family will be instructed and educated about the proper way of using the catheter, and how to perform pleural draining at home.~the duration of treatment with the Pleurax depends on the rate and amount of pleural effusion draining."
2961088|NCT02825069|Experimental|Intervention group|Early introduction of solid foods starting at the age of 4 months, with foodstuff from all major groups in diet by the age of 6 months (vegetables and fruits, wheat and other grains, meat, fish, egg, dairy products). Babies presenting with mild symptoms are encouraged to continue the symptom-eliciting food.
2961089|NCT02825069|No Intervention|Control group|Families are advised to follow the official Finnish Nutrition Recommendations, including exclusive breastfeeding until the age of 6 months.
2961090|NCT02825056|Active Comparator|Bupivacaine|Intrathecal 8 ml single dose of 0.5% heavy Bupivacaine (Anawin heavy 0.5%).
2961091|NCT02825056|Experimental|Bupivacaine + Morphine|Intrathecal 8 ml single dose of 0.5% heavy Bupivacaine (Anawin heavy 0.5%) and 250 microgram of preservative free Morphine (VERMOR).
2961092|NCT02825043|Experimental|High Flow Nasal Cannula Participants|High Flow Nasal Cannula Participants will be their own control, they will be in study for 3 months prior to receiving equipment and then will be studied for 3 additional months on study.
2961093|NCT02825030|Experimental|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2961094|NCT02825017|Experimental|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2961095|NCT02825004|Experimental|Psychological Intervention|All the professionals workers involved in the experimental group will attend three intensive psychological meetings about emotional exhaustion, depersonalisation, low personal accomplishment and how to improve coping skills.
2961096|NCT02825004|No Intervention|Control Group|There is not any intervention.
2961097|NCT02824991|Experimental|Deep Dry Needling|"Deep Dry Needling (DN) with the purpose of obtaining local twitch responses (LTRs). Description: Latent MTrPs were identified in both MG using according the presence of a palpable taut band and hypersensitive spot in the palpable taut band as diagnostic criteria.~The deep DN was administered by a physical therapist with three years of experience in the technique. The ultrasound video (SonoSite Titan; Sonosite, Bothell, WA, USA) was recorded at 60 frames per second captured through an external capture device from Epiphan Systems Inc. (Ottawa, Ontario, Canada). According to the perception of the physical therapist and the ultrasound assessment, the filament needle was inserted into the MTrP to achieve three LTRs. Posterior to DN application, the ROMs of the MG and HA were measured"
2961098|NCT02824965|Experimental|Pembrolizumab+1x10^8 TCID50 CVA21|CVA21 will be administered IV on days: 1, 3, 5, 8 29, 50, 71, 92, 113 134, and 155. 200mg Pembrolizumab will be administered as per normal dosing frequency at Q3W IV, and will continue for up to 24 months.
2961099|NCT02824965|Experimental|Pembrolizumab+3x10^8 TCID50 CVA21|CVA21 will be administered IV on days: 1, 3, 5, 8 29, 50, 71, 92, 113 134, and 155. 200mg Pembrolizumab will be administered as per normal dosing frequency at Q3W IV, and will continue for up to 24 months. Should dose limiting toxicities be observed participants may be transferred a lower dosage of CVA21.
2961100|NCT02824965|Experimental|Pembrolizumab+1x10^9 TCID50 CVA21|CVA21 will be administered IV on days: 1, 3, 5, 8 29, 50, 71, 92, 113 134, and 155. 200mg Pembrolizumab will be administered as per normal dosing frequency at Q3W IV, and will continue for up to 24 months. Should dose limiting toxicities be observed participants may be transferred a lower dosage of CVA21.
2961101|NCT02824952|Experimental|Tagrisso 80 mg|80 mg of Tagrisso(AZD9291) will be given every day for 6 or 12 weeks.
2961102|NCT02824939|Experimental|Transversus Abdominis Plane group|
2961103|NCT02824939|Experimental|Quadratus Lumborum group|
2961104|NCT02824939|No Intervention|Control group|
2961105|NCT02824926|Experimental|Dapaconazole|(cream; 2%; topical)
2961106|NCT02824926|Active Comparator|Ketoconazole|(cream; 2%; topical)
2961107|NCT02824913|Experimental|P-321 Ophthalmic Solution|0.017% P-321 Ophthalmic Solution will be administered to approximately 8 patients in Phase I and either 0.05% P-321 Ophthalmic Solution or 0.01% P-321 Ophthalmic Solution or additional 0.017% P-321 Ophthalmic Solution will be administered to approximately 16 patients in Phase II
2961108|NCT02824913|Placebo Comparator|Drug: P-321 Ophthalmic Solution placebo|Placebo treatment administered to approximately 8 patients in Phase I and approximately 16 patients in Phase II
2961109|NCT02824900|Experimental|Vibration stimuli to neck|Vibration stimuli to contralesional neck muscles, 5 days per week, for 2 weeks, 20 minutes per day + structured (conventional exercises) daily physiotherapy ~ 45 minutes.
2961110|NCT02824900|Active Comparator|Vibration stimuli to hand|Vibration stimuli to contralesional hand, 5 days per week, for 2 weeks, 20 minutes per day + structured (conventional exercises) daily physiotherapy ~ 45 minutes.
2961111|NCT02824887||Exposed group|Long term curative effect of electroacupuncture treatment of lumbar intervertebral disc herniation in exposure group
2961112|NCT02824887||control group|Long term efficacy of conventional treatment of lumbar disc herniation in the control group
2961113|NCT02824874|Experimental|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Duvie Tab. 0.5mg)*1T/day for 5 days, QD, PO~Period 2: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO~Each treatment period was separated by a washout period of at least 10 dyas."
2961114|NCT02824874|Experimental|Group 2(Treatment B/Treatment A)|"Period 1: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO~Period 2: Treatment A(Duvie Tab. 0.5mg)*1T/day for 5 days, QD, PO~Each treatment period was separated by a washout period of at least 10 dyas."
2961115|NCT02824861|Experimental|Text Intervention|Participants receive text messages to a personal cell phone over 8 weeks, wear a fitbit to monitor physical activity, and communicate with a health coach intermittently over 2 weeks
2961116|NCT02824861|Active Comparator|Active Control|Participants receive and wear a fitbit only for 8 weeks
2961117|NCT02824848|Active Comparator|Passive Stretching|Passive Stretching intervention components include static passive stretching, active assistive range of motion, assisted stretching of the involved cervical musculature, and associated strengthening activities aimed to elicit head righting in developmentally appropriate positions and during developmentally appropriate movement transitions. Intervention is progressed by increasing head tilt angles, duration of head righting, and frequency and number of repetitions.
2961118|NCT02824848|Active Comparator|Perception-Action Approach|P-A Approach intervention components include environmental set-up for activity and participation in play, and manual guidance in the form of light pressure applied to the infant's body in developmentally appropriate positions. Both components are designed to promote spontaneous exploration of the environment by the infant by suggesting small, incremental changes in his/her perceptual-motor orientation and contact with the support surface. Intervention is progressed by gradually removing environmental supports provided to the infant's body parts, and by removing the therapist's hands from the infant's body to allow for spontaneous exploration of a newly found contact with the support surface or new body configuration.
2961119|NCT02824835||adenoma group|Patients with adenoma. Biopsies are taken before endoscopic resection.
2961312|NCT02823405|Experimental|X4P-001 + Pembrolizumab|X4P-001 alone, then adding pembrolizumab
2961121|NCT02824822||High SUDEP risk cohort|Patients with epilepsy who have a high SUDEP-7 risk score and/or a blood-relative with epilepsy, seizure, cardiac arrest, sudden death, drowning/near-drowning, syncope or arrhythmia.
2961122|NCT02824822||Low SUDEP risk cohort|Patients with epilepsy and a low SUDEP-7 score.
2961123|NCT02824796|Experimental|Schema Parent Behavioral Training|An enhanced protocol which combines a Schema Focused Therapy (SFT) and Behavioral Parent Training (PBT)
2961124|NCT02824796|Active Comparator|Parent Behavioral Training|Usually medication & The usual PBT treatment
2961125|NCT02824770|Active Comparator|Usual Care|After a major abdominal surgery, the control group will receive the usual postoperative care including continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour and infusion of Tramadol HCl (Tramosel®) via PCA (Gemstar®) in the surgical intensive care unit.
2961126|NCT02824770|Experimental|Dimming of lights and decreasing noise|After a major abdominal surgery, the patients in the experimental group will be screened in the side-rooms where normally the patients who either have infections or are at risk of infection, are nursed and will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour and infusion of Tramadol HCl (Tramosel®) via PCA (Gemstar®) as in the control group. The study intervention will include dimming of lights and decreasing noise. The lights will be dimmed to 40 lux. The doors of the side-rooms will be closed decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m.
2961127|NCT02824757||known diabetes|Participants have been diagnosed diabetes.
2961128|NCT02824757||known prediabetes|Participants have been diagnosed impaired glucose tolerance or impaired fasting glucose before.
2961129|NCT02824757||normal glucose tolerance|Participants have done the oral glucose tolerance test and been confirmed the normal glucose tolerance.
2961130|NCT02824757||unclear glucose tolerance condition|Participants who have not done oral glucose tolerance test or been diagnosed diabetes before.
2961131|NCT02824744|Active Comparator|treatment by 2l/min/kg in HFNC|treatment by 2l/min/kg in High Flow Nasal cannula (HFNC) during the initial management of severe bronchiolitis in infants (0-6 months years old)
2961132|NCT02824744|Experimental|treatment by 3l/min/kg in HFNC|treatment by 3l/min/kg in High Flow Nasal cannula (HFNC) during the initial management of severe bronchiolitis in infants (0-6 months years old)
2961133|NCT02824731|Active Comparator|supratentorial, grade III/IV, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.
2961134|NCT02824731|Experimental|supratentorial, grade III/IV, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.
2961135|NCT02824731|Active Comparator|supratentorial, grade I/II, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients, bening tumors.
2961136|NCT02824731|Experimental|supratentorial, grade I/II, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients, bening tumors.
2961137|NCT02824731|Active Comparator|infratentorial, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.
2961138|NCT02824731|Experimental|infratentorial, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.
2961139|NCT02824731|Active Comparator|pre-radiation, photon|> 40Gy in the region of recurrence. Radiation with photons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)/fraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).
2961140|NCT02824731|Experimental|pre-radiation, proton|> 40Gy in the region of recurrence. Radiation with protons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)/fraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).
2961141|NCT02824718|Experimental|rh PTH(1-34)|40 µg/day rhPTH(1-34) (teriparatide or FORSTEO® 20 µg twice daily) over 7 to 8 weeks (52±3 days).
2961142|NCT02824718|Active Comparator|Thiazide + potassium sparing diuretic|hydrochlorothiazide 25 mg/day (ESIDREX®) + amiloride 5 mg/day (MODAMIDE®) + 0.5 µg/day alfacalcidol (ALFACALCIDOL®) over 7 to 8 weeks (52±3 days).
2961143|NCT02824679|Active Comparator|20mg hyoscine butylbromide|They received (20mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
2961144|NCT02824679|Active Comparator|40 mg hyoscine butylbromide|They received (40mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
2961145|NCT02824679|Placebo Comparator|Saline|They received two ml of normal saline intravenously as a placebo
2961146|NCT02824666|Experimental|0.5 mg/kg|• Cohort 1: ATI-9242 - Single IV bolus dose of 0.5 mg/kg
2961147|NCT02824666|Experimental|ATI-9242 1.0 mg/kg|• Cohort 2: ATI-9242 - Single IV bolus dose of 1.0 mg/kg
2961148|NCT02824653|Experimental|Mesenchymal Stem Cells|The experimental arm is comprised of GVHD patients receiving allogenic bone marrow mesenchymal stem cells
2961149|NCT02824640|Active Comparator|Patient Navigation|"The study will follow a PN model (Check Hep C) developed by NYCDOH in collaboration with Montefiore and the community. HCV PNs will provide the following interventions to those randomized to the PN arm: coordination of HCV treatment; health promotion; assisting patients to overcome barriers; and psychosocial support.~Health Promotion Sessions: PNs will deliver 4 standardized health promotion sessions to all patients either individually or within a group.~Optional Weekly Support Groups: Subjects randomized to the PN arm will be offered weekly support groups led by Peers."
2961150|NCT02824640|Active Comparator|modified Directly Observed Therapy|"OAT clinic setting: Observation of HCV medications will be linked to methadone visits among patients receiving methadone. Patients will be receiving methadone as part of routine clinical care for opioid addiction and not as an intervention related to this study. The schedule of five days per week will be considered modified DOT (mDOT). Subjects will initiate HCV treatment on Mondays if feasible. Take home medications will be packed in a weekly electronic blister pack.~Community health clinic setting: This intervention is considered modified DOT (mDOT) since between 3-5 weekly doses will be directly observed. A minimum of one dose will be observed in person by clinic/study staff. For the remaining observed doses, the research staff and provider will present the participant with a menu of options and determine what will work best for that participant."
2961151|NCT02824627|Experimental|Oxytocin|Subjects weighing >40kg will receive a total of 24 IU of oxytocin delivered as 2- 6 IU puffs to each nostril once daily. Subjects weighing < 40kg will receive a total of 12 IU of oxytocin delivered as 1- 6 IU puff to each nostril daily. Subjects will receive 14 to 21 days of daily oxytocin administration.
2961313|NCT02823379|Experimental|Physical Activity|A culturally relevant physical activity promotion program delivered using a Smartphone application.
2961152|NCT02824627|Placebo Comparator|Placebo|Subjects weighing>40kg will 2 puffs of placebo to each nostril daily. Subjects weighing <40kg will receive 1 puff per day. Subjects will receive 14-21 days of placebo administration.
2961153|NCT02824614|No Intervention|Control|20 obese, non-diabetic candidates will serve as control-group. All assessments are carried out just as in the intervention groups.
2961154|NCT02824614|Active Comparator|E967-Xylitol|20 obese, non-diabetic candidates will receive a daily dose of 24g of xylitol.
2961155|NCT02824614|Active Comparator|E968-Erythritol|20 obese, non-diabetic candidates will receive a daily dose of 36g of erythritol.
2961156|NCT02824601|Experimental|One-visit treatment PDT|Intervention: Chemo-mechanical preparation (CMP) was performed by using the single-file reciprocating technique + 2.5% NaOCL and a final rinse with 17% EDTA. Next, the root canals were irrigated with 10 mL of saline solution, with calcium hydroxide medication being neutralized with 0.5% citric acid. Afterwards, the photosensitizer agent (methylene blue 10 mg/mL) was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP in the one-visit treatment
2961157|NCT02824601|Experimental|Two-visit treatment PDT|Intervention: Chemo-mechanical preparation (CMP) was performed by using the single-file reciprocating technique + 2.5% NaOCL and a final rinse with 17% EDTA. In the following, 14-day inter-appointment medication with Ca(OH)2 + SSL was placed in the root canal. After 14 days with intracanal medication, the tooth was isolated for surgery and disinfection, including removal of provisional restoration. Next, the root canals were irrigated with 10 mL of saline solution, with calcium hydroxide medication being neutralized with 0.5% citric acid. Afterwards, the photosensitizer agent (methylene blue 10 mg/mL) was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP in the one-visit treatment
2961158|NCT02824588|Experimental|Intervention|Working Memory Training
2961159|NCT02824588|Active Comparator|Control|Internet use
2961160|NCT02824575|Experimental|Arm A1-2: Paclitaxel plus Rebastinib.|"Arm A1 (Dose Escalation Cohort): Paclitaxel 80 mg/m2 weekly x 12 weeks plus Rebastinib (50 mg PO BID or 100 mg PO BID) beginning on cycle 1, day 1 and given continuously.~Arm A2 (Expansion Cohort): Paclitaxel 80 mg/m2 weekly x 12 weeks. Patients will be randomized to receive Rebastinib (at RP2D) beginning on cycle 1, day 1 OR cycle 2, day 1."
2961161|NCT02824575|Experimental|Arm B1-2: Eribulin plus Rebastinib.|"Arm B1 (Dose Escalation Cohort): Eribulin Mesylate 1.4 mg/m2 day 1 & 8 q21 days plus Rebastinib (50 mg PO BID or 100 mg PO BID) beginning on cycle 1, day 1 and given continuously.~Arm B2 (Expansion Cohort): Eribulin Mesylate 1.4 mg/m2 day 1 & 8 q21 days. Patients will be randomized to receive Rebastinib (at RP2D) beginning on cycle 1, day 1 OR cycle 2, day 1."
2961162|NCT02824562|Experimental|Intervention|The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain.
2961163|NCT02824562|No Intervention|Control|"The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group."
2961164|NCT02824536|Experimental|Group 1|Participants will be randomized in a 3:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.
2961165|NCT02824536|Experimental|Group 2|Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 3 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.
2961166|NCT02824536|Experimental|Group 3|Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.
2961167|NCT02824523||High-dose aspirin|
2961168|NCT02824510|Active Comparator|Patients under insulin pump therapy.|Patients under insulin pump therapy. Intervention= 2 treadmill exercises to evaluate the efficacy of algorithmic changes in insulin therapy (insulin aspart).
2961169|NCT02824510|Active Comparator|Patients under MDI.|Patients under multiple daily injection regimen. Intervention= 2 treadmill exercises to evaluate the efficacy of algorithmic changes in insulin therapy (insulin aspart and glargine or detemir).
2961170|NCT02824484|Experimental|Guided Written Disclosure Protocol|GWDP consists of three 20-minutes writing sessions. Participants write every two weeks at home following the specific instructions for each session.
2961171|NCT02824484|Placebo Comparator|Control|Control condition consists of three 20-minutes writing sessions. Participants write every two weeks at home following the instructions. Their task is constructed to be emotionally neutral.
2961172|NCT02824471||Minor SCD Group, Ages 12-17|No Intervention. Use of discarded blood/tissue only
2961173|NCT02824471||Adult SCD. Ages 18+|No Intervention. Use of discarded blood/tissue only
2961174|NCT02824458|Experimental|Gefitinib + Apatinib|"(Part A) Phase I, Open-label, Dose-escalation Study Escalating doses(500mg, 750mg, or 250mg) of Apatinib in combination with 250mg Gefitinib daily orally. Participants may continue to receive treatment until progress or intolerable.~(Part B)Multicenter, Randomized, Double-Blind Study Apatinib (dose determined from Part A of study) in combination with 250mg Gefitinib."
2961175|NCT02824458|Placebo Comparator|Gefitinib + Placebo|"(Part A) Not Applicable~(Part B) Placebo in combination with 250mg Gefitinib. Participants may continue to receive treatment until progress or intolerable."
2961201|NCT02824263|Experimental|CPAP withdrawal;|Cessation of established CPAP therapy for 3 nights. CPAP will NOT be worn during this period, and a metabolic sleep study off CPAP is performed in the research laboratory on the third night.
2961202|NCT02824250|Experimental|MBSR + Usual Care|8-week standard Mindfulness-Based Stress Reduction (MBSR) course + standard of care
2961203|NCT02824250|No Intervention|Usual Care|Standard of care
2961176|NCT02824445|Sham Comparator|Sham|The double-blind is used during the first 2 weeks. From week 3 and on, the study becomes open label. Subjects in Group I (active MeRT treatment group) will continue receive active MeRT treatment for W3/4; subjects in Group II (placebo/sham group) will receive active MeRT treatment from W3 to W6 for 4 weeks. All subjects will receive 4 weeks active MeRT treatment. The study ends in 8th wk. The data collection points are baseline, weeks of 2, 4, 6, and 8. The data from weeks 1-2 (Phase I) will be utilized to analyze the safety and any effect of MRT procedure may have over placebo. The data from weeks 3 on (Phase II) will be used to address if any benefit of longer MeRT treatment (4 vs 2 weeks). The study design offers both groups 4 weeks of the experimental therapy in a row. This will provide potentially equal benefit to those participants assuming that MeRT helps to improve PTSD symptoms.
2961177|NCT02824445|Experimental|Treatment|The double-blind is used during the first 2 weeks. From week 3 and on, the study becomes open label. Subjects in Group I (active MeRT treatment group) will continue receive active MeRT treatment for W3/4; subjects in Group II (placebo/sham group) will receive active MeRT treatment from W3 to W6 for 4 weeks. All subjects will receive 4 weeks active MeRT treatment. The study ends in 8th wk. The data collection points are baseline, weeks of 2, 4, 6, and 8. The data from weeks 1-2 (Phase I) will be utilized to analyze the safety and any effect of MRT procedure may have over placebo. The data from weeks 3 on (Phase II) will be used to address if any benefit of longer MeRT treatment (4 vs 2 weeks). The study design offers both groups 4 weeks of the experimental therapy in a row. This will provide potentially equal benefit to those participants assuming that MeRT helps to improve PTSD symptoms.
2961178|NCT02824432|Experimental|TAK-085 2g|A dose of 2 grams of omega-3-acid ethyl esters (TAK-085 ) will be orally administered once a day immediately after meal.
2961179|NCT02824432|Experimental|TAK-085 4ｇ|A dose of 4 grams of omega-3-acid ethyl esters (TAK-085 ) will be orally administered twice a day immediately after meal.
2961180|NCT02824419|Experimental|C11-methionine|To compare FDG and C11-methionine in the detection of sarcoidotic lesions.
2961181|NCT02824419|Experimental|68Ga-Dotanoc|To compare FDG and 68Ga-DOTANOC in the detection of sarcoidotic lesions.
2961182|NCT02824406||Patients|CVR assessment consists of CBF measurement with arterial spin labelling (ASL)-MRI before and after intravenous administration of 16mg/kg acetazolamide (Diamox)
2961183|NCT02824406||Controls|CVR assessment consists of CBF measurement with arterial spin labelling (ASL)-MRI before and after intravenous administration of 16mg/kg acetazolamide (Diamox)
2961184|NCT02824393|Experimental|Mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
2961185|NCT02824393|No Intervention|Control patients|The patients who treated with the conventional therapy for urticaria, but not treat with mesenchymal stem cell.
2961186|NCT02824380|Experimental|Sequence A|Period 1: DA-4001 H(High dose) Period 2: DA-4001 L(Low dose)
2961187|NCT02824380|Experimental|Sequence B|Period 1: DA-4001 L(Low dose) Period 2: DA-4001 H(High dose)
2961188|NCT02824367|Other|Parkinsonian|Patient Arm: Parkinsonian will complete several scale of evaluation. Behavioral: Completion of scales evaluation
2961189|NCT02824367|Other|Dystonic|Comparator Arm: Dystonic patient will complete several scale of evaluation. Behavioral: Completion of scales evaluation
2961190|NCT02824354|Placebo Comparator|placebo|"The placebo will have the same composition as the active treatment (without the drug substance) and an identical appearance. White, oval, biconvex, 6.0 x 8.75 mm film-coated tablet engraved with S on one side."
2961191|NCT02824354|Experimental|Nalmefene|"Drug : 'Nalmefene (Selincro®) 18 mg tablet is a white, oval, biconvex, 6.0 x 8.75 mm film-coated tablet engraved with S on one side. It contains 18.06 mg nalmefene (in the form of hydrochloride dihydrate).~Nalmefene must be taken as-needed: on each day the patient perceives a risk of drinking alcohol, one tablet should be taken, preferably 1-2 hours prior to the anticipated time of drinking. If the patient has started drinking alcohol without taking nalmefene, the patient should take one tablet as soon as possible.~The maximum dose of nalmefene is one tablet per day. Nalmefene can be taken with or without food."
2961192|NCT02824341|Other|Parkinson's disease patients with RBD|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
2961193|NCT02824341|Other|Parkinson's disease without RBD|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
2961194|NCT02824341|Other|Healthy volunteers|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
2961195|NCT02824315|Experimental|AL-335+Simeprevir (SMV)+Odalasvir (ODV)|Participants will receive AL-335 800 milligram (mg) once daily from day 1-3; SMV 75 mg once daily from Day 4-13; loading dose of ODV 150 mg on Day 14, followed by ODV 50 mg once daily from Day 15 to 23; ODV 50 mg once daily + AL-335 800 mg once daily from day 24-26; ODV 50 mg once daily + SMV 75 mg once daily from Day 27-33 and ODV 50 mg once daily + SMV 75 mg once daily + AL-335 800 mg once daily from Day 34 to 36.
2961196|NCT02824289|Experimental|Sun Safe Workplaces Program|Program promoting the adoption of occupational sun protection policies by the local government organization comprised of personal visits with senior managers and in-person training of outdoor workers by research staff over two years.
2961197|NCT02824289|Active Comparator|Attention Control|Program promoting occupational sun protection practices by employees in local government organizations through two mailings containing educational materials and presentations at state professional meetings by project staff.
2961198|NCT02824276|Experimental|Oral Opioid Medication|The primary study medication will be oxycodone, with morphine sulfate immediate release (MSIR) as a backup in case of side effects
2961199|NCT02824276|Placebo Comparator|Placebo Treatment|Placebo medications will be encapsulated in an opaque blinding capsule to ensure adequate blinding of study medications
2961200|NCT02824263|No Intervention|CPAP|Continuation of established CPAP therapy. CPAP will be worn during a metabolic sleep study in the research laboratory.
2961270|NCT02823756|Experimental|Physical Therapy|Treatment arm: manipulation, exercise, and education
2961204|NCT02824237|Experimental|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
2961205|NCT02824224|Experimental|Tamoxifen|Tamoxifen 10mg tablet by mouth twice daily for 7 days
2961206|NCT02824224|Placebo Comparator|Placebo|Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
2961207|NCT02824211|Experimental|Right Dose System|Use of automated oxygen titration during exertion
2961208|NCT02824198|Experimental|CYD Dengue Vaccine booster|Participants from a previous CYD dengue vaccine study randomized to receive CYD dengue vaccine booster
2961209|NCT02824198|Placebo Comparator|Placebo Vaccine Group|Participants from a previous CYD dengue vaccine study randomized to receive a placebo vaccine
2961210|NCT02824185|Experimental|FCH-PET/MRI|FCH-PET/MRI exam performed in addition to the usual examinations for monitoring hepatocellular carcinoma.
2961211|NCT02824172|Experimental|Cast immobilization|36 patients in the experimental cast immobilization
2961212|NCT02824172|Active Comparator|complete sport rest|36 patients in the complete sport rest group
2961213|NCT02824159||Patient with haematologic malignancies|"Interventions to be administrated are :~Clinical examinations~Biological statement~Blood samples for pharmacokinetics exploration~Imagery with positron emission tomography scan or resonance magnetic imagery~Saliva samples for genetics analyses~Blood samples for treatment mutation resistance search~Quality of life scale questionary~Detection of adverse events"
2961214|NCT02824146|No Intervention|Control group|Patients received standard protective mechanical ventilation during all surgery, with tidal volumen 6 ml/kg and positive end-expiratory pressure (PEEP) level of 5 (centimeter of water) cmH2O.
2961215|NCT02824146|Experimental|Recruitment maneuver group|"Patient received a lung recruitment maneuver after pneumoperitoneum insufflation.~The recruitment maneuver consists in 10 breaths at 30/15 cmH2O of plateau pressure and PEEP, respectively. Then, the ventilatory settings back to protective ventilation but adding 8 cmH2O of PEEP to keep the lungs open."
2961216|NCT02824133|Experimental|AZD4547|AZD4547: intake of 80mg bd (160mg/day), on a continuous schedule.
2961217|NCT02824120|Experimental|Comedy|patients in this group will watch a comedy film that will not exceed 30 minutes
2961218|NCT02824120|Experimental|Documentary|patients in this group will watch a documentary film that will not exceed 30 minutes.
2961219|NCT02824107|Experimental|patients with myocardial infarction|
2961220|NCT02824107|Experimental|patients with stroke|
2961221|NCT02824081|Other|Depressive patients|Blood samples (inflammatory biomarkers and genetic purpose) on depressive patients with or without story of suicidal behavior
2961222|NCT02824055|Placebo Comparator|Placebo first; then RO5545965 15 mg; then RO5545965 5mg|Participants will receive placebo matched to RO5545965 capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 5 mg capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
2961223|NCT02824055|Placebo Comparator|Placebo first; then RO5545965 5 mg; then RO5545965 15 mg|Participants will receive placebo matched to RO5545965 capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 5 mg capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
2961224|NCT02824055|Experimental|RO5545965 15 mg first; then Placebo; then RO5545965 5 mg|Participants will receive RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 1 to 3 in first intervention period; then placebo matched to RO5545965 capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 5 mg capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
2961225|NCT02824055|Experimental|RO5545965 15 mg first; then RO5545965 5 mg; then Placebo|Participants will receive RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 5 mg capsules orally daily from Weeks 6 to 8 in second intervention period; followed by placebo matched to RO5545965 capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
2961226|NCT02824055|Experimental|RO5545965 5 mg first; then Placebo; then RO5545965 15 mg|Participants will receive RO5545965 5 mg capsules orally daily from Weeks 1 to 3 in first intervention period; then placebo matched to RO5545965 capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
2961227|NCT02824055|Experimental|RO5545965 5 mg first; then RO5545965 15 mg; then Placebo|Participants will receive RO5545965 5 mg capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 6 to 8 in second intervention period; followed by placebo matched to RO5545965 capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
2961228|NCT02824042|Experimental|Anetumab ravtansine|The evaluation of multiple ECG parameters and the drug-drug interaction (DDI) potential of anetumab ravtansine parameters when administered alone and together with itraconazole 100 mg oral capsules will be conducted in 2 sequential parts. On Cycle 1 Day 1, anetumab ravtansine will be given alone at a dose of 6.5 mg/kg in Part 1 and Part 2. On Cycle 2 Day 1, anetumab ravtansine will be given together with itraconazole at a dose of 0.6 mg/kg in Part 1, and at a dose of 6.5 mg/kg (planned) in Part 2.
2961229|NCT02824029|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2961230|NCT02824016|Active Comparator|with supraclavicular irradiation|Patients received supraclavicular irradiation according to local policies. Biological samples were obtained in order to evaluate hypothyroidism during the follow-up period
2961271|NCT02823743|Experimental|Low dose aspirin|75 mg aspirin orally daily from gestational week 7-35
2961272|NCT02823743|Placebo Comparator|Placebo|Placebo pill orally daily from gestational week 7-35
2961231|NCT02824016|Active Comparator|without supraclavicular irradiation|Patients did not receive supraclavicular irradiation according to local policies. Biological samples were obtained in order to evaluate hypothyroidism during the follow-up period
2961232|NCT02824003|Experimental|ISIS-GCGRRx|ISIS-GCGRRx once weekly dosing for 13 weeks
2961233|NCT02824003|Placebo Comparator|Placebo|once weekly dosing for 13 weeks
2961234|NCT02823990|Experimental|Treatment TG4010 + nivolumab|Patients receive TG4010 SC once per week for courses 1-3 and every 2 weeks for courses thereafter and nivolumab IV over 30 minutes every 2 weeks. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2961235|NCT02823977|Experimental|Ketamine / Dexmedetomidine|Ketamine 0.25 mg/kg bolus followed by 0.5 mg/kg per hour AND Dexmedetomidine by continuous infusion at a fixed rate of 0.6 µg/kg per hour, both administered for up to 72 hours
2961236|NCT02823977|Placebo Comparator|Placebo / Dexmedetomidine|Normal saline, as a 500 mL infusion bag, to represent placebo AND Dexmedetomidine by continuous infusion at a fixed rate of 0.6 µg/kg per hour, both administered for up to 72 hours
2961237|NCT02823964|Experimental|Liprotamase|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
2961238|NCT02823951||Rebif - 1 year MRI cohort|Treatment naive patients starting with Rebif, 1 year follow-up available, MRI scan available at baseline and at 12 months
2961239|NCT02823951||Rebif - 1 year clinical cohort|Treatment naive patients starting with Rebif, 1 year follow-up available, MRI scan available at baseline
2961240|NCT02823951||Rebif - early discontinuation cohort - tolerability|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to tolerability
2961241|NCT02823951||Rebif - early discontinuation cohort - adverse events|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to adverse events
2961242|NCT02823951||Rebif - early discontinuation cohort - disease activity|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to disease activity
2961243|NCT02823951||Tecfidera - 1 year MRI cohort|Treatment naive patients starting with Tecfidera, 1 year follow-up available, MRI scan available at baseline and at 12 months
2961244|NCT02823951||Tecfidera - 1 year clinical cohort|Treatment naive patients starting with Tecfidera, 1 year follow-up available, MRI scan available at baseline
2961245|NCT02823951||Tecfidera - early discontinuation cohort - tolerability|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to tolerability
2961246|NCT02823951||Tecfidera - early discontinuation cohort - adverse events|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to adverse events
2961247|NCT02823951||Tecfidera - early discontinuation cohort - disease activity|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to disease activity
2961248|NCT02823912|Experimental|Capsaicin|75 mg capsaicin every 12 hours for 90 days
2961249|NCT02823912|Placebo Comparator|Control|75 mg magnesia calcinada every 12 hours for 90 days
2961250|NCT02823899|Experimental|HL-OCV|Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.
2961251|NCT02823899|Active Comparator|Shanchol|The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.
2961252|NCT02823886|Experimental|STEMI patients|
2961253|NCT02823873||Normotensive|Normotensive pregnant and postpartum women will have blood pressure measurements administered with standard clinical equipment and the Pulsewave oscillometric wrist cuff blood pressure monitor.
2961254|NCT02823873||Hypertensive|Hypertensive pregnant and postpartum women will have blood pressure measurements administered with standard clinical equipment and the Pulsewave oscillometric wrist cuff blood pressure monitor.
2961255|NCT02823860|Other|Biospecimens and Quality of Life (QoL)|Only if patient's consent is obtained, biospecimens, including tumor and/or peripheral blood are collected.
2961256|NCT02823847|Experimental|Oral Screening|Participants given a screening interview at baseline. Carbon monoxide testing given to participants at baseline. Participants who want to stop smoking are given referral information for a tobacco cessation program. Participants undergo an oral examination using conventional light, and oral examination using a fluorescence light-based hand held device at baseline, and again two weeks later. Oral lesions still present after two weeks are biopsied. Participants with premalignant and malignant oral lesions [PMOL]) given printed materials and web-based programs for tobacco and alcohol cessation.
2961257|NCT02823834||PROFEMUR® Gladiator Plasma Femoral Stems|Single study group either previously implanted with the following combination of components: PROFEMUR® Gladiator Plasma Femoral Stems, PROCOTYL® L Beaded Acetabular Shells, Polyethylene or Ceramic Liners, and Metal or Ceramic Femoral Heads.
2961258|NCT02823821|Active Comparator|137mmol/l|Participating dialysis sites will be randomised to a default dialysate sodium concentration of 137mmol/l
2961259|NCT02823821|Active Comparator|140mmol/l|Participating dialysis sites will be randomised to a default dialysate sodium concentration of 140mmol/l
2961260|NCT02823808|Experimental|ALO+PIO|Group who takes Alogliptin 25mg+Pioglitazone 15mg, once daily.
2961261|NCT02823808|Active Comparator|GMPD+MET|Group who takes Glimepiride 2mg+Metformin 500mg, once daily.
2961262|NCT02823795|Experimental|sPATH|Motivational Interviewing in five sessions post hospital discharge
2961263|NCT02823795|No Intervention|Control|Care as usual
2961264|NCT02823782|Experimental|Laminar HP|Structural and functional MRI markers
2961265|NCT02823782|Experimental|Complex HP|Structural and functional MRI markers
2961266|NCT02823782|Experimental|ADHD|Structural and functional MRI markers
2961267|NCT02823782|Other|Control|Structural and functional MRI markers
2961268|NCT02823769|Experimental|SI-R21204 resin composite|Fillings made with a new dental filling material
2961269|NCT02823769|Active Comparator|Nanohybrid resin composite|Fillings made with nanohybrid resin composite (Clearfil Majesty)
2961346|NCT02823171|Experimental|Sequence I|Sequence I: treatment A/B
2961273|NCT02823730||Synergy Stent Cohort|Retrospective registry of 500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).
2961274|NCT02823730||Xience V Cohort|500 patients that are propensity matched to the 500 patients that underwent PCI with a Synergy stent, eligible for similar time points of follow-up following the PCI.
2961275|NCT02823691|Experimental|Lanreotide and Metformin|"Dose and Treatment Regimen:~LANREOTIDE ATG 120 mg/28 days (equivalent to 1 cycle), deep subcutaneous injection (SC) in combination with METFORMIN 2550 mg daily (maximum dose), oral administration (OS).~Metformin starting dose 850 mg/day to be increased up to 1700 mg/day at day 14, 2550 mg/day at day 28, (maximum dose), if well tolerated."
2961276|NCT02823678||Pancreatectomy|Patients scheduled to undergo a pancreatectomy
2961277|NCT02823665|Experimental|Exendin-(9-39)|To evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
2961278|NCT02823665|Experimental|Atropine|to evaluate the effect of neural activation on insulin secretion and glucose metabolism
2961279|NCT02823652|Experimental|Group I (internet-based intervention)|Patients receive web-based genetic education consisting of general information about testing tumors for genetic mutations.
2961280|NCT02823652|Active Comparator|Group II (usual care control)|Patients receive standard genetic education consisting of conversations with the treating physicians, interaction with and information from the clinical staff, and information from usual resources about testing for genetic mutations.
2961281|NCT02823652|Experimental|Group III (genetic counseling)|Patients who meet the criteria for the remote counseling substudy will receive genetic counseling over the telephone and undergo germline testing.
2961282|NCT02823639|Active Comparator|Transcranial direct current stimulation|tDCS with varying intensity, location and polarity
2961283|NCT02823639|Placebo Comparator|Sham stimulation|Double blind sham stimulation with sham mode of neuroConn device
2961284|NCT02823626|Experimental|Intervention|Spironolactone and patiromer
2961285|NCT02823613|Experimental|Healthy male test subjects 1-5|High salt diet followed by low salt diet
2961286|NCT02823613|Experimental|Healthy male test subjects 6-10|Low salt diet followed by high salt diet
2961287|NCT02823600|Other|RetinaVue 100 camera|Participants will have a retinal screening completed by study staff using the FDA-approved RetinaVue 100 hand-held camera
2961288|NCT02823587|Experimental|Bronchiectasis Pulmonary Rehabilitation|The volunteers will receive supervised physical training twice a week and will be instructed to adopt a routine of home exercises, for 12 weeks.
2961289|NCT02823587|Experimental|Healthy Pulmonary Rehabilitation|In this arm, the volunteers healthy will receive supervised physical training twice a week and will be instructed to adopt a routine of home exercises, for 12 weeks.
2961290|NCT02823587|Sham Comparator|Bronchiectasis Group Control|The volunteers with bronchiectasis will be informed only about the benefits of physical activities
2961291|NCT02823587|Sham Comparator|Healthy Group Control|Volunteers healthy will be informed only about the benefits of physical activities
2961292|NCT02823574|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
2961293|NCT02823574|Active Comparator|Nivolumab and Ipilimumab-placebo|Specified dose on specified days
2961294|NCT02823561|Active Comparator|Garcinia mangostana (treatment group)|Balanced low-calorie diet and regular exercise in combination with integration
2961295|NCT02823561|Other|Control group|balanced low-calorie diet and regular exercise
2961296|NCT02823548|Experimental|Droglican|Patients take one sacchet of Droglican (Chondroitin Sulfate 1,500mg + Glucosamine Hydrochloride 1,200mg) Once a day during 6 months.
2961297|NCT02823548|Placebo Comparator|Placebo|Patients take one sacchet of Placebo once a day during 6 months.
2961298|NCT02823535|Experimental|Iwin: Individual Well-Being Navigator|Iwin intervention during 6-month intervention period plus study assessments at baseline, 6, and 9 months.
2961299|NCT02823535|No Intervention|Control group|Study assessments at baseline, 6 months, and 9 months, plus two short surveys unrelated to the study behaviors at 4 and 5 months.
2961300|NCT02823509|Experimental|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2961301|NCT02823496|Experimental|Arm 1|All subjects are patched with the same product
2961302|NCT02823483|Experimental|Arm 1|All subjects are patched.
2961303|NCT02823470|Experimental|Arm A: activated smart device alerts and feedback|LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
2961304|NCT02823470|Experimental|Arm B: de-activated smart device alerts/feedback features|LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
2961305|NCT02823457|Other|VBMI intervention group|All patients will receive a 12 week VBMI intervention to promote treatment completion
2961306|NCT02823444||Peripheral Vascular Disease|Gender distribution will be approximately equal. The age range is 18-95, with increased prevalence in the elderly population.
2961307|NCT02823444||Control|In the initial sequence optimization stage, healthy volunteers will also be recruited.
2961308|NCT02823431|Active Comparator|Analgesia Arm|Participants randomized to this arm will undergo uroflow studies then be given a 2-hour rest. Urodynamics with the use of Urojet (lidocaine hydrochloride 2%) will then be performed. The lidocaine gel will be placed in and around the urethra. It will be allowed to set for 3 minutes, then the remainder of the standard urodynamic evaluation will be performed. We are using Urojet (lidocaine gel) in an FDA approved manner (for analgesia).
2961309|NCT02823431|Placebo Comparator|Placebo Arm|Participants randomized to this arm will first undergo uroflow studies then be given a 2-hour rest. Urodynamic testing without analgesia (standard of care) will then be performed.
2961310|NCT02823418||No neuraxial labor analgesia|For patients who do not accept neuraxial labor analgesia, analgesics will be prescribed by obstetricians according to routine practice.
2961311|NCT02823418||Neuraxial labor analgesia|For patients who accept neuraxial labor analgesia, epidural analgesia or combined spinal-epidural analgesia will be provided when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
2961347|NCT02823171|Experimental|Sequence II|Sequence II: treatment B/A
2961314|NCT02823379|Active Comparator|Wellness Contact Control|A wellness contract control condition delivered using a Smartphone application.
2961315|NCT02823366|Experimental|Fenofibrate + UDCA|Fenofibrate in combination with ursodeoxycholic acid
2961316|NCT02823366|Active Comparator|Monotherapy|UDCA alone
2961317|NCT02823353|Experimental|Fenofibrate + UDCA|Fenofibrate in combination with ursodeoxycholic acid
2961318|NCT02823353|Active Comparator|Monotherapy|UDCA alone
2961319|NCT02823340|Experimental|Fractional Microneedle Radiofrequency Treatment|Fractional Microneedle Radiofrequency Treatment
2961320|NCT02823327||Chart review, RNA sequencing, microarray|Laboratory Biomarker Analysis. Medical chart review is performed and patient information is collected regarding human immunodeficiency virus HIV/AIDS medical history, staging of AIDS related malignancy, and type of treatment. Previously collected tissue samples are analyzed via RNA sequencing and microarray.
2961321|NCT02823314|Experimental|Intervention group|One piece of a special hypoallergenic adhesive tape, called Cure Tape®, they will have a size of 12-20 cm and will be attached in the front and back torso area on the T7- T8 dermatomes.
2961322|NCT02823314|Placebo Comparator|Placebo group|Two piece of a special hypoallergenic adhesive tape, called Cure Tape®, have a size of 2.5 cm x 2 cm and they will have to be placed near the greater trochanter area.
2961323|NCT02823301|Experimental|VAMOS group|Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
2961324|NCT02823301|No Intervention|Control group|Group that will not receive the VAMOS program as intervention.
2961325|NCT02823288|Experimental|Sonke CHANGE intervention condition|This arm (n=9 clusters) will receive the Sonke CHANGE intervention for 12 months.
2961326|NCT02823288|No Intervention|Control condition|In this arm (n=9 clusters), no activities will take place during the trial period outside of data collection.
2961327|NCT02823275|Active Comparator|Functional mobilisation|
2961328|NCT02823275|Experimental|plaster cast fixation|
2961329|NCT02823262|Experimental|Decision Aid|"Post Initial Surgical Consultation~Including background questionnaire and randomization into Decision Aid Group or Control Group:~The Decision Aid Group (workbook and CD) explains each treatment including its benefits and risks.~-- The DA asks women 10 questions about their health;the response to each question is associated with a point value and women are asked to tally their points. The DA groups women into 4 health categories based on their health score.~Assessment at One week after participants surgical consultation and five months after surgical consultation"
2961330|NCT02823262|Active Comparator|No Decision Aid|"Post Initial Surgical Consultation~Including background questionnaire and randomization into Decision Aid Group or Control Group:~Participant will receive Usual Care assistance when making treatment decisions.~Assessment at One week after participants surgical consultation and five months after surgical consultation"
2961331|NCT02823249|Active Comparator|1.56 g L-Tryptophan|"1.56 g L-Tryptophan in 300 mL tap water given via nasogastric tube~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
2961332|NCT02823249|Active Comparator|1.56 g L-Leucine|"1.56 g L-Leucine in 300 mL tap water given via nasogastric tube~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
2961333|NCT02823249|Active Comparator|50 g Xylitol|50 g Xylitol in 300 mL tap water given via nasogastric tube
2961334|NCT02823249|Active Comparator|75 g Erythritol|75 g Erythritol in 300 mL tap water given via nasogastric tube
2961335|NCT02823249|Placebo Comparator|75 g Glucose and mixed liquid meal|"75 g Glucose in 300 mL tap water given via nasogastric tube~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
2961336|NCT02823249|Placebo Comparator|Tap water and mixed liquid meal|"300 mL tap water given via nasogastric tube~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
2961337|NCT02823236|Active Comparator|Intralesional Triamcinolone|A dosage of 4mg/cm2 of intralesional triamcinolone will be injected in the keloid scar every 4 weeks during 6 months.
2961338|NCT02823236|Experimental|Topical Pirfenidone|Dosage commensurate with scar surface to be treated. After washing and drying the affected area, a thin layer of 8% pirfenidone will be applied on the scar, three times a day, for 6 months.
2961339|NCT02823236|Experimental|Triamcinolone + Pirfenidone|A dosage of 4mg/cm2 of intralesional triamcinolone will be injected in the keloid scar every 4 weeks during 6 months. Simultaneously, a thin layer of 8% pirfenidone will be applied on the scar, three times a day, for 6 months.
2961340|NCT02823223|Experimental|ELVR with Endobronchial Valves|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Endobronchial Valves (Zephyr valve) inserted into the target lobe of the lung with the aim of complete lobar exclusion.
2961341|NCT02823223|No Intervention|Standard of Care|Patients will receive optimal drug therapy and medical management according to clinical practice
2961342|NCT02823197|Experimental|active transport lesson|Participants receive a 2-hour lesson (at school) promoting active transport for short distance travel to various destinations.
2961343|NCT02823197|Experimental|active transport lesson and Facebook group|Participants receive a 2-hour lesson (at school) promoting active transport for short distance travel to various destinations. Furthermore, they are asked to join a Facebook group on active transport in which 3 messages per week are posted during an eight-week period. The Facebook posts aim to promote the use of active transport for short distance travel.
2961344|NCT02823197|No Intervention|control group|Participants in the control group do not receive the active transport lesson or the Facebook group.
2961345|NCT02823184||Patients|ET or PV patients diagnosed before acceleration phase and treated by hydroxyurea with a follow up period of at least 6 months following treatment start, with a RNA sample of total leukocytes before start of treatment available
2961350|NCT02823145|Experimental|ZX008|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
2961351|NCT02823132||patients who develop a fungal infection|
2961352|NCT02823132||patients without fungal infection|
2961353|NCT02823119|Experimental|Mini-hysteroscopy|A rigid 2.7-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 3.3 mm.
2961354|NCT02823119|Active Comparator|Conventional Office Hysteroscopy|A rigid 2.9-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 5 mm
2961355|NCT02823106|Experimental|Verapamil and Citicoline|10mg of verapamil in 10 cc of normal saline and 1000mg of citicoline in 10cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot to the treatment group
2961356|NCT02823106|Placebo Comparator|Placebo|The control group will receive saline only.
2961357|NCT02823080|Active Comparator|cetrotide|study group (24 patients = intervention) received intervention for 3-daysCetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
2961358|NCT02823080|No Intervention|no cetrotide|control group (24 patients) did not receive 3-daysCetrorelix Acetate (no intervention). Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
2961359|NCT02823067||Nursing home patients|Nursing home patients aged 65 years or above. One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
2961360|NCT02823054|No Intervention|Standard group|bi lung ventilation usual practice
2961361|NCT02823054|Experimental|EZ-Blocker group|one lung ventilation 'EZ-Blocker'
2961362|NCT02823041|Experimental|Cognitive Training & Exercise|This arm involves a combination of systematic computerized cognitive training plus 150 minutes per week of aerobic exercise. All participants will also receive individual case management and supportive psychotherapy as well as Individual Placement and Support.
2961363|NCT02823041|Active Comparator|Cognitive Training|This arm includes the same systematic computerized cognitive training as the experimental condition, but without the additional aerobic exercise. All participants will also receive individual case management and supportive psychotherapy as well as and Individual Placement and Support.
2961364|NCT02823028|Active Comparator|NRT + Web Guide|NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges)
2961365|NCT02823028|Experimental|NRT + Web Guide + Tweet2Quit-Coed|NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges) plus assignment to a coed Tweet2Quit group
2961366|NCT02823028|Experimental|NRT + Web Guide + Tweet2Quit-Women|Experimental: NRT + Web Guide + Tweet2Quit-Women NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges) plus assignment to a women-only Tweet2Quit group
2961367|NCT02823015||Study population|The study population consists of adult surgery patients, scheduled for breast cancer surgery at St-Luc University Hospital.
2961368|NCT02823002|Experimental|Slow, Room Temperature|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
2961369|NCT02823002|Experimental|Rapid, Room Temperature|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
2961370|NCT02823002|Experimental|Slow, Warmed|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
2961371|NCT02823002|Experimental|Rapid, Warmed|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
2961372|NCT02823002|Experimental|Buffered|In Part B, subject will be randomized to receive an injection of lidocaine that is buffered or non-buffered.
2961373|NCT02823002|Placebo Comparator|Non-Buffered|In Part B, subject will be randomized to receive an injection of lidocaine that is buffered or non-buffered.
2961374|NCT02822989|Active Comparator|Vagus Nerve Stimulation|Subjects randomized to this arm will receive transcutaneous vagus nerve stimulation for 5 minutes on 4 consecutive days.
2961375|NCT02822989|Sham Comparator|Sham Vagus Nerve Stimulation|Subjects randomized to this arm will receive sham stimulation for 5 minutes for 4 consecutive days.
2961376|NCT02822976||Critically Ill Patient HbA1c<6.5|Patients admitted to an intensive care unit with a HbA1c <6.5.
2961377|NCT02822976||Critically Ill Patient HbA1c≥6.5|Patients admitted to an intensive care unit with a HbA1c ≥6.5.
2961378|NCT02822963||A|Non anticoagulant and/or antiplatelet users.
2961379|NCT02822963||B|Anticoagulant and/or antiplatelet users that hold their drugs during perioperative periods.
2961380|NCT02822963||C|Anticoagulant and/or antiplatelet users that doesn't hold their drugs during perioperative periods.
2961381|NCT02822950|Other|Ceftazadime/avibactam|Ceftazadime/avibactam 2500 mg (1250 mg for CrCl 31-50 mL/min) IV over 120 minutes, every 8 hours [other antibiotics can also be administered as needed]. Patients will receive at least 3 doses (steady-state) of Avycaz prior to obtaining serum samples.
2961382|NCT02822937|Experimental|Placebo, Methylphenidate, Triazolam|The participants will receive placebo on the first day, 40mg Methylphenidate on the second day, and 0.375mg Triazolam on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
2961383|NCT02822937|Experimental|Placebo, Triazolam, Methylphenidate|The participants will receive placebo on the first day, 0.375mg Triazolam on the second day, and 40mg Methylphenidate on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
2961577|NCT02821598|Experimental|Upper limb pattern|Upper Limb pattern with flexion - abduction - external rotation
2961384|NCT02822937|Experimental|Methylphenidate, Placebo, Triazolam|The participants will receive 40mg Methylphenidate on the first day, placebo on the second day, and 0.375mg Triazolam on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
2961385|NCT02822937|Experimental|Methylphenidate, Triazolam, Placebo|The participants will receive 40mg Methylphenidate on the first day, 0.375mg Triazolam on the second day, and placebo on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
2961386|NCT02822937|Experimental|Triazolam, Placebo, Methylphenidate|The participants will receive 0.375mg Triazolam on the first day, placebo on the second day, and 40mg Methylphenidate on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
2961387|NCT02822937|Experimental|Triazolam, Methylphenidate, Placebo|The participants will receive 0.375mg Triazolam on the first day, 40mg Methylphenidate on the second day, and placebo on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
2961388|NCT02822924|Other|Prostate artery embolization treatment|Prostatic artery embolization (PAE) as a new treatment technology is a potentially promising, minimally invasive alternative procedure for BPH, which has been shown to be safe and effective in both animal models and clinical trials.
2961389|NCT02822911|Other|Alcohol Used Disorders Identification Test (AUDIT C)|Submission of Audit-C questionnaire to all the patients of the study. When the result to the AUDIT-C questionnaire reaches at least 1 point, the analysis of the Carbohydrate deficient transferrin (CDT) is performed within 3 days after the beginning of the study. Results of Gamma glutamyl transpeptidase (GGT) and Mean Corpuscular Volume (MCV) performed as routine practice collected at the same time as the CDT analysis.
2961390|NCT02822898|Active Comparator|Isotonic Maintenance Fluid|Isotonic Maintenance Fluid
2961391|NCT02822898|Active Comparator|Hypotonic Maintenance Fluid|Hypotonic Maintenance Fluid
2961392|NCT02822885|Experimental|ultrasonography|Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
2961393|NCT02822872||infertile couples|"couples addressing IVF treatment due to known infertility will fill questionnaire in order to assess their stress level (as mentioned above), after filling the questionnaire scalp hair sample will be taken to assess chronic cortisol secretion.~during the IVF treatment the stress level will be assessed every 3 month by using the same system (in order to find match between the stress level and cortisol secretion with the fertility treatment"
2961394|NCT02822859|Active Comparator|Wright|Methacholine challenge performed using the Wright nebulizer
2961395|NCT02822859|Active Comparator|Bennett-Twin|Methacholine challenge performed using the Bennett-Twin nebulizer
2961396|NCT02822859|Active Comparator|Aeroneb Solo|Methacholine challenge performed using the Aeroneb Solo nebulizer
2961397|NCT02822833|Experimental|Sentinel lymph node mapping|Sentinel lymph node mapping with indocyanine green injection to cervix in endometrial cancer patients operated laparoscopically
2961398|NCT02822820|Active Comparator|Advanced bipolar (Ligasure-Covidien)|Devices with advanced bipolar energy (Ligasure-Covidien) will be used during laparoscopic hysterectomy and pelvic lymphadenectomy
2961399|NCT02822820|Active Comparator|Conventional bipolar (RoBi forceps-Karl Storz)|Devices with conventional bipolar energy (RoBi rotating bipolar forceps-Karl Storz) will be used during laparoscopic hysterectomy and pelvic lymphadenectomy
2961400|NCT02822807|Other|Q fever without valvular disease|Q fever without valvular disease
2961401|NCT02822807|Other|Q fever with valvular disease|Q fever with valvular disease
2961402|NCT02822807|Other|Q fever infective endocarditis|Q fever infective endocarditis
2961403|NCT02822807|Other|Other Coxiella burnetii infections (including pregnant women)|Other Coxiella burnetii infections (including pregnant women)
2961404|NCT02822794|Experimental|SOF/VEL FDC + RBV 12 weeks|SOF/VEL FDC + RBV for 12 weeks in participants with genotype 1 or 2 HCV infection
2961405|NCT02822794|Experimental|SOF/VEL FDC + RBV 24 weeks|SOF/VEL FDC + RBV for 24 weeks in participants with genotype 1 or 2 HCV infection
2961406|NCT02822768|Active Comparator|Packing|The patient is to have a long piece of gauze within the abscess cavity in an attempt to keep it open and allow purulent material to continue to drain after the initial incision and release of purulent material has been performed.
2961407|NCT02822768|Placebo Comparator|No packing|The patient is not to have packing of the abscess as part of the incision and drainage procedure
2961408|NCT02822755|Experimental|Video Recording Group|The experimental group participants will be recorded on their personal smartphone performing their prescribed exercises with individualized instruction from the participating physical therapist. The prescribing therapist will record participants on their own smartphones doing the exercise program in the clinic so that participants can have that video recording of the exercises to help remind them how to do the exercises properly at home. Participants will not be asked to record themselves performing future exercise sessions as documentation of improvement. Intervention: Home Exercise Program and Adherence Logs
2961409|NCT02822755|Active Comparator|Conventional Printed Group|The active comparator group will receive individualized instruction from the participating physical therapist on how to perform their home exercise program as well as printed instructions of the exercises. No video recording of the control group participants will be performed. Intervention: Home Exercise Program and Adherence Logs
2961410|NCT02822742|Other|DE-117 ophthalmic solution and Latanoprost|DE-117 is Experimental. Latanoprost is Active Comparator.
2961411|NCT02822729|Experimental|DE-117 ophthalmic solution (Group1)|Monotherapy
2961412|NCT02822729|Experimental|DE-117 ophthalmic solution (Group2)|Monotherapy
2961413|NCT02822729|Other|DE-117 ophthalmic solution + Timolol (Group3)|Concomitant Use
2961414|NCT02822716|Other|IRE treatment|Irreversible electroporation (IRE) is a form of non-thermal local ablation for solid tumors, it induces apoptosis of tumor cells by creating irreversible damage in the cell membrane using electric current. IRE treatment is given for a therapeutic purpose as a non-surgical alternative to those patients with an inoperable condition.
2961415|NCT02822703|Experimental|Active 20Hz|The rTMS device used in this study is the Mastim Super Rapid2 Stimulator with a 70mm Double Air Film Coil. Guidelines indicate that the maximum safe duration of a single train of 20Hz at 110% of the Motor Threshold (MT) is 1.6 seconds. In this study, the stimulator and the coils will be used to stimulate neurons in the left dorsolateral prefrontal cortex (DLPFC), the same location in the brain as that stimulated in the studies supporting the efficacy of this treatment in depression, in order to examine the feasibility of testing this intervention for efficacy in the treatment of tobacco dependence.
2961416|NCT02822703|Sham Comparator|Sham|The rTMS sham coil used in this study is manufactured by Magstim and currently classified as an investigational device. There is no intention to treat or prevent a disease and/or alter a function in the body with the sham stimulation provided by the sham coil. In this project, the sham coil will be placed in the same location in the brain as that stimulated in the studies supporting the efficacy of this treatment for depression.
2961417|NCT02822690||University Medical Center Groningen|all patients that died on one of the wards with the exception of children; on several wards the Hospice care will be introduced as an intervention
2961418|NCT02822690||Martini Ziekenhuis|all patients that died on one of the wards with the exception of children
2961419|NCT02822690||Ommelander ZorgGroep|all patients that died on one of the wards with the exception of children
2961420|NCT02822664|Other|Pedophiles patients|Adults diagnosed with pedophilia
2961421|NCT02822664|Other|Healthy subjects|Healhy subjects (not diagnosed with pedophilia)
2961422|NCT02822651|Experimental|Vitamin D status|The 2500 subjects included in this unique arm will complete a self-administered questionnaire and will have a blood sampling to measure vitamin D blood concentration.
2961423|NCT02822638||STEMI PATIENT Cohort|STEMI PATIENT Cohort
2961424|NCT02822625|Experimental|arm 1|Patients, followed in the institut and for whom a new application of QUTENZA® is required, will receive standard care.
2961425|NCT02822625|Active Comparator|arm 2|"Patients, followed in the institut and for whom a new application of QUTENZA® is required.~Patients will receive QUTENZA® according to standard procedure with a standardized hypnotic message"
2961426|NCT02822625|Placebo Comparator|arm 3|"Patients, followed in the institut and for whom a new application of QUTENZA® is required.~Patients will receive QUTENZA® according to standard procedure with a music therapy"
2961427|NCT02822612||Retinal Disease|Fifteen subjects with retinal disease. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
2961428|NCT02822612||Glaucoma|Fifteen subjects with glaucoma. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
2961429|NCT02822612||Strabismus|Fifteen subjects with strabismus. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
2961430|NCT02822612||Healthy volunteers|Fifteen healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
2961431|NCT02822599|Active Comparator|RiaSTAP|Group 1 will receive an infusion of RiaSTAP after termination of CPB at a dose of 70 mg/kg after randomization to this group.
2961432|NCT02822599|Placebo Comparator|Saline|Group 2 will receive a placebo consisting of Normal Saline 0.9% (NS) after randomization to this group.
2961433|NCT02822586|Experimental|Cohort A (Stage IB and Stage IIA to IIIB [if N0-1])|"(Eligible patients with Stage IB, IIA, IIB, and IIIA [if N0-1])~Brentuximab Vedotin 1.8 mg/kg IV every 3 weeks for 3 doses beginning 3 weeks prior to initiation of TSEB.~TSEB 12 Gy in 6 fractions at 2 Gy/fraction treated twice/week."
2961434|NCT02822586|Experimental|Cohort B(Stage IIA to IIIB; IVA;transformed CTCL)|"(Eligible patients with Stage IIA, IIB, IIIA [if N2-3]; IIIB; Stage IVA; and transformed CTCL)~Brentuximab Vedotin 1.8 mg/kg IV every 3 weeks for 3 doses beginning 3 weeks prior to initiation of TSEB.~TSEB 12 Gy in 6 fractions at 2 Gy/fraction treated twice/week.~Continuation of brentuximab every 3 weeks until disease progression or unacceptable toxicity or for up to 2 years as a study participant, (whichever occurs first)."
2961435|NCT02822573|Active Comparator|Donepezil 5 mg|Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
2961436|NCT02822573|Placebo Comparator|Matching Placebo|Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
2961437|NCT02822560|Active Comparator|pEVAR|percutaneous femoral access using a suture-mediated closure system
2961438|NCT02822560|Active Comparator|open femoral access|cutdown to femoral artery and surgical closure
2961439|NCT02822547|Experimental|Peginterferon alfa-2a|
2961440|NCT02822534|Experimental|SP2086 50mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
2961441|NCT02822534|Experimental|SP2086 100mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
2961442|NCT02822534|Experimental|SP2086 200mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
2961443|NCT02822521|Experimental|Mobile Application + Population Manager|This arm of the study will contain half the study population after randomization. The participants in this arm will receive the mobile application with daily questions after the first visit. A population manager will review patient-reported symptoms via a web-base dashboard and contact the subject based on pre-specified guidelines.
2961575|NCT02821611|Experimental|Meditation Group|Participants in the experimental group are practicing a mantra-based meditation twice daily for 20 minutes over the 8 week intervention period to reduce stress and blood pressure and enhance quality of sleep.
2961444|NCT02822521|No Intervention|No Mobile Application|This arm of the study will contain half the study population after randomization. The participants in this arm will not receive the mobile application after the first visit. Although participants will be provided with the contact information of a study staff member, there will be no active contact with the subject unless he/she initiates.
2961445|NCT02822508|Experimental|BLI801 Laxative (high dose)|BLI801 Laxative (high dose)
2961446|NCT02822508|Experimental|BLI801 Laxative (mid dose)|BLI801 Laxative (mid dose)
2961447|NCT02822508|Experimental|BLI801 Laxative (low dose)|BLI801 Laxative (low dose)
2961448|NCT02822508|Placebo Comparator|BLI801 Placebo|BLI801 Placebo
2961449|NCT02822482|Experimental|Copanlisib + Cetuximab|All patients will be treated by Copanlisib in association with Cetuximab.
2961450|NCT02822469|Experimental|Manual Therapy Treatment Group|Severe and Moderate TMD patients who filled the inclusion criteria who will receive the Manual Therapy Treatment
2961451|NCT02822469|Placebo Comparator|Placebo Ultrasound Treatment Group|Severe and Moderate TMD patients who filled the inclusion criteria who will receive the Placebo Treatment.
2961452|NCT02822456|Experimental|Individual 3D-printed guided tube|IOE tube feeding using individual 3D-printed guided tube and nelaton tube whenever they eat
2961453|NCT02822456|Active Comparator|traditional IOE tube|classic IOE tube feeding using nelaton tube only whenever they eat
2961454|NCT02822456|Active Comparator|nasogastric tube|nasogastric tube feeding using levin tube always
2961455|NCT02822443|Experimental|TAU - EFT|This arm integrates emotion focused components (EFT; Greenberg, 2010) into psychological therapy (PT) as treatment-as-usual (TAU), aiming at clarifying and transforming maladaptive emotions. 25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
2961456|NCT02822443|Experimental|TAU - SR|This arm focuses on the training of self-regulation strategies (SR; Carver & Scheier, 2000) in the context of psychological therapy (PT) as treatment-as-usual (TAU). 25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions.
2961457|NCT02822430||Patients|"Patients with psychiatric disorders will be assessed using five evaluation of pain scales :~Visual analogic scale pain~Pain behaviour scale~Short-FormHealth Survey (SF-36)~Global Clinical Impression (GCI) for severity and improvement~Mini International Neuropsychiatric Interview (MINI)"
2961458|NCT02822417||patients after general anesthesia|Laparoscopic surgery, orthopedics surgery or open surgery patients after general anesthesia
2961459|NCT02822404|Experimental|Urinary and blood sample|Urinary and blood samples for cystatin C dosage
2961460|NCT02822391||Stroke-group|Screened and recruited from the Division of Neurorehabilitation, Department of Clinical Neurosciences, University Hospital and University of Geneva, Geneva, Switzerland by a senior consultant neurologist (BL). Patients were included if they were hospitalized for stroke rehabilitation, were able to undergo psychophysical testing and presented with a facial impairment according to the House-Brackmann criteria ≥2 15. They were excluded if they presented with acute pain in the oro-facial sphere (nominal question) or an additional neuro-muscular disease.
2961461|NCT02822391||Control-group|Similar to stroke group in regard to age, gender and dental state. no stroke
2961462|NCT02822378|Experimental|Ca2+/VitD Control|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Participants will be asked to refrain from consumption of dried plums for the duration of the intervention (52 weeks).
2961463|NCT02822378|Experimental|50g Dried Plums|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 6 (50g) dried plums per day for the duration of the intervention (52 weeks).
2961464|NCT02822378|Experimental|100g Dried Plums|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 12 (100g) dried plums per day for the duration of the intervention (52 weeks).
2961465|NCT02822365||Diagnostic (PET/CT)|Patients undergo a PET/CT scan as part of their standard clinical care. While still positioned for the clinical scan, patients undergo additional research PET/CT scans in a smaller region over 10 minutes with the pocket phantom placed nearby and a low-dose single bed position CTAC.
2961466|NCT02822352|No Intervention|High Definition White Light|Surveillance colonoscopy using High Definition White Light alone
2961467|NCT02822352|Active Comparator|High Definition Virtualchromoendoscopy|High Definition Virtualchromoendoscopy
2961468|NCT02822339|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2961469|NCT02822326|Experimental|CD19-CAR-T2 T Cells|The subject's T cells will be modified to those which could identify and kill the tumor cells (CD19+ cells). These CD19-CAR-T2 T cells will be infused over 10-15 minutes on days Day 1, 2 and 3 tentatively according to the response to infusion.
2961470|NCT02822313|Experimental|BAY987518|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2961471|NCT02822300|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2961472|NCT02822287|Experimental|2% Acetylcystine Solution|Participants will be orally administered with the clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle over 1 minute or less using an oral syringe.
2961473|NCT02822274|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2961576|NCT02821611|No Intervention|Control Group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
2961474|NCT02822261|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2961475|NCT02822248|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2961476|NCT02822235||Cohort 1|Retrospective data including previous inflammatory bowel disease (IBD) treatments (drug, dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years will be collected from participants with UC or CD. Prospective data will be collected for a period of 12 months after Day 1 in participants with active IBD (UC or CD) and CD participants with no or light disease activity at Day 1 but with colonoscopy or calprotectin levels (i.e, calprotectin >200 µg/g) in the previous year suggestive of inadequate control of activity.
2961477|NCT02822222|Experimental|RMJH-111b|Four (4) RMJH-111b (magnesium citrate, tribasic anhydrous) soft gelatin capsules (110 mg elemental magnesium/capsule) orally bid for 7 days
2961478|NCT02822222|Placebo Comparator|Placebo|Four (4) placebo soft gelatin capsules (0 mg elemental magnesium/capsule) orally bid for 7 days
2961479|NCT02822209|Experimental|Coordinating nurse added to the personalized care program|"The coordinating nurse (CN) is dedicated to the newly diagnosed patient to optimize their personalized care program.~The CN is the connection between the medical team and the patient. They act according to the instructions from the multidisciplinary staff in charge of bronchopulmonary cancer patients.:~e.g. Schedule an exam or an hospitalization, collect and share results of useful information to correct treatment's side effects etc~Main contact of the patient, the general practitioner and the patient's relatives, they give practical information for the patient's case~Quality of life questionnaires - EORTC QLQ-C30 and EORTC QLQ-LC13 - completed by the patient throughout the study.~2 Satisfaction questionnaires completed :~satisfaction questionnaire - patient,~satisfaction questionnaire - general practitioner or home nurse"
2961480|NCT02822209|Active Comparator|Personalized care program as routine practice|"A personalized care program is decided for the newly diagnosed patient by the multidisciplinary team in charge of lung cancer.~The care provided will be organized by the medical team, and besides the oncologist, no principal coordinating contact will be in charge of the patient.~The quality of life questionnaire - EORTC QLQ-C30 and QLQ-LC13 - will be completed by the patient throughout the study.~2 Satisfaction questionnaires completed :~satisfaction questionnaire - patient,~satisfaction questionnaire - general practitioner or home nurse"
2961481|NCT02822196|Experimental|Serratus Anterior Muscle Plane Block|The US probe will be placed in the mid-axillary line at the level of the 5th intercostal space. The latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior) will be identified. Using in-plane approach, the block needle (22 G, 50 mm) will be inserted until the tip is visualized between the serratus anterior muscle and the intercostal muscles. As an extra reference point thoracodorsal artery will be used which aids in the identification of the plane superficial to the serratus muscle. After negative aspiration of blood, local anesthetic (20 ml of 0.25 % bupivacaine) will be injected and visualized in real-time.
2961482|NCT02822196|Active Comparator|Thoracic Paravertebral Block|Patients will be placed in the sitting position, leaning forward. After skin disinfection using chlorhexidine solution, target spinous processes of T1- T5 will be identified and at parasagittal plan at 2.5 cm, skin wheel will be raised using 1% lidocaine. A 20-gauge, bevel needle will be advanced until the transverse process is located. The depth from skin to transverse process will be marked/identified by needle marking. The needle will be withdrawn 1-2 cm and angled down (walked off the transverse process). The needle will be re-advanced 1cm past the initial marking. After negative aspiration, 4-5 ml of 0.25% bupivacaine will be slowly injected. The same procedure will be repeated at each level from T2 to T6 ensuring total dose of bupivacaine does not exceed the maximum dose recommended.
2961483|NCT02822170|Experimental|IV amino acids and in-bed cycle ergometry|"Beginning within 96 hours of ICU admission, participants will receive the following combined intervention:~IV amino acids (15% solution) delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day.~In-bed cycle ergometry exercise delivered in 45-minute sessions 5 days per week according to a detailed specific protocol that includes a safety check and gradual increases in resistance if the participant is actively cycling."
2961484|NCT02822157|Experimental|Olaparib|olaparib 300mg oral tablets twice daily for 28 days in 28-day cycles
2961485|NCT02822157|Active Comparator|Chemotherapy|physician's choice chemotherapy
2961486|NCT02822144|Experimental|general anesthesia|General anesthesia with etomidate, succinylcholine, propofol and remifentanil
2961487|NCT02822144|Experimental|sedation|Sedation with remifentanil and local anesthesia with lidocaine
2961488|NCT02822131|Other|low phosphate|low phosphate will be induced by low phosphate diet and additional treatment with oral phosphate binder sevelamer.
2961489|NCT02822131|Other|high phosphate|high phosphate diet will be induced by oral supplementation with sodium phosphate.
2961490|NCT02822118|Experimental|Chang'an I Recipe|Patients in this group were administered the Chang'an I Recipe for 8 weeks.
2961491|NCT02822118|Placebo Comparator|Placebo|Patients in this group were administered the placebo for 8 weeks.
2961492|NCT02822105|Experimental|H3N2 M2SR monovalent influenza vaccine|This group will receive a low, medium or high dose of the H3N2 M2SR monovalent influenza vaccine administered intranasally. It will be compared with placebo in a 3:1 ratio.
2961493|NCT02822105|Experimental|placebo|This group will receive saline administered intranasally.
2961494|NCT02822092||Patients with Psychotic Disorders taking Risperidone|Risperidone will be administered. Subjects will start risperidone 1 mg qhs; on day 4 the daily dose will be increased to 2 mg and to 3 mg at day 7. The target risperidone dose is 3 mg daily but patients who remain psychotic can be increased to 4 mg day at week 4; 5 mg at week 6 and 6 mg at week 8. Study Psychiatrists will be able to increase faster if symptoms don't improve as well as decrease for side effects. These dose ranges conform with standard clinical practice and are within the FDA approved dosing ranges for schizophrenia, and schizoaffective disorder. Subjects advance in the risperidone titration schedule until they respond or develop dose-limiting side effects.
2961495|NCT02822092||Healthy Volunteers|Healthy Volunteers will participate in MR imaging, Electroencephalogram , and cognitive testing.
2961496|NCT02822066|Experimental|IRE for refractory neoplasms in liver and pancreas|To evaluate the safety and efficacy of irreversible electroporation (IRE) for refractory neoplasms in liver and pancreas, the investigators used preoperative and postoperative US/CEUS/CT/MRI to assess lesions, and laboratory tests including the tumor markers to evaluate the general condition of patients. Intraoperative US/CEUS/CT would be applied to monitor ablation lesions.
2961497|NCT02822053|Experimental|US-guided laser ablation for refractory neoplasms|The investigators used percutaneously US-guided laser ablation for patients with small hepatocellular carcinoma (single or multiple nodules of less than 3 cm in diameter), Child-Pugh A/B, PLT ≥ 50*10E9/L and PT ≤ 20s. Then the investigators estimated the safety and efficacy of this treatment through follow-up of US/CEUS/CT/MRI and the tumor markers every three months.
2961498|NCT02822040||Experimental group|All patients who have initial and final records qualify in the experimental group.
2961499|NCT02822027|Experimental|human gamma globulin|human gamma globulin for infants with encephalopathy of prematurities
2961500|NCT02822027|Active Comparator|non-human gamma globulin|non-human gamma globulin for infants with encephalopathy of prematurities
2961501|NCT02822014|Other|FDG-PET/CT arm|We performed baseline FDG-PET/CT, another FDG-PET/CT after 2 months of TB treatment and a PET/CT at the end of treatment in 18 HIV/TB patients. We correlated evolution of FDG uptake with clinical evolution of patients.
2961502|NCT02822001|Experimental|Sugammadex|The Investigators plan to administer the smallest dose of sugammadex recommended for shallow neuromuscular block (2 mg/kg), a dose that has not been reported to cause allergic or any other side effects. The use of sugammadex may lead to complete reversal of residual neuromuscular block, and avoidance of the respiratory complications (CREs) associated with incomplete reversal after neostigmine. Once the decision to extubate the trachea is made, the patient will receive intravenously either sugammadex 2 mg/kg or placebo in a blinded manner.
2961503|NCT02822001|Placebo Comparator|Placebo|"In all patients, intraoperative surgical and anesthetic management will follow the usual clinical routine at the two enrolling institutions. Once surgery is finished, emergence from anesthesia will occur as per usual clinical routine until the clinician determines that the patient is ready for tracheal extubation.~The patient's trachea will be then extubated, and postoperative anesthetic care will proceed as per usual routine."
2961504|NCT02821988|Experimental|Nonstress test|"Subjects will undergo weekly nonstress tests beginning at 32 weeks until delivery in addition to monitoring fetal kick counts.~A nonstress test is a test in which an external fetal monitor is placed on the mother to defect the fetal heart rate for 20 to 40 minutes. A test is considered reactive if there are more than 2 accelerations in fetal heart rate defined as an increase of at least 15 beats per minute lasting at least 15 seconds in a 20 minute period."
2961505|NCT02821988|Experimental|Biophysical profile|Subjects will undergo weekly biophysical profile testing beginning at 32 weeks until delivery in addition to monitoring fetal kick counts. A Biophysical profile is a test using real time ultrasonography to determine the presence of absence of certain components of fetal well being. There components include: an episode of fetal breathing lasting at least 30 seconds, 3 or more discrete body movements, 1 or more episodes of extension of a fetal extremity with return to flexion, and determination of amniotic fluid volume to detect a maximum vertical pocket of >2cm. The duration of this test is no more than 30 minutes.
2961506|NCT02821988|No Intervention|Kick counts only|Subjects will monitor fetal kick counts only.
2961507|NCT02821975|Experimental|Cognitive computer training|This is the intervention group receiving cognitive computer training three times a week for three months.
2961508|NCT02821975|No Intervention|cogntrol group|The control group do not receive cognitive computer training for three months
2961509|NCT02821962|Experimental|Sedentary prompts (VTAP)|Participants will complete supervised exercise sessions as part of cardiac rehabilitation programming on-site twice weekly for a total of 8 weeks. Participants will also be provided with a VTAP (activPAL3 VT) monitor to wear during waking hours for weeks 1 through 7 of cardiac rehabilitation. The VTAP will alert participants when they have been sedentary for 30 consecutive minutes.
2961510|NCT02821962|No Intervention|Usual care|Participants will complete supervised exercise sessions as part of cardiac rehabilitation programming on-site twice weekly for a total of 8 weeks.
2961511|NCT02821949||Patients|Patients with Non Small Cells Lung Cancer PCT dosage
2961512|NCT02821936|Experimental|Parametric Imaging|"one parametric PET at the inclusion and one at 42 Gray after the beginning of radiotherapy.~Two PET scans at 3 months and one year after inclusion"
2961513|NCT02821923|No Intervention|Control|no treatment
2961514|NCT02821923|Active Comparator|E967-Xylitol|24g xylitol/d
2961515|NCT02821923|Active Comparator|E968-Erythritol|36g erythritol/d
2961516|NCT02821910|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
2961517|NCT02821910|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fasted conditions
2961518|NCT02821910|Experimental|Low dose, fed|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
2961519|NCT02821897|Experimental|Target-controlled Intravenous Anaesthesia|Patients have a target controlled intravenous anaesthesia to implant the spinal cord stimulation lead with active cooperation during the surgery.
2961520|NCT02821897|Active Comparator|Total anesthesia|Patients have a total anaesthesia to implant the spinal cord stimulation lead without active cooperation during the surgery.
2961521|NCT02821884|Experimental|Combination of tDCS and NMES|Both tDCS and NMES conduct simultaneously for 30 minutes.
2961522|NCT02821884|Active Comparator|Combination of tDCS and sham NMES|Both tDCS and sham NMES conduct simultaneously for 30 minutes. Sham NMES electrodes are placed away from all motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation.
2961523|NCT02821884|Sham Comparator|Combination of sham tDCS and sham NMES|"Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Shame tDCS is started in a ramp-like fashion but fade out slowly after 30 seconds.~Sham NMES electrodes are placed away from all motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation."
2961524|NCT02821871|Active Comparator|SP2086|All subjects were ransomed to A and B sequence.In A sequence,subjects take SP2086 100mg once in fasting the first day,and the B sequence subjects need to take SP2086 100mg after the high fat diet.In Day 8，the medicine strategy of two sequence subjects were alternately.
2961525|NCT02821871|Other|high fat diet|All subjects were ransomed to A and B sequence.In A sequence,subjects take SP2086 100mg once in fasting the first day,and the B sequence subjects need to take SP2086 100mg after the high fat diet.In Day 8，the medicine strategy of two sequence subjects were alternately.
2961526|NCT02821858|Experimental|Panel 1: Treatment A|Participants will receive odalasvir (ODV) 50 milligram (mg) (n=8) or placebo (n=2) on Day 1.
2961527|NCT02821858|Experimental|Panel 1: Treatment B|Participants will receive ODV 100 mg (n=8) or placebo (n=2) on Day 1.
2961528|NCT02821858|Experimental|Panel 1: Treatment C|Participants will receive ODV 300 mg (n=8) or placebo (n=2) on Day 1.
2961529|NCT02821858|Experimental|Panel 2: Treatment D|Participants will receive AL-335 400 mg (n=8) or placebo (n=2) on Day 1 of Period 1. Each treatment period will be separated by a washout period of 7 days.
2961530|NCT02821858|Experimental|Panel 2: Treatment E|Participants will receive AL-335 800 mg (n=8) or placebo (n=2) on Day 1 of Period 2. Each treatment period will be separated by a washout period of 7 days.
2961531|NCT02821858|Experimental|Panel 2: Treatment F|Participants will receive AL-335 1,200 mg (n=8) or placebo (n=2) on Day 1 of Period 3. Each treatment period will be separated by a washout period of 7 days.
2961532|NCT02821845|No Intervention|Control|Individuals with no spinal cord injury or other neurological deficits.
2961533|NCT02821845|No Intervention|Unexercised SCI Hip|"Individuals with spinal cord injury who have been discharged from a locomotor training programs at least 6 months prior to enrollment in this study. This group will serve as unexercised controls for the Trained SCI Hip group."
2961534|NCT02821845|Experimental|Trained SCI Hip|Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. Training will focus specifically on rehabilitation of the hip joint.
2961535|NCT02821832|Other|A|Standard of Care DSTB treatment (2 months HRZE followed by 4 months HR)
2961536|NCT02821832|Active Comparator|B|Standard of Care DSTB treatment(2 months HRZE followed by 4 months HR)
2961537|NCT02821832|Experimental|C|2 months HRZE followed 2 months HR followed by 2months placebo
2961538|NCT02821819|Experimental|Random start ovarian stimulation|"Egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase at LH peak +3,+5,+7,+9 or +11. They will receive urinary FSH 150-225 IU/d and five days later cetrorelix acetate 0,25 mg/d will be added until achieving criteria for receiving triptorelin 0,2 mg to induce final follicular maturation. Egg collection will take place 36 hours later.~Interventions:~Random start ovarian stimulation~Gonadotrophins: Urinary FSH 150-225 UI/d~GnRH antagonists: Cetrorelix 0,25 mg/d~GnRH agonist for triggering: Triptorelin 0,2 mg single dose"
2961539|NCT02821793||Elderly patient (70 years and older)|
2961540|NCT02821793||Young patient (18 years - 69 years)|
2961541|NCT02821754|Experimental|3/A3|Durvalumab + Tremelimumab+ RFA
2961542|NCT02821754|Experimental|1/A1|Durvalumab + Tremelimumab
2961543|NCT02821754|Experimental|4/A4|Durvalumab + Tremelimumab+ Cryo
2961544|NCT02821754|Experimental|2/A2|Durvalumab + Tremelimumab + TACE
2961545|NCT02821728|Experimental|Normal diet|No dietary intervention
2961546|NCT02821728|Experimental|Dietary intervention|3 portions of broccoli soup per week
2961547|NCT02821715|Active Comparator|Modafinil|3 tablets modafinil 100 mg + 3 capsules placebo
2961548|NCT02821715|Experimental|THN102 300/3|3 tablets modafinil 100 mg + 3 capsules flecainide 1 mg (THN102 as 300 + 3 mg)
2961549|NCT02821715|Experimental|THN102 300/27|3 tablets modafinil 100 mg + 3 capsules flecainide 9 mg (THN102 as 300 + 27 mg)
2961550|NCT02821702|Experimental|Post surgery and embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
2961551|NCT02821702|Active Comparator|Control group|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
2961552|NCT02821702|Active Comparator|Post surgery with accreta without embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
2961553|NCT02821702|Active Comparator|Post surgery without accreta without embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH)
2961554|NCT02821702|Active Comparator|Normal Vaginal Delivery - no suspected accreta|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH)
2961555|NCT02821689|Experimental|pirfenidone|Eligible participants for clinical trial were randomized in a 2:1 ratio to pirfenidone/blank add-on. Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. Investigators were allowed to adjust the dose according to the participants' tolerance.
2961556|NCT02821689|No Intervention|Blank|Eligible participants for clinical trial were randomized in a 2:1 ratio to pirfenidone/blank add-on.
2961557|NCT02821676|Experimental|PEC1/SPB Block|
2961558|NCT02821676|Active Comparator|Intercostal Block|
2961559|NCT02821663|Experimental|Vocal intervention|Vocal intervention
2961560|NCT02821650|Experimental|Intervention|Intervention arm will be administered with improved cook stoves (TEJ- Traditional stove to Efficient stove in Jhuggi).
2961561|NCT02821650|No Intervention|control|control arm will continue using traditional cook stoves (chulha) or a combination of the traditional stove and the kerosene/diesel stove.
2961562|NCT02821637|Other|Effort rehabilitation program|"An effort rehabilitation program designed for obese and overweight children or teens : 13 weekly sessions of 1hour30 then 1 session 2 months, 6 months and 12 months later.~This program is part of the routine practice of the Pediatric Obesity and Pediatric Diabetes Organization of Mulhouse.~Child Health Questionnaire (CHQ) of quality of life are completed by parents and children on the 1st and the 13th session, then 3 more times : 2, 6 and 12 months after the 13th session.~Eurofit tests of Physical Fitness performed on the 1st and the 13th session, then 3 more times : 2, 6 and 12 months after the 13th session."
2961563|NCT02821624|Experimental|Cohort 1|G1T38 or placebo
2961564|NCT02821624|Experimental|Cohort 2|G1T38 or placebo
2961565|NCT02821624|Experimental|Cohort 3|G1T38 or placebo
2961566|NCT02821624|Experimental|Cohort 4|G1T38 or placebo
2961578|NCT02821598|Experimental|Lower limb pattern 1|Lower Limb pattern with flexion - adduction - external rotation with knee flexion;
2961579|NCT02821598|Experimental|Lower limb pattern 2|Lower Limb pattern with flexion - abduction - internal rotation with knee flexion;
2961580|NCT02821598|Experimental|Lifting to the right|
2961581|NCT02821598|Active Comparator|Sit to Stand|Sit to Stand task
2961582|NCT02821585|Active Comparator|Mediterranean Diet|Participants will receive nutritional lessons on the principles of the Mediterranean diet. This type of diet is defined with a carbohydrate intake of 45-55% of total energy intake, 15-20% of proteins, 30-35% of lipids and less than 7% for saturated fat. Nine sessions with a nutritionist are planned to cover various topics of the diet.
2961583|NCT02821585|Placebo Comparator|Low Fat Diet|Participants will receive nutritional lessons on the principles of the low fat diet. This type of diet is defined with a carbohydrate intake greater than 45% of total energy intake, 15-20% of proteins, less than 30% of lipids and less than 7% for saturated fat. Nine sessions with a nutritionist are planned to cover various topics of the diet.
2961584|NCT02821572||patient|
2961585|NCT02821572||control|
2961586|NCT02821559|Experimental|triweekly then biweekly|The arm A consisted of 2 cycles of triweekly TOMOX (standard dose 3mg/m2 of Raltitrexed in 15-minutes infusion, and 130mg/m2 of oxaliplatin in 2h infusion, every 3 weeks), followed by 2 cycles of biweekly TOMOX (2mg/m2 of Raltitrexed in 15-minutes infusion, and 85mg/m2 of oxaliplatin in 2h infusion, every 2 weeks).
2961587|NCT02821559|Experimental|biweekly then triweekly|The arm B consisted of the reserve sequence starting with 2 cycles of biweekly TOMOX followed by 2 cycles of triweekly TOMOX regimen.
2961588|NCT02821546|Placebo Comparator|standard hydration|Patients underwent first-time ERCP to receive standard fluid hydration with Lactated Ringer's solution at a rate calculated by the Holliday-Segar method given peri-procedurally starting 2 hours prior to procedure, and continued during and after procedure to complete 24 hours.
2961589|NCT02821546|Active Comparator|aggressive hydration|Patients underwent first-time ERCP to receive aggressive fluid hydration with Lactated Ringer's solution at a rate of 150 ml/hr starting 2 hours prior to procedure, and continued during and after procedure to complete 24 hours.
2961590|NCT02821533|Other|TACE using a high dose of cisplatin|Two consecutive treatments at two months apart will be given. A delay in the second treatment is allowed if patients do not recover to an acceptable state for subsequent cycle of treatment. Two treatment sessions at one month apart may be required for each complete treatment to cover all lesions when the lesions are diffusely distributed and involving both lobes.
2961591|NCT02821520|Experimental|Initial PDT combination with Conbercept|"Conbercept 0.5 mg(0.05ml): Administered at baseline, and then PRN based on retreatment criteria monthly from month 1 to 11.~PDT: PDT with verteporfin is administered at baseline and then PRN PDT combination with conbercept injection based on retreatment criteria from month 3 to 11.~PDT treatment must be administered within 7 days after the injection. If same day treatment of conbercept and PDT is performed, conbercept injection is to be administered at least 2 hours after the PDT.~PDT should cover the whole area of polyps and branch vascular net (BVN).The PRN PDT retreatment intervals should be no less than 3 months."
2961592|NCT02821520|Active Comparator|Delayed PDT combination with Conbercept|"Conbercept 0.5 mg(0.05ml): Administered at baseline, and then PRN based on retreatment criteria monthly from month 1 to 11.~PDT:PRN PDT combination with conbercept injection based on retreatment criteria from month 3 to 11.~PDT treatment must be administered within 7 days after the injection. If same day treatment of conbercept and PDT is performed, conbercept injection is to be administered at least 2 hours after the PDT.~PDT should cover the whole area of polyps and branch vascular net (BVN).The PRN PDT retreatment intervals should be no less than 3 months."
2961593|NCT02821507|Experimental|sirolimus and cyclophosphamide|combining sirolimus 4mg daily orally and cyclophosphamide 200mg day 1 to 7 and 15 to 21 orally in a 4 week schedule
2961594|NCT02821494|Experimental|Hespecta|Four dose groups of Hespecta
2961595|NCT02821481|Experimental|Beta-alanine and muscular endurance exercise|Receive 3.2 g/day beta-alanine and 3 days per week of endurance resistance training for 12 weeks
2961596|NCT02821481|Experimental|Beta-alanine without muscular endurance training|Receive 3.2 g/day beta-alanine with no endurance resistance training for 12 weeks
2961597|NCT02821481|Placebo Comparator|Placebo and muscular endurance exercise|Receive similar dextrose placebo and 3 days per week of endurance resistance training for 12 weeks
2961598|NCT02821481|Placebo Comparator|Placebo without muscular endurance training|Receive similar dextrose placebo with no endurance resistance training for 12 weeks
2961599|NCT02821468|Experimental|Droglican|Chondroitin Sulfate 1,200mg + Glucosamine Hydrochoride 1,500mg
2961600|NCT02821468|Experimental|Control|Untreated arm
2961601|NCT02821455||Lung Surgery with One-Lung Ventilation|A single cohort of patients undergoing one-lung ventilation during lung surgery
2961602|NCT02821442|Experimental|Acupuncture|Acupuncture will consist of acupuncture points ST36, LR3, LI4 bilaterally x 30 minutes, once a week over 6 weeks. ST36 will have EA with 2Hz at the maximum tolerated intensity (ES-130 Portable Japanese Electro-Acupuncture Device, UPC Medical Supplies Inc. South El Monte, CA, USA).
2961603|NCT02821442|Sham Comparator|Sham Acupuncture|Sham acupuncture (Streitberger Placebo Needles, Asiamed) uses the same points and treatment parameters but the placebo needle does not penetrate the skin and the current for EA is not turned on.
2961604|NCT02821429||Patient with mechanical ventilation|Patient will be followed with combined Thoracic Echography Record
2961605|NCT02821416|Experimental|Benralizumab|Benralizumab administered subcutaneously
2961606|NCT02821416|Placebo Comparator|Placebo|Placebo administered subcutaneously
2961607|NCT02821403|Experimental|Young adults|adults without presbyopia who aged 18-35 years
2961608|NCT02821403|Experimental|Middle-aged adults|adults with presbyopia who aged over 40 years
2961609|NCT02821390|Active Comparator|Nepafenac 0.1% Eye Drops|One drop of Nepafenac 0.1% Eye Drops will be instilled to the eye's cul de sac prior to the intravitreal injection.
2961610|NCT02821390|Placebo Comparator|Artificial Tears|One drop of Artificial Tears will be instilled to the eye's cul de sac prior to the intravitreal injection.
2961611|NCT02821377|Experimental|intravenous furosemide|intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge Intervention: drug: furosemide ; other name: lasix
2961612|NCT02821377|Experimental|intravenous hypertonic saline solutions|small volumes of hypertonic saline solutions (HSS) (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge Intervention: Hypertonic saline solutions (1.4-4.6%NaCl) Intervention other name: not specified
2961613|NCT02821377|Active Comparator|seriated paracentesis|no intervention Intervention: no drug only seriated paracentesis repeated paracentesis from the first day after admission until 3 days before discharge
2961614|NCT02821364|Other|Advanced Life Support|ALS providers are trained and able to perform certain procedures such as intubation with endotracheal tubes and placement of intravenous catheters. Endotracheal intubation is often performed by pre-hospital providers in critically ill trauma patients because it is believed that it allows for protection of the airway and better delivery of oxygen. However, most studies actually show that intubation does not provide a survival advantage to this patient population and actually could result in worse outcomes. Intravenous catheter placement and administration of intravenous fluids is also routinely performed however, studies have shown that it is also not helpful.
2961615|NCT02821364|No Intervention|Basic Life Support|Subjects randomized to the study group will receive basic life support (BLS) level care. This means that pre-hospital procedures such as endotracheal intubation and intravenous fluid administration will not be carried out. However, passive oxygen and needle thoracostomy, if required for tension pneumothorax, will be permitted if medically necessary.
2961616|NCT02821351|Experimental|DiamondTemp|Bilateral pulmonary vein isolation by RF ablation using DiamondTemp temperature controlled catheter and RF generator/pump system
2961617|NCT02821338|Active Comparator|Sequence 1|The treatments will be administered according to a randomly assigned pre-generated sequence involving the randomized, four-period, two sequence, fully replicate crossover design. Two study drugs involved are: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
2961618|NCT02821338|Active Comparator|Sequence 2|The treatments will be administered according to a randomly assigned pre-generated sequence involving the four-period, two sequence, fully replicate crossover design. Two study drugs involved are: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
2961619|NCT02821325||MRI|Radiology
2961620|NCT02821312|Active Comparator|Active in Group A1~A7|In each of Groups A1 to A7, 8 subjects will receive DA-8010.
2961621|NCT02821312|Placebo Comparator|Placebo in Group A1~A7|In each of Groups A1 to A7, 2 subjects will receive placebo.
2961622|NCT02821312|Active Comparator|Active in Group B1~B4|In each of Groups B1 to B4, 8 subjects will receive DA-8010.
2961623|NCT02821312|Placebo Comparator|Placebo in Group B1~B4|In each of Groups B1 to B4, 2 subjects will receive placebo.
2961624|NCT02821299|Experimental|Laryngeal transplantation|Laryngeal transplantation
2961625|NCT02821273|Experimental|Modified INSURE|Modified INSURE is intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.
2961626|NCT02821273|Active Comparator|INSURE|INSURE technique meas surfactant administration through intubation-surfactant-extubation. And noninvasive ventilation is immediately used after surfactant.
2961627|NCT02821247||Group 1|adult wet Age Related Macular degeneration (AMD) treatment naïve and will be treated intravitreal aflibercept injection
2961628|NCT02821234|Experimental|Insomnia group|Patients with insomnia: sleep complaints, of at least 3 nights a week, for at least 3 months, affected daytime functioning, objectified low sleep quality (SE <85%) with 10 days actigraphy occurred in the last 2 months
2961629|NCT02821234|Experimental|Control group|Volunteer without sleep problems either self-reported or objectified through actigraphy (SE ≥85%)
2961630|NCT02821208||One cohorte : patient psychogenic nonepileptic seizures|The Psychogenic nonepileptic seizures (PNESs) are paroxysmal episodes type of abnormal movements, behavior modification or alteration of the contact-like seizures. These episodes are involuntary and underpinned by an unconscious psychological processes. In the International Classification of Disease-10 (ICD-10), they are classified as dissociative phenomena as conversing syndromes in the Manual of Diagnostic and Statistical Mental Disorders-IV (DSM-IV). The participants of the study only receive the usual care they would have if they were not included (no new/different intervention allocated in the study).
2961631|NCT02821182|Experimental|Anti-PD1 treatment in combination with SBRT|Patients receiving anti-PD1 treatment will be treated with high-dose radiotherapy to one lesion in 3 fractions prior to the second cycle of systemic therapy.
2961632|NCT02821169|Placebo Comparator|saline solution 0.9%|injection of saline solution in the sphenopalatine area in both nasal fossa
2961633|NCT02821169|Active Comparator|ropivacaine (2mg/ml)|injection of ropivacaine in the sphenopalatine area in both nasal fossa
2961634|NCT02821143|Experimental|Intervention group|Every patient identified as belonging to a palliative care after the inclusion criteria will receive intervention with a follow-up with Telemedicine consultation
2961635|NCT02821143|Other|Control group|Every patient identified as belonging to a palliative care after the inclusion criteria will receive Usual palliative care
2961636|NCT02821130||Cystic Fibrosis Patients|Participants diagnosed with cystic fibrosis
2961637|NCT02821117|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
2961638|NCT02821104||Healthy Adolescents|
2961639|NCT02821091|No Intervention|Control young adults|Healthy adults, age between 20 to 59 yeas old
2961640|NCT02821091|No Intervention|Control old adults|Healthy adults, age between 60 to 80 yeas old
2961641|NCT02821091|Experimental|Exercise old adults|Healthy adults, age between 60 to 80 yeas old received interactive dynamic balance training
2961642|NCT02821078|Experimental|Participants|"In addition to the standard clinical MR protocol, 2 added sequences:~4D flow imaging sequence~standard 2D-PhaseContrast at portal trunk level as reference"
2961643|NCT02821065|Experimental|Home Telemonitoring|
2961644|NCT02821052||insulin degludec/insulin aspart|
2961737|NCT02820363|Experimental|Test|"Tibial fracture fixation with IM Nail. Apply CERAMENT™|G applied to bony void(s)."
2961738|NCT02820363|Active Comparator|Control|Tibial fracture fixation with IM nail.
2961739|NCT02820337||non comparative|Bariatric surgery patients infected with HIV, overweight with controlled viral load and HIV lipohypertrophy particularly truncal
2961740|NCT02820324|Experimental|Treatment 1 Oliceridine|
2961741|NCT02820324|Experimental|Treatment 2 Oliceridine|
2961742|NCT02820324|Experimental|Treatment 3 Oliceridine|
2961645|NCT02821026|Experimental|Omental islet transplant|At the time a suitable islet preparation becomes available, the patient will receive allogeneic islet cells placed in an omental pouch. Islet transplant will be performed under Anti-Thymocyte Globulin induction immunosuppression (5 doses, day -2 prior to transplant to day 2 post-transplant). Maintenance mycophenolate mofetil therapy (1-2 g/day as BID dosing) will be started on Day -1 pre-transplant. Tacrolimus will be administered orally twice daily on Day 1 post-transplant to maintain a trough level of 10-12 ng/mL for 3 months, then 6-10 ng/mL thereafter. Etanercept will be given IV before the islet transplant (50 mg), and then at 25 mg (subcutaneously) on POD +3, +7 and +10. Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
2961646|NCT02821013|Active Comparator|Arm 1: Intermittent PD-1 Inhibitor therapy|Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.
2961647|NCT02821013|Active Comparator|Arm 2: Continuous PD-1 Inhibitor therapy|Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.
2961648|NCT02821000|Experimental|Pembrolizumab|Participants receive pembrolizumab 2 mg/kg intravenously on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
2961649|NCT02820987|Active Comparator|MEROPENEM|After enrollment, patients of MEROPENEM arm will receive an initial 2g bolus of MEROPENEM and 2g infusion over 3 hours every eight hours, during 48 hours, without modification of rhythm and dose according to renal function.
2961650|NCT02820987|Active Comparator|PIPERACILLIN-TAZOBACTAM|After enrollment, patients of PIPERACILLIN - TAZOBACTAM arm will receive an initial 4g bolus of PIPERACILLIN - TAZOBACTAM and a 16g continuous infusion per day, during 48 hours, without modification of rhythm and dose according to renal function.
2961651|NCT02820987|Active Comparator|CEFEPIME|After enrollment, patients of CEFEPIME arm will receive an initial 2g bolus of CEFEPIME and a 6g continuous infusion per day, during 48 hours, without modification of rhythm and dose according to renal function.
2961652|NCT02820974||Healthy control|Healthy women of child bearing age (25-39) with regular cycles.
2961653|NCT02820974||Perimenopause|Women at the age of 40-54 with irregular cycles filling in th criteria of perimenopause.
2961654|NCT02820974||Menopause|Women at the age of over 55 without normal cycles filling in th criteria of menopause.
2961655|NCT02820961|Active Comparator|Cohort 1|Cohort 1 will evaluate exemestane's effect on the PK of entinostat. Each treatment cycle is 28 days.
2961656|NCT02820961|Active Comparator|Cohort 2|Cohort 2 will enroll when Cohort 1 enrollment is complete. Cohort 2 will evaluate entinostat's effect on the PK of exemestane. Each treatment cycle is 28 days.
2961657|NCT02820948|Experimental|Vitamin E ointment application|Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.
2961658|NCT02820948|No Intervention|No Vitamin E ointment application|No vitamin E ointment was performed.
2961659|NCT02820935|Experimental|Part 1, Period 1: CC-220|Single dose of 0.6mg CC-220
2961660|NCT02820935|Experimental|Part 1, Period 2: itraconazole with CC-220|Multiple does of 200 mg itraconazole alone, with a single dose of 0.6 mg CC-220 plus itraconazole
2961661|NCT02820935|Experimental|Part 2, Period 1: CC-220|Single dose of 0.6mg CC-220
2961662|NCT02820935|Experimental|Part 2, Period 2: rifampin with CC-220|Multiple doses of 600 mg rifampin alone, with a single dose of 0.6 mg CC-220 plus rifampin
2961663|NCT02820922||Orthopedic emergency surgery|Patients of all ages who have undergone emergency orthopedic surgery The analysis of medical data with regard to age, sex, the American Society of Anesthesiologists (ASA) score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
2961664|NCT02820909|Experimental|Ultrasound guidance|46 patients in the experimental ultrasound group
2961665|NCT02820909|Active Comparator|Anatomical guidance|46 patients in the anatomical group
2961666|NCT02820896|Placebo Comparator|Multiple Dose Placebo IV|Healthy participants or participants with Alzheimer's disease will receive multiple doses of matching placebo IV QW, a total of 4 doses.
2961667|NCT02820896|Experimental|Multiple Dose RO7105705 IV|Healthy participants or participants with Alzheimer's disease will receive multiple doses of RO7105705 IV QW, a total of 4 doses.
2961668|NCT02820896|Experimental|Single Dose RO7105705 SC|Healthy participants will receive a single dose of RO7105705 SC on Day 1.
2961669|NCT02820896|Placebo Comparator|Single dose Placebo IV|Healthy participants will receive a single dose of placebo IV on Day 1.
2961670|NCT02820896|Experimental|Single dose RO7105705 IV|Healthy participants will receive a single dose of RO7105705 IV on Day 1.
2961671|NCT02820883|Experimental|High dosage vaccine|High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)
2961672|NCT02820883|Experimental|Middle dosage vaccine|Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)
2961673|NCT02820883|Experimental|Low dosage vaccine|Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)
2961674|NCT02820870|Experimental|Primary Care Intervention Group|"Primary care providers will receive a generated print-out of statin recommendations for patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant). Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the teamlets for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guidelines."
2961675|NCT02820870|No Intervention|Usual Care Group|PACT teams that were not randomized to the intervention will serve as a usual care group and will be expected to follow the VA guidelines and HEDIS measures as part of the VA national roll-out.
2961676|NCT02820857|Experimental|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
2961677|NCT02820857|Active Comparator|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
2961743|NCT02820324|Placebo Comparator|Treatment 4 Placebo|
2961744|NCT02820324|Active Comparator|Treatment 5 Morphine|
2961745|NCT02820311|Experimental|TD-4208 175 mcg|double-blind
2961746|NCT02820311|Experimental|TD-4208 700 mcg|double-blind
2961747|NCT02820311|Placebo Comparator|Placebo for TD-4208|double-blind
2961748|NCT02820311|Active Comparator|Moxifloxacin 400 mg|open-label
2961678|NCT02820844|Experimental|GSK1358820 Injection 100 U|"Initially, subjects will receive a single (double-blind) treatment with GSK1358820 (20 injections of 0.5 mL each) into the detrusor muscle of the bladder, using cystoscopy, and under local anesthesia. If the criteria for re-treatment are met between 12 and 36 weeks after the first treatment, subjects will receive a second treatment with GSK1358820 (open-label). A third treatment with GSK1358820 (open-label) may be given until 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.~Subjects will receive prophylactic antibiotic therapy beginning up to 3 days prior to treatment and continuing up to 3 days following treatment."
2961679|NCT02820844|Placebo Comparator|Placebo Injection|"Initially, subjects will receive a single (double-blind) treatment with Placebo (20 injections of 0.5 mL each) into the detrusor muscle of the bladder, using cystoscopy, and under local anesthesia. If the criteria for re-treatment are met between 12 and 36 weeks after the first treatment, subjects will receive a second treatment, this time with open-label GSK1358820. A third treatment with open-label GSK1358820 may be given until 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.~Subjects will receive prophylactic antibiotic therapy beginning up to 3 days prior to treatment and continuing up to 3 days following treatment."
2961680|NCT02820805|Experimental|Meal skipping|No meal given
2961681|NCT02820805|Experimental|Mashed potatoes|Carbohydrate Test Meal (50 g of available carbohydrates)
2961682|NCT02820805|Experimental|French fries|Carbohydrate Test Meal (50 g of available carbohydrates)
2961683|NCT02820805|Experimental|Hash browns|Carbohydrate Test Meal (50 g of available carbohydrates)
2961684|NCT02820805|Experimental|Rice|Carbohydrate Test Meal (50 g of available carbohydrates)
2961685|NCT02820805|Experimental|Beans|Carbohydrate Test Meal (50 g of available carbohydrates)
2961686|NCT02820792|Active Comparator|LMA ProtectorTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
2961687|NCT02820792|Active Comparator|Ambu AuraGainTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
2961688|NCT02820779|Experimental|WILLIS|Patients undergo WILLIS intracranial covered stent interventional treatment
2961689|NCT02820766||Journey II BCS Knee|Physical Therapy Observational
2961690|NCT02820766||All Other Posterior Stabilized Knees|Physical Therapy Observational
2961691|NCT02820753|No Intervention|Enhanced Usual Care|Patients will receive EHR tools (patient-friendly MedSheets about their medicines, MedList putting their medicines into the Universal Medication Schedule, and UMS sigs on their Rx bottles).
2961692|NCT02820753|Active Comparator|EHR + Text|Patients receive EHR tools, as well as text reminders telling them to take their medicine. Texts will be set to patients' personal schedules and will have a standard length of time before patients then can opt back in to continue.
2961693|NCT02820753|Active Comparator|EHR + Portal|Patients receive EHR tools, as well as enrollment into their clinic's portal. Patients will be prompted every other week to fill out an online survey, asking if they filled their medication, about any side effects, or concerns. Any concerns or questions will be followed up by a nurse, providing a feedback loop for patients.
2961694|NCT02820753|Active Comparator|EHR + Text + Portal|Patients in this arm will receive all interventions - EHR tools, text reminders, and portal communication.
2961695|NCT02820740|Other|NeuroBlate LITT Treatment|This is a single arm study. All eligible study subjects will undergo LITT with the NeuroBlate System.
2961696|NCT02820714|Experimental|BLI801 Laxative|BLI801 oral laxative
2961697|NCT02820701|No Intervention|Control|All participants will receive an initial palpatory assessment of the sacral base asymmetry and then an initial ultrasound evaluation of sacral base asymmetry. After the ultrasound assessment, the control group will wait in another room for approximately 30 minutes.
2961698|NCT02820701|Experimental|Treatment|All participants will receive an initial palpatory assessment of the sacral base asymmetry and then an initial ultrasound evaluation of sacral base asymmetry. Participants in the Treatment group will receive OMT to address sacral base asymmetry after the initial ultrasound assessment.
2961699|NCT02820688|Active Comparator|Concentrated|Infraclavicular nerve block under guidance of ultrasonography will be performed using an undiluted solution of 45mg bupivacaine and 180mg prilocaine (bupivacaine 0.25% and prilocaine 1%, 18mL in total) to patients in this group
2961700|NCT02820688|Active Comparator|Diluted by 33%|Infraclavicular nerve block under guidance of ultrasonography will be performed using a solution of 45mg bupivacaine and 180mg prilocaine diluted by 33% (bupivacaine 0.167% and prilocaine 0.66%, 27mL in total) to patients in this group
2961701|NCT02820688|Active Comparator|Diluted by 50%|Infraclavicular nerve block under guidance of ultrasonography will be performed using a solution of 45mg bupivacaine and 180mg prilocaine diluted by 50% (bupivacaine 0.125% and prilocaine 0.5%, 36mL in total) to patients in this group
2961702|NCT02820675|Other|intervention|all hospitals participating in the icosmos trial will be supported in implenatation of the two main interventions.
2961703|NCT02820662|Experimental|RETCAM|
2961704|NCT02820649|Experimental|Exercise training|7 weeks of exercise training
2961705|NCT02820649|Sham Comparator|Control|Sedentary group
2961706|NCT02820636|Experimental|InVita|Participants receive the Socio-Cognitive Behavior Therapy (S-CBT) treatment.
2961707|NCT02820636|Active Comparator|Treatment as Usual|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents
2961708|NCT02820623|Experimental|Self-report|Therapists randomized to this condition will complete a brief self-report measure, the Therapy Process Observational Coding System for Child Psychotherapy Strategies Scale-Self Report version (TPOCS-SR) for each of the recorded clinical encounters with enrolled youth. The TPOCS-SR will be a self-report version of the Therapy Process Observational Coding System for Child Psychotherapy-Strategies Scale (TPOCS-S) and will be created in collaboration with the instrument developer (McLeod). In this condition, the investigators will (a) provide an operational definition for each item on the TPOCS-SR (e.g., cognitive education: teaches client the cognitive model (e.g., thoughts influence behavior)/identifies how the cognitive model applies to a specific aspects of the client's life), and (b) provide therapists with a 30-minute training session that includes sample vignettes of particular behaviors and information about how those vignettes should be rated.
2961709|NCT02820623|Experimental|Chart Stimulated Recall|"Therapists randomized to this condition will be asked to bring the charts of three enrolled youth to the chart-stimulated recall interview. A trained interviewer will ask the therapists how well they recall the encounter (rating of memory quality) followed by an open-ended question (Talk me through your last session with your client. Tell me what you did.). While the therapists are speaking, the interviewer will note any elements that represent a prescribed CBT strategy. The interviewer will go through a list of cognitive-behavioral strategies based upon the TPOCS-S and probe to determine if the therapists completed any of the strategies. Follow-up questions will be used to explore to what degree an element was used and how skillfully and responsively the strategies were used."
2961710|NCT02820623|Experimental|Behavioral Rehearsal|"Therapists randomized to this condition will be asked to engage in role-plays demonstrating the CBT strategies used with the three enrolled youth. The investigators will provide therapists with a list of the TPOCS-S CBT strategies and ask them to identify the CBT strategies used in their recorded encounter. The investigators will randomly select one of the strategies they report for each role-play. The investigators will then tell them, Please role-play how you used this strategy in session with your client, with the trained actor in front of you. Later, an independent rater will rate therapists' adherence and skill based on established scoring criteria."
2961711|NCT02820610|Active Comparator|Dexmedetomidine|2 mg/kg bupivacaine 25% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
2961712|NCT02820610|Active Comparator|Magnesium sulfate|2 mg/kg bupivacaine 25% and 50 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
2961713|NCT02820610|Placebo Comparator|Control group|2 mg/kg bupivacaine 25% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
2961714|NCT02820597|Experimental|Intervention|Treatment with the ClariFix Device
2961715|NCT02820584|Experimental|GSC-loaded autologous dendritic cells|DC-GSC immunotherapy. Six vaccinations are envisaged. The first three vaccinations will be performed every two weeks; subsequent three vaccinations every month. The first vaccination will be performed using 20 million DC, the second and third with 10 million DC; and from the 4th vaccine 5 million DC
2961716|NCT02820558|Experimental|Substance P - 1nmol/kg|Substance P 1nmol/kg intra-celiac artery, single treatment
2961717|NCT02820558|Experimental|Substance P - 5nmol/kg|Substance P 5nmol/kg intra-celiac artery, single treatment
2961718|NCT02820558|Experimental|Substance P - 15nmol/kg|Substance P 15nmol/kg intra-celiac artery, single treatment
2961719|NCT02820558|Experimental|Substance P - 45nmol/kg|Substance P 45nmol/kg intra-celiac artery, single treatment
2961720|NCT02820545||Sociological interview|Patients will take a sociological interview with a sociologist during their hospital stay
2961721|NCT02820545||Self-administrated questionnaire|Patients will take a self-administrated questionnaire at the end of their hospital stay and one week after they left hospital
2961722|NCT02820532|Other|Tracking|The volunteers will be placed on the treatment couch. Their respiratory motion will be measured and the treatment couch will be moved accordingly. During the couch motion experiment the heartbeat, the skin humidity, the respiratory characteristics and the pupil motion will be additionally measured.
2961723|NCT02820519|Experimental|Loxapine|Loxapine Capsules 10 mg Day 1- 14: 10 mg b.i.d Day 15-28: 10 mg t.i.d Day 29-42: 20 mg b.i.d. Day 43-56: 20 mg t.i.d. Dosages will be escalated according to analgesic efficacy and tolerability.
2961724|NCT02820506|Other|High risk endometrial cancer|Patients will receive sentinel node mapping, followed by removal of PET-positive lymph nodes and finally conventional pelvic lymphadenectomy.
2961725|NCT02820506|Other|Cervical cancer tumor size 2-4 cm|Patients will receive sentinel node mapping, followed by removal of PET-positive lymph nodes and finally conventional pelvic lymphadenectomy.
2961726|NCT02820493|Other|single arm study|Vedolizumab 300 mg iv at week 0, week 2 and week 6, than every 8 weeks.
2961727|NCT02820480|Experimental|Patients/health professionals|Stroke AND cerebral palsy PATIENTS: greater than 18 years of age, who are more than 3 months post stroke, as well as health professionals who have considerable experience in stroke rehabilitation will be asked to evaluate the design of the Rehab in a Crate system. The aim is to survey stroke survivors and healthcare professionals on the design, ease of use, utility, and various features of, both existing and those yet-to-be-developed.
2961728|NCT02820467|Experimental|patients with suspicion of CLI|patients presenting with peripheral artery disease and suspicion of critical limb ischemia as assessed by TASK II consensus 30 patients will be enrolled and will benefit of measures of TcPO2, too systolic blood pressure and skin perfusion pressure and in the same time angiography with fluorescence (Indocyanine grey 0.05 mg/kg by intravenous injection
2961729|NCT02820454|Experimental|AGuIX and radiotherapy|"Patients receive a single intravenous injection of AGuIX on day 1. Then patients undergo a whole brain radiation therapy, 5 days a week in weeks 1-2. The first radiotherapy session will be performed 4 hours after AGuIX injection.~Five dose escalation cohorts : 15 mg/kg, 30mg/kg, 50mg/kg, 75mg/kg and 100 mg/kg"
2961730|NCT02820441|Experimental|ZOPICLONE|Zopiclone 3.5 mg capsule by mouth daily for 2 weeks
2961731|NCT02820441|Placebo Comparator|PLACEBO|Placebo 3.5 mg capsule by mouth daily for 2 weeks
2961732|NCT02820428|Other|Healthy participants|Submission of the scale 'Evaluation of behaviour in Parkinson's Disease' to healthy subjects
2961733|NCT02820415||infertile couples undergoing ICSI for PGS/PGT|patients aged between 29.0 and 42.3 years, with basal FSH on day 3 between 2.9 and 12.0 IU/l. Undergoing 36 patients for RIF or RM. In each couple, the two partners had a normal karyotype. The patients underwent one to two cycles of ovarian stimulation to vitrify and accumulate oocytes and a last (second or third) cycle of ovarian stimulation. Ovarian stimulation was performed by the administration of recombinant FSH and LH (Gonal-F and Luveris: Merck-Serono, London, UK or Puregon, MSD, Franklin Lakes, USA) from cycle day 3 and luteal gonadotrophin-releasing hormone antagonist flexible schema (Cetrotide : Merck-Serono, London, UK).
2961734|NCT02820389||Optical colonoscopy|Patients with suspected colorectal cancer will undergo optical colonoscopy as the initial imaging modality.
2961735|NCT02820389||CT Colonography|Patients with suspected colorectal cancer will undergo Computed Tomography Colonography (CTC) as the initial imaging modality. Subsequent imaging might be required based on the findings from the CTC scan.
2961736|NCT02820376|Other|All patients|"Differential renal function assessment by 4D CT:~All patients will undergo both CT and SPECT assessment of differential renal function; each patient will be his own comparator"
2961749|NCT02820298|Experimental|Group 1 - Bexagliflozin with food|"Group 1 subjects will take one dose of 20 mg of bexagliflozin with food on day 1 after an overnight fast and will take a second dose of bexagliflozin without food on day 8 after an overnight fast.~Group 2 subjects will take inosine without food on day 1 after an overnight fast and will take a second dose of inosine with food on day 8 after an overnight fast."
2961750|NCT02820298|Experimental|Group 2 - Bexagliflozin without Food|Group 2 subjects will take one dose of 20 mg bexagliflozin without food on day 1 after an overnight fast and will take a second dose of bexagliflozin with food on day 8 after an overnight fast.
2961751|NCT02820285|Other|Morbid obese patients|
2961752|NCT02820285|Other|Control patients|
2961753|NCT02820285|Other|Patients with overweight, steatosis and steatohepatitis|
2961754|NCT02820272|Experimental|NPWT with cold water|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was the intervention with injection of cold sterile water kept in 4°C temperature into sponge 10 minutes before dressing change.
2961755|NCT02820272|Active Comparator|NPWT with normal saline room temp|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was the intervention with injection of room temperature sterile water kept in room temperature into sponge 10 minutes before dressing change.
2961756|NCT02820272|Placebo Comparator|NPWT without other intervention|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was no injection of any liquids into sponge before dressing change.
2961757|NCT02820246||hospitalised patients|all patients present in a hospital ward during the morning shift
2961758|NCT02820220||Patient/patient attendants|"Study subjects will be females.~Age at enrolment should be more than 18 years.~Attending Department of Paediatrics OPD/emergency/well-baby clinics/immunisation clinics OR Department of Gynaecology and Obstetrics OPD/emergency/Ante-natal clinics/Post-natal clinics of Lady Hardinge Medical College and associated hospitals.~Written informed consent to participate in the study."
2961759|NCT02820220||Students,nursing|"Pursuing Bsc Nursing(in their final year) or intern of college of nursing LHMC~Written informed consent to participate in the study"
2961760|NCT02820220||In-service nurses|"Posted in Department of Paediatrics indoor/OPD/well-baby clinics/immunisation clinics or Department of Gynaecology and Obstetrics indoor/OPD/emergency/Ante-natal clinics/Post-natal clinics of Lady Hardinge Medical College and associated hospitals.~Written informed consent to participate in the study."
2961761|NCT02820207||Vulnerable plague|The patients suffering from carotid artery stenosis were identified as the vulnerable plague group by Contrast Enhanced Ultrasound whose plagues were found intraplaque neovascularization
2961762|NCT02820194|Active Comparator|Stereotactic body radiation therapy|Patients are treated with Stereotactic Body Radiation Therapy, a methodology for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule.
2961763|NCT02820194|Active Comparator|Microwave Ablation|Patients are treated with Microwave Ablation,a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis.
2961764|NCT02820181|Experimental|novel tracheostomy bi-ties|those with the novel tracheostomy bi-ties
2961765|NCT02820181|Active Comparator|traditional tracheostomy tie|those with traditional tracheostomy tie
2961766|NCT02820155|Placebo Comparator|Placebo|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
2961767|NCT02820155|Experimental|RGN1016_50mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
2961768|NCT02820155|Experimental|RGN1016_100mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
2961769|NCT02820155|Experimental|RGN1016_200mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
2961770|NCT02820155|Experimental|RGN1016_400mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
2961771|NCT02820155|Experimental|RGN1016_800mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
2961772|NCT02820142||Bacteremia with Sepsis group|Patients aged 20 years or older with a diagnosis of bacteremia will be eligible for inclusion in the study.
2961773|NCT02820129|Experimental|Wallet Card Group|"The intervention arm is comprised of:~Patients from the TAPER study who receive a medication wallet card with their medications and medical conditions listed."
2961774|NCT02820129|Placebo Comparator|Control Group|"Standard of care as well as wait list control. These participants will receive a reminder wallet card which states, Remember to keep an up-to-date listing of your medications and bring your medications to your doctor's appointments."
2961775|NCT02820116|Experimental|Icotinib|Patients receive Icotinib PO TID for 8 weeks and then undergo thoracotomy.
2961776|NCT02820103|Active Comparator|Information leaflet (control)|Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge. The information from two leaflets: 1. 'Using GTN', produced by the hospital and 'Angina' produced by the British Heart Foundation, published 08/04/2014 and available at https://www.bhf.org.uk/publications/heart-conditions/angina . The information explains the symptoms of angina and heart attack and advises what to do in the event of experiencing these symptoms. This information will be presented in written text format on screen.
2961777|NCT02820103|Experimental|Text+Visual BCT-based intervention (Intervention Group 1)|Participants in the visual intervention group will receive the control condition specified above PLUS a specifically developed Text+Visual BCT-based intervention, comprising the 12 BCTs identified earlier in a Systematic Review and expert consensus study. The BCTs are Problem solving; Action planning; Social support (practical); Social support (emotional); Instruction on how to perform the behaviour; Information about health consequences; Salience of health consequences; Prompts/cues; Credible source; Pro's & Con's; Comparative imagining of future outcomes; Mental rehearsal of successful performance
2961807|NCT02819921|Experimental|Desvenlafaxine succinate 50mg|50 mg Desvenlafaxine succinate tablet once daily for 1 week, then 1 tablets of 50mg Desvenlafaxine succinate tablet and 1 tablet of 50mg placebo tablet once daily for 3 weeks, then 50mg placebo tablet once daily for 3 days.
2961850|NCT02819687|Experimental|RDX5791 900mg QD (SAD phase)|900mg of RDX5791 administered once daily PO fasting
2961778|NCT02820103|Experimental|Text-only BCT-based intervention (Intervention Group 2)|Information leaflet (usual care) plus text-only BCT-based intervention (Intervention group 2) Participants in the text-only BCT-based intervention group will receive the control condition specified above plus a text-only BCT-based intervention. This was developed in the same way as the text+visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen instead.
2961779|NCT02820090||Success with SBT|The patient have a success in SBT.
2961780|NCT02820090||Success with mechanical ventilation|Weaning from mechanical ventilation is successful
2961781|NCT02820090||failure with SBT|The patient have a failure in SBT.
2961782|NCT02820090||failure with mechanical ventilation|Weaning from mechanical ventilation is failed
2961783|NCT02820077|Experimental|Hemospray|Patients treated with hemostatic powder
2961784|NCT02820077|No Intervention|Clinical support|Patients treated with optimal clinical management, as it is been advised by the latest guidelines
2961785|NCT02820064|Other|only one arm|Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
2961786|NCT02820051|Active Comparator|Midazolam|"In the group of midazolam, the initial dose was 0.05 mg/kg. Additional doses of 2 mg of midazolam were allowed to reach a score level of 3 to 4 in the Observer´s assessment of alertness/ sedation scale. All patients received nalbuphine in a starting dose of 2 mg with additional doses of 1 mg if it was necessary. Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.~Intervention: Transcutaneous CO2 monitor"
2961787|NCT02820051|Experimental|Propofol|"In the group of propofol, the starting dose was 0.1 mg /kg. Additional doses of 10 mg of propofol were allowed to reach a score level of 3 to 4 in the Observer´s assessment of alertness/ sedation scale. All patients received nalbuphine in a starting dose of 2 mg with additional doses of 1 mg if it was necessary. Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.~Intervention: Transcutaneous CO2 monitor"
2961788|NCT02820038|Active Comparator|Medication Guides|Approximately 75 participants will be assigned to this study group. Participants will ONLY receive medication guides for rheumatoid arthritis medications.
2961789|NCT02820038|Experimental|Medication Guides & SMART Program|Approximately 75 participants will be assigned to this study group. Participants will receive medication guides for rheumatoid arthritis medications AND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
2961790|NCT02820038|Experimental|Drug Facts Boxes|Approximately 75 participants will be assigned to this study group. Participants will ONLY receive Drug Facts Boxes for rheumatoid arthritis medications.
2961791|NCT02820038|Experimental|Drug Facts Boxes & SMART Program|Approximately 75 participants will be assigned to this study group. Participants will receive Drug Facts Boxes for rheumatoid arthritis medicationsAND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
2961792|NCT02820025|Experimental|doxapram group|the doxapram group iv doxapram 1mg/kg,
2961793|NCT02820025|Placebo Comparator|Controlled group|the controlled group given equal volume of saline with the doxapram group.
2961794|NCT02820012|Other|Scoliosis|"Preoperative data: demographics, clinical diagnosis and etiology, relevant prior medical treatment, x-rays, and patient questionnaire will be completed in the database.~The self-questionnaire (SAQ parents, patients, SR22) provided will assess the state of health and disability of patients.~After surgery: the clinical questionnaire will be completed by the investigator to collect the parameters of the operation and the patient's clinical data Immediate Postoperative visit: J1 to S1: radiological and clinical examinations .~Visit Month 1 to M3, M 12, M 24 , M 36 , M 60 : During these visits, clinical and radiological examinations will be realized."
2961795|NCT02819999|Experimental|Rovalpituzumab Tesirine|Rovalpituzumab Tesirine 0.3 mg/kg IV infusion
2961796|NCT02819999|Experimental|Rovalpituzumab Tesirine followed by Cisplatin, Etoposide|Rovalpituzumab Tesirine 0.3 mg/kg IV infusion followed by Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion
2961797|NCT02819999|Experimental|Rovalpituzumab Tesirine with Cisplatin, Etoposide|Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion and Rovalpituzumab Tesirine 0.1 mg/kg IV infusion
2961798|NCT02819999|Experimental|Rovalpituzumab Tesirine following Cisplatin, Etoposide|Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion followed by Rovalpituzumab Tesirine 0.3 mg/kg IV infusion
2961799|NCT02819986|Experimental|Progressive Goal Attainment Program|10 one hour weekly therapy sessions focused on behavioural interventions
2961800|NCT02819973|Experimental|Educational Video 1|African American/ Black Video
2961801|NCT02819973|Experimental|Educational Video 2|Caucasian Video
2961802|NCT02819973|Experimental|Usual Care (no video) 3|Standard Care/ No video
2961803|NCT02819960|Active Comparator|active probiotic formula|"Intervention: Probiotic formula PROBIO-FIX INUM® will be administered at a dose of 3x1 cps per day orally for 6 weeks. No premedication or patient monitoring after administration of probiotic formula is required. Probiotic formula may be taken after meals or snacks to reduce stomach upset. Swallow the capsule or in case of problems with swallowing, capsule can be opened, content mixed with small amount of food. Food must not be hot.~Patients should receive full supportive care during the study, including transfusion of blood and blood products, treatment with antibiotics, anti-emetics, anti-diarrheal agents, analgesics, erythropoetin, or bisphosphonates, when appropriate."
2961804|NCT02819960|Placebo Comparator|placebo|"Intervention: Maltodextrin will be used for placebo group and will be administered at a the same dose as active formula (3x1 cps per day orally for 6 weeks).~Patients should receive full supportive care during the study, including transfusion of blood and blood products, treatment with antibiotics, anti-emetics, anti-diarrheal agents, analgesics, erythropoetin, or bisphosphonates, when appropriate."
2961805|NCT02819934|Experimental|Arm1|experimental group
2961806|NCT02819921|Experimental|Desvenlafaxine succinate 100mg|Titration with 50 mg Desvenlafaxine succinate tablet once daily for 1 week, then 2 tablets of 50mg Desvenlafaxine succinate tablet once daily for 3 weeks, then taper with 50 mg Desvenlafaxine succinate tablet once daily for 3 days.
2961913|NCT02819323|Experimental|BLI800 low dose|BLI800 bowel preparation (low dose)
2961808|NCT02819921|Placebo Comparator|Placebo|50 mg placebo tablet once daily for 1 week, then 2 tablets of 50mg placebo tablet once daily for 3 weeks, then 50 mg placebo tablet once daily for 3 days.
2961809|NCT02819908|Active Comparator|Imprimis Dropless|TriMoxiVanc 0.2cc intravitreal one time
2961810|NCT02819908|Active Comparator|Imprimis Less Drops|Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.
2961811|NCT02819895|Experimental|Intervention|Parents of healthy newborn infants delivered at Mother and Child Hospital Ondo (Akure or Ondo), who live in Akure or Ondo Town and plan to receive their immunizations at MCH Ondo will receive their usual care (an immunization card). In addition they will received automated text, calls and emails (if applicable) reminders through a customized windows® software application when their child's immunization visit is due.
2961812|NCT02819895|No Intervention|Control|Parents of healthy newborn infants delivered at Mother and Child Hospital Ondo (Akure or Ondo), who live in Akure or Ondo Town and plan to receive their immunizations at MCH Ondo will receive usual care (an immunization card)
2961813|NCT02819882||Luminal A-like subtype|Patients that express ER, express PgR+ (≥ 20%), don't express HER2 and have Ki-67 'low' (< 14%).
2961814|NCT02819882||Luminal B-like (HER2 negative) subtype:|Patients that express ER and are either PgR- or low (< 20%) and/or Ki67 'high' (≥ 14%).
2961815|NCT02819882||Luminal B-like (HER2 positive) subtype:|Patients that express ER and HER2 irrespective of PgR or Ki67 status.
2961816|NCT02819882||HER2-enriched subtype|Patients that express HER2 and don't express ER or PgR.
2961817|NCT02819882||TN subtype|Patients who are negative for the expression of ER, PgR and HER2.
2961818|NCT02819869|Experimental|Taking both statin and metformin Group|The experimental group take Lotidon 500mg/ tablet per day and Lipitor 10mg/ tablet per day for two years or until of a recurrence.
2961819|NCT02819869|No Intervention|Non- taking both statin and metformin Group|Non- taking both statin and metformin.
2961820|NCT02819856|Placebo Comparator|SPI-1000 Capsule 0mg Ebselen Placebo|0mg Ebselen SPI-1000 bid po x 21d
2961821|NCT02819856|Experimental|SPI-1005 Ebselen 200mg Capsule x1|200mg SPI-1005 bid po x 21d Low Dose Arm
2961822|NCT02819856|Experimental|SPI-1005 Ebselen 200mg Capsule x2|400mg SPI-1005 bid po x 21d Mid Dose Arm
2961823|NCT02819856|Experimental|SPI-1005 Ebselen 200mg Capsule x3|600mg SPI-1005 bid po x 21d High Dose Arm
2961824|NCT02819843|Experimental|Intralesional TALIMOGENE LAHERPAREPVEC with radiotherapy|Patients will receive 3 radiotherapy treatments (one treatment every 3-5 days) during weeks 3 and 4. The first treatment will occur 6 (+/- 2) hours after the Talimogene Laherparepvec administration at week 3.Talimogene Laherparepvec will be administered at weeks 0, 3, 5, 7, 9, 11, 13 and 15. The first dose of Talimogene Laherparepvec will be 10^6 plaque forming units (PFU)/mL, followed three weeks later by a dose of 10^8 pfu/mL.
2961825|NCT02819843|Experimental|Intralesional TALIMOGENE LAHERPAREPVEC without radiotherapy|Patients will receive Talimogene Laherparepvec alone, as described above, without radiotherapy.
2961826|NCT02819830|Experimental|Intervention group|"Participants, who have been randomly assigned to the intervention group, will take part in a six-week supervised exercise training programme. This programme takes place in a rehabilitation gymnasium. The exercise programme consists of two group sessions per week (scheduled for evenings, after typical working hours, approximately 12 patients per session). Each session lasts for approximately 70 minutes and includes a 5 minute warm up, 30 minutes of aerobic cycling exercise, 30 minutes of strength training, and a 5 minute cool down.~Participants will also perform a 30 minute walk each weekend as part of the intervention."
2961827|NCT02819830|No Intervention|Control group|Participants who have been randomly assigned to the control group will not undertake the exercise intervention. These participants are instructed to maintain their usual lifestyle.
2961828|NCT02819817|Experimental|Aloe Vera Gel|Experimental gel placed in identical opaque tube as placebo gel.
2961829|NCT02819817|Placebo Comparator|Ultrasound Gel|Placebo placed in identical opaque tube as experimental gel.
2961830|NCT02819817|No Intervention|Standard care|Standard care
2961831|NCT02819804|Experimental|Treatment (dasatinib, nivolumab)|Patients receive dasatinib PO QD on days 1-28 and nivolumab IV over 30 minutes on days 8 and 22 of course 1 and on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2961832|NCT02819791|Active Comparator|Control group|
2961833|NCT02819791|Experimental|Intervention group|
2961834|NCT02819778|Other|Control group|"The study protocol corresponds to a diagnostic prospective, controlled, multicenter study using a randomized stepped wedge cluster design, in which pediatric patients (aged ≤ 16 years) presenting to the pediatric emergency room for mTBI with a GCS score of 15 will benefit from usual care (conventional management arm) in the control group, and from S100B management in the interventional group"
2961835|NCT02819778|Other|interventional group|"The study protocol corresponds to a diagnostic prospective, controlled, multicenter study using a randomized stepped wedge cluster design, in which pediatric patients (aged ≤ 16 years) presenting to the pediatric emergency room for mTBI with a GCS score of 15 will benefit from usual care (conventional management arm) in the control group, and from S100B management in the interventional group"
2961836|NCT02819752|Experimental|HPV-ve stage IVA/IVB SCCHN|Pembrolizumab and Chemoradiotherapy
2961837|NCT02819752|Experimental|HPV+ve stage IVA/IVB SCCHN|Pembrolizumab and Chemoradiotherapy
2961838|NCT02819739|Experimental|normoxia|During cardiopulmonary bypass inspired fraction of oxygen is adapted to maintained a oxygen arterial pressure below 150 mmHg.
2961839|NCT02819739|Active Comparator|hyperoxia|During cardiopulmonary bypass inspired fraction of oxygen is set to 100 %.
2961840|NCT02819726|Experimental|SAIT101|
2961841|NCT02819726|Active Comparator|Rituxan|
2961842|NCT02819726|Active Comparator|MabThera|
2961843|NCT02819726|Active Comparator|Rituxan/SAIT101|
2961844|NCT02819713|Placebo Comparator|ultrasound gel|
2961845|NCT02819713|Active Comparator|Instillagel|
2961846|NCT02819687|Experimental|RDX5791 10mg QD (SAD phase)|10mg of RDX5791 administered once daily PO fasting
2961847|NCT02819687|Experimental|RDX5791 50mg QD (SAD phase)|50mg of RDX5791 administered once daily PO fasting
2961848|NCT02819687|Experimental|RDX5791 150mg QD (SAD phase)|150mg of RDX5791 administered once daily PO fasting
2961849|NCT02819687|Experimental|RDX5791 450mg QD (SAD phase)|450mg of RDX5791 administered once daily PO fasting
2961851|NCT02819687|Experimental|RDX5791 3mg QD (MAD phase)|3mg of RDX5791 administered once daily PO fasting
2961852|NCT02819687|Experimental|RDX5791 10mg QD (MAD phase)|10mg of RDX5791 administered once daily PO fasting
2961853|NCT02819687|Experimental|RDX5791 30 mg QD (MAD phase)|30mg of RDX5791 administered once daily PO fasting
2961854|NCT02819687|Experimental|RDX5791 100 mg QD (MAD phase)|100mg of RDX5791 administered once daily PO fasting
2961855|NCT02819674||early-onset hypertension|early-onset hypertension patients recruited in Chinese multiple centers
2961856|NCT02819661|Active Comparator|women BMI<30 POD 1|Pregnant healthy women with BMI<30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 1 after elective cesarean section.
2961857|NCT02819661|Active Comparator|women BMI≥30 POD 1|Pregnant healthy women with BMI≥30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 1 after elective cesarean section.
2961858|NCT02819661|Active Comparator|women BMI<30 POD4|Pregnant healthy women with BMI<30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 4 after elective cesarean section.
2961859|NCT02819661|Active Comparator|women BMI≥30 POD 4|Pregnant healthy women with BMI≥30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 4 after elective cesarean section.
2961860|NCT02819648|Experimental|Prednisolone|40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France); administered 30 minutes before endodontic treatment
2961861|NCT02819648|Placebo Comparator|Control|Milk tablet administered 30 minutes before endodontic treatment
2961862|NCT02819635|Experimental|Updacitinib (ABT-494) Dose B|Administered orally, once daily.
2961863|NCT02819635|Experimental|Updacitinib (ABT-494) Dose A|Administered orally, once daily.
2961864|NCT02819635|Experimental|Updacitinib (ABT-494) Dose C|Administered orally, once daily.
2961865|NCT02819635|Experimental|Updacitinib (ABT-494) Dose D|Administered orally, once daily.
2961866|NCT02819635|Placebo Comparator|Placebo|Administered orally, once daily.
2961867|NCT02819622||Control group|control (no disease)
2961868|NCT02819622||central serous retinopathy group|Central serous retinopathy (with CSCR disease) by exam and OCT
2961869|NCT02819609||Myomectomy|Women with uterine fibroids who underwent myomectomy as their index procedure as part of their routine clinical care
2961870|NCT02819609||Endometrial ablation|Women with uterine fibroids who underwent endometrial ablation as their index procedure as part of their routine clinical care
2961871|NCT02819609||Uterine artery embolization|Women with uterine fibroids who underwent uterine artery embolization as their index procedure as part of their routine clinical care
2961872|NCT02819609||MRI-guided focused ultrasound ablation|Women with uterine fibroids who underwent MRI-guided focused ultrasound ablation as their index procedure as part of their routine clinical care
2961873|NCT02819596|Experimental|Savolitinib|600 mg of Savolitinib monotherapy will administered once a day until study completion or withdrawal
2961874|NCT02819596|Experimental|MEDI4736|1500 mg MEDI4736 will be administered every 4 weeks until study completion or withdrawal
2961875|NCT02819596|Experimental|Savolitinib and MEDI4736|Savolitinib and MEDI4736 will be administered at the Recommended Phase 2 dose ascertained in the phase Ib.
2961876|NCT02819596|Experimental|Tremelimumab and MEDI4736|Subjects will receive 75 mg of Tremelimumab and 1500 mg medi4736 every 4 weeks for the first four cycles, then 750 mg MEDI4736 every 4 weeks until study completion or withdrawal.
2961877|NCT02819583|Experimental|PCAR-019|Enrolled patients will receive PCAR-019 with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
2961878|NCT02819570|Experimental|cefuroxime|I.V cefuroxime 750 mg*3/d for 2days followed by P.O cefuroxime 500 mgx2/d in addition to P.O roxithromycin 150 mg*2/d for 7 days
2961879|NCT02819570|Active Comparator|ampicillin|I.V ampicillin 2 gram x4/d for 2 days followed by P.O moxypen 500 mgx3/d for 5 days in addition to P.O roxithromycin 150 mg*2/d for 7 days
2961880|NCT02819557|Experimental|Ataluren|Oral administration of ataluren at a dose of 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 52 weeks.
2961881|NCT02819544|Active Comparator|Ropivacaine|Ropivacaine 7.5 mg/mL administration
2961882|NCT02819544|Placebo Comparator|Sodium chloride|NaCl 0.9% administration
2961883|NCT02819531|Active Comparator|Rotational atherectomy|RA protocol: After IVUS protocol, patients who are randomized to RA will undergo coronary wiring of the target lesion and subsequent advancement of the RA burr. The RA system is performed using standard technique under intravenous infusion of heparin. The atherectomy burr size will be determined by the operator.
2961884|NCT02819531|Active Comparator|Orbital atherectomy|OAS protocol: After IVUS protocol, patients who are randomized to OAS will undergo coronary wiring of the target lesion and subsequent advancement of the OAS according to the manufacturer's guidelines.
2961885|NCT02819531|Active Comparator|Scoring balloon system|SBS protocol: After IVUS protocol, patients who are randomized to SBS will undergo coronary wiring of the target lesion and balloon inflation with SBS performed by standard technique under intravenous infusion of heparin. SBS will be used according to the manufacturer's guidelines.
2961886|NCT02819518|Experimental|Part 1: Pembrolizumab + Nab-paclitaxel|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS nab-paclitaxel 100 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle.
2961887|NCT02819518|Experimental|Part 1: Pembrolizumab + Paclitaxel|Participants receive pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle.
2961888|NCT02819518|Experimental|Part 1: Pembrolizumab + Gemcitabine/Carboplatin|Participants receive pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS gemcitabine/carboplatin 1000 mg/m^2 (gemcitabine) and an Area Under the Curve (AUC) 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.
2961914|NCT02819323|Active Comparator|PEG-ELS|PEG based bowel preparation
2961915|NCT02819310|Experimental|BLI400 Laxative|BLI400 Laxative
2961916|NCT02819297|Experimental|BLI400 Laxative|BLI400 Laxative
2961917|NCT02819297|Placebo Comparator|Placebo|BLI400 placebo
2961889|NCT02819518|Experimental|Part 2: Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS one of three chemotherapy regimens: 1) nab-paclitaxel 100 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle, 2) paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle, OR 3) gemcitabine/carboplatin 1000 mg/m^2 (gemcitabine) and an AUC 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.
2961890|NCT02819518|Active Comparator|Part 2: Placebo + Chemotherapy|Participants receive placebo (normal saline) IV on Day 1 of each 21-day cycle PLUS one of three chemotherapy regimens: 1) nab-paclitaxel 100 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle, 2) paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle, OR 3) gemcitabine/carboplatin 1000 mg/m^2 (gemcitabine) and an AUC 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.
2961891|NCT02819505|Experimental|Beta-alanine supplementation|Participants will be supplemented with 6.4g·d-1 β-alanine (CarnoSyn™, NAI, USA). The β-alanine dosing regimen will consist of two 800 mg tablets four times per day at 3-4 hour intervals or the same regimen for placebo tablets. The use of multiple small doses throughout the day has been used in numerous studies using β-alanine in solutions or gelatine capsules (Hoffman et al., 2008; Sale et al., 2011; Saunders et al., 2012; Sale et al., 2012; Tobias et al., 2013) in order to circumvent potential symptoms of paraesthesia (see box xii for possible risks and discomforts). Overall increases have been shown to be between 40% and 80% depending upon dose (between 3.2 and 6.4 g·d-1) and duration of administration (between 4 and 10 weeks) (Sale et al., 2012).
2961892|NCT02819505|Placebo Comparator|Placebo supplementation|Participants will be supplemented with 6.4g·d-1 placebo (maltodextrin; NAI, USA).
2961893|NCT02819492||Routine colonoscopy Cohort|Patients receiving routine colonoscopy at the study site
2961894|NCT02819479|Experimental|Low-dose Intra-arterial Bevacizumab|A single intra-arterial dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.
2961895|NCT02819466||volunteers|Healthy volunteers over the age of 18 years employed by Amiens University Hospital 3D echography
2961896|NCT02819453|Experimental|Corticosteroid group|Patients with acute respiratory distress syndrome were treated with corticosteroid, which determined by two clinicians.
2961897|NCT02819440|Active Comparator|Tadalafil|Subjects will be randomized to one of two arms. 100 obese adult subjects will be randomized to the Tadalafil arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of Tadalafil (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the active comparator subjects will undergo the following visit protocol: baseline visit (two half-days), an interim visit (6 weeks post-baseline), and a 12-week visit (two half-days).
2961898|NCT02819440|Placebo Comparator|Placebo|Subjects will be randomized to one of two arms. 100 obese adult subjects will be randomized to the placebo arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of a placebo pill (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the placebo comparator subjects will undergo the following visit protocol: baseline visit (two half-days), an interim visit (6 weeks post-baseline), and a 12-week visit (two half-days).
2961899|NCT02819427||epilepsy|children with absence epilepsy presenting either typical or atypical seizures
2961900|NCT02819414|Placebo Comparator|Control Group|Treatment with placebo at a volume of 2.25 cc/kg/dose x 4/day to be given with feeds, or in place of feed when baby is receiving <2 cc/kg/feed.
2961901|NCT02819414|Active Comparator|Treatment Group|Treatment with paracetamol drops at 15 mg/kg/dose x 4/day. Drops will be diluted 1:15 in order to reduce osmolality. This will yield a dose of 2.25 ml/kg/dose, to be given with feeds, or in place of feed when baby is receiving <2 cc/kg/feed.
2961902|NCT02819388|Experimental|Intervention|Contraceptive counseling
2961903|NCT02819388|No Intervention|Control|Control group without counseling
2961904|NCT02819375|Active Comparator|Group Propofol|anesthesia will induced 1 mg/kg propofol
2961905|NCT02819375|Active Comparator|Group propofol/remifentanil|anesthesia will induced 0.5 mg/kg propofol and 1 µg/kg remifentanil
2961906|NCT02819375|Active Comparator|Group propofol/ketamine|anesthesia will induced propofol 0.5 mg/kg and ketamine 0.5 mg/kg
2961907|NCT02819362||Prospective cohort - MRI|Patients with pathological nipple discharge
2961908|NCT02819349|Experimental|Texting for Relapse Prevention (T4RP)|T4RP is a relapse prevention mHealth program text messaging to people who have schizophrenia/SAD. The intervention will include an online interface for clinicians and an automated text messaging program for patients. Firstly, patients and providers will meet in an intake session, to identify the patient's personal early warning signs from a pre-identified list. Using the online interface, providers will enter additional warning signs or personalize the wording of the messages as requested by the patient. The patient also will determine the threshold at which the provider will be alerted about a possible relapse and whether additional contact people should be alerted.
2961909|NCT02819349|No Intervention|Treatment-As-Usual Control|The control group will be a treatment as usual comparison group. For the majority of individuals with schizophrenia/SAD in care at JHCPP, this involves meeting with their therapist every 2 to 4 weeks and meeting with their psychiatrist at least once every 90 days or more frequently as clinically indicated. All routine appointments are scheduled, but individuals can walk in or call if they do not feel well between sessions.
2961910|NCT02819336|Experimental|Electroacupuncture (EA) group|"Electroacupuncture therapy (10 sessions within 21 days)~CV2, CV3, CV4, CV6, and bilateral points of SP11, SP6 (8 acupoints in total)~20 minutes duration with middle frequency (30 Hz) of electrical stimulation~Conventional treatments (drugs, traditional herbal medications, rehabilitation therapies, or acupuncture therapies without electrostimulation for stroke and urinary incontinence / electroacupuncture therapies other than the acupoints (CV2, CV3, CV4, CV6, SP1 and SP6) for stroke and urinary incontinence) are permitted."
2961911|NCT02819336|Sham Comparator|Park sham (PS) group|"Non-penetrating Park sham electroacupuncture treatment (10 sessions within 21 days)~CV2, CV3, CV4, CV6, and bilateral points of SP11, SP6 (8 acupoints in total)~20 minutes duration with undelivered electrostimulation of middle frequency (30 Hz)~Conventional treatments (drugs, traditional herbal medications, rehabilitation therapies, or acupuncture therapies without electrostimulation for stroke and urinary incontinence / electroacupuncture therapies other than the acupoints (CV2, CV3, CV4, CV6, SP1 and SP6) for stroke and urinary incontinence) are permitted."
2961912|NCT02819323|Experimental|BLI800 high dose|BLI800 bowel preparation (high dose)
2961918|NCT02819284|Active Comparator|Active Comparator: KPI-121 0.25% Ophthalmic Suspension|
2961919|NCT02819284|Placebo Comparator|Placebo Comparator: Vehicle of KPI-121 0.25% Ophthalmic Suspe|
2961920|NCT02819271|Experimental|CXL-1427 (BMS-986231)|Experimental
2961921|NCT02819271|Placebo Comparator|Placebo|Placebo
2961922|NCT02819258|Other|Endodontic treatment for a tooth with a periapical pathology|
2961923|NCT02819245|Other|Age before and after 18 years old|Surgical treatment before and after skeletal maturity
2961924|NCT02819232|Other|Patient with a prescription of a microbiologic diagnostic of|Patient with a prescription of a microbiologic diagnostic of keratitis
2961925|NCT02819219|Placebo Comparator|Placebo|Participants will receive a flavored water placebo supplement. Part of the supplemental intervention. This, and all groups, simultaneously took part in the exercise intervention.
2961926|NCT02819219|Experimental|ElevATP|Participants will receive the flavored water placebo with an additional 150mg of ElevATP (blend of ancient peat and apple extracts). Part of the supplemental intervention.This, and all groups, simultaneously took part in the exercise intervention.
2961927|NCT02819219|Experimental|ElevATP w/Caffeine|Participants will receive the flavored water placebo with an additional 150mg of ElevATP (blend of ancient peat and apple extracts), a 180 mg blend of caffeine (caffeine anhydrous, pterostilbene-bound caffeine), and 38mg B vitamins. Part of the supplemental intervention.This, and all groups, simultaneously took part in the exercise intervention.
2961928|NCT02819206|Other|Uveitis|Patient with a prescription of a microbiologic diagnostic of uveitis
2961929|NCT02819193||exposed group : early raw mother's own milk|"The use of raw MOM is considered as early when it begins before day 7."
2961930|NCT02819193||unexposed group : no use of raw mother's own milk|Neonates who receive, or not, raw MOM before day 7.
2961931|NCT02819180||Healthy adults group|Healthy men and women between 18 and 59 years of age.
2961932|NCT02819180||Elderly group|Elderly over 60 years old.
2961933|NCT02819167|Other|neurologic and neuropsychological evaluation|
2961934|NCT02819141|No Intervention|Control|These patient will get usual care - sedation administered by ICU Nurses as deemed necessary by primary care team
2961935|NCT02819141|Experimental|Dexmedetomidine|These patients will receive a basal intravenous infusion of medication (Dexmedetomidine) and have access to self-administered sedation medication (Dexmedetomidine) for anxiety.
2961936|NCT02819128|Other|Homeless people|Populations of homeless households in Marseille.
2961937|NCT02819115||Healthy adults group|Healthy adults aged 18 to 59 years
2961938|NCT02819115||Elderly group|Elderly over 60 years old.
2961939|NCT02819102|Experimental|Metabolic Probes and BCX7353|"Day 1: 1 mg midazolam will be administered as an IV bolus simultaneously to administration of 500 mg tolbutamide, 40 mg omeprazole, and 30 mg dextromethorphan orally.~Day 2: a single oral dose of 2 mg midazolam. Days 3 to 9: 350 mg BCX7353 once a day. Day 10: 1 mg midazolam will be administered as an IV bolus simultaneously to administration of 500 mg tolbutamide, 40 mg omeprazole, 30 mg dextromethorphan and 350 mg BCX7353, orally.~Day 11: a single oral dose of 2 mg of midazolam along with 350 mg BCX7353."
2961940|NCT02819089|Active Comparator|Dexmedetomidine|Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
2961941|NCT02819089|Placebo Comparator|NSS|NSS loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
2961942|NCT02819076||Painless Children|30 children
2961943|NCT02819076||Painful Children|70 children
2961944|NCT02819050|Experimental|Sprinting|Take off NCPAP twice daily for 3hours (day 1), Take off NCPAP twice daily for 6hours (day 2), Take off NCPAP twice daily for 9hours (day 3), Placed back on NCPAP for 24hours (day 4), Switch to nasal cannula at a flow rate of 1.5-2 L/min (day 5)
2961945|NCT02819050|Active Comparator|Non-Sprinting|"If the infant was on NCPAP 6, Infant was weaned down to CPAP 5 for 96 hours. If they met stability criteria, then infant was switched to room air (no flow) or no more than 2L NC.~If the infant was on NCPAP 5, the infant was continued on CPAP 5 for 96 hours If they met stability criteria, then infant was switched to room air (no flow) or no more than 2L NC."
2961946|NCT02819037|Experimental|Gas chromatography and stool analysis|gas chromatography and stool analysis for detection of malabsorption
2961947|NCT02819024|Experimental|Treatment (dexamethasone, 18F-FLT PET)|Patients receive dexamethasone PO BID on days 1-5. Patients undergo 3 18F-FLT PET scans. One scan within 7 days prior to the start of dexamethasone, one scan on day 3 after the 5th dose of dexamethasone, and one scan 6-9 days after the last dose of dexamethasone.
2961948|NCT02819011|Experimental|MBB AFO Group|This group will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO for the duration of the study.
2961949|NCT02819011|Active Comparator|No MBB AFO Group|This group will be provided with a pair of New Balance 813 shoes for the duration of the study.
2961950|NCT02818998|Experimental|Aflibercept [Treatment A]|Patients receive 2 mg aflibercept per injection once every 8 weeks
2961951|NCT02818998|Experimental|Aflibercept [Treatment B]|Patients receive 2 mg aflibercept per injection with interval equal to or more than 8 weeks
2961952|NCT02818998|Experimental|Aflibercept [Treatment C]|Patients receive 2 mg aflibercept per injection on an as needed basis
2961953|NCT02818985|Active Comparator|Dexamethasone|patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.
2961954|NCT02818985|Active Comparator|Dexmedetomidine|patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.
2961955|NCT02818985|Placebo Comparator|Control|patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.
2961956|NCT02818972|Experimental|RelayPro|Endovascular treatment with the investigational device.
2961957|NCT02818959|Experimental|Transcatheter Aortic Valve Replacement|In this study, transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial TAVR System, which is intended for use in subjects with severe aortic stenosis. The JenaValve replacement valve is placed inside the aortic valve by using a delivery system.
2961958|NCT02818946|Other|MRI|Patients who have undergone mammography, breast sonography, and planning to have a contrast-enhanced breast MRI for evaluation of nipple discharge.
2962204|NCT02817347|Experimental|YH1177-D (8/1.0%)|piperacillin 8% + tazobactam 1.0%
2961959|NCT02818933||Aim 1|This group follows a crossover design where adolescents 12-17 years old (n=10) complete a diet recall using one of the two methods (interviewer-administered vs web-based), and then does another diet recall using the other method about a week later. Participants are randomly assigned to the order in which they complete each method of diet recall.
2961960|NCT02818933||Aim 2, interviewer-administered recall|This group of adolescents 12-17 years old (n=10) completes an interviewer-administered diet recall once a week for 6 weeks.
2961961|NCT02818933||Aim 2, web-based recall|This group of adolescents 12-17 years old (n=10) completes a web-based self-administered diet recall once a week for 6 weeks.
2961962|NCT02818920|Experimental|Pembrolizumab prior to and after surgery|
2961963|NCT02818907|Other|Additional biological samples|"Additional blood samples will be realized specifically to the study at baseline, after neoadjuvant chemotherapy (if applicable) and before surgery, 1 month after surgery and 1 month after the last adjuvant chemotherapy cycle.~Peripheral blood mononuclear cell (PBMC), plasma and circulating tumor DNA and RNA will be collected.~Tumor tissue will be collected during surgery."
2961964|NCT02818894|Active Comparator|Lidocaine prior to THA|Participants receiving Total Hip Arthroplasty through anterior approach with Lidocaine spinal anesthesia and completing telephone questionnaires to see how they are feeling post-operation.
2961965|NCT02818894|Active Comparator|Bupivacaine prior to THA|Participants receiving Total Hip Arthroplasty through anterior approach with Bupivacaine spinal anesthesia and completing telephone questionnaires to see how they are feeling post-operation.
2961966|NCT02818881|Experimental|High-speed then low-speed yoga|Subjects received a single session of High-speed yoga and within one week a single session of Low-speed yoga
2961967|NCT02818881|Experimental|Low-speed then high-speed yoga|Subjects received a single session of Low-speed yoga and within one week a single session of High-speed yoga
2961968|NCT02818855|Experimental|Collagen Matrix plus coronally advanced flap (CAF)|A new collagen matrix (Mucograft) associated to coronally advanced flap
2961969|NCT02818855|Active Comparator|Subepithelial connective tissue graft plus CAF|Subepithelial connective tissue graft associated to coronally advanced flap
2961970|NCT02818842||Pregnant Women|"Medical and personal data will be collected for all the pregnant women who want to participate.~The source of data are :~Primary Health Insurance Fund data~Prenatal Diagnostic Center of Toulouse University Hospital data~Mother and child protection data collection~Medicalisation Program of Information Systems data"
2961971|NCT02818829||Cohort|Collection of biological samples
2961972|NCT02818816|Experimental|Brimonidine Tartrate 0.2% (2mg/mL)|One (I) drop of brimonidine tartrate 0.2% (2mg/mL) will be placed in the randomized eye preoperatively thirty minutes before robotic-assisted radical laparoscopic prostatectomy (RALP)
2961973|NCT02818816|Placebo Comparator|Carboxymethylcellulose Eye Drops|One drop of Carboxymethylcellulose eye drops will be placed in the randomized eye half an hour before RALP
2961974|NCT02818803|Experimental|Propolis|Standardized-propolis extract (EPP-AF®) oral gel formulation, 3 times a day, for 14 days
2961975|NCT02818803|Active Comparator|Miconazole|Miconazole 20mg/g oral gel,3 times a day, for 14 days
2961976|NCT02818790|No Intervention|Group 1. Control|
2961977|NCT02818790|Experimental|Group 2. Intervention 1|
2961978|NCT02818790|Experimental|Group 2. Intervention 2|
2961979|NCT02818777|Experimental|cannabidiol|"GWP42003-P oral solution, is purified cannabidiol (purity of ≥98%, 100 mg/ml cannabidiol in sesame oil with anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring).~Started at 5 mg/kg/day and is increased by 2.5-5 mg/kg at 3-5 day intervals to a target dose of 20 mg/kg/day."
2961980|NCT02818777|Placebo Comparator|placebo|Same with GWP42003-P, except for the active product, CBD. Started at 5 mg/kg/day and is increased by 2.5-5 mg/kg at 3-5 day intervals to a target dose of 20 mg/kg/day.
2961981|NCT02818764|Experimental|Elderly People|Subjects undergoing elective total hip arthroplasty will be have blood drawn, CAM, DRS, and mBDRS administered preoperatively. Optode monitoring, EEG, blood draw, and possible CSF will be done interoperatively. Blood draw, CAM, and DRS testing will also be done days 1 and 2 after surgery.
2961982|NCT02818751|Experimental|Escitalopram|Patients being randomized to receive escitalopram, at an initial dose of 5 mg (oral) daily for 2 days. On day 3, escitalopram will be increased to 10 mg daily and continued for 7 days. Then, on day 10, escitalopram will be increased to 15 mg. At the week 4 visit, the dose of escitalopram may be increased to 20 mg, based on the investigator's clinical judgment and if significant anxiety symptoms are still present.
2961983|NCT02818751|Placebo Comparator|Placebo|Patients will receive placebo (sugar pill) at an initial dose of 5 mg daily for 2 days. On day 3, placebo will be increased to 10 mg daily and continued for 7 days to match the experimental group.
2961984|NCT02818751|No Intervention|Healthy Controls|Healthy adolescents will receive fMRI scans at the same time points, which will provide assessments of the stability of neurophysiologic measures and will be used to adjust and interpret comparisons within the patients (i.e., whether patient values are changing toward or away from those of healthy adolescents).
2961985|NCT02818738|Experimental|Levamisole Hydrochloride|Dosage : 5, 10, 25 et 50mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
2961986|NCT02818738|Placebo Comparator|Placebo|matching verum
2961987|NCT02818725|Active Comparator|Chemotherapy|Intensified- Methotrexate Vinblastin Doxorubicin Cisplatin
2961988|NCT02818725|Experimental|Arm B: chemotherapy + panitumumab|Intensified- Methotrexate Vinblastin Doxorubicin Cisplatin +/- panitumumab
2961989|NCT02818712||Patients with IPF|
2961990|NCT02818699|Placebo Comparator|Placebo Capsule|Participants assigned to this group will receive placebo capsules identical in appearance to EMIQ capsules.
2961991|NCT02818699|Experimental|EMIQ Capsule|Participants assigned to this group will receive EMIQ capsules identical in appearance to placebo capsules.
2961992|NCT02818686|Experimental|TD-1473 low dose|10 subjects will be randomized to receive low-dose TD-1473 orally daily for 28 days
2961993|NCT02818686|Experimental|TD-1473 mid dose|10 subjects will be randomized to receive mid-dose TD-1473 orally daily for 28 days
2961994|NCT02818686|Experimental|TD-1473 high dose|10 subjects will be randomized to receive high-dose TD-1473 orally daily for 28 days
2961995|NCT02818686|Placebo Comparator|Placebo|10 subjects will be randomized to receive placebo orally daily for 28 days
2961996|NCT02818673|Experimental|Ascites in Patients With Cirrhosis|Patients will be further classified according to the refractory or sensitive ascitis
2961997|NCT02818660|Experimental|Synacthen|The patient get Synacthen to stimulate the adrenals to produce cortisol
2961998|NCT02818647|Active Comparator|COLD-DISSECTION|Cold Dissection Technique
2961999|NCT02818647|Active Comparator|HOT-DISSECTION|Needle Electrocautery Dissection Technique
2962000|NCT02818634|Active Comparator|Muscle-sparing|Following skin incision with No.15 blade; all layers including the subcutaneous fat, muscle fascia and muscles covering the cartilage were passed with blunt dissection. Muscle fibers were dissected parallel to their positioning.
2962001|NCT02818634|Active Comparator|Muscle-cutting|Following skin incision with No.15 blade; all layers including the subcutaneous fat, muscle fascia and muscles covering the cartilage were cut with Monopolar electrocautery at (25 watts).
2962002|NCT02818621|Active Comparator|Group Dex|"The Dex group received 1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure.~Interventions:~◦Drug: Dexmedetomidine"
2962003|NCT02818621|Placebo Comparator|Group Placebo|"The Placebo group received equal amount of normal saline.~Interventions:~◦Drug: Normal saline"
2962004|NCT02818608|Active Comparator|Functional electrical stimulation (FES)|Chronic stroke patients submitted to functional electrical stimulation (FES).
2962005|NCT02818608|Experimental|Combination of transcranial direct current stimulation and FES|Chronic stroke patients submitted to transcranial direct current stimulation (tDCS) and functional and to functional electrical stimulation (FES).
2962006|NCT02818595|Experimental|Normal children|Every child meet the age criteria and without ductus arteriosus persistence ultrasound or detectable neurological disorders after clinical, neurophysiological and radiological
2962007|NCT02818595|Experimental|Abnormal children|Every child meet the criteria of age and having a detectable neurological disease after clinical, neurophysiological and radiological as intraventricular hemorrhage .
2962008|NCT02818582|Experimental|1|Daily GS-5734 delivered intraveneously (IV) for 5 days.
2962009|NCT02818582|Placebo Comparator|2|Daily placebo delivered intraveneously (IV)
2962010|NCT02818569|Experimental|Experimental|Oral Dexmedetomidine
2962011|NCT02818569|Placebo Comparator|Placebo Comparator|Saline
2962012|NCT02818556|Other|Restylane Right, Belotero Left|Patients will receive one treatment with Restylane® Silk (right side of the face) and one treatment of Belotero Balance® (left side)
2962013|NCT02818556|Other|Restylane Left, Belotero Right|Patients will receive one treatment with Restylane® Silk (left side of the face) and one treatment of Belotero Balance® (right side)
2962014|NCT02818543|Experimental|Cohort 1|LYC-30937 25 mg single oral dose
2962015|NCT02818543|Experimental|Cohort 2|LYC-30937 100 mg single oral dose
2962016|NCT02818530|Experimental|IOP by tomoneter and ultrasound|Intraocular pressure will be measured by electronic tomometer (tonopen) at different point of time after induction of anaesthesia in patients undergoing robotic assisted surgery under steep Trendelenberg position. Anterior chamber depth will be measured by ultrasound at the same time intervals.
2962017|NCT02818517||Heart failure|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
2962018|NCT02818504|Experimental|Repeatability and reproducibility study|"Monitoring of system (Wize MIrror) measurements with changes in environmental conditions (fasting state, light, temperature)"
2962019|NCT02818504|Experimental|Validation study|"Longitudinal monitoring of cardiometabolic risk factors through an user--‐friendly, unobtrusive, personalized system for lifestyle self--‐management (the Wize Mirror)"
2962020|NCT02818491|Placebo Comparator|Control group|Patients will receive ropivacaine 0.5% 20 mls with normal saline 0.9% 2 mls
2962021|NCT02818491|Active Comparator|Dex 1|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 1 mg in 2 mls
2962022|NCT02818491|Active Comparator|Dex 2|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 2 mg in 2 mls
2962023|NCT02818491|Active Comparator|Dex 3|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 3 mg in 2 mls
2962024|NCT02818491|Active Comparator|Dex 4|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 4 mg in 2 mls
2962025|NCT02818478|Other|RA; at home first|Patients in this arm (10 patients with rheumatoid arthirtis, RA) will be randomised to initially fill in patient reported outcome measures from home via their own computer or tablet; subsequently these patients will fill in patient reported outcome measures at the outpatient clinic
2962026|NCT02818478|Other|RA; outpatient clinic first|Patients in this arm (10 patients with rheumatoid arthirtis, RA) will be randomised to initially fill in patient reported outcome measures at the outpatient clinic; subsequently these patients will fill in patient reported outcome measures from home via their own computer or tablet
2962027|NCT02818478|Other|AxSpa; at home first|Patients in this arm (10 patients with axial spondyloarthritis, AxSpa) will be randomised to initially fill in patient reported outcome measures from home via their own computer or tablet; subsequently these patients will fill in patient reported outcome measures at the outpatient clinic
2962028|NCT02818478|Other|AxSpa; outpatient clinic first|Patients in this arm (10 patients with axial spondyloarthritis, AxSpa) will be randomised to initially fill in patient reported outcome measures at the outpatient clinic; subsequently these patients will fill in patient reported outcome measures from home via their own computer or tablet
2962029|NCT02818465|Experimental|Patients|
2962030|NCT02818452|Experimental|Oatmeal containing beta-glucan|27 g oatmeal
2962031|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 1|27.72g oatmeal
2962032|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 2|28.43g oatmeal
2962033|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 3|29.86g oatmeal
2962034|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 4|32.72g oatmeal
2962035|NCT02818452|Placebo Comparator|Hot Cereal - Cream of Rice|20g oatmeal
2962071|NCT02818231||NON EXPOSED|"Male, >50 years, unexposed to wood dust, without any nasal pathology, without known tumor~-> Brushing of the olfactory cleft"
2962072|NCT02818231||EXPOSED|"Male, >50 years, exposed to wood dust, without any nasal pathology, without known tumor~-> Brushing of the olfactory cleft"
2962036|NCT02818426|Experimental|UCPVax|"UCPVax is a therapeutic cancer vaccine composed of two peptides called UCP2 and UCP4 derived from telomerase combined with Montanide ISA 51 VG as adjuvant.~The two peptides UCP2 and UCP4 will be emulsified in Montanide ISA 51 and injected subcutaneously in separate sites (one site per peptide), at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination every 8 weeks for 12 months."
2962037|NCT02818413||U.S. Olympic Team and elite athletes|Biospecimens will be collected from and questionnaires will be administered to U.S. Olympic team members and other elite athletes
2962038|NCT02818400|Experimental|Composite tissue allotransplantation|
2962039|NCT02818387|Active Comparator|Group P|Induction with propofol bolus. Dose will be started at 0.5 mg/kg and will be adjusted as described in summary.
2962040|NCT02818387|Active Comparator|Group PR|Induction with propofol and remifentanil. Remifentanil infusion 0.125 mcg/kg/min for 5 min followed by propofol bolus Propofol dose will be started at 0.5 mg/kg and will be adjusted as described in summary.
2962041|NCT02818387|Active Comparator|Group PMR|"Induction with propofol, midazolam and remifentanil. Remifentanil infusion 0.125 mcg/kg/min for 5 min followed by midazolam 0.015 mg/kg bolus 1 min after remifentanil infusion start and propofol bolus administration.~Propofol dose will be started at 0.5 mg/kg and will be adjusted as described in summary."
2962042|NCT02818374|Experimental|Disabled People with behavioral trouble|
2962043|NCT02818361|Experimental|topical TwHF gel group|Topical TwHF gel recipe composes Tripterygium wilfordii Hook F, Mangxiao (Mirabilite), Chuanxiong (Rhizoma Ligustici), Ruxiang (Olibanum), Moyao (M yrrh) (prescription proportion is 4:4:2:2:1).Each gel is 20 gram(g). TwHF gel is applied for 1st to 5th metacarpophalangeal joints, 1st to 5th proximal interphalangeal joints, wrists, knees and ankles 20g for 1 hour, once per day from week 0 through week 4 and 10g for 1 hour, once per day from week 5 through week 8.
2962044|NCT02818361|Placebo Comparator|placebo group|Placebo recipe composes viscous agent which matches by the sucrose. The usage and dosage of topical TwHF and placebo are the same.
2962045|NCT02818348|Experimental|DRV cohort|Darunavir/Cobicistat 800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
2962046|NCT02818348|Experimental|ETR cohort|Etravirine 400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
2962047|NCT02818335|Experimental|LY3023414 Reference Fasted|Single oral dose of LY3023414 (Reference) on day one fasting.
2962048|NCT02818335|Experimental|LY3023414 Test Fasted|Single oral dose of LY3023414 (Test) on day one fasting.
2962049|NCT02818335|Experimental|LY3023414 Test Fed|Single oral dose of LY3023414 (Test) on day one after a meal.
2962050|NCT02818322|Experimental|telemedical monitoring ( T)|Home care by a nurse trained in the management of diabetic foot lesions with transmission diabetologist doctor a photograph and a full description of the diabetic foot lesion every week
2962051|NCT02818322|Active Comparator|classic monitoring|Home care by a nurse trained in the management of diabetic foot lesions without transmission diabetologist doctor a photograph and a full description of the diabetic foot lesion
2962052|NCT02818309|Experimental|Lesogaberan|Lesogaberan
2962053|NCT02818309|Placebo Comparator|Placebo|Placebo
2962054|NCT02818296|Experimental|Active IU CBM-I|This paradigm was designed to train individuals to endorse benign interpretations of ambiguous information and reject negative/threatening interpretations of ambiguous information. Participant's baseline interpretation bias was measured at baseline. Participants then underwent two training phases in which their responses were either reinforced (i.e., they were told they were correct) or punished (i.e., they were told that they were incorrect). Interpretation bias was measured again at post-training.
2962055|NCT02818296|Sham Comparator|Control CBM-I|This paradigm was identical to the active condition except that the word/sentence pairings used were not relevant to IU and/or anxiety.
2962056|NCT02818283|Experimental|Soy Pretzel-Short Feasibility|6 week intervention involving daily consumption of soy pretzel (two packets, 5 oz./packet) for 28 days. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. This arm will precede the longer 28 week study
2962057|NCT02818283|Active Comparator|Soy Pretzel|28 week intervention involving daily consumption of soy pretzel (two packets, 5 oz./packet) for 12 weeks. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. Participants will be randomized to start with soy pretzel or wheat pretzel arm and crossover to the other pretzel at week 14.
2962058|NCT02818283|Placebo Comparator|Wheat Pretzel|28 week intervention involving daily consumption of wheat pretzel (two packets, 5 oz./packet) for 12 weeks. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. Participants will be randomized to start with soy pretzel or wheat pretzel arm and crossover to the other pretzel at week 14.
2962059|NCT02818270|Experimental|Drug depositions|Aerosol drug deposited delivered on the inhaled and exhaled filters and protective filters were evaluated. Salbutamol and Acetylcysteine were delivered by a jet nebulizer through a mechanical ventilator.
2962060|NCT02818257|Experimental|Strip A (wet)|Six strips of Strip A are applied on skin wetted with two different buffers (3 strips each)
2962061|NCT02818257|Experimental|Strip A (dry)|Six strips of Strip A are applied on skin that is dry (3 strips) and wetted with buffer (3 strips)
2962062|NCT02818257|Experimental|Strip B (wet)|Six strips of Strip B are applied on skin wetted with two different buffers (3 strips each)
2962063|NCT02818257|Experimental|Strip B (dry)|Six strips of Strip B are applied on skin that is dry (3 strips) and wetted with buffer (3 strips)
2962064|NCT02818257|Experimental|Strip C (wet)|Six strips of Strip C are applied on skin wetted with two different buffers (3 strips each)
2962065|NCT02818257|Experimental|Strip C (dry)|Six strips of Strip C are applied on skin that is either dry (3 strips) or wetted with buffer (3 strips)
2962066|NCT02818244|Active Comparator|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
2962067|NCT02818244|Active Comparator|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
2962068|NCT02818244|Active Comparator|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
2962069|NCT02818244|Active Comparator|Apple Watch|Apple Watch Heart Rate Monitoring Device
2962070|NCT02818244|Active Comparator|Scosche Rhythm +|Scosche Rhythm + Heart Rate Monitoring Device
2962073|NCT02818205||Children with Autism Spectrum Disorder|Boys between the age of 4 to 11 years old with Autism Spectrum disorder will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation
2962074|NCT02818205||Typically Developing Children|Typically developing boys between the age of 4 to 11 years will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
2962075|NCT02818179|Other|Patients undergoing radiation|In this study, patients undergoing radiation treatment will undergo thermography imaging during radiation treatment course. Patients will be evaluated with thermography imaging every week during the brachytherapy treatment for 5 procedures
2962076|NCT02818166|Experimental|Endoaortic Clamp|Right mini-thoracotomy mitral valve surgery with retrograde perfusion and endoaortic balloon clamp
2962077|NCT02818166|Active Comparator|Transthoracic Clamp|Right mini-thoracotomy mitral valve surgery with retrograde perfusion and transthoracic clamp.
2962078|NCT02818153|Experimental|questionnaire for allergic rhinitis control|Teenagers from 12 to 17 years old who complete a Self questionnaire regarding allergic rhinitis control during the consultation and after 15 days
2962079|NCT02818140|Active Comparator|Ropivacaine TQL block|Unilateral single shot ultrasound-guided TQL block with 30 ml of ropivacaine 0.75%
2962080|NCT02818140|Placebo Comparator|Placebo TQL block|Unilateral single shot ultrasound-guided TQL block with 30 ml saline 0.9%
2962081|NCT02818127|Active Comparator|normal coronary artery|coronary angiography will be performed by transfemoral or transradial route.
2962082|NCT02818127|Active Comparator|coronary slow flow|coronary angiography will be performed by transfemoral or transradial route.
2962083|NCT02818127|Active Comparator|coronary artery ectasia|coronary angiography will be performed by transfemoral or transradial route.
2962084|NCT02818127|Active Comparator|non-obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
2962085|NCT02818127|Active Comparator|obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
2962086|NCT02818114|Experimental|PEET|Peer support interventions as an adjunct to prolonged exposure
2962087|NCT02818101|No Intervention|Control group|No hypnosis session before the coronary angiography
2962088|NCT02818101|Experimental|Hypnotised group|Hypnosis session before the coronary angiography
2962089|NCT02818088|Experimental|Cognitive Training|Cognitive Training - n Back.
2962090|NCT02818075|Experimental|Mobile Phone Based Peer Support|Mobile phone-based peer support (MPPS)
2962091|NCT02818075|Active Comparator|Usual Care|Standard community prenatal and postpartum support services
2962092|NCT02818062||Endophthalmitis|The diagnosis of endophthalmitis was made on the basis of clinical features including pain, decreased visual acuity (VA), diffuse bulbar conjunctival hyperaemia, chemosis, inflammation of the anterior segment and posterior segment inflammation (all patients had vitreous infiltration diagnosed by biomicroscopy or ophthalmic ultrasound).
2962093|NCT02818062||Cataract (Control)|Controls were patients who underwent cataract surgery.
2962094|NCT02818049|Experimental|Bronchoalveolar Lavage|BAL was performed in accordance with current practice. Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure. Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor. O2 saturation (SpO2) is monitored continuously by pulse oximetry.
2962095|NCT02818036|Experimental|naltrexone|single 50mg dose of naltrexone
2962096|NCT02818036|Placebo Comparator|sugar pill|single sugar pill
2962097|NCT02818023|Experimental|Pembrolizumab plus vemurafenib and Cobimetinib|"Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ), and vemurafenib/cobimetinib will be given at 480 mg twice daily/20 mg daily, 720 mg twice daily/40 mg daily, or 960 mg twice daily/60 mg daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
2962098|NCT02818010||exposed = patient practicing physical activity|"The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire)~A patient is defined as practicing physical activity (exposed) when he meets one of the conditions following:~At least 20 minutes of vigorous-intensity physical activity for at least 3 days per week~At least 30 minutes of moderate-intensity physical activity or walking daily for at least 5 days per week~At least 5 days of walking and moderate- or vigorous-intensity physical activity achieving at least 600 MET-minutes per week.~The Metabolic equivalents (MET) is the ratio of metabolic rate during activity physical and metabolic rate at rest. One MET corresponds to the energy spent by a person sitting still and is equivalent to a consumption of 1 kcal / kg / hour. It is estimated that a moderately active person has an energetic cost four times higher, and a very active person eight times higher than the energy cost of a person sitting without move."
2962099|NCT02818010||unexposed = patient not practicing physical activity|"The practice of physical activity is measured by the GPAQ 2 questionnaire(Global Physical Activity Questionnaire)~A patient is defined as unexposed if he does not fulfill any of these conditions :~At least 20 minutes of vigorous-intensity physical activity for at least 3 days per week~At least 30 minutes of moderate-intensity physical activity or walking daily for at least 5 days per week~At least 5 days of walking and moderate- or vigorous-intensity physical activity achieving at least 600 MET-minutes per week.~The Metabolic equivalents (MET) is the ratio of metabolic rate during activity physical and metabolic rate at rest. One MET corresponds to the energy spent by a person sitting still and is equivalent to a consumption of 1 kcal / kg / hour. It is estimated that a moderately active person has an energetic cost four times higher, and a very active person eight times higher than the energy cost of a person sitting without move."
2962100|NCT02817984|Experimental|Treatment Group|Participants (n=10) will be enrolled and assigned chronologically to one of five excision time points: Weeks 2 (n=10), 4 (n=2), 6 (n=2), 8 (n=2), and 12 (n=2) post-injection. Implants will be injected on Day 0. All participants will be administered up to five (5) 2 milliliter (mL) subcutaneous injections of acellular adipose tissue (AAT) via sterile injection into the area identified for planned excision. Total injected AAT volume per patient will not exceed 10 mL.
2962144|NCT02817685||5|ultrasound-difficult patient
2962145|NCT02817685||6|ultrasound-difficult patient
2962146|NCT02817672|Active Comparator|PRIME 1.0|8 weeks use of PRIME 1.0 (current version). Mobile application designed to improve psychosocial functioning and motivational deficits.
2962101|NCT02817971|Experimental|Enhanced feedback|"Monthly written feedback incorporating goal setting, and action planning delivered by a senior clinical coordinator for selected pneumonia indicators~Two-monthly written feedback on multiple quality of paediatric care indicators~Clinical network promoting clinical leadership linked to mentorship and peer to peer support~Improved use of health information on service delivery"
2962102|NCT02817971|Active Comparator|Standard feedback|"Two-monthly written feedback on multiple quality of paediatric care indicators~Clinical network promoting clinical leadership linked to mentorship and peer to peer support~Improved use of health information on service delivery"
2962103|NCT02817958|Experimental|A-Adjuvant Chemotherapie TIP|Lymphadenectomy (+/- sentinel node) + adjuvant chemotherapie TIP modified bilateral lymphadenectomy 4 cycles every 21 days
2962104|NCT02817958|Experimental|B-Neoadjuvant Chemotherapie TIP|fine needle biopsy or sentinel node + neoadjuvant chemotherapie TIP followed by a lymphadenectomy modified bilateral lymphadenectomy 4 cycles every 21 days
2962105|NCT02817945|Experimental|68Ga-NOTA-3PTATE-RGD PET/CT|The patients were injected with 111-185 MBq of 68GaNOTA-3PTATE-RGD in one dose intravenously and underwent PET/CT scan 45-60 min later.
2962106|NCT02817932|Experimental|Group 1 (Korean, 375 mg)|Group 1 (Korean, 375 mg): Ranolazine PR 375 mg
2962107|NCT02817932|Experimental|Group 2 (Korean, 500 mg):|Group 2 (Korean, 500 mg): Ranolazine PR 500 mg
2962108|NCT02817932|Experimental|Group 3 (Korean, 750 mg):|Group 3 (Korean, 750 mg): Ranolazine PR 750 mg
2962109|NCT02817932|Experimental|Group 4 (Caucasian, 375mg)|Group 4 (Caucasian, 375mg) : Ranolazine PR 375 mg
2962110|NCT02817932|Experimental|Group 5 (Caucasian, 750mg)|Group 5 (Caucasian, 750mg) : Ranolazine PR 750 mg
2962111|NCT02817906|Experimental|ITI-007|9 mg ITI-007 administered as a solid oral dose formulation once daily for 4 weeks
2962112|NCT02817906|Placebo Comparator|Placebo|Placebo administered as a visually-matched solid oral dose formulation once daily for 4 weeks
2962113|NCT02817880|Experimental|rTMS (repetitive transcranial magnetic stimulation)|rTMS (repetitive transcranial magnetic stimulation)
2962114|NCT02817880|Experimental|tDCS (transcranial direct-current stimulation)|tDCS (transcranial direct-current stimulation)
2962115|NCT02817880|Experimental|tsDCS (transcutaneous spinal Direct Current Stimulation)|tsDCS (transcutaneous spinal Direct Current Stimulation)
2962116|NCT02817867|Active Comparator|tDCS|Patients who will be treated with Transcranial direct-current stimulation (tDCS) in the ipsilesional motor cortex.
2962117|NCT02817867|Active Comparator|rTMS|Patients who will be treated with Magnetic brain stimulation (rTMS) in the contralesional motor cortex.
2962118|NCT02817867|Experimental|tDCS + rTMS|Patients who will be treated with the association between Transcranial direct-current stimulation (tDCS) and magnetic brain stimulation (rTMS), in the ipsilesional and contralesional motor cortex, respectively.
2962119|NCT02817854||Patients with acute diverticulitis|Patients admitted in emergency setting for acute diverticulitis
2962120|NCT02817841|Experimental|15 mg E4/3 mg DRSP|15 mg estetrol (E4)/3 mg drospirenone (DRSP) combined oral contraceptive
2962121|NCT02817828|Experimental|15 mg E4/3 mg DRSP|15 mg E4/3 mg DRSP tablet
2962122|NCT02817815|Active Comparator|Group 1|Volunteers
2962123|NCT02817815|Experimental|Group 2|Paroxysmal AF patients in sinus rhythm the day of inclusion
2962124|NCT02817815|Experimental|Group 3|Paroxysmal AF patients in atrial fibrillation the day of inclusion
2962125|NCT02817815|Experimental|Group 4|Persistent AF patients in sinus rhythm the day of inclusion
2962126|NCT02817815|Experimental|Group 5|Persistent AF patients in atrial fibrillation the day of inclusion
2962127|NCT02817802||Magmaris|Magmaris Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold
2962128|NCT02817789|Active Comparator|Standard group|154 patients
2962129|NCT02817789|Experimental|Ticagrelor group|154 patients
2962130|NCT02817776|Experimental|Treatment group|Pulmonary vein isolation by Radiofrequency ablation treatment with the THERMOCOOL SMARTTOUCH® SF catheter in persistent AF population.
2962131|NCT02817763|Active Comparator|Connective tissue graft (CTG)|After local anesthesia, the surgical procedure performed was the trapezoidal-type of Coronally advanced flap (CAF). After the flap was raised, the exposed root surface was gently scaled and planed until it became smooth. Afterward, a thin and small connective tissue graft that was sutured over the root surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
2962132|NCT02817763|Experimental|CTG plus resin composite restoration|After local anesthesia, a sterile rubber dam was placed to isolate the operative field and the coronal zone of the non-carious cervical lesion restoration was performed with a nanocomposite resin, following the manufacturer's instructions. The apical margin of the restoration was place 1 millimeter beyond to the cemento-enamel junction estimation. In the next session, the surgical procedure performed was the trapezoidal-type of CAF. After the trapezoidal-type of CAF flap was raised, a thin and small connective tissue graft that was sutured over the restoration surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
2962133|NCT02817750|Experimental|zolpidem hemitartarate (fasting + post-prandial)|zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
2962134|NCT02817750|Experimental|zolpidem hemitartarate (post-prandial + fasting)|zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
2962135|NCT02817737||CT|Measured with computed tomography
2962136|NCT02817737||plain Radiography|Measured with plain Radiography
2962137|NCT02817724|Active Comparator|m-Health group|BENECA System: The m-health group will use the BENECA app for 8 weeks.
2962138|NCT02817724|Experimental|Integral Group|BENECA System and Supervised-occupational therapy program: The integral groups will use the BENECA app and they will receive a face-to-face occupational therapy rehabilitation program for 8 weeks.
2962139|NCT02817698|Experimental|Drug of dependence|There is only one arm to the study. All subjects will receive their drug of dependence in this study. Nicotine dependent subjects will receive tobacco cigarettes, cannabis dependent subjects will receive cannabis cigarettes, and cocaine dependent subjects will receive IV cocaine.
2962140|NCT02817685||1|Chronic Hepatitis B patient
2962141|NCT02817685||2|Chronic Hepatitis B patient
2962142|NCT02817685||3|cirrhotic patient
2962143|NCT02817685||4|cirrhotic patient
2962147|NCT02817672|Experimental|PRIME 2.0|8 weeks use of PRIME 2.0 (version with the NLP-powered dashboard). Mobile application designed to improve psychosocial functioning and motivational deficits.
2962148|NCT02817659|Experimental|Glucagon Infusion|Glucagon infusion in escalating manner at 12.5, 25, 37.5 and 50 ng/kg/min (each step for 60 min). At 30 and 60 mins of each infusion rate, we will administer a previously established questionnaire to assess overall nausea intensity.
2962149|NCT02817646||Intensive care patients|Patients admitted to the intensive care unit for 4 days or more with a computed tomography scan made for clinical reasons early during intensive care stay and who receive enteral and/or parenteral nutrition as per hospital protocol
2962150|NCT02817633|Experimental|Part 1- Dose Escalation|"1a: Dose escalation TSR-022 alone~1b: Dose escalation TSR-022 in combination with an anti-PD-1 antibody~1c: TSR-022 dose in combination with an anti-PD-1 antibody"
2962151|NCT02817633|Experimental|Part 2- Expansion Cohorts|Part 2 of the study will further explore the safety and clinical activity of TSR-022 as monotherapy and in combination with anti-PD-1 antibody in patients with select tumor types
2962152|NCT02817620|Experimental|Spirulysat®|Food supplement packaged in 10 ml vials called Spirulysat®. This product is a phycocyanin concentrated fresh spirulina water extract (Spirulina Platensis). 2 vials daily to consume in the morning, just before the breakfast, in a glass of water, during 12 weeks (from V1 to V3 visit).
2962153|NCT02817620|Placebo Comparator|Placebo|Placebo with the same characteristics, appearance, packaging and composition as the active formula except for active ingredient (Spirulina) replaced by a classical blue food colorant used to colour desserts. 2 vials daily to consume in the morning, just before the breakfast, in a glass of water, during 12 weeks (from V1 to V3 visit).
2962154|NCT02817607|Experimental|Surgery|
2962155|NCT02817594||HCV Genotype 1 or 4 participants|Participants receiving Paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV)
2962156|NCT02817568||Aggressive Periodontitis (case)|Single intervention has been performed for each subject. Peripheral blood sample was obtained in conjunction with clinical measurements in this intervention.(Drawing Blood)
2962157|NCT02817568||Healthy (Control)|Single intervention has been performed for each subject. Peripheral blood sample was obtained in conjunction with clinical measurements in this intervention. (Drawing Blood)
2962158|NCT02817555|Active Comparator|Epoetin alfa|Patients who are enrolled and randomized to the Epoetin arm will remain on their current dose and frequency. After the first hemoglobin (Hb) measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on epoetin for the required run-in phase followed by the 12 month active phase.
2962159|NCT02817555|Active Comparator|Darbepoetin alfa|"Patients who are enrolled and randomized to the Darbepoetin arm will have their epoetin discontinued at the end of the week preceding entry into the study and will switch to darbepoetin on the date that they would normally be receiving their next dose of epoetin.~Switching patients to darbepoetin will be done using the conversion ratio of 200 units of epoetin to 1 μg of darbepoetin as used per week, rounded up or down to the nearest available pre-filled syringe dose available from the manufacturer.~After the first Hb measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on darbepoetin for the required run-in phase followed by the 12 month active phase."
2962160|NCT02817542||STEMI TA hyperglycemic subjects|STEMI hyperglycemic patients, percutaneous coronary intervention with TA
2962161|NCT02817542||STEMI without TA hyperglycemic subjects|STEMI hyperglycemic patients, percutaneous coronary intervention without TA
2962162|NCT02817529|Experimental|Pulmonica|The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through the PEP device at least ten times daily for up to six months.
2962163|NCT02817529|Active Comparator|RC-Cornet|The RC-Cornet is a device that provides oscillatory positive expiratory pressure (OPEP) therapy for the detachment and removal of pulmonary secretions. Through variable pressure settings and optional aerosolized medication delivery, patients realize maximum efficacy specific to their unique clinical needs.The RC-Cornet uses the patient's full expired air volume to produce pressure and oscillatory vibrations. Participants who will be instructed to inhale and exhale through the PEP device at least ten times daily for up to six months.
2962164|NCT02817516|Experimental|Part 1: TAK-828 15 milligram (mg)|TAK-828 15 mg, solution (0.2 milligram per milliliter [mg/mL] or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
2962165|NCT02817516|Experimental|Part 1: TAK-828 45 mg|TAK-828 45 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
2962166|NCT02817516|Experimental|Part 1: TAK-828 75 mg|TAK-828 75 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
2962167|NCT02817516|Experimental|Part 1: TAK-828 100 mg|TAK-828 100 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
2962168|NCT02817516|Experimental|Part 2: TAK-828 45 mg|TAK-828 45 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy Japanese participants.
2962169|NCT02817516|Experimental|Part 2: TAK-828 100 mg|TAK-828 100 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy Japanese participants.
2962170|NCT02817516|Placebo Comparator|Part 1: Placebo|TAK-828 placebo-matching solution, orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
2962171|NCT02817516|Placebo Comparator|Part 2: Placebo|TAK-828 placebo-matching solution, orally, twice daily on Days 1-14 in healthy Japanese participants.
2962172|NCT02817503|Experimental|Standard BP control|"SBP within 140 - <150 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
2962203|NCT02817347|Experimental|YH1177-D (4/0.5%)|piperacillin 4% + tazobactam 0.5%
2962173|NCT02817503|Active Comparator|Moderate BP control|"SBP within 130 - <140 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
2962174|NCT02817503|Active Comparator|Intensive BP control|"SBP <130 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
2962175|NCT02817490||Patients with hypermobility type Ehlers-Danlos Syndrome|Patients with hypermobility type Ehlers-Danlos Syndrome participating to one out of the three patient education sessions included in the study.
2962176|NCT02817490||Caregivers|Caregivers participating to one out of the three patient education sessions included in the study.
2962177|NCT02817477|Experimental|IN Ketamine|A single administration of 1 mg/kg ketamine hydrochloride delivered in an intranasal route using an atomizer
2962178|NCT02817477|Active Comparator|IM Morphine|A single administration of 0.15 mg/kg intramuscular morphine
2962179|NCT02817477|Active Comparator|IV Morphine|A single administration of 0.1 mg/kg slow intravascular bolus of morphine.
2962180|NCT02817464|Experimental|TV-46046 - 1|
2962181|NCT02817464|Experimental|TV-46046 - 2|
2962182|NCT02817464|Experimental|TV-46046 - 3|
2962183|NCT02817451|Experimental|Study Group A|HIV exposed and infected infants
2962184|NCT02817451|Experimental|Study Group B|HIV exposed and uninfected infants
2962185|NCT02817438|Experimental|Online Intervention|Participants randomized to the online intervention arm will be given access to the Good Days Ahead program for 12 weeks.
2962186|NCT02817438|No Intervention|Waitlist|Participants randomized to the waitlist arm will wait for 12 weeks without doing an online intervention.
2962187|NCT02817425|Active Comparator|SOX Sequential S-1 Group|"Patients received chemotherapy with oxaliplatin+ S-1  for 6 months and sequential S-1 for 6 months"
2962188|NCT02817425|Active Comparator|SOX Group|"Patients received chemotherapy with oxaliplatin+ S-1  for 12 months"
2962189|NCT02817425|Experimental|TEGAFOX Sequential S-1|"Patients received chemotherapy with TEGAFOX (oxaliplatin+ Tegafur +Leucovorin Calcium)  for 6 months and sequential S-1 for 6 months"
2962190|NCT02817412|Experimental|Go/No-Go Training|In the go/no go training, participants are shown images in which high-calorie foods are shown on one side of the screen and low-calorie foods on the other. They are told to press response keys as quickly as possible to indicate the side of presentation (go-trials). On half of the trials, the rectangular frame surrounding the image is not solid but hatched, which is a signal for them to withhold their response (no-go trials). This training is divided into 4 blocks of 50 trials.
2962191|NCT02817412|Experimental|Stop-Signal Training|In the stop signal training, participants are shown images in either a dark blue or light gray border. They are told to press the space bar as quickly as possible when the border is blue (go trials) and to withhold a response when the border is gray (no-go trials). This training is divided into 20 blocks of 32 trials.
2962192|NCT02817412|Experimental|Dot-Probe Training|In the dot-probe training, participants are shown images in which high-calorie foods are shown on one side of the screen and low-calorie foods on the other. Immediately after the images disappear, a small dot probe appears in the location of one of the images. Participants are told to press response keys as quickly as possible to indicate whether a visual probe appeared behind the left or right image during the trials. The probe appears in the location occupied by a high-calorie food image 10% of the time and in the location occupied by a low-calorie food image 90% of the time. This training is divided into 6 blocks of 40 trials.
2962193|NCT02817412|Placebo Comparator|Generic Training|In the generic training, participants complete a generic go/no-go training that uses images of flowers and office supplies instead of the images of high-calorie and low-calorie food images. This generic go/no go training is identical in duration and contact time to the go/no-go food training.
2962194|NCT02817399|Active Comparator|Neuro-muscular electrical stimulation|Active exercises & Neuro-muscular electrical stimulation in a stationary position (lying and/or sitting).
2962195|NCT02817399|Experimental|Functional electrical stimulation|Active exercises & Functional electrical stimulation while walking.
2962196|NCT02817386||POD and Non-POD;|Trained clinical research assistants interviewed the patients on the first and second day post surgery. The assessment of post deliriu (POD) was performed once per day between 8:00 AM to 10:00 AM. Patient notes were not reviewed for episodes of delirium which could occur outside the time of assessment. The clinical research assistants who performed the delirium assessments in this study had good training and went through quality control procedures. We used state-of-the-art delirium detection methods, which tend to report a higher incidence of delirium. The interview included the Confusion Assessment Method (CAM) and Memorial Delirium Assessment Scale (MDAS).
2962197|NCT02817373|Other|transvaginal ultrasound study|Patients with a well established infertility requiring IVF treatment and who are <40. Cohort will consist of patients going through a fresh day 5 transfer with a planned transfer of a single good quality embryo. Patients will go thorough a Ultrasound scan performed through a vaginal probe on the morning of the embryo transfer.
2962198|NCT02817360|Experimental|Intensive therapy|RAS-antagonist and beta-blocker up-to maximal dosages as permitted and tolerated and following national guidelines.
2962199|NCT02817360|Other|Conventional therapy|No RAS-antagonist and beta-blocker or at stable dose as per study entrance. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase.
2962200|NCT02817347|Experimental|YH1177 (4/0.5%+0.1%)|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%
2962201|NCT02817347|Experimental|YH1177 (8/1.0%+0.1%)|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%
2962202|NCT02817347|Experimental|YH1177-D (2/0.25%)|piperacillin 2% + tazobactam 0.25%
2962205|NCT02817334|Experimental|indocyanine green|"As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.~Intervention: Drug: indocyanine green"
2962206|NCT02817321|Experimental|single-injection TPVB(thoracic paravertebral block)|Single-injection of TPVB is given preoperatively + postoperative IPCA.
2962207|NCT02817321|Experimental|Single-injection TPVB +continuous TPVB|Single-injection of TPVB is given preoperatively followed with continuous infusion+ postoperative IPCA.
2962208|NCT02817321|Active Comparator|IPCA|postoperative IPCA is given alone
2962209|NCT02817308|Experimental|Patients|"Patients with a proven diagnosis of ductal adenocarcinoma of the pancreas with elevated levels of CA19-9 and possibly elevated CEA levels.~intervention: samples of blood, saliva and urine"
2962210|NCT02817308|Other|Control|"Patients or healthy volunteers with out a known evidence of malignancy with presumably normal levels of CA19-9 and CEA.~intervention: samples of blood, saliva and urine"
2962211|NCT02817295||elderly|patients underwent bariatric surgery and are above 65 years old
2962212|NCT02817295||non-elderly|patients underwent bariatric surgery and are below 65 years old
2962213|NCT02817282|Other|Hand hygiene implementation strategy|The implementation strategy will be tested in a stepped wedge cluster randomized trial which is based on a random sequential roll-out of the CHANGE implementation strategy to all participating NHs (n=20) for comparison. All groups (hence all NHs) start with the control situation (no CHANGE implementation activities) at the beginning of the study. At each time point, a new group of five NHs crosses over from the control situation to the implementation situation. Each group will start the implementation phase of 4 months at a different time point, directly after one of the measurements periods (Point of Time (PT) 0, PT1, PT2, PT3, PT4, PT5). The time point a group crosses over is randomized (over the groups).
2962214|NCT02817269|Experimental|Manual palpation group|For the manual palpation group, the reference position will be a lateral position, lying on the non affected shoulder while the affected side will be explored. The arm and elbow are flexed 90° resting on a pillow and legs placed with 90° hip and knee flexion to stabilize the body, with the head resting on a pillow to maintain body alignment. The physiotherapist will be in front of the participant and carried out the examination with flat palpation using the thumb to identify soreness taut band tried to elicit local twitch response and referred pain in the infraspinatus area. First, three attempts will be made to elicit an local twitch response (LTR) using snapping palpation if a response will be obtained. After LRT, referred pain could also be evoked by palpation.
2962215|NCT02817269|Experimental|Deep dry needling group|For the deep dry needling group, the reference position will be a lateral position, lying on the non affected shoulder while the affected side will be explored. The arm and elbow are flexed 90° resting on a pillow and legs placed with 90° hip and knee flexion to stabilize the body, with the head resting on a pillow to maintain body alignment. The physiotherapist will be in front of the participant and carried out the examination with flat palpation using the thumb to identify soreness taut before making the needle insertion. Sterile stainless steel needles (length 40mm/caliber 0.32 with a cylindrical plastic guide) will be used.
2962216|NCT02817256|Active Comparator|Group A, 'vitamins and minerals'|"Ergocalciferol , Vitamin B12, Calcium /D , Iron or Centrium.~Ergocalciferol 300,000 IM - Every 3 months Oral Vitamin B12 tablets daily (500mcg) Calcium /D Tab 600-200mg Centrium -1 Tablet Daily~Mineral:~Iron preparation - Daily (47mg)"
2962217|NCT02817256|Active Comparator|Group B, 'vitamins and minerals'|"Ergocalciferol , Vitamin B12, Calcium /D , Iron or Centrium.~Centrium - 1 Tablet daily Ergocalciferol 50000 IU once every two weeks Vitamin B12 1000mcg IM every three months Calcium /D Tab 600-200mg~Minerals:~Iron preparation - Daily (47mg)"
2962218|NCT02817243|Other|SP2086 and Simvastatin|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
2962219|NCT02817230||Patients|Patients referred to the out-patient clinic with LDL levels >4.9 mmol/l
2962220|NCT02817230||Controls|Matched normocholesterolemic control subjects
2962221|NCT02817217|Other|SP2086 and Valsartan|
2962222|NCT02817204|Experimental|Aerobic Exercise group|Cardio Pulmonary Exercise Test(CPET) Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
2962223|NCT02817204|Other|Health Education Group|Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol Cardio Pulmonary Exercise Test(CPET) No Cycle ergometer exercise
2962224|NCT02817191|Experimental|Hylo-Comod|The patients used Hylo-Comod eye drop after phaco+IOL in this group.
2962225|NCT02817191|Experimental|Tears Naturale Forte|The patients used Tears Naturale Forte eye drop after phaco+IOL in this group.
2962226|NCT02817178|Other|Additional biological samples|"Additional blood samples will be realized specifically to the study at baseline, at 1 month, at 3 months, and 1 month after surgery (if applicable).~Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected. Tissue tumor is collected during surgery if applicable."
2962227|NCT02817165|Experimental|Probiotic (BioK+)|Children will receive 10-40 billion CFUs/day of Bio-K+ (Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2), with dose based on their weight. The product will be administered as a strawberry flavored tub of milk.
2962228|NCT02817165|Placebo Comparator|Placebo|Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.
2962229|NCT02817152|Sham Comparator|Periodontal ultrasonic debridement|Periodontal pockets received ultrasonic periodontal debridement intervention.
2962230|NCT02817152|Active Comparator|Low-level laser therapy|Periodontal pockets received ultrasonic periodontal debridement plus low-level laser therapy intervention.
2962231|NCT02817139|Active Comparator|active tDCS over primary motor cortex|Duration: 20 minutes; Intensity: 2 mA; Placement: left primary motor cortex.
2962232|NCT02817139|Experimental|active tDCS over prefrontal cortex|Duration: 20 minutes; Intensity: 2 mA; Placement: left prefrontal cortex.
2962233|NCT02817139|Placebo Comparator|sham tDCS over primary motor cortex|Duration: 20 minutes; The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham; Placement: left primary motor cortex.
2962234|NCT02817126|Experimental|Robot-assisted surgery|Patients undergo robot-assisted resections.
2962235|NCT02817126|Active Comparator|Laparoscopic surgery|Patients undergo laparoscopic resections.
2962236|NCT02817113|Experimental|NC-6004, Cetuximab and 5-FU|Cetuximab will be administered before the start of chemotherapy at a loading dose of 400 mg/m2 given, followed by a subsequent weekly doses of 250 mg/m2; NC-6004 will be administered on Day 1 every 3 weeks, and 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
2962237|NCT02817100|Experimental|BAY1817080|Study Part 1: Dose 1 to 7 of BAY1817080 (increasing dose levels; redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food [American breakfast]); Study part 2: Dose 1 to 4 of BAY1817080 together with an American breakfast (increasing dose levels; redosing of BAY1817080 at dose group 1, 2 and 4 together with food [Continental breakfast])
2962238|NCT02817100|Placebo Comparator|Placebo|Study Part 1: Placebo Dose 1 to 7 of BAY1817080; Study Part 2: Placebo Dose 1 to 4 of BAY1817080
2962239|NCT02817087|Active Comparator|Active treatment w/rTMS|Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap and are provided ACTIVE treatment delivering transcranial magnetic stimulation; the cap's rTMS capability is on.
2962240|NCT02817087|Sham Comparator|Sham treatment w/rTMS|Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap and are provided SHAM treatment not delivering any transcranial magnetic stimulation; the cap's rTMS capability is not turned on.
2962241|NCT02817074|Active Comparator|MIND Diet +Weight loss|3-year intervention of dietary counseling to adhere to the MIND diet plus reduce calorie intake by 250 kcal /day for mild weight loss
2962242|NCT02817074|Placebo Comparator|Usual Diet + Weight Loss|3-year intervention of usual diet + counseling to reduce calorie intake by 250 kcal/day for mild weight loss
2962243|NCT02817061|Experimental|NIR brain stimulation|"An Omnilux device will be used to put NIR light on the head and forehead of the subject age 18-25 or 65-85. The device is a low risk device as determined by the IRB. Thirty (30) subjects will receive this light at 6 visits over 16 weeks.~An automated interactive software self-test will be used at baseline and at three subsequent visits to quantify subject cognitive functions."
2962244|NCT02817061|Sham Comparator|Sham|"An Omnilux Device will be used at a safe wavelength not associated with photobiomodulation, putting sham light on the head and forehead of the subject age 18-25 or 65-85. The device is a low risk device as determined by the IRB. Thirty (30) subjects will receive this light at 6 visits over 16 weeks.~An automated interactive software self-test will be used at baseline and at three subsequent visits to quantify subject cognitive functions."
2962245|NCT02817048|Active Comparator|Tubeless|Interventions: VATS without chest tube placement
2962246|NCT02817048|Active Comparator|Chest tube|VATS with chest tube placement
2962247|NCT02817035|Experimental|noninvasive mechanical ventilation|To investigate the change of the neural inspiratory time and expiratory delay noninvasive mechanical ventilation ,in comparison to spontaneous breathing
2962248|NCT02817022|Other|developmentally supportive care|enrolled neonates will be provided routine supportive care as per existing NICU protocols. This will be carried out in the initial 6 months (0-180 days) of study commencement. This group will serve as control group (group A). During subsequent 6 months (181-360 days) of the study period, enrolled neonates fulfilling the inclusion criteria will be provided routine supportive care and the components of developmentally supportive care(DSC). DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment. This group will be designated as group B
2962249|NCT02817009|No Intervention|Nutrition Group|This group will go through standard of care and visit the nutritionist on a monthly basis for the three months that they are a part of the study.
2962250|NCT02817009|Experimental|Healthy Families Group|Participants and their families will attend a weekly nutrition session, social support session and physical activity session for 12 weeks.
2962251|NCT02816996|Experimental|Hand-holding|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
2962252|NCT02816996|Experimental|Stress Ball|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
2962253|NCT02816996|No Intervention|Nothing|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
2962254|NCT02816983||SBRT for oligometastatic prostate cancer|
2962255|NCT02816970|Experimental|A Test|Test drug (Gliptus) 1 tablet contains 50 mg vildagliptin
2962256|NCT02816970|Active Comparator|B Reference|Reference drug (Galvus) 1 tablet contains 50 mg vildagliptin
2962257|NCT02816957|Active Comparator|patients receiving Nigella|40 patients in the treatment group that will receive nigella sativa powder (2 gm/day) for 3 consecutive months.
2962258|NCT02816957|No Intervention|patients not received nigella as controls|40 patients in the control group will not receive nigella sativa and continued on the usual chelators
2962259|NCT02816944|Experimental|EUS-guided laser ablation for refractory neoplasms|
2962260|NCT02816918|Experimental|Extraluminal use of Univent Blocker|"Patients assigned to the Extraluminal use of Univent Blocker group were first inserted Univent bronchial Blocker into the glottis via direct laryngoscopy then advanced the Blocker to the target bronchus until slight resistance was encountered.A conventional tracheal tube with appropriate size was intubated via direct laryngoscopy into the appropriate depth, inflating the tracheal tube cuff, and fixing the tube firmly at the patient's mouth with cloth tape .~So the Univent Blocker Extraluminal of the endotracheal tube,then the fibreoptic bronchoscopy was inserted into the tracheal tube and guided bronchial blocker cuff to the target main bronchus under direct vision"
2962261|NCT02816918|Experimental|Innerluminal use of Univent Blocker|Patients in Innerluminal use of Univent Blocker group: When the endotracheal tube had been intubated via direct laryngoscopy, the bronchial blocker was advanced Innerluminal of the endotracheal tube and directed into the right or left mainstem bronchus, then the fibreoptic bronchoscopy was inserted into the tracheal tube. After further pushing and twisting, the bronchial blocker tube will move into the mainstem bronchus under direct vision by FOB.the tracheal tube cuff is inflated with the tube being fixed firmly at the patient's mouth with cloth tape
2962262|NCT02816905|Active Comparator|Group A|20 eyes that received topical 0.1% Dexamethasone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
2962263|NCT02816905|Active Comparator|Group B|20 eyes that received topical 0.1 % Fluorometholone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
2962264|NCT02816905|Active Comparator|Group C|40 eyes that received topical 1% Rimexolone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
2962265|NCT02816892||Rupture group|Rupture was defined by direct visualisation of the discontinuity of the aortic wall by computed tomography, sonography, intraoperative findings or at autopsy with detection of blood in the pleural, pericardial or abdominal cavity.
2962266|NCT02816892||Covert rupture group|Covert rupture was defined as an intramural haematoma without detection of free blood in the body cavities.
2962267|NCT02816892||Acute dissection group|Acute dissection was defined when blood separating the layers of the aortic media was newly diagnosed.
2962268|NCT02816892||Chronic dissection group|Chronic dissection was defined as the absence of any visible propagation of a known dissection compared to preexisting examinations.
2962269|NCT02816892||Ectatic aneurysm group|Ectatic aneurysm was defined as a permanent localised dilatation of the aorta with a diameter of at least 50% greater than normal
2962270|NCT02816879|Experimental|Screening (anal cytology collection)|Patients undergo anal cytology collection using 2 NF swabs and 1 Dacron swab for analysis via Pap staining, HPV genotyping, and PCR.
2962271|NCT02816866|Experimental|empowered primary care model|"patients receive an individualized prescription for survivorship care prepared by a cancer survivor specialist to be implemented by the primary care doctor"
2962272|NCT02816866|Experimental|specialty survivor clinic|patient attends a specialty survivor clinic at Yale for survivorship care
2962273|NCT02816853|Experimental|Sequence 1|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
2962274|NCT02816853|Experimental|Sequence 2|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
2962275|NCT02816853|Experimental|Sequence 3|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
2962276|NCT02816853|Experimental|Sequence 4|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
2962277|NCT02816840|Experimental|PET-CT|Patients in this arm take radiotherapy positioning with PET-CT.
2962278|NCT02816840|Experimental|PET-MRI|Patients in this arm take radiotherapy positioning with PET-MRI.
2962279|NCT02816840|No Intervention|Computed Tomography|Patients in this arm take radiotherapy positioning with CT.
2962280|NCT02816827|Experimental|E-AG-01|550 mg of 2 capsules having AG-01 and AG-07 will be administered orally twice daily for one day.
2962281|NCT02816827|Experimental|E-AG-02|550 mg of 2 capsules having AG-05 and AG-06 will be administered orally twice daily for one day.
2962282|NCT02816827|Experimental|E-AG-03|550 mg of 2 capsules having AG-01 and AG-05 will be administered orally twice daily for one day.
2962283|NCT02816827|Experimental|E-AG-04|550 mg of 2 capsules having AG-06 and AG-07 will be administered orally twice daily for one day.
2962284|NCT02816814|Active Comparator|Love Diet|Overweight females (BMI > 25) in menopause
2962285|NCT02816814|Experimental|LωVE diet|Overweight females (BMI > 25) in menopause
2962286|NCT02816801|Experimental|Intervention|Access to Butler-Program 2.0
2962287|NCT02816801|No Intervention|Waitlist|
2962288|NCT02816788|Experimental|Equine Assisted Therapy (EAT)|Equine Assisted Therapy (EAT) treatment group
2962289|NCT02816775|Active Comparator|Group Laryngoscope|Group Laryngoscope; intubation will be made by Macintosh laryngoscope
2962290|NCT02816775|Active Comparator|Group Videolaryngoscope|Group Videolaryngoscope; intubation will be made by McGRATH Videolaryngoscope
2962291|NCT02816762|Experimental|CPAP treatment|Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents plus continuous positive airway pressure (CPAP)
2962292|NCT02816762|Active Comparator|Control treatment|Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
2962293|NCT02816749|Experimental|Maggot debridement therapy(MDT)|Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
2962294|NCT02816749|Active Comparator|Conventional Dressing Therapy(CDT)|Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
2962295|NCT02816736|Active Comparator|LCZ696 (Entresto) + placebo|LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks
2962296|NCT02816736|Active Comparator|valsartan + placebo|valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks
2962297|NCT02816723|Experimental|Mindfulness|mindfulness/meditation/movement training
2962298|NCT02816723|Active Comparator|Brain Health|Brain Health education class
2962299|NCT02816710|Experimental|Conbercept 1|Conberecep injection before vitrectomy
2962300|NCT02816710|Experimental|Conbercept 2|First Conberecep injection before vitrectomy and second at the end of operation.
2962301|NCT02816710|Experimental|Conbercept 3|Conberecep injection at the end of vitrectomy
2962302|NCT02816697|Active Comparator|Cease-Aim 1|"Cease Implementation~100 Patients after CEASE Implementation~Exit Interview and Tobacco Use Survey"
2962303|NCT02816697|Active Comparator|Pre Cease Implementation Aim 2|"50 Current or former smokers (3 months +/-2 month) patients in usual care (before CEASE implementation)~Tobacco Use Survey (Baseline,1- 6 Months)~Biochemical verification"
2962304|NCT02816697|Experimental|After Cease Implementation Aim 2|"50 Current or former smokers (3 months +/-2 month)~Tobacco Use Survey (Baseline,1- 6 Months)~Biochemical verification"
2962305|NCT02816697|Active Comparator|Usual Care-Aim 1|"Usual Care Tobacco Treatment Services~100 patients in usual care~Exit Interview and Tobacco Use Survey"
2962306|NCT02816697|No Intervention|Clinician and Staff Survey|- Interview clinicians and support staff (40)
2962307|NCT02816684|Active Comparator|SET-C|Social Effectiveness Therapy for Children (SET-C; Beidel et al., 2000) includes social skills training, peer generalization experiences, and in vivo exposure.
2962308|NCT02816684|Experimental|Pegasys-VR|SET-C SST and individual exposure sessions are the same as the active comparator. Peer generalization sessions are replaced by a virtual environment, known as Pegasys School. children engage with artificially intelligent avatars throughout the school.
2962309|NCT02816658|Active Comparator|Laparoscopic Surgery|Laparoscopic Inguinal Hernia Repair through a Transabdominal, Preperitoneal Approach
2962310|NCT02816658|Active Comparator|Robotic Surgery|Robotic Inguinal Hernia Repair
2962311|NCT02816645|Experimental|<5 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:~< 5 years~Between 5 and 10 years~Between 10 and 15 years~> 15 years"
2962312|NCT02816645|Experimental|Between 5 and 10 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:~< 5 years~Between 5 and 10 years~Between 10 and 15 years~> 15 years"
2962313|NCT02816645|Experimental|Between 10 and 15 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:~< 5 years~Between 5 and 10 years~Between 10 and 15 years~> 15 years"
2962314|NCT02816645|Experimental|> 15 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:~< 5 years~Between 5 and 10 years~Between 10 and 15 years~> 15 years"
2962315|NCT02816632|Experimental|healthy volunteers|
2962316|NCT02816619|Experimental|APA+|APA + : patients will beneficiate of Personalized Physical Activity coaching program during 3 months (1 hour, twice by week, during 3 months)
2962317|NCT02816619|Other|APA-|APA- : patients will do free practice of physical activity during 3 months.
2962318|NCT02816606||Standard Reconstruction Technique|ACL reconstruction using hamstring autograft Using 30-degree arthroscope Using rigid femoral tunnel reamer (Rigid Reamers)
2962319|NCT02816606||Alternative Reconstruction Group|ACL reconstruction using hamstring autograft Using 30-degree and 70-degree arthroscopes Using flexible femoral tunnel reamer (Flexible Reamers)
2962320|NCT02816593|Experimental|Group 1 - HP 6%|Group 1: Experimental: Office; hydrogen peroxide 6%,
2962321|NCT02816593|Experimental|Group 2 - HP 15%|Group 2: Experimental: Office; hydrogen peroxide 15%,
2962322|NCT02816593|Active Comparator|Group 3 - CP 10%|Group 3: Control: Homemade; Carbamide Peroxide 10%,
2962323|NCT02816580|Experimental|elderly subjects|
2962324|NCT02816567|Experimental|NMBA group|
2962325|NCT02816567|Placebo Comparator|placebo group|
2962326|NCT02816554|Experimental|JECEVAX-1|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1.0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12days
2962327|NCT02816554|Experimental|JECEVAX-0.8|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
2962328|NCT02816554|Experimental|JECEVAX-0.5|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
2962329|NCT02816554|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
2962330|NCT02816541|Experimental|Pelvis Retroverted|Pilates-based therapeutic exercises performed with a posterior pelvic tilt
2962331|NCT02816541|Experimental|Pelvis in Neutral Position|Pilates-based therapeutic exercises performed with a neutral position of the pelvis
2962332|NCT02816541|Active Comparator|Control Group|Aerobic exercise performed on a treadmill
2962333|NCT02816528||Training program|Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.
2962334|NCT02816528||Nothing|Not Trained Physicians
2962335|NCT02816515||Ectoin® mouth wash|The treatment will be started on the first day of radio- and/or chemotherapy, before development of mucositis
2962336|NCT02816515||Ectoin mouth wash|The treatment will be started after oral mucositis development in patients receiving radio- and/or chemotherapy
2962337|NCT02816515||Supersaturated electrolyte mouth rinse|The treatment will be started after oral mucositis development in patients receiving radio and/or chemotherapy
2962372|NCT02816242|Sham Comparator|placebo|teaching anatomy by traditional method
2964032|NCT02804711|Placebo Comparator|Four doses of placebo|four doses of placebo
2962338|NCT02816502|Experimental|Stress Management Skill Building Program A|An eight week skill building group in which subjects meet with the teacher and other students in the group once a week, and complete homework and practice log during the week.
2962339|NCT02816502|Active Comparator|Stress Management Skill Building Program B|An eight week skill building group in which subjects meet with the teacher and other students in the group once a week, and complete homework and practice log during the week.
2962340|NCT02816489|Experimental|Group I|"will be treated using passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner (3M Unitek - USA).~Intervention: Device: passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner (3M Unitek - USA)."
2962341|NCT02816489|Experimental|Group II|"will be treated using conventional stainless steel orthodontic brackets ligated with elastomeric ligature (3M Unitek - USA).~Intervention: Device: conventional stainless steel orthodontic brackets ligated with elastomeric ligature (3M Unitek - USA)."
2962342|NCT02816476|Experimental|Daratumumab|Patient will receive Daratumumab every week for the first 2 cycles then every 2 weeks from cycle 3 through cycle 6.
2962343|NCT02816463|Experimental|Ambu AuraGain (Group A)|Laryngeal mask Ambu AuraGain will be used, and oropharyngeal leak pressure (OLP) after insertion will be recorded as the primary outcome measure
2962344|NCT02816463|Active Comparator|LMA Supreme (Group S)|Laryngeal mask Supreme will be used, and oropharyngeal leak pressure (OLP) after insertion will be recorded as the primary outcome measure
2962345|NCT02816450|Experimental|HIGH|Increase water intake to 2.5 liters per day for 4 days
2962346|NCT02816450|Experimental|LOW|Decrease water intake to 0.5 liter per day for 4 days
2962347|NCT02816437|Experimental|OpenBiome FMT retention enema|OpenBiome Fecal Microbiota Transplantation retention enema, one rectal application.
2962348|NCT02816424|Experimental|Brief Motivational Interviewing|Principles and skills of motivational interviewing will be used with participants assigned to brief intervention. These participants will receive feedback that they are at risk for unintended pregnancy. They will receive information on the likelihood of pregnancy given their self-reported frequency of unprotected sex. They will be given information regarding negative consequences associated with teen pregnancy. They will be provided with information on the chances of pregnancy with abstinence, condom use, oral contraceptives, and Long Acting Reversible Contraceptives (LARC). Following information exchange, participants who are high in readiness to change will engage in action planning, whereby a specific plan for reducing risk for unintended pregnancy will be collaboratively developed with the interventionist. Patients who are low in readiness to change will complete a motivational interviewing-based roadmap activity that is designed to strategically evoke motivational speech.
2962349|NCT02816424|No Intervention|Control|
2962350|NCT02816411|Experimental|Protein|Milk protein isolate supplementation: orally, 20g of protein immediately post-exercise and then 20g every 3h on 3 occasions (+3, +6, +9), on the exercise day. The remaining 8 days, 20g daily with breakfast.
2962351|NCT02816411|Active Comparator|Placebo|Placebo administration: orally 500 ml, immediately post-exercise as well as at +3, +6 and +9 hours, on the exercise day. The remaining 8 days, 500 ml daily with breakfast.
2962352|NCT02816398|Experimental|Treatment|Interventional use of experimental Ellipsys catheter system for percutaneous creation of an arteriovenous fistula
2962353|NCT02816385|Active Comparator|Antegrade Cardioplegia|Coronary artery bypass grafting (CABG) surgery in patients with a normal left ventricular ejection fraction (FEVG)
2962354|NCT02816385|Experimental|Retrograde Cardioplegia|Coronary artery bypass grafting (CABG) surgery in patients with a normal left ventricular ejection fraction (FEVG)
2962355|NCT02816372|Experimental|Tidal volume 4 ml/kg Predicted Body Weight (PBW)|
2962356|NCT02816359|Other|head-bed position|Head-bed position at 0° for 30 minutes then head-bed position at 30° for 30 minutes
2962357|NCT02816346|Experimental|A|dose 500 cfu
2962358|NCT02816346|Experimental|B|250 cfu or 1000 cfu (based on results of cohort A)
2962359|NCT02816346|Experimental|C|TBD based on cohort A and B
2962360|NCT02816346|Experimental|D|Based on results of previous cohorts
2962361|NCT02816333||Type B aortic dissection|Patients with Type B aortic dissection requiring TEVAR
2962362|NCT02816320||Inpatient stays|All patients who were hospitalized in participating hospitals in France during the study period were eligible for inclusion.
2962363|NCT02816307|Experimental|Infective endocarditis|
2962364|NCT02816294|Experimental|Housing Prescription|Participants in the intervention group will be referred to the Care Coordinator at Project Hope, who will conduct case management with the family to stabilize their housing. The Care Coordinator will refer families all families to benefit maximization services and complete Problem Solving Education. The Care Coordinator will also refer families as necessary to Medical-Legal Partnership Boston for pro-bono legal services and/or the Boston Housing Authority for priority on a subsidized housing waitlist.
2962365|NCT02816294|No Intervention|Resource List|At present, for families facing housing insecurity, Children's HealthWatch offers paper resources with contact information for local social service agencies that may assist with housing stability.
2962366|NCT02816281||Reasons of case cancellation|"will be recorded and categorized into 6 groups including~patient issue such as surgery refusal, no show on the day of surgery, transport problems~facility such as equipment needs, improper estimate case time, case bumps~Surgeon unavailable, due to administrative schedules and other problems or changed line of management respectively~anesthesiologist fail to adequately prepare the patient, lead to some misunderstanding communication such as NPO violation, preoperative drug error~medical condition that may impact the patient's ability to endure anesthesia techniques or surgical procedure~miscellaneous."
2962367|NCT02816268|Other|Conventional Pulmonary vein isolation|Conventional pulmonary vein isolation was gained by using an irrigated tip ablation catheter
2962368|NCT02816268|Other|Contact force pulmonary vein isolation|Contact force was meassured by using the SMART-Touch ablation catheter (Biosense-Webster®)
2962369|NCT02816255|Placebo Comparator|Full Face Mask with same CPAP Pressure|After the two week period all will switch to a full face mask with half using the same CPAP pressure.
2962370|NCT02816255|Active Comparator|Full Face Mask with new Pressure|After the two week period all will switch to a full face mask with half using with a new cpap pressure derived from our formula.
2962371|NCT02816242|Experimental|intervention|teaching anatomy by concept map
2962373|NCT02816229|Experimental|Insertion of endobronchial valve|Patients in this group will have one or more EBV inserted into the relevant lung regions to manage the haemoptysis via flexible bronchoscopy.
2962374|NCT02816229|No Intervention|Best care|Patients will receive best medical care.
2962375|NCT02816216|Other|End User Iterative Testing - CampAir|To ensure the software and website function as intended, investigators will systematically test each of the seven CampAir modules with target end users. Participants will review one module per week for seven weeks. As part of each module, participants will also complete a daily asthma checklist. Following the review of each module, participants will be prompted to complete measures assessing technology acceptability and usability and product quality. Results will be used to modify and finalize the user interface and navigation to maximize usability.
2962376|NCT02816203|Experimental|Primary Hemostatic Intra-Uterine suction cup|Patients who present primary postpartum hemorrhage requiring administration of Nalador and the suction cup placed in the uterine cavity
2962377|NCT02816177|Experimental|Telemedicine|Usual care and telemedicine consultations during12 months.
2962378|NCT02816177|Active Comparator|Usual care alone|Usual care during12 months.
2962379|NCT02816164|Active Comparator|Neupogen for 5 days|Neupogen injection for 5 days
2962380|NCT02816164|Active Comparator|Neupogen for 7 days|Neupogen injection for 7 days
2962381|NCT02816164|Active Comparator|Neupogen for 10 days|Neupogen injection for 10 days
2962382|NCT02816151|Experimental|Group 1|
2962383|NCT02816151|Experimental|Group 2|
2962384|NCT02816138|Experimental|Transdermal nicotine patch|Transdermal nicotine patch, administered on awakening and removed at bedtime (16h/d). Dosing 3.5mg patch/daily, titrated over study to maximum dose of 21mg patch/daily.
2962385|NCT02816125|Active Comparator|Habitual supplemented|habitual diet with 1.2 g EPA+DHA in capsule form/day.
2962386|NCT02816125|Experimental|Low-fat supplemented|Reduce dietary fat to less than 20% energy, add 1.2 g EPA+DHA in capsule form/day.
2962387|NCT02816112|Active Comparator|Ciprofloxacin|Oral tablet taken twice a day at home starting 5 days after chemotherapy for 14 days for every cycle of TC
2962388|NCT02816112|Active Comparator|G-CSF|Daily injection at home for the number of days as chosen by the treating physician
2962389|NCT02816099|Experimental|Type-1 diabetes patients|
2962390|NCT02816099|Other|Controls|
2962391|NCT02816086|No Intervention|Standard care|The study participants receives standard care in the ward, this does not include a pharmacist.
2962392|NCT02816086|Experimental|Intervention|Interdisciplinary collaboration structure
2962393|NCT02816073|Active Comparator|1,700|Patients receive 1,700 (+/- 5%) laser shots in a single session of pan-retinal photocoagulation using pattern scanning laser
2962394|NCT02816073|Active Comparator|2,500|Patients receive 2,500 (+/- 5%) laser shots in a single session of pan-retinal photocoagulation using pattern scanning laser
2962395|NCT02816060|Experimental|neural tensionner exercise|This group will receive a specific tensionner nerve exercise to provide mechanical stress across the median nerve. This technique have two positions, start and end. It consists on going from one to the other position constantly, controlling the speed of the technique to be constant. In the start position, the subject will be supine lying on a couch with the following parameters: contralateral cervical side bending, shoulder depression, shoulder abduction and external rotation to 90°, elbow flexion to 90º, and forearm supination. In the final position, the therapist will perform full elbow extension while maintaining all the joints previously situated as described above until the patients feel tension, then return to the start position.
2962396|NCT02816060|Placebo Comparator|sham neural tensionner exercise|The control group will receive a sham technique (ST) with minimal mechanical stress across the median nerve. Patients will be placed in neutral cervical spine position with no shoulder depression, shoulder abduction and external rotation to 45°, 45° of elbow extension, and forearm pronation.. This technique will be passively repeated from elbow flexion to extension in the same way than the NTE group
2962397|NCT02816034|Experimental|Experimental Explicit|Cannabis user performs visuo-motor rotation tasks informed of an explicit strategy to maximise performance
2962398|NCT02816034|Active Comparator|Control Explicit|Healthy subject performs visuo-motor rotation tasks informed of an explicit strategy to maximise performance
2962399|NCT02816034|Experimental|Experimental Implicit|Cannabis user performs visuo-motor rotation tasks without being informed of the explicit strategy
2962400|NCT02816034|Active Comparator|Control Implicit|Healthy subject performs visuo-motor rotation tasks without being informed of the explicit strategy
2962401|NCT02816021|Experimental|Arm A: Metastatic Melanoma - PD-1 Naive|"Thirty-six participants with metastatic melanoma that are PD-1 naïve enrolled in treatment Arm A.~Treatment consists of 3-week cycles and continues until disease progression. Oral Azacitidine administered by mouth daily for 15 days (Days 1-15) of every cycle. Pembrolizumab administered by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days."
2962402|NCT02816021|Experimental|Arm B: Metastatic Melanoma - Post PD-1 Progression|"Thirty-five participants with metastatic melanoma that have progressed on PD-1 directed therapy enrolled in treatment Arm B.~Treatment consists of 3-week cycles and continues until disease progression. Oral Azacitidine administered by mouth daily for 15 days (Days 1-15) of every cycle. Pembrolizumab administered by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days."
2962403|NCT02816008|Experimental|Cognitive rehabilitation group|Cognitive rehabilitation training with RGS in the clinic.
2962404|NCT02816008|Active Comparator|Passive control group|Passive/conventional cognitive training at home.
2962405|NCT02815995|Experimental|Adipocytic Tumors Group|"Adipocytic Tumors Group consists of well-diff/de-differentiated, pleomorphic and myxoid LPS.~Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
2962451|NCT02815748|Other|SP2086|SP2086 was taken only one time at 100mg dose in health volunteers
2962452|NCT02815735|Experimental|comfilcon A|Participants wear comfilcon A lens for 4 weeks during the cross over study.
2962453|NCT02815735|Active Comparator|lotrafilcon B|Participants wear lotrafilcon B lens for 4 weeks during the cross over study.
2962406|NCT02815995|Experimental|Vascular Tumors Group|"Vascular Tumors Group consists of leiomyosarcomas, angiosarcomas, epithelioid hemangioendotheliomas, and hemangiopericytomas.~Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
2962407|NCT02815995|Experimental|Undifferentiated Pleomorphic Sarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
2962408|NCT02815995|Experimental|Synovial Sarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
2962409|NCT02815995|Experimental|Osteosarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
2962410|NCT02815995|Experimental|Other Sarcomas Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
2962411|NCT02815982|Experimental|NOURISH-T|"The intervention aims to increase caregivers' self-efficacy for behavioral change, and facilitate an authoritarian approach to parenting. Behavioral strategies such as self-monitoring, contingency management, and stimulus control are integrated in these sessions. Further, because participatory experiences enhance overall intervention efficacy, these activities are incorporated throughout, including self-assessments, discussions and experiential activities. Homework will be assigned between sessions so skills can be practiced. We also focus on the caregivers' relationship with everyone in the family, not just the identified patient or overweight child."
2962412|NCT02815982|Active Comparator|Enhanced Usual Care|Caregivers randomized to the EUC will attend assessment sessions and an initial session moderated by an independent interventionist. The session will address the role of diet and exercise in pediatric overweight. In addition, EUC caregivers will receive nationally available print or web-based brochures on pediatric overweight on 2 occasions during the study so that similar (but not as intensive) information is provided in the intervention and EUC arms of the study. Participants will also receive a booster phone call 2 months after the end of the intervention period.
2962413|NCT02815969||Healthy volunteers|If no material of healthy volunteers of the SERT study can be used, then other matched volunteers are asked for a vena punction and urine collection
2962414|NCT02815969||Patients|Patients are asked for a vena punction and urine collection, if not already done because of medical care.
2962415|NCT02815956|Experimental|percutaneous tibial nerve stimulation (ST)|"Stimulation the day before surgery (x1), 30 minutes Stimulation the day of surgery, before surgery (at least 2 hours before surgery) and after surgery.~Stimulation every day (x3) after surgery until gastrointestinal functions recovery.~The protocol of stimulation is the same, that the one performed for fecal incontinence."
2962416|NCT02815956|Placebo Comparator|placebo (P)|"Stimulation the day before surgery (x1), 30 minutes Stimulation the day of surgery, before surgery (at least 2 hours before surgery) and after surgery.~Stimulation every day (x3) after surgery until gastrointestinal functions recovery.~The device delivers ineffective impulses."
2962417|NCT02815943|Other|Before DBP-DS surgery|
2962418|NCT02815943|Experimental|After DBP-DS surgery|It is a bariatric surgery. BPD consists in the exclusion of the duodenum from the alimentary tract with re-anastomosis of the blind loop 100 to 150 cm proximal to the ileo-coecal valve. This leads to bypass of the biliopancreatic secretions towards the distal small intestine, resulting in fat malabsorption. BPD also entails a distal gastrectomy to avoid the occurrence of peptic ulceration of the gastrointestinal anastomosis.
2962419|NCT02815943|Other|Before SG surgery|
2962420|NCT02815943|Experimental|After SG surgery|It is a bariatric surgery where the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.
2962421|NCT02815930||HCUs|Newly incident seniors with annual total healthcare expenditures in the top 5% of Ontarians
2962422|NCT02815930||Non-HCUs|Seniors with annual total healthcare expenditures below the top 5% of Ontarians
2962423|NCT02815917|Experimental|Cohort 1a: Lorazepam; 1b: Perphenazine|"Up to 5 healthy volunteers will participate in a double-blind, placebo controlled serial imaging cohort 1a. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days. On one scan day the patient will receive an IV injection of normal saline (placebo) prior to the FTP brain scan, on the other scan day the patient will receive an IV injection of lorazepam prior to the planned FTP injection scan. The type of injection (placebo versus lorazepam) will be double-blinded to the patient and the injecting nuclear medicine Authorized User. Up to 5 subjects will participate in Cohort 1b where subjects will undergo two FTP PET/CT with and without perphenazine.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
2962484|NCT02815488|Placebo Comparator|Placebo|
2962485|NCT02815475|Placebo Comparator|Placebo|Starch filled capsule
2962486|NCT02815475|Experimental|Curcumin|400mg of Curcumin via capsule to be consumed every other day
2964168|NCT02803632|Experimental|suicide attempt|questionnaires actigraphic recording
2962424|NCT02815917|Experimental|Cohort 2: Healthy Volunteer Test/Retest|"Up to 10 healthy volunteers will participate in a serial imaging cohort. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
2962425|NCT02815917|Experimental|Cohort 3: Arterial sampling|"Up to 5 cocaine-dependent males who are voluntarily seeking treatment for cocaine dependence will participate in this imaging cohort. Each subject will undergo one dynamic [18F]FTP PET/CT brain scan. Patients will have an arterial line placed for blood draws during the scan. This group will be used to determine the arterial blood input and FTP parent to metabolite ratio curves for FTP for a cocaine-dependent patient population for comparison with previously collected data in healthy normal volunteers.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
2962426|NCT02815917|Experimental|Cohort 4: Cocaine-dependent Test/Retest|"Up to 5 cocaine-dependent males who are voluntarily seeking treatment for cocaine dependence will participate in this imaging cohort. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days. This group will be used to test the variability of the [18F]FTP uptake measures in cocaine-dependent patients when scans are done following the consistent procedures with no other interventions.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
2962427|NCT02815904|Experimental|Yakson touch and Kinesthetic stimulation|"Yakson touch (YT) The therapist will relax arms and shoulder muscles for 1 minute and will do deep breathing to accumulate Ki energy on the palms. The Therapist will apply Yakson on the neonate.~Kinesthetic stimulation (KS) For giving kinesthetic stimulation the neonate will be placed in supine position. There will be six passive flexion and extension movements. Each of the movement will each last for approximately 10 seconds. The movements will be performed in the following order -right arm, left arm, right leg, left leg, both legs simultaneously"
2962428|NCT02815904|Active Comparator|Conventional Handling and KMC|"Conventional Handling (CH) The neonates in control group will receive developmental positioning(positioning of preterm infants for optimal physiological development) for 20 minutes per hour for 5 days.~Kangaroo mother care (KMC) Holding the neonate skin to skin by mother for one hour a day"
2962429|NCT02815878|Experimental|Group 1: Intervention with Disability|Participants with a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older receive Enhance Wellness for 6 months and complete pre and post outcome assessments.
2962430|NCT02815878|Active Comparator|Group 2: Intervention without Disability|Participants without a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older receive Enhance Wellness for 6 months and complete pre and post outcome assessments.
2962431|NCT02815878|No Intervention|Group 3: No intervention|Participants with a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older complete pre and post outcome assessments.
2962432|NCT02815865|Active Comparator|Foley catheter and pitocin|Intervention: Foley catheter and pitocin Foley catheter will be inserted through the cervix and inflated with 80 ml saline, pitocin will be initiated 1 hour later in the delivery room
2962433|NCT02815865|Active Comparator|Foley catheter and dinoprostone|Intervention: Foley catheter and dinoprostone Foley catheter will be inserted through the cervix and inflated with 80 ml saline dinoprostone 3 mg will be inserted 1 hour later to the posterior fornix
2962434|NCT02815865|Active Comparator|Dinoprostone|Intervention: Dinoprostone 3 mg will be inserted to the posterior fornix
2962435|NCT02815839|Experimental|Cohort 1|2.5-mg SHR4640 or placebo
2962436|NCT02815839|Experimental|Cohort 2|5-mg SHR4640 or placebo
2962437|NCT02815839|Experimental|Cohort 3|7.5-mg SHR4640 or placebo
2962438|NCT02815839|Experimental|Cohort 4|10-mg SHR4640 or placebo
2962439|NCT02815839|Experimental|Cohort 5|20-mg SHR4640 or placebo
2962440|NCT02815826||Barefoot training|16 weeks of progressive barefoot running training
2962441|NCT02815813|Experimental|PeerFIT|PeerFIT is a group-based lifestyle intervention enhanced by mobile health technology and social media designed to achieve clinically significant improvements in weight loss and cardiorespiratory fitness in young adults with serious mental illness.
2962442|NCT02815813|Active Comparator|BEAT|BEAT involves basic education in fitness and nutrition supported by a wearable activity tracking device designed to achieve clinically significant improvements in weight loss and cardiorespiratory fitness in young adults with serious mental illness.
2962443|NCT02815800|Experimental|ETHNODYNE VISIO|Administration 2 times a day of a dietary supplement, as add on therapy, in patients with Parkinson s disease
2962444|NCT02815787|Active Comparator|SP2086 and Glyburide|The A sequence was that Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.The B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.The trial period were 25 days. In this group,the subjects was given the drugs from A sequence to the B sequence.
2962445|NCT02815787|Active Comparator|Glyburide and SP2086|The A sequence was that Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.The B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.The trial period were 25 days.In this group,the subjects was given the drugs from B sequence to the A sequence.
2962446|NCT02815774|Active Comparator|health volunteers|this group patients were given SP2086 50mg only one time.
2962447|NCT02815774|Active Comparator|mild renal insufficiency|this group patients were given SP2086 50mg only one time.
2962448|NCT02815774|Active Comparator|moderate renal insufficiency|this group patients were given SP2086 50mg only one time.
2962449|NCT02815774|Active Comparator|severe renal insufficiency|this group patients were given SP2086 50mg only one time.
2962450|NCT02815774|Active Comparator|end-stage renal insufficiency|this group patients were given SP2086 50mg only one time.
2962454|NCT02815722|Active Comparator|SP2086 and Simvastatin|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.There were 5 days washout period between the two stages.The whole study needs 27 days.This group patient was given treatment from A stage to B stage.
2962455|NCT02815722|Active Comparator|Simvastatin and SP2086|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.There were 5 days washout period between the two stages.The whole study needs 27 days.This group patient was given treatment from B stage to A stage.
2962456|NCT02815709|Experimental|Treatment 1 Oliceridine|
2962457|NCT02815709|Experimental|Treatment 2 Oliceridine|
2962458|NCT02815709|Experimental|Treatment 3 Oliceridine|
2962459|NCT02815709|Placebo Comparator|Placebo|
2962460|NCT02815709|Active Comparator|Morphine|
2962461|NCT02815696|Experimental|lumbar spine segmental instability|Patients with a segmental instability of the lumbar spine having undergone surgery. Lumbar spine instability diagnosis is based on imaging (Magnetic resonance imaging, standard radiography, and EOS imaging). Surgical treatment is indicated if the pain is relieved by wearing a brace during at least three months.
2962462|NCT02815670|Experimental|Idarucizumab|
2962463|NCT02815657|Active Comparator|SP2086 and Valsartan|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12.There were 6 days washout period between the two stages.The whole study needs 31 days.This group patient was given treatment from A stage to B stage.
2962464|NCT02815657|Active Comparator|Valsartan and SP2086|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12.There were 6 days washout period between the two stages.The whole study needs 31 days.This group patient was given treatment from B stage to A stage.
2962465|NCT02815644|Experimental|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
2962466|NCT02815631|Experimental|Cardiogoniometry (CGM)|"Every patient involved in the study will undergo a series of CGM recordings whilst having their FFR procedure. These recordings will all be done whilst they are in the catheterisation laboratory and will be taking at the following points during the procedure.~First baseline recording - taken when the patient first enters the catheterisation laboratory and is prepped for their procedure.~Second baseline recording - taken when the FFR guide wire is in place in the coronary artery being assessed.~Maximal hyperaemia recording - this will be taken when the patient is at maximal hyperaemia during their adenosine infusion for their FFR procedure.~The patients involvement will then be finished in the study and will be cared for as per clinical practice.~If the CGM records a result of anything less than 0, it will be regarded as a positive result."
2962467|NCT02815631|Active Comparator|Fractional flow reserve (FFR)|"Every patient involved in the study will undergo an FFR assessment of their coronary arteries. These recordings will all be done whilst they are in the catheterisation laboratory. They will have the following recordings:~A baseline FFR will be recorded once the pressure wire has been advanced down the coronary artery being assessed.~Maximal hyperaemia FFR will be recorded during adenosine infusion.~An FFR ratio of <0.80 will be regarded as a positive result."
2962468|NCT02815618||Infants delivered by elective caesarean|Infants to be measured immediately after birth and on their second day of life.
2962469|NCT02815618||Infants on mechanical ventilation|Infants to be measured while changing ventilator settings to normalize arterial pCO2.
2962470|NCT02815618||Infants on ventilatory support|Infants to be measured for 24 hours continuously to assess user-friendliness and loss of signal.
2962471|NCT02815592|Experimental|Experimental Arm 1|BMS-986012/Cisplatin/Etoposide
2962472|NCT02815592|Experimental|Experimental Arm 2|BMS-986012/Carboplatin/Etoposide
2962473|NCT02815592|Experimental|Experimental Arm 3A|BMS-986012/Platinum/Etoposide
2962474|NCT02815592|Active Comparator|Active Comparator Arm 3B|Platinum/Etoposide
2962475|NCT02815579|Experimental|Intervention|The Shamba Maisha Intervention includes: a) a microcredit loan (~$140) from a well-established Kenyan bank for purchasing agricultural implements and commodities; b) agricultural implements to be purchased with the microcredit loan including the KickStart treadle pump, seeds, fertilizers and pesticides; and c) education in financial management and sustainable farming practices occurring in the setting of patient support groups.
2962476|NCT02815579|No Intervention|Control|Participants in the control arm will receive the standard of care.
2962477|NCT02815566|Experimental|Immediate switch|Open label tenofovir-alafenamide (25/10mg)-emtricitabine (200mg) tablet once daily by mouth for 96 weeks
2962478|NCT02815566|Active Comparator|delayed switch|Open-label tenofovir (300mg)-emtricitabine (200mg) tablet once daily by mouth for 48 weeks followed by open label tenofovir-alafenamide (25/10mg)-emtricitabine (200mg) tablet once daily by mouth for an additional 48 weeks
2962479|NCT02815553|Experimental|Cardiac tumors|
2962480|NCT02815527||Fresubin Intensive|Adult critically ill non-septic ventilated patients admitted to the intensive care unit with an expected intensive care stay of four days or more.
2962481|NCT02815514||Aortic valve procedures|"percutaneous transfemoral aortic valve implantation~percutaneous transapical aortic valve implantation~percutaneous transaortic aortic valve implantation~aortic valve valvuloplasty~surgical aortic valve replacement~conservative treatment"
2962482|NCT02815501||women|"attending the emergency room and/or hospitalised or followed for: Spontaneous and/or repeated miscarriage Foetal death Pre-eclampsia Retroplacental haematoma Post-partum haemorrhage Premature delivery~Blood samples"
2962483|NCT02815488|Experimental|CHF6297 Active|
2962487|NCT02815475|Active Comparator|Turmeric powder|2 teaspoons of dried turmeric powder to be consumed every other day
2962488|NCT02815462|Experimental|Intervention|FAM-FACE-SG risk score + decision making algorithm
2962489|NCT02815462|Active Comparator|Control|Usual Care
2962490|NCT02815449|Experimental|Low stabilizer level|Meals prepared with iron fortified cube with low stabilizer level
2962491|NCT02815449|Experimental|Medium stabilizer level|Meals prepared with iron fortified cube with medium stabilizer level
2962492|NCT02815449|Experimental|High stabilizer level|Meals prepared with iron fortified cube with high stabilizer level
2962493|NCT02815436|Active Comparator|Telephone reminder|subjects in this arm will receive a telephone reminder
2962494|NCT02815436|Active Comparator|SMS reminder|Subjects in this arm will receive a SMS reminder
2962495|NCT02815436|No Intervention|No reminder|usual care, where no additional intervention will be offered
2962496|NCT02815423|Experimental|UCMSCs|Transplantation of umbilical cord mesenchymal stem cells (UCMSCs) in patients with fracture and bone nonunion.
2962497|NCT02815423|Placebo Comparator|Placebo|The patients with fracture and bone nonunion who underwent percutaneous injection of placebo.
2962498|NCT02815410|Other|Levetiracetam|Newly diagnosed histologically proven supratentorial glioblastoma patients received levetiracetam during and after their CCRT
2962499|NCT02815397|Experimental|Single arm, open label|Metformin added to standard of care treatment for all patients
2962500|NCT02815371|Experimental|Needle Acupuncture|Sterile, disposable needles were inserted into specific acupoints until Deqi sensation was elicited. The needles were retained for 25 minutes before and after embryo transfer.
2962501|NCT02815371|Experimental|Laser Acupuncture|Each point was stimulated with a laser (Luminex Laser Therapy System: Medical Laser Systems, Branford, CT) set at 5 joules/cm2 (J/cm2) in continuous mode for 0.10 seconds. Based on various studies, a minimum of 4 J/cm2 produces an improved circulatory effect.
2962502|NCT02815371|Sham Comparator|Sham Laser Acupuncture|However, support staff uninvolved in the design of the trial or analysis of the data disarmed the machine, such that no laser irradiation was emitted. This system created an illusion for both the patient and the acupuncturist, and allowed for a truly double blinded control group.
2962503|NCT02815371|No Intervention|No Treatment|This control group was not exposed to any additional physical contact or acupuncture related protocol. They were only exposed to dim light and calming music before and after embryo transfer, mimicking the natural waiting room and procedure room setting for all patients undergoing embryo transfer.
2962504|NCT02815358|Experimental|Segmental Stabilization Group|Patients receiving segmental stabilization exercises.
2962505|NCT02815358|Active Comparator|Control Group|Patients receiving home exercises.
2962506|NCT02815345|Experimental|Measure of the nasal cavity|"The nasal cavity of all the included neonates will be measured using rhinometry during their hospitalization every weeks. So one to 8 measurement will be performed for each neonates.~Some included neonates will also have rhinomanometry measurements."
2962507|NCT02815332|Placebo Comparator|BPX-01 Vehicle Topical Gel|Approximately 1 gram applied once daily for 12 weeks
2962508|NCT02815332|Experimental|BPX-01 1% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
2962509|NCT02815332|Experimental|BPX-01 2% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
2962510|NCT02815319|Active Comparator|Standard of care|Physician's treatment recommendation for dexamethasone premedication
2962511|NCT02815319|Active Comparator|8mg PO dexamethasone|8mg PO dexamethasone premedication
2962512|NCT02815306|Experimental|Brace goup|The infants who were brace group treated by braces which were designed and made by us.
2962513|NCT02815293|Experimental|AGN-195263|
2962514|NCT02815293|Placebo Comparator|Vehicle|
2962515|NCT02815280|Experimental|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
2962516|NCT02815280|Placebo Comparator|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
2962517|NCT02815267|Experimental|FMX-101, 4% minocycline foam|Subjects will apply the assigned FMX-101, 4% minocycline foam topically once daily for 12 weeks as directed
2962518|NCT02815267|Placebo Comparator|Vehicle foam|Subjects will apply the assigned vehicle foam topically once daily for 12 weeks as directed
2962519|NCT02815254|Active Comparator|Low dose exercise intervention|
2962520|NCT02815254|Experimental|High dose exercise intervention|
2962521|NCT02815241|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2962522|NCT02815228|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2962523|NCT02815215|Experimental|Intervention group|Minimally Invasive Carroll's Technique
2962524|NCT02815215|Active Comparator|Control group|Ponseti method
2962525|NCT02815202|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2962526|NCT02815189|Experimental|Post operative Pain after a RCT|Ibuprofen for Post operative pain. Take 400 mg taken a week after. Incidence of flare ups after a single vs multiple visits root canal treatments.
2962527|NCT02815189|Experimental|Flare up|Acetaminophen 325 mg for Flare Up. Taken second day after. Incidence of Post operative pain after root canal treatment in one vs two visits.
2962528|NCT02815176||Central serous chorioretinopathy|De novo eligible CSC patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
2962529|NCT02815176||Polypoidal choroidal vasculopathy|De novo eligible PCV patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
2962698|NCT02814019|Experimental|idebenone 150 mg film-coated tablets|900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
2962530|NCT02815176||Epiretinal membrane|Idiopathic ERM patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
2962531|NCT02815163|No Intervention|comparison group|The CG received no extra care; they could receive the usual routine care for THR in the unit as they had before participation in the study. The routine care included oral instruction by nurses follow by the handout. Also, a brochure was provided of the structure of hip, the risk factors of THR, care before and after THR, complications, care of discharge, and demonstration of rehabilitation with pictures) of THR designed by researchers in this study. Five orthopedics health care experts independently reviewed and rated each item in the brochure on a five-point Likert-type scale in terms of relevance, representativeness, specificity, and clarity.
2962532|NCT02815163|Experimental|Empowerment education group|"The 5 times total, 12-week EE intervention was aimed to empower older patients with THR to develop their own self-management program to meet their needs. This empowerment education intervention based on 6 empowerment components: Partnership, listening, dialogue, reflection, action, feedback and 5-step empowerment strategies: motivating patients self-awareness, assessing the causes of the problem, goal setting, individual self-care plan development, and checking whether goals or plans have been achieved who modified from Freire's 3-stage methodology. The difference between this program and the other health educations for patients with THR are that this program encourages them to explore their needs and worries, their own ability and power to meet their needs, and their capacity to seek and use their social support and resources etc."
2962533|NCT02815150|Experimental|Treatment group|Preoperative oral carbohydrate drink: patients drink 5% glucose solution 250ml 2-3 hours before surgery.
2962534|NCT02815150|No Intervention|Control group|Patients undergo 6-8 hours of preoperative fasting.
2962535|NCT02815137|Other|XPO1 E571K mutation detection|Determination of mutation of XPO1571K in patient with classical hodgkin Lymphoma by digital PCR on blood samples and biopsy
2962536|NCT02815124|Active Comparator|Standard of Care|Cochlear Implant programming using standard of care
2962537|NCT02815124|Experimental|Image-Guided Cochlear Implant Programming|Cochlear Implant programming using Image-Guided Cochlear Implant Programming
2962538|NCT02815111||Control Group|Intensivists will proceed with analgesia utilizing conventional opioid based pain order sets.
2962539|NCT02815111||Study Group|The investigators plan to study an analgesic regimen of Ketamine and lidocaine as infusions with Neurontin and Acetaminophen delivered orally for postoperative analgesia and the subsequent effect on ventilator days and ICU stay.
2962540|NCT02815085|Experimental|RecoverLINK technology|RecoverLINK is a two-part mHealth technology designed to supplement traditional care transitional programs for heart failure (HF) patients.
2962541|NCT02815059|Experimental|Ibrutinib, Dasatinib and prednisone, all patients|
2962542|NCT02815033|Other|Single arm|Experimental: Single arm Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
2962543|NCT02815020|Other|Boot Camp Translation|"Boot Camp Translation is rolled out in a stepped wedge design across participating PBRNs to assist practices with SMS implementation. The Boot Camp Translation intervention initiates practices to review and begin uptake and implementation of tools from the AHRQ Self-Management Support tool library."
2962544|NCT02815007|Experimental|Chidamide with EGFR-TKI|"Chidamide: Per Os, 30mg (5mg*6), twice a week, time interval between 2 medications should be ≥3 days, medicine taken 30 minutes after breakfast.~EGFR-TKI:~Taken according to the instruction book"
2962545|NCT02814994|Experimental|tidal volume guided by respiratory system compliance|effects of tidal volume guided by respiratory system compliance on mortality in patients suffering from ARDS
2962546|NCT02814994|Experimental|low tidal volume|Ventilated patients with low tidal volume
2962547|NCT02814968|Experimental|Single arm|Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
2962548|NCT02814955||referred for paroxysmal atrial fibrillation with fluindione|
2962549|NCT02814955||referred for paroxysmal atrial fibrillation with previscan|
2962550|NCT02814955||referred for paroxysmal atrial fibrillation with apixaban|
2962551|NCT02814955||referred for paroxysmal atrial fibrillation with rivaroxaban|
2962552|NCT02814955||referred for paroxysmal atrial fibrillation with dabigatran|
2962553|NCT02814942||Heart Failure receiving CRT|Heart failure patients with QRS > 120ms receiving CRT
2962554|NCT02814929||Demographic and Prenatal Characteristics|Gender, multiple pregnancy antenatal steroid therapy, invitro fertilisation, preeclampsia/eclampsia, infants of diabetic mother, chorioamnionitis will be compared among infants with and without ROP
2962555|NCT02814929||Neonatal Characteristics of infants|Neonatal characteristics: GA, BW, SGA, resuscitation in delivery room, RDS, duration of mechanical ventilation and oxygen therapy, intracranial hemorrhage, hemodynamically significant PDA, early/late sepsis, NEC, number of blood transfusions, BPD, breastfeeding and weight gain at postnatal 28th day will be compared among infants with and without ROP.
2962556|NCT02814929||Incidence of any ROP and severe ROP|Incidence of any ROP, severe ROP and its treatment in relation to BW and GA will be evaluated. The same parameters will also be evaluated in preterm babies of refugees.
2962557|NCT02814916|Experimental|dalbavancin, single dose|
2962558|NCT02814916|Experimental|dalbavancin, two dose|
2962559|NCT02814916|Active Comparator|Comparator|
2962560|NCT02814903||Planned cardiac surgery. POAF occurence or not|The ALDO-POAF study is an observational, 1-center and prospective pilot study that will enroll patients undergoing CABG ± aortic valve replacement. Patients who had emergency CABG, need for concomitant mitral surgery, left ventricular ejection fraction (LVEF) < 50%, a history of AF or other atrial arrhythmia, unstable angina or heart failure, cardiogenic shock, atrioventricular block, hypothyroidism/hyperthyroidism, previous heart surgery, and off-pump or on-pump beating CABG will be excluded.
2962561|NCT02814890|Experimental|Ropivacaine and dexmedetomidine|Thoracic paravertebral block is performed using 75mg/20ml ropivacaine + 1μg/kg dexmedetomidine at the end of video-assisted pneumonectomy.
2962699|NCT02814019|Placebo Comparator|placebo|matching placebo tablets
2962562|NCT02814890|Active Comparator|Ropivacaine only|Thoracic paravertebral block is performed using 75mg/20ml ropivacaine at the end of video-assisted pneumonectomy.
2962563|NCT02814864|Experimental|Mesenchymal Stromal Cell (MSC)|Patient with chronic radiotherapy-induced abdomino-pelvic complications refractory to standard therapy: 12 patients suffering of PRD (LENT-SOMA scale>2)
2962564|NCT02814851|Experimental|Non valvular cardiac surgery|The study will be conducted at the CHU Brugmann Hospital, with collaboration between cardiac surgery and cardiology wards. Subjects referred for non valvular cardiac surgery will be prospectively included during the first 6 months following the onset of the protocol.
2962565|NCT02814838|Experimental|Ladarixin|Ladarixin oral capsule
2962566|NCT02814838|Placebo Comparator|Placebo|Placebo oral capsule
2962567|NCT02814825||ViviGen|Patients undergoing a two or three level ACDF using ViviGen Cellular Bone Matrix in conjunction with cervical allograft spacers and DePuy Synthes anterior cervical plate systems.
2962568|NCT02814812|Experimental|pancreatic surgery|
2962569|NCT02814799||bone donors|
2962570|NCT02814786|Experimental|Equinus cohort|"15 childrens who have a fixed equinus defined as a fixed limitation of dorsiflexion inferior to 0°.~Interventions: MRI scanner and gait analysis"
2962571|NCT02814786|Experimental|Control cohort|"In this cohort, there will be 15 childrens with age and gender matched to equinus cohort and with no history of lower limb musculo-skeletal injury in past 6 months.~Interventions: MRI scanner and gait analysis"
2962572|NCT02814773||AD group|group suffering from Alzheimer-type dementia (mild to moderate dementia)
2962573|NCT02814760||Pre-intervention group (Control group)|"AVC-II trial involves 18 ED and 10 stroke units in the Rhone-Alpes and Bourgogne area. All adult patients admitted to one of the participating ED for suspected ischemic stroke less than or equal to 4 hours from symptoms onset were included in the study.~Patients of this group are included before the intervention (training of emergency professionals to acute stroke management) in this ED or stroke units."
2962574|NCT02814760||Post-intervention group (Training course group)|"AVC-II trial involves 18 ED and 10 stroke units in the Rhone-Alpes and Bourgogne area. All adult patients admitted to one of the participating ED for suspected ischemic stroke less than or equal to 4 hours from symptoms onset were included in the study.~Patients of this group are included after the intervention (training of emergency professionals to acute stroke management) in this ED or stroke units."
2962575|NCT02814747|Experimental|quantitive study: 500 patients likely to be candidates for HTS|quantitive study: 500 patients likely to be candidates for HTS at CR in Dijon and Lyon, that is to say patients with development anomalies and/or intellectual deficiency with no etiological diagnosis.
2962576|NCT02814747|Experimental|qualitative study: 30 patients who have benefited from HTS and|qualitative study: 30 patients who have benefited from HTS and the medical geneticists who accompanied them in this approach.
2962577|NCT02814721|No Intervention|Standard cannulation|The standard cannulation protocol of the center was defined as using 17 gauge needles for the first 3 dialysis sessions, followed by 16 gauge for the next 3, and finally 15 gauge for subsequent sessions.
2962578|NCT02814721|Active Comparator|Ultrasound guided cannulation|The study protocol involved similar up titration of needle size over a 3-week period, except that a pre-cannulation evaluation of the fistula was performed using the Sonic Window ultrasound device. The device was used to evaluate and identify the optimal site of cannulation (image 1). Depending upon the cannulator's preference, real-time guidance could be employed during cannulation (image 2, 3). The cannulations were performed by 4 selected personnel trained in device use and successfully completed a competency evaluation on simulator models and a mature dialysis fistula.
2962579|NCT02814708|Experimental|Dose Group 1|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 1
2962580|NCT02814708|Experimental|Dose Group 2|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 2
2962581|NCT02814708|Experimental|Dose Group 3|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 3
2962582|NCT02814708|Experimental|Dose Group 4|rTSST-1 Variant Candidate Vaccine 100µg Number of Immunizations: 1
2962583|NCT02814708|Experimental|Dose Group 5|rTSST-1 Variant Candidate Vaccine 100µg Number of Immunizations: 2
2962584|NCT02814708|Experimental|Dose Group 6|rTSST-1 Variant Candidate Vaccine 100 µg Number of Immunizations: 3
2962585|NCT02814708|Placebo Comparator|Dose Group 7|Al(OH)3 Adjuvant, 1mg Number of Immunizations: 3
2962586|NCT02814695|No Intervention|Control|First fraction was control, 0.1ml of liquefied semen mixed with 0.1ml Ham's F10 medium and incubated at 37o C for 30 minutes.
2962587|NCT02814695|Experimental|Vit E|2nd, 3rd, 4th fractions (Vit. E 1,2,3), 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (1, 2, 5 mg/ml) Vitamin E respectively and incubated at 37o C for 30 minutes.
2962588|NCT02814695|Experimental|YE|5th, 6th, 7th parts fractions ( YE 1,2,3), 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (10, 20, 50 mg/ml) Yeast extraction and incubated at 37o C for 30 minutes.
2962589|NCT02814695|Experimental|Vit C|8th, 9th, 10th fractions (Vit. C. 1,2,3), 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.02, 0.04, 0.06 mg/ml) Vitamin C respectively and incubated at 37o C for 30 minutes.
2962590|NCT02814669|Experimental|Cohort 1: ATZ + R-223-D (Concurrent)|Participants will receive concurrent radium-223 dichloride and atezolizumab for a single-cycle, 28-day dose limiting toxicity (DLT) assessment. If the combination is initially found to be safe and tolerable, additional participants will be randomized to Arms A, B, and C.
2962591|NCT02814669|Experimental|RT Arm A: ATZ + R-223-D (Concurrent)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm (randomized treatment [RT]) to receive concurrent radium-223 dichloride and atezolizumab.
2962592|NCT02814669|Experimental|RT Arm B: ATZ + R-223-D (Staggered, 28-Day R-223-D Run-In)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm to receive radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward.
2962593|NCT02814669|Experimental|RT Arm C: ATZ + R-223-D (Staggered, 28-Day ATZ Run-In)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm to receive atezolizumab in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward.
2962700|NCT02814006|Experimental|every other day|participants will visualize educational video with timed intercourse as recommended by NICE and ASRM
2964328|NCT02802410|Experimental|Kinesiotape|Kinesiotape application on leg muscles
2962594|NCT02814669|Experimental|Cohort 2: ATZ + R-223-D (Staggered, 28-Day R-223-D Run-In)|If Cohort 1 regimen is not tolerable, Arms A, B, and C will not be introduced and additional participants will be enrolled in this cohort to receive radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab in Cycle 2. If the regimen is found to be safe, additional participants will be enrolled to receive this same treatment (radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward). If, at Cycle 2, Cohort 2 regiment is not tolerable, additional participants will be enrolled in Cohort 3.
2962595|NCT02814669|Experimental|Cohort 3: ATZ + R-223-D (Staggered, 56-Day R-223-D Run-In)|If Cohort 2 regimen is not tolerable, additional participants will be enrolled in this cohort to receive radium-223 dichloride in Cycles 1, 2 and radium-223 dichloride and atezolizumab in Cycle 3. If the regimen is found to be safe, additional participants will be enrolled to receive this same treatment (radium-223 dichloride in Cycles 1, 2 and radium-223 dichloride and atezolizumab from Cycle 3 onward). If, at Cycle 3, Cohort 3 regiment is not tolerable, no additional participants will be enrolled in this study.
2962596|NCT02814656|Experimental|Cohort 1|In Cohort 1, participants will receive a single dose of AZD8871 300 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
2962597|NCT02814656|Experimental|Cohort 2|"In Cohort 2, participants will receive a single dose of AZD8871 or placebo on Day 1, followed by once daily dosing on Days 5 to 16.~The planned dose for Cohort 2 is either 600 or 900 μg, however the safety review committee may decide on a different dose level."
2962598|NCT02814656|Experimental|Cohort 3|"In Cohort 3, participants will receive a single dose of AZD8871 or placebo on Day 1, followed by once daily dosing on Days 5 to 16.~The planned dose range for Cohort 3 is 1500-1800 μg, however the safety review committee may decide on a different dose level."
2962599|NCT02814643|Experimental|Benralizumab|1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
2962600|NCT02814643|Placebo Comparator|Placebo|1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
2962601|NCT02814630|Other|Open-label Xolair|"The patients will receive one subcutaneous injection of omalizumab at a dose of 300 mg on Days 1, 30, and 60.~There is no control drug."
2962602|NCT02814617|Experimental|Cordyceps sinensis mycelium culture extract|Cordyceps sinensis mycelium culture extract 1.68 g
2962603|NCT02814617|Placebo Comparator|Placebo|Placebo
2962604|NCT02814604|Experimental|Traffic Light|"Participants in this group will download an app which features the nutrition information of the selected product in a multiple coloured traffic light format (i.e. the traffic light system shows a coloured round indicator for each of saturated fat, sugar, and sodium; shaded red (high), amber (medium) or green (low), according to thresholds set for each nutrient). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
2962605|NCT02814604|Experimental|Health Star Rating System|"Participants in this group will download an app which features the nutrition information of the selected product in a form of 0-5 stars to provide an overall healthy rating. The Health Star Rating provides a rating for all products and products not meeting the criteria still carry the symbol (with no colored stars). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
2962606|NCT02814604|No Intervention|Control|Participants in this group will only see the Nutrition Facts Table (as it appears on the product's package) when the product is scanned in the app.
2962607|NCT02814591||Cohort 1: Controls|40 volunteers free from bone disease. No family histroy of osteogenesis imperfecta (OI). No history of non-accidental fracture. No history of osteoarthritis (OA) or clinical manifestations of disease. No clinical features of OI, OA or osteoporosis (OP). Normal haemoatology and biochemical blood screen. Controls will be gender and age matched (within five years) to the disease cohort patients. Children and adults both required.
2962608|NCT02814591||Cohort 2: Patients with ostegenesis imperfecta (OI).|40 patients with OI. Patients must have been clinically diagnosed with OI. Participants will be identified form the Royal National Orthopaedic Hospital, Metabolic Unit database. Bone mineral density (BMD) confirmed with DXA.
2962609|NCT02814591||Cohort 3: Patients with osteoarthritis (OA)|40 patients with OA. Patients must have been clinically diagnosed with OA. Participants will be identified from the Royal National Orthopaedic Hospital, Metabolic Unit database.
2962610|NCT02814591||Cohort 4: Patients with osteoporosis (OI)|40 patients with OI receiving treatment with bisphosphonates. Patients must have been clinically diagnosed with OI and bisphosphonates prescribed as a course of treatment. 20 Adults and 20 Children. Where possible participants will be identified from the Royal National Orthopaedic Hospital (RNOH), Metabolic Unit Database; if not from the RNOH then diagnosis will be otherwise confirmed.
2962611|NCT02814591||Cohort 5: Patients with osteoporosis (OP) (2 treatment groups)|Patients must have been clinically diagnosed with OP. The first group will have been prescribed with bisphosphonate anti-resorptive treatment; the second with anabolic agents. Where possible participants will be identified from the Royal National Orthopaedic Hospital (RNOH), Metabolic Unit Database; if not from the RNOH then diagnosis will be otherwise confirmed. Bone mineral density (BMD) will be confirmed with DXA. Where possible measurements will be acquired prior to the start of treatment and then up to 4 follow up visits at flexible time points to allow scheduling to coincide with hospital appointments. Minimum time between vistis should be 2 months.
2962612|NCT02814591||Cohort 6: Patients with rickets and osteomalacia|10-15 participants with rickets and 10-15 participants with osteomalacia. Patients must have been clinically diagnosed with rickets/osteomalacia. Blood tests for 25-hydroxyvitamin D should be less than or equal to 25 nmol/L. Once participants are on treatment further measurements will be made 6 months afterwards. Participants for rickets and osteomalacia groups will be recruited to give a total of 10 complete sets of data per group.
2962613|NCT02814591||Cohort 7: 5 patients with suspected bone infection.|Participants will have been diagnosed at RNOH with a suspected bone infection. Participants will be scanned around the localised area of suspected infection. Participants may have 1 or 2 vists; the latter to take place after all infection has cleared up. This is not subject to a fixed time frame.
2962701|NCT02814006|Experimental|fertile window|participants will visualize educational video with timed intercourse as recommended by well-know evidence of better conception rates when using this strategy
2962614|NCT02814578|Experimental|Optical coherent tomography|Optical coherent tomography provides more detailed information about the morphology of scaffolds, microstructures and coronary vasculature based on tissue characteristics as compared to conventional IVUS. In spite of angiographic success in BVS placement, further scaffold optimization was required in over a quarter of cases based on OCT findings due to malapposition or scaffold under expansion.
2962615|NCT02814578|Active Comparator|IntraVascular UltraSound|Intravascular ultrasound guidance has been associated with improved event-free survival compared with angiographic guidance after DES placement.
2962616|NCT02814565|Experimental|Cyclobenzaprine HCl 15 mg|Cyclobenzaprine Hydrochloride (HCl) extended-release 15 mg capsules, orally, once, daily for 14 days.
2962617|NCT02814565|Placebo Comparator|Placebo|Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once, daily for 14 days.
2962618|NCT02814552|Other|High Blood Pressure Consented|Participants will have the following performed: medical history and blood pressure levels will be collected, and blood samples. Then using the HTN PRA App recommendation regarding standard of care medication dosing will be adjusted for optimal blood pressure control.
2962619|NCT02814552|No Intervention|De-identified historical data|De-identified historical data will be collect based on age (no dates), blood pressure of treated (noted with medications), blood pressure of non-treated (noted without medications), and list of medications. The data will be compared to the High Blood Pressure Consented group to determine the effect of using the HTN PRA App.
2962620|NCT02814539||congenital heart disease|children with severe congenital heart disease who undergo open heart surgery during infancy
2962621|NCT02814539||healthy controls|
2962622|NCT02814526|Experimental|Aerobic|Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .
2962623|NCT02814526|Active Comparator|Stretching/balance/range of motion|The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
2962624|NCT02814513|Experimental|ANDAGO|ANDAGO
2962625|NCT02814500|Experimental|A group|Amlodipine and Rosuvastatin, DP-R212
2962626|NCT02814500|Experimental|B group|DP-R212, Amlodipine and Rosuvastatin
2962627|NCT02814474|Placebo Comparator|SALINE|Infusion of saline (0.9 %)
2962628|NCT02814474|Experimental|KETONE|Infusion of Na-3-Hydroxybutyrate (0.18 g/kg/hour) for 390 minutes
2962629|NCT02814461|Experimental|Axitinib|Combined axitinib and radiotherapy (fixed strength)
2962630|NCT02814448|Active Comparator|CO2 standard cryotherapy- double freeze|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
2962631|NCT02814448|Active Comparator|CO2 standard cryotherapy- single freeze|Single freeze treatment consists of one five-minute freeze
2962632|NCT02814448|Active Comparator|CryoPen- double freeze|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
2962633|NCT02814448|Active Comparator|CryoPen- single freeze|Single freeze treatment consists of one five-minute freeze
2962634|NCT02814448|Experimental|Thermocoagulator|Single heat application at 100 ºC for 40 seconds
2962635|NCT02814435||Patients|Patients with inherited retinal degeneration will answer two questionnaires and undergo a computerised contrast sensitivity function test.
2962636|NCT02814435||Normal controls|Normal controls recruited by advertising will answer two questionnaires and undergo a computerised test that assess contrast sensitivity function.
2962637|NCT02814409|Active Comparator|Alteplase - standard care|Alteplase 0.9 mg/kg with 10% of the total dose administered as an initial intravenous bolus and remaining 90% of the total dose administered as an intravenous infusion over 1 hour (maximum dose 90mg).
2962638|NCT02814409|Experimental|Tenecteplase|Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg).
2962639|NCT02814383||ELBW Infants|This study seeks to collect data on premature ELBW infants (less than or equal to 2.2 lbs) at high risk of developing brain injury.
2962640|NCT02814357|Placebo Comparator|Control (market standard)|100 g wheat flour (atta)
2962641|NCT02814357|Active Comparator|High fibre 1|81% wheat flour (atta) + 15% chickpea + 4% guar gum
2962642|NCT02814357|Active Comparator|High fibre 2|80% wheat flour (atta) + 15% chickpea + 2% guar gum + 3% barley
2962643|NCT02814357|Active Comparator|High fibre 3|77% wheat flour (atta) + 15% chickpea + 3% guar gum + 5% barley
2962644|NCT02814344||pregnant women not in labour|"from 24 weeks of gestation until term, provided that they are not in labour~Electrohysterography"
2962645|NCT02814344||women in labour|Electrohysterography
2962646|NCT02814331||symptomatic partial epilepsy|whose brain MRI is abnormal multimodal high-resolution EEG-NIRS
2962647|NCT02814331||not symptomatic partial epilepsy|whose brain MRI is normal multimodal high-resolution EEG-NIRS
2962648|NCT02814318||IV Vancomycin|GBS positive laboring women who are allergic to penicillin and clindamycin and are treated using IV vancomycin.
2962649|NCT02814318||IV Penicillin|GBS positive laboring women who are not allergic to penicillin and are treated using IV penicillin.
2962650|NCT02814305|No Intervention|Control|Patient receives neither educational nor financial interventions
2962651|NCT02814305|Experimental|Financial intervention only|Patient receives financial (pharmacy offer) intervention only
2962652|NCT02814305|Experimental|Educational intervention only|Patient receives educational (narrative) intervention only
2962653|NCT02814305|Experimental|Both interventions|Patient receives both educational and financial interventions
2962654|NCT02814279|Active Comparator|CAF plus connective tissue graft|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. The connective tissue graft was removed from the palate according to Bruno technique (1994) and sutured in position. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions.
2962747|NCT02813694|Active Comparator|Moxifloxacin|oral moxifloxacin, 400mg
2962655|NCT02814279|Experimental|Tunnel plus connective tissue graft|The tunnel flap was performed according to Zuhr et al., 2007. Following initial sulcular incisions, spit thickness flap was prepared using specific tunneling knives beyond the mucogingival junction and until flap gain mobility. The flap was laterally extended to adjacent papillae that were carefully detached by means of a full-thickness preparation. The connective tissue graft was insert into the tunnel. Sling sutures were performed involving the flap and graft to coronally cover 2 mm above the CEJ.
2962656|NCT02814266|Other|difficult intubation|Intubation difficulty score >5
2962657|NCT02814266|Other|Easy intubation|Intubation difficulty score >5
2962658|NCT02814253||Community Based Group|Patients who regularly present with exacerbations of COPD and have chronically-elevated CO2 levels. These patients are supported intensively in an out-patient setting (case-managed) and are potentially eligible for the community-based group.
2962659|NCT02814253||Acute Admissions Group|Patients who are admitted to hospital with an acute exacerbation of COPD. These patients are potentially eligible for the acute admission group.
2962660|NCT02814240|Experimental|Pituitary gland failure|
2962661|NCT02814227|Experimental|Zansors® sleep screening device|Zansors device compared to overnight polysomnography
2962662|NCT02814214||ECG+IEGM|Surface ECG and intracardiac electrogram recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy settings
2962663|NCT02814201||Parkinson best-On|two hours after taking two tablets of 125 mg dispersible Modopar®
2962664|NCT02814201||Parkinson worst-off|after a drug withdrawal period ( morning fasting all dopaminergic treatment since the day before midnight)
2962665|NCT02814201||Huntington|
2962666|NCT02814201||Control|Data collected from the existing database
2962667|NCT02814188|Experimental|Carbohydrate Beverage|
2962668|NCT02814188|Placebo Comparator|Placebo Beverage|
2962669|NCT02814175|Active Comparator|Arm 2/Part 1|MTX highest recommended or tolerable dose
2962670|NCT02814175|Active Comparator|Arm 1/Part 1|adalimumab + MTX low dose
2962671|NCT02814175|Active Comparator|Arm 3/Part 2|MTX highest recommended or tolerable dose
2962672|NCT02814175|Active Comparator|Arm 4/Part 2|adalimumab +MTX highest recommended or tolerable dose
2962673|NCT02814175|Active Comparator|Rescue Arm|adalimumab and/or MTX
2962674|NCT02814175|Active Comparator|Arm 2/Part 2|adalimumab + MTX low dose
2962675|NCT02814175|Active Comparator|Arm 1/Part 2|adalimumab
2962676|NCT02814149|Active Comparator|Type 1 implant placement|Implant is placed immediately following tooth extraction in one surgical procedure
2962677|NCT02814149|Active Comparator|Type 3 implant placement|Implant is placed in the site which is left to heal for 3 months following tooth extraction
2962678|NCT02814136|Active Comparator|WACA|wide area circular ablation
2962679|NCT02814136|Active Comparator|EWACA|extra-wide area circular ablation
2962680|NCT02814123|Active Comparator|Rapid Insulin-alone closed-loop delivery|Rapid Insulin will be delivered by subcutaneous infusion. Interventions: 24-hour inpatient intervention Drug: Rapid acting Insulin (aspart, lispro, glulisine)
2962681|NCT02814123|Experimental|Rapid Insulin-plus-pramlintide closed-loop delivery|"Rapid insulin and pramlintide will be delivered by subcutaneous infusion using a fixed ratio (6 µg pramlintide/unit insulin).~Interventions: 24-hour inpatient intervention Drug: Rapid acting Insulin (aspart, lispro, glulisine) Drug: Pramlintide"
2962682|NCT02814123|Experimental|Regular Insulin-plus-pramlintide closed-loop delivery|"Regular insulin and pramlintide will be delivered by subcutaneous infusion using a fixed ratio (6 µg pramlintide/unit insulin).~Interventions: 24-hour inpatient intervention Drug: Regular Insulin (humulin R) Drug: Pramlintide"
2962683|NCT02814110|Other|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor Muscle strength Muscular dystrophy
2962684|NCT02814097|Experimental|40 mg elamipretide|40 mg elamipretide once daily for 28 consecutive days
2962685|NCT02814097|Placebo Comparator|Placebo|Placebo once daily for 28 consecutive days
2962686|NCT02814084|Active Comparator|Bilateral Internal Mammary Artery grafts|Standard care wound dressings used as part of coronary artery bypass graft operation
2962687|NCT02814084|Experimental|Prevena|Prevena dressing used as part of coronary artery bypass graft operation.
2962688|NCT02814071|No Intervention|Fasting with intravenous fluids|The child will be kept fasted. Intravenous fluids will be at a rate and type as directed by the treating clinician. A low fat oral diet will be commenced once abdominal pain resolves and serum amylase/lipase levels decrease from the peak levels as per treating clinician. In the event that the patient is unable to tolerate oral feeding, tube feeding or parenteral nutrition may be commenced based on the clinical decision of the treating clinician(s). This will be recorded as an adverse event. Patients will be re-trialed on oral feeds once initial limiting symptoms or factors have improved or settled as per treating clinician's discretion
2962689|NCT02814071|Experimental|Early enteral feeding|Patients will commence on an unrestricted oral diet within 24 hours of presentation, meeting 50% of EER with a regular diet and no fat restriction for the first 24 hours of enteral feeding. A 75-100% EER is targeted ≥ 24 hours of enteral feeding.If the targeted EER is not met orally, a nasogastric tube will be inserted to provide bolus feeds of a standard formula with standard fat content. If the patient fails to tolerate both oral and bolus nasogastric tube feeding, continuous nasogastric tube feeding will be provided. If all fails, enteral nutrition by nasojejunal tube feeding or parenteral nutrition may be commenced based on the clinical decision. Patients will be re-trialed on oral feeds once initial limiting symptoms or factors have improved or settled.
2962690|NCT02814058|Experimental|Sequency 1|zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
2962691|NCT02814058|Experimental|Sequency 2|zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
2962692|NCT02814045||Alzheimer with OSA|Alzheimer with OSA after PSG
2962693|NCT02814045||Alzheimer without OSA|Alzheimer without OSA after PSG
2962694|NCT02814032||PTC group 1|papillary thyroid carcinoma patients with cervical lymph node metastasis
2962695|NCT02814032||PTC group 2|papillary thyroid carcinoma patients without cervical lymph node metastasis
2962696|NCT02814032||Positive control group|benign disease
2962697|NCT02814032||Negative control group|histologically normal
2962702|NCT02814006|No Intervention|CG|participants will respond to questionnaire with no knowledge of intervention
2962703|NCT02813993|Experimental|Intervention Group|A five-minute video concerning age-related fertility decline, fertility risk factors, success of infertility treatments and emotional consequences of childlessness
2962704|NCT02813993|No Intervention|Control|No intervention
2962705|NCT02813980||High SUDEP-7 score|Patients with epilepsy who have a high SUDEP-7 score
2962706|NCT02813980||Low SUDEP-7 score|Patients with epilepsy who have a low SUDEP-7 score
2962707|NCT02813967|Experimental|chemoradiotherapy|Radiotherapy 54 Gy was administered in 1.8 Gy fractions 5 times weekly. S-1 70mg/m2 was administered on days 1-14 and 29-42
2962708|NCT02813967|Active Comparator|Radiotherapy 60 Gy|Radiotherapy 60 Gy was administered in 2Gy fractions 5 times weekly.
2962709|NCT02813954|Experimental|Study Group|Neonates with respiratory distress
2962710|NCT02813954|No Intervention|Control Group|Healthy Infants
2962711|NCT02813941|Experimental|Alternative GRADE SoF table|Two SoF tables (alternative GRADE SoF table and EPC SoF table) will be used in this randomized controlled non-inferiority trial as an intervention. The alternative GRADE SoF table format will be developed from a user-testing survey.
2962712|NCT02813941|Experimental|EPC SoF table|For the EPC SoF table, the investigators will use one of their format which was recently published.
2962713|NCT02813941|Active Comparator|Current GRADE SoF table|The current GRADE SoF table will be the common comparator for the other two SoF tables
2962714|NCT02813928|Experimental|ccfDNA analysis|The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance.
2962715|NCT02813915||Use of Cheetah medical NICOM|For those who consent to the study, the Cheetah NICOM will be used to obtain cardiac output, stroke volume, and fluid responsiveness.
2962716|NCT02813902|Active Comparator|Heliocare|240 mg administered orally daily
2962717|NCT02813902|Placebo Comparator|Sugar pill|a sugar pill matching the Heliocare tablet in look and weight will be administered orally daily
2962718|NCT02813889|Experimental|Infants|Two populations will be involved in testing in the SmarToyGym: 1. Infants exhibiting typical development between 3 months and 11 months of age 2 . Infants exhibiting atypical development (at-risk for neuromotor delay) between 3 months and 11 months of age.
2962719|NCT02813876|Experimental|Enhanced recovery|Enhanced recovery protocol for nursing, diet and analgesic regimen
2962720|NCT02813876|No Intervention|Standard care|Standard care arm
2962721|NCT02813863|Experimental|SP2086 and Metformin|In the first day,the subject takes metformin 1000mg once,and from Day 4 to Day 7 they need to take SP2086 100mg everyday. In Day 8,they will be given SP2086 100mg and metformin 1000mg.
2962722|NCT02813850|No Intervention|control|standard medical care
2962723|NCT02813850|Experimental|oxygen therapy|
2962724|NCT02813837|Experimental|single arm|Experimental: CD19 CART cell.The target dose range administered in this study is 1x10e5-1x10e7 CART-19 cells/kg.
2962725|NCT02813824|Active Comparator|Aspirin300|Acetylsalicylic acid 300 mg tablet by mouth, daily dose during 4 years
2962726|NCT02813824|Placebo Comparator|Placebo300|Placebo (like Acetylsalicylic acid 300 mg) tablet by mouth, daily dose during 4 years
2962727|NCT02813824|Active Comparator|Aspirin100|Acetylsalicylic acid 100 mg tablet by mouth, daily dose during 4 years
2962728|NCT02813824|Placebo Comparator|Placebo100|Placebo (like Acetylsalicylic acid 100 mg) tablet by mouth, daily dose during 4 years
2962729|NCT02813798|Experimental|Mild Renal Impairment|A single dose of IV Rivipansel over 20 minutes
2962730|NCT02813798|Experimental|Moderate Renal Impairment|A single dose of IV Rivipansel over 20 minutes
2962731|NCT02813798|Experimental|Severe Renal Impairment|A single dose of IV Rivipansel over 20 minutes
2962732|NCT02813798|Experimental|Normal Renal Functions|A single dose of IV Rivipansel over 20 minutes
2962733|NCT02813785|Experimental|Atezolizumab|Participants will receive atezolizumab until loss of clinical benefit and will thereafter enter survival follow-up until death, loss to follow-up, withdrawal, or study end.
2962734|NCT02813785|Active Comparator|Docetaxel|Participants will receive docetaxel until disease progression per standard RECIST v1.1 criteria or unacceptable toxicity and will thereafter enter survival follow-up until death, loss to follow-up, withdrawal, or study end.
2962735|NCT02813772|Experimental|group 1|Patients with infantile colics who will receive the milk formula NAN Sensitive, Nestlè
2962736|NCT02813772|Active Comparator|group 2|Patients with infantile colics who will receive the milk formula NAN Optipro, Nestlè
2962737|NCT02813759|Experimental|Sucralose|14 mg sucralose (Zero K sucralose powder, IANSA®) an 200 mL of water
2962738|NCT02813759|Placebo Comparator|Water|200 mL of water
2962739|NCT02813746||Obese non smoker vs Normoweight non smoker|Endometrial fluid (EF) will be obtained from non-smokers normo-weight and obese patients in the receptive state. Samples will be collected 7 days after Luteinizing Hormone (LH) peak. They will be classified following the guidelines of the obesity classification system by the World Human Organization (WHO). Patients will be subjected to a fitness program during a year with the aim to achieve a weight reduction to normal values (19-24.9 kg/m2). The modifications in the miRNAs expression will be studied. After the weight loss, new EF will be collected from these patients.
2962740|NCT02813746||Normoweight smoker vs Normoweight non-smoker|EF will be obtained from non-smokers and smokers normo-weight in the receptive state. Samples will be collected 7 days after Luteinizing Hormone (LH) peak. Smokers patients will be urge to give up smoking during at least one year. After this time, new samples will be collected to determine if the non-exposition to this contaminant could exert any effect in the miRNAs signature. A regular control will be done in this group of patients to ensure that they have not been exposed to tobacco in 12 months. Professional support will be given in the same centre of the study to help the patient to accomplish its objective.
2962741|NCT02813733||Thyroid surgery|All patients who underwent a thyroid procedure in 5 high volume referral centers in France were eligible for inclusion.
2962742|NCT02813720||Patients with peripheral PsA|
2962743|NCT02813720||Patients with psoriatic nail onycholysis|
2962744|NCT02813720||Patients with PsO only|
2962745|NCT02813720||Healthy match control subjects|
2962746|NCT02813694|Experimental|lefamulin|oral lefamulin, 600mg
2962748|NCT02813681|Active Comparator|US-epidural SVD|Group 1: (US-epidural SVD) - participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity
2962749|NCT02813681|Sham Comparator|(US sham- epidural SVD)|Group 2: (US sham- epidural SVD) - participants who received US examination process but with the monitor turned off. The purpose of this group is to determine if the standard of care epidural placement technique will increase pressure sensitivity at the insertion site. The purpose of this group will also be to reduce the placebo effect from the US exam and to maintain blinding of the participant to their group status (US epidural or US sham epidural).
2962750|NCT02813681|Active Comparator|US-epidural CS|Group 3: (US-epidural CS) Same as group 1 except subject delivers by cesarean section (CS)
2962751|NCT02813681|Sham Comparator|US sham - epidural CS|Group 4: (US sham - epidural CS) Same as group 2 except subject delivers by spontaneous vaginal delivery (SVD).
2962752|NCT02813681|Placebo Comparator|Spontaneous vaginal delivery without an Epidural|Group 5: Spontaneous vaginal delivery without an Epidural The purpose of the control group is to serve as a baseline (or a measure of normal). The control participant's measurement will be compared to those that did receive treatments (either epidural alone or ultrasound and epidural). This information will tell the investigator how many women have back pain after spontaneous vaginal delivery. Participant must meet the inclusion requirements and not meet any of the exclusion requirements
2962753|NCT02813681|Placebo Comparator|Cesarean section without an Epidural.|Group 6: Cesarean section without an Epidural. The purpose of the control group is to serve as a baseline (or a measure of normal). The control participant's measurement will be compared to those that did receive treatments (either epidural alone or ultrasound and epidural). This information will tell the investigator how many women have back pain after cesarean section. Participant must meet the inclusion requirements and not meet any of the exclusion requirements
2962754|NCT02813668|Experimental|Lifestyle Intervention Training Program|Participants at risk for developing diabetes or with unmedicated diabetes will participate in a lifestyle intervention training program. Individuals in the training program, as well as un-enrolled workers at the study sites, will be exposed to positive changes at the worksite to promote increased physical activity and healthier diets.
2962755|NCT02813655|Experimental|Experimental arm|Tetracosactide (Synacthène®)
2962756|NCT02813655|Placebo Comparator|Control arm|placebo saline (0.9% NaCl)
2962757|NCT02813642|Experimental|Cardiovascular risk evaluation|Measurement of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 2 year follow-up
2962758|NCT02813629|Active Comparator|SS-tDCS (active) plus PES (active)|tDCS plus PES (n=15).
2962759|NCT02813629|Active Comparator|SS-tDCS (active) plus PES (simulated)|tDCS plus PES (n=15).
2962760|NCT02813629|Active Comparator|SS-tDCS (simulated) plus PES (active)|tDCS plus PES (n=15).
2962761|NCT02813629|Sham Comparator|SS-tDCS (simulated) plus PES (simulated)|tDCS plus PES (n=15).
2962762|NCT02813629|Active Comparator|SC-tDCS (active) plus PES (active)|tDCS plus PES (n=15).
2962763|NCT02813629|Active Comparator|SC-tDCS (active) plus PES (simulated)|tDCS plus PES (n=15).
2962764|NCT02813629|Active Comparator|SC-tDCS (simulated) plus PES (active)|tDCS plus PES (n=15).
2962765|NCT02813629|Sham Comparator|SC-tDCS (simulated) plus PES (simulated)|tDCS plus PES (n=15).
2962766|NCT02813603||Study Product (19-gauge)|After randomization, the subject undergo EBUS-TBNA either with the 19-gauge needle or the 22-gauge needle
2962767|NCT02813603||Control Intervention (22-gauge)|After randomization, the subject undergo EBUS-TBNA either with the 19-gauge needle or the 22-gauge needle
2962768|NCT02813590||Patients with liver cirrhosis and with SBP|
2962769|NCT02813590||Patients with liver cirrhosis and without SBP|
2962770|NCT02813577|Other|Lutonix® 035 Drug Coated Balloon PTA Catheter|This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
2962771|NCT02813564|Experimental|Training group|This group of children will receive the software based intervention program (CAVINS) and will train at home during the training phase.
2962772|NCT02813564|No Intervention|Control group|This group of children will play video-games-as-usual and return in about 3 weeks for their next assessment appointment.
2962773|NCT02813564|Experimental|fMRI-training group|"This sub-group of children from the Training group will carry out two of the tasks in the fMRI scanner during the baseline appointment. They will then go home and train on CAVINS (the intervention) during the training phase."
2962774|NCT02813564|No Intervention|fMRI-Control group|"This sub-group of children from the Control group will carry out two of the tasks in the fMRI scanner during the baseline appointment. They will then go home and play video-games-as-usual until their next assessment appointment (after about 3 weeks)."
2962775|NCT02813551|Experimental|Torsemide|Torsemide 20 mg daily for 5 days
2962776|NCT02813551|Placebo Comparator|Placebo|Placebo 20 mg daily for 5 days
2962777|NCT02813538||IGC and thromboelastometry|Patients that have hyper, normo o hypcoagulability measured by tromboelastometry and anticoagulant proteins levels early after major liver resection and clinical evolution and patients with liver funcion impairment or without it, measured by indocyanine green clearance early after surgery and clinical evolution
2962778|NCT02813525||IUGR group|estimated fetal weight <10th percentile associated with an abnormal umbilical artery Doppler with IP>95th percentile or a confirmation of placental vascular disease by histological examination
2962779|NCT02813525||CONTROL group|non IUGR fetuses for gestational age (normal for weight, Doppler, and structural analyse)
2962780|NCT02813512|Experimental|GXNPC1|Three subjects will be to treatment (n=3) groups. The treatment group will receive brain transplants of autologous ADSCs. Treatment group will receive rehabilitation after the transplantation. Subjects will be assessed by magnetic resonance imaging (MRI) and four standardized stroke indices: National Institutes of Health Stroke Scale (NIHSS), European Stroke Scale (ESS), European Stroke Motor Subscale (EMS), Barthel Index, MMSE and Gait analyses at 1 month, 3 months, and 6 months after treatment.
2962781|NCT02813499||CARE Rule|Evaluation of the clinical suspicion of myocardial infarction and calculation of CARE rule.
2962782|NCT02813486|Experimental|GC3111 Vaccine Group|Participants randomized to receive a single dose of GC3111 vaccine (Biological: GC3111 vaccine).
2964329|NCT02802410|Experimental|No-Tape|No-Tape on leg muscles
2962783|NCT02813486|Active Comparator|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine (Biological: Boostrix® vaccine).
2962784|NCT02813460|Experimental|Session 1: Sequence 1|Participants will sequentially receive 5 milliliters (mL) of each 6 ALS-008176 formulations A B F C E D on day 1.
2962785|NCT02813460|Experimental|Session 1: Sequence 2|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations B C A D F E on day 1.
2962786|NCT02813460|Experimental|Session 1: Sequence 3|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations C D B E A F on day 1.
2962787|NCT02813460|Experimental|Session 1: Sequence 4|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations D E C F B A on day 1.
2962788|NCT02813460|Experimental|Session 1: Sequence 5|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations E F D A C B on day 1.
2962789|NCT02813460|Experimental|Session 1: Sequence 6|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations F A E B D C on day 1.
2962790|NCT02813460|Experimental|Session 2: Sequence 1|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G1 G2 H3 G3 H2 H1).
2962791|NCT02813460|Experimental|Session 2: Sequence 2|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G2 G3 G1 H1 H3 H2).
2962792|NCT02813460|Experimental|Session 2: Sequence 3|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G3 H1 G2 H2 G1 H3).
2962793|NCT02813460|Experimental|Session 2: Sequence 4|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H1 H2 G3 H3 G2 G1).
2962794|NCT02813460|Experimental|Session 2: Sequence 5|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H2 H3 H1 G1 G3 G2).
2962795|NCT02813460|Experimental|Session 2: Sequence 6|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H3 G1 H2 G2 H1 G3).
2962796|NCT02813447|Active Comparator|Pulmonary Rehab + Study Drug|Subjects randomized into this arm will be given active study drug (sertraline). Subjects will take 25mg tablets by mouth daily starting at visit 1 along with participating in the intensive pulmonary rehab program. Subjects will be assessed at one week intervals +/- 7 days for tolerability and side effects, and if tolerating study drug, the dose will be increased weekly by 25mg over the course of the first four weeks with maximum effective dose of 100mg daily by the end of week four. Subjects will continue this dose over the course of the remaining 8 weeks of the study, while participating in the graduate program of pulmonary rehab.
2962797|NCT02813447|Placebo Comparator|Pulmonary Rehab + Placebo|Subjects randomized to the placebo arm will have the same procedures as described above in the study drug arm with the exception that they will be receiving matched placebo drug.
2962798|NCT02813434|Experimental|Florbetapir|
2962799|NCT02813421|Experimental|CGM Informed|CGM data was available for use when determining starting insulin pump doses.
2962800|NCT02813421|No Intervention|Control|CGM data will remain secure and not used. Starting insulin pump doses will be made by standard of care.
2962801|NCT02813408||Participants with Prostate Cancer (abiraterone acetate)|Participants with metastatic castration resistant prostate cancer (mCRPC) will receive abiraterone acetate at the discretion of his treating physician.
2962802|NCT02813408||Participants with Prostate Cancer (enzalutamide)|Participants with metastatic castration resistant prostate cancer (mCRPC) will receive enzalutamide at the discretion of his treating physician.
2962803|NCT02813395|No Intervention|Control group|Volunteers remained at rest before and after the fatigue protocol.
2962804|NCT02813395|Placebo Comparator|Placebo group|Volunteers were subjected to laser application simulation for approximately four minutes with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
2962805|NCT02813395|Experimental|Laser before|Volunteers received effective application of laser before fatigue protocol.
2962806|NCT02813395|Experimental|Laser after|Volunteers received effective application of laser after fatigue protocol.
2962807|NCT02813382||B-group|Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).
2962808|NCT02813382||C-group|Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
2962809|NCT02813382||P-group|Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).
2962810|NCT02813369||naloxegol|patients exposed to naloxegol
2962811|NCT02813369||non-PAMORA laxative|patient exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
2962812|NCT02813356||naloxegol|patients exposed to naloxegol
2962813|NCT02813356||non-PAMORA|patients exposed to non-peripherally acting mu-opioid antagonist
2962814|NCT02813343|Experimental|Immediate Treatment Group|The Immediate Treatment group will receive access to the study intervention - BlueStar app, immediately after consenting for a total duration of 6 months.
2962815|NCT02813343|Other|Delayed Treatment Group|The Delayed Treatment group will receive access to the study intervention - BlueStar app, 3 months after consenting for a total duration of 3 months.
2962816|NCT02813330|Experimental|Sterile Water injection|Subcutenous injection at low back portion during labor pain
2962817|NCT02813330|Experimental|saline injection|Subcutenous injection at low back portion during labor pain
2962818|NCT02813304|Experimental|Gradual reloading|Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction (see Table 1). In a sitting position (with folded towel between body and arm), participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand (the uninvolved side) will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force; practice during the meeting with the treating physiotherapist using EMG recording) over five seconds.
2962858|NCT02813031|Placebo Comparator|Traditional meat products|Healthy people consuming the same amount of traditional meat products
2962859|NCT02813018|Experimental|preemptive group|Group who will be received ropivacaine bolus and continous infusion 5 minutes before skin incision.
2964356|NCT02802241|Experimental|double-blind peppermint oil|
2962819|NCT02813304|Active Comparator|Rest and cryotherapy|Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap and a towel cloth. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
2962820|NCT02813291|Experimental|Stimulation group (Young Stim)|Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex.
2962821|NCT02813291|Experimental|Stimulation group (Elderly Stim)|Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex.
2962822|NCT02813291|Sham Comparator|Sham group (Young Sham)|Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex.
2962823|NCT02813291|Sham Comparator|Sham group (Elderly Sham)|Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex.
2962824|NCT02813278|Experimental|simo decoction and acupuncture with vitamin B1|Patients will receive simo decoction (10 mL/piece,three times per day) and bilateral tsusanli acupoint injections with vitamin B1 two times per day, starting in the first day after resection for 5 days or until flatus.
2962825|NCT02813278|Active Comparator|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection for 5 days or until flatus.
2962826|NCT02813278|No Intervention|empty control|Patients only receive best support care.
2962827|NCT02813265|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
2962828|NCT02813265|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
2962829|NCT02813252||JCAR015-treated|Patients who received previous treatment with JCAR015
2962830|NCT02813239||HCG triggering|Patients were scheduled by prescribing oral contraceptive (OC) for 12-16 days and recombinant FSH and/or highly purified u-hMG according to the patient`s age, BMI, antral follicular count, AMH and previous responses to ovarian controlled stimulation. GnRH antagonist was added when at least one follicle reached 13 mm. Ovulation was induced by hCG when at least 2 follicles had a mean diameter of 17 mm.
2962831|NCT02813239||HCG + GnRH agonist triggering|Patients were scheduled by prescribing oral contraceptive (OC) for 12-16 days and recombinant FSH and/or highly purified u-hMG according to the patient`s age, BMI, antral follicular count, AMH and previous responses to ovarian controlled stimulation. GnRH antagonist was added when at least one follicle reached 13 mm. Ovulation was induced by hCG and GnRH agonist when at least 2 follicles had a mean diameter of 17 mm.
2962832|NCT02813226|Other|Imaging|Molecular Imaging
2962833|NCT02813213|Active Comparator|Standard skin graft|"This group is comprised of patients' wound halves that will receive meshed (1:3) split thickness skin graft (0.3-0.5mm thickness). This half will be covered with a standard tie over dressing. The dressing will be removed at day 5, and then it will be removed every 3 days up to the 14th day."
2962834|NCT02813213|Experimental|Skin micro graft|"This group is comprised of the patients' wound halves that will receive skin micro grafts. To obtain this grafts the investigators will use Xpansion micro-autografting system. They will use 0.8 x 0.8 mm skin grafts with a graft to graft distance of 4mm (1:50 expansion).This half will be covered with a special hydrogel dressing with keratinocyte growth factor (Epilife medium with calcium) 1.5ml for each 14 square centimeters of the wound. This half will be covered with a wet adhesive foam dressing and then it will be covered up with a non-adherent interface dressing (tegaderm). The dressing will be removed at day 5, and then it will be removed every 3 days up to the 14th day. Each time of dressing change only the non-adherent interface dressing will be removed, and the area will be bathed with keratinocyte growth factor solution."
2962835|NCT02813200|Experimental|Group 1|
2962836|NCT02813200|Experimental|Group 2|
2962837|NCT02813200|Experimental|Group 3|
2962838|NCT02813174|Experimental|Automated online Compassionate Mind Training|
2962839|NCT02813135|Experimental|ARM A. Ribociclib + Topotecan and Temozolomide|Topotecan iv QD and temozolomide capsules orally QD Days 1 to 5; Ribociclib capsules or oral solution orally QD from Day 6 to 20 of a 28 day cycle.
2962840|NCT02813135|Experimental|ARM B. Ribociclib + Everolimus|Ribociclib capsules or oral solution orally QD for 21 days of each 28 day cycle; Everolimus orodispersible tablets orally QD for 28 days.
2962841|NCT02813135|Experimental|ARM C. AZD1775 + Carboplatin|AZD1775 capsules orally BID 3 days on / 4 days off in week 1; Carboplatin iv QD AUC 5 on Day 1 of a 21 day cycle.
2962842|NCT02813135|Experimental|ARM D. Olaparib + Irinotecan|Olaparib tablets orally BID on Day 1-10 of a 21 day cycle; Irinotecan iv QD Day 4-8 of a 21 day cycle.
2962843|NCT02813135|Experimental|Arm I. Enasidenib|Enasidenib orally on a continuous dosing once daily (QD) per 28 day cycle.
2962844|NCT02813135|Experimental|Arm J. Lirilumab + Nivolumab|Nivolumab iv QD every 2 weeks of a 28 day cycle (Days 1 and 15); Lirilumab iv QD every 4 weeks of a 28 day cycle (Day 1)
2962845|NCT02813122||with x-ray|patients underwent bariatric surgery and underwent x-ray
2962846|NCT02813122||without x-ray|patients underwent bariatric surgery and did not underwent x-ray
2962847|NCT02813096|Experimental|folfox4 chemotherapy regimen|"details in the Intervention Description"
2962848|NCT02813096|Placebo Comparator|Placebo|"details in the Intervention Description"
2962849|NCT02813083||Rheumatoid Arthritis|Rheumatoid arthritis patients
2962850|NCT02813070|Experimental|Healthy volunteers|185 MBq [18F] Flutemetamol
2962851|NCT02813070|Experimental|Mild cognitive impairment|185 MBq [18F] Flutemetamol
2962852|NCT02813070|Experimental|Alzheimer's Disease|185 MBq [18F] Flutemetamol
2962853|NCT02813057|Active Comparator|Stoppa repair|Stoppa inguinal hernia repair
2962854|NCT02813057|Experimental|TEP repair|Total extraperitoneal inguinal hernia repair
2962855|NCT02813044|Experimental|TIVA group|Anesthesia is maintained with propofol during surgery
2962856|NCT02813044|Active Comparator|inhalation anesthesia group|Anesthesia is maintained with sevoflurane during surgery
2962857|NCT02813031|Experimental|Functional meat products with healthy lipids from olive oil|Healthy people consuming 300g/week of functional meat products with high diglyceride lipid from olive oil
2962860|NCT02813018|Placebo Comparator|saline group|Group who will be received saline bolus and continous infusion 5 minutes before skin incision
2962861|NCT02813005|Experimental|Jet ventilation/ group A|Frequency : 120-200/min Pressure : 1-2 bars Inspiratory fraction of oxygen : 100% and 50% if Expiratory pressure : 5 -10 cmH2O
2962862|NCT02813005|Sham Comparator|Standard ventilation/ group B|Apnea made by the anesthesiologist to the request of the radiologist.
2962863|NCT02812992|Active Comparator|GO-GO arm|Nab-paclitaxel 125 mg/m^2 i.v. over 30 minutes followed by gemcitabine infusion 1000 mg/m^2 on days D1, D8, D15 of a 28-day cycle.
2962864|NCT02812992|Active Comparator|SLOW-GO arm|Gemcitabine 1000 mg/m^2 i.v. on days D1, D8, D15 of a 28-day cycle.
2962865|NCT02812992|Active Comparator|FRAIL arm|Best supportive care as determined by the investigator.
2962866|NCT02812979|Experimental|Airvo2 with Aerogen Solo|"AIRVOTM2 will be set to deliver air (21% oxygen concentration ) at a rate of 30 L / min at 100 % relative humidity at 37 ° C.~Nebulization of salbutamol will be effected by means of a nebulizer to the vibrating screen (Aerogen® Solo, Aerogen , Galway, Ireland ) which is a nebulizing device for single use, commonly used in invasive and non invasive mechanical ventilation.~Nebulizer will be responsible for a salbutamol solution available in the form of containers of 2.5 ml containing 2.5 mg of salbutamol"
2962867|NCT02812979|Active Comparator|Mask|"During nebulization in the usual way ( oral facial mask ) , it will be used a pneumatic nebulizer powered by a 6 L / min air flow rate ( usual method ).~Nebulizer will be responsible for a salbutamol solution available in the form of containers of 2.5 ml containing 2.5 mg of salbutamol"
2962868|NCT02812979|Placebo Comparator|arm control Airvo2 without nebulization of salbutamol|control procedure is to be placed under humidified high flow nasal alone
2962869|NCT02812966|Active Comparator|Lutonix DCB|Lutonix 035 Drug coated Balloon PTA Catheter
2962870|NCT02812966|Active Comparator|IN.PACT DCB|IN.PACT Admiral Paclitaxel-Coated PTA Balloon Catheter
2962871|NCT02812940|Experimental|Everolimus as part of GvHD prophylaxis after allogeneic SCT|Everolimus from day +5 to day +100
2962872|NCT02812927|Other|Standard infusion line|The standard insulin infusion system consisted in regular human insulin administration through a six-stopcock manifold connected to the distal line of a multilumen central venous catheter by 150 cm tubing. Insulin was systematically infused by syringe pump on the patient proximal port of the manifold. Carrier was infused via pump through the manifold. All others medicines were infused through the other five stopcocks.
2962873|NCT02812927|Experimental|Optimised infusion line|The optimised insulin infusion system consisted in regular human insulin administration through a multilumen device (Edelvaiss Multiline-8, Doran International, Toussieu, France). This device had ports for eight infusions which run through separate channels within a 150 cm flexible plastic tube. Since fluids from the individual channels do not meet until they exit the distal tip. Carrier was infused through the high flow (HF) line and insulin was infused by syringe pump systematically next to the HF line port. All others medicines were administered via adjacent ports on the Multiline-8.
2962874|NCT02812914|Experimental|Phase 1|In Phase I, 25 pregnant women will receive a low-cost gas stove and will be taught by peer educators in group classes how to safely use gas stoves and how to reduce exposure to air pollution.
2962875|NCT02812914|Experimental|Phase 2|In Phase 2, the investigators will assess a more resource-intensive behavioral intervention approach with a different group of 25 women who will follow the same study procedures described in Phase I.
2962876|NCT02812901|Other|morning group|cardiac surgery scheduled in the morning
2962877|NCT02812901|Other|afternoon group|cardiac surgery scheduled in the afternoon
2962878|NCT02812888||Hyperthyroid Patients|Patients with hyperthyroidism
2962879|NCT02812888||NC group|Normal control subjects
2962880|NCT02812875|Experimental|CA-170|Taken orally in a once daily schedule.
2962881|NCT02812862||treatment group|"50 male and female patients suffering from chronic heart failure and chronic obstructive pulmonary disease.~Ultibro/ Breezhaler combination therapy"
2962882|NCT02812862||control group|50 male and female patients suffering from chronic heart failure but not COPD and NOT receiving LAMA/ LABA
2962883|NCT02812849||Suspected cardiac sarcoidosis|Cu-64 DOTATATE PET/CT or PET/MRI
2962884|NCT02812849||Known cardiac sarcoidosis|Cu-64 DOTATATE PET/CT or PET/MRI
2962885|NCT02812849||Other inflammatory cardiac disease|Cu-64 DOTATATE PET/CT or PET/MRI
2962886|NCT02812836|Other|Manometry|All patients will be investigated by anorectal manometry and after the procedure with balloon expulsion test as previously described.
2962887|NCT02812823|Other|High resolution anorectal manometry|All subjects will be investigated by high-resolution anorectal manometry. At the beginning the anorectal cather will be used to record conventional parameters and after that 3D high-definition anorectal manometric catheter will be inserted in order to measure conventional parameters and 3D picture of anorectum.
2962888|NCT02812810|Experimental|active rTMS|
2962889|NCT02812810|Placebo Comparator|placebo rTMS|
2962890|NCT02812771|Experimental|Efinaconazole|Efinaconazole
2962891|NCT02812758||patients|All sedated, intubated, mechanically ventilated adult patients admitted for elective cardiac surgery, monitored for sedation depth (with the BIS) and for preload dependence indices (SVV, PPV and PVI) transthoracic echocardiography
2962892|NCT02812745||patients|"patients presenting an indication for general anaesthesia during elective cardiac surgery and being monitored for sedation depth~recording of cardiac output~other parameters"
2962893|NCT02812732|Other|Intervention|Providers at each clinic will receive the intervention (DOSE HPV) on a rolling basis. Vaccination rates will be compared pre- and post-intervention at each clinic, and changes in rates will be compared across clinics.
2962894|NCT02812719|Active Comparator|Glycolic acid peel alone|"One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals"
2962895|NCT02812719|Experimental|Glycolic and salicylic acid peel|"The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals."
2963057|NCT02811536||Arterial hypertension|Patients with a history of arterial hypertension
2962896|NCT02812706|Experimental|Isatuximab|Isatuximab will be administered intravenously (IV) once every week (QW) for 4 weeks followed by once every other week (Q2W)
2962897|NCT02812693|Experimental|Treatment (pembrolizumab, imatinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and imatinib mesylate orally PO QD on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
2962898|NCT02812680||Esophageal Cancer Patients - Blood Draw|Look at blood samples to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy in patients with Esophageal Adenocarcinoma.
2962899|NCT02812667|Experimental|Nivolumab + Plinabulin|Nivolumab 240mg IV, day 1 and 15 until disease progression Plinabulin 3.5mg/m2, 20mg/m2, 30 mg/m2 or 40mg/m2 IV, day 1,8 and 15 until disease progression
2962900|NCT02812654|Experimental|Doxorubicin, Ifosfamide, radiotherapy|Doxorubicin 75mg/m2 (cycle 1,2 and 3), ifosfamide 9 g/m2 (cycle 1 and 3) and radiotherapy: 25 Gy / 5 x 500 cGy/day, beginning at Cycle2/Day1. The surgery will performed after 4-6 weeks from cycle 3. The remain viable cells in surgical specimen will be analyzed and if it accounts less than 30% the patient will receive more 3 cycles of cT. A boost of RT is indicated if margins are considered R1.
2962901|NCT02812641|Experimental|BPF-CCRT (Run-in Phase)|"Neoadjuvant CCRT with Bevacizumab, Cisplatin and 5-fluorouracil~Chemotherapy:~Bevacizumab(B): 10 mg/kg on day 1~Cisplatin(P): 75 mg/m2 on day 1~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
2962902|NCT02812641|Experimental|BPF-CCRT (Randomized Phase)|"Neoadjuvant CCRT with Bevacizumab, Cisplatin and 5-fluorouracil~Chemotherapy:~Bevacizumab(B): 10 mg/kg on day 1~Cisplatin(P): 75 mg/m2 on day 1~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
2962903|NCT02812641|Active Comparator|PF-CCRT (Randomized Phase)|"Neoadjuvant CCRT with Cisplatin and 5-fluorouracil~Chemotherapy:~Cisplatin(P): 75 mg/m2 on day 1~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
2962904|NCT02812628|Active Comparator|Conventional LAPR|Patients undergoing conventional laparoscopic abdominoperineal resection (LAPR).
2962905|NCT02812628|Experimental|LAPR-TILT|Patients undergoing LAPR with transabdominal individualized levator transection (TILT).
2962906|NCT02812615|Experimental|Malnourished participants|After screening the participants for any organic diseases and application of inclusion/exclusion criteria, stunted children, children who are at risk of stunting and malnourished adult cases will receive one egg, 150 ml of milk 6 days a week for 3, 2 and 2 months respectively. Along with that participants will also get Anti-helminthic treatment (Albendazole/Pyrantel Pamoate) and nutritional counselling. Children will get one sachet of multiple micro-nutrient sprinkles per day to be administered at home with the mid-day meal for two months.
2962907|NCT02812602|Experimental|Lidocaine patch|The patients was randomly assigned to experimental group or placebo group. In this arm, lidocaine patches will be applied to the skin surrounding the surgical wound by one nurse practitioner. After more than 20 minutes the patch will be removed. Another nurse practitioner (double blinded) will remove the metal staples and record pain scale.
2962908|NCT02812602|Placebo Comparator|Placebo|The patients was randomly assigned to experimental group or placebo group. In this arm, a placebo patch will be applied to the skin surrounding the surgical wound by one nurse practitioner. After more than 20 minutes the patch will be removed. Another nurse practitioner (double blinded) will remove the metal staples and record pain scale.
2962909|NCT02812589|Experimental|Diffusion tensor imaging (DTI) in breast MRI|
2962910|NCT02812550|Other|full-spectrum colonoscopy|Colonoscopy is performed with a full-spectrum colonoscopy (330º angle of view)
2962911|NCT02812550|Other|standar forward-viewing colonoscopy|Colonoscopy is performed with standar forward-viewing colonoscopy (170º angle of view)
2962912|NCT02812537||patients with conduct disorders|Girls and boys having less than 16 years old and admitted to emergency room for aggressiveness, violence, fugue or theft.
2962913|NCT02812524|Experimental|Intratumoral Ipilimumab|Patients receive a 3mg intratumoral injection of ipilimumab during a biopsy procedure.
2962914|NCT02812511|Experimental|Skin biopsy|
2962915|NCT02812498|Experimental|Teleconsultation|Teleconsultation for patients affected by type 1 diabetes mellitus
2962916|NCT02812498|Other|Control|Standard visit in outpatient clinic for the same type of patients
2962917|NCT02812472|Experimental|treadmill training with functional electrical stimulation|Subjects in the experimental group received additional treadmill training with functional electric stimulation for 25 minutes per session, followed by 5 minutes cool down for 12 sessions.
2962918|NCT02812472|Active Comparator|treadmill training without functional electrical stimulation|Subjects in the control group received additional treadmill training without functional electric stimulation for 25 minutes per session, followed by 5 minutes cool down for 12 sessions.
2962919|NCT02812459|Experimental|Kinesio taping plus exercise|Kinesio taping application for low back plus back exercises.This protocol will be administered three a week for 4 weeks.
2962920|NCT02812459|Active Comparator|Electrical stimulation plus exercise|Electrical stimulation for control pain applied in low back plus exercises.This protocol will be administered three a week for 4 weeks.
2962921|NCT02812446||IAI patients group|patients with Staphylococcus aureus of implant-associated infections
2962922|NCT02812446||control group|patients with Staphylococcus aureus nasal carriage
2962923|NCT02812433|Active Comparator|Sildenafil|Sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
2962924|NCT02812433|Placebo Comparator|Ora-Blend|Ora-Blend 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
2962925|NCT02812420|Experimental|Durvalumab + Tremelimumab|"Participants receive Durvalumab and Tremelimumab by vein on Day 1 of Weeks 1 and 5.~Surgery (cystectomy with pelvic lymph node dissection) performed 4-6 weeks after the last infusion of Durvalumab and Tremelimumab.~Every 3 months for a total of 1 year from the start on the study, participants called and asked how they are doing."
2963058|NCT02811536||Carotid artery occlusion|Patients with a history of carotid artery occlusion
2963059|NCT02811536||Age related macular degeneration|Patients with a history of Age related macular degeneration
2963060|NCT02811536||Macroaneurysms|Patients with a history of retinal macroaneurysms
2962926|NCT02812407|Experimental|Mucosal Impedance|"Patient's having a clinically indicated endoscopy, a high resolution impedance manometry and a 24 hour pH impedance study.~During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. This device has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it."
2962927|NCT02812394|Experimental|CVT-301|"CVT-301 (Dose Level 1): two (low dose) levodopa fine particle dose (FPD) capsules administered to the lung via oral inhalation using the CVT 301 inhaler.~CVT-301 (Dose Level 2): two (high dose) levodopa FPD capsules administered to the lung via oral inhalation using the CVT 301 inhaler.~Sinemet® (carbidopa/levodopa)"
2962928|NCT02812381|Active Comparator|SCS (Jones tecnique)|18 patients were treatment with straincounterstrain
2962929|NCT02812381|Sham Comparator|KT Kinesiotaping|18 patients were treatment with neuromuscular bandage
2962930|NCT02812368|Experimental|Clonidine|Taken once a day at bedtime; with the dose titrated from 0.05mg to 0.20mg over the course of 6 weeks
2962931|NCT02812368|Placebo Comparator|Placebo (for clonidine)|Taken once a day at bedtime
2962932|NCT02812355|Experimental|half heparinization|heparin I.V. 150 U/kg
2962933|NCT02812355|Active Comparator|full heparinization (300 U/kg)|heparin I.V. 300 U/kg
2962934|NCT02812342|Experimental|Tofacitinib ointment|Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
2962935|NCT02812329|Experimental|HIV prevention videogame|Participants will play PlayForward on a tablet computer for 1 hour, two times per week for 3 weeks.
2962936|NCT02812316|Experimental|Scleral lenses|Subjects who meet all eligible requirements for entry into the study will be instructed to insert the Hi-Brite Large Diameter Rigid Gas Permeable contact lens in daily wear basis for clinical evaluation purposes.
2962937|NCT02812303||Population Health Coordinator Support|"8 practices received the support of central population health coordinators (PHCs). PHCs utilized a population health management (PHM) information technology (IT) tool and performed administrative tasks including appointment scheduling, ordering overdue laboratory testing, chart reviews, and obtaining outside tests/labs. In addition, PHCs regularly met with physicians to review those patients who required clinical intervention to develop an action plan.~The network did not have sufficient resources to implement a PHC in all of the 18 network practices. So PHCs were allocated by responses from the practice leader, baseline quality scores, size of the practice, nature of the practice (health center vs not), and location of the practice. These decisions were made in a way that sought to equitably distribute available PHC resources within the practice network as a way to get network buy-in and maximize the impact of the program, both for practices with and without PHCs."
2962938|NCT02812303||No Population Health Coordinator Support|Ten practices without PHC support were provided training on how to use the PHM IT tool. The staff in these practices remained primarily responsible for managing administrative tasks.
2962939|NCT02812277||Anastrozole treatment group|The study group was about HR positive postmenopausal breast cancer patients who were hospitalized between January, 2008 and October, 2010, and ever accepted anastrozole therapy with the completed follow-up data.
2962940|NCT02812277||letrozole treatment group|The study group was about HR positive postmenopausal breast cancer patients who were hospitalized between January, 2008 and October, 2010, and ever accepted letrozole therapy with the completed follow-up data.
2962941|NCT02812264|Experimental|API App|use of API weight loss mobile application for 12 months, plus fitness tracker and scale.
2962942|NCT02812264|Active Comparator|Attention Control|use of non-API app for weight loss over 12 months, plus fitness tracker and scale.
2962943|NCT02812251|Experimental|Part 1: Cohort 1|Participants will receive 1 milligram (mg) JNJ-61393215 or placebo.
2962944|NCT02812251|Experimental|Part 1: Cohort 2|Participants will receive 5 mg JNJ-61393215 or placebo.
2962945|NCT02812251|Experimental|Part 1: Cohort 3|Participants will receive 15 mg JNJ-61393215 or placebo.
2962946|NCT02812251|Experimental|Part 1: Cohort 4|Participants will receive 30 mg JNJ-61393215 or placebo.
2962947|NCT02812251|Experimental|Part 1: Cohort 5|Participants will receive 45 mg JNJ-61393215 or placebo.
2962948|NCT02812251|Experimental|Part 1: Cohort 6|Participants will receive 60 mg JNJ-61393215 or placebo.
2962949|NCT02812251|Experimental|Part 1: Cohort 7|Participants will receive 90 mg JNJ-61393215 or placebo.
2962950|NCT02812251|Experimental|Part 1: Cohort 8|Participants will receive 120 mg JNJ-61393215 or placebo.
2962951|NCT02812251|Experimental|Part 2|Participants will receive JNJ-61393215 (dose to be determined).
2962952|NCT02812251|Experimental|Part 3|Participants will receive JNJ-61393125 (dose to be determined) or placebo under fed conditions.
2962953|NCT02812238|Experimental|Arm 1|Either NR at 10000mg/days/7days, followed by a washout period of 2-3 weeks, then placebo or start with placebo, followed by a 2-3 week washout period, then NR at 1000mg/day/7days
2962954|NCT02812225|Experimental|BrainPulse|BrainPulse recordings will be obtained from patients when they come in to the ED after a trauma event. BrainPulse recordings will be also obtained from those subjects who also consent for follow-up.
2962955|NCT02812212|Experimental|Open-label|"Device: ultrasonography and diuretic renography Bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.~Diuretic renography to measure the cortical transit time"
2962956|NCT02812199|Experimental|pilot study group 1|Patients in pilot study group 1 will undergo post-FESS bilateral implantation of Composite Removable Sinus Stent into middle meatus. Nasal tampon will be placed to stop bleeding if necessary. Patients in pilot study group scheduled for 6 follow up visits at 1,2,3,4,6 and 12 weeks after implantation and for tampon removal at day 2 - 3 after FESS surgery. Stent will be removed between 14 and 28-day implantation. Before removal adrenaline - lidocaine administration will be used locally to minimize bleeding and cold saline wash applied to induce stent crimping.
2962957|NCT02812199|Experimental|study group 2|Patients in study group 2 will undergo post-FESS bilateral implantation of Composite Removable Sinus Stent into middle meatus. Nasal tampon will be placed to stop bleeding if necessary. Patients in 2nd study group scheduled for 4 follow up visits at 2, 4, 6 and 12 weeks after implantation. Before removal adrenaline - lidocaine administration will be used locally to minimize bleeding and cold saline wash applied to induce stent crimping.
2962958|NCT02812199|No Intervention|control group 3|control group patients will undergo post-FESS bilateral Standard of Care (tampon) placement into middle meatus as standard of care. Frontal tampon will be placed to stop bleeding. Patients in control group scheduled for 3 follow up visits at 2, 6 and 12 weeks after surgery and for tampon removal at day 2 - 3 after FESS surgery.
2962959|NCT02812186|Other|deep neuromuscular blockade|This group will undergo deep neuromuscular blockade, defined as post tetanic count (PTC) of 1 to 2, in the beginning portion of the surgery followed by a period of moderate blockade.
2962960|NCT02812186|Other|moderate neuromuscular blockade|This group will undergo moderate neuromuscular blockade, defined as 1-2 twitches, in the beginning portion of the surgery followed by a period of deep blockade.
2962961|NCT02812173|Active Comparator|suprapubic tube ex 2 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a suprapubic tube, which was withdrawn on the 2th day after the surgery
2962962|NCT02812173|Active Comparator|suprapubic tube ex 5 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a suprapubic tube, which was withdrawn on the 5th day after the surgery
2962963|NCT02812173|Active Comparator|transurethral catheter ex 5 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a transurethral catheter, which was withdrawn on the 5th day after the surgery
2962964|NCT02812147|Active Comparator|L-DOPS|All participants will be on levodopa/carbidopa, and may be on additional dopaminergic drugs including dopamine agonists and/or monoamine type B oxidase inhibitors or amantadine. L-dihydoxyphenylserine will be added, administered as an oral capsule 3 times a day for 4 months. Dosing will begin at 100 mg of L-DOPS three times per day and titrated upward, by 100 mg three times a day, as tolerated. Tolerability will be evaluated based upon questionnaires, patient interviews, vital signs and investigator examination. In order to participate in the study, all subjects must be able to tolerate a minimum tolerated dose of 400 mg three times per day (1200mg/day). Subject maximum dose will be 600 mg three times per day (1800mg/day). Patients will be maintained on this dose for 4 months (until the cross-over). After a 7-day washout, participants will cross over to the Placebo arm.
2962965|NCT02812147|Placebo Comparator|Placebo|All participants will be on levodopa/carbidopa, and may be on additional dopaminergic drugs including dopamine agonists and/or monoamine type B oxidase inhibitors or amantadine. Placebo will be added, administered as an oral capsule 3 times a day for 4 months. Dosing will begin at 100 mg of placebo three times per day and titrated upward, by 100 mg three times a day, as tolerated. Tolerability will be evaluated based upon questionnaires, patient interviews, vital signs and investigator examination. In order to participate in the study, all subjects must be able to tolerate a minimum tolerated dose of 400 mg three times per day (1200mg/day). Subject maximum dose will be 600 mg three times per day (1800mg/day). Patients will be maintained on this dose for 4 months (until the cross-over) After a 7-day washout, participants will cross over to the L-DOPS arm.
2962966|NCT02812134||anorexic|
2962967|NCT02812121|Experimental|Group MSC-1|Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 8 weeks.
2962968|NCT02812121|Experimental|Group MSC-2|Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 4 weeks.
2962969|NCT02812121|No Intervention|Group Control|Patients in Group Control received standard medical treatment, including bed rest, nutritional supplementation, administration of human serum albumin (10g per day until serum albumin was 35g/L) and plasma (200 ml to 400 ml per day until the international normalized ratio was less than 1.5), anti-viral therapy, glycyrrhizin,S-adenosylmethionine and appropriate treatment for complications (such as infection, encephalopathy, hepatorenal syndrome and intestinal paralysis).
2962970|NCT02812108||HARET|All patients with intracranial aneurysms, ruptured or unruptured, treated by endovascular treatment
2962971|NCT02812095|Experimental|The refeeding group|Refeeding is initiated when 120mL/kg/day of enteral feed reaches or stoma loss exceeds more than 50ml/kg/day after operation.
2962972|NCT02812095|No Intervention|The control group|
2962973|NCT02812082|Experimental|video web-based patient education application|This is a single-arm design. Development of the web-based application will occur over a 6 month period. Patient accrual will not occur until development of the program is complete. Controlled usability testing during the development/design process of the computer program will not be employed as we do not aim to assess the mechanics of patient use, but rather overall time spent interacting with the application in an uncontrolled environment. Following completion of the tool, patient accrual will occur over a six month time period in order to meet our target sample size of up to 50 participants. Participants will be directed to complete a pre-test questionnaire at the time of accrual and will have 3 months to use the program before being directed to complete the post-test questionnaire.
2962974|NCT02812069|Other|minor to moderate surgical procedure|The ThermaZone® Device will be used for 30 minutes to warm the cervical spine during
2962975|NCT02812056|Experimental|Alisertib + TAK-228|"Dose Escalation Phase:~Starting dose of Alisertib: 30 mg by mouth 2 times a day on Days 1 - 7 each 21 day cycle.~Starting dose of TAK-228: 1 mg by mouth daily Days 3 - 18, with the exception of 2 mg daily Days 3 - 7 and 10 - 14 schedule in a 21 day cycle.~Dose Expansion Phase:~Alisertib and TAK-228 taken at the maximum tolerated dose from Dose Escalation Phase."
2962976|NCT02812043|Experimental|Amorolfine|This group of patients will receive only amorolfine nail lacquer to apply on the affected nail and the KOH examination and fungal culture will be performed every month
2962977|NCT02812043|Experimental|Long-pulsed Nd:YAG|This group of patients will receive only the long-pulsed Nd:YAG (Cynergy®, 5 Carlisle Road Westford, MA USA) fluence 35-45 J/Cm2, spot size 4mm for 2 passes each visit with 4-week intervals and the KOH examination and fungal culture will be performed every month
2962978|NCT02812043|Experimental|Amorolfine+Long-pulsed Nd:YAG|This group of patients will receive both amorolfine nail lacquer and the long-pulsed Nd:YAG laser treatment each visit with 4-week intervals and the KOH examination and fungal culture will be performed every month
2962979|NCT02812030||aflibercept in real world|Patients receiving aflibercept for diabetic macular oedema at Bristol Eye Hospital or Gloucestershire Hospitals NHS Foundation Trust
2963061|NCT02811536||Central serous chorioretinopathy|Patients with a history of central serous chorioretinopathy
2963062|NCT02811523|Experimental|Doxorubicin 5 mcg/ml|Doxorubicin 5mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
2962980|NCT02812017|Experimental|1 - Intervention|The treatment group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will then view the Thirty Million Words-Well Baby intervention, which consists of educational, multimedia modules at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
2962981|NCT02812017|Placebo Comparator|2 - Neutral|The Neutral Video group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will then view the neutral videos about car safety at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
2962982|NCT02812017|No Intervention|3 - Usual care|The treatment group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will receive care as usual at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
2962983|NCT02812004|Experimental|Study Eye|Ultra Q Reflex YAG laser (Ellex)
2962984|NCT02812004|Sham Comparator|Contralateral Eye|Short light impulse is simulated
2962985|NCT02811991|Active Comparator|Experimental:Paracetamol Injection|325mg(32.5mL)or 500mg(50mL) iv q6h according to assignment
2962986|NCT02811991|Placebo Comparator|Placebo:Normal Saline Injcetion|32.5mLor 50mL iv q6h according to assignment.
2962987|NCT02811978|Experimental|Group 1 : Intravenous Bortezomib plus Dexamethasone|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2) bortezomib intravenously on Days 1, 4, 8, and 11 of a 3 week cycle. Participants will receive Dexamethasone at a dose of 20 mg oral (PO) on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
2962988|NCT02811978|Experimental|Group 2 : Subcutaneous Bortezomib plus Dexamethasone|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2) bortezomib subcutaneously on Days 1, 4, 8, and 11 of a 3 week cycle. Participants will receive Dexamethasone at a dose of 20 mg oral (PO) on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
2962989|NCT02811965|No Intervention|Control|Pressure mapping is performed without a heel offloading intervention applied.
2962990|NCT02811965|Experimental|Pillow Condition 1|Pressure mapping is performed with the Pillow condition 1 intervention applied to the heel.
2962991|NCT02811965|Experimental|Pillow Condition 2|Pressure mapping is performed with the Pillow condition 2 applied to the heel.
2962992|NCT02811965|Experimental|Heel Foam Pillow|Pressure mapping is performed with the heel foam pillow device applied to the heel.
2962993|NCT02811965|Experimental|Offloading Device A|Pressure mapping is performed with Offloading Device A applied to the heel.
2962994|NCT02811965|Experimental|Offloading Device B|Pressure mapping is performed with Offloading Device B applied to the heel.
2962995|NCT02811965|Experimental|Offloading Device C|Pressure mapping is performed with Offloading Device C applied to the heel.
2962996|NCT02811952||study group|Patients that need that need cystoscopy due to suspicion/known bladder malignancy.
2962997|NCT02811952||control group|Patients that need cystoscopy due to others reasons than malignancy.
2962998|NCT02811939|Experimental|Active THC and Placebo Pregnenolone|
2962999|NCT02811939|Experimental|Active THC and Active Pregnenolone|
2963000|NCT02811939|Experimental|Placebo THC and Active Pregnenolone|
2963001|NCT02811939|Placebo Comparator|Placebo THC and Placebo Pregnenolone|
2963002|NCT02811926||Ileostomy or colostomy|Patients with a ileostomy or colostomy in the Capital Region of Denmark
2963003|NCT02811913|Other|stroke cohort|Each subject is provided with three different brain stimulation interventions in a single arm, single session crossover design study
2963004|NCT02811887|Active Comparator|Usual care|12 weeks of supervised physical exercise followed by usual care in the outpatient liver cirrhosis rehabilitation clinic
2963005|NCT02811887|Experimental|SMS-messages|12 weeks of supervised physical exercise followed by usual care in the outpatient liver cirrhosis rehabilitation clinic + regular text messages via SMS over a 12-week period
2963006|NCT02811874|Experimental|diabetes education|Four community health workers receive a one-month diabetes education program (intervention group, patients n= 62)
2963007|NCT02811874|Active Comparator|education in other areas|Four community health workers receive an education course in other health issues (control group, patients n= 56).
2963008|NCT02811861|Experimental|Lenvatinib 18 mg plus everolimus 5 mg|Lenvatinib 18 milligrams (mg) administered orally, once daily, plus everolimus 5 mg administered orally, once daily
2963009|NCT02811861|Experimental|Lenvatinib 20 mg plus pembrolizumab 200 mg|Lenvatinib 20 mg administered orally, once daily, plus pembrolizumab 200 mg administered intravenously (IV), every 3 weeks
2963010|NCT02811861|Active Comparator|Sunitinib 50 mg|Sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment
2963011|NCT02811848||Barbers|Barbers that service African American clientele mainly will be recruited for this study; there is no intervention.
2963012|NCT02811835||Renal Transplant Recipients|Renal Transplant Recipients that were more than 1 year post-transplantation
2963013|NCT02811835||Healthy Controls|Healthy subjects being evaluated as potential living kidney donors
2963014|NCT02811822|Experimental|Dose 1|
2963015|NCT02811822|Experimental|Dose 2|
2963016|NCT02811822|Experimental|Dose 3|
2963017|NCT02811822|Experimental|Dose 4|
2963018|NCT02811809|Experimental|Apalutamide + IHT|Participants will be treated with 240 mg (4-60 mg tablets) oral Apalutamide daily plus 22.5 mg 3-month depot intramuscular leuprolide intermittently.
2963019|NCT02811809|Active Comparator|IHT only|Participants will receive 22.5 mg 3-month depot intramuscular leuprolide until PSA progression, then they will crossover to Apalutamide + IHT
2963063|NCT02811523|Experimental|Doxorubicin 7 mcg/ml|Doxorubicin 7mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
2964357|NCT02802241|No Intervention|no additional treatment|
2963020|NCT02811796||angio-based FFR estimation|The investigators will include all patients receiving successful coronary stent implantation. In these patients the investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
2963021|NCT02811783|Active Comparator|Naloxone Hydrochloride Lotion, 0.5%|Naloxone Hydrochloride Lotion 0.5%
2963022|NCT02811783|Placebo Comparator|Placebo Lotion|Placebo Lotion
2963023|NCT02811770||children with HSN|
2963024|NCT02811757|Experimental|tenodesis|
2963025|NCT02811757|Active Comparator|tenotomy|
2963026|NCT02811744|Experimental|Amnestic MCI cohort|Patients with Mild Cognitive Impairment (MCI) (up to 14) will be recruited primarily from the Penn Memory Center (PMC). Clinical diagnostic criteria (described in further detail in Study Procedures section) will be used to identify subjects who are meet criteria for amnestic MCI. Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
2963027|NCT02811744|Other|Control cohort|Normal control subjects in the same age range (up to 6) will be recruited from a current ongoing study investigating neuroinflammation in late life depression and healthy controls, from the control group in which all subjects receive MRI and LP and from the PMC research cohort. Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
2963028|NCT02811731|Experimental|Candesartan and Amlodipine|Candesartan 16mg and Amlodipine 5mg, PO, 1days or 22days
2963029|NCT02811731|Experimental|CKD-330|CKD-330 16/5mg - B, PO, 1days or 22days
2963030|NCT02811718|Experimental|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
2963031|NCT02811718|Experimental|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
2963032|NCT02811705||PFAPA group|Life quality for PFAPA patient report by themselves or parent
2963033|NCT02811705||FMF group|Life quality for FMF patient report by themselves or parent
2963034|NCT02811692||BAY86-5321|Anti-Vascular Endothelial Growth Factor (VEGF) - naive patients starting intravitreal Aflibercept injection treatment for Neovascular age-related macular degeneration (AMD), macular edema following Branch Retinal Vein Occlusion (BRVO), macular edema following central retinal vein occlusion (CRVO), and diabetic macular edema (DME)
2963035|NCT02811679|Experimental|Blinatumomab|Blinatumomab will be administered as a continuous IV infusion through a central venous catheter for a 42 day cycle. Blinatumomab will start with a 7 day infusion at 9mcg/d. If no dose limiting toxicity (table 6.1) after 7 days, the dose will be escalated to 28 mcg/d for 7 additional days. If no dose limiting toxicity (table 6.1) after 14 days, blinatumomab will be infused at a target dose of at 112mcg/d for 28 days. Subjects will be restaged after a 6 week treatment free period by PET CT. All subjects without disease progression will receive an additional 4 week cycle starting at the target dose of 112 mcg/d.
2963036|NCT02811666|Experimental|Patients operated for liver or pancreas cancer|
2963037|NCT02811653|Experimental|Alzheimer disease|Alzheimer disease patients Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation
2963038|NCT02811653|Active Comparator|control|"Healthy age- and gender-matched volunteers will be recruited into the study from the general population.~Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation"
2963039|NCT02811640||Study Participants|Adults with chronic kidney disease who will have a PD catheter inserted at the Ottawa Hospital
2963040|NCT02811627|Experimental|Memantine and Magnetic Resonance Imaging|"Subjects will be started on memantine post the imaging session.~Memantine is available commercially as Namenda, Namenda XR and in the liquid form (for subjects who do not wish to take pills). Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks."
2963041|NCT02811614|Experimental|Experimental 1: Endoscopic Evacuation|Endoscopic hematoma evacuation with the help of a self-developed working channel.
2963042|NCT02811614|Experimental|Experimental 2: Stereotactic Aspiration|Place a catheter into the main body of the hematoma and aspirate blood.
2963043|NCT02811614|Active Comparator|Active Comparator: Craniotomy|Craniotomy with a big bone flap to for hematoma evacuation.
2963044|NCT02811601|Experimental|PEAL surgery|Patients will undergo percutaneous externally-assembled laparoscopic surgery
2963045|NCT02811588||Screening phase: normocapnic group|Normocapnic COPD patients
2963046|NCT02811588||Screening phase: hypercapnic group|Hypercapnic COPD patients
2963047|NCT02811588||Treatment phase: control group|Hypercapnic COPD patients in whom NIV is not indicated or who have contraindication(s) for, or refuse, NIV treatment.
2963048|NCT02811588||Treatment phase: non-invasive ventilation group|Hypercapnic COPD patients in whom NIV is indicated and who accept NIV treatment.
2963049|NCT02811575||Patients with diabetes|Patients with type 2 diabetes will have biopsy during coloscopy.
2963050|NCT02811575||Control|Patients without type 2 diabetes will have biopsy during coloscopy.
2963051|NCT02811562|Active Comparator|fiberoptic bronchoscope|Tracheal intubation in manikin using fiberoptic bronchoscope
2963052|NCT02811562|Experimental|fiberoptic bronchoscope with pentax-airwayscope|Tracheal intubation in manikin using fiberoptic bronchoscope with pentax-airwayscope
2963053|NCT02811549|Experimental|HiResolution Bionic Cochlear Implant|HiRes 90K™ Advantage implant with HiFocus™ 1J electrode, HiRes 90K™ Advantage implant with the HiFocus Helix™ electrode, HiRes 90K™ Advantage implant with the HiFocus™ Mid-Scala electrode or the HiRes™ Ultra Implant with the HiFocus™ Mid‐Scala electrode will be implanted in adults who have severe to profound sensorineural hearing loss in one ear, and up to moderate sensorineural hearing loss in the other ear (asymmetric hearing loss).
2963054|NCT02811536||Diabetic retinopathy|Patients with various degrees of diabetic retinopathy
2963055|NCT02811536||Retinal detachment|Patients with a history of retinal detachment
2963056|NCT02811536||Retinal vein occlusion|Patients with a history of retinal vein occlusion
2963064|NCT02811523|Experimental|Doxorubicin 9 mcg/ml|Doxorubicin 9mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
2963065|NCT02811523|Experimental|Doxorubicin 11 mcg/ml|Doxorubicin 11mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
2963066|NCT02811523|Experimental|Doxorubicin 13 mcg/ml|Doxorubicin 13mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
2963067|NCT02811523|Experimental|Doxorubicin 15 mcg/ml|Doxorubicin 15mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
2963068|NCT02811523|Experimental|Doxorubicin 17 mcg/ml|Doxorubicin 17mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
2963069|NCT02811523|Experimental|Doxorubicin 20 mcg/ml|Doxorubicin 20mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
2963070|NCT02811510|Active Comparator|THC|10 mg Dronabinol will be administered orally.
2963071|NCT02811510|Placebo Comparator|Placebo|Placebo pill (no active cannabinoids).
2963072|NCT02811497|Experimental|Azacitidine and Durvalumab|"Azacitidine will be given by mouth at a fixed dose of 300 mg daily for 14 consecutive days of every 28 day cycle for 3 cycles.~Durvalumab will be given intravenously (by vein) at a fixed dose of 1500 mg (over 1 hour) on Day 1 of every 28 day cycle for 12 months or until disease progression."
2963073|NCT02811484|Other|Group 1|Insulin titration and behavioral therapy.
2963074|NCT02811484|Placebo Comparator|Group 2|Exenatide-LAR plus Dapagliflozin placebo, basal insulin titration, and behavioral therapy.
2963075|NCT02811484|Experimental|Group 3|Exenatide-LAR plus Dapagliflozin, basal insulin titration, and behavioral therapy.
2963076|NCT02811458|Experimental|Transdiagnostic CBT|Group psychotherapy according to the Transdiagnostic Cognitive-Behavioral Therapy treatment protocol (Norton, 2012)
2963077|NCT02811458|No Intervention|Treatment-as-usual|Treatment-as-usual and a differed intervention (if desired by participants) after the 8-month follow up.
2963078|NCT02811445||High Functioning|Defined by a short physical performance battery score (SPPB) greater than or equal to 11.
2963079|NCT02811445||Low Functioning|Defined by a short physical performance battery score (SPPB) less than or equal to 7.
2963080|NCT02811432|Experimental|Kangaroo mother care|
2963081|NCT02811432|Active Comparator|Incubator care|
2963082|NCT02811419|Active Comparator|i-scan|Inspection with i-scan surface enhancement
2963083|NCT02811419|Active Comparator|Standard high-definition white light|Inspection with standard high-definition white light (usual care)
2963084|NCT02811406|Experimental|Receives IV albumin infusion|IV albumin 20% 50 mL for every 1L of ascitic fluid drained
2963085|NCT02811406|Placebo Comparator|Do not receive IV albumin infusion|No IV albumin infusion
2963086|NCT02811393||Bariatric surgery|Women who have been submitted to a Roux-en-Y Gastric Bypass Surgery for at least 2 years
2963087|NCT02811393||Unoperated|Women with similar characteristics to control group (age, body mass index, physical activity level), but they have not been submitted to bariatric surgery
2963088|NCT02811380|Experimental|BIP CVC|Bactiguard Infection Protection Central Venous Catheter
2963089|NCT02811380|Placebo Comparator|Uncoated standard CVC|Uncoated standard Central Venous Catheter
2963090|NCT02811367|Experimental|HPV self-test|Women will perform the HPV self-test.
2963091|NCT02811354|Experimental|AZD9291|Patient will be treated with AZD9291 at a starting dose of 80mg once a day until the patient completes the study, withdraws from the study or closure of the study. A cycle of treatment is defined as 28 days of once daily AZD9291 treatment. Patients may continue to receive AZD9291 until objective disease progression (determined by RECIST 1.1) or if the subject is no longer receiving clinical benefit in the Investigator's opinion.
2963092|NCT02811341|Placebo Comparator|A group|Using normal saline before pcle examination
2963093|NCT02811341|Experimental|B group|Using Scopolamine Hydrobromide before pcle examination
2963094|NCT02811302|Other|Patients monitored by capnography|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
2963095|NCT02811289|Experimental|Mirabegron|Mirbetriq (Mirabegron) (50mg) will be administered orally at time 0 to activate brown adipose tissue.
2963096|NCT02811289|Active Comparator|Cold exposure|Cold exposure protocol using a water-conditioned cooling suit will be applied
2963097|NCT02811276|No Intervention|Control Group|Those assigned to the Control Group will receive a eucaloric diet (a diet designed to meet the person's energy needs and maintain body weight) composed of 55% of carbohydrate, 15% of protein, and 30% of lipid.
2963098|NCT02811276|Experimental|High-Protein Diet Group|Those assigned to the High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®).
2963099|NCT02811263|Active Comparator|Erythropoietin|Erythropoietin 1000 U/kg IV, at about 1, 2, 3, 4 and 7 days of age (i.e., 5 doses)
2963100|NCT02811263|Placebo Comparator|Placebo|Normal saline IV (equal volume), at about 1, 2, 3, 4 and 7 days of age
2963101|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 8 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 8 Gy
2963102|NCT02811250|Experimental|Stereotactic radiotherapy 5 x 8 Gy|Patient receive 5 stereotactic radiotherapy sessions with a dose of 8 Gy
2963103|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 10 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 10 Gy
2963104|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 12 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 12 Gy
2963105|NCT02811237|Other|HESTIA group|
2963106|NCT02811237|Other|sPESI group|
2963107|NCT02811224||Ovarian Cancer|
2963108|NCT02811224||Benign Neoplasm|
2963109|NCT02811198||MDD with SI and No Attempt|Subjects will have MDD with current MDE, current suicidal ideation and no lifetime suicide attempts
2963110|NCT02811198||MDD with SI and Recent Attempt|Subjects with have MDD with current MDE, current suicidal ideation and a suicide attempt within the past 6 months
2963111|NCT02811198||MDD with no SI and Lifetime Attempt|Subjects with MDD and current MDE but no current suicidal ideation and a lifetime suicide attempt.
2963112|NCT02811198||Healthy Controls|Subjects will have no personal or family psychiatric history and no suicide attempts.
2963113|NCT02811185|Other|PET/CT Scan|Subjects will receive a single dose of [F-18]-FDG Injection at Visit 1, followed by PET/CT scanning according to departmental practice.
2963114|NCT02811185|Other|PET Scan|Subjects will receive a single dose of [F-18]-FDG Injection at Visit 1, followed by PET scanning according to departmental practice.
2963115|NCT02811172||Healthy pregnant women|Healthy pregnant women
2963116|NCT02811172||Risk pregnant women|Hypertensive, obese and diabetic women
2963117|NCT02811159|Experimental|Proellex 12 mg|Telapristone acetate, 1 oral capsule, once a day, for three 18-week courses separated by an Off Drug Interval (ODI)
2963118|NCT02811146|Experimental|Cardiopulmonary exercise testing|Assess whether people who wore noninvasive ventilation during aerobic exercise have greater functional capacity than those who did not wear.
2963119|NCT02811146|Experimental|ADL Glitre test|Check that people who wore noninvasive ventilation during aerobic exercise have greater submaximal functional capacity than those who did not wear. Compare a ventilatory metabolic response of the ADL Glitre test with an six-minute walk test. .
2963120|NCT02811146|Experimental|Minnesota Living with Heart Failure|Check if people undergoing heart rehabilitation has improved quality of life.
2963121|NCT02811146|Experimental|Bioimpedance balance|Check if people undergoing heart rehabilitation has improved the body composition.
2963122|NCT02811146|No Intervention|Six-minute walk test|Compare a ventilatory metabolic response of the six-minute walk test with an ADL Glitre test.
2963123|NCT02811146|Experimental|Metabolic ventilatory response|"To verify if non-invasive ventilation during aerobic exercise modifies the ventilatory metabolic response in patients with heart failure.~Check the metabolic ventilatory response during the Glittre ADL test and six-minute walk test."
2963124|NCT02811133|Experimental|Inositol|Subjects will receive inositol
2963125|NCT02811120||single arm|single venepuncture
2963126|NCT02811107||Patients in preoperative area|Patients in preoperative area before surgery or interventional procedure will complete questionnaires on tablet computers
2963127|NCT02811094|Other|Adult patients with Systemic LupusErythematosus (SLE)|Adult patients with SLE, clinically quiescent and with no change in treatment in the past 3 months, will be included and followed-up for 12 months. Blood samples will be drawn every 3 months during 12 months in the absence of flare. Patients presenting a flare will be sampled at the time of the flare and 1 month later.
2963128|NCT02811081|Experimental|Control|Passive deflation of residual carbon dioxide
2963129|NCT02811081|Experimental|Normal Saline Instillation|Instillation of isotonic normal saline in the sub-diaphragmatic region
2963130|NCT02811081|Experimental|Combined Intervention|Normal Saline Instillation + Pulmonary Recruitment
2963131|NCT02811068||Venepuncture|Collection of single blood sample to assess antibody persistence over time
2963132|NCT02811055|Experimental|Administration of Aprepitant|Administration of Aprepitant 80 mg once per day during 14 days; Blood sampling, electrocardiogram, orthostatic test and Blood Pressure Measurement are done after 14 days
2963133|NCT02811055|Placebo Comparator|Administration of placebo|Administration of Placebo once per day during 14 days; Blood sampling, electrocardiogram, orthostatic test and Blood Pressure Measurement are done after 14 days
2963134|NCT02811042|Active Comparator|Oropharyngeal leak pressure|Ambu AuraOnce
2963135|NCT02811042|Experimental|Fiberoptic position|Ambu AuraGain
2963136|NCT02811029|Experimental|premature infants less than 32 weeks of age|measurement of phonology in premature infants less than 32 weeks of age who participated to LAMOPRESCO-1 study
2963137|NCT02811016|Experimental|budesonide 200|inhaled budesonide 200 µg bid
2963138|NCT02811016|Experimental|budesonide 800|inhaled budesonide 800 µg bid
2963139|NCT02811016|Placebo Comparator|placebo|inhaled placebo bid
2963140|NCT02811003|Experimental|Treatment|Treatment with Rotation Medical Bioinductive Implant
2963141|NCT02810990|Experimental|Bosutinib treatment|
2963142|NCT02810964|Experimental|Sulforaphane Nutraceutical|The sulforaphane nutraceutical contains inactive glucoraphanin, a glucosinolate from broccoli seeds, and myrosinase from broccoli sprouts. The ingestion of this compound leads to the hydrolysis of glucoraphanin, the generation of sulforaphane within the gastrointestinal (GI) tract, and the subsequent systemic absorption of the sulforaphane. The dose per tablet is 16 mg of glucoraphanin or 37 µmol; 6 tablets per day should yield about 100 µmol of sulforaphane. The tablets, which will be swallowed, are provided as .375 punch size, round concave tablets. In this arm, the participant will take 6 tablets of the sulforaphane nutraceutical daily for 16 weeks after a 2-week placebo run-in.
2963143|NCT02810964|Placebo Comparator|Identical-appearing Placebo|The inert compound placebo looks identical to the sulforaphane nutraceutical. In this arm, the participant will take 6 tablets of the placebo daily for 16 weeks after a 2-week placebo run-in.
2963144|NCT02810951|Experimental|FCX-007|"In Phase I, a target of three adult subjects will be enrolled into Group A and a target of three adult subjects will be enrolled into Group B.~In Phase II the study will target enrolling subjects (aged seven (7) or older) to each arm, but will allow a disproportionate distribution of subjects between Group A and Group B to equal 6 total subjects.~All subjects will receive FCX-007 into intact skin as well as to one or more paired target wounds at least one time during the study with a possible second administration pending laboratory results.~One wound in each target wound pair will be used as control for efficacy and safety evaluations. FCX-007 administered wounds will be compared within paired target wounds to untreated wounds."
2963145|NCT02810925|Experimental|PENS T6 and 1200 Kcal/day diet|Patients undergo 12 sessions of percutaneous electrical stimulation of dermatome T6 (PENS T6), weekly, during 12 weeks. During this period they follow a hypocaloric 1200 Kcal/day diet.
2963146|NCT02810925|Active Comparator|PENST6 + Normocaloric 2000 Kcal/day diet|Patients undergo 12 sessions of percutaneous electrical stimulation of dermatome T6 (PENS T6), weekly, during 12 weeks. During this period they follow a normocaloric 2000 Kcal/day diet.
2963147|NCT02810925|Placebo Comparator|TENS T11/ T12 + 1200 Kcal/day diet|Patients undergo 12 sessions of transcutaneous electrical stimulation of dermatomes T11-T12 , weekly, during 12 weeks. During this period they follow a hypocaloric 1200 Kcal/day diet.
2963148|NCT02810925|Active Comparator|1200 Kcal/day diet|Patients follow only a hypocaloric 1200 Kcal/day diet.
2963149|NCT02810912||Supraglottic airway device-based anesthesia|Investigators planned to enroll 200 cases who will receive scheduled surgery under supraglottic airway device-based general anesthesia.
2963150|NCT02810899|Experimental|Dexmedetomidine group|A loading dose of dexmedetomidine (0.5 ug/kg IV infusion in 15 minutes) will be administered after induction of general anesthesia, followed by continuous infusion at a rate of 0.5 ug/kg/h until the closure of the duramater of the brain.
2963151|NCT02810899|Placebo Comparator|Control group|Normal saline will be administered in the same rate and volume as that in the dexmedetomidine group.
2963152|NCT02810886|Experimental|Single, arm exploratory|Patients will undergo a 68Ga-PSMA PET/CT within 1 month after routine imaging diagnostic work-up.
2963153|NCT02810873|Experimental|F-18-FDG Whole body Scan|STAGE I: Patients with a positive biopsy and abnormal (positive) fludeoxyglucose F18-labeled PET whole-body scan undergo a whole-body copper Cu 64 TP3805-labeled PET scan.
2963154|NCT02810873|Experimental|No F-18-FDG Scan|STAGE II: Patients with a positive biopsy, but no fludeoxyglucose F18 scan undergo a breast fludeoxyglucose F18-labeled PEM Positron Emission Mammography scan followed by a breast copper Cu 64 TP3805-labeled PEM scan.
2963155|NCT02810860|Other|Open Label|Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
2963156|NCT02810847|Experimental|I-BiT Plus|6 weeks of I-Bit treatment plus (at least 30 mins/day, 6 days/week)
2963157|NCT02810847|No Intervention|Control|Refractive adaption or observation
2963158|NCT02810834|Experimental|Walking/Running Program|Walking/running/jogging program; school-based.
2963159|NCT02810834|Experimental|Classroom activity break program|Classroom physical activity break program; school-based.
2963160|NCT02810834|No Intervention|Control|Control/Delayed Intervention
2963161|NCT02810821||male|
2963162|NCT02810821||female, premenopause|Women with regular menstrual cycles in normal range (22-35 days) for the previous three cycles.
2963163|NCT02810821||female, perimenopause|Women with variability in menstrual cycle length, defined as a persistent difference of 7 days or more in the length of consecutive cycles, or amenorrhea of at least 60 days but no longer than 12 months.
2963164|NCT02810821||female, postmenopause|Women with amenorrhea of at least 12 consecutive months.
2963165|NCT02810808|Experimental|Ranibizumab 0.5 mg 1+PRN|PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization in the 11 month treatment period Intervention: Drug: Ranibizumab
2963166|NCT02810808|Active Comparator|Ranibizumab 0.5 mg 3+PRN|PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization after three Monthly intravitreal injections of the same dose.
2963167|NCT02810782|Experimental|Phenobarbital|Phenobarbitone loading dose 10 mg/kg body weight maintenance dose 0.83 mg/kg body weight every 4 hours
2963168|NCT02810782|Active Comparator|Chlorpromazine|Chlorpromazine loading dose 0.5 mg/kg body weight maintenance dose 0.25 mg/kg every 4 hours
2963169|NCT02810782|Active Comparator|Morphine|Morphine (tinctura opii) 0.25 mg/kg body weight every 4 hours
2963170|NCT02810769|Placebo Comparator|Control|Sugar matched control containing no phytochemicals
2963171|NCT02810769|Experimental|Juiced berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
2963172|NCT02810769|Experimental|Powdered berry drink|Berry drink made up from a powdered concentrate. each drink will be standardised to contain 500mg of polyphenols
2963173|NCT02810756|Experimental|Treated patients|
2963174|NCT02810743|Active Comparator|ddAC-CP-Olaparib|"ddAC; doxorubicin 60 mg/m² as an i.v. bolus and cyclophosphamide 600 mg/m² as an i.v. bolus on day 1 every 2 weeks ddAC must be supported with prophylactic pegfilgrastim 6 mg s.c. given 24-48 hours after completion of administration of EVERY chemotherapy cycle~CP; carboplatin/paclitaxel (CP) consisting of carboplatin (AUC 6) on day 1 and paclitaxel (80 mg/m2) on day 1,8 and 15 of a 21 days cycle. In total 4 courses of CP will be administered.~Olaparib will be administered as monotherapy for one year at a dose of 300 mg BID, starting 3 weeks after adjuvant radiotherapy, or, if radiotherapy is not indicated, 3-5 weeks after the last CP cycle."
2963175|NCT02810743|Active Comparator|ddAC-mini CTC|"ddAC; doxorubicin 60 mg/m² as an i.v. bolus and cyclophosphamide 600 mg/m² as an i.v. bolus on day 1 every 2 weeks ddAC must be supported with prophylactic pegfilgrastim 6 mg s.c. given 24-48 hours after completion of administration of EVERY chemotherapy cycle~intensified alkylating 'mini' CTC (2x) cyclophosphamide 3000 mg/m2 day 1 mesna 500 mg (push) + 2000 mg in 24 hours day 1 carboplatin (400 mg/m2; (or AUC=5 in patients with a calculated creatinine-clearance of <100 ml/min)) days 1,2 thiotepa 250 mg/m2 day 2"
2963176|NCT02810730|Other|Single arm|Pancreatic MRI in the 6 months following the first consultation
2963177|NCT02810717|Experimental|active TBS|40 patients with TRD will receive active theta-burst stimulation using a MagPro X1000 between the two PET measurements
2963178|NCT02810717|Sham Comparator|sham TBS|40 patients with TRD will receive sham stimulation using a MagPro X1000 between the two PET measurements. After the second PET scan they will receive active TBS
2963179|NCT02810704|Experimental|Arm 1: Enteric Coated Aspirin|Enteric coated aspirin (162 mg po) will be administered on the day of operation, prior to surgery, with a sip of water. Thereafter, starting on postoperative day #1, all patients in the aspirin group will receive 81 mg po bid to complete the treatment period of 30 days. Patients on preoperative cardiac dose aspirin may continue their usual dosing regimen prior to the morning of surgery, and then commence the PEPPER trial aspirin dose of 81 mg po bid on the day after operation.
2963180|NCT02810704|Experimental|Arm 2: Warfarin Other Names: Coumadin|Warfarin will be administered starting on the day of operation, prior to surgery, with a sip of water. The initial dose will be empirically determined by body weight: less than 125 lbs (56.7 kg) - 2.5 mg; 125-250 lbs (56.7-113.4 kg) - 5 mg; greater than 250 lbs (113.4 kg) - 7.5mg. The initial dose will be repeated on the evening of surgery if the preoperative dose was administered prior to noon on the day of operation; no warfarin will be given on the evening of surgery if the preoperative dose was received after noon on the day of operation. Thereafter, starting on postoperative day #1, warfarin will be given each evening based on INR values to achieve a target of 2.0 (range 1.7-2.2).
2963181|NCT02810704|Experimental|Arm 3: Rivaroxaban Other Names: Xarelto|Rivaroxaban 10 mg will be first administered approximately 24 hours after completion of the index operation. Medication will then be administered in the evening on postoperative day #2 and thereafter each evening until completion.
2963182|NCT02810691|Active Comparator|Soluble fiber, dose #1|Soluble fiber supplementation with dose #1 (smaller dose) of psyllium fiber.
2963183|NCT02810691|Active Comparator|Soluble fiber, dose #2|Soluble fiber supplementation with dose #2 (bigger dose) of psyllium fiber.
2963184|NCT02810691|Placebo Comparator|Placebo|A 250 ml placebo solution of orange-flavored water will be drink at breakfast.
2963185|NCT02810678|No Intervention|Control|No Intervention: Program runs as per usual. Minimal interference and visits from study staff. Main study outcomes evaluated at start and end of trial. Minimal visits to collect information on costing at control sites.
2963186|NCT02810678|Active Comparator|Intervention|Latent Tuberculosis Infection program evaluation & diagnosis: In intervention health facilities the current Latent Tuberculosis Infection program will be evaluated and gaps in the Latent Tuberculosis Infection cascade of care will be identified. Gaps in the current cascade will be quantified and solution proposed that are unique to the problems identified in each site. In phase 2 of the study low cost solutions will be implemented and the Latent Tuberculosis Infection program scaled up and improved. Study outcomes (proportion of Latent Tuberculosis Infection cases starting treatment) are evaluated at the start and end of the trial. Costing evaluations are done throughout the trial.
2963187|NCT02810665||Normal vision group|Individuals with VA 20/20 to 20/25
2963188|NCT02810665||Impaired vision group|Individuals with impaired vision: VA of 20/32 to 20/200 due to either cataract, diabetic macular edema, or age-related macular degeneration
2963189|NCT02810652|Experimental|Perioperative Geriatrics Intervention|Evaluation with a board-certified geriatric clinician, both pre- and post-operatively.
2963190|NCT02810652|Active Comparator|Standard Care|Usual care participants will not meet with a geriatric clinician perioperatively, but may receive a geriatric consult upon request or at the discretion of their treating clinician(s).
2963191|NCT02810626|No Intervention|Control|Control Group (surgical standard of care): Subjects 18 years and younger diagnosed with a pediatric brain tumor, and who are eligible for surgical treatment will be recruited. All subjects will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol. Surgery will be carried out according to usual standard of care, without the use of processing for DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative quality of life assessments, functional testing and clinical outcome tests will be conducted at this post-operative period (6-months).
2963192|NCT02810626|Other|Interventional|Interventional Group (involvement of all BrightMatter™ products): Subjects 18 years and younger diagnosed with a pediatric brain tumor and who are eligible for surgical treatment will be recruited. All subjects will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol and will be sent to the interventional technology (BrightMatter Bridge) for quality control. The QC'ed images will then be sent to a pre-operating planning software (BrightMatter Plan) for planning the surgical approach. Surgery will be carried out with guidance from the exported plan and the intra-operative neuro-navigation software, BrightMatter Guide, with the use of post-processing DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative quality of life assessments, functional testing and clinical outcome tests will be conducted at this post-operative period (6-months).
2963193|NCT02810587||Topical antibiotics group|Those who receive topical antibiotics after intravitreous injection as home medication for 7 days.
2963194|NCT02810587||No topical antibiotics group|Those who does NOT receive topical antibiotics after intravitreous injection as home medication.
2963195|NCT02810574|Active Comparator|Active noninvasive brain stimulation and cognitive training|In active condition, subject will receive stimulation during all the 30-minute stimulation period combined with cognitive training.
2963196|NCT02810574|Sham Comparator|Sham noninvasive brain stimulation|In sham condition, subject will receive stimulation only during the first 30 seconds of the 30-minute stimulation period combined with cognitive training.
2963197|NCT02810548|Placebo Comparator|OFD alone|Control group: including 15 defects that will receive open flap debridement (OFD).
2963198|NCT02810548|Active Comparator|PRF + OFD|Test group (1): including 15 defects that will receive platelet rich fibrin (PRF) with open flap debridement (OFD).
2963199|NCT02810548|Active Comparator|Bone + OFD|Test group (2): including 15 defects that will receive nanohydroxyapatite bone graft with open flap debridement OFD).
2963200|NCT02810548|Active Comparator|PRF + Bone + OFD|Test group (3): including 15 defects that will receive nanohydroxyapatite bone graft with platelet rich fibrin (PRF) after open flap debridement (OFD).
2963201|NCT02810535|Active Comparator|Allergic rhinitis|Clinical observation of 24 subjects with nasal symptoms and positive prick test for house dust mite
2963202|NCT02810535|Experimental|Non-allergic rhinitis|Clinical observation of 24 subjects with nasal symptoms and negative prick test for house dust mite
2963203|NCT02810535|Other|Healthy Control|Clinical observation of 20 subjects without nasal symptoms and with negative prick test
2963204|NCT02810509||Warfarin-initiated cohort|"Admission due to AF-related ischemic stroke~Initiation of warfarin therapy and treatment at least for more than 7 days of warfarin adjustment period~For Time in therapeutic range (TTR) calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment"
2963205|NCT02810509||Long term Warfarin-treated cohort|"Admission due to AF-related ischemic stroke~Long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period~For Time in TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment~TTR evaluable days ≥ 90 days"
2963206|NCT02810496|Experimental|patient|
2963207|NCT02810483|Experimental|Arm 1: Topiramate|Topiramate Arrow 50 mg hard capsules
2963208|NCT02810483|Placebo Comparator|Arm 2: Placebo Comparator|50 mg hard capsules with the same shape, color and taste than the active product
2963209|NCT02810470|Experimental|Cream appreciation tests|
2963210|NCT02810470|Experimental|Beverages appreciation tests|
2963211|NCT02810457|Experimental|FKB238 / paclitaxel / carboplatin|Drug: FKB238 15 mg/kg IV infusion on Day 1 of a 21-day cycle Drug: Paclitaxel 200 mg/m2 IV infusion on Day 1 of a 21-day cycle for each of at least 4 and no more than 6 cycles Drug: Carboplatin Area Under Curve (AUC) = 6.0 IV infusion on Day 1 of a 21-day cycle for each of at least 4 and no more than 6 cycles
2963212|NCT02810457|Active Comparator|Avastin / paclitaxel / carboplatin|Drug: Avastin 15 mg/kg IV infusion on Day 1 of a 21-day cycle Drug: Paclitaxel 200 mg/m2 IV infusion on Day 1 of a 21-day cycle for each of at least 4 and no more than 6 cycles Drug: Carboplatin AUC = 6.0 IV infusion on Day 1 of a 21-day cycle for each of at least 4 and no more than 6 cycles
2963213|NCT02810444|Experimental|BT595|Patients will receive BT595 according to their usual regime treatment every 3 or 4 weeks
2963214|NCT02810418|Experimental|Arm A1 (Phase 1, short infusion)|MTD determination in patients with pancreaticcancer receiving short infusion LMB-100+nabpaclitaxel
2963215|NCT02810418|Experimental|Arm B2 (continous infusion combination therapy)|Dose determination in patients with pancreatic cancer receiving contious infusion LMB-100 +nabpaclitaxel
2963216|NCT02810418|Experimental|Arm B1 (Continuous infusion single agent leadin)|MTD determination in patients with pancreatic cancer receiving contious infusion LMB-100 as single agent
2963217|NCT02810418|Experimental|Arm A2 (Phase 2, short infusion)|efficacy determination in patients with pancreatic cancer receiving short infusion LMB-100 + nabpaclitaxel
2963218|NCT02810405||Patient Samples|Patients treated at NCI with available tissue samples
2963219|NCT02810392|Active Comparator|Intranasal Insulin|Intranasal Insulin (20 IU BID): Humulin insulin packaged is in single-dose ampules and inserted into the VianaseTM chamber. Ampoules are dispensed in 3 week supplies per study visit. Patients/caregivers, investigators, and outcome assessors are masked to group assignment. Subjects will receive their first dose in clinic, and wait 2 hrs to determine any adverse effects of inhaled dose. Glucose levels will be measured to monitor for hypoglycemia and documented. All subjects will check peak dose blood sugar levels with glucometer, 3 times per week during insulin treatment.
2963220|NCT02810392|Placebo Comparator|Intranasal Saline|Intranasal saline: Saline is packaged in single-dose ampules and inserted into the VianaseTM chamber. Ampoules are dispensed in 3 week supplies per study visit. Patients/caregivers, investigators, and outcome assessors are masked to group assignment. Subjects will receive their first dose in clinic, and wait 2 hrs to determine any adverse effects of inhaled dose. Glucose levels will be measured to monitor for hypoglycemia and documented. All subjects will check peak dose blood sugar levels with glucometer, 3 times per week during insulin treatment.
2963221|NCT02810379|Placebo Comparator|written informed consent|participants read the written informed consent documents befor ERCP
2963222|NCT02810379|Experimental|video+written informed consent|participants watch a video about the ERCP and read the written informed consent documents before ERCP
2963223|NCT02810366|Active Comparator|Physician Coded Verbal Autopsy|"Of the approximately 12,500 VAs collected, 50% in each district will be randomly collected using the electronic Verbal Autopsy (eVA) instrument.~In addition to general information about the deceased (e.g. name, sex, age, etc.), this VA instrument contains a short checklist questionnaire to capture from the respondent the signs and symptoms noted during the final illness, followed by a free-text narrative.~Cause of death for these VAs will be assigned by trained physicians using the MDS physician coding system; this includes dual, independent coding of VA records, disagreements resolved by reconciliation, and remaining cases by adjudication by a third physician. The assignment of cause of deaths will be in line with the international classification of disease version 10 (ICD-10)."
2963224|NCT02810366|Experimental|Computer Coded Verbal Autopsy|"Of the approximately 12,500 VAs collected, 50% in each district will be randomly collected using the Extended Symptom List (ESL) VA instrument.~In addition to general information about the deceased (e.g. name, sex, age, etc.), this VA instrument contains a long checklist questionnaire to capture from the respondent the signs and symptoms noted during the final illness. This VA instrument does not contain a free-text narrative.~The cause of death for these VAs will be independently assigned by five leading computer-coding VA algorithms. The assignment of cause of deaths will be in line with 17 broad cause of death categories."
2963225|NCT02810353|Experimental|Expander with differential opening group|The experimental group will comprise 25 patients who will be submitted to rapid maxillary expansion using the expander with differential opening. The expander will be composed by two 11-mm screws, one anteriorly and the other posteriorly positioned on the palate (Great lakes Orthodontics Ltd, NY, EUA).
2963226|NCT02810353|Active Comparator|Hyrax group|The control group will be comprised by 25 patients who will undergo rapid maxillary expansion using the conventional Hyrax expander. The expander will be composed by one 11-mm screw centrally positioned on the palate (Dentaurum, Ispringen, Germany).
2963227|NCT02810340|Experimental|MCV-5 with adjuvant|MCV-5 adjuvanted with Alum administered as a single IM injection, each dose contains 5 micrograms of each of meningococcal polysaccharide A, C, Y, W, and X, along with 125 micrograms of Alum adjuvant
2963228|NCT02810340|Experimental|MCV-5 without adjuvant|MCV-5 without adjuvant administered as a single IM injection, each dose contains 5 micrograms of each of meningococcal polysaccharide A, C, Y, W, and X
2963229|NCT02810340|Active Comparator|Menactra|Menactra administered as a single IM injection, each dose contains 4 micrograms of each of meningococcal polysaccharide A, C, Y, and W
2963230|NCT02810327||MZ heterozygote with symptoms of COPD|Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort have symptoms or clinical diagnosis of COPD.
2963231|NCT02810327||MZ heterozygote without symptoms of COPD|Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort do not have symptoms or clinical diagnosis of COPD.
2963232|NCT02810314|Experimental|Clinical measures|MS patients recruited for this study will complete a resting state functional magnetic resonance image (rs-fMRI) session that will provide information on how DMN network works for each group and all MS patients will also complete a comprehensive neuropsychological battery including cognitive and behavioural tests of interest in MS
2963233|NCT02810314|Other|Control measures|Healthy participants recruited for this study will complete a resting state functional magnetic resonance image (rs-fMRI) session that will provide information on how DMN network works
2963234|NCT02810301|Experimental|Treatment (Probiotic ES1)|Capsules containing 1 billion CFU of B. longum ES1 per capsule. One capsule taken before and after consuming 2 slices of bread for 7 days.
2963235|NCT02810301|Placebo Comparator|Placebo|Capsules not containing the active ingredient B. longum ES1. One capsule taken before and after consuming 2 slices of bread for 7 days.
2963236|NCT02810288||Expert|Anaesthesiologist with large paediatric daily practice. All participant voluntarily response all items in the questionnaire database.
2963237|NCT02810288||Non-experts|Anaesthesiologist with little paediatric daily practice. All participant voluntarily response all items in the questionnaire database.
2963238|NCT02810275|Experimental|Folinic Acid|Folinic acid group received 5 mg daily during four weeks
2963239|NCT02810275|Placebo Comparator|Placebo|Placebo group received a tablet daily during four weeks
2963240|NCT02810262||First bone metastasis of adenocarcinoma lung cancer|Patients entering the group have a suspected first bone metastasis of adenocarcinoma lung cancer and should undergo bone biopsy to histologically prove the diagnosis.
2963241|NCT02810249||African American YMSM|
2963242|NCT02810236|Active Comparator|No ultrasound|No ultrasound recommended. Discussion with radiologist.
2963243|NCT02810236|Active Comparator|Ultrasound|Ultrasound recommended.
2963244|NCT02810223|Experimental|Single dose of CART-19|2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
2963245|NCT02810210||Cohort 1|Monitoring of children born without congenital anomalies to mothers with biologically confirmed ZIKV's infection during the pregnancy
2963246|NCT02810210||Cohort 2|Monitoring of children born with congenital anomalies to mothers with biologically confirmed ZIKV's infection during the pregnancy
2963247|NCT02810210||Cohort 3|Monitoring of children born without congenital anomalies to mothers with no biologically confirmed ZIKV's infection during the pregnancy
2963248|NCT02810197|Experimental|Exposed group|Psychopathological assessment Neuropsychological assessment Functional magnetic resonance imaging (fMRI)
2963249|NCT02810197|Experimental|unexposed group|Psychopathological assessment Neuropsychological assessment Functional magnetic resonance imaging (fMRI)
2963250|NCT02810184|Other|CBCT arm|all participating patients receive an additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
2963251|NCT02810171|Active Comparator|Cognitive Behavioral Therapy|
2963252|NCT02810171|Other|Relaxation Therapy|
2963253|NCT02810171|No Intervention|No Intervention: Healthy youth only|Healthy control adolescents matched to gender, race and socioeconomic status (SES) with child and adolescent patients with anxiety will be enrolled. These healthy adolescents will be scanned with fMRI before and after 12 weeks, but without any intervention (i.e., no therapy).
2963254|NCT02810158||Patients with suspected OSA|Persons with clinical suspicion of obstructive sleep apnoea syndrome (OSA)
2963255|NCT02810145||TBI with GCS <or= 8|Adult patients admitted to the surgical intensive care unit with traumatic brain injury and a Glasgow coma score less than or equal to 8.
2963256|NCT02810132|Active Comparator|Metformin|Drug: Metformin Target dose: 1000 mg x 2 (if eGFR 30-60 ml/min: 500 mg x 2) Other name: Glucophage XR 500
2963257|NCT02810132|Placebo Comparator|Placebo|Drug: Placebo
2963258|NCT02810119|Experimental|LO2A|Sodium Hyaluronate
2963259|NCT02810119|Placebo Comparator|Placebo-Controlled Saline|Placebo
2963260|NCT02810093||Breast cancer patients between 2000 and 2016|Patients treated for a breast cancer between 2000 and 2016 in the Hospital of Strasbourg (France).
2963261|NCT02810067|Active Comparator|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
2963262|NCT02810067|Experimental|Tunnel + Novomatrix|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (Novomatrix).
2963263|NCT02810054|Sham Comparator|Control Group (MIST without EMD)|Those participants who will receive the minimally invasive surgical techniques but without application Enamel Matrix Derivative (EMD) .
2963264|NCT02810054|Experimental|Test Group (MIST with EMD)|Those participant who will receive the minimally invasive surgical techniques with the application of Enamel Matrix Derivative (EMD) .
2963265|NCT02810041|Experimental|yoghurts enriched with XXS|
2963266|NCT02810041|Placebo Comparator|yoghurts non enriched with XXS|
2963267|NCT02810028|Experimental|ACT + Standard Medical Care (SMC)|This consists of 4 self-guided psycho-education modules supported by weekly telephone contact with a health professional trained in Acceptance and Commitment Therapy (ACT). Standard medical care will be provided as usual.
2963268|NCT02810028|No Intervention|Standard Medical Care (SMC)|All participants will receive SMC. As such, they will receive all the treatment and support they would otherwise receive outside of a research trial including a personalised assessment from the physiotherapist.
2963269|NCT02810015|Experimental|Botulinum Toxin A|BTX-A will be reconstituted as directed by the manufacturer. 2.5 mL of diluent (0.9% Saline) per 100 U vial will be used to reconstitute the solution while swirling. This creates a solution with a concentration of 4 U/0.1 mL. Patients will be seated and all usual precautions of sterility and skin preparation will be completed (i.e. alcohol wipes) Injections will be administered unilateral and/or bilaterally in accordance with the topography of the corresponding muscles (temporalis and masseter) into areas of maximal tenderness and pain. Plastic single use insulin syringes with 30 gauge needles will be used to inject 30 U intramuscularly into each masseter, divided evenly into 5 sites and 20 U will be injected into each temporalis, divided evenly over 5 sites. Injections will be completed by the principal investigator and supervisors who will be trained in botulinum toxin injections.
2963270|NCT02810002|Experimental|DEFINITE-REGULATOR|Training with DEFINITE-REGULATOR experiment infantry boots manufactured by Brill Industries, Rishon LeZion, Israel
2963271|NCT02810002|Active Comparator|modified Belleville 390 TROP|Standard issue infantry boot
2963272|NCT02809989||Ovaleap®|Single group prospective treatment cohort
2963273|NCT02809976|Experimental|Ruxolitinib 1.5% phosphate cream|Ruxolitinib 1.5% phosphate cream twice daily to vitiligo patches.
2963274|NCT02809963|Active Comparator|Eplerenone|Eplerenone 50 mg tablets. 2-4 tablets once daily for 26 weeks
2963275|NCT02809963|Placebo Comparator|placebo|sugar pill manufactured to mimic Eplerenone 50 mg tablet. 2-4 tablets once daily for 26 weeks.
2963276|NCT02809950|Experimental|oral carbohydrate beverage group|
2963277|NCT02809950|Placebo Comparator|control group|
2963278|NCT02809937|Experimental|dexmedetomidine group|For patients who were not intubated, dexmedetomidine was infused at a rate of 0.1 microgram/kg per hour from study recruitment on the day of surgery until 8:00 am on the first day after surgery. For patients who were intubated and mechanically ventilated, dexmedetomidine infusion was started after the Richmond Agitation Sedation Scale was -2 or higher after intensive care unit admission until 8:00 am on the first day after surgery.
2963279|NCT02809937|Placebo Comparator|placebo group|Normal saline was infused in the same rate for the same duration as that in the placebo group.
2963312|NCT02809651|Active Comparator|Intracranial hemorrhage|patients with intracranial hemorrhage diagnosed by clinical examination and CT-scan
2963280|NCT02809924|Experimental|Simulation-based just-in-time training|Viewing a short video showing the neonatal glottis of similar gestational age to the patient that is being intubated followed by practice on a mannequin (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada) with supervision and feedback from a senior provider (low fidelity simulation).
2963281|NCT02809924|Active Comparator|Video training|5 minutes video regarding endotracheal intubation
2963282|NCT02809911|Other|Sham of Provant|Sham of Provant Therapy System
2963283|NCT02809911|Other|Active Provant|Active Provant Treatment
2963284|NCT02809885|Experimental|Transplanted patients|All patients included are in the same arm.
2963285|NCT02809872||Study Group|Study Group with Pleural effusion for any cause and receiving chest CT scan and thoracic Ultrasounds.
2963286|NCT02809859|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
2963287|NCT02809846|Active Comparator|Quell Device|Quell is a class II medical device with FDA 510(k) clearance for the symptomatic relief and management of chronic intractable pain, without a prescription. It operates by using an electrical stimulator to activate peripheral sensory nerves and trigger analgesia.
2963288|NCT02809846|Sham Comparator|Sham Device|Identical to Active Comparator
2963289|NCT02809833||Tocilizumab for RA in Routine Practice|Participants from routine clinical practice in Germany who are receiving tocilizumab for RA according to SmPC are eligible.
2963290|NCT02809820|Active Comparator|Carvedilol|Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume carvedilol.
2963291|NCT02809820|Active Comparator|Metoprolol|Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume metoprolol.
2963292|NCT02809807|Experimental|Baseline|Without a gas mask. We measure baseline respiratory index, parameters and the comfort.
2963293|NCT02809807|Experimental|Assessment with gas mask and canister A|With a gas mask, the measurement have been done with a high resistive canister. We measure baseline respiratory index, parameters and the comfort. These would serve for conduction comparison with the baseline.
2963294|NCT02809807|Experimental|Assessment with gas mask and canister B|With a gas mask, the measurement have been done with a low resistive canister. We measure baseline respiratory index, parameters and the comfort. These would serve for conduction comparison with the baseline.
2963295|NCT02809794|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
2963296|NCT02809781|Experimental|Intravenous infusion of MSCs|Human bone marrow-derived MSCs at a dose of 1.0E+6 MSC/kg, receive infusion per week in the first 4 weeks and every two weeks in the second 8 weeks. total for 12 weeks.
2963297|NCT02809781|Active Comparator|Etanercept|50mg,hypodermic injection,once per week, for 12 weeks
2963298|NCT02809768|Experimental|Avatrombopag plus fluconazole|Part A: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, fluconazole (400-mg) will be administered once daily on Days 1 to 16, and a single dose of avatrombopag (20-mg) on Day 7 in Treatment Period 2. Each dose of avatrombopag will be administered under fed conditions 30 minutes after the start of a meal.
2963299|NCT02809768|Experimental|Avatrombopag plus itraconazole|Part B: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, itraconazole (200-mg) will be administered twice daily on Day 1 and 200-mg once daily on Days 2 to 16. A single dose of avatrombopag (20-mg) will be administered on Day 7 of Treatment Period 2. Each dose of avatrombopag will be administered under fed conditions 30 minutes after the start of a meal.
2963300|NCT02809768|Experimental|Avatrombopag plus rifampin|Part C: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, rifampin (600-mg) will be administered once daily on Days 1 to 16. In order to avoid a food-effect on rifampin absorption, each dose will be administered 1 hour before participants consume a meal. On Day 7 of Treatment Period 2, rifampin (600-mg) and avatrombopag (20-mg) will be administered 1 hour before meal and 30 minutes after starting meal consumption.
2963301|NCT02809755|Experimental|4% lidocaine|10 mL vials filled with 4% lidocaine or normal saline (50 vials of each solution) and pharmacist will code the vials from 1 to 100 using a computer-generated randomization scheme.
2963302|NCT02809755|Placebo Comparator|Placebo Saline|10 mL vials filled with 4% lidocaine or normal saline (50 vials of each solution) and pharmacist will code the vials from 1 to 100 using a computer-generated randomization scheme.
2963303|NCT02809742||Epidural group|Epidural : automatic intermittent boluses ( 8-12 mL per hour) + patient controlled bolus (4 mL evrey 20 min) using ropivacaine
2963304|NCT02809729|Placebo Comparator|placebo|The patients will receive 0.9% saline for intravenous bottle with 100ml looks identical to the antibiotic at the start of anesthetic induction
2963305|NCT02809729|Active Comparator|cefazolin|The patients will receive 2 g of cefazolin diluted in 0.9% saline by endovenous at the start of anesthetic induction
2963306|NCT02809716||Ancillary-Correlative (blood and tumor tissue collection)|Patients undergo collection of blood collection 1 week prior surgery, before and after surgery on the same day, and 1 week and 3 months after surgery. Patients also undergo and tissue collection during the surgery. Blood and tissue samples are processed for high definition single cell analysis including, whole-genome CNV profiles, protein expression, and cell morphology.
2963307|NCT02809690|Experimental|Diagnostic (18F-FMAU PET/CT)|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT on day 1. Patients then undergo standard of care multiparametic MRI and standard of care transrectal ultrasound-guided biopsy.
2963308|NCT02809677|Other|Non-Interventional Longitudinal Study|This is a 52 week non-placebo controlled and non-randomized clinical research study to see whether treating Major Depressive Disorder (MDD) in caregivers of children with asthma will improve asthma outcomes in children. Caregivers may choose to receive an antidepressant medication that is considered standard medical care for MDD, or may opt out of antidepressant treatment. No treatment is withheld from participants and no placebos are used, thus there is no active intervention in this study.
2963309|NCT02809651|Experimental|Ischemic stroke|patients suffering from ischemic stroke diagnosed by clinical examination and CT-scan
2963310|NCT02809651|Experimental|Brain tumor|patients diagnosed with a brain tumor diagnosed by clinical examination and CT-scan or MRI
2963311|NCT02809651|Experimental|Brain surgery|patients that have undergone brain surgery
2963313|NCT02809651|Experimental|Headache|patients with headache complaints and a normal CT-scan of the brain
2963314|NCT02809651|Experimental|Headtrauma|patients with head trauma and a normal CT-scan of the brain
2963315|NCT02809638||DVT of the lower limbs|patients with first suspected episode of unprovoked DVT of the lower limbs and patients with episode of unprovoked DVT of the lower limbs at third month of follow-up
2963316|NCT02809612|Experimental|Internet-based intervention|"Patients randomized to the internet-based intervention will be given access to the information in the internet-based platform directly after randomization. During the first 6 weeks, information will be offered in a structured way, with a theme changing weekly. After this time-point, the patients will have the possibility to navigate through all information. The platform encompasses internet-based training including information on the disorder, psycho-education and information of simple self-implemented intervention strategies cope with vulvodynia and ameliorate dyspareunia. The platform will also include videos where team members will describe their role in treating patients with the disorder, but also short videos from former patients willing to share their individual stories."
2963317|NCT02809612|No Intervention|Control group|Patients randomized to the control group through the platform will immediately be informed about the fact that there is available information and resources on the internet and that they will be called for a visit to the physiotherapist-midwife at due time, according to the present guidelines of care followed in the respective clinic (Uppsala, Falun, Gävle).
2963318|NCT02809599|No Intervention|Pre-intervention|Patients in hospitals that have not received the intervention (DIZZTINCT) and that meet eligibility criteria will have their medical charts abstracted to assess BPPV processes at the ED Index visit. A random sample of these patients will be contacted by phone for a brief phone interview regarding their recent visit to the Emergency Department for dizziness.
2963319|NCT02809599|Experimental|Post-intervention|Patients in hospitals that have received the intervention (DIZZTINCT) and that meet eligibility criteria will have their medical charts abstracted to assess the main study outcome, behavior change in medical providers. A random sample of these patients will be contacted by phone for a brief phone interview regarding their recent visit to the Emergency Department for dizziness.
2963320|NCT02809586|Active Comparator|SMI + Incentives|A Social Media + Incentives (SMI + I) condition
2963321|NCT02809586|Active Comparator|SMI|A Social Media Intervention (SMI) condition
2963322|NCT02809586|No Intervention|Control|An Attention-Control E-News (CONTROL) condition
2963323|NCT02809573|Experimental|study drugs|Lead-in period is 4 days. Patients take a single dose of Chidamide tablet, then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle. Cyclophosphamide, adriacin and vincristine are given in intravenous infusion on Day 1. On Day 1 to 5, prednisone is given orally. Treatment cycles are repeated every 3 weeks .The combination therapy lasts for at most 6 cycles. Patients enter the single agent therapy if attained complete response after 6-cycle combination therapy. In this stage, patients take chidamide orally on Day 1, 4, 8 and 11 of each cycle.
2963324|NCT02809560|Experimental|Asthmatic children|Induced sputum method using hypertonic serum
2963325|NCT02809560|Sham Comparator|Control children|Induced sputum method using hypertonic serum
2963326|NCT02809547|Active Comparator|In Clinic monitoring|70 method comparison patients who represent a C-reactive protein (CRP) reference range and have retrievable study outcome measures will have a whole blood sample and DBSS taken at recruitment and at a routine six week review.
2963327|NCT02809547|Experimental|At Home monitoring|30 Prospective patients will provide (i) one whole blood sample and one set of dried blood spot samples (DBSS) at recruitment, (ii) a set of DBSS once a week for six weeks from recruitment, with a matched whole blood sample at six week appointment, (iii) two extra sets of DBSS to be taken during a flare and 24 hours after (iv) 6 prospective patients will have daily hand movement data collected for 5 minutes on each occasion using a provided data glove.
2963328|NCT02809534|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2963329|NCT02809521|Other|Activity Liking|Subjects will look at images of people doing different types of activities (e.g., walking, skiing, watching television) and rate their liking of the activity.
2963330|NCT02809508|Experimental|Oily fish|
2963331|NCT02809508|Experimental|Poultry (control)|
2963332|NCT02809495||Patients who will use the clinical application|
2963333|NCT02809495||Patients who do not make use of clinical application|
2963334|NCT02809482|Other|Eucaloric Feeding|
2963335|NCT02809482|Other|Overfeeding|
2963336|NCT02809469|Experimental|Dose reduction|Eligible patients with apixaban levels persistently above 170ng/mL on two occasions, 2 weeks apart, will undergo apixaban dose reduction.
2963337|NCT02809456|Experimental|Nicorandil|Beginning 4-6 weeks during radiation therapy, patients receive nicorandil is given during radiotherapy interval, 5mg each time, 3 times daily oral. Treatment repeats after completion of radiation therapy in the absence of disease progression or unacceptable toxicity.
2963338|NCT02809456|Active Comparator|observation|regular radiotherapy as our protocol
2963339|NCT02809443|Experimental|GLS-5700 at 1 mg|DNA/dose
2963340|NCT02809443|Experimental|GLS-5700 at 2 mg|DNA/dose
2963341|NCT02809430|Experimental|CPAP intervention|Participants will receive 3 nights of auto-CPAP in order to identify those with OSA using flow resistance detected by the device. After 3 nights, those without apparent OSA or with central apnea, and those who simply do not tolerate CPAP will be excluded from the study. An intensive CPAP adherence protocol (iCAP) will be initiated, including collaborative care with rehabilitation nurses, the study's sleep technologist and overnight respiratory therapists. After the run-in period, the sleep technologist will meet at least twice weekly with CPAP-tolerant participants during their rehabilitation stay for further OSA education and encouragement with a target adherence of 4 hours per night. Participants diagnosed with OSA by the device and tolerant will continue CPAP therapy during rehabilitation and at home for a treatment period of 3 months. Adherence will be downloaded remotely from participant's machines to encourage adherence to treatment and troubleshoot any problems with the device.
2963342|NCT02809417||LICORNE platform|
2963343|NCT02809417||Control|
2963411|NCT02809014|Experimental|Dentifrice F-Complex|Dentifrice experimental with fluoride (1100 ppm) all incorporated in tara gum.
2963344|NCT02809391|Active Comparator|Orthotic|Recruited participants will be asked to wear the customizable foot orthotic, from baseline testing to a follow-up at 6 weeks post-baseline. Outcome measures at 6 weeks will be compared to those at baseline.
2963345|NCT02809391|Active Comparator|Orthotic+Textured Top Cover|At 6 weeks post-baseline, participants will received a different orthotic which has a textured material used as its top cover. Testing at 6 weeks post-baseline will determine if acute changes occur as a result of wearing the orthotic with textured top cover. Testing at 12 weeks post-baseline will determine if long-term changes occur as a result of the orthotic with textured top cover.
2963346|NCT02809378|Experimental|Sevoflurane|anesthesia induction with pentothal sodium (4-5 mg/kg), maintenance with sevoflurane(1.6-2.5 vol%)
2963347|NCT02809378|Experimental|sevoflurane, remifentanil, and propofol|anesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%)
2963348|NCT02809378|Experimental|Sevoflurane, remifentanil, propofol, and palonosetron|anesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%), and palonosetron 75 ug administration prior to anesthesia induction.
2963349|NCT02809365|Other|Libre|FreeStyle Libre users: FreeStyle Libre Flash Glucose Monitoring System is an interstitial glucose monitoring system intended to be replacement for the capillary blood glucose measurement. The system contains several features that distinguish it from exiting sensor technology including no user calibration during 14 days of wear. The sensor is applied to the upper arm of the patient and the hand-held reader is used to scan the sensor to receive glucose result along with historic results with a 15 min frequency for up to 8 hours.
2963350|NCT02809365|Other|SMBG|Self monitoring blood glucose: patients in this arm will measure blood glucose with personal glucometer
2963351|NCT02809352||women tested positive for hrHPV|All women participating in START-HPV pilot program for cervical cancer screening and tested positive for hrHPV with the Hybrid Capture 2 test (Qiagen).
2963352|NCT02809339||Epithelial ovarian cancer|
2963353|NCT02809326|Experimental|17 week Trauma Management Therapy (TMT)|TMTconsists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions (14 sessions) are followed by Social and Emotional Regulation (SER) sessions conducted in small groups. Individual exposure therapy includes virtual reality to assist in augmenting exposure therapy. Group therapy includes anger management, social skills training, problem solving and behavioral activation for depression. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
2963354|NCT02809326|Experimental|3 week Trauma Management Therapy (TMT)|Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
2963355|NCT02809326|Active Comparator|17 week Exposure Therapy Control Arm|The Control Arm of the study contains 15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
2963356|NCT02809313|Experimental|Treatment Gingivitis with Probiotic|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral hygiene instruction) and adjunct probiotic containing one sachet Lactobacillus rhamnosus per day during 3 month
2963357|NCT02809313|Placebo Comparator|Treatment Gingivitis conventional|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral hygiene instruction) and adjunct placebo containing one sachet placebo (talc power) per day during 3 month
2963358|NCT02809300|Experimental|ankylosing spondylarthritis|
2963359|NCT02809287||study group|patients with left lateral position plus jackknife posture when perform laparoscopic hepatectomy
2963360|NCT02809274||Patients with PV, not newly diagnosed|"Patients with clinically overt PV treated with watchful waiting (with or without aspirin), Phlebotomy (PHL), Hydrea or any other treatment.~Influence of iron parameters on Patient-reported symptoms will be evaluated by questionnaires Blood serum samples will be taken for iron parameters analysis"
2963361|NCT02809274||Newly diagnosed patients with PV|"Patients with clinically overt PV, newly diagnosed, before any treatment and before phlebotomy initiation.~Influence of iron parameters on Patient-reported symptoms will be evaluated by questionnaires Blood serum samples will be taken for iron parameters analysis"
2963362|NCT02809261|Experimental|Perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% Dextrose (3cc) between proximal carpal tunnel and median nerve.
2963363|NCT02809261|Placebo Comparator|Perineural injection with normal saline|Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and median nerve.
2963364|NCT02809248|Active Comparator|coated stent|the patient get a coated coronary stent implantation (ZES - zotarolimus eluting stent)
2963365|NCT02809248|Active Comparator|uncoated stent|the patient get a uncoated coronary stent implantation (BMS - bare metal stent)
2963366|NCT02809235|Experimental|coconut oil|Subjects will be instructed to supplement their diet with 3 tablespoons of coconut oil daily for three weeks.
2963367|NCT02809222|Other|Patients with MDS at diagnosis|The intervention, specific to the study, is to take blood samples on patients with MDS at diagnosis. A quality of life questionnaire will also be used to monitor patients
2963368|NCT02809222|Other|Patients with MDS in treatment|The intervention, specific to the study, is to take blood samples on patients with MDS receiving treatment. A quality of life questionnaire will also be used to monitor patients
2963369|NCT02809222|Other|Healthy volunteers|The intervention, specific to the study, is to take blood samples on patients healthy volunteers.
2963437|NCT02808871|Placebo Comparator|Placebo|Placebo for 52 weeks
2963370|NCT02809196|Active Comparator|1: Tailored, friend and mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.~Friend and mother are invited to participate."
2963371|NCT02809196|Active Comparator|2: Standardized, friend and mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.~Friend and mother are invited to participate."
2963372|NCT02809196|Active Comparator|3:Tailored, friend and not mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.~Friend is invited to participate but not mother."
2963373|NCT02809196|Active Comparator|4: Standardized, friend and not mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.~Friend is invited to participate but not mother."
2963374|NCT02809196|Active Comparator|5:Tailored, mother and not friend|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.~Mother is invited to participate but not friend."
2963375|NCT02809196|Active Comparator|6: Standardized, mother and not friend|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.~Mother is invited to participate but not friend."
2963376|NCT02809196|Active Comparator|7:Tailored, not friend, not mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.~Neither friend nor mother is invited to participate."
2963377|NCT02809196|Active Comparator|8: Standardized, not friend, not mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.~Mother is invited to participate but not friend. Neither friend nor mother is invited to participate."
2963378|NCT02809196|Other|9: No SMS program|Control Group; no SMS-based educational program
2963379|NCT02809183|Placebo Comparator|Placebo-BID|Administered twice daily (BID) for 14 days
2963380|NCT02809183|Experimental|TRC101 (Dose 1-BID)|Administered twice daily (BID) for 14 days
2963381|NCT02809183|Experimental|TRC101 (Dose 2-BID)|Administered twice daily (BID) for 14 days
2963382|NCT02809183|Experimental|TRC101 (Dose 3-BID)|Administered twice daily (BID) for 14 days
2963383|NCT02809183|Experimental|TRC101 (Dose 2-QD)|Administered once daily (QD) for 14 days
2963384|NCT02809183|Placebo Comparator|Placebo-QD|Administered once daily (QD) for 14 days
2963385|NCT02809170|Active Comparator|Arginine|Endothelial function will be assessed before and after arginine supplementation
2963386|NCT02809170|Active Comparator|Citrulline|Endothelial function will be assessed before and after citrulline supplementation
2963387|NCT02809144|Other|Nerve block|One novel nerve block combination
2963388|NCT02809131|Experimental|Saline irrigation|Saline irrigation
2963389|NCT02809131|Active Comparator|Antibiotic irrigation and PO antibiotics|Antibacterial irrigant (polymyxinB/bacitracin) and postoperative oral antibiotics (cephalexin, clindamycin, or levofloxacin)
2963390|NCT02809118|Placebo Comparator|Placebo|Placebo gel for intratympanic use
2963391|NCT02809118|Experimental|AM-111 0.4 mg/ml|AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
2963392|NCT02809118|Experimental|AM-111 0.8 mg/ml|AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
2963393|NCT02809105|Experimental|Part I ASP0456|ASP0456 will be administered orally for 4 weeks.
2963394|NCT02809105|Placebo Comparator|Part I Placebo|Placebo will be administered orally for 4 weeks.
2963395|NCT02809105|Experimental|Part II ASP0456|ASP0456 will be administered orally.
2963396|NCT02809092|Experimental|NK Cells + Chemotherapy Starting|"Starting on Day -7, G-CSF daily by vein until post nadir of absolute neutrophil counts (ANC) are equal or over 1000. Day -6 to Day -2 Fludarabine administrated by vein at 30 mg/m^2. Four hours later Cytarabine administrated by vein at 2 g/m^2. Natural killer (NK) cell infusion Days 0 to 14 for 6 doses total. The first group of participants receive lowest dose level. Each new group receives a higher dose than the group before it, if no intolerable side effects were seen. This will continue for up to 6 dose levels or until the highest tolerable dose of NK cells is found. One (1) to 10 participants will be treated in each dose level.~NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema."
2963397|NCT02809079|Experimental|Mycophenolate mofetil plus prednisone|Mycophenolate mofetil 500mg Bid and prednisone 10mg Qd
2963398|NCT02809066|Experimental|Interventional group|8-week follow- up with dietary sufficient calcium intake
2963399|NCT02809066|No Intervention|Control group|8-week follow- up with no specific diet
2963400|NCT02809053|Experimental|SAIT101|
2963401|NCT02809053|Active Comparator|MabThera®|
2963402|NCT02809040||Hypertensive Heart Disease|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
2963403|NCT02809040||Volunteer subjects|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
2963404|NCT02809040||Diagnosed Hypertension|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
2963405|NCT02809027|Active Comparator|Ginger|Ginger capsule (500 mg), oral form, 2 capsules 3 time after meal for 3 days
2963406|NCT02809027|Sham Comparator|Placebo|Placebo capsule, oral form, 2 capsules 3 time after meal for 3 days
2963407|NCT02809014|Placebo Comparator|Placebo|Dentifrice without fluoride and tara gum.
2963408|NCT02809014|Active Comparator|Dentifrice standard|Dentifrice 1100 ppm sodium fluoride (NaF) without tara gum. Positive control
2963409|NCT02809014|Placebo Comparator|Dentifrice with tara gum|Dentifrice without fluoride but with hydrocolloid tara gum.
2963410|NCT02809014|Experimental|Dentifrice F-Complex + NaF|Dentifrice experimental with fluoride (1100 ppm) being half of fluoride incorporated in tara gum and other half freeform of NaF
2963412|NCT02809001|Experimental|Experimental: Fat grafting|Autologous fat graft transplantation subdermally to expanded skin.
2963413|NCT02809001|No Intervention|Control|Expansion was discontinued until the early signs of complication disappeared.
2963414|NCT02808988|Active Comparator|group A|periodontal phase 1 therapy consisted of scaling and root planning, bisphosphonate therapy (zoledronic acid), gingival crevicular fluid collection
2963415|NCT02808988|Active Comparator|group B|periodontal phase 1 therapy consisted of scaling and root planning, no bisphosphonate therapy,gingival crevicular fluid collection
2963416|NCT02808988|Active Comparator|group C|no periodontal phase 1 therapy, bisphosphonate therapy (zoledronic acid), gingival crevicular fluid collection
2963417|NCT02808988|Active Comparator|group D|no periodontal phase 1 therapy, no bisphosphonate therapy,gingival crevicular fluid collection
2963418|NCT02808975|Placebo Comparator|Placebo|Participants randomized to the placebo arm will receive placebo.
2963419|NCT02808975|Active Comparator|Adalimumab|Participants randomized to the adalimumab arm will receive active drug, adalimumab.
2963420|NCT02808949|Experimental|Age Groups|Dapivirine levels in breast milk will be measured in 16 participants. All participants will wear the Dapivirine Vaginal Ring for 14 consecutive days.
2963421|NCT02808936|Experimental|RIPC group|remote ischemic conditioning group with three cycles of ischemia (5 min) / reperfusion (5 min) of upper or lower limb available with automated RIPC machine using blood pressure cuff
2963422|NCT02808936|Sham Comparator|Control group|No remote ischemic conditioning, but blood pressure cuff applied to the upper or lower limb available
2963423|NCT02808923|Experimental|Foam rolling|"Participants in the foam rolling group will perform unilateral rolling of the hamstring musculature from ischial tuberosity to posterior knee in supine for 2 repetitions of 1 minute with 15 second rest between repetitions at a consistent cadence of 1 second superiorly and 1 second inferiorly. Subjects will be asked to adjust pressure as needed to maintain a consistent moderate pressure on the treatment area. Participants will use new and individually issued high density foam rollers that are 6 diameter x 36 length."
2963424|NCT02808923|Experimental|Static stretching|Participants in the static stretching group will perform sustained static hamstring stretching for 2 repetitions of 1 minute bouts for the same leg before switching sides using moderate pressure in supine against the wall. Subjects will rest for 15 seconds between repetitions and adjust distance from the wall to perceive moderate intensity.
2963425|NCT02808923|No Intervention|Control|The control group will perform their regular baseline activities without the addition of a specific lower extremity flexibility program. If the subjects are currently performing stretching of any mode at baseline, they will be allowed to continue with that activity.
2963426|NCT02808910|Experimental|Salt nudge|The following changes will be made in the cafeteria: Salt will be placed in a corner of the buffet, rather than on each dining table. Other spices, without sodium, will be provided on the table. A sign will be placed on the table that nudges participants to try the other spices. Food in the buffet that is high in salt will be labeled with a negative-appearing symbol, and food in the buffet that is low in salt will be labeled with a positive symbol.
2963427|NCT02808910|Experimental|Vegetable nudge|The following changes will be made in the cafeteria: Names of the vegetable dishes in the buffet will be made more attractive. Signs will be placed with reminders to eat more vegetables. Signs will be placed with a visual indication of the percentage of a meal that should consist of vegetables.
2963428|NCT02808910|Experimental|Portion size nudge|The following changes will be made in the cafeteria: Smaller plates will replace the regular plates. Verbal and visual nudges to reduce portion size will be given. Utensils for self-serving calorie-dense foods in the buffet will be smaller than normal.
2963429|NCT02808910|Experimental|Combined nudge|All three nudges are combined in this intervention.
2963430|NCT02808910|No Intervention|Control groups|No changes are made to the cafeteria, compared to the pre-study situation. One control group participates after each of the nudges to control for effects of time of the year.
2963431|NCT02808897|Active Comparator|Standard drainage|The control arm consist of consecutively enrolled cardiac surgery patients receiving < four (4) commercially available standard chest tubes.
2963432|NCT02808897|Experimental|Active Clearance Technology drainage|The test arm consists of consecutively enrolled cardiac surgery patients receiving < two (2) PleuraFlow® chest tubes with Active Clearance Technology® and < two (2) other commercially available standard chest tubes.
2963433|NCT02808884|Experimental|Circulating tumor DNA assay- First test - Negative result|Once the data is analyzed, participants with a negative result will be sent an email thanking them for their participation and informing them of the negative result.
2963434|NCT02808884|Experimental|Circulating tumor DNA assay - Second test- Negative result|Participants whose sample provided a positive result after first test, will be contacted immediately by telephone by an oncologist co-investigator and concurrently sent a letter by mail informing them of the result and asking them to return for a second blood draw. We expect that this communication will happen with about a month of the original blood draw. The letter will include contact information for the study team and the oncologist co-investigators, in case the participant has any questions or concerns at this stage. A requisition form will be sent with the letter. Two 10mL tubes of blood will be drawn at the blood collection visit, to allow repeat testing and confirmation that the mutation is present consistently. Once the data is analyzed, participants with a negative result will be sent an email thanking them for their participation and informing them of the negative result.
2963435|NCT02808884|Experimental|Circulating tumor DNA assay - Second test- Positive result|Participants with positive results after first test will be contacted by an oncologist and sent a letter informing them of the result. They will be ask to return for a second blood draw. The letter will include contact info of the study team and the oncologist co-investigators. A requisition form will be sent with the letter. Two 10mL tubes of blood will be drawn to allow repeat testing and confirmation that the mutation is consistently present. Participants whom additional blood sample yields a positive result for the same cancer mutations seen in the first blood draw, will be contacted by an oncologist to explain the results and next steps. This should happen within about a week of the second blood draw. Pending oncological evaluation of the participant and study results, a PET-CT scan with FDG agent, and possibly other tests will be requested. Unless exams suggest otherwise, the default follow-up will be a full body PET-CT.
2963436|NCT02808871|Experimental|Pirfenidone|Pirfenidone 2403 mg/d for 52 weeks
2963438|NCT02808845||microalbuminuria with eGFR≥60ml/min|microalbuminuria group with estimated glomerular filtration rate (eGFR) ≥60ml/min.
2963439|NCT02808845||normal-albuminuria group with eGFR≥60ml/min|normal-albuminuria group with estimated glomerular filtration rate (eGFR) ≥60ml/min.
2963440|NCT02808845||microalbuminuria group with eGFR<60ml/min|microalbuminuria group with estimated glomerular filtration rate (eGFR) <60ml/min.
2963441|NCT02808845||normal-albuminuria group with eGFR<60ml/min|normal-albuminuria group with estimated glomerular filtration rate (eGFR) <60ml/min.
2963442|NCT02808832|Experimental|Educational materials|5-minute video and information sheet with a list of suggested questions to ask the provider
2963443|NCT02808832|No Intervention|Usual care|Usual care
2963444|NCT02808819|Other|Benralizumab Arm A|Benralizumab administered subcutaneously every 4 weeks
2963445|NCT02808819|Other|Benralizumab Arm B|Benralizumab administered subcutaneously every 8 weeks
2963446|NCT02808806|Active Comparator|real-time audio-visual feedback|real-time audio-visual feedback to caregivers (i.e. both in- and outside the hospital) bringing the patient to the location where IVT/IAT is administered . The real time audio-visual feedback consists in information on the actual TSD for a particular patient and whether or not this exceeds pre-set median time delay. The feedback is provided by handhelds in the ambulance and by pre-set monitors on different locations in the participating hospitals.
2963447|NCT02808806|No Intervention|regular care|no real-time audio-visual feedback
2963448|NCT02808793|Experimental|AK002|IV dose of AK002
2963449|NCT02808780||Simponi-exposed cohort|Participants receiving Simponi at enrollment and are still receiving Simponi after participation in a therapeutic trial or participants scheduled to receive Simponi within 30 days after enrollment. Participants in this cohort may be receiving Simponi alone or in combination with thiopurines but must not be receiving other approved biologics or investigational agents at enrollment. Participants may have received other approved biologics or investigational agents prior to enrollment.
2963450|NCT02808780||comparator cohort|Participants currently receiving thiopurines, having received at least 12 consecutive weeks of therapy prior to registry entry. Participants must not be receiving approved biologic agents, including Simponi, or investigational agents at enrollment. These patients may have received biologics other than Simponi or investigational agents prior to enrollment.
2963451|NCT02808767|Experimental|Patients treated with Prasugrel|Prasugrel Loading dose: 60 mg Maintenance dose: 10 mg once-daily; patients >75 years of age or < 60 kg of weight receive a maintenance dose of 5 mg o.d.
2963452|NCT02808767|Experimental|Patients treated with ticagrelor|Ticagrelor Loading dose: 180 mg Maintenance dose: 90mg twice-daily
2963453|NCT02808754|No Intervention|Usual Care|Patients in the usual care arm will undergo CEA without RIPC.
2963454|NCT02808754|Experimental|Remote Ischemic Preconditioning|Patients in the RIPC arm will undergo CEA with RIPC.
2963455|NCT02808741|Experimental|F901318 SDD|Liquid formulation
2963456|NCT02808741|Experimental|F901318 IR|Solid formulation
2963457|NCT02808741|Experimental|F901318 IR Fasting|Fasting solid formulation
2963458|NCT02808741|Experimental|F901318 IR Fed|Fed solid formulation
2963459|NCT02808728|Active Comparator|Pain Cocktail with Ropivacaine|"patients given the standard intra-articular pain cocktail injection, consisting of ropivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 100cc preparation.~given in one single dose"
2963460|NCT02808728|Experimental|Pain Cocktail with Exparel|"patients given a similar intra-articular injection consisting of bupivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 80cc preparation as well as an injection of Exparel, 20cc of 1.3% Exparel, to total 100cc.~given in one single dose"
2963461|NCT02808702|Experimental|Cognitive-behavioral therapy|Twelve weekly sessions of individual cognitive-behavioral therapy
2963462|NCT02808689|Active Comparator|Asthma Center|"Use of Currently Accepted Asthma Care Guidelines:~Assessment and monitoring: the use of objective measures of lung function to assess severity of asthma and to monitor the course of therapy,~Control of factors contributing to symptom exacerbation: environmental control measures to avoid or eliminate factors that precipitate asthma symptoms or exacerbations,~Pharmacotherapy: comprehensive pharmacologic therapy for long-term management, and~Education for partnership in care: patient education that fosters a partnership among the patient, his/her family, and clinicians."
2963463|NCT02808689|Active Comparator|Asthma Center plus Functional Medicine|"All the factors in the Asthma Center Arm plus:~Address lifestyle factors such as nutrition and exercise that influence long-term health and chronic diseases. The intention is to reduce ongoing biologic imbalances from deficiencies in dietary oxidants/antioxidants via vitamin supplementation, hormonal imbalances through evaluation and management, and the need for medications with unwarranted side effects that compound the chronic medical conditions and adverse effects (e.g. excess use of antibiotics), and to systematically evaluate intolerances to certain foods and additives."
2963464|NCT02808676|Experimental|Exercises+CognitiveTraining+Vitamin D3|"Exercises will combine aerobic+resistance training. Cognitive training will be performed before exercise intervention and using using an ad-hoc software developed by us for tablets. Vitamin D3 (10000IU) will be provided orally three time per week for 20 weeks."
2963465|NCT02808676|Experimental|Exercises+CognitiveTraining+Placebo D3|"Exercises will combine aerobic+resistance training. Cognitive training will be performed before exercise intervention and using using an ad-hoc software developed by us for tablets. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks."
2963466|NCT02808676|Experimental|Exercises+Control CogTraining+Vitamin D3|Exercises will combine aerobic+resistance training. Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc.). Vitamin D3 (10000IU) will be provided orally three time per week for 20 weeks
2963467|NCT02808676|Experimental|Exercises+Control CogTraining+Placebo D3|Exercises will combine aerobic+resistance training.Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks.
2963468|NCT02808676|Placebo Comparator|Placebo exercise+Control Cog+Placebo D3|This will be the comparator arm with control/placebo activities.
2963469|NCT02808663|Experimental|Severe Alcoholic Hepatitis|
2963470|NCT02808650|Experimental|Treatment (prexasertib)|Patients receive prexasertib IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
2963471|NCT02808637|Experimental|Manual Pressure|
2963472|NCT02808637|Experimental|Rapid Injection without Aspiration|
2963473|NCT02808637|Experimental|Manual Pressure + Rapid Injection without Aspiration|
2963474|NCT02808637|Experimental|Control|
2963475|NCT02808624|Experimental|Treatment group|this arm will receive L-CARNOSINE PO (each patient will receive 1 tablet daily and each tablet contains 500 mg thus a total of 500 mg per day) together with their chemotherapy wich is oxaliplatin.
2963476|NCT02808624|No Intervention|Control group|This arm wont receive L-CARNOSINE, they will receive their chemotherapy (oxaliplatin) only.
2963477|NCT02808611|Active Comparator|Propranolol|Propranolol is a beta-blocker
2963478|NCT02808611|Placebo Comparator|Placebo|Placebo
2963479|NCT02808598|Experimental|Clinical Trials Education Program|Breast Cancer Clinical Trials Education program is offered to women in the experimental arm. This program was designed to promote increased clinical trials literacy among African American and Hispanic American women. Increased clinical trials knowledge and a better understanding of clinical trials is anticipated to create more positive attitudes, and perceptions about clinical trials among these two groups of women who are traditionally underrepresented in breast cancer clinical trials.
2963480|NCT02808598|Placebo Comparator|Neighborhood Watch Education Program|The Neighborhood Watch Program created by the Bureau of Justice Assistance and the National Crime Prevention Council was selected for inclusion in the control arm of this study. It provided participants with a program of equivalent length and format, as well as an equivalent focus on improving the well-being of African American and Hispanic Americans. It also provided an opportunity to evaluate the impact of the Neighborhood Watch Program.
2963481|NCT02808585|Experimental|PB1046 Injection|Four weekly doses of PB1046 Injection.
2963482|NCT02808585|Placebo Comparator|Placebo Injection|Four weekly doses of Placebo Injection.
2963483|NCT02808572|Experimental|Cardiovascular risk evaluation|Measurement at inclusion of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 3 year follow-up
2963484|NCT02808559|Experimental|Bodystudio ATBM|The PASI of the patients will be evaluated by two dermatologists then by the bodystudio ATBMs.
2963485|NCT02808546||Case Group|All the patients who were diagnosed as gallbladder stone disease with definite clinical symptoms and underwent cholecystectomy in Cheju Halla General Hospital, Jeju, Korea during 2009-2013
2963486|NCT02808546||Control Group|Control group was determined as 1:1 age-sex matched subjects selected from the participants without GBS among Health Promotion Center in the same institute and periods.
2963487|NCT02808533|Experimental|Topiramate|Topiramate will be dispensed on a biweekly basis, and pill counts conducted at each visit.
2963488|NCT02808533|Placebo Comparator|Placebo|Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
2963489|NCT02808520||Hodgkin-lymphoma|Children and adolescents aged 10-18 years
2963490|NCT02808507|Experimental|Facility-based screening|This strategy will be implemented at all clinics (n=28) within this arm for 18 months. Study staff will encourage providers at each of the clinics to screen all consenting patients attending the clinic, regardless of the original reason for clinic presentation. Upon presenting for care (e.g., while waiting for their healthcare provider), patients will be informed about the study and screened for cough of any duration, fever, weight loss, or night sweats. Participants who are symptomatic and provide a sputum specimen (according to the clinic standard of care) will be given a study flyer informing them that they may be contacted by study staff, and a brief summary of the study. Per standard of care, all sputum samples will be sent to the local National Health Laboratory Service laboratory for Xpert testing.
2963491|NCT02808507|Experimental|Contact screening|"This arm is comprised of two sub-arms:~In the household contact screening sub-arm, a mobile field team visits the household of each consenting newly diagnosed pulmonary TB index case. Each visit consists of a household census, consent of all eligible household members for TB screening, administration of a brief questionnaire, sputum collection for testing with Xpert Mycobacterium tuberculosis (MTB)/rifampin (RIF) and the offer of HIV testing.~In the incentive-based contact screening sub-arm, all consenting newly diagnosed active TB cases are provided with 10 coupons for free TB screening to give to close contacts. When a contact presents at clinic with a coupon, they and the index case each receive a small amount of money. If the contact is diagnosed with active TB and starts treatment, the index case receives an additional larger amount of money. Each contact receives a brief questionnaire, TB symptom screen, optional HIV testing, and sputum sample collection for Xpert MTB/RIF."
2963492|NCT02808494||Affected Group|Women with a diagnosis of preeclampsia or fetal growth restriction.
2963493|NCT02808494||Control/Unaffected Group|Women who do not have a diagnosis of preeclampsia or fetal growth restriction.
2963494|NCT02808468|Active Comparator|Brief Cognitive Intervention|One in person session (90 minutes) of trauma focused cognitive therapy followed by 4 weekly coaching calls (20 minutes each) with the same study therapist
2963495|NCT02808468|No Intervention|Assessment Only|Assessment session followed by weekly completion of assessment measures
2963496|NCT02808455|Experimental|Sequence I: A/B|Treatment A: pacritinib 400 mg capsule
2963497|NCT02808455|Experimental|Sequence II: B/A|Treatment B: pacritinib 80 mg solution
2963498|NCT02808442|Experimental|UCART19|
2963499|NCT02808429|Experimental|Part A: Atacicept 25 mg|
2963500|NCT02808429|Experimental|Part A: Atacicept 75 mg|
2963501|NCT02808429|Placebo Comparator|Part A: Placebo|
2963502|NCT02808429|Experimental|Part B: Atacicept 25 mg|
2963503|NCT02808429|Experimental|Part B: Atacicept 75 mg|
2963504|NCT02808429|Experimental|Part B: Atacicept 150 mg|
2963505|NCT02808429|Placebo Comparator|Part B: Placebo|
2963506|NCT02808416|Experimental|Personalized cellular vaccine|Patients will undergo tumor resection or biopsy, and receive a total of 12 cellular vaccines consisting of autologous tumor cells, autologous DCs or allogeneic PBMCs.
2963507|NCT02808403||Evolocumab exposed|Patients for whom evolocumab is prescribed. Dosage, period (start/end date), frequency of injection (Every 2 weeks (Q2W), Every 4 weeks (Q4W)), drug withdrawal (Yes or No, date, reason) and injection site (upper arm, abdomen, thigh) of evolocumab will be collected.
2963508|NCT02808390|Experimental|80 mg BID|GED-0507-34-Levo 80 mg BID for 8 Weeks
2963509|NCT02808390|Experimental|160 mg BID|GED-0507-34-Levo 160 mg BID for 8 Weeks
2963510|NCT02808390|Experimental|Placebo|Placebo BID for 8 Weeks
2963511|NCT02808377|Active Comparator|SPOP|This arm will have the soft silicone pessary inserted post operatively and it will remain in-situ for 3 weeks.
2963512|NCT02808377|No Intervention|Non Intervention|Routine post operative care
2963513|NCT02808364|Experimental|Personalized cellular vaccine|Subjects will undergo tumor resection. They will receive a total of 12 cellular vaccines consisting of autologous tumor cells, autologous DCs and allogeneic PBMCs.
2963514|NCT02808351|Experimental|Berberine|Preoperative berberine 300 mg administration for at least 6 hours before interventional procedure, post-procedure berberine administration 100 mg at 24, 48 hours after procedure.
2963515|NCT02808351|No Intervention|Blank control|Blank control of berberine administration
2963516|NCT02808325|Experimental|balanced gelatine solution|isotonic colloidal volume substitute
2963517|NCT02808325|Active Comparator|non-balanced gelatine solution|colloidal volume substitute
2963518|NCT02808312|Experimental|Mild Hepatic Impairment (Cohort 1)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of GS-9674 (30 mg) on Day 1.
2963519|NCT02808312|Experimental|Moderate Hepatic Impairment (Cohort 2)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of GS-9674 (30 mg) on Day 1.
2963520|NCT02808312|Experimental|Severe Hepatic Impairment (Cohort 3)|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of GS-9674 (10 mg) on Day 1.
2963521|NCT02808299||all the antigen and antibody of HBV are negative|Hepatitis B Virus surface antigen (HBsAg), Hepatitis B Virus surface antibody (HBsAb), Hepatitis B Virus e antigen (HBeAg), Hepatitis B Virus e antibody (HBeAb), Hepatitis B Virus core antibody (HBcAb) are all negative.
2963522|NCT02808299||HBV infection history|One or more of HBsAb,HBeAb, HBcAb are positive, while HBsAg and HBeAg are negative. If only HBsAb is positive, the history of HBV vaccination need to be excluded.
2963523|NCT02808299||HBV carriers|One or two of HBsAg and HBeAg are positive, accompanied by any HBV antibody is positive or not.
2963524|NCT02808286|Experimental|Hybrid|"The hybrid emotion-focused treatment consists of 10-15 individual 1/1,5 hour sessions. It includes the following stages (examples of methods in parathesis)~Stage I. Analysis of emotions and pain (Validation, Compassion, Chain analysis, Values & goals).~Stage II. Developing skills (Dialectics, Self-validation, Self-compassion, emotion regulation skills).~Stage III. Exposure training (Exposure for emotionally sensitive stimuli, exposure in vivo for avoided movements).~Stage IV. Maintenance (Identifying key elements, Planning for flare-ups)."
2963525|NCT02808286|Active Comparator|internet Cognitive Behavior Therapy (iCBT)|CBT pain treatment, delivered via the internet consists of 8, weekly, modules and includes topics such as pain education, pain coping strategies (e.g. pacing), relaxation, cognitive restructuring, problem solving, stress and sleep management, conflict resolution. Patients read materials included in each module and do homework tasks on which they report back to the therapist via the internet. The therapist gives written feedback and guidance after each module. See reference for details.
2963526|NCT02808273||Retrospective control|Patients who had received enoxaparine as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
2963527|NCT02808273||Prospective Cohort|Patients who will receive bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
2963528|NCT02808247|Experimental|Experimental arm (arm A): Nintedanib|Nintedanib 200 mg twice daily orally. Nintedanib will be given continuously until clinically relevant disease progression according to the investigator's assessment or until other criteria for treatment discontinuation are met as specified in the protocol. Dosing beyond RECIST 1.1 progression is allowed for the oral agent if the patient still derives benefit from the treatment.
2963529|NCT02808247|Active Comparator|Standard arm (arm B): Ifosfamide|Ifosfamide 3 g/m2 intravenously on days 1, 2 and 3 every 21 days for up to a maximum of 6 cycles.
2963530|NCT02808234|Other|Nucel treatment group|One or two level lumbar interbody fusion surgery with Nucel
2963531|NCT02808208|Experimental|Group 1 AMSC Treatment|Patients have tissue biopsy and Adipose Derived Mesenchymal Stem Cells (AMSC) treatment.
2963532|NCT02808208|No Intervention|Group 2 No Treatment|Patients receive standard of care.
2963533|NCT02808195|Experimental|constraint-induced therapy|training of the more affected arm and restraint the less affected arm
2963534|NCT02808195|Experimental|kinect-based constraint-induced therapy|training of the more affected arm and restraint the less affected arm by kinect-game
2963535|NCT02808182|Other|A0: PET/scan with [11C] palmitate|A bolus of 180 MBq of [11C]-acetate at time 90min and PET acquisition
2963536|NCT02808182|Other|A1: PET/scan with [11C] palmitate|A bolus injection of 180 MBq of [11C]-acetate at time 90min, followed by PET acquisition
2963537|NCT02808182|Other|B0: PET/scan with [18F]-FTHA|At time 0, a standard liquid meal will be drunk over 20 minutes with 70 MBq of 18FTHA . PET acquisition at time 90 min.
2963538|NCT02808182|Other|B1: PET/scan with [18F]-FTHA|At time 0, a standard liquid meal will be drunk over 20 minutes with 70 MBq of 18FTHA followed by a PET acquisition at time 90 min.
2963539|NCT02808156|Experimental|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
2963540|NCT02808156|Experimental|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
2963567|NCT02807961|Active Comparator|Active treatment|ELX-02, active comparator
2963568|NCT02807948|Other|Pacemaker, ICD, or CRT device patients|Subjects who need a non-thoracic clinically indicated scan
2963639|NCT02807532||atrial fibrillation group|In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.
2963640|NCT02807532||non-atrial fibrillation group|Patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
2963541|NCT02808143|Experimental|Treatment (pembrolizumab, BCG solution)|"PRE-INDUCTION PHASE: Patients receive pembrolizumab intravesically once on day -14.~INDUCTION PHASE: Patients receive BCG solution intravesically once weekly for 6 weeks at weeks 0-5 and pembrolizumab intravesically every 2 weeks at weeks 0, 2, and 4.~MAINTENANCE PHASE: Beginning 2 weeks after the last dose of BCG solution, patients receive pembrolizumab intravesically every 2 weeks for 12 weeks at weeks 7, 9, 11, 13, 15, and 17 for a total of 6 doses. Patients then receive pembrolizumab intravesically every 4 weeks at weeks 21, 25, 29, 33, 37, 41, 45, and 49 for a total of 8 doses."
2963542|NCT02808130||group H|"Group H: normolipidemic+ periodontally healthy individuals The healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
2963543|NCT02808130||Group G|"Group G: normolipidemic + gingivitis individuals the healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
2963544|NCT02808130||Group CP|"Group CP: normolipidemic + generalized chronic periodontitis individuals the healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
2963545|NCT02808130||Group HH|"Group HH: hyperlipidemic + periodontally healthy individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
2963546|NCT02808130||Group HG|"Group HG: hyperlipidemic + gingivitis individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
2963547|NCT02808130||group HCP|"Group HCP: hyperlipidemic + generalized chronic periodontitis individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
2963548|NCT02808117||Targeted initially|Children who were in the Haiti villages and targeted by the MFI program with MNP delivery initially.
2963549|NCT02808117||Targeted later|Children who were in the Haiti villages and not targeted by the MFI program with MNP delivery until later.
2963550|NCT02808104|Experimental|Mazindol Controlled Release|Mazindol controlled release taken once daily. Dosage starting at 1 mg increasing or decreasing in increments of 1 mg depending on efficacy and tolerability. Maximum dose during the study is 3 mg taken once daily.
2963551|NCT02808104|Placebo Comparator|Placebo|Matching placebo
2963552|NCT02808091|Experimental|Early stage (IB or bulky disease - II)|who will receive GIFOX-B chemotherapy followed by involved field radiotherapy.
2963553|NCT02808091|Experimental|Advanced stage (III - IV)|will receive only chemotherapy alone
2963554|NCT02808078|Experimental|Augmented reality training|Gait training with augmented reality
2963555|NCT02808078|Active Comparator|Standard training|Gait training without augmented reality
2963556|NCT02808065||Tacrolimus + Mycophenolate mofetil|
2963557|NCT02808052|Experimental|Minocin (minocycline) for Injection|Minocin (minocycline) for Injection will be supplied as a sterile lyophilized powder in single-use 10-mL glass vials. Each vial contains 108 mg of minocycline hydrochloride equivalent to 100 mg of minocycline. Each cohort receives a single 200-mg dose of Minocin (minocycline) for Injection except for the hemodialysis therapy/end stage renal disease cohort, which receives two 200-mg doses.
2963558|NCT02808039||DAPT patients|Patients planned for cessation of DAPT regimen containing Ticagrelor after 12 months of treatment following coronary stent implantation . the platelet reactivity will be assessed 1 week prior to cessation of DAPT and than at 1,3,and 12 weeks post DAPT cessation.
2963559|NCT02808026|Experimental|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast for 8 weeks
2963560|NCT02808013|Experimental|NDS-446|NDS-446
2963561|NCT02808013|Placebo Comparator|Placebo|Placebo
2963562|NCT02808000|Active Comparator|Group 1 (also called Group A )|Group 1/A will use standard catheter during the first ~6 months (observational period 1). Then the patients in this group will switch to the noble metal alloy urinary catheter (BIP Foley catheter of latex or silicone produced by Bactiguard AB) and be observed for another ~6 months (the second observational period).
2963563|NCT02808000|Experimental|Group 2 (also called Group B)|Group 2/B will use the BIP Foley (latex or silicone) during the first ~6 months (observational period 1). Then the patients in this group will switch to the standard catheter and be observed for another ~6 months (the second observational period).
2963564|NCT02807987|Experimental|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally, once daily after breakfast for 12 weeks
2963565|NCT02807974|Experimental|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally, once daily after breakfast for 12 weeks
2963566|NCT02807961|Placebo Comparator|Placebo|Placebo comparator arm
2963569|NCT02807935|Other|OCT imaging of surgical/pharmacological/laser branch|"to evaluate the effect on the conventional outflow pathway, and specifically on the Schlemm's canal (SC) anatomy in the surgical branch:~Before and after trabeculotomy~Before and after cataract surgery~Before and after vitrectomy surgery~Before and after XEN™ Gel Stent implant~pharmacological branch-~Before and during the treatment with prostaglandins analogs~Before and during the treatment with alpha blockers~Before and during the treatment with beta blockers~Before and during the treatment with carbonic anhydrase inhibitor~laser branch-~Before and after trabeculoplasty~Before and after laser iridotomy~Before and after yag capsulotomy laser"
2963570|NCT02807922|Active Comparator|Zopiclone|Zopiclone six nights
2963571|NCT02807922|Placebo Comparator|Placebo|Placebo six nights
2963572|NCT02807909|Experimental|BMS-986177 and Itraconazole|Single dose BMS-986177 on day 1 followed by Itraconazole and BMS-986177 on specified days
2963573|NCT02807909|Experimental|BMS-986177 and Diltiazem|Single dose BMS-986177 on day 1 followed by Diltiazem ER and BMS-986177 on specified days
2963574|NCT02807896||pancreatic cancer|pancreatic cancer 88
2963575|NCT02807896||bile duct cancer|bile duct cancer 101
2963576|NCT02807896||stomach cancer|stomach cancer 9
2963577|NCT02807896||colon cancer|colon cancer 5
2963578|NCT02807896||normal group|normal group 29
2963579|NCT02807883|Experimental|Blinatumomab|Blinatumomab as continuous intravenous infusion at dose of 28 µg/24 hours over 4 weeks followed by 2 week treatment-free period for 6-week treatment cycle; 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
2963580|NCT02807870|Experimental|Methylphenidate and psychoeducational groups|Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments) and weekly psychoeducational groups for parents during 8 weeks.
2963581|NCT02807870|Experimental|Parental training and placebo medication|Weekly parental training conducted by behavioral psychologists and placebo pill during 8 weeks.
2963582|NCT02807870|Placebo Comparator|Psychoeducational groups and placebo medication|Weekly psychoeducational groups for parents and placebo pill during 8 weeks.
2963583|NCT02807857|Other|Patients' heart failure and non-heart failure|No treatments are stipulated by this protocol - patients' HF and non-HF treatments will be observed throughout the study. The patients' treatment is entirely in the discretion of the primary care physicians
2963584|NCT02807844|Experimental|Pancreatic cancer|
2963585|NCT02807844|Experimental|Triple Negative Breast cancer|
2963586|NCT02807844|Experimental|Endometrial Carcinoma|
2963587|NCT02807844|Experimental|Melanoma|
2963588|NCT02807831|Experimental|Executive functions training|
2963589|NCT02807831|Experimental|Language skills training|
2963590|NCT02807831|Active Comparator|Regular school curriculum|
2963591|NCT02807818|Experimental|Nurse home visits|Nurse biweekly home visit.
2963592|NCT02807818|No Intervention|Usual care|Usual care.
2963593|NCT02807805|Experimental|Treatment (abiraterone acetate, niclosamide, prednisone)|Patients receive abiraterone acetate PO QD, niclosamide PO BID and prednisone PO BID. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
2963594|NCT02807792|Experimental|Perianal access device|
2963595|NCT02807779|Experimental|Dexamethasone|Patients randomized to the Dexamethasone group will receive dexamethasone infusion to the adventitia of the artery following plain-old-balloon-angioplasty (POBA).
2963596|NCT02807779|Active Comparator|Drug Coated Balloon|Patients randomized to the Drug Coated Balloon (DCB) group will not receive dexamethasone infusion to the adventitia of the artery following (POBA). They will receive additional angioplasty with a paclitaxel coated balloon.
2963597|NCT02807766|Experimental|Sensory Integration Training|Behavior modification and Sensory Integration Training
2963598|NCT02807766|Experimental|applied behavioral analysis|Behavior modification and applied behavioral analysis.
2963599|NCT02807766|Experimental|TEACCH|Behavior modification and TEACCH.
2963600|NCT02807766|Other|Behavior modification|Behavior modification.
2963601|NCT02807766|No Intervention|healthy control group|No intervention.
2963602|NCT02807753||Severe Hemophilia A or B|"Medical history, physical exam, vital signs,physical therapist targeted exam and ultrasound joint assessment (ankles and knees) every 6 months.~MRI joint assessment (knees and ankles) at End of Trial Visit (Month 60)."
2963603|NCT02807753||Mild/Moderate Hemophilia A or B|"Medical history, physical exam, vital signs,physical therapist targeted exam and ultrasound joint assessment (ankles and knees) every year.~MRI joint assessment (knees and ankles) at End of Trial Visit (Month 60)."
2963604|NCT02807740|Experimental|Virtual Reality|Patients will be treated with a virtual reality rehabilitation program
2963605|NCT02807740|Other|Conventional Rehabilitation Program|Patients will be treated with a conventional rehabilitation program.
2963606|NCT02807727|Active Comparator|Intralipid 20%|Intravenous single bolus of 1.5 ml/kg of Intralipid 20% over 3 minutes.
2963607|NCT02807727|Placebo Comparator|Modified Ringers Lactate|Intravenous single bolus of 1.5 ml/kg of MRL over 3 minutes.
2963608|NCT02807714||No CAD|Patients scheduled for elective cardiac catheterization for evaluation of suspected CAD that are found to not have CAD
2963609|NCT02807714||Obstructive CAD (non-ACS) Group|Patients scheduled for elective cardiac catheterization for evaluation of known or suspected CAD that are found to have obstructive CAD requiring intervention.
2963610|NCT02807714||Stable CAD, no intervention required|Patients scheduled for elective cardiac catheterization for evaluation of known or suspected CAD that are found to have non-obstructive CAD not requiring intervention.
2963611|NCT02807714||Acute Coronary Syndrome (ACS)|Patients who undergo an emergent cardiac catheterization for evaluation of known or suspected STEMI, NSTEMI, Unstable Angina (UA).
2963612|NCT02807701|Active Comparator|Laparoscopic pancreaticoduodenectomy|"Laparoscopic pancreaticoduodenectomy Under general anesthesia, the patient is placed in a supine position with the legs abducted. Carbon dioxide pneumoperitoneum is established using an open technique through a 10-mm trocar over the umbilicus. A 30 telescope is inserted to examine the peritoneal cavity, liver, stomach, and mesentric vessels.Then 4 to 6 more trocars are inserted under direct vision in the epigastrium and upper quadrants~dissection~reconstruction"
2963878|NCT02805920|Active Comparator|GROUP 3 : G30|Postoperative pain for ACLR : G30 received ACB with 30 ml 0.25% Bupivacaine
2963613|NCT02807701|Active Comparator|Open pancreaticoduodenectomy|"Open pancreaticoduodenectomy Abdomen is opened from the Bilateral Subcostal incision. (Chevron's Incision) 2. Abdominal cavity is explored for metastasis especially in liver, base of mesentary, mesocolon and pelvis.~Dissection Reconstruction Pancreaticogastrostomy Hepaticojejunostomy is next- Done in single layer and can be performed in interrupted or continuous fashion.~Gastrojejunostomy is the final step of reconstruction."
2963614|NCT02807688|Experimental|Intervention|"Health Promotion Intervention package including elements of psychoeducation on healthy lifestyles and practical sessions of physical activity, with the use of motivational techniques."
2963615|NCT02807688|No Intervention|Control|Control subjects receive treatment as usual at the Community Mental Health Services of the Department of Mental Health.
2963616|NCT02807675|Experimental|CVT-301, levodopa inhalation powder (LIP)|designed to deliver l-dopa to the lung using the CVT-301 inhaler.
2963617|NCT02807675|Placebo Comparator|Placebo|Administered in the same way as the investigational product, except that it does not contain l-dopa.
2963618|NCT02807662|Experimental|Experimental|Intervention mothers receive adapted Seeking Safety intervention delivered by prenatal care advocate over 8 sessions
2963619|NCT02807662|No Intervention|No intervention|Treatment as usual mothers receive usual services of a prenatal care advocate
2963620|NCT02807649|Placebo Comparator|Placebo|Placebo: Methyl cellulose and dextrose
2963621|NCT02807649|Active Comparator|Low dose|This blend contains Ginko at 120 mg/day and Cistanche at 300 mg/day
2963622|NCT02807649|Active Comparator|High dose|This blend contains Ginko at 180 mg/day and Cistanche at 450 mg/day
2963623|NCT02807636|Experimental|Atezolizumab+Gemcitabine+Carboplatin/Cisplatin|Participants will receive blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
2963624|NCT02807636|Placebo Comparator|Placebo+Gemcitabine+Carboplatin/Cisplatin|Participants will receive blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
2963625|NCT02807636|Experimental|Atezolizumab Monotherapy|Eligible participants will receive open-label atezolizumab as monotherapy.
2963626|NCT02807623|Experimental|Ibuprofen|Randomized and double blinded study participants assigned to Group A intervention will receive an oral NSAID of ibuprofen 800 mgs three times a day for 48 hours.
2963627|NCT02807623|Placebo Comparator|Placebo|Randomized and double blinded study participants assigned to Group B intervention will receive an oral placebo three times a day for 48 hours starting immediately after influenza vaccine receipt.
2963628|NCT02807623|Experimental|Compound Exercise of Pushups|Randomized study participants assigned to Group C will perform an exercise intervention of pushups immediately after influenza vaccine receipt.
2963629|NCT02807610|Experimental|IV Propofol and IV Etomidate lipuro|After premedication with IV midazolam 0.2mg kg-1, IV Fentanyl 2ug kg-1, Group P Patients received IV Propofol 2mg kg-1 slowly over 60 seconds till Entropy of 40 as a comparator agent in patients undergoing Medical termination of pregnancy(MTP) and Group ' E' Patients received IV Etomidate Lipuro 0.3mg kg-1 slowly over 60 seconds till Entropy of 40 as intervention agent in patients undergoing MTP
2963630|NCT02807610|Active Comparator|IV Etomidate Lipuro and Placebo|After premedication with IV midazolam 0.2mg kg-1, IV Fentanyl 2ug kg-1, Group ' E' Patients received IV Etomidate Lipuro 0.3mg kg-1 slowly over 60 seconds till Entropy of 40 as intervention agent in patients undergoing MTP and placebo group received normal saline
2963631|NCT02807597|Experimental|Arm 1: LS301 Dose Escalation|"Patient will undergo intravenous injection of the appropriate cohort dose of LS301 at least four hours before surgery (24 hours is the preferred time point wherever possible)~Starting dose level will be 100 µg/kg, dose level 2 will be 150 µg/kg, and dose level -1 will be 50 µg/kg~Before removing the tissues, the surgeon will determine the presence of NIR fluorescence in the tumor or SLN.~After removing the tumor tissue, the CVG will be used to assess LS301 fluorescence in the surgical margins, as well as the cavity where the tumor was removed."
2963632|NCT02807597|Experimental|Arm 2: LS301 Dose Expansion|"Patient will undergo intravenous injection of the appropriate cohort dose of LS301 at least four hours before surgery (24 hours is the preferred time point wherever possible)~Dose of LS301 will be based on the maximum tolerated dose found in the Dose Escalation arm~Before removing the tissues, the surgeon will determine the presence of NIR fluorescence in the tumor or SLN.~After removing the tumor tissue, the CVG will be used to assess LS301 fluorescence in the surgical margins, as well as the cavity where the tumor was removed."
2963633|NCT02807584|Experimental|ELECT|Adhesive Foam Dressing
2963634|NCT02807558|Experimental|SY-1425 (tamibarotene)|Continuous days 1-28 of a 28-day cycle of SY-1425 at 6mg/m2/day orally divided into twice a day dosing.
2963635|NCT02807558|Experimental|SY-1425 (tamibarotene) in combination with azacitidine|"SY-1425 days 8-28 of a 28-day cycle at 6mg/m2/day orally divided into twice a day dosing.~Azacitidine 75 mg/m2/day IV or SC days 1-7 of a 28-day cycle in combination with SY-1425."
2963636|NCT02807558|Experimental|SY-1425 (tamibarotene) in combination with daratumumab|"SY-1425 during a 7-day lead-in and days 1-28 of a 28 day cycle at 6mg/m2/day orally divided into twice a day dosing.~Daratumumab at 16 mg/kg/day IV starting on Cycle 1 Day 1 weekly for 8 weeks, followed by dosing every two weeks for 16 weeks, followed by dosing every 4 weeks in combination with SY-1425."
2963637|NCT02807545|Experimental|Physical Therapy Exercise Group|"Each patient assigned to the SSE group will attend at least 8 hours of supervised exercise training led by a Schroth-based certified physical therapist over the course of 6 months. Ideally, patients will be seen for 7 sessions.~Patients will perform a home exercise program for 15 minutes a day, 5 days a week, when they can independently execute their prescribed exercises. An exercise log initialed by the guardian will help families keep track of their exercise adherence and serve as a way to monitor exercise adherence for patients who may not have a smartphone, tablet, or computer.~Patients will also be able to meet with the therapists at their return-to-clinic visits and every 2-3 months thereafter until their 1 year follow-up to assess performance quality, maintain motivation, and progress intensity. Patients will be withdrawn if they do not achieve 80% exercise adherence within 6 months."
2963638|NCT02807545|No Intervention|Control Group|Patients randomized to this group will continue receiving standard-of-care treatment from their orthopaedic physician which includes regularly scheduled clinic visits and observation. Observation consists of no treatment of the scoliosis, only routine clinical assessment by the orthopaedic surgeon to detect curve progression every 3 to 6 months.
2963641|NCT02807519||Oncological patients|Children with confirmed haematological/oncological diagnosis who are admitted to the paediatric oncology ward at the Universitätsspital Beider Basel (UKBB), who will require radio- and/or chemotherapy . Collection of salivary cytokines will be performed in this group.
2963642|NCT02807519||Control group|Healthy children which are seen routinely at the Schulzahnklinik/Volkzahnklinik Basel. Collection of salivary cytokines will be performed in this group.
2963643|NCT02807506|Experimental|Clinicians, Caregivers and Elders|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept, 2nd mobile base, and 3rd mobile base with arm in daily supportive tasks
2963644|NCT02807493|Experimental|Occlusal Support Device|Support device for women in labor
2963645|NCT02807493|Placebo Comparator|Control|No device given for women in labor
2963646|NCT02807480|Experimental|Exposure-based therapy|Participants will complete 10, 90-minute sessions of Exposure-based therapy, conducted using a group format. Each group will include 8-12 participants. Exposure-based therapy seeks to increase abilities to manage anxiety through repeated practice in facing the situations or thoughts that are the focus of worry or fear. All participants will complete computer-based behavioral assessments, surveys and interviews, functional magnetic resonance imaging (fMRI), and electroencephalography (EEG).
2963647|NCT02807480|Experimental|Behavioral Activation therapy|Participants will complete 10, 90-minute sessions of Behavioral Activation therapy, conducted using a group format. Each group will include 8-12 participants. Behavioral Activation therapy seeks to target behaviors that might maintain or worsen negative mood. All participants will complete computer-based behavioral assessments, surveys and interviews, functional magnetic resonance imaging (fMRI), and electroencephalography (EEG).
2963648|NCT02807467|Experimental|Dexmedetomidine|Dexmedetomidine is a potent selective α-2-adrenergic receptor agonist frequently used for sedation in the ICU, also among critically ill patients. It promotes sedation, anxiolysis, and moderate analgesia with minimal respiratory depression and has been shown to reduce severity and duration of ICU delirium.
2963649|NCT02807467|Active Comparator|Propofol|Standard therapy for ICU delirium.
2963650|NCT02807454|Experimental|Daratumumab Plus Durvalumab Treatment|"Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle~IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward"
2963651|NCT02807454|Experimental|Pomalidomide+ Daratumumab+ Durvalumab+ Dexamethasone Treatment|"Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle~IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward~oral POM at 4mg/day on days 1 to 21~oral/IV dex at 40mg/day (>75 years old) or 20mg/day (>75 years old) on days 1, 8, 15 and 22"
2963652|NCT02807441|No Intervention|No aspirin|Patients will not be given any Acetylsalicylic acid in the perioperative period.
2963653|NCT02807441|Experimental|Low-dose aspirin|Patients will be given low-dose Acetylsalicylic acid (81 mg) in the perioperative period.
2963654|NCT02807441|Experimental|High-dose aspirin|Patients will be given high-dose Acetylsalicylic acid (325 mg) in the perioperative period.
2963655|NCT02807428|Experimental|AYX1 Injection 660 mg/6 mL|Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery.
2963656|NCT02807428|Placebo Comparator|Placebo Injection 6 mL|Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
2963657|NCT02807402||Patients with chronic infection of HCV Genotype 1 (GT1)|Treatment-naïve or -experienced adult male or female patients with confirmed CHC, genotype 1 , receiving combination therapy with the interferon-free ABBVIE REGIMEN± RBV according to standard of care and in line with the current local label
2963658|NCT02807389|Experimental|MSC Fistula plug: Single Treatment Group|All patients received treatment of a stem cell coated fistula plug.
2963659|NCT02807376|Active Comparator|Surgeon's 'standard of care' stapler|Surgeon's standard of care stapler
2963660|NCT02807376|Experimental|Ethicon Powered Vascular Stapler|Ethicon Powered Vascular Stapler
2963661|NCT02807363|Experimental|Leuprolide Oral Tablet, 4 mg QD|Leuprolide Oral Tablet QD: 4 mg for 28 consecutive days.
2963662|NCT02807363|Experimental|Leuprolide Oral Tablet, 4 mg BID|Leuprolide Oral Tablet BID: 4 mg, 12 hours apart for 28 consecutive days.
2963663|NCT02807363|Active Comparator|Leuprolide 1 month depot|Leuprolide Depot : intramuscular (IM) 3.75 mg depot injection administered for one month of therapy
2963664|NCT02807363|Experimental|Leuprolide Oral Tablet, 10 mg BID|Leuprolide Oral Tablet BID: 10 mg, 12 hours apart for 28 consecutive days
2963665|NCT02807350|Experimental|Overminus Treatment|spectacles with full cycloplegic refraction plus 2.50 D overminus added to the sphere
2963666|NCT02807350|Active Comparator|Non-overminus Treatment|spectacles with full cycloplegic refraction without overminus
2963667|NCT02807337|Experimental|Caphosol rinse group|Caphosol consists of two solutions (A and B) which are mixed immediately before use. Caphosol mouth rinse will begin concomitantly (the same day) with the beginning of chemotherapeutic drugs. It will be continued for seven consecutive days.
2963668|NCT02807337|Active Comparator|0,9% NaCl group.|0,9% NaCl consists of two solutions (A and B). Two vials of 0.9% NaCl will be mixed to maintain blinding. The study mouth rinse will begin concomitantly (the same day) with the beginning of chemotherapeutic drugs. It will be continued for seven consecutive days.
2963669|NCT02807324||Controls|Controls are women (18 years or older) with an uncomplicated pregnancy (i.e no foetal or maternal placental complications, such as pregnancy induced hypertension, preeclampsia or HELLP-syndrome, or small for gestational birth infancies)
2963670|NCT02807324||Early PE with IUGR|These cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
2963702|NCT02807103|Placebo Comparator|Conventional therapy with FFS=0|"All patients will receive corticosteroids with a predefined tapering schedule similar to the experimental group.~Patients with FFS=0 will receive placebo-rituximab at day 1 and day 15."
2963671|NCT02807324||Early PE without IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
2963672|NCT02807324||Late PE with IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
2963673|NCT02807324||Late PE without IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
2963674|NCT02807324||HELLP syndrome|Cases consist of women (18 years or older) with HELLP syndrome in the current pregnancy (defined as (1) the presence of microangiopathic hemolytic anemia with abnormal blood smear, low serum haptoglobin and elevated lactate dehydrogenase (LDH) levels, (2) aspartate transaminase (ASAT) above 70 IU/L and lactate dehydrogenase (LD) above 600 IU/L or bilirubin more than 1.2 mg/dL, (3) platelet count below 100 x 10^9 L-1 )
2963675|NCT02807298|Active Comparator|2% Lignocaine (lidocaine)|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine (adrenaline)
2963676|NCT02807298|Experimental|4% Articaine|intraligamentary injections of 0.9 ml of 4%articaine and 1:100,000 epinephrine (adrenaline)
2963677|NCT02807272|Experimental|Tipifarnib, Oral|
2963678|NCT02807259|Experimental|Multi-level intervention|This is a cluster-randomised controlled trial design. The unit of randomisation is village.
2963679|NCT02807259|Other|Control|The intervention will rolled out to all participating villages after 24 months.
2963680|NCT02807246|Active Comparator|Probiotic|Experimental: Breast milk+ Probiotics(Maflor®, Mamsel Pharmaceuticals, Turkey) The study group will be fed with probiotics at a dose of 1x109 CFU/day (Lactobacillus rhamnosus GG 109colony ). Probiotic is in a liquid drop form at a dose of 5 drops a day and is used orally for 10 days.
2963681|NCT02807246|Active Comparator|Saline|Active Comparator: Breast milk+five drops of saline The control group will be given Breast milk without the addition of probiotics
2963682|NCT02807220|Experimental|Imuneks 10mg|Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
2963683|NCT02807207|Experimental|Sequence I|treatment sequence: A/B/C
2963684|NCT02807207|Experimental|Sequence II|treatment sequence: A/C/B
2963685|NCT02807207|Experimental|Sequence III|treatment sequence: B/A/C
2963686|NCT02807207|Experimental|Sequence IV|treatment sequence: B/C/A
2963687|NCT02807207|Experimental|Sequence V|treatment sequence: C/A/B
2963688|NCT02807207|Experimental|Sequence VI|treatment sequence: C/B/A
2963689|NCT02807194|Experimental|general anesthesia|'lumbar disc herniation'
2963690|NCT02807194|Experimental|spinal anesthesia|'lumbar disc herniation'
2963691|NCT02807181|Active Comparator|Chemotherapy (Cisplatin-Gemcitabine)|Cisplatin 25mg/m2 in 1000ml 0.9% saline given over 1 hour followed by 500 ml 0.9% saline over 30 minutes, followed by Gemcitabine 1000 mg/m2 in 250-500 ml 0.9% saline over 30 minutes by intravenous infusions on days 1, and 8 of a 21-day cycle.
2963692|NCT02807181|Experimental|Radiation: SIRT + chemotherapy (Cisplatin-Gemcitabine)|A single treatment of hepatic arterial injection of SIR-Spheres Y-90 resin microspheres (SIRT) followed 14-16 days later by systemic chemotherapy (ABC-02 CIS-GEM protocol) with an intention to treat with 8 cycles of cisplatin + gemcitabine, or until progression, toxicity or patient choice. Treatment may be continued beyond 8 cycles in the absence of significant disease progression, at the treating clinicians' discretion.
2963693|NCT02807168|No Intervention|Usual care|Control Group
2963694|NCT02807168|Experimental|Usual care plus NT-proBNP|Experimental Group
2963695|NCT02807155|No Intervention|Non-Intervention Control|No intervention will be delivered.
2963696|NCT02807155|Experimental|Continuity Group|"Continuity Group participants aged 20-21 (i.e. the last year of the LEAP Program) will be seen at one of the 2 study centers - 1) the newly established LAC+USC Diabetes Transition Clinic; or 2) Children's Hospital Los Angeles Pediatric Endocrinology Clinic, and will receive the full 1-year Transition Empowerment Program - Continuity Group"
2963697|NCT02807155|Experimental|Rescue Group|"Rescue Group participants aged 21-25 will be connected to a diabetes healthcare home (medical clinic or doctor's office) in Los Angeles County based on geography and personal preference. Those individuals connected to the LAC+USC Diabetes Transition Clinic will receive the full 1-year Transition Empowerment Program - Rescue Group (TEP-RG). Those assigned to other providers in LA County will have access to the web-based curriculum."
2963698|NCT02807142|Experimental|NC 1 cell therapy|All patients will be treated with the same treatment: NC1 cell therapy
2963699|NCT02807129|Experimental|patients|
2963700|NCT02807116|Experimental|Pacritinib and Rifampin|On Day 1, subjects received a single oral 400-mg dose of pacritinib. On Days 8 through 17, following a 7-day washout period, 600-mg oral doses of rifampin were administered QD. It was anticipated that steady-state concentrations of rifampin would be achieved by Day 17. On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
2963701|NCT02807103|Experimental|Rituximab with FFS=0|"All patients in the rituximab group will receive corticosteroids with a predefined tapering schedule similar to the conventional therapy group.~Patients with FFS=0 will receive 1 gram of rituximab at day 1 and day 15 as induction treatment"
2963734|NCT02806960|Experimental|LY900018 - Treatment 4|Two doses of LY900018 administered intranasally, one immediately after the other, in opposite nostrils, in one of four study periods.
2963703|NCT02807103|Experimental|Rituximab with FFS≥1|"All patients in the rituximab group will receive corticosteroids with a predefined tapering schedule similar to the conventional therapy group.~Patients with FFS≥1 will receive a total of 9 pulses :~1 gram of rituximab at day 1 and day 15 as induction treatment~placebo-cyclophosphamide at days 1, 15, 29, 50, 71, 92, 113, 134 and 155.~Maintenance therapy by azathioprine will be started at day 180 according to the standard of care of these patients, as recommended by the French Vasculitis Study Group."
2963704|NCT02807103|Active Comparator|Conventional therapy with FFS≥1|"All patients will receive corticosteroids with a predefined tapering schedule similar to the experimental group.~Patients with FFS≥1 will receive intravenous pulses of cyclophosphamide for a total of 9 pulses: 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.~Maintenance therapy by azathioprine will be started at day 180 according to the standard of care of these patients, as recommended by the French Vasculitis Study Group."
2963705|NCT02807090|Experimental|Lumbar Stabilization Exercise|There will be 16 sessions, twice a week, with 40-60 minutes each session. In this arm the participants will learn basic notions about anatomy and biomechanics and the lumbar stabilization technique. They will be evaluated by a pressure biofeedback in the first day that will be used in the training. The lumbar stabilization technique consists of three stages: cognitive, associated and automatic. The biofeedback is used in the first stage and it helps patients to do the best contraction of stabilization muscles in different levels of pressure. Then, in stage two the patients do the contraction without the use of biofeedback and in the last phase different exercises are associated with the contraction of stabilization muscles.
2963706|NCT02807090|Experimental|Circular Dance|There will be 16 sessions, twice a week, with 60 minutes each session. In this arm the participants will do the exercises in a group of 20 subjects. In every meeting there will be the follow stages: reception, reflection, warming/stretching, explanation about circular dance, choreography orientation, practice and finishing.
2963707|NCT02807077|Experimental|Group 1|Subjects with mild renal impairment
2963708|NCT02807077|Experimental|Group 2|Subjects with moderate renal impairment
2963709|NCT02807077|Experimental|Group 3|Subjects with severe renal impairment
2963710|NCT02807077|Experimental|Group 4|Subjects with ESRD
2963711|NCT02807077|Experimental|Group 5|Healthy subjects
2963712|NCT02807064|Active Comparator|Bifidobacteria mixture 0.5 ml|Bifidobacteria 0.5 ml per os all days for 2 months
2963713|NCT02807064|Placebo Comparator|placebo|Placebo 0.5 ml per os all days for 2 months
2963714|NCT02807051|Experimental|Pacritinib and Clarithromycin|Single 400-mg (four 100-mg capsules; lot number 21341) oral doses of pacritinib were administered in the fasted state on Days 1 and 12. Twice daily, 500-mg (1 tablet) oral doses of clarithromycin were administered with or without food on Days 8 through 11 and in the fasted state on the morning of Day 12
2963715|NCT02807038|Experimental|Lung function test|Pregnant women performed one spirometry at each trimester of pregnancy
2963716|NCT02807025||Idiopathic Pulmonary Fibrosis(IPF)|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
2963717|NCT02807025||Sarcoidosis|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
2963718|NCT02807025||Tuberculosis(TB)|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
2963719|NCT02807025||Chronic Obstructive Pulmonary Disease|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
2963720|NCT02807025||Asthma|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
2963721|NCT02807025||Healthy|Nasal, tracheal and bronchial sampling of MLF in patients from healthy controls for comparative data.
2963722|NCT02807012|Experimental|Nursing educational intervention|The intervention will consist in three home visits (14, 21, 30 days after discharge) by nurses to family caregivers. The nurses will give verbal information and printed materials related to the care of older adults por stroke.
2963723|NCT02807012|No Intervention|Usual care|The family caregivers won't receive the home visits and could have or not the usual care guidelines provide by health services that have access.
2963724|NCT02806999|Experimental|Berberine; Insulin|"Follow the previous administration program，participants will continue to receive intensive insulin therapy; Besides injecting insulin, participants will receive 500mg berberine twice a day for 8 days.~Drug: Berberine; Insulin"
2963725|NCT02806999|Active Comparator|Insulin|"Besides receiving intensive insulin therapy, participants will take a placebo twice a day for 8 days.~Drug: Insulin"
2963726|NCT02806986|Experimental|IGSC 20%|13 doses of IGSC 20% in Treatment Stage 1 and 39 doses of IGSC 20% in Treatment Stage 2 for a total of 52 doses if IGSC 20%
2963727|NCT02806973|Experimental|LY900018 - Treatment 1|One dose of LY900018 administered intranasally in one of four study periods.
2963728|NCT02806973|Experimental|LY900018 - Treatment 2|Two doses of LY900018 administered intranasally, 15 minutes apart, in the same nostril, in one of four study periods.
2963729|NCT02806973|Experimental|LY900018 - Treatment 3|Two doses of LY900018 administered intranasally, 15 minutes apart, in opposite nostrils, in one of four study periods.
2963730|NCT02806973|Experimental|LY900018 - Treatment 4|Two doses of LY900018 administered intranasally, one immediately after the other, in opposite nostrils, in one of four study periods.
2963731|NCT02806960|Experimental|LY900018 - Treatment 1|One dose of LY900018 administered intranasally in one of four study periods.
2963732|NCT02806960|Experimental|LY900018 - Treatment 2|Two doses of LY900018 administered intranasally, 15 minutes apart, in the same nostril, in one of four study periods.
2963733|NCT02806960|Experimental|LY900018 - Treatment 3|Two doses of LY900018 administered intranasally, 15 minutes apart, in opposite nostrils, in one of four study periods.
2963735|NCT02806947|Experimental|Sirolimus|Sirolimus, a steroid-free therapy, will be administered after a diagnosis of standard-risk aGVHD is clinically established.
2963736|NCT02806947|Active Comparator|Prednisone|Prednisone, standard of care therapy for GVHD, will be administered after a diagnosis of standard-risk aGVHD is clinically established.
2963737|NCT02806921|Active Comparator|ZenLens with Low limbal clearance|Scleral contact lens designed to provide approximately 25 microns of limbal clearance.
2963738|NCT02806921|Active Comparator|ZenLens with High limbal clearance|Scleral contact lens designed to provide approximately 80 microns of limbal clearance.
2963739|NCT02806908|Placebo Comparator|Placebo|Once daily dosing
2963740|NCT02806908|Active Comparator|JZP-110|150 mg/day for first 3 days and 300 mg/day for next 4 days
2963741|NCT02806895|Placebo Comparator|Placebo|Once daily dosing
2963742|NCT02806895|Active Comparator|JZP-110|150 mg/day for first 3 days and 300 mg/day for next 4 days
2963743|NCT02806882|Experimental|Ceftaroline fosamil|600mg 1 hour intravenous infusion ZINFORO
2963744|NCT02806869|Experimental|Arm #1 - Fasting State, 2 study visits|"Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red~Washout period of at least 7 days~Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red"
2963745|NCT02806869|Experimental|Arm #2 - Fed State, 2 study visits|"Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red~Washout period of at least 7 days~Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red"
2963746|NCT02806856|Active Comparator|Active tDCS|
2963747|NCT02806856|Sham Comparator|Sham|
2963748|NCT02806843|Experimental|Stroke survivors and healthy subjects|Stroke survivors greater than 18 years of age with hemiplegia and varying levels of impairment as well as healthy subjects greater than 18 years old with no motor disabilities will be asked to interact with a therapist. The Patient-Therapist interactions will be recorded using the Rehab Intercap System and 3D Kinect Device.
2963749|NCT02806830|Experimental|Optive after the second anti-VEGF injection|Naive patients requiring intravitreal injection. Patients will be enrolled in this study within the 2 first intravitreal injections to assess quality of life and ocular discomfort without wetting agent (ie after the first injection) and with wetting agent (ie after the second injection)
2963750|NCT02806817|Experimental|Bevacizumab + ME-344|"Bevacizumab single dose (15 mg/kg infused IV) on day 1. ME-344 will be administered at 10 mg/kg infused IV over 30 minutes on days 8, 15 and 22 (arm 1).~ME-344 will be suspended in 250 mL sterile saline."
2963751|NCT02806817|Placebo Comparator|Bevacizumab + normal saline|Bevacizumab single dose (15 mg/kg infused IV) on day 1. Placebo: will be administered normal saline 250 mL infused IV over 30 minutes on days 8, 15 and 22 (arm 2).
2963752|NCT02806804|Experimental|one dose test vaccine|One dose of quadrivalent influenza virus vaccine will be randomly given in aged 3-60 years old.
2963753|NCT02806804|Experimental|one dose commercially available trivalent influenza vaccine|One dose of trivalent influenza virus vaccine will be randomly given in aged 3-60 years old.
2963754|NCT02806804|Experimental|One dose quadrivalent influenza virus vaccine|One dose of quadrivalent influenza virus vaccine (trivalent influenza virus vaccine added to a new influenza B component) will be randomly given in aged 3-60 years old.
2963755|NCT02806778||Hypoxic brain injury|Consecutive out-of-hospital, post-cardiac arrest patients who remain comatose after successful resuscitation, admitted on ICU of University Hospital Ostrava. The patients will undergo BIS monitor-guided sedation and jugular bulb catheterisation.
2963756|NCT02806765|Experimental|Dietary Supplement|This experimental arm reflects administration of a softgel capsule containing a dose of (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol below the upper tolerable limit
2963757|NCT02806765|Experimental|Control|This experimental arm reflects administration of placebo in softgel capsule
2963758|NCT02806752|Experimental|Ranibizumab + Triamcinolone Acetonide|intravitreal injection: Ranibizumab 0.5mg + Triamcinolone Acetonide 2mg
2963759|NCT02806752|Active Comparator|Ranibizumab|intravitreal injection: Ranibizumab 0.5mg
2963760|NCT02806739|Experimental|Soy Group (Soy Protein + Isoflavones)|"Intervention: Soy-based whole foods containing about 25 grams of soy protein and 60-75 mg isoflavones.~Intervention group will consume soy foods containing about 25 grams of soy protein and 60-75 mg isoflavones per day, from 16th gestational week to birth. Examples of soy foods that contain 25 grams of soy protein and 60-75mg isoflavones include: 2 cups of soy milk, or 12 ounces tofu, or a half cup of soy nuts. Women in the Soy Group will be instructed by a registered dietitian how to incorporate the soy foods into their daily diet."
2963761|NCT02806739|Placebo Comparator|Control Group (Minimize Soy Intake)|Control Group will avoid soy supplements and minimize intake of soy foods.
2963762|NCT02806713|Placebo Comparator|no phenazopyridine|Patients not receiving phenazopyridine (standard of care)
2963763|NCT02806713|Experimental|phenazopyridine|Patients receiving phenazopyridine
2963764|NCT02806700|No Intervention|Twitter Diabetes Control|This group will be identified as having diabetes from Twitter. This group will be contacted and asked to complete brief surveys
2963765|NCT02806700|Experimental|Twitter Diabetes Intervention|This group will be identified as having diabetes from Twitter. This group will be contacted and asked to complete brief surveys. This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)
2963766|NCT02806687|Experimental|Gene Therapy product CYL-02|Two EUS-guided intratumor injections of CYL-02 at one month interval plus Gemcitabine (3 weeks/month) during two months followed by four months Gemcitabine alone (3 weeks/month) or until progression.
2963767|NCT02806687|Active Comparator|Standard of care|Gemcitabine alone 3 weeks/month during 6 months (or until progression).
2963768|NCT02806674|Experimental|Successful treatment|
2963769|NCT02806674|Experimental|Refractory infection of H.pylori|
2963770|NCT02806661|Experimental|VPRDG for AGC|Vagus nerve-preserving Robot-assisted distal subtotal gastrectomy (VPRDG) with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
2963876|NCT02805920|Active Comparator|GROUP 1 : G20|Postoperative pain for ACLR : G20 : received ACB with 20 ml 0.25% Bupivacaine
2963771|NCT02806661|Active Comparator|CRDG FOR AGC|Conventional Robot-assisted distal subtotal gastrectomy (CRDG) with D2 lymphadenectomy without preserving vagus nerve will be performed for the treatment of patients assigned to this group.
2963772|NCT02806648|Experimental|Palbociclib|Palbociclib
2963773|NCT02806635|No Intervention|Waitlist|Participants are assessed start, during, and end wait list; however, no active intervention is given.
2963774|NCT02806635|Experimental|OurRelationship|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner. The first conversation between partners centers on discussing possible core relationship issues and jointly deciding on the problem(s) to focus on during the program. During the second conversation, both partners' previous written responses are displayed on the screen and conversation is encouraged. During the final conversation, couples share their strategies to decrease stress, improve patterns of communication, and engage in problem-solving exercises specific to their core issue(s).
2963775|NCT02806635|Experimental|PREP Online|The PREP Online program is based on the in-person Prevention and Relationship Enhancement Program. The PREP Online program consists of seven sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour.
2963776|NCT02806622||Division II Collegiate Athletes|Student athletes (18-45) currently enrolled and participating on a sports team.
2963777|NCT02806609|Other|Group 1|Cold water immersion, with 10 degrees, for 10 minutes
2963778|NCT02806609|Other|Group 2|immersion in water at room temperature
2963779|NCT02806609|Other|Group 3|active recovery - running
2963780|NCT02806609|Other|Group 4|rest in the chair
2963781|NCT02806596|Other|sevoflurane|"induction of anesthesia using sevoflurane administered with facial mask at inspired concentration of 6% (in a mixture of oxygen and nitrous oxyde)~intervention : titration of inspired sevoflurane concentration until targeted bispectral index"
2963782|NCT02806583|Experimental|intervention|telephone based structured support groups
2963783|NCT02806583|No Intervention|control|Active Comparator: Usual care (intervention as experimental group after 3 month (after T1)
2963784|NCT02806570|Experimental|AccuCinch® Ventricular Repair System|
2963785|NCT02806557||High risk group|"Defined as risk of severe neutropenia >20% or risk of neutropenic infective complications >10%, with severe neutropenia defined as absolute neutrophil count <1.0 x10^9/L.~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
2963786|NCT02806557||Frequently given regimens|"Defined as high number of cases of neutropenia, but risk of severe neutropenia <5%.~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
2963787|NCT02806557||Prophylactic GCSF|"Patients on primary prophylactic granulocyte colony stimulating factor (GCSF).~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
2963788|NCT02806544|Experimental|Tamoxifen|Tamoxifen 20mg by mouth daily
2963789|NCT02806531|Experimental|two doses enterovirus 71 vaccine|Two doses of enterovirus 71 vaccine will be given in aged 6-35 months old, 28 days interval.
2963790|NCT02806518||Women scheduled for DIEP|Women scheduled for DIEP breast reconstruction after mastectomy due to breast cancer are examined with DIRT, hand-held Doppler and CTA
2963791|NCT02806505|Experimental|Peginterferon alfa-2a 135 microgram (mcg)|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 135 mcg subcutaneously (SC) once weekly up to Week 48.
2963792|NCT02806505|Experimental|Peginterferon alfa-2a 90 mcg|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 90 mcg SC once weekly up to Week 48.
2963793|NCT02806492|Experimental|Patient for cardiac surgery|All patient undergo the 5 different intervention in a randomised matter.
2963794|NCT02806479||Case: Hypertrophic cardiomyopathy|HCM patients at high risk for ventricular arrhythmia
2963795|NCT02806479||Control I: Healthy|Healthy Controls
2963796|NCT02806479||Control II: Post-MI with arrhythmogenic substrate|Ischemic cardiomyopathy patients with documented history of ventricular tachyarrhythmia and left ventricular hypertrophy
2963797|NCT02806479||Control III: VT/VF-free ischemic cardiomyopathy|Ischemic cardiomyopathy patients without ventricular arrhythmia, as proven by non-inducibility and history of freedom from ventricular tachyarrhythmia during at least one ICD generator life
2963798|NCT02806466|Active Comparator|Asthmatic children|
2963799|NCT02806466|Sham Comparator|Non-asthmatic children|
2963800|NCT02806453|Active Comparator|Group A|Group A: Mg alginate/thickened formula
2963801|NCT02806453|Active Comparator|Group B|Group B: thickened formula/Mg alginate
2963802|NCT02806440|Active Comparator|Low dose naltrexone|Low dose naltrexone 4.5 mg/tablet, 1 tablet a day for 21 days
2963803|NCT02806440|Placebo Comparator|Placebo|"Placebo tablet~1 tablet a day for 21 days"
2963804|NCT02806427||enterally fed adults|Adults subjects with a condition for which a calorically dense enteral formula is appropriate, with established enteral access, anticipated to require enteral tube feeding for at least 3 days.
2963805|NCT02806414|Experimental|Ivermectin|All subjects will be treated with topical ivermectin daily for up to 12 weeks.
2963806|NCT02806401|Experimental|landmark|landmark method_subclavian venous cannulation
2963807|NCT02806401|Active Comparator|US_Ax|ultrasound guided axillary venous cannulation
2963808|NCT02806388||tumor tissue for molecular profiling|
2963809|NCT02806375|Experimental|PTCy and ruxolitinib|
2963810|NCT02806362|Experimental|Ombitasvir/paritaprevir/ritonavir (12 weeks)|Ombitasvir/paritaprevir/ritonavir (25/50/100mg once daily) for 12 weeks
2963811|NCT02806349|Placebo Comparator|Control|3g/d Cornstarch and 14g/d wheat bran control
2963812|NCT02806349|Experimental|K-GB&AG|3g/d American Ginseng and 7g/d Konjac-glucomannan fiber blend
2963877|NCT02805920|Active Comparator|GROUP 2 : G25|Postoperative pain for ACLR : G25: received ACB with 25 ml 0.25% Bupivacaine
2963813|NCT02806336|Experimental|Multi Modal Balance Training & Weight Loss|Supervised exercise 3 times per week for about 1 hour. The classes will consist of a group balance class (about 30 minutes), a supervised obstacle course (about 10 minutes), and lower body and core body strength exercises (about 20 minutes). Weekly nutrition sessions for individual dietary recommendations designed to produce about a 10% weight loss over the first six months of the study.
2963814|NCT02806336|Active Comparator|Multi Modal Balance Training Only|Supervised exercise 3 times per week for about 1 hour. The classes will consist of a group balance class (about 30 minutes), a supervised obstacle course (about 10 minutes), and lower body and core body strength exercises (about 20 minutes).
2963815|NCT02806323|Experimental|Yoga Practice|12 week yoga intervention; 45 minutes/weekly practice Participants will be encouraged to practice their prescribed program of yoga at home, daily, for 20 minutes each day.
2963816|NCT02806310||Prospective|Group A: Patients with known BAV who are scheduled to have a cardiac MRI.
2963817|NCT02806310||Historic|Group B: Patients with known BAV who have already had an MRI within the past year
2963818|NCT02806297|Experimental|Early cholecystectomy with IOC|The experimental arm will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.
2963819|NCT02806297|Active Comparator|Late cholecystectomy with IOC|The comparator will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
2963820|NCT02806284|Active Comparator|Neurotrauma|Patients with basilar skull fracture with or without known cerebrospinal fluid leakage were enrolled in the neurotrauma (NT) group. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b.The vaccines were administered by subcutaneous injections within 10 days from trauma.
2963821|NCT02806284|Active Comparator|Neurosurgery|Patients scheduled for elective, transsphenoidal pituitary gland surgery were assigned to the neurosurgery (NS) group. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b.The vaccines were administered by subcutaneous injections within 10 days from surgery.
2963822|NCT02806284|Active Comparator|Control|All control patients had undergone neurotrauma with or without basilar skull fracture, or had neurosurgery, at least three weeks earlier. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b. They were vaccinated at least three weeks after trauma or surgery. The vaccines were administered by subcutaneous injections.
2963823|NCT02806271|Experimental|Worry Postponement|Two weeks of daily worry postponement
2963824|NCT02806271|Active Comparator|Worry Monitoring|Two weeks of daily worry monitoring
2963825|NCT02806271|No Intervention|Assessment Only Control|No intervention, participants will complete three assessment time points
2963826|NCT02806258|Active Comparator|Arm A|6-8 cycles of Primary systemic therapy using anthracycline and/or taxane based regimens, according to their physician's preference and center policy
2963827|NCT02806258|Experimental|Arm B|The patients will receive 3D conformal or other modality (eg IMRT, VMAT) APBI during their PST sequence. APBI will be planned sequentially between the Primary systemic therapy cycles, 2 weeks after the 3rd/6 or the 4th/8 cycle of PST.
2963828|NCT02806245|Experimental|Biventricular pacing|Patients will be randomized pre-operatively to either the pacing group or to the control group. Patients randomized to receive pacing will 1st undergo an acute pacing phase where the order of the pacing mode will be randomized and then will continue to an extended pacing phase of biventricular pacing.
2963829|NCT02806245|No Intervention|Control|Controls will receive standard of care treatment consisting of placement of 2 pacing leads (right atrial and right ventricular), monitoring of the study outcomes, monitoring of oxygen consumption and echocardiography, but no pacing.
2963830|NCT02806232|Experimental|Part 1-Biltricide (racemate praziquantel) 20 mg/kg(Cohort 1)|Biltricide (600 mg tablet) will be administered orally at a dosage of 20 milligram per kilogram (mg/kg), three times a day as a one day treatment.
2963831|NCT02806232|Experimental|Part 1-Biltricide (racemate praziquantel) 40 mg/kg(Cohort 2)|Biltricide (600 mg tablet) will be administered orally at a dosage of 40 mg/kg as a single dose.
2963832|NCT02806232|Experimental|Part 1 - Racemate Praziquantel 40 mg/kg (Cohort 3)|Racemate Praziquantel (PZQ) Oral Dispersible Tablet (ODT) (150 mg tablet) will be administered orally at a dosage of 40 mg/kg as a single dose.
2963833|NCT02806232|Experimental|Part 1 - Racemate Praziquantel 60 mg/kg (Cohort 4)|Racemate PZQ ODT (150 mg tablet) will be administered orally at a dosage of 60 mg/kg as a single dose
2963834|NCT02806232|Experimental|Part 1 - Levo Praziquantel 30 mg/kg (Cohort 5)|Levo PZQ ODT (150 mg tablet) will be administered orally at a dosage of 30 mg/kg as a single dose.
2963835|NCT02806232|Experimental|Part 1 - Levo Praziquantel 45 mg/kg (Cohort 6)|Levo PZQ ODT(150 mg tablet) will be administered orally at a dosage of 45 mg/kg as a single dose.
2963836|NCT02806232|Experimental|Part 1 - Levo Praziquantel 60 mg/kg (Cohort 7)|Levo PZQ ODT (150 mg tablet) will be administered orally at a dosage of 60 mg/kg as a single dose.
2963837|NCT02806232|Experimental|Part 2- Racemate Or Levo Praziquantel (Cohort 8)|Racemate or Levo PZQ ODT will be administered orally at an optimal dose level selected by safety monitoring committee (SMC) from Part 1. Subjects aged between 13-24 months will be enrolled in this cohort.
2963838|NCT02806232|Experimental|Part 2- Racemate Or Levo Praziquantel (Cohort 9)|Racemate or Levo PZQ ODT will be administered orally at an optimal dose level selected by safety monitoring committee (SMC) from Part 1 and Part 2a. Subjects aged between 3-12 months will be enrolled in this cohort.
2963839|NCT02806219|Active Comparator|Certolizumab Pegol injection by prefilled syringe|
2963840|NCT02806219|Experimental|Certolizumab Pegol injection by e-Device|
2963841|NCT02806206|Experimental|Drug: Prucalopride|A single 2 mg dose of prucalopride before ingesting the capsule endoscopy pill.
2963842|NCT02806206|Placebo Comparator|Drug: Placebo|A placebo pill just before ingesting the capsule endoscopy pill.
2963843|NCT02806193||Cardiovascular Magnetic Resonance Imaging|Cardiovascular imaging techniques (other subsidiary techniques such as CT and ECG will also be followed)
2963844|NCT02806180|Experimental|Single-Operator|For the 'Single Operator Ultrasound Guided IV placement' arm the RN operator will use the ultrasound probe to identify the target vein, and continue to hold and adjust the probe while placing the IV.
2963845|NCT02806180|Experimental|Dual-Operator|For the 'Dual Operator Ultrasound Guided IV placement' arm the RN operator will use the US to identify the target vein, at which time the study coordinator will hold the ultrasound probe in position. The RN operator will then place the IV.
2963846|NCT02806167|Experimental|Clinical algorithm|This is a single arm study. All eligible patients will be subject to our clinical algorithm.
2963847|NCT02806154||Elderly cancer patients|Elderly cancer patients treated with chemotherapy will have DEXA
2963848|NCT02806141|Experimental|Aerosolized plus intravenous colistin|Neonates with VAP due to PDR-A. baumannii who receive aerosolized colistin (4 mg/kg/dose twice daily) plus intravenous colistin (3.5 mg/kg/dose twice daily)
2963849|NCT02806141|Active Comparator|Intravenous colistin|Neonates with VAP due to PDR-A. baumannii who receive only intravenous colistin (3.5 mg/kg/dose twice daily)
2963850|NCT02806128|Experimental|Treatment group|"Injection of Human Urinary Kallidinogenase for Injection (KLK) three times a day, 14 days .~Patients need to complete laboratory tests within a specified time."
2963851|NCT02806128|Experimental|Control group|"Injection of Human Urinary Kallidinogenase for Injection (KLK) Once times a day, 14 days .~Patients need to complete laboratory tests within a specified time."
2963852|NCT02806115|Experimental|acetic acid-enhanced endoscopy|Acetic acid-enhanced endoscopy combines conventional endoscopy with the instillation of acetic acid.
2963853|NCT02806102||High-risk|"Acute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have at least one of the following risk factors:~Age ≥ 65 years~Diabetes mellitus requiring medication~Documented history of a second prior presumed spontaneous MI (>1 year ago)~Documented history of angiographic evidence of multivessel coronary artery disease~Chronic, non-end stage renal dysfunction"
2963854|NCT02806102||Low-risk|Acute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have none of the pre-specified risk factors
2963855|NCT02806089|Experimental|Muscle strength|"single evaluation (the day of inclusion) of muscle strength (by handheld dynamometer), muscle mass (by creatinine index estimation), lean body mass (by electrical bioimpedance analysis), physical activity (by Voorrips score questionnaire), inflammatory and nutritional status."
2963856|NCT02806076|Experimental|No-touch RFA arm|No-touch RFA arm indicates RFA procedure without direct tumor puncture. In this study, RFA is done by using dual cooled electrode.
2963857|NCT02806076|Active Comparator|Conventional tumor puncture RFA arm|"Conventional tumor puncture RFA arm indicates RFA procedure using conventional tumor puncture technique. In this study, RFA is done by using dual cooled electrode."
2963858|NCT02806063|Other|Intraoperative samples|During this study of health care procedure evaluating microbiological setting in PJI prior prosthesis implantation with one stage surgery, 3 additional perioperative samples will be performed prior prosthesis implantation for every patient.
2963859|NCT02806050|Experimental|Palbociclib and FES PET|To evaluate whether low uptake on FES-PET at baseline is related to non-response to letrozole plus palbociclib treatment.
2963860|NCT02806024|Experimental|Treatment Arm (Tranexamic Acid, or TXA)|Patients will be randomized to treatment or placebo arms preoperatively. In our treatment arm of pregnant patients with suspected placenta accreta or at high risk for placenta accreta, patients will receive 1 gram intravenous TXA administered over 10 minutes immediately after delivery of the infant. The drug will be prepared and ready to hang at the beginning of the case. The study drug will be administered only once.
2963861|NCT02806024|Placebo Comparator|Placebo Arm|Patients will be randomized to treatment or placebo arms preoperatively. In our placebo arm of pregnant patients with suspected placenta accreta, patients will receive plain normal saline in a 50 cc bag identical to the preparation of study drug immediately after delivery of the infant.
2963862|NCT02806011|No Intervention|no Intervention|Long-term follow up of no intervention group
2963863|NCT02806011|Experimental|1-time injection group|Long-term follow up of 1-time injection group
2963864|NCT02806011|Experimental|2-time injection group|Long-term follow up of 2-time injection group
2963865|NCT02805998|Experimental|Web-based CBT-I|Sleepio delivers CBT-I through 6 weekly web-sessions (www.sleepio.com). Treatment content is based on CBT for insomnia manuals (Espie et al., 2007, 2008) and includes a behavioral component (sleep restriction, stimulus control, and relaxation), a cognitive component (paradoxical intention, cognitive restructuring, mindfulness, positive imagery, putting the day to rest) and an educational component (psycho-education, sleep hygiene).
2963866|NCT02805998|Other|Treatment as Usual|Our control condition was designed to reflect standard care for insomnia patients. No limits are placed on receiving non-study treatment, including medication or psychotherapy. Use of non-study treatment will be tracked.
2963867|NCT02805985|Experimental|FLXfit™ TLIF Interbody Fusion Device|The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
2963868|NCT02805972|Experimental|Naloxone|4 mg / 0.1 ml naloxone
2963869|NCT02805972|Placebo Comparator|Placebo|0.1 ml saline
2963870|NCT02805959||Constipated, Elderly|Investigation with MTS for motility
2963871|NCT02805959||Constipation, Young|Investigation with MTS for motility
2963872|NCT02805959||Normal Bowel, Elderly|Investigation with MTS for motility
2963873|NCT02805959||Normal Bowel, Young|Investigation with MTS for motility
2963874|NCT02805946|Other|intravenous followed by oral|"Start with posaconazole IV 300mg BID on the first day. Posaconazole will be infused over a period of 90 minutes.~Days 2-7 patients will receive posaconazole IV 300mg QD.~Days 8-12 patients will receive posaconazole PO 300mg QD.~Days 13-16 patients will receive posaconazole PO 200mg QD.~3 PK curves will be determined on days 7, 12 and 16 (after the 7th, 12th and 16th dosage)."
2963875|NCT02805946|Other|oral followed by intravenous|"Start with posaconazole PO 300mg BID on the first day.~Days 2-7: patients will receive posaconazole PO 300mg QD.~Days 8-12: patients will receive posaconazole IV 300mg QD. Posaconazole will be infused over a period of 90 minutes.~Days 13-16 patients will receive posaconazole IV 200mg QD.~3 PK curves will be determined on days 7, 12 and 16 (after the 7th, 12th and 16th dosage)."
2963879|NCT02805907|Experimental|Intervention Group (IG)|Calcifediol (Hidroferol®) in 16,000-IU ampoules taken weekly by the oral route
2963880|NCT02805907|Placebo Comparator|Control Group (CG)|Placebo in a presentation with an identical appearance taken weekly by the oral route
2963881|NCT02805894|Experimental|NBTXR3 activated by IMRT only|"Part I Dose Escalation~NBTXR3 will be administered by intra-prostate injection and then activated 10 days later by:~- EBRT delivered as 45 Gy in 25 fractions of 1.8 Gy each; to the prostate and seminal vesicles, followed by 34.2 Gy in 19 fractions to the prostate and proximal seminal vesicles , over 9-10 weeks, utilizing intensity modulated radiotherapy (IMRT) with daily image guidance aligned to implanted fiducial markers (COHORT A)"
2963882|NCT02805894|Experimental|NBTXR3 activated by Brachytherapy & IMRT|"Part I Dose Escalation~NBTXR3 will be administered by intra-prostate injection and then activated 10 days later by:~- Brachytherapy Boost and EBRT delivered as a single fraction of 15 Gy in one day to the prostate by High Dose Rate Brachytherapy followed by EBRT (initiated within 2-4 weeks after completion of Brachytherapy), delivered as 45 Gy in 25 fractions of 1.8 Gy to the prostate and seminal vesicles utilizing intensity modulated radiotherapy (IMRT) with daily image guidance aligned to implanted fiducial markers (COHORT B)"
2963883|NCT02805881|Experimental|Neurolief System treatment|Treatment with the Neurolief system will be applied by the subject at his home and/or surrounding daily during a period of six weeks
2963884|NCT02805868|Experimental|Treatment (siltuximab)|Patients receive siltuximab IV over 60 minutes on day 1. Patients also undergo bone marrow biopsy and aspiration at baseline and at the end of treatment (within 30 days of last siltuximab dose) or as clinically indicated. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who are responding after 6 courses may receive additional siltuximab treatment for up to 1 year at the discretion of the study doctor.
2963885|NCT02805855|Experimental|S50|Subjects in the S50 cohort will receive one injection of 50 million AMSCs.
2963886|NCT02805855|Experimental|S100|Subjects in the S100 cohort will receive one injection of 100 million AMSCs.
2963887|NCT02805855|Experimental|M50|Subjects in the M50 cohort will receive three injections of 50 million AMSCs at one-month intervals.
2963888|NCT02805855|Experimental|M100|Subjects in the M100 cohort will receive three injections of 100 million AMSCs at one-month intervals.
2963889|NCT02805842|Active Comparator|Tacrolimus BID|20 patients receiving twice daily (BID) Tacrolimus
2963890|NCT02805842|Active Comparator|Advagraf QD|40 patients randomized to receive once daily (QD) Advagraf
2963891|NCT02805829|Experimental|Trastuzumab + NK cells|"On Cycle 1,day -2, patients will receive IV loading dose 8mg/Kg trastuzumab, followed by collection blood on day 0. After NK expansion and verification that the resulting NK cells meet release criteria, NK cells were washed and resuspended in isotonic sodium chloride for intravenous transfusion on day 14.~NK cellular therapy conduct 2 cycles per year. The maintenance dose of trastuzumab monotherapy is 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks till to disease progress."
2963892|NCT02805816||Study group|Children with suspicion of CD based on positive serology (TG2 >2 times upper limit of normal) and classical clinical manifestations or belonging to high risk groups, who underwent gastroscopy with intestinal biopsies.
2963893|NCT02805816||Control group|Children without suspicion of CD who underwent gastroscopy and duodenal biopsies for other reasons (abdominal pain, failure to thrive, vomiting, eg)
2963894|NCT02805803|Other|Quality of life questionary|"During this study of health and care procedure, we will assess the quality of life of patients treated with suppressive antibiotique therapy using three questionaries:~SF12~Beck~WOMAC"
2963895|NCT02805790|Experimental|Drug|Patients will be randomly assigned to receive 40 mg of elamipretide in either Treatment Period 1 or Treatment Period 2.
2963896|NCT02805790|Placebo Comparator|Placebo|Patients will be randomly assigned to receive placebo comparator either in Treatment Period 1 or Treatment Period 2
2963897|NCT02805764|Experimental|Homeoblock functional dental appliance|Removable functional dental appliance to be used at during sleep for one year.
2963898|NCT02805751|Active Comparator|Control|This constitutes the currently accepted regime and is therefore consider the control group (CTRL) with early range of motion and early weight bearing. The control group was allowed to have weight-bearing as tolerated from day 0. They are also instructed to perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
2963899|NCT02805751|Experimental|Early loading|The patients in the early loading group are also allowed to have weight-bearing as tolerated from day 0 and perform tendon strain exercises 3 times each day from 2 weeks after the rupture. The patients in this group will also remove the walker twice a day and use a special training pedal for 5 weeks (until walker removal).
2963900|NCT02805738|Experimental|Experimental Group|once a time per a day, CKD-390 1 Tablet for each other, PO, During 24 weeks, once a time per a day, 1 tab(CKD-390 1 Tablet) for each other, PO, From 24 weeks to 48 weeks
2963901|NCT02805738|Active Comparator|Active comparator Group|once a time per a day, Viread 1 Tablet for each other, PO, During 24 weeks, once a time per a day, 1 tab(CKD-390 1 Tablet) for each other, PO, From 24 weeks to 48 weeks
2963902|NCT02805725|Experimental|Phase 1: Trabectedin + Cyclophosphamide|Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule. Trabectedin will be administered intravenously, 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks.
2963903|NCT02805725|Experimental|Phase 2: Trabectedin + Cyclophosphamide|Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule. Trabectedin will be administered intravenously, 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks.
2963904|NCT02805712|Active Comparator|Control|Participant will receive usual care for Heart Failure patients, which include standard written material on Advanced Care planning and supportive cardiology/palliative care consult if ordered by attending.
2963905|NCT02805712|Experimental|Verbal Information and Discussion|Participants will participate in a guided goals of care conversation and the support of a Palliative Care Social Worker who is working closely with the patients' primary cardiology team. Social worker has ongoing clinical review of participants with a Palliative Care physician who will provide a full medical consult if appropriate.
2963906|NCT02805699|Experimental|Baofeikang Granule|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant,cough,give BaoFeikang Granules(by Beijing KangRentang Pharmaceutical Co., Ltd.), 1 bag, twice each day.
2963907|NCT02805699|Placebo Comparator|Placebo|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant,coughand give Chinese medicine placebo (by Beijing Kang Rentang Pharmaceutical Co., Ltd., requirements and Chinese medicine BaoFeikang Granules in appearance and taste similar),1bag，twice each day.
2963908|NCT02805686|Experimental|"En face OCT (C-scan)"|
2963909|NCT02805673|Experimental|OSTEO group|usual medical treatment + 6 osteopathic interventions
2963910|NCT02805673|No Intervention|witness group|usual medical treatment
2963911|NCT02805660|Experimental|Mocetinostat and Durvalumab|Mocetinostat oral capsules, three times weekly along with durvalumab intravenously administered in 28 day cycles
2963912|NCT02805647||Fracture/study group|The study group consisted of 100 children aged 3 to 18 years (78% boys) hospitalized in the Department of Pediatric Orthopedics in 2011-2013 due to low-energy fractures
2963913|NCT02805647||Control group|The control group (122 children, 68% boys) consisted of children aged 3 to 17 years, hospitalized for other reasons (injuries, diagnosis of knee ligament injuries and others) without fractures
2963914|NCT02805634|Experimental|Multiple sclerosis|Patients with multiple sclerosis, followed by Dr Dachy within the CHU Brugmann Hospital.
2963915|NCT02805634|Other|Control group|Control group without neurological pathology
2963916|NCT02805621||Subject|Patients with know or suspected coronary artery disease, who underwent both CT angiography and invasive coronary angiography including invasive FFR measurements.
2963917|NCT02805608|Experimental|uPAR PET/CT and FDG PET/MR|One injection of 68Ga-NOTA-AE105 followed by PET/CT and on a separate day one injection of 18F-FDG followed by PET/MRI. Both scans will be evaluated for possible regional lymph node metastases.
2963918|NCT02805595|Experimental|Hypertonic Saline|23.4% Hypertonic Saline injection(s) with a maximum of 0.6cc per treatment. If necessary every two weeks, with a maximum of three treatments.
2963919|NCT02805595|Placebo Comparator|Saline (Placebo)|"If a patient has two active HS sites with fistulas or sinus tracts, patients will be their own control.~Injection with normal saline (placebo) in one site randomly allocated by side. The subject and ultrasound operator will be blinded to the treatment allocation."
2963920|NCT02805582|Active Comparator|Anterior musculus serratus block|"Proximal nerve block above the second intercostal space between Musculus serratus anterior and Musculus pectoralis minor.~Intervention: 10ml ropivacain 0.5%"
2963921|NCT02805582|Active Comparator|Subpectoral block|"Distal nerve block under the Musculus pectoralis major at the medial border of the axillary triangle.~Intervention: 10ml ropivacain 0.5%"
2963922|NCT02805569|Active Comparator|Group A|articulating stylet
2963923|NCT02805569|Active Comparator|group C|conventional stylet
2963924|NCT02805556|Experimental|Oral dose of BMS-663068 + intravenous dose of [13C]BMS 626529|Single oral dose of BMS-663068 followed by Single intravenous dose of [13C]BMS 626529
2963925|NCT02805543||diabetes group|34 T2DM patients without vascular complications as diabetes group
2963926|NCT02805543||control group|32 healthy people were recruited as control group
2963927|NCT02805530|Experimental|single arm|"Patients with synchronous metastases at Central Nervous System (CNS), evaluated in less than one week by the Multidisciplinary Committee at National Cancer Institute of Mexico to define the initial treatment. Patients with metastases at other sites than CNS will receive first line systemic treatment, in those EGFR-mutated with tyrosine kinase inhibitors (TKI) and in patients without a driver mutation with first line duplet of chemotherapy based on platin. The type of TKI or chemotherapy will be at discretion of the treating physician.~After 4 cycles of treatment, patients with stable disease or partial response will be evaluated by de Multidisciplinary Committee to establish the type of radical treatment to the primary and to the metastases, radiation therapy and chemoradiotherapy."
2963928|NCT02805517|Experimental|PEAL laparoscopic nephrectomy|Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy using 3 mm instruments.
2963929|NCT02805504|Experimental|Exparel|This arm will receive intraoperative local Liposomal Bupivacaine injection (Exparel) at the port placement site.
2963930|NCT02805504|Active Comparator|Marcaine|This group will receive will local bupivacaine HCl (Marcaine) injection at the port placement site.
2963931|NCT02805491||with hypospadias|parent-child triads as cases (male newborns with hypospadias)
2963932|NCT02805491||without hypospadias|parent-child triads as controls (male newborns without hypospadias)
2963933|NCT02805465|Experimental|HBP Group|CRT Device and His-bundle Pacing. Patients will get His-bundle pacing through a CRT device first for 9 months then switch to Bi-ventricular pacing by the same CRT device for another 9 months.
2963934|NCT02805465|Active Comparator|BiVP Group|CRT Device and Bi-ventricular Pacing. Patients will get BiV pacing for 9 months through a CRT device then switch to His-bundle pacing by the same CRT device for another 9 months.
2963935|NCT02805452|Experimental|Succinate of Solifenacin|1 tablet of 5 mg of succinate of Solifenacin will be administered each day for 3 months.
2963936|NCT02805452|Placebo Comparator|Placebo of Succinate of Solifenacin|1 tablet of placebo of succinate of solifenacin will be administered each day for 3 months.
2963937|NCT02805439|Experimental|S47445 15mg|
2963938|NCT02805439|Experimental|S47445 50mg|
2963939|NCT02805439|Placebo Comparator|Placebo|
2963940|NCT02805426|Experimental|Tranexamic acid|1950 mg oral tranexamic acid + 800 mcg sublingual misoprostol
2963941|NCT02805426|Placebo Comparator|Placebo|oral placebo + 800 mcg sublingual misoprostol
2963942|NCT02805413|Other|DETERMINATION OF BLOOD PRESSURE|"determination and comparison of blood pressure by/with :~Pulse Curve Analysis~Inert gas re-breathing~Central blood pressure device~Vascular ultrasound device~Thoracic Impedance (ICG) - Electrocardiography (ECG) - Phonocardiography (Phono) - Carotid plethysmography (Pneumo)"
2963943|NCT02805400|Other|Neurocognitive performance|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.~For these methods only commercially available CE marked devices will be used."
2963944|NCT02805387|No Intervention|no treatment|Dystocic women where no bicarbonate was given
2963945|NCT02805387|Experimental|Treatment|Dystocic women where bicarbonate was ingested
2963946|NCT02805374|Experimental|ASP1517 fasting then fed|Subjects will receive a single oral dose of ASP1517 under fasting conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fed conditions in period 2.
2963947|NCT02805374|Experimental|ASP1517 fed then fasting|Subjects will receive a single oral dose of ASP1517 under fed conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fasting conditions in period 2.
2963948|NCT02805348||Chronic kidney disease|Patients with pre-dialysis chronic kidney disease complicated by hyperphosphatemia who used bixalomer for the first time.
2963949|NCT02805335|No Intervention|Control group|Group with the sutureless device actually used
2963950|NCT02805335|Experimental|Innovative group|Group with the new device ( KTFIX PLUS)
2963951|NCT02805322|Experimental|Temporal Temperature Measurement|Infrared Temporal Temperature Measurement using the ARC InstaTemp MD in three different age groups with a specified percentage reporting as febrile.
2963952|NCT02805322|Active Comparator|Tympanic and/or Sublingual Temperature|"Tympanic and/or Sublingual Temperature Measurement using one or both of two widely used reference clinical thermometers in three different age groups with a specified percentage reporting as febrile.~Choice between Tympanic and/or Sublingual is determined based on standard of care in study site~Reference Thermometer 1 - Covidien Genius 2 Tympanic Thermometer~Reference Thermometer 2 - Welch Allen SureTemp Plus Sublingual Thermometer"
2963953|NCT02805309|Experimental|Exercise & Cognitive Behavioral Int.|A physical therapist will make home visits, beginning within 1 week of discharge, to deliver an individualized exercise program and cognitive behavioral interventions.
2963954|NCT02805309|Experimental|Exercise Alone|A physical therapist will make home visits, beginning within 1 week of discharge, to deliver an individualized exercise program, without cognitive behavioral interventions.
2963955|NCT02805309|Active Comparator|Attention Control Education Program|Participants will receive telephone-based education sessions from a study health professional.
2963956|NCT02805296|Active Comparator|Double light|"High-intensity phototherapy with blue LED light from above combined with a fiber optic, blue LED blanket from below.~Intervention: Light irradiance: 66 µW/cm2/nm + 39 µW/cm2/nm"
2963957|NCT02805296|Active Comparator|Single light|High-intensity phototherapy with blue LED light from above. Intervention: Light irradiance: 66 µW/cm2/nm
2963958|NCT02805283||Dapagliflozin, dapagliflozin/met ER|Dapagliflozin cohort have at least one pharmacy claim for either dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.
2963959|NCT02805283||Sulfonylurea|Sulfonylurea cohort have at least one pharmacy claim for sulfonylurea in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.
2963960|NCT02805270|Experimental|medication reconciliation intervention|medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
2963961|NCT02805270|No Intervention|usual care|Usual care provided by ward pharmacist, nurses and doctors in the ward
2963962|NCT02805257|Experimental|Mitomycin-C|0.1 ml of Mitomycin-C 0.4mg/ml injection intraoperatively and twice postoperatively.
2963963|NCT02805257|Placebo Comparator|Balanced Salt Solution (BSS)|0.1ml Balanced Salt Solution injection intraoperatively and twice postoperatively.
2963964|NCT02805244|Experimental|JTZ-951, 14C-JTZ-951|Single oral administration on Day 1; 10 mg JTZ-951, 100 μCi of 14C-JTZ-951
2963965|NCT02805231||primary open-angle glaucoma patients|vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in primary open-angle glaucoma patients.
2963966|NCT02805231||randomly age-matched people|vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in randomly age-matched people.
2963967|NCT02805218|Experimental|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy
2963968|NCT02805205|Experimental|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy
2963969|NCT02805192|Other|one Arm: size measurement by Smart phone App|
2963970|NCT02805179|Experimental|High Dose Chemoradiation|Patients will receive high dose radiation based in part on advanced imaging, and concurrent temozolomide. Four weeks after the completion of chemoradiation, patients will receive adjuvant temozolomide.
2963971|NCT02805166|Experimental|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy.
2963972|NCT02805153|Experimental|Experimental/PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy.
2963973|NCT02805153|Active Comparator|Active Comparator/rhG-CSF|patients received daily subcutaneous injections of rhG-CSF(filgrastim) 5 ug/ kg/day. Injections on day 3 after chemotherapy and continued daily until an ANC of at least 10.0 X 10^9/L was documented after the expected nadir, or for a maximum of 14 days
2963974|NCT02805140|Experimental|Virtual exercise and mobile apps|Participants randomized to the intervention arm will join a virtual group convenient for them. They will plan and participate in 8 weeks (every week day) of virtual exercise sessions. Sessions will all be under 30 minutes and include a brief check in amongst participants. The investigators will provide links to information on physical activity and links to online resources for being active.
2963975|NCT02805140|Active Comparator|Exercise resources and information|The investigators will provide links to information on physical activity and links to online resources for being active. Women will be invited to join the exercise groups at the end of the 8 weeks.
2963976|NCT02805127||Patients with COPD and Asthma .|"Patients with COPD and Asthma. Continuous capnography and spirometry measurements of the subjects will be taken form the subjects with at least two minutes recording before the first spirometry assessment.~All clinical diagnoses and treatments will be performed according to the department's protocols.~This is an observational study with no interventions"
2964031|NCT02804711|Experimental|Three doses of high dose vaccine and one dose of placebo|three doses of 60µg/0.6ml per dose and one dose of placebo
2963977|NCT02805114||Asthma and COPD patients|"Patients with COPD and Asthma. Continuous capnography and spirometry measurements of the subjects will be taken from the subjects with at least two minutes recording before the first spirometry assessment.~All clinical diagnoses and treatments will be performed according to the department's protocols.~This is an observational study with no interventions"
2963978|NCT02805101|Experimental|Biodentine|The perforation area of the root is going to be covered by Biodentine
2963979|NCT02805101|Active Comparator|MTA|The perforation area of the root is going to be covered by MTA.
2963980|NCT02805088|Experimental|Bipolar Disorder patients|
2963981|NCT02805088|Experimental|Schizophrenia patients|
2963982|NCT02805088|Experimental|Healthy Volunteers|
2963983|NCT02805075|Experimental|Supportive care (Fructooligosaccharide)|Patients receive FOS PO BID for 21 days starting at 7 days before allogeneic hematopoietic stem cell transplant in the absence of disease progression or unexpected toxicity.
2963984|NCT02805062||Pleural Effusion|Malignant pleural effusion patients requiring investigation with thoracoscopy.
2963985|NCT02805049|Experimental|The study population|The study population consisted of patients admitted to the ICU for septic shock associated with secondary peritonitis and requiring antifungal therapy via echinocandins (micafungin or caspofungin).
2963986|NCT02805036||30 cmH20 for 30 seconds|"plateau pressure is hold on at 30 cmH20 pour 30 seconds. The cardiac output and the lung aeration is assessed by ultrasound measures at 3 times: before, at the end of the recruitment and 30 minutes later.~echocardiography - arterial oximetry"
2963987|NCT02805036||10 cmH20 above|"plateau pressure is hold on at 10 cmH20 above. The cardiac output and the lung aeration is assessed by ultrasound measures at 3 times: before, at the end of the recruitment and 30 minutes later.~echocardiography - arterial oximetry"
2963988|NCT02805023|Placebo Comparator|Placebo|Intramuscular injection of control medium only
2963989|NCT02805023|Experimental|BGC101|Intramuscular injection of BGC101 (autologous EnEPC preparation)
2963990|NCT02805010|Experimental|Subcutaneous(SC) Abatacept|
2963991|NCT02805010|Placebo Comparator|Placebo|
2963992|NCT02804984||ICUS|idiopathic cytopenia of undetermined significance (ICUS)
2963993|NCT02804958||STEMI treated with primary PCI|Patients diagnosed with acute ST-segment elevation myocardial infarction and treated with primary percutaneous coronary intervention were consecutively registered.
2963994|NCT02804945|Experimental|Mesenchymal Stem Cells|"Participants receive Mesenchymal Stem Cells (MSCs) for adult respiratory distress syndrome (ARDS).~Participants receive a maximum dose of 3 x 10^6 cell/Kg by vein one time on Day 1."
2963995|NCT02804932|Experimental|Beetroot crystals (nitrate)|Participants will receive a nitrate rich beetroot powder (10g/day) for 8 weeks.
2963996|NCT02804932|Placebo Comparator|Placebo (beetroot powder, no nitrate)|Participants will receive a beetroot powder placebo (no nitrate) for 8 weeks.
2963997|NCT02804919|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
2963998|NCT02804906|Experimental|Home-Based Physical Therapy|
2963999|NCT02804906|Active Comparator|Control-30-minute counseling session|Participants in the control arm will be provided with a 30-minute counseling session on risk factor modification prior to discharge.
2964000|NCT02804893|Active Comparator|VATS GROUP|VATS lobectomy or segmentectomy
2964001|NCT02804893|Active Comparator|RATS GROUP|Robotic lobectomy or segmentectomy
2964002|NCT02804880|Experimental|Group A|HAR + AWARD + Referral Card + A4 leaflet
2964003|NCT02804880|Experimental|Group B|LTM + AWARD + Referral Card + A4 leaflet
2964004|NCT02804880|Active Comparator|Group C|Brief advice + 12-page booklet
2964005|NCT02804867||Depression|
2964006|NCT02804867||Bipolar disorder|
2964007|NCT02804867||Control|
2964008|NCT02804854|Experimental|Patients in ICU|Delivery of Neutrophil Activation Probe (NAP) (80mcgs) to ventilated patients up to three times.
2964009|NCT02804841|Experimental|Intervention|Healthy, Community Dwelling; Aged 60-80 years; Cholecalciferol -Vitamin D3, 4000 international units (IU) on alternating days.
2964010|NCT02804841|Placebo Comparator|Placebo|Healthy, Community Dwelling; Aged 60-80 years; Placebo -gel capsule containing no vitamin D on alternating days.
2964011|NCT02804828|Active Comparator|Arm 1|
2964012|NCT02804828|Sham Comparator|Arm 2|
2964013|NCT02804815|Active Comparator|Aspirin 100mg|Aspirin 100mg
2964014|NCT02804815|Placebo Comparator|Placebo 100mg|100mg Placebo
2964015|NCT02804815|Active Comparator|Aspirin 300mg|Aspirin 300mg
2964016|NCT02804815|Placebo Comparator|Placebo 300mg|300mg Placebo
2964017|NCT02804776|Experimental|Gefitinib|Gefitinib 250mg oral daily will be given for 4 weeks prior to surgery
2964018|NCT02804763|Placebo Comparator|Standard-of-care + Placebo|Placebo in a specified sequence for a total of 24 weeks
2964019|NCT02804763|Experimental|Standard-of-care + DZP dose 1|Dapirolizumab pegol (DZP) dose 1 in a specified sequence for a total of 24 weeks
2964020|NCT02804763|Experimental|Standard-of-care + DZP dose 2|Dapirolizumab pegol (DZP) dose 2 in a specified sequence for a total of 24 weeks
2964021|NCT02804763|Experimental|Standard-of-care + DZP dose 3|Dapirolizumab pegol (DZP) dose 3 in a specified sequence for a total of 24 weeks
2964022|NCT02804750|Experimental|CORT125134|"Group 1: 100 mg/day for 4 weeks, then 150 mg/day for 4 weeks, then 200 mg/day for 4 weeks.~Group 2: 250 mg/day for 4 weeks, then 300 mg/day for 4 weeks, then 350 mg/day for 4 weeks, then 400 mg/day for 4 weeks."
2964023|NCT02804737||Web Group|Patients given web site (aiddly) instructions for colonoscopy
2964024|NCT02804737||Paper Group|Patients given paper instructions for colonoscopy
2964025|NCT02804724||Newly diagnosed individuals with HIV|Individuals newly diagnosed with HIV in Grampian between January 2009 and December 2014
2964026|NCT02804711|Experimental|Four doses of low dose vaccine|four doses of 15µg/0.6ml per dose
2964027|NCT02804711|Experimental|Four doses of middle dose vaccine|four doses of 30µg/0.6ml per dose
2964028|NCT02804711|Experimental|Four doses of high dose vaccine|four doses of 60µg/0.6ml per dose
2964029|NCT02804711|Experimental|Three doses of low dose vaccine and one dose of placebo|three doses of 15µg/0.6ml per dose and one dose of placebo
2964030|NCT02804711|Experimental|Three doses of middle dose vaccine and one dose of placebo|three doses of 30µg/0.6ml per dose and one dose of placebo
2964033|NCT02804698|Experimental|Meta Salud Diabetes-Intervention|"Attend the thirteen weekly educational classes and physical activity group (prior physician approval) that are part of the Meta Salud Diabetes program.~Allow the research staff to collect your cholesterol, glucose, A1c, triglyceride levels, as well as your blood pressure, height, weight, and waist and hip circumference.~Respond to a survey about your nutrition and physical activity habits on three separate occasions (at the start of the 13-week program, just after you finish the program, and nine months after you finish the program).~You may also be invited to participate in a follow-up interview, where you will be asked about your experience during and after the Meta Salud Diabetes program."
2964034|NCT02804698|No Intervention|Meta Salud Diabetes-Comparison Group|"Allow the research staff to collect your cholesterol, glucose, A1c, triglyceride levels, as well as your blood pressure, height, weight, and waist and hip circumference.~Respond to a survey about your nutrition and physical activity habits on three separate occasions (you will answer the first survey as soon as you finish reading and agree to participate by signing this form, the second survey will be three months from now, and the third survey will be 12 months from now)."
2964035|NCT02804685|No Intervention|Control|It consists on only a regular training performance
2964036|NCT02804685|Experimental|Experimental|It consists on performing the protocol which includes 6 strength, agility and balance exercises together with the regular training. The exercise program has to be performed twice a week during 6 weeks
2964037|NCT02804646|Experimental|endostar and chemotherapy group|recombinant human endostatin(endostar) injection was continuous intravenous transfusion for 7 days,with the dose of 15mg/m2 per one day,every 21 days of a cycle,combined with pemetrexed plus cisplatin or carboplatin.
2964038|NCT02804646|Active Comparator|chemotherapy group|pemetrexed injection was intravenous with the dose of 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin,without recombinant human endostatin.
2964039|NCT02804633|Active Comparator|IV acetaminophen group|In addition to PCA (morphine or hydromorphone) all patients receive 1 gram of IV acetaminophen (100 ml ) 30 minutes prior to operation and every 6 hours thereafter for up to 5 days post-operatively or discharge.
2964040|NCT02804633|Placebo Comparator|Placebo Group|In addition to PCA (morphine or hydromorphone) all patients received placebo (100 ml normal saline) given 30 minutes prior to operation and every 6 hours thereafter for up to 5 days post-operatively or discharge
2964041|NCT02804620|Experimental|PLEASED|The PLEASED intervention arm will receive peer leader who is patients with diabetes that has been gone through our trainings. Also, they will receive three free health screenings (baseline, 3 months, 12 months) and monetary compensation for their time and effort.
2964042|NCT02804620|No Intervention|Wait List|The wait list will receive three free health screening (at baseline, 3months, 12 months) and monetary compensation for their time and effort.
2964043|NCT02804607||skin lesion|severe skin traumatism occurring during childhood and which had required an initial graft.
2964044|NCT02804594|Active Comparator|N-acetyl cysteine|1250 mg of N-acetyl cysteine three times daily
2964045|NCT02804594|Placebo Comparator|Placebo|placebo three times daily
2964046|NCT02804581|Experimental|Gum Arabic|Oral intake of 30 gram of Gum Arabic daily for 12 weeks
2964047|NCT02804568|Experimental|Group 1|Olanzapine/samidorphan 10 mg/10 mg
2964048|NCT02804568|Experimental|Group 2|Olanzapine/samidorphan 20 mg/10 mg
2964049|NCT02804555|Active Comparator|Oxygen support|5 liter / minute oxygen has given to the mothers on face mask.
2964050|NCT02804555|No Intervention|Room air|Oxygen support has not given to the mothers.
2964051|NCT02804542||Fascia Iliaca Block Cohort|Prospective patients receiving fascia iliaca blocks A prospective Observational study of Hip fracture patients that are offered fascia iliaca blocks as standard of care in the ED.
2964052|NCT02804542||Retrospective Control Cohort|No fascia iliaca block performed A retrospective review will be done of hip fracture patients that did not receive fascia iliaca blocks (before fascia iliaca blocks being offered in the ED as standard of care).
2964053|NCT02804529|Experimental|Meng's Point entry|Meng's entry involved a 0.2 cm horizontal or vertical incision using the Veress needle in the cross of lateral border of the left rectus abdominis and rib arch.
2964054|NCT02804529|Experimental|Palmer's Point entry|Palmer's entry involved a 0.2 cm horizontal or vertical incision with the Veress needle in the left midclavicular line approximately 3 cm caudal to the 10th rib
2964055|NCT02804529|Experimental|Periumbilllicus entry|Periumbilllicus entry involved a 0.2 cm horizontal or vertical midline incision using the Veress needle in the lower or uper border of the umbilicus.
2964056|NCT02804516|Experimental|the nurse did early mobilization|the nurses know and do what is the early mobilization in ICU
2964057|NCT02804516|Experimental|the nurse do not do early mobilization|the nurses do not know and do what is the early mobilization in ICU
2964058|NCT02804503|Experimental|Calorie Labels|A menu with rank ordered calorie labels and a statement on the energy needs per meal.
2964059|NCT02804503|Experimental|Exercise Labels|A menu with rank ordered exercise labels showing minutes of brisk walking necessary to burn the food calories.
2964060|NCT02804503|Active Comparator|No Labels|A menu with no labels
2964061|NCT02804490|Placebo Comparator|White maize|Conventional maize flour
2964062|NCT02804490|Experimental|Biofortified maize|Provitamin A carotenoid biofortified maize flour
2964063|NCT02804490|Active Comparator|Fortified maize|Retinyl palmitate fortified maize flour
2964064|NCT02804451|Experimental|Intubation without chest compression|normal airway, without chest compression during intubation.
2964065|NCT02804451|Experimental|Intubation with uninterrupted chest compression|normal airway, with continuous chest compressions
2964066|NCT02804425|Experimental|"actor-spectator group"|actor at least once during the immersive simulation session
2964067|NCT02804425|No Intervention|"spectator-only group"|observer during the whole one-day session but participation in the debriefing part of the four scenarios
2964068|NCT02804412|Active Comparator|Control group|Patients received a standard, house-typical aphasia therapy in single and group therapy sessions
2964069|NCT02804412|Experimental|CIAT-group|Patients received constraint-induced aphasia therapy.
2964070|NCT02804412|Active Comparator|communication treatment group (CTG)|Patients received aphasia group therapy without constraints
2964169|NCT02803606||hypothermia|Preterm neonates less than 32 weeks of gestational age admitted at birth to the Neonatal Medicine unit
2964071|NCT02804399|Experimental|all subjects|subjects will receive a 100 mg single oral dose of PF-06463922 followed by a 100 mg single dose of PF-06463922 combined with 600 mg QD dose of rifampin with at least 10 days of washout period between two PF-06463922 doses.
2964072|NCT02804386|Experimental|treatment|Sofosbuvir, 400 mg OD for 6 months
2964073|NCT02804373|Placebo Comparator|placebo daily|daily administration of placebo during 28 days : placebo continuous
2964074|NCT02804373|Active Comparator|24 IU of oxytocin daily|24 IU of daily oxytocin administration during 28 days : oxytocin continuous
2964075|NCT02804373|Active Comparator|24 IU of oxytocin every 3 days|24 IU of daily oxytocin every 3 days and placebo the following 2 days after each oxytocin administration during 28 days
2964076|NCT02804360|Experimental|therapy|Dexamethasone injection
2964077|NCT02804347||Patient|Patients will be receiving either ECT or iTBS as a depression management. Olfactory functioning will be assessed at pre-treatment and 6 weeks later at post-treatment using Sniffin Sticks. Cognition will also be tested using Cognitive Function Imaging and Battery in the fMRI as well as Cognitive Batteries outside of the scanner at pre-treatment, 6 weeks later at post-treatment, and 3 months after the final treatment session.
2964078|NCT02804347||Control|Controls will have their olfactory functioning assessed at baseline and 6 weeks after the baseline assessment using Sniffin Sticks. Cognition will also be tested using Cognitive Function Imaging and Battery in the fMRI as well as Cognitive Batteries outside of the scanner at pre-treatment, 6 weeks later at post-treatment, and 3 months after the final treatment session.
2964079|NCT02804334||Healthy Volunteers|Participants with no current or lifetime psychiatric disorders
2964080|NCT02804334||Untreated Bipolar Disorder|Participants who meet criteria for current bipolar disorder but who are not currently taking any psychotropic medications
2964081|NCT02804308|No Intervention|Group Control with breast cancer and without breast cancer|Stretching exercises, lasting 40 minutes each session, 2 times a week for nine months
2964082|NCT02804308|Experimental|Combined Training with breast cancer and without breast cancer|Combined Training: 36 weeks duration, 3 times a week on nonconsecutive days. The combined training program lasts 70 minutes per session, with 40 minutes of resistance training and 30 minutes of aerobic training.
2964083|NCT02804295|Other|Collaborative Care Intervention|All enrolled participants received the collaborative care intervention over 6 months.
2964084|NCT02804282|Experimental|sc2Wear Furosemide Combination Product|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump) for subcutaneous administration of 80 mg dose delivered over 5 hours.
2964085|NCT02804269||Healthy Volunteer|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
2964086|NCT02804269||Dilated Cardiomyopathy|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
2964087|NCT02804269||Hypertrophic cardiomyopathy|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
2964088|NCT02804269||Ischemic heart disease with reduced EF|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
2964089|NCT02804269||Ischemic heart disease with normal EF|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
2964090|NCT02804243|Active Comparator|nasal high flow therapy|In this group, patients have undergone rehabilitation under the nasal high flow therapy (FiO2 100%, oxygen flow from 30 to 60 L/min) during four weeks.
2964091|NCT02804243|No Intervention|oxygen therapy|In this group, patients have undergone rehabilitation under the oxygen therapy via a nasal canula (6 L/min) during four weeks.
2964092|NCT02804230|Experimental|MRgFUS Ablation of Epileptic Foci|MR-Guided Focused Ultrasound
2964093|NCT02804204||Anti-TNF|
2964094|NCT02804191|Experimental|LO2A|Sodium Hyaluronate
2964095|NCT02804191|Placebo Comparator|Placebo-Controlled|Saline.
2964096|NCT02804178|Experimental|ATR-101|Ascending dose levels of ATR-101 beginning with 125 mg by mouth BID up to 1000 mg BID.
2964097|NCT02804165|Other|Target high-risk subjects or subpopulations for T1D|Confirmation of the role of enteroviral infection in T1D and characterization of gene-enterovirus interactions should open up new avenues for understanding the pathogenesis of T1D and give clues on possible new therapeutic perspectives. Clinical applications might be further developed in order to extend the lag period might between positive autoantibodies detection and T1D age at onset in genetically predisposed subjects. This innovative project opens the door of the development of preventive therapy for T1D, as enterovirus vaccination.
2964098|NCT02804152|Other|CBT for Chronic Pain|single arm open-label design
2964099|NCT02804139|Active Comparator|Standard care|Standard Care after C-section with no additional physical therapy.
2964100|NCT02804139|Experimental|Standard care plus physical therapy|Subjects attend 1 to 2 physical therapy sessions per week for 6 weeks beginning 8-10 weeks post-C section. The physical therapy program includes scar management, core retraining, and lumbar and pelvic joint mobilization
2964101|NCT02804126|Experimental|TAP (transversus abdominis plane)|Ultrasound-guided transversus abdominis plane block at the end of cesarean section
2964102|NCT02804126|Experimental|QL (quadratus lumborum)|Ultrasound-guided quadratus lumborum block at the end of cesarean section
2964103|NCT02804113|Experimental|Supera Peripheral Stent System|
2964104|NCT02804087|Experimental|MobiusHD Implantation|
2964105|NCT02804087|Sham Comparator|Sham Implantation|Sham
2964106|NCT02804074|Active Comparator|Group 1|Management strategy of blood pressure based on office BP as a guide to treatment
2964107|NCT02804074|Experimental|Group 2|Management strategy of blood pressure based on 24-hour ABPM as a guide to treatment
2964108|NCT02804061|Active Comparator|Full NELIP|This group will receive the full Nutrition and Exercise Lifestyle Intervention Program (two behavior changes) from enrollment until birth and serves as the comparator control (Group A).
2964109|NCT02804061|Experimental|Nutrition followed by Exercise (N+E)|Intervention - Nutrition component only (one behaviour) until 24 week assessment, then the addition of the second behavior change (Exercise component) at 25 weeks, with both behaviours followed until birth (Group B).
2964230|NCT02803073|Placebo Comparator|Control|Patients in the control group will receive intramuscular normal saline injections.
2964110|NCT02804061|Experimental|Exercise followed by Nutrition (E+N)|Intervention - Exercise component only (one behaviour) until 24 week assessment, after which there will be the addition of the second behaviour change (Nutrition component), with both behaviours followed until birth (Group C).
2964111|NCT02804048|Experimental|Pelvic Floor Muscle Training|"superficial heat pelvic floor muscle intra vaginal manual therapy. PERFECT scale is applied in 5 sessions and based on the result of each assessment is performed the treatment plan with exercises of the pelvic floor muscles.~It is performed manual therapy in iliopsoas, diaphragm and piriformis. From the fourth session, initiate treatment with electromyographic biofeedback based on the result of PERFECT scale."
2964112|NCT02804048|Placebo Comparator|Low back|superficial heat low back Manual therapy in piriform, lumbar, iliopsoas and diaphragm.
2964113|NCT02804035|Experimental|sc2Wear Furosemide Combination Product|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump) for subcutaneous administration of 80 mg dose delivered over 5 hours.
2964114|NCT02804022|Experimental|VPIA analgesia system|Vital-signs-integrated patient-assisted intravenous opioid analgesia system (VPIA). The vital signs (oxygen saturation, respiratory rate, heart rate) will be close monitored when patients is using VPIA pump. The drug used is intravenous morphine (1mg per milligram) with bolus of 1 mg.
2964115|NCT02803996|Active Comparator|Part A- Single Dose- 400 mg Aramchol|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
2964116|NCT02803996|Active Comparator|Part A- Single Dose- 600 mg Aramchol|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
2964117|NCT02803996|Placebo Comparator|Part A-Single Dose-Placebo|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
2964118|NCT02803996|Active Comparator|Part B-Multiple Dose-400 mg Aramchol|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
2964119|NCT02803996|Active Comparator|Part B-Multiple Dose-600 mg Aramchol|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
2964120|NCT02803996|Placebo Comparator|Part B-Multiple Dose-Placebo|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
2964121|NCT02803983||Pediatric hip plate|The children were treated with pediatric hip plate.
2964122|NCT02803983||Cannulated screw|The children were treated with cannulated screw.
2964123|NCT02803957|Experimental|Treatment Group|Subjects with degenerative mitral valve insufficiency treated with artificial chordae implanted using the NeoChord DS1000
2964124|NCT02803957|Active Comparator|Control Group|Subjects with degenerative mitral valve insufficiency treated with standard surgical mitral valve repair
2964125|NCT02803944||Cystic fibrosis patients taking azithromycin|Cystic fibrosis patients taking azithromycin continuously for two years.
2964126|NCT02803931|Experimental|Cardiogoniometry|Every patient in the study will have a cardiogoniometry recording performed by the Cardiologic Explorer whilst an inpatient on the ward. This will then be taken for interpretation to see if it indicates what vessel is the culprit causing their NSTEMI. The researcher interpreting the cardiogoniometry recording will be blind to the results of the ECG and the coronary angiography,
2964127|NCT02803931|Active Comparator|12-lead ECG|For every patient in the study, copies of their 12-lead ECGs performed during their admission will be taken for interpretation by an independent cardiologist. This will then be taken for interpretation to see if it indicates what vessel is the culprit causing their NSTEMI.The researcher interpreting the ECG recordings will be blind to the results of the cardiogoniometry and the coronary angiography,
2964128|NCT02803918|Experimental|Lixisenatide|Administration of 3 ascending repeated doses of lixisenatide once daily and subcutaneously. Background therapy (metformin and basal insulin) will be administered daily about the same time as usually done.
2964129|NCT02803918|Placebo Comparator|Placebo|Administration of 3 ascending repeated doses of matching placebo once daily and subcutaneously. Background therapy (metformin and basal insulin) will be administered daily about the same time as usually done.
2964130|NCT02803905|Active Comparator|standard procedure: intrahepatic|Liver infusion: the islet mixture is delivered slowly via injection through a syringe attached to the catheter in the portal vein or portal vein tributary. Access to the portal vein is achieved by percutaneous transhepatic access under fluoroscopic, ultrasonographic, or real-time CT guidance. Alternatively access to a mesenteric or omental venous tributary of the portal vein can be obtained by mini-laparotomy under general anesthesia (transplant site preference or in the extremely rare circumstance that percutaneous access cannot be achieved). At a minimum, portal pressure will be monitored before and after infusion of the islet product. Portal pressure measurements will be documented in the medical record. Gel foam plugs and/or collagen/thrombin paste will be used to embolize the entire peripheral catheter tract immediately before the catheter is withdrawn, to reduce the chances of bleeding.
2964131|NCT02803905|Experimental|experimental procedure: omentum|Omentum infusion: briefly, islets are spread in the surface of the omentum, in a single omental pouch site. Transplanting in a single site will reduce risks. A single dose of at least 5000 IEQ/KG will be transplanted. The investigators should be able to achieve a meaningful metabolic improvement and prevention of severe hypoglycemia, as previously seen in experience with intraportal islet transplants. Recombinant human thrombin is added to the islets placed on the omentum to promote formation of a gel clot and facilitate adherence to the surface of the omentum. A pouch is then created by folding the omentum. The pouch is secured inn place with stitches.
2964132|NCT02803892|Placebo Comparator|Group 1: Placebo|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received placebo x 2 placebo (Group 1) After 4 weeks of treatment, patients will discontinue relevant placebo treatment, but continue the second placebo for a further 8 weeks
2964133|NCT02803892|Experimental|Group 2: Rapamycin plus Placebo|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received rapamycin plus placebo. After 4 weeks of treatment, patients will discontinue rapamycin, but continue the second placebo for a further 8 weeks
2964134|NCT02803892|Experimental|Group 3: Rapamycin plus Vildagliptin|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received rapamycin plus vildagliptin. After 4 weeks of treatment, patients will discontinue rapamycin , but continue Vildagliptin o for a further 8 weeks
2964135|NCT02803879|Experimental|Cardiogoniometry (CGM)|All patients attending clinic for follow up appointments following the implantation of a CRT device will be eligible for inclusion in the study. If they consent for enrolment in the study each patient will undergo a series of 4 CGM recordings whilst in their follow up appointment. They will undergo each of these during different pacemaker settings. These are: 1) No pacing, 2) Paced from the right ventricular lead; 3) Paced from the left ventricular lead and 4) Paced from both ventricular leads. After this has been done the participants involvement in the study will have finished.
2964136|NCT02803866||Parents of preterm newborns (25-32 weeks of gestation)|Parents (mother or mother+father) of preterm newborns admitted at the Gregorio Marañón Hospital from birth, recruited during the first 10 days of preterm newborn hospitalization and receiving the training program CAP-PREM
2964137|NCT02803853|Experimental|Intervention|The intervention is a multi-level, multi-component intervention designed to increase access to and consumption of healthier foods in Native American Communities. Intervention components will occur at the policy level; food retail outlet level; neighborhood level- schools and worksites, and household level.
2964138|NCT02803853|No Intervention|Control|Similar to many community- based public health research programs, the control arm will not receive any intervention components during the initial intervention period. However, after all assessments are completed they will receive a 'delayed intervention' protocol, where the community receives the intervention elements as described in the intervention arm after assessment measures have been completed.
2964139|NCT02803840|Other|Experimental|DLBCL patients with indication for palliative radiotherapy
2964140|NCT02803827|Experimental|Rapid diagnostics and probiotic|Participants randomized to this arm will have rapid enteric diagnostics performed on the day of enrolment. Those found to have a treatable pathogen will be prescribed antimicrobials that day. Participants will also be given Lactobacillus reuteri DSM 17938 5 x 10e8 cfu/mL x 60 days.
2964141|NCT02803827|Other|Rapid diagnostics and placebo|Participants randomized to this arm will have rapid enteric diagnostics performed on the day of enrolment. Those found to have a treatable pathogen will be prescribed antimicrobials that day. Participants will also be given placebo x 60 days.
2964142|NCT02803827|Other|No rapid diagnostics and probiotic|Participants randomized to this arm will have stool specimens processed after the conclusion of the study. Participants will also be given Lactobacillus reuteri DSM 17938 5 x 10e8 cfu/mL x 60 days.
2964143|NCT02803827|Placebo Comparator|No rapid diagnostics and placebo|Participants randomized to this arm will have stool specimens processed after the conclusion of the study. Participants will also be given placebo x 60 days.
2964144|NCT02803814|Experimental|Superior mesenteric artery approach|Initial approach of the superior mesenteric artery to perform a pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area
2964145|NCT02803814|Active Comparator|Classic approach|Classic approach to perform a pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area
2964146|NCT02803801|Experimental|Build Your Parenting Toolkit Program|Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
2964147|NCT02803788|Active Comparator|Group O|this group will receive inj. ondansetron 4mg iv stat and inj. dexamethasone 8mg iv stat just before extubation.
2964148|NCT02803788|Experimental|Group R|this group will receive inj. ramosetron 0.3mg iv stat just before extubation.
2964149|NCT02803775|Active Comparator|Paced|Paced arm in which the left heart lead electrode is selected utilizing the longest time to when patient right ventricle lead is pacing. The result of the pacing algorithm becomes the patient's pacing location for the study duration (self-assigned algorithm within this cohort).
2964150|NCT02803775|Active Comparator|Sensed|Sensed arm is based on the longest time that patient own heart's conduction reaches the left heart lead electrode.The result of the sensing algorithm becomes the patient's pacing location for the study duration (self-assigned algorithm within this cohort).
2964151|NCT02803762|Experimental|Investigational: [14C] Pacritinib|All enrolled subjects are checked in the day before drug administration. Following at least a 10-hour fast (not including water), each subject will receive an oral dose of 400 mg [14C]pacritinib (containing 100 μCi radioactivity).
2964152|NCT02803749|Experimental|Buspirone|Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
2964153|NCT02803749|Placebo Comparator|Placebo|Flexible dosage placebo for 12 weeks.
2964154|NCT02803736|Experimental|Real acupuncture group|Patients in the real acupuncture group will receive true acupuncture 3 times a week for 4 weeks (12 sessions). A standardized prescription of six acupuncture points is used unilaterally. Needles are inserted and manipulated manually until needling sensation (de qi) is obtained, and are retained for 20 minutes with manual manipulation at 10 minutes. Acupuncturists are trained to inquire about specific needle sensations when providing true acupuncture.
2964155|NCT02803736|Sham Comparator|Sham acupuncture group|Patients in the sham acupuncture group will receive sham acupuncture 3 times a week for 4 weeks (12 sessions).
2964156|NCT02803723|Experimental|Holding-cuddling + Sucrose|The Holding-cuddling is started 5 minutes before and the sucrose administration is started 2 minutes before blood sampling.
2964157|NCT02803723|Active Comparator|Sucrose alone|The sucrose administration is started 2 minutes before blood sampling.
2964158|NCT02803710||Case group|patients with decreased susceptibility to carbapenems Enterobacteriaceae isolate
2964159|NCT02803710||Control-group|patients with Enterobacteriaceae isolate without decreased susceptibility to carbapenems
2964160|NCT02803697||Patients|All patients who underwent surgery for a NFPA in Reims university hospital between 01/01/1991 and 31/12/2004
2964161|NCT02803684|Experimental|Single arm|Whole cohort
2964162|NCT02803671|Experimental|patent ductus arteriosus|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
2964163|NCT02803671|Experimental|without patent ductus arteriosus|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
2964164|NCT02803671|Experimental|patent ductus arteriosus + cardiac or respiratory therapy|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
2964165|NCT02803658|Experimental|infertile couples|smoking behavior
2964166|NCT02803658|Active Comparator|Fertile couples|smoking behavior
2964167|NCT02803645|Experimental|healthy|blood sample
2964170|NCT02803593|No Intervention|Control|165 Asian American breast cancer survivors (55 per sub-ethnic group) who do not use the TICAA, but use the information on breast cancer by the American Cancer Society (ACS)
2964171|NCT02803593|Experimental|Intervention (TICAA)|165 Asian American breast cancer survivors (55 per sub-ethnic group) who use the intervention (TICAA) and the information by the ACS. The intervention is a technology-based information and coaching/support program to enhance survivorship experience of Asian American breast cancer survivors.
2964172|NCT02803567|Experimental|Intervention|Those in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education on substance use. Content in the intervention will focus on health promotion and will deliver positive messages about health.
2964173|NCT02803567|No Intervention|Control|Those in the control arm will receive treatment as usual.
2964174|NCT02803554|Experimental|Young donor plasma|An infusion of plasma derived from donors aged 25 years or younger
2964175|NCT02803541|Experimental|12 day mainstream summer camp experience|The 12 day mainstream camp experience involves increased exercise from baseline at home. Can this exercise and peer contact improve physical endurance as measured by the 6 minute walk test and self concept as measured by a modified Harter scale
2964176|NCT02803528|Experimental|Biodentine|The exposed area of the pulp is going to be covered with Biodentine.
2964177|NCT02803528|Active Comparator|MTA|The exposed area of the pulp is going to be covered with MTA
2964178|NCT02803515|Experimental|Patient with HIPEC|
2964179|NCT02803515|Sham Comparator|Patient without HIPEC|
2964180|NCT02803502|Experimental|hemophilia|Patients with severe hemophilia (or moderate hemophilia if presence of hemorrhages) under prophylaxy and subjected to a pharmacokinetic profile of factor VIII
2964181|NCT02803489|Experimental|medical device intervention|
2964182|NCT02803476||Cases|Polycystic ovary syndrome (PCOS) female patients. 20-35 years of age.
2964183|NCT02803476||Controls|Non-PCOs female subjects. 20-35 years of age.
2964184|NCT02803463|Active Comparator|Peritoneal Closure|open appendectomy with peritoneal closure
2964185|NCT02803463|Active Comparator|Peritoneal Non Closure|open appendectomy without peritoneal closure
2964186|NCT02803450|Experimental|High Volume, Low Concentration via Epidural Needle|"Epidural loading: Participants will receive 20ml of 0.0625% bupivacaine with fentanyl 1mcg/ml epidural loading dose in 10ml increments five minutes apart via epidural needle followed by catheter placement.~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.03125% bupivacaine with 1mcg/ml fentanyl. The infusion rate will be set at 20ml/hr basal rate and 8ml every 15 minutes on demand with lockout of 52ml/hr.~For inadequate analgesia: One additional 10ml boluses of the experimental 0.0625% bupivacaine with 1mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
2964187|NCT02803450|Experimental|High Volume, Low Concentration via Epidural Catheter|"Epidural loading: Participants will receive 20ml of 0.0625% bupivacaine with fentanyl 1mcg/ml epidural loading dose in 10ml increments five minutes apart via the epidural catheter administration following catheter placement.~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.03125% bupivacaine with 1mcg/ml fentanyl. The infusion rate will be set at 20ml/hr basal rate and 8ml every 15 minutes on demand with lockout of 52ml/hr.~For inadequate analgesia: One additional 10ml boluses of the experimental 0.0625% bupivacaine with 1mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
2964188|NCT02803450|Active Comparator|Low Volume, High Concentration via Epidural Catheter|"Standard of Care Epidural Administration Epidural loading: Participants will receive 10ml of 0.125% bupivacaine with fentanyl 2mcg/ml in 5 ml increments 5 minutes apart via the epidural catheter following epidural catheter placement, per standard of care.~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.0625% bupivacaine with 2mcg/ml fentanyl. The infusion rate will be set at 10ml/hr basal rate and 4ml every 15 minutes on demand with lockout of 26ml/hr.~For inadequate analgesia: One additional 5ml boluses of the standard 0.125% bupivacaine with 2mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
2964189|NCT02803437||Xofigo / Cohort 1|Patients suffered from CRPC with bone metastases are enrolled after the physician's decision of Xofigo treatment under the routine clinical practice.
2964190|NCT02803424|Experimental|Volume controlled ventilation|During the steep trendelenburg position and pneumoperitoneum, volume controlled ventilation will be applied with 8ml/kg (ideal body weight) and inspiration:expiration ratio (I:E) = 1:2.
2964191|NCT02803424|Active Comparator|Autoflow-volume controlled ventilation|During the steep trendelenburg position and pneumoperitoneum, Autoflow-volume controlled ventilation will be applied with 8ml/kg (ideal body weight) and inspiration:expiration ratio (I:E) = 1:2.
2964192|NCT02803398|Experimental|Patient at risk of venous thrombosis|
2964193|NCT02803385|Active Comparator|Continous Epidural Analgesia|Continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The Patient Controlled Analgesia pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes
2964194|NCT02803385|Active Comparator|Patient Controlled Epidural Analgesia|Patient controlled epidural analgesia in form of PCA pumps with continuous rate of 5-8ml/hour & demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .
2964195|NCT02803372|Experimental|Intervention group|In addition to routine monitoring, invasive LiDCOrapid is used to monitor mean arterial pressure (MAP), stroke volume variation (SVV) and cardiac index (CI). Intraoperative goal-directed circulatory management is performed, i.e., to maintain MAP > 95 mmHg, SVV < 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery.
2964196|NCT02803372|Active Comparator|Control group|Routine monitoring is performed, which includes invasive blood pressure and urine output. Intraoperative routine circulatory management is performed, i.e., to maintain blood pressure within 20% from baseline level and urine output > 0.5 ml/kg/h.
2964231|NCT02803060|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2964299|NCT02802579|Active Comparator|A: standard protocol|Standard dual-source computed tomography coronary angiography protocol
2964300|NCT02802579|Experimental|B: enhanced protocol|enhanced dual-source computed tomography coronary angiography protocol
2964197|NCT02803359|Experimental|Planned Procedure|Endoscope will be connected to a camera and monitor. Needle electrodes will then be positioned into the false vocal fold mucosa bilaterally, under direct visualization of the needle tip on the monitor, but the needles will be passed trans-orally in the operating room. For those participating during an open-neck surgery, the surgery will commence as planned and once exposure of the superior laryngeal nerve is obtained, the surgeon will insert the electrodes directly into the nerve trunk for the purposes of recording. In Surgery or cervical lymphadenectomy, the electrode will be placed at a superficial depth and needle placement will be performed with one on each side at a location approximately mid-fold.
2964198|NCT02803359|Experimental|Routine Laryngoscopy|Nasolaryngoscopy will be performed in the office in the standard fashion with the use of oxymetazoline for topical decongestion of the nasal mucosa, In both settings, the electrode will be placed at a superficial depth and needle placement will be performed with one on each side at a location approximately mid-fold
2964199|NCT02803346||septic shock patients|
2964200|NCT02803333||Data Capture Participants|This is a prospective observational cohort study of advanced non-small cell lung cancer patients (stage 3b/4) receiving treatment at the Moffitt Cancer Center (MCC) or The Ohio State Comprehensive Cancer Center (OSUCCC) to assess treatment impact at monthly intervals from baseline to 6 months post-enrollment.
2964201|NCT02803320|Experimental|SPF 50 Y65 110|All subjects received baseline skin evaluation and 1 day of sun exposure.
2964202|NCT02803307|Experimental|6 mg TLC599|6 mg DSP with 50 μmol PL
2964203|NCT02803307|Experimental|12 mg TLC599|12 mg DSP with 100 μmol PL
2964204|NCT02803294|Experimental|Aortic Stenosis/regurgitation|Transcatheter aortic valve replacement
2964205|NCT02803281||Lung Cancer - Frialty Assessment|Patients who will undergo surgery for lung cancer
2964206|NCT02803281||Esophageal Cancer - Frailty Assessment|Patients who will undergo esophagectomy for esophageal cancer
2964207|NCT02803268|Experimental|MT-8554 low dose|Patients who meet eligibility criteria will be administered once daily either low dose of MT-8554 or a matching Placebo from Day 1 to 14.
2964208|NCT02803268|Experimental|MT-8554 middle dose|Patients who meet eligibility criteria will be administered once daily either middle dose of MT-8554 or a matching Placebo from Day 1 to 14.
2964209|NCT02803268|Experimental|MT-8554 high dose|Patients who meet eligibility criteria will be administered once daily either high dose of MT-8554 or a matching Placebo from Day 1 to 14.
2964210|NCT02803255|Experimental|Assist-As-Needed Control|"Subjects in this group will interact with a robotic exoskeleton, the MAHI Exo-II, programmed with an adaptive mode. In this mode, the robot will continuously assist motion along pre-defined trajectories, but will employ an assist-as-needed protocol.~Here, the amount of assistance provided by the robot will not be always the 100% of that required to complete the task (as in the position control mode), but only a fraction of it. The robot will continuously estimate the residual movement capabilities of the subject, depending on the specific joint addressed in the movement, and will estimate the remaining contribution needed to complete the movement following a predefined trajectory, thus avoiding to over-support motion."
2964211|NCT02803255|Active Comparator|Subject-Triggered Control|Subjects in group B will interact with a robotic exoskeleton, the MAHI Exo-II, controlled via the subject-triggered mode, as in a previous clinical trial with the MAHI Exo II robotic system. In the subject triggered mode, the MAHIExo II is commanded to regulate joints motion following a position-control control scheme, and using as desired trajectories standardized single-joints profiles that require motion of one of the axes of the exoskeleton (i.e. elbow flexion and extension, forearm pronation and supination, wrist radial and ulnar deviation, wrist flexion and extension). The switch to position control of the exoskeleton is triggered by the application of sufficient force by the subject, in a previous phase where the robot implements a virtual wall.
2964212|NCT02803229|Placebo Comparator|Placebo|matched Placebo arm
2964213|NCT02803229|Experimental|Adderall-XR|Adderall-XR (MAS-XR) 80 mg/day maximum maintenance dose
2964214|NCT02803216|Experimental|standard triple region|The patients in this group were given 10-day standard triple therapy.
2964215|NCT02803216|Active Comparator|standard triple region +2-week TCM|The patients in this group were given 10 days of standard triple therapy + 2-week Xiang-sha-liu-jun decoction.
2964216|NCT02803216|Active Comparator|standard triple region +4-week TCM|The patients in this group were given 10days of standard triple therapy + 4-week Xiang-sha-liu-jun decoction.
2964217|NCT02803203|Experimental|osimertinib and bevacizumab|"Phase 1:~3+3 dose escalation design 2 dose levels Dose level -1: Osimertinib 40mg daily Maximum accrual = 12 Bevacizumab 15mg/kg q3 weeks Dose level 1: Osimertinib 80mg daily Bevacizumab 15mg/kg q3 Weeks~Phase 2:~Use MTD determined during phase 1"
2964218|NCT02803190|Experimental|ICG- integrated care group|Integraded Care Group
2964219|NCT02803190|Experimental|MTG- muscle training group|Muscle Traing Group
2964220|NCT02803177|Experimental|BMC2012 + beta-TCP Chronos® Synthes|The large bone defect will be bridged as per clinical standard, filled with a clinically established scaffold (beta-TCP Chronos® Synthes), and loaded with 1.3 x 10E6 BMC/ml TCP per 1 ml beta-TCP in situ.
2964221|NCT02803177|Placebo Comparator|beta-TCP Chronos® Synthes|The large bone defect will be bridged as per clinical Standard and filled with a clinically established scaffold (beta-TCP Chronos® Synthes).
2964222|NCT02803164|Other|Intervention|Treatment of wound with Vacuum-assisted dressing.
2964223|NCT02803151|Experimental|Stereotactic ablative radiotherapy|Image-guided stereotactic ablative radiotherapy
2964224|NCT02803138||HCV Genotype 1 or 4 participants|Participants receiving Paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV)
2964225|NCT02803125|Active Comparator|Developed psychosocial intervention|The active intervention in this study that will be compared to support group control
2964226|NCT02803125|Placebo Comparator|Support group control|This is the comparison group
2964227|NCT02803099|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2964228|NCT02803086||1|Patients treated with Radiotherapy for Prostate Cancer
2964229|NCT02803073|Experimental|Testosterone Replacement|The experimental group will receive 0.5 ml (100 mg) testosterone cypionate Intramuscular injections each week for 11 weeks.
2964232|NCT02803047|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2964233|NCT02803034|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2964234|NCT02803021|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2964235|NCT02803008|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2964236|NCT02802995|Experimental|Treatment arm|Subjects receiving the study drug which is PRP/thrombin mixture
2964237|NCT02802995|No Intervention|Control arm|Subjects receiving the standard of care for chronic venous wounds
2964238|NCT02802969|Experimental|[18F]FAZA PET/CT|In residual chordoma tumors after surgery, Investigators propose a protontherapy guided by conventional imaging (CT/MRI) and a boost guided by FAZA PET/CT, in order to target the hypoxic zones and to increase the dose in an adequate manner, which could result in improving long-term local control and reducing complications.
2964239|NCT02802956|Experimental|intervention group|Daily Life Promotion Program
2964240|NCT02802956|Experimental|control group|general rehabilitation treatment
2964241|NCT02802943|Experimental|Peptide Vaccine MRD +|MRD-positive (MRD+) patients (flow cytometry based, CLL cells in peripheral blood or bone marrow ≥ 10-4 6-10 weeks after the end of first line treatment)
2964242|NCT02802943|Experimental|Peptide Vaccine MRD-|MRD-negative (MRD-) patients (flow cytometry based, CLL cells in peripheral blood and bone marrow <10-4 6-10 weeks after the end of first line treatment)
2964243|NCT02802930|Experimental|SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104|All test products (SPF 50 Y65 110,SPF 50 Y51 002, and SPF 15 V27 l 04 compared to that of a negative control [0.9% NaCl]) were tested simultaneously on each subject.
2964244|NCT02802917|Experimental|SPF 50 Y49 091|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
2964245|NCT02802917|Experimental|SPF 50 X15 158|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
2964246|NCT02802917|Experimental|SPF 50 X15 160|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
2964247|NCT02802917|Experimental|SPF 50 X57 162|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
2964248|NCT02802904|Experimental|Palm olein IV 64|Palm olein IV 64, n= 15, 4 weeks intervention
2964249|NCT02802904|Experimental|Cocoa butter|Cocoa butter, n= 15, 4 weeks intervention
2964250|NCT02802904|Experimental|Virgin olive oil|Virgin olive oil, n= 15, 4 weeks intervention
2964251|NCT02802891||Recruitment group|"Group of individuals (aged 6 to 18 years old) recruited for the JOIN project. Consent was obtained from legal guardians for individuals under 18.~Exclusion criteria:~Individuals who refused to partake in the clinical assessment, despite the legal guardians consent.~Individuals who provided an insufficient amount of sample (ex: low volume of EBC)"
2964252|NCT02802878|Experimental|Hybrid Training|"The hybrid training system combines the applications of neuromuscular electrical stimulation (NMES) with voluntary contractions (NMES-VC). Training will be performed in a seated position with feet not touching the ground, and will involve each knee flexing and extending alternately. The joint range of motion will be restricted to a 90º arc from approximately 10º to 100º of flexion. Each session will consist of 5 sets of 10 repetitions, 3-second knee flexion and extension contractions on each leg. Sets will be separated by 30-sec rest intervals.~Electrodes will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and over the medial and lateral hamstrings on the posterior thigh. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM). A joint motion sensor will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
2964253|NCT02802878|Active Comparator|Low Intensity Exercise|40% 1-repetition maximum isokinetic training with HUMAC NORM in same repetitions/sets as experimental group.
2964254|NCT02802865|Active Comparator|Letrozole|Letrozole 2.5 mg orally for 5 days on cycle days 3-7
2964255|NCT02802865|Experimental|Letrozole + Clomiphene|Letrozole 2.5 mg orally for 5 days on cycle days 3-7 AND Clomid 50 mg orally for 5 days on cycle days 3-7
2964256|NCT02802852|Experimental|Calf Compression, Filgrastim injection|All patients enrolled in the study will undergo pneumatic calf compression though use of the Art Assist device as well as stem cell mobilization through administration of Filgrastim 10 mcg/kg subcutaneously, every 3rd day for 30 days.
2964257|NCT02802839|Experimental|Sperimental|The patient will be shown the headset for VR and a selection of age appropriate virtual realities to immerge in by the nurse not performing the procedure. There will be two lists of VRs to choose from, one for age 6 to 12 and one for age 12 to 18 with the following themes: amusement rides /carousel, space rides, zoo, safari, dinosaurs, city touring, landscapes, caverns. Once the patient is ready to wear the headset the application will start and 120 seconds later the procedure will take place. The nurse performing venipuncture will be a different one than the one handling distraction. Once the procedure ends the video will last for one more minute or up to the child' s desire. Only the first venipuncture attempt will be observed.
2964258|NCT02802839|No Intervention|Observational|Control intervention When arriving to the CF centre for routine visit that implies also the taking of blood samples, after having obtained the informed consent, a trained nurse of the CF Centre, will apply to each child recruited -in the presence of the parent, who may hold the child- the anesthetic cream. Only the first venipuncture attempt will be observed.
2964259|NCT02802826|Experimental|Tailored Exercise Prescription|"Participants will have a discussion on the 'My Exercise Prescription' booklet on the benefits of increasing levels of physical activity. They will be encouraged to read this in more detail and guided through its completion. The participant will receive an exercise prescription using the Pre-Intervention Assessment Tool (PIAT) and following discussion with the participant on a realistic and achievable starting point.~The booklets provided will guide participants through the exercise programme which is a graduated walking-based activity intervention. Both booklets provide participants with a suggested starting point for walking distance per week based on their PIAT score as well as motivational and behaviour change strategies to encourage participation."
2964260|NCT02802826|No Intervention|Standard Care|No sham or placebo conditions will be used in the study. At visit 1 standard care participants will be given the Standard Care Information Sheet and asked to simply continue with standard care.
2964261|NCT02802813|Active Comparator|Intervention arm|Dihydroartemisinin-piperaquine (DP) therapy plus 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
2964262|NCT02802813|Placebo Comparator|Control arm|Dihydroartemisinin-piperaquine therapy plus 14 days identical placebo not containing primaquine.
2964263|NCT02802800|Experimental|Water|Power training in water, twice per week for 6 weeks.
2964264|NCT02802800|Experimental|Land|Power training on land, twice per week for 6 weeks.
2964265|NCT02802787|Experimental|Camp Discovery|One week activity based camp
2964266|NCT02802774|Active Comparator|Plaster Splint|
2964267|NCT02802774|Active Comparator|Velcro Brace|
2964268|NCT02802774|Active Comparator|Soft Dressing|
2964269|NCT02802748|Experimental|Metronomic Vinorelbine + Letrozole|"Oral Vinorelbine: 50 mg (30 mg + 20 mg) three times a week, for 3 weeks~Letrozole: 2.5mg daily, for 3 weeks"
2964270|NCT02802748|Active Comparator|Letrozole alone|Letrozole: 2.5mg daily, for 3 weeks
2964271|NCT02802748|Active Comparator|Metronomic Vinorelbine alone|Oral Vinorelbine: 50 mg (30 mg + 20 mg) three times a week, for 3 weeks
2964272|NCT02802735|Experimental|Part 1: Apremilast 20mg|A single oral dose of 20 mg (1 tablet) apremilast
2964273|NCT02802735|Experimental|Part 1: Apremilast 30mg|A single dose of oral 30 mg (1 tablet) apremilast
2964274|NCT02802735|Experimental|Part 1: Apremilast- 40mg|A single dose of oral 40 mg (2 x 20 mg tablets) apremilast
2964275|NCT02802735|Experimental|Part 2: Apremilast 60mg or matching placebo|A daily dose of 60 mg oral apremilast (one 30 mg tablet orally in the morning and one 30 mg tablet orally in the evening) or matching placebo will be administered to subjects since this is the targeted therapeutic dosing regimen for the indications of PsA and psoriasis.
2964276|NCT02802722|Active Comparator|Immediate supplementation|Dietary supplement: Vitamin D3 supplementation - oral capsules 6400 International Units once daily for 6 weeks Peripheral blood and induced sputum sampling Chest computerised tomography (CT) scans Symptom questionnaire
2964277|NCT02802722|Placebo Comparator|Delayed supplementation|Placebo: oral placebo capsules once daily for 6 weeks Peripheral blood and induced sputum sampling Chest computerised tomography (CT) scans Symptom questionnaire
2964278|NCT02802709|Experimental|SB-061|SB-061
2964279|NCT02802709|Placebo Comparator|Placebo|Placebo
2964280|NCT02802696|Experimental|Furosemide|Diuretic
2964281|NCT02802696|Placebo Comparator|Placebo|Normal saline
2964282|NCT02802683|Experimental|"BUPI,P"|patients who received hyperbaric bupivacaine and continous infusion of phenylephrine
2964283|NCT02802683|Placebo Comparator|"BUPI,N"|patients who received hyperbaric bupivacaine and continous infusion of normal saline
2964284|NCT02802683|Experimental|"LEVO,P"|patients who received isobaric levobupivacaine and continous infusion of phenylephrine
2964285|NCT02802683|Active Comparator|"LEVO,N"|patients who received isobaric levobupivacaine and continous infusion of normal saline
2964286|NCT02802670|Experimental|GDC-0810|GDC-0810 300-mg dose administered as oral solution, containing approximately 100 microcuries of [14C]-labeled GDC-0810.
2964287|NCT02802657|Experimental|Conbercept 0.5mg Treat-and-Extend regimen|"Monthly intravitreal injections of Conbercept 0.5mg in the core treatment period and Treat-and-Extend Regimen of the same dose guided by BCVA stabilization and OCT in the extension treatment period.~Intervention: Drug: Conbercept"
2964288|NCT02802657|Active Comparator|Conbercept 0.5mg Pro Re Nata|"Monthly intravitreal injections of Conbercept 0.5mg in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization in the extension treatment period.~Intervention: Drug: Conbercept"
2964289|NCT02802644|Experimental|DPP-4 Inhibitor|Any dose of Sitagliptin for 6 months with any other oral anti-diabetic medication
2964290|NCT02802644|Active Comparator|Non DPP-4 Inhibitor|Oral anti-diabetic medication except DPP-4 inhibitor
2964291|NCT02802631|Experimental|Minocin for Injection (minocycline)|Minocin (minocycline for injection) for will be supplied as a sterile lyophilized powder in single-use 10-mL glass vials. Each vial contains 108 mg of minocycline hydrochloride equivalent to 100 mg of minocycline. Each cohort receives one of the following dosages of Minocin (minocycline) for Injection: 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg. Within each cohort, subjects will receive a single dose on Day 1, followed by 7 days of multiple-doses (Days 4-10, given every 12 hours), followed by a single dose on Day 11.
2964292|NCT02802631|Placebo Comparator|0.9% Sodium Chloride Injection USP|Placebo is in the form of the same 100-mL bags of normal saline (0.9% Sodium Chloride Injection USP). Dosing is to the same schedule as subjects randomized to Minocin (minocycline) for Injection.
2964293|NCT02802618|Experimental|Interactive 3D visualization technique|"The pulmonary rehabilitation consists of exercise training during 10 weeks and a theoretic part presented with 3D technique.~Patients randomized into education by 3D technique."
2964294|NCT02802618|No Intervention|Conventional technique|The pulmonary rehabilitation consists of exercise training during 10 weeks and a theoretic part presented with conventional technique. Patients randomized into education by conventional technique.
2964295|NCT02802605|Experimental|Bemiparin|Bemiparin 3.500 U, once a day during hospitalization
2964296|NCT02802605|No Intervention|No drug|Clinical practice as usual
2964297|NCT02802592|Active Comparator|Epogen|1000 IU/kg Epogen in 250 ml of normal saline infused over 1 hr
2964298|NCT02802592|Placebo Comparator|Normal Saline|250 ml normal saline infused over 1 hr
2964301|NCT02802579|Experimental|C: enhanced obesity protocol|enhanced obesity-mode dual-source computed tomography coronary angiography protocol
2964302|NCT02802566|Experimental|Investigative|This arm receives a standard prenatal (provided by the study) and a micronutrient supplement.
2964303|NCT02802566|Active Comparator|Control|Standard prenatal vitamin provided by the study
2964304|NCT02802553|Experimental|Integrated Imaging Goggles|Cardio-GreenTM (indocyanine green) peritumorally injected to breast tumor with 1 cycle. Viewed by Smart Googles and compare lesions detected by SPY Elite in addition to those detected by gamma probe and blue dyes.
2964305|NCT02802540|Experimental|Nabilone|Patients start receiving a dose of 0.5 mg daily oral nabilone the first 2 weeks and then 1 mg to complete 8 weeks.
2964306|NCT02802540|Placebo Comparator|placebo|Patients start receiving a dose of 0.5 mg daily oral placebo the first 2 weeks and then 1 mg to complete 8 weeks.
2964307|NCT02802527|Other|Bronchoscopy Guided|Percutaneous tracheostomy will be guided by bronchoscopy. Initially, the tube will be placed according to the desired height observed by the bronchoscope, phase two will be tracheal perforation by a needle under trans illumination and real-time view on the income of the needle and the passage of the guide wire.
2964308|NCT02802527|Other|Direct Laryngoscopy|Performing percutaneous tracheostomy by placing the tube higher up, near the vocal cords by direct laryngoscopy. In the second stage tracheal perforation by a needle will be carried out by palpation of the anatomical placement of the neck.
2964309|NCT02802514|Experimental|With Off therapy MRI in S1:Albiglutide-S1 & Exenatide-S2|In session 1, eligible subject will undergo off-therapy MRI scan Subject will receive single dose each of 50 mg albiglutide on Day 5 and exenatide placebo on Day 8 followed by a post-dose MRI. In session 2, subject will receive single dose each of albiglutide placebo on Day 1 (Week 9) and 10 microgram exenatide on Day 4 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
2964310|NCT02802514|Experimental|Without Off therapy MRI in S1:Albiglutide-S1 & Exenatide-S2|In session 1, eligible subject will receive single dose each of 50 mg albiglutide on Day 1 and exenatide placebo on Day 4 followed by a post-dose MRI scan. In session 2, Day 1 (Week 9) subject will undergo off-therapy MRI scan. Subject will receive single dose each of albiglutide placebo on Day 5 and 10 microgram of exenatide on Day 8 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
2964311|NCT02802514|Experimental|With Off therapy MRI in S1:Exenatide-S1 & Albiglutide-S2|In session 1, Day 1 subject will undergo off-therapy MRI scan Subject will receive single dose each of albiglutide placebo on Day 5 and 10 microgram of exenatide on Day 8 followed by a post-dose MRI scan In session 2, eligible subject will receive single dose each of 50 mg albiglutide on Day 1 (Week 9) and exenatide placebo Day 4 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
2964312|NCT02802514|Experimental|Without Off therapy MRI in S1: Exenatide-S1 & Albiglutide-S2|In session 1, subject will receive single dose each of albiglutide placebo on Day 1 and 10 microgram exenatide on Day 4 followed by a post-dose MRI scan. In session 2, subject will undergo off-therapy MRI scan on Day 1 (Week 9). Subject will receive single dose each of 50 mg albiglutide on Day 5 and exenatide placebo on Day 8 followed by a post-dose MRI scan.. There will be 6-9 week washout period between Session 1 and Session 2
2964313|NCT02802501|Experimental|DHA-PQP plus tafenoquine 300 mg single dose|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to the body weight) from Day 1 to Day 3. They will receive double-blind 300 mg single dose of tafenoquine (TQ) on Day 1 and matched-placebo for primaquine (PQ) from Day 1 to Day 14.
2964314|NCT02802501|Active Comparator|DHA-PQP plus primaquine 15 mg for 14 days|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind 15 mg primaquine (PQ) from Day 1 to Day 14 and matched-placebo for tafenoquine (TQ) on Day 1.
2964315|NCT02802501|Placebo Comparator|DHA-PQP alone (placebo arm)|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind matched-placebo for tafenoquine (TQ) on Day 1 and matched-placebo for primaquine (PQ) from Day 1 to Day 14.
2964316|NCT02802488|Experimental|D-dimers|This arm encompasses patients between 18 and 80 years old and diagnosed with atrial fibrillation.
2964317|NCT02802475||acquired chronic, focal, epilepsy|patients ≥18 years of age, with acquired chronic epilepsy of unknown origin
2964318|NCT02802475||new onset epilepsy|patients ≥18 years of age, with new onset status epilepticus or new onset seizures with suspicion of limbic encephalitis
2964319|NCT02802462|Experimental|High intensity-interval (HIT)|
2964320|NCT02802462|Experimental|moderate intensity-continuous (MCT)|
2964321|NCT02802462|No Intervention|control (CTL)|
2964322|NCT02802449|Placebo Comparator|Placebo|The participant will be randomized to receive two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
2964323|NCT02802449|Active Comparator|25 hydroxy-Vitamin D3 or [25 (OH) D3]|The participant will be randomized to receive two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.
2964324|NCT02802436|Experimental|Extraction with socket graft and GEM21|"Intervention - Extraction will be done as usual standard of care to preserve socket walls. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used, site will be filled slightly below marginal bone level (1mm). Test site (active arm) will be injected with Bioactive Agent (PDGF - Platelet derived growth factor). At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd.~Bioactive agent - GEM21S (Growth factor enhanced matrix) Dosage - one cup containing 0.5 cc of ß-TCP particles (0.25 to 1.0 mm); and one syringe containing a solution of 0.5 mL rhPDGF-BB (0.3 mg/mL)"
2964325|NCT02802436|Other|Extraction with socket graft|Extraction will be done as usual standard of care to preserve socket walls. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used, site will be filled slightly below marginal bone level (1mm). Normal saline will be used and no growth factor to maintain the volume in control sites
2964326|NCT02802423|Experimental|BLEX 404 Oral Liquid|During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Docetaxel monotherapy among 6 patients in the Phase I study.
2964327|NCT02802410|Experimental|IQ-Tape|IQ-application on leg muscles muscles
2964330|NCT02802397|Other|Cases|"Cases and controls will benefit, as usual in France concerning infertility etiology examinations, of a follicle antral count by transvaginal ultrasound and AMH measurement.~At baseline, physicians will complete a short questionnaire to check the inclusion criterion, the results of the measurement of follicle count and hormone measurement (including AMH). Cases and controls will respond to self-administered questionnaire at inclusion with information about their medical history, their demographics, their tobacco and alcohol consumption, their occupation and products handled in the workplace. Blood samples (for measure of persistent organic pollutants and heavy metals) and urine (for measure of metabolites of glycol ethers) will be collect at baseline. Occupational exposures to solvents will be defined using job exposures matrices. The risk of decreased ovarian reserve will be analyzed using logistic regressions for each exposure of interest adjusting for potential confounders."
2964331|NCT02802397|Other|Controls|"Cases and controls will benefit, as usual in France concerning infertility etiology examinations, of a follicle antral count by transvaginal ultrasound and AMH measurement.~At baseline, physicians will complete a short questionnaire to check the inclusion criterion, the results of the measurement of follicle count and hormone measurement (including AMH). Cases and controls will respond to self-administered questionnaire at inclusion with information about their medical history, their demographics, their tobacco and alcohol consumption, their occupation and products handled in the workplace. Blood samples (for measure of persistent organic pollutants and heavy metals) and urine (for measure of metabolites of glycol ethers) will be collect at baseline. Occupational exposures to solvents will be defined using job exposures matrices. The risk of decreased ovarian reserve will be analyzed using logistic regressions for each exposure of interest adjusting for potential confounders."
2964332|NCT02802384||Cases|People with active Paget's Disease of Bone
2964333|NCT02802384||Controls|Age and sex matched people without history of Paget's Disease of Bone
2964334|NCT02802371|No Intervention|control group|Patients and caregivers randomized in the control group will receive the current management in geriatric or memory consultation without multidisciplinary psychosocial intervention and pharmaceutical collaborative care.There will be a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, but the recommendations will not be transmitted to the referring physicians of patients and caregivers.
2964335|NCT02802371|Active Comparator|Psychosocial intervention|Psychosocial intervention including collective sessions and individual interview in face-to-face and by phone. These sessions will allow an extended psychosocial follow-up over one year.
2964336|NCT02802371|Experimental|Pharmaceutical care and psychosocial support|Pharmaceutical collaborative care integrated in a psychosocial program. The clinical pharmacist will intervene in: 1) the pharmaceutical need assessment of caregivers; 2) collective session on medication management; and 3) optimization of drug prescribing. These collective and individual sessions of pharmaceutical care will allow an extended 18 month follow-up. Psychosocial intervention including collective sessions and individual interview in face-to-face and by phone. These sessions will allow an extended psychosocial follow-up over one year.
2964337|NCT02802358||Hip fracture|Patients with a hip fracture due to an accidental fall
2964338|NCT02802358||Wrist fracture|Patients with a wrist fracture due to an accidental fall
2964339|NCT02802345|Experimental|Nintedanib + placebo matching sildenafil|
2964340|NCT02802345|Active Comparator|Nintedanib + Sildenafil|
2964341|NCT02802332|Active Comparator|Footlength Card|Pregnant women will receive a card that enables them to measure the length of their baby's foot. The card contains a phone number to pre-recorded message that provides basic information/advice regarding care of preterm and/or low birth weight babies
2964342|NCT02802332|No Intervention|No Footlength Card|Women in this group do receive any footlength card.
2964343|NCT02802319|Experimental|Test: Porcine Xenograft (Zcore)|Ridge preservation bone grafting surgery with porcine xenograft (Zcore)
2964344|NCT02802319|Active Comparator|Active Control: Bovine Xenograft (Bio-Oss)|Ridge preservation bone grafting surgery with bovine xenograft (Bio-Oss)
2964345|NCT02802306|Experimental|Tack Implant|Implantation of a Tack implant using the Intact Vascular Tack Endovascular System for the repair of post DCB-angioplasty dissections.
2964346|NCT02802293|Active Comparator|Standard rTMS Aiming|Active repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left DLPFC using the standard aiming strategy with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
2964347|NCT02802293|Active Comparator|Anterior DLPFC targeting|Active rTMS will be delivered to the left anterior DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
2964348|NCT02802293|Active Comparator|Posterior DLPFC targeting|Active rTMS will be delivered to the left posterior DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
2964349|NCT02802280|Other|Cardiovascular risk in HCV patients|"Intervention:~The only intervention to be carried out along the study will consist of a complete evaluation of cardiovascular risk of HCV patients both at baseline (pre-treatment) and after HCV treatment, through performing different tests (see below)~Chronic HCV patients who are going to be treated with new DAAs according to current guidelines will be studied at different times before and after the end of the treatment.~The participation in the study will not influence neither the indication to treat nor the treatment used.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines"
2964350|NCT02802267|Experimental|inecalcitol|Two tablets of Inecalcitol 2mg each (total 4mg) taken orally every other day.
2964351|NCT02802267|Placebo Comparator|placebo|Two tablets of placebo 2mg each (total 4mg) taken orally every other day
2964352|NCT02802254|Experimental|Pedometer+physical-activity-feedback|At cardiac consultation patients receive a patient-targeted individual physical-activity-feedback.
2964353|NCT02802254|Active Comparator|Pedometer-only|Patients use a Pedometer in order to measure their daily step number
2964354|NCT02802241|Experimental|open-label placebo|
2964355|NCT02802241|Experimental|double-blind placebo|
2964358|NCT02802228|Experimental|Ifetroban|90 day course of oral ifetroban following intravenous loading dose
2964359|NCT02802228|Placebo Comparator|Placebo|90 day course of placebo following intravenous dose of D5W
2964360|NCT02802215|Active Comparator|Metformin group|40 women will receive metformin in dose of 1500 mg per day orally (500 mg every 8 hrs in the middle of meal) starting from 12th week of gestation till delivery.
2964361|NCT02802215|Placebo Comparator|control group|40 women will receive placebo which will be folic acid 500 micro gram which looks like metformin tablet.
2964362|NCT02802202||Fibromyalgia|Individuals who met the criteria for a diagnosis of FM based upon the ACR diagnostic criteria.
2964363|NCT02802202||Myofascial Pain Syndrome|Individuals with a diagnosis of MPS that does not meet the American College of Rheumatology (ACR) diagnostic criteria for FM.
2964364|NCT02802202||Control|Individuals with no current or prior diagnosis consistent with MPS or FM.
2964365|NCT02802189|Experimental|exercise and INIT group|The first group (experimental) followed the exersice programme in combination with the integrated neuromuscular inhibition technique (INIT).
2964366|NCT02802189|Active Comparator|exercise group|"The protocol for this group was identical to the previous group with the sole difference that the application of INIT was not included.~At the end of the exercise programme, relaxing breathing exercise and gentle stretching was applied for 15 min"
2964367|NCT02802176|Experimental|Intra-vaginal culture - INVOcell device|3 day intra-vaginal incubation using the INVOcell device
2964368|NCT02802176|Active Comparator|Traditional IVF culture|3 day traditional IVF incubation
2964369|NCT02802163|Experimental|Combination Therapy|Combination Therapy: Panobinostat, Carfilzomib, Lenalidomide, Dexamethasone (Ca-R-Pa-Diem) . Participants will receive up to 8 cycles of the combination as induction after which will proceed with consolidation therapy with transplant as per institutional standards. After transplant, participants receive maintenance with panobinostat/lenalidomide. The maintenance dose and schedule of panobinostat will be same given during induction for 1 year. The maintenance dose of lenalidomide will be 10 mg given for 21 days of 28 days cycle until disease progression.
2964370|NCT02802150|Active Comparator|Zanthoxylum schinifolium seed Oil|Zanthoxylum schinifolium seed Oil 100% (4g/day)
2964371|NCT02802150|Placebo Comparator|soy bean oil|soy bean oil 99.9%, edible dyes 0.01% (4g/day)
2964372|NCT02802137|Active Comparator|Tafluprost drops|Treatment with preservative-free talfuprost drops administered once in the evening. Evaluation of 24-hour efficacy and ocular surface health after 3 months of therapy.
2964373|NCT02802137|Active Comparator|Tafluprost and dorzolamide/timolol drops|Concomitant therapy with preservative-free talfuprost drops administered once in the evening and dorzolamide/timolol fixed combination drops given twice daily. Evaluation of 24-hour efficacy and ocular surface health after 3 months of therapy.
2964374|NCT02802124|Experimental|carbon-ion radiotherapy|For tumor location which is away from gastrointestine (the distance is more than 1 cm). We use carbon-ion radiotherapy for the treatment of hepatocellular carcinoma. Four dose levels [55 Gray equivalent (GyE)/10 fractions (Fx), 60GyE/10Fx, 65GyE/10Fx, 70GyE/10Fx] are planned within the Phase I part.
2964375|NCT02802124|Experimental|proton plus carbon-ion radiotherapy|"For tumor location which is adjacent to gastrointestine (less than 1 cm).We use proton plus carbon-ion radiotherapy for the treatment of hepatocellular carcinoma.~Four dose levels (proton 50GyE/25Fx+ carbon 15GyE/5Fx,proton 34GyE/17Fx+ carbon 30GyE/10Fx, proton 18GyE/9Fx+ carbon 45GyE/15Fx,carbon 60GyE/20Fx ) are planned within the Phase I part."
2964376|NCT02802111|Experimental|Albuterol|Patient receives albuterol 5 mg aerosolized first and then 4 hours or greater after receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
2964377|NCT02802111|Experimental|Levalbuterol|Patient receives levalbuterol 2.5 mg aerosolized first and then 4 hours or greater after receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
2964378|NCT02802098|Experimental|Bevacizumab + Durvalumab|Treatment with 750 mg Q2W DURVALUMAB (equivalent to 10 mg/kg Q2W) IV infusion, if ≥ 30 kg, commences on day 1 following confirmation of eligibility into the study and continues on a Q2W schedule + Bevacizumab 10 mg/ Kg Q3W, IV infusion for a maximum duration of treatment of 12 months (maximum of 26 doses, last infusion on week 50). Study treatment should be discontinued prior to 12 months if there is confirmed PD (unless the investigator considers the subject to continue to receive benefit from treatment), initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or if other reasons to discontinue study treatment occur.
2964379|NCT02802085||Knee Arthroplasty|Vega Knee Arthroplasty
2964380|NCT02802072|Experimental|Enterprise stent implantation group|Patients with atherosclerotic ischemic stroke will be randomly allocated to receive Enterprise stent implantation in combination with antiplatelet medication for carotid artery stenosis.
2964381|NCT02802072|Experimental|Only aspirin medication group|Patients with atherosclerotic ischemic stroke will be randomly allocated to receive only antiplatelet medication for carotid artery stenosis.
2964382|NCT02802059|Experimental|EcN-Suspension|279 healthy functionally mature newborn infants up to 35 weeks gestational age, treated with EcN-Suspension
2964383|NCT02802059|Placebo Comparator|Placebo|279 healthy functionally mature newborn infants up to 35 weeks gestational age, treated with Placebo
2964384|NCT02802046||FFR≦0.8|FFR is a score of 0 to 1, FFR < 0.75, has proved almost always accompanied by myocardial ischemia.
2964385|NCT02802046||FFR>0.8|FFR > 0.80 almost never associated with myocardial ischemia.
2964386|NCT02802020|Experimental|WallFlex FCSEMS Recipients|"The WallFlex™ Pancreatic RX Fully Covered Soft Stent System consists of a flexible delivery system preloaded with a self-expanding pancreatic metal stent. Patients who meet all eligibility criteria will receive the WallFlex Pancreatic stent for up to 6 months stent indwell and 6 months follow-up after stent removal. A patient is considered enrolled after signing the study-specific Informed Consent Form (ICF). Patients who sign the ICF but subsequently do not meet one or more of the selection criteria will be considered screen failures and excluded from the study."
2964387|NCT02802007|Experimental|Elipse Intragastric Balloon|Patients seeking weight loss received the Elipse Intragastric Balloon.
2964416|NCT02801799|Experimental|Infusion group 2|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 60 mL/h. This infusion rate is experimental."
2964388|NCT02801994|Experimental|Ventilator settings, PAV|"A first 30-minutes recording in PSV will be performed. Dyspnea-VAS, IC-RDOS will be measured at the beginning and at the end of this period. EMG and EEG will be recorded continuously. Patients will be subsequently switched to PAV.~The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min."
2964389|NCT02801981|Experimental|Sequence 1: GSK2230672 10mg, 30mg, 90mg, and Placebo|Subjects will receive GSK2230672 10 mg in period 1, GSK2230672 30 mg in Period 2, GSK2230672 90 mg in Period 3 and placebo in period 4.
2964390|NCT02801981|Experimental|Sequence 2:GSK2230672 10mg, 30mg, Placebo, and GSK2230672 90mg|Subjects will receive GSK2230672 10 mg in period 1, GSK2230672 30 mg in Period 2, placebo in period 3, and GSK2230672 90 mg in period 4.
2964391|NCT02801981|Experimental|Sequence 3:GSK2230672 10mg, Placebo, GSK2230672 90mg and 180mg|Subjects will receive GSK2230672 10 mg in period 1, placebo in Period 2, GSK2230672 90 mg in Period 3 and GSK2230672 180 mg in period 4.
2964392|NCT02801981|Experimental|Sequence 4: Placebo, GSK2230672 30mg, 90mg and 180mg|Subjects will receive placebo in period 1, GSK2230672 30 mg in Period 2, GSK2230672 90 mg in Period 3 and GSK2230672 180 mg in period 4.
2964393|NCT02801968|Experimental|Tap block|Tap block with ropivacaine 2 mg/kg at the end of cesarean delivery. Postoperative analgesia with acetaminophen and tramadol plus NSAIDs (nonsteroidal anti-inflammatory drugs) as rescue dose.
2964394|NCT02801968|Active Comparator|control group|Postoperative analgesia after cesarean delivery with acetaminophen and tramadol plus NSAIDs (nonsteroidal anti-inflammatory drugs) as rescue dose.
2964395|NCT02801955||tumor marker|serum CEA and CA 19-9 levels in patients with curative gastrectomy preoperatively and peritoneal CEA and CA 19-9 levels in patients taken at the beginning of curative gastrectomy via sampling of peritoneal washing aspirate
2964396|NCT02801942|Experimental|Healthy subjects|Up to 30 mL of blood sample will be collected from healthy subjects. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, Human Leukocyte antigen D related (HLA-DR) and forkhead box P3 protein also called scurfin (FOXP3).
2964397|NCT02801942|Experimental|Subjects with NOT1D|Up to 30 mL of blood sample will be collected from subjects with NOT1D. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, HLA-DR and FOXP3.
2964398|NCT02801929|Experimental|BAY987518|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2964399|NCT02801916|Other|Study subjects|Each healthy subject will receive each of the interventions in randomized order.
2964400|NCT02801903|Experimental|SB204 4%|Topically Once Daily (AM)
2964401|NCT02801890|Experimental|AD-MSC|The patients with ultra filtration failure (UFF) underwent AD-MSC injection.
2964402|NCT02801890|Placebo Comparator|Placebo|The patients with ultra filtration failure (UFF) underwent Placebo injection.
2964403|NCT02801877|Experimental|IntelliCare Hub recommender, coach|Participant is randomly assigned to receive the IntelliCare Hub App with the recommender system, and receive coaching for the 8 week IntelliCare program.
2964404|NCT02801877|Experimental|IntelliCare Hub recommender, no coach|Participant is randomly assigned to receive the IntelliCare Hub App with the recommender system, and independently use the IntelliCare program for 8 weeks.
2964405|NCT02801877|Experimental|IntelliCare Hub no recommender, coach|Participant is randomly assigned to receive the IntelliCare Hub App without the recommender system, and receive coaching for the 8 week IntelliCare program.
2964406|NCT02801877|Experimental|IntelliCare Hub no recommender, no coach|Participant is randomly assigned to receive the IntelliCare Hub App without the recommender system, and independently use the IntelliCare program for 8 weeks.
2964407|NCT02801864|Experimental|Combined real tDCS + IST|Participants will receive tDCS via a Starstim device at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. The stimulation will be ramped up for 45 seconds and ramped down for 15 seconds. For the experimental group, the stimulation will be ramped up for 45 seconds and stay there for 20 min. The participants will receive three weeks of tDCS and continue receiving only intensive speech therapy for five weeks for three hours a day.
2964408|NCT02801864|Sham Comparator|Combined sham tDCS + IST|Participants will receive tDCS via a Starstim device at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. For the sham group, the stimulation will be ramped up for 45 seconds and ramped down for 15 seconds. The stimulation will be ramped up for 45 seconds and then ramp down after the initial 45 seconds. The participants will receive three weeks of tDCS and continue receiving only intensive speech therapy for five weeks for three hours a day.
2964409|NCT02801851|Experimental|Intervention SCREEN-ED|This is the arm that will receive the SCREEN-ED. SCREEN-ED is an innovative, yet practical intervention that combines screening with informing clinicians of the results and provides a checklist for delirium management that is tailored to the time-limited ED setting.
2964410|NCT02801838|Experimental|Ventilator settings, morphine titration|First, ventilator settings optimization and when the clinician judges necessary (remains discomfortable), opioid titration with a maximum of 10mg of morphine
2964411|NCT02801825|Experimental|Axillary artery.|Cannulation of the axillary artery.
2964412|NCT02801825|Experimental|Femoral artery.|Cannulation of the femoral artery.
2964413|NCT02801812||Systemic Lupus Erythematosus|patients ≥18 years diagnosed SLE upon classification according to 2012 SLICC criteria and disease onset ≥16 years.
2964414|NCT02801812||Healthy controls|subjects ≥18 years fulfilling the definition proposed in the protocol.
2964415|NCT02801799|Active Comparator|Infusion group 1|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 12 mL/h. This infusion rate is normal clinical practice when administering a perineural infusion of ropivacaine."
2964417|NCT02801799|Experimental|Infusion group 3|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 300 mL/h. This infusion rate is experimental."
2964418|NCT02801799|Experimental|Infusion group 4|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 600 mL/h. This infusion rate is experimental."
2964419|NCT02801799|Active Comparator|Infusion group 5|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 1800 mL/h. This infusion rate is normal clinical practice when administering a perineural bolus of ropivacaine."
2964420|NCT02801786|Placebo Comparator|Placebo|Five capsules containing placebo
2964421|NCT02801786|Experimental|Tamoxifen|Five capsules containing 20mg of tamoxifen.
2964422|NCT02801786|Experimental|Lidocaine|One sachet containing lidocaine gel at 4%
2964423|NCT02801773|Experimental|Treatment Gingivitis with Probiotic|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral higiene instruction) and adjunct probiotic one lozenge containig Lactobacillus reuteri per day during 3 month
2964424|NCT02801773|Placebo Comparator|Treatment Gingivitis conventional|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral higiene instruction) and one lozenge containig placebo (mint lozenge) per day during 3 month
2964425|NCT02801760||Subjects Currently or Previously Enrolled in ATN 110/ATN 113|Younger and older YMSM and transgender women who have sex with men, ages 15 through 22 years, inclusive, at the time of consent into the ATN 110 or ATN 113 study.
2964426|NCT02801760||Sub-Sample of Subjects to Complete Qualitative Interview|A sub-sample of subjects who completed the web-based survey and indicated willingness to complete the qualitative interview.
2964427|NCT02801747|Experimental|Condition 1|Receives a core intervention session and the navigation intervention component (long duration; that is, up to 6 months).
2964428|NCT02801747|Experimental|Condition 2|Receives a core intervention session, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
2964429|NCT02801747|Experimental|Condition 3|Receives a core intervention session, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
2964430|NCT02801747|Experimental|Condition 4|Receives a core intervention session, the peer mentorship component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
2964431|NCT02801747|Experimental|Condition 5|Receives a core intervention session, the pre-adherence preparation component, and the navigation intervention component (short duration, that is, up to 3 months).
2964432|NCT02801747|Experimental|Condition 6|Receives a core intervention session, the pre-adherence preparation component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
2964433|NCT02801747|Experimental|Condition 7|Receives a core intervention session, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (long duration, that is, up to 6 months).
2964434|NCT02801747|Experimental|Condition 8|Receives a core intervention session, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
2964435|NCT02801747|Experimental|Condition 9|Receives a core intervention session, the Motivational Interviewing sessions component, and the navigation intervention component (short duration, that is, up to 3 months).
2964436|NCT02801747|Experimental|Condition 10|Receives a core intervention session, the Motivational Interviewing sessions component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
2964437|NCT02801747|Experimental|Condition 11|Receives a core intervention session, the Motivational Interviewing sessions component, the peer mentorship component, and the navigation intervention component (long duration, that is, up to 6 months).
2964438|NCT02801747|Experimental|Condition 12|Receives a core intervention session, the Motivational Interviewing sessions component, the peer mentorship component, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
2964439|NCT02801747|Experimental|Condition 13|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, and the navigation intervention component (long duration, that is, up to 6 months).
2964440|NCT02801747|Experimental|Condition 14|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
2964441|NCT02801747|Experimental|Condition 15|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
2964442|NCT02801747|Experimental|Condition 16|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the peer mentorship component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
2964443|NCT02801734|Experimental|Intervention|"Participants in the EQUIP intervention group will individually receive four face-to-face sessions with a palliative care nurse.~For all participants, whether in intervention or control, usual care is provided - the primary oncologist may make a referral for palliative care input if deemed appropriate."
2964444|NCT02801734|No Intervention|Control|For all participants, whether in intervention or control, usual care is provided - the primary oncologist may make a referral for palliative care input if deemed appropriate.
2964445|NCT02801721|Active Comparator|Stimulation|Stimulation group received psycho social stimulation. In the stimulation there were anemic and non anemic children. All anemic children received iron(syrup) supplementation.
2964446|NCT02801721|No Intervention|No stimulation|No stimulation group did not receive any stimulation. In the no stimulation group there were anemic and non anemic children. All anemic children received iron (syrup) supplementation
2964447|NCT02801695|Experimental|L-Citrulline|Bolus (9g) after patient stabilization, then 3g 3 times a day until delivery
2964448|NCT02801695|Placebo Comparator|Lactose|Bolus (9g) after patient stabilization, then 3g 3 times a day until delivery
2964449|NCT02801682||Healthy Controls|
2964450|NCT02801682||Invasive Candidiasis|
2964451|NCT02801682||Bacterial Sepsis (Bacteremia)|
2964452|NCT02801682||ICU patients without infectious disease|
2964453|NCT02801669|Experimental|DU-176b 15 mg group|DU-176b orally administered at a dose of 15 mg once daily.
2964454|NCT02801669|Placebo Comparator|Placebo group|Placebo orally administered once daily.
2964455|NCT02801656|Experimental|Fecal Microbiota Transplantation|Oral, encapsulated fecal microbiota transplantation
2964456|NCT02801656|Active Comparator|Vancomycin|125 mg po qid x 10 days
2964457|NCT02801630|Sham Comparator|Sham Crossover|"After the enrollment and lead in period, subjects will be given a sham device to sleep with every night for a month. They will be asked to fill out their pain and analgesic use logs, and undergo the bi weekly assessments. After a month they will be crossed over to an active Painshield SAW patch device and will continue to complete their pain and analgesic use logs as well as undergo biweekly assessments for months two and 3."
2964458|NCT02801630|Active Comparator|Active Device|After the enrollent and lead in period, subjects will be given an active PainSHield SAW Patch device to sleep with every night. They will be asked to fill out their pain and analgesic use logs, and undergo bi weekly assessments. They will continue to use the device while completing their logs and undergoing assessments for 3 months.
2964459|NCT02801617|Experimental|Sequence 1 (PRO-067)|"50 study subjects will be allocated to receive PRO-067 QD for 30 days, after which they will be crossed over to the other medication (GAAP Ofteno®) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.~Washout period: 21 hours"
2964460|NCT02801617|Active Comparator|Sequence 2 (GAAP Ofteno®)|"50 study subjects will be allocated to receive GAAP Ofteno® QD for 30 days, after which they will be crossed over to the other medication (PRO-067) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.~Washout period: 21 hours"
2964461|NCT02801591||GH AQ|
2964462|NCT02801578|Experimental|Ibrutinib|"Participants take Ibrutinib capsules by mouth every day for 3, 28 day cycles.~During Cycle 1, participants receive the highest dose of Ibrutinib by taking 3 capsules each day. During Cycle 2, participants receive the second-highest dose and will take 2 capsules each day. During Cycle 3, participant takes the lowest dose of Ibrutinib and takes 1 capsule each day."
2964463|NCT02801565|Experimental|GH AQ|Controlled ovarian stimulation in the middle of the corpus (D21 days) of the previous menstrual cycle to use recombinant Human Growth Hormone Injection（rhGH） Injection 15IU/5mg/3mL/cartridge, 5IU per day, Subcutaneous injection after 20:00 until the HCG trigger day.
2964464|NCT02801552|Experimental|Regenerative Endodontic Procedure + PRF|Visit 1: root canal dressing with triple antibiotic paste. Visit 2: a 5 ml sample of whole blood was drawn intravenously from the patient's forearm. The blood sample is centrifuged at 400 g for 10 min. The prepared PRF membrane is cut into segments, the fragments are placed into the canal space. The coronal is sealed mineral trioxide aggregate and composite resin.
2964465|NCT02801552|No Intervention|Regenerative Endodontic Procedure|Regenerative Endodontic Procedure Visit 1: root canal dressing with triple antibiotic paste. Visit 2: Blood clot formation is induced in the root canal after disinfection. No PRF was used in this group. Then the canal access is sealed with mineral trioxide aggregate and composite resin.
2964466|NCT02801539|Experimental|Respiratory muscle training (RMT)|Subjects in the experimental arm will be given an inspiratory and expiratory RMT device to use during Duke-based and home-based RMT therapy.
2964467|NCT02801539|Sham Comparator|Sham-RMT|Subjects in control arm will be given an inspiratory and expiratory sham-device and will complete Duke-based and home-based sham-RMT therapy.
2964468|NCT02801526|Experimental|Candesartan and Amlodipine|Candesartan 16mg and Amlodipine 5mg, PO, 1days or 22days
2964469|NCT02801526|Experimental|CKD-330|CKD-330 16/5mg - A, PO, 1days or 22days
2964470|NCT02801513|Experimental|Brief Mindfulness Training|The brief mindfulness training comprised of three 1.5-hour weekly individual sessions and included intensive daily home practice. Participants were asked to engage in formal meditation practice for about 25 minutes twice per day on six out of seven days of each week using recorded guided meditations. Practices were shorter in duration than the practices in Mindfulness-Based Cognitive Therapy (MBCT, Segal et al., 2002) in order to allow for more flexibility in scheduling the practices, but followed the standard sequence of mindfulness-based interventions.
2964471|NCT02801513|Active Comparator|Resting Control Training|The resting control training comprised of three 1.5-hour weekly individual sessions and included intensive daily home practice. Participants were asked to schedule regular rest periods as a means of deliberately retreating from the activities of the day. Length and frequency of the rest periods mirrored the time demands of the meditation training. Participants received a plausible rationale for the control training that linked acute depression to stress and suggested rest, relaxation, and disengagement from negative thinking as an initial and preliminary step towards recovery.
2964472|NCT02801500|Experimental|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis.
2964473|NCT02801500|Active Comparator|Traditional Manual Anastomosis|A handsewn technique will be used during bilioenteric anastomosis.
2964474|NCT02801487|Experimental|CIRT with concurrent chemo arm|Treated with carcon ion radiotherapy along with concurrent chemotherapy (Cisplatin 40mg/m^2, weekly).
2964475|NCT02801474|Experimental|direct reduction|Intervention: The posterior and lateral malleoli were accessed via a posterolateral approach with the patients in prone position. The fibular fracture was exposed and reduced anatomically in the first place. The posterior malleolus was then exposed between the fiexor halluces longus and peroneus longus interval. The posterior malleolar fragment was then reduced with reference to the typical metaphyseal-diaphyseal spike of the posterior malleolus. One-third tubular plate, reconstruction plate, or distal radius plate were applied spanning the fracture in a buttress mode. Cannulated screws could also be used.
2964476|NCT02801474|Experimental|indirect reduction|Intervention: After open reduction and internal fixation of lateral and medial malleolar fractures, the posterior malleolus was then reduced through ligamentotaxis with the ankle in dorsiflexion. One or two 4.0 mm cannulated screws were used to fix the posterior malleolar in anterior-to-posterior direction.
2964477|NCT02801461|Experimental|Three-sessions of ESWT|ESWT was given once a week for 3 weeks.
2964478|NCT02801461|Active Comparator|One-session of ESWT|Single ESWT was given.
2964479|NCT02801448|Placebo Comparator|Placebo|Placebo containing maltodextrine but no active sulforaphane
2964480|NCT02801448|Active Comparator|BSE|Broccoli sprout extract once daily for 12 weeks
2964481|NCT02801435|Experimental|Cohort 1-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 0.5% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
2964482|NCT02801435|Placebo Comparator|Cohort 1-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
2964483|NCT02801435|Experimental|Cohort 2-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 1.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
2964484|NCT02801435|Placebo Comparator|Cohort 2-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
2964485|NCT02801435|Experimental|Cohort 3-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 2.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
2964486|NCT02801435|Placebo Comparator|Cohort 3-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
2964487|NCT02801435|Experimental|Cohort 4-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 4.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
2964488|NCT02801435|Placebo Comparator|Cohort 4-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
2964489|NCT02801422||Cannabis Dependence|ages 18-40
2964490|NCT02801422||Healthy control subjects|socio-demographically matched
2964491|NCT02801409|Experimental|Combined Epi-GA/PCEA|Combined epidural-general anesthesia (combined Epi-GA) will be performed during surgery and patient-controlled epidural analgesia (PCEA) will be provided after surgery
2964492|NCT02801409|Active Comparator|GA/PCIA|General anesthesia (GA) will be performed during surgery and patient-controlled intravenous analgesia (PCIA) will be provided after surgery
2964493|NCT02801396|Active Comparator|Group Sequence A, B, C|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
2964494|NCT02801396|Active Comparator|Group Sequence B, C, A|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
2964495|NCT02801396|Active Comparator|Group Sequence C, A, B|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
2964496|NCT02801396|Active Comparator|Group Sequence C, B, A|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
2964497|NCT02801396|Active Comparator|Group Sequence A, C, B|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
2964498|NCT02801396|Active Comparator|Group Sequence B, A, C|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
2964499|NCT02801383|Active Comparator|Treatment group|received 1g recombinant human α-2b interferon gel every other day for consecutive 6-10 courses of treatment
2964500|NCT02801383|Placebo Comparator|controlled group|received 1g gel (without biological active ingredient) every other day for consecutive 6-10 courses of treatment
2964501|NCT02801370|Experimental|OTO-201|
2964502|NCT02801370|Sham Comparator|Control|
2964503|NCT02801357|Experimental|lofexidine with tapering buprenorphine|Enrolled subjects must be on a daily dose of between 8 - 24 mg of buprenorphine for at least 30 days. Once enrolled, subjects will receive lofexidine as follows: Days 1 through 3, 0.6 mg 4 times daily (QID; 2.4 mg daily); Days 4 through 6, 0.8 mg QID (3.2 mg daily), and Day 7 0.8 mg at 8 AM. Subjects will take their scheduled lofexidine doses at approximately 8 AM, 1 PM, 6 PM and 11 PM. Subjects will also reduce their current buprenorphine dose by at least 4 mg on Day 1.
2964504|NCT02801344|Experimental|Normal protein intake|participants will receive the controlled-diet containing 0.8 g protein /kg/day and the test drink containing 0.14 g protein/kg/d.
2964505|NCT02801344|Experimental|Moderate protein intake|participants will receive the controlled-diet containing 1.20 g protein /kg/day and the test drink containing 0.40 g protein/kg/d.
2964506|NCT02801344|Experimental|High protein intake|participants will receive the controlled-diet containing 1.83 g protein /kg/day and the test drink containing 1.03 g protein/kg/d.
2964507|NCT02801331|Experimental|Stochastic Vibrotactile Stimulation (SVS)|Infants randomized to this arm will receive daily intervals of continuous SVS (ON) and no SVS (OFF) throughout hospitalization, starting within 24-hrs post birth. Periods of stimulation will be complementary to standard of clinical care (e.g., clinically-determined pharmacological management; routine parental/volunteer holding; breast and/or bottle feed). Infants will be scored for severity of withdrawal using standardized, modified Finnegan scoring system by clinical care nurses per routine clinical care throughout hospitalization.
2964552|NCT02801032|Active Comparator|Active Treatment|Tadalafil 20 mg Capsule. MRI of cerebrum pre dose. Transcranial Doppler, near-infrared spectroscopy (NIRS), endothelial response with EndoPAT2000, and endothelial biomarkers (pre and post dose).
2965104|NCT02796989|Placebo Comparator|Obese - Placebo|Placebo 20 g each day
2965105|NCT02796976|No Intervention|healthy older active|only cross-sectional
2964508|NCT02801331|No Intervention|Standard Clinical Care (SCC)|Infants randomized to this arm will be enrolled within 24-hours post birth and receive standard of clinical care (e.g., clinically-determined pharmacological management, routine/volunteer holding; breast and/or bottle feed). Infants will not receive any SVS. Infants will be scored for severity of withdrawal using standardized, modified Finnegan scoring system by clinical care nurses per routine clinical care throughout hospitalization.
2964509|NCT02801318|Other|Polysomnography|
2964510|NCT02801305|Placebo Comparator|Vaseline|About 60 patients will be considered to be in control group receiving vaseline ointment as the placebo applying 2 times daily on their ulcers for 8 weeks.
2964511|NCT02801305|Experimental|Diltiazem Gel 2%|About 30 patients will receive Diltiazem Gel 2% applying 2 times daily for 8 weeks on their digital ulcers.
2964512|NCT02801305|Experimental|Nitroglycerin Ointment 2%|About 30 patients will receive nitroglycerin 2% applying 2 times daily for 8 weeks on their digital ulcers.
2964513|NCT02801292|Other|administering of ketamine|adjuvant to standard of care
2964514|NCT02801279|Experimental|Kinect-based bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
2964515|NCT02801279|Experimental|Conventional bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
2964516|NCT02801266|Experimental|Intervention|The intervention arm receives contraceptive counseling from counselors who underwent training on the use of evidence informed birth control counseling.
2964517|NCT02801266|No Intervention|No intervention|The no intervention arm receives contraceptive counseling from counselors who underwent no additional training beyond what they normally receive.
2964518|NCT02801240|Experimental|Nutrition Support Product|Participants will be asked to take a nutrition support product twice per day for a period of 12 weeks.
2964519|NCT02801227|Experimental|Oxytocin|
2964520|NCT02801227|Experimental|Prostaglandin E2|
2964521|NCT02801214||Recreational Cannabis Use|ages 18-40
2964522|NCT02801214||Healthy control subjects|socio-demographically matched
2964523|NCT02801201|Active Comparator|sedation|Midazolam : 0,10 mg/kg
2964524|NCT02801201|Active Comparator|spinal anesthesia|Bupivacain 10 mg
2964525|NCT02801188|Placebo Comparator|Bupivacaine group|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
2964526|NCT02801188|Active Comparator|Mixture of bupivacaine and dexmedetomidine group|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye and 1 ug/kg of dexmedetomidine
2964527|NCT02801175||RF|Patients with paroxysmal atrial fibrillation slated for radiofrequency pulmonary vein isolation
2964528|NCT02801175||Cryoballoon|Patients with paroxysmal atrial fibrillation slated for cryoballoon pulmonary vein isolation
2964529|NCT02801162|Active Comparator|Conventional ABG analyser|
2964530|NCT02801162|Experimental|Proxima 3® arterial blood gas|
2964531|NCT02801149|No Intervention|No further imaging|Patients randomised to this group will receive standard care, i.e. will not undergo additional imaging scans at A&E/Urgent Care Centre.
2964532|NCT02801149|Experimental|Wrist Magnetic Resonance Imaging (MRI)|Patients randomised to this group will undergo an additional 3-sequence wrist MRI during the initial A&E/Urgent Care Centre episode.
2964533|NCT02801136|Experimental|CBT for PNES|CBT-PNES consists of 8 weekly sessions of therapy focused on teaching adolescents to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. It teaches parents how to respond to PNES in a manner that encourages the adolescents to regain control of their body. The PNES is explained as behaviors learned through classical and operant conditioning .
2964534|NCT02801136|Active Comparator|Supportive Therapy|The supportive therapy treatment consists of 8 weekly sessions of therapy focused on discussing daily difficulties and/or stressors they experience and identifying stress triggers for PNES. The PNES is explained as physical manifestations of psychological stress.
2964535|NCT02801136|No Intervention|Healthy Control|Healthy controls are matched to patients with PNES based on age (+ or - 1 year), gender, race and family income. They come to one laboratory visit to complete initial visit questionnaires.
2964536|NCT02801123|Experimental|Preference: MBCR (im)|Individuals with a preference for 'Mindfulness-Based Cancer Recovery (MBCR)' randomized to immediate treatment
2964537|NCT02801123|Experimental|Preference: TCQ (im)|Individuals with a preference for 'Tai Chi/Qigong (TCQ) for Cancer Patients' randomized to immediate treatment
2964538|NCT02801123|Active Comparator|Preference: MBCR (wl)|Individuals with a preference for 'Mindfulness-Based Cancer Recovery (MBCR)' randomized to waitlist
2964539|NCT02801123|Active Comparator|Preference: TCQ (wl)|Individuals with a preference for 'Tai Chi/Qigong (TCQ) for Cancer Patients' randomized to waitlist
2964540|NCT02801123|Experimental|No Preference: MBCR (im)|Individuals with no preference randomized to 'Mindfulness-Based Cancer Recovery (MBCR)' - immediate
2964541|NCT02801123|Experimental|No Preference: TCQ (im)|Individuals with no preference randomized to 'Tai Chi/Qigong (TCQ) for Cancer Patients' - immediate
2964542|NCT02801123|Active Comparator|No Preference: MBCR (wl)|Individuals with no preference randomized to 'Mindfulness-Based Cancer Recovery (MBCR)' - waitlist
2964543|NCT02801123|Active Comparator|No Preference: TCQ (wl)|Individuals with no preference randomized to 'Tai Chi/Qigong (TCQ) for Cancer Patients' - waitlist
2964544|NCT02801097|Experimental|RRx-001 + Irinotecan|Patients enrolled in this trial will receive study drug (RRx-001) on Day 1 as a single agent. Irinotecan (180 mg) will be administered on Day 2 or 3 as a single agent. Both agents will be administered once every two weeks.
2964545|NCT02801084|Experimental|Float|One arm only: restricted environmental stimulation
2964546|NCT02801071|Experimental|L-citrulline|15 g L-citrulline p.o. per day (3x 5g) for 24 weeks
2964547|NCT02801071|Placebo Comparator|Placebo|L-citrulline Placebo 3 times daily p.o. for 24 weeks
2964548|NCT02801058|No Intervention|Control|Simple observation
2964549|NCT02801058|Sham Comparator|Shame|Light touch manipulative simulation
2964550|NCT02801058|Experimental|Treatment|Osteopathic manipulative techniques on the abdominal diaphragm
2964551|NCT02801045|Experimental|art therapy|Individual 30-60 minutes art therapy sessions, twice a week, offering visual arts materials.
2964553|NCT02801032|Placebo Comparator|Control|Placebo Capsule. MRI of cerebrum pre dose. Transcranial Doppler, near-infrared spectroscopy (NIRS), endothelial response with EndoPAT2000, and endothelial biomarkers (pre and post dose).
2964554|NCT02801019|Experimental|E-XLPE|E-poly
2964555|NCT02801019|Active Comparator|C-XLPE|ArComXL
2964556|NCT02801006|Experimental|stenfilcon A|Participants will be randomized to wear stenfilcon A lens pair for two weeks during the cross over study.
2964557|NCT02801006|Active Comparator|etafilcon A|Participants will be randomized to wear etafilcon A lens pair for two weeks during the cross over study.
2964558|NCT02800980||Drainage and sclerotherapy.|Patients with symptomatic lymphocele who are managed with percutaneous drainage and sclerotherapy.
2964559|NCT02800980||Drainage alone.|Patients with symptomatic lymphocele who are managed with percutaneous drainage alone.
2964560|NCT02800967|Active Comparator|Pure Aronia juice|Participants will consume 100 ml of pure Aronia juice per day for 28 days
2964561|NCT02800967|Active Comparator|Aronia juice-based beverage|Participants will consume 100 ml of Aronia juice-based beverage per day for 28 days.
2964562|NCT02800967|Placebo Comparator|Placebo beverage|Participants will consume 100 ml of Placebo beverage per day for 28 days
2964563|NCT02800954|Experimental|multiple myeloma group|case group = patients with multiple myeloma
2964564|NCT02800954|Experimental|MGUS group|monoclonal gammopathy of undetermined significance
2964565|NCT02800954|Other|healthy control group|control group = healthy subjects
2964566|NCT02800941||Oral anticoagulant treatment|Patients with pulmonary hypertension are treated with oral anticoagulants according to the usual practice. Patients have follow-up at 3, 6 and 12 months.
2964567|NCT02800928|Experimental|CERC-501|Administered orally once daily, 10mg daily, 8 days
2964568|NCT02800928|Placebo Comparator|Placebo|Administered orally daily, 8 days
2964569|NCT02800915|Experimental|Intervention, telemedicine and interdisciplinary cooperation|The intervention group will be offered regular interdisciplinary outpatient follow-up via telemedicine.
2964570|NCT02800915|Active Comparator|Control, interdisciplinary guidance on request.|The control group will receive guidance based on existing routines, and based on initiative taken by the local healthcare service/ patient/ next of kin.
2964571|NCT02800902|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
2964572|NCT02800902|Active Comparator|group 2|SRP followed by 1.2% rosuvastatin (RSV) gel
2964573|NCT02800902|Active Comparator|group 3|SRP followed by 1.2% Atorvastatin (ATV) gel
2964574|NCT02800889|Experimental|Treatment: Pixantrone|Each patient will receive pixantrone monotherapy administered intravenously once on days 1, 8, and 15 up to six 28-day cycles of pixantrone monotherapy, with two additional cycles in patients who continue to benefit from treatment. At least 6 patients each from Age Cohorts 1 and 2 will be accrued into dose escalation cohorts. The study will be opened to patients of Age Cohort 3 only after at least 6 patients in Age Cohorts 1 and 2 (combined) have been evaluated for toxicity. During the dose escalation phase, participants who are inevaluable for DLT for reasons unequivocally unrelated to toxicity will be replaced. Expansion cohort accrual quota-At least 15 evaluable patients treated with the MTD/optimal dose will be accrued in total, of which 7 patients will be in Age Cohort 2.
2964575|NCT02800876||asymptomatic not ruptured aneurysm|Patients with asymptomatic not ruptured aortic aneurysms greater than 3 cm who received a clinical indicated CT
2964576|NCT02800876||symptomatic not ruptured aneurysm|Patients with symptomatic aortic aneurysms greater than 3 cm who received a clinical indicated CT
2964577|NCT02800876||symptomatic ruptured aneurysm|Patients with symptomatic ruptured aortic aneurysms greater than 3 cm who received a clinical indicated CT
2964578|NCT02800876||patients with small aneurysms|Patients with small aortic aneurysms approximately 5.5 cm, ruptured and not ruptured, who received a clinical indicated CT
2964579|NCT02800863||Dorsal Root Ganglion (DRG) Stimulation|
2964580|NCT02800850|Experimental|Bright Light Group|Bright Light Exposure
2964581|NCT02800850|Placebo Comparator|Control Group|Placebo Light Exposure
2964582|NCT02800824|Experimental|Budesonide rectal foam|
2964583|NCT02800824|Active Comparator|Uceris rectal foam|
2964584|NCT02800811|Experimental|Part 1: Cohort A, Group 1, FR104|Dose: single 0.005 mg/kg.
2964585|NCT02800811|Experimental|Part 1: Cohort A, Group 2, FR104|Dose: single 0.05 mg/kg.
2964586|NCT02800811|Experimental|Part 1: Cohort A, Group 3, FR104|Dose: single 0.2 mg/kg.
2964587|NCT02800811|Experimental|Part 1: Cohort A, Group 4, FR104|Dose: single 0.5 mg/kg.
2964588|NCT02800811|Placebo Comparator|Part 1: Cohort A, placebo|Placebo, single administration, double blind (1/4 healthy subject in group 1, 1/4 in group 2, 2/5 in group 3 and 2/5 in group 4).
2964589|NCT02800811|Experimental|Part 1: Cohort B, Group 7, FR104|Dose: single 0.5 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
2964590|NCT02800811|Experimental|Part 1: Cohort B, Group 8, FR104|Dose: single 0.2 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
2964591|NCT02800811|Experimental|Part 1: Cohort B, Group 9, FR104|Dose: single 1.5 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
2964592|NCT02800811|Experimental|Part 1: Cohort B, Group 9 bis, FR104|Dose: single 0.02 mg/kg group. Healthy subject naïve to KLH and that will receive a KLH challenge.
2964593|NCT02800811|Placebo Comparator|Part 1: Cohort B, placebo|placebo, single administration, double-blind: healthy subjects naïve to KLH and that will receive a KLH challenge (2/5 in each group of cohort B)
2964594|NCT02800811|Experimental|Part 2: Group 10, FR104|Dose: repeat, 0.2 mg/kg. Two administrations separated by an interval of 28 days.
2964595|NCT02800811|Experimental|Part 2: Group 11, FR104|Dose: repeat, 0.5 mg/kg. Two administrations separated by an interval of 28 days.
2964596|NCT02800811|Placebo Comparator|Part 2: placebo|placebo, repeat, double-blind: 2/5 subjects in each group of Part 2. Two administrations separated by an interval of 28 days.
2964597|NCT02800798||High risk for OSA|High risk OSA defines as Stop-bang score ≥ 3
2964598|NCT02800798||Low risk for OSA|Low risk OSA defines as Stop-bang score < 3
2964619|NCT02800642|Experimental|Aflibercept / Arm 1|Subjects with macular edema secondary to CRVO will be treated with the study drug intravitreal aflibercept.
2964599|NCT02800785|Active Comparator|Antibiotics Therapy Arm|Patients in the antibiotics (abx) arm will receive a total of 10 days of abx, with a minimum of 24 hours using an IV abx formulation (administered in q8, q12, or q24 hour regimens with or without concurrent oral abx) followed by oral abx for the remainder of the 10 days. Patients will be offered a treatment regimen of abx based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. Any of the IV abx options (Single antibiotic-Cefoxitin, Ertapenem, Moxifloxicin, Tigecycline, Ticarcillin-Clavulanic Acid or Dual antibiotics-Metronidazole plus one of the following-Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, Levofloxacin) will be considered acceptable. After IV abx, a regimen of oral abx will be continued for a total treatment length of 10 days.
2964600|NCT02800785|Active Comparator|Appendectomy Arm|Patients in the appendectomy arm will have an appendectomy performed by an open or laparoscopic approach, depending on patient and surgeon preference. Prior to their operation, patients in this arm will receive one dose of antibiotics per currently accepted standards when appendicitis diagnosis is confirmed. Patients may also receive preoperative antibiotics per hospital standards for surgical infection prevention bundle.
2964601|NCT02800772|Experimental|acetic acid|spray 50ml acetic acid to duodenal bulb
2964602|NCT02800772|Placebo Comparator|saline|spray 50ml saline to duodenal bulb
2964603|NCT02800759|Active Comparator|100% of JOINTRUS®|After randomization, 100% dose of JOINTRUS® is taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
2964604|NCT02800759|Active Comparator|80% of JOINTRUS®|After randomization, 80% dose of JOINTRUS® was taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
2964605|NCT02800759|Active Comparator|62.4% of JOINTRUS®|After randomization, 62.4% dose of JOINTRUS® was taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
2964606|NCT02800759|Placebo Comparator|Starch 100%|After randomization, starch 100% was taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
2964607|NCT02800746|Experimental|Experimental group|Ferric carboxymaltose
2964608|NCT02800746|Placebo Comparator|Control Group|Placebo
2964609|NCT02800733|Experimental|saffron|450 mg of saffron capsule once a day for 6 weeks
2964610|NCT02800733|Placebo Comparator|placebo|placebo capsule once a day for 6 weeks
2964611|NCT02800720|Experimental|Meditation Awareness Training|"Target Intervention Arm:~8-week meditation intervention"
2964612|NCT02800720|Active Comparator|Cognitive Behavioural Therapy for Groups|"Active Comparator Arm:~8-week CBT-based intervention"
2964613|NCT02800707|Active Comparator|Sucralose|Participants will be asked to consume 180 mg/day of sucralose (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 340 mg/day of sucralose (or 5.5 12-oz cans of sucralose-sweetened diet soda).
2964614|NCT02800707|Active Comparator|Stevia|Participants will be asked to consume 180 mg/day of stevia (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 800 mg/day of stevia (or about 12 cans of stevia-sweetened diet soda).
2964615|NCT02800681||Asperger syndrome|"Expert panel evaluation for identification of participants with typical symptoms~Semi-structured psychopathological interviews for general psychopathology, psychopathology within the schizophrenia spectrum, and psychopathology within the autism spectrum~Self-administered rating scales for assessment of autistic traits, schizotypal personality and subjective psychological well-being~Other general interviewer ratings for assessing functioning and severity of psychopathology"
2964616|NCT02800681||Schizotypal disorder|"Expert panel evaluation for identification of participants with typical symptoms~Semi-structured psychopathological interviews for general psychopathology, psychopathology within the schizophrenia spectrum, and psychopathology within the autism spectrum~Self-administered rating scales for assessment of autistic traits, schizotypal personality and subjective psychological well-being~Other general interviewer ratings for assessing functioning and severity of psychopathology"
2964617|NCT02800668||DJBL implant-group|"T2DM Patients implanted with a DJBL (Duodenal jejunal Bypass liner, EndoBarrier, GI Dynamics) due to medical reasons.~The subjects were regular in-patients of the Diabetes Center at the Heart and Diabetes Center NRW, Germany and gave informed consent for related procedures and data handling. The subjects had BMI ≥35 kg/m2, T2DM, and a history of frustrated weight loss attempts. Exclusion criteria: history of gastric surgery, gastric or duodenal ulcers, thyroid disorders, gastrointestinal disorders with intestinal resorption dysfunction, therapy with oral anticoagulants, use of acetyl salicylic acid or non-steroidal anti-inflammatory drugs, drug abuse (incl. alcohol), symptomatic cardiovascular disease, renal insufficiency (GFR <50 ml/min), pregnancy or breast feeding."
2964618|NCT02800655|Experimental|DHFS with IS-ARV|Digital Health Feedback System (DHFS) with either IS- Odefsey®, IS- Genvoya®, IS- Tivicay® and Truvada® or IS- Tivicay® and Descovy ® (IS-co-encapsulated with ingestion sensor) -1 or 2 capsules daily (QD), depending on the treatment regimen, administered orally for 16 weeks.
2964620|NCT02800629|Active Comparator|Intervention|Patients will be given Modified Citrus Pectin twice daily for 12 weeks, and have their change in knee pain as measured by survey instruments assessed
2964621|NCT02800629|Placebo Comparator|Control|Patients will be given placebo twice daily for 12 weeks, and have their change in knee pain as measured by survey instruments assessed
2964622|NCT02800616|Experimental|Full intervention group|The full intervention ('The Healthy Primary School of the Future') is implemented in two schools involving extended school hours in which healthy nutrition, physical exercise, environmental, social, and educational activities are incorporated, during a period of four years.
2964623|NCT02800616|Experimental|Partial intervention group|The partial intervention ('The Physical Activity School') is implemented in two other schools: involving extended school hours in which healthy nutrition, physical exercise, environmental, social, and educational activities are incorporated, during a period of four years. Hence, this intervention only differs from the full intervention on the absence of nutritional intervention. Instead, children bring their own food from home, as they normally do.
2964624|NCT02800616|No Intervention|Control group|Four primary schools will function as control schools. The control schools have a representative Dutch school environment in terms of lifestyle education, school hours and amount of Physical Education (PE) lessons.
2964625|NCT02800603|Experimental|Family Check Up|FCU Intervention: All 280 participants will undergo screening and a baseline FCU assessment before randomization. Once randomized, the FCU group (n=140) will be provided with a feedback visit and up to 6 optional sessions of the EDP curriculum over 16 weeks.
2964626|NCT02800603|No Intervention|Community Control|The Community Control group (n=140) will receive general information that includes a list of all the relevant services available in Hamilton. As such, the community control group would be provided with all the information needed to obtain standard care.
2964627|NCT02800590|Experimental|ABP-700 30 μg/kg/min|Starting intravenous (IV) infusion rate of 50 micrograms per kilogram per minute (μg/kg/min) for 5 minutes, followed by 30 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
2964628|NCT02800590|Experimental|ABP-700 40 μg/kg/min|Starting IV infusion rate of 70 μg/kg/min for 3 minutes, followed by 40 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
2964629|NCT02800590|Experimental|ABP-700 45 μg/kg/min|Starting IV infusion rate of 80 μg/kg/min for 3 minutes, followed by 45 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
2964630|NCT02800577|Other|All participants|Study has a single, non-interventional arm where the General Practitioner Emotional Test Battery (GP-ETB) will be administered.
2964631|NCT02800564|Experimental|Active mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months plus interactive voice response systems (IVRS) and monthly open community meetings.
2964632|NCT02800564|Experimental|Passive mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months
2964633|NCT02800551|Experimental|SBRT (Arm A)|"dose-intensified image-guided SBRT using simultaneous integrated boost:~in the case of no epidural involvement: 40 Gy and 20 Gy in 5 fractions to the high-dose and conventional-dose target volume, respectively;~In the case epidural involvement: 48.5 Gy and 30 Gy in 10 fractions to the high-dose and conventional-dose target volume, respectively;"
2964634|NCT02800551|Active Comparator|Conventional Radiation Therapy (Arm B)|"External 3-dimensional conformal radiotherapy (3D-CRT):~Homogeneous irradiation of the affected vertebra delivering either~20 Gy in 5 fractions or~30 Gy in 10 fractions."
2964635|NCT02800538|Experimental|Lauric acid|the nutrient that can be widely found in daily food.
2964636|NCT02800538|Experimental|Palmitic acid|the nutrient that can be widely found in daily food.
2964637|NCT02800538|Experimental|Capric acid|the nutrient that can be widely found in daily food.
2964638|NCT02800538|Placebo Comparator|Saline|physiological salt water
2964639|NCT02800525|Experimental|Picosecond laser|"The pigmented lesions on this half-side of the face would be treated with picosecond laser.~For epidermal lesions, 1 laser treatment would be performed. For dermal lesions, 5 laser treatments would be performed every 3 month-interval.~The wavelength of 532 or 1064 nm would be chosen for appropriate lesions"
2964640|NCT02800525|Active Comparator|Q-switched Nd:YAG laser|"The pigmented lesions on this half-side of the face would be treated with q-switched Nd:YAG laser.~For epidermal lesions, 1 laser treatment would be performed. For dermal lesions, 5 laser treatments would be performed every 3 month-interval.~The wavelength of 532 or 1064 nm would be chosen for appropriate lesions"
2964641|NCT02800512|Active Comparator|Sacrocolpopexy|Robotic sacrocolpopexy
2964642|NCT02800512|Active Comparator|HUSLS|Vaginal high uterosacral ligament suspension
2964643|NCT02800499||KOCOSS|The KOrea COpd Subgroup Study team (KOCOSS) cohort is an ongoing, longitudinal, prospective, non-interventional observational study within the Korean COPD patients
2964644|NCT02800486|Experimental|Intra-arterial Cetuximab with Re-Irradiation|Mannitol 20% 12.5ml over two minutes for blood brain barrier (BBB) disruption followed by Cetuximab administered intra-arterially for three doses at a dose of 250 mg/m2 combined with hypofractionated re-irradiation
2964645|NCT02800473|Other|Experimental|"Patients with a suspicion of a bladder cancer or suspected recurrence of bladder cancer will have a cystoscopy under their care.~Patients will be randomized to know the order of carrying out cystoscopy with one or the other medical devices.~24 hours and 48 hours after the exam, a nurse will contact the patient to detect potential adverse effects"
2964646|NCT02800460|Other|Deep brain stimulation with fMRI-3T|Patients will have a 3T-fMRI before their usual MRI-1,5T
2964647|NCT02800447|Experimental|Treatment|baseline BEACOPP regimen
2964648|NCT02800447|Active Comparator|controlled group|ABVD regimen
2964649|NCT02800434|Experimental|hand allograft|
2964650|NCT02800421||no organ damage|no evidence of HLI and CI-AKI
2964651|NCT02800421||CI-AKI only|CI-AKI, but no HLI
2964652|NCT02800421||HLI only|HLI, but no CI-AKI
2964653|NCT02800421||combined CI-AKI and HLI|Both CI-AKI and HLI
2964654|NCT02800408|Experimental|Whole grain high-BCX maize|Whole grain, high-beta-cryptoxanthin (BCX; orange) maize will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
2964655|NCT02800408|Experimental|Refined grain high-BCX maize|Refined (degermed) grain, high-beta-cryptoxanthin (BCX; orange) maize will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
2964656|NCT02800408|Placebo Comparator|Whole grain white maize|Whole grain, white maize (low in beta-cryptoxanthin) will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
2964657|NCT02800395|Other|Nutritional evaluation|
2964658|NCT02800382|Other|Lung Malignancy|"Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.~The samples (fine-needle aspiration biopsy and fine-needle aspiration cytology) were diagnosed by pathological examination."
2964659|NCT02800382|Other|Lung bening Diseases|Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
2964660|NCT02800369|Experimental|ZFN-603 and ZFN-758|Subjects will receive suppository with ZFN-603 or ZFN-758
2964661|NCT02800356|Experimental|Pseudodrusen|Subthreshold 577 nm yellow wavelength laser photo-coagulator
2964662|NCT02800356|Experimental|Geographic atrophy|Subthreshold 577 nm yellow wavelength laser photo-coagulator
2964663|NCT02800343||Cardiovascular surgery|All adult patients undergoing elective or emergency cardiovascular surgery at the study site
2964664|NCT02800330|Other|Arm A (e.g. sequence phase A-B-C)|In this arm patients will use regorafenib alone in the first cycle (treatment A), then regorafenib with esomeprazole concomitantly in the second cycle (treatment B) and at last they will use regorafenib with esomeprazole 3 hours before (treatment C)
2964665|NCT02800330|Other|Arm B (e.q. sequence phase C-B-A)|In this arm patients will use regorafenib with esomeprazole 3 hours before (treatment C), then regorafenib with esomeprazole concomitantly in the second cycle (treatment B) and at last they will use regorafenib alone (treatment A),
2964666|NCT02800317|Experimental|RISAS|All patients will undergo RISAS procedure, followed by axillary lymph node dissection in a one-step surgical procedure.
2964667|NCT02800265|Experimental|Avmacol during week 2 for 3 days|"Buccal cells line the inner cheek, and will be collected from the inner right cheek with a cytobrush (a q-tip like swab) by a trained investigator.~During the second week the participant will take 8 Avmacol tablets every evening for 3 evenings (Day 2, 3, 4), and record the time of each dose in the provided diary. Research blood collection: on days 1 and 5. Overnight urine collection."
2964668|NCT02800252|Placebo Comparator|Control Group|Full-mouth periodontal debridement and placebo
2964669|NCT02800252|Active Comparator|Test 1|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
2964670|NCT02800252|Active Comparator|Test 2|omega-3 plus aspirin before periodontal therapy
2964671|NCT02800239|Experimental|Active, adolescent females|Subjects will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
2964672|NCT02800226|Experimental|10Hz|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4-6 weeks
2964673|NCT02800226|Active Comparator|iTBS|intermittent Theta Burst Stimulation (iTBS) five days per week for 4-6 weeks
2964674|NCT02800213|Experimental|Modified Ambu Spur II bag mask first|A health volunteer uses a modified Ambu Spur II bag valve mask with integrated internal handle (experimental device, not yet FDA approved) to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a conventional Ambu Spur II bag valve mask.
2964675|NCT02800213|Active Comparator|Conventional Ambu Spur II bag mask first|A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a modified Ambu Spur II bag valve mask.
2964676|NCT02800200|Experimental|Platelet rich plasma|The ultrasoud-guided injection with Platelet rich plasma (3cc) was perfomed in both groups.
2964677|NCT02800200|Experimental|Active shock wave|One-session active shock wave 2 weeks later after PRP injection was performed in intervention group.
2964678|NCT02800200|Placebo Comparator|Sham shock wave|One-session sham shock wave 2 weeks later after PRP injection was performed in control group.
2964679|NCT02800187|Experimental|three-sessions of ESWT|Active three-sessions of ESWT ( once a week for 3 weeks) was given.
2964680|NCT02800187|Active Comparator|one-session of ESWT|One-session of ESWTactive ESWT was given.
2964681|NCT02800187|Active Comparator|Night splint|The night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study. Another 3 sessions of sham ESWT was given.
2964682|NCT02800174|Experimental|Smart nitinol stent implantation group|The Smart nitinol stent system was used (import product registration number YZB/USA 0115-2008; Nitinol stent system, trade name SMART Control). The stent system comprises a self-expanding stent and a delivery system. The self-expanding stent is composed of a nickel titanium alloy and the ends of the stent are equipped with tantalum radiopaque markers. The Smart nitinol stent system is sterilized with ethylene oxide gas and is intended for single use only.
2964683|NCT02800174|Active Comparator|Antiplatelet drug group|Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
2964684|NCT02800161|Active Comparator|Trehalose|Trehalose 70g/die
2964685|NCT02800161|Placebo Comparator|Placebo|Maltose 70g/die
2964686|NCT02800148|Experimental|Azelaic acid foam|
2964687|NCT02800148|Active Comparator|Finacea Foam|
2964688|NCT02800148|Placebo Comparator|Placebo Foam|
2964689|NCT02800135|Experimental|Furosemide stress test|
2964731|NCT02799667|Active Comparator|Standard Dressing|Women will be randomized to receive the standard dressing (sterile gauze, non absorbent sterile gauze, and a waterproof bandage) at the time of fascial closure in a cesarean delivery.
2965106|NCT02796976|No Intervention|healthy older sedentary|only cross-sectional
2964690|NCT02800122||Patients with acute dyspnea|"Patients with acute dyspnea treated by a medical team of emergencies of CHRU of Nancy.~All patients admitted to the emergencies in the last 5 years matching the inclusion criteria will be evaluated. About 4,000 patients will be affected, including more than 800 patients with acute heart failure. (Figures based on export of ICD X codes (R06.0: Dyspnea) of patients cared in extra-hospital for acute dyspnea (diagnosis Dyspnea + Heart Failure) over the last 5 years)."
2964691|NCT02800096|Active Comparator|Gambling Internet intervention|The gambling only Internet intervention (G-only) will consist of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
2964692|NCT02800096|Experimental|Gambling Internet intervention + MoodGYM|The G+MH intervention condition will consist of the G-only intervention and an online intervention for depression and anxiety. The mental health intervention chosen is MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
2964693|NCT02800083|Experimental|Pitolisant (BF2.649)|Histamine H3 receptor H3R antagonist/ inverse agonist
2964694|NCT02800083|Placebo Comparator|Placebo|placebo
2964695|NCT02800070|Experimental|Treatment Arm|Patients will receive Health Canada approved transduced autologous CD34+ cell product.
2964696|NCT02800044|Experimental|Wearing glucose sensor|The study team will measure glucose readings from the non-invasive sensor and from a glucometer at the following time points: fasting, 1.5 to 2 hours after a meal, and before and after 15-30 minutes of pedaling on a stationary bicycle at 80% maximum heart rate..
2964697|NCT02800031|Experimental|Participants|"Level-II Transvaginal ultrasonography will be done by the principle investigator (who is unaware about the recognition pattern method) to confirm the presence of the ovarian mass and measure its size and to apply the IOTA simple rules on it (complimentary transabdominal ultrasound might be done for huge pelvi-abdominal masses originating from the ovary).~Level-III ultrasound will be done by expert ultrasound operator (who is blinded to the results of IOTA simple rules assessment of the examined mass) to classify the mass (either benign or malignant) using the pattern recognition method.~Plan of management for each patient will be based solely on the findings of pattern recognition and the patient's wishes.~Exploratory laparotomy for excision of the ovarian mass either by ovarian Cystectomy or oophorectomy.~All specimens will be examined histopathologically."
2964698|NCT02800005|Other|BMI group (Successive patients)|All successive patients meeting the including criteria and signed the informed consent will be measured BMI and the data will be recorded in the prospective database. The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese. Investigators declare that there exists no conflicts of interest.
2964699|NCT02800005|Experimental|AFA group(Successive patients)|All successive patients meeting the including criteria and signed the informed consent will be measured BMI and the data will be recorded in the prospective database. The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit. No contrast agent is needed. Patients in the AFA group will be also measured by BMI. Investigators declare that there exists no conflicts of interest.
2964700|NCT02799992|Active Comparator|Half Dose Photodynamic Therapy|Half Dose Photodynamic Therapy The safety enhanced PDT protocol for CSC was performed using half the normal dose of verteporfin (Visudyne, Novartis Pharma, Switzerland), which is 3 mg/m2 verteporfin
2964701|NCT02799992|Experimental|689 nm Laser Treatment|A 689 nm laser treatment delivering 95 J/cm2 by application of an intensity of 805 mW/cm2 over 118 seconds was performed. No verteporfin or other drugs were administered to the patients.
2964702|NCT02799979||Case|Echocardiographic data : 3D right ventricular imaging on 100 pulmonary hypertension patients at Baseline and after six months
2964703|NCT02799979||Control|Echocardiographic data : 3D right ventricular Imaging on 50 patients without pulmonary hypertension only at baseline
2964704|NCT02799966|Other|Early Treatment Group|Initiate treatment with MyndMove device on or after 10 days to 6 months (182 days) post spinal cord injury
2964705|NCT02799966|Other|Late Treatment Group|Initiate treatment with MyndMove device on or after 6 months plus one day (183 days+) post spinal cord injury
2964706|NCT02799953|Experimental|Technology-based self-management model|Participants randomized to the intervention group will be given a tablet-based, interactive touch-screen self-monitoring system free of charge to perform disease self-monitoring in their homes.
2964707|NCT02799953|No Intervention|Conventional self-management|Participants randomized to the usual care group will not be provided access to tablet computers but a 2-in-1 blood pressure and blood glucose monitor and a paper-based log book to perform conventional self-monitoring.
2964708|NCT02799940||Computed tomography in acute respiratory distress syndrome|The lung on computed tomography (CT) in patients with acute respiratory distress syndrome (ARDS) has revealed a heterogeneous pattern of lung injury, with areas of normal lung interspersed with altered regions: ground-glass opacification and consolidation among the most frequent. It has been performed quantitative assessments of ARDS by means of CT, thus enabling a correlation of such pathologic details with physiologic, clinical parameters and with patient outcomes. Therefore, the primary objective of the study is to determine the correlation between the extent of oxygenation (PaO2/FiO2) and the degree of consolidation (total CO) in the CT. The secondary objectives are to determine: the correlation between the driving pressure, ventilator variables and the total CO; the independent variables associated with total CO; differences in the CT with respect to the total lung-disease score (total CO plus total value of ground-glass opacification) between survivors and nonsurvivors.
2964732|NCT02799667|Experimental|Negative Pressure Wound Therapy Dressing|Women will be randomized to receive the Negative Pressure Wound Therapy (NPWT) dressing at the time of fascial closure in a cesarean delivery.
2964733|NCT02799641|Placebo Comparator|Control|Control arm receives ibuprofen, placebo pill, and placebo injection.
2964734|NCT02799641|Experimental|Treatment|Treatment arm receives ibuprofen, diazepam pill, and lidocaine injection.
2964709|NCT02799927|Experimental|Biodentine|"Biodentine (Septodont, Saint-Maur-des-Fosses, France) has been recently introduced and marketed as a bioactive dentin substitute. The Biodentine powder contains tricalcium silicate, dicalcium silicate and calcium oxide, while its liquid consists of calcium chloride and a carboxylate-based hydrosoluble polymer (water-reducing agent).~After local anesthesia and rubber dam isolation, carious peripheral dentin is eliminated with a high speed tungsten-carbide bur # 3, and air-water spray. Then, the cavity's floor soft dentin layer is carefully removed with a sharply-edged sterilized hand excavator, leaving only the hard dentin adjacent to the pulp ceiling. The cavity is thoroughly rinsed only with water and dried with sterilized cotton pellets. The next step consists in the preparation of Biodentine liner (a mix of powder and liquid), following the manufacturers' instructions, and its placement over the remanent carious dentin layer."
2964710|NCT02799927|Active Comparator|Ultra-Blend plus (Calcium hydroxide)|"Ultra-Blend plus® (Ultradent Products Inc., South Jordan, UT, USA). This material is a light-activated calcium hydroxide based-liner. Calcium hydroxide has demonstrated to reduce and promote immediate deactivation of the residual microorganisms after IPT.~After local anesthesia and rubber dam isolation, carious peripheral dentin is eliminated with a high speed tungsten-carbide bur # 3, and air-water spray. Then, the cavity's floor soft dentin layer is carefully removed with a sharply-edged sterilized hand excavator, leaving only the hard dentin adjacent to the pulp ceiling. The cavity is thoroughly rinsed only with water and dried with sterilized cotton pellets. The next step consists in the placement of Ultra-Blend plus liner over the remanent carious dentin layer, using a dycal metallic applicator. Finally, the liner is cured through light exposure during 20 seconds ."
2964711|NCT02799901|Experimental|Patient|patient with Advanced melanoma
2964712|NCT02799888|Experimental|Maraviroc + standard GVHD prophylaxis|Maraviroc administration (in addition to the standard prophylaxis therapy of cyclosporine/tacrolimus and methotrexate) will start on day -2 and will end on day +30 after stem cell transplant, making the total number of days of drug administration 33 days. Maraviroc will be administered 300mg twice daily orally.
2964713|NCT02799875|Active Comparator|Higher permissive hypercapnia|Extubation criteria: partial pressure carbon dioxide (pCO2) ≥ 60mmHg with an upper limit ≤ 75mmHg; pH ≥ 7.20; oxygen saturation (SpO2) ≥ 88% with fraction of inspired oxygen (FiO2) ≤ 0.50; mean airway pressure (MAP) < 8 cm H2O, ventilator rate ≤ 20 bpm, amplitude < 2X MAP if on high frequency ventilation (HFV); hemodynamically stable (clinically acceptable blood pressure and perfusion per clinical team opinion). In addition, reintubation may occur if any of the following are met: PCO2 > 75mmHg; pH < 7.20; FiO2 ≥0.80 required to maintain SpO2 ≥ 88% for one hour; hemodynamic instability; clinically defined shock; repetitive apnea (> 1 episode per hour) requiring bag and mask ventilation; sepsis; and/or need for surgery.
2964714|NCT02799875|Active Comparator|Lower permissive hypercapnia|Extubation criteria: pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg; pH ≥ 7.25; SpO2 ≥ 88% with FiO2 ≤ 0.50; mean airway pressure (MAP) < 8 cm H2O, ventilator rate ≤ 20 bpm, amplitude < 2X MAP if on high frequency ventilation (HFV); hemodynamically stable (clinically acceptable blood pressure and perfusion per clinical team opinion). In addition, reintubation may occur if any of the following are met: PCO2 > 55mmHg; pH < 7.25; FiO2 ≥0.80 required to maintain SpO2 ≥ 88% for one hour; hemodynamic instability; clinically defined shock; repetitive apnea (> 1 episode per hour) requiring bag and mask ventilation; sepsis; and/or need for surgery.
2964715|NCT02799849|Other|Narcoleptic patients|
2964716|NCT02799849|Other|hypersomnic patients|
2964717|NCT02799836|Experimental|Light deprived study subjects|Study subjects who are blindfolded for 48 hours
2964718|NCT02799823|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
2964719|NCT02799797|Active Comparator|short axis (SAX) placement of adductor canal catheters|Procedure: Ultrasound guided short axis (SAX) placement of adductor canal catheters Philip CX50 ultrasound scanner guided insertion of a PAJUNK Contiplex S catheter along the short axis of the middle part of adductor canal
2964720|NCT02799797|Experimental|long axis (LAX) placement of adductor canal catheters|Procedure: Ultrasound guided long axis (LAX) placement of adductor canal catheters Philip CX50 ultrasound scanner guided insertion of a catheter along the long axis of the middle part of adductor canal
2964721|NCT02799784|Experimental|Sequence 1: UMEC/VI 62.5/ 25 mcg|Subjects will receive UMEC/VI 62.5/25 mcg (as one inhalation) administered QD via the ELLIPTA Inhaler for 8 weeks followed by a washout period of 3 weeks
2964722|NCT02799784|Experimental|Sequence 2: TIO/OLO 5/5 mcg|Subjects will receive TIO/OLO 5/5 mcg (as 2 inhalations of 2.5/2.5 mcg per inhalation) administered QD via the RESPIMAT inhaler for 8 weeks followed by a washout period of 3 weeks
2964723|NCT02799758|Experimental|NK-104-CR|NK-104-CR 8 mg tablet and Placebo (for Livalo® IR 4 mg tablet) orally once daily for 52 weeks.
2964724|NCT02799758|Active Comparator|Livalo® IR|Livalo® IR 4 mg tablet and Placebo (for NK-104-CR 8 mg tablet) orally once daily for 52 weeks.
2964725|NCT02799745|Active Comparator|Enzalutamide|Taken once daily
2964726|NCT02799745|Other|Active Surveillance (AS)|AS arm will not receive any study drug
2964727|NCT02799706|Active Comparator|GnRH agonist + radiation therapy (RT)|"As the study investigates the effect of a drug given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT) + A GnRH-agonist will be given for the duration selected for each patient.~A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.~Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm."
2964728|NCT02799706|Experimental|GnRH antagonist + radiation therapy (RT)|"As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT) +a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy.~Each institution has to adhere to the chosen duration of treatment for all patients throughout the study"
2964729|NCT02799693||Recurrent VT failing RF ablation|Patients undergoing intramural needle catheter ablation of recurrent monomorphic ventricular tachycardia who have failed prior attempted radiofrequency catheter ablation.
2964730|NCT02799680|Experimental|allogeneic CART-33|infusions of allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
2964735|NCT02799628|Active Comparator|intervention|"Give the physical therapy of low back pain educational video + therapist introduction and recommendation video, at the first time of clinic visit.~Physical therapy with hot packing + interference current therapy + pelvic traction + therapeutic exercise, 3 times per week for 4 weeks."
2964736|NCT02799628|Placebo Comparator|placebo|"Give the physical therapy of low back pain educational video, at the first time of clinic visit.~Physical therapy with hot packing + interference current therapy + pelvic traction + therapeutic exercise, 3 times per week for 4 weeks."
2964737|NCT02799602|Experimental|BAY1841788 /darolutamide (ODM-201)+standard ADT+Docetaxel|Co-administration of BAY 1841788 / darolutamide (ODM-201), standard ADT and docetaxel
2964738|NCT02799602|Placebo Comparator|Placebo + standard ADT + Docetaxel|Co-administration of Placebo matching BAY 1841788 / darolutamide (ODM-201) tablets, standard ADT and docetaxel
2964739|NCT02799589|Experimental|Remifentanil-dexmedetomidine and caudal|Anesthesia will be induced with inhaled sevoflurane which will be discontinued once IV access is obtained and the airway is secured with an endotracheal tube. Patients will receive remifentanil loading dose of 1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min) and dexmedetomidine load at 1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr) A caudal block with 0.2% ropivacaine will be performed in all patients for intraoperative and postoperative pain control.
2964740|NCT02799576|Experimental|Curved needle|This will utilize the curved block needle of performance of regional block
2964741|NCT02799576|No Intervention|Traditional needle|This will utilize the traditional block needle of performance of regional block
2964742|NCT02799563|Experimental|Cohort A: Coach, Preselected number of cases|Cohort A completed the DKA simulator cases during two one-hour coached sessions. They were assigned a pre-selected number of DKA simulator cases (2 cases with 2 reps each, for 4 reps in total).
2964743|NCT02799563|Experimental|Cohort B: Coach, Self-selected number of cases|Cohort B completed the DKA simulator cases during two one-hour coached sessions. They were assigned a self-selected number of DKA simulator cases and were instructed to complete as many cases until they felt comfortable with DKA management.
2964744|NCT02799563|Experimental|Cohort C: No coach, Preselected number of cases|Cohort C completed the DKA simulator cases in a non-coached setting, on their own time. They were assigned a pre-selected number of DKA simulator cases (2 cases with 2 reps each, for 4 reps in total).
2964745|NCT02799563|Experimental|Cohort D: No coach, Self-selected number of cases|Cohort D completed the DKA simulator cases in a non-coached setting, on their own time. They were assigned a self-selected number of DKA simulator cases and were instructed to complete as many cases until they felt comfortable with DKA management.
2964746|NCT02799550|Experimental|allogeneic CART-19|infusions of allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
2964747|NCT02799537|Experimental|Intervention|Participants in the intervention arm complete the Stanford letter advance directive
2964748|NCT02799537|Active Comparator|Control|Participants in the control arm complete the California state traditional advance directive
2964749|NCT02799511|Other|protein expression|
2964750|NCT02799498|Active Comparator|A-etanercept (ENBREL®) by auto-injector|Single dose of etanercept (ENBREL®) in a pre-filled syringe administered with an auto-injector device manufactured by Scandinavian Health Limited (SHL)
2964751|NCT02799498|Other|B-etanercept (ENBREL®) by Manual injection|Single dose of etanercept (ENBREL®) in a syringe given by manual injection (reference treatment)
2964752|NCT02799485|Experimental|Treatment (recombinant EphB4-HSA fusion protein)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1 and 15. Patients with disease progression after 2 or more courses who have not experienced toxicity may receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of further disease progression or unacceptable toxicity.
2964753|NCT02799472|Experimental|GSK3196165 + MTX arm|Subjects will receive GSK3196165 (initially weekly, then every other week) in combination with MTX (15-25 mg/week) and folic (or folinic) acid (>=5 mg/week).
2964754|NCT02799472|Placebo Comparator|Placebo + MTX arm|Subjects will receive placebo (initially weekly, then every other week) in combination with MTX (15-25 mg/week) and folic (or folinic) acid (>=5 mg/week).
2964755|NCT02799459||General anaesthesia|this group will allow us to compare the results like it is the treatment used in current practice ie general anesthesia.
2964756|NCT02799459||Hypnosis in conization|This group is the treatment being tested , where hypnosis is used in the conization
2964757|NCT02799446|Experimental|Reslizumab|Reslizumab will be administered intravenously every 4 weeks at a dose of 3mg/kg.
2964758|NCT02799446|Placebo Comparator|Placebo|Matching placebo.
2964759|NCT02799433|Active Comparator|Usual Services|This group of child care centers receives standard services from the San Francisco Department of Public Health Child Care Health Program. CCHP offers services to child care centers annually. The standard services include nurse consultation, health education, monitoring of nutrition and physical activity resource need, vision, hearing, oral health, and height and weight screenings.
2964760|NCT02799433|Experimental|Usual services + HAP|This group of child care centers receives all the standard services plus invitation to participate in the voluntary Healthy Apple Program (HAP). The Healthy Apple program involves child care provider self-assessment, followed by an iterative process of goal setting, technical assistance/training, and re-assessment.
2964761|NCT02799420|Experimental|pCLE group|The intervention group
2964762|NCT02799420|Active Comparator|WLE group|The control group
2964763|NCT02799407|No Intervention|Traditional Long Form Consent|Participants will receive the traditional long-form consent form.
2964764|NCT02799407|Experimental|ResearchKit Consent|Participants will receive the Apple ResearchKit consent form.
2964765|NCT02799394|Experimental|Activity modification, exercises and gradual return to sport|
2964766|NCT02799381|Active Comparator|Optimized Medical Treatment|12 Week Period
2964767|NCT02799381|Experimental|ABT-SLV187|12 Week Period
2964768|NCT02799368|Experimental|CJ Plasma Solution A Injection|Before contrast media administration : CJ Plasma Solution A Injection (3mL/kg for 1 hour) After contrast media administration : CJ Plasma Solution A Injection (1.5 mL/kg/h for 4 hours)
2964805|NCT02799030|Placebo Comparator|BF-200 ALA 0%|Topical application of matched placebo gel without containing 5-ALA. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
2964769|NCT02799368|Active Comparator|CJ 0.9% Normal Saline Injection|Before contrast media administration : CJ 0.9% Normal Saline Injection (3mL/kg for 1 hour) After contrast media administration : CJ 0.9% Normal Saline Injection (1.5mL/kg/h for 4 hours)
2964770|NCT02799316|Other|rheumatic disease with HBs-ag positive|• HBV core antibodies testing. • Real time PCR testing.
2964771|NCT02799303|Experimental|Multi-parametric MRI|Patients from the general population without history of previous prostate biopsy will be allocated to receive mpMRI in order to evaluate for risk of prostate cancer.
2964772|NCT02799303|Active Comparator|PSA Only|"Patients from the general population without history of previous prostate biopsy will be allocated to receive serum PSA testing in order to evaluate for risk of prostate cancer.~Patients with a serum PSA level less than 4.0 ng/mL will be managed expectantly with results provided to their primary care physician."
2964773|NCT02799290|No Intervention|CONTROL|No intervention
2964774|NCT02799290|Experimental|ADIPOSE TISSUE EXTRACT|Adipose Tissue extract application
2964775|NCT02799290|Experimental|PLATELET-RICH PLASMA GEL|PLATELET RICH PLASMA GEL APPLICATION
2964776|NCT02799277|Experimental|Testosterone|17mg testosterone will be administered intranasally in a 1mL aqueous solution
2964777|NCT02799277|Placebo Comparator|Placebo|1ml blank (containing no drug) aqueous solution will be administered intranasally
2964778|NCT02799264|Experimental|Cabotegravir 30 mg: Sequence AB (fasted followed by fed)|There will be two administration periods with 14 days of wash out. In Period 1, eligible subjects will receive a single tablet of cabotegravir 30 mg,(micronized 500 mg core weight) orally under fasted condition with at least 10 hours of prior fast. In Period 2, eligible subjects will receive single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally following a high fat meal. Blood samples will be withdrawn from subjects prior to dosing and upto 8 days after the last dose of cabotegravir.
2964779|NCT02799264|Experimental|Cabotegravir 30 mg: Sequence BA (fed followed by fasted)|There will be two administration periods with 14 days of wash out. In Period 1, eligible subjects will receive single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally following a high fat meal. In Period 2, eligible subjects will receive a single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally under fasted condition with at least 10 hours of prior fast. Blood samples will be withdrawn from subjects prior to dosing and upto 8 days after the last dose of cabotegravir.
2964780|NCT02799251||Collection of plasma cell rate|Post operative infections and their association with lymphopenia are assessed in this study for patients over 18 years of age undergoing digestive or thoracic cancer surgery under general anesthesia.
2964781|NCT02799238|Active Comparator|Radiotherapy in combination with Temozolomide (TMZ)|radiotherapy combined with TMZ treatment followed by adjuvant TMZ
2964782|NCT02799238|Experimental|ALECSAT + Radiotherapy in combination with TMZ|3 doses of ALECSAT /4 weeks followed by ALECSAT every 3 months
2964783|NCT02799225||Enterobacteria|
2964784|NCT02799212|Experimental|Experimental group|postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day
2964785|NCT02799212|Placebo Comparator|Control group|Placebo infusion (50ml of 0.9% NaCl/day) during 6 days
2964786|NCT02799186|Experimental|SCAD (spontaneous coronary artery dissection)|Every patient included with a SCAD or hematoma, will systematic benefit a tomographic or MRI angiography of renal, cerebrovascular and iliac arteries, to look for the presence of a fibromuscular displasia. A blood sample will be collected for the genetic analysis which will be realized by the Team 3 of the INSERM UMR970, Paris Cardiovascular research Center, France.
2964787|NCT02799173|Experimental|Systemic lupus erythematosus|RANKL/OPG ratio bone densitometry fan beam CT scan Doppler ultrasound
2964788|NCT02799147|Experimental|280 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3 and +4: Bendamustine 140 mg/m2/day iv.
2964789|NCT02799147|Experimental|200 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3 and +4: Bendamustine 100 mg/m2/day iv
2964790|NCT02799147|Experimental|210 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3, +4, +5: Bendamustine 70 mg/m2/day iv.
2964791|NCT02799134|Experimental|group1|take Dexamethasone at 22:00 on the first day, 0.5mg
2964792|NCT02799134|Placebo Comparator|group2|take Vitamin C at 22:00 on the first day, 0.5mg
2964793|NCT02799134|Other|group3|take Dexamethasone at 15:00 on the second day, 0.5mg
2964794|NCT02799121|Experimental|ReGenerCell™|Debridement and/or a sterile saline rinse of ulcer, as clinically indicated, followed by ReGenerCell™ treatment and appropriate dressing and off-loading
2964795|NCT02799108|Experimental|patients|children with drug-resistant partial epilepsy, in whom preoperative assessment is indicated
2964796|NCT02799095|Experimental|ALKS 4230|
2964797|NCT02799095|Experimental|ALKS 4230 + pembrolizumab|
2964798|NCT02799082|Placebo Comparator|Vehicle|Topical application of matched placebo gel (without containing active ingredient). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1.0 cm surrounding margin.
2964799|NCT02799082|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1.0 cm surrounding margin.
2964800|NCT02799069|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid (ALA). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
2964801|NCT02799069|Active Comparator|MAL Cream|Topical application of MAL cream (Metvix) containing 160 mg/g methyl-aminolevulinate (MAL). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
2964802|NCT02799069|Placebo Comparator|Vehicle|Topical application of matched Placebo to BF-200 ALA gel (without containing active ingredient) ). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
2964803|NCT02799043|Active Comparator|Standard PVI|Standard catheter ablation including pulmonary vein isolation (PVI) procedure.
2964804|NCT02799043|Experimental|FIRM-guided Procedure and PVI|FIRM-guided procedure followed by PVI.
2965535|NCT02794259|Experimental|Cathodal tDCS|Cathodal stimulation during resting state fMRI
2964806|NCT02799030|Experimental|BF-200 ALA 1%|Topical application of BF-200 ALA gel containing 0.78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
2964807|NCT02799030|Experimental|BF-200 ALA 3%|Topical application of BF-200 ALA gel containing 3.8 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
2964808|NCT02799030|Experimental|BF-200 ALA 10%|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
2964809|NCT02799017|Experimental|Intensive Phonology Treatment|"The participants in the experimental group will receive an hour of phonology treatment, an hour of group therapy, and an hour of reading. They will work on writing, generative naming during group time focusing on self-cueing with the sounds they learn during the individual session. They will be read to or read aloud depending on their level.~The participants in the experimental group will be taught all consonants and vowels over the course of 16 weeks."
2964810|NCT02799017|Active Comparator|Intensive SFA Treatment|The participants in the control group will receive an hour of individual therapy, an hour of reading and an hour of group therapy in a traditional setting. They will work on writing, generative naming during group time following the semantic feature analysis to retrieve the name.They will be read to or read aloud depending on their level.
2964811|NCT02799004||Patients in acute pain|
2964812|NCT02798991|Experimental|10 mg of GSK3179106 QD-Cohort 1|Eligible six subjects will receive 10 mg oral dose once daily for 14 days
2964813|NCT02798991|Experimental|50 mg of GSK3179106 QD-Cohort 2|Eligible six subjects will receive 50 mg oral dose once daily for 14 days
2964814|NCT02798991|Experimental|200 mg of GSK3179106 QD-Cohort 3|Eligible six subjects will receive 200 mg oral dose once daily for 14 days
2964815|NCT02798991|Experimental|400 mg of GSK3179106 QD-Cohort 4|Eligible six subjects will receive 400 mg oral dose once daily for 14 days
2964816|NCT02798991|Experimental|25 mg of GSK3179106 BID-Cohort 5|Eligible six subjects will receive 25 mg oral dose twice daily for 14 days
2964817|NCT02798991|Experimental|200 mg of GSK3179106 BID-Cohort 6|Eligible six subjects will receive 200 mg oral dose twice daily for 14 days
2964818|NCT02798991|Placebo Comparator|Matching placebo QD-Cohort 1, 2, 3, 4|Eligible two subjects, per cohort, will receive oral dose of matched placebo once daily for 14 days
2964819|NCT02798991|Placebo Comparator|Matching placebo BID-Cohort 5, 6|Eligible two subjects, per cohort, will receive oral dose of matched placebo twice daily for 14 days
2964820|NCT02798978|Experimental|Part 1: GSK1795091 or Placebo|In Part 1, subjects in sequential cohorts will receive single ascending doses of intravenous (IV) injection of GSK1795091 or matching placebo, with a starting dose of 7 nanogram (ng), on Day 1 until the highest dose is evaluated.
2964821|NCT02798978|Experimental|Part 2 Cohort 1: GSK1795091|In Part 2 Cohort 1, subjects will receive IV injection of GSK1795091 on Day 1, at dose determined in part 1, and second dose on Day 8 (one week apart)
2964822|NCT02798978|Experimental|Part 2 Cohort 2: GSK1795091|In Part 2 Cohort 2, subjects will receive IV injection of GSK1795091 on Day 1, at dose determined in part 1, and a second dose on Day 15 (two weeks apart)
2964823|NCT02798965|Other|Control|patients with goiter or nodule
2964824|NCT02798965|Experimental|Graves' disease|patients with Graves' disease
2964825|NCT02798952|Experimental|HBV Group|Subjects will receive a single challenge dose of Engerix™-B Kinder.
2964826|NCT02798939||cirrhotic patients|
2964827|NCT02798926||with the use of a polyethylene bag|
2964828|NCT02798926||without the use of a polyethylene bag|
2964829|NCT02798913|Experimental|Short DAPT|Patients who will be treated after PTA with acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months
2964830|NCT02798913|Experimental|Long DAPT|Patients who will be treated after PTA with acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
2964831|NCT02798900|Experimental|Functional task-training and Ultrasound|This group will receive 16 sessions of functional task-training program and therapeutic ultrasound will be applied prior to functional task-training.
2964832|NCT02798900|Active Comparator|Functional task-training|This group will receive 16 sessions of functional task-training program.
2964833|NCT02798887|Experimental|Ridge preservation membrane|Positive control Patients will receive ridge preservation intrasocket allograft and overlay xenograft resorbable with membrane
2964834|NCT02798887|Experimental|Ridge preservation no membrane|test patients will receive ridge preservation intrasocket allograft and overlay xenograft with no membrane
2964835|NCT02798874|Experimental|Ticagrelor Group|ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
2964836|NCT02798874|Active Comparator|Clopidogrel Group|Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
2964837|NCT02798861|Other|CAP assessment|Controlled Attenuation Parameter with Fibroscan 402/530 before liver procurement and after liver transplantation to assess steatosis, and its association with clinical outcomes
2964838|NCT02798848|Experimental|Assistive technology: tablet computer|iPad tablet computers
2964839|NCT02798848|Active Comparator|Standard optical low vision devices|standard optical devices including magnifiers, telescopes, CCTV
2964840|NCT02798835|Active Comparator|Adductor Canal block|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB.
2964841|NCT02798835|Active Comparator|Adductor canal block with dexamethasone|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB along with 8mg IV dexamethasone.
2964842|NCT02798835|Active Comparator|Adductor canal catheter|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their adductor canal block and have a catheter placed in the adductor canal at the mid-thigh. 0.2% ropivacaine at 5ml/hr will be run for 48 hours.
2964843|NCT02798822|Active Comparator|RME on upper first permanent molars|Intervention/Procedure: Rapid maxillary expansion. When RME was in situ, patients started the screw activation (Snap-lock expander screw, Forestadent, Pforzheim, Germany) of one-quarter turn a day (0.22 mm) until overcorrection was achieved (ie, the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp), and the RME remained in place for 10 months. The screw was turned for 35 ± 6 days for Gr6, and the average treatment time was 12 ± 1.3 months.
2964844|NCT02798822|Active Comparator|RME on upper second deciduous molars|Intervention/Procedure: Rapid maxillary expansion. When RME was in situ, patients started the screw activation (Snap-lock expander screw, Forestadent, Pforzheim, Germany) of one-quarter turn a day (0.22 mm) until overcorrection was achieved (ie, the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp), and the RME remained in place for 10 months. The screw was turned for 41 ± 8 days, and the average treatment time was 12 ± 1.3 months.
2964845|NCT02798809||GeOrGS cohort|Clinical dental examination of all Children born in 2008 and 2009 in Chivari District (Italy)
2964846|NCT02798796|Experimental|MRI Group|MRI Group - all patients will be submitted to clinical examination, mammography and / or ultrasound, and breast MRI
2964847|NCT02798796|No Intervention|Control Group|Control group - all patients will be submitted to clinical examination, mammography and / or ultrasound of the breasts.
2964848|NCT02798783||Diagnosed with EVA|Self-reported Enlarged Vestibular Aqueduct (EVA), or, when available, radiological diagnosis of EVA will be used to define the cohort.
2964849|NCT02798770||Stroke Center Basel|
2964850|NCT02798757|Experimental|Dapagliflozin|All patients will take dapagliflozin, the intervention does not refer to a drug or device but to the specific 1HNMR test spectroscopy
2964851|NCT02798744|Experimental|Empagliflozin 25mg once daily|Empagliflozin (Jardiance™) 25mg once daily (orally)
2964852|NCT02798744|Experimental|Empagliflozin 25mg once daily + diet|Empagliflozin (Jardiance™) 25mg once daily (orally) + energy restriction diet
2964853|NCT02798744|Placebo Comparator|Placebo once daily|Placebo once daily (orally)
2964854|NCT02798744|Active Comparator|Placebo once daily + diet|Placebo once daily (orally) + energy restriction diet
2964855|NCT02798718|Active Comparator|lactose digesters|Participants in arm 1 are grouped as lactose digesters based on breath hydrogen test after a 25-g lactose load. The breath hydrogen excretion is less than 20 ppm.
2964856|NCT02798718|Active Comparator|lactose maldigesters|Participants in arm 2 are also grouped as lactose maldigesters based on breath hydrogen test after a 25-g lactose load. The breath hydrogen excretion is not less than 20 ppm.
2964857|NCT02798692|Active Comparator|Low dose HB-101 group|Intervention:Three administrations of a low dose of HB-101
2964858|NCT02798692|Active Comparator|Medium dose HB-101 group|Intervention:Three administrations of a middle dose of HB-101.
2964859|NCT02798692|Active Comparator|High dose HB101 group|Intervention:Three administrations of a high dose of HB-101.
2964860|NCT02798692|Placebo Comparator|Placebo group|Intervention:Three administrations of placebo (diluent)
2964861|NCT02798666|Experimental|High intensity exercise training|The participants exercised for 40 minutes, twice a week, under supervision of two physiotherapists for in total 10 weeks. Each training session included a warming up, a sprint interval block [10 minutes], continuous aerobic exercise [10 minutes], another sprint interval block [10 minutes] and cooling down. For the first 5 weeks, each sprint interval block consisted of 10 sprint bouts [>100 r/min] of 15 seconds at a cycling resistance matching with the ventilatory threshold [VTR], alternated with 45 seconds relative rest [50 r/min at VTR]. Starting from week 6 until week 10, the intensity of sprinting and relative rest was increased up to 110% of VTR.
2964862|NCT02798666|Active Comparator|Continuous exercise training|The comparative group performed a continuous aerobic training [CAT] for 10 weeks, twice a week and 40 minutes per session [volume and frequency is equal to HIIT]. The protocol of the CAT group consisted of warming up [stretching of the large muscle groups and cardiovascular exercises at 30% of peak cycling power output for five minutes], continuous aerobic exercise training [3 times 10 minutes] and cooling down [stretching of the large muscle groups and cardiovascular exercises at 30% of peak cycling power output for five minutes]. During the continuous aerobic protocol [cycling or stepping] participants exercised for 10 minutes at a HR similar to the HR at VT [60 r/min], which was increased to 110% of VT from week 6 onwards.
2964863|NCT02798653|Experimental|Choriomon®|subjects receive 1,500 IU of hCG (Choriomon®; IBSA) intramuscular (IM) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
2964864|NCT02798653|Experimental|Choriomon®+Endometrin ®|patients will receive 1,500 IU of hCG (Choriomon®; IBSA) (IM) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
2964865|NCT02798653|Experimental|Endometrin ®|patients will receive only Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
2964866|NCT02798640|Active Comparator|Active|Subject wearing Celliant garment
2964867|NCT02798640|Placebo Comparator|Control|Subject wearing non-celliant control garment
2964868|NCT02798627|Experimental|NS2359|The initial dose of the NS2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
2964869|NCT02798627|Placebo Comparator|placebo|Placebo pills matched to NS2359 pills will be given once daily. Patients with difficult adverse events at the 2 mg placebo will be allowed to reduce to 1 mg placebo once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
2964870|NCT02798614|Active Comparator|10-day cast|Removal of plaster cast 10 Days after reduction
2964871|NCT02798614|No Intervention|1-month cast|Removal of plaster cast 1 month after reduction
2964872|NCT02798601|Experimental|Hypernatremia|Serum sodium between 150 - 155 milliequivalent/L. 7,5% sodium chloride (2 ml/kg every 4 hours), with controls of serum sodium every 4 hours, to achieve a goal of serum sodium between 150 - 155 milliequivalent/L. If after 4 doses of 7.5% sodium chloride the serum sodium is below the target, a bolus of 1 ml/kg of 12% sodium chloride will be used every 4 hours. The goal of serum sodium will be maintained for 48 hours.
2964957|NCT02798003||Cachectic cancer patients|Cachectic cancer patients, including non-small cell lung cancer (NSCLC) and gastro-intestinal cancer. The study participants will undergo fMRI scanning.
2964958|NCT02798003||Non-cachectic cancer patients|Non-cachectic cancer patients, including NSCLC and gastro-intestinal cancer. The study participants will undergo Functional magnetic resonance imaging (fMRI) scanning.
2965536|NCT02794259|Sham Comparator|Sham tDCS|Sham stimulation during resting state fMRI
2964873|NCT02798601|No Intervention|Normonatremia|Serum sodium between 135 - 145 milliequivalent/L. Mannitol 100 ml every 4 hours for the first three days; 80 ml every 4 hours the fourth day; 60 ml every 4 hours the fifth day and 40 ml every 4 hours the sixth day and then stopping. The mannitol protocol will be interrupted at any moment if serum sodium is below 135, the systolic blood pressure is below 90 mmHg or the patient has signs of hypovolemia. In this case, 2 ml/kg of 3% sodium chloride every 4 hours will be used until the target of serum sodium is achieved and both, normovolemic state and blood pressure are restored. In addition, the mannitol protocol will be suspended when serum osmolality is above 320.
2964874|NCT02798588|Experimental|Comatose patients in ICU|
2964875|NCT02798562|Experimental|Native and dynamic contrast-enhanced CT|Patients will undergo a native high-resolution and a dynamic contrast-enhanced CT, both sides respectively.
2964876|NCT02798549|Other|Viraemic|
2964877|NCT02798549|Other|Remission|
2964878|NCT02798536|Experimental|B2/LMB-100+ nab- paclitaxel dose expansion|Fixed dose of LMB-100 as determined in Arm B1 + fixed dose of nab-paclitaxel in up to 16 subjects
2964879|NCT02798536|Experimental|B1/LMB-100+ nab- paclitaxel dose escalation|De-escalating doses of LMB-100 + fixed dose of nab-paclitaxel in up to 12 subjects
2964880|NCT02798536|Experimental|A1/LMB-100 dose escalation (closed)|De-escalating doses of LMB-100 in up to 18 subjects
2964881|NCT02798536|Experimental|A2/LMB-100 dose expansion (closed)|Fixed dose of LMB-100 as determined in Arm A1 in up to 16 subjects
2964882|NCT02798523|Experimental|1|Following collection of a 3-mm skin punch biopsy sample and a preinfusion whole-blood sample, volunteers will receive a single intravenous dose of 250 milligrams (mg) of methylprednisolone sodium succinate infused over 15 minutes, and a single application of topical methylprednisolone 0.1% to a small area (2 x 2 cm) of the skin. Whole blood samples will then be obtained serially, at 2 and 4 hours after the start of drug administration. A second skin punch biopsy will be performed 4 hours after the start of drug administration, in the area of skin where topical methylprednisolone was applied.
2964883|NCT02798510|Experimental|Arm 1|Patients in arm 1 will receive adjuvant chemotherapy followed by concurrent chemoradiotherapy. Patients will receive four cycles of gemcitabine (1,000mg/m2 intravenously on days 1 and 8) and capecitabine (1,500mg/m2 per day on days 1 to 14) every 21 days followed by concurrent capecitabine (1,330mg/m2 per day) and radiotherapy (50.4Gy/28fx to regional lymphatics with or without tumor bed)
2964884|NCT02798510|Active Comparator|Arm 2|Patients in arm 2 will receive six cycles chemotherapy of gemcitabine (1,000mg/m2 intravenously on days 1 and 8) and capecitabine (1,500mg/m2 per day on days 1 to 14) every 21 days
2964885|NCT02798497|Other|staphylococcus aureus PVL-|patients with staphylococcus aureus PVL-
2964886|NCT02798497|Other|staphylococcus aureus PVL+|patients with staphylococcus aureus PVL+
2964887|NCT02798484|Experimental|Breast cancer|Patients diagnosed with breast cancer and placed under neo-adjuvant treatment (hormonotherapy, chemotherapy) within the CHU Brugmann hospital.
2964888|NCT02798471|Experimental|Edoxaban|"Edoxaban treatment will be dispensed to the participant on a monthly visit schedule.~Edoxaban will be started orally at the age/weight/renal function appropriate dose, depending on the results of the ongoing U157 study (NCT02303431) for the Treatment Period."
2964889|NCT02798471|Experimental|Standard of Care|Standard of Care (SOC) treatment will be dispensed to the participant on a monthly visit schedule.
2964890|NCT02798458|Experimental|SmartPill Test|All subjects will be asked to complete a SmartPill test. The SmartPill capsule is pill-shaped and about an inch long and ½ inch wide, or about the size of a vitamin pill. The receiver unit is about the size of a paperback book. The receiver gets signals from the capsule and stores the signals on a computer chip. The capsule detects the level of acidity, temperature, and pressures in your stomach and intestines and sends the information by radio wave signals to the receiver.
2964891|NCT02798458|Experimental|Endoscopic Mucosal Resection|An additional small group of subjects will also be asked to complete a Sigmoidoscopy (an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed. In the Endoscopy Mucosal Resection (EMR) procedure we will use an instrument called an endoscope (a lighted, flexible tube) to take a tissue sample from the rectum. This is the same type of instrument used in a routine colonoscopy
2964892|NCT02798445|Experimental|tapirs|this group will have surgery with endovascular laser treatment (EVLT) in the axial vein and foam sclerotherapy echo-guided in perforator veins and veins in relation with the ulcer, after the surgery the patients will have conventional wound care plus juxta cure system that give a continuous compression in the leg.
2964893|NCT02798445|Active Comparator|multilayer bandage|multilayer bandage and conventional wound care (grade 1A) recommendation in management of vein ulcers. gold standard
2964894|NCT02798432|Experimental|Hybrid NEXGEN LPS|Noncemented femoral component with cemented tibial component with the NexGen LPS Total Knee Arthroplasty
2964895|NCT02798432|Sham Comparator|Cemented NEXGEN LPS|Cemented femoral component with cemented tibial component with the NexGen LPS Total Knee Arthroplasty
2964896|NCT02798419|Experimental|DFD05 Cream|DFD05 Cream
2964897|NCT02798419|Active Comparator|Active01 Cream|Active01 Cream
2964898|NCT02798406|Experimental|DNX-2401 + pembrolizumab|Intratumoral dose (1.0 mL) of DNX-2401 followed 7-9 days later by intravenous pembrolizumab, 200 mg, given every three weeks through 105 weeks (2 yrs.) or until progressive disease or unacceptable toxicity.
2964899|NCT02798393|Sham Comparator|HL-Sham|The placebo device (also referred to as the HL-SHAM device) will have an identical appearance to the HL-NIR device. Though the HL-NIR device will be applied, there will be no treatment administered.
2964900|NCT02798393|Experimental|HL-NIR|The device referred to as the HL-NIR device includes both a podiatric or foot and leg component, similar to a loose fitting boot, that is easily applied to all subjects (one size fits all). Application of the device is snug but comfortable without risk for constriction of soft tissue.
2964901|NCT02798380|Experimental|HTS-519 Insert|Active treatment
2964959|NCT02798003||Cachectic COPD patients|Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.
2964960|NCT02798003||Non-cachectic COPD patients|Diagnosis of COPD consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.
2965537|NCT02794246|Experimental|Single Arm|
2964902|NCT02798367|Experimental|CBT-I plus Melatonin 3 mg|"It's a tablet manufactured by Aché S.A., composed of melatonin 3mg. Melatonin 3mg tablet will be dispensed to 48 participants (first stage) of this group in a cartridge of 3 blisters with 10 tablets each, totalizing 30 tablets. If this arm is the best set for the second stage, more 56 participants will be randomly allocated in this group.The participant shall administer 01 tablet orally every 24 hours one hour before bedtime. The duration of treatment may be 21(±2) days.~CBT-I is a non-pharmacological effective treatment for insomnia disorder. Behavioral techniques of Sleep Hygiene and Stimuli control are the most used. The CBT-I guidelines are standardized in protocol."
2964903|NCT02798367|Experimental|CBT-I plus Melatonin 5 mg|"It's a tablet manufactured by Aché S.A., composed of melatonin 5mg. Melatonin 5mg tablet will be dispensed to 48 participants (first stage) of this group in a cartridge of 3 blisters with 10 tablets each, totalizing 30 tablets. If this arm is the best set for the second stage, more 56 participants will be randomly allocated in this group.The participant shall administer 01 tablet orally every 24 hours one hour before bedtime. The duration of treatment may be 21(±2) days.~CBT-I is a non-pharmacological effective treatment for insomnia disorder. Behavioral techniques of Sleep Hygiene and Stimuli control are the most used. The CBT-I guidelines are standardized in protocol."
2964904|NCT02798367|Other|CBT-I plus placebo|"It's a tablet manufactured by Aché S.A,. composed of placebo. The participants shall administer the placebo tablets to enable the double-blind study.~Sleep hygiene is a psychoeducational intervention that teaches patients to prevent external or environmental factors generate adverse effects and harmful to sleep. The stimulus control technique is based on five instructions that encourages the patient to establish a proper sleep-wake rhythm and strengthens the links between the way for a quick and well consolidated sleep. The CBT-I guidelines are standardized in clinical protocol."
2964905|NCT02798354|Experimental|Reduce Elevated Blood Pressure Errors First|"Will provide baseline data on elevated blood pressure diagnosis and first intervene to reduce missed opportunities for elevated blood pressure diagnosis. Will then intervene to reduce missed opportunities for depression diagnosis and finally, intervene to reduce delayed diagnosis attributable to abnormal laboratory values.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
2964906|NCT02798354|Experimental|Reduce Depression Errors First|"Will provide baseline data on depression diagnosis and first intervene to reduce missed opportunities for depression diagnosis. Will then intervene to reduce delayed diagnosis attributable to abnormal laboratory values and finally, intervene to reduce missed opportunities for elevated blood pressure diagnosis.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
2964907|NCT02798354|Experimental|Reduce Lab Related Errors First|"Will provide baseline data on delayed diagnosis attributable to abnormal laboratory values and first intervene to reduce delayed diagnosis attributable to abnormal laboratory values. Will then intervene to reduce missed opportunities for elevated blood pressure diagnosis results and finally, to reduce missed opportunities for depression diagnosis.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
2964908|NCT02798328||Reference Range|Healthy Subjects
2964909|NCT02798328||DOAC Pivotal|DOAC Eligible Subjects
2964910|NCT02798315||HCV Genotype 1 or 4 participants|Participants receiving Paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV)
2964911|NCT02798302|Active Comparator|Non rebreather|
2964912|NCT02798302|Active Comparator|Bag valve mask without leak|
2964913|NCT02798302|Active Comparator|Bag valve mask with simulated mask leak|
2964914|NCT02798289|Experimental|Active - Device|The Oculeve Intranasal Neurostimulator will be administered once to induce aqueous tear production once following study enrollment.
2964915|NCT02798276|Experimental|AGTP-treatment|Patients in which the non-revascularizable area will be covered by the adipose graft and the revascularizable area will be treated with the normal procedure.
2964916|NCT02798276|Other|Control|Patients in with the non-revascularizable area will be left untouched and the revascularizable area will be treated normally.
2964917|NCT02798263|Experimental|Group I kinesiotherapy|Treated with standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes
2964918|NCT02798263|Experimental|: Group II Acupuncture|Treated with 30 minutes of classical acupuncture using predefined points
2964919|NCT02798263|Experimental|Group III Stiper|They will be used the same acupuncture points of the group II, but using the needles in place Stiper®
2964920|NCT02798250|Active Comparator|Dual-hormone CL with overestimation of meal size category|A regular size standardized meal of 45g of carbohydrates will be provided to the patient and the meal size will be overestimated by one category, which will result in a meal insulin bolus for a meal of 65g of carbohydrates.
2964921|NCT02798250|Active Comparator|Dual-hormone CL with adequate estimation of meal size category|A regular size standardized meal of 45g of carbohydrates will be provided to the patient and the meal size will be adequately estimated, which will result in a meal insulin bolus for a meal of 35g of carbohydrates.
2964922|NCT02798237|Experimental|Aerobic treadmill training|"Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of aerobic treadmill training at 60-80% of heart rate reserve). The training intensity progression will be individualized.~Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously during training. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program. Device: treadmill."
2964961|NCT02797977|Experimental|Standard-Dose Triplet Combination|SRA737 will be administered orally on Days 2, 3, 9, and 10 of each 21-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Gemcitabine will be administered intravenously on Days 1 and 8 of each 21-day cycle. Cisplatin will be administered on Day 1 of each 21-day cycle. Subjects can continue taking the study treatment if they are safely receiving clinical benefit and able to follow the requirements of the study.
2964923|NCT02798237|Sham Comparator|Control (overground walking)|Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of comfortable walking below 40% of heart rate reserve). Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program.
2964924|NCT02798224|Experimental|e-assist: Colon Health (treatment arm)|Eligible patients identified will receive a prompt (via email) to log into portal for an important health message. Once eligible patient initiates portal session, continuing past IRB consent screen, patient is enrolled.
2964925|NCT02798224|Active Comparator|Healthwise Educational Program (active control)|Eligible patients identified will receive a prompt (via email) to log into portal for an important health message. Once eligible patient initiates portal session, continuing past IRB consent screen, patient is enrolled.
2964926|NCT02798224|No Intervention|Usual care control (observational only)|There will be no participant contact in this arm. We will use existing data sources only (e.g., EHRs) to obtain information on participants in this arm (i.e., an observational data review only).
2964927|NCT02798211|Active Comparator|Group 1|secukinumab 300mg
2964928|NCT02798211|Active Comparator|Group 2|secukinumab 150 mg
2964929|NCT02798211|Placebo Comparator|Group 3|Placebo
2964930|NCT02798198||Diabetes group|37 T2DM adults (diabetes group) without DKD
2964931|NCT02798198||Control group|33 healthy adults (control group)
2964932|NCT02798185||Former NFL Players|120 former National Football League players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study.
2964933|NCT02798185||Former College Football Players|60 former college football players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study.
2964934|NCT02798185||Control Group|60 asymptomatic same-age men without any history of participation in contact sports, military service, or traumatic brain injury will be enrolled in this study.
2964935|NCT02798172|Experimental|Alogliptin+metformin|Alogliptin (alogliptin benzoate) is the most recent DPP-4 inhibitor; it entered the market in 2006. It is a potent and highly selective DPP-4 inhibitor with oral antidiabetic activity; Metformin is the most commonly prescribed first-line drug worldwide for the treatment of T2DM, it acts by decreasing both hepatic glucose production and intestinal glucose absorption, while improving insulin sensitivity, metformin as a safe and valid oral antidiabetic drug was recommended to the obese patients with a body mass index (BMI) >30 kg/m2, it has some value in reducing or preventing weight gain and changes in metabolic parameters during treatment, and it can be combinated with other antidiabetic drug
2964936|NCT02798172|Experimental|metformin|Metformin is the most commonly prescribed first-line drug worldwide for the treatment of T2DM, it acts by decreasing both hepatic glucose production and intestinal glucose absorption, while improving insulin sensitivity, metformin as a safe and valid oral antidiabetic drug was recommended to the obese patients with a body mass index (BMI) >30 kg/m2, it has some value in reducing or preventing weight gain and changes in metabolic parameters during treatment, and it can be combinated with other antidiabetic drug
2964937|NCT02798159|Experimental|Part A- Arm 1|Investigational dose = 0.25 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
2964938|NCT02798159|Experimental|Part A- Arm 2|Investigational dose = 0.5 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
2964939|NCT02798159|Experimental|Part A- Arm 3|Investigational dose = 1 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
2964940|NCT02798159|Experimental|Part A- Arm 4|Investigational dose = 1.25 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
2964941|NCT02798159|Experimental|Part B- Arm 1|"Investigational dose = optimal dose in Part A. The drug should not be taken more than one time a day or 3 times a week.~Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month"
2964942|NCT02798159|Active Comparator|Part B- Arm 2|Sildenafil Citrate 50 mg on demand The drug should not be taken more than one time a day or 3 times a week. Administered orally once a day, 1 hour before sexual activity, for 1 month
2964943|NCT02798146|Other|hormonal levels|Blood samples are collected for analysis of LH, E2, hCG and progesterone.
2964944|NCT02798133|Experimental|OLA|recruitment maneuver + individualized PEEP
2964945|NCT02798133|Active Comparator|RM-5|recruitment maneuver + fixed standard PEEP
2964946|NCT02798120|Experimental|SB204 4%|SB204 4% once daily
2964947|NCT02798107||All patients treated with idarucizumab|
2964948|NCT02798094||Depressed Participants|No intervention
2964949|NCT02798094||Healthy Control Participants|No intervention
2964950|NCT02798081|Experimental|Single arm study|A minimum of 46 elderly, students of a informatics course, will participate in the study. Initially, the students will have 8 usual informatics classes in the institution where they were enrolled spontaneously. Then, during the next 8 classes (from class 9 to class 16) they will practice 10 minutes of virtual reality games, as part of the class.
2964951|NCT02798068|Active Comparator|Solu - Medrol|Solu - Medrol (methylprednisolone sodium succinate) 500mg IV once single administration
2964952|NCT02798068|Placebo Comparator|Placebo|NaCl 0,9% 100ml IV once single administration
2964953|NCT02798042||Patient population|Patients undergoing bariatric surgery
2964954|NCT02798029|Experimental|Frameless Fractionated Stereotactic Radiation Therapy (FFSRT)|Participants receive FFSRT daily for 3-5 days (weekdays only), based on what the doctor thinks is needed.
2964955|NCT02798016|Experimental|Platelet-Rich Plasma alone|The scars will be injected with Platelet-Rich Plasma alone.
2964956|NCT02798016|Active Comparator|Platelet-Rich Plasma with micro-needling|The scars will be dealt with using micro-needling as well as injecting Platelet-Rich Plasma
2965098|NCT02797015|Experimental|0.5 mg RPC1063|0.5 mg RPC1063 oral capsule daily
2964962|NCT02797977|Experimental|Low-Dose Gemcitabine Combination|SRA737 will be administered orally on Days 2, 3, 9, 10, 16, and 17 of each 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle. Gemcitabine will be administered intravenously on Days 1, 8, and 15 of each 28-day cycle. Subjects can continue taking the study treatment if they are safely receiving clinical benefit and able to follow the requirements of the study.
2964963|NCT02797964|Experimental|Open label|
2964964|NCT02797951|Experimental|Galcanezumab|Galcanezumab given subcutaneously (SQ) up to once a month.
2964965|NCT02797938|Experimental|Taper guard tube|Taper guard tube was intubated in 26 patients
2964966|NCT02797938|Active Comparator|Cylindrical tube|Cylindrical tube was intubated in 26 patients
2964967|NCT02797925||Tendinopathy|Long slow strength training for 3 months that are performed at home or gym. Participants receive initial guidance to the exercises from a physiotherapist assigned to Bispebjerg H.
2964968|NCT02797925||Healthy|No intervention. No training
2964969|NCT02797912||CF children and young people|Observational study involving clinical procedures: lung function testing, respiratory muscle strength testing, body composition analysis & exercise tolerance.
2964970|NCT02797899|Active Comparator|Palatal donor site received PRF|Following profound anesthesia and harvesting free gingival graft from the palate, the graft was positioned to the recipient area. The donor area were cleaned with sterile saline and received platelet rich fibrin and periodontal pack as assigned randomly by a flip of coin during the screening visits.
2964971|NCT02797899|Active Comparator|Palatal donor site NOT receiving PRF|Following profound anesthesia and harvesting free gingival graft from the palate, the graft was positioned to the recipient area. The donor area were cleaned with sterile saline and sutured followed by periodontal pack application.
2964972|NCT02797886|Experimental|FES+VOL|Electrical stimulation (FES) in concert with volitional effort. The subject is visually cued to initiate the movement and when they begin the movement (as ascertained by EMG response), the stimulation is immediately applied until the completion of the trial.
2964973|NCT02797886|Active Comparator|FES|Electrical stimulation alone. The subject is asked to do nothing as electrical stimulation initiates and completes the movement for them.
2964974|NCT02797886|Active Comparator|VOL|Volitional effort alone. When cued, the subject initiates and completes the movement on their own until the completion of the trial. There is no electrical stimulation in this group.
2964975|NCT02797873|Experimental|EIP|"Patients from the DBT unit suffering from symptoms of Emotional Instability (n=30), with different levels of ADHD symptoms as assessed by questionnaires Brown-ADD, ASRS and SDQ.~Interventions:~fMRI - Stroop task~fMRI - MID task~Stop Signal task~Structural T1 MRI scan~Structural T2 MRI scan~DTI MRI scan~Resting state MRI scan~FEFA 2~SCID-II~SDQ~ASRS~AQ~TAS-20~Raven's SPM~Reading ability~Ishihara's tests for colour deficiency~Additional questionnaire~Brown-ADD~MFQ~STAI-T~BIS~DAWBA~STAI-S~Sleepiness rating x 6~Motivation rating x 6"
2964976|NCT02797873|Experimental|Healthy controls|"Matched healthy controls (according to age, IQ and socio economic status) recruited from high schools in Stockholm area (n=30).~Interventions:~fMRI - Stroop task~fMRI - MID task~Stop Signal task~Structural T1 MRI scan~Structural T2 MRI scan~DTI MRI scan~Resting state MRI scan~FEFA 2~SCID-II~SDQ~ASRS~AQ~TAS-20~Raven's SPM~Reading ability~Ishihara's tests for colour deficiency~Additional questionnaire~Brown-ADD~MFQ~STAI-T~BIS~DAWBA~STAI-S~Sleepiness rating x 6~Motivation rating x 6"
2964977|NCT02797860||transabdominal cervicoisthmic cerclage|Second Stage of Labor pregnant women who are scheduled for transabdominal cervicoisthmic cerclage due to incompetent internal os of cervix
2964978|NCT02797860||control|women of childbearing age between 20 and 45
2964979|NCT02797847|Active Comparator|ALN-TTRSC02|
2964980|NCT02797847|Placebo Comparator|Sterile normal saline 0.9% for SC administration|
2964981|NCT02797834||Patients Endometrial Fluid|"Endometrial fluid samples from healthy and fertile women in their natural cycles, with ages ranging from 18 to 35 years, normal karyotype, negative for HIV, HBV, HCV and RPR, BMI ranging from 18 to 30 Kg/m2 (both included) and regular menstrual cycle (3-4/28-30 days).~This unique assignment group will be divided into 5 subgroups attending to the moment of the menstrual cycle in which the patient could be classified: phase I (days 0-8), phase II (days 9-14), phase III (days 15-18), phase IV (days 19-24) and phase V (days 25-30)."
2964982|NCT02797821|Experimental|Asfotase Alfa 0.5 mg/kg Dose|Participants received 0.5 milligrams (mg) per kilogram (kg) of asfotase alfa administered subcutaneously (SC) 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
2964983|NCT02797821|Experimental|Asfotase Alfa 2.0 mg/kg Dose|Participants received 2.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
2964984|NCT02797821|Experimental|Asfotase Alfa 3.0 mg/kg Dose|Participants received 3.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
2964985|NCT02797808|Experimental|OCD|
2964986|NCT02797808|Active Comparator|Healthy Controls|
2964987|NCT02797795|Experimental|NEV801|"Part A - Dose escalation and de-escalation for the determination of the Maximum tolerated dose. All subjects will receive NEV801 intravenously on days 1, 8, 15 and 22 during each 28-day cycle.~Part B - Subjects will receive NEV801 at or below the highest tolerable dose from Part A."
2964988|NCT02797769||Non-TNFi Biologics|Real world patients with RA with a dispensing history for non-TNFi biologics (such as abatacept or tofacitinib) will be included.
2964989|NCT02797769||TNFi Biologics|Real world patients with RA with a dispensing history for TNFi biologics will be included.
2964990|NCT02797769||Tocilizumab|Real world patients with RA with a dispensing history for tocilizumab will be included.
2964991|NCT02797756||Case|CC/GER+ presence of chronic cough and presence of GER evidenced by esophago-gastro-duodenoscopy (EGD) with biopsy and Esophageal Impedance Monitoring (EIM)
2964992|NCT02797756||Control|CC/GER- presence of chronic cough and absence of GER by esophago-gastro-duodenoscopy (EGD) with biopsy and Esophageal Impedance Monitoring (EIM)
2964993|NCT02797743||Whole blood from all ages and gender|- Ages from 0 to Adults (18 yrs of age or older)
2964994|NCT02797730|Experimental|art-therapy sessions|Caregivers will receive 6 art-therapy sessions
2964995|NCT02797730|No Intervention|no art-therapy sessions|Caregivers will not receive 6 art-therapy sessions during the evaluation period
2964996|NCT02797717|Other|"A-COPDAC-28"|"standard COPDAC-28 (chemotherapy cycle:Cyclophosphamide,Doxorubicin,Prednisone,Dacarbazine), chemotherapy and standard involved node radiotherapy.~drugs: Prednisone 40mg/m2/day,P.O,day 1-day 15. Dacarbazine 250mg/m2, I.V. , infusion,day 1- day 3. Vincristine 15mg/m2 , I.V. , day1+day 8. Cyclophosphamide 500mg/m2,infusion,day 1+day 8."
2964997|NCT02797717|Experimental|"B- DECOPDAC-21"|"DECOPDAC-21(chemotherapy cycle:Dacarbazine,Etoposide,Doxorubicin,Cyclophosphamide,Prednisone,Vincristine) intensified chemotherapy and no RT or restricted fields of radiotherapy.~Drugs: Prednisone 40mg/m2/day,P.O,day 1-day 15:~Dacarbazine 250mg/m2, I.V. , infusion,day 1- day 3 Vincristine 15mg/m2 , I.V. , day1+day 8 Cyclophosphamide 625mg/m2,infusion,day1+day2 Etoposide 100mg/m2/day,infusion,day 1- day 3 Doxorubicin 25mg/m2, infusion, day 1"
2964998|NCT02797704|Experimental|SC Aflibercept|The patients will be treated with a single subconjunctival injection of 0.08 ml aflibercept (25 mg/ml) in a single quarter of the conjunctiva, near the limbus in a proximity to the area of pathological neovascularization
2964999|NCT02797691|Experimental|CaCBT plus Treatment As Usual|"Receiving CaCBT intervention in addition to the Treatment as usual"
2965000|NCT02797691|Active Comparator|Treatment As Usual (TAU)|Receiving Treatment as usual
2965001|NCT02797665|Active Comparator|Steroids group|The patients will be treated with oral corticosteroids (prednisone 0.6mg/kg/d) alone.
2965002|NCT02797665|Active Comparator|Stent group|The patients will be treated with oral corticosteroids and biliary stent.
2965003|NCT02797652||Neoadjuvant chemotherapy|ctDNA of operable breast cancer patients with neoadjuvant chemotherapy before surgery in different periods: before neo-chemotherapy, during neo-chemotherapy, on surgery day, after surgery and follow-up time.
2965004|NCT02797652||Surgery|ctDNA of operable breast cancer patients with surgery followed by adjuvant chemotherapy in different periods: on surgery day, after surgery, before adjuvant chemotherapy, during adjuvant chemotherapy, and follow-up time.
2965005|NCT02797639|Experimental|Co-PID|Eight collaborative consultation meetings between occupational therapist to each teacher in purpose of enhancing participation of students in class
2965006|NCT02797639|Active Comparator|In-service|Three in- service meetings to all homeroom teachers together, in purpose of enhancing participation of students in class
2965007|NCT02797626|Other|Primary RPNLD|
2965008|NCT02797613|Experimental|Restricted Reporting|"Microbiology laboratory will report Positive urine cultures may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call 777-xxxx (researcher mobile phone) for identification and susceptibility results"
2965009|NCT02797613|No Intervention|Standard Reporting|Microbiology laboratory will report identification and susceptibility results
2965010|NCT02797600||ARM I|Woman residing in Appalachian counties who have prevalent invasive cervical cancer. Invasive cervical cancer cases participants will include women previously and currently treated for ICC during the past 10 years. Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. Biological samples will be collected during a scheduled visit with the research staff.
2965011|NCT02797600||ARM II|Woman residing in Appalachian counties who are newly diagnosed with invasive cervical cancer(ICC). Newly diagnosed with ICC, and currently being treated for ICC. Questionnaires will be used to obtain Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. All biological samples will be collected during a scheduled clinic visit.
2965012|NCT02797600||ARM III|Healthy controls (women without a diagnosis of any type of cancer. Healthy controls will be women who are coming into one of the participating clinic or physician practice for a routine Pap test. Questionnaires will be used to obtain Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. All biological samples will be collected at the time of the clinical Pap smear.
2965013|NCT02797587|Active Comparator|Varenicline + Nicotine Replacement Therapy placebo|Study participants will receive active varenicline and be instructed to take the medication for 12 weeks; participants will also receive a placebo Nicotine Replacement Therapy mouth spray for 8 weeks.
2965014|NCT02797587|Placebo Comparator|Varenicline placebo + Nicotine Replacement Therapy|Study participants will receive placebo varenicline and be instructed to take the placebo medication for 12 weeks; participants will also receive an active Nicotine Replacement Therapy mouth spray for 8 weeks.
2965015|NCT02797587|Active Comparator|Cytisine + Nicotine Replacement Therapy placebo|Study participants will receive active cytisine and be instructed to take the medication for 25 days; participants will also receive a placebo Nicotine Replacement Therapy mouth spray for 8 weeks.
2965016|NCT02797587|Placebo Comparator|Cytisine placebo + Nicotine Replacement Therapy|Study participants will receive placebo cytisine and be instructed to take the medication for 25 days; participants will also receive an active Nicotine Replacement Therapy mouth spray for 8 weeks.
2965017|NCT02797574|Active Comparator|Vitiligo Diagnosed Group|Clinically diagnosed with non-segmental vitiligo
2965018|NCT02797574|Active Comparator|Healthy Control Group|20 normally pigmented control subjects who are between the ages of 18 and 50
2965019|NCT02797561||Tandem lesion evaluated by FFR|
2965020|NCT02797548|Experimental|Aspirin only|
2965021|NCT02797548|Active Comparator|No antiplatelet therapy|
2965022|NCT02797535|Other|GI fluids samples collection|GI fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.
2965023|NCT02797522|Experimental|Healthy Volunteers (NHV) Single Dose|NHV participants receiving a single dose of ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg
2965024|NCT02797522|Experimental|CHB Patients Multiple Dose|CHB patients receiving 3 doses of ARC-521 Injection at 2, 4 and 6 mg/kg
2965025|NCT02797522|Placebo Comparator|Placebo|Participants receiving 0.9% normal saline
2965099|NCT02797002||Chronic non specific neck pain|Experiencing neck pain for at least 3 months in the last year
2965100|NCT02797002||Without neck pain (asymptomatic)|No history of neck pain
2965101|NCT02796989|Active Comparator|Healthy - Wheat Bran|Wheat bran 20 g each day
2965102|NCT02796989|Placebo Comparator|Healthy - Placebo|Placebo 20 g each day
2965103|NCT02796989|Active Comparator|Obese - Wheat bran|Wheat bran 20 g each day
2965026|NCT02797509|Experimental|Psychosocial Skills-Based Intervention|Based on information from Phase I (semi-structured interviews), the investigators will develop a detailed psychosocial intervention manual. The intervention will be tailored consistent with American Heart Association (AHA) recommendations for stroke skills based interventions and will include 2 general and 4 specific modules (selected from 7 available). Generally, in the intervention, stroke patients and stroke caregivers will learn skills to cope and manage stroke-related stressors. It is anticipated that the intervention will have 6 sessions with 2 general sessions delivered within the NICU face to face and 4 tailored specific sessions to be delivered via live video using Vidyo. Participants in the intervention group will also receive treatment as usual.
2965027|NCT02797509|No Intervention|Minimally Enhanced Usual Care (MEUC)|Those in the MEUC will continue with their current care. This may include meeting with nurses, physical therapist, medical doctors, and other members of the stroke patient's medical team. Treatment as usual may also involve administration of Selective Serotonin Reuptake Inhibitors (SSRIs) to those patients with motor problems. They will also received a pamphlet with educational information on stroke and recovery
2965028|NCT02797496|Experimental|Asymmetric Motor Strengthening|
2965029|NCT02797496|Active Comparator|Conventional Therapy|
2965030|NCT02797483|Experimental|Test Fat Blue|16 weeks interventions
2965031|NCT02797483|Experimental|Test Fat Green|16 weeks interventions
2965032|NCT02797483|Experimental|Test Fat Red|16 weeks interventions
2965033|NCT02797470|Experimental|Treatment (anti-HIV gene transduced CD34+ cells)|Patients receive BEAM regimen administered as standard of care comprising carmustine on day -6, cytarabine BID on days -5 to -2, etoposide BID on days -5 to -2, and melphalan on day -1. Patients undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells over 1 hour.
2965034|NCT02797457|Other|Allograft|Bilateral allograft of the hands and forearms.
2965035|NCT02797457|Other|Prostheses|Prosthetic forehands
2965036|NCT02797431|Experimental|CYT107 high frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for 4 weeks
2965037|NCT02797431|Experimental|CYT107 low frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for the first week, followed by CYT107 and Placebo once a week for the three following weeks
2965038|NCT02797431|Placebo Comparator|Control|Patients will receive Placebo (NaCl 0.9%) twice a week for 4 weeks
2965039|NCT02797418|Experimental|Cognitus and Me|Cognitus & Me is a cognitiv remediation program focused on the functions of attention and visuospatial that is to say that can move in space, to perceive objects of our environment and organize them, to mentally imagine a physically absent operation object very involved in social behavior, in order to limit the presence of behavioral disorders among children with intellectual disabilities.
2965040|NCT02797418|Active Comparator|control group|the control management that involves fine motor skills and research computer information,management control is usually done
2965041|NCT02797405|Other|Standard treatment|The patients will receive standard treatment according to international recommendations depending on their type of cancer.
2965042|NCT02797392|Experimental|Lifestyle intervention|All included citizens receive a questionnaire to estimate risk of disease and risk behavior. Information about lifestyle is collated with existing Electronic Patient Record (EPR) data and the citizen's risk of lifestyle-related disease is estimated based on validated algorithms for risk of type-2 diabetes, cardiovascular disease and COPD (Stratification). All citizens receive an electronic health profile and targeted advice. Citizens at increased risk of disease are offered a preventive program at the GP including an initial health examination and subsequent lifestyle counselling. Citizens with risk behavior are offered lifestyle counselling in the municipality and community health services, if necessary. Citizens diagnosed with a lifestyle related disease are already being treated by the GP, and therefore, like citizens with a healthy lifestyle, they are not offered any further services.
2965043|NCT02797379|Other|Immediate start|This group receive the intervention (psychoeducation guide) immediately following baseline assessment and are assessed 4 and 8 weeks later.
2965044|NCT02797379|Other|Delayed start|This group do not receive the intervention for 4 weeks. They are assessed after the wait period (4 weeks) and again after 4 weeks of having the intervention (psychoeducation guide) at week 8.
2965045|NCT02797366|Other|Proton radiotherapy|Proton radiation therapy daily (Monday through Friday) for 4-8 weeks. This is a single arm study.
2965046|NCT02797353|Experimental|Intervention Arm|Antenatal Care, Post natal care, Skilled birth attendance, recognition and referrals of complicated cases, immunization
2965047|NCT02797353|No Intervention|Control|This arm will receive the standard MNCH services as outlined in the MNCH policy of Government of Pakistan
2965048|NCT02797340|Experimental|Interventional|All participants
2965049|NCT02797314|Other|Type 2 diabetic population|Bone biopsies
2965050|NCT02797314|Other|Non-diabetic control population|Bone biopsies
2965051|NCT02797301|Experimental|synthetic test & computerised test|Seventeen preschool children (G1), with no motor impairments, from a private school. The children in G1 performed the synthetic test before the computerised test.
2965052|NCT02797301|Experimental|computerised test & synthetic test|Sixteen preschool children (G2), with no motor impairments, from a private school. The children in G2 performed the computerised test before the synthetic test.
2965053|NCT02797301|Experimental|computerised test|Seven volunteers (G3), two males and five females, with moderate mobility impairment, patients from the Physical Therapy and Rehabilitation Clinic.
2965054|NCT02797275|Experimental|Albuterol & Placebo|Participants will be placed on the albuterol treatment (2 puffs twice a day, equivalent to 360 mcg per day) after the completion of the baseline screening visit. They will use albuterol for 4 weeks prior to their scheduled second visit during which they will undergo testing. Subsequently, and after a minimum washout period of 2 weeks, they will be placed on the placebo treatment for 4 weeks prior to their scheduled third visit, after which they will come back to undergo testing.
2965055|NCT02797275|Experimental|Placebo & Albuterol|Participants will be placed on the placebo treatment after the completion of the baseline screening visit. They will use placebo for 4 weeks prior to their scheduled second visit during which they will undergo testing. Subsequently, and after a minimum washout period of 2 weeks, they will be placed on the albuterol treatment (2 puffs twice a day, equivalent to 360 mcg per day) for 4 weeks prior to their scheduled third visit, after which they will come back to undergo testing.
2965056|NCT02797262|Experimental|Intervention|"Building on the available Proteus devices, the investigators will design and create a Proteus digital health feedback (PDHF) system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).~The investigators will test overall utility (including feasibility, acceptability and sustainability) of the PDHF system, its accuracy for measuring adherence and its impact on enhancing patients' level of adherence and the effect on virologic and clinical outcomes (exploratory), the retention of its impact on keeping up with adherence and improvement of plasma HIV RNA and CD4 cell count after the 16-week usage of the PDHF system."
2965057|NCT02797262|No Intervention|Control|UC is chosen as the control condition because it meets ethical and moral requirements to attempt treatment. Eligible patients will be randomized to one of the two conditions using a stratified urn randomization procedure to increase the likelihood of balanced allocation of prognostic variables at baseline.
2965058|NCT02797249|Experimental|aspirin|Low dose aspirin (100 mg) starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy, taking at night.
2965059|NCT02797249|Other|blank|Routine examination during pregnancy.
2965060|NCT02797236|Experimental|vaccine dose 1|SF2a-TT15 vaccine, 2 μg
2965061|NCT02797236|Experimental|vaccine dose 1+ adjuvant|SF2a-TT15 vaccine, 2 μg + alum
2965062|NCT02797236|Experimental|vaccine dose 2|SF2a-TT15 vaccine, 10 μg
2965063|NCT02797236|Experimental|vaccine dose 2 + adjuvant|SF2a-TT15 vaccine, 10 μg + alum
2965064|NCT02797236|Placebo Comparator|Placebo|Tris buffer
2965065|NCT02797236|Placebo Comparator|Placebo + adjuvant|Tris buffer + Alum
2965066|NCT02797210|Experimental|Sham then Active Stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks, then active rTMS to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks
2965067|NCT02797210|Experimental|Active then Sham Stimulation|Active repetitive transcranial magnetic stimulation (rTMS) to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks, then sham rTMS to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks
2965068|NCT02797197|Experimental|patient undergoing to chemotherapy during 6 months|
2965069|NCT02797184|Experimental|Aim 1. KNO3 dose response|Intervention: Subjects with heart failure will receive a single oral dose of potassium nitrate (10 or 20 mmol KNO3) in 2 gelatin capsules during dose visit 1 and the other dose (10 or 20 mmol KNO3) during dose visit 2. The dose order will be randomized.
2965070|NCT02797171|Experimental|Group 1|Participants will receive 10 mg/kg of VRC01 at Months 0, 2, 4, and 6.
2965071|NCT02797171|Experimental|Group 2|Participants will receive 30 mg/kg of VRC01 at Months 0, 2, 4, and 6.
2965072|NCT02797171|Experimental|Group 3|Participants will receive 30 mg/kg of VRC01LS at Months 0, 3, and 6.
2965073|NCT02797171|Experimental|Group 4|Participants will receive 30 mg/kg of VRC01 at Month 0.
2965074|NCT02797171|Experimental|Group 5|Participants will receive 30 mg/kg of VRC01LS at Month 0.
2965075|NCT02797158|Experimental|Interventional Arm|
2965076|NCT02797145|Active Comparator|Intensive Group|Dose adjusted digoxin by the recommended range for the serum digoxin: 0.5-0.9 nanogram/mL
2965077|NCT02797145|Placebo Comparator|Conventional|Use digoxin as recommended by the guidelines.
2965078|NCT02797132|Experimental|Part A: LUM/IVA Subjects < 14Kg|lumacaftor 100 mg/ivacaftor 125 mg q12h
2965079|NCT02797132|Experimental|Part A: LUM/IVA Subjects >= 14Kg|lumacaftor 150 mg/ivacaftor 188 mg q12h
2965080|NCT02797132|Experimental|Part B: LUM/IVA Subjects < 14Kg|lumacaftor 100 mg/ivacaftor 125 mg q12h
2965081|NCT02797132|Experimental|Part B: LUM/IVA Subjects >= 14Kg|lumacaftor 150 mg/ivacaftor 188 mg q12h
2965082|NCT02797119|Experimental|tranexamic acid 1 g (TA1)|"To measure the efficacy of a standard 1g dose TA to reduce blood loss in ongoing hemorrhagic cesarean section.~To correlate this clinical effect with the fibrinolysis inhibition and the TA venous and uterine blood concentration"
2965083|NCT02797119|Experimental|tranexamic acid 0.5 g (TA1/2)|To measure the efficacy of a low 0,5g dose TA to reduce blood loss in ongoing hemorrhagic cesarean section To correlate this clinical effect with the fibrinolysis inhibition and the TA venous and uterine blood concentration
2965084|NCT02797119|Placebo Comparator|Saline Solution (TA0)|To measure the evolution of blood loss without TA in ongoing hemorrhagic cesarean section To correlate this clinical evolution with fibrinolysis.
2965085|NCT02797119|No Intervention|NH|To measure the reference fibrinolytic activity in non-hemorrhagic cesarean section
2965086|NCT02797106||health care professionals|health care professionals potentially involved in assessment and/or treatment of drooling in children with Cerebral Palsy.
2965087|NCT02797093||HIV suppressed individuals|HIV suppressed individuals on chronic ART, suboptimal adherence and exposure, measured through TFV-DP in DBS.
2965088|NCT02797080|Experimental|interferon γ-1b|ACTIMMUNE® will be administered 3 times per week (TIW) by subcutaneous (SC) injection.
2965089|NCT02797067|Experimental|Indomethacin|
2965090|NCT02797067|Placebo Comparator|Glycerin|
2965091|NCT02797054|Experimental|Tailored Intervention|Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
2965092|NCT02797054|Other|Untailored Intervention|Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
2965093|NCT02797054|Other|Usual Care|Intervention: usual care as experienced during appointment with primary care provider. Participants in the usual care arm will not view any educational materials or complete the baseline survey.
2965094|NCT02797028|Placebo Comparator|Placebo capsule|Simple hyperuricemia patients and with coronary heart disease in hospital. Double blind, randomized method. Control group taking placebo capsule
2965095|NCT02797028|Experimental|Anthocyanidins capsule|Simple hyperuricemia patients and with coronary heart disease in hospital. Double blind, randomized method. The experimental group taking anthocyanins capsule.
2965096|NCT02797028|Experimental|Allopurinol|The experimental group taking allopurinol.
2965097|NCT02797015|Experimental|1 mg RPC1063|1 mg RPC1063 oral capsule daily
2965107|NCT02796976|Active Comparator|older sedentary at risk|cross-sectional and training or control condition
2965108|NCT02796963|Experimental|Immediate Intervention|Men will be exposed immediately to a comprehensive intervention promoting HIV testing.
2965109|NCT02796963|Experimental|Delayed Intervention|Men will be exposed to a comprehensive intervention promoting HIV testing after a delay period.
2965110|NCT02796950|Experimental|Acipimox|Administration of acipimox 250 mg p.o.
2965111|NCT02796950|No Intervention|Control|No intervention.
2965112|NCT02796937|Experimental|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
2965113|NCT02796924|Experimental|Patients|30 sessions of high-frequency (20Hz) repetitive stimulation applied over the right temporal-parietal junction in patients with psychogenic non-epileptic seizures using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
2965114|NCT02796911|No Intervention|Corticotomy alone|Group I will be treated with a modified technique of corticotomy assisted orthodontic treatment (CAOT) alone
2965115|NCT02796911|Experimental|Corticotomy + xenograft|group II (included 6 females and 5 males) that treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
2965116|NCT02796911|Experimental|Corticotomy + bioactive glass|group III (included 7 females and 4 males) that treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
2965117|NCT02796898|Experimental|Treated Group|"SM88 is a combination therapy consisting of 4 agents. One agent, the tyrosine isomer will be increased in each of 2 dose cohorts as follows:~Cohort 1:~Tyrosine isomers - 230 mg qd~Phenytoin - 50 mg qd.~Methoxsalen - 10 mg qd~Sirolimus - 0.5 mg qd~Cohort 2:~Cohort 2 has increasing tyrosine isomer from q.d. to b.i.d.~Expansion Cohort:~The optimum dose will be expanded in 2nd stage of the study to 30 subjects."
2965118|NCT02796885||Possible hypophosphatasia|Patients attending metabolic bone services, not previously know to have HPP, with biochemistry suggestive of HPP Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
2965119|NCT02796885||Normal|Patients attending metabolic bone services, not previously know to have HPP, with normal HPP biochemistry Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
2965120|NCT02796885||Known hypophosphatasia|Patients attending metabolic bone services or registered with RUDY database, known to have HPP Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
2965121|NCT02796872|Placebo Comparator|mother's breast milk.|mother's breast milk.
2965122|NCT02796872|Active Comparator|other GOS|Commercial infant formula containing 4% w/w FOS:GOS (1:3)
2965123|NCT02796872|Experimental|B-GOS 3%|Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)
2965124|NCT02796872|Experimental|B-GOS 2%|Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)
2965125|NCT02796859|Active Comparator|Treatment Group|Subjects in the siltuximab group will receive an 11 mg/kg infusion at baseline, and weeks 3 and 6, as per the recommended dosing for multicentric Castleman's disease
2965126|NCT02796859|Placebo Comparator|Control Group|Subjects in the placebo group will receive an infusion of normal saline (with the same packaging and volume as the siltuximab group) at baseline, and weeks 3 and 6.
2965127|NCT02796846||CPAP prescription group|Patients with a CPAP prescription (both compliant and noncompliant)
2965128|NCT02796846||Without a CPAP prescription|Patients without a CPAP prescription to satisfy our primary goals/objectives.
2965129|NCT02796833|Other|SMOF/Intralipid|"Patients that are randomized to receive for the first 6 months SMOF as a lipid emulsion in their PN, and for the next 6 month (after 28 days of active washout on Intralipid) Intralipid, which is the standard lipid emulsion used in the hospital. SMOF is approved by Health Canada.~The parenteral nutrition bags are compounded individually for each patient based on their specific needs."
2965130|NCT02796833|Other|Intralipid/SMOF|Patients that are randomized to receive Intralipid, which is the standard lipid emulsion used in the hospital for the first 6 months, and for the next 6 month (after 28 days of active washout on Intralipid) SMOF as a lipid emulsion in their PN. SMOF is approved by Health Canada.The parenteral nutrition bags are compounded individually for each patient based on their specific needs.
2965131|NCT02796820|Experimental|Huaier Granule|Huaier Granule will be administrated from 4 to 48 weeks after surgery or until study termination. Huaier Granule is continuously taken three times per day, 20g per time.
2965132|NCT02796820|No Intervention|Regular follow-up observation|Regular follow-up observation after surgery.
2965133|NCT02796807|Experimental|68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT|
2965134|NCT02796794|Active Comparator|Genistein|Intervention group will receive supplemental genistein (60 mg/day) to enteral nutrition
2965135|NCT02796794|Other|control|Control group are the patients receiving enteral nutrition
2965136|NCT02796781|Experimental|lung stem cells|Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.
2965137|NCT02796768||Participants|"Study participants will be 0 to 4 months of age and undergoing DDH screening. They will have the following scans:~BASELINE - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2, 1 2D US scanning session of right and left hip by Specialist 1, 1 2D US scanning session of right and left hip by Specialist 2.~FOLLOW-UP (OPTIONAL) - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2,~1 2D US scanning session of right and left hip by Specialist 1,~1 2D US scanning session of right and left hip by Specialist 2."
2965138|NCT02796755|Experimental|Riluzole Arm|Participants will take a daily oral dose of 100 mg of riluzole (50 mg two times per day). Participants will be instructed to take the study medication on an empty stomach (1 hour before or 2 hours after meals).
2965139|NCT02796755|Placebo Comparator|Placebo Arm|Participants will take a daily oral dose of 100 mg of a placebo that appears identical to riluzole (50 mg two times per day). Participants will be instructed to take the study medication on an empty stomach (1 hour before or 2 hours after meals).
2965140|NCT02796742||Group MSSA|
2965141|NCT02796742||Group MRSA|
2965142|NCT02796742||Group PVL-negative strains|
2965143|NCT02796742||Group PVL-positive strains|
2965310|NCT02795715|Experimental|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
2965144|NCT02796729|Experimental|dynamic glucose enhanced MRI after D-glucose injection|"IV catheter preparation: Catheter will be placed in one arm. Fasting glucose levels measured with a glucometer using a 1-2 mL sample of blood. Only participants with normal fasting blood glucose levels (70-125 mg/dL) will proceed with the study. First IV catheter will monitor blood glucose every 10 min after bolus injection until it returns to normal. Second IV catheter is placed on the opposite arm for glucose infusion and GBCA (gadobutrol) infusion.~Glucose infusion protocol: Occurs when the participant is in the MRI. Bolus injection of hospital grade 25g of 50% dextrose solution over 1 min is to increase blood glucose concentrations to about 3-4 times the normal level. Blood glucose levels should return to normal levels within 30 to 60 min.~GBCA infusion protocol: Occurs when the participant is in the MRI; approximately 20 min after glucose infusion. Standard intravenous bolus injection of 0.1mM/kg of gadobutrol (Gadovist) at an injection rate of 5 mL/sec."
2965145|NCT02796703|Placebo Comparator|Control Group|Dietary Supplement: Placebo 2 cc/day of placebo diluted in mother's milk (when available) or premature formula.
2965146|NCT02796703|Active Comparator|Treatment Group|"Dietary Supplement: Heat Inactivated Probiotics~1 tsp heat inactivated Biotikid powder will be diluted in 2 cc of mother's milk (when available) or premature formula."
2965147|NCT02796690||Group Methicillin susceptible Staphylococcus aureus (MSSA)|
2965148|NCT02796690||Group methicillin resistant Staphylococcus aureus (MRSA)|
2965149|NCT02796677|Experimental|AB/FF 400/12 μg BID|Participants were administered AB/FF 400/12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
2965150|NCT02796677|Experimental|AB 400 μg BID|Participants were administered AB 400 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
2965151|NCT02796677|Experimental|FF 12 μg BID|Participants were administered FF 12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
2965152|NCT02796677|Experimental|TIO 18 μg QD|Participants were administered TIO 18 μg via Handihaler® inhale once daily for 24 weeks of treatment.
2965153|NCT02796664|Active Comparator|Ginseng|2grams twice per day (0.5gram/capsule, 2capsules twice a day) for 12months
2965154|NCT02796664|Placebo Comparator|Placebo|Placebo has the same appearance (same size and color) of the real drug. 2grams twice per day (0.5gram/capsule, 2capsules twice a day) for 12months
2965155|NCT02796651|Experimental|Formoterol 6 μg|Participants received formoterol fumarate 6 μg administered via Pressair twice daily (BID).
2965156|NCT02796651|Experimental|Formoterol 12 μg|Participants received formoterol fumarate 12 μg administered via Pressair BID.
2965157|NCT02796651|Experimental|Formoterol 24 μg|Participants received formoterol fumarate 24 μg administered via Pressair BID.
2965158|NCT02796651|Placebo Comparator|Placebo|Participants received placebo to formoterol fumarate administered via Pressair BID.
2965159|NCT02796651|Experimental|Formoterol 20 μg|Participants received Perforomist inhalation solution and were instructed to take one puff from each of the two Pressair inhalers or to inhale one vial from the Perforomist 20 μg inhalation solution BID for 7 ± 1 consecutive days.
2965160|NCT02796651|Experimental|Formoterol 40 μg|Participants received Perforomist 40 μg (2 vials of Performist 20 μg) as a single dose of administration.
2965161|NCT02796638|Experimental|Minute Ventilation Adaptive Servo-Ventilation plus SOC|Patients in this arm will be instructed to use the adaptive servo-ventilation (ASV) device for up to five days of inpatient stay while in the hospital. Patients are encouraged to use the device during any and all hours of sleep, and as needed during waking hours. Apart from this treatment, no other interventions will be administered, and the patient's standard of care will not otherwise be altered for the purposes of the study.Two 6-mL tubes of blood will be drawn once daily for up to 5 days, and daily questionnaires will be administered regarding sleep and health quality.
2965162|NCT02796638|No Intervention|Standard of Care (SOC)|Patients in this arm will not have their standard of care as dictated by their provider altered in any way. Two 6-mL tubes of blood will be drawn once daily for up to 5 days, and daily questionnaires will be administered regarding sleep and health quality.
2965163|NCT02796625|Experimental|Painful Stimuli|Participants will be exposed to painful heat
2965164|NCT02796612|Active Comparator|No intervention|Patients receive the current standard of care and are asked to answer the questionnaires mentioned below.
2965165|NCT02796612|Experimental|Intervention group|"Patients receive the current standard of care and are asked to answer the questionnaires mentioned below.~Additionally, delivery of a take-home brochure to the patients during the first visit is planned. The biopsy is explained to the patient and performed by a psychological trained physician. Patient care by a psychologically trained physician is performed in the sense that patients are informed about their biopsy result by a specifically trained physician."
2965166|NCT02796599|Experimental|CWLT with facial mask|This study has a cross-over design. Patients will achieve CWLT with non-invasive ventilation using facial or nasal mask in a randomised order.
2965167|NCT02796599|Experimental|CWLT with nasal mask|This study has a cross-over design. Patients will achieve CWLT with non-invasive ventilation using facial or nasal mask in a randomised order.
2965168|NCT02796586|Placebo Comparator|Individual Contraceptive Counseling|Performed by a medical provider and planned to simulate a typical clinic visit addressing contraception.
2965169|NCT02796586|Experimental|Group Contraceptive Counseling|Performed by a bicultural study staff member who speaks the primary languages of participants and had been formally trained in contraception counseling.
2965170|NCT02796573|Experimental|B-CBT|6 face-to-face consultations plus 6 online modules.
2965171|NCT02796573|Active Comparator|Face-to-Face CBT|12 face-to-face consultations.
2965172|NCT02796560|Experimental|Brand name travoprost|Patients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks.
2965173|NCT02796560|Experimental|Generic travoprost|Patients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks.
2965174|NCT02796547|Experimental|Levobupivacaine|Primiparous patients in whom a instrumental delivery with episiotomy is conducted. The infiltration of the banks of the episiotomy will be done with Levobupivacaine. This is the only intervention specific to the study, as compared to the standard of care.
2965175|NCT02796547|Placebo Comparator|Placebo|Primiparous patients in whom a instrumental delivery with episiotomy is conducted. The infiltration of the banks of the episiotomy will be done with physiological serum.This is the only intervention specific to the study, as compared to the standard of care.
2965176|NCT02796521|Other|control group|The control group will receive usual dietary counseling for enrichment.
2965177|NCT02796521|Other|workshop group|The workshop group will have informations about interest of foods. They will enrich a meal with foods which can easily be added without cooking.
2965178|NCT02796508|Experimental|Non-action video game training|Experimental: Non-action video game training 16 1-hour training sessions with 10 non-action video game training selected games from Lumosity.
2965179|NCT02796508|Active Comparator|Non-cognitive video game training|Active Control: Non-cognitive social video game training 16 1-hour training sessions with non-cognitive video game training with social games from The Sims.
2965180|NCT02796495|Experimental|Operation of hand prosthesis with direct nerve stimulation|"A system composed by the integration of the following non-CE marked medical devices specifically designed for the study will be used in one or two amputees:~STIMEP (multichannel electrical stimulator for the peripheral nervous system; AXONIC)~TIME-4H Intraneural Electrodes (ALBERT-LUDWIGS-UNIVERSITAET FREIBURG)~Sensorized Hand Prosthetics for amputees IH2 Prosthetic Azurra Prensilia (Prensilia Ltd.)~Prosthetics sensorized hand for amputees DLR/HIT Hand II (Wessling Robotics)~ODROID software integration within the afferent and efferent bi-directional control of the robotic hand~The EPIONE Psychophysical Testing Platform software for stimulator control"
2965181|NCT02796482|Other|EnergieShake 1.5 kcal Complete Intervention|Single am of intervention of ONS, EnergieShake 1.5 kcal Complete, in the open label study are to be given to participants for 8 days, i.e. two bottles twice daily.
2965182|NCT02796469||Pentoxifylline + Corticosteroid|Association of treatment by pentoxifylline and corticosterone during 28 days
2965183|NCT02796469||Corticosteroid|treatment by corticosteroid during 28 days
2965184|NCT02796469||Pentoxifylline|treatment by pentoxifylline during 28 days
2965185|NCT02796469||Placebo|
2965186|NCT02796456||Normal weight women|BMI between 18.5 and 25 kg/m2 and without gestational diabetes
2965187|NCT02796456||Obese women without gestational diabetes|BMI more than 30 kg/m2 and without gestational diabetes
2965188|NCT02796456||Obese women with gestational diabetes|BMI more than 30 kg/m2 and with gestational diabetes
2965189|NCT02796443||Early laparoscopic cholecystectomy (ELC)|Operation within 72 hours after onset of symptoms
2965190|NCT02796443||Intermediate cholecystectomy (ILC)|Operation within 14 days after onset of symptoms
2965191|NCT02796443||Delayed LC (DLC)|Operation after 6-12 weeks
2965192|NCT02796443||Elective laparoscopic cholecystectomy|Biliary colic with no acute cholecystitis
2965193|NCT02796430||Mechanically ventilated patients|Ease of use will be assessed by analysing the time needed to start indirect calorimetry measurement, and results of indirect calorimetry measurements by both the new indirect calorimeter and the currently used calorimeters at each study center.
2965194|NCT02796417|Experimental|Rehacop group|Cognitive rehabilitation
2965195|NCT02796417|Active Comparator|Control group|Occupational activities
2965196|NCT02796404|Experimental|Homebased cardiac rehabilitation program|Homebased Cardiac rehabilitation program with monitoring vest and mixed surveillance.
2965197|NCT02796404|Other|Traditional cardiac rehabilitation|Multidisciplinary program in a cardiac rehabilitation gym. Routine clinical practice
2965198|NCT02796391|Experimental|Study 1: Immediate Reduction|"This group will receive the lowest nicotine dose (.03 mb nicotine yield) very low nicotine content (VLNC) cigarettes, each of four pre-quit weeks (immediate reduction.~Study 1: Participants will be randomly assigned to 1 of 2 groups (Immediate or gradual nicotine reduction). They will all receive a targeted intervention workbook (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) and will be provided with brief one-on-one counseling."
2965199|NCT02796391|Experimental|Study 1: Gradual Reduction|"This group will receive VLNC cigarettes containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4 (gradual reduction).~Study 1: Participants will be randomly assigned to 1 of 2 groups (Immediate or gradual nicotine reduction). They will all receive a targeted intervention workbook (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) and will be provided with brief one-on-one counseling."
2965200|NCT02796391|Experimental|Study 2: Targeted/Immediate Reduction|"This group will receive the lowest nicotine dose (.03 mg nicotine yield) very low nicotine content (VLNC) cigarettes, each of four pre-quit weeks (immediate reduction).~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
2965201|NCT02796391|Experimental|Study 2: Targeted/Gradual Reduction|"This group will receive VLNC cigarettes containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4 (gradual reduction).~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
2965202|NCT02796391|Experimental|Study 2: Generic/Immediate Reduction|"This group will receive the lowest nicotine dose (.03 mg nicotine yield) very low nicotine content (VLNC) cigarettes, each of four pre-quit weeks (immediate reduction).~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
2965203|NCT02796391|Experimental|Study 2: Generic/Gradual Reduction|"This group will receive VLNC cigarettes containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4 (gradual reduction).~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
2965311|NCT02795715|Sham Comparator|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
2965204|NCT02796378|Active Comparator|Training+Simvastatin+Q10-placebo|Training+Simvastatin+Q10-placebo. 8 Weeks of exercise training on a bicycle ergometer three times a week and 40 mg of Simvastatin pr day and Q10-placebo.
2965205|NCT02796378|Placebo Comparator|Training+Simvastatin-placebo+Q10-placebo|Training+Simvastatin-placebo+Q10-placebo. 8 Weeks of exercise training on a bicycle ergometer three times a week, Simvastatin-placebo and Q10-placebo.
2965206|NCT02796378|Active Comparator|Training+Simvastatin+Q10|Training+Simvastatin+Q10. 8 Weeks of exercise training on a bicycle ergometer three times a week and 40 mg of Simvastatin pr day in combination with 400 mg of oral supplementation with Q10.
2965207|NCT02796365|Experimental|Exercise|Patients will participate in a 10 week outpatient cardiac rehabilitation program. Exercise will consist of 3 days per week of interval training on a treadmill or bike at an intensity between 50-90% of heart rate reserve. Additionally patients will perform resistance exercises 1-2 days per week and attend 8 nutrition and lifestyle classes.
2965208|NCT02796365|No Intervention|Usual care|Control group will not be instructed on exercise, but encouraged to follow standard medical advice.
2965209|NCT02796352|Experimental|High dose bolus interleukin-2 (HD IL2)|
2965210|NCT02796339|Active Comparator|Mastiha|This arm of patients will receive natural Mastiha supplements at the dosage of 2.8g daily. Patients with active disease will be administered with supplements for 3 months, whereas patients in remission will be administered with supplements for 6 months.
2965211|NCT02796339|Placebo Comparator|Placebo|This arm of patients will receive placebo . Patients with active disease will be administered with placebo for 3 months, whereas patients in remission will be administered with placebo for 6 months.
2965212|NCT02796326|Experimental|Dilatation|Patients undergoing tracheal dilatation with the study device
2965213|NCT02796313|Experimental|Intervention Group|Participants in the intervention group will receive tailored advice on adopting a low-sodium DASH diet, comprising nutritional education and ongoing guidance for purchasing heart-healthy foods, plus a weekly $30 credit for groceries.
2965214|NCT02796313|Active Comparator|Control Group|Participants in the control group will receive printed educational materials with general information about low-salt diets plus a weekly $30 credit for groceries.
2965215|NCT02796300|Active Comparator|Bioflo Goup|This group will have dialysis using the Bioflo catheter.
2965216|NCT02796300|Active Comparator|Palindrome Group|This group will have dialysis using the Palindrome catheter.
2965217|NCT02796287|Experimental|Patients with Ictus amnesic|Patients admitted in the hospital as part of their medical care with amnesic Ictus episode
2965218|NCT02796261|Experimental|Eflornithine + Lomustine|Eflornithine dosed on a 2 weeks on, 1 week off schedule + Lomustine dosed every 6 weeks
2965219|NCT02796261|Active Comparator|Lomustine|Lomustine dosed every 6 weeks
2965220|NCT02796235|Other|Spinal cord injury (SCI) patient|
2965221|NCT02796222||Hemophilia A patients on rFVIIIFc|Patients with hemophilia A who switch from on-demand or prophylactic treatment with rFVIII to rFVIIIFc
2965222|NCT02796222||Hemophilia A patients on rFVIII|Patients with hemophilia A who remain on on-demand or prophylactic treatment with rFVIII
2965223|NCT02796222||Hemophilia B patients on rFIXFc|Patients with hemophilia B who switch from on-demand or prophylactic treatment with rFIX to rFIXFc
2965224|NCT02796222||Hemophilia A patients on rFIX|Patients with hemophilia B who remain on on-demand or prophylactic treatment with rFIX
2965225|NCT02796209|Experimental|Atomexetine|Following the dose optimization phase, investigators will stratify the treatment assignment by Atomexetine dose (10mg or 19mg twice a day)
2965226|NCT02796209|Placebo Comparator|Placebo|The placebo capsules will be of identical color, size, and approximate weight to provide an authentic blinded effect. The capsule contents will be a microcrystalline cellulose, NF (PH-105), which should not produce any adverse effects. It is a common pharmaceutical capsule filler used in the industry.
2965227|NCT02796196||Supportive care (monitoring device, medical chart review)|Data including demographics, type of HCT (e.g., allogeneic or autologous), preexisting physical conditions (e.g., chronic joint injury), CRF, steroid use data, ECOG and KPS scores are collected from patients' medical charts at time of enrollment. Patients are prescribed participation in a primarily self-directed physical activity program which encourages them to spend 6 hours out of bed daily and to perform 30 minutes of light-to-moderate daily aerobic activity. Patients who are able to maintain independent mobility undergo physical therapist assessment 2 times a week until hospital discharge. Patients wear a physical activity monitoring device and daily activity and sleep data are collected continuously during hospital LOS.
2965228|NCT02796183|Other|Diabetic macular edema|Bevacizumab (Altuzan) was injected subconjunctival space of the patients.
2965229|NCT02796170|Active Comparator|Dapagliflozin|This arm will undergo either 6 weeks of Dapagloflozin then 6 weeks of placebo, or 6 weeks of placebo then 6 weeks of Dapagloflozin
2965230|NCT02796170|Other|Sulfonylurea|This arm will be open label, participants will receive usual care for 6 weeks, then be provided a sulfonylurea medication for 6 weeks.
2965231|NCT02796157|Active Comparator|absorb arm|PCI with Absorb everolimus-eluting bioresorbable vascular scaffold
2965232|NCT02796157|Experimental|Xience arm|PCI with Xience everolimus-eluting metallic stent
2965233|NCT02796144|Active Comparator|Lorcaserin and Metformin|"Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.~Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg."
2965234|NCT02796144|Active Comparator|Lorcaserin|Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.
2965235|NCT02796144|Placebo Comparator|Placebo|Matching placebos will be administered for each active drug.
2965236|NCT02796131|Experimental|30 mg bid|30 mg of RDX5791 administered twice daily PO (60 mg total dose/day).
2965237|NCT02796131|Experimental|30 mg tid|30 mg of RDX5791 administered three times daily PO (90 mg total dose/day).
2965238|NCT02796131|Experimental|60 mg bid|60 mg of RDX5791 administered two times daily (120 mg total dose/day).
2965239|NCT02796131|Experimental|15 mg bid|15 mg of RDX5791 administered two times daily (30 mg total dose/day).
2965240|NCT02796131|Experimental|30 mg QD|30 mg of RDX5791 administered once daily (30 mg total dose/day).
2965241|NCT02796131|Experimental|Escalating dose bid|15 mg or 30 mg or 45 mg of RDX5791 administered two times daily (30, 60, or 90 mg total dose/day respectively). The stopping criteria for the dose escalation is based on Bristol Stool Score and AEs.
2965242|NCT02796131|Experimental|30 mg bid with psyllium|30 mg of RDX5791 administered two times daily (60 mg total dose/day) with psyllium taken up to three times per day (maximum of 15 g psyllium/day).
2965243|NCT02796118|Experimental|ASP2151 Low dose in non-elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
2965244|NCT02796118|Experimental|ASP2151 High dose in non-elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
2965245|NCT02796118|Experimental|ASP2151 Low dose in elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
2965246|NCT02796118|Experimental|ASP2151 High dose in elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
2965247|NCT02796118|Placebo Comparator|Placebo in non-elderly subjects group|Subjects will receive matching placebo daily on Days 1 to 7.
2965248|NCT02796118|Placebo Comparator|Placebo in elderly subjects group|Subjects will receive matching placebo daily on Days 1 to 7.
2965249|NCT02796105|Experimental|Progevera|Progevera 10 mg
2965250|NCT02796105|Active Comparator|Orgalutran|Orgalutran 0.25 mg
2965251|NCT02796092|Active Comparator|Fibered platinum coils|Embolization of the pelvic veins with platinum fibered coils (Nester. Cook Europe, Bjaeverskov, Denmark)
2965252|NCT02796092|Experimental|Vascular plugs|Embolization of the pelvic veins with vascular plugs (Amplatzer Vascular Plugs II. St. Jude Medical. St. Paul, MN, USA)
2965253|NCT02796079|Experimental|Autologous Bone Marrow Stem Cell|Mesenchymal stem cells derived from bone marrow infusion
2965254|NCT02796079|Placebo Comparator|saline|saline injections
2965255|NCT02796066|Placebo Comparator|Vehicle|Vehicle gel
2965256|NCT02796066|Experimental|Low Dose Active|Low Dose of TSN2898
2965257|NCT02796066|Experimental|Mid Dose Active|Mid Dose of TSN2898
2965258|NCT02796066|Experimental|High Dose Active|High Dose of TSN2898
2965259|NCT02796053|Placebo Comparator|Placebo|Placebo to TAB08
2965260|NCT02796053|Experimental|TAB08 Dose 1|Drug: TAB08 biologic
2965261|NCT02796040|Experimental|patients with ICD (impulse control disorder)|More precisely, the main purpose is to demonstrate that fractional anisotropy (FA) (data obtained with DTI) in the ventral tegmental area (VTA) is different between patients with ICD and patients without ICD
2965262|NCT02796040|Other|patients without ICD (impulse control disorder)|More precisely, the main purpose is to demonstrate that fractional anisotropy (FA) (data obtained with DTI) in the ventral tegmental area (VTA) is different between patients with ICD and patients without ICD
2965263|NCT02796027|Experimental|Experimental: BRIDGE|Subjects assigned to this arm would receive an integrated HIV service model
2965264|NCT02796027|No Intervention|Pre-implementation|Subjects assigned to this arm would receive standard care (treatment as usual) and would not be exposed to the integrated HIV service model.
2965265|NCT02796001|Active Comparator|RV16|volunteers re-challenged with RV16
2965266|NCT02796001|Active Comparator|RV39|volunteers re-challenged with RV39
2965267|NCT02795988|Experimental|Low Dose|10 μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine
2965268|NCT02795988|Experimental|Mid Dose|30 μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine
2965269|NCT02795988|Experimental|High Dose|50 μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine
2965270|NCT02795962|Active Comparator|Transfer to an Endovascular Center|Acute stroke patients with suspected acute large vessel occlusion identified by EMS at first assistance on the field will be directly transferred to the nearest Endovascular Center bypassing the Local Stroke Center.
2965271|NCT02795962|No Intervention|Transfer to the Local Stroke Center|Acute stroke patients with suspected acute large vessel occlusion identified by EMS at first assistance on the field will be transferred to the Local Stroke Center as done accordingly with the current stroke code protocol.
2965272|NCT02795949|Experimental|Antipseudomonal beta-lactam antibiotic|"Ampicillin 2g IV/6h~Trimethoprim/sulfamethoxazole 160/800 mg IV/8 -12h~Cefuroxime 750-1000 mg IV/8h~Cefotaxime 1-2g IV/8h ó ceftriaxone 1 g/12-24h~Amoxicillin/clavulanate 1000/125 mg IV/8h~Ciprofloxacin 400 mg IV/12h~Ertapenem 1-2g/24h."
2965273|NCT02795949|Active Comparator|De-escalation(short-spectrum antibiotic)|"Piperacillin/tazobactam 4/0.5 g IV/8h~Meropenem 1-2 g IV/8h~Imipenem 0.5 g IV/6h - 1g IV/6h~Aztreonam 1-2 g IV/8h~Ceftazidime 1-2 g IV/8h~Cefepime 2 g IV/8-12h"
2965274|NCT02795936|Active Comparator|Institutional based rehabilitation|Conduct cardiac rehabilitation exercise protocol within the hospital
2965275|NCT02795936|Active Comparator|Home based rehabilitation|Conduct cardiac rehabilitation exercise protocol at home
2965276|NCT02795936|Placebo Comparator|Observational arm|No prescribed exercises, followed up monthly
2965277|NCT02795910|Experimental|Intervention|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) and outreach education training. First trainers will be trained, then trainers will train groups of doctors and nurses at their workplaces, showing them how to use the guidelines, and using their own patients and clinical problems as examples. This outreach training is repeated several times in short sessions
2965278|NCT02795910|Active Comparator|Control|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) but will receive no outreach education training.
2965279|NCT02795884|Experimental|Intercalation arm|"Intercalation phase (Duration: 3wks x 4 cycles = 12 wks) Pemetrexed 500mg/m2 D1, Cisplatin 75mg/m2 D1, Erlotinib 150mg D8-21 q3wks~Maintenance phase (Duration: 1 year) Erlotinib 150mg D1-28"
2965280|NCT02795884|Active Comparator|Chemotherapy alone arm|Duration: 3wks x 4 cycles = 12 wks Vinorelbine 25mg/m2 D1,8, Cisplatin 75mg/m2 D1 q3wks
2965281|NCT02795871|Experimental|Group D+ 1|Girls and boys at risk of CAH treated in utero by Dexamethasone but unaffected.
2965282|NCT02795871|Experimental|Group D+ 2|Girls and boys affected by CAH and treated in utero by Dexamethasone.
2965283|NCT02795871|Active Comparator|: Group D - 1|Girls and boys not affected by CAH and not treated in utero by Dexamethasone.
2965284|NCT02795871|Active Comparator|Group D - 2|Girls and boys affected by CAH and not treated in utero by Dexamethasone.
2965285|NCT02795871|Other|Group D - 3|Girls and boys enrolled in school closed to Lyon
2965312|NCT02795702|Experimental|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
2965763|NCT02792673|Experimental|Autologous Follicular Fluid|a novel technique
2965286|NCT02795858|Experimental|Ramucirumab In Combination With Somatostatin Analog|"Patients will receive treatment with Ramucirumab at a pre-determined dose intravenously every 14 days of a 28-day treatment cycle.~Patients will receive treatment with a Somatostatin Analog at a pre-determined dose.~Toxicity and adverse events will be examined in the first 10 patients who complete one cycle of therapy before expanding enrollment."
2965287|NCT02795845|Experimental|Primary prevention- probiotic capsules|"patients with normal vaginal flora in the experimental arm will be treated with Probiotic capsules (containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus, Bifidobacterium bifidum and B. Lactis).~one capsule twice a day until delivery."
2965288|NCT02795845|Placebo Comparator|Primary prevention - Placebo|patients with normal vaginal flora in the placebo arm will be treated with a capsule without active ingredient, one capsule twice a day until delivery.
2965289|NCT02795845|Experimental|Secondary prevention - probiotic capsules|Patients with abnormal vaginal flora/bacterial vaginosis or vaginal candidiasis in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if necessary) or antimycotic treatment. Once the infection was eradicated, the patient will be given probiotic capsules.
2965290|NCT02795845|Placebo Comparator|Secondary prevention - Placebo|Patients with abnormal vaginal flora/bacterial vaginosis or vaginal candidiasis in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if necessary) or antimycotic treatment. Once the infection was eradicated, the patient will be given placebo without active ingredient.
2965291|NCT02795832|Experimental|Cohort 1a|ZPL-5212372 1% w/w OIntment BID
2965292|NCT02795832|Placebo Comparator|Cohort 1b|Placebo Ointment BID
2965293|NCT02795832|Experimental|Cohort 2a|ZPL-5212372 1% w/w OIntment BID
2965294|NCT02795832|Placebo Comparator|Cohort 2b|Placebo Ointment BID
2965295|NCT02795832|Experimental|Cohort 3a|ZPL-5212372 1% w/w OIntment BID
2965296|NCT02795832|Placebo Comparator|Cohort 3b|Placebo Ointment BID
2965297|NCT02795819|Experimental|Pazopanib + AR42|"AR-42 will be taken orally once per day on 3 non-consecutive days each week during the first 3 weeks of each 4-week cycle. Pazopanib will be taken by mouth once daily continuously during each cycle.~A modified 3+3 dose-escalation design will be followed until the maximum tolerated doses (MTDs) have been determined. Different doses of AR-42 and pazopanib will be given to several study participants. Two different Pazopanib doses of 600 mg and 800 mg will be used. The AR-42 will continue to be increased for each group of participants until side effects occur that require dose of one study drug to be lowered."
2965298|NCT02795793|Experimental|Non-operative management group (NOM)|Children in the NOM group will receive intravenous Piperacillin with Tazobactam (Tazocin) 100mg/kg/dose every 8 hours for at least 24 hours, and they will be observed and reassessed within 24 hours after randomisation. A further 24 hours of intravenous Piperacillin with Tazobactam therapy will be offered to children in invariable condition. A clinical decision will be made by the attending surgeon to offer OM if a patient's condition deteriorates at any time, or if a patient has failed to improve after 48 hours of intravenous antibiotic therapy. Once the patient is clinically improving and tolerating oral intake, the antibiotic regimen will be changed to oral Amoxicillin plus Clavulanic acid (Augmentin) 22.5mg/kg/dose twice per day to complete a total seven day course of antibiotics. Oral Ciprofloxacin 15mg/kg/dose twice daily and oral Metronidazole 10mg/kg/dose twice daily will be offered to children who are known to have an intolerance or allergy to Amoxicillin or Clavulanic acid.
2965299|NCT02795793|Active Comparator|Appendectomy group (Operative management, OM)|Children allocated to OM may receive preoperative antibiotic prophylaxis as clinically indicated. Appendicectomy will be performed laparoscopically, or via open surgery according to the surgeon's standard practice. Postoperative antibiotic treatment will be determined on the basis of intraoperative findings in accordance with the institutional practice. The appendix specimen will be examined by a paediatric pathologist, and the formal histopathology report will be recorded.
2965300|NCT02795780|Experimental|A05 Confirmatory Cohort|Subjects from the 18F-AV-1451-A05 (NCT02016560) confirmatory cohort who have completed the 18F-AV-1451-A05 study and consented to participate in the 18F-AV-1451-A18 study. Subjects will receive an IV injection, 370 megabecquerel (MBq) (10 millicurie [mCi]), single dose of 18F-AV-1451.
2965301|NCT02795767|Experimental|Cohort A: Emicizumab QW|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg QW SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
2965302|NCT02795767|Experimental|Cohort B: Emicizumab Q2W|Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 3 mg/kg every 2 weeks (Q2W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
2965303|NCT02795767|Experimental|Cohort C: Emicizumab Q4W|Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 6 mg/kg every 4 weeks (Q4W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
2965304|NCT02795754|Experimental|GSK2838232 PIB (50 mg+100 mg+200 mg)+Placebo|During Part 1A, subjects will receive QD single dose of either GSK2838232 50 mg, 100 mg or 200 mg or placebo in each of the four visits (one treatment per visit).Subjects will also receive RTV along with all the doses and QD RTV for 48hours (2 doses) before all doses of GSK2838232 and placebo.
2965305|NCT02795754|Experimental|GSK2838232 PIB+IR1+IR2|During Part 1B, subjects will receive either GSK2838232 PIB, GSK2838232 IR1 or IR2 in each of the three visits (one treatment per visit) after at least 10 hours fasting and IR1 or IR2 after fat meal at visit 4.
2965306|NCT02795754|Experimental|GSK2838232 PIB (20mg/50 mg/100 mg/200 mg)/Placebo|During Part 2, subjects will receive repeated QD doses of either GSK2838232 (20 mg, 50 mg, 100 mg or 200 mg) or placebo for 11 days. Subjects will also receive RTV along with all the doses of GSK2838232 and placebo.
2965307|NCT02795741|Experimental|Cooling Bolero|All participants will use the Cooling Bolero for one month
2965308|NCT02795728|Experimental|Experimental arm|Fuji type VII is a GIC based sealant with an additional property of high fluoride release
2965309|NCT02795728|Active Comparator|Resin based sealant|Helioseal F is a resin based sealant
2965353|NCT02795429|Experimental|PDR001 single agent|PDR001 single agent treatment in Phase II
2965313|NCT02795702|Sham Comparator|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
2965314|NCT02795676|Experimental|PRX-102 (pegunigalsidase alfa)|PRX-102 infusion every 2 weeks
2965315|NCT02795676|Active Comparator|agalsidase beta|agalsidase beta infusion every 2 weeks
2965316|NCT02795663|Experimental|parkinson's patient stimulated at STN level|15 parkinson's disease patients stimulated at STN level NIRS EEG HR recording
2965317|NCT02795663|Experimental|non STN|5 Parkinson's Disease patients who received stimulation in another target that the STN NIRS EEG HR recording
2965318|NCT02795663|Experimental|control|20 control patients undergoing DBS for the treatment of OCD NIRS EEG HR recording
2965319|NCT02795650|Experimental|Experimental arm|Personalised treatment will be chosen for patients based on the results of tumor sequencing, bioinformatics and avatar model drug testing.
2965320|NCT02795650|Active Comparator|Control|Investigators are allowed to chose the best option of standard treatment for patients.
2965321|NCT02795637|Experimental|dasotraline|dasotraline 8mg capsule/day
2965322|NCT02795624||Flight attendants|Flight attendants
2965323|NCT02795611|Experimental|Treatment group|Patients who receive 'family-centered occupational therapy' in our hospital
2965324|NCT02795611|Active Comparator|Control group 1|Patients who receive regular occupational therapy in our hospital
2965325|NCT02795611|Other|Control group 2|Patients who don't receive intervention in our hospital
2965326|NCT02795598|Active Comparator|Single Injection Supraclavicular Block|Patients scheduled for surgery distal to the elbow will have an ultrasound guided single injection supraclavicular nerve block for surgical anesthesia.
2965327|NCT02795598|Active Comparator|Double Injection Supraclavicular Block|Patients scheduled for surgery distal to the elbow will have an ultrasound guided double injection supraclavicular nerve block for surgical anesthesia.
2965328|NCT02795585||QFR group|Patients with stable angina pectoris and indication for FFR.
2965329|NCT02795572|Experimental|Intervention Group|The intervention group will receive a daily dose of Vitamin D 2000 IU, Vitamin B6 100 mg, Vitamin B12 100 mcg and Omega-3 Fatty Acids 2700 mg [900 mg TID (600 mg EPA, 300 mg DHA)].
2965330|NCT02795572|No Intervention|Reference Group|Reference group will receive usual care.
2965331|NCT02795559|Other|Lean|Subjects within the range of desirable body weight (BMI<25)
2965332|NCT02795559|Other|OWO|Subjects who are overweight or obese (BMI between 25 and 40)
2965333|NCT02795546|Experimental|Test group|400µg Alendronate sodium+ β-TCP + saline. 400µg alendronate sodium is combined with beta-tricalcium phosphate bone substitute and wetted with saline and used as bone grafting material in periodontal intra-osseous defects.
2965334|NCT02795546|Active Comparator|Control group|β-TCP + saline Beta-tricalcium phosphate bone substitute and wetted with saline and used as bone grafting material in periodontal intra-osseous defects.
2965335|NCT02795533||Clinical follow-up|As part of the regular follow-up of aSAH patients at Oslo University Hospital patients with as aSAH in 2011-2012 will be invited to a clinical interview, medical examination and neuropsychological test. Patients will also be asked to answer Quality of Life Questionnaires.
2965336|NCT02795520|Experimental|OTS167IV|
2965337|NCT02795507|Experimental|Device with feedback & exercises|"Training using Rehabit-Tec System - patient's hand will be positioned in this specialized motion control apparatus which allows movement of the non involved hand while receiving visual feedback of a virtual hand in the paretic side and a passive movement of the paretic hand + followed by 30 minutes of exercises (conventional sensorimotor active and passive exercises of the upper limb).~5 days per week for 3 weeks, 1 hour per day."
2965338|NCT02795507|Active Comparator|Device without feedback & exercises|"Training using Rehabit-Tec System - patient's hand will be positioned in a specialized motion control apparatus which allows movement of the non involved hand but without receiving visual feedback of a virtual hand in the paretic side and a passive movement of the paretic hand + followed by 30 minutes of exercises (conventional sensorimotor active and passive exercises of the upper limb).~5 days per week for 3 weeks, 1 hour per day."
2965339|NCT02795494||Perthes Group|Participants with Perthes disease. Will be given WOMAC questionnaire at baseline and WOMAC questionnaire at 2 weeks, and ASK-P questionnaire at baseline.
2965340|NCT02795494||Fracture Control Group|Participants with an upper extremity fracture but no hip-related conditions. Will be given WOMAC questionnaire at baseline.
2965341|NCT02795481||Stroke patients|Adult stroke patients with suspected stroke will be recruited on admission to hospital. Recruitment will continue until 100 patients have received an MRI at 24h-72h post admission, up to a maximum recruitment threshold of 300 patients.
2965342|NCT02795481||Control patients|50 adult control patients will be recruited from the non-vascular, non-oncological surgical lists at each participating site
2965343|NCT02795481||Feeding control participants|15 healthy adult members of NHS staff will be recruited to participate in the feeding control sub-study at University Hospitals Coventry and Warwickshire NHS Trust only.
2965344|NCT02795481||Spasticity sub-group controls|10 healthy adult members of NHS staff at University Hospitals of North Midlands, will be recruited to take part as spasticity sub-study controls
2965345|NCT02795468|Active Comparator|Palpation group|The operator will use the pulsation of the radial artery as a guide for the cannulation.
2965346|NCT02795468|Experimental|Ultrasound group|The ultrasound guided technique will be used to find a radial artery and insert a radial arterial catheter.
2965347|NCT02795455|Experimental|Interoceptive Exposure (IE)|IE is an exposure-based intervention that involves consuming a food in session and tolerating uncomfortable feelings around eating.
2965348|NCT02795455|Active Comparator|Family Based Therapy-Weight Gain Control (FBT-WG)|Family-based therapy uses parent(s) to help modify disordered eating and develop contingencies to motivate eating.
2965349|NCT02795455|No Intervention|Healthy Controls (HC)|HC participants will only participate in the pre and post-intervention visits and not in the intervention sessions.
2965350|NCT02795442|Experimental|Even protein|Menu to provide 90 g of protein per day in an even distribution of 30 g at each meal.
2965351|NCT02795442|Experimental|Skewed protein|Menu to provide 90 g of protein per day in a skewed distribution of 10 g at breakfast, 15 g at lunch and 65 g at dinner.
2965352|NCT02795429|Experimental|INC280+PDR001|PDR001 + INC280 treatment in Phase II
2965354|NCT02795416|Experimental|"Secukinumab Cosentyx TM"|"Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month"
2965355|NCT02795403|Experimental|Viraemic|
2965356|NCT02795403|Experimental|responder group|
2965357|NCT02795390|Experimental|Chinese herbal medicine|MaZiRenWan 10g plus HuangQi 20g are chosen as the core prescription. Furthermore, six herbal granules can be added according to the syndrome differentiated for individual participant. They are ShuDiHuang 15g and Danggui 10g for deficiency of blood, Maidong 15g and ShengDiHuang 10g for deficiency of Yin, and RouCongRong 15g and Niuxi 10g for deficiency of Yang.
2965358|NCT02795390|Placebo Comparator|Placebo|Placebo is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%), and caramel (0.34%) to achieve color, smell, taste, and texture comparable to the herbal granules.
2965359|NCT02795377||male subjects with arterial hypertension|Measurements will be taken at baseline.
2965360|NCT02795377||male subjects without arterial hypertension and no CAD|Measurements will be taken at baseline.
2965361|NCT02795377||male subjects with hypertensive crises|Measurements will be taken before and after 4 hours and normalization of arterial blood pressure by urapidil.
2965362|NCT02795377||male subjects with stable CAD|Measurements will be taken before and after transfemoral coronary diagnostic angiography.
2965363|NCT02795364|Active Comparator|Structural Image Guidance|In this arm, the patients will receive maximum resection of the tumor with the MRI T1W-enhanced image guidance, in addition to the standard therapy
2965364|NCT02795364|Experimental|Metabolic Image Guidance|In this arm, the patients will receive quantitative resection of the tumor with both the MRI T1W-enhanced and the MRS Cho-to-NAA index (CNI) image guidance, in addition to the standard therapy.
2965365|NCT02795351|Experimental|Active|Sildenafil 100 mg single dose
2965366|NCT02795351|Placebo Comparator|Placebo|Placebo capsule
2965367|NCT02795325|Experimental|PH Patients|
2965368|NCT02795325|Experimental|Healthy Volunteers|
2965369|NCT02795312|Experimental|Smoking Cessation Training Program|Participants will take part in a 9-week Smoking Cessation Program class curriculum consisting of weekly 2.5 hour classes and complete pre and post questionnaires
2965370|NCT02795299|Active Comparator|Gerilimzumab 5/2 mg/Methotrexate/folate|• 5 mg gerilimzumab loading dose followed by 2 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
2965371|NCT02795299|Active Comparator|Gerilimzumab 10/5mg/Methotrexate/folate|• 10 mg gerilimzumab loading dose followed by 5 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
2965372|NCT02795299|Active Comparator|Gerilimzumab 20/10mg/Methotrexate/folate|• 20 mg gerilimzumab loading dose followed by 10 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
2965373|NCT02795299|Placebo Comparator|Placebo/Methotrexate/folate|• Placebo every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
2965374|NCT02795286|Experimental|ASIST A|Artis Haemodialysis Machine w/ ASIST Software - Isonatremic
2965375|NCT02795286|Experimental|ASIST B|Artis Haemodialysis Machine w/ ASIST Software - Isotonic
2965376|NCT02795286|Active Comparator|Conventional HD|Artis Haemodialysis Machine w/o ASIST Software
2965377|NCT02795273|Experimental|Grass-SPIRE|Eight intradermal injections of Grass-SPIRE
2965378|NCT02795273|Placebo Comparator|Placebo|Eight intradermal injections of Placebo
2965379|NCT02795260|Experimental|ESAT6-CFP10 in the right arm|Each volunteer is intradermally injected two agents in different arms 12 weeks after Bacillus Calmette - Guerin (BCG) or placebo of BCG immunization :ESAT6-CFP10 in the right arm and TB-PPD in the left arm concomitantly,according to a randomisation scheme.
2965380|NCT02795260|Experimental|ESAT6-CFP10 in the left arm|Each volunteer is intradermally injected two agents in different arms 12 weeks after Bacillus Calmette - Guerin (BCG) or placebo of Bacillus Calmette - Guerin immunization :ESAT6-CFP10 in the left arm and TB-PPD in the right arm concomitantly,according to a randomisation scheme.
2965381|NCT02795247|Active Comparator|Hybrid Transtibial Technique|Reconstruction of the ACL using the hybrid transtibial technique
2965382|NCT02795247|Active Comparator|Accessory Anteromedial Portal Technique|Reconstruction of the ACL using the accessory anteromedial portal technique
2965383|NCT02795247|Active Comparator|Transtibial Technique|Reconstruction of the ACL using the transtibial technique.
2965384|NCT02795234|Other|Participants with Vitamin D deficiency|Blood sample, venous blood, about 10 ml will be drawn from participants and tested for the presence of Vitamin D antibodies
2965385|NCT02795234|Other|Participants with sufficient Vitamin D Level|Blood sample, venous blood, about 10 ml will be drawn from participants and tested for the presence of Vitamin D antibodies
2965386|NCT02795208|No Intervention|Control group|Patients received standard protective ventilation along the protocol.
2965387|NCT02795208|Experimental|Recruitment maneuver group|Patient received a lung recruitment maneuver after cardiopulmonary bypass. The recruitment maneuver consists in 10 breaths at 40/20 cmH2O of plateau pressure and PEEP, respectively. Then, the .ventilatory settings back to protective ventilation but adding 10 cmH2O of PEEP to keep the lungs open.
2965388|NCT02795195|Experimental|CIRT arm (3GyE per fraction)|treated with carcon ion radiotherapy with a fraction size of 3GyE.
2965389|NCT02795182|Experimental|BGB-3111 and BGB-A317|In the dose -escalation part, the dose levels and regimens will be evaluated.
2965390|NCT02795156|Experimental|Arm 1|Patients with non-small cell lung cancer who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
2965391|NCT02795156|Experimental|Arm 2|Patients with urothelial carcinoma who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
2965392|NCT02795156|Experimental|Arm 3|Patients with non-colon gastrointestinal cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
2965764|NCT02792660|Experimental|Injeq IQ-Needle|Lumbar puncture is performed using Injeq IQ-Needle
2965393|NCT02795156|Experimental|Arm 4|Patients with upper aerodigestive tract cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
2965394|NCT02795143|Experimental|Isotretinoin|"Isotretinoin will be given at the following dosage:~Dosing will be as listed on the table below.~Weight in Kg Total Daily Dose 40-49 Kg 40mg 50-89 Kg 80mg 90-150 Kg 120mg"
2965395|NCT02795143|Placebo Comparator|Placebo|Subjects will be given placebo capsules twice a day.
2965396|NCT02795130|Experimental|8-0 polyglactin 910|
2965397|NCT02795130|Experimental|6-0 plain gut suture|
2965398|NCT02795117|Experimental|Test product|
2965399|NCT02795117|Active Comparator|Reference product|
2965400|NCT02795117|Placebo Comparator|Placebo product|
2965401|NCT02795104|Experimental|ARM I (TIDVD)|Educational Intervention via DVD: In this arm of the intervention participants watch a tailored interactive DVD program and answer questions posed by the DVD program.
2965402|NCT02795104|Experimental|ARM II (TIDVD, PN)|Educational Intervention-DVD & Telephone based Navigation: In this arm of the intervention participants watch a TIDVD and are called by a patient navigator.
2965403|NCT02795104|Experimental|ARM III (UC)|Educational Intervention via brochure: In this arm of the intervention participants receive brochures that explain and provide information and encouragement for cancer screening.
2965404|NCT02795091|Other|Manual clean|clean the rag and floor towel manually
2965405|NCT02795091|Other|machine clean|clean the rag and floor towel by machine
2965406|NCT02795065|Active Comparator|Enoxaparin 40 mg subcutaneous once daily|
2965407|NCT02795065|Experimental|Bemiparin 3500 IU subcutaneous once daily|
2965408|NCT02795052|Active Comparator|Arm 1 - Intravenous BMSC|Intervention- Autologous bone marrow aspiration and separation of Bone Marrow Derived Stem Cell (BMSC) fraction then provided intravenously.
2965409|NCT02795052|Active Comparator|Arm 2- Intravenous and Intranasal BMSC|Intervention- Autologous bone marrow aspiration and separation of Bone Marrow Derived Stem Cell (BMSC) fraction then provided intravenously and intranasally (lower 1/3 of nasal passages).
2965410|NCT02795039|Experimental|Fulvestrant 50mg/mL (Fresenius Kabi)|5 mL intramuscular injection
2965411|NCT02795039|Active Comparator|Fulvestrant 50 mg/mL (Faslodex®)|5 mL intramuscular injection
2965412|NCT02795026|Active Comparator|Manual therapy|Intervention to be administered is manual therapy with myofascial release of trigger points for pelvic floor muscles, pelvis and abdominal musculature.
2965413|NCT02795026|Active Comparator|Dry needling & manual therapy|Intervention to be administered is Trans-perineal trigger point dry needling, done externally to target the trigger points in the pelvic floor muscles along with dry needling of the pelvis and abdominal musculature.Manual therapy will only be used in areas difficult to reach with the acupuncture needles.
2965414|NCT02795013||Participants with Hodgkin Lymphoma|Those with a confirmed diagnosis of Hodgkin Lymphoma (HL) and family members who consent and enroll in this study.
2965415|NCT02795013||Family Members without Hodgkin Lymphoma|Those unaffected by HL will serve as a control group to compare with those with HL.
2965416|NCT02795000||Primary Ovarian insufficiency group|"amenorrhea one year or more than one year~amenorrhea more than 4 months and FSH≥40IU/L~≤42 years old and AMH≤0.071"
2965417|NCT02795000||The normal group|"normal regular menorrhea~≤42 years old~normal FSH and AMH level"
2965418|NCT02794987||Classification group|Group of endoscopists that will use the previous classification to select the bile duct tissular lesion images detected by SpyGlass® choledoscopy as benign or malignant with the different subtypes
2965419|NCT02794987||No classification group|Group of endoscopists that will classified the bile duct tissular lesion images detected by SpyGlass® choledoscopy as benign or malignant with the different subtypes without using the classification.
2965420|NCT02794974|Experimental|cervical plexus, perivascular and facial nerve block|1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. block of the facial nerve (cervical branch) (5ml prilocaine 1%) 3. perivascular local anesthetic infiltration (5ml prilocaine 1%)
2965421|NCT02794974|Experimental|cervical plexus and facial nerve block|1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. block of the facial nerve (cervical branch) (5ml prilocaine 1%)
2965422|NCT02794961|Experimental|CD22 CAR-T|Enrolled patients will receive three escalating doses of autologous CAR-T.
2965423|NCT02794948|Experimental|Chinese Medicine intervention|Chinese medicine HuYang Yang Kun Formula 1 capsule every time per day for 3 day per month, DHEA(dehydroepiandrosterone) placebo 1 sack every time, twice a day for three months
2965424|NCT02794948|Active Comparator|Western intervention|DHEA(dehydroepiandrosterone) 1 sack every time twice a day for three months. Chinese medicine formula granules placebo 1 capsule every time per day for 3 day per month.
2965425|NCT02794935|Experimental|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
2965426|NCT02794935|Placebo Comparator|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
2965427|NCT02794922|Experimental|Interventional|Name: Neurovit Forte tab Dosage: Each tablet contains Vitamin B1 242.5mg, Vitamin B6 250mg, Vitamin B12 1mg Frequency: One tab, once per day Duration: 6 weeks
2965428|NCT02794922|Placebo Comparator|Placebo|Capsule containing 250mg corn starch
2965459|NCT02794740|Placebo Comparator|Placebo Second Dose|2 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
2965429|NCT02794909|Experimental|CPUS group|The group of patients in the CPUS group will be those who receive a cardiopulmonary ultrasound exam in accordance with a specified CPUS scanning protocol in addition to their routine care. Patients will be in this group if their treating physician has received specific training in the CPUS protocol.
2965430|NCT02794909|No Intervention|Control group|The group of patients in the control group will be those who do not receive an ultrasound exam in accordance with a specified CPUS scanning protocol in addition to their routine care. Patients will be in this group if their treating physician has not received specific training in the CPUS protocol.
2965431|NCT02794896|Experimental|Deep Anesthesia|Standard anesthesia with fentanyl, propofol for shoulder surgery together with a interscalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS 45 (group 1, deep anesthesia). Anesthesia depth was measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes below or equal to a BIS level of 45 were counted.
2965432|NCT02794896|Experimental|Shallow Anesthesia|Standard anesthesia with fentanyl, propofol for shoulder surgery together with a inter scalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS ≥ 55 (group 2, shallow anesthesia). Anesthesia depth as measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes above a BIS level of 45 were counted.
2965433|NCT02794883|Active Comparator|Treatment (durvalumab)|Patients receive durvalumab IV over 1 hour on days 1 and 15. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
2965434|NCT02794883|Active Comparator|Treatment (tremelimumab and durvalumab)|Patients receive tremelimumab IV over 1 hour on day 1 then durvalumab IV over 1 hour on days 1 and 15. Courses repeat every 4 weeks for up to 7 courses. Patients then receive both tremelimumab and durvalumab IV over 1 hour every 12 weeks in the absence of disease progression or unacceptable toxicity.
2965435|NCT02794883|Experimental|Treatment (tremelimumab)|Patients receive tremelimumab IV over 1 hour on day 1. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2965436|NCT02794870|Experimental|RSV LID ΔM2-2 1030s vaccine|Participants received a single dose of the RSV LID ΔM2-2 1030s vaccine at study entry (Day 0).
2965437|NCT02794870|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
2965438|NCT02794857|Experimental|NP001|NP001 2 mg/kg by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6
2965439|NCT02794857|Placebo Comparator|Placebo|Normal saline by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6
2965440|NCT02794844|Experimental|Genotype Guided PPI Dosing|"Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.~No other ARM will be studied."
2965441|NCT02794831||patient|Adult patient hospitalized in MCO in one of the study centers for severe community bacterial infection, infected with more than one site, and / or abscess collection, and / or a per-cutaneous drainage of the infection, and / or septic surgery.
2965442|NCT02794831||control|Patient hospitalized in the same center (different service or not), during the week or months of the inclusion of cases for infection without abscess or invasive procedure, only one infected site
2965443|NCT02794818||Participating Patients|Participating patients will receive a prescription for weekly CSA produce boxes with nutritional education
2965444|NCT02794818||Participating Providers|Participating providers will be surveyed at the end of the pilot to evaluate their perceived program efficacy, the benefit of the program to their patients, and elicit program feedback.
2965445|NCT02794805|Experimental|HCC positive|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
2965446|NCT02794805|Experimental|HCC negative|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
2965447|NCT02794792|Active Comparator|Metformin and placebo|Participants will receive daily dosage of Metformin and Placebo as single tablets.
2965448|NCT02794792|Experimental|Metformin and Ipragliflozin|Participants will receive daily dosage of Metformin and Ipragliflozin (2 dose strengths) as single tablets.
2965449|NCT02794792|Other|Metformin, placebo and Ipragliflozin|Participants will receive daily dosage of Metformin, placebo and Ipragliflozin (1 dose strength) as single tablets.
2965450|NCT02794779|Experimental|Rule of three|Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
2965451|NCT02794779|Active Comparator|Continuous infusion|Continuous infusion of variable rate if 0,4 UI of oxytocin until obstetrician determines that uterine tone is adequate.
2965452|NCT02794766|Experimental|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion colony forming units (CFU) per oral each 12 hours for 10 days
2965453|NCT02794766|Active Comparator|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
2965454|NCT02794766|Placebo Comparator|Placebo|Placebo 1 gum per oral each 12 hours, for 10 days
2965455|NCT02794753|Experimental|True intervention|Working memory training on computer 5 weeks 25 sessions (5 sessions per week) 50 minutes per session
2965456|NCT02794753|Active Comparator|Active control|Similar time spent playing on computer 5 weeks 25 sessions (5 sessions per week) 50 minutes per session
2965457|NCT02794740|Experimental|X0002 First Dose|Preliminary Experiment,4 Subjects,Single-Dose,Once,Non-Blind.
2965458|NCT02794740|Experimental|X0002 Second Dose|8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
2965765|NCT02792647|Placebo Comparator|Placebo|Placebo
2965460|NCT02794740|Experimental|X0002 Third Dose|8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
2965461|NCT02794740|Placebo Comparator|Placebo Third Dose|2 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
2965462|NCT02794740|Experimental|X0002 Fourth Dose|8 Subjects,Single Dose,Once,Double-Blind.
2965463|NCT02794740|Placebo Comparator|Placebo Fourth Dose|2 Subjects,Single Dose,Once,Double-Blind.
2965464|NCT02794727|Sham Comparator|Blinded Fitbit|Subjects will wear the physical activity monitor (fitbit) for 12 weeks but will be blinded to the monitor display.
2965465|NCT02794727|Active Comparator|Unblinded Fitbit|Subjects will wear the physical activity monitor (fitbit) for 12 weeks. They will have access to the monitor display and will have consults with study physician to set goals for the duration of the study.
2965466|NCT02794727|No Intervention|No Fitbit|Subjects will not wear any activity monitor for 12 weeks.
2965467|NCT02794714|Experimental|deep neuromuscular blockade|Rocuronium will be administered to achieve PTC 1-2 throughout surgery.
2965468|NCT02794714|Active Comparator|moderate neuromuscular blockade|Rocuronium will be administered to achieve TOFC 2 throughout surgery
2965469|NCT02794701||people with silicosis|
2965470|NCT02794688||Ductal lavage group|The patients will receive ductal lavage therapy every other day for two weeks, and will be followed up for one year.
2965471|NCT02794675|Experimental|Cesium 131 brachytherapy|Cesium 131 is the radioactive isotope in the protocol. The prescribed dose will range from 50-80 Gy at maximal delivery. It comes in 0.5 cm seeds that will be placed in the tumor resection bed at 1cm intervals. They are implantable seeds that do not require removal.
2965472|NCT02794662|Experimental|Oxygen Environment|Blended oxygen delivered by servo-controlled incubator
2965473|NCT02794662|Active Comparator|Nasal cannula oxygen|Blended oxygen delivered by nasal cannula
2965474|NCT02794649||healthy|Individuals without a history of kidney or bowel disease
2965475|NCT02794649||primary hyperoxaluria|Patients diagnosed with type I PH by genetic testing
2965476|NCT02794649||enteric hyperoxaluria|Patients with Roux-en-Y-gastric-bypass.
2965477|NCT02794649||calcium oxalate stone formers|History of passing or having surgically removed a calcium oxalate kidney stone within 5 years of recruitment.
2965478|NCT02794636||IFN Treatment|Adult (age ≥ 18 years) patients identified as having stage III melanoma and no other primary or secondary cancer who initiated treatment with IFN between 1/1/2007 and 12/31/2011. Patients are required to have continuous pharmaceutical benefit enrollment for 180 days before (pre-index) and after (post-index) IFN initiation and no evidence of treatment with systemic chemotherapy during the pre- or post-index period
2965479|NCT02794623|Experimental|Cochlear Implant Recipients|
2965480|NCT02794610|Experimental|Topical tacrolimus|Ten patients will be include. Topical tacrolimus 0.05% will be instilled into the eyes of patients 15 minutes before cataract surgery. Aqueous samples will be collected at the time of cataract surgery and will be subjected to detection of presence and level of tacrolimus.
2965481|NCT02794597|No Intervention|Opioid Medication-Assisted Treatment|Usual care - Opioid Medication Assisted Treatment
2965482|NCT02794597|Experimental|Intervention|Peer led, behavioral sexual health intervention
2965483|NCT02794584|Active Comparator|Off-pump hybrid closure|Hybrid closure is that a periventricular technique uses an occluding device to closure ventricular septal defects of patients through the delivery system by transthoracic minimally invasive small incision without cardiopulmonary bypass.
2965484|NCT02794584|Placebo Comparator|Control|Control group: Conventional closure of ventricular septal defects was aided with cardiopulmonary bypass.
2965485|NCT02794571|Experimental|Phase Ia Dose-Escalation Stage: MTIG7192A|Cohorts of at least 3 participants each will be treated with escalating doses of MTIG7192A to determine the MTD or maximum administered dose (MAD).
2965486|NCT02794571|Experimental|Phase Ia Expansion Stage: MTIG7192A|Approximately 20 to 40 participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of MTIG7192A in different cancer types.
2965487|NCT02794571|Experimental|Phase Ib Dose-Escalation Stage: MTIG7192A+Atezolizumab|Cohorts of at least 3 participants each will be treated with escalating doses of MTIG7192A in combination with a fixed dose of atezolizumab to determine the MTD or MAD.
2965488|NCT02794571|Experimental|Phase Ib Expansion Stage: MTIG7192A+Atezolizumab|At least approximately 160 participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of MTIG7192A in combination with atezolizumab in different cancer types.
2965489|NCT02794545|Experimental|Recent infection patient|The patient who infected with HIV-1 and screened out by P24 ELISA, and they would receives early cART course.
2965490|NCT02794532|No Intervention|Pre oxygenation with 100% oxygen via tight fitting mask|Pre Oxygenation will be done using a tight mask
2965491|NCT02794532|Experimental|Pre oxygenation with 100% oxygen in high-flow nasal cannula|Pre Oxygenation will be done using high-flow nasal canula
2965492|NCT02794519|Experimental|Sirukumab 50 mg/mL administered subcutaneously every 4 weeks|Subjects will receive sirukumab 50 milligram/milliliter (mg/mL) subcutaneously every 4 weeks. They will receive the treatment for minimum of 20 weeks but up to 44 weeks of dosing. Sirukumab will be administered by the trained site staff at Baseline, Weeks 4 and Week 8. From the Week 12 visit onwards, subjects may start to self-administer study drug at the site under the supervision of the trained site staff if they are able and willing to do so. If not, study drug will continue to be administered by the trained site staff.
2965493|NCT02794519|Placebo Comparator|Placebo administered subcutaneously every 4 weeks|Subjects will receive placebo subcutaneously every 4 weeks. They will receive the treatment for minimum of 20 weeks but up to 44 weeks of dosing. Placebo will be administered by the trained site staff at Baseline, Weeks 4 and Week 8. From the Week 12 visit onwards, subjects may start to self-administer study drug at the site under the supervision of the trained site staff if they are able and willing to do so. If not, study drug will continue to be administered by the trained site staff.
2965494|NCT02794506|Experimental|Propolis|400 mg oral proplois (capsule) was given to participants once daily for 6 months after performing scaling and root planing.
2965495|NCT02794506|Placebo Comparator|Placebo|Placebo capsule was given to participants once daily for 6 months after performing scaling and root planing.
2965496|NCT02794493|Experimental|Arm I|Patients receive Traditional Chinese Medicine Formula LC09 by soaking their affected hand and feet 20 min twice daily.
2965497|NCT02794493|Placebo Comparator|Arm II|Patients receive placebo by soaking their affected hand and feet 20 min twice daily.
2965498|NCT02794480|Experimental|Placebo ELLIPTA DPI (QD) in P1 and Placebo AZ MDI (BD) in P2|Eligible subject will receive ELLIPTA DPI taken as one inhalation once daily (QD) for 28 days and Placebo AZ MDI taken as two inhalations twice daily (BD) for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
2965499|NCT02794480|Experimental|Placebo AZ MDI (BD) in P1 and Placebo ELLIPTA DPI (QD) in P2|Eligible subject will receive AZ MDI taken as two inhalations twice daily for 28 days and Placebo ELLIPTA DPI taken as one inhalation once daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
2965500|NCT02794480|Experimental|Placebo ELLIPTA DPI (QD) in P1 and Placebo GSK MDI (BD) in P2|Eligible subject will receive ELLIPTA DPI taken as one inhalation once daily for 28 days and Placebo GSK MDI taken as two inhalations twice daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period.
2965501|NCT02794480|Experimental|Placebo GSK MDI (BD) in P1 and Placebo ELLIPTA DPI (QD) in P2|Eligible subject will receive GSK MDI taken as two inhalations twice daily for 28 days and Placebo ELLIPTA DPI taken as one inhalation once daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
2965502|NCT02794467|Experimental|Epelsiban 75 mg|Approximately 24 subjects will receive 75 mg of epelsiban three times a day (TID) via oral administration
2965503|NCT02794467|Experimental|Epelsiban 200 mg|Approximately 24 subjects will receive 200 mg of epelsiban TID via oral administration
2965504|NCT02794467|Placebo Comparator|Placebo|Approximately 24 subjects will receive a matching placebo TID via oral administration
2965505|NCT02794454|Active Comparator|HeezOn Ultra-1|HeezOn Ultra-1 includes ingredients like Shilajit, Galangal, Fenugreek. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
2965506|NCT02794454|Active Comparator|HeezOn Ultra-2|HeezOn Ultra-2 includes ingredients like Arjuna, Galangal, Fenugreek. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
2965507|NCT02794454|Placebo Comparator|Placebo|Placebo consists of Micro-crystalline Cellulose. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
2965508|NCT02794441|Experimental|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
2965509|NCT02794441|Placebo Comparator|Placebo|Matched oral solution in same volume per kg as dexamethasone
2965510|NCT02794428|Active Comparator|Eflornithine|
2965511|NCT02794428|Placebo Comparator|Eflornithine Placebo|
2965512|NCT02794415|Other|Community-based exercise|
2965513|NCT02794402|Active Comparator|Bydureon|s.c. once Weekly
2965514|NCT02794402|Placebo Comparator|Placebo|s.c. once Weekly
2965515|NCT02794389|Experimental|N-acetyl cysteine|1200mg for 2 days 2400mg for 7 days
2965516|NCT02794389|Placebo Comparator|Placebo|Magnesium stearate capsules
2965517|NCT02794376|Experimental|Immediate Treatment Group|Mindfulness course consisting of six weekly two hour mindfulness sessions plus meditation homework assignments.
2965518|NCT02794376|Other|Delayed Treatment Group|Waiting period plus Mindfulness course consisting of six weekly two hour mindfulness sessions plus meditation homework assignments after the waiting period has finished.
2965519|NCT02794363|Other|Autologous platelet rich plasma|Autologous platelet rich plasma injection into vulvar skin. There are no placebo, sham, or active comparator arms
2965520|NCT02794350||Cohort|
2965521|NCT02794337|Active Comparator|DEB TACE Arm|Patients randomized to drug eluting beads(DEB) TACE arm will undergo 3 cycles of DEB-TACE (100 mg of doxorubicin drug eluting beads which will be repeated after 4-6 weeks. CT/MRI will be repeated prior to each cycle. Sorafenib will be omitted on the day of TACE and will be reinitiated after the TACE procedure. After completing all TACE cycles patients will continue to be on sorafenib till progression, or 12 months whichever is later, or in patients who fail to tolerate it after dose modifications. Hepatobiliary CTCAE will be completed at baseline, at each TACE cycle and subsequently at each follow up. QOL will be evaluated at the same time and also at two months after completing all sessions of TACE (matched time point with completion of SBRT in interventional arm)
2965522|NCT02794337|Experimental|DEB-TACE+SBRT arm|Patients randomized to DEB TACE/SBRT arm will undergo DEB-TACE as in standard arm. SBRT will be initiated 4-6 weeks after last TACE procedure. During this period patients will stop Sorafenib. SBRT once initiated will continue for 2-2.5 weeks. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier, or in patients who fail to tolerate it after dose modifications. QOL will be evaluated at baseline, before each cycle of TACE, 1 month after SBRT and three monthly thereafter. Hepatobiliary CTCAE will be completed at baseline, after each TACE, before SBRT and after completion of SBRT and subsequently at each follow up.
2965523|NCT02794324|Experimental|Voluntary deep-inspiratory breath hold|Stage 1A: Voluntary deep-inspiratory breath hold (v_DIBH) vs Active-breathing-controlled deep-inspiratory breathhold (ABC_DIBH)
2965524|NCT02794324|Active Comparator|Active-breathing-controlled deep-inspiratory breathhold|Stage 1A: Voluntary deep-inspiratory breath hold (v_DIBH) vs Active-breathing-controlled deep-inspiratory breathhold (ABC_DIBH)
2965525|NCT02794324|Active Comparator|Prone treatment|Stage 1B: Optimised supine DIBH vs prone position
2965526|NCT02794298|Experimental|Anodal tDCS|Anodal stimulation during resting state fMRI
2965527|NCT02794298|Experimental|Cathodal tDCS|Cathodal stimulation during resting state fMRI
2965528|NCT02794298|Sham Comparator|sham tDCS|Sham stimulation during resting state fMRI
2965529|NCT02794285|Experimental|Anifrolumab|Anifrolumab
2965530|NCT02794285|Placebo Comparator|Placebo|Placebo
2965531|NCT02794272|Experimental|Anodal tDCS|Anodal stimulation during resting state fMRI
2965532|NCT02794272|Experimental|Cathodal tDCS|Cathodal stimulation during resting state fMRI
2965533|NCT02794272|Sham Comparator|sham tDCS|Sham stimulation during resting state fMRI
2965534|NCT02794259|Experimental|Anodal tDCS|Anodal stimulation during resting state fMRI
2965538|NCT02794233|Experimental|PD patients with implanted DBS|Impedance measurements at different time points.
2965539|NCT02794220|Experimental|CN Electronic cigarette 10 mg|"10 mg strength~- Administration once every hour for a total of 4 hours."
2965540|NCT02794220|Experimental|CN Electronic cigarette 15 mg|"15 mg strength~- Administration once every hour for a total of 4 hours."
2965541|NCT02794220|Active Comparator|Nicorette Inhalator 15 mg|"15 mg strength~- Administration once every hour for a total of 4 hours."
2965542|NCT02794220|Active Comparator|Cigarette|"Subjects will all smoke the same brand.~- Administration once every hour for a total of 4 hours."
2965543|NCT02794207||Participants|One qualitative, semi-structured interview will be conducted. Each interview will last approximately 30-45 minutes and may be audio recorded (if consent is provided). Interviews will consist of several open-ended questions focusing on having the participant reflect upon past experiences with neutropenia management and the impact of the participant's illness and treatment. Several close-ended questions regarding participant's thoughts on potential outcomes will also be included.
2965544|NCT02794207||Caregivers|One qualitative, semi-structured interview will be conducted. Each interview will last approximately 30-45 minutes and may be audio recorded (if consent is provided). Interviews will consist of several open-ended questions focusing on having the participant reflect upon past experiences with neutropenia management and the impact of their child's illness and treatment. Several close-ended questions regarding participant's thoughts on their child's potential outcomes will also be included.
2965545|NCT02794194|No Intervention|Control group|No intervention
2965546|NCT02794194|Experimental|Vibration group|Proprioceptive training on a whole body vibration platform. Participants in the Vibration group trained with a BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).
2965547|NCT02794194|Experimental|Non-vibration group|Proprioceptive training with the BOSU® on the floor. Participants in the Non-Vibration group trained with a BOSU® on the floor.
2965548|NCT02794168|Experimental|VAS203 (Ronopterin)|Intravenous infusion of 17 mg/kg VAS203 over 48 hours, daily dose 8.5 mg/kg
2965549|NCT02794168|Placebo Comparator|Saline|Intravenous infusion of physiological saline over 48 hours
2965550|NCT02794155|Experimental|Test Group|HDV Insulin Lispro subcutaneous, pre-prandial dosing, 26 week treatment period
2965551|NCT02794155|Active Comparator|Control Group|Insulin Lispro subcutaneous, Pre-prandial dosing, 26 week treatment period
2965552|NCT02794142|Experimental|HD patient|
2965553|NCT02794129|Experimental|Bipolar Disorder patients|
2965554|NCT02794129|Experimental|Healthy Controls|
2965555|NCT02794116|Active Comparator|Control group: Sound teeth|"20 first permanent molars sound, that not affected by MIH will be included.~The teeth were treated with conventional sealants to prevent caries lesion"
2965556|NCT02794116|Experimental|Test: Hypomineralized teeth|"20 first permanent molars affected by MIH will be included.~The MIH teeth were treated with a resin sealants."
2965557|NCT02794103|Experimental|Virtual Reality Distraction|The child will visualize and interact with the virtual environment throughout the hydrotherapy session.
2965558|NCT02794090|Active Comparator|Usual care, individual visits|Usual care according to regular treatment routines at the clinic during 18 months. The Child and parent(s) at regular visits to the nurse at the clinic.
2965559|NCT02794090|Active Comparator|Telephone coaching|Intervention: Telephone consultation each months except for summer holidays during 18 months. The treating nurse communicated with one of the parents.
2965560|NCT02794077|Experimental|Cyclophosphamide|Patients receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progression or unacceptable toxicity.
2965561|NCT02794064|Experimental|Tri-modal imaging|Ultrasound and photoacoustic imaging of breast and adjacent lymph nodes. Imaging time: Approximately 30 minutes
2965562|NCT02794051|Experimental|Unified Protocol for Children|Child participants with behavior problems between the ages of 8-12 and their caregivers will participate in a transdiagnostic group therapy protocol.
2965563|NCT02794038|Active Comparator|Soberlink Cellular Device|BAC reading with Soberlink Cellular Device
2965564|NCT02794038|Active Comparator|BACtrack S80 Pro|BAC reading with BACtrack S80 Pro
2965565|NCT02794025|Experimental|esmolol group|patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava.
2965566|NCT02794025|Sham Comparator|control group|Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol.
2965567|NCT02794012||At-Risk Rheumatoid Arthritis subjects|
2965568|NCT02794012||Early Rheumatoid Arthritis subjects|
2965569|NCT02794012||Healthy Controls|
2965570|NCT02794012||Non-Rheumatoid Arthritis Autoimmune Controls|
2965571|NCT02793986|Experimental|dexmedetomidine sedation|Patients received local anesthesia, in this arm, the sedation of patients was achieved with a bolus of dexmedetomidine at 1.0 μg/kg (over a period of 15 to 20 min) and followed by an infusion of dexmedetomidine at 0.2-0.7 μg/kg/h.
2965572|NCT02793986|Experimental|propofol sedation|Patients received local anesthesia, in this arm, the sedation of patients was achieved with a target-controlled infusion (TCI) of propofol, and the effect site concentration was set to 0.8-1.0μg/ml.
2965573|NCT02793973|Active Comparator|80% discrepancy lift height correction|Each participant will be given 80% discrepancy shoe lift height correction through analyzing kinematic performance of center mass of body and will be required to wear the lifts in their shoes when they are walking or standing for 6 month.
2965574|NCT02793973|Experimental|optimal lift height correction|Each participant will be given the optimal shoe lift height correction through analyzing kinematic performance of center mass of body and will be required to wear the lifts in their shoes when they are walking or standing for 6 month.
2965575|NCT02793960|Experimental|Topical BPM31510 3.0% Cream|Patients/ caregiver will apply topical BPM31510 3.0% cream from every other day to twice per week to wounded skin, and every day to a section of intact skin for up to 12 weeks.The area to be covered may not exceed 10% BSA inclusive of intact skin area, and other lesions.
2965599|NCT02793804|No Intervention|Control|All HIV testing and counselling services will be conducted as currently.
2965666|NCT02793323|Placebo Comparator|NSAID|Patients will receive 100 mg (100 ml) IV NSAIDs (Profenid) before induction of anesthesia. Superficial cervical nerve block containing 5 ml placebo will be performed.
2965576|NCT02793947|Experimental|Peri-incisional injection|A 100 cc multimodal analgesic cocktail will be injected into the superficial and deep peri-incisional tissues after the completion of femur fracture fixation/instrumentation while the patient remains under general anesthesia and prior to wound closure. This cocktail includes 400 mg of 0.75% ropivacaine (53.33 mL), 0.6 mg of 1 mg/mL epinephrine (0.6 mL), 5 mg of 0.5 mg/mL morphine sulfate (10 mL), and 36.07 mL 0.9% sodium chloride solution. All infiltrations will be completed with a blunt trochar to minimize the risk of intravascular injection.
2965577|NCT02793947|No Intervention|Control (no injection)|Femur fracture fixation/instrumentation will be completed per the standard of care. No peri-incisional injection will be completed.
2965578|NCT02793934||1st phase|"In the 1st phase of the study the staff of the medical organizations continue to work in the familiar old scheme, but using the set of scales."
2965579|NCT02793934||2nd phase|"In the 2nd phase, medical organizations will start to work on a new model with the implementation of problem-oriented multidisciplinary approach and the use of modern rehabilitation technologies. There is planning to use clearly defined criteria for transfer from stage to stage, developed by the professional community. When doctors will be trained program ICF-reader will have an opportunity to establish a rehabilitation diagnosis on the basis of the ICF, and the option for ICF assessment using rating scales."
2965580|NCT02793921|Experimental|Moderate-intensity aerobic exercise|Participants engage in a supervised 6-month moderate-intensity aerobic exercise intervention.
2965581|NCT02793921|No Intervention|Usual Care|Physical activity neither limited nor withheld. Participants engage in activity in the same manner as if they were not part of an active intervention.
2965582|NCT02793908|Experimental|Pleyris|Subcutaneous progesterone will be administered 25 mg a day from the day following the ovulation for 14 days
2965583|NCT02793908|Active Comparator|Crinone8|Vaginal progesterone will be administered 90 mg a day from the day following the ovulation for 14 days
2965584|NCT02793895|Experimental|Enhanced cardiac rhythm monitoring|Subjects in this group will receive 30 days of continuous cardiac rhythm monitoring with an adhesive monitor. Cardiac rhythm monitoring will begin on the day of randomization. The device that will be used is the Medtronic SEEQ™ mobile cardiac telemetry system. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device.
2965585|NCT02793895|Active Comparator|Usual care|Subjects randomized to the usual care arm will be discharged from hospital without protocol-mandated continuous cardiac rhythm monitoring. Within the first 30 days after randomization, no protocol-mandated cardiac rhythm assessment will be arranged. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device.
2965586|NCT02793869||Total cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
2965587|NCT02793869||Anterior cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
2965588|NCT02793869||Interior cataracts group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
2965589|NCT02793869||Posterior cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
2965590|NCT02793856|Experimental|A - Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 1 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
2965591|NCT02793856|Experimental|B- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
2965592|NCT02793856|Experimental|C- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 4 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
2965593|NCT02793843|Active Comparator|Ondansetron|
2965594|NCT02793843|Experimental|Ondansetron+ dexamethasone|
2965595|NCT02793830|Experimental|Mobile App Group|Participants in the experimental group will receive daily reminders and educational materials from mobile applications.
2965596|NCT02793830|Active Comparator|Control Group|The control group will receive the same educational materials, but no daily reminder.
2965597|NCT02793817|Active Comparator|KPI-121 1.0% Ophthalmic Suspension|dosed BID
2965598|NCT02793817|Placebo Comparator|Vehicle of KPI-121 Ophthalmic Suspension|dosed BID
2965600|NCT02793804|Experimental|HIV Self-Testing|Community-based distribution agents (CBDA), including Voluntary Male Medical Circumcision (VMMC) mobilisers, will deliver OraQuick® HIV Self-Tests (Orasure Technologies, Thailand). The kits will also be available at the health facility.
2965601|NCT02793791|Experimental|Ablation|
2965602|NCT02793791|No Intervention|Observation|
2965603|NCT02793778|Experimental|CROWN|CROWN: A nutritionally based therapy with a high protein content, formulated as a powder. Twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
2965604|NCT02793778|Placebo Comparator|CROWN Placebo|Placebo: An appearance and volume matched formulated powder. Twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
2965605|NCT02793765|Experimental|Docetaxel & Sipuleucel-T|75 mg/m2 docetaxel IV over 1-hour every 21 days x 6 cycles; 28 day rest then Sipuleucel-T IV over 1-hour every 14 days for 3 doses
2965606|NCT02793752||Mitochondrial Activity of Cumulus Cells|One way that cumulus cells influence oocyte competence is via metabolism (Dumesic et al., 2015). Analysis of mitochondria respiration is an established methodology used for evaluation of cell metabolic homeostasis and for diagnosis of different pathologies.
2965607|NCT02793752||Competence to Blastocyst|The percentage of fertilized eggs that develop to the blastocyst stage.
2965608|NCT02793739|Experimental|20 subjects|20 subjects will be enrolled to take part in this study and followed for a period of 12 months. Subjects will receive hyaluronic acid filler injection in the dorsal fingers (2-4 syringes) at the initial visit for volume restoration. If warranted, subjects will receive touch-up of hyaluronic acid at day 14 (1-2 syringes). The investigators expect volume restoration to last 9-12 months.
2965609|NCT02793726||Symptomatic|Patients with pain and or other sign of prothesis failure
2965610|NCT02793726||Asymptomatic|Patients with regular clinical and radiographic evolution of the implant. No pain
2965611|NCT02793687|Experimental|Mexidol|"Sequential therapy with MEXIDOL® as follows: MEXIDOL® (i.v. solution) - 500 mg / day. for 10 days, followed by application MEXIDOL® 1 tablet of 125 mg three times a day (daily dose 375 mg) for 8 weeks.~The use of the study drug is held with basic therapy."
2965612|NCT02793687|Placebo Comparator|Placebo|"Sequential therapy as follows: Placebo (i.v. solution) for 10 days followed by placebo 1 tablet three times a day for 8 weeks.~The use of a placebo is held with basic therapy."
2965613|NCT02793674|Other|Fisher & Paykel high flow nasal cannula|All participants in the study were on one or two high flow nasal cannula (HFNC) delivery systems. All were measured on the Fisher & Paykel HFNC delivery system. The flow rate of the HFNC was adjusted to determine if there exists a change in their effort of breathing.
2965614|NCT02793674|Other|Vapotherm high flow nasal cannula|All participants in the study were on one or two high flow nasal cannula (HFNC) delivery systems. A subgroup was measured on the Vapotherm HFNC delivery system. The flow rate of the HFNC was adjusted to determine if there exists a change in their effort of breathing.
2965615|NCT02793661|Experimental|RenalGuard Arm|In order to prevent patients from acute kidney injury, patients will receive the RenalGuard Therapy delivered by the RenalGuard system from one hour before the cardiovascular intervention to 4 hours after the intervention.
2965616|NCT02793661|Active Comparator|Control Arm|Patient will received standard treatment, as per ESC Guidelines 2014, to prevent from acute kidney injury.
2965617|NCT02793648|Experimental|Treatment|Ascorbic acid 200mg twice a day for twelve weeks Alpha tocopherol 200mg twice a day for twelve weeks
2965618|NCT02793648|Placebo Comparator|Placebo|colloidal Silica 200mg twice a day for twelve weeks
2965619|NCT02793635|Experimental|SCI Patients|"10 subjects with complete or incomplete SCI (> 1 year post-injury) with preserved LE function will be recruited.~No control group"
2965620|NCT02793622|Active Comparator|Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|Women will be given SP (3 full strength tabs, 500 mg/25 mg) every four weeks times during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
2965621|NCT02793622|Active Comparator|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy|Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
2965622|NCT02793609|Other|Outpatient group|After insertion of double balloon induction catheter of labor, women are discharged overnight to home. Intervention is to let patient to go home.
2965623|NCT02793609|Other|Inpatient group|After insertion of double balloon induction catheter of labor, women are observed in the prenatal ward. Intervention is to observe women in the ward.
2965624|NCT02793596|Experimental|Obstetrical patients|Obstetrical patients requiring epidural analgesia for delivery
2965625|NCT02793583|Experimental|TGR-1202 + Ublituximab|TGR-1202 oral daily dose in combination with Ublituximab intravenous administration
2965626|NCT02793583|Experimental|TGR-1202|TGR-1202 oral daily dose
2965627|NCT02793583|Experimental|TGR-1202 + Ublituximab + Bendamustine|TGR-1202 oral daily dose in combination with Ublituximab intravenous administration and Bendamustine intravenous administration
2965628|NCT02793557|Placebo Comparator|Placebo|Intradermal injection of 50 μl solution. One application in SAD part for each dosing occasion. 2 or 3 times weekly for 3 month in MD part.
2965629|NCT02793557|Experimental|FOL-005: Solution 1|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
2965630|NCT02793557|Experimental|FOL-005: Solution 2|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
2965631|NCT02793557|Experimental|FOL-005: Solution 3|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
2965632|NCT02793557|Experimental|FOL-005: Solution 4|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
2965667|NCT02793310|Active Comparator|DMEK|The intervention group will receive cornea transplantation by DMEK
2965633|NCT02793544|Active Comparator|Regimen A (RIC: Flu/Cy/TBI)|"Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2~Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5~Total Body Irradiation (TBI) 200cGy on Day -1~Infusion of non-T-cell depleted bone marrow on Day 0~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
2965634|NCT02793544|Active Comparator|Regimen B 2a (FIC: Bu/Cy)|"Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO)~Cyclophosphamide 50mg/kg/day IV on Days -2,-1~Infusion of non-T-cell depleted bone marrow on Day 0~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
2965635|NCT02793544|Active Comparator|Regimen B 2b (FIC: Bu/Flu)|"Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO)~Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2~Infusion of non-T-cell depleted bone marrow on Day 0~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
2965636|NCT02793544|Active Comparator|Regimen C (FIC: Cy/TBI)|"Cyclophosphamide 50mg/kg/day IV on Days -5,-4~Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1~Infusion of non-T-cell depleted bone marrow on Day 0~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
2965637|NCT02793531|Experimental|Healthy matched controls|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
2965638|NCT02793531|Experimental|Cancer subjects|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
2965639|NCT02793518|Experimental|Bipolar Disorder patients|
2965640|NCT02793518|Experimental|Healthy Controls|
2965641|NCT02793505||Pregnant patient exposed to metformin|Pregnant women seeking counseling by themselves or through their healthcare provider for exposure to metformin (Anatomical Therapeutic Chemical A10BA02) any time during pregnancy (i. e. any time from conception to week 42 after last menstrual period (LMP)).
2965642|NCT02793505||Reference group|Pregnant women seeking counseling by themselves or through their healthcare provider for exposure to any drug not known as a major teratogen or fetotoxicant and different than metformin, insulin or any other hypoglycaemic agent.
2965643|NCT02793492|Experimental|Misago® RX Self-expanding Stent|Eligible participants will undergo stent implantation with the Misago® RX Self-expanding Stent
2965644|NCT02793479||BE|Patients presenting Barrett's Esophagus as a complication of a gastroesophageal reflux disease.
2965645|NCT02793466|Experimental|Durvalumab; MEDI4736|Open label
2965646|NCT02793453|Other|Diseased|Patients suffering of moderate to severe chronic periodontitis
2965647|NCT02793453|Other|Healthy|Healthy Patients not suffering of any periodontal disease a
2965648|NCT02793440|Active Comparator|cortivazol|anti-inflammatory therapy and epidural
2965649|NCT02793440|Experimental|Traction arm|Medical treatment associated with 5 lumbar traction sessions
2965650|NCT02793427|Experimental|Type 1 diabetes|
2965651|NCT02793427|Experimental|control|
2965652|NCT02793414||Malaria patients|
2965653|NCT02793414||Febrile controls|
2965654|NCT02793401|Active Comparator|HILT group|71 of the patients were in the HILT group
2965655|NCT02793401|Active Comparator|US Group|70 of the patients were in the US group.
2965656|NCT02793388|Active Comparator|Supervised primaquine arm|Following standard schizontocidal treatment according to national guidelines and if haemoglobin levels are above 8g/dL and G6PD testing is normal, the patient receives primaquine (0.5mg/kg/day) for 14 days for radical cure. Supervision of primaquine is done on alternate days at home (attended by a home visitor) or at the health centre.
2965657|NCT02793388|Active Comparator|Unsupervised primaquine arm|Following standard schizontocidal treatment according to national guidelines and if haemoglobin levels are above 8g/dL and G6PD testing is normal, the patient receives primaquine (0.5mg/kg/day) for 14 days for radical cure for self administration.
2965658|NCT02793375|Placebo Comparator|Control|Patients receiving placebo preoperatively (blinded)
2965659|NCT02793375|Experimental|Study group|Patients receiving montelukast preoperatively (blinded)
2965660|NCT02793362||Normal subjects without stroke|"subjects who can walk independent without any difficult~subjects without history of CNS or PNS lesion~Modified ranking scale (MRS) <=2~Functional ambulation category (FAC) >=2"
2965661|NCT02793362||Post stroke patients with sarcopenia|Existence of sarcopenia will be determined by DEXA scan where sarcopenia index of male less than 7.40 kg/m2, that of female less than 5. 14 kg/m2 are considered as sarcopenia.
2965662|NCT02793362||Post stroke patients without sarcopenia|Existence of sarcopenia will be determined by DEXA scan where sarcopenia index of male less than 7.40 kg/m2, that of female less than 5. 14 kg/m2 are considered as sarcopenia.
2965663|NCT02793349|Experimental|Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
2965664|NCT02793336||infant cohort|"The study is designed as a continuation of a cohort of infants from 12 to 48 months of age. This follows on from two previous cohorts: STOP MIP, which is a cohort of pregnant women followed up until delivery and the Baby-Cohort study, which enrols babies from mothers in the STOP MIP trial and follows them until their first year of live. When participants of the Baby-cohort Study reach study end, they are offered to participate in this study."
2965665|NCT02793323|Experimental|Superficial cervical block|Patients will receive superficial cervical nerve block in which we inject 5 ml of local anaesthetic mixture. Each 17 ml of the mixture contain: 6 ml lidocaine 2%, 6 ml lidocaine 2% with adrenaline 5 µg/ml, and 5 ml bupivacaine 0.5. Patients will also receive 100 ml IV saline.
2965760|NCT02792686|Experimental|ABX464|50, 100, 150 or 200 mg once a day / Single Administration
2965668|NCT02793310|Active Comparator|DSAEK|The usual care / control group will receive cornea transplantation by DSAEK
2965669|NCT02793297|Experimental|refined wheat crisp bread|refined wheat crisp bread was served as part of a complete standardized breakfast
2965670|NCT02793297|Experimental|sourdough fermented rye crisp bread|Sourdough fermented rye crisp bread was served as part of a complete standardized breakfast
2965671|NCT02793297|Experimental|unfermented rye crisp bread|Unfermented rye crisp bread was served as part of a complete standardized breakfast
2965672|NCT02793284|Experimental|Intervention 18F-DCFPyL PET/CT|18F-DCFPyL PET/CT scan obtained at the time of restaging for biochemical recurrence after primary radiotherapy
2965673|NCT02793271|Active Comparator|PRIME|The behavioral intervention will be the PRIME/mhGAP training. This is standard mental health training for prescribers (primary care workers who can prescribe psychotropic medication, e.g., health assistants) and non-prescribers (primary care workers who cannot prescribe medications, e.g., auxilliary nurse midwives). For prescribers, training includes introduction to psychosocial techniques and mhGAP. For non-prescribers, training includes psychosocial techniques.
2965674|NCT02793271|Experimental|PRIME+RESHAPE|The behavioral intervention will be the PRIME/mhGAP training plus the RESHAPE training adjunct. This is the PRIME training plus social contact component in which mental health service users participate as training co-facilitators. The intended goal of the additional component is to reduce stigma against persons with mental illness.
2965675|NCT02793258|Placebo Comparator|Placebo tDCS|"Subjects will receive 10 30-minutes sessions of sham tDCS, twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
2965676|NCT02793258|Experimental|Active tDCS|"receive 10 30-minutes sessions of two milliamps tDCS, twice a day for 5 consecutive day.~Stimulation will be performed using an tDCS stimulator with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system) The twice daily sessions will be separated by at least 2 hours."
2965677|NCT02793245|Experimental|Studied population|Patients will be questioned about their main characteristics (age, gender, height, weight, smoking), they will also perform a simplified a pulmonary function test (if possible).
2965678|NCT02793232|Experimental|Single Ascending Dose Crossover|Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
2965679|NCT02793232|Experimental|Multiple Ascending Dose|Multiple dose administration to Healthy Subjects in parallel cohorts (PF-06751979).
2965680|NCT02793232|Experimental|Multiple Dose Elderly|Multiple dose administration to Healthy Elderly Subjects (PF-06751979). This cohort is optional.
2965681|NCT02793219|Experimental|Sipuleucel-T then Docetaxel|Sipuleucel-T IV over 1-hour every 14 days for 3 doses; 28 day rest; 75 mg/m2 docetaxel IV over 1-hour every 21 days for 6 cycles
2965682|NCT02793193|Experimental|Probiotic then antibiotic|Participants take probiotic B. longum 1714 for 4 weeks, and then antibiotic Xifaxan ® for another 4 weeks.
2965683|NCT02793193|Experimental|Probiotic then placebo|Participants take probiotic B. longum 1714 for 4 weeks, and then placebo for antibiotic Xifaxan ® for another 4 weeks.
2965684|NCT02793193|Experimental|Antibiotic then placebo|Participants take antibiotic Xifaxan ® for 4 weeks, and then placebo for probiotic B.longum 1714 another 4 weeks.
2965685|NCT02793193|Experimental|Antibiotic then probiotic|Participants take antibiotic Xifaxan ® for 3 weeks, and then wash out by taking placebo for antibiotic Xifaxan ® for 1 week, and then take probiotic B.longum 1714 for another 4 weeks.
2965686|NCT02793193|Placebo Comparator|Placebo then placebo|Participants take placebo for antibiotic Xifaxan ® for 4 weeks, and then placebo for another 4 weeks.
2965687|NCT02793167|No Intervention|Usual care|patients will receive standard clinical care by the doctor in charge.
2965688|NCT02793167|Experimental|AKI alert|an AKI alert will send to the the doctor in charge.Our team of nephrologists would give suggestions if the doctor in charge issue consultation application.
2965689|NCT02793154|Experimental|Part A: Exenatide|Part A is a single arm design and all subjects will receive 10 mcg subcutaneous injection (SC) of exenatide twice daily for 5 days
2965690|NCT02793154|Experimental|Part B: Albiglutide|In Part B, half of the subjects will be randomized to receive albiglutide: On Day 1: Once weekly SC injection at 30 mg for 4 weeks From Week 5, Day 1: Dose will be increased to 50 mg once weekly SC injection for 4 weeks
2965691|NCT02793154|Active Comparator|Part B: Exenatide|"In Part B, half of the subjects will be randomized to receive exenatide: On Day 1: Twice daily SC injection at 5 mcg for 4 weeks.~From Week 5, Day 1: Dose will be uptitrated to 10 mcg twice daily SC injection for 4 weeks"
2965692|NCT02793141||ICU Nosocomial Pneumonia|Nosocomial pneumonia (hospital-acquired pneumonia) with onset in non-intubated ward patients (= or > 48 hours after hospital admission) that due to deterioration are subsequently admitted to ICU or nosocomial pneumonia (hospital-acquired pneumonia) with onset in non-intubated ICU patients (= or >48 hours after hospital admission) or ventilator-associated pneumonia with onset = or > 48 hours after intubation. No intervention will be administered.
2965693|NCT02793128|Experimental|MitoGel™ instillations|The MMC concentration of MitoGel™ to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, maximum dose is 15ml. 6 once weekly intravesical instillations for the ablation treatment.
2965694|NCT02793115|Experimental|Arm 1|Disclosure Letter-RISKS
2965695|NCT02793115|Experimental|Arm 2|Disclosure Letter-BENEFITS
2965696|NCT02793115|Experimental|Arm 3|Disclosure Letter-RISKS AND BENEFITS
2965697|NCT02793115|Experimental|Arm 4|Disclosure Letter-NO RISKS OR BENEFITS
2965698|NCT02793115|Placebo Comparator|Arm 5|Letter-APPOINTMENT REMINDER
2965699|NCT02793102|Experimental|Olfactory workshop + Somesthesia workshop|Olfactory workshop, Twenty odorants. Somesthesia workshop, time for moving the body, Talk Time
2965700|NCT02793102|Experimental|Auditory workshop + Somesthesia workshop|Auditory workshop, Twenty extracts of music tracks. Somesthesia workshop, time for moving the body, Talk Time
2965701|NCT02793089||First quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7).
2965702|NCT02793089||Second quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7).
2965703|NCT02793089||Third quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
2965704|NCT02793089||Fourth quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
2965705|NCT02793076|Experimental|Bollywood Dance|Bollywood dance is a routine that doubles as both physical and mental exercise.
2965706|NCT02793063||BBD Consortium Contact Registrants|Osteogenesis Imperfecta patients who have self-registered at the Brittle Bone Disorders Consortium (BBD) Consortium Contact Registry, a web-based contact registry developed and supported by the Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Consortium (RDCRN), located at the University of South Florida.
2965707|NCT02793050||Trabectedin|Trabectedin give according the market authorization for advanced soft tissue sarcoma
2965708|NCT02793037|Experimental|A proof of concept of using zirconia bonded bridge|
2965709|NCT02793024|Experimental|Arm 1 - Intervention|Counties will be randomized to receive the intervention or act as a delayed control. Students in the intervention arm will receive the 12-week intervention to improve shopping choices.
2965710|NCT02793024|No Intervention|Arm 2 - Intervention|Control adolescents will not receive the intervention and will receive routine information normally distributed through schools.
2965711|NCT02793011|Experimental|Dexamethasone|Liquid or capsule dexamethasone - to be taken orally the evening before scheduled tonsillectomy with or without adenoidectomy
2965712|NCT02793011|Placebo Comparator|Placebo|Placebo liquid or capsule to be taken orally the evening before scheduled tonsillectomy with or without adenoidectomy
2965713|NCT02792998|Experimental|IW-1701|IW-1701 tablets administered orally in multiple ascending dose.
2965714|NCT02792998|Placebo Comparator|Placebo|Matching placebo tablets administered orally.
2965715|NCT02792985|Experimental|Multisensory stimulation protocol|The Experimental group will follow an intervention protocol.
2965716|NCT02792985|Active Comparator|Control protocol|The Control group will follow the current protocol for patients in PTA at the Institut Guttmann.
2965717|NCT02792972|Active Comparator|Acmella oleracea|The plant extract A. oleracea manipulated with Transcutol® were used in the volunteers 3 minutes before the venipuncture
2965718|NCT02792972|Placebo Comparator|alcohol 70%|70% alcohol were used in the volunteers 3 minutes before the venipuncture
2965719|NCT02792959|Experimental|Functional imaging|A pilot study to evaluate the response to neoadjuvant chemotherapy for advanced ovarian cancer by multimodal functional imaging (Fusion MRI and FDG-PET-CT)
2965720|NCT02792946|Experimental|Sulfolase CR (200mg, QD)|for 7 days with or without meal
2965721|NCT02792946|Active Comparator|Sulfolase Capsule (100mg, BID)|for 7 days with or without meal
2965722|NCT02792933|Active Comparator|air in epidural space|When the ALOR epidural localization technique will be used, an intermittent pressure with fast movements will be exerted on the plunger of the syringe while the Tuohy needle will be inserted until loss of resistance was felt.
2965723|NCT02792933|Experimental|saline in epidural space|When the SLOR technique is used, a continuous pressure will be exerted on the plunger of the Tuohy needle until loss of resistance was felt.
2965724|NCT02792920|Other|CoCr-EES|
2965725|NCT02792907|Experimental|Compressive Stockings group|Patients with compressive stockings at the operated foot for 4 weeks
2965726|NCT02792907|No Intervention|No compressive stockings group|Patients with no compressive stockings at the operated foot
2965727|NCT02792894|No Intervention|Enhanced Usual Care (EUC)|Enhanced Usual Care comprises of normal routine visits conducted by the local community health workers / Lady Health Workers (LHWs). Care is enhanced in 2 ways: (a) LHWs in the EUC arm will receive training in identifying children with developmental disorders and delays, as well as making referrals to their primary care physicians for treatment using the WHO mhGAP training program for developmental disorders and (b) The primary care physicians will receive the training in WHO mental health GAP(mhGAP) program developmental disorders module, by WHO Collaborating Center in Rawalpindi, Pakistan.
2965728|NCT02792894|Experimental|Family Networks program|Intervention is administered once weekly over 9-10 weeks in a group format over 3 hours per sessions. Family networks Program (FaNs) is based on WHO mhGAP module for developmental disorders and incorporates WHO Parent Skills Training program for children with developmental disorders and delays. Parents Skills Training Program includes modules on communication, play, daily living skills, managing challenging behavior, coping with stress. Intervention is provided by the family volunteers (members of community, mostly women, who have a child affected in their families).
2965729|NCT02792881|Experimental|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group
2965730|NCT02792868||patient|patient with cardiovascular risk (moderate)
2965731|NCT02792855|Experimental|snifﬁng Position|Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
2965732|NCT02792855|Experimental|Simple Head Extension|Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
2965733|NCT02792842|Experimental|ART-123 (High Frequency)|
2965734|NCT02792842|Experimental|ART-123 (Low Frequency)|
2965735|NCT02792842|Placebo Comparator|Placebo|
2965761|NCT02792673|Active Comparator|"Embryo Glue®"|Hyaluronan-enriched medium
2965762|NCT02792673|Active Comparator|"Global Total®"|30% Protein-supplemented Culture Medium
2965736|NCT02792829|Experimental|Lenvatinib 11 mg (suspension formulation)|"Arm 1 will have 2 sequences:~Sequence 1 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg)~Sequence 2 - Treatment Period 1: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg)"
2965737|NCT02792829|Experimental|Lenvatinib 11 mg (2 vs 5 capsules)|"Arm 2 will have 4 sequences:~Sequence 3 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg) WATER; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg) APPLE JUICE~Sequence 4 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER~Sequence 5 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE~Sequence 6 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) WATER"
2965738|NCT02792829|Experimental|Lenvatinib 23 mg|"Arm 3 will have 2 sequences:~Sequence 7 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation~Sequence 8 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation"
2965739|NCT02792816||Kawthaung Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Kawthaung is one of the sentinel site and located at the Southern Myanmar.
2965740|NCT02792816||Myawaddy Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Myawaddy is one of the sentinel site and located at the northern part of the Southern Myanmar.
2965741|NCT02792816||Thanbyuzayat Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Thanbyuzayat is one of the sentinel site and located at the northern part of the Southern Myanmar.
2965742|NCT02792816||Shwegyin Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Shwegyin is one of the sentinel site and located at the southern part of the central Myanmar.
2965743|NCT02792816||Magway Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Magway is one of the sentinel site and located at the middle part of the central Myanmar.
2965744|NCT02792816||Rakhine Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Rakhine is one of the sentinel site and located at the western Myanmar.
2965745|NCT02792803|Experimental|Xalatan --> Apo-/Co-Latanoprost|Patients in this arm will be prescribed Xalatan for the first four week period of the study and one of the generics, Apo- or Co-Latanoprost, for the second four week period. Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)
2965746|NCT02792803|Experimental|Apo-/Co-Latanoprost --> Xalatan|Patients in this arm will be prescribed one of the generics, Apo- or Co-Latanoprost, for the first four week period of the study and Xalatan for the second four week period. Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)
2965747|NCT02792790||Patients with carpal tunnel syndrome.|Patients undergoing carpal tunnel release surgery.
2965748|NCT02792777||Interviews|Interview participants will be recruited from 3 different care settings: an acute care visit (in the emergency department), a post-acute care visit (within 1 week of a hospital discharge), and a routine primary care visit. Target sample size within each healthcare setting is 30 patients, which is the anticipated number needed for thematic saturation. The total recruitment goal for this cohort is 90-120 participants.
2965749|NCT02792777||Concept Mapping|Concept mapping participants will be recruited from existing clinical and research databases for 3 separate concept mapping groups, each with a target of 20 patients. The total recruitment goal for this cohort is 60 people.
2965750|NCT02792764||Port|Subjects receiving chemotherapy through a port
2965751|NCT02792764||Peripheral Intravenous (PIV) Lines|Subjects receiving chemotherapy through a peripheral IV
2965752|NCT02792751|Active Comparator|Group R (Ramsey)=25 patients|Propofol infusion was administered to provide Ramsey Sedation Scale 3-4 in Group R
2965753|NCT02792751|Experimental|Group B (BIS)=25 patients|Propofol infusion was given to maintain the Bispectral index monitorisation (BIS) levels between 60 and 85 in Group B.
2965754|NCT02792738|Experimental|hypnosis, visual distraction|"This is a crossover study in which each subject will be exposed to a 5 min phase of hypnotic suggestion and visual distraction.~For hypnotic suggestion, subject will be invited to experience a pleasant memory . Indirect and permissive suggestion will be used.~For visual distraction, subject will be watching the movie la marche des empereurs"
2965755|NCT02792712|Experimental|STEMI_MRI_Ticagrelor|A Magnetic Resonance Imaging Study in myocardial salvage in patients with ST-Elevation myocardial infarction (STEMI) undergoing pRimary percutaneous coronary intervention - Ticagrelor Arm
2965756|NCT02792712|Active Comparator|STEMI_MRI_Clopidogrel|A Magnetic Resonance Imaging Study in myocardial salvage in patients with ST-Elevation myocardial infarction (STEMI) undergoing pRimary percutaneous coronary intervention - Clopidogrel Arm
2965757|NCT02792699|Experimental|ABP 798|Concentrate for solution, ABP 798 IV infusion x 2 at baseline and repeat at week 24.
2965758|NCT02792699|Active Comparator|Rituximab (US)|Concentrate for solution, Rituxan IV infusion x 2 at baseline and repeat at week 24.
2965759|NCT02792699|Active Comparator|Rituximab (EU)|Concentrate for solution, MabThera IV infusion x 2 at baseline and repeat at week 24.
2965766|NCT02792647|Experimental|Experimental: IX-01|2 different dose groups 1,600 mg and 2,400 mg of IX-01 oral aqueous dispersion, administered once daily for 10 days
2965767|NCT02792621|Experimental|active oral supplement|The active supplement will contain the prescription drug Acipimox (250 mgs) , a nicotinic acid precursor traditionally used to lower blood lipid levels. The supplement will be administered 3 times per day, for a 14 day period.
2965768|NCT02792621|Placebo Comparator|placebo supplement|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
2965769|NCT02792608|Experimental|Mindfulness-based Therapy|5 week, manual-based group MBI treatment for depression
2965770|NCT02792595|Sham Comparator|Negative Control|Untreated area will be irradiated using a sun simulator with UV irradiation increment of 1.25 to detect MED of the unprotected skin.
2965771|NCT02792595|Active Comparator|Positive Control|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, positive control will be applied. The dose of positive control will be measured in accordance to the application volume (2 milligram (mg)/centimeter (cm)^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Positive control will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 seconds (s). After waiting for 15 to 30 minutes (min), the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the SPF of positive control, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2965772|NCT02792595|Experimental|Test Product A|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2965773|NCT02792595|Experimental|Test Product B|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2965774|NCT02792595|Experimental|Test Product C|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2965775|NCT02792595|Experimental|Test Product D|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2965776|NCT02792595|Experimental|Test Product E|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2965777|NCT02792595|Experimental|Test Product F|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2966687|NCT02786251|Other|BAT+|Individuals with significant amounts of BAT ( > 20 ml)
2965778|NCT02792595|Experimental|Test Product G|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2965779|NCT02792595|Experimental|Test Product H|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2965780|NCT02792582|Active Comparator|Tumor-Surgery|"Participants who are eligible to undergo surgery to remove the tumor will proceed to surgery. If all tumor is removed, they will be followed over 5 years for outcome comparison to the other participant groups.~If the entire tumor is not removed by surgery, participants will receive 6 weeks of proton therapy. They will then be followed for 5 years to collect outcome data for comparison to the other participant groups."
2965781|NCT02792582|Active Comparator|Tumor-No Surgery|Participants whose tumor cannot be resected through surgery will receive 6 weeks of proton therapy. They will then be followed over 5 years for outcome comparison to the other participant groups.
2965782|NCT02792569|Experimental|Biopsy at Right side|Biopsy of ovarian cortical tissue (50% right side)
2965783|NCT02792569|Experimental|Biopsy at Left side|Biopsy of ovarian cortical tissue (50% left side)
2965784|NCT02792556||patient having a drug abortion|Urine pregnancy test for adult women having a drug abortion until 8 weeks of amenorrhea, presenting to the control visit between the 14th and 21th day after drug intake.
2965785|NCT02792543|Active Comparator|parenteral nutrition|Parenteral nutrition consists of electrolyte supplementation, hydration, and nutrition through a central venous catheter.
2965786|NCT02792543|Experimental|chyme reinfusion|Chyme reinfusion consists of continuously reinfusing the chyme collected from the proximal small bowel segment via the enterostomy, and into the diverted distal small bowel segment. It implies the use of the Entéromate™ pump.
2965787|NCT02792530|Other|arm 1|Unuric hemodialytic patients who accumulate above 2.5 (4%) in intradialytic intervals before the nutritional intervention.
2965788|NCT02792517|Experimental|AMG 334 + Estrogen/Progestin|
2965789|NCT02792491|Experimental|Reduced dose R-CHOP|"Reduced dose R-CHOP is regimen including Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.~In this study, Rituximab 375 mg/m2, Cyclophosphamide 600 mg/m2, Doxorubicin 30 mg/m2 and Vincristine fixed dose of 1mg will be administrated through intravenous on day 1. and Prednisone 40mg will be administrated orally on day 1-5. This chemotherapy will be repeated every 21 days."
2965790|NCT02792478||RAS wild-type subjects|The blood samples will be collected according to the site's routine clinical practice usually prior to each treatment cycle and at the follow-up visits. Analysis of the RAS mutation status will be carried out on blood samples taken at baseline, on those carried out at 20 +/-2 weeks after the start of treatment (in any case, prior to the second tumour assessment) and on the sample obtained upon progression, coinciding with routine clinical practices for collecting blood. Blood Samples will be collected to all subjects participating (119 subjects) Objective is To evaluate the RAS mutation status at baseline in liquid biopsies in subjects with RAS wild-type metastatic colorectal cancer
2965791|NCT02792465|Experimental|CFI-402257|CFI-402257 capsules will be taken orally, once a day, every day.
2965792|NCT02792426|Active Comparator|Group 1 AB|Smoker subject's own brand of combustion cigarette
2965793|NCT02792426|Active Comparator|Group 1 BA|Smoker subject's own brand of combustion cigarette
2965794|NCT02792426|Active Comparator|Group 2|E-cigarette user's own brand of electronic nicotine delivery system (ENDS)
2965795|NCT02792413|Experimental|Denosumab|Denosumab 60 mg, subcutaneous injection every 6 months for 24 months
2965796|NCT02792413|Placebo Comparator|Placebo|NaCl 0.9% (1 mL), subcutaneous injection every 6 months for 24 months
2965797|NCT02792400|Placebo Comparator|A1: GRA-placebo + MEAL + DPP4-placebo|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + linagliptin placebo
2965798|NCT02792400|Placebo Comparator|A2: GRA-active + MEAL + DPP4-placebo|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + linagliptin placebo
2965799|NCT02792400|Active Comparator|A3: GRA-placebo + MEAL + DPP4-active|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + 5 mg linagliptin (Trajenta)
2965800|NCT02792400|Active Comparator|A4: GRA-active + MEAL + DPP4-active|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + 5 mg linagliptin (Trajenta)
2965801|NCT02792400|Placebo Comparator|B1: GRA-placebo + MEAL + SGLT2-placebo|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + empagliflozin placebo
2965802|NCT02792400|Placebo Comparator|B2: GRA-active + MEAL + SGLT2-placebo|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + empagliflozin placebo
2965803|NCT02792400|Active Comparator|B3: GRA-placebo + MEAL + SGLT2-active|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + 25 mg empagliflozin (Jardiance)
2965804|NCT02792400|Active Comparator|B4: GRA-active + MEAL + SGLT2-active|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + 25 mg empagliflozin (Jardiance)
2965805|NCT02792374||Dental patients group|Psychological measurement is done when they refer to a dental clinic.
2965806|NCT02792374||Control group|Psychological measurement is done when they refer to a dental clinic.
2965807|NCT02792361|No Intervention|Control Group|Subjects who did not have a suction drain placed post-operatively following a Pterional Craniotomy.
2965808|NCT02792361|Experimental|Treatment Group|Subjects who did have a suction drain placed post-operatively following a Pterional Craniotomy at the location of surgical incision.
2965809|NCT02792348||children with congenital urine flow impairment|this group contain children with an unilateral urinary tract dilatation diagnosed by prenatal ultrasonography
2965810|NCT02792348||control group|this group contains children, between 1 and 3 months of age, without nephrological or urological anomaly
2965811|NCT02792335||patients naive to oral anticoagulant treatment|NVAF patients naïve to oral anticoagulant treatment (Naïve)
2965812|NCT02792335||patients with prior warfarin therapy|NVAF patients with prior warfarin therapy (Warfarin treated)
2965813|NCT02792322|Other|Trans Oral Robotic Surgery (TORS)|Patient's are having TORS surgery in a seated position
2965814|NCT02792309|Experimental|MotherWise Programming|Three components: (1) 18 hours of core workshop sessions using the Within My Reach relationship education curriculum supplemented with content on mother-infant relationships; (2) case management services; and (3) optional relationship education workshops for couples.
2965815|NCT02792309|No Intervention|Control|No program services
2965816|NCT02792296|Experimental|Daily measurement|This arm will be asked to use the Project: EVO Monitor once a day for four weeks..
2965817|NCT02792296|Experimental|Multiple times per day measurement|This arm will be asked to use the Project: EVO Monitor at least once per day and six times over the day every three days for four weeks.
2965818|NCT02792296|Experimental|Weekly measurement|This arm will be asked to use the Project: EVO Monitor once a week for eight weeks.
2965819|NCT02792283|Experimental|patients undergoing hemodialysis|
2965820|NCT02792270|Experimental|Caloric Restriction Diet|"Patients will meet with the Registered Dietitian to discuss calorie, protein and fluid needs.The dietitian will calculate calorie needs.~Calorie needs will then be reduced to 30%.~Protein needs will be estimated based on 0.8g/kg BW and then reduced by 70%.~Dietitian will educate participants on electrolytes and fluid intake based on the reduced food intake."
2965821|NCT02792270|No Intervention|Normal Diet|Participant will follow a normal diet.
2965822|NCT02792257|Experimental|Dronabinol|Study medication will be administered twice daily. Capsules of dronabinol will contain 2.5 mg per dose (5mg daily) during Week 1, then increase to 5 mg per dose (10mg daily) for Weeks 2 and 3.
2965823|NCT02792257|Placebo Comparator|Placebo|Placebo medication will be administered twice daily.
2965824|NCT02792231|Experimental|Ofatumumab|"Syringes for subcutaneous injection~Patients will also take a placebo capsule (matching in appearance to teriflunomide)"
2965825|NCT02792231|Active Comparator|Teriflunomide|"Oral capsule~Patients will also take subcutaneous injections of placebo (syringes matching in appearance to ofatumumab)"
2965826|NCT02792218|Experimental|Ofatumumab|"Syringes for subcutaneous injection~Patients will also take a placebo capsules (matching in appearance to teriflunomide)"
2965827|NCT02792218|Active Comparator|Teriflunomide|"Oral capsule~Patients will also take subcutaneous injections of placebo (syringes matching in appearance to ofatumumab)"
2965828|NCT02792192|Experimental|Cohort 1A: Atezolizumab (BCG-unresponsive NMIBC)|Participants will receive atezolizumab 1200 mg IV infusion q3w, for a maximum of 32 doses or 96 weeks of therapy, whichever comes first.
2965829|NCT02792192|Experimental|Cohort 1B: Atezolizumab + BCG (BCG-unresponsive NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. Optional BCG maintenance courses 2−5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
2965830|NCT02792192|Experimental|Cohort 2: Atezolizumab + BCG (BCG-relapsing NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. During BCG maintenance courses 2−5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
2965831|NCT02792192|Experimental|Cohort 3: Atezolizumab + BCG (BCG-naive NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. During BCG maintenance courses 2−5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
2965832|NCT02792179|Experimental|[18F]RO6958948|Each participant will receive a single intravenous (IV) dose of [18F]RO6958948 and a single PET scan approximately 9-24 months after the baseline scan (in Study BP29409).
2965833|NCT02792166|Active Comparator|BPD-DS|BPD-DS involves creating a sleeve gastrectomy and creation of a Roux-en-Y bypass involving a Roux limb (150cm) which is anastomosed to the transected first-stage of the duodenum and a short common channel (100cm).
2965834|NCT02792166|Experimental|SADI-S|SADI-S involves creating a sleeve gastrectomy but simplifies the bypass part of the BPD-DS by a single anastomosis of a loop of jejunum at 250cm from the ileocecal valve (longer common channel) to the transected first-stage of the duodenum instead of the Roux-en-Y construct.
2965835|NCT02792153|Experimental|Estrogen|AN participants receive a course of transdermal estradiol treatment.
2965836|NCT02792140|No Intervention|Baseline|reporting of dreams
2965837|NCT02792140|Experimental|Naltrexone|daily administration of 50mg Naltrexone, reporting of dreams
2965838|NCT02792140|Placebo Comparator|Placebo|daily administration of Placebo, reporting of dreams
2965839|NCT02792127|Experimental|Experimental|These participants will be given access to a six-month online program for social anxiety.
2965840|NCT02792127|No Intervention|Wait List Control|These participants will not be given an intervention until after they have completed the study.
2965841|NCT02792114|Experimental|T-cell infusion|A single blood volume leukapheresis for harvesting of PBMCs will be performed, As the transduced T cells will be frozen, the timing of leukapheresis is not defined & can vary from patient to patient. Subsequently, a single dose of mesothelin-targeted T cells will be infused via intravenous catheter or central line (i.e., mediport). Patients will be monitored in the hospital and discharged home after a minimum of 48 hours. Patients will be monitored closely as outpatients for the next 2 months. Patients will be followed weekly as outpatients for the first 8 weeks after treatment. All patients will be hydrated intravenously, premedicated with acetaminophen & diphenhydramine, & administered cyclophosphamide at 1.5 g/m2 2 to 7 days (Day -7 to Day -2) before administration of mesothelin-targeted T cells.
2965842|NCT02792088|Experimental|Besifovir|Besifovir 150 mg q.d.
2965843|NCT02792088|Active Comparator|Tenofovir|Tenofovir 300 mg q.d.
2965844|NCT02792075||VH-IVUS|Patients with IVUS-derived virtual histology
2965845|NCT02792075||OCT|Patients with Optical coherence tomography
2965846|NCT02792075||NIRS|Patients with Near-infrared spectroscopy
2965847|NCT02792075||gray scale IVUS|Patients with gray-scale IVUS(Intravascular ultrasound)
2965848|NCT02792062|Experimental|TAK-385 40 mg (Group A)|A single oral dose of TAK-385 40 milligram (mg) (one tablet) in fasted condition without breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 3.
2965849|NCT02792062|Experimental|TAK-385 40 mg (Group B)|A single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 3.
2965850|NCT02792062|Experimental|TAK-385 40 mg (Group C)|A single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 3.
2965851|NCT02792062|Experimental|TAK-385 40 mg (Group D)|A single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 3.
2965852|NCT02792062|Experimental|TAK-385 40 mg (Group E)|A single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 3.
2965853|NCT02792062|Experimental|TAK-385 40 mg (Group F)|A single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 3.
2965854|NCT02792049|Experimental|Modified Ambu Spur II bag valve mask|A health volunteer uses a modified Ambu Spur II bag valve mask with integrated internal handle (experimental device, not yet FDA approved) to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model).
2965855|NCT02792049|Active Comparator|Conventional Ambu Spur II bag valve mask|A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model).
2965856|NCT02792036|Experimental|Treatment|"Participants with retinoblastoma that is refractory or has relapsed inside the eye.~Interventions: Carboplatin, Maxitrol® , focal therapy, plaque radiotherapy."
2965857|NCT02792023|Other|Colonoscopy followed by upper endoscopy|In case of a positive immunochemical fecal occult blood test result, colonoscopy will be the first examination
2965858|NCT02792023|Other|Upper endoscopy followed by colonoscopy|In case of a negative immunochemical fecal occult blood test result, upper endoscopy will be the first examination
2965859|NCT02792010|Experimental|T1rho MRI|Patients included had hip cartilage MRI with acquisition of T1rho MRI sequence.
2965860|NCT02791997|Experimental|Brain-damaged patients|
2965861|NCT02791997|Experimental|Control participants|
2965862|NCT02791997|Experimental|Migraine patients|
2965863|NCT02791984|Experimental|Fluid challenge with 250 ml of Ringer Lactate|
2965864|NCT02791971|Experimental|SpeakOut Intervention|"Primary participants will be randomized to this arm or the Alcohol Control Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the SpeakOut intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will not receive intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
2965865|NCT02791971|Active Comparator|Alcohol Control Intervention|"Primary participants will be randomized to this arm or the SpeakOut Intervention Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the Alcohol Control Intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will receive an intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
2965866|NCT02791958|Experimental|CV Fixed Dose Combination Pill AAR|Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg).
2965867|NCT02791958|Active Comparator|Atorvastatin|Atorvastatin 40 mg (Lipitor®).
2965868|NCT02791958|Active Comparator|Ramipril|Ramipril 10 mg (Altace®).
2965869|NCT02791945|Experimental|N-acetylcysteine|N-acetylcysteine capsules daily - up to 3200 mg
2965870|NCT02791945|Placebo Comparator|Placebo|Placebo capsules daily - up to 3200 mg
2965871|NCT02791932|Experimental|Exercise|The intervention will last 8-10 months depending on when during pregnancy the participant is randomized. The intervention will consist of three components (i.e., telephone, print materials, and exercise log/goal setting) designed to increase exercise. Social Cognitive Theory (SCT) and Self-Determination Theory will guide the exercise intervention. The counseling sessions will be a collaboration between the counselor and participants on how to best integrate exercise into the participant's daily routine. Participants will receive 15 intervention phone calls lasting approximately 15-20 minutes each. There will be a one-month intensive phase (weekly contacts), followed by bi-weekly contacts for two months, and then monthly until delivery. Beginning at 6 weeks postpartum, bi-weekly contacts will resume through 3 months postpartum.
2965872|NCT02791932|No Intervention|Usual Care|Participants in the usual care condition will follow their usual standard of care as suggested by their healthcare provider. Participants will complete the same assessments and incentives as the active interventions but will not receive the exercise counseling sessions. Following completion of the nine-month follow-up, the usual care arm can choose to receive a six-month version of the exercise intervention.
2965873|NCT02791919|Experimental|Treatment (AZD1775, FLAG chemotherapy)|Patients receive filgrastim IV or SC daily, fludarabine intravenously IV over 30 minutes, cytarabine IV over 1-3 hours and wee1 kinase inhibitor AZD1775 PO on days 1-5. Patients who meet criteria for CR, CRp or PR may receive a second course of therapy. Courses repeat every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2965874|NCT02791906|Experimental|ISMN Only|Patients receive only ISMN
2965875|NCT02791906|Experimental|ISMN AND Vitamin C|Patients receive both ISMN and Vitamin C
2965876|NCT02791893|Experimental|VNS device|Vagus Nerve Stimulation (VNS) hand held device - subjects to utilize the VNS hand held device for 20 weeks total, putting it on the skin overlying the vagus nerve in their neck and then turning it on for 120 second periods three times a day. The device is programmed to deliver only 6 bouts of stimulation per day - one to each side of the neck three times a day
2965877|NCT02791893|Placebo Comparator|Inactive device|Inactive hand held device - subjects to utilize the inactive device for 10 weeks and then will receive the VNS device for the next 10 weeks.
2965878|NCT02791880||TAVR patients|The group of interest is the patient population with aortic stenosis who are undergoing transcatheter aortic valve replacement (TAVR)
2965879|NCT02791867|Active Comparator|Active|AphoelineBrake administration
2965880|NCT02791867|Placebo Comparator|Placebo|Placebo Administration
2965881|NCT02791854||Registry participant|This is a registry study, the same information is collected from all participants.
2965882|NCT02791841|Experimental|RRT|Rhythmic Reading Training, administered for 13 hours over 9 days (two 45-minute training sessions per day).
2965883|NCT02791841|Experimental|VHSS+AVG|Visual Hemispheric-Specific Stimulation + Action Video Games, administered for 13 hours over 9 days (two 45-minute training sessions per day).
2965884|NCT02791841|Experimental|AVG|Action Video Games only, administered for 13 hours over 9 days (two 45-minute training sessions per day).
2965885|NCT02791815|Experimental|Sequence AB|Subjects participate in two study periods: During the first period, they receive a single oral dose of midazolam on Day 1. During the second period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. There is a washout period of 14 to 21 days between the two periods.
2965886|NCT02791815|Experimental|Sequence BA|Subjects participate in two study periods: During the first period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. During the second period, they receive a single oral dose of midazolam on Day 1. There is a washout period of 14 to 21 days between the two periods.
2965887|NCT02791802||Group A: Lipoprotein apheresis subjects|All subjects must have used established lipid lowering therapies for at least 24 months at time of screening. A stable and maximum tolerated statin therapy has to be used for a minimum of 12 months prior to enrolment. Additional lipoprotein apheresis is established following enrolment using the following established systems: Dextran-sulfate adsorption (DSA) from plasma and whole blood, Heparin-induced LDL precipitation apheresis (HELP®), Polyacrylate adsorption from whole blood and simple DFPP (DALI® and Monet®), ApoB100-immunoadsorption (TheraSorbLDL®, Temperature-optimized double filtration plasmapheresis (DFPP).
2965888|NCT02791802||Group B: Control group|All subjects must have used established lipid lowering therapies for at least 24 months at time of screening. A stable and maximum tolerated statin therapy has to be used for a minimum of 12 months prior to enrolment. The control group will not undergo a sham apheresis procedure. It is an open trial.
2965889|NCT02791789|Other|Autism Spectrum Disorder|clinical exam, speech and language therapy and neuropsychological evaluations, Training to the SEMATIC serious game
2965890|NCT02791776|Other|Scoliosis|"self-administered questionnaire (SRS 30) to assess the state of health and disability of patients.~collection of patient's radiographic and clinical parameters"
2965891|NCT02791763|Experimental|Cohort 1 (ND): GSK1278863 group|Eligible ND subjects will take one to four tablets with water once daily according to the dose level indicated at each study visit. Subjects will start oral treatment with GSK1278863 at the starting dose of 4 milligram (mg) once daily (Day 1) and remain on the same regimen until Week 4. Dose changes will be made every 4 weeks, from Weeks 4 to 52.
2965892|NCT02791763|Active Comparator|Cohort 1 (ND): Epoetin beta pegol group|Eligible ND subjects will receive epoetin beta pegol subcutaneously once every 2 or 4 weeks at the site. Dose changes will be made every 4 weeks
2965893|NCT02791763|Experimental|Cohort 2 (PD): GSK1278863 group|Eligible PD subjects will receive GSK1278863 at the starting dose of 4 mg once daily (Day 1) and remain on the same regimen until Week 4. Dose changes will be made every 4 weeks, from Weeks 4 to 52.
2965955|NCT02791334|Experimental|LY3300054 + Merestinib (Pancreatic Cancer) Expansion|LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle.
2965894|NCT02791763|Experimental|Cohort 3 (ND): GSK1278863 Group|ESA non-users with Baseline Hgb >=8.0 g/dL and <9.0 g/dL and ESA users will start oral treatment with GSK1278863 at the starting dose of 4 mg once daily on Day 1 and remain on the same regimen until Week 4. ESA non-users with Baseline Hgb >=9.0 g/dL and <11.0 g/dL will start oral treatment with GSK1278863 at the starting dose of 2 mg once daily (Day 1) and remain on the same regimen until Week 4. If the subject has an Hgb increase of >1.0 g/dL at Week 2, the dose of GSK1278863 will be reduced by one step or treatment will be interrupted.
2965895|NCT02791763|Active Comparator|Cohort 3 (ND): Epoetin beta pegol group|Eligible ND subjects will receive epoetin beta pegol subcutaneously once every 2 or 4 weeks. Dose changes will be made every 4 weeks. If the subject has an Hgb increase of >1.0 g/dL at Week 2, the dose of epoetin beta pegol will be reduced by one step or treatment will be interrupted.
2965896|NCT02791750||Observational|Patients followed for a medical consultation in the Institut de Cancérologie de Lorraine at 5 years of the beginning of an adjuvant hormonal therapy.
2965897|NCT02791737|Experimental|Supportive care (otago exercise programme)|Patients attend 8 physical therapy visits twice monthly for 4 months or until transplant. Patients also undergo an individualized exercise program at home for 6 months. The program comprises 3 main components: walking over 30 minutes twice a week, strengthening and balance retraining exercise over 30 minutes three times a week.
2965898|NCT02791724|Experimental|Desiconnect|Desiconnect is an Internet-administered intervention developed for persons with epilepsy and elevated depression symptoms.
2965899|NCT02791724|Active Comparator|Care-as-Usual (CAU) / wait list|In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Desiconnect three months post-baseline (i.e., wait list with respect to Desiconnect access).
2965900|NCT02791711|Other|High Flow Nasal Cannula|Use of High Flow Nasal Cannula
2965901|NCT02791685|Experimental|Cardiac Rehabilitation - Movn Program|Participants with coronary artery disease (CAD) and chronic obstructive pulmonary disease (COPD) who are eligible for cardiac rehabilitation will undergo an in-home program.
2965902|NCT02791685|Experimental|Pulmonary Rehabilitation - Movn Program|Participants with stable chronic obstructive pulmonary disease (COPD) or hospitalized with an acute exacerbation of COPD will undergo an in-home pulmonary rehabilitation program.
2965903|NCT02791685|Active Comparator|Traditional Cardiac Rehabilitation|Participants enrolled in a facility's traditional cardiac rehabilitation program will be seen at baseline and during a 12 and 24 week follow-up visit.
2965904|NCT02791672||Same Day Discharge|Following a Latissimus Dorsi flap reconstruction patients will be offered discharge at 24 hours. Patients successfully discharged within 24 hours of their surgery will be included in the cohort group.
2965905|NCT02791659|Active Comparator|Left lateral decubitus|In this group, the position will be assigned to Left lateral decubitus during ERCP. The radiation from fluoroscopy will be adjusted by automatic beam adjustment function to obtain the image quality.
2965906|NCT02791659|Experimental|Prone|In this group, the position will be assigned to Prone during ERCP. The radiation from fluoroscopy will be adjusted by automatic beam adjustment function to obtain the image quality.
2965907|NCT02791646|Experimental|PCST-Full|PCST-full will consist of a 5-session intervention delivered to participants at the medical center by their therapist.
2965908|NCT02791646|Experimental|PCST-Brief|Pain coping skills training brief (PCST-Brief) will consist of a 60 minute, in-person session followed by 4-weeks of daily text messaging
2965909|NCT02791620|Experimental|A nanofractional radiofrequency device|
2965910|NCT02791581||Observational Non-Anthracycline|"Breast cancer patients receiving non-anthracycline chemotherapy~Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, on 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.~Measurements will be repeated at 3±1, 12±2 (after the completion of radiation) and 24±2 months after initiation of Adj-C."
2965911|NCT02791581||Anthracycline Observational - Data Collection|"Breast cancer patients receiving anthracycline chemotherapy~Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.~Measurements will be repeated at 3±1, 12±2 (after the completion of radiation) and 24±2 months after initiation of Adj-C."
2965912|NCT02791581||Non-Cancer Observational - Assessments|"Non-Cancer Controls~Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.~Measurements will be repeated at 3±1, 12±2 (after the completion of radiation) and 24±2 months after initiation of Adj-C."
2965913|NCT02791568||Pilot Study|"Ultrasound Scan~MRI Scan~Blood/Urine collection"
2965914|NCT02791568||Main Study- Control Group|"Ultrasound Scan~MRI Scan~Blood/Urine collection"
2965915|NCT02791568||Main Study- Study Group|"Ultrasound Scan~MRI Scan~Blood/Urine collection"
2965916|NCT02791555||Pradaxa|20 men and 20 women on Pradaxa for non valvular atrial fibrillation
2965917|NCT02791555||Warfarin|20 men and 20 women on warfarin for non valvular atrial fibrillation, age matched to Pradaxa cohort
2965918|NCT02791542||Asthma|Participants with a history of asthma
2965919|NCT02791542||Healthy controls|Participants without a history of asthma
2965920|NCT02791529|Active Comparator|Scalpel|Skin incision performed by scalpel
2965921|NCT02791529|Experimental|Electrocautery|Skin incision performed by electrocautery
2965922|NCT02791516|Active Comparator|Romosozumab|Arm is to receive monthly SC injections of Romosozumab (AMG 785).
2965923|NCT02791516|Placebo Comparator|Placebo|Arm is to receive monthly SC injections of placebo.
2965924|NCT02791503|Experimental|IRE group|FOLFIRINOX + IRE For patients diagnosed with LAPC, a combination of chemotherapy plus local tumor destruction using irreversible electroporation (IRE), a novel tumor ablation technique, has recently shown great promise. IRE is based on permeabilization of the cell membrane through electrical pulses leading to apoptosis. Theoretically, IRE only affects viable tumor tissue, leaving surrounding vital structures relatively intact. It is therefore considered to cause less morbidity than thermal ablative strategies.
2966688|NCT02786251|Other|BAT-|Individuals with no/minimal amounts of BAT ( < 10 ml)
2965925|NCT02791503|Active Comparator|SABR group|FOLFIRINOX + SABR Focal therapy using external beam radiation therapy (EBRT) may further improve survival, but outcome remains poor. Stereotactic ablative radiotherapy (SABR) is a form of EBRT that has important advantages over conventional radiotherapy such as a more precise and greater biological dose delivery and hence less toxicity and presumably better outcome.
2965926|NCT02791490|Experimental|Sitagliptin 100 mg + Metformin 1000 mg/b.i.d|Participants will receive sitagliptin 100 mg plus metformin 2000 mg/day for 20 weeks. Participants can receive glycemic rescue therapy as needed.
2965927|NCT02791490|Placebo Comparator|Placebo + Metformin 1000 mg/b.i.d|Participants will receive placebo matching sitagliptin plus metformin 2000 mg/day for 20 weeks. Participants can receive glycemic rescue therapy as needed.
2965928|NCT02791477|Other|Attune FB PS|Attune FB PS knee arthroplasty
2965929|NCT02791464|No Intervention|wait list control|Waitlist control subjects interested in learning the TM program will be asked to wait for 4 months before learning if they were randomly assigned to this comparison group. Controls will receive usual medical care during 4 month intervention period.
2965930|NCT02791464|Experimental|Transcendental Meditation|The TM technique is a simple, effortless, mental technique to reducing stress which allows the mind to experience finer levels of the thinking process to achieve a state of restful alertness. The Transcendental Meditation program will be taught as a standard seven-step program over five consecutive days.
2965931|NCT02791451|Experimental|Telemonitoring|Exacerbation of COPD with wireless telemonitoring of respiratory rate, heart rate and sleep.
2965932|NCT02791438|Experimental|TAK-536 2.5 mg (Weight < 50 kg)|For the participants weighing < 50 kg, TAK-536 2.5 mg (titrated as needed to the highest dose of 20 mg) will be administered orally once daily before or after breakfast
2965933|NCT02791438|Experimental|TAK-536 5 mg (Weight ≥ 50 kg)|For the participants weighing ≥ 50 kg, TAK-536 5 mg (titrated as needed to the highest dose of 40 mg) will be administered orally once daily before or after breakfast
2965934|NCT02791425|Experimental|Brain Computer Interface (BCI) device|The patient uses the Brain Computer Interface (BCI) device in the ICU for communication for 2 hours a day for 3 consecutive days. The patient then uses a communication picture board for 2 hours a day for 3 consecutive days on the same days that the BCI device is used for comparison.
2965935|NCT02791412||unprotected left main|undergone percutaneous coronary intervention or coronary artery bypass graft
2965936|NCT02791399|No Intervention|Control|Treatment as usual
2965937|NCT02791399|Experimental|ISOP Intervention|Primary care providers and PACT nurses will participate in the same workshop as those randomized to the control condition (or academic detailing for those unable to attend the workshop). Clinicians randomized to the intervention will additionally collaborate with a nurse care manager (NCM) who will maintain a registry of enrolled patients, track UDT administrations and results, query prescription drug monitoring databases, monitor other evidence of potential problems, and collaborate with expert consultants to provide decision support when patients have evidence of prescription opioid misuse or abuse. The NCM will also meet with patients to discuss methods to reduce opioid adverse effects, prevent misuse, and provide rationale for prescription opioid adherence monitoring.
2965938|NCT02791386||Chinese Patients With CHB and Drug Resistance to NA Therapy|
2965939|NCT02791373|Active Comparator|Mobilisation Chemotherapy: Vinorelbine|Vinorelbine is given at a standard dose of 35mg/m2 i.v. at day 1 as an infusion over 10 minutes, on an ambulatory basis.
2965940|NCT02791373|Experimental|Mobilisation Chemotherapy: Gemcitabine|Gemcitabine is given at the standard dose of 1250 mg/m2 i.v. in 500ml NaCl 0.9% (sodium chloride) as an infusion over 30 minutes, on an ambulatory basis.
2965941|NCT02791360|Other|MRI evaluation|Patient pretreated for brain tumor and witness
2965942|NCT02791347|No Intervention|Control|"Upon discharge from the medical center, patients would be advised on a qualitative, neutropenic diet. Participants' quality of life, physical activity level, functional and nutritional status would be assessed at days +30, +60 and +100 post transplantation.~These participants will not receive nutritional counseling by the dietitian as outpatients except if referred by the medical team."
2965943|NCT02791347|Experimental|Nutrition Intervention Group|"Upon discharge from the medical center, NIG patients will receive tailored nutrition counseling with the provision of patient education material and oral nutritional supplements if needed. Patients will be advised on a diet high in energy and proteins and tailored to their medical condition in the hospital before discharge.~Patients will be followed up at days +30, +60 and +100 post transplantation. Compliance will be measured at each visit by comparing patients caloric and protein needs to their actual protein and energy intake. Compliance will be reinforced to meet patients' goals using nutritional tips, oral supplementation, and artificial nutrition use."
2965944|NCT02791334|Experimental|LY3300054|LY3300054 given intravenously (IV) on day 1 and day 15 of a 28 day cycle or LY3300054 given IV on day 1 of a 21 (or 28) day cycle.
2965945|NCT02791334|Experimental|LY3300054 + Ramucirumab|LY3300054 and ramucirumab given IV on day 1 and day 15 of a 28 day cycle or ramucirumab given IV on day 1 and day 8 and LY3300054 given IV on day 1 of a 21 day cycle.
2965946|NCT02791334|Experimental|Abemaciclib + LY3300054|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
2965947|NCT02791334|Experimental|LY3300054 + Abemaciclib (Concurrent Dosing)|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
2965948|NCT02791334|Experimental|LY3300054 + Abemaciclib|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. This arm will only be initiated if required.
2965949|NCT02791334|Experimental|LY3300054 + Merestinib|LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle.
2965950|NCT02791334|Experimental|LY3300054 Expansion (Metastatic Cutaneous Melanoma)|LY3300054 given IV on day 1 and day 15 of a 28 day cycle.
2965951|NCT02791334|Experimental|LY3300054 Expansion (MSI-H Solid Tumors)|LY3300054 given IV on day 1 and day 15 of a 28 day cycle.
2965952|NCT02791334|Experimental|: LY3300054 + Abemaciclib (HR+, HER2- Breast Cancer) Expansion|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
2965953|NCT02791334|Experimental|LY3300054 + LY3321367 Expansion (PD-1/PD-L1 Naïve, MSI-H)|LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle.
2965954|NCT02791334|Experimental|LY3300054 + LY3321367 Expansion|LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle.
2965956|NCT02791321|Other|Patients with ADS-MR|Patients presenting Autism Spectrum Disorder and mental retardation who are evaluated for their ADS severity, their adaptative and intellectual functioning, psychiatric and somatic comorbidities
2965957|NCT02791308|Experimental|Pimecrolimus Cream, 1%|Pimecrolimus Cream, 1% (Actavis)
2965958|NCT02791308|Active Comparator|Elidel Cream, 1%|Reference listed drug: Elidel 1% cream (Valeant Pharmaceuticals North America LLC)
2965959|NCT02791308|Placebo Comparator|Vehicle Cream|Cream vehicle of the test product (Actavis)
2965960|NCT02791295|Experimental|Diet and physical activity program|Diet and physical activity program with individual coaching
2965961|NCT02791295|No Intervention|control|standard care
2965962|NCT02791282|Other|Index test: functional dynamic contrast enhanced (DCE)-MRI|Patients with clinical suspicion for CTEPH, scheduled for SPECT
2965963|NCT02791269|Experimental|HBeAg Negative Participants|HBeAg negative participants will receive peginterferon alfa-2a 180 micrograms (mcg) subcutaneous (SC) injection once weekly (QW) for 48 weeks followed by a 24 weeks treatment-free follow-up period.
2965964|NCT02791269|Experimental|HBeAg Positive Participants|HBeAg Positive participants will receive peginterferon alfa-2a 180 mcg SC injection QW for 48 weeks followed by a 24 weeks treatment-free follow-up period.
2965965|NCT02791256|Experimental|Peginterferon Alfa-2a + Ribavirin|Participants will receive 360 microgram (mcg) of Peginterferon Alfa-2a subcutaneous (SC) once a week plus ribavirin (1000 - 1200 milligram per day [mg/day] orally as a split dose in the morning and the evening based on the participant's body weight) for 32 weeks.
2965966|NCT02791243|Experimental|Finasteride 0.25%|approximately 0.2 ml of P-3074 (0.25% finasteride)
2965967|NCT02791243|Placebo Comparator|Placebo for Finasteride 0.25%|approximately 0.2 ml of the vehicle cutaneous solution
2965968|NCT02791243|Other|Negative Control|approximately 0.2 ml of 0.9% aqueous NaCl
2965969|NCT02791230|Experimental|Tafamidis|Active treatment - 61 mg or if not available, tafamidis megulmine 80 mg
2965970|NCT02791217||Diffused Large B cell Lymphoma|
2965971|NCT02791217||Follicular Lymphoma|
2965972|NCT02791217||Multiple Myeloma|
2965973|NCT02791217||Hodgkin Lymphoma|
2965974|NCT02791217||Healthy individuals|
2965975|NCT02791204|Experimental|Participants with PAD|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
2965976|NCT02791204|Active Comparator|Controls|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
2965977|NCT02791191|Experimental|Dose 1 LY3202626|LY3202626 given orally once daily for 52 weeks.
2965978|NCT02791191|Experimental|Dose 2 LY3202626|LY3202626 given orally once daily for 52 weeks.
2965979|NCT02791191|Experimental|Placebo|Placebo given orally once daily for 52 weeks.
2965980|NCT02791178||STEMI patients|"The patients presenting with a STEMI and undergoing PPCI will be screened and approached to participate in this study.~All patients to do Optical Coherence Tomography (OCT), Index of Microcirculatory Resistance (IMR) and Cardiac MRI."
2965981|NCT02791139||Control|Healthy Volunteers will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) Echocardiography Tonometry Genetic Testing (Blood) Hand-Grip Strength Measurement Body Fat Mass Analysis
2965982|NCT02791139||Ageing|"Ageing cohort will undergo the following studying procedures:~Cardiovascular Magnetic Resonance Imaging (CMRI) Echocardiography Tonometry Genetic Testing (Blood) Body Fat Mass Analysis"
2965983|NCT02791126||Heart Failure|"Patients presented to hospital with a primary diagnosis of Heart Failure or are attending a hospital clinic for management of Heart Failure within 6 months of an episode of decompensated heart failure, which either resulted in a hospital admission (primary diagnosis) or was treated in out-patient clinic.~Cardiovascular Magnetic Resonance and Echocardiogram will be performed."
2965984|NCT02791100|No Intervention|No promotion of chicken eggs|The community receives no chickens and therefore has no additional eggs or egg shell powder for children
2965985|NCT02791100|Experimental|Promotion of Chicken eggs for children|The community receives chickens so that each study child receives 2 eggs a day and also receives some egg shell daily (1/4 bottle cap which provides 500 mg Ca). The community receives information on using the egg and eggshell, and has help in caring for the chickens.
2965986|NCT02791087||Coronary Artery Disease for CABG|Patients undergoing or underwent Coronary Bypass Surgery with at least one saphenous vein graft. Intra-operative graft flow rate measurement will be done during CABG surgery.
2965987|NCT02791087||Stable/Unstable Angina|Patients with no known history of coronary artery disease undergoing Computed Tomography Angiography scan due to stable/Unstable Angina.
2965988|NCT02791074||Control|"Healthy Volunteers will undergo the following studying procedures:~Echocardiography Arterial tonometry"
2965989|NCT02791074||Heart Failure Patients|"Patients will undergo the following studying procedures:~NTproBNP Echocardiography Arterial tonometry"
2965990|NCT02791061||Control|"Healthy Volunteers will undergo the following studying procedures:~Cardiovascular Magnetic Resonance Imagine (MRI) Cardiopulmonary exercise testing (CPET) Echocardiography"
2965991|NCT02791061||Congenital Disease|"Patients will undergo the following studying procedures:~Cardiovascular Magnetic Resonance Imagine (MRI) Cardiopulmonary exercise testing (CPET) Echocardiography"
2965992|NCT02791048|Experimental|Experimental Group|Music therapy for up to 45 minutes twice a week for three weeks, in addition to usual care from the hospice multidisciplinary team.
2965993|NCT02791048|No Intervention|Control Group|Usual care only from the hospice multidisciplinary team. The dose and frequency of usual care will be as deemed appropriate by the hospice practitioner in charge of their treatment.
2965994|NCT02791035|Experimental|Ipragliflozin|Ipragliflozin 50 mg/tablet, orally, 1 tablet once daily for 12 weeks
2965995|NCT02791009||Diagnosed Heart Failure [Prior]|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
2966181|NCT02789618|Active Comparator|B99|Toothpaste containing Stannous Fluoride and a dentinal bonding agent
2965996|NCT02791009||Control [Prior]|Control will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
2965997|NCT02791009||Control [New]|Control will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
2965998|NCT02791009||Diagnosed Heart Failure [New]|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection, Cognitive Test and Clinical Assessment.
2965999|NCT02790996|Experimental|Vancomycin - Optimised Regimen|"A single loading dose of 25 mg/kg followed by a maintenance dose of:~Postmenstrual age ≤ 35 weeks - 15 mg/kg 12 hourly; Postmenstrual age > 35 weeks - 15 mg/kg 8 hourly"
2966000|NCT02790996|Active Comparator|Vancomycin - Standard Regimen|Postmenstrual age < 29 weeks - 15 mg/kg given 24 hourly; Postmenstrual age 29 - 35 weeks - 15 mg/kg 12 hourly; Postmenstrual age > 35 weeks - 15 mg/kg 8 hourly
2966001|NCT02790970|Experimental|PReDicT Test|To determine whether use of the PReDicT Test to direct antidepressant treatment results in an increased proportion of depressed patients showing a response to treatment at week 8
2966002|NCT02790970|Placebo Comparator|Treatment as usual|Treat patients as usual without using the predict test to determine treatment.
2966003|NCT02790957|Experimental|Plerixafor|Single subcutaneous injection of Plerixafor (0.24 mg/kg)
2966004|NCT02790957|Placebo Comparator|Placebo|Single injection of an equal volume of NaCl solution
2966005|NCT02790931|Experimental|Intervention Group|Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months.
2966006|NCT02790931|No Intervention|Control Group|Patients will not receive any exercise treatment, will not have acess to the software, but they will keep their recommended clinical treatment.
2966007|NCT02790918||Diagnosed Pulmonary Hypertension|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) and 6MWT.
2966008|NCT02790918||Healthy Volunteer|Healthy Volunteer will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) and 6MWT.
2966009|NCT02790892|Other|Art therapy - pre and post test measures|20 young adults aged 15-24 years with diabetes (10 with type 1 diabetes and 10 with type 2 diabetes) receiving 12 weeks of group art therapy. Participants serve as their own controls.
2966010|NCT02790879||Transition|Patients who switched from pediatric cystic fibrosis care center to an adult cystic fibrosis care center during 2013 or 2014, regardless of their clinical status.
2966011|NCT02790866|Experimental|LuCaS Decision Aid|Access to LuCaS, a web-based lung cancer screening decision aid
2966012|NCT02790866|Active Comparator|NCI Website|Access to NCI website on lung cancer screening
2966013|NCT02790853|Experimental|Mouth Exam + Diagnostic Optical Imaging|"Participants undergo a standard white light (WL) mouth exam. After the white light mouth exam, pictures of the inside of mouth taken using a wide-field auto-fluorescence imaging device (PS2.1/PS3) imaging device.~After the white light mouth exam, proflavine hemisulfate placed on the mucosa around the involved area. Then oral mucosa re-imaged with the high-resolution optical system (HRME).~Brush and tissue biopsies then performed."
2966014|NCT02790840|Experimental|Gefapixant + Omeprazole|Gefapixant oral tablets (15mg and 30 mg) administered twice daily for 15 days + Omeprazole oral capsules (20 mg or 40 mg) administered once or twice daily for 10 days
2966015|NCT02790827|Experimental|CETA|Participants in the experimental arm will receive the CETA intervention. The intervention period will last for approximately 4 months with weekly sessions. There will be separate groups for men, women, and children. Each group will have approximately six participants. Individuals who cannot attend group therapy (e.g., conflicting work schedules) may be offered the therapy individually.
2966016|NCT02790827|Active Comparator|Treatment as usual|There is no standard of care for domestic violence or alcohol use problems in Zambia. We will track any treatment or care that families receive during the course of the study. The active comparator arm will not receive any formal services provided by the study.
2966017|NCT02790814|Experimental|Moyo strap-on|Continous fetal heart rate monitoring
2966018|NCT02790814|Active Comparator|Hand-held fetoscope|Intermittent fetal heart rate monitoring
2966019|NCT02790801||1 group|observation of patients with chronic heart failure and atrial fibrillation
2966020|NCT02790788|Experimental|Steroids Group|Intervention: Stress-dose Steroids. Patients will receive methylprednisolone 40 mg (on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation). After resuscitation, patients will be treated with stress-dose hydrocortisone 240 mg daily for 7 days maximum, followed by gradual taper over the next 2 days.
2966021|NCT02790788|Placebo Comparator|Control Group|Intervention: Saline placebo. Patients will receive saline placebo on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation. After resuscitation, patients will be treated with saline placebo for a maximum of 9 days (i.e. 7 days corresponding to the stress-dose hydrocortisone treatment of the experimental arm plus 2 days corresponding to the gradual taper of the stress-dose hydrocortisone treatment of the experimental arm).
2966022|NCT02790775|Active Comparator|Injection Anti-VEGF in quadrant 1|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 1
2966023|NCT02790775|Active Comparator|Injection Anti-VEGF in quadrant 2|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 2
2966024|NCT02790775|Active Comparator|InjectionAnti-VEGF in quadrant 3|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 3
2966025|NCT02790775|Active Comparator|InjectionAnti-VEGF in quadrant 4|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 4
2966026|NCT02790762|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
2966027|NCT02790749|Experimental|PAO with adjunctive hip arthroscopy|Patients undergoing periacetabular osteotomy (PAO) with adjunctive hip arthroscopy.
2966182|NCT02789618|Placebo Comparator|M89|Toothpaste containing sodium fluoride (1450ppm F)
2966028|NCT02790749|Active Comparator|PAO WITHOUT adjunctive hip arthroscopy|Patients undergoing periacetabular osteotomy (PAO) WITHOUT adjunctive hip arthroscopy.
2966029|NCT02790736|Experimental|Propranolol|Propranolol 40 mg capsule, given once after fear activation procedure
2966030|NCT02790736|Placebo Comparator|placebo capsule|Placebo capsule, given once after fear activation procedure
2966031|NCT02790723|Experimental|Low Dose Group|Subjects will receive a single intra-articular 10mL injection consisting of 10{11} viral genomes.
2966032|NCT02790723|Experimental|Medium Dose Group|Subjects will receive a single intra-articular 10mL injection consisting of 10{12} viral genomes.
2966033|NCT02790723|Experimental|High Dose Group|Subjects will receive a single intra-articular 10mL injection consisting of 10{13} viral genomes.
2966034|NCT02790710|Experimental|Propanolol|Propranolol 40 mg capsule, given once after fear reactivation procedure
2966035|NCT02790710|Placebo Comparator|Placebo capsule|Placebo capsule, given once after fear reactivation procedure
2966036|NCT02790697||Mechanically ventilated ICU patient|Indirect calorimetry measurements will be conducted using the new calorimeter and the mass spectrometer system at the same time for all enrolled patients.
2966037|NCT02790684|Experimental|DS-8500a|
2966038|NCT02790671|Experimental|single study arm|DS-8500a and itraconazole
2966039|NCT02790658|Other|Grumixama Juice|"Juice of grumixama purple fruit (Eugenia brasiliensis Lam.), which is good source of anthocyanins and ellagitannins. It was made with filtered water and sanitized fruits, with a blender. It was administered in single dose of 0.97 mg of anthocyanins and of 4.71 mg of ellagitannins per mL of juice. Which volunteers ingested 10 mL of juice per each Kg body weight.~The metabolomic approach of plasma and urine samples following acute intake of grumixama juice was done by the collection of blood samples and urine, following the intake of grumixama juice."
2966040|NCT02790645|Other|Group 1a. Control|Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
2966041|NCT02790645|Other|Group 2a. Telemedicine program|CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
2966042|NCT02790645|Other|Group 1b. Telemedicine program|After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
2966043|NCT02790645|Other|Group 2b. Control|After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months).
2966044|NCT02790632|Experimental|EG-1962 Group|"1 dose of intraventricular EG-1962 (nimodipine microparticles) 600 mg~Up to 21 days of placebo capsules/tablets"
2966045|NCT02790632|Active Comparator|Enteral Nimodipine Group|"1 dose of intraventricular normal saline~Up to 21 days of oral nimodipine capsules/tablets"
2966046|NCT02790619|Active Comparator|Meditation and Active Stimulation 1|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.Participant will then receive 20 minutes of tDCS with Anode over F8 and cathode over left supraorbital area with 1 milliamp(mA) stimulation with intervention administration delivered by tDCS via Chattanooga Ionto Iontophoresis System-Phoresor.
2966047|NCT02790619|Active Comparator|Meditation and Active Stimulation 2|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.Participant will then receive 20 minutes of tDCS with Anode over F8 and cathode over left supraorbital area with 2 mA stimulation with intervention administration delivered by tDCS via Chattanooga Ionto Iontophoresis System-Phoresor.
2966048|NCT02790619|Sham Comparator|Meditation and Sham Stimulation|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.The participants in the sham study will receive Sham tDCS (no stimulation) with Anode over F8 and cathode over left supraorbital area with intervention administration delivered by Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor
2966049|NCT02790593|Experimental|Juxta-Cures™|Patients randomised to the Juxta-Cures™ device. These patients will also have pressure monitoring using the PicoPress device, and ulcer imaging and surface area measurement using the Silhouette system.
2966050|NCT02790593|Active Comparator|Standard compression|Patients randomised to standard compression. These patients will also have pressure monitoring using the PicoPress device, and ulcer imaging and surface area measurement using the Silhouette system.
2966051|NCT02790580|Active Comparator|Dose-dense doxorubicin/cyclophosphamide|Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles, Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles, Subcutaneous pegfilgrastim 6mg, 24-36 hours after doxorubicin/cyclophosphamide
2966052|NCT02790580|Experimental|Dose-dense doxorubicin/cyclophosphamide + sunitinib|Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles, Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles, Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide, Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0), Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)
2966053|NCT02790567||HIT study group|The HIT study group will include all patients admitted in our surgical intensive care unit (ICU) during the study period if the clinician in charge of the patient suspects the diagnosis of HIT. The HEP score, the 4Ts score, the immuno-diffusion particle gel immunoassay (ID-PaGIA) and the HIT-Ab(PF4-H) test will be done for each patient the day the diagnosis of HIT will be suspected.
2966054|NCT02790554|Experimental|Moyo strap-on|Continous fetal heart rate monitoring
2966055|NCT02790554|Active Comparator|Hand-held Doppler|Intermittent fetal heart rate monitoring
2966056|NCT02790541|Experimental|Treatment|Hyperbaric Oxygen Therapy: 3 months of treatment consisting of 60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
2966057|NCT02790541|Other|Control/Crossover|Hyperbaric Oxygen Therapy: 3 months control period (no treatment) followed by 3 months of treatment consisting of 60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
2966058|NCT02790528|Experimental|Atorvastatin|20mg QD
2966059|NCT02790528|Placebo Comparator|Placebo|
2966183|NCT02789605|Experimental|Bacilor|Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months
2966060|NCT02790515|Experimental|Treatment|"Participants receive a conditioning regimen of antithymocyte globulin (rabbit), cyclophosphamide, mesna, fludarabine, thiotepa, tacrolimus (first 5 participants enrolled), sirolimus (used beginning with 6th enrolled participant), melphalan, rituximab. This is followed by HPC,A infusion (transplant), then by G-CSF and blinatumomab.~Cells for infusion are prepared using the CliniMACS System."
2966061|NCT02790502|Other|Intervention|Intervention Group
2966062|NCT02790489|Experimental|Valedia|Dose 1 : 2,5 g (4 capsules) Valedia per day during 4 weeks Dose 2 : 5 g (8 capsules) Valedia per day during 4 weeks 2 weeks (wash-out period) between the 2 doses
2966063|NCT02790476|Experimental|Letter intervention|The intervention arm will involve letters sent to prescribers in San Diego County.
2966064|NCT02790476|No Intervention|Control|The control group will involve prescribers not receiving letters
2966065|NCT02790463|No Intervention|Usual Care|Participants recruited in this arm will receive their usual care for gout as they normally would
2966066|NCT02790463|Active Comparator|Intervention|Participants recruited to this arm will receive their usual gout care + pharmacist-led intervention
2966067|NCT02790450|Experimental|Benzbromarone|1x200mg Benzbromarone
2966068|NCT02790437|Experimental|Treatment IdeS|IdeS intravenous infusion
2966069|NCT02790424|Experimental|Patients|Imaging devices
2966070|NCT02790411|Experimental|healthy volunteers|Imaging devices New Non Invasive Devices
2966071|NCT02790398|Experimental|Transdiagnostic treatment protocol|Transdiagnostic treatment protocol.
2966072|NCT02790398|Active Comparator|Transdiagnostic treatment protocol + PA regulation component|Transdiagnostic treatment protocol that includes a component aimed at the regulation of PA.
2966073|NCT02790385|Experimental|NPWT|subjects will undergo negative pressure wound therapy
2966074|NCT02790385|Active Comparator|Standard Gauze|standard method of using gauze and dressing will be utilized
2966075|NCT02790372|No Intervention|Control nursing homes|Nursing homes carries out usual care
2966076|NCT02790372|Active Comparator|Intervention nursing homes|Nursing homes that carries out regularly case conferencing
2966077|NCT02790359|Active Comparator|Patient group 1|Air
2966078|NCT02790359|Active Comparator|Patient group 2|Carbon dioxide
2966079|NCT02790346|Experimental|arthrodesis talonavicular|arthrodesis talonavicular in addition to tendon gestures
2966080|NCT02790346|Active Comparator|tendon gestures|tendon gestures only
2966081|NCT02790333|Experimental|Tri-Staple reloads|Tri-Staple reloads were used for pancreatic stump texture
2966082|NCT02790333|Active Comparator|traditional reloads|the traditional reloads were used for pancreatic stump texture
2966083|NCT02790320||Patients with locally recurrent or metastatic breast cancer|Patients received 1.4 mg/m2 eribulin, administered intravenously on day 1 and 8 of each 21 day cycle until disease progression or unmanageable toxicity, per routine clinical practice.
2966084|NCT02790307|Experimental|Daily stimulation (30mins/day)|30 minutes daily for 12 weeks of Tibial nerve stimulation using the Geko device
2966085|NCT02790307|Experimental|Weekly stimulation (30mins/week)|30 minutes daily for 12 weeks of Tibial nerve stimulation using the Geko device
2966086|NCT02790294|Experimental|Postoperative Magnetic Resonance Imaging|Three MRIs will be performed. One at baseline, one within 72 hours postoperative, and one 2-3 weeks postoperative.
2966087|NCT02790268||Lens Subluxation|Pediatric eyes with lens subluxation undergoing Cionni Ring Bag fixation with in-the-bag IOL Implantation
2966088|NCT02790255|Experimental|Cold air|Subjects to be seated in an airtight chamber at an ambient temperature between 16 to 20 degrees Celsius for 1 hour.
2966089|NCT02790255|Experimental|Cold water|Subjects to be seated in an airtight chamber at an ambient temperature of 24 degrees Celsius, with their hands and feet fully immersed in cold water for 5 minutes.
2966090|NCT02790229|Experimental|anti-gravity treadmill arm|Treatment with anti-gravity treadmill (alter G®)
2966091|NCT02790229|Other|control arm|Treatment with standardized physiotherapy
2966092|NCT02790216||Brachytherapy|men eligible for monotherapy seed implant brachytherapy
2966093|NCT02790203|Experimental|Celecoxib|"Celecoxib will be given orally to patients participating in the study and allocated to the treatment group, for an intervention period of 6 days, starting from the day of surgery.~Celecoxib will be given throughout the intervention period of the study orally at a dose of 400 mg per day divided into two doses, a dose which is within the recommended and a widely used dosage and is expected to induce a significant inhibition of prostaglandin synthesis by the COX2 pathway. Celecoxib will be given throughout the intervention period of the study orally at a dose of 400 mg per day divided into two doses."
2966094|NCT02790203|Placebo Comparator|Placebo|"Placebo will be given orally to patients participating in the study and allocated to the control group that will receive placebo, for an intervention period of 6 days, starting from the day of surgery.~Placebo will be given throughout the intervention period of the study orally in capsules that resemble the drug, twice a day."
2966095|NCT02790190|Experimental|Individualized Adaptive radiotherapy|GTV dose per fraction will be 2.2-2.4 y per fraction for 20 fractions and PTV dose per fraction will be 2.0 Gy per fraction.Perform PET/CT before radiotherapy and at 36 Gy for treatment response assessment and adaptive plan.Adaptive plan treated at 2.2-3.8 Gy per fraction for GTV and 2.0 Gy for PTV in the final 10 fractions.
2966096|NCT02790190|No Intervention|Conventional radiotherapy|2 Gy per fraction for all patient,perform PET/CT before radiotherapy and at 40 Gy for treatment response assessment .Continue treatment to a total dose of 60 Gy.
2966097|NCT02790177|Experimental|HiB|This group will receive the compound for the reduction of adhesions
2966098|NCT02790177|Placebo Comparator|Normal saline|This group will just receive normal saline to ensure blinding.
2966099|NCT02790164|Experimental|Rocuronium|Patients will receive a bolus dose of 0.6 mg/kg, then a continuous I.V. infusion of 0.3-0.6 mg/kg/hr as per standard intensive care unit practice.
2966100|NCT02790164|Placebo Comparator|Usual Care|Patients will receive 100 mL of normal saline over 5-10 minutes at the beginning of the study in addition to usual care.
2966101|NCT02790151|Active Comparator|Standard Therapy|Learning and practicing memory strategies
2966102|NCT02790151|Experimental|Experimental Intervention|Computerbased working memory training and Recollection training
2966184|NCT02789605|Placebo Comparator|Placebo|Patient receiving placebo, orally taken, 4 times a day, during 3 months
2966103|NCT02790138|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.
2966104|NCT02790138|Placebo Comparator|Placebo|Vedolizumab placebo-matching IV infusion, once at Weeks 0, 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.
2966105|NCT02790125|Experimental|Dose Panel 1|"BMS-986166 or Placebo matching BMS-986166~Single oral dose of solution as specified"
2966106|NCT02790125|Experimental|Dose Panel 2|"BMS-986166 or Placebo matching BMS-986166~Single oral dose of solution as specified"
2966107|NCT02790125|Experimental|Dose Panel 3|"BMS-986166 or Placebo matching BMS-986166~Single oral dose of solution as specified"
2966108|NCT02790125|Experimental|Dose Panel 4|"BMS-986166 or Placebo matching BMS-986166~Multiple ascending solid dose formulation as specified"
2966109|NCT02790125|Experimental|Dose Panel 5a/b/c|"BMS-986166~Single oral solid dose formulation under fasting/fed/fasting with famotidine conditions"
2966110|NCT02790112|Other|GnRHas - Not GnRHas patients|Compared long term outcome of treated and untreated patients with idiopathic central precocious puberty : hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
2966111|NCT02790112|Other|GnRHas - controls patients|Compared long term outcome of treated patients with idiopathic central precocious puberty and control patients for: hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
2966112|NCT02790112|Other|Not GnRHas - Controls patients|Compared long term outcome of untreated patients with idiopathic central precocious puberty and control patients for: hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
2966113|NCT02790099|Experimental|Rectus sheath block only|Patient will be given surgical rectus sheath block postoperatively with 40ml of bupivacaine (2.5mg/mL) and 0.1ml of normal saline will be injected intrathecally at time of spinal anaesthesia.
2966114|NCT02790099|Active Comparator|Intrathecal morphine group|0.1mg preservative free morphine will be injected intrathecally at time of spinal anesthesia and 40ml of normal saline will be injected as rectus sheath block.
2966115|NCT02790099|Active Comparator|Both intervention|Patient will be given 0.1mg preservative free morphine intrathecally at time of spinal anaesthesia and surgical rectus sheath block with 40ml of bupivacaine (2.5mg/ml).
2966116|NCT02790073|Other|SNF472|SNF472 for calciphylaxis
2966117|NCT02790047|Active Comparator|Home-base exercise|"Patients will receive intervention as following~A home-base exercise program~Health education~Breathing strategies for self secretion clearance~The medication following the COPD GOLD guidelines (2015)"
2966118|NCT02790047|Experimental|Home-base exercise with a PEP mask|"Patients will receive intervention as following~A home-base exercise program with using a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise~Health education~Breathing strategies for self secretion clearance~The medication following the COPD GOLD guidelines (2015)"
2966119|NCT02790034|Active Comparator|Sarizotan|Between 2 to 10 mg bid based on age and weight criteria.
2966120|NCT02790034|Placebo Comparator|Placebo|Placebo bid respectively
2966121|NCT02790021|No Intervention|Complex decongestive therapy|Group A will continue complex decongestive therapy consisting of skin care, manual lymphatic drainage, and compression therapy using compression stockings.
2966122|NCT02790021|Experimental|Lymphaticovenous anastomosis (LVA)|Group B will undergo an LVA procedure under local anesthesia in surgical daycare setting. Patients are not allowed to wear compression stockings or have decongestive therapy for four weeks after the surgery.
2966123|NCT02790008||Aortic valve disease|Patients with aortic stenosis referred to surgery. Exclusion criteria are concomitant heart valve disease, congenital heart disease, hemodynamic instability, previous cardiac surgery, history of myocardial infarction and coronary artery disease.
2966124|NCT02789995|Experimental|Patients with and without sepsis|"Patients with sepsis, Patients with inflammatory disease without sepsis, Patients without inflammatory disease without sepsis.~Human biological samples collected for research :~Blood sample~Muscle biopsy~Bone marrow sample (mesenchymal stem cells)"
2966125|NCT02789982|Experimental|Reconsolidation blockade|β-adrenergic blocker propranolol 1 mg / kg to each of the 6 treatment sessions
2966126|NCT02789982|Active Comparator|Treatment as usual|Treatment as usual like SSRIs, psychotherapy, ...
2966127|NCT02789969|Experimental|Hydromorphone 15mcg/kg IV|Patient randomly assigned to hydromorphone
2966128|NCT02789969|Experimental|Fentanyl 1.5 mcg/kg IV|Patient randomly assigned to fentanyl
2966129|NCT02789956|Experimental|Test: internal connection|Evaluate marginal bone level (MBL) changes at implants that are placed semi-edentulous patient when they are treated with implant level Co/cr Cad/Cam framework.
2966130|NCT02789956|Active Comparator|Test: external connection|Evaluate marginal bone level (MBL) changes at implants that are placed semi-edentulous patient when they are treated with abutment level Co/cr Cad/Cam framework.
2966131|NCT02789917|Experimental|Dual therapy (incl. NOAC)|Apixaban plus Clopidogrel
2966132|NCT02789917|Active Comparator|Triple therapy (incl. VKA)|Phrenprocoumon plus Clopidogrel plus ASA
2966133|NCT02789904||Chest pain patients in DEM|Recruitment done at SGH DEM. Blood taking will be done at 0, 1 and 2 hr.
2966134|NCT02789891|Experimental|D2 Lymphadenectomy including No. 14v|Laparoscopic distal gastrectomy with D2 lymphadenectomy including No. 14v lymph node dissection will be performed for the treatment of patients assigned to this group
2966135|NCT02789891|Active Comparator|D2 lymphadenectomy excluding No. 14v|Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v lymph node dissection will be performed for the treatment of patients assigned to this group
2966136|NCT02789878|Experimental|ADT and Abiraterone|"Goserelin 10.8 mg, single dose, subcutaneously.~Abiraterone 1,000 mg, once daily, orally for 3 months.~Prednisone 5 mg, once daily, orally for 3 months."
2966137|NCT02789878|Experimental|ADT, Abiraterone and Apalutamide|"Goserelin 10.8 mg, single dose, subcutaneously.~Abiraterone 1,000 mg, once daily, orally for 3 months.~Prednisone 5 mg, once daily, orally for 3 months.~Apalutamide 240 mg, once daily, orally for 3 months."
2966361|NCT02788435|Experimental|Absolute Voice Rest|Patients in the experimental arm will undergo 7 days of absolute voice rest following surgery.
2966138|NCT02789865|Active Comparator|Antibiotic therapy group|The patients will be treated with intravenous broad-spectrum antibiotics (Ertapenem 1g/d) for 3 days and oral antibiotics (Levofloxacin 500mg once daily and Metronidazole 500mg 3 times per day) for 7 days. If patients in the antibiotic group deteriorate during the hospital stay (suspicious perforation or any symptoms of peritonitis) patients will be operated.
2966139|NCT02789865|Experimental|ERAT group|The patients will receive emergent endoscopic retrograde appendicitis therapy (ERAT).
2966140|NCT02789865|Active Comparator|Appendectomy group|The patients will receive laparoscopic appendectomy according to standard routines.
2966141|NCT02789852|Experimental|Orthosis Group|Will use the night orthosis for interphalangeal in the treatment of OA hand.
2966142|NCT02789852|No Intervention|Control Group|wait for treatment
2966143|NCT02789839|Experimental|Healthy volunteer|Blood test Medullar test
2966144|NCT02789826|Experimental|Laparoscopic gastrectomy|Patients allocated to the 'laparoscopic Gastrectomy' group will undergo laparoscopic gastrectomy. If, during surgery, laparoscopic resection does not seem feasible, the procedure may be converted to an open one.
2966145|NCT02789826|Active Comparator|Open gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive gastrectomy via laparotomy. This group is considered the control group
2966146|NCT02789813|Experimental|Valproic Acid and fear reactivation|This group will receive once a combination of 500mg Valproic Acid (oral solution) and fear reactivation before exposure therapy.
2966147|NCT02789813|Active Comparator|Valproic Acid and no fear reactivation|This group will receive once 500mg Valproic Acid (oral solution) before exposure therapy.
2966148|NCT02789813|Placebo Comparator|Placebo and fear reactivation|This group will receive once a combination of Placebo (oral solution) and fear reactivation before exposure therapy.
2966149|NCT02789813|Placebo Comparator|Placebo and no fear reactivation|This group will receive once Placebo (oral solution) before exposure therapy.
2966150|NCT02789800|Active Comparator|Group A|Intervention group (n = 163) Intervention: Participates in DIMAC02 Program
2966151|NCT02789800|No Intervention|Group B|Control group (n = 163)
2966152|NCT02789800|No Intervention|Group C|Health Administrative Data Group (n = 1630) Number of matched data controls. Not taking part in intervention.
2966153|NCT02789787||Maxillary protraction|Early adolescents (11 - 14 yrs) with cleft lip and palate and Cl III malocclusion
2966154|NCT02789787||Orthognathic surgery|Late adolescents to young adults (16-21 years) with cleft lip and palate and Cl III malocclusion
2966155|NCT02789774|Experimental|Surgical treatment|Stabilization of odontoid fracture with posterior fusion C1-C2
2966156|NCT02789774|Active Comparator|Conservative treatment|External stabilization of odontoid fracture with a rigid cervical collar for 3 months.
2966157|NCT02789761|Active Comparator|High-flavanol milk chocolate|Bi-daily consumption of 12 g portion of a high-flavanol milk chocolate containing approximately 35 mg of (-)-epicatechin for 2-weeks (14 days)
2966158|NCT02789761|Placebo Comparator|Low-flavanol milk chocolate|Bi-daily consumption of 12 g portion of a low-flavanol milk chocolate containing approximately <1 mg of (-)-epicatechin for 2-weeks (14 days)
2966159|NCT02789748|Experimental|Treatment ON|Kinesthetic stimulation administered during one night
2966160|NCT02789748|No Intervention|Treatment OFF|NO kinesthetic stimulation administered during one night
2966161|NCT02789735|Active Comparator|Device: LiteCure LCT-1000®|Treatment with 10 J/cm²
2966162|NCT02789735|Sham Comparator|Device: Sham LiteCure|Sham i.e. visible red light
2966163|NCT02789722|Experimental|Yerba Mate Extract 750 mg|Yerba Mate Extract - Capsules: daily dose of 2.250 g, distributed in 3 doses of 750 mg, for 28 days.
2966164|NCT02789722|Placebo Comparator|Placebo|Starch - Capsules: 3 times daily for 28 days.
2966165|NCT02789709||Non metastatic colon cancer patients|Consecutive patients undergoing elective surgery for non-metastatic colon or rectal cancer with curative intent.
2966166|NCT02789696|Other|Acromegaly|Diagnosis of acromegaly
2966167|NCT02789683|Experimental|Fine emulsion|Emulsion with small lipid droplet size served together with white bread
2966168|NCT02789683|Experimental|Coarse emulsion|Emulsion with large lipid droplet size served together with white bread
2966169|NCT02789683|Experimental|Control|Non-emulsified oil and water served together with white bread
2966170|NCT02789670||MS patients|MS patient group is composed by 20 Individuals with inflammatory brain lesions seen in MRI (Radiologically Isolated syndrome) 20 patients with only one clinically isolated syndrome (CIS) 20 patients with relapsed remittent Multiple sclerosis (RRMS) 20 patients with primary progressive Multiple Sclerosis (PPMS)
2966171|NCT02789670||Control group patients|"Control patient cohort is composed by 20 patients suffering from inflammatory neurological disease other than MS Devic syndrome, Neurosarcoidosis, Neurobehcet... (autoimmune disease control group with neurological disease) 20 patients with systemic sclerosis (autoimmune disease control group) without neurological disease)~40 healthy subjects"
2966172|NCT02789657|Experimental|Optimal- 18 weeks|18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post treatment, patients will undergo surgery.
2966173|NCT02789657|Experimental|Sub-optimal with AC|12 weeks (4 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post 12 weeks, initiation of doxorubicin and cyclophosphamide for 4 cycles (6 weeks), followed by surgery.
2966174|NCT02789657|Experimental|Optimal with AC|Less than 18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab, followed by initiation of doxorubicin and cyclophosphamide. Post treatment, patients will undergo surgery.
2966175|NCT02789657|Experimental|Sub-optimal no AC|18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post treatment, patients will undergo surgery.
2966176|NCT02789644|Experimental|Ursodeoxycholic acid 400mg|Day 1: Ursodeoxycholic acid 400mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
2966177|NCT02789644|Experimental|Ursodeoxycholic acid 800mg|Day 1: Ursodeoxycholic acid 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
2966178|NCT02789631||chronic neck pain|experiencing neck pain for at least 3 months in the last year
2966179|NCT02789631||without neck pain (asymptomatic)|no history of neck pain
2966180|NCT02789618|Active Comparator|A01|Toothpaste containing calcium silicate and Sodium Monofluorophosphate (1450ppm F) and a gel containing sodium fluoride (1450ppm F)
2966185|NCT02789592|Experimental|Group 1|Phase 1: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
2966186|NCT02789592|Experimental|Group 2|Phase 1: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
2966187|NCT02789592|Experimental|Group 3|Phase 1: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks
2966188|NCT02789592|Experimental|Group 4|Phase 1: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks
2966189|NCT02789592|Experimental|Group 5|Phase 1: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
2966190|NCT02789592|Experimental|Group 6|Phase 1: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
2966191|NCT02789579|Experimental|levofloxacin 3 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives levofloxacin 0.5g,qd,po 3 days before Minimally invasive upper tract lithotomy.
2966192|NCT02789579|Experimental|nitrofurantoin 3 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives nitrofurantoin 0.1g, tid, po 3 days before Minimally invasive upper tract lithotomy.
2966193|NCT02789579|Experimental|cefuroxime group|There are 150 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and does not receive oral antibiotics 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
2966194|NCT02789579|Experimental|levofloxacin 7 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives levofloxacin 0.5g,qd,po 7 days before Minimally invasive upper tract lithotomy.
2966195|NCT02789579|Experimental|nitrofurantoin 7 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives nitrofurantoin 0.1g, tid, po 7 days before Minimally invasive upper tract lithotomy.
2966196|NCT02789566|Experimental|Regimen|Primaquine (PQ) 30 mg base single dose
2966197|NCT02789553|Experimental|Meal with glucose syrup|Meal with glucose syrup : 30g of glucose mixed with 150 mL of water and dived into three 50 mL portions. It will be consumed in 15 minutes
2966198|NCT02789553|Experimental|Starch meal|Starch meal with 30g mixed in 120 mL of water. It will be consumed in 15 minutes and it represents 30g of glucose
2966199|NCT02789527|Experimental|Healthy volunteers in Ethiopia|Phenotype and genotype of enzymes involved in drug metabolism in Ethiopia population
2966200|NCT02789527|Experimental|Healthy volunteers in Oman|Phenotype and genotype of enzymes involved in drug metabolism in Oman population
2966201|NCT02789527|Experimental|Healthy volunteers in the Czech Republic|Phenotype and genotype of enzymes involved in drug metabolism in Czech Republic population
2966202|NCT02789527|Experimental|Healthy volunteers in Greece|Phenotype and genotype of enzymes involved in drug metabolism in Greek population
2966203|NCT02789514||children|Investigators give observation to the patients who need esophagogastroduodenoscopic procedures.
2966204|NCT02789501|Active Comparator|Control|Non-systemic intraluminal application of 4% citrate lock solution (CitraFlow™ 4%, MedXL, Montreal, Canada) 3 times per week after dialysis.
2966205|NCT02789501|Experimental|Test|"TauroLock™ based lock solution regimen:~Non-systemic intraluminal application of TauroLock™-Hep500, Tauropharm, Waldbüttelbrunn, Germany, 2x/week after dialysis (before short intervals) and TauroLock™-U25.000, Tauropharm, Waldbüttelbrunn, Germany, 1x/ week after dialysis (before long interval).~TauroLock™-Hep500 contains 1% (cyclo)-taurolidine, 4% citrate and 500 IU/mL heparin.~TauroLock™-U25.000 contains 1% (cyclo)-taurolidine, 4% citrate and 25.000 IU urokinase."
2966206|NCT02789488|Other|Furocyst|Furocyst one caps BID
2966207|NCT02789475|Experimental|amplodipine group|Amlodipine for 8 days and Amlodipine+Rosuvastatin for 5 days
2966208|NCT02789475|Experimental|rosuvastatin group|Rosuvastatin for 5 days and Amlodipine+Rosuvastatin for 8 days
2966209|NCT02789462||Patients undergoing laser-assisted PCI|Patients of VAMC centers who undergone laser-assisted percutaneous coronary interventions.
2966210|NCT02789449||precapillary|patients with PH and PAWP<12mmHg
2966211|NCT02789449||postcapillary|patients with PH and PAWP>18mmHg
2966212|NCT02789436|Experimental|L. reuteri Prodentis® lozenges|"15 subjects~Probiotic lozenges used in the trial is a non-commercial product provided by BioGaia AB, Lund, Sweden. The Probiotic lozenges consist of a minimum of 200 million live L. reuteri (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 (L. reuteri Prodentis®). Probiotic lozenges are used twice daily for 28 days."
2966213|NCT02789436|Placebo Comparator|Placebo lozenges|"15 subjects~Placebo lozenges used in the trial is non-commercial product provided by BioGaia AB, Lund, Sweden.Placebo lozenges are taken twice daily for 28 days."
2966253|NCT02789267|Experimental|Regular dietary support|Group of patients will benefit from a systematic and regular dietary support. Patients will be followed by a dietitian 1 month and 3 month after radiotherapy in hospital. Then, dietitian will realize a telephon interview 2 and 5 months after radiotherapy
2966254|NCT02789254|Experimental|Experimental: FLYSYN|IV infusion over a 3-hr duration
2967233|NCT02782481|Placebo Comparator|ND0612 Placebo|ND0612 Placebo SC infusion over 24 h
2966214|NCT02789423|Active Comparator|Dycal|Intervention: drug: Dycal, Other names: Calcium Hydroxide. Intervention Description:DPC using Dycal for direct pulp exposure was performed in 30 primary molar teeth after proper case selection.Clinical and radiographic evaluation was done.One month post operative criteria evaluated were-Clinical criteria:Spontaneous pain,Defective restoration/Recurrent caries,Sinus formation,TOP,Soft tissue swelling & Mobility. Radiographic criteria:Defective restoration/Recurrent caries,Periapical or furcal radiolucency,Pathological internal resorption,Replacement resorption,Intracanal calcification & Physiological resorption.The follow-up was at 3 and 6 months.
2966215|NCT02789423|Active Comparator|Biodentine|Intervention: drug: Biodentine, Other names: Calcium Silicate. Intervention Description:DPC using Biodentine for direct pulp exposure was performed in 30 primary molar teeth after proper case selection.Clinical and radiographic evaluation was done.One month post operative criteria were-Clinical criteria:Spontaneous pain,Defective restoration/Recurrent caries,Sinus formation,TOP,Soft tissue swelling & Mobility.Radiographic criteria:Defective restoration/Recurrent caries, Periapical or furcal radiolucency,Pathological internal resorption,Replacement resorption,Intracanal calcification & Physiological resorption.The follow-up was at 3 and 6 months.
2966216|NCT02789410|Active Comparator|Intrathecal hydromorphone|Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.
2966217|NCT02789410|Active Comparator|Intrathecal morphine|Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.
2966218|NCT02789397|Active Comparator|Rituximab (RTX) and Azathioprine (AZA)|Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12. Azathioprine: Starting dose of azathioprine will be 50 mg and increased in 25 mg increments to a maximum dose of 150 mg or 2 mg/k/day (whichever is lowest) as tolerated. Azathioprine will be administered by mouth daily for 18 months.
2966219|NCT02789397|Placebo Comparator|Placebo|IV placebo will be administered on the same schedule as Rituximab. Oral placebo will be administered by mouth daily for 18 months.
2966220|NCT02789384|Experimental|Procedure/Surgery|Newly obtained biopsy if applicable and blood samples collection according to the usual medical practices.
2966221|NCT02789371|Other|Arm A|the first pass is made with 5ml suction technique
2966222|NCT02789371|Other|Arm B|the first pass is made with modified wet suction technique
2966223|NCT02789358|Active Comparator|Control Arm|"Conventional protocol for cryoablation:~At least 2 applications of 180s each"
2966224|NCT02789358|Experimental|Study Arm|"Experimental protocol for cryoablation:~Time to effect + 1 minute and a bonus application of 120s"
2966225|NCT02789345|Experimental|Ramucirumab + Osimertinib|"Dose Finding: Ramucirumab given intravenously (IV) on day 1 every 2 weeks (Q2W) and osimertinib given orally daily during each 14 day cycle.~Expansion: Ramucirumab given IV on day 1 Q2W and osimertinib given orally daily during each 14 day cycle."
2966226|NCT02789345|Experimental|Necitumumab + Osimertinib|"Dose Finding: Necitumumab given IV on days 1 and 8 every 3 weeks (Q3W) and osimertinib given orally daily during each 21 day cycle.~Expansion: Necitumumab given IV on days 1 and 8 Q3W and osimertinib given orally daily during each 21 day cycle."
2966227|NCT02789332|Active Comparator|Paclitaxel with Carboplatin (PwCb)|paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (37 patients) followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
2966228|NCT02789332|Experimental|Paclitaxel with Olaparib (PwO)|"paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (65 patients)~followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery."
2966229|NCT02789319|Other|FreeStyle Lite|Blood Glucose Meter type
2966230|NCT02789319|Other|Contour Next|Blood Glucose Meter type
2966231|NCT02789319|Other|OneTouch Ultra2|Blood Glucose Meter type
2966232|NCT02789319|Other|ACCU-CHEK AVIVA Plus|Blood Glucose Meter type
2966233|NCT02789319|Other|Prodigy Auto Code|Blood Glucose Meter type
2966234|NCT02789319|Other|Walmart ReliOn Prime|Blood Glucose Meter type
2966235|NCT02789319|Other|Embrace|Blood Glucose Meter type
2966236|NCT02789319|Other|True Result|Blood Glucose Meter type
2966237|NCT02789319|Other|True Track|Blood Glucose Meter type
2966238|NCT02789319|Other|Walmart ReliOn Confirm|Blood Glucose Meter type
2966239|NCT02789319|Other|Advocate Redi-Code +|Blood Glucose Meter type
2966240|NCT02789319|Other|CVS Advanced|Blood Glucose Meter type
2966241|NCT02789319|Other|OneTouch Verio|Blood Glucose Meter type
2966242|NCT02789319|Other|Contour|Blood Glucose Meter type
2966243|NCT02789319|Other|Accu-Chek Nano|Blood Glucose Meter type
2966244|NCT02789319|Other|Walmart ReliOn Ultima|Blood Glucose Meter type
2966245|NCT02789319|Other|Gmate Smart|Blood Glucose Meter type
2966246|NCT02789319|Other|SolusV2|Blood Glucose Meter type
2966247|NCT02789306||Peri-implantitis|"Peri-implantitis' - Loss radiographic bone beyond the biological bone remodeling at baseline (after prosthesis delivery) from the implant neck~Early:> 4 mm probing depth; <25% radiographic bone loss~Moderate:> 6mm probing depth; <50% radiographic bone loss~Severa:> 8 mm probing depth; > 50% radiographic bone loss"
2966248|NCT02789306||Healthy|No signs of inflammation and otherwise no bone loss beyond the biological bone remodeling
2966249|NCT02789293|Experimental|Focused Ultrasound treatment|Ultrasound ciliary pasty (UCP) using focused ultrasound
2966250|NCT02789280|Experimental|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated."
2966251|NCT02789280|Active Comparator|Wait List|Participants will be asked to wait for a week until they receive the behavioral activation condition
2966252|NCT02789267|No Intervention|Control|"Group of patients with standard of care: the nutritional support is conducted by physicians.~No systematic dietary support"
2966322|NCT02788721|Placebo Comparator|Placebo single dose|Single dose of Placebo oral suspension
2966255|NCT02789241|Experimental|Endotoxin (LPS)|The safety and tolerability will be assessed at different doses that will consist of 4 groups; each consisting of 4 subjects receiving endotoxin (LPS). Group 1 will test the low dose of LPS (0.6 ng/kg); Group 2 will test the 1.0 ng/kg dose; Group 3 will test the 2.0 ng/kg dose and Group 4 will test the 4.0 ng/kg dose.
2966256|NCT02789241|Placebo Comparator|Placebo|The trial will consist of 4 groups each group will have 2 subjects receiving Placebo (normal saline)].
2966257|NCT02789228|Experimental|Tumor associated antigen lymphocytes (TAA-CTL)|"Tumor associated antigen lymphocytes (TAA-CTL). Three different dosing schedules will be evaluated.~Dose Level One: 1 x 107 cells/m2 Dose Level Two: 2 x 107 cells/m2 Dose Level Three: 4 x 107 cells/m2~Patients will receive cells due to the presence of refractory disease and/or high risk for disease relapse and/or residual detectable disease following conventional therapy at the time of the infusion. Ideally, patients should not receive other systemic antineoplastic agents for at least 6 weeks after infusion of TAA CTL (for purposes of evaluation), although such treatment may be added if deemed critical for patient care by the attending physician."
2966258|NCT02789215|Experimental|Intervention|Receive new CACFP menu pattern
2966259|NCT02789215|No Intervention|Control|Follow existing CACFP menu pattern
2966260|NCT02789202|Experimental|Silver Diamine Fluoride|Control treatment
2966261|NCT02789202|Active Comparator|Fluoride Varnish|Test treatment
2966262|NCT02789189|Experimental|nedaplatin combined with gemcitabine|
2966263|NCT02789176||Outpatient Enrollees|This is a cohort of 150 subjects who were previously enrolled in the Neonatal Seizure Registry, a multi-center association of institutions across the United States, They will be contacted to participate in the study after discharge from the Neonatal Intensive Care Unit (NICU) but prior to the prospective follow up. They will be asked to take part in all prospective follow up surveys at 12, 18, & 24 months of age.
2966264|NCT02789176||NICU Enrollees|This is a cohort of 150 subjects who will be enrolled in the study prior to discharge from the NICU. They will be asked to complete surveys prior to discharge from the NICU, return to the hospital for a 1 hour EEG to monitor brain activity between 2-4 months of age, & complete the follow surveys at 12, 18, & 24 months of age.
2966265|NCT02789150|Experimental|MAP 65-70|Goal MAP of 65-70
2966266|NCT02789150|Active Comparator|MAP greater than or equal to 85|MAP greater than or equal to 85
2966267|NCT02789124|Experimental|Carotid Artery Flow Time|Patients with radial aline and flotrac vigileo will have carotid dopper measured for carotid flow time and a passive leg raise
2966268|NCT02789111|Active Comparator|Alvimopan|12 mg alvimopan twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.
2966269|NCT02789111|Placebo Comparator|Placebo|Placebo twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.
2966270|NCT02789098|Other|STEMI|All patients included in this study (1 arm)
2966271|NCT02789085|No Intervention|Control|without tens stimulation
2966272|NCT02789085|Experimental|Test|with tens stimulation
2966273|NCT02789072|Other|Microgravity|effect of microgravity on central aortic blood pressure.
2966274|NCT02789059|Experimental|muscle oxygenation|assesment of muscle oxygenation and gas exchanges
2966275|NCT02789033|Active Comparator|Chitosan|Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
2966276|NCT02789033|Active Comparator|Isosorbide dinitrate spray|Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.
2966277|NCT02789033|Placebo Comparator|Placebo|Placebo in the same pharmacological presentation
2966278|NCT02789020|Experimental|Rasagiline|This group will receive a 1 mg rasagiline tablet to be taken once daily for one year. In addition, the following test will be performed: a Magnetic Resonance Imaging (MRI), functional Magnetic Resonance Imaging (fMRI), the Montreal Cognitive Assessment, Stroop, Digit Span, Hopkins Verbal Learning Test, Brief Test of Attention, Beck Depression Index, Hamilton Anxiety and Depression Rating Scales, Physical Function Performance Test, and Epworth Sleepiness Scale.
2966279|NCT02789020|Placebo Comparator|Placebo|This group will receive a placebo tablet in the same forum as the rasagiline tablet to be taken once daily for one year. In addition, the following test will be performed: a Magnetic Resonance Imaging (MRI), functional Magnetic Resonance Imaging (fMRI), the Montreal Cognitive Assessment, Stroop, Digit Span, Hopkins Verbal Learning Test, Brief Test of Attention, Beck Depression Index, Hamilton Anxiety and Depression Rating Scales, Physical Function Performance Test, and Epworth Sleepiness Scale.
2966280|NCT02789007|Other|parabolic flight|To evaluate Structural and functional changes, Cognitive performance, and specifically spatial cognition, Key neurotrophins...
2966281|NCT02788994|Experimental|Endovis BA2 Nail|"The EBA2 intramedullary nailing system is designed for the treatment of lateral proximal femoral fractures, and consists of a standard or medium length nail implantable with the same set of instruments.~The system has been designed to allow:~stable fracture synthesis for fast rehabilitation and early mobilization~an efficient set of instruments (only 11) for a swift, reproducible operating technique (just 7 surgical steps)~This is a one off surgical fixation."
2966282|NCT02788994|Active Comparator|Dynamic Hip Screw (DHS)|"The DHS is designed to provide strong and stable internal fixation of a variety of intertrochanteric, subtrochanteric and basilar neck fractures, with minimal soft tissue irritation.~This Dynamic Hip Screw method is currently used and is a one off surgical fixation."
2966283|NCT02788981|Experimental|Nab-Paclitaxel+Mifepristone|Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle)
2966284|NCT02788981|Placebo Comparator|Nab-Paclitaxel+Placebo|Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle)
2966285|NCT02788968|Other|Adolescents|MRI 11-15 years
2966286|NCT02788968|Experimental|Young adults|MRI 19-25 years
2966323|NCT02788708|Experimental|Treatment (lenvatinib, paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and lenvatinib mesylate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2966287|NCT02788955|Active Comparator|Standard Protein Diet|In the standard protein diet, participants will be instructed to follow a diet that will provide them with the amount of calories enough to meet their energy needs without changing their body weight and will contain 1 g of protein per kilogram of body weight. Participants will be instructed to consume protein primarily from animal food sources. A high quality whey protein supplement will be provided as needed.
2966288|NCT02788955|Experimental|High Protein Diet|In the high protein diet, participants will be instructed to follow a diet that will provide them with the amount of calories enough to meet their energy needs without changing their body weight and will contain 2 g of protein per kilogram of body weight. Participants will be instructed to consume protein primarily from animal food sources. A high quality whey protein supplement will be provided as needed.
2966289|NCT02788942|No Intervention|Umbilical|The cholecystectomy material will be removed from umbilical port as usual. This will be control group. Port site infection rates will be measured.
2966290|NCT02788942|Experimental|Epigastric|The cholecystectomy material will be removed from epigastric port. This will be experimental group. Port site infection rates will be measured.
2966291|NCT02788929|Active Comparator|Fitbit Charge HR|"Use of the Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.~All patients will wear the Actigraph wGT3X-BT, from which data is extracted. Actigraph does not provide patient any feedback."
2966292|NCT02788929|No Intervention|No Device|No Fitbit used and no feedback on exercise goal adherence. All patients will wear the Actigraph wGT3X-BT, from which data is extracted. Actigraph does not provide patient any feedback.
2966293|NCT02788916||Cohort 1|Assessment of tumor biopsies and histological preparations of participants diagnosed with peripheral T-cell lymphoma (PTCL) in the six years between 01 January 2008 and 31 December 2013 will be performed.
2966294|NCT02788903||Diabetes|During year 1 of the proposed project, the investigative team will identify a valid cohort of patients with type 2 diabetes using EHR data. The cohort of patients under study will be defined as all patients age 18 and older with an indication of type 2 diabetes during the proposed study time frame (2009-2019).
2966295|NCT02788903||Pre-Diabetes|The cohort of patients under study will be defined as patients age 18 and older who are at risk for the development of diabetes, based on being overweight. Patients seen at one of the six PaTH institutions will be included in the at-risk cohort if they have a BMI ≥ 25 kg/m2, based on most recent recorded weight and at least one recorded height.
2966296|NCT02788890|Active Comparator|Control Group (T0)|The supragingival scaling without LA
2966297|NCT02788890|Experimental|Test Group 1 (T1)|The simple restoration under LA
2966298|NCT02788890|Experimental|Test Group 2 (T2)|The simple exodontia under LA
2966299|NCT02788877|Experimental|treat-and-extend|Aflibercept 2mg is injected into the vitreous cavity. An injection is given every 4 weeks five times and then the Treat-and-Extend process begins. If 1mm central subfield macular thickness (CSMT) improved (10% or more reduction) compared to the previous visit, the next treatment will be performed at the same interval. If CSMT is maintained (less than 10% changes), the next interval will be extended by two weeks (up to 12 weeks). If CSMT is worsened (10% or more increase), the next interval will be shortened by two weeks (minimum 4 weeks). If CSMT is stable two times at 12 weeks-interval, the injection will be deferred, and the next visit will be 8 weeks later. These process will be continued for 2 years.
2966300|NCT02788864|Active Comparator|Arterakine|Active drug: Arterakine (DHA/piperaquine) one tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinin; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
2966301|NCT02788864|Placebo Comparator|Placebo|Placebo (visually matched to Arterakine for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
2966302|NCT02788851|Active Comparator|Medication only|Stimulant or non-stimulant medication only - Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine. Investigators will be using a product approved for clinical use in Canada), with dose optimized for each participant based on report of efficacy and side effects. Once on an optimal dose of stimulant or non-stimulant medication they will attend 8 weekly education sessions about ADHD.
2966303|NCT02788851|Experimental|Aerobic Exercise only|Participants attend a structured aerobic exercise class, twice a week for 8 weeks.
2966304|NCT02788851|Active Comparator|Combination Group|Participants assigned to this group will be optimally medicated (either stimulant or non-stimulant medication - approved for clinical use in Canada) and will attend a structured aerobic exercise class, twice a week for 8 weeks.
2966305|NCT02788812|Active Comparator|Open modified Lichtenstein repair|
2966306|NCT02788812|Active Comparator|Laparoscopic TAPP inguinal hernia repair|
2966307|NCT02788799||Control|
2966308|NCT02788799||Intervention|
2966309|NCT02788786|Experimental|chlorhexidine|0.12% w/v chlorhexidine oral rinse; 15ml, twice-daily, for 12 weeks
2966310|NCT02788786|Experimental|cetylpyridinium chloride|non-alcoholic cetylpyridinium chloride oral rinse; 15ml, twice-daily, for 12 weeks
2966311|NCT02788786|Active Comparator|Salt and Water|Salt and water based oral rinse; 15ml, twice-daily, for 12 weeks
2966312|NCT02788786|No Intervention|No oral rinse|No rinse provided in this group
2966313|NCT02788773|Experimental|Arm A - Durvalumab plus Tremelimumab|Durvalumab-IV for 60 minutes day 1 every 4 weeks Tremelimumab-IV every 60 minutes day 1, cycles 1-4
2966314|NCT02788773|Experimental|Arm B - Durvalumab alone|Durvalumab-IV for 60 minutes day 1 every 4 weeks
2966315|NCT02788760|Other|6 weeks|This group of patients will be treated for 6 weeks with a cervical collar (Miami J collar - Össur)
2966316|NCT02788760|Other|12 weeks|This group of patients will be treated for 12 weeks with a cervical collar ( (Miami J collar - Össur)
2966317|NCT02788747|Experimental|4 mg elamipretide|4 mg elamipretide once daily for 28 consecutive days
2966318|NCT02788747|Experimental|40 mg elamipretide|40 mg elamipretide once daily for 28 consecutive days
2966319|NCT02788747|Placebo Comparator|Placebo|Placebo once daily for 28 consecutive days
2966320|NCT02788734||INC Contact Registry|INC Contact Registry will complete the online questionnaires
2966321|NCT02788721|Experimental|GLPG2451 single dose|Single dose of GLPG2451 oral suspension at up to 4 dose levels in ascending order
2966324|NCT02788695||Group 1 - aged 20-90 years|25 participants from each decade from 20-90. Those from 50+ will be recruited from the NICOLA study and retinal/lens images assessed to confirm normality.
2966325|NCT02788695||Group 2: aged 60 years|Group 2: 250 participants NICOLA participants aged 60 will be invited to participate; only those whose ocular images confirm normality will be included.
2966326|NCT02788682||Patients|WT+ Diplotype
2966327|NCT02788682||Controls|WT- Diplotype
2966328|NCT02788656|Experimental|Group A|Group A will receive sacubitril/valsartan + placebo for weeks 1-12. and then sacubitril/valsartan only for weeks 13-32. All subjects in Group A will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device).
2966329|NCT02788656|Active Comparator|Group B|"Group B will receive an Angiotensin-Converting Enzyme Inhibitor (ACEi) or Angiotensin II Type 1 Receptor Blocker (ARB) + placebo for weeks 1-6 (depending on previous background therapy) and then switch to sacubitril/valsartan + placebo for weeks 7-12.~Group B will then receive sacubitril/valsartan only for weeks 13-32. All subjects in Group B will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device)."
2966330|NCT02788630|Experimental|Intervention group|Arm: Experimental: Intervention group Field workers trained in sleep hygiene counseling will advice the mothers randomly allocated to the intervention group. The intervention will be delivered at the child household and will include information on: Normal sleep behaviors during the first year of life; ideal conditions to promote sleep onset like environmental improvements that ensure restful sleep (no screen media, low noise and light); calming naptime routines and avoiding stimulating or stressing children just before naptime; practices that promote child self-regulation of sleep, including putting infants to sleep drowsy but awake; and how to handle nighttime awakenings. A booklet with the intervention content to aid the mother in implementing the intervention will be used.
2966331|NCT02788630|No Intervention|Control group|Mothers randomly allocated to the control group will be visited at home following the same schedule as the intervention group. The control group will receive a written material describing the advantages of breastfeeding over maternal and child health. No advice in relation to child sleep hygiene will be delivered to the mothers from the control group.
2966332|NCT02788617||Non treatment group|This is a non-interventional study in which embryo selection is performed according to standard of care. The Diafert output, the granulocyte colony-stimulating factor (G-CSF) concentration in follicular fluid (FF), will be recorded but will not be used in patient management, ie, values will not be used for embryo selection in the assisted reproduction procedure.
2966333|NCT02788604|Experimental|Experimental Group|Participants in this arm will have a summary of their family's psychosocial risk factors provided to the treatment team. This will occur twice: once shortly after diagnosis (within 2-4 weeks) and once approximately 6 months following diagnosis.
2966334|NCT02788604|Active Comparator|Control Group|Participants in this arm will NOT have a summary of their family's psychosocial risk factors provided to the treatment team shortly after diagnosis. However, the risk factors will be distributed to the treatment team 6 months following diagnosis.
2966335|NCT02788591|Other|Proton Pump Inhibitor (PPI) Therapy|2x daily Proton Pump Inhibitor (PPI) Therapy for 8 weeks
2966336|NCT02788591|Other|Sucralfate|4x daily Sucralfate slurry, 1g, for 8 weeks
2966337|NCT02788552|Active Comparator|Acute Symptomatic WKS- 300mg|Thiamine Hydrochloride 300mg daily (i.e. 100mg 3 times/day) for 5 days
2966338|NCT02788552|Active Comparator|Acute Symptomatic WKS - 900mg|Thiamine Hydrochloride 900mg daily (i.e. 300mg 3 times/day) for 5 days
2966339|NCT02788552|Active Comparator|Acute Symptomatic WKS - 1500mg|Thiamine Hydrochloride 1500mg daily (i.e. 500mg 3 times/day) for 5 days.
2966340|NCT02788552|Active Comparator|High-risk subclinical WKS- 100mg|Thiamine Hydrochloride 100mg once daily for 3 days.
2966341|NCT02788552|Active Comparator|High-risk subclinical WKS- 300mg|Thiamine Hydrochloride 300mg (i.e. 100mg 3 time/day) for 3 days
2966342|NCT02788552|Active Comparator|High-risk subclinical WKS - 900mg|Thiamine Hydrochloride 900mg daily (i.e. 300mg 3 times/day) for 3 days.
2966343|NCT02788539|No Intervention|Science Cafe|One time event, Group discussion for 30 participants who are chronic pain stakeholders on pain in their community.
2966344|NCT02788539|Experimental|Cohort 1- Pilot OWL Study|Participants will pilot test a website- Our Whole Lives website for nine weeks in order to determine if it will help with their chronic pain management.
2966345|NCT02788526|Experimental|Adjuvant TACE|Adjuvant TACE were performed 4-6 weeks after surgery
2966346|NCT02788526|Other|Follow-up|Routine follow-up were performed instead of adjuvant TACE
2966347|NCT02788513|Experimental|BI 425809 dose 1|
2966348|NCT02788513|Experimental|BI 425809 dose 2|
2966349|NCT02788513|Experimental|BI 425809 dose 3|
2966350|NCT02788513|Experimental|BI 425809 dose 4|
2966351|NCT02788513|Placebo Comparator|Placebo|
2966352|NCT02788500||Swedish para-athletes|The total population of athletes in the Swedish Paralympic program, which covers candidates for the Paralympic Summer or Winter Games, will be invited by mail to participate in the study and report their incidence of sports-related injuries and illnesses
2966353|NCT02788487|Active Comparator|CPAP1 use and TRD 2use|Wash-in period 1 week and Continuous positive airway pressure (CPAP) is used for 3 weeks then wash-out 1 week and Tongue retaining device (TRD) is used for another 3 weeks
2966354|NCT02788487|Experimental|TRD1 use and CPAP2 use|Wash-in period 1 week and Tongue retaining device (TRD) is used for 3 weeks then Wash-out period 1 week and Continuous positive airway pressure (CPAP) is used for another 3 weeks
2966355|NCT02788474|Placebo Comparator|placebo|
2966356|NCT02788474|Experimental|nintedanib|
2966357|NCT02788461|Active Comparator|Chemoradiotherapy|Patients randomized to the standard arm will receive radiotherapy (5x per week) of 60 gray (Gy) in 30 fractions with concurrent cisplatin and etoposide chemotherapy.
2966358|NCT02788461|Experimental|Chemoradiotherapy with Integrated Boost Dose|Patients randomized to the experimental arm will receive radiotherapy (5x per week) with an integrated boost dose of up to 85Gy in 30 fractions to tumor subvolumes, with concurrent cisplatin and etoposide chemotherapy.
2966359|NCT02788448|Experimental|VIVASURE CLOSURE DEVICE|Large hole closure device
2966360|NCT02788435|No Intervention|Control|Patients in the control arm will undergo a graduated prescription of voice use immediately following surgery.
2966362|NCT02788422|Experimental|Video|Video discharge instructions developed using Easy Sketch Pro3TM software (Easy Sketch Pro, United Kingdom). It was created by the primary and co-investigator based results on a focus group consisting of two paediatric residents, two paediatric emergency medicine fellows, a paediatric emergency medicine nurse, and a paediatric emergency medicine staff physician.
2966363|NCT02788422|Active Comparator|Standard of care|This is a one-page paper handout created by the primary and co-investigator based results on a focus group consisting of two paediatric residents, two paediatric emergency medicine fellows, a paediatric emergency medicine nurse, and a paediatric emergency medicine staff physician.
2966364|NCT02788409||Medicare CRPC|Men in the US older than 65 years old having CRPC
2966365|NCT02788370|Sham Comparator|Sham-PEP breathing|Patients will perform a constant work load cycling test with sham-positive expiratory pressure breathing util symptom limit.
2966366|NCT02788370|Experimental|Conical-PEP breathing|Patients will perform a constant work load cycling test with positive expiratory pressure breathing using a conical positive expiratory pressure device until symptom limit.
2966367|NCT02788357|Experimental|Atomoxetine with motor training|40 mg atomoxetine paired with task-oriented therapy for 10 consecutive weekdays
2966368|NCT02788357|Placebo Comparator|Placebo with motor training|Placebo capsules paired with task-oriented therapy for 10 consecutive weekdays
2966369|NCT02788331||Hospitals with increasing activity|Hospitals experiencing an increase in the volume of surgical procedures over the study period
2966370|NCT02788331||Hospitals with decreasing activity|Hospitals experiencing a decrease in the volume of surgical procedures over the study period
2966371|NCT02788331||Hospitals with stable activity|Hospitals experiencing no change in the volume of surgical procedures over the study period
2966372|NCT02788318||diagnostic of SUDEP|patient with epilepsy in whom anamnestic and post-mortem evidence does not identify a particular cause (diagnosis of SUDEP). Brain samples and skin samples are collected.
2966373|NCT02788318||Control 1|Subjects with a known epilepsy, whose death is linked to a specific cause. Brain samples and skin samples are collected.
2966374|NCT02788318||Control 2|Subjects without known pathological history, remained victims of unexplained sudden unexpected death (SUDEP) after all investigations and for which a heart rhythm disorder is suspected in first intention. Brain samples and skin samples are collected.
2966375|NCT02788305||non obese|BMI<30. Misoprostol is given for induction of labour according to Bishop score
2966376|NCT02788305||obese|BMI>30. Misoprostol is given for induction of labour according to Bishop score
2966377|NCT02788292|Experimental|Acetylcysteine (NAC)|NAC added to tumescent solution for liposuction and eventual fat grafting.
2966378|NCT02788292|No Intervention|Control|Just tumescent solution for liposuction and fat grafting.
2966379|NCT02788279|Experimental|Atezolizumab|Participants will receive atezolizumab monotherapy 1200 milligrams (mg) intravenous (IV) on Day 1 in a 21-day cycle until disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
2966380|NCT02788279|Experimental|Cobimetinib + Atezolizumab|Participants will receive cobimetinib 60 mg orally on Days 1 to 21 plus atezolizumab 840 mg IV on Day 1 and Day 15 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
2966381|NCT02788279|Active Comparator|Regorafenib|Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
2966382|NCT02788266|Active Comparator|connective tissue graft+composite resin|connective tissue graft plus composite resin
2966383|NCT02788266|Active Comparator|connective tissue graft+ glass ionomer|connective tissue graft plus resin modified glass ionomer cement
2966384|NCT02788266|Active Comparator|connective tissue graft+giomer|connective tissue graft plus giomer
2966385|NCT02788240|Experimental|Peg GCSF with standard medical therapy|
2966386|NCT02788240|Active Comparator|Placebo with standard medical therapy|
2966387|NCT02788227|Experimental|1|Open label vaccine arm with booster.
2966388|NCT02788201|Experimental|Arm 1|Treatment regimen selected by COXEN model
2966389|NCT02788188|Experimental|Cohort 1|Cohort 1: 1mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%)
2966390|NCT02788188|Placebo Comparator|Placebo|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
2966391|NCT02788188|Experimental|Cohort 2|Cohort 2: 2.5 mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%)
2966392|NCT02788188|Experimental|Cohort 3|Cohort 3: 5mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%)
2966393|NCT02788188|Experimental|Cohort 4|Cohort 4: 10mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%)
2966394|NCT02788188|Experimental|Cohort 5|Cohort 5: 20mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
2966395|NCT02788188|Experimental|Cohort 6|Cohort 6: 50mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
2966396|NCT02788175|Experimental|1|HIV-infected Adults (age 18 - 65) on CART with suppressed viremia and CD4 greater than 450
2966397|NCT02788162|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2966398|NCT02788149|Experimental|STUDY GROUP|Model development group: This group will get Ultrasound of neck exam followed by polysomnography. We will use this group to identify the ultrasonographic parameters that have strong association of predicting obstructive sleep apnea. We will use these these predictors to estimate the patient's probability of severe OSA, which then will be used to test the receiver operating characteristic (ROC) curve of diagnosing severe OSA. The optimal cut-off value of the ROC curve will be defined as the one with the least (1 - sensitivity)2+ (1- specificity)2 in the model-development group. This formula will then tested in the validation group.
2966399|NCT02788149|Active Comparator|validation group|One third patients in the cohort will be randomly assigned to this group. This group will get ultrasound of neck exam followed by polysomnography. The predictors will be tested in his group.
2966400|NCT02788136|Experimental|Klinefelter syndrome|13 men with diagnosis of Klinefelter syndrome were stimulated with human chorionic gonadotropin (hCG)
2966401|NCT02788136|Active Comparator|Control|12 healthy age-related men were stimulated with human chorionic gonadotropin (hCG)
2966402|NCT02788123|Experimental|bismuth tripotassium dicitrate and pantoprazole|Participants will receive bismuth tripotassium dicitrate (twice daily) and pantoprazole (once daily) as single tablets
2966403|NCT02788123|Active Comparator|pantoprazole|Participants will receive pantoprazole (once daily) as single tablet
2966404|NCT02788110|Other|NIV NAVA then NIPPV|Infants will receive 15 minute trials of noninvasive neurally adjusted ventilatory assist (NIV NAVA) and nasal intermittent positive pressure ventilation (NIPPV) in random order with the first 10 minutes after changing to be considered a washout period and the last 5 minutes used for data collection. This group will receive NIV NAVA then NIPPV.
2966405|NCT02788110|Other|NIPPV then NIV NAVA|Infants will receive 15 minute trials of noninvasive neurally adjusted ventilatory assist (NIV NAVA) and nasal intermittent positive pressure ventilation (NIPPV) in random order with the first 10 minutes after changing to be considered a washout period and the last 5 minutes used for data collection. This group will receive NIPPV then NIV NAVA.
2966406|NCT02788097|Experimental|Progesterone + 4|the transfer of day 5 blastocyst on the 5th day of progesterone supplementation
2966407|NCT02788097|Active Comparator|Progesterone + 5|the transfer of day 5 blastocysts on the 6th day of progesterone supplementation
2966408|NCT02788084||B cell Non-Hodgkin Lymphoma|18 years of age or older with new diagnosis of non-Hodgkin lymphoma with FFPE specimen demonstrating enough tissue for elucidation of lymphoma specific variant and immunoglobulin clonotype, willing to provide baseline and follow up bloodwork to look for presence of variant and clonotype.
2966409|NCT02788071|Experimental|FMT capsules|FMT capsules
2966410|NCT02788071|Placebo Comparator|FMT placebo|Placebo capsules
2966411|NCT02788058|Experimental|EGFR-TKI|Patients take EGFR-TKI alone till tumor progression
2966412|NCT02788058|Active Comparator|EGFR-TKI+hypofractionated radiotherapy|After 3 mos TKI, patients with limited metastatic take EGFR-TKI concurrent with hypofractionated radiotherapy till tumor progression.
2966413|NCT02788045|Experimental|Group 1A: Ad26.Mos.HIV|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12, followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
2966414|NCT02788045|Placebo Comparator|Group 1B: Placebo|Participants will receive placebo at Weeks 0, 12, 24 and 48.
2966415|NCT02788045|Experimental|Group 2A: Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12; followed by Ad26.Mos4.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48. Participants will be included in an optional Long-term Extension (LTE) phase (3 year Follow-up after Week 72, every 6 months visit) to assess immunogenicity and safety (serious adverse events [SAEs]).
2966416|NCT02788045|Placebo Comparator|Group 2B: Placebo|Participants will receive placebo at Weeks 0, 12, 24 and 48.
2966417|NCT02788032|Other|EnergieShake Intervention|Single arm of intervention of Oral Nutritional Supplement in the open label study to be given to participants for 8 days Two 57g sachets of EnergieShake daily to be given to participants during the 8 day intervention period.
2966418|NCT02788019|Experimental|Mid-Thigh Adductor Block|Subject will receive a mid-thigh adductor block method using ropivacaine (0.5%, 15 mL).
2966419|NCT02788019|Active Comparator|Distal-Thigh Adductor Block|Subject will receive a distal-thigh adductor block method using ropivacaine (0.5%, 15 mL).
2966420|NCT02788006|Experimental|Regorafenib 160 mg|
2966421|NCT02787993|Active Comparator|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via (Cognitive Behavioral Multi-Symptom management (CBT) four one hour sessions.
2966422|NCT02787993|No Intervention|Treatment as usual|Treatment as usual
2966423|NCT02787980|Other|Patients = premature newborns|"Patients will consist of all premature babies (<37 weeks of amenorrhea), managed in the first 24 hours of life at the Reims university hospital for whom parents accepted to participate in the research Additional taking blood"
2966424|NCT02787980|Other|"Controls = children born full term"|"For controls the participation to research would be proposed to parents of children born full term, just after each patient child included.~Additional taking blood"
2966425|NCT02787967|Experimental|NEXThaler® 35/4µg|CHF 1535 35/4µg NEXThaler® Dry Powder Inhaler, 4 inhalations. Total Dose: BDP 200µg FF 16µg
2966426|NCT02787967|Active Comparator|Reference treatment|Drug: free comb. beclomethasone DPI and formoterol DPI 2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
2966427|NCT02787954||Transcatheter Chemoembolization or TACE|A technique called transcatheter chemoembolization (TACE) is used for some patients with liver cancer that cannot be treated surgically. The procedure is a way of delivering cancer treatment directly to a tumor through minimally-invasive means.
2966428|NCT02787954||Yittrium 90 or Y-90|Radioembolization is a minimally invasive procedure that combines embolization and radiation therapy to treat liver cancer. Tiny glass or resin beads filled with the radioactive isotope yttrium Y-90 are placed inside the blood vessels that feed a tumor. This blocks the supply of blood to the cancer cells and delivers a high dose of radiation to the tumor while sparing normal tissue.
2966429|NCT02787954||Microwave Ablation or MWA|Microwave ablation (MWA), destroys liver tumors using heat generated by microwave energy. A CT scan or ultrasonic guidance is used to pinpoint the exact location of the tumor. A thin antenna, which emits microwaves, is then inserted into the tumor. The probe produces intense heat that ablates (destroys) tumor tissue, often within 10 minutes.
2966430|NCT02787954||electroporation|Irreversible electroporation (IRE) is a nonthermal method of destroying the cell. A cell is subjected to a powerful electrical field using high-voltage direct current (up to 3 kV); this creates multiple holes in the cell membrane and irreversibly damages the cell's homeostasis mechanism, leading to instant cell death.
2966431|NCT02787941|Experimental|Intervention group|The intervention group will receive the pharmacist-delivered multifaceted intervention with two counselling sessions in addition to usual care.
2966432|NCT02787941|No Intervention|Control group|The control group will receive usual care without the pharmacist-delivered multifaceted intervention.
2966433|NCT02787928|Experimental|Intrathecal Dilaudid|This will be a prospective up/down dosage study. After obtaining informed consent, eligible participants will be part of an up/down dose titration study. This first phase of our study will be conducted using intrathecal (spinal) hydromorphone to determine an appropriate dose range for our study population. Study drug dose will initially be 40 mcg. The only deviation from the current standard of care will be that patients will be given hydromorphone intrathecally instead of morphine. The rest of the care provided will be standard of care and per current practices at VCU labor and delivery floor.
2966434|NCT02787915|Experimental|dendritic cell vaccine|DC1-CTL cellular therapy
2966435|NCT02787902|Experimental|Communication|Behavioral weight loss program with communication skills training
2966436|NCT02787902|Active Comparator|Standard|Standard behavioral weight loss program
2966437|NCT02787889|Experimental|Uneven Protein Intake Pattern|Subjects consumed either dietary protein intake at 1.1g protein/kg/day over 8 weeks.Each participant will consume 15%/2-%/65% of total protein in breakfast, lunch, and dinner, respectively)] on net protein synthesis over 8 weeks.
2966438|NCT02787889|Experimental|Even Protein Intake Pattern|Subjects consumed either dietary protein intake at 1.1g protein/kg/day over 8 weeks. Each participant will consume 33% of total protein consumed each meal
2966439|NCT02787876|Experimental|Chemotherapy induced neutropenia|Pegteograstim 100 ug/kg (maximum 6 mg) on day 7 of the chemotherapy cycle
2966440|NCT02787863|Experimental|COPD with immunovac VP4|35 patients with COPD will receive Immunovac VP4 on a combined scheme route + parenterally in combination with a base of antibacterial and symptomatic therapy
2966441|NCT02787863|Experimental|Asthma with immunovac VP4|35 patients with asthma, will receive Immunovac VP4 on a combined scheme route + parenterally in combination with basic and symptomatic therapy
2966442|NCT02787863|No Intervention|Asthma and COPD without vaccines|Patients with COPD and bronchial asthma: standard therapy without the use of vaccine preparation.
2966443|NCT02787863|Experimental|C-a pneumonia with Immunovac VP4 per os|35 patients with community-acquired pneumonia will receive Immunovac VP4 on a combined scheme route + oral in combination with basic antibacterial and symptomatic therapy
2966444|NCT02787863|Experimental|C-a pneumonia with Immunovac VP4 p/e|35 patients with community-acquired pneumonia will receive Immunovac VP4 on a combined scheme route + parenterally in combination with a base of antibacterial and symptomatic therapy
2966445|NCT02787863|No Intervention|C-a pneumonia without Immunovac VP4|35 patients with community-acquired pneumonia will be therapy without the use of vaccine preparation.
2966446|NCT02787863|Experimental|COPD with Polioxidonium|35 patients with COPD. Standard and antibacterial therapy with Polioxidonium.
2966447|NCT02787863|No Intervention|COPD without Polioxidonium|35 patients with COPD. Standard and antibacterial therapy without Polioxidonium.
2966448|NCT02787863|Experimental|COPD with Prevenar-13|30 patients with COPD. Standard therapy with Prevenar-13.
2966449|NCT02787863|Experimental|Asthma with Prevenar 13|30 patients with asthma. Standard therapy with Prevenar 13.
2966450|NCT02787863|Experimental|COPD with Pneumo-23|30 patients with COPD. Standard therapy with Pneumo-23
2966451|NCT02787863|Experimental|Asthma with Pneumo-23|30 patients with asthma. Standard therapy with Pneumo-23
2966452|NCT02787863|Experimental|COPD with Prevenar 13 & Pneumo-23|30 patients with COPD. Standard therapy, vaccinated with Prevenar 13 and after with Pneumo-23
2966453|NCT02787863|Experimental|Asthma with Prevenar 13 & Pneumo-23|30 patients with Asthma. Standard therapy, vaccinated with Prevenar 13 and after with Pneumo-23
2966454|NCT02787863|Experimental|COPD with Pneumo-23 and Prevenar 13|30 patients with COPD. Standard therapy, vaccinated with Pneumo-23 and after with Prevenar 13
2966455|NCT02787863|Experimental|Asthma with Pneumo-23 and Prevenar 13.|30 patients with Asthma. Standard therapy, vaccinated with Pneumo-23 and after with Prevenar 13
2966456|NCT02787850|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the abdomen with a new applicator design.
2966457|NCT02787837||Abiraterone Acetate|Abiraterone Acetate 1000 mg/24h plus Prednisone 5mg/12h
2966458|NCT02787824|Experimental|continuous iv administration of iron sucrose|Prior to the study, all our patients were receiving intravenous iron sucrose in an intermittent mode (every 1-4 weeks).Patients on this arm will receive the same previous dose of iron glucose but in a continuous mode (smaller doses of iron sucrose in every session).
2966459|NCT02787824|Active Comparator|intermittent iv administration of iron sucrose|Patients on this arm will continue to receive the same previous intermittent mode of iron sucrose.
2966460|NCT02787811|Active Comparator|Pregnant|women with positive serum beta HCG done 14 days after Intrauterine insemenation
2966461|NCT02787811|Active Comparator|Nonpregnant|women with negative serum beta HCG done 14 days after Intrauterine insemenation
2966462|NCT02787798|Experimental|Entresto|"Stop of all angiotensin-converting-enzyme inhibitor or antagonist of angiotensin II receptor during 2 days.~valsartan/sacubitril 100 mg tablets (51 and 49 mg) during 2 to 4 weeks twice a day.~valsartan/sacubitril 200 mg tablets (103 and 97 mg) during 2 to 4 weeks twice a day.~Microneurography recording of sympathetic activity in muscle destiny (MSNA)"
2966463|NCT02787798|Placebo Comparator|Control|"Hearth failure treatment as usual (angiotensin-converting-enzyme inhibitor or antagonist of angiotensin II receptor)~Microneurography recording of sympathetic activity in muscle destiny (MSNA) will be done"
2966464|NCT02787785|No Intervention|Conventional Medical Therapy|This arm of the trial continues with their current conventional medical therapy.
2966465|NCT02787785|Active Comparator|Subcutaneous Implantable Cardioverter Defibrillator|This arm of the trial receives a subcutaneous implantable defibrillator.
2966466|NCT02787772|Experimental|Elective Hernia Repair|Elective abdominal wall hernia surgery was performed in randomized cirrhotic patients.
2966467|NCT02787772|No Intervention|Clinical follow up|"Cirrhotic patients were kept in clinical follow up concerning their abdominal wall hernia.~If a complication occured at the hernia site (such as skin rupture, bowel strangulation,..) the patient underwent emergency hernia repair."
2966468|NCT02787759|Active Comparator|Hands-Free Walking|Body-weight supported treadmill training
2966469|NCT02787759|Experimental|Challenge Based plus Hands-Free|9 different balance and locomotor challenges applied during walking while not holding onto anything
2966875|NCT02784964|Experimental|Elixcyte 8mL|ADSC 6.4*10^7 cells, allogeneic injection, one time injection on Day 1
2966470|NCT02787746|Other|donepezil|This is a multi-center single-arm study, which assess the safety and efficacy of donepezil in mild to moderate Alzheimer's disease in China.
2966471|NCT02787733|Experimental|Citrus flavonoid|Citrus peel extract containing >90% flavonoids
2966472|NCT02787733|Placebo Comparator|Placebo|Identical looking placebo
2966473|NCT02787720|Experimental|Family centered empowerment model|The Family-Centered Empowerment Model (FCEM)
2966474|NCT02787720|Experimental|Continuous care model|The Continuous Care Model
2966475|NCT02787707|Active Comparator|intervention|2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour from 24 hour before to fifth day after chemotherapy.
2966476|NCT02787707|Placebo Comparator|control|2.7 grams Lactose every 8 hour from 24 hour before to fifth day after chemotherapy.
2966477|NCT02787694|Experimental|Factor Targeted Walking Training|Individuals undergo 5x 2 week periods of targeted training based upon evaluation of walking factor results
2966478|NCT02787681|Experimental|NEMO Gauge|Measurement and adjustment of endotracheal tube position by stylet.
2966479|NCT02787668|Experimental|Carbohydrate-restricted diet|This diet is designed to minimize intake of carbohydrate sources such as added sugars, high glycemic grains, and fructose and will provide ≤10% energy from CHO, 25% energy from protein, and ≥65% energy from fat. During the first two weeks of the intervention,
2966480|NCT02787668|Active Comparator|Control, low-fat diet|The control, low-fat diet will contain 55:25:20 %energy from CHO:protein:fat based on the USDA MyPlate Daily Food Plan. For example, an 1800kcal/d plan will include 5 ounces lean meats, 3 cups low-fat dairy, 6 ounces of whole grains, 1 ½ cups fruit, 2 ½ cups vegetables (starchy and non-starchy) and limited fats.
2966481|NCT02787655|Active Comparator|Aerobic Exercise + Cognitive Training Group|Exercise 3 times a week on a stationary ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes per session; plus 20 minutes of cognitive training using Mindfit program
2966482|NCT02787642|Experimental|Olaparib in association with concomitant radiotherapy|Olaparib will be administered per os bi-daily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression. Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
2966483|NCT02787629|Experimental|Simultaneous|Simultaneous Intubation with GlideScope and ETT inserted simultaneously
2966484|NCT02787629|Active Comparator|Control Standard|Standard Intubation with GlideScope inserted first and ETT inserted after the GlideScope view is obtained
2966485|NCT02787616||Rosacea Group|
2966486|NCT02787616||Non-Rosacea Group|
2966487|NCT02787603|Experimental|group A|Interruption of antibiotic treatment due to PCT measurement
2966488|NCT02787603|No Intervention|group B|Antibiotic therapy period will be determined by the physician without the knowledge of PCT levels.
2966489|NCT02787590|Active Comparator|Simvastatin|A one month low dose phase of 40mg oral simvastatin daily will be followed by a 23 month high dose phase of 80mg oral simvastatin daily and a final two month phase off trial medication
2966490|NCT02787590|Placebo Comparator|Matched Placebo|A one month low dose phase of 40mg matched placebo daily will be followed by a 23 month high dose phase of 80mg matched placebo daily and a final two month phase off trial medication
2966491|NCT02787577|Experimental|Sleep Lengthening|The intervention group will receive a personalised sleep consultation session to lengthen sleep by 1-1.5 hours per night by targeting sleep hygiene using behaviour change techniques for 4 weeks.
2966492|NCT02787577|No Intervention|Control|The control group will be asked to resume their normal lifestyle.
2966493|NCT02787564|Experimental|Free Fruit and Vegetables|After baseline assessment of food intake patterns, the intervention will consist of providing free fruits and vegetables of their choice for a period of four weeks which will be provided fresh each week. At baseline and at the end of the 4-week period, a FFQ, two 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered.
2966494|NCT02787564|No Intervention|Control Goup|At baseline and at the end of the 4-week period, a FFQ, four 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered. At the end of the intervention period they receive once a basket of free fruits and vegetables.
2966495|NCT02787551|Experimental|Insulin glargine/lixisenatide fixed ratio combination|Insulin glargine/lixisenatide fixed ratio combination (FRC) is injected subcutaneously (SC, under the skin) once daily (QD). Dose individually adjusted. Metformin, pioglitazone (if taken prior to entry in the trial), and SGLT2 inhibitor (if taken prior to entry in the trial) treatments should be continued.
2966496|NCT02787551|Active Comparator|Liraglutide/Exenatide/Exenatide ER/Albiglutide/Dulaglutide|Liraglutide will be injected SC (under the skin) QD, and exenatide will be injected SC (under the skin) twice daily (BID). Exenatide extended-release, albiglutide, and dulaglutide are injected SC (under the skin) once weekly. Metformin, pioglitazone (if taken prior to entry in the trial), and SGLT2 inhibitor (if taken prior to entry in the trial) treatments should be continued.
2966497|NCT02787538|Experimental|US-ANSWER-2 decision aid|The intervention group will receive simple instructions to access the US-ANSWER-2 decision aid and complete the program on their own computers within two days. At the end of the session, US-ANSWER-2 will produce a one-page summary with the participant's questions, concerns, and preferred medication option.
2966498|NCT02787538|Active Comparator|Control group (Online medication guide)|The control group will receive the online medication guide, reflective of usual practice. The online medication guide contains standard information about biologics, including an introduction about biologic options, dosages, and effects.
2966499|NCT02787525||A: patients on anticoagulation|Questionnaire to patients with non-valvular atrial fibrillation on OAC or NOAC
2966500|NCT02787525||B: patients treated by LAA-Closure|Questionnaire to patient with non-valvular atrial fibrillation who underwent LAAC between 2009 and 2014 at the University hospitals Bern or Zurich
2966501|NCT02787512|Active Comparator|Plastic stent|10 Fr plastic stent (Percuflex Amsterdam® or C-flex pigtail® or Advanix® Biliary stent)
2966502|NCT02787512|Experimental|Uncovered metal stent|Uncovered metal stent (WallFlex® Biliary RX stent)
2966503|NCT02787499|No Intervention|Standard of Care|Follows the 2013 World Health Organization (WHO) HIV treatment guidelines. Study participants will receive adherence support and return for a repeat viral load test in 3 months (or in 1 month for pregnant participants). Treatment failure will be defined by two consecutive viral load measurements greater than 1,000 copies/mL. Participants who meet this criteria will be switched to second-line therapy. Those with a viral load <1,000 copies/mL at repeat testing will be retained on first-line therapy.
2966504|NCT02787499|Experimental|HIV-1 RNA Resistance Testing|Participants will receive HIV-1 RNA drug resistance testing at study enrollment. ART treatment regimen decisions will be determined based on the results of resistance testing.
2966505|NCT02787486||Aneuploidy Arm|Includes pregnant women at high risk for fetal chromosome aneuploidy for serum screening
2966506|NCT02787486||TORCH Arm|Infectious disease arm: Toxoplasmosis, other viruses, rubella, cytomegalovirus, and herpes simplex virus (TORCH). Includes pregnant women at low-risk for fetal aneuploidy that may be at increased risk for fetal infection for serum screening
2966507|NCT02787473|Experimental|pemetrexed+carboplatin/cisplatin+radiation therapy->docetaxel|Patients received pemetrexed 500mg/m2 days 1,29+cisplatin 25 mg/m2 days 1-3,29-31 + Radiation 6000 cGy (200 cGy/day). Patients with complete response(CR), partial response(PR) or stable disease(SD) with manageable toxicity received docetaxel 60 mg/m2 days 57,78.
2966508|NCT02787460|Experimental|Behavioral Text Messages|Couples assigned to a treatment group will receive weekly behavioral theory-based messages encouraging them to attend the sessions.
2966509|NCT02787460|No Intervention|Simple Reminder Text Messages|"Couples in the control group will receive simple reminder text messages that include the date, time, and location of their next group session"
2966510|NCT02787447|Experimental|1|After 3 mos TKI, patients showed stable disease take TKI, radiotherapy and thymosin alpha 1 till tumor progression.
2966511|NCT02787434|Experimental|PCSPrep decision aid|All participants recruited to the trial will receive the decision aid. This a one-group study with a quasi-experiemental pre/post evaluation design.
2966512|NCT02787421|Experimental|Functional Rhinoplasty|Participants undergoing functional rhinoplasty for nasal valve compromise and obstruction at the Emory Aesthetics Center.
2966513|NCT02787408|Experimental|EW Tricuspid Transcatheter Repair System|Edwards (EW) Tricuspid Transcatheter Repair System
2966514|NCT02787395|Experimental|Milch|modified Milch technique for self reduction
2966515|NCT02787395|Experimental|Boss Holtzach|Boss Holtzach technique for self reduction
2966516|NCT02787395|Experimental|Stimson|Stimson technique for self reduction
2966517|NCT02787382|Experimental|Pregnant women with CMV infection|"An attempt to record the fetal myocardium will be done at the initial examination and at all the follow up examinations performed during pregnancy (every 3-4 weeks according to the clinical protocol currently in use at the OB-GYN US Unit).~The participants will undergo a detailed fetal echocardiography according to standard guidelines (see below, section echocardiography)."
2966518|NCT02787382|Experimental|Pregnant women with suspected CMV infection|"The healthy women from the group will serve as controls. An attempt to record the fetal myocardium will be done at the initial examination and at all the follow up examinations performed during pregnancy (every 3-4 weeks according to the clinical protocol currently in use at the OB-GYN US Unit).~The participants will undergo a detailed fetal echocardiography according to standard guidelines (see below, section echocardiography). As the control group-Newborns found to be negative for CMV will serve as control group."
2966519|NCT02787369|Experimental|Combination of ACY-1215 With Ibrutinib|ACY-1215 and Ibrutinib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.
2966520|NCT02787369|Experimental|Combination of ACY-1215 With Idelalisib|ACY-1215 and Idelalisib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.
2966521|NCT02787356|Experimental|TDS Lidocaine 5%; generic|TDS Lidocaine 5%; generic with trained skin graders and images of skin
2966522|NCT02787356|Experimental|TDS Lidocaine 5%; RLD|TDS Lidocaine 5%; RLD with trained skin graders and images of skin
2966523|NCT02787330|Active Comparator|Control Group|Behavioural: Participants in this arm will experience an 8-week manualized intervention program with activities and games. Sessions will NOT be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will NOT have a specific focus. Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
2966524|NCT02787330|Experimental|Experimental Group|Behavioural: Participants in this arm will experience an 8-week manualized intervention program which focuses on education, therapeutic problem solving, and social support. Each intervention session is structured by theme relevant to the cancer experience and themes are addressed through fun activities, games, arts, and crafts.To maximize the therapeutic effect of the intervention fun work (homework) will be assigned after each session. Training for the EG facilitators requires reading and studying the manual to become fully familiarized with the intervention approaches, observing group sessions through a one-way mirror prior to participation as a group facilitator, and participating as a group facilitator assistant for the intervention program.
2966525|NCT02787317|Active Comparator|heparin|For the heparin group, a bolus dose of 100 U/kg was administered according to current guidelines.
2966526|NCT02787317|Experimental|not prolong infusion Bivalirudin|Bivalirudin was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure .
2966527|NCT02787317|Experimental|prolong infusion bivalirudin|Bivalirudin was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and prolong for 4 hours after procedure.
2966528|NCT02787304|Experimental|SHP626 5 Milligram (mg)|Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
2966529|NCT02787304|Experimental|SHP626 10 Milligram (mg)|Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
2966530|NCT02787304|Experimental|SHP626 20 Milligram (mg)|Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
2966531|NCT02787304|Placebo Comparator|Placebo (PBO)|Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
2966632|NCT02786628||Solid tumor malignancies|15 patients. Will participate in physical performance testing and patient-generated health data.
2966532|NCT02787291|Other|Ellipse VR ICD and Durata/Optisure lead|Pts with Ellipse VR ICD and Durata or Optisure RV lead implanted for at least 60 days will receive a non-diagnostic MRI scan of head and chest region
2966533|NCT02787278|Experimental|SP-8203 High dose group|SP-8203 160mg (80mg/dose twice a day for three days)
2966534|NCT02787278|Experimental|SP-8203 Low dose group|SP-8203 80mg (40mg/dose twice a day for three days)
2966535|NCT02787278|Placebo Comparator|Placebo group|Placebo group: twice a day for three days
2966536|NCT02787265||spinal cord stimulation|Failed back surgery syndrome patients will receive high density spinal cord stimulation
2966537|NCT02787252|Experimental|HF DRG|HF DRG Implants
2966538|NCT02787239|Experimental|HLX01|375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
2966539|NCT02787239|Active Comparator|Rituximab|375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
2966540|NCT02787226|Active Comparator|TSA - Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension for postoperative analgesia after total shoulder arthroplasty (TSA).
2966541|NCT02787226|Active Comparator|Reverse TSA - Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension for postoperative analgesia after reverse total shoulder arthroplasty (TSA).
2966542|NCT02787226|Active Comparator|TSA - Continuous Perineural Ropivacaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine for postoperative analgesia after TSA.
2966543|NCT02787226|Active Comparator|Reverse TSA - Continuous Perineural Ropivacaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine for postoperative analgesia after reverse TSA.
2966544|NCT02787213||Women with preterm delivery|
2966545|NCT02787213||Women without preterm delivery|
2966546|NCT02787187|Active Comparator|Standard resection|Pancreaticoduodenectomy (child's digestive reconstruction); Standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
2966547|NCT02787187|Experimental|Extended resection|Pancreaticoduodenectomy (child's digestive reconstruction)extended lymphadenectomy No8p 12a 12p 14c 14d 16
2966548|NCT02787174|No Intervention|Control|Participants will receive routine clinical treatment care.
2966549|NCT02787174|Experimental|Intervention|Participants will receive interactive tailored asthma medication adherence education on an iPad.
2966550|NCT02787161|Active Comparator|Hemodialysis|Patients already on high flux hemodialysis, continue the same treatment with high flux hemodialysis.
2966551|NCT02787161|Experimental|Hemodiafiltration|Patients who already make high flux hemodialysis, have become hemodiafiltration.
2966552|NCT02787148|Experimental|Cognitive behavioral therapy|Cognitive behavioral therapy for Major Depression
2966553|NCT02787148|No Intervention|Waitlist group|Waitlist group to control for repeated physiological measures and fluctuations over time
2966554|NCT02787135|Active Comparator|CBTd-E|Experimental: emotion-oriented Cognitive Behavior Therapy focused on delusions for patients with schizophrenia-spectrum disorders and delusions. The therapeutical intervention follows a treatment-manual consisting of two modules. Patients work on two modules every week for 25 weeks in a row. Module I comprises psychoeducation on emotions, training radical acceptance of emotions and mindfulness, cognitive and behavioral strategies in order to change negative emotions and in order to foster positive emotions and suggestions for life-style changes (positive activities, sports, stress reduction). In the second module, the focus is on self-acceptance. Patients receive psychoeducation on self-acceptance and learn strategies in order to reduce negative self-schema and foster positive self-schema.
2966555|NCT02787135|Placebo Comparator|Treatment as Usual|Patients who are randomized and assigned to the Wait-list receive treatment as usual (regular visits to a physicist every third month and antipsychotic medication). After six month the waiting list patients receive the treatment specified above.
2966556|NCT02787122|Active Comparator|CBT-E|"Emotion-focussed Cognitive behavior therapy:~Patients receive 25 sessions of individual emotion-focused Cognitive Behavior Therapy. Interventions are behavioral activation, training of emotion regulation strategies, improvement of self-esteem and relapse prevention."
2966557|NCT02787122|Placebo Comparator|Treatment as Usual|Patients who are randomized and assigned to the Wait list are required to wait for half a year, while they receive standardized care (antipsychotic medication). After half a year, they receive CBT-E, as well.
2966558|NCT02787109|Experimental|CTH522-CAF01|"CTH522-CAF01: CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration (preferably the non-dominant arm)~CTH522 chlamydia antigen diluted with Tris buffer for IN administration"
2966559|NCT02787109|Experimental|CTH522-Al(OH)3|"CTH522-Al(OH)3: CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration (preferably the non-dominant arm)~CTH522 chlamydia antigen diluted with Tris buffer for IN administration"
2966560|NCT02787109|Placebo Comparator|Placebo|Saline for IM and In administrations
2966561|NCT02787096|Experimental|laxIRM|Patients will have dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear
2966562|NCT02787083|Experimental|Mirabegron|These patients will receive mirabegron 50mg tablets daily for 12 weeks.
2966563|NCT02787083|Placebo Comparator|Placebo|These patients will receive placebo tablets daily for 12 weeks.
2966564|NCT02787070|Active Comparator|Primaquine supervised|14 days of supervised primaquine treatment (0.5mg/kg/day).
2966565|NCT02787070|Active Comparator|Primaquine unsupervised|14 days of unsupervised primaquine treatment (0.5mg/kg/day).
2966566|NCT02787057|Experimental|Control group|IP vancomycin 1g every 5 days combined with IP ceftazidime 1g QD. The duration of treatment was based on internatinal society of peritoneal dialysis (ISPD) guideline recommendations.
2966567|NCT02787057|Active Comparator|study group|IP vancomycin 1g every 5 days combined with oral moxifloxacin 400mg QD. The duration of treatment was based on ISPD guideline recommendations.
2966568|NCT02787044|Experimental|High Dose Influenza Vaccine|High Dose Influenza Vaccine
2966569|NCT02787044|Active Comparator|Standard Dose Influenza Vaccine|Standard Dose Influenza Vaccine
2966570|NCT02787031||Neuraxial anesthesia|Participants in this group will be those who had a spinal or epidural anesthetic without concurrent general anesthesia
2966571|NCT02787031||General anesthesia|Participants in this group will be those who had general anesthesia, including those who had a general plus a concurrent spinal or epidural anesthetic.
2966572|NCT02787018|Placebo Comparator|Block with Ropivacaine and Normal saline|Patients will receive brachial plexus block with 20 ml 0.5% ropivacaine with 1ml normal saline: Total volume 21 ml
2966573|NCT02787018|Active Comparator|Block with Ropivacaine and Dexamethasone|Patients will receive brachial plexus block with 20ml 0.5% ropivacaine with 4mg (1ml) dexamethasone: Total volume 21 ml
2966574|NCT02787018|Experimental|Block with Ropivacaine and Dexmedetomidine|Patients will receive brachial plexus block with 20ml 0.5% ropivacaine with 50mcg (1ml) dexmedetomidine: Total volume 21 ml
2966575|NCT02787005|Experimental|Cohort 1: PD-L1 positive with measurable disease|Participants with programmed cell death ligand 1 (PD-L1)-positive, measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
2966576|NCT02787005|Experimental|Cohort 2: PD-L1 negative with measurable disease|Participants with PD-L1 negative, measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
2966577|NCT02787005|Experimental|Cohort 3: Bone metastases with non-measurable disease|Participants with bone metastases and non-measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
2966578|NCT02787005|Experimental|Cohort 4: RECIST 1.1-measureable disease|Participants with Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)-measureable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle and enzalutamide via oral capsules once daily for up to 2 years. The dose of enzalutamide will be the same dose each participant was receiving before the start of pembrolizumab treatment.
2966579|NCT02787005|Experimental|Cohort 5: Bone metastases only or bone-predominant disease|Participants with bone metastases only or bone-predominant disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle and enzalutamide via oral capsules once daily for up to 2 years. The dose of enzalutamide will be the same dose each participant was receiving before the start of pembrolizumab treatment.
2966580|NCT02786992|Active Comparator|Misoprostol + Oxytocin|400 ug sublingual misoprostol + 10 IU Oxytocin IVI
2966581|NCT02786992|Active Comparator|Carbetocin|100 ug Carbetocin IV
2966582|NCT02786979|Experimental|Beraprost sodium tablet and Aspirin combination group|Oral
2966583|NCT02786979|Experimental|Aspirin Group|Oral
2966584|NCT02786966|Other|Canadian C-Spine Rule|Paramedic assessment for potential cervical spine injuries using the Canadian C-Spine Rule
2966585|NCT02786953|Experimental|Sleep Promotion|Behavioral sleep-promoting intervention, including components such as limiting caffeine, establishing a media curfew, and positive bedtime routines, as well as needs unique to adolescents with T1D, such as fear of hypoglycemia.
2966586|NCT02786953|No Intervention|Usual Care|Usual Care
2966587|NCT02786940|Experimental|Live Remote Cardiac Monitoring|Live remote cardiac monitoring with transmission of cardiac rhythm (device-triggered: if rhythm abnormalities detected by device algorithm; or patient-triggered by pressing the transmit button because of symptoms) for 15 days.
2966588|NCT02786940|Active Comparator|Usual Care|Mobile Cardiac Telemetry (PocketECG; Medicalgorithmics S.A) will be used in the control arm. This device combines holter, event monitoring and mobile cardiac telemetry (continuous live cardiac monitoring of every single beat) into one unit. The holter functionality will be used for the first 48 hours (usual care). The diagnostic yield from the 48 hour holter monitoring and patients seeking care based on their symptoms for the additional 13 days will be compared to the 15-day live monitoring.
2966589|NCT02786927|Experimental|ELLIPTA - HANDIHALER; HANDIHALER Questionnaire Version 1|Subjects will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the HANDIHALER inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 1 of the inhaler preference questionnaire.
2966590|NCT02786927|Experimental|ELLIPTA - HANDIHALER; Questionnaire Version 2|Subjects will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the HANDIHALER inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 2 of the inhaler preference questionnaire.
2966591|NCT02786927|Experimental|HANDIHALER - ELLIPTA; Questionnaire Version 1|Subjects will be dispensed the HANDIHALER inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 1 of the inhaler preference questionnaire.
2966592|NCT02786927|Experimental|HANDIHALER - ELLIPTA; Questionnaire Version 2|Subjects will be dispensed the HANDIHALER inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 2 of the inhaler preference questionnaire.
2966593|NCT02786901|Experimental|Loteprednol Etabonate Ophthalmic Gel dosed TID|Gel
2966594|NCT02786901|Experimental|Loteprednol Etabonate Ophthalmic Gel dosed BID|Gel
2966595|NCT02786901|Active Comparator|Vehicle Gel dosed TID|Vehicle
2966596|NCT02786901|Active Comparator|Vehicle Gel dosed BID|Vehicle
2966597|NCT02786888||conventional needle|conventional needle used
2966598|NCT02786888||fenestrated needle|fenestrated needle used
2966599|NCT02786875|Experimental|Group A (high intensity program):|
2966600|NCT02786875|Active Comparator|Group B (lower intensity program)|
2966601|NCT02786862|Experimental|Ventilation|Measurements were made for conventional and independent at 1:1 proportion ventilation in supine position; then independent ventilation was discontinued and patient was moved to right or left decubitus position due to left or right lung surgery. Then were made measurements for conventional anaesthetic practices and followed independent at 1:1, 2:1, 3:1, 5:1 proportions ventilation routines. Constantly were monitored expired volume, peak respiratory pressure, dynamic compliance separately for each lung. Measurements covered also hemodynamic (MAP, HR) and oxygenation (SpO2). These attributes were documented at each point of the study. Subsequently, the control system was disconnected and performed typical anaesthetic procedures for thoracic surgery with a one-lung ventilation procedure.
2966602|NCT02786849|Experimental|Group of high frequency and intensity|Group realized high frequency and intensity neuromuscular electrical stimulation
2966603|NCT02786849|Experimental|Group of low frequency and intensity|Group realized neuromuscular electrical stimulation of low frequency and intensity
2967331|NCT02781753|Active Comparator|Pegasys|Peginterferon 180 μg single dose S.C.
2966604|NCT02786836|Experimental|13C-Methacetin Testing|All patients enrolled into the ALFSG Registry with the duration of illness <26 weeks with (1) severe acute liver injury; International Normalized Ratio (INR) ≥2.0) and not related to acetaminophen overdose, with no evidence of hepatic encephalopathy (HE); and (2) acute liver failure; INR ≥1.5 with presence of any degree of HE will perform the Breath Test.
2966605|NCT02786823|Experimental|Folic acid|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive tab. Folic acid 5 mg once daily for 8 weeks
2966606|NCT02786823|Experimental|Vitamin B12|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive tab. Vitamin B12 500 mcg once daily for 8 weeks
2966607|NCT02786823|Experimental|"Folic acid and Vitamin B12"|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive both tab. Folic acid 5 mg once daily and tab. Vitamin B12 500 mcg once daily for 8 weeks
2966608|NCT02786823|Active Comparator|Control|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and receive no additional supplementation
2966609|NCT02786810|Other|Contrast|All subjects will be recruited into this arm. All subjects will receive 0.03 ml/kg IV sulfur hexafluoride type-a lipid microspheres one time, unless a second, adjusted dose is necessary.
2966610|NCT02786797|Experimental|MBSR(BC) 6 Week Program|Participants who are randomized to MBSR(BC) program will receive of educational material; group practice of mindfulness meditation (MM) and homework assignments; and group processes related to the practice of MM and supportive group interaction. Participants who receive MBSR will receive training in (1) sitting meditation anchored to the breath; (2) body scan (observing body sensations from the toes to the head); (3) Gentle Yoga (postures and stretches that increase awareness and balance; and (4) walking meditation. Through this arm of the study the goal is to enhance executive cognition through training in self-regulation of attention and acceptance of experience.
2966611|NCT02786797|Active Comparator|BCES Education Support Program|Participants who are randomized to the BCES program will be scheduled for 6 weekly, 2-hour sessions. BCES compared to MBSR(BC) meets the following criteria: (1) professional contact and group support time matched equally to the MBSR(BC) program; and (2) the content or activities of the BCES program does not include meditation or attention, relaxation, yoga, body scan, or walking meditation. This program is as an active control condition that accounts for nonspecific effects related to attention from the leader and favorable outcome expectancy, the educational materials provided and supportive interaction between group members and is matched for homework activity time over the 6 months. This group will be offered the MBSR(BC) program within 4 to 6 months after study completion.
2966612|NCT02786797|No Intervention|Usual Care|Participants who are randomized to the Usual Care (UC) or control group will continue to receive standard post-treatment medical and nursing clinic visits that will not be modified by study participation. The UC participants will participate in their standard care appointments and will not be required to alter their UC regimen; however, they will be asked not to initiate a mindfulness program during the study period. The UC group will be offered the MBSR(BC) program within 4 to 6 months after study completion.
2966613|NCT02786784|Other|healthy control|patients with patellofemoral pain
2966614|NCT02786771|Experimental|Spire device without & with feedback|Participants will receive a Spire device with user-feedback switched off within 4 days of enrollment in the study (shipped within 2 business days after they finish enrollment survey). Participants will be given 4 days, after enrollment, to set up their device before the 2 weeks of baseline. The 2 week baseline will start 4 days after enrollment. After two weeks of baseline with user-feedback off (and a 3 day transition period), participants will turn on the user-feedback for the Spire device which would provide a relaxation aid for the participant for the 6 remaining weeks.
2966615|NCT02786771|Experimental|Muse device & spire device no feedback|Participants in this group will also receive Spire device to assess two weeks of baseline stress levels (with user-feedback off). Participants will be given 4 days, after enrollment, to set up their device before the 2 weeks of baseline. The 2 week baseline will start 4 days after enrollment. After these two weeks, participants will continue to use the Spire device with user feedback off for the remaining 6 weeks while they use the Muse device to manage stress through meditation. They will receive the Muse device 3 days before the end of baseline period with set up instructions and will utilize the three last days of baseline to set up their Muse device, Meditation will begin at the end of baseline (week three) and will continue for the remaining 6 weeks.
2966616|NCT02786745|Experimental|Dapsone gel|Dapsone gel applied topically to the face once daily for 12 weeks
2966617|NCT02786745|Placebo Comparator|Placebo|Vehicle control applied once daily for 12 weeks
2966618|NCT02786732|Experimental|210mg Brodalumab|Administered by subcutaneous injection until Week 12
2966619|NCT02786732|Experimental|140mg Brodalumab|Administered subcutaneous injection until Week 12
2966620|NCT02786732|Active Comparator|Ustekinumab|Administered subcutaneous injection until Week 52
2966621|NCT02786732|Placebo Comparator|Placebo|Administered subcutaneous injection until Week 12
2966622|NCT02786719|Experimental|Neuroblastoma treatment without G-CSF|Induction chemotherapy only, including 6 cycles of chemotherapy, tumor resection, and stem cell collection
2966623|NCT02786706|Other|Optic nerve ultrasound|All patients will undergo Optic Nerve Ultrasound (ONUS), with measurement of Optic Nerve Sheath Diameter (ONSD) by both an expert investigator as well as by the automated image analysis algorithm.
2966624|NCT02786693||FUO and SII patients|Patients with fever > 38,3°C for more than a week, OR CRP> 5mg/L, without diagnosis after a first step clinical examination and paraclinical exams.
2966625|NCT02786680|Experimental|stroop test in condition DBS off|Condition 1 : On Med /Off Stim
2966626|NCT02786680|Active Comparator|stroop test in condition DBS on|Condition 2 : On Med /On Stim
2966627|NCT02786667|Experimental|Rotigotine|6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month
2966628|NCT02786667|Placebo Comparator|Placebo|6 months treatment with Placebo up to 8 mg per day with a titration period for one month
2966629|NCT02786641|Active Comparator|Group A|low risk NPC treated with concurrent chemoradiotherapy
2966630|NCT02786641|Active Comparator|Group B|high risk NPC treated with concurrent chemoradiotherapy
2966631|NCT02786641|Experimental|Group C|high risk NPC treated with induction chemotherapy plus concurrent chemoradiotherapy
2966633|NCT02786628||Hematologic malignancies|15 patients. Will participate in physical performance testing and patient-generated health data.
2966634|NCT02786628||Hematopoietic cell transplantation|15 patients. Will participate in physical performance testing and patient-generated health data.
2966635|NCT02786615|Experimental|Peer Unity|Subjects assigned to this arm would receive a 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
2966636|NCT02786615|No Intervention|Pre-implementation|Subjects assigned to this arm would not receive the group-delivered intervention.
2966637|NCT02786589|Experimental|Blood-stage infection of P. vivax|This is a single arm study that enrolls 30 patients to receive Plasmodium immunotherapy.
2966638|NCT02786576||Participants receiving adalimumab|Hidradenitis Suppurativa (HS) participants receiving adalimumab
2966639|NCT02786563||Participants with RA receiving adalimumab|This group contains participants in China with RA receiving adalimumab
2966640|NCT02786550|Experimental|Botulinum Toxin|"Immediately after lower blepharoplasty surgery 3 injections of 2.5U of botulinum toxin over lateral part of orbicularis oculi muscle.~Intervention: Botulinum toxin injection"
2966641|NCT02786550|Placebo Comparator|Normal saline|"Immediately after lower blepharoplasty surgery 3 injections of same amount of normal saline over lateral part of orbicularis oculi muscle.~Intervention: Normal saline injection"
2966642|NCT02786537|Active Comparator|sofosbuvir/ledipasvir|Subjects will take 1 tablet sofosbuvir/ledipasvir orally once daily with or without food 12 to 24 weeks with or without ribavirin (RBV) (per discretion of provider)
2966643|NCT02786537|Active Comparator|ombitasvir/paritaprevir/ritonavir & dasabuvir (Phase 1 only)|Phase 1 only - Two ombitasvir/paritaprevir/ritonavir once daily and dasabuvir twice daily for 12 to 24 weeks +/- RBV (provider discretion)
2966644|NCT02786537|Active Comparator|elbasvir/grazoprevir tablet|Subjects will take elbasvir/grazoprevir tablet tablet once daily with or without RBV for 12 to 16 weeks (provider discretion)
2966645|NCT02786524|No Intervention|Standard of Care|Patients randomized to this arm receive standard symptom management care by their primary gynecologic oncologist and complete the NCCN distress thermometer and ESAS-r at each visit, every 3-4 weeks.
2966646|NCT02786524|Experimental|Symptom Management and Supportive Care|Patients randomized to this arm are referred to a specialized symptom management and supportive care clinic and seen within two weeks. Patients will be seen in follow-up as recommended by the symptom management providers, and at each visit they will complete the ESAS-r and NCCN distress thermometer and return their responses either in person or by mail to the study team in a pre-addressed postage paid envelope.
2966647|NCT02786511||Subjects with multiple myeloma|Subjects treated with ex vivo gene therapy in a bluebird bio sponsored trial who agree to participate in this study.
2966648|NCT02786498|Experimental|High Loading Dose|150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.
2966649|NCT02786498|Experimental|High Daily Dose|Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.
2966650|NCT02786498|Experimental|Low Daily Dose|Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.
2966651|NCT02786498|Placebo Comparator|Control Group|Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.
2966652|NCT02786485|Experimental|BPX-501 and Rimiducid (AP1903|"All subjects will receive 3 courses of BPX-501 T cell infusions at 30 day intervals with 2 escalating dose levels (DL). DL1 on Day 0 and DL2 on Days 30 and 60.~Escalating doses of AP1903 (0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion."
2966653|NCT02786472|Active Comparator|Haven|"Online Bystander Training or Haven provides students with definitions and statistics associated with sexual assault and relationship violence, bystander skills and strategies, and campus policies and resources. The trainings are personalized and reflective and incorporate the student's unique perspectives and experiences. This 45-minute training is mandatory and students are asked to complete a follow-up survey 45-days after the training. Because this training is mandatory for all incoming students, all students are expected to have exposure to this training."
2966654|NCT02786472|Active Comparator|AlcoholEdu|Online Substance Abuse Training or AlcoholEdu provides confidential substance abuse education course which uses a science-based approach to educate students about alcohol and its effects. Whether the student drinks or not, the course will help them make informed decisions about alcohol and better deal with drinking behavior that may occur around them. AlcoholEdu is used by more than 500 colleges nationwide through EVERFi.
2966655|NCT02786472|Experimental|ConnectEd|In-person Combination Training provides Green Dot Intensive Bystander Training AND Substance Abuse Prevention cross-programming to develop ConnectED. The intentional coordination between substance abuse and violence prevention programming would include in-depth information related to interpersonal violence and substance use/abuse, activities to help participants explore their connection to these issues; information and activities related to the culture of violence, drinking and drug use and how everyone has a role in impacting that culture; information about bystander behaviors and barriers to taking action when they encounter problem situations; participant self-evaluation of their own attitudes, beliefs and biases around these issues; and, in-depth skill building activities to prepare participants to safely intervene in problem situations.
2966656|NCT02786472|Experimental|GreenDot|"In-person Bystander Training provides Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions. While a Popular Opinion Leader strategy has been used in prior training, for this trial all incoming students randomized to this condition will be offered intensive bystander training.~NOTE: Green Dot Speeches will be supplemental to Intensive Green Dot Bystander training. These speeches will continue to occur as usual. As the aim of this study is to compare bystander intensive training, we will not attempt to limit participation to Green Dot Speeches."
2966685|NCT02786264||Dexmedetomidine-dominant Sedation|Patients receiving dexmedetomidine infusion for TAVR as the primary drug for sedation.
2966686|NCT02786264||Fentanyl and/or Midazolam Sedation|Patients receiving fentanyl +/- midazolam as the primary drugs for sedation for TAVR
2966657|NCT02786459|Experimental|Post Radical Prostatectomy|"Up to n=30 evaluable male patients, between ages 30-75, who were previously diagnosed with PCa, have undergone a RP at least 6 months before imaging and who experience rising PSA (biochemical failure). The RP group (n=30) will be stratified into PSA subgroups <0.005, 0.005-<0.2, >0.2.~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI."
2966658|NCT02786459|Active Comparator|Active Surveillance|"Up to n=10 men, between ages 30-75, on active surveillance with known prostate adenocarcinoma diagnosis and multiple positive biopsies.~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI, and also undergo a TRUS biopsy."
2966659|NCT02786459|Experimental|Multiple Negative Biopsies|"Up to n=20 men, between ages 30-75, who have previously undergone one/or multiple negative biopsies, with elevated PSA (≥4 ng/mL) and/or an abnormal digital rectal exam suspicious for prostate cancer with a planned sextant prostate biopsy but who do not have a definitive PCa diagnosis.~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI, and also undergo a TRUS biopsy."
2966660|NCT02786446|Active Comparator|Lidocaine gel|20 grams Lidocaine gel 2 % will be applied to corresponding lumber area of the patients 30 minutes before undergoing ESWL for renal stone.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
2966661|NCT02786446|Active Comparator|Naproxen Sodium|Oral Naproxen sodium 550 mg will given to patients 45 minutes before ESWL for renal stones.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
2966662|NCT02786446|Active Comparator|Lidocaine Gel and Naproxen Sodium|Oral Naproxen sodium 55o mg and locally applied 2 % lidocaine gel to patients before ESWL for renal stones.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
2966663|NCT02786433|Active Comparator|GROUP CONTROL|"Participants in the control group only underwent conventional physiotherapy. Conventional therapy includes stretching and strengthening exercises with cane aid, leggings , elastic band and overball for upper and lower limbs , in addition to gait and balance training.~The intervention for the control group was applied for five weeks with sessions of 60 minutes twice a week"
2966664|NCT02786433|Experimental|EXPERIMENTAL GROUP|The subjects in the experimental group underwent conventional physiotherapy (The same applied in the control group) associated with virtual reality , performed with the console X -Box Kinect® of Microsoft. Durante the achievement of the virtual reality practice, Kinect and Kinect games Adventures® Dance® demanded the anterior movements players -posterior and lateral , as well as jumps and squats to get rid of the game obstacles. They Kinect Dance® game were all required movements of the previous game more dance . The intervention lasted five weeks , with two weekly sessions lasting 30 minutes to conventional therapy and 30 minutes to virtual reality.
2966665|NCT02786420||Observational|
2966666|NCT02786407|Active Comparator|Botulinum Toxin Type A for Injection|Botulinum Toxin Type A is a specific formulation of a locally injected muscle relaxant whose active ingredient is botulinum toxin type A produced by clostridium botulinum A strain Hall. Excipients contain sucrose,dextran and gelatin.
2966667|NCT02786407|Placebo Comparator|Placebo|The placebo does not include botulinum toxin A ,but include sucrose,dextran and gelatin.
2966668|NCT02786394|Experimental|REACH Participant Course|This study will run twice a week over 8 weeks with 6 REACH sessions 8 optional walking program sessions. The optional walking program will be run by SportMedBC and may consist of one or more educational sessions (e.g., nutrition). Each REACH session introduces new topics, strength and balance activities and home practices which progressively build on each other. We will ask participants to provide feedback after each session, and in two to three 30 minutes recorded interviews (in-person or over the telephone) at the end of the study.
2966669|NCT02786368|Other|Control group|For year one, this arm will receive no intervention. Usual agriculture production and income will be assessed monthly for one year. Additionally, every season (twice yearly), household food security and usual dietary intake of woman of reproductive age (WRA) and their child aged 6-59 mo will also be collected. After one year of implementation, this group will be offered the Enhanced Homestead Food Production package fully subsidized, as well as training on nutrition, WASH, gender and business/marketing.
2966670|NCT02786368|Experimental|EHFP group|Households will receive training and inputs for an Enhanced Homestead Food Production (EHFP) package. Participants will also receive educational components through inter-personal behavioural change communication on nutrition (Essential Nutrition Actions), Water Sanitation and Hygiene (WASH), gender, and business/marketing.
2966671|NCT02786355|Other|Maximum effort|Squeeze through Frova bougie with maximum effort
2966672|NCT02786355|Other|Normal effort|Squeeze through Frova bougie with normal effort
2966673|NCT02786342||Advanced HCC patients treated with sorafenib|
2966674|NCT02786329|Active Comparator|TIVA + lidocaine|"TIVA-L. Patients allocated to receive TIVA (propofol-fentanyl) with lidocaine infusion.~Interventions: TIVA+lidocaine"
2966675|NCT02786329|Placebo Comparator|TIVA+placebo|TIVA-P. Patients allocated to receive TIVA without lidocaine (placebo). Intervention: TIVA+placebo (saline infusion)
2966676|NCT02786329|Placebo Comparator|Sevoflurane+placebo|"Sevo-P. Patients allocated to receive Sevoflurane anesthesia without lidocaine infusion (placebo).~Intervention: sevoflurane anesthesia +placebo (saline infusion)"
2966677|NCT02786329|Active Comparator|Sevoflurane+lidocaine|"Sevo-L. Patients allocated to receive sevoflurane anesthesia with lidocaine infusion for the first 48 h postoperatively.~Intervention: sevoflurane anesthesia+ lidocaine infusion"
2966678|NCT02786316|Experimental|intervention group|Hit program for the rehabilitation of persons with nonspecific chronic low backpain
2966679|NCT02786316|Active Comparator|Control group|a conventional rehabilitation program for persons with nonspecific chronic low backpain
2966680|NCT02786303|Other|arm whole-body MRI|
2966681|NCT02786290|Experimental|Treatment Group|Receives intervention with the Zenflow Spring System.
2966682|NCT02786277|No Intervention|Usual Care|No alert will be fired
2966683|NCT02786277|Experimental|Alert|An alert informing the provider of acute kidney injury will be fired.
2966684|NCT02786264||Propofol-dominant Sedation|Patients receiving propofol infusion for TAVR as the primary drug for sedation.
2966689|NCT02786238|Active Comparator|Standard Behavioral Treatment (SBT)|For the Standard Behavioral Treatment (SBT) condition, participants will participate in the standard behavioral weight loss programming, which utilizes strategies from existing obesity treatments (e.g., the Diabetes Prevention Program). These features include the following: 1) nutritional education, 2) diet and physical activity, 3) expectations for daily self-monitoring of calorie intake and activity, 4) stimulus control, behavior shaping, behavior analysis, and relapse prevention strategies, and 5) social support.
2966690|NCT02786238|Experimental|Acceptance-Based Treatment (ABT)|"The Acceptance-Based Treatment (ABT) group will receive most features listed in the SBT arm as well as unique ABT training designed to help individuals increase awareness of their cognitive and affective experiences, and the following exercises: 1) identifying weight-related goals from personal life values (e.g., health) and connecting these values to day-to-day eating, 2) increasing awareness of moment-by-moment behavior choices, 3) tolerating aversive internal states that include eating-related states as well as affective states such as stress, sadness, and anxiety (i.e., urge-surfing). These strategies that have been empirically tested and found to be effective in the NIH-funded Mind Your Health RCT (R21DK080430)."
2966691|NCT02786225|Experimental|Collaborative Care|Intervention Group: Women (n=118) will be seen one time, simultaneously by a Vanderbilt University Medical Center (VUMC) perinatologist and a Vanderbilt University School of Nursing (VUSN) nurse-midwife (the CARE visit). During the CARE visit, the nurse-midwife and perinatologist will complete the CARE checklist The checklist will be signed by the woman and providers and scanned into the medical record. Following the CARE visit, women will return to midwifery care or be referred to perinatology depending on their needs, remaining in the study. Women returning to the midwifery practice will see a primary midwife for the remainder of care.
2966692|NCT02786225|Active Comparator|Comparison Care- Usual Care + primary midwife|Comparison Group: Usual care enhanced with primary midwife. Women in the comparison group (n=118) will receive the standard individual consult visit with a perinatologist and then, if they return to midwifery care, have one consistent midwife (primary midwife) for the majority of remaining prenatal care.
2966693|NCT02786212|Experimental|dexmedetomidine|Patients receiving intraoperative dexmedetomidine infusion. Infusion duration: from 10 minutes after anesthetic induction to the end of surgery.
2966694|NCT02786212|Placebo Comparator|control|control group, receiving same volume of normal saline infusion.
2966695|NCT02786199||Hepatocellular carcinoma|patients HCC who are going to receive surgical resection
2966696|NCT02786186||Secikinumab|Patients treated with secukinumab
2966697|NCT02786186||Approved standard of care|Patients treated with other indicated therapies (systemic, phototherapy, or biologic therapy)
2966698|NCT02786160|Active Comparator|HMO1|Daily bolus of HMO1
2966699|NCT02786160|Active Comparator|HMO2|Daily bolus of HMO2
2966700|NCT02786160|Placebo Comparator|Dextropur|Daily bolus of Dextropur
2966701|NCT02786147||Patient Initiated|Patients randomized into this group will receive a standard handout explaining their result, which includes information on how to obtain cancer genetics services through Winship. However, neither the patient nor their ordering clinician will be directly contacted regarding the B-RST result.
2966702|NCT02786147||Physician Notification|Patients randomized into this group will also receive the standard handout explaining their result. In addition, their primary care physician or ordering physician will be notified via Emory Electronic Medical Record (EeMR) that the patient screened positive on the B-RST. The note will provide specific instructions on how to refer the patient for cancer genetic counseling services.
2966703|NCT02786147||Automatic Follow-Up By Genetic Counseling Staff|Patients randomized into this group will also receive the standard handout explaining their result. Within 1-2 weeks after their mammogram appointment, patients will receive a phone call from a genetics counseling staff person to explain their screening result and to offer to set up a genetics counseling appointment. This call may take up to 10 - 15 minutes.
2966704|NCT02786134|Experimental|low-dose methotrexate (LDM)|Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dipyridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.
2966705|NCT02786134|Experimental|placebo|Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dypridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.
2966706|NCT02786108|Experimental|left gastric artery embolization|Patients undergoing left gastric artery embolization
2966707|NCT02786108|Active Comparator|healthy diet and exercise|Patients undergoing healthy diet and exercise
2966708|NCT02786095||Code-AF registry|
2966709|NCT02786082|Experimental|Group I|"For Pharmacokinetics Studies of Azilsartan with Single-dose oral administration, 12 subjects in group I, half are male and half are female, will take Azilsartan tablet 20mg orally on fasting.~For Pharmacokinetics Studies of Azilsartan with Multiple-dose oral administration, 12 subjects in group I will take 20mg Azilsartan orally once daily for 7 day (day 3~day 9) after completing the last time blood sample collection (in day 2, 48h) of the first time administration (day 1)"
2966710|NCT02786082|Experimental|Group II|"For Pharmacokinetics Studies of Azilsartan with Single-dose oral administration, 12 subjects in group II, half are male and half are female, will take Azilsartan tablet 40mg orally on fasting.~For The effects of diet for pharmacokinetic study: The 12 healthy subjects, in group II (in single-dose administration study), after 7-day washout period after the first administration (at day 1, 40mg) will receive Azilsartan tablet 40mg after high-fat diet at day 8"
2966711|NCT02786069|Experimental|Single arm|
2966712|NCT02786056|Experimental|Lung MRI examination|
2966713|NCT02786043|Experimental|Single arm|
2966752|NCT02785757|Experimental|Patients with adenocarcinoma|60 Patients recently diagnosed with locally advanced or metastatic adenocarcinoma of any origin, who are scheduled for systemic chemotherapy
2967332|NCT02781740|Active Comparator|CPAP therapy|Continuation of the already established CPAP therapy.
2966714|NCT02786030|Experimental|Intervention|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) and outreach education training. First trainers will be trained, then trainers will train groups of doctors and nurses at their workplaces, showing them how to use the guidelines, and using their own patients and clinical problems as examples. This outreach training is repeated several times in short sessions.
2966715|NCT02786030|Active Comparator|Control|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) but will not receive outreach education training.
2966716|NCT02786017|Sham Comparator|Conventional therapy|
2966717|NCT02786017|Experimental|Injectable Collagen Scaffold + HUC-MSCs|
2966718|NCT02786004|Experimental|Full Field Digital Mammography|2-dimensional breast imaging
2966719|NCT02786004|Experimental|Digital Breast Tomosynthesis|3-dimensional breast imaging
2966720|NCT02785978|Experimental|Parkinson Disease Patients Group #1|PD patients with programmed levodopa challenge
2966721|NCT02785978|Experimental|Parkinson Disease Patients Group #2|PD patients without programmed levodopa challenge
2966722|NCT02785978|Experimental|Healthy volunteers|Healthy volunteers
2966723|NCT02785965|Experimental|acupuncture & lifestyle modification|Electro-acupuncture is given three times a week with diet restriction to 1400 calories a day and moderate aerobic exercise 3h a week for 12 weeks.
2966724|NCT02785965|Active Comparator|lifestyle modification|diet restriction to 1400 calories a day and moderate aerobic exercise 3h a week for 12 weeks
2966725|NCT02785952|Experimental|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third course (every 42 days). Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2966726|NCT02785952|Active Comparator|Arm II (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2966727|NCT02785939|Experimental|Arm I - closed to accrual 09/01/2016 (palbociclib)|Patients receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2966728|NCT02785939|Experimental|Arm II - closed to accrual 12/18/15 (docetaxel)|Patients receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, patients may be eligible to re-register to Arm III.
2966729|NCT02785939|Experimental|Arm III - closed to accrual 09/01/2016 (palbociclib re-reg)|Patients in Arm II eligible for re-registration receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2966730|NCT02785913|Experimental|Arm I (GDC-0032)|Patients receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2966731|NCT02785913|Experimental|Arm III (taselisib re-registration)|Patients in Arm II eligible for crossover re-registration receive taselisib PO on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2966732|NCT02785900|Experimental|33A + HMA|33A plus azacitidine or decitabine
2966733|NCT02785900|Active Comparator|placebo + HMA|placebo plus azacitidine or decitabine
2966734|NCT02785887|Experimental|Oncological and geriatrician review|Routine oncological care plus geriatric intervention
2966735|NCT02785887|No Intervention|Oncological care|Routine oncological care only
2966736|NCT02785874|Experimental|Statin(Crestor) taken|Subjects take Statin(Crestor) 10mg per day for a- year
2966737|NCT02785874|No Intervention|non Statin(Crestor) taken|non Statin(Crestor) taken as a reference for experimental group.
2966738|NCT02785861|Experimental|supervised practice|"brisk walking program twice a week over a period of 6 weeks, at an intensity of 60% of HR pic during 20 minutes.~Biweekly session from 60% of the heart rate pic during 20 minutes will be proposed.~Each patient of supervised walking group will meet the student each session"
2966739|NCT02785861|Experimental|distance supervised physical activity|"brisk walking program twice a week over a period of 6 weeks, at an intensity of 60% of HR pic during 20 minutes.~Biweekly session from 60% of the heart rate pic during 20 minutes will be proposed.~Each patient of home-based walking group will be called by phone every week by the student to inform the patient of the progress of the training, collect the work and answer any questions"
2966740|NCT02785848||Asthma and/or Sickle Cell Anemia|The investigators will examine patients with sickle cell disease, asthma, or both who are aged 12-70 years who take daily medications.
2966741|NCT02785822|Active Comparator|Fostipur|
2966742|NCT02785822|Experimental|Meriofert|
2966743|NCT02785796|Experimental|CV4|The practitioner will contact the participant's occiput (lateral to the external occipital protuberances, but medial to the occipital-mastoid suture) with his or her thenar eminences. When no cranial mobility will be found, operators will be free to use any kind of technique to enhance the cranial movement before CV4 procedure. Once the practitioner will detect the CRI, the practitioner will resist the flexion phase of the CRI and exaggerate the extension phase. This compressive pressure will be maintained until the CRI stopped, and the still-point is reached. The still-point will be held until the CRI return, at which point the compressive pressure will be slowly release
2966744|NCT02785796|Placebo Comparator|sham technique|"The operator will overlap the hands so that the thumbs formed a V. The operator's thenar eminences will contact the occiput very lightly well below the positioning used in the CV4 procedure but with no pressure on the occiput between the occipitomastoid sutures. Once placement will be achieved, the operator's hands will remain motionless for 10 min. Finally, the practitioner's hands will be gently removed and the participant's head will be placed on the table for both procedures"
2966745|NCT02785796|No Intervention|Control|The control group will not receive ant type of treatment: subject just stay quietly in supine position in ambulatory room for ten minutes
2966746|NCT02785783|Active Comparator|Standard colonoscopy|A standard colonoscope will be used to complete the procedure
2966747|NCT02785783|Active Comparator|EndoRings™|An EndoRings™ device will be placed at the distal end of a standard colonoscope
2966748|NCT02785770|Experimental|PF-04447943 low dose|25 mg of PF-04447943
2966749|NCT02785770|Experimental|PF-04447943 high dose|100 mg of PF-04447943
2966750|NCT02785770|Placebo Comparator|Placebo|Matching placebo for PF-04447943
2966751|NCT02785770|Active Comparator|Moxifloxacin|400 mg of moxifloxacin
2966753|NCT02785744||Patients receiving DEXA Scan|Gaucher patients referred for dual energy X-ray absorptiometry (DEXA scan), who were found to have T-score <-1.0.
2966754|NCT02785731||Women with a pelvic mass|Women diagnosed with a pelvic mass (defined as a simple, complex or a solid ovarian cyst / pelvic mass) who are scheduled for a laparotomy or laparoscopy for removal of the pelvic mass. Must have a pelvic imaging study performed within 60 days prior to surgery and a research blood draw within 60 days prior to surgery.
2966755|NCT02785718|Experimental|Patients with FXI or FXII deficiency|12 patients with FXI deficiency and 6 patients with FXII deficiency
2966756|NCT02785705|Experimental|cIPV-bOPV-bOPV poliovirus vaccine|Participants would be vaccine with trivalent conventional inactivated poliovirus vaccine, and two bivalent types 1 and 3 oral poliovirus vaccine sequentially.
2966757|NCT02785705|Experimental|cIPV-tOPV-tOPV poliovirus vaccine|Participants would be vaccine with trivalent conventional inactivated poliovirus vaccine, and two trivalent types 1, 2 and 3 oral poliovirus vaccine sequentially.
2966758|NCT02785705|Experimental|cIPV-cIPV-bOPV poliovirus vaccine|Participants would be vaccine with two shots of trivalent conventional inactivated poliovirus vaccine, and one bivalent types 1 and 3 oral poliovirus vaccine sequentially.
2966759|NCT02785705|Experimental|cIPV-cIPV-tOPV poliovirus vaccine|Participants would be vaccine with two shots of trivalent conventional inactivated poliovirus vaccine, and one trivalent types 1, 2 and 3 oral poliovirus vaccine sequentially.
2966760|NCT02785705|Experimental|cIPV-cIPV-cIPV poliovirus vaccine|Participants would be vaccine with three shots of trivalent conventional inactivated poliovirus vaccine.
2966761|NCT02785705|Experimental|tOPV-tOPV-tOPV poliovirus vaccine|Participants would be vaccine with three times of trivalent types 1, 2 and 3 oral poliovirus vaccine .
2966762|NCT02785692||Combined Radiation/ Surgery|All patients treated with combined radiotherapy and surgery at Balgrist University Hospital and University Hospital Zurich
2966763|NCT02785679|No Intervention|Exclusive breast feeding|Exclusive breast feeding
2966764|NCT02785679|No Intervention|Exclusive CMF feeding|Exclusive CMF feeding
2966765|NCT02785679|Active Comparator|Breast feeding with small amount of CMF|Breast feeding with addition (as intervention) of 20 cc of cow's milk formula (CMF) per day
2966766|NCT02785679|Active Comparator|Breast feeding with one meal of CMF|Breast feeding with addition (as intervention) of one meal per day of cow's milk formula (CMF)
2966767|NCT02785666|Experimental|Treatment and behavioural intervention:|"Treatment intervention: Patients with a replicating GT 1 and/or 4 HCV infection without or with cirrhosis will be treated with grazoprevir/elbasvir (100mg/50mg) for 12 weeks. GT 1a infected patients with baseline RAV's and GT 4 infected patients with a history of prior HCV treatment failure without or with cirrhosis will be treated with the same regimen for 16 weeks, in combination with weight-adjusted ribavirin.~Behavioural Intervention: Participants with inconsistent condom use with occasional partners will receive the behavioral Intervention and in addition standard of care written and oral information on prevention of HCV reinfection. Study participants with consistent condom use or those reporting inconsistent condom use with occasional partners but not willing to participate in the intervention will receive standard of care written and oral information on prevention of HCV reinfection only"
2966768|NCT02785653|Experimental|sevoflurane and rocuronium|After induction of general anaesthesia, patients in the sevoflurane group were ventilated with fresh gas flow of 5 lites per minute consisting of 66.6% nitrous oxide and 33.3% oxygen with 2% inspired concentration of sevoflurane. After stabilization of end tidal carbondioxide to 30-35 mmHg ,intravenous rocuronium 0.6mg per Kg body weight was injected
2966769|NCT02785653|Active Comparator|rocuronium|After induction of general anaesthesia, patients in the control group were ventilated with fresh gas flow of 5 lites per minute consisting of 66.6% nitrous oxide and 33.3% oxygen . After stabilization of end tidal carbondioxide to 30-35 mmHg ,intravenous rocuronium 0.6mg per Kg body weight was injected
2966770|NCT02785640|Experimental|Prompt group|Following feedback on their baseline sitting behaviour and an education session on the health benefits of breaking prolonged sitting, the prompt group will receive hourly prompts on their PC to stand. The prompts will be delivered via Microsoft Outlook and will run for a period of 10 weeks. The messages will be short in length, varied and centre around the key message of breaking prolonged sitting by standing
2966771|NCT02785640|No Intervention|Control group|The control group will receive the same education session as the prompt group, as well as feedback on their baseline sitting behaviour. However, the will not receive prompts on their PC.
2966772|NCT02785627||Group A: ADT|Men with non-metastatic prostate cancer, about to start or within 2 weeks of starting ADT
2966773|NCT02785627||Group B: ADT + chemotherapy|Men with newly diagnosed hormone sensitive metastatic prostate cancer, starting ADT and who will have chemotherapy
2966774|NCT02785627||Group C: Controls|Healthy age matched men
2966775|NCT02785614|Experimental|II-1|"This is 2-period, 2 cross (2x2) crossover design was used. each 3 males and 3 females, give the following two different crossover treatments in the following sequence:~R: trazodone hydrochloride tablets 50mg for 3 times per day for 7 days T: trazodone hydrochloride prolonged-release tablets 150 mg per day for 7 days. Wash-out period is 14 days."
2966776|NCT02785614|Experimental|II-2|"This is 2-period, 2 cross (2x2) crossover design was used. each 3 males and 3 females, give the following two different crossover treatments in the following sequence:~T: trazodone hydrochloride prolonged-release tablets 150 mg per day for 7 days R: trazodone hydrochloride tablets 50mg for 3 times per day for 7 days. Wash-out period is 14 days."
2966777|NCT02785601|Experimental|I-1|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;
2966778|NCT02785601|Experimental|I-2|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times)
2968247|NCT02775864||Mood stabilizer|Individuals initiating treatment with a mood stabilizer
2966779|NCT02785601|Experimental|I-3|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg;
2966780|NCT02785601|Experimental|I-4|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;
2966781|NCT02785588|Other|3.0 T Neonatal MRI scanner|
2966782|NCT02785575|Active Comparator|HeProCalc|This arm receives heparin and protamine doses according to the novel HeProCalc calculation model.
2966783|NCT02785575|No Intervention|Traditional calculations|This arm receives heparin and protamine doses according to the standard protocol (using calculations with body weight and ACT)
2966784|NCT02785562|Other|Assessment of PDL1 expression|Other : assess clinical and pathological characteristics of PDL1 expression in Non Small Cell Lung Cancer patients.
2966785|NCT02785549|Experimental|Symptomatic treatment with NSAID|1 g/8 h acetaminophen alternating with 600 mg/8 h ibuprofen
2966786|NCT02785549|Active Comparator|Antibiotic+symptomatic treatment with NSAID|875/125mg /8h amoxicillin/clavulanic acid and symptomatic treatment with 1 g/8 h acetaminophen alternating with 600 mg/8 h ibuprofen
2966787|NCT02785536|Active Comparator|Standard Treatment|The standard treatment was a well-established, manual-driven, multicomponent CBT for tobacco dependence that has been delivered in multiple modalities (i.e., group, individual, and telephone), used in numerous studies, and considered intensive, comprehensive, and consistent with the Public Health Service Clinical Practice Guideline.
2966788|NCT02785536|Experimental|RITCh Treatment|The RITCh treatment is an adaptation of the standard treatment which proactively addresses the needs and experiences of a diverse group of lower SES smokers as well as ensures that the treatment is culturally congruent and experientially resonant for African Americans while maintaining the same amount of treatment contact (i.e., six one-hour sessions).
2966789|NCT02785523|Experimental|G. SPORE LIPIDS|"Form: Capsule Dosage and frequency: This group receives ganoderma spore lipids capsules 600mg TID in addition to the chemotherapy.~Duration: 6 chemotherapy cycles."
2966790|NCT02785523|Placebo Comparator|Placebo|"Form: Capsule Dosage and frequency: This group receives placebo capsules 600mg TID in addition to the chemotherapy.~Duration: 6 chemotherapy cycles."
2966791|NCT02785497|Experimental|Treatment group|"Chronic ulcer patients will be treated with 50 minutes of the high-voltage current or 10 minutes of the diadynamic current. To burn patients 50 minutes high voltage current in the donor area. For both group the metal electrodes will be sterilized and the negative polarity in the active electrode.~50 min, 100Hz, intensity according to the sensitivity patient - High Voltage; 10 min, intensity according to the sensitivity patient - Diadynamic"
2966792|NCT02785497|Sham Comparator|Control group|"For the control group the unit is turned on, the time will pass but will not be given intensity~50min, 100Hz, Intensity according to the sensitivity patient"
2966793|NCT02785484|Experimental|Label with constituent disclosure message|
2966794|NCT02785484|Other|Label with litter message|
2966795|NCT02785471|Active Comparator|Screening for Mental Health only|Participants in the Screening for Mental Health only (control) group will complete the online depression and suicide screening and receive immediate feedback and referrals.
2966796|NCT02785471|Experimental|Screening for Mental Health & Man Therapy|Participants assigned to Screening for Mental Health & Man Therapy (intervention) group will be offered the Man Therapy program in conjunction with Screening for Mental Health.
2966797|NCT02785458|No Intervention|Usual Care|Subjects will receive the current standard of care.
2966798|NCT02785458|Experimental|EMC2 Strategy|Subjects will receive the EMC2 Strategy. See description of strategy below.
2966799|NCT02785445|Other|All participants (single arm)|All study participants once enrolled into the study were asked to collect their midstream urine in the designated device urine cups. The urine sample was then tested sequentially; first by the Dip.io Home Based Dipstick Analyzer (first intervention) and by the ACON U500 Mission® U500 Urine Analyzer (comparative device - second intervention). Part of the participants (100 out of 302) were asked to perform the Dip.io urine test by themselves for the user performance evaluation.
2966800|NCT02785432|Sham Comparator|Pre-program low level laser therapy|"Phase 1: Conducted during the period between acceptance to pain program and start the of the pain program (2-4 weeks). Baseline testing pre (T1) will be completed at the time of initial evaluation and enrollment to the study.~A. Follow-up testing post (T2 a, b, c) will be completed weekly during this phase.~B. Phase 1 final testing (T3) will be on the first clinic visit of the formal pain program. The last testing period of phase 1 will also serve as baseline for Phase 2."
2966801|NCT02785432|Sham Comparator|Program low level laser therapy|"Phase 2: This phase is the 4-week formal pain program (2 visits/week x 4 weeks, total 8 visits). Baseline testing (T3) will be on the first clinic visit of the formal pain program.~C. Follow-up testing post (T4-T7) will be completed weekly during phase 2. D. Following completion of the pain program. Follow up measurements will be completed 4 weeks post discharge (T8)."
2966802|NCT02785419|Experimental|Arm Training with Action Selection|Task-oriented, functional arm training with the addition of action selection cues to practice. All participants receive the same arm training intervention.
2966803|NCT02785406|Experimental|suvorexant|Subjects will receive suvorexant (10 mg week 1, 20 mg week 2), once daily at 10 PM.
2966804|NCT02785406|Placebo Comparator|Placebo|Subjects will receive placebo once daily at 10 PM.
2966805|NCT02785393|Placebo Comparator|Sugar Pill|
2966806|NCT02785393|Active Comparator|Doxazosin|
2966836|NCT02785224||Control|Patients with in-hospital cardiac arrest treated with normal saline placebo, normal saline placebo, and epinephrine during cardiopulmonary resuscitation, and also with normal saline placebo for postresuscitation shock.
2966873|NCT02784977||Obstructive Sleep Apnea (OSA)|Patients with apnea hypopnea index of at least 5 events per hour. Intervention with positive airway pressure, or intraoral device, or uvuloplasty, or conservative treatment.
2966807|NCT02785380|Experimental|laparoscopic surgery(LS)|For LS,the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg.Intra-operative ultrasonography was performed routinely. Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. The Pringle maneuver was not used. Wedge resection, segmentectomy or subsegmentectomy was performed. The surgeon aimed to achieve a 1.0-cm safety margin during the liver resection.
2966808|NCT02785380|Active Comparator|Radiofrequency ablation(RFA)|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA).
2966809|NCT02785367|Experimental|Cord blood samples|8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml washed with Heparin.
2966810|NCT02785354||NOAC|New oral anticoagulant groups
2966811|NCT02785354||VKA|VKA group
2966812|NCT02785341|Other|Immediate adaptated physical activity (Group A)|"Group A began a physical activity program for 12 consecutive weeks from inclusion in the protocol, then underwent the usual care for 12 additional weeks.~Then to complete five evaluations with several questionnaires, and 6-minute walk test every 6 weeks (T0, T1, T2, T3 and T4) and leptin level with a blood test every 12 weeks (T0, T2 and T4)."
2966813|NCT02785341|Other|Without immediate adaptated physical activity (Group B)|"Group B followed the usual care for 12 weeks then started the physical activity program for 12 additional weeks.~Then to complete five evaluations with several questionnaires, and 6-minute walk test every 6 weeks (T0, T1, T2, T3 and T4) and leptin level with a blood test every 12 weeks (T0, T2 and T4)."
2966814|NCT02785328|Experimental|obstructive sleep apnoea|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from obstructive sleep apnoea syndrome.
2966815|NCT02785328|Experimental|narcolepsy|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from narcolepsy.
2966816|NCT02785328|Experimental|BECTS (Benign epilepsy with centro-temporal spikes)|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from BECTS.
2966817|NCT02785328|Experimental|high intellectual potential|The objective of this task is to evaluate the sleep-dependent consolidation abilities in children with high intellectual potential.
2966818|NCT02785328|Experimental|healthy children|The objective of this task is to evaluate the sleep-dependent consolidation abilities in healthy children.
2966819|NCT02785315|Experimental|rehabilitation & remediation approach|The intervention group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention with various compensatory strategies. Investigators will use group discussion to discuss everyday situations with memory problem and specific strategies (internal and external) related to real-life situations. Investigators will also include one individual session in the 12 group sessions.
2966820|NCT02785315|Active Comparator|remediation approach|The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
2966821|NCT02785302||Adolescents and Young Adults:|Behaviorally-infected, HIV-positive, adolescents and young adults enrolled in ATN 125, aged 18 through 24, inclusive who are transition eligible. All subjects with available endpoint data will be included in the analysis.
2966822|NCT02785302||AMTU and Adult Clinic Staff|Clinical staff at the Adolescent Medical Trials Units (AMTUs) and at adult clinics where the AMTUs refer their transitioning patients will be recruited to complete quantitative surveys and semi-structured interviews.
2966823|NCT02785289|Experimental|Flocked|Patients will perform vaginal cell collection beginning with the flocked swab, followed by the coton swab.
2966824|NCT02785289|Experimental|Coton|Patients will perform vaginal cell collection beginning with the coton swab, followed by the flocked swab.
2966825|NCT02785276|Experimental|Ropivacaine infusion|Following the insertion of the 2mm fenestrated catheter, the wound catheter will be connected to the 270mL AutoFuser Pain Pump. The intraperitoneal infusion with ropivacaine (0.2%) at 4 mL/hour will start immediately and continue for 68 hours post-operatively uninterrupted.
2966826|NCT02785276|Placebo Comparator|Placebo infusion|In the same manner as described for the ropivacaine infusion arm, 0.9% Normal Saline will be administered over 68 hours.
2966827|NCT02785263|Other|Standard radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 28 treatments
2966828|NCT02785263|Other|High dose radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 28 treatments
2966829|NCT02785263|Other|Low dose radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 25 treatments
2966830|NCT02785250|Experimental|Experimental|DPX-Survivac, Cyclophosphamide, Epacadostat
2966831|NCT02785237|Active Comparator|Coroflex® ISAR Drug-eluting stent in first lesion|Patients with Coroflex® ISAR Drug-eluting stent in the first lesion
2966832|NCT02785237|Active Comparator|Ultimaster® Drug-eluting stent in first lesion|Patients with Ultimaster® Drug-eluting stent in first lesion
2966833|NCT02785237|Active Comparator|Coroflex® ISAR Drug-eluting stent in second lesion|Patients with with Ultimaster® Drug-eluting stent in first lesion
2966834|NCT02785237|Active Comparator|Ultimaster® Drug-eluting stent in second lesion|Patients with Coroflex® ISAR Drug-eluting stent in the first lesion
2966835|NCT02785224||Vasopressin Steroids Epinephrine (VSE)|Patients with in-hospital cardiac arrest treated with vasopressin, methylprednisolone, and epinephrine during cardiopulmonary resuscitation, and also with stress-dose hydrocortisone for postresuscitation shock.
2966874|NCT02784977||No-OSA|Patients with apnea hypopnea index less than 5 events per hour. No intervention.
2966837|NCT02785211|Experimental|Behavioral Activation Treatment|The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.
2966838|NCT02785211|Placebo Comparator|control group|For the control group, participants will receive regular physical examinations and education by village doctors weekly during the 8 week intervention.The weekly visits for every old people whose age above 65 by country doctors are not arranged by our study, it is the country doctors‟ routine work by government health policy. This study was permitted by the local community health center, the director with specific responsibility will inform all country doctors to support our study.
2966839|NCT02785198|No Intervention|Control group|A control group receiving standard wound treatment consisting of debridement, dressings, compression, offloading footwear and if necessary antibiotics.
2966840|NCT02785198|Experimental|Passive training group|An Intervention group doing passive exercise for 8 weeks and receiving standard wound treatment consisting of debridement, dressings, compression, offloading footwear and if necessary antibiotics.
2966841|NCT02785185|Experimental|IDP-122 Lotion|Lotion
2966842|NCT02785185|Active Comparator|Ultravate Cream|Cream
2966843|NCT02785185|Active Comparator|IDP-122 Vehicle Lotion|Lotion
2966844|NCT02785185|Active Comparator|IDP-122 Vehicle Cream|Cream
2966845|NCT02785172|Experimental|IDP-118 Lotion|Lotion
2966846|NCT02785172|Active Comparator|Ultravate Cream|Cream
2966847|NCT02785172|Active Comparator|IDP-118 Vehicle Lotion|Lotion
2966848|NCT02785172|Active Comparator|IDP-118 Vehicle Cream|Cream
2966849|NCT02785159|Experimental|IDP-118 Lotion|Lotion
2966850|NCT02785159|Active Comparator|Tazorac Cream|Cream
2966851|NCT02785159|Active Comparator|IDP 118 Vehicle Lotion|Lotion
2966852|NCT02785159|Active Comparator|IDP-118 Vehicle Cream|Cream
2966853|NCT02785146|Experimental|mFOLFOX6 + Huaier Granule|Twelve cycles of mFOLFOX6 (oxaliplatin, 85 mg/m²; calcium folinate, 400 mg/m²; 5-fluorouracil, 2800 mg/m²). Patients will be treated with chemotherapy every 2 weeks (+/- 2 days ). Huaier Granule will be administrated from the first cycle of chemotherapy until 48 weeks after surgery or until study termination. Huaier Granule is continuously taken three times per day, 20g per time.
2966854|NCT02785146|Active Comparator|mFOLFOX6|Twelve cycles of mFOLFOX6 (oxaliplatin, 85 mg/m²; calcium folinate, 400 mg/m²; 5-fluorouracil, 2800 mg/m²). Patients will be treated with chemotherapy every 2 weeks (+/- 2 days ).
2966855|NCT02785133|Experimental|Treatment group|Polychromatic light emitting diode system is a non-significant risk device that administers low-dose light generated by a light emitting diode. Small adapter attaches directly to a standard 20-gauge catheter that threads a small fiber optic through the distal end of the catheter. The optic terminates at the distal end of the catheter. Polychromatic light is emitted to illuminate the catheter and site of catheter entrance. Concurrently, normal saline flows through the optic adapter and through into the 20-gauge catheter.
2966856|NCT02785120|Placebo Comparator|High dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
2966857|NCT02785120|Placebo Comparator|Middle dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
2966858|NCT02785120|Placebo Comparator|Low dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
2966859|NCT02785107|Experimental|Intervention|Those who were randomized into the intervention group attended a workshop where the PI delivered a presentation that focused on establishing a preparatory exercise habit by using the M-PAC approach and proposed habit model. Participants were then provided with instructions on completing their exercise plan sheet.
2966860|NCT02785107|No Intervention|Control|Participants exercised on their own without receiving any instructions.
2966861|NCT02785094||A|Group of High Education level
2966862|NCT02785094||B|Group of Low/Non Education level
2966863|NCT02785094||C|Group has Accessibility to Social Media
2966864|NCT02785094||D|Group has not Accessibility to Social Media
2966865|NCT02785068|Experimental|Phase 1b/2a|"Phase 1b: Safety Evaluation - MM-151 (weekly dosing) in combination with fixed doses of nal-IRI 70mg/m2 + Leucovorin 400 mg/m2 + 5-FU 2400mg/m2 every two weeks.~Phase 2a: Expansion - MM-151 (Maximum Tolerated Dose or Recommended Phase 2 Dose) in combination with fixed doses of nal-IRI 70mg/m2 + Leucovorin 400 mg/m2 + 5-FU 2400 mg/m2."
2966866|NCT02785055|Active Comparator|Ultrasound-Assisted|Ultrasound assisted marking of the thoracic spine on the skin for Thoracic Epidural Placement
2966867|NCT02785055|Active Comparator|Palpation|Palpation marking of the thoracic spine on the skin for Thoracic Epidural Placement
2966868|NCT02785042|Experimental|Normal healthy volunteers|imaging with Heidelberg Spectralis OCT
2966869|NCT02785029|Experimental|Normal healthy Volunteers|OCT imaging
2966870|NCT02785016||Stress Urinary Incontinence|Females with stress urinary incontinence, who undergo a tension free surgical sling procedure.
2966871|NCT02785003|Experimental|Ketamine Infusion|All infusion rates will be calculated based on ideal body weight. Patients will receive a bolus of the ketamine solution at a calculated dose of 0.25 mg/kg. A continuous infusion of ketamine will immediately follow at a rate of 2 mcg/kg/min. The continuous infusion to run for a duration of 48-hours.
2966872|NCT02785003|Placebo Comparator|Saline Placebo|All infusion rates will be calculated based on ideal body weight. Patients will receive a bolus of the saline solution at a calculated dose of 0.25 mg/kg. A continuous infusion of saline will immediately follow at a rate of 2 mcg/kg/min. The continuous infusion to run for a duration of 48-hours.
2966876|NCT02784964|Active Comparator|Hya Joint Plus|Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc., one time injection on Day 1
2966877|NCT02784964|Experimental|Elixcyte 4mL|ADSC 3.2*10^7 cells, allogeneic injection, one time injection on Day 1
2966878|NCT02784964|Experimental|Elixcyte 2mL|ADSC 1.6*10^7 cells, allogeneic injection, one time injection on Day 1
2966879|NCT02784951||Single group|Patients in haemorrhagic shock needing volume replacement and receiving prehospital transfusion of blood products, either red blood cells (RBC), freeze dried plasma (FDP) or whole blood (WB).
2966880|NCT02784938|Experimental|Vocational Empowerment Photovoice (VEP)|The VEP program is a 10-week manualized, structured, peer-led intervention delivered in 2-hour group sessions. The VEP program integrates Photovoice methodology, Rehabilitation Readiness technology and elements of the Anti-Stigma Photovoice (ASP) curriculum previously developed and tested by the Boston University Center for Psychiatric Rehabilitation (BU CPR). VEP group sessions combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing employment services and opportunities, all refined with input from individuals with a lived experience.
2966881|NCT02784938|No Intervention|Wait-list Control|Services as usual
2966882|NCT02784925|Other|fatty liver subjects|Ultrasound (US) B mode image is an alternative method to measure tissue structure and has proven to be an accurate technique to measure subcutaneous fat thickness.
2966883|NCT02784899|Experimental|iloprost group|iloprost inhalation group
2966884|NCT02784899|Placebo Comparator|control group|normal saline inhalation group
2966885|NCT02784873|No Intervention|Usual care|"Usual care cardiac rehabilitation with exercise training as per current guidelines~Warm up: 15 mins, < 40% heart rate reserve (HRR) Cardiovascular component: progress towards 20 - 40 mins continuous cardiovascular exercise at 40-70% HRR.~Muscular strength and endurance programme. Cool down: 10 mins, < 40% HRR. Initial duration based on participant's previous and current physical activity (PA) levels and cardiopulmonary exercise test (CPEX) performance.~Duration and workload of cardiovascular component adjusted, as tolerated, within the above parameters, in response to exercising heart rate (HR), participant reported rating of perceived exertion (RPE) and symptoms."
2966886|NCT02784873|Experimental|High intensity interval training|"High intensity interval training within a standard cardiac rehabilitation programme.~Warm up: 15 mins total, 10 mins <40-70% HRR, 5 mins <70% HRR. Cardiovascular component: exercise bike interval training: 10 x high @ 85-90% peak power output (PPO) from CPEX, 10 x low @ 20-25% PPO (exercise intensity will not to be prescribed from gas exchange data i.e. %VO2 peak). Change in intensity from low to high achieved by altering cadence (rpm).~Muscular strength and endurance programme. Cool down: 10 mins, <40% HRR. Duration of intervals and total programme duration increased in a standardised fashion.~Workload increased bi-weekly in response to participant reported RPE (only after the full 10 x 1 protocol has been achieved). If RPE < 17 then workload will be increased."
2966887|NCT02784860|Active Comparator|Lidocaine|Lidocaine. Administration of lidocaine is started with 1.5 mg/kg bolus injection followed by a continuous infusion of 4mg/kg/h.
2966888|NCT02784860|Placebo Comparator|Placebo|Placebo Administration of normal saline: same volume of saline as lidocaine.
2966889|NCT02784847|Other|treatment arm|pilot-study with single arm of 10 migraine patients treated for 3 months with triheptanoin 1mg/kg/day
2966890|NCT02784834|Experimental|Dimethyl fumarate (DMF)|"Cohort 1: dimethyl fumarate 120 mg PO BID (approximately 12 hours apart) for 2 x 28 day cycles.~Cohort 2: dimethyl fumarate 120 mg PO BID (approximately 12 hours apart) for 1 week, then escalating to the assigned dose of (240mg PO BID for the remainder of 2 x 28 day cycles.~Cohort 3: dimethyl fumarate 120 mg PO BID for 1 week, then escalate to the dose of 360mg PO BID for the remainder of 2 x 28 day cycles."
2966891|NCT02784821|Other|Antibiotics Control|"These neonates have a clinical indication to receive antibiotics, such as maternal chorioamnionitis with fetal tachycardia. The standard of care antibiotics include Ampicillin and Gentamicin or Cefotaxime and as part of standard of care blood tests such as complete blood cell counts, blood cultures, and C-reactive proteins will be performed.~Study interventions will include the collection of samples for the following: breast milk, gastric fluid, skin swabs and stool samples for analysis of the microbiome and metabolome."
2966892|NCT02784821|Other|No Antibiotics Control|"These neonates show no signs of respiratory distress(RDS) or have no indications of maternal chorioamnionitis. Antibiotics is not indicated for this group as standard of care.~Study interventions will include the collection of samples for the following: breast milk, gastric fluid, skin swabs and stool samples for analysis of the microbiome and metabolome, along with standard of care complete blood counts, blood cultures, and C-reactive proteins."
2966893|NCT02784821|Other|Randomized to pre-emptive antibiotics|"This group will be randomized to receive standard of care antibiotics which include Ampicillin and Gentamicin or Cefotaxime. Standard of care blood tests such as complete blood cell counts, blood cultures, and C-reactive proteins will be performed.~Study interventions will include the collection of samples for the following: breast milk, gastric fluid, skin swabs and stool samples for analysis of the microbiome and metabolome."
2966894|NCT02784821|Other|Randomized to no pre-emptive antibiotics|This group will be randomized not to receive standard of care antibiotics. Study interventions will include the collection of samples for the following: breast milk, gastric fluid, skin swabs and stool samples for analysis of the microbiome and metabolome, along with standard of care complete blood counts, blood cultures, and C-reactive proteins.
2966895|NCT02784808||Biologic DMARDs|Participants who received biologic DMARDs as per standard of care were included in this arm.
2966896|NCT02784808||Non-biological DMARDs|Participants who received non-biologic DMARDs as per standard of care were included in this arm.
2966897|NCT02784795|Experimental|LY3039478 + Taladegib|LY3039478 given orally 3 times per week (TIW) in combination with taladegib given orally daily on a 28 day cycle. A single dose of taladegib will also be given on day 1 during a 3-day lead-in period.
2966898|NCT02784795|Experimental|LY3039478 + LY3023414|LY3039478 given orally TIW in combination with LY3023414 given orally every 12 hours on a 28-day cycle. A single dose of LY3023414 will also be given on day 1 during a 3-day lead-in period.
2966899|NCT02784795|Experimental|LY3039478 + Abemaciclib|LY3039478 given orally TIW in combination with abemaciclib given orally every 12 hours on a 28-day cycle. A single dose of abemaciclib will also be given on day 1 during a 3-day lead-in period.
2966900|NCT02784795|Experimental|LY3039478 + Cisplatin/Gemcitabine|LY3039478 given orally TIW in combination with cisplatin and gemcitabine given as intravenous (IV) infusions on days 1 and 8 of a 21 day cycle.
2966901|NCT02784795|Experimental|LY3039478 + Gemcitabine/Carboplatin|LY3039478 given orally TIW in combination with gemcitabine and carboplatin given as IV infusions on days 1 and 8 of a 21 day cycle.
2966902|NCT02784782|Experimental|Orthesis|Subjects will wear a TLSO for 6 weeks 24 hours a day or they will not. After 6 weeks the subjects in the TLSO group will decrease and stop the use of the orthesis. Depending on their pain complaints patients will be admitted to the hospital and will get adequate pain management following local protocol Intervention: After fitting the patient starts mobilising, under supervision of a physiotherapist, until pain is under control with oral analgesia. Sports and heavy lifting are prohibited for 3 months. No physiotherapy treatment is needed. During two year follow up patients will be seen at the outpatient clinic during standard care follow up moments. At or just before each scheduled appointment they will fill in questionnaires. These questionnaires will take 15-45 minutes.
2966903|NCT02784782|Active Comparator|No Orthesis|"Subjects will wear a TLSO for 6 weeks 24 hours a day or they will not. After 6 weeks the subjects in the TLSO group will decrease and stop the use of the orthesis. Depending on their pain complaints patients will be admitted to the hospital and will get adequate pain management following local protocol.~Control: The patient starts mobilising, under supervision of a physiotherapist, until pain is under control with oral analgesia. Sports and heavy lifting are prohibited for 3 months. No physiotherapy treatment is needed. During two year follow up patients will be seen at the outpatient clinic during standard care follow up moments. At or just before each scheduled appointment they will fill in questionnaires. These questionnaires will take 15-45 minutes."
2966904|NCT02784769|Experimental|aneurysm diameter of below 75 mm|
2966905|NCT02784769|Experimental|aneurysm diameter above 75 mm|
2966906|NCT02784756|Other|Quantiferon-CMV assay|All patients will receive a CMV-immunity test at specific time points during the study. This is a single arm design
2966907|NCT02784743|Experimental|albendazole and ivermectin|Before and after design with all eligible volunteers receiving the study drugs. Administration of a yearly unique dose of albendazole 400mg and ivermectin 150ug/kg weight ( according to the height).
2966908|NCT02784730|Experimental|Iterative PICC placement|New PICC placement at each chemotherapy cycle (removed after treatment administration)
2966909|NCT02784730|Active Comparator|Long term implantable device|Port-a-cath inserted prio first chemotherapy cycle and maintained throughout the study
2966910|NCT02784717||Rivaroxaban (Xarelto, BAY 59-7939)|Female and male patients, who are at least 18 years of age with a diagnosis of non-valvular atrial fibrillation will be enrolled after the decision for a pharmacologic prophylaxis with rivaroxaban to prevent stroke or non-CNS systemic embolism has been made.
2966911|NCT02784704|Experimental|Eravacycline|
2966912|NCT02784704|Active Comparator|Meropenem|
2966913|NCT02784691|Experimental|Patients|
2966914|NCT02784678|Experimental|closed reduction group|Patients will be assigned to C-arm fluoroscopy-assisted minimally invasive closed reduction and internal fixation with fully threaded headless cannulated compression screws (experimental group).
2966915|NCT02784678|Experimental|open reduction group|Patients will be assigned to open reduction (palmar and dorsal incisions) and internal fixation with titanium plate (control group).
2966916|NCT02784665|Experimental|577-MPL|"577nm micropulse laser(577-MPL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Multiple laser spots will be applied, covering the leakage area."
2966917|NCT02784665|Active Comparator|577-TL|"577nm Traditional laser(577-TL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Traditional laser spots will be applied, covering the leakage area."
2966918|NCT02784652|Experimental|RT & Zoledronic acid|Radiotherapy: 5 days/ week, 3 Gy * 10-13 fractions or 4 Gy * 5 fractions, Zoleronic acid: every 4 weeks, 6 times, 4.0 mg iv
2966919|NCT02784639|Other|determination of KRAS mutation|circulating cell free DNA (ccfDNA) plasma analysis
2966920|NCT02784626|Experimental|Dexmedetomidine|Patients who received dexmedetomidine during the operation
2966921|NCT02784626|Experimental|Propofol|Patients who received propofol during the operation
2966922|NCT02784613|Experimental|Open Label|60 mg ospemifene daily for 20 weeks
2966923|NCT02784600||Partial or full-thickness rotator cuff tear|Rotation Medical bioinductive implant
2966924|NCT02784587|Experimental|Stellate Ganglion Block|All patients in the study will receive a stellate ganglion block in order to asses the feasibility and efficacy of this procedure performed by cardiac anesthesiologists in the operating room.
2966925|NCT02784561|Experimental|Busulfan/FLAG conditioning regimen|"All recipients in this arm received the conditioning regimen consisting of Busulfan/FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor).~The conditioning regimen for peripheral blood stem cell transplantation consisted of busulfan (3.2 mg/kg/ day intravenously [i.v.], days -10 to -8), fludarabine (30 mg/m2, day -7 to -3), cytarabine (1.6 g/m2/day, days~-7 to -3), granulocyte colony-stimulating factor (5 ug/ kg, day -8 to -3). ATG (Thymoglobuline, rabbit) for haploidentical and matched unrelated donors transplantation recipients was used on 2.5 mg/kg/d from days -5 to -2)."
2966926|NCT02784548|Experimental|Virtual reality|Using a Virtual reality (VR) headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
2966927|NCT02784548|Placebo Comparator|Mirror Therapy|Standard mirror therapy makes use of an external mirror, wherein an amputee carries out simple exercises (e.g., clenching & relaxing their fist) with their intact limb while positioned by the mirror in a manner that gives the visual illusion of the missing limb also being engaged in the exercise.
2966928|NCT02784535|Placebo Comparator|placebo|placebo capsules
2966929|NCT02784535|Active Comparator|atomoxetine|atomoxetine capsules 10 mg or 18 mg
2966930|NCT02784522|Experimental|locking compression plate group|In the experimental group, patients will undergo closed reduction via a lateral approach to the shoulder followed by locking compression plate fixation using a minimally invasive technique.The locking compression plate is purchased from Xiamen Dabo Yingjing Medical Devices Co., Ltd., Xiamen, China.
2967017|NCT02783911|Experimental|Mineral Trioxide Aggregate|Subject with pulpotomy treated with MTA MTA paste (< 1gm) will be placed on pulp orifice once for the life of the primary teeth
2966931|NCT02784522|Active Comparator|conventional locking plate group|Patients in the control group will be subjected to closed reduction via a lateral approach to the shoulder followed by conventional steel plate fixation using a minimally invasive technique. The conventional locking plate is purchased from Xiamen Dabo Yingjing Medical Devices Co., Ltd., Xiamen, China.
2966932|NCT02784496|Experimental|Ruxolitinib|"Participants take ruxolitinib tablets by mouth either 1 or 2 times each day at the same dose and schedule that they were assigned in Study 2007-016. Each study cycle is 28 days.~Questionnaires completed every 6 cycles and at end of study visit."
2966933|NCT02784483|Experimental|Atezolizumab (1200mg via IV infusion)|
2966934|NCT02784470|Experimental|gastrojejunostomy arm|
2966935|NCT02784470|Active Comparator|gastroduodenal stent placement|
2966936|NCT02784457|Active Comparator|GnRHant|women who received GnRH antagonist
2966937|NCT02784457|No Intervention|Control|women who did not receive GnRH antagonist
2966938|NCT02784444|Active Comparator|MSDC-0602K Dose 1 capsules|MSDC-0602K Dose 1 capsule taken once daily for 360 days
2966939|NCT02784444|Active Comparator|MSDC-0602K Dose 2 capsules|MSDC-0602K Dose 2 capsules taken once daily for 360 days
2966940|NCT02784444|Active Comparator|MSDC-0602K Dose 3 capsules|MSDC-0602K Dose 3 capsules taken once daily for 360 days
2966941|NCT02784444|Placebo Comparator|Placebo capsules|Matching Placebo capsule taken once daily for 360 days
2966942|NCT02784418|Active Comparator|PCI of CTO|Intervention: PCI of CTO (Chronic Total Occlusion Percutaneous Coronary Intervention) Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice. Hospitalized overnight after the procedure, with post procedure monitoring practices as per standard of care for PCI. CTO PCI patients will receive blinded clopidogrel 75 mg daily for 6 months.
2966943|NCT02784418|Sham Comparator|Sham Procedure|"Intervention: Sham procedure Subjects will be blinded to randomization assignment using a combination of conscious sedation and sensory isolation (e.g., blindfold and noise isolation). Control subjects will only undergo a Sham procedure, wherein they will undergo bilateral arterial access, without angiography or PCI being performed. Hospitalized overnight after the procedure, with post procedure monitoring practices as per standard of care for PCI. Sham group will receive blinded placebo clopidogrel for 6 months."
2966944|NCT02784392|Experimental|Active|Ulimorelin
2966945|NCT02784392|Active Comparator|Comparator|Metoclopramide
2966946|NCT02784379||The breast with mastalgia|Electromyography will be performed to the pectoral muscle that is placed behind the breast with mastalgia.
2966947|NCT02784379||The breast without mastalgia|Electromyography will be performed to the pectoral muscle that is placed behind the breast without mastalgia.
2966948|NCT02784366||Cancer immunotherapy patients - no GI side effect|Cancer immunotherapy patients who do not develop GI side effects.
2966949|NCT02784366||Cancer immunotherapy patients - develop GI side effects|Cancer immunotherapy patients who develop GI side effects
2966950|NCT02784353|Active Comparator|Conventional|No intervention; conventional perioperative management without perioperative rehabilitation program
2966951|NCT02784353|Experimental|Intervention - PReHeBP|conventional perioperative management with preoperative and postoperative rehabilitation program
2966952|NCT02784340|Active Comparator|IV dexamethasone|40 women received 16 mg Dexamethasone IV drip.
2966953|NCT02784340|Active Comparator|Local dexamethasone|40 women received 16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
2966954|NCT02784340|Placebo Comparator|placebo|Placebo in the form of IV fluids 500 cc saline infusion
2966955|NCT02784327|Experimental|PRF110- oily solution|Post-operative application of new extended release PRF110- oily solution (Ropivacaine)
2966956|NCT02784314|Experimental|Robotic-Assisted Radical Prostatectomy|Robotic-Assisted Radical Prostatectomy using da Vinci Surgical System
2966957|NCT02784314|Active Comparator|Laparoscopic Radical Prostatectomy|Standard laparoscopic Radical Prostatectomy
2966958|NCT02784301|Experimental|Belly breathing with biofeedback app|
2966959|NCT02784301|No Intervention|Standard of Care|
2966960|NCT02784301|Active Comparator|Belly breathing without biofeedback app|
2966961|NCT02784301|Active Comparator|Belly breathing + visual distraction|
2966962|NCT02784288|Experimental|Surgery|
2966963|NCT02784288|Experimental|Radiation|
2966964|NCT02784288|Experimental|Radiation and Chemotherapy|
2966965|NCT02784275|Experimental|Dose A|Cyclo-Z containing 23 mg zinc plus 3 mg CHP
2966966|NCT02784275|Experimental|Dose B|Cyclo-Z containing 23 mg zinc plus 9 mg CHP
2966967|NCT02784275|Experimental|Dose C|Cyclo-Z containing 23 mg zinc plus 15 mg CHP
2966968|NCT02784275|Placebo Comparator|Dose D|Placebo
2966969|NCT02784262|Experimental|botox injection|"Preoperative medication: Paracetamol 1,5g oral, diclofenac 50mg (evt ibuprofen 600mg) oral and/or diazepam 5-10 mg oral.~Skin and tissue inside the projected injection canal will be infiltrated with 5-10ml Marcain-Adrenalin (5mg/ml + 5microg/ml) for local anaesthesia.~Localization will be confirmed with help of navigation before the medication will be given. Intravascular injection will be prevented by control of aspiration."
2966970|NCT02784249|Experimental|Goniotomy|Procedure: Goniotomy and trabecular excision in combination with planned cataract extraction via Phaco and PCIOL implant.
2966971|NCT02784249|Active Comparator|Trabecular Micro-Bypass Stent|Procedure: Device implantation in combination with planned cataract extraction via Phaco and PCIOL implant.
2966972|NCT02784236|Other|pre-post evaluation|All patients undergo the condition of telemedicine.
2966973|NCT02784223|Experimental|PET-CT with F18-choline|PET-CT with F18-choline examination will be performed before surgery
2966974|NCT02784210|Experimental|Steroid 5 day dose|5 days of high-dose steroids
2966975|NCT02784210|No Intervention|No Treatment|
2966976|NCT02784210|Experimental|Steroid 3 day dose|3 days of high-dose steroids
2966977|NCT02784184||1 year follow-up group|1 year follow-up group including 6 measurements
2966978|NCT02784184||40 days diaper study subgroup|"Subgroup of the 1 year follow-up group including 15 girls undergoing daily measurement of urinary hormone excretion"
2966979|NCT02784171|Active Comparator|Arm A - Cisplatin/Pemetrexed|Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles
2966980|NCT02784171|Active Comparator|Arm B - Cisplatin/Pemetrexed/Pembrolizumab|Pembrolizumab 200 mg* IV Day 1 over 30 min every 21 days for a total of 2 years Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles
2966981|NCT02784171|Active Comparator|Arm C - Pembrolizumab (Phase II only)|Pembrolizumab 200 mg* IV 30 min Day 1 every 21 days for a total of 2 years
2966982|NCT02784145|Other|RS|Resistant starch supplementation (5 g twice a day)
2966983|NCT02784145|Other|No RS|PD patients who do not receive resistant starch, but who receive recommendations concerning healthy Nutrition (based on the guidelines of the German Society for Nutrition)
2966984|NCT02784132|Other|Study Arm A|Right eye examined first with video diversion then left eye examined without video diversion
2966985|NCT02784132|Other|Study Arm B|Right eye examined first without video diversion then left eye examined with video diversion
2966986|NCT02784132|Other|Study Arm C|Left eye examined first with video diversion then right eye examined without video diversion
2966987|NCT02784132|Other|Study Arm D|Left eye examined first without video diversion then right eye examined with video diversion
2966988|NCT02784119|Experimental|temporary porto-caval shunt|patients in whom temporary porto-caval shunt is performed during orthotopic liver transplantation
2966989|NCT02784119|No Intervention|no temporary porto-caval shunt|patients in whom temporary porto-caval shunt is not performed during orthotopic liver transplantation
2966990|NCT02784106|Placebo Comparator|Placebo: Double-Blind Treatment Period|
2966991|NCT02784106|Experimental|M2951: Double-Blind Treatment Period|
2966992|NCT02784106|Experimental|Placebo/M2951: Open Label Extension Period|
2966993|NCT02784106|Experimental|M2951/M2951: Open Label Extension Period|
2966994|NCT02784093|Experimental|Exposure Group|Participants were allocated to receive 100 mL of Gastrograﬁn orally once daily for 6 consecutive days.
2966995|NCT02784093|Placebo Comparator|Control Group|Participants were allocated to receive enemas twice daily for 6 consecutive days.
2966996|NCT02784080||HLA-alloantibodies exposure|Preformed, persistent, and de novo HLA-alloantibody exposure in the whole cohort.
2966997|NCT02784067|Experimental|Treatment|Subjects randomized to the active treatment arm will take Sucraid, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
2966998|NCT02784067|Placebo Comparator|Placebo|Subjects randomized to the placebo treatment arm will take Sucraid placebo, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
2966999|NCT02784054|Experimental|Intracranial NGGCT|"Six cycles of chemotherapy with carboplatin, etoposide, bleomycin (CEB) and cyclophosphamide, etoposide, bleomycin (CyEB) regimen.~Peripheral blood stem cell collection during the first cycle of chemotherapy.~Surgery, if there is residual tumor after chemotherapy.~Tandem high dose chemotherapy (HDCT) and autologous stem cell transplantation (auto-SCT)~1st HDCT: Carboplatin, thiotepa, etoposide~2nd HDCT: Cyclophosphamide, melphalan~Reduced dose of radiotherapy"
2967000|NCT02784041|Experimental|single adductor-canal-block|Patients in this group will receive ultrasound guided single adductor-canal- block with 0.35% ropivacaine 25ml.
2967001|NCT02784041|Experimental|periarticular infiltration|patients in this group will receive periarticular infiltration of local anesthetic.
2967002|NCT02784028|Experimental|SGM-101|6 dose levels of SGM-101 (5mg/patient, 7.5mg/patient, 10 mg/patient, 12.5mg/patient , 15 mg/patient - 24 h prior surgery and 15 mg/patient - 48h prior surgery
2967003|NCT02784015|Experimental|Unresectable localized soft tissue sarcoma|"Six cycles of chemotherapy with cisplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen.~Surgery, if possible~Concurrent chemoradiotherapy according to the treatment response (necrosis rate, tumor volume reduction, and residual FDG uptake in PET scan)~Tandem high dose chemotherapy (HDCT) and autologous stem cell transplantation, if there are still residual tumors after 9 cycle of chemotherapy, surgery, and radiotherapy.~1st HDCT: carboplatin, thiotepa, etoposide~2nd HDCT: cyclophosphamide, melphalan"
2967004|NCT02784002|Experimental|Ridinilazole (SMT19969)|200 mg capsule of Ridinilazole (SMT19969) twice a day for 10 days
2967005|NCT02784002|Active Comparator|Fidaxomicin|200 mg tablet of Fidaxomicin twice a day for 10 days
2967006|NCT02783989|Active Comparator|White wine|Two glasses of a market white wine (2x135 mL, 13º), each (135 mL) equivalent to 14 g of ethanol (in case of women only one glass, 135 mL), being the daily dose of 28 g (14 g in women). It is estimated that wine will contain about 8-9 mg/l of tyrosol. Therefore the dose of tyrosol ingested in two glasses would be 2-2.5 mg (1-1.25 mg in women).
2967007|NCT02783989|Experimental|White wine plus tyrosol capsules|Two glasses of white wine (2x135 mL, 13º), each (135 mL) equivalent to 14 g of ethanol (in case of women only one glass, 135 mL), being the daily dose of 28 g (14g in women), in combination with capsules of 25 mg of TYR (each one to be ingested with a glass of wine), two capsules along the day for men (at lunch and at dinner) and one for woman (at lunch).
2967008|NCT02783989|No Intervention|Water|Drinking water along with meals
2967009|NCT02783976||Sovaldi-based regimens|Adult patients with chronic HCV infection living in Mexico who take Sovaldi as part of routine clinical care at a participating clinical site.
2967010|NCT02783963|Other|MI with nonobstructive CAD at coronary angiography|MI with nonobstructive CAD investigated by means of OCT and CMR
2967011|NCT02783950|Other|GC (Decipher) Arm|If enrolled during the Genomic Classifier (GC) period, both subjects and their treating physician will be provided GC (Decipher Prostate Cancer Classifier from GenomeDx) and CAPRA-S scores following prostatectomy.
2967012|NCT02783950|No Intervention|Usual-Care-Based (UC) Arm|If enrolled during the UC period, only the CAPRA-S results will be provided.
2967013|NCT02783937|Active Comparator|Filgrastim arm|Intervention: Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days
2967014|NCT02783937|Placebo Comparator|Placebo arm|Intervention: Injection of saline SC injection twice daily for five consecutive days.
2967015|NCT02783924|Active Comparator|Cholecalciferol|Vitamin d (as a 20.000 IU capsule) will be given i a dose of 40.000 IU per week for two months
2967016|NCT02783924|Placebo Comparator|Placebo|two capsules (identical looking to the vitamin D capsules) will be given per week for two months
2967018|NCT02783911|Experimental|Ferric Sulfate|Subject with pulpotomy treated with FS FS paste (<1gm) will placed on pulp orifice once for 15 secs and removed on primary teeth
2967019|NCT02783898|Experimental|Study|All STUDY arm participants will be given an AliveCor Heart Monitor and trained in the use of the device. They will be followed up at 90 days. If a participants allocated to the Study arm, gets an episode of palpitations or pre-syncope and is able to record an AliveCor Heart Monitor ECG during the episode, the participant will email the ECG recorded by the AliveCor app directly to the study team. The study team will review the ECG. If specialist follow-up is not required the study team will inform the participant of this and ask them to arrange general practitioner follow up. If the participant records a serious significant arrhythmia during the study period, the study team will alert the participant immediately and refer them to the cardiac electrophysiology service.
2967020|NCT02783898|No Intervention|Control|All CONTROL arm participants will receive no other intervention. Participants in both groups will be admitted, referred or discharged by the treating clinician according to current hospital protocols. Participants in both groups will be followed up at 90 days through hospital electronic patient record (EPR) systems and through a standardised written questionnaire and follow-up telephone call including symptoms and contact with medical services, satisfaction and compliance.
2967021|NCT02783872||Loss of control|30 overweight or obese (BMI≥85th %ile) youth endorsing loss of control eating within the past 3 months
2967022|NCT02783872||Overweight control|30 overweight or obese controls without any history of loss of control eating
2967023|NCT02783872||Normal-weight control|15 normal-weight controls without any history of loss of control eating
2967024|NCT02783859|Experimental|Active arm: Amoxicillin-clavulanic Acid|8 days of oral amoxicillin-clavulanic Acid 400/57 duo formulation (70-90mg/kg/day, twice daily dosing: max 980mg per day)
2967025|NCT02783859|Placebo Comparator|Placebo arm|8 days of oral placebo (equivalent volume as the active arm)
2967026|NCT02783846|Placebo Comparator|Group control|24 eligible patients are received equal volumes of saline intravenously for 10 minutes
2967027|NCT02783846|Active Comparator|Group dexmedetomidine 0.5 µg/kg|24 eligible patients are received dexmedetomidine 0.5 µg/kg intravenously for 10 minutes
2967028|NCT02783846|Active Comparator|Group dexmedetomidine 1.0 µg/kg|25 eligible patients are received dexmedetomidine 1.0 µg/kg intravenously for 10 minutes
2967029|NCT02783833|Experimental|MMV390048 40 mg|MMV390048 40 mg, tablets, single dose
2967030|NCT02783833|Experimental|MMV390048 dose to be determined mg|MMV390048 dose to be determined mg, tablets, single dose
2967031|NCT02783820|Experimental|MMV390048 40 mg|MMV390048 40 mg, tablets, single dose
2967032|NCT02783820|Placebo Comparator|Placebo to match MMV390048 40 mg|Placebo to match MMV390048 40 mg, tablets, single dose
2967033|NCT02783820|Experimental|MMV390048 80 mg|MMV390048 80 mg, tablets, single dose
2967034|NCT02783820|Placebo Comparator|Placebo to match MMV390048 80 mg|Placebo to match MMV390048 80 mg, tablets, single dose
2967035|NCT02783820|Experimental|MMV390048 120 mg|MMV390048 120 mg, tablets, single dose
2967036|NCT02783820|Placebo Comparator|Placebo to match MMV390048 120 mg|Placebo to match MMV390048 120 mg, tablets, single dose
2967037|NCT02783807|Experimental|Eyenez Retinal Camera v200|Retinal images from Eyenez Retinal Camera v200 of healthy and diseased subjects
2967038|NCT02783807|Active Comparator|Volk Pictor Ret 1|Retinal images from Volk Pictor Ret 1 of healthy and diseased subjects
2967039|NCT02783794|Experimental|BP-C1|Patients randomized to BP-C1 arm will be treated for 32 consecutive days. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they will be offered to continue treatment with BP-C1.
2967040|NCT02783794|Placebo Comparator|Placebo|Patients randomized to Placebo arm will be treated for 32 consecutive days. Thereafter the patients will cross over to 32-day treatment with BP-C1. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they will be offered to continue treatment with BP-C1.
2967041|NCT02783781||Cardiac surgery|All patients (planned and urgent) needed cardiac surgery, and agreed to participate
2967042|NCT02783768|Experimental|E-cigarette first|Participants will undergo the e-cigarette exposure prior to the first two MRI measures, and then they will undergo the sham exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.
2967043|NCT02783768|Experimental|Sham first|Participants will undergo the sham exposure prior to the first two MRI measures, and then they will undergo the e-cigarette exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.
2967044|NCT02783755|Experimental|Mobile Health Pain Coping Skills Training (mPCST)|Mobile Health Pain Coping Skills Training (mPCST) protocol for breast cancer survivors with persistent pain that will produce significant improvements in pain, pain disability, fatigue, physical disability, and adherence to post-treatment lifestyle recommendations that are impacted by pain (i.e., daily activity, self-monitoring of symptoms).
2967045|NCT02783742|Experimental|Intervention|Providers in this arm will receive a communication coaching intervention immediately post-randomization.
2967046|NCT02783742|Other|Waitlist Control|Providers assigned to this arm will be offered the option of receiving the communication coaching intervention after follow up data collection is complete.
2967047|NCT02783729|Experimental|Lemborexant 5 milligrams (mg)|Participants will receive one lemborexant 5 mg tablet and one zolpidem-matched placebo tablet each night
2967048|NCT02783729|Experimental|Lemborexant 10 mg|Participants will receive one lemborexant 10 mg tablet and one zolpidem-matched placebo tablet each night
2967049|NCT02783729|Active Comparator|Zolpidem tartrate|Participants will receive one zolpidem 6.25 mg tablet and one lemborexant-matched placebo tablet each night
2967050|NCT02783729|Placebo Comparator|Placebo|Participants will receive one zolpidem-matched placebo tablet and one lemborexant-matched placebo tablet each night
2967051|NCT02783716|Active Comparator|Cardiac Resynchronization Therapy (CRT)|Participants will be undergoing Cardiac Resynchronization Therapy Implantation (CRT) implantation for heart failure
2967118|NCT02783287|Experimental|Medication text message|Once daily text message reminder.
2967119|NCT02783287|Experimental|Exercise text message|4x daily text message reminder.
2967052|NCT02783716|Active Comparator|Control Group|Participants will undergo device pacemaker or implantable cardioverter-defibrillator (ICD) implantation or pack change for sinus node dysfunction or Atrioventricular (AV) block.
2967053|NCT02783703|Experimental|MCT|Medium chain triglyceride (MCT) oil ingested daily for 6 weeks
2967054|NCT02783690|No Intervention|Conventional Fractionation|50.0 Gy (RBE) in 25 daily fractions
2967055|NCT02783690|Experimental|Hypofractionation|40 Gy (RBE) in 15 daily fractions
2967056|NCT02783677||DM with PAD before angioplasty|Diabetic patients diagnosed with peripheral artery disease via vascular Duplex.
2967057|NCT02783677||DM without PAD|Diabetic patients diagnosed without peripheral artery disease via vascular Duplex.
2967058|NCT02783677||Healthy volunteers|Healthy volunteers
2967059|NCT02783677||DM with PAD after angioplasty|Diabetic patients diagnosed with PAD underwent balloon-angioplasty
2967060|NCT02783664||Questionnaires to Evaluate Patient Stress Levels|
2967061|NCT02783651||No treatment 1|It is planned to have 20-30 sites participating on the trial for chart review of approximately 150-200 patients initiating treatment for Philadelphia chromosome-negative (Ph-) Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) between January 2013 and March 2019.
2967062|NCT02783651||No Treatment 2|Initial record abstraction will occur at study site with subsequent reviews occurring at the site every 3 months thereafter until study conclusion on March 2020.
2967063|NCT02783638|Experimental|YHD1119 (Pregabalin 300mg)|YHD1119 (Pregabalin 300mg)
2967064|NCT02783638|Active Comparator|Lyrica (Pregabalin 150mg)|Lyrica (Pregabalin 150mg)
2967065|NCT02783625|Experimental|Romidepsin + duvelisib|Romidepsin/duvelisib: Cycle 1 and beyond Days 1, 8, 15* Romidepsin IVPB over 4 hours, days 1, 8, 15 duvelisib by mouth twice daily, days 1-28
2967066|NCT02783625|Experimental|Bortezomib + duvelisib|Bortezomib/duvelisib: Cycle 1 and beyond Days 1, 4, 8, and 11* Bortezomib subcutaneous injection, days 1, 4, 8, 11** duvelisib by mouth twice daily, days 1-28
2967067|NCT02783612|Experimental|glucose application|Regular high risk pregnancy clinic surveillance in addition to a Smart phone application for registering the Blood glucose levels and submitting via email every 3-5 days to the High risk Doctor involved in the trial.
2967068|NCT02783612|No Intervention|Regular monitoring|Regular high risk pregnancy clinic surveillance
2967069|NCT02783599|Experimental|Olaratumab + Doxorubicin|"Cycle 1: Olaratumab given intravenously (IV) on day 1 and day 8 (21 day cycle).~Cycle 2: Olaratumab given IV on day 1 and day 8 plus doxorubicin given IV on day 1 (21 day cycle).~Cycle 3 through Cycle 7: Olaratumab given IV on day 1 and day 8 plus doxorubicin given IV on day 1 (21 day cycles)."
2967070|NCT02783586|Experimental|Quadratus Lumborum Block type II|Unilateral ultrasound guidance QLB on the operated side after induction of general anaesthesia - 20 ml of 0,25%bupivacaine with adrenaline injected with ultraplex needle
2967071|NCT02783586|Active Comparator|Transversus Abdominalis Plane Block|Unilateral ultrasound guidance TAPB on the operated side after induction of general anaesthesia - 20 ml of 0,25% bupivacaine with adrenaline injected with ultraplex needle
2967072|NCT02783573|Experimental|Dose 1 of Lanabecestat|Dose 1 of lanabecestat given orally once daily for 156 weeks.
2967073|NCT02783573|Experimental|Dose 2 of Lanabecestat|Dose 2 of lanabecestat given orally once daily for 156 weeks.
2967074|NCT02783573|Experimental|Placebo (Dose 1 of Lanabecestat)|Placebo given orally once daily for 78 weeks and then dose 1 of lanabecestat given orally once daily until week 156.
2967075|NCT02783573|Experimental|Placebo (Dose 2 of Lanabecestat)|Placebo given orally once daily for 78 weeks and then dose 2 of lanabecestat given orally once daily until week 156.
2967076|NCT02783560|Experimental|Sleep First|Families in this condition will receive a behavioral sleep intervention program (The Sleep Train Program) first, prior to a parent training intervention for disruptive behavior. After the completion of the parent training program and several assessment periods, families will receive the mealtime intervention (The Family Mealtimes Program).
2967077|NCT02783560|Active Comparator|Mealtimes First|Families in this active comparison condition will receive a behavioral treatment to promote positive family mealtimes first, prior to a parent training intervention for disruptive behavior. After the completion of the parent training program and several assessment periods, families will receive a behavioral sleep intervention (The Sleep Train Program).
2967078|NCT02783547|Experimental|SyB C-1101 and Azacytidine|
2967079|NCT02783534|Experimental|Verum acupuncture|Participants will receive verum acupuncture plus usual care. Participants will receive acupuncture treatment start from the 5th or 7th day before the estimated first day of menstrual cycle, and for each cycle, participants will receive one session of treatment each day for 5 consecutive days, totally be treated with 15 sessions.Verum needles will be inserted into the skin and manipulated manually until deqi occurs. The needles are retained for 30 min in each session. During the treatment, the acupuncturist inquires the patient about deqi sensations and manipulates the needles to maintain the intensity of deqi. Participants will receive the same usual care as those in the usual care group.
2967080|NCT02783534|Sham Comparator|Sham acupuncture|Participants will receive sham acupuncture plus usual care. The Streitberger placebo needle will be placed at non-acupuncture points which are distant from the meridian parts and not located on the same neuromuscular segments as the prescribed points used in the VA group, so as to minimize any therapeutic and segmental effects. The same acupuncture schedule as that in the verum acupuncture group will be applied. The needles are retained for 30 min in each session. During the treatment, the acupuncturist inquires the patient about deqi sensations and pretends to manipulate the needles but deqi is not sought.Participants will receive the same usual care as those in the usual care group.
2967081|NCT02783534|Placebo Comparator|Usual care|Participants will not receive acupuncture treatment besides health education as a control group.
2967082|NCT02783521|Experimental|Intervention|Includes changing eating behaviors, increasing physical activity, and attending regular in-person weight loss meetings for 12 weeks. To support additional weight loss/weight maintenance, participants will receive bi-weekly phone calls across a 12 week follow-up.
2967083|NCT02783521|Other|Wait List Control|Wait-list control participants will not receive any intervention for the first 12 weeks. After 12 weeks, participants will receive the weight loss intervention plus mHealth technology support.
2967120|NCT02783287|No Intervention|Usual care, medication adherence|Usual care for medication adherence.
2967121|NCT02783287|No Intervention|Usual care, exercise regimen|Usual care for exercise regimen.
2967084|NCT02783508|Active Comparator|IV Meperidine|Intravenous injection of meperidine 50mg given in 100cc NaCl 0.9% over 10 minutes. Repeated doses (if needed) will be given in intervals of 2 hours minimum until a maximum of 4 doses.
2967085|NCT02783508|Active Comparator|Inhaled Nitrous Oxide|Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, the parturient will be advised not to breath through the mask.
2967086|NCT02783495|Experimental|Device: iPad|Patients with brain tumors receive an iPad with the ReMind app. The patients will use the app to train neurocognitive and compensatory skills for 3 hours per week over the course of 12 weeks (36 hours in total)
2967087|NCT02783482|Experimental|GC5107|GC5107 Immune globulin intravenous (human) solution, 10% liquid
2967088|NCT02783469||Diabetic neuropathic pain|Those with type 2 diabetes and painful neuropathy
2967089|NCT02783469||Controls|Type 2 diabetics with non-painful neuropathy, or pain without neuropathy
2967090|NCT02783456|Active Comparator|Noise and silence|Exposition of 80dB flight noise for 30 minutes and 30 minutes silence.
2967091|NCT02783456|Active Comparator|silence and noise|Exposition of 30 minutes silence.and 80dB flight noise for 30 minutes
2967092|NCT02783443||General anesthesia|Adult patients ASA 2-3 undergoing elective total knee replacement surgery under general anaesthesia.
2967093|NCT02783443||Regional anesthesia|Adult patients ASA 2-3 undergoing elective total knee replacement surgery under regional anaesthesia.
2967094|NCT02783430|Experimental|Milnacipran + Ketamine|Ketamine 0,5mg/kg single intravenous perfusion during 40 minutes. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
2967095|NCT02783430|Active Comparator|Milnacipran + Placebo|Placebo single intravenous perfusion during 40 minutes. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
2967096|NCT02783417|Experimental|Training with vascular occlusion|Strength Training: intensity of 30% of 1RM, with vascular occlusion pressure in members.
2967097|NCT02783417|Experimental|Traditional strength training|Strength Training: intensity of 80% of 1RM, without vascular occlusion pressure in members
2967098|NCT02783417|No Intervention|Control|Subject untrained.
2967099|NCT02783404|No Intervention|Control|Receiving no prophylaxis
2967100|NCT02783404|Active Comparator|Amoxicillin|"Receiving 2 gr oral Amoxicillin before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin"
2967101|NCT02783404|Experimental|Amoxicillin-Potassium Clavulanate|"Receiving 2gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate"
2967102|NCT02783391|Experimental|BRAINSPEAK|Electrocorticographical (ECoG) and intracortical electrodes
2967103|NCT02783378|Other|Gaviscon syrup|"Gaviscon will be given to threat patients with reflux after first 24 hours of oesophagal pH-monitoring.~This is a syrup and will be given after every meal. dosage depends from age between 1ml and 5ml after every meal"
2967104|NCT02783365|Experimental|Intervention|The intervention uses photo-elicitation and online group support (via Facebook) to improve patients' overall experience of chronic pain and patient-identified areas of function. This intervention was informed by the Photovoice methodology developed by Wang and Burris (1994). Photovoice participants will utilize cameras that enable them to record issues related to their experiences, and subsequently display them in office visits with their physician or mid-level clinician.
2967105|NCT02783365|No Intervention|Control|Patients in the control practices will receive usual care and will be eligible to participate in the intervention after their participation in the study is completed at 12 months.
2967106|NCT02783352|Experimental|treatment group|arthroscopic rotator cuff repair + injection of autologous micro-fragmented adipose tissue (10 mL)
2967107|NCT02783352|Other|control group|arthroscopic rotator cuff repair only
2967108|NCT02783326|Experimental|COPD Group|Evaluation of oxidative stress, heart rate variability, quality of life with AQ20 questionary, function with TC6 before the application of rehabilitation protocol, after 10 weeks during protocol application and 2 months after protocol application
2967109|NCT02783326|Active Comparator|Control Group|Evaluation of oxidative stress, heart rate variability, quality of life with AQ20 questionary, function with TC6 before the application of rehabilitation protocol, after 10 weeks during protocol application and 2 months after protocol application
2967110|NCT02783313|Experimental|PR-plasma-PCs|Pooled buffy coat-derived pathogen reduced plasma-stored platelet concentrates (PR-plasma-PCs)
2967111|NCT02783313|Active Comparator|Plasma-PCs|Pooled buffy coat-derived plasma-stored platelet concentrates (plasma-PCs)
2967112|NCT02783300|Experimental|Part 1: Dose Escalation|In Part 1, subjects will receive GSK3326595 12.5 mg once daily and escalate until the maximum tolerated dose (MTD) is reached. Projected daily dose levels are 12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, and 1200 mg. BID dosing may divide this total daily dose into two equal doses, administered twice daily. Additional doses (either lower than 12.5 mg, higher than 1200 mg, or intermediate doses between those listed above) and schedules may be explored based on emerging safety, PK, and PD data.
2967113|NCT02783300|Experimental|Part 2a: Disease-Specific TNBC|This part 2 expansion cohort will enroll subjects with TNBC. The final dose and regimen for Part 2 will be decided upon completion of dose escalation in Part 1.
2967114|NCT02783300|Experimental|Part 2b: Disease-Specific MTCC|This part 2 expansion cohort will enroll subjects with metastatic transitional cell carcinoma (MTCC) of the bladder. The final dose and regimen for Part 2 will be decided upon completion of dose escalation in Part 1.
2967115|NCT02783300|Experimental|Part 2c: Disease-Specific recurrent GBM|This part 2 expansion cohort will enroll subjects with recurrent GBM. The final dose and regimen for Part 2 will be decided upon completion of dose escalation in Part 1.
2967116|NCT02783300|Experimental|Part 2d: Disease-Specific NHL p53 mutant|This part 2 expansion cohort will enroll subjects with NHL p53 mutant gene. The final dose and regimen for Part 2 will be decided upon completion of dose escalation in Part 1
2967117|NCT02783300|Experimental|Part 2e: Disease-Specific NHL p53 wild|This part 2 expansion cohort will enroll subjects with NHL p53 wild-type gene. The final dose and regimen for Part 2 will be decided upon completion of dose escalation in Part 1.
2967122|NCT02783274|Active Comparator|Actis Total Hip System|The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
2967123|NCT02783261||Post Y90 hypertrophy measurement|All prospective patients who undergo unilobar SIRT for HCC at SGH or NCC are potential candidates for this study. The study aims to recruit 25 subjects and it is anticipated that 50% will be from SGH and 50% will be from NCC
2967124|NCT02783248||Mitral Stenosis|"No specific protocol intervention occurs. All the cares are made as done usually.~Patients who may be included are all consecutive patients who agreed to participate in the study and having a PMC in a French medical-surgical centers that perform more than 5 year PMC.~All patients undergoing echocardiography with the realization of the score Wilkins and Cormier.~Will then be included to validate the result of late score that patients who had a good immediate result of the PMC defined by: mitral valve area ≥ 1.5 cm² and IM ≤ 2/4. Patients with a poor immediate result of the PMC will not be monitored as part of the study but their data will be collected for the description of the population and analysis of immediate results.~Patients in the study will receive an annual monitoring as recommended, independently of the study."
2967125|NCT02783235|Other|cervical cancer|cervical cancer screening and training for ANMs/ASHAs/PHWs To develop video-based tutorials to train ANMs/ASHAs/PHWs in conducting cervical cancer related health education, screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
2967126|NCT02783222|Active Comparator|Arm B|Nab-paclitaxel 125 mg/mq weekly for 3 out of every 4 weeks
2967127|NCT02783222|Experimental|Arm A|Nab-paclitaxel 100 mg/mq weekly for 3 out of every 4 weeks
2967128|NCT02783209|Other|Cataract surgery|Patient acts as his own control
2967129|NCT02783196|Experimental|Liraglutide (LIR)|Type 2 diabetic randomized to start with two 40 days treatment periods starting with Liraglutide ( IR) treatment, and then after 2 weeks of wash-out, will crossover to second treatment period of 40 days with placebo (PLA)
2967130|NCT02783196|Placebo Comparator|Placebo (PLA)|Type 2 diabetic randomized to start with two 40 days treatment periods starting with placebo ( PLA) treatment, and then after 2 weeks of wash-out, will crossover to second treatment period of 40 days with Liraglutide ( LIR)
2967131|NCT02783183|Experimental|YHD1119|Pregabalin 300mg
2967132|NCT02783183|Active Comparator|Lyrica|Pregabalin 150mg
2967133|NCT02783170|Other|Simultaneous vaccination arm|In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
2967134|NCT02783170|Other|Sequential vaccination arm|In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
2967135|NCT02783157|Experimental|Transcutaneous low-level vagal nerve stimulation (LLVNS)|n=100 patients will be randomized to transcutaneous low-level vagal nerve stimulation (LLVNS), via a clip applied to the ear. Stimulation will be delivered throughout the procedure.
2967136|NCT02783157|Sham Comparator|Sham LLVNS|n=100 patients will be randomized to sham LLVNS, with the clip applied but no stimulation delivered.
2967137|NCT02783144|Experimental|TAP Block and Dexamethasone|After general anesthesia and before the beginning of surgery, 4 mg of Dexamethasone are added to 20 ml of 0,375% Levobupivacaine in Ultrasound-guided Tranversus Abdominis Plain Block.
2967138|NCT02783144|Placebo Comparator|TAP Block and Saline|After general anesthesia and before the beginning of surgery, 2 ml of saline are added to 20 ml of 0.375% Levobupivacaine in Ultrasound-guided Tranversus Abdominis Plain Block.
2967139|NCT02783144|Active Comparator|TAP Block and Dexamethasone i.v.|After general anesthesia and before the beginning of surgery, 20 ml of 0,375% Levobupivacaine are used in Ultrasound-guided Tranversus Abdominis Plain Block. In this group 4 mg of dexamethasone are injected intravenously.
2967140|NCT02783131|Experimental|MedNav|Team getting taught to use mednav, and using mednav in simulation managing Post partum Haemorrhage.
2967141|NCT02783131|No Intervention|non MedNav|Team undergoing routine simulation training in Post Partum Haemorrhage.
2967142|NCT02783118|Experimental|Healthy sample, active intervention|Healthy participants will be testing a depression prevention app employing a self administered online CBT intervention, for 4 weeks.
2967143|NCT02783118|No Intervention|Healthy sample, delayed intervention|Healthy participants will be put on a wait list for 4 weeks, after which access to the depression prevention app will be given.
2967144|NCT02783118|Experimental|Mild depression, active intervention|Mildly depressed participants will be testing a depression prevention app, employing a self administered online CBT intervention, for 4 weeks.
2967145|NCT02783118|No Intervention|Mild depression, delayed intervention|Mildly depressed participants will be put on a wait list for 4 weeks, after which access to the depression prevention app will be given.
2967146|NCT02783105|Experimental|Musical intervention|"Music is provided through headphones: Two 30-min musical sessions per day (one in the morning and one in the evening) beginning at the onset of desedation (Day 0) until day 21.~Both have inverted U shape."
2967147|NCT02783105|Sham Comparator|Control|Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
2967148|NCT02783092|Experimental|Cannabidiol|Concentration unit: 200mg/ml; 5 - 25 mg/Kg/day ; Oral solution
2967149|NCT02783092|Placebo Comparator|Placebo|Oral solution
2967150|NCT02783079|Active Comparator|Arm 1|Cognitive Behavioral Therapy (CBT)
2967151|NCT02783079|Active Comparator|Arm 2|Mindfulness Based Stress Reduction (MBSR)
2967152|NCT02783066|Experimental|"PulseFlow group"|Eligible subjects will try a new offloading boot for 4 weeks
2967153|NCT02783053|Other|Metformin use|The investigators compare the use of metformin vs no metformin
2967154|NCT02783053|No Intervention|Lean or Obese|The investigators compare the effect of metformin on 18F-FDG uptake between lean and obese men.
2967155|NCT02783040|Experimental|single dose cocktail (Midazolam, Warfarin, Omeprazole)|
2967156|NCT02783040|Experimental|single dose Midazolam|
2967157|NCT02783040|Experimental|single dose Digoxin|
2967158|NCT02783040|Experimental|multiple dose BI 425809|
2967200|NCT02782741|Active Comparator|alglucosidase alfa|alglucosidase alfa administered intravenously every 2 weeks
2967201|NCT02782728|Active Comparator|TIPS-Basic|Providers receive tailored scripts based on the patient's responses to the questions administered via tablet.
2968968|NCT02770690|Placebo Comparator|placebo|apply the saline before propofol injection
2967159|NCT02783027|Experimental|SleepTrackTXT2|Participants will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). Participants in the experimental group that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
2967160|NCT02783027|No Intervention|Text-Message Assessments Only|Participants in the non-intervention group/arm will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). The inter-shift assessments will query the participant about his/her sleep hours, fatigue, sleepiness, and difficulty with concentration. No intervention messages sent to this group/arm.
2967161|NCT02782988||CMV symptomatic at birth|olfactory tests, otoacoustic emissions (OAE)
2967162|NCT02782988||CMV asymptomatic at birth|olfactory tests, otoacoustic emissions (OAE)
2967163|NCT02782988||Healthy controls|olfactory tests, otoacoustic emissions (OAE)
2967164|NCT02782975|Experimental|aducanumab IV|Infusion of aducanumab over approximately 1 hour
2967165|NCT02782975|Experimental|aducanumab SC|Subcutaneously via injection
2967166|NCT02782962||Cohort|Patients with acute vertigo/unsteadiness
2967167|NCT02782949|Experimental|Arm I (curcumin)|Patients receive curcumin PO BID for 180 days in the absence of unacceptable toxicity.
2967168|NCT02782949|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 180 days in the absence of unacceptable toxicity.
2967169|NCT02782936|Experimental|Baseline|Randomised baseline without and with gas mask.
2967170|NCT02782936|Experimental|Induced Hypoxemia|Randomised hypoxemia: i. without gas mask; ii. with gas mask; and iii. correction with FreeO2 and gas mask.
2967171|NCT02782936|Experimental|Effort|Randomised effort without and with gas mask
2967172|NCT02782923|Experimental|s-ACDFwith STISIM|Single-level anterior cervical discectomy fusion
2967173|NCT02782923|Experimental|m-ACDF with STISIM|Multi-level anterior cervical discectomy and fusion
2967174|NCT02782923|Experimental|CDR with STISIM|Cervical disc replacement
2967175|NCT02782923|Experimental|PCLF with STISIM|Posterior laminectomy and fusion
2967176|NCT02782923|Experimental|PCD with STISIM|Posterior cervical decompression procedure
2967177|NCT02782923|Sham Comparator|Control Group with STISIM|
2967178|NCT02782910|Experimental|SBAA+|Upon exceeding pre defined SBAA-threshold limits during the randomisation phase the treating physician is alerted (+) to this signal and required to contact the patient so as to assess the current mental status and collaboratively discuss the potential need for medical/psychiatric treatment with the patient.
2967179|NCT02782910|No Intervention|SBAA|Continuous monitoring will occur analogous to SBAA+. Exceeding the pre defined SBAA-threshold will not result in any action taken.
2967180|NCT02782897|Experimental|IVIg group|Participants will receive immunoglobulin therapy plus standard management. The first intravenous infusion of immunoglobulin must be given within 72 hours after the onset.
2967181|NCT02782897|Other|Control group|Participants will receive standard management according to Chinese guidelines for intracerebral Hemorrhage.
2967182|NCT02782884||Outpatient general surgery operation|Patients undergoing outpatient general surgical operations They will be given a specified number of narcotic pills based on our retrospective analysis of patient post-operative opioid use
2967183|NCT02782884||Inpatient general surgical patients|Inpatients who are being discharged They will be given a specified number of narcotic pills based on the number of pills they took in the 24 hrs prior to discharge
2967184|NCT02782871|No Intervention|Control|Manual ventilation with Mapleson C-circuit
2967185|NCT02782871|Experimental|Intervention|Pneupac VR1 portable ventilator
2967186|NCT02782858|Experimental|Dose 1 GNbAC1|Monthly IV repeated dose
2967187|NCT02782858|Experimental|Dose 2 GNbAC1|Monthly IV repeated dose
2967188|NCT02782858|Experimental|Dose 3 GNbAC1|Monthly IV repeated dose
2967189|NCT02782858|Placebo Comparator|Placebo|Monthly IV repeated dose
2967190|NCT02782845|Experimental|Pegfilgrastim|Participants will receive CT or ICT for 6 cycles on Days 1-6, as per standard of care. Protocol does not specify any choice of CT or ICT drugs. Participants will receive pegfilgrastim at a fixed dose of 6 mg subcutaneously, 24 hours after the last dose of CT or ICT in each treatment cycle. CT or ICT cycles of 21 days, as per standard of care.
2967191|NCT02782819|Placebo Comparator|Crystalloid|Isotonic crystalloid solution resuscitation
2967192|NCT02782819|Active Comparator|Crystalloid plus Colloid|Colloid solution resuscitation
2967193|NCT02782793||Patient's with complex colon polyps|
2967194|NCT02782780|Experimental|CBTi|CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep as well as to work with the patient toward altering sleep habits to increase sleep propensity and regularity. Specifically, participants will receive 8 weekly individual sessions of CBTi according to the VA CBTi protocol. The investigators will follow the semi-structured approach to treatment described in the VA CBTi protocol, which allows the case conceptualization to drive the order in which treatment components are introduced.
2967195|NCT02782780|No Intervention|Monitor Only|Study participants who are randomized to the Monitor Only (MO) control group will be followed for 8 weeks of usual care (i.e., they will be advised to continue doing whatever they were doing to manage their GWI and insomnia symptoms without change dosage or frequency of treatment). Participants randomized to the Monitor Only condition will have the option of receiving CBTi delivered by telephone, at no cost to them, upon completion of post-study procedures.
2967196|NCT02782767|Active Comparator|Epidural catheter infusion|epidural catheter in the thoracic vertebra level to provide local anesthetic infusion
2967197|NCT02782767|Experimental|Wound catheter infusion|A multiorificed wound infusion catheter kept within the incision site to provide continuous local anesthetic infusion
2967198|NCT02782754|Experimental|Intracranial germinoma|"Four cycles of chemotherapy with carboplatin, etoposide, (+ bleomycin) and cyclophosphamide, etoposide, (+ bleomycin) regimen~Reduced dose of radiotherapy~Without seeding: 18 Gy to ventricle + 12.6 Gy to primary site~With seeding: craniospinal irradiation 18 Gy + 12.6 Gy to primary site"
2967199|NCT02782741|Experimental|GZ402666|GZ402666 administered intravenously every 2 weeks
2967202|NCT02782728|Experimental|TIPS-Plus|Patients receive tailored messages in addition to the scripts given to providers.
2967203|NCT02782715|Experimental|Radiotherapy & Microwave Ablation|"3+3 dose-escalation wherein three dose levels of stereotactic body radiation therapy (SBRT) would be evaluated:~Dose level I: 6 Gy x 5 fractions~Dose level II: 8 Gy x 5 fractions~Dose level III: 10 Gy x 5 fractions~Radiation treatments will be delivered two to three times a week, with five fractions completed over two weeks.~Four to six weeks after radiation treatment, patients will undergo repeat CT or MRI imaging to assess tumor response and suitability for microwave ablations.~Eight weeks after the conclusion of SBRT, patients will undergo microwave ablation (approximately 12 weeks after registration)."
2967204|NCT02782702|Experimental|Botulism Toxin treatment|Injection of 50 UI Botulism toxin for the treated zone
2967205|NCT02782689|Experimental|Kit Biflex|The Kit Biflex® will be applied according to manufacturer recommendations for 16 weeks or until full healing.
2967206|NCT02782689|Active Comparator|Profore|The compression system Profore will be applied according to manufacturer recommendations for 16 weeks or until full healing.
2967207|NCT02782676|Experimental|Investigational Healon5 OVD|Subjects to receive investigational Healon5 OVD in one eye and control Healon5 in the fellow eye.
2967208|NCT02782676|Active Comparator|Approved Healon5 OVD|Subjects to receive investigational Healon5 OVD in one eye and control Healon5 in the fellow eye.
2967209|NCT02782663|Experimental|Upadacitinib (ABT-494) Dose A|Open label dose A once daily (QD)
2967210|NCT02782663|Experimental|Upadacitinib (ABT-494) Dose B|Open label dose B QD
2967211|NCT02782650||Survey and interviews|"* part one * (quantitative)~Survey on:~A) prenatal counseling at the limits of viability, both current and preferred, within three domains of interest:~organization of prenatal counseling~content of prenatal counseling~decision-making in prenatal counseling~B) treatment options at the limits of viability against the background of the Dutch guideline~* part two * (qualitative)~Focus groups interviews (qualitative) to in-depth explore preferences in prenatal counseling~insight in the specific preferred content of prenatal counseling.~study influencing factors on preferences in the domains of organization and decision-making."
2967212|NCT02782637||Survey and interviews|"*part one* (quantitative)~Survey on:~A. prenatal counseling at the limits of viability, within three domains of interest:~organization of prenatal counseling~content of prenatal counseling~decision-making in prenatal counseling Domains used to evaluate current counseling and counseling preferences~B. decision-making at the limits of viability: evaluation of the made decision (decisional conflict and regret)~*part two* (qualitative)~Individual interviews (qualitative) to in-depth explore preferences in prenatal counseling~insight in the specific preferred content of prenatal counseling.~study influencing factors on preferences in the domains of organization and decision-making."
2967213|NCT02782624|Experimental|Treatment A: Empagliflozin|5 mg bid
2967214|NCT02782624|Experimental|Treatment B: Empagliflozin|10 mg qd
2967215|NCT02782611|Experimental|Treatment|ENHANCE (Enduring Happiness and Continued Self-Enhancement) is a 12-week program that includes an introductory session, 10 weekly sessions focusing on different happiness principles, and a final session focusing on integrating aspects of the program and continuing to practice these principles moving forward. Through completing this program, participants will gain an education on a wide-range of happiness principles and an arsenal of strategies for developing happiness boosting habits and skills.
2967216|NCT02782611|No Intervention|Waiting Group Control|The waiting group control will complete the same assessments as the experimental group but without receiving the intervention.
2967217|NCT02782598|Experimental|CRT+NAVH|Surface ECG and pressure-volume loop recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy and Negative Atrioventricular Hysteresis settings at the device implant procedure
2967218|NCT02782585|Experimental|Experimental group 1|Cervical Manipulation
2967219|NCT02782585|Experimental|Experimental group 2|Cervical lateral glide
2967220|NCT02782585|Placebo Comparator|Control group|Cervical Mobilisation
2967221|NCT02782572|Experimental|Exercise with Non-invasive ventilation|Patients with acute haert failure who performed aerobic exercise with non-invasive ventilation. This group also received conventional medical treatment.
2967222|NCT02782572|Sham Comparator|Exercise|Patients with acute haert failure who performed aerobic exercise with placebo of non-invasive ventilation. This group also received conventional medical treatment.
2967223|NCT02782572|Other|Control|Patients who receiveid only conventional medical treatment and not performed exercise during protocol.
2967224|NCT02782559|Experimental|Sildenafil|Sildenafil 40mg oral tablet three times a day from randomization until delivery
2967225|NCT02782559|Placebo Comparator|Placebo|Matched to oral capsule of active treatment three times a day from randomization until delivery
2967226|NCT02782546|Experimental|Recipient|"Standard of care reduced intensity preparative regimen consisting of fludarabine, cyclophosphamide, and single dose total body irradiation (TBI) on Day -1~Graft cell infusion on Day 0~Post-transplant cyclophosphamide on Days +3 and +4~GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD~G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines~The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes.~ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously from Day +7 (on the day of CIML NK cell infusion), Day +12, Day +17, and Day +22 for a total of 4 doses."
2967227|NCT02782546|Experimental|Donor|"Donors will receive 10mg/kg-BW of subcutaneous G-CSF from Day -5 till Day -1 and then undergo 20L apheresis per institutional guidelines.~Two consecutive days for collection are allowed in case of the target CD34+ cell dose being less than the target 4 x106/kg-bw from the first day of collection.~On Day +6 (one day before the planned CIML NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard 20-L apheresis over 4-5 hours from the same haploidentical related donor that provided the HCT graft."
2967228|NCT02782533|Experimental|DBS V3|Deep Brain Stimulation V3
2967229|NCT02782520|Active Comparator|Ringer Lactate|Ringer Lactate group
2967230|NCT02782520|Experimental|Hypertonic saline|Hypertonic saline group
2967231|NCT02782494||Dialysis group|Patient receiving long term dialysis
2967232|NCT02782481|Experimental|ND0612 (Levodopa/Carbidopa solution)|ND0612 SC infusion over 24 h
2967234|NCT02782468|Experimental|Arm 1, Cohort 1: Pevonedistat 25 mg/m^2|Pevonedistat, 25 milligram per square meter (mg/m^2), 60-minute infusion, intravenously, on Days 1, 3 and 5, followed by a rest period of 16 days, in 21-day treatment cycles.
2967235|NCT02782468|Experimental|Arm 1, Cohort 2: Pevonedistat 44 mg/m^2|Pevonedistat, 44 mg/m^2, 60-minute infusion, intravenously, on Days 1, 3, and 5, followed by a rest period of 16 days, in 21-day treatment cycles.
2967236|NCT02782468|Experimental|Arm 2, Cohort 1: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2|Pevonedistat 10 mg/m^2, 60-minute infusion, intravenously, on Days 1, 3, and 5 and azacitidine 75 mg/m^2, on Days 1 to 5, and Days 8 and 9, intravenously or subcutaneously, followed by a rest period of 19 days, in 28-day treatment cycles.
2967237|NCT02782468|Experimental|Arm 2, Cohort 2: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2|Pevonedistat 20 mg/m^2, 60-minute infusion, intravenously, on Days 1, 3, and 5 and azacitidine 75 mg/m^2, on Days 1 to 5, and Days 8 and 9, intravenously or subcutaneously, followed by a rest period of 19 days, in 28-day treatment cycles.
2967238|NCT02782455|Experimental|CDobi|Calcium dobesylate is given in this group
2967239|NCT02782455|Active Comparator|Flavono|Flavonoids are given in this group
2967240|NCT02782442|Experimental|Structured Cognitive Training & PRIME|Structured cognitive training consists of social cognition and auditory exercises.
2967241|NCT02782442|Active Comparator|Computer Games Control & PRIME|Computer games control condition comes in the official PositScience wrapper.
2967242|NCT02782429|Experimental|Ketamine|This group received ketamine in a dose 0.5 mg / in anesthesia, in addition to other drugs used for induction, which will be standardized.
2967243|NCT02782429|Placebo Comparator|Placebo|This group received the equivalent volume of saline, in addition to other drugs used for induction, which will be standardized.
2967244|NCT02782416|No Intervention|Waiting for renal transplant_no screening of LTBI|patients with renal failure and are waiting for renal transplant We do routine examination but no LTBI check
2967245|NCT02782416|Placebo Comparator|Not waiting for renal transplant|Dialysis patients who are not waiting for renal transplant
2967246|NCT02782416|Other|Status post renal transplant|patients who have received renal transplant
2967247|NCT02782416|Experimental|Waiting for renal transplant_ screening of LTBI|patients with renal failure and are waiting for renal transplant We do routine examination in addition to LTBI check
2967248|NCT02782403|Experimental|Chronic Phase CML Group|"At least 10 participants with the T315I mutation included in group. Participants with BCR-ABL T315I begin therapy with Axitinib, whereas those without this KD mutation begin therapy with Bosutinib.~Participants receive starting dose of Axitinib 5 mg twice a day by mouth daily, and starting dose of Bosutinib 500 mg by mouth daily in alternating, 3-month cycles. At the end of 3 months, participants switch to the other drug for 3 months. This continues every 3 months while on the study.~Participants may continue taking the study drugs for as long as the doctor thinks it is in their best interest."
2967249|NCT02782403|Experimental|Advanced Phase CML Group - (CML-AP) or CML-BP|"Participants have either blast phase (BP) or accelerated phase (AP) chronic myeloid leukemia (CML).~Phase I: Starting dose level of Axitinib 3 mg twice a day by mouth daily, and Bosutinib 400 mg by mouth daily.~Phase II Dose Expansion Phase: Starting Dose of Axitinib and Bosutinib is maximum tolerated dose from Phase I Dose Escalation Phase."
2967250|NCT02782390|Experimental|Hall Technique|single placement of stainless dental crowns on atypical cavities
2967251|NCT02782390|Active Comparator|Composite Resin|single placement of composite resin on atypical cavities
2967252|NCT02782377||Pelvic Floor Dysfunction|Observational study where patients with pelvic floor dysfucntion undergo three AAR measurements. One at baseline, one with the catheter alongside and a third with the rectal balloon inflated. No intervention is performed
2967253|NCT02782364||Faecal Incontinence|Observational study where patients with faecal incontinence undergo two AAR measurements; one with the original step-wise technique and the second with the newer fast-fill technique. A further standard manometry measurement will be taken. 16 patients will undergo fast-fill measurement first and another 16 patients will have step-wise measurement first
2967254|NCT02782351|Experimental|CAR-T|In interventional studies, patients enrolled will receive autologous 2nd generation CAR-T cells, which contain a humanized single chain antibody sequence against CD19.
2967255|NCT02782325|Active Comparator|Fecal Microbiota Transplantation (FMT)|Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3
2967256|NCT02782325|Placebo Comparator|Placebo Transplantation (FMT)|Endoscopic application of placebo FMT followed by 2 weeks of treatment with placebo Capsules G3
2967257|NCT02782325|Active Comparator|Open Label FMT - Extension phase|In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension with an additional endoscopic FMT followed by 2 weeks of oral FMT and clinical follow up at week 10, 14 and 22.
2967258|NCT02782312|Experimental|ICS+LABA Group|Seretide 250，inhalation，twice daily，one year
2967259|NCT02782312|Active Comparator|Control Group|routine therapy for one year
2967260|NCT02782299|No Intervention|Control|This group will not be exposed to the decision aid. Patients will complete the same surveys, and will be followed for the same length of time.
2967261|NCT02782299|Experimental|Decision Aid|This group will be exposed to the decision aid before the patients appointment with the surgeon. Patients will also complete the same outcome surveys, and will be followed for the same length of time.
2967262|NCT02782286|Active Comparator|Ketorolac|The patients randomised to this arm will receive 30 mg intravenous ketorolac.
2967263|NCT02782286|Active Comparator|Morphine|The patients randomised to this arm will receive 0,1 mg/kg intravenous morphine.
2967264|NCT02782273|Active Comparator|Ketorolac|The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
2967265|NCT02782273|Active Comparator|Morphine|The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
2967266|NCT02782260|Experimental|Active|"Dipyridamole eye drops 8.48 mg in 100ml~1 drop three times a day for 1 year"
2967267|NCT02782260|Placebo Comparator|Placebo|"Fluorescein in Active Vehicle~1 drop three times a day for 1 year"
2967298|NCT02781987||CP group|Those patients with chronic pancreatitis underwent ERCP for pancreatic stone clearance, pancreatic stent placement, etc..
2969811|NCT02765022|Experimental|Clip|Clip closure of mucosal defects after endoscopic mucosal resection.
2967268|NCT02782247|Other|Short term Hepatitis C patients|60 patients with chronic hepatitis C infection and cirrhosis who are planning to start antiviral therapy will be enrolled. Patients will be tested within 3 months prior to starting treatment. This will be repeated at 16 weeks (+/- 1 week) and again 1 calendar year after treatment initiation. Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
2967269|NCT02782247|Other|Medium term Hepatitis C patients|60 patients with chronic hepatitis C infection and cirrhosis who have been successfully treated in the past 3 or 5 years (+/- 3 months). Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
2967270|NCT02782247|Other|Hepatitis B Patients|60 patients with chronic hepatitis B and cirrhosis will be tested within 3 months prior to starting treatment. This will be repeated at 16 weeks (+/- 1 week) and again 1 calendar year after treatment initiation. Patients who have started treatment past 3 or 5 years (+/- 3 months) will also be tested. Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
2967271|NCT02782234|No Intervention|not contract management|monthly follow-up phone or family visit completed as regulation, and instruct them proper healthy training.
2967272|NCT02782234|Experimental|Contract management|In accordance with the contract content, researchers and participants should manage and maintain the liquid balance of the participants. Signed doctors and nurses should undergo the follow-up phone or family visit on time, instruct them proper healthy training, and provided necessary information data. By telephone, SMS, wechat, remind and urge the participants to take the lifestyle and behavior regulate in the contract. Participants should supervise and manage the fluid unbalance (Edema, hypertension, heart failure, and fluid imbalance of intake and output etc.), and feedback the Management and supervision to researchers according to contract.
2967273|NCT02782221|Active Comparator|Growth hormone|Subjects are receiving growth hormone
2967274|NCT02782221|Placebo Comparator|Placebo|Subjects are receiving pegvisomant to block the action of growth hormone
2967275|NCT02782208|Active Comparator|Acipimox/GH substitution|Drug: Acipimox Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day Other Name: Tablet Olbetam 250 mg Continue GH substitution as usually.
2967276|NCT02782208|Active Comparator|Acipimox/GH pause|Drug: Acipimox Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day Other Name: Tablet Olbetam 250 mg Pause GH substitution to days prior to the study day.
2967277|NCT02782208|Placebo Comparator|Placebo/GH substitution|Drug: Placebo tablets Continue GH substitution as usually.
2967278|NCT02782208|Placebo Comparator|Placebo/GH pause|Drug: Placebo tablets Pause GH substitution to days prior to the study day.
2967279|NCT02782182|Experimental|FOLFIRINOX+surgery|4 cycles of pre-operative FOLFIRINOX, followed by surgery, followed by 2 more cycles of FOLFIRINOX
2967280|NCT02782169|Active Comparator|Pregabalin|
2967281|NCT02782169|Placebo Comparator|Placebo|
2967282|NCT02782130|Active Comparator|Intervention Group|Subjects randomized to the Epic Allies Intervention will download and install the intervention branch of the Epic Allies app and receive a tour of the app guided by site staff. During the 26-week intervention phase, intervention arm subjects will receive daily adherence reminders set up through Epic Allies with tailored feedback for encouragement and reinforcement. Intervention arm subjects will have 24-hour access to all features of Epic Allies and will receive supportive messages from other subjects on the intervention arm.
2967283|NCT02782130|Placebo Comparator|Control Group|Subjects randomized to the control arm will download and install the control branch of the Epic Allies app (phone-based notifications only) and be provided with instructions on using the app. During the 26-week intervention phase, the control arm subjects will receive weekly phone-based notifications to encourage the subjects to view educational information presented in the app.
2967284|NCT02782104|Experimental|Intranasal Esketamine|Open-Label Induction Phase: Participants will self-administer with esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 milligram [mg] or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585), ESKETINTRD3003 (NCT02493868), ESKETINTRD3004 (NCT02497287), or ESKETINTRD3006 (US sites only) will self-administer intranasal esketamine (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer Esketamine intranasally (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
2967285|NCT02782091|Experimental|Schizophrenia Patient|
2967286|NCT02782091|Experimental|Control Subject|
2967287|NCT02782078|Other|Clindamycin and rifampicin dosages|blood samples for clindamycin and rifampicin dosages (for each patient)
2967288|NCT02782065||Pediatric patients with Asthma|165 patients aged 7 to 18 years, and 30 patients aged 2 to 6 years
2967289|NCT02782052|Experimental|Nebulized ipratropium bromide|Administration in a random order nebulized ipratropium bromide at V3 or V4 or V5
2967290|NCT02782052|Experimental|Nebulized combination ipratropium bromide with salbutamol|Administration in a random order combination Ipratropium bromide and Salbutamol at V3 or V4 or V5
2967291|NCT02782052|Placebo Comparator|Placebo|Administration in a random order placebo at V3 or V4 or V5
2967292|NCT02782026|Experimental|idiopathic PAH|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
2967293|NCT02782026|Experimental|heritable PAH with BMPR2 mutation|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
2967294|NCT02782026|Experimental|chronic thromboembolic PH|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
2967295|NCT02782026|Experimental|Controls|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
2967296|NCT02782000|Experimental|Long-term supervision group|Firstly, this group will having lessons about dementia early recognition. Second, this group will receive face-to-face supervision and key messages by Wechat about dementia early recognition once a month in the following 6 months.
2967297|NCT02782000|Active Comparator|Short-term supervision group|Firstly, this group will having lessons about dementia early recognition. Second, this group will receive face-to-face supervision and key messages by Wechat about dementia early recognition once a month in the following 3 months.
2967299|NCT02781987||BD group|Those patients with biliary ductal disease, such as choledocholithiasis, underwent ERCP to relieve outflow obstruction of the common bile duct.
2967300|NCT02781974|Experimental|Intervention|Intervention consists of strength and balance exercise in group sessions, twice a week for 12 weeks
2967301|NCT02781974|No Intervention|Control|"Participants allocated in the control group are instructed to live as usual"
2967302|NCT02781948||Normal|Not having any history of refractive surgery, contact lens, dry eye or pathology
2967303|NCT02781948||Corneal condition|History of refractive surgery, contact lens, dry eye or keratoconus
2967304|NCT02781922|Experimental|Autologous cardiac stem cells (JRM-001)|
2967305|NCT02781922|No Intervention|Usual care|
2967306|NCT02781909|Active Comparator|Control: Standard of Care TB treatment|Individuals with confirmed pulmonary XDR-TB and receiving Standard of Care TB treatment according to national and WHO guidelines; n=12
2967307|NCT02781909|Experimental|Ibuprofen-treated|Individuals with confirmed pulmonary XDR-TB and receiving Standard of Care TB treatment according to national and WHO guidelines plus ibuprofen (400mg/day/2 months); n=12
2967308|NCT02781896|Active Comparator|Right ventricular pacing|Rapid pacing during TAVI is provided by a temporary pacing catheter placed in the right ventricle. An additional venous vascular access is required.
2967309|NCT02781896|Experimental|Left ventricular pacing|Rapid pacing during TAVI is provided by the valve delivery guidewire inserted into the left ventricle using two alligator clamps. One clamp is attached directly to the skin at the femoral entry site, the other is attached to the body of the valve delivery guidewire. No additional venous vascular access is required.
2967310|NCT02781883|Experimental|BP1001 + LDAC|BP1001 in combination with LDAC
2967311|NCT02781870|Other|No-fixation|These patients will be randomized during the operation, at the time of mesh placement to receive the 3D ENDOLAP visible without fixation.
2967312|NCT02781870|Experimental|LiquiBand Fix glue fixation|"These patients will be randomized during the operation, at the time of mesh placement to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.~Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation."
2967313|NCT02781857||60 patients with lung cancer|"Group A: 30 patients with squamous cell carcinoma eligible for lung cancer surgery~Group B: 30 patients with any type of lung cancer not eligible to surgery (small-cell carcinoma, squamous cell carcinoma, adenocarcinoma, large-cell carcinoma)."
2967314|NCT02781857||60 controls|60 controls (group C) matched for age, gender, smoking history and lung function testing.
2967315|NCT02781844|Experimental|A/B or B/A|Participants will be randomized to either receive 25 microgram (mcg) rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 25mcg rhPTH(1-84) BID with no calcium for treatment period 2
2967316|NCT02781844|Experimental|C/B or B/C|Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 2
2967317|NCT02781844|Experimental|D/E or E/D|Participants will be randomized to either receive 25mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 25mcg rhPTH(1-84) twice daily with calcium for treatment period 2
2967318|NCT02781844|Experimental|F/E or E/F|Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with calcium for treatment period 2
2967319|NCT02781831|Active Comparator|Standard Rehabilitation|Patient with stroke receiving standard hospital based rehabilitation program
2967320|NCT02781831|Experimental|Robot-assisted Rehabilitation|Patient with stroke receiving standard hospital based rehabilitation as well as robot-assisted gait rehabilitation program
2967321|NCT02781818|Experimental|Triamcinolone Acetonide 10mg/mL|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of triamcinolone 10mg/mL solution.
2967322|NCT02781818|Experimental|Triamcinolone Acetonide 40mg/mL|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of triamcinolone 40mg/mL solution.
2967323|NCT02781818|Placebo Comparator|Normal Saline Placebo|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of sterile normal saline solution.
2967324|NCT02781805|Experimental|Alendronate|Subjects will take the study drug alendronate, a nitrogenous bisphosponate, for approximately one to three weeks before their breast surgery.
2967325|NCT02781792|Experimental|Arm 1: Temozolomide morning|"Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m^2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the morning (before 10:00).~FACT-Br quality of life at baseline, at the beginning of each cycle of chemotherapy, and 2 months after the final chemotherapy treatment"
2967326|NCT02781792|Experimental|Arm 2: Temozolomide evening|"Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the evening (after 20:00).~FACT-Br quality of life at baseline, at the beginning of each cycle of chemotherapy, and 2 months after the final chemotherapy treatment"
2967327|NCT02781779|Active Comparator|Silverlon®|Subjects randomized to this arm will receive Silverlon® dressing postoperative.
2967328|NCT02781779|Active Comparator|AQUACEL® AG|Subjects randomized to this arm will receive AQUACEL® AG dressing postoperative.
2967329|NCT02781766|Other|One arm: patients with severe haemophilia A on prophylaxis|Patients with severe haemophilia A (FVIII < 1 IU/dl), currently on prophylactic therapy , having the same prophylaxis regimen in the last six months, aged between 2 (with a body weight ≥12.5 kg ) and 45 years , with adequate venous access, having patient's diary or equivalent regularly completed and able to give informed consent
2967330|NCT02781753|Experimental|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C.
2967333|NCT02781740|Sham Comparator|Sham CPAP therapy|Sham-CPAP is achieved by setting the CPAP machine to the lowest pressure, insertion of a flow-restricting connector at the machine outlet, and insertion of six extra holes in the collar of the main tubing at the end of the mask to allow air escape and to prevent rebreathing of CO2.
2967334|NCT02781727|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
2967335|NCT02781727|Active Comparator|human growth hormone (Genotropin)|Once daily subcutaneous injection of Genotropin
2967336|NCT02781714|Experimental|Two-way SMS|Pre-programmed SMS messages by partner track will be delivered twice weekly to participants in participants' preferred languages from enrollment to 6 months postpartum. They will include a question soliciting a response from the participant(s). Interactive SMS communication will be responded to and managed by the study nurse at each site. Content themes will include: general support/encouragement, postpartum visit reminders, postpartum pregnancy risk and benefits of birth spacing, postpartum contraceptive options and side effects, family planning misconceptions, and couple communication.
2967337|NCT02781714|No Intervention|Control|The control arm will receive standard education and counseling provided in antenatal care and in postnatal care.
2967338|NCT02781701|Experimental|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.~Therefore, participants will work out about 20 minutes a day for 6 weeks."
2967339|NCT02781688|Experimental|Physical Activity Intervention|Participants will participate in a multi-component physical activity intervention for 12 weeks.
2967340|NCT02781675|Experimental|Western Diet|Dietary Intervention: 3 wks of a typical Western Diet
2967341|NCT02781675|Experimental|Mediterranean Diet|Dietary Intervention: 3 wks of a Mediterranean-style diet
2967342|NCT02781675|Experimental|Modified Mediterranean Diet|Dietary Intervention: 3 wks of a Mediterranean-style diet including full fat dairy products
2967343|NCT02781662|No Intervention|Control|
2967344|NCT02781662|Experimental|Intervention|Behavioral: Pharmacist Home-Visit
2967345|NCT02781649|Experimental|Donor genotype 1a no resistance or 1b|Participants who receive donors found to have hepatitis C genotype 1a without resistance Zepatier one tablet daily for 12 weeks
2967346|NCT02781649|Experimental|Donor genotype 1a with resistance|Participants who receive donors found to have hepatitis C genotype 1a with nonstructural protein 5A associated resistance mutations Zepatier one tablet daily for 16 weeks Ribavirin weight based dosing for 16 weeks
2967347|NCT02781649|Experimental|Donor genotype 2 or 3|Participants who receive donors found to have hepatitis C genotype 2 or 3 Zepatier one tablet daily for 12 weeks Sofosbuvir 400 mg daily for 12 weeks
2967348|NCT02781636|Experimental|Chronic Tibial Implant Arm|StimGuard Protect System (Chronic Tibial Nerve Stimulation) Implant Procedure. Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
2967349|NCT02781623||MRI|An MRI will be conducted pre-operatively, 3 months post-operatively, and 1 year post-operatively.
2967350|NCT02781610|Other|ERR-10|ERR treatment duration - 10 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
2967351|NCT02781610|Other|ERR-14|ERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
2967352|NCT02781610|Other|NERR-14|NERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
2967353|NCT02781610|Other|NERR-21|NERR treatment duration - 21 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
2967354|NCT02781597|Active Comparator|Tranexamic acid|All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients in group T will receive Inj Tranexamic acid in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h.
2967355|NCT02781597|Placebo Comparator|Placebo|All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients will receive 0.9% normal saline instead of Tranexamic acid.
2967356|NCT02781584|Experimental|SEL (Cohort 1)|SEL (1 x 18 mg tablet) for 12 weeks
2967357|NCT02781584|Experimental|GS-0976 (Cohort 2)|"GS-0976 (2 x 10 mg capsules) for 12 weeks~Enrollment into Cohort 2 will begin upon completion of enrollment for Cohort 1."
2967358|NCT02781584|Experimental|GS-9674 (Cohort 3)|"GS-9674 (3 x 10 mg tablets) for 12 weeks~Enrollment into Cohort 3 will begin upon completion of enrollment for Cohort 2."
2967359|NCT02781584|Experimental|SEL+GS-9674 (Cohort 4)|"SEL (1 x 18 mg tablet) + GS-9674 (1 x 30 mg tablet) for 12 weeks~Enrollment into Cohort 4 will begin upon completion of enrollment for Cohort 3."
2967360|NCT02781584|Experimental|SEL+GS-0976 (Cohort 5)|"SEL (1 x 18 mg tablet) + GS-0976 (1 x 20 mg tablet) for 12 weeks~Enrollment into Cohort 5 will begin upon completion of enrollment for Cohort 4."
2967361|NCT02781584|Experimental|GS-0976+GS-9674 (Cohort 6)|"GS-0976 (1 x 20 mg tablet) + GS-9674 (1 x 30 mg tablet) for 12 weeks~Enrollment into Cohort 6 will begin upon completion of enrollment for Cohort 5."
2967362|NCT02781584|Experimental|GS-0976 Cirrhotic (Cohort 7)|"GS-0976 (1 x 20 mg tablet) for 12 weeks (participants with Child-Pugh-Turcotte Class A (CPT A) cirrhosis)~Enrollment into Cohorts 7 and 8 will be randomized in parallel."
2967363|NCT02781584|Experimental|GS-9674 Cirrhotic (Cohort 8)|"GS-9674 (1 x 30 mg tablet) for 12 weeks (participants with CPT A cirrhosis)~Enrollment into Cohorts 7 and 8 will be randomized in parallel."
2967364|NCT02781584|Experimental|SEL + GS-0976 + GS-9674 (Cohort 9)|"SEL (1 x 18 mg tablet) + GS-0976 (1 x 20 mg tablet) + GS-9674 (1 x 30 mg tablet) for 12 weeks~Enrollment into Cohort 9 will begin upon completion of enrollment for Cohort 6."
2967365|NCT02781584|Experimental|GS-0976 + Fenofibrate 48 mg (Cohort 10)|Pre-treatment with fenofibrate 48 mg from Day -14 to Day -1 and will be treated with GS-0976 (1 x 20 mg tablet) + fenofibrate (1 x 48 mg tablet) for 24 weeks
2967407|NCT02781246|Active Comparator|0.5 mcg/kg dexmedetomidine (Group B)|(perineural ropivacaine plus 0.5 mcg/kg dexmedetomidine),
2967366|NCT02781584|Experimental|GS-0976 + Fenofibrate 145 mg (Cohort 11)|Pre-treatment with fenofibrate 145 mg from Day -14 to Day -1 and will be treated with GS-0976 (1 x 20 mg tablet) + fenofibrate (1 x 145 mg tablet) for 24 weeks
2967367|NCT02781571|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
2967368|NCT02781558|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
2967369|NCT02781558|Experimental|SOF/VEL + RBV|SOF/VEL FDC + RBV for 12 weeks
2967370|NCT02781519|Active Comparator|THC|Active THC (0.015mg/kg) administered intravenously over 10 minutes.
2967371|NCT02781519|Placebo Comparator|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 10 minutes.
2967372|NCT02781506|Experimental|Nivolumab and SABR|Nivolumab alone: IV, 3 mg/kg q2 weeks, until disease progression or unacceptable toxicity. SABR, dose variable, in 1-3 fractions.
2967373|NCT02781493|Experimental|Prucalopride group|2 mg Prucalopride plus 2 L Polyethylene Glycol regimen
2967374|NCT02781493|Placebo Comparator|Placebo group|2 mg Placebo plus 2 L Polyethylene Glycol regimen
2967375|NCT02781480|Experimental|Low dose AAV-RPE65|Subretinal administration of a single low dose of range AAV-RPE65
2967376|NCT02781480|Experimental|Intermediate dose AAV-RPE65|Subretinal administration of a single intermediate dose of range AAV-RPE65
2967377|NCT02781480|Experimental|High dose AAV-RPE65|Subretinal administration of a single high dose of range AAV-RPE65
2967378|NCT02781467|Experimental|Cyclophosphamide + Fludarabine + PNK-007 + rhIL-2|Fludarabine Day -6 to -2 and Cyclophosphamide Day -5 and -4. On Day 0 PNK-007 at 4 varying dose levels followed by Human recombinant Interleukin-2 (rhIL-2) every other day, Day 0 to Day 10.
2967379|NCT02781454|Active Comparator|Mexiletine, 300 milligrams|Mexiletine, 300 milligrams by mouth per day for 4 weeks.
2967380|NCT02781454|Active Comparator|Mexiletine, 600 milligrams|Mexiletine, 600 milligrams by mouth per day for 4 weeks.
2967381|NCT02781454|Placebo Comparator|Placebo|Placebo, by mouth per day for 4 weeks.
2967382|NCT02781441|Active Comparator|Control group|Patients will receive only the education brochure of GFM
2967383|NCT02781441|Experimental|General QPL group|Patients will receive the brochure and the newly developed QPL (general version)
2967384|NCT02781441|Experimental|Targeted QPL group|Patients will receive the brochure and the newly developed QPL (general version)
2967385|NCT02781415|Experimental|Acupuncture|Traditional Acupuncture Session:Patients in this group will benefit from a 30 minutes acupuncture session made by an experimented physician.
2967386|NCT02781415|Active Comparator|Titrated Morphine|Morphine Titration:Patients will receive an intravenous titration of morphine by a qualified nurse.
2967387|NCT02781402|Experimental|4 weeks of Aerobic Training for normal BMI group|4 weeks of aerobic training on treadmill 3 times per week.
2967388|NCT02781402|Experimental|4 weeks of Aerobic Training for overweight BMI group|4 weeks of aerobic training on treadmill 3 times per week.
2967389|NCT02781376|Experimental|CHICA-OSA|Two clinics will be randomized to receive the advanced CHICA-OSA computer decision support system designed to support PCPs in evidence-based identification and management of pediatric OSA. This module includes a snoring identification component (received by the control group).
2967390|NCT02781376|Other|Control|Two clinics will be randomized to receive a control computer decision support system module that automates screening for snoring and alerts the PCP, but does not provide any additional guidance on evidence-based diagnosis or management.
2967391|NCT02781363|Other|Candidates patients chest X-ray with pneumonia|thoracic sonography CXR Clinical control 48h
2967392|NCT02781363|Other|Candidates patients chest X-ray without pneumonia|thoracic sonography CXR Clinical control 48h
2967393|NCT02781350|Placebo Comparator|High fat high carbohydrate (HFHC) meal|Subjects will consume a HFHC meal. HFHC meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%). 35 ml of blood will be obtained at 1h ,2h,3h and 4 h and 5 ml at 15 min,30 min,45 min,75 min and 90 min . A total of 165 ml (11 tablespoon) blood will be collected.
2967394|NCT02781350|Experimental|HFHC meal plus Fiber|HFHC meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%). Subjects will also receive FiberOne Original cereal 14 grams (half cup) before and after the HFHC meal. 35 ml of blood will be obtained at 1h ,2h,3h and 4 h and 5 ml at 15 min,30 min,45 min,75 min and 90 min . A total of 165 ml (11 tablespoon) blood will be collected.
2967395|NCT02781324|Experimental|Ultrasonic Bone Scalpel Group|Surgeons will use the ultrasonic bone scalpel, to their discretion, along with standard of care manual devices when performing the posterior spinal fusion.
2967396|NCT02781324|Active Comparator|Standard of Care Group|Surgeons will use, to their discretion, only standard of care manual devices when performing the posterior spinal fusion.
2967397|NCT02781311|Experimental|Setipiprant|1000 mg setipiprant (two 500 mg tablets) twice daily (BID) at 12-hour intervals for 24 weeks.
2967398|NCT02781311|Placebo Comparator|Placebo|Two placebo tablets BID at 12-hour intervals for 24 weeks.
2967399|NCT02781298|Experimental|New Infant Cereal|amount ingested according to pediatricians recommendations
2967400|NCT02781298|Active Comparator|Multicereals Infant Cereal|amount ingested according to pediatricians recommendations
2967401|NCT02781285||1group one|patients with standard TCM diagnosis and treatment of gastric cancer
2967402|NCT02781285||2 group two|patients take Chinese Medicine but not with standard TCM diagnosis and treatment of gastric cancer
2967403|NCT02781285||3group three|patients take no Chinese Medicine
2967404|NCT02781272||Women with a pelvic mass|Women diagnosed with a pelvic mass (ovarian, uterine, retroperitoneal, etc.) who are scheduled for an imaging guided biopsy, surgical biopsy or surgical excision for evaluation of their pelvic mass. Must have a pelvic imaging study performed within 60 days prior to surgery and a research blood draw within 30 days prior to surgery.
2967405|NCT02781259|Experimental|Selective Lymph Node Dissection|10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery. Routine axillary lymph node dissection is performed. Acquired lymph nodes are separated to fluorescent positive lymph nodes and fluorescent negative lymph nodes with imaging devices.
2967406|NCT02781246|Active Comparator|saline (Group A)|perineural ropivacaine
2967408|NCT02781246|Active Comparator|1 mcg/kg dexmedetomidine (Group C)|(perineural ropivacaine plus 1 mcg/kg dexmedetomidine)
2967409|NCT02781246|Active Comparator|1.5 mcg/kg dexmedetomidine (Group D)|(perineural ropivacaine plus 1.5mcg/kg dexmedetomidine)
2967410|NCT02781246|Active Comparator|2 mcg/kg dexmedetomidine (Group E)|(perineural ropivacaine plus 2 mcg/kg dexmedetomidine)
2967411|NCT02781233|Experimental|Training group|Each subject will participate in 2 sessions each week during 12 weeks, with 3 days of difference (rest) between the sessions.
2967412|NCT02781233|Placebo Comparator|Control group|Usual daily activities
2967413|NCT02781220||Qualifying participants|All consented IDEAS trial participants will have additional data collected: visual and semi-quantitative software aided amyloid PET scan interpretation, care partner questionnaires and documented provider diagnosis, diagnostic confidence, and management plan following the IMPACT design
2967414|NCT02781194|Experimental|forced-air warming blanket|Forced-air warming blanket via 3M™ Bair Hugger™.
2967415|NCT02781194|Experimental|warmed, humidified insufflation|Warmed, humidified insufflation via the F&P HumiGard™ Surgical Humidification System.
2967416|NCT02781194|Experimental|forced-air warming blanket & warmed, humidified insufflation|Combination of forced-air warming blanket via 3M™ Bair Hugger™ and warmed, humidified insufflation via the F&P HumiGard™ Surgical Humidification System.
2967417|NCT02781181|Other|CAS with CPD|CAS performed under neuroprotection
2967418|NCT02781181|Active Comparator|CAS without CPD|CAS without neuroprotection
2967419|NCT02781168|Experimental|Use of earmuffs|The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels.
2967420|NCT02781168|Active Comparator|No use of earmuffs|No use of earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels.
2967421|NCT02781155|Other|Self administration of moxibustion|Participants will be taught to self administer moxibustion to the acupuncture point Zusanli St-36, and apply it daily throughout their chemotherapy treatments
2967422|NCT02781142|Experimental|Motor imagery training|Persons with multiple sclerosis
2967423|NCT02781142|No Intervention|Control group|Persons with multiple sclerosis
2967424|NCT02781142|No Intervention|Healthy controls|Healthy participants
2967425|NCT02781129|Experimental|RNS® Neurostimulator|Subjects with pharmaceutically intractable seizures who have been implanted with a RNS® Neurostimulator.
2967426|NCT02781103|Experimental|Guided imagery plus active tDCS|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
2967427|NCT02781103|Sham Comparator|Guided imagery plus Sham tDCS|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will be turned off. The device will remain in place, however, for 20 minutes while the subject listens to a guided imagery CD specifically designed for women with chronic pelvic pain.
2967428|NCT02781090|Experimental|Positively Smoke Free on the Web+|Subjects will be assigned to the PSFW+ website and social network. They will also be offered a three-month supply of nicotine patches.
2967429|NCT02781090|Placebo Comparator|American Heart Assoc Getting Healthy|Subjects will be assigned to the AHA Getting Healthy website. They will also be offered a three-month supply of nicotine patches.
2967430|NCT02781064|Active Comparator|Atorvastatin 20mg|Atorvastatin to be taken daily in 2 month treatment periods, 3 treatment periods in 12 months
2967431|NCT02781064|Placebo Comparator|Placebo - Microcrystalline Cellulose|Placebo to be taken daily in 2 month treatment periods, 3 treatment periods in 12 months
2967432|NCT02781051|Experimental|Physical Activity Intervention|Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up.
2967433|NCT02781038|Experimental|Interventional|All subjects will receive a baseline attitude survey. At some point in their hospitalization, preferably at least one day later and no greater than one week later, the patients will be given a teaching intervention and receive another attitude survey.
2967434|NCT02781038|Other|Control|All subjects will receive a baseline attitude survey. At some point in their hospitalization, preferably at least one day later and no greater than one week later, the patients will receive another attitude survey.
2967435|NCT02781025||Oligometastatic Disease|Patients with oligometastatic cancer, defined as biopsy proven disease involving at least one organ other than the primary tumor organ. Regional lymph node metastases are not considered metastatic.
2967436|NCT02781012||Healthy|Healthy volunteers without any known pancreatic disease
2967437|NCT02781012||Healthy At-Risk|Healthy volunteers with no known benign or malignant pancreatic disease, AND with one first-degree relative with pancreatic cancer, OR two second-degree relatives with pancreatic cancer. These subjects also include those who have undergone surgery for suspected pancreatic cancer, and who are found to have a non-pancreatic cancer pathology upon final local site or central pathology review.
2967438|NCT02781012||Pancreatitis|Subjects diagnosed with acute or chronic pancreatitis
2967439|NCT02781012||Early Stage/Borderline/Locally Advanced|Subjects diagnosed with early stage pancreatic cancer who undergo surgery as standard of care therapy with or without preoperative (neoadjuvant) chemotherapy and/or radiation therapy; subjects diagnosed with borderline pancreatic cancer, or subjects diagnosed with locally advanced pancreatic cancer.
2967440|NCT02781012||Metastatic|Subjects diagnosed with metastatic pancreatic cancer and treated with any standard of care therapy/therapies.
2967441|NCT02780999|Experimental|Experimental group|It is a thumb orthotic that does not include wrist joint but includes the metacarpophalangeal joint.
2967442|NCT02780999|Active Comparator|Control group|It is a thumb orthotic that does not include wrist joint neither metacarpophalangeal joint.
2967469|NCT02780791|Active Comparator|Transplantation into pelvic wall|Ovarian transplantation into the pelvic wall after cryopreservation of ovarian tissue before cytotoxic therapies
2967470|NCT02780791|Active Comparator|Transplantation into the ovary|Ovarian transplantation into ovary after cryopreservation of ovarian tissue before cytotoxic therapies
2967471|NCT02780778|Experimental|Treatment group|Apatinib：500 mg，po，qd； Docetaxel：60mg/m²，vein input 1hour，every 3w
2967443|NCT02780986|Active Comparator|Female entertainment worker intervention group|The intervention program for the female EE workers aims to increase STI/HIV prevention knowledge and develop their condom negotiation and application skills so as to increase condom use with both casual and paid partners. It consists of a total of 4 sessions: 2 on-site and 2 online sessions. For each on-site session, groups of 4 to 5 female EE workers will be gathered. The 2 on-site sessions would be delivered by peer educators. The 2 online sessions would be conducted via phone and other modes of network communication (e.g. SMS message or WhatsApp message) depending on the preference of each participant. In addition, all the intervention materials and video demonstrations will also be uploaded onto the web portal for the participant to access during their free time.
2967444|NCT02780986|No Intervention|Female entertainment worker control group|"The female EE workers in the control group will receive the same number of 2 onsite and 2 online sessions but covering healthy eating and physical activity.~The following gives a summarised breakdown and content of each session:~Session 1 (on-site immediately after baseline survey, 10 minutes):~The peer educator will share information on healthy eating and physical activity using the educational pamphlets from the Health Promotion Board (HPB) with the participants.~Session 2 (online 1-2 weeks after baseline survey, 5 minutes):~The peer educator will share an app on healthy eating with the participants.~Session 3 (online 3-4 weeks after baseline survey, 5 minutes):~The peer educator will share an app on physical activity with the participants.~Session 4 (onsite during follow-up survey, 10 minutes):~The peer educator will reinforce information on healthy eating and physical activity based on the educational pamphlets from HPB with the participants."
2967445|NCT02780986|Active Comparator|Heterosexual men intervention group|The intervention program for heterosexual men patronising EEs will be a holistic non disease-centric, non-stigmatising and non-judgemental program addressing sexual well-being, avoidance of casual and paid sex if possible and safe sex such as condom use.
2967446|NCT02780986|No Intervention|Heterosexual men control group|There will be a simultaneous programme on healthy eating and physical activity at the control site at Tanjong Pagar. Health promoters will go around Tanjong Pagar and distribute pamphlets and brochures developed by the HPB on healthy eating and physical activity to the heterosexual men who step into or out of the EEs there. These health promoters have been trained to give simple health advice on healthy eating and physical activity if the heterosexual men wish to find out more information.
2967447|NCT02780973||Females|Female volunteers
2967448|NCT02780973||Males|Male volunteers
2967449|NCT02780960|Experimental|HPV self-testing|Patients will perform HPV self-testing at home, prior to their follow-up visit. At the colposcopy visit, the doctor or nurse will also perform HPV testing. This procedure will be repeated at 6 and 12 months following LEEP.
2967450|NCT02780947|Active Comparator|Prophylactic substrate ablation group|Prophylactic substrate ablation group will undergo substrate mapping and ventricular tachycardia substrate ablation
2967451|NCT02780947|No Intervention|Control group|Control group will undergo substrate mapping
2967452|NCT02780934|Active Comparator|Pressure Dressing|Participants randomized to this group will receive the standard post-operative dressing following their Mohs procedure: a pressure dressing consisting of high absorbency gauze and retention tape.
2967453|NCT02780934|Experimental|Simple Adhesive Dressing|Participants randomized to this group will receive the experimental post-operative dressing following their Mohs procedure: a simple adhesive dressing consisting of a non-adherent pad and transparent dressing.
2967454|NCT02780921|Experimental|Prehab Group|In the experimental group (Prehab group) compared to the control group, the main objective will be to demonstrate an improvement of the percentage of patients reaching the complete oncological treatment fixed in a multidisciplinary tumour board
2967455|NCT02780921|Other|control group|The control group will be treated according to conventional care; will not receive any specific intervention before surgery except nutritional support and physiotherapy at the surgeon's discretion
2967456|NCT02780908|Experimental|Hypoxia at rest and exercise|The participants will perform a resting test, hypoxia sensitivity test and a graded exercise test to voluntary exhaustion in normoxic condition ((HYPO; FiO2=0.120 corresponding to terrestrial altitude of approx. 4000 m)
2967457|NCT02780908|Placebo Comparator|Normoxia at rest and exercise|The participants will perform a resting test and a graded exercise test to voluntary exhaustion in normoxic condition ((NORM; fraction of inspired oxygen (FiO2)=0.209, placebo)
2967458|NCT02780895|Experimental|Single Arm Study|stereotactic brain surgery of human stem cells (OK99)
2967459|NCT02780882|Experimental|Pasireotide|Each patient will be treated with pasireotide at an initial dose of 600 μg twice daily for one month. The dose will be further increased to 900 μg twice daily for month 2 and 3. After month 3, patients who continue to meet the inclusion and exclusion criteria will be entered into an additional 3 months of treatment.
2967460|NCT02780869|Experimental|Investigational|HEMOBLAST Bellows
2967461|NCT02780869|Active Comparator|Control|Absorbable gelatin sponge, USP with thrombin
2967462|NCT02780856|Other|Sound and unsound teeth|Sound (ICDAS 0) canines or incisors and unsound (ICDAS 2 or 3) molars or pre-molars - imaging with the Calcivis System
2967463|NCT02780843|Experimental|Computerized Tomography|Patients will be examined with Computerized Tomography (CT) at admission
2967464|NCT02780843|Experimental|Magnetic Resonance Imaging|Patients will be examined with Magnetic Resonance Imaging (MRI) at admission
2967465|NCT02780830|Experimental|AZD2014 plus Ibrutinib Combination|AZD2014 and ibrutinib will be dosed together in the morning under fasting conditions. When possible, the morning doses of AZD2014 and ibrutinib should be taken at approximately the same time each day. The morning doses must be taken in a fasted state (water to drink only) from at least 2 hours prior to the dose to at least 1 hour post dose. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
2967466|NCT02780817|Experimental|Error enhancement|Arm reaching rehabilitation training with error-augmentation perturbation forces. One session of about 25 minutes of practicing arm reaching movements on 3D robotic device.
2967467|NCT02780817|Other|Control group|Arm reaching rehabilitation training without error-augmentation perturbation forces. One session of about 25 minutes of practicing arm reaching movements on 3D robotic device.
2967468|NCT02780804|Experimental|Treatment (entinostat)|Patients receive entinostat PO on days 1, 8, 15, and 22. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
2967472|NCT02780765|Experimental|Heated humidifier group|30 postoperative patients with overnight endotracheal intubation will be supplied humidified oxygen using Heated Humidifier (HH). Temperature of inspired gas at the Y piece will be measured as surrogate marker for quality of humidification. The suctioning of ETT will be done once every 2 hourly by nurse/ doctor/trained personnel.
2967473|NCT02780765|Active Comparator|Mist humidifier group|30 postoperative patients with overnight endotracheal intubation will be supplied humidified oxygen using mist nebuliser. Temperature of inspired gas at the Y piece will be measured as surrogate marker for quality of humidification. The suctioning of ETT will be done once every 2 hourly by nurse/ doctor/trained personnel.
2967474|NCT02780752|Experimental|Hymecromone|Hymecromone 300 mg orally three times per day for 3 months followed by hymecromone 600 mg orally three times per day for an additional 3 months (i.e. total 6 months of drug treatment).
2967475|NCT02780739|Experimental|Cognitive Training - 48 sessions|56 hours of video game training with Mind Frontiers adaptive cognitive training software (48 70-min sessions distributed over 16 weeks)
2967476|NCT02780739|Experimental|Fitness, Cognitive Training, sham tDCS|32 hours and 40 min of high-intensity cardiorespiratory fitness training (28 70-min sessions distributed over 16 weeks); 23 hours and 20 min of video game training with Mind Frontiers adaptive cognitive training software with simultaneous sham tDCS (20 70-min sessions distributed over weeks 5-16)
2967477|NCT02780739|Experimental|Fitness, Cognitive Training, active tDCS|32 hours and 40 min of high-intensity cardiorespiratory fitness training (28 70-min sessions distributed over 16 weeks); 23 hours and 20 min of video game training with Mind Frontiers 1.0 adaptive cognitive training software with simultaneous active tDCS for a total of 10 hrs (20 70-min sessions distributed over weeks 5-16)
2967478|NCT02780739|Active Comparator|Active Control|56 hours of video game training with visual search and change detection tasks using open sesame software (48 70-min sessions distributed over 16 weeks)
2967479|NCT02780739|No Intervention|No Contact Control|Completed no study activities for 16 weeks after pre-assessment, then returned for post-assessment
2967480|NCT02780726|Experimental|ASP1517 Low Dose Group (ESA Untreated)|This group includes subjects who have not received Erythropoieses Stimulating Agents (ESAs). Study drug will be dosed three times weekly and dose adjustments will be made during the study.
2967481|NCT02780726|Experimental|ASP1517 High Dose Group (ESA Untreated)|This group includes subjects who have not received ESAs. Study drug will be dosed three times weekly and dose adjustments will be made during the study.
2967482|NCT02780726|Experimental|ASP1517 ESAs Treated Group|This group includes subjects who have received ESAs. The treatment was converted from ESAs to study drug. Study drug will be dosed three times weekly and dose adjustments will be made during the study.
2967483|NCT02780713|Experimental|AZD9496|"This is a fixed sequence study with 5-sequential treatment periods in healthy volunteers. Each volunteer will receive 5 single doses of AZD9496 in different forms, formulations and doses.~Treatment period 1 will assess AZD9496 Variant A: 100mg.~Treatment period 2 will assess AZD9496 Reference: 100mg.~Treatment period 3 will assess one of AZD9496 Variants, B, C or D: 100mg.~Treatment period 4 will assess one of AZD9496 Variants, B, C or D: 100mg.~Treatment period 5 will assess one of AZD9496 Variants A, B, C or D: *300mg. *Based on a review of PK and safety results from Treatment Periods 1, 3 and 4, a lower dose of 200 mg may be administered in Treatment Period 5"
2967484|NCT02780700|Experimental|Nintedanib|
2967485|NCT02780700|Experimental|Nintedanib plus capecitabine|
2967486|NCT02780687|Experimental|Afatinib|
2967487|NCT02780674|Active Comparator|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
2967488|NCT02780674|Placebo Comparator|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
2967489|NCT02780661|Experimental|Denture Cleanser Daily Use Period|Participants will be instructed to soak upper arch dentures in the evening in cup of very warm water (150 millilitre [ml]) with 1 denture cleansing tablet from Day 0 to Day 7 for 15 minutes (mins). Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds. Cleaning of upper arch dentures in the morning is not permitted. Lower arch dentures will be cleaned using the participant's normal oral hygiene procedures in the morning and evening. If the participants will have lower removable partial or complete dentures, the soaking of these dentures will be done in a separate cup from the cup provided for soaking the upper denture.
2967490|NCT02780661|Experimental|Denture Cleanser Weekly Use Period|Participants will be instructed to soak upper arch dentures in the evening in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds. Cleaning of upper arch dentures in the morning is not permitted. Lower arch dentures will be cleaned using the participant's normal oral hygiene procedures in the morning and evening. If the participants will have lower removable partial or complete dentures, the soaking of these dentures will be done in a separate cup from the cup provided for soaking the upper denture.
2967491|NCT02780648|Experimental|Stereotactic Body Radiation|Patients will receive 5 fractions of 5 Gy or 6.6 Gy (dose depending upon whether or not they have received prior radiation therapy to the pancreatic region) delivered over a five-day period.
2967492|NCT02780635|Experimental|App + Couples Coach Intervention|Both members of the couple will receive a mobile app for PTSD: PTSD Coach for the Veteran and PTSD Family Coach for the partner/spouse. Those assigned to this arm will also receive mailed materials that are designed to help increase positive communication strategies.
2967493|NCT02780635|Active Comparator|App Alone|Both members of the couple will receive a mobile app for PTSD: PTSD Coach for the Veteran and PTSD Family Coach for the partner/spouse.
2967494|NCT02780622|Experimental|First Warfarin Then Warfarin and Oseltamivir|Participants will receive warfarin (on Days 1-5) in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive oseltamivir 75 milligram (mg) (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
2967573|NCT02780167|Experimental|Cohort 3|100 mg of PF-04965842 QD
2967574|NCT02780167|Experimental|Cohort 4|200 mg of PF-04965842 QD
2967575|NCT02780167|Placebo Comparator|Cohort 5|placebo QD
2967495|NCT02780622|Experimental|First Warfarin and Oseltamivir Then Warfarin|Participants will receive oseltamivir 75 mg (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive warfarin (on Days 1-5) in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
2967496|NCT02780609|Experimental|Selinexor Plus HDM HCT|The conditioning regimen begins 3 days prior to autologous transplant. Day 0 is the day of the autologous hematopoietic cell transplant. Melphalan will be given intravenously (IV) on Day -3 and Day -2; Dexamethasone will be given through via IV on Day -3, Day -2 and Day -1; fosaprepitant at 150 IV on days -3 and -2 will be given to patients an an antiemetic.Selinexor will be taken by mouth (PO) daily on the same day participants receive chemotherapy with melphalan.
2967497|NCT02780596|Experimental|Items1;3|Caregiver is randomly assigned to receive screening items 1 and 3. Item 1: Does CHILD NAME often wake one or more times during the night? Item 3: Do you think CHILD NAME's sleep is a problem?
2967498|NCT02780596|Experimental|Items1;4|Caregiver is randomly assigned to receive screening items 1 and 4. Item 1: Does CHILD NAME often wake one or more times during the night? Item 4: Does you think CHILD NAME has a sleep problem?
2967499|NCT02780596|Experimental|Items1;5|Caregiver is randomly assigned to receive screening items 1 and 5. Item 1: Does CHILD NAME often wake one or more times during the night? Item 5: Do you have any concerns about CHILD NAME's sleep?
2967500|NCT02780596|Experimental|Items2;3|Caregiver is randomly assigned to receive screening items 2 and 3. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 3: Do you think CHILD NAME's sleep is a problem?
2967501|NCT02780596|Experimental|Items2;4|Caregiver is randomly assigned to receive screening items 2 and 4. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 4: Does you think CHILD NAME has a sleep problem?
2967502|NCT02780596|Experimental|Items2;5|Caregiver is randomly assigned to receive screening items 2 and 5. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 5: Do you have any concerns about CHILD NAME's sleep?
2967503|NCT02780596|Experimental|Items3;5|Caregiver is randomly assigned to receive screening items 3 and 5. Item 3: Do you think CHILD NAME's sleep is a problem? Item 5: Do you have any concerns about CHILD NAME's sleep?
2967504|NCT02780596|Experimental|Items4;5|Caregiver is randomly assigned to receive screening items 4 and 5. Item 4: Does you think CHILD NAME has a sleep problem? Item 5: Do you have any concerns about CHILD NAME's sleep?
2967505|NCT02780583|Placebo Comparator|placebo|methylprednisolone intravenously, placebo shots every 6 hours
2967506|NCT02780583|Experimental|anakinra (Kineret)|methylprednisolone intravenously, anakinra shots every 6 hours
2967507|NCT02780570|Active Comparator|GBS patients|Small Volume Plasma Exchange
2967508|NCT02780570|No Intervention|non-GBS|non-GBS patients with central venous catheter
2967509|NCT02780557|Experimental|Contingent Reading Intervention|
2967510|NCT02780557|Other|Book Provision Control|
2967511|NCT02780544|Experimental|skin-to-skin contact + sucrose|the infants get 2 eye examinations within 1 week in randomized order, one in skin-to-skin position with a parent (intervention group) and one in the incubator (standard care). Sucrose (0.2 ml) lingual will be given for pain relief according to standard care two minutes before either eye examination.
2967512|NCT02780544|Active Comparator|incubator + sucrose|the infants get 2 eye examinations within 1 week in randomized order, one in the incubator (standard care) and one in skin-to-skin position with a parent (intervention group). Sucrose (0.2 ml) lingual will be given for pain relief according to standard care two minutes before either eye examination
2967513|NCT02780518|Experimental|Airvo|All patients scheduled for elective microlaryngeal surgery under general anaesthesia and subglottic high frequency jet ventilation
2967514|NCT02780505|Active Comparator|vitamin c|vitamin C supplement orally up to 250 mg per day for 6 weeks was prescribed. Plasma levels of vitamin C and other clinical parameters including hemoglobin, ferritin, TIBC, iron and CRP were measured at the beginning and end of the study.
2967515|NCT02780505|Placebo Comparator|placebo|ُPlacebo prescribed to Group B. Plasma levels of vitamin C and other clinical parameters including hemoglobin, ferritin, TIBC, iron and CRP were measured at the beginning and end of the study
2967516|NCT02780492||Ambulant patients|A set of assessment tools (blood analyses, functional, respiratory, quality of life questionnaires, Dexa scan, MRI) will be performed.
2967517|NCT02780492||Non-ambulant patients|A set of assessment tools (blood analyses, functional, respiratory, quality of life questionnaires, Dexa scan, MRI) will be performed.
2967518|NCT02780492||Healthy volunteers and Disease controls|A set of assessment tools (upper limb function tests, MRI, blood analyses) will be performed
2967519|NCT02780479|Experimental|Dexamethasone|Dexamethasone arm: will receive second dose of oral Dexamethasone 0.6 mg/kg/dose max of 16 mg, 24 hour from the first dose given in emergency department.
2967520|NCT02780479|Active Comparator|Prednisone|Prednisone arm: will receive oral Prednisone 1mg/kg with max of 30 mg twice daily starting 24 hours after the Dexamethasone dose given in emergency department for 8 additional doses.
2967521|NCT02780466||Patients with septic shock|
2967522|NCT02780453|Experimental|Negative pressure dressing|Negative pressure dressing
2967523|NCT02780453|Active Comparator|Standard dressing|Standard wound dressing
2967524|NCT02780440||Control Group|Subjects will participate in standard occupational therapy rehabilitation protocol plus a traditional home based exercise program.
2967525|NCT02780440||Experimental Group 1|Subjects will participate in standard rehabilitation protocol plus unimanual home based mirror therapy program
2967526|NCT02780440||Experimental Group 2|Subjects will participate in standard rehabilitation protocol plus bimanual home based mirror therapy program.
2967527|NCT02780427|Active Comparator|1-6 months (Group 1)|
2967528|NCT02780427|Active Comparator|7-12 months (Group 2)|
2967529|NCT02780427|Active Comparator|13-18 months (Group 3)|
2967530|NCT02780427|Active Comparator|19-24 months (Group 4)|
2967531|NCT02780414||Study Cohort|A group of at least 1,541 pregnant women with NO Pre-E diagnosis
2967532|NCT02780414||Positive Pre-E Control|A group of at least 250 pregnant women diagnosed with Pre-E
2967533|NCT02780401|Experimental|Treatment (WOKVAC with sargramostim)|"Patients receive WOKVAC with sargramostim ID on day 1. Courses repeat every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients with ALND will have vaccine administered to the contralateral arm. Patients with bilateral ALND will have vaccine administered in the thigh. As much as possible each vaccine dose will be given within the same draining lymph node site. Patients will be monitored for a minimum of 60 minutes post vaccine administration."
2967534|NCT02780388|Experimental|Cohort 1|Medi4920 (CD40L antagonist)
2967535|NCT02780388|Placebo Comparator|Placebo|Saline
2967536|NCT02780388|Experimental|Cohort 2|Medi4920 (CD40L antagonist)
2967537|NCT02780388|Experimental|Cohort 3|Medi4920 (CD40L antagonist)
2967538|NCT02780375||Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points before and during their radiotherapy
2967539|NCT02780362|Experimental|A Test|Test drug (Prodactariv)1 tablet contains 60 mg Daclatasvir
2967540|NCT02780362|Active Comparator|B Reference|Reference drug (Clatazev) 1 tablet contains 60 mg Daclatasvir
2967541|NCT02780349|Experimental|WIRION EPS|Single arm study. All patients undergo procedure with the WIRION EPS
2967542|NCT02780336||Blepharospasm (BL)|Participants in this group should be diagnosed with blepharospasm, but may have dystonia in other body parts as well.
2967543|NCT02780336||Disease Control Group|Participants in this group should be diagnosed with a disorder affecting their eyes or face, such as hemifacial spasm, facial tics, or apraxia.
2967544|NCT02780336||Normal Control Group|Participants in this group should not have any neurologic problems or other disorders affecting patients eyes or face.
2967545|NCT02780323|Experimental|CELBESTA® and CELEBREX® placebo|CELBESTA® and CELEBREX® placebo is administered twice daily for 6 weeks
2967546|NCT02780323|Active Comparator|CELEBREX®|CELEBREX® and CELBESTA® placebo is administered twice daily for 6 weeks
2967547|NCT02780310|Experimental|Lenvatinib|All eligible patients will receive a starting lenvatinib dose of 24 mg daily taken orally for each 4-week cycle. Patients may remain on study until progression of disease or unacceptable toxicity. Alternatively, Lenvatinib may be dissolved in fluid per the Food and Drug Administration (FDA) label and administered orally or via a feeding tube.
2967548|NCT02780297||Primary Hyperoxaluria Patients|Patients with confirmed diagnosis of Primary Hyperoxaluria.
2967549|NCT02780297||Dent Disease Patients|Patients with confirmed diagnosis of Dent Disease.
2967550|NCT02780297||Cystinuria Patients|Patients with confirmed diagnosis of Cystinuria.
2967551|NCT02780297||APRT deficiency Patients|Patients with confirmed diagnosis of adenine phosphoribosyltransferase deficiency (APRTd)
2967552|NCT02780297||Lowe Syndrome or Dent 2 patients|Patients with confirmed diagnosis of Lowe Syndrome or Dent 2.
2967553|NCT02780297||Dent 1 carriers|Patients with confirmed diagnosis of Dent 1. Dent 1 carriers
2967554|NCT02780297||Enteric Hyperoxaluria Patients|Patients with confirmed diagnosis enteric hyperoxaluria.
2967555|NCT02780284|Experimental|Physical activity intervention|Observation phase of usual activity and an intervention phase of regular physical activity
2967556|NCT02780271|Experimental|Arm A|Subjects will receive in-person education plus e-communication AND subjects will receive control intervention
2967557|NCT02780271|Experimental|Arm B|Subjects will receive e-communication alone AND subjects will receive control intervention
2967558|NCT02780271|Experimental|Arm C|Subjects will receive in-person education alone AND subjects will receive control intervention
2967559|NCT02780271|Active Comparator|Arm D|Subjects will receive control intervention
2967560|NCT02780258|Experimental|Restylane Silk Treated Hand|The dorsal aspect of one hand will be injected with Restylane Silk.
2967561|NCT02780258|No Intervention|Control Hand|The dorsal aspect of the hand that is not treated will be used for baseline comparison.
2967562|NCT02780245|Experimental|Group (X) Prophylactic Tranexamic Acid|Intravenously at 20 minutes preoperatively had an intervention of a single bolus TXA dose of 20•0 mg/kg, which was administered in Z solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g) (NCT02739815).
2967563|NCT02780245|Experimental|Group (Y) Intraoperative Uterine Cooling|Firstly intravenously at 20 minutes preoperatively had only the Z solution, and secondly [Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen].
2967564|NCT02780232|Experimental|Internet-based program|"Adolescents in the intervention will receive a tailored online program during 3 months.~Adolescents interact with the program via a monitoring e-mail that they receive every two weeks (Monitoring) and a website which allows them to access a number of links."
2967565|NCT02780232|No Intervention|Treatment as usual|-Waiting list control group.
2967566|NCT02780219|Experimental|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions with blood draws, acute exercise, cognition testing"
2967567|NCT02780219|Experimental|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions with blood draws, acute exercise, cognition testing"
2967568|NCT02780206|Experimental|obese|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~3 study days (one baseline, one approx 2 weeks of diet, one post-diet): muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
2967569|NCT02780180|Experimental|QGC001|QGC001 from 50mg to 500mg capsule twice daily, for 28 days, oral use
2967570|NCT02780180|Placebo Comparator|Placebo|Placebo, capsule twice daily, for 28 days, oral use
2967571|NCT02780167|Experimental|Cohort 1|10 mg of PF-04965842 QD
2967572|NCT02780167|Experimental|Cohort 2|30 mg of PF-04965842 QD
2967576|NCT02780154|Experimental|1600 7G8 PfSPZ|N= 7-9 participants will receive 1600 7G8 PfSPZ DVI in a volume of 500mcL
2967577|NCT02780154|Experimental|3200 7G8 PfSPZ|N= 9 participants will receive 3200 7G8 PfSPZ DVI in a volume of 500mcL
2967578|NCT02780154|Experimental|3200 NF54 PfSPZ|N= 5-6 participants will receive 3200 NF54 PfSPZ DVI in a volume of 500mcL
2967579|NCT02780154|Experimental|4800 7G8 PfSPZ|N= 2-3 participants will receive 4800 7G8 PfSPZ DVI in a volume of 500mcL
2967580|NCT02780154|Experimental|800 7G8 PfSPZ|N= 7-9 participants will receive 800 7G8 PfSPZ DVI in a volume of 500mcL
2967581|NCT02780141|Experimental|ASP1517 Low dose Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
2967582|NCT02780141|Experimental|ASP1517 High dose Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
2967583|NCT02780128|Other|Molecular Analysis|All participants with relapsed or refractory neuroblastoma will have a tumor biopsy to identify genetic mutations. There is no drug given in this arm of the trial.
2967584|NCT02780128|Experimental|Group 1: ALK|"Qualified participants whose tumors show certain mutations in the anaplastic lymphoma kinase (ALK) pathway (based on genetic sequencing results) will receive a combination therapy of ceritinib and ribociclib, to be administered orally in 28-day cycles.~Two different doses of ceritinib and three different doses of ribociclib will be evaluated. Once the investigators have identified the highest safe dose of both drugs that can be given at the same time, additional participants will be enrolled in the study at this dose level.~It is possible that if starting at a lower dose, participants may take a higher dose once that dose has been deemed safe."
2967585|NCT02780128|Experimental|Group 2B: RAS-MAPK or CDK4/6|"Qualified participants whose tumors show certain mutations in the rat sarcoma - mitogen activated protein kinase (RAS-MAPK) or CDK4/6 pathway (based on genetic sequencing results) will receive a combination therapy of trametinib and ribociclib, to be administered orally in 21-day cycles.~Two different doses of trametinib and three different doses of ribociclib will be evaluated. Once the investigators have identified the highest safe dose of both drugs that can be given at the same time, additional participants will be enrolled in the study at this dose level.~It is possible that if starting at a lower dose, participants may take a higher dose once that dose has been deemed safe."
2967586|NCT02780128|Experimental|Group 3: p53|"Qualified participants that do not match Groups 1 or 2, and whose tumors show wild-type p53 (based on genetic sequencing results) will receive HDM201 as a single agent, to be administered orally on Day 1 and Day 8 in 28-day cycles.~The investigators will perform a dose-escalation of HDM201. Once the investigators have identified the highest safe dose of HDM201, additional participants will be enrolled in the study at this dose level."
2967587|NCT02780115|Experimental|Cohort 1: Vehicle Control|Vehicle dosed in both eyes administered once daily during office visits 1 through 5.
2967588|NCT02780115|Experimental|Cohort 2: AGN-199201 Dose A and AGN-190584 Dose A|Fixed combinations of AGN-199201 Dose A and AGN-190584 Dose A dosed in both eyes administered once daily during office visits 1 through 5.
2967589|NCT02780115|Experimental|Cohort 3: AGN-199201 Dose B and AGN-190584 Dose B|Fixed combinations of AGN-199201 Dose B and AGN-190584 Dose B dosed in both eyes administered once daily during office visits 1 through 5.
2967590|NCT02780115|Experimental|Cohort 4: AGN-199201 Dose C and AGN-190584 Dose C|Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in both eyes administered once daily during office visits 1 through 5.
2967591|NCT02780115|Experimental|Cohort 5: Vehicle, AGN-199201 Dose C and AGN-190584 Dose C|Dominant eye dosed with Vehicle. Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in nondominant eye. Treatment administered once daily during office visits 1 through 5.
2967592|NCT02780102|Experimental|Cognitive-Motor Rehabilitation|Cognitive-Motor Rehabilitation (CMR): 20 sixty-minute sessions of cognitive-motor rehabilitation
2967593|NCT02780102|Experimental|Ritalin|2 to 3 doses of 10 mg Ritalin tablets per day during 8 week.
2967594|NCT02780102|Active Comparator|Active Control|Active Control group simultaneously received 20 sixty-minute sessions of low dose cognitive-motor exercises
2967595|NCT02780089||Prospective Patients|There will be 1,600 prospective patients recruited over a period of two years and followed-up for a planned minimum of three years. For the prospective cohort, patients will be recruited after the course of treatment has been decided by the physician and prior to the start of treatment.Prior advanced melanoma treatment information will be collected from patient charts for pre-treated patients. Patients will be followed for a minimum of 3 years from their study index date until death, withdrawal of consent, lost to follow-up/record, or end of study, whichever comes first. Study index date will be the date when first study therapy is initiated.
2967596|NCT02780089||Treatment Group No. 1|Immune checkpoint inhibitor patients who remain on an immune checkpoint inhibitor therapy. Defined as immune checkpoint inhibitor therapy patients who either remained on their initial (index) immune checkpoint inhibitor therapy or switched to another immune checkpoint inhibitor therapy during the study period. Patients in this group remained on an immune checkpoint inhibitor therapy and did not switch to a non-immune checkpoint inhibitor therapy anytime during the study period.
2967597|NCT02780089||Treatment Group No. 2|Immune checkpoint inhibitor patients who switched to a non-immune checkpoint inhibitor therapy. Defined as patients who switched from their index immune checkpoint inhibitor therapy to a non-immune checkpoint inhibitor therapy anytime during the study period.
2967598|NCT02780089||Treatment Group No. 3|Targeted therapy patients who remain on a targeted therapy. Defined as targeted therapy patients who either remained on their initial (index) targeted therapy or switched to another targeted therapy during the study period. Patients in this group remained on a targeted therapy and did not switch to a non-targeted therapy anytime during the study period.
2967599|NCT02780089||Treatment Group No. 4|Targeted therapy patients who switched to a non-targeted therapy. Defined as patients who switched from their index targeted therapy to a non-targeted therapy anytime during the study period.
2967600|NCT02780089||Treatment Group No. 5|Chemotherapy/other therapy patients who remain on a chemotherapy/other therapy. Defined as chemotherapy/other therapy patients who either remained on their initial (index) chemotherapy/other therapy or switched to another chemotherapy/other therapy during the study period. Patients in this group remained on a chemotherapy/other therapy and did not switch to an immune checkpoint inhibitor therapy or targeted therapy anytime during the study period.
2967630|NCT02779881||Subjects outgrown cow's milk allergy with formula+probiotic|Tolerant with extensively hydrolyzed casein formula with Lactobacillus rhamnosus GG
2967601|NCT02780089||Treatment Group No. 6|Chemotherapy/other patients who switched to an immune checkpoint inhibitor therapy or targeted therapy. Defined as patients who switched from their index chemotherapy/other therapy to an immune checkpoint inhibitor therapy or targeted therapy anytime during the study period.
2967602|NCT02780089||Retrospective Patients|Retrospective cohort of 600 patients with unresectable or metastatic melanoma, receiving therapies other than immune checkpoint inhibitor or targeted therapies during the four year period prior to the release of ipilimumab (March 25, 2007 -March 24, 2011), will be identified. The data for these 600 retrospective patients will be used as a benchmark for treatment patterns and outcomes prior to the marketed availability of immune checkpoint inhibitors or targeted therapies.
2967603|NCT02780076|Experimental|Functional training group|Participation in a functional training program in addition to usual care. The functional training program is initiated by the nurses and consists of walking, sit-to-stands, balance training, weight transfer training, knee squats. The program is performed 4 times a day for 3 weeks while at short-term stays.
2967604|NCT02780076|No Intervention|Control group|Usual care only. No participation in the functional training program while at short-term stays.
2967605|NCT02780063|Experimental|Lenstar Biometry|Lenstar biometry will be performed on each eye prior to dilation. Subjects eyes will be dilated and subject will wait 20 minutes. Lenstar biometry will be performed after the 20 wait time.
2967606|NCT02780050|No Intervention|chest compression before physical fitness|"The subjects consist of 25 medical school students and interns had experienced in cardiopulmonary resuscitation (CPR) education.~2 instructors, they had physical therapy (PT) certificate, take an exam for subject's muscle strength of each muscle. After that time, subjects take a rest for 10 minutes. Researchers educate to subjects for high quality CPR including 5 to 6cm compression depth, 100 to 120 beat per minute (bpm) rate, complete chest recoil. Subjects perform chest compression to manikin with skill reporting system during 4min under guidance of 110 bpm metronome sound (first chest compression). Researchers record subject's chest compression depth and rate in 1st chest compression."
2967607|NCT02780050|Experimental|after core muscle activation using physical fitness|"The subjects consist of 25 medical school students and interns had experienced in cardiopulmonary resuscitation (CPR) education.~After 1st chest compression, subjects take a rest during an hour and carry out PT. PT consist of 30 second plank for 3 sets, 12 times bridge for 3 sets and 20 times leg extension for 3 sets. Subjects take a rest during 30 seconds between sets, 1 minute every 3 sets.~After PT completion, subjects take a rest during 10 minutes, and then perform 2nd chest compression in the same way of 1st chest compression. Researchers record subject's chest compression depth and rate in 2nd chest compression."
2967608|NCT02780037|Experimental|Prevention|Regulatory frame: prevention
2967609|NCT02780037|Experimental|Promotion|Regulatory frame: promotion
2967610|NCT02780037|Sham Comparator|Neutral|Regulatory frame: not implied
2967611|NCT02780024|Experimental|Registered one arm study|Two weeks of neo-adjuvant Metformin+Temozolomide followed by accelerated hypofractionation using an IMRT technique+TMZ & Metformin followed by TMZ, and Metformin as adjuvant component.
2967612|NCT02780011|Experimental|Alsertib and Brentuximab Vedotin|Brentuximab vedotin at a fixed dose of 1.8 mg/kg will be administered by intravenous infusion on day 1 of every 21-day cycle. MLN8237 at a dose of 60 mg will be orally administered daily in 2 divided doses (30 mg qAM, 30 mg qPM) from days 1 to 7 of each 21-day cycle. MLN8237 dose will be escalated in 20-mg increments to the maximum dose of 100 mg (Level 2) or de-escalated in a 20-mg decrement to the minimum dose of 40 mg (Level -1).
2967613|NCT02779998|Active Comparator|standard oxygen therapy with facial mask|Patients assigned to standard medical therapy will received supplemental oxygen via a facial Venturi mask at a rate of up to 15 liters per minute in order to maintain peripheral oxygen saturation (SpO2) above 94% during electrophysiology procedure under light sedation.
2967614|NCT02779998|Experimental|non invasive ventilation|non invasive ventilation (NIV) which associated positive end expiratory pressure (PEEP: 5 to 10 cmH2O) and pressure support ventilation (PSV: 5 to 15 cmH2O, to achieve total Pressure bellow 20cmH2O) will be delivered during electrophysiology procedure under light sedation. The patient will received supplemental oxygen through facial mask to achieve an oxygen saturation level above 94%.
2967615|NCT02779985|Experimental|Lycium Barbarum mixed meal|Subjects will receive a high-fat mixed meal containing Lycium Barbarum once.
2967616|NCT02779985|Active Comparator|Control mixed meal|Subjects will receive a high-fat mixed meal without Lycium Barbarum as a control.
2967617|NCT02779972||60's decade|60's decade Echo stress test
2967618|NCT02779972||70's decade|70's decade Echo stress test
2967619|NCT02779972||80's decade|80's decade Echo stress test
2967620|NCT02779959|Experimental|Buccal Prochlorperazine|Experimental arm of two buccally absorbable prochlorperazine tablets (6 mg) plus 2 cc IV saline
2967621|NCT02779959|Active Comparator|Intravenous Prochlorperazine|Accepted Standard of care receiving 10 mg (2 cc) of intravenous prochlorperazine plus two saccharin absorbable placebo tablets.
2967622|NCT02779946||CHD-positive|positive tested for coronary artery disease
2967623|NCT02779946||CHD-negative|negative tested for coronary artery disease
2967624|NCT02779920|Experimental|Per oral pylorotomy|Patients with gastroparesis (significant prolongation of gastric emptying) not improved prokinetic and antiemetic treatments undergoing per oral pylorotomy
2967625|NCT02779907||Study Population|Children aged 4-6 years resident in Chikwawa District.
2967626|NCT02779894|No Intervention|Hospital group|Patients referred to the sleep unit and randomized to Hospital group. Participants will be diagnosed in the hospital either by Polysomnography , Respiratory Polygraphy or one night Home Respiratory Polygraphy. In case of requiring CPAP treatment, the titration and adjustment of patient's will be accomplished at the hospital. This patient's will be monitored during 3 months of the study at the hospital.
2967627|NCT02779894|Other|ICT group|Patients referred to the sleep unit and randomized to intervention group. Participants will be diagnosed at home by 3 night Home Respiratory Polygraphy. In case of requiring CPAP treatment, the adjustment will be performed at the CPAP supplier center, titration will be performed at home and patient's compliance and treatment will be controlled via remote. During the 3 months of the study patient's will be controlled via phono/video conferences and with a platform designed for the study.
2967628|NCT02779881||Healthy controls|Healthy controls
2967629|NCT02779881||Children at diagnosis of cow's milk allergy|Children at diagnosis of cow's milk allergy
2967631|NCT02779881||Subjects outgrown cow's milk allergy assuming other formulas|Subjects tolerant with other formulas
2967632|NCT02779868|Experimental|Omega-3|Group who will receive 2g eicosapentaenoic (4 capsules) acid per day during the chemoradiotherapy protocol.
2967633|NCT02779868|Placebo Comparator|Olive oil|Group who will receive olive oil per day (4 capsules) during the chemoradiotherapy protocol.
2967634|NCT02779855|Experimental|Talimogene laherparepvec + Chemotherapy|Talimogene laherparepvec with Neoadjuvant Paclitaxel Chemotherapy treatment administration on an outpatient basis. Phase I: Dose Escalation to Determine Maximum Tolerated Dose (MTD). Phase II: Treatment at MTD.
2967635|NCT02779842|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2967636|NCT02779829|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2967637|NCT02779777|Experimental|Tipifarnib, Oral|900 mg b.i.d. Days 1 -7, 15-21 in 28-day cycle
2967638|NCT02779764|Experimental|ASP1517 Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
2967639|NCT02779751|Experimental|NSCLC KRAS mt, PD-L1+|Abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
2967640|NCT02779751|Experimental|NSCLC Squamous|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
2967641|NCT02779751|Experimental|HR+, HER2- Metastatic Breast Cancer|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
2967642|NCT02779738|Experimental|Merestinib Fasted|Single dose of merestinib administered in fasted state in one of three periods
2967643|NCT02779738|Experimental|Merestinib Standard Meal|Single dose of merestinib administered with a standard meal in one of three periods
2967644|NCT02779738|Experimental|Merestinib High-Fat Meal|Single dose of merestinib administered with a high-fat meal in one of three periods
2967645|NCT02779725|Active Comparator|Group 1 SCC/SSR|This arm includes self-care coaching (SCC) message during daily self-reported symptom severity report (SSR) calls to the automated system.
2967646|NCT02779725|Active Comparator|Group 2 NP/SSR|Alert reports are generated during the patient's daily symptom severity monitoring call if alert thresholds are reached. These alerts are monitored and follow-up care is given by a nurse practitioner.
2967647|NCT02779725|Active Comparator|Group 3 NP/DSS/SSR|Alert reports are generated during the patient's daily symptom severity monitoring call if alert thresholds are reached. Nurse practitioner follow-up calls utilize the evidenced based SCH decision support system (DSS) when symptoms exceed alert thresholds
2967648|NCT02779725|Active Comparator|Group 4 Full Intervention SSR/SCC/NP/DSS|Complete intervention with all components used in prior efficacy study (Symptom Severity Report (SSR)+Self Care Coaching (SCC) +Nurse Practitioner (NP) +Decision Support System (DSS))
2967649|NCT02779725|Active Comparator|Group 5 SSR/SCC/AT|Symptom severity reporting (SSR), automated self-care coaching (SCC) based on daily symptom reporting plus activity tracker (AT)
2967650|NCT02779712|Active Comparator|Remote Ischaemic Conditioning|Remote ischaemic conditioning (RIC group): 4 cycles of intermittent limb ischaemia - alternating 5 minutes inflation (20mmHg above systolic BP) followed by 5 minutes deflation of a standard upper arm blood pressure cuff
2967651|NCT02779712|Sham Comparator|Control|Control: 4 cycles of alternating 5 minutes inflation (up to 30 mmHg) followed by 5 minutes deflation of a standard upper arm blood pressure cuff
2967652|NCT02779699|Experimental|AL2846|AL2846 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2967653|NCT02779686||ARMD Free|Patient free of ARMD on clinical examination
2967654|NCT02779686||ARMD Positive|Patients with evidence of ARMD on clinical examination
2967655|NCT02779673|Experimental|Test group|Subjects randomized to the test group consumed yoghurt drink containing 3.4g plant stanol as ester for 1 per day for a period of 4 weeks.
2967656|NCT02779673|Placebo Comparator|Placebo group|Subjects randomized to the placebo group consumed yoghurt drink without plant stanol as ester for 1 per day for a period of 4 weeks.
2967657|NCT02779660|Experimental|RIPC-Group|After randomization patients will undergo 3 sessions of RIPC (Remote ischemic preconditioning) intervention: I) on preoperative day, II) 1 h before and III) directly before the blood sample collection and invasive measurement of electrophysiological parameters.
2967658|NCT02779660|Placebo Comparator|Control-Group|After randomization patients will undergo 3 sessions of sham-intervention: I) on preoperative day, II) 1 h before and III) directly before the blood sample collection and invasive measurement of electrophysiological parameters.
2967659|NCT02779647|Experimental|Study group|Consisting of 27 children who were recommended a programme of physical activity, play and nutritional advice, for both the children and their parents
2967660|NCT02779647|No Intervention|Control group|27 children, who received only nutritional advice
2967661|NCT02779634|Placebo Comparator|Placebo|Placebo three times daily
2967662|NCT02779634|Active Comparator|Active|Pills of 100 mg ubiquinol three times daily
2967663|NCT02779621|Experimental|Self-sampling|(Self-collecting a vaginal sample with a swab for HPV testing) Women in the experimental arm will have the option of vaginal self-sampling for HPV testing, in addition to the routine screening test. They can choose one of them.
2967664|NCT02779621|Active Comparator|Routine smear|(Collection of cervical sample for routine cervical screening) Women in the control arm will only receive the routine cervical screening invitation letter.
2967696|NCT02779387|No Intervention|non GnRH-a|patients treated with outpatient guidance only.
2967779|NCT02778841|Experimental|conventional balance exercises|conventional balance exercises group performed three times per week on non-consecutive days for eight weeks
2967665|NCT02779608|Experimental|intraperitoneal docetaxel and oral S-1|"Docetaxel is diluted in 1litre normal saline and administered intraperitoneal（IP）at a dose of 60 mg/m2 over 1 hour on day 1. S-1 was administered orally twice daily at a dose of 40mg/m2 per day for 14 consecutive days, followed by 7 days of rest.~Intervention: Drug: Intraperitoneal docetaxel Intervention：Drug：Oral S-1"
2967666|NCT02779595||Lung surgery|26 patients (up to 36) undergoing lung surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
2967667|NCT02779595||Flail chest|8 patients undergoing an operative stabilization of a flail chest will be examined by perioperative pulmonary function tests
2967668|NCT02779582|Experimental|Progesterone|Oral micronized progesterone, 300 mg po daily, taken as three capsules daily before sleep for three months
2967669|NCT02779582|Placebo Comparator|Placebo|Placebo, each taken as three capsules daily before sleep for three months
2967670|NCT02779569|Experimental|Ultra-low-dose group|decitabine was subcutaneously administered at 5 to 7 mg/m2 once daily for successive 3 days at the first week, and once daily at weeks 2 to 4, with a total dose of 60 mg in a 4-week cycle.
2967671|NCT02779569|Active Comparator|Low-dose group|decitabine was subcutaneously given at 20 mg/m2 once daily for successive 3 days, with a total dose of 60 mg/m2 in a 4-week cycle.
2967672|NCT02779556|Other|Enhanced Usual Care|ADA Living Well with Diabetes Workbook, 15 minute in-person counseling, follow-up every 3 months
2967673|NCT02779556|Other|Intervention|ACP Living with Diabetes Guide, 15 minute in-person counseling , 15 minute follow-up counseling (3, 6, and 9 months), monthly phone calls after 3 months
2967674|NCT02779543|Active Comparator|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
2967675|NCT02779543|Active Comparator|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
2967676|NCT02779543|Active Comparator|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
2967677|NCT02779530|Experimental|Diclofenac|
2967678|NCT02779530|Placebo Comparator|Placebo|
2967679|NCT02779517|Experimental|Focus groups|Healthcare Professionals and subjects with or without an upper extremity disability will be asked to observe and interact with the mobile service robot.
2967680|NCT02779504||Aguna treated METS|Patient implanted with Agluna treated METS
2967681|NCT02779504||Untreated METS|Patient implanted with untreated METS
2967682|NCT02779491|Experimental|Intervention|Receipt of the mobile phone application
2967683|NCT02779491|No Intervention|Control|Usual habitual activity - no receipt of mobile phone application
2967684|NCT02779478||Positive NTM Culture|Subjects that meet inclusion criteria and have culture positivity for NTM: at least two separate expectorated induced sputum samples or from one bronchoalveolar lavage (BAL) or lung biopsy
2967685|NCT02779478||Negative NTM Culture|Subjects that meet inclusion criteria and have less than two separate expectorated induced sputum samples culture negative or culture negative bronchoalveolar lavage (BAL) or lung biopsy.
2967686|NCT02779465|Experimental|Vitamin D|Drug: Vitamin D3 800 IU daily besides the anti-virus treatment with nucleos(t)ide medicine
2967687|NCT02779465|No Intervention|Control|chronic hepatitis B patients with long term anti-virus therapy
2967688|NCT02779452||GDM newborns|Newborns from gestational diabetes mellitus pregnancy
2967689|NCT02779452||No GDM newborns|Newborn from a normal pregnancy
2967690|NCT02779439|Experimental|3rd party CTL infusion|Virus specific CTLs
2967691|NCT02779426|Experimental|Text Message Intervention + Standard Care|Enrolled patients and their caregivers who are randomized to this group will receive the usual standard of care for atopic dermatitis patients treated at this institution as well as daily text messages with information about atopic dermatitis and treatment reminders. 1-2 times/week they will receive a message asking if they were able to complete their treatments in the last day. They will respond with 1=yes, 2=no, 3= I have questions about the treatment. Those who respond with 3 will be sent the contact information for the office. No other communications will be sent through text messages. Caregivers will take two in-office surveys: one upon enrollment, and one follow-up survey at the follow-up visit. Patient EASI Score will be assessed by the pediatric dermatologist and initial and follow up exam.
2967692|NCT02779426|No Intervention|Standard Care|Enrolled patients and their caregivers who are randomized to this group will receive the usual standard of care for atopic dermatitis patients treated at this institution. They will not receive text messages. Caregivers will take two in-office surveys: one upon enrollment, and one follow-up survey at the follow-up visit. Patient EASI Score will be assessed by the pediatric dermatologist and initial and follow up exam.
2967693|NCT02779413||Insulin degludec|
2967694|NCT02779400|Experimental|Evaluation of the device perfomance|
2967695|NCT02779387|Experimental|GnRH-a|patients treated with GnRH-a after surgery and Outpatient guidance
2967697|NCT02779374|Experimental|Autologous bone marrow transplantation|autologous bone marrow will be given by intravenous infusion. the intervention will be preceded by a period of 6 months of follow up the a period of 12 months follow up
2967698|NCT02779361|Experimental|Green tea|Green tea consumption along 7 days.
2967699|NCT02779348|Experimental|Nebicapone plus warfarin|BIA 3-202 200 mg tid + Warfarin 25 mg
2967700|NCT02779348|Experimental|Warfarin|Warfarin 25 mg
2967701|NCT02779335|Other|Enteral formula tube feeding|Enteral fed children, ages 1-13, with establish enteral feeding access
2967702|NCT02779322|Active Comparator|Minigastric bypass|Intervention(s): The patient will have done a Laparoscopic one anastomosis gastric bypass (minigastric bypass) at the time of the surgical procedure.
2967703|NCT02779322|Active Comparator|Gastric bypass|The patient will have a Laparoscopic Roux-en-Y gastric bypass at the time of the surgical procedure
2967704|NCT02779309||Development Cohort|437,000 home care recipients who received services from January 1, 2007 to December 31, 2012.
2967705|NCT02779309||Validation Cohort|122,000 home care recipients who received services from January 1, 2013 to December 31, 2013.
2967706|NCT02779296|Experimental|2-Octyl Cyanoacrylate Glue|At the surgical site, a thin layer of cyanoacrylate glue will be applied over the sutures at the time of closure.
2967707|NCT02779296|No Intervention|No Glue|No cyanoacrylate glue will be applied.
2967708|NCT02779283|Experimental|Arm I (AML)|Patients receive cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 30 minutes on days 1-3.Patients receive cyclophosphamide IV over 3 hours twice daily (BID) on days 1-3, vincristine sulfate IV on days 4 and 11, doxorubicin hydrochloride IV on day 4, dexamethasone PO on days 1-4 and 11-14, and rituximab IV on day 1 and 11 (day 11 only of course 1). Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Based on the results of the kinase inhibitor assay (In Vitro Kinase Inhibitor Assay), patients receive either sorafenib tosylate PO BID, sunitinib malate PO daily, dasatinib PO daily, ponatinib hydrochloride PO daily, ruxolitinib phosphate or idelalisib PO BID on days 8-28 in the absence of disease progression or unacceptable toxicity.
2967709|NCT02779283|Experimental|Arm II (ALL)|Patients receive cytarabine IV over 2 hours BID on days 2-3, methotrexate IV over 2-22 hours on day 1, methylprednisolone sodium succinate IV BID on days 1-3, leucovorin calcium IV every 6 hours until methotrexate level is < 0.05 uM and rituximab IV on days 1 and 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Based on the results of the kinase inhibitor assay (In Vitro Kinase Inhibitor Assay), patients receive either sorafenib tosylate PO BID, sunitinib malate PO daily, dasatinib PO daily, ponatinib hydrochloride PO daily, ruxolitinib phosphate or idelalisib PO BID on days 8-28 in the absence of disease progression or unacceptable toxicity.
2967710|NCT02779270|Experimental|BAY987518|Subject will apply the test product to all sun exposed areas of face and body, wait for 15 minutes, then sunbathe for 30 minutes, exercise for 20 minutes, and then sunbathe for additional 30 minutes. Immediately after the second sunbathing, enter the pool and remain in the water for 20 minutes. Then repeat the sun and water exposure activities again.
2967711|NCT02779270|Active Comparator|Sunscreen control|Subject will apply the test product to all sun exposed areas of face and body, wait for 15 minutes, then sunbathe for 30 minutes, exercise for 20 minutes, and then sunbathe for additional 30 minutes. Immediately after the second sunbathing, enter the pool and remain in the water for 20 minutes. Then repeat the sun and water exposure activities again.
2967712|NCT02779257|Experimental|Pasireotide|Off label use of pasireotide to treat refractory hypoglycemia due to an insulin-producing pancreatic neuroendocrine tumor
2967713|NCT02779244|Experimental|Early Weight Bearing + Cam boot|
2967714|NCT02779244|Active Comparator|Standard Treatment Cam boot|
2967715|NCT02779231|Experimental|Texting group|This group will be enrolled in bi-directional texting to send back blood pressure.
2967716|NCT02779231|No Intervention|Standard of care group|
2967717|NCT02779218|Experimental|Sequence 1|"The patients will receive in order :~Paired Associative Stimulation~Paired Associative Stimulation + Motor Imagery exercises~Placebo Paired Associative Stimulation + Motor Imagery exercises"
2967718|NCT02779218|Experimental|Sequence 2|"The patients will receive in order :~Paired Associative Stimulation + Motor Imagery exercises~Placebo Paired Associative Stimulation + Motor Imagery exercises~Paired Associative Stimulation"
2967719|NCT02779218|Experimental|Sequence 3|"The patients will receive in order :~Placebo Paired Associative Stimulation + Motor Imagery exercises~Paired Associative Stimulation~Paired Associative Stimulation + Motor Imagery exercises"
2967720|NCT02779205|Other|0-1 year old child|Adipose tissue sample in 0-1 year old child with an act of surgery settled by cure of inguinal hernia, or by vesico-ureteral ebb by abdominal way
2967721|NCT02779205|Other|>1-10 year old child|Adipose tissue sample in >1-10 year old child with an act of surgery settled by cure of inguinal hernia, or by vesico-ureteral ebb by abdominal way
2967722|NCT02779192|Active Comparator|SPI-1005 200 mg|200 mg SPI-1005, capsule, bid, po, x7d
2967723|NCT02779192|Active Comparator|SPI-1005 400 mg|400 mg SPI-1005, capsule, bid, po, x7d
2967724|NCT02779192|Placebo Comparator|Placebo|0 mg SPI-1005, capsule, bid, po, x7d
2967725|NCT02779179|Experimental|Immediate Periodontal treatment group|
2967726|NCT02779179|Active Comparator|Delayed Periodontal treatment Group|
2967727|NCT02779166|Experimental|Intervention|Received 400mg celecoxib prior to surgery
2967728|NCT02779166|Placebo Comparator|Placebo|Received placebo pill prior to surgery
2967729|NCT02779153|Experimental|Acthar low dose (40 U)|
2967730|NCT02779153|Experimental|Acthar high dose (80 U)|
2967731|NCT02779140|Experimental|0.033 mg/kg NTM-1632|N=6 administered 0.033 mg/kg NTM-1632 IV, N=2 administered placebo IV
2967732|NCT02779140|Experimental|0.165 mg/kg NTM-1632|N=6 administered 0.165 mg/kg NTM-1632 IV, N=2 administered placebo IV
2967733|NCT02779140|Experimental|0.33 mg/kg NTM-1632|N=6 administered 0.33 mg/kg NTM-1632 IV, N=2 administered placebo IV
2967734|NCT02779127|Other|Intervention|"Subjects exposed to passive smoking at least 1 hour per day since 1 year, non active smokers, non exposed to passive smoking at home~Subject will receive a complete medical follow-up including : medical examination, medical interrogatory, general bioassay, specific bioassay and endothelial function evaluation"
2969904|NCT02764346|Active Comparator|Attention control app|Control group: iCanCope attention control app
2967735|NCT02779127|Other|Control|"Subjects non expose to passive smoking at home or at work, non active smokers~Subject will receive a complete medical follow-up including : medical examination, medical interrogatory, general bioassay, specific bioassay and endothelial function evaluation"
2967736|NCT02779114|Other|Control group|After 1:1:1 randomization patients in the control group receive their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during 12 months of the study.
2967737|NCT02779114|Other|Reduction group 1|Patients in reduction group 1 receive exactly 50% of their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study.
2967738|NCT02779114|Other|Reduction group 2|Patients in reduction group 2 receive exactly 50% of their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study. If they are still in remission they will discontinue their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study.
2967739|NCT02779101|Experimental|Single arm|pembrolizumab
2967740|NCT02779088|No Intervention|control|sarcopenic patients without strength training
2967741|NCT02779088|Experimental|exercise|sarcopenic patients with strength training
2967742|NCT02779075|Placebo Comparator|Saline|0.9% NaCL (saline) intravenously for 6 hours.
2967743|NCT02779075|Active Comparator|Exendin-9,39|Exendin-9,39 intravenously for 6 hours.
2967744|NCT02779049||MAC-LD|patients with MAC-LD Do Blood examination
2967745|NCT02779049||Control|controls without NTM or tuberculosis infection Do Blood examination
2967746|NCT02779049||Tuberculosis infection|patients with tuberculosis infection which diagnosis by culture or typical pathology Do Blood examination
2967747|NCT02779049||MAC colonization|patients with MAC pulmonary colonization by American Thoracic Society guideline Do Blood examination
2967748|NCT02779036|Experimental|Task-oriented Exercise|Structured, progressive, task-oriented, home exercise program
2967749|NCT02779036|Active Comparator|Usual Care|Usual Physiotherapy Care
2967750|NCT02779023|Experimental|ICHP + CBT-I|Participants in this arm will receive the usual care (ICHP program) plus 6 Cognitive-Behavior Therapy for Insomnia (CBT-I) treatment sessions. Four of the treatment sessions will be in person and two will be over the phone.
2967751|NCT02779023|No Intervention|ICHP Only|Participants in this arm will receive the usual care (ICHP program).
2967752|NCT02779010|Experimental|Hand washing with soap|Hand washing with soap and health education every 2 weeks for 6 months
2967753|NCT02779010|No Intervention|Books and pens|Books and pens for every 2 months for 6 months
2967754|NCT02778984|Active Comparator|standard face masks|The standard mask is used in usual care
2967755|NCT02778984|Experimental|QuadraLite face masks|This study will compare tightness of 2 face masks during preoxygenation and after induction of anesthesia with propofol, sufentanil and rocuronium. During preoxygenation, a 10 l.min-1 fresh gas flow and 8 cm H2O PEEP will be applied. After induction of anesthesia, patients will receive pressure-controlled ventilation (fresh gaz flow 3 L.min-1, pressure set to obtain a 7 ml.kg-1 ideal body weight, 10 cpm, peep 5 cm H2O).
2967756|NCT02778971||Qualifying participants|All consented participants referred by a dementia expert physician to receive an amyloid PET scan with [18F]Flutametamol and meeting eligibility criteria will have visual and semi-quantitative software aided scan interpretation, complete care partner questionnaires and providers will document diagnosis, diagnostic confidence, and management plan before and after the scan.
2967757|NCT02778958|Experimental|ibuprofen and morphine|iv ibuprofen 800 mg infusion at 30 min before skin incision closed and per 6 hours during postoperative period; iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
2967758|NCT02778958|Active Comparator|paracetamol and morphine|iv paracetamol 1 gram infusion at 30 min before skin incision closed and per 6 hours during postoperative period; iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
2967759|NCT02778945|Experimental|Group D (Deep NMB group)|Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
2967760|NCT02778945|Active Comparator|Group I (Intermediate NMB group)|Use NMB as conventional clinical usage Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
2967761|NCT02778932||ITN|General anesthesia including intubation and muscle relaxation
2967762|NCT02778932||LM|General anesthesia including laryngeal mask without muscle relaxation
2967763|NCT02778919|Experimental|KLH-2109, lowest dose|
2967764|NCT02778919|Experimental|KLH-2109, low dose|
2967765|NCT02778919|Experimental|KLH-2109, medium dose|
2967766|NCT02778919|Experimental|KLH-2109, high dose|
2967767|NCT02778919|Placebo Comparator|Placebo|First 12 week period; Placebo, Second 12 week period; randomize to one of the KLH-2109 dose levels
2967768|NCT02778919|Other|Leuprorelin acetate|Active reference
2967769|NCT02778906|Active Comparator|Abatacept|Abatacept 125 mg s.c. weekly
2967770|NCT02778906|Placebo Comparator|Placebo|Placebo (NaCl 0,9%) s.c. weekly
2967771|NCT02778893|Experimental|Conmana and Thalidomide|"Conmana(Icotinib Hydrochloride Tablets) and Thalidomide:~Conmana(Icotinib Hydrochloride Tablets) will be administered at 125mg three times a day(TID）continuously; Thalidomide will be administered at 100mg one a day（QD)at night continuously,If can tolerance after 1 weeks to add to 200mg."
2967772|NCT02778880|Experimental|Ketamine|Ketamine 1.5 mg/kg intranasally for one dose
2967773|NCT02778880|Active Comparator|Fentanyl|Fentanyl 2 mcg/kg intranasally for one dose
2967774|NCT02778867|Active Comparator|Phase 1|Phase 1 will evaluate the effectiveness of the 1FED and the 6FED.
2967775|NCT02778867|Active Comparator|Phase 2|Phase 2 will evaluate the effectiveness of the 6FED in 1FED non-responders and the effectiveness of swallowed glucocorticoids (Flovent, fluticasone propionate) in the 6FED non-responders.
2967776|NCT02778854||cohort 1|Participants are recruited for diagnostic test
2967777|NCT02778854||cohort 2|participants are recruited for follow-up
2967778|NCT02778841|Experimental|XBox Kinact Exercise|Kinact game intervention group performed three times per week on non-consecutive days for eight weeks
2967780|NCT02778841|Experimental|concurrent exercise group|Concurrent group performed mixed conventional balance and Xbox Kinact exercises three times per week on non-consecutive days for eight weeks
2967781|NCT02778841|No Intervention|control Group|There is no exercise for this group
2967782|NCT02778828|Experimental|Patients with Multi-Resistant Tb|
2967783|NCT02778815|Experimental|Kindness for Mums|An online self-help course designed to promote self-kindness and self-compassion in new mothers
2967784|NCT02778815|No Intervention|Wait list control|A waiting list control group, who will receive access to the online self-help intervention once the RCT is complete.
2967785|NCT02778789||Tocilizumab|Drug administration of Tocilizumab s.c. or i.v. depending on the preference of the patient and/or physician according to the label
2967786|NCT02778789||TNF-alpha Inhibitor|Drug administration s.c. or i.v. of the TNF-Alpha Inhibitor depending on the preference of the patient and/or physician according to the label
2967787|NCT02778776|Experimental|Agave inulin + Metfomin|5 g of Agave inulin powder every 12 hrs + 500 mg tablet of metformin every 24 hrs
2967788|NCT02778776|Active Comparator|Metformin + Placebo of agave inulin|500 mg tablet of metformin every 24 hrs + 5 g every 12 hrs of calcinated magnesia powder
2967789|NCT02778776|Active Comparator|Agave Inulin+Placebo of Metformin|5 g of agave inulin powder every 12 hrs + 500 mg tablet of calcinated magnesia as metformin placebo every 24 hrs
2967790|NCT02778776|Placebo Comparator|Placebo of Inulin + Placebo of Metformin|5 g of calcinated magnesia powder every 12 hrs + 500 mg tablet of calcinated magnesia every 24 hrs
2967791|NCT02778763|Experimental|One injection of CBLB612 after Сhemo|One injection of placebo at Day -2 (48 hours prior AC chemotherapy treatment) and one injection of 4 μg CBLB612 at Day 1 (24 hours after AC chemotherapy treatment)
2967792|NCT02778763|Experimental|One injection of CBLB612 prior Сhemo|One injection of 4 μg CBLB612 at Day -2 (48 hours prior AC chemotherapy treatment) and one injection of placebo at Day 1 (24 hours after AC chemotherapy treatment)
2967793|NCT02778763|Placebo Comparator|Placebo|Two injections of placebo at Day -2 and Day 1 (48 hours prior and 24 hours after AC chemotherapy treatment)
2967794|NCT02778750||Stable Group|
2967795|NCT02778750||Rapid Decliner Group|
2967796|NCT02778737|Experimental|ACT-based intervention|The Acceptance and Commitment Therapy + MTAU consists of an unpublished manual developed for the purposes of the project (Karekla et al., 2013). The 8, 90-min weekly group sessions focus in fostering psychological flexibility or the capacity to engage or change behaviors based on what a situation affords and an individual's goals, needs, and desires (Hayes et al., 2004). The ACT protocol involves helping patients to engage in values-based behaviors while remain in contact with pain, especially, when efforts to control or reduce it fail or contribute to suffering.
2967797|NCT02778737|Active Comparator|CBT-based intervention|The Cognitive Behavioral group + MTAU consists of an unpublished manual developed by Kalantzi-Azizi & Karademas (2003). It includes 8, 90-min weekly group session and primarily focuses on teaching patients to manage their pain by utilizing various techniques, such as activity pacing, muscle relaxation(i.e., progressive muscle relaxation, diaphragmatic breathing, guided imagery), pain recording, thought challenging, problem solving skills, relapse prevention, etc. The CBT protocol involves helping patients to learn to control their pain and to modify dysfunctional thoughts that accompany it.
2967798|NCT02778711|Experimental|Cosentyx|secukinumab (anti-IL-17)
2967799|NCT02778685|Experimental|Treatment (letrozole, palbociclib, pembrolizumab)|Patients receive letrozole PO QD on days 1-28 and palbociclib PO QD for 3 weeks. Courses with letrozole and palbociclib repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses with pembrolizumab repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2967800|NCT02778672||Infants with potential pneumonia|
2967801|NCT02778659|Experimental|Zolpidem Normoxia|Acute zolpidem intake at sea level
2967802|NCT02778659|Sham Comparator|Placebo Normoxia|Acute placebo intake at sea level
2967803|NCT02778659|Experimental|Zolpidem Hypoxia|Acute zolpidem intake at high altitude
2967804|NCT02778659|Sham Comparator|Placebo Hypoxia|Acute placebo intake at high altitude
2967805|NCT02778646||MINAP Audit|Individuals within this group are those that have been admitted into a United Kingdom (UK) based hospital following a major cardiac event. The FH status of individuals within this group is unknown.
2967806|NCT02778646||BCIS Audit|Individuals within this group are those who have undergone percutaneous coronary intervention in the United Kingdom (UK). The FH status of individuals within this group is unknown.
2967807|NCT02778633||Sepsis|Patients diagnosed with septic shock, admitted to the intensive care unit, with a good left ventricular ejection fraction without significant co-morbidity are highly eligible for this study. Patients must be equipped with a pulse-contour cardiac output (PICCO)-system with a central venous catheter which will be applied by the intensivist on admission.Patients will be subsequently connected to the hemodynamic monitoring device Navigator™. In those patients with clinical signs of inadequate tissue perfusion, passive leg raising and standardized fluid challenge will be performed.
2967808|NCT02778620||Aortic Valve Replacement|Post Anaesthetic Care Unit (PACU) patients treated with aortic valve replacement (AVR) are highly eligible for this study.These are patients with an indication for fast track treatment (PACU) post-cardiac surgery with a good left ventricular ejection fraction without significant co-morbidity. The final decision for PACU-classification is taken by the responsible anaesthesiologist and intensivist in close collaboration with the cardiothoracic surgeon performing the operation, as well as the cardiologist.
2967809|NCT02778607||Progressive Supranuclear Palsy|Patients with a current clinical diagnosis of Progressive Supranuclear Palsy (PSP)
2967810|NCT02778607||Multiple System Atrophy|Patients with current clinical diagnosis of Multiple System Atrophy (MSA).
2967811|NCT02778607||Atypical Parkinsonian Syndrome|Atypical Parkinsonian Syndrome (APS) patients who do not fulfil existing criteria for PSP/CBD/MSA, but may represent variant clinical syndromes related to tau pathology including pure akinesia with gait freezing (PAGF), PSP-parkinsonism, overlap syndromes and atypical parkinsonian disorders not meeting clinical diagnostic criteria at entry
2967812|NCT02778607||Controls|Participants unaffected by neurological or psychiatric disease
2967813|NCT02778607||Corticobasal Degeneration|Patients with a current clinical diagnosis of Corticobasal Degeneration (CBD)
2967814|NCT02778594|Placebo Comparator|Placebo|Placebo (4 tablets) Simultaneously with the placebo dose, subjects were administered 1 capsule of Madopar® HBS 125
2967815|NCT02778594|Experimental|Nebicapone 50 mg|Nebicapone 50 mg (1 tablet of 50 mg plus 3 tablets of placebo). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
2967816|NCT02778594|Experimental|Nebicapone 100 mg|Nebicapone 100 mg (2 tablets of 50 mg plus 2 tablets of placebo). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
2967817|NCT02778594|Experimental|Nebicapone 200 mg|Nebicapone 200 mg (4 tablets of 50 mg). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
2967818|NCT02778581|Active Comparator|Lipidic Blend 1|Glass bottle with 45 ml of vegetal mixture oil. 1 bottle per day
2967819|NCT02778581|Active Comparator|Lipidic Blend 2|Glass bottle with 45 ml of vegetal mixture oil. 1 bottle per day
2967820|NCT02778581|Placebo Comparator|Placebo|Glass bottle with 45 ml of Olive oil. 1 bottle per day
2967821|NCT02778568|Experimental|Resistance Training|Patients performed resistance exercises
2967822|NCT02778568|Active Comparator|Control|Patients who performed flexibility exercise
2967823|NCT02778555||Sample 1|In Sample 1 (N=186), our 14-item Daily PCS was administered daily for 14 days to replicate the 3-factor structure at the daily level, and to select the ideal 5 items for a brief Daily PCS.
2967824|NCT02778555||Sample 2|In Sample 2 (N=209), the 5-item Daily PCS was administered daily for 14 days with short forms for PROMIS Pain Intensity, Depression, Anger, and Anxiety included on days 1, 7, and 14.
2967825|NCT02778542|Active Comparator|Electronic Pill Bottle|Participants will be mailed an electronic pill bottle for their blood pressure medication.These pill bottles will track how often the participant opens the bottle to take their medication and will transmit that information to study team via cellular data. Participants will also receive a daily text message reminder to take your blood pressure medication.
2967826|NCT02778542|Active Comparator|Bidirectional Text Messaging|Participants assigned to bi-directional texting, will receive a daily text message reminder to take their blood pressure medication. Patients in this arm are expected to send a response to the reminder message, indicating if they took their medication that day.
2967827|NCT02778542|No Intervention|Usual Care|Participants in this arm do not receive a medication reminder system.
2967828|NCT02778529|Other|Upper Limb Assessment on ADLs|Bilateral assessment robots (BiAS) Evaluate upper limb kinematics of Stroke, Amputees, SCI, Cerebral Palsy and Health Subjects will be assessed as they complete unilateral and bilateral activities of daily living. Subjects will complete exercises in 1 session
2967829|NCT02778516|Active Comparator|Sodium Restriction 1500mg Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
2967830|NCT02778516|Active Comparator|Sodium Restriction 2400mg Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
2967831|NCT02778516|No Intervention|Control Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
2967832|NCT02778503|Active Comparator|High Cost|Restoration using a high-cost glass ionomer cement.
2967833|NCT02778503|Experimental|Low Cost|Restoration using a low-cost glass ionomer cement.
2967834|NCT02778477|Experimental|Part A_Cohort 1_Active|Multiple ascending dose of PF-06423264
2967835|NCT02778477|Placebo Comparator|Part A_Cohort 1_Placebo|Multiple dose of placebo
2967836|NCT02778477|Experimental|Part A_Cohort 2_Active|Multiple ascending dose of PF-06423264
2967837|NCT02778477|Placebo Comparator|Part A_Cohort 2_Placebo|Multiple dose of placebo
2967838|NCT02778477|Experimental|Part A_Cohort 3_Active|Multiple ascending dose of PF-06423264
2967839|NCT02778477|Placebo Comparator|Part A_Cohort 3_Placebo|Multiple dose of placebo
2967840|NCT02778477|Experimental|Part A_Cohort 4_Active|Multiple ascending dose of PF-06423264
2967841|NCT02778477|Placebo Comparator|Part A_Cohort 4_Placebo|Multiple dose of placebo
2967842|NCT02778477|Experimental|Part A_Cohort 5_Active|Multiple ascending dose of PF-06423264
2967843|NCT02778477|Placebo Comparator|Part A_Cohort 5_Placebo|Multiple dose of placebo
2967844|NCT02778477|Experimental|Part A_Cohort 6_Active|Multiple ascending dose of PF-06423264
2967845|NCT02778477|Placebo Comparator|Part A_Cohort 6_Placebo|Multiple dose of placebo
2967846|NCT02778477|Experimental|Part A_Cohort 7_Active|Multiple ascending dose of PF-06423264
2967847|NCT02778477|Placebo Comparator|Part A_Cohort 7_Placebo|Multiple ascending dose of placebo
2967848|NCT02778477|Experimental|Part B_Cohort 1_Active|Multiple doses of PF-06423264
2967849|NCT02778477|Placebo Comparator|Part B_Cohort 1_Placebo|Multiple doses of placebo
2967850|NCT02778477|Experimental|Part B_Cohort 2_Active|Multiple doses of PF-06423264
2967851|NCT02778477|Placebo Comparator|Part B_Cohort 2_Placebo|Multiple doses of placebo
2967852|NCT02778464||Group A: Female IBD and RA (non-pregnant)|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All diaries and stool sample consumables for disease activity will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
2967853|NCT02778464||Group B: Female IBD|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All diaries and stool sample consumables for disease activity will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
2967854|NCT02778464||Group C: Female - Healthy Pregnant|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All stool sample consumables will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
2967855|NCT02778464||Group D: Female - RA Pregnant|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All stool sample consumables will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
2967856|NCT02778451|Other|Ultrasonography-experienced surgeons|Attending physicians and consultants in head and neck surgery using head and neck Ultrasonography on a daily basis.
2967857|NCT02778451|Other|Ultrasonography novices|Physicians participating in their one-year internship at other surgical or medical departments with no experience with head and neck US or head and neck surgery.
2967858|NCT02778425|No Intervention|Primary prevention-1|Endoscopic therapy
2967859|NCT02778425|No Intervention|Primary prevention-2|beta blockers
2967860|NCT02778425|Experimental|Primary prevention-3|Endoscopic therapy+PSE
2967861|NCT02778425|No Intervention|Control of acute bleeding-1|Endoscopic therapy+ somatostatin
2967862|NCT02778425|Experimental|Control of acute bleeding-2|Endoscopic therapy+ somatostatin+PSE
2967863|NCT02778425|No Intervention|Secondary prevention-1|Endoscopic therapy+ beta blockers
2967864|NCT02778425|Experimental|Secondary prevention-2|Endoscopic therapy+ PSE+beta blockers
2967865|NCT02778399|Experimental|OBE2109 dose 1|
2967866|NCT02778399|Experimental|OBE2109 dose 2|
2967867|NCT02778399|Experimental|OBE2109 dose 3|
2967868|NCT02778399|Experimental|OBE2109 dose 4|
2967869|NCT02778399|Experimental|OBE2109 dose 5|
2967870|NCT02778399|Placebo Comparator|Placebo / OBE2109 dose 6|
2967871|NCT02778386|Experimental|Cohort 1|6 subjects, male & female will receive one dose each of 200 mg of N-Methanocarbathymidine orally in capsules. Each subject will be evaluated for any clinical signs of any toxicity.
2967872|NCT02778386|Experimental|Cohort 2|6 subjects, male & female will receive one dose each of 400 mg of N-Methanocarbathymidine orally in capsules. Each subject will be evaluated for any clinical signs of any toxicity.
2967873|NCT02778386|Experimental|Cohort 3|8 subjects, males and females, 6 subjects will receive one dose each 800 mg of N-Methanocarbathymidine orally in capsules and 2 will receive a placebo capsule. Each subject will be evaluated for any clinical signs of any toxicity.
2967874|NCT02778386|Experimental|Cohort 4|8 subjects, males and females, 6 subjects will receive one dose each 1200 mg of N-Methanocarbathymidine orally in capsules and 2 will receive a placebo capsule. Each subject will be evaluated for any clinical signs of any toxicity.
2967875|NCT02778373|Placebo Comparator|Placebo|Flavored Water
2967876|NCT02778373|Active Comparator|Low Molecular Weight Carbohydrate|low molecular weight carbohydrate delivered post-endurance exercise in a 10% solution providing 1.2 grams/kg body weight carbohydrate
2967877|NCT02778373|Experimental|High molecular weight carbohydrate|high molecular weight carbohydrate delivered post-endurance exercise in a 10% solution providing 1.2 grams/kg body weight carbohydrate
2967878|NCT02778360|Experimental|Neurofeedback NFT|"Neurofeedback Training based on real time electroencephalography (EEG) signal. The patient is trained to modulate his brain activity thanks to a tablet installed with serious game.~Initiation/Discovery period during 21 days: initiation and discovery sessions Treatment period during 9 weeks: 36 training sessions at home"
2967879|NCT02778360|Active Comparator|Methylphenidate MPH|"Methylphenidate long acting preparation.~Open titration protocol during 21 days: 10 mg/day as a start until optimal dose is reached (maximum dose: 60 mg/day).~Treatment period during 9 weeks: optimal dose with MPH LA 10 and 30 mg (dose range: 10 mg/day to 60 mg/day)."
2967880|NCT02778334|No Intervention|patients who return home|
2967881|NCT02778334|Experimental|patients who continued hospitalization in rehabilitation|
2967882|NCT02778321|Other|Uses of SpiderFlash monitor|"The intervention corresponds to the use of Spiderflash as Holter monitor. Investigators will use the SpiderFlash®, Holter monitor (technology Secure Data) to have a storage capacity enabling a registration up to 30 days with sufficient autonomy.~A questionnaire evaluating the safety of SpiderFlash® will be given to the patient and the results of Holter will be communicated at the end of the recording to the blinded rhythm specialist."
2967883|NCT02778308|Active Comparator|chemotherapy group|6 cycles of Gemcitabine + Cisplatin as per the following schedule Injection Gemcitabine 1 gm/kgm2 intravenous over 30 min Day1 and Day8 Injection Cisplatin 70 mg/kg m2 intravenous on Day1
2967884|NCT02778308|No Intervention|control group|follow up
2967885|NCT02778295||Observation|Patients at 2 months with a Fabry disease or high-grade suspicion for a Fabry disease
2967886|NCT02778282|No Intervention|Standard Care|Standard Care through office-based opioid treatment with buprenorphine/naloxone and weekly urine toxicology screening
2967887|NCT02778282|Experimental|Standard Care + MySafeRx™ Intervention|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. This arm represents Standard Care plus MySafeRx™.
2967888|NCT02778269|Experimental|Study Treatment|The patients wear a 12-lead ECG T-shirt for 7 days. During this time period ECG data are measured continuously. In addition the continous glucose monitoring system (CGM) records glucose levels via Dexcom G4-System.
2967889|NCT02778256|Experimental|Vestibular stimulation|Patients of this group will receive a specific vestibular stimulation technique.
2967988|NCT02777645||Study group|Study group(n=50) included CP children with chewing disorder. Growth, feeding evaluation will be done.
2967890|NCT02778256|Sham Comparator|Sham vestibular stimulation|This group of patients will receive sham vestibular stimulation, similar to experimental group vestibular stimulation in the range of under threshold frequencies undistinguished from real vestibular stimulation. The absence of vestibular nystagmic response confirms that the stimulus is sham.
2967891|NCT02778243|Experimental|Bladder cancer|▪ Patients justifying prostatectomy together with the bladder (radical cystectomy for bladder cancer).
2967892|NCT02778243|Other|benign prostate hyperplasia|▪ Patients with benign prostate hyperplasia who justified a prostatectomy.
2967893|NCT02778230|Experimental|Pea Fiber|Two fiber snacks fortified with 5 g/each of pea fiber (Best Pea Fiber 200) will be consumed each day for a period of two weeks.
2967894|NCT02778230|Other|Control|Two control snacks will be consumed each day for a period of two weeks.
2967895|NCT02778217|No Intervention|Uninterrupted single embryo culture|The same single medium is used throughout the 5-6 days of culture with no replenishment on day 3.
2967896|NCT02778217|Experimental|Interrupted single medium culture|The single step medium is renewed on Day 3 of embryo culture.
2967897|NCT02778204|Experimental|Cohort 1|Infants in both stratum of this cohort will receive a single dose of maraviroc solution within 3 days of birth and at Week 1 of life.
2967898|NCT02778204|Experimental|Cohort 2|Infants in both stratum of this cohort will receive maraviroc solution twice daily starting within 3 days of birth and continuing for up to 42 days.
2967899|NCT02778191||Concomitant cisplatin|Patients treated with concomitant cisplatin
2967900|NCT02778191||Carboplatin plus 5-FU|Patients treated with carboplatin plus 5-FU
2967901|NCT02778178|Experimental|TAP block with ropivacaine|Bilateral single shot TAP block under ultrasound guidance: 20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
2967902|NCT02778178|Placebo Comparator|TAP block with placebo|Placebo administration: bilateral single shot TAP block under ultrasound guidance: 20 mL saline 0.9%, per side
2967903|NCT02778165|No Intervention|Usual Care|Patients receiving usual care are typically referred to CR at the time of discharge from the acute care center via paper or electronic systematic referral (completed by a physician or nurse practitioner). Additionally, a conversation with the patient regarding CR by a healthcare provider may occur, however this communication is not always a consistent occurrence. Once referred, patients will await contact from a CR program in their region/area and if actual program enrollment occurs, this usually happens between 8 to 10 weeks post discharge.
2967904|NCT02778165|Experimental|MyCaRe Android Application|The MyCaRe application and Fitbit monitor will be provided to patients receiving intervention group allocation for the initial 6 to 8 weeks recovery post cardiac surgery. The patients will be provided a temporary loan mobile device loaded with MyCaRe and Fitbit before leaving hospital. They will be asked to input data (pain, mood, wounds, activity) daily if possible in first 2 weeks and once weekly thereafter until 6 weeks or entry to a cardiac rehabilitation program.
2967905|NCT02778152|Experimental|Laser depilation|Laser depilation to the natal cleft (pilonidal region) monthly for 5 treatments with either an 810nm of Nd:YAG laser dependent on Fitzpatrick skin type and tolerability.
2967906|NCT02778139||youth smokers|
2967907|NCT02778139||non-smokers|
2967908|NCT02778126|Experimental|[¹⁴C]LY2606368|A single dose containing [¹⁴C]LY2606368 will be administered intravenously (IV) as a 1 hour continuous infusion
2967909|NCT02778126|Experimental|LY2606368|A single dose of LY2606368 administered IV as a 1 hour continuous infusion once every 14 days (14 day cycles). Treatment may continue until discontinuation criteria are met.
2967910|NCT02778113|Experimental|LY900018 - Dose 1|LY900018 at dose level 1 administered once intranasally in one of four study periods.
2967911|NCT02778113|Experimental|LY900018 - Dose 2|LY900018 at dose level 2 administered once intranasally in one of four study periods.
2967912|NCT02778113|Experimental|LY900018 - Dose 3|LY900018 at dose level 3 administered once intranasally in one of four study periods.
2967913|NCT02778113|Active Comparator|Glucagon - SC|Glucagon administered once, SC, in one of four study periods.
2967914|NCT02778100|Experimental|LY900018 - Common Cold|Cohort 1 - LY900018 administered once, intranasally, in participants with a common cold.
2967915|NCT02778100|Experimental|LY900018 - Symptom-Free|Cohort 1 - LY900018 administered once, intranasally, in participants who have recovered from a common cold.
2967916|NCT02778100|Experimental|LY900018 - Common Cold+Oxymetazoline|Cohort 2 - LY900018 administered once, intranasally, in participants with a common cold who are taking oxymetazoline.
2967917|NCT02778087|Experimental|TAU plus 30 minutes of BT.|Intervention: Subjects randomized to the 30 minute intervention will perform the above 15 minute Mirror Box Therapy intervention independently two times per day in addition to their treatment as usual.
2967918|NCT02778087|Experimental|TAU plus 60 minute of BT.|Intervention: Subjects randomized to the 60 minute intervention will perform the above 15 minute Mirror Box Therapy intervention independently four times per day in addition to their treatment as usual.
2967919|NCT02778087|Sham Comparator|TAU plus 30 minutes of sham BT.|Intervention: Subjects randomized to the control (sham) group will perform the above Sham Mirror Box Therapy intervention independently two times per day. The control group will be using a mirror box with an opaque surface as opposed to a reflective mirror.
2967920|NCT02778074|Experimental|Internet Cognitive Behavioural Therapy|Participants will perform a nine-week tailored I-CBT program developed to fit CVD patients. The program consists of psychoeducation, relaxation, problem-solving and behavioral activation.
2967921|NCT02778074|Placebo Comparator|Moderated discussion forum|In this arm the participants are allocated to a non mandatory discussion forum for nine weeks. Evert week will participants discuss issues regarding their CVD. Themes discussed are suggested by the study team, and a new theme is added every week. A moderator from the study group act as a supervisor and checks that issues discussed are ok. After the nine week discussion forum the participants are offered the nine week CBT program.
2967922|NCT02778048||fecal incontinence patients (m/f)|patients suffering from fecal incontinence (m/f) are going to be assessed via MRI, US, FLIP, and HRAM
2967923|NCT02778035|Experimental|60 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 60 min).
2967989|NCT02777645||Control group|Control group(n=35)= healthy children without chewing disorder Growth, feeding evaluation will be done.
2967924|NCT02778035|Experimental|30 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 30 min).
2967925|NCT02778035|Experimental|0 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 0 min).
2967926|NCT02778022|Experimental|Immediate PriCARE|Parent-child dyads assigned to the immediate PriCARE group will receive the PriCARE intervention as soon as possible plus usual treatment. The intervention will last approximately 6-8 weeks. Each group will have 4-13 participants and 2 facilitators and will meet 6 times for 1-2 hours per session. Parents are expected to practice the skills they learn with their children between sessions.
2967927|NCT02778022|No Intervention|Delayed PriCARE|The delayed PriCARE group will not receive the PriCARE intervention until data collection for this study is complete (in 3-6 months). In addition, they will be immediately offered usual treatment. Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment and/or provided with a 1-2 page informational handout on child behavior problems from the CHOP patient care manual.
2967928|NCT02778009|Experimental|Fit Physician Group|"Subjects will receive activity monitor and will be required to attend monthly wellness lectures and weekly exercise intervention.~Every subject will undergo an iDEXA scan to measure body mass composition"
2967929|NCT02778009|Active Comparator|Activity Monitor Only Group|"Subjects will receive an activity monitor without any intervention Every subject will undergo an iDEXA scan to measure body mass composition~)"
2967930|NCT02778009|Other|Control Group|Subjects will not an activity monitor nor will they receive any intervention Every subject will undergo an iDEXA scan to measure body mass composition
2967931|NCT02777996|Active Comparator|Screening arm|Low Dose Computed Tomography offered at baseline and for 3 repeated rounds
2967932|NCT02777996|No Intervention|Passive Arm|Eligible subjects were randomized to follow up in usual care (in Europe lung cancer screening is not raccomended), according with the GP.
2967933|NCT02777983|Experimental|Education Group|This will consist of a 6-minute educational video app created and delivered within an application (mobile app) that will be interactive in nature, asking multiple-choice questions at the end to help reinforce key points of the video message. It will include self-management guidance based on evidence related to activity, exercise, and other behavioral components known to influence the prognosis of low back pain. Subjects will also receive the 1-page general conditioning handout that the usual care group will receive.
2967934|NCT02777983|No Intervention|Usual Care Group|Subjects randomized to usual care will receive a 1-page generic informational handout on general conditioning recommended for low back pain, in addition to whatever education the subject's PCP decides to provide.
2967935|NCT02777970|Experimental|Tramadol/Dexketoprofen|"One film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single-dose;~Two tablets of Placebo matching Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single-dose."
2967936|NCT02777970|Active Comparator|Tramadol/Paracetamol|"Two film-coated tablets of Tramadol Hydrochloride/Paracetamol 75 mg/650 mg [2 x 37.5mg/325mg] oral single dose;~One tablet of Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol oral single dose."
2967937|NCT02777970|Placebo Comparator|Placebo|"One tablet of Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;~Two tablets of Placebo matching Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose."
2967938|NCT02777957||mPAP ≥ 25 mmHg|mean pulmonary artery pressure (mPAP) ≥ 25 mmHg (37 patients)
2967939|NCT02777957||mPAP < 25 mmHg|mean pulmonary artery pressure (mPAP) < 25 mmHg (28 patients).
2967940|NCT02777944|Experimental|Intervention|Access to Motivate: a web-based intervention, in addition to Usual Care
2967941|NCT02777944|No Intervention|Control|Usual Care
2967942|NCT02777931|Experimental|NFC-1|Doses of NFC-1 will be administered as 100, 200, or 400 mg twice daily as capsules for oral administration.
2967943|NCT02777931|Placebo Comparator|Placebo|Matching placebo capsules.
2967944|NCT02777918|Experimental|Intervention|6 recipes will be sent by post every 2 weeks for a 12 week period. Dietary recommendations will also be provided at the start of the intervention period to increase the relevance of the recipes.
2967945|NCT02777918|No Intervention|Control|Dietary recommendations will be provided at the start of the study period, such that the intervention regards the recipes, not the recommendations
2967946|NCT02777905|Experimental|MBCT intervention|"Mindfulness Based Cognitive therapy (MBCT) will consist of group meditative practices, lasting 2 hours per week (or whatever the patient can tolerate). The interventions will be conducted at the centre local de services communautaires (CLSC) Benny Farm, once a week. Patients will be invited to try various techniques during sessions. The patients will be encouraged to practice the Mindfulness techniques, that includes formal mindfulness meditation and informal mindfulness practices (e.g. being in the present moment while not meditating), at home, between sessions, and will be provided with meditation compact discs to help them do so. MBCT interventions also include a cognitive therapy perspective. Specifically, the interventionists will offer education regarding depression and anxiety and will work on automatic mental processes that are believed to be at the root of the recurrence of depressive and anxious symptoms."
2967947|NCT02777905|No Intervention|Control Group|Patients randomized to the control group will be offered literature on mental health promotion and will receive treatment as usual in the primary care health center setting. After the end of the study, the control group will be offered MBCT.
2967948|NCT02777892||pulmonary valve replacement|SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection
2967949|NCT02777879||Chronic Obstructive Pulmonary Disease (COPD)|Case of early COPD (GOLD 1-2, FEV1/FVC<70 and FEV1>50%)
2967950|NCT02777879||Control|No obstruction (FEV1/FVC<70). Controls will be recruited after each case and will be matched by: age (±5 year), 2) gender, 3) smoking (±5 pack-year) and 4) BMI (±5).
2967951|NCT02777866|Experimental|1: Bupivacaine 0.5%|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
2967952|NCT02777866|Placebo Comparator|2: 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs, who will be infiltrated in the total thickness of the abdominal wall with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound.
2967953|NCT02777853|Experimental|Active (green) tea|Tea to be ingested 3 times per day for 7 days.
2967954|NCT02777853|Placebo Comparator|Placebo tea|Tea to be ingested 3 times per day for 7 days.
2967955|NCT02777840|Active Comparator|Face mask group|Patients will be given oxygen via face mask as per routine practice, blood gas sample taken after airway is secured, heart rate of anaesthetist monitored and time for desaturation noted.
2967956|NCT02777840|Active Comparator|THRIVE group|Patients will be given oxygen via high flow oxygen in Optiflo, blood gas sample taken after airway is secured, heart rate of anaesthetist monitored and time for desaturation noted.
2967957|NCT02777827|Experimental|Abediterol dry powder inhaler 0.156 μg|Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)
2967958|NCT02777827|Experimental|Abediterol dry powder inhaler 2.5 μg|Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).
2967959|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 0.05μg|Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).
2967960|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 0.156 μg|Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).
2967961|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 2.5μg|Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).
2967962|NCT02777827|Placebo Comparator|Placebo|Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).
2967963|NCT02777814|Experimental|Prophylactic Entecavir|Entecavir is prophylactically used from the time of chemotherapy initiation at the dose of 0.5 mg p.o daily
2967964|NCT02777814|Active Comparator|Preemptive Entecavir|Entecavir is preemptively used from the time that hepatitis B virus DNA copies are more than 100 IU/ml at the dose of 0.5 mg p.o daily
2967965|NCT02777801|Experimental|Prophylactic Entecavir|use of entecavir in the dose of 0.5mg p.o. every day from the initiation of chemotherapy till 6 months after the end of chemotherapy.
2967966|NCT02777801|Active Comparator|Preemptive Entecavir|use of entecavir in the dose of 0.5mg p.o. every day from the time that the DNA copies of hepatitis B virus are more than 100 IU/ml till 6 months after the end of chemotherapy.
2967967|NCT02777788|Active Comparator|chemotherapy|"Eligible subjects will be treated with platinum-doublet 2 cycles chemotherapy:pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin. Each cycle was 21-days.~Dosage:pemetrexed i.v.500mg/m2 d1 ; docetaxel i.v.75mg/m2 d1 ; gemcitabine i.v.1250 mg/m2 d1,d8 ; paclitaxel i.v.175mg/m2 d1 ; vinorelbine i.v.25mg/m2 d1,d8; carboplatin i.v.area under curve (AUC) 5 d1 ；cis-platinum i.v.75mg/m2 d1（or divided into 3days）；nedaplatin i.v.80mg/m2 d1."
2967968|NCT02777788|Experimental|TCM combined chemotherapy|TCM：JinFuKang plus XingZaoRuanJian, chemotherapy will be the same. JinFuKang po.tid.30ml d6-d21 XingZaoRuanJian po.tid.30ml d6-d21
2967969|NCT02777762|Experimental|Fun First|Strategies to promote enjoyment of physical activity
2967970|NCT02777762|Active Comparator|Close at Hand|Strategies to promote tracking of physical activity
2967971|NCT02777749|Active Comparator|Adductor Canal Block|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.~Adductor Canal Block (ACB)"
2967972|NCT02777749|Active Comparator|Periarticular SB|20 cc's of bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
2967973|NCT02777749|Active Comparator|Periarticular LB|20 cc's of liposomal bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
2967974|NCT02777749|Active Comparator|ACB + SB|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.~20 cc's of bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon."
2967975|NCT02777749|Active Comparator|ACB + LB|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.~20 cc's of liposomal bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon."
2967976|NCT02777736|Experimental|Arm A - Methotrexate i.v.|Patients with risk factors for CNS relapse ≥ 2 or with occult meningeal involvement will receive 2 cycles of methotrexate 3g/m2 i.v. after the 3rd and 6th cycle of systemic chemotherapy (R CHOP or DA EPOCH R).
2967977|NCT02777736|Active Comparator|Arm B - Methotrexate i.t.|Patients with risk factors for CNS relapse ≥ 2 or with occult meningeal involvement will receive intrathecal methotrexate 12mg in each cycle of systemic chemotherapy (6x).
2967978|NCT02777736|No Intervention|Arm C - no Methotrexate|Patients with 0-1 risk factor for CNS relapse will not receive CNS prophylaxis.
2967979|NCT02777723|Experimental|CKD-350|Xenobella
2967980|NCT02777723|Active Comparator|Sodium Hyaluronate|Isotonic 0.3% Sodium Hyaluronate
2967981|NCT02777710|Experimental|Combination Pexidartinib-Durvalumab|"DURVALUMAB (MEDI4736): therapeutic Class anti-PD-L1 mAb, given IV every 4 weeks at a fixed dose of 1500mg, AstraZeneca~PEXIDARTINIB (PLX3397): therapeutic Class Kinase inhibitor targeting CSF1-R, Flt3 and Kit. Administered daily as split dose regimen, orally. Five dose-levels possible in dose escalation part: 400mg 5 days on 2 days off (intermittent schedule), 400 mg, 600 mg, 800 mg or 1000 mg.~In this combination trial, Pexidartinib should be taken first and the Durvalumab IV infusion should be scheduled 1 hour after the Pexidartinib morning dose."
2967982|NCT02777697||cancer patients|
2967983|NCT02777684||knee osteoarthritis|
2967984|NCT02777671|Experimental|Group A|Period 1 - BIA 2-093 + Gliclazide Period 2 - Gliclazide
2967985|NCT02777671|Experimental|Group B|Period 1 - Gliclazide Period 2 - BIA 2-093 + Gliclazide
2967986|NCT02777658||Primary Study Cohort|Patients with prior confirmed EGFR mutation-positive locally advanced or advanced NSCLC (Non-Small Cell Lung Cancer) who have progressed on or after EGFR-TKI (Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitor) therapy
2967987|NCT02777658||Secondary Study Cohort|Patients diagnosed with de-novo (wild-type) EGFR T790M mutation-positive (alone or in combination with other mutations) locally advanced or advanced NSCLC
2967990|NCT02777632||HCV patients following living donor liver transplantation|single infection episode group
2967991|NCT02777632||patients following living donor liver transplantation|recurrent Infections episode group
2967992|NCT02777619|Placebo Comparator|Propofol and 0.0ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.0ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
2967993|NCT02777619|Experimental|Propofol and 0.4ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.4ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
2967994|NCT02777619|Experimental|Propofol and 0.6ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.6ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
2967995|NCT02777619|Experimental|Propofol and 0.8ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.8ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
2967996|NCT02777606|Experimental|Si-Ni-Tang (a Chinese Herbal Formula)|Treatment for severe sepsis adheres to the International guidelines for management of sepsis and septic shock 2012 and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015. Besides, 150ml of Si-Ni-Tang will be given by p.o. or a nasogastric tube once per day for 3 days in the treatment group.
2967997|NCT02777606|No Intervention|Control|Treatment for severe sepsis adheres to the International guidelines for management of sepsis and septic shock 2012 and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015.
2967998|NCT02777593|Other|Zone 2 Aortic aneurysm|Zone 2 Aortic Aneurysm
2967999|NCT02777593|Other|Zone 2 Non-aneurysm aortic lesions|Includes dissection, traumatic transection and other isolated lesion types
2968000|NCT02777580|Experimental|Pharmaco-invasive strategy|Half-dose tenecteplase and additional antiplatelet therapy with a loading dose of 300 mg clopidogrel, aspirin and coupled with antithrombin therapy followed by coronary angiography within 6-24 hours or rescue coronary intervention as required.
2968001|NCT02777580|Active Comparator|Standard primary PCI|Primary PCI with a P2Y12 antagonist and antithrombin treatment according to local standards.
2968002|NCT02777554|Experimental|Treatment A: 60mg Apremilast reference IR formulation|One 30 mg Immediate Release oral tablet in the morning and one 30 mg IR oral tablet in the evening of the dosing days) for 7 days under the fed condition.
2968003|NCT02777554|Experimental|Treatment B: 75mg Apremilast Once-daily (QD)|75 mg apremilast QD formulation once daily for 7 days under the fed conditions
2968004|NCT02777554|Experimental|Treatment C: 60 mg reference IR tablet|One 30 mg IR oral tablet administered in the morning in the fasting state and one 30 mg IR oral tablet administered in the evening after a minimum of a 2 hr fast for 1 day.
2968005|NCT02777554|Experimental|Treatment D: Single dose of QD apremilast|Single dose of 75mg apremilast QD administered in the fasting state
2968006|NCT02777554|Experimental|Treatment E: Single dose of QD apremilast|Single dose of 75mg apremilast QD administered approximately 30 minutes after a standard meal
2968007|NCT02777554|Experimental|Treatment F: Single dose of QD apremilast|Single dose of 75mg apremilast QD administered approximately 30 minutes after a high-fat meal
2968008|NCT02777541|Other|Early enteral nutrition|3 hours after PEG implantation
2968009|NCT02777541|Other|Late enteral nutrition|8 hours after PEG implantation
2968010|NCT02777528|Other|Zone 0/1 Aortic aneurysm|Zone 0/1 Aortic aneurysm
2968011|NCT02777528|Other|Zone 0/1 Non-aneurysm aortic lesions|Includes dissection and other isolated lesion types
2968012|NCT02777515|Other|Patients using electronic cigarette|The patients under the age of 35 followed at the consultation of rythmology for a cardiovascular assessment and already smoking the electronic cigarette and this since at least 1 month. The patient will receive a clinical examination, an electrocardiogram, a Holter-ECG and an echocardiogram before and after electronic cigarette consumption for 15 minutes.
2968013|NCT02777489|Experimental|Perindopril Bluepharma 8 mg|Each participant will have an at least 4-week run-in period, followed by a 6 weeks treatment period with Perindopril 8 mg.
2968014|NCT02777476|Experimental|procedure with B-Lite® Light Weight Breast Implant|
2968015|NCT02777450||Block group|Lumbar facet block. Levobupivacaine 0,25% and corticosteroids
2968016|NCT02777437|No Intervention|Laparoscopic surgery|Patients with T4 colon cancer receive laparoscopic surgery only.
2968017|NCT02777437|Experimental|Neoadjuvantive chemotherapy + Laparoscopic surgery|Patients with T4 colon cancer receive neoadjuvantive chemotherapy and laparoscopic surgery.
2968018|NCT02777424|Experimental|Prothrombin Complex Concentrate|Administration of a single dose of prothrombin complex concentrate (25 U/kg equivalent factor IX)
2968019|NCT02777424|Active Comparator|Fresh Frozen Plasma|Administration of a single dose of fresh frozen plasma of 15 mL/kg
2968020|NCT02777411|Experimental|Group A1|3 to 6 years
2968021|NCT02777411|Experimental|Group A2|3 to 6 years
2968022|NCT02777411|Experimental|Group A3|3 to 6 years
2968023|NCT02777411|Experimental|Group A4|3 to 6 years
2968024|NCT02777411|Experimental|Group B2|6 to 35 months
2968025|NCT02777411|Experimental|Group B3|6 to 35 months
2968026|NCT02777411|Experimental|Group B4|6 to 35 months
2968027|NCT02777398|Experimental|Trans-Quadrant Channel Surgery|Patients in the experimental arm (experimental group, i.e. microsurgery through trans-Quadrant channel pathway) will be operated using Quadrant channel system. All the tumor resection will be operated through the Quadrant channel with assistance of microsurgical techniques.
2968028|NCT02777398|Active Comparator|Conventional Open Surgery|Patients in the active comparator arm (control group, i.e. conventional open surgery) will be operated using the conventional open surgery. All the tumor resection will be operated directly with conventional procedures. More posterior structures of spine will be removed.
2968029|NCT02777385|Experimental|Arm 1|Cisplatin, Radiation, and Pembrolizumab started 3 weeks after completion of cisplating and radiation.
2970291|NCT02761928||Trigger point injection|Positive response (>50% pain relief) to trigger point injection
2968030|NCT02777385|Experimental|Arm 2|Cisplatin and Radiation and Pembrolizumab given 1 week prior to the start of cisp/radiation and given every 3 weeks
2968031|NCT02777372|Experimental|Sertraline|To determine the impact of short term luteal phase treatment with Sertraline 50mg tablets (PMD group only) on arousal regulation across the menstrual cycle.
2968032|NCT02777359|Experimental|the closure group|In the closure group, the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA, in combination of clopidogrel(50mg/d, 3mon) and aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
2968033|NCT02777359|No Intervention|the medication group|In the medication group, in combination of clopidogrel (50mg/d, 3mon) and aspirin (0.1g/d, 6mon), current medication resumed, including conventional prescription for migraine as β-receptor blockers, calcium-ion antagonists, antiepileptics, antidepressants and non-steroid anti-inflammatory drugs (NSAID).
2968034|NCT02777346|Experimental|Absorbable|Suture material: Polyglactin 910 thread (Vicryl Rapide®, Ethicon Inc).
2968035|NCT02777346|Active Comparator|Non Absorbable|Suture material: Polypropylene thread (Prolene®, Ethicon Inc).
2968036|NCT02777333|Experimental|Simulation training|Addition of simulation training during usual clinical training as part of a GMC (General Medical Council) recognised Deanery training programme
2968037|NCT02777333|No Intervention|Non-simulation/Routine training|Usual clinical training as part of a GMC (General Medical Council) recognised Deanery training programme
2968038|NCT02777320|Experimental|paracetamol group|First Group: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes. (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
2968039|NCT02777320|Experimental|Ibuprofen group|Second Group: 400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
2968040|NCT02777307|Experimental|Hemopatch Sealing Hemostat|
2968041|NCT02777307|No Intervention|No Hemopatch Sealing Hemostat|
2968042|NCT02777294|Experimental|Online intervention|Therapist-facilitated, cognitive behavioral therapy
2968043|NCT02777294|Active Comparator|Psycho-educational website|Self-help, psycho-educational website
2968044|NCT02777281|Other|Shoulder pain and SCI|Manual wheelchair users with SCI
2968045|NCT02777281|Other|Shoulder pain and able bodies|No SCI or wheelchair use but presence of shoulder pain
2968046|NCT02777268|Experimental|Infacort 0.5 mg|Multi-particulate granules from 1 (0.5 mg) capsule
2968047|NCT02777268|Experimental|Infacort 2 mg|Multi-particulate granules from 1 (2 mg) capsule
2968048|NCT02777268|Experimental|Infacort 5 mg|Multi-particulate granules from 1 (5 mg) capsule
2968049|NCT02777268|Experimental|Infacort 10 mg|Multi-particulate granules from 1 (10 mg) capsule
2968050|NCT02777268|Active Comparator|Hydrocortisone|1 (10 mg) tablet
2968051|NCT02777242|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate administered subcutaneously once each week. Auto-injection of QST 50 mg or 75 mg or 100 mg [Device: QuickShot® Testosterone (QST)]
2968052|NCT02777229|Experimental|Dolutegravir|Dolutegravir 50 mg Quaque die (QD) + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg Fixed Dose Combination (FDC) QD
2968053|NCT02777229|Active Comparator|Efavirenz|Efavirenz 400 mg QD + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg FDC QD
2968054|NCT02777216|Experimental|ConfidenHT system|ConfidenHT system
2968055|NCT02777190|Experimental|Oral misoprostol|oral misoprostol given 25 mcg every 2 hours
2968056|NCT02777190|Active Comparator|Vaginal misoprostol|vaginal misoprostol given 25 mcg every 4 hours
2968057|NCT02777164|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
2968058|NCT02777151|Experimental|Cohort 1|REGN3470-3471-3479 dosing level 1 or placebo
2968059|NCT02777151|Experimental|Cohort 2|REGN3470-3471-3479 dosing level 2 or placebo
2968060|NCT02777151|Experimental|Cohort 3|REGN3470-3471-3479 dosing level 3 or placebo
2968061|NCT02777151|Experimental|Cohort 4|REGN3470-3471-3479 dosing level 4 or placebo
2968062|NCT02777138||Young males aged 20-35 years old|"Maintaining a normal daily living lifestyle~Healthy~Reasonably active- PAL: 1.4-1.9~Non-obese- Fat mass index based on DEXA of 4-8kg/m2~Weight stable for more than 3 months (±3% body mass)~Non-smoker~No chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, peripheral arterial disease, insulin- or non-insulin dependent diabetes or other metabolic disorders~No daily consumption of analgesic or anti-inflammatory drug(s) including NSAIDs and corticosteroids, prescription or non-prescription~No medications that may influence lipid or carbohydrate metabolism or immune system function~No known negative reaction to lidocaine~No participation in heavy resistance training"
2968063|NCT02777138||Old males aged 65-85 years old|"Maintaining a normal daily living lifestyle~Healthy~Reasonably active- PAL: 1.4-1.9~Non-obese- Fat mass index based on DEXA of 4-8kg/m2~Weight stable for more than 3 months (±3% body mass)~Non-smoker~No chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, peripheral arterial disease, insulin- or non-insulin dependent diabetes or other metabolic disorders~No daily consumption of analgesic or anti-inflammatory drug(s) including NSAIDs and corticosteroids, prescription or non-prescription~No medications that may influence lipid or carbohydrate metabolism or immune system function~No known negative reaction to lidocaine~No participation in heavy resistance training"
2968064|NCT02777125|Active Comparator|Albuterol by Metered Dose Inhaler|Albuterol administered via MDI and spacer device with weight and severity based dosing. For weight less than 20 kg: mild and moderate disease 540mcg of albuterol per dose. For weight greater than or equal to 20 kg: mild disease 540 mcg of albuterol per dose and moderate disease 1080 mcg of albuterol per dose.
2968089|NCT02776956|Other|non-atorvastatin group|atrial fibrillation in non-atorvastatin group will not receive atorvastatin before and after operation..
2968090|NCT02776943|Experimental|Mesenchymal stem cell treatment|Umbilical Cord Mesenchymal stem cells (UCMSC) expanded and treated for 1-2 weeks. Then administer 5x10^6 of UCMSC per cm^2 of the cartilage defect.
2968091|NCT02776943|Active Comparator|Hyaluronic acid treatment|Administer hyaluronic acid (30 mg) in a single injection
2970329|NCT02761707||Essential Tremor|Non-smokers, ages 18-80, diagnosed with Essential Tremor.
2968065|NCT02777125|Active Comparator|Albuterol Breath Actuated Nebulizer|Subjects randomized to BAN were evaluated for proper breath actuation technique. For subjects unable to coordinate breath actuation, the RT attached an appropriately sized mask to the device, changed the setting to continuous nebulization and returned upon completion of the treatment. Albuterol dosing was based upon the subject's weight and presenting symptom severity. Children presenting in the mild and moderate severity category weighing less than 20kg, received 2500mcg of albuterol. Children weighing more than 20kg, received 2500mcg of albuterol if their presentation met mild severity criteria, or 5000mcg if they met moderate criteria.
2968066|NCT02777112|Placebo Comparator|Control|This group will receive generic information about depression and serve as control
2968067|NCT02777112|Experimental|e-mental health program|This group will receive the developed e-mental health program
2968068|NCT02777112|Experimental|e-mental health program and job coaching|This group will receive the developed e-mental health program plus interactive job coaching through telephone.
2968069|NCT02777099|Experimental|RIPostC|Receiving RIPostC with pressure set at 200 mmHg. Intervention:Procedure:Remote Ischemic Postconditioning
2968070|NCT02777099|Sham Comparator|sham RIPostC|"Receiving sham RIPostC with pressure set at the patient's diastolic blood pressure.~Intervention:Procedure:Sham Remote Ischemic Postconditioning"
2968071|NCT02777086|Experimental|StaySafe|Participants are asked to complete 12 brief, self-administered tablet computer sessions designed to improve decision-making around health risk behaviors. Sessions typically take about 10 minutes each to complete and are scheduled prior to or after probationer group or individual appointments at their probation facility. Sessions are scheduled about every two weeks.
2968072|NCT02777086|No Intervention|Comparison|Participants are asked to complete baseline, 6-month and 12-month surveys but are not asked to complete StaySafe sessions or other alternate activities.
2968073|NCT02777073|Active Comparator|liraglutide 1.8 mg|single dose of Victoza ( liraglutide) 1.8 mg
2968074|NCT02777073|Experimental|dapagliflozin 10|single dose of Farxiga ( dapagliflozin) 10 mg
2968075|NCT02777073|Placebo Comparator|Placebo|Single dose of placebo
2968076|NCT02777060|Experimental|Exergame|inertial sensor based system (wearable sensors, LEGSys, Biosensics LLC) will be used for balance training with computerized feedback. The balance training program is focused on lower extremities including ankle joint exercise and virtual obstacle crossing tasks.
2968077|NCT02777060|Active Comparator|Home based balance training|The control group will ask to perform a home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback. Exercises include postural balance tasks, such as backward and forward weight shifting, as well as dynamic balance exercises, such as marching in place (comparable to virtual obstacle crossing in experimental group).
2968078|NCT02777047|Experimental|Intervention|Complex Intervention including focused discharge medication reconciliation; structured handovers to family physician, community pharmacy, patient and family, home care, telehealth providers; telehealth follow-up focused on anticoagulation monitoring.
2968079|NCT02777047|No Intervention|Control|Usual care. Patients will be provided with the URL to Thrombosis Canada website.
2968080|NCT02777034|Experimental|Enhanced Recovery|"Preoperative protocols：Multidisciplinary patient information、no bowel preparation、no fasting（drink 10% glucose 1000 at 21：30 night before the surgery）.~Intraoperative protocols：Laparoscopic standardized technique、fluid restriction (max 500 ml/h)、no abdominal drains.~Postoperative protocols：no nasogastric tube、early solid dietary intake and mobilization、urinary catheter removal on postoperative day 1、restrictive fluid management（<2000ml/d）."
2968081|NCT02777034|Other|Unenhanced Recovery|"Preoperative protocols：Patient information、Mechanical bowel preparation、Fasting since midnight before operation.~Intraoperative protocols：Laparoscopic standardized technique、fluid overload (over 500 ml/h) 、place abdominal drains.~Postoperative protocols：no nasogastric tube、mobilization from postoperative day 1、fluids and solids intake after first passage of stool、Urinary catheter removal on postoperative day 2/3、no restrictive fluid management（>2000ml/d）."
2968082|NCT02777021||Early Discharge Patients|"Patients receiving or having received chemotherapy for AML who are discharged to outpatient management within 3 days after chemotherapy completion. Subjects will complete a health related quality of life (HRQOL) survey at baseline and again at the start of the next treatment course. Survey questions will collect information such as patient race and educational level.~HRQOL questions will be scored on a 5-point Likert response scale (0=never a problem to 4=almost always a problem). The total score includes a 23 item multidimensional core (physical, emotional, social and school functioning); an 18 item multidimensional fatigue scale (general, sleep/rest and cognitive fatigue) and a 27 item multidimensional cancer module (pain, nausea, anxiety, communication, and cognitive problems). Total score is calculated with a lower score representing a higher health related quality of life."
2968083|NCT02777021||Inpatient Management Patients|"Patients receiving or having received chemotherapy for AML who remain in the hospital more than 3 days after chemotherapy completion. Subjects will complete a health related quality of life (HRQOL) survey at baseline and again at the start of the next treatment course. Survey questions will collect information such as patient race and educational level.~HRQOL questions will be scored on a 5-point Likert response scale (0=never a problem to 4=almost always a problem). The total score includes a 23 item multidimensional core (physical, emotional, social and school functioning); an 18 item multidimensional fatigue scale (general, sleep/rest and cognitive fatigue) and a 27 item multidimensional cancer module (pain, nausea, anxiety, communication, and cognitive problems). Total score is calculated with a lower score representing a higher health related quality of life."
2968084|NCT02777008|Experimental|CTP-543 Single Dose|Single oral dose
2968085|NCT02777008|Experimental|CTP-543 Multiple Dose|Multiple oral dose for 7 consecutive days
2968086|NCT02776995|Other|Patients undergoing radiation|In this study, patients undergoing radiation treatment will undergo thermography imaging during radiation treatment course. Patients will be evaluated with thermography imaging every 5 fraction of radiation, starting prior to the first radiation treatment, periodically, until the end of radiation therapy (a period of several weeks).
2968087|NCT02776982|Other|Research procedures|Participants enrolled in study will have confocal endomicroscopy, research biopsies, mucosal impedance, and Bravo ambulatory pH capsule performed at the time of clinically indicated endoscopy.
2968088|NCT02776956|Experimental|atorvastatin group|atrial fibrillation in atorvastatin group will orally receive atorvastatin before and after operation.
2968092|NCT02776930||Return to Duty after Rehab from Injury|Patients deemed healthy enough to return to full duty without any restrictions after completing a course of rehabilitation for a lumbar/thoracic spine or lower extremity injury.
2968093|NCT02776917|Experimental|Cirmtuzumab + Paclitaxel|"Cirmtuzumab 600 mg is administered intravenously on Days 1 and 15 of each 28-day cycle.~Paclitaxel 80 mg/m^2 is administered weekly on Days 1, 8, 15, and 22 of each 28-day cycle."
2968094|NCT02776904|Other|Neuro-cognitive Assessment|Immediate Post-concussion Assessment and Cognitive Testing will be administered three times (pre-season, post season and end of year) during the school year and testing will not exceed 1 hour per athlete.
2968095|NCT02776904|Other|Psychomotor Vigilance Task|The Psychomotor Vigilance Task will be administered to each athlete and scores will be compared to the reaction time portion of the Immediate Post-concussion Assessment and Cognitive Testing examination.
2968096|NCT02776891|Other|Gallium citrate|The patients will be organized into two cohorts. Cohort 1 will receive 10 mCi and will be imaged 4 and 6 hours post injection. Cohort 2 will receive 15 mCi and will be imaged 4 and 6 hours post injection. Cohort 2 will be imaged if the optimal protocol identified image quality from cohort 1 does not allow for the resolution of cancer lesions.
2968097|NCT02776878|Experimental|Dasatinib|Dasatinib is given orally 50 mg 2 times a day for the first week, if subject is tolerate, then increased to 70 mg 2 times a day. Dasatinib will be continued until unacceptable toxicity and progression.
2968098|NCT02776865|Experimental|physical therapy and suprascapular nerve block|patient received ultrasound-guided suprascapular nerve block as well as physical therapy.
2968099|NCT02776865|Active Comparator|physical therapy only|patient received physical therapy only.
2968100|NCT02776852|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2968101|NCT02776839|Other|Mobile Sensing|This phase of the study is designed to develop the app. due to algorithms the app should lern to detect depressive symptoms
2968102|NCT02776813|Experimental|ACTR087, in combination with rituximab|
2968103|NCT02776800|Experimental|Allevyn Life|Foam Dressing
2968104|NCT02776800|Other|Foam Dressing|Standard Care - Foam Dressing
2968105|NCT02776787||Patients|Patients with diverticulitis
2968106|NCT02776787||Surgeons|Surgeons who perform elective colon resections
2968107|NCT02776761|Experimental|Hantaan Vaccine:|1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
2968108|NCT02776761|Experimental|Puumala Vaccine:|1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
2968109|NCT02776761|Experimental|Hantaan/Puumala Vaccine|The HTNV and PUUV vaccine will be combined (equal volumes) before use: 1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
2968110|NCT02776748|Other|FTC-TDF|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) PrEP: 200mg FTC /300 mg TDF
2968111|NCT02776735|Experimental|Sarilumab|Participants will receive one of three ascending dose regimens of sarilumab by subcutaneous (SC) injection based on body weight. All the participants will receive the selected dose regimen once this is identified. Sarilumab will be given during 12-week core treatment phase followed by a 144-week extension treatment phase.
2968112|NCT02776709||Bile duct Stricture|Patients referred for the evaluation of indeterminate strictures.
2968113|NCT02776709||Common bile duct Stones|Patients referred for the removal of difficult stones.
2968114|NCT02776696|Experimental|Advanced HybridClosed Loop System (AHCL)|Advanced Hybrid Closed Loop System (AHCL) - all subjects wearing the study system during 36 hours in the clinic during segment 1or 2 days in a camp setting during segment 2 or 12 days in a camp setting during segment 3
2968115|NCT02776696|Experimental|Hybrid Closed Loop System (HCL)|"Hybrid Closed Loop System (HCL) - all subjects wearing the study system during:~36 hours in the clinic during segment 1or 2 days in a camp setting during segment 2 or 12 days in a camp setting during segment 3"
2968116|NCT02776683|Experimental|All patients|
2968117|NCT02776670|Experimental|SYSTANE BALANCE|Preservative-free 0.9% saline solution, 1 drop in each eye 4 times a day for 7-14 days as run-in, followed by propylene glycol, 0.6% eye drops, 1 drop in each eye 4 times per day for 35 days
2968118|NCT02776670|Active Comparator|REFRESH OPTIVE|Preservative-free 0.9% saline solution, 1 drop in each eye 4 times a day for 7-14 days as run-in, followed by lubricant eye drops, 1 drop in each eye 4 times per day for 35 days
2968119|NCT02776657|Active Comparator|Cohort 1 (Stable Angina)|20 patients with stable angina planned to undergo elective coronary angiography will be recruited and each participant will undergo magnetic resonance imaging (MRI) prior to invasive coronary angiography. During the angiogram, Optical Coherence Tomography (OCT) may be used to identify thrombus within the coronary arteries.
2968120|NCT02776657|Active Comparator|Cohort 2 (Acute Coronary Syndrome)|20 patients diagnosed with acute coronary syndrome will be recruited and each participant will undergo magnetic resonance imaging (MRI) prior to invasive coronary angiography. During the angiogram, Optical Coherence Tomography (OCT) may be used to identify thrombus within the coronary arteries. If thrombus is identified, participants will be asked to undergo a repeat MRI scan at one and three months.
2968121|NCT02776631|Experimental|Pinloc|Plate and 3 interlocked pins. A new device for fixation of femoral neck fractures.
2968122|NCT02776631|Active Comparator|LIH (Hansson pins)|2 pins. An established method for fixation of femoral neck fractures.
2968123|NCT02776618|Experimental|Polyglactin 910|One half of excision site will be randomly assigned superficial closure with polyglactin 910 suture
2968124|NCT02776618|Experimental|poliglecaprone 25|One half of excision site will be randomly assigned superficial closure with poliglecaprone 25
2968155|NCT02776410|No Intervention|Control group|Group who will not download the mobile application
2968156|NCT02776397|Active Comparator|Hp 2-2 Vitamin E|The Haptoglobin 2-2 group randomised to Vitamin E
2968157|NCT02776397|Placebo Comparator|Hp 2-2 Placebo|The Haptoglobin 2-2 group randomised to placebo
2968158|NCT02776397|Active Comparator|Non Hp 2-2 Vitamin E|The Non Haptoglobin 2-2 group randomised to Vitamin E
2968159|NCT02776397|Placebo Comparator|Non Hp 2-2 Placebo|The Non Haptoglobin 2-2 group randomised to placebo
2968125|NCT02776605|Experimental|Ponatinib|"Pre-phase (maximum 7 days, -7 to -1) with Prednisone and triple intrathecal therapy (TIT)~Induction (day 1 to day 28 or up to hematological recovery) Vincristine (VCR): 1.5 mg/m2 IV days 1, 8, 15 and 22. Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22. Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27. Ponatinib 30 mg, PO from day 1 to consolidation. TIT, days 1 and 22.~Consolidation Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63. MTX: 1,5 g/m2, IV days 1, 28 and 56. VP-16: 100 mg/m2/12 h, IV, days 14 and 42. ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43. TIT days 1, 28 and 56. Ponatinib 30 mg/d PO, from day 1 to 15 days before transplantation (HSCT).~HSCT (performed ideally within 1 month from the end of consolidation).~Post HSCT therapy (MRD monitoring)"
2968126|NCT02776592|Experimental|Experimental|A cow's milk-based formula with added nutrients
2968127|NCT02776592|Active Comparator|Control|A cow's milk-based formula
2968128|NCT02776579|Experimental|Girls-only resistance training|8 weeks of 2-3x/week girls-only resistance training class with a female strength and conditioning specialist.
2968129|NCT02776579|No Intervention|No resistance training|8 weeks of usual activity.
2968130|NCT02776566|Active Comparator|Anticoagulation Clinic|"Usual care through pharmacist managed anticoagulation clinic~Anticoagulation Clinic (control): subjects will have their INR tested in clinic monthly (or more frequently if clinically indicated) via the Coaguchek® point-of-care device (which is the standard of care in the Anticoagulation Clinic) and receive dosing instructions and standardized education related to warfarin by a clinical pharmacist who provides care in the Anticoagulation Clinic."
2968131|NCT02776566|Experimental|Patient Self-Monitoring|"In home self-monitoring and pharmacist guided education~Patient Self-Monitoring (intervention): entails 3 education sessions of 90-120 minutes each (week 0, week 2, week 4): 2 provided on site in clinic and 1 in the patient's home, during which, self-testing competency and barriers and facilitators to self-monitoring will be evaluated. Subjects will follow with weekly (or sooner, if clinically indicated) in-home self-monitoring and follow-up weekly phone calls over 6 months by clinical pharmacists to guide warfarin dosing and reinforce key educational messages."
2968132|NCT02776553|Experimental|Active (physical training program)|physical activity + behavioral therapy + nutritional intervention
2968133|NCT02776553|Active Comparator|Control|nutritional intervention
2968134|NCT02776540|Active Comparator|900 mg Clopidogrel|67 patients will receive 12 tablets clopidogrel ( each 75 mg) as total 900 mg each patient
2968135|NCT02776540|Active Comparator|600 mg Clopidogrel|67 patient will receive 8 tablets clopidogrel (each 75 mg) as total 600 mg each patient and 4 tablets placebo to receive 12 tablets as total
2968136|NCT02776540|Placebo Comparator|400 mg Aspirin|67 patients will receive 4 tablets Aspirin ( each 75 mg) as total 300 mg for each patient and 8 tablets placebo to receive 12 tablets as total
2968137|NCT02776527|Experimental|A group|D2 Radical Gastrectomy adding received postoprative adjuvant chemotherapy of eight cycles of Xelox,and taking Apatinib 500mg/qd orally, 28 days as a cycle, till disease progresses.
2968138|NCT02776527|No Intervention|B group|D2 Radical Gastrectomy adding received postoprative adjuvant chemotherapy of eight cycles of Xelox
2968139|NCT02776514|Active Comparator|Triamcort (1 ml, 40 mg/ml)|60 patients receive intraarticular injection with steroids (and contrast media Iopamiro 200)
2968140|NCT02776514|Active Comparator|Platelet-rich-plasma (PRP 3 ml)|60 patients receive intraarticular injection with platelet-rich-plasma (PRP) (and contrast media Iopamiro 200)
2968141|NCT02776514|Active Comparator|Suplasyn1-shot (60 mg/ ml)|60 patients receive intraarticular injection with hyaluronic acid (and contrast media Iopamiro 200)
2968142|NCT02776514|Placebo Comparator|Placebo (Iopamiro 200)|60 patients receive intraarticular injection with contrast media only
2968143|NCT02776501|Experimental|BAY987521|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2968144|NCT02776488|No Intervention|Control|Standard of Care
2968145|NCT02776488|Experimental|Glucose|Infusion of glucose as supplemental fuel (dosage form = solute, dosage to be determined, frequency = 1x, duration = 3hr)
2968146|NCT02776488|Experimental|Lactate|Infusion of sodium lactate as supplemental fuel (dosage form = solute, dosage TBD, frequency = 1x, duration = 3hr)
2968147|NCT02776488|Experimental|Beta-hydroxybutyrate|Infusion of beta-hydroxybutyrate as supplemental fuel (dosage form = solute, dosage TBD, frequency = 1x, duration = 3hr)
2968148|NCT02776475|Other|Sacral neuromodulation device turned off|Patients who are currently being successfully treated with sacral neuromodulation for the primary diagnosis of urinary urge incontinence or urgency and frequency (implantation for minimum 12 months) will be to have the sacral neuromodulation device turned off for four consecutive weeks.
2968149|NCT02776462||Healthy, Uninjured Controls|This group will consist of subjects that have not been exposed to any major trauma in the previous 12 months. They will be older than age 5, have no major neurologic or psychiatric disorder, be developmentally normal, no current alcohol or illicit/prescription drug abuse, and will not be prisoners.
2968150|NCT02776462||Traumatic Brain Injury Cases|This group will consist of people admitted to the ER, Trauma Bay, or Neurosurgery for traumatic brain injury.
2968151|NCT02776449||Normal Tension Glaucoma|Patients with manifest normal tension glaucoma
2968152|NCT02776436|Experimental|Breast cancer|"Dose of prophylactic dexamethasone will be reduced as follows:~STEP 1: 12 mg dexamethasone per day (8-4mg/day) for 3 days starting 1 day before administration. (n=6)~STEP 2: 8mg dexamethasone per day (8mg once a day) for 3 days starting 1 day before administration. (n=6)~STEP 3: day -1: 4 mg, day 0: 8 mg, day 1: 4 mg. (n=6)~STEP 4: day -1: 0 mg, day 0: 8 mg, day 1: 4 mg. (n=6)~STEP 5: day -1: 0 mg, day 0: 8 mg, day 1: 0 mg. (n=6)~STEP 6: day -1: 0 mg, day 0: 4 mg, day 1: 0 mg. (n=6)"
2968153|NCT02776436|Experimental|Prostate cancer|"Dose of prophylactic dexamethasone will be reduced as follows:~STEP 1: 2dd 8 mg at 12 and 1 hr before treatment (besides standard prednisone 5mg bid) (n=6)~STEP 2: 8mg dexamethasone 1 hour before treatment (and standard prednisone 5mg bid). (n=6)~STEP 3: 4mg dexamethasone 1 hour before treatment (and standard prednisone 5mg bid). (n=6)~STEP 4: 0mg dexamethasone (only standard prednisone 5mg bid). (n=6)"
2968154|NCT02776410|Experimental|Intervention group|Group receiving tailored messages promoting sustainable and healthy eating through an mobile-application together with six principles of sustainable healthy eating that will be included in the mobile application,
2968160|NCT02776384||chronic heart failure|patients who are diagnosed with chronic heart failure with either preserved or reduced ejection fraction
2968161|NCT02776371|Experimental|Modified non-clarithromycin triple therapy|H.pylori infected patients treated with 20 mg esomeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 10 days.
2968162|NCT02776371|Active Comparator|Sequential therapy|H.pylori infected patients treated with 20 mg esomeprazole and 1 g amoxicillin, twice daily for 5 days, followed by 20 mg esomeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 5 days.
2968163|NCT02776358|Experimental|High Fidelity Simulation|Students will receive a 1 hour High fidelity simulation session
2968164|NCT02776358|Experimental|Video Case|Students will receive a 1 hour assisted Video Case learning session
2968165|NCT02776345|Active Comparator|Ultrasound guided Needle Fragmentation|"Ultrasound guided Needle Fragmentation (Intervention):~Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudocapsule. The needle tip will be retracted into the subacromial bursa and 3 ml of 0.5% sensorcaine and 1 ml of steroid ( Depomedrol- 40mg/ml) will be injected into the bursa. The needle will then be removed."
2968166|NCT02776345|Active Comparator|US guided needle fragmentation & Lavage|Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.
2968167|NCT02776345|Placebo Comparator|Ultrasound guided subacromial injection|Using local anesthetic and strict aseptic precautions, the tip of the 22 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 4 ml. of local anesthetic ( 0.5% xylocaine) and 1 ml of steroid( Depomedrol 40 mg/ml) will be injected into the bursa. The needle will then be removed. Post procedure US images in the short and long axis planes will be obtained and documented. The patient's post procedure pain on a scale of 10 and their range of shoulder movement (abduction) will be assessed and documented.
2968168|NCT02776332|Active Comparator|3 day group|Manual expression for 3 days after delivery Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery
2968169|NCT02776332|Active Comparator|7 day group|The 7 day group will manually express for 7 days after delivery. Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery follow up phone call at 5 days to encourage continued manual expression
2968170|NCT02776319|Experimental|Active|Non-invasive brain stimulation (active)
2968171|NCT02776319|Placebo Comparator|Sham/Placebo|Non-invasive brain stimulation (sham)
2968172|NCT02776306|Experimental|Mirror box therapy|The participants in the mirror box therapy arm will receive mirror box therapy for 3 weeks for upper limb rehabilitation post stroke.
2968173|NCT02776306|No Intervention|Standard treatment group|The participants will receive the standard treatment arm for 3 weeks for upper limb rehabilitation post stroke.
2968174|NCT02776293|Active Comparator|Relaxation Group|The relaxation group was asked to listen to their assigned audio file for at least 20 minutes a day and to record each time they had engaged in this activity. The audio file consisted of a two minute introduction. Following this, participants were instructed to sit undisturbed for 20 minutes.
2968175|NCT02776293|Experimental|Music Group|The music group was asked to listen to their assigned audio file for at least 20 minutes a day and to record each time they had engaged in this activity. The audio file consisted of a two minute introduction. Following this, participants were instructed to listen to pre-recorded songs specifically composed for pregnancy.
2968176|NCT02776280|Placebo Comparator|Negative control|Meal prepared with non-fluoridated water and salt
2968177|NCT02776280|Experimental|Fluoridated water|Meal prepared with fluoridated water
2968178|NCT02776280|Experimental|Fluoridated salt|Meal prepared with fluoridated salt
2968179|NCT02776267|Experimental|Angiolite stent - 3-month angiogram/OCT|Patients scheduled for PCI (and whot meet pre-specified inlcusion criteria) are enrolled to receive the Angiolite DES. They will undergo a scheduled repeat coronary angiogram and OCT evaluation at 3-month post index PCI.
2968180|NCT02776267|Experimental|Angiolite stent - 6-month angiogram/OCT|Patients scheduled for PCI (and whot meet pre-specified inlcusion criteria) are enrolled to receive the Angiolite DES. They will undergo a scheduled repeat coronary angiogram and OCT evaluation at 6-month post index PCI.
2968181|NCT02776254|Experimental|START|The START model aims to deliver a higher intensity of treatment services by offering same-day CD4 testing and results, streamlined adherence counseling, and quicker initiation of life-long ART to patients enrolling in HIV care and treatment services.
2968182|NCT02776254|Experimental|FAST Track|In the FAST-TRACK model a pharmacy technician will dispense drugs) and lay health care workers will provide brief symptom screening to identify patients in need of higher-level care. If there is no need of higher-level care, then the clinic visit is over.
2968183|NCT02776254|Experimental|CAG (intervention)|CAG intervention, consists of facilitated groups of six people based on geographic proximity of home address and patient preference. This group of six people, will meet monthly at a designated place in the community to provide support and receive medications. Each month one of the members will rotate visiting the clinic for their routine medical visit and will pick up medications for the entire CAG and bring them back to the community. This rotation schedule will recur every six months. Lay health care workers will provide brief symptom screening to identify patients in the group that need of higher-level care.
2968184|NCT02776254|Active Comparator|CAG (comparison)|Eligible patients at control sites will be approached for willingness to participate in the study. Those who are willing will be enrolled in the study and consent will be obtained to use patient data within SmartCare to evaluate the primary outcome of retention.
2968245|NCT02775864||Antidepressant|Individuals initiating treatment with an antidepressant medication
2968246|NCT02775864||Benzodiazepine|Individuals initiating treatment with a benzodiazepine
2968185|NCT02776254|Experimental|UAG (intervention)|Urban sites will be eligible for the UAG model in which patients will be joined into a UAG group consisting of 30 people. Each UAG group will meet every two to three months at a designated site (either at the clinic facility or another site in the community). Patients will receive (a) group adherence counseling led by a lay HCW (b) two to three month supply of ART medications via a pharmacy tech (c) attendance record and symptom assessment. As in the CAG model, patients may be referred up-referred for care based on acute illness or patient preference. Patients will continue to visit the facility for a routine medical visit with a professional HCW every six months.
2968186|NCT02776254|Active Comparator|UAG (comparison)|Eligible patients at control sites will be approached for willingness to participate in the study. Those who are willing will be enrolled in the study and consent will be obtained to use patient data within SmartCare to evaluate the primary outcome of retention.
2968187|NCT02776241|No Intervention|water restriction|20 patients will be subjected to 3 hours of water restriction following MR scan of the kidneys.
2968188|NCT02776241|Active Comparator|high water intake|20 patients will be subjected to 1 hour of high water intake (20 ml/kg) following MR scan of the kidneys.
2968189|NCT02776228|Experimental|benzodiazepine|The patient which will be in the Experimental arm (after randomization) will receive 0.25 mg of Brotizolam (short acting benzodiazepine) for six weeks from the day of discharge.
2968190|NCT02776228|Placebo Comparator|placebo|The patient which will be in the placebo arm (after randomization) will receive placebo for six weeks from the day of discharge.
2968191|NCT02776215|Experimental|Pharmacokinetic Dosing|Single-dose pharmacokinetics of tasimelteon
2968192|NCT02776202|Experimental|Reduced-intensity conditioning regimen|"The HSCT preparative regimen will consist of~Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5~Fludarabine: 35 mg/m2/day IV on Days -8 through -4~Melphalan: 140 mg/m2 IV on Day -3~Rest on Day -2 and -1~Day 0 is the day of transplant~GVHD prophylaxis: sirolimus beginning on Day -1 for at least one year and mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later."
2968193|NCT02776189|Experimental|Midazolam & Dexmedetomidine|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation. Intravenous dexmedetomidine 1 mcg per kg body weight over 10 minutes followed by infusion of dexmedetomidine at dose of 1 mcg per kg body weight per hour till end of procedure
2968194|NCT02776189|Active Comparator|Midazolam & Propofol|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation. Intravenous propofol 2 mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
2968195|NCT02776176|Experimental|ERAS group|Patients receive the Enhanced Recovery After Surgery program during the peri-operative period.
2968196|NCT02776176|Other|Traditional group|Patients receive the Traditional program during the peri-operative period.
2968197|NCT02776163|Experimental|Cisplatin Group|Intensity-modulated radiotherapy+concurrent chemotherapy with cisplatin for squamous carcinoma of salivary gland
2968198|NCT02776163|Experimental|Docetaxel+Cisplatin|Intensity-modulated radiotherapy+concurrent chemotherapy with docetaxel and cisplatin for adenogenous types carcinoma of salivary gland
2968199|NCT02776150||MGIT liquid culture+drug sensitivity test|MGIT: The bactec MGIT 960 system is non-radiometric. It uses MGIT media and patented sensors, making efficient use of advanced fluorometric technology, which permits highly accurate detection of O2 consumption without sharps. Automated quality control is performed continuously to ensure precise and reliable operation. Results are provided as positive/negative and numerical growth units.
2968200|NCT02776150||Xpert-MTB/RIF|xpert-MTB/RIF: The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System. A sputum sample is collected from the patient with suspected TB. The sputum is mixed with the reagent that is provided with the assay, and a cartridge containing this mixture is placed in the GeneXpert machine. All processing from this point on is fully automated.The test simultaneously detects Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) in less than 2 hours.
2968201|NCT02776150||probe melting curve detection|Probe-based fluorescence melting curve analysis (FMCA) is a powerful tool for mutation detection based on melting temperature generated by thermal denaturation of the probe-target hybrid, which performed for Mycobacterium tuberculosis's drug resistant monitor. The method was explored two dual-labeled, self-quenched probes, TaqMan and shared-stem molecular beacons, in their ability to conduct FMCA. Both probes could be directly used for FMCA and readily integrated with closed-tube amplicon hybridization under asymmetric PCR conditions. Improved flexibility of FMCA by using these probes was illustrated in three representative applications of FMCA: mutation scanning, mutation identification and mutation genotyping, all of which achieved improved color-multiplexing with easy probe design and versatile probe combination and all were validated with a large number of real clinical samples.
2968202|NCT02776137|Experimental|Docetaxel Group|Concurrent Chemoradiotherapy With Docetaxel
2968203|NCT02776124|Experimental|ONS group|Individualized dietary counseling+ONS(Healing elements)during CRT Interventions: (Healing elements)
2968204|NCT02776124|No Intervention|control group|Individualized dietary counseling during CRT
2968205|NCT02776111||Healthy Controls|Participants in this group will have a one time blood sample taken.
2968206|NCT02776111||Kidney Transplant Group|Participants in this group have had a kidney transplant and blood samples will be obtained as described in study plan
2968207|NCT02776098||Cystic Fibrosis without Cystic Fibrosis-related Diabetes|Subjects with a confirmed diagnosis of Cystic Fibrosis (CF) without Cystic Fibrosis-related diabetes will be followed annually for 2 years for a total of four study visits over 2 years (screening, baseline, 12 and 24 month visits).
2968208|NCT02776098||Newly Diagnosed Cystic Fibrosis-Related Diabetes|Subjects with a confirmed diagnosis of Cystic Fibrosis (CF) and new diagnosis of Cystic Fibrosis-Related Diabetes (CFRD) will be followed for a total of 3 study visits over 6 months (screening, baseline and 6 months).
2968209|NCT02776098||Healthy Controls|Age, sex, ethnicity and body mass index matched (at time of enrollment to CF without CFRD subjects) healthy controls will be followed annually for 2 years for a total of four study visits (screening, baseline, 12 and 24 month visits).
2968210|NCT02776085||Asymptomatic|Group of patients with CSF shunts who are evaluated for a reason other than concern for shunt failure. The optic nerve sheath diameter of these patients will be used as baseline measurements for children with CSF shunts.
2968211|NCT02776085||Symptomatic, Not Admitted|Group of patients with CSF shunts who are evaluated for concerns of shunt malfunction or failure, but either have shunt failure ruled out, or are felt to be safe for discharge to home. They are not admitted to the hospital. The optic nerve sheath diameter of these patients will be measured once in the emergency department.
2968212|NCT02776085||Symptomatic, Admitted|Group of patients with CSF shunts who are evaluated for concerns of shunt malfunction or failure, and then are admitted to the hospital secondary to these concerns. The optic nerve sheath diameter of these patients will be measured once in the emergency department or as close to admission as possible, and then measured again while they are still inpatient, but after they have an intervention performed (medical or surgical) to relieve their shunt malfunction or failure. These patients will have their initial optic nerve sheath diameters compared to the other two populations, but they will also have their initial and final optic nerve sheath diameters compared to each other.
2968213|NCT02776072||dimethyl fumarate (DMF)|Participants who initiated DMF during the specified time period
2968214|NCT02776072||glatiramer acetate (GA)|Participants who initiated GA during the specified time period
2968215|NCT02776072||teriflunomide|Participants who initiated teriflunomide during the specified time period
2968216|NCT02776072||fingolimod|Participants who initiated fingolimod during the specified time period
2968217|NCT02776059|Experimental|prednisolone or pentoxifylline + pegfiltrastim|prednisolone or pentoxifylline for 28 days PO plus pegfilgrastim subcutaneous weekly shot
2968218|NCT02776059|Active Comparator|prednisolone or pentoxifylline|prednisolone or pentoxifylline for 28 days
2968219|NCT02776046|Experimental|High FiO2|"Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.~Postoperatively 3h with 0.8 FiO2 and individualized CPAP"
2968220|NCT02776046|Active Comparator|Conventional FiO2|"Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.3. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.~Postoperatively 3h with 0.3 FiO2 and individualized CPAP"
2968221|NCT02776033|Experimental|GSK2982772 receivers in Cohort 1|Randomized subjects will receive GSK2982772 BID (approximately 12 hours apart) via oral route for 84 days.
2968222|NCT02776033|Placebo Comparator|Placebo receivers in Cohort 1|Randomized subjects will receive placebo BID via oral route for 84 days.
2968223|NCT02776033|Experimental|GSK2982772 receivers in Cohort 2|Randomized subjects will receive GSK2982772 TID (approximately 8 hours apart) via oral route for 84 days
2968224|NCT02776033|Placebo Comparator|Placebo receivers in Cohort 2|Randomized subjects will receive placebo TID via oral route for 84 days.
2968225|NCT02776020||Propofol sedated patients|Women undergoing a short trans vaginal ovum retrieval (TVOR) will be sedated with propofol , and monitored non-invasively for changes in blood propofol concentration levels. Propofol dosages will be adapted according to patients vital signs and their reaction to noxious stimuli exerted during the trans vaginal ovum retrieval (TVOR) procedure, irrespective to the proposed study in which these participants undergo.Those changes of administered propofol dosages will be observed by the anesthetic drug monitor (ADM). Propfol is administered by the anesthesiologist in a routine manner and according to anesthesiologist discretion .
2968226|NCT02776007|Experimental|Libre Flash CGMS (Continuous Monitoring System)|Patients will use the Libre Flash Continuous Glucose Monitoring System for 12 weeks for their glucose Management
2968227|NCT02776007|Active Comparator|SMBG|Patients will use Self-Monitoring of Blood Glucose for 12 weeks for their glucose management
2968228|NCT02775994|Experimental|Treatment Arm|Single dose of Canakinumab 4mg/kg
2968229|NCT02775981|Experimental|Active|RX0041-002
2968230|NCT02775955|Experimental|RX0041-002|Active
2968231|NCT02775942|Experimental|IPOVAC 1.5:5:5|IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
2968232|NCT02775942|Experimental|IPOVAC 3:10:10|IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
2968233|NCT02775942|Experimental|IPOVAC 6:20:20|IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
2968234|NCT02775942|Active Comparator|IMOVAC-POLIO|IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval
2968235|NCT02775929|Other|PrEP as a bridge to ART|FTC-TDF PrEP for HIV uninfected partners and ART for HIV infected partners
2968236|NCT02775916|Experimental|CDZ173|Capsule
2968237|NCT02775916|Placebo Comparator|Placebo|Capsule matching Placebo
2968238|NCT02775903|Experimental|Azacitidine in combination with Durvalumab|Subcutaneous azacitidine (75 mg/m2 for 7 days Q4W) in combination with IV durvalumab at a dose of 1500 mg on Day1 Every 4 weeks (Q4W)
2968239|NCT02775903|Active Comparator|Azacitidine alone|Subcutaneous azacitidine alone at the dose of 75 mg/m2 for 7 days Every 4 weeks (Q4W)
2968240|NCT02775890||Eating lead-shot wild game|Hunters that have eaten lead-shot in the past week will have blood lead levels measured.
2968241|NCT02775890||Not eating lead-shot wild game|Hunters that have not eaten lead-shot in the past week will have blood lead levels measured.
2968242|NCT02775877|Experimental|letrozole and clomiphene|Letrozole 5 mg tablet orally from 3-7 day of once a day menstrual cycle and clomiphene100 mg tablet orally once a day from 11-15 day of menstrual cycle.
2968243|NCT02775877|Active Comparator|Letrozole and human menopausal gonadotropin (HMG)|Letrozole 5 mg tablet orally from 3-7 day of once a day menstrual cycle and HMG 75u once a day by intramuscular injection from 11-15day of menstrual cycle
2968244|NCT02775864||Antipsychotic|Individuals initiating treatment with an antipsychotic medication
2968248|NCT02775851|Experimental|Cohort A (pembrolizumab, surgery)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 courses. Patients with potentially resectable disease undergo surgery. Patients with tumor progression and unresectable disease may receive one additional course of pembrolizumab.
2968249|NCT02775851|Active Comparator|Cohort B (pembrolizumab)|Patients with unresectable disease receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 34 courses in the absence of disease progression or toxicity.
2968250|NCT02775838|Experimental|kidney transplantation|Intravenous injection of Indocyanine Green in patients receiving kidney transplantation
2968251|NCT02775812|Experimental|Treatment (cisplatin, pembrolizumab, IMRT)|Patients receive cisplatin IV over 1-2 hours once weekly for weeks 1-6 and pembrolizumab IV over 30 minutes every 3 weeks in weeks 9, 12, 15, 18, and 21. Patients also undergo IMRT in weeks 1-6. Patients may also receive pembrolizumab IV over 30 minutes in weeks 3, 6, 24, and 27.
2968252|NCT02775786|No Intervention|Healthy Volunteers|Normal volunteers with no pancreas mass or risk factors for pancreas cancer will be recruited for MRI protocol optimization and nothing more. No intravenous contrast will be given. They will be asked to lie in the scanner for up to 1 hour and non-contrast imaging will be performed.
2968253|NCT02775786|Experimental|Pancreatic Mass or Risk Factors Group|Participants with pancreatic adenocarcinoma who are planning to undergo surgical resection. Participants will undergo up to two MRIs with and without intravenous contrast. The first MRI will be performed using an extracellular contrast agent and the second 1-14 days later, with a macromolecular contrast agent. If patient cannot undergo the second MRI for any reason eg. not enough time before surgery, one MRI with either contrast agent will still be used for analysis .
2968254|NCT02775773|Experimental|arm A (TXA)|2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery(third stage after labor)
2968255|NCT02775773|Active Comparator|arm B (OXY)|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
2968256|NCT02775760|Experimental|Cardiovascular endurance|Participants will undergo cardiovascular endurance training. The trainer-supervised endurance training will involve walking on a treadmill at moderate intensity
2968257|NCT02775760|Active Comparator|Strength, balance, and flexibility|Participants will undergo Strength, balance, and flexibility training.
2968258|NCT02775747|Experimental|platelet rich plasma gel|Injection of Platelet rich plasma (PRP) gel in 64 cases at time of wound closure in women undergoing cesarean section for improving wound healing after fullfit to all the inclusion and exclusion craiteria
2968259|NCT02775747|Placebo Comparator|Saline|64 Controlled Women with recurrent cesarean section and fullfit to all the inclusion and exclusion craiteria will reseve saline injection at time of wound closure
2968260|NCT02775734|Active Comparator|N-acetyl-cysteine|N-acetyl-cysteine + Clomiphene citrate + LOD
2968261|NCT02775734|Active Comparator|NO N-acetyl-cysteine|Clomiphene citrate + LOD
2968262|NCT02775721|Other|Cohort A|"Head and Neck Cancer patients receiving Radiation Therapy Only. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts B and C.~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.~Nutritional therapy education and evaluation is assessed per the attending dietitian.~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
2968263|NCT02775721|Other|Cohort B|"Head and Neck Cancer patients receiving Chemotherapy Only. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts A and C.~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.~Nutritional therapy education and evaluation is assessed per the attending dietitian.~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
2968264|NCT02775721|Other|Cohort C|"Head and Neck Cancer patients receiving Chemotherapy and Radiation therapy. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts A and B.~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.~Nutritional therapy education and evaluation is assessed per the attending dietitian.~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
2968265|NCT02775708|Experimental|capsule endoscopy|open label arm ; up to 100 subjects indicated for capsule endoscopy (CE) procedure will undergo the CE procedure with the Pillcam endoscopy system
2968266|NCT02775695|Experimental|Doxycycline Administered to Patients|Patients will receive oral doxycycline and trough serum concentrations for pharmacokinetic studies will be obtained.
2968267|NCT02775682||patients with epilepsy|
2968268|NCT02775682||normal individuals without epilepsy|
2968269|NCT02775669||intracranial ICP monitoring|invasive intracranial ICP monitoring
2968270|NCT02775669||tranfontanel ICP monitoring|Noninvasive transfontanel ICP monitoring
2968271|NCT02775656||Prospective cohort|For a pregnancy to be enrolled in the prospective cohort, the pregnancy outcome cannot be known (ie, no prenatal diagnosis of a fetus with a congenital defect and the pregnancy is still ongoing at the time of consent).
2968272|NCT02775656||Retrospective cohort|For a pregnancy to be enrolled in the retrospective cohort, the pregnancy outcome must already be known (ie, a congenital defect has already been identified at the time of consent into the pregnancy follow-up study, or the pregnancy has been completed at the time of consent).
2968273|NCT02775630|Experimental|Examination under hypnosis in addition to local anesthesia|Patients will have hypnosis add-on local anesthesia
2968274|NCT02775630|No Intervention|Examination under local anesthesia|Patients will receive a local anesthesia only without hypnosis
2968275|NCT02775617|Other|Parallel Treatment|Site 1- Parallel Treatment Arm Single dose azithromycin (for yaws) and Ivermectin/Permethrin (for scabies) will be offered on D1. A second dose of Ivermectin/Permethrin will be offered 7-14 days later.
2968276|NCT02775617|Other|Sequential Treatment|"Site 2- Serial Treatment Arm Ivermectin/Permethrin (for scabies) will be offered on D1 with a second dose of Ivermectin/Permethrin offered 7-14 days later..~Single dose azithromycin (for yaws) will be offered at the twelve month follow-up visit."
2968277|NCT02775604|Other|Home-Based Video|GoPro Camera
2968278|NCT02775604|Other|Paper Checklist|Homeowner Print Checklist
2968279|NCT02775591|Experimental|Motilitone arm|DA-9701 (Motilitone) 30mg 1T three times per day for 4+8 weeks
2968280|NCT02775591|Placebo Comparator|Placebo arm|DA-9701 placebo 30mg 1T three times per day for 4 weeks, DA-9701 (Motilitone) 30mg 1T three times per day for 8 weeks
2968281|NCT02775578|Experimental|Coronary Artery Bypass Grafting|Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.
2968282|NCT02775578|Experimental|Percutaneous Coronary Intervention|Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.
2968283|NCT02775578|Experimental|Hybrid Coronary Revascularization|Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.
2968284|NCT02775552|Experimental|A&T intervention areas|
2968285|NCT02775552|Active Comparator|Comparison areas|(Receive standard government services)
2968286|NCT02775539|Active Comparator|Mirabegron|Oral mirabegron, starting with 50 mg once a day and titrated till a maximum of 200 mg once a day.
2968287|NCT02775539|Placebo Comparator|Placebo|Oral placebo, similarly titrated to ensure blindness.
2968288|NCT02775526|Active Comparator|TOT|TOT
2968289|NCT02775526|Active Comparator|TVT|TVT
2968290|NCT02775526|Active Comparator|Burch colposuspension|Burch colposuspension
2968291|NCT02775513||Mutation|Patients with functional mutation in ion channels
2968292|NCT02775513||Control|Matched control
2968293|NCT02775500||Apremilast-Exposed Cohort|Women who have been exposed to apremilast in pregnancy for an approved indication in the first trimester of pregnancy for any length of time from the date of conception.
2968294|NCT02775500||Diseased Comparison Cohort|Women with an approved disease who have not been exposed to apremilast at any time in pregnancy.
2968295|NCT02775500||Healthy Comparison Cohort|Healthy women who have no diagnosis of an approved indication or other chronic illness, have not taken apremilast in pregnancy, nor have they been exposed to any known human teratogen during pregnancy.
2968296|NCT02775500||Apremilast-Exposed Registry Group|Women who have been exposed to apremilast in pregnancy, for any length of time following the first day of the last menstrual period until the end of pregnancy who do not qualify for the prospective cohort study.
2968297|NCT02775487||COPD and air quality|Persons enrolled in the study will have been diagnosed with Stage III or IV COPD and samples of air taken from their home environment.
2968298|NCT02775474|Experimental|Methadone|Methadone used as anesthesia opioid: induction with 0,15 mg / kg intravenous methadone. Boluses of 0,05 mg / kg intravenous methadone as needed intraoperatively
2968299|NCT02775474|Active Comparator|Fentanyl|Fentanyl used as anesthesia opioid: induction with 6 mcg / kg intravenous fentanyl. Boluses of 2 mug / kg intravenous fentanyl as needed intraoperatively
2968300|NCT02775461||Hereditary Pancreas Cancer Syndrome|Patients that have a diagnosis or any family history of a hereditary pancreas cancer syndrome, such as, but not limited to, Familial Pancreatic Cancer, hereditary pancreatitis, FAMMM syndrome, FAP and its variants, HNPCC (Lynch syndrome), Peutz-Jeghers syndrome, or BRCA1 and/or BRCA2 germline mutations.
2968301|NCT02775461||Personal or FHx of Pancreas Cancer or Pancreas Cysts|Patients that have personal or family history of pancreatic cancer or pancreatic cysts.
2968302|NCT02775461||Inflammatory Pancreatic Diseases|Patients that have a personal or family history of pancreatic dysplasia or inflammatory pancreatic diseases.
2968303|NCT02775448|Experimental|Diet + exercise + Carduus marianus 6cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 6cH, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
2968304|NCT02775448|Experimental|Diet + exercise + Carduus marianus 12cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 12cH, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
2968305|NCT02775448|Experimental|Diet + exercise + Carduus marianus 30cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 30c, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
2968306|NCT02775448|Placebo Comparator|Diet + exercise + placebo|Diet (1600 cal/day) + aerobic exercise (30 min daily) + placebo (87°alcohol), 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
2968307|NCT02775435|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
2968308|NCT02775435|Active Comparator|Chemotherapy|Participants receive normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
2968309|NCT02775422|Experimental|Pregnant women|Pregnant women
2968310|NCT02775409|Active Comparator|Subcutaneous|Subcutaneous placement of tissue expander
2968311|NCT02775409|Active Comparator|Submuscular|Submuscular placement of tissue expander
2968312|NCT02775396|Experimental|Adult computer user|Wearing each of the two spectacle lens designs for one month in random sequence
2968313|NCT02775383||Longitudinal|Participants with MDS, MDS/MPN overlap disorder, or ICUS who are followed long term
2968314|NCT02775383||Cross-sectional|Participants who do not have MDS, MDS/MPN overlap disorder, or ICUS and have the baseline visit only
2968315|NCT02775370|Experimental|Apatinib group|Apatinib Mesylate administered as a daily oral treatment
2968316|NCT02775357|Experimental|Enhanced HIV counseling and testing|In addition to standard HIV testing and counseling,men randomized to this arm received Measurement and communication of HIV risk from the HIV counselors using an index developed and validated through the Rakai community cohort study. Their risk was communicated to them and subsequent HIV risk reduction counseling including male circumcision was given.
2968317|NCT02775357|Active Comparator|Standard HIV testing and counseling|Men randomized to this arm were given standard HIV testing and counseling following the current Uganda Ministry of Health guidelines. Following the counseling HIV risk reduction counseling including male circumcision was given.
2968318|NCT02775344|Experimental|three dimension laparoscopy|This group of patients will have laparoscopic ovarian cystectomy performed using three-dimension laparoscopy. The procedure will be performed in usual manner.
2968319|NCT02775344|No Intervention|Two dimension laparoscopy|Two-dimension laparosocpy would be used in this group of patient. The procedure will be performed in usual manner.
2968320|NCT02775331|Experimental|Units using Titania1 software|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
2968321|NCT02775331|Experimental|Units using Titania2 software|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
2968322|NCT02775331|No Intervention|Units using Titania3 software|Employees working in shift planning units (clusters) where a standard shift planning software (Titania3) without interactive shift rostering or guidance for health-supporting shift ergonomics is used by shift planners.
2968323|NCT02775318|Other|Stellate Ganglion Block|After diagnosis of vasospasm patients were administered ultrasound guided Stellate Ganglion block using 10 cc of 0.5% Inj Bupivacaine on the same side of vasospasm or the side contralateral to the focal neurological deficit.Patients were then assessed using transcranial Doppler and digital subtraction angiography after 30 minutes
2968324|NCT02775305|No Intervention|Not frail|Source of these participants will be the same as those who screen into the study; patients with chronic kidney disease receiving care at the San Francisco Veteran Affairs Medical Center. Based on initial screening if participants do not meet criteria for frailty, baseline screening data will be used for comparative analysis as the no intervention arm.
2968325|NCT02775305|Experimental|Frail|Source of these participants will be the same as those who screen into the study; patients with chronic kidney disease receiving care at the San Francisco Veteran Affairs Medical Center. Based on initial screening if participants meet criteria for frailty participants will be enrolled in the intervention arm. Participants who are ambulatory regardless of co-morbidities will not be excluded from the study.
2968326|NCT02775292|Experimental|Treatment (NY-ESO-1 TCR transduced PBMC, vaccine, nivolumab)|"CONDITIONING REGIMEN: Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 30 minutes on days -4 to -1.~NY-ESO-1 TCR PBMC INFUSION: Patients receive NY-ESO-1 TCR PBMC IV on day 0.~NIVOLUMAB: Patients receive nivolumab IV over 60 minutes on day 0 or 1. Treatment repeats every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.~NY-ESO-1(157-165) PEPTIDE PULSED DC: Patients receive NY-ESO-1(157-165) peptide pulsed DC ID on days 1, 14, and 28.~LOW DOSE ALDESLEUKIN ADMINISTRATION: Patients receive aldesleukin SC BID for 7 days beginning on day 1 for a maximum of 14 doses."
2968327|NCT02775279||Acute coronary syndrome group|200 consecutive patients were recruited, who have diagnosed with acute coronary syndrom(ACS) by quantitative coronary angiography.
2968328|NCT02775279||Control group|The 200 healthy controls without previous CHD history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
2968329|NCT02775266|Active Comparator|ALA + Scaling and Root planing|Systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months(group B)
2968330|NCT02775266|Placebo Comparator|Scaling and root planing only|Patients will receive scaling and root planning at baseline and 3 months(group A)
2968331|NCT02775253|Experimental|Chronic cold acclimation group|All patients will be conducted a chronic cold acclimation intervention for 33 days.
2968332|NCT02775240|Active Comparator|Digoxin|On Day 1, subjects will receive a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin.
2968333|NCT02775240|Experimental|Maribavir|On Day 8 through Day 15, subjects will receive a 400 mg (2 x 200 mg) BID oral dose of maribavir. Subjects will be given the second dose of maribavir approximately 12 hours after the first dose. On Day 13, subjects will receive a coadministration of a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin and a single 30 mg oral dose of dextromethorphan given with the morning dose of maribavir.
2968334|NCT02775240|Active Comparator|Dextromethorphan|On Day 1, subjects will receive a single 30 mg oral dose of dextromethorphan.
2968335|NCT02775227|Experimental|Hydrocortisone|
2968336|NCT02775227|Active Comparator|Pasireotide|
2968337|NCT02775214|No Intervention|Conventional Direct Laryngoscopy|Endotracheal intubation will be performed by conventional direct laryngoscopy.
2968338|NCT02775214|Active Comparator|Video Laryngoscopy|Endotracheal intubation will be performed by video laryngoscopy with the C-MAC.
2968339|NCT02775201|Active Comparator|Plantaris release under ultrasound guidance|Patients diagnosed with non-insertional Achilles tendinopathy will have plantaris released under ultrasound guidance by a consultant radiologist
2968340|NCT02775201|Active Comparator|Plantaris excision surgically|Patients diagnosed with non-insertional Achilles tendinopathy will have plantaris excised in surgery by a consultant orthopaedic surgeon
2968341|NCT02775188|Experimental|Physical Therapy with InterACTION|After ACL Reconstruction, subjects will undergo physical therapy 1 time per week supplemented by home exercise program with InterACTION device.
2968342|NCT02775188|Other|Physical Therapy|After ACL Reconstruction, subjects will undergo physical therapy 1 time per week
2968343|NCT02775175|No Intervention|Fasting as Usual|This group will continue to practice their usual fasting regimen during Ramadan
2968344|NCT02775175|Experimental|Modified Ramadan Fasting|This group will receive an educational intervention providing knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
2968969|NCT02770677|No Intervention|Control group|Control group will be asked to continue their normal daily life without Yoga training
2968345|NCT02775162|Experimental|Normothermic Machine Perfusion (NMP)|Following the routine retrieval procedure of the liver, it will be placed on the OrganOx metra for Normothermic Machine Perfusion (NMP) for transport per the Investigational Plan and the Instructions For Use.
2968346|NCT02775162|Other|Standard of Care (Ice)|Following the routine retrieval procedure of the liver, it will be placed in ice-cold perfusion solution within an ice box for transport as dictated by logistics and local policy.
2968347|NCT02775149||Reflux patients|Patients who are treated at the Clinic for Gastroenterology and Gastrointestinal Oncology and have a 24-hours pH monitoring or impedance measurement performed for medical reasons
2968348|NCT02775136|Experimental|HS-1000 recording|Non-invasive measurements duration with HS-1000 device will be for at least 30 minutes and up to 1 hour of aggregate recording either continuously in the event the patient's clinical condition allows it or in separate recording iterations in the event patient's condition will not allow continuous recording. For each patient, there may be several monitoring intervals from three times a day and up to as long as the patient undergoes brain monitoring, per the discretion of the investigator, patient and/or family members.
2968349|NCT02775123|No Intervention|Control|Conventional cardio-pulmonary bypass
2968350|NCT02775123|Experimental|Cytosorb|Cytosorb added to cardio-pulmonary bypass
2968351|NCT02775110|Active Comparator|Immediate Discontinuation Group|Patients will discontinue the natalizumab therapy at once and initiate another disease modifying therapy at 1 month following the last natalizumab infusion. The disease modifying therapy at 1 month following natalizumab discontinuation will be at the discretion of the neurologist and may differ among patients.
2968352|NCT02775110|Experimental|Taper-off Group|Patients will be administered two more natalizumab infusion, one at six weeks and the second at eight weeks (14 weeks from study entry), followed by six months natalizumab discontinuation. Another DMT will be initiated within two months after the last natalizumab infusion.
2968353|NCT02775097||Normal|Not having any history of refractive surgery, contact lens, dry eye or pathology
2968354|NCT02775097||Corneal condition|History of refractive surgery, contact lens, dry eye or keratoconus.
2968355|NCT02775084|Experimental|Healthy Fish Oil|8 grams fish oil
2968356|NCT02775084|Placebo Comparator|Olive Oil|8 grams olive oil
2968357|NCT02775058||patients|The subjects enrolled in this CI just received dental grafting by the device under evaluation and in any case will be subject to the same procedures foreseen for this CI for the dental implant surgery.
2968358|NCT02775045||Eosinophil esophagitis|Adult patients (>18 yr) will be recruited from the Gastroenterology clinic following a diagnostic endoscopy for esophageal dysfunction with predominant symptom(s) of solid food dysphagia and/or esophageal food impaction. Patients with esophageal biopsy showing greater than 15 eosinophil/hpf (pathology results typically available within three business days) despite greater than two months use of high dose proton pump inhibitor will be invited to participate and enroll in the study within 1 week of the endoscopy.
2968359|NCT02775019|Active Comparator|Lactobacillus reuteri lonzenges|2x daily repeated intake of lozenges containing 10E9 CFU Lactobacillus reuteri each for 42 days
2968360|NCT02775019|Placebo Comparator|Placebo lozenges|2x daily repeated intake of lozenges being void of Lactobacillus reuteri for 42 days.
2968361|NCT02775006|Active Comparator|Docetaxel|Docetaxel 75mg/m2 every 21 days until disease progression or toxicity related
2968362|NCT02775006|Active Comparator|Docetaxel plus erlotinib|Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days, until disease progression, or toxicity related.
2968363|NCT02774993|Experimental|Doxycycline|Doxycycline 100 mg twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 20 mg/kg, pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. These will be given daily for 14 days. Subsequently doxycycline will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician
2968364|NCT02774993|Placebo Comparator|Placebo|Placebo twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 20 mg/kg, pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. These will be given daily for 14 days. Subsequently placebo will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician
2968365|NCT02774967|Active Comparator|extended flap technique|"root coverage comparing two techniques The aim of this study was to compare and show the benefits of the extended flap technique compared to Tunnel technique both techniques using the acellular dermal matrix for root coverage.~Other Names:~acellular dermal matrix extended flap technique"
2968366|NCT02774967|Experimental|tunnel technique|"root coverage comparing two techniques The aim of this study was to compare and show the benefits of the extended flap technique compared to Tunnel technique both techniques using the acellular dermal matrix for root coverage.~Other Names:~acellular dermal matrix extended flap technique"
2968367|NCT02774954|Experimental|Change the cycle|CTC uses the Information-Motivation-Behavioral skills (IMB) model to achieve changes among active PWID through seven short modules. Information and motivational domains are addressed in guided conversations about (1) their own first injection episode and consequences, (2) past experiences initiating injection-naive people and consequences, (3) health, legal, and social risks related to injection drugs, (4) health, legal, social risks of initiating people, and (5) identifying their own behaviors that might promote injection among others. The behavioral skills domain is addressed through a (6) skill-building discussion and rehearsal of responses to possible initiation scenarios, and (7) safer injection education.
2968368|NCT02774954|Active Comparator|Nutrition|The nutrition equal attention control intervention is a single-session, 60- minute Information-Motivation-Behavioral (IMB) skills-based intervention addressing healthy eating. The healthy eating intervention uses a one-on-one guided conversation between the interventionist and the participant. The intervention addresses (1) information about current eating patterns and recommendations for healthy alternatives (20 minutes), (2) motivations for improving healthy eating by providing feedback to participants on personal responsibility, a menu of alternative change options, a decision balance exercise, and eating goal setting (10 minutes), and (3) Behavioral Self-Management Component (30 minutes) that covers eating scenarios, participant responses, and healthy alternatives to the scenario and the participants feedback.
2968426|NCT02774486|Experimental|IQP-AK-102|2 capsules to be taken 3 times daily orally, 30 min before each main meal (breakfast, lunch, dinner) with 250 mL of water
2968369|NCT02774928||Chronic Obstructive Pulmonary Disease|Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality throughout the world.COPD, a common preventable and treatable disease, is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients.Spirometry is required to make a clinical diagnosis of COPD; the presence of a post-bronchodilator FEV1/FVC < 0.70 confirms the presence of persistent airflow limitation and thus of COPD .
2968370|NCT02774928||Interstitial lung diseases|Interstitial lung disease is a general category that includes many different lung conditions. All interstitial lung diseases affect the interstitium, a part of the lungs' anatomic structure.
2968371|NCT02774928||Obstructive sleep apnea (OSA)|"Obstructive sleep apnea (OSA) is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. It is the most common type of sleep-disordered breathing and is characterized by recurrent episodes of upper airway collapse during sleep.~These episodes are associated with recurrent oxyhemoglobin desaturations and arousals from sleep.~OSA that is associated with excessive daytime sleepiness is commonly called obstructive sleep apnea syndrome—also referred to as obstructive sleep apnea-hypopnea syndrome."
2968372|NCT02774902|Experimental|TAK-438 40 mg + Clarithromycin 500 mg|TAK-438 40 mg, tablets, orally once on Days 1 and 8 along with clarithromycin 500 mg, tablets, orally twice daily from Days 3 to 9.
2968373|NCT02774889|Active Comparator|Stepping Online|"Stepping On graduates receive Stepping Online, a password-protected continuation website to maintain fall prevention behaviors.~Fall prevention tips~Fall prevention exercise videos noting technique and safety~Guest expert videos and communication with expert~Tools to set exercise goals, reminders and track progress~Fall prevention specialist for feedback and group activities~Discussion and messaging (1:1, small and large group)~Fall prevention resources."
2968374|NCT02774889|No Intervention|Stepping On Usual Care Control|Subjects control workshops in the condition will not have access to Stepping Online.
2968375|NCT02774876|Active Comparator|Carbohydrate meal|
2968376|NCT02774876|Active Comparator|Carbohydrate + fat meal|
2968377|NCT02774876|Active Comparator|Carbohydrate + protein meal|
2968378|NCT02774876|Active Comparator|Carbohydrate + fat + protein meal|
2968379|NCT02774863||"Group Maternal and Child Protection"|Followed by the doctor and pediatric nurse of the Maternal and Child Protection . A child psychiatric consultation (usual care) can take place during the monitoring of this patient.
2968380|NCT02774863||"Group Home passages"|A child psychiatric consultation is scheduled in the month following the inclusion and three home passages between the 2nd and 3rd months of follow up.
2968381|NCT02774850||Early Discharge Management|Discharge to outpatient management during neutropenia within 3 days after chemotherapy completion in a given course
2968382|NCT02774850||Inpatient Management|Remain hospitalized during chemotherapy-induced neutropenia
2968383|NCT02774837|Experimental|combination|Tenofovir disoproxil oral tablets 300mg once daily for 96 weeks and Telbivudine 600mg oral tablets once daily for 96 weeks
2968384|NCT02774837|Active Comparator|mono therapy|Tenofovir disoproxil oral tablets 300mg once daily for 96 weeks
2968385|NCT02774824||CABG patients from protocol 003-03|"Patients who will agree to be followed for an additional 9 months, which include:~2 phone calls at 6 and 9 months after coronary artery bypass graft surgery~1 clinic visit at 12 months after coronary artery bypass graft surgery ( 64-slice or better MDCT angiography)"
2968386|NCT02774811|Active Comparator|SLT|Selective laser trabeculoplasty
2968387|NCT02774811|Active Comparator|PGA|Prostaglandin analogue topical medical therapy
2968388|NCT02774798||Rectal Intussusception and Prolapse|"AAR measurements will be taken from patients with suspected intra-rectal intussusception or rectal prolapse. Subgroup analysis will be performed after grading of rectal prolapse according to the Oxford Grading system. The subgroups will be:~Oxford Grades 1 & 2 - intra-rectal intussusception~Oxford Grades 3 & 4 - intra-anal intussusception~Oxford grade 5 - Overt Rectal Prolapse"
2968389|NCT02774785|Experimental|Device Arm|Randomized for MarginProbe device to be used during surgical procedure
2968390|NCT02774785|No Intervention|Control Arm|Randomized for surgical procedure to happen as per standard care
2968391|NCT02774759|Experimental|NEXT-Steps- Aerobic Exercise and Resistance Training (NS-ART)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.~Participants placed into an exercise plan focused on physical activity and resistance training. Physical activity guidelines workbook distributed along with activity monitor. Participants receive phone calls and text messages for support in reaching exercise and diet goals.~Participants receive resistance bands to perform resistance exercises. Exercise handouts and an iPad mini with training videos used to video chat with a research team member.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
2968392|NCT02774759|Experimental|NEXT-Steps- Aerobic Exercise (NS-A)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.~Participants placed into an exercise plan focused on physical activity only. Physical activity guidelines workbook distributed along with activity monitor. Participants receive phone calls and text messages for support in reaching exercise and diet goals.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
2968393|NCT02774759|Active Comparator|Standard Care Control Group (CG)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.~Participants receive standard of care consisting of phone calls asking about their health and self-help materials.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
2968394|NCT02774746|Active Comparator|35-week delivery group|Subjects to be delivered at 35 0/7 weeks through 35 6/7 weeks.
2968395|NCT02774746|Active Comparator|38-week delivery group|Subjects to be expectantly managed to spontaneous delivery, delivered by 38 0/7 weeks through 38 6/7 weeks.
2968550|NCT02773628|Active Comparator|treatment group|stable asthmatics receiving Acar'up system
2968396|NCT02774720|Experimental|Centre-based physical activity|People with Mild Cognitive Impairment (MCI) and early dementia will receive centre-based physical activity for one hour each week for three months, plus at-home prescribed exercise.
2968397|NCT02774720|Experimental|Home-based exercise|People with Mild Cognitive Impairment (MCI) and early dementia be prescribed at-home prescribed exercise and will received monthly support phone calls.
2968398|NCT02774694||observational cohort|patients undergoing interventional pain management procedures
2968399|NCT02774681|Experimental|Treatment (palbociclib)|Patients receive palbociclib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with HER2 positive breast cancer may also receive trastuzumab IV over 30-90 minutes every 3 weeks.
2968400|NCT02774668|Active Comparator|"Grab-and-Go meal plan"|"The intervention of this arm is to use a Grab-and-Go meal plan. This meal plan provides Atkins shakes and bars for breakfast, lunch, and snacks for 2 weeks. For dinner the subject is given a freshly-prepared meal. Upon finishing the 2-week provided food phase, the subject will consume a self-prepared meal of similar nutrient composition at home for another 2 weeks. For the next four weeks while he/she is still enrolled in the study, he/she will have his/her options for food choices which are not controlled for the study."
2968401|NCT02774668|Active Comparator|"Jump-Start meal plan"|"The intervention of this arm is to use a Jump Start meal plan. This meal plan provides Atkins frozen meals at breakfast, lunch and dinner for 2 weeks and these meals are supplemented with fresh salads and vegetables. Upon finishing the 2-week provided food phase, the subject will consume a self-prepared meal of similar nutrient composition at home for another 2 weeks. For the next four weeks while he/she is still enrolled in the study, he/she will have his/her options for food choices which are not controlled for the study."
2968402|NCT02774655|Experimental|PAI APP|personal activity index application
2968403|NCT02774655|Active Comparator|FitBit APP|
2968404|NCT02774642|Experimental|CBTI-PE|Integrates the core components of CBT-I and PE in 14 90-minute weekly sessions.
2968405|NCT02774642|Active Comparator|Hygiene-PE|Uses non-active sleep hygiene to account for the dose response of experimental condition before starting PE. Uses 14 90-minute weekly sessions.
2968406|NCT02774616|Other|Ilivia ICD Family|Implant of the new Ilivia ICD Family. Device measurements, pre-defined programming and Adverse Event Reporting
2968407|NCT02774616|Other|Plexa ICD lead|Implant of the new Plexa ICD lead. Device measurements and Adverse Event Reporting
2968408|NCT02774603|Active Comparator|Aquatic Locomotor Training|Aquatic Locomotor Training is a Locomotor Training technique utilizing an underwater treadmill to help increase a patient's independence and function. Aquatic Locomotor Training may require up to three people to obtain desirable gait kinematics: one at each of the patient's legs, and one at the patient's pelvis; however, typically with ambulatory patients, only one therapist is utilized. Therapists are highly trained, using their legs and feet to provide properly timed underwater cues throughout the gait cycle.
2968409|NCT02774603|Active Comparator|Land Locomotor Training|Locomotor Training encompasses a variety of interventions ranging from BWSTT to overground gait training to robotic-assisted walk training. Overground Locomotor Training, depending upon the technique used, can require up to four people to complete the intervention (one at each participant's leg, one at the participant's trunk and/or pelvis, and one monitoring the computer and/or treadmill).
2968410|NCT02774590|Experimental|Timolol to split face for 8 weeks|All 24 subjects will receive study drug and everyone will be randomized to which side of the face is treated with study drug first (right half-face versus left half-face). After 8 weeks of split-face treatment every night before bed, the subjects will be instructed to start treating both sides for another 8 weeks. Up to 30 subjects may be enrolled to ensure a target sample size of 24 (12 acne cases, 12 rosacea cases). This is an exploratory study. No part of this protocol will be considered routine care.
2968411|NCT02774577|Experimental|healthy young and elderly|young adults (20 to 30 years) compare to elderly (60 to 74 years)
2968412|NCT02774564|Experimental|Nebicapone 50 mg|1 tablet of 50 mg plus 3 tablets of placebo concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
2968413|NCT02774564|Experimental|Nebicapone 100 mg|2 tablets of 50 mg plus 2 tablets of placebo concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
2968414|NCT02774564|Experimental|Nebicapone 200 mg|4 tablets of 50 mg concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
2968415|NCT02774564|Placebo Comparator|Placebo|4 tablets concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
2968416|NCT02774551|Experimental|Physical activity intervention group|The physical activity program includes 150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week are demonstrated by the research nurse. The resistance training is progressive by increasing resistance in the band based on patient's adaptability during the intervention.
2968417|NCT02774551|No Intervention|Standard care control group|Patients follow their routine daily physical activity.
2968418|NCT02774538|Other|Experimental arm|
2968419|NCT02774525|Active Comparator|Treatment as Usual (TAU)|Outpatient substance-abuse treatment plus drug and alcohol screening plus brief support for personal goal setting
2968420|NCT02774525|Experimental|Contingency Management|Contingency management for drug and alcohol abstinence plus TAU
2968421|NCT02774525|Experimental|Parenting Intervention|Parenting intervention plus TAU
2968422|NCT02774525|Experimental|Parenting Intervention + Contingency Management|Parenting intervention plus contingency management for drug and alcohol abstinence plus TAU
2968423|NCT02774512|Experimental|Nilotinib|A specific colonoscopy is performed in order to take biopsy for biological studies to determine the ZAK-0 expression status. Then the patient receives nilotinib orally at the dose of 800 mg/day (400 mg twice a day) for 7 days. The patient is scheduled for surgery the morning after the last take of the nilotinib (12 hours). When the colectomy is performed, the surgeon collects different tumoral samples which are immediately delivered to the laboratory.
2968424|NCT02774499|Experimental|Methadone|Methadone 0.3 mg/kg (to a maximum of 30 mg) will be given to the patient preoperatively.
2968425|NCT02774499|Placebo Comparator|Placebo|Equivalent volume (5mL) of syrup will be given to the patient preoperatively.
2968427|NCT02774460|Active Comparator|Zestril® (Lisinopril)|Inhibition of angiotensin converting enzyme (ACE inhibitor). Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)
2968428|NCT02774460|Active Comparator|Atacand® (Candesartan)|Angiotensin receptor blocker. Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)
2968429|NCT02774460|Active Comparator|Norvasc® (Amlodipine)|Calcium channel blocker. Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)
2968430|NCT02774460|Active Comparator|Hydrochlorothiazide® (Hydrochlorothiazide)|Diuretic agent. Treatment step up: 1-2 weeks (12,5 mg tablet) Target dose: 5-7 weeks (25 mg tablet)
2968431|NCT02774460|Active Comparator|Repeated treatment X|"Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y.~The repeated arms will be given with the same duration and dosing as the other arms."
2968432|NCT02774460|Active Comparator|Repeated treatment Y|"Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y.~The repeated arms will be given with the same duration and dosing as the other arms."
2968433|NCT02774460|Placebo Comparator|Placebo|This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
2968434|NCT02774447||Rectal cancer patients with ileostoma|"In association with anterior resection of rectal cancer these patients obtain loop-ileostoma in order to avoid complications. These are closed within a few months and according to previous studies the admission time is 3-5 days after operation. This study is a single-arm study. The arm include patients having had rectal cancer operation and who have obtained a loop-ileostoma and that meet the inclusion criteria.~The operation procedure is standardized; shortly described by dissecting the ileostoma from the abdominal wall and everting the stoma ledges, which will be sutured or stapled. The patients will be observed for 23 hours, and if there are no contraindications according to described criteria the patient can be discharged form the hospital, however all patients will be followed up."
2968435|NCT02774434|Experimental|JM-105|Within 15 minutes of each ordered blood sample 2 TcB measurements will be performed using the JM-105 on the sternum and forehead. Subject's participation will end after a 10 day period.
2968436|NCT02774421|Experimental|IT trastuzumab after subQ GM-CSF|Patients with localized recurrent PFEPN will be treated with IT trastuzumab following 5-day course of subQ GM-CSF. Surgical resection should be planned (based on institutional surgical scheduling standards) for ideally 2-7 days after IT trastuzumab dosage.
2968437|NCT02774421|Experimental|IT trastuzumab in combination with subQ GM-CSF|Patients with localized recurrent PFEPN will be treated with IT trastuzumab in combination with GM-CSF to establish a maximum tolerated dosage. GM-CSF will be administered at 250 mcg/m2/dose subQ daily for three (3) days prior to the IT trastuzumab dose.
2968438|NCT02774408|Other|CPAP|"Infants on CPAP will receive backup breafs whenever the SpO2 <88 % along with~automated FiO2 controller. In the control period they will receive automated FiO2~alone"
2968439|NCT02774408|Other|NIMV/NIPPV|"Infants on NIMV NIPPV will receive an increase in the backup rate to 2 times the rate~of the backup triggered by apnoe (apnoe time 5s), whenever the SpO2 under 88%~( max rate 100/min) in the reference period as compared to baseline (automated FiO2~- control + unchanged SIPPV settings)"
2968440|NCT02774395||endometrioid adenocarcinoma grade I|
2968441|NCT02774395||endometrioid adenocarcinoma grade II|
2968442|NCT02774395||endometrioid adenocarcinoma garde III|
2968443|NCT02774395||healthy endometrioid|obtain after hysterectomia provided for
2968444|NCT02774382|Active Comparator|Vancomycin|"Oral vancomycin according to number of recurrences (Danish guidelines):~First recurrence: Capsule vancomycin 125 mg x 4 p.o. times daily for 14 days~≥2 recurrences:~capsule vancomycin 125 mg x 4 times daily p.o. for 14 days followed by~capsule vancomycin 125 mg x 2 times daily p.o. for 7 days followed by~capsule vancomycin 125 mg x 1 times daily p.o. for 7 days followed by~capsule vancomycin 125 mg x 1 p.o. every second day for 7 days followed by~capsule vancomycin 125 mg x 1 p.o. every third day for 14 days"
2968445|NCT02774382|Experimental|Vancomycin + fecal microbiota transplantation|Capsule vancomycin 125 mg x 4 times daily p.o. for 7-14 days followed by Fecal Microbiota Transplantation with 200 ml fecal suspension administrated with a rectal catheter.
2968446|NCT02774382|Experimental|Vancomycin + rectal bacteriotherapy|Capsule vancomycin 125 mg x 4 times daily p.o. for 7-14 days followed by Rectal bacteriotherapy with 200 ml suspension of a fixed mixture of bacterial strains administrated with a rectal catheter.
2968447|NCT02774369|Experimental|Physical exercise|A 6-week individualised, aerobic intervention program elaborated by a kinesiologist following a complete assessment of the individual's physical condition.
2968448|NCT02774369|Active Comparator|Cognitive-behavioral therapy|A 6-week self-administered cognitive-behavioral therapy for insomnia composed of a 60-min video (DVD format) and 6 booklets.
2968449|NCT02774356||Native Chinese speakers|
2968450|NCT02774356||Native English speakers without experience of a tonal language|
2968451|NCT02774343|Experimental|Pioglitazone + Therapy + Contingency Management|Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
2968452|NCT02774343|Placebo Comparator|Placebo + Therapy + Contingency Management|Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
2968453|NCT02774330||Minneapolis, Minnesota Customers|"Minneapolis, Minnesota has a policy in place whereby minimum quantities and varieties of healthy food are required for all licensed food stores. The policy is our intervention condition."
2968454|NCT02774330||St. Paul, Minnesota Customers|No policy exists in St. Paul, Minnesota. This is the control condition.
2968455|NCT02774317|Active Comparator|FFP|Patients receive FFP as clinically indicated (INR 1.5 or more)
2968456|NCT02774317|Experimental|FP24|Patients receive FP24 as clinically indicated (INR 1.5 or more)
2968457|NCT02774304|Active Comparator|arterial line|invasive haemodynamic monitoring
2968458|NCT02774304|Experimental|Cheetah®|non-invasive cardiac output
2968584|NCT02773407|Active Comparator|Group A|Azithromycin tablets 20mg/kg/day for 7 days (Maximum dose 1000mg/day)
2968970|NCT02770677|Experimental|Yoga group|Yoga group will be exposed to Modified Dantien Salee Yoga Training Program for 12 weeks
2968459|NCT02774291|Experimental|Treatment (mTCR, aldesleukin)|Patients receive standard cyclophosphamide IV over 1 hour on days -7 to -6 and fludarabine phosphate via IVPB over 30 minutes on days -5 to -1 followed by anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes IV over 20-30 minutes on day 0 and aldesleukin IV over 15 minutes approximately every 8 hours on days 0-4. Patients also receive filgrastim SC on days 1-4.
2968460|NCT02774278|Experimental|Erlotinib|Participants will receive erlotinib orally daily until disease progression, unacceptable toxicity or death.
2968461|NCT02774265|Active Comparator|VTE prophylaxis with Enoxaparin 30mg BID|The group receiving VTE prophylaxis with enoxaparin 30mg subcutaneous BID.
2968462|NCT02774265|Active Comparator|VTE prophylaxis with Aspirin 81mg BID|The group receiving VTE prophylaxis with ASA 81mg PO BID
2968463|NCT02774252|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2968464|NCT02774239|Experimental|SC Treatment Period|"Participants will receive 2gm/kg of Human normal immunoglobulin G (IgG) infused over 4 weeks in a dose escalating manner as follows:~1st week: 2-3 SCIG infusions of 10ml per site at four sites (total dose 16 to 24g)*~2nd week: 2-3 SCIG infusions of 15ml per site at four sites (total dose 24 to 36g)*~3rd week: 2-4 SCIG infusions of 20ml per site at four sites (total dose 32 to 64g)*~4th week: 2-4 SCIG infusions of 25ml per site at four sites (total dose 40 to 80g)*~Doses indicated are study recommended. Doses may be adjusted depending on tolerance and total dose required by the patient."
2968465|NCT02774226|Experimental|Tetrahydrobiopterin (BH4)|Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline, 4 weeks, 8 weeks, and 12 weeks following, 5mg/kg, 10mg/kg, or 20mg/kg of Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4), taken once a day.
2968466|NCT02774226|Experimental|Antioxidant Cocktail|Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline, 4 weeks, 8 weeks, and 12 weeks following an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day.
2968467|NCT02774200|Experimental|test group|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
2968468|NCT02774187|Experimental|Sorafenib combined with HAIC|Sorafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
2968469|NCT02774187|Active Comparator|Sorafenib alone|Sorafenib alone
2968470|NCT02774174||METS Proximal Humeral system|Implanted with METS Proximal Humerus
2968471|NCT02774161|Experimental|Diagnostic (B-mode ultrasound imaging)|Patients undergo B-mode ultrasound imaging of the liver over 15 minutes.
2968472|NCT02774148|Active Comparator|PO Acetaminophen|1,000mg Acetaminophen po every 8 hours until discharge.
2968473|NCT02774148|Experimental|IV Acetaminophen|1,000mg Acetaminophen IV every 8 hours until the patient has received 3 doses post-operatively. Then 1,000mg Acetaminophen po every 8 hours until discharge.
2968474|NCT02774135||direct occupational therapy intervention|group will be evaluated 4 times: on referral to waiting list for treatment, before and after 9-12 direct individual treatments of 45 minutes, and follow-up after 3 months.
2968475|NCT02774122|Active Comparator|masking therapy|Masking intervention was a standard monophone tinnitus masking therapy.
2968476|NCT02774122|Experimental|CAABT|CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
2968477|NCT02774109|Experimental|Experimental group|Participants in the experimental group will take fish oil (five 1000mg fish oil soft capsules per day, each capsule containing 350mg EPA and 250mg DHA) and receive physical modality treatment (hotpacking 15min and transcutaneous electrical nerve stimulation (TENS) 15min, three times a week) for 8 weeks
2968478|NCT02774109|Placebo Comparator|Control group|Participants in the control group will take placebo (five 1000mg sunflower oil soft capsules per day) and receive physical modality treatment (hotpacking 15min and transcutaneous electrical nerve stimulation (TENS) 15min, three times a week) for 8 weeks
2968479|NCT02774096|No Intervention|Control group（Ascending aorta）|undergo ascending aorta Dissection Repair and thoracoabdominal aortic Dissection Repair
2968480|NCT02774096|Experimental|Xenon Post-conditioning|undergo ascending aorta Dissection Repair and thoracoabdominal aortic Dissection Repair
2968481|NCT02774083|Active Comparator|Feuerstein Program|The participants of the Intervention Group will participate in the Feuerstein mediated learning cognitive program.
2968482|NCT02774083|Placebo Comparator|Adler Program|The Control Group will participate in the program of the Adler Institute dealing with social and emotional development without specific cognitive skills training.
2968483|NCT02774070|Other|Symptomatic atlantoaxial joint affection|Undergo plain X-ray and magnetic resonance imaging
2968484|NCT02774070|Other|Asymptomatic atlantoaxial joint aff.|Undergo plain X-ray and magnetic resonance imaging
2968485|NCT02774057|Experimental|Initial therapy with Captafer®|This arm will consist of 10 patients who will begin Captafer® therapy twice daily for 6 weeks, then undergo a 2 week washout period before crossing over to Iron Sulfate therapy twice daily for an additional 6 weeks.
2968486|NCT02774057|Experimental|Initial therapy with Iron Sulfate|This arm will consist of 10 patients who will begin Iron Sulfate therapy twice daily for 6 weeks, then undergo a 2 week washout period before crossing over to Captafer® therapy twice daily for an additional 6 weeks.
2968487|NCT02774044|Experimental|Cadisurf (goat lung surfactant extract)|Neonates in the intervention group will be intratracheally administered 100 mg/kg of GLSE (CADISURF®).
2968488|NCT02774044|Active Comparator|Survanta (Beractant)|
2968489|NCT02774031|Experimental|Aisys with Et control|the ventilation modus will be pressure control ventilation with volume guarantee (PCV-VG). Settings: tidal volume (TV) 7-9 ml/kg BW, respiratory rate (RR) 12 -14/min, and 8-10 cmH2O positive end expiratory pressure (PEEP). Target for end expired desflurane concentration (F A des) is set to 4.2%, and target for end expired oxygen (F AO2) is set to 35%.
2968585|NCT02773407|Active Comparator|Group B|Co-trimoxazole tablets (Trimethoprim 10 mg/kg+Sulphamethoxazole 50 mg/kg) in two divided doses everyday for 7 days (maximum 3000mg/day)
2968490|NCT02774031|Active Comparator|Aisys conventional ventilation|50% oxygen and 50% air in 1 liter FGF will be administered. To be started with a FGF of 5l/min and vaporizer setting at 6 Vol% for 5 min. Then the FGF will be reduced to 1 l/min. 25 min later the vaporizer setting will be reduced to 5.5 Vol % for the rest of the study period. Ventilation modus for this group will be the same as for 'Aisys with PCV-VG'
2968491|NCT02774031|Experimental|Flow-i with ACG|the following parameters will be preset: FIO2= 40%; end expired gas concentration (FA des) to 4.2%; speed 6; and ventilation modus = pressure regulated volume control (PRVC) with tidal volume (TV) 7-9 ml/kg BW, respiratory rate (RR)12-14/min, and 8-10 cmH2O positive end expiratory pressure (PEEP).
2968492|NCT02774031|Active Comparator|Flow-I conventional ventilation|50% oxygen and 50% air in 1 liter FGF will be administered. To be started with a FGF of 5l/min and vaporizer setting at 6 Vol% for 5 min. Then the FGF will be reduced to 1 l/min. 25 min later the vaporizer setting will be reduced to 5.5 Vol % for the rest of the study period. Ventilation modus for this group will be the same as for 'Flow-i with ACG'
2968493|NCT02774018|Experimental|12 institutionalized elderly people|Mindfulness-Based Stress Reduction program.
2968494|NCT02774005|Experimental|Raxone|
2968495|NCT02773992||The IoT group|
2968496|NCT02773992||The routine management group|
2968497|NCT02773979|Active Comparator|Group 1: PfSPZ 51200 sporozoites/Placebo|Chloroquine (CQ)/PfSPZ Challenge 51200 sporozoites or CQ/normal saline (NS). N=12, randomized 3:1
2968498|NCT02773979|Active Comparator|Group 2: PfSPZ 102400 sporozoites/Placebo|CQ/PfSPZ Challenge 102400 sporozoites or CQ/NS. N=4, randomized 3:1
2968499|NCT02773979|Active Comparator|Group 3: PfSPZ 102400 sporozoites|CQ/PfSPZ Challenge 102400 sporozoites N=9
2968500|NCT02773966|Experimental|Arm A: Kypho-IORT|balloon kyphoplasty/vertebroplasty + intraoperative radiotherapy
2968501|NCT02773966|Active Comparator|Arm B: EBRT|external beam radiotherapy with 30 Gy during 10 days (3 Gy/day)
2968502|NCT02773953|Experimental|CPAP + T4PTelemonitoring device|T4P® (Telemonitoring device) is added to CPAP at home. Sleep lab technical staff are connecting to the web portal 2 X/ week. In case of air leaks, persistant significant apnea-hypopnea index, use < 3h on three consecutive days, they have to call the patient .
2968503|NCT02773953|Active Comparator|CPAP standard care|After CPAP titration night, patients are instructed to use the device each night for the whole night. They receive written instruction and can reach the sleep unit (phone call, visit) how often they need, during week days, to resolve CPAP-related problems. A group educational session is scheduled 1 month after and a visit to the pneumologist 1.5 months after.
2968504|NCT02773940|Experimental|ClariCore System|Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during the patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
2968505|NCT02773927|Experimental|Agave inulin + Metformin|5 g of Agave inulin powder every 12 hrs + 500 mg tablet of metformin every 24 hrs
2968506|NCT02773927|Active Comparator|Metformin + Placebo of agave inulin|500 mg tablet of metformin every 24 hrs + 5 g every 12 hrs of calcinated magnesia powder
2968507|NCT02773927|Active Comparator|Agave Inulin+Placebo of Metformin|5 g of agave inulin powder every 12 hrs + 500 mg tablet of calcinated magnesia as metformin placebo every 24 hrs
2968508|NCT02773927|Placebo Comparator|Placebo of Inulin + Placebo of Metformin|5 g of calcinated magnesia powder every 12 hrs + 500 mg tablet of calcinated magnesia every 24 hrs
2968509|NCT02773914|Experimental|CGA intervention|The CGA intervention will include multidisciplinary teams consisting of physician, nurse (RN), physiotherapist (PT), occupational therapist (OT) and social worker (SW). The team will work according to CGA, and have the primary and continuing responsibility for planning of hospital care and discharge. CGA will include assessment of socio-demographic background, social network, health and medical history, medications, functional status, cognitive status, nutritional status, somatic status and psychosocial status including depression, as well as treatment and planning for discharge and follow-up.
2968510|NCT02773914|No Intervention|Control group|The control group receives usual hospital care, that is care given at an ordinary medical hospital ward, without the specialized multi-disciplinary team approach and CGA.
2968511|NCT02773901|Experimental|HS-1000 recording|ICP monitoring will be done with the HS-1000 to compare to CSF measurement from lumbar puncture (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals last 10 minutes.
2968512|NCT02773888|Experimental|HS-1000 recording|ICP readings will be recorded in parallel from both the invasive ICP monitor, and HeadSense's non-invasive ICP monitor. Each recording session will be done until an aggregate of at least 30 minutes worth of quality data is collected, depending on the patient's clinical condition. For each patient, two recording sessions will be completed for 30-60 minutes each for 120 minutes total.
2968513|NCT02773875|No Intervention|Sensor Augmented Pump (control)|Use sensor augmented pump (SAP) for 3 weeks.
2968514|NCT02773875|Experimental|Artificial Pancreas (intervention)|Artificial pancreas system (Algorithm + CGM + pump)--use the AP system for 3 weeks which consists of: (1) Fault detection and Zone MPC algorithm housed on the DiAs platform + (2) Roche insulin pump + (3) Dexcom CGM
2968515|NCT02773862|Experimental|HS-1000 recording|ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an invasive monitoring device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 48 hours, continuously depending on the patient's clinical condition.
2968516|NCT02773849|Experimental|INSTILADRIN|Intravesical administration of INSTILADRIN into the bladder
2968517|NCT02773836||Greek cohort|Participants recruited from Greece
2968518|NCT02773836||German cohort|Participants recruited from Germany
2968519|NCT02773836||Romanian Cohort|Participants recruited from Romania
2968520|NCT02773836||Spanish Cohort|Participants recruited from Spain
2968521|NCT02773836||Hungarian Cohort|Participants recruited from Hungary
2968522|NCT02773836||Polish cohort|Participants recruited from Poland
2968523|NCT02773823|Experimental|Lifestyle intervention|"Lifestyle intervention:~Diet instruction: The children were asked to increase fruit/vegetables consumption, reduce high fat food, etc.~Exercise intervention: The children participated sports 60 min/day,5d/week for 8 months."
2968524|NCT02773823|No Intervention|No intervention|"No intervention in the group with intervention."
2968971|NCT02770664|Experimental|LC28-0126 Dose A|
2968972|NCT02770664|Experimental|LC28-0126 Dose B|
2968525|NCT02773810|Experimental|Integrated Family Planning Services|Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
2968526|NCT02773797|Placebo Comparator|IN-DEX 1.0 mcg/kg, intranasal saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label Intranasal-Dexmedetomidine (IN-DEX) intranasal 1.0 mcg/kg will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
2968527|NCT02773797|Placebo Comparator|IN-DEX, 1.5 mcg/kg intranasal saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label IN-DEX intranasal 1.5 mcg/kg will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
2968528|NCT02773797|Active Comparator|Placebo - Saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label Placebo - Saline will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
2968529|NCT02773784||invasive breast cancer|Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.
2968530|NCT02773771|Placebo Comparator|Placebo + Vital HP|GROUP 1 will receive Placebo (within 24 hours of ICU admission) and Vital HP ® (while on tube feeds). Vital HP® is on the Massachusetts General hospital formulary, but it is often restricted to patients with malabsorption due to its higher cost compared to other standard enteral nutrition formulas.
2968531|NCT02773771|Experimental|B-hydroxy-B-methylbutyrate (HMB) + Vital HP|GROUP 2 will receive beta-hydroxy-beta-methylbutyrate (within 24 hours of ICU admission) and Vital HP ® (while on tube feeds). Vital HP® is on the Massachusetts General hospital formulary, but it is often restricted to patients with malabsorption due to its higher cost compared to other standard enteral nutrition formulas. The investigators will limit HMB dosing to 3g/day since this is the most widely studied dose.
2968532|NCT02773758|Experimental|Stannous Fluoride Dentifrice|Participants will be instructed to topically dose a dry toothbrush with a full strip of toothpaste, then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute twice daily (morning and evening). Participants will be permitted to rinse with tap water.
2968533|NCT02773758|Other|Sodium monofluorophosphate Dentifrice|Participants will be instructed to topically apply a full brush head of toothpaste to a dry toothbrush, then brush the whole mouth thoroughly for at least 1 minute. Participants will be permitted to rinse with tap water.
2968534|NCT02773745|No Intervention|Standard of Care|Participant will receive standard of care and a brochure on healthy eating.
2968535|NCT02773745|Active Comparator|Aquatic Prehabilitation Group|The prehabilitation group will undergo 6-8 weeks of individualized aquatic exercise in a heated pool (60 min/session, 3 times per week). Aquatic equipment maybe used to challenge balance and trunk stabilization.
2968536|NCT02773732|Experimental|Ciprofloxacin and Etoposide|
2968537|NCT02773719|Experimental|True biofield therapist|Subject will have a 40 minutes therapy with a real biofield therapist to treat the wart
2968538|NCT02773719|Placebo Comparator|Fake biofield therapist|Subject will have a 40 minutes therapy with a fake biofield therapist to treat the wart
2968539|NCT02773706|Experimental|Usual Subspecialty Care|"Once a subject is screened positive for anxiety or depression, the subspecialty provider is informed of the positive screen, and left to manage or refer the condition as per usual care by that provider.~Intervention: Depression / anxiety screen + clinician informed."
2968540|NCT02773706|Active Comparator|Integrated Psychology Care|"Once a subject is screened positive for anxiety or depression, an automated psychology referral occurs, in addition to any intervention determined by the subspecialty provider.~Intervention: Depression / anxiety screen + clinician informed + automated psychologist visit."
2968541|NCT02773693|Active Comparator|CPT|Cognitive Processing Therapy-cognitive only version (typically labeled CPT-C, but labeled CPT in this grant for simplicity) is a type of Cognitive Therapy addressing daytime symptoms of PTSD. This arm will have 12 twice-weekly sessions, followed by 6 weekly sessions.
2968542|NCT02773693|Active Comparator|CBTin+CPT|Cognitive Behavioral Therapy of Insomnia and nightmares (CBTin) will be used to address nighttime symptoms of PTSD during 6 weekly sessions, followed by 12 twice-weekly sessions of CPT.
2968543|NCT02773693|Active Comparator|CPT+CBTin|12 twice-weekly sessions of CPT followed by 6 sessions of CBTin.
2968544|NCT02773680|Experimental|Study cohort 1|"electrical impedance tomography"
2968545|NCT02773654||Healthy Volunteers|Asymptomatic subjects: subjects without complaints or history of shoulder pain or obvious movement abnormalities.
2968546|NCT02773654||Symptomatic Volunteers|Symptomatic subjects: subjects with shoulder pain who have active range of motion beyond 120° of elevation.
2968547|NCT02773641|Active Comparator|Botulinum Toxin Type A|50 Allergan units (0.5 ml) injected in m bulbocavernosus twice with 3 months in between treatments
2968548|NCT02773641|Placebo Comparator|Sterile saline solution|0.5 ml of sterile saline injected in m bulbocavernosus twice with 3 months in between treatments
2968549|NCT02773628|Placebo Comparator|control group|stable asthmatics receiving an Acar'up placebo system
2968973|NCT02770664|Experimental|LC28-0126 Dose C|
2968551|NCT02773602|Experimental|Dexamethasone|Dexamethasone has been used for adult epidurals and nerve blocks and in spine surgeries. It prolongs the duration of pain relief and causes less sedation. It is commonly administered to children during surgery to help decrease nausea and vomiting after surgery. It is also much cheaper than clonidine The patient will receive Ropivacaine plus 200 μgm/kg of dexamethasone in 1 ml saline
2968552|NCT02773602|Active Comparator|Clonidine|"Clonidine has been added to caudal analgesia for infants and children for many years. It increases the duration of pain relief of ropivicaine by itself, however, it may lead to prolonged sedation following the surgical procedure (an undesired effect) and it is expensive.~The patient will receive Ropivacaine plus 2 μg/kg of clonidine in 1 ml saline."
2968553|NCT02773602|Placebo Comparator|Normal Saline|The patient only will receive Ropivacaine
2968554|NCT02773589|Experimental|Peroral endoscopic myotomy|
2968555|NCT02773576|Experimental|2x360 mg risperidone implant|2, 360 mg risperidone implants
2968556|NCT02773576|Experimental|3x300 mg risperidone implant|3, 300 mg risperidone implants
2968557|NCT02773563||EUS with CO2 insufflation|Patients undergoing EUS with CO2 insufflation
2968558|NCT02773563||EUS with air insufflation|Patients undergoing EUS with air insufflation
2968559|NCT02773550|Experimental|Velcadito|Bortezomib 1.3 mg/m2 days 1,4,8 and 11 first cycle, the 1.0 mg/m2 days 1 and 4. Melphalan 9 mg/m2 days 1 to 4 Prednisone 60 mg/m2 days 1 to 4 Cycles of 28 days
2968560|NCT02773537|Active Comparator|Randomization Group 1|Femoral nerve catheter and sciatic nerve block
2968561|NCT02773537|Active Comparator|Randomization Group 2|Adductor canal catheter and selective tibial block
2968562|NCT02773537|Active Comparator|Randomization Group 3|Adductor canal catheter only
2968563|NCT02773524|Experimental|Regorafenib|Regorafenib 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + Best Supportive Care until progression
2968564|NCT02773524|Placebo Comparator|Placebo|Placebo 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + Best Supportive Care until progression
2968565|NCT02773511|Other|Bone healing|Bone healing in surgical or conservative treatment for children type 1 humeral condyle fracture
2968566|NCT02773511|Other|Fracture displacement|Fracture displacement in surgical or conservative treatment for children type 1 humeral condyle fracture
2968567|NCT02773498|Active Comparator|conventional TESE|Conventional multiple TESE is performed under general or locoregional anesthesia. Through a small vertical incision in the median scrotal raphe, the skin, dartos muscle, and tunica vaginalis are opened to expose the tunica albuginea. The tunica albuginea is ordinarily incised for about 4 mm at the medium region of the testis. A similar biopsy will be systematically performed in the contralateral testis. The biopsy is analyzed by the biologist in the theatre in order to precise if sufficient spermatozoa is retrieved.
2968568|NCT02773498|Experimental|micro TESE|Microdissection TESE is also performed under general or locoregional anesthesia. After the tunica albuginea is opened widely along the antiepididymal border, direct examination of the testicular parenchyma is performed under the operating microscope. An attempt is made to identify individual seminiferous tubules that are larger, more opaque and whiter than other tubules in the testicular parenchyma, which are considered to contain spermatozoa. The extracted tubules are analyzed by the biologist in the theatre. The procedure is terminated when sperm are retrieved or further biopsy is thought likely to jeopardize the blood supply of the testis. If all tubules are seen to have an identical morphological appearance, at least three samples (upper, middle, and lower) are obtained. A similar microTESE will be systematically performed in the contralateral testis
2968569|NCT02773485|Active Comparator|Systemic Chemotherapy|Irrespective of arm allocation Baseline Positron Emission Tomography(PET) scan and hepatic function assessment will be done. Those randomized to this arm will receive systemic chemotherapy delivered on day 1 and 8 every 3 weekly, with gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2. After first 4 cycles patients will undergo repeat Contrast Enhanced Computed Tomography(CECT)/PET scan. If CECT/PET scan shows stable/ responding disease then patients will continue to receive the same chemotherapy. In case of locally progressive/ systemic disease on chemotherapy patients may be considered for second line palliative chemotherapy or best supportive care. The use of radical chemoradiation is not allowed on disease progression in this arm. However palliative radiation may be used.
2968570|NCT02773485|Experimental|Chemotherapy and radiation|In those randomized to radiation arm with receive high dose radiation with Intensity Modulated Radiation Therapy in addition to systemic and concurrent chemotherapy. The gross tumor will comprise the high dose volume. The adjacent areas of suspected microscopic disease will form the low dose volume. When only external radiation is used the aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
2968571|NCT02773472|Experimental|Electroacupuncture Group|In addition to morphine, patients will receive 4 sessions of electroacupuncture after surgery over four days, with each session lasting 30 minutes.
2968572|NCT02773472|Other|Morphine Group|Neither electroacupuncture nor sham acupuncture will be given. Patient use morphine for analgesia.
2968573|NCT02773459|Experimental|Phase 1 part|to assess the maximal tolerated dose (MTD) of MEK162+Capecitabine combination
2968574|NCT02773459|Experimental|Expansion part|to assess the efficacy (PFS) of MEK162+Capecitabine combination
2968575|NCT02773446|Experimental|Cohort 1 group A|Volunteers will receive 8 logs of E. coli strain B7A after overnight fast
2968576|NCT02773446|Experimental|Cohort 1 group B|Volunteers will receive 9 logs of E. coli strain B7A after 90 minute fast
2968577|NCT02773446|Experimental|Cohort 1 group C|Volunteers will receive 9 logs of E. coli strain B7A after overnight fast
2968578|NCT02773446|Experimental|Cohort 1 group D|Volunteers will receive 10 logs of E. coli strain B7A after 90 minute fast
2968579|NCT02773446|Experimental|Cohort 2 group A|subjects from Cohort 1 who met primary endpoint will receive optimal regimen as determined by analysis after Cohort 1.
2968580|NCT02773446|Experimental|Cohort 2 group B|Naive subjects who will receive optimal regimen as determined by analysis after Cohort 1
2968581|NCT02773433|Experimental|PAV group|Using Proportional Assist Ventilation after failed Spontaneous Breathing Trial
2968582|NCT02773433|No Intervention|Control group|Using Volume Assist Control mode after failed SBT
2968583|NCT02773420|Experimental|HET application arm|Patients with grade I-II internal hemorrhoids will undergo HET application
2968586|NCT02773394||Group 1|Brazilian participants with Hepatitis C virus (HCV) chronic infection who are registered at the Brazilian reference centers and meet all the inclusion criteria and have sufficient information to identify the diagnosis of chronic HCV infection with identification of genotype.
2968587|NCT02773381|Experimental|Semaglutide 3 mg, 7 mg, 14 mg|
2968588|NCT02773381|Placebo Comparator|Placebo|
2968589|NCT02773368|Experimental|IDegLira|
2968590|NCT02773368|Active Comparator|IGlar|
2968591|NCT02773355||Saxenda®|
2968592|NCT02773342||Pathological findings in chest CT|
2968593|NCT02773329|Experimental|Intervention with game-based exercise|Subjects will be receiving sensor-based interactive exercise program (game-based exercise) intervention twice a week for 6 weeks.
2968594|NCT02773329|Active Comparator|Intervention without game-based exercise|Subjects will be receiving non-technology based foot and ankle exercise twice a week for 6 weeks
2968595|NCT02773316|Experimental|MR902 50/0.5 mg|MR902 50/0.5 mg PR tablets, single dose oral
2968596|NCT02773316|Experimental|MR902 200/2 mg|MR902 200/2 mg PR tablets, single dose oral
2968597|NCT02773316|Active Comparator|IR morphine sulphate 10 mg/5mL solution|IR morphine sulphate 10 mg/5mL solution, single dose oral
2968598|NCT02773303|Active Comparator|Active|Children receiving Mente Autism™ neurofeedback therapy to use at home for 40 minutes a day for 12 weeks
2968599|NCT02773303|Sham Comparator|Control|Children not receiving neurofeedback based therapy, but receiving the Sham therapy
2968600|NCT02773290|Experimental|Romiplostim|Weekly Subcutaneous (SC) administration
2968601|NCT02773277|Experimental|Single intervention arm|All patients will be assigned the intervention arm and will receive head-impulse testing before and in the days after skull base surgery.
2968602|NCT02773264||UltraSound Patients|All patients will undergo next to the clinical indicated conventional US-examination, US Elastography after informed consent. After completion of these three examinations, the participation in the study is completed.
2968603|NCT02773251|Experimental|hyaluronic acid-carboxymethylcellulose treatment group|the HA/CMC treatment group after laparoscopic pelvic surgery
2968604|NCT02773251|No Intervention|control group|the HA/CMC non-treatment group after laparoscopic pelvic surgery
2968605|NCT02773238|Experimental|Treatment|Patients undergo functional avoidance radiation therapy during weeks 1-3. Patients undergo fludeoxyglucose F-18 FDG PET/CT at baseline, 3 weeks, and 3 months post-radiation therapy and undergo technetium Tc-99m albumin aggregated (99mTc-MAA) and technetium Tc-99m sulfur colloid SPECT/CT radiation therapy at baseline and 3 months post-radiation therapy. Baseline PET/CT must be performed at University of Washington Medical Center/Seattle Cancer Care Alliance and be within one month of treatment start, therefore some patients may need to repeat a baseline PET/CT if their PET/CT is from an outside institution or > 1 month old. Patients not responding to treatment at 3 weeks, will receive an increased daily radiation therapy dosage.
2968606|NCT02773225|Experimental|Eltrombopag + Ciclosporin A|"Eltrombopag, 75 mg film tablets, starting dose: 2 tablets (150 mg per day), daily, per os~+ According to European guidelines CSA is administered orally with an initial daily dose of 5 mg/kg/day divided into two doses. Then dosage should be adjusted with the aim of a trough CSA blood level of 200‒400 ng/mL (using a polyclonal assay) or 150‒250 ng/mL (using a monoclonal assay)."
2968607|NCT02773225|Placebo Comparator|Placebo + Ciclosporin A|"Placebo for Eltrombopag 75 mg film tablets, 2 tablets, daily, per os~+ According to European guidelines CSA is administered orally with an initial daily dose of 5 mg/kg/day divided into two doses. Then dosage should be adjusted with the aim of a trough CSA blood level of 200‒400 ng/mL (using a polyclonal assay) or 150‒250 ng/mL (using a monoclonal assay)."
2968608|NCT02773212|Experimental|d-Amphetamine and Contingency Management|Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine with contingency management treatment for cocaine use disorder.
2968609|NCT02773212|Active Comparator|d-Amphetamine alone|Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine but will not receive contingency management treatment for cocaine use disorder.
2968610|NCT02773212|Active Comparator|Placebo and Contingency Management|Participants in this group will receive 4 weeks of of placebo treatment, paired with contingency management treatment for cocaine use disorder.
2968611|NCT02773199||Cohort 1- Morning Surgery|Patients' who are scheduled for surgery under spinal anesthesia with bupivacaine in morning hours (until 12pm) will be included in this cohort. Since all patients are ordered to stop oral ingestion by 12am at the day of the surgery, patients in this cohort will be exposed to a preoperative fasting for 8 hours
2968612|NCT02773199||Cohort 2- Afternoon Surgery|Patients' who are scheduled for surgery under spinal anesthesia with bupivacaine in afternoon hours (after 12pm) will be included in this cohort. Since all patients are ordered to stop oral ingestion by 12am at the day of the surgery, patients in this cohort will be exposed to a preoperative fasting for more than 12 hours
2968613|NCT02773173|Experimental|Individualized Pneumoperitoneum Pressure|In Individualized Pneumoperitoneum Pressure (IPP) group, measures to optimize and individualize intra-abdominal pressure (PIA) will be apply.
2968614|NCT02773173|Other|Standard Pneumoperitoneum Pressure|In Standard Pneumoperitoneum Pressure (SPP) group, a conventional operation without optimization measures and PIA preset to 12 mmHg will be conducted.
2968615|NCT02773160|Experimental|Sensor-based postural feedback|Subjects will receive visual feedback on a computer screen while practicing the motor control task. The feedback is based on information from from motion sensors that mointor the movements of the lumbar spine
2968616|NCT02773160|Experimental|Mirror Feedback|Subjects will receive feedback from a mirror while practicing the motor control task
2968617|NCT02773160|Active Comparator|control group|Subjects will receive no feedback while practicing the motor control task
2968618|NCT02773147|Experimental|Triobe|Cyanocobalamin 0,5 mg. Daily for 24 months. Folate 0,8 mg. Daily for 24 months. Pyridoxine 3,0 mg. Daily for 24 months.
2968619|NCT02773147|No Intervention|Control|
2968646|NCT02772965|Placebo Comparator|Sugar pill (placebo)|"Placebo for methotrexate, once weekly. Placebo for ondansetron, twice weekly, 1 hour prior to methotrexate placebo dose and the morning after methotrexate placebo dose.~Folic Acid (1 mg) daily"
2968647|NCT02772952|Other|Control Group|a control group whose intervention will be to review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
2968620|NCT02773134|Active Comparator|Brace Group|Patients in the brace group will be fitted by an orthotist postoperatively and will be instructed to wear a rigid molded Lumbosacral Orthosis (LSO) full time for 8 weeks except during hygiene and wound care followed by daytime wear for another 4 weeks. All patients will start wearing the brace 48 hours after the surgery following removal of the wound drain. All braces will be molded and fitted by the same experienced orthotist affiliated with the hospital. Self-compliance to brace wear will be noted every day for 3 months by each patient on a specific form.
2968621|NCT02773134|Experimental|Control Group|No brace prescription postoperatively. Patients in this group will be observed and results will be compared to the brace group.
2968622|NCT02773121|Experimental|Physical activity monitoring|"Participants will wear a physical activity sensor on the hip or waist with a belt. They will be instructed to increase their physical activity level to at least 150 min of moderate-intensity physical activity per week. They will be asked to follow guidelines in the Go4Life brochure, website, and/or videos by the National Institute on Aging. Participants will receive weekly phone calls to monitor their progress, to provide feedback, and to suggest example exercises."
2968623|NCT02773121|Active Comparator|Flexibility and balance|"Participants will wear a physical activity sensor on the hip or waist with a belt. They will be instructed to increase their balance and flexibility over the 12 week period of the intervention. They will be asked to follow guidelines in the Go4Life brochure, website, and/or videos by the National Institute on Aging. Participants will receive weekly phone calls to monitor their progress, to provide feedback, and to suggest example exercises."
2968624|NCT02773108||Hospitalized|Hospitalized psychiatric patients
2968625|NCT02773108||Daily hospital|
2968626|NCT02773108||Outpatients|
2968627|NCT02773095|Experimental|Intervention counties|In intervention counties, a Novartis Access portfolio of 15 medicines will be sold to local purchasers at a cost of 150 Kenyan Shillings (KES), around US$1.50, per monthly dose.
2968628|NCT02773095|No Intervention|Control counties|Control counties not exposed to the intervention.
2968629|NCT02773082|Experimental|Reclaim™ DBS Therapy|Procedure: Reclaim™ DBS Therapy The DBS lead is stereotactically introduced into the target in the brain (AIC) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region. This is performed by a neurosurgeon skilled in this technique, as the same procedure is routinely performed in patients with other diseases (using other brain targets).
2968630|NCT02773069|Experimental|Weight loss program|Participants will attend a 12 session weight loss program accompanied by maintenance support delivered by a church. Program will include peer education, telenutrition counseling and mobile health feedback.
2968631|NCT02773056|Active Comparator|Socket 1 (Ischial Ramus Containment)|This arm included unilateral transfemoral amputees who were assessed while using the Ischial Ramus Containment socket.
2968632|NCT02773056|Active Comparator|Socket 2 (Dynamic Socket IRC)|This arm included unilateral transfemoral amputees who were assessed while using the Dynamic Socket Ischial Ramus Containment socket.
2968633|NCT02773056|Active Comparator|Socket 3 (Sub-Ischial Interface)|This arm included unilateral transfemoral amputees who were assessed while using the Sub-Ischial Interface socket.
2968634|NCT02773043|Other|non invasive imaging technique|
2968635|NCT02773030|Experimental|Cohort A: CC-220 Monotherapy - Part 1|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
2968636|NCT02773030|Experimental|Cohort B: CC-220 in combination with Dexamethasone - Part1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.~For subjects ≤ 75 years old, oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, DEX will be administered at 20 mg on Days 1, 8,15, and 22 of each 28-day cycle. Subjects who surpass the age of 75 years while on treatment may be switched to the 20 mg QD dosage based on the investigator's best judgment."
2968637|NCT02773030|Experimental|Cohort C: CC-220 Monotherapy - Part 2|Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle
2968638|NCT02773030|Experimental|Cohort D: CC-220 in combination with Dexamethasone - Part2|"Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle~Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle. Subjects who surpass the age of 75 years while on treatment may be switched to the 20 mg QD dosage based on the Investigator's best judgment."
2968639|NCT02773017|Experimental|Youth female group|patients in the Youth female group, aged 20~35, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
2968640|NCT02773017|Experimental|Middle-aged female group|patients in the Middle-aged female group, aged 40~60, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
2968641|NCT02773017|Experimental|Elderly female group|Patient in the elderly female group, aged 65~79, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
2968642|NCT02773004|Other|EndoPredict (EP)clin testing|Once the patient is registered, the most representative block of the primary tumor from surgery (or 10 paraffin slides) are sent to the central analysis platform for EP clin testing. The EPclin method is based on analysis of tumour genes in combination with the classical prognostic factors of nodal status and tumour size.
2968643|NCT02772991|Experimental|Cases|All patients will be submmited to troponin measurements and CCTA. If CCTA shows coronary stenosis ≥ 50%, patient will initiate the ACS treatment and be hospitalized to have coronary cineangiography. If CCTA shows lesions < 50%, the patient will be discharged and monitored for 30 days. A second sampling of the troponin will be obtained from all patients three hours after the first collection in order to evaluate for an increase/decrease of troponin.
2968644|NCT02772978|Experimental|functional MRI arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
2968645|NCT02772965|Experimental|Methotrexate|"Methotrexate (10, 12.5, or 15 mg), once weekly. Weight-based dosing. Ondansetron (4 mg), twice weekly, 1 hour prior to methotrexate dose and the morning after methotrexate dose.~Folic Acid (1 mg) daily"
2968678|NCT02772770||Operative: Physeal sparing by Micheli/Kocher Technique|
2968648|NCT02772952|Experimental|Experimental Group|Experimental group whose intervention will be a Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program.
2968649|NCT02772939|Experimental|Renal Denervation|Renal denervation for therapy resistant arterial hypertension
2968650|NCT02772926|Placebo Comparator|Placebo|450 g per pill, 2 pills per day to get 900 mg per day
2968651|NCT02772926|Active Comparator|Benfotiamine|Benfotiamine (S-Benzoylthiamine O-monophosphate) 450 mg per pill, 2 pills per day to get 900 mg per day
2968652|NCT02772913||acute mesenteric ischemia|patients with abdominal pain and acute mesenteric ischemia
2968653|NCT02772913||non-acute mesenteric ischemia|patients with abdominal pain without mesenteric ischemia
2968654|NCT02772900|Active Comparator|Beetroot gel (dietary nitrate)|Beetroot-based nutritional gel containing approximately 10.0 mmol of nitrate per dose
2968655|NCT02772900|Active Comparator|Placebo gel (nitrate-depleted)|Nutritional gel nitrate-depleted
2968656|NCT02772887|Experimental|Citrulline|Oral L-citrulline, 3 grams once per day for 3 weeks.
2968657|NCT02772887|Placebo Comparator|Placebo|Placebo, 3 grams once per day for 3 weeks.
2968658|NCT02772874||Urge-predominant|All subjects who report fecal incontinence that is primarily urge-predominant will undergo self-administered questionnaires, pelvic examination, endoanal ultrasound, and anorectal manometry.
2968659|NCT02772874||Passive-predominant|All subjects who report fecal incontinence that is primarily passive-predominant will undergo self-administered questionnaires, pelvic examination, endoanal ultrasound, and anorectal manometry.
2968660|NCT02772861|Experimental|Citrulline|Citrulline is a non-protein amino acid that is present in substantial amounts in watermelon (Citrullus vulgaris), with a mean content of 2.1 mg/g fresh weight, ranging from 0.5 to 3.6 mg/g according to variety. The oral dose can reach 20 g, which was administered orally in the present study in one single dose, followed by a washout period of one week Amino Acid Supplement - One dose
2968661|NCT02772861|Experimental|Glutamine|"L-glutamine is a protein amino acid found in proteins of all life forms. It is classified as a semi-essential or conditionally essential amino acid. This means that under normal circumstances the body can synthesize sufficient l-glutamine to meet physiological demands. However, there are conditions where the body cannot do so. Recently, l-glutamine has come to be regarded as one of the most important of the amino acids when the body is subjected to such metabolic stress situations as trauma (including surgical trauma), cancer, sepsis and burns. In the present study, glutamine was administered orally in one single dose of 20 g, followed by a washout period of one week.~Amino Acid Supplement - One dose"
2968662|NCT02772861|Experimental|Arginine|"Arginine was administered orally in 20 g for one single dose, followed by a washout period of 1 week.~Amino Acid Supplement - One dose"
2968663|NCT02772861|Experimental|3-Methyl-Histidine|"This amino acid is made by methylation of the actin and myosin peptide chains in the muscle. Metabolism after intravenous administration of L-3-methylhistidine involves excretion in the urine of 75% of the administered dose in 24 h and 95% in 48 h.~3-Methyl-Histidine was administered orally in 120 mg for one single dose, followed by a washout period of 1 week."
2968664|NCT02772861|Placebo Comparator|Placebo|Dextrose (glucose) was used in a dose of 20 g in this study.
2968665|NCT02772835|Active Comparator|nHFOV|Starting treatment mode: nHFOV with Medin-cno. Targeted oxygen saturation: 87-94%. Four 1 h study blocks, alternating from the initial mode to the alternate mode twice. All the data will be recorded at 1-min intervals. The following data will be recorded: tcPCO2, tcPO2, heart rate, respiratory rate, SaO2, Silverman score, cer-rSO2, ren-rSO2. Blood pressure will be taken 30 minutes after the beginning of each treatment block. At the beginning of the first period a BGA will be performed in order to test the reliability of the TcPCO2 data. A second capillary BGA will be performed at the end of second period.
2968666|NCT02772835|Active Comparator|nCPAP|Starting treatment mode: nCPAP with Medin-cno. Targeted oxygen saturation of 87-94%. Four 1 h study blocks, alternating from the initial mode to the alternate mode twice. All the data will be recorded at 1-min intervals. The following data will be recorded: tcPCO2, tcPO2, heart rate, respiratory rate, SaO2, Silverman score, cer-rSO2, ren-rSO2. Blood pressure will be taken 30 minutes after the beginning of each treatment block. At the be-ginning of the first period a BGA will be performed in order to test the reliability of the TcPCO2 data. A se-cond capillary BGA will be performed at the end of second period.
2968667|NCT02772822|Experimental|Experimental|SCT400 plus CHOP, six cycles SCT400: 375 mg/m2, IV, day 1 of each cycle Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle Doxorubicin: 50 mg/m2, IV, day 2 of each cycle Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle Prednisone: 100 mg, po, day 2 to day 6 of each cycle
2968668|NCT02772822|Active Comparator|Active Comparator|Rituximab plus CHOP, six cycles Rituximab: 375 mg/m2, IV, day 1 of each cycle Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle Doxorubicin: 50 mg/m2, IV, day 2 of each cycle Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle Prednisone: 100 mg, po, day 2 to day 6 of each cycle
2968669|NCT02772809|Other|Haptic Robot Therapy with Games|Subjects with low and moderate motor deficits will 1) complete exercises with 2 commercial (joystick and wheel) and the Theradrive haptic robot after pre assessment 2) then experience 12 therapy sessions on the Theradrive haptic robot with Adaptive Feedback. 3) Assessments pre and post therapy.
2968670|NCT02772796|Experimental|SENS-218|2 x 10 mg administered once on Day 1.
2968671|NCT02772783|Experimental|high GI meal, euglycemic insulin clamp|A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia.This condition results in euglycemia with high insulin levels.
2968672|NCT02772783|Experimental|high GI meal, fixed insulin infusion|A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously at a rate previously established to maintain euglycemia after a low glycemic index meal. This condition results in moderate hyperglycemia with low insulin levels.
2968673|NCT02772783|Active Comparator|low GI meal, euglycemic insulin clamp|A nutritional shake with low GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia. This condition results in euglycemia with low insulin levels.
2968674|NCT02772770||Non Operative: Rehabilitation, Bracing, Activity Restriction|
2968675|NCT02772770||Operative: Transphyseal|
2968676|NCT02772770||Operative: Partial Transphyseal|
2968677|NCT02772770||Operative: Physeal sparing by Anderson Technique|
2968679|NCT02772757|Active Comparator|Standard of Care group|Standard of Care group will receive the standard, face-to-face hearing aid fitting and verification approach
2968680|NCT02772757|Experimental|Average RECD group|This group will have their hearing aid fitting via the coupler using average RECD values during the fitting
2968681|NCT02772757|Experimental|Measured RECD group|This group will have their hearing aid fitting via the coupler using measured RECD values during the fitting
2968682|NCT02772744||Group 1: Easy to treat group|"Treatment naïve~Total serum bilirubin ≤ 1.2 mg/dl~Serum albumin ≥ 3.5 g/dl~International normalized ratio ≤ 1.2~Platelet count ≥ 150000 mm3~This group will be receiving Sofosbuvir + daclatasvir for 12 weeks."
2968683|NCT02772744||Group 2: Difficult to treat group|"Peg interferon treatment experienced.~Total serum bilirubin ≥ 1.2 mg/dl~Serum albumin ≤ 3.5 g/dl~International normalized ratio ≥ 1.2~Platelet count ≤ 150000 mm3~This group will be receiving Sofosbuvir + daclatasvir + ribavirin for 12 weeks."
2968684|NCT02772744||Group 3: Sofosbuvir resistant cases|This is the group of patients who failed in previous Sofosbuvir treatment regiment. This group will be receiving Sofosbuvir + daclatasvir + ribavirin for 24 weeks.
2968685|NCT02772731|Experimental|Shave Margin|After partial mastectomy, patients will be subject to intraoperative randomization to the shave margin group where additional tissue will be resected.
2968686|NCT02772731|Active Comparator|No Shave Margin|After partial mastectomy, patients will be subject to intraoperative randomization to the no shave margin group, where after initial surgery, no further tissue will be removed.
2968687|NCT02772718|Experimental|Part 1 - single dose|Cohorts A, B, and C
2968688|NCT02772718|Experimental|Part 2 - multiple doses|Cohort 1
2968689|NCT02772705||Hyperthyroidism|Those with Grave's Disease(GD,Hyperthyroidism),with lower TSH, and higher FT3, FT4.
2968690|NCT02772705||Health Humans|Those humans who are healthy, without GD, without any treatment, with normal TSH, FT3, FT4.
2968691|NCT02772692|Experimental|Squatting pan|Defecation using a squatting pan
2968692|NCT02772692|No Intervention|Toilet|defecation using a standard-sized toilet
2968693|NCT02772679|Experimental|PolyTregs+IL-2|Patients with type 1 diabetes mellitus will receive ex vivo expanded human autologous polyclonal regulatory T cells plus IL-2
2968694|NCT02772666|Experimental|O-Glass|All study participants who were diagnosed Relative Afferent Pupillary defect(RAPD) positive according to expert specialist investigations, were enrolled in this study. They were all examined with new device named O-Glass.
2968695|NCT02772666|Active Comparator|Swinging Flash light Test|All study participants who were diagnosed Relative Afferent Pupillary defect(RAPD) positive according to expert specialist investigations were also examined with manual diagnostic method, Swinging Flash light Test(SFT). The standard and most common method for Marcus-Gunn test is Swinging Flashlight Test (SFT), which needs a dark room, and the patient will be asked to look toward a distant object, so the pupils are not focused. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
2968696|NCT02772653||Severe trauma patients|"No interventions are done. It's a prospective and descriptive observational study where different markers are analyzed:~Blood Lactate levels~Blood Base Excess levels~Blood B-type Natriuretic Peptide levels~Blood Thromboelastometry (ROTEM) alterations~Near-infrared spectroscopy alterations~Sublingual videomicroscopy alterations~All these markers are analyzed at the 1rst, 8th and 24th hour from hospital admission."
2968697|NCT02772640|Active Comparator|Arm I: R+E morning->evening|Rosuvastatin and Ezetimibe morning or evening administration: Rosuvastatin (R) plus Ezetimibe (E) administration in the morning (8:00) for 6 weeks. After 6 weeks - intervention - change of the timing of study drug administration to the evening hours (20:00).
2968698|NCT02772640|Active Comparator|ARM II: R+E evening->morning|Rosuvastatin and Ezetimibe evening or morning administration: Rosuvastatin (R) plus Ezetimibe (E) administration in the evening (20:00) for 6 weeks. After 6 weeks - intervention - change of the timing of study drug administration to the morning hours (8:00).
2968699|NCT02772627|Experimental|Nebicapone 100 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
2968700|NCT02772627|Experimental|Nebicapone 200 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
2968701|NCT02772627|Experimental|Nebicapone 300 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
2968702|NCT02772614|Experimental|Nebicapone (200 mg)|"Each subject was to receive one single dose of 2.5 MBq [14C]-labelled BIA 3-202 (200 mg) together with a total of 250 mL non-carbonated water.~The study drug was given after an overnight fast of at least 10 hours after the in-house stay. During waking hours on Day 1, subjects had to have a fluid intake of at least 150 mL per hour starting 1 hour before study drug administration."
2968703|NCT02772601|Experimental|All patients|
2968704|NCT02772588|Experimental|patients with prostate cancer|Eligible patients will receive a total of 6 months of leuprolide, abiraterone, and ARN-509 to begin three months prior to RT and continuing until approximately 3 months post-RT. Patients will be assessed every 4 weeks (±1 week) (a cycle = 28 days) throughout their treatment with the study drugs, and at least once during RT.
2968738|NCT02772276|Experimental|Cohort 2|MB-102 and iohexol administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-4), and fluorescence measured by the QuantumLeap ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. MB-102 will be administered by IV injection over 30 seconds, followed by a 10 mL saline flush IV over 30 seconds. Iohexol will be administered to each subject following the MB-102 administration by IV injection over 30 seconds, followed by a 10 mL saline flush IV over 30 seconds.
2968705|NCT02772575||patients with primary liver or liver metastases|A biopsy will be performed as standard of care either at time of Hepatic trans-arterial embolization (TAE) or within 4 months prior to TAE. TAE is a standard of care procedure. Within 8 weeks of TAE, patient will have a clinic visit which will include medical history, physical examination, vital signs, EKG (if one is not available), and ECOG assessment. Additionally a dedicated liver CT or MR will be obtained as well as standard of care labs. IMPACT blood test will be performed at the time of any of the standard of care labs. As IMPACT platform at MSKCC continually evolves to include more genes, we will use the platform available at the time of initiation of the protocol, therefore all patients will be subjected to the same platform. RNA-seq has been demonstrated to be superior in detecting low abundance transcripts, demonstrating a broader dynamic range, and detecting different isoforms and genetic variants.
2968706|NCT02772562|Experimental|PROSTVAC-V/F|
2968707|NCT02772536|Other|Visual Stimulus Condition Set|"In this single arm study all participants are subject to a set of three visual stimulus conditions.~These are: Low ambient light; Self selected tinted light; White light"
2968708|NCT02772523|Other|Intervention|
2968709|NCT02772510|Experimental|Smart glove system with functional electrical stimulation|game-based virtual reality rehabilitation combined with functional electrical stimulation for upper extremity
2968710|NCT02772510|Active Comparator|Functional electrical stimulation|functional electrical stimulation on upper extremity
2968711|NCT02772497|Experimental|Ziv aflibercept|Intravitreal ziv aflibercept 1.25 mg (0.05ml) every 4 weeks
2968712|NCT02772484|Experimental|HS-1000 recording|The recording session should be performed in a quiet environment with no disturbance to the patient for a total of up to 60 minutes.
2968713|NCT02772471|Experimental|HS-1000 recording|ICP monitoring will be done in parallel for both HS-1000 and invasive ICP monitoring. HS-1000 ICP monitoring intervals will last at least 30 minutes, continuously depending on the patient's clinical condition.
2968714|NCT02772458|Experimental|Crohn's Disease|Active Crohn's Disease
2968715|NCT02772458|Experimental|Healthy|Healthy volunteers
2968716|NCT02772445|Experimental|STROKE-CARE Intervention|In STROKE-CARE, caregivers will learn a problem-solving strategy. Participants will receive approximately 10 sessions by an occupational therapist in the home over a 5 week process.
2968717|NCT02772432|Experimental|3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
2968718|NCT02772432|Active Comparator|Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities.
2968719|NCT02772419|Experimental|benralizumab A|Subcutaneous (SC) administration
2968720|NCT02772419|Experimental|benralizumab B|SC administration
2968721|NCT02772419|Placebo Comparator|Placebo|Placebo SC administration
2968722|NCT02772406|Experimental|Experimental group|(With LCI endoscopy and 1 month later with white light endoscopy) The patients will be evaluated by Linked Color Imaging and 1 month later evaluated by White Light endoscopy
2968723|NCT02772406|Active Comparator|Control group|(With white light endoscopy and 1 month later with LCI endoscopy) The patients will be evaluated by White Light endoscopy and 1 month later evaluated by Linked Color Imaging
2968724|NCT02772380|Experimental|VT/ VF induction and defibrillation|Ventricular Tachycardia and Ventricular Fibrillation (VT/VF) induction and termination through use of a defibrillator, will be carried out as the intervention in all subjects undergoing study procedures.
2968725|NCT02772367||Breast Cancer Patients|In study participants undergoing breast reconstruction surgery prior to breast radiation therapy, we will obtain skin tissue at the time of reconstruction surgery from the surgical specimen.
2968726|NCT02772354|Experimental|Ablation|Standard radiosurgery ablation of premature ventricular complexes using navigation system.
2968727|NCT02772354|Active Comparator|Control|Antiarrhythmic therapy of premature ventricular complexes according to the guidlines
2968728|NCT02772341|Active Comparator|Salt room with halogenerator|Asthmatic patients sitting in a salt room with salt aerosol produced by a halogenerator.
2968729|NCT02772341|Placebo Comparator|Salt room without halogenerator|Asthmatic patients sitting in a salt room without salt aerosol
2968730|NCT02772328|Experimental|Peer Mentor|Individuals in this arm will be trained in communication skills to promote HIV and HCV testing to their social network members, linkage to care and risk reduction behaviors.
2968731|NCT02772328|No Intervention|Neighborhood Matters|Participants in this arm will view a 15-20 minute video on issues in neighborhoods such as crime and violence, restoring communities and incarceration and discuss their reactions and thoughts.
2968732|NCT02772315||Hypertensive patients|Diagnostic procedures in patients with hypertension applying omics results
2968733|NCT02772302|Experimental|mindBEAGLE|Application of bedside, EEG-based mindBEAGLE Brain-Computer Interface
2968734|NCT02772289|Experimental|Mesenchymal Stem Cells low-dose group|Target dose of 3 million Mesenchymal Stem Cells
2968735|NCT02772289|Experimental|Mesenchymal Stem Cells high-dose group|Target dose of 6 million Mesenchymal Stem Cells
2968736|NCT02772289|Placebo Comparator|Placebo|Placebo without Mesenchyme Stem Cells
2968737|NCT02772276|Experimental|Cohort 1|MB-102 and iohexol administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the QuantumLeap ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. In order to determine the optimal dose of MB-102, Cohort 1 subjects may receive different doses. The maximum dose of 4 µmol/kg has already been tested in 8 subjects in a prior clinical study (Pilot 1B) and found to be safe and well tolerated. Coefficient of Variation (CV) will be used as the criterion for selecting dose. The initial dose will be 4 µmol/kg, and the target CV will be 5%. MB-102 will be administered by IV injection over 30 seconds, followed by a 10 mL saline flush IV over 30 seconds. Iohexol will be administered to each subject following the MB-102 administration by IV injection over 30 seconds, followed by a 10 mL saline flush IV over 30 seconds.
2968831|NCT02771665||Breast cancer women without recurrences|Breast cancer women without recurrences
2968832|NCT02771652|Active Comparator|e-training intervention|Resistance and endurance training
2968833|NCT02771652|Other|Control|no exercise
2968739|NCT02772276|Experimental|Cohort 3|MB-102 and iohexol administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Radiance ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. MB-102 will be administered by IV injection over 30 seconds, followed by a 10 mL saline flush IV over 30 seconds. Iohexol will be administered to each subject following the MB-102 administration by IV injection over 30 seconds, followed by a 10 mL saline flush IV over 30 seconds.
2968740|NCT02772276|Experimental|Cohort 4|MB-102 and iohexol administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-4), and fluorescence measured by the Radiance ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. MB-102 will be administered by IV injection over 30 seconds, followed by a 10 mL saline flush IV over 30 seconds. Iohexol will be administered to each subject following the MB-102 administration by IV injection over 30 seconds, followed by a 10 mL saline flush IV over 30 seconds.
2968741|NCT02772276|Experimental|Cohort 5|MB-102 and iohexol administered to participants with chronic kidney disease (CKD) Stage 5, and fluorescence measured by the Radiance ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. MB-102 will be administered by IV injection over 30 seconds, followed by a 10 mL saline flush IV over 30 seconds. Iohexol will be administered to each subject following the MB-102 administration by IV injection over 30 seconds, followed by a 10 mL saline flush IV over 30 seconds.
2968742|NCT02772263|Experimental|CHAP-EMS Intervention|Participants guided through a 15-20 minute defined risk assessment by a trained paramedic. Risk factors assessed were those related to cardiovascular and diabetes risk (blood pressure, diabetes-risk status, lifestyle factors), and potential for falls. Based on these, the paramedic provided education and developed an individualized action plan directing participants to use available community resources to assist them in addressing their risk factors. They were advised to return to CHAP-EMS sessions regularly for BP monitoring and follow-up. Each participant's information was faxed to his/her family physician once a month.
2968743|NCT02772250|Active Comparator|telephone re-education(TRE)|Subjects who are randomized into this group receive regular instructions at the time of their appointment to discuss colonoscopy (a nurse provides education of 5 minutes and meanwhilet sent a bookle to the patient) and a TRE which was conducted by a investigator at 15:00-17:00 on the day before colonoscopy.
2968744|NCT02772250|Experimental|face-to-face re-education (FFRE)|Subjects who are randomized into this group receive regular instructions on the day of their appointment to discuss colonoscopy and also a FFRE which was conducted by a investigator on the same-day of procedure at hospital.
2968745|NCT02772237|Active Comparator|Treatment group|Riboflavin 400mg daily
2968746|NCT02772237|Placebo Comparator|Placebo group|Placebo
2968747|NCT02772224|Experimental|Drug eluting balloon angioplasty|Paclitaxel coated balloon angioplasty
2968748|NCT02772224|Active Comparator|Conventional balloon angioplasty|Conventional balloon angioplasty
2968749|NCT02772211|Experimental|D-cycloserine|Participants in this group would receive 6 infusions of ketamine. Participants who demonstrate symptoms reduction following ketamine infusions would receive oral D-cycloserine, titrated slowly up to 1000mg/d over the next 8 weeks.
2968750|NCT02772211|Placebo Comparator|Placebo|Participants in this group would receive 6 infusions of ketamine. Participants who demonstrate symptoms reduction following ketamine infusions would receive oral Placebo pills, titrated slowly up to 1000mg/d over the next 8 weeks.
2968751|NCT02772198|Experimental|Single Arm|All patients will be treated on this single arm
2968752|NCT02772185|Experimental|active tDCS plus real CT|Participants will receive active transcranial direct current stimulation and real cognitive training.
2968753|NCT02772185|Experimental|sham tDCS plus real CT|Participants will receive sham transcranial direct current stimulation and real cognitive training.
2968754|NCT02772185|Experimental|active tDCS plus placebo CT|Participants will receive active transcranial direct current stimulation and placebo cognitive training.
2968755|NCT02772185|Placebo Comparator|sham tDCS plus placebo CT|Participants will receive sham transcranial direct current stimulation and placebo cognitive training.
2968756|NCT02772172|Active Comparator|GuideMia surgical template|A radiographic guide is prepared before CT/CBCT scan. The CT/CBCT scan DICOM ﬁles are loaded in GuideMia program and converted into 3D computer images. A surgical template is fabricated through this virtual planning.
2968757|NCT02772172|Active Comparator|Control surgical template|A radiographic guide is prepared before CT/CBCT scan. The CT/CBCT scan DICOM ﬁles are loaded in control program and converted into 3D computer images. A surgical template is fabricated through this virtual planning.
2968758|NCT02772159|Experimental|Study Population|One dose each of treatments A: [14C] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: [14C] TD-4208 200 μg oral solution administered in a fasted state.
2968759|NCT02772146|Experimental|Device: CLS UF|The purpose of CLS UF is ultrafiltration and drain of excess fluid in patients with congestive heart failure. The function of the device is to extra corporeally recirculate profiled glucose based PD fluid in a system and maintain glucose levels by adding extra glucose, to an adjustable and constant level, in order to maintain a stable ultrafiltration.
2968760|NCT02772133||STEMI patients|
2968761|NCT02772133||Healthy subjects|
2968762|NCT02772120|Active Comparator|Vaginal progesterone gel (Crinone® 8%)|Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
2968763|NCT02772120|Active Comparator|Intramuscular Progesterone|Progesterone—25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
2968764|NCT02772107|Experimental|BSC group|Patients in the study will receive the following for the duration of the study:First-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cycles of therapy for the first-line chemotherapy. Radiotherapy was allowed. Follow-up until disease progression.
2968834|NCT02771639||Femoral neck fractures|Patients admitted to Sundsvall hospital for a displaced femoral neck fracture and treated with a hip arthroplasty
2968765|NCT02772107|Experimental|TMZ group|"Patients will receive platinum-based first-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cyclesfor the first-line chemotherapy. After first-line treatment, temozolomide will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.~Re-staging will be performed every 2 cycles (every 8 weeks) during the study, radiotherapy was allowed."
2968766|NCT02772094|Experimental|Single arm, open-label|"Experimental:~ADCTA-G total 10 doses, each dose (30+/-5 millions autologous dendritic cells plus 6+/-0.5 millions 100Gy-irradiated short-term cultured autologous GBM tumor cells) divided in 2 halves for subcutaneous injection into both axillar areas, in a course of 6 months (sequential series of weekly injections 4 times, bi-weekly injections twice; then monthly injections 4 times.~Experimental: ADCTA-G total 10 doses, each dose (similar fore-mentioned numbers of 5:1 ratio of autologous dendritic cells and irradiated short-term cultured autologous GBM tumor cells) divided into 2 injections administered subcutaneously in both axillar areas, in a course of 8 months (sequential series of bi-weekly injections 4 times, then monthly injections 6 times)."
2968767|NCT02772081|Experimental|Curosurf LISA|Single dose of poractant alfa 200 mg/kg via brief catheterization of the trachea with a thin catheter (CHF 6440) in neonates with RDS
2968768|NCT02772081|Active Comparator|Curosurf Endotracheal Tube|Single dose of poractant alfa 200 mg/kg via the conventional intubation with endotracheal tube in neonates with RDS
2968769|NCT02772068|Active Comparator|Healthy Senior Control|Fifteen healthy senior subjects will perform light exercise at a fixed heart rate of 100 beats per minute. Subjects will then be given either placebo infusion (normal saline) or Istaroxime infusion for one hour. Subjects will be blinded to which infusion they are receiving. Subjects will then repeat light exercise at a fixed heart rate of 100 beats per minute. Primary outcome is changes in cardiac filling pressures during exercise.
2968770|NCT02772068|Experimental|Heart failure patients|Fifteen HFpEF subjects will perform light exercise at a fixed heart rate of 100 beats per minute. Subjects will then be given either placebo infusion (normal saline) or Istaroxime infusion for one hour. Subjects will be blinded to which infusion they are receiving. Subjects will then repeat light exercise at a fixed heart rate of 100 beats per minute. Primary outcome is changes in cardiac filling pressures during exercise.
2968771|NCT02772055|Experimental|moxibustion group|Conventional moxibustion treatment for knee osteoarthritis participants.12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
2968772|NCT02772055|Experimental|smoke-free moxibustion group|Conventional moxibustion treatment for knee osteoarthritis participants and have a purification device at the top of the moxibustion to remove the moxa smoke.12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
2968773|NCT02772042|Experimental|Intervention Group|Investigators will performed traction manipulation of those articulations of upper cervical spine with indication for this treatment. Before manipulation soft tissue techniques will be applied in order to prepare the joint. After manipulation the patient rest in supine position. The intervention will have a duration of 10 minutes.
2968774|NCT02772042|Other|Control Group|The patient of the control group maintain the supine position for 10 minutes.
2968775|NCT02772029|Experimental|Apatinib Mesylate Tablets|Apatinib (Apatinib Mesylate Tablets) 750 mg is administered orally daily, until disease progression or intolerable toxicity.
2968776|NCT02772016|Experimental|Intervention group|Patients in the treatment group received daily 15 g oral Colla corii asini(Shandong Dong-E E-Jiao Co., Ltd) in powder form for 4 consecutive weeks. The dosage was adjusted to 10 g per day for 6 consecutive weeks if patients encounter any of the following side effects: swollen gums, dry or sore throat, ulcers in oral cavity.
2968777|NCT02772016|No Intervention|Control group|Patients in control groups do not receive any intervention.
2968778|NCT02772003|Experimental|Treatment (INO-8000, INO-9012, EP)|Patients receive INO-8000 IM and DNA plasmid encoding interleukin-12 INO-9012 IM (dose levels 2-4) followed by EP at day 0 and at weeks 4, 12, and 24.
2968779|NCT02771990|Sham Comparator|sham tDCS|10 sessions sham transcranial direct current stimulation (tDCS)
2968780|NCT02771990|Experimental|active tDCS|10 sessions active transcranial direct current stimulation (tDCS)
2968781|NCT02771977|No Intervention|Usual Care|No alert will be fired.
2968782|NCT02771977|Experimental|Generic Alert|A generic alert, informing healthcare providers about the presence of AKI, but without specific drug-information will be fired.
2968783|NCT02771977|Experimental|Drug-specific alert|A drug-specific AKI alert, including information about the drug of interest as well as the presence of AKI will be fired.
2968784|NCT02771964||All patients|All patients receive both types of quality of life assessment, thus serving as their own controls.
2968785|NCT02771951|Experimental|Special Intervention|Study participants randomized to receive Special Intervention receive a series of 7 group classes taught by trained clinic health educators; a series of phone calls; clinical visits with a mid-level provider; and a series of 6 booster group classes over 1 year.
2968786|NCT02771951|Placebo Comparator|Usual Care|Study participants randomized to receive Usual Care receive up to 2 visits with a usual care health educator over 1 year.
2968787|NCT02771938|Experimental|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
2968788|NCT02771925|Experimental|gabapentin|Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2g/day divided in two doses for 24 weeks All patient will receive standard of care treatment
2968789|NCT02771925|Placebo Comparator|Placebo|Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2g/day divided in two doses for 24 weeks All patient will receive standard of care treatment
2968790|NCT02771912|Experimental|Propofol|"Infusion containing Propofol lipuro® 2% at a concentration of 2 mg/ml (100 ml of 5% glucose at which is removed 20 ml replaced with 20 ml of Propofol lipuro® 2 %).~Self administration of propofol via patient-controlled sedation pump (ambIT pump) : bolus of 0.125 ml/kg of the solution (0.25 mg/kg propofol) with a programmed lock-out period of 3 minutes.~Maximal dose of propofol : 1,25 mg/kg corresponding to 5mg/kg/h."
2968974|NCT02770664|Placebo Comparator|Placebo|
2968791|NCT02771912|Placebo Comparator|Intralipid|"Infusion containing Intralipid® (100 ml of 5% glucose at which is removed 20 ml replaced with 20 ml of Intralipid® 20%) to obtain an identical aspect to that of propofol infusion.~Self administration via patient-controlled sedation pump (ambIT pump) : bolus of 0.125 ml/kg of the solution with a programmed lock-out period of 3 minutes."
2968792|NCT02771899|Experimental|EOS + sterEOS software in adults|Participants will receive standard of care (EOS) - 2D planning with 3D modeling.
2968793|NCT02771899|Active Comparator|EOS in adults|Participants will receive standard of care (EOS) - 2D planning performed with current practice.
2968794|NCT02771899|Experimental|EOS + sterEOS software in children|Participants will receive standard of care (EOS) - 2D planning with 3D modeling.
2968795|NCT02771899|Active Comparator|EOS in children|Participants will receive standard of care (EOS) - 2D planning performed with current practice.
2968796|NCT02771886|Active Comparator|2-week intervention group|"The Surf the Urge intervention will be provided to the participant during his or her 2nd week in the study. The duration of the study will be 6 weeks."
2968797|NCT02771886|Active Comparator|4-week intervention group|"The Surf the Urge intervention will be provided to the participant during his or her 4th week in the study. The duration of the study will be 6 weeks."
2968798|NCT02771873|No Intervention|Usual care|Screening for CVD risk factors plus one time education regarding management of risk factors will be provided to all family members.
2968799|NCT02771873|Experimental|Life style Intervention and care coordination|Integrated cardiovascular disease risk management.
2968800|NCT02771860|Active Comparator|Experimental: denosumab|50 patients will be enrolled in this group for a total treatment duration of 24 months (96 weeks): 48 weeks denosumab 60mg sc every 12 weeks followed by a 48-weeks open label phase denosumab 60mg sc every 12 weeks. Calcium and vit D supplementation will be installed at baseline.
2968801|NCT02771860|Placebo Comparator|Comparator|"50 patients will be enrolled in this group for a total treatment duration of 24 months (96 weeks): 48 weeks placebo sc every 12 weeks followed by a 48-weeks open label phase denosumab 60mg sc every 12 weeks.~Calcium and vit D supplementation will be installed at baseline"
2968802|NCT02771834||Experimental|women with osteoporosis
2968803|NCT02771834||Control|women without osteoporosis
2968804|NCT02771821|Experimental|Group Intervention|Individual routine consultation with the Family Health Unit team and participation in operative groups based on methodology of problematization
2968805|NCT02771821|No Intervention|Control Group|Individual routine consultation with the Family Health Unit team
2968806|NCT02771808||diabetic patients|obtain biomarker samples from diabetic patients and examine for 1-1 & 1-2 & 2-2 haptoglobin genotype
2968807|NCT02771795|Active Comparator|Herceptin (trastuzumab)|Intravenous administration
2968808|NCT02771795|Experimental|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
2968809|NCT02771782|Experimental|BCG|Subjects are vaccinated with BCG vaccine (SSI) alone, 0,1ml intradermal
2968810|NCT02771782|Experimental|TDaP-IPV|Subjects are vaccinated with TDaP-IPV vaccine (Boostrix Polio) vaccine alone, 0,5ml intramuscular
2968811|NCT02771782|Experimental|BCG+TDaP-IPV|Subjects are vaccinated with BCG vaccine (SSI) (0.1ml intradermal) and TDaP-IPV vaccine Boostrix Polio (0.5ml intramuscular) simultaneously
2968812|NCT02771756|Experimental|test group|Zhen qishen capsule (2 capsules, Bid) and Oral Supplement of Yuyikang (50g, Bid), a total of 150 people, are used for 42 days continuously.
2968813|NCT02771756|Placebo Comparator|placebo group|Zhen qishen capsule placebo (2 capsules, Bid) and Oral Supplement of Yuyikang placebo (50g,Bid), a total of 150 people, are used for 42 days continuously.
2968814|NCT02771743|Experimental|High risk neuroblastoma|"Nine cycles of induction chemotherapy with cisplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen~Upfront surgery or surgery after 6 cycles of chemotherapy~Peripheral stem cell mobilization after 7 cycles of chemotherapy~Tandem high dose chemotherapy with autologous stem cell transplantation (Tandem HDCT/auto-SCT)~Dose of chemotherapeutic agents of 1st HDCT is tailored according to the residual positron emission tomography (PET)/Metaiodobenzylguanidine (MIBG) uptake before 1st HDCT~Dose of MIBG of 2nd HDCT is tailored according to the residual PET/MIBG uptake before 2nd HDCT~Radiotherapy after tandem HDCT~Immunotherapy and differentiation therapy with Interleukin-2/isotretinoin"
2968815|NCT02771730|Experimental|Vaccine A|Receive Ad4-mgag three times at 0,2,and 6 months with a boost at 8months
2968816|NCT02771730|Experimental|Vaccine B|Receive Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
2968817|NCT02771730|Experimental|Vaccine A & B|Receive both Ad4-mgag and Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
2968818|NCT02771730|Placebo Comparator|Placebo|Receive placebo three times at 0,2,and 6 months with a boost at 8 months
2968819|NCT02771730|Experimental|Vaccine A & B (previously received study vaccine)|People who have previously had a study vaccine: Receive both Ad4-mgag and Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
2968820|NCT02771717|Experimental|Budesonide (Pulmicort)|Low dose inhaled corticosteroid.
2968821|NCT02771717|Placebo Comparator|Placebo - dummy inhaler|Placebo - dummy inhaler
2968822|NCT02771704|Experimental|Silver diamine fluoride|Intervention: Silver diamine fluoride will be applied in vivo on carious dentine lesions
2968823|NCT02771704|Experimental|Potassium iodide|Potassium iodide will be applied in vivo on carious dentine lesions.
2968824|NCT02771704|Experimental|Chlorhexidine|Chlorhexidine will be applied in vivo on carious dentine lesions
2968825|NCT02771704|Experimental|Silver diamine fluoride+Potassium iodide|Silver diamine fluoride and potassium iodide mixture will be applied in vivo on carious dentine lesions
2968826|NCT02771704|Experimental|Saline|Sterile physiological saline will be applied in vivo on carious dentine lesions
2968827|NCT02771691|Experimental|MBT therapy plus treatment as usual|Mentalization based group treatment for adolescents plus standard care
2968828|NCT02771691|No Intervention|Treatment as usual alone|Standard care provided by local Child and Adolescent Mental Health Services
2968829|NCT02771678||Asthma|All participants will have an asthma-related crisis event due to an asthma exacerbation that resulted in A&E attendance and/or hospital admission.
2968830|NCT02771665||Breast cancer women with known recurrences|Breast cancer women with known recurrences (locoregional recurrence and distant metastasis)
2968835|NCT02771626|Experimental|CB-839 + Nivolumab Dose Escalation|Phase 1: CB-839 administered as oral capsules twice daily in combination with standard dose nivolumab in patients with advanced/metastatic ccRCC, MEL, and NSCLC to select the recommended Phase 2 dose (RP2D).
2968836|NCT02771626|Experimental|Clear Cell RCC Naïve to Checkpoint Inhibitors|Cohort 1: CB-839/ nivolumab combination in patients with advanced/metastatic ccRCC who have previously received at least one TKI but are treatment naive to checkpoint modulators anti-PD-1/PD-L1, CTLA-4, or any other agent that specifically targets a T-cell checkpoint or co-stimulation pathway.
2968837|NCT02771626|Experimental|Clear Cell RCC Recently Treated with Nivolumab|Cohort 2: CB-839/ nivolumab combination in patients with advanced/metastatic ccRCC who received nivolumab in most recent treatment line that had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.
2968838|NCT02771626|Experimental|Clear Cell RCC with Prior PD-1 Therapy|Phase 2 - Cohort 3: CB-839/ nivolumab combination in patients with advanced/metastatic ccRCC that had documented radiological disease progression while receiving an anti-PD-1/PD-L1 therapy in any prior line of therapy.
2968839|NCT02771626|Experimental|Melanoma with Prior PD-1 Therapy|Cohort 4: CB-839/ nivolumab combination in patients with unresectable or metastatic melanoma that had documented radiological disease progression while receiving an anti-PD-1 therapy in their most recent line of therapy.
2968840|NCT02771626|Experimental|NSCLC with Prior PD-1 Therapy|Cohort 5: CB-839/ nivolumab combination with NSCLC that does not harbor an activating mutation in the epidermal growth factor receptor (EGFR) oncogene and who received nivolumab in most recent treatment line and had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.
2968841|NCT02771613||Active experience feedback|Multi professional, in situ simulation , with scenarios based on the adverse events analyzed in MMR : After analysis of adverse effects in Morbidity Mortality reviews, we will create scenarios adapted to these events. Education of the randomized department's arm's staff will be performed by multi professional in situ simulation with these scenarios
2968842|NCT02771613||Passive experience feedback|Large diffusion of information about discussions and decisions of Morbidity Mortality Reviews : after the analysis of adverse effects in Morbidity Mortality reviews, a large scale dissemination activity of information about discussions and decisions towards the staff of the randomized departments' arms will be carried out.
2968843|NCT02771613||No experience feedback|MMR will be performed as usual, without any feedback to the medical staff
2968844|NCT02771600|Experimental|Buzzy|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
2968845|NCT02771600|Active Comparator|Standard Care (Maxilene)|Maxilene topical anaesthetic cream will be applied 30 minutes before the needle-related procedure on the insertion site
2968846|NCT02771587|Experimental|Alcohol and energy drink|Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 energy drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
2968847|NCT02771587|Active Comparator|Alcohol|Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
2968848|NCT02771587|Active Comparator|Energy drink|3 energy drinks (750 ml), multiple dose (375 ml+ 375 ml), oral administration. Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration.
2968849|NCT02771587|Placebo Comparator|Placebo|"3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.~Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration."
2968850|NCT02771574|Active Comparator|Dose A|Subcutaneous injection of Dose A of Exendin (9-39)
2968851|NCT02771574|Active Comparator|Dose B|Subcutaneous injection of Dose B of Exendin (9-39)
2968852|NCT02771574|Active Comparator|Dose C|Subcutaneous injection of Dose C of Exendin (9-39)
2968853|NCT02771574|Active Comparator|Dose D|Subcutaneous injection of Dose D of Exendin (9-39)
2968854|NCT02771561|Other|Patent Foramen Ovale Closure|All eligible participants undergo a patent foramen ovale closure procedure
2968855|NCT02771548||Anterior Cruciate Ligament Reconstruction|Those who have undergone unilateral anterior cruciate ligament reconstructive surgery in the Sports Surgery Clinic.
2968856|NCT02771548||Control|Healthy volunteers with no previous knee injury, no current lower limb injuries and take part in regular multidirectional team sports.
2968857|NCT02771535|Experimental|D-MCT Group|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
2968858|NCT02771535|Active Comparator|Health Training Group|Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
2968859|NCT02771522|Other|Active post-othodontic lesions|Imaging with the Calcivis System
2968860|NCT02771509|Active Comparator|BB3|Study drug will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.
2968861|NCT02771509|Placebo Comparator|Normal Saline|The placebo will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.
2968862|NCT02771496||Patients with OCD|Patients with diagnosis of OCD as confirmed by x-ray or MRI. Surveys collected from patients at 2 years, 5 years, 10 years, and 25 years.
2968863|NCT02771483||Suspected GCA|
2968864|NCT02771483||Case controls|
2968865|NCT02771470|Experimental|Probiotic|Microbial composition using probiotics,3 capsules/times,3 times/day for 3 to 4 weeks
2968866|NCT02771470|Placebo Comparator|Placebo|Microbiota modulation using probiotics,3 capsules/times,3 times/day for 3 to 4 weeks
2969061|NCT02770079||Control|20 women with no gestational diabetes.
2968867|NCT02771457|Experimental|Infliximab at weeks 0,2, and 6|In this arm subjects will receive re-induction treatment of infliximab at weeks 0,2, and 6.
2968868|NCT02771457|Experimental|Infliximab at weeks 0,4, and 8|In this arm subjects will receive re-induction treatment of infliximab at weeks 0, 4, and 8
2968869|NCT02771457|Active Comparator|Infliximab at weeks 0, and 8|In this arm subjects will not be randomized. They will receive re-induction therapy weeks 0 and 8.
2968870|NCT02771444|Experimental|Tomo Assessment|Subjects will have a 4-view tomosynthesis examination with the study device.
2968871|NCT02771431|No Intervention|Standard|Group 1 will consist of patients receiving in-person attending-patient encounters while inpatients.
2968872|NCT02771431|Experimental|Tele-rounding|Group 2 will consist of patients receiving video-conference attending-patient encounters. The intervention is being seen via ipad
2968873|NCT02771418|Sham Comparator|TIVA with propofol|Induction and maintenance of general anesthesia using TIVA with propofol
2968874|NCT02771418|Active Comparator|VIMA with sevoflurane|Induction and maintenance of general anesthesia using VIMA with sevoflurane
2968875|NCT02771405|Experimental|Sofosbuvir +Ribavirin|Sofosbuvir 400 mg/day +ribavirin for 24 weeks
2968876|NCT02771405|Experimental|Sofosbuvir+Simeprevir±Ribavirin|Sofosbuvir 400 mg/day +Simeprevir 150 mg/day ± ribavirin for 12 weeks
2968877|NCT02771405|Experimental|Sofosbuvir+Daclatasvir±Ribavirin|Sofosbuvir 400 mg/day +Daclatasvir 60 mg/day ± ribavirin for 12 weeks
2968878|NCT02771405|Experimental|Sofosbuvir+Ledipasvir±Ribavirin|Sofosbuvir 400 mg/day +Ledipasvir 90 mg/day ±ribavirin for 12 weeks
2968879|NCT02771392|Experimental|Tetracaine Group|Patients with he primary diagnosis of corneal abrasion will be treated with ophthalmic tetracaine. Tetracaine will be supplied in three plastic prefilled, commercially available vials, each containing 0.5 mL of preservative-free, undiluted 1% tetracaine hydrochloride (a total of 1.5 mL or approximately 50 drops will be provide to avoid overuse). Patients will be instructed to use 1-2 drops of up to every 30 min for pain control over a 48 hour period with subsequent followup with the ophthalmologist.
2968880|NCT02771392|Placebo Comparator|Normal Saline Group|Patients with the primary diagnosis of corneal abrasion will be treated with normal saline eye drops. Normal saline will be supplied in three plastic prefilled, commercially available vials, each containing 0.5 mL of normal saline. Patients will be instructed to use 1-2 drops of up to every 30 min for pain control over a 48 hour period with subsequent followup with the ophthalmologist.
2968881|NCT02771379||Patients who are treated with Raxone®|
2968882|NCT02771366|Experimental|Fermented Papaya Preparation, then granulated sugar|Participants will start taking the Fermented Papaya Preparation (FPP) three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the granulated sugar in the same way as the FPP was taken. In addition, the following test will be performed: Magnetic Resonance Spectroscopy (MRS) of the brain, functional magnetic resonance imaging (fMRI), RAND 36-item Health Survey (SF-36) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) blood samples,
2968883|NCT02771366|Placebo Comparator|Granulated Sugar, then Fermented Papaya Preparation|Participants will start taking the granulated sugar three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the Fermented Papaya Preparation (FPP) in the same way as the granulated sugar was taken. In addition, the following test will be performed: Magnetic Resonance Spectroscopy (MRS) of the brain, functional magnetic resonance imaging (fMRI), RAND 36-item Health Survey (SF-36) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) blood samples,
2968884|NCT02771353|Active Comparator|WT_vDIBH|Wide tangent radiotherapy in voluntary deep inspiratory breath hold
2968885|NCT02771353|Active Comparator|VMAT_FB|Volumetric modulated arc therapy in free breathing.
2968886|NCT02771340|Experimental|ICON-1 0.3 mg Singe Dose|Patients will receive a single intravitreal dose of ICON-1 0.3 mg
2968887|NCT02771340|Experimental|ICON-1 0.3 mg Repeat Dosing|Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart
2968888|NCT02771340|Experimental|ICON-1 0.6 mg Repeat Dosing|Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart
2968889|NCT02771327|Experimental|CPAP plus gas|Treatment with Boussingnac valve CPAP during 6 hour, starting immediately after weaning
2968890|NCT02771327|Active Comparator|Usual treatment(ventimask plus gas)|ventimask
2968891|NCT02771314|Experimental|AZD9291|AZD9291
2968892|NCT02771301|Other|dendritic cell|Patients will receive autolgous IDH1R132H dendritic cells and cytotoxic lymphocytes treatment.
2968893|NCT02771288|Other|Kawasaki disease|
2968894|NCT02771275|Experimental|Mitral Valve Repair|Implanting ePTFE sutures as artificial chordae tendineae using the Harpoon Medical device
2968895|NCT02771249|Experimental|B|(1) DRV/c once daily alone (days 1-4) and (2) DRV/c once daily + weightbased RPT and INH (with pyridoxine) once weekly (days 5-19)
2968896|NCT02771223||Study group|patients scheduled for prolonged cardiac surgery (over 3 hours anticipated ECC time) with no known coagulation disorders
2968897|NCT02771210|Experimental|AIN457/Secukinumab|Secukinumab 150 mg s.c. or Secukinumab 300 mg s.c., respective dose will be assigned according to underlying condition, in case of PsA according to severity of concomitant Psoriasis or pre-exposure to anti-TNFα
2968898|NCT02771210|Placebo Comparator|AIN457/Secukinumab Placebo|Secukinumab Placebo s.c.
2968899|NCT02771197|Experimental|Lymphodepletion plus Pembrolizumab|Fludarabine & Melphalan followed by autologous stem cell transplantation. Pembrolizumab will begin on Day +1.
2968900|NCT02771184|Other|Lung-Healthy|Subjects with no diagnosed lung disease. The intervention is the recording of lung sounds with the Lung Sound Recording System.
2968901|NCT02771184|Other|Pneumothorax|Subjects with pneumothorax. The intervention is the recording of lung sounds with the Lung Sound Recording System.
2968902|NCT02771184|Other|Pulmonary Fibrosis|Subjects with pulmonary fibrosis. The intervention is the recording of lung sounds with the Lung Sound Recording System.
2968903|NCT02771171||Age groups|The cohort is divided into on the basis of age
2968904|NCT02771158|Experimental|midodrine|randomization to midodrine 20 mg every 8 hours to be increased to a maximum of 40 mg every 8 hours until intravenous vasopressor discontinuation
2968905|NCT02771158|Placebo Comparator|placebo|randomization to placebo control
2970361|NCT02761538|Experimental|AVIITAM Group|Utilization of the web platform Aviitam
2968906|NCT02771145|Experimental|FID 120947A|FID 120947A contact lens disinfecting solution used with soft contact lenses (study lenses) on a daily basis for 180 days. SCL preservative solution used standard-of-care.
2968907|NCT02771132|Experimental|Intervention|"12-hour intervention IMPower empowerment self defense course for girls and 12-hour Source of Strength for boys+ 2 refresher sessions (at 2 hrs. per session)"
2968908|NCT02771132|Other|Standard of Care|1-2 hour course based on Ministry of Education life skills course (no refresher sessions)
2968909|NCT02771106||vision dysfunction|This group are subjects with mild TBI who have been diagnosed with profound oculomotor (vision) dysfunction per objective measurements taken by the HCMC developmental optometrist. These subjects will undergo neuro vision rehabilitation.
2968910|NCT02771106||control|This group are subjects with mild TBI who have no oculomotor (vision) dysfunction per objective measurements taken by the HCMC developmental optometrist
2968911|NCT02771093|Experimental|Trelagliptin 100 mg group|Trelagliptin 100 mg once weekly taken orally before breakfast
2968912|NCT02771093|Experimental|Alogliptin 25 mg group|Alogliptin 25 mg once daily taken orally before breakfast
2968913|NCT02771067|Experimental|Pulse pressure variation|Pulse pressure variation will be recorded via an arterial catheter after anesthetic induction, before pneumoperitoneum, after pneumoperitoneum, before infusion of 6% hydroxyethyl starch, and after infusion of 6% hydroxyethyl starch. Stroke volume will be also measured to differentiate the fluid responders.
2968914|NCT02771054|Experimental|TAF/emtricitabine (FTC)|All 20 patients will switch their nucleoside backbone, either ABC/3TC or TDF/FTC to TAF/FTC
2968915|NCT02771041|Experimental|Group with D-8 medical consultation|"A medical consultation 8 days before surgery would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions."
2968916|NCT02771041|No Intervention|Group without D-8 medical consultation|
2968917|NCT02771028|Experimental|Intervention group|Patients assigned to intervention group receive an 8-week EFT-program
2968918|NCT02771028|No Intervention|Control group|Patients assigned to control group are placed on a waitlist for a period of 8 weeks
2968919|NCT02771015|Active Comparator|Mepilex Border®|Mepilex Border® wound dressing at patients after hip-knee or primary spine surgery
2968920|NCT02771015|Active Comparator|Cosmopor steril®|Standard wound dressing at patients after hip-knee or primary spine surgery
2968921|NCT02771002||septic shock patients|measurements of peripheral perfusion including capillary refill time, mottling score, temperature gradient and peripheral perfusion index hourly until normalisation of lactate sonographic assesment of perfusion of solid organs once within 24h after admission
2968922|NCT02771002||patients rewarming after cardiac surgery|measurements of peripheral perfusion including capillary refill time, mottling score, temperature gradient and peripheral perfusion index hourly until extubation
2968923|NCT02771002||healthy volunteers|measurements of peripheral perfusion including capillary refill time and peripheral perfusion index in ambient temperature and after cooling of extremity
2968924|NCT02770989|Experimental|Vimecon Laser CAI Cardiac Ablation|Ablation of the cardiac tissue by the use of the Vimecon Laser CAI (Cardiac Ablation Instrument).
2968925|NCT02770976|Experimental|NAVA|Seven increasing and decreasing NAVA levels (0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0 and 0.5 cmH2O/uV) will applied to 20 preterm infants each for 10 minutes.
2968926|NCT02770963|Experimental|Acupuncture|"Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.~Huatuo Brand needle (0.3*75 mm) will be used for BL25 and Huatuo Brand needle (0.3*40mm) will be used for BL23, BL40 and BL57."
2968927|NCT02770963|Sham Comparator|Sham acupuncture|The acupoints will be the same as the acupuncture group. Specially designed sham needles (0.3*25 mm) will be used . The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).
2968928|NCT02770950|Active Comparator|High dose group|"High dose of Zushima plaster: a piece of Zushima plaster will be used topically for each knee for 24h per day.~Eligible subjects will use a piece of Zushima plaster topically for each knee for 24h per day."
2968929|NCT02770950|Active Comparator|Low dose group|"Low dose of Zushima plaster: a piece of Zushima plaster will be used topically for each knee for 12h per day.~Eligible subjects will use a piece of Zushima plaster topically for each knee for 12h per day."
2968930|NCT02770950|Active Comparator|Controlled group|Indometacin Cataplasms will be used topically on the knee for 24h per day
2968931|NCT02770937|Active Comparator|Virtual reality simulator|The virtual reality simulator group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on laparoscopic suturing.
2968932|NCT02770937|Active Comparator|Box trainer|The box trainer group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on box trainer.
2968933|NCT02770937|No Intervention|Control|The control group will not receive further training.
2968934|NCT02770924|Experimental|AT LISA TRI TORIC|All patients will be undergo to phacoemulsification with IOL implantation bilateral
2968935|NCT02770924|Experimental|AT LISA TRI|All patients will be undergo to phacoemulsification with IOL implantation bilateral
2968936|NCT02770911|Experimental|"without Dog Ear group"|Before anastomosis, the surgeon made a laparoscopic suturing on the two dog ears by using 3-0 monofilament sutures, and pull two dogears of staple line around the trocar by a tied suture through two dog ears. By this way, the staple line was kept within the circular knife when the circular stapler was closed. Then a true end-to-end anastomosis was performed after stapler firing.
2968937|NCT02770911|Active Comparator|"with Dog Ear group"|traditional double-stapled anastomosis was used for laparoscopic anterior resection
2968964|NCT02770703|Experimental|Total extraperitoneal inguinal hernia repair (TEP)|Total extraperitoneal inguinal hernia repair using a DynaMesh visible mesh
2968965|NCT02770703|Experimental|Trans abdominal preperitoneal hernia repair (TAPP)|Trans abdominal preperitoneal hernia repair using a DynaMesh visible mesh
2968966|NCT02770690|Experimental|spray|apply the ethyl chloride spray before propofol injection
2968967|NCT02770690|Active Comparator|lidocaine|apply the lidocaine 0.5 mg/kg under the touniquette state before propofol injection
2968938|NCT02770898|Experimental|Brief Intervention|The brief intervention is individual focus and consists of three main components, which include enhancing the individual personal attributes such as participant's knowledge, values, and behaviors related to physical exercise. Second, the intervention will promote changes in behavioral attributes by providing opportunities and experience in goal setting, skills development in physical exercise and self-monitoring. Finally, the brief intervention promotes family relations and well-being by encouraging individuals to share their knowledge and increase physical activities with other family members. The brief intervention will be delivered by the probation officer during regular monthly consultation.
2968939|NCT02770898|Experimental|Combined Intervention|Participants allocated to the combined intervention will receive the individual brief intervention and participate in a community group program. The components in the brief intervention will also be reinforced in the group program. The group nature is designed to create an environment that is supportive of physical exercise, through role models, peer support, and encourages families to exercise with probationers.
2968940|NCT02770898|No Intervention|Care-as-usual|Participants allocated to Care-as-usual arm will receive their usual services. Participants will be offered the combined interventions upon completion of 3-months follow up assessment.
2968941|NCT02770885|Experimental|Verum first|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.
2968942|NCT02770885|Placebo Comparator|Placebo first|Placebo: 0.5 ml normal saline (0.9% sodium chloride [0.9% sodium chloride (NaCl)]), injection sc via syringe once weekly for 3 weeks.
2968943|NCT02770872||Obese, normal|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2. Observation of SAA on apoB containing lipoproteins
2968944|NCT02770872||Obese, MetS|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2, blood pressure above 135/80, HDL less than 40 mg/dl, triglycerides greater the 150 mg/dl and fasting blood glucose greater than 100 mg/dl but less than 126 mg/dl. Observation of SAA on apoB containing lipoproteins
2968945|NCT02770872||Obese, diabetic|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2 and physician diagnosed diabetes mellitis. Observation of SAA on apoB containing lipoproteins
2968946|NCT02770846|Experimental|Immediate loading|Immediate loading of single dental implant in the anterior maxilla with temporary crown in central occlusion
2968947|NCT02770846|Active Comparator|Delayed loading|Delayed loading. 2-stage procedure with a 4 months healing period before fabrication of temporary crown.
2968948|NCT02770833|Experimental|Salmon vs. veal and CHO with low or high GI|"In the first clinical study (Study 1), subjects will eat salmon or veal combined with high or low GI carbohydrates. Each subject will be engaged in each of the following four 1-day test meals:~Meat balls with salmon served with tomato sauce and other accompaniments with low GI~Meat balls with salmon served with tomato sauce and other accompaniments with high GI~Meat balls with veal served with tomato sauce and other accompaniments with low GI~Meat balls with veal served with tomato sauce and other accompaniments with high GI"
2968949|NCT02770833|Experimental|Cod vs. veal and CHO with low or high GI|"In the second clinical study (Study 2), subjects will eat codfish or veal combined with high or low GI carbohydrates. Each subject will be engaged in each of the following four 1-day test meals:~Meat balls with codfish served with tomato sauce and other accompaniments with low GI~Meat balls with codfish served with tomato sauce and other accompaniments with high GI~Meat balls with veal served with tomato sauce and other accompaniments with low GI~Meat balls with veal served with tomato sauce and other accompaniments with high GI"
2968950|NCT02770820|Experimental|Treatment (autologous CD8 T cells)|Beginning 4 weeks after completion of last course of consolidation chemotherapy, patients receive autologous WT1-TCRc4 gene-transduced CD8+ TCM/TN lymphocytes IV over 1-4 hours on days 0 and 14. Beginning 6 hours after the second infusion of T cells, patients also receive aldesleukin SC BID for 14 days in the absence of disease progression or unacceptable toxicity. Patients who have clinically benefitted from T cell therapy may receive additional infusions of T cells and aldesleukin at the discretion of the PI and the attending physician.
2968951|NCT02770807|Experimental|EDS-EP dose range of ~5-10 mg DSP/infusion|"Drug: EDS-EP dose range of ~5-10 mg DSP/infusion EDS-EP dose range of ~5-10 mg DSP/infusion: A DSP loading quantity of 50.0 mg will be added to the EDS process, by using 2.0 mL of the 25 mg/mL DSP solution to deliver an EDS dose range of ~5-10 mg. DSP is diluted with 11 mL sterile water for injection in the same syringe, for a total of 13.0 mL.~Other Names:~EryDex System end product"
2968952|NCT02770807|Experimental|EDS-EP dose range of ~14-22 mg DSP/infusion|"Drug: DSP/infusion EDS-EP dose range of ~14-22 mg DSP/infusion DSP/infusion EDS-EP dose range of ~14-22 mg DSP/infusion: A DSP loading quantity of 125 mg will be added to the EDS process, by using 5.0 mL of the 25 mg/mL DSP solution to deliver an EDS dose range of 14-22 mg. DSP is diluted with 11 mL sterile water for injection in the same syringe, for a total of 16 mL.~Other Names:~EryDex System end product"
2968953|NCT02770807|Placebo Comparator|Placebo EDS infusion|Patients will be treated with autologous erythrocytes prepared with the EDS process using a placebo solution (5 mL of 0.372% NaCl solution) instead of experimental drug (DSP). Placebo is diluted with 11 mL sterile water for injection in the same syringe, for a total of 16 mL.
2968954|NCT02770794|Experimental|All patients|Discontinue infliximab; Receive infliximab when relapse
2968955|NCT02770781|Experimental|Personal Trainer|All subjects will meet a set amount of times with a personal trainer over the course of the study to participate in an exercise regimen.
2968956|NCT02770768|Active Comparator|Flibanserin|"Drug: Flibanserin~8 weeks~100mg once daily at bedtime"
2968957|NCT02770768|Placebo Comparator|Placebo|Drug: Matching Placebo Matching placebo capsules taken in same amount of pills as the active medication (for 8 weeks once daily at bedtime)
2968958|NCT02770742||Patients for outpatient colonoscopy|The cohort consists of subsequent patients who present for routine colonoscopy. There is no active Intervention. However, groups who choose to perform colonoscopy with or without sedation will be compared.
2968959|NCT02770729|Active Comparator|Intracameral moxifloxacin|Intracameral injection of 0.5% moxifloxacin at conclusion of cataract surgery (150 micrograms)
2968960|NCT02770729|Sham Comparator|No injection of moxifloxacin|No injection of moxifloxacin at conclusion of cataract surgery
2968961|NCT02770716|Experimental|Terlipressin|Lyophilized terlipressin acetate, IV, 1 mg by bolus injection q 6 hours
2968962|NCT02770716|Placebo Comparator|Placebo Comparator|Placebo, IV, 1 mg by bolus injection q 6 hours
2968963|NCT02770703|Experimental|Open inguinal hernia repair (Lichtenstein)|Open inguinal hernia repair using a DynaMesh visible mesh
2968975|NCT02770651||Optical Coherence Tomography|To evaluate the incidence of late incomplete stent apposition (ISA) and un-coverage by optical coherence tomography (OCT) following everolimus-eluting stent (EES) with bioabsorbable polymerversus zotarolimus-eluting stent (ZES) with permanent polymer implantation in patients with AMI at 12 months.
2968976|NCT02770638|Experimental|Scoop Stretcher|Participant wearing light sports clothing will start with forty five minutes laid supine on the scoop stretcher with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps). Followed by a forty five minute washout period (participant can mobilise freely). Participants will complete the observation with forty five minutes laid supine on the long back spinal board with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps).
2968977|NCT02770638|Active Comparator|Long Back Spinal Board|Participant wearing light sports clothing will start with forty five minutes laid supine on the long back spinal board with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps). Followed by a forty five minute washout period (participant can mobilise freely). Participants will complete the observation with forty five minutes laid supine on the scoop stretcher with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps).
2968978|NCT02770625|Experimental|ISU302|60 U/kg (once every 2 weeks for 6 months)
2968979|NCT02770612|Other|Massachusetts General Hospital|"Identify eligible women on post-operative day 3. A physician member of the study team will approach participants with study information and consent forms.~After informed consent is obtained, the participant will be taken through a 10 minute shared decision making session. The participant will then have the opportunity to ask questions, following which they will indicate the number of prescription opioid tablets to be discharged with.~The next contact will be at two weeks after discharge, at which time a member of the study team will contact the participant and administer a brief telephone survey with questions pertaining to perceived pain over time, pain management methods, opioid/pain medication consumption/disposal, and satisfaction with postoperative pain control.~A chart review will be performed by physicians in the research group on participants to gather additional information on demographics, indications for surgery, and other relevant variables."
2968980|NCT02770599||IBD multidisciplinary team model (MDT)|IBD multidisciplinary team model including IBD nurse
2968981|NCT02770599||IBD conventionally follow up model (CF)|IBD patient treated by doctors with specialist qualifications, assistant doctors, general practitioner or scarcity of follow-up-service.
2968982|NCT02770586|Other|Breast PET|Breast PET
2968983|NCT02770573|Experimental|Patients with dentin hypersensitivity|"Patients with evident clinical signs of dentin hypersensitivity The following dental materials will be used following the manufacturers' instructions: Cavex Bite&White ExSense; Kuraray Teethmate™ Desensitizer; Ghimas Dentin Desensitizer.~In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.~The application of the materials will be made only once. The effectiveness will be evaluated: immediately after application and after 1, 4, 12 weeks."
2968984|NCT02770560||Chronic hemodialysis patients with a tunneled cuffed catheter|In case of thrombotic dysfunction of the dialysis catheter : administration of Urokinase (100 000 units in total) as locking solution in the dead space of the catheter lumen, interdialytic (between two dialysis sessions) or intradialytic (during the dialysis in case of complete obstruction of the dialysis catheter)
2968985|NCT02770547|Active Comparator|Low Heat Thermotherapy|Low heat thermotherapy will be applied to subject's leg. Subject will wear a garment through which heated water is circulated which in turn supplies low heat to the subject's leg.
2968986|NCT02770547|Experimental|High Heat Thermotherapy|High heat thermotherapy will be applied to subject's leg. Subject will wear a garment through which heated water is circulated which in turn supplies high heat to the subject's leg.
2968987|NCT02770534||Sickle patients in steady state|Well sickle cell patients attending the outpatient clinic
2968988|NCT02770534||Sickle cell patients admitted in crisis|Inpatients with acute vaso-occlusive crisis
2968989|NCT02770534||Sickle patients on transfusion program|Sickle patients managed on a regualar transfusion program
2968990|NCT02770534||Sickle patients on Hydroxycarbamide|Sickle cell patients managed on hydroxycarbamide and on a stable dose for at least 3 months
2968991|NCT02770534||Health controls|Well age and race matched individuals without a known diagnosis of sickle cell anaemia
2968992|NCT02770521|Experimental|Treprostinil (Part A)|Treprostinil administered as a single subcutaneous (SC) bolus injection.
2968993|NCT02770521|Placebo Comparator|Placebo (Part A)|Placebo administered as a single SC bolus injection.
2968994|NCT02770521|Experimental|LY900014 (Part B)|LY900014 (test) administered as a single SC bolus injection.
2968995|NCT02770521|Active Comparator|Insulin Lispro (Part B)|Insulin lispro (reference) administered as a single SC bolus injection.
2968996|NCT02770508|Experimental|Darunavir/ritonavir plus lamivudine|Darunavir/ritonavir 800/100 mg, 1 coformulated tablet QD and lamivudine 300 mg, 1 tablet QD
2968997|NCT02770508|Active Comparator|Darunavir/ritonavir plus emtricitabine/tenofovir(FTC/TFD)|Darunavir/ritonavir 800/100 mg1 coformulated tablet QD (FDC) plus FTC/TDF 200/300 mg, 1 coformulated tablet QD
2968998|NCT02770495|Experimental|Postoperative endoscopic recurrence|Patients with a diagnosis of Crohn's disease who undergo an ileo-colonic curative resection
2968999|NCT02770482|Experimental|AD Patients|
2969000|NCT02770469|Active Comparator|Standard Intervention|The standard intervention group received linguistically and culturally tailored information regarding breast cancer and survivorship.
2969001|NCT02770469|Experimental|Enhanced Intervention|The enhanced intervention group received linguistically and culturally tailored information regarding breast cancer and survivorship as well as cognitive-behavioral stress management.
2969002|NCT02770456|Experimental|High dose fish oil|Women will be offered 4 capsules per day containing fish oil
2969003|NCT02770456|Experimental|Low dose fish oil|Women will be offered 4 capsules per day containing mixed fish oil and olive oil
2969004|NCT02770456|Placebo Comparator|Control|Women will be offered 4 capsules per day containing olive oil
2969005|NCT02770443|Experimental|Treatment|Withdrawal of beta blockers and ACE inhibitors
2969006|NCT02770443|Placebo Comparator|control|no withdrawal, standard of care
2969092|NCT02769806||GBM patients undergoing MRI|GBM patients undergoing standard-of-care post-operative combination chemoRT and clinically indicated MRI including standard DSC-PWI for follow-up.
2969007|NCT02770430|Active Comparator|conventional treatment|"After randomization, patients will be allocated to receive conventional treatment:~Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.~If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR."
2969008|NCT02770430|Experimental|mesenchymal stem cells|Patients in the study group will receive two infusions of MSC per week during two weeks and 1 more MSC infusion (2 + 2 + 1 scheme). Dosage: 2x10E6/Kg
2969009|NCT02770417|Active Comparator|COPD (beta-alanine)|
2969010|NCT02770417|Placebo Comparator|COPD (placebo)|
2969011|NCT02770417|Other|Healthy controls|
2969012|NCT02770404|Experimental|Nafithromycin|"Subjects in Cohorts 1 through 5 receive active treatments. Subjects in Cohort 6 will receive an IV dose of nafithromycin and a single oral dose of nafithromycin in each crossover period.~Subjects in each of Cohorts 1, 2, and 3 will receive a single dose of 100, 200, or 400 mg, respectively, of nafithromycin on Day 1"
2969013|NCT02770404|Placebo Comparator|Placebo|Subjects in Cohorts 1 through 5 will be randomly assigned in an 8:2 allocation to receive active or placebo treatments.
2969014|NCT02770391|Experimental|ARN-509 + Leuprolide Acetate|All participating patients will receive a single dose of leuprolide 7.5 mg intramuscularly (IM) in addition to ARN-509 240 mg orally daily for four weeks prior to radical prostatectomy (RP). Treatment will be started on day (-28) ± 3 from the scheduled RP date to minimize the variability of treatment duration. ARN-509 will be continued till the day of RP.
2969015|NCT02770378|Experimental|Temozolomide combined with 9 repurposed drugs|"After enrollment, the subject goes into the induction cycle, which lasts 35 days. The induction cycle consists of a drug-by-drug addition and up-dosing process.~Hereafter, the subject will enter the treatment cycles (up to 12). During the induction cycle and the first 2 treatment cycles, regimen adjustments (dropping of certain drugs, dose modification of certain drugs) may be executed to accommodate to the patients' individual toxicity reactions that may occur during this period."
2969016|NCT02770365|Experimental|Test Product|estradiol cream
2969017|NCT02770365|Active Comparator|Reference Product|estradiol cream
2969018|NCT02770365|Placebo Comparator|Placebo product|Placebo cream
2969019|NCT02770326|Experimental|Fecal Microbiota Transplantation (FMT)|Patients with recurrent or refractory CDI who meet study eligibility criteria, will consent to undergo either colonoscopy or upper endoscopy with infusion of stool admixture. Safety will be assessed by monitoring infections that occurred within 2 weeks of the FMT procedures. Additionally, 24-hours, 1 week, 2 weeks, 4 weeks, and 6 months post-FMT, a stool sample will be collected. The time window for each time point listed is +/- 48 hours, with the exception of the first, 24 hour, time point. The time window for the 24 hour time point is +48 hours post FMT.
2969020|NCT02770313|Experimental|Intermittent Fasting|Water-only Intermittent Fasting
2969021|NCT02770313|No Intervention|Control|ad libitum Usual Diet
2969022|NCT02770300|No Intervention|Conventional therapy|"The control group of patients will perform a conventional therapy without the use of the exoskeleton. The conventional therapy will consist in a traditional treatment of occupational therapy or physiotherapy without the use of the robotic device. The therapist will provide a specific conventional treatment comparable with the robotic treatment in terms of session time and therapeutic goals (i.e., 45 minutes per session, about 100, 150, 200 and 250 movements respectively for the first, second, third and fourth week). The level of difficulty of the exercises will be increased by the physiotherapist according to the degree of impairment of the patients.~The muscle and cerebral activity during the execution of the conventional therapy could be acquired."
2969023|NCT02770300|Experimental|Traditional robotic rehabilitation with ALEx RS|The rehabilitative task will be constituted of 3D reaching movements covering a sphere of fourteen centimeter of radius in front of the patient. The initial rehabilitative task will be the same for all the patients belonging to this group and the workspace will be extended accordingly to the therapist evaluation during the following training sessions. In order not to bias the comparisons of the effects of the different rehabilitative treatments, the therapist assisting this group during the rehabilitation will be the same for all the subjects belonging to this group and he/she will not take part in the rehabilitative treatment of the other groups. Initially, the patients will execute reaching movements in different directions in the horizontal plane. If the therapist will evaluate that the movements have been sufficiently recovered, reaching movements in the other planes will be proposed.
2969024|NCT02770300|Experimental|Automatic personalized robotic rehabilitation with ALEx RS|
2969025|NCT02770287|Experimental|Venus Freeze Diamond Polar|Subjects will receive three treatments with the study device, at four week intervals, followed by a one month follow-up visit after the last treatment.
2969026|NCT02770274|Experimental|Group Cilostazol|Patients receiving dual antiplatelet therapy with cilostazol 100mg twice daily and aspirin 100mg once daily for 12 months.
2969027|NCT02770274|Active Comparator|Group Aspirin|Patients receiving monotherapy with aspirin 100mg once daily for 12 months.
2969028|NCT02770261|Experimental|CR group|DP-R208+Candesartan 32mg pla+Rosuvastatin 20mg pla
2969029|NCT02770261|Active Comparator|CP group|DP-R208 pla+Candesartan 32mg+Rosuvastatin 20mg pla
2969030|NCT02770261|Active Comparator|PR group|DP-R208 pla+Candesartan 32mg pla+Rosuvastatin 20mg
2969031|NCT02770248|Experimental|SIMBRINZA|Brinzolamide 1% / Brimonidine 0.2% tartrate ophthalmic suspension, 1 drop 3 times per day in each eye at 8 AM, 3 PM, and 10 PM for 28 days
2969032|NCT02770248|Active Comparator|Vehicle|Vehicle, 1 drop 3 times per day in each eye at 8 AM, 3 PM, and 10 PM for 28 days
2969033|NCT02770235|Experimental|DE assessment and AGE measurements|To evaluate the association between erectile dysfunction (DE) and AGE levels by using non-invasive measurement AGE-ReaderTM, in diabetic patients
2969034|NCT02770222|Experimental|Part 1, sequence AB|Subjects participate in two study periods: During the first period (Treatment A), they receive oral selexipag on Day 1. During the second period (Treatment B), they receive multiple oral dose of gemfibrozil from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 4 concomitantly with gemfibrozil. There is a washout period of 14 to 21 days between the two periods.
2969093|NCT02769793|Experimental|Levodopa dispersible|Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
2970362|NCT02761538|No Intervention|Control group|No utilization of web-platform Aviitam
2969035|NCT02770222|Experimental|Part 1, sequence BA|Subjects participate in two study periods: During the first period (Treatment B), they receive multiple oral dose of gemfibrozil from Day 1 to Day 9. They also receive a single oral dose of selexipag on Day 4 concomitantly with gemfibrozil. During the second period (Treatment A) they receive oral selexipag on Day 1. There is a washout period of 14 to 21 days between the two periods.
2969036|NCT02770222|Experimental|Part 2, sequence AB|Subjects participate in two study periods: During the first period (Treatment A), they receive oral selexipag on Day 1. During the second period (Treatment B), they receive rifampicin once daily from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 7 together with the dose of rifampicin.There is a washout period of 14 to 21 days between the two periods.
2969037|NCT02770222|Experimental|Part 2, sequence BA|Subjects participate in two study periods: During the first period (Treatment B), they receive rifampicin once daily from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 7 together with the dose of rifampicin. During the second period (Treatment A), they receive oral selexipag on Day 1. There is a washout period of 14 to 21 days between the two periods.
2969038|NCT02770209|Experimental|the experimental group|Patients in the experimental group will be treated with the biomimetic cartilage matrix combined with autologous chondrocytes. The entire course of treatment includes two surgeries. The first surgery will be performed to observe articular cartilage damage by arthroscopy and assess treatment potential. If the patient's condition meets the surgical requirement, we will extract cartilage from the fossa intercondylar non-weight-bearing area during the first surgery. Chondrocytes will be in vitro-amplified and inoculated into the cartilage scaffold. The fully prepared seeded scaffold will be implanted into the site of injury during the second surgery.
2969039|NCT02770209|Experimental|the control group|Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.
2969040|NCT02770196|Experimental|Group One (Two-year Intervention, 2016 Enrollment)|Group one intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year in 2016 and 2017. During the 2016 season they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
2969041|NCT02770196|Experimental|Group Two (Delayed Two-year Intervention, 2016 Enrollment)|Group two intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year in 2017 and 2018. During the 2017 season they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
2969042|NCT02770196|Experimental|Group Three (One-year Intervention, 2017 Enrollment)|Group three intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks in 2017 and will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
2969043|NCT02770196|Experimental|Group Four (Delayed One-year Intervention, 2017 Enrollment)|Group four delayed intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks in 2018 and will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
2969044|NCT02770183||Consecutive patients|"Consecutive patients waiting to have elective cardiac surgery will be eligible. Each week the principal investigator will track patients in the operating program. The day of the consultation or the day before the operation, one of the investigators will have a talk with the patient to provide information and clarify doubts, also allowing the patient to read and look good all the details before giving its approval. For the screening, the principal investigator will use the criteria of inclusion and exclusion to select patients for the study. The screening uses clinical, laboratory or without other biological information.~To minimize confounding factors, it will be taken consecutive patients, that will also be analyzed regarding all known variables that can affect the systolic function, as non-modifiable (age, cardiovascular risk factors, heart-rate variability and preoperative basal systolic function) and modifiable."
2969045|NCT02770170|Experimental|BI 655064 dose 1|
2969046|NCT02770170|Experimental|BI 655064 dose 2|
2969047|NCT02770170|Experimental|BI 655064 dose 3|
2969048|NCT02770170|Placebo Comparator|Placebo|
2969049|NCT02770157|Experimental|DA-3002|1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).
2969050|NCT02770157|Active Comparator|Genotropin®|1.44 IU (0.48mg)/kg/week of Genotropin is injected for 52 weeks by changing injecting areas(six or seven times per week).
2969051|NCT02770157|Other|Non-treatment control group|After no treatment for 26 weeks, 1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).
2969052|NCT02770144|Experimental|Financial Coaching & Social Services Referral|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
2969053|NCT02770144|Active Comparator|Access to Referrals to Social Services|Enrollment provides access to referrals to social services to meet basic needs.
2969054|NCT02770131||Group 1|To describe the clinical characteristics of subjects at initiation of Repatha® (up to 2000 subjects).
2969055|NCT02770118|Experimental|PSR-TSD|Partial sleep restriction (PSR) followed by total sleep deprivation (TSD). Experimental procedures will begin with a 3-day period of habitual sleep (HS).
2969056|NCT02770118|Experimental|TSD-PSR|Total sleep deprivation (TSD) followed by partial sleep restriction (PSR). Experimental procedures will begin with a 3-day period of habitual sleep (HS).
2969057|NCT02770092|Experimental|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
2969058|NCT02770092|Experimental|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
2969059|NCT02770092|Experimental|Congestive Heart Failure|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
2969060|NCT02770079||Gestational diabetes|20 women with gestational diabetes
2969062|NCT02770053|Experimental|Intervention|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Foraminal enlargement will be achieved with #35 K-files in foraminal enlargement group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit.
2969063|NCT02770053|Active Comparator|Control|In the control group, no foraminal enlargement will be performed.
2969064|NCT02770040|Active Comparator|Intensified Infliximab Induction|Infliximab 10mg/kg at Week 0 and Week 1
2969065|NCT02770040|Active Comparator|Accelerated Infliximab Induction|Infliximab 5mg/kg at Week 0, Week 1 and Week 3
2969066|NCT02770040|Active Comparator|Standard Infliximab Induction|Infliximab 5mg/kg at Week 0, Week 2 and Week 6
2969067|NCT02770027|Placebo Comparator|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
2969068|NCT02770027|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
2969069|NCT02770014|Experimental|EGFR Exon 19 Positive Treatment With Erlotinib|Erlotinib will be initially dosed at a pre-determine dosage daily, and it will be given on a 6-week cycle with treatment administered on an outpatient basis
2969070|NCT02769988||Project SHARE|
2969071|NCT02769962|Experimental|Phase I|CRLX101 + olaparib
2969072|NCT02769962|Experimental|Phase II|CRLX101 + olaparib at MTD/RP2D
2969073|NCT02769936|Placebo Comparator|Healthy Adult - Placebo|Single dose placebo pill in healthy adults
2969074|NCT02769936|Experimental|Healthy Adult - D-cycloserine|Single 100 mg dose D-cycloserine pill in healthy adults
2969075|NCT02769936|Placebo Comparator|Schizophrenia - Placebo|Single dose placebo pill in schizophrenia patients
2969076|NCT02769936|Experimental|Schizophrenia - D-cycloserine|Single 100 mg dose D-cycloserine pill in schizophrenia patients
2969077|NCT02769923|Active Comparator|Arm A|Westpharma ID Adapter
2969078|NCT02769923|Active Comparator|Arm B|Star ID syringe
2969079|NCT02769923|Active Comparator|Arm C|BCG NS
2969080|NCT02769910|Other|Cowhage|Cowhage is used to induce non-histaminergic itch on the volar forearm at the locations treated with Capsaicin 24 Hours, Capsaicin 1 Hours and Qutenza Demo Patch.
2969081|NCT02769910|Other|Histamine|Histamine is used to induce histaminergic itch on the volar forearm at the locations treated with Capsaicin 24 Hours, Capsaicin 1 Hour and Qutenza Demo Patch.
2969082|NCT02769897|Experimental|Intervention group|The exercise program, nutritional counseling and oral health will last for five to six months and will be held in the gym and rooms of the University of Santa Cruz do Sul (UNISC). The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
2969083|NCT02769897|No Intervention|Control group|The control group did not receive the intervention.
2969084|NCT02769884|Experimental|MMPPC arm|Subjects in this arm will wear the experimental MMPPC algorithm artificial pancreas for 72 hours in a hotel/house setting. The study period will involve unannounced meals and exercise
2969085|NCT02769871|Active Comparator|Standardized smoking cessation counseling|Standardized smoking cessation counseling will be provided at the participant's initial interview. Participants will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
2969086|NCT02769871|Experimental|Neuroimages of stroke|Participants in the intervention group will undergo standardized smoking cessation counseling (as offered to the active comparator group) and will also be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, participants will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Participants will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
2969087|NCT02769858|Experimental|Light Therapy|Participants will use commercially-available light therapy glasses (Re-Timer) daily for 60 minutes for five weeks.
2969088|NCT02769845|Experimental|Longitudinal Portion|All enrolled children will undergo yearly TCD examination. The goal of serial examination is to help define the natural history of cerebrovascular disease, specifically to determine the incidence of new conditional or abnormal velocities. The goal is to obtain a total of 3 TCD examinations per enrolled patient, regardless of treatment status.
2969089|NCT02769845|Experimental|Treatment Phase|Those children with TCD velocities between 170-199 cm/sec will be eligible for protocol-directed hydroxyurea therapy. Most participants will initiate hydroxyurea treatment but those who are already on hydroxyurea and have conditional velocities will receive dose optimization. Participants will be followed until a common study termination date, defined as 3 years from the first treatment. Participants with abnormal TCD velocities ≥200 cm/sec will commence with transfusion therapy per current practice guidelines at the clinical site. Patients already on transfusion therapy identified to have conditional velocities will also be eligible for hydroxyurea and those with abnormal velocities may require re-calculation of transfusion dosing.
2969090|NCT02769832|Experimental|Nab-Paclitaxel with Gemcitabine|Nab-paclitaxel 100 mg/m2, day 1, 8 q 21 days; Gemcitabine 1000 mg/m2, day 1, 8 q 21 days
2969091|NCT02769819|Experimental|Intubation with a flexible fiberscope|Following induction of general anesthesia and administration of a neuromuscular blocking agent, intubation will be performed using a flexible fiberscope.
2969094|NCT02769793|Active Comparator|Levodopa|Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
2969095|NCT02769767||Cases|Subjects with Relapsing-Remitting Multiple Sclerosis. Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
2969096|NCT02769767||Controls|Healthy subjects. Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
2969097|NCT02769767||Responders|Subjects with MS treated for at least two years that have less than one relapse per year or who had an increase of <1.5 points on the Expanded Disability Status Scale (EDSS) (if baseline EDSS was 0) or no increase in EDSS (baseline EDSS ≥1). Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
2969098|NCT02769767||No responders|Subjects with MS that have more than one relapse per year treated for at least two years, and who had ≥1 relapse(s) or an increase of 1.5 points on the EDSS (if baseline EDSS was 0) or an increase of ≥0.5 points (baseline EDSS ≥1). Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
2969099|NCT02769754|Placebo Comparator|Control|In the control group (group A) no additional treatment will be applied after performing the usual surgical hemostasis.
2969100|NCT02769754|Experimental|Hemopatch|Hemopatch will be apply in the treatment group (group B), once the standard surgical hemostasis is achieved
2969101|NCT02769741|Other|Crossover 1: Control Diet followed by Active Diet|Treatment Period 1: Controlled diet without cashew nuts; Treatment Period 2: Controlled diet with cashew nuts
2969102|NCT02769741|Other|Crossover 2: Active Diet followed by Control Diet|Treatment Period 1: Controlled diet with cashew nuts; Treatment Period 2: Controlled diet without cashew nuts
2969103|NCT02769728|Experimental|EndoBarrier|EndoBarrier will be implemented for 9 months.
2969104|NCT02769715|Active Comparator|cast removable partial denture|patients received cast removable partial dentures fabricated using traditional lost-wax casting technique.
2969105|NCT02769715|Experimental|laser-sintered removable partial denture|patients received removable partial dentures fabricated using laser-sintering.
2969106|NCT02769702|Experimental|Intervention|Acthar 80 IU SC twice w eek
2969107|NCT02769689|Experimental|Methylprednisolone|The primary purpose of this protocol is to investigate the impact of high dose of oral methylprednisolone, given once a month during the washout period between NTZ and Fingolimod (FTY).
2969108|NCT02769689|Placebo Comparator|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
2969109|NCT02769676|Experimental|3-week visit|Participants randomized to this arm will receive an additional visit at 3-weeks postpartum
2969110|NCT02769676|Active Comparator|usual care|Participants randomized to this arm will receive usual postpartum care, including the standard timing for a postpartum visit.
2969111|NCT02769663||OSA|Patients with newly diagnosed obstructive sleep apnea and no medical comorbidity affecting cognition.
2969112|NCT02769663||healthy controls|Participants with no sleep disorder or other medical comorbidity affecting cognition.
2969113|NCT02769650|Experimental|Stress-MRI + Chronic total occlusion PCI|Pre- and postoperative stress-MRI with evaluation of myocardium perfusion defects + Coronary angioplasty with stenting of RCA CTO
2969114|NCT02769650|Active Comparator|Stress-MRI + Optimal medicamentous treatment|Pre- and postoperative stress-MRI with evaluation of myocardium perfusion defects + Optimal medicamentous treatment
2969115|NCT02769637||ON PPI|Subjects on proton pump inhibitor (PPI) treatment
2969116|NCT02769637||OFF PPI|Subjects off proton pump inhibitor (PPI) treatment
2969117|NCT02769624|Experimental|Treprostinil|A dose of 18mcg (3 breaths) will be administered using the Tyvaso® (treprostinil) inhalation system. Tyvaso® (treprostinil) inhalation solution is supplied in 2.9 mL clear ampules packaged as four ampules in a foil pouch. Frequency and duration- 3 times over 1 study visit.
2969118|NCT02769624|Placebo Comparator|Placebo|A dose of 3 breaths of placebo will be administered using the Tyvaso® (treprostinil) inhalation system. Placebo will be supplies in matching ampules to treprostinil. Volume will match that of treprostinil. Frequency and duration- 3 times over 1 study visit.
2969119|NCT02769611|Experimental|Ruboxistaurin 64 mg|ruboxistaurin, 64 mg as 1 capsule by mouth with water, 1 time administration
2969120|NCT02769611|Experimental|Ruboxistaurin 128 mg|ruboxistaurin, 128 mg as 2 capsules by mouth with water, 1 time administration
2969121|NCT02769611|Experimental|Ruboxistaurin 256 mg|ruboxistaurin, 256 mg as 4 capsules by mouth with water, 1 time administration
2969122|NCT02769598||ANI Index for Hospitalized children|"Each child will be registered upon arrival in the service and for a period of 24 hours. Registration will finish at the end of 24 hours or when the patient is discharged from the service. A FLACC scale (Face, Legs, Activity, Cry, Consolability scale) will be performed at the patient's input and then once every 4 hours corresponding to the patient's baseline. A FLACC scale will then be performed at each painful episode of the patient and 30 minutes after the end of production of analgesic treatment corresponding to the post-treatment painful condition of the patient.~A measurement of blood pressure will be performed at each pain rating by the patient assisted by the nurse."
2969123|NCT02769585|Experimental|Self-hypnosis|Subjects underwent two group sessions one week apart with a certified hypnotherapist to teach them the process of self-hypnosis for the purpose of attaining weight loss. Subjects were asked to perform self-hypnosis once or twice a day for the duration of the one year trial.
2969124|NCT02769585|Active Comparator|CDE training|Subjects underwent two group sessions one week apart with a certified diabetes educator to teach them re: diet and nutrition specifically as regards to a diabetic striving to lose weight. Subjects were asked to remain compliant with dietary restrictions for the duration of the one year trial.
2969125|NCT02769572|Experimental|real moxibustion plus placebo gel|In subjects with osteoarthritis of the knee
2969126|NCT02769572|Active Comparator|diclofenac sodium gel plus sham moxibustion|In subjects with osteoarthritis of the knee
2969127|NCT02769559||Patients with macromasty|Female adult patients with symptomatic macromasty selected for elective reduction surgery
2969128|NCT02769520|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
2969129|NCT02769520|Placebo Comparator|Placebo|Placebo consists of an intravenous (IV) bag containing 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP at a volume similar to pembrolizumab
2969160|NCT02769338|No Intervention|Control|Non-Intervention VA Medical Centers
2969130|NCT02769507|Experimental|real tDCS|DC Stimulator PLUS (NeuroConn) The real tDCS condition comprises two daily sessions of 20 min tDCS, separated by a minimum break of 3h, for five consecutive days. Anodal and cathodal tDCS will be applied with 2mA to the left dorsolateral prefrontal cortex (a point midway between F3 and FP1) and the left peri‐Sylvian region (a point midway between T3 and P3), respectively. Electrode size is 7cm x 5cm.
2969131|NCT02769507|Sham Comparator|sham tDCS|"DC Stimulator PLUS (NeuroConn) The sham condition is identical to the real tDCS condition except that after 40s of tDCS stimulation is going to be reduced to a small pulse every 550msec (110 μA over 15 msec) through the remainder of the 20 minute period."
2969132|NCT02769494|Experimental|Mesalazine Group|Mesalazine Sustained-Release Tablets and 0.02L glycerol mixed, 2.5% mesalazine glycerol suspension liquid, gently apply to the ulcer surface, 3 times/day. Daily treatment time of the drug is 8 am,12 pm and 4 pm.
2969133|NCT02769494|Active Comparator|Riboflavin Sodium Phosphate Group|wipe the riboflavin sodium phosphate injection to the ulcer surface, 3 times/day. Daily treatment time of the drug is am,12 pm and 4 pm.
2969134|NCT02769481|Active Comparator|Bexagliflozin|Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for glimepiride daily for the duration of the study.
2969135|NCT02769481|Active Comparator|Glimepiride|Subjects will receive a glimepiride capsule, 2, 4 or 6 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
2969136|NCT02769468|Active Comparator|The Back|The probe is placed lateral from the spine, 1 cm above the intergluteal cleft, and in side position to the flank between the hips and the ribs.
2969137|NCT02769468|Active Comparator|Chest|The probe is placed on the chest, 1 cm above the left nipple.
2969138|NCT02769468|Active Comparator|Left Axilla|The probe is placed deep in the left axilla
2969139|NCT02769455|No Intervention|Control|The control group will not be exposed to any FOP nutrition labels
2969140|NCT02769455|Experimental|Front-of-pack labelling (Reference Intakes)|The second group will be exposed to a FOP nutrition label which is already in use on a portion of food products in France: the 'Reference Intakes' (RIs). The RIs are presented in the form of a chain of rectangles presenting the contribution of a portion of the product to a reference balanced diet of an average person (2000kcal) for each of the following nutrients: energy, lipids, saturated fat, sugars and sodium.
2969141|NCT02769455|Experimental|Front-of-pack labelling (5-CNL)|"The 5-CNL was developed as a colour-coded summary system nutrition label, following the elements pointed out in reviews.~The format of the 5-CNL system therefore includes five categories of nutritional quality of food products, ranging from green (Associated with the A grade) for foods of the highest nutritional quality to red (associated with the E grade), for products with lower nutritional quality. The format is presented in the form of a continuous chain of rectangles, each with its own letter/colour, the letter/colour corresponding to the product being enlarged."
2969142|NCT02769442|Experimental|Terumo SurFlash Plus catheter|Patients randomized to the Terumo catheter
2969143|NCT02769442|Active Comparator|BD Insyte Autoguard catheter|Patients randomized to the BD catheter
2969144|NCT02769429||ultrasound-guided CISB|Group 1 will receive ultrasound-guided CISB with the catheter placed on the upper trunk of the brachial plexus
2969145|NCT02769429||nerve stimulator-guided CCPVB|Group 2 will receive landmark with nerve stimulator based needle placement and then nerve stimulator-guided CCPVB with the catheter placed on the 6th cervical spinal root
2969146|NCT02769416||Spinal Cord and Traumatic Brain Injury Subjects|Patients with a history of spinal cord and/or traumatic brain injury will provide data and samples so that they may be queried for interventional studies.
2969147|NCT02769416||Family Members and Healthy Volunteers|Healthy volunteer controls or family members may be enrolled for identification of genetic mutations.
2969148|NCT02769403|Experimental|Treatment|Participants will use HeartMath EmWave Pro for at least one 5-minute session daily, Monday through Friday. The treatment participants will use it daily for all 12 weeks, and will have the added component of weekly visits for the first 6 weeks of the study from the study team. The weekly visits is focused on reinforcing accountability and achievement of coherence. The participants will also complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance. Participants' blood pressure and heart rate will be collected at those three time points. Additionally, information about participants' use of HeartMath EmWave Pro, sick days, and patient satisfaction will be collected after week 12.
2969149|NCT02769403|Active Comparator|Control|Participants will use HeartMath EmWave Pro for at least one 5-minute session daily, Monday through Friday. The control participants will use it daily only for weeks 7-12. The participants will also complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance. Participants' blood pressure and heart rate will be collected at those three time points. Additionally, information about participants' use of HeartMath EmWave Pro, sick days, and patient satisfaction will be collected after week 12.
2969150|NCT02769390|No Intervention|Bupivacaine 0,166%|General Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% for hypospadia surgery
2969151|NCT02769390|Active Comparator|Clonidine 1 mcg/Kg|IGeneral Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 1 mcg/ Kg of clonidine for hypospadia surgery
2969152|NCT02769390|Active Comparator|Clonidine 2 mcg/ Kg|IGeneral Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 2 mcg/ Kg of clonidine for hypospadia surgery
2969153|NCT02769390|Active Comparator|Clonidine 3 mcg/Kg|General Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 3 mcg/ Kg of clonidine for hypospadia surgery
2969154|NCT02769377|No Intervention|Control|patients who decline or unable to do self-monitoring of blood glucose
2969155|NCT02769377|Active Comparator|Breeze2 glucometer|patients who do self-monitoring of blood glucose, but do not transfer data via mobile-phone
2969156|NCT02769377|Experimental|Breeze2 glucometer and H2|patients who do self-monitoring of blood glucose and transfer data via mobile-phone
2969157|NCT02769364||Participants treated with eribulin for at least 7 months|
2969158|NCT02769351||periph. minimal invasive ultrafiltration|Patients with volume overload receiving ultrafiltration
2969159|NCT02769338|Experimental|QI with External Facilitation|Receive external facilitation to support implementation of the quality improvement program
2969161|NCT02769325|Experimental|Atropine|Patients under a standardised general surgery will receive 1mg atropine (10ml) at induction of anesthesia
2969162|NCT02769325|Placebo Comparator|placebo|Patients under a standardised general surgery will receive 10 ml of saline at induction of anesthesia
2969163|NCT02769312|Sham Comparator|Sham Stimulation|A sham coil is being used to compare against active coil.
2969164|NCT02769312|Active Comparator|Active Stimulation|An active coil is being used to compare against sham coil.
2969165|NCT02769286|Experimental|Osimertinib in cohort 1|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA
2969166|NCT02769286|Experimental|Osimertinib in cohort 2|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring T790M which were detected from circulating tumor DNA
2969167|NCT02769260|No Intervention|No toothbrushing during experiment and Pyrosequencing|Volunteers will not brush their teeth during 48 hours. Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope) and 16S DNA pyrosequencing.
2969168|NCT02769260|No Intervention|No toothbrushing during experiment|Volunteers will not brush their teeth during 48 hours. Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope).
2969169|NCT02769260|Active Comparator|Toothbrushing during experiment|48hours-Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope).
2969170|NCT02769247|Experimental|Placebo|Patient will receive placebo oral medication and intrauterine normal saline prior to IUD insertion
2969171|NCT02769247|Experimental|Naproxen/Normal saline|Patient will receive naproxen and intrauterine normal saline prior to IUD insertion
2969172|NCT02769247|Experimental|Placebo oral medication/Lidocaine|Patient will receive placebo oral medication and intrauterine lidocaine prior to IUD insertion
2969173|NCT02769247|Experimental|Naproxen/Lidocaine|Patient will receive naproxen and intrauterine lidocaine prior to IUD insertion
2969174|NCT02769234||Alzheimer's disease|Subjects with a diagnosis of Alzheimer's disease that successfully performed an ERP/EEG test with the COGNISION(TM) System prior to enrollment for the current study are eligible to participate.
2969175|NCT02769221|Experimental|Optiscope|Endotracheal intubation by rigid video stylet, manufactural named Optiscope.
2969176|NCT02769221|Active Comparator|McGrath|Endotracheal intubation by video laryngoscope, manufactural named McGrath.
2969177|NCT02769208|Active Comparator|Group A: Pre-Filter Only Intervention|Subjects in Group A start with baseline conditions of pre-filter + HEPA + ESP in their offices and dorms. After a baseline biological measurement, they then receive a 5-week intervention in which both the HEPA and ESP are removed, leaving only a pre-filter. This intervention period includes a biological measurement 2 weeks into the intervention and other 4-5 weeks into the intervention. The baseline air purification conditions are then restored, and another biological measurement is taken 2 weeks after that.
2969178|NCT02769208|Active Comparator|Group B: Pre-filter + HEPA Intervention|Subjects in Group B start with baseline conditions of pre-filter + HEPA + ESP in their offices and dorms. After a baseline biological measurement, they then receive a 5-week intervention in which the ESP is removed, leaving a pre-filter + HEPA combination. This intervention period includes a biological measurement 2 weeks into the intervention and other 4-5 weeks into the intervention. The baseline air purification conditions are then restored, and another biological measurement is taken 2 weeks after that.
2969179|NCT02769182|Experimental|Monitoring and training using the system|
2969180|NCT02769182|Active Comparator|Standard of care|
2969181|NCT02769169|Experimental|double-dose|"double-dose~Lucentis® (Raibizumab), 1mg, 3+prn"
2969182|NCT02769169|Active Comparator|regular-dose|"regular-dose~Lucentis® (Raibizumab), 0.5mg, 3+prn"
2969183|NCT02769143|Experimental|Whole-Body Vibration Group (WBV)|Will be exposed to five minutes on a vibrating platform (Oscillating Platform Semi-Professional Horizontal - Arktus, Cascavel, Brazil), this type of platform vibrates through an anteroposterior axis, causing the right and left sides alternate horizontally denominated: alternating side vibration platforms, will be performed three times per week on alternate days (5 minutes). a frequency of 20 Hz (1 = 1 Hz oscillation / second) and a magnitude of 3.2 g (1 g = 9,81 m / s gravity) is used. The volunteers will be guided to stand on the platform with semi-flexed knees, barefoot and apart about hip width.
2969184|NCT02769143|Experimental|Pilates Group (PG)|Will be exposed to 60 minutes, held three times a week on alternate days. Pilates equipment used for the exercises are: Combo Chair, Cadillac Trapeze, Ladder Barrel, Reformer Universal, Step Barrel and Wall Unit. Will be selected for this study, 21 strengthening exercises and stretching to the main body segments. All exercises are performed in a series of ten repetitions with one minute interval between exercises. To determine the level of effort and consequently to changing loads, will be used verbal command according to the Borg CR10 scale. The level of effort will be maintained during the session heavy (Borg between 5 and 6).
2969185|NCT02769143|No Intervention|Control Group (CG)|The control group will be instructed to maintain their usual activities both in relation to their daily activities, dietary habits, failure to use drugs that can influence the increase in bone mass and participate in monthly meetings to address on issues osteoporosis and postmenopausal women. After the end of the interventions with WBV and GP groups, GC volunteers will be invited to also perform whole body vibration for six months. Exposure of vibration will be for five minutes on a vibrating platform, three times per week on alternate days. a frequency of 20 Hz (1 = 1 Hz oscillation / second) and a magnitude of 3.2 g (1 g = 9,81 m / s gravity) is used. Likewise which was offered for the WBV group.
2969186|NCT02769130|Experimental|Losartan|"Losartan will be given to children with stenosis in greater or equal to 2 pulmonary veins.~Maintenance daily dosing is 1mg/kg/day using suspension or tablet formulation of losartan. Losartan will be given for 1 year."
2969187|NCT02769117|Active Comparator|Ultrasound on fractured bone|An ultrasound technique will be used to record the acoustic response of the fractured bone at each clinical visit until the fracture is healed. The ultrasound probe and a small hydrophone are placed on the exposed portion of the forearm on either sides of the fracture. The ultrasound intensity will be at the safe level according to the FDA regulation. Investigators will conduct the tests on the fracture and on the unaffected (contralateral) bone as the control. Typically this is at 1-, 2-, 4-, and 6- weeks following the fracture.
2969307|NCT02768402|Experimental|Treatment Arm|All eligible patients will be in the treatment arm for the 'Caisson TMVR System' (transcatheter mitral valve replacement) procedure. No control or comparator in this study.
2969188|NCT02769117|Active Comparator|Ultrasound on contralateral intact bone|An ultrasound technique will be used to record the acoustic response of the intact bone as control at each clinical visit. The ultrasound probe and a small hydrophone are placed on the exposed portion of the forearm or clavicle. The ultrasound intensity will be at the safe level according to the FDA regulation. Investigators will conduct the tests on the fractured forearm/clavicle and on the unaffected (contralateral) forearm/clavicle as the control. Typically this is at 1-, 2-, 4-, and 6- weeks following the fracture.
2969189|NCT02769104|Experimental|AI+Chemo|aromatase inhibitors (Letrozole 2.5mg po. QD for 5 years) starts at the beginning of neoadjuvant treatment combined with chemotherapy (AC*4-T*4) in patients with postmenopausal hormone receptor-positive breast cancer
2969190|NCT02769104|Active Comparator|Chemo|chemotherapy (AC*4-T*4) as neoadjuvant treatment without aromatase inhibitors in patients with postmenopausal hormone receptor-positive breast cancer
2969191|NCT02769091|Experimental|TEV-45478|80 mg (2x40mg) tablets once daily for up to 24 weeks
2969192|NCT02769091|Placebo Comparator|Placebo|Matching placebo
2969193|NCT02769078||Patients who received dabigatran|Patients who received dabigatran
2969194|NCT02769078||Patients who received rivaroxaban|Patients who received rivaroxaban
2969195|NCT02769078||Patients who received apixaban|Patients who received apixaban
2969196|NCT02769078||Patients who received warfarin|Patients who received warfarin
2969197|NCT02769065|Experimental|SRD: Cohort 1: TAK-071 1 mg|TAK-071 1 mg, capsule or matching placebo, orally, once on Day 1 to non-Japanese healthy participants.
2969198|NCT02769065|Experimental|SRD: Cohort 2: TAK-071 TBD|TAK-071 capsule or matching placebo, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.
2969199|NCT02769065|Experimental|SRD: Cohort 3: TAK-071 TBD|TAK-071 capsule or matching placebo, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.
2969200|NCT02769065|Experimental|SRD: Cohort 4: TAK-071 TBD|TAK-071 capsule or matching placebo, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on the 24-hour post-dose safety and tolerability data from previous cohort.
2969201|NCT02769065|Experimental|SRD: Cohort 5: TAK-071 TBD|TAK-071 capsule or matching placebo, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.
2969202|NCT02769065|Experimental|SRD: Cohort 6: TAK-071 TBD|TAK-071 capsule or matching placebo, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5.
2969203|NCT02769065|Experimental|MRD: Cohort 7: TAK-071 TBD|TAK-071 capsules or matching placebo, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.
2969204|NCT02769065|Experimental|MRD: Cohort 8: TAK-071 TBD|TAK-071 capsules or matching placebo, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.
2969205|NCT02769065|Experimental|MRD: Cohort 9: TAK-071 TBD|TAK-071 capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.
2969206|NCT02769065|Experimental|MRD: Cohort 10: TAK-071 TBD + Donepezil 5 mg|TAK-071 capsules or matching placebo, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 will be that used in MRD Cohort 7.
2969207|NCT02769065|Experimental|MRD: Cohort 11: TAK-071 TBD + Donepezil 5 mg|TAK-071 capsules or matching placebo, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 will be that used in MRD Cohort 8.
2969208|NCT02769065|Experimental|MRD: Cohort 12: TAK-071 TBD + Donepezil 5 mg|TAK-071 capsules or matching placebo, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 will be that used in MRD Cohort 9.
2969209|NCT02769065|Experimental|MRD: Cohort 13: TAK-071 TBD|TAK-071 capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 will be that used in MRD Cohort 7.
2969210|NCT02769065|Experimental|MRD: Cohort 14: TAK-071 TBD|TAK-071 capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 will be that used in MRD Cohort 8.
2969211|NCT02769065|Experimental|MRD: Cohort 15: TAK-071 TBD|TAK-071 capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 will be that used in MRD Cohort 9.
2969212|NCT02769065|Experimental|MRD: Cohort 16: TAK-071 + Placebo|TAK-071 capsules, orally, once daily from Day 1 up to Day 21 followed by a 21 day washout period, followed by matching placebo capsules, orally, once daily from Day 42 up to Day 62 to healthy elderly or participants with MCI or mild AD. Dose of TAK-071 will not exceed the highest dose in MRD Cohorts 10 to 12. Donepezil 10 mg tablet orally once daily in run in period (Day -49 to Day -1).
2969213|NCT02769065|Experimental|BA/Food Effect:Cohort 17:TAK-071 DIC 10mg+TAK-071 Tablet 10mg|TAK-071 10 mg capsule or tablet, once on Day 1 to non-Japanese healthy participants. 3-single dose regimens in a 3-way cross over design.
2969214|NCT02769065|Experimental|SRD: Cohort 18: TAK-071 TBD|TAK-071 capsule or matching placebo, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.
2969385|NCT02767869|Experimental|Placebo|Calcined magnesia capsules, 500mg, two times per day before meals during 90 days
2969215|NCT02769065|Experimental|SRD: Cohort 19: TAK-071 TBD|TAK-071 capsule or matching placebo, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.
2969216|NCT02769065|Experimental|SRD+Donepezil: Cohort 20: TAK-071 TBD|TAK-071 capsule or matching placebo, orally, once on Day 1 along with donepezil 10 mg or matching placebo, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.
2969217|NCT02769065|Experimental|SRD+Donepezil: Cohort 21: TAK-071 TBD|TAK-071 capsule or matching placebo, orally, once on Day 1 along with donepezil 10 mg or matching placebo, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety and tolerability data from Cohort 20.
2969218|NCT02769065|Experimental|SRD+Donepezil: Cohort 22: TAK-071 TBD|TAK-071 capsule or matching placebo, orally, once on Day 1 along with donepezil 10 mg or matching placebo, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety and tolerability data from Cohort 21 .
2969219|NCT02769052|Active Comparator|Follow-up/Treatment Group|Composed of three phases of 8 weeks each (follow-up - treatment - follow-up). The treatment using the self-applied Transcutaneous Electrical Nerve Stimulation (TENS) will prescribe with daily application, twice a day for 20 minutes each application.
2969220|NCT02769052|Active Comparator|Treatment/Follow-up Group|Composed of two phases of 8 weeks each (treatment - follow-up). The treatment using the self-applied Transcutaneous Electrical Nerve Stimulation (TENS) will prescribe with daily application, twice a day for 20 minutes each application.
2969221|NCT02769039||Parkinson's Disease participants|People with early Parkinson's disease with mild-to-moderate severity of disease.
2969222|NCT02769039||Control participants|Volunteers who are age (+/- 3 years) and sex matched to the participants with Parkinson's disease
2969223|NCT02769013||S. haematobium positives in Gabon|Asymptomatic volunteers infected with S. haematobium and living in Gabon
2969224|NCT02769013||S. haematobium negatives in Gabon|Volunteers not infected with S. haematobium and living in Gabon
2969225|NCT02769013||S. haematobium positives in Ghana|Asymptomatic volunteers infected with S. haematobium and living in Ghana
2969226|NCT02769013||S. haematobium negatives in Ghana|Volunteers not infected with S. haematobium and living in Ghana
2969227|NCT02769000|Experimental|Subjects 1-30|15 subjects in each RT dose schedule 10 GY in 5 daily fractions 20 GY in 10 daily fractions
2969228|NCT02768987|Experimental|Overweight|Sedentary adolescents with T1D and overweight
2969229|NCT02768987|Experimental|Normal Weight|Sedentary adolescents with T1D and normal weight
2969230|NCT02768974|Experimental|OPRX-106 2 mg|Open label, 1:1 randomization ration (up to 10 subjects)
2969231|NCT02768974|Experimental|OPRX-106 8 mg|Open label, 1:1 randomization ration (up to 10 subjects)
2969232|NCT02768961|Experimental|Active treatment|"All HCV chronic infected patients will be treated with oral anti-HCV regimens containing sofosbuvir, ledipasvir (associated or not to ribavirin) according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver (EASL). EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
2969233|NCT02768948|Experimental|telmisartan|treatment with telmisartan at doses of 80 mg / day for 6 months
2969234|NCT02768948|Experimental|losartan|Losartan at a dose of 100 mg / d for 6 months.
2969235|NCT02768935|Other|Diabetes|
2969236|NCT02768935|Other|normoglycaemic|
2969237|NCT02768922|Experimental|Aphasia telerehabilitation|Speech and language therapy is given by telemedicine to improve expressive language function. The therapy will include knowledge based tasks of aphasia rehabilitation including training of language forms and overall functional communication. A special emphasis will be put on naming training. The telerehabilitation will be given in a addition to standard face-to-face aphasia rehabilitation
2969238|NCT02768922|Active Comparator|Control|Control Group receives standard face-to-face aphasia rehabilitation
2969239|NCT02768909|Experimental|Pulmonary TB|"This arm will enroll 100 patients older than 15 years old, from Caracas, with pulmonary TB, culture proved.~Intervention:~They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.~Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.~Chest X-ray.~Sputum samples for Ziehl Neelsen smear and Culture in L-J.~Follow Up 5 days after beginning of Tx~Follow Up 15 days after beginning of Tx~Follow Up 30 days after beginning of Tx~Follow Up 60 days after beginning of Tx"
2969240|NCT02768909|Active Comparator|Non - Pulmonary TB|"This arm will enroll 75 patients older than 15 years old, from Caracas, with non TB pulmonary infections, culture negative.~Intervention:~They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.~Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.~Chest X-ray.~Sputum samples for Ziehl Neelsen smear and Culture in L-J."
2969241|NCT02768909|Active Comparator|Healthy Individuals|"This arm will enroll 75 patients older than 15 years old, from Caracas, without any symptom or sign of lower track infection.~Intervention:~They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.~Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.~Chest X-ray.~Sputum samples for Ziehl Neelsen smear and Culture in L-J."
2969242|NCT02768896|No Intervention|Baseline|Patients will walk naturally with EEG measuring brain waves
2969243|NCT02768896|Experimental|Visual stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
2969244|NCT02768896|Experimental|Auditory stimuli|Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
2969245|NCT02768896|Experimental|Visual and auditory stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
2969246|NCT02768883|Experimental|Clinic + Home + Community|"Clinic Intervention = 4 clinical visits with provider over 12 months, 4 visits with clinic asthma educator~Home Intervention = 4 home visits with community health worker over 2 months, 4 mailers, and 4 phone calls~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
2969386|NCT02767856|Experimental|Intense 12-hour IO-therapy Group|Participants wear 12-hour daily IO-therapy glasses for 4 weeks
2969247|NCT02768883|Experimental|Clinic + Community|"Clinic Intervention = 4 clinical visits with provider over 12 months, 4 visits with clinic asthma educator~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
2969248|NCT02768883|Experimental|Home + Community|"Home Intervention = 4 home visits with community health worker over 2 months, 4 mailers, and 4 phone calls~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
2969249|NCT02768883|Active Comparator|Community only|Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook.
2969250|NCT02768870|Experimental|Mitral Valve Repair|The Harpoon Medical TSD-5 will be used to implant of 1 of more ePTFE suture(s), as artificial chordae tendineae, to reduce the severity of Mitral Regurgitation as confirmed by echocardiography
2969251|NCT02768857|Experimental|Early sensorimotor reeducation intervention|The experimental group received 15 minutes of touch-observation and task-based mirror therapy program, followed by 20 minutes of regular hand therapy and 20 minutes of physiotherapy in each treatment session before the returning of the touch of a Semmes-Weinstein monofilament marked 4.31. Once the patients had regained the protective sense (SWM < 4.31), the mirror therapy program was replaced with a discriminative sensory reeducation program. Treatment duration was 12 weeks, at a frequency of three sessions per week.
2969252|NCT02768857|Active Comparator|Traditional sensorimotor reeducation intervention|The control group received received 15 minutes traditional sensory reeducation program, 20 minutes of regular hand therapy and 20 minutes of physiotherapy in each treatment session before the returning of the touch of a Semmes-Weinstein monofilament marked 4.31. Once the patients had regained the protective sense (SWM < 4.31), the protective sensory reeducation program was replaced with a discriminative sensory reeducation program. Treatment duration was 12 weeks, at a frequency of three sessions per week.
2969253|NCT02768844|Experimental|SVS vs Control|Prospective, within-subject design. Compare effects of mattress SVS (ON) and Control (SVS OFF) on physiology in opioid-exposed newborns. SVS is alternated in intervals between continuous stimulation (ON) and no stimulation (OFF/Control) throughout inter-feed intervals. The order of the ON-OFF cycles is randomized across subjects and counterbalanced between feeding periods within subjects.
2969254|NCT02768831|Experimental|Cuffed ETT|
2969255|NCT02768818|Experimental|Intervention|Probiotic VIVOMIXX™
2969256|NCT02768818|Placebo Comparator|Control|Placebo
2969257|NCT02768805|Experimental|15 µg/strain of Quadrivalent VLP Vaccine|
2969258|NCT02768805|Experimental|30 µg/strain of Quadrivalent VLP Vaccine|
2969259|NCT02768805|Active Comparator|15 µg/strain of the licensed quadrivalent vaccine|
2969260|NCT02768792|Other|open-label, multicenter, single-arm|Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2-years of maintenance therapy (i.e., beginning on day 1 of maintenance). Patients who are ineligible for pembrolizumab administration by day 21 will be removed from the study.
2969261|NCT02768779||HIV negative and positive individuals|HIV Negative or HIV positive individuals, aged 18 years or older, who have been taking their ARV medication for at least 3 months and are adherent based on blood plasma HIV RNA of <50 copies/mL or HIV negative status. Hair analysis.
2969262|NCT02768766|Experimental|Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles starting at a dose of 125mg. The doses to be studied on a 3 day on, 4 day off schedule are 100mg, 125mg, 150mg, 175mg, 200mg and 225mg as per the time to event continual reassessment (TITE-CRM) design.
2969263|NCT02768753||The Axillary Bilateral-breast Approach (ABBA) group|All patients were told about the operative techniques involved in robotic thyroidectomy via the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA), and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
2969264|NCT02768753||The bilateral Axillo-breast Approach (BABA) group|All patients were told about the operative techniques involved in robotic thyroidectomy via the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA), and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
2969265|NCT02768740|Active Comparator|200 mg group|Patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days.
2969266|NCT02768740|Experimental|300 mg group|Patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
2969267|NCT02768727|Experimental|Xenon|Xenon anesthesia to determine if neural inertia is present in humans as visualized by CT imaging.
2969268|NCT02768714|Experimental|Eurofarma's pegfilgrastim|A single 6 mg dose on Day 2 of each chemotherapy cycle of Eurofarma's pegfilgrastim (subcutaneous injection)
2969269|NCT02768714|Active Comparator|Neulastim|A single 6 mg dose on Day 2 of each chemotherapy cycle of Neulastim (subcutaneous injection)
2969270|NCT02768701|Experimental|Experimental: Single Arm|Subjects will receive a single dose (300 mg/m2) of cyclophosphamide given the day before cycle 1 of pembrolizumab (200 mg), which will be administered every 3 weeks.
2969271|NCT02768688|Experimental|Brain connectivity and physiology|Dexmedetomidine anesthesia on glymphatic flow in human subjects as visualized by diffusion tensor MRI.
2969272|NCT02768675|Experimental|LOADPRO arm|Participants will temporarily receive a LOADPRO device affixed to kyphotic corrective rods. The device will not be implanted and will be removed prior to surgery closure.
2969273|NCT02768662|Experimental|OTO-104|12 mg dexamethasone
2969274|NCT02768649|Experimental|Cohort 1|Eligible subjects received a test dose of 0.25 risperidone prior to dosing with RBP-7000. Fifteen eligible subjects then received low dose RBP-7000
2969275|NCT02768649|Experimental|Cohort 2|After safety and tolerability review of the data from Day 1 to Day 15 of the low dose arm, 3 subjects were dosed in Cohort 2 with a higher dose of RBP-7000. A safety and tolerability review of the data from Day 1 to Day 15 was completed for the 3 subjects before the remaining 12 were dosed.
2969276|NCT02768649|Experimental|Cohort 3|After safety and tolerability review of the data from Day 1 to Day 15 of the medium dose arm, 3 subjects were dosed in Cohort 3 with a higher dose of RBP-7000. A safety and tolerability review of the data from Day 1 to Day 15 was completed for the 3 subjects before the remaining 12 were dosed.
2969277|NCT02768636|Experimental|Before and after omega-3 used|Before and after omega-3 used
2969278|NCT02768623|Active Comparator|Control Group|Patients in the control group will receive standard, dispensing services they currently receive from pharmacists. Control group pharmacists will continue to provide these services in accordance with the standards of practice adopted by the Ontario College of Pharmacists. They will not provide either of the 3 intervention components outlined above. Should a control group patient request additional information and/or services, the pharmacist will comply and provide these as deemed necessary for the particular patient. This could include the full range of educational and drug therapy optimization services outlined for the intervention group. If this occurs then the pharmacists will document all services provided in order for the research team to account for this in the analysis.
2969279|NCT02768623|Experimental|Intervention Group|"Pharmacists in the intervention group will provide patients with a comprehensive disease management program for asthma. The 3 major components of pharmacists' intervention are outlined below. The services delivered will be customized based on each patient's case.~Medication review and drug therapy optimization~Patient education~Improving patient adherence"
2969280|NCT02768610|Experimental|dexmedetomidine|0.5 mcg/kg dexmedetomidine is administered before endotracheal intubation for 10 minutes
2969281|NCT02768610|Placebo Comparator|Normal Saline|
2969282|NCT02768597|Active Comparator|Large-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset
2969283|NCT02768597|Active Comparator|Small-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset
2969284|NCT02768597|Active Comparator|Large-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset
2969285|NCT02768597|Active Comparator|Small-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset
2969286|NCT02768571|Experimental|Cerebrolysin|"Cerebrolysin 30 ml with 100 ml dilution/day * 21 days with rehabilitation~Study drug schedule - given from day 8 after stroke, but, if day 8 is weekend, the given day is the next Monday(day 9~10)~Rehabilitation~3 hours (physiotherapy: 2 hours, occupational therapy: 1 hour) / day~5 times/week for 3 weeks~Duration of Treatment:~Study drug will be given once daily by intravenous infusion for 21 consecutive days on study day 8 ~ 28.~The clinical observation period for each patient will be 90 days and will include four clinical evaluation visits at Screening(day ≤ 7), Baseline(day 8) and on study day 29, and 90."
2969287|NCT02768571|Placebo Comparator|Placebo|"Saline 100 ml/day * 21 days with rehabilitation~Study drug schedule - given from day 8 after stroke, but, if day 8 is weekend, the given day is the next Monday(day 9~10)~Rehabilitation~3 hours (physiotherapy: 2 hours, occupational therapy: 1 hour) / day~5 times/week for 3 weeks~Duration of Treatment:~Study drug will be given once daily by intravenous infusion for 21 consecutive days on study day 8 ~ 28.~The clinical observation period for each patient will be 90 days and will include four clinical evaluation visits at Screening(day ≤ 7), Baseline(day 8) and on study day 29, and 90."
2969288|NCT02768558|Experimental|Arm I (Thoracic RT, Cisplatin, Etoposide and Nivolumab)|Patients will receive 60 Gy of thoracic RT; Cisplatin and Etoposide followed by Nivolumab given via IV administration every 2 weeks for 1 year
2969289|NCT02768558|Placebo Comparator|Arm II (Thoracic RT, Cisplatin, Etoposide and Placebo)|Patients will receive 60 Gy of thoracic RT; Cisplatin and Etoposide followed by Placebo (0.9% Sodium Chloride solution or 5% Dextrose solution) given via IV administration every 2 weeks for 1 year
2969290|NCT02768545|Experimental|Liver transplant candidates|Ezetimibe in a dose of 10 mg/d for 12 weeks.
2969291|NCT02768532|Experimental|Crohn's disease patients|The patients will receive vedolizumab in compliance with the marketing authorization regimen (300 mg at weeks 0, 2, 6 and then every 8 weeks) in Crohn's Disease patients in clinical failure or intolerant to anti-TNF (Tumor Necrosis Factor) drugs. In case of lack of clinical response at week 10 or loss of response in the follow-up, all patients will be optimized with vedolizumab 300 mg at week 10 (additional infusion) and every following 4 weeks in contrast with responder patients at week 10 who will not have vedolizumab infusion at this time-point but will receive the next vedolizumab infusion at week 14 and then every 8 weeks, as recommended.
2969292|NCT02768519|Experimental|OTS167IV|Cohort 1: 0.5 mg, Cohort 2: 1.0 mg, and Cohort 3: 2.0 mg without food on Period 1 Day 1 and with food on Day 1 Period 2.
2969293|NCT02768519|Placebo Comparator|Placebo|Cherry syrup
2969294|NCT02768506||Gastric bypass|Subjects submitted to gastric bypass
2969295|NCT02768506||SADI-S|Subjects submitted to SADI-S
2969296|NCT02768493|Experimental|low dose group|Patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block.
2969297|NCT02768493|Active Comparator|high dose group|Patients in the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block.
2969298|NCT02768480|Active Comparator|Primary Care|Patients will be followed by primary care team exclusively.
2969299|NCT02768480|Experimental|Phone Calls Support and Primary Care|Patients will be followed by primary care team and supported by periodic nurse phone calls.
2969300|NCT02768467|Experimental|Tissue Matrix Graft Placement|After the buccal mucosa is removed during reconstructive surgery, the wound is covered with an acellular tissue collagen matrix
2969301|NCT02768467|Active Comparator|Without stitches|After the buccal mucosa is removed during reconstructive surgery, no stitches will be used for the wound to heal.
2969302|NCT02768454||inpatient under broad-spectrum antibiotics|medical review
2969303|NCT02768441|Experimental|Study group|Participants receiving Dexamphetamine 60 mg SR
2969304|NCT02768428|Experimental|Video-Audio Media|watching the entire video in 15 mins
2969305|NCT02768428|No Intervention|Handbooks|study the hand book in 15 mins
2969306|NCT02768415|Experimental|lapatinib+oral vinorelbine|"apatinib 425/500mg qd, 21days/cycle~oral vinorelbine 60mg/m2 d1, 8, 15 21days/cycle*3cycles, after 3 cycles: 80mg/m2 d1, 8, 15 21days/cycle"
2969387|NCT02767856|Active Comparator|Standard 4-hour IO-therapy Group|Participants wear 4-hour daily IO-therapy glasses for 12 weeks
2969308|NCT02768389|Experimental|Modified Atkins Diet and Bevacizumab|Patients and caregivers will be educated by a nutritionist skilled in the MAD. Patients will also be receiving Bevacizumab as standard of care.
2969309|NCT02768376|Active Comparator|General anesthesia group|General anesthesia group: Standard anesthetic technique will be applied.Anesthesia will be induced by propofol 1% (1-2 mg/kg), Fentanyl 1-2 mic/kg, and Atracurium 0.5 mg/kg then according to train of four response. Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
2969310|NCT02768376|Experimental|Spinal anesthesia group|While in sitting position; intrathecal injection using 25 G spinal needle using 3 mls of Bupivacaine 0.5% with 20 mic Fentanyl, at L 2-3 level the patient head will be lowered till sensory blockade of T6 obtained at least.
2969311|NCT02768363|Active Comparator|ProstAtak®|Patients randomized to the ProstAtak arm will receive two courses of aglatimagene besadenovec + valacyclovir
2969312|NCT02768363|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive two corresponding courses of placebo + valacyclovir
2969313|NCT02768350|Experimental|Control group|All of the participants in control group will be treated with conventional treatment for 3 days, The conventional treatments consist of: (1) Passive chest mobilization, (2) Positioning, (3) Side lying (good lung down), (4) Vibration. The conventional treatment consists of three consecutive periods; (1) baseline period: 10 minutes, (2) intervention period, and (3) recovery period: 10 minutes.
2969314|NCT02768350|Experimental|Experimental group|All of the participants of the experimental group will be treated with ventilator hyperinflation technique (VHI) for 3 days. Tidal volume will increase from baseline (100% VT) to the tidal volume target at 1.5 times (150% VT). At this level, patients will receive six breathes and in each breathe will be sustained for 5 second (6 hyperinflation breathe per set); expiratory VT will return to baseline after each breath. Four sets of hyperinflation breathing will be used. After this, VT will decrease to baseline and patients have a 60 second for rest between hyperinflation set. The ventilator hyperinflation technique (VHI) consists of three consecutive periods; (1) baseline period: 10 minutes, (2) intervention period, and (3) recovery period: 10 minutes.
2969315|NCT02768337|Other|Arm 1: Afatinib only at Recommended Phase 2 dose (RP2D)|No targeted radiotherapy. Afatinib at Recommended Phase 2 Dose for 11 days.
2969316|NCT02768337|Experimental|Arm 2: Afatinib RP2D + 2 Gy targeted radiotherapy|Patient will receive the RP2D of afatinib for 11 days and will receive targeted radiotherapy at a dose level of 2 Gy on Day 10 of treatment.
2969317|NCT02768337|Experimental|Arm 3: Afatinib RP2D + 4 Gy targeted radiotherapy|Patient will receive the RP2D of afatinib for 11 days and will receive targeted radiotherapy at a dose level of 4 Gy on Day 10 of treatment.
2969318|NCT02768324||sepsis with diarrhea|
2969319|NCT02768324||sepsis without diarrhea|
2969320|NCT02768311|Experimental|neolix rotary system (continuous rotation system)|Procedure: neolix rotary system post-treatment pain after using neolix rotary system
2969321|NCT02768311|Experimental|waveone rotary system (reciprocating system)|Procedure: waveone rotary system post-treatment pain after using waveone rotary system
2969322|NCT02768311|Experimental|hand files k-files|Procedure: hand files post-treatment pain after using hand files
2969323|NCT02768298|Experimental|LCZ696|All randomized patients in this arm will be initiated with one tablet of LCZ696 100mg and one tablet of enalapril matching placebo twice a day (bid). Dose will be up-titrated after 2 weeks to the final dose of LCZ696 200mg bid to receive one tablet of LCZ696 200mg and one tablet of enalapril matching placebo twice daily (bid). Patients will be in study drug for 12 weeks.
2969324|NCT02768298|Active Comparator|Enalapril|All randomized patients in this arm will be initiated with one tablet of Enalapril 5mg and one tablet of LCZ696 matching placebo twice a day (bid). Dose will be up-titrated after 2 weeks to the final dose of Enalapril 10mg bid to receive one tablet of enalapril 10mg and one tablet of LCZ696 200mg matching placebo twice daily (bid). Patients will be in study drug for 12 weeks.
2969325|NCT02768285|Experimental|Intervention|Endodontic treatment was performed in posterior teeth with necrotic pulp and periapical periodontitis using a reciprocating single-file system (Reciproc). Local anesthesia was provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation was done.Using 2.5 % sodium hypochlorite, canal negotiation was done & apical patency was achieved with #10 K-files in patency group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills was done. The canals were obturated with gutta-percha and epoxy resin sealer. The treatments were carried out in one-visit.
2969326|NCT02768285|No Intervention|Control|In the control group, apical patency did not maintained.
2969327|NCT02768272|Experimental|Epidural analgesia|Randomized allocation to receive patient controlled epidural analgesia or programed intermittent epidural boluses
2969328|NCT02768272|Experimental|Epidural technique|Randomized allocation to be punctioned a conventional epidural or a combined spinal-epidural technique
2969329|NCT02768246|Active Comparator|Begin with BVGA|The volunteers will be asked to breathe 5 minutes of room air through the BVGA, followed by, 5 minutes 100% oxygen, and 5 minutes room air again. This will be followed by 5 minutes room air breathing without the BVGA. Then the same volunteers will be asked to repeat the protocol with the face mask.
2969330|NCT02768246|Active Comparator|Begin with Face-mask|The volunteers will be asked to breathe 5 minutes of room air through the face mask, followed by, 5 minutes 100% oxygen, and 5 minutes room air again. This will be followed by 5 minutes room air breathing without the face mask. Then the same volunteers will be asked to repeat the protocol with the BVGA.
2969331|NCT02768233|Experimental|Educational programme|Group 1: Educational programme + standard treatment
2969332|NCT02768233|No Intervention|Standard treatment|Standard treatment
2969333|NCT02768220|Active Comparator|Linagliptin|Eligible patients were randomized to receive linagliptin 5mg daily for 30 days.
2969334|NCT02768220|Experimental|Empagliflozin|Eligible patients were randomized empagliflozin 25mg daily for 30 days.
2969335|NCT02768207|Experimental|Treatment Phase: Vemurafenib+Cobimetinib|Participants with BRAF V600 mutation will receive vemurafenib 960 milligrams (mg) tablets orally twice daily (BID) on Days 1 to 28 along with cobimetinib 60 mg tablets orally once daily (OD) for 21 consecutive days (Days 1 to 21) of each 28-day cycle until disease progression, consent withdrawal, or the development of unacceptable toxicity.
2969388|NCT02767843|Experimental|treatment|continuous negative external pressure (cNEP) at various negative pressures
2969336|NCT02768194|Experimental|Test Product (0.454% stannous fluoride)|Participants will use dentifrice containing 0.454% stannous fluoride. Appliances brushed ex situ in 1:3 slurry of freshly prepared dentifrice twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in a 1:3 slurry of assigned dentifrice. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
2969337|NCT02768194|Active Comparator|Reference Product (0.76% sodium monofluorophosphate)|Participants will use dentifrice containing 0.76% sodium monofluorophosphate. Appliances brushed ex situ in 1:3 slurry of freshly prepared dentifrice twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in a 1:3 slurry of assigned dentifrice. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
2969338|NCT02768194|Other|Negative Control (Mineral water)|Participants will use commercially available mineral water. Appliances brushed ex situ in mineral water twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in mineral water. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
2969339|NCT02768181|Experimental|Arm 1: BCC+PNS+CNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth, along with nutritional supplement to pregnant women till delivery. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children, along with nutritional supplement to children 6m to 2 years.
2969340|NCT02768181|Experimental|Arm 2: BCC+PNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth, along with nutritional supplement to pregnant women till delivery. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children.
2969341|NCT02768181|Experimental|Arm 3: BCC+CNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children, along with nutritional supplement to children 6m to 2 years.
2969342|NCT02768181|Experimental|Arm 4: BCC only|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children.
2969343|NCT02768181|No Intervention|Arm 5: comparison|No intervention will be provided by the study. The existing services delivered though government health systems will be continued. Government /NGO-led routine counseling and supplementary services available at Upazila and union levels, which include prenatal counseling, exclusive breastfeeding counseling, and maternal iron-folic acid supplementation and vitamin-A supplementation for children will continue. However, assessment of outcomes will be conducted in same frequency and schedule, alike in intervention arms, described in data collection section.
2969344|NCT02768168|Experimental|Group D|40 patients receive dezocine 0.1 mg/Kg
2969345|NCT02768168|Placebo Comparator|Group C|40 patients receive matching placebo （normal saline）
2969346|NCT02768155|Experimental|AF 4.0|Amniotic Fluid 4.0ml dose
2969347|NCT02768155|Experimental|AF 2.0|Amniotic Fluid 2.0ml dose
2969348|NCT02768155|Placebo Comparator|Placebo|Saline Placebo Control
2969349|NCT02768142|Experimental|Natural cesarean delivery|Placing the neonate on maternal chest immediately after the extraction from the uterus, and permitting breastfeeding during surgery.
2969350|NCT02768142|Active Comparator|Standard cesarean delivery|Presentation of the neonate to the mother during the operation.
2969351|NCT02768129|Sham Comparator|sham tDCS|10 sessions sham transcranial direct current stimulation (tDCS)
2969352|NCT02768129|Experimental|active tDCS|10 sessions active transcranial direct current stimulation (tDCS)
2969353|NCT02768116|Experimental|ATP technique|This arm plan to enroll 158 subjects. Sirolimus-eluting Drug stent implantation via Active transfer of Plaque technique in the treatment of non-left-main bifurcation lesion.In the ATP technique treatment of bifurcation lesions, by the balloon pre-dilation in the target side branch, the plaque will be actively transferred from side branch to main vessel. Subsequently, the plaque will be fixed by the expansive stent in main vessel. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI or stent in SB is recommended if there is at least one of following: residual stenosis>75%, >type B dissection and TIMI flow<3.
2969354|NCT02768116|Active Comparator|Provisional T stenting technique|This arm plan to enroll 158 subjects. Sirolimus-eluting Drug stent implantation via Provisional T stenting technique in the treatment of non-left-main bifurcation lesions.Provisional T stenting technique is the typic step-T stenting. In brief, two wires are advanced to distal MV and SB. Pre dilation is left at operator's discretion, however, pre dilating SB is not encouraged. Kissing balloon inflation before stenting MV is left at operator's discretion. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI is recommended if there is at least one of following: residual stenosis>75%, >type B dissection and TIMI flow<3.
2969355|NCT02768103|Experimental|SCI transfer + training|Individuals with tetraplegia and brachioradialis to flexor pollicis longus transfer will participate in 10 week home training program to improve surgical outcome (pinch strength)
2969356|NCT02768090|Experimental|Skin Patch|Sweat will be collected from inflammatory and neoplastic skin lesions with an FDA approved diagnostic skin patch for analysis with mass spectrometry
2969357|NCT02768077|Experimental|Melatonin(Circadin®)|Melatonin(Circadin®) is taken orally, once daily before going to sleep for a period of 4 weeks.
2969358|NCT02768077|Placebo Comparator|Placebo|Placebo tablet is taken orally, once daily before going to sleep for a period of 4 weeks.
2969359|NCT02768064|Experimental|Flexible screwed electrode|In the TAVI patients, during the intervention procedure, a temporary pacemaker will be implanted, using a flexible screwed electrode.
2969360|NCT02768064|Active Comparator|Stiff standard electrode|In the TAVI patients, during the intervention procedure, a temporary pacemaker will be implanted, using a stiff standard temporary electrode
2969361|NCT02768051|Experimental|AF Ablation Intervention|Subjects who are scheduled to undergo ablation procedure due to atrial flutter.
2969362|NCT02768025|Experimental|Intervention group|NRT, counselling, traditional & complementary medicine treatment (Body acupuncture, Ear acupuncture and aromatic therapy).
2969363|NCT02768025|Active Comparator|Control group|NRT, counselling
2969364|NCT02768012|Active Comparator|mindfulness-based cognitive therapy|The practice of mindfulness will be followed plus the basics of cognitive therapy given in small group format.
2969365|NCT02768012|No Intervention|waitlist|Women diagnosed with AISD randomised to wait list will receive no active treatment during the trial period.
2969366|NCT02767999|Experimental|Fluoxetine|One group will take a 20 mg of fluoxetine capsule per day from D0 to D90 and have fMRI
2969367|NCT02767999|Placebo Comparator|Placebo|The other group will take a cellulose placebo per day from D0 to D90 and have fMRI
2969368|NCT02767973|Experimental|Woodsmoke Exposure|
2969369|NCT02767960||STEMI group|The study population consists of 30 patients with ST-elevated acute myocardial infarction (STEMI,n = 30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
2969370|NCT02767960||NSTEMI group|The study population consists of 30 patients with non-ST elevated acute myocardial infarction (NSTEMI,n=30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
2969371|NCT02767960||UAP group|The study population consists of 30 patients with unstable angina pectoris (UAP, n = 30). They will all undergo coronary angiography for the diagnosis of acute coronary syndrome. The diagnosis is made according to the criteria of the American Heart Association (AHA, 2014 and 2015). Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
2969372|NCT02767960||control group|15 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Normal group.
2969373|NCT02767947|Experimental|Luliconazole Cream 1%|Cream
2969374|NCT02767947|Active Comparator|Vehicle Cream|Vehicle Cream
2969375|NCT02767934|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving complete MRD response may receive up to 1 additional year of treatment at the discretion of the investigator.
2969376|NCT02767921|Experimental|Treatment (recombinant EphB4-HSA fusion protein, surgery)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes once weekly for 3 weeks (3 doses) in the absence of disease progression or unacceptable toxicity. Patients who agree may receive the fourth dose after an additional week as determined by the study medical oncologist. Two to four weeks after the last dose of recombinant EphB4-HSA fusion protein, patients undergo robotic-assisted radical cystectomy or robotic-assisted radical or partial nephrectomy.
2969377|NCT02767908|No Intervention|Usual Care|Participants in the usual care group will be offered and, if accepted, provided with smoking cessation support that meets the recommendations of NICE PH48 guidance including pharmacotherapy and behavioural support before leaving hospital, referral to NHS SSS for continued care after discharge, and ascertainment of smoking status at 4 weeks; participants will also be asked to consent to smoking status ascertainment at three months. Those who report cessation at 4 weeks and/or three months will be requested to agree to a home visit for CO validation. All will be asked at four weeks and 3 months to list the cessation support, in terms of pharmacotherapy and behavioural support from local or other services, delivered since the last contact.
2969378|NCT02767908|Active Comparator|Intervention|A home visit will be carried out as soon as practicable after discharge and typically within 48 hours, to deliver a multi-component intervention. Intervention components all have an existing evidence base proving or suggesting potential efficacy for smoking cessation and/or relapse prevention, though their feasibility and importance when delivered as a combined package have not been tested.
2969379|NCT02767895|Experimental|Prehabilitation|Participants will be referred to the Michigan Surgical & Health Optimization Program in the month leading up to their surgery. Individuals are encouraged to increase their physical activity, practice stress reduction, and other behaviors associated with good health
2969380|NCT02767895|No Intervention|Usual Care|Participants will follow the pre-operative instructions provided by their surgical team.
2969381|NCT02767882|Active Comparator|Group D1|Patients from group D will be given a bolus injection of 2 ml saline with 2 ml dexamethasone (4mg/ml) before skin incision.
2969382|NCT02767882|Experimental|Group D2|4ml bolus injection of dexamethasone (4mg/ml) will be given intravenously prior to incision.
2969383|NCT02767882|Placebo Comparator|Group C|4ml bolus injection of 0.9% saline will be given intravenously prior to incision
2969384|NCT02767869|Experimental|Banaba|Banaba capsules, 500mg, two times per day before meals during 90 days
2969389|NCT02767830|Experimental|Excercise and Nutrition Program|Children and their care givers will receive 5 lectures on nutrition and exercise and will be given a weekly running program. At the end of the study children will be encouraged to participate in an annual 0.25-0.5 mile race.
2969390|NCT02767817|Sham Comparator|Stereotactic Hematoma Evacuation|
2969391|NCT02767817|Experimental|MSCs Transplantation|
2969392|NCT02767817|Experimental|Injectable Collagen Scaffold with MSCs Transplantation|
2969393|NCT02767804|Experimental|X-396 (ensartinib)|Eligible patients with ALK+ NSCLC will receive oral X-396 (ensartinib) at 225mg QD with or without food until progression or unacceptable toxicity develops
2969394|NCT02767804|Active Comparator|crizotinib|Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID with or without food until progression or unacceptable toxicity develops
2969395|NCT02767791|Active Comparator|Acupuncture|Acupuncture wrist 6
2969396|NCT02767791|Active Comparator|Auriculotherapy|Auriculotherapy
2969397|NCT02767791|Experimental|Auriuclotherapy and acupuncture|Auriuclotherapy and acupuncture
2969398|NCT02767791|No Intervention|No treatment|No treatment
2969399|NCT02767778|Experimental|REAL Pulsed ELF-MF stimulation|Patients will receive REAL pulsed ELF-MF stimulation and the standard of care for acute ischemic stroke, according to current guidelines.
2969400|NCT02767778|Sham Comparator|SHAM Pulsed ELF-MF stimulation|Patients will receive SHAM pulsed ELF-MF stimulation and the standard of care for acute ischemic stroke, according to current guidelines.
2969401|NCT02767765|Experimental|r-HuEPO|Anemic cancer participants will receive r-HuEPO for 4 weeks.
2969402|NCT02767752|Experimental|T-ChOS + Gemcitabine + Capecitabine|"T-ChOS: 600 mg given p.o. (two capsules, each 300 mg) daily in the morning 30 minutes before food.~Gemcitabine: 1000 mg/m²i.v. on day 1, day 8 and day 15 of every 28 day cycle. Capecitabine: 1660 mg/m²/day p.o. twice daily 21/28 day i. e. 24 weeks."
2969403|NCT02767752|Placebo Comparator|Placebo + Gemcitabine + Capecitabine|"Placebo: 600 mg given p.o. (two capsules, each 300 mg) daily in the morning 30 minutes before food.~Gemcitabine: 1000 mg/m²i.v. on day 1, day 8 and day 15 of every 28 day cycle. Capecitabine: 1660 mg/m²/day p.o. twice daily 21/28 day i. e. 24 weeks."
2969404|NCT02767739|Experimental|Physical, social and cultural activities|"Physical Activity: The training program will be supervised by a physical activity specialist and will consiste of two aerobic exercise sessions per week, including walking and stretching exercises after walking. Each session will be 60 minutes and the size of groups will be from 15 to 30 participants. Additionally, participants will receive advice about the health benefits of PA and PHC nurses using different strategies to encourage the adherence of participants to the program.~Social and cultural support activities. Activities will include: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons. These activities will be performed once a month."
2969405|NCT02767739|No Intervention|Control Group|No intervention. We will measure the variables at the begining and after 9 months.
2969406|NCT02767713|Experimental|Dexamethasone|Dexamethasone dose of 0.1 mg/kg was administered intravenously 10h before surgery
2969407|NCT02767713|Placebo Comparator|Control|Equal volume of normal saline (placebo) was administered intravenously 10h before surgery
2969408|NCT02767687|Experimental|Noninvasive ventilation (NIV)|Noninvasive mechanical ventilation is a resource used to treat respiratory failure or to reestablish respiratory comfort and function. It is commonly used in the ICU with a regular mechanical ventilator and is offered using an interface that connects the machine to the patient. The interface used for adults and in this study, was a silicon facial mask that covers the nose and mouth of the patient, allowing him or her to open the eyes.
2969409|NCT02767674|Experimental|R-GemOx|Rituximab: 375 mg/m2 IV day0, Gemcitabine 1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1(every 14 days)
2969410|NCT02767674|Active Comparator|R-miniCHOP|Rituximab, 375 mg/m2 IV d0 Cyclophosphamide 400 mg/m2 IV d1 Doxorubicin 25 mg/m2 IV d1 Vincristine 1 mg IVP d1 Prednisone 40mg/m2 PO d1-5(every 21 days a cycle)
2969411|NCT02767661|Experimental|Capecitabine+Aromatase inhibitor|Capecitabine, 625mg/m2, orally twice daily in combination with an aromatase inhibitor (Anastrozole 1 mg, orally once daily or Letrozole 2.5mg, orally once daily or Exemestane 25mg, orally once daily)
2969412|NCT02767661|Active Comparator|Aromatase inhibitor|Aromatase inhibitor (Anastrozole 1 mg, orally once daily or Letrozole 2.5mg, orally once daily or Exemestane 25mg, orally once daily)
2969413|NCT02767648||cholestasis|infant suffering from cholestasis proteomic urine analysis
2969414|NCT02767635|Experimental|Botox-Epic group|20 units of Botox injection into lateral epicondyle in Botox-Epic group
2969415|NCT02767635|Experimental|Botox-Tend group|20 units of Botox injected into tender point of muscles in Botox-Tend group
2969416|NCT02767635|Active Comparator|Steroid group|40mg of triamcinolone acetonide but not Botox injected into lateral epicondyle in Steroid group
2969417|NCT02767622||Patient Group|Twenty right handed patients with biopsy-proven liver cirrhosis listed for liver transplantation.
2969418|NCT02767622||Control Group|Twenty age-matched healthy persons. They were similar to the patient group in respect to the number of education years, sex, and handedness.
2969419|NCT02767609|Experimental|Magentic Resonance Imaging|magnetic Resonance Imaging.
2969420|NCT02767596|Experimental|Lixisenatide|S.C. Lixisenatide 10 mcg for 2 weeks and then 10 mcg for 10 weeks
2969421|NCT02767583|Experimental|Non diabetic obese|Non diabetic obese with BMI 35-55 kg / m2 consulting for the first time at the Centre of obesity of Paris Saint Joseph Hospital Group will got a themotest and Sudoscan exams de determine their neuropathology.
2969422|NCT02767570|Experimental|Gait Training; Altered Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback. The goal of the training is to encourage participants to adopt an altered foot progression angle in an attempt to alter the distribution of forces crossing the knee joint. Training will occur once a week for six weeks. This will be followed by a 46-week home and community-based walking program to practice and internalize the new personalized, gait pattern and to encourage daily walking. Refresher training with haptic feedback will be offered at weeks 11, 25 and 39 to enhance internalization of the new foot progression angle.
2969450|NCT02767375|Active Comparator|HAIC treatment group|HAIC treatment after resection Intervention: Drug: Oxaliplatin, 5-fluorouracil (5-FU) Procedure/Surgery: Hepatic arterial catheter implantation
2969423|NCT02767570|Experimental|Gait Training; Consistent Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with haptic feedback. The goal of the training is to encourage participants to maintain a consistent foot progression angle in an attempt to minimize the variability in the forces crossing the knee joint. Training will occur once a week, for 6 weeks. This will be followed by a 46-week home and community-based walking program to encourage daily walking. Refresher training with haptic feedback will be offered at weeks 11, 25 and 39 to maintain foot progression angle consistency.
2969424|NCT02767557|Experimental|Tocilizumab & Gemcitabine and nab-Paclitaxel|"Tocilizumab:~8 mg/kg given I. V. on day 1 over 60 minutes every 28 day cycle.~Gemcitabine:~1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.~Nab-Paclitaxel:~125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle."
2969425|NCT02767557|Active Comparator|Gemcitabine and nab-Paclitaxel|"Gemcitabine:~1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.~Nab-Paclitaxel:~125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle."
2969426|NCT02767544|Experimental|ropivacaine group|Vaginal wound local analgesia by 10ml ropivacaine 7.5mg/ml injection after laparoscopic hysterectomy
2969427|NCT02767544|No Intervention|Control group|Vaginal wound no local analgesia by 10 ml ropivacaine 7.5mg/ml injection after laparoscopic hysterectomy
2969428|NCT02767531|Experimental|Orlistat|120 mg of Orlistat will be given 3 times to patients weighing greater than 50 kg and patients weighing less than 40 kg will be given 60 mg of Orlistat 3 times a day for 3 months.
2969429|NCT02767531|No Intervention|Off drug|Standard therapy will be given for three months
2969430|NCT02767518|Experimental|Prehabilitation|Participants will be referred to the Michigan Surgical & Health Optimization Program in the month leading up to their surgery. Individuals are encouraged to increase their physical activity, practice stress reduction, and other behaviors associated with good health.
2969431|NCT02767518|No Intervention|Usual Care|Participants will follow the pre-operative instructions provided by their surgical team.
2969432|NCT02767505|Experimental|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
2969433|NCT02767505|Active Comparator|Gastric bypass|Laparoscopic Roux-en-Y gastric bypass
2969434|NCT02767492|Experimental|BioDRestore™|BioDRestore™ Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from amniotic tissues. 2cc will be injected in the knee joint.
2969435|NCT02767492|Active Comparator|Corticosteroid|Kenalog (40 mg of 40 mg/ml) will be the steroid utilized as the active comparator to be injected in the knee joint.
2969436|NCT02767479|Active Comparator|rabeprazole group|rabeprazole-based regimen. This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
2969437|NCT02767479|Active Comparator|esomeprazole group|'esomeprazole^based regimen. This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
2969438|NCT02767466||G|"All participants were randomly exposed to two different treatments:~Conventional physical therapy (no specific device used)~Robotic assisted gait training (Lokomat, Hocoma AG, Switzerland)~We consider the study as observational, since the both interventions of the study (physical therapy, robotic assisted gait training) did not change in the patients' usual therapy plan, as they received both interventions daily.~We only added diagnostic interventions to assess the affective responses."
2969439|NCT02767453|Active Comparator|TSA with drain placement|Hemovac drains are placed in subjects during standard Total Shoulder Arthroplasty involving the replacement of damaged shoulder components with shoulder prosthesis.
2969440|NCT02767453|Active Comparator|TSA without drain placement|Hemovac drains will not be placed in subjects during standard Total Shoulder Arthroplasty involving the replacement of damaged shoulder components with shoulder prosthesis.
2969441|NCT02767440|Experimental|Families on Track Intervention|This is a pre-post study. Enrolled parents will receive the Families on Track intervention plus usual care at the Healthy Lifestyles clinic at Duke University.
2969442|NCT02767427|Active Comparator|At-Home Chlorhexidine|Those randomized into the chlorhexidine group will be asked to shower the night before surgery, and to use a standardized pre-packaged Chlorhexidine Wipes (chlorhexidine gluconate wipes) on their surgical site after thoroughly drying those areas. They will be asked to use a second wipe in each area the morning of surgery. Those who forget to use the wipe in the morning were allowed to use the wipe in the pre-operative area and included if this occurs more than one hour before skin prep.
2969443|NCT02767427|Experimental|No At-Home Chlorhexidine|Participants in this group will not use chlorhexidine wipes (no intervention), as is standard of care, prior to their surgical site being cleansed by the surgical team pre-operatively.
2969444|NCT02767414|Experimental|Respirio Flu Test and eLab Flu Test|"Upper respiratory tract samples from participants will be tested with:~Respirio Flu Test; eLab Flu Test; and Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)"
2969445|NCT02767401|Active Comparator|PCI using stenting or balloon expansion|Opening single CTO lesions using drug-eluting stents (such as Xience V and Prime, Endeavor Resolute, Taxus express and Libete, Excel, Partner, BUMA, YINYI, TIVOLI,Firebird2,FireHawk, and Coroflex) or balloon expansion plus optimal medical therapy. Intravascular ultrasound (IVUS),optimal coherence tomgraphy (OCT) or fractional flow reserve (FFR) is used if they are needed. Optimal medical therapy includes dual antiplatelet therapy and statins. And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-angina therapy should be used if the patients have symptoms.
2969446|NCT02767401|No Intervention|Optimal medical therapy|Optimal medical therapy. It includes dual antiplatelet therapy and statins. And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
2969447|NCT02767388||HM - Chemotherapy|Study patients diagnosed with HM that are scheduled to receive chemotherapy treatment.
2969448|NCT02767388||HM - No Chemotherapy|Study patients diagnosed with HM that are scheduled to receive non-chemotherapy treatment options.
2969449|NCT02767388||Healthy Controls|Study participants that are demographically matched to HM study patients and meet all inclusion criteria
2969451|NCT02767375|No Intervention|No HAIC treatment group|Best support care and follow up
2969452|NCT02767362|Experimental|Single Arm|Patients will undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgery. At the time of hysterectomy and surgical staging, women will undergo repeat endometrial biopsy in the operating room under general anesthesia.
2969453|NCT02767349|Experimental|MNK-155|MNK-155, initial dose of two or three tablets followed by 2 tablets every 12 hours up to a maximum of five doses.
2969454|NCT02767336|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
2969455|NCT02767323|Active Comparator|repetitive TMS|excitatory rTMS applied over the DLPFC (fMRI-guided)
2969456|NCT02767323|Sham Comparator|Sham repetitive TMS|electrical sham coil applied over the DLPFC (fMRI-guided)
2969457|NCT02767310|Experimental|Test Product|Rosuvastatin 20 mg film-coated tablets
2969458|NCT02767310|Active Comparator|Reference product|Crestor 20 mg film-coated tablets
2969459|NCT02767297|Experimental|Part 1: Single dose (cross over)|FDL169 reference formulation and test formulation administered as a single dose in healthy subjects
2969460|NCT02767297|Experimental|Part 2: Multiple dose (dose level 1)|FDL169 test formulation (Dose level 1) administered as repeat doses in healthy subjects
2969461|NCT02767297|Experimental|Part 2: Multiple dose (dose level 2)|FDL169 test formulation (Dose level 2) administered as repeat doses in healthy subjects
2969462|NCT02767297|Experimental|Part 2: Multiple dose (dose level 3)|FDL169 test formulation (Dose level 3) administered as repeat doses in healthy subjects
2969463|NCT02767297|Experimental|Part 3: Single dose|FDL169 test formulation administered as a single dose in CF subjects
2969464|NCT02767284|Experimental|UCST-V1|The UCST-V1 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
2969465|NCT02767284|Experimental|UCST-V2|The UCST-V2 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
2969466|NCT02767284|Experimental|UCST-V3|The UCST-V3 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
2969467|NCT02767284|Experimental|Quick-CSF|The Quick-CSF test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
2969468|NCT02767284|Active Comparator|Pelli-Robson|The Pelli-Robson contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
2969469|NCT02767284|Active Comparator|Optec 6500|The Optec 6500 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
2969470|NCT02767271|Experimental|Luliconazole Cream 1%|Luliconazole Cream 1%
2969471|NCT02767258|Active Comparator|Sham Comparator: Eye drop|Eye drop LACRIBELL® - two drops each eye, two times a day, after eye cleansing.
2969472|NCT02767258|Experimental|VIDISIC® GEL|Ocular gel VIDISIC® GEL applied two times a day at the lower palpebra from medium line to the lateral border.
2969473|NCT02767245|Active Comparator|Thiamine|Thiamine intravenously 100 mg/day for 3 days
2969474|NCT02767245|No Intervention|No thiamine|No thiamine was given to the patient
2969475|NCT02767232|Active Comparator|Standard Anticoagulation Therapy|Anticoagulant therapy will be prescribed in accordance with 2012 ACCP Guidelines for children. Initial therapy generally will consist of low molecular weight heparin (LMWH) or unfractionated heparin (UFH), monitored to achieve and maintain a target anti-Xa activity of 0.5-1.0 IU/mL for LMWH and 0.35-0.7 IU/mL for UFH. Long-term therapy generally will consist of warfarin/coumadin, monitored to achieve and maintain a target INR of 2.0-3.0. The use of novel anticoagulants is permitted based on investigator preference.
2969476|NCT02767232|Experimental|Catheter-Directed Thrombolysis|Catheter-Directed Thrombolysis (CDT) with intrathrombus delivery of Recombinant tissue plasminogen activator (rt-PA) (maximum allowable total dose 35 mg/24 hours) into the DVT over a period of up to 24 hours. CDT will be initiated within 72 hours of diagnosis. Two methods of initial rt-PA delivery will be used: 1.) AngioJet Thrombectomy System- maximum first-session rt-PA dose 25 mg; or 2.) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole catheter. Before and after CDT, patients will receive standard DVT therapy as in the standard anticoagulation group
2969477|NCT02767219|Other|Dexamethasone and 5-fluorouracil|The control arm consists of current standard therapy of subconjunctival injections of dexamethasone 3.3mg/ml and pre filled syringes of 5-fluorouracil as required for 4 consecutive weeks after entry into the trial.
2969478|NCT02767219|Active Comparator|Dexamethasone and Avastin|Subconjunctival injections of dexamethasone 3.3mg/ml and pre filled syringes of bevacizumab will be given for 4 consecutive weeks from time of entry into trial
2969479|NCT02767206||portal hypertension|Patients with cirrhosis or non-cirrhotic portal hypertension.
2969480|NCT02767193|Experimental|DCV3|Autologus differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus
2969481|NCT02767193|Experimental|DCV3 with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus with PEG-INF
2969482|NCT02767193|Placebo Comparator|CD placebo|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded
2969483|NCT02767193|Placebo Comparator|CD placebo + PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded with PEG-INF
2969484|NCT02767180||Critical care survivors|Former ICU-patients recruited six months to three years after discharge from the ICU
2969485|NCT02767180||Matched controls|Control patients who have not been critically ill, matched for age and sex.
2969486|NCT02767167|Active Comparator|Milk treatment group|Semi-skimmed cow's milk + normal diet for 12 weeks
2969487|NCT02767167|No Intervention|Control group|Normal diet for 12 weeks
2969488|NCT02767154|Active Comparator|PrimECC|1250 ml of a priming solution based on the colloid Dextran 40 to use for extracorporeal circulation.
2969489|NCT02767154|Active Comparator|Ringer-Acetate/Mannitol|1250 ml of a priming solution based on the crystalloid Ringer-Acetate (1000ml) and Mannitol (250ml).
2969490|NCT02767128|Experimental|Fer-In-Sol Orally|Patients will receive A single oral dose of Fer-In-Sol at 3 mg Fe/kg body weight (bw).
2969491|NCT02767128|Experimental|Shohl's solution followed by Fer-In-Sol Orally|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7ml/kg bw) followed after 10 minutes by Fer-In-Sol at 3 mg Fe/kg bw.
2969492|NCT02767128|Experimental|Triferic Orally|Patients will receive a single oral dose of Triferic at 3 mg Fe/kg bw.
2969493|NCT02767128|Experimental|Shohl's solution followed by Triferic Orally|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7 ml/kg bw) administered 10 minutes prior to a single oral dose of Triferic at 3 mg Fe/kg bw.
2969494|NCT02767128|Experimental|Shohl's solution followed immediately by Triferic|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7 ml/kg bw) followed immediately by a single oral dose of Triferic at 3 mg Fe/kg bw.
2969495|NCT02767128|Experimental|Triferic via IV|Patients will receive IV Triferic iron 6.6 mg diluted in an appropriate amount of D5W administered as a 120 mL infusion intravenously for 4 hours.
2969496|NCT02767128|No Intervention|Baseline|baseline serum iron profile will be determined for each patient. no study drug will be administered.
2969497|NCT02767115|Experimental|GSE mucoadhesive gel|2%GSE mucoadhesive gel administered in the periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0
2969498|NCT02767115|Placebo Comparator|Control mucoadhesive gel|GSE free mucoadhesive gel administered in the periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0
2969499|NCT02767102|Experimental|Red wine with Melatonin|Rosso di Marco is a wine without MLT (previous screening). This wine will be enriched with 10 ng mL-1 MLT (MLT+) and used as experimental wine.
2969500|NCT02767102|Placebo Comparator|Red wine without Melatonin|Rosso di Marco is a wine without MLT (previous screening). This wine will be used as placebo treatment (PLC).
2969501|NCT02767089|Other|Sequence A|Period 1: Placebo Period 2: Prednisone 2.5 mg Period 3: Prednisone 10 mg
2969502|NCT02767089|Other|Sequence B|Period 1: Prednisone 2.5 mg Period 2: Prednisone 5 mg Period 3: Prednisone 20 mg
2969503|NCT02767089|Other|Sequence C|Period 1: Prednisone 5 mg Period 2: Prednisone 10 mg Period 3: Prednisone 40 mg
2969504|NCT02767089|Other|Sequence D|Period 1: Prednisone 10 mg Period 2: Prednisone 20 mg Period 3: Prednisone 60 mg
2969505|NCT02767089|Other|Sequence E|Period 1: Prednisone 20 mg Period 2: Prednisone 40 mg Period 3: Placebo
2969506|NCT02767089|Other|Sequence F|Period 1: Prednisone 40 mg Period 2: Prednisone 60 mg Period 3: Prednisone 2.5 mg
2969507|NCT02767089|Other|Sequence G|Period 1: Prednisone 60 mg Period 2: Placebo Period 3: Prednisone 5 mg
2969508|NCT02767076|Active Comparator|Conventional|conventional paramedian spinal anesthesia
2969509|NCT02767076|Experimental|Ultrasound|ultrasound guided paramedian spinal anesthesia
2969510|NCT02767063|Experimental|Experimental Arm_ACTOS|"TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months~PIOGLITAZONE (Actos®):~30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade >1 related AE."
2969511|NCT02767063|No Intervention|controled Arm|TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months
2969512|NCT02767063|Experimental|Experimental Arm_AVELUMAB|TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months AVELUMAB: 10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period.(If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
2969513|NCT02767050||GROUP 1: CONTROL GROUPS|Patients with no habit history of tobacco are included in group 1.
2969514|NCT02767050||GROUP 2: SMOKING TOBACCO|Patients with a history of tobacco consumption in the form of smoking.
2969515|NCT02767050||GROUP 3: SMOKELESS TOBACCO|Patients with a history of tobacco consumption in the form of chewing.
2969516|NCT02767037|Active Comparator|Parkinson's disease (PD) patients|40 patients will be recruited. All will meet criteria for probable PD, according to the new MDS Clinical Diagnostic criteria. All participants will be 40 or older (young-onset PD includes many genetic causes, which often have normal autonomic function).
2969517|NCT02767037|Active Comparator|parkinsonsism (non-PD) patients|20 patients will also be recruited. These will include patients with progressive supranuclear palsy, multiple system atrophy, 'vascular parkinsonism' or corticobasal syndrome. All patients will have parkinsonism according to UK brain bank criteria, with a diagnosis of one of the above conditions made according to gold-standard expert evaluation. No patient will meet MDS Criteria for probable PD.
2969518|NCT02767037|Active Comparator|idiopathic REM sleep behavior disorder patient|40 patients will be recruited. All patients will have polysomnogram-confirmed RBD according to American Academy of Sleep Medicine Criteria. Patients will be free of parkinsonism and dementia according to neurological examination and will have no untreated sleep apnea, epilepsy, or other abnormalities that could cause dream enactment behavior.
2969519|NCT02767037|Placebo Comparator|Controls|40 controls will be age matched (within 5 years) and sex-matched (with >90% concordance). All controls will have an examination confirming the absence of parkinsonism, and will have no symptoms of REM sleep behavior disorder, as assessed with the RBD1Q and expert interview.
2969520|NCT02767024|Experimental|Sodium Nitroprusside|Dose titration will start at 25 μg/min and increased by 25 μg every 5 minutes to maximal dose of 400 μg/min while maintaining SBP ≥ 90 mmHg. Every 5 minutes, the Pulmonary Capillary Wedge Pressure (PCWP), SBP will be measured. If PCWP > 16 mmHg while maintaining SBP ≥ 90 mmHg, the investigator will proceed to titrate dose with the goal to achieve the target of PCWP ≤ 16 mmHg and Cardiac Index (CI) > 2.2 L·min−1·m−2, or maximal infusion dose has been reached, whichever comes earliest. Continuous intravenous furosemide infusion dose will be maintained by protocol.
2969521|NCT02767024|Active Comparator|Dobutamine|Dose titration will start at 2.5 μg/kg/min and increased to doses of 5, 7.5 and 10 μg/kg/min (maximal dose). Every 30 minutes, the investigator will collect Pulmonary Artery (PA) blood samples for PA sat measurement to calculate Cardiac Output (CO) and CI by Fick. If CI ≤ 2.2 L·min−1·m−2, the investigator will proceed to titrate dose until CI > 2.2 L·min−1·m−2 or maximal infusion dose has been reached, whichever comes earliest. Continuous intravenous furosemide infusion dose will be maintained by protocol.
2969522|NCT02767011|Experimental|THEM|Patients receive telehealth electronic health care monitoring.
2969523|NCT02767011|No Intervention|Standard of Care (SOC)|Patients receive normal standard of follow-up care
2969524|NCT02766998|Experimental|Preserved umbilical vein|Preserved umbilical vein as shunt/conduit
2969525|NCT02766985||FSHD|Participants with FSHD-1 or FSHD-2. No intervention is given to participants. Participants will undergo series of tests and procedures in order to make a standardized and scalable Rasch-built clinical severity scale.
2969526|NCT02766972|Experimental|RVP|
2969527|NCT02766959||PAV/PAV Tasters|Individuals homozygous for the taster allele of the TAS2R38 gene, PAV/PAV.
2969528|NCT02766959||AVI/PAV.|Individuals heterozygous for the taster allele of the TAS2R38 gene, AVI/PAV.
2969529|NCT02766959||AVI/AVI|Individuals homozygous for the non-taster allele of the TAS2R38 gene, AVI/AVI.
2969530|NCT02766946|Experimental|Mechanical Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Mechanical Ventilation~Interventions :~Ultrasound of the right diaphragm~Ultrasound of the pectoral muscle~Neuromyopathy score~Respiratory performances"
2969531|NCT02766946|Active Comparator|Non-invasive Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Non-invasive Ventilation~Interventions :~Ultrasound of the right diaphragm~Ultrasound of the pectoral muscle~Neuromyopathy score~Respiratory performances"
2969532|NCT02766946|Active Comparator|Spontaneous Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Spontaneous Ventilation~Interventions :~Ultrasound of the right diaphragm~Ultrasound of the pectoral muscle~Neuromyopathy score~Respiratory performances"
2969533|NCT02766933||hepatitis B cohort|CBCHB employees and/or spouses found to be hepatitis B surface antigen positive on screening
2969534|NCT02766907|Active Comparator|Study|prospective arm receiving cryopreserved amniotic membrane
2969535|NCT02766907|No Intervention|Control|Retrospective review of debridement without cryopreserved amniotic membrane
2969536|NCT02766881||Patients with DCIS|Whether patients with DCIS receive radiotherapy based on Oncotype DX DCIS score, radiation oncologist treatment recommendation and patient's decision.
2969537|NCT02766868|Experimental|FACE-Flu/Bu/Cy|Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
2969538|NCT02766855|Experimental|cysteamine eye drops|Patients used cysteamine eye drops every 2 hours while awake to both eyes.
2969539|NCT02766842|Active Comparator|EUS-FNB with ProCore needle|General anesthesia or conscious sedation will be started and an upper endoscopic ultrasound will be inserted into the participants mouth and advanced to the site of the lesion. The lesion will be punctured by the ProCore needle, then the stylet is completely removed, and negative suction pressure is applied using a 10 ml syringe for 30 seconds while the needle is stationary with the target. Then, the needle is moved back and forth several times within the target, utilizing the fanning technique. Finally, suction is released by closing the lock of the syringe and the needle is removed.
2969540|NCT02766842|Active Comparator|EUS-FNB with SharkCore needle|The procedure will be done in the same manner with same endoscopic technique and method of tissue procurement. The only difference will be using the SharkCore needle to acquire tissue.
2969541|NCT02766829|Experimental|CLSP Group|Those with cross leg sitting position: patients sit with both their knees flexed medially, hip flexed, resulting in pelvic leaning posteriorly and reducing lumbal lordosis.
2969542|NCT02766829|Active Comparator|TSP Group|Those with traditional sitting position: patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion.
2969543|NCT02766816|Experimental|Part 1 Study - BBio bOPV|
2969544|NCT02766816|Active Comparator|Part 1 Study - Licensed bOPV|
2969545|NCT02766816|Experimental|Part 2 Study - BBio bOPV Lot 1|
2969546|NCT02766816|Experimental|Part 2 Study - BBio bOPV Lot 2|
2969547|NCT02766816|Experimental|Part 2 Study - BBio bOPV Lot 3|
2969548|NCT02766816|Active Comparator|Part 2 Study - Licensed bOPV|
2969549|NCT02766803|Active Comparator|Simvastatin + resveratrol|simvastatin 20 mg daily micronized trans-resveratrol 500 mg daily
2969550|NCT02766803|Placebo Comparator|simvastatin+ placebo|simvastatin 20 mg daily Placebo
2969551|NCT02766790|Placebo Comparator|Placebo|Placebo taken once daily in the morning and once daily in the evening
2969552|NCT02766790|Active Comparator|TA-65MD 100 units Dose|TA-65MD 100 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
2969553|NCT02766790|Active Comparator|TA-65MD 250 units Dose|TA-65MD 250 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
2969554|NCT02766790|Active Comparator|TA-65MD 500 units Dose|TA-65MD 500 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
2969555|NCT02766790|Active Comparator|TA-65MD 250 units a.m. and p.m. Dose|Two TA-65MD 250 units capsules; one of them will be taken in the a.m. and one of them will be taken in the p.m.
2969556|NCT02766777|Experimental|Lubiprostone|12 mcg or 24 mcg, assigned based on weight
2969557|NCT02766764|Active Comparator|Study group|Women will receive oral DHEA 25 mg t.d.s daily for 12 weeks before ICSI in addition to daily GH injections from day 6 of hMG administration until the day of hCG administration.
2969558|NCT02766764|Placebo Comparator|Placebo group|Women will receive an oral placebo similar to DHEA t.d.s daily for 12 weeks before ICSI in addition to daily placebo injections similar to GH from day 6 of hMG administration until the day of hCG administration.
2969559|NCT02766751|Placebo Comparator|Health Education|The seven sessions will cover: 1) nutrition (2 sessions), 2) sleep hygiene, 3) building immunity (e.g., how to avoid colds/flu), 4) injury/disease prevention (e.g., seat belts, sunscreen, when to get regular check-ups/screenings etc.), 5) benefits of exercise/cardiac health, 6) alternative medicine (massage, acupuncture). These sessions will be primarily didactic and consist of health education, followed by discussion as to how this information compares to that which the participants may have been exposed to in the past.
2969586|NCT02766608|Experimental|FF MDI 9.6 μg|Formoterol Fumarate Inhalation Aerosol-4.8 μg per actuation MDI/ 120 inhalations Taken as 2 inhalations BID
2969587|NCT02766608|Experimental|BD MDI 320 μg|Budesonide inhalation Aerosol 160 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
2969588|NCT02766608|Other|Symbicort® TBH 400/12 μg|Symbicort Turbuhaler 400/12 μg Taken as 2 inhalations BID
2969589|NCT02766595|Other|hyperventilation|Non-drug: performing hyperventilation while sitting up during routine EEG
2969560|NCT02766751|Experimental|HIVPASS|Over 7 sessions, the interventionist and the participant will explore the relationship between pain, depressive symptoms, and HIV. General information about pain, HIV and depression will be discussed, as will avoidance of physical activity. Psychoeducation about these areas will be tied to the participant's stated life goals, and exposure exercises and goal lists will be developed. Later sessions will integrate continued efforts towards reaching goals and reducing avoidance. A release of information will be obtained from the participant to allow study session chart notes to be placed in the medical record at the participant's PCP office and to allow the PCP and the study interventionist to discuss treatment coordination.
2969561|NCT02766738|No Intervention|Control|All participants assigned to the control group will be given the option to engage in other activities that were offered by the facility during the 24-week intervention period. However, no specific resistance exercises were offered in these activities.
2969562|NCT02766738|Experimental|GrACE program|Participants in the exercise group will perform twice weekly training for 24 weeks. In brief, the program will include weight-bearing exercises and a range of seated, non-resisted upper- and lower-body dynamic and reaching movements. The following-weight bearing and resistance exercises: chair stands, chair dips, calf raises and hip flexor/abdominal lifts, trunk twists, and bicep curl and shoulder press. In total the sessions will be 45 minutes twice weekly.
2969563|NCT02766738|Experimental|GrACE + gait program|GrACE program as mentioned above plus focus on gait specific training will be one-hour training sessions for 24 weeks. Gait exercises will be a combination of exercises: heel and toe raises, stepping in different directions, single leg stand¬ing, step-ups, and task-specific balance work (e.g. reaching outward from the base of support while standing, sitting, and standing and turning). Gait exercises will be upgraded by: 1) reducing hand support and/or 2) narrowing the base of support, and/or 3) introducing a cognitive challenge (e.g. counting backwards while performing exercise) or perform¬ing exercise with the eyes closed.
2969564|NCT02766725|Experimental|preparation F12 sildenafil in-situ gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + preparation F12 sildenafil gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator (25 mg) per dose
2969565|NCT02766725|Active Comparator|preparation F2 sildenafil in-situ gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + preparation F2 sildenafil gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator (25 mg) per dose
2969566|NCT02766725|Placebo Comparator|placebo gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + placebo gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator
2969567|NCT02766712|Experimental|CA 1st Half of lesion|During each of the 15 pre-specified lesions, pacing will be initiated at a 500ms cycle length from a catheter in the coronary sinus or right ventricle prior to the start of the lesion. Pacing will be stopped at the halfway point (e.g. after 10 seconds for a 20-second lesion and after 15 seconds for a 30-second lesion). In the event that Wenckebach behavior is noted, pacing will be adjusted to a 550ms cycle length. In the event that Wenckebach behavior persists, the cycle length will be adjusted to 600ms. In the event that Weckebach behavior continues, the pacing catheter will be moved to the right ventricle, which and pacing will be performed at a 500ms cycle length. If Wenckebach behavior still persists, the patient will be withdrawn from the study.
2969568|NCT02766712|Experimental|CA 2nd Half of Lesion|During each of the 15 pre-specified lesions, pacing will be stopped at the halfway point (e.g. after 10 seconds for a 20-second lesion and after 15 seconds for a 30-second lesion). In the event that Wenckebach behavior is noted, pacing will be adjusted to a 550ms cycle length. In the event that Wenckebach behavior persists, the cycle length will be adjusted to 600ms. In the event that Wenckebach behavior persists, the pacing catheter will be moved to the right ventricle and pacing will be performed at a 500ms cycle length. If Wenckebach behavior still persists, the patient will be withdrawn from the study.
2969569|NCT02766699|Experimental|EGFR(V)-EDV-Dox|EGFR(V)-EDV-Dox administered via 20 minute intravenous infusion once a week for seven weeks (1 Cycle). Subjects will receive one of two dose levels: 5 x 10^9 or 8 x 10^9. Subjects may receive further cycles of treatment if the tumor remains stable or is responding, and/or they are deriving clinical benefit from the therapy and are tolerating treatment.
2969570|NCT02766686|Experimental|Radiotherapy with protons|Proton radiotherapy 74-80 Gray equivalent (GyE), 2Gy per fraction, 5 fractions peer week
2969571|NCT02766686|Active Comparator|Radiotherapy with photons|Photon-Intensity-Modulated Radiation Therapy (IMRT) without lymph drainage vessels, 74-80 Gy, 2Gray (Gy) per fraction, 5 fractions peer week
2969572|NCT02766686|Other|Radiotherapy with photons with lymph drainage vessels|Photon-IMRT with lymph drainage vessels, 74-80 Gy, 2Gy per fraction, 5 fractions peer week
2969573|NCT02766673|Active Comparator|Full Dose Albuterol Sulfate|2.5mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
2969574|NCT02766673|Active Comparator|Half Dose Albuterol Sulfate|1.25mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
2969575|NCT02766673|Placebo Comparator|Sterile Saline|3ml of 0.9% sterile saline will be administered via nebulizer and mechanical ventilator
2969576|NCT02766660|Other|Thyroid ophthalmopathy|Thyroid associated ophthalmopathy patients were measured by optical coherence tomography.
2969577|NCT02766660|Other|Control|Control group was consisted by age and sex- macthed healthy people adn they were measured by optical coherence tomography.
2969578|NCT02766647|Experimental|Filgrastim Hospira (US) followed by U.S.-approved Neupogen®|
2969579|NCT02766647|Experimental|U.S.-approved Neupogen® followed by Filgrastim Hospira (US)|
2969580|NCT02766634|Experimental|Filgrastim Hospira (US) followed by U.S.-approved Neupogen®|
2969581|NCT02766634|Experimental|U.S.-approved Neupogen® followed by Filgrastim Hospira (US)|
2969582|NCT02766621|Placebo Comparator|Placebo injection SC/IV|Placebo for injection SC/IV
2969583|NCT02766621|Active Comparator|PF-06823859|Study Drug being used in the study
2969584|NCT02766608|Experimental|BFF MDI 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
2969585|NCT02766608|Experimental|BFF MDI 160/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol-80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
2969683|NCT02765880|Experimental|Patient with bipolar disorder|
2969590|NCT02766582|Experimental|Chemotherapy combined with pembrolizumab|"Single arm study:~Pembrolizumab IV every 21 days (200 mg) Carboplatin IV every 21 days Paclitaxel IV infusion (80 mg/m2) every 21 days for 6 cycles Followed by 12 months pembrolizumab IV every 21 days"
2969591|NCT02766556|Active Comparator|arm 1|received ISB with 8mL of ropivacaine with 100 μg (1ml) of dexmedetomidine
2969592|NCT02766556|Placebo Comparator|arm 2|received ISB with 8mL of ropivacaine with 1ml of normal saline
2969593|NCT02766543|Experimental|MRI-Guided TULSA-PRO device|Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue.
2969594|NCT02766530|Experimental|PETMR study|All the study participants will receive PET MR examinations before neoadjuvant chemotherapy and during neoadjuvant chemotherapy (during early cycle as well as during mid-cycle of chemotherapy treatment). There will be two groups of patients after completion of neoadjuvant chemotherapy, that is, responders versus non-responders. We will compare the PET MR imaging parameters before, during neoadjuvant chemotherapy between the two groups of patients.
2969595|NCT02766517|Experimental|Capsaicin|Single topical dose of capsaicin
2969596|NCT02766491|Experimental|Strengthening and stretching|The intervention group will follow a strengthening-stretching program of the calf muscles.
2969597|NCT02766491|Active Comparator|conventional stretching|The control group will receive conventional stretching and strengthening exercises to the upper limb to assure that the same systemic physiological stimuli and a similar number of contact hours is received.
2969598|NCT02766478|Experimental|Genistein|Participants with and without diabetes will receive 60 mg/day oral genistein (30 mg taken twice daily) for 12 weeks.
2969599|NCT02766478|Placebo Comparator|Placebo|Participants with and without diabetes will receive placebo taken twice daily for 12 weeks.
2969600|NCT02766465|Experimental|Donor Arm|The donor arm will be treated with a preparative regimen of busulfan, fludarabine, and r-ATG before undergoing the bone marrow transplant. Graft-vs-Host-Disease (GVHD) prophylaxis will be tacrolimus combined with methotrexate.
2969601|NCT02766465|Active Comparator|No-Donor Arm|No-donor arm will continue with standard of care per their SCD physician.
2969602|NCT02766452|Experimental|Pre-operative educational DVD preparation|"After their pre-assessment clinic (PAC) appointment, parents in the intervention group took the hospital's 20 minute surgical virtual tour in the hospital's family library. Parents in the intervention group also watched the 12 minute DVD entitled, You and Your Child in the RR. This pre-operative educational tool was developed and tested in a previous study (Chartrand 2014). It was designed to enable parents to gain knowledge about the equipment and procedures related to the RR, and about nurses' and parents' roles in supporting their child in the RR. The DVD also focused on potential reactions of children waking up after a general anesthesia and strategies parents can use to support their child in the RR. The DVD included images of RR equipment and positive nurse-family and parent-child interactions."
2969603|NCT02766452|Placebo Comparator|Standard pre-operative preparation|After their PAC appointment, parents in the control groups took the hospital's 20 minute surgical virtual tour in the hospital's family library.
2969604|NCT02766439||Rhupus syndrome, SLE without RA|Rhupus syndrome, SLE without RA
2969605|NCT02766426|Other|Lifestyle change intervention|Overweight/obese pregnant women enrolled in a healthy lifestyle change programm
2969606|NCT02766400|Experimental|Guided Training|"Guided training is a rehabilitation training approach that maximizes the expertise of the patient, by teaching patients to identify and prioritize activities, identify barriers to performing activities, generate their own strategies for addressing these barriers, and apply this process through iterative practice. Guided training equips patients with practical skills that have the potential to generalize beyond activities addressed during the intervention program to novel problematic activities that arise after the intervention program, thereby promoting long-term independence."
2969607|NCT02766400|Active Comparator|Directed Training|Directed training is a rehabilitation approach that maximizes the expertise of the rehabilitation practitioner. Rehabilitation practitioners identify and prioritize problematic activities, identify barriers to performing these activities, generate strategies to address these barriers and instruct patients in these strategies, and repeat the process with a variety of problematic activities identified during the rehabilitation program. Directed training promotes independence with training activities, however the benefits of direct training are likely to be activity-specific (i.e., only promote improvement on the trained activity) and not generalizable to other daily activities. This therapist-directed approach is currently the method used most frequently in acute rehabilitation.
2969608|NCT02766387|Experimental|2 minutes walk test|fast walk test during 2 minutes in first and the 10 meters walk test, the 6 minutes walk test and the 2 kilometers walk test
2969609|NCT02766387|Experimental|6 minutes walk test|comfortable walk test during 6 minutes in first and the 10 meters walk test, the 2 minutes walk test and the 2 kilometers walk test
2969610|NCT02766374|Experimental|HRV-BF|"During the first training session, we will measure heart rate variability biofeedback amplitude while the patient breathes for two minutes at a frequency ranging between 4.5-6.5 breaths/min, providing a pacing stimulus for this purpose. In subsequent sessions, the individual will be given personal HRV biofeedback, and instructed to increase the amplitude of heart rate oscillations, using a cardiotachometer tracing and frequency peaks as biofeedback stimuli, while avoiding hyperventilation symptoms, by breathing more shallowly, although slowly, at whatever frequency produces maximum-amplitude HRV."
2969611|NCT02766374|Placebo Comparator|PBO-BF|"The method consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
2969612|NCT02766361|Experimental|Cognitive Behavioral Rehabilitation|12 sessions of new intervention of cognitive behavior therapy and cognitive rehabilitation
2969613|NCT02766361|Active Comparator|Treatment as Usual|standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
2969614|NCT02766348|Experimental|DC-CTL|After accepting chemotherapy of gGemcitabine and Cisplatin according to National comprehensive Cancer Network(NCCN) guidelines, patients will receive 3 cycles of DC-CTL treatment
2969615|NCT02766348|Active Comparator|Chemotherapy|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines, patients will just regularly follow up.
2969616|NCT02766335|Experimental|Arm I (MEDI4736 - closed to accrual 12/2015)|Patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
2969617|NCT02766335|Active Comparator|Arm II (docetaxel - closed to accrual 4/2015)|Patients receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #2 4/22/15)
2969618|NCT02766335|Experimental|Arm III (MEDI4736 retreatment)|For patients assigned to Arm 1, MEDI4736: Upon evidence of progression following discontinuation of 12 months of treatment, patients may restart treatment with Arm 3, MEDI4736 for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period. Patients will only be able to restart treatment once; thus a maximum of two 12-month periods will be allowed. Patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
2969619|NCT02766322||Gastric Bypass longitudinal|Morbidly obese subjects undergoing gastric bypass surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose ~ 16% of their presurgery body weight.
2969620|NCT02766322||Gastric Banding longitudinal|Morbidly obese subjects undergoing laparoscopic gastric banding surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose ~ 16% of their presurgery body weight.
2969621|NCT02766322||Sleeve gastrectomy longitudinal|Morbidly obese subjects undergoing sleeve gastrectomy surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose ~ 16% of their presurgery body weight..
2969622|NCT02766322||Gastric Bypass (cross-sectional)|Subjects who underwent gastric bypass surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
2969623|NCT02766322||Gastric Banding (cross-sectional)|Subjects who underwent gastric banding surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
2969624|NCT02766322||Sleeve gastrectomy (cross-sectional)|Subjects who underwent sleeve gastrectomy surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
2969625|NCT02766296|Experimental|Active Emotional Working Memory Training|Each participant will receive 15 sessions (each lasting 20 minutes) over a 5 week. This will be Internet-based cognitive training based on the adaptive dual n-back paradigm.
2969626|NCT02766296|Placebo Comparator|Control Working Memory Training|Participants in this condition will receive 15 sessions (each lasting 20 minutes) over a 5-week period. This will also be home-based training over the Internet. This training will be based on a fixed 1-back training program.
2969627|NCT02766283||Iodinated contrast agents|children age 0-3 years (inclusive), who underwent a iodine contrast enhanced radiological examination.
2969628|NCT02766270|Experimental|Chemoradiotherapy with Temozolomide|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks (for a total of 60 Gy) and receive temozolomide PO QD (75 mg/m2/day, 7 days/week) for up to 7 weeks. Beginning 4 weeks after completion of chemotherapy and radiation therapy, patients receive temozolomide PO QD on days 1-5 (150-200 mg/m2). Treatment with temozolomide repeats every 28 days for up to 12 courses
2969629|NCT02766270|Active Comparator|Radiotherapy alone|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks (for a total of 60 Gy)
2969630|NCT02766257|Other|children undergoing ambulatory surgery|
2969631|NCT02766244|Experimental|ICG/SPY|Daily wound care with antibiotic ointments after cleansing plus evaluation using ICG/SPY fluorescence.
2969632|NCT02766231||Physica CR|
2969633|NCT02766231||Physica PS|
2969634|NCT02766218||Behavioral: Lifestyle Intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
2969635|NCT02766218||No Intervention: Standard Care|
2969636|NCT02766192|Experimental|TIMBER-Ketamine arm|This arm received TIMBER psychotherapy and ketamine infusion.
2969637|NCT02766192|Placebo Comparator|TIMBER-placebo arm|This arm received TIMBER psychotherapy and placebo (normal saline) infusion.
2969638|NCT02766179|Active Comparator|CPAP Therapy|Continuous Positive Airway Pressure
2969639|NCT02766179|Experimental|Somnoguard|Somnoguard
2969640|NCT02766166||Predictive Monitoring|
2969641|NCT02766166||No Predictive Monitoring|
2969642|NCT02766153||patients|
2969643|NCT02766153||healthy volunteers|intrafamily marrow donors
2969644|NCT02766140|Experimental|SHR1020 plus Docetaxel|
2969645|NCT02766140|Placebo Comparator|Placebo plus Docetaxel|
2969684|NCT02765867|Experimental|RBP-6000|A single dose of RBP-6000 will be administered on Study Day 1
2969646|NCT02766127|Experimental|Xerostomic Patients|"Patients with evident clinical signs of xerostomia who experienced dentinal hypersensitivity after undergoing radiation therapy due to head and neck cancer.~The following dental materials will be used following the manufacturers' instructions: Veritise Flow; Universal Dentin Sealant; Clearfil Protect Bond, and Flor-Opal® Varnish. In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.~the application of the materials will be made only once. The effectiveness will be evaluated: immediately after application and after 1, 4, 12 weeks."
2969647|NCT02766114|Experimental|Issa1|After local anesthesia, through transverse approach on the middle of dorsal wrist crease the incision is made for 1.5 cm length, then the subcutaneous fat is dissected, soon we see the the palmaris longus tendon or its connection with the carpal ligament , take the ulnar side of the palmaris longus tendon and cut the carpal ligament axillary by scalpel, not going deep with the scalpel to avoid medial nerve injury, soon we see the nerve, we use the scissors to cut the proximal part then the distal part of the carpal ligament by enclosing it between the blades of the scissors, now the full released carpal tunnel most be observed, and one stitch is enough, in this operation most be an assistant exist.
2969648|NCT02766101|Experimental|Aerobic Exergaming PE|Progressive aerobic curriculum utilizing virtual reality exergaming stationary bicycles. Classes held 2 times per week for 30-40 minutes, aerobic exercise beginning at 10 minutes at moderate to vigorous intensity and building to 20 minutes plus.
2969649|NCT02766101|Active Comparator|Standard PE|Traditional PE focused on gross motor skill and sports skill acquisition, and team building. Typically non-aerobic.
2969650|NCT02766088|Experimental|Prospective|3000 subjects aged between 6 months and 50 years at the time of enrolment living in geographically-defined communities in Latin America and Southeast Asia.
2969651|NCT02766075|Experimental|Supervised TAVR Exercise Program (STEP)|Subjects in the experimental arm will participate in an individualized 4-week STEP prior to undergoing TAVR. All subjects will undergo serial frailty assessments by a blinded research assistant at baseline, pre-TAVR, and 30-days post-TAVR.
2969652|NCT02766075|No Intervention|Standard of Care|Subjects in the no intervention arm will proceed with their TAVR after a minimum 4 weeks without an exercise intervention. All subjects will undergo serial frailty assessments by a blinded research assistant at baseline, pre-TAVR, and 30-days post-TAVR.
2969653|NCT02766062|Active Comparator|propofol group|Patients with metabolic syndrome were randomly assigned to receive propofol anesthesia
2969654|NCT02766062|Active Comparator|sevoflurane group|Patients with metabolic syndrome were randomly assigned to receive sevoflurane anesthesia
2969655|NCT02766049|Active Comparator|(a) DC|Autologous dendritic cells (3x10e7)
2969656|NCT02766049|Active Comparator|(b) DC 10e6+HIV-AT2|Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
2969657|NCT02766049|Active Comparator|(c) DC 10e7+HIV-AT2|Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
2969658|NCT02766036|Active Comparator|Propolis|Patients will continue to receive standard treatment for their comorbidities, determined by the attending physician. Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses.
2969659|NCT02766036|Placebo Comparator|Placebo|Patients will continue to receive standard treatment for their comorbidities, determined by the attending physician. Patients will receive 500 mg / day of the propolis-placebo in the form of tablets split in two daily doses.
2969660|NCT02766023|Experimental|LACTIN-V|Subjects receive 5-day course of metronidazole gel 7.5 mg/gm daily applied vaginally. Subjects then receive LACTIN-V 2x10^9 cfu/dose applied vaginally for 5 days then twice weekly for 10 weeks. N=152
2969661|NCT02766023|Placebo Comparator|Placebo|Subjects receive 5-day course of metronidazole gel 7.5 mg/gm daily applied vaginally. Subjects then receive placebo applied vaginally for 5 days then twice weekly for 10 weeks. N=76
2969662|NCT02766010|Experimental|group A TensorTip|Male or female, age > 18
2969663|NCT02765997|Active Comparator|Unmanipulated UCB|Subjects will receive unmanipulated umbilical cord blood transplantation after a myeloablative CY/FLU/TBI conditioning.
2969664|NCT02765997|Experimental|StemRegenin-1 UCB|Subjects will receive StemRegenin-1 (SR-1) cultured umbilical cord blood transplantation after a myeloablative CY/FLU/TBI conditioning.
2969665|NCT02765984||normal placental site|women with normal implantation site at early trimester with normal placental site
2969666|NCT02765984||Low placental site|women with low implantation site at early trimester with low placental site
2969667|NCT02765971|Active Comparator|chewing gum group|180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval
2969668|NCT02765971|Active Comparator|laxatives group|180 women will receive laxatives after their operating room discharge by 3 hours
2969669|NCT02765971|Placebo Comparator|control|they will not receive neither gum nor oral fluids. They will be on intravenous fluid. starting oral fluids after hearing intestinal sounds
2969670|NCT02765958||Healthy|subjects without heart disease or arrhythmia, no evidence of obstructive sleep apnea
2969671|NCT02765958||OSA|obstructive sleep apnea
2969672|NCT02765932|Active Comparator|Placebo Therapy|Dummy Movements
2969673|NCT02765932|Experimental|Psychosensory Therapy|Will involve touch technique, havening.
2969674|NCT02765919|Experimental|Radiation HDR Brachytherapy 9 Gy|High dose rate (HDR) Brachytherapy of weekly 9 Gray in two fractions in two weeks after 50 Gray of EBRT in 2 Gray per fraction of 5 weeks with chemotherapy cisplatin 40 mg /m2 weekly for five weeks in locally advanced carcinoma cervix
2969675|NCT02765919|Active Comparator|Radiation HDR Brachytherapy 7 Gy|High dose rate (HDR) brachytherapy of weekly 7 Gray in three fractions in three weeks after 50 Gray EBRT of 2 Gray per fraction of 25 fractions concurrently with weekly chemotherapy cisplatin40 mg /m2 in five weeks in locally advanced carcinoma cervix
2969676|NCT02765906|No Intervention|No intervention|No additional education
2969677|NCT02765906|Experimental|Graphic card|Education with graphic card
2969678|NCT02765906|Experimental|Video|Education with video
2969679|NCT02765893|No Intervention|Foley|Patients will have Foley in place overnight after completion of surgery, which is currently standard of care at our institution.
2969680|NCT02765893|Active Comparator|No Foley|Patients will have Foley catheter removed 6 hours post-op.
2969681|NCT02765880|Experimental|Healthy volunteer|
2969682|NCT02765880|Experimental|Patients with schizophrenia|
2969685|NCT02765854|Experimental|Arm B (ixazomib and dexamethasone)|MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A.
2969686|NCT02765854|Experimental|Arm C (ixazomib, dexamethasone, lenalidomide)|MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21.
2969687|NCT02765854|Active Comparator|Arm A (ixazomib and dexamethasone)|UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone.
2969688|NCT02765841|Experimental|Lomitapide|
2969689|NCT02765828||Late-Onset Pompe Disease|
2969690|NCT02765828||Acquired/Hereditary Myopathy|
2969691|NCT02765828||Neuropathy|
2969692|NCT02765815|Active Comparator|Exparel plus multi-drug cocktail|Liposomal bupivacaine, 266mg plus Bupivacaine 0.25% with Epinephrine, Ketorolac 30mg, and Morphine 10mg.
2969693|NCT02765815|Active Comparator|Multi-drug cocktail alone|Bupivacaine 0.5% with Epinephrine, Ketorolac 30mg, Morphine 10mg.
2969694|NCT02765802|Experimental|Lambda 180 μg|Lambda 180 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
2969695|NCT02765802|Experimental|Lambda 120 μg|Lambda 120 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
2969696|NCT02765789|Experimental|Immunoadsorption|All (anticipated) 8 participants will be treated with immunoadsorption
2969697|NCT02765763|Sham Comparator|Group 1 Sham|Null Formula of the Test System
2969698|NCT02765763|Active Comparator|Group 2 Treated|Full Formulas of Test System
2969699|NCT02765750|Experimental|BIS 40-60|Patient with intraoperative Bispectral Index (BIS) 40-60.
2969700|NCT02765750|Experimental|BIS 20-40|Patient with intraoperative Bispectral Index (BIS) 20-40.
2969701|NCT02765750|Placebo Comparator|Placebo|Placebo group
2969702|NCT02765737|Active Comparator|Group 1|Treatment 1 - dHACM plus Control Burn Area A Treatment 2 - Control Burn Area B
2969703|NCT02765737|Active Comparator|Group 2|Treatment 1 - dHACM plus Control Burn Area B Treatment 2 - Control Burn Area A
2969704|NCT02765724|Experimental|Group 1|Patients with mild hepatic impairment
2969705|NCT02765724|Experimental|Group 2|Patients with moderate hepatic impairment
2969706|NCT02765724|Experimental|Group 3|Patients with severe hepatic impairment
2969707|NCT02765724|Experimental|Group 4|Healthy subjects
2969708|NCT02765711||the use of ticagrelor in hospital|
2969709|NCT02765685|Experimental|ODRA|
2969710|NCT02765685|Active Comparator|usual care|
2969711|NCT02765672|Active Comparator|Control Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation's clinical battery tests and a simulated driving evaluation, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, Fitness-to-Drive Screening Measure (FTDS), and a Satisfaction with Life Questionnaire. Driving Safety Education by a traffic safety professional, three x 1 hour sessions to discuss traffic safety rules regarding person, vehicle, environmental factors.
2969712|NCT02765672|Experimental|Experimental Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation's clinical battery tests and a simulated driving tests, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, Fitness-to-Drive Screening Measure(FTDS), and a Satisfaction with Life Questionnaire. Occupational Therapy Driving Intervention (OT-DI) consisting of three x 1 hour sessions to review explicit driving errors, strategies to mitigate errors and receiving feedback from the evaluator after driving the simulator.
2969713|NCT02765672|Active Comparator|Caregiver Control Group|Caregiver control group will fill out a Fitness-to-Drive Screening Measure (FTDS) questionnaire at baseline and at the end of the study.
2969714|NCT02765672|Active Comparator|Caregiver Experimental Group|Caregivers of the experimental group will fill out a Fitness-to-Drive Screening Measure (FTDS) questionnaire at baseline and at the end of the study.
2969715|NCT02765672|Active Comparator|On-road driving Group|A subset of 30 Combat Veterans will be drawn from the control group (15 no.) and experimental group (15 no.). This group of Combat Veterans will will undergo an on-road driving test at baseline and month 5
2969716|NCT02765672|Active Comparator|Simulator-drives Evaluation Group|This group will comprise of 30 Combat Veterans who will be drawn outside of the randomized experimental and and control groups participants. This group will only perform simulator driving triggers evaluation
2969717|NCT02765659|Other|Community 1|Receives Mzake ndi Mzake T1 immediately after baseline
2969718|NCT02765659|Other|Community 2|Receives Mzake ndi Mzake T2 immediately after Post-T1 evaluation
2969719|NCT02765659|Other|Community 3|Receives Mzake ndi Mzake T3 immediately after Post-T2 Evaluation
2969720|NCT02765633|Experimental|Cangrelor|Cangrelor in four (4) dose cohorts consisting of five participants in each cohort. One cohort of five participants will be enrolled at a time, beginning with the lowest cangrelor dose and escalating sequentially to the highest planned dose based on a review of the PK, PD, and safety parameters.
2969721|NCT02765620||drug|Early treatment response assessment: using baseline data and early follow-up data Evaluate treatment response: using baseline data, early follow-up data and final data Compare PERCIST to RECIST criteria: correlation analysis Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot
2969722|NCT02765620||radiation|Early treatment response assessment: using baseline data and early follow-up data Evaluate treatment response: using baseline data, early follow-up data and final data Compare PERCIST to RECIST criteria: correlation analysis Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot
2969723|NCT02765594|Experimental|valsartan only:control group|valsartan (160mg/d)
2969724|NCT02765594|Experimental|hydroxychloroquine with valsartan:study group|valsartan (160mg/d) and Hydroxychloroquine Sulfate ( 400mg/d, twice daily)
2969725|NCT02765581|Experimental|Verum acupuncture (VA)|Participants will be treated by verum acupuncture and usual care. They will be treated every other day to fulfill a 10-session treatment course, and another course will begin after resting 9 days. Each acupuncture treatment session for patients will be 30 minutes in duration.
2969812|NCT02765022|Active Comparator|No clip|No clip closure of mucosal defects after endoscopic mucosal resection. Observation.
2969726|NCT02765581|Sham Comparator|Sham acupuncture (SA)|Participants will be treated by sham acupuncture and usual care. They will be treated every other day to fulfill a 10-session treatment course, and another course will begin after resting 9 days. Each acupuncture treatment session for patients will be 30 minutes in duration.
2969727|NCT02765581|Placebo Comparator|Usual care (UA)|Participants will undergo a clinical interview once a month, complete the headache diary assessment, have counseling and health education, and rescue medication if necessary. In addition, they will be scheduled to receive 20 sessions of verum acupuncture treatments for free after a waiting period of 24 weeks.
2969728|NCT02765568|Experimental|Moderate Intensity Continuous Exercise|Moderate Intensity Continuous Exercise Training
2969729|NCT02765568|Experimental|Nordic Walking|Nordic Walking
2969730|NCT02765568|Experimental|High Intensity Interval Training|High Intensity Interval Training
2969731|NCT02765555|Experimental|RBP-7000|All subjects that meet initial study entry criteria will receive a test dose of 0.25mg of oral risperidone. Subjects who continue to be eligible will return to the clinical unit in one week and receive a single dose of 60mg RBP-7000 after a 2 hour fast. Subjects will remain in the clinical unit for 14 days, then return for 10 additional weeks after discharge.
2969732|NCT02765542|Experimental|Automated phone calls|Automated disease assessment & self-care support phone calls for up to 12 weeks.
2969733|NCT02765529|Experimental|20-30 years|Blood sampling
2969734|NCT02765529|Experimental|45-55 years|Blood sampling
2969735|NCT02765529|Experimental|70-80 years|Blood sampling
2969736|NCT02765529|Experimental|Control|Blood sampling for standardization of technical procedures
2969737|NCT02765516|Active Comparator|Plant sterols|
2969738|NCT02765516|Placebo Comparator|Placebo|
2969739|NCT02765503|Active Comparator|Control|'Standard' external beam radiotherapy to deliver 66Gy in 33 fractions treating with 6 fractions a week.
2969740|NCT02765503|Experimental|HYPNO|The experimental regimen in which patients receive external beam radiotherapy to deliver 55Gy in 20 fractions treating 5 times a week.
2969741|NCT02765490|Experimental|Group A|AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 6 weeks.
2969742|NCT02765490|Experimental|Group B|AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 8 weeks.
2969743|NCT02765477||Angiogram Cohort w Acute Coronary Occlusion|Inclusion Criteria: Angiogram Cohort. Patients who present 1) directly through the study site Emergency Department (ED) OR 2) as a transfer or referral patient from the ED of another institution OR 3) as a direct admission to the study site's Catheterization Laboratory by an ambulance service, who also met the following criteria: 1.Underwent urgent or emergent coronary angiography during the index presentation for suspected ischemic symptoms (including but not limited to chest pain [CP] and/or shortness of breath [SOB]) AND 2. Had a VPR ECG recorded during the index presentation prior to the angiogram AND 3. Had sufficient troponins to rule in or rule out acute myocardial injury, per the study site's institutional protocol. From this Angiogram Cohort, a group of patients will be identified who had angiographic evidence of ACO, defined as an acute lesion with TIMI flow 0 or 1 when evaluated by an experienced study-site adjudicator.
2969744|NCT02765477||Non-ACO Angiogram Cohort|Inclusion Criteria: Angiogram Cohort. Each study site will first identify adult patients (age 18 years or older) who presented to the study site 1) directly through the study site ED OR 2) as a transfer or referral patient from the ED of another institution OR 3) as a direct admission to the study site's Catheterization Laboratory by an ambulance service, who also met the following criteria: 1. Underwent coronary angiography during the index presentation for suspected ischemic symptoms (including but not limited to CP and/or SOB AND 2. Had a VPR ECG recorded during the index presentation prior to the angiogram AND 3. Had sufficient troponins to rule in or rule out acute myocardial injury, per the study site's institutional protocol. From this Angiogram Cohort, those who had TIMI-2 or greater flow will be identified for several research questions.
2969745|NCT02765477||Random ED Sample w Paced Rhythm but No AMI|"Each site will select a random sample of all adult patients who present to the ED (or by ambulance directly to the Catheterization Lab) with suspected ischemic symptoms and a VPR ECG.~Each study site will randomly select 5 unique encounters for every one 1 ACO subject identified by the site. If a study site identifies no ACO subjects, they will randomly select 30 unique encounters.~Study subjects who are included as subjects in the Angiogram Cohort (data set #1, above) and who are also selected as part of the random sample (data set #2) will be identified in REDCap as subjects for analysis in both groups, but their data will be submitted only once.~The primary control group selected from this search will be all patients in this group who do not meet criteria for acute myocardial injury, as defined by 1) all troponins below the 99th percentile or 2) Peak troponin < 3x the upper limit of normal AND no rise and/or fall of > 30%."
2969746|NCT02765477||ED Patients w Paced Rhythm Without AMI excluded|"Each site will select a random sample of all adult patients who present to the ED (or by ambulance directly to the Catheterization Lab) with suspected ischemic symptoms and a VPR ECG.~Each study site will randomly 5 unique encounters for every 1 ACO subject identified by the site. If a study site identifies no ACO subjects, they will randomly select 30 unique encounters.~Study subjects who are included as subjects in the Angiogram Cohort (data set #1, above) and who are also selected as part of the random sample (data set #2) will be identified in REDCap as subjects for analysis in both groups, but their data will be submitted only once.~The secondary control group will include patients in this group in whom Acute MI cannot be excluded because they either have at least 1 troponin > 3x the upper limit of normal or they have at least 1 troponin between 1x and 3x the ULN AND have a rise and/or fall of at least 30%."
2969747|NCT02765451|Active Comparator|A : 1 year of intervention|interventions of Cancéropôle Nord-Ouest during 1 year after an observational period of 2 years.
2969748|NCT02765451|Active Comparator|B : 2 years of intervention|interventions of Cancéropôle Nord-Ouest during 2 years after an observational period of 1 year.
2969749|NCT02765438|Experimental|BOBO|"Playing with the BOBO system."
2969750|NCT02765425|Experimental|Training Group|Subjects will receive the same outcome measures at baseline, after 3 months training and 6 months later. Intervention will comprise of three sessions seated at the AMES device. Each training session will include 15 min of training of each ankle. Training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
2969781|NCT02765204|Experimental|DS-DG-D|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
2969751|NCT02765425|No Intervention|Control Group|Subjects will receive no intervention. Subjects will receive all outcome measures at baseline and at 3 months post enrollment. Subjects will also receive a fall-incidence reporting form 9 months post enrollment. No other intervention - i.e. no treatment - is given.
2969752|NCT02765412||standard implementation|Webinar, Promotion, and Tool Access + Audit and Feedback
2969753|NCT02765412||intensive implementation|Webinar, Promotion, and Tool Access + Audit and Feedback + LEAP
2969754|NCT02765399|Experimental|Liraglutide|"Liraglutide subcutaneous injection once daily with following dose escalation:~liraglutide 0.6 mg once daily for one week; liraglutide 1.2 mg once daily for one week and thereafter liraglutide 1.8 mg once daily for 3.5 months."
2969755|NCT02765399|Placebo Comparator|Placebo|"Placebo subcutaneous injection once daily with following dose escalation:~placebo 0.1 ml once daily for one week; placebo 0.2 ml once daily for one week and thereafter placebo 0.3 ml once daily for 3.5 months."
2969756|NCT02765386|Experimental|Cochlear Implant Recipients|Newly implanted cochlear implant recipients with post-implantation acoustic hearing.
2969757|NCT02765373||steroidal aromatase inhibitors(AIs)|Exemestane 25mg Qd for 5 years
2969758|NCT02765373||non-steroidal aromatase inhibitors(AIs)|Letrozole 2.5mg Qd or Anastrozole 1mg Qd for 5 years
2969759|NCT02765360|Experimental|Treatment|Each patient will be assigned to Continuous Positive Airway Pressure (CPAP), Pressure Support Ventilation (PSV) and Pressure Control Ventilation (PCV) modes in a random order with a 10 minute washout period modes.
2969760|NCT02765347|Other|Metformin and Insulin|MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g bid or tid) for 24 weeks
2969761|NCT02765347|Other|Insulin|Accept insulin for 24 weeks
2969762|NCT02765334|Experimental|nBETTER and Conventional Therapy|Intervention: nBetter therapy
2969763|NCT02765321|Experimental|Physical activity and healthy eating promotion|
2969764|NCT02765308||Healthy volunteers|healthy age matched with cases volunteers as controls
2969765|NCT02765308||Uveitis with raised IOP|Recurrent (> 5 attacks) idiopathic acute anterior uveitic with raised intraocular pressure
2969766|NCT02765308||Uveitis with with normal IOP|Recurrent (> 5 attacks) idiopathic acute anterior uveitic with normal intraocular pressure
2969767|NCT02765295|Active Comparator|hydrogen inhalation|The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixture gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min). Usual care referred to mucolytics (see below for details) alone or plus chest physiotherapy.
2969768|NCT02765295|Sham Comparator|oxygen inhalation|Oxygen will be generated by an instrument provided by the sponsor, that would be capable of generating oxygen equivalent to that generated by the MUNHO (3L/min mixed gas containing 33.3% oxygen). Usual care referred to mucolytics [[ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily)/ serrapeptase (10mg thrice daily), or carbocisteine (500mg thrice daily)] alone or in combination with chest physiotherapy.
2969769|NCT02765282|Experimental|DBS-Expert Programming First|These patients will be undergo algorithm based programming using Kinesia-based assessment (DBS-Expert) first and then be programmed by a clinician within five days.
2969770|NCT02765282|Experimental|Traditional Programming First|These patients will be programmed by a clinician first and then undergo algorithm based programming using Kinesia-based assessment (DBS-Expert) within five days.
2969771|NCT02765269|Experimental|IPMS group|Cancer patients with pain are asked to use the Intelligent Pain Management System as much as possible to record the degree and location of pain at least once every day. Through assessments of these pain record, physicians could give the patients appropriate advice.
2969772|NCT02765269|No Intervention|Control group|The control group are communicated through conventional method such as telephone calls or door-to-door visit to collect the pain assessment to guide doctors' therapy.
2969773|NCT02765256|Experimental|Fluconazole|Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
2969774|NCT02765256|Placebo Comparator|Placebo|Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
2969775|NCT02765243|Experimental|effectiveness of Anti-GD2 CART|Anti-GD2 CART cells can recognize and kill neuroblastoma through the recognition of GD2. This study will evaluate the side effects and effective doses of Anti-GD2 CART cells in treating refractory and/or recurrent neuroblastoma
2969776|NCT02765217|Experimental|Study group 1|"Amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) and Lactobacillus reuteri DSM 17938 (5 drops per day, same time with the first dose of antibiotics).~Study Group 1a will received L. reuteri for 10-14 days. Study Group 1b will received L. reuteri for 21 days."
2969777|NCT02765217|Placebo Comparator|Study group 2|Amoxicillin-clavulanic acid (50-90 mg / kg / day) and placebo ( 5 drops per day, same time with the antibiotics) Study Group 2a will received placebo for 10-14 days. Study Group 2b will received placebo for 21 days.
2969778|NCT02765217|Experimental|Study group 3|Amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) and Lactobacillus reuteri DSM 17938 (2 x 5 drops per day) Study Group 3a will received L. reuteri for 10-14 days. Study Group 3b will received L. reuteri for 21 days.
2969779|NCT02765217|Placebo Comparator|Study group 4|Amoxicillin-clavulanic acid (50-90 mg / kg / day) and placebo ( 2 x 5 drops per day, same time with the antibiotics) Study Group 4a will received placebo for 10-14 days. Study Group 4b will received placebo for 21 days.
2969780|NCT02765204|Experimental|DS-D-DG|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
2969782|NCT02765204|Experimental|D-DG-DS|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
2969783|NCT02765204|Experimental|D-DS-DG|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
2969784|NCT02765204|Experimental|DG-D-DS|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
2969785|NCT02765204|Experimental|DG-DS-D|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
2969786|NCT02765191|Experimental|Study group|Subjects investigated according to protocol after titrated dosage of norepinephrine and administration of bolus of Ringer's Acetate
2969787|NCT02765178||Patients with Tourette Syndrome|The primary caregiver will be asked to fill the Children's motivation Scale. Other measures will be collected including a clinician filled Yale Global Tic Severity Scale (YGTSS) - severity score, Center for Epidemiological Studies Depression Scale for Children (CES-DC) and Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL). Demographic data will also be collected for each study patient. Demographic data will also be collected for each study patient.
2969788|NCT02765178||Patients with Diabetes type 1|The primary caregiver will be asked to fill the Children's motivation Scale. Demographic data will also be collected for each study patient.
2969789|NCT02765165|Experimental|Dose-Escalation USL311|
2969790|NCT02765165|Experimental|Dose-Escalation USL311 plus lomustine|
2969791|NCT02765165|Experimental|Dose-Expansion USL311|
2969792|NCT02765165|Experimental|Dose-Expansion USL311 plus lomustine|
2969793|NCT02765152|Active Comparator|Conventional Physical Therapy|Usual therapy: joint mobility exercises, stimulating joint movement of the main active components of the upper limb; major muscle groups stretching, especially in the affected muscles by tone impairment; manual resistance training according to the degree of the patient's muscle strength, prioritizing the functional specificity of the upper limb, so the majority of the exercises will be held in open chain; motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks.
2969794|NCT02765152|Experimental|discrete movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
2969795|NCT02765152|Experimental|rhythmic movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
2969796|NCT02765139|Experimental|EMAP Treatment|Engaging Men through Accountable Practice: 30 communities are matched into 15 pairs on a set of socio-demographic characteristic and within each pair, 15 treatment sites are randomly selected. Within each treatment community, all adult men (20+ years old) are eligible to participate in the EMAP intervention. A random draw of 50 participants determines who will participate in EMAP in case more than 50 eligible men express interest.
2969797|NCT02765139|Other|Control|In the 15 control sites, the male participants will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
2969798|NCT02765126|Active Comparator|Group 1|Diphtheria-tetanus-acellular pertussis vaccine administered day 0, followed by seasonal influenza vaccination four weeks later. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week, 4 weeks, 4 weeks + 24 hours, 5 weeks, 8 weeks and 30 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
2969799|NCT02765126|Active Comparator|Group 2|Seasonal influenza vaccine administered on day 0, to be offered DTP vaccine at week 26. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week 1, 4 weeks and 26 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
2969800|NCT02765126|Active Comparator|Group 3|Seasonal influenza vaccine and DTP vaccine administered together on day 0. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week 1, 4 weeks and 26 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
2969801|NCT02765113|Active Comparator|Facial nerve combing|Facial nerve combing and Microvascular Decompression(MVD) was performed in all the patients in this group.
2969802|NCT02765113|Active Comparator|Facial and Trigeminal nerve combing|Facial nerve combing、trigeminal nerve combing and Microvascular Decompression(MVD) was performed in all the patients in this group.
2969803|NCT02765100|Experimental|Pilot Study|This will be to conduct a proof of concept add-on treatment study of the antibiotic minocycline for bipolar patients who are depressed at the time of screen. This will examine the value of minocycline augmentation in bipolar depressed patients who are incompletely responsive to initial treatment with anti depressants and/or mood stabilizers. This will be completely open trial and offered to any participant who is depressed at screen.
2969804|NCT02765087|Experimental|Pleural TB|"This group consist of patients with TB pleural effusion.~Intervention:~Inform Consent~Medical History~E-Nose Device~Chest CT~Cytomorphologic & Cytochemistry of pleural Fluid.~Adenosine Deaminase value of pleural Fluid."
2969805|NCT02765087|Active Comparator|Control|"Patients with pleural effusion with different aetiologies than Tuberculosis.~Intervention:~Inform Consent~Medical History~E-Nose Device~Chest CT~Cytomorphologic & Cytochemistry of pleural Fluid.~Adenosine Deaminase value of pleural Fluid."
2969806|NCT02765074|Experimental|Roactemra|subcutaneous tocilizumab
2969807|NCT02765048|Experimental|GAIN Program|Subjects randomly assigned to receive the GAIN Program intervention
2969808|NCT02765048|No Intervention|Usual Care|Subjects randomly assigned to receive community-based services as part of their usual care
2969809|NCT02765035|Experimental|C-Leg 4/C-Leg 3|The participants will be firstly fitted with C-Leg 4 and then with C-Leg 3.
2969810|NCT02765035|Experimental|C-Leg 3/C-Leg 4|The participants will be firstly fitted with C-Leg 3 and then with C-Leg 4.
2969813|NCT02765009|No Intervention|Control|Usual care provided according to the ward policy. Patients have to be weighed at least on admission (day 0), day 7 and day 14.
2969814|NCT02765009|Experimental|Strategy|Patients have to be weighed every day. Use of an algorithm based on weight changes from day 2 to day 14 in order to reduce weight gain (fluid overload) using diuretics, fluid restriction,albumin, and ultrafiltration (the latter when ongoing renal replacement)
2969815|NCT02764996|Experimental|Acupuncture for Migraine|Acupuncture treatments will be subject dependent, and points could include the N point (on scalp); various auricular points to include Shen Men, Point Zero, thalamus and Omega-2; body points to include Liver 2, Liver 3, Gall Bladder 20, bladder 10; and surface release over tense areas in the neck or shoulders
2969816|NCT02764983|Active Comparator|Control Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation (I-MAP's) clinical battery of tests and a simulated driving test, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, and a Satisfaction with Life Questionnaire. Driving safety professional, three x 1 hour sessions to discuss traffic safety, rules of the road, defensive driving, driving under influence, driver attitudes and safety. Additionally, the study will obtain real world driving data from the Department of Motor Vehicles (public records) which will include citations, violations, and recorded collisions/ crashes.
2969817|NCT02764983|Experimental|Experimental Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation (I-MAP's) clinical battery of tests and a simulated driving test, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, and a Satisfaction with Life Questionnaire. Occupational Therapy Driving Intervention (OT-DI) consisting of three x 1 hour sessions to review explicit driving errors, strategies to mitigate errors, and driving simulator with feedback. The study will also obtain real world driving data from the Department of Motor Vehicles (public records) which includes citations, violations, and recorded collisions/crashes.
2969818|NCT02764983|Active Comparator|Caregiver Control Group|Participants in this group will perform the following: Fitness-to-Drive Screening Measure(FTDS) will be filled out at baseline and again at the end of the study.
2969819|NCT02764983|Active Comparator|Caregiver Experimental Group|Participants in this group will perform the following: Fitness-to-Drive Screening Measure(FTDS) will be filled out at baseline and again at the end of the study.
2969820|NCT02764983|Other|Focus Group Discussion Interview Guide|This group will comprise of a subset of the control and experimental groups. A focus group with 8 participants (4 with Traumatic Brain Injury/Post Traumatic Stress Disorder and 4 with orthopedic conditions). The focus group will meet once for a discussion which will be guided with a semi-structured interview that will explore the driving behavior prior to war, during war and post-deployment. Responses will be outlined in an intervention matrix.
2969821|NCT02764970||ivabradine 7.5mg orally|patients are pretreated with ivabradine and bisoprolol orally before Cardiac CT angiogram
2969822|NCT02764970||bisoprolol|patients are only pretreated with bisoprolol orally before Cardiac CT angiogram
2969823|NCT02764957|Active Comparator|intervention|400 mg green coffee extract capsules twice per day for 8 weeks The Green coffee extract is standardised with 45% total chlorogenic acid by HPLC
2969824|NCT02764957|Placebo Comparator|control|placebo capsules twice per day for 8 weeks have identical appearance to Green coffee extract capsules and contain starch
2969825|NCT02764944|Experimental|Intervention|simple non-exposure EFTR group (single arm study)
2969826|NCT02764931|Experimental|Oat meal 1|A single gluten-free oat containing meal number 1 before ingesting the SmartPill capsule. Dietary intervention. Gluten free oats and gastrointestinal health
2969827|NCT02764931|Placebo Comparator|Placebo meal|A single meal which does not contain oats before ingesting the SmartPill capsule. Dietary intervention: gluten-free oats and gastrointestinal health.
2969828|NCT02764931|Experimental|Oat meal 2|A single gluten-free oat containing meal number 2 before ingesting the SmartPill capsule. Dietary intervention. Gluten free oats and gastrointestinal health
2969829|NCT02764918||Children|
2969830|NCT02764918||Mothers|
2969831|NCT02764905|Other|information communication technology (ICT) group|an intervention based on weekly SMS that will remind the individual to implement his personal treatment plan.
2969832|NCT02764905|Other|intensive cognitive-physical rehabilitation group|will include a 2 phase multi-disciplinary intervention. The 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies
2969833|NCT02764892|Experimental|V81444|Single oral dose of V81444
2969834|NCT02764879|Experimental|omega 3 group|scaling and root planing omega3 received 2 times daily-for 6 months
2969835|NCT02764879|Placebo Comparator|control group|scaling and root planing placebo soft gelatin capsules 2 times daily-for 6 months
2969836|NCT02764866|Experimental|Sleep testing|Enrolled patients with lung cáncer will undergo home sleep testing during their initial oncologic evaluation, prior to treatment.
2969837|NCT02764853|Experimental|STEP-AD (10 sessions)|"Participants in this arm will receive the manualized 10 session behavioral medicine intervention titled Striving Towards EmPowerment and Medication Adherence."
2969838|NCT02764853|Active Comparator|Enhanced Treatment as Usual (E-TAU)|Participants in this arm will receive 1 session of Lifesteps and appropriate services and referrals as needed, followed by bi-weekly check-ins with a study research assistant.
2969839|NCT02764840|Experimental|experimental group isokinetic dynamometer (GEDI)|Isokinetic Biodex System Pro 4
2969840|NCT02764840|Experimental|experimental group elastic tube (GETE)|elastic tube brand LEMGRUBER 203
2969841|NCT02764814|Active Comparator|Treatment|subjects receiving cryopreserved amniotic membrane
2969842|NCT02764814|No Intervention|Control|no intervention
2969843|NCT02764801|Experimental|Contrast ultrasound arm|Patients receiving contrast-enhanced ultrasound for diagnosis of chemoembolization response.
2969844|NCT02764788|Experimental|Specific auriculotherapy|Auriculotherapy on specific points with needles
2969845|NCT02764788|Sham Comparator|Non-specific auriculotherapy|Auriculotherapy on non-specific auriculotherapy points with needles
2969846|NCT02764788|Placebo Comparator|Seed auriculotherapy|Auriculotherapy on non-specific auriculotherapy points with seeds
2969847|NCT02764775|Experimental|Headed utilization|Use of Headpod for 6 months duration; 3 x per day for a minimum of 15 minutes each time;
2969848|NCT02764762|Experimental|Vedolizumab 300 mg+Adalimumab 160-40 mg+Methotrexate 15 mg|In Triple Combination Therapy Phase, vedolizumab 300 milligram (mg), intravenous infusion, once at Weeks 0, 2, 6, 14 and 22, along with adalimumab 160 mg subcutaneously, once at Week 0, then 80 mg once at Week 2, then 40 mg once at Week 4 and every 2 weeks thereafter until Week 26 along with oral Methotrexate 15 mg tablets orally once weekly from Weeks 0 up to Week 34. In Monotherapy Phase, vedolizumab 300 mg intravenous infusion once at Weeks 30, 38, 46, 54, 62, 70, 78, 86, 94 and 102.
2969849|NCT02764749|Experimental|freeze dried powder whole cranberry dissolved in water|Dietary Supplement: freeze dried cranberry powder
2969850|NCT02764749|Placebo Comparator|freeze dried cranberry deprived powder dissolved in water|Placebo comparator: freeze dried cranberry deprived powder
2969851|NCT02764736|Experimental|atorvastatin|Patients in this arm will receive 20mg atorvastatin PO daily for 12 weeks followed by 40mg atorvastatin PO daily for 12 weeks.
2969852|NCT02764723|Active Comparator|Hyperbaric bupivacaine|12.5 mg of 0.5% hyperbaric bupivacaine
2969853|NCT02764723|Experimental|Isobaric ropivacaine|15 mg of 0.5% isobaric ropivacaine
2969854|NCT02764710|Experimental|Short treatment|Short course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily for a total of 2 doses.
2969855|NCT02764710|Active Comparator|Long treatment|Long course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily up until and including postoperative day 7.
2969856|NCT02764697|Other|H.P. Acthar Subcutaneous Gel Injection|For the current protocol we are proposing, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses, using the approved route, with the option to do 4 additional doses if resolution is incomplete.
2969857|NCT02764684|Experimental|HIV-infected patients|Probiotics (lactobacillus rhamnosus)
2969858|NCT02764671|Experimental|10μg/0.5ml recombinant HBV vaccine|5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.
2969859|NCT02764658|Experimental|Pulmonary recovery on the AECOPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in AECOPD Patients
2969860|NCT02764658|Other|Routine care on the AECOPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in AECOPD Patients
2969861|NCT02764658|Other|Routine care on the stable COPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in stabel COPD Patients
2969862|NCT02764645|Experimental|CardioGard group|"Patients in whom the CardioGard Cannula will be used, while In these patients there would be a measurement of the gaseous emboli in two points: 1. The aortic vent.~2. The suction cannula of the 'Cardiogard cannula'."
2969863|NCT02764645|Active Comparator|Control group|Patients in whom a 22Fr curved Cannula will be used, while In these patients there would be a measurement of the gaseous emboli in the aortic vent alone.
2969864|NCT02764632|Active Comparator|Didgital group|After induction of anesthesia, and after ensuring muscle relaxation, NGT will be inserted through the selected nostril and advanced for 12 cm then the NGT was advanced according to study group advancing. In control group; NGT was inserted with patient head flexed. In D group, after feeling the NGT in pharynx, with the head in neutral position,the index finger was used to support the NGT with slight direction towards the left side. This will prevent tube kinking at this point in front of the resistance offered by the inflated tube cuff or arytenoids cartilage. Also, this digital support reinforces the tube at the area weakened by its openings
2969865|NCT02764632|No Intervention|Control group|
2969866|NCT02764619|Active Comparator|Aldo group|Fixed dose of spironolactone, Spirix (Takeda Pharma A/S), 25 mg once daily, added to optimal medical treatment (usual care) for atrial fibrillation.
2969867|NCT02764619|Placebo Comparator|Control group|Matched placebo, 1 pill once daily, added to optimal medical treatment (usual care) for atrial fibrillation.
2969868|NCT02764606||Patients with a non-small cell lung cancer|Serum and plasma samples (at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases).
2969869|NCT02764593|Experimental|Arm 1 (Nivolumab + Cisplatin)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. Cisplatin will be given weekly. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
2969870|NCT02764593|Experimental|Arm 2 (Nivolumab + High-dose Cisplatin)|Patients will receive Nivolumab via IV administration starting 14 days prior to IMRT, then Day 1 of IMRT and then every 21 days for 6 doses. Cisplatin will be given every 21 days for 3 doses. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
2969871|NCT02764593|Experimental|Arm 3 (Nivolumab + Cetuximab)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. Cetuximab will be given for 7 doses. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
2969872|NCT02764593|Experimental|Arm 4 (Nivolumab + IMRT)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
2969901|NCT02764359|Experimental|IV Vancomycin loading dose- higher|IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 4,000mg
2969902|NCT02764359|Experimental|IV Vancomycin loading dose- lower|IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 2,000mg
2969873|NCT02764567|Experimental|Aromatherapy|"The participants randomized to aromatherapy will be offered one of three essential oils, 'applied' to their smell zone via cotton ball that are known to have anti-anxiety effect. These are:~ginger~calming~lavender The participant's choice will be documented in a database. The participant can chose an oil each time (i.e., they are not bound to use only the first choice oil). Pain and anxiety will be measured prior to receiving the essential oils and again after the phlebotomy procedure. Blood pressure and pulse will also be measured post-phlebotomy."
2969874|NCT02764567|No Intervention|Standard of Care|The participants randomized to standard of care will proceed to the outpatient phlebotomy room in the Heart Care Clinic as per usual care. Pain, anxiety, blood pressure and pulse will be assessed pre and post-procedure.
2969875|NCT02764554||Lenvatinib 4 milligram (mg) and 10 mg capsule|Participants who are prescribed with Lenvatinib per approved prescribing information of lenvatinib in normal clinical practice setting.
2969876|NCT02764541|Experimental|Arm A Tamoxifen followed by Endocrine Therapy|Tamoxifen is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy for 24 weeks.
2969877|NCT02764541|Experimental|Arm B Letrozole Followed By Endocrine Therapy|Letrozole is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy for 24 weeks.
2969878|NCT02764541|Experimental|Tamoxifen Followed By Endocrine Therapy and Palbociclib|Tamoxifen is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy in combination with Palbociclib for 24 weeks.
2969879|NCT02764541|Experimental|Letrozole Followed By Endocrine Therapy and Palbociclib|Letrozole is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy in combination with Palbociclib for 24 weeks.
2969880|NCT02764528|No Intervention|Control|Women will receive standard antenatal care but will not receive any additional handwashing promotion, soap, or handwashing device during their enrollment. At the end of data collection, handwashing with soap will be recommended to participants in the control arm and their families.
2969881|NCT02764528|Experimental|Clinic|Handwashing promotion from healthcare workers at antenatal care clinic.
2969882|NCT02764528|Experimental|Clinic + home|Handwashing promotion from healthcare workers at antenatal care clinic and from community health volunteers at home visits.
2969883|NCT02764528|Experimental|Clinic + home + handwashing device|Handwashing promotion from healthcare workers at antenatal care clinic and from community health volunteers at home visits with provision of one handwashing device.
2969884|NCT02764515|Experimental|Kunxian capsule group|"Intervention:~Drug: Kunxian 2 capsules BID taken by mouth for 24 weeks. Kunxian capsule is composed of 4 ingredients: Tripterygium wilfordii Hook F 300mg, extracts from Gouqizi,Tusizi and yinyanghuo."
2969885|NCT02764515|Active Comparator|Methotrexate group|"Intervention:~Drug: Methotrexate tablet 10mg taken by mouth every week for 24 weeks."
2969886|NCT02764502|Experimental|Pressure Gauge Manometer|Tuohy needle is introduced into intervertebral space at the level of L3-L4 up to the interspinous ligaments . The needle is advanced slowly using both hands while monitoring the manometer reading and is stopped when the pressure suddenly dropped ( the pressure usually drops by 5-10 mm Hg when the tip of the needle inters the epidural space ).
2969887|NCT02764489|Experimental|Part 1 Regular then reduced volume Part 2 Faster infusion rate|STUDY PART 1- FEIBA reconstituted in regular volume then FEIBA reconstituted in 50% reduced volume; STUDY PART 2- Infusion rate escalation to 4 U/min/kg and reconstituted in 50% reduced volume; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 4 U/min/kg; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 10 U/min/kg
2969888|NCT02764489|Experimental|Part 1 Reduced then regular volume Part 2 Faster infusion rate|STUDY PART 1- FEIBA Reconstituted in 50% Reduced Volume then FEIBA Reconstituted in Regular Volume; STUDY PART 2- Infusion rate escalation to 4 U/min/kg and reconstituted in 50% reduced volume; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 4 U/min/kg; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 10 U/min/kg
2969889|NCT02764476|Experimental|Virtual Reality Therapy|Eight 30 minute sessions of embodied virtual reality therapy with use of a body transfer experience into an egocentric perspective avatar that encourages motor activity and desensitization to emotional cues.
2969890|NCT02764476|Active Comparator|Control|Eight 30 minute sessions of virtual reality therapy.
2969891|NCT02764463|Other|FRCFPDs|Fiber reenforced Composite Fixed Partial Dentures
2969892|NCT02764450|Experimental|Astralis 10 HPM|Polymerization High-power mode: 1300 mW/cm2 for 10 s
2969893|NCT02764450|Experimental|Astralis 10 RM|Polymerisation regular mode: 650 mW/cm2 for 20
2969894|NCT02764437|Other|MRI-Bronch, PET-WLAC (Stress vs Control)|Subjects will have a functional MRI scan 24 hours before a bronchoscopy with segmental allergen challenge. 48 hours post segmental allergen challenge, the subject will have another MRI and bronchoscopy. 4-6 weeks later, subjects will have a PET scan and whole lung antigen challenge under a stress condition or control condition. 4-6 weeks later, subject will have another PET scan and whole lung antigen challenge under a stress condition or control condition (whatever they did not have the first time).
2969895|NCT02764424||Preterm or term newborns|Preterm or term newborns, hospitalized in neonatal intensive care units of our university hospital (Saint-Etienne - France), who have to acute painful stimuli related to their care will be included in the study. This painful stress is made in the patient's usual care and is not modified by the protocol. Their stress due to the painful stimuli will be measured with different scales (2 PIPP (Premature Infant Pain Profile) and DAN (Newborn Acute Pain)) and compared with the index obtained with the NIPE (Newborn Infant Parasympathetic Evaluation - MDoloris®).
2969896|NCT02764411|Experimental|Onreltea ( Brimonidine)|All the patients enrolled in the study will apply Onreltea ( Brimonidine 0.33%) gel on the affected skin area for 12 weeks (from Day 0 to Week 12 visit).
2969897|NCT02764385|Other|AAC only|This is a system-based intervention that involves changes in the EHR regarding documenting tobacco assessment and the capability to order an eReferral to the Quitline. This system-based intervention also changes the role of the medical technical assistant.
2969898|NCT02764385|Other|AAC + TMCP|The Teachable Moment Communication Process is a clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
2969899|NCT02764372|Experimental|Serious games|The experimental group received Serious Games-based upper extremity therapy through Kinect
2969900|NCT02764372|Active Comparator|Exergames|The control played the same amount of time with commercial exergames of the Wii
2969905|NCT02764333|Experimental|vaccine|Patients will receive an intradermal (ID) injection of TPIV200 (500 μg per peptide) and GM-CSF (125 μg per peptide) on Day 1 of cycles 1-6. They will also receive intravenous (IV) injections of durvalumab (750mg) on Days 1 and 15 of cycles 1-12. Radiologic tumor assessment will be repeated every 12 weeks (or 3 cycles) during and after treatment, until time of progression. Treatment will continue until progression, intolerance, withdrawal, study completion, or study termination.
2969906|NCT02764320|Active Comparator|Discontinuation|Immediate discontinuation of the overused medication(s) and migraine preventive therapy
2969907|NCT02764320|Active Comparator|Preventive Therapy Only|Migraine preventive therapy without immediate discontinuation of the overused medication(s)
2969908|NCT02764307|Experimental|Aerosolized drug depositions|Aerosol drug deposited on the inhaled and exhaled filters and the residual dose were evaluated delivered by four types of nebulizer: 1) a constant jet nebulizer, a breath enhanced nebulizer, a manual-actuated nebulizer, and a breath-actuated nebulizer.
2969909|NCT02764294|Active Comparator|Music Group|Music group was listened to a music of their choise with a headset. The music intervention was started about 10-15 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
2969910|NCT02764294|Active Comparator|Stress Ball Group|"Stress ball group was given stress ball into both their palms about 10-15 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure."
2969911|NCT02764294|Active Comparator|DVD Group|DVD group was watched a DVD of their choice (documentaries, interesting and amazing videos, comedies) on a ceiling-mounted monitor positioned at a comfortable distance to the participant.
2969912|NCT02764294|No Intervention|Control Group|Participants received usual care from health professionals. They didn't receive any intervention.
2969913|NCT02764281|Experimental|MEDA/Auto-HSCT|Patients will be initially treated with four cycles MEDA chemotherapy, followed by autologous hematopoietic stem cell transplantation (Auto-HSCT).
2969914|NCT02764268|Experimental|Apatinib|
2969915|NCT02764255||embryoscope group|cases with embryos continuously monitored by the embryoscope followed by embryo selection based on a multivariable model
2969916|NCT02764255||control group|cases with embyos cultured in the standard incubator and evaluated only by morphology
2969917|NCT02764242|Other|insect sting allergy|"Skin prick tests to local and imported insect sting allergen with different concentration are performed.~sIgE Measurement (to insect and the recombinant venom)"
2969918|NCT02764229|Experimental|LYC-30937-EC 25 mg PO QD|LYC-30937-EC 25 mg by mouth once daily
2969919|NCT02764216|Experimental|EMI group|Elective mucosal irradiation
2969920|NCT02764203|Experimental|Chocolate consumption|Subjects will consume 50g of dark chocolate for 2 weeks and have their blood pressure compared before chocolate and after chocolate
2969921|NCT02764190|Experimental|I-ACT with Check Yourself|Adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Check Yourself includes the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers will receive I-ACT and the Check Yourself summary report of health risk behaviors before an adolescent patient's appointment. I-ACT will provide training in adolescent-preferred communication methods and use of Check Yourself as a framework for the provider to use motivational interviewing to consider the patients' change readiness and their personal health goals. I-ACT includes online interactive, case-based learning, with booster sessions and feedback reports to reinforce new skills.
2969922|NCT02764190|No Intervention|Usual care|In the usual care group, adolescents are asked to complete health risk screening on a computer. No personalized feedback is provided to adolescents and primary care providers do not receive I-ACT or the Check Yourself summary report of the adolescent's health risk behaviors.
2969923|NCT02764177|Experimental|Protein|In this arm the subjects were provided with a PROTEIN drink to consume after exercise. This protein drink contained whey protein isolate that provided 0.3 g/ kg body mass of protein.
2969924|NCT02764177|Experimental|Carbohydrate|In this arm the subjects were provided with a CARBOHYDRATE drink to consume after exercise. This carbohydrate drink was energy matched to the protein drink in the other arm of the experiment.
2969925|NCT02764164|Experimental|Intervention Active tDCS|Affected subjects receiving up to 2 milliamps (mA) active tDCS, open label
2969926|NCT02764151|Experimental|PF-06840003|Daily Oral PF-06840003
2969927|NCT02764138|Experimental|BaSICS Intervention|"Intervention = Building a String Identity and Coping Skills (BaSICS). Children randomized to participate in 16 twice weekly BaSICS intervention sessions. Children learn coping skills, identity development, and collective action as ways to buffer against chronic stress.~These children also complete pre- and post-intervention assessments, as well as 3-month and 12-month follow-up assessments."
2969928|NCT02764138|No Intervention|Comparison|These children complete assessments only--timed to coincide with the intervention groups' assessments: pre- and post-intervention assessments, as well as 3-month and 12-month follow-up assessments. No intervention.
2969929|NCT02764125|Active Comparator|Stalevo|levodopa/carbidopa/entacapone
2969930|NCT02764125|Experimental|levodopa MR|Levodopa MR/carbidopa/ODM-104
2969931|NCT02764099|Active Comparator|Life Skills Training|"All youth who consent to participate in the proposed study will 1) complete the youth peer court sanction delivered by the jury of peers (e.g., apologies or essays, restitution, curfew and travel restrictions, counseling, etc.), which will constitute treatment as usual; and 2) complete pre, post, and six-month follow-up surveys. Those randomized to the intervention condition (n=280) will participate in the LST program concurrently during the weeks when they serve as peer court jurors."
2969932|NCT02764099|No Intervention|Control|"All youth who consent to participate in the proposed study will 1) complete the youth peer court sanction delivered by the jury of peers (e.g., apologies or essays, restitution, curfew and travel restrictions, counseling, etc.), which will constitute treatment as usual; and 2) complete pre, post, and six-month follow-up surveys. Those randomized to the control group (n=280) will not participate in LST but will participate in a ten session, lecture-style, didactic health education course. This course will include general information on several health-related topics, but will not contain any type of skill building exercises."
2969933|NCT02764086|Other|Trial Cohort Description|"Escalated dose of min 65Gy to the iGTV, with 60Gy to PTV delivered to successive cohorts of patients(pts) until the MTD oesophageal dose is determined. Toxicity will be analysed 2 months post 6pts treated in a cohort.~If: ≤2pts have ≥G3 toxicity, next cohort will be enrolled & receive escalated dose (an additional +5Gy at each escalation upto max 75Gy)/3 of 6pts have ≥G3 toxicity, a further 6pts will be recruited into that dose level/≥4pts have ≥G3 toxicity, the MTD is fixed at dose level of previous cohort~Cohort is extended to 12pts:~If: ≤4pts have ≥G3 toxicity, next cohort will be enrolled & receive escalated dose/5 of 12pts have ≥G3 toxicity, the MTD is fixed at that dose level & recruitment continues up to 24pts/≥6pts have ≥G3 toxicity, the MTD is fixed at the dose level of previous cohort.~Once the max dose cohort is established, recruiting will continue at that dose until 24pts. Concurrent & neo-adjuvant/no chemotherapy arms will be escalated independently of each other"
2969934|NCT02764060|Experimental|Tongue scraper|In this group the subjects are explained how to use a plastic loop-formed tongue cleaner (Halita® tongue cleaner (Dentaid, Spain)) to clean their tongues.
2969935|NCT02764060|Experimental|Toothbrush|In this group the subjects are explained how to use a toothbrush (Oral-B® Indicator® medium tooth brush) to clean their tongues.
2969936|NCT02764047|Placebo Comparator|Placebo|Placebo capsule
2969937|NCT02764047|Active Comparator|Probiotic|Probiotic capsule
2969938|NCT02764021|Experimental|1.|Subjects will be randomly assigned to initially receive 6 weeks of standard antidiabetic dietary treatment or 6 weeks of experimental carbohydrate-restricted dietary treatment, crossing over to the opposite diet from week 6 to 12.
2969939|NCT02764021|Active Comparator|2.|Subjects will be randomly assigned to initially receive 6 weeks of standard antidiabetic dietary treatment or 6 weeks of experimental carbohydrate-restricted dietary treatment, crossing over to the opposite diet from week 6 to 12.
2969940|NCT02764008|Active Comparator|Low thoracic paravertebral block|T8-T9 Ultrasound guided paravertebral block with 20 ml %0,25 bupivacaine
2969941|NCT02764008|Active Comparator|Peritubal infiltration|Peritubal infiltration with 20 ml %0,25 bupivacaine
2969942|NCT02764008|No Intervention|Control Group|No drug
2969943|NCT02763995|Experimental|Pharmaceutical care|Dader method. Health education for lifestyle modification. Improve adherence. Resolution of negative outcome associated with medication.
2969944|NCT02763982||G1|High or normal left ventricular ejection fraction
2969945|NCT02763982||G2|Moderate left ventricular ejection fraction
2969946|NCT02763982||G3|Reduced left ventricular ejection fraction
2969947|NCT02763969|Experimental|Part A: Single Ascending Dose|BMS-986202 or Placebo specified dose on specified days
2969948|NCT02763969|Experimental|Part B: Multiple Ascending Dose|BMS-986202 or Placebo + Interferon alpha-2a recombinant specified dose on specified days
2969949|NCT02763969|Experimental|Part C: Multiple Ascending Dose-Japanese descent|BMS-986202 or Placebo specified dose on specified days in patients of Japanese descent
2969950|NCT02763969|Experimental|Part D: Relative Bioavailability|BMS-986202 (Liquid) or BMS-986202 (Capsule) + Famotidine specified dose on specified days
2969951|NCT02763969|Experimental|Part E: Proof of Mechanism|BMS-986202 or Placebo + Ustekinumab specified dose on specified days
2969952|NCT02763956|Experimental|Gelstix|The intradiscal insertion of the GelStix™ Nucleus Augmentation Device.
2969953|NCT02763956|Placebo Comparator|Placebo|Intradiscal saline solution (1 mL NaCl 0.9%) injection.
2969954|NCT02763930|Experimental|CONTROL (dairy-free)|6 weeks experimental diet with all meals and foods provided to participants. The diet contain 32% of fat, 11% of saturated fat (SFA), 13% of mono-unsaturated fat (MUFA), 8% of polyunsaturated fat (PUFA) and 15% of proteins.
2969955|NCT02763930|Experimental|MILK (low fat dairy)|6 weeks experimental diet with all meals and foods provided to participants including 3 servings/day of milk (1% fat) per 2500 kcal. The diet contain 32% of fat, 11% of SFA, 13% of MUFA, 8% of PUFA and 15% of proteins.
2969956|NCT02763930|Experimental|GABA-rich cheese (high-fat dairy )|6 weeks experimental diet with all meals and foods provided to participants including 50g/day of GABA-rich cheddar cheese (approximately 32% fat). The diet contain 32% of fat, 13% of SFA, 13% of MUFA, 6% of PUFA and 15% of proteins.
2969957|NCT02763917|Active Comparator|Active Air Purifier|Two portable air purifiers containing HEPA filters will be placed in the bedroom and room where the participant reports spending the most time. We have chosen to deploy two air purifiers because we have observed a 50% reduction in indoor PM concentrations with two air purifiers. Participants will be instructed to run the air purifiers continually. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies. Participants will also receive educational materials about health benefits of maintaining a normal weight.
2969958|NCT02763917|Placebo Comparator|Placebo Air Purifier|Homes in the control group will receive placebo air purifiers that have the internal air filters removed, but which will run normally. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight. At the end of the study, participants in the control group will receive active air purifiers. A control group is needed to ensure that reduced pollutant levels and health effects are not due to temporal trends and 'placebo effects' of being enrolled in an intervention trial. Participants will also be informed that being in the study does not prevent them from purchasing and using air cleaners during the study period.
2969959|NCT02763904|Experimental|Intensive nutritional counseling|Dietary counseling + energy dense oral nutritional supplements
2969960|NCT02763904|Active Comparator|Dietary counseling|Dietary counseling
2969961|NCT02763891|Experimental|Intervention group|Subjects submitted to a 30-minute session of suspension and tilting exercises on the Chordata equipment (PI: 0804871-1 and BR 10 2012 009901-2) twice a week for eight weeks.
2969962|NCT02763891|Sham Comparator|Control group|Subjects submitted to a 30-minute passive muscle stretching session twice a week for eight weeks.
2969963|NCT02763878|Experimental|uncut Roux-en-Y anastomosis|After distal gastrectomy, duodenal stump closure, side to side anastomosis was underwent on the remnant stomach and jejunum,which was 25cm from Treitz ligament. Then underwent side to side anastomosis between jejunum about 35cm distance from gastrojejunostomy and jejunum about 5cm from Triez ligament . close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis by using uncut Closure devices
2969964|NCT02763878|Sham Comparator|Billroth II anastomosis|After distal gastrectomy, duodenal stump closure, the investigators first underwent remnant stomach and upper jejunum side anastomosis. Then choose the jejunum about 25cm from Treitz ligament, premenstrual colon using a disposable cutting closure (or tubular stapling) in the rear wall of the stomach and jejunum anastomosis, common opening was closed with the (barbed wire) hand-stitched. After that, steps were same with the group A.
2969965|NCT02763865|Experimental|Active pre-SMA rTMS|The intervention to be administered is the MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil l to administer active rTMS at 1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total. Two Thymapad Stimulus Electrodes will be placed in the appropriate position during active rTMS administration.This intervention method will be used for all 15 treatment sessions (20 minutes/session).
2969966|NCT02763865|Sham Comparator|Sham pre-SMA rTMS|The intervention to be administered is the eSHAM system used in conjunction with the MagVenture MagProx100 Stimulator with the Cool-B65 A/P Coil. For eSHAM administration two Thymapad Stimulus Electrodes will be placed on the scalp location that corresponded to left DLPFC. This intervention method will be used for all 15 treatment sessions (20 minutes/session). Previous studies have shown the eSHAM system effectively blinds participants to rTMS treatment (active versus sham).
2969967|NCT02763852|Experimental|BIA 3-202 50 mg|BIA 3-202 single-dose plus 1 tablet of Madopar 125. BIA 3-202 50 mg: 5 tablets of 10 mg. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
2969968|NCT02763852|Experimental|BIA 3-202 100 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 100 mg: 1 tablet of 100 mg + 4 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
2969969|NCT02763852|Experimental|BIA 3-202 200 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 200 mg: 2 tablet of 100 mg + 3 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
2969970|NCT02763852|Experimental|BIA 3-202 300 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 300 mg: 3 tablet of 100 mg + 2 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
2969971|NCT02763852|Experimental|BIA 3-202 400 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 400 mg: 4 tablet of 100 mg + 1 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
2969972|NCT02763839|Experimental|BIA 3-202 50 mg|BIA 3-202 single-dose plus 1 tablet of Sinemet 25/100 BIA 3-202 50 mg: 5 tablets of 10 mg. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
2969973|NCT02763839|Experimental|BIA 3-202 100 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 100 mg: 1 tablet of 100 mg + 4 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
2969974|NCT02763839|Experimental|BIA 3-202 200 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 200 mg: 2 tablet of 100 mg + 3 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
2969975|NCT02763839|Experimental|BIA 3-202 300 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 300 mg: 3 tablet of 100 mg + 2 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
2969976|NCT02763839|Experimental|BIA 3-202 400 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 400 mg: 4 tablet of 100 mg + 1 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
2969977|NCT02763826|Experimental|tDCS Application|transcranial direct current stimulation. tDCS currents are applied in increasing strengths and then in different electrode montages.
2969978|NCT02763813|Experimental|Propulsion type appliance (Herbst)|
2969979|NCT02763813|Active Comparator|Retention type appliance (ORM)|Retention type appliance
2969980|NCT02763800|Experimental|Group 1: BIA 3-202 50 mg/placebo|"Group 1: BIA 3-202 50 mg/placebo on Day 1; BIA 3-202 50 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 50 mg/placebo on Day 9.~50 mg BIA 3-202: 5 x 10 mg BIA 3-202 tablets"
2969981|NCT02763800|Experimental|Group 2: BIA 3-202 100 mg/placebo|"Group 2: BIA 3-202 100 mg/placebo on Day 1; BIA 3-202 100 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 100 mg/placebo on Day 9.~100 mg BIA 3-202: 1 x 100 mg BIA 3-202 tablet"
2969982|NCT02763800|Experimental|Group 3: BIA 3-202 200 mg/placebo|"Group 3: BIA 3-202 200 mg/placebo on Day 1; BIA 3-202 200 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 200 mg/placebo on Day 9.~200 mg BIA 3-202: 2 x 100 mg BIA 3-202 tablets"
2969983|NCT02763800|Experimental|Group 4: BIA 3-202 200 mg/placebo|"Group 4: BIA 3-202 200 mg/placebo on Day 1; BIA 3-202 200 mg/placebo t.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 200 mg/placebo on Day 9.~200 mg BIA 3-202: 2 x 100 mg BIA 3-202 tablets"
2969984|NCT02763787|Experimental|Placebo|Matched placebo was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
2969985|NCT02763787|Experimental|10 mg|1 x 10 mg BIA 3-202 tablet BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
2969986|NCT02763787|Experimental|30 mg|3 x 10 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
2969987|NCT02763787|Experimental|50 mg|5 x 10 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
2969988|NCT02763787|Experimental|100 mg|1 x 100 mg BIA 3-202 tablet BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
2969989|NCT02763787|Experimental|200 mg|2 x 100 mg BIA 3-202 tablets
2969990|NCT02763787|Experimental|400 mg|4 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
2969991|NCT02763787|Experimental|800 mg|8 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
2969992|NCT02763787|Experimental|Food Effect (fed/fasted)|400 mg BIA 3-202: 4 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
2969993|NCT02763774|Experimental|Walking exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs, stationary running and walking. The intensity of walk will be determined by the Borg's sujective effort perception scale - (modified from zero to 10). On first postoperative day, participants will perform exercises in supine position. From the second to the fifth postoperative day, they will perform progressive walking.
2969994|NCT02763774|Experimental|Stationary cycling exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, they will perform progressive cycling exercise.The intensity of cycling will be determined by the Borg's sujective effort perception scale - (modified from zero to 10).
2969995|NCT02763774|Experimental|Neuromuscular electrical stimulation|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, quadriceps and gastrocnemius muscles will be percutaneous stimulated with the following parameters: Synchronic mode, 50Hz, 400uS, time on 10s, time off 20s, intensity as tolerated by the patient.
2969996|NCT02763761|Experimental|Infliximab + Prednisone|Infliximab intravenous solution (single dose) + low dose prednisone per oral for 18 days
2969997|NCT02763761|Experimental|Methylprednisolone + Prednisone|Methylprednisolone intravenous solution (single dose) + high dose prednisone per oral for 40 days
2969998|NCT02763748|Experimental|Laparoscopic surgery|Laparoscopic endoscopy combined surgery. This is a kind of traditional surgical method.
2969999|NCT02763748|Experimental|laparoscopic and endoscopic|LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .
2970000|NCT02763748|Experimental|Single-arch laparoscopic and endoscopic|Single-arch LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
2970001|NCT02763735|Experimental|Pulmonary Arterial Hypertension|Patients diagnosed with idiopathic or heritable pulmonary arterial hypertension according to consensus guidelines exposed to C11 acetate.
2970002|NCT02763735|Active Comparator|Subjects without cardiopulmonary disease|Subjects without known cardiopulmonary disease exposed to C11 acetate
2970003|NCT02763722|Experimental|Emollient spray product|"Study design~A 3 visits are planned:~0 week (first visit) 2nd week (second visit) 4th week (third visit)~B. During each visit will be made:~The clinical examination (including an assessment of any adverse effects)~Evaluation of transepidermal water loss (TEWL) and capacitance of outer areas of the stratum corneum as an indirect assessment of skin hydration,~fill out questionnaires CDLQI (The Children's Dermatology Life Quality Index)~will assess VAS (visual analogue scale)~C. All patients will be instructed to use emollients spray the entire surface of the skin at least twice daily for four weeks."
2970004|NCT02763709||Cases|Children admitted in Pediatric ICU for more than 24 hours with Pediatric Risk of Mortality (PRISM) score III > 20
2970005|NCT02763696||normal women|Composition of Viginal flora of Child-Bearing women in normal woman
2970006|NCT02763696||vaginitis women|Women of childbearing age with vaginitis
2970007|NCT02763683||Parkinsons Disease|Individuals with Parkinsons Disease
2970008|NCT02763683||Healthy Controls|Individuals without Parkinsons Disease
2970009|NCT02763670|Other|Interventional|PRETICARD patient care management
2970010|NCT02763670|Other|Control|"Heterogenous as usual patient care management."
2970011|NCT02763657|Experimental|Brain activity during reasoning|
2970012|NCT02763644|Active Comparator|Standard of Care (SoC)|SoC as per site standard
2970013|NCT02763644|Experimental|LFG316 plus SoC|LFG316 plus SoC (excluding plasmapheresis and prohibited treatment)
2970014|NCT02763631|Experimental|Run In Phase|Eligible patients will have 6-Minute Walk Test (6-MWT) on self ventilation and on CPAP
2970015|NCT02763631|Experimental|Treatment|"Those patients who improve their 6-MWT by more than 30 meters will then be randomised to either:~Treatment arm - Patients will be setup onto portable CPAP during the day"
2970016|NCT02763631|Sham Comparator|Standard Care Arm|"Those patients who improve their 6-MWT by more than 30 meters will then be randomised to either:~Control Arm - Standard care arm."
2970017|NCT02763618|Active Comparator|Group A: Theta/beta ratio Neurofeedback|"In this condition, participants will receive three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions.~Theta beta ratio Neurofeedback signal will be used to simultaneously down-train the EEG theta frequency band and up-train the beta frequency band. Three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions."
2970018|NCT02763618|Active Comparator|Group B: Theta/beta ratio Neurofeedback|"In this condition, participants will receive nine baseline sessions and continue with eight theta/beta ratio Neurofeedback sessions.~Theta beta ratio Neurofeedback signal will be used to simultaneously down-train the EEG theta frequency band and up-train the beta frequency band. Three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions."
2970019|NCT02763618|Placebo Comparator|Group C: Placebo Neurofeedback training|Three baseline sessions and continue with 14 placebo training sessions. The placebo training will be a previously recorded Neurofeedback session of a participant in group A (receiving 14 real Neurofeedback sessions). Before the participants in group C (placebo trainings) start, they will be matched to a participant in group A, and receive the exact same (prerecorded) feedback per session of their matched participant. In this way, participants in the placebo training are then made to think that the video and EEG feedback is their own, however they are actually not able to influence the continuation of the video.
2970020|NCT02763605||patients diagnosed with acanthamoeba keratitis|"Inclusion Criteria:~- All patients presenting to National Taiwan University Department from Jun. 1st, 2003 to dec. 30th , 2016 with the tissue proven corneal AK will be included.~Exclusion Criteria~- Patients with tissue proven corneal AK during from Jun. 1st, 2003 to dec. 30th , 2016, but without in vivo confocal data, or complete chart records."
2970021|NCT02763592|Experimental|Lidocaine|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo
2970022|NCT02763592|Placebo Comparator|placebo|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo
2970023|NCT02763579|Experimental|Atezolizumab + Carboplatin + Etoposide|Participants will receive intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) followed by etoposide 100 milligrams per square meter (mg/m^2) on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m^2 will be administered alone. Thereafter, participants will receive maintenance (Cycle 5 onward) atezolizumab 1200 mg on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
2970024|NCT02763579|Active Comparator|Placebo + Carboplatin + Etoposide|Participants will receive intravenous infusions of placebo in combination with carboplatin to achieve an initial target AUC of 5 mg/mL/min followed by etoposide 100 mg/m^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m^2 will be administered alone. Thereafter, participants will receive maintenance (Cycle 5 onward) placebo on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
2970025|NCT02763566|Experimental|Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)|Abemaciclib given orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.
2970026|NCT02763566|Experimental|Placebo + NSAI|Placebo given orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.
2970027|NCT02763566|Experimental|Abemaciclib + Fulvestrant|Abemaciclib given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
2970028|NCT02763566|Experimental|Placebo + Fulvestrant|Placebo given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
2970029|NCT02763553|Experimental|Ketogenic Feed|A low-carbohydrate, high-fat enteral feed (Nutrison KetoCal 4:1) containing 0.4g of carbohydrate and 10g of fat per 100kcal. Given as a continuous feed via a naso-gastric tube as per standard feeding protocol.
2970030|NCT02763553|Active Comparator|Standard Feed|Standard enteral feed (Nutrison ProteinPlus MF 1.28) containing 11.1g of carbohydrate and 3.8g of fat per 100kcal. Given as a continuous feed via a naso-gastric tube as per standard feeding protocol.
2970031|NCT02763540|Other|Lung cryobiopsy|
2970032|NCT02763527|Experimental|Smoking reduction|"Subjects will receive a brief intervention on smoking reduction with a warning message plus a smoking reduction leaflet. They will be asked to think about a tailored smoking reduction schedule for themselves after the negotiation with the trained counsellor. The trained counsellor will negotiate a schedule with subjects to reduce their smoking over an acceptable level. For the subsequent telephone follow up in the intervention group, information on reduction and cessation will be collected, followed by a booster intervention, which will repeat the health warning to positively encourage them to reinforce their efforts and the next reduction target. Four consecutive (1, 3, 6 and 12 months) follow-ups will be conducted over the telephone by trained interviewers."
2970033|NCT02763527|Placebo Comparator|Smoking Cessation|"Subjects in the QI group will always be advised to quit immediately rather than to quit progressively. Subjects will receive a brief advice on quitting with a warning message similar to subjects in the QP group. In addition, subjects will receive a self-help quitting pamphlet published by the Hong Kong Council on Smoking and Health (COSH). Unlike the QP group, subjects in the QI group will not receive smoking reduction intervention and leaflet, and booster intervention during telephone follow-ups. However, they will undergo a similar schedule of telephone follow-up as those in the QP group."
2970034|NCT02763514|Active Comparator|DHA-enriched oil|3 g PronovaPure 150:500 EE EU
2970035|NCT02763514|Active Comparator|EPA-enriched oil|3 g PronovaPure 500:200 EE EU
2970036|NCT02763514|Placebo Comparator|Placebo|3 g Olive oil
2970037|NCT02763501|Active Comparator|RCT|"patients operated with laparoscopic gastric bypass surgery within a register based RCT from May 1st 2010 until Nov 14th 2011.~1:1 randomization to closure of mesenteric defects by running, non-absorbable sutures"
2970038|NCT02763501|Active Comparator|non-RCT|"patients operated with laparoscopic gastric bypass surgery outside of the RCT from May 1st 2010 until Nov 14th 2011.~Intervention of mesenteric defects according to local tradition or choice of surgeon (non-randomized)"
2970039|NCT02763488|Active Comparator|Standard physical therapy|These individuals will conduct physical therapy for 12 sessions as per the institutional standard physical therapy protocol
2970040|NCT02763488|Experimental|Blood flow restriction|These individuals will conduct physical therapy for 12 sessions with the addition of blood flow restriction interventions to their standard physical therapy
2970041|NCT02763475|Experimental|Natural Killer (NK) Cells + Chemotherapy|Starting on day -6, 60mg/Kg cyclophosphamide by vein will be administrated. Day -5 to -1 fludarabine administrated by vein at 25 mg/m2. 24-48 hours after chemotherapy completion, NK cell infusion will be injected (day 0). On day 7 a second NK cell infusion will be administrated. First infusion consist of 5x10^7/kg NK CD3-CD56+ NK cells. The second NK cell infusion will include up to 5x10^8 CD3-CD56+ cells if no treatment related toxicity occurred. Subcutaneous IL-2 (1x10^6 UI/m2) three times a week for two weeks will be administrated after first NK infusion.
2970042|NCT02763449|Experimental|Sedentary|Individuals will reduce their physical activity level for 14-days
2970043|NCT02763449|Experimental|Active|Individuals will increase their physical activity level for 14-days
2970044|NCT02763436|No Intervention|"Group immediate cord clamping (ICC)"|The cord will be clamped within the first minute after birth, afterwards the newborn will be placed on the mothers chest/abdomen. This corresponds to the present routine approach in Graz.
2970363|NCT02761525|Experimental|gel silver nanoparticles|topic gel silver nanoparticles 12 ppm
2970045|NCT02763436|Active Comparator|"Group physiological based cord clamping (PBCC)"|"The newborn will be placed on mother's chest/abdomen with intact cord. After the newborn has established stable breathing efforts (continuous regular breathing pattern and SpO2 values >25th percentile from Dawson et al reference range for oxygen saturation -minute 2>58%, minute 3>67%, minute 4>76%) the cord is clamped. This will need 2 - 4 minutes."
2970046|NCT02763423|Experimental|umbilical cord mesenchymal stem cell|single- or double-dose intravenous injection of umbilical cord mesenchymal stem cells for the treatment of severe type 1 diabetes patients
2970047|NCT02763410||control group|Patients who received between 1 and 5 PRBCs between incision and the 6th hour post-surgery, with no renal failure at the 48th hour after surgery, based on the RIFLE classification, and regardless of the transfusion received after the H6 assessment.
2970048|NCT02763410||Renal failure group|Patients who received between 1 and 5 PRBCs between incision and the 6th hour post-surgery and who developed renal failure before H48 with no new transfusion prior to diagnosis of kidney failure.
2970049|NCT02763397|Experimental|NBM-DBS on|DBS is programmed to stimulate the NbM
2970050|NCT02763397|Placebo Comparator|DBS off|DBS is turned off, no stimulation will be exerted
2970051|NCT02763384|Experimental|Arm 1: BL-8040 and Nelarabine|"Cycle 1: BL-8040 subcutaneous daily from Day 1 to Day 6 and nelarabine intravenously over 2 hours on Days 2, 4, and 6~Cycles 2-4: BL-8040 subcutaneous daily from Day 1 to Day 5 and nelarabine intravenously over 2 hours on Days 1, 3, and 5~Treatment may be repeated every 21 days for up to 4 cycles"
2970052|NCT02763371|Experimental|Dietary: high GI lunch|High GI-rice lunch ad libitum on test day 1 and low GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
2970053|NCT02763371|Experimental|Dietary: low GI lunch|Low GI-rice lunch ad libitum on test day 1 and high GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
2970054|NCT02763358|Other|Bites and Steps displayed|All subjects will be assigned to one arm-daily bites and steps displayed on Bite Counter device
2970055|NCT02763345|Active Comparator|Paper-based CCM (Standard Care)|Children are assessed and treated according to the WHO and UNICEFs paper-based Community Case Management decision aid for Malawi for a minimum of 2 and a maximum of 7-weeks. Clinical assessment is guided by the paper-based 'Sick Child Form' presented in English, and clinical data is recorded by Health Surveillance Assistants manually in the Village Clinic Register.
2970056|NCT02763345|Experimental|SL eCCM App + paper CCM|Health Surveillance Assistants use the Supporting LIFE electronic Community Case Management App (SL eCCM App) deployed on a smartphone and replicating paper-based CCM guidelines to assess and treat children in conjunction with standard care, for a minimum of 2-weeks and maximum of 7-weeks. Clinical data is recorded in both the SL eCCM App and Village Clinic Register.
2970057|NCT02763332|Experimental|Upper trunk group (UTG)|In the UTG, the bandage was applied over the superior fibbers of the trapezious and levator scapulae muscle using a strip in a 'Y' shape. The individuals were asked to remain in an upright sitting position and the base of the strip was attached to the skin beyond the acromion without any tension. Later, we placed the two straps of the bandage with a range of tension from 15 to 25%. The main goal of this shape is achieve muscular relaxation of the trapezius, scapula levator and supraspinatus.
2970058|NCT02763332|Active Comparator|Global trunk group (GTG)|In the GTG the bandage was applied parallel to the paravertebral muscles in a 'C' shape. The individuals were sit in the same position with the head in the neutral position. The strip was pasted with approximately 25% of tension all over the paravertebral musculature. The main goal was procuring a global mechanical correction of the superior part of the trunk.
2970059|NCT02763319|Experimental|MOR208 and bendamustine|MOR208 and bendamustine
2970060|NCT02763319|Active Comparator|Rituximab and bendamustine|Rituximab and bendamustine
2970061|NCT02763306|Experimental|Treatment with cryotherapy|Treatment with dermal cooling system.
2970062|NCT02763293|Experimental|Manual Therapy|Cranial therapy (CT). Neuro-lymphatic reflexes treatment (NL) Viscerosomatic reflexes (VR) Induction myofascial Visceral osteopathic therapy (VOT)
2970063|NCT02763293|No Intervention|Control Group|Patients only came to make assessments, without receiving any treatment.
2970064|NCT02763280|Experimental|Ginseng extract 1g|Ginseng extract 1g
2970065|NCT02763280|Experimental|Ginseng extract 3g|Ginseng extract 3g
2970066|NCT02763280|Placebo Comparator|Placebo|Placebo
2970067|NCT02763267||Pregnant Women|Pregnant women with history of GDM or at risk for diabetes mellitus will enter study during first trimester (4-14 weeks) and receive an oral glucose tolerance test (OGTT) at baseline, mid-pregnancy, and at delivery.
2970068|NCT02763267||Nonpregnant Women|Nonpregnant women with a history of GDM will undergo an OGTT at baseline.
2970069|NCT02763254|Experimental|CMD-003|Treatment consist of up to 5 doses of 2x10E7 cells/m2 administered intravenously every 2 weeks.
2970070|NCT02763241|Experimental|Cleanoze®|"Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.~The patient will be instructed to use this isotonic solution for nasal irrigation daily."
2970071|NCT02763241|Active Comparator|Syringe irrigation|"Nasal irrigation using sterile 0.9% NaCl 250 ml by 20 ml syringe~The patient will be instructed to use this isotonic solution for nasal irrigation daily."
2970072|NCT02763228|Experimental|Group 1: Exercise Program|"The exercise in this study will consist of two types of exercise training: resistance training and aerobic exercise. Resistance training is like weight lifting to improve strength and function. Participants will complete resistance training by using resistance machines and free weights. Aerobic exercise is exercise that intends to improve the cardiopulmonary or oxygen/lung and heart systems. It is often referred to as cardio exercise. Treadmill walking, stationary cycling sessions, and/or other exercises will be used for aerobic exercise.~Participants will be instructed in the exercise routine by physical fitness experts and trainers."
2970073|NCT02763228|Active Comparator|Group 2: Support Group|"First 20 Weeks: Participants will take part in a structured Health Education and Support Group sessions once a week.~Last 32 weeks: Participants will be encouraged to take part in any of the Support Group sessions offered regularly on their own schedule."
2970113|NCT02762994|Experimental|BCD-085, 120 mg|Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
2970364|NCT02761525|Placebo Comparator|placebo|topic innocuous gel
2970074|NCT02763202|No Intervention|Usual Care Group|Participants assigned to the usual care group will continue have the current standard of care including any discharge services for example those usually arranged by case managers, hospitalists, and primary care physicians.
2970075|NCT02763202|Experimental|CHS-TS Group|Participants assigned to the Carolinas Healthcare Services Transition Services (CHS-TS) group will be introduced to a patient navigator prior to discharge from the hospital and if interested enter the CHS-TS pathway that includes the following key services: integrated access to medical, pharmacist, and specialty providers; access to CHS disease specific management programs; dedicated care management services delivered in home and at the clinic; lab and infusion services; palliative care consultations when appropriate; and paramedicine for 24 hour support.
2970076|NCT02763189|Active Comparator|Control|Control group will study the learning material independently. 'Self-study'.
2970077|NCT02763189|Experimental|Mentored|Mentored group will study the learning materials and then receive expert mentoring
2970078|NCT02763163||outdoor workers|Subjects with an excessive exposure to the sun on a daily basis
2970079|NCT02763163||office workers|Subjects who spend most of the day in a closed shaded room
2970080|NCT02763150|Experimental|Lifestyle Intervention|Intervention group will receive a comprehensive, multicomponent weight loss intervention targeting diet, physical activity, and behavioral strategies.
2970081|NCT02763150|Active Comparator|Health Promotion|Health promotion group will receive education on healthy eating and activity before pregnancy.
2970082|NCT02763137|Active Comparator|Standard LD/CD|Standard LD/CD administered at patient's usual dose and frequency
2970083|NCT02763137|Experimental|Semi continuous intra-oral administration of LD/CD|Semi continuous intra-oral administration of LD/CD at a dose equivalent to the patient's regular dose of standard LD/CD
2970084|NCT02763124|Experimental|Verion-LenSx|The Verion-LenSx femtosecond laser system will be used to perform one or two corneal arcuate incisions.
2970085|NCT02763111|Experimental|BCD-085, 40 mg|Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
2970086|NCT02763111|Experimental|BCD-085, 80 mg|Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
2970087|NCT02763111|Experimental|BCD-085, 120 mg|Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
2970088|NCT02763111|Placebo Comparator|Placebo|Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
2970089|NCT02763098|Experimental|Remi 0.1|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses [(0.1), 0.2, 0.3 µg/kg/min] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-Roi, France) for two minutes.
2970090|NCT02763098|Experimental|Remi 0.2|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses [0.1, (0.2), 0.3 µg/kg/min] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-RoiFrance) for two minutes.
2970091|NCT02763098|Experimental|Remi 0.3|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses [0.1, 0.2, (0.3) µg/kg/min] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-Roi, France) for two minutes.
2970092|NCT02763085|Experimental|Basic Filling Material|Fillings made with a new dental filling material.
2970093|NCT02763072|Experimental|Picosecond Q-switched Laser|12 subjects will receive one treatment with a dual wavelength 532 nm KTP and/or 1064 nm Nd: YAG picosecond pulse duration laser.
2970094|NCT02763072|Active Comparator|KTP Laser|12 subjects will receive up to four treatments with a dual wavelength 532nm KTP long pulsed laser and/or 1064 nm Nd: YAG.
2970095|NCT02763059|Active Comparator|Group 1- Received Ibuprofen (N=44)|
2970096|NCT02763059|Active Comparator|Group 2- Received Dexamethasone (N=44)|
2970097|NCT02763059|Placebo Comparator|Group 3 - Received Placebo (N=44)|
2970098|NCT02763046|Experimental|AIN457/Secukinumab - delayed tapering|Secukinumab 150 mg s.c. from week 0 with NSAID tapering allowed from week 4 (delayed tapering)
2970099|NCT02763046|Experimental|AIN457/Secukinumab - early tapering|Secukinumab 150 mg s.c. from week 4 with NSAID tapering allowed from week 4 (early tapering)
2970100|NCT02763046|Placebo Comparator|AIN457/Secukinumab Placebo|Secukinumab Placebo s.c.
2970101|NCT02763033|Experimental|Bob's Red Mill®|"Patients will follow the standard BMT (bone marrow transplant) diet and add potato-starch produced by Bob's Red Mill® beginning on day -7 and continuing through day +100.Patients will consume 20 g of Bob's Red Mill®, Potato-based dietary starch, orally twice daily.~Initially, subjects will take 20g daily for first three days prior to increasing dose to 20 g BID."
2970102|NCT02763033|Placebo Comparator|Starch Placebo|Patients will receive an iso-caloric, non-resistant starch placebo.
2970103|NCT02763020|Placebo Comparator|Food bar without fruit|snack bar without fruit
2970104|NCT02763020|Experimental|Food bar with cranberry extract (0.5%)|Snack bar with cranberry extract (0.5% total weight)
2970105|NCT02763020|Experimental|Food bar with cranberry extract (1.0%)|Snack bar with cranberry extract (1.0% total weight)
2970106|NCT02763020|Experimental|Food bar w/ dried black raspberry (10%)|Snack bar with freeze-dried black raspberry(10% total weight)
2970107|NCT02763020|Experimental|Food bar w/ dried black raspberry (20%)|Snack bar with freeze-dried black raspberry (20% total weight)
2970108|NCT02763007|Experimental|alogliptin+pioglitazone|A group who treat with alogliptin+pioglitazone: The Combination of Alogliptin 25 mg and pioglitazone 30 mg daily add on metformin for 28 week as extension and followed by 2 years of observation
2970109|NCT02763007|Active Comparator|alogliptin|A group who treat with alogliptin: Alogliptin 25 mg daily add on metformin for for 28 week as extension and followed by 2 years of observation
2970110|NCT02763007|Active Comparator|pioglitazone|A group who treat with pioglitazone: Pioglitazone 30 mg daily add on metformin for for 28 week as extension and followed by 2 years of observation
2970111|NCT02762994|Experimental|BCD-085, 40 mg|Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
2970112|NCT02762994|Experimental|BCD-085, 80 mg|Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
2970114|NCT02762994|Placebo Comparator|Placebo|Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
2970115|NCT02762981|Experimental|CORT125134 with nab-paclitaxel|"Part I - Dose Escalation:~Patients will be treated with CORT125134 in combination with nab-paclitaxel at escalating dose levels in either a Continuous-Dosing Regimen or an Intermittent-Dosing Regimen.~Part 2 - Dose Expansion:~Expansion cohorts in the Continuous-Dosing and Intermittent-Dosing Regimens will be enrolled to better characterize the antitumor activity in patients with specific tumor types and to better define the safety profile."
2970116|NCT02762968|Placebo Comparator|Placebo|Placebo capsules similar to the experimental treatments.
2970117|NCT02762968|Experimental|HMB|HMB capsules providing 3 g of calcium HMB per day.
2970118|NCT02762968|Experimental|HMB + BC30|Capsules providing 3 g calcium HMB per day plus Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
2970119|NCT02762955|Experimental|BCD-057 group|"BCD-057 group includes patients with moderate to severe plaque psoriasis, who will receive BCD-057 subcutaneously at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23. Patients will be invited for randomization at week 24 (in order to keep the double-blind design of the study), but it will have a formal character (assignment of a new randomization number and lot). From week 25 patients of this group will continue to receive BCD-057 at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.~BCD-057 is adalimumab biosimilar, monoclonal antibody to tumor necrosis factor alfa."
2970120|NCT02762955|Active Comparator|Humira® group|"Humira® group includes patients with moderate to severe plaque psoriasis, who will receive Humira® subcutaneously at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23. At week 24 participants will re-randomized (1:1) to treatment with Humira® or will transitioned to BCD-057. Patients will receive BCD-057 or Humira® at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.~BCD-057 is adalimumab biosimilar, monoclonal antibody to tumor necrosis factor alfa.~Humira® is original drug of adalimumab, monoclonal antibody to tumor necrosis factor alfa."
2970121|NCT02762942|Active Comparator|Vaginal misoprostol alone|Women in this group will receive 25mcg of vaginal misoprostol every 4 hours up to a maximum of 5 doses. Misoprostol will be stopped in case of a favorable cervix or if the patient is in active labor. In case of no progression after 5 doses of misoprostol, intravenous oxytocin will be perfused 4 hours after the last dose of misoprostol according to local protocols
2970122|NCT02762942|Experimental|Vaginal misoprostol + Foley catheter|Women in this group will receive 25mcg of vaginal misoprostol every 4 hours up to a maximum of 5 doses. At the same time a 16French Foley catheter will be inserted through the internal os with visualization of the cervix by sterile speculum examination. The catheter balloon will be inflated with 30 ml of sterile normal saline solution and then the catheter will be taped with gentle traction to the inner thigh of the patient until spontaneous expulsion. If this does not occur, the catheter will be deflated and removed after 12 hours. Misoprostol will be stopped in case of a favorable cervix or if the patient is in active labor. In case of no progression after 5 doses of misoprostol, intravenous oxytocin will be perfused 4 hours after the last dose of misoprostol.
2970123|NCT02762929|Experimental|Part A Cohort A|200 mg of HTX-011A via closed wound infiltration
2970124|NCT02762929|Experimental|Part A Cohort B|200 mg of HTX 011A via open wound infiltration
2970125|NCT02762929|Experimental|Part A Cohort C|200 mg of HTX-011B via closed wound infiltration
2970126|NCT02762929|Experimental|Part A Cohort D|200 mg of HTX 011B via open wound infiltration
2970127|NCT02762929|Active Comparator|Part A Cohort E|50 mg 0.5% bupivacaine hydrochloride injection via a closed wound infiltration
2970128|NCT02762929|Placebo Comparator|Part A Cohort F|Saline Placebo via a closed wound infiltration
2970129|NCT02762929|Experimental|Part B Cohort A|200 mg HTX 002 via closed wound infiltration
2970130|NCT02762929|Experimental|Part B Cohort B|200 mg HTX 002 via open wound infiltration
2970131|NCT02762929|Placebo Comparator|Part B Cohort C|Saline placebo via a closed and open wound infiltration
2970132|NCT02762929|Experimental|Part C Cohort A|120 mg of HTX-011B via closed wound infiltration
2970133|NCT02762929|Experimental|Part C Cohort B|120 mg of HTX-011B via open wound infiltration
2970134|NCT02762929|Experimental|Part C Cohort C|120 mg of HTX-011B local administration via instillation
2970135|NCT02762929|Placebo Comparator|Part C Cohort D|Saline placebo via open wound infiltration
2970136|NCT02762929|Experimental|Part D Cohort A|60 mg of HTX-011B via closed wound infiltration
2970137|NCT02762929|Experimental|Part D Cohort B|60 mg of HTX-011B via open wound infiltration.
2970138|NCT02762929|Placebo Comparator|Part D Cohort C|Saline placebo via open wound infiltration
2970139|NCT02762929|Experimental|Part E Cohort A|120 mg HTX 002 via closed wound infiltration
2970140|NCT02762929|Experimental|Part E Cohort B|120mg HTX 002 via open wound infiltration
2970141|NCT02762929|Placebo Comparator|Part E Cohort C|Saline placebo via closed and open wound infiltration
2970142|NCT02762929|Experimental|Part F Cohort A|HTX 009 via closed wound infiltration
2970143|NCT02762929|Experimental|Part F Cohort B|HTX 009 via open wound infiltration
2970144|NCT02762929|Placebo Comparator|Part F Cohort C|Saline placebo via closed and open wound infiltration
2970145|NCT02762929|Experimental|Part G Cohort A|30 mg of HTX 011B via closed wound infiltration
2970146|NCT02762929|Placebo Comparator|Part G Cohort B|Saline placebo via closed wound infiltration
2970147|NCT02762929|Experimental|Part H Cohort A|120 mg of HTX-011-056
2970148|NCT02762929|Experimental|Part H Cohort B|60 mg of HTX-011-056
2970149|NCT02762929|Placebo Comparator|Part H Cohort C|4.1 mL of normal saline
2970150|NCT02762916|Experimental|1- Telemedicine arm|"The intervention arm (IA), telehealth control, were followed up by himself helped by CONTECI program. They have to use every three months and if somethings was wrong the patient have to send mail to the doctor.~The intervention consisted to use the CONTECI program (included test) for the following of the patients."
2970151|NCT02762916|No Intervention|2- Control arm|The Control Arm (CA) were followed up as usual every 6 months in outpatient vascular visits in the clinical hospital. If some patient have a complications or and emergency they have to do usual protocol, go to primary care or emergency.
2970152|NCT02762903|Active Comparator|Tenotomy|Subjects will receive shoulder prosthesis for subscapularis repair during TSA with tenotomy technique.
2970153|NCT02762903|Active Comparator|Osteotomy|Subjects will receive shoulder prosthesis for subscapularis repair during TSA with lesser tuberosity osteotomy technique.
2970154|NCT02762890|Experimental|Deep neuromuscular blockade|Rocuronium will be administered continuously to achieve post-tetanic count 1-2 during surgery.
2970155|NCT02762890|Active Comparator|Moderate neuromuscular blockade|Rocuronium will be administered continuously to achieve Train-of-four 1-2 during surgery.
2970156|NCT02762864|Experimental|PRU-guided|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patients with PRU <234 seconds and followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period. For patients in the PRU-target group with PRU ≥234 seconds, rescue medicine (ticagrelor) will be added to keep PRU<234 seconds.
2970157|NCT02762864|Active Comparator|non PRU-guided|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patients with PRU <234 seconds and followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period, regardless the levels of PRU.
2970158|NCT02762851|Experimental|Influenza vaccine|Participants at high risk for adverse vascular events will be immunized with 0.5 ml dose of inactivated trivalent influenza vaccine prior to the influenza season.
2970159|NCT02762851|Placebo Comparator|Placebo vaccine|Participants at high risk for adverse vascular events will be vaccinated with a 0.5 ml dose of sterile saline prior to the influenza season.
2970160|NCT02762838|Experimental|BCD-055|Patients in this group will receive BCD-055 in a dose of 3 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, Week 54.
2970161|NCT02762838|Active Comparator|Remicade®|Patients in this group will receive Remicade® in a dose of 3 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, Week 54.
2970162|NCT02762825|Experimental|Higher Intensity Interval Training (HIIT)|
2970163|NCT02762825|Active Comparator|Moderate Continuous Training (MCT)|
2970164|NCT02762812|Experimental|BCD-055|Patients in this group will receive BCD-055 in a dose of 5 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Wekk 38, Week 46, Week 54.
2970165|NCT02762812|Active Comparator|Remicade®|Patients in this group will receive Remicade® in a dose of 5 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Wekk 38, Week 46, Week 54.
2970166|NCT02762799|Experimental|Leucostim® --> Neupogen®, subcutaneous injections|Healthy volunteers in this group will receive single subcutaneous injection Leucostim® on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
2970167|NCT02762799|Experimental|Neupogen® --> Leucostim®, subcutaneous injections|Healthy volunteers in this group will receive single subcutaneous injection Neupogen®, on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
2970168|NCT02762799|Experimental|Leucostim® --> Neupogen®, intravenous injections|Healthy volunteers in this group will receive single intravenous injection Leucostim® on Day 1 followed by single intravenous injection Leucostim® on Day 29.
2970169|NCT02762799|Experimental|Neupogen® --> Leucostim®, intravenous injections|Healthy volunteers in this group will receive single intravenous injection Neupogen® on Day 1 followed by single subcutaneous intravenous Leucostim® on Day 29.
2970170|NCT02762786|Experimental|Experimental|Participants in the experimental group will receive weekly one-hour lessons on musical training for 12 weeks, conducted by the Music Children Foundation. The Music Children Foundation is a non-governmental organization established by a group of professional musicians with the objective of transforming children's lives and instils positive values in the entire community through music. It aims to provide free musical training to low-income children and children with chronic diseases, including those with Down's syndrome, mucopolysaccharidoses, skeletal dysplasia and visual impairment.
2970171|NCT02762786|No Intervention|Wait-list control group|Participants in the waitlist control group will receive the same training after the experimental group had completed the intervention.
2970172|NCT02762773|Experimental|Experimental|Patients will undergo non-dissection of the inferior rectus sheath at time of primary cesarean delivery
2970173|NCT02762773|Placebo Comparator|Control|Patients will undergo standard practice which is dissection of the superior and inferior rectus sheath at time of cesarean delivery
2970174|NCT02762760|Experimental|AMPION™|AMPION™, up to 3 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
2970175|NCT02762760|Experimental|Saline|Saline placebo, up to 3 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride
2970176|NCT02762747|Experimental|Drain|preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
2970177|NCT02762747|No Intervention|No-drain|No drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
2970178|NCT02762734|Experimental|MEDIA|"The patient will benefit of the usual care with additional text message (SMS or mail or other new media). The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt."
2970179|NCT02762734|No Intervention|CLASSIC|The patient will benefit of the usual care.
2970180|NCT02762708|Active Comparator|Roux-en-Y Gastric Bypass (RYGB)|Subjects between the ages of 20-65 years of age seen for weight management in the Nutrition Clinic at Mayo Clinic, who have been approved for RYGB.
2970181|NCT02762708|Sham Comparator|Caloric restriction|Subjects between the ages of 20-65 years of age, with diagnosis of Type 2 diabetes mellitus or impaired fasting glucose. Subjects will undergo caloric restriction alone to mimic weight loss seen after gastric bypass surgery.
2970182|NCT02762708|Active Comparator|Exendin-9,39|Four subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of Exendin-9,39 or normal saline.
2970183|NCT02762708|Placebo Comparator|Normal Saline|Four subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of Exendin-9,39 or normal saline.
2970184|NCT02762695|Experimental|Case Management|
2970185|NCT02762695|Active Comparator|Control|Usual Care at Primary Health Care
2970218|NCT02762435|Placebo Comparator|control|No pressure applied to the 3 points
2970219|NCT02762435|Sham Comparator|sham|Light touch applied to the 3 points (2 minutes each at PC6, LI4, and HT7, three times per day for 2 days)
2970186|NCT02762682||CASES OF ITS AND PRE ITS|"Either sex, age less than 3 years~Clinical diagnosis of Infantile Tremor Syndrome as evidenced by the following features:~[Developmental delay or regression WITH history of exclusive or predominant breast feeding WITH two or more of the following; skin pigmentation, hair depigmentation, tremors] ITS:1 and 2 plus tremors PreITS:1 and 2 without tremors"
2970187|NCT02762682||HEALTHY CONTROLS|Developmentally normal child not suffering from any acute or chronic neurological illness
2970188|NCT02762669|No Intervention|Control (no oxytocin) + No recovery|A control experiment will be undertaken in which the myometrial explants will be exposed to PSS for 2-hours without any oxytocin. No recovery time.
2970189|NCT02762669|Active Comparator|Continuous oxytocin + No recovery|10-5M oxytocin for 2 hours. No recovery time.
2970190|NCT02762669|Active Comparator|Continuous oxytocin + 30 minute recovery|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 30 minutes.
2970191|NCT02762669|Active Comparator|Continuous oxytocin + 60 minute recovery|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 60 minutes.
2970192|NCT02762669|Active Comparator|Control (no oxytocin) + No recovery + 10-7 oxytocin|A second control experiment will be undertaken in which the myometrial explants will be exposed to PSS for 2-hours without any oxytocin. After 2 hours, the solution will be drained from the organ baths, and replaced with fresh PSS. Following this, the strip will be exposed to 10-7 oxytocin for 10 minutes.
2970193|NCT02762669|Active Comparator|Continuous oxytocin + No recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to 10-7 oxytocin for 10 minutes.
2970194|NCT02762669|Active Comparator|Continuous oxytocin + 30 minute recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 30 minutes. The strip will then be exposed to 10-7 oxytocin for 10 minutes.
2970195|NCT02762669|Active Comparator|Continuous oxytocin + 60 minute recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 60 minutes. The strip will then be exposed to 10-7 oxytocin for 10 minutes.
2970196|NCT02762656|Active Comparator|Lidocaine|Patients will receive Lidocaine drip during spine surgery
2970197|NCT02762656|Placebo Comparator|Placebo|Patients will receive placebo during spine surgery
2970198|NCT02762643|Experimental|RT group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
2970199|NCT02762643|Experimental|TR group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
2970200|NCT02762617|Experimental|TDF IVR group|"The Tenofovir Disoproxil Fumarate intravaginal ring (TDF-IVR) is a white (with clear segment), flexible torus-shaped device with an inner core which contains the experimental drug, TDF, and sodium chloride. The intravaginal ring is worn continuously for 28 days and replaced with new rings twice (every 28 days) for total of 84 days (3 months).~Participants will be stratified by site and will be randomized in a 3:1 ratio (TDF:Placebo)."
2970201|NCT02762617|Placebo Comparator|Placebo IVR group|"The placebo intravaginal ring (IVR) is a clear, flexible torus-shaped device with an inner core which contains sodium chloride. The intravaginal ring is worn continuously for 28 days and replaced with new rings twice (every 28 days) for total of 84 days (3 months).~Participants will be stratified by site and will be randomized in a 3:1 ratio (TDF:Placebo)."
2970202|NCT02762604|Experimental|Imagined Gait Intervention|During the phone-based imagined gait intervention, participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
2970203|NCT02762604|Active Comparator|Visual Imagery Intervention|During the phone-based visual imagery intervention, participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
2970204|NCT02762578|Experimental|IDegAsp BID|
2970205|NCT02762578|Active Comparator|BIAsp 30 BID|
2970206|NCT02762552|Experimental|Transcranial-holter monitoring|Transcranial doppler in patient with ischemic stroke
2970207|NCT02762539|No Intervention|Control group|Control group in which patients will follow our local protocol for TBI management without SMOF-lipid infusion
2970208|NCT02762539|Experimental|SMOF group|SMOF-lipid group in which patients will receive 0.5 g/Kg SMOF lipid 10% emulsion (Lipid emulsion for intravenous nutrition containing; 6% soybean oil / 6% medium chain triglycerides / 5% olive oil / 3%fish oil) daily over 12 hours starting once admitted to ICU for 7 days.
2970209|NCT02762513|Experimental|Axitinib|Participants will receive 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities
2970210|NCT02762500|Experimental|LYC-30937-EC 25 mg PO QD|LYC-30937-EC 25 mg by mouth once daily for 8 weeks
2970211|NCT02762500|Placebo Comparator|Placebo PO QD|Matching placebo by mouth once daily for 8 weeks
2970212|NCT02762487|Experimental|LINX arm|Previous LSG patient will be treated with the LINX device and serve as their own control
2970213|NCT02762474|Experimental|nab-paclitaxel group|Weekly Regimens of paclitaxel Plus Cispaltin Combined With Concurrent IMRT
2970214|NCT02762461||Exposed group|Women with peritoneal/ovarian endometriosis and DIE (rectovaginal and rectosigmoid endometriosis) undergoing ART (IVF or ICSI).
2970215|NCT02762461||Reference group 1|Women with infertility because of factors other than endometriosis, e.g. male factor, undergoing ART (IVF or ICSI).
2970216|NCT02762461||Reference group 2|Women with medically treated endometriosis not undergoing ART.
2970217|NCT02762448||Daclatasvir + Asunaprevir|Prospectively collect cases with NHL (n=10), having HCV genotype 1b related NHL, who will be treated with ASV (200 mg twice daily) + DCV(60 mg once daily) for 24 weeks .
2970220|NCT02762435|Experimental|acupressure|Moderate pressure applied to the 3 points (2 minutes each at PC6, LI4, and HT7, three times per day for 2 days)
2970221|NCT02762422|Experimental|Phlebotomy plus normal saline|Four serial phlebotomy procedures followed by infusion of normal saline
2970222|NCT02762422|Experimental|Phlebotomy plus intravenous iron|Four serial phlebotomy procedures followed by infusion of intravenous iron sucrose
2970223|NCT02762422|Placebo Comparator|Sham Phlebotomy|Four serial sham phlebotomy procedures followed by infusion of normal saline
2970224|NCT02762409||patients exposed|Patients exposed will be estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015, and in 17 centers of the group control some study IPREA3 during October 2015
2970225|NCT02762409||patients non exposed|"The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015 and in 17 centers of the interventional group during October 2014"
2970226|NCT02762383|Experimental|Peginterferon Alfa-2a|Participants will receive a low dose of peginterferon alfa-2a for 18 months.
2970227|NCT02762370|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release Formulation
2970228|NCT02762370|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-release Formulation
2970229|NCT02762357||Novosyn® Quick|episiotomy closure using suture material
2970230|NCT02762344||ACT < 150 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal below 150 sec
2970231|NCT02762344||ACT between 150 and 249 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal between 150 and 249 sec
2970232|NCT02762344||ACT >= 250 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal above 250 sec
2970233|NCT02762331|Experimental|Vitamin C|Intravenous ascorbic acid 50 mg/kg in 50 mL normal saline every six hours for 48 hours.
2970234|NCT02762331|Placebo Comparator|Normal saline|Intravenous normal saline 50 mL every six hours for 48 hours
2970235|NCT02762305|Experimental|RSVP Bone Builder group exercise|A group of older adults who are participating in the RSVP Bone Builder group exercise.
2970236|NCT02762292|Experimental|Patients|
2970237|NCT02762279|Experimental|Patients|"Patient baseline characteristics will be collected.~Specific nasogastric tube installation: a specific nasogastric tube equipped with pressure transducers (Gaeltec® probe) will be installed.~Connection of a pressure transducer to the existing chest-tube.~Simultaneous recordings of PES (Gaeltec®), PPL, PAW, respiratory volume and flow (5 minutes).~Removal of the Gaeltec® probe, and repositioning of the pre-existing nasogastric tube in the esophagus for PES measurement.~Simultaneous recordings of PES (feeding tube), PPL, PAW, respiratory volume and flow (5 minutes).~Repositioning of the nasogastric tube in the stomach, and disconnection of the different recording equipment."
2970238|NCT02762266|Active Comparator|Arm I (TACE)|Patients undergo TACE.
2970239|NCT02762266|Experimental|Arm II (SBRT)|Beginning within 2 weeks of the radiation set-up scan and within 4 weeks of fiducial seed implantation (if applicable), patients undergo image guided SBRT 3 fractions within 1 week or 5 fractions within 2 weeks.
2970240|NCT02762253|Other|Riboflavin drops - epithelium on or off|Riboflavin is applied with Epithelium on or with it off. 6 months follow up to find out magnitude of Decrease in Kmax
2970241|NCT02762240|Active Comparator|DHQP 2016|This group consists of general practices allocated to undergo accreditation scheme in 2016.
2970242|NCT02762240|Placebo Comparator|DHQP 2018|This group consists of general practices allocated to undergo accreditation scheme in 2018.
2970243|NCT02762227|Experimental|gallbladder polyps patients|"All patients with a gallbladder polypoid lesion visited our department, diagnosed by conventional transabdominal US, were enrolled in this study.~Of these patients, we excluded: (1) gallbladder polyp with a diameter less than 10 mm. (2) lesions highly suspected to be cancer due to visible metastasis. (3) allergy to contrast agents and cannot received CT or CEUS examination. (4) women in pregnancy or lactation.~All patients received transabdominal US, abdominal high resolution CT and contrast-enhanced ultrasonography (CEUS) before the cholecystectomy."
2970244|NCT02762214|Active Comparator|With Uterine Manipulator|77 Patients affected by early stage endometrial cancer submitted to elective laparoscopic/robotic hysterectomy for endometrial cancer using uterine manipulator.
2970245|NCT02762214|Experimental|Without Uterine Manipulator|77 Patients affected by early stage endometrial cancer submitted to elective laparoscopic/robotic hysterectomy for endometrial cancer without support of uterine manipulator.
2970246|NCT02762201|Experimental|PASI|PASI dental prosthesis delivery
2970247|NCT02762201|Active Comparator|PAC|PAC dental prosthesis delivery
2970248|NCT02762188|Experimental|wet ARMD patients|Patients with the wet form of ARMD who receive or have received in the past anti VEGF intra vitreal injections. Diagnosis of wet ARMD is made based on clinical data-visual acuity, fundus presence of subretinal fluid and/or haemorrhage and/or hard exudates, fundus photographs -color and red free, optical coherence tomography (SD-OCT), fluorescein angiography and indocyanine green angiography showing the presence and activity of subretinal neovascularisation.
2970249|NCT02762149|Active Comparator|0.1ms pulse width|The nerve stimulator will be connected to the epidural catheter through an adapter, which will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle. All patients will have the trans-catheter electric stimulation test (TCEST) performed with both a 1 ms pulse width and 0.1 ms pulse width and the order of administration will be randomized.
2970250|NCT02762149|Active Comparator|1ms pulse width|The nerve stimulator will be connected to the epidural catheter through an adapter, which will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle. All patients will have the trans-catheter electric stimulation test (TCEST) performed with both a 1 ms pulse width and 0.1 ms pulse width and the order of administration will be randomized.
2970251|NCT02762136|Placebo Comparator|placebo|Participants will orally take the placebo granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.
2970252|NCT02762136|Active Comparator|Xiang-sha-liu-jun granules|Participants will orally take the herbal formula granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.
2970253|NCT02762123|Experimental|Cohort 1 (BMS-986142: 200 mg)|200mg BMS-986142 administered orally once daily on specified days.
2970254|NCT02762123|Experimental|Cohort 2 (BMS-986142: 350 mg)|350mg BMS-986142 administered orally once daily on specified days.
2970255|NCT02762097|Experimental|intervention|All women would undergo saline sonography with normal saline. Women with endometrial polyps who consent to the removal of polyps will be offered polypectomy
2970256|NCT02762097|Placebo Comparator|control|All women would undergo saline sonography with normal saline. Women with endometrial polyps who do not consent to the removal would serve as controls
2970257|NCT02762084|Experimental|patidegib gel 2%,|patidegib gel 2%, applied topically, twice daily for 26 weeks
2970258|NCT02762084|Experimental|patidegib gel 4%,|patidegib gel 4%, applied topically, twice daily for 26 weeks
2970259|NCT02762084|Placebo Comparator|vehicle gel|vehicle gel, applied topically, twice daily for 26 weeks
2970260|NCT02762071|Active Comparator|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
2970261|NCT02762071|Experimental|Liposomal Bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
2970262|NCT02762058|Experimental|Experimental Group|Patients receiving Virtual Reality Mirror Therapy
2970263|NCT02762058|Experimental|Control Group|Patients receiving Traditional Mirror Therapy
2970264|NCT02762045|Experimental|Low dose Ad5-gag or Placebo|1ml low dose Ad5-gag(2x10^9VP) or Preservation solution at weeks 0 and weeks 4.
2970265|NCT02762045|Experimental|Medium dose Ad5-gag or Placebo|1ml medium dose Ad5-gag(2x10^10VP) or Preservation solution at weeks 0 and weeks 4.
2970266|NCT02762045|Experimental|High dose Ad5-gag or Placebo|1ml high dose Ad5-gag(2x10^11VP) or Preservation solution at weeks 0 and weeks 4.
2970267|NCT02762032|Active Comparator|Arm 1|15 subjects will be randomized to receive PrimaVie Herbal Supplement 125 mg to take twice daily for 14 weeks.
2970268|NCT02762032|Active Comparator|Arm 2|15 subjects will be randomized to receive PrimaVie Herbal Supplement 250 mg to take twice daily for 14 weeks.
2970269|NCT02762032|Placebo Comparator|Arm 3|15 subjects will be randomized to receive placebo (control supplement) to take twice daily for 14 weeks.
2970270|NCT02762019|Experimental|Laser therapy|Children are allocated to receive Laser therapy
2970271|NCT02762019|Sham Comparator|Sham therapy|Children are allocated to receive Sham therapy
2970272|NCT02762006|Experimental|Durvalumab + Tremelimumab with Nephrectomy|"Following systemic therapy, patients will undergo nephrectomy. Adjuvant therapy will be administered within 4-6 weeks of surgery. Subsequent follow-up will then be completed to assess adverse event resolution and long-term outcomes.~Cohort 1: Durvalumab x 1 dose (n=6)~Cohort 2: Durvalumab + Tremelimumab (25 mg) x 1 dose (n=6)~Cohort 3: Durvalumab + Tremelimumab (75 mg) x 1 dose (n=6)~Cohort 4: Durvalumab + Tremelimumab x 2 doses (n=6)~Cohort 5: Randomized Durvalumab x 2 doses vs. Durvalumab + Tremelimumab x 2 doses (n=15 each)"
2970273|NCT02761993|Active Comparator|Group 1|Group 1: 1XST266 dosed as per regimen 1.
2970274|NCT02761993|Active Comparator|Group 2|Group 2: 1XST266 as per regimen 2.
2970275|NCT02761993|Placebo Comparator|Group 3|Group 3: Placebo dosed as per regimen 1.
2970276|NCT02761980|Experimental|Ibuprofen 250 mg / Acetaminophen 500 mg|Single dose of 2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg by mouth
2970277|NCT02761980|Active Comparator|Ibuprofen 250 mg|Single dose of 2 caplets of IBU 125 mg by mouth
2970278|NCT02761980|Active Comparator|Acetaminophen 500 mg|Single dose of 1 APAP 500 mg caplet + 1 placebo caplet by mouth
2970279|NCT02761980|Placebo Comparator|Placebo|Single dose of 2 caplets of Placebo by mouth
2970280|NCT02761967|Experimental|Physical activity|"The woman he joins the intervention group meets once a week 20 of gestation and ends after serving 37 semanas. La intervention will consist of physical exercise of moderate character in water, according to the methodology of the method of SWEP, for an hour a day, three days a semana.~After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes."
2970281|NCT02761967|No Intervention|No exercise|"Not take place during the gestation period between gestation week 20 to 37 any physical exercise.~Not take place during the postpartum period any physical exercise."
2970282|NCT02761928||Epidural|Positive response (>50% pain relief) to any epidural (e.g. interlaminar/paramedian, transforaminal, caudal)
2970283|NCT02761928||Selective nerve root block|Positive response (>50% pain relief) to selective nerve root block
2970284|NCT02761928||Facet injection|Positive response (>50% pain relief) to intra-articular facet injection
2970285|NCT02761928||Medial branch block|Positive response (>50% pain relief) to median branch nerve block
2970286|NCT02761928||Medial branch RFA|Positive response (>50% pain relief) to median branch nerve radiofrequency ablation
2970287|NCT02761928||SIJ injection|Positive response (>50% pain relief) to sacroiliac joint injection
2970288|NCT02761928||Lateral branch block|Positive response (>50% pain relief) to lateral branch nerve block for SIJ
2970289|NCT02761928||Greater trochanter injection|Positive response (>50% pain relief) to greater trochanteric bursa injection
2970290|NCT02761928||Piriformis injection|Positive response (>50% pain relief) to piriformis injection
2970292|NCT02761915|Other|Dose Level 1|Patients in Dose Level1 will receive 1x10^7 1RG-CART/m^2 on Day 0 (intravenously).
2970293|NCT02761915|Other|Dose Level 2|Patients in Dose Level 2 will receive 300mg/m^2/day of cyclophosphamide for four days (Days -4 to -1) followed by 1x10^7 1RG-CART/m^2 on Day 0.
2970294|NCT02761915|Other|Dose Level 3|Patients in Dose Level 3 will receive 300mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10^7 1RG-CART/m^2 on Day 0.
2970295|NCT02761915|Other|Dose Level 4|Patients in Dose Level 4 will receive 300mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10^8 1RG-CART/m^2 on Day 0.
2970296|NCT02761915|Other|Dose level 5|If the required level of 1RG-CART survival is not reached, a further cohort of patients (Dose Level 5) will receive 300mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 5-10x10^8 1RG-CART/m^2 on Day 0 .
2970297|NCT02761902||Preschool group|3-6 years old
2970298|NCT02761902||school age group|7-12 years old
2970299|NCT02761902||Adolescence group|13-15 years old
2970300|NCT02761889|Experimental|IGRT 45 Gy in 5 fractions of 9 Gy|Patients will be treated using volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility. Patients will be treated with 45 Gy in five fractions of 9 Gy over 5 consecutive days.
2970301|NCT02761876|Experimental|Intervention (Participatory education)|Participatory education
2970302|NCT02761876|No Intervention|Control|Delayed participatory education
2970303|NCT02761863||CD74 - VEGF arm|
2970304|NCT02761837|Active Comparator|IVR call/text|Identify gaps in care and contact patients by IVR phone call or text
2970305|NCT02761837|Active Comparator|Email|Identify gaps in care and contact patients by email
2970306|NCT02761824|Experimental|Camp Discovery|One week activity based camp.
2970307|NCT02761811|Experimental|Renal Sympathetic Denervation|Percutaneous renal denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator.
2970308|NCT02761811|Sham Comparator|Masked Procedure|Percutaneous renal artery angiography
2970309|NCT02761798||Automated Mobile Interactive Audiometer, Test Retest|Each participant will act as his/her own control. The iPad audiogram will be compared to the audiogram in sound booth or to a second iPad audiogram.
2970310|NCT02761798||Automated Mobile Interactive Audiometer, Validation.|iPad testing will be compared to conventional audiometry in the sound booth.
2970311|NCT02761798||Automated Mobile Interactive Audiometer, Speech Recognition|Testing with NU-6 word lists will be conducted by the iPad and by an audiologist in the sound booth.
2970312|NCT02761798||Automated Mobile Interactive Audiometer, Cochlear Implant|Participants with cochlear implants will be tested using iPad against conventional audiometry (warble tone) in the sound booth.
2970313|NCT02761785||Celiacs with oat-related symptoms|Celiac patients who have self-reported gastrointestinal symptoms after ingestion of gluten-free oats
2970314|NCT02761785||Celiacs without oat-related symptoms|Celiac patients who include gluten-free oats in their diet and have no symptoms related to oats
2970315|NCT02761785||Healthy controls|Healthy controls (without celiac disease) who include oats in their diet
2970316|NCT02761785||Non-celiac gluten sensitive subjects|Subjects with manifestations precipitated by ingestion of gluten in whom celiac disease and wheat allergy are excluded.
2970317|NCT02761772||PEP-A|See detailed description
2970318|NCT02761772||PEP-S|See detailed description
2970319|NCT02761746|Experimental|Intervention Condition (MESA)|MESA involves two sessions (ACASI assessment and intervention), one at study entry (prior to beginning ART) and one a month later. Then, participants will complete ACASI assessments only at 3, 6, 9, and 12 months. The first MESA session is tailored based on how important and how confident the person feels about taking medications as prescribed. The participant is also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, the participant may engage in goal setting. The second MESA session focuses on adherence behavior over the previous month and the consequences (good or bad) of that behavior.
2970320|NCT02761746|No Intervention|Control Condition (SH)|The SH control condition involves two sessions (ACASI assessment and control condition), one at study entry (prior to beginning ART) and one a month later. Then, participants will complete ACASI assessments only at 3, 6, 9, and 12 months. The first SH session targets healthy eating and physical activity and is matched for dose and length of time of the intervention session. Feedback and education are provided, if desired. Finally, the participants may engage in goal setting for healthy eating and physical activity. The second SH session focuses on the goals set during the first session and behavior over the previous month.
2970321|NCT02761733|Experimental|mPOWR System|Moving Patient Outcomes toward Wellness and Recovery (mPOWR) consists of an assessment questionnaire and decision support tools which map onto 6 life domains which are measured by the questionnaire.
2970322|NCT02761733|No Intervention|Control|Treatment as usual
2970323|NCT02761720||MyPennMedicine (MPM)|Participants assigned to this arm downloaded only the MyPennMedicine mobile app.
2970324|NCT02761720||MPM and Ginger iO|Participants assigned to this arm downloaded both the MyPennMedicine mobile app and Ginger iO mood tracking app.
2970325|NCT02761720||Lottery|Participants assigned to this arm downloaded both the MyPennMedicine mobile app and Ginger iO mood tracking app. They were also given a lottery incentive if they completed 70% of the daily mood ratings.
2970326|NCT02761707||Parkinson's Disease|Non-smokers, ages 18-80, diagnosed with Parkinson's Disease. Must be Hoehn and Yahr stage 2 or less with a history of motor symptoms less than two years.
2970327|NCT02761707||Alzheimer's Disease|Non-smokers, ages 18-80, diagnosed with Alzheimer's Disease. Must meet the 2011 National Institute on Aging-Alzheimer's Association and the 1984 National Institute for Neurological and Communicative Disorders and Stroke-Alzheimer's disease and Related Disorders Association criteria for probable AD.
2970328|NCT02761707||Progressive Supranuclear Palsy|Non-smokers, ages 18-80, diagnosed with Progressive Supranuclear Palsy. Must meet the NINDS-SPSP criteria for probable PSP, which requires vertical supranuclear gaze palsy, prominent postural instability, and falls in the first year of onset, as well as a number of other clinical features.
2970330|NCT02761707||Drug-Induced Parkinson's Disease|Non-smokers, ages 18-80, diagnosed with Drug-Induced Parkinson's Disease.
2970331|NCT02761707||Myasthenia Gravis|Non-smokers, ages 18-80, diagnosed with Myasthenia Gravis.
2970332|NCT02761707||Multiple System Atrophy|Non-smokers, ages 18-80, who have been diagnosed with Multiple System Atrophy.
2970333|NCT02761707||Diffuse Lewy Body Disease|Non-smokers, ages 18-80, diagnosed with Diffuse Lewy Body Disease. Must meet the Consensus Criteria for the clinical diagnosis of DLBD.
2970334|NCT02761707||Healthy Controls|Non-smokers, ages 18-80, with no neurodegenerative disease, and no first-degree relatives with a neurodegenerative disease.
2970335|NCT02761707||Spinal Cord Injury|
2970336|NCT02761707||Asymptomatic Relatives|
2970337|NCT02761694|Experimental|ARQ 751|Subjects will receive ARQ 751 orally at the dose level and administration schedule specified for their respective dose cohort on a 28 day cycle. Subjects will receive treatment with ARQ 751 until unacceptable toxicity, disease progression (clinical or radiological), or another discontinuation criterion is met. It is expected that most subjects will receive between one and six cycles of ARQ 751 for a treatment period of 4 to 24 weeks.
2970338|NCT02761681|Experimental|ACT-CL Web-based guided self-help|Behavioral: Experimental Web-based guided self-help Program This intervention will involve counselor training and student use of the developed program. Counselors will complete training and invite students to participate, and will monitor and guide students in completing the series of 8 web-based sessions based on Acceptance and Commitment Therapy.
2970339|NCT02761681|Active Comparator|Control Web-based guided self-help|Behavioral: Control Web-based guided self-help program This intervention will be created for the current study. It will involve psycho-education on how students might get the most out of counseling. Counselors will go through the psycho-education session before inviting students to participate.
2970340|NCT02761668|Experimental|ParS+Ortho 4W|Orthodontic alignment starts 4 weeks post surgical
2970341|NCT02761668|Active Comparator|ParS+Ortho 6M|Orthodontic alignment starts 6 months post surgical
2970342|NCT02761655|No Intervention|Control Group|Patients in both experimental and control groups will receive educations on cognitive impairment, dementia, community resources, and related medication as well as health promotion for PWCIs. The teaching material will be derived from the online resources such as Alzheimer Disease International and Taiwan Alzheimer's Disease Association (TADA) and reviewed by the expert panel as well. Written information will be given to both groups (patients and FCGs), which will be suitable to general public and address issues of cognitive impairment and FCG involvement.
2970343|NCT02761655|Experimental|Intervention Group|Patients in both experimental and control groups will receive educations on cognitive impairment, dementia, community resources, and related medication as well as health promotion for PWCIs. The teaching material will be derived from the online resources such as Alzheimer Disease International and Taiwan Alzheimer's Disease Association (TADA) and reviewed by the expert panel as well. Written information will be given to both groups (patients and FCGs), which will be suitable to general public and address issues of cognitive impairment and FCG involvement. The intervention group will further receive memory strategies training on encoding and retention, retrieval, as well as execution and monitoring.
2970344|NCT02761642|Experimental|Epoetin Beta|Anemic breast cancer participants will receive epoetin beta treatment for 12 weeks.
2970345|NCT02761629|Experimental|Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks|Participants will receive Peg-IFN-Alpha-2A and ribavirin for 48 weeks.
2970346|NCT02761629|Active Comparator|Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks|Participants will receive Peg-IFN-Alpha-2A and ribavirin for 72 weeks.
2970347|NCT02761616||eBC treated participants|Participants with metastatic disease after previously being treated for eBC were observed for 24 months.
2970348|NCT02761603|Active Comparator|Healthy Aging Practice-centered Instruction (HAPI)|24 hours of group instruction in which experts present on a variety of health-related topics followed by class discussion, goal-setting, and goal review. Themes will include: sleep, nutrition, mental health, social support, bone-health, diabetes prevention, cognitive wellness, and resilience.
2970349|NCT02761603|Experimental|Tai Chi (CHI)|24 hours of group instruction in 8 meditative Tai Chi movements.
2970350|NCT02761590|Experimental|Circuit training protocol|"The CT protocol will be held in three sessions per week for 14 weeks. The volume of work is defined by the training section of time and intensity of effort by the heart rate response to exercise.~The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. that concludes in favor of the organization of training adapted to the reality of the public to be trained."
2970351|NCT02761590|No Intervention|Control group|The control group (NTG) hand will be submitted to circuit training intervention but will be encouraged to maintain their usual activities without starting any type of physical therapy or regular physical activity.
2970352|NCT02761577|No Intervention|control|perorally 1500 ml water on the day of the procedure
2970353|NCT02761577|Experimental|Sodium bicarbonate|3 mL/kg/hour IV (in vein) of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography
2970354|NCT02761577|Experimental|N-acetylcysteine plus Sodium bicarbonate|N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure in addition to Sodium bicarbonate solution on the day of the angiography.
2970355|NCT02761564|Experimental|ScVO2 group|Anemia (<9g/dL) requiring blood transfusion Measure of ScvO2 : ScVO2 is measured using the central venous catheter placed in the superior vena cava. Transfusion is performed if the ScVO2 is inferior or equal to 65%.
2970356|NCT02761564|Other|Control group|Anemia (<9g/dL) requiring blood transfusion : Transfusion is performed following national guidelines for red blood cell transfusion
2970357|NCT02761551|No Intervention|Usual Care|Patients in this group will not receive any reminders for influenza vaccine.
2970358|NCT02761551|Experimental|1 notice|Patients in this group will receive one reminder for influenza vaccine across the 2016 influenza season.
2970359|NCT02761551|Experimental|2 notices|Patients in this group will receive up to two reminders for influenza vaccine across the 2016 season.
2970360|NCT02761551|Experimental|3 notices|Patients in this group will receive up to three reminders for influenza vaccine across the 2016 season.
2970365|NCT02761512|Experimental|CJ-12420 50 mg QD|CJ-12420 50 mg, tablet, once daily, oral administration for up to 8 weeks
2970366|NCT02761512|Experimental|CJ-12420 100 mg QD|CJ-12420 100 mg, tablet, once daily, oral administration for up to 8 weeks
2970367|NCT02761512|Active Comparator|Lansoprazole 30 mg QD|Lansoprazole 30 mg, capsule, once daily, oral administration for up to 8 weeks
2970368|NCT02761499||Total Hip Arthroplasty|The United Hip System consist of several components, and for this clinical evaluation it includes the U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem.
2970369|NCT02761486|Active Comparator|Aspirin|The subjects will receive 325 mg of aspirin once a day for 6 weeks followed by a 6-week washout.
2970370|NCT02761486|Placebo Comparator|Placebo|The subjects will receive placebo once a day for 6 weeks followed by a 6-week washout.
2970371|NCT02761473||Patients with Urticaria Pigmentosa|This group will undergo skin biopsy, blood and buccal swab analyses
2970372|NCT02761473||Family members of affected patients|This group will undergo blood and buccal swab analyses
2970373|NCT02761460|Experimental|PEG-rhG-CSF|PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy,
2970374|NCT02761447|Experimental|Treatment Traditional and Motor Imaginary Program|"Amputees patients also conservative protocol will undergo physiotherapy techniques work Motor Imaginary Program, based on a system of two videos that allow the patient to recreate the normal way. The first video will include two sequences of a harmonic gear that will allow the patient to examine, with the physiotherapist, the characteristics of the different body segments involved in locomotion and place the member in space. The second video include an analysis in five phases. This protocol will be applied 3 days a week (25-30minutos) for one month."
2970375|NCT02761447|Active Comparator|Treatment Traditional and Mirror Therapy|Amputees patients also conservative protocol will undergo physical therapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
2970376|NCT02761434|Active Comparator|Dehydration|Infusion of 3% sodium chloride for osmotic stimulation of vasopressin
2970377|NCT02761434|Placebo Comparator|Euhydration|Infusion of 0.9% sodium chloride that will induce similar expansion of plasma volume without any significant change in osmolality and vasopressin
2970378|NCT02761421||patients with IOPD|observation all patients with IOPD
2970379|NCT02761395|Experimental|Group 1: ALhijama|20 patients under went Al-hijamah procedure for iron chelation
2970380|NCT02761395|Experimental|Group 2: AL-hijama with deferasirox|20 patients receive deferasirox and Al-hijamah.
2970381|NCT02761395|Active Comparator|Group 3:deferasirox|20 patients already receiving deferasirox
2970382|NCT02761382|Experimental|Mindfulness-based treatment|"The mindfulness-based psychological treatment consists of 10 weekly group sessions of 3 hours duration. The treatment is based on Mindfulness-based stress reduction (MBSR), Mindfulness-based cognitive therapy (MBCT) and Acceptance and commitment therapy (ACT). The intervention is partly manualized to accommodate demands of methodology, accuracy and repeatability. The group sessions will include:~mindfulness-training (including meditation and yoga),~therapy based on ACT, and~patient-education in themes specifically targeted living with endometriosis-related chronic pelvic pain."
2970383|NCT02761382|Experimental|Non-specific treatment|"The non-specific general psychological treatment is matched the mindfulness-based psychological treatment and consists of 10 weekly group sessions of 3 hours duration. The treatment is based on Client-centered therapy. The intervention is partly manualized to accommodate demands of methodology, accuracy and repeatability. The group sessions will include:~relaxation and physical training,~therapy based on the non-specific factors of psychological treatment which emphasize a focus on the relation and alliance between the therapist and the client and the therapist being a warm empathic, non-directive and unconditionally accepting support, and~patient-education in themes specifically targeted living with endometriosis-related chronic pelvic pain."
2970384|NCT02761382|No Intervention|Waiting list control|Participants in this arm will be on the waiting list to participate in one of the two experimental treatments after a period of six months. Participants will receive medical treatment as usual in this period.
2970385|NCT02761369|Experimental|A PAS protocol, right-to-left, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a PAS protocol, starting with the right DLPFC
2970386|NCT02761369|Experimental|A PAS protocol, left-to-right, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a PAS protocol, starting with the left DLPFC
2970387|NCT02761369|Sham Comparator|A sham PAS protocol, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a sham PAS protocol, starting with the right DLPFC (@ 40% of individual MT)
2970388|NCT02761356||Tc99-MAA and SPECT-CT|26 of the patients were examined with Tc99-MAA and SPECT-C
2970389|NCT02761356||Tc99-MAA , SPECT-CT and PET-CT|24 patients were examined with Tc99-MAA , SPECT-CT and PET-CT.
2970390|NCT02761343|Other|MRI scan|Post ablation MRI scan will be performed for all subjects who are clinically stable.
2970391|NCT02761330|Active Comparator|Etomidate + ECT|General anesthesia for ECT will be induced with etomidate, approximately 0.2 mg/kg (0.1-0.6 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
2970392|NCT02761330|Experimental|Ketamine + ECT|General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
2970393|NCT02761330|Sham Comparator|Ketamine alone|General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, no ECT charge will be administered.
2970394|NCT02761317|Active Comparator|GroupA：standard preparation|Subjects who are randomized into group A receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
2970395|NCT02761317|Experimental|Group B:low-volume preparation|Subjects who are randomized into group B receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure. ( 2L PEG-ELS and 10mg bisacodyl )
2970396|NCT02761317|Experimental|Group C：high-volume preparation|Subjects who are randomized into group C will receive 2L PEG-ELS at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure. (4 L PEG-ELS)
2970397|NCT02761304|Experimental|ultrasound results given to obstetrical practionnair|
2970398|NCT02761304|Other|ultrasound results shaded to obstetrical practionnair|
2970399|NCT02761291|Experimental|gemcitabine dose escalation|In three combined drugs used in nasopharyngeal carcinoma, the valproic acid and valganciclovir administration will be followed by indication to find the maximum tolerance dose of gemcitabine.
2970400|NCT02761278|Active Comparator|HOXA10 and HOXA11 Expression Before Polypectomy|A biopsy will taken in infertility patients with endometrial polyp before polypectomy
2970401|NCT02761278|Active Comparator|HOXA10 and HOXA11 Expression After Polypectomy|A biopsy will taken in infertility patients with endometrial polyp 1-3 months after polypectomy
2970402|NCT02761265|Experimental|Surgical Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
2970403|NCT02761265|Other|Control Group|Gait and balance testing to be administered once in healthy subjects
2970404|NCT02761252|Experimental|Bilastine+montelukast|Bilastine 20 mg, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each for treatment
2970405|NCT02761252|Active Comparator|Bilastine|Bilastine 20 mg, 10 blister containing 10 tablets + Placebo Montelukast, 10 blister containing 10 film coated tablets each.
2970406|NCT02761252|Active Comparator|Montelukast|Placebo Bilastine, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each.
2970407|NCT02761239|Other|Cricopharyngeal muscle innervation|The recurrent laryngeal nerve (RLN), vagus nerve, external branch of the superior laryngeal nerve (EBSLN) and pharyngeal plexus were stimulated intraoperatively by the NIM 3.0 Nerve Monitoring System (Medtronic Xomed, Jacksonville, FL, USA). Responses were evaluated by visual observation of the cricopharyngeal muscle and electromyographies via needle electrodes inserted into the cricopharyngeal muscle.
2970408|NCT02761226|Experimental|Group A (Platform Matched Design)|10 Patients with missing tooth in upper posterior area will receive dental implant (implants with the same abutment diameter)
2970409|NCT02761226|Active Comparator|Group B (intervention - Platform Switching Design)|10 patients with missing tooth in upper posterior area will receive dental implant (implants with smaller diameter abutment)
2970410|NCT02761213|Experimental|Oral sulfate solution (OSS)|oral sulfate solution (OSS)
2970411|NCT02761213|Active Comparator|2-L PEG/Asc|low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc)
2970412|NCT02761200||volunteer who completion of a recent ATI|
2970413|NCT02761187||Relapsed/refractory (R/R) MM|Patients who have received 1 to 3 prior lines of therapy
2970414|NCT02761187||Newly diagnosed (ND) MM|Patients within 3 months from initiation of treatment
2970415|NCT02761174|Active Comparator|Brimonidine (Mirvaso cream)|This is a split-face study, and patients are thereby their own control. Patients receive IPL-treatment and air-cooling to the whole face (control) and 0.5 g of brimonidine (Mirvaso cream) to the randomized side of the face.
2970416|NCT02761174|Other|IPL+air-cooling|This is a split-face study, and patients are thereby their own control. Patients receive IPL-treatment and air-cooling to the whole face and IPL+air-cooling (control) are thereby compared to IPL+air-cooling+brimonidine (Mirvaso cream).
2970417|NCT02761161|No Intervention|Treatment as usual|TAU: medicine according to algorithm, manual-based cognitive therapy, psychoeducation
2970418|NCT02761161|Active Comparator|Mianserin|10-30 mg of mianserin af sleep enhancing
2970419|NCT02761161|Active Comparator|Imagery Rehearsal Therapy|Therapy focusing on nightmares
2970420|NCT02761161|Active Comparator|mianserin and Imagery Rehearsal Therapy|Both mianserin and IRT
2970421|NCT02761148||Control|
2970422|NCT02761148||White matter hyperintensity|
2970423|NCT02761135||Side-fire|Using side-fire technique during transrectal ultrasound.
2970424|NCT02761135||End-fire|Using end-fire technique during transrectal ultrasound.
2970425|NCT02761122|Experimental|Patients with lichen|"Patients with non-erosive lichen planus, erosive lichen planus or lichen sclerosus.~Human biological samples :~Blood sample~Skin or mucosal brushing~Skin or mucosal biopsy"
2970426|NCT02761096|Experimental|Study group|The acupuncture intervention will start no more than 48 hours after craniotomy and will be given once a day for 6 days (a total of 6 sessions within 8 days). It will be given in addition to conventional treatments. All interventions will be performed by one Korean Medicine doctor with over 5 years of working experience with a college education of 6 years. This doctor will be trained in the study protocol before the start of the trial.
2970427|NCT02761096|Other|Control group|The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery.
2970428|NCT02761083|Experimental|Novosyn® Quick|Eye surgery using suture material
2970429|NCT02761083|Active Comparator|Vicryl® Rapid|Eye surgery using suture material
2970430|NCT02761070|Active Comparator|Bevacizumab (BEV) alone|Bevacizumab 10 mg/kg, day 1 div, every 2 weeks
2970431|NCT02761070|Experimental|Dose Dense Temozolomide Followed by BEV|Temozolomide (120 mg/m2, po, 7 days on/7 days off, every 2 weeks per cycle) up to 48 cycles. The dose will be escalated to 150 mg/m2 at 3rd cycle if the defined conditions are met throughout the first 2 cycles. At recurrence or progression, bevacizumab alone(10 mg/kg, day 1 div, every 2 weeks)
2970432|NCT02761057|Experimental|Arm I (sunitinib malate)|Patients receive sunitinib malate PO on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
2970433|NCT02761057|Experimental|Arm II (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO on days 1-42. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
2970434|NCT02761057|Experimental|Arm III (crizotinib)|Patients receive crizotinib PO BID on days 1-42. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
2970435|NCT02761057|Experimental|Arm IV (volitinib)|Patients receive volitinib PO on days 1-42. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
2970436|NCT02761018|Experimental|Fitness Tracker|will use a fitness tracker but will not be able to see other participant's data
2970437|NCT02761018|Experimental|Fitness Tracker with Group Participation|will use a fitness tracker and will be able to see other member's daily and weekly results
2970438|NCT02761005|Experimental|23S rRNA wt|As the 23S rRNA mutation guided selection of antimicrobial agent, patients infected with strains without mutation of 23S rRNA are assigned to this arm. In this arm, they are treated with vonoprazan 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg bid for 1 week for the eradication of H. pylori.
2970439|NCT02761005|Experimental|23S rRNA mutation|As the 23S rRNA mutation guided selection of antimicrobial agent, patients infected with strains with mutation of 23S rRNA are assigned to this arm. In this arm, they are treated with vonoprazan 20 mg bid, amoxicillin 750 mg bid and metronidazole 250 mg bid for 1 week for the eradication of H. pylori,
2970440|NCT02760992|Active Comparator|Oral Baclofen|Subject will start baclofen at a 5 mg oral dose every 8 hours. Oral baclofen will be increased incrementally and self-administered over 13 days to a maximum dose of 20 mg every 8 hours. Following IV administration, subjects will be changed back to oral baclofen at a 15 mg dose self-administered every 8 hours and tapered off of baclofen over 15 days.
2970441|NCT02760992|Experimental|IV Baclofen|Subjects will be crossed over to 16 mg intravenous baclofen infused over 120 or 150 minutes every 8 hours for 11 doses.
2970442|NCT02760979|Active Comparator|Denosumab|Patients treated with Denosumab
2970443|NCT02760979|Placebo Comparator|Placebo|Patients treated with placebo
2970444|NCT02760966|Experimental|Alcohol 70º|Umbilical cord care will be carried out using alcohol 70º at least 3 times a day. Firstly, there must be a proper hand hygiene. Then, with sterile gauzes alcohol will be applied from the abdominal part to the end of the stump.
2970445|NCT02760966|Active Comparator|Soap|Umbilical cord care will be carried out using soap at least 3 times a day. Firstly, there must be a proper hand hygiene. Then, with sterile gauzes alcohol will be applied from the abdominal part to the end of the stump.
2970446|NCT02760953|Experimental|TUR with Cryoablation|Patients received TUR to treat bladder cancer and immediate cryoablation was applied on the tumor bed in order to eliminate possible residual tumor. Two or three cycles of freeze could be give to fully cover the lesion. One cycle last three to five minutes base on our previous animal experiments.
2970447|NCT02760953|Active Comparator|TUR with instant instillation|Patients received TUR to treat bladder cancer and pirarubicin instillation was given within 24 hours after TUR. This is in accord with the current guideline.
2970448|NCT02760940|Experimental|Oral liposomal iron treatment|Oral liposomal iron - 28 mg per day over 8 weeks
2970449|NCT02760927|Experimental|Endotracheal Tube Fastener|The intervention administered is a revised commercially available endotracheal tube holder with a tract to accommodate a subglottic suction lumen of an oral endotracheal tube.
2970450|NCT02760914||Coronary heart disease|Patients with coronary heart disease undergoing planned coronary artery bypass surgery
2970451|NCT02760901|Active Comparator|Mannitol group|patients received mannitol 20 % 100 ml half an hour before cisplatin and saline hydration.
2970452|NCT02760901|Active Comparator|ACTZ group|patients received acetazolamide 250 mg half an hour before cisplatin with saline hydration.
2970453|NCT02760901|Active Comparator|NAC group|patients received acetylcysteine NAC (600 mg every 12 hours) for 4 doses beginning 24 hours before cisplatin with saline hydration.
2970454|NCT02760888|Active Comparator|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
2970455|NCT02760888|Active Comparator|Diclofenac|Women will receive 100 mg diclofenac 1 hour before the procedure
2970456|NCT02760888|Placebo Comparator|Placebo|Women will receive a placebo 1 hour before the procedure
2970457|NCT02760875||Early Weight Bearing|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from day 1. The orthosis was worn 24 hours / day the first 2 weeks.~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
2970458|NCT02760875||control|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from week 6. The orthosis was worn 24 hours / day the first 2 weeks.~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
2970459|NCT02760862|Active Comparator|Group (I) (N=25)|Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours (Hydrocortisone as sodium succinate, vial, equivalent to hydrocortisone 100mg, Egyptian INT, Pharmaceutical Industries CO. ARE,EIPICO.EGYPT).
2970460|NCT02760862|Active Comparator|Group (II) (N=25)|group (II), received mannitol 20% intravenous fluid (100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis for 48 hours) (Manufactured by Allmed Middle East, Egypt).
2970461|NCT02760849|Experimental|Interval Salpingectomy with Delayed Oophorectomy (ISDO)|"Participants who choose Group 1 will have ISDO. During salpingectomy, the inside of the abdomen is looked at and both fallopian tubes removed.~Quality-of-life questionnaires completed at baseline, 6 months after salpingectomy, and every year or until delayed oophorectomy.~During oophorectomy, the inside of the abdomen is looked at and both ovaries removed.~Quality-of-life questionnaires completed before oophorectomy, and at 6 months, 1 year, and 2 years after oophorectomy."
2970462|NCT02760849|Experimental|Risk-Reducing Salpingo-Oophorectomy (RRSO)|"Participants who choose Group 2 will have RRSO. During salpingo-oophorectomy, the inside of the abdomen looked at and both ovaries and fallopian tubes removed.~Quality-of-life questionnaire completed at 6 months, 1 year, and 2 years after salpingo-oophorectomy surgery."
2970463|NCT02760823|Active Comparator|Alpha Lipoic Acid|Subjects in this arm will receive ALA IV, as a dose of 600 mg/12 hours.
2970464|NCT02760823|Placebo Comparator|Non-Alpha Lipoic Acid|Subjects in this arm will to receive standard treatment only (without Alpha Lipoic Acid, instead they will receive placebo , which is determined by the attending physician who maintains clinical responsibility for all patients. It consists of patient resuscitation, gastric decontamination (with sodium bicarbonate, and activated charcoal [1 g/Kg, orally] in the first 6 hours after onset of poisoning), adequate hydration and supportive treatment.
2970465|NCT02760810|Experimental|narafilcon A|Subjects who are new contact lens wearers (neophytes) between the ages of 18-45 will be dispensed the Test Lens and evaluated over a period of 2 weeks.
2970466|NCT02760797|Experimental|Part I (Dose-Finding Stage)|Emactuzumab and RO7009789 will be administered intravenously (IV) at a starting dose of 500 milligrams (mg) for emactuzumab and 2 mg for RO7009789. Treatment will continue as long as there is clinical benefit until unacceptable toxicity, symptomatic deterioration, or withdrawal of consent.
2970467|NCT02760797|Experimental|Part II (Dose Expansion Stage)|Emactuzumab and RO7009789 will be administered IV at the maximum tolerated dose defined in Part I of the study. Treatment will continue as long as there is clinical benefit until unacceptable toxicity, symptomatic deterioration, or withdrawal of consent.
2970468|NCT02760784||Early Weight Bearing|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from day 1. The orthosis was worn 24 hours / day the first 2 weeks.~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
2970469|NCT02760784||Control|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Weight bearing was allowed from week 6. The orthosis was worn 24 hours / day the first 2 weeks.~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
2970470|NCT02760771||with BAV|patients undergoing transfemoral trans-catheter aortic valve implantations (TF-TAVI) with predilation of the aortic valve
2970471|NCT02760771||without BAV|patients undergoing transfemoral trans-catheter aortic valve implantations (TF-TAVI) without predilation of the aortic valve
2970472|NCT02760758|Experimental|Cohort 1A HV|CDI-31244 20 mg active or placebo single dose (SD)
2970473|NCT02760758|Experimental|Cohort 2A HV|CDI-31244 50 mg active or placebo SD
2970474|NCT02760758|Experimental|Cohort 3A HV|CDI-31244 100 mg active or placebo SD
2970475|NCT02760758|Experimental|Cohort 4A HV|CDI-31244 200 mg active or placebo SD; food effect
2970476|NCT02760758|Experimental|Cohort 5A HV|CDI-31244 400 mg active or placebo SD
2970477|NCT02760758|Experimental|Cohort 6A HV|CDI-31244 200 mg active or placebo multiple dose (MD)
2970478|NCT02760758|Experimental|Cohort 7A HV|CDI-31244 200 mg active or placebo MD
2970479|NCT02760758|Experimental|Cohort 8A HV|CDI-31244 400 mg active or placebo MD
2970480|NCT02760758|Experimental|Cohort 1B HCV genotype (GT) 1|CDI-31244 400 mg active or placebo MD
2970481|NCT02760758|Experimental|Cohort 2B HCV GT 1|CDI-31244 600 mg active or placebo MD
2970482|NCT02760758|Experimental|Cohort 3B HCV GT 1|CDI-31244 800 mg active or placebo MD
2970483|NCT02760745||Febrile Shivering|
2970484|NCT02760745||Fever without Shivering|
2970485|NCT02760732|Experimental|drug eluting balloon group|patients with unstable angina were randomised to drug eluting balloon group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon(Flextome Cutting Balloon, Boston Scientific Corporation, US) pre-dilation first and then drug eluting balloon(Sequent please; B. Braun, Melsungen, Germany) .
2970486|NCT02760732|Experimental|drug eluting stent group|patients with unstable angina were randomised to this group for drug eluting stent (YINYI® Polymer-free Drug-coated (Paclitaxel) Coronary Stent System, Liaoning Biomedical Materials R&D Center Co., Ltd. China) implantation.
2970487|NCT02760719|Experimental|hypertonic saline|4 ml of nebulized 3 % hypertonic saline + salbutamol 0,03 ml/kg every 8 hours for the time of hospitalisation and standard supportive care (oxygen to correct hypoxia, minimal handling to minimise the risk of exhaustion, provision of fluids, gentle nasal aspiration)
2970488|NCT02760719|No Intervention|supportive care|Standard supportive care (oxygen to correct hypoxia, minimal handling to minimise the risk of exhaustion, provision of fluids, gentle nasal aspiration)
2970489|NCT02760693||bipolar patients|unselected admissions of bipolar patients
2970490|NCT02760680|Placebo Comparator|Polysomnography|"The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines."
2970491|NCT02760680|Active Comparator|Diagnostic Device (WatchPAT 200 (TM))|The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
2970492|NCT02760667|Experimental|Induction Therapy with 3 cycles|Cisplatin 75mg/m2 IV and Taxotere 75mg/m2 every 3 weeks for 3 cycles (Induction Chemotherapy) followed by surgical treatment
2970493|NCT02760654|Experimental|Online Self Management|Participants will interact with an online self management program based on cognitive behavioral principles for 8 weeks as much as they want.
2970494|NCT02760654|No Intervention|Control|Treatment as usual
2970495|NCT02760641|Experimental|Egg-based diet (EBD)|This arm will provide ≤25% energy from CHO, 25% energy from protein, and ≥50% energy from fat. EBD participants will be asked to consume ≥2 eggs per day along with other protein sources including meat, fish, pork, and poultry. Carbohydrate (CHO) sources will be primarily derived from leafy greens and non-starchy vegetables and CHO intake will be equally distributed across meals throughout the day.
2970496|NCT02760641|Placebo Comparator|Carbohydrate-based diet (CBD)|The CBD group will be asked to avoid whole egg consumption when possible during the 8 week intervention period. They will be counseled to consume a low fat diet with 55:25:20 %energy from CHO:protein:fat. This diet will place an emphasis on consuming lean meats, low fat dairy, whole grains, legumes, fruits and vegetables.
2970497|NCT02760628|Experimental|The First Twenty (TF20)|Participants in TF20 will be provided an online wellness program focused on fitness and nutrition tailored to firefighters. TF20 is interactive and involves health coaching.
2970498|NCT02760628|Placebo Comparator|Life Simple Seven (LS7)|Participants assigned to the LS7 arm will be directed to a website that contains information about health and wellness from the American Heart Association that was developed for the general population. No health coaching is present and the site is not tailored for the fire service.
2970538|NCT02760407|Experimental|Arm 2: Olokizumab q2w + Methotrexate|Experimental, Olokizumab 64mg q2w Subcutaneous + Methotrexate (oral)
2970499|NCT02760615|Other|Part 1: UC and CD Participants|Participants with UC or CD and not concurrently treated with vedolizumab or other biologics will receive caffeine 200 milligram (mg), tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan, 30 mg (2*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
2970500|NCT02760615|Other|Part 1: Healthy Participants|Healthy participants will receive caffeine 200 mg, tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan 30 mg (2*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
2970501|NCT02760615|Experimental|Part 2: Vedolizumab|Participants who are on established vedolizumab intravenous (IV) maintenance treatment of 300 mg for treatment of UC or CD and in clinical remission will receive vedolizumab 300 mg IV infusion, once, caffeine 200 mg, tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan 30 mg (2*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
2970502|NCT02760602|Experimental|Solanezumab|Solanezumab given intravenously (IV) once every 4 weeks for up to 2 years.
2970503|NCT02760602|Experimental|Placebo|Placebo given IV once every 4 weeks for up to 2 years.
2970504|NCT02760589||ACL tear - conservative|conservative treatment
2970505|NCT02760589||ACL tear - ACL reconstruction|reconstruction of the ACL with autologous tendons
2970506|NCT02760589||ACL tear - Internal brace|augmentation of the ruptured ACL with Internal brace
2970507|NCT02760589||healthy subjects|control group of healthy subjects with no previous injury
2970508|NCT02760576|Experimental|BAY 987521|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2970509|NCT02760563|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2970510|NCT02760550||never smokers|who have never smoked at all
2970511|NCT02760550||ex-smokers|formerly smokers but currently do not smoke at all
2970512|NCT02760550||current smokers|current smokers who, at the time of the survey, smoke any tobacco product either daily or occasionally. Social smokers fall into this category and are defined as those who smoke less than one cigarette per week or smoke only in some occasions
2970513|NCT02760537|Experimental|Lay Health Worker Intervention|LHWs conducted phone interventions by reminding participants of a series of vaccinations at months 1, 2, and 5 among those assigned to the intervention group. Those who had health insurance were encouraged to complete vaccinations through their providers. If participants did not have health insurance, LHWs provided resources to help those in the intervention access vaccinations by referring them to free vaccine events in the community.
2970514|NCT02760537|Placebo Comparator|Placebo (a list of resources)|Those in the control group received a list of resources along with their results by mail that offered free vaccinations, such as local health departments.
2970515|NCT02760524|Experimental|Intervention|Subjects will receive NET intervention treatment immediately
2970516|NCT02760524|Active Comparator|Control|Subjects will receive NET intervention treatment and serve as a wait-list control
2970517|NCT02760511|Placebo Comparator|Control|Intake of placebo capsules
2970518|NCT02760511|Active Comparator|20 mg|Daily intake of 20 mg anthocyanin
2970519|NCT02760511|Active Comparator|40 mg|Daily intake of 40 mg anthocyanin
2970520|NCT02760511|Active Comparator|80 mg|Daily intake of 80 mg anthocyanin
2970521|NCT02760511|Active Comparator|160 mg|Daily intake of 160 mg anthocyanin
2970522|NCT02760511|Active Comparator|320 mg|Daily intake of 320 mg anthocyanin
2970523|NCT02760498|Experimental|Group 1|Patients with metastatic CSCC: to distant sites or lymph nodes. REGN2810 administered intravenously every 2 weeks.
2970524|NCT02760498|Experimental|Group 2|Patients with unresectable locally advanced CSCC. REGN2810 administered intravenously every 2 weeks.
2970525|NCT02760498|Experimental|Group 3|Patients with metastatic CSCC: to distant sites or lymph nodes. REGN2810 administered intravenously every 3 weeks.
2970526|NCT02760485|Experimental|itacitinib + ibrutinib|
2970527|NCT02760472|Active Comparator|Clinoleic|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
2970528|NCT02760472|Experimental|SMOFlipid|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
2970529|NCT02760459|Active Comparator|Dexamethasone|The steroid group will receive Dexamethasone 10 mg IV immediately prior to induction of spinal anesthesia and will receive a second and third dose of Dexamethasone 10 mg IV postoperatively at 24 and 48 hrs.
2970530|NCT02760459|Placebo Comparator|Placebo|The control group will receive sterile normal saline solution, serving as placebo, IV immediately prior to induction of spinal anesthesia and will receive a second and third dose of placebo IV postoperatively 24 and 48 hrs. Both Dexamethasone and normal saline solution will be administered as an IV push.
2970531|NCT02760446|Other|CAM-ICU.fr|CAM-ICU and ICDSC evaluation proceed by two investigators and a Neuropsychologist (Speech & language therapist specialized in neuropsychology)
2970532|NCT02760433|Experimental|Arm 1: Olokizumab q4w + Methotrexate|Olokizumab 64 mg Subcutaneous q4w + Methotrexate (oral)
2970533|NCT02760433|Experimental|Arm 2: Olokizumab q2w + Methotrexate|Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)
2970534|NCT02760433|Placebo Comparator|Arm 3: Placebo q2w + Methotrexate|Placebo Subcutaneous q2w + Methotrexate (oral)
2970535|NCT02760420|Experimental|Placebo|250 mg of placebo (dispersible tablet) DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age)
2970536|NCT02760420|Active Comparator|3 Days|250 mg amoxicillin (dispersible tablet) DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age)
2970537|NCT02760407|Experimental|Arm 1: Olokizumab q4w + Methotrexate|Experimental, Olokizumab 64mg q4w Subcutaneous + Methotrexate (oral)
2970539|NCT02760407|Active Comparator|Arm 3: Adalimumab q2w + Methotrexate|Active Comparator, Adalimumab 40mg q2w Subcutaneous + Methotrexate (oral)
2970540|NCT02760407|Placebo Comparator|Arm 4: Placebo q2w + Methotrexate|Placebo Comparator, Placebo q2w Subcutaneous + Methotrexate (oral)
2970541|NCT02760394|Active Comparator|Treated group|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
2970542|NCT02760394|Other|Control group|Following 2 months of follow up the group will be crossed over to receive the same treatment as the treated group
2970543|NCT02760381|Experimental|Routine colonoscopy Cohort|Patients receiving routine colonoscopy receive the intervention: NBI + Acetic Acid (AA)
2970544|NCT02760368|Experimental|Arm 1: Olokizumab q4w + Methotrexate|Olokizumab 64 mg Subcutaneous q4w + Methotrexate (oral)
2970545|NCT02760368|Experimental|Arm 2: Olokizumab q2w + Methotrexate|Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)
2970546|NCT02760368|Placebo Comparator|Arm 3: Placebo q2w + Methotrexate|Placebo Subcutaneous q2w + Methotrexate (oral)
2970547|NCT02760355|Experimental|Active treatment|Ledipasvir 90 mg/Sofosbuvir 400 mg, one tablet once a day + b.w. dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients <75 Kg of body weight, or 1,200 mg in two administrations for those >75 Kg) for 12 weeks
2970548|NCT02760342|Experimental|ASP015K and Metformin|Subjects will receive a single oral dose of metformin on Days 1 and 10, a single dose of ASP015K on Day 3 and multiple doses of ASP015K once daily Day 5 to Day 11. Subjects will receive a single dose of metformin and ASP015K concurrently on Day 10.
2970549|NCT02760329||Chronic airways disease|Patients with suspected or primary diagnosis of asthma or COPD
2970550|NCT02760316|Experimental|AZD9567 oral suspension of 10 mg|Participants will receive oral supension of 10 mg dose strength
2970551|NCT02760316|Experimental|AZD9567 oral suspension of 20 mg|Participants will receive oral suspension of 20 mg dose strength
2970552|NCT02760316|Experimental|AZD9567 oral suspension of 40 mg|Participants will receive oral suspension of 40 mg dose strength
2970553|NCT02760316|Experimental|AZD9567 oral suspension of 80 mg|Participants will receive oral suspension of 80mg dose strength
2970554|NCT02760316|Active Comparator|Prednisolone oral capsules of 20 mg|Participants will receive oral capsules of 5 mg dose strength
2970555|NCT02760316|Experimental|AZD9567 oral suspension of 125 mg|Participants will receive oral suspension of 125 mg dose strength
2970556|NCT02760316|Experimental|AZD9567 oral suspension of 155 mg|Participants will receive oral suspension of 155 mg dose strength
2970557|NCT02760316|Active Comparator|Prednisolone oral capsules of 5 mg|Participants will receive oral capsules of 5 mg dose strength
2970558|NCT02760316|Active Comparator|Prednisolone oral capsules of 40 mg|Participants will receive oral capsules of 5 mg dose strength
2970559|NCT02760303|Experimental|Cognitive Behavioral Therapy|Hains' adaptation of cognitive behavioral therapy for adolescents and young adults with type 1 diabetes
2970560|NCT02760303|Experimental|Mindfulness Based Stress Reduction|Sabinga's adaptation of Mindfulness Based Stress Reduction for adolescents and young adults with type 1 diabetes
2970561|NCT02760303|Active Comparator|Diabetes Support and Education|Investigator developed peer support group and diabetes education
2970562|NCT02760290|Experimental|Extraperitoneal group|Extraperitoneal cesarean section will perform after rectus sheat incision and carefully bladder dissecting.
2970563|NCT02760290|Active Comparator|Intraperitoneal group|Conventional transperitoneal cesarean will perform
2970564|NCT02760277|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
2970565|NCT02760277|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
2970566|NCT02760277|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
2970567|NCT02760277|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
2970568|NCT02760264|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
2970569|NCT02760264|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
2970570|NCT02760264|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
2970571|NCT02760264|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
2970572|NCT02760251|Experimental|Romiplostim|Romiplostim (a thrombopoietin-receptor agonist, TPO-RA) will be administered subcutaneously once weekly over 22 weeks with a starting dose of 1mcg/kg body weight. The dose will be adjusted based on platelet counts as described in the summary of Product Characteristics (SmPC). Followup examination at week 52.
2970573|NCT02760238||Patients with a diagnosis of MPN|"Patients with a myeloproliferative neoplasm (MPN) diagnosis:~Atypical chronic myeloid leukemia (aCML), chronic eosinophilic leukemia-not otherwise specified (CEL NOS), chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia (CNL), polycythemia vera (PV), essential thrombocythemia (ET), JMML, mastocytosis, MPN unclassifiable, myeloproliferative neoplasm/myelodysplastic syndrome unclassifiable (MPN/MDS unclassifiable), primary myelofibrosis (PMF), post-ET MF, post-PV MF, or (refractory anemia with ringed sideroblasts associated with marked thrombocytosis) RARS-T"
2970574|NCT02760225|Experimental|89Zr-Pembrolizumab PET imaging|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
2970575|NCT02760212|Experimental|Group 1 - Radial Shockwave Therapy Group|Participants in Group 1 will receive RSWT to the most painful spot within each of the 3 most painful regions as described by the participant. Treatments will be spaced one week apart over a 5 week period of time. 5 weekly sessions with treatment to the painful areas will be undertaken with 500 shocks (1.5 bar, 15 Hz), then 1000 shocks (2 bar, 8 Hz), and finally 500 shocks (1.5 bar, 15 Hz) to the most painful spot.
2970652|NCT02759744|Experimental|1|ultrasound image-guided focal laser ablation (FLA)
2970576|NCT02760212|Placebo Comparator|Group 2 - Placebo Group|Participants in Group 2 will receive a placebo treatment with a soft rubber cap applied to the applicator, leaving air between the transmitter and the cap and the participant's skin so that no shockwave will be generated nor applied to the participant's skin. Treatments will be spaced one week apart over a 5 week period of time. 5 weekly sessions with placebo treatment to the painful areas will be undertaken with 2000 placebo shocks (15 Hz) producing an audible sound but no therapeutic dosage to the most painful spot. Upon completion of the placebo treatment, participant's will be offered the experimental treatment but this data will not be used for comparison and analysis.
2970577|NCT02760199|Experimental|89Zr-AMG211 and 89Zr-AMG211 PET|
2970578|NCT02760186|Experimental|Altitude Exposure|Acute high altitude exposure followed by 7 day acclimatization and reexposure after 7 days at low altitude
2970579|NCT02760173|Experimental|Single intervention arm|This is the only arm in this study, measuring verticality perception after prolonged roll-tilt over 5min.
2970580|NCT02760160|Other|Reconstituted grape powder|Open grape powder pouch and pour contents into volumetric measuring device. Add approximately 180 mL of water to container with grape powder. Stir for a minimum of 30 seconds and ingest.
2970581|NCT02760147|Other|Pressure Support Over Support|Pressure Support Level upward by 50%, 2 hours
2970582|NCT02760147|Other|Pressure Support Under Support|Pressure Support Level downward by 50%, 2 hours
2970583|NCT02760147|Other|PEEP Over Level|PEEP Level upward by 50%, 2 hours
2970584|NCT02760147|Other|PEEP Under Level|PEEP Level downward by 50%, 2 hours
2970585|NCT02760134|Other|SMP with F14 sheath|Patients undergo Super-Mini Percutaneous Nephrolithotomy with F14 suction-evacuation sheath.
2970586|NCT02760134|Other|SMP with F12 sheath|Patients undergo Super-Mini Percutaneous Nephrolithotomy with F12 suction-evacuation sheath.
2970587|NCT02760121|Experimental|Acetazolamide|Participants will be dosed 250mg Acetazolamide (p.o.) three times per day for two days prior to and a single dose on the day of study.
2970588|NCT02760121|Experimental|Methazolamide|Participants will be dosed 100mg Methazolamide (p.o.) twice daily separated by a placebo for two days prior to and a single dose on the day of study. The placebo dose is provided to match the dosing schedule between conditions.
2970589|NCT02760121|Placebo Comparator|Placebo|Participants will take (p.o.) placebo pills three times per day for two days prior to and a single dose on the day of study.
2970590|NCT02760108||Index case|Patients with a family history of Parkinson's/parkinsonism, and/or early onset Parkinson's/parkinsonism. The first individual member from a family who is recruited to the study.
2970591|NCT02760108||Affected relatives|Patients with Parkinson's/parkinsonism who are first or second degree relatives of an Index Case.
2970592|NCT02760108||Unaffected relatives|Participants who do not have Parkinson's/parkinsonism and are first or second degree relatives of an Index Case.
2970593|NCT02760095||Children with EED|Children are placed in this arm if they screen positive for EED using the urinary lactulose:mannitol (L:M) recovery ratio. Children will receive a one-time 3 mg standard dose of zinc sulfate with stable isotope zinc tracer and 0.5 mg standard dose of 13C10-retinyl-acetate (vitamin A isotope).
2970594|NCT02760095||Children without EED|Children are placed in this arm if they screen negative for EED using the urinary lactulose:mannitol (L:M) recovery ratio. Children will receive a one-time 3 mg standard dose of zinc sulfate with stable isotope zinc tracer and 0.5 mg standard dose of 13C10-retinyl-acetate (vitamin A isotope).
2970595|NCT02760082||Semi-structured interviews|20 participants (anticipated)
2970596|NCT02760082||Questionnaire survey|400 respondents (anticipated)
2970597|NCT02760082||Focus group interviews|3-5 focus group interviews (anticipated)
2970598|NCT02760069|Active Comparator|Inhaled ISO + oral ondansetron|Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral elixir comprising ondansetron (4 mg).
2970599|NCT02760069|Experimental|Inhaled ISO + oral placebo|Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
2970600|NCT02760069|Active Comparator|Inhaled placebo + oral ondansetron|Inhaled normal saline pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
2970601|NCT02760056|Active Comparator|Liothyronine (cytomel)|Subjects will be divided into 4 groups. The first group will take 25 mcg twice daily for one week. The second group will take 37.5 mcg twice daily for one week. The third group will take 50 mcg twice daily for one week. The firth group will take 75 mcg twice daily for one week
2970602|NCT02760056|Placebo Comparator|Placebo|Subject will take matching placebo twice a day for one week
2970603|NCT02760043|Experimental|Dexamethasone|LIA mixture with the addition of 8mg Dexamethasone.
2970604|NCT02760043|Sham Comparator|Saline|LIA mixture with the addition of 2mL of 0.9% NaCl Saline.
2970605|NCT02760030|Experimental|Treatment (fulvestrant, palbociclib)|Patients receive fulvestrant IM on days 1 and 15. Patients also receive palbociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2970606|NCT02760017|Placebo Comparator|placebo|capsules containing placebo for B forticata
2970607|NCT02760017|Experimental|B. forficata|capsules of B. forficata containing 200 mg of plant extracts
2970608|NCT02760004|Experimental|Prism Intervention|PRogram In Support of Moms (PRISM)
2970609|NCT02760004|Experimental|Enhanced Usual Care|Enhanced Usual Care group (Access to MCPAP for Moms)
2970610|NCT02759991|Active Comparator|HEV vaccine|Hecolin, 0.6 ml intramuscular injection day 0, 1 month and 6 months.
2970611|NCT02759991|Placebo Comparator|HBV vaccine|Hepa-B, 1 ml intramuscular injection day 0, 1 month and 6 months.
2970612|NCT02759978||Suspicion NVE|Patients with suspicion of native valve endocarditis, infective endocarditis and no intracardiac prosthetic material in situ
2970613|NCT02759978||Suspicion (PVE)|Patients with a suspicion of prosthetic valve endocarditis (PVE), infective endocarditis and one or more prosthetic valves in situ
2970614|NCT02759978||Suspicion pacemaker/ICD related endocarditis|Patients with a suspicion of infective endocarditis and a pacemaker or implantable cardiac defibrillator (ICD) in situ
2970615|NCT02759939|Experimental|Arm 1|
2970616|NCT02759939|Experimental|Arm 2|
2970617|NCT02759939|Experimental|Arm 3|
2970618|NCT02759939|No Intervention|Arm 4|
2970884|NCT02758418|Experimental|Online Computerized Program group.|"Intervention group that uses TAO program."
2970619|NCT02759926|Active Comparator|Denatonium benzoate intragastric|1 µmol/kg bodyweight (10mM) was administered as a bolus into the stomach through a nasogastric feeding tube.
2970620|NCT02759926|Active Comparator|Quinine hydrochloride intragastric|10 µmol/kg bodyweight (100mM) was administered as a bolus into the stomach through a nasogastric feeding tube.
2970621|NCT02759926|Placebo Comparator|Tap water intragastric|An equal amount of tap water was administered as a bolus into the stomach through a nasogastric feeding tube.
2970622|NCT02759926|Active Comparator|Denatonium benzoate intraduodenal|1 µmol/kg bodyweight (10mM) was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
2970623|NCT02759926|Active Comparator|Quinine hydrochloride intraduodenal|10 µmol/kg bodyweight (100mM) was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
2970624|NCT02759926|Placebo Comparator|Tap water intraduodenal|An equal amount of tap water was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
2970625|NCT02759913||Amyotrophic lateral sclerosis|Participants recently diagnosed with ALS in a neuromuscular clinic, using the ALS functional rating scale (ALSFRS-R). Lumbar puncture (LP) for cerebro-spinal fluid (CSF) collection The ALSFRS-R is a quickly administered (5 min) ordinal rating scale used to determine a subject's assessment of their capability and independence in 12 functional activities. There are 12 questions, graded by the subject 0-4 (4 is normal). Score of 0 (worst) to 48 (best). Reflects speech and swallowing, fine motor skills, large motor skills, and breathing.
2970626|NCT02759913||ALS mimics|Other motorneuron disorders, isolated upper and lower motoneuron disorders Lumbar puncture (LP) for cerebro-spinal fluid (CSF) collection
2970627|NCT02759900|Experimental|Non-thermal atmospheric plasma treatment|Device treatment
2970628|NCT02759887|Other|DS adult group|Consists of 15 DS subjects aged 21 and older who do not qualify for the diagnosis of dementia at the beginning of the study. Interventions include biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
2970629|NCT02759887|Other|DS/AD group|Consists of 15 DS subjects aged 40 and older who do qualify for the diagnosis of dementia by DSM-IV criteria. Diagnoses will be by standard consensus review of all cases. Interventions include biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
2970630|NCT02759887|Other|NC adult|Consists of 10 cognitively normal, non-DS individuals, age-matched to the DS adult group. Interventions include biospecimen collection, cognitive assessments, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
2970631|NCT02759874|Experimental|Experimental|Intervention is pregnant women enrolled and using specialized breathalyzer device w face recognition technology linked to a cellphone
2970632|NCT02759874|No Intervention|Control Group|No intervention. No breathalyzer given. Access granted by participant to IHE to collect data from Alberta Health Services (medical records)
2970633|NCT02759861|Experimental|Harvoni x 8 or 12 weeks|patient will receive 8 or 12 weeks depending on clinical data
2970634|NCT02759848||with history of TB|
2970635|NCT02759848||without history of TB|
2970636|NCT02759835|Experimental|Arm 2|LAT followed by osimertinib
2970637|NCT02759835|Experimental|Arm 1|osimertinib followed by LAT followed by osimertinib
2970638|NCT02759822||Group A: Acute Lymphoblastic Leukemia|"Haploidentical Stem Cell Transplantation with Post Transplant Cyclophosphamide (PTCy)~Preferred conditioning:~Total Body Irradiation 1200 cGy (TBI1200) + Fludarabine 120 mg/m2 (Flu120)~Alternative conditionings:~Melphalan 100-140 mg/m2 (Mel100-140) + Fludarabine 160 mg/m2 (Flu160) + Total Body Irradiation 200 cGy (TBI200)~Busulfan 9.6 mg/kg (Bu9.6) + Fludarabine 150 mg/m2 (Flu150) + TBI200 Graft versus host disease Prophylaxis: Post-Transplant Cyclophosphamide (PTCy) + Tacrolimus (FK) or Cyclosporin (CSA) + Mycophenolate Mofetil (MMF)"
2970639|NCT02759822||Group B: Acute Myeloid Leukemia|"Haploidentical Stem Cell Transplantation with Post Transplant Cyclophosphamide (PTCy) Preferred Conditioning: Mel100-140 + Flu160 + TBI200~Alternative conditionings:~Bu9,6 + Flu150 + TBI200~Cyclophosphamide 29 mg/kg + Flu150 + TBI200 Graft versus host disease Prophylaxis: PTCy + FK or CSA + MMF"
2970640|NCT02759809||Children previously assigned to donor milk in the DoMINO trial|This study is an observational study of children who were enrolled in a previous trial (DoMINO trial) between 2010 and 2012 during which they were randomized to receive donor milk when mother's own breastmilk was unavailable. Donor milk was from a milk bank part of the Human Milk Banking Association of North America (HMBANA).
2970641|NCT02759809||Children previously assigned to formula in the DoMINO trial|This study is an observational study of children who were enrolled in a previous trial (DoMINO trial) between 2010 and 2012 during which they were randomized to receive preterm formula when mother's own breastmilk was unavailable. Preterm formula was either Similac Special Care or Enfamil Premature depending on hospital contract with formula companies.
2970642|NCT02759796|Placebo Comparator|Clinical assessment of flap perfusion|Tailoring the flap according to clinical assessment of flap perfusion
2970643|NCT02759796|Experimental|Angiography assessment of flap perfusion|Tailoring the flap according to ICG Angiography assessment of flap perfusion
2970644|NCT02759783|Active Comparator|Standard of Care|Standard of care (SOC) is at the discretion of the local oncologist.
2970645|NCT02759783|Experimental|Standard of Care + SBRT|Patients randomised to SBRT will receive a dose and fractionation regimen dependent on the metastatic site and proximity to normal tissues. If allocated to SBRT, SBRT will precede SOC.
2970646|NCT02759770||ARDS|ARDS patients after cardiac surgery
2970647|NCT02759770||non-ARDS|non-ARDS patients after cardiac surgery
2970648|NCT02759770||propective group|patients of cardiac surgery including ARDS and non-ARDS patients
2970649|NCT02759757|Experimental|Kinesio Taping|"Patients from this group will receive the kinesio Taping® Tex Gold tape according to the manufacturer's instructions. Kinesio Taping will be applied for the purpose of inhibiting the erector spinal muscle from the twelfth thoracic vertebrae (longissimus portion) up to the first sacral vertebrae with 10 to 15% tension (paper-OFF) in a I position bilaterally."
2970650|NCT02759757|Placebo Comparator|Placebo|Patient from this group will receive a 5cm-wide Micropore® tape from the twelfth thoracic vertebrae (longissimus portion) up to the first sacral vertebrae bilaterally.
2970651|NCT02759757|No Intervention|Control|Patients allocated will not receive any intervention.
2970653|NCT02759731|Experimental|Arm 1|Baricitinib starting at a dose of 2mg daily for 12 weeks. If the response at 12 weeks is a CR and there has not been a DLT, the dose will be remain at 2mg daily for an additional 12 weeks. If there has been a DLT within the first 4 weeks, the dose will be decreased to 1mg daily, and will continue at this dose as tolerated. If there has been DLT at this dose (1 mg), patients will be taken off treatment.
2970654|NCT02759731|Experimental|Arm 2|If the response is a PR or stable disease (from cohort 1), the dose will be increased to 4mg daily for an additional 12 weeks. If there has been a DLT within the first 4 weeks will have a dose reduction back to 2mg daily. For patients who experience cGVHD progression at any time within the first 12 weeks on 2mg daily, the dose can be increased to 4mg daily until 24 weeks.
2970655|NCT02759718|Experimental|pancreatic neuroendocrine tumor|chromogranin A
2970656|NCT02759692|Active Comparator|Group 1 (Test/Control/Test)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the TEST / CONTROL / TEST wearing sequence will wear lenses as daily disposable on both eyes for approximately one week each with no washout period between lenses for at least five days, and 8 hours per day.
2970657|NCT02759692|Active Comparator|Group 2 (Control/Test/Control)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the CONTROL / TEST / CONTROL wearing sequence will wear lenses as daily disposable on both eyes for approximately one week each with no washout period between lenses for at least five days, and 8 hours per day.
2970658|NCT02759679|Other|Lung cancer|Patients with lung cancer
2970659|NCT02759679|Other|Controls|Controls being either healthy or having other lung disease
2970660|NCT02759666|Experimental|SHR3162|"The 6 dose levels in this study are 20 mg once daily (QD), 40 mg QD, 40 mg twice daily (BID), 60 mg BID, 80 mg BID, 100 mg BID, 150mg BID and 200mg BID. In each dose cohort, 3 to 6 participants (traditional 3+3 design) will be enrolled. SHR3162 was administered once daily in dose levels 1 and 2 and will be administered twice daily in dose levels 3 to 6."
2970661|NCT02759653||Symptomatic|Symptomatic carotid artery disease
2970662|NCT02759653||Asymptomatic|Asymptomatic carotid artery disease
2970663|NCT02759640|Experimental|HS-10241|HS-10241 is administered orally starting at 100 mg/day.
2970664|NCT02759627|No Intervention|Conventional Training|Conventional physical therapy consisted of neurophysiological concepts such as Bobath and Brunnstrom.Training sessions focused on static and dynamic postural tasks, improving lower and upper extremity range of motion, strengthening and overground walking. During walking training, emphasis was on distance walked than on gait quality. Symmetrical weight distribution was encouraged through verbal and tactile cues and was made more difficult by the addition of arm activities or actions requiring trunk rotation. In an effort to improve rhythmic weight-shifting ability, subjects practiced shifting their weight in forward and backward directions and side to side while performing reaching tasks. A session lasted 45 minutes, for 5 days per week for 6 weeks.
2970665|NCT02759627|Experimental|Robotic-Assisted Gait Training|Lokomat (Hocoma) was used in Robotic-Assisted Gait Training group with 20 % body weight reduced. The participants walked on device at 1.8 km/h (0.5 m/sec) velocity. For each participant body weight portion was ensured by a security belt while walking. Each session took 45 minutes including setup, commands and rest time. Verbal instructions were used for encouragement but no manual assistance was given to improve gait. Robotic-Assisted Gait Training sessions lasted 45-minute sessions, 2 days a week during 6 weeks.
2970666|NCT02759627|No Intervention|Combined Training|Combined Training consisted of inpatient participants who were treated with 45 minute-conventional training, 5 days a week during 6 weeks. Additionally this group had 45 minute-Robotic-Assisted Gait Training, 2 days a week during 6 weeks.
2970667|NCT02759614|Experimental|Bevacizumab and Erlotinib|Bevacizumab 15 mg/kg shall be intravenous infusion on day 1 once every 3 weeks, Erlotinib 150 mg tablets shall be administered orally every day at least one hour before or two hours after the ingestion of food.
2970668|NCT02759614|Active Comparator|Erlotinib|Erlotinib 150 mg tablets shall be administered orally every day at least one hour before or two hours after the ingestion of food.
2970669|NCT02759601|Other|Tefinostat|"This is an open label, dose escalating, phase I/II study of Tefinostat administered orally, once or twice daily in 28 day cycles of treatment in patients with advanced hepatocellular carcinoma.~Up to 5 cohorts of 3-6 patients (number is dependent on DLT occurrence) will be treated for 28 days once or twice daily (360, 480mg once daily, then 240, 360, 480mg twice daily) to determine safety and tolerability of Tefinostat and to identify the recommended dose for Phase II."
2970670|NCT02759588|Experimental|GL-ONC1|
2970671|NCT02759575|Experimental|Pembrolizumab|Pembrolizumab every 3 weeks in combination with 7 weeks of radiation therapy and every 3 week cisplatin
2970672|NCT02759562|Experimental|Andecaliximab 600 mg (Part 1)|Andecaliximab 600 mg weekly for 8 weeks
2970673|NCT02759562|Placebo Comparator|Placebo (Part 1)|Placebo weekly for 8 weeks
2970674|NCT02759562|Experimental|Andecaliximab 300 mg (Part 2)|Andecaliximab 300 mg weekly for 8 weeks
2970675|NCT02759562|Experimental|Andecaliximab 150 mg (Part 2)|Andecaliximab 150 mg + placebo weekly for 8 weeks
2970676|NCT02759562|Placebo Comparator|Placebo (Part 2)|Placebo weekly for 8 weeks
2970677|NCT02759562|Experimental|Open-Label Extension|(Part 1) Andecaliximab 600 mg weekly for 16 weeks; (Part 2) Andecaliximab 300 mg weekly for 16 weeks
2970678|NCT02759549|Experimental|eSMART-MH|Participants undergoing radiation treatment for breast cancer will receive the Electronic Self-Management Resource Training for Mental Health (eSMART-MH) intervention.
2970679|NCT02759549|Other|Theater Testing|Participants undergoing radiation treatment for breast cancer will participate in a theater testing workshop.
2970680|NCT02759536|Experimental|Boronophenylalanine and IHNI-based BNCT|
2970681|NCT02759510|Active Comparator|phenylephrine|phenylejphrine (one bolus for 40 ug/ml)
2970682|NCT02759510|Experimental|norepinephrine|norepinephrine (one bolus for 2 ug/ml)
2970683|NCT02759497||Serum amyloid A level in SBP|serum amyloid A level
2970684|NCT02759497||Serum amyloid A level in cirrhosis|Serum amyloid A level
2970685|NCT02759484|Experimental|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home.
2970744|NCT02759159|Experimental|Mild Cognitive Impairment(MCI)-true acupuncture|"True acupuncture at the four-gateacupoints will be administered on MCI patients"
2970686|NCT02759484|Active Comparator|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of group diabetes self-management education, delivered by a Certified Diabetes Educator, plus mailed diabetes self-management education.
2970687|NCT02759471|Experimental|comfilcon A sphere (control) and comfilcon A asphere (test)|Habitual wearers of comfilcon A sphere lens (control) are refitted with comfilcon A asphere lens (test).
2970688|NCT02759458|Experimental|Healicoil|Patients that met the inclusion criteria who were randomly selected to receive the Healicoil anchor for their rotator cuff repair.
2970689|NCT02759458|Active Comparator|Twinfix|Patients that met the inclusion criteria who were randomly selected to not receive the Healicoil anchor for their rotator cuff repair.
2970690|NCT02759432|Experimental|Intervention|Participants in the intervention group will complete a 4-week school-based high-intensity interval exercise training programme. The intervention will take place twice per week, and comprise of 6-8 repetitions of 45 s maximal effort exercise (boxing, running, soccer and basketball drills), each interspersed with 90-s rest. Participants will be encouraged to work maximally during the 45-s repetitions.
2970691|NCT02759432|No Intervention|Control|Participants in the control group will be instructed not to change their lifestyle, dietary or physical activity habits during the intervention period, and maintain their normal school physical education routine
2970692|NCT02759419|Experimental|BAY63-2521|Single-arm, uncontrolled
2970693|NCT02759406|Experimental|Mach-5 Grooved|grooved
2970694|NCT02759406|Experimental|Mach 5 Bare Metal|bare metal
2970695|NCT02759393|Experimental|DEX group|receiving 8-week dexlansoprazole 60 mg per day
2970696|NCT02759393|Active Comparator|Double-dose PPI group|receiving 8-week lansoprazole 30 mg twice daily
2970697|NCT02759380|Experimental|Phytoestrogen-rich foods|"Introduced to the study by a dietitian.~Receive general information about healthy food choices (according to the Swedish National Food Agency's recommendations for the general public).~Be told not not to eat any dietary supplements, though no other dietary restrictions will be given.~Called one time during the study and perform a 24-hour recall.~The intervention continues until the day before the surgery (at least 6 weeks).~The patients in the experimental group will be given a package containing food with a high amount of phytoestrogens."
2970698|NCT02759380|No Intervention|Control group|"Introduced to the study by a dietitian.~Receive general information about healthy food choices (according to the Swedish National Food Agency's recommendations for the general public).~Be told not not to eat any dietary supplements, though no other dietary restrictions will be given.~Called one time during the study and perform a 24-hour recall.~The intervention continues until the day before the surgery (at least 6 weeks)."
2970699|NCT02759367|Experimental|High potassium diet group|Individuals in this arm were asked to increase dietary potassium intake over a 4 week period. This was achieved through an increase in consumption of fruits and vegetables.
2970700|NCT02759367|No Intervention|Usual diet group|Individuals in this group were asked to continue habitual dietary intake.
2970701|NCT02759354|Experimental|Group V3|Subjects previously vaccinated with a 3+1 schedule with VAXELIS
2970702|NCT02759354|Active Comparator|Group I3|Subjects previously vaccinated with a 3+1 schedule with Infanrix hexa
2970703|NCT02759354|Experimental|Group V2|Subjects previously vaccinated with a 2+1 schedule with VAXELIS
2970704|NCT02759354|Active Comparator|Group I2|Subjects previously vaccinated with a 2+1 schedule with Infanrix hexa
2970705|NCT02759341|Other|Cardiac X Syndrome (CSX)|patients with Cardiac X Syndrome (CSX), according to the diagnostic criteria previously proposed by Lanza (Lanza, Heart. 2007)
2970706|NCT02759341|Other|Takotsubo Cardiomyopathy (TTC)|Tako-Tsubo Cardiomyopathy (TTC), according to Mayo diagnostic criteria at least six months after the event. (Prasad A, et al. Am Heart J. 2008)
2970707|NCT02759341|Other|Acute myocardial infarction (AMI)|Type 1, 4a, 4b myocardial infarction (ST-segment elevation acute myocardial infarction [STEMI] and Non ST-segment elevation acute myocardial infarction [NSTEMI] acute coronary syndrome [ACS] with significant ≥70% coronary stenosis) at least six months after the event. (Thygesen K, et al. Eur Heart J. 2012)
2970708|NCT02759328|Experimental|Xbox Kinect™ training group|60 minutes/day, 5 days/week, 4 weeks (20 sessions) conventional rehabilitation program plus 60 minutes/day, 5 days/week, 4 weeks (20 sessions) Xbox Kinect™ upper extremity training. Two games both of which require using upper extremities, were chosen and each game was played for 30 minutes per session.
2970709|NCT02759328|Active Comparator|Conventional rehabilitation group|60 minutes/day, 5 days/week, 4 weeks (20 sessions) conventional rehabilitation program only. The treatment protocol was individualized according to the goals which were determined depending on each patient's needs and functional level.
2970710|NCT02759315|Experimental|GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT1 Arm is sub-divided into GT1a and GT1b Arms. GT1a Arm will enroll approximately 35 participants including up to 10 participants who are compensated cirrhotics and GT1b Arm will enroll approximately 15 participants including up to 5 participants who are compensated cirrhotics.
2970711|NCT02759315|Experimental|GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT2 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
2970712|NCT02759315|Experimental|GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT3 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
2970713|NCT02759315|Experimental|GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT4 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
2970745|NCT02759159|Sham Comparator|MCI-sham acupuncture|"Sham acupuncture at the four-gateacupoints will be administered on MCI patients"
2970714|NCT02759315|Experimental|GT5: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT5 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.
2970715|NCT02759315|Experimental|GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT6 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.
2970716|NCT02759302||Patients with LGMD2N|Five patients over 18 years old with genetically verified LGMD2N
2970717|NCT02759289||Group A|Prediabetes glycohemoglobin test A1c 5.7-6.4%
2970718|NCT02759289||Group B|"T2D glycohemoglobin test= A1c 6.5-7.9% without T2D medications~T2D glycohemoglobin test=A1c ≥ 8.0% with/without T2D medications"
2970719|NCT02759289||Group C|Control
2970720|NCT02759276||Resistant Hypertension (RH)|uncontrolled hypertension, with values ≥140/90 mmHg, using three or more antihypertensive drugs of different classes, including a diuretic, or controlled hypertension with four or more drugs.
2970721|NCT02759276||Stages 1 and 2 Hypertension (MMH)|According to the VI Brazilian Guidelines of hypertension, with blood pressure levels ranging from 140/90 mmHg to 179/109 mmHg, with up to two antihypertensive drugs of different classes and blood pressure levels controlled in the last two months.
2970722|NCT02759276||Normotensive (CG)|Blood Pressure <140/90 mmHg and without comorbidities.
2970723|NCT02759263|Experimental|Working Memory Intervention|The group randomized to the Working Memory intervention will receive Cogmed computerized training of executive function and attention skills. The standard Cogmed RM will be used for this trial arm. This is a child-friendly web-based software program. The investigators will use a version of the program that contains 12 different neurocognitive tasks. Tasks become more difficult as a function of performance on a session-by-session basis. Each training session lasts 35-40 minutes, with one session to be completed per day 5 days each week for 5 weeks, for a total of 25 sessions. The program yields individual session-by-session and task-by- task training results, including the adolescents' responses, time spent on each task, and evolution curves.
2970724|NCT02759263|No Intervention|Control group - Standard of Care|Adolescents randomly assigned to the control group will receive the standard of care recommended for patients with critical CHD. This includes cardiac surveillance and neurodevelopmental counseling and screening at our Cardiac Neurodevelopmental Program if needed. Once enrolled in our study, an adolescent in the control group will not receive Cogmed intervention or any other cognitive intervention that targets executive functions or ADHD symptoms until after the 3-month follow-up neurodevelopmental evaluation is performed, i.e., 5-6 months after initial enrollment. Like adolescents assigned to the intervention group, controls can continue on treatments that are already in place for other neurodevelopmental disabilities (e.g., speech therapy, occupational services).
2970725|NCT02759250|Experimental|adjuvant monotherapy|ARGX-110 5mg/kg once every three weeks for a maximum of 18 cycles
2970726|NCT02759250|Experimental|metastatic/recurrent monotherapy|ARGX-110 5mg/kg once every three weeks until disease progression
2970727|NCT02759250|Experimental|metastatic/recurrent combination therapy|ARGX-110 5mg/kg once every three weeks plus chemotherapy until disease progression. The choice of the chemotherapy agents is limited to: cisplatin, carboplatin, 5-fluorouracil, gemcitabine and paclitaxel.
2970728|NCT02759237||Patient Group|Patients identified for treatment of symptomatic aortic sten
2970729|NCT02759224|Other|Arm A (Lafutidine and Irsogladine maleate --> BRI-1501)|Subjects of Arm A take Lafutidine and Irsogladine maleate Individual tablets at 1st day as period I. And then, after wash out for 35 days, as period II, subjects of Arm A take a BRI-1501 tablet at 36th day
2970730|NCT02759224|Other|Arm B (BRI-1501 --> Lafutidine and Irsogladine maleate)|Subjects of Arm B take a BRI-1501 tablet at 1st day as period I. And then, after wash out for 35 days, as period II, subjects of Arm B take Lafutidine and Irsogladine maleate Individual tablets at 36th day
2970731|NCT02759211|Active Comparator|Forwards Walking Group (FWG)|The intervention will consist of three (3), treadmill exercise sessions per week, for eight (8) weeks, for a total of 24 exercise sessions.
2970732|NCT02759211|Experimental|Backwards Walking Group (BWG)|The intervention will consist of three (3), treadmill exercise sessions per week, for eight (8) weeks, for a total of 24 exercise sessions.
2970733|NCT02759198|Experimental|YH23537|YH23537 750/1500/3000mg
2970734|NCT02759198|Active Comparator|Celebrex|Celecoxib 200mg
2970735|NCT02759198|Placebo Comparator|Placebo|YH23537 Placebo
2970736|NCT02759185|Experimental|High THC marijuana|Provided with up to 1.8 g of marijuana with more tetrahydrocannabinol than cannabidiol
2970737|NCT02759185|Experimental|High CBD marijuana|Provided with up to 1.8 g of marijuana per day of marijuana with more cannabidiol than tetrahydrocannabinol
2970738|NCT02759185|Experimental|High THC/high CBD marijuana|Provided with up to 1.8 g per day of marijuana with an approximately equal amount of tetrahydrocannabinol and cannabidiol
2970739|NCT02759185|Placebo Comparator|Placebo marijuana|Provided with 1.8 per day of marijuana with very low levels of tetrahydrocannabinol and cannabidiol
2970740|NCT02759172|Experimental|Safety Planning Intervention|Brown and Stanley's Safety Planning Intervention (SPI) is a brief, adjunctive intervention designed to reduce subsequent suicidal behavior in high-risk populations. The core element of SPI is the collaborative development of the Safety Plan, which is a prioritized written list of coping strategies and supports that individuals can use during or preceding suicidal crises. In this study, safety planning will occur during pretrial jail detention, with telephone follow-up in the community to conduct risk assessment, review the Safety Plan, problem-solve obstacles to treatment, and assist with linkage to services.
2970741|NCT02759172|No Intervention|Standard Care|Standard Care for pretrial jail detainees is assessment of risk and stabilization to the extent possible during their jail detention. No post-release community follow-up is typically provided. This study will augment standard care with regular assessment and emergency referral post-release, as well as provision of a list of community resources.
2970742|NCT02759159|Experimental|AD-true acupuncture|"True acupuncture at the four-gateacupoints will be administered on AD patients"
2970743|NCT02759159|Sham Comparator|AD-sham acupuncture|"Sham acupuncture at the four-gateacupoints will be administered on AD patients"
2970746|NCT02759146|Experimental|Reflexology|Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
2970747|NCT02759146|Experimental|Mindfulness Meditation|Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
2970748|NCT02759146|No Intervention|Control|Control - no intervention
2970749|NCT02759133|Active Comparator|A - A standard Localization technique|A standard Localization technique : Metal wire as localization technique for breast cancer surgery
2970750|NCT02759133|Experimental|B - Experimental Localization technique|Experimental Localization technique: Radioactive Iodine seed as localization technique for breast cancer surgery
2970751|NCT02759120|Experimental|Antimicrobial therapy|Co-trimoxazole OR doxycycline
2970752|NCT02759120|Other|Standard of care|Standard of care for patients with IPF for comparison
2970753|NCT02759107|Experimental|LY3298176 (Part A)|Escalating doses of LY3298176 administered subcutaneously (SC) once in healthy participants.
2970754|NCT02759107|Placebo Comparator|Placebo (Part A)|Placebo administered SC once in healthy participants.
2970755|NCT02759107|Experimental|LY3298176 (Part B)|Escalating doses of LY3298176 administered SC once weekly for four weeks in healthy participants.
2970756|NCT02759107|Placebo Comparator|Placebo (Part B)|Placebo administered SC once weekly for four weeks in healthy participants.
2970757|NCT02759107|Active Comparator|Dulaglutide (Part B)|Dulaglutide administered SC once weekly for four weeks in healthy participants
2970758|NCT02759107|Experimental|LY3298176 (Part C)|Two dose levels of LY3298176 administered SC once weekly for four weeks in participants with T2DM.
2970759|NCT02759107|Placebo Comparator|Placebo (Part C)|Placebo administered SC once weekly for four weeks in participants with T2DM.
2970760|NCT02759094|Experimental|Treatment with RefluxStop device|A standard laparoscopic approach will be used to reposition the lower oesophageal sphincter (LES) to its intra-abdominal position. The RefluxStop device will be then positioned and fixed in the gastric funds to ensure intra-abdominal positioning of the GEJ at all time
2970761|NCT02759081|Active Comparator|water exchange|The air was turned off at the beginning of colonoscopy. Water was infused and suctioned at the same time during insertion. The air was turned on when the colonoscope reached the cecum.
2970762|NCT02759081|Experimental|cap-assisted water exchange|Cap was mounted to the tip of the colonoscope when water exchange was performed.
2970763|NCT02759068|Experimental|patients behavior|Behavior (motor reaction) to stimuli (sounds and odors)
2970764|NCT02759068|Active Comparator|healthy volunteers behavior|Behavior (motor reaction) to stimuli (sounds and odors)
2970765|NCT02759055|Experimental|Clinical Decision Support (CV Wizard)|In the Intervention arm, primary care providers will be provided with an EHR-linked, Web-based clinical decision support system that identifies patients with prediabetes and provides patients and their primary care providers personalized, evidence-based CDS and follow up to reduce risk of heart attacks or stroke, optimizing management and follow up of pre-diabetes patients with uncontrolled CV risk factors.
2970766|NCT02759055|No Intervention|Usual Care|In the No Intervention arm, patients receive usual care from their primary care clinic and care providers.
2970767|NCT02759029|Active Comparator|Susceptibility-guided group|Drugs according to antimicrobial susceptibility-guided treatment
2970768|NCT02759029|Sham Comparator|triple therapy group|Drugs - Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk
2970769|NCT02759029|Sham Comparator|concomitant therapy group|Drugs - Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk
2970770|NCT02759016|Experimental|BI 836826|BI 836826 administered in combination with Standard of Care Ibrutinib
2970771|NCT02759003|Active Comparator|inpatients group|"In-hospital nightime NIV initiation. For the inpatients Group, NIV was initiated in the respiratory wards of the two hospitals and continued during night for a minimum of 4 hours/night.~Inpatients had a 24-h availability of health staff care. During the night, they had nurses and physicians available on-hand."
2970772|NCT02759003|Experimental|outpatients group|"Home nightime NIV initiation. For the outpatients group, diurnal NIV was initiated during a scheduled visit in a hospital dedicated room(at least 4 hours/day of care), the trial proceeded at home during the night with a personal caregiver.~A minimum of 4 hours/night was required. No support during the night was provided to these patients."
2970773|NCT02758990|Experimental|Predictions: BMI vs. Broccoli|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970774|NCT02758990|Experimental|Predictions: BMI vs. Caffeine|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970775|NCT02758990|Experimental|Predictions: BMI vs. Coffee|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970776|NCT02758990|Experimental|Predictions: BMI vs. Spinach|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970777|NCT02758990|Experimental|Predictions: BMI vs. Vitamin A|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970778|NCT02758990|Experimental|Predictions: BMI vs. Vitamin C|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970779|NCT02758990|Experimental|Predictions: Headache vs. Vitamin B6|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970828|NCT02758743|Experimental|Acetium Lozenge|Acetium lozenge (L-cysteine 3mg) is used in context of each cigarette smoked.
2971153|NCT02756624|Experimental|AC-170 0.24%|1 drop in each eye 3 times daily for up to 6 weeks
2970780|NCT02758990|Experimental|Predictions: Headache vs. Vitamin C|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970781|NCT02758990|Experimental|Predictions: Headache vs. Nicotinamide|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970782|NCT02758990|Experimental|Predictions: Headache vs. Axon Eyewear|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970783|NCT02758990|Experimental|Predictions: Rhinitis vs Broccoli|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970784|NCT02758990|Experimental|Predictions: Rhinitis vs Caffeine|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970785|NCT02758990|Experimental|Predictions: Rhinitis vs Chocolate|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970786|NCT02758990|Experimental|Predictions: Rhinitis vs Coffee|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970787|NCT02758990|Experimental|Predictions: Rhinitis vs Vitamin A|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970788|NCT02758990|Experimental|Predictions: Insomnia vs Axon Eyewear|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970789|NCT02758990|Experimental|Predictions: Insomnia vs Vitamin A|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970790|NCT02758990|Experimental|Predictions: Insomnia vs Vitamin E|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970791|NCT02758990|Experimental|Predictions: Insomnia vs Nicotinamide|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970792|NCT02758990|Experimental|Predictions: Insomnia vs Vitamin D3|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970793|NCT02758990|Experimental|Predictions: Joint pain vs Broccoli|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970794|NCT02758990|Experimental|Predictions: Joint pain vs Caffeine|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970795|NCT02758990|Experimental|Predictions: Joint pain vs Coffee|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970796|NCT02758990|Experimental|Predictions: Joint pain vs Spinach|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2970797|NCT02758977|Experimental|ALPPS|"ASSOCIATING LIVER PARTITION WITH PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY (ALPPS)~Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) is performed according to local practice in the respective centers. Preconditions to participation are experience with major liver resections and documentation of having performed at least 5 ALPPS cases prior to participation due to the learning curve with this quite complex procedure.~The amount of transsection (in-situ split/liver partition) in Step 1 is left to the participating center, no minimal % of transsection is specified."
2970882|NCT02758431|Active Comparator|Group 2: Acyline plusTestosterone|Acyline plus transdermal testosterone gel plus placebo tablet.
2970798|NCT02758977|Active Comparator|TWO STAGE HEPATECTOMY|"TWO STAGE HEPATECTOMY (TSH)~Two-Stage Hepatectomy is defined as:~Partial resection + portal vein ligation (RES PVL)~Partial resection + secondary portal vein embolization (RES PVE). Followed by (extended) hemihepatectomy after an interval to induce hypertrophy of the liver.~Conventional Two- Stage Hepatectomies will be standard procedures of the centers participating in the study."
2970799|NCT02758951|Experimental|Cytoreductive surgery with perioperative systemic therapy|Neoadjuvant combination chemotherapy (FOLFOX or CAPOX) with bevacizumab, followed by CRS + HIPEC, followed by adjuvant combination chemotherapy (FOLFOX or CAPOX).
2970800|NCT02758951|Other|Cytoreductive surgery with HIPEC alone|Cytoreductive surgery with HIPEC
2970801|NCT02758938|Experimental|Patient Subjects|Patients that are part of the UW LUTD Program (n=30) will undergo 3 weekly biofeedback sessions each lasting 1 hour. All interactive biofeedback sessions will be conducted by American Family Children's Hospital nurses that are experienced in standard biofeedback techniques. After the patient has completed all of the biofeedback sessions, he/she will complete a feedback form about their satisfaction with the device.
2970802|NCT02758938|Experimental|Biofeedback Nurse Subjects|"The nurses (n=3) involved in the biofeedback portion of the UW LUTD Program will undergo a Nurse Training Session where they will be asked to think aloud while completing an outlined scenario. Their feedback will be used to update the software to make it more user friendly. After the session, they will be asked to complete the System Usability Scale (SUS). Additionally, after guiding patients through biofeedback sessions using the new software, they will be asked to complete the Nurse Feedback Form."
2970803|NCT02758938|Experimental|Biofeedback Physician Subject|The physician (n=1) that oversees the UW LUTD Program will assess data from each patients session. Based on the information he gathers from the session, he will complete a feedback form. Each patient's EMG activity will be stored by the video game which will allow the physician to review the patient's performance. Specifically, the physician will look for the minimum relaxation and the maximum contraction levels of the patient throughout play as well as muscular isolation.
2970804|NCT02758938|Experimental|Focus Group Subjects|A Focus Group session will involve the physician involved in this study, an advisor on the project and staff involved in the project as well as three random individuals outside of the project (n=7). These individuals will provide feedback on the software that will be used to improve the software.
2970805|NCT02758925|Experimental|DLBCL patients|they will receive a combination of: Rituximab 375mg/m2 IV at Day 1 Bendamustine 90mg/m2 IV at Day 1 and 2 Cytarabine 1000mg/m2 IV at day 2 every 21 days for 6 cycles
2970806|NCT02758912|Experimental|arm 1, Cardionat®|oral intake of study drug capsules at a dose of 1 g per day for 3 weeks.
2970807|NCT02758912|Experimental|arm 2, Cardionat®|oral intake of study drug capsules at a dose of 2 g per day for 3 weeks.
2970808|NCT02758899||Diabetic Patients|Patients with diagnosis of type I or type II diabetes, in addition to clinical diagnosis of cervical myelopathy or cervical spondylosis requiring anterior cervical discectomy and fusion.
2970809|NCT02758899||Control Patients|Patients with no diagnosis of diabetes, with a clinical diagnosis of cervical myelopathy or cervical spondylosis requiring anterior cervical discectomy and fusion.
2970810|NCT02758886|Experimental|Stress reduction method|Participants randomized into the PYSA group engaged in a 10 minute direct interaction with the animals (dogs and cats) of the Pet Your Stress Away program
2970811|NCT02758886|Placebo Comparator|Control|Participants randomized into the Control group watched a 10 minute slide show of dog and cat photos
2970812|NCT02758886|No Intervention|Non-treatment|Participants randomized into the No-treatment group silently waited for 10 minutes without engaging in any physical or electronic social interactions.
2970813|NCT02758886|Placebo Comparator|Observation|Participants randomized into the observation group observed 10 minutes of others in the general PYSA program petting cats and dogs, while they 'waited in line' for there turn.
2970814|NCT02758873|Experimental|Personalised Medicine|If an add-on controller is required, young people in this arm will be prescribed personalised medicine by results of the genotyping for the adrenergic beta2-receptor gene (ADRB2). Health professional's will be advised to prescribe inhaled salmeterol as 'add-on' controller if trial participants have the Gly/Gly variant on ADRB2, and montelukast if they have Arg/Arg or Arg/Gly variant on ADRB2.
2970815|NCT02758873|Active Comparator|Standard care|If an add-on controller is required, young people will be prescribed medication as per the choice of the primary or secondary care physician, without knowledge of genotypic status.
2970816|NCT02758847|Other|Critical Limb Ischemia (CLI) and Tissue Loss|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Patients with CLI will receive either Angiogram, Medtronic DCB (paclitaxel)/stent or Angiogram, Bard DCB (paclitaxel)/stent
2970817|NCT02758821|Other|CRP-Control|The health care provider will manage the patient using standard guidelines. No CRP will be measured onsite
2970818|NCT02758821|Other|CRP-A|CRP will be measured by a study nurse onsite and the result will be communicated to the health care provider.
2970819|NCT02758821|Other|CRP-B|CRP will be measured by a study nurse onsite and the result will be communicated to the health care provider.
2970820|NCT02758795|Placebo Comparator|CONTROL|A placebo nutrient drink with no anti-inflammatory bioactivity (measure by cell bioassay in vitro) Dose provided per kg of body mass: 0.33g protein mixed in 500ml of water as a protein 'shake' Energy ~ 160 kcal
2970821|NCT02758795|Active Comparator|NUTRIENT|A nutrient drink with confirmed anti-inflammatory bioactivity (measured by cell bioassay in vitro) Dose provided per kg of body mass: 0.33g protein mixed in 500ml of water as a protein 'shake' Energy ~ 160 kcal
2970822|NCT02758782|Active Comparator|Golimumab monotherapy|Treatment with 50 mg Golimumab subcutaneous once monthly
2970823|NCT02758782|Active Comparator|Golimumab combined with Celecoxib|Treatment with Golimumab 50 mg subcutaneous once monthly in combination with Celecoxib 400 mg orally every day
2970824|NCT02758769||ORENCIA with Exposure|ORENCIA with Exposure
2970825|NCT02758756|Active Comparator|Massage|Subjects assigned to Arm 1 will receive two massage treatments approximately two weeks apart.
2970826|NCT02758756|Experimental|Two Reiki Tx|Subjects assigned to Arm 2 will receive two Reiki treatments approximately two weeks apart.
2970827|NCT02758756|Experimental|Four Reiki Tx|Subjects assigned to Arm 3 will receive four Reiki treatments approximately 1 week apart.
2971154|NCT02756624|Placebo Comparator|AC-170 Vehicle|1 drop in each eye 3 times daily for up to 6 weeks
2970829|NCT02758743|Placebo Comparator|Placebo|Identical in appearance with Acetium lozenge, placebo lozenges will be used in the same manner as in experimental arm.
2970830|NCT02758730|Experimental|AFFITOPE® PD01A + Adjuvant|3 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
2970831|NCT02758730|Placebo Comparator|Adjuvant without active component|3 injections of Placebo once every 4 weeks
2970832|NCT02758717|Experimental|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for 7 courses and 6-8 weeks in course 8 in the absence of disease progression or unacceptable toxicity.
2970833|NCT02758704|Experimental|High-Stress (HS)|In the HS environment, the resident will be exposed to various stressors. There will be the presence of audio alarms as well as the presence of a senior physician who will be supervising the performance of the resident. In addition, the mannequin will be slightly unstable which will be reflected in its oxygen saturation dropping throughout the first 30 seconds the procedure.
2970834|NCT02758704|Active Comparator|Low-Stress (LS)|In the LS environment, there will be absence of audio (alarms), physical (third-party supervisor, nurse and respiratory therapist) and situational (unstable infant) stressors.
2970835|NCT02758691|Experimental|Intranasal Insulin|Healthy participants will self-administer 20 IU of Humulin® R U-100 with the Precision Olfactory Delivery (POD) delivery device and complete a memory task in an fMRI (functional Magnetic Resonance Imaging) scanner.
2970836|NCT02758691|Placebo Comparator|Saline Placebo|Healthy participants will self-administer a saline solution with the Precision Olfactory Delivery (POD) delivery device and complete a memory task in an fMRI (functional Magnetic Resonance Imaging) scanner.
2970837|NCT02758678||1-patients with operating tumor|"1- 23 patients with operating tumor; In 1 group the specimens of blood will be collected day before surgery and 1-2 month after surgery. Will be collected: histopathology outcomes - type carcinoma, tumore volume and before surgery: morphology and coagulation system. Will be assessed correlation between mentioned above factors and concentration of P-selectin.~Will be compared concentration of P-selectin in 3 groups of patients.~Serum separation and Raman spectroscopy analysis. A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. The Raman spectra (RS) of the solid residues from serum samples were measurement by placing 10µl of serum from the aliquots onto an aluminium substrate and allowed to dry for at least 30 min."
2970838|NCT02758678||2-patients with advanced desease.|"2- ten patients with advanced and metastatic disease who received palliative RT (RT - radiotherapy);~In 2 group - the specimens of blood we collected before palliative treatment-radiotherapy. Will be collected: histopathology outcomes - type carcinoma, morphology. Will be assessed correlation between mentioned factors and concentration of P-selectin. Will be compared concentration of P-selectin in 3 groups of patients. Serum separation and Raman spectroscopy analysis:~A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens.The Raman spectra (RS) assessed as above"
2970839|NCT02758678||3-patients with inoperable disease|"In group 3 - the specimens of blood we collected before radical treatment and one month after completion treatment. Will be collected: histopathology outcomes - type carcinoma, morphology. Will be assessed correlation between mentioned above factors and concentration of P-selectin. Will be compared concentration of P-selectin in 3 groups of patients. Serum separation and Raman spectroscopy analysis:~A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. The Raman spectra (RS) of the solid residues from serum samples were measurement by placing 10µl of serum from the aliquots onto an aluminium substrate and allowed to dry for at least 30 min."
2970840|NCT02758665|Experimental|Obinutuzumab, Ibrutinib, Venetoclax|Obinutuzumab i.v.: Cycle 1 (3000 mg), Cycle 2-6 (1000 mg) Ibrutinib (tablet): Cycle 1-15 (420 mg daily) Venetoclax (tablet): Cycle 1 (last 7 days 20 mg daily), Cycle 2 (ramp up 50 mg to 400 mg) Cycle 3-12 (400 mg daily)
2970841|NCT02758639|Experimental|W & W Intervention|Wonders & Worries Psychosocial intervention is a 6 week group or individual sessions for children who have a parent with cancer focusing on psycho-educational information about cancer, treatment and its side effects, feelings expression, positive coping strategies, and family communication about the illness.
2970842|NCT02758639|Other|Wait list control|Wait list group will complete baseline, 6 week and 8 week follow up measures and then will be enrolled to receive W & W intervention.
2970843|NCT02758626|Active Comparator|Ataluren Followed By Placebo|Cross Over Design: Treatment Period 1 with Ataluren (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Placebo Treatment Period 2 (Week 16 to Week 28), and Follow-up (Week 28 to Week 32).
2970844|NCT02758626|Active Comparator|Placebo Followed by Ataluren|Treatment Period 1 with Placebo (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Treatment Period 2 with Ataluren(Week 16 to Week 28).
2970845|NCT02758613|Experimental|2 milligram (mg) Baricitinib|2mg Baricitinib administered orally, once on Day 1 and once a day (QD) on Days 4 through 10 (7 days).
2970846|NCT02758613|Experimental|4mg Baricitinib|4mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
2970847|NCT02758613|Experimental|10mg Baricitinib|10mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
2970848|NCT02758613|Placebo Comparator|Placebo|Placebo matching Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
2970849|NCT02758600|Experimental|LVEF < 45%|Patients with left ventricular dysfunction will be evaluated before and 6 days after after coronary arterial bypass graft surgery. Postoperatively, subjects will be submitted to a portable cycle ergometer exercise protocol from the first day until hospital discharge.
2970850|NCT02758600|Experimental|LVEF > 45%|Patients without left ventricular dysfunction will be evaluated before and 6 days after after coronary arterial bypass graft surgery. Postoperatively, subjects will be submitted to a portable cycle ergometer exercise protocol from the first day until hospital discharge.
2970851|NCT02758587|Experimental|Dose - escalation|"Does-escalation in an all-comers phase I population, with treatment-refractory advanced solid malignancies, unselected by tumour type. Two cohorts of up to evaluable 6 patients in each:~Cohort 1: 200mg (IV) pembrolizumab every 3 weeks; plus 200mg (oral) defactinib twice daily~Cohort 2: 200mg (IV) pembrolizumab every 3 weeks; plus 400mg (oral) defactinib twice daily~Interventions:~Drug: Defactinib~Drug: Pembrolizumab"
2970883|NCT02758431|Active Comparator|Group 3: Acyline plus Testosterone plus Arimidex)|Acyline plus transdermal testosterone gel plus Aromatase inhibitor (Arimidex) oral.
2970852|NCT02758587|Experimental|Pancreatic|Pancreatic expansion for response assessment (single arm). Optional paired biopsies prior to treatment and after 14 days of treatment. All would have concurrent therapy with pembrolizumab + defactinib (VS-6063) from the start (c.f. NSCLC & mesothelioma expansions below). 15 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 6
2970853|NCT02758587|Experimental|NSCLC|NSCLC paired-biopsy expansion for tissue biomarkers. Mandatory biopsies prior to treatment and after around 14 days of treatment. 1:1 randomised split of patients having their mandatory on-treatment biopsy after concurrent therapy, or after a defactinib (VS-6063) monotherapy run-in. 16 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 11.
2970854|NCT02758587|Experimental|Mesothelioma|Mesothelioma paired-biopsy expansion for tissue biomarkers. Mandatory biopsies prior to treatment and around 14 days of treatment. 1:1 randomised split of patients having thier on-treatment biopsy after concurrent therapy, or after defactinib (VS-6063) monotherapy run-in. 16 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 11.
2970855|NCT02758574|Active Comparator|CDT without ultrasound acceleration|Standard Catheter-Directed Thrombolysis: Utilization of a standard infusion catheter, placed at the site of pulmonary thrombus. The catheter will be used for the delivery of thrombolytic medications to treat/dissolve pulmonary embolus
2970856|NCT02758574|Experimental|CDT ultrasound accelerated|Ultrasound Accelerated Catheter-Directed Thrombolysis: Utilization of an infusion catheter that incorporates an ultrasound emitting wire both placed at the site of pulmonary thrombus. The catheter will be used for the delivery of thrombolytic medications with the ultrasound emitting wire activated to treat/dissolve pulmonary embolus
2970857|NCT02758561|No Intervention|Standard of care|Standard of care
2970858|NCT02758561|Experimental|Workshop|90 minute workshop on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (POP)
2970859|NCT02758548|Other|Capillary Blood Sampling|Capillary blood sampling, collected as two fingerprick samples with POCT device and two venous samples
2970860|NCT02758535|Experimental|Core needle biopsy with coaxial method|The patients undergo renal biopsy with a coaxial Tru-Cut needle
2970861|NCT02758535|Experimental|Core needle biopsy with noncoaxial method|The patients undergo renal biopsy with a noncoaxial Tru-Cut needle
2970862|NCT02758522|Active Comparator|Once-daily insulin|60% of total dose of insulin as NPH insulin in the once-daily regimen was administered subcutaneously before breakfast. Also, 40% in rapid insulin before meals (every 8 hours).
2970863|NCT02758522|Active Comparator|Twice-daily insulin|60% of total dose of insulin as NPH insulin in the twice-daily regimen it was given before breakfast and before dinner. Also, 40% in rapid insulin before meals (every 8 hours).
2970864|NCT02758522|Active Comparator|Triple-daily insulin|60% of total dose of insulin as NPH insulin in the triple daily regimen it was administered before each meal. Also, 40% in rapid insulin before meals (every 8 hours).
2970865|NCT02758509||PEG/RBV|Pegylated interferon alfa-2a 180 microg/week plus ribavirin 800-1200 mg during 48 weeks according to routine practice and European Guidelines (EASL recommendations 2011)
2970866|NCT02758509||PEG/RBV+BOC or TVR|Boceprevir 800 mg/8h or Telaprevir 750 mg/8h plus Pegylated interferon alfa-2a 180 microg/week plus ribavirin 800-1200 mg during 48 weeks according to routine practice and European Guidelines (EASL recommendations 2014)
2970867|NCT02758509||IF-DAAs|"Interferon-free direct-acting antiviral combinations according to routine practice and European Guidelines (EASL recommendations 2015)~Fixed-dose combination of sofosbuvir (400 mg) and ledipasvir (90 mg) daily +/- ribavirin 12-24 weeks~Fixed-dose combination of ombitasvir (75 mg), paritaprevir (12.5 mg) and ritonavir (50 mg) in one single tablet (two tablets once daily) and dasabuvir (250 mg) (one tablet twice daily) with ribavirin 800-1200 mg 12 weeks (Genotype 1b) or 24 weeks (genotype 1a)~Daily sofosbuvir (400 mg) and daily simeprevir (150 mg) +/- ribavirin 12-24 weeks~Daily sofosbuvir (400 mg) and daily daclatasvir (60 mg) +/- ribavirin 12-24 weeks"
2970868|NCT02758496||ASD Subjects|Approximately two hundred (200) male and female subjects of any ethnic background between the ages of 2-20 years old seen at the Brain Treatment Center (BTC) between 2010 and 2015.
2970869|NCT02758496||Healthy Controls|Twenty (20) male and female subjects of any ethnic background between the ages of 2-20 years old with 'neurotypical' EEGs will be selected for comparison to the ASD group
2970870|NCT02758483|Other|Test diet|"Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).~Note: Both diets had the same calories, carbohydrates, proteins, fat, and fiber, and were prescribed according to the American Diabetes Association recommendations."
2970871|NCT02758483|Other|Control diet|"Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).~Note: Both diets had the same calories, carbohydrates, proteins, fat, and fiber, and were prescribed according to the American Diabetes Association recommendations."
2970872|NCT02758470|Experimental|Acetazolamide|Participants will be dosed 250mg acetazolamide (p.o.) three times per day for two days prior to and a single dose on the morning of the experimental day.
2970873|NCT02758470|Experimental|Methazolamide|Participants will be dosed 100mg Methazolamide (p.o.) two times per day separated by a placebo dose for two days prior to and a single dose on the morning of the experimental day. The placebo dose is used to match the timing and number of pills taken between all arms of the study.
2970874|NCT02758470|Placebo Comparator|Placebo|Participants will take three placebo pills per day for two days prior to and a single dose on the morning of the experimental day.
2970875|NCT02758457|Active Comparator|metal-based restorations|single crown with a metal framework and pressed ceramic
2970876|NCT02758457|Experimental|zirconia-based restorations|single crown with a zirconia framework and pressed ceramic
2970877|NCT02758444|Active Comparator|Micronutrient Powder (MNP) + 15 mg Zn|1 sachet of Micronutrient Powder (MNP) + 15 mg Zn will be added to a single meal on study day 8
2970878|NCT02758444|Active Comparator|MNP + 10 mg Zn|1 sachet of MNP + 10 mg Zn will be added to a single meal on study day 8
2970879|NCT02758444|Active Comparator|MNP + 5 mg Zn|1 sachet of MNP + 5 mg Zn will be added to a single meal on study day 8
2970880|NCT02758444|Placebo Comparator|MNP without Zn|1 sachet of MNP without Zn will be added to a single meal on study day 8
2970881|NCT02758431|Placebo Comparator|Group 1: Acyline plus placebo (No Testosterone Add-Back)|Acyline plus placebo gel and placebo tablet.
2970885|NCT02758418|No Intervention|Waiting list control group.|Participants of this group are able to access the treatment program after 7 weeks of waiting period. After this waiting period of 7 weeks, those participants still interested in receiving assistance are randomly assigned to one of two intervention conditions (Online Computerized Program group or Bibliotherapy group).
2970886|NCT02758405|Experimental|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2970887|NCT02758405|Experimental|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2970888|NCT02758405|Experimental|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2970889|NCT02758405|Experimental|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2970890|NCT02758392|Experimental|Dose 1: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 0.1 milligram/kilogram (mg/kg) or Placebo Intravenously (IV) on Day 1.
2970891|NCT02758392|Experimental|Dose 2: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 0.3 mg/kg or Placebo IV on Day 1.
2970892|NCT02758392|Experimental|Dose 3: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 1 mg/kg or Placebo IV on Day 1.
2970893|NCT02758392|Experimental|Dose 4: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 3 mg/kg or Placebo IV on Day 1.
2970894|NCT02758392|Experimental|Dose 5: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 10 mg/kg or Placebo IV on Day 1.
2970895|NCT02758392|Experimental|Dose 6: JNJ-61178104 OR Placebo SC|Participants will receive either JNJ-61178104 1 mg/kg or Placebo Subcutaneously (SC) on Day 1.
2970896|NCT02758379|Experimental|Shockwave Coronary Lithoplasty System|Patients receive Lithoplasty treatment prior to placement of coronary stent. IVUS or OCT documents patency pre and post Lithoplasty. Patient is followed for patency at discharge, 30 days and 6 months following treatment.
2970897|NCT02758366|Experimental|Doxorubicin|"Patients are treated with Weller-Stupp protocol: initial radiotherapy (1.8 Gy/die, days 1-5; total dose 54-60 Gy) with concomitant oral temozolomide (75mg/m2/die, days 1-7) per 6 weeks.~At week 10 (4 weeks after the chemo-radiotherapy treatment completion): 1 cycle of oral temozolomide (150-180 mg/m2, days 1-5)~At week 14 (8 weeks after the chemo-radiotherapy treatment completion) 1 cycle of prolonged infusion of Doxorubicin (25mg/m2/die in 24 hours, days 1-4; total cumulative dose 100 mg/m2).~At week 18 (4 weeks after the end of doxorubicin administration): 16 cycles of oral temozolomide (initial dose of 150 mg/m2 increasing to 180 mg/m2 days 1-5, 28-day cycle).~Oral valproic acid (20-30 mg/Kg/die bid) is administered from week 1 until the last treatment day."
2970898|NCT02758353|Experimental|Community distribution of SP|All the eligible pregnant women were reached with SP either at health clinic and/or at community/household level with sulphadoxine-pyrimethamine (SP). Alerts and reminders were sent to them by community-based health volunteers ahead of subsequent SP doses.
2970899|NCT02758340|Experimental|M=misoprostol|Patients who would receive Only oral misoprostol{(50 micrograms) tab cytotec ¼ tablets (Searle)}. All patients in this group will be given oral misoprostol 50 μg per dose. The dose will be repeated at 4 hours interval up to a maximum of 4 doses till labor is induced (3 contractions per 10 minutes). If labor is not established within 4 hours of the administration of the fourth dose, induction will be considered to be failed
2970900|NCT02758340|Experimental|M+F=MISOPROSTOL+FOLEY'S BALLOON CATHETER|All patients in this group will be explained the technique of foley's catheter ballooning and informed consent will be taken. The cervix will be visualized with the help of Cusco's speculum. The balloon will be inflated with about 30 cc of sterile water. The catheter will be pulled down to bring the balloon into the cervical canal and will be tapped around the thigh. Patients will also be given oral misoprostol 50 μg per dose. The dose will be repeated at 4 hours interval up to a maximum of 4 doses till labor is induced (3 contractions per 10 minutes).
2970901|NCT02758327|Experimental|TheraTears Lubrication Drop|TheraTears Lubricating Eye Drops to be instilled 1 drop in both eyes 4 times per day over a period of 8 weeks.
2970902|NCT02758314||Cases / NSCLC patients|"Evaluation of PD-1/PDL-1 expression.~Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations (CD3 + (CD4 +, CD8 +), B cells (CD19 + CD20 +), natural killer (NK) cells (CD16 + CD56 +) NK T-cells (CD3 + CD16 + CD56 + ) peripheral blood samples in 150 NSCLC, free treatment by flow cytometry.~Evaluate the expression of PD-1 / PD-L1 in tumor tissue obtained by biopsy of patients with NSCLC by immunohistochemistry.~The patients for the enrollment have to be diagnosed with advanced Non-Small Cell Lung Adenocarcinoma (clinical stages IIIA, IIIB and IV), treated at the Instituto Nacional de Cancerología (INCan) who had not received radiotherapy and / or chemotherapy prior to obtaining samples to analyze. ECOG performance status 0-2 and present evidence of measurable disease."
2970903|NCT02758314||Control / Healthy subjects|"Evaluation of PD-1/PDL-1 expression.~Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations (CD3 + (CD4 +, CD8 +), B cells (CD19 + CD20 +), natural killer (NK) cells (CD16 + CD56 +) NK T-cells (CD3 + CD16 + CD56 + ) peripheral blood samples in 50 samples, by flow cytometry.~Healthy subjects blood cells will be obtained from the blood bank at the Instituto Nacional de Cancerología (INCan)"
2970904|NCT02758301||Diagnostic|The Reveal LINQ™ Insertable Cardiac Monitor (ICM) device will be inserted in all subjects for continuous monitoring. After the Reveal LINQ™ device is inserted, the LINQ™ HF investigational RAMware will be downloaded to the LINQ™ ICM.
2970905|NCT02758288||New Protocol to treat BK viremia or BKVAN|Adult kidney recipients who are determined to have BK viremia with a BK PCR viral load over 500 copy post-transplant treated with a new treatment protocol, prospective data collection approach
2970906|NCT02758288||Standard Protocol to treat BK viremia or BKVAN|Adult kidney recipients who are determined to have BK viremia with a BK PCR viral load over 500 copy post-transplant treated with a traditional standard of care protocol, retrospective data collection approach
2970999|NCT02757651|No Intervention|Radiotherapy alone|Patients randomised to the control group in phase II will receive standard radiotherapy for breast cancer alone.
2970907|NCT02758275|Experimental|Teaching: Individual (5606)|People will receive an education session per month for a period of six months with an average duration of 30 minutes. These will be performed by nurses outside the collection of phase base line and follow-up measurements, previously trained for the purpose.
2970908|NCT02758275|No Intervention|Usual care|People will continue to receive usual care in the health center where they usually assist to medical controls.
2970909|NCT02758262|Active Comparator|Noninvasive brain stimulation: active|In active condition, subject will receive stimulation during all the duration of the experimental session.
2970910|NCT02758262|Placebo Comparator|Noninvasive brain stimulation: sham|In sham condition, subject will receive stimulation only at the beginning and at the end of the experimental session.
2970911|NCT02758249|Active Comparator|sevoflurane|patients under sevoflurane anesthesia
2970912|NCT02758249|Active Comparator|propofol|patients under propofol anesthesia
2970913|NCT02758223|Experimental|Treatment|Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65*10^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
2970914|NCT02758210|Experimental|Participants with MICRA Device|Participants that received the MICRA device prior to study enrollment will have monitored use of Smart Phone and Tablet at one study visit. Electrogram printing will take place during use of each device to see if there is any pacing inhibition or asynchronous pacing.
2970915|NCT02758197|Experimental|Interdisciplinary program including MBSR|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
2970916|NCT02758197|No Intervention|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
2970917|NCT02758184|Experimental|ROTEM Group|Patients who are randomized to receive ROTEM
2970918|NCT02758184|No Intervention|Control Group|Patients who are randomized not to receive ROTEM
2970919|NCT02758171|Experimental|Empagliflozin+Linagliptin FDC|One tablet fix dose combination (FDC)
2970920|NCT02758171|Active Comparator|Empagliflozin+Linagliptin single tablets|
2970921|NCT02758158|Experimental|Tri-modal imaging|Ultrasound and photoacoustic imaging of thyroid and adjacent lymph nodes. Imaging time: Approximately 30 minutes
2970922|NCT02758145|Active Comparator|Influenza vaccine information (G1)|During the recruitment visit at the occupational medicine unit between the 04/25/16 and the 10/31/16, the workers in this group (G1) in addition to their recruitment visit, will benefit from a short intervention given by the nurse concerning the flu, the advantages of the flu vaccination, and how they can be vaccinated in the institution. The nurse also transmits an information sheet concerning the benefits of the vaccination. 2 weeks after the beginning of the next flu vaccination campaign, they will receive a reminder letter to encourage vaccination.
2970923|NCT02758145|No Intervention|No information (G2)|Workers in the control group (G2) receive no intervention, only recruitment visit.
2970924|NCT02758132|Active Comparator|Alliance A031201|Denosumab plus enzalutamide, abiraterone and prednisone
2970925|NCT02758132|Active Comparator|Standard of Care|Denosumab plus enzalutamide alone
2970926|NCT02758119|Experimental|Serious Game|"Participants in the serious game group will be pre-trained before the hands-on sessions with the serious game Staying Alive, available at http://www.stayingalive.fr/index_us.html This game aims at teaching the management of an out-of-hospital cardiac arrest to the general public and health professionals. In this game, the player faces a man who has experienced sudden cardiac arrest and learns the appropriate behavior, movements and techniques that can contribute to saving his life. The first level of the game lasts 4-5 minutes, depending on the skills of the player. It is a point and click game, displayed on a PC computer."
2970927|NCT02758119|Active Comparator|Online course|Participants in the lecture group will watch individually a 4-min video of a PowerPoint presentation with voiceover narration, given in the medical school of Paris Descartes University. The video is edited to contain the same informations on out-of-hospital cardiac management than the serious game, with the same duration.
2970928|NCT02758106|Active Comparator|HFCW oscillation|"HFCWO was performed using a Vest Airway Clearance System Model 105 (Hill-Rom, St. Paul, Minnesota). HFCWO was applied to each subject at a frequency of 10-12 Hz and a pulse pressure setting of 1-2 selected for 15 minutes. The patients receiving HFCWO were placed in a semi-upright sitting position. Following HFCWO, suction was performed immediately via an endotracheal tube.~Changes to the initial ventilator settings during HFCWO were recorded before and at 5, 10 and 15 minutes. The variables included peak airway pressure, positive-end expiratory pressure, respiratory rate, fraction of inspired oxygen, inspiratory time, and sensitivity settings. Following HFCWO, suction was performed immediately via an endotracheal tube."
2970929|NCT02758106|Placebo Comparator|placebo intervention|the patients undergoing CCPT received cup-hand percussion with the hands positioned 3 inches from the chest, striking the chest with a waving movement while they were placed in right and left decubitus positions for 5-10 minutes each. Following CCPT, suction was performed immediately via an endotracheal tube.
2970930|NCT02758093|Experimental|Speed of Processing Training (10 hours)|Participants randomized to this arm will receive 10 hours of speed of processing training; this training is designed to improve the speed/accuracy in which they identify and locate visual information using five games/exercises from the POSIT Science Speed of Processing Training. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
2970931|NCT02758093|Experimental|Speed of Processing Training (20 hours)|Participants randomized to this arm will receive 20 hours of speed of processing training; this training is designed to improve the speed/accuracy in which they identify and locate visual information using five games/exercises from the POSIT Science Speed of Processing Training. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
2970932|NCT02758093|Sham Comparator|Internet Navigational (10 hours)|In this group, participants will receive 10 hours of Internet Navigation Training. Specifically, participants will be given instructional materials and exercises on how to navigate the Internet. For more computer savvy participants, they will be directed to the Thinks.com website. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
2970933|NCT02758080|Experimental|Matched|A molecular profile is identified using next generation sequencing. A participant in this arm is assigned to early clinical trial studying targeted agent, which is anticipated to have the best response rate.
2970934|NCT02758080|Other|Not matched|A participants in this arm is assigned to a clinical trial at physician's choice.
2970935|NCT02758067|Experimental|brexpiprazole|
2970936|NCT02758067|Experimental|risperidone|
2970937|NCT02758054|No Intervention|Usual Care|Participants will experience standard practice for lung cancer early detection.
2970938|NCT02758054|Experimental|Usual Care + Patient Navigation|Participants will experience standard practice for lung cancer early detection plus the intervention.
2970939|NCT02758041|Experimental|Sebacia Microparticles|
2970940|NCT02758028|Other|Brief counseling|"Peer counselling is delivered based on the queries and the needs of individual clients, according to the smoking status, dependency level and the perceived barriers of each individual with the use of motivational intervention approach. Counsellors will emphasizes the identification, use, and modification of personally relevant coping strategies. Advice will be provided on overcoming expected difficulty, withdrawal symptoms and relapse prevention during quitting.~The subjects will be followed up at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month via telephone assessing their smoking status and reinforce intervention."
2970941|NCT02758015|Active Comparator|Standardized Meal|Standardized meal given to patients.
2970942|NCT02758015|Experimental|Beatine PO (by mouth) 1500mg|Betaine (natural supplement)
2970943|NCT02758015|Experimental|Betaine PO (by mouth) 3000mg|Betaine (natural supplement)
2970944|NCT02758015|Experimental|Betaine PO (by mouth) 4500mg|Betaine (natural supplement)
2970945|NCT02758002|Experimental|Firm ablation for transitional AF rotors|All subjects will undergo this ablation, in addition to their standard PVI and Firm ablation for sustained AF rotors.
2970946|NCT02757989|Experimental|Patients with donor|Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling)
2970947|NCT02757989|No Intervention|Patients without donor|Patients without a matched donor
2970948|NCT02757976|Active Comparator|Conventional CRT|Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave > 7 mV, pacing threshold < 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging
2970949|NCT02757976|Experimental|LV endocardial CRT|Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
2970950|NCT02757963|Other|BPE/BPO screening and IPSS screening tool|Subjects presenting to a GP with a primary complaint other than LUTS will be screened for probable BPH using BPE/BPO screening tool and the IPSS screening tool. Subjects testing positive on the BPE/BPO screening tool or on the IPSS will be enrolled and offered a prostate specific antigen (PSA) test and urinalysis to establish a diagnosis of probable benign prostatic hyperplasia (BPH) (Part I - Visit 1). If the GP determines that the subject has probable BPH (IPSS >=8 and/or BPE/BPO questionnaire >=3 with a PSA >=2 ng per ml), the subject will proceed to Part II and will be scheduled for an urologist assessment and diagnostic tests to confirm or refute a BPH diagnosis and to assess risk of progression of BPH.
2970951|NCT02757950||Exposed cohort|Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) from May 2015 and who received one dose of Refortrix during 27 to 36 weeks of pregnancy (or as late as 20 days before delivery due date).
2970952|NCT02757950||Unexposed cohort|Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) before implementation of the maternal immunization program in Brazil in September 2014 and who did not receive Tdap vaccination during pregnancy.
2970953|NCT02757937|Experimental|Health & Wellness Website|Subjects will receive access to an interactive health & wellness website for 9 months. The site aims to provide patients with information, tools, and resources to manage their chronic condition (e.g., Type 2 diabetes). The website will send subjects emails with tips to help them take better care of their diabetes, such as how to track diet and exercise habits and how to cook healthy meals. The study researchers will keep track of how many times subjects access the website and which parts of the site are most commonly viewed. Intervention subjects will receive questionnaires assessing engagement and satisfaction with the website. Subjects will also complete questionnaires at baseline and 2, 4, 6, and 9 months post-baseline.
2970954|NCT02757937|Other|Control Arm|Subjects in the control arm will continue with standard diabetes care without getting access to the intervention website. Subjects will also complete questionnaires at baseline and 2, 4, 6, and 9 months post-baseline. Control subjects will be granted access to the health & wellness website after the study is completed.
2970955|NCT02757924|Experimental|Infant formula supplemented with prebiotics|infant formula powder, feed ad libitum
2970956|NCT02757911|Experimental|open label|X vivo gene therapy
2970957|NCT02757898|Experimental|Biotin-Labeled Red Blood Cell (RBC) Infusion|Blood will be drawn from participants and labeled with biotin before being re-infused back to the participant. Blood samples will be obtained weekly over 10 weeks.
2970958|NCT02757885|Other|Bone Marrow Donor|Participants who are related marrow donors and are 2-4 (out of 8) human leukocyte antigen (HLA) antigen mismatched and towards whom the recipient does not have donor specific antibodies.
2970959|NCT02757885|Experimental|Bone Marrow Recipient|Participants with sickle cell disease (SCD) will receive bone marrow from a human leukocyte antigen (HLA) matched donor.
2970960|NCT02757872|Active Comparator|Vitamin D and fish oil|Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), 2000 IU per day. Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
2970961|NCT02757872|Active Comparator|Vitamin D and fish oil placebo|Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), 2000 IU per day. Dietary Supplement: Fish oil placebo Fish oil placebo
2970962|NCT02757872|Active Comparator|Vitamin D placebo and fish oil|"Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).~Dietary Supplement: Vitamin D placebo Vitamin D3 placebo"
2970963|NCT02757872|Placebo Comparator|Vitamin D placebo and fish oil placebo|Dietary Supplement: Vitamin D placebo Vitamin D3 placebo Dietary Supplement: Fish oil placebo Fish oil placebo
2970964|NCT02757859|Active Comparator|Arm I (EIPL-S)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after removal of tumor, patients receive extensive intraoperative peritoneal saline EIPL-S lavage 10 times over 15 minutes.
2970965|NCT02757859|Active Comparator|Arm II (EIPL-D)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after removal of tumor, patients receive extensive intraoperative peritoneal distilled water EIPL-D lavage 10 times over 15 minutes
2970966|NCT02757859|Sham Comparator|ARM III (NO LAVAGE)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy with no extensive lavage after removal of tumor.
2970967|NCT02757833|Other|Late Life Depressed Arm|Participants in the Late Life Depressed arm will have a confirmed diagnosis of late-life depression.
2970968|NCT02757833|Other|Healthy Control Arm|Participants in the Healthy Control Arm will have no history of mental illness.
2970969|NCT02757820|Active Comparator|LMA classic|Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
2970970|NCT02757820|Active Comparator|I-gel|Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
2970971|NCT02757820|Active Comparator|Air-Q|Patients will be anesthetized using Air-Q_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
2970972|NCT02757807|Experimental|Utilization of Serenita for Relaxation|Intervention is that Users continue to take their PDE-5 Inhibitor prior to sexual interaction and IN ADDITION Utilize the Serenita App daily and before any sexual encounters.
2970973|NCT02757794|Active Comparator|Cognitive remediation parents|
2970974|NCT02757794|Placebo Comparator|Remediation standard|
2970975|NCT02757781|No Intervention|Control Group|Group of healthcare professionals that NOT receive the intervention (community of practice)
2970976|NCT02757781|Experimental|Intervention group|Group of healthcare professionals that receive the intervention (community of practice)
2970977|NCT02757768|Experimental|Mirabegron|Continued treatment with tamsulosin hydrochloride after adding mirabegron
2970978|NCT02757768|Placebo Comparator|Placebo|Continued treatment with tamsulosin hydrochloride after adding placebo
2970979|NCT02757755|Experimental|Cohort 10^8|AB-SA01 (10^8) and Placebo
2970980|NCT02757755|Experimental|Cohort 10^9|AB-SA01 (10^9) and Placebo
2970981|NCT02757742||Non-ischemic cardiomyopathy|Non-ischemic cardiomyopathy patients with baseline cardiac magnetic resonance LVEF≤35%
2970982|NCT02757729|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 8 weeks
2970983|NCT02757729|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 8 weeks
2970984|NCT02757729|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 8 weeks
2970985|NCT02757729|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 8 weeks
2970986|NCT02757716|Other|Sleeve Gastrectomy|Obese patients who undergo sleeve gastrectomy fill in questionnaire
2970987|NCT02757716|Other|Roux-en-Y-Gastric Bypass|Obese patients who undergo roux-en-y-gastric bypass fill in questionnaire
2970988|NCT02757716|Other|Omega-Loop-Gastric Bypass|Obese patients who undergo omega-loop gastric bypass fill in questionnaire
2970989|NCT02757703|Active Comparator|somatostatin group|Somatostatin (Somatosan, BAG Health Care GmbH, Lich, Germany) was given by intravenous bolus (250 μg) followed by 250 μg/hour and continued for 3 days in group S.
2970990|NCT02757703|Placebo Comparator|terlipressin group|Terlipressin (Glypressin, Ferring GmbH, Kiel, Germany) was started at 2mg bolus injection and followed by 1 mg infusion every 6 hours for 3 days in group T.
2970991|NCT02757690|Active Comparator|2-dimenasional distal pancreatectomy|device: 2 dimensional laparoscopy of Olympus
2970992|NCT02757690|Experimental|3-dimenasional distal pancreatectomy|device : 3 dimensional laparoscopy of Olympus
2970993|NCT02757677||Longitudinal arm|Evaluate optic nerve head blood flow using the new OCT-A software in surgically and medically treated glaucoma patients and in different types of glaucoma
2970994|NCT02757677||24-h Intraocular pressure (IOP) arm|Evaluate the correlation between circadian IOP changes and optic nerve head blood flow using the new OCT-A software
2970995|NCT02757677||Surgery arm|Evaluate blood flow using the new OCT-A software in surgically treated glaucoma patients
2970996|NCT02757664|Active Comparator|Shock wave plus eccentric exercises|Shock wave therapy associated with eccentric exercises rehabilitation program.
2970997|NCT02757664|Placebo Comparator|Placebo plus eccentric exercises|Placebo associated with eccentric exercises rehabilitation program.
2970998|NCT02757651|Experimental|Radiotherapy + radiation sensitizer|Patients in phase I and patients randomised to the test group in phase II will receive standard radiotherapy for breast cancer + a radiation sensitizer
2971150|NCT02756650|Experimental|"Canakinumab.Ilaris®"|Patients will take canakinumab monthly
2971000|NCT02757638|Experimental|Healthy matched controls|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
2971001|NCT02757638|Experimental|Obese subjects|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~3 study days (one baseline, one pre-surgery, one post-surgery): muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
2971002|NCT02757625|Experimental|DA-9501|A single vial contains an injection solution with 2 mL of dexmedetomidine hydrochloride solution (100 µg/mL as dexmedetomidine) dissolved in physiological saline
2971003|NCT02757612|Active Comparator|Interventional|"Device Laser diode parameters: spot size of 0.04 mm2, average power (output) of 40 mW and 0.4 J per irradiation point, energy density of 10 J cm2, irradiation time of 10 seconds per point~1 session per week during 4 session"
2971004|NCT02757612|Sham Comparator|Comparator|"laser probe inactive for similar duration as for the laser diode group; only a beep sound was produced by the laser machine~1 session per week during 4 session"
2971005|NCT02757599|Other|Top-down (TD)|The group having the transvaginal ultrasound image top-down. During training and transfer test.
2971006|NCT02757599|Other|Bottom-up (BU)|The group having the transvaginal ultrasound image bottom-up. During training and transfer test.
2971007|NCT02757573|Experimental|Hypercarbia|Hypercarbia: PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
2971008|NCT02757560|Experimental|SFA versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour saturated fatty acids enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the SFA diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (SFA or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
2971009|NCT02757560|Experimental|MUFA versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour monounsaturated fatty acids (MUFA) enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the MUFA diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (MUFA or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
2971010|NCT02757560|Experimental|CARB versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour carbohydrate (CARB) enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the CARB diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (CARB or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
2971011|NCT02757547|Sham Comparator|Placebo TMS|A placebo stimulation coil is used that looks and sounds the same and provides a superficial scalp sensation without delivering significant coverage to brain.
2971012|NCT02757547|Experimental|Active TMS|Active transcranial magnetic stimulation at 90% of the resting motor threshold at 0.5 Hz is delivered over the seizure focus.
2971013|NCT02757534|Experimental|Domperidone|Study drug that all subjects will receive is Domperidone. Subjects will take 10 mg of the drug, up to four times a day for a dosage maximum of 40 mg. Duration of treatment period will depend on subject, they may take the drug for as long as they are able to tolerate it.
2971014|NCT02757521|Placebo Comparator|Placebo|50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
2971015|NCT02757521|Experimental|Nitrous Oxide|50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
2971016|NCT02757508|Active Comparator|Control|Vitamins/minerals-200 mg premix
2971017|NCT02757508|Experimental|Group 1|Vitamins/minerals + Milk Protein (8.75 g)-the milk protein is a skim milk powder with the sugar lactose.
2971018|NCT02757508|Experimental|Group 2|Vitamins/minerals + Milk/plant Protein (8.75g)-the milk protein is a skim milk protein powder and the plant protein is a rice protein concentrate and the sugar lactose.
2971019|NCT02757508|Experimental|Group 3|Vitamins/minerals + Milk Protein (4.38g)-the milk protein is a skim milk protein powder with the sugar lactose.
2971020|NCT02757495|No Intervention|Traditional|This will utilize the traditional method of performance of single dose caudal epidural block
2971021|NCT02757495|Experimental|Caudal dexmedetomidine|In this arm, single dose caudal epidural injection will be done patients in this arm will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%
2971022|NCT02757482|Experimental|intervention|Patient training
2971023|NCT02757482|No Intervention|control|no patient training
2971024|NCT02757469|Experimental|Yasmin|Pregnancies will occur while the women are taking oral contraceptives (Yasmin). The possible role of exogenous estrogens in sensitizing the granulosa cells to the effect of follicle-stimulating hormone and thereby inducing ovulation and conception in some women with premature ovarian failure is examined.
2971025|NCT02757456|Other|Aerobic Exercise program|Intervention of aerobic exercise
2971026|NCT02757456|Other|Control|no aerobic exercise program
2971151|NCT02756637||Prognostic|Patients with NLR who completed curative therapy (surgery with or without chemo)
2971027|NCT02757443|Experimental|Phosphocreatine|"Participants randomly assigned to the phosphocreatine arm receive:~after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV);~together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L);~immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV;~immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV"
2971028|NCT02757443|Placebo Comparator|Control|"Participants randomly assigned to the placebo arm receive:~after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes;~together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany);~immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes;~immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes"
2971029|NCT02757417|Active Comparator|Sodium Fluorescein|Patients will receive an intravenous dose of 0.25 mL of 10% (500 mg, 5 mL) sodium fluorescein at the time of cystoscope insertion, for a total dose of 25 mg. Cystoscopy will be performed in the standard fashion during the course of the operation.
2971030|NCT02757417|Active Comparator|oral phenazopyridine|Patients randomized to the phenazopyridine arm will be given a 200 mg pill with a sip of water in the pre-operative area 1 hour before their scheduled procedure. Cystoscopy will be performed in the standard fashion during the course of the operation.
2971031|NCT02757404|Experimental|Ultrasonography guidance|Ultrasonography guidance injection of Meditoxin®.
2971032|NCT02757404|Experimental|Electrical stimulation guidance|Electrical stimulation guidance injection of Meditoxin®.
2971033|NCT02757404|Experimental|Manual needle placement|Manual needle placement injection of Meditoxin®.
2971034|NCT02757391|Experimental|Adoptive T Cells + Pembrolizumab|"Participant has least 1 type of chemotherapy after enrollment in this study, but before T cell dose. Chemotherapy used at the discretion of treating physician.~On Day -2, participants receive Cyclophosphamide 300 mg/m2 by vein over 30 minutes 48 to 72 hours prior to T cell infusion as an outpatient procedure.~On Day 0 participants receive adoptive t cell infusion. A target of at 20 x 10^9 T cells / m2 infused.~On Day 0 to Day +13, participants receive low-dose IL-2 250,000 units/m2 subcutaneously every 12 hours within 6 hours of T cell infusion and continue for a total of 14 days (28 doses).~On Day +1 and Weeks 3, 6, 9, 12, and 15, Pembrolizumab 200 mg by vein.~Participant called twice by study staff in the 6 months after they are off the study."
2971035|NCT02757378|Experimental|Neuroplasticity Education Group|Patients who receive manual physical therapy treatment with a neuroplasticity explanation of the basis for the technique
2971036|NCT02757378|Active Comparator|Biomechanical Education Group|Patients who receive manual physical therapy treatment with a traditional, biomechanical explanation of the basis for the technique
2971037|NCT02757365|Experimental|the NSAIDs group|Patients in the this Group will received the aspirin 100mg qd until the experiment finished
2971038|NCT02757365|Experimental|the antibiotics group|Patients in the this Group will received the Levofloxacin 0.5g qd for 4~8 weeks
2971039|NCT02757365|Experimental|the NSAIDs+antibiotics group|Patients in the this Group will received the Levofloxacin 0.5g qd for 4~8 weeks and aspirin 100mg qd until the experiment finished
2971040|NCT02757365|No Intervention|the control group|No treatment
2971041|NCT02757352|Experimental|Q2W Ixekizumab|Ixekizumab given subcutaneously (SC) every two weeks (Q2W) to week 52.
2971042|NCT02757352|Experimental|Q4W Ixekizumab|Ixekizumab given SC every four weeks (Q4W) to week 52.
2971043|NCT02757352|Placebo Comparator|Placebo|Placebo given SC Q2W to week 52.
2971044|NCT02757339||Women with History of Childhood Abuse|The study will enroll up to 90 female patients with either DID or PTSD ages 18-89
2971045|NCT02757339||Healthy Control Group|We will recruit up to 60 control subjects matched for demographics (age, race, gender).
2971046|NCT02757326|Experimental|Phase 1b/II|"For Phase 1b, the planned ABC294640 doses for the escalation phase are: 250, 500, and 750 mg BID given continuously. The dose will be given under fasting conditions (at least 1 hour before or 2 hours after eating). One cycle is 28 days of treatment.~For phase II study, the patients will be treated with single agent ABC294640 at the MTD determined from the phase IB study (or at the highest dose used, if MTD is not reached) until disease progression or intolerable toxicity occurs in an individual patient."
2971047|NCT02757313|Experimental|Regular Users|People who use marijuana regularly will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the study visits.
2971048|NCT02757313|Experimental|Occasional Users|People who use marijuana occasionally will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the study visits.
2971049|NCT02757300|Experimental|Hypopharyngeal packing|"Patients with indication for surgery of the sinuses were randomly assigned to one of the two study groups.~After standardized anaesthetic management and PONV prophylaxis routinely applied the patients were screened for mucosal injury on second postoperative day. Furthermore, the amount of analgetic and anti-emetic drugs and the severity of pain and PONV were recorded throughout the hospital stay."
2971050|NCT02757300|Active Comparator|Without hypopharyngeal packing|"Patients with indication for surgery of the sinuses were randomly assigned to one of the two study groups.~After standardized anaesthetic management and PONV prophylaxis routinely applied the patients were screened for mucosal injury on second postoperative day. Furthermore, the amount of analgetic and anti-emetic drugs and the severity of pain and PONV were recorded throughout the hospital stay."
2971051|NCT02757287|Experimental|FSH-CTP + DESOGESTREL|Single injection of FSH-CTP and oral desogestrel since the first menstruation day, until bolus of GnRH agonist to follicular maturation
2971052|NCT02757261|Experimental|Application of Low-level laser therapy.|The intervention will be twelve sessions (two per week). Laser parameters: wavelength - 786.94 nm; conventional tip; energy density - 25 J/cm²; intensity - 1.675 mW/cm²; output power - 70 mW (0.070 W); and exposure time - 20 seconds per point. The point application method will be used with direct contact with the skin (spot beam of 0.04 cm²), following the protocol suggested by Carvalho et al.50 and Venezian et al.44 A potentiometer will be used to determine the mean power of the laser equipment to ensure the safety of the operator.
2971053|NCT02757261|Experimental|Treatment with Occlusal splint.|The intervention will be a maxillary occlusal splint will be used on the maxilla with palatal and occlusal coverage. Following the protocol established by Hachmann et al., the children will only use the splint at night for two months, with weekly adjustments of a quarter turn.46
2971054|NCT02757261|Active Comparator|Placebo laser|Placebo laser will be performed using the same equipment.
2971055|NCT02757261|No Intervention|Children without bruxism|Control group
2971056|NCT02757248|Experimental|Cohort 1|Volasertib 75mg/m2 on days 1 and 8 Romidepsin 12mg/m2 on days 1, 8 and 15
2971057|NCT02757248|Experimental|Cohort 2|Volasertib 100mg/m2 on days 1 and 8 Romidepsin 12mg/m2 on days 1, 8 and 15
2971058|NCT02757248|Experimental|Cohort 3|Volasertib 100mg/m2 on days 1 and 8 Romidepsin 14mg/m2 on days 1, 8 and 15
2971059|NCT02757248|Experimental|Cohort 4|Volasertib 150mg/m2 on days 1 and 8 Romidepsin 14mg/m2 on days 1, 8 and 15
2971060|NCT02757248|Experimental|Cohort -1|Volasertib 50mg/m2 on days 1 and 8 Romidepsin 10mg/m2 on days 1, 8 and 15
2971061|NCT02757235|Active Comparator|Irrigation fluid of body temperature|During burr hole evacuation of the chronic subdural hematoma the irrigation fluid used will be of body temperature (approximately 37 degrees Celsius)
2971062|NCT02757235|Active Comparator|Irrigation fluid of room temperature|During burr hole evacuation of the chronic subdural hematoma the irrigation fluid used will be of room temperature (approximately 22 degrees Celsius)
2971063|NCT02757222|Active Comparator|Standard dose|Patients receive a radiation dose of 66Gy in 30 fractions to the planning target volume 1 (PTV1) and 54 Gy in 30 fractions to the PTV2 concurrent with platinum chemotherapy weekly
2971064|NCT02757222|Experimental|Escalated dose|Patients receive a radiation dose of 73.5 Gy in 30 fractions to the boost target volume (BTV), 63Gy in 30 fractions to PTV1 and 54 Gy in 30 fractions to PTV2 concurrent with platinum chemotherapy weekly
2971065|NCT02757209|Active Comparator|Spiromax Inhaler|"Evaluation of correct use of Spiromax inhaler - DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup"
2971066|NCT02757209|Active Comparator|Turbohaler inhaler|"Turbohaler® - Symbicort® 160/4.5 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate). Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup"
2971067|NCT02757209|Active Comparator|Diskus Inhaler|"Diskus® inhaler - Seretide Diskus 50/250 mcg ® or 50/500 mcg (50 mcg salmeterol & 250/500 mcg fluticasone propionate). Dose of one inhalation twice a day for 1 week.~Additional 8 weeks in one subgroup"
2971068|NCT02757196|Experimental|Rituximab plus methylprednisolone|Combination therapy with rituximab （1000mg IV day1, week 3, week 17 , and week 19）plus short-term methylprednisolone (1mg/kg, oral or IV; reduce to 50% of base dose at week 4, then reduce 8mg every 1 week until stopped).
2971069|NCT02757196|Active Comparator|Methylprednisolone|standard dose methylprednisolone alone (1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks).
2971070|NCT02757170|Experimental|I|Thromboelastography Acute on chronic liver failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
2971071|NCT02757170|Active Comparator|Group II|Thromboelastography Healthy Controls: Healthy persons' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation.
2971072|NCT02757170|Experimental|Group III|Thromboelastography Chronic Liver Failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
2971073|NCT02757170|Experimental|Group IV|Thromboelastography Acute Liver Failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
2971074|NCT02757157|Experimental|COPD (normal weight)|People with COPD (BMI 21 kg/m2 to 29 kg/m2)
2971075|NCT02757157|Experimental|COPD (obese)|People with COPD (BMI >/= 30 kg/m2)
2971076|NCT02757144|Experimental|Cohort 1: DWP14012 Amg|DWP14012 Amg, tablets, orally, single dose administration
2971077|NCT02757144|Experimental|Cohort 2: DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single dose administration
2971078|NCT02757144|Experimental|Cohort 3: DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single dose administration
2971079|NCT02757144|Experimental|Cohort 4: DWP14012 Dmg|DWP14012 Dmg, tablets, orally, single dose administration
2971080|NCT02757144|Experimental|Cohort 5: DWP14012 Emg|DWP14012 Emg, tablets, orally, single dose administration
2971081|NCT02757144|Experimental|Cohort 6: DWP14012 Fmg|DWP14012 Emg, tablets, orally, single dose administration
2971082|NCT02757144|Placebo Comparator|Cohort 1-6: Placebo|DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, single dose administration
2971083|NCT02757144|Active Comparator|Cohort 1-6: Esomeprazole|Nexium® tablets, orally, single dose administration
2971084|NCT02757144|Experimental|Cohort 7: DWP14012 Amg|DWP14012 Amg, tablets, orally, repeated dose administration(for 7days)
2971085|NCT02757144|Experimental|Cohort 8: DWP14012 Bmg|DWP14012 Bmg, tablets, orally, repeated dose administration(for 7days)
2971086|NCT02757144|Experimental|Cohort 9: DWP14012 Cmg|DWP14012 Cmg, tablets, orally, repeated dose administration(for 7days)
2971087|NCT02757144|Placebo Comparator|Cohort 7-10: Placebo|DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 7days)
2971088|NCT02757144|Active Comparator|Cohort 7-10: Esomeprazole|Nexium®, orally, repeated dose administration(for 7days)
2971089|NCT02757144|Experimental|Cohort 9: DWP14012 Dmg|DWP14012 Dmg, tablets, orally, repeated dose administration(for 7days)
2971090|NCT02757131|Experimental|Intervention|"Patients randomized to the intervention group will be asked to participate in the ambulation protocol outlined by the Physical Therapy (PT) staff 3 times daily under the supervision of the dedicated ambulator PCNA.~The ambulator will be trained by the physical therapy team on how to implement the protocol prior to initiation of the study."
2971091|NCT02757131|No Intervention|Control|"The cohort of patients randomized to usual care will not be seen by the dedicated ambulator, but will not otherwise be restricted in nursing's baseline ability to execute nursing specific recommendations placed by the PT team."
2971092|NCT02757118|Placebo Comparator|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
2971093|NCT02757118|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
2971094|NCT02757105|Experimental|Group A|BEKINDA 12 mg (Ondansetron Bimodal Release Tablets), once daily for 8 weeks
2971095|NCT02757105|Placebo Comparator|Group B|Placebo, once daily for 8 weeks
2971096|NCT02757092|Experimental|6weeks pulmonary rehabilitation|study group accept the pulmonary rehabilitation( smoking cession before operation, breathing exercise, extremities exercise, breathing muscle training, incentive spirometry (Triflo-II) training, intermittent positive pressure ventilation, chest physical therapy and pain control) in operation stage on before op-day 3 day and after op-day 2 weeks and keep home based pulmonary rehabilitation on discharge 2 weeks, 6 weeks and after 12 weeks.
2971097|NCT02757092|Experimental|2weeks pulmonary rehabilitation|control group accept the pulmonary rehabilitation (smoking cession before operation, breathing exercise, extremities exercise, breathing muscle training, incentive spirometry (Triflo-II) training, intermittent positive pressure ventilation, chest physical therapy and pain control) only in operation stage on before op-day 3 day and after op-day 2 weeks and without home based pulmonary rehabilitation.
2971098|NCT02757079|Experimental|NPC-15 Granule|NPC-15 granule 1 mg, 2 mg or 4 mg once a day, administered orally before going to bed.
2971099|NCT02757066|Experimental|NPC-15 Granules Lower Dose|NPC-15 Granules Lower Dose group which is administered 1mg melatonin
2971100|NCT02757066|Experimental|NPC-15 Granules Higher Dose|NPC-15 Granules Higher Dose group which is administered 4 mg melatonin
2971101|NCT02757066|Placebo Comparator|NPC-15 Placebo Granule|NPC-15 Placebo Granules group which is administered placebo melatonin
2971102|NCT02757053|Experimental|Guardian Cap|The set of high school football players wearing the Guardian Cap on their helmets
2971103|NCT02757053|No Intervention|No Guardian Cap|The set of high school football players not wearing the Guardian Cap on their helmets
2971104|NCT02757040|Experimental|Ibrutinib combined with As2O3|Ibrutinib combined with As2O3
2971105|NCT02757040|Active Comparator|Ibrutinib|Ibrutinib only
2971106|NCT02757027|Placebo Comparator|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
2971107|NCT02757027|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
2971108|NCT02757014|Experimental|Coppertone (BAY987517)|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2971109|NCT02756988|Experimental|Coppertone (BAY987704)|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2971110|NCT02756975|Experimental|transperineal prostate biopsy with coaxial method|The patients undergo transperineal biopsy with a coaxial Tru-Cut needle (18-gauge Core Biopsy Instrument with a 17-gauge Disposable Coaxial Needle).
2971111|NCT02756975|Experimental|transperineal prostate biopsy with noncoaxial method|The patients undergo transperineal biopsy with a noncoaxial 18-gauge needle.
2971112|NCT02756962|Experimental|Cohort A: HiDAC|"At the time of diagnostic bone marrow biopsy, samples will be clinically sequenced~Patients who have clearance of their leukemia-associated mutations, defined as a LAM VAF <2.5% will be assigned to the high-dose cytarabine consolidation (HiDAC) arm.~HiDAC = Standard regimen of cytarabine 1.5 g/m^2 or 3 g/m^2 over 2-3 hours twice a day on Days 1, 3, & 5 of each 28 day cycle for 3-4 cycles.~For patients with the FLT3-ITD or a FLT3-TKD mutation, therapy with the FDA-approved FLT3 inhibitor midostaurin is permitted at the discretion of the treating physician."
2971113|NCT02756962|Experimental|Cohort B: Investigator's choice (HiDAC, AlloSCT)|"At the time of diagnostic bone marrow biopsy, samples will be clinically sequenced~Patients who have persistent leukemia-associated mutations, defined as a LAM VAF ≥2.5% will be assigned to the investigator's choice arm.~Patients assigned to this arm may received either HiDAC or AlloSCT.~HiDAC = Standard regimen of cytarabine 1.5 g/m^2 or 3 g/m^2 over 2-3 hours twice a day on Days 1, 3, & 5 of each 28 day cycle for 3-4 cycles.~The source of stem cell product, donor selection, conditioning regimen, graft-versus-host-prophylaxis, and supportive care will be at the discretion of the treatment physician~For patients with the FLT3-ITD or a FLT3-TKD mutation, therapy with the FDA-approved FLT3 inhibitor midostaurin is permitted at the discretion of the treating physician."
2971114|NCT02756949|Experimental|App|Participants in this arm are randomised to receive the smartphone application.
2971115|NCT02756949|No Intervention|Control|Participants in this arm are randomised to receive no intervention.
2971116|NCT02756936|Experimental|A Test|Test drug (Daclatasvir zeta)1 tablet contains 60 mg Daclatasvir
2971117|NCT02756936|Active Comparator|B Reference|Reference drug (Clatazev)) 1 tablet contains 60 mg Daclatasvir
2971118|NCT02756910||Surgery Patients >1.5 Hrs|Use esophageal catheter for core temperature monitoring, Foley catheter for bladder temperature monitoring, and iThermonitor (WT701) for axillary temperature monitoring
2971119|NCT02756897|Experimental|Relapsed/Refractory CLL Group|Participants receive Ibrutinib monotherapy for 3 cycles. Each cycle is 4 weeks. At the start of cycle 4, Venetoclax added as a weekly dose escalation. The combination of Venetoclax and Ibrutinib continues for an additional 24 cycles for a total of 27 cycles of treatment.
2971120|NCT02756897|Experimental|High-Risk CLL Participants With No Prior Therapy Group|Participants receive Ibrutinib monotherapy for 3 cycles. Each cycle is 4 weeks. At the start of cycle 4, Venetoclax added as a weekly dose escalation. The combination of Venetoclax and Ibrutinib continues for an additional 24 cycles for a total of 27 cycles of treatment.
2971152|NCT02756637||Predictive|Patients with NLR who were assigned to a trial arm (chemo or no chemo)
2971121|NCT02756884|Experimental|LoFU and aADSC|Low Frequency Ultrasound LFUS will be delivered in a non-sterile manner using a custom modified LFUS combined imaging/therapy probe. Adipose derived stem cells from the patient will be harvested through lipoaspiration. This solution will be injected intra-venous, intra-adventitia and intramuscular in the affected vessel and area after the administration of the low frequency ultrasound
2971122|NCT02756884|Active Comparator|Adipose Derived Stem Cells|Adipose derived stem cells from the patient will be harvested through lipoaspiration. This solution will be injected intra-venous, intra-adventitia and intramuscular in the affected vessel and area without the administration of the low frequency ultrasound
2971123|NCT02756871|Experimental|Online guided self-help intervention|CBT based online guided self-help intervention. Intervention can be found at www.overcomingperfectionism.co.uk
2971124|NCT02756871|No Intervention|Control|No intervention.
2971125|NCT02756858|Experimental|ANAVEX2-73 Oral as assigned in ANAVEX2-73-002|
2971126|NCT02756845|Experimental|Talimogene Laherparepvec (TVEC)|The first dose of talimogene laherparepvec will be administered at a dose of up to 4.0 mL of 10ᶺ6 PFU/mL followed by a dose of up to 4.0 mL of 10ᶺ8 PFU/mL 21 days (+3 days) later. Subsequent doses of up to 4.0 mL of 10ᶺ8 PFU/mL will be administered every 14 days (± 3 days) thereafter. Cohorts will be assigned as follows: Cohort A1 (age 12 to <=21 years). Cohort B1 (age 2 to < 12 years). The DLRT will review the safety data of the first 3 subjects in the older age cohort A1 to decide if the younger age cohort B1 can be opened for enrollment. If dose de-escalation is needed and if permissible based on the incidence of DLTs, additional DLT-evaluable subjects will be enrolled and treated at a lower dose level of talimogene laherparepvec. Dose de-escalation cohorts will be assigned as follows and the same DLT rules will be applied: Cohort A2 (age 12 to <=21 years), Cohort B2 (age 2 to < 12 years).
2971127|NCT02756832||Alogliptin Benzoate|Participants with diabetes mellitus type 2 who will receive alogliptin benzoate tablets, orally, as prescribed by physician according to Russian summary of product characteristics (SmPC) will be observed for approximately 6 months.
2971128|NCT02756819||Azilsartan Medoxomil|Overweight or obese participants with hypertension who will receive azilsartan medoxomil tablets,orally, as prescribed by physician according to local summary of product characteristics (SmPC) will be observed for approximately 6 months.
2971129|NCT02756806|Experimental|Picosecond Q-switched Laser|Treatment with investigational wavelengths of the Cutera enlighten laser for tattoo removal.
2971130|NCT02756793|Active Comparator|Standard of Care Treatment|"Patient treatment may include the following 3 options, at the discretion of the treating physicians:~Continue with current systemic agent(s)~Observation~Switch to next-line treatment"
2971131|NCT02756793|Experimental|Stereotactic Ablative Radiotherapy (SABR)|SABR is delivered to all sites of progressive disease with continuation of current systemic agents. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in Arm 1.
2971132|NCT02756780|Experimental|Tenovus Cancer Choir|Participants will be asked to attend 12 weeks of weekly choir rehearsals lasting approximately 1 hour. Following the first 12 weeks, participants will no longer be asked to attend rehearsals, but are welcome to do so. Whether or not they do and how many they attend will be measured as an outcome variable to assess whether initial 3-month involvement leads to long-term engagement.
2971133|NCT02756780|No Intervention|Control (no choir) Group|If eligible participants are unable to make the dates and times or live too far away but fulfil all the same criteria (including expressing an interest in singing) they will become part of the control group. This will involve the same data collection as the Cancer Choir Group but participants will not sing in a weekly choir.
2971134|NCT02756767||First 50 Subjects|The first 50 patients enrolled onto the study will be used to assess feasibility.
2971135|NCT02756767||SA2|For SA2, feasibility will be defined as 80% of patients completing at least 80% of assessments at the appropriate time interval
2971136|NCT02756754|Experimental|Radiofrequency ablation|"Radiofrequency ablation (RFA) is a minimally invasive technique for eliminating both primary tumors and metastases.~The needles that will be used are monopolar RFA, the LeVeen™ Needle Electrode Family with a generator RF 3000 by Boston Scientific. The radiofrequency system will be used as the RFA generator device standard cycle of ablation will be applied in the patient. During RFA, blood pressure, pulse and oxygen saturation will be continuously monitored."
2971137|NCT02756741|Active Comparator|STANDARD DOSE|Albumin 1.5gm/kg on day 1 and 1gm/kg on day 3
2971138|NCT02756741|Placebo Comparator|LOW DOSE|Albumin 20g/d for 5 days
2971139|NCT02756728|Active Comparator|HDM+ASCT|Standard of care; High dose Melphalan + Autologous Stem Cell Transplantation
2971140|NCT02756728|Experimental|BI-505|Biweekly infusions of BI-505 in addition to High dose Melphalan + Autologous Stem Cell Transplantation
2971141|NCT02756715|Active Comparator|propofol group|The patient who anesthetized by using propofol.
2971142|NCT02756715|Active Comparator|Desflurane group|The patient who anesthetized by using sevoflurane.
2971143|NCT02756702||All-Poly|All-polyethylene tibia VEGA System® PS - A posterior stabilized total knee arthroplasty (TKA) system using solely all-polyethylene tibia components
2971144|NCT02756689|Active Comparator|Inpatient Group|Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.
2971145|NCT02756689|Active Comparator|Outpatient Group (Intervention)|Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (treatment arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next morning to be admitted to labor and delivery for oxytocin administration.
2971146|NCT02756676|Experimental|Rehabilitative treatment (MIRT)|Rehabilitative treatment MIRT consist in daily sessions of: motor treatment, occupational therapy and language speech therapy
2971147|NCT02756663|Experimental|Arm A: PAN (10mg) + CFZ + Dex|Panobinostat (PAN) 10mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
2971148|NCT02756663|Experimental|Arm B: PAN (20mg) + CFZ + Dex|Panobinostat (PAN) 20mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
2971149|NCT02756663|Active Comparator|Arm C: CFZ + Dex|Carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
2971155|NCT02756611|Experimental|Venetoclax|Venetoclax will be administered orally 20 mg once daily (QD) beginning with a dose-titration phase, and then escalated up to 400 mg QD.
2971156|NCT02756598|Active Comparator|Sufentanil I|"Randomized arm moderate sufentanil I: bolus 1 microgram/kg propofol I: infusion 0.03 mg/kg/min"
2971157|NCT02756598|Active Comparator|Sufentanil II|"Randomized arm low sufentanil II bolus 0.5 microgram/kg propofol II: infusion 0.06 mg/kg/min"
2971158|NCT02756585|Other|ct perfusion|All participants will undergo the imaging protocol with CTP of head at the time of initial diagnostic imaging upon hospital arrival.
2971159|NCT02756572|Experimental|Treatment (chemotherapy, HCT)|See Detailed Description
2971160|NCT02756559||sepsis, severe sepsis and septic shock|Septic patients were divided into sepsis, severe sepsis and septic shock
2971161|NCT02756546|No Intervention|Control|Healthy volunteers
2971162|NCT02756546|Active Comparator|Patients|SLE patients further divided into mild and severe patients
2971163|NCT02756533|Experimental|Telemonitoring|Telemonitoring of daily parameters recorded by NIV, transmitted to a remote monitoring platform. When an alert is received the patient is contacted by phone by a nurse to evaluate the worsening of symptoms. Information are transferred to a referent physician for further medical care if needed.
2971164|NCT02756533|Placebo Comparator|control|"Telemonitoring of daily parameters by NIV, transmitted to a remote monitoring platform with no generation of alerts.~Phone calls to patient during the follow-up like false alerts for the blind procedure."
2971165|NCT02756520||Chronic kidney disease (pre-dialysis)|Observational study: supplemented protein-restricted diet
2971166|NCT02756507|Experimental|video-based transdiagnostic REBT|Children and adolescents in the experimental group attend 6 modules of video-based transdiagnostic rational emotive behavioral therapy (REBT). Each of the six modules aimes a different component: Psychoeducation, Relaxation, Relationship between cognitive distortions/irrational beliefs and emotions, Cognitive restructuring, Exposure/ behavior activation and problem solving, Maintenance of gaining.
2971167|NCT02756507|Sham Comparator|wait list|The wait-list is a delayed treatment condition.
2971168|NCT02756494||Ischemic Stroke in Young Adults|Patients between 18 and 45 years of age with a first ever ischaemic stroke are eligible for this study from the Department of Beijing Chaoyang Hospital between January 1, 2016 and December 31, 2016. All patients were defined as a sudden loss of global or focal cerebral function that persisted with a probable vascular cause for 24h and confirmed by brain CT or MRI.
2971169|NCT02756494||matched control subjects|The age-, sex-, and time of enrollment-matched control cohort was randomly identified after eliminating the study subjects and those who had been given a diagnosis of any stroke at any time.
2971170|NCT02756481||NVAF Treatment patterns|"Treatment patterns will be collected during the follow-up period. Data will be directly extracted from medical charts of the arrhythmia unit.~Anticoagulation use will be reported as drug class: Vitamin K antagonist, antiplatelet, nonsteroidal anti-inflammatory drugs. The following data on anticoagulation use will be collected:~Type of treatment, start & stop dates, dosage, administration schedule, method of administration, reason for discontinuation if applicable~Type of therapy utilized (monotherapy/combination therapy)~Total number of therapy changes or switches through the course of treatment~Monitoring visit (visits per month) for International normalized ratio (INR) control by Time in Therapeutic Range(cTTR)~Routine care (visits per month) by anticoagulation regimen"
2971171|NCT02756468||pts operated for pancreatic cancer|all pts operated of pancreatic resection for cancer in the involved units
2971172|NCT02756455||gastric cancer pts undergoing surgery|all pts receiving gastric resection for cancer, with anastomosis
2971173|NCT02756442|Experimental|pregnant women with gestational diabetes|
2971174|NCT02756442|Active Comparator|pregnant women without gestational diabetes|
2971175|NCT02756429|Experimental|atrial fibrillation|Patients with atrial fibrillation
2971176|NCT02756429|Experimental|Control|Patients without atrial fibrillation
2971177|NCT02756416|Experimental|ASL MRI and MRA|All participants will undergo ASL-MRI and MRA at three points; baseline, month 1, and month 3.
2971178|NCT02756403|Active Comparator|Azithromycin|500 mg of Azithromycin
2971179|NCT02756403|Active Comparator|Doxycycline|200 mg of Doxycycline
2971180|NCT02756403|Active Comparator|Metronidazole|500 mg of Metronidazole
2971181|NCT02756403|Placebo Comparator|Placebo|Inactive Ingredient
2971182|NCT02756390|Experimental|Arm A (Sleep Hygiene & CBTI-CS)|Participants receive a single educational session describing principles of Sleep Hygiene for Cancer Survivors. Those who continue to have significant symptoms of insomnia then receive 3 groups CBTI-CS sessions
2971183|NCT02756390|Other|Arm B (Telehealth Pilot of CBTI-CS)|Descriptive data collected on 10 participants (non-randomized) receiving CBTI-CS via Telehealth.
2971184|NCT02756377|Active Comparator|cetylpyridinium chloride|mouthwash (cetylpyridinium chloride)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
2971185|NCT02756377|Active Comparator|Chlorhexidine mouthwash|mouthwash ( Alcohol-free chlorhexidine)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
2971186|NCT02756364|Active Comparator|Fulvestrant 500 mg|Fulvestrant 500 mg, intramuscularly (IM), once on Cycle 1 Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until progressive disease, unacceptable toxicity, or withdrawal of consent.
2971187|NCT02756364|Experimental|Fulvestrant 500 mg + MLN0128 4 mg|Fulvestrant 500 mg, IM, once on Cycle 1 Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle along with MLN0128 4 mg, capsule, orally, once daily of a 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent.
2971188|NCT02756364|Experimental|Fulvestrant 500 mg + MLN0128 30 mg|Fulvestrant 500 mg, IM, once on Cycle 1 Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle along with MLN0128 30 mg, capsule, orally, once weekly of a 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent.
2971189|NCT02756351|Experimental|CytaCoat Nasal Prong|The CytaCoat Nasal Prong is composed of the reference device coated with CytaCoat technology.
2971190|NCT02756351|Active Comparator|Reference Nasal Prong|Inspiration Healthcare Inspire nCPAP Nasal Prong consists of silicone. Is a Conformité Européenne marked (CE-marked) commercially available medical device.
2971191|NCT02756325|Experimental|MRI|
2972057|NCT02750436|Experimental|Ultrasound guided|Ultrasound guided sacral lateral branch block
2971192|NCT02756312|Other|Intravenous anesthesia|Patients will receive total intravenous anesthesia undergoing brain tumor resection.
2971193|NCT02756312|Other|Inhalation anesthesia|Patients will receive volatile inhalational anesthesia undergoing brain tumor resection.
2971194|NCT02756299|Active Comparator|Device and Standard Care|Positive Airway Pressure Device and Standard Support
2971195|NCT02756299|Active Comparator|Device and Educational Care|Positive Airway Pressure Device and Educational Support
2971196|NCT02756286||ADHD: Adults with ADHD|NAT electroencephalography (EEG) test
2971197|NCT02756286||Controls: Healthy adults without ADHD|NAT electroencephalography (EEG) test
2971198|NCT02756273|Experimental|no bridge device|After the ileostomy creation, no bridge device was placed.
2971199|NCT02756273|Active Comparator|bridge device|A bridge device was placed after the stoma creation.
2971200|NCT02756247|Experimental|Buparlisib and Ibrutinib|"This is a two stage protocol comprised of a single institution phase Ib dose escalation trial. The first stage is a standard 3+3 phase I dose escalation trial to assess the safety of buparlisib and ibrutinib. The second stage is a single center expansion cohort in MCL, FL and DLBCL respectively evaluating the efficacy of buparlisib and ibrutinib combination.~Treatment will be with ibrutinib orally daily and buparlisib orally daily. A cycle is defined as 4 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death with a maximum duration of treatment of 3 years on therapy."
2971201|NCT02756234||Qualifying CTP patients|A convenience sample of all qualifying patients for CTP procedure
2971202|NCT02756221|Experimental|Probiotics|Probiotics capsules, one capsule daily for 90 days.
2971203|NCT02756221|Placebo Comparator|Placebo|Starch capsules, one capsule daily for 90 days
2971204|NCT02756208|Experimental|0.25 mL FLSC Vaccine Group ENROLLED|Fifteen volunteers will be vaccinated with 75 mcg (0.25 mL) FLSC on study days 0, 28, 56 and 168.
2971205|NCT02756208|Placebo Comparator|0.25 mL Placebo Group ENROLLED|Five volunteers will be vaccinated with 0.25 mL placebo on study days 0, 28, 56 and 168.
2971206|NCT02756208|Experimental|0.5 mL FLSC Vaccine Group ENROLLED|Fifteen volunteers will be vaccinated with 150 mcg (0.5 mL) FLSC on study days 0, 28, 56 and 168.
2971207|NCT02756208|Placebo Comparator|0.5 mL Placebo Group ENROLLED|Five volunteers will be vaccinated with 0.5 mL placebo on study days 0, 28, 56 and 168.
2971208|NCT02756208|Experimental|1.0 mL FLSC Vaccine Group ENROLLED|Fifteen volunteers will be vaccinated with 300 mcg (1.0 mL) FLSC on study days 0, 28, 56 and 168.
2971209|NCT02756208|Placebo Comparator|1.0 mL Placebo Group ENROLLED|Five volunteers will be vaccinated with 1.0 mL placebo on study days 0, 28, 56 and 168.
2971210|NCT02756195||Neonates receiving first-time non-cardiac surgery|No intervention will be administered. This is a prospective observational patient safety study focusing on the safety of care delivered to neonates in perioperative care settings. Neonates who receive NICU care both pre- and post-operatively will be eligible for this study.
2971211|NCT02756182|Experimental|Urodynamics with AC and WP|Patients will undergo a conventional urodynamics study utilizing a single catheter technique
2971212|NCT02756169|Experimental|Intervention|One workshop during pregnancy Support for breastfeeding at immediate postpartum Telephonic support after delivery
2971213|NCT02756169|No Intervention|Control|Standar procedures of neonatal and pregnancy health care at the clinics or hospitals.
2971214|NCT02756143|No Intervention|Control Group|Non- supervised physical exercise program during pregnancy
2971215|NCT02756143|Experimental|Exercise Group|Supervised physical exercise program during pregnancy
2971216|NCT02756130|Experimental|Treatment (birinapant, carboplatin)|Patients receive birinapant IV over 30 minutes on days 1 and 8, and carboplatin IV over 30 minutes to 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2971217|NCT02756117|Experimental|Healthy|"10 Healthy subjects will be enrolled and each will undergo study procedures at one study visit. After screening and consent have been conducted over the phone, subjects will participate in the study procedures. Subjects will arrive in a fasting state (no eat or drink for 8 hours, excluding water). Following collection of blood pressure, height, weight, and a urine and blood sample, subjects will be given an oral bolus of L-lysine (10 g) in 100 ml water. This amount of lysine is equivalent to that which is found in a 10oz. serving of beef. Subjects will provide additional urine and blood samples serially post-ingestion. Because blood draws will be collected through an IV, Normal (0.9%) Saline (NS) will be infused at a rate of 10 ml/hr to flush the canula prior to each blood draw.~All subjects will undergo the same procedures and interventions."
2971218|NCT02756104|Other|Volunteers|Healthy People on each collecting blood for phenotyping Tcells
2971219|NCT02756104|Other|Patients with ALS|"Patients with ALS deficient or not in Vitamin D on each collecting blood for phenotyping Tcells.~The patients who are deficient in Vitamin D will have supplementation in vitamin D"
2971220|NCT02756078|Active Comparator|Group 1 (TEST / CONTROL wear sequence)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the TEST / CONTROL wearing sequence will wear each of the study lenses for 4 weeks according to the manufacturer's guidelines. Subjects will be dispensed the other (second) lens type at the second dispense visit.
2971221|NCT02756078|Active Comparator|Group 2 (CONTROL / TEST wear sequence)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the CONTROL / TEST wearing sequence will wear each of the study lenses for 4 weeks according to the manufacturer's guidelines. Subjects will be dispensed the other (second) lens type at the second dispense visit.
2971222|NCT02756065||Control|Individuals between 18-30 years old No diagnosis of Bipolar Disorder or Schizophrenia No intervention used
2971223|NCT02756065||Bipolar Disorder|Individuals between 18-30 years old Diagnosis of Bipolar Disorder No intervention used
2971224|NCT02756065||Schizophrenia|Individuals between 18-30 years old Diagnosis of Schizophrenia or Schizoaffective Disorder No intervention used
2971225|NCT02756052|Sham Comparator|Medical Student - Sham tDCS|"Participants: 1st to 3rd year medical students from the Cumming School of Medicine (University of Calgary).~Device: Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
2971488|NCT02754206||Concussed|Subjects who have recently suffered a sports-related concussion and are currently a collegiate athlete playing a contact-collision sport.
2971226|NCT02756052|Sham Comparator|General Surgery Resident - Sham tDCS|"Participants: 1st to 5th year general surgery residents from the Cumming School of Medicine (University of Calgary).~Device: Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
2971227|NCT02756052|Experimental|Medical Student - Anodal tDCS|"Participants: 1st to 3rd year medical students from the Cumming School of Medicine (University of Calgary).~Device: Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
2971228|NCT02756052|Experimental|General Surgery Resident - Anodal tDCS|"Participants: 1st to 5th year general surgery residents from the Cumming School of Medicine (University of Calgary).~Device: Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
2971229|NCT02756026|Experimental|Micronutrient supplementation|"On day 3, all mothers are given a commercial multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).~On day 4, all mothers are given two commercial multiple micronutrient supplements (Nutri-Fem) manufactured by Thorne, containing twice the Recommended Dietary Intake (RDA)."
2971230|NCT02756013|Experimental|Paclitaxel + Carboplatin|Paclitaxel dosed by actual body surface area and not maxed at BSA 2.0. The Carboplatin dose will be calculated according to the Calvert formula using as estimated glomerular filtration rate from the Cockcroft-Gault formula and will be subject to maximum allowed doses.
2971231|NCT02756000|Experimental|complete PCI at initial hospitalization|Staged, complete revascularization of all non-culprit significant lesions in a single PCI session during initial hospitalization for ST elevation myocardial infarction
2971232|NCT02756000|Experimental|complete PCI after 30 days|Staged, complete revascularization of all non-culprit significant lesions in a single PCI session after 30 days from initial hospitalization for ST elevation myocardial infarction
2971233|NCT02756000|Active Comparator|Dobutamine stress testing|Revascularization by PCI or deferral of revascularization of non-culprit coronary artery lesions based on ischemia testing using Dobutamin stress echocardiography
2971234|NCT02755961|No Intervention|Control group|No intervention was performed
2971235|NCT02755961|Experimental|Education group|Dietary education and education on phosphate binder use. Pharmacists instructed patients about how to take phosphate binders properly. Dietitians educated on dietary phosphate restriction.
2971236|NCT02755948|Experimental|RSV A Memphis 37|Half the participants will be inoculated with RSV Memphis 37 10(4) plaque forming units (PFU) in 1 milliliter (mL) 25% sucrose/Dulbecco's Modification of Eagle's Medium (DMEM) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
2971237|NCT02755948|Experimental|Influenza A/California/04/2009|Half the participants will be inoculated with Influenza A/California/04/09 3.5x10(4) tissue culture infective dose 50% (TCID50) in 1 mL in Dulbecco's phosphate buffered saline (DPBS) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
2971238|NCT02755935|Experimental|Implanted|Subjects who meet the specified inclusion criteria and are implanted with the CI532 cochlear implant
2971239|NCT02755922|Experimental|Fractures with Mesenchymal Stem Cells|10 patients with mandibular fractures were managed by open reduction and internal fixation, with application of autologous mesenchymal stem cells on the fracture site.
2971240|NCT02755922|No Intervention|Fractures without Mesenchymal Stem Cells|10 patients with mandibular fractures were managed by open reduction and internal fixation, without application of autologous mesenchymal stem cells on the fracture site.
2971241|NCT02755909|Other|Subjects|Pra-anesthetic education given to the subjects includes the anatomy of a normal heart, normal blood circulation, anatomy and pathophysiology of the disease in the respected subject, surgery procedures needed, anesthetic procedures needed for the surgery, and cardiopulmonary bypass procedures. Education and discussion were given repeatedly until subjects could repeat the materials given correctly.
2971242|NCT02755896|Other|Arm 1 - 600 cGY x 5 fractions|Patients will receive 600 cGY x 5 fractions of radiation therapy over 5 consecutive days.
2971243|NCT02755896|Other|Arm 2 - 800 cGY x 3 fractions|Patients will receive 800 cGY x 3 fractions of radiation therapy every other day for 3 days.
2971244|NCT02755883|Experimental|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and the positive affect component
2971245|NCT02755883|Active Comparator|Physical activity plus education|Subjects will be randomized to a physical activity goal and education
2971246|NCT02755870|Experimental|CNM-Au8|"CNM-Au8 is an orally administered, clean-surface gold nanocrystal suspension drug. It is atomically clean-surface elemental nanocrystals, free of any residual surface chemicals or surface-capping agents.~CNM-Au8 15, 30, 60, 90mg as an oral suspension"
2971247|NCT02755870|Placebo Comparator|Placebo|Placebo oral suspension which matches the volume of the experimental nanocrystal suspension
2971248|NCT02755857|Experimental|Lozanoc|65 mg, capsules, at least 2 capsules twice a day
2971249|NCT02755844|Experimental|Olaparib, metformin and metronomic cyclophosphamide|"Phase 1: Dose escalation scheme: a continual reassessment method (CRM) will be used to guide inclusion of patients in drug dose levels pre-specified based on observations of dose-limiting toxicity.~Phase 2 (expansion of cohort): once RP2D will be determined, additional patients will be enrolled, in order to obtain preliminary data about efficacy in a 2 stage Simon's design."
2971250|NCT02755831|Experimental|Sleep Study + CPAP group (n = 180)|Pregnant women in early pregnancy may be randomized to this arm and be assigned Sleep study + CPAP treatment
2971251|NCT02755831|Other|Standard Prenatal Care group (n=180)|Pregnant women in early pregnancy may be randomized to this arm and will receive standard prenatal care without CPAP treatment.
2971252|NCT02755818||control|heparin at 50unit/kg of body weight
2971253|NCT02755818||chronic renal disease (CKD)|heparin at 50unit/kg of body weight
2971668|NCT02753010||Acute hip fracture|Women preoperatively with acute hip fracture with gastric emptying of carbohydrate-rich beverage
2971254|NCT02755805|Experimental|CO-OP|Cognitive Orientation to daily Occupational Performance (CO-OP) is a strategy training approach that trains individuals to identify problems in the performance of their daily activities, develop strategies to address these problems, and monitor their own performance in the course of their daily routines. Participants use a workbook to support their application of the strategy training.
2971255|NCT02755805|Placebo Comparator|Attention Control|The attention control intervention controls for the non-specific effects of strategy training. The therapists administer the standardized and dose-matched protocol, using scripted open-ended questions to facilitate participants' reflections on their rehabilitation activities and experiences. Participants complete a daily journal, merely reviewing their rehabilitation activities.
2971256|NCT02755792|Experimental|Calligraphy Training|This group receives a Chinese calligraphy training program of 16 sessions over 8 weeks in a class of 8-12 participants. Each session is 1.5 hours.
2971257|NCT02755792|Active Comparator|iPad Training|This group receives an iPad training program of 16 sessions over 8 weeks in a class of 8-12 participants. Each session is 1.5 hours.
2971258|NCT02755766||Clubfeet|Babies, ages 0-1, with a diagnosis with clubfoot or clubfeet who are beginning treatment with foot abduction bracing following casting treatment.
2971259|NCT02755766||Adolescent Idiopathic Scoliosis|Patients, ages 10-14, with a diagnosis of AIS who are beginning treatment with TLSO (initial bracing).
2971260|NCT02755766||Guardians (CF babies)|Clubfoot patients' guardians.
2971261|NCT02755753|Experimental|Study Group|"Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast~Mucosta® (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner"
2971262|NCT02755753|Placebo Comparator|Control Group|"Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast~Mucosta®-placebo (rebamipide-placebo), 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner"
2971263|NCT02755740|Other|receiving age and gender-specific SC advice|"After delivering the AWARD advice, the trained SCRA will seek consent from and refer adult female smokers (aged over 25 years) to our intensive smoking cessation telephone or face-to-face counselling interventions, which has already counselled 509 female smokers with a quit rate of 29.7% at 6-month and 26.7% at 3-year follow up. Female youth smokers will give consent and be referred to our Youth Quitline (5111 4333), a smoking cessation telephone counselling for young people aged 25 or below which has counselled 1257 smokers with a quit rate of 21.9% at 6 months. If necessary, the female smokers can be referred to other smoking cessation services (e.g., the integrated smoking cessation hotline by the Department of Health (1833-183)."
2971264|NCT02755727|Experimental|Platelet Rich Plasma injection|"In the outpatient setting a sample of venous whole blood will be taken from the patient (40mls), from the antecubital fossa using standard phlebotomy techniques. The Angel™ system will be in the available also in the outpatient clinic and will be used to separate the blood to yield a PRP sample (approximately 15 minutes preparation time). The PRP sample is then injected into the common extensor origin.~2 injections will be used per patient over 2 weeks."
2971265|NCT02755727|Active Comparator|Open Surgical Release|Standardised surgical technique based on the Nirschl technique will be used. The patient will then have a small scar centred over the lateral epicondyle and the plane opened between ECRL (Extensor Carpi Radialis Longus) and EDC (Extensor Digitorum Communis) to expose the damaged ECRB (Extensor Carpi Radialis Brevis) tendon. The amount of abnormal tendon will be documented and excised. EDC will also be inspected and any abnormal tissue documented then excised. The footprint of the excised ECRB +/- EDC is cleared of soft tissue and the bone scored with an osteotome to promote bleeding. The interval is closed with suture material and the skin wound closed.
2971266|NCT02755714|No Intervention|No Atrovent ®|NO INTERVENTION: The patient will not receive Ipratropium bromide spray (MDI) 20 μg ,(Atrovent ®) prior to CLE testing
2971267|NCT02755714|Experimental|Atrovent ®|INTERVENTION: Ipratropium bromide spray (MDI) 20 μg (Atrovent ®) prior to CLE testing
2971268|NCT02755701|Experimental|BCAA group|Branched-chain amino acid, 4.15g, Tid
2971269|NCT02755701|Placebo Comparator|Placebo group|Placebo, 4.15g, Tid
2971270|NCT02755688|Experimental|Thoracoscopic surgical ablation|Pulmonary vein isolation, ganglionic plexi ablation, left atrial appendage exclusion
2971271|NCT02755688|Active Comparator|Catheter ablation|Pulmonary vein isolation, linear lines
2971272|NCT02755675|Experimental|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before treatment start to evaluate the prognostic value of uPAR PET/CT.
2971273|NCT02755662|Active Comparator|Narval O.R.M CC™|First mandibular retention device : Narval O.R.M CC™
2971274|NCT02755662|Active Comparator|Narval O.R.M™ trad|Second mandibular retention device : Narval O.R.M TRAD™
2971275|NCT02755649|Experimental|Dosing regimen 1|Participants in this arm will receive Dupilumab dosing regimen 1
2971276|NCT02755649|Experimental|Dosing regimen 2|Participants in this arm will receive Dupilumab dosing regimen 2
2971277|NCT02755649|Experimental|Placebo|Participants in this arm will receive matching placebo
2971278|NCT02755636|Experimental|PCPHC intervention|PCPHC intervention during 6-month intervention period plus study assessments at baseline, 6, and 12 months
2971279|NCT02755636|Active Comparator|Usual care|Usual primary care plus study assessments at baseline, 6, and 12 months
2971280|NCT02755623|Active Comparator|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|low-frequency (1 Hertz) rTMS
2971281|NCT02755623|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|sham TMS
2971282|NCT02755610|Experimental|PD Product Check List|PD Product Check List was developed based on the 28 routine steps of standard orientation manual for new Thai PD patients. Of these, step 2 (weighting the PD solution bag), step 3 (checking expiration date, volume, glucose concentration, clarity, and color, step 27 (weighting the PD solution bag), and step 28 (recording time, volume, and any abnormality encountered) are relevant to product defect report.
2971283|NCT02755610|No Intervention|Control|
2971284|NCT02755597|Placebo Comparator|Placebo + Bortezomib and Dexamethasone|Cycles 1-8: Placebo (to match venetoclax 100mg tablet) 800mg orally every day (QD) on days 1 - 21 plus bortezomib 1.3mg/m2 on days 1,4,8 & 11 and dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 Cycles 9 and beyond: Placebo (to match venetoclax 100mg tablet) 800mg orally every day (QD) on days 1 - 35 plus bortezomib 1.3mg/m2 on days 1, 8, 15 and 22 and dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23
2971285|NCT02755597|Experimental|Venetoclax + Bortezomib and Dexamethasone|Cycles 1-8: Venetoclax 800mg orally every day (QD) on days 1 - 21 plus bortezomib 1.3mg/m2 on days 1,4,8 & 11 and dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 Cycles 9 and beyond: Venetoclax 800mg orally every day (QD) on days 1 - 35 plus bortezomib 1.3mg/m2 on days 1, 8, 15 and 22 and dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23
2971286|NCT02755558|Experimental|Low energy density, small portion|Low milk energy density and small portion size
2971287|NCT02755558|Experimental|Low energy density, large portion|Low milk energy density and large portion size
2971288|NCT02755558|Experimental|High energy density, small portion|High milk energy density and small portion size
2971289|NCT02755558|Experimental|High energy density, large portion|High milk energy density and large portion size
2971290|NCT02755545|Active Comparator|Product A (adapalene)|Product A applied topically to the entire face or other affected area of the skin once daily
2971291|NCT02755545|Active Comparator|Product B (salicylic acid)|Product B applied topically to the affected area of the skin 1 to 3 times daily.
2971292|NCT02755532|Active Comparator|Bupivacaine 0,25%|Routine surgical procedure monitoring with an electrocardiogram, sphygmomanometer, and pulse oximeter was performed. One experienced anesthesiologist performed an ultrasound guided axillary brachial plexus block (S Series, FUJIFILM Sonosite, Seattle, USA) with the patient in the supine position. Local anesthetic injection was performed on each nerve identified in this pathway (i.e., the radial nerve, the ulnar nerve, the median nerve, and the musculocutaneous nerve) In the group bupicavaine 0.25%, 10 ml of 0.25% bupivacaine was injected into each nerve, for a total of 40 ml per patient.
2971293|NCT02755532|Active Comparator|Bupivacaine 0,5%|Routine surgical procedure monitoring with an electrocardiogram, sphygmomanometer, and pulse oximeter was performed. One experienced anesthesiologist performed an ultrasound guided axillary brachial plexus block (S Series, FUJIFILM Sonosite, Seattle, USA) with the patient in the supine position. Local anesthetic injection was performed on each nerve identified in this pathway (i.e., the radial nerve, the ulnar nerve, the median nerve, and the musculocutaneous nerve). In the group bupivacaine 0.5% , 5 ml of 0.5% bupivacaine was injected into each nerve, for a total of 20 ml per patient.
2971294|NCT02755519||Primary Aldosteronism|"Those with hypertension, and with or without hypoglycemia;~Those with PAC/PRC≥42.95 pg·mL-1/µIU·mL-1"
2971295|NCT02755519||Non-Primary Aldosteronism|"Those with Primary Hypertension;~Those with adrenal diseases except for Primary Aldosteronism"
2971296|NCT02755506|Experimental|patients with thoracic lesions|Patients with thoracic lesions is going to undergo endobronchial ultrasound elastography followed by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).
2971297|NCT02755493|Experimental|Sleep Deprivation|Sleep deprivation
2971298|NCT02755480|Experimental|ultralow dose research|"An Ultralow Dose Thoracic Computed Tomography scan will be added to the standard of care Low dose CT scan.~The image quality of the ultralow dose CT will be compared to the Low dose thoracic Computed Tomography."
2971299|NCT02755467|Experimental|Laser treatment|Each subject will receive a 532 nm KTP laser treatment for their spider angioma(s).
2971300|NCT02755454|Other|open label|Perfusion CT Imaging
2971301|NCT02755428|Experimental|retinal pigment epithelium transplantation|Subretinal transplantation of human embryonic stem cell derived retinal pigment epitheliums.
2971302|NCT02755415|Active Comparator|Static Standing Table Training|Patients in this group will receive standard hospital based rehabilitation as well as static standing table training
2971303|NCT02755415|Experimental|Robotic Gait Training|Patients in this group will receive standard hospital based rehabilitation as well as robot-assisted gait rehabilitation training
2971304|NCT02755402|Experimental|Rapid evaluation|Transient elastography, Xpert HCV Viral load, medical and nurse visits
2971305|NCT02755389|Placebo Comparator|0 L/min|These participants will receive 0 L/min oxygen via conventional nasal cannulae during the apneic period.
2971306|NCT02755389|Experimental|15 L/min|These participants will receive 15 L/min oxygen via conventional nasal cannulae during the apneic period.
2971307|NCT02755389|Experimental|60 L/min|These participants will receive 60 L/min oxygen via high-flow nasal cannulae during the apneic period.
2971308|NCT02755376|Active Comparator|ACL reconstruction only|only ACL reconstruction without any injection
2971309|NCT02755376|Experimental|ACL reconstruction + Cartistem(TM)|ACL reconstruction and concomitant Cartistem(TM) injection which is human cord blood derived mesenchymal stem cell under arthroscopy.
2971310|NCT02755376|Experimental|ACL reconstruction + Hyaluronic acid|ACL reconstruction and concomitant hyaluronic acid injection under arthroscopy
2971311|NCT02755363|Active Comparator|osteopathic manual therapy (OMT group)|patients who will undergo manual osteopathic therapy.
2971312|NCT02755363|Placebo Comparator|control group (C group)|patients who will undergo manual therapy not aimed to decrease hyperinflation.
2971313|NCT02755350|Experimental|Truvada|Daily oral PrEP (Truvada) is provided to a cohort of 2100 participants who will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period. In between some visits, they will return to the pharmacy for a refill of PrEP, counselling on adherence and medication of side effects.
2971314|NCT02755324|Experimental|Intervention|Volunteers will be exposed to escalating doses of male Schistosoma mansoni cercariae
2971315|NCT02755311|Experimental|liver resection|Resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. The investigators performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
2971350|NCT02755064|Placebo Comparator|Placebo IV|Saline was given as an initial bolus over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
2971559|NCT02753738|Experimental|SSRI treatment|Subjects will receive 21 days of 10mg escitalopram treatment while performing learning paradigms.
2971316|NCT02755311|Active Comparator|transarterial chemoembolization|A microcatheter was inserted into the feeding arteries as selectively as possible through the lobar, segmental, or subsegmental arteries, dependent on the tumor distribution and hepatic functional reserve. Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin. Subsequently, chemolipiodolization was performed mixed with 5 ml of lipiodol. According to the number and size of the lesions, and liver and kidney function of the patient, the chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team. If residual flow remained after infusion of these agents, additional lipiodol was injected. Embolization was performed with absorbable gelatin sponge particles 350-560 μm in diameter.
2971317|NCT02755298|Experimental|Acetazolamide|Twice a day 250 mg acetazolamide for 5 weeks
2971318|NCT02755298|Placebo Comparator|Placebo|Placebo capsule 250 mg (Mannitol) twice a day 5 weeks
2971319|NCT02755272|Experimental|Pembrolizumab with Standard Chemotherapy|Pembrolizumab plus standard chemotherapy using carboplatin and gemcitabine.
2971320|NCT02755272|Active Comparator|Standard Chemotherapy Alone|Standard chemotherapy alone using carboplatin and gemcitabine.
2971321|NCT02755259|Experimental|Acetazolamide|Diamox 500mg i.v. (1x)
2971322|NCT02755259|Placebo Comparator|Placebo|Placebo Saline injection (1x)
2971323|NCT02755246|Experimental|Polyamine supplementation|
2971324|NCT02755246|Placebo Comparator|Placebo|
2971325|NCT02755233||Pulmonary function|Patients in whom treatment with ipilimumab due to metastatic melanoma is indicated
2971326|NCT02755220|Experimental|Cingularbio® Heart valve|the patients will replaced by artificial heart valve
2971327|NCT02755207||Suspected ACS group|Patients admitted to the hospital with the diagnosis of ACS
2971328|NCT02755207||Blank control group|Patients admitted to the hospital without the diagnosis of ACS
2971329|NCT02755194||Breastfeeding women on the study medications|The study population consists of lactating/breastfeeding women over the age of 18, who are able to communicate in English and are taking one or more of the study drugs (Infliximab, Adalimumab, Golimumab, Certolizumab, Etanercept, Methotrexate, Ezetimibe, Bupropion, Citalopram, Venlafaxine)
2971330|NCT02755181||BPD|Borderline Personality Disorder as diagnosed by DSM-5
2971331|NCT02755181||normal volunteers|normal volunteers
2971332|NCT02755168|Other|External Pop-Out Cesarean Section|
2971333|NCT02755168|Other|Classic technique|
2971334|NCT02755155|Experimental|Continuous low dosage (CLD)|The subjects will received human serum albumin infusion 4%.CLD patients are infused with15ml/kg/day of 4% human serum albumin from inclusion to the day norepinephrine infusion is weaned by 30% (provided their plasma albumin stays in the range 30+3g/L)
2971335|NCT02755155|Active Comparator|Intermittent high dosage (IHD)|The subjects will received human serum albumin infusion 20%.IHD patients are infused with 20% human serum albumin (up to 600 ml/day) until the plasma albumin concentration is in the range 30+3g/L from inclusion to the day norepinephrine infusion is weaned by 30%
2971336|NCT02755142|Active Comparator|Dose level 1|0,2 mg/Kg
2971337|NCT02755142|Active Comparator|Dose level 2|2,0 mg/Kg
2971338|NCT02755142|Active Comparator|Dose level 3|20 mg/Kg
2971339|NCT02755129|Other|single arm|"Single arm, all the patients enrolled will perform the same walking exercises.~On arrival to the rehabilitation center subjects will have the Reveal LINQ, the 3D-accelerometers (one on the chest by medical-grade adhesives and a second at the level of the waist over the top of a medical grade adhesive) and the Holter attached externally. Then, they will be asked to perform the following exercises:~Walking Exercises-4 Meter Gait Speed (4MGS) Test Walking exercises - Six Minute Walk (6MW) Test~Walking exercises - 4 Meter Gait Speed (4MGS) Test~Walking Exercises - Five Times Sit to Stand (FTSTS) Test~Walking Exercises - Expanded Timed Get-Up-and-Go (ETGUG) Test"
2971340|NCT02755116|Experimental|Olanzapine|10mg pill
2971341|NCT02755116|Placebo Comparator|Placebo|
2971342|NCT02755103|Experimental|Women receiving MBRP plus TAU|Women will receive the Mindfulness Based Relapse Prevention (MBRP) plus treatment as usual (TAU less trauma focused group).
2971343|NCT02755103|No Intervention|Women receiving TAU|Women will only receive treatment as usual (TAU less trauma focused group).
2971344|NCT02755090|Experimental|Nitrous oxide and IV saline|Participants in the nitrous oxide group will receive a scented face mask through which nitrous oxide will be administered. The nitrous content of the gas will be titrated up by 20% every 5 breaths with a goal of 70% N2O/ 30% O2 as tolerated by the participant. This group will also receive saline through an IV. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
2971345|NCT02755090|No Intervention|Standard Care (IV Sedation and Oxygen)|Within the IV sedation group, women will receive 100mcg fentanyl and 2mg midazolam at least two minutes prior to initiation of the procedure. This group will also receive 100% oxygen by a scented face mask. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
2971346|NCT02755077|Experimental|Mask ventilation in rotated head position|Patient's head will be axially rotated 45 degrees to the right
2971347|NCT02755077|No Intervention|Mask ventilation in neutral head position|
2971348|NCT02755064|Experimental|Erythromycin lactobionate IV 2 mg/kg|During the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Thereafter, an infusion of 1.5 mg/kg was given over the next 50 min with the same infusion pump.
2971349|NCT02755064|Active Comparator|Erythromycin lactobionate IV 3 mg/kg|During the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.Thereafter, an infusion of 1.5 mg/kg was given over the next 50 min with the same infusion pump.
2971404|NCT02754739|Experimental|Pravastatin|Pravastatin 40mg tablet by mouth, once daily for 24 weeks. Also, nutritional education was provided to participants in all arms by a nutritionist, and participants were instructed to follow the educated guideline.
2971351|NCT02755064|Experimental|Erythromycin Ethylsuccinate Suspension|In Phase 2 of the study, subjects randomized to this arm will receive Erythromycin Ethylsuccinate Suspension 250 mg tid orally for a total period of 7 days. The GEBT was performed approximately on day 7. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
2971352|NCT02755064|Placebo Comparator|Placebo Suspension|In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days. The GEBT was performed approximately on day 7. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
2971353|NCT02755051|Experimental|CBT-CI-A Therapy|Participants in this group receive Cognitive Behavioral Therapy for children with Chronic Insomnia and Autism Spectrum Disorder (CBT-CI-A)
2971354|NCT02755038||premenopausal and postmenopausal women|One group will include 20 premenopausal women under the age 40 years old, with regular menstruation cycles and without any illness or medication including birth control pills or steroidal ointments, and without known diagnosis of polycystic ovaries or fertility disorder. The second group will include 20 postmenopausal women over the age of 60, with no menstruation at least for the last five years, and without hormone therapy or treatment of any Steroidal therapy for the last year.
2971355|NCT02755025||Prospective cohort|This group will include ICU patients for the two month period after the automated SOFA score has been activated within the electronic patient care dashboard.
2971356|NCT02755012||Longitudinal|155 women enrolled in 2nd or 3rd trimester of pregnancy, and seen again, with their infant, at 0-6 wk postpartum, and 4-6 mo postpartum
2971357|NCT02755012||Early Postpartum|60 women enrolled at 0-6 wk postpartum and seen once with their infant (cross-sectional)
2971358|NCT02755012||Later Postpartum|56 women enrolled at 0-6 wk postpartum and seen once with their infant (cross-sectional)
2971359|NCT02754999|Experimental|SANGUINATE™|As Needed Dosing of SANGUINATE
2971360|NCT02754986|Experimental|measuring Holter electrocardiogram|Hotter ECG will be recorded continuously during hemodialysis
2971361|NCT02754973|Experimental|Experimental group|During hospitalization for cancer treatment, besides receiving usual care, participants in the experimental group will first receive a health education talk Participants will then be taught and encouraged to practice with some stretching and relaxing exercises during their hospitalization. After hospitalization, participants will receive an integrated experiential training program with coaching by nursing students through home visits.
2971362|NCT02754973|Placebo Comparator|Placebo Control group|Since participants in both groups are hospitalized in the same unit, to avoid contamination, participants in the placebo control group will receive the same intervention as those participants in the experimental group during their hospitalization. When discharged home, participants will receive an amount of time and attention (home visits by research assistants) that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures.
2971363|NCT02754960|Active Comparator|Thalidomide group|Patients were randomly assigned to the thalidomide group and received 100 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang Zhou, China) orally four times daily at 10 p.m. for four months.
2971364|NCT02754960|Placebo Comparator|Placebo group|Patients were randomly assigned to the placebo group and received 100 mg of thalidomide placebo (Pharmaceutical Co., Ltd. of Chang Zhou, China) orally four times daily at 10 p.m. for four months.
2971365|NCT02754921|Experimental|Ultra-perc|
2971366|NCT02754921|Experimental|Ciaglia Blue Dolphin|
2971367|NCT02754908|Experimental|Experimental group|In addition to medical follow-up, the subjects in the experimental group will receive weekly 45-minute lessons on musical training for one year (52 weeks), conducted by the Music Children Foundation. Qualified orchestral performers will provide the musical training. Training will start at the lowest level (hitting simple notes) and end at the highest level (able to play an entire song). The subjects will continue on to the next level if they successfully pass the relevant test; those who do not will be encouraged to repeat test.
2971368|NCT02754908|Placebo Comparator|Placebo Control group|"The subjects will receive medical follow-up according to the schedule of the oncology units.~They will receive the same amount of time and attention as those in the experimental group but not in a way designed to have any specific effect on the outcome measures. They will be invited to attend free, weekly 45-minute tutoring classes organised by the community for one year (52 weeks)."
2971369|NCT02754895|Experimental|PP-weekly|Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per week.
2971370|NCT02754895|Experimental|PP-daily|Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per day.
2971371|NCT02754895|Experimental|Shortened PP-weekly plus MI|Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per week.
2971372|NCT02754895|Experimental|Shortened PP-daily plus MI|Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per day.
2971373|NCT02754895|Experimental|PP-weekly with boosters|"Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per week. Participants will also receive three booster phone calls following the completion of the 8 week intervention."
2971374|NCT02754895|Experimental|PP-daily with boosters|"Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per day. Participants will also receive three booster phone calls following the completion of the 8 week intervention."
2971375|NCT02754895|Experimental|Shortened PP-weekly plus MI + boosters|"Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per week. Participants will also receive three additional booster phone calls following the completion of the 8 week intervention."
2971429|NCT02754596|Active Comparator|Timolol Maleate Ophthalmic Solution, 0.5%|Timolol, a beta blocker, will be dosed twice daily
2971773|NCT02752256||Intervention/Transfer|Patients who are transferred via air ambulance to a comprehensive stroke center
2971376|NCT02754895|Experimental|Shortened PP-daily plus MI with boosters|"Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per day. Participants will also receive three additional booster phone calls following the completion of the 8 week intervention."
2971377|NCT02754882|Active Comparator|Bevacizumab (Avastin)|Avastin® + Carboplatin/Paclitaxel
2971378|NCT02754882|Experimental|SB8 (A proposed bevacizumab biosimilar)|SB8 + Carboplatin/Paclitaxel
2971379|NCT02754869||Control Subject-Drug Study|The first part of this investigation is an interventional blinded cross over study with two dosing dates spread at least one week apart. Each volunteer will receive baseline scans before drug/placebo which will be used to assess intra--‐patient variation over the two study dates after which the drug or saline placebo will be administered with each volunteer acting as their own control to assess software ability to quantify changes in bowel motility.
2971380|NCT02754869||Dysmotility Subjects-Drug Study|The second component of this study will be exactly the same for the participants with dysmotility except the time to repeat scan will be reduced with a follow up time aimed at around 1--‐3 days reducing patient time off medication
2971381|NCT02754869||Reference Range Study|The third component of this study will assess basal small bowel motility in larger numbers of healthy controls, dysmotility subjects and irritable bowel syndrome to establish reference ranges to inform future clinical investigations and guide clinical decision making using global motility scoring. Each scan will last around 20 minutes and will not involve follow up or use of pharmaceutical agents.
2971382|NCT02754869||Desmotility Reversibility Study|The fourth component of the study will assess small bowel motility in a cohort of Crohns disease patients will small bowel disease before and 11--‐16 weeks after starting anti TNF alpha therapy, or undergoing endoscopic dilatation of a small bowel stricture. Each scan will last around 45 minutes
2971383|NCT02754856|Experimental|Tremelimumab + MEDI4736|"Participants receive Tremelimumab by vein over about 1 hour and MEDI4736 by vein over about 4 hours during Week 11. After Week 11, participants receives MEDI4736 alone by vein over about 1 hour during Weeks 21, 25, 29, and 33.~Between Weeks 15 and 17, participant undergoes scheduled liver surgery."
2971384|NCT02754843|Active Comparator|Naida Q90-SP|Phonak's commercial power Behind-The-Ear (BTE) device, type 1.
2971385|NCT02754843|Active Comparator|Naida Q90-UP|Phonak's commercial power Behind-The-Ear (BTE) device, type 2.
2971386|NCT02754830|Experimental|LY3303560|Single IV infusion or SC injection of LY3303560 on Day 1
2971387|NCT02754830|Placebo Comparator|Saline Solution|Single IV infusion of saline solution to match LY3303560 on Day 1
2971388|NCT02754817||Insulin degludec/liraglutide|
2971389|NCT02754804||PAD patients|Patients with grade 1 claudication Measurement of biomechanic parameters while walking on treadmill
2971390|NCT02754791|No Intervention|Monthly report|A monthly report will be submitted to department heads describing their departments rate of blood culture contamination and comparing it to blood culture contamination rate in previous months and to blood culture contamination rate of the hospital as a whole
2971391|NCT02754791|Experimental|Steripath|The Steripath device (Magnolia) will be used to take blood cultures in this arm instead of standard methods. This will be in addition to a departmental monthly report (described above).
2971392|NCT02754791|Experimental|Soluprep wipes|In this arm, skin sterilization will be achieved using Soluprep wipes (3M) instead of standard methods (alcohol wipes).This will be in addition to a departmental monthly report (described above).
2971393|NCT02754778|No Intervention|control group|no intervention, regular family life
2971394|NCT02754778|Active Comparator|intervention group|6 month of regular conditional workout 1-3 times a week
2971395|NCT02754765|Experimental|endTB regimen 1 (BeLiMoZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based.
2971396|NCT02754765|Experimental|endTB regimen 2 (BeLiCLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based.
2971397|NCT02754765|Experimental|endTB regimen 3 (BeDeLiLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based.
2971398|NCT02754765|Experimental|endTB regimen 4 (DeLiCLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based.
2971399|NCT02754765|Experimental|endTB regimen 5 (DeCMoZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based.
2971400|NCT02754765|Active Comparator|endTB regimen 6 (Control)|endTB regimen 6 is the control regimen.
2971401|NCT02754752|Experimental|Electro-Acupuncture Group - Specific Body Points|"Participants receive up to 10 electro-acupuncture sessions over 4 weeks. Fixed core points used for the treatment of PMPS and supplemented by the addition of other fixed points based on location of pain and the one additional symptom causing the patients the most problems.~Questionnaires completed at baseline, weeks 1 - 4 and at week 8."
2971402|NCT02754752|Sham Comparator|Electro-Acupuncture Group - Different Body Points|"Participants receive up to 10 electro-acupuncture sessions over 4 weeks using slightly different techniques. Fixed core points used for the treatment of PMPS and supplemented by the addition of other fixed points based on location of pain and the one additional symptom causing the patients the most problems. Participants offered EA at the end of their participation.~Questionnaires completed at baseline, weeks 1 - 4 and at week 8."
2971403|NCT02754752|Other|Wait-List Control (WLC) Group|"Participants in WLC group receive standard medical care as prescribed by their oncologists/primary care physicians. Participants offered EA at the end of their participation.~Questionnaires completed at baseline, weeks 1 - 4 and at week 8."
2971774|NCT02752256||Control|Patients presenting directly to the comprehensive stroke center
2971405|NCT02754739|Placebo Comparator|Placebo|Placebo drug indistiguishable from pravastatin 40mg tablet, by mouth, once daily for 24 weeks. Also, nutritional education was provided to participants in all arms by a nutritionist, and participants were instructed to follow the educated guideline.
2971406|NCT02754739|Other|Open-label control|No medication. Only nutritional education was provided to participants by a nutritionist, and participants were instructed to follow the educated guideline.
2971407|NCT02754726|Other|single arm|open label using combination therapy
2971408|NCT02754713||Patients with acute pericarditis|300 patients with a first episode of acute pericarditis
2971409|NCT02754700|Experimental|Biofeedback Hip|Hip focused biofeedback with neuromuscular training
2971410|NCT02754700|Experimental|Biofeedback Knee|Knee focused biofeedback with neuromuscular training
2971411|NCT02754700|Active Comparator|Neuromuscular Training|Neuromuscular Training component
2971412|NCT02754687|Placebo Comparator|Placebo|Placebo
2971413|NCT02754687|Experimental|11βmethyl nortestosterone dodecylcarbonate|11β-MNTDC in doses of 100 mg, 200 mg, 400 mg, and 800 mg
2971414|NCT02754674|Experimental|Transportal|this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with transportal technique
2971415|NCT02754674|Experimental|Outside in|this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with patients who underwent operation with outside in technique
2971416|NCT02754661|Experimental|COLON Capsule endoscopy|"Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the CCE procedure day. With the exception of Gastrografin, all colon preparation products will be standard colon cleansing products approved by the FDA.~Between 45 and 75 minutes after the final PEG ingestion, the subject will swallow the PillCam COLON Capsule with a cup of water.~If necessary, capsule position will be monitored to ensure adequate booster administration. Subjects will keep a timed diary of key preparation steps and bowel activity, including capsule excretion. Subjects will be allowed to leave the unit 10 hours after capsule ingestion if the capsule is not yet excreted. Subjects leaving before excretion will be instructed to disconnect the recorder at excretion or 12 hours after capsule ingestion (whichever comes first)."
2971417|NCT02754661|Active Comparator|Computed Tomographic Colonography|"Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the Computed Tomographic Colonography (CTC) procedure day.~The CTC procedure and study interpretation will be conducted in accordance with the ACR-SAR-SCBT-MR Practice Parameter for the Performance of CT Colonography in Adults. Colon insufflation will be performed with the subject in the lateral decubitus or supine position.With the subject in the supine position, a CT scout image will be taken to confirm adequate colon distention. If adequate bowel distention is not achieved, additional air will be insufflated into the colon. After scanning the subject in the supine position, the subject will be placed in the prone position, and additional CO2 will be administered. Subsequently, CT will be performed with the subject in the prone position. If a prone position is not possible for the subject, a left lateral decubitus position is preferred for optimal gas and fluid redistribution."
2971418|NCT02754648|Active Comparator|Group A; laparoscopic ovarian endometrial aspiration|Laparoscopic ovarian endometrial aspiration will be done for thirty patients with ovarian endometriotic cyst. .
2971419|NCT02754648|Active Comparator|group B; laparoscopic ovarian endometrial stripping|Laparoscopic ovarian endometrial stripping will be done for thirty patients with ovarian endometriotic cyst.
2971420|NCT02754648|Active Comparator|Group c laparoscopic ovarian endometrial de-roofing|Laparoscopic ovarian endometrial de-roofing and bed cauterization will be done for thirty patients with ovarian endometriotic cyst.
2971421|NCT02754635|Active Comparator|Induction of labour|Induction of labour at 38-39 weeks
2971422|NCT02754635|Active Comparator|Expectant management|Expectant management until 41 weeks.
2971423|NCT02754622||Observational Group|"2hours before planned physical rehabilitation patients will have their regular ventilator changed to the study ventilator by an ICU Consultant and patients will be clinical stable for 30mins prior to the start of the planned physical rehabilitation.~Intended physical rehabilitation as planned will continue without change. This session will be observed by a member of the research team to ensure accurate documentation of the exact timing of performance of the physical rehabilitation activity.~Patients will also undergo an assessment by the Medical Research Council Sum-score and maximal inspiratory pressure (all part of routine physiotherapy assessment).~Following the physical rehabilitation session, the patient to rate their perceived exertion then patients will also undergo ultrasound assessment of peripheral skeletal muscle architecture.~Patients return to their original ventilator after 30mins by an ICU Consultant."
2971424|NCT02754609|Experimental|Necator americanus-hookworm larvae L3-10|A total of 40 participants week 0 and week 8 will have low dose hookworms present in 2-3 drops of water applied to their skin and then covered in a light dressing. The hookworms are Necator americanus-hookworm larvae L3; 10 L3 in 200 microliter (uL) of deionized water presented in an Eppendorf tube. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge. At week 42, participants will have the option of going on the liberal diet.
2971425|NCT02754609|Placebo Comparator|Tabasco® Sauce|A total of 10 participants at week 0 and week 8 will have Tabasco® Sauce present in 2-3 drops of water applied to their skin and covered in a light dressing. Tabasco® Sauce is an ideal placebo as the sensation to the skin is similar to a hookworm. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge.
2971426|NCT02754609|Experimental|Necator americanus-hookworm larvae L3-20|A total of 10 participants at week 0 and week 8 will have medium dose hookworms present in 2-3 drops of water applied to their skin and then covered in a light dressing. The hookworms are Necator americanus-hookworm larvae L3; 20 L3 in 200 uL of deionized water presented in an Eppendorf tube. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge. At week 42, participants will have the option of going on the liberal diet.
2971427|NCT02754596|Experimental|Travoprost Intraocular Implant, high elution|This implant will be surgically implanted and elute travoprost, a prostaglandin.
2971428|NCT02754596|Experimental|Travoprost Intraocular Implant, low elution|This implant will be surgically implanted and elute travoprost, a prostaglandin.
2972125|NCT02749981||Cefazolin|patients receiving cefazolin as part of routine clinical care
2971430|NCT02754583|Experimental|WASH arm|Behavioral: Water, sanitation, and hygiene (WASH) intervention: Communities will receive the water, sanitation, and hygiene (WASH) intervention including water point construction, hygiene and sanitation promotion, and educational materials.
2971431|NCT02754583|Other|Standard of care WASH arm|Standard of care WASH intervention: Communities will continue to receive the standard of care WASH programming offered by the Ethiopian government. These communities will receive a WASH package at the conclusion of the study, including water point construction, hygiene and sanitation promotion, and educational materials.
2971432|NCT02754583|Experimental|Targeted antibiotics arm|Targeted antibiotic treatment: Communities will receive targeted antibiotic treatments for children testing positive for ocular chlamydia at 3, 6, 9, and 12 months after baseline testing. After testing for ocular chlamydia at 12 months, any children testing positive at this time point will receive antibiotic treatments at 15, 18, 21, and 24 months. Children 6 months and up will be offered azithromycin 20mg/kg; those under 6 months will be offered tetracycline.
2971433|NCT02754583|Other|Delayed mass antibiotics arm|Delayed mass antibiotic treatment: Communities will receive no mass azithromycin treatment during the study period. Communities in this treatment group have previously received at least 8 rounds of mass azithromycin treatment. These clusters will be enrolled in an antibiotics treatment program (azithromycin or tetracycline) after the completion of the study.
2971434|NCT02754583|Active Comparator|Mass antibiotics arm|Mass antibiotic treatment: Communities will receive mass azithromycin treatment of all individuals aged 6 months and up (20mg/kg for children; 1 g for adults); those younger than 6 months, pregnant, or allergic to macrolide antibiotics will be offered a 2-week course of tetracycline.
2971435|NCT02754583|Experimental|Intestinal microbiome|Children will be randomized in a factorial design to oral albendazole treatment on day 0 versus albendazole treatment on day 7, and to azithromycin treatment on day 0 versus azithromycin treatment on day 7. Note that all children will receive both a single dose of azithromycin and a single dose of albendazole; the only difference is that the doses will be spaced 1 week apart.
2971436|NCT02754570|Experimental|Pilocarpine group|Subjects with open-angle glaucoma and ocular hypertension.
2971437|NCT02754557|Experimental|Breath-Focused Meditation|Women with post traumatic stress disorder (PTSD) will receive breath-focused meditation.
2971438|NCT02754557|Experimental|Breath-Focused Meditation + Physiological Feedback|Women with post traumatic stress disorder (PTSD) will receive breath-focused meditation and physiological feedback.
2971439|NCT02754544|Experimental|PMT High-Resolution Grid Group|Electrocorticography (ECoG) mapping takes place during participant's scheduled surgery. PMT High-Resolution Grids with fixed contact diameter used during ECoG. Mapping grid placed directly on the surface of participant's brain during surgery. A wireless digital glove used with the high-definition grid. When the grid is in place, the anesthesiologist will wake participant up and they will be asked to wear the special glove and perform hand movements. Continuous hand grasp force levels and resting state measured with a grip sensor during surgery. Direct electrical stimulation mapping performed by neurosurgeon during surgery. Neurological exam performed one day after surgery.
2971440|NCT02754544|Experimental|CorTec High-Resolution Hybrid Grid Group|Electrocorticography (ECoG) mapping takes place during participant's scheduled surgery. CorTec High-Resolution Hybrid Grids with fixed contact diameter used during ECoG. Mapping grid placed directly on the surface of participant's brain during surgery. A wireless digital glove used with the high-definition grid. When the grid is in place, the anesthesiologist will wake participant up and they will be asked to wear the special glove and perform hand movements.Continuous hand grasp force levels and resting state measured with a grip sensor during surgery. Direct electrical stimulation mapping performed by neurosurgeon during surgery. Neurological exam performed one day after surgery.
2971441|NCT02754544|Experimental|Ad-Tech Grid Group|Electrocorticography (ECoG) mapping takes place during participant's scheduled surgery. Ad-Tech Grids with fixed contact diameter used during ECoG. Mapping grid placed directly on the surface of participant's brain during surgery. A wireless digital glove used with the high-definition grid. When the grid is in place, the anesthesiologist will wake participant up and they will be asked to wear the special glove and perform hand movements. Continuous hand grasp force levels and resting state measured with a grip sensor during surgery. Direct electrical stimulation mapping performed by neurosurgeon during surgery. Neurological exam performed one day after surgery.
2971442|NCT02754531|Experimental|Subjects|USG was used to measure the internal transversal subglottic diameter on the crichoid cartilago level while the head was in sniffing position. After USG measurement was recorded, Cole formula was used to measure internal diameter of uncuffed endotracheal tube.
2971443|NCT02754518|Other|Open label Entresto|All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.
2971444|NCT02754505|Other|Early rehabilitation group|Directly after transfer to a general ward the early rehabilitation group started with an early rehabilitation program, as ordered by an experienced physiatrist. The applied intervention (early rehabilitation) is a combination out of different therapeutic modalities (for further information please see interventions).
2971445|NCT02754505|Other|Usual care group|The usual care group received single physical therapy sessions as ordered by the primary care team after transfer from the ICU to the general ward. The applied intervention (usual care) is a combination out of different therapeutic modalities (for further information please see interventions).
2971446|NCT02754492|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
2971447|NCT02754492|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
2971448|NCT02754492|Experimental|Triple Platelet Product|Healthy adult volunteer blood donors that qualify for a triple unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections
2971449|NCT02754479|Experimental|Laser treatments|Each subject will receive a combination of 532 nm KTP and/or 1064 nm Nd:YAG laser treatment
2971450|NCT02754466|Experimental|Deep dentin lesions|Subjective vs objective criteria in selective excavation of carious lesions Group 1: selective carious dentin excavation using subjective criteria (standard protocol in Dentistry) Group 2: selective carious dentin excavation using objective criteria (polymer burs) All restorations performed using high-viscosity glass-ionomer.
2971451|NCT02754466|Experimental|Shallow and medium depth dentin lesion|Glass-ionomer vs Bulk fill composites in the ART approach All cavities excavated using hand-instruments only (ART approach) Group 1: restorations using high-viscosity glass-ionomer Group 2: restorations using self-etch adhesive and bulk fill composite
2971452|NCT02754453|Other|Behavioral|
2971453|NCT02754440|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
2971454|NCT02754440|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
2971455|NCT02754440|Experimental|Triple Platelet Product|Healthy adult volunteer blood donors that qualify for a triple unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
2971456|NCT02754427|Experimental|Prospective Surveillance Group|Women assigned to surveillance group were assessed for arm morbidity at pre-surgery and at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any time-point post-surgery, then a physiotherapy intervention was prescribed.
2971457|NCT02754427|Active Comparator|Education Group|Participants in the education group received the usual post-operative follow-up.
2971458|NCT02754414|Experimental|Healthy Volunteers|Autologous, cold stored, PAS/plasma suspended platelets stored for various periods (3 to 20 days).
2971459|NCT02754401|Other|group 1|non-periodontitis persons (PSI 0-2)
2971460|NCT02754401|Other|group 2|periodontitis persons (PSI 3-4)
2971461|NCT02754375|Experimental|Patient|Patient with resistant depression treated with rTMS
2971462|NCT02754362|Experimental|Block 1|
2971463|NCT02754362|Experimental|Block 2|
2971464|NCT02754362|Experimental|Block 3|
2971465|NCT02754349|Experimental|Validation|SphygmoCor version 7, AtCor Medical, Sydney, Australia
2971466|NCT02754336|Active Comparator|Cogmed Robomemo, working memory training|Robomemo working memory training, 25 sessions with 8 verbal and non-verbal tasks per session.
2971467|NCT02754336|Active Comparator|Othmer, neurofeedback|Othmer method neurofeedback, 25 sessions a 30 minutes.
2971468|NCT02754323|Other|apparatus CODESNA|correlation between job stress measurement by the Maslach Burnout INVENTORY and KARASEK questionnaires and measurement of chronic stress by CODESNA tool
2971469|NCT02754310|Active Comparator|Repeated scenarios|Participants in the repeated scenario group will learn the management of a pediatric asthma exacerbation on the same scenario repeated three times. The scenario is a pediatric moderate asthma exacerbation not responding to treatment, .
2971470|NCT02754310|Experimental|Varied scenarios|"Participants in the varied scenarios group will learn the management of a pediatric asthma exacerbation on three different scenarios: a moderate asthma exacerbation, a mild one, and a severe one, for the same length of time than the repeated scenarios group. In this group, there is a variation of scenarios."
2971471|NCT02754297|Experimental|Personalized PRRT (P-PRRT)|"177Lu-Octreotate (LuTate) P-PRRT will be administered as follows:~Renal absorbed radiation dose will be prescribed for the 4-cycle induction course (23 Gy) and for each subsequent cycle (6 Gy), with a reduction in cases of impaired renal or bone marrow function, or significant toxicity from prior cycles.~The personalized activity to be administered at each cycle will be derived from renal dose per unit of injected activity that is predicted by patient characteristics or renal dose delivered during prior cycle(s).~Participants responding to the induction course of P-PRRT will be eligible to receive additional consolidation and/or maintenance cycles.~Participants with prior PRRT exposure outside the trial may receive less induction cycles, or only consolidation/maintenance cycle(s)."
2971472|NCT02754284|Experimental|Autologous fat transplantation|
2971473|NCT02754284|Experimental|Functional collagen scaffold transplantation|
2971474|NCT02754271|Experimental|Intervention|A research-based film (Fit for Dialysis) and a 16-week exercise program involving activities during dialysis, at home, and in the community.
2971475|NCT02754271|No Intervention|Control|The 16-week exercise program involving activities during dialysis, at home, and in the community.
2971476|NCT02754258|Placebo Comparator|Placebo|60 day oral administration of sugar placebo twice per day before lunch and supper.
2971477|NCT02754258|Experimental|Methylphenidate (MPH)|60 day oral administration of active study drug (methylphenidate) twice per day before lunch and supper.
2971478|NCT02754245||JPS|study sample at JPS included for analysis
2971479|NCT02754245||BUMC Dallas|study sample at Baylor University Medical Center Dallas included for analysis
2971480|NCT02754245||BUMC at Gardin|study sample at Baylor University Medical Center Gardin included for analysis
2971481|NCT02754245||BUMC Waxahachie|study sample at Baylor University Medical Center Waxahachie included for analysis
2971482|NCT02754245||BUMC Carrolton|study sample at Baylor University Medical Center Carrolton included for analysis
2971483|NCT02754245||BUMC McKinney|study sample at Baylor University Medical Center McKinney included for analysis
2971484|NCT02754232|Active Comparator|Telemedical training|Patients in the intervention group will receive telemedical training 21 times, three times weekly for seven weeks. During the first three weeks the regional physiotherapists will be responsible for the training. Municipal occupational -and physiotherapists will manage the last four weeks' training.
2971485|NCT02754232|No Intervention|The usual training or no training|Patients in the control-group will receive no telemedical training. They will be discharged to the municipal sphere with a rehabilitation plan, where they have the possibility to receive training.
2971486|NCT02754219|Experimental|Evogliptin|Hepatic dysfunction, Healthy control
2971487|NCT02754206||Control|Subjects who are collegiate level athletes who do not have a concussion and are currently playing a contact-collision sport.
2971489|NCT02754193|Experimental|Moderate hypothermia|Moderate hypothermia :Patients with cardiogenic shock treated with arteriovenous ECMO to a strategy of moderate hypothermia during 24 hours (Temperature at 33°C≤ T°C ≤34°C) associated with usual care
2971490|NCT02754193|No Intervention|Normothermia|Normothermia: Patients with cardiogenic shock treated with arteriovenous ECMO to a strategy of normothermia (37 °C ± 0.3°C) associated with usual care
2971491|NCT02754180|Active Comparator|chemotherapy|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles.
2971492|NCT02754180|Experimental|chemotherapy with chemoradiation|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.
2971493|NCT02754167|Experimental|PRS-080#022-DP|Hepcidin antagonist, single administration, ascending doses
2971494|NCT02754167|Placebo Comparator|PRS-080-Placebo#001|Comparator treatment, single administration
2971495|NCT02754154||Patients using Warfarin|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Warfarin
2971496|NCT02754154||Patients using Apixaban|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Apixaban
2971497|NCT02754154||Patients using Dabigatran|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Dabigatran
2971498|NCT02754154||Patients using Rivaroxaban|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Rivaroxaban
2971499|NCT02754141|Experimental|Arm A-Monotherapy|BMS-986179, dose as specified
2971500|NCT02754141|Experimental|Arm B- Combination Therapy|BMS-986179 + nivolumab, dose as specified
2971501|NCT02754141|Experimental|Arm C-Combination Therapy|BMS-986179 + rHuPH20, dose as specified
2971502|NCT02754128|Active Comparator|BeFAST|Motor learning-based program involving athletic lower extremity training of gait-related skills.
2971503|NCT02754128|Active Comparator|BeSTRONG|Lower limb strength training program involving progressive muscle resistance exercises.
2971504|NCT02754102|Experimental|Sunscreen Spray-Liquid|All subjects are patched with the same product
2971505|NCT02754089|Experimental|Rhus|500 mg twice daily after meal for 6 weeks
2971506|NCT02754089|Placebo Comparator|Placebo|500 mg twice daily after meal for 6 weeks
2971507|NCT02754076|Experimental|BMN 250|In Part 1, patients will receive up to 3 escalating doses of BMN 250 (30, 100 and 300 mg) via ICV infusion every week until the maximum tolerated tested dose (MTTD) is established. In Part 2, patients will receive weekly doses of BMN250 via ICV infusion that will continue for 48 weeks at the MTTD established in Part 1.
2971508|NCT02754063|Active Comparator|ICP Management|
2971509|NCT02754063|Experimental|PbtO2 + ICP Management|
2971510|NCT02754050|Experimental|Polypectomy|When a 6-25mm polyp is identified the Tandem snare will be inserted through the colonoscope, remove and retrieve the polyp.
2971511|NCT02754024||Total shoulder arthroplasty (TSA)|Replacement of humeral head and glenoid
2971512|NCT02754024||Hemi shoulder arthroplasty (HSA)|Replacement of humeral head only
2971513|NCT02754011|Experimental|combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
2971514|NCT02753998|Experimental|Conventional angioplasty + paclitaxel-coated balloon|Treatment of stenosis of AVF by conventional angioplasty + 1 minute additional angioplasty with paclitaxel-coated balloon
2971515|NCT02753998|Placebo Comparator|Conventional angioplasty + placebo balloon|Treatment of stenosis of AVF by conventional angioplasty + 1 minute additional angioplasty with placebo balloon.
2971516|NCT02753972|Experimental|Mindful Eating and Living|The goal of the Mindful Eating and Living (MEAL) intervention was to apply mindfulness to apply mindfulness to eating behavior. The content for the MEAL sessions included group discussion, mindfulness meditation, and group eating exercises. The course, based on the work of Kristeller, Baer, & Quillian-Wolever (31), emphasized brief daily meditation and pairing meditation with eating, but was more streamlined in terms of didactic content and course length. Participants examined hunger and satiety cues, the qualities of foods they crave, and emotional and cognitive states associated with eating. Each session included an eating exercise with a variety of foods. The monthly refresher sessions included a brief meditation, a brief eating exercise, and group discussion. (The MEAL curriculum is available from the authors.)
2971517|NCT02753972|Active Comparator|Active Control|The Active Control (CONT) group matched the MEAL group regarding schedule. The agenda for the CONT sessions involved giving each participant the opportunity to discuss issues such as food choices, activity levels, and caloric goals. The sessions began by having the participants check-in about their experiences with eating. Next, the clinical psychology graduate student led the participants in goal setting and finally there was a question and answer period when the registered dietician answered questions about food selection. The monthly refresher sessions had the same agenda as the initial weekly sessions.
2971518|NCT02753959|Experimental|Acute Intervention|Patients will need to be Clinically stable patients with established neuromuscular disease with clinical secretions or cough PEF <270 and history of chest infections. Patients are required to be stable for the preceding 4 weeks with no changes to medications or ventilator settings.
2971519|NCT02753959|Experimental|Stable Intervention|Patients with established neuromuscular disease admitted to either the Lane Fox Respiratory Unit or Critical Care at St Thomas' Hospital with acute respiratory deteriorations and with the need for respiratory physiotherapy for secretion management.
2971520|NCT02753946|Experimental|ZTI-01|6 g ZTI-01 (IV fosfomycin) intravenously administered every 8 hours (18g total daily dose for 7-14 calendar days)
2971521|NCT02753946|Active Comparator|piperacillin tazobactam|4.5 g piperacillin/tazobactam (4 g piperacillin/0.5 g tazobactam) intravenously administered every 8 hours (13.5g total daily dose for 7-14 calendar days)
2971522|NCT02753933||MRI scan|Direct referral from Primary Care (GPs) to an MRI scan as the initial Secondary Care point of contact.
2971523|NCT02753933||Neurology Appointment|Referral from Primary Care (GPs) to Neurology Services in Secondary Care as the initial Secondary Care point of contact.
2971560|NCT02753738|Placebo Comparator|Placebo treatment|Subjects will receive 21 days of placebo treatment while performing learning paradigms.
2971561|NCT02753725|Active Comparator|Fentanyl group|Fentanyl given at a dose of one micro gram per kilogram body weight
2972368|NCT02748499|Active Comparator|Control|The control group maintains daily activities.
2971524|NCT02753920|Active Comparator|Retrograde fill voiding trial method|"Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water.~Catheter is removed~Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction).~The patient will subjectively quantify their force of stream via visual analog scale (VAS) scale (however this information will only be used for research purposes).~If she voids >/= 2/3 (200cc) the catheter will remain out as she will have passed her voiding trial. If she voids <200cc she will be discharged home with a catheter and instructed to follow-up in 2-5 days for an in-office retrograde voiding trial."
2971525|NCT02753920|Active Comparator|Force of Stream (FAST) voiding trial method|"Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water.~Catheter is removed~Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction).~The patient will subjectively quantify their force of stream via VAS scale.~If VAS scale >/=50 (>/=50%) the catheter will remain out, patient is discharged home without measuring a PVR~If VAS scale is from 0-49 (=0-49%) a PVR will be checked via bladder scan. If PVR is <500cc, the patient will be discharged without a catheter; if PVR is >/=500cc, the patient will be discharged with a catheter. If she is discharged with an indwelling foley catheter, she will have an in-office retrograde voiding trial in 2-5 days."
2971526|NCT02753907|Experimental|Low LA (linoleic acid)|Individuals who replaced 10 mL soy oil with one apple
2971527|NCT02753907|No Intervention|Medium LA|Individuals who maintained their usual food intake
2971528|NCT02753907|Experimental|High LA|Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9 g of soy oil as a supplement
2971529|NCT02753894|Experimental|4.5 g/day group|Three times a day
2971530|NCT02753894|Experimental|6.0 g/day group|Three times a day
2971531|NCT02753894|Experimental|7.5 g/day group|Three times a day
2971532|NCT02753881|Active Comparator|whole liver lobe cTACE doxorubicin|Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a lobar (whole liver) manner.
2971533|NCT02753881|Active Comparator|superselective cTACE doxorubicin|Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a super-selective (close to the tumor) manner.
2971534|NCT02753868|Experimental|Standard Hemodialysis|Participants will be monitored during their normal hemodialysis treatment with no intervention administered
2971535|NCT02753868|Experimental|Hemodialysis with Exercise (1-st hr)|Participants will be monitored during a normal dialysis treatment in which they cycle at mild to moderate intensity for 30 minutes during 1-st hour into treatment
2971536|NCT02753868|Experimental|Hemodialysis with Exercise (3-rd hr)|Participants will be monitored during a normal dialysis treatment in which they cycle at mild to moderate intensity for 30 minutes during 3-rd hour into treatment
2971537|NCT02753855|Experimental|Telavancin Administration|Single dose of telavancin administered as a 1-hour intravenous infusion
2971538|NCT02753842|Experimental|Fitted condoms|Participants will receive all conditions (fitted condoms, thin condoms, and standard condoms), with the order in which condoms are received based on permuted block randomization.
2971539|NCT02753842|Active Comparator|Thin condoms|Participants will receive all conditions (fitted condoms, thin condoms, and standard condoms), with the order in which condoms are received based on permuted block randomization.
2971540|NCT02753842|Active Comparator|Standard condoms|Participants will receive all conditions (fitted condoms, thin condoms, and standard condoms), with the order in which condoms are received based on permuted block randomization.
2971541|NCT02753829|Experimental|Experimental group 1|Cardiovascular rehabilitation program using Kinect of Xbox, in home care context,virtual format
2971542|NCT02753829|Experimental|Experimental group 2|Cardiovascular rehabilitation program using paper manual, in home care context, conventional format
2971543|NCT02753829|Other|Control Group|Educational component
2971544|NCT02753816|Experimental|Tranexamic Acid|1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery
2971545|NCT02753816|Placebo Comparator|Placebo|Placebo given over 10 minutes into the vein once prior to surgery
2971546|NCT02753803|Experimental|A group|Evogliptin Pioglitazone Evogliptin+Pioglitazone
2971547|NCT02753803|Experimental|B group|Pioglitazone Evogliptin Evogliptin+Pioglitazone
2971548|NCT02753803|Experimental|C group|Evogliptin Evogliptin+Pioglitazone Pioglitazone
2971549|NCT02753803|Experimental|D group|Pioglitazone Evogliptin+Pioglitazone Evogliptin
2971550|NCT02753803|Experimental|E group|Evogliptin+Pioglitazone Evogliptin Pioglitazone
2971551|NCT02753803|Experimental|F group|Evogliptin+Pioglitazone Pioglitazone Evogliptin
2971552|NCT02753790|Experimental|Intensity Modulated Radiotherapy (IMRT)|Radiation therapy to a dose of 60 Gray (Gy)/45 Gy to gross disease and 30 Gy to subclinical sites, delivered over 15 fractions
2971553|NCT02753764|No Intervention|Normal control|Health volunteers will be recruited as an additional control group.
2971554|NCT02753764|Other|Corticosteroid sensitive (CS) asthmatics|After the initial visit, asthmatics will be given oral prednisone for 1 week and patients will return for the spirometer assessment. Patients will be defined as CR if <10% improvement in FEV1 % predicted is observed and as CS in >12% improvement in FEV1% predicted is observed.
2971555|NCT02753764|Active Comparator|Corticosteroid resistant (CR) asthmatics active|The study will have a 1 week oral corticosteroid (OSC) run-in period. Subjects unresponsive to OCS will be defined as corticosteroid resistant (CR) and randomized to two crossover treatment sequences consisting of 4 weeks of inhaled AZD7624 or placebo, followed by 4 weeks of a washout period, and another 4 weeks of placebo or ASD7624
2971556|NCT02753764|Placebo Comparator|Corticosteroid resistant (CR) asthmatics placebo|The study will have a 1 week oral corticosteroid (OSC) run-in period. Subjects unresponsive to OCS will be defined as corticosteroid resistant (CR) and randomized to two crossover treatment sequences consisting of 4 weeks of inhaled AZD7624 or placebo, followed by 4 weeks of a washout period, and another 4 weeks of placebo or ASD7624
2971557|NCT02753751|No Intervention|Usual Care|No alert will be fired.
2971558|NCT02753751|Experimental|Electronic AKI Alert|A pop-up alert will fire when a provider opens the electronic health record of a patient with AKI until such time as AKI is documented in the problem list, or AKI resolves.
2971562|NCT02753725|Placebo Comparator|normal saline group|placebo arm will be given normal saline at a volume equivalent to Fentanyl dose as per body weight.
2971563|NCT02753712|Active Comparator|fluticasone/vilanterol DPI (Relvar Ellipta DPI)|Inhalation powder. 92/22µg, I inhalation od
2971564|NCT02753712|Experimental|Fluticasone/formoterol BAI|Pressurised suspension for inhalation 125/5µg, 2 inhalations bid
2971565|NCT02753699|Experimental|From Study 2210|All participants enrolled from CDEB025A2210 (n=164) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
2971566|NCT02753699|Experimental|From Study 2301|All participants enrolled from CDEB025A2301 (n=397) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
2971567|NCT02753699|Experimental|From Study 2211|All participants enrolled from CDEB025A2211 (n=162) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
2971568|NCT02753686||Cohort 1: Endocrine Therapy (ET)|HR+ HER2- postmenopausal advanced breast cancer patients with previous exposure to NSAI therapy in either the adjuvant or metastatic setting and being treated with endocrine therapy
2971569|NCT02753686||Cohort 2: Endocrine Therapy (ET) plus Targeted Therapy (TT)|HR+ HER2- postmenopausal advanced breast cancer patients with previous exposure to NSAI therapy in either the adjuvant or metastatic setting and being treated with endocrine therapy in combination with targeted therapy
2971570|NCT02753673||Breast Cancer|The assessments are all qualitative. The assessments include an in-person, open-ended qualitative interview, during which the interviewer will use an interview guide to ensure that all relevant topics are discussed. Participants will also complete the Patient Expectations with Breast Reconstruction questionnaire using the think-aloud technique in order to identify which questions reflect the expectations of BCT patients, which questions need modification to reflect the expectations of BCT patients and which questions are not appropriate for BCT patients. The responses to the expectations questionnaire for this portion of the interview will not be recorded or analyzed; only the participants' thoughts and opinions about the questions will be recorded.
2971571|NCT02753660|Active Comparator|Traditional sitting position|Patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion before spinal anesthesia begun.
2971572|NCT02753660|Experimental|Pendant position|Patients sit with both their underarms propped up on a metal prop, thus both arms hanging from the prop before spinal anesthesia begun.
2971573|NCT02753647|Experimental|Chidamide plus R-CHOP|Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Doxorubicin 50mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2－6 Chidamide 20mg/d PO d1, 4, 8, 11 Frequency every 21 days for 6 cycles
2971574|NCT02753634|Experimental|Square-stepping exercise Intervention|Participant attend sessions 2 times per week for 24-weeks at a community location. An instructor demonstrated increasingly difficulty walking or stepping patterns across a gridded mat and participants are asked to try and remember and repeat the patterns. Social engagement is encouraged.
2971575|NCT02753634|No Intervention|Usual care wait-list control group|This group will be invited to participate in square-stepping exercise after final assessments are completed.
2971576|NCT02753621|Experimental|Singing Intervention|Twelve weekly group singing classes lasting 60-90 minutes under the direction of a professional choir director and a social worker with a music background.
2971577|NCT02753621|Active Comparator|Discussion/Support Group Intervention|Twelve weekly 60-90 minute discussion groups led by a facilitator trained in discussion group facilitation; occurring at the same time and in the same location (next door) as experimental intervention (group singing).
2971578|NCT02753608|Sham Comparator|No ventilator-associated pneumonia (VAP)|Collection of exhaled breath condensate (EBC) in patients without clinical signs of VAP
2971579|NCT02753608|Experimental|Ventilator-associated pneumonia (VAP)|Collection of exhaled breath condensate (EBC) in patients displaying clinical signs of VAP
2971580|NCT02753595|Experimental|Eribulin mesylate plus PEGPH20 (Phase 1b)|"Recommended Phase 2 dose (RP2D) will be assessed in the below dose levels:~RP2D level 1: PEGPH20 (3.0 microgram per killogram (μg/kg)) plus eribulin mesylate (1.4 milligrams per square meter (mg/m2)) or~RP2D level 0: PEGPH20 (1.6 μg/kg) plus eribulin mesylate (1.4 mg/m2) or~RP2D level -1: PEGPH20 (1.6 μg/kg) plus eribulin mesylate (1.1 mg/m2)~Dose level 1 can be selected as the RP2D if no more than 1 out of 6 participants has a DLT; otherwise, Dose level 0 will be assessed in a second cohort of 6 subjects and will be selected as the RP2D if no more than 1 subject has a DLT. Otherwise, Dose level - 1 will be assessed in a third cohort of 6 subjects. If no more than 1 of 6 subjects in this third cohort has a DLT, the Phase 2 part will proceed with dose level -1 as the RP2D. Otherwise, alternative doses will be explored prior to the start of Phase 2."
2971581|NCT02753595|Experimental|Eribulin mesylate plus PEGPH20 (Phase 2)|Participants will receive eribulin mesylate and PEGPH20 at the established RP2D level achieved in the Phase 1b.
2971582|NCT02753595|Experimental|Eribulin mesylate (Phase 2)|Participants will receive eribulin mesylate at 1.4 mg/m2.
2971583|NCT02753582|Active Comparator|Intervention|SOD+Gliadin capsule is given in a dosage of 250 mg twice a day, for 24 weeks.
2971584|NCT02753582|Placebo Comparator|Placebo|Placebo capsule is given in a dosage of 250 mg twice a day, for 24 weeks.
2971585|NCT02753543|Experimental|Chidamide plus previous chemotherapy|Chidamide 20mg/d Biw p.o. on d1,4,8,11 for of each cycle for 3 cycles
2971586|NCT02753530|Experimental|Arimoclomol|Participants will be asked to take 400mg arimoclomol three times a day.
2971587|NCT02753530|Placebo Comparator|Placebo|Participants will be asked to take 400mg placebo three times a day.
2971588|NCT02753517|Other|Extended hepatectomy|Hepatic Scintigraphy
2971589|NCT02753504|Experimental|CKD-519 50mg|CKD-519 50mg or placebo
2971590|NCT02753504|Experimental|CKD-519 100mg|CKD-519 100mg or placebo
2971591|NCT02753504|Experimental|CKD-519 200mg|CKD-519 200mg or placebo
2971592|NCT02753491|Active Comparator|Intervention|In intervention group, three or four motivational short interview made with every participants.
2971593|NCT02753491|No Intervention|Control|non intervention group,
2971662|NCT02753023||warfarin intoxication|No intervention related
2971594|NCT02753478|Experimental|intracoronary hypothermia group|Patients who will receive intracoronary hypothermia before and during percutaneous coronary intervention
2971595|NCT02753465|Experimental|left colic artery group|Laparoscopic D3 Lymph Node Dissection with preservation of the left colic artery
2971596|NCT02753465|Active Comparator|High ligation group|Laparoscopic D3 Lymph Node Dissection with high ligation
2971597|NCT02753452|Active Comparator|Residential Immersive Life Skills group|Youth will take part in a residential life skills program of between one and three weeks, consisting of formal workshops, peer learning, outings in the community, one-on-one coaching and daily living tasks carried out with peers (e.g. cooking, laundry, grocery shopping).
2971598|NCT02753452|Active Comparator|Non-residential life skills program|Youth will take part in programs focusing on increasing specific life skills, but taking place only during the day (i.e. non- residential).
2971599|NCT02753452|No Intervention|Deferred RILS applicants|Youth who applied to a Residential Immersive Life Skills program but are deferred to a subsequent year. These youth are included as a comparator group to match the motivation level required to apply to a RILS program.
2971600|NCT02753452|No Intervention|No life skills program|Youth who did not apply or take part in any group life skills program. These youth provide a diagnosis and age matched comparator group.
2971601|NCT02753439|Experimental|3rd molar|Drug: Geistlich Bio Oss
2971602|NCT02753426|Other|Doxycycline-Placebo|Doxycycline 20mg capsule for 30 days, 30-day washout, and then placebo capsule for 30 days.
2971603|NCT02753426|Other|Placebo-Doxycycline|Placebo capsule for 30 days, 30-day washout, and then Doxycycline 20mg capsule for 30 days.
2971604|NCT02753413|Experimental|RSV group|Subjects in this group will receive a single dose of the RSV vaccine.
2971605|NCT02753413|Active Comparator|Boostrix group|Subjects in this group will receive a single dose of Boostrix.
2971606|NCT02753400|Experimental|Emixustat hydrochloride|"Week 1- Four tablets (2 placebo, 2 emixustat HCl Strength A)~Week 2- Four tablets (2 placebo, 2 emixustat HCl Strength B)~Week 3- Four tablets (2 placebo, 2 emixustat HCl Strength C)~Week 4- Four emixustat HCl tablets (Strength C)~All tablets are administered orally once daily. After week 4, all subjects will be held at a stable dose for the remainder of the 12-week dosing regimen."
2971607|NCT02753400|Placebo Comparator|Placebo|Four placebo tablets are administered orally once daily for 12 weeks; Subjects in the placebo group will be mock-titrated on the same schedule as those in the active arm.
2971608|NCT02753387|Experimental|CHLORHEXIDINE|Patients will receive 1 preoperative oral preparation and 1 peroperative oral preparation of chlorhexidine
2971609|NCT02753387|Placebo Comparator|NaCl 0.9 %|Patients will receive 1 preoperative oral preparation and 1 peroperative oral preparation of NaCl 0.9%
2971610|NCT02753361|No Intervention|Traditional|This will utilize the traditional method of performance of regional block
2971611|NCT02753361|Experimental|US-guided|In this arm, regional block will be performed under the ultrasound guidance
2971612|NCT02753348||Newborns|Newborns (within 14 days from birth)
2971613|NCT02753335|Experimental|GMI and Desensitization|Left/right judgement, imagine movements of the affected area, mirror treatment and tactile stimulation of the affected limb with different materials.
2971614|NCT02753335|Experimental|Desensitization|Tactile stimulation of the affected limb with different materials.
2971615|NCT02753322|Experimental|Dual-task training group|"Subjects in this group will have 30 minutes of dual-task training with simultaneously performing balance and walking exercise and attention demanding tasks, and 30 minutes of stretching exercises.~The training program will last for 8 weeks with frequency of 2 sessions a week."
2971616|NCT02753322|Active Comparator|Single-task training group|"Subjects in this group will have single-task training with 30 minutes of balance and walking exercise and 30 minutes of attention demanding task performed separately.~The training program will last for 8 weeks with frequency of 2 sessions a week."
2971617|NCT02753322|Active Comparator|Limbs exercise group|"Subjects in this group will have stretching and strengthening exercise for 60 minutes.~The training program will last for 8 weeks with frequency of 2 sessions a week."
2971618|NCT02753309|Active Comparator|Rapamycin 0.5mg|Subject will take Rapamycin (Sirolimus) 0.5mg once daily for approximately 28 days
2971619|NCT02753309|Active Comparator|Rapamycin 2.0mg|Subject will take Rapamycin (Sirolimus) 2.0mg once daily for approximately 28 days
2971620|NCT02753309|No Intervention|Control|Subject will be apart of the control group and won't take the study drug being tested
2971621|NCT02753283|Experimental|Active Medication Group|Semi-annual dose: denosumab 60 mg semi-annual injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements)
2971622|NCT02753283|Placebo Comparator|Placebo Group|Semi-annual: placebo saline injection; Vitamin D 800-1000 IU/daily and Calcium approximately1200 mg/daily (dietary + supplements)
2971623|NCT02753270|Active Comparator|Short catheter|Twenty-five patients will receive the sclerosant foam by a short catheter 18 G. They will be treated with 3% polidocanol foam prepared with a three-way tap and two plastic disposable syringes, according to Tessari's method.
2971624|NCT02753270|Experimental|Long catheter preceded by tumescence|Twenty-five patients will be receive foam sclerosant by an angiographic catheter 4 French. They will be treated with 3% polidocanol foam prepared with a three-way tap and two plastic disposable syringes, according to Tessari's method.
2971625|NCT02753244|Experimental|Intendu FBT inpatient|Other: Motion Based Cognitive Video Games Software
2971626|NCT02753244|Active Comparator|iPad games|Other: iPad apps
2971627|NCT02753244|Experimental|Intendu FBT community|Other: Motion Based Cognitive Video Games Software
2971628|NCT02753231|Experimental|Low physical activity program|Three Physical Education sessions / week
2971629|NCT02753231|Experimental|High physical activity program|Three Physical Education sessions / week (increased volume)
2971630|NCT02753231|Experimental|Low and High physical activity program|Three Physical Education sessions / week (increased volume and intensity)
2971631|NCT02753231|Active Comparator|Conventional physical activity program|One Physical Education sessions / week
2971632|NCT02753218|Experimental|Midazolam and LEO 32731|
2971633|NCT02753205|Experimental|Control|Infusion of normal saline
2971634|NCT02753205|Active Comparator|Dexmedetomidine|infusion of dexmedetomidine 0.5ug/kg/h for 10 min and after that, infusion of dexmedetomidine 0.4ug/kg/h until the end of surgery
2971635|NCT02753192|Other|Patients|Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons.
2971636|NCT02753179|Experimental|Bilateral vestibular hypofunction|Patients suffering from chronic bilateral vestibular hypofunction.
2971637|NCT02753166|Experimental|Dexamethasone|
2971638|NCT02753166|No Intervention|Control|
2971639|NCT02753153|Experimental|Mucograft®, Geistlich Biomaterials|A Mucograft membrane will be used in state of a connective tissue graft. The dimension of the Mucograft® will be previously calculated according to the site dimensions and inserted into buccal pouch and sutured to be stabilized on the buccal aspect. The membrane is then positioned to cover the socket and inserted and sutured in the palatal pouch by the means of vertical interrupted sutures
2971640|NCT02753153|Active Comparator|Soft tissue graft|
2971641|NCT02753140|Experimental|RT concurrent with cetuximab|Selected 60 patients with locally advanced squamous cell carcinoma of the head and neck. They will be randomized to concurrent chemoradiotherapy versus concomitant cetuximab with radiotherapy after neoadjuvant chemotherapy.To observe the curative effect of the treatment of the cetuximab
2971642|NCT02753140|Experimental|RT concurrent with TP|Selected 60 patients with locally advanced squamous cell carcinoma of the head and neck. They will be randomized to concurrent chemoradiotherapy versus concomitant cetuximab with radiotherapy after neoadjuvant chemotherapy. To observe the curative effect of concurrent radiotherapy and chemotherapy
2971643|NCT02753127|Experimental|Napabucasin plus FOLFIRI|Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion or at least 2 hours following the first daily dose of napabucasin if bevacizumab is not administered. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.
2971644|NCT02753127|Active Comparator|FOLFIRI|Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.
2971645|NCT02753114|Experimental|Intranasal Ketamine|Ketamine dosing will be weight-based as follows: 30mg of IN ketamine for patients weighing 50 kg or less; 50 mg of IN ketamine for patients weighing 50 kg to 100 kg; and 75 mg of IN ketamine for patients weighing greater than 100 kg (i.e. 0.5 mg/kg to 1.0 mg/kg of intranasal ketamine). Syringes containing ketamine will be prepared from the intravenous formulation of Ketamine (50 mg / ml) solution (Sandoz; DIN 02246796) and stored in pre-filled 5 ml syringes. Ketamine will be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses will be administered.
2971646|NCT02753114|Placebo Comparator|Placebo|"Syringes containing normal saline will be prepared such that the volume of normal saline in 5 ml syringes matches that of the ketamine for each of the weight based groups previously specified in the Treatment Arm Description. Syringes containing normal saline will also be labeled Study Drug. The normal saline will also be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses of placebo will be administered."
2971647|NCT02753101|Experimental|Single Arm|[18F]-FTC-146
2971648|NCT02753088|Experimental|BCD-063 (glatiramer acetate)|Subcutaneous injection of glatiramer acetate BCD-063 subcutaneously every day
2971649|NCT02753088|Active Comparator|Copaxone-Teva (glatiramer acetate)|Subcutaneous injection of glatiramer acetate Copaxone-Teva subcutaneously every day
2971650|NCT02753088|Placebo Comparator|Placebo|Subcutaneous injection of mannitol 40 mg, water for injections till 1 ml, every day
2971651|NCT02753075|Experimental|Experimental Oral Rinse 1|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 1 for 1 minute. This regimen will be performed twice daily for 8 weeks.
2971652|NCT02753075|Experimental|Experimental Oral Rinse 2|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
2971653|NCT02753075|Placebo Comparator|Placebo Oral Rinse|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Placebo Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
2971654|NCT02753062|Experimental|bendamustine, rituximab|Bendamustine plus subcutaneous Rituximab treatment of 6 cycles. Rituximab 1400mg subcutaneous over 5mins on day 1 and bendamustine 120mg/m2 + NS 500mL iv over 1hour on day 1 and 2.
2971655|NCT02753049|Experimental|Peer led mHealth adherence intervention|Eligible participants enrolled will receive five, weekly-60 minute, 'ACCESS' sessions, delivered by a peer adherence coach via remote videoconferencing, using smartphones. Cognitive behavioral strategies will be employed to target beliefs about antiretroviral treatment (ART), knowledge of ART, and adherence self-efficacy.
2971656|NCT02753036||Chemotherapy Ovarian|patients with ovarian cancer and paclitaxel/ carboplatin combination chemotherapy
2971657|NCT02753036||Control Ovarian|patients with benign gynecological tumors after surgical tumor resection
2971658|NCT02753036||Chemotherapy Breast|patients with breast cancer and epirubicin/cyclophosphamide/paclitaxel combination chemotherapy
2971659|NCT02753036||Control Breast|patients with breast cancer and radiation and/or antihormonal treatment
2971660|NCT02753023||acute coronary syndromes|No intervention related
2971661|NCT02753023||acute decompensated heart failure|No intervention related
2971669|NCT02753010||Elective hip replacement|Women on waiting list for elective hip replacement with gastric emptying of carbohydrate-rich beverage
2971670|NCT02753010||Healthy volunteers|Healthy female volunteers with gastric emptying of carbohydrate-rich beverage
2971671|NCT02752997|Experimental|Intervention|"Discharge medication services included:~Discharge medication reconciliation~Identification of medication discrepancies and resolution~Medication counseling using health coaching techniques with short term goal setting and follow up phone call"
2971672|NCT02752997|No Intervention|Comparator|Current standard of care provided by nursing staff.
2971673|NCT02752984||PICC insertion|Peripherally Inserted Central Catheter insertion
2971674|NCT02752971|Experimental|Bupivacaine|A dilution of Bupivacaine 0,25% , 15 ml was infiltrated in surgical wound after close the aponeurosis
2971675|NCT02752971|Experimental|Bupivacaine, sodium diclofenac|A dilution of Bupivacaine 0,25% and sodium diclofenac 75 mgr, was infiltrated in surgical wound after close the aponeurosis
2971676|NCT02752971|Experimental|Sodium diclofenac|A dilution of sodium diclofenac 75 mgrs (3ml) and 12 ml of solution 0,9% was infiltrated in surgical wound after close the aponeurosis
2971677|NCT02752958|Experimental|stannous fluoride|This was a non-comparative design study, all the participants applied dentifrice containing stannous fluoride for 1 timed minute, twice daily (morning and evening) for 24 weeks.
2971678|NCT02752945|Experimental|One-day CBT workshop (+Usual Care)|"One-day CBT-based workshop (DISCOVER), followed by up to three brief telephone contacts to review goals set in workshop."
2971679|NCT02752945|Active Comparator|Usual care|Usual care afforded by local CAMHS services
2971680|NCT02752932|Other|HNSCC -PDX development|Participants with HNSCC who will undergo curative surgery will be included in this group. This involves PDX development only, no drug testing will be done on the PDX.
2971681|NCT02752932|Other|RMHNSCC -PDX drug testing|Participants with RMHNSCC who are under palliative treatment will be included in this group. Drug testing on PDX per Investigator's choice (upto 4): PDX will be developed and upto four Chemotherapeutics (that are funded in Ontario) will be tested on the PDX. Chemotherapeutics will be selected at the discretion of the treating Medical Oncologists. Result of the drug testing will be provided to the responsible physician and can be utilized in patient care.
2971682|NCT02752919|Experimental|Part A Galunisertib - 1 tablet|Single oral dose of galunisertib in Japanese participants
2971683|NCT02752919|Experimental|Part A Galunisertib - 2 tablets|Single oral dose of galunisertib in Japanese participants
2971684|NCT02752919|Experimental|Part B Galunisertib - 1 tablet|Single oral dose of galunisertib in non-Japanese participants
2971685|NCT02752919|Experimental|Part B Galunisertib - 2 tablets|Single oral dose of galunisertib in non-Japanese participants
2971686|NCT02752906|Experimental|MenACYW conjugate vaccine Group|Participants randomized to receive a dose of MenACYW conjugate vaccine
2971687|NCT02752906|Active Comparator|Licensed MCV4 Group|Participants randomized to receive a dose of a licensed MCV4
2971688|NCT02752880|Experimental|YH1|YH1 three times per day for 12 consecutive weeks.
2971689|NCT02752880|Placebo Comparator|placebo|placebo three times per day for 12 consecutive weeks.
2971690|NCT02752867|Experimental|Jianpi Yishen Huatan Granules group|Treat with the prescription of Jianpi Yishen Huatan Granules and conventional treatment of ischemic stroke.
2971691|NCT02752867|Placebo Comparator|The control group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin and conventional treatment of ischemic stroke.
2971692|NCT02752854||Group A|Pain threshold measurement in high altitude
2971693|NCT02752854||Group B|Pain threshold measurement in low altitude
2971694|NCT02752841|Experimental|Intervention|Nutritional vitamin D repletion and maintenance
2971695|NCT02752828|Experimental|LixiLan|"LixiLan (insulin glargine/lixisenatide) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
2971696|NCT02752828|Active Comparator|insulin glargine|"Insulin glargine (HOE901) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
2971697|NCT02752815|Active Comparator|6R-CHOP+2R|"6 cycles of R-CHOP Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Epirubicin 70mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2－6 Frequency 21days~2 cycles of Rituximab monotherapy Rituximab 375 mg/m2 IV d1 Frequency 21days"
2971698|NCT02752815|Experimental|4R-CHOP+4R|"4 cycles of R-CHOP Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Epirubicin 70mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2－6 Frequency 21days~2 cycles of Rituximab monotherapy Rituximab 375 mg/m2 IV d1 Frequency 21days"
2971699|NCT02752802|Active Comparator|Treatment|The treatment group will include standard of care for diagnostic angiogram along with the utilizization of the DyeVert system.
2971700|NCT02752802|Active Comparator|Control|The control group will include standard of care for diagnostic coronary angiograms.
2971701|NCT02752789||Pediatric Heart Transplant Recipients|CTOTC-04 (ClinicalTrials.gov ID NCT01005316) participants who consent to long-term follow-up as part of this study as well as candidates less than 21 years of age who are listed for isolated orthotopic heart transplantation at one of the participating sites
2971702|NCT02752776|Experimental|Secukinumab|"All patients are scheduled to receive s.c. injections of secukinumab 300 mg at Week 0, 1, 2 and 3 during the first 4 weeks followed by monthly maintenance dosing of 300 mg secukinumab starting at Week 4 until Week 48. Consideration should be given to discontinuing treatment in patients who have shown no response up to 16 weeks of treatment (e.g. patients who did not achieve a PASI 50 response). If discontinued, patients will complete the end of study visit assessments. Some patients with an initially partial response (e.g.~patients who achieve a PASI 50 response but not a PASI 75 response) may subsequently improve with continued treatment beyond 16 weeks."
2971740|NCT02752490|Experimental|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% fraction of inspired oxygen (FiO2) at 10 liters/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
2971703|NCT02752763|Experimental|preservative free artificial tear drop|preservative free artificial tears drop is a drop group declaring different kind of active agent like hydroxypropyl methylcellulose, carboxymethyl cellulose etc commonly used in dry eye treatment. Preservative free artificial tear( carboxymethyl cellulose, hydroxypropyl methylcellulose) was used as four times one drop daily. In our study, we prescribed to patients preservative free artificial tears drop(hydroxypropyl methylcellulose or carboxymethyl cellulose) four times one drop daily.
2971704|NCT02752763|Experimental|%40 Autologous serum(AS)|peripheral venous blood (14-20 ml) that drawn from antecubital vein of patients to prepare Autologous Serum. Blood sample was left at room temperature over 2 hours for clotting. Serum was obtained after centrifugation at 4000 revolutions per minute (rpm) for 10 minutes at 4 °C using a Nuve NF1200R. Next, in a laminar flow cabinet under sterile conditions, approximately 10 mL of supernatant was collected and diluted to 40 % with isotonic saline solution. It is recommended for dry eye diseases, too. %40 diluted Autologous Serum used as four times one drop daily.
2971705|NCT02752750||AD_GROUP|Patients with Alzheimer's disease
2971706|NCT02752750||HC_GROUP|Healthy controls
2971707|NCT02752724|Experimental|Ketamine Interventional Arm|1.0 mg/kg IV ketamine (experimental arm) intravenously (IV) for the duration of their ECT index course over 2-3 weeks
2971708|NCT02752724|Active Comparator|Methohexital Control Arm|1mg/kg of methohexital (standard arm) intravenously (IV) for the duration of their ECT index course over 2-3 weeks
2971709|NCT02752698||control group|no surgery
2971710|NCT02752698||Micro Hand S robotic group|Micro Hand S robotic surgery group
2971711|NCT02752698||laparoscopic surgery|laparoscopic surgery group
2971712|NCT02752698||Da Vinci robotic surgery|Da Vinci robotic surgery group
2971713|NCT02752685||triple negative breast cancer (TNBC)|
2971714|NCT02752685||hormone receptor (HR)-positive cohort|
2971715|NCT02752672||Psoriasis|Psoriasis patients treated with dithranol
2971716|NCT02752672||Non-Psoriasis|Non-Psoriasis patients undergoing surgery for skin lesions. Tumor-adjacent skin is collected for control purposes.
2971717|NCT02752659|Experimental|Women with breast cancer-related lymphedema|Participants will measure their own arm circumference and be measured by a specialized physiotherapist and by a perometer.
2971718|NCT02752659|Experimental|Women at risk of breast cancer-related lymphedema|Participants will measure their own arm circumference and be measured by a specialized physiotherapist and by a perometer.
2971719|NCT02752646|Active Comparator|nepafenac 0.3%|Patients in this arm will receive nepafenac 0.3% eye drops once daily following cataract surgery, combined with a topical antibiotic and steroid. This regimen is FDA approved and withing the standard of care.
2971720|NCT02752646|Active Comparator|ketorolac 0.5%|Patients in this arm will receive ketorolac 0.5% eye drops four times daily following cataract surgery, combined with a topical antibiotic and steroid. This regimen is FDA approved and withing the standard of care.
2971721|NCT02752633|Experimental|Study subjects|Following a 7 day washout period all patients receive allopurinol (400 mg/day) as a single daily dose for 2 weeks. Following another 7 day washout period all participants receive febuxostat, 80 mg/day as a single daily dose, for 2 weeks.
2971722|NCT02752620|Experimental|Osteopathic Manipulative Treatment|"We selected two types of osteopathic techniques for this study:~Technical articulation: rhythmic technique with low speed in which the goal is the full gain range of motion.~Myofascial techniques (Neuromuscular): techniques involving lateral stretching, linear, deep pressures and pulls of the origins and insertions aiming at a myofascial relaxation.~Sacroiliac articulatory technique; Dorsal articulatory technique; Lumbar paraspinal muscles stretching technique; Lumbar myofascial technique (inhibitory)."
2971723|NCT02752620|Active Comparator|Exercise Therapy|"2 types of therapeutic exercises techniques were used:~Stabilization exercises~Stretches~Stabilization exercises:~Bridge on the ball 10 - 15 sec Side plank 10 - 15 sec Front board 10 - 15 sec active mobilization lumbopelvic 3 x 6 rep Squats with the ball on the wall 3 x 8 rep~Static-passive stretch (2 x 30 sec):~Paraspinal; Abdominals; Quadratus lumborum; Hip extenders; Hip flexors; Hip abductors; Hip adductors."
2971724|NCT02752594|Experimental|probiotic|2 mg of probiotic powder mixed in 10 ml of distilled water
2971725|NCT02752594|Placebo Comparator|placebo|10 ml of distilled water
2971726|NCT02752581|Other|Drain Group|Suction drain was applied to these patients after arthroscopic knee surgery.
2971727|NCT02752581|Other|Control Group|No suction drain was applied to this group, therefore used as a control group.
2971728|NCT02752568|Active Comparator|Endometrial scratch group|endometrial scratch controlled ovarian hyperstimulation
2971729|NCT02752568|Active Comparator|Assisted hatching group|assisted hatching controlled ovarian hyperstimulation
2971730|NCT02752568|Sham Comparator|ovarian stimulation only group|controlled ovarian hyperstimulation
2971731|NCT02752555|No Intervention|Antioxidant group|In the control group, all patients will go a double-blind therapy of a three-months period of treatment with oral carnitine (2g daily). After this period, all patients will undergo conventional intacytoplasmic sperm injection (ICSI).
2971732|NCT02752555|Experimental|Antioxidant+modifiable lifestyle factors|In the study group, all patients underwent a double-blind therapy of a six-month period of treatment with oral carnitine (2g daily) combined with modifiable lifestyle factors. Patients were requested to follow a healthy standard diet, avoid excessive heat exposure, avoid or minimize exposure to pollutants, and stop smoking, coffee, alcohol, and drugs uptake.After this period, all patients will undergo conventional ICSI.
2971733|NCT02752542|Experimental|Psychotherapy|Cognitive Behavioral Therapy
2971734|NCT02752542|Experimental|Pharmacotherapy|Antidepressant medication
2971735|NCT02752529|Experimental|Tacrolimus/dose1|Tacrolimus 5mg tablet and dosage based on Co once/twice a day for 7 days
2971736|NCT02752529|Active Comparator|Tacrolimus/dose2|Tacrolimus 5mg tablet and dosage based on Co once/twice a day for 7 days
2971737|NCT02752516|Experimental|Anlotinib|
2971738|NCT02752503|Experimental|Nalmafene|
2971739|NCT02752490|Active Comparator|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by the American Congress of Obstetrics and Gynecology (ACOG) at the discretion of the primary nurse or physician
2971741|NCT02752477|Experimental|Opioid-free anesthetic (OFA) group|
2971742|NCT02752477|Active Comparator|Traditional Anesthesia (TA) group|
2971743|NCT02752464|Experimental|Feedback report plus peer counseling|Feedback report plus peer counseling Participants receive 12 sessions of behavioral counseling and a brief printed feedback report
2971744|NCT02752464|Active Comparator|Feedback report|Feedback report Participants receive a brief printed feedback report
2971745|NCT02752451|Other|CO|8 subjects who did not undergo arthroscopy simulation training prior to assessment on cadaveric specimens. These served as controls.
2971746|NCT02752451|Experimental|CBAT|8 Subjects who received 4 hours of simulation training on the Cigar Box Arthroscopy Trainer. They then underwent assessment on cadaveric specimens.
2971747|NCT02752451|Experimental|AKAT|8 Subjects who received 4 hours of simulation training on the Anatomic Knee Arthroscopy Trainer. They then underwent assessment on cadaveric specimens.
2971748|NCT02752438||Survived|Patients who are treated with HFOV at least for 4 h in case of unresponse to conventional ventilation and survived.
2971749|NCT02752438||Death|Patients who are treated with HFOV at least for 4 h in case of unresponse to conventional ventilation but died.
2971750|NCT02752425|Experimental|With visual feedback|Session of speech therapy conducted with the additional use of articulatory visual feedback based on ultrasound echography, which allows to visualize the patient's tongue in real time on a computer screen
2971751|NCT02752425|No Intervention|Without visual feedback|Session of speech therapy without use of ultrasound echography
2971752|NCT02752412|Experimental|LixiLan|"LixiLan (insulin glargine/lixisenatide fixed ratio combination) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Metformin will be continued."
2971753|NCT02752412|Active Comparator|insulin glargine|"Insulin glargine U100 (Lantus) will be injected subcutaneously (under skin) once daily. Dose will be individually adjusted.~Metformin will be continued."
2971754|NCT02752386|Experimental|Biofeedback Training 1|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback to provide pain relief when relaxation is achieved.
2971755|NCT02752386|Active Comparator|Biofeedback Training 2|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback to provide a painful context in which to practice relaxing.
2971756|NCT02752386|Active Comparator|Biofeedback Training 3|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback.
2971757|NCT02752360|Experimental|BSA Group|Patients accept the management of Biodegradable Stenting Anastomoses for reconstruction in the surgery of Intestinal Anastomosis
2971758|NCT02752360|Experimental|DHS Group|Patients accept the management of Double-layer Hand Sutures for reconstruction in the surgery of Intestinal Anastomosis
2971759|NCT02752347|Experimental|unilateral crossbite|unilateral crossbite patients with constricted maxilla, going to be treated by rapid maxillary expanders the surface Electromyography (surface EMG device) device will be used to examine the muscle activities before and after expansion
2971760|NCT02752347|No Intervention|control|the surface Electromyography (surface EMG device) device will be used to examine the muscle activities on normal patients
2971761|NCT02752347|Experimental|Bilateral crossbite|Bilateral crossbite patients with constricted maxilla, going to be treated by rapid maxillary expanders the surface Electromyography (surface EMG device) device will be used to examine the muscle activities before and after expansion
2971762|NCT02752334|No Intervention|group Bupivacaine|patients will receive 23 mL of Bupivacaine HCL 0.5% (Marcaine, 5 mg per mL; Hospira, USA) in addition to 2 mL normal saline using Ultrasound-guided Supraclavicular Brachial Plexus Block
2971763|NCT02752334|Active Comparator|group Bupivacaine Magnesium|patients will receive 23 mL of Bupivacaine HCL 0.5% in addition to 2 mL (100 mg) Magnesium Sulphate (Magnesium Sulphate 50 %, 500 mg per mL; Hospira, USA) diluted with normal saline. using Ultrasound-guided Supraclavicular Brachial Plexus Block
2971764|NCT02752321|Experimental|eDischarge + Standard Discharge (SDeD)|"Patients in this arm will be enrolled in the eDischarge technology prior to hospital discharge. Upon hospital discharge, these patients will receive a personalized eDischarge, containing text and multimedia information, in addition to receiving the standard discharge process.~Follow-up interviews and surveys will be conducted at 7-14 days post discharge, and at 30-45 days post discharge."
2971765|NCT02752321|No Intervention|Standard Discharge (SD)|"Patients in this arm will receive the standard discharge process upon hospital discharge.~Follow-up interviews and surveys will be conducted at 7-14 days post discharge, and at 30-45 days post discharge."
2971766|NCT02752308|Active Comparator|General anesthesia + caudal block|Patients who receive general anesthesia plus caudal epidural block and dilute epinephrine injection before hypospadias repair, intraoperative fentanyl, intraoperative intravenous fluid and reversing the muscle relaxants' effect at the end of operation
2971767|NCT02752308|Active Comparator|General anesthesia only|Patients who receive only general anesthesia and dilute epinephrine injection before hypospadias repair, intraoperative fentanyl, intraoperative intravenous fluid and reversing the muscle relaxants' effect at the end of operation
2971768|NCT02752295|No Intervention|Waiting list, intervention after EOS|control group / waiting list one week stress-coping intervention planned after end of study (EOS) without one week stress-coping intervention AND without an additional two days follow-up care
2971769|NCT02752295|Active Comparator|Stress-coping week without follow-up|active comparator with one week stress-coping intervention BUT without an additional two days follow-up weekend
2971770|NCT02752295|Active Comparator|Stress-coping week with follow-up|active comparator with one week stress-coping intervention AND with an additional two days follow-up weekend
2971771|NCT02752282|Sham Comparator|Control Video|Participants in this study arm will be assigned to watch a short educational video about new pap screening guidelines for women. Intervention: Cancer Screening Guidelines.
2971772|NCT02752282|Active Comparator|Intervention Video|Participants in this group will be assigned to watch a short educational video providing anticipatory counseling on their LNG-IUS' side effects and expected changes in bleeding. Intervention: Anticipatory Counseling
2971775|NCT02752243|Experimental|CIK-Cells|IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
2971776|NCT02752230|Active Comparator|Exparel (Bupivicaine Liposome)|Patient will have Exparel (Bupivicaine Liposome) injected at Laparoscopic Port sites during the Laparoscopic Roux en Y or Laparoscopic Sleeve Gastrectomy.
2971777|NCT02752230|Active Comparator|Marcaine (Bupivicaine)|Patient will have Marcaine (Bupivicaine) injected at Laparoscopic Port sites during the Laparoscopic Roux en Y or Laparoscopic Sleeve Gastrectomy.
2971778|NCT02752217|Experimental|Inspiratory Muscle Training (IMT)|"Subjects in the inspiratory muscle training (IMT) group will perform loaded deep breathing exercise at 6 breaths/min using BreatheMaxยฎ device. The IMT protocol at 6 breathing rate (inspiratory time = 4 seconds and expiratory time = 6 seconds) with load at 25 percent of MIP for eighth weeks.~The pressure will be control by pressure manometer and duty cycle are control by subjects count duration for inspiration and expiration during training. The program will perform at home for 10 breaths/min/set, 6 sets/day with at least 1 minutes rest between sessions, 7 days/week for 8 weeks"
2971779|NCT02752217|Placebo Comparator|Control|Subjects in the control (CON) group will perform breathing exercise with inspiratory load at 2 cmH2O at 6 breathing rate using one BreatheMAXยฎ device. The pressure will be control by pressure manometer and duty cycle are control by subjects count duration for inspiration and expiration during training. The program will perform at home for 10 breaths/min/set, 6 sets/day with at least 1 minutes rest between sessions, 7 days/week for 8 weeks
2971780|NCT02752204|Other|Stage 1|AZD 2014 oral tablets will be given to patients
2971781|NCT02752204|Other|Stage 2|AZD 2014 oral tablets and rituximab infusion will be given to patients
2971782|NCT02752191|Active Comparator|Ferumoxytol|Ferumoxytol, 4mg/kg of body weight, one time infusion of several minutes
2971783|NCT02752191|Active Comparator|gadofosveset|gadofosveset, 0.03mmol/kg, one time bolus injection
2971784|NCT02752178||DEP+MA+|Incompletely responsive patients (approximately N ~100) who are currently depressed after greater than 6 weeks of treatment with one or more monoaminergic antidepressants
2971785|NCT02752178||DEP-MA+|Responsive patients (approximately N~50) who are not currently depressed after greater than 6 weeks of treatment with a monoaminergic antidepressant
2971786|NCT02752178||DEP+MA-|Untreated patients (approximately N~50) who are currently depressed but have not been treated with monoaminergic antidepressants in the previous 6 weeks
2971787|NCT02752178||DEP-MA-|Healthy volunteers (approximately N~50) who have no personal history of depression requiring treatment with either monoaminergic antidepressants or other clinical interventions including psychotherapy
2971788|NCT02752165|Experimental|TEAM-ED Intervention Group|Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting
2971789|NCT02752165|Active Comparator|Enhanced Usual Care|Report of symptoms to primary care physician
2971790|NCT02752152|Experimental|Computer-assisted counseling|Computer-assisted informational/educational interactive session followed by an interactive face-to-face session to discuss personal issues with a counselor
2971791|NCT02752152|Experimental|On-demand counseling|The counselor asks whether the participant has any questions
2971792|NCT02752152|Active Comparator|Standard counseling|Interactive face-to-face counseling session
2971793|NCT02752152|Experimental|Appointment + reminder|Make appointment and send SMS for reminder
2971794|NCT02752152|Experimental|Reminder only|Send SMS reminder only
2971795|NCT02752152|Active Comparator|No appointment and no reminder|No appointment and not send SMS reminder
2971796|NCT02752139||patients with sleep disorders|
2971797|NCT02752139||normal individuals without sleep disorders|
2971798|NCT02752126|Active Comparator|Standard Palliative Radiation|Patients in the standard arm will receive a conventional radiotherapy dose will be either 30 gray (Gy) in 10 fraction or 20Gy in 5 fractions. Patients will be stratified by intended dose prior to randomization. Radiation for patients in the standard arm should adhere to the principles of palliative radiation, with goals of alleviating symptoms or preventing potential complications.
2971799|NCT02752126|Experimental|Esophageal Sparing IMRT|Patients on the experimental arm will receive esophageal-sparing intensity-modulated radiotherapy, with the same dose(s) as in the standard arm.
2971800|NCT02752113|Active Comparator|Empagliflozin and Linagliptin|After the 4 weeks run-in phase (stable metformin medication), patients will be consecutively randomized (1:1) to empagliflozin 10 mg and linagliptin 5 mg orally once daily. After 14 days empagliflozin will be up-titrated to 25 mg (once daily), if fasting blood glucose is ≥ 100 mg /dl and no hypoglycemic symptoms are recognized.
2971801|NCT02752113|Active Comparator|Metformin and Insulin sc|Metformin p.o. and insulin sc After the 4 weeks run-in phase (stable metformin medication), patients will maintain on their metformin dosage (850 or 1000 mg orally twice daily) and insulin glargine (Lantus™) once daily subcutaneous will be added. Initially 2 - 4 U Lantus™ daily (depending on body weight) will be given, and adjusted every third day (telephone counseling) by adding 2 U if fasting blood glucose is not ≤ 125 mg/dl (16). After a stable dosage (i.e. no change of dosage for 1 week) has been reached, adjustments regarding an increment of Lantus™ will be based on confirmed fasting blood glucose of ≥ 126 mg/dl (on at least two consecutive day).
2971802|NCT02752100|Experimental|Interventional Therapy|Percutaneous transluminal angioplasty.
2971803|NCT02752100|No Intervention|Non-Interventional Therapy|
2971804|NCT02752087|Experimental|LY900014 Test|LY900014 test dose administered via subcutaneous (SC) injection
2971805|NCT02752087|Active Comparator|LY900014 Reference|LY900014 reference dose administered via SC injection
2971806|NCT02752074|Experimental|Pembrolizumab + Epacadostat|Pembrolizumab + Epacadostat
2971807|NCT02752074|Active Comparator|Pembrolizumab + Placebo|Pembrolizumab + Placebo
2971808|NCT02752061|Experimental|Kweneng East District|Patient presenting with possible cancer symptoms/sign to a clinic or hospital in Kweneng East District during study period.
2971809|NCT02752061|No Intervention|All other districts|Patient presenting with possible cancer symptoms/sign to a clinic or hospital in all other districts of Botswana (or Kweneng East prior to implementation of intervention).
2971810|NCT02752048|Experimental|TAS-205（Low dose group）|
2971811|NCT02752048|Experimental|TAS-205（High dose group）|
2971812|NCT02752048|Placebo Comparator|Placebo|
2971813|NCT02752035|Experimental|Dose escalation of ASP2215 given with azacitidine|Subjects will be treated with ASP2215 daily (days 1-28) and azacitidine daily for 7 days (days 1-7).
2971814|NCT02752035|Experimental|Arm A: ASP2215|Subjects will be treated daily each 28-day cycle.
2971815|NCT02752035|Experimental|Arm AC: ASP2215 + azacitidine|Subjects will be treated with ASP2215 daily and azacitidine daily for 7 days (days 1-7) each 28-day cycle.
2971816|NCT02752035|Active Comparator|Arm C: azacitidine|Subjects will be treated with azacitidine for 7 days (days 1-7) each 28-day cycle.
2971817|NCT02752022||Heavy smokers|Heavy smokers (continuous smoking of >10 cigarettes per day) for at least 6 months who will give up smoking and switch to nicotine containing e-cigarettes for 28 days to help them quit smoking.
2971818|NCT02752009|Experimental|Axillary Lymph Node Sampling Clip|"Axillary Lymph Node Biopsy~-- Axillary lymph node sampling with clip placement into the sampled lymph node. After the tissue sampling of any suspicious nodes, a marker clip will be placed to allow for intra-operative identification of the biopsied nodes.~Neoadjuvant therapy at the discretion of the treating Medical Oncologist. Once Neoadjuvant therapy is completed, surgery in the form of either Lumpectomy or Mastectomy is performed.~Wire-localization of the clipped node on the day of surgery.~Lymphatic mapping performed with either radiocolloid and/or blue dye.~Sentinel lymph node biopsy will be performed on the day of surgery.~--- If the clipped node which contains the wire is not part of this sentinel lymph node specimen, then it will be removed separately and be sent to Pathology as a separate specimen.~Axillary lymph node dissection as is the standard of care."
2971819|NCT02751996|Active Comparator|Part A Cohort 1: 25mg SB 9200|Part A Cohort 1: 25mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2971820|NCT02751996|Placebo Comparator|Part A Cohort 1: 25mg Placebo|Part A Cohort 1: 25mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2971821|NCT02751996|Active Comparator|Part A Cohort 2: 50mg SB 9200|Part A Cohort 2: 50mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2971822|NCT02751996|Placebo Comparator|Part A Cohort 2: 50mg Placebo|Part A Cohort 2: 50mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2971823|NCT02751996|Active Comparator|Part A Cohort 3: 100mg SB 9200|Part A Cohort 3: 100mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2971824|NCT02751996|Placebo Comparator|Part A Cohort 3: 100mg Placebo|Part A Cohort 3: 100mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2971825|NCT02751996|Active Comparator|Part A Cohort 4: 200mg SB 9200|Part A Cohort 4: 200mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2971826|NCT02751996|Placebo Comparator|Part A Cohort 4: 200mg Placebo|Part A Cohort 4: 200mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2971827|NCT02751996|Active Comparator|Part B: SB 9200 with tenofovir|Part B: SB 9200 selected dose from Part A administered in combination with tenofovir 300 mg qd. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2971828|NCT02751996|Active Comparator|Part B: Tenofovir 300 mg|Part B: Tenofovir 300 mg qd monotherapy. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2971829|NCT02751983|Experimental|Treatment as usual plus ACT|Participants in this condition will be enrolled in the ACT for Life intervention and still able to engage in treatment as usual.
2971830|NCT02751983|Active Comparator|Treatment as usual|Participants in this condition will not be enrolled in ACT for Life, but will continue to participate in treatment as usual (e.g., inpatient and outpatient mental health care).
2971831|NCT02751970|Active Comparator|3 step ER & Dental restoration|Dental restoration with etching the dental substrates 35% phosphoric acid, followed by the application of a primer and subsequently an adhesive resin.
2971832|NCT02751970|Experimental|2 step ER & Dental restoration|Dental restoration with etching the dental substrates 35% phosphoric acid, followed by the application of an adhesive/primer step.
2971833|NCT02751970|Active Comparator|2 step SE & Dental restoration|Dental restoration with etching the dental substrates with acidic primer, followed by the application of adhesive resin.
2971834|NCT02751970|Experimental|1 step SE & Dental restoration|Dental restoration with etching and infiltrate the dental substrates with acidic primer/adhesive system.
2971835|NCT02751957|Experimental|Intervention|Receives caregiver coaching version of the Early Start Denver Model (ESDM) intervention, delivered by non-specialist workers. ESDM is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
2971836|NCT02751957|No Intervention|Community care as usual|Community care typically consists of one, 1 hour speech therapy or occupational therapy session per month.
2971837|NCT02751944|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 2 weeks
2971838|NCT02751944|Placebo Comparator|Placebo|Placebo, 500 mg, once daily, orally for 2 weeks
2971839|NCT02751931|Experimental|Mirabegron|Participants will receive daily dosage of mirabegron as single tablets or suspension (2 dose strengths)
2971840|NCT02751918|Experimental|Anetumab ravtansine|Anetumab ravtansine in combination with pegylated liposomal doxorubicin in subjects with mesothelin-expressing platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal cancer. Increase/Decrease of Anetumab ravtansine until maximum tolerated dose identified.
2971841|NCT02751905|Experimental|BIIB074|Single oral dose on Day 1
2971881|NCT02751632|Experimental|Step 2- Regular SPS Therapy|Participants are randomised to receive regular sessions of Support and Problem Solving Therapy, with a minimum of six sessions delivered over an 18-week period.
2971882|NCT02751632|Experimental|Step 2- Regular CBCM|Participants are randomised to receive regular sessions of Cognitive Behavioural Case Management, with a minimum of six sessions delivered over an 18-week period.
2971842|NCT02751892|Experimental|Active Lifestyle Programme|Supervised exercises for 3 months and motivational interviewing to facilitate physical activity behaviour change. Supervised exercise sessions took place twice per week for the first four weeks. This was tapered off to once per week for the second four weeks. During the last month of the intervention participants continued with the exercise at home and were encouraged to achieve 150min of moderate to vigorous PA per week.
2971843|NCT02751892|No Intervention|Standard Care|Received usual care. Was offered the intervention after the completion of the study.
2971844|NCT02751879||NSCLC|patients with EGFR mutation (common mutations), TKI-naïve advanced NSCLC, treated with Gi(l)otrif® as the first-line treatment for NSCLC within the approved label
2971845|NCT02751866|Active Comparator|Active supplement, low carbohydrate|Whole fruit berry powder, low carbohydrate diet
2971846|NCT02751866|Placebo Comparator|Placebo, Control|placebo powder, higher carbohydrate diet
2971847|NCT02751853|Experimental|HFPEF|Patient with heart failure with preserved ejection fraction (HFPEF)
2971848|NCT02751853|Experimental|HFREF|Patient with heart failure with reduced ejection fraction (HFREF)
2971849|NCT02751853|Active Comparator|No HFPEF/HFREF|Patient without heart failure with preserved ejection fraction (HFPEF) or heart failure with reduced ejection fraction (HFREF)
2971850|NCT02751840|Experimental|Caffeine|Caffeine capsule (200 mg) is taken prior to RMR measurement
2971851|NCT02751840|Placebo Comparator|Placebo|Placebo (starch) capsule is taken prior to RMR measurement
2971852|NCT02751840|Experimental|Coffee|Black coffee (9 grams) is consumed prior to RMR measurement
2971853|NCT02751840|Placebo Comparator|Decaffeinated|Decaffeinated Black coffee (9 grams) is consumed prior to RMR measurement
2971854|NCT02751827||Prospective cohort - Blood sample|All patients without major violations of the eligibility criteria are included in this population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.
2971855|NCT02751801||Adults and children with hypophosphatasia|Healthcare use interview
2971856|NCT02751762||Prospective Longitudinal Cohort|Patients who have recently initiated at least 30 days of ER/LA opioid therapy
2971857|NCT02751762||Cross-sectional Cohort|Patients who have been treated with opioids (including at least one ER/LA opioid) for greater than 1 year
2971858|NCT02751749|Experimental|Unified Protocol|"CBT based Internet delivered treatment targeting transdiagnostic vulnerability and maintaining factors for chronic pain and emotional problems.~Since this is a new target Group, a replicated single case design was used and participants are their own Control Group (no other treatment arms)."
2971859|NCT02751736|Experimental|Intervention|"2 g sachet (CJLP 243) once a day for 3 weeks~10 billion lactic acid bacteria(lactobacillus plantarum CJLP243), maltodextrin, glucose(anhydrous)"
2971860|NCT02751736|Placebo Comparator|Control|"2g sachet (near identically appearing placebo) once day for 3 weeks~maltodextrin, glucose(anhydrous)"
2971861|NCT02751723||lung cancer|validated questionnaires
2971862|NCT02751723||malignant melanoma|validated questionnaires
2971863|NCT02751723||cancer of the hepatobiliary system|validated questionnaires
2971864|NCT02751723||head and neck cancer|validated questionnaires
2971865|NCT02751723||breast cancer|validated questionnaires
2971866|NCT02751723||ovarian carcinoma|validated questionnaires
2971867|NCT02751723||pancreatic cancer|validated questionnaires
2971868|NCT02751723||stomach cancer|validated questionnaires
2971869|NCT02751723||oesophageal cancer|validated questionnaires
2971870|NCT02751723||colorectal cancer|validated questionnaires
2971871|NCT02751710|Experimental|Whole-body FDG PET-CT alone|
2971872|NCT02751710|No Intervention|Conventional breast cancer staging|Conventional breast cancer staging consisting of a bone scan and CT imaging with contrast of the chest / abdomen & pelvis
2971873|NCT02751671|Experimental|POCUS before clean catch sampling|The intervention of interest will be the use of emergency point-of-care ultrasound performed by a research assistant to evaluate bladder fullness before clean-catch stimulation manoeuvre. More specifically, following randomisation, children in the experimental group will have ePOCUS to measure the transversal bladder diameter. If the transversal bladder diameter is > 2 cm, the CCU procedure will be started without a prior feeding period. If the diameter is < 2 cm, the CCU will be postponed for a 20 minute feeding period and a new ePOCUS will be done. After the second ePOCUS, the CCU will be done if the transversal bladder diameter reaches > 2cm. If not, the child will have another 20 minute feeding period and a third ePOCUS prior to proceeding to the CCU regardless the bladder diameter.
2971874|NCT02751671|Experimental|Standard clean catch sampling|Patients allocated to this arm will have a 20 minute feeding period either being breastfed or provided with formula intake appropriate to the infant's age and weight. If possible, the genital areas of the infant will be cleaned with warm water and soap and dried with sterile gauze prior to the feeding. The parents will let the diaper opened and will be will be ready to collect urine if the child voids during the feeding period. After the feeding, the stimulated clean-catch procedure will be performed without prior ultrasound
2971875|NCT02751658|Other|patients in the Otorhinolaryngology|patients in the Otorhinolaryngology department realization of a levy into the mouth swab on the day of admission to hospital and the day of release
2971876|NCT02751645|No Intervention|Standard of Care Control|This group will consist of all the participants that receive the standard of care treatment for elective surgical repair or palliation of their cardiac defect with the use of the cardiopulmonary bypass machine.
2971877|NCT02751645|Experimental|Acute Normovolemic Hemodilution|This group will consist of all the participants that receive the acute normovolemic hemodilution prior to their elective surgical repair or palliation of their cardiac defect with the use of the cardiopulmonary bypass machine.
2971878|NCT02751632|Experimental|Step 1-Regular SPS Therapy|Support and Problem Solving Therapy delivered to all study participants over a six-week period with a minimum of three sessions.
2971879|NCT02751632|Experimental|Responders- Monthly SPS Therapy|Participants are randomised to receive monthly Support and Problem Solving Therapy for up to 12 months.
2971880|NCT02751632|Experimental|Responders- 3-monthly monitoring|Participants are randomised to be monitored for risk every 3 months for up to 12 months.
2972007|NCT02750748|Experimental|50mg Naltrexone|Administer 50mg formulation orally
2971883|NCT02751632|Experimental|Step 3- Regular CBCM + Fluoxetine|Participants are randomised to receive either Cognitive Behavioural Case Management plus an antidepressant medication for six months .
2971884|NCT02751632|Placebo Comparator|Step 3- Regular CBCM+ placebo|Participants are randomised to receive Cognitive Behavioural Case Management plus placebo medication for six months.
2971885|NCT02751619|Experimental|Lidocaine Group|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, PA, USA) measuring 10 x 14 cm and containing 700 mg of Lidocaine, was applied to cover the planned skin incision, marked with a pen by surgeon. Patch was applied for 12 hours during the night, removed for the subsequent 12 hours during the day, and then a new patch was applied at the same level the night after. This process was continued for 3 days before thoracotomy
2971886|NCT02751619|Active Comparator|Placebo Patch|A patch, that was identical in appearance to the active patch but did not contain Lidocaine, was applied to cover the planned skin incision, marked with a pen by surgeon. Patch was applied for 12 hours during the night, removed for the subsequent 12 hours during the day, and then a new patch was applied at the same level the night after. This process was continued for 3 days before thoracotomy
2971887|NCT02751606|Experimental|Breast and rectal cancer|Subjects will receive intravenous dose of ferumoxtran-10. 24-36 hours later a 7 Tesla MRI scan will be performed, to detect lymph node metastases. In rectal cancer patients the mesorectum will be imaged and for breast cancer patients this will be performed in the ipsilateral axilla. Subjects will also undergo a 3 Tesla MRI scan as a comparison to the 7 Tesla MRI scan.
2971888|NCT02751593|Experimental|dexamethasone|dexamethasone 40mg/d for 4 days
2971889|NCT02751580|Experimental|Health services research (telehealth)|Patients undergo their first post-treatment visit as a virtual telehealth visit using the JeffConnect application downloaded onto their electronic device.
2971890|NCT02751567|Experimental|Arm 1|All subjects are patched with the same product
2971891|NCT02751541|Experimental|BAY987519|All subjects are patched
2971892|NCT02751528|Experimental|ETBX-021|Ad5 [E1-, E2b-]-HER2/neu Vaccine, Suspension for Injection
2971893|NCT02751515|Experimental|Bain De Soliel - Solid|All subjects are patched with the same product
2971894|NCT02751502|Experimental|Bimanual-to-unimanual device home training program|
2971895|NCT02751502|No Intervention|Conventional non-device home training program|Subjects receive 6 weeks of ongoing usual and customary care schedule of home physical and occupational therapy as usual and customary care independent of the study.
2971896|NCT02751489|Experimental|Bain De Soliel - Solid|All subjects are patched with the same product
2971897|NCT02751476|Active Comparator|standard SAM treatment (control group)|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure.
2971898|NCT02751476|Experimental|SAM treatment + flocculent-disinfectant|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a flocculent-disinfectant for household level application.
2971899|NCT02751476|Experimental|SAM treatment + chlorine disinfectant|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a chlorine disinfectant for household level application.
2971900|NCT02751476|Experimental|SAM treatment + ceramic water filter|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a ceramic water filter for household level application.
2971901|NCT02751463|Experimental|BAY987519|All subjects are patched .
2971902|NCT02751450|Experimental|Stannous Fluoride dentifice|Participants will apply (under supervision) a pea-sized dose of experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm) to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted
2971903|NCT02751450|Other|Sodium Monofluorophosphate dentifrice|Participants will apply (under supervision) a pea-sized dose of dentifrice containing Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted.
2971904|NCT02751437|No Intervention|Low Arginine unsupplemented|These infants identified as having low blood arginine levels will receive standard care.
2971905|NCT02751437|Experimental|Low Arginine supplemented|These infants identified as having low arginine levels will receive an additional arginine infusion between days 3 and 10 of life.
2971906|NCT02751437|No Intervention|Normal Arginine|These infants identified as having normal arginine levels will receive standard care.
2971907|NCT02751424|Experimental|GSK3342830 single dose in Part 1|Enrolled subject will receive single escalation dose of GSK3342830. The escalating doses will be evaluated in six cohorts as A- 250 mg, B-500 mg, C-1000 mg, D-2000 mg, E-4000 mg, and F-=<6000 mg. In each cohort 6 subjects will receive GSK3342830 in form of infusion for 1 h, therefore approximately 36 subjects will receive GSK3342830. Dose escalation will be based on evaluation of the preceding dose levels in the study.
2971908|NCT02751424|Placebo Comparator|Placebo single dose in Part 1|Enrolled subject will receive single escalation dose of placebo. In each cohort, 2 subjects will receive placebo in form of infusion for 1 h, therefore approximately 12 subjects will receive placebo.
2971909|NCT02751424|Experimental|GSK3342830 repeat Dose in Part 2|Enrolled subject will receive repeat escalating dose of GSK3342830. GSK3342830 as a single IV infusion will be administered on Day 1, TID (8 hours apart) IV infusions on Days 2 through 14, and a single IV infusion on Day 15. The escalating doses will be evaluated in three cohorts as G-1000 mg, H-2000 and I-4000 mg. In each cohort 8 subjects will receive GSK3342830 in form of infusion for 1 h, therefore approximately 24 subjects will receive GSK3342830. The starting dose and maximum dose may change based on clinical safety and PK findings in Part 1 or earlier doses in Part 2 respectively.
2971910|NCT02751424|Placebo Comparator|Placebo repeat Dose in Part 2|Enrolled subject will receive repeat escalation dose of placebo. Placebo as a single IV infusion will be administered on Day 1, TID (8 hours apart) IV infusions on Days 2 through 14, and a single IV infusion on Day 15. In each cohort, 2 subjects will receive placebo in form of infusion for 1 h, therefore approximately 6 subjects will receive placebo.
2972058|NCT02750436|Active Comparator|Fluoroscopy guided|Fluoroscopically guided sacral lateral branch block
2971911|NCT02751411|Experimental|micro-enema with Promelaxin|2,5 g, 5 g or 2X5 g (calculated considering patient age) have to be administered daily (in the evening) for one week, once every other day for the second week and as needed for the following 6 weeks
2971912|NCT02751411|Active Comparator|Macrogol 4000|One/Two sachets of the study treatment has to be solubilized in 50mL of water and then administered daily. The administration should take place in the morning (the first sachet or in the event that only one sachet/day should be administered) and in the evening (second sachet).
2971913|NCT02751398|Experimental|Dapagliflozin|Dapagliflozin 10mg/day
2971914|NCT02751398|Placebo Comparator|Placebo|
2971915|NCT02751385|Experimental|All Patients|Microgynon alone in Period 1 then with Nintedanib in Period 2
2971916|NCT02751372|Experimental|BAY 987517|All subjects are patched .
2971917|NCT02751359|Active Comparator|Active CBD|Each subject will receive each active dose of cannabidiol, one active dose per 3 of the 4 study days. The active cannabidiol doses include 200, 400 and 800 mg of cannabidiol.
2971918|NCT02751359|Placebo Comparator|Placebo|On 1 of the 4 study days, participants will receive placebo cannabidiol (0 mg)
2971919|NCT02751346||Patients with Pain|Patients with pain identified through the survey will be invited to undergo sensory assessment by quantitative sensory testing (QST) around the surgical scar and a control area: Thermal (cold and heat) detection and pain thresholds; mechanical detection and pain threshold; dynamic mechanical allodynia; temporal summation (wind-up).
2971920|NCT02751346||Patients without Pain|Patients without pain age and gender matched to patients with pain identified through the survey will be invited to undergo sensory assessment by quantitative sensory testing (QST) around the surgical scar and a control area: Thermal (cold and heat) detection and pain thresholds; mechanical detection and pain threshold; dynamic mechanical allodynia; temporal summation (wind-up).
2971921|NCT02751333|Active Comparator|FCSEMS with Endostitching (ES)|General anesthesia or conscious sedation will be started and an upper endoscope will be inserted into the participants mouth and advanced into the stomach. Endoscopic stenting with a fully covered self-expanding metal stents (FCSEMS) will then be performed. Once the stent is in place, the endoscope will be withdrawn from the participant to set-up the endostitch device unto the endoscope. Bites are taken separately with the first on the esophageal mucosa followed by a second on the stent itself and finishing with a last bite on esophageal mucosa. A cinch is then used to secure the deployed suture. An attempt at placing 2 sutures will be performed. Stent removal will then be performed at 8-weeks post-stent insertion.
2971922|NCT02751333|Active Comparator|FCSEMS with No Suturing (NS)|The procedure will be done in the same manner with same endoscopic technique, stent deployment, and timing of stent removal. The only difference would be the lack of suturing and naturally the need for suture cutting at stent removal.
2971923|NCT02751320|Experimental|Experimental Dentifrice1|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
2971924|NCT02751320|Experimental|Experimental Dentifrice 2|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
2971925|NCT02751320|Experimental|Experimental Dentifrice 3|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
2971926|NCT02751320|Placebo Comparator|Reference Product 1|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
2971927|NCT02751320|Active Comparator|Reference Product 2|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
2971928|NCT02751320|Active Comparator|Reference Product 3|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
2971929|NCT02751307|Active Comparator|metformin 500 mg/d; clozapine 100 mg|In the first week, 500 mg of metformin was administered in the morning. In the second week, the dosage was revised to 500 mg of metformin in the morning and the placebo in the evening. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
2971930|NCT02751307|Active Comparator|metformin 1000 mg/d; clozapine 100 mg|In the first week, 500 mg of metformin was administered in the morning. In the second week, 500 mg of metformin twice a day was administered. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
2971931|NCT02751307|Placebo Comparator|placebo; clozapine 100 mg|In the first week, one pill of placebo was given and in the second week, placebo BID was given. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
2971932|NCT02751294|Experimental|TQ Control+ TQ SIL|Subjects received TQ Control product (2 tablets) and 30 mg TQ SIL solution orally with water after a meal.
2971933|NCT02751294|Experimental|TQ X + TQ SIL|Subjects received 2 tablets of Tafenoquine dissolution profile X and 30 mg TQ SIL solution orally with water after a meal.
2971934|NCT02751281|Active Comparator|pneumatic percutaneous nephrolithotomy|pneumatic percutaneous nephrolithotomy is type of surgery in treatment of kidney stone
2971935|NCT02751281|Active Comparator|Ultra-sonic percutaneous nephrolithotomy|Ultra-sonic percutaneous nephrolithotomy is type of surgery in treatment of kidney stone
2971936|NCT02751268|Placebo Comparator|Control|placebo for the realization of infraorbital and infratrochlear block
2971937|NCT02751268|Active Comparator|Ropivacaine|ropivacaine for the realization of infraorbital and infratrochlear block
2972123|NCT02749994|Experimental|R10/E10|Rosuvastatin 10mg/Ezetimibe 10mg
2971938|NCT02751255|Experimental|daratumumab--> daratumumab + ATRA|In part A of the study patients will be treated with daratumumab as a single agent. In case patients have progressive disease after cycle 1, or in case patients achieve less than minimal response after cycle 2, or patients achieve less than PR after cycle 3, or in case patients experience progression during daratumumab therapy after having obtained a response, then ATRA will be added to daratumumab (part B).
2971939|NCT02751242||Usual Care|All patients will receive a dose of intravenous furosemide.
2971940|NCT02751229|Experimental|Honest Open Proud|"The group program is about disclosure ('coming out') versus secrecy of one's mental illness. The groups are facilitated by peers (young adults with mental illness) and mental health professionals. Each group runs for three weeks, one meeting per week, and two hours per meeting.~Fidelity to manual: rated by PhD student in each session as proportion of key topics covered"
2971941|NCT02751229|No Intervention|Control Group|treatment as usual (TAU)
2971942|NCT02751216|Experimental|spinal cord stimulation|
2971943|NCT02751203|Experimental|Make Safe Happen App Intervention|Pre- and post-test delivered to online survey panel participants. Instruction to download and use the intervention (Make Safe Happen Mobile App) for 1 week.
2971944|NCT02751203|No Intervention|Make Safe Happen App Control|A subset of online survey panel participants (n=200) will complete a pre- and post-test survey but will receive a non-safety app (e.g. a free recipe app). After the study, participants will be asked to download the intervention app.
2971945|NCT02751177|Experimental|OncoBEAM|KRAS, NRAS and BRAF mutations will be analyzed in circulating plasma DNA using ONCOBEAM technique.
2971946|NCT02751164||Weekday daytime|Admitted to the critical care unit Monday-Friday 08:00-17:59
2971947|NCT02751164||Weekend daytime|Admitted to the critical care unit Saturday-Sunday 08:00-17:59
2971948|NCT02751164||Weekday night|Admitted to the critical care unit Monday-Friday 18:00-07:59 the next day
2971949|NCT02751164||Weekend night|Admitted to the critical care unit Saturday-Sunday 18:00-07:59 the next day
2971950|NCT02751151|Experimental|1|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
2971951|NCT02751138||Isocitrate dehydrogenase - 1 mutated|Immunophenotype of Glioblastoma and correlation with outcome
2971952|NCT02751138||Isocitrate dehydrogenase - 1 wild type|Immunophenotype of Glioblastoma and correlation with outcome
2971953|NCT02751125|Experimental|Augmentation of new alveolar bone|Augmentation of atrophied alveolar ridge with mesenchymal stem cells( MSC) and bis calcium phosphate(BCP)
2971954|NCT02751112|Experimental|Couple donor / recipient|"Each couple will be treated the same way :~An additional blood sample of the donor will be taken prior GCSF mobilization. This blood sample will then be analyzed via Predictor's kit, by the immunology laboratory of the hospital where the graft will be done.~Whatever the result given by the Predictor' kit, the graft will be done for the recipient patient. No change will be done on the usual graft process."
2971955|NCT02751099||de novo renal transplanted patients|renal transplanted patients
2971956|NCT02751086||Robotic Gastrectomy|Patients who will be treated for gastric cancer with the assistance of the robotic surgical system
2971957|NCT02751086||Laparoscopic Gastrectomy|Patients who will be treated for gastric cancer through laparoscopic devices.
2971958|NCT02751086||Open Gastrectomy|Patients who will be treated for gastric cancer with traditional open surgery.
2971959|NCT02751060||patients with coronary heart disease symptoms|
2971960|NCT02751047|Placebo Comparator|Manual ventilation|During anesthetic induction, facemask ventilation is performed by manual bagging, after setting adjustable pressure limiting (APL) valve at 13 cmH2O. During mask ventilation, gastric ultrasonography is continuously performed to detect gastric insufflation.
2971961|NCT02751047|Active Comparator|Pressure controlled mechanical ventilation|During anesthetic induction, facemask ventilation is performed with mechanical ventilator by pressure controlled mode, with inspiratory pressure of 13 cmH2O. During mask ventilation, gastric ultrasonography is continuously performed to detect gastric insufflation.
2971962|NCT02751034|Experimental|Neuramis® Deep Lidocaine|Neuramis® Deep Lidocaine Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
2971963|NCT02751034|Active Comparator|Restylane® PERLANE-L|Restylane® PERLANE-L Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
2971964|NCT02751021|Other|Sleep apnea diagnosis|The intervention is the use of the pacemaker diagnostic algorithm named Sleep Apnea Monitoring to detect sleep apnea and the attended cardiorespiratory sleep study to confirm the diagnostic.
2971965|NCT02750995|Experimental|Vaccination|Azacitidine + NPMW-peptide vaccine
2971966|NCT02750982|Experimental|Laughter therapy|effects of Laughter therapy (LT) on mood, self-efficacy and other wellness measures in people with neurological conditions.
2971967|NCT02750969|Experimental|1. lidoderm patches first|"29 tinnitus patients treated first with 3 patches of lidoderm for 1 day, for 12 consecutive hours. 60 hours after removal of the patches the patients will have 3 neutral patches (containing no drug) attach to their back for 12 hours.~after the removal of each kind of patch the patient will fill 4 types of questionnaires that assess his amount of tinnitus we will compare the questionnaires results before and after the application of those patches."
2971968|NCT02750969|Experimental|2. tegaderm patches first|"29 tinnitus patients treated first with 3 patches of tegaderm (neutral patch containing no drug) for 1 day, for 12 consecutive hours. 60 hours after removal of the patches the patients will have 3 lidoderm patches attach to their back for 12 hours.~after the removal of each kind of patch the patient will fill 4 types of questionnaires that assess his amount of tinnitus we will compare the questionnaires results before and after the application of those patches."
2971969|NCT02750956||Group 1|Periodontal healthy individuals
2971970|NCT02750956||Group 2|Patients with chronic periodontitis
2971971|NCT02750956||Group 3|the same patients in group 2 after they had been treated with scaling and root planing (SRP) were considered as Group 3.
2971972|NCT02750943|Experimental|Stannous Fluoride|Participants will apply a full ribbon of dentifrice containing 0.454% w/w stannous fluoride to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)
2972124|NCT02749994|Experimental|R20/E10|Rosuvastatin 20mg/Ezetimibe 10mg
2971973|NCT02750943|Active Comparator|Sodium Monofluorophosphate|Participants will apply a full ribbon of dentifrice containing Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)
2971974|NCT02750930|Experimental|Albiglutide arm|Subjects will receive 50 milligrams (mg) albiglutide liquid drug product once weekly via auto-injector for 26 weeks.
2971975|NCT02750917|Experimental|GROUP LORNOXICAM|Immediately in postoperative care unit patients received lornoxicam 8 mg PO/12 hours for 48 hours
2971976|NCT02750917|Active Comparator|GROUP ETORICOXIB|Immediately in postoperative care unit patients received etoricoxib 120 mg PO and another pill at 24 hours.
2971977|NCT02750904|Experimental|Experimental therapy|
2971978|NCT02750904|Active Comparator|Control Therapy|
2971979|NCT02750891|Experimental|DSP-7888|
2971980|NCT02750878|No Intervention|Control group|Participants will receive only the standard verbal TOT surgical consent counseling.
2971981|NCT02750878|Other|Intervention group|Participants will receive the standard verbal TOT surgical consent counseling plus a handout describing their surgical intervention
2971982|NCT02750865|No Intervention|Control Usual Care|In this arm the subject receives usual care and just completes the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment.
2971983|NCT02750865|Experimental|Embodied Conversational Agent (ECA)|In this arm the subject is trained how to use a tablet device which they take home for the duration of the study. These subjects complete the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment.
2971984|NCT02750852||Analysis group|Create an algorithm to predict blood loss using patients data
2971985|NCT02750852||Control group|The algorithm was applied to analyze sensitivity and specificity
2971986|NCT02750839||proximal humerus fracture|Patients with proximal humerus fracture treated with mini-invasive plate.
2971987|NCT02750826|Other|Arm 1: Health Education Program|Patients will receive a standardized intervention focusing on healthy living. This will include mailings at study entry and one year later describing healthy lifestyle behaviors. All participants will also receive a 2-year subscription to a health magazine. In addition, all study participants will be invited to join twice-yearly Webinars/teleconferences that focus on breast cancer and other health topics, such as treatment updates in breast cancer, management of menopausal side effects, general cancer screening, etc. Finally, the study will also provide birthday and holiday greeting cards and a twice-yearly study newsletter with study updates and other general breast cancer news.
2971988|NCT02750826|Other|Arm 2: Health Education Program + Weight Loss Intervention|Patients will receive a standardized intervention focusing on healthy living as described in the Arm 1 (Health Education Program). In addition, patients will utilize a standardized, 2-year, telephone-based weight loss intervention. The intervention will include individual weight loss, caloric restriction, and physical activity goals for each participant. It will be administered through semi-structured phone calls delivered by trained coaches at the BWEL call center and supplemented through print and on-line materials. The intervention will utilize a toolbox approach that will allow for tailoring for the individual participant.
2971989|NCT02750813|Other|DT1, then AO1D|Delefilcon A contact lenses worn first, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 14 days in a daily wear, daily disposable modality.
2971990|NCT02750813|Other|AO1D, then DT1|Senofilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product worn bilaterally for 14 days in a daily wear, daily disposable modality.
2971991|NCT02750800||Patients with psoriatic arthritis|Patients with psoriatic arthritis
2971992|NCT02750800||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis
2971993|NCT02750800||Patients with Crohn's disease|Patients with Crohn's disease
2971994|NCT02750800||Patients with ulcerative colitis|Patients with ulcerative colitis
2971995|NCT02750800||Patients with ankylosing spondylitis|Patients with ankylosing spondylitis
2971996|NCT02750800||Patients with psoriasis|Patients with psoriasis
2971997|NCT02750787|Experimental|Nutritional Study Product|A ready-to-drink peptide-based liquid formula for patients with impaired gastro-intestinal function.
2971998|NCT02750774|Experimental|Low-Glycemic Index Group|Women in the low- glycaemic index group received a dietary intervention based on 3 main meals and 3 snacks, with a precise macronutrient composition, and a physical activity counseling according to the ACOG and ACSM recommendations.
2971999|NCT02750774|Other|Standard Care Group|Women in the Standard Care Group received a simple nutritional booklet regarding lifestyle, which was in agreement with the Italian Guidelines for a healthy diet during pregnancy that included general advice regarding food consumption and physical activity.
2972000|NCT02750761|Experimental|Part A, Group 1: Tedizolid Phosphate (IV)|Single IV infusion of tedizolid phosphate administered to participants 6 to <12 years of age. Cohort 1 will receive 5 mg/kg of total body weight. Cohort 2 will receive 4 mg/kg of total body weight.
2972001|NCT02750761|Experimental|Part A, Group 2: Tedizolid Phosphate (IV)|Single IV infusion of tedizolid phosphate administered to participants 2 to <6 years of age. Cohort 1 and Cohort 2 will receive 6 mg/kg of total body weight with a potential adjustment up to a maximum dose of 200 mg of tedizolid phosphate.
2972002|NCT02750761|Experimental|Part B, Group 3: Tedizolid Phosphate (oral)|Single dose of tedizolid phosphate administered as an oral suspension at 4 mg/kg of total body weight to participants 6 to <12 years of age. Administration of tedizolid phosphate as an oral suspension is to occur within 15-60 minutes following a meal.
2972003|NCT02750761|Experimental|Part B, Group 4: Tedizolid Phosphate (oral)|Single dose of tedizolid phosphate administered as an oral suspension at 6 mg/kg of total body weight with a potential adjustment up to a maximum dose of 200 mg of tedizolid phosphate to participants 2 to <6 years of age. Administration of tedizolid phosphate as an oral suspension is to occur within 15-60 minutes following a meal.
2972004|NCT02750748|Experimental|4mg Intranasal Naltrexone|Administer one 0.1 mL spray of a 40 mg/mL solution in one nostril
2972005|NCT02750748|Experimental|4mg Intranasal Naltrexone with Intravail|Administer 0.1 mL spray of a 40 mg/mL solution with 0.25% Intravail in one nostril
2972006|NCT02750748|Experimental|2mg Intramuscular Naltrexone|Administer 2 mg formulation intramuscularly
2972008|NCT02750735||Retrospective NCWS patients|The clinical charts of NCWS patients attending the outpatient centers of the Department of Internal Medicine at the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca were retrospectively reviewed. Patients had all been diagnosed with NCWS between January 2001 and June 2011, by a DBPCC method, and included in a previously published study. These charts included specific sections for the presence of associated atopic diseases, including nickel allergy. In this way, the characteristics of the NCWS patients suffering from nickel allergy were compared with those of the NCWS patients who did not suffer from nickel allergy. Incomplete clinical charts were excluded.
2972009|NCT02750735||Prospective NCWS patients|The investigators also prospectively surveyed adult patients with functional gastroenterological symptoms according to the Rome III criteria, and a definitive diagnosis of NCWS. The patients were recruited between December 2014 and March 2016 at 3 centers: the two already mentioned and the Gastroenterology Unit of the ARNAS Civico Hospital of Palermo, Italy. Most of the patients had been referred due to gastrointestinal symptoms, the onset of which, they reported, could be related to wheat ingestion. Again, the characteristics of the NCWS patients suffering from nickel allergy were compared with those of the NCWS patients who did not suffer from nickel allergy.
2972010|NCT02750735||Retrospective NCWS control patients|To compare the frequency of nickel allergy in NCWS and non-NCWS patients, a control group composed of 70 irritable bowel syndrome (IBS) patients, was selected. These controls were randomly chosen by a computer-generated method from subjects diagnosed during the same period and age- (+/-2 years) and sex-matched (+/-5%) with the NCWS patients. The IBS controls had been receiving the same elimination diet as the NCWS patients and had not shown any clinical improvement; they belonged to the cohort of subjects the investigators had studied previously.
2972011|NCT02750735||Prospective NCWS control patients|As for the retrospective study, to compare the frequency of nickel allergy in NCWS and non-NCWS patients, a control group composed of 70 patients with functional gastroenterological symptoms, was selected, with the same criteria adopted for the retrospective study.
2972012|NCT02750722|Experimental|Cycling in combination with Flutter® therapy|Participants perform 30 minutes of moderately intense cycling exercise in 4-min intervals at 75% of their maximal heart rate and interspersed with 2-min resting periods during which 6-8 breathing maneuvers are performed with the Flutter®.
2972013|NCT02750722|Active Comparator|Cycling without Flutter® therapy|Participants perform 30 minutes of continuous moderately intense cycling exercise at 75% of their maximal heart rate without additional Flutter® breathing maneuvers.
2972014|NCT02750709|Experimental|Treatment Sequence A (TP 1) - B (TP 2) - C (Reference)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
2972015|NCT02750709|Experimental|Treatment Sequence A (TP 1) - C (Reference) - B (TP 2)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
2972016|NCT02750709|Experimental|Treatment Sequence B (TP 2) - A (TP 1) - C (Reference)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
2972017|NCT02750709|Experimental|Treatment Sequence B (TP 2) - C (Reference) - A (TP 1)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
2972018|NCT02750709|Experimental|Treatment Sequence C (Reference) - A (TP 1) - B (TP 2)|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
2972019|NCT02750709|Experimental|Treatment Sequence C (Reference) - B (TP 2) - A (TP 1)|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
2972020|NCT02750696|Active Comparator|Co/ Ac|Codeine/acetaminophen (30 mg/500 mg) analgesic association tablets. Patients in this group received one fixed-dose oral tablet of codeine/acetaminophen (30 mg/500 mg) every 4 hours for 3 days.
2972021|NCT02750696|Experimental|Tr/ Ac|Tramadol/acetaminophen (37.5 mg/325 mg) analgesic association tablets. Patients in this group received one fixed-dose oral tablet of tramadol/acetaminophen (37.5 mg/325 mg) every 4 hours for 3 days.
2972022|NCT02750670|Experimental|GD2P|Obinutuzumab 1000mg by IV for 1.5-6.5 hours with Gemcitabine 1000mg/m^2 by IV for 30 minutes with dexamethasone 40mg by mouth daily and Cisplatin 75mg/m^2 by IV for 1 hour all for a duration of 3 cycles
2972023|NCT02750657||Patients with advanced pancreatic ductal adenocarcinoma|
2972024|NCT02750644||High-risk|Patients with atherosclerotic carotid disease with (1) severe comorbidity (class III/IV congestive heart failure, class III/IV angina, coronary disease involving ≥ 2 major vessels, left ventricular ejection fraction ≤ 30%, myocardial infarction, severe pulmonary disease, severe renal failure) and (2) Technical/challenging anatomical criteria (previous neck surgery, cervical irradiation, contralateral carotid occlusion, post-endarterectomy restenosis, inaccessible lesions or tracheotomy).
2972054|NCT02750462|Experimental|Immediate coronary angiography|Immediate coronary angiography in survivors of out-of-hospital cardiac arrest without ST-segment elevation
2972055|NCT02750462|Active Comparator|Delayed/selective coronary angiography|Initial intensive care evaluation to further stratify the etiology of out-of-hospital cardiac arrest with delayed/selective coronary angiography if indicated
2972025|NCT02750644||Standard-risk|Patients with atherosclerotic carotid disease without (1) severe comorbidity (class III/IV congestive heart failure, class III/IV angina, coronary disease involving ≥ 2 major vessels, left ventricular ejection fraction ≤ 30%, myocardial infarction, severe pulmonary disease, severe renal failure) and (2) Technical/challenging anatomical criteria (previous neck surgery, cervical irradiation, contralateral carotid occlusion, post-endarterectomy restenosis, inaccessible lesions or tracheotomy).
2972026|NCT02750631|Experimental|Triple Therapy|Combined Wake Therapy (one night of missed sleep), early morning bright light and sleep phase advance
2972027|NCT02750618|Experimental|Burosumab Q2W|Burosumab subcutaneous (SC) injections every 2 weeks (Q2W) for a total of 160 weeks.
2972028|NCT02750605|Experimental|Drug eluting balloon angioplasty|Intervention with DEB angioplasty in long lesions of crural arteries
2972029|NCT02750605|Active Comparator|Plain old balloon angioplasty|Intervention with plain old balloon angioplasty POBA in long lesions of crural arteries
2972030|NCT02750592|Experimental|secukinumab 150mg|A screening (SCR) epoch running 4-10 weeks before baseline (BSL) will be used to assess eligibility followed by 52 weeks of treatment. The treatment periods consist of Treatment period 1 (BSL to Week 24) and Treatment period 2 (Week 24 to Week 52). After Week 52 follows a post-treatment follow-up until Week 60. A follow-up visit is to be done at 12 weeks after last study treatment administration for all patients, regardless of whether they complete the entire study as planned (Week 60) or discontinue prematurely.
2972031|NCT02750579|Active Comparator|Control group|control group: Percutaneous coronary intervention for revascularization delayed intervention (12 to 72 hours)
2972032|NCT02750579|Experimental|experimental group|experimental group: early Percutaneous coronary intervention for revascularization intervention (<2 hours)
2972033|NCT02750566|Experimental|Osteopathic Manipulative Treatment|A board certified NMM/OMM or FP/OMM physician will perform an osteopathic structural exam and osteopathic treatment for a 30 minute session. The investigators will follow a generalized protocol for diagnosis and treatment of the head, neck, spine, rib cage, and pelvis. The following techniques will be included in the treatment protocol, OA (Occipitoatlantal) decompression, V-Spread, venous sinus drainage, balanced membranous tension (BMT), cranial lifts, CV4, and a mix of balanced ligamentous tension (BLT), muscle energy techniques, facilitated positional release, articulatory techniques (ART), high-velocity low-amplitude, and counterstrain to address any somatic dysfunctions.
2972034|NCT02750566|Active Comparator|Counseling|"For the control group, an investigator will complete a 30-minute counseling session with the subject. The focus of discussion will be from the CDC's What to expect after a concussion article. Other resources that will also be used come from the American Academy of Family Physicians (AAFP), FamilyDoctor.org, and the Brain Care Center. Each counseling session will follow the same protocol. The counseling session will provide subject with similar face-to-face time with the OMT arm."
2972035|NCT02750553|Experimental|Pre-test|Three healthy male subjects were randomized in 2:1 ratio to receive single and then multiple (14 days) oral dose of 5 mg SHR0534 or matching placebo.
2972036|NCT02750553|Experimental|Cohort 1|Eight healthy subjects were randomized in 3:1 ratio to receive single and then multiple (14 days) oral dose of 5 mg SHR0534 or matching placebo.
2972037|NCT02750553|Experimental|Cohort 2|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 10 mg SHR0534 or matching placebo.
2972038|NCT02750553|Experimental|Cohort 3|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 25 mg SHR0534 or matching placebo.
2972039|NCT02750553|Experimental|Cohort 4|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 50 mg SHR0534 or matching placebo.
2972040|NCT02750553|Experimental|Cohort 5|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 100 mg SHR0534 or matching placebo.
2972041|NCT02750540|Active Comparator|Product A dose|Product A will contain tenofovir (TFV) 220 mg in 125 mL iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
2972042|NCT02750540|Active Comparator|Product B dose|Product B will contain tenofovir (TFV) *660 mg in 125 mL iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
2972043|NCT02750540|Active Comparator|Product C dose|Product C will contain tenofovir (TFV) *660 mg in 125 mL hypo-osmolar solution at half the osmolarity of iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
2972044|NCT02750540|Placebo Comparator|Take-home normal saline (NS) enema|The normal saline (NS) solution will be provided following administration of Product A which is iso-osmolar. The volume of NS enema (120 mL) was selected to approximately match that of Product A (125 mL)
2972045|NCT02750540|Placebo Comparator|Take-home half normal saline (½ NS) enema|The ½ normal saline (½ NS) solution will be provided following administration of Product C which is hypo-osmolar. The volume of the ½ NS enema (120 mL) was selected to approximately match that of Product C (125 mL)
2972046|NCT02750514|Active Comparator|Nivolumab|Nivolumab Monotherapy - Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator
2972047|NCT02750514|Experimental|Nivolumab & Dasatinib|Nivolumab in combination with Dasatinib
2972048|NCT02750514|Experimental|Nivolumab & Relatlimab|Nivolumab in combination with Relatlimab
2972049|NCT02750514|Experimental|Nivolumab & Ipilimumab|Nivolumab in combination with Ipilimumab
2972050|NCT02750514|Experimental|Nivolumab & BMS-986205|Nivolumab in combination with BMS- 986205
2972051|NCT02750501|Other|Single Arm: Open label RELiZORB Cartridge & Impact Peptide 1.5|RELiZORB (immobilized lipase) cartridge and Impact Peptide 1.5 with enteral feedings ranging from 500 mL to 1,000 mL per feeding for a period of 90 days.
2972052|NCT02750488|Experimental|BAY987517|All subjects are patched with the same product
2972053|NCT02750475|Experimental|Arm 1|All subjects are patched.
2972056|NCT02750449|Experimental|Arm 1|All subjects are patched.
2972059|NCT02750423|Active Comparator|DHCA+RCP|Participants undergoing ascending aortic and hemiarch replacement will receive deep hypothermic circulatory arrest and retrograde cerebral perfusion (DHCA+RCP).
2972060|NCT02750423|Active Comparator|MHCA+uSACP|Participants undergoing ascending aortic and hemiarch replacement will receive moderate hypothermic circulatory arrest and unilateral selective antegrade cerebral perfusion (MHCA+uSACP).
2972061|NCT02750410|Experimental|Dulaglutide|Dulaglutide administered once weekly for 52 weeks.
2972062|NCT02750410|Placebo Comparator|Placebo|Placebo administered once weekly for 16 weeks. After 16-weeks, dulaglutide administered once weekly for 36 weeks.
2972063|NCT02750397||HIV D+/R+|HIV+ recipients who receive an organ transplant from an HIV+ donor
2972064|NCT02750397||HIV D-/R+|HIV+ recipients who receive an organ transplant from an HIV- donor
2972065|NCT02750384|Experimental|50% SDD granules, fasting|50% spray dried dispersion granules, fasting
2972066|NCT02750384|Active Comparator|25% SDD powder for suspension, fasting|25% spray dried dispersion powder for suspension, fasting
2972067|NCT02750384|Experimental|50% SDD granules, fed|50% spray dried dispersion granules, fed
2972068|NCT02750371|Experimental|Patients with brain tumors treated by radiotherapy|"Patients with:~- meningioma of the cavernous sinus for which radiotherapy is planned~Or~- a pituitary adenoma for which radiotherapy is planned"
2972069|NCT02750358|Experimental|Enzalutamide|160mg orally as daily continuous dosing for 52 weeks. Patients will be seen for protocol visits every 4 weeks (+/- 2 week window) for the first 12 weeks followed by every 12 weeks (+/- 2 week window) to complete 52 weeks. An assessment will also be performed at 52 weeks (+ 4 week window).
2972070|NCT02750345|Experimental|Sequence TP 1 - TP 2 - Reference|Subjects will receive a single 10 mg tablet of Nitisinone (Test Product 1 (TP 1)) in treatment period 1, 10 mg tablet of Nitisinone Baked Tablet (Test Product 2 (TP 2)) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
2972071|NCT02750345|Experimental|Sequence TP 1 - Reference - TP 2|Subjects will receive a single 10 mg tablet of Nitisinone (Test Product 1) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
2972072|NCT02750345|Experimental|Sequence TP 2 - TP 1 - Reference|Subjects will receive a single 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
2972073|NCT02750345|Experimental|Sequence TP 2 - Reference - TP 1|Subjects will receive a single 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
2972074|NCT02750345|Experimental|Sequence Reference - TP 1 - TP 2|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
2972075|NCT02750345|Experimental|Sequence Reference - TP 2 - TP 1|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 2, and 10 mg tablet of Nitisinone (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
2972076|NCT02750332|Experimental|Treatment Sequence A (Fed) - B (Fasted)|Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fed conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
2972077|NCT02750332|Experimental|Treatment Sequence B (Fasted) - A (Fed)|Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fasting conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fed conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
2972078|NCT02750319|Placebo Comparator|Amiodarone + Placebo|Amiodarone loading: 150 mg IV in PACU over one hour, then 1.0 gm/24h x 2 + NAC loading matching placebo; 50 mg/kg IV in PACU over one hour, then 50 mg/kg/24h x 2 NAC matched placebo continuously for 48 hours.
2972079|NCT02750319|Experimental|Amiodarone + N-Acetylcysteine|Amiodarone loading: 150 mg IV in PACU over one hour, then 1.0 gm/24h x 2 + NAC loading: 50 mg/kg IV in PACU over one hour, then 50 mg/kg/24h x 2 and then continuously for 48 hours.
2972080|NCT02750306|Experimental|Suvorexant 10 mg (may be increased to 20 mg)|After 2 weeks of treatment with suvorexant 10mg, the dose may be increased to suvorexant 20mg, oral, 1 tablet every night, based upon acceptable tolerability and CGI-S score of >=3
2972081|NCT02750306|Placebo Comparator|Placebo|Placebo to suvorexant 10mg, oral, 1 tablet every night for 4 weeks. After 2 weeks of treatment, the placebo may be changed to match the suvorexant 20mg tablet based upon acceptable tolerability and CGI-S score of >= 3.
2972082|NCT02750293|Active Comparator|cholecalciferol|vitamin D (as a 20 000 IU capsule) will be given once a week for 4 months
2972083|NCT02750293|Placebo Comparator|placebo|placebo capsules (identical looking to the vitamin D capsules) will be given once a week for 4 months
2972084|NCT02750280|Experimental|Urinary Bladder matrix (UBM)|UBM covered with silicone foam dressing plus total contact cast
2972085|NCT02750280|Active Comparator|Standard Care|Silicone foam dressing plus total contact cast
2972086|NCT02750267|Experimental|Group A|In this randomized, cross-over study, the intervention involves blood glucose control using a Closed Loop system run by the Diabetes Assistant (DiAs) during a stay at a Research House/Hotel. All subjects will have blood glucose data compared between their usual diabetes care (at home, using home insulin pump) and this Closed-Loop care (at Research House/Hotel using the DiAs system). Subjects who are randomized to Group A will have home care evaluated before the Research House/Hotel admission. Subjects in this arm will participate in CGM training and data collection prior to the Research House/Hotel admission.
2972087|NCT02750267|Experimental|Group B|Group B is identical to Group A with the exception that usual diabetes care (at home, using home insulin pump) will be evaluated after the Research House/Hotel admission. Subjects who are randomized to Group B will participate in CGM training and data collection after the Research House/Hotel admission. As with Group A, all subjects will use Diabetes Assistant (DiAs) with Closed-Loop during the admission.
2972088|NCT02750254|Experimental|Arm 1: Azacitidine|"Treating physician must choose from one of these conditioning regimens (will be given per standard of care)~fludarabine and fractionated total body irradiation (Flu/FrTBI)~fludarabine and busulfan (Flu/Bu4)~fludarabine, cyclophosphamide, and single dose total body irradiation (Flu/Cy/sdTBI)~fludarabine and melphalan (Flu/Mel)~reduced-intensity fludarabine and busulfan (Flu/Bu2)~G-CSF from Day -5 through Day -1 per standard of care~On Day 0, the allograft will be infused per standard of care.~Azacitidine will be administered on Day +1 and +2 post-stem cell transfusion days~Cyclophosphamide on Days +3 and +4 post-transplant"
2972089|NCT02750241|Experimental|Active video game-based intervention|This arm will receive the active video game-based intervention, which will include attending 12 weekly group sessions at the UTMB Breast Health Clinic, participate in self-paced home session, and monitor daily, weekly, and monthly steps using Wii Fit Meter. All participant will be provided a water bottle and a tote bag as a token of appreciation for participation.
2972090|NCT02750241|Active Comparator|Pedometer|This arm will receive the pedometer intervention, which will include attending 3 monthly UTMB Breast Cancer Support Group sessions, and monitor daily, weekly, and monthly steps using a pedometer (Digit-Walker CW-700/701). All participant will be provided a water bottle and a tote bag as a token of appreciation for participation.
2972091|NCT02750215|Experimental|Capmatinib (INC280)|"Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib.~After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles"
2972092|NCT02750202|Active Comparator|Quadrivalent HPV vaccine|Three doses of 4 HPV vaccine is given at registered intervals.
2972093|NCT02750202|Sham Comparator|Hepatitis B vaccine|Three doses of Hepatitis B vaccine is given at the same intervals as the quadrivalent HPV vaccine.
2972094|NCT02750189||Mild Group|FEV₁/FVC ＜70% and FEV₁≥80% direct/indirect cost
2972095|NCT02750189||Moderate Group|FEV₁/FVC ＜70% and 50%≤FEV₁≤80% direct/indirect cost
2972096|NCT02750189||Severe Group|FEV₁/FVC ＜70% and 30%≤FEV₁≤50% direct/indirect cost
2972097|NCT02750189||Very Severe Group|FEV₁/FVC ＜70% and FEV₁＜30% direct/indirect cost
2972098|NCT02750176|Experimental|CERCT|Closed chain exercises
2972099|NCT02750150|Experimental|Freezed-dried plasma|transfusion of 4 units of freezed dried plasma when available in patients at risk pf massive bleeding (transfusion of 4 red blood cells units in the first 6 hours after trauma)
2972100|NCT02750150|Active Comparator|Fresh-frozen plasma|transfusion of 4 units of fresh frozen plasma when available in patients at risk pf massive bleeding (transfusion of 4 red blood cells units in the first 6 hours after trauma)
2972101|NCT02750124|Active Comparator|HPV self sampling test sent|A Cobas PCR (polymerase chain reaction) Female swab sample Packet will be sent directly to women with a study invitation letter and instructions. Response rate will be measured.
2972102|NCT02750124|Active Comparator|HPV self sampling test ordered|An invitation to order a Cobas PCR Female swab sample Packet through an online application will be sent. Response rates will be measured.
2972103|NCT02750124|Active Comparator|Nurse navigator contact|An invitation to call the coordinating midwife with questions and concerns regarding screening will be sent. The coordinating midwife can help the participant order a Cobas PCR Female swab sample Packet or book a standard screening visit, if desired. Response rates will be measured
2972104|NCT02750124|Placebo Comparator|Control|The standard, annual renewed invitation to cervical screening will be sent (control, routine practice). Response rate will be measured as a baseline.
2972105|NCT02750098|Experimental|Diabetic patients|Diabetic patients planned to undergo elective cataract surgery
2972106|NCT02750085||2-point and 6-point PK sampling|
2972107|NCT02750072|Active Comparator|Infrapatellar approach|Infrapatellar approach using the surgeon's incision of choice (i.e., patellar tendon split, tendon retraction medial, tendon retraction lateral).
2972108|NCT02750072|Experimental|Semi-extended suprapatellar approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed suprapatellar percutaneous instrumentation (patellofemoral protection sleeve).
2972109|NCT02750059|Experimental|TDF/3TC/EFV + Telmisartan|The subjects will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART
2972110|NCT02750059|Active Comparator|TDF/3TC/EFV only|Subjects will receive ART only
2972111|NCT02750046|Experimental|osteoporotic fractures|patients with osteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
2972112|NCT02750046|Sham Comparator|nonosteoporotic fractures|patients with nonosteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
2972113|NCT02750033||Basal Cell Carcinoma (BCC)|Adult patients undergoing Mohs surgery to remove basal cell carcinoma (BCC) will have surgical margins assessed with multimodal optical spectroscopy (MMS) device, as well as standard histopathology evaluation.
2972114|NCT02750033||Squamous Cell Carcinoma (SCC)|Adult patients undergoing Mohs surgery to remove squamous cell carcinoma (BCC) will have surgical margins assessed with multimodal optical spectroscopy (MMS) device, as well as standard histopathology evaluation.
2972115|NCT02750020||never smokers|Around 1667 never smokers will be required to answer a questionnaire via telephone.
2972116|NCT02750020||ex-smokers|Around 1667 ex-smokers will be required to answer a questionnaire via telephone.
2972117|NCT02750020||current smokers|Around 1667 current smokers will be required to answer a questionnaire via telephone.
2972118|NCT02750007|Experimental|Experimental|Weekly-dose titration from 0.04mg/day HS-20004 to the maximum tolerable dose or of the ultimate 0.18mg/day
2972119|NCT02749994|Active Comparator|R5|Rosuvastatin 5mg
2972120|NCT02749994|Active Comparator|R10|Rosuvastatin 10mg
2972121|NCT02749994|Active Comparator|R20|Rosuvastatin 20mg
2972122|NCT02749994|Experimental|R5/E10|Rosuvastatin 5mg/Ezetimibe 10mg
2972126|NCT02749968|Active Comparator|Liposomal bupivacaine|1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
2972127|NCT02749968|Placebo Comparator|0.9% sodium chloride|1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
2972128|NCT02749955|Experimental|PS-PrEP Intervention Group|
2972129|NCT02749955|Active Comparator|PrEPLine Control Group|
2972130|NCT02749955|No Intervention|CDPH Prevention Projects|
2972131|NCT02749942|Active Comparator|AutoRIC: Remote Ischemic Conditioning|Daily cuff treatment of arm with 4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG of pressure) on top of standard care.
2972132|NCT02749942|Sham Comparator|AutoRIC: Sham device treatment|Daily sham device treatment of arm, 4 cycles of 5 minute (0 mmHG of pressure) on top of standard care. No ischemia induced.
2972133|NCT02749929|Experimental|Low-Level Laser therapy|"After inclusion in the study, a small window of approximately 1 cm2 opening will be made in the cast in order for the laser to make skin contact. The laser is a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. The light from the laser is not visible to the eye, and will not give any perceptible stimulus.~Low-Level Laser therapy (LLLT) will be given according to the recommended dosage from World Association of Laser Therapy (WALT). A LLLT dose of 3.6 Joules will be administered at two points over the fracture site."
2972134|NCT02749929|Placebo Comparator|Placebo Low-Level Laser therapy|After inclusion in the study, a small window of approximately 1 cm2 opening will be made in the cast in order for the placebo laser to make skin contact. The placebo laser is identical in apperance to a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Since the light from the laser is invisible, neither the participant nor the therapist will know whether the laser is a placebo. The treatment time and number of treated points will be identical to group 1.
2972135|NCT02749916||Patients with acute or recent (within 3months) stroke|
2972136|NCT02749903|Other|Enzalutamide|Patients receive 160 mg enzalutamide orally once daily (1 cycle=28 days). Patients will remain on therapy until progression of disease or development of unacceptable toxicities or patient or physician withdrawal. Patients will undergo radiographic imaging every 2 months while on study treatment in order to determine response.
2972137|NCT02749890|Experimental|LixiLan|"LixiLan (insulin glargine/lixisenatide fixed ratio combination) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
2972138|NCT02749890|Active Comparator|lixisenatide|"Lixisenatide (AVE0010) is injected subcutaneously (under the skin) once daily. It will be initiated with Dose 1 for 1 week and then continue with Dose 2 for 1 week followed by the maintenance dose of Dose 3 up to the end of treatment period.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
2972139|NCT02749877|Experimental|Cognitive Training|"This group will undergo a working memory training program (Training A). The children will receive individual memory training based on the computer program Cogmed RM and will be supervised by trained neuropsychologists. Its efficacy in the use with children with cancer has been recently published. The children will undergo 25 training sessions online; each session takes about 45 minutes and consists of a selection of various tasks that target the different aspects of working memory."
2972140|NCT02749877|Experimental|Physical Training|This group will receive a physical training that can be executed at home (Training B). The training will be based on xbox Kinect games and comprise games and activities such as jump'n'run games, physical training, and dance activities. One training session will last approximately 45 minutes and will be performed 3 days a week over a period of 8 weeks (in total 25 sessions).
2972141|NCT02749877|Active Comparator|Waiting Control Group|This group will serve as a waiting control group and will receive either the physical or the working memory training program after completion of the Neuropsychological Assessment II
2972142|NCT02749864||A: Age 20-34 yr|No intervention Cohort of subjects aged 20-34 years old.
2972143|NCT02749864||B: Age 35-49 yr|No intervention Cohort of subjects aged 35-49 years old.
2972144|NCT02749864||C: Age 50-79 yr|No intervention Cohort of subjects aged 50-79 years old.
2972145|NCT02749851||Non-smokers|Pregnant women that identify as non-smokers with low risk for placental insufficiency will receive the MRI Imaging intervention.
2972146|NCT02749851||Smokers|Pregnant women that identify as smokers will receive the MRI Imaging intervention.
2972147|NCT02749851||High risk/Non-Smokers|Pregnant women that identify as non-smokers who are at a high risk for adverse outcomes based on prior clinical history will receive the MRI Imaging intervention.
2972148|NCT02749851||Confirmed IUGR|Pregnant women identified by their clinical care provided to have confirmed IUGR during their current pregnancy
2972149|NCT02749825|Experimental|Trelstar|Per prescribing information
2972150|NCT02749825|Active Comparator|Lupron|Per prescribing information
2972151|NCT02749825|Active Comparator|Zoladex|Per prescribing information
2972152|NCT02749812|Experimental|Constant Continuous Positive Airway Pressure|
2972153|NCT02749812|Experimental|automatic Continuous Positive Airway Pressure|
2972154|NCT02749799|Experimental|DFD-01|
2972155|NCT02749786|Other|Control Group|Ten participants who does not have rosacea will be used as the control group.
2972156|NCT02749773|Active Comparator|Oocyte aspiration with 17G needle|Oocyte Aspiration with 17G needle.
2972157|NCT02749773|Active Comparator|Oocyte aspiration with (20-17G) needle|Oocyte Aspiration (20-17G) needle.
2972158|NCT02749760|Other|Minor league pitchers|Minor league pitchers from a single professional baseball organization. Strength tests of the elbows will be administered at spring training and end of season for 5 years. If strength correlates to injury, strengthening and exercise programs may be established to target the stabilizers of the elbows.
2972159|NCT02749747|Active Comparator|Sulpiride use|50mg sulpiride once a day use for 60 days
2972160|NCT02749747|Placebo Comparator|Placebo|50mg placebo once a day use for 60 days
2972161|NCT02749734|Experimental|hESC-RPE|Subretinal transplantation of Human embryo stem cell derived retinal pigment epitheliums
2972162|NCT02749721|Other|Open-label vortioxetine|
2972163|NCT02749708|Experimental|IRX5183|
2972164|NCT02749695|Experimental|Group 1 (Melsmon)|20 women used placental extract Melsmon® (Japan), 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
2972165|NCT02749695|Placebo Comparator|Group 2 (placebo)|20 patients used placebo (normal saline solution): 2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
2972166|NCT02749682||constipation & hernia group|The effect of constipation on study group whether there is a correlation between subgroups of operated patients on the view of direct and indirect hernias(Nyhuss classification).
2972167|NCT02749682||constipation & normal population|The level of constipation on normal population using constipation severity scale.
2972168|NCT02749669|Other|Qualitative research|Semi-structured interviews
2972169|NCT02749669|No Intervention|Economic evaluation|Questionnaire
2972170|NCT02749656|Experimental|0.25% Desoximetasone cream (Topoxy®)|"0.25% Desoximetasone cream (Topoxy®): apply on scalp psoriasis lesion twice a day for 8 weeks.~(Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)"
2972171|NCT02749656|Active Comparator|0.25% Desoximetasone cream (Topicorte®)|"0.25% Desoximetasone cream (Topicorte®): apply on scalp psoriasis lesion twice a day for 8 weeks.~(Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)"
2972172|NCT02749656|Placebo Comparator|Placebo|Placebo: apply on scalp psoriasis lesion twice a day for 8 weeks. (Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)
2972173|NCT02749643|Experimental|Vibrotactile feedback|Vibrotactile system - comprises of force sensors, attached to the fingertips of the prosthetic hand, and a set of 8 vibration actuators attached to a fabric arm cuff. When the subject applies force on the sensors with his prosthetic hand, he receives a vibration on the skin of his arm. The sensors and actuators are connected to an electronic control board, which transforms the resistance from the sensors to an electric signal that activates the vibration actuators.
2972174|NCT02749630|Experimental|Healthy Volunteer|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
2972175|NCT02749630|Experimental|Ulcerative Colitis|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
2972176|NCT02749630|Experimental|Crohn's Disease|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
2972177|NCT02749617|Experimental|apixaban|apixaban 2.5 mg PO BID
2972178|NCT02749604|Active Comparator|Non-ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate
2972179|NCT02749604|Experimental|Ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate with preservation of the ejaculatory hood
2972180|NCT02749591|Experimental|Robot-assisted therapy (RT)|After injection with Botulinum Toxin Type A, a schedule of robot-assisted therapy appointments will be established. Each intervention includes 45 minutes of robotic training and 30 minutes of training in functional activities.
2972181|NCT02749591|Experimental|Mirror therapy (MT)|After injection with Botulinum Toxin Type A, a schedule of mirror therapy appointments will be established.The MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
2972182|NCT02749591|Active Comparator|Control Intervention (CI)|After injection with Botulinum Toxin Type A, a schedule of control intervention appointments will be established.The CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
2972183|NCT02749578|Other|Treatment|Atorvastatin followed by MGL-3196 daily followed by separate co-administration of atorvastatin
2972184|NCT02749565||asthmatic patients with OSA|CPAP titration will be applied patients decided CPAP treatment by themselves
2972185|NCT02749565||asthmatic patients without OSA|No CPAP treatment
2972186|NCT02749552|Experimental|Acceptance and Commitment Therapy|ACT intervention
2972187|NCT02749539|Experimental|Kinesio tape|The first 3 kinesio tape application was inhibition technique for supraspinatus, deltoid and teres minor muscles. the fourth Kinesio tape was mechanical correction for the shoulder joint. in addition to active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
2972188|NCT02749539|Active Comparator|Physiotherapy program|active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
2972189|NCT02749526|Experimental|Endostar combined with MPFC|"Chemotherapy regimens (er degree + mPFC) :~Endostar:~degrees 30 mg civ24h d0-6;~Liposo:~135 mg/m2 D1; cisplatin: D1-3, 25 mg/m2~Gimeracil and Oteracil Potassium (Tegafur):~(40 mg bid Tegafur), D1-14. A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy."
2972190|NCT02749513|Experimental|Itraconazole|Itraconazole 300 mg po bid for 14-17 days
2972191|NCT02749500|Active Comparator|Conventional Occupational Therapy (OT)|Standard of care occupational therapy for stroke recovery
2972192|NCT02749500|Experimental|OT + Device-assisted therapy|Conventional OT plus 1 hour additional bimanual-to-unimanual device-assisted therapy. The m2 BAT will enable repeated movement of the affected body part without the help of a therapist, providing the opportunity to maintain range-of motion in the affected limb to limit spasticity, contracture and the ensuing deformity, a major goal of rehabilitation therapy and produces movement in the affected limb from activating the patient's own brain, rather than from being acted on by an external powered source such as a robot.
2972193|NCT02749487||cured (c)|Neutrophil Lymphocyte and platelet lymphocyte ratios as Predictors of Outcome in Traumatic Critically ill Patients
2972194|NCT02749487||Died ( M)|Neutrophil Lymphocyte and platelet lymphocyte ratios as Predictors of Outcome in Traumatic Critically ill Patients
2972195|NCT02749474||Pregnant women diagnosed with cancer|Any pregnant woman diagnosed with any cancer within 6 weeks prior to their last menstrual period, or up to 6 months after the end of their pregnancy can be enrolled.
2972196|NCT02749448|Other|mesenchymal stem cell|There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers
2972197|NCT02749435||Standard of Care + digital disease management cohort|Participants will have access to the smart phone- and web portal-based digital disease management tool in addition to standard care.
2972198|NCT02749435||Standard of Care cohort|Participants will have standard care with no access to the digital disease management tool.
2972199|NCT02749422|Active Comparator|Healthy Subjects|
2972200|NCT02749422|Experimental|Temporal Lobe Epilepsy Patients|
2972201|NCT02749409|Active Comparator|Control group|The control group will be given Morphine prn after admission
2972202|NCT02749409|Experimental|Experimental group|the experimental group will be given parecoxib after admission by intravenous method every 12 hours for 4 days. Then Morphine agent will be given prn usage
2972203|NCT02749396||IFN-β / Cohort 1|Exposure to IFN-β only
2972204|NCT02749396||FN-β + other MSDMDs / Cohort 2|Women with MS exposed to IFN-β regardless of exposure to other MSDMDs
2972205|NCT02749396||No MSDMDs / Cohort 3|Women with MS exposed with no exposure to any MSDMDs
2972206|NCT02749396||No IFN-β + other MSDMDs / Cohort 4|Women with MS exposed to IFN-β exposure regardless of exposure to other MSDMDs
2972207|NCT02749396||Other MSDMDs / Cohort 5|Women with MS exposed to other MSDMD only excluding IFN-β or glatiramer acetate (Copaxone) or dimethyl fumarate (Tecfidera)
2972208|NCT02749396||Control / Cohort 6|Women from the general population without MS
2972209|NCT02749383|Experimental|PAC-14028 cream 0.3%|Twice daily for 4 weeks
2972210|NCT02749383|Experimental|PAC-14028 cream 1.0%|Twice daily for 4 weeks
2972211|NCT02749383|Placebo Comparator|PAC-14028 cream vehicle|Twice daily for 4 weeks
2972212|NCT02749370|Experimental|Etanercept|Participants received etanercept 50 mg subcutaneously twice weekly for 12 weeks followed by 50 mg once weekly for an additional 12 weeks.
2972213|NCT02749357|Active Comparator|Control|"Intervention: Control group, with 30 training sessions in robotic orthosis with duration of 30 minutes during 6 weeks.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen.The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
2972214|NCT02749357|Experimental|Experimental|"Intervention: Experimental group, with 30 training sessions in robotic orthosis with duration of 60 minutes during 6 weeks.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen.The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
2972215|NCT02749344|Experimental|FET after endometrial preparation|Natural cycle/progesterone fortified endometrial preparation before embryo transfer
2972216|NCT02749331|Experimental|AdVince|"Dose escalation, minimum 3 patients per dose in Phase I. Dose levels:~10 000 000 000 virus particles~100 000 000 000 virus particles~300 000 000 000 virus particles~1000 000 000 000 virus particles~Maximum tolerated dose will be confirmed by 12 additional patients treated at this dose level in Phase IIa."
2972217|NCT02749318|Experimental|Experimental Group|Consented patients who complete the initial Experimental Group Questionnaire, receive a prophylaxis, have the IL-1 genetic test for risk of severe periodontitis performed, their dental records monitored for 18 months post-enrollment, and answer a Study Completion Questionnaire 18 months post-enrollment.
2972218|NCT02749318|No Intervention|Usual Care Group|Consented patients who complete the initial Usual Care Group Questionnaire, receive a prophylaxis and have their dental records monitored for 18 months post-enrollment.
2972219|NCT02749305|Other|Preop Metabolic & Bariatric Patients|Attempted collection of patient-reported outcome measures preoperatively and annually postoperatively will occur with all metabolic and bariatric surgery patients scheduled for surgery at a participating center.
2972220|NCT02749305|Other|Postop Metabolic & Bariatric Patients|Attempted collection of patient-reported outcome measures annually postoperatively will occur with all metabolic and bariatric surgery patients who had surgery at a participating center within the preceding 12 months.
2972221|NCT02749292|Active Comparator|B cell reconstitution|Subjects will no longer receive regularly-scheduled every six-month doses of rituximab (1000mg IV) and will instead be monitored every three months for B cell return. Once peripheral B cells rise to ≥ 10cells/mm3 they will receive rituximab 1000 mg IV x 2 (doses spaced approx. 2-3 weeks apart). Subsequent dosing will be again based on B cell return (≥ 10 B cells/mm3), with patients seen in clinic and B cells monitored every 3 months.
2972222|NCT02749292|Active Comparator|Serologic ANCA flare|Subjects will not receive regularly-scheduled every six-month doses of rituximab (1000mg IV) and will instead be monitored every three months in clinic. Re-dosing will occur once the subject's ANCA titer has risen above the predetermined treatment value (MPO treatment value defined as a 5-fold rise from baseline and a level greater than 4 times the cutoff value for the assay; PR3 treatment value defined as a 4-fold rise from baseline and a level greater than 2-fold above the cutoff for the assay). Subjects who meet this criteria will then be re-dosed with rituximab 1000 mg IV x2 (spaced 2-3 weeks apart). If the ANCA titer remains 2-fold above baseline and above a specified threshold (the cutoff value of the assay for PR3 and 4 times the cutoff value for MPO), subjects will then receive rituximab 1000mg IV every 6 months x 2 doses and a new ANCA titer baseline will be established. The cycle will then re-start.
2972223|NCT02749266|Experimental|Chiropractic Activator Adjustment|Participant will receive a chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
2972224|NCT02749266|Sham Comparator|Chiropractic sham adjustment|Participant will receive a sham (simulated) chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
2972225|NCT02749253|Experimental|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants will receive training in SKY soon after completing baseline assessments.
2972369|NCT02748486|Experimental|Jumping To Conculsions|Metacognitive Training Jumping to conclusions module
2972226|NCT02749240|Other|Youth Empowerment Seminar, YES!|An 8-week innovative bio-psycho-social program (Youth Empowerment Seminar, YES!) will be offered to at risk youth participating in programs or resources offered by Youth Opportunities Unlimited. The YES! program will be taught in two phases: (1) an active learning phase which consists of four consecutive days (3 hrs/day) of SEL skills taught in a multi-modality interactive format as well as SKY training, and (2) a reinforcement phase which involves weekly follow up sessions (75-90 mins each) for the 7 weeks following the active phase. Two certified instructors from the Art of Living Foundation (Spencer Delisle and Mark Frye) will deliver this training under supervision of Ronnie Newman (RN). After the initial 4 day training, participants will be asked to practice SKY daily for 20-25 minutes in addition to attending the weekly follow up sessions.
2972227|NCT02749227|Experimental|Pasireotide LAR Therapy|Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed.
2972228|NCT02749214||Parkinson's Disease (PD)|Participant's with Parkinson's Disease will provide peripheral blood and breath samples. Participants will also be asked to complete a neurologic exam and questionnaires.
2972229|NCT02749214||Healthy Control|Age and gender-matched healthy controls will provide peripheral blood and breath samples. Participants will also be asked to complete a neurologic exam and questionnaires.
2972230|NCT02749201|Experimental|Analysis|Light Intensity and gastric wall thickness analysis
2972231|NCT02749188|Other|bladder stimulation|Bladder stimulation as a noninvasive technique of urine collection. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes.
2972232|NCT02749175|Experimental|Cricoid force sensor monitor system|Nurse applied cricoid pressure with a sensor guided by monitoring Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons.
2972233|NCT02749175|Sham Comparator|Sham cricoid force sensor monitor system|Nurse applied pressure on a sham sensor with no monitor input. Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons
2972234|NCT02749175|No Intervention|Current standard|Nurse applied cricoid force according to memory. Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons
2972235|NCT02749162|Placebo Comparator|Group A|After the spinal anesthesia regressed, the investigators performed a single shot femoral block with ropivacaine 0,5% 200 mg + lidocaine 1% 200 mg. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
2972236|NCT02749162|Active Comparator|Group B|After the spinal anesthesia regressed, the investigators performed a single shot femural block with ropivacaine 0,5% 200 mg + lidocaine 1% 200 mg and 4 mg dexamethasone phosphate. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
2972237|NCT02749162|Active Comparator|Group C|After the spinal anesthesia regressed, the investigators performed a single shot femural block with ropivacaine 0,5% 200 mg+ lidocaine 1% 200 mg and 8 mg dexamethasone phosphate.After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
2972238|NCT02749149||Cardiac Surgery|Patients undergoing cardiac surgery: coronary artery bypass graft (CABG); valve replacement/repair; or transcatheter aortic valve implantation (TAVI) surgery
2972239|NCT02749136|Experimental|Perioperative chemotherapy|"Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles~Postoperative gemcitabine, every 4 weeks, 3-6 cycles"
2972240|NCT02749123|Active Comparator|Lidocaine5% v Lidocaine3.6%,Menthol1.25%|Daily patch Q12 followed by Q12 of no patch
2972241|NCT02749123|Placebo Comparator|Lidocaine 3.6%, menthol 1.25% v placebo|Daily patch Q12 followed by Q12 of no patch
2972242|NCT02749110|Experimental|Self-sampling for HPV test|Invitation to participate to the screening process by means of the usual care (pap-test) or the provision of a vaginal self-sampling brush (Evalyn Brush°). Self-collected samples are mailed to a central lab for HPV testing.
2972243|NCT02749110|No Intervention|Usual care (Pap test)|Intervention: invitation to participate to the screening process by means of the usual care (pap-test).
2972244|NCT02749097|Experimental|Cohort 1|Single oral dose of 10 mg SHR0534 or matching placebo
2972245|NCT02749097|Experimental|Cohort 2|Single oral dose of 25 mg SHR0534 or matching placebo
2972246|NCT02749097|Experimental|Cohort 3|Single oral dose of 50 mg SHR0534 or matching placebo
2972247|NCT02749097|Experimental|Cohort 4|Single oral dose of 100 mg SHR0534 or matching placebo
2972248|NCT02749097|Experimental|Cohort 5|Single oral dose of 200 mg SHR0534 or matching placebo
2972249|NCT02749084|Experimental|T reg DLI|"This is a INTERVENTIONAL TRANSPLANTATION STUDY WITHOUT DRUGS.~The INTERVENTION is represented by the INFUSION of DONOR T REGULATORY CELL-ENRICHED LYMPHOCYTES to PATIENTS suffering from REFRACTORY CHRONIC GVHD after ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.~The study is single center single arm open label and includes a DOSE ESCALATION phase followed by an EXTENDED PHASE with the MAXIMUM TOLERATED DOSE (MTD).~During the dose escalation phase each patient will receive three doses of purified donor T reg cells each administered intravenously 1 month apart. Dose levels of purified Tregs will be 5x10e5/kg, 1x10e6/kg and 2x10e6/kg, resulting in three doses of 1.7x10e5/kg, 3.3x10e5/kg and 6.6x10e5/kg, respectively.~In the dose escalation study at least 9 patients will be required depending on the occurrence of adverse events during the study).~Patients in the MTD study should be about 10, according to Fleming."
2972250|NCT02749071|Sham Comparator|Control Group|This group will undergo laparoscopic implantation surgery. The device will not be activated: Sham EndoStim stimulation for first six months of study. It will be activated at the Month 6 visit and provide lower esophageal stimulation from Month 6 thru end of study.
2972308|NCT02748772|Active Comparator|Two Anti-angiogenesis Drugs（Endostar and Thalidomide）|Two Anti-angiogenesis Drugs（Endostar and Thalidomide） Combined With Chemotherapy for the patients of Advanced Colorectal Cancer
2972251|NCT02749071|Experimental|Treatment Group|The group will undergo laparoscopic implantation surgery. The device will be activated two weeks post-implantation and the subject will receive EndoStim stimulation for first six months of study and continue with EndoStim stimulation from Month 6 thru end of study.
2972252|NCT02749058|Other|Capsulectomy|Procedure: Capsulectomy in Direct Anterior Total Hip Arthroplasty
2972253|NCT02749058|Other|Capsulotomy|Procedure: Capsulotomy in Direct Anterior Total Hip Arthroplasty
2972254|NCT02749045|Other|Image acquisition arm|Subjects who have undergone a clinically indicated fractional flow reserve measurement in the cardiac catheterization laboratory will receive standard dose Tc-99m sestamibi and undergo resting SPECT image acquisition within three hours from end of cardiac catheterization procedure.
2972255|NCT02749032|Active Comparator|Vildagliptin - stratum diet/exercise|"Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.~Mixed meal test were performed in the morning after an overnight fast."
2972256|NCT02749032|Active Comparator|Vildagliptin - stratum metformin|"Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.~Mixed meal test were performed in the morning after an overnight fast."
2972257|NCT02749032|Active Comparator|Sitagliptin - stratum diet/exercise|"The dosage of sitagliptin depended on the stratum defined by the background diabetes medication. In patients treated with diet and exercise (no other glucose-.lowering medication), sitagliptin was given as one 100 mg in the morning (15 minutes prior to breakfast or the test meal, on the last day of the treatment period), and a corresponding placebo tablet was administered in the evening (no temporal relation to dinner required).~Mixed meal test were performed in the morning after an overnight fast."
2972258|NCT02749032|Active Comparator|Sitagliptin - stratum metformin|"In patients treated with metformin, sitagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening.~Mixed meal test were performed in the morning after an overnight fast."
2972259|NCT02749032|Placebo Comparator|Placebo - stratum diet/exercise|"Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).~Mixed meal test were performed in the morning after an overnight fast."
2972260|NCT02749032|Placebo Comparator|Placebo - stratum metformin|"Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).~Mixed meal test were performed in the morning after an overnight fast."
2972261|NCT02749019|Experimental|68Ga-NOTA-BBN-RGD PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-BBN-RGD in one dose intravenously and underwent PET/CT scan 15-30 min later.
2972262|NCT02749006|Active Comparator|Active iTBS rTMS|The active arm involves magnetic stimulation of the brain to the left dorsolateral prefrontal cortex (DLPFC) daily for four weeks. The active arm will be receiving intermittent Theta-Burst (iTBS) repetitive Transcranial Magnetic Stimulation (rTMS) to deliver magnetic pulses.
2972263|NCT02749006|Sham Comparator|Sham rTMS|sham rTMS treatment involves scalp stimulation with no magnetic pulse daily for four weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
2972264|NCT02748993|Experimental|PAC-14028 Cream 0.1%|PAC-14028 Cream 0.1%, Twice daily for 4 weeks
2972265|NCT02748993|Experimental|PAC-14028 Cream 0.3%|PAC-14028 Cream 0.3%, Twice daily for 4 weeks
2972266|NCT02748993|Experimental|PAC-14028 Cream 1.0%|PAC-14028 Cream 1.0%, Twice daily for 4 weeks
2972267|NCT02748993|Placebo Comparator|PAC-14028 Cream Vehicle|PAC-14028 Cream Vehicle, twice daily for 4 weeks
2972268|NCT02748980||Non- obstructive coronary artery disease, non- diabetic|Clinical evidences such as Holter, Treadmill exercise test and cardiac ECT support myocardial ischemia. CAG showed 20%-70% arterial stenosis. Patients are diagnosed without diabetes.
2972269|NCT02748980||Non- obstructive coronary artery disease, diabetic|Clinical evidences such as Holter, Treadmill exercise test and cardiac ECT support myocardial ischemia. CAG showed 20%-70% arterial stenosis. Patients are diagnosed with type 2 diabetes.
2972270|NCT02748967|Experimental|Group 1|Participants with age (greater than or equal to [>=] 20 to less than [<] 50 years) will receive single dose of 0.5 milliliter (mL) of ExPEC4V (4:4:4:4) or placebo on Day 1.
2972271|NCT02748967|Experimental|Group 2|Participants with age >= 20 to < 50 will receive single dose of 0.5 mL of ExPEC4V (8:8:8:8) or placebo on Day 1.
2972272|NCT02748967|Experimental|Group 3|Participants with age >= 20 to < 50 will receive single dose of 0.5 mL of ExPEC4V (16:16:16:16) or placebo on Day 1.
2972273|NCT02748967|Experimental|Group 4|Participants with age greater than or equal to [>=] 50 will receive single dose of 0.5 mL of ExPEC4V (4:4:4:4) or placebo on Day 1.
2972274|NCT02748967|Experimental|Group 5|Participants with age >= 50 will receive single dose of 0.5 mL of ExPEC4V (8:8:8:8) or placebo on Day 1.
2972275|NCT02748967|Experimental|Group 6|Participants with age >= 50 will receive single dose of 0.5 mL of ExPEC4V (16:16:16:16) or placebo on Day 1.
2972276|NCT02748954|Experimental|Thoughts.|"Increasing helpful thoughts consisted of two psychoeducational segments (i.e., thoughts affect emotions, and how to manage harmful thoughts), and a list of helpful thoughts that participants could choose to use to increase their mood for the next week"
2972277|NCT02748954|Experimental|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated."
2972278|NCT02748954|Experimental|Assertiveness|Increasing assertiveness, consisting of tips for communicating assertively, and an example of an assertive statement. Participants were asked to describe a recent conflict and apply the intervention's assertiveness techniques to address the conflict
2972309|NCT02748772|Placebo Comparator|Pure chemotherapy（Xelox）|chemotherapy alone for the patients of Advanced Colorectal Cancer
2972279|NCT02748954|Experimental|Sleep hygiene|"Increasing sleep hygiene included a description on how sleep can affect mood. Participants were also asked to select from a list of helpful sleep hygiene suggestions to be practiced within the next week such as, Don't take naps during the day and Use the bed/bedroom for sleep or sex only."
2972280|NCT02748954|Active Comparator|Own Methods|wherein participants were asked to identify four of their own personal strategies that have helped them improve their mood in the past.
2972281|NCT02748941|Experimental|symptomatic and asymptomatic patients|
2972282|NCT02748928|Experimental|UltraShape Power treatment to abdomen|"Eligible subjects will receive 3 treatments, 2 weeks interval, with the UltraShape Power device according to the study protocol and user manual.~The subject will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment, for total expected study duration of 16 weeks"
2972283|NCT02748915|Experimental|Patients using cochlear implants|All patients using cochlear implants included in the study will take electrophysiological and psychoacoustic tests to measure auditive parameters regarding the study objectives : ECAP, EABR, speech recognition and MCL.
2972284|NCT02748915|Experimental|Patients using EAS device|Patients using EAS device for more than 11 months will take electrophysiological and psychoacoustic tests with the implant functioning only with electrical pulses or in bimodal mode to measure ECAP, EABR, speech recognition and MCL ; this will allow to perform bimodal comparison.
2972285|NCT02748915|Experimental|Patients with bilateral cochlear implant|Patients with bilateral cochlear implant for more than 11 months will take electrophysiological and psychoacoustic tests to measure ECAP, EABR, speech recognition, and MCL. The binaural interaction component will also be measured ; this will allow to perform binaural comparison.
2972286|NCT02748902|Experimental|ingenol mebutate 0.05% gel|Single group, open label. All subjects will receive active product.
2972287|NCT02748889|Active Comparator|Carboplatin plus etoposide|Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles
2972288|NCT02748889|Experimental|Carboplatin, etoposide and MPDL3280A|Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles MPDL3280A (Atezolizumab) 1200mg iv on day 1 every 21 days until progression
2972289|NCT02748876|Experimental|His-Ventricular (HV)-optimised|His-Ventricular (HV) optimised atrioventricular delay
2972290|NCT02748876|No Intervention|Non-optimised|Standard atrioventricular delay
2972291|NCT02748863|Placebo Comparator|Placebo|Placebo, provided in a 2 mL pre-filled syringe Placebo, provided in a 1 mL pre-filled syringe
2972292|NCT02748863|Experimental|Secukinumab 2 mL form|Secukinumab 300 mg, provided in a 2 mL pre-filled syringe
2972293|NCT02748863|Active Comparator|Secukinumab 1 mL form|Secukinumab 300 mg provided in 2 pre-filled syringes of 1 mL/150 mg (current approved form)
2972294|NCT02748850|Active Comparator|leukemia patients|Patients with acute leukemia and / or refractory anemia with excess blasts and comprising a number of blasts in the blood greater than 5% device.
2972295|NCT02748850|Placebo Comparator|apheresis patients|patients with non-myeloid hematological malignancy
2972296|NCT02748837|Experimental|Dose escalation cohort of ERY974|Dose escalation (DE) will proceed with the dose level increment and the dose cohort size being guided by a safety evaluations during and at the end of each cohort. DE initially utilizes an accelerated titration design (ATD) and once the first dose limiting toxicity (DLT) is observed, DE will continue using a modified continual reassessment method (mCRM) until MTD.
2972297|NCT02748837|Experimental|Cohort expansion in gastric cancer|Patients with GPC3 positive advanced gastric cancer or gastroesophageal junction cancer will receive ERY974 at recommended dose until disease progression.
2972298|NCT02748837|Experimental|Cohort expansion in esophageal carcinoma|Patients with GPC3 positive advanced squamous cell esophageal carcinoma will receive ERY974 at recommended dose until disease progression.
2972299|NCT02748837|Experimental|Cohort expansion in other solid tumors|Patients with other GPC3 positive advanced solid tumors will receive ERY974 at recommended dose until disease progression
2972300|NCT02748811|No Intervention|Control group|The control group receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change in treatment or progression. If the patient has other health problems, those issues will be assessed either by the oncologist or by the general practitioner. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
2972301|NCT02748811|Active Comparator|Intervention group|The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. They will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
2972302|NCT02748798|Experimental|Healthy Participants|Participants will inhale investigational gases (HP 3He, HP 129Xe, PFP and SF6) according to the procedure for that intervention. All participants can potentially inhale all the gases. Magnetic resonance imaging will be performed during breath-holds or continuous breathing (gas-dependent) with the appropriate investigational human lung coil (3He Human Lung Coil, 129Xe Small and Large Human Lung Coil, or PFP and SF6 Human Lung Coil), using the 3T Research MRI at the Thunder Bay Regional Health Sciences Centre.
2972303|NCT02748798|Experimental|Lung Disorder Participants|Participants will inhale investigational gases (HP 3He, HP 129Xe, PFP and SF6) according to the procedure for that intervention. All participants can potentially inhale all the gases. Magnetic resonance imaging will be performed during breath-holds or continuous breathing (gas-dependent) with the appropriate investigational human lung coil (3He Human Lung Coil, 129Xe Small and Large Human Lung Coil, or PFP and SF6 Human Lung Coil), using the 3T Research MRI at the Thunder Bay Regional Health Sciences Centre.
2972304|NCT02748785|Experimental|Group 1|Group 1 will continue MTX
2972305|NCT02748785|Experimental|Group 2|Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
2972306|NCT02748785|Experimental|Group 3|Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
2972307|NCT02748785|Experimental|Group 4|Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
2972310|NCT02748759|Active Comparator|EXP 1: Manual mobilization / CPM|Patients were subjected to a manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist. After a pause of 5 minutes, the patient was collocated in a commercially available CPM device (Kinetec Advanced Prima) and received 15 repetitions of flexo-extension.
2972311|NCT02748759|Active Comparator|EXP 2: CPM / Manual mobilization|Patients were collocated in a commercially available CPM device (Kinetec Advanced Prima) and received 15 repetitions of flexo-extension. After a pause of 5 minutes, patients were subjected to a manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist.
2972312|NCT02748746|Experimental|Surgery no Lymphedema|The inclusion criteria for involving the first group is surgery time. No one will be involved into the first group if surgery was applied 18 months ago before enrollment to this study. Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum. Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
2972313|NCT02748746|Experimental|Surgery having Lymphedema|The second group will contain patients who had breast cancer surgery and having upper extremity lymphedema.Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio Impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum.Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
2972314|NCT02748746|Active Comparator|Healthy Women|The third group will contain healthy women. Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio Impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum.Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
2972315|NCT02748733|Active Comparator|Adapted double mini PET|"PET = Peritoneal Equilibration Test, a test routinely performed to measure peritoneal transport rates of solutes and water in peritoneal dialysis patients. To this end the routinely administered dialysis fluid is infused into the peritoneal cavity. The test will be modified (adapted):~A short, small cycle (0.6 mL/m² BSA, 30 min) followed by a long, large cycle (1.4 mL/m², 120 min) will be performed in each patient and compared to a standard double mini PET."
2972316|NCT02748733|Placebo Comparator|Standard double mini PET|The Standard double mini PET consists of two identical cycles (fill volume 1 L/m², 75 min of dwell time)
2972317|NCT02748720|Experimental|RFM Visible|Patients will be randomize in other Group 1, where these parameters (from the device Respiratory Function Monitor) of lung mechanics would be visible by the rescuer (the usual parameters of PIP and PEEP will be visible). We adapt or change PIP using visible TVe.
2972318|NCT02748720|No Intervention|RFM No Visible|Patients will be randomize in a Group 2, where the parameters of TVe and respiratory flow would not be visible by the rescuer (the usual parameters of PIP and PEEP will be visible). Always, in both groups, current recommendations ventilation measures included in cardiopulmonary resuscitation of newborns of the Spanish Society of Neonatology, based on international recommendations (1-3.5) apply. In turn, the results analyzed in two subgroups between 24 and 27 + 6 weeks gestational age and 28 to 32 + 6 weeks
2972319|NCT02748707|Experimental|Arm 1|Celecoxib 200mg twice daily for 21 days
2972320|NCT02748707|Experimental|Arm 2|Erlotinib 150 mg once daily for 21 days
2972321|NCT02748707|Experimental|Arm 3|Celecoxib 200 mg twice daily for 21 days and Erlotinib 150 mg once daily for 21 days
2972322|NCT02748707|Sham Comparator|Arm 4|Control group with no drug
2972323|NCT02748694|Experimental|Part 1: Cohort 1: TAK-041 5-20 mg|TAK-041 5 milligram (mg) and 20 mg suspension or matching placebo, orally, once on Day 1 of treatment periods 1 and 2, respectively. Each treatment period will be separated by a washout period of at least 7 days.
2972324|NCT02748694|Experimental|Part 1: Cohort 2: TAK-041 10-40 mg|TAK-041 10 mg and 40 mg suspension or matching placebo, orally, once on Day 1 of treatment periods 1 and 2 respectively. Each treatment period will be separated by a washout period of at least 7 days.
2972325|NCT02748694|Experimental|Part 1: Cohort 3: TAK-041 80 mg|TAK-041 80 mg, suspension or matching placebo, orally, once on Day 1. Although planned, all subsequent doses after the dose of 80 mg for Cohort 3 will be determined based on the emerging safety, tolerability, and PK data from the preceding cohorts.
2972326|NCT02748694|Experimental|Part 1: Cohort 4: TAK-041 TBD|Cohort 4 will participate in a sequential-panel, double-blind study design to evaluate single-rising doses of TAK-041 or matched placebo. The planned dose levels of TAK-041 to be evaluated in Cohorts 4 is 120 mg. Although planned, all subsequent doses after the dose of 80 mg for Cohort 3 will be determined based on the emerging safety, tolerability, and PK data from the preceding cohorts.
2972327|NCT02748694|Experimental|Part 1: Cohort 5: TAK-041 TBD|Cohort 5 will participate in a sequential-panel, double-blind study design to evaluate single-rising doses of TAK-041 or matched placebo. The planned dose levels of TAK-041 to be evaluated in Cohorts 5 is 160 mg. Although planned, all subsequent doses after the dose of 80 mg for Cohort 3 will be determined based on the emerging safety, tolerability, and PK data from the preceding cohorts.
2972328|NCT02748694|Experimental|Part 2: Cohort 1: TAK-041 20mg|TAK-041 20 mg, suspension or matching placebo, orally, initial loading dose on Day 1 followed by a maintenance dose that is half the initial dose on Days 8, 15, and 22. The dose levels for Part 2 Cohort 1 will be based on emerging safety/tolerability and PK data from Part 1.
2972329|NCT02748694|Experimental|Part 2: Cohort 2: TAK-041 TBD|TAK-041, suspension or matching placebo, initial loading dose on Day 1 followed by a maintenance dose that is half the initial dose on Days 8, 15, and 22. The dose levels for Part 2 Cohort 2 onwards will be based on emerging safety/tolerability and available PK data from Part 1 and from preceding cohorts in Part 2.
2972330|NCT02748694|Experimental|Part 2: Cohort 3: TAK-041 TBD|TAK-041, suspension or matching placebo, initial loading dose of on Day 1 followed by a maintenance dose that is half the initial dose on Days 8, 15, and 22. The dose levels for Part 2 Cohort 2 onwards will be based on emerging safety/tolerability and available PK data from Part 1 and from preceding cohorts in Part 2.
2972331|NCT02748694|Experimental|Part 2: Cohort 4: TAK-041 TBD|TAK-041, suspension or matching placebo, initial loading dose of on Day 1 followed by a maintenance dose that is half the initial dose on Days 8, 15, and 22. The dose levels for Part 2 Cohort 2 onwards will be based on emerging safety/tolerability and available PK data from Part 1 and from preceding cohorts in Part 2.
2972332|NCT02748694|Experimental|Part 3: TAK-041 40 mg Tablet Fasted State|TAK-041 40 mg, tablet, orally, once on Day 1 under fasted state.
2972333|NCT02748694|Experimental|Part 3: TAK-041 40 mg Tablet Fed State|TAK-041 40 mg, tablet, orally, once on Day 1 under fed state.
2972334|NCT02748694|Experimental|Experimental: Part 4: TAK-041 TBD|TAK-041 TBD, suspension or TAK-041 placebo-matching suspension administered as an initial loading dose on Day 1 followed by a maintenance dose on Days 8, 15, and 22. The dose levels for Part 4 will be based upon the emerging safety/tolerability and PK data of same dose in healthy participants from Part 2.
2972335|NCT02748681|Active Comparator|Telemedicine Group|Patient group with a telemedicine monitoring system
2972336|NCT02748681|Active Comparator|Standard Group|Patient Group without a telemedicine monitoring
2972337|NCT02748668||ECMO|No intervention. Blood specimen collection.
2972338|NCT02748668||Control|No intervention. Blood specimen collection.
2972339|NCT02748655|Placebo Comparator|Tap water|Oral consumption of tap water
2972340|NCT02748655|Active Comparator|Alkaline ionized water|Oral consumption of alkaline ionized water
2972341|NCT02748642|Experimental|Part A Cohort A: BITS7201A Dose Level 1 Subcutaneous (SC)|Healthy participants will receive a single SC dose of BITS7201A dose Level 1 on Day 1.
2972342|NCT02748642|Experimental|Part A Cohort B: BITS7201A Dose Level 2 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 2 on Day 1.
2972343|NCT02748642|Experimental|Part A Cohort C: BITS7201A Dose Level 4 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 4 on Day 1.
2972344|NCT02748642|Experimental|Part A Cohort D: BITS7201A Dose Level 4 Intravenous (IV)|Healthy participants will receive a single IV dose of BITS7201A dose Level 4 on Day 1.
2972345|NCT02748642|Experimental|Part A Cohort E: BITS7201A Dose Level 6 IV|Healthy participants will receive a single IV dose of BITS7201A dose Level 6 on Day 1.
2972346|NCT02748642|Placebo Comparator|Part A: Placebo|Healthy participants will receive a single SC or IV dose of placebo matched to BITS7201A on Day 1.
2972347|NCT02748642|Experimental|Part B Cohort F: BITS7201A Dose Level 3 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 3 every 4 weeks (Q4W) on Days 1, 29, and 57.
2972348|NCT02748642|Experimental|Part B Cohort G: BITS7201A Dose Level 4 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 4 Q4W on Days 1, 29, and 57.
2972349|NCT02748642|Experimental|Part B Cohort H: BITS7201A Dose Level 5 SC|Healthy participants will receive SC dose of BITS7201A dose Level 5 Q4W on Days 1, 29, and 57.
2972350|NCT02748642|Experimental|Part B Cohort I:BITS7201A Dose Level 5 SC (Mild Atopic Asthma)|Mild atopic asthma participants will receive SC dose of BITS7201 dose Level 5 Q4W on Days 1, 29, and 57.
2972351|NCT02748642|Placebo Comparator|Part B: Placebo|Healthy participants or mild atopic asthma participants will receive SC doses of placebo matched to BITS7201A Q4W on Days 1, 29, and 57.
2972352|NCT02748629|Active Comparator|ProGrip Mesh Repair|80 patients are randomized to inguinal hernia repair using selfgripping ProGrip Mesh (Covidien Parietex ProGrip Self-Fixating Mesh) - sutureless fixation.
2972353|NCT02748629|Active Comparator|Lichtenstein Operation|80 patients are randomized to inguinal hernia repair using lightweight polypropylene mesh (<40 g/m2) with standard Lichtenstein technique.
2972354|NCT02748616|Experimental|Ursodiol|Subjects will begin to take 300 mg Ursodiol following Visit #1 and continue for a total of 8 (eight) weeks.
2972355|NCT02748603||Patient with non ST Elevation - Acute Coronary Syndrome|
2972356|NCT02748603||Patient with stable Coronary Artery Disease (CAD)|
2972357|NCT02748590|Experimental|Neuromodulation|
2972358|NCT02748577|Experimental|Migraine|Participants with migraines will complete one study visit where they will complete several questionnaires and will also complete Quantitative Sensory Testing (QST) Pain Measurements. They must be migraine-free during the visit and no migraine within 48 hrs of study visit
2972359|NCT02748577|Active Comparator|Healthy Controls|Healthy Controls will complete one study visit where they will complete several questionnaires and will complete Quantitative Sensory Testing (QST) Pain Measurements.
2972360|NCT02748564|Experimental|Treatment (pembrolizumab, aldesleukin)|Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks and aldesleukin IV every 8 hours for up to 14 doses at weeks 4, 7, 16, 19, 28, and 31 in the absence of disease progression or unacceptable toxicity.
2972361|NCT02748551|Experimental|Laparoscopic surgery|Traditional open procedure for patient with locally advanced gastric cancer
2972362|NCT02748551|Active Comparator|Open surgery|Minimum invasive procedure (laparoscopic) for patient with locally advanced gastric cancer
2972363|NCT02748538||Face Down|To posture in the face down position for the first 24 hours following surgery.
2972364|NCT02748538||Position to Support the Break|The head is positioned so that the retinal breaks (which caused the retinal detachment) are positioned at the highest point of the eye and well supported by the intra-ocular gas bubble left within the eye at the completion of surgery.
2972365|NCT02748525|Experimental|CCK then Milk|CCK administered and HIDA scan performed. Results analyzed, if ejection fraction is low, patient is given milk to drink, and HIDA scan performed again. Results are analyzed to determine if ejection fraction is still low.
2972366|NCT02748512|Experimental|FAI insert|FAI insert (0.18 mg fluocinolone acetonide)
2972367|NCT02748499|Experimental|Healthy Beat Accupunch|The HBA exercise program includes: 1) warm-up: 5 slow and gentle exercises to regulate qi, loosen up the body, and elevate the energy for a safe transition to the next phase, 2) accupunch: 14 low-to-medium speed exercises to punch the 14 meridians to enhance the cardiovascular-respiratory workout, and 3) relaxation: 5 low-speed, muscle relaxing exercises with deep breaths to sooth the body and mind. It is conducted 3 times per week and 40 minutes per practice.
2972370|NCT02748486|Experimental|Theory of Mind|Metacognitive Training To empathize... module
2972371|NCT02748486|Sham Comparator|Control|group discussion of current events
2972372|NCT02748473|Other|pelvic floor muscle strength|evaluated pelvic floor muscle strength before and after Pilates exercises program on sedentary nulliparous women
2972373|NCT02748473|Other|Device: 3D perineal ultrasound|evaluated the pubovisceral muscle thickness and the levator hiatus area before and after Pilates exercises program on sedentary nulliparous women
2972374|NCT02748460||Patients treated with Esmya|
2972375|NCT02748447|Experimental|A-FiO2|24 hours in automated FiO2 adjustment to maintain SpO2 within a target range
2972376|NCT02748447|No Intervention|M-FiO2|24 hours in manual adjustment of FiO2 to maintain SpO2 within a target range
2972377|NCT02748434|Other|Lipohypertrophy|Participants inject their insulin into the abdomen into areas of lipohypertrophy that were identified by ultrasound in Phase 1 of the study.
2972378|NCT02748434|Other|Normal Subcutaneous Tissue|Participants inject their insulin into the abdomen into areas with normal subcutaneous tissue.
2972379|NCT02748421|Other|Lumera Microscope with OCT RESCAN|in the group microscope coupled to OCT, patients will undergo retinal surgery using the Lumera microscope with Rescan OCT Zeiss
2972380|NCT02748421|Other|Conventional Microscope|control group without OCT RESCAN
2972381|NCT02748395|Placebo Comparator|Placebo|Injection of 3.5mL of normal saline into the point of maximal tenderness in the abdomen
2972382|NCT02748395|Experimental|Treatment|Injection of 20mg triamcinolone and 1% lidocaine into the point of maximal tenderness in the abdomen
2972383|NCT02748382|Active Comparator|higher chloride solutions|higher chloride crystalloid (Normal saline) higher chloride albumin (5% Octalbin)
2972384|NCT02748382|Active Comparator|lower chloride solutions|lower chloride crystalloid (Ringer's lactate) lower chloride albumin (5% Plasbumin)
2972385|NCT02748369|No Intervention|Control Group|No somatostatin and glucagon infusions
2972386|NCT02748369|Active Comparator|Intervention Group|Somatostatin and glucagon infusions
2972387|NCT02748356|Experimental|Individuals with Spina Bifida|Lactobacillus rhamnosus GG
2972388|NCT02748343|Active Comparator|allograft bone|traditional allograft bone
2972389|NCT02748343|Experimental|tissue-engineered bone|tissue-engineered bone
2972390|NCT02748330|Experimental|Ticagrelor|Oral ticagrelor 90 mg tablet, twice daily for 15±2 days. Oral aspirin 100 mg tablet, once daily for 15±2 days
2972391|NCT02748330|Active Comparator|Clopidogrel|Oral clopidogrel 75 mg tablet, once daily for 15±2 days. Oral aspirin 100 mg tablet, once daily for 15±2 days
2972392|NCT02748317|Experimental|Adults with Spinal Cord Injury|Lactobacillus rhamnosus GG
2972393|NCT02748304|Placebo Comparator|control|just follow up after liver resection in HCC patients
2972394|NCT02748304|Active Comparator|sorafenib|use sorafenib after liver resection in HCC patients
2972395|NCT02748304|Active Comparator|sorafenib and aspirin|use sorafenib and aspirin after liver resection in HCC patients
2972396|NCT02748291|Experimental|Walking|Randomised participants will be instructed to walk 6,000 steps per day and throughout the day for 12 weeks. Step counts will be monitored by an issued pedometer. A 12 week paper diary will be provided for daily recording of step counts.
2972397|NCT02748291|Active Comparator|Control|Department of Health (United Kingdom) Physical Activity Guidelines flyer (current standard of care).
2972398|NCT02748265|Other|Inhaled Epoprostenol, phenylephrine, sevoflurane|Inhaled Epoprostenol (Flolan), phenylephrine, volatile anesthesia maintenance (Sevoflurane)
2972399|NCT02748265|Other|Inhaled Epoprostenol phenylephrine & Propofol|Inhaled Epoprostenol (Flolan), phenylephrine and intravenous anesthesia maintenance (Propofol)
2972400|NCT02748252||HIV patients|HIV patients admitted in Stroke units for the first occurence of acute stroke
2972401|NCT02748252||non HIV patients|non HIV patients admitted in Stroke units for the first occurence of acute stroke
2972402|NCT02748239|Active Comparator|MEDIAS 2 CT|The MEDIAS CT is a newly developed education program for the initiation of a conventional insulin therapy in type 2 diabetic patients.
2972403|NCT02748239|Placebo Comparator|Current CT program|This program is currently used for the initiation of conventional insulin therapy in type 2 diabetic patients.
2972404|NCT02748226||Retrospective cohort|This cohort retrospectively enrolls patients with lower extremity artery disease who underwent endovascular treatment from January 2006 to the date of approval by IRB in the participating hospitals.
2972405|NCT02748226||Prospective cohort|This cohort prospectively enrolls patients with lower extremity artery disease who undergo endovascular treatment from the date of approval by IRB to July, 2018 in the participating hospitals.
2972406|NCT02748213|Experimental|Herceptin + Taxotere|Participants will receive dual therapy with Herceptin and Taxotere until disease progression, unmanageable toxicity, or withdrawal.
2972407|NCT02748213|Experimental|Herceptin + Taxotere + Xeloda|Participants will receive triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal.
2972408|NCT02748200|Experimental|external beam radiotherapy: Dose level 1|57.6 Gray (Gy) (20 x 2.88 Gy, 5 fractions/week, 4 weeks)
2972409|NCT02748200|Experimental|external beam radiotherapy: dose level 2|60 Gy (20 x 3.00 Gy, 5 fractions/week, 4 weeks)
2972410|NCT02748200|Experimental|external beam radiotherapy: dose level 3|62.4 Gy (20 x 3.12Gy, 5 fractions/week, 4 weeks)
2972411|NCT02748187|Experimental|Intervention|Cognitive Behavioural Analysis System of Psychotherapy
2972412|NCT02748174|Experimental|Episodic Migraine group|100 patients with chronic or episodic migraine
2972413|NCT02748174|Experimental|Chronic Migraine Group|100 patients with chronic or episodic migraine
2972414|NCT02748174|Experimental|Post concussive Headache Group|75 patients
2972415|NCT02748161|Active Comparator|DEB-TACE: Standard Endhole Catheter|Subjects will undergo DEB-TACE using a standard endhole catheter.
2972416|NCT02748161|Active Comparator|DEB-TACE: Surefire Infusion System|Subjects will undergo DEB-TACE using the Surefire Infusion System.
2972417|NCT02748148|Experimental|Medication therapy management|Medication therapy management service that is enhanced by the incorporation of pharmacogenomics and medication risk mitigation factor technology
2972418|NCT02748135|Experimental|TB-403 20mg/kg|
2972419|NCT02748135|Experimental|TB-403 50mg/kg|
2972422|NCT02748135|Experimental|TB-403 x mg/kg|In part B of the study, subjects will receive the maximum tolerated dose as determined in part A.
2972423|NCT02748122|Experimental|Adolescents with T2DM|
2972424|NCT02748109|Experimental|Vestibular Rehabilitation + audio biofeedback|"Vestibular rehabilitation paired with audio biofeedback~This arm will receive individual rehabilitation with a PT 2 times per week for 6 weeks and will receive vestibular rehabilitation paired with the use of a novel audio biofeedback device for training balance."
2972425|NCT02748109|Active Comparator|Vestibular Rehabilitation|"Vestibular rehabilitation~This arm will receive individual rehabilitation with a PT 2 times per week for 6 weeks and will receive standard vestibular rehabilitation."
2972426|NCT02748096|Experimental|Patient Specific Instrumentation|Patients undergoing unicompartmental knee replacement with the additional aid of patient specific instrumentation.
2972427|NCT02748096|Active Comparator|Conventional Instrumentation|Patients undergoing unicompartmental knee replacement using standard instrumentation.
2972428|NCT02748083|Active Comparator|tDCS group|The active tDCS group will be stimulated with transcranial Direct Current Stimulation (tDCS).
2972429|NCT02748083|Sham Comparator|Sham tDCS group|The sham tDCS group will have stimulation with sham transcranial Direct Current Stimulation (tDCS).
2972430|NCT02748070|Experimental|Prednisone|Provided oral steroid and topical steroid
2972431|NCT02748070|Placebo Comparator|Placebo|Provided oral placebo and topical steroid
2972432|NCT02748057|Experimental|Ezetimibe 10 mg + Rosuvastatin 2.5 mg|1 Ezetimibe 10 mg tablet and 1 Rosuvastatin 2.5 mg capsule/tablet orally, once daily for 52 weeks. If participant does not achieve LDL-C goal after Week 12, dosage of Rosuvastatin may be increased to 5.0 mg
2972433|NCT02748057|Experimental|Ezetimibe 10 mg + Rosuvastatin 5.0 mg|1 Ezetimibe 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules/tablets orally, once daily for 52 weeks.
2972434|NCT02748044|Experimental|Eligible patients for CC-Cruiser test|
2972435|NCT02748031|Experimental|eligible patients group|
2972436|NCT02748018|Experimental|Hybrid Closed Loop Arm|The HCL Arm will use the 670G insulin pump and the fourth generation glucose sensor (i.e. using the Auto Mode feature) for 6 months during the study period.
2972437|NCT02748018|Active Comparator|Control Arm|The Control Arm will use individual subject's current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump). Each cohort (CSII, MDI, or SAP) will be used as the control arm to be compared to the experimental arm (HCL).
2972438|NCT02748005|Experimental|Fenugreek seeds extract 500 mg|Fenugreek seeds extract(Furosap) 500 mg
2972439|NCT02747992||PECS 0|receiving paravertebral block
2972440|NCT02747992||PECS 1|receiving paravertebral block and blocks targeting pectoral musculature
2972441|NCT02747979|Experimental|hemodialysis+hemoperfusion (HA330)|Combination of hemodialysis and hemoperfusion (HA330) therapy All subjects in the study phase will receive hemodialysis plus hemoperfusion(HA330) treatment once per week, and regular hemodialysis treatment in the remaining two sessions.
2972442|NCT02747979|Experimental|hemodialysis+hemoperfusion (HA130)|Combination of hemodialysis and hemoperfusion (HA130) treatment All subjects in the study phase will receive hemodialysis and hemoperfusion(HA130) treatment once per week, and regular hemodialysis treatment in the remaining two sessions.
2972443|NCT02747979|Active Comparator|hemodialysis only|hemodialysis only All subjects in the study phase will receive regular hemodialysis treatment three times per week.
2972444|NCT02747953|Experimental|afatinib|
2972445|NCT02747940|Experimental|patients with chronic migraine|flunarizine for patients with chronic migraine
2972446|NCT02747940|Experimental|patients with fibromyalgia|pregabalin for patients with fibromyalgia
2972447|NCT02747940|Experimental|patients with chronic migraine and fibromyalgia|flunarizine and pregabalin for patients with chronic migraine and myalgia
2972448|NCT02747927|Experimental|Tetravalent Dengue Vaccine Candidate|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) 0.5 mL, subcutaneous injection on Day 1 and Day 90.
2972449|NCT02747927|Placebo Comparator|Placebo|Placebo-matching TDV, 0.5 mL, subcutaneous injection on Day 1 and Day 90.
2972450|NCT02747914|Experimental|Transcranial magnetic stimulation therapy|Group of patients treated with rTMS low than 5Hz
2972451|NCT02747914|Active Comparator|Conventional exercise treatment|Group of patients treated with conventional exercise
2972452|NCT02747901|Experimental|Kinesiotaping Group|Kinesiotaping group received kinesiotape for lymphatic correction and rectus femoris facilitation technique.
2972453|NCT02747901|Active Comparator|Cold Therapy Group|Cold Therapy group received cold pack immediately after operation and following postoperative days.
2972454|NCT02747901|No Intervention|Control Group|Control group have no intervention.
2972455|NCT02747888|No Intervention|Lower Suspected Familial Predisposition|"Lower Suspected Familial Predisposition~Screening and Enrollment:~Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.~- Sample stored in Biorepository"
2972456|NCT02747888|Experimental|Higher Suspected Familial Predisposition|"Higher Suspected Familial Predisposition~Screening and Enrollment:~Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.~- Specimen Testing and Analysis~•Referral to Genetic Counselor, if indicated"
2972457|NCT02747875|Active Comparator|Control - Fentanyl|Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. The medication will be prepared as described and all research and staff personnel as well as the study participant will be blinded to treatment group assignment.
2972458|NCT02747875|Active Comparator|Treatment - Methadone|Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. The medication will be prepared as described and all research and staff personnel as well as the study participant will be blinded to treatment group assignment.
2972459|NCT02747862||Attenuated Familial Adenomatous Polyposis|Chart review study to evaluate the outcomes of subjects with Attenuated Familial Adenomatous Polyposis (AFAP) who have not undergone surgical resection of the colon.
2972460|NCT02747862||Deleterious Familial Adenomatous Polyposis|Chart review study to evaluate the outcomes of subjects with Deleterious Familial Adenomatous Polyposis (FAP) who have not undergone surgical resection of the colon.
2972495|NCT02747602|Experimental|Group BCA|caprylic triglyceride oil standard breakfast, caprylic triglyceride high fat breakfast, AC-1204
2972461|NCT02747849|Placebo Comparator|Hand neuromodulation|The stimulation characteristics for this arm include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for finger twitching - or the intensity that the subject feels comfortable with. Subjects will be asked to use the stimulator for a minimum of 60 minutes prior to bedtime for two weeks, or longer if they can tolerate it, have the time, and accurately record the total duration. Stimulation will be performed during the first, second, and third weeks of the study.
2972462|NCT02747849|Active Comparator|Foot Neuromodulation|The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will be asked to wear socks on their foot to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a minimum of 60 minutes prior to bedtime for two weeks, or longer if they can tolerate it, have the time, and accurately record the total duration. Stimulation will be performed during the first, second, and third weeks of the study.
2972463|NCT02747836||Healthy Volunteers|Ultrasound of the wrist
2972464|NCT02747836||Participants with Carpal Tunnel Syndrome|Ultrasound of the wrist
2972465|NCT02747823|Experimental|CBT124|CBT124, single dose of 1 mg/kg, IV infusion
2972466|NCT02747823|Active Comparator|EU Sourced Avastin®|EU Sourced Avastin®, single dose of 1 mg/kg, IV infusion
2972467|NCT02747823|Active Comparator|US Sourced Avastin®|US Sourced Avastin®, single dose of 1 mg/kg, IV infusion
2972468|NCT02747810|Experimental|New TENS design|To determine the function and safety of the strap design by evaluating the electrical connection to electrode, 2) the security in the insole and the electronic unit, and 3) facilitating observation and hand access to the top panel for adjusting the stimulation strength. 4) to elicit toe twitching with stimulation of tribal nerve
2972469|NCT02747797|Experimental|Advanced cancer with lucitanib-targeting biomarker(s)|Lucitanib 10 mg orally daily
2972470|NCT02747784|Experimental|Study group experimental|24 female patients aged 18 years or older undergoing urogynecological or breast cancer surgery; the patients are recommended to perform the RehaCom® training modules 'Topological Memory (MEMO)' and 'Divided Attention 2 (GEA2)' daily during inpatient hospital stay, and at least three times a week for 30 to 60 minutes until month 3.
2972471|NCT02747784|Active Comparator|Study group active comparator|24 female patients aged 18 years or older undergoing urogynecological or breast cancer surgery; the patients are recommended to perform the RehaCom® training modules 'Topological Memory (MEMO)' and 'Working memory (WOME)' daily during inpatient hospital stay, and at least three times a week for 30 to 60 minutes until month 3.
2972472|NCT02747784|No Intervention|Control group|48 female control subjects aged 18 years or older (24 without surgery, 24 with urogynecological or breast cancer surgery) with a similar health status and age as the study group patients (similar distribution in the American Society of Anaesthesiologists physical status classification and relevant co-morbidities, e.g. diabetes, coronary artery disease, hypertension and hyperlipidemia). The patients are analyzed to correct for learning effects of the cognitive assessment testings in the study groups.
2972473|NCT02747758|Sham Comparator|Control|sham transcranial direct current stimulation (tDCS)
2972474|NCT02747758|Experimental|cathodal stimulation|cathodal transcranial direct current stimulation (tDCS)
2972475|NCT02747758|Experimental|anodal stimulation|anodal transcranial direct current stimulation (tDCS)
2972476|NCT02747745|No Intervention|Control Group|Group receive no intervention
2972477|NCT02747745|Experimental|Interventional Group|Four risk areas reflecting the great needs of FCGs of PWDs: depressive symptoms, burden, distress to problematic behaviors of PWDs and healthy behaviors.
2972478|NCT02747732|Experimental|one arm|"Therapy initiation 30 days max from screening.~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT"
2972479|NCT02747719|Experimental|Light and exercise|Exposure to light with exercise
2972480|NCT02747706|Experimental|Parent Mentoring|1-on-1, phone, SMS/text, and smartphone-based parent-to-parent mentoring.
2972481|NCT02747706|No Intervention|Usual Care|No intervention through study.
2972482|NCT02747680|Other|type 1 diabetes|type 1 diabetes >5 years duration Well controlled (a1c <7.5%)
2972483|NCT02747680|Other|healthy controls|healthy controls
2972484|NCT02747667||Eye with late IOL complication|Alle patients with IOL complication (subgroup: in-the-bag dislocation; out-of-the-bag dislocation; haptic dislocation)
2972485|NCT02747667||Eyes with no late IOl complication|
2972486|NCT02747654|No Intervention|standard dosing|a standard treatment group; INH dose of 300 mg or 200 mg based on the body weight
2972487|NCT02747654|Experimental|Genotype-guided dosing|INH dose determined based on developed model
2972488|NCT02747641|Other|treatment|only one arm
2972489|NCT02747628|Placebo Comparator|C group, (n=20)|C group (n=20) (placebo group) each patient received transdermal placebo patch, identical placebo patches custom-made by 1-800-Patches (Salt Lake City, UT) placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
2972490|NCT02747628|Active Comparator|TDN group, (n=20)|TDN group (n=20) each patient received transdermal therapeutic system- nicotine (15 mg/16 h),Nicorette® invisi 15mg patch releasing 15mg of nicotine over 16h, produced by Lohmann Therapie-System, Germany placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
2972491|NCT02747628|Active Comparator|TDM group, (n=20)|TDM group (n=20) each patient received transdermal therapeutic system- melatonin (7 mg/8h),melatonin sleep patch from Respro Labs ™ containing 7 mg of melatonin placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
2972492|NCT02747615|Other|Control group (n=30)|The control group, which consisted of 30 patients who were transfused only allogeneic blood.
2972493|NCT02747615|Active Comparator|Preoperative blood donation (n=30)|the study group including 30patients who were transfused pre-operatively donated autologous blood, either during surgery or after it.
2972494|NCT02747602|Experimental|Group ABC|AC-1204, caprylic triglyceride oil standard breakfast, caprylic triglyceride high fat breakfast
2972657|NCT02746419|Experimental|Experimental|Subjects will receive renal denervation.
2972496|NCT02747602|Experimental|Group CAB|caprylic triglyceride high fat breakfast, AC-1204, caprylic triglyceride oil standard breakfast
2972497|NCT02747589|Experimental|Treatment Group|Subjects will be implanted to assess the feasibility of stimulating visual cortex to restore vision in blind volunteers.
2972498|NCT02747576||Medulloblastoma Group|Medulloblastoma survivors, 30 between the ages of 12-20 years and 30 between 21-30 years.
2972499|NCT02747576||Control Group|Health comparison group frequency matched on age (30 between the ages of 12-20 years and 30 between 21-30 years), gender and race.
2972500|NCT02747563|Experimental|Active Surveillance|Patients with known prostate cancer eligible for active surveillance Intervention - PSA measurement
2972501|NCT02747563|Active Comparator|Controls|Patients without known diagnosis of prostate cancer Intervention - PSA measurement
2972502|NCT02747550|Experimental|LM with TESTO|In subjects allocated to the experimental group, the temporary simultaneous two-arterial occlusions (TESTO) procedure was performed to minimize operative blood loss during laparoscopic myomectomy.
2972503|NCT02747550|Active Comparator|LM without TESTO|In the control group, no intervention for the temporary simultaneous two-arterial occlusions (TESTO) procedure was made during laparoscopic myomectomy.
2972504|NCT02747537|Experimental|Arm 1: Sorafenib and Irinotecan|"Sorafenib is an oral drug which will be administered on an outpatient basis twice a day continuously (every day of a 21-day cycle) at approximately the same times each day. For patients unable to swallow whole pills, an oral suspension may be prepared with tablets.~Irinotecan will be administered orally (mixed with cranberry type juice) on an outpatient basis once a day on Days 1-5 of a 21-day cycle. Irinotecan should be given at least 1 hour after sorafenib."
2972505|NCT02747524|Experimental|Vita Mamba|Nutrient fortified peanut butter paste for 26 weeks.
2972506|NCT02747524|No Intervention|Control|
2972507|NCT02747511|Active Comparator|Haloperidol|
2972508|NCT02747511|Placebo Comparator|Placebo|
2972509|NCT02747498|Active Comparator|circumferential pulmonary vein isolation|Procedure with circumferential pulmonary vein isolation for atrial fibrillation
2972510|NCT02747498|Experimental|Linear ablation in addiction to pulmonary vein isolation|Procedure with linear ablation in addiction to pulmonary vein isolation
2972511|NCT02747485|Experimental|organic left-sided regurgitant valve|
2972512|NCT02747472|Placebo Comparator|Placebo|Infusion of saline
2972513|NCT02747472|Active Comparator|GIP(1-42)|Infusion of agonist, GIP(1-42)
2972514|NCT02747472|Experimental|GIP-A|Infusion of GIP-A alone
2972515|NCT02747472|Experimental|GIP-A + GIP(1-42)|Infusion of GIP-A and GIP(1-42)
2972516|NCT02747459|Experimental|SSS Intervention|Sensory Supported Swimming-eight, 30 minute lessons
2972517|NCT02747446|Experimental|Honey|added sugar: diet with 25% acacia honey
2972518|NCT02747446|Experimental|Fructose:glucose mixture|added sugar: Diet with 25% energy as a fructose:glucose mixture
2972519|NCT02747446|No Intervention|control|no intervention: Diet with 45% starch and no honey or added sugars
2972520|NCT02747433|Active Comparator|Robot-Assisted Therapy (RT)|Armeo and Amadeo robot-assisted intensive upper extremity therapy 1 hr sessions 3x week for 6 weeks plus ALPS training
2972521|NCT02747433|Active Comparator|Robot & Task-Oriented Training (RT-TOT)|Armeo and Amadeo robot-assisted intensive upper extremity therapy 30 mins, 3x week for 6 weeks plus ALPS training. Task oriented training will be provided for remaining 30 min of each treatment session
2972522|NCT02747420|Experimental|Post Tibial Nerve Stimulation Group (PTNS)|
2972523|NCT02747420|Sham Comparator|Sham Group|
2972524|NCT02747407|Experimental|Group II (vaccination at 9 months)|Patients undergo standard of care treatment and collection of blood samples as in Group I. Patients then receive hepatitis A and tetanus toxoid vaccinations at month 9.
2972525|NCT02747407|Experimental|Groups I (vaccination pre-treatment)|Patients receive standard of care hepatitis A or B vaccine, tetanus toxoid vaccine, and trivalent influenza vaccine and then undergo standard of care treatment external beam radiation therapy and receive standard of care temozolomide. Patients also undergo collection of blood Samples monthly for the first 8 months and then bimonthly for up to 12 months for analysis via flow cytometry, (CFSE) assay, live cell/dead cell distinction assay, and determination of naïve and memory immune response.
2972526|NCT02747394|Experimental|Adaptive Cogmed|5 days per week for 5-6 weeks of parent aided visual working memory training, consisting of adaptive Cogmed
2972527|NCT02747394|Other|Non-Adaptive Cogmed|5 days per week for 5-6 weeks of parent aided visual working memory training, consisting of non-adaptive Cogmed
2972528|NCT02747381|Experimental|intervention|receive Alfacalcidol 1 mcg daily for 4 months beside the conventional asthma medications
2972529|NCT02747381|No Intervention|control|Asthmatic patients receiving conventional asthma medications
2972530|NCT02747368|Other|Wet age related macular degeneration|Ocusweep system is compared to results of conventional devices.
2972531|NCT02747342|Experimental|SHR3680|SHR3680 will be administered orally at the starting dose of 40 mg/day.
2972532|NCT02747329|Experimental|1st month OCT group implanted BuMA Supreme™ stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of BuMA Supreme™ stent. The Primary Endpoint of this group is 1st month QCA and OCT assessment.
2972533|NCT02747329|Active Comparator|1st month OCT group implanted Xience V/Prime stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of Xience V/Prime stent. The Primary Endpoint of this group is 1st month QCA and OCT assessment.
2972534|NCT02747329|Experimental|2st month OCT group implanted BuMA Supreme™ stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of BuMA Supreme™ stent. The Primary Endpoint of this group is 2st month QCA and OCT assessment.
2972535|NCT02747329|Active Comparator|2st month OCT group implanted Xience V/Prime stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of Xience V/Prime stent. The Primary Endpoint of this group is 2st month QCA and OCT assessment.
2972536|NCT02747316|Experimental|Isotopically labeled test meal week of pregnancy 18|
2972537|NCT02747316|Experimental|Isotopically labeled test meal week of pregnancy 28|
2972538|NCT02747303|Active Comparator|Stereotactic Radiosurgery to 2 mm GTV to PTV margins|
2972539|NCT02747303|Experimental|Stereotactic Radiosurgery to 0 mm GTV to PTV margins|
2972540|NCT02747290|Experimental|68Ga-NOTA-BBN-RGD PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-BBN-RGD in one dose intravenously and underwent PET/CT scan 15-30 min later.
2972541|NCT02747264|Experimental|eRAPID intervention|Participants in the intervention arm will receive training in using the eRAPID system to report their symptoms and side effects (at least on a weekly basis) from home via the internet whilst they are receiving treatment online and weekly for 6 weeks post treatment (a total of 12 weeks) and then at 18 & 24 weeks. Hospital staff will be able to review eRAPID reports and use the information during the consultation in clinic, when attending radiotherapy or answering phone calls. Alerts will also be sent to the relevant clinical team when severe symptoms are reported by patients.
2972542|NCT02747264|No Intervention|Usual care|The Usual care patients act as a comparison to the patients using eRAPID. They complete a paper-based quality of life questionnaire at baseline and then 6, 12 and 24 weeks after. The researchers will also collect clinical process measures for this group including number of hospital contacts and admissions.
2972543|NCT02747251|Experimental|Strengthen your Shoulder & Usual Care|"Instructions in a home-based intervention consisting of progressive high volume resistance training with an elastic band. Instructions provided 0, 2, 5, and 10 weeks after baseline. Usual care includes all treatment received by a patient during the time between baseline and follow-up, except that included in Strengthen your Shoulder."
2972544|NCT02747251|Active Comparator|Usual Care|"Includes all treatment received by a patient during the time between baseline and follow-up, except that included in Strengthen your Shoulder."
2972545|NCT02747238|Active Comparator|Ultrasound|Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started
2972546|NCT02747238|Active Comparator|No ultrasound|Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started
2972547|NCT02747199|Active Comparator|Coronary artery implanted with SYNERGY stent|One of the blocked coronary artery of a patient will received SYNERGY stent
2972548|NCT02747199|Active Comparator|Coronary artery implanted with ABSORB scaffold|Another blocked coronary artery of the same patient will received ABSORB scaffold
2972549|NCT02747186|Active Comparator|Buffered 1% lidocaine with 1/100/000 Epinephrine|"In week One each subject would receive the anesthetic, 5cc, to block the Posterior alveolar, Anterior alveolar, Palatal nerves.Maxillary molar and canine tested for pulpal anesthesia.~At least a week later, injections for the maxillary field block would involve the alternate local anesthetic combination. Maxillary molar and canine tested for pulpal anesthesia."
2972550|NCT02747186|Active Comparator|Non-Buffered lidocaine with 1/100,000 Epinephrine|"In week One each subject would receive the anesthetic, 5cc, to block the Posterior alveolar, Anterior alveolar, Palatal nerves. Maxillary molar and canine tested for pulpal anesthesia.~At least a week later, injections for the maxillary field block would involve the alternate local anesthetic combination. Maxillary molar and canine tested for pulpal anesthesia."
2972551|NCT02747173||RCC patients with bone metastases|Patients will receive the standard TKI treatment for first line treatment naive metastatic RCC. Sunitinib or pazopanib as decided by the investigator.
2972552|NCT02747160|Experimental|Managing Anxiety from Cancer (MAC)|Older adults with cancer and their primary informal caregiver will receive a six-session cognitive-behavior therapy intervention administered over the telephone by a trained study interventionist. The intervention is administered weekly and each session is 45-50 minutes in length. Patients and caregivers will receive the intervention independently and from separate therapists.
2972553|NCT02747147|No Intervention|A- Control|Group A will have their PIVs assessed daily and record kept of PIV dislodgement or replacement
2972554|NCT02747147|Experimental|B - Device Intervention|patients will have their PIVs assessed daily and record kept of PIV displodgement or replacement. patients will additionally have a single blood collection attempted using the study device
2972555|NCT02747134|Experimental|Emotion Regulation and Mindfulness skills|A 10 week intervention including emotion regulation and mindfulness skills from dialectical behavioral therapy (DBT) was delivered.
2972556|NCT02747134|Active Comparator|Psychoeducation|Psychoeducation consisted of 5 session in which basic information about depressive symptoms and how to prevent depression relapse was given.
2972557|NCT02747121|Other|Control before intervention|External inspection of health services. The intervention is external inspection of sepsis detection and treatment. The intervention is delivered on the organizational Level. Patient are not assigned to the intervention. The intervention is rolled out sequentially to 24 hospitals. We collect data at base line, before the inspections and 8 and 14 month after the inspections. The first arm is the Control period before the inspections.
2972558|NCT02747121|Experimental|Intervention|External inspection of health services. We compare the effect measures before and after the inspection. The intervention arm is data after the hospitals have received the inspection.
2972559|NCT02747108|Experimental|Blood Test Group|Patients will complete an HbA1c test and then receive brief counseling and written information about their test result based on the American Diabetes Association and National Diabetes Prevention Program guidelines.
2972560|NCT02747108|Active Comparator|Brochure Group (usual care)|Patients will not complete an HbA1c test and will instead receive brief counseling and written information about recommended screenings and immunizations.
2972561|NCT02747095|Experimental|Spectral CT image|Interventions: IQon Spectral CT
2972562|NCT02747082|Active Comparator|1% sodium hypochlorite (NaOCl)|"Retreatment of root-filled teeth with infection with 1% NaOCl as irrigation solution.~Total bacterial counts, Streptococcal species and Enterococcus faecalis species were quantified using qPCR against 16SrRNA before irrigation (S1), after irrigation (S2), and after intracanal medication (S3)."
2972563|NCT02747082|Active Comparator|2% chlorhexidine gluconate (CHX)|"Retreatment of root-filled teeth with infection with 2% CHX as irrigation solution.~Total bacterial counts, Streptococcal species and Enterococcus faecalis species were quantified using qPCR against 16SrRNA before irrigation (S1), after irrigation (S2), and after intracanal medication (S3)."
2972564|NCT02747069||NICU electronic stethoscope|Neonatal patients of any gestation admitted to the neonatal intensive care unit (NICU) and undergoing routine monitoring with ECG and pulse oximetry Heart rate will be evaluated using an electronic stethoscope
2972565|NCT02747069||Newborns <32 weeks and ECG|Neonatal patients <32 weeks gestation Heart rate will be assessed at the time of delivery with both an electronic stethoscope and ECG using a pre placed lead system
2972566|NCT02747056|Experimental|Autism spectrum disorder studyA part1|The subjects will perform clinical, psychological and neuropsychological assessment. the subjects will do 3 tests about executive functions. Finally, the participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
2972567|NCT02747056|Experimental|Autism spectrum disorder studyA part2|The subjects will perform Autobiographical memories Assessment. The subjects will tell autobiographical memories freely first and secondly by answering focused questions to specify the characteristics of subjects' memories
2972568|NCT02747056|Other|Control adults Study A, part 1|The subjects will perform clinical, psychological and neuropsychological assessment. The subjects will do 3 tests about executive functions. The participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
2972569|NCT02747056|Other|Control adults Study A, part 2|The subjects will perform Autobiographical memories Assessment. The subjects will tell autobiographical memories freely first and secondly by answering focused questions to specify the characteristics of subjects' memories
2972570|NCT02747056|Experimental|Autism spectrum disorder Study B, part 1|The subjects will perform clinical, psychological and neuropsychological assessment. The subjects will do 3 tests about executive functions. The participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
2972571|NCT02747056|Experimental|Autism spectrum disorder Study B, part 2|The subjects will perform Autobiographical memories assessment characteristics. The subjects will say the self statements which define them. Then, the participants will have to tell and specify the characteristics of the autobiographical memories linked to the self statements.
2972572|NCT02747056|Other|Control adults, Study B part 1|The subjects will perform clinical, psychological and neuropsychological assessment.The subjects will do 3 tests about executive functions. Finally, the participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
2972573|NCT02747056|Other|Control adults, Study B part 2|The subjects will perform Autobiographical memories assessment characteristics. The subjects will say the self statements which define them. Then, the participants will have to tell and specify the characteristics of the autobiographical memories linked to the self statements
2972574|NCT02747043|Experimental|ABP 798|Concentrate for solution for infusion, ABP 798 at a dose of 375 mg/m2 administered as an intravenous (IV) infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20
2972575|NCT02747043|Active Comparator|Rituximab|Concentrate for solution for infusion, Rituximab at a dose of 375 mg/m2 administered as an IV infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20
2972576|NCT02747030|Experimental|Ocriplasmin intravenously|All subjects included in this phase I study are in the experimental treatment arm and will undergo a vitrectomy augmented with retinal vein cannulation and intravenous Ocriplasmin infusion.
2972577|NCT02747017||CDI patients|Adults with a first episode of CDI within 2 years after solid-organ or stem-cell transplant.
2972578|NCT02747004|Experimental|Abemaciclib + Tamoxifen|Abemaciclib given orally every 12 hours (Q12H) in combination with tamoxifen given orally every day. Participants may continue to receive treatment until discontinuation criteria are met.
2972579|NCT02747004|Experimental|Abemaciclib|Abemaciclib given orally Q12H. Participants may continue to receive treatment until discontinuation criteria are met.
2972580|NCT02747004|Experimental|Abemaciclib + Prophylactic Loperamide|Abemaciclib given orally Q12H in combination with prophylactic loperamide given orally. Participants may continue to receive treatment until discontinuation criteria are met.
2972581|NCT02746991|Sham Comparator|Sham Injection|Sham Injection
2972582|NCT02746991|Experimental|FAI Insert|FAI Insert (0.18 mg fluocinolone acetonide)
2972583|NCT02746978|Active Comparator|Peer directed education|A revised education approach that focuses on problem solving discussions delivered by peers and grounded clinical information is compared to traditional approach of didactic clinician-driven education lectures
2972584|NCT02746978|Other|Patient Engagement Portal|A patient-owned portal to manage injury information is maintained in real-time by patients and families and shared with other care providers after inpatient rehabilitation discharge.
2972585|NCT02746965|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
2972586|NCT02746965|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
2972587|NCT02746952|Experimental|UCART19|
2972588|NCT02746939|No Intervention|Pre-curriculum assessment|Assessments will be administered to 3rd and 4th grade students prior to receiving curriculum training in fitness and nutrition.
2972589|NCT02746939|Experimental|Post-curriculum assessment|Assessments will be administered to 3rd and 4th grade students (matched from pre-curriculum assessment) after receiving 4-6 week InSciEd Out Fitness and Nutrition Curriculum.
2972590|NCT02746926|Experimental|4x20 mg tafamidis meglumine soft gel capsule|
2972591|NCT02746926|Experimental|48.8 mgA tafamidis free acid capsule|
2972592|NCT02746926|Experimental|61 mgA tafamidis free acid capsule|
2972593|NCT02746913|Experimental|Urodynamics, followed by Pessary|
2972594|NCT02746913|Experimental|Pessary, followed by Urodynamics|
2972595|NCT02746900|Experimental|Cervical cerclage|After the woman is placed in the dorsal lithotomy position and the bladder is emptied with a urinary catheter to reduce the chance of bladder injury, surgical preparation with Betadine will be performed. Breisky retractors and Sims retractors will be used to exposure the entire cervix. Sponge ring forceps will be used to optimized visualization of the cervix and provide the necessary countertraction at the suture entry and exit sites. McDonald technique will be performed placing 4-6 bites circumferentially around the cervix. Only one stitch will be used. The suture will be places as high as feasible
2972596|NCT02746900|No Intervention|No intervention|Bed rest will be not recommended.
2972597|NCT02746887||Preterm cohort|Preterm infants with a gestational age less than 32 weeks or birth weight less than 1,500 g
2972598|NCT02746887||Term control cohort|Healthy term infants
2972599|NCT02746874|Active Comparator|Active Group|Radiofrequency ablation procedure of the three articular branches of the knee joint. The targets will be thermally lesioned for 2 minutes 30 seconds thereby causing neurolysis.
2973031|NCT02743871|Experimental|Cohort 5|1000 mg of PF-06817024 or placebo
2972600|NCT02746874|Sham Comparator|Placebo Group|Simulated Radiofrequency Ablation procedure of the three articular branches of the knee joint.The targets will be not be thermally lesioned for 2 minutes 30 seconds therefore not causing neurolysis.
2972601|NCT02746861|Experimental|Diabetes Self-Management Support (DSMS)|Patient receives 6-months of DSMS while receiving support from a trained peer mentor (Peer-supported DSMS).
2972602|NCT02746861|No Intervention|Usual Care|Patient continues to receive usual care.
2972603|NCT02746848|Experimental|Patients with cornea injury|Patients with cornea injury who received healing Amniotic Membrane Extract Eye Drop.
2972604|NCT02746835|Experimental|Exercise Protocol|Set of exercises for balance, endurance, muscle strength and flexibility
2972605|NCT02746809|Experimental|CoreValve Evolut 34R TAVR system|Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
2972606|NCT02746796|Experimental|ONO-4538 + SOX Therapy Cohort (Part 1)|"ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (BSA) solution intravenously for 2 hours once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 14 days, followed by 7 days off Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
2972607|NCT02746796|Experimental|ONO-4538 + CapeOX Therapy Cohort (Part 1)|"ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Capecitabine 1200 - 2100 mg bid orally in 14 days, followed by 7 days off. Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
2972608|NCT02746796|Experimental|ONO-4538 + chemotherapy group (Part 2)|"With regard to the ONO-4538 + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject.~ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off.~Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
2972609|NCT02746796|Placebo Comparator|Placebo + Chemotherapy group (Part 2)|"With regard to the placebo + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject.~Placebo solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off.~Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
2972610|NCT02746783|Active Comparator|Group 1|Single dose of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012.
2972611|NCT02746783|Experimental|Group 2|Double dose of MUTAGRIP® (one dose into the right deltoid area and the other one into the left deltoid area) containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012.
2972612|NCT02746770|Experimental|Cawthorne and Cooksey exercises group|Intervention: Participants allocated in both control and experimental groups were receiving treatment for their specific vestibular disorders. Patients assigned to the experimental group also performed the Cawthorne and Cooksey exercises for vestibular rehabilitation during a six week of treatment period.
2972613|NCT02746770|No Intervention|control group|intervention: The control group will not perform the active exercise that will be applied to intervention group.
2972614|NCT02746757|No Intervention|Ischemia-reperfusion no intervention|Ischemia-reperfusion without intervention
2972615|NCT02746757|Experimental|Ischemia-reperfusion with RIPC|Ischemia-reperfusion with intervention by RIPC
2972616|NCT02746757|Experimental|Ischemia-reperfusion with RIPC and Ex 9-39|Ischemia-reperfusion with RIPC and Ex 9-39
2972617|NCT02746744|Experimental|Rituximab|Infusion of Mabthera/Rituximab every 6 months
2972618|NCT02746744|Active Comparator|Dimethyl Fumarate|Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
2972619|NCT02746744|Sham Comparator|Sodium Chloride solution|Sham infusion with sodium chloride solution for the Tecfidera/Dimethyl Fumarate arm every 6 months (so that the examining physician will be blinded)
2972620|NCT02746731|Experimental|Prehabilitation|'Cardiorespiratory and resistance training.
2972621|NCT02746731|Active Comparator|Reference|Usual care.
2972622|NCT02746718|Other|Restrictive Respiratory Failure|A CPK dosage, muscular questionnaires and a Pompe Disease test are practiced on patient with Restrictive Respiratory Failure without etiology
2972623|NCT02746705|Active Comparator|Transcranial Direct Current Stimulation (tDCS)|
2972624|NCT02746705|Sham Comparator|Sham Transcranial Direct Current Stimulation (tDCS)|
2972625|NCT02746692|Experimental|Intervention|
2972626|NCT02746692|Active Comparator|Comparison|
2972627|NCT02746679|Experimental|MBSR Group|The Mindfulness Based Stress Reduction program consisted of eight weekly sessions, each 2.5 hours long, and delivered on consecutive weeks.The Mindfulness Based Stress Reduction therapist participated in the mindfulness exercises with group members during the weekly sessions, and group members were instructed to practice these mindfulness exercises outside group meetings for at least 45 minutes per day, 6 days per week.Group members were taught three main varieties of mindfulness skills: the body scan exercise, sitting meditation, and yoga exercises.The daily homework exercises consisted of repeating body scan work, sitting meditation and yoga exercises at home to provide practice and generalization of the skills.
2972628|NCT02746679|No Intervention|wait-list control group|The patients assigned to the wait-list control group did not receive MBSR intervention for 8 weeks when participants in MBSR were engaged in the MBSR intervention.They only received conventional therapy.
2972629|NCT02746666|Experimental|Intervention|Under pharmacist's behavioral intervention
2972630|NCT02746666|No Intervention|Control|No pharmacist's behavioral intervention
2972631|NCT02746653|Experimental|Use of TroClose1200(TM) for access port and closure device|TroClose in 1 port
2973032|NCT02743871|Experimental|Cohort 6|2000 mg of PF-06817024 or placebo
2972632|NCT02746627|Active Comparator|Education|Participants receive educational materials in the mail every 2 weeks for 8 weeks.
2972633|NCT02746627|Experimental|Positive Affect - Text|Participants receive positive affect intervention (weekly reminders to use gratitude, self-affirmations, parental affirmations, and gift cards) by SMS. Participants also receive educational materials in the mail every 2 weeks for 8 weeks.
2972634|NCT02746627|Experimental|Positive Affect - Phone|Participants receive positive affect intervention (weekly reminders to use gratitude, self-affirmations, parental affirmations) by phone. Participants receive small gifts in the mail every 2 weeks for 8 weeks. educational materials in the mail every 2 weeks for 8 weeks.
2972635|NCT02746614|Active Comparator|Psychomotor Therapy & Adaptive Behavior|After the initial assessment of adaptive behavior, i.e.., set of skills that each individual with intellectual disability should train to cope with environmental demands, a Psychomotor Intervention Program was designed specifically. The program integrated individual and group sessions during 3 months, and the main goals of the program were related to independent functioning, motor development, economic and professional activities, academic and verbal skills.
2972636|NCT02746614|Active Comparator|Psychomotor Therapy & Motor Proficiency|Motor Proficiency After the initial assessment, a Psychomotor Intervention Program was designed specifically for participants with IDD. This program integrated individual and group sessions during 3 months, and the main goals of the program were related to motor coordination (balance, manual dexterity and coordination, global and fine praxis).
2972637|NCT02746601|Experimental|Risk Assessment, Counselling & Resources|Patients complete an electronic preconception health risk assessment tool. Results from the tool are directly uploaded or scanned into the patients' electronic medical record. A healthcare provider provides behavioural counselling, based on results of the risk assessment. Patients are given a customized handout that includes health recommendations and resources based on the patient's identified risk factors.
2972638|NCT02746575|Experimental|treatment|Postsurgical: 5mg metoprolol, IV, prior to extubation, every 5 minutes to achieve target heart rate of 65/min, up to 15mg; then 25mg metoprolol, oral, every 8 hours for 72 hours.
2972639|NCT02746562|Experimental|Freeze all|Transfer of a frozen, thawed blastocyst in a subsequent natural menstrual cycle
2972640|NCT02746562|No Intervention|Fresh embryo transfer|Standard procedure
2972641|NCT02746549|Experimental|1.5 Tesla MRI|Measurement of renal perfusion by 1.5 Tesla MRI with arterial spin labelling
2972642|NCT02746549|Experimental|3.0 Tesla MRI|Measurement of renal perfusion by 3.0 Tesla MRI with arterial spin labelling
2972643|NCT02746536|Experimental|Slow chest compression|Patients will receive the slow chest compression for one minute, immediately after 6MST and 6MWT.
2972644|NCT02746536|Placebo Comparator|No slow chest compression|Immediately after 6MST and 6MWT, the patient will not receive the SCC and will remain seated at rest for one minute, without any intervention.
2972645|NCT02746523||Case / Retired NHL Players|"All interventions for this group are described below:~Sensory Organization Test (SOT): Balance and proprioception test~Connor's Adult ADHD Rating Scale (CAARS): A computer based questionnaire used to measure the presence of adult attention deficit hyperactivity disorder.~Beck's Depression Inventory: A 21 question multiple choice self report measuring the severity of depression~Patient Health Questionnaire 9 (PHQ-9): Self administered screening questionnaire for mental health disorders~Montreal Cognitive Assessment (MoCA): A validated screening tool to assess cognitive mild impairment~Blood/Urine/Saliva Biomarker analysis: These samples will be analyzed for relevant biomarkers"
2972646|NCT02746523||Age Matched Controls|"All interventions for this group are described below:~Sensory Organization Test (SOT): Balance and proprioception test~Connor's Adult ADHD Rating Scale (CAARS): A computer based questionnaire used to measure the presence of adult attention deficit hyperactivity disorder.~Beck's Depression Inventory: A 21 question multiple choice self report measuring the severity of depression~Patient Health Questionnaire 9 (PHQ-9): Self administered screening questionnaire for mental health disorders~Montreal Cognitive Assessment (MoCA): A validated screening tool to assess cognitive mild impairment~Blood/Urine/Saliva Biomarker analysis: These samples will be analyzed for relevant biomarkers"
2972647|NCT02746510|Experimental|Array comparative genomic hybridization|The investigators plan to include 150 patients with defined (DSM V) schizophrenia and aged 15 years and more. The clinical grid will be prospectively fulfilled for every patients on the basis of his/her medical history and clinical examination. Array comparative genomic hybridization (CGH-a) will be performed on jugal mucosae sample to detect precisely syndromic forms of schizophrenia linked to the presence of a pathogenic Copy Number Variation (CNV).
2972648|NCT02746497|Active Comparator|Group E (early intervention)|One weekly treatment with acupuncture in five consecutive weeks. In trial week 1-5 Group E will receive treatment and Group L will act as control group.
2972649|NCT02746497|Active Comparator|Group L (late intervention)|After trial week five the Groups must cross-over. Group L will then receive treatment for five weeks (trial week 6-11) and Group E will act as follow up group.
2972650|NCT02746484|Experimental|Ability platform program|Multi-domain at home rehabilitation program delivered through the Ability platform.
2972651|NCT02746484|Active Comparator|Usual care program|Usual care at home program (paper and pencil cognitive activities; promotion of physical activity according to healthcare professional's advice)
2972652|NCT02746458|No Intervention|Standard of Care Physical Therapy|This group will receive the standard of care physical therapy program for 6 weeks.
2972653|NCT02746458|Experimental|Blood Flow Restriction Plus Standard of Care Physical Therapy|This group will receive the same standard of care physical therapy program for 6 weeks plus blood flow restriction.
2972654|NCT02746445||ASD Subjects|No interventions. This is an observation of subjects who received MeRT utilizing assessment documentation.
2972655|NCT02746432|No Intervention|Control group|Routine intra operative saline infusion to be administered.pre-operation and timed assessment lab set to be obtained.
2972656|NCT02746432|Experimental|Intervention group.Hyper insulinemic euglycemic clamp|After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin (Human regular insulin) ) infusion, and when the blood glucose is <6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
2972658|NCT02746419|Sham Comparator|Control|Subjects will receive all procedures as experimental group but renal denervation system will not be turned on.
2972659|NCT02746406|Experimental|Peritron+|SMIP assessment using Peritron+, Air-Trap Tubing, and a conventional CIC catheter
2972660|NCT02746393|Experimental|Intervention|Health Advocates Program
2972661|NCT02746393|Active Comparator|211 Arm|211 Information Sheet
2972662|NCT02746380|Experimental|LBAL|Adalimumab
2972663|NCT02746380|Active Comparator|Humira®|Adalimumab
2972664|NCT02746367||MDD|Patients diagnosed with Major Depressive Disorder
2972665|NCT02746367||BPI|Patients diagnosed with bipolar I
2972666|NCT02746367||BPII|Patients diagnosed with bipolar II
2972667|NCT02746354|Experimental|The MySupport tool|Utilization of the MySupport tool, a tailored patient-centered assessment
2972668|NCT02746354|No Intervention|Usual care|
2972669|NCT02746328|Experimental|GTx-024 9 or 18 mg|Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
2972670|NCT02746315|Experimental|Experimental 1|Once daily subcutaneous dose for 7 Days of HS-20004 0.02 mg or Matched Placebo.
2972671|NCT02746315|Experimental|Experimental 2|Once daily subcutaneous dose for 7 Days of HS-20004 0.04 mg or Matched Placebo.
2972672|NCT02746315|Experimental|Experimental 3|Once daily subcutaneous dose for 7 Days of HS-20004 0.06 mg or Matched Placebo.
2972673|NCT02746315|Experimental|Experimental 4|Once daily subcutaneous dose for 7 Days of HS-20004 0.08 mg or Matched Placebo.
2972674|NCT02746302|Experimental|HS-20004|One dose of HS-20004(0.02,0.04,0.05,0.06,0.08,0.1mg) Injected s.c. (under the skin) once for one subject.
2972675|NCT02746302|Placebo Comparator|Placebo|Placebo Injected s.c. (under the skin) once for one subject.
2972676|NCT02746276|Other|Ceftriaxone and metronidazole|Pharmacokinetic study of ceftriaxone and metronidazole in malnourished children
2972677|NCT02746263|Experimental|IV acetaminophen/Morphine|IV acetaminophen 1000 mg every 6 hours over 18 hours
2972678|NCT02746263|Active Comparator|Oral acetaminophen/Morphine|Oral acetaminophen two 500 mg tablets every 6 hours over 18 hours
2972679|NCT02746250|Active Comparator|Tension type headache|The investigator measures the muscle soreness and muscle stiffness before the patients starts their prescribed treatment with amitriptyline - and again after they have reached their optimal dosage of amitriptyline.
2972680|NCT02746250|No Intervention|Healthy controls|The investigator measures the muscle soreness and muscle stiffness once.
2972681|NCT02746237|Experimental|KAR5585|KAR5585 Capsules
2972682|NCT02746237|Placebo Comparator|Placebo|Placebo capsules
2972683|NCT02746224|Other|group 1A|the surgical technique initially dissects the inferior mesenteric vein (IMV).
2972684|NCT02746224|Other|group 1B|the surgical technique initially dissects the inferior mesenteric artery (IMA).
2972685|NCT02746224|Other|group 2A|the patients will have a latero-terminal colorectal anastomosis
2972686|NCT02746224|Other|group 2B|the patients will have a termino-terminal colorectal anastomosis.
2972687|NCT02746211|Experimental|High Titre Influenza virus|High Titre Influenza virus
2972688|NCT02746211|Experimental|Medium - High Influenza virus|Medium - High Influenza virus
2972689|NCT02746211|Experimental|Medium Low Titre Influenza virus|Medium Low Titre Influenza virus
2972690|NCT02746211|Experimental|Low titre Influenza Vaccine|Low titre Influenza Vaccine
2972691|NCT02746198|Experimental|Verum|2 bottles (á 65ml) of a probiotic dairy drink consumed daily for 6 weeks
2972692|NCT02746198|Placebo Comparator|Placebo|2 bottles (á 65ml) of a dairy drink containing chemically acidified milk without bacterial strains consumed daily for 6 weeks
2972693|NCT02746185|Active Comparator|Low-molecular-weight heparin|dalteparin, 200 IU/kg subcutaneously once daily for one month followed by 150 IU/kg subcutaneously once daily for 2 months
2972694|NCT02746185|Experimental|Rivaroxaban|rivaroxaban, orally, 15 mg twice daily for 3 weeks followed by 20 mg once daily for 9 weeks
2972695|NCT02746172|Experimental|Cochlear Implant Recipients|cochlear implant recipients
2972696|NCT02746172|No Intervention|Normal Hearing Volunteers|Normal hearing volunteers
2972697|NCT02746146|Experimental|Chronic dialysis patients|"The study population consists of patients over 70 (≥) and under 85 years (<) of age with stage 5 chronic renal disease and initiating a first session of chronic dialysis in the Languedoc-Roussillon and Midi-Pyrénées regions. Eligible patients must have a 3 year prognostic mortality score less than (<) 7 points (Dusseux et al. 2015).~Intervention: Systematic use of a prognostic score"
2972698|NCT02746133||Chronic kidney disease (pre-dialysis)|Observational study: Supplemented protein-restricted diet
2972699|NCT02746107|Experimental|risk presented on 1 diagram|decision aid with risk of stroke presented on 1 diagram (risk under OAC treatment)
2972700|NCT02746107|Active Comparator|risk presented on 2 diagrams|decision aid with risk of stroke presented on 2 diagrams (one presenting risk without and one presenting risk with treatment)
2972701|NCT02746107|Active Comparator|1year risk estimate|risk of stroke presented over a timeframe of 1 year
2972702|NCT02746107|Experimental|5year risk estimate|risk of stroke presented over a timeframe of 5 years
2972703|NCT02746107|Other|CHA2DS2-VASC risk score 1|CHA2DS2-VASC risk score =1
2972704|NCT02746107|Other|CHA2DS2-VASC risk score 2|CHA2DS2-VASC risk score =2
2972705|NCT02746107|Other|CHA2DS2-VASC risk score 3|CHA2DS2-VASC risk score =3
2972706|NCT02746107|Other|CHA2DS2-VASC risk score 4|CHA2DS2-VASC risk score =4
2972707|NCT02746107|Other|CHA2DS2-VASC risk score 5|CHA2DS2-VASC risk score =5
2972708|NCT02746107|Active Comparator|prescription to virtual patient|prescription is done for a virtual patient
2972709|NCT02746107|Experimental|prescription to physician himself|prescription is done to physician himself
2972710|NCT02746094|Experimental|The study population|"The study population is comprised of adult men less than 80 years of age who are consulting for ED lasting for over 6 months following a prostatectomy that took place 18 to 60 months ago. The patients are currently in a stable relationship that has been going on for at least 3 months, have an IIEF-EF score between 6 and 25, and have at least a natural tumescence during sexual stimulation (EHS score ≥ 1).~Intervention: 8 bi-weekly LIESWT sessions"
2973033|NCT02743871|Experimental|Cohort 7|30 mg subcutaneous dose of PF-06817024 or placebo
2972711|NCT02746081|Experimental|BAY1436032|"Dose escalation: Patients with any type of IDH1-R132X-mutant solid tumor may be eligible for enrollment. BAY1436032 tablets will be administered continuously in 21-day cycles. The starting dose is 300 mg/day (150 mg twice daily) and a minimum of 3 patients per cohort will be treated. If dose limiting toxicities (DLTs) occur, Bayesian dose-DLT modeling will be performed to help guide dosing decisions and to identify the maximum tolerated dose (MTD). If the MTD is not reached, a recommended phase II dose (RP2D) will be chosen based on available safety, tolerability, PK, PD and clinical efficacy data.~Dose expansion: The dose and schedule that was determined to be most appropriate in the dose escalation part of the study, which may be the MTD and / or the RP2D, will be used. Cohorts will consist of patients with the following IDH-R132X-mutant tumor types: (1) anaplastic glioma; (2) glioblastoma; (3) intrahepatic cholangiocarcinoma; (4) tumor types other than those in Cohorts 1-3."
2972712|NCT02746068|Experimental|AXS-02|Administered orally in the morning for 6 weeks
2972713|NCT02746068|Placebo Comparator|Placebo|Administered orally in the morning for 6 weeks
2972714|NCT02746042|Experimental|Sinupret extract coated tablets|"Sinupret extract coated tablets: one tablet three times a day orally during the 16-week treatment phase.~There will be no dose change during the trial."
2972715|NCT02746042|Placebo Comparator|Placebo coated tablets|Placebo coated tablets: One tablet three times a day orally during the 16-week treatment Phase.
2972716|NCT02746029||Children with cardiac murmur|
2972717|NCT02746016|Experimental|Infant Formula supplemented with Oligosaccharides|Ready to feed infant formula ; Feed ad libitum.
2972718|NCT02746003|Other|Managed Aquifer Recharge water|All the study population will receive the intervention by a random allocation over the study period. The study participants will be in both intervention and control at different times.
2972719|NCT02746003|Other|Control|All the study population will receive the intervention by a random allocation over the study period. The study participants will be in both intervention and control arms at different times.
2972720|NCT02745990|Experimental|EPO group|In EPO group, The recombinant human erythropoietin (rhEPO) will be given by 500 U/kg/dose at 48 hour intervals intravenously from the time of enrollment, and until to 32 weeks postmenstrual age.
2972721|NCT02745977|Other|Dairy Free Diet- guaiac + on dairy free diet|Dairy Free Diet x 3 weeks then stool guaiac positive
2972722|NCT02745977|Other|Guaiac negative on dairy free diet|on dairy free diet x 3 weeks, then stool guaiac negative
2972723|NCT02745964|Experimental|LMA supreme|Anesthesia is maintained using LMA supreme during surgery.
2972724|NCT02745964|Active Comparator|I-gel|Anesthesia is maintained using I-gel during surgery.
2972725|NCT02745951|Experimental|Heliox|Cardioplegia enriched with a 70:30 (Helium:Oxygen) Heliox mixture while the patient is on cardiopulmonary bypass
2972726|NCT02745951|Active Comparator|Standard of care|Cardioplegia enriched with a Nitrogen and Oxygen mixture while the patient is on cardiopulmonary bypass
2972727|NCT02745938||Mitochondrial disease|Patients with mitochondrial disease, investigated by blood samples and exercise test.
2972728|NCT02745938||Metabolic myopathy|Patients with metabolic myopathy, investigated by blood samples and exercise test.
2972729|NCT02745938||Muscular dystrophy|Patients with muscular dystrophy, investigated by blood samples and exercise test.
2972730|NCT02745938||Healthy controls|Healthy controls, investigated by blood samples and exercise test.
2972731|NCT02745925|Experimental|normal-weight|normal-weight women
2972732|NCT02745925|Experimental|obesity|obese women
2972733|NCT02745912|Experimental|Metformin + Naltrexone/Bupropion|Metformin (850 mg, immediate release tablet, orally, once on Day 1 and Day 14) naltrexone/bupropion (8/90 mg/mg, extended-release tablets, orally, twice daily from Day 3 through Day 5 and 16/180 mg/mg, twice daily from Day 6 through Day 15.
2972734|NCT02745899|Active Comparator|Soy milk substitute Healthy|Healthy children aged 6-18 will drink 240 ml of soy milk substitute.
2972735|NCT02745899|Active Comparator|Soy milk substitute Asthma|Asthmatic children aged 6-18 will drink 240 ml of soy milk substitute.
2972736|NCT02745899|Experimental|Cow milk Healthy|Healthy children aged 6-18 will drink 240 ml of cow milk.
2972737|NCT02745899|Experimental|Cow milk Asthma|Asthmatic children aged 6-18 will drink 240 ml of cow milk.
2972738|NCT02745886|Experimental|Metformin group|Metformin 0.85 twice daily for 6 months
2972739|NCT02745886|No Intervention|Standard diet group|
2972740|NCT02745886|Other|CR group|Calorie restriction diet will be given to this group.
2972741|NCT02745873|Experimental|Arm A|Ascorbic Acid 250 mg in tablet form was used.
2972742|NCT02745873|Experimental|Arm B|Ascorbic Acid 500 mg in tablet form was used.
2972743|NCT02745860|Experimental|Sequence AB|Subjects receive 200 µg of selexipag (adult formulation) as a single oral dose during Period 1 and 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 2
2972744|NCT02745860|Experimental|Sequence BA|Subjects receive 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 1 and 200 µg of selexipag (adult formulation) as a single oral dose during Period 2
2972745|NCT02745847|Experimental|Re-irradiation with SBRT|Patients with relapsed pancreatic cancer meeting all inclusion criteria will receive re-irradiation with SBRT.
2972746|NCT02745834|Experimental|Chronic Ankle Instability|Soldiers who suffer from chronic ankle instability who had a first major ankle sprain one year or more ago, and did not sustained any major ankle sprain in the last two months, will go through Gait analysis intervention.
2972747|NCT02745834|Experimental|Healthy controls|Healthy soldiers who are not suffering from chronic ankle instability, will go through Gait analysis intervention.
2972748|NCT02745821|Experimental|Coronary physiology|Non-target and target vessels of patients with diabetes mellitus referred for PCI will be assessed for FFR, CFR and IMR. Intravenous adenosine at 140 micrograms/kg/min will be used to induce maximal hyperemia.
2972749|NCT02745808|Experimental|HUC-MSCs|Intracavernous injection of 15 million HUC-MSCs.
2972750|NCT02745808|Experimental|Injectable Collagen Scaffold + HUC-MSCs|Intracavernous injection of injectable collagen scaffold combined with 15 million HUC-MSCs.
2972751|NCT02745795|Experimental|MIG: Motivational Interview Group|Group submitted to three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
2972752|NCT02745795|Sham Comparator|CIG: Conventional Intervention Group|Group submitted to three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
2972753|NCT02745769|Experimental|Ramucirumab + Merestinib|Ramucirumab intravenously (IV) on day 1 and day 15 in combination with merestinib orally once a day over a 28 day cycle. Participants receiving benefit may continue until disease progression.
2972754|NCT02745769|Experimental|Ramucirumab + Abemaciclib|"Ramucirumab IV on day 1 and day 15 in combination with abemaciclib orally twice a day over a 28 day cycle. Participants receiving benefit may continue until disease progression.~On June 21st 2017 the Ramucirumab + Abemaciclib arm was cancelled with no participants enrolled."
2972755|NCT02745756|Experimental|Combined Cell Therapy|Hematopoietic progenitor cell (HPC) transplant (HPCT) with autologous tumor cell lysate and keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine.
2972756|NCT02745743|Experimental|Arm 1|Biomarker-enriched advanced hematological neoplasms
2972757|NCT02745743|Experimental|Arm 2|Other selected advanced hematological neoplasms
2972758|NCT02745730|Active Comparator|Glucose|Shake sweetened with glucose
2972759|NCT02745730|Active Comparator|Fructose|Shake sweetened with fructose
2972760|NCT02745730|Experimental|Sucralose|Shake sweetened with sucralose
2972761|NCT02745730|Experimental|Allulose|Shake sweetened with allulose
2972762|NCT02745717|Experimental|cord blood transfusion group|patients receive the same dose and course of ATG and CSA as the control group and one unit of cord blood having no more than 2 HLA-A,B and DRB1 mismatches is transfused 24h after last dose of ATG administration.
2972763|NCT02745717|Active Comparator|IST group|patient receive standard IST only, which includes ATG 3.5mg/kg/d for 5 days plus oral CSA started from 5mg/kg/d and adjusted to maintain trough serum concentration of 200-300ng/ml
2972764|NCT02745704|Experimental|PEG-IFN group|Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg <1500 IU/ mL and Hepatitis B virus DNA not detectable, are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for 48 weeks.
2972765|NCT02745704|No Intervention|NAs group|Patients do not need to change their NAs treatment.
2972766|NCT02745691||A. Surgery|A.1 Surgery alone and/or before any adjuvant therapy A.2 Surgery (late effects)
2972767|NCT02745691||B. Radiochemotherapy|B.1 Chemotherapy alone B.2 Radiotherapy alone B.3 Sequential radiochemotherapy B.4 Concurrent radiochemotherapy
2972768|NCT02745691||C. Targeted therapy|C.1 Targeted therapy alone C.2 Targeted therapy in combination with any other therapy
2972769|NCT02745691||D. Immunotherapy|Any new immunotherapy for lung cancer
2972770|NCT02745678|Experimental|Thermosensitive gel formulation|Thermosensitive gel rectal formulation.
2972771|NCT02745665||1-Elite Cyclist|"10 symptomatic cyclists with unilateral diagnosis of iliac EF,~FLOW MEDIATED DILATION Ankle brachial pressure index (ABPI) PULSE WAVE VELOCITY AND AUGMENTATION INDEX Blood pressure RAMP Test"
2972772|NCT02745665||2-Amateur Cyclist|"10 asymptomatic cyclists with no evidence of EF~FLOW MEDIATED DILATION ABPI PULSE WAVE VELOCITY AND AUGMENTATION Blood pressure RAMP Test"
2972773|NCT02745665||3-Control|"10 age-matched healthy male group~FLOW MEDIATED DILATION ABPI PULSE WAVE VELOCITY AND AUGMENTATION Blood pressure RAMP Test"
2972774|NCT02745652|Experimental|pulsed electromagnetic field (PEMF)|patients in this group received the pulse electromagnetic field with frequency 50 Hz and intensity 80 gauss for 30 min.The patient was in sitting position, while the forearm was rested on the bed inside the solenoid in supination position
2972775|NCT02745652|Experimental|Therapeutic ultrasound (US)|Pulsed mode US was applied over the volar surface of the forearm (the carpal tunnel area) 15 min per session with a frequency of 1 MHz and intensity of 1.0 W/cm2
2972776|NCT02745639|Experimental|VMAT-SIB + XELOX|"A VMAT-SIB technique was used. Radiation dose prescribed to PTV2 was 45 Gy (1.8 Gy/fraction), five sessions weekly in 25 daily fractions. A simultaneous boost was delivered on PTV1 with a total dose of 57.5 Gy (2.3 Gy/fraction). Dose-volume histograms (DVHs) were calculated for the PTV1, PTV2 and Organs at risks.~The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment."
2972777|NCT02745626|Experimental|Clear Aligner Appliance|Clear Aligners, Align Technology Inc., Santa Clara, California
2972778|NCT02745626|Experimental|Self-ligating Appliance|Carriere Self-Ligating Bracket, Carlsbad, CA
2972779|NCT02745626|Experimental|Conventional bracket appliance|Preadjusted edge wise brackets using elastomeric ties.
2972780|NCT02745613|Experimental|Family history of T2D|The participants will undergo 8 weeks of combined exercise
2972781|NCT02745613|Experimental|No Family history of T2D|The participants will undergo 8 weeks of combined exercise
2972782|NCT02745600|Other|Software assisted RFA treatment|Non-controlled, prospective, multicenter study arm, to evaluate RFA therapy simulation software.
2972783|NCT02745587|Experimental|Prostate(bed) only|external beam radiotherapy limited to the prostate(bed)
2972784|NCT02745587|Active Comparator|Prostate(bed) and pelvis|external beam radiotherapy to the prostate(bed) and pelvic lymph node regions
2972785|NCT02745574|Experimental|Combined maneuver|Combined maneuver: the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity. Then, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm dihydrogen monoxide (H2O). The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
2972786|NCT02745574|Experimental|Intraperitoneal infusion|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity.
2972787|NCT02745574|No Intervention|Control group|CO2 was removed by passive exsufflation through the port site.
2972788|NCT02745561|Experimental|Chemoradiotherapy Arm|Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks. Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy. Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.
2973034|NCT02743871|Experimental|Cohort 8|300 mg of PF-06817024 or placebo
2972789|NCT02745535|Experimental|SOF/VEL/VOX|Fixed dose combination of SOF/VEL/VOX (Sofosbuvir 400mg/Velpatasvir 100mg/ Voxilaprevir 100mg) dosed once daily for 12 weeks.
2972790|NCT02745522|Experimental|Oxytocin|Oxytocin nasal spray
2972791|NCT02745522|Placebo Comparator|Placebo|Placebo nasal spray
2972792|NCT02745509|Experimental|Extensive Intraoperative Peritoneal Lavage|Gastrectomy with D2 lymphadenectomy is performed. The peritoneal cavity of subject will be washed with 10 liters of warmed normal saline (1 liter per cycle for 10 cycles), followed by complete aspiration of the fluid . The abdomen will be closed as per standard.
2972793|NCT02745509|No Intervention|Standard Treatment|Gastrectomy with D2 lymphadenectomy is performed. The peritoneal lavage will be done < 3 cycles with 3 liters or less of warmed normal saline. The abdomen will be closed as per standard.
2972794|NCT02745496|Other|TRUS Biopsy|Standard of Care Treatment
2972795|NCT02745496|Other|TRUS/FUSION Biopsy|Interventional Treatment
2972796|NCT02745483|Experimental|Separable clustered electrodes|Enrolled patients in the prospective study (RFA using separable clustered electrodes (Octopus®)) for treatment-naive HCC (n=79)
2972797|NCT02745483|No Intervention|Historical control group|Patients who received RFA according to routine protocol in our center (multiple internally-cooled electrodes) for treatment-naive HCC from Jan 2011 to July 2013 in our institution (n=74) .
2972798|NCT02745470|Experimental|Lixisenatide injection|intervention : Lyxumia® pen injection 10 microgram (Lixisenatide) subcutaneous injection 30 minutes before functional MRI
2972799|NCT02745470|Placebo Comparator|Normal saline|control : normal saline 0.3 cc subcutaneous injection before functional MRI
2972800|NCT02745444|Other|low-calorie formula diet|Donor taking low-calorie formula diet, 50% of basal energy rate, individually calculated with Mifflin-St. Jeor formula.
2972801|NCT02745444|No Intervention|no diet|Donor ingesting food as usual.
2972802|NCT02745444|Other|protein-restricted diet|Donor taking protein-restricted diet according to diet plans of clinical dietetics of University Hospital of Cologne, with unchanged calorie supply, individually calculated with Mifflin-St. Jeor formula.
2972803|NCT02745444|No Intervention|Normal protein supply|Donor taking same dishes as protein-restricted diet group but with customary protein levels, with unchanged calorie supply.
2972804|NCT02745431|Experimental|Oxytocin nasal spray|Oxytocin nasal spray
2972805|NCT02745431|Placebo Comparator|Placebo nasal spray|Placebo nasal spray
2972806|NCT02745405|Experimental|Fat Suit Condition|Participants are randomly assigned to wear a fat suit and then walk across campus.
2972807|NCT02745405|Other|Control Condition|Participants are randomly assigned to wear the same clothing that is on the fat suit but in their own size and then walk across campus.
2972808|NCT02745392|Experimental|ZP-Zolmitriptan 1 mg|ZP-Zolmitriptan 1 mg patch single administration
2972809|NCT02745392|Experimental|ZP-Zolmitriptan 1.9 mg|ZP-Zolmitriptan 1.9 mg patch single administration
2972810|NCT02745392|Experimental|ZP-Zolmitriptan 3.8 mg|ZP-Zolmitriptan 3.8 mg (1.9 mg x 2 patches) single administration
2972811|NCT02745392|Placebo Comparator|Placebo|Placebo (either single or double patch) single administration
2972812|NCT02745379|Experimental|BFPSC+|The group receives a combination (DFDBA)+buccal fat pad derived stem cells BFPSC and PRF for sinus augmentation
2972813|NCT02745379|Active Comparator|BFPSC-|The group receives a combination of demineralized freeze-dried bone allografts DFDBA (lacking any cells) and PRF for sinus augmentation
2972814|NCT02745366|Experimental|BFPSC+|The combination of BFPSC+FDBA+PRF is utilized in cortical tenting technique with block graft obtained from lateral ramus for posterior mandible augmentation procedure.
2972815|NCT02745366|Active Comparator|BFPSC-|The combination of FDBA+PRF is utilized in cortical tenting technique with block graft obtained from lateral ramus for posterior mandible augmentation procedure
2972816|NCT02745353|Active Comparator|A|Patients in Arm A will receive a single daily dose of 25mg naloxegol for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover treatment period in which the patient will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication.
2972817|NCT02745353|Active Comparator|B|Patients in Arm B will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover period in which the patient will receive a single daily dose of 25mg naloxegol.
2972818|NCT02745340|Active Comparator|Acetate|
2972819|NCT02745340|Experimental|Citrate|
2972820|NCT02745314||>74 years|Older than 74 year-old patients
2972821|NCT02745288|Experimental|Nerve block|This arm will receive inferior alveolar nerve block
2972822|NCT02745288|No Intervention|control|Control arm will not receive inferior alveolar block
2972823|NCT02745275|Experimental|Peer-led Health Education|A single 60 minute interactive workshop led by the trained health coach followed by a series of three one hour discussion groups
2972824|NCT02745275|No Intervention|Control|No intervention
2972825|NCT02745262||Controlled ovarian stimulation|No drugs are administered. It is an observational study. Collect retrospectively the follow-up data
2972826|NCT02745262||Non Controlled ovarian stimulation|No drugs are administered. It is an observational study. Collect retrospectively the follow-up data
2972827|NCT02745249|Experimental|A&T- intensive|A&T-intensive arm receive standard MNCH services and intensified maternal nutrition behavior change intervention which focus on improving dietary practices, specifically improved diversity of foods and energy intakes of pregnant women, and improved intake of calcium and iron/folic acid (IFA) supplements.
2972828|NCT02745249|No Intervention|A&T-non intensive|A&T-non intensive aim only receive MNCH services
2972829|NCT02745236|Experimental|Nurse Practitioner Led-Care|"Nurse Practitioner (NP) Intervention Initial Visit and Interventions: An experienced nurse practitioner with extra atrial fibrillation (AF) management training will complete the initial assessment to determine a treatment plan based on current AF Guidelines. The NP will provide patient education on AF management.~Follow-up: Follow-up will occur at 3 and 6 months from baseline to evaluate the patient's response to treatment and will be modified as required based on AF symptoms, testing results and physical assessment.~A physician will be consulted for advanced specialty AF management or if a patient requires admission to hospital."
2973035|NCT02743871|Experimental|Cohort 9|IV dose to be determined of PF-06817024 or placebo
2972830|NCT02745236|Active Comparator|Cardiologist Led-Care|"Standard Care Initial Visit and Intervention: A general cardiologist will manage patients as per their usual practice.~Follow-up: As per the cardiologist's usual practice. The patient's care will remain with the family physician if no follow-up is required.~Follow-up: Follow-up will be determined as per the cardiologist's usual practice. If a follow-up appointment is required it will done in the cardiologist's own independent clinic. The patient's care will be referred back to the family physician if no follow-up is required."
2972831|NCT02745223|Experimental|PresbiDrops (CSF-1)|Participants self-administered PresbiDrops (CSF-1), 1 drop in each eye each morning for 2 weeks.
2972832|NCT02745223|Placebo Comparator|Placebo|Participants self-administered placebo, 1 drop in each eye each morning for 2 weeks.
2972833|NCT02745210|Experimental|Experimental|Magnetic resonance (MR) spectroscopy study.
2972834|NCT02745197|Experimental|Nutritional Supplement|2 nutritional supplement capsules, taken by mouth 3 times per day, for approximately 10 to 15 weeks.
2972835|NCT02745197|Placebo Comparator|Placebo|2 placebo capsules, taken by mouth 3 times per day, for approximately 10 to 15 weeks.
2972836|NCT02745184|Experimental|lung stem cells|Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
2972837|NCT02745171|No Intervention|Control group|This group will be evaluated after three months there will be a reassessment, in this case the participating subjects do not perform any kind of therapy.
2972838|NCT02745171|Experimental|Experimental group|There will be an initial evaluation, after a month of physical therapy at the end of the protocol, and twice more after the protocol, both interval a month.
2972839|NCT02745158||FOP Patients|
2972840|NCT02745145|Experimental|Abituzumab 1500 milligram (mg)|
2972841|NCT02745145|Experimental|Abituzumab 500 mg|
2972842|NCT02745145|Placebo Comparator|Placebo|
2972843|NCT02745132|Other|Cognitive evaluation in HCV patients|"Neuropsychological evaluation and Brain MRI~Intervention: The only intervention to be carried out along the study will consist of complete neuro-psychological tests and MRI studies performed at different times.~Chronic HCV patients who are going to be treated with new DAAs according to current guidelines will be studied: A neuro-psychological battery of tests and brain MRI studies will be performed at different times before and after the end of the treatment. The participation in the study will not influence neither the indication to treat nor the treatment used.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines"
2972844|NCT02745119|Experimental|Lampalizumab Every 4 Weeks|Participants who received either lampalizumab or sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit will receive open-label lampalizumab as 10 milligrams (mg) via ITV injection, administered every 4 weeks.
2972845|NCT02745119|Experimental|Lampalizumab Every 6 Weeks|Participants who received either lampalizumab or sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit will receive open-label lampalizumab as 10 mg via ITV injection, administered every 6 weeks.
2972846|NCT02745106|Experimental|PADN treatment|"Procedure/Surgery: Right heart catheterization, Radiofrequency pulmonary artery denervation using following devices:~Ablation catheter~Carto 3, Carto RMT, Stereotaxis~Swan-Ganz catheter"
2972847|NCT02745106|Sham Comparator|Control (Sham)|"Procedure: Right heart catheterization~Using following device:~- Swan-Ganz catheter"
2972848|NCT02745093|Experimental|64-84 days gestational age|Women whose pregnancies are estimated to have a gestational age of 64-84 days will receive 200 µg mifepristone followed by misoprostol 24-48 hours later.
2972849|NCT02745093|No Intervention|57-63 days gestational age|Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range: 200 µg mifepristone administered orally in the clinic on Day 1 then 800 μg misoprostol administered sublingually 24-48 hours later at home with a subsequent dose of 400 μg misoprostol sublingually 6 hours later if she has not expelled the pregnancy).
2972850|NCT02745080|Experimental|Secukinumab 300 mg s.c.|Secukinumab 300 mg will be administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 48.
2972851|NCT02745080|Active Comparator|Adalimumab 40 mg s.c.|Adalimumab 40 mg will be administered at Baseline followed by dosing every 2 weeks until Week 50.
2972852|NCT02745067|Other|Enhanced cognitive behavioral therapy|Enhanced cognitive behavioral therapy (CBT-E) for eating disorders
2972853|NCT02745041|Experimental|Fibrinogen Concentrate|Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm [FIBTEM ≤ A5 10mm]
2972854|NCT02745041|Active Comparator|Cryoprecipitate|Fibrinogen replacement using Cryoprecipitate as per ROTEM guided treatment algorithm [FIBTEM A5 ≤ 10mm]
2972855|NCT02745028|Other|With monosodium glutamate|Results of one time gastric emptying study with a single dose of monosodium glutamate; 1 g for weight greater than 45 kg, 700mg between 35 and 44,900 kg, 600mg between 25 and 34,900, 500mg between 15 and 25 kg and 250mg in less than 15 kg
2972856|NCT02745015|Experimental|treatment|immediate non-surgical periodontal treatment
2972857|NCT02745015|Other|control|non-surgical periodontal treatment scheduled for the following 3-monthly visit
2972858|NCT02745002|Experimental|navigated bronchoscopy|
2972859|NCT02744989|Experimental|Active tDCS|Stimulation will be performed using an tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl). The anode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex, assumed to correspond to a region including Brodmann's Areas (BA) 8, 9, 10, and 46, depending on the patient). The cathode will be located over a point midway between T3 and P3 (left temporo-parietal junction, assumed to correspond to a region including BA 22, 39, 40, 41, and 42, depending on the patient). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day for 5 consecutive weekdays. The twice daily sessions will be separated by at least 2 hours.
2972860|NCT02744989|Sham Comparator|Sham tDCS|
2972861|NCT02744976|Experimental|Prediabetes, metformin|Patients with HbA1c 5.7-6.4 receiving metformin and lifestyle recommendations
2972862|NCT02744976|Active Comparator|Prediabetes, lifestyle|Patients with HbA1c 5.7-6.4 receiving lifestyle recommendations
2972863|NCT02744976|No Intervention|No prediabetes|Patients with HbA1c <5.7
2972864|NCT02744963|Experimental|Free and convenient medicine access|Free access to a list of essential medicines. Medicines are either mailed to the patient or dispensed at the point of care.
2972865|NCT02744963|No Intervention|Usual medicine access|Usual access to medicines.
2972866|NCT02744950|Active Comparator|Intermediate/complex repair|This arm will have closures of scalp defects with deep and superficial suture placement.
2972867|NCT02744950|Experimental|Pulley stitches|This arm of the study will have only pulley stitches to close the entire defect.
2972868|NCT02744937|Experimental|A|continuing LDA
2972869|NCT02744937|No Intervention|B|discontinuing LDA
2972870|NCT02744924|Experimental|Physical activity intervention|Participants undergo the community-based physical activity promotion (see Intervention)
2972871|NCT02744911|Experimental|Telemedicine group|People with Parkinson's disease and their caregivers obtaining treatment using the SpeechVive device via the internet using the telemedicine application. Also includes speech-language pathologists providing treatment via the telemedicine application.
2972872|NCT02744911|Active Comparator|In person group|People with Parkinson's disease and their caregivers obtaining treatment using the SpeechVive device in person. Also includes speech-language pathologists providing treatment in person.
2972873|NCT02744898|Experimental|Carboplatin AUC and Abraxane 100mg/m2|
2972874|NCT02744885|Experimental|Crave Crush|Crave Crush is a plant-based tablet that alters taste perception by affecting sweet taste receptors on the tongue.
2972875|NCT02744885|Placebo Comparator|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
2972876|NCT02744872|Active Comparator|Felodipine|Tablet Felodipin 10 mg x 1 daily
2972877|NCT02744872|Placebo Comparator|Placebo|Identical placebo once daily
2972878|NCT02744859|Experimental|Calorie Label|"Labels will read [lower calorie bound] - [upper calorie bound] calories per container. 2,000 calories a day is used for general nutrition advice but calorie needs vary."
2972879|NCT02744859|Experimental|Warning Label|"Labels will read WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay."
2972880|NCT02744859|Experimental|Warning Label with Graphics|"Labels will read WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay. These labels will also have graphic depictions of each health condition above the corresponding text."
2972881|NCT02744859|No Intervention|No label|We will also have a condition where no labels are presented-- business as usual.
2972882|NCT02744846||Children from birth to 5 years|"Children from birth to 5 years where:~1 or more encounters with length and weight measured in the following age interval: 0-12 m, 12-30 m, and~> 1 encounter with height and weight measured in either or both of the following age intervals: 4.0 to 5.9 y (age 5 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data"
2972883|NCT02744846||Children from birth to 10 years|"Children from birth to 10 years where:~1 or more encounters with length and weight measured in each of the following age intervals: 0-12 m, 12-30 m, and~> 1 encounter with height and weight measured in the following age interval: 9.0 to 10.9 y (age 10 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data."
2972884|NCT02744833|Experimental|GMI-1271|
2972885|NCT02744833|Active Comparator|Enoxaparin Sodium (Lovenox®)|
2972886|NCT02744820|Placebo Comparator|Cohort 1 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Salt Other: Placebo"
2972887|NCT02744820|Placebo Comparator|Cohort 2 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Salt Other: Placebo"
2972888|NCT02744820|Placebo Comparator|Cohort 3 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Salt Other: Placebo"
2972889|NCT02744820|Placebo Comparator|Cohort 4 (Part 2)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Salt Other: Placebo"
2972890|NCT02744807||non-Chronic endometritis|patients with intrauterine adhesion only
2972891|NCT02744807||Chronic endometritis|patients with intrauterine adhesion as well as Chronic endometritis
2972892|NCT02744794|Experimental|Treatment with cryotherapy|Treatment with dermal cooling system.
2972893|NCT02744781|Experimental|Lumbar disc degeneration; LDD|The LDD group included subjects with at least 1 abnormal disc from L1-2 to L5-S1 of grade III, IV, or V. The non-LDD group included subjects with 5 normal discs of grade I or II. For further assessment, the most damaged disc of the 5 constituted the highest grade of LDD.
2972894|NCT02744768|Experimental|Treatment|"Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84. Prednisone (PDN) will be administered from day -6 to day +0 (during which the presence of the BCR/ABL1 alteration will be established), at escalating doses up to 60 mg/m2; PDN will be continued up to day +24 and progressively tapered up to day +31.~HLA typing will be performed immediately after the diagnosis for eligible patients.~MRD will be evaluated by RT-PCR at fixed time points (days +22, +45, +57) during the induction and at day +85, the latter for molecular response evaluation."
2972895|NCT02744755|Experimental|GP2017|Group 1 will receive treatment with 40mg GP2017 (Adalimumab - GP2017) by subcutaneous injection every other week up to 24 weeks (Study Period 1) at which patients achieving at least a moderate clinical response continue treatment with 40mg GP2017 subcutaneous injection every other week up to 48 weeks (Study Period 2).
2972896|NCT02744755|Active Comparator|US Licensed Humira|Group 2 will receive treatment with 40mg Humira® (Adalimumab - US licensed Humira®) by subcutaneous injection every other week up to 24 weeks (Study Period 1) at which patients achieving at least a moderate clinical response will be switched to treatment with 40mg GP2017 subcutaneous injection every other week up to 48 weeks (Study Period 2).
2972897|NCT02744742|Experimental|G-CSF + Decitabine + BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，Granulocyte Colony-Stimulating Factor(G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5-10ug/kg/day on days -17 and -10 (when white blood cell is more than 20G/L, stop using G-CSF)；Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
2973036|NCT02743871|Experimental|Cohort 10|PF-06817024 or placebo
2973037|NCT02743871|Experimental|Cohort 11|PF-06817024 or placebo
2972898|NCT02744742|Active Comparator|BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
2972899|NCT02744729|Experimental|Esophagus Cancer, 99mTc-3PRGD2, SPECT/CT|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis of Esophagus cancer patients.
2972900|NCT02744716|Experimental|non-balloon group|with aspirin
2972901|NCT02744716|Experimental|balloon group|with aspirin and intrauterine balloon
2972902|NCT02744716|No Intervention|control group|without aspirin and intrauterine balloon
2972903|NCT02744703|Active Comparator|self-etch adhesive|application of self-etch adhesive on cavities.
2972904|NCT02744703|Experimental|CAPE-S|CAPE before self-etch adhesive
2972905|NCT02744703|Active Comparator|total-etch adhesive|total-etch adhesive on cavities.
2972906|NCT02744703|Experimental|CAPE-T|CAPE before total-etch adhesive application
2972907|NCT02744690|Experimental|MMC Injection|Intervention: At the intended surgical site and about 6mm from the limbus, 0.2ml of 0.2mg/ml of mitomycin-C (MMC) will be injected subconjunctivally before peritomy
2972908|NCT02744690|Active Comparator|MMC Sponge Application|Intervention: After peritomy, three half-sponges soaked in 0.2mg/ml mitomycin-C (MMC) will be placed posterior to the area of intended filtration. After 2 minutes, the sponges will be removed
2972909|NCT02744677|Experimental|TPVI|Transcatheter Pulmonary Valve Implantation with the SAPIEN 3 THV
2972910|NCT02744664|Experimental|Experimental|The subject receive Cryotherapy and than receive Icotinib 125mg, 3 times a day, orally administered until disease progression or intolerable toxicity reaction.
2972911|NCT02744651|Active Comparator|EUS-FNA|All patients with a confirmed suspicion of a submucosal tumor in the upper GI tract will be included in this study. A senior endoscopist will perform multiple passes of EUS-FNA until she/he has collected enough material for the pathologist to establish a possible diagnosis.
2972912|NCT02744651|Active Comparator|EUS-Endodrill biopsy|All patients who are included in the study will also be examined by a senior endoscopist performing multiple EUS guided passes with the Endodrill biopsy. The harvested tissue from the tumor will be examined by a pathologist in order to establish a diagnosis.
2972913|NCT02744638|Experimental|probiotic yoghurt & Arilin|probiotic yoghurt, 2 units (125 g), containing living strains of L.crispatus, L.gasseri, L.rhamnosus, L.jensenii, each in a concentration of 1 x 107 CFU/ml product for 4 weeks Two yoghurts are consumed every day for 28 days. 2 tablets Metronidazol 500mg daily for 7 days
2972914|NCT02744638|Placebo Comparator|chemically acidified milk & Arilin|chemically (H3PO4) acidified milk (125g) without bacterial strains. Two products are consumed every day for 28 days. 2 tablets Metronidazol 500mg daily for 7 days
2972915|NCT02744625|Active Comparator|Shock lower Mean Arterial Pressure (MAP)|Vasopressor-dependent treated to lower MAP (65 mmHg)
2972916|NCT02744625|Experimental|Shock higher MAP|Vasopressor-dependent treated to higher MAP (75 mmHg)
2972917|NCT02744625|No Intervention|Healthy participant awake|Healthy participant awake
2972918|NCT02744625|Experimental|Healthy participant sedated|Healthy participant Under light sedation
2972919|NCT02744612|Experimental|Treatment (Ibrutinib plus Brentuximab Vedotin)|
2972920|NCT02744599|Experimental|Device prompting|
2972921|NCT02744599|No Intervention|Control|Patients receive standard of care
2972922|NCT02744586|Experimental|Strengthening our Vows (SOV) Group|"Participants in the SOV arm will participate in the Together HIV Free and Protecting My Spouse plans."
2972923|NCT02744586|Placebo Comparator|Good Health Package Plus (GHPP) Group|Participants in the GHPP arm will receive education on the prevention of helminths, schistosomiasis, hypertension, diabetes, and diarrheal diseases through participatory and interactive group sessions.
2972924|NCT02744573||General Anaesthesia|ANI and SPI values under general anaesthesia
2972925|NCT02744573||Spinal Anaesthesia|ANI and SPI values under spinal anaesthesia
2972926|NCT02744573||Spinal Anaesthesia + Sedation|ANI and SPI values under spinal anesthesia in combination with sedation
2972927|NCT02744573||Control|ANI and SPI values under no anaesthesia
2972928|NCT02744560|Experimental|patients|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
2972929|NCT02744547|Experimental|thalassemic children with hepatitis C|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
2972930|NCT02744547|No Intervention|thalassemic children without hepatitis C|30 multitransfused beta thalassemic children without hepatitis C virus infection
2972931|NCT02744534|Experimental|Abnormalities found with FACBC PET-CT|All participants with suspected recurrence of prostate cancer will have the FACBC PET-CT scan performed. Participants with abnormal FACBC PET-CT scan results will have a PET/ultrasound fusion targeted prostate biopsy followed a standard of care prostate biopsy.
2972932|NCT02744534|Active Comparator|No abnormalities found with FACBC PET-CT|All participants with suspected recurrence of prostate cancer will have the FACBC PET-CT scan performed. Participants without abnormal FACBC PET-CT scan results will have a standard of care prostate biopsy.
2972933|NCT02744521|Experimental|Symptom based screening intervention|
2972934|NCT02744521|No Intervention|control|
2972935|NCT02744508|Active Comparator|P group|Palonosetron group
2972936|NCT02744508|Experimental|PD group|Palonosetron and dexamethasone group
2972937|NCT02744495|Experimental|postoperative nausea and vomiting risk factors|Preoperative collection of postoperative nausea and vomiting risk factors available for practicians.
2972938|NCT02744495|No Intervention|control|No prophylaxis whatever risk score is. Postoperative nausea and vomiting risk factors not available for practicians.
2972939|NCT02744482|Experimental|Risedronate|Patients take an oral tablet of Risedronate 75 mg, 2 consecutive days per month during 18 months.
2972940|NCT02744482|Placebo Comparator|Placebo|Patients take an oral tablet of Placebo, 2 consecutive days per month during 18 months.
2973038|NCT02743871|Experimental|Cohort 12|PF-06817024 or placebo
2973039|NCT02743871|Experimental|Cohort 13|PF-06817024 or placebo
2972941|NCT02744469||New patients|''New tuberculosis patients'' are patients just diagnosed for tuberculosis, and who were never treated for tuberculosis or who are treated for less than 1 month. In total, 1192 new patients will be recruited.
2972942|NCT02744469||Retreatment patients|''Retreatment tuberculosis patients'' are patients just diagnosed for tuberculosis and who were previously treated for tuberculosis (for a duration of 1 month at least). This group includes: patients with treatment relapse, failure and patients who return after default. In total, 298 retreatment patients will be recruited.
2972943|NCT02744456|Other|N-of-1 trial|Patients with hypertension who are taking none or one BP medication will be will be provided with prescriptions for up to 3 BP medications representative of different BP medication classes (i.e., losartan, an angiotensin system blocking agent; amlodipine, a calcium channel blocker; and hydrochlorothiazide, a thiazide diuretic). Patients will be asked to take each medication for 2 weeks at a low dose, 2 weeks at a medium dose, and then 2 weeks at a high dose; provide health information and identify which medication they prefer to remain on following the N-of-1 trial (i.e., for long-term use).
2972944|NCT02744443|Experimental|Leucine|Leucine supplementation (10 g/d)
2972945|NCT02744443|Placebo Comparator|Placebo|Placebo supplementation (alanine, 10 g/d)
2972946|NCT02744430|Active Comparator|Arm 1 - Active|Mirabegron 50 mg orally once every 24 hours starting immediately
2972947|NCT02744430|Placebo Comparator|Arm 2 - Placebo|Placebo orally once every 24 hours starting immediately
2972948|NCT02744417|Experimental|Smoking cessation therapy|Non-surgical periodontal therapy and concurrent smoking cessation therapy, with Smoking cessation counseling, Nicotine replacement therapy, use of bupropion hydrochloride and varenicline
2972949|NCT02744404||POC EID|Point of Care Early Infant Diagnosis qualitative technologies (Alere q) will be implemented. Sample collection and testing will happen in the same location within the health care facility.
2972950|NCT02744404||Laboratory-based testing|Conventional laboratory-based testing using the Abbott m2000 technology will continue to be used per standard of care in Malawi. Dried blood spot samples will be collected at health care facilities and transported within the national network to centralized laboratories for testing.
2972951|NCT02744391|Experimental|L-DOPA|Patients will receive titration of L-DOPA from 150 mg to 450 mg.
2972952|NCT02744378|Active Comparator|Clobetasol Group|clobetasol propionate (0.05%) cream
2972953|NCT02744378|Active Comparator|Tacrolimus Group|tacrolimus (0.1%) cream
2972954|NCT02744365||Prediction Group|The women recruited in the biobank through the Prediction Study (NCT02189148) are low-risk pregnant women between 11 and 13 6/7 weeks of gestation (N=7600 maximum).
2972955|NCT02744365||PEARL Group|"The women recruited in the biobank through the PEARL Study (NCT02379832) are :~low-risk pregnant women between 11 and 13 6/7 weeks of gestation (controls, N=45)~pregnant women with diagnosis of preeclampsia between 20 and 41 6/7 weeks of gestation (cases, N=45)"
2972956|NCT02744365||GAP Group|The women recruited in the biobank through the GAP Trial (NCT02280031) are women pregnant with twins between 11 3/7 and 13 6/7 weeks of gestation(N=50 maximum) randomized for placebo or aspirin.
2972957|NCT02744365||PREDICTION 2 Group|The women recruited in the biobank through the Prediction-2 Study (NCT03067298) are nulliparous pregnant women between 14 and 15 6/7 weeks of gestation (N=1000 maximum).
2972958|NCT02744365||HAUPE Study|Women that are at risk of pre-eclampsia and great obstetrical syndroms (elevated maternal age, invitro fertilization, chronic disease) (N=60) and a control group not at risk (N=60)
2972959|NCT02744352|Active Comparator|continuous IBP block|Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain
2972960|NCT02744352|Active Comparator|single shot IBP block|Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
2972961|NCT02744339|Experimental|Riociguat|Riociguat up-titrated to a maximum of 1.5mg TID
2972962|NCT02744339|Placebo Comparator|Placebo|Placebo sham-titrated TID
2972963|NCT02744326|Experimental|Text message reminder group|A subset of patients discharged from the ED with an outpatient referral will be randomized to receive text message reminders to attend or schedule a follow-up outpatient referral.
2972964|NCT02744326|No Intervention|Usual Care group|A subset of patients discharged from the ED with an outpatient referral will be randomized to receive the usual standard of care.
2972965|NCT02744313||AP Naive|Group followed over 12 weeks to measure fat deposition, insulin resistance, and glucose tolerance.
2972966|NCT02744300|Experimental|BABI-2 Lifestyle Intervention|Participants in this group will take part in the web-based lifestyle intervention which includes access to the lifestyle intervention website and personalized coaching from a Lifestyle Coach.
2972967|NCT02744300|No Intervention|Post-GDM Follow-up Group|Participants in this group will have access to a separate website containing links to information about diabetes prevention.
2972968|NCT02744287|Experimental|BPX-601 and Rimiducid (AP1903)|PSCA specific CAR modified autologous T cells and dimerizer agent which stimulates CAR
2972969|NCT02744274|Experimental|Verum acupuncture|16 patients will be randomized to receive verum acupuncture two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
2972970|NCT02744274|Placebo Comparator|Sham acupuncture|16 patients will be randomized to receive sham acupuncture two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
2972971|NCT02744248|Active Comparator|IOP Injection|Participants will receive 1 injection of the IOP at Days 1,once time.
2972972|NCT02744248|Placebo Comparator|0.9% normal saline|Participants will receive 1 injection of 0.9% normal saline at Days 1,once time.
2972973|NCT02744235|Other|Patients undergoing Polysomnography|
2972974|NCT02744222|Experimental|BCD-054, 180 mcg, biweekly|Patients of Groups 1 will receive blinded BCD-054 180 mcg intramuscularly once every two weeks for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive). Between every two injections of the active drug, once every 2 weeks, patients will receive intramuscular injections of placebo.From Week 53 until Week 100, patients of Groups 1 will receive open-label BCD-054 180 mcg or 240 mcg intramuscularly once every 2 weeks
2973135|NCT02743182|No Intervention|Control|HBeAg-negative patients receiving nucleos(t)ide analogues
2972975|NCT02744222|Experimental|BCD-054, 240 mcg, biweekly|Patients of Groups 2 will receive blinded BCD-054 240 mcg intramuscularly once every two weeks for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive). Between every two injections of the active drug, once every 2 weeks, patients will receive intramuscular injections of placebo.From Week 53 until Week 100, patients of Groups 2 will receive open-label BCD-054 180 mcg or 240 mcg intramuscularly once every 2 weeks
2972976|NCT02744222|Active Comparator|Avonex®, 30 mcg, weekly|Patients of Group 3 (reference group) will receive blinded Avonex® 30 mcgintramuscularly once a week for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive).
2972977|NCT02744222|Placebo Comparator|Placebo, 0,5 ml, weekly|Patients of Group 4 (placebo) will receive blinded placebo once a week for the first 20 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive)
2972978|NCT02744196|Experimental|Acellbia + methotrexate|"106 patients of this group will receive methotrexate in combination with a drug Acellbia to be used at a dose of 600 mg as a slow intravenous infusion carried out on day 1 and day 15.~If a follow-up examination at 24 weeks or later (up to 48 weeks) reveals that the patient still has active arthritis (evaluation index DAS28-4 (ESR)> 2,6 points), the therapy with Acellbia is repeated by the same scheme - 2 infusion at a dose of 600 mg at intervals of 14 days."
2972979|NCT02744196|Placebo Comparator|Placebo + methotrexate|"53 patients of this group will receive methotrexate in combination with a placebo to be used as a slow intravenous infusion carried out on day 1 and day 15.~If a follow-up examination at 24 weeks or later (up to 48 weeks) reveals that the patient still has active arthritis (evaluation index DAS28-4 (ESR)> 2,6 points), the patient receives open therapy with Acellbia is initiated: 2 infusion at a dose of 600 mg at intervals of 14 days."
2972980|NCT02744183|Active Comparator|Control Group|Maintain habitual habits
2972981|NCT02744183|Active Comparator|Fed Exercise|6 weeks of moderate intensity exercise with breakfast consumption
2972982|NCT02744183|Experimental|Fasted Exercise|6 weeks of moderate intensity exercise with breakfast omission
2972983|NCT02744170|Experimental|COPD patients with delivery order 1, 2, 3|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
2972984|NCT02744170|Experimental|COPD patients with delivery order 2,3, 1|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
2972985|NCT02744170|Experimental|COPD patients with delivery order 3, 2, 1|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
2972986|NCT02744170|Experimental|COPD patients with delivery order 1, 3, 2|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
2972987|NCT02744170|Experimental|COPD patients with delivery order 2, 1, 3|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
2972988|NCT02744170|Experimental|COPD patients with delivery order 3, 1, 2|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
2972989|NCT02744157|Other|structured lifestyle program|The program consisted of an individual visit to a nurse for a health check-up and lifestyle counseling at baseline, six month and one year. The program also consisted of five group educations which included lectures on nicotine, alcohol, physical inactivity, eating habits, stress, sleeping habits and behavior changes
2972990|NCT02744144||Non-infection|Patients without clinical infection or positive wound culture
2972991|NCT02744144||Infection|Patients with clinical infection and positive wound culture
2972992|NCT02744131|Active Comparator|OCP|Arm 1: oral contraceptive pill, combination pill of ethyl estradiol 20 micro gram with Cyproterone acetate.
2972993|NCT02744131|Active Comparator|Metformin|Arm 2: Metformin . Oral insulin sensitising drug in the dose of 1500gms daily.
2972994|NCT02744118|Experimental|Marijuana Screening and Brief Counseling|The marijuana screening and brief counseling intervention will be developed based on a tested adolescent tobacco cessation intervention and the Public Health Service 5As model. The proposed intervention will be adapted using current literature, input from content experts, and qualitative data gathered using focus groups.
2972995|NCT02744118|Active Comparator|Healthy Internet Use Model|The media screening and brief counseling intervention is based on a media use screening and brief counseling intervention tested as the active comparator for a 5As tobacco cessation randomized control trial (NCT01312480) and the 2010 American Academy of Pediatrics policy statement on children and media.
2972996|NCT02744105|Experimental|thalassemic children with hepatitis C|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
2972997|NCT02744105|No Intervention|thalassemic children without hepatitis C|30 multitransfused beta thalassemic children without hepatitis C virus infection
2972998|NCT02744092|Experimental|Randomized Arm 1|Randomized Arm 1 will get anticoagulation therapy with a Direct Oral AntiCoagulant (DOAC). There are four FDA-approved DOAC drugs that may be used for this study: Rivaroxaban, Apixaban, Edoxaban, or Dabigatran. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.
2972999|NCT02744092|Active Comparator|Randomized Arm 2|Randomized Arm 2 will get anticoagulation therapy with low molecular weight heparin (LMWH) with or without a transition to warfarin. There are three FDA-approved LMWH drugs that may be used for this study: Dalteparin, Enoxaparin, or Fondaparinux. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.
2973064|NCT02743650|Experimental|Sodium Bicarbonate|"All participants will receive oral sodium bicarbonate for 6 weeks (On-treatment period). After the 6 week visit, participants will stop taking sodium bicarbonate and return for a final visit 4 weeks later (Off-treatment period).~The initial dose of sodium bicarbonate prescribed is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d. Half the dose will be taken by mouth in the morning and the other half in the evening."
2973000|NCT02744092|Experimental|Preference Cohort|"If an eligible participant is offered randomization and declines randomization, then a limited number of participants (up to N=190) will be allowed to enroll in the Preference Cohort. In this case, the treating physician and patient choose Arm 1 or Arm 2 (non-randomized).~Preference cohort: Non-randomized Arm 1 will get anticoagulation therapy with a Direct Oral AntiCoagulant (DOAC).~Preference cohort: Non-randomized Arm 2 will get anticoagulation therapy with low molecular weight heparin (LMWH) with or without a transition to warfarin."
2973001|NCT02744079|Active Comparator|Low carbohydrate diet|45 subjects will receive a very low carbohydrate diet between a positive breast biopsy and surgical tumor removal
2973002|NCT02744079|Active Comparator|Low fat diet|20 subjects will receive a lo fat diet between a positive breast biopsy and surgical tumor removal
2973003|NCT02744066|Other|Neonates|Neonates admitted to the NICU will be fitted for NEATCAP, non-invasive novel hearing protection device.
2973004|NCT02744053|Experimental|Multimodality Breast Imaging|Participants receive Tc99m Sestamibi Molecular Breast Imaging (MBI), and Dynamic Contrast Enhanced Molecular Resonance Imaging (DCE-MRI) before they start anthracycline therapy, when they finish receiving anthracycline therapy, and when they finish receiving neoadjuvant therapy.
2973005|NCT02744040|Other|Early ART initiation|Immediate ART initiation at the time of HIV diagnosis; daily dose of combination ART (one pill/day)
2973006|NCT02744040|Other|Deferred ART initiation|ART initiation at 24 weeks after HIV diagnosis; daily dose of combination ART (one pill/day)
2973007|NCT02744027|Other|Dynamic Contrast Enhanced Magnetic Contrast Imaging|Dynamic Contrast Enhanced Magnetic Resonance (MR) Lymphangiogram and heavy T2 Magnetic Resonance imaging data will be evaluated for abnormal lymphatic perfusion of the lung parenchyma. Abdominal and thoracic lymphatic malformations will be characterized by location, number, size, relationship to other organs and perfusion patterns in order to create a basis of imaging classification of lymphatic abnormalities (LA). Subjects will undergo both Dynamic Contrast Enhanced Magnetic Resonance Lymphangiogram (DCMRL) and Heavy Weighted T2 Imaging.
2973008|NCT02744014|Experimental|Early intervention group|The program starts with a 30-days training course led by course instructor Wim Hof and supervised by the research team. The mindset & physical therapy based on the Wim Hof Method includes breathing techniques, training of mindset and concentration, and gradual cold exposure.
2973009|NCT02744014|Other|Late intervention group|This group will receive the same training with a delay of 60-90 days, serving initially as control.
2973010|NCT02744001|Experimental|Low Added Sugar Diet|Menu containing <10% of total daily energy intake from added sugars.
2973011|NCT02743988|Experimental|Low target range|Low oxygen saturation target range: SpO2 85-89%
2973012|NCT02743988|Active Comparator|High target range|High oxygen saturation target range: SpO2 91-95%
2973013|NCT02743975|Experimental|Treatment group|Bevacizumab-800CW
2973014|NCT02743962|Active Comparator|Usual physiotherapy treatment group|This group will receive standard specialist physiotherapy intervention for bladder pain syndrome: dietary advice regarding fluid and fibre intake, advice regarding bladder retraining and 15 minutes manual intra-vaginal pelvic floor muscle myofascial release and gentle stretching each week for 6 weeks. They will be instructed to briefly contract and then fully relax their pelvic floor muscles independently (clothed, in a seated or lying position) for 5 minutes daily.
2973015|NCT02743962|Experimental|Therapeutic Wand group|This group will receive the standard specialist physiotherapy intervention for bladder pain syndrome for 6 weeks, but will also be provided with an intra-vaginal therapeutic wand and taught how to use it. They will then be asked to use the therapeutic wand at home twice a week to release and relax their pelvic floor muscles for 5 minutes.
2973016|NCT02743949|Experimental|Vonoprazan 20 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 20 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the treatment period.
2973017|NCT02743949|Experimental|Vonoprazan 40 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 40 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the active treatment period.
2973018|NCT02743949|Active Comparator|Esomeprazole 40 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by esomeprazole 40 mg, over-encapsulated tablets, orally, once daily for 4 weeks during the active treatment period.
2973019|NCT02743936|Experimental|NIPPV with nasal cannula|Non-invasive positive pressure ventilation with nasal cannula in place
2973020|NCT02743936|Active Comparator|NIPPV without nasal cannula|Non-invasive positive pressure ventilation without nasal cannula
2973021|NCT02743923|Active Comparator|carboplatin-paclitaxel- bevacizumab|carboplatin AUC 6, paclitaxel 200 mg/m2, bevacizumab 15 mg/kg all administered intravenously on day 1 every 3 weeks for 4-6 cycles, followed by bevacizumab maintenance every 3 weeks until progression
2973022|NCT02743923|Active Comparator|cisplatin-pemetrexed|pemetrexed 500 mg/m2 administered intravenously on day 1 and cisplatin 75 mg/m2 administered intravenously on day 1 every 3 weeks for 4-6 cycles, followed by maintenance pemetrexed every 3 weeks until progression.
2973023|NCT02743910||Stage II-III breast cancer|Up to 229 newly diagnosed stage II-III invasive HER2-positive or triple-negative breast cancer patients planning neoadjuvant therapy (NAT) will be enrolled. ptDNA blood samples as well as a representative tumor tissue sample from both the diagnostic and surgical procedure (if available) will be collected.
2973024|NCT02743897|Experimental|Zepatier (grazoprevir 100mg and elbasvir 50 mg) once daily|Zepatier is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
2973025|NCT02743884|Experimental|Esophageal Cooling Device|Esophageal cooling
2973026|NCT02743884|Experimental|Esophageal Warming|Esophageal warming
2973027|NCT02743871|Experimental|Cohort 1|10 mg of PF-06817024 or placebo
2973028|NCT02743871|Experimental|Cohort 2|30 mg of PF-06817024 or placebo
2973029|NCT02743871|Experimental|Cohort 3|100 mg of PF-06817024 or placebo
2973030|NCT02743871|Experimental|Cohort 4|300 mg of PF-06817024 or placebo
2973040|NCT02743858||Breast Cancer-Related Lymphedema|Bilateral arm measurements will be obtained using the Perometer (Model 350 NT Perometer, Per-System) circumferential arm measurements with elastic tape taken at 4-cm intervals from the wrist to the shoulder and the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements. Measurements will be performed at baseline (prior to surgery), post-operatively (after surgery) and at scheduled timepoints of 6 months, 12 months, 18 months, and 24 months after surgery for a total of 2 years. For a patient who is diagnosed with lymphedema at ≥ 13 months after surgery, surveillance will continue for an additional 12 months after [lymphedema] diagnosis, and total surveillance time may exceed 2 years. Height and weight will be obtained for each patient at baseline and at each scheduled visit for the purpose of calculating BMI. All patients will complete the ULL-27 (upper limb lymphedema) quality-of-life questionnaire at baseline and at each scheduled visit.
2973041|NCT02743832|Experimental|High-level tumor budding group with CLND|Resection for primary lesion and cervical lymph node dissection(CLND) are performed in the early-stage oral squamous cell carcinoma which tumor budding is a high level.
2973042|NCT02743832|Active Comparator|High-level group without CLND|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma which tumor budding is a high level.
2973043|NCT02743832|Experimental|Low-level group with CLND|Resection for primary lesion and cervical lymph node dissection(CLND) are performed in the early-stage oral squamous cell carcinoma which tumor budding is a low level.
2973044|NCT02743832|Active Comparator|Low-level group without CLND|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma which tumor budding is a low level.
2973045|NCT02743819|Other|Initial progression|Progression on anti-PD1/L1 antibody (or combination not containing anti-CTLA4),
2973046|NCT02743819|Other|Stable disease|Stable disease more than 24 weeks or initial response on anti-PD1/L1 antibody (or combination not containing anti-CTLA4)
2973047|NCT02743806|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once every 8 weeks until vedolizumab is commercially available. (Per MM approval, dosing regimen may be modified per physician's decision).
2973048|NCT02743793||Operationally Tolerant Kidney or Liver Allograft Recipients|"Operational tolerance at baseline is defined as:~an absence of any immunosuppressive therapy for >= 52 weeks prior to the screening visit and~no evidence of allograft rejection in the 52 weeks prior to the screening visit (Day 0), based on the participant's medical history."
2973049|NCT02743780|Experimental|MGV354|Part 3: MGV354 ophthalmic suspension, 1 drop in both eyes once per day for 7 days
2973050|NCT02743780|Placebo Comparator|Placebo|Part 3: MGV354 placebo, 1 drop in both eyes once per day for 7 days
2973051|NCT02743767|No Intervention|Before interventions|Only observational activity for this arm, to record the frequency and triggering factors of airway complications during general anaesthesia.
2973052|NCT02743767|Experimental|After interventions|After introducing five different treating adaptations in airway management we want to record the frequency of airway complications during general anaesthesia.
2973053|NCT02743754|Placebo Comparator|Standard Therapy|Standard supportive therapies for Acute Kidney Injury (AKI), which entail optimization of hemodynamics and hemoglobin levels.
2973054|NCT02743754|Active Comparator|Standard Therapy and hyperbaric oxygen|Standard therapies and treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 atmospheres absolute (ATA).
2973055|NCT02743741|Experimental|Lutetium-177 Octreotate|Lutetium-177 Octreotate 200 mCi (7.4 GBq) by IV for 18-30 weeks
2973056|NCT02743728|Experimental|All Infants|Each infant will receive an Magnetic Resonance Imaging, then Transcranial Magnetic Stimulation Cortical Excitability testing, and General Movement Assessment. These 3 different components of the one arm in which all infants are involved will be collectively assessed.
2973057|NCT02743715|Active Comparator|Active tDCS|Electric current of 2mA delivered to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks.
2973058|NCT02743715|Sham Comparator|Sham tDCS|In this group, the cathode is positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks, without delivery of the electric current.
2973059|NCT02743702|Experimental|GROUP RECEIVING RESPIRATORY PHYSIOTHERAPY|Respiratory Physiotherapy sessions were held once a week by the physiotherapist, and four times more for the family at home, for one year. The sessions have a duration between 30 and 45 minutes, varying according to the level of patient cooperation. The exercise program should be repeated in three cycles, although younger children took longer than older in performing them.
2973060|NCT02743702|Experimental|GROUP RECEIVING THEIR USUAL THERAPIES|This group received no approach of their respiratory difficulties by Physiotherapy. Only continued their usual therapies.
2973061|NCT02743676||Avian influenza A|Natural history of Avian influenza A, particularly H5N1 strain which has a high potential of causing a global human pandemic, and real-world treatment practices will be observed in this study. This registry program will not require, recommend, or provide any specific treatment or medications.
2973062|NCT02743663||Wheezing subjects|Two study visits will be completed with wheezing subjects. The baseline visit will be completed within a 5 day window from the child's discharge from the emergency department. The follow-up visit will be completed 3 months after the baseline visit. At both visits, participants will provide a nasal swab and urine sample, complete three breathing tests: multiple-breath washout, forced oscillation technique, and Spirometry. In addition, at the follow-up visit, children will have an allergy skin test done, a nasal brush to collect epithelial cells and provide a blood sample. Whole blood will be used for basophil activation test (BAT). Children age 4+ will also complete post-bronchodilator testing using Salbutamol to capture information about bronchodilator response.
2973063|NCT02743663||Healthy cohort|One study visit will be completed with healthy participants. At this visit, three breathing tests will be performed: multiple-breath washout, forced oscillation technique, and spirometry. As well, an allergy skin test will be performed at the visit.
2973065|NCT02743637|Experimental|SDX-7320|Increasing dose cohorts, until the maximum tolerated dose (MTD) is determined.
2973554|NCT02740452|Other|standard technique|Ligamys technique (device) or standard technique
2973066|NCT02743624|Other|Pressure Support Titration|The analysis of the diagnostic accuracy of the breathing pattern variables, P 0.1 and the rate of tracheal muscle relaxation.
2973067|NCT02743611|Experimental|BPX-701 and Rimiducid (AP1903)|"BPX-701: autologous T cells genetically modified to express αβ T cell receptor reacting with PRAME peptide/human leukocyte antigen (HLA)-A2.01 and containing the suicide switch~Rimiducid (AP1903): administered to induce apoptosis of the BPX-701 T cells in the event of toxicity"
2973068|NCT02743598|Experimental|Liraglutide|
2973069|NCT02743585|Experimental|Rapid diagnostic arm|"Standard Tan Tock Seng Hospital (TTSH) practices (bacterial culture and susceptibility testing) AND FilmArray Blood Culture ID (BCID) Panel test AND Rosco Diagnostica ESBL and carbapenemase screen will be performed.~The Interventions to be administered are the rapid diagnostic tests: FilmArray Blood Culture ID (BCID) Panel test AND Rosco Diagnostica ESBL and carbapenemase screen.~Subjects will be recruited 8am-3pm daily, weekdays only. Results of the BCID and Rosco test will be communicated to the managing physicians by phone in real-time."
2973070|NCT02743585|No Intervention|Standard of care (control)|Standard Tan Tock Seng Hospital (TTSH) practices (bacterial culture and susceptibility testing) will be used. FilmArray BCID and Rosco Diagnostica ESBL and carbapenemase screen will NOT be performed. Subjects will be recruited 8am-3pm daily, weekdays only.
2973071|NCT02743572|No Intervention|control group|preterm infants of this group with iron-free PN for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
2973072|NCT02743572|Experimental|iron sucrose-1|preterm infants of this group with iron supplementation of 100μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
2973073|NCT02743572|Experimental|iron sucrose-2|preterm infants of this group with iron supplementation of 200μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
2973074|NCT02743572|Experimental|iron sucrose-3|preterm infants of this group with iron supplementation of 300μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
2973075|NCT02743572|Experimental|iron sucrose-4|preterm infants of this group with iron supplementation of 400μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
2973076|NCT02743559|Active Comparator|Vitamin D group|Children born to mothers who received vitamin D during pregnancy will undergo mechanical stimulation using whole body vibration(WBV) by standing on the vibration platform(LivMd) for 10 minutes on 5 consecutive mornings, at 7.30-8 am.
2973077|NCT02743559|Placebo Comparator|Placebo group|Children born to mothers who received placebo during pregnancy will also undergo mechanical stimulation using whole body vibration(WBV) by standing on the vibration platform (LivMd) for 10 minutes on 5 consecutive mornings, at 7.30-8 am.
2973078|NCT02743546|Experimental|Dose Optimization:Participant with Certain B-Cell Malignancies|Participants with certain B-cell malignancies (diffuse large B-cell lymphoma [DLBCL], mantle cell lymphoma [MCL], or follicular lymphoma [FL]) will receive rising doses of intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met. Dose escalation will continue until the recommended phase 2 dose or maximum tolerated dose is reached.
2973079|NCT02743546|Experimental|Dose Expansion: Participants with DLBCL|Participants with DLBCL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
2973080|NCT02743546|Experimental|Dose Expansion: Participants with FL|Participants with FL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
2973081|NCT02743546|Experimental|Dose Expansion: Participants with MCL|Participants with MCL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
2973082|NCT02743546|Experimental|Dose Expansion: Participants with CLL|Participants with chronic lymphocytic leukemia (CLL) will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
2973083|NCT02743520|Experimental|Cardiac event monitor|Participants will under go evaluation with a four week cardiac event monitor.
2973084|NCT02743494|Experimental|Nivolumab|Specified dose on specified days.
2973085|NCT02743494|Placebo Comparator|Placebo|Specified dose on specified days.
2973086|NCT02743455|Experimental|(Vaccine+Placebo)MVA-BN-YF + ISA 720|MVA-BN-YF + ISA 720 1.0x10^8 TCI50 intramuscularly on day 1(Vaccine)+ day 29(Placebo), 15 subjects
2973087|NCT02743455|Experimental|MVA-BN|MVA-BN 1.0x10^8 TCID50 subcutaneously on days 1 and 29, 15 subjects
2973088|NCT02743455|Experimental|MVA-BN-YF|MVA-BN-YF 1.0x10^8 TCI50 intramuscularly on days 1 and 29, 15 subjects
2973089|NCT02743455|Experimental|MVA-BN-YF + ISA 720|MVA-BN-YF + ISA 720 1.0x10^8 TCI50 intramuscularly on days 1 and 29, 15 subjects
2973090|NCT02743455|Experimental|MVA-BN-YF*|MVA-BN-YF 1.0x10^8 TCI50 intramuscularly on days 1 and 29, 15 subjects* *- Prior receipt of MVA-BN
2973091|NCT02743455|Experimental|YF-Vax|YF-Vax =/ > 4.74 log10 PFU subcutaneously on day 1(Vaccine)+ day 29 (Placebo), 15 subjects
2973092|NCT02743442|Experimental|Transoral surgery|
2973093|NCT02743429|Experimental|Long term infusion of ch14.18/CHO|10 day continuous Infusion of ch14.18/CHO.
2973094|NCT02743416||ECG screening|Will be screened for AF using only one-stop protocol
2973095|NCT02743416||Control group|as per regular standard as of today
2973133|NCT02743195|Other|Polyphenol/prebiotic blend|Nutritional Supplement. Active ingredients include: Inulin, Fructooligosaccharides, Polyphenol blend of anthocyanin sources--Blueberry extract, Black Currant extract, Black Rice extract. Participants will be instructed to consume one sachet of powder product every morning with breakfast by mixing into beverage or food of choice.
2973096|NCT02743403|Active Comparator|Neurodyn Portable TENS|"Subjects in this study arm will receive active treatment. The active TENS device will be Neurodyn Portable TENS the IBRAMED® and application of carboxytherapy device will be Carboxyderm S20-1C equipment, Tone Derm® brand.~The subject receives both devices at the same time. The parameters of the active TENS are: frequency (f) of 100 Hertz (Hz) oscillator every 0.5 seconds pulse duration (T) 200 microseconds (microsiemens) and the amplitude (I) will be adjusted at the time of application the carboxiterapia.~The application of Carboxytherapy is realized by a carboxy Derm S20-1C equipment Derm® mark, which uses carbon dioxide (CO2) medical and non-toxic.~Each prick with a needle carboxiterapia will 100ml / min and will last 1 minute long.~Before each puncture will be adjusted to the intensity of TENS as sensitivity of the subject."
2973097|NCT02743403|Placebo Comparator|Placebo TENS- Neurodyn Portable TENS|"Subjects in this study arm will receive placebo treatment. The placebo TENS device will be Neurodyn Portable TENS the IBRAMED® and application of carboxytherapy device will be Carboxyderm S20-1C equipment, Tone Derm® brand.~The application of placebo TENS will be made by the same unit of active TENS; however, it is used a device specially developed for this study. The device remains active only during the first 30 seconds of application. After this time, the current amplitude will gradually decrease over the next 15 seconds until it reaches zero, thereby interrupting the emission of electrical power to the remainder of the application time. The display of placebo TENS device shows a light on all the time of application, indicating the patient that the device is active."
2973098|NCT02743403|No Intervention|Control|"Subjects in this study arm only receive the application carboxiterapia through Carboxyderm S20-1C equipment, Tone Derm® brand.~The group (active - control Carboxytherapy) will be submitted to the application of Carboxytherapy and off TENS."
2973099|NCT02743390|Active Comparator|TNF-alpha inhibitor drug|Infliximab infusion (TNF-α inhibitor, 3 mg/kg, 250mL)
2973100|NCT02743390|Placebo Comparator|Placebo drug|Saline infusion (250mL)
2973101|NCT02743364|Experimental|Arm I (simvastatin)|Patients receive simvastatin PO QD for 6 months.
2973102|NCT02743364|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months.
2973103|NCT02743351|Experimental|ProTmune|
2973104|NCT02743351|Active Comparator|Control Arm|
2973105|NCT02743338|Experimental|Sleep Restriction followed by additional CBT-i components|Sleep Restriction treatment during 5+5 weeks. Followed by being offered an additional intervention consisting of other ICBT-i components during 10 weeks.
2973106|NCT02743338|Active Comparator|Sleep Compression followed by additional CBT-i components|Sleep Compression treatment during 5+5 weeks. Followed by being offered an additional intervention consisting of other ICBT-i components during 10 weeks.
2973107|NCT02743338|Active Comparator|Sleep Restriction followed by no intervention|Sleep Restriction treatment during 5+5 weeks. Followed by NOT being offered or informed of an additional intervention consisting of other ICBT-i components during 10 weeks.
2973108|NCT02743338|Active Comparator|Sleep Compression followed by no intervention|Sleep Compression treatment during 5+5 weeks. Followed by NOT being offered or informed of an additional intervention consisting of other ICBT-i components during 10 weeks.
2973109|NCT02743325|Active Comparator|ALARA protocol|SVT ablation by ALARA protocol
2973110|NCT02743325|Active Comparator|current treatment|SVT ablation by conventional protocol
2973111|NCT02743312|Other|No Weight (NW)|Outcome measures collected with no weights applied. Participants wear the Fitbit Flex.
2973112|NCT02743312|Experimental|Balance-Based Torso-Weighting (WT)|BBTW garment worn 2-4 hours daily for 2 weeks. Participants wear the Fitbit Flex.
2973113|NCT02743312|Placebo Comparator|Sham Weight (SW)|Garment with sham weights worn 2-4 hours daily for 2 weeks. Participants wear the Fitbit Flex.
2973114|NCT02743299|Experimental|CPR simulation|CPR simulation with and without ventilator
2973115|NCT02743286|No Intervention|Control condition (Protocol A)|Following a one-hour sitting run-in period, participants will sit for a 5-hour period including a mid-point bathroom break.
2973116|NCT02743286|Experimental|Frequent sit-to-stands (Protocol B)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 15 2-minute standing interruptions, 3 per hour, and a mid-point bathroom break.
2973117|NCT02743286|Experimental|Walking breaks (Protocol C)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 2-minute walking interruptions, 3 per hour, and a mid-point bathroom break.
2973118|NCT02743286|Experimental|Stand More (Protocol D)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 10-minute standing breaks, 1 per hour, and a mid-point bathroom break.
2973119|NCT02743260|Experimental|pitavastatin (OATP1B1)|2 mg pitavastatin single dose
2973120|NCT02743260|Experimental|metformin (MATE1, MATE2K, OCT1, OCT2)|500 mg metformin single dose
2973121|NCT02743260|Experimental|digoxin (intestinal & renal P-glycoprotein)|0.5 mg digoxin single dose
2973122|NCT02743260|Experimental|adefovir dipivoxil (OAT1)|10 mg adefovir dipivoxil single dose
2973123|NCT02743260|Experimental|sitagliptin (OAT3)|100 mg sitagliptin single dose
2973124|NCT02743260|Experimental|cocktail (all substances)|combination of all individual drugs at respective single doses
2973125|NCT02743247|Experimental|Tacrolimus and Mycophenolate mofetil|Tacrolimus 5mg single dose, Mycophenolate 1,000mg single dose, Tacrolimus 5mg and Mycophenolate 1,000mg single dose.
2973126|NCT02743234|Experimental|FMT|Fecal microbiota transplantation (FMT) following 4-10 days of vancomycin 125 mg x 4, using cryopreserved feces from a healthy anonymous donor
2973127|NCT02743234|Active Comparator|Fidaxomicin|10 days fidaxomicin 200 mg x 2 daily
2973128|NCT02743234|Active Comparator|Vancomycin|10 days vancomycin 125 x 4 daily
2973129|NCT02743221|Experimental|S 95005 + bevacizumab|
2973130|NCT02743221|Active Comparator|Capecitabine + bevacizumab|
2973131|NCT02743208|Experimental|Furlong Evolution femoral stem|Short stem hip arthroplasty (SHA) using a Furlong Evolution femoral stem, and a Furlong H-A.C. Cortical Scree Fit (CSF) plus acetabular cup system.
2973132|NCT02743208|Active Comparator|Furlong H-A.C. femoral stem|Total hip arthroplasty (THA) using a Furlong H-A.C. femoral stem, and a Furlong H-A.C. CSF plus acetabular cup system.
2973134|NCT02743182|Active Comparator|Pegylated interferon alfa-2a|adding Pegylated interferon alfa-2a (180 microgs /week during 48 weeks) in HBeAg-negative patients receiving nucleos(t)ide analogues
2973136|NCT02743169||Standard Practice|This group will consist of ambulance calls under the standard practice of Aman Foundation for ambulance placement.
2973137|NCT02743169||Post-Intervention|This group will consist of ambulance calls after the spatially-optimized placement of ambulances.
2973138|NCT02743156|Active Comparator|angiography-guided PCI|angiography-guided percutaneous coronary intervention
2973139|NCT02743156|Experimental|IVUS-guided PCI|intravascular ultrasound guided percutaneous coronary intervention
2973140|NCT02743143|Experimental|Exercise therapy|High aerobic intensity training and maximal strength training 2 times per week in 1 year at the Hospital's Exercise Training Clinic. Patients receive comprehensive support from Trondheim municipal administration to facilitate adherence.
2973141|NCT02743143|Active Comparator|Follow-up care as usual|The usual care (UC) group will receive the usual physical activity offered by the primary health care system. UC includes the traditional physical activity advice from the Health Directorate. The UC group are invited to supervised exercise at the exercise training Clinic after 1 year.
2973142|NCT02743130|Experimental|Blackcurrant nectar|Contains 17.5 g glucose and 17.5 g fructose representing 35 g completely inverted sucrose
2973143|NCT02743130|Experimental|Lingonberry nectar|Contains 17.5 g glucose and 17.5 g fructose representing 35 g completely inverted sucrose
2973144|NCT02743130|Active Comparator|Reference|Sugar control, contains 17.5 g glucose and 17.5 g fructose in water
2973145|NCT02743117|Experimental|Monovalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
2973146|NCT02743117|Placebo Comparator|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
2973147|NCT02743104|Active Comparator|Ketamine for procedural sedation|"All patients will be sedated according to a written protocol which includes intravenous administration of midazolam and atropine. In addition, local anesthesia will be performed using lidocaine 1% sprayed once just above the vocal cords, and again at the level of the carina. Lidocaine doses are limited to a maximum total dose of 5mg/kg.~This study group will be exposed to ketamine as the main drug for sedation, as an initial bolus of 1-2 mg/kg initially and then titrated by additional doses of 1mg/kg per dose."
2973148|NCT02743104|Active Comparator|Propofol for procedural sedation|"All patients will be sedated according to a written protocol which includes intravenous administration of midazolam and atropine. In addition, local anesthesia will be performed using lidocaine 1% sprayed once just above the vocal cords, and again at the level of the carina. Lidocaine doses are limited to a maximum total dose of 5mg/kg.~This study group will be exposed to propofol as the main drug for sedation, as an initial bolus of 1-2 mg/kg initially and then titrated by additional doses of 1mg/kg per dose."
2973149|NCT02743078|Experimental|Arm I (Bevacizumab and TTFields)|Patients will receive bevacizumab at a dose of 10 mg/kg every 2 weeks on a 4-week cycle and TTFields continuously. Treatment is given until disease progression or the development of adverse events that require complete discontinuation. Bevacizumab starts on the first day (+/- 1 day) of TTFields therapy.
2973150|NCT02743065||Device: HepaSphere Microspheres|HepaSphere Microsphere
2973151|NCT02743039|Experimental|CareerAdvance®|CareerAdvance® provides education, career coaching, and soft-skills training for parents while their children attend Head Start programs.
2973152|NCT02743039|No Intervention|Control Standard of CAP|No assignment to participate in the CareerAdvance® program, but given community referrals and resources
2973153|NCT02743026|Experimental|Intervention|participants will complete the FOXY intervention
2973154|NCT02743013|Active Comparator|CHF 5993 100/6/12,5 pMDI|with/without Charcoal Block
2973155|NCT02743013|Active Comparator|CHF 5993 100/6/12,5 pMDI (replicate)|with/without Charcoal Block
2973156|NCT02743013|Active Comparator|CHF 5993 100/6/12,5 pMDI VHC|with/without Charcoal Block with Valved Holding Chamber
2973157|NCT02743013|Experimental|CHF 5993 100/6/12,5 DPI test 1|with/without Charcoal Block
2973158|NCT02743013|Experimental|CHF 5993 100/6/12,5 DPI test 2|with/without Charcoal Block
2973159|NCT02743000||Women ages 18-35|Women ages 18-35 who do and do not engage in binge eating will be included in the study
2973160|NCT02742987|Experimental|Ticagrelor group|Ticagrelor 90 mg twice daily + standard medical therapy
2973161|NCT02742987|Experimental|Clopidogrel group|Clopidogrel 150 mg once daily + standard medical therapy
2973162|NCT02742974|No Intervention|FloTrac™ and EV1000™ pre and post-operatively|Cardiovascular management guided by minimally invasive hemodynamic monitoring via FloTrac™ and EV1000™ will be utilized in the pre and post-operative period in the control arm.
2973163|NCT02742974|Experimental|FloTrac™ and EV1000™ peri-operatively|Cardiovascular management guided by minimally invasive hemodynamic monitoring via FloTrac™ and EV1000™ will be utilized in the perioperative period for the intervention arm
2973164|NCT02742961||Peripheral nerve block|Intervention arm. Participants who receive a peripheral nerve block identified through submission of an appropriate physician billing code
2973165|NCT02742961||No peripheral nerve block|Control arm. Participants who do not receive a peripheral nerve block identified through lack of a submission of an appropriate physician billing code
2973166|NCT02742948|Active Comparator|preoperative antibiotic group|200 women will receive IV ceftriaxone (2g) 60 minutes before skin incision
2973167|NCT02742948|Active Comparator|early intraoperative antibiotic group|200 women will receive IV ceftriaxone (2g) immediately with skin incision
2973168|NCT02742948|Active Comparator|post cord clamping antibiotic group|200 women will receive IV ceftriaxone (2g) immediately after umbilical cord clamping
2973169|NCT02742935|Experimental|Injection SHR-1210|SHR-1210 injection, 60,200,400mg/dose, intravenous infusion over 30 minutes.
2973170|NCT02742922|Experimental|Culturally adapted therapy (C-MAP)|Culturally adapted manual assisted (C-MAP) brief problem solving therapy
2973171|NCT02742922|No Intervention|Treatment as usual|This arm will receive no intervention only TAٓU.
2973172|NCT02742909|Active Comparator|rhBNP|the study is a self controlled study. Each patient was studied on two occasions (6 hours apart). One occasion the subject received rhBNP 1.5ug/kg IV bolus followed by an infusion of 0.0075ug/kg/min for 24 hours; other occasion the subject received IV placebo bolus followed by a placebo infusion for 24 hours .these were administered in random order in double blind fashion.The date of this arm is from the occasion the subject received rhBNP.
2973173|NCT02742909|Placebo Comparator|Placebo|the study is a self controlled study. Each patient was studied on two occasions (6 hours apart). One occasion the subject received rhBNP 1.5ug/kg IV bolus followed by an infusion of 0.0075ug/kg/min for 24 hours; other occasion the subject received IV placebo bolus followed by a placebo infusion for 24 hours .these were administered in random order in double blind fashion.The date of this arm is from the occasion the subject received placebo.
2973174|NCT02742896||Restoration of Erectile dysfunction|The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm.
2973175|NCT02742883|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for up to 104 days. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dosage is reached, but not exceeding 12.0 g/kg/d Atengenal or 0.4 mg/kg/d Astugenal.
2973176|NCT02742870||Patients with MRI pelvic imaging|Women over 18 years old, having undergone a magnetic resonance imaging of the pelvis within the CHU Brugmann Hospital
2973177|NCT02742857|Experimental|Treatment Group|
2973178|NCT02742844|Experimental|APZ2 application|Topical, single application of APZ2; 500000 cells per square cm;
2973179|NCT02742831|Experimental|Intervention|"The intervention group will receive a one-on-one in-person intervention of 6 sessions, each lasting approximately 60 minutes. The intervention is intended to be delivered over a period of 12 weeks, with sessions occurring every 1-2 weeks. The overview of the 6 sessions is as follows:~Behavioral chain analysis of episodes where parent felt stressed and episode where things went well. Identification of sources of interpersonal support.~Stress relief. Development of a detailed crisis plan.~Problem solving techniques.~Emotional regulation exercises.~Positive parenting, review of parenting challenges.~Reflection, repeat behavioral chain analysis. Update crisis plan."
2973180|NCT02742831|Active Comparator|Control|The families in the control group will be contacted by a member of the study team 6 times in 12 weeks to approximate the frequency of contact that the intervention group receives. The study team member will check in with families on the telephone or in person and will help them connect with clinic and community resources as needed.
2973181|NCT02742818|Active Comparator|Upper body blanket|Patients undergoing EVAR and LEA will use this type of warming blanket.
2973182|NCT02742818|Active Comparator|Underbody blanket|Patients undergoing EVAR and LEA will use this type of warming blanket.
2973183|NCT02742805|Experimental|High Dose Vitamin D|Participants receive high dose of Vitamin D (4,000 IU/day) in addition to standard of care dose of Omalizumab.
2973184|NCT02742805|Active Comparator|Low Dose Vitamin D|Participants receive low dose of Vitamin D (400 IU/day) in addition to standard of care dose of Omalizumab.
2973185|NCT02742792|Experimental|Resistance training|Resistance training, twice a week during 12 weeks.
2973186|NCT02742792|Other|Advice on lifestyle|Patients receive advice on lifestyle. Patients will be asked to participate in the elderly group meetings the basic health unit linked to the hospital.
2973187|NCT02742779|Experimental|High-Fat Meal SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a high-fat meal after a 8-hour/overnight fast using PIC on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
2973188|NCT02742779|Experimental|High-Fat Meal SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a high-fat meal after a 8-hour/overnight fast using solution on Day 1 of the treatment period (5 days) in an additional cohort of Part 3.
2973189|NCT02742779|Experimental|Low-Fat Meal SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose given orally using PIC based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a low-fat meal after an 8-hour/overnight fast using PIC on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
2973190|NCT02742779|Experimental|Low-Fat Meal SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose given orally using PIC based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a low-fat meal after an 8-hour/overnight fast using solution on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
2973191|NCT02742779|Experimental|MD Cohort: PIC (Part 2)|Participants will receive multiple ascending dose administered orally using PIC from Day 1 to Day 13 twice daily (BID) or may even be thrice daily (TID) or four times a day (QD) depending on clinical PK, followed by morning dose on Day 14 in 7 cohorts of Part 2.
2973192|NCT02742779|Experimental|MD Cohort: Solution Formulation (Part 4)|Participants will receive multiple ascending dose in fed or fast condition, administered orally using solution from Day 1 to Day 13 BID or may even be TID or QD depending on clinical PK, followed by morning dose on Day 14 in 7 cohorts of Part 2.
2973193|NCT02742779|Placebo Comparator|Placebo PIC|Participants will receive placebo matched to GDC-0310 single or multiple ascending dose administered orally in the fasted (SD cohorts) or fed state using PIC on Day 1 of the treatment period (5 days) to the SD cohorts and from Day 1 to 14 BID or may even be TID or QD depending on clinical PK, to the MD cohorts.
2973194|NCT02742779|Placebo Comparator|Placebo Solution|Participants will receive placebo matched to GDC-0310 single or multiple ascending dose administered orally in the fasted (SD cohorts) or fed state using PIC on Day 1 of the treatment period (5 days) to the SD cohorts and from Day 1 to 14 BID or may even be TID or QD depending on clinical PK, to the MD cohorts.
2973195|NCT02742779|Experimental|SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose administered orally in the fasted state using PIC on Day 1 of the treatment period (5 days) in the 9 cohorts of Part 1.
2973196|NCT02742779|Experimental|SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose administered orally in the fasted state using solution formulation on Day 1 of the treatment period (5 days) in the 9 cohorts of Part 3.
2973222|NCT02742597|No Intervention|Group D|Health Administrative Data Group (n = 1630) Number of matched data controls. Not taking part in intervention.
2973223|NCT02742584|Experimental|Group A|Cough Stress Test with a comfortably full bladder.
2973224|NCT02742584|Experimental|Group B|Cough Stress Test with an empty bladder after straight catheterization.
2973197|NCT02742766|Experimental|Part 1 - GSK3008356 single dose and multiple doses|Healthy subjects will receive GSK3008356 in morning as single dose or multiple doses of 5 milligrams (mg), 10 mg, 30 mg,45 mg, 75 mg, 90 mg, 125, 180 mg, 200 mg, 250 mg total daily dose or matching placebo in eleven sequential cohorts while receiving a standard fat meal. The initial dosing for the first cohort will be staggered so that 2 subjects will be dosed as sentinel subjects. Provided there are no safety concerns, the remainder of the subjects scheduled for the cohort may be dosed. Eight subjects will be enrolled in each cohort.
2973198|NCT02742766|Experimental|Part 2 - GSK3008356 14 day repeat dose|Healthy subjects will receive GSK3008356 or matching placebo, as 14 daily doses in the three sequential cohorts. Subjects in cohort 1 will receive their daily dose in morning, while subjects in cohort 2 and cohort 3 will receive their daily dose in evening. In all the three cohorts, Day 1 and day 14 dosing will occur while receiving a standard fat meal in morning. Eight subjects will be enrolled in each cohort.
2973199|NCT02742766|Experimental|Part 3 - GSK3008356 28 day repeat dose|Obese subjects will receive GSK3008356 or matching placebo, as 28 daily doses in the three parallel cohorts. Cohort 1 will evaluate 1 dose strength of GSK3008356 (or matching placebo) administered as morning doses. Cohorts 2 and 3 will evaluate 2 dose strengths (1 per cohort) of GSK3008356 (or matching placebo) administered in the evening. Ten subjects will be enrolled in each cohort.
2973200|NCT02742753||Study cohort|The Total population will include all subjects included in the study. Only aggregated information will be collected for these subjects.
2973201|NCT02742740|No Intervention|Control|Standard of care for chemotherapy treatment.
2973202|NCT02742740|Experimental|Chemo Buddy|Subject receives instructions on how to use the personalized touch screen tablet and takes it home for 2 months.
2973203|NCT02742727|Experimental|CAR-pNK Cell immunotherapy|Enrolled patients will receive CAR-pNK cell immunotherapy with a novel specific chimeric antigen receptor targeting CD7 antigen by infusion.
2973204|NCT02742714|Experimental|PillCam SBC|The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
2973205|NCT02742688|Experimental|Pyrus pyrifolia var. culta(Makino) NaKai peel extract|
2973206|NCT02742688|Placebo Comparator|Placebo|
2973207|NCT02742675|Experimental|androgen deprivation therapy|Patients will receive androgen-deprivation therapy comprising luteinizing-hormone releasing-hormone (LHRH) agonist (leuprolide acetate, goserelin acetate, buserelin, or triptorelin) subcutaneously or as an injection AND an oral antiandrogen therapy (flutamide 3 times daily or bicalutamide once daily).
2973208|NCT02742675|Experimental|androgen deprivation therapy plus definitive treatment|Patients will receive androgen-deprivation therapy as in arm I in addition to definitive treatment including surgery to remove prostate or radiation therapy to the prostate.
2973209|NCT02742662|Experimental|Smart Technology Group|The Smart Technology Group will receive a technology-based lifestyle intervention program which uses wearable technology, smartscales and smartphone applications to track and deliver feedback on caloric expenditure, physical activity, caloric intake and body weight. Participants will receive information through smartphone applications on strategies to make changes to their diet, physical activity, and weight-related behaviors along with standard 3 monthly in-person weight management visits.
2973210|NCT02742662|Other|Standard Weight Management Group|The Standard Weight Management Group will receive 3 monthly in-person weight management visits during which they will receive standard of care lifestyle recommendations in accordance with the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guideline.
2973211|NCT02742649|Experimental|Fixed Combination (FC) Ocular Insert|one segment of bimatoprost and one segment of timolol maleate combined onto a single Ocular Insert
2973212|NCT02742649|Experimental|Bimatoprost Ocular Insert|one segment of bimatoprost and one segment of placebo (no drug product) combined onto a single Ocular Insert
2973213|NCT02742649|Experimental|Timolol Ocular Insert|one segment of timolol and one segment of placebo (no drug product) combined onto a single Ocular Insert
2973214|NCT02742636|Experimental|Group A (treatment group)|The patients in this group will have their catheter directly removed in the OR after LH.
2973215|NCT02742636|Active Comparator|Group B (control group)|The patients in the control group will have their catheter removed according to the regular protocol of the hospital (at least 6 hours in place).
2973216|NCT02742623||Rivaroxaban|Female and male patients with active cancer and treated with rivaroxaban after a diagnosis of DVT/ and/or PE
2973217|NCT02742610|Experimental|Mindfulness with Contingency Management|The intervention (MSI-CM) will involve two individual pre-quit in-person sessions and two post-quit phone counseling sessions, a series of brief mindfulness trainings that will be delivered via smartphone, that prompts participants to practice a mindfulness exercise five times a day while abstinent during the 2-week incentivized abstinence period (using CM) plus an additional 2 weeks (without CM) following the participant's target quit date. The MSI-CM participants will be asked to provide CO video via smartphone twice daily with monetary incentives provided (CM). Participants will receive monetary incentives contingent on each confirmed CO level (less than 7 ppm) for the CM period. We will use CM as an adjunct strategy to enhance the efficacy of mindfulness training.
2973218|NCT02742610|Active Comparator|Active Control|Participants assigned to the control group will receive two individual pre-quit in-person sessions and two post-quit phone counseling sessions, similar to the MSI-CM except for mindfulness introduction/discussion. Participants in the control group will receive the same monetary incentives on average as the participants in the MSI-CM for submitting CO videos, regardless of CO levels (non-abstinent contingent), during the 2-week post-TQD period. Each participant in the group (the non-contingent CO group) will be yoked to a single participant (selected randomly with stratification) in the MSI-CM. The yoked participant receives the same amount of monetary incentives as his or her matched participant in the contingent CO (MSI-CM) group.
2973219|NCT02742597|Active Comparator|Group A|Intervention group (n = 163) Intervention: Participates in Telemedicine Impact Plus (TIP)/ IMPACT Plus Care Coordination meeting
2973220|NCT02742597|Active Comparator|Group B|Before/After Intervention group (n = 24) Intervention: Participates in TIP / IMPACT Plus Care Coordination meeting
2973221|NCT02742597|No Intervention|Group C|Control group (n = 163)
2973225|NCT02742584|Experimental|Group C|Cough Stress Test with a bladder infused with 200 cc of saline.
2973226|NCT02742584|Experimental|Group D|Cough Stress Test with the bladder filled to half functional capacity as determined from the largest voided volume recorded in the patient's voiding diary.
2973227|NCT02742558|Experimental|cholvax|Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
2973228|NCT02742558|Active Comparator|shanchol|The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
2973229|NCT02742545|Experimental|MayoExpertAdvisor|Clinicians in care teams assigned to the intervention arm will have access to MayoExpertAdvisor (MEA) in the electronic medical record (EMR). MEA will provide patient-specific knowledge and treatment suggestions for patients with hyperlipidemia, atrial fibrillation, and/or heart failure via a clickable tab in the Mayo Clinic EMR.
2973230|NCT02742545|No Intervention|Usual Care|Clinicians in care teams assigned to the standard of care arm will continue to provide up-to-date, patient-specific guideline-based treatment recommendations as is the standard of care at Mayo Clinic.
2973231|NCT02742532|Experimental|Oxytocin|Intra-nasal oxytocin (40 IUs; 5 puffs in each nostril)
2973232|NCT02742532|Placebo Comparator|Placebo|Intra-nasal saline placebo (5 puffs in each nostril)
2973233|NCT02742519|Experimental|Part 1-Sequence 1|ivacaftor in Treatment Period 1 →washout→placebo in Treatment Period 2
2973234|NCT02742519|Experimental|Part 1 - Sequence 2|placebo in Treatment Period 1→washout→ivacaftor in Treatment Period 2
2973235|NCT02742519|Experimental|Part 2: ivacaftor|open label period
2973236|NCT02742506|Experimental|Brain-damaged patients|Electroencephalography (EEG) will be performed in patients in coma, in a vegetative state or in a minimally conscious state to assess the P300 response after different auditive stimulations
2973237|NCT02742506|Active Comparator|Healthy volunteers|Electroencephalography (EEG) will be performed in healthy participants to assess the P300 response and medial prefrontal cortex activity after different auditive stimulations
2973238|NCT02742493|Experimental|0.028 bonded to canines|lower fixed canine and canine retainer and upper removable Hawley (Intervention A)
2973239|NCT02742493|Experimental|0.027 7-strand bonded to all 6|lower fixed canine to canine retainer and upper removable Hawley (Intervention B)
2973240|NCT02742493|Active Comparator|removable Hawley-type|lower hawley-type and upper hawley removable retainer (Control)
2973241|NCT02742480||Dabigatran|300 patients treated with dabigatran under the habitual clinical practice.
2973242|NCT02742480||Acenocoumarol|200 patients treated with acenocoumarol under the habitual clinical practice.
2973243|NCT02742467|Experimental|1|Perindopril plus Amlodipine at a dose of 4mg/5mg once daily for two months and 8mg/10mg once daily for the remaining four months.
2973244|NCT02742467|Active Comparator|2|Perindopril Plus Hydrochlorothiazide at a dose of 4mg/12.5mg and 8mg/25mg once daily for the remaining four months.
2973245|NCT02742467|Active Comparator|3|Amlodipine plus Hydrochlorothiazide 5mg/12.5mg for two months and 10mg/25mg for the remaining four months.
2973246|NCT02742454|Active Comparator|Standard 30-60 Seconds Cord Clamping|Standard treatment for extremely preterm infants which is delayed cord clamping 30-60 seconds after birth, and assisted ventilation after cord clamping.
2973247|NCT02742454|Experimental|VentFirst 120 Seconds Cord Clamping|Assisted ventilation (face mask Continuous Positive Airway Pressure, CPAP, or Positive Pressure Ventilation, PPV) will be provided prior to cord clamping at 120 seconds.
2973248|NCT02742441|Experimental|122-0551 Foam|"122-0511 Foam, topically applied twice daily~Intervention: Drug: 122-0551 Foam"
2973249|NCT02742441|Placebo Comparator|Vehicle Foam|"Vehicle Foam, topically applied twice daily~Intervention: Drug: Vehicle Foam"
2973250|NCT02742428|Experimental|Ascites drainage before surgery.|A group of patients with (or suspected for) advanced ovarian cancer and significant ascites. An indwelling catheter insertion into abdominal cavity and slow, systematic ascites evacuation for 7 or more days before surgery (if it cannot be scheduled immediately) will be performed. Patients will undergo an interview, will be asked to fill in questionnaires concerning a quality of life and nutritional status. If available noninvasive bioimpedance analysis will be performed and 2ml of blood will be taken for serum prealbumin concentration evaluation. If possible 20ml of ascitic fluid will be taken for cytology examination.
2973251|NCT02742428|Other|Observation.|A group of patients with (or suspected for) advanced ovarian cancer and significant ascites. A standard of care: observation or acute paracentesis (>5000ml) will be performed while waiting for the surgery (if it cannot be scheduled immediately). Patients will undergo an interview, will be asked to fill in questionnaires concerning a quality of life and nutritional status. If available noninvasive bioimpedance analysis will be performed and 2ml of blood will be taken for serum prealbumin concentration evaluation. If possible 20ml of ascitic fluid will be taken for cytology examination.
2973252|NCT02742415|Experimental|Cancer patients receiving hand massage|Caring Hand massage will be provided to the outpatients undergoing chemotherapy
2973253|NCT02742402|Experimental|Observation|Clinical follow-up for at least 6-8 hours, after follow-up repeated laboratory tests and repeated clinical examination is done. Adult Appendicitis Score is calculated after observation to determine further actions. Observation is continued in patients with decreasing score. Patients with the same or higher score undergo diagnostic imaging (score 11-15) or laparoscopy (score 16 or higher). Diagnostic imaging is abdominal ultrasound first and if the result is inconclusive or negative for appendicitis abdominal computed tomography is done. Laparoscopic appendectomy is done for those patients with appendicitis in diagnostic imaging.
2973254|NCT02742402|Active Comparator|Diagnostic imaging|Patients undergo abdominal ultrasound and if the result is inconclusive or negative for appendicitis patients will have abdominal computed tomography. Laparoscopic appendectomy is done for patients with appendicitis in diagnostic imaging.
2973255|NCT02742389|No Intervention|Standard counseling|This group will receive the standard counseling that all our patients would receive if they are scheduled to have urodynamic testing. This counseling will include a description of the procedure and a handout about urodynamic testing
2973314|NCT02741934||Term control cohort|The infants who were born from 2008 to 2009 with term gestational age will be enrolled.
2973256|NCT02742389|Other|Standard + Preprocedure Telephone Call|The participants will receive the standard counseling that all our patients who are scheduled for urodynamic testing receive (just like those who are assigned to group 1). In addition, the participants will receive intervention: a pre-procedural telephone call from the investigators 1 week before their testing to talk about the procedure.
2973257|NCT02742376|Other|Soft surface|A soft sponge used for physiotherapy is placed on the floor along a path,
2973258|NCT02742376|Other|Floor|The subject will walk on the floor.
2973259|NCT02742376|Other|Shoes|Special shoes (Kyboot) with air cushions that are meant to relieve pressure will be used.
2973260|NCT02742350|Experimental|IMT+Exercise|The inspiratory muscle training protocol (IMT) high intensity is achieved with a device with linear load pressure (POWERbreathe Plus Light Resistance®, SP, BR) that allows loads up to -90cmH2O. IMT is performed for 36 sessions (12 weeks) with weekly frequency of three times a week under supervision prior to the cardiac rehabilitation. The training protocol consists of five series with 10 repetitions each set until the 8th week with increase in the number of sets of repetitions of the 8th to 12th week, with two minutes or according to patient feedback using the modified Borg scale . Aerobic training lasts 40 minutes (5 minutes heating 30 minute workout and 5 minutes desaqueciemento. During training vital signs such as heart rate, blood pressure (BP) and peripheral oxygen saturation (SpO2) are evaluated and the feeling of effort the patient should not exceed the level of 8 according to the modified Borg scale.
2973261|NCT02742350|No Intervention|Exercise Control|Aerobic Exercise and Stretching
2973262|NCT02742337||Test|Newly diagnosed female patients with rheumatoid arthritis who have not previously used a disease modifying anti-rheumatic drug.
2973263|NCT02742337||Control|Female patients not having a diagnosis of rheumatoid arthritis and who have not previously used a disease modifying anti-rheumatic drug.
2973264|NCT02742324|Experimental|Ruxolotinib and peg-IFN alpha -2a|"Phase I~LeveL 1 Ruxolotinib 10 mg BID and peg-IFN alpha -2a 45 mcg weekly increasing doses to level 9 : Ruxolotinib 20 mg BID and peg-IFN alpha -2a 135 mcg weekly~Phase II~Ruxolotinib and peg-IFN alpha -2a randomized between selected doses from phase I"
2973265|NCT02742311|Active Comparator|transforaminal endoscopic discectomy|
2973266|NCT02742311|Active Comparator|interlaminar endoscopic discectomy|
2973267|NCT02742298|Other|QMUS|All patients will undergo serial quantitative muscle ultrasound.
2973268|NCT02742298|Other|EIM|All patients will undergo serial electrical impedance myography measures.
2973269|NCT02742285|Other|Artemether + lumefantrine|One single adult dose of artemether + lumefantrine 80 + 480 mg
2973270|NCT02742272||ED Headache or Migraine Patients|The investigators will perform a prospective cohort study of patients ages 6-18 years presenting to the ED with a complaint of headache or migraine over a 12 month period.
2973271|NCT02742259||Beta Cutoff|Assay
2973272|NCT02742259||Pivotal|Assay
2973273|NCT02742246|No Intervention|Standard treatment as usual (TAU)|This is the regular treatment a participant would normally receive at the clinic and generally includes individual and/or group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as teaching about the treatment program, teaching important ideas about recovery, increasing knowledge about specific problems participants may have with addiction and/or demonstrating new ways of coping with skills designed to fit their lifestyle. Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
2973274|NCT02742246|Active Comparator|Individual clinician-provided CBT|This is individual treatment provided by a trained Cognitive Behavioral Therapy (CBT) clinician who will focus on teaching skills to understand and change participants behaviors to help them avoid alcohol use. Sessions with the clinician will generally last for 1 hour one time per week for 8 weeks. Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
2973275|NCT02742246|Experimental|CBT4CBT|In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on. The CBT4CBT program will cover the same skills as the individual clinician-provided CBT, only here it will be done by a computer. Participants will be taught how to use the computer program by a staff member and will be asked to spend about 8 hours using the program (approximately one hour per week) at the clinic.Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
2973276|NCT02742233|Experimental|saxagliptin|"saxagliptin & Regular treatment:~saxagliptin, brand name，Bristol-Myers, Squibb, dose: 5mg, po, qd"
2973277|NCT02742233|Placebo Comparator|placebo|"placebo & Regular treatment:~placebo, dose: 5mg, po, qd"
2973278|NCT02742220|Experimental|Isometric Handgrip Training Group|Experimental group will perform home-based unilateral handgrip exercise and will be recommended to increase daily physical activity levels.
2973279|NCT02742220|Sham Comparator|Control Group|Control group will be recommended to increase daily physical activity levels.
2973280|NCT02742207||Observational|All comers with Atrial fibrillation
2973281|NCT02742194|Placebo Comparator|Placebo|Conventional treatment (restrictive diet) plus capsules of 200 mg of cellulose (placebo) to be taken three times a day for six months.
2973282|NCT02742194|Experimental|Ginger group|Conventional treatment (restrictive diet) plus capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
2973283|NCT02742181|Experimental|Alvimopan group|In addition to standard postoperative care, patients randomized to the study group will be given 12mg of alvimopan orally twice a day, from the time of diagnosis of postoperative ileus to the time of return of bowel function or for 5 days.
2973284|NCT02742181|Other|Control Group|Patients randomized to the control group receive standard postoperative care which includes but is not limited to NPO status, IV fluid rehydration, and nasogastric decompression.
2973285|NCT02742168|Experimental|Breast Cancer,99mTc-3PRGD2,SPECT/CT|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and efficacy evaluation of breast cancer
2973313|NCT02741934||Preterm cohort|Among the infants who were born and admitted to Seoul National University Hospital from 2008 to 2009, the birth weight of the infants less than 1,500g or gestational age less than 32 weeks patients were enrolled.
2973286|NCT02742155|Experimental|Play2Sleep|For the experimental intervention, Play2Sleep consists of video-recording the mother and father separately while engaged in a structured play session. Immediately following the play session, the home visitor will review the video recording with each parent separately to provide positive feedback on parental behaviors that promotes contingent interaction and identification of infant cues. At the end of the visit, standard public health handouts on infant sleep will be provided to both parents.
2973287|NCT02742155|Active Comparator|Comparison|In the comparison group, only standard public health handouts on infant sleep will be reviewed with parents.
2973288|NCT02742142|Placebo Comparator|control|Distilled water as placebo with a bitter flavor added (to mimic the bitter metallic taste of SDF) was painted onto all exposed tooth root surfaces using a small disposable brush. This procedure will be repeated after 12 and 24 months.In addition, instructions on oral hygiene (OHI) tailored to the individual's condition was given, and a tube of toothpaste containing 1,000 ppm fluoride (the most popular type of adult toothpaste in the Hong Kong market) was provided. The OHI and provision of toothpaste will be repeated at 6-month intervals.
2973289|NCT02742142|Experimental|silver diammine fluoride|the subjects received the same intervention as those provided to subjects in the control group except that a 38% SDF solution (Saforide, Toyo Seiyaku Kasei Co. Ltd, Osaka, Japan) instead of the placebo solution was painted onto the exposed tooth root surfaces. This treatment was repeated after 12 and 24 months.
2973290|NCT02742129|Experimental|AIR001 Crossover to Placebo|Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug Nebulized Sodium Nitrite (AIR001) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Placebo instead of AIR001.
2973291|NCT02742129|Placebo Comparator|Placebo crossover to AIR001|Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug (Placebo) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Nebulized Sodium Nitrite (AIR001) instead of Placebo.
2973292|NCT02742103|Experimental|CSL_112|CSL112 will be administered intravenously, once weekly for 4 consecutive weeks (4 infusions in total).
2973293|NCT02742103|Placebo Comparator|Placebo|Placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
2973294|NCT02742090|Experimental|TGR-1202|Oral daily dose of TGR-1202
2973295|NCT02742077|Other|Robotic-assisted PVI|Robotic-assisted peripheral vascular intervention
2973296|NCT02742064||MDD-Single Episode|1. Subjects who have experienced 1 episode of major depressive disorder (MDD) in their lifetime.
2973297|NCT02742064||MDD-Recurrent|1. Subjects who have experienced 2 or more episodes of depressive disorder (MDD) in their lifetime.
2973298|NCT02742064||Bipolar Disorder|1. Subjects who have been diagnosed with bipolar disorder in their lifetime.
2973299|NCT02742051|Experimental|Everolimus+Letrozole|everolimus 10mg/d,po + letrozole 2.5mg/d,po * 18 weeks
2973300|NCT02742051|Active Comparator|Fluorouracil+epirubicin+cyclophosphamide|Fluorouracil 600mg/m2,iv,d1 + epirubicin 90mg/m2,iv,d1 + cyclophosphamide 600mg/m2,iv,d1 * 6 cycles (every 21 days per cycle)
2973301|NCT02742038|Experimental|Fluoride varnish plus education|Biannual fluoride varnish every 6 month/ 24 months plus educational component
2973302|NCT02742038|Placebo Comparator|Placebo varnish plus education|Biannual placebo varnish every 6 month/ 24 months plus educational component
2973303|NCT02742025|Other|Standard Care|"Patients randomized to this arm will have standard care with no extra interventions.~Intervention: Inclusion visit~Intervention: Coronarography on day 0"
2973304|NCT02742025|Experimental|HEARTLINK|"Patients randomized to this arm will participate in the HEARTLINK program, which includes a specific nurse consultation and telephone contact.~Intervention: Inclusion visit~Intervention: Nurse consultation~Intervention: Telephone contact~Intervention: Coronarography on day 0"
2973305|NCT02741986||Physicians|"All surgeons and anesthesiologists at large single-center tertiary academic center will be recruited to participate in this study.~Intervention: Risk estimation prior to surgery and immediately after the surgery.~Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS."
2973306|NCT02741986||Intelligent Perioperative System (IPS)|"Intelligent perioperative system (IPS) is designed as the set of computer softwares and algorithms that in real-time predict risk for postoperative complications using routine clinical data in electronic health records. The system is designed as the self-learning system with the ability to interact with physicians and solicit their feedback.~Intervention: Risk estimation prior to surgery and immediately after the surgery.~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
2973307|NCT02741973|Experimental|Yoga|Students have 10 weeks yoga instead of school sport.
2973308|NCT02741973|Active Comparator|School sport|Students have 10 weeks regular school sport.
2973309|NCT02741960|Experimental|metformin|Eligible patients for clinical trial were randomized in a 1:1 ratio to metformin/placebo add-on. Subjects randomized to metformin will receive a target dose of 500 mg three times daily. Investigators were allowed to adjust the dose according to the patients' tolerance.
2973310|NCT02741960|Placebo Comparator|placebo|Eligible patients for clinical trial were randomized in a 1:1 ratio to metformin/placebo add-on. Subjects randomized to placebo will receive a target dose of 500 mg three times daily. Investigators were allowed to adjust the dose according to the patients' tolerance.
2973311|NCT02741947|Active Comparator|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
2973312|NCT02741947|Experimental|Levodopa Benserazide Teva Italia|Levodopa Benserazide Teva Italia100+25mg and 200+50mg, tablet, tid e qid, for four weeks
2973315|NCT02741921|Experimental|Normal airway|intubation with normal airway Cormack-Lehane classivication I
2973316|NCT02741921|Experimental|difficult airway|intubation with difficult airway Cormack-Lehane classivication III
2973317|NCT02741908|Experimental|Fixed diet plan|Patients received a fixed diet plan to assist in the choice of foods aimed at changing eating behavior. Dietary intake was evaluated by using 3 nonconsecutive 24-hour dietary recalls collected at each visit. Received a reduction of 500 calories in the total energy expenditure calculated by the equation predicted by Dietary Reference Intake (DRI) from the Institute of Medicine (2005). Also received qualitative information regarding healthy food behaviours, by a same dietitian, based on the DRI for Acceptable Macronutrient Ranges, appropriated for age and gender.
2973318|NCT02741908|Experimental|Calorie counting diet|Patients underwent a calorie counting diet, in which each patient has received a table list with equivalent points for food and drinks, and was instructed to record all daily food or drink intake and calculate the total score of points consumed (1 point = 3.6 calories). They were allowed to eat any food but were limited to the recommended amount of points (or calories equivalents). Received a reduction of 500 calories in the total energy expenditure calculated by the equation predicted by Dietary Reference Intake (DRI) from the Institute of Medicine (2005). Also received qualitative information regarding healthy food behaviours, by a same dietitian, based on the DRI for Acceptable Macronutrient Ranges, appropriated for age and gender.
2973319|NCT02741895||Postoperative patients|The target populations for the study are patients undergoing robotic cystectomy, open colectomy, abdominal hysterectomy, esophagectomy, lung lobectomy, gastric bypass, and hip replacement at Cedars-Sinai Medical Center.
2973320|NCT02741882||Cases|Mothers who delivered a baby with microcephaly at Nossa Senhora de Lourdes maternity hospital located in Aracaju, state of Sergipe, Brazil from September 1, 2015 through January 5, 2016. The intervention will be a questionary.
2973321|NCT02741882||Controls|Mothers who delivered a baby without microcephaly at Nossa Senhora de Lourdes maternity hospital located in Aracaju, state of Sergipe, Brazil from September 1, 2015 through January 5, 2016. The intervention will be a questionary.
2973322|NCT02741869|Experimental|single arm|This is a single arm, open label study. Subjects who meet eligibility criteria will be treated with photodisinfection therapy (MRSAid™).
2973323|NCT02741856|Experimental|Arm 1 (carboplatin/paclitaxel+standard RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 2: Week 4-6: carboplatin AUC 5 on D1 and paclitaxel 175mg/m2 on D1~Week 7-11: Weekly carboplatin AUC 2 and paclitaxel 50mg/m2 concomitant with radiotherapy (50Gy/25 fractions)"
2973324|NCT02741856|Experimental|Arm 2 (cisplatin/capecitabine+standard RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 2: Week 4-6: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 3: Week 7-9: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 4: Week 10-11: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-14~Cycles 3 and 4 are given concomitantly with radiotherapy (50Gy/25 fractions). Capecitabine stops on last day of RT."
2973325|NCT02741856|Experimental|Arm 3 (carboplatin/paclitaxel+high RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 2: Week 4-6: carboplatin AUC 5 on D1 and paclitaxel 175mg/m2 on D1~Week 7-11: Weekly carboplatin AUC 2 and paclitaxel 50mg/m2 concomitant with radiotherapy (60Gy/25 fractions)"
2973326|NCT02741856|Experimental|Arm 4 (Cisplatin+Capecitabine+high RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 2: Week 4-6: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 3: Week 7-9: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 4: Week 10-11: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-14 Cycles 3 and 4 are given concomitantly with radiotherapy (60Gy/25 fractions). Capecitabine stops on last day of RT."
2973327|NCT02741843|Experimental|Patient Education|
2973328|NCT02741843|No Intervention|Control|
2973329|NCT02741830||Uterosacral ligament suspension (USLS)|This group of patients underwent the procedure of native tissue vaginal reconstructive surgery using uterosacral ligament suspension for pelvic organ prolapse.
2973330|NCT02741830||Robotic sacrocolpopexy (RSC)|This group of patients underwent the reconstructive pelvic surgery of robotic sacrocolpopexy using synthetic mesh.
2973331|NCT02741817|Experimental|Aspirin 20mg|Supplied with sachets of 100mg soluble aspirin and training, instructions and equipment will be provided to prepare 20 mg dose twice daily x14 then aspirin 75mg once daily x14
2973332|NCT02741817|Experimental|Aspirin 75mg|This is the standard dose of aspirin the participant will already be taking. The study will require the participants to switch to soluble aspirin for two weeks to enable accurate comparison with the other dose and to take their aspirin dose in the morning. Participants will be provided with a supply of soluble aspirin, along with training, instructions and equipment to help prepare it. They should not take their usual aspirin tablets whilst receiving the study medication, but should continue all other usual medications.
2973333|NCT02741804|Active Comparator|BBH-1001 Brain Health Supplement|Patients will be given supplement containing ingredients all approved by the FDA: Turmeric (125mg), fisetin (16.65mg), green tea leaf extract (17.5mg), EPA (75mg), DHA (150mg) and Vitamin D3 (250IU). Patients will take 4 softgels once per day for entire study duration (18 months).
2973334|NCT02741804|Placebo Comparator|Brain Health Placebo|Patients will be given a pill resembling the study supplement, but instead consisting of Soybean oil (608mg). Patients will take 4 softgels once per day for the entire study duration (18 months).
2973335|NCT02741791|Experimental|AXS-05|
2973336|NCT02741791|Active Comparator|Bupropion|
2973337|NCT02741778|Other|Minimally invasive group|"In this group, all manipulations are finished by laparoscopy and thoracoscopy.~Horizontal position, undergoing laparoscopy through 5-port method. The sequence: gastric mobilization, lymph nodes dissection(including paracardial nodes, left gastric nodes, and detecting splenic nodes and common hepatic nodes ), gastric tube making, and jejunostomy.~Left lateral position, undergoing thoracoscopy through 3-port method. The sequence: mobilization of lower esophagus, lower paraesophagesl nodes and diaphragmatic nodes dissection, gastro-esophageal anastomosis by using CEEA."
2973338|NCT02741778|Other|Open group|"Right lateral position, Traditional thoracotomy through the 7th intercostal incision. The sequence: mobilization of lower esophagus, lower paraesophagesl nodes and diaphragmatic nodes dissection.~Then,oped the diaphragm,undergoing gastric mobilization, lymph nodes dissection(including paracardial nodes, left gastric nodes, and detecting splenic nodes and common hepatic nodes), gastric tube making, gastro-esophageal anastomosis by using CEEA. Nasointestinal tube is placed for feeding."
2973339|NCT02741765|Active Comparator|Group 1: Sham Group|Sham group will receive Sham rTMS+Aerobic Exercise
2973340|NCT02741765|Experimental|Group 2: Real Group|rTMS+Aerobic Exercise
2973341|NCT02741752|Experimental|test group|decortication group
2973342|NCT02741752|No Intervention|control|without decortication
2973343|NCT02741739|Experimental|Reference Drug|REGN1033 Reference Formulation
2973344|NCT02741739|Experimental|Test Drug|REGN1033 Test Formulation
2973345|NCT02741726|Experimental|dual acupoint stimulation|The acupoints of dual point group are bilateral Neiguan points(PC6) combined with Danzhong point(RN17), electric stimulation was given through electrode attached to the acupoints.
2973346|NCT02741726|Experimental|single acupoint stimulation|The acupoints of single point group is bilateral Neiguan points(PC6), Electric stimulation was given through electrode attached to the acupoints.
2973347|NCT02741726|Placebo Comparator|no stimulation|false stimulation group only attach electrodes without electric current.
2973348|NCT02741713|Sham Comparator|Interscalene Block plus Sham Block|"Twenty subjects will receive an ultrasound guided interscalene nerve block using the Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. A Sham Block of in area of PECS Pectoralis block will be done to allow for assessment of the intervention. Using the Solution for Injection in Sham Block."
2973349|NCT02741713|Active Comparator|Interscalene plus PECS Blocks|"Twenty patients will receive an ultrasound guided interscalene nerve block Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. For the Intervention, these subjects will also a PECS Pectoralis 1 and 2 Blocks using the Solution for Injection PECS Blocks, dosed at the PECS1 location and PECS2 location as described by Blanco, et al."
2973350|NCT02741700|Experimental|Gout storytelling video|Patients view a culturally relevant patient storytelling in African-American Veterans' own voices about gout and its treatment.
2973351|NCT02741700|Active Comparator|Video about management of another chronic condition|Patient narrated slide show of roughly the same duration as the experimental arm, summarizing management of a non-gout condition.
2973352|NCT02741687|Experimental|Sitagliptin Arm|"Participants will receive sitagliptin beginning the day prior to surgery and continuing daily during hospitalization (up to 10 days post-surgery).~Point of care (POC) testing will be done four times daily, before meals and at bedtime, or every 6 hours for patients who are not eating (NPO). Patients developing hyperglycemia during or after surgery will be treated with insulin per standard of care.~Patients with fasting and/or premeal blood glucose levels >180 mg/dl will receive supplemental insulin provided on a sliding scale. Patients with two consecutive fasting and/or premeal blood glucose levels >180 mg/dl, or with average daily blood glucose levels >180 mg/dl will be started on rescue therapy with subcutaneous insulin once daily plus correction doses by a sliding scale."
2973353|NCT02741687|Placebo Comparator|Placebo Arm|"Participants will receive a placebo tablet beginning the day prior to surgery and continuing daily during hospitalization (up to 10 days post-surgery).~Point of care (POC) testing will be done four times daily, before meals and at bedtime, or every 6 hours for patients who are not eating (NPO). Patients developing hyperglycemia during or after surgery will be treated with insulin per standard of care.~Patients with fasting and/or premeal blood glucose levels >180 mg/dl will receive supplemental insulin provided on a sliding scale. Patients with two consecutive fasting and/or premeal blood glucose levels >180 mg/dl, or with average daily blood glucose levels >180 mg/dl will be started on rescue therapy with subcutaneous insulin once daily plus correction doses by a sliding scale."
2973354|NCT02741674||Roux-en-y gastric bypass (RYGB)|"Adults and children age ≤79 years at time of surgery~Had a primary (not revision) Roux-en-y gastric bypass from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)~Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
2973355|NCT02741674||Adjustable gastric banding (AGB)|"Adults and children age ≤79 years at time of surgery~Had a primary (not revision) adjustable gastric banding procedure from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)~Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
2973356|NCT02741674||Sleeve gastrectomy (SG)|"Adults and children age ≤79 years at time of surgery~Had a primary (not revision) sleeve gastrectomy from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)~Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
2973357|NCT02741661||Normal coronary arteries|Patients in whom coronary arteriography has demonstrated no significant tortuosity.
2973358|NCT02741661||Tortuous coronary arteries|Patients in whom coronary arteriography has demonstrated tortuous coronary arteries defined as >1 major bend of >45 degrees in a major coronary artery
2973359|NCT02741648||ELBW Infants with Prolonged Irradiation Storage Time|Extremely Low Birth Weight Infants whose Red Blood Cell (RBC) transfusion had prolonged Irradiation Storage Time (IST) being tested with metabolomics profile.
2973360|NCT02741648||ELBW Infants without Irradiation Storage|Extremely Low Birth Weight Infants whose Red Blood Cell (RBC) transfusion did not have Irradiation Storage being tested with metabolomics profile.
2973361|NCT02741648||ELBW Infants with NEC|"Extremely Low Birth Weight Infants with Necrotizing Enterocolitis (NEC defined as Bell's Stage II or greater) and receiving Red Blood Cell (RBC) Transfusions being tested with Near Infrared Spectroscopy."
2973362|NCT02741648||ELBW Infants without NEC|Extremely Low Birth Weight Infants without Necrotizing Enterocolitis being tested with Near Infrared Spectroscopy.
2973363|NCT02741622|Experimental|Exercise|Acute High aerobic intensity training (HIT) and long slow distance training (LSD)
2973364|NCT02741609|Experimental|Early/Late Stage Lyme disease|Have early Lyme disease based on the following criteria: Signs, symptoms and clinical history consistent with early stage Lyme disease. Subjects must have a physician-diagnosed erythema migrans (EM) rash and should have systemic symptoms indicative of disseminated infection. Symptoms may include fever, headache, fatigue, myalgias, arthralgias, and stiff neck. Paired acute and convalescent titers will be drawn (first draw at time of initial visit and second draw 4 weeks later). Have late Lyme disease based on the following criteria: Signs, symptoms and clinical history consistent with late stage Lyme disease, including but not limited to disseminated rash, arthritis, meningitis, facial palsy, or carditis. Qualified subjects will be administered the Borrelia Diagnostic Test.
2973365|NCT02741596|Experimental|Rollover Participants|Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.
2973366|NCT02741596|Experimental|Non-rollover Participants|Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
2973367|NCT02741583|Experimental|altitude rehabilitation program|3 weeks rehabilitation program at high altitude (3200m)
2973368|NCT02741583|Active Comparator|rehabilitation program|3 weeks rehabilitation program at low altitude (760m)
2973369|NCT02741570|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
2973370|NCT02741570|Active Comparator|Extreme Regimen|Specified dose on specified days
2973371|NCT02741557|Experimental|DTG/RPV FDC-DTG plus RPV|Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet in Period 1 under fed state. After a washout period of at least 21 days, subjects will receive a single oral dose of separate tablet formulations of DTG 50 mg and RPV 25 mg together in Period 2 under fed state.
2973372|NCT02741557|Experimental|DTG plus RPV-DTG/RPV FDC|Subjects will receive a single oral dose of separate tablet formulations of DTG 50 mg and RPV 25 mg together in Period 1 under fed state. After a washout period of at least 21 days, subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet in Period 2 under fed state.
2973373|NCT02741544||Patients with newly-diagnosed multiple myeloma (NDMM)|Patients with newly-diagnosed multiple myeloma (NDMM) who are treated with Revlimid Capsules (Revlimid)
2973374|NCT02741531|Experimental|Intervention|Patients in this group will have their bladder filled with 150 cubic centimeters (cc) of saline solution prior to being moved to the PACU.
2973375|NCT02741531|No Intervention|Control|patients in this group will have their bladders drained completely prior to being moved to the PACU as is the current standard of care.
2973376|NCT02741518|Active Comparator|Treatment Arm|The treatment arm will receive an induction dose of FMT via capsules (30) followed by monthly maintenance oral capsules(12) at week 4 and week 8. Donor Stool from healthy lean donors and placebo material will be obtained from OpenBiome. OpenBiome, is a nonprofit 501(c)(3) organization that provides hospitals with screened, filtered, and frozen material ready for clinical use
2973377|NCT02741518|Placebo Comparator|Placebo Arm|The placebo group will receive a placebo FMT capsules at the time of their screening colonoscopy followed by monthly intake of oral placebo capsules at week 4 and week 8
2973378|NCT02741505|Experimental|Sleep Deprivation followed by Normal Sleep|Subjects will be sleep deprived at the sleep laboratory.
2973379|NCT02741492|Active Comparator|Block Group|Continuous Transversus Abdominis Plane Catheter
2973380|NCT02741492|Sham Comparator|Sham Group|Continuous Sham Catheter
2973381|NCT02741479|Experimental|K Tape Group|
2973382|NCT02741479|Active Comparator|Sham Group|
2973383|NCT02741479|Experimental|No Tape|
2973384|NCT02741466|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application
2973385|NCT02741453|Active Comparator|Standard Practice|Placement of a CVC by standard practice
2973386|NCT02741453|Experimental|Bilateral IJ Ultrasound Scanning|Placement of a CVC after mandatory ultrasound scanning of both right and left internal jugular veins
2973387|NCT02741427|Placebo Comparator|G1 (group 1) - Conventional toothpaste|G1 used a conventional toothpaste in daily oral regimen
2973388|NCT02741427|Experimental|G2 (group 2) - Whitening toothpaste|G2 used a whitening toothpaste containing blue pigment in daily oral regimen
2973389|NCT02741427|Active Comparator|G3 (group 3) - 10 % Carbamide peroxide|G3 made an at-home tooth bleaching with 10 % Carbamide peroxide
2973390|NCT02741414|Experimental|H pylori culture negative group|The patients who have the negative result of H pylori culture were classified into H pylori culture negative group.
2973391|NCT02741414|Experimental|The first successful eradication group|The patients with first eradication therapy of H. pylori infection have the first successful treatment based on the standardized treatment including antibiotics selection from antibiotic susceptibility testing and proton pump inhibitors （PPIs) dose selection from CYP2C19 gene sequencing.
2973392|NCT02741414|Experimental|The refractory infection of H. pylori group|The patients with first eradication therapy of H. pylori infection have the two failure treatment based on the standardized treatment including antibiotics selection from antibiotic susceptibility testing and PPIs dose selection from CYP2C19 gene sequencing.
2973393|NCT02741401|Active Comparator|Therapy standard|Patients receive usual postoperative care
2973394|NCT02741401|Experimental|Therapy standard + hand-foot massage|Patients receive usual postoperative care and hand-foot massage
2973395|NCT02741388|Experimental|Selinexor + immunochemotherapy|"Selinexor will be administered orally on Day1, 3, 8 and 10 of each 3-week cycle with an immunochemotherapy, R-DHAOx (Group A: rituximab + dexamethasone + oxaliplatin + cytarabine) or R-GDP (Group B: rituximab + dexamethasone + gemcitabine + cisplatin) for 3 cycles (choice of the immunochemotherapy left at the investigator's decision before patient's inclusion).~Different dose levels of selinexor will be examined sequentially in each group: 20 mg flat (DL-1), 40 mg flat (DL1), 60 mg flat (DL2), 80 mg flat (DL3)."
2973396|NCT02741375||Brain Death Group (BD group)|Patients assessed as brain-dead at the first clinical evaluation by the OTBD committee were definitively diagnosed with BD through repeat clinical evaluation after 24 h or through CT angiography as a corroboratory test. Patients regarded as definitely brain-dead on the basis of this evaluation were classified as the BD group.
2973397|NCT02741375||Non-Brain Death Group (Non BD group)|Patients assessed as brain-dead at the first clinical evaluation by the OTBD committee were definitively diagnosed with BD through repeat clinical evaluation after 24 h or through CT angiography as a corroboratory test. Patients regarded as definitely not brain-dead on the basis of this evaluation were classified as the non-BD group.
2973424|NCT02741193|Experimental|nTMS|Patients will receive a single-pulse TMS mapping of the motor area for the following reasons to determine the motor threshold, measure concurrent EMG, and mapping of the upper extremity.
2973398|NCT02741362|Experimental|ADSC arm|Single intravenous administration of Stromal Vacsular Fraction (SVF) cells soinating Adipose Derived Stem Cells (ADSC) 6 week baseline data prior to the injection of ADSC will be collected. 6 week, 3 months and 6 months follow up data will be compared against baseline.
2973399|NCT02741336|Experimental|CBT-I Intervention|For those randomized to the CBT-I group, the therapist will initiate telephone-delivered cognitive-behavioral therapy within 2 weeks of baseline assessment. Participants will complete 4 telephone sessions over a period of 8 weeks. Sessions last approximately 45 minutes. CBT-I is a short-term, focused psychotherapy that is action-oriented, practical, rational, and helps the patient gain independence and effectiveness in dealing with real-life issues. Techniques utilized in CBT-I include psychoeducation, sleep hygiene, cognitive restructuring, stimulus control, sleep restriction, and relaxation training.
2973400|NCT02741336|Active Comparator|Self-Monitoring Control Group|Individuals randomized to the self-monitoring control group will be asked to complete a weeklong sleep diary every other week for 8 weeks. The sleep diary will inquire about (1) the time of getting into bed; (2) the time at which the individual attempted to fall asleep; (3) sleep onset latency; (4) number of awakenings; (5) duration of awakenings; (6) time of final awakening; (7) final rise time; (8) perceived sleep quality (rated via Likert scale); and (9) an additional space for open-ended comments from the respondent. The control condition is designed to increase self-monitoring, which has been demonstrated to be an effective means of inducing change for various health behaviors such as diet and exercise.
2973401|NCT02741323|Experimental|Arm 1: Maraviroc (MVC)|Participants will receive MVC at the time of admission for transplantation and prior to transplant. Participants will receive MVC throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
2973402|NCT02741323|Placebo Comparator|Arm 2: Placebo|Participants will receive placebo at the time of admission for transplantation and prior to transplant. Participants will receive placebo throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
2973403|NCT02741310|Placebo Comparator|Placebo|
2973404|NCT02741310|Active Comparator|AMG 334|
2973405|NCT02741297|Experimental|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
2973406|NCT02741284|Experimental|No Oxygen|Room air
2973407|NCT02741284|Active Comparator|Oxygen|10L oxygen by nonrebreather mask
2973408|NCT02741271|Experimental|MF/F 100/10 mcg BID|"After a 2 week run-in period on open-label mometasone furoate (MF; MK 0887), administered by MDI, 100 mcg BID, a group of eligible participants will be assigned randomly to receive double-blinded mometasone furoate/formoterol fumarate (MF/F; MK-0887A) MDI 100/10 mcg BID for 24 weeks.~Participants may use study-provided short-acting beta agonist (albuterol/salbutamol), as needed (PRN) for the relief of asthma symptoms and/or may receive study-provided systemic corticosteroid (prednisone/prednisolone) for acute asthma worsening per investigator discretion."
2973409|NCT02741271|Active Comparator|MF 100 mcg BID|"After a 2 week run-in period on open-label MF MDI 100 mcg BID, a group of eligible participants will be assigned randomly to receive double-blinded MF MDI 100 mcg BID for 24 weeks.~Participants may use study-provided short-acting beta agonist (albuterol/salbutamol), PRN for the relief of asthma symptoms and/or may receive study-provided systemic corticosteroid (prednisone/prednisolone), for acute asthma worsening per investigator discretion."
2973410|NCT02741258|Experimental|Mepitel Film|Mepitel film will be placed on the patients' skin just before the start of the radiotherapy and will be replaced once a week until the end of the radiotherapy. In case of skin toxicities mepitel film will be placed until resolution of the toxicities. In case of new skin toxicities appearance the patient will be retreated with Mepitel.
2973411|NCT02741258|Active Comparator|Excipial U hydrolotion, Flammazin skin cream|Patients will be treated with aqueous (Excipial U hydrolotion) or antiseptic (Flammazine or Ialugen Plus) cream in case of skin erythema due to radiotherapy. In case of new skin toxicities appearance the patient will be retreated with standard of care treatment.
2973412|NCT02741245|Active Comparator|Ezetimibe 10 mg|1 Ezetimibe 10 mg tablet and 2 Rosuvastatin placebo capsules once daily for 12 weeks
2973413|NCT02741245|Active Comparator|Rosuvastatin 2.5 mg|1 Rosuvastatin 2.5 mg capsule, 1 Rosuvastatin placebo capsule and 1 Ezetimibe placebo tablet once daily for 12 weeks.
2973414|NCT02741245|Active Comparator|Rosuvastatin 5.0 mg|2 Rosuvastatin 2.5 mg capsules and Ezetimibe placebo tablet once daily for 12 weeks.
2973415|NCT02741245|Experimental|Ezetimibe 10 mg+ Rosuvastatin 2.5 mg|1 Ezetimbie 10 mg tablet, 1 Rosuvastatin 2.5 mg capsule and 1 Rosuvastatin placebo capsule once daily for 12 weeks.
2973416|NCT02741245|Experimental|Ezetimibe 10 mg+ Rosuvastatin 5.0 mg|1 Ezetimbie 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules once daily for 12 weeks.
2973417|NCT02741232|Active Comparator|Pectoral nerve block|After induction of general anesthesia and under ultrasound visual guidance, pectoral block is performed with 30 mL total of local anesthetic (1% lidocaine + 1/400000 epinephrine). 10 mL of local anesthetic between pectoralis major muscle and pectoralis minor muscle and 20 mL between pectoralis minor muscle and serratus anterior muscle at the third rib.
2973418|NCT02741232|Sham Comparator|Sham block|No needle or injection will be used
2973419|NCT02741219|Placebo Comparator|Control Group|Parturients in this group receive 20ml intravenous normal saline immediately after delivery. Their patient controlled analgesia (PCA) protocol after surgery consists of 100 mcg sufentanil diluted into 100ml and administer at a background infusion of 1ml/h,and a bolus of 2ml, with a lock-out of 8min.
2973420|NCT02741219|Experimental|Dex Group|Parturients in this group receive 0.5mcg/kg intravenous dexmedetomidine diluted to 20ml with normal saline. Their PCA protocol after surgery is 100mcg sufentanil and 300mcg dexmedetomidine diluted to 100ml in saline, with the continuous infusion of 1ml/h, and a bolus of 2 ml, with a lock-out of 8min.
2973421|NCT02741206|Active Comparator|High Risk PTSD Group 1|Forty women who are eligible for the study will be randomized into either the Bellevue ROSE intervention (treatment group) or a psycho-education session and usual, standard of care (control group 1)
2973422|NCT02741206|Active Comparator|High Risk PTSD Group 2|Forty women who are eligible for the study will be randomized into either the Bellevue ROSE intervention (treatment group) or a psycho-education session and usual, standard of care (control group 1)
2973423|NCT02741206|Experimental|Low Risk PTSD Control|Twenty additional women, who are at lower risk and thus not eligible for randomization, will also receive one psycho-education session and usual care (control group 2).
2973425|NCT02741180|Other|Patients with Arrhythmias|
2973427|NCT02741167||CRS and HIPEC|Patients subjected to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) due to primary or secondary peritoneal malignancy
2973428|NCT02741154|Experimental|aromataze group|patients will receive induction with HMG plus aromataze inhibitor plus GnRh antagonist plus HCG injection
2973429|NCT02741154|Active Comparator|classic group|same protocol for induction without aromataze inhibitor
2973430|NCT02741141|Active Comparator|Classical partograph|Labour dystocia is diagnosed when cervical dilation is less than 1 cm per hour or after 3 hours at complete cervical dilation without engagement of the presentation. In this case, active management of labour is started with introduction of oxytocin, artificial rupture of membranes and supportive therapy.
2973431|NCT02741141|Experimental|New partograph|The second strategy is based on the partograph developped by Neal and Lowe. An active management of labour is started when crossing the dystocia line or when there are no cervical modifications after 4 hours beyond 5 cm of cervical dilation. In this case, active management of labour is started with introduction of oxytocin, artificial rupture of membranes and supportive therapy.
2973432|NCT02741128|Experimental|CYD Dengue vaccine group|Subjects will receive 3 doses of CYD dengue vaccine at 0, 6, and 12 months
2973433|NCT02741128|Placebo Comparator|Placebo vaccine group|Subjects will receive 3 doses of placebo (NaCl, 0.9%) vaccine at 0, 6, and 12 months
2973434|NCT02741115|Experimental|Drug|Udenafil. One tablet twice daily for 26 weeks
2973435|NCT02741115|Experimental|Placebo|Placebo. One tablet twice daily for 26 weeks
2973436|NCT02741102|Experimental|Women with AUFI|Women with AUFI must meet criteria for uterine transplant. In vitro fertilization to obtain 6 (screened) healthy embryos for cryo-preservation precedes uterine transplant from an appropriate donor The recipient will be required to take potent anti rejection medications including Thymoglobulin, Prednisone, Tacrolimus, Mycophenolate Mofetil (MMF) , later substituted with Azathioprine to avoid birth defects. One year later, up to 6 attempts using 1 screened embryo at a time will be tried to achieve pregnancy. During pregnancy, the high risk pregnancy and transplant teams will follow the recipient. The goal is a full term baby and delivery will be by Caesarian section. A second pregnancy may be attempted. Afterward, the uterus will be explanted.
2973437|NCT02741089||Indication for a flexible bronchoscopy|Patients representing to the hospital with the indication for a flexible bronchoscopy
2973438|NCT02741076|Experimental|Suboptimal Responders, continuation arm - Morphine|Suboptimal responders to high-dose opioid therapy that will receive ER opioid tablets + placebo tablets during tapering to maintain the blind
2973439|NCT02741076|Experimental|Suboptimal Responders, discontinuation arm - Morphine Placebo|Suboptimal responders to high-dose opioid therapy that will receive matching placebo tablets for the ER opioid + ER opioid tablets only during the first 3-4 weeks after randomization
2973440|NCT02741076|Experimental|Optimal Responders, continuation arm - Morphine|Optimal responders to high-dose opioid therapy that will receive ER opioid tablets + placebo tablets during tapering to maintain the blind
2973441|NCT02741076|Experimental|Optimal Responders, discontinuation arm - Morphine Placebo|Optimal responders to high-dose opioid therapy that will receive matching placebo tablets for the ER opioid + ER opioid tablets only during the first 3-4 weeks after randomization
2973442|NCT02741076|Experimental|Suboptimal Responders, continuation arm - Oxycodone|Suboptimal responders to high-dose opioid therapy that will receive ER opioid tablets + placebo tablets during tapering to maintain the blind
2973443|NCT02741076|Experimental|Suboptimal Responders, continuation arm - Oxymorphone|Suboptimal responders to high-dose opioid therapy that will receive ER opioid tablets + placebo tablets during tapering to maintain the blind
2973444|NCT02741076|Experimental|Suboptimal Responders, discontinuation arm - Oxycodone Placebo|Suboptimal responders to high-dose opioid therapy that will receive matching placebo tablets for the ER opioid + ER opioid tablets only during the first 3-4 weeks after randomization
2973445|NCT02741076|Experimental|Suboptimal Responders discontinuation arm-Oxymorphon Placebo|Suboptimal responders to high-dose opioid therapy that will receive matching placebo tablets for the ER opioid + ER opioid tablets only during the first 3-4 weeks after randomization
2973446|NCT02741076|Experimental|Optimal Responders, continuation arm - Oxycodone|Optimal responders to high-dose opioid therapy that will receive ER opioid tablets + placebo tablets during tapering to maintain the blind
2973447|NCT02741076|Experimental|Optimal Responders, continuation arm - Oxymorphone|Optimal responders to high-dose opioid therapy that will receive ER opioid tablets + placebo tablets during tapering to maintain the blind
2973448|NCT02741076|Experimental|Optimal Responders, discontinuation arm - Oxycodone Placebo|Optimal responders to high-dose opioid therapy that will receive matching placebo tablets for the ER opioid + ER opioid tablets only during the first 3-4 weeks after randomization
2973449|NCT02741076|Experimental|Optimal Responders, discontinuation arm - Oxymorphone Placebo|Optimal responders to high-dose opioid therapy that will receive matching placebo tablets for the ER opioid + ER opioid tablets only during the first 3-4 weeks after randomization
2973450|NCT02741063|Experimental|high autistic and oxytocin group|subject with high ASQ scores will receive oxytocin treatment
2973451|NCT02741063|Experimental|low autistic and oxytocin group|subject with low ASQ scores will receive oxytocin treatment
2973452|NCT02741063|Placebo Comparator|high autistic and placebo group|subject with high ASQ scores will receive placebo treatment
2973453|NCT02741063|Placebo Comparator|low autistic and placebo group|subject with low ASQ scores will receive placebo treatment
2973454|NCT02741050|Experimental|Tailored Physical Activity Intervention|Intervention group will receive Spanish-language physical activity print intervention based on SCT and Transtheoretical Model, (TTM) that emphasizes behavioral strategies for increasing activity levels.
2973455|NCT02741050|Active Comparator|Standard of Care Control Group|Control group will receive standard of care through the Family Medicine clinic as well as monthly questionnaires on topics other than physical activity (e.g. diet) to complete.
2973456|NCT02741037|Experimental|Dyadic lifestyle intervention|Mothers and daughters participate in the Unidas partner intervention together.
2973457|NCT02741037|Experimental|Individual lifestyle intervention|Mothers participate in the Unidas intervention alone, without their related daughters. Unrelated daughters participate in the Unidas intervention alone without their related mothers.
2973458|NCT02741037|Other|Usual Care|Mothers and daughters receive usual care.
2973459|NCT02741024|Active Comparator|Amodiaquine-Artesunate (ASAQ)|Treatment regimen consisted of Amodiaquine-Artesunate (ASAQ) fixed dose (FD) (Winthrop Sanofi Aventis), given as 1 tablet/day 3 days (5-8 kg 1 tab of 25mg artesunate/67.5 mg amodiaquine base, 9-17 kg 50 mg artesunate/135 mg amodiaquine base)
2973460|NCT02741024|Active Comparator|Artemether-Lumefantrine (AL)|Treatment consisted of Artemether-Lumefantrine (AL) (Coartem, Novartis) given as six twice/daily doses over three days (5-14 kg 1tab of 20mg artemether/120mg lumefantrine BD, 15-24 kg 2tabs of 20mg artemether/120mg lumefantrine BD with fatty food).
2973461|NCT02741011|Other|Radiological imaging|Mentally handicapped patients underwent sedation anesthesia with IV Propofol and then tomographic images were obtained with NewTom 5G. Orthopantomographies (OPGs) were obtained by processing the raw images and radiological examination of the patients were performed on OPGs.
2973462|NCT02740998||Depo Provera|Ten women ages 18-40 who elect to start a using Depo Provera for contraception.
2973463|NCT02740998||Mirena IUD|Ten women ages 18-40 who elect to start a using a Mirena IUD for contraception.
2973464|NCT02740998||Nexplanon|Ten women ages 18-40 who elect to start a using Nexplanon for contraception.
2973465|NCT02740998||Control: Tubal Sterilization|Five women ages 18-40 who elect to have a tubal sterilization.
2973466|NCT02740985|Experimental|AZD4635 Monotherapy|"AZD4635 monotherapy will be given twice daily in a dose escalation scheme in Part 1a. Patients will receive a single dose of AZD4635 on Day 1 and will have blood samples collected to assess pharmacokinetics over 24 hours. On Day 2, twice daily dosing will commence and continue daily. Other dosing schedules (e.g., once daily, three times daily) may be investigated during the study on the basis of emerging safety, PK, and exploratory mechanism of action (MOA) data. During monotherapy dosing, a cycle will be 3 weeks. The Safety Review Committee (SRC) will determine whether dose escalation should occur based on safety assessments in the first cycle supported by a Bayesian Logistic Regression Model (BLRM) approach.~In Phase 1b additional expansion cohorts will be investigated based on the activity observed in the Phase 1a monotherapy dose escalation cohorts as well as monotherapy responses seen in other A2aR inhibitor studies."
2973467|NCT02740985|Experimental|AZD4635 + Durvalumab Combination|"In the combination therapy cohorts AZD4635 will be given as monotherapy during a 2-week lead-in. After the 2-week lead-in durvalumab will be given by IV infusion on Day 1 of each 4-week cycle. Other dosing schedules (e.g., once daily, three times daily) may be investigated during the study on the basis of emerging safety, PK, and exploratory mechanism of action (MOA) data. During combination therapy dosing, a cycle will be 4 weeks. The Safety Review Committee (SRC) will determine whether dose escalation should occur based on safety assessments in the first cycle supported by a Bayesian Logistic Regression Model (BLRM) approach.~In Phase 1b additional expansion cohorts receiving combination therapy with AZD4635 and durvalumab will be investigated in patients with non small-cell lung cancer or metastatic castrate-resistant prostate cancer."
2973468|NCT02740972|Experimental|NS-065/NCNP-01 40mg/kg|Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 40mg/kg dose once a week for 24 weeks
2973469|NCT02740972|Experimental|NS-065/NCNP-01 80mg/kg|Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 80mg/kg once a week for 24 weeks
2973470|NCT02740972|Placebo Comparator|Placebo|Two patients in each of the dose groups will be administered placebo as an intravenous infusion once a week for 4 weeks followed by 20 weeks of open label treatment
2973471|NCT02740959|Experimental|Astragalus Polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
2973472|NCT02740959|Experimental|Astragalus Polysaccharides 250 mg|PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
2973473|NCT02740946|Experimental|Exercise therapy|Exercise therapy 5 months
2973474|NCT02740933|Experimental|Demeclocycline|"All subjects will take Demeclocycline 300 mg po bid. Patients will be advised to take demeclocycline on an empty stomach, at least 1-2 hours before meals, and they will be warned that it can reduce the efficacy of oral contraceptives.~The investigators will begin by treating subjects with 2 days of demeclocycline. The investigators will increase the numbers of days that subjects are exposed to demeclocycline in increments of 1 day until at least 80% of patients at a given dose have detectably fluorescent tumors, or participants reach 5 days of drug, whichever comes first."
2973475|NCT02740920|Experimental|Pembrolizumab|200mg IV Day 1 every 3 weeks.
2973476|NCT02740894||targeted therapy|according to national healthy policy, targeted therapy is the optional therapy
2973477|NCT02740894||traditional chemotherapy|according to national healthy policy, chemotherapy is the first line treatment.
2973478|NCT02740881|Experimental|Training Support System|Participants receive training in Contingency Management and immediately receive the full training support system and quality assurance feedback for 15 months while they provide the treatment.
2973479|NCT02740881|Active Comparator|CM-CAT then TSS|Participants are trained in Contingency Management and use the treatment without training support and quality assurance feedback for 9 months. After 9 months they continue using Contingency Management but now receive the full training support system and quality assurance feedback for 6 months.
2973480|NCT02740868|Active Comparator|Healthy|Healthy Participants ages 8 and older. Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
2973481|NCT02740868|Active Comparator|Cystic Fibrisos|Participants with cystic fibrosis ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
2973482|NCT02740868|Active Comparator|Asthma|Participants with asthma ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
2973483|NCT02740842|Active Comparator|Non-intensive group|Essential Health Care (EHC) only This arm is the basic comparison arm, which will receive the standard package of health services offered through BRAC's essential health care (basic antenatal care, basic counseling on health and nutrition through health worker home visits. In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm.
2973555|NCT02740439|Experimental|Intervention Meal|Intervention meals will contain 1 large avocado and be consumed daily for 12 weeks.
2973484|NCT02740842|Experimental|Intensive group|"Interpersonal behavioral change communication This arm will have a behavior change communications intervention to improve infant and young child feeding practices. The intervention will be delivered primarily by the frontline health workers who will visit mothers in their homes and counsel them on essential IYCF practices.~In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm."
2973485|NCT02740829|Placebo Comparator|Intranasal placebo|placebo comparator
2973486|NCT02740829|Experimental|Intranasal glucagon|active intervention
2973487|NCT02740803|Experimental|NaF - R|Participants will use sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
2973488|NCT02740803|Experimental|NaF - NR|Participants will use sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
2973489|NCT02740803|Experimental|NaMFP- R|Participants will use sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
2973490|NCT02740803|Experimental|NaMFP- NR|Participants will use sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
2973491|NCT02740803|Experimental|SnF + NaF - R|Participants will use stannous fluoride combined with sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
2973492|NCT02740803|Experimental|SnF + NaF - NR|Participants will use stannous fluoride combined with sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
2973493|NCT02740803|Experimental|NaF + NaMFP - R|Participants will use sodium fluoride combined sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
2973494|NCT02740803|Experimental|NaF + NaMFP - NR|Participants will use sodium fluoride combined sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
2973495|NCT02740803|Experimental|AmF - R|Participants will use amine fluoride toothpaste (1,400 ppmF) to brush for two minutes followed by rinsing with distilled water.
2973496|NCT02740803|Experimental|AmF - NR|Participants will use amine fluoride toothpaste (1,400 ppmF) to brush for two minutes not followed by rinsing with distilled water.
2973497|NCT02740803|Experimental|0 Fluoride - R|Participants will use non-fluoridated toothpaste (0 ppmF) to brush for two minutes followed by rinsing with distilled water.
2973498|NCT02740803|Experimental|0 Fluoride - NR|Participants will use non-fluoridated toothpaste (0 ppmF) to brush for two minutes not followed by rinsing with distilled water.
2973499|NCT02740790|Experimental|HPV vaccine 1|300 women between 9-17 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
2973500|NCT02740790|Placebo Comparator|Placebo 1|300 women between 9-17 yeas of age, receiving 0,2,6 month-schedule Placebo.
2973501|NCT02740790|Experimental|HPV vaccine 2|120 women between 18-26 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
2973502|NCT02740790|Experimental|HPV vaccine 3|180 women between 27-45 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
2973503|NCT02740790|Placebo Comparator|Placebo 2|120 women between 18-26 yeas of age, receiving 0,2,6 month-schedule Placebo.
2973504|NCT02740790|Placebo Comparator|Placebo 3|180 women between 27-45 yeas of age, receiving 0,2,6 month-schedule Placebo.
2973505|NCT02740777|Experimental|2-dose adolescent|300 adolescent girl will receive a two-dose schedule (0 day, 6 months) immunization of HPV-16/18 vaccine.
2973506|NCT02740777|Experimental|3-dose adolescent|300 adolescent girl will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.
2973507|NCT02740777|Experimental|3-dose adult|300 adult women will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.
2973508|NCT02740764|Experimental|Optimization of drug prescribing|The group with optimization program will have: (i) a medical history of the drug prescribing; (ii) analysis and pharmaceutical recommendations and (iii) preparation of a management plan. Notices will be sent only to referring physicians in this experimental group.
2973509|NCT02740764|No Intervention|No intervention|This group will receive the current management of patients in geriatric or memory consultation, during which the intervention of a clinician pharmacist is not provided. There will be a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, accepted by the specialist physicians in charge of the patient at the hospital, but the recommendations will not be transmitted to the referring physicians of patients.
2973510|NCT02740751|Active Comparator|Still-Tee|Generic name: galactogoe herbal tee, still-tee Dosage: Three cups (each 200 ml) of tea of Still-Tee galactogogue tea will be used Frequency: Three times in a day Duration: for 4 weeks after birth
2973511|NCT02740751|Placebo Comparator|Placebo|The mothers of the babies will receive placebo tea which does not contain galactogogue herbs
2973512|NCT02740751|No Intervention|Water|The mothers of the babies will receive water
2973513|NCT02740725|Active Comparator|Recommendation of Patching|Patients will receive two hours of patching in the case of one line difference of best corrected visual acuity(BCVA) between two eyes during one month.
2973514|NCT02740725|Active Comparator|Recommendation of Patching and interactive binocular treatment|Patients will receive interactive binocular treatment addition to patch therapy in the least of 4 to 5 days of a week within 20-30 minutes in each day during one month.
2973515|NCT02740712|Other|single arm probe drugs and rucaparib|Caffeine Warfarin Vitamin K Omeprazole Midazolam Digoxin rucaparib
2973516|NCT02740699|Other|Moderate|Moderate intensity treatment
2973517|NCT02740699|Other|High|High intensity treatment
2973518|NCT02740686||Frequent exacerbators|"Exacerbations will be defined as a respiratory event which led to a hospitalisation or the prescription of antibiotics and/or oral corticosteroids. Clinicians will ask patients to retrospectively recall how many exacerbations they have had in the past 12 months. Patients will be allocated to the frequent exacerbators group based on whether they have had 2 or more hospitalisations for exacerbations or have taken 2 or more courses on steroids/antibiotics within the past 12 months. Blood sample collection at the following pulmonary rehabilitation sessions: 1st (pre-exercise), 2nd (pre and post-exercise), 8th (pre-exercise), last session (pre and post exercise). Sputum samples collected pre-exercise at the following pulmonary rehabilitation sessions: 1st, 8th, and last session."
2973519|NCT02740686||Infrequent exacerbators|"Exacerbations will be defined as a respiratory event which led to a hospitalisation or the prescription of antibiotics and/or oral corticosteroids. Clinicians will ask patients to retrospectively recall how many exacerbations they have had in the past 12 months. Patients will be allocated to the infrequent exacerbators group based on whether they have had no more than 1 hospitalisation for exacerbations or have not taken more than 1 course of steroids/antibiotics within the past 12 months. Blood sample collection at the following pulmonary rehabilitation sessions: 1st (pre-exercise), 2nd (pre and post-exercise), 8th (pre-exercise), last session (pre and post exercise). Sputum samples collected pre-exercise at the following pulmonary rehabilitation sessions: 1st, 8th, and last session."
2973520|NCT02740686||Healthy smokers|Recruited in accordance with inclusion/exclusion criteria with no medical history of COPD diagnosis and currently smoke.This group will be recruited by a nurse using medical records to assess smoking status and age-matching to the COPD groups. A resting blood sample will be taken from these patients and used to compare baseline measurements with the COPD groups.
2973521|NCT02740686||Healthy never smokers|Recruited in accordance with inclusion/exclusion criteria with no medical history of COPD diagnosis and have never smoked.This group will be recruited by a nurse using medical records to assess smoking status and age-matching to the COPD groups. Resting blood samples will be taken from these patients and used to compare baseline measurements with the COPD groups.
2973522|NCT02740673|Other|Driving simulator|Using the driving simulator for 30 min.
2973523|NCT02740660|Experimental|Caffeine 100mg / Albuterol 4mg|One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.
2973524|NCT02740660|Placebo Comparator|Placebo|One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.
2973525|NCT02740647|Experimental|Intervention group|Intervention group will be getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery.
2973526|NCT02740647|Placebo Comparator|Control group|the Control group will be getting intra-venous Placebo (0.9% 50 ml of sodium chloride) for 5 days.
2973527|NCT02740634|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will receive two Tau PET scans during this study.
2973528|NCT02740634|Experimental|PiB PET Scan, C-11 PiB|All subjects will receive two PiB PET scans during this study.
2973529|NCT02740621||Patients with coronary heart disease|coronary angiography with finding coronary heart disease currently no cancer 40 years or older
2973530|NCT02740621||control patients|coronary angiography with exclusion coronary heart disease or other patients with non-cardiac diseases currently no cancer 40 years or older
2973531|NCT02740608|Other|Liver transplantation|All Participants will receive liver transplantation using the OrganOx metra device
2973532|NCT02740595|Experimental|Nicotine|Use an e-cig filled with liquid with nicotine
2973533|NCT02740595|Experimental|no nicotine|Use an e-cig filled with liquid without nicotine
2973534|NCT02740595|Sham Comparator|sham comparator|Use an empty e-cigarette (sham control)
2973535|NCT02740582|Experimental|Tolcapone|40 moderate to heavy social alcohol users will receive 6 days of 100 mg tolcapone TID with an additional 100 mg one time immediately prior to the laboratory bar testing.
2973536|NCT02740582|Placebo Comparator|Placebo|40 moderate to heavy social alcohol users will receive 6 days of matched placebo TID with an additional placebo capsule immediately prior to the laboratory bar testing.
2973537|NCT02740556|Placebo Comparator|AdhereTech Passive Monitoring|Patients not using the HepCure patient app while AdhereTech passively monitors adherence (no chimes or reminders).
2973538|NCT02740556|Experimental|HepCure Toolkit|Patients using the HepCure patient app linked to a provider using the HepCure Provider Dashboard with AdhereTech passively monitoring adherence (no chimes or reminders).
2973539|NCT02740556|Experimental|HepCure Toolkit and AdhereTech Active Features|Patients using the HepCure patient app linked to a provider using the HepCure Provider Dashboard and with AdhereTech actively monitoring adherence (chimes and reminders enabled).
2973540|NCT02740543|Active Comparator|Irritant-Induced Asthma|
2973541|NCT02740543|Active Comparator|Allergic Asthma|
2973542|NCT02740543|Placebo Comparator|Irritant-Induced Asthma Control|
2973543|NCT02740543|Placebo Comparator|Allergic Asthma Control|
2973544|NCT02740530|Experimental|rTMS Active|High frequency pulsed repetitive magnetic stimulation at 100 % resting motor threshold will be delivered using a figure of 8 air film cooled coil attached to the Magstim® Rapid 2 machine. Resting motor threshold will be determined minimum energy needed to elicit the a reliable visible contraction in the contra-lateral first interosseous muscle using single pulse rTMS applied to the area between C1-C3 using the 10-20 international EEG electrode system. For stimulation, the coil will be positioned on the scalp corresponding to F4 then F3 electrode position using the 10-20 international EEG system. Real stimulation will consist of delivering 1200 pulses at 20 hz frequency to F4 location followed by the same stimulation to F3. The total time needed to deliver pulses is 20 minutes.
2973545|NCT02740530|Placebo Comparator|rTMS Sham|Sham stimulation will also involve delivering the same stimulus but with angulation of the coil at 45 degrees, which will give similar scalp sensation but unlikely to deliver magnetic stimulation to the cortex
2973546|NCT02740517||HUT1|First phase of the home user trial. 19 users, 12 who were part of a couple and 7 who were single.
2973547|NCT02740517||HUT2|"Second phase of home user trial, testing improvements to the device user interface as a result of the experience from HUT1. Total 11 users.~Main change to device was a simpler set of displays and button-sequence on a 24 hour period."
2973548|NCT02740517||HUT3|"Third phase of home user trial, testing the final improvements to the device. A total of 18 users, 16 of which who were part of a couple and 2 who were single.~Main change was the introduction of a scheduled recording option, making the device totally automatic in routine use."
2973549|NCT02740504||Subjects|All 20 subjects. Selected to have a range of ages (18 to 65) and BMI from 18.5 to 45
2973550|NCT02740491||The study population|The study population consists of adult patients diagnosed with localized breast cancer who have completed adjuvant treatment (chemotherapy, radiotherapy) and who are cared for in the Medical Oncology department of the Nîmes University Hospital.
2973551|NCT02740478||Volunteers|20 volunteer subjects, no selection criteria
2973552|NCT02740465|Experimental|COPD Patients|
2973553|NCT02740452|Other|Ligamys technique|Ligamys technique (device) or standard technique
2973556|NCT02740439|Placebo Comparator|Control Meal|Control meals will be isocaloric to the intervention meals but without avocado. They will also be consumed daily for 12 weeks.
2973557|NCT02740426|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy.
2973558|NCT02740426|Experimental|Single intravesical instillation|intravesical instillation within 24 hours postoperatively
2973559|NCT02740413||Patients with Haemophilia A|Patients in The MHR diagnosed with Haemophilia A
2973560|NCT02740413||Patients with Haemophilia B|Patients in The MHR diagnosed with Haemophilia B
2973561|NCT02740400|Experimental|CT-TTNB|patients receive CT-TTNB to diagnose PPLs.
2973562|NCT02740400|Experimental|EBUS-GS|patients receive EBUS-GS to diagnose PPLs.
2973563|NCT02740387|Experimental|OTO-104|12 mg dexamethasone
2973564|NCT02740374|Experimental|ROTEM|"ROTEM will be performed in patients with signs of clinically relevant bleeding and in whom blood transfusion is considered (Temp above 35 Celsius degrees; pH below 7.2; Cai above 4.6 mg/dL; Hb below 9g/dL, or below 10g/dL with anticipated greater blood loss) or at a fixed range every 2 hours or at Anesthesiologist criteria based on patient's clinical situation.~There will be also be performed standard of care test for this set of patients, as described for the CONTROL arm. ROTEM results will guide transfusion strategy."
2973565|NCT02740374|Active Comparator|CONTROL/STANDARD OF CARE|"If patients are randomized to standard coagulation tests (SCT), these will be performed according to Ohio State Wexner University Medical Center standard practices and attending's criteria, or at 2 hour intervals per protocol.~Standard of care tests include but are not limited to: hemoglobin, platelet count, fibrinogen concentration, INR, aPTT, and PT. These will be performed at fixed time points (preoperatively, every 2 hours intraoperatively, procedure completion, and 24 hours after procedure completion). Arterial blood gases will be performed repetitively intraoperatively at a fixed range every 1-hour or at attending's criteria, as well as any postoperative laboratory tests. SCT will guide transfusion management."
2973566|NCT02740361|Experimental|Deprexis|This group will receive access to the web-based Deprexis program, an online tool based on principles of cognitive behavioral therapy. Contents include (1) psychoeducation, (2) behavioral activation, (3) cognitive modification, (4) mindfulness and acceptance, (5) interpersonal skills, (6) relaxation, physical exercise and lifestyle modification, (7) problem solving, (8) expressive writing and forgiveness, (9) positive psychology, and (10) emotion-focused interventions.
2973567|NCT02740361|Experimental|DeprexisPlus|This group will receive the web-based Deprexis program (see above) plus scheduled e-mail contact (1x/week)
2973568|NCT02740361|No Intervention|Waitlist Control|Participants randomized to the control group will wait for access to the Deprexis program (waitlist control) for 6 months. After the 6-month waiting period, participants in this group will have full access to Deprexis.
2973569|NCT02740348|Experimental|ZocDoc Assistance|Research assistant sets up follow-up appointment for subject using ZocDoc.
2973570|NCT02740348|Active Comparator|ZocDoc Information|Research assistance provides subject with written information about ZocDoc.
2973571|NCT02740348|No Intervention|Usual Care|ED staff gives written and verbal discharge instructions to subject.
2973572|NCT02740335|Experimental|Octaplex|Participants to receive1 Octaplex infusion intravenously
2973573|NCT02740335|Active Comparator|Beriplex P/N (Kcentra)|Participants to receive1 Kcentra infusions intravenously
2973574|NCT02740322|Other|Hum Test|To examine and compare the Hum Test, Weber Test, and audiogram in their ability to detect and identify hearing loss, hearing loss will be simulated with the use of ear plugs (mimicking conductive hearing loss). Subjects will serve as their own control as these tests will be conducted with and without ear plugs.
2973575|NCT02740309|Experimental|Integrated Brief Behavior Therapy (IBBT) Intervention|4-sessions of IBBT for youth anxiety and depression.
2973576|NCT02740309|Active Comparator|Treatment as usual|Treatment as usual
2973577|NCT02740296||Healthy controls|Healthy controls
2973578|NCT02740296||RRMS|Relapsing-Remitting Multiple Sclerosis
2973579|NCT02740296||RRMS+MDD|Relapsing-Remitting Multiple Sclerosis and Major Depressive Disorder
2973580|NCT02740296||MDD|Major Depressive Disorder
2973581|NCT02740283|Experimental|Pregnant women|As a diagnostic study, the cohort will recruit 300 pregnant women who meet inclusion and exclusion criteria outlined below. OGTTs will be performed between 18 and 20 gestational weeks (early-OGTT) and 24 to 28 gestational weeks (regular-OGTT). Clinical and laboratory information of the mother and their offspring will be collected for analysis.
2973582|NCT02740270|Experimental|Arm A|
2973583|NCT02740270|Experimental|Arm B|
2973584|NCT02740257||Group 1 Artificial Lesions|Photos will be taken of skin lesion markings using a smartphone
2973585|NCT02740257||Group 2 high risk|A convenience sample of patients will be recruited. This population will consist of patients with known high risk to have new/changing lesions, and who fall within the Fitzpatrick skin types I-IV. High risk patients include, but are not limited to, those with dysplastic nevus syndrome, previous history of melanoma/non-melanoma skin cancer, fair skin, >16 nevi, family history of melanoma, and/or immunosuppressed status. The first photography session will be taken by the research team in all 13 projections. After the first visit, the patient will be instructed to take photographs every month for 12 months using the TBDP app on their smart phone or tablet, and have follow-up research appointments every 6 months.
2973586|NCT02740244|Active Comparator|active iTBS|Participants will receive 10 to 30 sessions of active intermittent theta burst stimulation (iTBS) consisting in delivering 2 s train of bursts containing three pulses at 50 Hz repeated each 200 ms every 10 s (iTBS). Each iTBS session contained 990 pulses and lasted 6 min. Stimulation intensity will be set at 80% of the patient's resting motor threshold. iTBS will be applied twice per day, with at least three hours between each session. Ten to 30 sessions will be delivered until patient achieved remission (i.e., 13-item Beck Depression Inventory (BDI13) score < 10). iTBS will be applied over the left dorsolateral prefrontal cortex (DLPFC) according to the individual's 3D-T1 MRI.
2973587|NCT02740244|Sham Comparator|sham iTBS|The same protocol (location, intensity, parameters of stimulation) will be applied using a commercial sham coil.
2973588|NCT02740231|Active Comparator|Reference product|
2973589|NCT02740231|Experimental|JTA-004 50 (2 ml)|
2973590|NCT02740231|Experimental|JTA-004 50 (4 ml)|
2973591|NCT02740231|Experimental|JTA-004 100 (2 ml)|
2973592|NCT02740218||Psoriasis patients|Single cohort of psoriasis patients treated with OTEZLA (apremilast)
2973593|NCT02740205|No Intervention|Control group|Hospital's standard EN support at the discretion of the Clinical Nutrition Service that is composed by physicians, dietitians, and students, provides nutritional assessments, recommendations and consultations for the in-patients that required nutrition support during their hospitalization stay. There is no protocols or algorithms for the nutritional support in our institution, the currently clinical practice of the EN is prescribed by the physician, dietitians and students during the morning rounds each 24h, the kind of EN formulas prescribed depends of the clinical status of the patient, when the patients required protein supplements modular protein supplements are added.
2973594|NCT02740205|Experimental|Algorithm for enteral nutrition support|Initial infusion of 20 to 40 ml/h, evaluated the tolerability in the next 8-12h, then the infusion can be increased 25 ml/ 8-12h for gastric infusion and 10-20 ml/h for the post-pyloric feeding, for bolus infusion an initial infusion of 125 ml each 4-5hrs and evaluated the tolerability in the next 8-12h. If the subject present intolerability to the EN, the action in the algorithm indicate hold the infusion 4h then restarted at 10 ml/h with prokinetics agents rather than the suspension. As a part of the intervention, several educational sessions for the medical, nutritionist and nurse staff were performed during the period of the study.
2973595|NCT02740192|Experimental|Adductor Canal Block|Patients in this group received local infiltration of bupivacaine in the adductor canal after surgery, in addition to the periarticular injection intra-op.
2973596|NCT02740192|Sham Comparator|Periarticular Injection|Patients in this group received a bandaid at the presumed adductor canal injection site, in addition to the periarticular injection intra-op.
2973597|NCT02740179|Experimental|Eplerenone|Eplerenone 50 mg daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
2973598|NCT02740179|Placebo Comparator|Placebo|Placebo daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
2973599|NCT02740166|No Intervention|Banding ligation group|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
2973600|NCT02740166|Experimental|Propranolol group|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
2973601|NCT02740153||Urea Cycle Disorder with Liver Transplant|"Age 18 and under~Diagnosed with the following Neonatal-type urea cycle disorders: CPSD, OTCD, ASD or ALD, as defined as follows:"
2973602|NCT02740153||Urea Cycle Disorder without Transplant|"Age 18 and under~Diagnosed with the following Neonatal-type urea cycle disorders: CPSD, OTCD, ASD or ALD, as defined as follows:"
2973603|NCT02740153||Primary Caretakers|"Primary caretaker(s) of a patient age 25 and under who has been diagnosed with either CPSD, OTCD, ASD or ALD (typically a parent, but broadly defined as those individuals who are responsible for making the child's treatment decisions and who also provide the majority of the child's physical and emotional care)~Considered, are currently considering, or opted for, liver transplantation as a treatment for UCD.~Willing to participate in a 60-minute semi-structured interview and/or a 60-90 minute focus group discussion~OR~Health care provider (e.g. metabolic disease physician, liver transplant surgeon, gastroenterologist, genetic counselor, or nurse) that participates in treating patients diagnosed with either CPSD, OTCD, ASD or ALD,~Willing to participate in a 60-minute semi-structured interview and/or a 60-90 minute focus group discussion"
2973604|NCT02740127|Experimental|Caudal Nerve Block + General Anesthesia Group|"Participants receive a caudal nerve block (CNB) prior to surgery and receive general anesthesia during surgery.~Study staff calls participant about 3 days after surgery."
2973605|NCT02740127|Active Comparator|General Anesthesia Alone Group|"Participants receive general anesthesia (GA) during surgery without a caudal nerve block.~Study staff calls participant about 3 days after surgery."
2973606|NCT02740114|Active Comparator|Bupivacaine Group|"Local wound infiltration with Bupivacaine immediately prior to wound closure during gynecological surgery.~Participants discharged with analgesic opioid regimen of Oxycodone 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.~Participants complete a pill diary every day for 30 days after hospital discharge.~Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks."
2973607|NCT02740114|Experimental|Liposomal Bupivacaine + Bupivacaine Group|"Local wound infiltration with Liposomal Bupivacaine and 0.25% Bupivacaine admixed immediately prior to wound closure during gynecological surgery.~Participants discharged with analgesic opioid regimen of Oxycodone 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.~Participants complete a pill diary every day for 30 days after hospital discharge.~Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks."
2973608|NCT02740101|Experimental|oxytocin nasal spray|subjects administrating oxytocin were divided into experimental group
2973609|NCT02740101|Placebo Comparator|placebo nasal spray|subjects administrating placebo were divided into controlled group
2973610|NCT02740075||Hand-ventilated|This group will be transported from the operating room to the intensive care unit with the anesthesia provider ventilating the patient by hand via Mapleson circuit and supplemental oxygen. Vital signs and end-tidal carbon dioxide will be monitored and recorded by one of the investigators. The anesthesia provider will be blinded to the end-tidal carbon dioxide levels and respiratory rate.
2973611|NCT02740075||Mechanically ventilated|This group will be transported from the operating room to the intensive care unit with the patient being ventilated by a transport ventilator with controlled tidal volume, respiratory rate, and positive end-expiratory pressure. Vital signs and end-tidal carbon dioxide will be monitored and recorded by one of the investigators.
2973612|NCT02740062|Active Comparator|Active treatment|Active tDCS treatment
2973613|NCT02740062|Sham Comparator|Sham treatment|Sham tDCS treatment
2973614|NCT02740049|Experimental|Astma patients|Participant undergoes a bronchoscopy to isolate epithelial cells
2973615|NCT02740023|Active Comparator|Phonak Audéo V90-13|The Phonak Audéo V90-13 will be fitted to the participants individual hearing loss.
2973616|NCT02740023|Experimental|Successor of Phonak Audéo V90-13|The successor of Phonak Audéo V90-13 will be fitted to the participants individual hearing loss.
2973617|NCT02739997|Experimental|MK-7625A + metronidazole|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) plus metronidazole 500 mg administered as an intravenous (IV) infusion every 8 hours for 4 to 14 days. The dose may be reduced to 750 mg (ceftolozane 500 mg/tazobactam 250 mg) for participants with a creatinine clearance (CrCl) of 30-50 mL/min.
2973618|NCT02739984|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every month (QM) for 12 weeks.
2973619|NCT02739984|Experimental|Evolocumab|Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks.
2973620|NCT02739971|Active Comparator|Low AGEs diet|In addition to nutritional instructions for type 2 diabetes, this arm will receive additional instructions on how to reduce AGEs in diet
2973621|NCT02739971|Placebo Comparator|Regular diet (high AGEs)|Nutritional instructions for type 2 diabetes
2973622|NCT02739958|Active Comparator|Propofol group|Patients receive only intravenous anesthetics
2973623|NCT02739958|Placebo Comparator|Isoflurane group|Patients receive isoflurane /fentanyl anesthesia
2973624|NCT02739945|Other|Open cubital tunnel release|In situ decompression (MacKinnon and Novak 2005) is made through a 6-10 cm longitudinal incision along the course of the ulnar nerve midway between the medial epicondyle and the olecranon.
2973625|NCT02739945|Other|Endoscopic cubital tunnel release|Endoscopic release follows Hoffmann's technique (Hoffmann 2006) that demonstrated the safety and efficacy of this technique in a cadaveric model and in a clinical study.
2973626|NCT02739906|Experimental|HinsBet®|
2973627|NCT02739906|Active Comparator|Humalog®|
2973628|NCT02739906|Active Comparator|Huminsulin® Normal|
2973629|NCT02739893|Experimental|Scope Guide Assisted|Scope Guide Assist to be utilized during colonoscopy
2973630|NCT02739893|Placebo Comparator|Standard|Colonoscopy completed using current SOC without scopeguide assist.
2973631|NCT02739880|Experimental|The study population|"The study population consists of postmenopausal patients (more than 2 years and less than 10 years) with a body mass index <35 with sexual disorders (dyspareunia) or vaginal discomfort associated with vaginal dryness.~Intervention: Intra-mucosal Injections of Cross-linked Hyaluronic Acid"
2973632|NCT02739867||Unprovoked VTE|Patients aged 40 years or older with a first episode of objectively confirmed, symptomatic, unprovoked deep vein thrombosis of the leg (distal or proximal) or pulmonary embolism
2973633|NCT02739841|Experimental|Ventilator hyperinflation|For the ventilator hyperinflation techniques (VHI), the study consists of three consecutive periods 1) baseline period: 10 minutes rest in side lying by effected lung uppermost with head-up 30 degree 2) Intervention period: Patients were positioned as same as baseline period and 4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial 3) recovery period: 10 minutes rest in the same position but reduce VT to initial.
2973634|NCT02739841|Experimental|Chest physical therapy|For the conventional chest physical therapy (CPT), the study will be performed in the similar procedure except the intervention period, the patient will be received vibration and passive of the both upper extremity.
2973635|NCT02739828||Patients with Hidradenitis Suppurativa|Patients with moderate or severe HS treated prescribed adalimumab according to the Swedish Summary of Product Characteristics and treated as per routine clinical practice.
2973636|NCT02739815|Placebo Comparator|Placebo|Will receive a placebo (10 ml of distilled water) in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
2973637|NCT02739815|Active Comparator|T1|Will receive Tranexamic acid 15 mg/kg in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
2973638|NCT02739815|Active Comparator|T2|Will receive Tranexamic acid 20 mg/kg in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
2973639|NCT02739815|Active Comparator|T3|Will receive Tranexamic acid 25 mg/kg in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
2973640|NCT02739802|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application
2973641|NCT02739789|Sham Comparator|Sham tDCS|"tDCS stimulation will be administered over the brain area of interest, but will be shorter in duration than the active treatment"
2973642|NCT02739789|Active Comparator|Active tDCS|tDCS stimulation will be administered over the brain area of interest
2973643|NCT02739776||A|Pt receiving standard Epidural block care for vaginal delivery
2973644|NCT02739763|Experimental|Plasmodium falciparum sprozoite (PfSPZ) challenge|Challenge agent
2973645|NCT02739737|Experimental|Blinded Reviewers|Subjects receiving randomized sham manuscript for review
2973646|NCT02739737|Experimental|Unblinded Reviewers|Subjects receiving randomized sham manuscript for review
2973647|NCT02739724|Active Comparator|Classic laparoscopy|Patients will undergo laparoscopy surgery with classic laparoscopy technic.
2973648|NCT02739724|Experimental|Laparoscopy single port access|Patients will undergo laparoscopy surgery by single port access technic.
2973649|NCT02739711|Active Comparator|Glycoprotein IIb/IIIa inhibitor|Glycoprotein IIb/IIIa inhibitor administration
2973650|NCT02739711|No Intervention|Standard therapy|No glycoprotein IIb/IIIa inhibitors
2973651|NCT02739698|Experimental|normothermic (36-37ºC)|Group 1, n=16(normothermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1.5% dextrose in room temperature (36-37ºC).
2973652|NCT02739698|Experimental|hyperthermic (41-42ºC)|Group 2, n=16 (hyperthermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1.5% dextrose in continuous hyperthermic perfusion (41-42ºC).
2973653|NCT02739685|Experimental|Bioresorbable vascular scaffold|Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion
2973654|NCT02739685|Active Comparator|Stent|Implantation everolimus-eluting stent in chronic total occlusion
2973655|NCT02739672|Experimental|TAH tablet|Telmisartan/Amlodipine besylate/Hydrochlorothiazide tablet
2973656|NCT02739672|Active Comparator|Telmisartan+Amlodipine besylate+Hydrochlorothiazide|coadministration of Telmisartan, Amlodipine besylate and Hydrochlorothiazide
2973657|NCT02739659|Experimental|carbon-ion radiotherapy|Four dose levels [59.2 GyE(Gray equivalent)/16Fx, 60.8 GyE/16Fx, 62.4 GyE/16Fx, 64.0 GyE/16Fx] are planned within the Phase I part. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 64 GyE/16Fx are safely delivered, the recommended dose (or 64 GyE/16Fx) will be the prescribed dose in the Phase II part of the study.
2973658|NCT02739646|Experimental|Females|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
2973659|NCT02739646|Experimental|Males|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
2973660|NCT02739633|Experimental|Genexol-PM + Gemcitabine|Genexol-PM125 mg/m2 will be administered in combination with gemcitabine 1,000 mg/m2 weekly for 3 weeks followed by one week of rest. Each cycle is 28 days.
2973661|NCT02739620|Experimental|NMES|Neuromuscular electrical stimulation (NMES) group
2973662|NCT02739620|No Intervention|Control|Control group
2973663|NCT02739607|Experimental|Transdiagnostic program|This arm represents the Transdiagnostic intervention program for emotional disorders. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms.
2973664|NCT02739607|No Intervention|Wait list control group|This arm represents the wait-list comparison group.
2973665|NCT02739594|Experimental|Ibandronate|Participants with multiple myeloma will be randomized to receive ibandronate every 4 weeks for a planned duration of 92 weeks.
2973666|NCT02739594|Active Comparator|Zoledronate|Participants with multiple myeloma will be randomized to receive zoledronate every 4 weeks for a planned duration of 92 weeks.
2973667|NCT02739581|Experimental|Endoscopic variceal ligation with Non-selective B-blockers|
2973668|NCT02739581|Active Comparator|Endoscopic variceal ligation with Placebo|
2973669|NCT02739568|Experimental|Pitolisant (BF2.6449|Histamine H3 receptor H3R antagonist/ inverse agonist
2973670|NCT02739568|Placebo Comparator|Placebo|Placebo
2973671|NCT02739555|Active Comparator|1: Percutaneous treatment|Percutaneous treatment of OO is a thermal tumor destruction by radiofrequency or laser photocoagulation performed under CT control with strict aseptic approach and most often under general anesthesia. The introductive needle is inserted toward the nidus. Then the optic fiber or the radiofrequency probe is inserted in the nidus center and thermal destruction of the tumor is obtained.When the distance between the nidus and a nerve or the skin is less than 10 mm, infusion of normal saline or CO2 is introduced as spacing agent. When the nidus is in the subchondral bone, cold normal saline is introduced in the joint to protect the cartilage. In addition, a thermocouple is placed in the epidural or foraminal space to continuously monitor the temperature. A procedure typically required between 1 and 2 h from the time the patient entered the CT unit.
2973672|NCT02739555|Experimental|2: Bisphosphonate treatment|"The treatment consists of 3 infusions of zoledronic acid administered at a monthly interval. Bisphosphonate treatment is considered finished 1 month after the third bisphosphonate infusion (V4 visit). In few cases, the analgesic efficacy provided by 3 bisphosphonate infusions cannot be sufficient: 1 to 3 additional infusions could be proposed to the patient.~Zoledronic acid is supplied as a 4 mg/100 ml solution for infusion. It will be administered as infusion over 30 minutes under the supervision of a nurse. Adults will receive intravenous infusion of 4 mg of zoledronic acid. Children will receive infusion of 0.025 mg/kg of zoledronic acid.~The solution for infusion will be diluted in a specific volume of an injectable solution of sodium chloride 9 mg / ml (0.9%). The investigators propose abacus corresponding to zoledronic acid volume to sample and volume of sterile sodium chloride for dilution and infusion during 30 minutes."
2973673|NCT02739542|Active Comparator|Tecfidera|Tecfidera (120mg by mouth twice daily for 7 days with dose escalation to 240mg by mouth twice daily)
2973674|NCT02739542|Placebo Comparator|Placebo|Placebo by mouth twice daily.
2973675|NCT02739529|Experimental|Cohort 1|Genexol-PM 100mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1
2973676|NCT02739529|Experimental|Cohort 2|Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1
2973677|NCT02739529|Experimental|Cohort 3|Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 6 AUC IV infusion D1
2973678|NCT02739516|Active Comparator|Control|In letrozole stimulated cycle: On the day of ovulation trigger the patient received standard dose of Human chorionic gonadotropin (10,000 IU).
2973679|NCT02739516|Experimental|Study|In letrozole stimulated cycle: On the day of ovulation trigger the patient received hCG 10000 IU plus FSH co-trigger (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once .
2973680|NCT02739490|No Intervention|Group control|It does not perform any kind of guided exercise.
2973681|NCT02739490|Experimental|Core Training Group|The training was distributed in four positions defined ventral plank, side plank left, right side board and bridge semiflexion knees, respectively. With time isometric contraction of 30 seconds repeated four times with rest 30 seconds between repetitions. During 10 sessions distributed twice weekly.
2973682|NCT02739477|Experimental|Favipiravir|Favipiravir (oral administration, 200 mg light yellow, round-shaped, coated divisible tablets that can be crushed and mixed with liquid)
2973683|NCT02739464|Experimental|Experimental (MP-10)|SOC treatment plus a personalized, structured, and quantifiable exercise program (MP10) carried out soon after admission until hospital discharge (including during the BICU stay and time on ventilation.
2973684|NCT02739464|Active Comparator|Control|Only SOC for treating in-patient burn subjects
2973685|NCT02739451|Active Comparator|standard oxygen group|Oxygen therapy will be delivered using any device or combination of devices that are part of usual care: nasal oxygen, and mask with or without a reservoir bag and with or without the Venturi system
2973686|NCT02739451|Experimental|High-flow nasal oxygen (HFNO) group|"Device that delivers humidified and warmed high-flow oxygen at flows greater than 15 L/min.~HFNO will be initiated at a flow rate of 50 L/min and 100% FiO2. If the target SpO2 is not reached, the flow rate will be increased to 60 L/min. Then, FiO2 will be tapered to target an SpO2≥95. The minimal flow rate will be 45 L/min"
2973687|NCT02739438||E Cigarette users|Subjects who use electronic cigarettes daily and have not used conventional cigarettes in the previous 3 months. Total pack years of smoking should be less than 20 for their smoking history, with normal lung function (FEV1 and FEV1/FVC) and no clinical symptoms of airway obstruction/inflammation (cough, dyspnea, sputum and wheeze).
2973688|NCT02739438||Cigarette smokers|Subjects who smoke at least ¼ pack cigarettes per day for the past 1 year, with no history of electronic cigarette use in the last 30 days.
2973689|NCT02739438||Control group|Subjects with no history of prior conventional cigarette (< 100 cigarettes lifetime) or electronic cigarette use.
2973718|NCT02739204|Experimental|Celecoxib|Combination of concurrent radiotherapy and/or Cisplatin with or without Celcoxib
2973690|NCT02739425|Other|Standard Procedure plus use of sentimag|Detection of the nodes carried out using the gamma probe and also the sentimag - all patients receive both diagnostic interventions
2973691|NCT02739412|Experimental|Interleukin-2|IL-2 (Interleukin-2; Aldesleukin; Proleukin) administered daily as a single subcutaneous injection 0.30 MIU per meter squared body surface area for a duration of 4 weeks.
2973692|NCT02739399|Other|Patient receiving phenylephrine 2ug/kg|phenylephrine 2ug/kg in case of hypotension
2973693|NCT02739386||Cohort Population|Individuals included in a large US-based administrative medical claims database with underlying autoimmune disorder exposed to ipilimumab for the treatment of melanoma.
2973694|NCT02739373|Experimental|BMS-986189|Specified Dose on Specified Day
2973695|NCT02739373|Placebo Comparator|Placebo|Specified Dose on Specified Day
2973696|NCT02739360|Experimental|Idelalisib|Participants will receive idelalisib until unacceptable toxicity, disease progression, study discontinuation, or death occurs.
2973697|NCT02739347|Experimental|Active Stimulation|Active stimulation group will receive 20 min of 2 mA direct current stimulation.
2973698|NCT02739347|Sham Comparator|Sham Stimulation|This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
2973699|NCT02739334|Experimental|ENRICH|The intervention will integrate the Play and Learning Strategies (PALS) program, a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler with Coordinated Approach To Child Health (CATCH), a behaviorally-based school health promotion program based on Social Cognitive Theory (SCT) to increase opportunities for healthy eating and activity.
2973700|NCT02739334|Active Comparator|Control - monthly handouts|The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
2973701|NCT02739321|Experimental|Mattress Technology On then Off|"Intervention: Sound to Sleep System will be turned on for the first two weeks of the study allowing the participant sleeping atop the mattress to feel the vibrations synced to the audio input. Sound to sleep system will be turned on during this phase of the study. The sound to sleep system will sync an audio input with the vibrations of the mattress technology and allow the user to control the intensity of the vibration.~No intervention: The mattress technology will be turned off for the second two weeks of the study. During this time, there will be no intervention."
2973702|NCT02739321|Experimental|Mattress Technology Turned Off then On|"No intervention: For the first two weeks of the study, the mattress technology will not be turned off. There will be no intervention during this time.~Intervention: Sound to Sleep System will be turned on for the second two weeks of the study allowing the participant sleeping atop the mattress to feel the vibrations synced to the audio input. Sound to sleep system will be turned on during this phase of the study. The sound to sleep system will sync an audio input with the vibrations of the mattress technology and allow the user to control the intensity of the vibration."
2973703|NCT02739308|Experimental|Intervention: Proprioceptive Training|"The intervention will be the implementation of a proprioceptive training program for the fencing athletes in the intervention group.~In this study the training program will be developed for 12 weeks and will be applied during the heating of the athletes, three times a week and the duration of each session is 30 minutes. Each week will be chosen three of the 14 exercises adapted for fencing athletes, and preferably one of each category. The categories have exercises with different levels of difficulty and can change the exercises occur by different proposed levels or the complexity of the exercise by changing category. The training program will be implemented by the same evaluator over the 12 weeks."
2973704|NCT02739308|Placebo Comparator|Control|The control group will not make the intervention and will continue with the usual training fencing.
2973705|NCT02739295|Experimental|G-CSF|An intravenous dose of 5 microg/kg of G-CSF (Neupogen) will be administered daily, from admission (day 0) to day 4.
2973706|NCT02739295|Placebo Comparator|Placebo|An intravenous dose of 5 ml of NaCl 0.9% will be administered daily, from admission (day 0) to day 4.
2973707|NCT02739282|Active Comparator|Systematic therapeutic drug monitoring|"Systematic therapeutic drug monitoring performed at each clinic consultation and automatically transmitted to the clinician will be compared with clinically required therapeutic drug monitoring (rescue therapeutic drug monitoring, transmitted only in case of predefined inefficacy or tolerance problems, as defined in the combine endpoint below), to assess if systematic therapeutic drug monitoring can prevent a proportion of treatment failure or adverse events."
2973708|NCT02739282|No Intervention|"Rescue therapeutic drug monitoring"|"In the rescue therapeutic drug monitoring arm, communication of levels results will only be provided if a study endpoint (treatment failure or side effect as discussed below) is reached."
2973709|NCT02739269|Active Comparator|AMH group|Serum AMH measurement
2973710|NCT02739269|Sham Comparator|AFC group|AFC measurement
2973711|NCT02739256|Experimental|voiding trial 4 hours post-op|
2973712|NCT02739256|Active Comparator|voiding trial post-op day 1|
2973713|NCT02739243|Experimental|Tailored group intervention|"Participants take part in the tailored group intervention which consists of five 90-minute group sessions over eight weeks. The sessions are in the form of structured group talk/discussions following specific themes:~Session 1 - Coping and acceptance: identification of common themes from participants' feedback, provision of information about support services, mindfulness practices~Session 2 - Distress: introduction of the distress model, identification of resources, breathing practices~Session 3 - Handling of stressful situations: individual identification in tandems, discussion of common pitfalls in the group~Session 4 - Self-care: inspection of individual daily routines, group collects positive experiences with windows for self-care~Session 5 - Feedback and outlook: stabilisation, retrospective reflection on the group experience and its benefits and, if applicable, potential adverse events"
2973714|NCT02739243|Active Comparator|Treatment as usual|Participants are provided with brief information in a leaflet, about the possibilities for individual counselling including referral to the local outpatient cancer counselling centre providing client-centred counselling and financial social work.
2973715|NCT02739230|Active Comparator|Exparel Injection|
2973716|NCT02739230|Active Comparator|On-Q intraarthicual catheter placement|
2973717|NCT02739217|Experimental|PBI-4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
2973719|NCT02739191|Experimental|Intervention|Prophylactic negative pressure wound therapy
2973720|NCT02739178|Experimental|GSF Sanitation intervention|This arm will receive the GSF sanitation intervention, a community-level sanitation intervention
2973721|NCT02739178|No Intervention|Comparator|This arm will receive the GSF intervention in 2017 or later.
2973722|NCT02739165|Experimental|ART-123|
2973723|NCT02739165|Placebo Comparator|Placebo|
2973724|NCT02739139|Placebo Comparator|Placebo|Placebo
2973725|NCT02739139|Experimental|AlphaBrain|AlphaBrain(TM)
2973726|NCT02739126|Active Comparator|Thick USS (1.7mm) with use of additional aspiration needle|
2973727|NCT02739126|Active Comparator|Thin USS (1.4mm)|
2973728|NCT02739113|Experimental|Cultivated oral mucosal epithelial cell|Cultivated oral mucosal epithelial cell transplantation (COMET) : To treat severe limbal stem cell deficiency using cultivated autologous oral mucosal epithelial cell transplantation.
2973729|NCT02739100|Experimental|Triferic via Hemodialysate|"Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic via the hemodialysate over the course of the dialysis treatment.~Intervention Drug: Triferic"
2973730|NCT02739100|Experimental|Triferic via IV infusion|"Patients will receive a single 6.6-mg dose of Triferic iron administered IV over 4 hrs during hemodialysis via the unused heparin infusion line (pre-dialyzer).~Intervention: Drug: Triferic"
2973731|NCT02739100|Experimental|Triferic IV infusion|"Patients will receive a single 6.6-mg dose of Triferic iron administered IV over 4 hrs during hemodialysis via an infusion port (post-dialyzer).~Intervention: Drug: Triferic"
2973732|NCT02739087|Experimental|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures.
2973733|NCT02739061|Active Comparator|cognitive behavioral group therapy|cognitive behavioral group therapy
2973734|NCT02739061|Active Comparator|drug therapy|drug therapy
2973735|NCT02739061|Active Comparator|The combination therapy|cognitive behavioral group therapy and drug therapy
2973736|NCT02739035|No Intervention|MUA alone|Subjects will be given manipulation under anesthesia, will fill out questionnaires about their knee and quality of life and will be followed throughout their routine follow up to assess their continued process. Subjects will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.
2973737|NCT02739035|Experimental|MUA with dexamethasone and celecoxib|For subjects assigned to the MUA with anti-inflammatory medication group, an intravenous (into the vein) dose of dexamethasone will be given at the time of MUA. Subjects in this group will also receive celecoxib. They will be asked to take the medicine one time daily either at morning or night time with food and water for 2 weeks following MUA. Subjects will also be followed throughout their routine follow up to assess their continued process, and they will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.
2973738|NCT02739022|Experimental|Early Psychological Support for the Critically Ill (EPSCI)|patients will receive EPSCI in parallel with medical treatment
2973739|NCT02739009|Experimental|MOR106|Single intravenous administration of MOR106
2973740|NCT02739009|Placebo Comparator|Placebo|Single intravenous administration of Placebo
2973741|NCT02739009|Experimental|MOR106 MAD|Multiple intravenous administration of MOR106
2973742|NCT02739009|Placebo Comparator|Placebo MAD|Multiple intravenous adminstration of Placebo
2973743|NCT02738996|Experimental|60-30 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min and 30 min
2973744|NCT02738996|Experimental|30-15 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min and 15 min
2973745|NCT02738996|Experimental|15-60 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min and 60 min
2973746|NCT02738996|Experimental|60-15|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min and 15 min
2973747|NCT02738996|Experimental|30-60 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min and 60 min
2973748|NCT02738996|Experimental|15-30 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min and 30 min
2973749|NCT02738983|Experimental|Bioradiotherapy|Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day) with concurrent radiotherapy to a total radiation dose of 60-66 Gray (Gy).
2973750|NCT02738970|Active Comparator|Part 1-Cohort 1: Pertuzumab 420 Milligrams (mg) IV|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 420 mg IV.
2973751|NCT02738970|Experimental|Part 1-Cohort 2: Pertuzumab 400 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 400 mg SC.
2973752|NCT02738970|Experimental|Part 1-Cohort 3: Pertuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 600 mg SC.
2973753|NCT02738970|Experimental|Part 1-Cohort 4: Pertuzumab 1200 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 1200 mg SC.
2973754|NCT02738970|Active Comparator|Part 1-Cohort 5: Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of trastuzumab 600 mg SC.
2973755|NCT02738970|Experimental|Part 1-Cohort 6: Pertuzumab 400 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 400 mg and trastuzumab 600 mg SC.
2973756|NCT02738970|Experimental|Part 1-Cohort 7: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC.
2973757|NCT02738970|Experimental|Part 1-Cohort 8: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC without recombinant human hyaluronidase (rHuPH20) excipient.
2973824|NCT02738450|Active Comparator|ACI-24 high dose|Vaccine formulation will be administrated s.c. 7 times.
2973825|NCT02738450|Placebo Comparator|Placebo|The placebo is ready-to-use solution for injection, administrated s.c. 7 times.
2973758|NCT02738970|Experimental|Part 2-Cohort A: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohort A will be enrolled only if FDC of pertuzumab and trastuzumab is not feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC administered separately. The dose of pertuzumab will be identified during Part 1.
2973759|NCT02738970|Experimental|Part 2-Cohort B: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents administered in one injection (co-mixed). The dose of pertuzumab will be identified during Part 1.
2973760|NCT02738970|Experimental|Part 2-Cohort C: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents formulated together and administered in one injection (FDC). The dose of pertuzumab will be identified during Part 1.
2973761|NCT02738957|Other|Prenatal Counseling Group|"Patients in the PCG will receive specific counseling on breastfeeding consisting of three different counseling sessions during prenatal visits given by one two midwives involved in the study. The information will include: breastfeeding importance; how to prepare the nipples and breast for breastfeeding; the main complications and difficulties during the breastfeeding process and how to identify and overcome them; breastfeeding techniques and alternative positions for the simultaneous breastfeeding of twins, for example, double cradle, cradle-football or double-football, using illustrations and hands-on demonstration with doll models. During the counseling sessions patients will have the opportunity to discuss questions on breastfeeding."
2973762|NCT02738957|No Intervention|Control Group|No breastfeeding counseling during the antenatal period will be provided. The Control Group will receive non-specific counseling with standard orientation regarding breastfeeding after delivery and during their postpartum hospitalization period. This standard orientation will be provided by one of the midwives of the hospital during a single counseling session with brief guidance covering the following topics: starting breastfeeding, hygiene, infants' conditions, colostrum/breast milk, infants' positions, duration of breastfeeding, frequency of feeds, mammary milking, and stopping breastfeeding.
2973763|NCT02738944|Active Comparator|Integrated Care|Telepsychiatry Collaborative Care
2973764|NCT02738944|Active Comparator|Referral Care|Telepsychiatry Enhanced Referral
2973765|NCT02738931|Experimental|Treatment Sequence ABC|Subject will receive reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 1, experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AA, treatment B) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AB, treatment C) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
2973766|NCT02738931|Experimental|Treatment Sequence BCA|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AA, treatment B) in period 1 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AB, treatment C) in period 2 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
2973767|NCT02738931|Experimental|Treatment Sequence CAB|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 1 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
2973768|NCT02738931|Experimental|Treatment Sequence ACB|Subject will receive reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 1, experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
2973769|NCT02738931|Experimental|Treatment Sequence BAC|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 1 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
2973770|NCT02738931|Experimental|Treatment Sequence CBA|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 1 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 2 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
2973771|NCT02738918|Experimental|Nulojix|
2973772|NCT02738905|Experimental|Rifaximin|Participants will receive study drug for a period of 7 days.
2973773|NCT02738879|Experimental|Sitagliptin|Sitagliptin 100 mg, oral, once daily for 30 weeks
2973774|NCT02738879|Placebo Comparator|Placebo|Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
2973775|NCT02738866|Experimental|Palbociclib and Fulvestrant|Participants will receive fulvestrant with palbociclib until disease progression or unacceptable toxicity.
2973776|NCT02738853|Experimental|Medtronic Transcatheter Aortic Valve 2.0 Replacement System|Treatment of Aortic Stenosis by replacing native valve with the Medtronic Transcatheter Aortic Valve 2.0 System
2973777|NCT02738827|Other|Laser treatment|Intervention is diode laser treatment of bladder cancer through a cystoscope without sedation of the patient.
2973778|NCT02738814|Experimental|PAED > 13|When severe emergence agitation(PAED is 14 or more) is occured, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.
2973779|NCT02738814|No Intervention|PAED < 14|Caregivers must first try to reassure patients.
2973780|NCT02738801|Experimental|GLPG1690 group 1|
2973781|NCT02738801|Placebo Comparator|group 2|
2973782|NCT02738775|Experimental|Ublituximab|Ublituximab IV infusion dose on Day 1, 15 and Week 24
2973783|NCT02738775|Placebo Comparator|Ublituximab Placebo|Placebo IV infusion dose on Day 1 and 15 only
2973826|NCT02738437|No Intervention|control|Control Group receiving standard treatment
2973784|NCT02738762|Active Comparator|intervention group|enteral glutamine supplementation guided by glutamine level Enteral glutamine supplementation is started (day 1) at a dose of 3 sachets per day given at 6.00, 14.00 and 22.00 hr. A sachet contains 9 grams of L-glutamine ( Glutaperos®, GLNP Life Sciences). Enteral glutamine supplementation will be given for a maximum of 10 days or until the patient is discharged from the ICU
2973785|NCT02738762|No Intervention|control group|patients receive normal treatment, no glutamine supplementation
2973786|NCT02738749|Other|ICD group|Adult patients with newly implanted ICD devices for primary prevention will be enrolled. At baseline, 3-, 6-, 9-, and 12-month followup visit, the medial information and blood samples will be collected.
2973787|NCT02738736|Experimental|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day).
2973788|NCT02738736|No Intervention|Usual Care|Participants randomized to usual care will also attend a dietitian-developed healthy eating guidance session but will not receive specific recommendations targeting sodium intake.
2973789|NCT02738723|Experimental|GROUP 1|SBRT plus EP
2973790|NCT02738723|Active Comparator|GROUP 2|IMRT plus EP
2973791|NCT02738710|Experimental|transumbilical wound|transumbilical incision
2973792|NCT02738710|Active Comparator|infra umbilical wound|infra umbilical incision
2973793|NCT02738697|Experimental|Adjuvant chemotherapy|8~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
2973794|NCT02738697|Other|Follow-up|Routine follow-up were performed instead of adjuvant chemotherapy
2973795|NCT02738684||lung cancer|A small sample exploratory study to predict gefitinib' s efficacy for late stage lung adenocarcinoma patients by plasma free nucleic acids EGFR gene mutation test
2973796|NCT02738671||Type 1 Diabetes Mellitus|These T1DM patients have late diabetes onset.(latent autoimmune diabetes in adult, LADA)
2973797|NCT02738671||Type 2 Diabetes Mellitus|A subgroup of these T2DM patients are obesity patients who will have the bariatric surgery. These obese T2DM subjects will undergo a physical exam, cognitive and olfactory test as well as structural and functional brain MRI at baseline and 6 months after their surgery.
2973798|NCT02738671||Control|A subgroup of these non-diabetic people are obesity patients who will have the bariatric surgery. These obese subjects will undergo a physical exam, cognitive and olfactory test as well as structural and functional brain fMRI at baseline and 6 months after their surgery.
2973799|NCT02738658|Experimental|Bioresorbable vascular scaffold (BVS)|Patients with stable coronary angina with coronary artery disease suitable to be treated with a bioresorbable vascular scaffold.
2973800|NCT02738658|Active Comparator|Everolimus-eluting stent (EES)|Patients with stable coronary angina with coronary artery disease suitable to be treated with a Everolimus-eluting stent .
2973801|NCT02738645||pneumonia in RICU|The patients admit in RICU because of pneumonia.
2973802|NCT02738632|Experimental|Telmisartan/Amlodipine+Hydrochlorothiazide|Telmisartan/Amlodipine combination drug and Hydrochlorothiazide
2973803|NCT02738632|Active Comparator|Telmisartan/Amlodipine|Telmisartan/Amlodipine combination drug and Placebo for Hydrochlorothiazide
2973804|NCT02738619|Active Comparator|vitamin d3|1600 UI
2973805|NCT02738619|Placebo Comparator|placebo|placebo
2973806|NCT02738606|Experimental|Liver Resection Surgery + Chemotherapy Group|"Participants have liver resection surgery, followed by standard of care. Standard of care chemotherapy decided by participant's physician.~Quality of life survey completed at baseline and every 3-6 months at follow up."
2973807|NCT02738606|Active Comparator|Chemotherapy Group|"Standard of care chemotherapy decided by participant's physician.~Quality of life survey completed at baseline and every 3-6 months at follow up."
2973808|NCT02738580|Active Comparator|rFSH|Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
2973809|NCT02738580|Active Comparator|HP-HMG|Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG with normal ovarian function.
2973810|NCT02738567||local anesthesia with adrenaline|patients undergoing surgery or medical procedure with the use of local anesthesia with adrenaline
2973811|NCT02738567||local anesthesia without adrenaline|patients undergoing surgery or medical procedure with the use of local anesthesia without adrenaline
2973812|NCT02738554|Other|Treatment cessation arm|Cessation of treatment as according to Asia-Pacific Association for the Study of the Liver Guidelines for chronic hepatitis B
2973813|NCT02738541|Active Comparator|Group 1|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS PRESCRIBED AND SUBJECTS WERE EVALUATED AT 3MONTH AND 6 MONTHS
2973814|NCT02738541|Placebo Comparator|Group 2|PLACEBO DENTRIFICE WITHOUT PYROPHOSPATE WAS PRESCRIBED AND SUBJECTS WERE EVALUATED AT 3MONTH AND 6 MONTHS
2973815|NCT02738528|Experimental|Experimental Group|Mental practice and brushing guidance in patients with Parkinson Disease
2973816|NCT02738528|No Intervention|Control group|Brushing guidance in patients without Parkinson Disease
2973817|NCT02738515|Active Comparator|Group 1|Scaling and Root Planing (SRP) with 0.75% BORIC ACID GEL for treating furcation defect
2973818|NCT02738515|Placebo Comparator|Group 2|Scaling and Root Planing (SRP) with PLACEBO GEL for treating furcation defect.
2973819|NCT02738502|Experimental|Single Group|Intervention: Darunavir monotherapy darunavir/ritonavir 600 mg/100mg twice day in monotherapy.
2973820|NCT02738489|Experimental|Injection SHR-1210|SHR-1210 injection, 60,200,400mg/dose, intravenous infusion over 30 minutes. Only one arm in this study
2973821|NCT02738463||Group 1 case|This group will include 32 pregnant females whose fetuses show intrauterine growth restriction at full term ( the 32 neonates with birth weight less than 10th percentile for corresponding gestational age will be included as small for gestational age and the investigator will thaw their maternal frozen samples for detection of serum ferritin level)
2973822|NCT02738463||Group 2 control|This group will include at least 32 pregnant females whose fetuses are appropriate for gestational age at full term ( the 32 neonates with birth more than or equal to the 10th percentile for corresponding gestational age will be included as average for gestational age and the investigator will thaw their maternal frozen samples for detection of serum ferritin level)
2973823|NCT02738450|Active Comparator|ACI-24 low dose|Vaccine formulation will be administrated s.c. 7 times.
2973827|NCT02738437|Active Comparator|intervention group|Intervention Group receiving the standard treatment and the kryptonite-bone cement
2973828|NCT02738424||3T patients : Calculate the ADC scores|In this group all the patients perform a 3 Tesla RMI. With these data, three methods will be used to calculate the ADC score : Siemens, PACS (picture archiving and communication system) Carestream, Osirix. The ADC scores obtained with these three post-processing softwares will be compared.
2973829|NCT02738424||1.5T patients : Calculate the ADC scores|In this group all the patients perform a 1,5 Tesla RMI. With these data, three methods will be used to calculate the ADC score : Siemens, PACS Carestream, Osirix. The ADC scores obtained with these three post-processing softwares will be compared.
2973830|NCT02738411||The study population|The study population corresponds to infants born at less than 33 weeks of gestation.
2973831|NCT02738385|Experimental|High Intensity Interval Training|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 300 kcal until the end of training.
2973832|NCT02738385|Active Comparator|Moderate Intensity Interval Training|Walking on a treadmill at 60-80% peak heart rate until expenditure of 300 kcal until the end of training.
2973833|NCT02738372||Chronic Shoulder Pain|"Men / women aged between 18 and 70 years.~Patients suffering from shoulder pain, defined as pain presented or exacerbated by movements in the shoulder, pain intensity ≥ 2 measured by a numerical scale with values from 0 to 10, meaning 0= no pain and 10= the worst pain, will be included in this study, among all these following shoulder pain conditions: (i) Rotator Cuff tendinopathy; (ii) Adhesive Capsulitis; (iii) glenohumeral instability; (iv) SLAP lesion; (v) and/or acromioclavicular pathology. Subjects will not be required to undergo diagnostic imaging (i.e. Magnetic Resonance Imaging) to diagnosis the pathology because of the recruitment will be carried out by clinical findings.~Duration of symptoms: greater than 3 months."
2973834|NCT02738359||1rst arm: optical colonoscopy (OC)|t0: optical colonoscopy; Follow-up: yearly by phone call for three years
2973835|NCT02738359||2nd arm: colon capsule endoscopy (CC)|t0: colon capsule endoscopy -> if positive: OC; At three years: OC for those patients with negative initial CC; Follow-up: yearly by phone call for 3 years
2973836|NCT02738359||3rd arm: fecal immunological test (FIT)|"FIT yearly for two years:~t0: FIT -> if positive : OC; t = 1 year: FIT -> if positive : OC; t = 2 years: FIT -> if positive : OC; At three years: OC for those patients with negative FIT during the study Follow-up: yearly by phone call for 3 years"
2973837|NCT02738346|Experimental|Arm A : Carboplatin-Etoposide|Intravenous administration of Carboplatin Auc 5 at Day 1 and Intravenous administration of 100 mg / m² / of Etoposide J Day 1 to Day 3 The CT scans evaluations will be conducted during chemotherapy every 6 weeks
2973838|NCT02738346|Active Comparator|Arm B : Topotecan|Per os administration of 2.3 mg / m² of Topotecan Day 1 to Day 5 The CT scans evaluations will be conducted during chemotherapy every 6 weeks
2973839|NCT02738333|Experimental|LDV/SOF (Cohort 1)|LDV/SOF FDC for 12 weeks
2973840|NCT02738333|Experimental|SOF+RBV (Cohort 1)|SOF+RBV for 12 weeks
2973841|NCT02738333|Experimental|LDV/SOF (Cohort 2)|Participants who are ineligible for or intolerant to RBV therapy will receive LDV/SOF FDC for 12 weeks.
2973842|NCT02738320|Experimental|Intervention|Intervention patients will receive access to NHCPlus when discharge to a nursing home from the hospital is expected.
2973843|NCT02738320|No Intervention|Usual Care|Control patients will receive the usual care when discharge to a nursing home from the hospital is expected.
2973844|NCT02738307|Experimental|altitude exposure|Altitude Exposure Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
2973845|NCT02738294|Experimental|Suspected EGC group|Participants with suspected EGC from white light endoscopy were enrolled.The endoscopist first used white light endoscopy to identify suspected gastric lesions and assessed lesions carefully with magnifying view, non-magnifying NBI view and ME-NBI view in sequence. After assessing suspected EGC in ME-NBI view, ME-NBI targeted biopsy was performed where abnormal phenomenon was identified in ME-NBI view.
2973846|NCT02738281||Rett Syndrome|This is a prospective natural history study examining the phenotypic variations of individuals with mutations in MECP2 or meeting the diagnostic criteria for classic (typical) or variant (atypical) Rett syndrome. The overwhelming majority will be female, but males meeting diagnostic criteria will be included. No interventions are planned.
2973847|NCT02738281||MECP2 Duplication|This is a prospective natural history study examining the phenotypic variations of individuals with MECP2 duplications. The majority are expected to be males, but females expressing a duplication will be included. No interventions are planned.
2973848|NCT02738281||RTT related disorders|This is a prospective natural history study examining individuals, both females and males who do not meet criteria for Rett syndrome, but have a mutation in MECP2, CDKL5, or FOXG1. No interventions are planned.
2973849|NCT02738268|Sham Comparator|Control group|Control group: receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
2973850|NCT02738268|Experimental|Treatment Group|Treatment Group: receives low-level laser therapy (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
2973851|NCT02738255|Active Comparator|Polysomnogram with Varnum Mouthpiece|Varnum mouthpiece, similar to a mouth tape with central opening
2973852|NCT02738255|No Intervention|Regular Polysomnogram|Overnight sleep study with no mouthpiece
2973853|NCT02738242|Experimental|Novus system users|Sixteen (16) subjects suffering from foot drop and thigh muscles weakness due to upper motor neuron injury or disease will be recruit for this study and will receive the Novus system for daily use.
2973854|NCT02738229|Experimental|Valacyclovir|"Valacyclovir will be given twice a day with following doses according to weight:~10 to 13,9 kg : Valacyclovir 250 mg PO twice per day 14 to 19,9 kg : Valacyclovir 375 mg PO twice per day 20 to 28 kg : Valacyclovir 500 mg PO twice per day"
2973855|NCT02738229|Placebo Comparator|control|placebo pill
2973856|NCT02738216|Experimental|Prenatal Yoga|A 9-week prenatal yoga program
2973857|NCT02738216|Active Comparator|Mother Baby Wellness Workshop|A 9-week workshop on mother and baby wellness in the first postpartum year
2973858|NCT02738203|Experimental|Experimental, IUD Insertion group|"If the subject is assigned to the experimental group (vaginal lidocaine jelly):~She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo."
2973859|NCT02738203|Placebo Comparator|Control, IUD Insertion group|"If the subject is assigned to the control group (sterile, surgical lubricant jelly):~•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo."
2973860|NCT02738190|Active Comparator|Albumin|5% Albumin to be added to the priming solution composed of concentrated red cells to reach a target of 28-30% hematocrit and albumin to reach the standard volume administered to these patients (400 ml)
2973861|NCT02738190|Active Comparator|Fresh Frozen Plasma|Fresh Frozen Plasma to be added to the priming solution composed of concentrated red cells to reach a target of 28-30% hematocrit and plasma to reach the standard volume administered to these patients (400 ml)
2973862|NCT02738177|Active Comparator|misoprostol group|30 candidates were receive 2 tablets of misoprostol (PGE1) 200ug (i.e. 400 ug) 4 hrs prior to surgical evacuation
2973863|NCT02738177|Active Comparator|Effox group|30 candidates were received 2 tablets of Effox (Isosorbide mononitrate) 20 mg (i.e 40 mg) 4 hrs prior to surgical evacuation
2973864|NCT02738177|Active Comparator|combination therapy group|30 candidates were received 1 tablets of misoprostol 200ug & 1 tablets of Effox 20 mg 4 hrs prior to surgical evacuation.
2973865|NCT02738151|Experimental|Insulin glargine (U300)|"Insulin glargine (U300) is self-administered once daily (OD). Treatment will be initiated and individually adjusted at least weekly according to fasting SMPG target.~Subjects should continue their background noninsulin antidiabetic treatment (oral antihyperglycemic drugs[OADs] and glucagon like peptide-1[GLP-1] receptor agonist) during the study period."
2973866|NCT02738151|Active Comparator|Insulin degludec|"Insulin degludec is self-administered OD. Treatment will be initiated and individually adjusted at least weekly according to fasting SMPG target.~Subjects should continue their background noninsulin antidiabetic treatment (OADs and GLP-1 receptor agonist) during the study period."
2973867|NCT02738138|Experimental|ABT-493/ABT-530 for 8 weeks|HCV Genotype (GT)1-6/HIV-1 co-infected non-cirrhotic subjects treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 8 weeks
2973868|NCT02738138|Experimental|ABT-493/ABT-530 for 12 weeks|HCV GT1-6/HIV-1 co-infected subjects with compensated cirrhosis treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 12 weeks
2973869|NCT02738125||Subjects starting/ receiving adalimumab|Subjects starting/ receiving Adalimumab for UC
2973870|NCT02738099||Arrest from presume Cardiac etiology|Comatose patients following arrest of presumed cardiac etiology arriving to receiving facility within 12 hours of event.
2973871|NCT02738086|Experimental|Early PABC Intervention|GROUP 1 will participate in the Physical Activity Behavior Change (PABC) intervention phase during the first 3 months. GROUP 1 will then participate in a non-exercise control phase during the second 3 months.
2973872|NCT02738086|Experimental|GROUP 2: PABC Intervention|GROUP 2 will participate in a non-exercise control phase during the first 3 months. GROUP 2 will then participate in the Physical Activity Behavior Change (PABC) intervention phase in the second 3 months.
2973873|NCT02738073|Placebo Comparator|Control|
2973874|NCT02738073|Active Comparator|Interventional|
2973875|NCT02738060|Experimental|Case group|The patients in case group will be received baked milk daily in the form of muffin for 6 months. They will be visited weekly in the first month and every 2 weeks in other 5 months. At the end of the 6 months, the patients will undergo oral food challenge by 30 grams baked cheese in the form of pizza cheese. If the test will be negative, they will receive pizza cheese 4 or 7 days per week for other 6 months. The patients will be followed every 2 weeks during this period.
2973876|NCT02738034|Experimental|Adaptive training group|The intervention group will be composed of hypertensive participants with cognitive decline that will be submitted to the training program (Cogmed) for approximately 10 weeks. Across training, task difficulty was adjusted as a function of individual performance.
2973877|NCT02738034|Active Comparator|Active control Group|In the control group, hypertensive patient will be submitted to a set of online games available on the internet and previously determined. In this way, the control group will receive the same motivation, as well as will be engaged in computerized activities, in the same way as the experimental group. The difference is that these varied games do not provide any type of intense and adaptive training, at the same time as they do not stimulate any specific cognitive function.
2973878|NCT02738021|Experimental|STRONG|A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
2973879|NCT02738008|Experimental|ARC-520 Injection|Multiple administrations of ARC-520 starting at a dose level of 2 mg/kg
2973880|NCT02737995|Experimental|Iron Replacement|
2973881|NCT02737982||IHD Men|Men with acute or chronic ischemic heart disease undergoing percutaneous coronary interventions
2973882|NCT02737982||IHD Women|Women with acute or chronic ischemic heart disease undergoing percutaneous coronary interventions
2973883|NCT02737969|Experimental|TEE/Angio fusion software|
2973884|NCT02737943|Experimental|Arm1 Mebo|20 : receiving Moist Exposed Burn Ointment (MEBO) at sites of donor graft and recipient at time of operation and in dressing
2973885|NCT02737943|Placebo Comparator|Arm2 Placebo|20 : receiving Standard cream Zagazig University Hospital (Antibiotics & analgesics)
2973886|NCT02737930|Experimental|Fluoxetine|20 mg fluoxetine capsule by mouth once daily for 90 days
2973887|NCT02737930|Placebo Comparator|Placebo|Matching placebo
2973888|NCT02737917|Experimental|Diffuse apneic oxygenation|This group of patients will receive the standard of care treatment of rapid sequence intubation (pre-oxygenation, induction and intubation) plus the application of oxygen.
2973889|NCT02737917|Other|Usual care|This group of patients will receive the standard of care treatment of rapid sequence intubation (pre-oxygenation, induction and intubation)
2973890|NCT02737904|Active Comparator|Control group|Usual care - conventional, personalised in-patient rehabilitation 4 weeks duration
2973891|NCT02737904|Experimental|Intervention group|Usual care - conventional, personalised in-patient rehabilitation - plus APT cycling programme 4 weeks duration
2973892|NCT02737891|Experimental|Tesofensine/Metoprolol|Oral tablets Tesofensine/Metoprolol
2973893|NCT02737891|Placebo Comparator|Placebo|Placebo tablets matching oral Tesofensine/Metoprolol
2973978|NCT02737358|Placebo Comparator|Placebo|Matched placebo will be given to half of the study participants.
2975150|NCT02729155|Experimental|Sham + RIPost|Intervention: Sham 10 mmHg + RIPost 200 mmHg
2973894|NCT02737878|Experimental|Aerobic Training and Resistance Training (A&RT)|The A&RT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form.
2973895|NCT02737878|Experimental|Aerobic Training (AT)|The AT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
2973896|NCT02737878|Experimental|Resistance Training (RT)|The RT program will be a four-times-per week program. Twice a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
2973897|NCT02737878|Active Comparator|Balance and Tone Program (CON)|The CON program will be a four-times-per week program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
2973898|NCT02737865|Experimental|SMI and sonazoid (single arm)|Patients with focal nodular hyperplasia will undergo ultrasonography with Superb-Microvascular imaging and additional sonazoid-enhanced ultrasonography. SMI is a software function in a Toshiba Aplio 500 system. Sonazoid is contrast-material for US and it is a intervention for patient with FNH. Sonazoid will be administered at a dose of 0.015 mL/kg by manual bolus injection, followed by a 10 mL normal saline flush via a peripheral venous line
2973899|NCT02737852|Experimental|Healthy subject|"Healthy subject exposed to Trojan Chameleon Personal Lubricant at least four times weekly for two weeks"
2973900|NCT02737839|Experimental|Arm 1: STEPPING ON|"Adaptation Waves is to adapt Stepping On to the oncology setting & Pilot Waves is to determine the feasibility & acceptability of the program for older adults receiving cancer care~Complete baseline questionnaires about Instrumental Activities of Daily Living, Medical Outcome Study Activities, Karnofsky Performance Status, falls in past 3 months, medications, comorbidities, vision & hearing, The Falls Behavioral Scale, The Falls Efficacy Scale-International, Patient Reported Outcome pain, PRO neuropathy~7 week STEPPING ON program is multi-component learning environment which has shown to help reduce falls~After completion of program, a home visit to gather any feedback on the experience of the program~Follow-up questionnaires will be completed either at the home visit or returned via mail up to 3 months after completion of the program~Participants may elect to participate in a booster session to reinforce concepts in the program 3-6 months after completion of the program"
2973901|NCT02737826|Experimental|Phase - Buprenorphine Initiation|"In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol. Buprenorphine tolerability will be defined as pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper."
2973902|NCT02737826|Active Comparator|Phase II - Gabapentin|Subjects who tolerate buprenorphine initiation in Phase I (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.
2973903|NCT02737826|Placebo Comparator|Phase II - Placebo|Subjects who tolerate buprenorphine initiation in Phase I (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.
2973904|NCT02737826|Experimental|Phase II - Buprenorphine taper|Subjects who tolerate buprenorphine initiation in Phase I (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.
2973905|NCT02737813|Experimental|Isobaric Marcaine|Isobaric Marcaine 2.2 mL for spinal block
2973906|NCT02737813|Active Comparator|Hyperbaric Marcaine|Hyperbaric Marcaine 2.2 mL for spinal block
2973907|NCT02737800|Active Comparator|1A endometrioma more than 5cm|Endometrioma aspiration GnRh agonist :Decapeptyl 3.75mg intramuscular Standard long stimulation protocol & ICSI
2973908|NCT02737800|Sham Comparator|1B endometrioma more than 5cm control|Endometrioma aspiration Standard long stimulation protocol & ICSI
2973909|NCT02737800|Active Comparator|2A endometrioma less than 5cm|Decapeptyl 3.75mg intramuscular Standard long stimulation protocol & ICSI
2973910|NCT02737800|Sham Comparator|2B endometrioma less than 5cm control|Standard long stimulation protocol & ICSI
2973911|NCT02737787|Experimental|WT1 Vaccine and Nivolumab|Patients will initially receive 6 vaccinations over 12 weeks and 7 infusions of nivolumab over 14 weeks. Toxicity assessments will be performed with each dose of vaccine, and 3 weeks after the completion of therapy at week 15. Patients who do not have disease progression at the week 15 evaluation are permitted to receive 4 additional vaccines administered approximately every 8 weeks. This maintenance vaccine course would begin at week 19.
2974046|NCT02736916|Experimental|HS-WBRT PCI|LD-SCLC patients with HS-WBRT PCI
2973912|NCT02737774|Experimental|Icotinib and Pemetrexed/Carboplatin|"Icotinib: Icotinib for 18 weeks, 125mg Tid，PO. Chemotherapy: pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.~Then continue with Icotinib, 125mg Tid，PO. until disease progression."
2973913|NCT02737761|Experimental|Optimal Adherence|"Participants will all undergo a qualitative interview and adherence measurements at baseline and 12 weeks after hospital discharge.~In person the participants will receive a MEMSCaps device and an Actigraph accelerometer. They will be asked to begin wearing the accelerometer after their initial interview and to begin using the MEMSCaps device once they arrive at home. Participants will use the MEMSCap throughout the entire study and will wear the Actigraph for 2 weeks at baseline and again at 12 weeks."
2973914|NCT02737748|Experimental|Treatment Group|TWB-103 add-on Tegaderm
2973915|NCT02737748|Placebo Comparator|Control Group|Placebo+Tegaderm
2973916|NCT02737735|Experimental|Chemotherapy combined with compound herbal medicine|Standard chemotherapy protocols on phase IIIB/IV non-small-cell lung cancer for 24 weeks combined with compound Chinese herbal medicine for 2 years，which include 15 kinds of Chinese herbs:Thunberg fritillary bulb,antimutangenic ,cimicifuga foetida,astragalus,pinellia ,Radix Ophiopogonis ,Solanum nigrum,Hedyotis diffusa,Prunella vulgaris ,cordate houttuynia,Herba Patriniae,dried orange peel ,Codonopsis,Wolfiporia extensa,Coix seed,Rhizoma Alismatis.
2973917|NCT02737735|Active Comparator|Chemotherapy|The therapy of standard chemotherapy protocols on phase IIIB/IV non-small-cell lung cancer for 24 weeks
2973918|NCT02737722|Experimental|Bisphosphocin Nu-3|Dosage Form: Topical Antibiotic, Dosage: 1mg/mL, 10 mg/mL, 20 mg/mL, 50 mg/mL, 100 mg/mL Frequency: QD for day 1, 2x daily for 7 days, Duration: 8 days
2973919|NCT02737722|Placebo Comparator|Placebo|Dosage Form: Topical Antibiotic, Dosage: 1mg/mL, 10 mg/mL, 20 mg/mL, 50 mg/mL, 100 mg/mL Frequency: QD for day 1, 2x daily for 7 days, Duration: 8 days
2973920|NCT02737709|Experimental|Paclitaxel and Carboplatin regimen|Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection. 21 days per cycle; 6 cycles in total.
2973921|NCT02737696|Active Comparator|Control|Participants in this group will have access to Drug Enforcement Administration's website (JustThinkTwice.gov). The JustThinkTwice website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz. Youth in this group will be informed that they will be prompted (by email and phone; described below) when the next online survey is available to complete. Youth will be asked to use this website for 30 minutes, twice per week (for a total of 60 minutes per week) for about 3-4 weeks.
2973922|NCT02737696|Experimental|Experimental|"Participants assigned to the Web-based prescription opioid prevention for adolescents will immediately (post-group assignment) be asked to start completing modules. All youth can choose to access modules in any order. Youth will be encouraged to complete 1-2 modules per login, 2x/week (about 30 mins. minimum per login to parallel the manner in which other evidence-based prevention programs have been provided to youth. We do not plan to place an artificial constraint on module access but will encourage youth to use the flexible, web- based tool in a manner that is most useful to them. In our experience providing online interventions, we expect that most youth will complete all 9 modules within 3-4 weeks."
2973923|NCT02737670|Active Comparator|Sulodexide|Sulodexide 25 mg twice per day for 40 days
2973924|NCT02737670|Placebo Comparator|Placebo|1 tablet twice per day for 40 days
2973925|NCT02737657||Cohort 1|Participants who are already receiving Canagliflozin and Metformin with or without a DPP-4 inhibitor daily during Ramadan period will be observed as the part of study.
2973926|NCT02737657||Cohort 2|Participants who are already receiving any sulphonylurea and Metformin with or without a DPP-4 inhibitor daily during Ramadan period will be observed as a part of study.
2973927|NCT02737644||CHD birth cohort|Cases are identified as those whose newborns screened and confirmed with CHD during the follow-up and four age- and delivery-hospital matched controls are selected for each case from the rest of the cohort.
2973928|NCT02737631|Experimental|Healthy subject|"Healthy subjects exposed to Trojan Chameleon personal lubricant via occlusive patch"
2973929|NCT02737618|Experimental|Healthy subject|"Healthy subjects exposed to Trojan Chameleon Personal Lubricant applied by occlusive patch"
2973930|NCT02737605|Experimental|Sequence 1|Participants will receive Treatment A (intravenous placebo, Intranasal placebo and Oral placebo tablet matched to the moxifloxacin tablet) on Day 1 of period 1, Treatment B (intravenous placebo, 84 milligram (mg) of intranasal esketamine and Oral placebo tablet matched to the moxifloxacin tablet) on Day 1 of period 2, Treatment C (intravenous placebo, Intranasal placebo and 400 mg oral moxifloxacin tablet) on Day 1 of period 3, Treatment D (0.8 milligram per kilogram of intravenous esketamine, Intranasal placebo and Oral placebo tablet matched to the moxifloxacin tablet ) on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
2973931|NCT02737605|Experimental|Sequence 2|Participants will receive Treatment A on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment B on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
2973932|NCT02737605|Experimental|Sequence 3|Participants will receive Treatment B on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
2973933|NCT02737605|Experimental|Sequence 4|Participants will receive Treatment B on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment C on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
2973934|NCT02737605|Experimental|Sequence 5|Participants will receive Treatment C on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment B on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
2973935|NCT02737605|Experimental|Sequence 6|Participants will receive Treatment C on Day 1 of period 1, Treatment B on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
2973936|NCT02737592|Experimental|Healthy subject|"Healthy subject exposed to Trojan Simply Pleasures Personal Lubricant at least four times weekly for two weeks"
2973937|NCT02737579|Other|XFM guidance|X-ray fused cardiac MRI images used for guidance tool to perform cardiac catheterization procedure
2973938|NCT02737566|Experimental|Standard Care + Financial Incentives|Participants randomized to Standard Care + Financial Incentives for Abstinence will be offered smoking cessation counseling and pharmacotherapy (standard care) and they will have the opportunity to earn small gift cards for biochemically-verified abstinence through 12 weeks post-quit. The amount of the gift cards will escalate each week from the quit date through 4 weeks post-quit with continuous abstinence. Participants who are non-abstinent at any visit may earn incentives for abstinence at the next visit, but the amount will reset to the starting level. Participants may additionally earn an additional gift card for abstinence at the 8 and 12 weeks post-quit visits.
2973939|NCT02737566|Active Comparator|Standard Care|Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.
2973940|NCT02737553|Active Comparator|enclosed morcellation|"In this group, after extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9.~doi: 10.1097/AOG.0000000000000823.)."
2973941|NCT02737553|Active Comparator|vaginal morcellation|In this group, after extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
2973942|NCT02737540||Major depressive episode|This study population consists of patients over 60 years of age with or without a personal history of suicide attempts, hospitalized in the Nîmes University Hospital psychiatry department or the Sophoras clinic for a major depressive episode.
2973943|NCT02737540||Healthy subjects|Healthy subjects over 60 years, not depressed and without personal history of severe mental illness or suicide attempts will be recruited.
2973944|NCT02737527|Experimental|Ultrasound with Fluoroscope|"This group undergoes lumbar sympathetic block using ultrasound and fluoroscope.~Preparation: Inserts 24G intravenous route for Lumbar Sympathetic Block (LSB) Device: Uses 15-cm Chiba needle for Lumbar Sympathetic Block (LSB) Device: Uses Ultrasound for Lumbar Sympathetic Block (LSB) Drug: 10 ml of 0.25% levobupivacaine injection for LSB Intervention: Temperature measurement for Lumbar Sympathetic Block (LSB) Intervention: Postprocedure care for LSB"
2973945|NCT02737527|Active Comparator|Fluoroscope only|"This group undergoes lumbar sympathetic block using fluoroscope only.~Device: Inserts 24G intravenous route for Lumbar Sympathetic Block (LSB) Device: Uses 15-cm Chiba needle for Lumbar Sympathetic Block (LSB) Device: Uses Fluoroscope for Lumbar Sympathetic Block (LSB) Drug: 10 ml of 0.25% levobupivacaine injection for LSB Intervention: Temperature measurement for Lumbar Sympathetic Block (LSB) Intervention: Postprocedure care for LSB"
2973946|NCT02737514|Active Comparator|air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
2973947|NCT02737514|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy
2973948|NCT02737514|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
2973949|NCT02737501|Experimental|Brigatinib|Brigatinib will be administered orally to eligible participants with locally advanced or metastatic ALK+NSCLC naive to ALK inhibitors at a dose of 90 milligram (mg) QD for 7 days, then 180 mg QD, continuously, with or without food until disease progression, unacceptable toxicity, withdrawal of consent or death.
2973950|NCT02737501|Active Comparator|Crizotinib|Crizotinib will be administered to eligible participants with locally advanced or metastatic ALK+ NSCLC naive to ALK inhibitors as 250 mg orally BID, with or without food until disease progression, unacceptable toxicity, withdrawal of consent or death.
2973951|NCT02737488|Experimental|TST|
2973952|NCT02737488|Active Comparator|TAU Group|
2973953|NCT02737475|Experimental|Part 1: Dose Escalation|BMS-986178 at specified doses at specified intervals
2973954|NCT02737475|Experimental|Part 2: Dose Escalation and Expansion|BMS-986178 in combination with Nivolumab at specified doses at specified intervals
2973955|NCT02737475|Experimental|Part 3: Dose Escalation and Expansion|BMS-986178 in combination with Ipilimumab at specified doses at specified intervals
2973956|NCT02737475|Experimental|Part 4: Dose Schedule and Exploration|BMS-986178/Nivolumab at specified doses at specified intervals
2973957|NCT02737475|Experimental|Part 5: Dose Schedule and Exploration|BMS-986178/Ipilimumab at specified doses at specified intervals
2973958|NCT02737475|Experimental|Part 6: Dose Safety and Expansion|BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals
2973959|NCT02737475|Experimental|Part 7: Dose Safety and Expansion|BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals
2973960|NCT02737475|Experimental|Part 8: Dose Schedule and Exploration|BMS-986178/Nivolumab with tetanus vaccine at specified doses and interval
2973961|NCT02737462|Experimental|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
2973962|NCT02737436|Experimental|Oxytocin|Intranasal oxytocin (24IU) given 50 minutes prior to behavior assessment or scanning
2973963|NCT02737436|Experimental|Placebo|Intranasal placebo spray given 50 minutes prior to behavior assessment or scanning
2973964|NCT02737423|Experimental|vitamin D|single IM dose 600,000 IU of cholecalciferol
2973965|NCT02737410|Active Comparator|Treatment|Treatment group obtaining Gut-directed Hypnotherapy
2973966|NCT02737410|No Intervention|Control|Control group
2973967|NCT02737397|Experimental|pain medicine and antihistamine|JMI-001 (SJP-304 and SJP-223)
2973968|NCT02737397|Active Comparator|pain medicine|SJP-304 and placebo
2973969|NCT02737397|Active Comparator|antihistamine|SJP-223 and placebo
2973970|NCT02737397|Placebo Comparator|placebo|placebo and placebo
2973971|NCT02737384|Experimental|Treatment|
2973972|NCT02737371|Experimental|F901318 Dose level A oral|F901318 adverse events days 1-10
2973973|NCT02737371|Placebo Comparator|Placebo Dose level A oral|Placebo adverse events days 1-10
2973974|NCT02737371|Experimental|F901318 Dose level B oral|F901318 adverse events days 1-10
2973975|NCT02737371|Placebo Comparator|Placebo Dose level B oral|Placebo adverse events days 1-10
2973976|NCT02737371|Experimental|F901318 Dose level C oral|F901318 adverse events days 1-10
2973977|NCT02737371|Placebo Comparator|Placebo Dose level C oral|Placebo adverse events days 1-10
2973979|NCT02737358|Active Comparator|N-Acetylcysteine (NAC)|NAC will be given to half of the study participants. The dose of NAC will be 2400 mg per day (1200 mg taken twice per day as two 600 mg capsules)
2973980|NCT02737345||Waiting list|Patients on the liver transplant waiting list
2973981|NCT02737332|Active Comparator|Zytiga® (Abiraterone Acetate)|1,000 MG (4 x 250 mg qd)
2973982|NCT02737332|Experimental|SoluMatrix™ (Abiraterone Acetate)|500 mg (4 x 125 mg qd)
2973983|NCT02737319|Experimental|Rosuvastatin|40 mg of Rosuvastatin up to 6 hours before elective percutaneous coronary intervention.
2973984|NCT02737319|No Intervention|Control|Use of standard therapy in elective angioplasty.
2973985|NCT02737306|Experimental|PRO 140|up to 60 subjects will be enrolled. PRO 140 will be administered as a 525 mg subcutaneous injection on Day -3 or Day -2 prior to stem cell infusion, on the day of stem cell infusion (Day 0), and then weekly for up to 100±7 days. Subjects will return to the clinic for three Follow-up visits at 2 weeks after the last treatment visit, 30 days after the last treatment visit and one year after the first treatment visit.
2973986|NCT02737293|Experimental|Control Diet|Menu based on the average American diet.
2973987|NCT02737293|Experimental|Med Diet|Menu based on the typical Mediterranean diet (Med Diet) pattern.
2973988|NCT02737293|Experimental|Med Diet + Whole Egg|Menu based on the typical Mediterranean diet (Med Diet) pattern with the addition of 1 whole egg per 1000 kilocalories.
2973989|NCT02737280|Active Comparator|Usual oxygen therapy|Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
2973990|NCT02737280|Experimental|High flow oxygen therapy|High flow nasal cannula oxygen therapy with Airvo (TM, Fisher & Paykel Healthcare) device
2973991|NCT02737267|Experimental|Moderately high protein diet|Caloric restriction (-30% total energy intake) Macronutrient distribution: 40% of the energy derived from carbohydrates, 30% of the energy derived from protein and 30% of the energy derived from fat
2973992|NCT02737267|Placebo Comparator|Low fat diet|Caloric restriction (-30% total energy intake) Macronutrient distribution: 60% of the energy derived from carbohydrates, 18% of the energy derived from protein and 22% of the energy derived from fat
2973993|NCT02737254|Experimental|Oxytocin and Secure CBM training|
2973994|NCT02737254|Active Comparator|Placebo and Secure CBM training|
2973995|NCT02737254|Active Comparator|Oxytocin and Neutral CBM training|
2973996|NCT02737254|Placebo Comparator|Placebo and Neutral CBM training|
2973997|NCT02737241|Active Comparator|LP-HoLEP|Low power Holmium laser enucleation of the prostate
2973998|NCT02737241|Active Comparator|HP-HoLEP|High power Holmium laser enucleation of the prostate
2973999|NCT02737228|Experimental|CG200745 PPA|CG200745 PPA plus Gemcitabine and Erlotinib
2974000|NCT02737215|Active Comparator|CPAP group|patients will receive CPAP therapy for the first 7 days after extubation from CABG
2974001|NCT02737215|No Intervention|Control Group|Patients will receive usal care
2974002|NCT02737202|Experimental|Saracatinib|Saracatinib will be given orally at a dose of 125 milligrams once daily for 9 months. Saracatinib is provided as a pink tablet.
2974003|NCT02737189|Experimental|Endovascular Arm|"Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration~Best Medical Treatment and maximum supportive care"
2974004|NCT02737189|Other|Control Arm|Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
2974005|NCT02737176|Experimental|Tobacco cessation intervention|Tobacco cessation intervention is implemented for 12 weeks. The nicotine dependence status is evaluated by the FTND (Fagerstrom Test for Nicotine Dependence) test. The point 3 or more is regarded as a moderate or high tobacco dependence and determining a cessation intervention. During the tobacco cessation intervention for the subjects, attending doctors implement standard treatments for their oral diseases. Even if participants fail to abstain from smoking, the oral treatment is continued. In case of the use of the NRTs (nicotine patch and/or gum), the investigators supply it for 2 weeks as a free of charge, and later the subjects themselves purchase it as over the counter (OTC) drugs at a pharmacy.
2974006|NCT02737176|No Intervention|Non-tobacco cessation intervention|Those who do not intention to abstinence from smoking strongly and/or having less than 3 points in FTND test are allocated to non-tobacco cessation intervention group. The same treatment as the tobacco cessation intervention group is carried out for their oral diseases.
2974007|NCT02737150|Active Comparator|Self-expandable valve under local anesthesia|CoreValve Evolut R valve under local anesthesia with conscious sedation
2974008|NCT02737150|Active Comparator|Self-expandable valve under general anesthesia|CoreValve Evolut R valve under general anesthesia
2974009|NCT02737150|Active Comparator|Balloon-expandable valve under local anesthesia|Edwards Sapien 3 valve under local anesthesia with conscious sedation
2974010|NCT02737150|Active Comparator|Balloon-expandable valve under general anesthesia|Edwards Sapien 3 valve under under general anesthesia
2974011|NCT02737137|Other|Manual measurement by the anesthetist|Monitoring by ultrasound, Neurostimulation and Measurement Manual of the injection pressure of the local anesthetic : Group 1
2974012|NCT02737137|Experimental|Measurement by a pressure gauge|Monitoring by ultrasound, Neurostimulation and measurement with a gauge of the injection pressure of the local anesthetic : Group 2
2974013|NCT02737124|Experimental|1000 Mg Acetaminophen|Acetaminophen will be given 24 hours before surgery
2974014|NCT02737124|Active Comparator|Placebo|A sugar pill will be given 24 hours before the scheduled surgery.
2974015|NCT02737098|Active Comparator|Standard Implementation|Standard VA implementation strategies will include disseminating a clinical intervention manual, a local champion guide, care manager training materials, PTSD case-finder tool, and technical support from the facility level telehealth technician. Internal facilitation will be conducted by the designated local champion. In addition, each VAMC will receive funds to hire a full time telephone care manager.
2974047|NCT02736916|Active Comparator|Conventional PCI|LD-SCLC patients with Conventional PCI
2974048|NCT02736903|Active Comparator|Individual intervention|Behavioral: PennFit mobile individual intervention. Participants were given a Fitbit (zip) to track their daily exercises. Participants used the PennFit app to track their own daily steps and the minutes for vigorous, moderate, and muscle-strengthening exercises that they completed for each day. Participants also received system-generated notifications that reminded them to wear their Fitbit in the morning and to log their activity minutes in the evening.
2974016|NCT02737098|Active Comparator|Enhanced Implementation Strategy|The enhanced implementation strategy will add external facilitation to the standard VA implementation strategies. External facilitation will begin with an assessment of the current workflow at the VHA Medical Center and the affiliated CBOCs using System Redesign methods. The external facilitation team will then generate a clinical workflow chart that describes the current process of care. With advice from the external facilitation team, the local champion will then incorporate the clinical process of the TOP intervention into the current clinical workflow chart, making changes to the TOP intervention and/or current clinical workflow as needed. The local champion will also meet monthly with external facilitators to troubleshoot and make refinements.
2974017|NCT02737085|Experimental|Diffuse Large B Cell Lymphoma(DLBCL)|The trial will be conducted in a manner of simon two-stage design with Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with Diffuse Large B Cell Lymphoma(DLBCL). Only when the expected reaction rate is achieved the 30 patients left can be recruited.
2974018|NCT02737072|Experimental|LY2510924 + Durvalumab|LY2510924 given subcutaneously (SQ) in combination with durvalumab given intravenously (IV).
2974019|NCT02737072|Experimental|LY2510924 + Durvalumab (Expansion 1)|LY2510924 given SQ in combination with durvalumab given IV.
2974020|NCT02737072|Experimental|LY2510924 + Durvalumab (Expansion 2)|LY2510924 given SQ in combination with durvalumab given IV.
2974021|NCT02737059|Placebo Comparator|Codeine/naloxegol placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.~Codeine tablet 30 mg q.i.d., and placebo tablet matching naloxegol q.d."
2974022|NCT02737059|Placebo Comparator|Naloxegol/ codeine placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.~Naloxegol tablet 25 mg q.d and placebo tablet matching codeine q.i.d."
2974023|NCT02737059|Active Comparator|Codeine/ naloxegol|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.~Codeine tablet 30 mg q.i.d., and naloxegol tablet 25 mg q.d."
2974024|NCT02737059|Active Comparator|codeine placebo/ naloxegol placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.~Placebo tablet matching codeine q.i.d., and placebo tablet matching naloxegol q.d."
2974025|NCT02737046|Experimental|Belinostat + Zidovudine|Belinostat + Zidovudine (AZT) in combination as consolidation therapy, followed by standard zidovudine (AZT)-based maintenance therapy with optional Interferon-Alfa-2b (IFNalfa-2b) or Pegylated Interferon-Alfa-2b (PEG-IFN-alfa-2b)
2974026|NCT02737033|Experimental|Rhodiola|Rhodiola rosea 800mg single dose
2974027|NCT02737033|Placebo Comparator|Placebo|placebo 800mg single dose
2974028|NCT02737020|Experimental|Rhodiola|Rhodiola rosea 200mg up to four times a day for 28 days
2974029|NCT02737020|Placebo Comparator|Placebo|Placebo pill manufactured to mimic Rhodiola rosea 200mg, up to four times a day for 28 days
2974030|NCT02737007|Experimental|[14C]-GSK3191607 IV Microdose|Subjects will receive a single microdose of 100 micrograms (mcg) of [14C]-GSK3191607 by intravenous infusion over 15 minutes on Day 1 of the study.
2974031|NCT02736994|Other|Immersion in water|water
2974032|NCT02736994|Active Comparator|Immersion in water + cleansing tablet|Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
2974033|NCT02736994|Experimental|Immersion in water with PIP|PIP toothbrush cleaner® (Chrisal, Lommel, Belgium)
2974034|NCT02736981|Active Comparator|Behavioral Weight Loss (BWL)|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment.
2974035|NCT02736981|Active Comparator|BWL + Autonomous Motivation|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
2974036|NCT02736981|Active Comparator|BWL + Extrinsic Motivation|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
2974037|NCT02736968|Experimental|E. histolytica- Active|N=34, 6mg auranofin daily x 7 days
2974038|NCT02736968|Placebo Comparator|E. histolytica- Placebo|N=34, 6mg placebo daily x 7 days
2974039|NCT02736968|Experimental|Giardia- Active|N=34, 6mg auranofin daily x 5 days
2974040|NCT02736968|Placebo Comparator|Giardia- Placebo|N=34, 6mg placebo daily x 5 days
2974041|NCT02736955|Experimental|Valbenazine|Fixed dose of valbenazine administered once daily for up to 72 weeks
2974042|NCT02736942|Active Comparator|Laparoscopic|Laparoscopic TME
2974043|NCT02736942|Experimental|Transanal|TaTME
2974044|NCT02736929|Active Comparator|Cognitive Processing Therapy - Cognitive|Cognitive Processing Therapy - Cognitive (CPT-C), is a brief cognitive behavioral treatment for PTSD. CPT-C consists of 2 hours of therapy each week for 6 weeks (i.e., two sessions).
2974045|NCT02736929|No Intervention|Waiting Period Control (WP-CON)|WP-CON group will receive minimal attention in the form of weekly telephone calls to assess current emotional state and to provide supportive, nondirective, brief counseling if participants report experiencing a crisis. Any participant assigned to the WP-CON group will be given the opportunity to receive CPT-C after the post-waiting period assessment.
2974049|NCT02736903|Experimental|Online network intervention|Behavioral: PennFit mobile online network intervention. Participants were given a Fitbit (zip) to track their daily exercises. Participants used the PennFit app to track their exercises. Participants also received system-generated notifications that reminded them to wear their Fitbit in the morning and to log their activity minutes in the evening. Participants were randomly assigned to 4-person online networks in the PennFit app. Participants in the online networks could see both their own information and the profiles and activity logs of the three other people assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
2974050|NCT02736890|Active Comparator|Botulinum Toxin A|Each vial of botulin toxin (100U, BOTOX, Allergan) will be reconstituted with 4ml non-preserved saline solution (0.9%) as recommended by the manufacturer (concentration of 5 units Botulinum Toxin A/0.2ml). Each injection will be 0.2mL (BOTOX, 5 units), administered through a 25 gauge needle. The marked area will have subcutaneous injections, each separated by a radius of 1 cm, from the other injections into the marked area,(maximum of 80 injections, 400 Units).
2974051|NCT02736890|Placebo Comparator|Placebo|Placebo consists of 0.9% normal saline. Each injection will be 0.2mL, administered with a 25 gauge needle subcutaneously into the affected area. The marked area will have subcutaneous injections (maximum of 80) each separated from the surrounding ones by a radius of 1 cm.
2974052|NCT02736877|Experimental|Lumera Microscope with OCT RESCAN|In the group microscope coupled to OCT, patients will undergo corneal surgery using the Lumera Microscope WITH RESCAN OCT - ZEISS. The team of surgeons will answer the questionnaire on the surgical difficulty regarding corneal transplantation
2974053|NCT02736877|Active Comparator|Conventional Microscope|The control group will undergo corneal transplant with conventional microscope without coupled OCT. The team of surgeons will answer the questionnaire on the surgical difficulty regarding corneal transplantation
2974054|NCT02736851|No Intervention|Control group|Usual care
2974055|NCT02736851|Active Comparator|Home-based telemedicine group|Nurse-tutor support at home for 6 months
2974056|NCT02736838|Experimental|Phase I|Interventions: Different positions will be applied to subjects to measure preipheral tissue oxygenation, pressure, and changes in microvascular flow. Subjects will be placed up to 4 hours in each of the standard positions for the experiment: supine decubitus (SD) right lateral decubitus (RLD), left lateral decubitus (LLD). SD measurements will be made at 0, 30 and 45 degrees of inclination to bed. RLD and LLD positions will be evaluated with a body inclination of 30 and 90ª. The subjects will lie down on a memory foam mattress for an articulated bed, as are commonly used at home, residential or hospital care. Between the subject and the mattress will be inserted the pressure measuring surface. Measurements in each position will be made during intervals of 0-4 hours in the same position (SD-RLD-LLD) in each of the inclinations of the bed (0º, 30°, 45 °) or body (30º, 90º), respectively.
2974057|NCT02736825|Active Comparator|Group A, Ultherapy® using Standard transducers|"Subjects randomized to Group A will receive an Ultherapy® treatment to the lower face and neck with a total minimum pulse count of 672 pulses (+5%) at the 4.5mm and 3.0mm depths using Standard transducers. Energy levels for each transducer will be set to Energy Level (EL)2:~Deep-See (DS) 4-4.5 at 0.9 Joules (J) with pitch of 1.5mm and 17 Thermal Coagulation Points (TCP)s per line~DS 7-3.0 at 0.30J with pitch of 1.1mm and 23 TCPs per line"
2974058|NCT02736825|Experimental|Group B, Ultherapy® using Simulines transducers|"Subjects randomized to Group B will receive a comparable treatment with a total minimum pulse count of 336 pulses (+5%) using the Simulines transducers at the 4.5mm and 3.0mm depths. Energy levels for each transducer will be set to EL2:~Deep-See 4-4.5 Simulines (DS 4-4.5S) at 1.23J with pitch of 1.5mm and 17 TCPs per line~DS 4-3.0S at 0.88J with pitch of 1.3mm and 20 TCPs per line"
2974059|NCT02736812|Experimental|French Lyophilized Plasma|receives French Lyophilized Plasma with the usual treatment for post traumatic hemorrhagic shock as given in the recommendations for best practice
2974060|NCT02736812|Active Comparator|Normal Saline Solution|receives Normale Saline Solution with the usual treatment of post traumatic hemorrhagic shock as given in the recommendations for best practice
2974061|NCT02736799|Sham Comparator|Sham vibrating capsule|Sham vibrating capsule
2974062|NCT02736799|Active Comparator|Vibrant Capsule (1 vibration)|1 vibration/min
2974063|NCT02736799|Active Comparator|Vibrant Capsule (3 vibration)|3 vibrations/min
2974064|NCT02736799|Active Comparator|Vibrant Capsule (5 vibration)|5 vibrations/min
2974065|NCT02736773|Experimental|xenograft material to slow resorption|xenograft material to slow resorption (Bio-Oss®)
2974066|NCT02736773|No Intervention|patients who did not wish or could not have filling|patients who have a tooth in the posterior mandibular area to extract but who did not wish or could not have filled.
2974067|NCT02736760|Experimental|Daylight photodynamic therapy (PDT)|"One intervention in the daylight photodynamic therapy arm:~Daylight photodynamic therapy using Methylaminolevulinate (MAL) will be performed five times within 18 months (visits 1-5). In the PDT group the patients will apply a chemical sunscreen (SPF 50+) to the whole face and other light-exposed, unprotected areas of the skin. After at least 15 minutes a lesion preparation of AKs (removal of crusts) will be performed and methylaminolevulinate (MAL) will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours."
2974068|NCT02736760|Active Comparator|Cryosurgery|In the control group, cryosurgery will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. In the control group, cryosurgery will be performed using liquid nitrogen spray in each AK lesion; this will be done at visit 1 and, if necessary, also at visits 2-5. At visits 2-6, the efficacy of the treatment will be evaluated by the observer by documenting all existing and newly appearing AKs in the face.
2974069|NCT02736747|Active Comparator|Cryotherapy (ice pack)|A pack with 1000g of crushed ice without air will be placed for 20 consecutive minutes on a pre-delimited rectangular area with dimensions of 25 x 35 cm and will be fixed with a non-compressive elastic band. One strip of plastic paper will encompass the paretic leg of the subjects, avoiding direct contact from the skin with the ice pack.
2974070|NCT02736747|Placebo Comparator|Placebo (sand pack)|"For placebo application, the pack will be filled with 1000g of thin sand, in environmental temperature, so that the pressure exerted will be the same as the ice pack. All other experimental procedures will follow the same protocol as cryotherapy application."
2974071|NCT02736734|Other|CRH condition|All HV first underwent a baseline manometry measurement. After 30 minutes, an intravenous CRH injection was done. The same measurement was repeated but now with CRH administered.
2974072|NCT02736721|Experimental|Peginterferon alfa-2a|Participants will receive peginterferon alfa-2a subcutaneously in doses between 90 and 450 microgram (mcg) once weekly until medically indicated as judged by the treating investigator.
2974073|NCT02736708||PSC|Male or female > 18 years of age Clinically Indicated for ERCP and/or cholangioscopy for dominant PSC stricture Inclusion of patients either previously stented or not
2974074|NCT02736695|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will receive a Tau PET scan.
2974075|NCT02736682|Experimental|Single dose antibiotic|2g of intra venous Ceftriaxone and 500 mgs Intra venous metronidazole is administered to the mothers as a Single dose pre-operative30-60 minutes before surgery.
2974076|NCT02736682|Active Comparator|multiple dose antibiotic.|Multiple doses of IV Ceftriaxone 1g and metronidazole 500mgs given to the mother during surgery there after Ceftriaxone 1g every day for 3 days and IV metronidazole 500 mgs every 8 hours for 3 days.
2974077|NCT02736669|Active Comparator|Fixed Energy (or Calorie) Reduction|Participants randomly assigned to this arm will be instructed to reduce their food intake by a moderate amount and stay at this level of moderate reduction until their weight loss goal is achieved.
2974078|NCT02736669|Experimental|Variable Energy (or Calorie) Reduction|Participants randomly assigned to this arm will be instructed to alternate between two levels of calorie reduction. One level will be a small amount of calorie reduction, while the other will be a more significant amount of calorie reduction. At the instruction of the research team, participants will periodically alternate back and forth between these two goals until their weight loss goal is achieved.
2974079|NCT02736656|Experimental|Open-Label Treatment|Subjects aged 6-12 years will be treated with SPN-812 ER followed by dose optimization. The subject will be given a choice to extend their participation in the study every 6-months for up to 36 months.
2974080|NCT02736617|Experimental|Treatment (obinutuzumab and ibrutinib)|Patients receive obinutuzumab IV on days 1, 8, 15 and ibrutinib PO QD of first treatment course. Patients then receive obinutuzumab IV on day 1 and ibrutinib PO QD from 2-6 treatment courses. Patients who have PR continue to receive obinutuzumab IV every 2 months and ibrutinib PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
2974081|NCT02736604|Experimental|Air anesthesia|air will be used as carrier agent for maintenance of anesthesia
2974082|NCT02736604|Active Comparator|Nitrous Oxide anesthesia|nitrous oxide will be used as carrier agent for maintenance of anesthesia
2974083|NCT02736591|Active Comparator|DHEA|Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI
2974084|NCT02736591|Active Comparator|Growth hormone|Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
2974085|NCT02736578|Experimental|Cetuximab IRDye800, 50 mg|On day 0, participants receive a 100 mg cetuximab loading dose by intravenous infusion (IV), followed 1 hour later by cetuximab-IRDye 800CW IV at 50 mg, followed by surgery with intraoperative imaging within 2 to 5 days.
2974086|NCT02736578|Experimental|Cetuximab IRDye800, 100 mg|On day 0, participants receive a 100 mg cetuximab loading dose by intravenous infusion (IV), followed 1 hour later by cetuximab-IRDye 800CW IV at 100 mg, followed by surgery with intraoperative imaging within 2 to 5 days.
2974087|NCT02736565|Experimental|pbi-shRNA™ EWS/FLI1 Type 1 LPX|"Subjects will accrue in 3 to 6-subject escalation cohorts up to a dose of 0.156mg/kg of DNA / single dose.~An intravenous infusion will be administered twice a week for 4 weeks (e.g. Mon and Thurs, preferred) for a total of 8 infusions of the product per cycle followed by 2 weeks of rest. Treatment may continue as long as there is clinical benefit, no evidence of disease progression, and no other withdrawal criteria are met."
2974088|NCT02736552|Experimental|S-1 for 6 months|S-1 80-120mg daily for 14 days in 3 weeks for totally 6 months after D2 resection
2974089|NCT02736552|Active Comparator|S-1 for 1 year|S-1 80-120mg daily for 14 days in 3 weeks for totally 1 year after D2 resection
2974090|NCT02736539|Experimental|Active|galacto-oligosaccharides
2974091|NCT02736539|Placebo Comparator|Placebo|Placebo
2974092|NCT02736526|Experimental|Surgical treatment|The recession or resection of the horizontal extraocular muscles will be processed in the beginning of the trial.
2974093|NCT02736526|No Intervention|Observation only|
2974094|NCT02736513|Experimental|AZD9291 80 mg - naive patients|naive patients with tumors harbouring either exon 19 deletion, L858R, T790M, or uncommon sensitizing EGFR mutations, will be treated with AZD9291 80 mg/day
2974095|NCT02736513|Experimental|AZD9291 80 mg - previously treated|Patients previously treated with first and second generation EFGR TKIs (either Gefitinib, Erlotinib or Afatinib) in whom T790Mwas diagnosed either in the tumor specimen or in the ctDNA after testing it following the most recent disease progression, will be treated with AZD9291 80 mg/day
2974096|NCT02736500|Experimental|28 GBq 177Lu-DOTATATE|5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) 177Lu-DOTATATE
2974097|NCT02736500|Experimental|22 GBq 177Lu-DOTATATE|6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi) 177Lu-DOTATATE
2974098|NCT02736487|Active Comparator|Group A: True-Washout-Sham|Subjects in group A receives true air filtration intervention, then at least two weeks of washout period, followed by sham air filtration intervention.
2974099|NCT02736487|Active Comparator|Group B: Sham-Washout-True|Subjects in group B receives sham air filtration intervention, then at least two weeks of washout period, followed by true air filtration intervention.
2974100|NCT02736474|Experimental|Naltrexone and Bupropion|Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.
2974101|NCT02736474|Placebo Comparator|Placebo Naltrexone and Bupropion|Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.
2974102|NCT02736461||Group 1- With strabismus|Study group with strabismus happening after floor fracture repair
2974103|NCT02736461||Group 2- Without strabismus|No strabismus happening after floor fracture repair
2974104|NCT02736448|Experimental|Arm Lu-PRRT-Cap|Arm Lu-PRRT-Cap: oral low dose of capecitabine in association with Lu-PRRT (at 3.7 Gbq per cycle x 7 cycles) followed by long acting octreotide or lanreotide (SS-LAR)
2974105|NCT02736448|Experimental|Arm Lu-PRRT|Arm Lu-PRRT: Lu-PRRT (at 3.7Gbq per cycle x 7 cycles) followed by long acting octreotide or lanreotide (SS-LAR)
2974106|NCT02736435|Experimental|Fibroid dimension < 8 cm|"Women with a maximum fibroid dimension less than 8 cm and a total uterine volume less than 900 cc.~Intervention: Treatment of fibroids with Magnetic Resonance Guided High Intensity Focused Ultrasound."
2974107|NCT02736435|Experimental|Fibroid dimension > 8 cm|"Women with a maximum fibroid dimension greater than 8 cm or a total uterine volume greater than 900 cc.~Intervention A: Pre-treated with 11.25mg leuprolide acetate for depot suspension for 3 months to reduce size of fibroids.~Intervention B: Treatment with Magnetic Resonance Guided High Intensity Focused Ultrasound if fibroids decrease to treatable size of less than 8cm and uterine volume less than 900cc."
2974108|NCT02736422|Other|hyperpolarised xenon|evaluating the sensitivity of pulse sequences for 129Xe magnetic resonance imaging in the lungs, heart and brain and monitoring the transient changes in vital signs during and following the gas inhalation
2974109|NCT02736409|Experimental|Arms A OBS Completers/ Responders|Arm A Oral Budesonide Suspension Completers/ Responders
2974110|NCT02736409|Placebo Comparator|Arm B OBS Completers/ Responders|Arm B Oral Budesonide Suspension Completers/ Responders. 1:1 randomization for Arms A and B
2974111|NCT02736409|Experimental|Arm C OBS Completers/ Non-Responders|Arm C Oral Budesonide Suspension Completers/ Non-Responders
2974112|NCT02736409|Experimental|Arm D Placebo Completers|Arm D Placebo Completers
2974113|NCT02736396||Healthy Controls|Medical History, Neuropsychological tests, clinical assessments, fMRI
2974114|NCT02736396||Cognitive impairment|Medical History, Neuropsychological tests, clinical assessments, fMRI
2974115|NCT02736383||Tranexamic Acid|Patients that receive 2 gm TXA during surgery
2974116|NCT02736383||No Tranexamic Acid|Patients that receive no TXA during surgery
2974117|NCT02736344|Experimental|BioNIR Ridaforolimus (drug eluting stent (DES)|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~Ridaforolimus drug - CAS Registry Number: 572924-54-0~The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
2974118|NCT02736331|Experimental|Treatment 1 Beverage|Treatment 1
2974119|NCT02736331|Placebo Comparator|Treatment 2 Beverage|Treatment 2
2974120|NCT02736318|Experimental|processed osteochondral allograft|Implantation of 1 to 3 osteochondral products in osteochondral lesion of talus.
2974121|NCT02736305|Experimental|Regorafenib|Patients will receive Regorafenib 120mg once daily, with consideration for dose escalation to 160mg if there are no toxicities
2974122|NCT02736292|Experimental|participant|
2974123|NCT02736266|Experimental|Pembrolizumab (MK-3475)|Pembrolizumab (MK-3475) will be administered at the dose of 200mg, as a 30-minute intravenous infusion, every 3 weeks, for a total of 3 cycles prior to radical cystectomy.
2974124|NCT02736240|Active Comparator|Control Arm|7-valent pneumococcal conjugate vaccine
2974125|NCT02736240|Experimental|Test Arm|13-valent pneumococcal conjugate vaccine
2974126|NCT02736227|Experimental|Tacrolimus Withdrawal and Everolimus Monotherapy|Tacrolimus will be tapered while continual use of everolimus.
2974127|NCT02736214|Experimental|Lifestyle counseling|The intervention group answered a baseline questionnaire in the waiting room and received the intervention (Reproductive Life Plan) in addition to standard care.
2974128|NCT02736214|No Intervention|Control group|The control group answered a baseline questionnaire in the waiting room and received standard care.
2974129|NCT02736201|Experimental|IMT+ T-CaRe®on; n = 10|The instrumental manual therapy with the switched on capacitive diathermy electrode
2974130|NCT02736201|Sham Comparator|IMT+ T-CaRe® off; n = 10|The instrumental manual therapy with the switched off capacitive diathermy electrode
2974131|NCT02736188|Experimental|Drug: Aceneuramic Acid Extended-Release Tablets|Subjects will take 4 tablets (500 mg Ace-ER each for 2 g per dose) orally 3 times per day (TID).The dose should be taken with food (i.e. within 30 minutes after a meal or snack).
2974132|NCT02736175|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
2974133|NCT02736175|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
2974134|NCT02736162||Perampanel|Participants with a diagnosis of epilepsy who received perampanel as primary or secondary (conversion) monotherapy at any time between 1 Jan 2013 and 15 Oct 2015.
2974135|NCT02736149|Experimental|ubenimex|"ubenimex capsules 150 mg three times a day (TID), administered orally, minimum of 24 weeks for all patients.~The maximum anticipated time an individual patient will participate will vary because treatment will continue until the last patient enrolled has received at least 24 weeks of open-label treatment."
2974136|NCT02736136|Experimental|Intervention|Joint observation and video feedback plus usual care in the neonatology (plus completion of self-report questionnaires and 15 min filmed mother-infant interaction)
2974137|NCT02736136|No Intervention|Control|Usual care in the neonatology (plus completion of self-report questionnaires and 15 min filmed mother-infant interaction)
2974138|NCT02736123|Experimental|Arm A consists of 3 phases or steps|"Induction Phase Nivolumab 3 mg/kg IV infusion every 2 weeks for 3 doses~Definitive Surgery Complete lymph node dissection/ lymphatic, cutaneous, subcutaneous disease resection (week 6-8+)~Maintenance Phase (after recovery from surgery) Nivolumab 3 mg/kg IV infusion every 3 weeks"
2974139|NCT02736123|Experimental|Arm B consists of 3 phases or steps|"Nivolumab 1 mg/kg IV infusion every 3 weeks for 2 doses given concurrently with Ipilimumab 3 mg/kg IV infusion every 3 weeks for 2 doses~Definitive Surgery Complete lymph node dissection/ lymphatic, cutaneous, subcutaneous disease resection (week 6-8+)~Maintenance Phase (after recovery from surgery) Nivolumab 1 mg/kg IV infusion every 3 weeks for 2 doses given concurrently with Ipilimumab 3 mg/kg IV infusion every 3 weeks for 2 doses; then, Nivolumab 3 mg/kg IV infusion every 3 weeks"
2974140|NCT02736084|Experimental|Positive Psychology|"The Positive Psychology intervention consists of 7 exercises that will be completed by the participant with the guidance of a trainer.~Exercises:~Gratitude for positive events Using personal strengths Gratitude letter Enjoyable and meaningful activities Recalling past success Performing acts of kindness Repeating one of the previous exercises."
2974141|NCT02736071|Active Comparator|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
2974142|NCT02736071|Active Comparator|Tramadol|Women will receive oral Tramadol 100 mg 2 hours before the procedure
2974143|NCT02736071|Placebo Comparator|Placebo|Women will receive an oral placebo similar to Tramadol and an oral placebo similar to Celecoxib 2 hours before the procedure
2974144|NCT02736058|Experimental|Participants|the included pregnant females will undergo trans-abdominal sonography as well as trans-vaginal sonography , to diagnose the abnormal placentation and the results will be compared to the intra- operative as well as the pathological examination of the specimen.
2974145|NCT02736045|No Intervention|Control|Sham control. Subjects will be asked to write a journal (per week).
2974146|NCT02736045|Experimental|emWave|Our approach will be to test the impact of a behavioral intervention through a smartphone application, emWave software, which will be provided to all our subjects. The intervention (emWave) is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention.
2974147|NCT02736032|Active Comparator|With GnRHa|Cryopreserved-thawed embryo transfer cycle, with endometrial preparation using GnRHa followed by external estradiol and progesterone. The GnRHa depot from will be given on day 21 of the preceding cycle, on day 1 of the transfer cycle, the patient will receive 6 mg/ day of estradiol followed up on day 12 of the cycle, if the endometrium is less than 8 mm, till day 15 of the cycle estradiol will be increased to 8 mg/day until 8 mm or more. Then, serum estradiol and progesterone levels are collected, and progesterone 800 mg vaginal suppository will be added and embryo transfer performed 2 to 3 days later.
2974148|NCT02736032|Active Comparator|Without GnRHa|Cryopreserved-thawed embryo transfer cycle, with endometrial preparation using external estradiol and progesterone only. On day 1 of the transfer cycle, the patient will receive 6 mg/ day of estradiol and followed up on day 12 of the cycle, if the endometrium did not reach 8 mm, till day 15 of the cycle the dose will be increased to 8 mg/day until the endometrium is 8 or more mm. When the endometrium is ready, serum estradiol and progesterone levels are collected, then progesterone 800 mg vaginal suppository will be added and embryo transfer performed 2 to 3 days later.
2974149|NCT02736019|Active Comparator|Celecoxib|Women will receive oral celecoxib 200mg 2 hours before the procedure
2974150|NCT02736019|Active Comparator|Tramadol|Women will receive oral Tramadol 100mg 2 hours before the procedure
2974151|NCT02736019|Placebo Comparator|Placebo|Women will receive a placebo similar to celecoxib and a placebo similar to Tramadol
2974152|NCT02736006|Experimental|20 meters air dive|
2974153|NCT02735980|Experimental|Prexasertib (Platinum Sensitive Disease)|Intravenous (IV) prexasertib administered on day 1 of every 14 day cycle
2974154|NCT02735980|Experimental|Prexasertib (Platinum Resistant Disease)|IV prexasertib administered on day 1 of every 14 day cycle
2974155|NCT02735980|Experimental|Prexasertib Exploratory Addendum (Platinum Sensitive Disease)|IV prexasertib
2974156|NCT02735967|Experimental|Group manual therapy + diadynamic|"Initially, the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.~Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minutes short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient."
2974157|NCT02735967|Active Comparator|Group manual therapy|Initially, the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
2974158|NCT02735967|Active Comparator|Group diadynamic|An electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF),4 minutes long periods (LP) and 4 minutes short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
2974159|NCT02735954||Marijuana Users|Individuals who use marijuana
2974160|NCT02735954||Combined Marijuana and Tobacco Users|Individuals who use marijuana and also smoke cigarettes
2974161|NCT02735954||Non-Marijuana Users|Individuals who do not use marijuana
2974162|NCT02735941||UC group|Patients with ulcerative colitis (active or remission)
2974163|NCT02735941||CD group|Patients with Crohn's disease (active or remission)
2974164|NCT02735941||Colon cancer group|Patients with colon cancer or metastasis
2974165|NCT02735941||control group|healthy individuals
2974166|NCT02735928|Experimental|PIPAC|PIPAC stands for Pressurized IntraPeritoneal Aerosol Chemotherapies. Enrolled patients will undergo to explorative laparoscopy as usual and PC index will be determined according to Fagotti score (PIV). Pathological response will be determined by serial peritoneal biopsies. Then a pressurized aerosol containing cisplatin followed by doxorubicin will be applied via a nebulizer. The PIPAC procedure can be repeated after 4-6 weeks until progression or limiting toxicity
2974167|NCT02735915|Experimental|Zoster vaccine Group|Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule.
2974168|NCT02735902|Experimental|AVK Monotherapy|"In this group, patients will receive monotherapy via anti vitamin K; this treatment given corresponds to the anticoagulant treatment the patient was receiving before surgery. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient.~Intervention: AVK"
2974169|NCT02735902|Active Comparator|AVK + Aspirin|"In this group, patients will receive combination therapy via anti vitamin K (AVK) and aspirin, whose daily dose is between 75 mg and 100 mg; the AVK treatment administered corresponds to the anticoagulant treatment the patient was receiving before the procedure, monitored and adapted according to current recommendations. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient.~Intervention: AVK Intervention: Aspirin"
2974170|NCT02735889|Other|No carbonation (control)|No carbonation (NC, control): Potable water + sugar
2974171|NCT02735889|Active Comparator|Low carbonation|Low carbonation (LC): Potable water + sugar + little CO2
2974172|NCT02735889|Active Comparator|High carbonation|High carbonation (HC): Potable water + sugar+ high CO2
2974198|NCT02735707|Active Comparator|Corticosteroid Domain: Hydrocortisone|The patient will receive Hydrocortisone 50 mg every 6 hours for up to 7 days.
2974173|NCT02735876|Experimental|acalabrutinib plus rituximab|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity. Rituximab IV infusions will be administered weekly for 4 weeks and on Day 1 of Cycle 3 through 8, and thereafter every other cycle for less than or equal to two years (approximately 200 subjects).
2974174|NCT02735876|Active Comparator|ibrutinib|Ibrutinib will be orally administered until disease progression or unacceptable toxicity (approximately 200 subjects).
2974175|NCT02735876|Experimental|acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity (approximately 50 subjects).
2974176|NCT02735863|Experimental|ABX464|Fixed dose of ABX464 50mg once daily given during 28 days in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)
2974177|NCT02735863|Placebo Comparator|ABX464 Matching placebo|Matching placebo of ABX464 given at 50mg once daily in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)
2974178|NCT02735850|Experimental|Ablative SBRT to all (max 3) sites followed by L19-IL2|Ablative cohort
2974179|NCT02735850|Active Comparator|Ablative SBRT to all (max 3) sites|Ablative cohort
2974180|NCT02735850|Experimental|SBRT 1 site, L19-IL2 and then standard of care|Non-ablative cohort
2974181|NCT02735850|Active Comparator|Standard of care|Non-ablative cohort
2974182|NCT02735837|Active Comparator|doxycycline gel|Doxycycline 3% topical gel was put into the periodontal pocket using an insulin syringe
2974183|NCT02735837|Placebo Comparator|placebo gel|placebo topical gel was put into the periodontal pocket using an insulin syringe
2974184|NCT02735824||patients with suspected PID|From included patients with suspected primary immunodeficiency (PID), i.e. patients with recurrent/unusual infection, immune dysregulation and/or susceptibility to malignancies from whom consent to participate was obtained, nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
2974185|NCT02735824||healthy relatives of patients with PID|From healthy relatives of patients with suspected PID from whom consent to participate was obtained, nucleated cells will be used for genetic testing in order to compare their genetic information with the one form their relatives with suspected PID.
2974186|NCT02735824||Healthy volunteers|From healthy volunteers from whom consent to participate was obtained, nucleated blood cells will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement. The data obtained will be compared to age matched patients with suspected PID.
2974187|NCT02735798|Experimental|Single Arm Study - Arm 1|10 patients will receive standard imaging at baseline, incl. FDG-PET/CT plus MR brain imaging. Patients will subsequently start protocol therapy with MM-302 and trastuzumab given on day 1 of an every 21-day dosing cycle, at recommended phase 2 dose of 30 mg/m2. Patients will receive 64Cu-labeled MM-302 (3-5 mg/m2 doxorubicin) 3 hours after unlabeled dose of MM-302. Integrated MR/PET imaging of brain and whole body will be performed at 2 time points following 64Cu-labeled MM-302 administration: (1) within 3 hours (+/- 1 hour) of labeled drug injection, and (2) 24 hours (+/- 6 hours) post-injection. Patients will continue to receive doses of unlabeled MM-302 plus trastuzumab every 3 weeks until clinical or radiographic disease progression (in brain or systemically) or unacceptable toxicity, whichever occurs soonest. MRI and FDG-PET/CT scans will be performed every 9 weeks to monitor for treatment response and disease progression.
2974188|NCT02735785|Experimental|intervention|behavioral intervention
2974189|NCT02735785|No Intervention|control|control
2974190|NCT02735772|Other|cystocele|"Arm: Patients with paravaginal defect cystocele~Intervention: transobturator approach for paravaginal repair"
2974191|NCT02735759|Other|Healthy Volunteers|This cohort will consist of ten healthy volunteers. The photoacoustic flow cytometry device will be used to establish device settings. The intervention with the subject will include the PAFC device to establish appropriate device settings.
2974192|NCT02735759|Other|Venous Thromboembolism|This cohort will consist of ten patients with newly diagnosed, non-life threatening acute venous thromboembolism. The intervention with the subjects is to perform the photoacoustic flow cytometry device to detect circulating emboli in vivo in patients with venous thromboembolism at diagnosis, during and after anticoagulation therapy.
2974193|NCT02735746|Experimental|High fidelity functional lung imaging|High fidelity functional lung imaging (HFFLI) is an improved method of measuring pulmonary function by analyzing 3-Dimensional (3D) motion. Using this technique, we are able to detect and localize pathological changes in the lung with sub-segmental resolution. The approach uses a unique cross-correlation analysis and non-linear optimization to reconstruct lung tissue motion from a small number of standard projections. All participants will undergo standard 4D Computed Tomography (CT), standard Cone Beam CT, research Low-dose Cinefluorography, and additional research Pulmonary Function Tests.
2974194|NCT02735733|Active Comparator|Room temperature arm|Intervention: The balloon catheter will be placed through the vagina into the uterus and inflated using normal saline at room temperature.
2974195|NCT02735733|Experimental|Cold arm|Intervention: The balloon catheter will be placed through the vagina into the uterus and inflated using normal saline at approximately 32 degrees F for the study group.
2974196|NCT02735720||TEVAR group|"Adult patients whose clinician's are managing their thoracic aortic aneurysms or with penetrating aortic ulcers with TEVAR.~Standard work-up examinations for TEVAR will be collected, consisting of computed tomography (CT), echocardiography, blood pressure, heart rate, ECG and blood tests. Prior to the TEVAR procedure, a non-invasive MRI scan and blood samples will be acquired. Intraoperative pressure measurements will be collected during the TEVAR. One year following TEVAR, the subject will undergo a second non-invasive MRI study in addition to the standard clinical imaging follow-up CT-scan. Measurements of blood pressure, heart rate, ECG, and blood testing will also be repeated at follow-up."
2974197|NCT02735720||Non-TEVAR medical treatment group|"Adult patients whose clinician's are managing their thoracic aortic aneurysms or with penetrating aortic ulcers with pharmacological treatment alone.~Patients with stable thoracic aortic aneurysms or with penetrating aortic ulcers not requiring aortic repair are monitored in the outpatient clinic as standard of care. The investigators will collect blood pressures and heart rates in these patients, which are acquired as standard of care. In addition, in this study, these subjects will undergo an ECG, blood testing and one non-invasive MRI scan at baseline. One year after baseline, this group will undergo a second non-invasive MRI study, with subsequent blood pressure and heart rate measurements, ECG and blood testing."
2974199|NCT02735707|No Intervention|Corticosteroid Domain: No Hydrocortisone|The patient will receive no corticosteroid for 7 days.
2974200|NCT02735707|Active Comparator|Antibiotic Domain: Ceftriaxone + Macrolide|
2974201|NCT02735707|Active Comparator|Antibiotic Domain: Moxifloxacin or Levofloxacin|
2974202|NCT02735707|Active Comparator|Antibiotic Domain: Piperacillin-tazobactam + Macrolide|
2974203|NCT02735707|Active Comparator|Antibiotic Domain: Ceftaroline + Macrolide|
2974204|NCT02735707|Active Comparator|Antibiotic Domain: Amoxicillin-clavulanate + Macrolide|
2974205|NCT02735707|Active Comparator|Macrolide Duration Domain: Short course macrolide|"The patient will receive macrolide therapy for 3 days, or until legionellosis is excluded.~This arm is nested within the Antibiotic Domain."
2974206|NCT02735707|Active Comparator|Macrolide Duration Domain: Extended course|The patient will receive macrolide therapy for up to 14 days. This arm is nested within the Antibiotic Domain.
2974207|NCT02735694|Active Comparator|Cycloserine|Cycloserine, 250 mg capsules by mouth, one hour prior to initiation of sleep study, single dose
2974208|NCT02735694|Placebo Comparator|Placebo|Placebo, sugar capsule by mouth, one hour prior to initiation of sleep study, single dose
2974209|NCT02735681|Active Comparator|Probing Treatment Right Eye|Meibomian gland will be performed on the right upper eye lid of each participant.
2974210|NCT02735681|Placebo Comparator|Fellow Eye (Left) Untreated|The fellow eye (left) will be used at the untreated control
2974211|NCT02735668|Active Comparator|Shoulder Conventional Exercises|"The protocol consists in:~Flexibility and Strengthening Exercises of the shoulder muscles conventionally performed in shoulder pathology treatment.~Therapeutic Education about chronic shoulder pain."
2974212|NCT02735668|Experimental|Invasive PT - Control Motor Exercises|"The protocol consists in:~Dry Needling in active myofascial trigger points.~Motor Control Exercises.~Therapeutic Education about chronic shoulder pain."
2974213|NCT02735668|Experimental|Control Motor Exercises|"The protocol consists in:~Motor Control Exercises.~Therapeutic Education about chronic shoulder pain."
2974214|NCT02735642|Experimental|SMART Randomization 1 - Referral|Participants who are HIV positive will be enrolled in the SMART trial adaptive linkage to care intervention pilot. (HIV Positive Cohort approximately N=108).
2974215|NCT02735642|Experimental|SMART Randomization 1 - Referral and SMS|Participants who are HIV positive will be enrolled in the SMART trial adaptive linkage to care intervention pilot. (HIV Positive Cohort approximately N=108).
2974216|NCT02735642|Experimental|SMART Randomization 2 - SMS|HIV positives that have not successfully linked to care after the first randomization will be re-randomized to receive either an SMS message or economic incentive to link to care. (HIV Positive Cohort approximately N=108).
2974217|NCT02735642|Experimental|SMART Randomization 2 - Incentive|HIV positives that have not successfully linked to care after the first randomization will be re-randomized to receive either an SMS message or economic incentive to link to care. (HIV Positive Cohort approximately N=108).
2974218|NCT02735642|Other|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185).
2974219|NCT02735642|Other|All participants. Approximately (N=1200)|HIV testing options that female youth can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).
2974220|NCT02735629|Experimental|CX1739 - 300 mg|Study Drug - low dose
2974221|NCT02735629|Placebo Comparator|Placebo|Placebo
2974222|NCT02735629|Experimental|CX1739 - 600 mg|Study drug - mid Dose
2974223|NCT02735629|Experimental|CX1739 - 900 mg|Study drug - high dose
2974224|NCT02735616||study|"15 CVA patients, 1-3 weeks after their first stroke. The patients will be hospitalized in the neurology department at the geriatric Beit-Rivka hospital at Petah-Tiva, Israel.~patients with pacemaker or those who use Beta-Blocker drugs, as well as patients with cerebellar injury, will be excluded from the research"
2974225|NCT02735616||control|15 patients from the orthopedic department at the same hospital, matching by age and gender to the study group.
2974226|NCT02735603|Experimental|Nalterxone/Bupropion + Placebo + Moxifloxacin|Naltrexone hydrochloride (HCl) 8 milligram (mg)/bupropion HCl 90 mg (NB) placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, and once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 3.
2974227|NCT02735603|Experimental|Placebo + Moxifloxacin + Naltrexone/Bupropion|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 3.
2974228|NCT02735603|Experimental|Moxifloxacin + Naltrexone/Bupropion + Placebo|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Day 4 to 10, and once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in the treatment period 3.
2974229|NCT02735603|Experimental|Naltrexone/Bupropion + Moxifloxacin + Placebo|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 3.
2974230|NCT02735603|Experimental|Placebo + Naltrexone/Bupropion + Moxifloxacin|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 3.
2974231|NCT02735603|Experimental|Moxifloxacin + Placebo + Naltrexone/Bupropion|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 1 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 3.
2974232|NCT02735590|Experimental|Open-label 3HP|Participants in the Treatment Arm will receive high dose INH (15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg) with Pyridoxine supplementation (25mg), and Rifapentine based on body weight (>32kg - 50kg: 750 mg; >50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months. Dispensing of IP and Directly Observed Treatment (DOT) field visits in Treatment Arm participants will be performed by staff members not involved in TB symptom screening or investigation. Participants receiving 3HP who develop symptoms of hepatotoxicity will be evaluated by an Investigator.
2974233|NCT02735590|No Intervention|Baseline Screening; Active Surveillance|Adult volunteers living in TB hyperendemic communities of South Africa will be consented and screened. Individuals with HIV infection and conditions likely to affect the performance of the COR assay, or the safety and/or efficacy of the 3HP investigational regimen, will not be enrolled. Active surveillance for TB disease (Observation Arm), including regular symptom screening and symptom-targeted TB investigation (all participants) will be conducted on this Arm.
2974234|NCT02735577|Experimental|Disulfiram|Patients in this arm will receive disulfiram 250 mg daily for a total of 40 days.
2974235|NCT02735564|Experimental|RYGB|Bariatric Surgery:Roux-en-y
2974236|NCT02735564|Experimental|SG|Bariatric Surgery: Sleeve Gastrectomy
2974237|NCT02735564|Placebo Comparator|Control|BMI matched control
2974238|NCT02735551|Active Comparator|Non-LARC Group: Short Acting Method|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice, as is the current practice for students who present for contraceptive services"
2974239|NCT02735551|Active Comparator|Control Group: Referral for LARC Placement|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to referral for LARC placement to local clinic."
2974240|NCT02735551|Active Comparator|LARC Group: Same Day LARC Placement|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to same day LARC placement (intervention)."
2974241|NCT02735538||osteonecrosis of femoral head group|The patients with osteonecrosis of femoral head undergo total hip replacement. Femoral head specimens will be collected and ex vivo specimens numbered. Using RT-PCR, Runx2, BMP-2, BMP-7 and osteoprotegerin, mRNA expression levels will be quantitatively analyzed. Osteocalcin immunoreactivity will be detected using immunohistochemical staining.
2974242|NCT02735538||osteoarthritis group|The patients with osteoarthritis will undergo total hip replacement. Femoral head specimens will be collected and ex vivo specimens numbered. Using RT-PCR, Runx2, BMP-2, BMP-7 and osteoprotegerin, mRNA expression levels will be quantitatively analyzed. Osteocalcin immunoreactivity will be detected using immunohistochemical staining.
2974243|NCT02735525|Experimental|Smartphone monitoring|Intervention arm
2974244|NCT02735512||Group I|Patients without cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and 4 months.
2974245|NCT02735512||Group II|Patients with localized bladder cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and within 4 weeks after cystectomy.
2974246|NCT02735512||Group III|Patients with metastatic cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and within 4 weeks after completion of 4 courses of systemic chemotherapy.
2974247|NCT02735499|Experimental|Treatment with Botox|Onabotulinum toxin A. 200 units of Botox installed into the bladder by catheter.
2974248|NCT02735486|Experimental|Ginger drink|Experimental: Ginger drink (300 ml) to be consumed during the study visit
2974249|NCT02735486|Placebo Comparator|Placebo: Super pure water|Super Pure water low in nitrate content
2974250|NCT02735473|Experimental|Choline bitartrate|Powdered drink mix containing choline bitartrate 19 mg. per kg.
2974251|NCT02735473|Placebo Comparator|Placebo|Powdered drink mix containing matching placebo
2974252|NCT02735460|Experimental|Treatment arm|In this arm the Andago V2.0 is used.
2974253|NCT02735434|Experimental|Internet-based ACT|Brief clinical psychiatric assessment to determine eligibility (video-based).
2974254|NCT02735434|Active Comparator|Internet-based discussion forum|Brief clinical psychiatric assessment to determine eligibility (video-based).
2974255|NCT02735421|Experimental|Adapalene / BPO gel|Adapalene 0.3% / BPO 2.5% gel, once daily in the evening on half of the face (determined by randomization)
2974256|NCT02735421|Placebo Comparator|Vehicle gel|Vehicle gel, once daily in the evening on half of the face (determined by randomization)
2974257|NCT02735408|Experimental|100% KT Tension|100% KT Tension
2974258|NCT02735408|Experimental|50% KT Tension|50% KT Tension
2974259|NCT02735408|Experimental|0% KT Tension|0% KT Tension
2974260|NCT02735408|No Intervention|Control (Without KT)|Control (Without KT)
2974261|NCT02735395|Placebo Comparator|Control|Scaling and root planing (SRP) + two placebo pills thrice a day (TID) for 14 days (control group)
2974262|NCT02735395|Active Comparator|MTZ 250 (7 days)|SRP + MTZ (250mg/TID) + AMX, for 7 days and placebos for another 7 days
2974263|NCT02735395|Active Comparator|MTZ 400 (7 days)|SRP + MTZ (400mg/TID) + AMX, for 7 days and placebos for another 7 days
2974264|NCT02735395|Active Comparator|MTZ 250 (14 days)|SRP +MTZ (250mg/TID) + AMX for 14 days
2974265|NCT02735395|Active Comparator|MTZ 400 (14 days)|SRP +MTZ (400mg/TID) + AMX for 14 days
2974266|NCT02735382|Experimental|EHR-based referral to quit line|"Clinics will use an EHR-based fully-electronic HIPAA-compliant tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication.~Intervention: Behavioral: Tobacco quitline EHR referral"
2974267|NCT02735382|Active Comparator|Fax-based referral to quit line|"Clinics will use a paper fax tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication.~Intervention: Behavioral: Tobacco quitline Fax referral"
2974268|NCT02735369|Placebo Comparator|Placebo|Placebo Comparator
2974269|NCT02735369|Experimental|2% OC-10X|2% OC-10X
2974270|NCT02735356|Experimental|Treatment (itraconazole and placebo)|Patients apply itraconazole topically BID and placebo topically BID for 12 weeks.
2974271|NCT02735343|Active Comparator|Standard treatment arm|compazine 10 mg Intravenously along with diphenhydramine 25 mg Intravenously
2974272|NCT02735343|Experimental|Research arm|Ketamine 0.3 mg/kg Intravenously along with ondansetron 4 mg Intravenously
2974273|NCT02735330|Active Comparator|GROUP 1|68 Patients undergo Frey's procedure with celiac plexus neurolysis using absolute alcohol
2974274|NCT02735330|Placebo Comparator|GROUP 2|68 Patients undergo Frey's procedure with Placebo celiac plexus injection using saline
2974275|NCT02735317|Experimental|FORRAD group|"This group of patients will receive Oral Ulcer Gargle (FORRAD®) during study for prevention and treatment of acute radiation-induced oral mucositis (OM).~This is the experimental group."
2974276|NCT02735317|Active Comparator|Quadruple mixture group|"This group of patients will receive quadruple mixture, which is composed of dexamethasone, gentamicin, vitamin B12, and procaine, during study for prevention and treatment of acute radiation-induced oral mucositis (OM).~This is the active comparator group."
2974277|NCT02735304|Other|Innovation treatment 3M ESPE materials|"The Innovation treatment arm will receive the innovation treatment first and then crossover to receive the standard clinical practice treatment during the Impression intervention.~Materials to be used all 3M ESPE - Astringent Retraction Paste, Imprint™ 4 Preliminary, Imprint™4 VPS, Imprint™ 4 Bite, Intra-oral syringes, Impression Tray,"
2974278|NCT02735304|Other|standard clinical practice treatment|"The standard clinical practice treatment will receive the standard clinical practice treatment first and then crossover to receive the innovation treatment during the Impression intervention~Materials as per the operating dentist's choice to be recorded on CRF"
2974279|NCT02735291|Experimental|Single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:The first day,the second day,29 days,injection once a day in this three days Duration:Only injection three times
2974280|NCT02735265|Experimental|Virtual reality group|45 min standard treatment plus 45 min virtual reality balance training used by Kinect for Xbox game. Game choosed based on motor learning principle. Training task such as reach or stepping in various direction, squat, stand up, upper trunk forward or lateral bench.
2974281|NCT02735265|Active Comparator|Standard treatment only group|90 min standard treatment. Depended on patient's ability, principle used by motor learning, sensory process, motor control, task oriented training, symmetry w't bearing.
2974282|NCT02735252||Group A: Androgen signaling inhibition|At the time of disease progression by PCWG2 criteria, patients may undergo optional repeat tumor biopsy, along with mandatory blood collection for analysis of circulating tumor DNA and CTCs.
2974283|NCT02735252||Group B: Immunotherapy|At the time of disease progression by PCWG2 criteria, patients may undergo optional repeat tumor biopsy, along with mandatory blood collection for analysis of circulating tumor DNA and CTCs.
2974284|NCT02735252||Group C: Chemotherapy|At the time of disease progression by PCWG2 criteria, patients may undergo optional repeat tumor biopsy, along with mandatory blood collection for analysis of circulating tumor DNA and CTCs.
2974285|NCT02735252||Group D: Targeted Therapy|At the time of disease progression by PCWG2 criteria, patients may undergo optional repeat tumor biopsy, along with mandatory blood collection for analysis of circulating tumor DNA and CTCs.
2974286|NCT02735252||Group E: Castration-sensitive|"Group 1, patients will undergo optional repeat tumor biopsy 6-8 months after the start of androgen deprivation therapy, along with mandatory blood collection for ctDNA and CTC analysis.~Group 2, patients will undergo optional repeat tumor biopsy at the time of development of castration resistance as defined by PCWG2 criteria, along with mandatory blood collection for ctDNA and CTC analysis."
2974287|NCT02735239|Experimental|Durvalumab and standard of care chemotherapy|Phase 1 will evaluate the safety of durvalumab alone (Cohort A1) administered before chemotherapy (oxaliplatin + capecitabine) in subjects with metastatic or locally advanced Oesophageal Cancer + Chemotherapy
2974288|NCT02735239|Experimental|Durvalumab + tremelimumab and standard of care chemotherapy|Dose-escalation for Tremelimumab 37.5mg - 75mg + Durvalumab 750mg + Chemotherapy (Cohort A2).
2974289|NCT02735239|Experimental|Recommended combination of doses from Cohort A1 or A2|Subjects in Cohort B are subjects with metastatic/locally advanced Oesophageal Cancer. Subjects in Cohort B will receive the recommended combination dose from Cohort A1 (durvalumab alone administered before chemotherapy (oxaliplatin + capecitabine)) or A2 (Dose-escalation for Tremelimumab 37.5mg - 75mg + Durvalumab 750mg + Chemotherapy) and Chemotherapy.
2974290|NCT02735239|Experimental|Durvalumab, surgery and standard of care chemotherapy|Durvalumab 750mg + Chemotherapy (Cohort C)
2974291|NCT02735239|Experimental|Durvalumab, surgery, standard of care chemo and radiotherapy|Durvalumab 750mg + Chemotherapy Radiotherapy (Cohort D)
2974292|NCT02735226||Acute Stroke patient|Patients who are presented to hospital within 7days from onset. The key measurement of clinical quality controlled in patients with acute stroke managment and inhouse stroke care were record automatically
2974293|NCT02735213|Experimental|577-MPL|"577nm subthreshold micropulse laser(577-MPL) will be performed on the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein. Multiple laser spots will be applied, covering the leakage area. Retreatment will be given in 12 weeks If SRF is not completely absorbed and CRT>= 250um."
2974294|NCT02735213|Active Comparator|TLT|"Traditional laser will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Traditional laser spots will be applied, covering the leakage area. Retreatment will be given in 12 weeks If SRF is not completely absorbed and CRT>= 250um."
2974295|NCT02735200|Experimental|Topical Vitamin D3 application|Intervention is Application of topical Vitamin D3 Frequency: Daily Dosage: 1 gram (5000 IU) Duration: 120 days
2974296|NCT02735200|Active Comparator|Aloe vera gel Application|Application of Aloe vera gel will be carried out Dosage: 1 gram Frequency: Daily Duration: 120 days
2974297|NCT02735187|Active Comparator|group30|Treatment of the target area with 30 minutes of blue light at 453nm compared to VitaminD creme Daivonex on contralateral Plaque of same patient.
2974298|NCT02735187|Active Comparator|group15|Treatment of the target area with 15 minutes of blue light at 453nm compared to VitaminD creme Daivonex on contralateral Plaque of same patient.
2974299|NCT02735174|Experimental|Single arm asthma self-management|"Interventions include:~Sensor cap system for inhalers App for SmartPhone Motivational interviews Telehealth clinic visits"
2974300|NCT02735161|Experimental|Exercise training|"Four exercise training sessions. Two endurance training sessions, one with high intensity interval training and one session of moderate intensity of longer duration. Two strength training session; one with high load and few repetitions and one with low load and many repetitions.~Fatigue and lactate will be measured before, after and 24 hours post-exercise. Trainings sessions will be randomized."
2974301|NCT02735148|No Intervention|Conventional Training|Conventional training sessions generally consisted of exercises which aimed to improve range of motion, strength, and movement quality in upper and lower extremity as an in-patient rehabilitation protocol. Also developing static and dynamic postural control and increasing walking distance were the other aims of training. Duration of the Conventional Training is 45 minute per session, 3 days a week for 6 weeks.
2974302|NCT02735148|Experimental|Body Weight Supported Treadmill Training|"Body weight supported treadmill training (BWSTT) was composed of outpatients who were undertaken only BWST training with 45-minute sessions, 2 days a week during 6 weeks.~BWST Training~Locomat (Hocoma) was used in BWSTT group with 20 % body weight reduced. The participants walked on device at 1.8 km/h (0.5 m/sec) velocity. For each participant body weight portion was ensured by a security belt while walking. Each session took 45 minutes including setup, commands and rest time. Verbal instructions were used for encouragement but no manual assistance was given to improve gait pattern."
2974303|NCT02735148|No Intervention|Combined Training|Combined Training consisted of inpatient participants who were treated with 45 minute-conventional training, 5 days a week during 6 weeks. Additionally this group had 45 minute-BWST training, 2 days a week during 6 weeks.
2974304|NCT02735135|Experimental|Airsoft Duo First|"Patients randomized to this arm will be placed on an AIRSOFT DUO mattress for day 0. They will then be switched to a SENTRY 1200 mattress until the end of month 1.~Intervention: AIRSOFT DUO for 1 day Intervention: SENTRY 1200 for 1 month"
2974305|NCT02735135|Experimental|SENTRY 1200 First|"Patients randomized to this arm will be placed on a SENTRY 1200 mattress for day 0. They will then be switched to an AIRSOFT DUO mattress until the end of month 1.~Intervention: SENTRY 1200 for 1 day Intervention: AIRSOFT DUO for 1 month"
2974306|NCT02735122|Experimental|Test acetaminophen|acetaminophen tablet and placebo caplet and placebo liquid-filled capsule
2974307|NCT02735122|Active Comparator|Commercial acetaminophen|acetaminophen caplet and placebo tablet and placebo liquid-filled capsule
2974308|NCT02735122|Active Comparator|Commercial ibuprofen|ibuprofen liquid-filled capsule and placebo tablet and placebo caplet
2974309|NCT02735122|Placebo Comparator|Placebo|Placebo tablet and placebo caplet and placebo liquid-filled capsule
2974310|NCT02735109|Other|description|photographies and biopsy on normal area
2974311|NCT02735096|Experimental|Vestibular Patients for EquiCue Testing|Subjects with vestibular deficiency will try the intraoral electronic balance aid to see whether there is improvement in balance.
2974312|NCT02735083|Experimental|UCART19 follow-up|
2974313|NCT02735070|Experimental|Corisitina D|The patient will use the medication 4 times a day - orally The tablets of Coristina® d contain 400 mg acetylsalicylic acid, dexchlorpheniramine 1 mg, 10 mg phenylephrine, and 30 mg of caffeine. Coristina® d is indicated as an analgesic, antipyretic, antiallergic, and nasal congestion for the treatment of the symptoms of influenza and common cold.
2974314|NCT02735070|Active Comparator|Resfenol|The patient will use the medication 4x / day - orally Resfenol® drug acts against the symptoms of colds and flu, such as nasal congestion, runny nose, fever, headache, muscle pain and other symptoms. The capsules containing 400mg of paracetamol, 4 mg chlorpheniramine and 4mg phenylephrine.
2974315|NCT02735057|Experimental|Phase I|"for chemotherapy 3 levels: 50%, 75% and 100% of the standard Dutch dose (carboplatin AUC 2 and paclitaxel 50 mg/m2)~for radiotherapy 3 levels: 41.4 Gy/1.8 Gy/f; 45 Gy/1.8 Gy/f; 50.4 Gy/1.8 Gy/f basel level being : 41.4 Gy and 50% of standard CT doses The phase I is conducted with increasing doses of each component with 9 levels."
2974316|NCT02735044|Experimental|Insulin glargine (U300)|Once daily subcutaneous injection with continuation of fast-acting mealtime insulin analogue.
2974317|NCT02735044|Active Comparator|Insulin glargine|Once daily subcutaneous injection with continuation of fast-acting mealtime insulin analogue.
2974318|NCT02735031|Active Comparator|EXENATIDE|"Exenatide~week 1-2: 5 µg twice daily~week 3-6: 10 µg twice daily (if tolerated)"
2974319|NCT02735031|Placebo Comparator|PLACEBO|"Placebo matched to exenatide~week 1-2: 5 µg twice daily~week 3-6: 10 µg twice daily (if tolerated)"
2974320|NCT02735018|Experimental|Epinephrine 1:100,000|Inferior alveolar nerve block with Epinephrine 1:100.000
2974321|NCT02735018|Experimental|Epinephrine 1:200,000|Inferior alveolar nerve block with Epinephrine 1:200.000
2974322|NCT02735005|Experimental|SMAF assessment|"Face to face interview for the Functional Autonomy Measurement System (SMAF) tool questionnaire For disabled patients living at home, the Social SMAF questionnaire is used in addition.~Data related to care consumption of each enrolled patients are collected too."
2974323|NCT02734992|Other|Acceptance and Commitment therapy + MTAU|The Acceptance and Commitment therapy + MTAU (active treatment) consists of an unpublished manual developed for the purposes of the Algea project (Vasiliou & Karekla, 2015). Sessions focus in fostering the six ACT processes targeting at increasing psychologically flexible responses to headache episodes and enhancing behavioral changes. The protocol specifies the following goals: (a) increase individuals' willingness to face uncomfortable internal experiences; b) promoting meaningful activities even in the present of head pain; (c) emphasizing acceptance as an alternative to avoidance in coping with headache; (d) clarifying individuals' values in important life domains; e) enhancing present moment-to-moment awareness.
2974324|NCT02734992|Other|MTAU/ Wait-list Control Gr|The MTAU/ Wait-list Control Gr will follow their usual treatments, including any new treatments their GPs or Neurologists might prescribe (mostly prophylactic and abortive medication), during the study at the time. Following the completion of the active group follow up 3months, participants allocated to the control group will receive the active treatment.
2974325|NCT02734979|Experimental|Biobridge and lymph node transfer|The investigators will investigate whether addition of the Biobridge scaffold to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm. The investigators will perform lymph scans (lymphoscintigrams) before surgery and one year following surgery to determine the success of the surgery. In addition, the volume of the operated arm will be monitored by repeated measurement with a tape measure. The investigators will also track bioimpedance, a painless technique to detect fluid in the tissues. The investigators will obtain small skin biopsies and blood samples to detect the biological changes that may occur as a result of successful surgery.
2974326|NCT02734966|Experimental|arm 1|lower dose： Magnesium Isoglycyrrhizinate injection 100mg OD for 4 weeks
2974327|NCT02734966|Experimental|arm 2|higher dose：Magnesium Isoglycyrrhizinate injection 200mg OD for 4 weeks.
2974328|NCT02734966|Active Comparator|Tiopronin Injection|Tiopronin Injection 200mg OD for 4 weeks
2974329|NCT02734953|Experimental|Intervention|Determination of non-invasive pulmonary pressures by CardioMems device interrogation pre- and post-administration of inhaled nitric oxide at 0.075 mg/kg IBW/hr
2974330|NCT02734940|Active Comparator|Unrestricted Fentanyl|"Will receive injection of sterile saline (2cc) in lower back area (to minimize participant bias) and unrestricted amount of intraoperative opioids (fentanyl) at the discretion of the Anesthesiologist.~Both groups will receive General Anesthesia with volatile agents and single dose of iv Tylenol intraoperatively. Both groups of patients will be transported to Intensive Care Unit (ICU) on Dexmedetomidine (dose range 0.25 - 0.7 mcg/kg/hr). Dose titration is based on sedation level and hemodynamic goals set by Cardiac Anesthesiologist."
2974331|NCT02734940|Experimental|Lidocaine, Dexmedetomidine and Ketamine|Will receive pre-operative spinal duramorph (4mcg/kg up to max dose of 300mcg), intra-operative intravenous (iv) infusion of Ketamine (0.4 mg/kg/hr), Lidocaine (20 mcg/kg/min) and Dexmedetomidine (0.25 mcg/kg/hr) started after induction of General Anesthesia and maintained through the Cardiopulmonary Bypass (CPB) towards the end of surgery. At this point all infusions will be turned off except Dexmedetomidine. The total intraoperative fentanyl dose will be limited to <250mcg (or 3mcg/kg) and total midazolam to ≤ 2mg in the study group.
2974332|NCT02734927|Active Comparator|schizophrenia group|Schizophrenia patients suffering
2974333|NCT02734927|Sham Comparator|control group|subjects showing no psychological or neurological disorder
2974334|NCT02734914|Experimental|SF-URS with automatic control of RPP|Participants in SF-URS with automatic control of renal pelvic pressure (RPP) group undergo ureteroscopy using the intelligent pressure control device (Medical irrigation and suctioning platform with pressure feedback function, and suctioning ureteral access sheath with function of pressure measuring).
2974335|NCT02734914|Active Comparator|conventional F-URS|Participants in conventional F-URS group undergo ureteroscopy using the classic flexible ureteroscope.
2974336|NCT02734901|Active Comparator|400 g frozen raspberries|Red raspberry beverage Acute intake of 600 mL (1x daily)
2974337|NCT02734901|Active Comparator|200 g frozen raspberries|Red raspberry beverage Acute intake of 600 mL (1x daily)
2974338|NCT02734901|Placebo Comparator|Placebo control|Raspberry deprived supplement Acute intake of 600 mL (1x daily)
2974339|NCT02734888|Other|Healthy control|"Will undergo PET scan as a negative control"
2974340|NCT02734888|Other|Tobacco cigarette smoker|"Will undergo PET scan as a positive control"
2974341|NCT02734888|Other|E-cigarette user|Will undergo PET scan
2974342|NCT02734875|Experimental|Intervention|Primary care providers in the intervention arm will receive lists of their patients with AF who are identified as being at high risk of stroke but not currently on anticoagulation therapy. Along with this list, which includes information on risks and benefits of anticoagulation, primary care providers will receive an offer of assistance from a respected Anticoagulation Management Service within the hospital network to help manage anticoagulation for referred patients.
2974343|NCT02734875|No Intervention|Usual Care|Primary care providers will provide usual care.
2974344|NCT02734862|Experimental|Group 1|"Subjects in the CD101 IV treatment group 1 (Part A Only - up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 400 mg on Day 15 (for all subjects) and an optional dose of 400 mg on Day 22 (only for subjects with IC), if needed.~Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down."
2974345|NCT02734862|Active Comparator|Group 3|"Subjects in the caspofungin group will receive IV caspofungin (a single 70 mg loading dose on Day 1 followed by 50 mg once daily) for ≥3 days up to a maximum of 21 days for subjects with candidemia only and up to a maximum of 28 days for subjects with IC (with or without candidemia).~After ≥3 days of IV therapy, subjects in the caspofungin group can be switched to oral step-down therapy of fluconazole (a loading dose of 800 mg [4 capsules] on the first day followed by 400 mg [2 capsules]/day thereafter). After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind."
2974587|NCT02733185|Active Comparator|Active/Active|Active disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
2974346|NCT02734862|Experimental|Group 2|"Subjects in the CD101 IV treatment group 2 (Part B Only - up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 200 mg on Day 15 (for all subjects) and an optional dose of 200 mg on Day 22 (only for subjects with IC), if needed.~Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down."
2974347|NCT02734849|Experimental|AK001 low dose|A low dose of AK001 will be administered in multiple doses
2974348|NCT02734849|Experimental|AK001 high dose|A high dose of AK001 will be administered in multiple doses
2974349|NCT02734849|Placebo Comparator|Placebo|A placebo comparator consisting of inactive excipients
2974350|NCT02734836|Experimental|Zilver PTX Stent|Diagnostic assessment of the lesion after implantation of drug eluting stent with Balloon Angioplasty and placement of the Zilver PTX Stent with Optical Coherence Tomography (OCT)
2974351|NCT02734823||Ancillary-Correlative (ovary imaging, hormonal analysis)|Patients undergo transvaginal ultrasound for antral follicles analysis and collection of serum for ovarian reserve markers and hormonal analysis before TKI therapy and at 12, 24, and 48 weeks.
2974352|NCT02734810|Experimental|Part A|Liprotamase Powder for Oral Solution in Subjects aged ≥7 years of age
2974353|NCT02734810|Experimental|Part B|Liprotamase Powder for Oral Solution in Subjects aged 28 days to <7 years
2974354|NCT02734797||Pediatric patients|This is an observational study. Validated measures of nutritional status, dietary intake, body composition, functional status and psychosocial factors will be used to measure outcomes in study patients at 4 time-points: (1) pre-HCT (Baseline), (2) 30-days post-HCT, (3) 100-days post-HCT and (4) one year post-HCT.
2974355|NCT02734784|Experimental|Photodynamic Therapy and SRP|
2974356|NCT02734784|Sham Comparator|SRP and Sham Photodynamic Therapy|
2974357|NCT02734771|Experimental|BV+mini-R-CHP|Brentuximab vedotin 1.8 mg/kg IV day 1 for six cycles Rituximab 375 mg/m2 IV day 1 for six cycles Cyclophosphamide 400 mg/m2 IV day 1for six cycles Doxorubicin 25 mg/m2 IV day 1 for six cycles Prednisone 40 mg/m1 PO days 1-5 for six cycles
2974358|NCT02734758||Atrial fibrillation stroke|
2974359|NCT02734758||Non-atrial fibrillation Stroke|
2974360|NCT02734745|Experimental|flash glucose monitoring|Patients will use a device: Freestyle Libre for 14 days
2974361|NCT02734732|Active Comparator|Ciprofloxacin|T. Ciprofloxacin 750mg, single dose immediately prior to prostate biopsy
2974362|NCT02734732|Active Comparator|Trimethoprim/Sulfamethoxazole|Trimethoprim/Sulfamethoxazole 160mg/800mg immediately prior to prostate biopsy
2974363|NCT02734719|Experimental|the group treated with electrical stimulation|
2974364|NCT02734706|Experimental|LRC™ capsule|
2974365|NCT02734706|Placebo Comparator|Placebo capsule|
2974366|NCT02734693|Experimental|Dasotraline 4mg|Dasotraline capsule 4mg/day
2974367|NCT02734693|Placebo Comparator|Placebo|Placebo capsule
2974368|NCT02734680|Experimental|Concurrent chemoradiotherapy(CCRT) Group|Concurrent chemoradiotherapy(CCRT) (Total dose: 46 Gy; Single dose: 2 Gy; Frequency: 23; Gemcitabine(GEM), 300 mg/m2 weekly); Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)
2974369|NCT02734680|Experimental|Stereotactic Radiotherapy(SBRT) Group|Stereotactic Radiotherapy(SBRT) (Total dose: 45 Gy; Single dose: 3 Gy; Frequency: 15) Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)
2974370|NCT02734667|Experimental|CGM at diagnosis of T1D|Participants start non-adjunctive use of CGM at diagnosis of T1D and continue for 6 months.
2974371|NCT02734667|No Intervention|Usual Care|Participants receive usual care for T1D for 6 months post diagnosis.
2974372|NCT02734654|No Intervention|Control group|patients do not receive remote preconditioning prior to lung lobectomy
2974373|NCT02734654|Experimental|RIPC group|patients receive remote preconditioning prior to lung lobectomy
2974374|NCT02734641||intravenous (IV) iron therapy|"Patients register to intravenous (IV) iron therapy due to iron deficiency anemia that wasn't responded to oral treatment or wasn't tolerable due to side effects.~20 mL of blood will be draw for complete blood count, renal function, electrolytes and ghrelin. In addition, the patient will fill a structured questionnaire that examines the appetite of the patient before and after treatment. At the end of Iron administration Ghrelin will be retested."
2974375|NCT02734641||healthy volunteer|healthy volunteer, will be asked 20 mL of blood will be draw for complete blood count, renal function, electrolytes and ghrelin. In addition, the patient will fill a structured questionnaire that examines his appetite. Ghrelin will be retested after 6 weeks.
2974376|NCT02734628|Experimental|Dexpanthenol|A squeeze of ointment, approximately 0.5 cm in length corresponding to an amount of about 0.3 g of ointment, which is equal to 15 mg dexpanthenol , twice daily (once in the morning and once in the evening) over a period of 14 days was applied topically under occluded conditions
2974377|NCT02734628|Placebo Comparator|Placebo|Subjects received applications of placebo corresponding to verum
2974378|NCT02734615|Experimental|Arm A|Patients will get LSZ102 single agent during dose escalation.
2974379|NCT02734615|Experimental|Arm B|Patients will get LSZ102 in combination with LEE011 during dose escalation.
2974380|NCT02734615|Experimental|Arm C|Patients will get LSZ102 in combination with BYL719 during dose escalation.
2974381|NCT02734615|Experimental|Arm 1|Patients will get LSZ102 single agent during dose expansion
2974382|NCT02734615|Experimental|Arm 2|Patients will get LSZ102 + LEE011 (LEE011 intermittent regimen) during dose expansion
2974383|NCT02734615|Experimental|Arm 3|Patients will get LSZ102 + LEE011 (LEE011 continuous regimen) during dose expansion
2974384|NCT02734602|Other|Cognitive Testing|Subjects will take part in verbal assessments as well as computer testing.
2974385|NCT02734602|Active Comparator|Magnetic Resonance Imaging|Anatomical MRIs will be performed on a Siemens 3T Trio at Yale. We will acquire the following: structural MRI, resting state MRI, diffusion tensor imaging data (DTI), and arterial spin labeling (ASL). We may also ask subjects to complete an emotional capture task.
2974438|NCT02734199||Enrollment Period 3 Cohort|Cohort 3 includes approximately 1350 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Financial barriers are removed for Period 3 participants and they can initiate which ever contraceptive method they want at no cost to them for three years. During enrollment period 3, a community-wide, media driven intervention will be implemented and population level changes in HER-C initiation will be examined.
2974386|NCT02734602|Active Comparator|Positron Emission Tomography|Subjects will participate in 2-3 PET scans (up to 4 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan. After a baseline scan, subjects will be administered a low dose of ketamine for the second scan.
2974387|NCT02734589|Active Comparator|Fecal microbiota transplantation (FMT) without Diet|undergo standard fecal transplantation by colonoscopy on day 1 and 60 ml rectal enemas on days 2 and 14 from the same donor without dietary conditioning.
2974388|NCT02734589|Experimental|FMT with Diet for the donor and for the recipient|undergo standard fecal transplantation by colonoscopy on day 1 and 60 ml rectal enemas on days 2 and 14 with dietary pre-conditioning of the donor for 14 days and dietary treatment of the recipient immediately after transplantation and for the following 12 weeks.
2974389|NCT02734589|Active Comparator|Dietary therapy only|The patient will receive detailed instructions regarding the UC diet to be used over 12 weeks without FMT.
2974390|NCT02734576|Experimental|Venous Sinus Stenting|Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain. Under general anesthesia, a catheter will be inserted through a vein the upper part of the leg (groin area) and guided through the veins all the way to neck and the head. Then, a balloon will be advanced through the catheter and positioned across the stenosis. The balloon will be carefully inflated for a few seconds. This process is called angioplasty and will partially re-open the narrowing, making placement of the stent easier. The balloon will be removed and then the stent will be advanced through the catheter in neck across the stenosis and carefully deployed. After the procedure, the participants will stay in the intensive care unit for 24 hours for observation
2974391|NCT02734563||Multiple hernia group|Males undergoing at least three repairs of abdominal wall hernias at three different anatomic locations. Collagen turnover is analysed.
2974392|NCT02734563||Control group|Males without any history or presence of hernias
2974393|NCT02734550|Active Comparator|Control|Diagnosis of invasive candida infection according to standard of care.
2974394|NCT02734550|Experimental|(1,3)-β-D-glucan guidance|Treatment according to BDG-result
2974395|NCT02734537|Experimental|Arm A (IMRT)|Patients undergo IMRT QD 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
2974396|NCT02734537|Experimental|Arm B (IMRT, cisplatin)|Patients undergo IMRT QD 5 days a week and receive cisplatin IV over 1-2 hours weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
2974397|NCT02734524|Experimental|NK infusion+chemotherapy|Treatment includes four cycles. For each cycle: Taxol and carboplatin will be given at the first week. Lymphodepletion will be conducted at the second week. Autologous NK cells will be infused at the third week. Each cycle includes four weeks.
2974398|NCT02734524|Active Comparator|chemotherapy|Receive the same taxol and carboplatin in experimental arm without NK cell infusion.
2974399|NCT02734511|Experimental|Drug: sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
2974400|NCT02734498|Active Comparator|Right unilateral (RUL) ECT|Right Unilateral placement of treatment electrodes in electroconvulsive treatment.
2974401|NCT02734498|Active Comparator|Bilateral (BL) ECT|Bilateral placement of treatment electrodes in electroconvulsive treatment.
2974402|NCT02734498|No Intervention|Control group|No ECT treatment for control group.
2974403|NCT02734485|Active Comparator|active Deep Tms|Each DTMS session consisted in two consecutive stimulations: a first low-frequency (1 Hz) stimulation in the motor cortex (110% of the motor threshold, for 15 minutes)and a second high-frequency (10Hz) one in the prefrontal cortex (100% motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).The coil contains two symmetric devices, perfectly designed to rouse both hemispheres at the same time.
2974404|NCT02734485|Sham Comparator|sham deep tms|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an inactive DTMS coil.
2974405|NCT02734472||Hanzhong cohort|A total of 4623 adolescents aged 6-15 years old in Hanzhong rural areas were recruited in 1987.During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
2974406|NCT02734472||Mei county cohort|A total of 675 individuals from 126 families were recruited in this family-based dietary intervention study. A community-based BP screening was conducted among adults aged 18-60 years in the study villages. The probands who had a mean systolic BP (SBP) between 130-160 mmHg and/or a diastolic BP (DBP) between 85-100 mmHg and no use of antihypertensive medications and their parents, siblings, spouses, and offspring were recruited in this study. During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
2974407|NCT02734459|Experimental|tobramycin and dexamethasone ophthalmic test ointment|The test drug (tobramycin is an aminoglycoside antibiotic and dexamethasone is a corticosteroid) will be administered in one eye before the cataract surgery.
2974408|NCT02734459|Active Comparator|TobraDex® ointment|The reference drug (tobramycin is an aminoglycoside antibiotic and dexamethasone is a corticosteroid) will be administered in another eye before the cataract surgery.
2974409|NCT02734446|Active Comparator|Reuterin D3 drops|Lactobacillus reuteri DSM 17938 (108 CFU) + Vitamin D3 (400 IU) 5 drops/day for 3 months (Reuterin D3 drops)
2974410|NCT02734446|Placebo Comparator|Placebo|The patients will receive 5 drops/day of placebo for 3 months
2974411|NCT02734433|Experimental|Pexidartinib|Pexidartinib capsules administered twice daily in the morning and evening. Each cycle of treatment is 28 days in duration. The cycle of treatment is continued until disease progression, unacceptable toxicity, or consent withdrawal.
2974439|NCT02734186|Experimental|Sh|Mono infected with Schistosoma haematobium
2974440|NCT02734186|Experimental|ShMp|Coinfected with Schistosoma haematobium andMansonella perstans
2974441|NCT02734173|Active Comparator|Genotype 1a Non-Cirrhotic Arm|• 8 non-cirrhotic genotype 1a-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy plus ribavirin
2974585|NCT02733198|Experimental|Prognosis-guided|Duration of bed rest and duration of length of stay will be guided according to a predefined prognostic algorithm.
2974412|NCT02734420|Experimental|PapacarieMBlue and PDT|Initial periapical and interproximal radiographs; Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up: Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
2974413|NCT02734420|Experimental|Toluidine Blue O and PDT|Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette; Follow up; Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
2974414|NCT02734407|Experimental|Open-Label Arm|"2mg Aflibercept, as needed, intravitreal administration.~All subjects will be treated with intravitreal (IVT) aflibercept injections as needed in the presence of clinically relevant diabetic macular edema (CR-DME). If CR-DME is not present the subject will not receive an IVT aflibercept injection and will be observed.~If a subject has recurrent CR-DME they will receive an IVT aflibercept 2.0 mg injection and interval between visits will be reduced to 4 weeks.~At week 12 through end of study, all subjects will be evaluated for focal laser treatment."
2974415|NCT02734394|Experimental|Cardiovascular and strength training exercise|24 sessions (~12 weeks) exercise
2974416|NCT02734368||Healthy non-smokers|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
2974417|NCT02734368||Asymptomatic smokers|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
2974418|NCT02734368||COPD subjects|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
2974419|NCT02734355|Active Comparator|Therapy|Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days
2974420|NCT02734355|Placebo Comparator|Placebo|Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days
2974421|NCT02734342|Experimental|Exercise, Kinesiophobia and Knee Osteoarthritis|Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. During the hour, participants will complete a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improve aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted.
2974422|NCT02734329|Experimental|Zero Ischemia group|Radiofrequency ablation(RFA) /Microwave ablation(MVA) will be performed for 1 to 4 cycles each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping in most cases.
2974423|NCT02734329|Active Comparator|Conventional group|Renal hilum will be accurately isolated and then the artery only will be clamped during surgery.
2974424|NCT02734290|Experimental|Arm A|pembrolizumab + weekly paclitaxel
2974425|NCT02734290|Experimental|Arm B|pembrolizumab + capecitabine
2974426|NCT02734277||Detectable C-peptide by MMTT|"This cohort includes participants with a detectable C-peptide by 4-hour mixed-meal tolerance test (MMTT) during their last study visit:~at week 104, in prior Immune Tolerance Network (ITN) studies ITN027AI (AbATE) or -045AI (T1DAL) -Reference ClinicalTrials.gov study IDs NCT00129259 and NCT00965458~in the ITN027AI (AbATE) follow-up study (NCT02067923) and~in this study, ITN066AI (T1DES).~Detectable C-peptide is defined as any value during a MMTT of ≥0.15 ng/mL."
2974427|NCT02734277||Undetectable C-peptide by MMTT|"This cohort includes participants with undetectable C-peptide by 4-hour mixed-meal tolerance test (MMTT):~during their last study visit at week 104, in prior Immune Tolerance Network (ITN) studies ITN027AI (AbATE) or ITN045AI (T1DAL) -Reference ClinicalTrials.gov study IDs NCT00129259 and NCT00965458~after two undetectable C-peptide results by MMTT in the current study, ITN066AI (T1DES).~Undetectable C-peptide is defined as any value during a MMTT of <0.15 ng/mL."
2974428|NCT02734251|Placebo Comparator|Placebo|Dietary Supplement: Placebo
2974429|NCT02734251|Experimental|Relora|Dietary Supplement: Relora, 750 mg/day
2974430|NCT02734238|Placebo Comparator|Energy Deficit|Participants randomly assigned to the control condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered sesame oil placebo injections during phase 2 of the trial.
2974431|NCT02734238|Experimental|Energy Deficit + Testosterone|Participants randomly assigned to the intervention condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered testosterone enanthate injections during phase 2 of the trial.
2974432|NCT02734225|Experimental|EXPERIMENTAL|Functional recovery Balance training
2974433|NCT02734225|Active Comparator|CONTROL|Functional recovery Balance training Dynamometric Platform training
2974434|NCT02734212|Experimental|Ending Self-Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
2974435|NCT02734212|Other|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
2974436|NCT02734199||Enrollment Period 1 Cohort|Cohort 1 includes approximately 650 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Contraceptive access will be the same as it was prior to the study beginning, meaning participants either have to use insurance or self-pay for their method of choice.
2974437|NCT02734199||Enrollment Period 2 Cohort|Cohort 2 includes approximately 1000 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Financial barriers are removed for Period 2 participants and they can initiate which ever contraceptive method they want at no cost to them for three years.
2974442|NCT02734173|Active Comparator|Genotype 1b Non-Cirrhotic Arm|• 8 non-cirrhotic genotype 1b-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy without ribavirin
2974443|NCT02734173|Active Comparator|Genotype 1a/1b Compensated Cirrhotic Arm|• 8 compensated cirrhotic genotype 1a or 1b-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy plus ribavirin
2974444|NCT02734160|Experimental|Galunisertib + Durvalumab|(Dose Escalation and Cohort Expansion) Galunisertib administered orally in combination with durvalumab administered intravenously (IV).
2974445|NCT02734147|Active Comparator|High dose IV ascorbic acid|Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.
2974446|NCT02734147|Placebo Comparator|Placebo|The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.
2974447|NCT02734134|Active Comparator|One-stage exchange|One surgery where the infected implants are removed and the hip or knee joint are 'washed out' before new joint replacement implants are re-implanted during the same surgical procedure.
2974448|NCT02734134|Active Comparator|Two-stage exchange|Two surgeries; during the first surgery the infected implants are removed and a spacer is placed in the hip or knee joint in place of the implants. A second surgery to re-implant the hip or knee joint replacement implants is performed if and when the infection has cleared.
2974449|NCT02734121|Experimental|Educational group intervention|The pre-consultation educational group intervention will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.
2974450|NCT02734121|No Intervention|Standard Care|Routine pre-consultation education
2974451|NCT02734108|Experimental|Transcranial direct current stimulation|10 patients will be stimulated twice a day for two weeks or 20 sessions. 2 milli ampere stimulation will be applied for 25 min respecting a period of four hours between sessions.
2974452|NCT02734095|Experimental|Intravascular Ultrasound data|Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
2974453|NCT02734082||Elevated Troponin and pathological EC|Patients with acute ischemic stroke with elevated Troponin
2974454|NCT02734082||No elevated Troponin or pathological EC|Patients with acute ischemic stroke without elevated Troponin
2974455|NCT02734082||Elevated Troponin, pathological ECG & coronary angiography|Patients with acute ischemic stroke with elevated Troponin T and pathological ECG and coronary angiography
2974456|NCT02734082||No elevated Troponin, pathological ECG & coronary angiography|Patients with acute ischemic stroke without elevated Troponin T and pathological ECG and coronary angiography
2974457|NCT02734069||Sarcopenic|Patients with sarcopenia (evaluated according to CT scans) will be followed up through treatment with carboplatin for identification of any toxicity grade 3 or 4 (Common Terminology Criteria of Adverse Events)
2974458|NCT02734069||Non Sarcopenic|Patients without sarcopenia (evaluated according to CT scans) will be followed up through treatment with carboplatin for identification of any toxicity grade 3 or 4 (Common Terminology Criteria of Adverse Events)
2974459|NCT02734056|Experimental|Music|The intervention to be administered is music
2974460|NCT02734056|Experimental|Control|There is no intervention listed here because this is the control group, in which there will be no intervention.
2974461|NCT02734030||Control Group|Knee pain-free females with no history of lower limb injuries serving as a control group.
2974462|NCT02734030||Anterior Knee Pain Group|Females with anterior knee pain syndrome were enrolled in this group.
2974463|NCT02734017|Other|standard course|group not receiving medication review
2974464|NCT02734017|Other|pharmacist-led standardized medication review|"pharmacist-led standardized medication review including :~Medical and pharmaceutical admission medication reconciliation and treatment review~Medical and pharmaceutical medication reconciliation at discharge and treatment review~Medication Liaison Service"
2974465|NCT02734004|Experimental|Arm 1|Includes initial stage cohorts (modules 1 to 4): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 5 day 1
2974466|NCT02734004|Experimental|Arm 2|Includes second stage cohorts (modules 5&7): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 1 day 1
2974467|NCT02734004|Experimental|Arm 3|Includes second stage cohort (module 6): Olaparib twice daily starting on week 1 day 1 / MEDI4736 every 4 weeks starting on week 1 day 1 / Bevacizumab every 2 weeks starting on week 1 day 1
2974468|NCT02733991|Experimental|Treatment|MiniMed™640G and Suspend before Low feature of SmartGuard™ turned on.
2974469|NCT02733991|Active Comparator|Control|MiniMed™640G alone
2974470|NCT02733978|Experimental|ozone treated group|Therapeutic effects will be graded into 4 levels from grade 0 (no change) to grade 3 (wound healing). The wound sizes will be measured at baseline and day 20, respectively. Tissue biopsies will be performed at baseline and day 20, expressions of VEGF, ETAR and AT1R autoantibodies proteins will be determined by immune-histochemical examinations
2974471|NCT02733978|No Intervention|non-ozone treated group|Therapeutic effects will be graded into 4 levels from grade 0 (no change) to grade 3 (wound healing). The wound sizes will be measured at baseline and day 20, respectively. Tissue biopsies will be performed at baseline and day 20, expressions of VEGF, ETAR and AT1R autoantibodies proteins will be determined by immune-histochemical examinations
2974472|NCT02733965|Other|standard course|"The patients in the control group will have a classic course of treatment. They will receive -An educational assessment consisting on evaluating the patient's educational needs.~Group workshops entitled Disease and drugs, Dietary and sports activity, Psychology Workshop during which the patient will be able to participate in order to get all the information he needs.~Individual therapeutic education sessions to specifically and personally highlight certain non-pharmaceutical educational needs identified at the time of the educational assessment.~Moreover, in the control arm, a systematic short pharmaceutical interview with an average duration of 15 minutes will be proposed to patients at the initiation of treatment, at D15 after the prescription (considered as the date of inclusion) at M1 and then every 3 months (M3, M6, M9 and M12):"
2974546|NCT02733471|Placebo Comparator|Control|Five placebo solution puffs on the four posterior quadrants of the pharynx and on the base of the tongue, 3 minutes before the oesophago-gastro-duodenoscopy
2974586|NCT02733198|No Intervention|Standard medical therapy|Duration of bed rest and duration of length of stay will be decided by the attending physician.
2974473|NCT02733965|Other|Long Pharmaceutical Consultations|The patients will receive the same course of treatment as in the control group, including the D0 short pharmaceutical interview, with the same prerogatives of acceptance or rejection of participation in the TPE program. Short pharmaceutical interviews from D15 to M12 will be replaced by long pharmaceutical consultations of 30 to 60 minutes. The latter consisting in a full clinical medication review and incorporating the pedagogic aspects addressed in the short pharmaceutical interviews but for all therapeutic drugs taken by the patient. Additional consultations are possible on the request of the oncologist and/or patient. The consultations carried out at the request of the oncologist and/or the patient will be counted The first part of the pharmaceutical consultation focuses on a complete clinical medication review including Establishment of the patient profile: medical history, drug allergies and intolerance, comorbidities, age, understanding capacities, organizational capacity
2974474|NCT02733952|Active Comparator|tranexamic acid|"bolus intravenous injection of tranexamic acid 10mg/kg (maximum1g) 15 min before incision followed by continuous infusion of 1mg/kg/h dissolved in 1L of saline for 10 h (maximum~1 g/10 h)"
2974475|NCT02733952|Active Comparator|Pericervical Tourniquet|The tourniquet method will be used where the urinary bladder will be dissected downwards from the lower uterine segment, and then a perforation will be made in the posterior leaflet of the broad ligament bilaterally at the level of uterine isthmus. A tourniquet (using 16- inch Foley catheter) will be passed through the perforation encircling the uterine arteries bilaterally. The Fallopian tubes and the ovaries will be carefully excluded from the line of the tourniquet to avoid direct compression and necrosis. The tourniquet will be released intermittently (at about 30 minutes interval) during the surgery and ﬁnally removed after the repair of the uterus
2974476|NCT02733939|Experimental|Technology intervention|Patients randomized in the intervention group will receive a technical home monitoring kit for 12 months. The kits will be composed of a control unit and a set of sensors that immediately notify caregivers, through their phones, of any potential risks for the person with dementia. The kit will have home leaving sensors, bed occupancy sensors, smoke and water leak sensors, automatic lights, and other interactive functions. These devices will be connected to a single-board microcontroller that will transmit alarm messages to the caregivers in case of need.
2974477|NCT02733939|No Intervention|Usual care|"Patients receiving usual care, as provided to people with dementia in Southern Sweden can vary. In the target area, people with dementia usually receive comparable pharmaceutical treatment depending on the dementia type, as prescribed by a general practitioner or a specialist at a memory clinic. The social worker from the Municipality (Biståndshandläggaren) where the person resides, together with the district nurse, have a meaningful role in tailoring the care plan by mediating access to other care services such as respite care homes, home help and (dementia) nurse home visits. Use of such services depends on the specific needs of the person with dementia, which can also be unrelated to dementia, but rather dependent upon concomitant health and social issues."
2974478|NCT02733926|No Intervention|City kindergarten|Children living in a normal city kindergarten that hardly has vegetation in backyards
2974479|NCT02733926|Experimental|adding of vegetation into the backyards.|"Children living in a normal city kindergarten that has plenty of vegetation in backyards.~Intervention: adding of vegetation into the backyards."
2974480|NCT02733926|No Intervention|Nature kindergarten|Children living in a city kindergarten where children go regularly into a natural forest
2974481|NCT02733900|Experimental|Osteonecrosis group|Patients with an aseptic osteonecrosis of the femoral head
2974482|NCT02733900|Other|Control group|Patients with coxarthrosis
2974483|NCT02733887|Experimental|lymphoma|The lymph nodes or masses, fludeoxyglucose F18 positron emission tomography/computed tomography(PET/CT) standard uptake value(SUV) results, whole body magnetic resonance imaging(MRI) intravoxel incoherent motion(IVIM) sequence D, D*,f values and MRI volumes of lymphoma were compared before and after the chemotherapy in this project prospectively to provide data for evaluating the dependency and differences of PET/CT and whole body MRI in lymphoma staging and therapeutic evaluation.
2974484|NCT02733874|Experimental|test group|Compound Clobetasol Propionate Ointment
2974485|NCT02733874|Active Comparator|control group|Calcipotriol Betamethasone Ointment
2974486|NCT02733848|Experimental|DIET|A registered dietician (RD) will meet with and thoroughly review the patients diet. The patient will be counseled on a diet lower in refined carbohydrates and higher in protein.
2974487|NCT02733848|Active Comparator|Creon|Subjects will be provided Creon at a dose of 500 units/kg of lipase to be taken with meals and snacks to see if this decreases frequency and severity of hypoglycemia.
2974488|NCT02733848|Placebo Comparator|Placebo|Subjects will be provided placebo and advised to take it with meals and snacks to provide.
2974489|NCT02733835|Experimental|Remifentanil|Remifentanil Patient Controlled Analgesia
2974490|NCT02733822|Experimental|IMP: buccal naloxone (single dose)|0.8 mg buccal (solution) of 1 mg/ml Naloxone Hydrochloride Injection
2974491|NCT02733822|Experimental|IMP: buccal naloxone (double dose)|1.6 mg buccal (solution) of 1 mg/ml Naloxone Hydrochloride Injection
2974492|NCT02733822|Active Comparator|Intramuscular (IM) reference|0.8 mg IM injection of 1 mg/ml Naloxone Hydrochloride Injection
2974493|NCT02733822|Active Comparator|Intravenous (IV) reference|0.8 mg IV injection of 1 mg/ml Naloxone Hydrochloride Injection
2974494|NCT02733809|Experimental|Sorafenib|Group under the treatment ( sorafenib ) Maximum dose of 400 mg BID If subjects devolves adverse events, dose can be reduced.
2974495|NCT02733783|Experimental|septorhinoplasty patients|Elective septorhinoplasty patients that will undergo bilateral osteotomies. All the patients will undergo cold dry air provocation and 3 hours later capsaicin provocation, during a preoperative visit, one week before the intervention and during three post-operative visits two weeks, three months and six months.
2974496|NCT02733770|Active Comparator|Sleeve gastrectomy|US DOopler for Patient with BMI of 40 or more than 35 with co-morbidities underwent Sleeve gastrectomy
2974497|NCT02733770|Active Comparator|Mini Gastric Bypass|US DOopler for Patient with BMI of 40 or more than 35 wtih co-morbidities underwent mini gastric bypass
2974498|NCT02733757|No Intervention|Sub-Tenon's group control|2% Lidocaine without epinephrine
2974499|NCT02733757|Experimental|Sub-Tenon's group clonidine|2% Lidocaine without epinephrine plus clonidine 1 µg/kg
2974500|NCT02733757|No Intervention|Peribulbar group control|2% Lidocaine without epinephrine
2974501|NCT02733757|Experimental|Peribulbar group clonidine|2% Lidocaine without epinephrine plus clonidine 1 µg/kg
2974502|NCT02733744|Experimental|Fecal Microbiota Transplant|"Each participant will undergo allogeneic hematopoietic stem cell transplantation, according to institutional standards.~Participants will receive a single standard dose of oral Fecal Microbiota Transplantation (FMT), which is 15 capsules per day for two consecutive days, for a total of 30 capsules. Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake. Capsules will be individually handed to participants by a research nurse or physician. Each capsule will be taken with a sip of water."
2974503|NCT02733731|Experimental|Chinese Herbal Compound Ointment|This kind of CHCO composed of several chinese herbs,dong quai,angelica,resina draconis and lithospermum.The dosage of medicine for single treatment once a day in two group is 0.5g,The total time for therapy is 3 weeks.
2974504|NCT02733731|Active Comparator|Estriol|The dosage of medicine for single treatment once a day in two group is 0.5g,The total time for therapy is 3 weeks in two groups.
2974505|NCT02733718|Other|Group 1: no enteral feeding|intervention: NIRS (near-infrared spectroscopy)
2974506|NCT02733718|Other|Group 2: Feeding is reduced by %50|intervention: NIRS (near-infrared spectroscopy)
2974507|NCT02733718|Other|Group 3: Feeding will be continued|intervention: NIRS (near-infrared spectroscopy)
2974508|NCT02733705|Placebo Comparator|Control|normal saline IV plus propofol infusion
2974509|NCT02733705|Active Comparator|Fentanyl|0.5 mcg/kg ideal body weight IV plus propofol infusion
2974510|NCT02733692|Experimental|GURHL Code Smartphone application|Experimental arm will receive the 'Understanding Reproductive Health for Ladeez (GURHL) Code 'app' (application) for their smartphone with sexual health information. The intervention is embedded in the smart phone application. This includes sexual and reproductive health knowledge, plus access to a National Planned Parenthood health educator, and directions to other nearby clinics. Participants will be assessed using A-CASI at 3 months after enrollment.
2974511|NCT02733692|No Intervention|Control|"The control arm will receive usual care. That is, they will receive a web-based flyer. This flyer will include a list of clinics and other trusted available resources, but without hyperlinks.~Participants will be assessed using A-CASI at 3 months after enrollment."
2974512|NCT02733679|Experimental|Ataxia Telangiectasia|Participants will receive two treatments - metformin and pioglitazone for eight weeks each, separated by a one week washout period.
2974513|NCT02733679|Active Comparator|Healthy controls|Participants will receive two treatments - metformin and pioglitazone for eight weeks each, separated by a one week washout period.
2974514|NCT02733666|Experimental|Absorbable screw group|One absorbable screw was used for fixation in the experimental group
2974515|NCT02733666|No Intervention|K-wires group|two 1.8-mm K-wires were used for the fixation in the control group. The K-wires were the most common used by the orthopaedic surgeon.
2974516|NCT02733653|Experimental|Jetstream Atherectomy System|Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention
2974517|NCT02733640|Active Comparator|Pantoprazole|Drug: Pantoprazole 40 mg once-daily
2974518|NCT02733640|Experimental|Ranitidine|Drug: Ranitidine 150 mg twice-daily
2974519|NCT02733627|Experimental|BI 1467335 low dose|
2974520|NCT02733627|Experimental|BI 1467335 medium dose|
2974521|NCT02733627|Experimental|BI 1467335 high dose|
2974522|NCT02733627|Placebo Comparator|Placebo|
2974523|NCT02733614|Experimental|SRX246|SRX246 160 mg BID, oral administration, capsules, daily for 8 weeks
2974524|NCT02733614|Placebo Comparator|Placebo|oral administration, capsules, daily for 8 weeks
2974525|NCT02733601||Breast Cancer Patients|Newly diagnosed with breast cancer all stages confirmed during the study period by an anatomopathologist, defined as a first diagnosis of breast cancer based on anatomopathological results from at least a microbiopsy
2974526|NCT02733588|Experimental|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
2974527|NCT02733575|Other|Compassion Focused Therapy|Intervention
2974528|NCT02733562||Binge eaters|Classificated preoperatively
2974529|NCT02733562||Volume eaters|Classificated preoperatively
2974530|NCT02733562||sweet eaters|Classificated preoperatively
2974531|NCT02733562||snack eaters|Classificated preoperatively
2974532|NCT02733549||patient|Patients with sudden onset dizziness (SOD) analysed LFTs
2974533|NCT02733549||control|The control group with 98 healthy volunteer analysed LFTs
2974534|NCT02733536|Experimental|Scenario A|manikin with normal standard airway
2974535|NCT02733536|Experimental|Scenario B|Cervical immobilization using a standard Patriot cervical extraction collar (Oessur Americas, Foothill Ranch, CA, USA), applied to the manikin's neck by an instructor.
2974536|NCT02733536|Experimental|Scenario C|Cervical immobilization using a vacuum mattress (Ferno-Washington, Inc. Wilmington, OH, USA), applied to the manikin's neck by an instructor
2974537|NCT02733523|Experimental|"Program Sentirnos bien"|"The intervention Program Sentirnos bien is based around a group dynamic, held once a week during 3 months, aimed at:~Promoting the uptake of self‐care healthy habits~Promoting social capital at individual level:~Promoting health literacy"
2974538|NCT02733523|No Intervention|Control arm|The control arm will receive no intervention. Once the trial is finished, i.e. after the last follow-up evaluation, this arm will receive the intervention (waiting-list approach).
2974539|NCT02733510||subclinical rejection group|patients whose protocol biopsy outcome is subclinical rejection and treat with steroid pulse therapy (methylprednisolone)
2974540|NCT02733510||No rejection group|patients whose protocol biopsy outcome is normal
2974541|NCT02733497|Active Comparator|Sympathectomy Group|Excision of ganglia at T3 level
2974542|NCT02733497|Active Comparator|Sympathicotomy Group|Resection of sympathetic chain at T3 level
2974543|NCT02733484|Experimental|Probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
2974544|NCT02733484|Placebo Comparator|Placebo|the patients in this arm will receive placebo with similar appearance of probiotics.
2974545|NCT02733471|Experimental|Lidocaine|Five lidocaine solution puffs (10mg lidocaine/puff) on the four posterior quadrants of the pharynx and on the base of the tongue, 3 minutes before the oesophago-gastro-duodenoscopy.
2974584|NCT02733211|Active Comparator|Sensor augmented pump therapy|Sensor augmented pump therapy - all subjects are using sensor augmented pump therapy over 4 weeks
2974547|NCT02733458|Experimental|GELAD/Radiation|Patients will be initially treated with two cycles GELAD chemotherapy, followed by 50-56Gy radiotherapy, and completed with another two cycles GELAD chemotherapy. GELAD chemotherapy will be repeated every 21 days. Radiotherapy will be delivered in 25-32 fractions.
2974548|NCT02733445||dasatinib cohort|Patients with CML receiving dasatinib
2974549|NCT02733445||nilotinib cohort|Patients with CML receiving nilotinib
2974550|NCT02733432|Experimental|Cohort 1|CD101 Vaginal Gel (3%) topically self-administered intravaginally as a single dose on days 1 and 2 and for symptomatic relief CD101 External Gel (1%)topically self-applied to external vulva up to twice per day over 72 hours.
2974551|NCT02733432|Experimental|Cohort 2|CD101 Vaginal Ointment (6%) topically self-administered intravaginally as a single dose on day 1 and for symptomatic relief CD101 External Ointment (1%) topically self-applied to external vulva up to twice per day over 72 hours.
2974552|NCT02733432|Active Comparator|Cohort 3|Oral fluconazole (150mg) administered on day 1.
2974553|NCT02733419|Experimental|Enfuvirtide + OB (Not Randomized)|Participants will receive enfuvirtide 90 milligram (mg) twice daily (b.i.d.) and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants not meeting the randomization criteria will receive enfuvirtide 90 mg b.i.d and OB for next 24 weeks (up to Week 52).
2974554|NCT02733419|Experimental|Enfuvirtide + OB (Randomized)|Participants will receive enfuvirtide 90 mg b.i.d. and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants meeting the randomization criteria will be randomized to receive enfuvirtide 90 mg b.i.d. and OB for next 24 weeks (up to Week 52).
2974555|NCT02733419|Experimental|OB alone (Randomized)|Participants will receive enfuvirtide 90 mg b.i.d. and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants meeting the randomization criteria will be randomized to receive OB alone for next 24 weeks (up to Week 52).
2974556|NCT02733406|Other|Target Controlled Infusion|This group of patients will have their anaesthesia induced with Target Controlled Infusion (TCI)
2974557|NCT02733406|Other|Velocity Controlled Infusion|This group of patients will have their anaesthesia induced with Velocity Controlled Infusion (VCI)
2974558|NCT02733393|Experimental|SPG Block|
2974559|NCT02733380|Experimental|Chidamide combined with VDDT regimen|Chidamide 30mg，Oral twice a week with an interval of no less than 3 days combined with regimen：VDDT（Vinorelbine，Liposomal doxorubicin or mitoxantrone ，Dexamethasone and Thalidomide）：repeated every 14 days ，up to 12 cycles
2974560|NCT02733367|Experimental|Infacort|Infacort® granules
2974561|NCT02733354||Control Group|Control Group:perform routine oral education.Both groups were asked to complete kidney disease knowledge questionnaire before education.
2974562|NCT02733354||Intervention Group|Intervention Group ：On the basis of Control Group, watching video demonstration of each type of dialysis. The videos were based on real cases, showing patients with peritoneal and hemodialysis life modes, lasting for 20 minutes respectively for each type of dialysis. Both groups were asked to complete kidney disease knowledge questionnaire before education.
2974563|NCT02733341|Active Comparator|Oral Ticagrelor|Patients in the oral Ticagrelor arm will receive Ticagrelor at a loading dose of 180mg followed by maintenance dose of 90mg twice daily for 12 months.
2974564|NCT02733341|Active Comparator|Intravenous Cangrelor|Patients in the intravenous Cangrelor arm will receive Cangrelor as an initial bolus dose given as per body weight followed by an intravenous infusion for no longer than three hours, they will then switch to oral Ticagrelor given at maintenance dose of 90mg twice daily for 12 months
2974565|NCT02733328||AKI Patients|Patients with AKI
2974566|NCT02733328||Non-AKI Patients|Patients without AKI
2974567|NCT02733315|Experimental|DCMP|
2974568|NCT02733302|Experimental|Hope theory|
2974569|NCT02733276|Experimental|Electroacupuncture|Using electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes. Acupoints are: 6 needles in each lower limb, 8 abdominal, 3 in upper extremity and 3 on the front
2974570|NCT02733276|Sham Comparator|Electroacupuncture sham|Using electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes. Acupoints are: needles on each forearm on nonselective points
2974571|NCT02733276|No Intervention|Control|Initially no intervention. In a second period in this group we will perform EAP
2974572|NCT02733263|Experimental|Group 1|Participants will first consume in the the order of 0 g RMD, 15 g RMD, 25 g RMD for 3 weeks each
2974573|NCT02733263|Experimental|Group 2|Participants will first consume RMD in the the order of 0 g RMD, 25 g RMD, 15 g RMD for 3 weeks each
2974574|NCT02733263|Experimental|Group 3|Participants will first consume RMD in the the order of 15 g RMD, 0 g RMD, 25 g RMD for 3 weeks each
2974575|NCT02733263|Experimental|Group 4|Participants will first consume RMD in the the order of 15 g RMD, 25 g RMD, 0 g RMD for 3 weeks each
2974576|NCT02733263|Experimental|Group 5|Participants will first consume RMD in the the order of 25 g RMD, 15 g RMD, 0 g RMD for 3 weeks each
2974577|NCT02733263|Experimental|Group 6|Participants will first consume RMD in the the order of 25 g RMD, 0 g RMD, 15 g RMD for 3 weeks each
2974578|NCT02733250|Other|Pembrolizumab + Nab-Paclitaxel|"Phase I will determine the recommended Phase II dose (RP2D) of nab-paclitaxel when given in combination with pembrolizumab. Escalation for nab-paclitaxel will be conducted following a 3+3 design. First cohort of 3 patients will receive nab-paclitaxel on Days 1 and 8 at a dose of 100 mg/m2 intravenous (IV) in combination with pembrolizumab at 200 mg IV every 3 weeks. If no dose limiting toxicities (DLT) occur, the dose of nab-paclitaxel will be escalated to 100 mg/m2 on Days 1, 8 and 15 every 3 weeks. The dose of pembrolizumab will remain the same. If no DLTs occur, dose level 2 will be defined as the RP2D. In the Phase II, pembrolizumab will be administered at 200 mg IV every 3 weeks and nab-paclitaxel will be administered at the RP2D."
2974579|NCT02733237|Experimental|male oxytocin group|male subjects with oxytocin treatment
2974580|NCT02733237|Experimental|female oxytocin group|female subjects with oxytocin treatment
2974581|NCT02733237|Placebo Comparator|male placebo group|male subjects with placebo treatment
2974582|NCT02733237|Placebo Comparator|female placebo group|female subjects with placebo treatment
2974583|NCT02733211|Experimental|Closed Loop System|MD-Logic automated insulin delivery system - all subjects wearing the study system during nights over 4 weeks
2974588|NCT02733185|Active Comparator|Active/Placebo|Active disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
2974589|NCT02733185|Active Comparator|Placebo/ Active|Placebo disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
2974590|NCT02733185|Placebo Comparator|Placebo/Placebo|Placebo disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
2974591|NCT02733159|Experimental|Pembrolizumab|Pembrolizumab: 200 mg Q3W, intravenous administration for a maximum of 2 years, or until progression or unacceptable toxicity.
2974592|NCT02733146||cardiac arrest patients|Patients who has suffered a cardiac arrest
2974593|NCT02733133|Experimental|Uncovered|Half of the male partners in each cohort will apply the Testagen® TDS Testosterone 5% HypoSpray® and cover the area before engaging in contact with the female partner.
2974594|NCT02733133|Experimental|Covered|Half of the male partners in each cohort will apply the Testagen® TDS Testosterone 5% HypoSpray® and will not cover the area before engaging in contact with the female partner.
2974595|NCT02733120|Experimental|Healthy matched controls|Study Day: The subject will arrive fasted. A catheter will be inserted in the arm for stable isotope infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable isotopes will be administered by the research nurse. Stable isotopes are given to measure amino acid metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet.
2974596|NCT02733120|Experimental|Adults with Autism Spectrum Disorder|The subject will arrive fasted. A catheter will be inserted in the arm for stable isotope infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable isotopes will be administered by the research nurse. Stable isotopes are given to measure amino acid metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet.
2974597|NCT02733107|Other|Apatinib+Etoposide|Apatinib combined with Etoposide
2974598|NCT02733094|Experimental|Open-label|300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 2 weeks until week 32.
2974599|NCT02733081|No Intervention|Arm 1: Traditional IUD Insertion|Standard IUD insertion according to package insert. Bimanual pelvic exam to assess uterine size and position will be performed. Uterine sound will be used to measure depth of uterus prior to insertion.
2974600|NCT02733081|Experimental|Arm 2: Simplified IUD Insertion|Simplified, investigational IUD insertion performed. No bimanual pelvic exam or uterine sounding.
2974601|NCT02733068|Experimental|HPV-16/18 vaccine|Including 6000 participants who received the HPV-16/18 vaccine 0.5ml.
2974602|NCT02733068|Placebo Comparator|HPV-16/18 placebo|Including 6000 participants who received the HPV-16/18 placebo 0.5ml.
2974603|NCT02733055|Experimental|subjects|participant undergoing posturographic evaluation
2974604|NCT02733042|Experimental|Arm A: Durvalumab and Lenalidomide plus or minus Rituximab|"Subjects assigned to Arm A will receive:~Durvalumab 1500 mg (IV) infusion on Day 1 of Cycles 1 through 13 (ie, 12 months) and~Lenalidomide (oral) at assigned dose levels (10 mg, 15 mg or 20 mg) once daily on Days 1 to 21 (inclusive) of:~Cycles 1 through 13 in indolent Non-Hodgkin lymphoma (NHL) (ie, FL or MZL) or~All cycles of treatment period until disease progression, unacceptable toxicity, or discontinuation for any other reason in aggressive NHL~Rituximab 375 mg/m2 (IV) infusion Schedule 1 (dose levels 2 and -1B) on Days 2, 8, 15 and 22 of Cycle 1 and on Day 1 from Cycles 2 through 5.~Rituximab 375 mg/m2 (IV) infusion Schedule 2 (dose levels -2 and -3) on Day 2 of Cycle 1 and on Day 1 from Cycles 2 through 8.~One cycle is 28-day."
2974605|NCT02733042|Experimental|Arm B: Durvalumab and Ibrutinib|"Subjects assigned to Arm B will receive:~Durvalumab (IV) infusion on Day 1 of Cycles 1 through 13~Ibrutinib (oral) at assigned dose levels (280 mg, 420 mg, or 560 mg)continuous once daily until disease progression, unacceptable toxicity or discontinuation for any other reason One cycle is 28-day."
2974606|NCT02733042|Experimental|Arm C: Durvalumab and Bendamustine plus or minus Rituximab|"Subjects assigned to Arm C will receive:~Durvalumab 1500 mg (IV) infusion on Day 1 of Cycles 1 through 13~Bendamustine (IV) infusion at assigned dose levels (70 mg/m2 or 90 mg/m2) on Days 1 and 2 of Cycles 1 through 6~Rituximab 375 mg/m2 (IV) infusion on Day 2 Cycles 1 through 6 One cycle is 28-day."
2974607|NCT02733042|Experimental|Arm D: Durvalumab Monotherapy|"Subjects assigned to Arm D will receive:~• Durvalumab (IV) infusion at a fixed dose of 1500 mg, on Day 1 of Cycles 1 through 13. One cycle is 28-day."
2974608|NCT02733029|Experimental|Sonazoid contrast|The contrast agent Sonazoid will be used during contrast enhanced ultrasonography. This will be a one-time administration of the contrast agent. The contrast agent, Sonazoid (GE Healthcare), is a lipid-stabilized suspension of perfluorobutane microbubbles with a median diameter of 2.4-3.5 μm and will be administered per package insert (intravenously as a continuous infusion). Sonazoid contrast agent will be given at a dose 0.0075 mL/Kg as a bolus intravenous injection while visualizing the kidney transplant.
2974609|NCT02733029|No Intervention|Medical Review|Ultrasound imaging will be taken from a group of subjects recruited for stage 2. These will be obtained through medical record review from subjects with successful renal transplant at BWH and no transplant rejection.
2974610|NCT02733003|Experimental|Women's Health CoOp (WHC)|This is an adapted behavioral intervention for women in South Africa, who use alcohol and other drugs and are living with HIV or at risk of acquiring HIV.
2974611|NCT02732990|Experimental|Exercise training - Whole body exercise|Control subjects will train 2-legged cycling (whole body exercise) for 6 weeks
2974612|NCT02732990|Experimental|Exercise training - One-legged exercise|Control subjects will train high intense one-legged exercise for 6 weeks
2974613|NCT02732990|Experimental|Exercise training - 2-legged cycling CHF|CHF patients will train 2-legged cycling (whole body exercise) for 6 weeks
2974614|NCT02732990|Experimental|Exercise training - CHF|CHF Patients will train high intense one-legged exercise for 6 weeks
2974615|NCT02732977|Other|expert system|System for predicting patients heart failure, that can predict response to a personalized treatment from the analysis of a set of data (images, physiological data , treatment outcomes ) .
2974616|NCT02732964|No Intervention|Control|baseline hemodynamics and anxiety screen; no music
2974617|NCT02732964|Experimental|Pandora Music|A study investigator will create a station in the Pandora® music application based on the patient's preferred music genre or artist.
2974618|NCT02732964|Experimental|Mozart Music|A study investigator will turn on a playlist of pre-selected Mozart music.
2974619|NCT02732951|Experimental|BI 1026706|
2974620|NCT02732951|Active Comparator|Placebo|
2974621|NCT02732938|Experimental|PF-04136309 + Nab-p + Gem|"PF-04136309 oral dosing~Nab-paclitaxel IV dosing Gemcitabine IV dosing"
2974622|NCT02732925|Sham Comparator|Arm 1 - Sham Procedure|"Sham Procedure & Conservative Treatment~Subjects will be blinded and randomised to Arm 1 and will undergo a general anaesthetic and undergo a sham procedure. They will also be treated under conservative management alone.~Below is a list of the conservative management they will be managed by their Doctor:~Bisphosphonates~Pain relief~Systemic chemotherapy for Myeloma disease~Bed rest~Radiotherapy~Physiotherapy~This is a non interventional as conservative treatment (standard of care for multiple myeloma patients) is used."
2974623|NCT02732925|Active Comparator|Arm 2 - Balloon Kyphoplasty|"Balloon Kyphoplasty & Conservative Treatment - Interventional Arm~Subjects will be blinded and randomised to Arm 2 (balloon kyphoplasty) and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.~Below is a list of the conservative management they will be managed by their Doctor:~Bisphosphonates~Pain relief~Systemic chemotherapy for Myeloma disease~Bed rest~Radiotherapy~Physiotherapy~This is a interventional arm (balloon kyphoplasty procedure) and the patient will receive conservative treatment (standard of multiple myeloma patients) is used."
2974624|NCT02732912|Active Comparator|Control|Patients in this arm will continue current standard management for sleep, which is largely reactive; if a patient requests night sedation or complains that they cannot sleep and that they want help, then zopiclone is prescribed, starting at 3.75 mg.
2974625|NCT02732912|Experimental|Eye mask and ear plugs|General management will be as for the control group. In addition, patients in this group will be given ear plugs and eye shades (masks) to use when trying to sleep. The patient will generally be responsible for using or not using the equipment, though ward nurses may remind patients if they notice that the patient has the equipment.
2974626|NCT02732899|Experimental|Group 1|Sirolimus 440ug for intravitreal injection will be provided in sterile single-use glass vials. One single-dose vial will be packaged in a box for each patient injection. Sirolimus injections will be given at baseline, week 4, 12, 20 and 28. EYLEA® (aflibercept) intravitreal injections will be given at week 1, 8, 16, 24 and 32.
2974627|NCT02732899|Active Comparator|Group 2|Intravitreal injection of EYLEA® (aflibercept) will be given at baseline, week 8, 16, 24 and 32. Sham injections will be given at week 1, 4, 12, 20, and 28 in order to maintain masking of patient to treatment assignment
2974628|NCT02732886|Experimental|Betafoam®|Brand name: Betafoam® Generic term: Wound dressing with 3% povidone iodine
2974629|NCT02732886|Active Comparator|Medifoam®|Brand name: Medifoam® Generic term: Wound dressing
2974630|NCT02732873|Experimental|FibroFix|
2974631|NCT02732860||Triple Negative Breast Cancer|"Triple negative breast cancer patients with residual invasive disease following neoadjuvant chemotherapy (n= up to 15) or with newly diagnosed metastatic disease (n=up to 30).~After the screening procedures confirms patient eligibility:~Molecular Profiling will be performed on clinical sample~pPDX generation for in vivo drug testing~In vitro organoid culture generation (if sufficient fresh tissue available)~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
2974632|NCT02732860||Colorectal Cancer|"Colorectal cancer patients with metastatic disease undergoing resection of liver metastases, or with lesions amenable to biopsy (n=up to 15).~After the screening procedures confirms patient eligibility:~Molecular Profiling will be performed on clinical sample~pPDX generation for in vivo drug testing~In vitro organoid culture generation (if sufficient fresh tissue available)~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
2974633|NCT02732860||High Grade Serous Ovarian Cancer|"High grade serous ovarian cancer patients with recurrent disease with a life expectancy of at least 12 months (n=up to 15), or Stage III or IV with residual disease following neoadjuvant chemotherapy, or at risk of high recurrence (n=up to 15).~After the screening procedures confirms patient eligibility:~Molecular Profiling will be performed on clinical sample~pPDX generation for in vivo drug testing~In vitro organoid culture generation (if sufficient fresh tissue available)~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
2974634|NCT02732860||Other tumor types|"Other selected tumor types at the discretion of the PI (n= up to 15)~After the screening procedures confirms patient eligibility:~Molecular Profiling will be performed on clinical sample~pPDX generation for in vivo drug testing~In vitro organoid culture generation (if sufficient fresh tissue available)~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
2974635|NCT02732847|Other|Post-Dated Prescription|a delayed prescription dated 2 days after clinical office visit
2974636|NCT02732847|Other|Usual|usual date
2974637|NCT02732834||Part 1: Lung patients|Following informed consent, the patient will complete the patient questionnaire, either electronically, by phone, or on paper. Patients who prefer to complete the survey electronically will be emailed a link to access to a secure electronic (web-based) version of the study assessment which they will have access to from any computer. We will include an introductory email with the survey link. Will audio-record actual patient-physician clinical consultations with lung cancer patients at Memorial Sloan Kettering (MSK). Completing the survey will take about 15 minutes. Answer a few open-ended questions about the consultation with the doctor. We will audio record your answers to these questions. This will take about 15 minutes.
2974638|NCT02732834||Part 1: Thoracic physicians and clinicians|Will have 5 visits/consultations with their patients audio recorded.
2974639|NCT02732834||Part 2: Lung patients|Following informed consent, the patient will complete the patient questionnaire, either electronically, by phone, or on paper. Patients who prefer to complete the survey electronically will be emailed a link to access to a secure electronic (web-based) version of the study assessment which they will have access to from any computer. Completing the survey will take about 15 minutes.
2974735|NCT02732054|Experimental|HIV-Group 2|Receiving four intramuscular injections of 20 µg of recombinant hepatitis B vaccine [(CIGB) La Habana, Cuba] at months 0, 1, 2, and 6
2974763|NCT02731807|Experimental|Dose D, E, C, B, A|All participants will receive all doses throughout the course of the study.
2974640|NCT02732834||Part 2: Thoracic and pulmonary clinicians|Following informed consent, clinicians will be scheduled to participate in a 2 hour training on empathic communication with lung cancer patients. Surveys will be collected from 6 patients (3 pre-training, 3 post-training). Clinicians will complete one standardized patient assessment before training (pre-SPA) and one assessment after training (post-SPA). These are 12-minute video-recorded clinic consultations with standardized patients (trained actors).
2974641|NCT02732821||Gastric Per Oral Endoscopic Myotomy|All patients presenting with Gastroparesis will undergo Per oral endoscopic gastric myotomy
2974642|NCT02732808|Experimental|poor ovarian responder|The women with diagnose of poor ovarian responder after IVF/ICSI treatments underwent ovulation stimulation and egg collection in the same IVF/ ICSI cycle ( Shanghai protocol)
2974643|NCT02732795|Experimental|Ideal body weight dosing|Evaluating inflammatory biomarker concentrations in obese patients with obstructive sleep apnea and randomizing them into ideal versus actual body weight dosing of morphine. This arm will receive ideal body weight dosing of morphine.
2974644|NCT02732795|Experimental|Actual body weight dosing|Evaluating inflammatory biomarker concentrations in obese patients with obstructive sleep apnea and randomizing them into ideal versus actual body weight dosing of morphine. This arm will receive actual body weight dosing of morphine.
2974645|NCT02732782|Experimental|Isometric exercise|Isometric exercise (90% maximum voluntary contraction (MVC), 12 weeks, 4 times a week, 5 sets of 4 repetitions a 3 seconds)
2974646|NCT02732782|Active Comparator|Eccentric exercise|"Eccentric training (Alfredson approach, 12 weeks, 2 sets per day with extended and two sets per day with bended knee, 15 repetitions per set)"
2974647|NCT02732782|No Intervention|Control|Control, no intervention
2974648|NCT02732769|Active Comparator|Group treated by radiosurgery|Subjects will receive a pituitary radiosurgery during a brief hospitalization by LeksellGammaKnifePerfexion® (LGKP)
2974649|NCT02732769|Experimental|Group treated by radiosurgery with the thermoformed mask|Subjects will receive a pituitary radiosurgery with thermoformed mask during a brief hospitalization by GammaKnifeICON® (GKI) with Efficast®
2974650|NCT02732756|Experimental|Sleep Restriction|The Sleep Restriction condition will allow 6.5 hours in bed, which in previous research results in an average of 6.1-6.3 hours of nightly sleep. This condition reflects a realistic dose of sleep restriction (similar to the school-night sleep of 15-20% of healthy adolescents) that has been shown to be feasible and to induce daytime sleepiness, inattention, and irritability/moodiness in typically developing adolescents.
2974651|NCT02732756|Experimental|Sleep Extension|The Sleep Extension condition will allow adolescents to obtain 9 hours of nightly sleep (9.5 hours in bed, leaving up to ½ hour to fall asleep), which (a) is how long adolescents sleep during controlled trials of sleep satiation and naturally on non-school nights, (b) has been shown to result in a well-rested state, and (c) matches clinical recommendations for adolescents.
2974652|NCT02732743|Other|Food Supplement Physiomanna® Baby|Dosage: 1g/kg body
2974653|NCT02732730|Experimental|PrEP Acceptor|"For those women who choose to accept PrEP (Truvada), the following adherence support package will be provided:~Cognitive Behavioral Theory adherence support sessions~Two-way SMS communications~Optional monthly adherence support clubs Drug level counseling for those randomized to that extra intervention (1:1)"
2974654|NCT02732730|No Intervention|PrEP Decliner|Standard of care
2974655|NCT02732717||abnormal ultrasound index|twin pregnancy with abnormal ultrasound index
2974656|NCT02732717||normal ultrasound index|twin pregnancy with normal ultrasound index
2974657|NCT02732704|Experimental|transcatheter aortic valve replacement|In this study, transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial TAVR System, which is intended to help treat severe aortic regurgitation. The JenaValve replacement valve is placed inside the aortic valve by using the JenaValve delivery system.
2974658|NCT02732691|Experimental|transcatheter aortic valve replacement|In this study, transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial TAVR System, which is intended to help treat severe aortic stenosis. The JenaValve replacement valve is placed inside the aortic valve by using the JenaValve delivery system.
2974659|NCT02732678|Experimental|Cohort of a dose of Propranolol 80 mg/day|
2974660|NCT02732678|Experimental|Cohort of a dose of Propranolol 120 mg/day|
2974661|NCT02732678|Experimental|Cohort of a dose of Propranolol 160 mg/day|
2974662|NCT02732639|Experimental|Pegylated Interferon (PEG-IFN) alfa-2a|Participants received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 48 weeks, followed by 24 weeks of treatment-free follow-up.
2974663|NCT02732626|Active Comparator|pulmonary vein isolation alone|patients randomized to this group receive stand alone pulmonary vein isolation regardless to their left atrial voltage map
2974664|NCT02732626|Experimental|pulmonary vein isolation + low voltage area guided ablation|patients randomized to this group receive pulmonary vein isolation + low voltage area guided linear substrate modification in the case if there are any
2974665|NCT02732613|Experimental|Actual weight Group|Patients in Actual weight Group: The selection of Laryngeal Mask Airway classic will be based on actual body weight, followed the recommendations of manufacturer (size 3 for weight < 50 kg, size 4 for weight 50-70 kg, and size 5 for weight > 70 kg ).
2974666|NCT02732613|Experimental|Ideal weight Group|Patients in Ideal weight Group: The selection of Laryngeal Mask Airway classic will be based on ideal body weight, followed the recommendations of manufacturer ( size 3 for weight < 50 kg, size 4 for weight 50-70 kg, and size 5 for weight > 70 kg ).
2974667|NCT02732600|No Intervention|Standard Implementation|Standard Implementation sites will receive written guidance and limited consultation by the investigators' team.
2974668|NCT02732600|Experimental|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation.
2974669|NCT02732587|Experimental|125 mg Saracatinib|125 mg Saracatinib once daily for 8-11 days
2974758|NCT02731833|Experimental|Test dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute
2974759|NCT02731833|Active Comparator|Control dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip (1 inch) of toothpaste. Participants will then brush whole mouth thoroughly for at least 1 minute
2974670|NCT02732574|Experimental|OPEP Device Treatment|Patients randomized to OPEP will receive the device on postoperative day (POD) 1 or day of extubation, whichever comes first. Patients will be seen on POD #1 by a blinded physiotherapist (PT) for mobility and education on supported coughing. The OPEP device group will also be instructed to complete 15 breaths twice per waking hour in a seated position and receive education on proper use of the device. The OPEP device will be set to the highest pressure setting unless deemed inappropriate by the PT, at which time the most appropriate pressure setting will be selected and then increased daily until the OPEP device is set to the highest pressure setting by POD #3 if able. The PT will reassess the patients on POD 2 and 3 to assess for proper technique and continued use of the device, as well as usual care. Patients will use the OPEP device up to POD#5 pressure settings and compliance will be recorded and measure by use of a daily log.
2974671|NCT02732574|Sham Comparator|SHAM Device|Patients randomized to the sham treatment will receive the sham device on postoperative day (POD) 1 or day of extubation, whichever comes first. Patients will be seen on POD #1 by a blinded physiotherapist (PT) for mobility and education on supported coughing. The sham group will also be instructed to complete 15 breaths twice per waking hour in a seated position and receive education on proper use of the device. The sham device is identical in exterior appearance to the OPEP device but does not contain the internal mechanism providing expiratory pressure. As such, the device will be set to the highest setting and will not need to be adjusted at all for patient tolerance. The PT will reassess the patients on POD 2 and 3 to assess for proper technique and continued use of the device, as well as usual care. Patients will use the OPEP device up to POD#5 pressure settings and compliance will be recorded and measure by use of a daily log.
2974672|NCT02732561|Sham Comparator|Sham Device|Sham device
2974673|NCT02732561|Active Comparator|Intervention|CES device. cranial electrotherapy stimulation device. Alpha Stim device
2974674|NCT02732548|Active Comparator|NPWT Only|Study subjects who are randomized to the control arm will be treated with Negative Pressure Wound Therapy (NPWT) and additional standard care treatments. No cellular or acellular biological tissue scaffold will be allowed for subjects in this study arm for the first 6 weeks of the study. Subjects who are randomized to this arm and who do not experience at least a 50% surface area reduction of the study wound by the 6 week study visit will have the option to cross over into the NPWT + MIRODERM treatment arm.
2974675|NCT02732548|Experimental|NPWT + MIRODERM|Subjects in this arm will receive NPWT and standard care, plus application(s) of the MIRODERM product.
2974676|NCT02732522|Experimental|Misoprostol sublingual|
2974677|NCT02732522|Active Comparator|Misoprostol vaginal|
2974678|NCT02732509||Lean|Body mass index less than 25 kg/m2
2974679|NCT02732509||Overweight/obese|Body mass index 25-45 kg/m2
2974680|NCT02732496|Experimental|Cognitive Training|Targeted Cognitive Training (TCT)
2974681|NCT02732496|Placebo Comparator|Youth Appropriate Online Games|Engaging games not designed to improve cognition
2974682|NCT02732483|Experimental|Endo-Clot(TM)|
2974683|NCT02732470|Experimental|Qi Gong|The effect of Qi Gong training on quality of life in patients with systemic lupus erythematosus
2974684|NCT02732444||COPD and APD patients in LTOT|• COPD and APD patients in LTOT
2974685|NCT02732444||Healthy Control|• Patients without significant cardiorespiratory disease, matched for age and body mass index with the other group.
2974686|NCT02732431|Other|trisomy 21|Parents will complete two sleep symptom questionnaires (PSQ-SRBD and CSHQ) and children will be evaluated by a paediatric pulmonologist and allergist with skin allergy test. An Ear, Nose and Throat specialist will complete two questionnaires (CAS-15 and SCR) carrying a nasopharyngoscopy. Then, children will perform an overnight polysomnography in the Department of Paediatric Functional Investigations of University Hospital in Nice.
2974687|NCT02732418|Experimental|Depo-Provera CI 45 mg|a single subcutaneous (SC) injection of 45 mg/0.3 mL
2974688|NCT02732418|Experimental|Depo-Provera CI 75 mg|a single subcutaneous (SC) injection of 75 mg/0.5 mL
2974689|NCT02732418|Experimental|Depo-Provera CI 105 mg|a single subcutaneous (SC) injection of 105 mg/0.7 mL
2974690|NCT02732418|Active Comparator|Depo-subQ 104|a single subcutaneous (SC) injection of 104 mg/0.65 mL
2974691|NCT02732405|Experimental|MK5172 /MK8742|
2974692|NCT02732392|Experimental|lymphadenectomy|
2974693|NCT02732379|Experimental|Lavender Aromatherapy|Aromatherapy with lavender essential oil.
2974694|NCT02732379|Experimental|Rose Aromatherapy|Aromatherapy with rose essential oil
2974695|NCT02732379|Experimental|Ginger Aromatherapy|Aromatherapy with ginger essential oil
2974696|NCT02732379|Placebo Comparator|Placebo Aromatherapy|Aromatherapy with pure water
2974697|NCT02732366|Experimental|Group-based exercise and peer coaching|This treatment arm will include physical therapist-led group-based exercise, goal-setting, peer coaching training, individualized home program, and activity monitoring.
2974698|NCT02732366|Active Comparator|Usual PT and attention control grp class|This arm consists of the continuation of one-on-one PT along with participation in an attention control - healthy living class.
2974699|NCT02732353|Active Comparator|Minced beef|Minced beef
2974700|NCT02732353|Experimental|Hydrolyzed beef|Hydrolyzed beef
2974701|NCT02732340|Experimental|triple-branched stent graft|The triple-branched stent graft was a branched 1-piece graft and included a main stent graft and 3 sidearm stent grafts (Yuhengjia Science and Technology, Corp, Ltd, Beijing, China). The main stent graft and sidearm stent grafts were individually mounted on 4 catheters and restrained by 4 silk sutures .The triple-branched stent graft was inserted into the true lumens of the aortic arch and proximal descending aorta; the three vascular stent branches were then grafted into the corresponding true lumens of the aortic arch branch vessels followed by the sequential release of the vascular stent backbone and the branch stents in the left subclavian artery, the left common carotid artery, and the innominate artery.
2974702|NCT02732327|Experimental|CAZ-AVI + Vancomycin or Linezolid|Ceftazidime-Avibactam (CAZ-AVI) 2.5 mg intravenous (IV) infusion every 8 hours for 5 to 14 days, duration determined by the investigator, plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local standard of care [SOC]) may be allowed after at least 72 hours (ie, minimum of 9 doses for CAZ-AVI) of inpatient IV study drug.
2974760|NCT02731820|Experimental|Treatment group|Potassium citrate Calcium carbonate Vitamin D3
2974761|NCT02731820|Placebo Comparator|Control group, Placebo|Placebo (Excipients) Calcium carbonate Vitamin D3
2974703|NCT02732327|Active Comparator|Standard of Care+Vancomycin or Linezolid|Standard of Care (cefepime 2 g IV infusion every 8 hours or meropenem 1 g IV infusion every 8 hours or piperacillin/tazobactam 4.5 g IV infusion every 6 hours for 5 to 14 days, duration determined by the investigator) plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local SOC) may be allowed after at least 72 hours (ie, minimum of 9 doses for SOC therapies, except piperacillin/tazobactam, which is a minimum of 12 doses) of inpatient IV study drug.
2974704|NCT02732314|Experimental|Investigational OTC Cream|Investigational OTC Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
2974705|NCT02732314|Placebo Comparator|Placebo Cream|Placebo Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
2974706|NCT02732314|Active Comparator|Cosmetic Eczema Cream|Cosmetic Eczema Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
2974707|NCT02732314|Active Comparator|0.05% Desonide Cream|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 4 weeks to atopic dermatitis lesions and then on any new lesions that appear for 4 weeks and as directed by the study doctor.~Placebo Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, anywhere the patient would apply their ordinary body moisturizer except atopic dermatitis lesions."
2974708|NCT02732288|Experimental|Melatonin, brain injured patients|Melatonin 3mg, orally, at 8pm, daily for 3 months
2974709|NCT02732288|Experimental|Healthy volunteers|Melatonin 3mg, orally, at 8pm
2974710|NCT02732275|Experimental|DS-3201b|
2974711|NCT02732262|Experimental|Oxycodone, 1.00 mg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 1.00 mg with lock out time of 10 min without basal infusion.
2974712|NCT02732262|Experimental|Oxycodone, 0.03 mg/kg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 0.03 mg/kg with lock out time of 10 min without basal infusion.
2974713|NCT02732262|Experimental|Oxycodone, 0.02 mg/kg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 0.02 mg/kg with lock out time of 10 min without basal infusion.
2974714|NCT02732249|Active Comparator|Triple regimen group|Esomeprazole 20mg bid, clarithromycin 500mg bid and metronidazole 400mg qid for 14 days
2974715|NCT02732249|Experimental|Low metronidazole group|Esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, clarithromycin 500mg bid and metronidazole 400mg bid for 14 days
2974716|NCT02732249|Experimental|High metronidazole group|Esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, clarithromycin 500mg bid and metronidazole 400mg qid for 14 days
2974717|NCT02732223|Experimental|Functional treatment|Daily functional treatment consisted of seven fish oil softgels (1.7g EPA+DHA), two dark chocolate truffles containing plant sterol esters and two green tea sachets.
2974718|NCT02732223|Placebo Comparator|Control treatment|Control treatment consisted of seven soy bean oil softgels, two regular dark chocolate truffles and two anise tea sachets
2974719|NCT02732197||Sedation (S)|Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
2974720|NCT02732197||No sedation (NS)|Parturients who did not receive any sedative agent after the spinal anesthesia performance.
2974721|NCT02732184|Experimental|AEB1102 (Co-ArgI-PEG) administered via IV weekly.|Co-ArgI-PEG modified human arginase I
2974722|NCT02732158|Experimental|Nutrition Products|Two servings per day of the sachet study product mixed with water; 1 carotenoid capsule per day
2974723|NCT02732145||Normal vulva|"Patients without vulvar discomfort and without any vulvar lesion undergoing planned labiaplasty, prior to surgery.~ISSVD Questionnaire, Three Rings Vulvoscopy, Histopathology."
2974724|NCT02732145||Impaired vulvar skin|"Patients without vulvar symptoms with some lesions of the vulva undergoing planned labiaplasty, prior to surgery.~ISSVD Questionnaire, Three Rings Vulvoscopy, Histopathology."
2974725|NCT02732145||Vulvodynia|"Patients with vulvar discomfort especially pain, without specific lesions of the vulva.~ISSVD Questionnaire, Three Rings Vulvoscopy, Histopathology."
2974726|NCT02732145||Vulvar dermatosis|"Patients with vulvar discomfort and specific lesions of the vulva (lesions specific for vulvar dermatosis).~ISSVD Questionnaire, Three Rings Vulvoscopy, Histopathology."
2974727|NCT02732132|Active Comparator|Ketamine and Midazolam|ketamine 1 mg/kg midazolam 0.1 mg/kg
2974728|NCT02732132|Experimental|Propofol and Fentanyl|propofol 1 mg/kg fentanyl 1 mcg/kg
2974729|NCT02732119|Experimental|ribociclib + everolimus + exemestane|ribociclib with everolimus and exemestane daily
2974730|NCT02732093|Active Comparator|stellate block|patients in this arm will receive ultrasonographic guided left stellate block with 6 ml of lidocaine 2% after routine induction of general anesthesia and before endotracheal intubation
2974731|NCT02732093|Placebo Comparator|control|patients in this arm will receive ultrasonographic guided left stellate block with 6 ml normal saline (Na.Cl 0.9%) (control group) after routine induction of general anesthesia and before endotracheal intubation
2974732|NCT02732080|Experimental|Deferred coronary stenting|In this arm, after establishing TIMI -3 flow in infarct related artery with balloon angioplasty, patients will undergo stent implantation when coronary autoregulatory function was recovered (initial hyperemic flow was subsided and baseline resistance was increased). Recovery of the auto regulatory function will be determined by measuring microvascular flow and resistance. After stenting microvascular flow / resistance will continue to be monitored using pressure/flow sensor tipped guide wire until the completion of 1 hour follow up period.
2974733|NCT02732080|Active Comparator|Immediate stenting|In this arm, patients will undergo stenting immediately after balloon angioplasty. After stent implantation, microvascular flow / resistance values will be continuously monitored using pressure/flow sensor tipped guide wire until the end of 1 hour follow up period.
2974734|NCT02732054|Active Comparator|HIV-Group 1|Receiving three intramuscular injections of 20 µg of recombinant hepatitis B vaccine [(CIGB) La Habana, Cuba] at months 0, 1, and 6
2974736|NCT02732015|Experimental|Part 2: Rolapitant Group|"Questionnaires completed at baseline, 1 week before each 21 day cycle, and at end of study visit.~Participants receive up to six weeks of chemotherapy prescribed by their doctor. Doxorubicin on Days 1, 2, 3, completing infusion on Day 4. Mesna given prior to Ifosfamide on Day 1 given simultaneously with Ifosfamide and then daily continuous infusion on Days 1 - 4 completing infusion on day 4. Mesna infusion completes 24 hours after the last dose of Ifosfamide. Ifosfamide by vein on Days 1, 2, 3, 4 Vincristine by vein on Day 1 may be given to participants with sarcomas of small cell histology.~Participants receive Rolapitant by mouth on Day 1 of each 21 day cycle.~Participants also receive Dexamethasone and Ondansetron before chemotherapy, every day for 5 days."
2974737|NCT02732015|Active Comparator|Part 2: Fosaprepitant Group|"Questionnaires completed at baseline, 1 week before each 21 day cycle, and at end of study visit.~Participants receive up to six weeks of chemotherapy prescribed by their doctor. Doxorubicin on Days 1, 2, 3, completing infusion on Day 4. Mesna given prior to Ifosfamide on Day 1 given simultaneously with Ifosfamide and then daily continuous infusion on Days 1 - 4 completing infusion on day 4. Mesna infusion completes 24 hours after the last dose of Ifosfamide. Ifosfamide by vein on Days 1, 2, 3, 4 Vincristine by vein on Day 1 may be given to participants with sarcomas of small cell histology.~Participants receive Fosaprepitant by vein Day 1 of each 21 day cycle. Depending on participant's response, they may also receive Fosaprepitant on Days 1 and 4 of Cycles 2 and beyond.~Participants also receive Dexamethasone and Ondansetron before chemotherapy, every day for 5 days."
2974738|NCT02732015|Experimental|Part 1: Rolapitant Group|"Questionnaires completed at baseline, 1 week before the 21 day cycle, and at end of study visit.~Rolapitant administered as single-dose by mouth on Day 1.~Doxorubicin on Days 1, 2, 3, completing infusion on Day 4. Mesna given prior to Ifosfamide on Day 1 given simultaneously with Ifosfamide and then daily continuous infusion on Days 1 - 4 completing infusion on day 4. Mesna infusion completes 24 hours after the last dose of Ifosfamide. Ifosfamide by vein on Days 1, 2, 3, 4 Vincristine by vein on Day 1 may be given to participants with sarcomas of small cell histology.~Study cycle is 21 days."
2974739|NCT02732002|Experimental|OCBRA group.|This group of patients will follow the proposed methodological approach for work related injuries rehabilitation.
2974740|NCT02731989||study group|The surgeon will estimate the size difference between the undescended and the normally located testis. Independently the ultrasonographer will measure the true size of both testes in the study group.
2974741|NCT02731989||Control group|The same measurments will be done by the surgeon and the ultrasonographer on boys without cryptorchism.
2974742|NCT02731976|Experimental|GFD|After instruction of a dietician, participants adhered to a gluten-free diet for 4 weeks.
2974743|NCT02731963|Experimental|Mechanical bowel preparation|80 Patients who received mechanical bowel preparation with 4 packets of polyethylene glycol in 4 liters of water, 4 hours before intervention.
2974744|NCT02731963|No Intervention|No mechanical bowel preparation|81 Patients who received clear liquid diet 1 day before intervention.
2974745|NCT02731950|Active Comparator|A magnesium|"Consists of 20 patients:~Each receive bupivacaine 0.125% with 5% magnesium sulfate by infusion through a small diameter multi-hole soft catheter generally used for epidural analgesia positioned anterior to the sternum above the fascia in the subcutaneous tissue during wound closure for 48 hours postoperative. A bolus of 5 ml of the study solution will be injected in the catheter after aspiration test before connection to infusion pump that delivers continuous infusion pump that delivers continuous infusion at a fixed rate of 5 ml/h.~postoperative : 25 µg fentanyl for breakthrough pain. placebo will be given in same intravenous instead of paracetamol and ketorolac of group B , to keep the investigator blinded"
2974746|NCT02731950|No Intervention|B control|"Consists of 20 patients:~saline as placebo infusion through a small diameter multi-hole soft catheter positioned anterior to the sternum above the fascia in the subcutaneous tissue during wound closure for 48 Postoperative pain control will be managed with 1gm paracetamol /6 hr, Ketorolac 30 mg every 8-12 hour .25 µg fentanyl for breakthrough pain."
2974747|NCT02731937|Other|GE Healthcare CT Revolution (CT scanner)|Each subject will be scanned twice: the first time will be the subjects' clinically indicated CT exam and the second scan will be performed on the GE Healthcare CT Revolution (CT scanner) both scans will will be obtained.
2974748|NCT02731924||Ultrasound for Appendicitis|Emergency department patients undergoing point-of-care ultrasound to evaluate for suspected appendicitis
2974749|NCT02731911||Ozurdex® (dexamethasone intravitreal implant)|Patients who received Ozurdex® in the treatment of Diabetic Macular Oedema per local standard of care in clinical practice.
2974750|NCT02731885|Experimental|Fasted Conditions|50mg of ABX464 (two 25mg capsules) /Fasted
2974751|NCT02731885|Experimental|Fed Conditions|50mg of ABX464 (two 25mg capsules) /Fed
2974752|NCT02731872|Experimental|High Flow humidification system|In addition to their usual oxygen apparatuses, the treatment group will have an Airvo humidifier system installed in the home. The supplied oxygen flow will be entrained along with room air through the Airvo humidification system. this combined respiratory gas will then be warmed and humidified and delivered to the patient via a nasal cannula. The total respiratory gas flow rate will be between 20-25 l/min, depending on participant´s preference. Then the oxygen fraction is adjusted until the subjects target oxygen saturation levels are achieved.
2974753|NCT02731872|No Intervention|Standard oxygen therapy|The control group will continue receiving the standard oxygen therapy prescribed by the department
2974754|NCT02731859||EndoBarrier|All patients with EndoBarrier treatment
2974755|NCT02731846|Experimental|FF/UMEC/VI (100/62.5/25 mcg) + placebo|Subjects will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg delivered via single ELLIPTA inhaler ('closed' triple) and matching placebo via ELLIPTA inhaler once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
2974756|NCT02731846|Experimental|FF/VI 100 mcg/25 mcg + UMEC 62.5 mcg|Subjects will receive FF/VI (100 mcg/25 mcg) and UMEC 62.5 mcg delivered via two ELLIPTA inhaler ('open' triple) once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
2974757|NCT02731846|Experimental|FF/VI 100 mcg/25 mcg + placebo|Subjects will receive FF/ VI (100 mcg/25 mcg) delivered via single ELLIPTA inhaler and matching placebo via ELLIPTA inhaler once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
2974762|NCT02731807|Experimental|Dose A, B, C, D, E|All participants will receive all doses throughout the course of the study.
2974764|NCT02731807|Experimental|Dose C, D, E, A, B|All participants will receive all doses throughout the course of the study.
2974765|NCT02731807|Experimental|Dose E, D, C, B, A|All participants will receive all doses throughout the course of the study.
2974766|NCT02731794|Experimental|LVA group|LVA group: left ventricular assist group.
2974767|NCT02731794|Active Comparator|BiVA group|BiVA group: Biventricular assist group.
2974768|NCT02731768|Active Comparator|Standard|Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively. They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
2974769|NCT02731768|Experimental|Social support-enhanced|Participants will receive the same intervention components as the Standard group, as well as two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
2974770|NCT02731755|Active Comparator|Oat intervention|66.8g instant oatmeal
2974771|NCT02731755|Placebo Comparator|Control|60g cream of rice
2974772|NCT02731742|Experimental|Dose A MK-1966 + Dose A SD-101|Participants will receive a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants will continue in one of two expansion cohorts (Part B or C) and may receive up to 8 cycles of treatment (approximately 24 weeks).
2974773|NCT02731742|Experimental|Dose A MK-1966 + Dose B SD-101|Participants will receive a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants will continue in one of two expansion cohorts (Part B or C) and may receive up to 8 cycles of treatment (approximately 24 weeks).
2974774|NCT02731742|Experimental|Dose B MK-1966 + Dose B SD-101|Participants will receive a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants will continue in one of two expansion cohorts (Part B or C) and may receive up to 8 cycles of treatment (approximately 24 weeks).
2974775|NCT02731742|Experimental|Dose C MK-1966 + Dose B SD-101|Participants will receive a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants will continue in one of two expansion cohorts (Part B or C) and may receive up to 8 cycles of treatment (approximately 24 weeks).
2974776|NCT02731742|Experimental|Part B Expansion Cohort|Participants will receive the MTD/MAD of MK-1966 and SD-101 established in Part A for 7 additional treatment regimens with MK-1966 and 6 additional treatment regimens with SD-101.
2974777|NCT02731742|Experimental|Part C Expansion Cohort|Participants will receive the MTD/MAD of MK-1966 and SD-101 established in Part A for 7 additional treatment regimens with MK-1966 and 6 additional treatment regimens with SD-101.
2974778|NCT02731729|Experimental|ipilimumab and nivolumab|For patients in the combination arm, nivolumab will first be administered intravenously at a dose of 1 mg/kg of body weight over a period of 60 minutes, once every 3 weeks for four doses. Thirty minutes after the completion of each nivolumab infusion, patients will receive 3 mg/kg of ipilimumab over a period of 30 minutes.
2974779|NCT02731729|Experimental|ipilimumab|In the ipilimumab monotherapy group, patients will receive 3 mg/kg of ipilimumab over a period of 30 minutes once every 3 weeks for four doses.
2974780|NCT02731716|Experimental|New Payment Model|Providers in the first arm will no longer be paid based upon FFS, but on the new payment model. Providers will receive a PMPM payment for attributed members, a quality incentive payment based upon attainment of sixteen quality metrics, and a possible bonus payment for savings in total cost of care at the provider organization level.
2974781|NCT02731716|Experimental|Social Comparisons|Providers will no longer be paid based upon FFS, but on the new payment model. Providers will receive a PMPM payment for attributed members, a quality incentive payment based upon attainment of sixteen quality metrics, and a possible bonus payment for savings in total cost of care at the provider organization level. Providers will also receive weekly emails that will show comparisons of their own performance against their peers within the same provider organization on specific quality measures and total cost of care.
2974782|NCT02731716|Experimental|A1c Member/Provider Incentive|Providers will no longer be paid based upon FFS, but on the new payment model, which includes a PMPM payment for attributed members, a quality incentive payment based upon attainment of quality metrics, and a possible bonus payment for savings in total cost of care. Providers will also receive weekly emails that will show comparisons of their own performance against their peers within the same provider organization on specific quality measures and total cost of care. There is also a shared incentive between the member and the provider. The member incentive will be a payment made to diabetic patients with an A1C of greater than or equal to 9% who experience a reduction of at least 0.5%. Each participating member and PCP can receive up to $75 per quarter for A1C reduction.
2974783|NCT02731703||Overdenture Treatment|Guided maxillary implant placement with palateless overdenture
2974784|NCT02731690|Experimental|Open Label, 6g/day|
2974785|NCT02731677|Experimental|Experimental|Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
2974786|NCT02731677|No Intervention|Control|The control group no suffered intervention.
2974787|NCT02731664|Experimental|GLP-1|Intravenous infusion of GLP-1 at 0.7 and 1.2 mol/kg per minute
2974788|NCT02731664|Placebo Comparator|Control|Intravenous saline
2974789|NCT02731651|Active Comparator|Open Hysterectomy|Open hysterectomy was performed with taking one of the ovaries at the beginning and the other ovary was removed at the end of the surgery.
2974790|NCT02731651|Active Comparator|LaparoscopicAssistedVaginalHysterectomy|Surgery in Group 2 (LAVH): Laparoscopic Assisted Vaginal Hysterectomy was performed with taking one of the ovary at the beginning of the procedure and the other ovary was removed at the end of the surgery.
2974791|NCT02731638|Experimental|Intrastromal voriconazole plus natamycin|Intrastromal voriconazole plus standard of care topical treatment for fungal keratitis
2974792|NCT02731638|Active Comparator|Natamycin alone|Standard of care topical treatment for fungal keratitis
2974793|NCT02731625|Experimental|Kettlebell Training|Army Physical Readiness Training (PRT) with kettlebell training in place of strength training circuits
2974794|NCT02731625|Active Comparator|Army Physical Readiness Training|Army Physical Readiness Training (PRT) per Army Field Manual 7-22
2974795|NCT02731612|Experimental|Lurasidone|Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.
2974796|NCT02731612|Placebo Comparator|Placebo|Placebo added to current treatment for 6 weeks
2974797|NCT02731599|Experimental|treadmill training|20-minutes treadmill training per day, 6 times a week, for 4 weeks
2974798|NCT02731586|Experimental|osseointegration using Allogenic MSC's|Evaluation of Osseointegration of Dental Implants to be done using Allogenic Mesenchymal Stem Cells.Primary and Secondary stability are measured using RFA.
2974799|NCT02731573|Experimental|Treatment arm|Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care with treatment by D-PLEX.
2974800|NCT02731573|Other|Control arm|Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care.
2974801|NCT02731560|Other|Single Arm|Treatment with Rituximab in RA patients showing inadequate response to standard DMARDs
2974802|NCT02731547|Experimental|Intervention group|The intervention group receives a school-based module taking about two hours delivered by medical students in the schools.
2974803|NCT02731547|No Intervention|Control group|
2974804|NCT02731534|Experimental|Z-213|
2974805|NCT02731534|Active Comparator|Saccharated Ferric Oxide|
2974806|NCT02731521||3 Tesla Scanning and 7 Tesla Scanning|Scanning at 3 Tesla and 7 Tesla: Magnetic Resonance Imaging (MRI)/Magnetic Resonance Spectroscopy (MRS) of glioma and non-glioma patients.
2974807|NCT02731508|Experimental|True stimulation|True repetitive bihemispheric transcranial direct current stimulation, anodal at ipsilesional M1 while cathodal at contralesional M1, daily 20 minutes for 10 sessions
2974808|NCT02731508|Sham Comparator|Sham stimulation|Repetitive bihemispheric transcranial direct current stimulation, as the experimental stimulation condition but only for 30 seconds
2974809|NCT02731495|Experimental|EGCG|Participants were randomly divided based on age, sex and severity of TBI in two groups. Randomization lists was computer-generated by a statistician and participants, project managers and employees at the clinic are completely unaware (blind) about intervention and control groups. At the first visit, baseline data were gathered and patients received EGCG supplement was in the form of 400 mg oral capsules with a purity of 80% catechin. EGCG powder of each capsule was dissolved in 10 ml deionized water and given to patients via gavage (1 capsule per day) for a week.
2974810|NCT02731495|Placebo Comparator|Placebo|Placebo group only received 10 ml of deionized water via gavage for a week.
2974811|NCT02731482|Experimental|Training Group|Patients with bronchiectasis in home-based pulmonary rehabilitation
2974812|NCT02731482|Active Comparator|Control Group|Patients with bronchiectasis in usual care and recommendations for performing exercises
2974813|NCT02731469|Experimental|BCD-131, 0.05 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.05 mcg/kg subcutaneously
2974814|NCT02731469|Experimental|BCD-131, 0.15 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.15 mcg/kg subcutaneously
2974815|NCT02731469|Experimental|BCD-131, 0.40 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.40 mcg/kg subcutaneously
2974816|NCT02731469|Experimental|BCD-131, 1.05 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 1.05 mcg/kg subcutaneously
2974817|NCT02731469|Experimental|BCD-131, 1.70 mcg/kg SC|Healthy volunteers will receive BCD-131 in a dose 1.70 mcg/kg subcutaneously
2974818|NCT02731469|Experimental|BCD-131, 2.25 mcg/kg SC|Healthy volunteers will receive BCD-131 in a dose 2.25 mcg/kg subcutaneously
2974819|NCT02731469|Experimental|BCD-131, 4.45 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 4.45 mcg/kg subcutaneously
2974820|NCT02731469|Active Comparator|Mircera®, 1.20 mcg/kg subcutaneously|Healthy volunteers will receive Mircera in a dose 1.20 mcg/kg subcutaneously
2974821|NCT02731469|Active Comparator|Aranesp®, 0.45 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.45 mcg/kg subcutaneously
2974822|NCT02731469|Experimental|BCD-131, optimal dose, intravenously|Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial intravenously
2974823|NCT02731469|Experimental|BCD-131, optimal dose, subcutaneously|Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial subcutaneously
2974824|NCT02731456|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude.
2974825|NCT02731443||ESx|Epilepsy patients undergoing elective surgical resection of brain tissue; study group: epilepsy surgery=ESx.
2974826|NCT02731443||DE|Epilepsy patients undergoing elective depth electrodes insertion in general anesthesia; control group: depth electrodes=DE.
2974827|NCT02731430|Active Comparator|group I: morphine group|received 0.3mg morphine (0.3ml) added to 1.2ml of bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
2974828|NCT02731430|Placebo Comparator|group II: control group|received 0.3ml saline added to 1.2mlof bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
2974829|NCT02731417|Experimental|Urinary retention-group 1|For women with post partum urinary retention designated for experimental treatment.
2974830|NCT02731417|Active Comparator|Urinary retention-group 2|For women with post partum urinary retention designated for current departmental protocol treatment.
2974831|NCT02731404|Other|IPPV ventilation|standard intermittent positive pressure ventilation in patients undergoing laparoscopic cholecystectomy
2974832|NCT02731404|Other|HFJV ventilation|high frequency jet ventilation in patients undergoing laparoscopic cholecystectomy
2974833|NCT02731391|Experimental|Mesh repairment|patients undergoing pelvic floor Reconstruction using mesh
2974834|NCT02731391|Active Comparator|Tradition Neoplasty|patients undergoing traditional surgical approaches
2974835|NCT02731378|Experimental|EPO plus sustained iron dextran|Group 1, EPO treatment at the original dose plus IV iron dextran 200 mg every three weeks (Q3W) for 15 weeks
2974836|NCT02731378|Experimental|EPO plus aggressive iron dextran|Group 2, EPO treatment at the original dose plus IV iron dextran 100 mg, twice a week (BIW) for five weeks
2974837|NCT02731378|Active Comparator|Double EPO|Group 3, the control group, doubling the EPO dose without preplanned iron supplementation
2974838|NCT02731365|Experimental|DBS LFP Activa PC+S|The study aims at testing a slightly modified device (battery) that is similar to the approved system that has the potential of offering future patients a closed loop system with automatic adjustments of stimulation. The purpose of this clinical study is to allow the investigation of local field potential (LFP) signals in patients treated with DBS of the STN. This study will identify common LFP biomarkers observed as a function of disease symptoms, medication effect, fluctuations in disease, and changes resulting from adjustments from current standard practices of DBS programming.
2974839|NCT02731352|Experimental|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
2974840|NCT02731339|Experimental|Women with Urinary incontinence|
2974841|NCT02731339|Experimental|Women without Urinary incontinence|
2974842|NCT02731326|Experimental|iHEART|Participants will transmit daily ECGs using AliveCor for 6 months following cardioversion or ablation procedure to treat AF/AFL. Participants will also receive read-only behavioral altering messaging three times per week focusing on AF, cardiovascular risk factors, and healthy living.
2974843|NCT02731326|No Intervention|Usual Care|Participants will continue with usual care with their physician.
2974844|NCT02731313||Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma|Tumor samples with histologically confirmed gastric or GEJ adenocarcinoma, any stage, were collected and analyzed. No study visits or interventions were planned.
2974845|NCT02731300|Active Comparator|Active tDCS|2 mA of cathodal tDCS placed over M1 for 20 mins
2974846|NCT02731300|Sham Comparator|Sham tDCS|0 mA of sham tDCS placed over M1 for 20 mins
2974847|NCT02731287|Experimental|Timolol|Timolol maleate 0.5% topical solution; 50% of the patients treated (randomized)
2974848|NCT02731287|Placebo Comparator|Placebo|Saline topical solution; 50% of the patients treated (randomized)
2974849|NCT02731274|Experimental|Motor memory consolidation|Subjects were divided in two groups: a control group and an experimental one. Before the intervention of physical exercise program, subjects performed a Tapping Pedal Test to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
2974850|NCT02731274|No Intervention|Control|
2974851|NCT02731261|Experimental|Experimental|
2974852|NCT02731261|No Intervention|Control|
2974853|NCT02731235|Other|Control|Prophylactic stroke medication and recommendations for lifestyle changes
2974854|NCT02731235|Active Comparator|Exercise|Prophylactic stroke medication and recommendations for lifestyle changes AND high-intensity training at home, 5 days a week in 12 weeks
2974855|NCT02731209|Experimental|catheter insertion for 2 weeks|50 randomized patients that will do urodynamic urinary examination and will be inserted urinary catheter for 2 weeks
2974856|NCT02731209|No Intervention|follow up|50 randomized patients that will do urodynamic urinary examination and will be regularly followed by nephrologist
2974857|NCT02731196|Experimental|Early exercise intervention group|Education, stabilization and neurodynamic level one exercises will be provided to the intervention group within one to two weeks following a unilateral lumbar microdiscectomy L3-4, L4-5, L5-S1. Within 4-6 weeks, this group will be provided with education, stabilization and neurodynamic level two exercises and a pedometer to monitor step count between week 4 and week 10 following the surgery.
2974858|NCT02731196|Active Comparator|Late exercise intervention group|Education, stabilization and neurodynamic level one and two exercises will be provided to the active comparator group within 4-6 weeks following a unilateral lumbar microdiscectomy L3-4, L4-5, L5-S1. Within 4-6 weeks, this group will also be given instructions and a pedometer to monitor step count between week 4 and week 10 following the surgery.
2974859|NCT02731183|Experimental|FMT|Patients included will receive standard FMT, and then will be followed up for 8 weeks.
2974860|NCT02731170|Experimental|rehabilitation treatment (MIRT)|MIRT consists of a 4-week physical therapy. daily sessions are subdivided in: motor treatment (2 hour), occupational therapy (1 hour) and speech Therapy (1 hour)
2974861|NCT02731157|Experimental|Transfusion with rejuveniated red blood cells (RBCs)|Subjects with sickle cell disease will receive RBCs treated with Rejuvesol. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
2974862|NCT02731157|Active Comparator|Transfusion with standard red blood cells|Subjects with sickle cell disease will receive standard RBCs. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
2974863|NCT02731144|Experimental|Study group|Individualization of caloric administration with indirect calorimetry and 2.0 to 2.2 g/kg/day of protein. Early initiation of nutritional support (24 hours of admission)
2974864|NCT02731144|Active Comparator|Control group|Nutritional support initiated in the first 24 hours of admission. Protein and caloric goals calculated as 25 Kcal/kg/day and 1.4 to 1.5 g/kg/day of protein.
2974865|NCT02731131|Experimental|Group A: Monotherapy with Peginterferon alfa-2a|Participants will receive peginterferon alfa-2a alone, administered over 48 weeks.
2974866|NCT02731131|Experimental|Group B: Combination with Peginterferon alfa-2a + Ribavirin|Participants will receive combination therapy with peginterferon alfa-2a plus ribavirin, administered over 48 weeks.
2974867|NCT02731118|Experimental|Placebo and Salovum|6 times 4 gr placebo/Salovum day 1-2, 5 times 4 gr placebo/Salovum day 3-5, 4 times 4 gr placebo/Salovum day 6-14
2974868|NCT02731118|Experimental|Salovum and placebo|6 times 4 gr Salovum/placebo day 1-2, 5 times 4 gr Salovum/placebo day 3-5, 4 times 4 gr Salovum/placebo day 6-14
2974869|NCT02731105|Active Comparator|Arm 1|Acnatac® Gel on left face and Epiduo® Gel on right face once daily for three weeks
2974870|NCT02731105|Active Comparator|Arm 2|Epiduo® Gel on left face and Acnatac® Gel on right face once daily for three weeks
2974871|NCT02731092|Experimental|Lactoferrin 100 mg/kg|100 mg/kg enteral administration daily for 30 days
2974872|NCT02731092|Experimental|Lactoferrin 200 mg/kg|200 mg/kg enteral administration daily for 30 days
2974873|NCT02731092|Experimental|Lactoferrin 300 mg/kg|300 mg/kg enteral administration daily for 30 days
2974874|NCT02731079|Active Comparator|Covidien|Group that will have sleeve gastrectomy performed using the Covidien iDrive powered stapler with absorbable polymer membrane staple line reinforcement.
2974875|NCT02731079|Active Comparator|Ethicon|Group that will have sleeve gastrectomy performed using the Ethicon Echilon powered stapler with absorbable polymer membrane staple line reinforcement.
2974876|NCT02731066|Experimental|High pro, carbo bev|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing ~1.8 g carbohydrate/min.
2974877|NCT02731066|Experimental|Standard pro, carbo bev|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing ~1.8 g carbohydrate/min.
2974878|NCT02731066|Experimental|High pro, placebo bev|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
2974879|NCT02731066|Experimental|Standard pro, placebo bev|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
2974880|NCT02731053|Experimental|Blues program|Participants will attend 6 weekly 1-hour sessions of group cognitive-behavioral therapy administered by school staff, and will do home practice between sessions and after the program individually using a web site (called the Blues App)
2974881|NCT02731053|No Intervention|Control|Participants will receive a brochure describing the nature, causes, and consequences of depression, as well as available prevention/treatment options
2974882|NCT02731040||Controls|Women who are/have been on bisphosphonate therapy for osteoporosis who have not suffered an atypical femoral fracture
2974883|NCT02731040||Fracture Group|Women who are/have been on bisphosphonate therapy for osteoporosis who have suffered an atypical femoral fracture
2974884|NCT02731027||Healthy Controls|
2974885|NCT02731027||Participants with Spinal Cord Injury|
2974886|NCT02731014|Experimental|Dry Needling Group|Dry Needling, Manual Therapy, and Exercise.
2974887|NCT02731014|Sham Comparator|Sham Dry Needling Group|Sham Dry Needling, Manual Therapy, and Exercise.
2974888|NCT02731001|Experimental|Proton therapy|Patients within the proton arm will receive 66 Gy(RBE) delivered with 6 fractions per week.
2974889|NCT02731001|Active Comparator|Photon therapy|Patients within the photon arm will be treated by intensity modulated radiotherapy with 6 fractions per week to a total dose of 66 Gy.
2974890|NCT02730988|Experimental|Weight Loss Lifestyle Counseling|The high protein weight loss group follows the Medifast 4 & 2 & 1 Plan™, a 1200 calorie, high protein diet targeting ~10% weight loss over 24-weeks through a combination of meal replacement products (MRPs), meal plans, and individual nutrition/behavioral counseling. Participants are guided by the study RD on food purchasing and preparation and encouraged to consume only what is approved from the menu. Participants meet bi-weekly for RD-lead behavioral counseling group classes to provide support and introduce new topics in behavioral weight control. Weight is also measured at each session with progress feedback provided to increase motivation. Participants complete daily food logs to verify compliance to the diet.
2974891|NCT02730988|Active Comparator|Weight Stable Lifestyle Counseling|The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 & 2 & 1 Plan.
2974892|NCT02730975|Experimental|AA Reduced dose-normal diet (A)|Abiraterone acetate at reduced dose of 250 mg po daily in cycles of 28 days administered with a standard breakfast
2974893|NCT02730975|Experimental|AA reduced dose-fat diet (B)|Abiraterone acetate at reduced dose of 250 mg po daily in cycles of 28 days administered with a fat breakfast
2974894|NCT02730975|Active Comparator|AA normal dose-fasting conditions (C)|Abiraterone acetate at approved dose of 1000 mg po daily in cycles of 28 days administered in fasting conditions
2974895|NCT02730962|Experimental|Antibiotics prior to FMT|One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.
2974896|NCT02730962|Placebo Comparator|Placebo prior to FMT|One week prior to FMT, a course of three sugar pills identical to each antibiotic.
2974897|NCT02730949|Experimental|1 g D-chiro-Inositol + 400 mcg Folic Acid|1 g D-chiro-Inositol + 400 mcg folic acid once daily
2974898|NCT02730949|Active Comparator|400 mcg folic|400 mcg folic acid only once daily
2974899|NCT02730936|Experimental|Antimicrobial Hernia Repair Device|Antimicrobial hernia repair device for repair of ventral or incisional hernias in Class II and III surgical fields.
2974900|NCT02730923|Experimental|Arm A: AZD2014 plus anastrozole|
2974901|NCT02730923|Active Comparator|Arm B: anastrozole alone|
2974902|NCT02730910|Experimental|Purple Wheat Crackers|Bran-enriched purple wheat wholegrain crackers served in 120 g portion.
2974903|NCT02730910|Experimental|Purple Wheat Granola Bars|Bran-enriched purple wheat wholegrain granola bars served in 160 g portion.
2974904|NCT02730897||VATS|Patients operated by means of minimal invasive technique (VATS or roboticVATS)
2974905|NCT02730897||Open|Patients operated by means of open thoracotomy
2974906|NCT02730884|Experimental|Rigosertib|Participants receive oral Rigosertib under fasting conditions twice a day on a continuous basis. Quality of life questionnaire completed on Day 1 of Cycle 1.
2974907|NCT02730871|Experimental|Simbrinza|Brinzolamide 1%/Brimonidine 0.2% suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) for 42 days (Treatment Phase)
2974908|NCT02730871|Placebo Comparator|Vehicle|Brinzolamide/Brimonidine vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) for 42 days (Treatment Phase)
2974909|NCT02730858|Experimental|Palliative and oncology care model|"After the screening procedure confirm eligibility to participate in the research study. Participants will be randomized into one of two study groups;~-- Standard oncology care with palliative care."
2974910|NCT02730858|Active Comparator|Standard oncology care|"After the screening procedure confirm eligibility to participate in the research study. Participants will be randomized into one of two study groups;~-- Standard oncology care"
2974911|NCT02730845|Active Comparator|Intra-articular dexmedetomidine|Patients will be subjected for elective knee arthroscopy under local anesthesia (Intra-articular dexmedetomidine + Intra-articular bupivacaine).
2974912|NCT02730845|Placebo Comparator|Intravenous dexmedetomidine|patients will be subjected for elective knee arthroscopy under local anesthesia (i.v. dexmedetomidine + Intra-articular bupivacaine).
2974913|NCT02730832|Experimental|Patients with schizophrenia|
2974914|NCT02730819|Experimental|Illuminate Cream|Illuminate Cream is a skin-lightening formulation containing multiple drugs, including a retinoid, calcineurin inhibitor, anti-tyrosinase agent and sunscreen microfine zinc oxide. Approximately 0.5 grams to be applied topically to affected areas of skin once per day for 20 weeks.
2974915|NCT02730806|Active Comparator|Group Therapy PTSD intervention protocol|Behavioral intervention (psychological) - intervention method will be 12 weekly PTSD-oriented Psychotherapy Group Therapy meetings led by a certified physiatrist, implementing the common PTSD protocol used at Macccabi Healthcare Services, such as Cognitive Behavioral Therapy (CBT) for PPPTSD cases
2974916|NCT02730806|Active Comparator|NLP PTSD intervention protocol|Behavioral intervention (NLP) - intervention method will be 5 weekly personal therapy and counseling sessions with a certified therapist specializing in NLP, implementing the NLP PTSD protocol, such as Visual Kinesthetic Dissociation (VKD) behavioral technique for PPPTSD cases
2974917|NCT02730793|Active Comparator|Standard Therapy|Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Nasal Placebo-Normal Saline twice per day
2974918|NCT02730793|Experimental|Study Therapy|Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Experimental- Nasal Aztreonam 75 mg twice per day
2974919|NCT02730780|Other|African-American|40 healthy African-American subjects will be enrolled and each will undergo study procedures at 4 separate visits, with each visit occurring 7-days apart. After a baseline visit, the subject will begin either a low-salt or high-salt diet, based upon randomization assignment to one of the two following dietary protocols: A) low-salt diet, washout, then high-salt diet; or B) high-salt diet, washout, then low-salt diet. Each dietary or washout period lasts for 7 days.
2974920|NCT02730780|Other|Whites|40 healthy white subjects will be enrolled and each will undergo study procedures at 4 separate visits, with each visit occurring 7-days apart. After a baseline visit, the subject will begin either a low-salt or high-salt diet, based upon randomization assignment to one of the two following dietary protocols: A) low-salt diet, washout, then high-salt diet; or B) high-salt diet, washout, then low-salt diet. Each dietary or washout period lasts for 7 days.
2974921|NCT02730767|Experimental|Intervention Group|Partially supervised exercise intervention: Survivors in the intervention group will be asked to add at least 2.5 hours of intense physical activities per week. These should include at least 30 min of strength building exercises and 2 hours of aerobic exercises per week. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
2974922|NCT02730767|No Intervention|Control Group|The control group will keep their physical activity level constant over the 1 year of the study. Thereafter, they will have the opportunity to receive the same intervention than the intervention group had received (off-trial) to benefit in the same way from an active lifestyle.
2974923|NCT02730741|Experimental|Lcr restituo® sachet and placebo|The active treatment (Total freeze-dried culture of Lcr restituo® sachet) at a rate of 2 sachets of 1.5 grams per day (one sachet in the morning and one in the evening) and the placebo at a rate of 2 sachets of 1.5 grams per day (one sachet in the morning and one in the evening).
2974924|NCT02730741|Experimental|Lcr restituo® sachet|The active treatment (Total freeze-dried culture of Lcr restituo® sachet) at a rate of 4 sachets of 1.5 grams per day (two sachets in the morning and two in the evening).
2974925|NCT02730741|Placebo Comparator|Placebo|The placebo at a rate of 4 sachets of 1.5 grams per day (two sachets in the morning and two in the evening).
2974926|NCT02730728|Active Comparator|Single shot adductor canal block|adductor canal block group will receive single shot adductor canal block with 20ml bolus of 0.5% ropivicaine for analgesia after TKA
2974927|NCT02730728|Active Comparator|24 hour continuous adductor canal block|adductor canal block group will receive 24 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
2974928|NCT02730728|Active Comparator|48 hour continuous adductor canal block|adductor canal block group will receive 48 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
2974929|NCT02730715|Other|Thymoglobulin|blood specimen collection
2974930|NCT02730715|Other|Basiliximab|blood specimen collection
2974931|NCT02730689|Experimental|A group|DP-R207 >> rosuvastatin+ezetimibe
2974932|NCT02730689|Active Comparator|B group|rosuvastatin+ezetimibe >> DP-R207
2974933|NCT02730676||Electronic Cigarette #1|VUSE® Original Digital Vapor Cigarettes (29 mg nicotine)
2974934|NCT02730676||Electronic Cigarette #2|VUSE® Menthol Digital Vapor Cigarettes (29 mg nicotine)
2974935|NCT02730663|Experimental|Niti-S SPAXUS Stent|Niti-S SPAXUS Stent (TaeWoong Medical Co., Ltd. Korea)
2974936|NCT02730650|Experimental|Platelet Rich Therapy|Each subject will receive six injections of Platelet Rich Plasma (PRP) at designated points on each side of their face (twelve total). Injection points are spaced evenly across the inferior border of the cheek and mid-cheek, and are consistent on each patient. Patients will receive a post-injection phone call within 48 hours of the procedure. Photographs will be taken at two time points as part of the research to serve as a point of comparison before and after platelet rich plasma. Patients will receive the Global Aesthetic Improvement Scale amd tje Face-Q Questionnaire 1 month post-op
2974937|NCT02730637|No Intervention|Standard care|Patients with elevated biomarkers receive a standard treatment.
2974938|NCT02730637|Active Comparator|Interventional care|Patients in the interventional population receive an early nephrologist consultation which deliberates with attending doctor on preventing measures according to AKI-KDIGO recommendations.
2974972|NCT02730364|No Intervention|No Treatment|Participants in this arm will not receive any medication
2974939|NCT02730624|Experimental|piperacillin/tazobactam|4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h
2974940|NCT02730611||Patients|Patients with morbid obesity and vertical sleeve gastrectomy
2974941|NCT02730598|Experimental|Hybrid Training System (HTS)|HTS stimulation while walking at a comfortable pace for 30 minutes.
2974942|NCT02730598|Active Comparator|Transcutaneous Electrical Nerve Stimulation (TENS)|Sensory TENS while walking at a comfortable pace for 30 minutes.
2974943|NCT02730585||Acute appendicitis|all patients admitted to our hospital with a clinically suspected acute appendicitis.
2974944|NCT02730572||Concerta to authorized generic (AG) formulation|Participants in the Truven Commercial Claims and Encounters (CCAE) database who enroll in the study will have a confirmed diagnosis of ADHD and continuously using Concerta for at least 60 days. Participants who will switch from Concerta to AG formulation will be observed.
2974945|NCT02730572||Concerta to equivalent generic (EG) formulation|Participants in the Truven Commercial Claims and Encounters (CCAE) database who enroll in the study will have a confirmed diagnosis of ADHD and continuously using Concerta for at least 60 days. Participants who will switch from Concerta to EG formulation will be observed.
2974946|NCT02730559|Experimental|Intervention Group|Group A (Parent-adolescent dyads)
2974947|NCT02730559|Active Comparator|Control Group - Active Comparator|Group B (Adolescents only)
2974948|NCT02730546|Experimental|Treatment (pembrolizumab, chemotherapy, radiation, surgery)|See Detailed Description
2974949|NCT02730533|Active Comparator|Control group|No PPI treatment should given after the initial allocation. Patient will be admitted, and ESD will be performed. Then a 3-day i.v. treatment of esomeprazole will be initiated after ESD procedure and followed by a 26 days oral treatment with esomeprazole tablets 40 mg.
2974950|NCT02730533|Experimental|Esomeprazole group|Esomeprazole should start as soon as possible after the initial allocation. During the 7 days of p.o. treatment, patient will be admitted, and ESD will be performed as soon as completing the p.o. treatment. Then a 3-day i.v. treatment of esomeprazole will be initiated after ESD procedure and followed by a 26 days oral treatment with esomeprazole tablets 40 mg.
2974951|NCT02730520||Immuno-allergology patients|Patients followed within the Immuno-Allergology Service of the CHU Brugmann Hospital, who received an allergy assessment between 01/01/2015 and 31/12/2015. At least 1400 dermis will be analyzed. The allergens tested include: dermatophagoides pteronyssinus (DEPT), dermatophagoides farinae (DPF), blomia, cat, dog, cockroach, orchardgrass, timothy grass, alder, hazel,birch, olive tree, cypress, ash, latex, aspergillus, alternaria, cladosporium, peanut, hazel.
2974952|NCT02730507|Experimental|PSR|Bras A : 167 patients in the experimental PSR group. Surgery with patient-specific rod, which are designed according to the preoperative surgical planning of the surgeon in collaboration with the manufacturer.
2974953|NCT02730507|Active Comparator|Conventional rod|Bras B: 167 patients in the experimental conventional rod group
2974954|NCT02730494|Active Comparator|Lcr Regenerans® vaginal capsule|Name: Lcr Regenerans® containing at least 10e7 CFU per intravaginal capsule. 1 vaginal capsule per day
2974955|NCT02730494|Experimental|Lcr Regenerans® vaginal tablet every 3 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 3 days
2974956|NCT02730494|Experimental|Lcr Regenerans® vaginal tablet every 4 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 4 days
2974957|NCT02730494|Experimental|Lcr Regenerans® vaginal tablet every 5 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 5 days
2974958|NCT02730481|Experimental|ORAXOL|"Oraxol (paclitaxel + HM30181AK-US) Oraxol paclitaxel - supplied as 30-mg capsules~Oraxol HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
2974959|NCT02730455|Experimental|natalizumab high dose|Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
2974960|NCT02730455|Experimental|natalizumab low dose|Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
2974961|NCT02730455|Experimental|Placebo|Single dose of Placebo IV at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
2974962|NCT02730442|Experimental|Single dose F901318 with fluconazole|AUC0-t for F901318 will be assessed before and after 5 days of treatment with fluconazole oral
2974963|NCT02730429|Placebo Comparator|Letrozole + placebo|"letrozole 2.5mg once daily days 1-28 every 28 days shall be administered until progression of disease or unacceptable toxicity. Letrozole is administered as standard of care in both study arms.~Placebo for palbociclib once daily days 1-21 every 28 days shall be administered until progression of disease or unacceptable toxicity."
2974964|NCT02730429|Experimental|Letrozole + palbociclib|"Palbociclib 125mg once daily days 1-21 every 28 days shall be administered until progression of disease or unacceptable toxicity.~letrozole 2.5mg once daily days 1-28 every 28 days shall be administered until progression of disease or unacceptable toxicity.~Letrozole is administered as standard of care in both study arms."
2974965|NCT02730416|Experimental|A: Nintedanib|Nintedanib 200mg twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatin-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
2974966|NCT02730416|Placebo Comparator|B: Placebo|Placebo twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatib-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
2974967|NCT02730403||Opioid Use Disorder Patients|
2974968|NCT02730390||Probucol Tablets|Target is 3,000 patients in the Philippines diagnosed with hyperlipidemia (including familial hypercholesterolemia and xanthoma).
2974969|NCT02730377|Experimental|Liraglutide 1.8 mg|Add-on to metformin
2974970|NCT02730377|Active Comparator|OAD|Add-on to metformin. Treatment with one OAD selected at the discretion of the investigator. Subjects randomised to the OAD arm must remain on the same OAD throughout the trial.
2974971|NCT02730364|Experimental|Theraflu night powder|Participants will receive a single dose (1 sachet) of Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
2974973|NCT02730351|Experimental|FF/VI 100/25 mcg + Placebo DISKUS®/ ACCUHALER®|Randomised subjects will receive FF/VI 100/25 mcg once daily via ELLIPTA inhaler and placebo twice daily via DISKUS / ACCUHALER for 2 weeks in Period 1. There will be a washout period of 2 weeks between treatment periods in which subjects will receive FP 250 mcg twice daily. Subjects will receive FP 250 mcg twice daily via DISKUS inhaler and placebo once daily via ELLIPTA inhaler for 2 weeks in Period 2.
2974974|NCT02730351|Experimental|FP 250 mcg + Placebo ELLIPTA®|Randomised subjects will receive FP 250 mcg twice daily via DISKUS inhaler and placebo once daily via ELLIPTA inhaler for 2 weeks in Period 1. There will be a washout period of 2 weeks between treatment periods in which subjects will receive FP 250 mcg twice daily. Subjects will receive FF/VI 100/25 mcg once daily via ELLIPTA inhaler and placebo twice daily via DISKUS inhaler for 2 weeks in Period 2.
2974975|NCT02730338|Active Comparator|Exercise Group|High intensity aerobic and resistance training- supervised exercise tapering to self management with psychosocial support
2974976|NCT02730338|Other|Control Group|Psychosocial support only
2974977|NCT02730325|Active Comparator|SBI 10 g BID|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10.0 grams twice per day
2974978|NCT02730325|Placebo Comparator|Placebo BID|Placebo
2974979|NCT02730312|Experimental|XmAb14045|Biological/Vaccine: XmAb14045 Administered IV weekly up to 8 weeks
2974980|NCT02730299|Experimental|NiCord|"NiCord® is a cryopreserved stem/progenitor cell based product comprised of:~ex vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells (NiCord® cultured fraction (CF))~the non-cultured cell fraction of the same Cord Blood Unit (CBU) (NiCord® Non-cultured Fraction (NF)) consisting of mature myeloid and lymphoid cells.~Both fractions, i.e. NiCord® CF and NiCord® NF, will be kept frozen until they are thawed and infused on the day of transplantation."
2974981|NCT02730299|Active Comparator|Unmanipulated CBU(s)|
2974982|NCT02730273|Experimental|Trial Nasal Mask|Participants to use nasal mask in-home for a week and one night in lab overnight polysomnography.
2974983|NCT02730260|Active Comparator|Directive|Participants receive up to 7 directive smoking cessation coaching telephone calls from the quitline over 9 weeks.
2974984|NCT02730260|Experimental|Nondirective|Participants receive up to 7 nondirective smoking cessation coaching telephone calls from the quitline over 9 weeks.
2974985|NCT02730247|Experimental|ramucirumab + nab-paclitaxel|"Ramucirumab will be administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.~The nab-paclitaxel will be administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle."
2974986|NCT02730234|Experimental|JetStream XC with balloon angioplasty|The intervention consists of JetStream atherectomy of femoropopliteal in-stent restenosis using the JetStream XC device followed by adjunctive balloon angioplasty in all patients.
2974987|NCT02730221||Patients admitted during measurement 1|All patients admitted to the Intensive Care and Medium Care Unit during a two-week study period before the implementation of a new electronic patient data management system
2974988|NCT02730221||Patients admitted during measurement 2|All patients admitted to the Intensive Care and Medium Care Unit during a two-week study period after the implementation of a new electronic patient data management system
2974989|NCT02730208|Experimental|VX-661/ivacaftor|Fixed-dose combination tablet of VX-661 100-mg/ivacaftor 150-mg and an evening dose of ivacaftor 150-mg to be taken approximately 12 hours after the morning dose
2974990|NCT02730208|Experimental|Placebo|visually-matched tablets to be taken on the same schedule as the active treatment.
2974991|NCT02730195|Experimental|Pioglitazone & TKI therapy|Patients receive pioglitazone PO QD on days 1-28. Patients also start or continue the same tyrosine kinase inhibitor (TKI) therapy at the pre-discontinuation doses. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
2974992|NCT02730182|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
2974993|NCT02730169|Experimental|Regimen 1|Drug: BGS649 Dose 1 weekly
2974994|NCT02730169|Experimental|Regimen 2|Drug: BGS649 Dose 2 weekly
2974995|NCT02730169|Experimental|Regimen 3|Drug: BGS649 Dose 3 weekly
2974996|NCT02730169|Placebo Comparator|Regimen 4|Placebo weekly
2974997|NCT02730156|Experimental|Altitude exposure|Acute high altitude exposure followed by 7 day acclimatization and reexposure after 7 days at low altitude
2974998|NCT02730143|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure after 6 days at low altitude
2974999|NCT02730130|Experimental|Pembrolizumab Plus Radiotherapy|Subjects will receive pembrolizumab 200 mg as an IV infusion. RT begins D1 prior to dose 1 of Pembrolizumab. Pembrolizumab will be administered as a 30 minute IV infusion. Radiotherapy will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice. The dose of radiation will be a standard regimen/fractionation used in palliation: 3000 cGy, delivered in five 600 cGy fractions within 5-7 days.
2975000|NCT02730117|Experimental|Early renal replacement therapy|"Dialysis with continuous renal replacement therapy machine e.g. Aquarius, Prismaflex, Infomed, starting within 12 hours after randomization~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate"
2975001|NCT02730117|Placebo Comparator|Conventional renal replacement therapy|"Dialysis with continuous renal replacement therapy machine e.g. Aquarius, Prismaflex, Infomed, after the patients reached at least one of the following criteria;~pH < 7.15 or serum HCO3 < 15 mEq/L~serum K >= 6 mEq/L~Signs of volume overload or P/F ratio < 200~BUN > 60 mg/dL~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate"
2975002|NCT02730104||Cohort A: Patients with small bowel NET|Patients with small bowel NET (including appendiceal NETs)
2975003|NCT02730104||Cohort B: Patients with gastric NET|Patients with gastric NET (gastroduodenal)
2975004|NCT02730104||Cohort C: Patients with pancreatic NET|
2975005|NCT02730104||Cohort D: Patients with colorectal NET|Patients with colorectal NET (this includes mid-gut)
2975006|NCT02730104||Cohort E: Unknown primary tumor|
2975007|NCT02730091|Active Comparator|Letrozole or anastrozole|Letrozole 2,5 mg once a day or anastrozole 1 mg once a day until disease progression, unacceptable toxicity, patient's refusal, consent withdrawal, death, or discontinuation from the study treatment for any other reason.
2975008|NCT02730091|Experimental|Vinorelbine + Anastrozole or letrozole|Oral vinorelbine 50 mg (1 soft capsule of 30 mg and 1 soft capsule of 20 mg) three times a week every ( Monday, Wednesday and Friday) before lunch and letrozole 2,5 mg once a day or anastrozole 1 mg once a day until disease progression, unacceptable toxicity, patient's refusal, consent withdrawal, death, or discontinuation from the study treatment for any other reason.
2975009|NCT02730078|Active Comparator|Attention-meetings (AG)|Attention-control
2975010|NCT02730078|Experimental|VEMOFIT (VG)|Personal value exploration, disease education, emotional skills and goal setting.
2975011|NCT02730065|Active Comparator|Structured Aerobic Dance Training Group|Active intervention will last for 24 weeks and consists of 60-minute/session, which includes 10 minutes warm-up, 40 minutes of dancing and 10 minutes of cool down. In groups of 5, participants will practice the dance led by a physiotherapist once per week for the first 2 months and twice per week for 3rd to 6th month.
2975012|NCT02730065|Placebo Comparator|Stretching plus education|Participants in the control group will receive a weekly 3-hour group-based (group of 5 participants) programme containing stretching exercise, stress reduction and health education on dementia and stroke prevention for 6 months. The programme consists of low-intensity seated stretching, psychoeducation on stress management, various relaxation methods with practice as well as education on the causes, identification, treatment and prevention of stroke and dementia. Benefits of physical exercise will also be discussed but will its weight will be evenly balanced with other forms of evidence-based preventive strategies.
2975013|NCT02730052|Active Comparator|Omron 9200T without Telemonitoring|In the control group doctors will receive information on the self-measured blood pressure as recorded at home via a diary card.
2975014|NCT02730052|Experimental|Omron 9200T plus Telemonitoring|In the intervention group, doctors will receive weekly reports via telemonitoring of self-measured blood pressure.
2975015|NCT02730039||Cancer Care Providers|"Provider will attend a MCPT two-day intensive workshop that will include:~Didactic Components~Experiential Exercises~Simulated patient role plays with actors~Provider completes MCPT Workshop Assessment MCPT POST-WORKSHOP IMPLEMTATION (OPTIONAL)~MCP Core Competency Trainer rated Assessment~MCP Pre & Post Workshop Knowledge Assessment~MCPT Session Evaluation Assessment Provider will participate in training follow-up calls & webinars for approximately 6 -12 months following completion of MCPT workshop.~Provider will have ongoing access to MCPT Website with a discussion board, training resources and materials for clinical care.~Provider will complete follow-up assessment at 3, 6, 9, & 12 months post-training~Training Update~Goal Evaluation Form~MCP Core Competency Self-Assessment MCPT POST-WORKSHOP IMPLEMTATION (OPTIONAL)"
2975016|NCT02730026|Experimental|Surgery with Ketoprofen|Fifty healthy volunteers underwent removal one of lower third molar, will be treated to control pain, swelling and trismus with ketoprofen 100 mg
2975017|NCT02730026|Experimental|Surgery with Ketoprofen and Omeprazole|Fifty healthy volunteers underwent removal the other lower third molars, will be treated to control pain, swelling and trismus with ketoprofen 200 mg associated with Omeprazole 20 mg
2975018|NCT02730013|Experimental|Square Stepping Exercise|Square-Stepping Exercise (SSE) Intervention Participants in this group will attend a square-stepping exercise intervention 60 minutes: 5 minute for attendance, 5-10 minute warm-up 40-45 minute SSE and 5-10 minute cool-down, on two days a week for a duration of 12 weeks.
2975019|NCT02730013|No Intervention|Usual-care wait-list control|This group will receive standard care and be invited to partake in the intervention after all assessments have been completed.
2975020|NCT02730000|Active Comparator|ART with Equia|Occlusal-proximal restoration in primary molars using Equia (Easy/Quick/Unique/Intelligent/Aesthetic) from GC Corp, encapsulated, pre-dosed and mechanized handling.
2975021|NCT02730000|Experimental|ART with Riva Self Cure|Occlusal-proximal restoration in primary molars using Riva Self Cure from SDI, encapsulated, pre-dosed and mechanized handling.
2975022|NCT02729987|Experimental|Minimum Support Group (MSG)|Intervention group with 8 week access to the online stress management programme with minimal support from a coach (WorkGuru).
2975023|NCT02729987|Experimental|Discussion Group|Intervention group with 8 week access to the online stress management programme with minimal support from a coach, plus access to an online facilitated messaging board (WorkGuru).
2975024|NCT02729987|No Intervention|Waiting List Control (WLC)|Control group with access to the intervention after 16 weeks
2975025|NCT02729974|Experimental|ROTEM|Participants randomized to this arm will have rapid testing of hematocrit and clotting function every 30 minutes during the hysterectomy portion of their surgery for placenta accreta, with transfusion of blood products based on defined abnormalities in these tests.
2975026|NCT02729974|Active Comparator|Standard treatment|Participants randomized to this arm will have standard visual assessment of blood loss and standard laboratory studies to assess blood count and clotting function when indicated during the hysterectomy portion of their surgery for placenta accreta. Transfusion of blood products will be based on abnormalities of these test results.
2975027|NCT02729961|Experimental|Treatment (brentuximab vedotin, ceritinib)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Patients also receive ceritinib PO QD on days 8-21 of course 1 and on days 1-21 for all subsequent courses. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
2975028|NCT02729948|Experimental|Screening (TCE)|Patients swallow the TCE and undergo endoscopic examination while they are seated on a standard endoscopy gurney. Patients undergo standard of care EGD on the same day.
2975029|NCT02729935|Experimental|Parecoxib|40 mg of intravenous parecoxib (DYNASTAT )30 min before surgery
2975030|NCT02729935|Placebo Comparator|Placebo|An equal volume of saline
2975031|NCT02729909|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
2975032|NCT02729909|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
2975033|NCT02729896|Experimental|Dose-Escalation Phase|During the induction treatment Cycle 1 (21-day cycles): participants will receive obinutuzumab on Days 1, 8, and 15 and Pola on Day 1; Cycles 2-6: participants will receive obinutuzumab on Day 1, Atezo on Day 1, and Pola on Day 1. This is followed by obinutuzumab on Day 1 of every other month starting with Month 1 and Atezo on Days 1 and 2 of each month for 24 months, during maintenance treatment for FL participants.
2975088|NCT02729558|Active Comparator|local stereotactic radiotherapy (SRT)|local SRT in three fractions of 8 Gy to the surgical cavity
2975034|NCT02729896|Experimental|Expansion Phase|"For FL during the induction treatment Cycle 1 (21-day cycles): participants will receive obinutuzumab on Days 1, 8, and 15 and Pola at identified RP2D (decided from dose-escalation phase) on Day 1; Cycles 2-6: participants will receive obinutuzumab on Day 1, Atezo on Day 1, and Pola at RP2D on Day 1. This is followed by obinutuzumab on Day 1 of every other month starting with Month 1 and Atezo on Days 1 and 2 of each month for 24 months (during maintenance treatment for FL participants).~For DLBCL, during consolidation treatment participants will receive rituximab on Day 1 of every other month starting with Month 1 and Atezo on Days 1 and 2 of each month for 8 months."
2975035|NCT02729896|Experimental|Safety Run-In Phase|For DLBCL, during the induction treatment Cycle 1 (21-day cycles): participants will receive rituximab on Day 1 and Pola on Day 1. Cycles 2-6: participants will receive rituximab on Day 1, Atezo on Day 1, and Pola on Day 1.
2975036|NCT02729883|Experimental|Supportive care (Take the Fight)|Patients receive patient navigation via strategists from the Take the Fight for 8 weeks. Patients also complete interviews regarding perceived physical, logistical, psychosocial, and informational challenges experienced prior to meeting with strategists/navigators and how challenges were addressed by navigator or others, perceived benefits or limitations of navigator assistance. Strategists also complete interviews regarding their perceptions on how patients benefited from participation, challenges patients experienced that were directly or indirectly related to their cancer diagnosis and treatment, how these concerns were addressed, barriers to addressing these concerns, and patient health literacy.
2975037|NCT02729870||Oral Glucose Gel|This group will consist of participants ages 1 - 7. The subject who are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
2975038|NCT02729870||Oral Placebo Gel|The group will consist of participants ages 1 - 7. The subjects who are less than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3- 7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
2975039|NCT02729857|Experimental|Familial hypercholesterolemia|Subjects diagnosed with familial hypercholesterolemia receive in randomized order muffin with saturated fat (SFA muffin) and polyunsaturated fat (PUFA muffin) at baseline
2975040|NCT02729857|Active Comparator|Healthy|Subjects with no chronic diseases receive in randomized order muffin with saturated fat (SFA muffin) and polyunsaturated fat (PUFA muffin) at baseline
2975041|NCT02729844||Neolifes Heart|All premature infants, admitted at the neonatal intensive care unit (NICU) of the University Medical Centre Groningen, born <30 weeks or birth weight < 1000 gram, who participate in NeolifeS
2975042|NCT02729831|Experimental|Interactive Decision Aid and Usual Care|Group receiving brief interactive decision aid and being seen by a provider assigned to usual care. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise.
2975043|NCT02729831|Experimental|Video decision aid and usual care|Group receiving long video decision aids and being seen by a provider assigned to usual care. The decision aids are the DVD and Booklets for hip and knee osteoarthritis from Health Dialog.
2975044|NCT02729831|Experimental|Interactive Decision Aid and Provider Report|Group receiving brief interactive decision aid and being seen by a provider assigned to intervention arm. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise. The provider intervention is a report that includes the patients' goals and treatment preferences.
2975045|NCT02729831|Experimental|Video decision aid and Provider report|Group receiving long video decision aids and being seen by a provider assigned to intervention arm. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog. The intervention is a report that includes the patients' goals and treatment preferences.
2975046|NCT02729805|Placebo Comparator|Saline|A syringe of 50 ml 0.9% normal saline will be prepared as placebo for infusion and a syringe of 10ml 0.9% normal saline for bolus injection.
2975047|NCT02729805|Active Comparator|Ketamine 0.5mg/kg|A bolus injection of intravenous ketamine at a dose of 0.5mg/kg during anaesthetic induction before skin incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation.
2975048|NCT02729805|Experimental|Ketamine 0.75mg/kg|A bolus injection of intravenous ketamine at a dose of 0.75mg/kg during anaesthetic induction before skin incision followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation.
2975049|NCT02729792|Experimental|Single site rTMS|"Each treatment session will consist of:~1200 pulses of iTBS over a posterior target location followed by a 60 minute interval, then 1200 pulses of iTBS over an anterior target location."
2975050|NCT02729792|Active Comparator|Dual site rTMS|"Each treatment session will consist of:~600 pulses of iTBS over the posterior target, followed immediately by 600 pulses of iTBS over the anterior target location followed by a 60 minute interval, then 600 pulses of iTBS over the posterior target, followed immediately by 600 pulses of iTBS over the anterior target location."
2975051|NCT02729779|Experimental|Pilates Group|Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
2975052|NCT02729779|Active Comparator|Aerobic Group|The Aerobic Group will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
2975089|NCT02729545|Experimental|acupuncture|Dong's extra-point acupuncture treatment,2 times a week for three month
2975151|NCT02729155|Sham Comparator|Sham + Sham|Intervention: Sham 10 mmHg + Sham 10 mmHg
2975053|NCT02729766|Active Comparator|Empagliflozin 25mg Tbl|Induced hypotonic hyponatremia - SIAD model: Hypotonic hyponatremia will be induced in healthy volunteers through oral overhydration and parenteral administration of desmopressin (Minirin)® 4ug. After administration of the study drug, the artificial SIAD will be sustained with infusion of hypotonic sodium-solution (NaCl 0.45%) over two hours.
2975054|NCT02729766|Placebo Comparator|Placebo P-Tablet|Induced hypotonic hyponatremia - SIAD model: Hypotonic hyponatremia will be induced in healthy volunteers through oral overhydration and parenteral administration of desmopressin (Minirin)® 4ug. After administration of the study drug, the artificial SIAD will be sustained with infusion of hypotonic sodium-solution (NaCl 0.45%) over two hours.
2975055|NCT02729753|Other|CryoBalloon™ Full Ablation System|To evaluate CryoBalloon™ Full Ablation System for the ablation of human esophageal epithelium in patients scheduled to undergo esophagectomy.
2975056|NCT02729740|Other|Penumbra SMART CoilTM System|Coil technology has evolved considerably since the initial introduction of the GDC coil over 25 years ago. In recent history, coil development has mostly focused on the delivery system, or pusher technology, and detachment. The new Penumbra SMART Coil not only addresses improvements in the delivery system, but importantly incorporates new technology into the actual coil implant itself. Penumbra SMART technology enables an individual coil to become progressively softer as it is deployed, utilizes advanced materials to improve stretch resistance, and incorporates new processes to create accurate complex and helical shapes.
2975057|NCT02729727|Other|Single Arm|To evaluate safety and treatment effect of the CryoBalloon Ablation System for the Ablation of human esophageal epithelium in patients scheduled to undergo esophagectomy
2975058|NCT02729714|Active Comparator|Suvorexant or Placebo|10 Suvorexant or Placebo mg orally at bedtime with an optional up-titration to 15 mg Suvorexant or Placebo orally at bedtime after 2 weeks. The first treatment period will be 4 weeks. Subjects will be randomized 1;1 to receive Suvorexant or matching placebo. Followed by a 2 week washout period with placebo. Subjects will then be crossed over into the alternate treatment group. Subjects on active treatment for period 1 will be switched to placebo, those on placebo in period 1 will switch to Suvorexant
2975059|NCT02729714|Placebo Comparator|Placebo or Suvorexant|First treatment period will be 4 week which subjects will be randomized 1;1 with either Suvorexant or placebo. Followed by 2 week washout period with placebo. Subjects will then be crossed over into the alternate treatment group. Subjects on active treatment for period 1 will be switched to placebo, those on placebo in period 1 will switch to Suvorexant.
2975060|NCT02729701|Experimental|Duavee|Participants will be asked to take Duavee for 6 months while on the study.
2975061|NCT02729688|Active Comparator|ordinary elastic bandage|Bandaging was applied by spiral methods. Three ordinary elastic bandages were applied with 50 % stretching and 50% overlapping from foot to just below knee level.
2975062|NCT02729688|Active Comparator|customized pressure guide bandage|Bandaging was applied by spiral methods. Three customized pressure guide elastic bandage were applied by stretching until the elliptical shape marker in the bandage turned into circular shape with 50% overlapping from foot to just below knee level.
2975063|NCT02729675|Experimental|Access Intervention|Worksites in this condition received weekly Fruit and Vegetable markets
2975064|NCT02729675|Experimental|Enhanced Intervention|Worksites in this condition received weekly Fruit and Vegetable markets and Educational Interventions including Campaigns, Newsletters, DVDs, A Website, and Chef Demonstrations
2975065|NCT02729675|Active Comparator|Comparison Intervention|Worksites in this condition received Stress and Physical Activity Interventions
2975066|NCT02729662|Other|Patients with ADPKD|This analysis set consists of patients whose at least 2 TKV data are available both before and after taking tolvaptan.
2975067|NCT02729649|Experimental|ArmAssist therapy|The group will be treated with ArmAssist robot therapy.
2975068|NCT02729649|Active Comparator|Conventional therapy|The group will be treated with conventional therapy.
2975069|NCT02729649|Active Comparator|Extended Conventional therapy|The group will be treated with extended conventional therapy.
2975070|NCT02729636|Experimental|FES:a|The group will be treated with multipad electrical stimulation device.
2975071|NCT02729636|Active Comparator|control|The group will be treated with conventional treatment.
2975072|NCT02729623|Experimental|Single CannaHALER dose 10 ± 0.1 mg|Single dose 10 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
2975073|NCT02729623|Experimental|Single CannaHALER dose 15 ± 0.1 mg|Single dose 15 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
2975074|NCT02729623|Experimental|Single CannaHALER dose 20 ± 0.1 mg|Single dose 20 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
2975075|NCT02729623|Experimental|Single CannaHALER dose 25 ± 0.1 mg|Single dose 25 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
2975076|NCT02729610|Active Comparator|DLT group|In this arm, patient will be intubated with a double lumen endotracheal tube
2975077|NCT02729610|Experimental|BB group|In this arm, patient will be intubated with an endobronchial blocker
2975078|NCT02729597||Myotonic dystrophy type 1 patients|"Patients with myotonic dystrophy type 1 (diagnosis confirmed by genetic testing) who meet all inclusion and exclusion criteria for patients.~To be assessed at baseline and follow-up:~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
2975079|NCT02729597||Myotonic dystrophy type 2 patients|"Patients with myotonic dystrophy type 2 (diagnosis confirmed by genetic testing) who meet all inclusion and exclusion criteria for patients.~To be assessed at baseline and follow-up:~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
2975080|NCT02729597||Controls|"Healthy control subjects who meet all inclusion and exclusion criteria for healthy controls.~To be assessed at baseline and follow-up:~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
2975081|NCT02729584||Normal weight|
2975082|NCT02729584||Obese|
2975083|NCT02729571|Experimental|MTBVAC Group 1|Intervention: MTBVAC live vaccine (low dose)
2975084|NCT02729571|Experimental|MTBVAC Group 2|Intervention: MTBVAC live vaccine (middle dose)
2975085|NCT02729571|Experimental|MTBVAC Group 3|Intervention: MTBVAC live vaccine (high dose)
2975086|NCT02729571|Active Comparator|BCG Control Group|Intervention: commercially available BCG live vaccine
2975087|NCT02729558|No Intervention|observation|Watchful waiting
2975090|NCT02729545|Active Comparator|Diane-35|one tablet a day, take continuously for 21 days, stop for 7 days, and take continuously for another 21 days, totally take 3 menstrual cycle.
2975091|NCT02729532||Xpert cohort|HIV-positive presumptive TB patients tested for TB using Xpert MTB/RIF assay (fluorescence microscopy and TB culture also done to serve as reference standard)
2975092|NCT02729532||Standard of Care cohort|HIV-positive presumptive TB patients tested for TB using standard of care testing (sputum smear microscopy plus clinical evaluation)
2975093|NCT02729519|Other|Group A|standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation)
2975094|NCT02729519|Experimental|Groupe B|standard procedure TAVI performed without pre dilatation (Without prior balloon dilatation)
2975095|NCT02729506|Active Comparator|Arm A|"Intervention:~Yttrium-90 Transarterial Radioembolization~Patients with measurable, locally advanced HCC those are not suitable to have or have failed potentially curable intervention (Radio frequency ablation for small tumor, resection or transplantation).~The diagnosis of HCC should be established either by cyto/histology; or, by characteristic imaging studies in patients with cirrhosis of the liver and/or chronic viral hepatitis B or C infection.~Patients must not be less than 18 and not more than 80 and can be either gender.~Patients must have a performance status of ECOG score equal to or less than 2.~Child-Pugh's A or Early B, score 8 and above"
2975096|NCT02729506|Active Comparator|Arm B|"Intervention:~Trans-arterial chemo-embolization using Drug-eluting beads~Patients with measurable, locally advanced HCC those are not suitable to have or have failed potentially curable intervention (Radio frequency ablation for small tumor, resection or transplantation).~The diagnosis of HCC should be established either by cyto/histology; or, by characteristic imaging studies in patients with cirrhosis of the liver and/or chronic viral hepatitis B or C infection.~Patients must not be less than 18 and not more than 80 and can be either gender.~Patients must have a performance status of ECOG score equal to or less than 2.~Child-Pugh's A or Early B, score 8 and above"
2975097|NCT02729493|Experimental|Single-arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days,the first day,the second day,28days,29days Duration:total five times
2975098|NCT02729480|Experimental|Continued Stimulation Group|Subjects randomized to this group will have the Halo Craniofacial Nerve Stimulator System activated immediately.
2975099|NCT02729480|Active Comparator|Delayed Continuation Group|Subjects randomized to this group with have the Halo Craniofacial Nerve Stimulator System activated after 90 days.
2975100|NCT02729467|Experimental|Panel 1|Participants will receive a single 250 milligram (mg) dose of JNJ-53718678 on Day 1 and 200 mg itraconazole once a day on Days 4 to 11 along with a single 250-mg dose of JNJ-53718678 on Day 9.
2975101|NCT02729467|Experimental|Panel 2|Participants will receive a single 500-mg dose of JNJ-53718678 on Day 1; a single 600-mg dose of rifampicin along with a single 500-mg dose of JNJ-53718678 on Day 4 and 600 mg rifampicin once daily on Days 5 to 11 along with a single 500-mg dose of JNJ-53718678 on Day 9.
2975102|NCT02729454|Active Comparator|Exclusively physical therapy|The patients will be submitted to 15 therapeutical sessions two times per week with length of 40 minutes for motor physiotherapy . Each session of the motor physiotherapy will be constituted of exercises that include stretching (emphasizing the front of the torso), reinforcement (with emphasis in inferior members extensores); active exercises as transference (for example, to put into motion it bed or uprising of a chair), to reach and to grasp and training of balance and march.
2975103|NCT02729454|Experimental|Mental Practice And Physical Therapy|In the group submitted to the mental Practice the sessions will be individualized and occur in tranquil room after physical therapy (Same performed with the control group). During the mental practice the patient will be guided to stand, where he will be requested initially to identify and to sequencer the necessary joints for the accomplishment of an only step, being they:flexion of the thigh and leg rights, extension of the right leg more dorsiflexed of the right foot; touch of the heel and discharge of weight of the right foot and inclined body to the front. The sessions occur two times per week during 15 minutes.
2975104|NCT02729441|Active Comparator|Ramipril|"Maximal recommended dose of ramipril Altace® (10 mg/d) given as an active comparator for 12 week."
2975105|NCT02729441|Experimental|Perindopril|"Perindopril Coversyl® at maximal recommended dose (8 mg/d) as experimental therapy for 12 weeks."
2975106|NCT02729428||Exercise trained young adults|Exercise trained young adults between the age of 18-35 years.
2975107|NCT02729428||Sedentary young adults|Sedentary young adults between the age of 18-35 years.
2975108|NCT02729428||Exercise trained older adults|Exercise trained older adults between the age of 55-75 years.
2975109|NCT02729428||Sedentary older adults|Sedentary older adults between the age of 55-75 years.
2975110|NCT02729415|Experimental|Stromal Vascular Fraction Cells (SVF Cells)|The participants will undergo a standard tumescent liposuction to harvest adipose tissue. The adipose tissue will then be processed for obtain the Stromal Vascular Fraction Cells (SVF Cells) for a single injection for the treatment of androgenetic alopecia. Before the procedure, hair measurements will be performed in the 2cm x 2cm site for density (number of hairs per square centimeter) and thickness (mm) of the hair to compare to the measurements after the procedure at pre-procedure, 6 weeks, 3 months and 6 months.
2975111|NCT02729402|Experimental|Older Cochlear Implant Subjects|We will assign the study participants to a diagnostic intervention (cognitive testing) before and after their cochlear implant.
2975112|NCT02729389|Experimental|High Social Status Condition|Participants will be provided with a high degree of privilege in a game of Monopoly.
2975113|NCT02729389|Experimental|Low Social Status Condition|Participants will be provided with a low degree of privilege in a game of Monopoly.
2975114|NCT02729376|Experimental|Single dose of [14C]-galeterone|[14C]-galeterone will be supplied as 325 mg capsules (powder in capsule [PIC]). The treatment to be administered will be 2600 mg (~500 µCi) (8 x 325 mg capsules).
2975115|NCT02729363|Experimental|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention delivered at the baseline visit to determine the immediate effects of guided relaxation intervention on stress and pain in outpatients with sickle cell disease.
2975147|NCT02729168|Experimental|Human rabies vaccines|Five doses 0.5 mL vaccine INDIRAB® on D0, D3, D7, D14, D28 using administered intramuscularly.
2975148|NCT02729155|Experimental|RIPre + RIPost|Intervention: RIPre 200 mmHg + RIPost 200 mmHg
2975149|NCT02729155|Experimental|RIPre + Sham|Intervention: RIPre 200 mmHg + Sham 10 mmHg
2975116|NCT02729363|Other|Sickle cell experience discussion|Attention Control Group: This intervention is a 12-minute sickle cell disease experience discussion. In this computer-based discussion, patients talk about their sickle cell disease experience. The audio-taped questions and onscreen directions were programmed for self-administration. Subjects' responses will be captured via the microphone so that Data Collectors are not involved in this discussion process, and it is equivalent to the guided relaxation activity.
2975117|NCT02729350|Experimental|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention delivered at the baseline (Day 1) visit to determine the immediate effects of guided relaxation intervention on stress and pain in inpatients with sickle cell disease. The GR intervention also includes six video clips, ranging from 2 to 20 minutes in length to determine the short-term (Day 5) effects of guided relaxation intervention on stress and pain.
2975118|NCT02729350|Other|Sickle cell experience discussion|Attention Control Group: This intervention is a 12-minute sickle cell disease experience discussion. In this computer-based discussion, patients will discuss their experience of having sickle cell disease. The audio-taped questions and onscreen directions were programmed to be self-administered. Subjects' responses will be captured via the microphone so that Data Collectors are not involved in this discussion process, and it is equivalent to the guided relaxation activity.
2975119|NCT02729337|Experimental|ITG (In This Together)|This will be a multi-week behavioral intervention delivered daily via text messaging. Content will be based upon the IMB model of HIV preventive behavior and informed by our formative work.
2975120|NCT02729337|No Intervention|Control Group|Given the preliminary nature of the intervention development, the control group will be inactive but blinded. They will receive two messages per week encouraging them to make healthy sexual decisions to reduce their HIV risk. Messages will be didactic and not driven by the IMB model.
2975121|NCT02729324|Experimental|FORRAD group|This group of patients will receive Medical Radiation Protectants (FORRAD®) during study for prevention and treatment of acute radiation-induced dermatitis. This is the experimental group.
2975122|NCT02729324|Active Comparator|Biafine group|This group of patients will receive Trolamine (Biafine) during study for prevention and treatment of acute radiation-induced dermatitis. This is the active comparator group.
2975123|NCT02729311|Experimental|Group 1|Paired PLIÉ Program, immediate start
2975124|NCT02729311|Other|Group 2|Paired PLIÉ Program, delayed start
2975125|NCT02729298|Experimental|Advanced Solid Tumors|"Phase 1a Single daily dose of TP-0903 by oral administration on Days 1-21 of a 28 day cycle~AND~Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle."
2975126|NCT02729298|Experimental|EGFR+ NSCLC|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
2975127|NCT02729298|Experimental|BRAF-, KRAS-, or NRAS-Mutated CRC|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
2975128|NCT02729298|Experimental|Persistent/Recurrent Ovarian Cancer|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
2975129|NCT02729298|Experimental|BRAF-Mutated Melanoma|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
2975130|NCT02729285|Experimental|Ketorolac Tromethamine|On operation day, the patients were randomly assigned to receive intramuscular Ketorolac 60-mg 30 minutes before scleral buckle surgery.
2975131|NCT02729285|Placebo Comparator|placebo|On operation day, the patients were randomly assigned to receive placebo before scleral buckle surgery.
2975132|NCT02729272|Experimental|Ultrasonic ESD|Laparoscopic colpotomy by ultrasonic ESD (Harmonic Synergy Hook Blade; Ethicon Endo-Surgery) during total laparoscopic hysterectomy.
2975133|NCT02729272|Active Comparator|Monopolar ESD|Laparoscopic colpotomy by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany) during total laparoscopic hysterectomy.
2975134|NCT02729259|Other|Virtual Reality Snowworld|The subjects will receive Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
2975135|NCT02729259|Other|Virtual Reality slides of nature|The subjects will see several slides of the nature through virtual reality goggles during their wound care. The nurse will be doing the wound care.
2975136|NCT02729259|Other|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
2975137|NCT02729246|No Intervention|Control Group|
2975138|NCT02729246|Other|Surgery Group|The patients in this group will undergo Laparoscopic Gastric Bypass surgery
2975139|NCT02729233|Other|patients receiving biopsies|UC patients who will be started on golimumab for treatment of UC (moderate to severe flare, steroid dependence, or failure of other therapies), epithelial barrier function will be characterized using probe-based confocal laser endomicroscopy (pCLE).
2975140|NCT02729220|Other|Healthy controls|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
2975141|NCT02729220|Other|Smokers|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
2975142|NCT02729220|Other|COPD rapid decline|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
2975143|NCT02729220|Other|COPD slow decline|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
2975144|NCT02729207|Active Comparator|Esflurbiprofen 1.5% Hydrogel Patch|One patch per 24hr for 7 days
2975145|NCT02729207|Placebo Comparator|Placebo comparator|Placebo One patch per 24hr for 7 days
2975146|NCT02729194|Experimental|Pazopanib|Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal) approximately, some sample meals are described in appendix 1) every day in 14 day cycles, with a starting dose of 400 mg and adjusted for the next cycle (dose level +1:600 mg; dose level +2: 800 mg; dose level -1: 200 mg) based on toxicity assessment during or at the end of each cycle.
2975153|NCT02729129|Experimental|Commercially available highly-efficient facemask|
2975154|NCT02729129|Sham Comparator|Sham facemask|
2975155|NCT02729116|Experimental|Sitafloxacin group|Sitafloxacin 100 mg oral twice daily
2975156|NCT02729116|Active Comparator|Ertapenem group|Ertapenem 1 gm IV every 24 h
2975157|NCT02729103||Treatment patterns, healthcare resource utilization and costs|Part 1 - Assessment of treatment patterns, healthcare resource utilization and costs. The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date. All patients must have no diagnosis of other cancers, no diagnosis of bone metastases or a claim for a treatment indicative of bone metastases, and no skeletal-related events (SREs) in the 12-month pre-index period. Additionally, all subjects must be continuously enrolled for at least 12 months before and at least 6 months after the index date.
2975158|NCT02729103||Mortality|Part 2 - Assessment of mortality. The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date. All patients must have no diagnosis of other cancers, no diagnosis of bone metastases or a claim for a treatment indicative of bone metastases, and no SREs in the 12-month pre-index period. Additionally, all subjects must be continuously enrolled for at least 12 months before the index date. Unlike in Part 1, there will be no required minimum follow-up time after the index date (in order to assess mortality).
2975159|NCT02729090|Experimental|Device: treadmill|Aerobic training on a treadmill continuously with speed and wave periodization. Frequency twice per week ( 2x ) for twelve weeks
2975160|NCT02729090|Active Comparator|Device: treadmill Train_Comb_aerobic|strength training with free weights, followed by active recovery on a treadmill with fixed intervals of 60 to 120 seconds between each workforce of series.
2975161|NCT02729077||Increased risk for OSA|Vital signs including oxygen saturation, respiratory rate, ECG, arterial pressure, BIS, blood pressure, heart rate will be monitored and hypoxemia will be measured during anesthetic care, and oxygen saturation and respiratory rate will be measured for 48 hours after surgery with pulse oximetry. Patients in this arm will be especially evaluated for hypoxemia and other complications.
2975162|NCT02729077||Not increased risk for OSA|Vital signs including oxygen saturation, respiratory rate, ECG, arterial pressure, BIS, blood pressure, heart rate will be monitored and hypoxemia will be measured during anesthetic care, and oxygen saturation and respiratory rate will be measured for 48 hours after surgery with pulse oximetry.
2975163|NCT02729064|Experimental|Intranasal 40|Patients will receive 40 IU of intranasal insulin (Humulin R) via a metered nasal dispenser
2975164|NCT02729064|Experimental|Intranasal 80|Patients will receive 80 IU of intranasal insulin (Humulin R) via a metered nasal dispenser
2975165|NCT02729064|Placebo Comparator|Placebo|Patients will receive intranasal normal saline via a metered nasal dispenser
2975166|NCT02729051|Experimental|FF/UMEC/VI closed triple therapy plus Placebo|Subjects will receive FF/UMEC/VI, 100 mcg/62.5 mcg/25 mcg and placebo inhalation powder via the dry powder inhaler (DPI), once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
2975167|NCT02729051|Active Comparator|FF/VI plus UMEC open triple therapy|Subjects will receive FF/VI, 100 mcg/25 mcg and UMEC, 62.5 mcg inhalation powder via the DPI, once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
2975168|NCT02729038|Experimental|Part 1: Subjects with normal renal function (Group A)|Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
2975169|NCT02729038|Experimental|Part 1: subjects with moderate renal impairment (Group B)|Subjects with moderate renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
2975170|NCT02729038|Experimental|Part 1: subjects with severe renal impairment (Group C)|Subjects with severe renal impairment and subjects with ESRD not on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
2975171|NCT02729038|Experimental|Part 2: subjects with normal renal function (Group D)|Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
2975172|NCT02729038|Experimental|Part 2: subjects with mild renal impairment (Group E)|Subjects with mild renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
2975173|NCT02729038|Experimental|Part 2: subjects with ESRD on hemodialysis (Group F)|Subjects with ESRD on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion starting approximately 2 hours before the initiation of the last hemodialysis session of the week (Period 1) and gepotidacin 750 mg administered as a 2 hour IV infusion starting within 2 hours after completion of the last hemodialysis session of the week (Period 2).
2975174|NCT02729025|Experimental|Repatha (Evolocumab)|Repatha (Evolocumab) subcutaneous injection every 4 weeks (QM) using 3 auto injector (AI) Pen
2975175|NCT02729025|Placebo Comparator|Repatha (Evolocumab) Matching Placebo|Repatha (Evolocumab) Matching Placebo subcutaneous injection every 4 weeks (QM) using 3 auto injector (AI) Pen
2975176|NCT02729012|Active Comparator|Case|Allergic Rhinitis Children treated with hypertonic saline solution (NACL 3%+NAHCO3)
2975177|NCT02729012|Placebo Comparator|Control|Allergic Rhinitis Children treated with saline solution (NACL 0,9%)
2975178|NCT02728999|Other|Group A|Steep Trendelenburg
2975179|NCT02728999|Experimental|Group B|Decreased Trendelenburg
2975180|NCT02728986|Active Comparator|Compression1|Multilayer compression bandage (Profore)
2975181|NCT02728986|Experimental|Compression2|Coban2 compression system
2975182|NCT02728973||ERAS program|The main elements of this program were: preoperative advice, no colon preparation, provision of carbohydrate-rich drinks one day prior and on the morning of surgery, goal directed fluid administration, body temperature control during surgery, avoiding drainages and nasogastric tubes, early mobilization, and the taking of oral fluids in the early postoperative period.
2975183|NCT02728973||conventional treatment program|conventional treatment
2975184|NCT02728960|Experimental|Traumatic Brain Injury|Documented history of Traumatic Brain Injury
2975185|NCT02728960|Active Comparator|Normal Controls|No prior history of concussion, TBI, blast exposure, stroke, or other major neurological disorder
2975186|NCT02728960|Active Comparator|Sequence Development Volunteers|
2975187|NCT02728947|Active Comparator|2mg|1 week on 2mg/24 hr patch
2975188|NCT02728947|Active Comparator|4mg|1 week on 4mg/24hr patch
2975189|NCT02728947|Active Comparator|6mg|1 week on 6mg/24hr patch
2975190|NCT02728947|Active Comparator|8mg|1 week on 8mg/24hr patch
2975191|NCT02728934||Golimumab Intravenous (IV)|Patients in the US who enroll in the study will have a rheumatologist confirmed diagnosis of Rheumatoid arthritis (RA) and will be medically eligible for, and will have been prescribed but not yet initiated treatment with Golimumab IV.
2975192|NCT02728934||Infliximab|Patients in the US who enroll in the study will have a rheumatologist confirmed diagnosis of Rheumatoid arthritis (RA) and will be medically eligible for, and will have been prescribed but not yet initiated treatment with Infliximab.
2975193|NCT02728921|Active Comparator|5% Albumin infusion 30 min|Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 30 min.
2975194|NCT02728921|Experimental|5% Albumin infusion 3 hours|Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 3 hours. Dose is based on ideal body weight
2975195|NCT02728895|Experimental|Cohort 1: Vedolizumab 75 mg|Vedolizumab 75 mg, injection, intravenously once on Days -1, 13 and 42.
2975196|NCT02728895|Experimental|Cohort 2: Vedolizumab 300 mg|Vedolizumab 300 mg, injection, intravenously once on Days -1, 13 and 42.
2975197|NCT02728895|Experimental|Cohort 3: Vedolizumab Dose 1|Vedolizumab first decided dose as determined from Cohort 1 or 2, injection, intravenously once on Days -1, 13 and 42.
2975198|NCT02728882|Experimental|single arm|"Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days，the first day,the fourth day,the seventh day,28 days,31 days,34 days.~Duration:Total seven times."
2975199|NCT02728869|Experimental|Heat Stable Rotavirus (HSRV) Vaccine|25 healthy adults who will be administered a single dose of test HSRV vaccine
2975200|NCT02728869|Placebo Comparator|Placebo for Heatstable Rotavirus vaccine|25 healthy adults who will be administered a single dose of placebo
2975201|NCT02728869|Experimental|Heat Stable Rotavirus Vaccine|25 healthy infants who will be administered 3-doses of test HSRV vaccine spaced at 4-week intervals
2975202|NCT02728869|Active Comparator|RotaTeq|25 healthy infants who will be administered 3-doses of comparator Rotateq® vaccine spaced at 4-week intervals
2975203|NCT02728856|Experimental|Sun Protection Factor (SPF) 50 Z15-034(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
2975204|NCT02728856|Experimental|Sunscreen Spray SPF50 Z15-038(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
2975205|NCT02728843|Experimental|Deferiprone 300 mg|One-half of a 600 mg tablet of deferiprone twice a day, for a total daily dosage of 600 mg
2975206|NCT02728843|Experimental|Deferiprone 600 mg|One 600 mg tablet of deferiprone twice a day, for a total daily dosage of 1200 mg
2975207|NCT02728843|Experimental|Deferiprone 900 mg|One and a half 600 mg tablets of deferiprone twice a day, for a total daily dosage of 1800 mg
2975208|NCT02728843|Experimental|Deferiprone 1200 mg|Two 600 mg tablets of deferiprone twice a day, for a total daily dosage of 2400 mg
2975209|NCT02728843|Placebo Comparator|Placebo|Depending on dosage cohort, either one half-tablet, one tablet, one and a half tablets, or two tablets of placebo, twice a day
2975210|NCT02728830|Experimental|Pembrolizumab|"Subjects will receive one dose of 200mg pembrolizumab by IV 14-21 days prior to surgery. Subjects will undergo standard surgical cytoreductive surgery as deemed appropriate by their gynecologic oncologist, followed by standard adjuvant chemotherapy for their cancer as deemed appropriate by their treating physician.~If subject's disease does not get worse following standard of care chemotherapy, they will receive pembrolizumab in the maintenance setting every three weeks for up to a year.~If subject's disease returns after completing a year of pembrolizumab and they have not had adverse reactions to pembrolizumab they may be eligible to continue receiving pembrolizumab for an additional year in the second course phase."
2975211|NCT02728817|Active Comparator|arteriovenous fistula (AVF)|Patient receiving a traditional arteriovenous fistula at the wrist (end-cephalic vein to side-radial artery)
2975212|NCT02728817|Experimental|RADAR|Patient receiving an arteriovenous fistula at the wrist using the Radial Artery Deviation And Reimplantation technique (end-radial artery to side-cephalic vein)
2975213|NCT02728804||Health Services Research (questionnaire administration)|Patients complete questionnaires (including the Baseline, Financial/Employment Impact, Insurance Impact, Quality of Life, and Treatment Perceptions questionnaires) over 30-60 minutes at baseline and at 3, 6, 9, and 12 months. Caregivers complete questionnaires over 30-60 minutes at baseline and at 6 and 12 months.
2975214|NCT02728778|Active Comparator|Botulinum toxin A|Single administration of incobotulinumtoxin A into the forehead (glabellar region); 34 U in five injection sites.
2975215|NCT02728778|Other|Acupuncture|Patients will receive four facial acupuncture treatments every two weeks.
2975216|NCT02728765|Active Comparator|auto CPAP|Each patient will be interviewed by the physician on duty and invited to participate in the overnight hospital based auto continuous positive airway pressure (CPAP) titration study for 1 night and then commencement of auto CPAP treatment for 6 months.
2975217|NCT02728765|Placebo Comparator|Subtherapeutic CPAP|Following detection of obstructive sleep apnea (OSA), each patient randomized to this arm will receive the same CPAP education, mask fitting and short auto CPAP trial for acclimatization but their auto CPAP device will be set at a subtherapeutic level of 4 cmH20 for use at home. The patients randomized to both arms will receive the same general education about OSA, sleep hygiene, avoidance of alcohol, and weight reduction if appropriate.
2975237|NCT02728635|Active Comparator|Group C- Men- Healthy 'apples'|The group will consist of men with a BMI between 23 and 35 kg/m2.
2975238|NCT02728622|Experimental|Tamoxifen|Tamoxifen 40 mg is given orally once daily until progression
2975239|NCT02728622|Active Comparator|Chemotherapy|Paclitaxel 80 mg/m2 is given as an 1 hour infusion every 7 days or Caelyx 40 mg/m2 is given iv, first dose over 2 hours, later doses are infused over 1 hour, administered every 4 weeks or up to a maximum dose of 550 mg/m2. Until progression
2975218|NCT02728752|Placebo Comparator|Placebo|Subjects eligible after screening, randomized to placebo arm, will receive 4 infusions of placebo every 4 weeks during the First Period (16 weeks). In case of deterioration at or after Week 6, subjects will be crossed-over to the alternate treatment, and will not drop-out before the primary endpoint assessment at Week 16 to keep the blind unless they deteriorate also on the alternate IMP after starting it at least 6 weeks before. After response assessment at Week 16, patients will be unblinded. From Week 16 onwards, all subjects, except subjects randomized to Octagam 10% who deteriorate in the First Period and who will drop-out, will enter the open-label Extension Period. In the Extension Period they will receive six infusions of 2.0 g/kg Octagam 10% every 4 weeks (± 4 days). At Week 28, subjects who are stable on 2.0 g/kg Octagam 10% can be switched to 1.0 g/kg Octagam 10%, at the discretion of the investigator.
2975219|NCT02728752|Experimental|Octagam10%|Subjects eligible after screening, randomized to Octagam10% arm, will receive 4 infusions of Octagam10% every 4 weeks during the First Period (16 weeks). In case of deterioration at or after Week 6, subjects will be crossed-over to the alternate treatment, and will not drop-out before the primary endpoint assessment at Week 16 to keep the blind unless they deteriorate also on the alternate IMP after starting it at least 6 weeks before. After response assessment at Week 16, patients will be unblinded. From Week 16 onwards, all subjects, except subjects randomized to Octagam10% who deteriorate in the First Period and who will drop-out, will enter the open-label Extension Period. In the Extension Period they will receive six infusions of 2.0 g/kg Octagam 10% every 4 weeks (± 4 days). At Week 28, subjects who are stable on 2.0 g/kg Octagam 10% can be switched to 1.0 g/kg Octagam 10%, at the discretion of the investigator.
2975220|NCT02728739|Experimental|Acute Heart Failure Patients|Acute Heart Failure patients with elevated levels of BNP ( >30pg/ml) will undergo Transthoracic Echocardiogram (TTE) for grading of MR severity within 7 days.
2975221|NCT02728726|Experimental|Treatment group|study drug (sugammadex) administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and patient is extubated.
2975222|NCT02728726|Placebo Comparator|Control group|placebo administered intravenously after routine reversal of anesthesia is performed and patient is extubated.
2975223|NCT02728713|Experimental|Cranial manipulation|"Assessment for cranial strain patterns, followed by indirect cranial manipulation to treat dysfunctions found on assessment, followed by reassessment.~Repeated for a total of eight visits no less than one week apart."
2975224|NCT02728713|Sham Comparator|Sham/placebo|Assessment for cranial strain patterns, followed a laying on of hands, followed by reassessment. Repeated for a total of eight visits no less than one week apart.
2975225|NCT02728700|Experimental|Treatment (sirolimus, HSCT, MMF)|Patients receive sirolimus PO starting on day -3, 3 times a week during hospitalization and then once a week for up to 6 months. Patients undergo HSCT on day 0. Patients also receive mycophenolate mofetil IV or PO TID on days 1-180. Treatment continues in the absence of disease progression or unacceptable toxicity.
2975226|NCT02728687|Experimental|Mannitol and menthol cream|Mannitol and menthol cream (Water, Mannitol, Propylene glycol, Isopropyl palmitate. Caprylic capric triglyceride, Ceteareth 20, Cetearyl alcohol, Glyceryl stearate, Polyethylene glycol 100 Stearate, Dimethicone, Octyldodecanol, Menthol, Lecithin, Ethylhexyl glycerin, Phenoxyethanol) applied as needed, up to 4 times daily for one month, to the feet of a person suffering from painful diabetic peripheral neuropathy. During the other month, the menthol cream will be applied to the participant's feet. Whether the mannitol and menthol cream will be given in the first or the second month will be chosen at random. At the end of the 2 months, if the participant chooses this cream, they will be given 3 months' supply of the cream to apply as needed to both feet.
2975227|NCT02728687|Active Comparator|Menthol cream|Cream containing menthol (Water, Propylene glycol, Isopropyl palmitate. Caprylic capric triglyceride, Ceteareth 20, Cetearyl alcohol, Glyceryl stearate, Polyethylene glycol 100 Stearate, Dimethicone, Octyldodecanol, Menthol, Lecithin, Ethylhexyl glycerin, Phenoxyethanol) applied as needed, up to 4 times daily for one month, to the feet of a person suffering from painful diabetic peripheral neuropathy. During the other month, the mannitol and menthol cream will applied to the participant's feet. Whether the menthol cream will be given in the first or the second month will be chosen at random. At the end of the 2 months, if the participant chooses this cream, they will be given 3 months' supply of the cream to apply as needed to both feet.
2975228|NCT02728674|Other|Man+Breathlessness|Person in the case is a male. Symptom in the case is breathlessness.
2975229|NCT02728674|Other|Man+Pain|Person in the case is a male. Symptom in the case is pain.
2975230|NCT02728674|Other|Woman+Breathlessness|Person in the case is a female. Symptom in the case is breathlessness.
2975231|NCT02728674|Other|Woman+Pain|Person in the case is a female.Symptom in the case is pain.
2975232|NCT02728661|Experimental|PACE|PACE participants will begin up to 6 weeks prior to their scheduled TKR and continue until 12 weeks after their TKR. Participants will be given personalized weight, dietary, and physical activity goals. Participants will be encouraged to monitor their dietary intake and physical activity using their preferred method of self-monitoring. Participants will have regular contact with their coaches either in-person or over the telephone on a weekly or bi-weekly basis, based on preference during the first 14 weeks (from up to 6 weeks pre-op to 12 weeks post-op). Further, participants may opt to receive regular text messages or emails from coaches if they prefer. At 12 weeks, PACE participants will enter a maintenance period and not have any contact with coaches.
2975233|NCT02728661|Experimental|Delayed PACE|After being notified of their randomized condition at baseline (up to 6 weeks prior to surgery), Delayed PACE participants will not have contact with coaches until 12 weeks after surgery. At 12 weeks after surgery, Delayed PACE participants will be given personalized weight, dietary, and physical activity goals. Participants will be encouraged to monitor their dietary intake and physical activity using their preferred method of self-monitoring. Participants will have regular contact with their coaches either in-person or over the telephone on a weekly or bi-weekly basis, based on preference during the first 14 weeks. Further, participants may opt to receive regular text messages or emails from coaches if they prefer.
2975234|NCT02728648|Other|Active|Open label IV Oxycodone 0.1 mg/kg Bolus Pharmacokinetic-Pharmacodynamic Study
2975235|NCT02728635|Active Comparator|Group A- Women- Healthy 'pears'|This group will consist of healthy women with a BMI between 23 and 35 kg/m2 as a waist-to-hip ratio of 0.78 or less.
2975236|NCT02728635|Active Comparator|Group B- Women- Healthy 'apples'|The group will consist of healthy women with a BMI between 23 and 35 kg/m2 as a waist-to-hip ratio of 0.85 or more.
2975240|NCT02728609||Blue towel: vacuum pack device|Trauma subjects undergoing temporary abdominal closure with vacuum pack technique
2975241|NCT02728609||ABThera abdominal closure|Trauma subjects undergoing temporary abdominal closure with the commercially available ABThera vacuum device
2975242|NCT02728596|Experimental|Clinic group 1 (clinic with automated system)|Patients with a high risk of developing FN receive CSF based on the automated system recommendations. The automated system suggests that CSFs not be used for drugs that have a low risk of FN.
2975243|NCT02728596|Experimental|Clinic group 2 (clinic with no automated system)|Patients receive CSF based on clinical practice guidelines.
2975244|NCT02728596|Experimental|Clinic group 3 (clinic with automated system)|Patients with a high or moderate risk of developing FN receive CSF based on the automated system recommendations. The automated system suggests that CSFs not be used for drugs that have a low risk of FN.
2975245|NCT02728596|Active Comparator|Clinic group 4 (clinic with automated system)|Patients with a high risk of developing FN receive CSF based on the automated system recommendations. The automated system suggests that CSF not be used for drugs that have a moderate risk of FN.
2975246|NCT02728583|Active Comparator|Margarine enriched with plant sterols and fish oil|Low-fat margarine (25 g per day) with added plant sterols and Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) from fish oil
2975247|NCT02728583|Placebo Comparator|Placebo margarine|Low-fat margarine (25 g per day) without added plant sterols and EPA + DHA
2975248|NCT02728570|Experimental|Low Flavonoids then High Flavonoids|Participants receive a prepared diet with Low Dietary Flavonoids (10 mg of flavonoids/1000 Kcals) for six weeks. After a minimum washout period of 2 weeks, participants receive a prepared diet with High Dietary Flavonoids (340 mg of flavonoids/1000 Kcals) for six weeks.
2975249|NCT02728570|Experimental|High Flavonoids then Low Flavonoids|Participants receive a prepared diet with High Dietary Flavonoids (340 mg of flavonoids/1000 Kcals) for six weeks. After a minimum washout period of 2 weeks, participants receive a prepared diet with Low Dietary Flavonoids (10 mg of flavonoids/1000 Kcals) for six weeks.
2975250|NCT02728557|Experimental|Supportive psychotherapy|Participants will receive supportive therapy.
2975251|NCT02728557|Experimental|Supportive-expressive psychotherapy|Participants will receive supportive-expressive therapy.
2975252|NCT02728544|Experimental|Prader Willi syndrome|16 (8 males) PWS adolescents and young adults
2975253|NCT02728544|Active Comparator|Obese controls|16 - sex, age, and BMI-matched controls
2975254|NCT02728531|Experimental|Bendamustine, Rituximab, Cytarabine|"Bendamustine on Days 1 and 2 of Cycles 1, 3, and 5.~In Cycle 1, rituximab on Day 1 or 2 at the investigator's discretion. Given on Day 1 of Cycles 2 through 6.~On Days 1 and 2 of Cycles 2, 4, and 6, cytarabine will be administered every 12 hours for a total of 4 doses.~Growth factor will be administered subcutaneously within 72 hours of completion of each even-numbered cycles of chemotherapy.~Leukapheresis will begin when the total WBC ≥ 5000/ μL and continue daily until collection of ≥ 2x106 CD34+ cells/kg (with a maximum of 5 courses of apheresis).~Standard of care peripheral blood autologous stem cell harvest will proceed per institutional guidelines and begin during Cycle 6 following rituximab and cytarabine therapy, when the total WBC ≥ 5000/ μL. Collection will continue on a daily basis until collection of ≥ 2x106 CD34+ cells/kg."
2975255|NCT02728518|Experimental|Nebulized Amikacin|patients in this arm will take amikacin nebulizer 400 mg twice daily in addition to standard beta lactam
2975256|NCT02728518|Active Comparator|Amikacin Intravenous|patients in this arm will take intravenous (IV) amikacin 20 mg/kg once daily in addition to standard beta lactam
2975257|NCT02728505|Active Comparator|SinuSurf irrigation twice daily|This arm is going to get low-concentration SinuSurf sinus irrigation solution, then a washout period, then standard NeilMed Sinus rinse.
2975258|NCT02728505|Placebo Comparator|NeilMed Sinus rinse irrigation twice daily|This arm is going to get standard NeilMed Sinus rinse, then a washout period, then low-concentration SinuSurf sinus irrigation solution.
2975259|NCT02728492|Experimental|Quisinostat 8 mg & Paclitaxel & Carboplatin|Quisinostat 8 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles
2975260|NCT02728492|Experimental|Quisinostat 10 mg & Paclitaxel & Carboplatin|Quisinostat 10 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles
2975261|NCT02728492|Experimental|Quisinostat 12 mg & Paclitaxel & Carboplatin|Quisinostat 12 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles
2975262|NCT02728492|Experimental|Quisinostat 8 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 8 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
2975263|NCT02728492|Experimental|Quisinostat 10 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 10 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
2975264|NCT02728492|Experimental|Quisinostat 12 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 12 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
2975265|NCT02728492|Experimental|Quisinostat 12 mg & Gemcitabine 1250 mg/m2 & Cisplatin|Quisinostat 12 mg capsule every other day and Gemcitabine 1250 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
2975266|NCT02728466|Active Comparator|Flavanol and procyanidin supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)
2975267|NCT02728466|Active Comparator|Procyanidin-containing supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)
2975268|NCT02728466|Placebo Comparator|Flavanols and procyanidins deprived supplement|Control supplement deprived of flavanols and procyanidins Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement
2975269|NCT02728453|Experimental|Empagliflozin|25 mg/d empagliflozin + matching glimepiride placebo for 24 weeks.
2975270|NCT02728453|Active Comparator|Glimepiride|2 or 4 mg/d glimepiride+ matching empagliflozin placebo for 24 weeks.
2975271|NCT02728440||Hypogonadotropic hypogonadism patients|30 patients with idiopathic hypogonadotrophic hypogonadism
2975272|NCT02728427|Experimental|Suprapubic Catheterization|Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients in this group.
2975273|NCT02728427|Active Comparator|Transurethral Catheterization|Transurethral catheterization using Foley catheter will be performed for patients in this group.
2975274|NCT02728414|Experimental|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
2975275|NCT02728414|Other|placebo|the patients in this arm will receive placebo with similar appearance of probiotics.
2975276|NCT02728401||INSI|Infection-negative systemic inflammation (INSI). The INSI group consists of children who have undergone congenital cardiac defect corrective surgery requiring cardiopulmonary bypass, known to induce an INSI response for ~24 hours thereafter; all children in this cohort are culture negative. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
2975277|NCT02728401||CSSS|Clinical severe sepsis syndrome (CSSS). Children assigned to the CSSS group had confirmed or highly suspected infection (microbial culture orders, antimicrobial prescription), exhibited 2 or more systemic inflammatory response syndrome criteria (including temperature and leukocyte criteria), and demonstrated at least cardiovascular ± pulmonary organ dysfunction. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
2975278|NCT02728401||Viral|The Viral Infection group consists of children who displayed signs and symptoms of severe viral infection, and who tested positive for respiratory viral infection(s) by a molecular virus panel test. These children were clinically evaluated to not have bacterial sepsis. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
2975279|NCT02728388|Experimental|PDT Treatment|"Each subject will have either placebo or Levulan Kerastick topical application applied to matched sets of neurofibromas. Each subject will have both sets, in order to serve as his/her own control subject.~After 24 hours, both sets of neurofibromas, Levulan and placebo treated, will be irradiated with red light (630 nm) from an Omnilux Revive light device at 100 mW/cm2 for 1000 seconds (16.7 minutes)."
2975280|NCT02728375|Experimental|Computer gaming hand exercise regimen|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 45 minutes,three times per week for sixteen weeks
2975281|NCT02728375|Active Comparator|Conventional hand exercise program|Exercises targeted to improve finger range of motion and hand strength. The exercises will be performed 45 minutes, three times per week for sixteen weeks
2975282|NCT02728349|Experimental|Chlorgenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
2975283|NCT02728336|Active Comparator|Heart Failure Patients|patients who are scheduled to undergo clinically ordered CRT for heart failure complicated by dyssynchrony
2975284|NCT02728336|Active Comparator|Control|20 matched control subjects
2975285|NCT02728323|Active Comparator|Levobupivacaine 100 mg, USG TAP Block|100 mg of Levobupivacaine by intramuscular injection, at the end of surgery
2975286|NCT02728323|Placebo Comparator|Placebo|20 ml of Saline (for 100 mg Levobupivacaine) intramuscularly, at the end of surgery
2975287|NCT02728310|Active Comparator|Levobupivacaine infusion|1500 mg of Levobupivacaine by an infusion rate of 10 ml/h for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected.
2975288|NCT02728310|Placebo Comparator|Saline infusion|300 ml of Saline (for Levobupivacaine as placebo) by an infusion rate of 10 ml/h for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected.
2975289|NCT02728297|Experimental|Staged ETS|Video-assisted endoscopic sympathicotomy from level of T3 to level of T12 on one side
2975290|NCT02728284|Active Comparator|Normal Cardiovascular System|70 with a history of heart or lung disease
2975291|NCT02728284|Active Comparator|Abnormal Cardiovascular System|30 without any history of heart or lung disease
2975292|NCT02728271|Experimental|HPC cell infusion|Autologous HPC will be infused within 24 hours of completing the chemotherapy. A total of 5 x 106/kg CD34+ HPC will be infused. The remaining HPC will be stored as back-up, to be used in case of graft failure.
2975293|NCT02728258|Experimental|Treatment (copanlisib)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2975294|NCT02728245|Placebo Comparator|Control group|"Placebo drug 1 tablet per day will be prescribed for 3months before surgery in ovarian endometrioma patients.~Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 2 months from 1month after surgery."
2975295|NCT02728245|Experimental|Case group|"Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 3months before surgery in ovarian endometrioma patients.~Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 2 months from 1month after surgery."
2975296|NCT02728232|Experimental|Internal Iliac artery ligation group|in this group the patients will undergo bilateral internal iliac artery ligation prior to the hysterectomy procedure
2975297|NCT02728232|Active Comparator|Hysterectomy only|in this group patients will undergo cesarean hysterectomy only
2975298|NCT02728219|Experimental|hepatectomy|Comparison of Treatment of recurrent hepatocellular carcinoma with repeat hepatectomy,and transcatheter arterial chemoembolization (TACE) with AFP conversion
2975299|NCT02728219|Active Comparator|TACE|
2975300|NCT02728206|Experimental|SOF/VEL|SOF/VEL FDC for 4 weeks starting on the day of or day after the participant's liver transplant
2975301|NCT02728193|Experimental|RFA|Radiofrequency ablation
2975302|NCT02728193|Experimental|MWV|Microwave ablation
2975303|NCT02728193|Experimental|PEI|Percutaneous ethanol injection
2975304|NCT02728180|Experimental|Xingnaojing and standard care|Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.
2975305|NCT02728180|Active Comparator|Standard care only|Subjects will receive guidelines-based standard care only.
2975306|NCT02728167|Experimental|Pre-coagulation by HIFU-AR|Pre-coagulation of the liver parenchyma with HIFU and standard liver resection
2975307|NCT02728167|No Intervention|Standard liver resection|Standard liver resection
2975308|NCT02728154||Normal control|The subjects in the normal heart function group will provide a blood sample and stool sample.
2975309|NCT02728154||heart failure|The subjects in history of heart failure group will provide a blood sample and stool sample.
2975310|NCT02728154||pre-HFpEF|The subjects in history of diastolic dysfunction but not had heart failure clinical presentations group will provide a blood sample and stool sample.
2975311|NCT02728141|Placebo Comparator|Water|Newborn infants with ID numbers ending in odd numbers offered 2ml distilled water by syringe once in the side of the infant's mouth 2 minutes before heel stick.
2975312|NCT02728141|Active Comparator|Sucrose|Newborn infants with ID numbers ending in even numbers offered 2 ml 25% sucrose in distilled water by syringe once in the side of the infant's mouth 2 minutes before heel stick.
2975313|NCT02728128||Low cardiac output syndrome|Patients who experience low cardiac output syndrome
2975314|NCT02728128||No low cardiac output syndrome|Group that does not experience low cardiac output syndrome.
2975315|NCT02728115|Experimental|Cellavita HD Lower Dose|Participants assigned to this arm will receive 3 administrations, one every 30 days, of 1x10^6 cells / kg per administration of Cellavita HD (n= 3) .
2975316|NCT02728115|Experimental|Cellavita HD Higher dose|Participants assigned to this arm will receive 3 administrations, one every 30 days, of 2x10^6 cells / kg per administration of Cellavita HD (n= 3).
2975317|NCT02728102|Experimental|Lenalidomide, vaccine, and GM-CSF|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will undergo leukapheresis and then will receive maintenance lenalidomide with myeloma vaccine and GM-CSF.
2975318|NCT02728102|Active Comparator|Lenalidomide and GM-CSF|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will receive maintenance lenalidomide with GM-CSF.
2975319|NCT02728102|Active Comparator|Maintenance Lenalidomide|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will receive maintenance lenalidomide.
2975320|NCT02728089|Experimental|MK-7625A|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion every 8 hours for 7 days. The dose may be reduced to 750 mg (ceftolozane 500 mg/tazobactam 250 mg) for participants with a creatinine clearance (CrCl) of 30-50 mL/min.
2975321|NCT02728076|Experimental|Radiation Therapy followed by Lumpectom|Phase II-Preoperative MRI-BasedRadiation followed by Lumpectomy
2975322|NCT02728063|Experimental|Single arm|Supplementation with Lactibiane Tolerance
2975323|NCT02728050|Experimental|Treatment (sorafenib, G-CLAM)|See Detailed Description.
2975324|NCT02728037|Experimental|Magnesium-Based Injection Formulation|Examination will involve systematic palpation of the 3 distinct levels of pelvic musculature. Injections into level 1 and level 2 muscles will be done under ultrasound guidance. Level 3 injections will be facilitated with a trumpet guide when needed. As the pelvic muscle trigger points are identified they will be injected with 2-3ml of the prepared injection formulation. The investigator will continue until no further trigger points can be identified, a maximum dose of lidocaine has been used, or the participant indicates they wish to stop. The maximum dose of lidocaine is 5mg per kg of body weight (280 mg of lidocaine in a 55kg woman or approximately 40cc of the final mixture).
2975325|NCT02728037|Active Comparator|Lidocaine-Only Injection Formulation|Examination will involve systematic palpation of the 3 distinct levels of pelvic musculature. Injections into level 1 and level 2 muscles will be done under ultrasound guidance. Level 3 injections will be facilitated with a trumpet guide when needed. As the pelvic muscle trigger points are identified they will be injected with 2-3ml of the prepared injection formulation. The investigator will continue until no further trigger points can be identified, a maximum dose of lidocaine has been used, or the participant indicates they wish to stop. The maximum dose of lidocaine is 5mg per kg of body weight (280 mg of lidocaine in a 55kg woman or approximately 40cc of the final mixture).
2975326|NCT02728037|No Intervention|Wait-Listed Patients|This arm is a non-randomized, no-treatment arm consisting of women who are on the waiting list for the chronic pain clinic.
2975327|NCT02728024||A|Complete the questionnaires with personal aid
2975328|NCT02728024||B|questionnaires are completed by patients alone
2975329|NCT02728011|Experimental|Intervention|Scientific Brain Training (SBT)
2975330|NCT02728011|Placebo Comparator|Controle|Tetris
2975331|NCT02727998|Experimental|Ketamine with prolonged exposure|After the reactivation of the scripted memories during PE on day 2, the ketamine infusion procedure will begin inside the MRI. A physician will oversee and administer the ketamine infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following ketamine infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady state ketamine infusion of 0.50 mg/kg/hour. The infusion will continue for 40 minutes.
2975332|NCT02727998|Active Comparator|Midazolam with prolonged exposure|After the reactivation of the scripted memories during PE on day 2, the midazolam infusion procedure will begin inside the MRI. A physician will oversee and administer the Midazolam infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following midazolam infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady midazolam infusions at a rate 0.045 mg/kg for 40 minutes.
2975333|NCT02727985|Experimental|Pharmacist weaning schedule|The Neuromodulation clinic pharmacist will develop a weaning schedule for these patients. Schedules will be individualized taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
2975334|NCT02727985|No Intervention|Self/Family Physician weaning schedule|Patients will wean off their opioids by themselves or with their family physician without the assistance of a prepared schedule.
2975335|NCT02727972|Other|Cognitive Testing|Cognitive assessments
2975336|NCT02727972|Active Comparator|Magnetic Resonance Imaging|All subjects will have one MRI with a possibility of one functional MRI (fmri).
2975337|NCT02727972|Active Comparator|Positron Emission Tomography|All subjects will have PET scan using FPEB or ABP688.
2975338|NCT02727959||Patients newly diagnosed with IBD|
2975339|NCT02727959||Symptomatic non IBD-controls|Patients referred with symptoms suspicious of IBD, but who, after examination, are found not to have the diagnosis.
2975444|NCT02727179|Experimental|Laparoscopic group|Liver resection performed by laparoscopic approach
2975340|NCT02727946|Other|optimal resuscitation|This group of multiple trauma patients will be resuscitated with crystalloids, analgesics, blood products as needed. Then follow up of the difference between arterial and venous CO2 to difference between arterial and venous oxygen tension, serum lactate, renal function, other organ affection along over the short hospital stay period
2975341|NCT02727920|Experimental|Experimental|drink containing pyridoxine, folate; B12); taurine, choline, glucuronic acid; tyrosine, phenylalanine*, malic acid, and caffeine administered one time.
2975342|NCT02727920|Placebo Comparator|Placebo drink|Placebo drink administered one time.
2975343|NCT02727907|Experimental|BCD-033|Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
2975344|NCT02727907|Active Comparator|Rebif|Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks, followed by 48 weeks of open-label BCD-033 usage
2975345|NCT02727907|Placebo Comparator|Placebo|Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for 48 weeks, followed by 72 weeks of open-label BCD-033 usage
2975346|NCT02727894||Screening|Patients with colorectal cancer diagnosed by screening procedures (primary screening colonoscopy, colonoscopy after FOBT).
2975347|NCT02727894||Others|Patients with colorectal cancer diagnosed by other diagnostic procedures (diagnostic colonoscopy, CT, MR, USG, urgent surgery, etc.)
2975348|NCT02727881|Experimental|Squalamine solution, 0.2% BID|Squalamine lactate ophthalmic solution, 0.2% bis in die (BID) + ranibizumab every 4 weeks
2975349|NCT02727881|Placebo Comparator|Placebo solution BID|Placebo ophthalmic solution BID + ranibizumab every 4 weeks
2975350|NCT02727868|Other|exclusive breast irradiation group|to assess the impact of irradiation areas
2975351|NCT02727868|Other|breast and sternal irradiation group|to assess the impact of irradiation areas
2975352|NCT02727842|Experimental|Treatment group|All patients will receive the CP950 Sound Processor and be part of the treatment group for one month which is programmed via the wireless programming pod
2975353|NCT02727816|Experimental|filcon IV I (BC 8.6) / ocufilcon D (pair one)|Participants were randomized to a test and control lens for each pair in a contralateral design.
2975354|NCT02727816|Experimental|filcon IV I (BC 8.7) / ocufilcon D (pair two)|Participants were randomized to a test and control lens for each pair in a contralateral design.
2975355|NCT02727816|Experimental|methafilcon A (BC 8.6) / ocufilcon D (pair three)|Participants were randomized to a test and control lens for each pair in a contralateral design.
2975356|NCT02727816|Experimental|methafilcon A (BC 8.7) / somofilcon A (pair four)|Participants were randomized to a test and control lens for each pair in a contralateral design.
2975357|NCT02727803|Experimental|Treatment Plan #1|"Participants with ALL, AML, NHL, CLL, CML, HD, and MM who are >/= 18 and </= 55 years old receive myeloablative regimen #1. Patients > 55 but < 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the Myeloablative Regimen 1 at the discretion of the investigator(s).~Participants receive busulfan, fludarabine, clofarabine, and antithymocyte globulin (ATG) by vein, as well as total body irradiation (TBI)."
2975358|NCT02727803|Experimental|Treatment Plan #2|"Participants with AML, ALL, NHL, CLL, CML, HD and MM who are > 55 and </= 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy receive Nonmyeloablative Regimen #2.~Participants receive rituximab (only for those with CD20+ malignancies) or no rituximab (without CD20+ malignancies), fludarabine, cyclophosphamide, mesna, and ATG by vein, as well as total body irradiation (TBI)."
2975359|NCT02727803|Experimental|Treatment Plan #3|"Participants with AML, ALL, NHL, CLL, CML, and HD who are >/= 18 and </= 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy receive Reduced Intensity Regimen #3.~Participants receive fludarabine, ATG, and melphalan by vein."
2975360|NCT02727790|Experimental|PES Treatment|Eligible patients will receive daily 5 min PES treatment for two weeks. Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) continuous glucose monitor (CGM) System
2975361|NCT02727790|No Intervention|Control|Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) CGM System
2975362|NCT02727777|Experimental|Aggressive Non-Hodgkin Lymphoma (NHL) - TAK228|"Phase II - Aggressive NHL: Diffuse Large B Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Transformed Large Cell Lymphoma, and Follicular Lymphoma (FL) grade 3b Group~Participants take TAK-228 1 time every day of a 28 day cycle.~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.~Participant checks blood sugar every day before TAK-228 dose."
2975363|NCT02727777|Experimental|Indolent Non-Hodgkin Lymphoma (NHL) - TAK228|"Phase II - Indolent NHL: Follicular Lymphoma (FL) grade 1-3a, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL) Group~Participants take TAK-228 1 time every day of a 28 day cycle.~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.~Participant checks blood sugar every day before TAK-228 dose."
2975364|NCT02727777|Experimental|Hodgkin Lymphoma - TAK228|"Phase II - Hodgkin Lymphoma Group~Participants take TAK-228 1 time every day of a 28 day cycle.~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.~Participant checks blood sugar every day before TAK-228 dose."
2975365|NCT02727764|Experimental|Cohort I|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e12 vg/ MCP joint, 0.6x10e12 vg/ PIP joint or 0.3x10e12 vg/ DIP joint single intra-articular injection
2975366|NCT02727764|Experimental|Cohort II|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e13 vg/ MCP joint, 0.6x10e13 vg/ PIP joint or 0.3x10e13 vg/ DIP joint single intra-articular injection
2975367|NCT02727764|Experimental|Cohort III|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e13 vg/ MCP joint, 0.6x10e13 vg/ PIP joint or 0.3x10e13 vg/ DIP joint ART-I02 or maximum Tolerated Dose (MTD) as assessed in cohorts I and II: single intra-articular injection
2975368|NCT02727751|Experimental|50mg BID|Tenapanor, 50 mg BID (100 mg total)
2975369|NCT02727738|Experimental|Methimazole plus selenium|Methimazole 5-30 mg daily for 90 days Selenium 80 bid for 90 days
2975370|NCT02727738|Active Comparator|Methimazole|Methimazole 5-30 mg daily for 90 days
2975371|NCT02727725|Experimental|Traminer MRI Sequence|The TRAMINER MRI sequence implementation to be tested allows the acquisition of high resolution MR images in the free-breathing patient, by combining multiple averages and motion correction with the TRAMINER preparation.
2975445|NCT02727179|Active Comparator|Open group|Liver resection performed by open approach
2975372|NCT02727712|Experimental|TPVB T2/3+T5/6+GA|the group A of patients has been received bilateral thoracic paravertebral block (TPVB T2/3+T5/6) by ropivacaine(0.3%,10ml*4), before general anesthesia management
2975373|NCT02727712|Experimental|TPVB T3/4+GA|the group Bof patients has been received bilateral thoracic paravertebral block (TPVB 3/4) by ropivacaine(0.3%,10ml*4), before general anesthesia management Device: The use of Transesophageal Echocardiography（TEE）、STAT PROFILE® and Haemonetics® during the surgery
2975374|NCT02727712|Placebo Comparator|GA|group C under control (without TPVB)program Device: The use of Transesophageal Echocardiography（TEE）、STAT PROFILE® and Haemonetics® during the surgery
2975375|NCT02727699|Experimental|Xanamem™|Oral Xanamem™ capsules 10mg, to be administered once daily
2975376|NCT02727699|Placebo Comparator|Placebo|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily
2975377|NCT02727686|Experimental|Water Load (WL) Post-Operative Day 1|All enrolled subjects passing conditions outlined in Intervention are eligible to be included. WL will be calculated (20 mL/kg body weight) and supplied at the bedside. Patient will have 30 minutes to consume WL, or will be excluded.
2975378|NCT02727673||healthy volunteers|matched group
2975379|NCT02727673||hepatitis cirrhosis|negative group
2975380|NCT02727673||hepatocellular carcinoma|patients with primary HCC
2975381|NCT02727660|Experimental|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol - 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
2975382|NCT02727660|Experimental|BFF MDI (PT009) 160/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol - 80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
2975383|NCT02727660|Experimental|FF MDI (PT005) 9.6 μg|Formoterol Fumarate Inhalation Aerosol - 4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
2975384|NCT02727647|Experimental|Arm 1|FVIII concentration at 35-40 U/kg/dose 1 time/week for 5 months
2975385|NCT02727647|Experimental|Arm 2|FVIII concentration at 15-20 U/kg/dose 2 time/week for 5 months
2975386|NCT02727634|Other|Postoperative elective CABG patients|Patients included for coronary artery bypass graft (CABG) surgery, secondary to ischaemic heart disease.
2975387|NCT02727621|Active Comparator|Dexmedetomidine group|
2975388|NCT02727621|Active Comparator|Propofol group|
2975389|NCT02727608|Experimental|Eculizumab|Intravenous infusion
2975390|NCT02727595|Experimental|CyclaPlex Implant|Implant device for reduction of the inter metatarsal angle (IMA) without osteotomy.
2975391|NCT02727569||Feasibility Study|10 subjects. Subjects will performed two different versions of the new visual field algorithm with DLS (differential light sensitivity) strategies. Two repeats of each strategy will be performed.
2975392|NCT02727569||Clinical evaluation study|100 subjects. Subjects will performed a visual field assessment with the new visual field algorithm with MMDT (Moorfields Motion Displacement Test) and DLS -like stimuli and a commercial available SITA algorithm (DLS-like strategy). Two repeats of each strategy will be performed.
2975393|NCT02727556|Experimental|Functional dyspepsia patient|Visual stimuli of food and non-food images will be presented to patients. Non-food images include positive, neutral, negative emotional pictures.
2975394|NCT02727556|Experimental|Healthy|Visual stimuli of food and non-food images will be presented to participants. Non-food images include positive, neutral, negative emotional pictures.
2975395|NCT02727543|No Intervention|Control|Participants randomized to this arm will not receive the intervention.
2975396|NCT02727543|Experimental|Intervention|Participants randomized to this arm will receive the intervention, Medisafe, a smartphone application.
2975397|NCT02727530|Experimental|GROUP RECEIVING VISCERAL MANUAL THERAPY-ADVICES|Subjects will receive 2 manual therapy sessions and advices.
2975398|NCT02727530|Experimental|GROUP RECEIVING ADVICES|Subjects will receive advices.
2975399|NCT02727517|Active Comparator|Early (≤ 60 seconds) cord clamping|Early (≤ 60 seconds) cord clamping
2975400|NCT02727517|Active Comparator|Delayed cord clamping|Delayed (≥ 180 seconds) cord clamping
2975401|NCT02727504||Patient with aortic valve stenosis|"115 patients will undergo a medical examination in order to analyse their medical history, cardiovascular parameters and check inclusion and non-inclusion criterions.~Then will be performed :~An electrocardiogram~2D and 3D echocardiography~Dobutamine stress echocardiography~Blood tests : blood electrolytes, creatinine, hemoglobin, N-terminal pro-brain natriuretic peptide (NT-ProBNP), C reactive protein (CRP), soluble suppression of tumorigenicity-2 (ST-2)~A cardiac MRI~A cardiac scanner~A 6-minutes walking test~An evolution of the Duke Activity Score"
2975402|NCT02727491|Experimental|dextromethorphan|1 mg/kg of dextromethorphan syrup orally 30 min preoperatively and then again 8 hours post-tonsillectomy
2975403|NCT02727491|Placebo Comparator|Placebo|30 min preoperatively and then again 8 hours postoperatively, received inactive placebo syrup identical in volume, appearance and taste as the experimental group
2975404|NCT02727478|Experimental|Balance training group|1 hour group balance training twice weekly for 10 weeks, as well as perform a home exercise program.
2975405|NCT02727478|No Intervention|Control group|Subjects in this group will receive no intervention and will be advised to continue their normal level of exercise throughout the intervention period.
2975406|NCT02727465||meningitis cases|any individual with culture-confirmed IMD in England from 01 September 2015 to 31 August 2019 with written informed consent from the individual, the parent (for children aged <16 years) or next-of-kin (for non-survivors)
2975407|NCT02727452|Experimental|immediate mother-skin-to-skin contact(SSC)|The immediate mother-SSC begins directly after birth (still during the C-section)
2975408|NCT02727452|Active Comparator|immediate father-SSC|The immediate father-SSC begins directly after birth (still during C-section)
2975409|NCT02727452|Other|Routine care;mother-SSC after 30 minutes|After birth (still during C-section) the newborn gets routine care of a midwife close to the mother. SSC with mother after 30 minutes
2975410|NCT02727439|Experimental|Sedentary Subjects|Healthy lean sedentary subjects.
2975411|NCT02727439|Experimental|Athletes|Active athletes.
2975412|NCT02727426|Experimental|low salt diet|All subjects will be instructed to maintain a low-sodium (LS) diet, with an intake of less than 2.3 g of salt per day (DASH eating plan; US Department of Health and Human Services, 2006) for 7 days (washout period).
2975413|NCT02727426|Experimental|high salt diet|After washout period, all subjects will be instructed to maintain a high-sodium (HS) diet, with an intake of 11.2 g of salt per day for 7 days.
2975414|NCT02727413||Infective endocarditis|Blood sample collection and assessment of signs of organ dysfunction in patients diagnosed with infective endocarditis in accordance with Duke criteria and scheduled for valve surgery
2975415|NCT02727413||Valvular heart disease|Blood sample collection and assessment of signs of organ dysfunction in patients diagnosed with valvular heart disease, with no signs of infection, scheduled for valve replacement surgery
2975416|NCT02727400||advanced maternal age|Infertile women due to advanced maternal age
2975417|NCT02727400||Young patients|women under 35 undergoing infertility treatments
2975418|NCT02727387|Experimental|TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL|2cycles of Temozolomide(500 mg/m2)+Irinotecan(250 mg/m2) and 2cycles of Vincristine(1.4mg/m2)+ Adriamycin(90mg/m2)+Ifosfamide (9gr/m2) alternes with 2 cycles of Ciclofosfamide(4g/m2)+Etoposide (600mg/m2) followed by radiotherapy (42-54 Gy) and 2cycles of Ifosfamide (9gr/m2) + Etoposide(300mg/m2) alternes with to 2cycles of Vincristine (1.4mg/m2)+ Adriamycin (80mg/m2)+ Ciclofosfamide(1.2g/m2) and Busulfan(0.8-1.2 mg/Kg)+Melfalan(140 mg/m2)+PBSCT and 6 months with Celecoxib (500mg/m2/die for<14 years old ,800 mg/die for>14 years old) Ciclofosfamide (oral therapy 35mg/m2/die for<14 years old, 50 mg/m2 for>14 years old)
2975419|NCT02727374|Experimental|EXPERIMENTAL|Physiotherapy intervention, plus cognitive-behavioural intervention
2975420|NCT02727374|Active Comparator|CONTROL|Physiotherapy intervention
2975421|NCT02727361|Experimental|Cholinergic striatal imaging|Cholinergic striatal imaging (IRM and TEP) to compare the intensity of the binding of cholinergic tracer
2975422|NCT02727348|Experimental|Sciatic block with or without femoral block|Sciatic block with or without femoral block performed on the patient with 3mg/kg of ropivacaine
2975423|NCT02727348|Active Comparator|Spinal anaesthesia|Spinal anaesthesia will be performed on the patient with heavy marcaine 0.5% up to 3mls
2975424|NCT02727335||patients ALK + who received crizotinib|patients with ALK rearrangement who started treatment with crizotinib (250 mg twice a day) between the 18/11/2010 and the 31/12/2013 (will include patients from the ATU programs and patients treated after the marketing of crizotinib)
2975425|NCT02727322|Active Comparator|Nitrofurantoin|Receives once daily nitrofurantoin 100mg
2975426|NCT02727322|Placebo Comparator|Placebo|Receives matching placebo
2975427|NCT02727309|Experimental|apatinib|Patients with advanced hepatocellular carcinoma after been treated with TACE receive apatinib (750mg) daily, until disease progression or unacceptable toxicity.
2975428|NCT02727296|Active Comparator|propofol|Group 1 PROP (control): propofol: a propofol-remifentanil based general anesthesia.
2975429|NCT02727296|Active Comparator|sevoflurane|Group 2 SEVO (intervention): Sevoflurane: a sevoflurane-remifentanil based general anesthesia.
2975430|NCT02727283|Experimental|Cohort 1|Subjects will receive 1 placebo and 3 escalating doses in one of the four treatment periods. The planned dose range is 10 mg to 200 mg. A review of safety and tolerability will occur prior to administration of the next dose level and the same procedure will be followed for each escalating dosing period. The actual doses to be administered may be adjusted based on safety, tolerability, and pharmacokinetic data at previous dose levels; these dose adjustments may involve either an increase or a decrease in the planned dose for both Cohorts 1 and 2
2975431|NCT02727283|Experimental|Cohort 2|Cohort 2 will proceed after completion of the treatment periods in Cohort 1. Subjects assigned to Cohort 2 will participate in up to 4 dosing periods which include up to 2 escalating doses and placebo in Periods 1 and 2, and a pilot food effect in Periods 3 and 4. A review of safety and tolerability will occur prior to administration of the next dose level and the same procedure will be followed for each escalating dosing period. The actual doses to be administered may be adjusted based on safety, tolerability, and pharmacokinetic data at previous dose levels; these dose adjustments may involve either an increase or a decrease in the planned dose for both Cohorts 1 and 2
2975432|NCT02727270||Parkinson's - High Stress|Parkinson's disease patients with self-reported high strain/stress.
2975433|NCT02727270||Parkinson's - Low Stress|Parkinson's disease patients with self-reported low strain/stress.
2975434|NCT02727270||Controls|Healthy controls (no neurological disease).
2975435|NCT02727257|Experimental|MIRT|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The first session comprise cardiovascular warm-up activities, relaxation, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. All the exercises are aerobic. The third is a session of occupational therapy to improve autonomy in day living activities. The last session includes one hour of speech therapy.
2975436|NCT02727257|No Intervention|healthy controls|we assessed the attentive Reaction Times in healthy controls, that don't receive rehabilitative treatment
2975437|NCT02727231|Experimental|day and night closed loop control|Subjects glucose levels are controlled by Florence D2A or similar closed loop insulin delivery system
2975438|NCT02727231|Active Comparator|usual insulin pump therapy management|Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (FreeStyle Navigator CGM)
2975439|NCT02727218|Experimental|chest tube removal after 3 hours|30 patients, post thoracoscopic lobectomy, segmentectomy, thoracoscopic mediastinal biopsy, will undergo chest tube removal after 3 hours.
2975440|NCT02727218|Active Comparator|delayed chest tube removal|30 patients, post thoracoscopic lobectomy, segmentectomy, thoracoscopic mediastinal biopsy, will undergo chest tube removal according to the department's protocol, most probably post operative day 1 (POD1)
2975441|NCT02727205|Experimental|Single Arm|One-half (½) of the test patch and one-half (½) of the reference patch (Rotigotine Transdermal System) was applied daily to the same site for each product over a 21 day period followed by a 14 day rest phase and a 48 hour challenge phase.
2975442|NCT02727192|Active Comparator|PAP-therapy (CPAP or ASV)|Patients are randomized to either intervention Group: Positive airway pressure therapy (PAP-therapy) or Control. Patients in the intervention arm will be treated with PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).
2975443|NCT02727192|No Intervention|Control group|No sleep apnea treatment
2975446|NCT02727166|Experimental|Inulin 8 g/d|Mixture of oligo- and polysaccharides composed of fructose units connected by β (2→1) links with a total number of fructose and glucose units ranging between 2 and 70.
2975447|NCT02727166|Placebo Comparator|maltodextrine 8 g/d|
2975448|NCT02727153|Experimental|"Ultra E.R.A.S."|Discharge patients on Post Operative Day 2
2975449|NCT02727153|Active Comparator|Classic E.R.A.S.|Discharge patients on Post Operative Day 4
2975450|NCT02727140|Experimental|Yoga with Asana (yoga postures)|
2975451|NCT02727140|Experimental|Yoga without Asana (yoga postures)|
2975452|NCT02727140|No Intervention|Wait-list control group|
2975453|NCT02727127||Healthy Volunteers|MRI on 3 Tesla (3T) or 7 Tesla (7T) scanner, without contrast
2975454|NCT02727127||Bipolar Patients|MRI on 3 Tesla (3T) or 7 Tesla (7T) scanner, without contrast
2975455|NCT02727114||participants aged 8 weeks to 3 years|"Echographic measurement of skin thickness at the proximal forearm, the deltoid region and medial thigh (till age of 2 years) in participants aged 8 weeks to 3 years.~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
2975456|NCT02727114||participants aged 3 to 6 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 3 to 6 years.~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
2975457|NCT02727114||participants aged 6 to 12 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 6 to 12 years.~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
2975458|NCT02727114||participants aged 12 to 18 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 12 to 18 years.~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
2975459|NCT02727101|Active Comparator|phenobarbital|"After 12 weeks of baseline observation on phenobarbital medication, the treatment with perampanel will introduced as add on medication."
2975460|NCT02727101|Active Comparator|valproate|"After 12 weeks of baseline observation on valproate medication, the treatment with perampanel will introduced as add on medication."
2975461|NCT02727101|Active Comparator|lamotrigine|"After 12 weeks of baseline observation on lamotrigine medication, the treatment with perampanel will introduced as add on medication."
2975462|NCT02727101|Active Comparator|levetiracetam|"After 12 weeks of baseline observation on levetiracetam medication, the treatment with perampanel will introduced as add on medication."
2975463|NCT02727101|Active Comparator|zonisamide|"After 12 weeks of baseline observation on zonisamide medication, the treatment with perampanel will introduced as add on medication."
2975464|NCT02727101|Active Comparator|pregabalin|"After 12 weeks of baseline observation on pregabaline medication, the treatment with perampanel will introduced as add on medication."
2975465|NCT02727101|Active Comparator|lacosamide|"After 12 weeks of baseline observation on lacosasmide medication, the treatment with perampanel will introduced as add on medication."
2975466|NCT02727101|Active Comparator|clobazam|"After 12 weeks of baseline observation on clobazam medication, the treatment with perampanel will introduced as add on medication."
2975467|NCT02727101|Active Comparator|ezogabine|"After 12 weeks of baseline observation on ezogabine medication, the treatment with perampanel will introduced as add on medication."
2975468|NCT02727101|Active Comparator|eslicarbazepine|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
2975469|NCT02727101|Active Comparator|topiramate|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
2975470|NCT02727101|Active Comparator|tiagabine|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
2975471|NCT02727088|Active Comparator|Pulpectomy : root canal treatment|Pulpectomy : ablation of the whole dental pulp, preparation and filling of the whole root canal system
2975472|NCT02727088|Experimental|Pulpotomy : Conservative pulp management|Pulpotomy : ablation of the coronal part of the pulp
2975473|NCT02727062|Experimental|OM Pain Smartphone Application|This study examines whether the smartphone OM Pain App is a feasible and valid tool to assess pain from radiation-induced oral mucositis.
2975474|NCT02727049|Experimental|injured athlete for OMM|Participating athletes who sustain an injury will receive standard of care with the Intervention osteopathic manipulative medicine (OMM)
2975475|NCT02727049|No Intervention|injured athlete no OMM|Participating athletes who sustain an injury will receive standard of care withOUT osteopathic manipulative medicine (OMM)
2975476|NCT02727036|Experimental|Pumpkin seed oil|Pumpkin seed oil (1g) capsules - 2 capsules per day for 12 weeks
2975477|NCT02727036|Active Comparator|Pumpkin seeds|Packet of pumpkin seeds (4.1 grams /~0.15ounces) - 1 pack per day for 12 weeks
2975478|NCT02727023|Experimental|Osteopathic Manipulative Medicine|The thoracic inlet release, The Miller Thoracic Pump, Pedal Pump will be performed. These techniques are gentle and would be rhythmic in motion.
2975479|NCT02727010||mothers with motor impairment due to a rare disease|20 Women with motor impairment due to a rare disease
2975480|NCT02727010||mothers with motor impairment not related to a rare disease|controls, 20 women with motor impairment not related to a rare disease
2975481|NCT02726997|Experimental|Durvalumab + Carboplatin + Paclitaxel|"Phase I (Safety Lead-In): Participants receive Durvalumab, Carboplatin, and Paclitaxel at dose depending on when they join the study. Once maximum tolerated dose combination is reached Phase II portion of study begins.~Phase II: Participants receive Durvalumab, Carboplatin, and Paclitaxel at the maximum tolerated dose from Phase I for three, 21 day cycles. Interval debulking surgery is then performed followed by 3 more cycles of drug combination.~Maintenance Phase: Participants receive Durvalumab alone every 2 weeks for 7 more 28 day cycles.~Questionnaires completed about possible side effects, symptoms, quality of life, and satisfaction with care completed at baseline, week 1 of cycles 7 - 13 during Maintenance Phase, end of treatment visit, and at follow up visit 30 days after Durvalumab therapy."
2975482|NCT02726984|Experimental|case|Patients with carotid plaque ≥ 50% symptomatic (ischemic stroke on CT or MR) during the last 15 days
2975483|NCT02726984|Experimental|control|Patients with asymptomatic carotid plaque ≥ 50%
2976415|NCT02720705|Placebo Comparator|Saline Control|2ml oral 0.9%saline half an hour before operation
2975484|NCT02726971|Experimental|Low dose of oestrogen|"Patients in this group will build artificial cycle by Femoston.(oral one red tablet daily for 11 days and oral one yellow tablet in the next 10 days). This process will last for 3 months after the surgery.~P.S.1.A red tablet contains 2mg estradiol. 2.A yellow tablet contains 2mg estradiol and 10mg dydrogesterone."
2975485|NCT02726971|Active Comparator|High dose of oestrogen|"Patients in this group will build artificial cycle by Femoston.(oral three red tablets daily for 11 days and oral two yellow tablets in the next 10 days). This process will last for 3 months after the surgery.~P.S.1.A red tablet contains 2mg estradiol. 2.A yellow tablet contains 2mg estradiol and 10mg dydrogesterone."
2975486|NCT02726958||group M|patients who died or suffered from stroke, acute coronary syndrome, heart failure, complete atrioventricular block or life-threatening ventricular arrhythmias within 30 days after the procedure
2975487|NCT02726958||group T|other patients
2975488|NCT02726945|Experimental|Low Dose SVF|This group of subjects will receive a low dose of SVF for treatment of knee OA.
2975489|NCT02726945|Experimental|High Dose|This group of subjects will receive a high dose of SVF for treatment of knee OA.
2975490|NCT02726945|Placebo Comparator|Placebo|This group of subjects will receive a placebo with no SVF Cells for treatment of knee OA.
2975491|NCT02726919|Other|Clobazam treatment|This will be an open label study comparing seizure frequency during 12 weeks of baseline observation period with seizure frequency during 16 weeks of clobazam adjunctive treatment
2975492|NCT02726906|Experimental|Moderate-aerobic walking|Participants will complete a 6-month home-based moderate-aerobic walking program of 150 minutes per week with the assistance of an interventionist.
2975493|NCT02726906|Placebo Comparator|Healthy Living Education|Participants will receive monthly topics on healthy living lifestyles for self-paced reading over 6 months with the assistance of an interventionist.
2975494|NCT02726893||patients undergoing colonoscopy|patients undergoing colonoscopy were observed in terms of the bowel preparation quality which is measured by Boston Bowel Preparation Scale (BBPS).
2975495|NCT02726880|Active Comparator|Referral for care|
2975496|NCT02726880|Experimental|Behavioral therapy|
2975497|NCT02726867|Active Comparator|levetiracetam|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 4000 mg levetiracetam.
2975498|NCT02726867|Active Comparator|lacosamide|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 600 mg lacosamide.
2975499|NCT02726867|Active Comparator|ketamine|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 2.5 mg/kg ketamine.
2975500|NCT02726867|Active Comparator|phenobarbital|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin (PHT) with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after PHT loading will receive intravenously (i.v.) phenobarbital 15 mg/kg.
2975501|NCT02726854|Experimental|Apatinib|Patients will be offered with Apatinib (850mg daily,orally)until their disease have progressed.
2975502|NCT02726841|Experimental|Hybrid TAAD repair|The group includes patients who underwent open thoracoabdominal aortic repair + abdominal stenting.
2975503|NCT02726841|Active Comparator|Conventional TAAD repair|The group includes patients who underwent classic thoracoabdominal aortic repair with dacron prosthesis.
2975504|NCT02726828|Active Comparator|group I: morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg morphine in 1 ml volume intrathecally.
2975505|NCT02726828|Active Comparator|group II: ketamine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume intrathecally.
2975506|NCT02726828|Active Comparator|group III: morphine + ketamine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg morphine plus 0.1 mg/kg of Ketamine in 1 ml volume intrathecally.
2975507|NCT02726802|Experimental|Physical Therapy route of entry|The subject will see a physical therapist as their initial encounter into the healthcare system
2975508|NCT02726802|Active Comparator|Primary Care Provider rout of entry|The subject will see a primary care provider as their initial encounter into the healthcare system
2975509|NCT02726789|Experimental|treatment naive|treatment naive patients receive REP 2139-Ca in combination with pegylated interferon.
2975510|NCT02726789|Experimental|previous exposure to entecavir|patients with previous entecavir exposure receive REP 2139-Ca in combination with pegylated interferon while continuing their entecavir therapy.
2975511|NCT02726776|Experimental|Suspension without prior climbing|Free Suspension in a harness after baseline measurements and without prior climbing
2975512|NCT02726776|Experimental|Suspension with prior climbing|Free Suspension in a harness after baseline measurements and after climbing in moderate intensity for 10 minutes
2975513|NCT02726763|Experimental|tDCS with cognitive training|We will collect: 1) self-reported demographic information (~5 min) 2) cognitive functioning data (PAOFI) at session 1 and session 4 (~10min) [60]; 3) behavioral data and EEG data from the tDCS stimulation task for each session (downloaded by investigators); 4) patient feedback on their experience with tDCS (tDCS Patient Experience Questionnaire (tPEQ)) for each session (~5 min); 5) tDCS accrual and session completion rates at the completion of treatment and 6) Brunoni Adverse Events Questionnaire (~5 min)
2975514|NCT02726750||Monoclonal Gammopathy of Unknown Significance (MGUS)|Participants with monoclonal gammopathy of unknown significance (MGUS) at MD Anderson Cancer Center.
2975515|NCT02726750||Smoldering Multiple Myeloma (SMM)|Participants with smoldering multiple myeloma (SMM) at MD Anderson Cancer Center.
2975516|NCT02726737|Experimental|sodium bicarbonate|0.7 mL of 8.4% sodium bicarbonate & 0.3 mL of 2% lidocaine with 1:100,000 epinephrine
2975517|NCT02726737|Active Comparator|Non-sodium bicarbonate|Sterile distilled water & 0.3 mL of 2% lidocaine with 1:100,000 epinephrine
2975518|NCT02726724|Experimental|Condition B|An audience of 5 people with at least 2 neonatologists will be present with the operator during the intubation of the mannequin.
2975519|NCT02726724|Experimental|Condition A|Only the staff will be present with the operator during the intubation of the mannequin.
2975520|NCT02726711|Experimental|Trimethaphan|"The investigator will measure cardiac output by studying the air the participant breathes in and out. The participant will also wear a facemask to apply a low air pressure to the airway.~After this, the trimethaphan infusion will begin with a small dose and the investigators increase at 1-2 minute intervals for up to five doses. The measurements will be collected again.~Next, a standard blood pressure cuffs will be wrapped around the participant's abdomen. the cuff will inflate to apply pressure for 5 - 15 minutes."
2975521|NCT02726711|Placebo Comparator|Placebo|"The investigator will measure cardiac output by studying the air the participant breathes in and out. The participant will also wear a facemask to apply a low air pressure to the airway.~After this, the placebo (saline) infusion will begin with a small dose and the investigators increase at 1-2 minute intervals for up to five doses. The measurements will be collected again.~Next, a standard blood pressure cuffs will be wrapped around the participant's abdomen. the cuff will inflate to apply pressure for 5 - 15 minutes."
2975522|NCT02726685|Experimental|RT (respiratory training) group|Besides traditional rehabilitation therapy, subjects also receive 12-week respiratory training.
2975523|NCT02726685|Sham Comparator|Control group|Besides traditional rehabilitation therapy, subjects receive 12-week sham training unrelated to respiratory function.
2975524|NCT02726672|Experimental|Respiratory rehabilitation|Respiratory rehabilitation: Powerbreathe training of the inspiratory muscles at home twice a day (2 sessions of 30 inspirations / day) during 10 weeks
2975525|NCT02726672|No Intervention|control group|No respiratory rehabilitation
2975526|NCT02726659|Experimental|Celecoxib|Adjunct celecoxib in 6 week treatment
2975527|NCT02726659|Placebo Comparator|Placebo|Adjunct placebo in 6 week treatment
2975528|NCT02726646|Placebo Comparator|Debridement|mechanical debridement in one session and application of 1 mg placebo microspheres in two periodontal pockts between 5 and 6 mm, and two periodontal pockts greater than or equal to 7 mm
2975529|NCT02726646|Experimental|Debridement plus Doxycycline|mechanical debridement in one session associated with the application of 1 mg of microspheres loaded with doxycycline per periodontal pockts, two periodontal pockts between 5 and 6 mm, and two periodontal pockts greater than or equal to 7 mm
2975530|NCT02726620|Experimental|Attending real-time decision support|Near real-time decision support elements will notify the attending anesthesiologists of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the pager system. The page will also display the associated increased risk of organ injury due to organ ischemia.
2975531|NCT02726620|Experimental|In-room real-time decision support|Near real-time decision support elements will notify the in-room anesthesia provider of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the anesthesia information management system. The decision support system will display the associated increased risk of organ injury due to organ ischemia.
2975532|NCT02726620|Experimental|Attending feedback emails|Attending anesthesiologists will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia. The feedback emails will be sent by the Perioperative Data Warehouse (PDW).
2975533|NCT02726620|Experimental|In-room provider feedback emails|In-room anesthesia providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia. The feedback emails will be sent by the Perioperative Data Warehouse (PDW).
2975534|NCT02726607|Experimental|HITSystem 2.0|Pregnant women who are eligible for PMTCT services will be enrolled in the HIV Infant Tracking System 2.0 (HITSystem 2.0) intervention during their first PMTCT appointment and followed until 12 weeks postpartum.
2975535|NCT02726607|Active Comparator|Standard of PMTCT Care|Pregnant women who are eligible for PMTCT services will receive standard of care PMTCT services at the control hospital. The records of women enrolled during their first PMTCT appointment will be used to assess outcomes during the same follow-up period.
2975536|NCT02726594||Patients|For the present study, patients who are assigned to the clinically indicated MRI scan, as well as healthy subjects will be included. Healthy volunteers will be recruited through public notices (flyer) (mainly in the district of the University Zurich / USZ). For all patients, the duration of clinical MRI routine examination is 30-90 minutes, depending on the requirements to answer the clinical question. The subjects are interviewed after the MRI scan by a visual analog scale oral and written on various aspects of their perception during the examination. This means an additional expenditure of time of about 10 minutes. The patients arises except for this additional time not a disadvantage by taking part in the study.
2975537|NCT02726594||Subjects|For the present study, patients who are assigned to the clinically indicated MRI scan, as well as healthy subjects will be included. Healthy volunteers will be recruited through public notices (flyer) (mainly in the district ETH / USZ). For all patients, the duration of clinical MRI routine examination is 30-90 minutes, depending on the requirements to answer the clinical question. The subjects are interviewed after the MRI scan by a visual analog scale oral and written on various aspects of their perception during the examination. This means an additional expenditure of time of about 10 minutes. The patients arises except for this additional time not a disadvantage by taking part in the study.
2975538|NCT02726581|Experimental|Investigational Arm|Nivolumab, Pomalidomide and Dexamethasone
2975539|NCT02726581|Active Comparator|Control Arm|Pomalidomide and Dexamethasone
2975540|NCT02726581|Experimental|Exploratory Arm|"Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone~Enrollment is closed for this arm"
2975541|NCT02726568|Experimental|Icotinib 375mg Tid|The human subject gets icotinib 375mg, Tid until intracranial PD or intolerable toxicity reaction.
2975542|NCT02726555|Experimental|Red yeast rice and atorvastatin|Participants will receive 4 identically appearing capsules twice daily for 24 weeks: 2 300mg of red yeast rice and 2 10mg of atorvastatin.
2975543|NCT02726555|Active Comparator|Atorvastatin alone|Participants will receive 4 identically appearing capsules twice daily for 24 weeks: 2 placebo and 2 10mg of atorvastatin.
2975544|NCT02726542|Experimental|Growth hormone|Somatropin given by daily subcutaneous injection. Dose will begin at 1mg and be titrated based on insulin-like growth factor 1 (IGF-1) levels.
2975545|NCT02726542|No Intervention|No treatment|(no study treatment - observation only)
2975546|NCT02726529|Experimental|Brighter Bites|Children of families in the intervention group will also receive the Coordinated Approach to Child Health (CATCH) school-based curriculum in addition to families receiving fresh fruits and vegetables to take home from school once a week along with nutrition education for 8 weeks in Fall and 8 weeks in Spring semesters of the school year.
2975547|NCT02726529|Active Comparator|Comparison|
2975548|NCT02726516|Experimental|Treated|Treated volunteers will be administered one dose of PRJ-205 1,5 hours before the exercise task for the acute testing and will be taking one dose per day of PRJ-205 for 4 days for the chronic testing.
2975549|NCT02726516|Placebo Comparator|Placebo|Placebo volunteers will be administered one dose of placebo 1,5 hours before the exercise task for the acute testing and will be taking one dose per day of placebo for 4 days for the chronic testing.
2975550|NCT02726503|Experimental|Treatment Arm|
2975551|NCT02726490|Active Comparator|Glyburide|"Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.~The starting dose of glyburide may be 2.5milligrams (mg) to 5mg every day(QD) or twice daily (BID) depending on the degree of hyperglycemia.~The dose of glyburide will be increased as needed to a maximum of 20mg /day.~Antenatal testing will be initiated at 28 weeks~Patients will receive monthly growth scans"
2975552|NCT02726490|Active Comparator|Glucovance|"Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.~The starting dose of glucovance may be 1.25/250milligrams (mg) either once daily (QD) or twice a day (BID) increased to a maximum of 20mg/2000mg as needed.~Patients will receive monthly growth scans~Antenatal testing will be initiated at 28 weeks."
2975553|NCT02726477|Experimental|Wuling San|"This is a double-blinded, randomized placebo-controlled, multi-center clinic trial, using before and after treatment measurements.~A total of 200 clinical diagnosed BCRL participants with affected arm circumference 10-40% larger than unaffected arm, are randomly allocated to two groups: the Wuling San group or the placebo group, where the intervention group administers Wuling San, at a dosage of 1g/kg, twice a day for six weeks. The primary outcome measurement will be the percentage of limb volume changes measured by perometry."
2975554|NCT02726477|Placebo Comparator|placebo|A total of 200 clinical diagnosed BCRL participants with affected arm circumference 10-40% larger than unaffected arm, are randomly allocated to two groups: the Wuling San group or the placebo group, where the placebo group administers a placebo powder, at a dosage of 1g/kg, twice a day for six weeks. The primary outcome measurement will be the percentage of limb volume changes measured by perometry.
2975555|NCT02726451|Placebo Comparator|Basic Skin Care|Subjects use a basic skin care regimen.
2975556|NCT02726451|Active Comparator|Active Skin Care|Subjects use the Sensi Peel®, Rejuvenating Serum, and C&E Strength Max skin care products in additional to a basic skin care regiment.
2975557|NCT02726438|Experimental|Debio 1450|"Participants will receive 3 oral administrations of Debio 1450 at a dose of 240 mg approximately 12 hours apart. The last dose should be given approximately 2, 4, 6 or 12 hours prior to surgery with 3 patients each to be dosed at each of these time points.~If the surgery is delayed by more than 12 hours postdose, the patients could receive up to 2 additional administrations (approximately 12 hours apart) to ensure that the last dose is administered between 2 and 12 hours before the surgery."
2975558|NCT02726438|No Intervention|Calibration|A single participant will not receive the study drug, providing data to be used as calibration.
2975559|NCT02726425|Experimental|Second Life Participants|Half of participants will receive the Diabetes Self Management Medical Group Visits intervention while meeting in the virtual world (Second Life platform)
2975560|NCT02726425|Active Comparator|Face-to-Face Participants|The other half of the participants will receive the Diabetes Self Management Medical Group Visitsintervention while meeting face-to-face in person at Boston Medical Center.
2975561|NCT02726399|Experimental|Ramucirumab With Trastuzumab and Capecitabine/Cisplatin|This will be a single arm study of ramucirumab 8mg/kg administered intravenously on days 1 and 8 + trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days. On subsequent cycles for all patients capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period, in addition to cisplatin 80mg/m2 administered as an IV infusion every 21 days. Each cycle consists of 21 days.
2975562|NCT02726386|Experimental|ND0612 (Levodopa/Carbidopa solution) - Regimen 1|Regimen 1 of ND0612 (LD/CD solution) continuous subcutaneous infusion over 24 hrs
2975563|NCT02726386|Experimental|ND0612 (Levodopa/Carbidopa solution) - Regimen 2|Regimen 2 of ND0612 (LD/CD solution) continuous subcutaneous for over 14-16 hrs .
2975564|NCT02726373|Experimental|Intermittent walking training|
2975565|NCT02726373|Active Comparator|Continuous Walking Training|
2975566|NCT02726360||Oncology physician|Physicians (MD or DO) in the oncology departments of participating hospitals will complete a survey. Non-English language proficiency will be assessed by self-assessment using Interagency Language Roundtable (ILR) scale, which the PI has previously used. The physician survey is collected among treating physicians of patients enrolled to MSK IRB approved protocols 12-099 and 12-223 at some of the participating hospitals. For physicians who already completed this survey as part of participation in protocol 12-099 or 12-223, data will be extracted from the respective study's REDCap database.
2975567|NCT02726360||patients|Audio record the initial visits between patients and their treating physician. Analyze 42 patient-physician dyad recordings using the Roter Interaction Analysis System (RIAS).
2975568|NCT02726347|Active Comparator|Smokers between the ages of 19-80|current smokers between the ages of 19 and 80
2975569|NCT02726347|Active Comparator|elderly individuals (over age 50)|elderly individuals, defined as subjects age 50 years or older, without a history of frequent infections, COPD, or asthma
2975570|NCT02726347|Active Comparator|COPD subjects|COPD subjects between the age of 19 and 80, without history of recurrent bacterial infections.
2975571|NCT02726347|Active Comparator|Asthmatics subjects|Asthmatics between the ages of 19 and 80
2975572|NCT02726347|Active Comparator|Subjects with recurrent bacterial infections|Individuals between the age of 19 and 80 who have a history of frequent bacterial infections and are being evaluated for humoral immunodeficiency
2975573|NCT02726334|Experimental|Group/Stream 1 - Monotherapy|"Patient group: Patients who have failed at least two lines of chemotherapy for metastatic disease.~Treatment: BNC101 administered via intravenous infusion over 60 minutes weekly.~Patients with stable disease or a response at or after day 56 (2 cycles) will be allowed to continue to receive weekly doses of BNC101 until disease progression."
2975574|NCT02726334|Experimental|Group/Stream 2 - Combination Chemo|"Patient Group: Patients who have failed at least one line of chemotherapy for metastatic disease.~Treatment: BNC101 administered in combination with FOLFIRI~Participants will be treated until disease progression, intolerable toxicity, withdrawal of consent, or study termination by the Sponsor, whichever occurs first."
2975575|NCT02726308|Active Comparator|Dexamethasone Group|I.V. Dexamethasone 5 mg just before induction plus intra-operative 10 ml/kg Ringer's lactate solution.
2975576|NCT02726308|Active Comparator|Dexamethasone and super-hydration Group|I.V. Dexamethasone 5 mg just before induction of anesthesia plus intraoperative 30 ml/kg Ringer's lactate solution
2975577|NCT02726295|Active Comparator|E. coli Nissle 1917 (Mutaflor®)|Mutaflor® group will receive E. coli Nissle 1917 (Mutaflor®) 28mg 2T tid for initial 2 days, then E. coli Nissle 1917, Mutaflor® 4T qd for the next 26 days.
2975578|NCT02726295|Placebo Comparator|Matched placebo|Matched placebo group will receive placebo drug 28mg 2T tid for initial 2 days, then placebo 4T qd for the next 26 days. Placebo drug has same shape and size with E. coli Nissle 1917 (Mutaflor®).
2975579|NCT02726269|Active Comparator|CLA (Clarithro+Lanso+Amoxi)|Clarithromycin 500 mg bid, Lansoprazole 30 mg bid and Amoxicillin 500 bid, tablets of oral administration, during 10 days.
2975580|NCT02726269|Experimental|PLA (Panto+Levoflox+Azithro)|Pantoprazole 80 mg od, Levofloxacin 500 mg od and Azithromycin 500 mg od, tablets of oral administration, during 10 days.
2975581|NCT02726256||Diabetes and Impaired glucose Tolerance (G-CREDIT)|Patients with either type 2 diabetes or impaired glucose tolerance who are older than 20 years old and have attended Gangnam Severance hospital for regular follow up.
2975582|NCT02726243||IBD without CRC|
2975583|NCT02726243||IBD with CRC|
2975584|NCT02726243||IBD with dysplasia|
2975585|NCT02726243||non IBD without CRC|
2975586|NCT02726243||non IBD with CRC|
2975587|NCT02726243||IBD-PSC without CRC|
2975588|NCT02726243||IBD-PSC with CRC|
2975589|NCT02726243||IBD-PSC with dysplasia or healthy subjects|IBD-PSC with dysplasia or healthy subjects for whom a colonoscopy is scheduled
2975590|NCT02726230|Experimental|Ananya Intervention|"Strengthen enumeration and mapping of areas to ensure reach of front line workers (FLWs: auxiliary nurse midwives- ANMs; community health workers- ASHAs; anganwadi workers- AWWs).~Convene monthly FLW meetings to build skills and get trained in job kits to increase the quantity and quality of household visits.~Train FLWs on communication skills and use of mobile kunji, a job-aid tool, to improve FLWs' communication with households.~A mass media campaign inclusive of street theatre, tv and radio, and a mobile van.~Community mobilization linking mass media efforts with self-help groups.~Quality improvement activities at public health facilities.~Facility-based skills training to staff delivering infants to improve quality of care"
2975591|NCT02726230|No Intervention|Control Condition|standard of care public health services in India
2975592|NCT02726217|Experimental|CareSmarts Intervention|Participants in the program receive text messages about diabetes self-care
2975593|NCT02726217|Active Comparator|Control|Standard of Care reminders and assessments for individuals with Diabetes
2975594|NCT02726204|Active Comparator|Healthy Subjects|Seven healthy patients will serve as controls based on preliminary data in healthy volunteers using CAREX with gravity elimination alone versus gravity elimination plus path assistance.
2975595|NCT02726204|Active Comparator|Chronic Post Stroke Right Side Hemiparesis|Radiologically verified unilateral stroke patients with at least 4 months previously.
2975596|NCT02726191|Experimental|Posit Science|
2975597|NCT02726191|Experimental|Lumosity|
2975598|NCT02726178|Experimental|Advil® Pediatric drops for infants|"Oral ibuprofen (Advil® Pediatric drops for infants less than 3 months of age; Wyeth-Ayerst 40 mg/ml, DIN 2242522), at a dosage of 5 mg/kg/dose.~The drug was administered 30 minutes prior to immunization, and then at 8 and 16 hours following the immunization for a total of 3 doses."
2975599|NCT02726178|Placebo Comparator|Control|"Oral placebo: composed of sodium stearate 0.25g + lactose 0.5g + 15 ml of simple syrup, with a measured osmolarity of about 750 mosml/kg.~The drug (or placebo) was administered 30 minutes prior to immunization, and then at 8 and 16 hours following the immunization for a total of 3 doses."
2975600|NCT02726152|Experimental|Polymer clips|Patients will be randomised to polymer clips for closure of the appendiceal stump
2975601|NCT02726152|Active Comparator|Endoloops|Patients will be randomised to endoloops for closure of the appendiceal stump
2975602|NCT02726139||Emory University|Samples obtained at and shipped from Emory University
2975603|NCT02726139||University of Michigan|Samples obtained at and shipped from University of Michigan
2975604|NCT02726126||C group, (n=25)|C group, (n=25) each patient received transdermal placebo patch
2975605|NCT02726126||TDF group, (n=25)|TDF group, (n=25) each patient received transdermal therapeutic system-fentanyl 50μg/h
2975606|NCT02726126||TDM group, (n=25)|TDM group, (n=25) each patient received transdermal therapeutic system containing 7 mg of melatonin
2975607|NCT02726113|Active Comparator|Intervention: Cholecalciferol|vitamin D3 (cholecalciferol) supplementation at 4000 IU daily for approximately two months prior to surgery (prostatectomy).
2975608|NCT02726113|Placebo Comparator|Placebo|softgel (containing no active ingredient) daily for approximately two months prior to surgery (prostatectomy).
2975609|NCT02726100|Experimental|Intervention arm|Participants in intervention communities will receive the SMARTHealth Diabetes intervention that connects community health service centers and family health providers for diabetes management. Medical staff and FHPs in the intervention communities will be provided with an initial training session on the installation and use of the platform.
2975610|NCT02726100|No Intervention|Control arm|"Control group doesn't use SMARTHealth Diabetes.The usual-care in our study will be conducted in a standard way which is defined in the Guidance of National Essential Public Health Service. All the relevant doctors in control group will be trained and required to record the activities defined in the guidance."
2975742|NCT02725229|Active Comparator|control group|Patients in this group will be randomized to receive an PCA.
2975611|NCT02726087|Experimental|ministernotomy|"Minimally invasive aortic valve replacement with Partial J upper hemisternotomy through right 4th intercostal space, performed according to current standard of care practice."
2975612|NCT02726087|Active Comparator|full sternotomy|Full sternotomy AVR through a standard median sternotomy, performed according to current standard of care practice.
2975613|NCT02726074|Experimental|Perampanel 12 mg|During the Titration Period, participants will receive perampanel 2 milligrams per day (mg/day) and be up-titrated in no less than 2-week intervals in increments of 2 mg up to 12 mg according to the investigator's judgment. Upon entering the Maintenance Period, participants will receive the last dose they achieved at the end of the Titration Period and will continue receiving this dose once daily for the remainder of the study.
2975614|NCT02726061|Experimental|Computer Based PST|A computer based Problem Solving Therapy program for depression.
2975615|NCT02726048|Experimental|Full face/Nasal masks|Simplus/Eson
2975616|NCT02726035|Experimental|Group 1 A-ABAB|After 4 week open label oral naltrexone run-in, participants are randomized to 2 groups (50% each). Group 1 will receive oral naltrexone 50 mg daily during weeks 5-7 (3 weeks). They will switch to placebo for weeks 8-10, then return to naltrexone for weeks 11-13, then placebo for weeks 14-16 (i.e., A-ABAB double crossover design, participants act as own controls). Study drug and placebo will be encapsulated so as to appear identical.
2975617|NCT02726035|Experimental|Group 2 A-BABA|After 4 week open label oral naltrexone run-in, participants are randomized to 2 groups (50% each). Group 2 will receive oral placebo once daily during weeks 5-7. They will then be switched to oral naltrexone 50 mg daily for weeks 8-10, then return to placebo for weeks 11-13, then naltrexone for weeks 14-16 (i.e., A-BABA double crossover design, participants act as own controls). Study drug and placebo will be encapsulated so as to appear identical.
2975618|NCT02726022||Chronic Hepatitis C Participants|Participants with chronic hepatitis C, who were under treatment with peg-interferon alfa-2a and ribavirin for four weeks, will be observed up to 24 weeks after end of treatment (EOT) (up to 72 weeks). Peg-interferon alfa-2a and ribavirin will be administered as per treating physician discretion and according to summary of product characteristics.
2975619|NCT02726009|Experimental|Degarelix|
2975620|NCT02725996|Experimental|curative therapy+NK infusion|Adjuvant adoptive immune therapy using NK cell 4 times after curative therapy
2975621|NCT02725996|Other|curative therapy|Patients who had undergone curative treatment(surgical resection or radiofrequency ablation[RFA]) for HCC of pretreatment clinical stage I or II according to the American Joint Committee on Cancer staging system(6th edition) based on radiologic imaging studies were eligible for this study with no adjuvant treatment
2975622|NCT02725983|Experimental|Intra Oral Camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation (Bardet et al. 1999), as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback as described by Newton and Asimakopoulou (2015). Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.
2975623|NCT02725983|Active Comparator|No Intra Oral camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation (Bardet et al. 1999), as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback as described by Newton and Asimakopoulou (2015) and considered crucial to the accomplishment of long term behavior change. Moreover, special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation) in order to focus patients´ attention on the varied facets of oral health care and increase their perception of the treatment needs. In this group, the device SOPROCARE® by Acteon was not used.
2975624|NCT02725970||Children's Nutrition Research Center|Survey, no intervention.
2975625|NCT02725970||Western Human Nutrition Research Center|Survey, no intervention.
2975626|NCT02725970||Human Nutrition Research Center On Aging|Survey, no intervention.
2975627|NCT02725970||Delta Obesity Prevention Research Center|Survey, no intervention.
2975628|NCT02725970||Beltsville Human Nutr Research Center|Survey, no intervention.
2975629|NCT02725970||Grand Forks Human Nutr Research Center|Survey, no intervention.
2975630|NCT02725957|Experimental|Trehalose 9%|Single dose administration of Trehalose 9% for IV infusion.
2975631|NCT02725957|Placebo Comparator|Saline 0.9%|Single dose administration of 0.9% saline in the same volume and duration as Treatment Arm 1 (9% trehalose)
2975632|NCT02725944||Patients with cryptogenic stroke and TIA|Implantation of ICRM in all participants.
2975633|NCT02725931|Experimental|Activity group|Pulmonary rehabilitation plus physical activity intervention
2975634|NCT02725918|Experimental|Pem mono|Patients in arm B will receive pemetrexed (500 mg/m2, d1) every 3 weeks until PD or intolerable toxicities.
2975635|NCT02725918|Active Comparator|Pem+Cis|Patients in arm A will receive 4 cycles of cisplatin (75 mg/m2, d1) and pemetrexed (500 mg/m2, d1) every 3 weeks, those without disease progression (PD) and being tolerable judged by investigator will continue single-agent pemetrexed (500 mg/m2, d1) every 3 weeks as maintenance until progression or intolerable toxicities.
2975636|NCT02725905|Experimental|Multi-Modal Education (MME)|1) The MME is a three year multi-modal educational intervention including a series of interactive learning components and interventions focused on integrated weight management counseling. Prior to its launch, each component of the curriculum will be refined using a school participatory approach to help ensure feasibility and acceptability.
2975637|NCT02725905|Active Comparator|Traditional Education (TE)|2) The TE arm of the study includes the school's current curriculum which may include topics related to the treatment of weight management and obesity.
2975638|NCT02725892||lungcancer patients|Men or women diagnosed with lung cancer all types and stages confirmed over 12 months of recruitment period by a pathologist
2975639|NCT02725879||HASIMOTO's PATIENTS (HT)|Children and Adolescents diagnosed with Hashimoto's clinical hypothyroidism.
2975640|NCT02725879||CONTROL GROUP (C)|Healthy individuals matched for gender and age
2975641|NCT02725866||HCV Genotype 1 or 4 participants|Participants receiving Paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV)
2975642|NCT02725853|Experimental|tDCS + personalized practice|Transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
2975643|NCT02725853|Active Comparator|tDCS + non-personalized practice|Transcranial direct current stimulation and non-personalized arm motor training spanning both active control and spasticity zones, 1 hour per day, 5 days per week for 2 weeks
2975644|NCT02725853|Sham Comparator|sham tDCS + personalized practice|Sham transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
2975645|NCT02725840||Proton beam radiation therapy|The participants in this group will be receiving proton therapy of the affected breast and chest wall as part of their standard of care. In addition, a Computed Tomography (CT) Scan of the chest wall will be performed, and pulmonary function test (PFT).
2975646|NCT02725840||X-ray based radiation therapy|The participants in this group will be receiving X-ray radiation therapy of the affected breast and chest wall as part of their standard of care. In addition, a Computed Tomography (CT) Scan of the chest wall will be performed, and pulmonary function test (PFT).
2975647|NCT02725827|Active Comparator|HA group|One the day of frozen-thawed embryo transfer, frozen embryos will be thawed and incubated for at least 10 minutes in embryo transfer medium. For women allocated to the HA group, EmbryoGlue (Vitrolife), a hyaluronan-enriched embryo transfer medium, will be used as embryo transfer medium. EmbryoGlue contains a higher concentration of hyaluronan than the control medium.
2975648|NCT02725827|Active Comparator|Control group|For women allocated to the control group, the usual transfer medium used in the study centers will be used and will serve as control. The main difference between the two media is that EmbryoGlue contains a higher concentration of HA.
2975649|NCT02725814|Experimental|Sucrose|
2975650|NCT02725801|Active Comparator|one-port|intervention is placement of one-port tissue expander at time of reconstruction
2975651|NCT02725801|Active Comparator|two-port|intervention is placement of two-port tissue expander at time of reconstruction
2975652|NCT02725788|Experimental|New PIV Dressing|Bordered, notched dressing that covers, secures peripheral intravenous (PIV) catheter
2975653|NCT02725788|Other|Standard PIV Dressing|Film,adhesive dressing that covers, secures peripheral intravenous (PIV) catheter and used with a medical grade tape
2975654|NCT02725775|Active Comparator|100% OJ|240ml 100% Florida Orange Juice consumed on a daily basis for 10 weeks.
2975655|NCT02725775|Placebo Comparator|Equicaloric Orange Drink|An equicaloric placebo orange drink (containing equivalent dose of sucrose, glucose, fructose, vitamin C and citric acid for flavour) consumed daily for 10 weeks.
2975656|NCT02725762|Experimental|Photobiomodulation Treatment|Treatment with Photobiomodulation to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.
2975657|NCT02725762|Sham Comparator|Sham Treatment|Sham treatment to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.
2975658|NCT02725749|Experimental|Laser|
2975659|NCT02725749|Experimental|Exercise|
2975660|NCT02725749|Experimental|Laser and Exercise|
2975661|NCT02725736|Experimental|Atosiban|Women with twin pregnancy with preterm labor between 24 weeks 0 days and 32 weeks 6 days of gestation will be included and randomly assigned to the Atosiban group.
2975662|NCT02725736|Experimental|Nifedipine|Women with twin pregnancy with preterm labor between 24 weeks 0 days and 32 weeks 6 days of gestation will be included and randomly assigned to the Nifedipine group.
2975663|NCT02725723|Experimental|Subject after epidural injection|Subjects are patients from the clinic who have been diagnosed with Lumbar spinal stenosis and determined eligible for receiving steroidal epidural injection for pain management
2975664|NCT02725710|Active Comparator|Group 1: Placebo|Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
2975665|NCT02725710|Active Comparator|Group 2: Gabapentin|Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
2975666|NCT02725697||TCM treatment|TCM treatment (e.g. acupuncture, Tuina massage, Chinese herbal medicine, moxibustion, electroacupuncture, ear acupuncture)
2975667|NCT02725684||Glioblastoma|Observational study, no intervention
2975668|NCT02725671|Other|Cardiogoniometry and ECG Assessment|The same patient will undergo both advanced ECG assessment using cardiogoniometry and standard ECG
2975669|NCT02725658|Other|DOSI|
2975670|NCT02725645|Experimental|Healthy school children|elementary school children will be presented with different backpack loading conditions
2975671|NCT02725632|No Intervention|Control|"An age-matched control group will be enrolled and consented. A Data Collection Sheet will be used to document data from the subject's medical records including history, physical exam, active medications, laboratory data, polysomnogram, electrocardiogram, echocardiography and cardiac catheterization.~At the time of enrollment, one blood drawn through peripheral venipuncture will be collected. Another blood drawn will be collected after one month. The blood samples will be processed and analyzed to assess for levels of SCN5A mRNA splicing variants."
2975672|NCT02725632|Active Comparator|OSA|"Newly diagnosed OSA patients will be enrolled and consented. A Data Collection Sheet will be used to document data from the patient's medical records including history, physical exam, active medications, laboratory data, polysomnogram, electrocardiogram, echocardiography and cardiac catheterization.~At the time of enrollment, one blood drawn through peripheral venipuncture will be collected. The patients on CPAP treatment will be followed-up for 1 month. Another blood drawn will be collected after one month of CPAP treatment. The blood samples will be processed and analyzed to assess for levels of SCN5A mRNA splicing variants."
2975698|NCT02725450|Experimental|Motor Imagery + Psychomotor Battery of fine motor skills|Application of Motor Imagery together with normal practice improves fine motor skills in disabled individuals.
2975699|NCT02725437|Experimental|Low-dose C. difficile Vaccine (accelerated schedule)|
2975700|NCT02725437|Experimental|High-dose C. difficile Vaccine (accelerated schedule)|
2975701|NCT02725437|Placebo Comparator|Placebo (accelerated schedule)|
2975702|NCT02725437|Experimental|Low-dose C. difficile Vaccine (non-accelerated schedule)|
2975703|NCT02725437|Experimental|High-dose C. difficile Vaccine (non-accelerated schedule)|
2975704|NCT02725437|Placebo Comparator|Placebo (non-accelerated schedule)|
2975673|NCT02725619|Experimental|Cognitive-Behavioral Therapy (CBT)|CBT is dedicated to developing coping skills for managing anxiety such as emotion regulation and cognitive reappraisal. Children first learn and practice these skills during one-on-one, weekly sessions with experienced therapists and then apply this skills to navigate anxiety-producing situations as home, school and community. A key component of CBT involves exposure exercises, facing feared situations repeatedly while using the emotion regulation skills and remaining in the situations until anxiety is substantially reduced or become easy to tolerate. The feared situations are ordered from least to most distressing during therapy sessions in collaboration with the child and their parent. The unique combination of anxiety and ASD symptoms of social impairment and restricted/repetitive behavior is addressed in dedicated child and parent modules.
2975674|NCT02725619|Active Comparator|Psychoeducation and Supportive Therapy (PST)|"Psychoeducation and Supportive Therapy includes learning about and discussing issues of diagnosis, treatment and educational services can also benefit children with ASD and their families. Each PST session starts with a review of events of the past week and include queries of topics such as school, interests, and family with an overarching goal of enhancing subjective well-being. The clinician, through the use of supportive, empathic and nondirective actions, will provide the participant with a sounding-board so that they can voice their concerns regarding specific problems that may require discussion and assistance. A major objective is to provide a clinical contact that enables participants to think through and discuss their concerns with a sympathetic adult. Subjects randomized to PST will be offered CBT after completion of the endpoint assessments."
2975675|NCT02725606|Active Comparator|Pegylated Recombinant Human G-CSF|100ug/kg 6 subjects (2 subjects per GW003 cohort)
2975676|NCT02725606|Experimental|GW003 300ug/kg|6-8 subjects
2975677|NCT02725606|Experimental|GW003 650ug/kg|6-8 subjects
2975678|NCT02725606|Experimental|GW003 850ug/kg|6-8 subjects
2975679|NCT02725593|Experimental|Dapagliflozin|
2975680|NCT02725593|Placebo Comparator|Dapagliflozin placebo|
2975681|NCT02725580|Experimental|Cohort 1|Twelve (n=12) Batten CLN6 subjects will receive a single injection of scAAV9.CB.CLN6 via intrathecal delivery. Subjects will receive a total dose of 1.5 x 10^13 vg.
2975682|NCT02725567|Experimental|Part A|"Group 1: Participants 12 to < 24 months~Group 2: Participants 6 to < 12 months (enrollment begins after an assessment of data from Group 1)~Group 3: Participants 3 to < 6 months (enrollment begins after an assessment of data from Group 2)~Group 4: Participants 0 to < 3 months (enrollment begins after an assessment of data from Group 3)"
2975683|NCT02725567|Experimental|Part B|"Group 5: Participants 12 to < 24 months (enrollment begins after an assessment of data from Part A, Group 1~Group 6: Participants 6 to < 12 months (enrollment begins after an assessment of data from Part A, Group 2~Group 7: Participants 0 to < 6 months (enrollment begins after an assessment of data from Part A, Group 3, and also enrollment for subjects < 3 months begins after review of data from Part A Group 4)"
2975684|NCT02725554|Active Comparator|Delayed Continuation Group|All Subjects will be implanted with the StimRelieve HALO System. Subjects randomized to the delayed continuation group will have their systems deactivated until their 3 months follow-up visit. After this visit the stimulation will be reactivated.
2975685|NCT02725554|Experimental|Continued Stim Group|All Subjects will be implanted with the StimRelieve HALO System. Subjects randomized to the continued stim group will continue with active stimulation and monitored at defined intervals for data collection and device reprogramming, if needed.
2975686|NCT02725541|Experimental|Experimental|Trastuzumab emtansine at a dose of 3.6 mg/kg will be administered via intravenous infusion for 6 weeks (two 21-day cycles).
2975687|NCT02725528|Active Comparator|collagenase injection|This procedure will be performed either in a minor procedure room or the hand clinic as per surgeon's routine practice. Collagenase will be administered with or without local anesthesia. As this is a pragmatic study there may be more than one digit injected at a time just as surgery occurs on more than one digit at a time. A recently published study by Gaston et al confirmed that two concurrent injections of collagenase to 2 affected joints in the same hand are generally well tolerated and the frequency of most adverse events (AEs) is similar to those reported in studies that use single sequential injections.
2975688|NCT02725528|Active Comparator|limited palmar fasciectomy|The Dupuytren's cord will be excised under local anesthesia in a minor procedure room setting or main operating room under local or general anesthetic depending on the complexity of the disease and the surgeon's routine. As this is a pragmatic study comparison of collagenase injections (novel intervention) to limited palmar fasciectomy as it is actually presently performed in all settings academic or community (local in minor room or general/local anesthetic in the main operating room) will be examined. Surgery will be performed according to the operating surgeon's preferred technique i.e. zig-zag Brunner incision or straight incision with z-plasty closure of the skin.
2975689|NCT02725515|Experimental|XmAb5871|XmAb5871 administered by IV infusion for up to a total of 16 infusions
2975690|NCT02725515|Placebo Comparator|Placebo|Placebo to match XmA5871 administered by IV infusion for up to a total of 16 infusions
2975691|NCT02725502|Active Comparator|Linagliptin treatment group|Group will receive linagliptin ( 5 mg / day ) for 3 months in addition to their insulin
2975692|NCT02725502|Placebo Comparator|Placebo group|Group will receive placebo for 3 months in addition to their insulin
2975693|NCT02725489|Experimental|Part 1 Cohort 1: 1x10^6 cells Vigil|The first part will be a safety run-in comprised of 2 cohorts that will use a 3 + 3 design to determine the Vigil dose in Part 2. Cohort 1 will receive a low dose of Vigil (1x10^6 cells/intradermal (ID) injection) in combination with durvalumab (1500 mg (if > 30 kg) IV over 60 minutes) every 4 weeks.
2975694|NCT02725489|Experimental|Part 1 Cohort 2: 1x10^7 cells Vigil|Cohort 2 will receive Vigil at 1x10^7 cells/ID injection and durvalumab (1500mg (if > 30 kg) IV over 60 minutes) every 4 weeks.
2975695|NCT02725489|Experimental|Part 1 Cohort -1: 1x10^5 cells Vigil|If needed, Cohort -1 will be used which will receive Vigil at 1x10^5 cells/ID injection and Durvalumab (1500mg (if > 30 kg) IV over 60 minutes) every 4 weeks.
2975696|NCT02725476|Experimental|XmAb5871|XmAb5871 administered by IV infusion for up to a total of 12 infusions
2975697|NCT02725463|Experimental|vestibular implant|From up to 60 enrolled and screened subjects, up to 15 subjects will undergo implantation, activation and deactivation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System
2975741|NCT02725229|Active Comparator|TENS group|Patients in this group will be randomized to receive an TENS and PCA.
2975705|NCT02725424|Active Comparator|Her2 Positive with SOX|Her-2 Positive patients treated with Oxaliplatin plus S-1（SOX） Oxaliplatin 130 mg/m2, iv, d1 S-1 80mg(Body Surface Areas<1.25m2) , 100mg(Body Surface Areas>1.25m2, <1.5 m2), 120 mg／day(Body Surface Areas>1.5m2), po,Bid， d1-14 Every 3weeks
2975706|NCT02725424|Experimental|Her2 Positive with SOXT|Her-2 positive patients treated with Oxaliplatin plus S-1 and Trastuzumab Oxaliplatin : As Above S-1: As Above Trastuzumab :6 mg/kg, iv, d1 ：8 mg/kg Every 3weeks
2975707|NCT02725424|Active Comparator|Her2 Negative with SOX|Her2 Negative patients treated with Oxaliplatin plus S-1（SOX） Oxaliplatin As Above S-1 As Above Every 3 weeks
2975708|NCT02725424|Experimental|Her2 Negative with DOS|Her-2 Negative patients treated with Docetaxel plus Oxaliplatin and S-1（DOS） Docetaxel 60 mg/m2, iv, d1 Oxaliplatin 100 mg/m2, iv, d1 S-1 60 mg/m2，po，Bid， d1-14 Every 3 weeks
2975709|NCT02725411|Active Comparator|Celecoxib|Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral celecoxib 100 mg twice daily for 56 weeks
2975710|NCT02725411|Experimental|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
2975711|NCT02725411|Experimental|Tanezumab 10 mg|Subcutaneous injection of tanezumab 10 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
2975712|NCT02725398|Experimental|Buscopan group|First to use standard white light to observe, to record spasm score, to observe the lesion.Buscopan (BSP, 20mg) is administered by endoscopic nurse, recorded blindly.
2975713|NCT02725398|Active Comparator|Scopolamine group|First to use standard white light to observe, to record spasm score, to observe the lesion.Scopolamine is administered by endoscopic nurse, recorded blindly.
2975714|NCT02725398|Placebo Comparator|physiological saline group|First to use standard white light to observe, to record spasm score, to observe the lesion. Physiological saline is administered by endoscopic nurse, recorded blindly.
2975715|NCT02725385||Ancillary-Correlative (stress and coping)|"PART I:~Participants complete a questionnaire that measures several psychological constructs including stress, anxiety, depression, coping mechanisms, uncertainty, positive and negative emotions, and life satisfaction over 15-30 minutes.~PART II:~Participants undergo a Trier Social Stress Test during a laboratory session over 1.5 hours."
2975716|NCT02725372|Experimental|Inhaled Nitric Oxide 75mcg/KgIBW/Hr|"Part 1:~15Mcg/kg IBW/hr during Run-in Period dose titrated to Inhaled Nitric Oxide / 75mcg/KgIBW/Hr upon randomization to treatment arm.~Part 2: iNO 75 mcg/kg IBW/hr Open Label Treatment (Open Label Treatment - All Subjects)"
2975717|NCT02725372|Placebo Comparator|Placebo|"Part 1:~Placebo dose setting 15mcg/kg IBW/hr Run In Period / Placebo dose setting 75 mcg/kg IBW/hr treatment period"
2975718|NCT02725359|Placebo Comparator|Placebo|Group Placebo (Group P) will receive placebo 1 hour before surgery and bilateral superficial cervical block with saline 10 ml each side
2975719|NCT02725359|Experimental|Tizanidine|Group Tizanidine (Group T) will receive 6 mg tizanidine 1 hour before surgery and bilateral superficial cervical block with %0.25 bupivacaine 10ml each side
2975720|NCT02725359|Active Comparator|Bupivacaine|Group Bupivacaine will receive placebo 1 hour before surgery and bilateral superficial cervical block with %0.25 bupivacaine 10ml each side
2975721|NCT02725346|Experimental|Computer-assisted planning|Acromioplasty with planification
2975722|NCT02725346|Active Comparator|No planning|Acromioplasty without planification
2975723|NCT02725333|Other|Shoulder Stabilization|Anteroposterior and superoinferior translations were assessed in patients, before and after shoulder stabilization, through a dedicated patient-specific measurement technique based on optical motion capture and computed tomography.
2975724|NCT02725320||Female Rotator Cuff Surgical Group|Females, 35-75 receiving surgery for predominantly unilateral rotator cuff syndrome
2975725|NCT02725320||Male Rotator Cuff Surgical Group|Males, 35-75 receiving surgery for predominantly unilateral rotator cuff syndrome
2975726|NCT02725294||COPD patients|Veterans with COPD who are cared for at VA Puget Sound Health Care System (Seattle, WA) or VA Eastern Colorado (Denver, CO) who are at high risk for a COPD exacerbation based on an exacerbation treated with prednisone or antibiotics in the year preceding enrollment.
2975727|NCT02725294||Informal Caregiver for COPD patients|Informal caregiver (ie. family member, friend, etc.) for the patient with COPD who is participating in the COPD patients cohort.
2975728|NCT02725281|No Intervention|Control group|"The patients in Group-I were not interfered by researchers before and during lithotripsy."
2975729|NCT02725281|Active Comparator|Stress ball|"The patients in Group II were given stress ball into their both palms as a before the lithotripsy and told to squeeze the ball whenever they would like."
2975730|NCT02725281|Active Comparator|Music|"The patients in Group-III were listened to the music chosen by them with a headset as a nonpharmacological method during lithotripsy."
2975731|NCT02725268|Experimental|Paclitaxel 80 mg/m^2|Paclitaxel 80 milligram per square meter (mg/m^2), IV, weekly on Days 1, 8, and 15 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent.
2975732|NCT02725268|Experimental|Paclitaxel 80 mg/m^2 + MLN0128 4 mg|Paclitaxel 80 mg/m^2, IV, weekly on Days 1, 8, and 15 of a 28-day cycle along with MLN0128 4 mg, capsule, orally on Days 2-4, 9-11, 16-18, and 23-25 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent.
2975733|NCT02725268|Experimental|MLN0128 30 mg|MLN0128 30 milligram (mg), capsule, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent.
2975734|NCT02725268|Experimental|MLN0128 4 mg + MLN1117 200 mg|MLN0128 4 mg, capsule, orally and MLN1117 200 mg, capsule, orally on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent.
2975735|NCT02725255|Experimental|Papaya seed porridge|Arm receiving porridge fortified with dried papaya seeds (Ujiplus)
2975736|NCT02725255|Active Comparator|Albendazole and Plain porridge|Arm receiving the approved albendazole treatment of 400mg once with plain porridge daily (without papaya seeds)
2975737|NCT02725255|Placebo Comparator|Plain porridge|arm receiving 300ml plain porridge daily (without papaya seeds)
2975738|NCT02725242|Experimental|Once-daily budesonide/formoterol (160/4.5 μg/d)|once-daily budesonide/formoterol (160/4.5 μg/d)
2975739|NCT02725242|Active Comparator|Twice-daily Budesonide (200μg)|twice-daily Budesonide (400μg/d)
2975740|NCT02725229|Active Comparator|parasternal block group|Patients in this group will be randomized to receive an parasternal block and PCA.
2975743|NCT02725203|Experimental|Intervention: Activate intervention|Participants in the intervention arm will visit their primary care nurse four times in a three-month period for structured and comprehensive support in achieving an improved level of physical activity.
2975744|NCT02725203|No Intervention|Control|Patients in the control arm will receive care as usual.
2975745|NCT02725190|Other|Group 1|Normal sleep night.
2975746|NCT02725190|Other|Group 2|Sleepless night.
2975747|NCT02725177|Experimental|H.P. Achtar Gel 80 U|H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 24 weeks on therapy.
2975748|NCT02725164|Placebo Comparator|Uncuffed tracheal tubes|After tracheal intubation with an uncuffed tube, the interventions will be the oxygen concentration, nitrous oxide concentration, carbon dioxide concentration and sevoflurane concentration measured in the tracheal tube compared with those in the oropharynx during spontaneous and controlled ventilation.
2975749|NCT02725164|Active Comparator|Cuffed tracheal tubes|After tracheal intubation with a cuffed tube, the interventions will be the oxygen concentration, nitrous oxide concentration, carbon dioxide concentration and sevoflurane concentration measured in the tracheal tube compared with those in the oropharynx during spontaneous and controlled ventilation.
2975750|NCT02725138|Experimental|Probiotic|subjects will be treated with probiotic containing Lactobacillus acidophilus，Lactobacillus rhamnosus, 1pack, twice daily, for 4 weeks
2975751|NCT02725138|Placebo Comparator|Placebo|subjects will be treated with placebo without Lactobacillus acidophilus，Lactobacillus rhamnosus, 1pack, twice daily, for 4 weeks
2975752|NCT02725125|Experimental|Single-arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0days,the first day,the second day,28 days,29 days Duration:total five times
2975753|NCT02725112|Experimental|Pregabalin ER- Target Release 330mg|A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
2975754|NCT02725112|Experimental|Pregabalin ER - Slow Release 330mg|B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
2975755|NCT02725112|Experimental|Pregabalin ER - Fast Release 330mg|C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
2975756|NCT02725112|Experimental|Pregabalin IR - 300mg|D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
2975757|NCT02725112|Experimental|Pregabalin ER - Target Release 82.5mg|E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
2975758|NCT02725112|Experimental|Pregabalin ER - Aberrant Fast 330mg|F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
2975759|NCT02725099|Active Comparator|Oral Ticagrelor|
2975760|NCT02725099|Experimental|Chewing Ticagrelor|
2975761|NCT02725086|Experimental|Part 1; Filgrastim 5 ㎍/kg|Neupogen®(Filgrastim) 5 ㎍/kg or Leucostim®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 5 ㎍/kg or Neupogen®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 2, Day 1.
2975762|NCT02725086|Experimental|Part 2; Filgrastim 10 ㎍/kg|Neupogen®(Filgrastim) 10 ㎍/kg or Leucostim®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 10 ㎍/kg or Neupogen®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 2, Day 1.
2975763|NCT02725073|Experimental|photodynamic therapy|Photodynamic therapy with a novel photosensitizer and flexible laser catheter
2975764|NCT02725060|Experimental|Autonomic and Antibody Assessments|"On up to 3 study days, POTS patients and control subjects will have several tests to assess autonomic function and to detect the presence of autoantibodies to adrenergic receptors. The following tests will de done but in some participants it may not be necessary to do all of them. The investigator will discuss with each participant which particular tests will be done in each particular case:~Posture study with blood samples for autoantibody testing~24-hour heart rhythm and blood pressure monitoring~autonomic function tests~Quantitative Axonal Sudomotor Reflex Testing~Total blood volume assessment~Pharmacologic testing with phenylephrine~Pharmacologic testing with isoproterenol~Cardiac output with rebreathing~Assessment of splanchnic capacitance~Microneurography"
2975765|NCT02725047|Experimental|TREATMENT - CRYOTHERAPY|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
2975766|NCT02725047|Placebo Comparator|PLACEBO - SAND|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
2975767|NCT02725034|Active Comparator|Group 1|Standard endoscopy with a standard biopsy protocol from the five standard biopsy sites following the updated Sydney System including two from the distal antrum (within 2-3cm from the pylorus, greater/lesser curvature), one from the incisura and two from the mid corpus (greater/lesser curvature).
2975768|NCT02725034|Experimental|Group 2|High definition endoscopy with Optic Enhancement targeted biopsies for gastric intestinal metaplasia.
2975769|NCT02725021|Experimental|Intervention group|The intervention group receives a school-based module taking about two hours delivered by medical students in the schools.
2975770|NCT02725021|No Intervention|Control group|
2975771|NCT02725008|Active Comparator|Control|Patients are given one dose of oral dexamethasone 0.6 milligrams per kilogram up to 16 milligrams in the ED and a second dose of 0.6 milligrams per kilogram up to 16 milligrams to take 24 hours after ED visit
2975772|NCT02725008|Experimental|Investigational|Patients are given one dose of oral dexamethasone 0.6 milligrams per kilogram up to 16 milligrams in the ED and placebo to be taken 24 hours after ED visit
2975773|NCT02724969|Experimental|MILK intervention group|This group will receive the MILK text message intervention, which consists of semi-automated text messages sent to women's cellular phones 3-5 times per week beginning Week 25 of pregnancy, through 8 weeks postpartum, specific to breastfeeding support and prevention of perceived insufficient milk supply.
2975774|NCT02724969|Active Comparator|Text4Baby control intervention group|This group will receive the Text4Baby text message intervention, which consists of automated texts sent to women's cellular phones 3-5 times per week from Week 25 of pregnancy through the postpartum period from the national Text4Baby system. Messages provide general prenatal and postpartum support, including breastfeeding.
2975798|NCT02724800|Active Comparator|CBTI|CBTI consists of five in-person sessions within an eight week period. Topics covered include: sleep education, stimulus control, sleep restriction, relaxation strategies, cognitive therapy, and sleep hygiene.
2976600|NCT02719652||asymptomatic ICAD|asymptomatic intracranial atherosclerosis diseases
2975775|NCT02724956|Experimental|Ambu AuraGain|"SGAD placement using Ambu AuraGain~Lubricate airway tube of SGAD & pass the aScope through until visualization of the carina.~Standard Parker Flex Tip endotracheal tube (ETT) size 6.0, 7.0, and 8.0 mm ETT will be used as per anesthesiologist preference.~Pass ETT tube down the insertion cord of the Ambu aScope & verify placement.~Inflate cuff and remove aScope."
2975776|NCT02724956|Experimental|Teleflex LMA Protector|"SGAD placement using the Teleflex LMA Protector~Lubricate airway tube of SGAD & pass the aScope through until visualization of the carina.~Standard Parker Flex Tip ETT size 6.0 and 7.0 mm. ETT will be used as per anesthesiologist preference.~Pass ETT tube down the insertion cord of the Ambu aScope & verify placement.~Inflate cuff and remove aScope."
2975777|NCT02724943|Experimental|TX CORD Intervention|TX CORD Intervention. The intervention entailed: (1) BMI screening, (2) Next Steps brief counseling materials for the healthcare provider, (3) a 3-month intensive Mind Exercise Nutrition Do It! and Coordinated Approach To Child Health (MEND/CATCH) phase, which included the Mind Exercise Nutrition Do it! ( MEND) programs for preschool (ages 2-5) and school-aged (ages 6-12) children coupled with adapted CATCH activities, and (5) a 9-month transition MEND/CATCH Transition phase, which offered monthly reinforcement sessions for parents and children, and twice weekly Young Men's Christian Association (YMCA) sports for children. Community Health Workers (CHWs) serve as program liaisons and assist in delivering all intervention group sessions as well as tracking families. Electronic Health Record (EHR) changes supported the screening and Next Steps delivery.
2975778|NCT02724943|Active Comparator|Brief Clinic Comparison|Next Steps brief clinical intervention. The comparison program was a 12-month clinic-based program conducted at twelve partner healthcare clinics and entailed (1) EHR changes to support childhood obesity clinical visits; (2) BMI screening, (3) Next Steps brief counseling materials for the healthcare provider, and (4) Next Steps self-paced booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity.
2975779|NCT02724930|No Intervention|Standard Implementation|Standard COPES implementation consists of provider education including brief in-person presentations and written material.
2975780|NCT02724930|Experimental|Implementation Facilitation|"Enhanced facilitation of COPES implementation.~All clusters start in the standard implementation group and cross-over from the control group to the intervention group in a randomized stepped-wedge fashion at 7 time points over the course of the 33 week implementation."
2975781|NCT02724917|Experimental|APN1125, Low Dose|APN1125, Low Dose
2975782|NCT02724917|Experimental|APN1125, Mid Dose|APN1125, Mid Dose
2975783|NCT02724917|Experimental|APN1125, High Dose|APN1125, High Dose
2975784|NCT02724917|Placebo Comparator|Placebo|Placebo to match
2975785|NCT02724904|Experimental|Allogeneic Stem Cell Transplantation|Patients will undergo reduced intensity conditioning (fludarabine and thiotepa) followed by fully matched related or unrelated allogeneic stem cell transplantation. Afterwards, patients will receive standard post-transplant care (Methotrexate).
2975786|NCT02724891||Arm 1 paper form first|paper questionnaires first then web/smart phone questionnaires after a 2-week washout period
2975787|NCT02724891||Arm 2 web/smartphone form first|web/smart phone questionnaires first then paper questionnaires after a 2-week washout period
2975788|NCT02724878|Experimental|Bevacizumab And Atezolizumab Combination|Patients will be administered a pre-determine dose of Bevacizumab and Atezolizumab intravenously every 3 weeks. Patients will be evaluated clinically every 3 weeks and will undergo disease assessments with imaging every 6 weeks.
2975789|NCT02724865|Active Comparator|Oral appliance therapy; Somnodent®|Somnodent is a duobloc appliance, which is frequently used in OSA treatment and is titratable.
2975790|NCT02724865|Active Comparator|Oral appliance therapy; Herbst®|Herbst is a duobloc appliance, which is frequently used in OSA treatment and is titratable.
2975791|NCT02724852|Active Comparator|HIV-infected adults|"Two-hundreds and forty-nine HIV-infected participants received a single dose of MMR vaccine (GlaxoSmithKline Biologicals) at deltoid region.~Interventions were a single dose of 0.5 ml of MMR vaccine. Each 0.5 ml of vaccine contained at least 1000 TCID50 of Schwarz measles strain, at least 1000 TCID50 of RIT 4385 mumps, and at least 1000 TCID50 of Wistar RA 27/3 rubella strains."
2975792|NCT02724852|Experimental|HIV-uninfected adults|"Forty-six HIV-uninfected participants received a single dose of MMR vaccine (GlaxoSmithKline Biologic) at deltoid region.~Interventions were a single dose of 0.5 ml of MMR vaccine. Each 0.5 ml of vaccine contained at least 1000 TCID50 of Schwarz measles strain, at least 1000 TCID50 of RIT 4385 mumps, and at least 1000 TCID50 of Wistar RA 27/3 rubella strains."
2975793|NCT02724839|Experimental|Intervention arm|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session.
2975794|NCT02724826|Experimental|Qigong therapy|The qigong treatment was done according to medical qigong, and is a way of affecting and directing qi (energy) for medical benefit. Each qigong practice included body posture adjustment, gentle movement, meditation, relaxation, breathing regulation practices and massage. The qigong was practiced in groups of ten to 15 participants. Each qigong session started with information about the philosophy and a general warm-up with soft movements and 14 selected qigong exercises according to the Biyun method.
2975795|NCT02724826|Active Comparator|Exercise therapy|Exercise therapy was carried out individually, adjusted for each participant. A physiotherapist instructed the participant with focused on the cervical and shoulder/thoracic regions. Each training session included stationary bicycle for ten minutes, 40 minutes of dynamic exercises. These exercises consisted of active movements in all neck directions and muscle exercises aimed to maintain/increase circulation, endurance and strength. The load at the muscle exercises was to achieve between 30 and 70% of maximum muscle capacity and was gradually increased as endurance and strength were gained.
2975796|NCT02724813|Experimental|Intervention arm|Participants will receive 16 one-hour tele-CO-OP sessions delivered over a 10-week period by a licensed health care professional. We will deliver tele-CO-OP via Skype™ and record all sessions using Pamela software for Skype™.
2975797|NCT02724813|Active Comparator|Wait-list arm|Participant in this arm will receive therapy 8 weeks after initial assessment. Participants will receive 16 one-hour tele-CO-OP sessions delivered over a 10-week period by a licensed health care professional. We will deliver tele-CO-OP via Skype™ and record all sessions using Pamela software for Skype™.
2975869|NCT02724267|Active Comparator|transcatheter arterial chemoembolization|Patients will be treated with TACE only.
2975799|NCT02724800|Active Comparator|BBTI|BBTI consists of one in-person session with three weekly follow-up sessions (in-person or phone) in a four week period. Topics covered include: sleep education, stimulus control, and sleep restriction.
2975800|NCT02724787|Other|Open Trial|All Veterans will receive the same emotion regulation treatment titled, Manage Emotions to Reduce Aggression.
2975801|NCT02724774|Experimental|Promoting First Relationships® (PFR)|10 week home visiting program
2975802|NCT02724774|No Intervention|Parent Information Packet|A packet is mailed to the families, including handouts related to child development, health, and local resources.
2975803|NCT02724761|Experimental|Experimental: Racemic Epinephrine|Over the Counter (OTC) - 0.5 mL Nebulized Racemic Epinephrine
2975804|NCT02724761|Placebo Comparator|Placebo: 0.9% Normal Saline|0.5 mL 0.9% Normal Saline
2975805|NCT02724748|Experimental|Educational intervention|Beside usual care the intervention will encourage collaborative practices between staff, patients and family members to adopt more human patient-centred approach on the unit. The intervention is designed to impact on treatment culture and thereby treatment practices on the study wards.
2975806|NCT02724748|No Intervention|Treatment as usual|Wards allocated to comparison wards continue with their usual care. No restrictions on how nursing staff works in these wards, although participation in corresponding projects is not supported.
2975807|NCT02724735||Longitudinal Observational Cohort|Following completion of the NS2014-1 final study visit procedures, Subjects will be offered the opportunity to enroll in this longitudinal observational cohort protocol to monitor their depression and to assess durability of effect and long-term safety of NSI-189.
2975808|NCT02724722|Experimental|Intervention|a simple flyer in one empty bag with face-to-face health education
2975809|NCT02724722|Placebo Comparator|No Intervention|a simple flyer in one empty bag with no face-to-face health education
2975810|NCT02724683||Symptomatic ascites drainage with CVC.|Patients with malignant, symptomatic, refractory ascites. Ascites drainage with vascular catheter (CVC) inserted into abdominal cavity will be performed. Patients will be asked to complete interview, quality of life questionnaire, nutritional status assessment and quality of procedure survey.
2975811|NCT02724670|Other|Radiation|IGRT 5x 2Gy/week, total dose: 78 Gy
2975812|NCT02724657|Experimental|Buteyko Method|Children will perform 6 sessions (twice a week) of treatment with the Buteyko Method.
2975813|NCT02724657|No Intervention|Control|Asthma education.
2975814|NCT02724644|Experimental|EN3835 Active|EN3835 0.84 mg (Collagenase Clostridium Histolyticum). Each subject can receive up to three treatment sessions. Each treatment session will be separated by approximately 21 days.
2975815|NCT02724644|Placebo Comparator|EN3835 Placebo|Placebo
2975816|NCT02724631|Experimental|TubeClear® (Phase I)|To determine feasibility and tolerability, 10 subjects will receive the TubeClear® intervention. If the TubeClear® intervention is unable to restore Enteral Access Device patency, further steps to restore patency of the occluded EAD will be determined by the clinical team per usual practice.
2975817|NCT02724618|Experimental|Curcumin plus RT|120mg/day nanocurcumin during RT course
2975818|NCT02724618|Placebo Comparator|Placebo plus RT|120mg/day placebo of nanocurcumin during RT course
2975819|NCT02724605|Other|Group A|Red blood cells unit age 14 days or less
2975820|NCT02724605|Other|Group B|Red blood cells unit age more than 14 days
2975821|NCT02724592|Experimental|intervention|intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)
2975822|NCT02724592|Active Comparator|control|control group, only Fluoride varnish (Duraphat®)
2975823|NCT02724579|Experimental|Treatment (reduced radiation therapy and chemotherapy)|"RADIATION THERAPY: Beginning 4-5 weeks after surgery, patients undergo craniospinal radiation therapy 5 days a week for 6 weeks.~MAITENANCE THERAPY (WEEKS 1, 3, 5, and 7): Beginning 4-6 weeks after completion of radiation therapy patients receive lomustine PO on day 1, vincristine sulfate IV over 1 minute or via minibag on days 1, 8, and 15, and cisplatin IV over 6 hours on day 1. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY (WEEKS 2, 4, AND 6): Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 2, mesna IV over 15-30 minutes on days 1 and 2, and vincristine sulfate IV over 1 minute or via minibag on days 1 and 8. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
2975824|NCT02724566|Other|Apelin then Placebo|First clamp during which an apelin infusion will be administered followed by a wash-out period and then, a second clamp in which a placebo infusion will be administered
2975825|NCT02724566|Other|Placebo then Apelin|First clamp during which a placebo infusion will be administered followed by a wash-out period and then, a second clamp in which an apelin infusion will be administered
2975826|NCT02724553|Other|Vertical orientation of Haptic orientation|The orientation of the IOL haptic will be implanted in the vertical position during routine cataract surgery
2975827|NCT02724553|Other|Horizontal orientation of Haptic orientation|The orientation of the IOL haptic will be implanted in the horizontal position during routine cataract surgery
2975828|NCT02724540|Experimental|Arm 1|Lobar or segmental bland embolization with tris-acryl gelatin microspheres (100-500 microns) to 2-5 heartbeat stasis monthly as needed until the entire tumor burden is treated.
2975829|NCT02724540|Experimental|Arm 2|Lobar or segmental lipiodol chemoembolization monthly as needed until the entire tumor burden is treated. Doxorubicin 50 mg, and Mitomycin C 10 mg dissolved in 10 mL dilute contrast and emulsified with 10 cc iodized oil, followed by 100-500 μm tris-acryl gelatin microspheres.
2975830|NCT02724540|Experimental|Arm 3|Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU monthly until entire tumor burden is treated.
2975831|NCT02724527|Placebo Comparator|Placebo|Matching capsule (BID administration Q12H)
2975832|NCT02724527|Experimental|Cavosonstat (N91115) 400 mg|Cavosonstat (N91115) at 400 mg dose (100 mg x 4 capsules) (BID administration Q12H)
2975833|NCT02724488||Part 1|Patients with a histological or cytological diagnosis of advanced solid tumors who are currently on immune checkpoint inhibitors will have archival tumor specimens requested and used for whole exome sequencing (WES) of tumor DNA. 3 tubes of blood at a single time point will be collected for ctDNA analysis and germ line DNA analysis (to study normal variants) using next generation sequencing.
2976743|NCT02718664|No Intervention|A (fasting)|Fasting condition
2975834|NCT02724488||Part 2|Patients with a histological or cytological diagnosis of advanced solid tumors who are candidates for a phase I, II, or III clinical trial testing immune checkpoint inhibitors (ICIs) or planning to have treatment with ICIs or other immunological therapy as standard of care will have image-guided fresh tumor core needle biopsy at a maximum of 3 time points: 1) prior to commencement of immune checkpoint inhibitors, 2) when disease response to therapy is confirmed using radiology RECIST 1.1 criteria and/or immune related response criteria, and 3) when radiological disease progression is confirmed by using RECIST 1.1. Blood samples for ctDNA analysis will be collected at the commencement of immunotherapy and every 6-12 weeks thereafter until radiological disease progression is confirmed.
2975835|NCT02724475|Experimental|LA group|Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated.
2975836|NCT02724475|Experimental|3D-CRT group|γ-knife treatment with radiation dose of 48-63 Gy/6-9 times.
2975837|NCT02724462|Experimental|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
2975838|NCT02724462|Active Comparator|Control|This is the control arm of the study. This includes receiving the standard of care smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
2975839|NCT02724449|Experimental|Cavilon Advanced Barrier Film|Cavilon Advanced Barrier Film applied to areas of IAD
2975840|NCT02724436|Experimental|TACE|transcatheter arterial chemoembolization
2975841|NCT02724436|Experimental|TACE+radioembolization|TACE plus radioembolization with Y-90: 100
2975842|NCT02724423|Experimental|NRL-1|A single intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
2975843|NCT02724410|Active Comparator|home intravenous ertapenem and PICC|Placement of peripheral inserted central catheter (PICC) and completion of ten day antibiotic treatment with home (IV) ertapenem (Drug Class:carbapenem antibiotic) (15 mg/kg IV every twelve hours not to exceed 1 gm/day for ages <13; age 13 or greater, then 1 gm daily)
2975844|NCT02724410|Experimental|home oral amoxicillin-clavulanate|Completion of ten day antibiotic treatment with home oral amoxicillin-clavulanate(Drug Class:beta lactam antibiotic)(15mg/kg every eight hours or 22.5mg/kg extended release tablets every twelve hours).
2975845|NCT02724397|Experimental|Experimental group|(White endoscopy and then LCI/BLI) The patients will be evaluated by Standard White Light and then Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI).
2975846|NCT02724397|Active Comparator|Control group|(LCI/BLI then white endoscopy) The patients will be evaluated by Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) and then White Light Endoscopy.
2975847|NCT02724384|Experimental|Group 1|Plasma treatment using Plasma delivery system A 3 treatments/week for 2 weeks, then monthly
2975848|NCT02724384|Experimental|Group 2|Plasma treatment using Plasma delivery system A 2 treatments/week for 2 weeks, then monthly
2975849|NCT02724384|Experimental|Group 3|Plasma treatment using Plasma delivery system B 3 treatments/week for 2 weeks, then monthly
2975850|NCT02724371|Experimental|Primary Breast Reconstruction|Participants who meet the requirements for primary breast reconstruction (have not had previous silicone or saline breast implants, not including tissue expanders) and have been implanted with Mentor Larger Size MemoryGel Ultra High Profile Breast implants
2975851|NCT02724371|Experimental|Revision Breast Reconstruction|participants who meet the requirements for revision breast reconstruction (have had previous silicone or saline breast implants) and have been implanted with Mentor Larger Size MemoryGel Ultra High Profile Breast implants
2975852|NCT02724358|Experimental|TACE|iodized oil (5ml) + Pirarubicin (20mg)
2975853|NCT02724358|Experimental|Rg3|20mg, BID, maintained though Month 12
2975854|NCT02724358|Experimental|TACE + Rg3|the combination of the treatments for the above two groups. Rg3 will be stopped on the day performing TACE.
2975855|NCT02724358|Experimental|Control|standard liver protective therapy
2975856|NCT02724345||CK18 positive|HCC patients with CK18 high expression levels in tumor tissue.
2975857|NCT02724345||CK18 negative|HCC patients with CK18 high expression levels in tumor tissue.
2975858|NCT02724332|No Intervention|control group|Patients will be treated with radical hepatectomy only.
2975859|NCT02724332|Active Comparator|transcatheter arterial chemoembolization|Patients will be treated with TACE
2975860|NCT02724319||Left heart catheterization patients|Patients presenting to the UF Health Jacksonville cardiac catheterization laboratory for left heart catheterization for suspected coronary artery disease and intent to undergo percutaneous coronary intervention will be targeted for enrollment and will be genotyped by SpartanRX
2975861|NCT02724306|Experimental|Active Lifestyle Programme|ALP will receive supervised exercise sessions twice per week for three months and once per week for the following three months. Participants will also take part in biweekly physical activity workshops for the period of the intervention. Each session consists of a warm-up (5-10min), aerobic (20-30min) and resistance exercises (15-20), and cool-down (5-10)stretches lasting in total 60min. The intensity of exercises will be at 65-85% of maximum heart rate as determined by maximal fitness test. Exercise will take place in small groups of two to five people. Behaviour change workshops to aid the uptake and maintenance of physical activity will be delivered every fortnight throughout the whole intervention period totalling 12 workshops. Workshops will also take place in small groups.
2975862|NCT02724306|No Intervention|Standard Care|The standard care group will not be offered the intervention until the end of the study at 12 months. Participants in this group will be encouraged to continue with their usual lifestyle.
2975863|NCT02724293|Placebo Comparator|Group I (placebo)|patients received placebo.
2975864|NCT02724293|Active Comparator|Group II (pregabaline 300 once)|patients received pregabalin 300 mg 2 hours preoperatively.
2975865|NCT02724293|Active Comparator|Group III (pregabaline 300 twice)|patients received pregabalin 300 mg 2 hours preoperatively and 12 hours after the preoperative dose.
2975866|NCT02724293|Active Comparator|Group IV (pregabaline 600)|patients received pregabalin 600 mg 2 hours preoperatively
2975867|NCT02724280||Group A|Patients with indications for gastroduodenoscopy will be evaluated with WLE and then LCI.
2975868|NCT02724280||Group B|Patients with indications for gastroduodenoscopy will be evaluated with LCI and then WLE.
2975870|NCT02724267|Experimental|internal radiation group|Patients will be treated with TACE combined with internal radiation.
2975871|NCT02724254|Experimental|AP611074 5% gel|100 mg twice daily doses of AP611074 5% gel
2975872|NCT02724254|Placebo Comparator|Placebo|AP611074 matching placebo gel
2975873|NCT02724241|Experimental|nicotine|use of an e-cigarette filled with liquid with nicotine
2975874|NCT02724241|Experimental|no nicotine|Use of an e-cigarette filled with liquid without nicotine
2975875|NCT02724241|Sham Comparator|sham comparator|Use of empty e-cigarette (sham control)
2975876|NCT02724228|Experimental|BMN 111 - Subcutaneous Injection|111-205 is an open-label, extension study. Subjects receive the same stable dose of BMN 111 received upon completion of the 111-202 study. BMN 111 will be administered in one of the following daily dosing regimens: 15 μg/kg or 30 μg/kg daily.
2975877|NCT02724215||Patients with Sleep Apnea|Patients with increased apnea-hypopnea-index (>5/h)
2975878|NCT02724215||Patients without Sleep Apnea|Patients with normal apnea-hypopnea-index (5/h and below)
2975879|NCT02724202|Experimental|Open Label|All subjects will receive induction oral curcumin 500 mg twice per day for 2 weeks. Patients will continue on curcumin at same dose for an additional 6 weeks while being treated with 3 cycles of 5FU.
2975880|NCT02724189||Patients attending the preoperative assessment clinic|Patients in preoperative assessment clinic
2975881|NCT02724176|Experimental|carbon nanoparticles|0.1 ml of CN suspension was injected per spot into the tissue surrounding the tumor using a skin test syringe. Two or three randomly selected spots were injected slowly for each tumor, and the total amount injected was no more than 0.5 mL per lobe.
2975882|NCT02724163|Active Comparator|Mitoxantrone|"Course 1~Mitoxantrone: 12 mg/m2 daily by IV infusion over 1 hour on days 1, 2, 3 and 4 (total 4 doses).~Cytarabine:100 mg/m2 12 hourly by IV bolus on days 1-10 inclusive (total 20 doses).~Course 2~Mitoxantrone: 12 mg/m2 daily by IV infusion over 1 hour on days 1, 2 and 3 (total 3 doses).~Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-8 inclusive (total 16 doses)."
2975883|NCT02724163|Experimental|Liposomal daunorubicin|"Course 1~Liposomal daunorubicin: 80 mg/m2 daily by 1 hour IV infusion on days 1, 3 and 5 (total 3 doses).~Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-10 inclusive (total 20 doses).~Course 2~Liposomal daunorubicin: 60 mg/m2 daily by 1 hour IV infusion on days 1, 3 and 5 (total 3 doses).~Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-8 inclusive (total 16 doses)."
2975884|NCT02724163|Experimental|Gemtuzumab Ozogamicin Dose Finding Study|"Cohort 1: 1x3mg/m2 IV infusion over 2hours on day 4.~Cohort 2: 2x3mg/m2 IV infusion over 2hours on day 4 and day 7.~Cohort 3: 3x3mg/m2 IV infusion over 2hours on days 4, 7 and 10."
2975885|NCT02724163|Active Comparator|High dose cytarabine|Two courses of Cytarabine: 3 g/m2 12 hourly by IV infusion over 4 hours on days 1, 3 and 5 (total 6 doses).
2975886|NCT02724163|Experimental|Fludarabine & cytarabine|"Two courses of:~Fludarabine: 30 mg/m2 daily by IV infusion over 30 minutes on days 1-5 inclusive (total 5 doses).~Cytarabine: 2 g/m2 daily by IV infusion over 4 hours on days 1-5 inclusive (total 5 doses).The cytarabine infusion should be started 4 hours after the start of the fludarabine infusion"
2975887|NCT02724163|Active Comparator|Myeloablative conditioning|"Busulfan Area Under the Curve (AUC) 70-100mg/L x hr by IV infusion over 3 hours, given 12 hourly on days -10 to -7 (8 doses).~Cyclophosphamide 50mg/kg/day by IV infusion over 1 hour, on days -5 to -2 (4 doses)."
2975888|NCT02724163|Experimental|Reduced intensity conditioning|"Busulfan AUC60-65mg/L X hr by IV infusion over 3 hours, given 12 hourly on days -5 to -2 (8 doses).~Fludarabine 30mg/m2/day by IV infusion over 30 minutes on days -8 to -3 (6 doses)."
2975889|NCT02724150|Active Comparator|Omeprazole High dose|Omeprazole 80 mg loading dose,then 8mg/h IV continuous infusion for 3 days
2975890|NCT02724150|Experimental|Omeprazole Low Dose|Omeprazole 80 mg loading dose IV then 40 mg two times per day IV for 3 days
2975891|NCT02724137|Experimental|Physical Therapy Rehab and Fitbit®|Standard outpatient physical therapy rehabilitation after total knee replacement with the addition of a Fitbit® to promote physical activity.
2975892|NCT02724137|Active Comparator|Physical Therapy Rehab|Standard outpatient physical therapy rehabilitation after total knee replacement.
2975893|NCT02724124|Experimental|static stretching|group of 11 volunteers (gSS)
2975894|NCT02724124|Experimental|warm up -|group of 11 volunteers (gWU)
2975895|NCT02724124|Experimental|static stretching + warm up|(group of 11 volunteers - SS+WU)
2975896|NCT02724124|Experimental|warm up+static stretching|(group of 11 volunteers - WU+SS)
2975897|NCT02724124|Other|Control Group|No intervention - athletes rested
2975898|NCT02724111|Experimental|deep neuromuscular blockade|This arm will be given sufficient dose of rocuronium. In this Arm group, rocuronium will be administered to maintain deep neuromuscular blockade [NMB] (train-of-four [TOF] count 0, post-tetanic count [PTC] of 1-2 twitches) until the end of surgery and the reversal of NMB will be performed by sugammadex 4 mg/kg at the end of surgery'.
2975899|NCT02724111|Active Comparator|restricted neuromuscular blockade|This arm will not be given sufficient dose of rocuronium. In this Arm group, sugammadex will be administered according to the prescribing indications (4 mg/kg for deep neuromuscular blockade [NMB] state or 2 mg/kg for moderate NMB or less) to reverse the NMB 10 min after position change (sugammadex 10 min after position change [a prone position]). Thereafter, muscle relaxants will not be injected any more throughout the surgery except the following situations: If the patients show any body movement during surgery or if surgeons express any complaint about muscle tone (the muscle tone: grade 3), rescue rocuronium 5 mg will be administered and the number of body movements and rescue rocuronium administration (dose) will be recorded.
2975900|NCT02724098|Active Comparator|intravenous|1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) diluted in 10 ml of sodium chloride will be administered intravenously in 10 min at a constant rate using an infusion pump.
2975901|NCT02724098|Active Comparator|subcutaneous|1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) will be administered subcutaneously undiluted.
2975902|NCT02724085|Active Comparator|Cohort A|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.15 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
2975903|NCT02724085|Active Comparator|Cohort B|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.45 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
2975904|NCT02724085|Active Comparator|Cohort C|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 1.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
2975905|NCT02724085|Active Comparator|Cohort D|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
2975906|NCT02724085|Active Comparator|Cohort E|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 3.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
2975907|NCT02724085|Active Comparator|Cohort F|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 4.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
2975908|NCT02724085|Active Comparator|Cohort G|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 5.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
2975909|NCT02724072|Experimental|Thoraflex™ Hybrid Device.|Plexus™ 4 and Ante-Flo™ configurations will be included in this study.
2975910|NCT02724059|Experimental|Patients with mediastinal lesions|Endo bronchial ultrasound (EBUS) with elastography followed by TBNA
2975911|NCT02724046|No Intervention|Standard care|No chemoprevention for contacts of cases of meningitis (current standard of care) with a health promotion visit by a study nurse after the first notification of cases during the epidemic
2975912|NCT02724046|Active Comparator|Household prophylaxis|Chemoprophylaxis with a single dose of oral ciprofloxacin for household members of reported cases of meningitis. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension).
2975913|NCT02724046|Active Comparator|Village prophylaxis|Chemoprophylaxis with ciprofloxacin in the setting of a village-wide distribution after the notification of the first case of meningitis in a village. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension).
2975914|NCT02724033|Active Comparator|Group A|Group A - regional nerve block
2975915|NCT02724033|Active Comparator|Group B|Group B - antiemetic
2975916|NCT02724033|Active Comparator|Group C|Group C - block and antiemetic
2975917|NCT02724020|Active Comparator|Everolimus 10 milligram (mg)|Everolimus 10 mg, capsules, orally, once daily (QD) in a 28-day cycle until disease progression, unacceptable toxicity, consent withdrawal, or death up to 24 months, or longer upon discussion with the investigator and the sponsor if the participant is believed that the participant would derive benefit.
2975918|NCT02724020|Experimental|MLN0128 30 mg|MLN0128 30 mg, capsules, orally, once weekly (QW) on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression, unacceptable toxicity, consent withdrawal, or death up to 24 month or longer upon discussion with the investigator and the sponsor if the participant is believed that the participant would derive benefits.
2975919|NCT02724020|Experimental|MLN0128 4 mg + MLN1117 200 mg|MLN0128 4 mg, capsules, orally, QD 3 days per week and MLN1117 200 mg, capsules, orally, QD 3 days per week on Days 1-3, 8-10, 15-17 and 22-24 of a 28-day cycle until disease progression, unacceptable toxicity, consent withdrawal, or death up to 24 months or longer upon discussion with the investigator and the sponsor if the participant is believed that the participant would derive benefit.
2975920|NCT02724007||All participants|
2975921|NCT02723994|Experimental|Ruxolitinib in combination with chemotherapy|
2975922|NCT02723981|Experimental|COMBO-Stent|Implantation of COMBO-Stent and medication with (N)OAC and clopidogrel for 3 months followed by (N)OAC alone
2975923|NCT02723981|Active Comparator|Any Drug eluting or bare metal stent|Implantation of any drug eluting oder bare metal stent combined with anticoagulant medication according to ESC guidelines
2975924|NCT02723968|Other|Continuous glucose monitoring system|OGTT followed by continuous glucose monitoring system and finally IGTT and HbA1C dosage
2975925|NCT02723955|Experimental|Part 1A: Dose escalation GSK33596069|Subjects will receive GSK3359609 as an intravenous (IV) infusion administered once every 3 weeks (Q3W) continuously at a dose level dependent on to which dose level the subject is accrued.
2975926|NCT02723955|Experimental|Part 1B: Expansion GSK33596069|Subjects will receive GSK3359609 as an IV infusion administered Q3W continuously at a dose level chosen for further exploration in dose expansion cohorts.
2975927|NCT02723955|Experimental|Part 2A: Dose escalation/safety run-in-GSK33596069|Subjects will receive GSK3359609 as an IV infusion administered Q3W continuously in combination with 200 milligram (mg) of pembrolizumab as an IV infusion administered once Q3W continuously. Subjects participating in Part 2A chemotherapy combination cohorts will receive GSK3359609 in combination with chemotherapy at doses and schedules based on standard of care practice.
2975928|NCT02723955|Experimental|Part 2B: Expansion-GSK33596069|Subjects receive GSK3359609 as an IV infusion administered Q3W continuously in combination with 200 mg of pembrolizumab as an IV infusion administered once Q3W continuously.
2975929|NCT02723942|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen by infusion.
2975930|NCT02723942|No Intervention|no intervention|no intervention
2975931|NCT02723929|Experimental|Active Electrical Stim/Active Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
2975932|NCT02723929|Sham Comparator|Sham Electrical Stim/Sham Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with sham transcranial ultrasound for 20 minutes.
2975933|NCT02723916|Experimental|Intervention: ezParent Program|
2975934|NCT02723916|Active Comparator|Control: Health-e Kids App|
2975935|NCT02723903|Other|with CAD and somatic symptom|Patients with the coronary artery disease and with the somatization symptom, the investigators treat the patients according to the guideline for coronary artery disease and anti-somatic agents (Deanxit, Prozac according to the somatization type)
2975936|NCT02723903|Other|without CAD, with somatic symptom|Only somatic symptom is presented, anti-somatic agents is prescribed (Deanxit, Prozac according to the somatization type)
2975937|NCT02723903|No Intervention|without CAD, without somatic symptom|Have neither coronary artery disease nor somatic symptom, continue follow-up.
2975938|NCT02723903|Other|with CAD, without somatic symptom|Patient with the coronary artery disease, without the somatization symptom, the investigators treat the patients according to coronary artery disease treatment guideline including coronary artery stent implantation,medication according to the severity of stenosis of the coronary arteries.
2975939|NCT02723890|Experimental|Tyto Device|examination with Tyto device carried out by a nurse and sent online to the principle and co-investigators for remote analysis.
2975940|NCT02723877|Experimental|Eribulin and PQR309|PQR309 in combination with standard approved dose of eribulin mesylate 1.4 mg/m2 intravenous (iv) on days 1 and 8 in a period of 21 days per cycle will be investigated. . PQR309 will be administered maximum 15 minutes after eribulin iv dosing.
2975941|NCT02723864|Experimental|1|VX-970 will be administered IV on Days 2 and 9 of each 21-day cycle; Veliparib will be administered orally twice a day (BID) Days 1-3 and 8-10 of each cycle; Cisplatin will be administered at 40 mg/m2 IV Day 1 (and Day 8 from DL3 onwards) of each cycle
2975942|NCT02723851||Acute MI patients|Corsens Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index [MCI] and isovolumetric contraction (IVCT).
2975943|NCT02723851||Non-MI patients|Corsens Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index [MCI] and isovolumetric contraction (IVCT).
2975944|NCT02723825|Placebo Comparator|Less or equal to 2mm|the residual displacement is less than or equal to 2mm
2975945|NCT02723825|Placebo Comparator|Between 2-4mm|the residual shift is between 2-4mm, manual reset once again, as still between 2-4mm
2975946|NCT02723825|Active Comparator|Greater than 4mm|the residual displacement is greater than 4mm
2975947|NCT02723812|Experimental|GCFLU® Influenza vaccine (Split virion, Inactivated)|One dose 0.5 mL vaccine GCFLU® administered intramuscularly.
2975948|NCT02723799|Experimental|Hope Promotion Program (HPP)|Plus to the standard treatment protocol, all the participants in this group attend the HPP, consisting of a three individual session's carried out by the nurse in patients' homes. It includes viewing the film Hopeful Living, enrolling in a hope activity from the Hope activity book, a relaxation activity and a negotiated plan to exercise hope in a regular basis.
2975949|NCT02723799|Other|Standard Treatment Protocol|Participants in this group has not access to a hope intervention. Data collection for outcome variables is the same as the participants in the other arms.
2975950|NCT02723786|Experimental|GSK1070806 single IV infusion|Subjects will receive a single intravenous (IV) dose of GSK1070806 prior to kidney allograft reperfusion
2975951|NCT02723773|Experimental|LTFU Group|Long-Term Follow-Up of the subjects who received at least one dose of the HZ/su vaccine in the primary studies ZOSTER-006/022
2975952|NCT02723773|Experimental|Additional Dose Group (1AdD Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive 1 additional dose of the HZ/su vaccine in the current study.
2975953|NCT02723773|Experimental|Revaccination Group (Rev Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive 2 additional doses of the HZ/su vaccine in the current study on a 0, 2 Month schedule (N=60).
2975954|NCT02723773|Sham Comparator|Control Group (Ctrl Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive no additional doses of the HZ/su vaccine in the current study and will control for the 1-Additional and Revaccination groups
2975955|NCT02723760|Experimental|99mTc-3PRGD2 SPECT/CT scanning|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and efficacy evaluation of rheumatoid arthritis
2975956|NCT02723747||Healthy volunteers|Healthy subjects with normal 12-lead electrocardiogram at rest.
2975957|NCT02723734||African-American Men (AAM)|AAM with low risk or intermediate risk prostate cancer (PCa). Decipher® testing and standard treatment.
2975958|NCT02723734||Non-African American Men (NAAM)|NAAM with low risk or intermediate risk prostate cancer (PCa). Decipher® testing and standard treatment.
2975959|NCT02723721|Experimental|Picato gel|application on1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.
2975960|NCT02723708|Experimental|Self activation of VTA bold signal|Participants meeting study inclusion will then be scheduled for 4 fMRI sessions to assess and manipulate the ability to self-stimulate VTA activation. Each session will contain the same tasks and instructions. The experimental imaging task sessions will be done 24-72 hours apart and will consist of two types of runs: Test Runs (one pre-test and post-test each) and three Training Runs. Participants will be instructed to achieve heightened state of motivation using personally relevant thoughts and imagery.
2975961|NCT02723695|Experimental|Patients|Surgery (cochlear implantation)
2975962|NCT02723695|Active Comparator|Controls|Asymptomatic subjects
2975963|NCT02723669|Experimental|AR10|AR10 acetylcysteine effervescent tablets for oral solution (two 0.5 g and four 2.5 g)
2975964|NCT02723669|Active Comparator|acetylcysteine|acetylcysteine solution; oral 20% (200 mg/mL)
2975965|NCT02723656|Active Comparator|Proactive mailed care coordination|
2975966|NCT02723656|Active Comparator|Proactive telephone care coordination.|
2975967|NCT02723630|Experimental|Sequence A:|Participants will receive one dose of Treatment 1 followed by one dose of Treatment 2, then one dose of Treatment 3
2975968|NCT02723630|Experimental|Sequence B|Participants will receive one dose of Treatment 2, followed by one dose of Treatment 3, then one dose of Treatment 1
2975969|NCT02723630|Experimental|Sequence C|Participants will receive one dose of Treatment 3, followed by one dose of Treatment 1, then one dose of Treatment 2
2975970|NCT02723630|Experimental|Sequence D|Participants will receive one dose of Treatment 3, followed by one dose of Treatment 2, then one dose of Treatment 1
2975971|NCT02723630|Experimental|Sequence E|Participants will receive one dose of Treatment 1, followed by one dose of Treatment 3, then one dose of Treatment 2
2975972|NCT02723630|Experimental|Sequence F|Participants will receive one dose of Treatment 2, followed by one dose of Treatment 1, then one dose of Treatment 3
2975973|NCT02723617|Other|MED 0.5|
2975974|NCT02723617|Other|MED 2.5|
2975975|NCT02723617|Other|MED 5.5|
2975976|NCT02723617|Other|AAD 2.5|
2976090|NCT02722876|Experimental|Contralateral rehabilitation|8-weeks of resistance training of the non-operative limb following ACL reconstruction
2976091|NCT02722876|Placebo Comparator|Placebo flexibility exercise|8-weeks of 'placebo' flexibility training of the upper limb
2975977|NCT02723604|Experimental|Experimental: Low Level Laser Therapy|Patients meeting the eligibility criteria will be enrolled to receive prophylactic LLLT in addition to standard of care measures for oral mucositis or other toxicity of therapy. The radiation and chemotherapy dose, schedule, modality, technique, and any required adjustments will not be influenced by this protocol and will follow standard existing institutional practices.
2975978|NCT02723591|Active Comparator|Tacrolimus, extended release (Astagraf XL®)|Astagraf XL (once daily)
2975979|NCT02723591|Active Comparator|Tacrolimus, immediate release|Prograf (twice daily), generic immediate release tacrolimus (twice daily)
2975980|NCT02723578|Experimental|Pemetrexed and Erlotinib|Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days and Erlotinib 150 mg PO once daily on days 1-21 every 21 days
2975981|NCT02723552|No Intervention|Control|Control participants undergo no intervention.
2975982|NCT02723552|Experimental|Exercise|Exercise group participants will undergo 16 weeks of 3x/week supervised aerobic exercise of at least 40 minutes per session. After the supervised exercise phase, they will be monitored and supported to maintain an increased physical activity level for eight months.
2975983|NCT02723539|Experimental|MBN-101|MBN-101: a suspension of 150, 375, or 600 microgram (µg)/milliliter (mL) (w:v) BisEDT drug particles in suspension in 3% methylcellulose / 0.5% polysorbate 80 / 10 millimole (mM) sodium chloride / 10 mM sodium phosphate.
2975984|NCT02723539|Placebo Comparator|Vehicle|MBN-101 diluent (placebo): 3% methylcellulose / 0.5% polysorbate 80 / 10 mM sodium chloride / 10 mM sodium phosphate
2975985|NCT02723526||Single arm|
2975986|NCT02723513|Experimental|Preterm Adults|All enrolled preterm adults will undergo non-contrast enhanced MRI (using ultra-short echo time methods), hyperpolarized noble gas MRI (using hyperpolarized xenon-129), x-ray computed tomography (CT), pulmonary function tests, and questionnaires in a single visit.
2975987|NCT02723500|Other|MRI at baseline and over time|Patients with chronic lung disease will undergo pulmonary function tests, hyperpolarized Xenon MRI at each visit.
2975988|NCT02723487|No Intervention|Group A|Control
2975989|NCT02723487|Active Comparator|Group B|patients will receive bilateral ultrasound guided TAP block using bupivacaine (0.125%), 0.5 ml/kg on each side.
2975990|NCT02723487|Active Comparator|Group C|patients will receive bilateral ultrasound guided TAP block using bupivacaine (0.25%), 0.5 ml/kg on each side.
2975991|NCT02723474|Other|MRI at baseline and over time|Patients with chronic lung disease will undergo pulmonary function tests, hyperpolarized Helium and or Xenon MRI at each visit.
2975992|NCT02723461|Active Comparator|pulsatile oxytocin|Using a programmable syringe pump, the pulsatile regime, oxytocin (Syntocinon, stock solution: 10 iU/mL) will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). This regime stems from the observation that physiologic oxytocin may be released in a pulsatile fashion every 4-6 minutes (Dawood et al.,1979)
2975993|NCT02723461|Active Comparator|continuous oxytocin|Continuous group will be administrated oxytocin (Syntocinon, stock solution: 10 iU/mL) at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
2975994|NCT02723448|Other|Single Arm Study|Aclarubicin (6 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days (Days 2-5) of each 28 day cycle to each participant [Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL) patients]. There is no maximum number of cycles.
2975995|NCT02723435|Experimental|Midostaurin|Beginning 30 days post-HCT, participants receive oral midostaurin twice-a-day in 28-day treatment cycles, continuing up to 12 cycles in the absence of disease progression or unacceptable toxicity.
2975996|NCT02723422|Experimental|Prehabilitation Visit/Increased Physical Therapy post-TAVR|
2975997|NCT02723422|Active Comparator|Control|Standard of care physical therapy post-TAVR
2975998|NCT02723409|Active Comparator|Round Procedure|umbilicoplasty technique
2975999|NCT02723409|Active Comparator|"Scarless round procedure"|umbilicoplasty technique
2976000|NCT02723409|Active Comparator|"Inverted U procedure"|umbilicoplasty technique
2976001|NCT02723409|Active Comparator|"Inverted V procedure"|umbilicoplasty technique
2976002|NCT02723409|Active Comparator|"Y deepithelialized procedure"|umbilicoplasty technique
2976003|NCT02723396||Parkinson|Prospective observation of a cohort of consecutive patients with idiopathic PD in an ecological setting.
2976004|NCT02723396||Healthy|The same assessments will be performed in a subgroup of age- and sex-matched healthy volunteers.
2976005|NCT02723383|Experimental|BACLOFEN|patient will receive baclofen caps
2976006|NCT02723383|Placebo Comparator|PLACEBO|patient will receive placebo caps (lactose)
2976007|NCT02723370|Experimental|Initial Intervention|Staff will receive the intervention during the initial intervention period.
2976008|NCT02723370|Experimental|Delayed Intervention|Staff will receive the intervention during the replication study.
2976009|NCT02723357|Experimental|Financial Coaching & Access to Services|Participants in this arm will receive monthly financial coaching and access to basic social service referrals until either one year, closure of all financial needs, or loss to follow up.
2976010|NCT02723357|Active Comparator|Access to Services|Participants in this arm will receive access to basic social service referrals until either one year, closure of all financial needs, or loss to follow up.
2976011|NCT02723344|Experimental|L. reuteri|Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.
2976012|NCT02723344|Placebo Comparator|Sunflower and medium chain triglyceride oils|Sunflower and medium chain triglyceride oils
2976092|NCT02722850|Experimental|ALIVE - Physical Activity|PA CONDITION: The goal of the PA condition is to encourage participants to gradually increase moderate to vigorous PA to 150 minutes per week and to increase resistance training to a total of 15 minutes per day twice per week.
2976013|NCT02723331|Experimental|Nab-paclitaxel/Gemcitabine for R-PDAC|Nab-paclitaxel and gemcitabine, for R-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.
2976014|NCT02723331|Experimental|Nab-paclitaxel/Gemcitabine for BR-PDAC|Nab-paclitaxel and gemcitabine, for BR-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.
2976015|NCT02723318|Experimental|Financia Coaching & Social Services Referrals|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
2976016|NCT02723318|Active Comparator|Social Services|Enrollment in the control arm offers access to social services referrals.
2976017|NCT02723305||Testosterone Naive|Boys with Klinefelter syndrome age 12-17 who are Tanner 3, 4, or 5. No exogenous testosterone exposure in the past 5 years
2976018|NCT02723305||Testosterone exposed|"Boys with Klinefelter syndrome age 12-17 who are Tanner 3, 4, or 5.~+topical testosterone treatment for >1 year"
2976019|NCT02723292|Experimental|Experimental group services|This study will replicate the evidence-based TOP™ in after-school sessions held during RC hours. The primary components of TOP™ include: Comprehensive age-appropriate sexuality education; 90-minute sessions, once a week after-school, during the school year for nine months, using the Changing Scenes© curriculum, and at least twenty hours of youth-led service learning, which involves youth in planning, implementing and reflecting on, community service and leadership.
2976020|NCT02723292|Active Comparator|Control group services|Youth in the control arm will receive a work readiness training curriculum focused on competencies to secure employment. This will include such topics as building customer service skills, clear and direct communication, and creating a work portfolio.
2976021|NCT02723279|Experimental|EPNS group|
2976022|NCT02723279|Active Comparator|TT group|
2976023|NCT02723266|Experimental|Intervention|Treatment receives the STOPPING-GDM intervention. Control does not receive the intervention.
2976024|NCT02723266|No Intervention|Control|Control does not receive the intervention.
2976025|NCT02723253|Experimental|Radiotherapy plus Tom-Ox|Patients received concomitant boost RT (55 Gy/5 weeks) with concurrent Tom-Ox chemotherapy. The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
2976026|NCT02723240|Other|Part 1|"NUC-3373 IV Infusion on Day 1, Day 8, Day 15, Day 22, (28 day cycle)~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
2976027|NCT02723240|Other|Part 2|"NUC-3373 IV Infusion on Day 1, Day 15 (28 day cycle)~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
2976028|NCT02723227|Experimental|Financial Coaching & Social Service Referral|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
2976029|NCT02723227|Active Comparator|Social Services Referral|Enrollment provides for access to referrals to social services.
2976030|NCT02723214|Active Comparator|Frame-based stereotactic brain biopsy|Brain biopsy
2976031|NCT02723214|Active Comparator|Frameless fiducial-less brain biopsy|Brain biopsy
2976032|NCT02723201|Experimental|Part-1, Period 1: TAK-020 17.5 mg Oral Solution|Single dose 17.5 milligram (mg), on Day 1, followed by 7 days of washout. Dose will be determined from TAK-020 single rising dose (SRD) trial.
2976033|NCT02723201|Experimental|Part-1, Period 2: TAK-020 17.5 mg Co-crystal Tablet (CCT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
2976034|NCT02723201|Experimental|Part-1, Period 3:TAK-020 17.5 mg Solid Dispersion Tablet (SDT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
2976035|NCT02723201|Experimental|Part-1, Period 4:TAK-020 17.5 mg Immediate Release Tablet(IRT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
2976036|NCT02723201|Experimental|Part 2, Period 1: TAK-020 25 mg CCT|Participants will be randomized to AB or BA crossover where A= Fasted, B =Fed. Sequence I: Single oral dose TAK-020 25 mg, Fasted (A), 7 days washout, single oral dose TAK-020 Fed (B) Sequence II: Single oral dose TAK-020 25 mg, Fed (B), 7 days washout, single oral dose TAK-020 Fasted (A) Dose will be determined from SRD trial and Part 1.
2976037|NCT02723201|Experimental|Part- 3 Cohort 1: TAK-020 Solid Formulation|Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2
2976038|NCT02723201|Experimental|Part 3 Cohort 2: TAK-020 Solid Formulation|Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2
2976039|NCT02723188|Sham Comparator|Sham|Sham electrical stimulation
2976040|NCT02723188|Experimental|DC: Direct current|Direct current electrical stimulation
2976041|NCT02723188|Experimental|AC: Alternating current|Alternating current electrical stimulation
2976042|NCT02723175|Experimental|Sham tDCS Stimulation|30 minutes of the sham transcranial Direct Current Stimulation
2976043|NCT02723175|Experimental|Anodal tDCS Stimulation of DLPFC|30 minutes of the active transcranial Direct Current Stimulation (tDCS)
2976044|NCT02723162|Experimental|VRN+ NAC|Titrated VRN up to 1mg BID with NAC at 1200mg BID for 28 days
2976045|NCT02723162|Active Comparator|NAC+ PBO|1200mg BID for 28 days plus VRN placebo for 28 days
2976046|NCT02723162|Active Comparator|VRN+ PBO|Titrated VRN up to 1mg BID with NAC placebo for 28 days
2976047|NCT02723162|Placebo Comparator|PBO+PBO|Double placebo taken for 28 days
2976048|NCT02723149|Experimental|Approach Avoidance Training Condition|The AAT group will push away the joystick from marijuana pictures 90% of the trials and pull towards the marijuana pictures 10% of the trials.
2976049|NCT02723149|Sham Comparator|Sham Condition|The sham group will undergo the same procedures, except the ratio for marijuana pictures will be 50% push and 50% pull.
2976213|NCT02721992||Graves' Disease|Patients with Graves' disease, without Graves' Orbitopathy
2976744|NCT02718664|Experimental|B (fed)|Fed condition (test meal)
2976050|NCT02723136|Experimental|Smartphone application|Participants allocated to this arm will receive a smartphone application developed to assist and guide the study of internal medicine and its subspecialties. The application will provide feedback to participants regarding their overall performance in terms of correct answers and the overall time required to solve a clinical vignette.
2976051|NCT02723136|No Intervention|Usual care|Students allocated to this arm will not receive any further assistance in studying for this trial's tests.
2976052|NCT02723123|Experimental|CPAP|CPAP will be provided for a approximately 45 minutes.
2976053|NCT02723123|Experimental|NIPPV|NIPPV will be provided for a approximately 45 minutes.
2976054|NCT02723123|Experimental|NIV-NAVA|NIV-NAVA will be provided for a approximately 45 minutes.
2976055|NCT02723110||rs78408340 heterozygous carriers|
2976056|NCT02723110||homozygous non-risk allele carriers|
2976057|NCT02723097|Experimental|Relaxation Response Resiliency Program (3RP)|
2976058|NCT02723084|Experimental|ABT-493/ABT-530, GT2 without cirrhosis (8 wks)|ABT-493/ABT-530 in HCV GT2 infected participants without cirrhosis for 8 weeks
2976059|NCT02723084|Active Comparator|sofosbuvir plus ribavirin, GT2 without cirrhosis (12 wks)|sofosbuvir plus ribavirin in HCV GT2 infected participants without cirrhosis for 12 weeks
2976060|NCT02723071|Experimental|Cohort A: Ocrelizumab 200 mg/m^2|Participants will receive a total of 8 infusions of ocrelizumab 200 milligram per square meter (mg/m^2) given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
2976061|NCT02723071|Experimental|Cohort B: Ocrelizumab 375 mg/m^2|Participants will receive a total of 8 infusions of ocrelizumab 375 mg/m^2 given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
2976062|NCT02723071|Experimental|Cohort C: Ocrelizumab 375/750 mg/m^2|Participants will receive first infusion of ocrelizumab 375 mg/m^2 followed by 7 infusions of 750 mg/m^2 given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
2976063|NCT02723058|Experimental|ICMHM|ICMHM mothers receive services of a primary care clinician (PCP) and a care manager both trained in depression care management in a shelter-based primary care clinic.
2976064|NCT02723058|No Intervention|Treatment as Usual|Treatment as Usual mothers receive usual services of a PCP and case manager from a shelter-based primary care clinic. .
2976065|NCT02723045|Active Comparator|Open modified Lichtenstein repair|Patients will undergo open repair of their inguinal hernias
2976066|NCT02723045|Active Comparator|Laparoscopic TEP inguinal hernia repair|Patients will undergo laparoscopic repair of their inguinal hernias
2976067|NCT02723032|Other|Healthy Subjects and patients|Validation of SpO2 sensor in healthy subjects as a first step. Validation of SpO2 sensor in patients as a second step.
2976068|NCT02723019|Experimental|Intervention Group|Volunteer Peer Mentor + Behavioral Health Nurse
2976069|NCT02723019|No Intervention|Control|Care as Usual
2976070|NCT02723006|Experimental|TAK-580 + nivolumab|TAK-580 orally, once weekly along with nivolumab, intravenous, every 2 weeks.
2976071|NCT02723006|Experimental|TAK-202 (plozalizumab) + nivolumab|TAK-202 (plozalizumab) 2 milligram (mg), intravenous, once in Week 1, 3, 5, 9, and every 4 weeks thereafter with nivolumab infusion, intravenous, every 2 weeks.
2976072|NCT02723006|Experimental|vedolizumab + nivolumab + ipilimumab|Vedolizumab intravenous, once in Week 1, 3, 5, and 13 along with nivolumab infusion, intravenous, once in Week 1, 4, 7, 10, and 13 and every 2 weeks thereafter, along with ipilimumab intravenous, once in Week 1, 4, 7, and 10.
2976073|NCT02722993|Active Comparator|Probiotics|
2976074|NCT02722993|Placebo Comparator|Placebo|
2976075|NCT02722980|Placebo Comparator|Placebo|Capsules
2976076|NCT02722980|Active Comparator|Active|Capsules.
2976077|NCT02722967|Experimental|Aripiprazole + IEM|Subjects will receive an intervention consisting of a drug-device combination that consists of an aripiprazole tablet with a tiny sensor embedded within it referred to as an Ingestible Event Marker (IEM) . They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole(2, 5, 10, 15, 20, or 30 mg) + IEM once daily for the 8-week assessment period for this trial.
2976078|NCT02722954|Experimental|Demcizumab and Pembrolizumab|Demcizumab will be administered prior to pembrolizumab
2976079|NCT02722941|Active Comparator|Cohort A: Maintenance Therapy|Panobinostat (LBH589): 20 mg by mouth three (3) times per week, every other week, of a 28-day schedule.
2976080|NCT02722941|Active Comparator|Cohort B: Maintenance Therapy|Panobinostat (LBH589): 10 mg by mouth daily for seven (7) days, every other week, of a 28-day schedule.
2976081|NCT02722928|No Intervention|Group A|80 patients will receive ventilation during the surgery with a 1:1 oxygen / air gas mixture
2976082|NCT02722928|Experimental|Group B|Patients will receive controlled ventilation with a conventional 1:1 oxygen / air gas mixture during the approach and tumor removal phases. Once tumor resection is completed and hemostasis started, this group of patients will be switched to ventilation with pure oxygen
2976083|NCT02722915|Experimental|fMRI Neurofeedback up-regulation|Study related procedures included: PANAS, AVHRS, SF 36 (questionnaires or evaluations)
2976084|NCT02722915|Experimental|fMRI Neurofeedback down-regulation|Study related procedures included: PANAS, AVHRS, SF 36 (questionnaires or evaluations)
2976085|NCT02722902|Experimental|LIPID + Carnitor|"intravenous Lipid infusion (IntraLipid) combined with carnitor (L-carnitine) infusion~L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.~Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h."
2976086|NCT02722902|Placebo Comparator|LIPID + PLAC|"Intravenous Lipid infusion (IntraLipid) combined with placebo infusion (saline)~Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h."
2976087|NCT02722902|Placebo Comparator|PLAC|"Infusion of saline (no IntraLipid and no carnitor)~Saline will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 ml/h."
2976088|NCT02722889||Healthy controls|Healthy control patients
2976089|NCT02722889||Type A dissection|Patients with proven type A dissection,
2976093|NCT02722850|Experimental|ALIVE - Dietary Modification|DIET CONDITION: The goal of the dietary condition includes increasing intake of fruit and vegetable to 5-servings per day. The program also encourages participants to increase the consumption of colorful fruits and vegetables. The fat goals consist of reducing saturated fats to <10% of total kilocalories per day, trans fats to <3 grams per day, and added sugar to <50 grams per day.
2976094|NCT02722837|Experimental|SOF/VEL|SOF/VEL for 12 weeks
2976095|NCT02722824|Placebo Comparator|Placebo|Wearable stimulators will be placed on the patients and controls without stimulation for 20 minutes
2976096|NCT02722824|Experimental|Active Stimulation|Instrinsic auricular muscles will be stimulated for 20 minutes
2976097|NCT02722824|Sham Comparator|Sham|An area out of the instrinsic auricular muscles region will be stimulated with the same parameters of the active group for 20 minutes
2976098|NCT02722824|No Intervention|Passive Control|Only the electrodes of the wearable stimulators will be inserted but there will not be electrostimulation for 20 minutes
2976099|NCT02722811|Experimental|Etanercept treatment group|Subcutaneous injection etanercept of 50 mg/w and Health education, exercise and diet guidance; treatment: 8 weeks
2976100|NCT02722811|Placebo Comparator|Routine care group|Health education, exercise and diet guidance; treatment: 8 weeks
2976101|NCT02722798|Experimental|KRN23|Subjects will receive subcutaneous injections of KRN23 every 4 weeks from Week 0 through Week 44
2976102|NCT02722785|No Intervention|Usual Care Observation Group|Patients allocated to usual care control will receive the standard patient care program as provided by the department of surgical gastroenterology, Rigshospitalet
2976103|NCT02722785|Experimental|Aerobic and Resistance Exercise Training|Patients allocated to this group will receive usual care plus a supervised aerobic and resistance exercise program at CFAS' facilities consisting of 2 weekly sessions of approximately 60 minutes.
2976104|NCT02722772|Experimental|Etanercept treatment group|Intra-articular injection of etanercept of 25 mg/w/joint and Health education, exercise and diet guidance; treatment: 5 weeks (If both knees are involved, the more significant symptomatic side is chosen for injection by etanercept)
2976105|NCT02722772|Placebo Comparator|Routine care group|Health education, exercise and diet guidance; treatment: 5 weeks
2976106|NCT02722759|Other|hemoglobin measurement arm|"In this arm hemoglobin measurement is done by four different devices~device Radical-7 for non-invasive measurement of SpHb~device HemoCue for taking capillary and venous blood for measurement of HcHb~device ABL 800 for measurement of BGAHb~device Siemens ADVIA for measurement of labHb~For measurement of haemoglobin by the devices the following interventions have to be done:~venous or arterial puncture (routine)~capillary puncture~placing of the Radical 7 sensor"
2976107|NCT02722746|Placebo Comparator|Ropivacaine only Control group|The participants in this group will receive standard anesthesia, epidural analgesia with 0.2% ropivacaine with no epinephrine added during the procedure.
2976108|NCT02722746|Active Comparator|Ropivacaine + 2 mcg/mL epinephrine|The participants in this group will receive standard anesthesia (Ropivacaine 0.2%) with the addition of 2mcg/mL of epinephrine during the procedure.
2976109|NCT02722746|Active Comparator|Ropivacaine + 5 mcg/mL epinephrine|The participants in this group will receive standard anesthesia (Ropivacaine 0.2%) with the addition of 5mcg/mL of epinephrine during the procedure.
2976110|NCT02722733|Active Comparator|G-CSF (filgrastim)|1.G-CSF at 10 μg/kg per day (divided into two doses every 12 hours) subcutaneously for up to 7 days.
2976111|NCT02722733|Active Comparator|Cytosine arabinoside + G-CSF (filgrastim)|"Cytosine arabinoside will be administered as a 2-hour i.v. infusion at a dose of 0.4 g/m2 twice daily on days 1 and 2 (total dose 1.6 g/m2).~G-CSF 5-10 μg/kg per day (divided into two doses every 12 hours) will be started on day 5 subcutaneously and continued until last leukapheresis."
2976112|NCT02722720|Experimental|Carotid stenting, Transradial approach|Internal carotid artery stenting using transradial arterial approach
2976113|NCT02722720|Active Comparator|Carotid stenting, Transfemoral approach|Internal carotid artery stenting using transfemoral arterial approach
2976114|NCT02722694|Experimental|Subcutaneous(SC) Abatacept|
2976115|NCT02722694|Placebo Comparator|Placebo|
2976116|NCT02722681||Symptomatic spinal lipoma patients|Spinal lipoma patients undergoing surgery due to symptomatic lipoma. Routine blood and urine samples will be taken pre-operatively, some will be kept aside for research. Cerebrospinal fluid is drained intraoperatively and usually discarded, some will be kept for research.
2976117|NCT02722681||Asymptomatic spinal lipoma patients|Spinal lipoma patients who remain asymptomatic. Routine blood and urine samples will be taken as part of routine clinical care, some will be kept for research.
2976118|NCT02722681||Non-lipoma spinal conditions|Patients undergoing spinal surgery for a non-lipoma related condition. Routine blood and urine samples will be taken pre-operatively, some will be kept aside for research. Cerebrospinal fluid is drained intra-operatively and usually discarded, some will be kept for research.
2976119|NCT02722668|Experimental|No ATG|Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.
2976120|NCT02722668|Experimental|ATG|Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.
2976121|NCT02722655||Type 1 diabetes mellitus|Sudden onset of symptoms and non-overweight/obese
2976122|NCT02722655||Type 2 diabetes mellitus|Insidious onset of symptoms and overweight/obese
2976123|NCT02722655||Type 1.5 diabetes mellitus|Overlap of type 1 and type2 diabetes mellitus clinical characteristics
2976124|NCT02722655||Other types of diabetes mellitus|According American Diabetes Association criteria
2976125|NCT02722642|Experimental|Bronchial basal cells|Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade bronchial basal cells (BBCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
2976126|NCT02722629|Experimental|Aspiration in COPD patients|All COPD patient will be evaluated systematically by FEESST (Flexible Endoscopic Evaluation of Swallowing with Sensory Testing) with direct evaluation of aspiration by direct observation.
2976214|NCT02721992||Graves' Orbitopathy|Patients with Graves' disease, with Graves' Orbitopathy
2976215|NCT02721979|Experimental|Treatment (apalutamide)|Patients receive apalutamide PO QD for 90 days.
2976127|NCT02722616|Active Comparator|Pancreatic Cancer|"A 4D ultrasound scan of the pancreas will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.~On each treatment day, 4D ultrasound images will be acquired continuously during beam on time to monitor pancreas motion. Intra-fraction CBCT images acquired during treatment will be registered with reference CT images. Organ motion registered by ultrasound will be compared to motion recorded by CBCT and the accuracy of the ultrasound system will be evaluated."
2976128|NCT02722616|Active Comparator|Liver Cancer|"A 4D ultrasound scan of the liver will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery.~On each treatment day, 4D ultrasound images will be acquired continuously during beam on time to monitor liver motion. The system will record all relevant images, but will not be used in clinical decision making. Intra-fraction CBCT images acquired during treatment will be registered with reference CT images. Organ motion registered by ultrasound will be compared to motion recorded by CBCT and the accuracy of the ultrasound system will be evaluated."
2976129|NCT02722616|Other|Healthy Volunteer|A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images. Additional registration of ultrasound images will be performed with Velocity software to evaluate accuracy of automated registration software in the ultrasound system.
2976130|NCT02722603|Experimental|gabapentin / placebo tramadol|gabapentin 75 mg/ml syrup / placebo tramadol, 3 times/day for 15 weeks.
2976131|NCT02722603|Active Comparator|tramadol / placebo gabapentin|tramadol oral drops 100 mg/ml / placebo gabapentin, 3 times/day for 15 weeks.
2976132|NCT02722590||Fycompa tablets 2/4/6/8/10/12 mg|Participants who are prescribed Fycompa film-coated tablets 2/4/6/8/10/12 milligrams (mg) per approved prescribing information in a normal clinical practice setting.
2976133|NCT02722564|Experimental|all study participants|subject will self estimate breath alcohol content and their actual BrAC will be recorded as measured by the Alco Sensor IV after each beer ingested.
2976134|NCT02722551|Experimental|Treatment|Treatment with the CardiAQ-Edwards™ Transcatheter Mitral Valve (transapical or transseptal delivery)
2976135|NCT02722538|Experimental|Residual Tumor following TURBT|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the Radical Cystectomy (RC).
2976136|NCT02722538|Experimental|No Residual Tumor Following TURBT|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the Radical Cystectomy (RC).
2976137|NCT02722525|Experimental|Diagnostic (cardiac MRI, skeletal muscle PMRS)|Patients undergo a treadmill stress CMR focused on cardiac muscle comprised of resting MRI over 10-15 minutes followed by treadmill exercise until peak stress. Patients then undergo MRI and gadopentetate dimeglumine perfusion imaging immediately after exercise and after a 6-8 minute recovery period. Within 24 hours of treadmill CMR exam, patients also undergo skeletal muscle PMRS while at rest, during, and in the recovery phase of resistive lower extremity exercise which patients complete over 30 seconds. Both procedures are performed before initiation of ADT treatment (baseline) and 4-7 months after initiation of ADT treatment.
2976138|NCT02722512|Experimental|Newly Diagnosed High Grade Glioma (HGG)|Heat Shock Protein Peptide Complex-96 (HSPPC-96) therapy will be given between 0-28 days after the completion of radiation therapy (XRT) AND no more than 60 days from completion of XRT. Vaccine will be given once weekly for 4 weeks. The 4 weeks (28 days) of vaccine administration will be followed by an observation visit. In patients with sufficient vaccine (on both Arms A and B), a maintenance therapy will be instituted. It will be administered at the same dose the patient was enrolled at and given every 2 weeks until vaccine is exhausted or there is evidence of tumor progression. The first dose of maintenance vaccine should be administered 7 days after completion of the observation visit.
2976139|NCT02722512|Experimental|Recurrent HGG and Ependymoma|On Arm B, Heat Shock Protein Peptide Complex-96 (HSPPC-96) will be given as soon as possible after tumor resection post-operative recovery and sufficient time for vaccine preparation (typically 0-28 days post-operatively) AND no more than 60 days post-operatively. Vaccine will be given once weekly for 4 weeks. These 4 weeks (28 days) of vaccines will be followed by an observation visit. In patients with sufficient vaccine, a maintenance therapy will be given. It will be given at the same dose the patient was enrolled at and given every 2 weeks until vaccine is exhausted or there is evidence of tumor progression. The first dose of maintenance vaccine should be given 7 days after completion of the observation visit.
2976140|NCT02722499|Experimental|High Frequency Financial Incentive|"The high frequency incentive structure will receive a reward or uploading glucose measurements, attending educational sessions, and absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300.~Each week participants can receive up to $10 for uploading glucose measurements and having good glucose control throughout the week.~Participants can also earn $5 each week if they attend the educational session. Educational sessions will last for 8 weeks, so they can receive up to $5 per week for 8 weeks.~After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $130, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $65."
2976216|NCT02721966|Experimental|AIN457 dose 1|Secukinumab dose amount 1 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 1 sc injection every 4 weeks for remaining 44 weeks
2976293|NCT02721537|Placebo Comparator|Arm B: Healthy Collegiate Athletes|Healthy collegiate athletes will take a matching placebo
2976141|NCT02722499|Experimental|Moderate Frequency Financial Incentive|"Each week participants in Group B can receive up to $10 for uploading glucose measurements and having good glucose control throughout the week. If they upload measurements every day of the week and their average glucose measurements at the end of the week are 150 or below they will receive an additional $3. Up to $10 per week for 3-months.~After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $170, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $85"
2976142|NCT02722499|Experimental|Low Frequency Financial Incentive|"After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $300, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $150.~Thus, the maximum reward for each subject will be $300 over the 3 months of intervention and follow up."
2976143|NCT02722486|Active Comparator|Standard Vestibular Rehabilitation|Subjects will undergo weekly vestibular rehabilitation sessions for 3 months (a total of 12 sessions of an hour each). During these sessions, standard balance training exercises will be done at the discretion of the physical therapists.
2976144|NCT02722486|Experimental|Vestibular Rehabilitation/Balance Belt|Subjects will undergo weekly vestibular rehabilitation sessions for 3 months (a total of 12 sessions). They will undergo standard balance training exercises with the physical therapists like the control group, but will also undergo an additional 15 minutes of Balance Belt exercises during each session.
2976145|NCT02722473|Active Comparator|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5°C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5°C for 24 hours.
2976146|NCT02722473|Placebo Comparator|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5°C for 48 hours
2976147|NCT02722447|Active Comparator|Rivaroxaban|Rivaroxaban 20 mg od for 6 weeks after an initial course of rivaroxaban for 6 weeks (15 mg bid for 3 weeks and 20 mg od for 3 weeks)
2976148|NCT02722447|Experimental|Placebo|Placebo for 6 weeks after an initial course of rivaroxaban for 6 weeks (15 mg bid for 3 weeks followed by 20 mg od for 3 weeks)
2976149|NCT02722434|Experimental|Arm I (MC5-A scrambler therapy)|Patients undergo MC5-A scrambler therapy over 30 minutes for 10 consecutive weekdays.
2976150|NCT02722434|Active Comparator|Arm II (TENS therapy)|Patients undergo TENS therapy over 30 minutes daily for 14 days.
2976151|NCT02722421|Experimental|Efavirenz group|HIV-infected women receiving efavirenz-based antiretroviral therapy plus increased dose levonorgestrel subdermal implants.
2976152|NCT02722408|Experimental|Gemcabene 300 mg QD|Gemcabene treatment on stable background statin therapy
2976153|NCT02722408|Experimental|Gemcabene 600 mg QD|Gemcabene treatment on stable background statin therapy
2976154|NCT02722408|Experimental|Gemcabene 900 mg QD|Gemcabene treatment on stable background statin therapy
2976155|NCT02722395||Single arm cohort study|
2976156|NCT02722382|No Intervention|Usual Nephrology Care|Nephrology care at Geisinger Health System.
2976157|NCT02722382|Active Comparator|Patient-Centered Kidney Transitions Care|Health system intervention which will implement informatics tools (including a disease registry, predictive modeling, and advance directives) and a disease specific care manager who will provide services and navigate patients through kidney disease transitions.
2976158|NCT02722369|Active Comparator|Control Arm|"IV carboplatin AUC5 (area under curve) on Day1~IV etoposide 120mg/m2 Day 1, followed by oral etoposide 100mg BD (twice daily) on Day 2 and Day 3"
2976159|NCT02722369|Experimental|Investigational Arm|"IV gemcitabine 1200mg/m2 on Day 1 and Day 8~IV carboplatin AUC5 on Day 1~Oral HCQ will be taken at a dose of 400mg BD from day 1 of cycle 1 (maximum of 30 months)"
2976160|NCT02722356|Experimental|Oxytocin|Oxytocin administered according to proposed protocol
2976161|NCT02722356|Active Comparator|Standard Practice|Oxytocin administered according to standard practice at facility
2976162|NCT02722343|Experimental|Tenofovir intravaginal ring|The tenofovir intravaginal ring (TFV IVR) is 55.0 mm in diameter, consisting of a single segment of polyurethane tubing with an outer diameter of 5.5 mm and filled with white TFV-containing paste. The IVR delivers 8-10mg/day of TFV.
2976163|NCT02722343|Active Comparator|Truvada oral tablets|"The tablets contain 200mg emtricitabine combined with 300mg tenofovir disoproxil fumarate (300mg). The tablets are commercially available as Truvada. The tablets are blue, capsule-shaped, film-coated, debossed with GILEAD on one side and with 701 on the other side"
2976164|NCT02722330|Experimental|Baha 5 SuperPower on Baha Attract System|"The device involves the following parts:~The sound processor unit, an actuator unit and a cable, the Sound Processor Magnet (SP Magnet) of the Baha Attract System, the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant, a snap coupling."
2976165|NCT02722304|Experimental|ARALAST NP 60 mg/kg|60 mg/kg body weight/week
2976166|NCT02722304|Experimental|ARALAST NP 120 mg/kg|120 mg/kg body weight/week
2976167|NCT02722304|Experimental|GLASSIA 60 mg/kg|60 mg/kg body weight/week
2976168|NCT02722304|Experimental|GLASSIA 120 mg/kg|120 mg/kg body weight/week
2976169|NCT02722304|Placebo Comparator|Placebo|Human Albumin 2%
2976170|NCT02722291|Experimental|presbyopia|All participants perform all exams under 3 conditions, that is baseline, with out pinhole glasses, and with multiple pinhole glasses
2976171|NCT02722278|Experimental|Oral Testosterone Undecanoate|Approximately 135 subjects will receive oral TU treatment during the study for approximately 3.5 months. Subjects randomly assigned to the oral TU treatment group will begin treatment at a dose of 237 mg TU twice daily (BID).
2976172|NCT02722278|Active Comparator|Axiron Testosterone Topical Solution|Subjects randomly assigned to the Axiron treatment group will begin treatment at a dose of 60 mg every morning.
2976173|NCT02722265|Experimental|CS-3150|CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
2976174|NCT02722252||Embryoscope group|
2976175|NCT02722252||Embryo culture without incorporated camera group|
2976176|NCT02722239|Experimental|T/R|Test product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release. Volunteers enrolled to group 1, on the first study period will take the study test product (Т), and on the second study period after wash out period of 7 days the volunteers will be given the Reference product (R)
2976177|NCT02722239|Experimental|R/T|Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long). Volunteers from group 2 will be administered with the study drug in reverse order. It means that group 1 will take the study products in sequence T-R and group 2 in the sequence R-T.
2976178|NCT02722226|Experimental|Simulation based sedation learning (Intervention Group)|The program includes online learning. It is followed by development of interactive presentations, based on simulated cases or simulated patients (actors), low fidelity simulation for specific technical skills as well as high fidelity scenarios of complications related to sedation.
2976179|NCT02722226|No Intervention|Control Group|
2976180|NCT02722213|Experimental|Mindfulness-Based Stress Reduction|"The primary intervention is an 8-week Mindfulness-Based Stress Reduction (MBSR) course, taught in 8 weekly 2.5-hour group sessions, and one all-day (6.5 hours) retreat. MBSR is taught per a standard protocol in a group setting and includes presentation of key MBSR constructs, meditation and breathing techniques, gentle yoga and Tai Chi poses, shared discussion time among participants and brief readings and home practice between sessions. Participants also will continue with usual care and receive standard educational materials on healthy lifestyles and stress management.~Note: This study will recruit patients who are eligible for traditional exercise-based cardiac rehabilitation (CR). Randomization will be stratified based on whether or not patients are actively enrolled in CR at the time of the study. Within each stratum, participants will be randomized to either the intervention (MBSR) or control (no MBSR) condition."
2976181|NCT02722213|No Intervention|Control (No MBSR)|"Those randomized to the control condition (no MBSR) will continue with their usual care, and will receive standard educational materials related to stress reduction and healthy lifestyles. At the end of the study the control condition participants will receive a compact disc and workbook on MBSR.~Note: This study will recruit patients who are eligible for traditional exercise-based cardiac rehabilitation (CR). Randomization will be stratified based on whether or not patients are actively enrolled in CR at the time of the study. Within each stratum, participants will be randomized to either the intervention (MBSR) or control (no MBSR) condition."
2976182|NCT02722200|Experimental|Intravenous glucocorticoids|Subjects in the glucocorticoids arm will receive an infusion of hydrocortisone overnight in the research unit prior to fMRI testing on either the first or second visit.
2976183|NCT02722200|Placebo Comparator|Intravenous saline|Subjects in the saline arm will receive an infusion of saline overnight in the research unit prior to fMRI testing on either the first or second visit.
2976184|NCT02722187|Experimental|microsurgery|40 patients will undergo subinguinal microscopic varicocelectomy
2976185|NCT02722187|Active Comparator|laparoscopy|20 patients will undergo laparoscopic varicocelectomy
2976186|NCT02722174||BED|Binge Eating Disorder
2976187|NCT02722174||ADHD|Attention Deficit Hyperactivity Disorder
2976188|NCT02722174||SUD, cocaine subtype|Stimulant Use Disorder, cocaine subtype
2976189|NCT02722174||BPD|Borderline Personality Disorder
2976190|NCT02722174||BPD, Cohort 2|Borderline Personality Disorder, Cohort 2
2976191|NCT02722174||HC|Healthy Controls
2976192|NCT02722161|Experimental|[14C]BI 1482694|
2976193|NCT02722148|Experimental|Enrolled Patients|All enrolled subjects will receive a novel allergen-specific immune signature directed approach to dietary elimination therapy
2976194|NCT02722135|Experimental|Volasertib|
2976195|NCT02722122|Experimental|AIR DNase™ 2.5 mg|2.5 mg of AIR DNase™ administered once daily via inhalation for 28 days
2976196|NCT02722096|Experimental|Axillary block anesthesia|Axillary brachial plexus block anesthesia (with Ropivacaine and Lidocaine) will be performed by anesthetist 30 to 45 minutes before surgery
2976197|NCT02722096|Active Comparator|Local anesthesia|Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
2976198|NCT02722083|Experimental|BAY X002134|Subjects will be given BAY X002134
2976199|NCT02722083|Placebo Comparator|Placebo|Subjects will be given a placebo
2976200|NCT02722070||Healthy Controls|Age matched control for the various clinical groups
2976201|NCT02722070||Neurodegenerative patients|
2976202|NCT02722070||Stroke patients|
2976203|NCT02722070||Neuropsychiatric patients|
2976204|NCT02722057||Cohort 1 - Interventional|The Interventional cohort will not be utilized.
2976205|NCT02722057||Cohort 2 - Non Interventional|A Non-Interventional Cohort comprising pediatric (<18 years of age) and adult R117H-CFTR patients treated with commercially-available Kalydeco.
2976206|NCT02722057||Cohort 3 - Historical|A Historical Cohort comprising data from an earlier time period for pediatric (<18 years of age) and adult patients with the R117H-CFTR mutation who have never been exposed to Kalydeco and matched on age, gender, and lung function to patients in the Non-Interventional Cohort.
2976207|NCT02722044|Experimental|All Study Participants|All study participants to receive M923 administered via a subcutaneous auto-injector (AI)
2976208|NCT02722018|Experimental|Part 1: GDC-0810 dose level A - Low Fat Meal|Participants will receive a single dose of GDC-0810 dose level A on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal in the form of Phase II tablet or one of three Phase III prototype tablets (Prototype 1, 2 or 3) in a crossover fashion.
2976209|NCT02722018|Experimental|Part 2 (Optional): GDC-0810 dose level A - Low Fat Meal|Participants will receive a single dose of GDC-0810 dose level A on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal in the form of Phase II tablet or one of two Phase III prototype tablets (Prototype 4 or 5) in a crossover fashion.
2976210|NCT02722018|Experimental|Part 3: GDC-0810 dose level B - Low Fat Meal/Fasted|Participants will receive a single dose of GDC-0810 dose level B on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal or under fasted condition either as Phase II tablet (with low fat meal) or as the Phase III prototype tablet selected from Parts 1 or 2 (with low fat meal or under fasted conditions), in a crossover fashion.
2976211|NCT02722005|Experimental|Financial Coaching & Access to Services|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
2976212|NCT02722005|Active Comparator|Access to Services|Participants will have access to a host of referrals to social services (this is the intervention for this group)
2976217|NCT02721966|Experimental|AIN457 dose 2|Secukinumab dose amount 2 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 2 sc injection every 4 weeks for remaining 44 weeks
2976218|NCT02721966|Placebo Comparator|AIN457 Placebo|Placebo sc injection weekly for 4 weeks and at week 8, followed by Secukinumab dose 1 or 300 mg sc injection every 4 week for remaining 40 weeks.
2976219|NCT02721953|Experimental|Hypocaloric diet plus butyrate|Hypocaloric diet plus butyrate
2976220|NCT02721953|Placebo Comparator|Hypocaloric diet plus placebo|Hypocaloric diet plus placebo
2976221|NCT02721940|Experimental|Treatment group|In the treatment group, patients will be given local injection of enriched autologous mononuclear cells and zoledronic acid into the necrotic area following core decompression by drilling.
2976222|NCT02721940|Experimental|Control group|In the control group, core decompression will be performed, but no treatment will be given.
2976223|NCT02721914|Experimental|GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC|Subjects will receive 4 massotherapy sessions and 4 of HYPOPRESSIVE ABDOMINAL GYMNASTIC (HAG).
2976224|NCT02721914|Experimental|GROUP RECEIVING MASSOTHERAPY|The subjects of this group will receive a total of 8 sessions of 30 minutes each.
2976225|NCT02721914|Experimental|GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC|The subjects of this group will receive a total of 8 sessions of 20 minutes each.
2976226|NCT02721901|Experimental|iEAT Manual Intervention|Caretakers of 10 children will be randomized to participate in the integrated Eating Aversion Treatment (iEAT) intervention. iEAT is a technology-based manual which aims to increase the child's food consumption.
2976227|NCT02721901|Active Comparator|Control group|Caretakers of 10 children will be randomized to participate in the control group. Participants assigned to the control group will be able to receive the iEAT treatment after the study ends.
2976228|NCT02721888|Experimental|Main study|
2976229|NCT02721875|Experimental|Volasertib monotherapy|
2976230|NCT02721875|Experimental|Volasertib + azacitidine combination|
2976231|NCT02721862|Experimental|Experimental|This arm will include 50 patients who, at baseline ultrasound, have no gallbladder pathology and have no previous cholecystectomy. Those patients will be taking an oral drug (Ursodeoxycholic Acid 250mg) twice daily for a period of six months and undergoing a total of three gallbladder ultrasounds (at 6 months, at 12 months, and at 18 months) to check for gallstones.
2976232|NCT02721862|Placebo Comparator|Control|This arm will include 50 patients who, at baseline ultrasound, have no gallbladder pathology and have no previous cholecystectomy. Those patients will be taking a placebo, that is dispensed from the pharmacy and having the same color as the ursodeoxycholic acid 250mg, twice daily for a period of six months and undergoing a total of three gallbladder ultrasounds (at 6 months, at 12 months, and at 18 months) to check for gallstones.
2976233|NCT02721849|Experimental|adolescent yoga / parent control|The adolescent will receive an 12 week yoga course, while one parent will only answer the questionnaires.
2976234|NCT02721849|Experimental|adolescent waitlist / parent yoga|One parent will participate in an 12 week yoga course, while the adolescent will receive the intervention after the follow-up period.
2976235|NCT02721849|Experimental|adolescent yoga / parent yoga|Both adolescent and parent will participate in an 12 week yoga course at the same time.
2976236|NCT02721849|No Intervention|adolescent waitlist / parent control|The adolescent will receive the intervention after the follow-up period, while one parent will only answer the questionnaires.
2976237|NCT02721836|Experimental|Yoga|12 week yoga course, two times a week 75 minutes each time
2976238|NCT02721836|Active Comparator|Nutrition|3 counselling sessions within 12 weeks
2976239|NCT02721823|Experimental|lifestyle-modification|Once a week for 10 weeks with a circumference of 60 hours with mindfulness-based stress reduction and further process of the Mind / body medicine.
2976240|NCT02721823|Active Comparator|control group|A unique education unit within the scope of 3 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training.
2976241|NCT02721810|No Intervention|Control|Prompts standard to rounds or electronic medical records.
2976242|NCT02721810|Experimental|Prompting Intervention|Prompting consideration of 3-month functional outcome.
2976243|NCT02721797||Skin|Patients with EDS diagnosis having surgery, have debrided skin retained for this research
2976244|NCT02721797||Tendon|Patients with EDS diagnosis having surgery, have debrided tendon retained for this research
2976245|NCT02721797||Uterine tissue|Patients with EDS diagnosis having surgery, have debrided uterine tissue retained for this research
2976246|NCT02721797||Vaginal tissue|Patients with EDS diagnosis having surgery, have debrided vaginal tissues retained for this research
2976247|NCT02721797||Ligaments|Patients with EDS diagnosis having surgery, have debrided ligaments retained for this research
2976248|NCT02721784|Other|Pre- and Post- Radiotherapy MRI|"mpMRI/VERDICT sequences to be preformed pre- and post- EBRT (external beam radiotherapy) according to the following schedule:~Pre-Androgen Deprivation Therapy 3 weeks before radiotherapy 6 week after starting radiotherapy 6 Months after starting radiotherapy~External Beam Radiotherapy to be given after 3 months of androgen deprivation"
2976249|NCT02721758|Experimental|Brief Motivational Intervention|Single, 60-minute, manualized behavioural intervention designed to support cardiac rehabilitation enrollment, informed by principles of motivational interviewing
2976250|NCT02721758|No Intervention|Usual Care|Standard encouragement to enroll in cardiac rehabilitation, and meeting with a researcher to complete study questionnaires
2976251|NCT02721745|Experimental|Natural Fatigue|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
2976252|NCT02721745|Experimental|tDCS anodal|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
2976253|NCT02721745|Experimental|tDCS cathodal|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
2976254|NCT02721745|Experimental|tDCS sham|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
2976255|NCT02721745|Experimental|inhibitory TMS|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
2976256|NCT02721745|Experimental|Sham TMS|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
2976257|NCT02721732|Experimental|Squamous Cell Carcinoma of the Skin Group|"Pembrolizumab given via intravenous (IV) infusion on Day 1 of every cycle. One treatment cycle consists of 3 weeks (21 days) of treatment. Participants restaged at the end of every three cycles (9 weeks). Participants may be allowed to continue treatment after restaging if there is continued clinical response or disease stabilization and they do not have significant toxicities.~Every 12 weeks after participant's last dose of pembrolizumab, study staff will contact them by phone to ask about their status."
2976258|NCT02721732|Experimental|Small Cell Malignancies of Non-Pulmonary Origin|"Pembrolizumab given via intravenous (IV) infusion on Day 1 of every cycle. One treatment cycle consists of 3 weeks (21 days) of treatment. Participants restaged at the end of every three cycles (9 weeks). Participants may be allowed to continue treatment after restaging if there is continued clinical response or disease stabilization and they do not have significant toxicities.~Every 12 weeks after participant's last dose of pembrolizumab, study staff will contact them by phone to ask about their status."
2976259|NCT02721732|Experimental|Adrenocortical Carcinoma Group|"Pembrolizumab given via intravenous (IV) infusion on Day 1 of every cycle. One treatment cycle consists of 3 weeks (21 days) of treatment. Participants restaged at the end of every three cycles (9 weeks). Participants may be allowed to continue treatment after restaging if there is continued clinical response or disease stabilization and they do not have significant toxicities.~Every 12 weeks after participant's last dose of pembrolizumab, study staff will contact them by phone to ask about their status."
2976260|NCT02721732|Experimental|Medullary Renal Cell Carcinoma Group|"Pembrolizumab given via intravenous (IV) infusion on Day 1 of every cycle. One treatment cycle consists of 3 weeks (21 days) of treatment. Participants restaged at the end of every three cycles (9 weeks). Participants may be allowed to continue treatment after restaging if there is continued clinical response or disease stabilization and they do not have significant toxicities.~Every 12 weeks after participant's last dose of pembrolizumab, study staff will contact them by phone to ask about their status."
2976261|NCT02721732|Experimental|Carcinoma of Unknown Primary Group|"Pembrolizumab given via intravenous (IV) infusion on Day 1 of every cycle. One treatment cycle consists of 3 weeks (21 days) of treatment. Participants restaged at the end of every three cycles (9 weeks). Participants may be allowed to continue treatment after restaging if there is continued clinical response or disease stabilization and they do not have significant toxicities.~Every 12 weeks after participant's last dose of pembrolizumab, study staff will contact them by phone to ask about their status."
2976262|NCT02721732|Experimental|Penile Carcinoma Group|"Pembrolizumab given via intravenous (IV) infusion on Day 1 of every cycle. One treatment cycle consists of 3 weeks (21 days) of treatment. Participants restaged at the end of every three cycles (9 weeks). Participants may be allowed to continue treatment after restaging if there is continued clinical response or disease stabilization and they do not have significant toxicities.~Every 12 weeks after participant's last dose of pembrolizumab, study staff will contact them by phone to ask about their status."
2976263|NCT02721732|Experimental|Vascular Sarcoma Group|"Pembrolizumab given via intravenous (IV) infusion on Day 1 of every cycle. One treatment cycle consists of 3 weeks (21 days) of treatment. Participants restaged at the end of every three cycles (9 weeks). Participants may be allowed to continue treatment after restaging if there is continued clinical response or disease stabilization and they do not have significant toxicities.~Every 12 weeks after participant's last dose of pembrolizumab, study staff will contact them by phone to ask about their status."
2976264|NCT02721732|Experimental|Germ Cell Tumor Group|"Pembrolizumab given via intravenous (IV) infusion on Day 1 of every cycle. One treatment cycle consists of 3 weeks (21 days) of treatment. Participants restaged at the end of every three cycles (9 weeks). Participants may be allowed to continue treatment after restaging if there is continued clinical response or disease stabilization and they do not have significant toxicities.~Every 12 weeks after participant's last dose of pembrolizumab, study staff will contact them by phone to ask about their status."
2976265|NCT02721732|Experimental|Paraganglioma-Pheochromocytoma Group|"Pembrolizumab given via intravenous (IV) infusion on Day 1 of every cycle. One treatment cycle consists of 3 weeks (21 days) of treatment. Participants restaged at the end of every three cycles (9 weeks). Participants may be allowed to continue treatment after restaging if there is continued clinical response or disease stabilization and they do not have significant toxicities.~Every 12 weeks after participant's last dose of pembrolizumab, study staff will contact them by phone to ask about their status."
2976266|NCT02721732|Experimental|Rare Tumor Histologies Group|"Pembrolizumab given via intravenous (IV) infusion on Day 1 of every cycle. One treatment cycle consists of 3 weeks (21 days) of treatment. Participants restaged at the end of every three cycles (9 weeks). Participants may be allowed to continue treatment after restaging if there is continued clinical response or disease stabilization and they do not have significant toxicities.~Every 12 weeks after participant's last dose of pembrolizumab, study staff will contact them by phone to ask about their status."
2976267|NCT02721719||Healthy Adults|[Not receiving Vedolizumab] Healthy adults who have not donated blood within the past two months and who have no history of blood-borne diseases.
2976268|NCT02721719||Adults with no Inflammatory Bowl Disease|[Not receiving Vedolizumab] Adult patients undergoing endoscopy for indications other than Inflammatory Bowel Disease or other inflammatory conditions of the bowel (such as colon cancer screening or polypectomy)
2976269|NCT02721719||Donors with Ulcerative Colitis|[Set to receive Vedolizumab] Adults with an established diagnosis of UC (≥ 6 months preceding involvement in study) who are both scheduled for an endoscopy and are about to receive Vedolizumab treatment (standard of care).
2976270|NCT02721706|Experimental|CIPA screening tool|Patients are evaluated by CIPA nutritional screening tool
2976271|NCT02721706|No Intervention|usual hospital clinical care|Patients are not subject of CIPA screening tool, and continue the usual hospital clinical care
2976272|NCT02721693|Experimental|Treadmill exercise test|Patients are subjected to an incremental Cardiopulmonary Exercise Test to exhaustion
2976273|NCT02721680|Experimental|Healthy Subjects- Awareness Training Group 1|Subjects in this arm will undergo an internal awareness training program.
2976274|NCT02721680|Experimental|Healthy Subjects - Awareness Training Group 2|Subjects in this arm will undergo an external awareness training program.
2976275|NCT02721667|No Intervention|Enhanced Usual Care|"Participants receive a home BP monitor, are taught how to measure home BP and are encouraged to take BP readings to appointments with their providers. In addition, they will be reminded to perform a home BP series each quarter for study outcome purposes, which will encourage self-monitoring.~Home BP readings will be teletransmitted for data collection purposes but neither participants nor providers will have access to the these readings. High BP levels that trigger safety alerts to research personnel are the only exception - participants and their primary care providers will be made aware of these."
2976276|NCT02721667|Active Comparator|Telemonitoring and Case Management|"Home BP series mean, trends and individual readings will be generated for use by the case manager. Participants in this arm will each be assigned a pharmacist case manager who holds full prescribing privileges and who will:~Administer health behaviour modification counselling, teach BP self-monitoring, and monitor medication adherence;~Review telemonitored health portal BP summaries and make medication regimen adjustments according to guideline-concordant study protocol;~Fax a summary of these adjustments to the participant's primary care provider (to make them aware of treatment changes); and~Facilitate communication between participants and providers."
2976277|NCT02721654|Experimental|Plasma-Lyte 148®|Following randomisation, each study participant will receive either Plasma-Lyte 148® or 0.9% saline alone for all resuscitation episodes and for all compatible intravenous crystalloid therapy while in ICU (for up to 90 days).
2976278|NCT02721654|Active Comparator|0.9% sodium chloride|Following randomisation, each study participant will receive either Plasma-Lyte 148® or 0.9% saline alone for all resuscitation episodes and for all compatible intravenous crystalloid therapy while in ICU (for up to 90 days).
2976279|NCT02721641|Experimental|Herceptin|Participants with stable disease and HER2-overexpressing metastatic or locally advanced cancer will receive expanded access to IV Herceptin until disease progression, unacceptable toxicity, death, or decision by the investigator or participant to discontinue treatment.
2976280|NCT02721628|Experimental|Epi-keratoplasty Group|Epi-keratoplasty Group: Reversible keratoplasty performed with only the removal of corneal epithelium of the host cornea. A donor graft is transplanted on the recipients' eye locating on the Bowman's layer.
2976281|NCT02721628|Active Comparator|Collagen Cross-Linking Group|Collagen Cross-Linking: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes
2976282|NCT02721615|Active Comparator|Laminectomy|Comparison of bone decompression versus no decompression for reducing intra spinal pressure
2976283|NCT02721615|Active Comparator|Duraplasty|Expansion duraplasty versus no duraplasty for reducing intraspinal pressure
2976284|NCT02721615|Active Comparator|Hypothermia|Localised hypothermia for reducing intra spinal pressure and improving spinal cord metabolism
2976285|NCT02721602|Experimental|Intervention Group|Families in the Families Preventing Diabetes Together intervention group will be asked to participate in four in-person sessions at a local Fairview North metropolitan area clinic over the course of two months. Sessions will focus on age-appropriate nutrition and diabetes education, meal planning and cooking skills, healthful eating, and eating meals as a family. All family members will be asked to attend and will be involved in all four, two-hour sessions. The parent with diabetes will also complete one goal setting telephone call based on motivational interviewing techniques during the intervention period.
2976286|NCT02721602|No Intervention|Measurement Only|No intervention only measurements
2976287|NCT02721589|Experimental|Injection SHR-1210|200mg/vial
2976288|NCT02721576|Experimental|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T>40Gy/20f,week 1->5"
2976289|NCT02721563|Active Comparator|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T60Gy/30f,week 1-6"
2976290|NCT02721563|Placebo Comparator|Control Group|"Placebo：dissolved in 100mlphysiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 6 weeks course.Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T60Gy/30f,week 1-6"
2976291|NCT02721550|Experimental|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-4 Cisplatin:20 mg/m²,d1,week 1-4 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T40Gy/20f,week 1-4"
2976292|NCT02721537|Active Comparator|Arm A: Healthy Collegiate Athletes|Healthy collegiate athletes will take active Nicotinamide Riboside
2976294|NCT02721524|Active Comparator|Group R (ring)|Patients in Group R will undergo tricuspid ring annuloplasty
2976295|NCT02721524|Active Comparator|Group S (suture)|Patients in Group S will undergo De Vega's suture annuloplasty
2976296|NCT02721511|Experimental|Furosemide injection solution 8mg/mL|8mg/mL (total dose=80mg) of furosemide injection solution administered subcutaneously as 30mg over the first hour and then as 12.5 mg per hours over the subsequent 4 hours.
2976297|NCT02721498|Active Comparator|Visit A|Rest period for 30-60 minutes
2976298|NCT02721498|Active Comparator|Visit B|Airway clearance session utilising the Active Cycle of Breathing techniques (ACBT) supervised by a specialist physiotherapist for 30-60 minutes.
2976299|NCT02721485|Other|Normal Saline|Half of the hospitals will be allocated to start the 90-day test period using Normal Saline administered as 250, 500 or 1000 ml boluses or infusions as specified by the treating physicians. After a 28 day washout, this half of participating hospitals will be crossed over to using Ringer's Lactate as 250, 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
2976300|NCT02721485|Other|Ringer's Lactate|Half of the hospitals will be allocated to start the 90-day test period using Ringer's Lactate administered as 250, 500 or 1000 ml boluses or infusions as specified by the treating physicians. After a 28 day washout, this half of participating hospitals will be crossed over to using Normal Saline as 250, 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
2976301|NCT02721472|Other|sickle cell disease patients|Sickle cell disease patients included in the study and Plasma DNA levels will be analyzed and compared in patients with a reactive hyperaemia index (RHI) < 1.67 (endothelial dysfunction) assessed by Endo-PAT 2000 versus those recorded in patients with a RHI ≥ 1.67 (no endothelial dysfunction).
2976302|NCT02721459|Experimental|Dose Escalation|Escalating Doses of XL888 with Vemurafenib plus Cobimetinib.
2976303|NCT02721446|Other|VHA Cohort|Investigators will use Veteran Health Administration (VHA) electronic health record (EHR) data to construct patient-level Framingham stroke risk scores using previously validated methodology. Investigators will establish a cohort of live patients with at least one primary care visit 12 months prior to study initiation (Oct 1, 2015). Investigators will obtain EHR data for Framingham measurements of age, sex, systolic blood pressure (SBP), blood pressure treatment (yes/no), total cholesterol, high-density lipoprotein cholesterol, and smoking status in the prior 12 month period. SBP will be obtained from outpatient primary care visits only; if > 1 SBP is available the investigators will use the average of the last 2 outpatient SBPs prior to study initiation.
2976304|NCT02721446|Other|Eskenazi Health System Cohort|Investigators will use EHR data from Indiana Network for Patient Care (INPC) to identify a cohort of live patients with at least one primary care visit in the prior 12 months. Investigators will use identical methods to construct Framingham risk score variables from the EHR data.
2976305|NCT02721433|Active Comparator|4 weekly bone-targeted agent x 1 year|Bone targeting agents as standard of care
2976306|NCT02721433|Active Comparator|12 weekly bone-targeted agent x 1 year|Bone targeting agents as standard of care
2976307|NCT02721420|Other|Drug + short message(SMS) reminder|dihydroartemesinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) with SMS reminders prior to each treatment course
2976308|NCT02721420|Other|Drug + no short message(SMS) reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) without SMS reminders prior to each treatment course.
2976309|NCT02721420|Other|Drug+ Health worker reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) with Health surveillance assistants reminders prior to each treatment course.
2976310|NCT02721420|Other|Drug at hospital + SMS reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) collected at the outpatient department without an SMS reminders prior to each treatment course.
2976311|NCT02721420|Other|Drug at Hospital+no SMS reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) collected at the outpatient department with a short message reminder prior to each treatment course
2976312|NCT02721407|Experimental|Anti-CD22 CAR-T|Administrated with CD22.CAR-T cells on day 0,1,2 in the lympho-depleted patients
2976313|NCT02721394|Experimental|Researcher Implemented FCT|Children receive functional communication training. Assessment and initial intervention sessions are completed by the researcher and family carers are trained to continue the intervention at home.
2976314|NCT02721394|Experimental|Family Carer Implemented FCT 1|Children receive functional communication training. Family carers are trained to implement all sessions (including assessment and initial intervention sessions) with coaching from the researcher in person.
2976315|NCT02721394|Experimental|Family Carer Implemented FCT 2|Children receive functional communication training. Family carers are trained to implement all sessions (including assessment and initial intervention sessions) with coaching from the researcher via videoconferencing and support from a family carer assistant in person.
2976316|NCT02721381|Experimental|Self-Directed Group|Participants assigned to the self-directed group will receive access to the secure, password-protected, ImPACT Online web-based program for four months. The web application contains 12, self-directed lessons, each of which takes approximately 75 minutes to complete. Participants will be encouraged to complete one lesson per week and to practice the intervention techniques with their child between each lesson. Each lesson consists of a Narrated Slideshow with embedded video clips, a Written Manual, a self-check quiz, short interactive exercises, a Homework Plan, and reflection questions. Participants in the self-directed group may contact project staff via phone or email for assistance with technology-related problems (e.g., difficulty with logins, problems playing video). However, they will receive no assistance or support in learning the intervention from project staff outside of the self-directed web-based program.
2976345|NCT02721199||Prospective Cohort|Neural Respiratory Drive Automated EMGpara assessment
2976346|NCT02721186|Experimental|MDA with DHAp and SLD Primaquine|MDA will be conducted at two time points with an approximate four-week interval. All consenting and eligible community members will be administered age-appropriate treatment dose of dihydroartemisinin-piperaquine (D-ARTEPP, Guilin Pharmaceutical (Shanghai) Co., Ltd., China) and single low dose (0.25mg/kg) primaquine (Primaquine, Remedica Ltd., Cyprus) in house-to-house campaigns.
2976416|NCT02720705|Active Comparator|DEX II|active comparator receive,2µg/kg dexmedetomidine orally half an hour before operation
2976317|NCT02721381|Experimental|Therapist-Assisted Group|"Participants assigned to the therapist-assisted group will be given access to the ImPACT Online web-based program for four months and will be encouraged to work through the program at the same pace as the self-directed group. Participants will also receive 2, 30-minute remote coaching sessions per week (24 total sessions) via video conferencing software by a trained therapist to assist them in learning the intervention. The first coaching session of the week will involve the coach and participant and will be used to help clarify the content of the relevant lesson and help the participant apply the lesson content to their own child. The second coaching session of the week will involve the coach, participant, and child and will be used to provide the participant with live feedback on their use of the intervention techniques as they practice with their child."
2976318|NCT02721381|No Intervention|Web-Based Information Control Group|Participants assigned to the web-based information control group will be given access the Resources page with links to the same ASD information websites, but will not receive access to other aspect of the ImPACT Online program. This condition will be used to control for participant maturation as well as the potentially confounding effect of having access to autism-related information via the internet.
2976319|NCT02721368|Experimental|Neuramis® Volume Lidocaine|Neuramis® Volume Lidocaine
2976320|NCT02721368|Active Comparator|Juvederm® Voluma® with Lidocaine|Juvederm® Voluma® with Lidocaine
2976321|NCT02721355|Experimental|Food supplement GastimunHP|The subjects take food supplement containing specific IgY (GastimunHP) during treatment with routine medical regime
2976322|NCT02721355|No Intervention|Control|The subjects undergo the routine treatment regime without taking food supplement
2976323|NCT02721342||Ramipril, Irbesartan and Atorvastin treatment|A multidrug approach, including Angiotensin II Converting Enzyme (ACE) inhibitor, Ramipril, and Angiotensin II Receptor Blocker (ARB), Irbesartan, and Atorvastin will be done. Treatment doses of drugs will be up-titrated gradually considering the tolerability.
2976324|NCT02721329|Active Comparator|APAP without SensAwake|Auto CPAP delivered from the ICON+ CPAP device.
2976325|NCT02721329|Experimental|APAP with SensAwake|Auto CPAP with SensAwake turned on and set at a pressure of 4cmH2O. SensAwake is a pressure relief function that reduces the CPAP pressure on the transition from sleep to wake.
2976326|NCT02721316|Experimental|Supported with intensive nursing follow|Supported with intensive nursing follow post hospitalization the team of hospital output of the unit to 12 weeks after discharge. These interviews will be conducted at the hospital, at home or by phone and their pace will be adjusted according to the patient's condition. The expected duration of close outpatient follow-up is of maximum 3 months.
2976327|NCT02721316|No Intervention|usual care|For control patients, monitoring will be identical to their usual care as part of their pathology.
2976328|NCT02721303|Active Comparator|obese older aged, aged 65-85, BMI 30-40|Older aged patients who are obese and between the ages of 65-85 with a BMI between 30-40.
2976329|NCT02721303|Active Comparator|normal weight older aged, aged 65-85, BMI 18-25|Older aged patients who are of normal weight and between the ages of 65-85 with a BMI between 18-25.
2976330|NCT02721303|Active Comparator|obese younger aged, aged 21-45, BMI 30-40|Younger aged patients who are obese and between the ages of 21-45 with a BMI between 30-40 .
2976331|NCT02721290|Active Comparator|Femoral nerve block using Ultrasound and neurostimulator|Femoral block using the standard technique of ultrasound for femoral nerve identification and neurostimulator set at between 0.3-0.5 mA with quads muscle response for needle placement confirmation before injecting 20cc of Ropivacaine 0.5%.
2976332|NCT02721290|Experimental|Femoral nerve block using femoral artery target|Femoral block using the alternate technique of aiming for the inferolateral aspect of the femoral artery and injecting 20cc of Ropivacaine 0.5%.
2976333|NCT02721277|Experimental|SMOFlipid|Subjects with cholestasis will receive 3 G/kg/day of intravenous SMOFlipid daily until parenteral nutrition (PN) is discontinued. In addition, the following monitoring for effects of SMOFlipid will be performed: total days of parenteral nutrition, maximum conjugated bilirubin, time to resolution of bilirubin, time to liver transplant, time to death, positive blood cultures, rates of increase in weight, length, and head circumference, time dependent changes in liver function tests, including triglycerides, and length of hospital stay.
2976334|NCT02721264|Experimental|Fecal Microbiota Transplantation (FMT)|The recipient will receive healthy donor, prepared fecal installations through a Naso-gastric tube, 100 ml once a month for 5 month.
2976335|NCT02721264|Active Comparator|Standard Treatment Care|
2976336|NCT02721251|Experimental|Exercise|16 week intervention, building up to 30-45 minutes of aerobic exercise 4 days per week, and 15 min of resistance exercise 2 days per week
2976337|NCT02721251|Experimental|Weight Loss|16 week intervention with a goal weight loss of 10%, accomplished with caloric and fat restriction, weekly sessions with a nutritionist, and some meal replacement
2976338|NCT02721251|Experimental|Exercise + Weight Loss|Combined components of the exercise and weight loss treatments
2976339|NCT02721238|Active Comparator|Resuscitation with 30ml/kg plasmalyte|
2976340|NCT02721238|Experimental|Resuscitation with 20% Albumin|
2976341|NCT02721225|Active Comparator|Fructooligosaccharide|"One kind of prebiotics agent defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health"
2976342|NCT02721225|Placebo Comparator|Pocari-Sweat|Commercially produced isotonic solution by Otsuka Pharmaceutical Co., Ltd., Tokyo,Japan
2976343|NCT02721212|Experimental|Armeo Spring|"All patients of experimental group were treated according to an established protocol for ARMEO Spring. In the first session the device was adjusted for patients arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station.~Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment 5 days per week, for 6 weeks."
2976344|NCT02721212|Active Comparator|Control Group|"The conventional treatment, under control of physiotherapist, consists of passive and active assisted mobilization of the upper limbs traditional training based on the Bobath concept (neuromuscular facilitation, postural control and proprioception exercises, verticalization and gait training).~Each training session consisted of 60 minutes with conventional treatment 5 days per week, for 6 weeks in a control group.~The conventional session in the experimental group lasted 30 minutes with the same techniques and methods."
2976347|NCT02721186|No Intervention|Control|The control arm (no MDA) will have the standard care offered by the Ministry of Health and Social welfare which applies to both arms. This includes passive case detection of individuals seeking treatment at local health facilities, and universal coverage of long lasting insecticide treated bed nets and indoor residual spraying in the study areas.
2976348|NCT02721173|Experimental|Tazarotene group|This group will receive tazarotene 0.1% gel plus clindamycin 1% gel for 4 weeks.
2976349|NCT02721173|Active Comparator|Adapalene group|This group will receive adapalene 0.1% gel plus clindamycin 1% gel for 4 weeks.
2976350|NCT02721160|Experimental|Nutrition PBF|45 health centres are assigned to this group. The intervention consists in a performance based financing scheme applied to nutrition services.
2976351|NCT02721160|No Intervention|Control|45 health centres are in the control group. Health centres in this group are not incentivized, but they receive an equivalent funding to the one received by the intervention group. The main difference is that this payment is not based on their own performance.
2976352|NCT02721147|Experimental|Intimacy Enhancing Intervention|Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.
2976353|NCT02721147|Active Comparator|Educational Control|Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.
2976354|NCT02721134|Other|additional blood tubes|
2976355|NCT02721121|Active Comparator|circumferential pulmonary vein isolation|circumferential pulmonary vein isolation
2976356|NCT02721121|Experimental|Linear ablation in addiction to pulmonary vein isolation|Linear ablation in addiction to pulmonary vein isolation
2976357|NCT02721108|Experimental|Mindfulness: Group A|Using a 60-day mindfulness instruction meditation app: 60 days of 10 and 20 minute long app modules with a spoken guide to mindfulness meditation, to be used once a day, including modules on the basics of mindfulness and a module targeted to pain, which can re-revisited until the end of the study
2976358|NCT02721108|Active Comparator|Relaxation: Group B|Using comparison relaxation app with a series of non-meditative progressive muscle relaxation instructions: 60 days of 10 and 20 minute long app modules to be used once per day with spoken words and relaxing sounds, which can re-revisited until the end of the study
2976359|NCT02721108|No Intervention|Treatment as usual: Group C|No app: treatment as usual (watch and wait, medication and/or surgery) to investigate if any app intervention makes a difference to wellbeing and to ascertain dropout rates for the full-scale trial in patients who perceive that they are getting no intervention.
2976360|NCT02721095|Experimental|0.9%NaCl|KCl plus 0.9%NaCl
2976361|NCT02721095|Active Comparator|0.45%NaCl|KCl plus 0.45%NaCl
2976362|NCT02721082|Experimental|OPT OUT|"Participants in this arm will be first enrolled to receive cessation treatment and will only not receive it by opting out. Participant will receive a treatment program. Participants will receive counseling and nicotine replacement therapy."
2976363|NCT02721082|Active Comparator|OPT IN|"Traditional approach to tobacco treatment program. Participants must first indicate they are ready to quit smoking by opting in to receive cessation treatment."
2976364|NCT02721069|Experimental|NRL-1|Intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
2976365|NCT02721056|Experimental|NBTXR3, IL or IA injection +SBRT|"Patients will receive a single intralesional (IL) injection of NBTXR3 at four increasing dose levels (Volume levels) equivalent to: 10%, 15%, 22%, and 33% of the baseline tumor volume, activated by SBRT.~Patients with primary and secondary nodular intra hepatic cancers only will receive a single superselective transcatheter arterial (IA) injection of NBTXR3 at five increasing dose levels (Volume levels) equivalent to: 10%, 15%, 22%, 33% and 45% of the baseline tumor volume, activated by SBRT."
2976366|NCT02721043|Experimental|Personalized Genome Vaccine 001|"PGV-001 (peptides + Poly-ICLC)~Peptides: 100mcg per peptide per dose.~Poly-ICLC (Hiltonol®, Oncovir): 1.4mg (0.7mL, 2mg/mL)"
2976367|NCT02721017|Experimental|Cryoanalgesia|Cryoanalgesia performed thoracoscopically under general anesthesia by the patient's surgeon at the time of the Nuss procedure
2976368|NCT02721017|Active Comparator|Thoracic Epidural|Thoracic epidural placed in the operating room by the pediatric anesthesiologist immediately prior to the Nuss procedure
2976369|NCT02721004||Rheumatoid arthritis participants|Rheumatoid arthritis participants receiving tocilizumab intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
2976370|NCT02720991|Experimental|Mifepristone and sublingual misoprostol|200 mg mifepristone and 400 ug sublingual misoprostol
2976371|NCT02720978|Experimental|Intravenous oxytocin|"Women that arrive to women's ER and diagnosed with rupture of membranes in week 34+0 and onward, are not in active labor and with Bishop score lower than 7.~Those who agreed to participate in the study after signing an informed consent form will undergo the following steps:~Verification rupture of membranes and gestational age.~Choosing the treatment group Intravenous oxytocin from red envelope, randomly.~Collecting basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way.~Data collecting after the delivery."
2976372|NCT02720978|Experimental|vaginal prostaglandin|"Women that arrive to women's ER and diagnosed with rupture of membranes in week 34+0 and onward, are not in active labor and with Bishop score lower than 7.~Those who agreed to participate in the study after signing an informed consent form will undergo the following steps:~Verification rupture of membranes and gestational age.~Choosing the treatment group vaginal prostaglandin from red envelope, randomly.~Collecting basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way.~Data collecting after the delivery."
2976373|NCT02720965|Experimental|Electronic pump|Continuous nerve blocks Remote-controlled perineural local anesthetics delivery
2976374|NCT02720965|No Intervention|single injection|single injection
2976414|NCT02720705|Active Comparator|DEX I|active comparator receive 1µg/kg dexmedetomidine orally half an hour before operation
2976375|NCT02720952|Experimental|Infacort|"Infacort® is a dry granule formulation of hydrocortisone stored in capsules that will be available in different strengths (0.5, 1.0, 2.0 and 5.0mg).~The clinically-appropriate dose, based on standard individualised treatment, will be administered, given as a single dose orally. This will usually be equivalent to the previous day's dose."
2976376|NCT02720939||ASD group|ASD patients who met the diagnostic criteria of either autistic disorder or Asperger's disorder defined by the DSM-IV criteria
2976377|NCT02720939||TD group|Typically development controls without lifetime diagnosis with ASD or any psychiatric disorders
2976378|NCT02720926|Experimental|TKI258 combined with Xeloda/Oxaliplatin|TKI258 200 mg once a day (OD) 5 days on/2 days off Capecitabine (Xeloda) 2000 mg/m2 bid d1-14 Oxaliplatin 130mg/m2 d1 q21days
2976379|NCT02720913|Experimental|COR-KNOT|The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.
2976380|NCT02720913|Active Comparator|Standard Suture Tying|Standard Suture Tying
2976381|NCT02720900|Placebo Comparator|Maltodextrin|powder, 1.8g/day
2976382|NCT02720900|Active Comparator|B-GOS|powder, 1.8g/day
2976383|NCT02720887||pregnant woman|Patient to receive an amniocentesis for medical reasons other than study and who will have a measure of nanoparticles load
2976384|NCT02720874|Experimental|Intervention Arm|In the multifaceted intervention, participants will first receive an educational session with monthly follow-up phone calls from a trained rheumatology nurse. A rheumatoid arthritis educational booklet will also be provided. During regularly scheduled clinic appointments (at baseline, 3 months, 6 months, 9 months, and 12 months), participants will receive multidisciplinary rheumatologic care, including evaluation by a rheumatologist, physical therapist and psychologist. In addition, participants will be scheduled for ad hoc rheumatology appointments if technology-based symptom monitoring and reporting indicates a marked increase in RA disease activity.
2976385|NCT02720874|Active Comparator|Control Arm|Participants will receive standard of care treatment from their assigned rheumatologists during routine clinic appointments scheduled quarterly for the 12-month trial duration. Referrals to ancillary services will occur in a standard of care fashion. Participants will additionally receive monthly healthcare coordinator calls and be given the rheumatoid arthritis educational booklet.
2976386|NCT02720861||non embolic ischemic stroke|acute ischemic stroke from atherosclerosis or lacunar stroke
2976387|NCT02720848|Experimental|Stiffening wire|A stiffening wire inserted into the instrument channel of the double/single balloon enteroscope will be used.
2976388|NCT02720848|Active Comparator|Standard technique|The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
2976389|NCT02720822|Placebo Comparator|Placebo|Double-blind placebo capsule, looking identical to capsules with active treatment, during all three treatment weeks.
2976390|NCT02720822|Experimental|Morphine Sulfate (0, 0, 8 mg)|Placebo on weeks one and two. Morphine 8 mg/day on week three.
2976391|NCT02720822|Experimental|Morphine sulfate (0, 8, 8 mg)|Placebo on week one. Morphine 8 mg/day on weeks two and three.
2976392|NCT02720822|Experimental|Morphine sulfate (0, 8, 16 mg)|Placebo on week one. Morphine 8 mg/day on week two. Morphine 16 mg/day on week three.
2976393|NCT02720822|Experimental|Morphine sulfate (8, 8, 8 mg)|Morphine 8 mg/day on weeks one, two and three.
2976394|NCT02720822|Experimental|Morphine sulfate (8, 8, 16 mg)|Morphine 8 mg/day on weeks one and two. Morphine 16 mg/day on week three.
2976395|NCT02720822|Experimental|Morphine sulfate (8, 16, 16 mg)|Morphine 8 mg/day on week one. Morphine 16 mg/day on weeks two and three.
2976396|NCT02720822|Experimental|Morphine sulfate (8, 16, 24 mg)|Morphine 8 mg/day on week one. Morphine 16 mg/day on week two. Morphine 24 mg/day on week three.
2976397|NCT02720822|Experimental|Morphine sulfate (16, 16, 16 mg)|Morphine 16 mg/day on weeks one, two and three.
2976398|NCT02720822|Experimental|Morphine sulfate (16, 16, 24 mg)|Morphine 16 mg/day on weeks one and two. Morphine 24 mg/day on week three.
2976399|NCT02720822|Experimental|Morphine sulfate (16, 24, 24 mg)|Morphine 16 mg/day on week one. Morphine 24 mg/day on weeks two and three.
2976400|NCT02720822|Experimental|Morphine sulfate (16, 24, 32 mg)|Morphine 16 mg/day on week one. Morphine 24 mg/day on week two. Morphine 32 mg/day on week three.
2976401|NCT02720796|Other|PDX drug sensitivity testing|Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
2976402|NCT02720783|Experimental|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg|One vaginal pessary (2.7 g) of Econazole nitrate 150 mg plus Benzydamine HCl 6 mg, once daily, for 3 consecutive days
2976403|NCT02720783|Active Comparator|Placebo plus Econazole nitrate 150 mg|One vaginal pessary (2,7 g) of Placebo plus Econazole nitrate 150 mg, once daily, for 3 consecutive days
2976404|NCT02720783|Active Comparator|Placebo plus Benzydamine HCl 6 mg|One vaginal pessary (2,7 g) of Placebo plus Benzydamine HCl 6 mg, once daily, for 3 consecutive days
2976405|NCT02720783|Placebo Comparator|Placebo|One vaginal pessary (2.7 g) of Placebo, once daily, for 3 consecutive days
2976406|NCT02720770|Experimental|norditropine simplex|
2976407|NCT02720757||Spiolto Respimat|COPD patients requiring a fixed combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved SmPC and GOLD guidelines
2976408|NCT02720744|Experimental|Sodium Oxybate|Patients will undergo a screening period and will then be titrated to the following daily doses: 4.5 g sodium oxybate, 6.0 g sodium oxybate, 7.5 g sodium oxybate, and 9.0 g sodium oxybate.
2976409|NCT02720744|Placebo Comparator|Placebo|Patients will undergo a screening period and will then be titrated to the following daily doses: 4.5 g placebo, 6.0 g placebo, 7.5 g placebo, and 9.0 g placebo.
2976410|NCT02720731||children|aged from 1 to 18 years with motor disorder
2976411|NCT02720731||adults|aged from 18 to 80 years with motor disorder
2976412|NCT02720718|Experimental|Stratafix|"Patients undergoing laparoscopic RYGB (antecolic, antegastric, linear anastomosis-technique) using unidirectional barbed (knotless) sutures: Stratafix Unidirectional 2/0."
2976413|NCT02720718|Active Comparator|Vicryl|"Patients undergoing laparoscopic RYGB (antecolic, antegastric, linear anastomosis-technique) using classic sutures: Vicryl 2/0."
2976417|NCT02720692|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 7 doses.
2976418|NCT02720692|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 7 doses.
2976419|NCT02720679||Study Participants|Participants will be (1) individuals with a non-malignant hematologic disorder confirmed or suspected to have a genetic basis, and (2) affected and unaffected family members of those individuals who are willing to provide clinical data and undergo genetic testing.
2976420|NCT02720666|Experimental|Group A:K-001 2700mg/d (1350mg BID)|K-001 1350mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
2976421|NCT02720666|Experimental|Group B: K-001 3240mg/d (1620mg BID)|K-001 1620mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
2976422|NCT02720666|Experimental|Group C: K-001 3780mg/d (1890mg BID)|K-001 1890mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
2976423|NCT02720666|Experimental|Group D: K-001 4320mg/d (2160mg BID)|K-001 2160mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
2976424|NCT02720653||Appropriate Medical Therapy|Patients will self-select continued, non-standardized, appropriate medical management of symptoms associated with chronic sinusitis.
2976425|NCT02720653||Endoscopic Sinus Surgery|Patients will self-select endoscopic sinus surgery for symptoms associated with chronic sinusitis.
2976426|NCT02720640|Experimental|Implant 'on' vs implant 'off'|Intra-individual comparison of implant 'on' vs implant 'off'
2976427|NCT02720627|Experimental|CB-03-01 cream, 1%|Topical CB-03-01 (cortexolone 17α-propionate) cream containing 1% active drug applied to the face and trunk twice daily for 14 days
2976428|NCT02720614|Experimental|Hypofractionated radiation/chemotherapy|"Hypofractionated radiation：Patients receive accelerated hypofractionated radiation: three-dimensional conformal radiation therapy (3-DCRT) with a total dose of 69 Gy, delivered at 3 Gy per fraction, once daily, five fractions per week, completed within 4.6 weeks.~Chemotherapy: Regimen 1 is as follows: vinorelbine (NVB) was administered by intravenous infusion at a dose of 25 mg/m2 on day 1 (d1) and day 8 (d8), and carboplatin (CBP) is administered at a concentration-time curve (AUC) of 5 mg/ml on d8. This treatment was repeated every 28 days. One cycle of chemotherapy is performed concurrently with the radiotherapy.~Chemotherapy: Regimen 2 is as follows: paclitaxel at 30 mg/m2 and cisplatin at 20 mg/m2 (TP) are administrated every week for 5 weeks continuously."
2976429|NCT02720601|Experimental|Irinotecan & Capecitabine|"Irinotecan at 120 mg/m2 intravenously every three weeks + Capecitabine at 1500 mg/m2/day orally twice per day for a total of 14 days.~The treatment cycle is once every 21 days."
2976430|NCT02720588||ASD group|Subjects have a clinical diagnosis of autistic disorder or Asperger disorder defined by the DSM-IV criteria
2976431|NCT02720588||Sibling group|Sex-matched unaffected siblings of ASD probands
2976432|NCT02720588||TD group|Typically developing controls without lifetime ASD or a family history of ASD
2976433|NCT02720575|Active Comparator|A|50,000 IU of crystalline D2 in 5 capsules.. Vitamin D2 in its natural state consumed orally via capsule
2976434|NCT02720575|Active Comparator|B|50,000 IU of crystalline D3 in 5 capsules.. Vitamin D3 in its natural state consumed orally via capsule
2976435|NCT02720575|Active Comparator|C|50,000 IU of vitamin D2 from vitamin D2 yeast in 5 capsules. Vitamin D generated in yeast. Acts as a comparator to the yeast in bread.
2976436|NCT02720575|Active Comparator|D|50,000 IU of vitamin D2 from yeast cell walls in 5 capsules. Yeast cell walls rich in Vitamin D. Acts as a comparator to the yeast in bread.
2976437|NCT02720575|Experimental|E|50,000 IU of vitamin D2 from 2 slices of bread made from bread. Bread raised with yeast rich in vitamin D. Main experimental arm.
2976438|NCT02720575|Experimental|F|50,000 IU of vitamin D2 from 2 slices of bread. Bread raised with yeast and yeast cell walls rich in vitamin D.
2976439|NCT02720562||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-IV criteria
2976440|NCT02720562||TD group|Typically development controls without lifetime diagnosis with ADHD
2976441|NCT02720549|Experimental|post-ischemic conditioning group|
2976442|NCT02720549|Placebo Comparator|valvular surgery with bypass group|
2976443|NCT02720536|Experimental|Deferasirox|Treatment will be administered daily for up to 24 months. For each patient the daily dose is calculated based on the patient's actual body weight.
2976444|NCT02720523|Experimental|ABT-494 Dose A|ABT-494 Dose A once daily for 12 weeks (Period 1) and up to regulatory approval of RA indication in Japan (Period 2).
2976445|NCT02720523|Placebo Comparator|Placebo followed by ABT-494 Dose A|Placebo once daily for 12 weeks (Period 1) followed by ABT-494 Dose A once daily up to regulatory approval of RA indication in Japan (Period 2).
2976446|NCT02720523|Experimental|ABT-494 Dose B|ABT-494 Dose B once daily for 12 weeks (Period 1) and up to regulatory approval of RA indication in Japan (Period 2).
2976447|NCT02720523|Experimental|ABT-494 Dose C|ABT-494 Dose C once daily for 12 weeks (Period 1) and up to regulatory approval of RA indication in Japan (Period 2).
2976448|NCT02720523|Placebo Comparator|Placebo followed by ABT-494 Dose C|Placebo once daily for 12 weeks (Period 1) followed by ABT-494 Dose C once daily up to regulatory approval of RA indication in Japan (Period 2).
2976449|NCT02720523|Placebo Comparator|Placebo followed by ABT-494 Dose B|Placebo once daily for 12 weeks (Period 1) followed by ABT-494 Dose B once daily up to regulatory approval of RA indication in Japan (Period 2).
2976450|NCT02720510|Active Comparator|Arm 1 - RVD + Pan|Revlimid, Velcade, dexamethasone and Farydak
2976451|NCT02720510|Active Comparator|Arm 2 - RVD|Revlimid, Velcade and Dexamethasone
2976452|NCT02720497|Experimental|60-minute Prolonged Exposure|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.
2976453|NCT02720497|Active Comparator|90-minute Prolonged Exposure|Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
2976454|NCT02720484|Experimental|Treatment (Nivolumab)|Patients receive nivolumab IV over 30 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity.
2976455|NCT02720471|Active Comparator|Locoregional anesthesia|Classical locoregional analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh will be performed in patients of this arm
2976456|NCT02720471|Experimental|Peroperative infiltration|Peroperative infiltration of local anesthetics (IAL) will be performed in patients of this arm
2976457|NCT02720458|Experimental|Standardized hypnotic taper and self-help program|
2976458|NCT02720458|Active Comparator|Standardized hypnotic taper only|
2976459|NCT02720445|Experimental|Nicotine Transdermal Patch|150 participants will wear nicotine transdermal patches during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment
2976460|NCT02720445|Placebo Comparator|Placebo Patch|150 participants will wear matching placebo patches during waking hours.
2976461|NCT02720432|Experimental|CIMT|"A soft splint or restraint will be posed to best functioning hand of the infant only during the therapy session. Parents will be educated to perform the therapy, which consists of stimulation of reaching and grasping with the hemiplegic arm.~The whole intervention period lasts 18 weeks, separated into 3 blocks of 4 weeks intervention and 2 blocks of 3 weeks of rest. During the intervention weeks parents will perform CIMTfor 30 minutes, 6 days a week."
2976462|NCT02720432|Experimental|HABIT|"No restraint will be implemented and instead of promoting unilateral grasping, bimanual grasping will be stimulated. Toys will be precisely selected to stimulate progressed bimanual grasping. The approach of the therapist and parents remain equal.~The whole intervention period lasts 18 weeks, separated into 3 blocks of 4 weeks intervention and 2 blocks of 3 weeks of rest. During the intervention weeks parents will perform HABIT for 30 minutes, 6 days a week."
2976463|NCT02720432|Sham Comparator|Baby-massage|3 sessions of baby-massage will be given by a qualified instructor
2976464|NCT02720419||Synergy stent|
2976465|NCT02720406|Active Comparator|Intravenous ketamine0.5mg/kg|intravenous ketamine 5mg/kg given after induction of anesthesia and before surgery.
2976466|NCT02720406|Active Comparator|Nebulized ketamine 0.5mg/kg|nebulized ketamine group received 0.5mg/kg ketamine by nebulzation before induction of anesthesia.
2976467|NCT02720406|Active Comparator|Nebulized ketamine 1mg/kg|nebulized ketamine group received 1mg/kg ketamine by nebulzation before induction of anesthesia.
2976468|NCT02720406|Placebo Comparator|control group|control group received placebo nebulization
2976469|NCT02720393|Placebo Comparator|Regular diet|Meals and snacks will contain carrageenan in the amount consumed in the typical daily diet and will be selected by the study dietician and distributed to study subjects randomized to the regular diet study arm.
2976470|NCT02720393|Experimental|No-carrageenan diet|No-carrageenan diet will be composed of meals and snacks selected by the study dietician and distributed to study participants who are randomized to the no-carrageenan diet study arm.
2976471|NCT02720380|Experimental|Buteyko|Children in the intervention group will perform 6 sessions (twice a week) of treatment with the Buteyko Method.
2976472|NCT02720380|Active Comparator|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
2976473|NCT02720367|Experimental|7-Day Regimen|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the TURBT.
2976474|NCT02720367|Experimental|21-Day Regimen|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 21. TAR-200 releases gemcitabine gradually during the 21 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 42.
2976475|NCT02720354|Experimental|A single Intravenous bolus injection|A single Intravenous bolus injection of 11C[DMDPA]
2976476|NCT02720341|Experimental|ARMin|Therapy on ARMin robotic device
2976477|NCT02720328|Other|DOAC-treated patients|Concerning patients taking DOACs, blood samples are drawn to evaluate DOAC plasma concentration. One EDTA tube is also drawn to extract DNA and determine the genetic profile of genes involved in the metabolism of DOACs. The aim will be to assess if genetic determinants can explain the observed interindividual variability in plasma concentrations.
2976478|NCT02720315|Experimental|Intensive cryotherapy|Application of ice in a plastic bag wrapped to the patient's site of pain, and kept in place for 20min.
2976479|NCT02720315|No Intervention|Control|Existing pain control practice of physicians and nurses, which includes application of a chemical cold pack.
2976480|NCT02720302|Experimental|SOFT|"All Children have their first and their last consultation at The Child Obesity Unit.~The investigators use Standardized Obesity Family Therapy SOFT as described by Nowicka & Flodmark (1-3). The intervention use psychological techniques developed in systemic family therapy applied on advice regarding exercise and diet as well as behavioural Life style Changes.~At each consultation with the overweight child and his/her biological parents there are two therapists present."
2976481|NCT02720302|Experimental|TeleSOFT|"The same method Lifestyle intervention SOFT is used. The only difference is that the communication in the second, third (and fourth) visit is made by use of video on distance. The investigators use Standardized Obesity Family Therapy SOFT as described by Nowicka & Flodmark (1-3)."
2976482|NCT02720289|Experimental|Video-based social learning|Video-based social learning class
2976483|NCT02720289|Active Comparator|Traditional didactic|Traditional didactic class
2976484|NCT02720276|Experimental|Training after acute stroke|Intervention: Outdoor walking and strength training.
2976485|NCT02720263|Experimental|Double-Blind ASP4345 Multiple Dose Levels|ASP4345 will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, ASP4345 will be administered under fasting conditions. On days 2-6 and 8-13, ASP4345 will be administered under fed conditions.
2976486|NCT02720263|Placebo Comparator|Double-Blind Placebo Multiple Dose|Matching placebo capsules will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, matching placebo capsules will be administered with food. On days 2-6 and 8-13, matching placebo will be administered under fed conditions.
2976487|NCT02720263|Experimental|Open-Label ASP4345|ASP4345 will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, ASP4345 will be administered with food. On days 2-6 and 8-13, ASP4345 will be administered under fed conditions. This is an optional cohort where subjects will be enrolled to further characterize pharmacodynamics in the event a higher sample size is necessary to determine changes in electrophysiological biomarkers.
2976488|NCT02720250|Experimental|Omega-3|Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.
2976489|NCT02720250|Experimental|Regular|Intake of 3 regular chicken eggs per day for three weeks.
2976490|NCT02720237|Experimental|Brief Intervention|Brief Intervention (2 in-person sessions and 2 phone sessions), study assessment visits, and standard of care from providers at the ART clinic
2976491|NCT02720237|Experimental|MET+CBT Intervention|MET+CBT Intervention (6 in-person sessions and 3 optional group sessions), study assessment visits, and standard of care from providers at the ART clinic
2976492|NCT02720237|No Intervention|Assessment-Only Control|Study assessment visits and standard of care from providers at the ART clinic
2976493|NCT02720224|Experimental|Estetrol|A single oral dose of 15 mg carbon 14 labelled estetrol ([14C]-estetrol), containing approximately 2.8 MBq (76 µCi) 14C
2976494|NCT02720211|Active Comparator|Gray tinted spectacle lenses|Subjects in this arm will be asked to wear a neutral gray tint that blocks all wavelengths equally
2976495|NCT02720211|Experimental|Thin-Film spectacle lenses|Subjects in this arm well be asked to wear a thin-film coating that specifically blocks 480-nm wavelength
2976496|NCT02720198|Active Comparator|Levomilnacipran|
2976497|NCT02720198|Active Comparator|Quetiapine|Quetiapine will be added in addition to current antidepressant
2976498|NCT02720185|Experimental|Dasatinib 100mg|Dasatinib 100mg for 7-10 days until day prior to surgery
2976499|NCT02720172|Experimental|Early Home Exercise Program|The early home exercise program is an exercise-based self-management program for patients immediately after cervical spine surgery.
2976500|NCT02720172|Other|Usual Care|Usual postoperative care.
2976501|NCT02720159|Experimental|TREATMENT|
2976502|NCT02720146||Artificital tear|The epitheliotrophic ability in cell and animal model
2976503|NCT02720146||Human peripheral serum|The epitheliotrophic ability in cell and animal model
2976504|NCT02720146||Human platelet lysate|The epitheliotrophic ability in cell and animal model
2976505|NCT02720133||Patients with cardiovascular risk factors who fast Ramadan|Stable clinical and biochemical parameters before Ramadan fasting
2976506|NCT02720120|Experimental|Part 1: Ocrelizumab 1000 mg|Participants will receive single IV infusion of ocrelizumab 1000 mg.
2976507|NCT02720120|Experimental|Part 1: Ocrelizumab 1500 mg|Participants will receive single IV infusion of ocrelizumab 1500 mg.
2976508|NCT02720120|Experimental|Part 1: Ocrelizumab 2000 mg|Participants will receive single IV infusion of ocrelizumab 2000 mg.
2976509|NCT02720120|Experimental|Part 1: Ocrelizumab 400 mg|Participants will receive single IV infusion of ocrelizumab 400 milligrams (mg)
2976510|NCT02720120|Placebo Comparator|Part 1: Placebo|Participants will receive single IV infusion of placebo matched to ocrelizumab.
2976511|NCT02720120|Experimental|Part 2: Ocrelizumab 1000 mg|Participants will receive single IV infusion of ocrelizumab 1000 mg.
2976512|NCT02720120|Experimental|Part 2: Ocrelizumab 1500 mg|Participants will receive single IV infusion of ocrelizumab 1500 mg.
2976513|NCT02720120|Experimental|Part 2: Ocrelizumab 400 mg|Participants will receive single IV infusion of ocrelizumab 400 mg.
2976514|NCT02720107|Experimental|Evaluation arm|The one singel arm, in which the evaluations shall be performed
2976515|NCT02720094|Experimental|Arm A|In Step 1, participants will receive daily oral CAB and daily oral TDF/FTC placebo for 5 weeks. In Step 2, participants will receive CAB LA and daily oral TDF/FTC placebo. In Step 3, participants will receive daily oral TDF/FTC no later than 8 weeks after the last injection, for up to 48 weeks.
2976516|NCT02720094|Experimental|Arm B|In Step 1, participants will receive daily oral TDF/FTC and daily oral CAB placebo for 5 weeks. In Step 2, participants will receive daily oral TDF/FTC and placebo for CAB LA. In Step 3, participants will receive daily oral TDF/FTC no later than 8 weeks after the last injection, for up to 48 weeks.
2976517|NCT02720081|Experimental|MK-1029 150 mg + Montelukast 10 mg|Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
2976518|NCT02720081|Placebo Comparator|MK-1029 Placebo + Montelukast 10 mg|Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
2976519|NCT02720068|Experimental|Part A: MK-4280 Dose A|Participants receive MK-4280 Dose A intravenous (IV) infusion on Day 1 of each 21-day cycle.
2976520|NCT02720068|Experimental|Part A: MK-4280 Dose B|Participants receive MK-4280 Dose B IV infusion on Day 1 of each 21-day cycle.
2976521|NCT02720068|Experimental|Part A: MK-4280 Dose C|Participants receive MK-4280 Dose C IV infusion on Day 1 of each 21-day cycle.
2976522|NCT02720068|Experimental|Part A: MK-4280 Dose D|Participants receive MK-4280 Dose D IV infusion on Day 1 of each 21-day cycle.
2976523|NCT02720068|Experimental|Part A: MK-4280 Dose E|Participants receive MK-4280 Dose E IV infusion on Day 1 of each 21-day cycle.
2976524|NCT02720068|Experimental|Part A: MK-4280 Dose A+Pembro|Participants receive MK-4280 Dose A IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion on Day 1 of each 21-day cycle.
2976525|NCT02720068|Experimental|Part A: MK-4280 Dose B+Pembro|Participants receive MK-4280 Dose B IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion on Day 1 of each 21-day cycle.
2976526|NCT02720068|Experimental|Part A: MK-4280 Dose C+Pembro|Participants receive MK-4280 Dose C IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion on Day 1 of each 21-day cycle.
2976527|NCT02720068|Experimental|Part A: MK-4280 Dose D+Pembro|Participants receive MK-4280 Dose D IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion on Day 1 of each 21-day cycle.
2976528|NCT02720068|Experimental|Part A: MK-4280 Dose E+Pembro|Participants receive MK-4280 Dose E IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion on Day 1 of each 21-day cycle.
2976563|NCT02719873||study group|The group with the BMI more than 24.9 kg per meter square to study the impact of maternal obesity in pregnancy outcome
2976564|NCT02719860|Experimental|Green tea|
2976529|NCT02720068|Experimental|Part B: Tumor Type A PD-1 Tx Naïve MK-4280|Programmed cell death-protein 1 (PD-1) treatment (Tx) naïve participants with Tumor Type A receive MK-4280 at the recommended Phase 2 Dose (RPTD) determined in Part A via IV infusion on Day 1 of each 21-day cycle.
2976530|NCT02720068|Experimental|Part B: Tumor Type A PD-1 Tx Naïve MK-4280+Pembro|PD-1 treatment naïve participants with Tumor Type A receive MK-4280 at the RPTD determined in Part A via IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion on Day 1 of each 21-day cycle.
2976531|NCT02720068|Experimental|Part B: Tumor Type B PD-1 Tx Failure MK-4280|PD-1 treatment failure participants with Tumor Type B receive MK-4280 at the RPTD determined in Part A via IV infusion on Day 1 of each 21-day cycle.
2976532|NCT02720068|Experimental|Part B: Tumor Type B PD-1 Tx Failure MK-4280+Pembro|PD-1 treatment failure participants with Tumor Type B receive MK-4280 at the RPTD determined in Part A via IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion on Day 1 of each 21-day cycle.
2976533|NCT02720068|Experimental|Part B: Tumor Type B PD-1 Tx Naïve MK-4280|PD-1 treatment naive participants with Tumor Type B receive MK-4280 at the RPTD determined in Part A via IV infusion on Day 1 of each 21-day cycle.
2976534|NCT02720068|Experimental|Part B: Tumor Type B PD-1 Tx Naïve MK-4280+Pembro|PD-1 treatment naive participants with Tumor Type B receive MK-4280 at the RPTD determined in Part A via IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion on Day 1 of each 21-day cycle.
2976535|NCT02720068|Experimental|Part B: Tumor Type C PD-1 Tx Naïve MK-4280|PD-1 treatment naive participants with Tumor Type C receive MK-4280 at the RPTD determined in Part A via IV infusion on Day 1 of each 21-day cycle.
2976536|NCT02720068|Experimental|Part B: Tumor Type C PD-1 Tx Naïve MK-4280+Pembro|PD-1 treatment naive participants with Tumor Type C receive MK-4280 at the RPTD determined in Part A via IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion on Day 1 of each 21-day cycle.
2976537|NCT02720055|Experimental|Psychological Workbook|Psychological work book containing information and activities aimed at improving outcomes.
2976538|NCT02720055|Active Comparator|Basic information workbook|Basic information which represents current practice
2976539|NCT02720042|Experimental|Phasix™ Mesh|Patients treated with Phasix™ Mesh for hernia repair
2976540|NCT02720029|Experimental|pH/impedance monitor|
2976541|NCT02720016|Experimental|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
2976542|NCT02720016|Active Comparator|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
2976543|NCT02720016|Active Comparator|PTSD Family Education (PFE)|Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
2976544|NCT02720003|Experimental|LTX DCB|Patients treated with Bard Lutonix DCB
2976545|NCT02719990|Experimental|Somavaratan in adults with GHD|Cohort 1: Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly in adult subjects with GHD irrespective of age and gender
2976546|NCT02719990|Experimental|Somavaratan in women on estrogen|Cohort 2: Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly in adult female subjects with GHD on oral estrogen (regardless of age)
2976547|NCT02719977|Experimental|CX-5461|CX5461 as intravenous infusion on day 1 and day 8 every 4 weeks. A day 1 every 3 weeks schedule may be used if the day 1 and day 8 every 4 weeks schedule is not tolerable
2976548|NCT02719964|Experimental|A: UCR Games→SP-Directed Therapy|Participants in Arm A will first participate in Visual Attention Program (UCR Games) followed by Speech Pathologist-Directed Therapy with assessment sessions prior to and following each treatment intervention.
2976549|NCT02719964|Experimental|B: Lumosity→SP-Directed Therapy|Participants in Arm B will first participate in General Cognitive Rehabilitation Games (Lumosity) followed by Speech Pathologist-Directed Therapy with assessment sessions prior to and following each treatment intervention.
2976550|NCT02719964|Experimental|C: SP-Directed Therapy→UCR Games|Participants in Arm C will first participate in Speech Pathologist-Directed Therapy followed by Visual Attention Program (UCR Games) with assessment sessions prior to and following each treatment intervention.
2976551|NCT02719964|Experimental|D: SP-Directed Therapy→Lumosity|Participants in Arm D will first participate in Speech Pathologist-Directed Therapy followed by General Cognitive Rehabilitation Games (Lumosity) with assessment sessions prior to and following each treatment intervention.
2976552|NCT02719951|Experimental|autistic patients|[18F]FPEB PET imaging MRI (Magnetic Resonance Imaging) Biological samples
2976553|NCT02719951|Experimental|FXS patients|[18F]FPEB PET imaging MRI Biological samples
2976554|NCT02719951|Experimental|Healthy subjects|[18F]FPEB PET imaging MRI Biological samples
2976555|NCT02719938|Experimental|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
2976556|NCT02719938|No Intervention|Control|Usual care.
2976557|NCT02719925|Experimental|Mineral water rich in magnesium|- 1,5 L per day of mineral water containing 160 mg/L of magnesium
2976558|NCT02719925|Active Comparator|Water low in magnesium|- 1,5 L per day of mineral water containing 50 mg/L of magnesium
2976559|NCT02719912|Experimental|Valve Replacement|Mitral valve replacement
2976560|NCT02719886|Experimental|Fetal growth ultrasound every 2 weeks|Ultrasound to measure fetal growth every 2 weeks (i.e. 28, 30, 32, 34, 36, 38 weeks gestation).
2976561|NCT02719886|Active Comparator|Fetal growth ultrasound every 4 weeks|Ultrasound to measure fetal growth every 4 weeks (i.e. 28, 32 and 36 weeks gestation). Usual Care.
2976562|NCT02719873||control group|the group with normal BMI
2976567|NCT02719847|Experimental|EBUS-TBNA|"Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.~A conventional flexible bronchoscopy performed to examine the tracheobronchial tree, followed by a systematic examination of the accessible intra-thoracic lymph nodes using a linear array ultrasound bronchoscope."
2976568|NCT02719834||Acetaminophen, then placebo|Participants in this group will receive acetaminophen for the first four weeks, then placebo for the next four weeks.
2976569|NCT02719834||Placebo, then acetaminophen|Participants in this group will receive placebo for the first four weeks, then acetaminophen for the next four weeks.
2976570|NCT02719821|Experimental|Intervention|Individuals treated with HSCT will learn behavioral techniques to improve sleep and increase daytime activity with the goal of alleviating insomnia, fatigue, and depression. Study investigators will conduct semi-structured interviews after each session to determine participant satisfaction with and acceptability of the behavioral strategies, timing, delivery mode, assessment strategy, and time commitment. Participants will be asked to complete a daily checklist indicating which intervention strategies they used daily. Participants will be asked to complete self-report assessments, to wear a wrist-worn actigraphy device, and to complete a sleep log at three time points: prior to HSCT and approximately 9 and 18 weeks post-HSCT.
2976571|NCT02719808||Tenofovir1|100 patients receive tenofovir （300mg/d）from (28±2） weeks of pregnancy to one week after delivery.
2976572|NCT02719808||Tenofovir2|100 patients receive tenofovir （300mg/d）from (28±2） weeks of pregnancy to one month after delivery.
2976573|NCT02719808||Tenofovir3|100 patients receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one week after delivery.
2976574|NCT02719808||Tenofovir4|100 patients receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one month after delivery.
2976575|NCT02719808||Group without any treatment|100 patients don't receive any blockade therapies
2976576|NCT02719795|Experimental|Ropivacaine|Ropivacaine hydrochloride injection； Generic name：Naropin； Dosage form：Liquid、Injectable formulation； Dosage：105mg；30ml； Frequency：Once.
2976577|NCT02719795|Placebo Comparator|Normal saline|Medical Normal saline Generic name：Normal saline； Dosage form：Liquid、Injectable formulation； Dosage：30ml； Frequency：Once.
2976578|NCT02719782|Experimental|HBV/TCR T cell Infusion|Biological: HBV antigen specific TCR redirected T cell
2976579|NCT02719756|Experimental|Metformin & Dapagliflozin|Metformin stable dose tablets and Dapagliflozin 10 mg tablets by mouths, once daily in morning for 3 months
2976580|NCT02719756|Active Comparator|Metformin up-titration|Metformin tablets up-titration by mouths, for 3 months
2976581|NCT02719743|Active Comparator|H5N1 Formulation 1 Group|Subjects will receive intramuscularly an adjuvanted H5N1 vaccine formulation 1.
2976582|NCT02719743|Experimental|H5N1 Formulation 2 Group|Subjects will receive intramuscularly an adjuvanted H5N1 vaccine formulation 2.
2976583|NCT02719743|Experimental|H5N1 Formulation 3 Group|Subjects will receive intramuscularly an adjuvanted H5N1 vaccine formulation 3.
2976584|NCT02719743|Experimental|H5N1 Formulation 4 Group|Subjects will receive intramuscularly an adjuvanted H5N1 vaccine formulation 4.
2976585|NCT02719743|Experimental|H5N1 Formulation 5 Group|Subjects will receive intramuscularly an adjuvanted H5N1 vaccine formulation 5.
2976586|NCT02719730|Experimental|Reimbursement arm|Participating caregivers will turn in receipts from grocery store purchases. At each of three study visits, participants in the reimbursement arm will receive reimbursement of up to 10% of their usual SNAP benefits for specific whole grain foods purchased at one of two chain stores in the previous month.
2976587|NCT02719730|No Intervention|Control arm|Participating caregivers will mail in receipts from grocery store purchases. Participants in the control arm will also be given the same guidance about preferred whole grain foods and whole grain products but will have no specific financial incentive related to purchases of whole grain foods during the 12-week study period.
2976588|NCT02719717|Experimental|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
2976589|NCT02719704|Experimental|"MEXA-SE"|Intervention on physical fitness, eating habits and body image
2976590|NCT02719704|No Intervention|Control|School of the control group carried out one semester with the regular and traditional activities. The control school had three physical educations lessons per week, similar of experimental schools.
2976591|NCT02719704|Experimental|"Espelho, espelho meu"|School-based intervention on body image
2976592|NCT02719691|Experimental|Dose-Escalation of Alisertib and MLN0128|This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 30 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 1 mg given by mouth (PO) once daily with continuous dosing.
2976593|NCT02719691|Experimental|Dose-Expansion of Alisertib and MLN0128|"Group 1:~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, single agent Alisertib will be administered at the MTD on days 1-7 and MLN0128 will be administered on days 8-21. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21.~Group 2:~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, MLN0128 will be administered at the MTD days 1-28 and Alisertib will be administered at the MTD on days 8-15. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21.~Pancreatic Cancer Cohort:~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. On each cycle, Alisertib will be administered on days 1-7, while MLN0128 will be administered continuously on days 1-21."
2976594|NCT02719678|Experimental|Intervention group|Invitation to up to three general health checks over a 10-year period
2976595|NCT02719678|No Intervention|Control group|Control group
2976596|NCT02719665|Experimental|Phase 1a (OMEGA-SPM-DOSE)|PAD patients and healthy volunteers in study for SPM Emulsion, dose-modality.
2976597|NCT02719665|Experimental|SPM - Phase 1b (OMEGA-SPM-PAD)|Asymptomatic PAD, claudicants, and patients with critical limb ischemia assigned to receive SPM Emulsion.
2976598|NCT02719665|Placebo Comparator|Placebo - Phase 1b (OMEGA-SPM-PAD)|Asymptomatic PAD, claudicants, and patients with critical limb ischemia assigned to receive Placebo.
2976599|NCT02719652||symptomatic ICAD|symptomatic intracranial atherosclerosis diseases
2976601|NCT02719613|Experimental|Elotuzumab|This is a continuation roll-over study for patients receiving benefit from prior elotuzumab protocols. All subjects will receive elotuzumab and/or other study drugs as per previous protocol.
2976602|NCT02719600|Experimental|Down Syndrome Group|Group with Down Syndrome
2976603|NCT02719600|Active Comparator|Typical Development Group|Control group with typical development
2976604|NCT02719587|Placebo Comparator|control group|Control group (8 males, 7 females; 42.54±5.82 years) (SRP): SRP followed by administration of a placebo. The placebo was identical except for the fish oil.
2976605|NCT02719587|Active Comparator|test group|Test group (8 males, 7 females; 40.87±9.7 years) (SRP+omega-3 PUFAs): SRP followed by omega-3 PUFAs supplementation. The test drug contained omega-3 PUFAs including 6.25 mg EPA and 19.19 mg DHA obtained from the Atlantic salmon Salmo salar.Both test and placebo drugs were taken twice a day by the patients for six months. Subjects came to the clinic every 4 weeks during the 6 month course of the experiment to replenish their medication. Remaining medications were checked for compliance. At each evaluation visit (1, 3 and 6 months), oral soft and hard tissue examinations and adverse-event evaluations were performed.
2976606|NCT02719574|Experimental|PH1 Dose Escalation & Expansion FT-2102|
2976607|NCT02719574|Experimental|PH1 Esc. and Exp. FT-2102+Azacitidine|
2976608|NCT02719574|Experimental|PH1 Esc. and Exp. FT-2102+Cytarabine|
2976609|NCT02719574|Experimental|PH2 Cohort 1 FT-2102 Single Agent|At the completion of Phase 1, Phase 2 Cohort 1 will commence enrollment wherein patients with relapsed or refractory (R/R) AML will be treated with the RP2D of FT-2102 as a single-agent.
2976610|NCT02719574|Experimental|PH2 Cohort 2 FT-2102 Single Agent|In Phase 2 Cohort 2, patients with AML/ MDS in morphologic complete remission or complete remission with incomplete blood count recovery (CR/CRi) after cytotoxic-containing induction therapy with residual IDH-R132 mutation will be treated at the RP2D of FT-2102 as a single-agent.
2976611|NCT02719574|Experimental|PH2 Cohort 3 FT-2102 Single Agent|In Phase 2 Cohort 3, patients with R/R AML/MDS, previously treated with an IDH1 inhibitor will be treated at the RP2D of FT-2102 as a single-agent.
2976612|NCT02719574|Experimental|PH2 Cohort 4 FT-2102+Azacitidine|In Phase 2 Cohort 4, patients with R/R AML/MDS that are naïve to prior hypomethylating therapy and IDH1 inhibitor therapy will be treated with the RP2D of FT-2102 in combination with azacitidine.
2976613|NCT02719574|Experimental|PH2 Cohort 5 FT-2102+Azacitidine|In Phase 2 Cohort 5, patients with R/R AML/MDS that have inadequately responded or have progressed immediately proceeding hypomethylating therapy will be treated with the RP2D of FT-2102 in combination with azacitidine.
2976614|NCT02719574|Experimental|PH2 Cohort 6 FT-2102+Azacitidine|In Phase 2 Cohort 6, patients with R/R AML/MDS that have been previously treated with single-agent IDH1 inhibitor therapy as their last therapy prior to study enrollment will be treated with the RP2D of FT-2102 in combination with azacitidine.
2976615|NCT02719561|Experimental|Fatigue intervention|Fatigue Intervention is to be co-designed by participants, and likely to include education, energy conservation and activity promotion. Participants will also decide the name of the Fatigue Intervention
2976616|NCT02719548|Experimental|Breastshield treatment group A|"Participants will be treated with the following three breast shields:~Soft edge oval - Hard oval - Modified PF breast shield Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
2976617|NCT02719548|Experimental|Breastshield treatment group B|"Participants will be treated with the following three breast shields:~Modified PF breast shield - Soft edge oval - Hard oval Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
2976618|NCT02719548|Experimental|Breastshield treatment group C|"Participants will be treated with the following three breast shields:~Hard oval - Soft edge oval - Modified PF breast shield Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
2976619|NCT02719535|Experimental|Corneal reshaping therapy|Subjects will be wearing corneal reshaping lenses for the correction of their myopia
2976620|NCT02719509||Observational Cohort|All emergency department patients who had a cardiac ultrasound performed as part of their diagnostic workup
2976621|NCT02719496|Experimental|IBEROGAST|Dose of 20 drops three times a day for 28 days, on constipation parkinsonian patients with disorders intestinal transit.
2976622|NCT02719483|Active Comparator|rESWT + traditional conservative therapy|Radial extracorporeal shock wave therapy (rESWT) performed with the Swiss DolorClast device (EMS Electro Medical Systems, Nyon, Switzerland) plus traditional conservative therapy.
2976623|NCT02719483|Other|Traditional conservative therapy|Traditional conservative therapy alone.
2976624|NCT02719470|Experimental|normal cognition|Group 1: patients with normal cognitive profile, assessed with MMSE (27 ≤ correct score ≤ 30) undergoing MIRT
2976625|NCT02719470|Experimental|mildly impaired cognition|Group 3: patients with middle cognitive decline, assessed with MMSE (20 ≤ correct score < 27) undergoing MIRT
2976626|NCT02719470|Experimental|moderately-severely impaired cognition|Group 2: patients cognitive decline, assessed with MMSE (correct score < 20) undergoing MIRT
2976627|NCT02719470|Experimental|patients with normal executive functions|Group 4: patients with pathological executive functions, assessed with FAB (FAB ≥ 13.8) undergoing MIRT
2976628|NCT02719470|Experimental|pathological executive functions|Group 5: patients with pathological executive functions, assessed with FAB (FAB < 13.8) undergoing MIRT
2976629|NCT02719457|Other|6 minute walk test (6 MWT)|patients will be perform the six minute walk test (6 mwt) to evaluate their exercise capacity.
2976630|NCT02719457|Other|spot marching test (SMT)|patients will be perform the spot marching test (SMT) to evaluate their exercise capacity.
2976631|NCT02719431|Other|Warfarin/Warfarin + K-877|
2976632|NCT02719418||Tinzaparin|Hospitalized patients with chronic renal insufficiency (eGFR ≤ 30 mL/min/1.73 m2) at risk of VTE secondary to non-surgical reasons and receiving thromboprophylactic doses of tinzaparin 3500 or 4500 unit sub-cutaneous once daily.
2976633|NCT02719405|Placebo Comparator|Amino Acid Formula|
2976634|NCT02719405|Active Comparator|EHCF|Extensively Hydrolyzed Casein Formula
2976635|NCT02719405|Active Comparator|EHCF + LGG|Extensively Hydrolyzed Casein Formula + Lactobacillus GG
2976885|NCT02717663|Experimental|Adaptive goals with immediate rewards|Participants will receive adaptive physical activity goals with immediate rewards
2976636|NCT02719392|Active Comparator|Minocycline|Patients in the minocycline group will take 1 minocycline (100mg) and 2 NAC placebo capsules in the morning and 1 minocycline (100mg) and 2 NAC placebo capsules in the evening for a total of 6 capsules per day over the course of the study.
2976637|NCT02719392|Active Comparator|N-acetylcysteine|Patients in the NAC group will take 2 NAC (500mg) capsules and 1 minocycline placebo capsule in the morning and 2 NAC (500mg) capsules and 1 minocycline placebo capsule in the evening for a total of 6 capsules per day over the course of the study.
2976638|NCT02719392|Active Comparator|Minocycline + N-acetylcysteine|Patients in the minocycline NAC combination group will take 2 NAC (500mg) and 1 minocycline (100mg) capsule in the morning and 2 NAC (500mg) and 1 minocycline (100mg) capsule in the evening for a total of 6 capsules per day over the course of the study.
2976639|NCT02719392|Placebo Comparator|Placebo Control|Patients in the placebo control group will take 2 NAC placebo capsules and 1 minocycline placebo capsule in the morning and 2 NAC placebo capsules and 1 minocycline placebo capsule in the evening for a total of 6 capsules per day over the course of the study.
2976640|NCT02719379|Experimental|Asthmatics|19-20 year old asthmatics who agree to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. Those who agree to receive the vaccine will have a second draw for serum 4-6 weeks post vaccination for immunization response. They will also be follow up after 1 year to assess for asthma control and outcomes. This arm will additionally allow for comparison of asthma outcomes and vaccine response
2976641|NCT02719379|Active Comparator|Non-asthmatics|19-20 year old non-asthmatic smokers who agree to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. Those who agree to receive the vaccine will have a second draw for serum 4-6 weeks post vaccination for immunization response. This arm will allow for comparison of vaccine response between asthmatics and non-asthmatics (smokers)
2976642|NCT02719379|Other|Asthmatics - Serum Stored|Once the accrual for the experimental arm is met, 19-20 year old asthmatics who wish to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. This arm will allow for study of baseline vaccine titers to pneumococcus in asthmatics at same time increase the vaccine uptake in the community.
2976643|NCT02719327|Experimental|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
2976644|NCT02719327|Placebo Comparator|placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
2976645|NCT02719314||Rh-GIOP(A)|Glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases
2976646|NCT02719314||Rh-GIOP(B)|Glucocorticoid-induced osteoporosis (GIOP) in the context of psoriasis
2976647|NCT02719314||Rh-GIOP(C)|Patients with or without chronic/inflammatory rheumatic diseases or psoriasis and/or without glucocorticoid treatment
2976648|NCT02719301||Men/Women between 18 & 85|Accepting both healthy and non-healthy subjects. A portion of the subjects will have a fluid management issue or heart failure.
2976649|NCT02719288|Experimental|CLARIX® CORD 1K|Applied in addition to standard of care tendon repair surgery.
2976650|NCT02719288|No Intervention|Standard of care tendon repair surgery only|
2976651|NCT02719275||Suicidal Behaviour|
2976652|NCT02719275||Suicidal Ideation|
2976653|NCT02719275||Other Mental Health|
2976654|NCT02719275||Other Health|
2976655|NCT02719262|Experimental|Intervention|installing ventilation in the workplace
2976656|NCT02719249||Men with ESRD on dialysis or transplant|
2976657|NCT02719236|Active Comparator|Direct anterior approach|Primary total hip arthroplasty using a direct anterior approach
2976658|NCT02719236|Active Comparator|Direct lateral approach|Primary total hip arthroplasty using a direct lateral approach
2976659|NCT02719223|Experimental|High Flux Hemodialysis|
2976660|NCT02719223|Experimental|OL-HDF|
2976661|NCT02719210|Experimental|High Volume Plasma Exchange with Standard Treatment|
2976662|NCT02719210|Active Comparator|Standard Treatment|"Standard Treatment is defined as anti raised Intra-cranial pressure~Elective positive pressure ventilation in hepatic encephalopathy grade 3 or 4 and in those with features of raised ICP (Intra-cranial pressure).~Mannitol~Hypertonic 3% Saline"
2976663|NCT02719197|Experimental|AC-083, Single Ascending Dose|AC-083 administered at different single dose levels in a sequential manner, and in a maximum of 9 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each dose level will be investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo)
2976664|NCT02719197|Placebo Comparator|Placebo, Single Ascending Dose|Matched placebo administered as single ascending doses in parallel to AC-083
2976665|NCT02719184||Healthy volunteers|
2976666|NCT02719184||COPD GOLD I|Chronic obstructive pulmonary disease
2976667|NCT02719184||COPD GOLD II|Chronic obstructive pulmonary disease
2976668|NCT02719184||COPD GOLD III|Chronic obstructive pulmonary disease
2976669|NCT02719184||A1AT Deficiency|Alpha one anti-trypsin deficiency
2976670|NCT02719171|Experimental|ABBV-066 high dose|
2976671|NCT02719171|Experimental|ABBV-066 medium high dose|
2976672|NCT02719171|Experimental|ABBV-066 medium dose|
2976673|NCT02719171|Experimental|ABBV-066 low dose|
2976674|NCT02719171|Placebo Comparator|Placebo|
2976675|NCT02719158|Experimental|6 mg OTO-201|
2976676|NCT02719158|Experimental|12 mg OTO-201|
2976677|NCT02719158|Sham Comparator|Sham|
2976678|NCT02719145||Control group (group 1)|10 healthy volunteer subjects.
2976679|NCT02719145||Asthma group (group 2)|10 asthmatic patients.
2976680|NCT02719145||COPD group (group 3)|10 COPD patients.
2976681|NCT02719132|Experimental|Arm 1|Arm 1 - therapy with dapagliflozin 10 mg once daily in combination with metformin ≤ 1,500 mg (daily dose) for 24 weeks (Treatment Regimen 1) followed by metformin monotherapy with dose titrated up to 2,500 mg/day for further 24 weeks (Treatment Regimen 2)
2976886|NCT02717650|Experimental|A-STEP|Study A) Observational Feasibility Study (no comparator).
2976682|NCT02719132|Active Comparator|Arm 2|Arm 2 - metformin monotherapy with dose titrated up to 2,500 mg/day for 24 weeks (Treatment Regimen 2) followed by therapy with dapagliflozin 10 mg once daily in combination with metformin ≤ 1,500 mg (daily dose) for further 24 weeks (Treatment Regimen 1)
2976683|NCT02719119|Experimental|monthly EVL|Elective band ligation was applied after premedication with hyoscine-N-butylbromide (20 mg intramuscularly). A multiband ligator and video endoscopes were utilized. Ligation was initiated at or slightly below the bleeding point. During each treatment session, each varix was ligated with one or two elastic bands. Variceal obliteration success was when all varices disappeared or residual varices were too small to be ligated further. Once esophageal varices were obliterated, surveillance endoscopy was performed every 3 months for 1 year and then every 6 months to check for recurrent varices. Patients in this group will underwent endoscopic variceal ligation monthly.
2976684|NCT02719119|Experimental|bi-weekly EVL|Elective band ligation was applied after premedication with hyoscine-N-butylbromide (20 mg intramuscularly). A multiband ligator and video endoscopes were utilized. Ligation was initiated at or slightly below the bleeding point. During each treatment session, each varix was ligated with one or two elastic bands. Variceal obliteration success was when all varices disappeared or residual varices were too small to be ligated further. Once esophageal varices were obliterated, surveillance endoscopy was performed every 3 months for 1 year and then every 6 months to check for recurrent varices. Patients in this group will underwent endoscopic variceal ligation bi-weekly.
2976685|NCT02719106||Ultimaster stent|
2976686|NCT02719093|Experimental|recombinant FSH|recombinant FSH 150UI daily
2976687|NCT02719067||ASD group|Subjects have a clinical diagnosis of autistic disorder or Asperger disorder defined by the DSM-IV and ICD-10 criteria
2976688|NCT02719067||TD group|Typically developing controls without lifetime ASD or a family history of ASD
2976689|NCT02719054|Experimental|stimulation|Cognitive behavioral therapy for mother and play stimulation for children aged 6 to 12 months
2976690|NCT02719054|No Intervention|Mother child dyad|
2976691|NCT02719041||Tissue samples|Tissue samples taken from women treated for ovarian cancer will be stained.
2976692|NCT02719028|Placebo Comparator|Placebo|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
2976693|NCT02719028|Experimental|Antroquinonol 50 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
2976694|NCT02719028|Experimental|Antroquinonol 100 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
2976695|NCT02719028|Experimental|Antroquinonol 150 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
2976696|NCT02719015|Experimental|rAd.CD40L + Pembrolizumab|"The dose escalation phase will include rAd.CD40L dose escalation and increase in the number of injected sites/lesions. Once patients tolerate dose level 1 (1 injection site and 1x1011vp-MTD) in Dose Escalation cohort, Expansion cohort will open with same maximum number of injection sites at maximum tolerated dose from Dose Escalation cohort.~All participants receive same dosage of Pembrolizumab in both phases."
2976697|NCT02719002|Experimental|OCT C-scan|
2976698|NCT02718989|Experimental|10 Kilohertz (KHz)|"Transcutaneous application of 10 Kilohertz (KHz) current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
2976699|NCT02718989|Experimental|Transcutaneous Electrical Stimulation|"Transcutaneous application of TENS current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are frequency 100 Hz and pulse width 100 microseconds"
2976700|NCT02718989|Sham Comparator|Sham stimulation|Electrodes are placed over the back for a 40 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
2976701|NCT02718976|Experimental|Shamrock guided by US/MR image fusion|Use of US/MR image fusion guided Shamrock technique to place lumbar plexus block (20 ml 2% lidocaine with epinephrine added gadoterate meglumine).
2976702|NCT02718976|Other|Shamrock guided by US|Use of US guided Shamrock technique to place lumbar plexus block (20 ml 2% lidocaine with epinephrine added gadoterate meglumine).
2976703|NCT02718963|Experimental|Control group|"control group(N=9):who does not have dysphagia symptom~apply Synchronized Electrical Stimulation Device~before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function~during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function"
2976704|NCT02718963|Experimental|Experimental group|"experimental group(N=9): who have dysphagia symptoms~apply Synchronized Electrical Stimulation Device~before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function~during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function"
2976705|NCT02718950|Experimental|Liraglutide 3.0 mg|Subjects will use liraglutide 3.0 mg for 2 weeks.
2976706|NCT02718937|Experimental|BTA-C585|BTA-C585 100 mg oral capsule
2976707|NCT02718937|Placebo Comparator|Placebo|Matching placebo capsule
2976708|NCT02718924||morbidly obese pregnant|Term pregnant women with BMI more than 40
2976709|NCT02718924||non obese pregnant|Term pregnant women with BMI less than 30
2976710|NCT02718911|Experimental|LY3022855 + Durvalumab (Dose Escalation)|LY3022855 given intravenously (IV) in combination with durvalumab given IV. Treatment may continue until disease progression or discontinuation.
2976711|NCT02718911|Experimental|LY3022855 + Tremelimumab (Dose Escalation)|LY3022855 given IV in combination with tremelimumab given IV. Treatment may continue until disease progression or discontinuation.
2976712|NCT02718911|Experimental|LY3022855 + Durvalumab (Expansion)|LY3022855 given IV in combination with durvalumab given IV. Treatment may continue until disease progression or discontinuation.
2976713|NCT02718898|Experimental|Ixekizumab|"Blinded Treatment Period: 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab every 2 weeks (Q2W) SC from week 2 to week 10. At week 12, 80 mg ixekizumab and placebo given SC.~Open Label Period: 80 mg ixekizumab given SC every 4 weeks (Q4W) with an option for Q2W dosing starting at week 24, week 28 or week 40."
2976714|NCT02718898|Placebo Comparator|Placebo|"Blinded Treatment Period: Placebo given SC at baseline followed by placebo given SC Q2W from week 2 to week 10. At week 12, 160 mg ixekizumab given SC.~Open Label Period: 80 mg ixekizumab given SC Q4W with an option for Q2W dosing starting at week 24, week 28 or week 40."
2976715|NCT02718885|Sham Comparator|Maltodextrin|Maltodextrin
2976716|NCT02718885|Active Comparator|Inulin|Inulin-type fructans
2976717|NCT02718872|Experimental|Tobacco cessation online training|Six hour smoking cessation online training addressed to health professionals from hospitals in 3 Latin American Countries. Participants are monitored by local coordinators that act as champions. They offer their assistance to log into the online platform, fill out the questionnaires, complete the evaluation, including other technical support. Participants' progress is monitored in real time onto the web platform. The project coordinator at ICO sends a report of the participants progress every other week to coordinators, and if necessary personal emails to motivate students to finish the course and complete the evaluations.
2976718|NCT02718859|Active Comparator|irreversible electroporation (IRE)|Advanced pancreatic cancer patients received only irreversible electroporation (IRE) without immunotherapy
2976719|NCT02718859|Experimental|IRE & NK cells|Advanced pancreatic cancer patients received both irreversible electroporation (IRE ) and immunotherapy of nature killer(NK) cells
2976720|NCT02718846|Experimental|Meniace and Isobide|co-administration Isobide solution and Meniace tablets
2976721|NCT02718846|Active Comparator|Meniace|single administration Meniace tablets
2976722|NCT02718833|Experimental|Elotuzumab, pomalidomide, bortezomib, dex|"Each cycle is 28 days.~Elotuzumab will be administered by intravenous infusion. For cycles 1-2, elotuzumab will ge given weekly. For cycles 3-8, elotuzumab will be given every other week. For cycles 9+, elotuzumab will be given on day 1.~Pomalidomide will be given orally on days 1-21.~Bortezomib will be given weekly subcutaneously on days 1, 8, 15.~Dexamethasone will be given as a combination orally and intravenously."
2976723|NCT02718820|Experimental|Docetaxel plus pembrolizumab|Docetaxel 75mg/m2 plus pembrolizumab 200mg will be administered every 3 weeks intravenously for 6 cycles. Thereafter pembrolizumab 200mg every 3 weeks will be given as maintenance therapy until progression.
2976724|NCT02718807||Post-partum Women|Post-partum women following an atraumatic pregnancy.
2976725|NCT02718807||Co-Parents|Co-parents to post-partum women following an atraumatic pregnancy.
2976726|NCT02718794|Experimental|Simulation training first|A highly customized interactive medium or program that allows individuals to learn and practice real world activities in an accurate, realistic, safe and secure environment.
2976727|NCT02718794|Experimental|Problem-based learning first|Instructional use of examples or cases to teach using problem-solving skills and critical thinking.
2976728|NCT02718781|Experimental|Talk and leaders|This group will comprise of health talk and regular contact with community leaders.
2976729|NCT02718781|Experimental|Talk, leaders and equipment|This group will comprise of health talk and regular contact with community leaders. Moreover, a home-based equipment (handgrip) will be delivered to them
2976730|NCT02718781|Active Comparator|Talk|This group will comprise of a health talk only.
2976731|NCT02718755|Experimental|Fludarabine + Cytarabine + Erwinase|"Induction Phase: Participants receive 1-2 cycles during the Induction phase.~Participants receive 1-2 cycles during the Induction phase.~Participants receive Fludarabine by vein on Days 1-5 and Cytarabine by vein.~Participants receive Erwinase by vein or as an injection into the muscle on Days 1-7.~Consolidation Phase: Participants receive up to 3 cycles during the Consolidation phase.~Participants receive Fludarabine by vein on Days 1-4 and Cytarabine by vein.~On Day 1 and then every other day for 15 days (3, 5, 7 and so on), participant receives Erwinase by vein or as an injection into the muscle."
2976732|NCT02718742|Experimental|Treatment (nab-paclitaxel)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2976733|NCT02718729|Other|Rectal cancer patients|All patients who will fulfill the inclusions criteria. Patients will undergo formal curative radical Laparoscopic resection for rectal cancer
2976734|NCT02718716|Experimental|UCB7665 dose 1|Subjects in this Arm will receive 5 subcutaneous (sc) doses of UCB7665 at 1-week intervals
2976735|NCT02718716|Experimental|UCB7665 dose 2|Subjects in this Arm will receive 3 subcutaneous (sc) doses of UCB7665 dose 2 at 1-week intervals
2976736|NCT02718716|Experimental|UCB7665 dose 3|Subjects in this Arm will receive 2 subcutaneous (sc) doses of UCB7665 dose 3 at 1-week intervals
2976737|NCT02718716|Experimental|UCB7665 dose 4|Subjects in this Arm will receive 1 subcutaneous (sc) dose of UCB7665 dose 4
2976738|NCT02718716|Experimental|UCB7665 dose 5|Subjects in this Arm will receive 1 subcutaneous (sc) dose of UCB7665 dose 5
2976739|NCT02718703|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
2976740|NCT02718690|Experimental|Transcutaneous nerve stimulation|"Transcutaneous application of TENS current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
2976741|NCT02718690|Sham Comparator|Sham stimulation|Electrodes are placed over the back for a 40 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel
2976742|NCT02718677||1. Refacto (NIS)|Non-Interventional Study
2976745|NCT02718638|Other|physical exercises group|Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months (36 sessions). The patients remained seated while performing the exercises that were performed in both lower limbs. Ankle-cuffs and elastic bands (Theraband®, Akron-OH, USA) were used for performed the exercises. The physical exercises consisted of four different exercises and they were administered by a physical therapist following the adapted protocol.
2976746|NCT02718625|Experimental|Santyl|Santyl collagenase ointment applied topically once per day for up to six weeks
2976747|NCT02718625|Active Comparator|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
2976748|NCT02718599|Active Comparator|Terlipressin|Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
2976749|NCT02718599|Placebo Comparator|CONTROL|Patients receive the same volume of 0.9% saline in place of terlipressin for the same duration(50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours).
2976750|NCT02718573||Non-liver transplants with HCV|
2976751|NCT02718573||Liver transplants with HCV|
2976752|NCT02718560|Experimental|Group 1 - Writing with 1 cm cue|This group uses to write space of 1 cm size
2976753|NCT02718560|Experimental|Group 2 - Writing with 1.5 cm cue|This group uses to write space of 1.5 cm size
2976754|NCT02718560|Experimental|Group 3 - Writing without cue|This group writes without using cues
2976755|NCT02718560|No Intervention|Group 4 - no writing|This group do not write. Only wrist mobilization is performed.
2976756|NCT02718547|Experimental|Participants receiving Combigan drops in order to reduce IOP|All of the Participants in this study will be instructed to instill combigan eye drops twice daily in one eye (randomly chosen)
2976757|NCT02718534||ERTAS-1|first limb rehabilitation therapy took place within 48h for patients with acute stroke (modified Rankin Scale Score 3-4)
2976758|NCT02718534||ERTAS-2|first limb rehabilitation therapy took place after 48h for patients with acute stroke (modified Rankin Scale Score 3-4)
2976759|NCT02718521|Experimental|Hydration Therapy Combined With Isosorbide Dinitrate|Intravenous Infusion of Isosorbide Dinitrate 2mg/h combined with normal saline 1 ml/kg·h 6 hours before angiography and 12 hours after angiography
2976760|NCT02718521|Active Comparator|Conventional hydration group|normal saline 0.5 ml/kg·h 6 hours before angiography and 12 hours after angiography
2976761|NCT02718508|No Intervention|Standard Care|All enrolled adolescents will continue to receive standard trauma center care, a brief intervention during their hospitalization by a trauma center social worker which is required by institutional policy.
2976762|NCT02718508|Experimental|Standard Care plus e-Parenting Group|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
2976763|NCT02718495|Placebo Comparator|Part A|Part A consists of two treatment groups, SAD and MAD. Both treatment groups will consist of 3 cohorts. In SAD, subjects will receive a single dose of PTI-428 or placebo. In MAD, subjects will receive once daily dosing of PTI-428 or placebo for 7 days.
2976764|NCT02718495|Placebo Comparator|Part B|Part B will consist of 2 cohorts. Subjects will receive once daily dosing of PTI-428 or placebo for 28 days.
2976765|NCT02718495|Placebo Comparator|Part C|Part C will consist of 3 cohorts. Subjects will receive once daily dosing of PTI-428 or placebo for 28 days.
2976766|NCT02718482|Experimental|Gemcitabine and Docetaxel|Gemcitabine i.v. 900 mg/m2 in 30 min on day 1 and day 8 every 3 weeks Docetaxel i.v. 75 mg/m2 in 60 min on day 8 every 3 weeks
2976767|NCT02718482|Experimental|Ifosfamide|Ifosfamide i.v. 14 g/m2 continous dose for 14 days every 3 weeks
2976768|NCT02718469|Experimental|Ebola Vaccine - low dose|Low Dose Zaire Ebola Vaccine
2976769|NCT02718469|Experimental|Ebola Vaccine - mid dose|Mid Dose Zaire Ebola Vaccine
2976770|NCT02718469|Experimental|Ebola Vaccine - high dose|High Dose Zaire Ebola Vaccine
2976771|NCT02718469|Placebo Comparator|Placebo|Placebo
2976772|NCT02718456|No Intervention|Standard of care|Standard HIV counseling and referral to care
2976773|NCT02718456|Experimental|CD4 testing|Standard HIV counseling and testing plus blood drawn for CD4 testing at time of HIV diagnosis. CD4 results are reported to participants via telephone within 1 week.
2976774|NCT02718456|Experimental|CD4 testing plus peer counseling|Standard HIV counseling and testing plus blood drawn for CD4 testing at time of HIV diagnosis. CD4 results are reported to participants via telephone within 1 week. Additionally, a trained peer counselor provides supplemental counseling at the time of diagnosis and at the 1 week telephone follow-up.
2976775|NCT02718443|Experimental|VXM01|VXM01 10E6 or 10E7 CFU
2976776|NCT02718430|Experimental|VXM01|VXM01 10E6 or 10E7 CFU
2976777|NCT02718417|Active Comparator|Arm A|Chemotherapy followed by observation
2976778|NCT02718417|Experimental|Arm B|Chemotherapy followed by avelumab in maintenance
2976779|NCT02718417|Experimental|Arm C|Chemotherapy in combination with avelumab followed by avelumab in maintenance
2976780|NCT02718404|Experimental|MR-HIFU Treatment|"The Philips MR-HIFU Sonalleve System integrates a high intensity phased array focused ultrasound transducer with a 3 Tesla Magnetic Resonance (MR) imaging system and electromechanical transducer positioning system to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively.~At HIFU day (day 0) before treatment patient will be performed a bone lesion MRI and a functional brain MRI.~During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.~Following the MR-HIFU procedure, a set of MR images of the target region will be acquired with the use of a MR contrast agent, together with a functional brain MRI."
2976820|NCT02718131|Placebo Comparator|Control Group|Children with NF1 and tibial pseudarthrosis who require surgery will receive the standard surgical protocol only. This includes resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest.
2976781|NCT02718391|Experimental|Arm A: Autologous Dendritic Cell vaccine|Daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days starting from the second day after each vaccine dose. Vaccine doses will be given intradermally in two sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis.The first dose (WK1) will consist of freshly prepared vaccine, whereas for all the further doses cryopreserved aliquots will be utilized. The remaining 5 doses will be administered every 4 weeks to complete six months of therapy (six vaccines).
2976782|NCT02718391|No Intervention|Arm B: follow up|Arm B: Patients will undergo laboratory and clinical assessment, tumor re-staging, blood collection for immunological biomarkers every 12 weeks until relapse.
2976783|NCT02718378|Placebo Comparator|No added active|placebo without estetrol
2976784|NCT02718378|Active Comparator|estetrol dose level 1|estetrol given in dose level 1
2976785|NCT02718378|Active Comparator|estetrol dose level 2|estetrol given in dose level 2
2976786|NCT02718378|Active Comparator|estetrol dose level 3|estetrol given in dose level 3
2976787|NCT02718365|Experimental|Group A|Wedge resection
2976788|NCT02718365|Active Comparator|Group B|Segmentectomy
2976789|NCT02718339|Experimental|Intensive counseling by a pulmonologist|Counselor visit during hospitalization, telephone follow up for 4 weeks and a follow up visits.
2976790|NCT02718339|No Intervention|Usual care|
2976791|NCT02718326|Experimental|Dosing regimen 1|In this arm, patients will receive IVT aflibercept dosing regimen 1
2976792|NCT02718326|Experimental|Dosing regimen 2|In this arm, patients will receive IVT aflibercept dosing regimen 2
2976793|NCT02718326|Sham Comparator|Dosing regimen 3|In this arm, patients will receive matching sham injections
2976794|NCT02718313||Intraventricular conduction delay|Transthoracic echocardiography will be performed to investigate whether the patients have the cardiac disease or not. The transthoracic echocardiography will be performed after the induction of general anesthesia and before the start of surgery.
2976795|NCT02718300|Experimental|Part 1: Ruxolitinib + INCB050465|Initial cohort dose of INCB050465 added to existing stable regimen of ruxolitinib, with subsequent cohort escalations based on protocol-specific criteria.
2976796|NCT02718300|Experimental|Part 2: Ruxolitinib + INCB050465|Part 2 will compare 2 doses of INCB050465.
2976797|NCT02718300|Experimental|Part 3: Ruxolitinib + INCB050465|Part 3 will compare 2 different long term dosing strategies.
2976798|NCT02718287|Experimental|Treatment:|Home visiting with PCCSF
2976799|NCT02718287|Experimental|Control|Home visiting no PCCSF
2976800|NCT02718274|No Intervention|Control|Standard of care.
2976801|NCT02718274|Active Comparator|Self-testing|Community-Based Distribution Agents (CBDAs) in the HIV Self-Testing (HIVST) Arm villages will be trained to provide HIVST services as well as reproductive health services.
2976802|NCT02718274|Active Comparator|Self-testing + home HIV care home initiation|CBDAs will be trained to provide HIV Self-Testing plus offer home assessment and HIV care initiation (first assessment and first 14 days of HIV care medications), with this additional intervention aimed at facilitating linkage into care.
2976803|NCT02718261|Experimental|Verum (pantoprazole)|
2976804|NCT02718261|Placebo Comparator|Placebo|0.9% saline
2976805|NCT02718248|Experimental|CHESS Mobile Health Group|The intervention will be six weekly one hour sessions of face-to-face problem solving therapy combined with the CHESS Mobile Health smart phone application (Comprehensive Health Enhancement Support System - CHESS). The CHESS Mobile Health smart phone application enables users to access relevant resources, create a support network and check in regularly with carers. The intervention will be delivered by Dr. Hatcher, a staff psychiatrist in Liaison Psychiatry at The Ottawa Hospital General Campus.
2976806|NCT02718235||Overall survival HCCIS low risk|HCCIS 2 points
2976807|NCT02718235||Overall survival HCCIS medium risk|HCCIS 1 point
2976808|NCT02718235||Overall survival HCCIS high risk|HCCIS 0 point
2976809|NCT02718222|Experimental|3-9 months PPIUD intervention|"Tanzania: Baseline (no intervention) period is 9 months. Post-partum IUD intervention begins after 9 months and continues for 3 months.~Nepal and Sri Lanka: Baseline (no intervention) period is 9 months. Post-partum IUD intervention begins after 9 months and continues for 9 months."
2976810|NCT02718222|Experimental|9-15 months PPIUD intervention|"Tanzania: Baseline (no intervention) period is 3 months. Post-partum IUD intervention begins after 3 months and continues for 9 months.~Nepal and Sri Lanka: Baseline (no intervention) period is 3 months. Post-partum IUD intervention begins after 3 months and continues for 15 months."
2976811|NCT02718209|Experimental|Frozen section|Frozen sections taken from women operated on for possible gynecologic malignancies.
2976812|NCT02718196|Experimental|Application Users|English-speaking parents of children ages 6-24 months who are interested in starting sleep training within the next month.
2976813|NCT02718183|Experimental|PH|Hydrogen peroxide 35% to intracoronal bleaching in discoloration teeth eith endodontic treatment
2976814|NCT02718183|Experimental|PC|Carbamide peroxide 37% to intracoronal bleaching in discoloration teeth eith endodontic treatment
2976815|NCT02718170|Experimental|Buried Intramedullary K-wire Fixation|Patients randomized to buried intramedullary k-wire fixation will undergo a standardized antegrade open reduction and fixation procedure with an intramedullary k-wire.
2976816|NCT02718170|Active Comparator|Plate and Screw Fixation|Patients randomized to Plate and Screw Fixation will undergo a standardized open reduction and internal fixation with plate and screws. Brand of plate will be left to the operating surgeon's discretion.
2976817|NCT02718157|Experimental|Accuracy Testing|Comparison between GenePOC PCR and Reference Method
2976818|NCT02718144|Experimental|estetrol|3 + 3 design with inter-patient dose escalation
2976819|NCT02718131|Active Comparator|INFUSE Bone Graft (BMP-2)|Children with NF1 and tibial pseudarthrosis who require surgery will have the INFUSE bone graft added to their surgical protocol. After a standard surgical approach of resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest; in addition, the INFUSE bone graft in the form of a collagen sponge will be wrapped around the tibia during the surgical process.
2976821|NCT02718118|Experimental|1.5 mL Reconstitution|Subjects will be treated with Dysport reconstituted at 1.5 mL (0.05 mL/injection) following the US on-label guidelines, with each subject receiving a single treatment session (50 units [U]) at the Day 1 visit.
2976822|NCT02718118|Experimental|2.5 mL Reconstitution|Subjects will be treated with Dysport reconstituted at 2.5 mL (0.08 mL/injection) following the US on-label guidelines, with each subject receiving a single treatment session (50 units [U]) at the Day 1 visit.
2976823|NCT02718105||Receiver patients in donor oocyte -ART|Maternal and fetal compatibility KIR HLA-C determinations in ART -oocyte donor
2976824|NCT02718092|Active Comparator|Plastic Stent|Three 7 Fr OR two 10 Fr Plastic Stents will be used
2976825|NCT02718092|Active Comparator|Axios FCSEMS|15 mm Axios Fully Covered Self Expanding Metal Stent
2976826|NCT02718079|Experimental|Standard medical therapy with High Volume Plasma|High Volume Plasma consecutively for three days and subsequently as needed whereas standard medical therapy is defined as ) Standard medical therapy included as per requirement,management of cerebral edema/intracranial hypertension: transfer to ICU,prophylactic antibiotics, intubation of trachea (as required),administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure,volume replacement and pressor support (norepinephrine, vasopressin) as needed, NAC, correction of metabolic parameters and nutrition.
2976827|NCT02718079|Active Comparator|Standard medical therapy alone|Standard medical therapy included as per requirement,management of cerebral edema/intracranial hypertension: transfer to ICU,prophylactic antibiotics, intubation of trachea (as required),administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure,volume replacement and pressor support (norepinephrine, vasopressin) as needed, NAC, correction of metabolic parameters and nutrition.
2976828|NCT02718066|Experimental|HBI-8000 in combination with nivolumab|HBI-8000 dose escalation 20mg, 30mg, 40mg, orally, twice weekly; in combination with Nivolumab 240mg intravenous infusions every 2 weeks.
2976829|NCT02718053||spasticity|patients affected by spasticity of the lower limbs
2976830|NCT02718053||controls|healthy subjects
2976831|NCT02718040|Experimental|Emervel Treatment Group|Eligible subjects receive bilateral treatment of Nasolabial Folds (NLFs) and Marionette Lines (MLs) with Emervel Classic and/or Emervel Deep
2976832|NCT02718027||Observation|Patients with Alport disease or high-grade suspicion for Alport disease
2976833|NCT02718014|Other|pre menopause with periodontitis|non surgical periodontal therapy (SCALING & ROOT PLANING) (SRP)
2976834|NCT02718014|Other|post menopause with periodontitis|non surgical periodontal therapy (SCALING & ROOT PLANING) (SRP)
2976835|NCT02718001|Experimental|Treatment|Treatment with the CardiAQ-Edwards™ Transcatheter Mitral Valve
2976836|NCT02717988|Experimental|SKI-O-703 50 mg|SKI-O-703 capsule (2x25 mg)
2976837|NCT02717988|Experimental|SKI-O-703 100 mg|SKI-O-703 capsule (4x25 mg)
2976838|NCT02717988|Experimental|SKI-O-703 200 mg|SKI-O-703 capsule (1x200 mg)
2976839|NCT02717988|Experimental|SKI-O-703 400 mg|SKI-O-703 capsule (2x200 mg)
2976840|NCT02717988|Experimental|SKI-O-703 600 mg|SKI-O-703 capsule (3x200 mg)
2976841|NCT02717988|Experimental|SKI-O-703 800 mg|SKI-O-703 capsule (4x200 mg)
2976842|NCT02717988|Placebo Comparator|Placebo|Placebo capsule
2976843|NCT02717975|Active Comparator|Without valve|"Trial removal of catheter without catheter valve in patients with urinary retention. These are those patients who have catheter on free drainage, attend the clinic for catheter removal and bladder to be filled naturally ( which may take upto 4-5 hours). After removal of catheter they will be asked to drink plenty of fluids while waiting for the bladder to fill up.~This is the traditional method of catheter removal."
2976844|NCT02717975|Experimental|With valve|"Trial removal of catheter in patients with urinary retention with closed catheter valve. These patients will be asked to close the valve 3-4 hours before attending the clinic prior to catheter removal. Here the intervention is catheter valve that allows bladder to be comfortably full by the time patient arrives in the clinic. By this intervention the investigators hypothesise that the investigators can save the clinic time as the patient will not need to wait for natural bladder filling which generally takes 4-5 hours.~Intervention: Urinary catheter valve"
2976845|NCT02717962|Experimental|VAL-083, Dianhydrogalactitol|VAL-083 at 40 mg/m2 IV on days 1, 2, and 3 of a 21-day treatment-cycle, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation. VAL-083 will be administered as an IV infusion over 30-60 minutes.
2976846|NCT02717949|Experimental|sofosbuvir/ledipasvir|sofosbuvir and ledipasvir fixed dose combination given orally once a day for genotype 1 and 4.
2976847|NCT02717949|Experimental|sofosbuvir and ribavirin|Sofosbuvir 400 mg given orally once a day with weight-base ribavirin of 1200 mg for those >75 kg and 1000 mg for those <75kg given in divided dose twice a day. This intervention is for genotype 2 and 3
2976848|NCT02717936|Other|Immunohistochemistry|Patients are investigated using immunohistochemistry with Pancytokeratin
2976849|NCT02717923|Experimental|Maintenance Treatment|A single arm of maintenance treatment with capecitabine plus cetuximab after first-line 5-fluorouracil based standard chemotherapy plus cetuximab.
2976850|NCT02717910|Experimental|Health game group|Participants in this arm will receive the health game intervention including both 20 minutes guided training session at school and 2 weeks free usage of the health game during free time.
2976851|NCT02717910|Sham Comparator|Web page group|Participants in this arm will receive the web page intervention including both 20 minutes guided training session at school and 2 weeks free usage of the web page during free time.
2976852|NCT02717910|No Intervention|Group with no intervention|The participants in this arm will receive no intervention.
2976853|NCT02717884|Experimental|TCP, ATRA, Cytarabine|"Phase I part:~The rolling-six phase I design will be used to determine the MTD of TCP in combination with fixed-dose of ATRA and with fixed-dose AraC in patients with AML/MDS.~Intervention: Four dose levels of TCP (20 mg, 40 mg**, 60 mg**, 80 mg** on days 1-28) will be examined in combination with ATRA (45 mg/m2 on days 10-28) and with fixed-dose AraC (40 mg on days 1-10) in the first cycle. In case of dose-limiting toxicity (DLT) on the starting level 1 of 20 mg a de-escalation to dose level of 10 mg (level -1) will be investigated.~**TCP dose will be slowly increased to achieve the necessary dose level and slowly tapered off at the end of treatment"
2976854|NCT02717871|Experimental|Treatment (PACK-CXL)|Photoactivated chromophore for infectious keratitis-corneal cross-linking (PACK-CXL)
2976883|NCT02717663|Experimental|Adaptive goals with delayed incentives|Participants will receive adaptive physical activity goals with delayed, non-contingent incentives
2976884|NCT02717663|Experimental|Static goals with immediate rewards|Participants will receive static physical activity goals with immediate rewards
2976855|NCT02717871|Active Comparator|Antimicrobial therapy|"Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml).~OR~1b. a Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)~2. Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.~3. Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium"
2976856|NCT02717858|Experimental|Liraglutide|
2976857|NCT02717858|Placebo Comparator|Placebo|
2976858|NCT02717845|Experimental|CT scan Ellipse|New medical device for high tibial osteotomy
2976859|NCT02717845|Active Comparator|CT scan Tomofix|Established medical device for high tibial osteotomy
2976860|NCT02717832|Experimental|Insulin Sensitivity|
2976861|NCT02717819|Experimental|Resistance training and protein|Daily supervised resistance training offered while hospitalized, and encouragement of self-training 4 times per week for duration of 12 weeks after discharge (standardized training program, which will be monitered). Daily intake of 2 x 125 ml protein-enriched, milk-based supplements (whey protein), in the same period (additional ~25 g protein and 1953 kJ per day). Daily vitamin D supplements.
2976862|NCT02717819|Placebo Comparator|Resistance training and placebo|Daily supervised resistance training offered while hospitalized, and encouragement of self-training 4 times per week for duration of 12 weeks after discharge (standardized training program, which will be monitered). Daily intake of 2 x125 ml iso-energetic placebo-supplements, in the same period. Daily vitamin D supplements.
2976863|NCT02717806|Experimental|PATHway|"Patients allocated to the PATHway intervention will be given a 4 week run-in period as an outpatient to get acquainted with the system. During this run-in period, the PATHway system will also be installed in each participant's home. They will be provided with a training manual and a quick set up guide for getting started with PATHway in the home.~After this 4 week run-in period, the PATHway system will be set up for each individual patient including a patient specific exercise prescription. The patient will then exercise with the PATHway platform for 6 months."
2976864|NCT02717806|No Intervention|Usual care|Patients randomized to the control group will receive usual care.
2976865|NCT02717793|Experimental|isometric muscle strength|"isometric muscle strength was measured with a digital hand-held dynamometer. The digital hand-held dynamometer was held by the therapist against the flexor aspect of the distal forearm of the subject, on the wrist joint. Subject was asked to maintain the position and a break test was done with progressive loading of 5 seconds given by the tester. The peak isometric strength was recorded by a second tester at the end of 5 seconds. A standardised instructions and verbal encouragement was given to the subject for motivation. Subject as well as the tester was blinded to the values recorded on the digital hand-held dynamometer. An average of three measurements (with a rest period of 4 minutes in between each trial session) was recorded for the analysis. After each trial session, the rate of perceived exertion (RPE) was asked to the subject using the 1-10 Borg rating of perceived exertion scale"
2976866|NCT02717793|Experimental|1RM measurement of muscle strength|1RM measurement was done using the Brzycki 1RM prediction equation. In first testing session, subject was instructed to perform a general warm up for 5 minutes. Thereafter, the subject was asked to perform 10 repetitions of the movement using the amount of resistance that the subject felt she will be able to lift for only less than 10 times. The selection of the weight is made based on a list of weights provided (1kg to 10kg). When the subject performed the movement for 10 times or more, then the resistance was increased 1kg at a time, until the subject can perform only 9 or fewer repetitions of the movement correctly throughout the range of motion. A 3 minutes rest period was given to the subject before the new attempt was done with the increased weight. A standardized verbal encouragement was provided for motivation
2976867|NCT02717780|Active Comparator|SEVO-FENTA|Patients scheduled for lower limb surgery will receive a balanced anesthesia with fentanyl and sevoflurane.
2976868|NCT02717780|Experimental|DES-REMI|Patients scheduled for lower limb surgery will receive a balanced anesthesia with remifentanil and desflurane.
2976869|NCT02717754|Experimental|Oseltamivir 100 mg|Participants will receive 100 mg oseltamivir intravenous BID for 5 days.
2976870|NCT02717754|Experimental|Oseltamivir 200 mg|Participants will receive 200 mg oseltamivir intravenous BID for 5 days.
2976871|NCT02717754|Placebo Comparator|Placebo|Participants will receive oseltamivir matched placebo intravenous BID for 5 days.
2976872|NCT02717741|Experimental|tafetinib|tafetinib administered daily for 2 weeks, followed by a 1-week off period
2976873|NCT02717728|Active Comparator|Drug group Fascia iliaca nerve block|"Device: Fascia Iliaca Catheter placement Drug: Local anesthetic bolus :Ropivacaine 0.2% 0.5 ml/kg total in divided doses~Device: Dressing: Catheter labeled: Fascia Iliaca Catheter~Drug:Infusion: Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
2976874|NCT02717728|Sham Comparator|Control group sham nerve block|"Device: Fascia Iliaca Catheter placement (20 g catheter tip laid at appropriate insertion site)~Device: Dressing: Catheter labeled: Fascia Iliaca Catheter~Drug: Infusion: Ropivacaine 0.1% to plastic bag. rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
2976875|NCT02717715|Experimental|Intervention group|Stroke patients from the intervention group will be, on top of usual care, offered a holistic home based and semi-supervised stroke rehabilitation program followed by a period of tele-supervision.
2976876|NCT02717715|No Intervention|Control group|The participants in the control group will only receive usual care.
2976877|NCT02717702||ACS Patients|Subjects will be patients presenting to the Emergency Department for evaluation of ACS.
2976878|NCT02717689|Experimental|Biomarker arm|Biomarker based adjustment of corticosteroid dose.
2976879|NCT02717689|No Intervention|Standard care|The subject's corticosteroid dose will be adjusted based upon asthma symptom control and lung function
2976880|NCT02717676|Experimental|Group A|Episiotomy
2976881|NCT02717676|No Intervention|Group B|no episiotomy
2976882|NCT02717663|Experimental|Static goals with delayed incentives|Participants will receive static physical activity goals with delayed, non-contingent incentives
2976887|NCT02717650|Experimental|A-STEPmax|Study B) Crossover Validity Study (random allocation).
2976888|NCT02717650|Active Comparator|CPET Godfrey Protocol|Study B) Crossover Validity Study (random allocation).
2976889|NCT02717624|Experimental|acalabrutinib in combination with BR in treatment TN patients|acalabrutinib in combination with bendamustine and rituximab (BR)
2976890|NCT02717624|Experimental|acalabrutinib in combination with BR in RR patients|acalabrutinib in combination with bendamustine and rituximab (BR)
2976891|NCT02717611|Experimental|ACP-196 (acalabrutinib)|
2976892|NCT02717598|Experimental|CSP|Cold snare polypectomy is an easy-to-apply technique and has been the most popular technique esprcially for small and diminutive polyps. Briefly, the endoscopist advances the snare sheath, opens the snare and encircles the polyp. The snare is then slowly and progressively closed, with the aim of capturing 1-2 mm of normal tissue around the polyp, until complete closure is achieved and the polyp is guillotined. The polyp can then be suctioned and retrieved for histologic assessment.
2976893|NCT02717598|Experimental|HSP|Hot snare polypectomy, the endoscopist advances the snare sheath, opens the snare and encircles the polyp. The snare is then slowly and progressively closed, with the aim of capturing 1-2 mm of normal tissue around the polyp,then use Electrocoagulation until complete closure is achieved and the polyp is guillotined. The polyp can then be suctioned and retrieved for histologic assessment.
2976894|NCT02717585|No Intervention|Control Group|For the no intervention group (Control), patients will only receive standardized treatment for FM at the Pain Clinic. All patients will receive a multifaceted tailored regimen that incorporates one or more lines of pharmacological and/or non-pharmacological therapy. All assessment and management will be performed according to evidence-based therapeutic recommendations put forward by the Canadian Rheumatology Association and Canadian Pain Society.
2976895|NCT02717585|Active Comparator|Treatment Group (CPAP)|In addition to standard FM treatment at the Pain Clinic, patients who are randomized to the treatment will meet with a sleep physician for possible therapy with a Continuous Positive Airway Pressure (CPAP) machine. A CPAP titration study will be arranged for in a laboratory setting, where in addition to the regular parameters of a diagnostic sleep study, CPAP will be titrated upwards starting from 5cm H2O to an optimal setting where the obstructive respiratory events are abolished. Patients will undergo regular follow-up as determined by their sleep physician. Adherence to CPAP treatment will be recorded at follow-up visits.
2976896|NCT02717572|Experimental|FDG-PET/CT and FDG-PET/MR|"10 mCI fludeoxyglucose IV bolus approximately 60 minutes before first PET/CT~Immediately following PET/CT scan, the participant will be moved to PET/MR scanner~The scans will take place at baseline and also one more time point between Day 1 and Day 7. There needs to be at least 24 hours between the baseline and repeat imaging"
2976897|NCT02717546||Group One|Distal Tibia Fracture repaired with Zimmer MotionLoc Screw
2976898|NCT02717533||blood volume|dry weight adjusted according to ideal blood volume obtained from absolute blood volume measurement (Daxor)
2976899|NCT02717520|Experimental|EQUIA Forte|permanent molar with an approximal and occlusal carious lesion restored with EQUIA Forte
2976900|NCT02717520|Experimental|Tetric EvoCeram|permanent molar with an approximal and occlusal carious lesion restored with Tetric EvoCeram
2976901|NCT02717507|Experimental|Arm I (carvedilol)|Patients receive low-dose carvedilol PO QD or BID for 24 months.
2976902|NCT02717507|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD or BID for 24 months.
2976903|NCT02717494|Experimental|Arm 1A (PPV-23)|In Step 1, women in Arm 1A will be administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
2976904|NCT02717494|Experimental|Arm 1B (PCV-10)|In Step 1, women in Arm 1B will be administered a 0.5 mL dose of PCV-10 intramuscularly once.
2976905|NCT02717494|Placebo Comparator|Arm 1C (placebo)|In Step 1, women in Arm 1C will be administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
2976906|NCT02717494|Experimental|Arm 2A (PPV-23)|In Step 2, women who received placebo in step 1 that are randomized to Arm 2A will be administered a 0.5 mL dose of PPV-23 intramuscularly once.
2976907|NCT02717494|Experimental|Arm 2B (PCV-10)|In Step 2, women who received placebo in step 1 that are randomized to Arm 2B will be administered a 0.5 mL dose of PCV-10 intramuscularly once.
2976908|NCT02717494|Experimental|Step 3 (PCV-10)|In Step 3, women who received placebo in step 1 and failed entry into step 2 due to ongoing new pregnancy will be administered a 0.5 mL dose of PCV-10 intramuscularly once.
2976909|NCT02717481||Patients with known aortic aneurysm|"Patients with known abdominal aortic aneurysm diagnosed in clinical follow-up or after an invasive procedure to repair it.~US-CT Fusion examination"
2976910|NCT02717455|Experimental|Treatment (STRATUM 1)|Patients with recurrent/progressive DIPG will be enrolled at the time of progression. All patients will take the study drug panobinostat (LBH589).
2976911|NCT02717455|Experimental|Treatment (STRATUM 2)|Patients with non-progressed DIPG will be enrolled. All patients will take the study drug panobinostat (LBH589).
2976912|NCT02717442|Experimental|OTO-104|12 mg dexamethasone
2976913|NCT02717442|Placebo Comparator|Placebo|
2976914|NCT02717429|Experimental|Mindfulness Meditation Training (MMT)|Participants will attend four weekly group mindfulness meditation sessions of a 2-hour duration. The classes are a mixture of experiential practices, discussions surrounding the experiences, and didactics on mindfulness. In addition to the time spent in session, participants will be asked to complete 40 minutes of daily homework, which includes further practice of in-session meditative exercises and brief readings.
2976915|NCT02717429|Active Comparator|Computerized Cognitive Training|The active control group will be in the form of a cognitive training course where the participants will meet for the same amount of time as the MMT group. Homework will be reading and engaging in cognitive video game exercises for the same duration, around 40 minutes daily, as the MMT group.
2976916|NCT02717429|No Intervention|Wait-List Control Group|This group will be used to compare the effects of the two active comparison groups and will not receive any intervention for the four week period.
2976917|NCT02717416|Experimental|Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group|The intervention group
2976918|NCT02717416|Active Comparator|Hemoclip (HX-610-135, Olympus, Japan) group|Patients in the control group will undergo endoscopic hemostasis with combination therapy, epinephrine injection therapy and hemoclip therapy.
2977267|NCT02715089||Precise treatment|All patients should accept next-generation sequencing (NGS) test before treatment.
2976919|NCT02717403|Experimental|Facebook + Website Group|Participants complete a self response electronic questionnaire at baseline. Participant shown how to access the Educational Website and the Facebook page on the internet about rheumatoid arthritis. Patients assessed at three and six months after baseline via email self response electronic questionnaires.
2976920|NCT02717403|Experimental|Educational Website Group|Participants complete a self response electronic questionnaire at baseline. Participant shown how to access the Educational Website on the internet about rheumatoid arthritis. Content includes the following: (i) a learning center; (ii) relevant links to other evidence-based web pages; (iii) news released by major rheumatology and dermatology organizations/societies; and (iv) chronic disease management strategies. Participants assessed at three and six months after baseline via email self response electronic questionnaires.
2976921|NCT02717403|Experimental|Pilot Testing Group|Participants access the Educational Website and Facebook page about rheumatoid arthritis for a period of one week. After 1 week, research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
2976922|NCT02717390|Experimental|Bright By Three (BB3) Intervention|The purpose of the BB3 intervention (annual home visit, written materials, and BB3 mobile application 'app') is to increase parental talking, reading, playing, and praise (TRPP) behaviors and improves children's social-emotional and language development at ages 2, 3, and 4 years
2976923|NCT02717390|Active Comparator|Texts for Child Safety (TCS) Intervention|The purpose of the injury prevention arm is to reduce the prevalence of safety hazards in the home and car environments, decrease the number of self-reported and medically-attended injuries among children, and increase caregiver's self-reported safety behaviors and knowledge of child safety. The Investigators will compare the results of our tailored child safety intervention (Texts for Child Safety [TCS]) among participants in the injury prevention arm with those randomized to the BB3 arm.
2976924|NCT02717377|No Intervention|Uninterrupted sitting|Subjects remained seated all day except to rise from the chair to void.
2976925|NCT02717377|Active Comparator|Sitting + one bout of activity|Subjects remained seated all day, except to rise from the chair to void, and to perform one bout of 30-minutes moderate-intensity walking. Physical activity was performed at 0800, after measures of vitals and basal questionnaire assessments, but before breakfast.
2976926|NCT02717377|Experimental|Sitting + microbursts of activity|Subjects rose from the seated position every hour for 6-hours from 0910 to 1430 to complete 5-minute bouts of moderate-intensity walking, yielding a total activity time of 30-minutes.
2976927|NCT02717364||Population With Yervoy Exposure|Population With Yervoy Exposure
2976928|NCT02717351|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2976929|NCT02717338|Experimental|Competence|Participants will be assigned to review our donor coping website.
2976930|NCT02717338|Experimental|Autonomy|Participants will be assigned to receive a brief telephone interview.
2976931|NCT02717338|Experimental|Relatedness|Participants will be asked to join a closed Facebook group for one month.
2976932|NCT02717338|Experimental|Competence + Autonomy|Participants will be assigned to the web site review, followed by the brief telephone interview.
2976933|NCT02717338|Experimental|Competence + Relatedness|Participants will be assigned to the web site review, followed by the one-month Facebook group membership.
2976934|NCT02717338|Experimental|Autonomy + Relatedness|Participants will be assigned to the brief telephone interview, followed by the one-month Facebook group membership.
2976935|NCT02717338|Experimental|Competence + Autonomy + Relatedness|Participants will be assigned to the web site review, brief telephone interview, and one-month Facebook group membership.
2976936|NCT02717338|No Intervention|Treatment-as-Usual Control|Participants will receive the standard communications that New York Blood Center has with all first-time donors.
2976937|NCT02717325|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application fo test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application
2976938|NCT02717299|Experimental|Sensor Guided Tissue Balancing|Patients in this group will have the Verasense trial sensor device inserted, and the data collected electronically. The surgeon will use this data to intraoperatively align the knee according to the indications of the data.
2976939|NCT02717299|Placebo Comparator|Surgeon Guided Tissue Balancing|Patients in this group will have the Verasense trial sensor device inserted, and the data collected electronically. The computer displaying the data will be turned away from the surgeon, so that he is not able to use the sensor data, and must balance the knee with feel and visual estimation of balance.
2976940|NCT02717286|Sham Comparator|Control|"20 first permanent molars from children aged between 6 to 12 years old presenting MIH will be included. A calibrated pediatric dentist examined the selected teeth to classify MIH according to the European Academy of Pediatric Dentistry (EADP) criteria.~Intervention of Control: The restorative treatment using a total-etching adhesive system, which was performed according to the following operative sequence: prophylaxis, infiltrative anesthesia, rubber dam, application of 37.5% phosphoric acid to enamel (30 s) and dentine (15 s), extensive washing, drying with cotton and air jet (5 s), priming (5 s), light curing (20 s), restoration with composite resin (Filtek XT350), examination of occlusal contact, and final polishing."
2976941|NCT02717286|Experimental|Test|"20 first permanent molars from children aged between 6 to 12 years old presenting Molar Incisor Hypomineralization will be included. A calibrated pediatric dentist examined the selected teeth to classify MIH according to the EAPD criteria.~Intervention of test: the restorative treatment using a self-etching adhesive system, which was performed according to the following operative sequence: prophylaxis, infiltrative anesthesia, rubber dam, application of 37.5% phosphoric acid to enamel (30 s) and dentine (15 s), extensive washing, drying with cotton and air jet (5 s), priming (5 s), air jet (5 s), adhesive application (5 s), light curing (20 s), restoration with composite resin (Filtek XT350), examination of occlusal contact, and final polishing."
2976942|NCT02717273|Active Comparator|standard peri-operative antibiotics|The standard of care at the University of Virginia Medical Center for liver transplantation patients is a 3.375 gram dose of piperacillin / tazobactam (Zosyn®) at the time of induction of anesthesia, though this dose may be adjusted for renal insufficiency. This dose is repeated during the operation every six hours.
2976943|NCT02717273|Experimental|extended three-day course of antibiotics|"For those patients randomized to the study group, antibiotics will be started as per the usual intra-operative dosing regimen, then continued to provide coverage for 72 hours.~This is typically provided as additional doses of 3.375 grams of piperacillin / tazobactam (Zosyn®) every 8 hours for 3 total days (giving a total of 72 hours of antibiotic coverage), though this may be altered based on kidney function."
2976944|NCT02717260|Sham Comparator|Sham transcranial noise stimulation|subjects are stimulated 3 times with sham transcranial random noise stimulation (tRNS) (Starstim) with a 30 seconds offset
2976945|NCT02717260|Active Comparator|1 Active transcranial random noise stimulation|subjects are stimulated 1 time with active transcranial random noise stimulation (tRNS) (Starstim) at 2mA with a oscillatory frequency between 100 and 500 Hz during 20 minutes and 2 times with sham tRNS
2976946|NCT02717260|Active Comparator|3 Active transcranial random noise stimulation|subjects are stimulated 3 times with active transcranial random noise stimulation (tRNS) (Starstim) at 2mA with a oscillatory frequency between 100 and 500 Hz during 20 minutes
2976947|NCT02717247|Experimental|Active tRNS treatment|"The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsalateral prefrontal cortex (F4).~100 (Hertz)Hz-650Hz, 2milliampere(mA), 30min, twice daily, 5 days"
2976948|NCT02717247|Sham Comparator|Placebo tRNS treatment|The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
2976949|NCT02717234|Active Comparator|Impact Advanced Recovery|Oral nutrition supplement intended for consumption at 3 servings per day
2976950|NCT02717234|Experimental|Impact Advanced Recovery-R|Oral nutrition supplement intended for consumption at 3 servings per day
2976951|NCT02717221|Experimental|18F-MPG:EGFR+|Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study.
2976952|NCT02717221|Experimental|18F-MPG:post-TKI EGFR+|Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study.
2976953|NCT02717221|Experimental|18F-MPG:post-chemo EGFR+|Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study.
2976954|NCT02717221|Experimental|18F-MPG:EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
2976955|NCT02717221|Experimental|18F-MPG:post-chemo EGFR wild type|Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study.
2976956|NCT02717221|Experimental|18F-MPG:unknown EGFR mutational status|Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group
2976957|NCT02717208|Active Comparator|HL036 0.5mg/ml|Administration : 2 times per day for one day
2976958|NCT02717208|Active Comparator|HL036 5mg/ml|Administration : 2 times per day for one day
2976959|NCT02717195|Experimental|Period A|Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
2976960|NCT02717195|Experimental|Period B, Lu AF35700 10 mg|Eligible patients from Period A (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) Double-blind treatment in Period B, 10 weeks
2976961|NCT02717195|Experimental|Period B, Lu AF35700 20 mg|Eligible patients from Period A (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) Double-blind treatment in Period B, 10 weeks
2976962|NCT02717195|Experimental|Period B, Continued treatment from Period A|Eligible patients from Period A (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) Double-blind treatment in Period B,10 weeks. Patients in this arm will continue with same the treatment and dose as at last visit of period A
2976963|NCT02717169|Other|Biometrical Tracker|The participants are equipped with an wrist watch. The activity tracker measures biometrical information like, steps, sleep duration and heart rate.
2976964|NCT02717156|Experimental|Treatment (EphB4-HSA and pembrolizumab)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, and 15 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
2976965|NCT02717143||Acute myocarditis|"Patients with a clinical picture suggestive of acute myocarditis: increase of troponin above the threshold defined by the pathological laboratory, associated with at least one of the three following criteria:~prolonged chest pain > 10 minutes,~recent infectious context <7 days~young subject and / or absence of cardiovascular risk factors and / or absence of significant coronary lesion~Patients will be included after completion of MRI confirm the diagnosis. They will be followed for 3 years, every year, by the doctor who included them in the study.~This is an observational study that does not affect the management of patients."
2976966|NCT02717130|Experimental|Aripiprazole (Abilify Maintena)|Aripiprazole once monthly (300-400 mg for entire study duration) plus 14 days oral antipsychotic medication (first injection only) (dosage according to package inserts). After the 14 day oral lead-in, after the first injection of aripiprazole once monthly, only oral aripiprazole will be allowed as a rescue medication.
2976967|NCT02717117|Experimental|Feeding|Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
2976968|NCT02717091|Experimental|FOLFIRINOX|4 course of FILFIRINOX before surgery
2976969|NCT02717091|Experimental|GEM + nab-PTX|2 course of GEM + nab-PTX before surgery
2976970|NCT02717078|Experimental|LoBAG Diet|This group of subjects will be instructed in preparation and consumption of the LoBAG diet (diet therapy). Subjects will be asked to avoid foods that are not a part of the diet plan. The diet intervention will be 12 weeks.
2976971|NCT02717078|Active Comparator|Control Diet|This group of subjects will be instructed in preparation and consumption of a balanced diet (diet therapy). Subjects will be asked to avoid foods that are not a part of the diet plan. The diet intervention will be 12 weeks.
2977025|NCT02716740|Experimental|Leucine-enriched amino acid : 4g/day|Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (4g/day).
2977264|NCT02715128|Sham Comparator|sham tDCS|frequency and duration correspondent active tDCS, ramp in and ramp out periods only without intermittent stimulation
2976972|NCT02717065|Experimental|Characterization, Audiovisual|"Characterization: Tinnitus characterization tools (Minimal Masking Level, Tinnitus Functional Index, Tinnitus Handicap Inventory, and Subjective rating scale) are assessed in an individual over time to determine baseline variability.~Audiovisual: The individual will watch a series of silent videos of a person speaking, both with and without a tone matched to their tinnitus as well as videos of a still face with and without the matched tone."
2976973|NCT02717052|Experimental|(S)-ketamine|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)~all patients and 10 HC (randomized, double blind)~Interventions:~Drug: (S)-ketamine (Main study) Other: Main study: PET1 Other: Main study: PET2"
2976974|NCT02717052|Placebo Comparator|Placebo|"0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)~10 HC (randomized, double blind)~Interventions:~Drug: Placebo Other: Main study: PET1 Other: Main study: PET2"
2976975|NCT02717052|Experimental|(S)-ketamine (Pilot Study II, 5 subj.)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.10mg/kg bodyweight bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight applied over the course of 130 minutes.~Pilot-study II is cross-over design!~Interventions:~Drug: (S)-ketamine (Pilot II) Other: PILOT Study II: PET1 Other: PILOT Study II: PET2"
2976976|NCT02717052|Experimental|(R,S)-ketamine (Pilot Study II, 5 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.20mg/kg bodyweight bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied over the course of 130 minutes.~Pilot-study II is cross-over design!~Interventions:~Drug: (R,S)-ketamine (Pilot II) Other: PILOT Study II: PET1 Other: PILOT Study II: PET2"
2976977|NCT02717052|Experimental|(R,S)-ketamine (Pilot Study I, 12 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 5 minutes before PET measurement)~Interventions:~Drug: (R,S)-ketamine (Pilot I) Other: PILOT Study I: PET1 Other: PILOT Study I: PET2"
2976978|NCT02717052|Experimental|(R,S)-ketamine (Pilot Study III, 12 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.80mg/kg bodyweight i.v. over 50 Minutes~Interventions:~Drug: (R,S)-ketamine (Pilot III) Other: PILOT Study III: PET1 Other: PILOT Study III: PET2"
2976979|NCT02717039||Blood Draw|A one time blood draw of 50mL or 15mL will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture. Participants will be enrolled in equal numbers from three categories determined by their observed clinical course: (1) participants without HIT testing negative for heparin/PF4 antibodies (controls); (2) participants without HIT testing positive for heparin/PF4 antibodies (seroconversion cases); (3) participants with HIT testing positive for both heparin/PF4 antibodies (HIT cases).
2976980|NCT02717013|Placebo Comparator|Placebo Diet Restriction|
2976981|NCT02717013|Placebo Comparator|Placebo No Diet Restriction|
2976982|NCT02717013|Active Comparator|HMB Diet Restriction|
2976983|NCT02717013|Active Comparator|HMB No Diet Restriction|
2976984|NCT02717000||NASH|
2976985|NCT02717000||No NASH|
2976986|NCT02716987|Experimental|Set A: TAK-831 + [18F]PGM299|TAK-831 500 mg, suspension, orally, once only on Day 1. Subsequent dose levels may be lower or higher (up to the highest safe dose level administered in the TAK-831-1001 study). [18F]PGM299 up to 12.5 mcg maximal mass per intravenous injection, not to exceed 300 MBq total for up to 3 PET scans (Baseline, Day 1, Day 2).
2976987|NCT02716987|Experimental|Set B: [18F]PGM299|[18F]PGM299 up to 12.5 mcg maximal mass per intravenous injection, not to exceed 300 MBq total for 2 PET scans (Day 1 and 10 [+/- 5]).
2976988|NCT02716974|Experimental|chemohormonal and definitive therapy|(1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of neoadjuvant androgen deprivation (Leuprolide Acetate) and up to 6 cycles of chemotherapy (Docetaxel), (2nd) definitive local tumor control with prostatectomy +/- adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions. The men will receive a total of 1 year of androgen deprivation. Androgen blockade (Bicalutamide) will be the same throughout the course of treatment.
2976989|NCT02716961|No Intervention|Monotherapy|Barely epirubicin was instilled after TURBT. Epirubicin was immediately instilled in 24h after TURBT. Instillation was conducted regularly for a year: once in a week for 8 times, once in two weeks for 8 times, once in a month for 6 times.
2976990|NCT02716961|Experimental|Combination|Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. Intervention: GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
2976991|NCT02716948|Experimental|Treatment (nivolumab, stereotactic radiosurgery)|Patients receive nivolumab IV over 60 minutes on day 1. Patients then undergo stereotactic radiosurgery on day 8 per standard of care. Courses with nivolumab repeats every 14 days in the absence of disease progression or unacceptable toxicity.
2976992|NCT02716935|Experimental|Fortified lipid based nutrient supplement|lipid based nutrient supplement (Nutributter) fortified with fructo-oligosaccharides and inulin
2976993|NCT02716935|Active Comparator|lipid based nutrient supplement|lipid based nutrient supplement (Nutributter)
2976994|NCT02716935|No Intervention|non intervention group|This group will not be supplemented
2976995|NCT02716922|Experimental|Cervical cerclage|Women randomized to receive cerclage should receive cervical cerclage Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
2976996|NCT02716922|No Intervention|No intervention|No cerclage Women randomized to not receive cerclage represent the control arm
2976997|NCT02716909|Experimental|Cervical Pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
2976998|NCT02716909|No Intervention|No intervention|No pessary No pessary will be used. Subjects will receive standard obstetrical management
2977026|NCT02716727|Active Comparator|Aquasil Ultra Cordless, Dentsply|Gingival displacement procedure that uses a pneumatic hand piece to inject the light body impression material into the gingival sulcus.
2976999|NCT02716896|Active Comparator|Surgery (radical cystectomy)|In brief, radical cystectomy is the removal of the entire bladder, nearby lymph nodes (lymphadenectomy), part of the urethra, and nearby organs that may contain cancer cells. In men the prostate, the seminal vesicles, and part of the vas deferens are also removed. In women the cervix, the uterus, the ovaries, the fallopian tubes, and part of the vagina are also removed. Participants in this group may also undergo neoadjuvant chemotherapy prior to the surgery. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, GFR, participant's preference, and availability of chemotherapeutic regimen.
2977000|NCT02716896|Active Comparator|Radiation and Chemoradiation|Those randomized to this group will undergo systematic chemotherapy and radiation. In brief, participants will receive 33-36 daily fractions of radiation therapy 5 days a week. Concurrently, radiosensitizing chemotherapy involves either cisplatin plus 5-fluorouracil (5-FU) or mitomycin C (MMC) plus 5-FU. Other concurrent chemotherapy regimens utilized include paclitaxel and gemcitabine. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, GFR, participant's preference, availability of chemotherapeutic regimen.
2977001|NCT02716883|No Intervention|Non AMT|"Freshly prepared fortified eye drops (cefazolin 50 mg/mL and amikacin 14 mg/mL) were applied as starting treatment. In the first 3 days, eye drops are applied round the clock followed by drops every 2 h during waking hours until results of laboratory investigation were available.~After preparation of the culture results, the antimicrobial treatment was narrowed according to bacterial sensitivity. Also topical betamethasone 0.1% four times a day on a tapering weekly dosage until 3-4 weeks is used for all patients. If the patient underwent any tectonic procedure during the treatment such as keratoplasty, cyanoacrylate glue are documented"
2977002|NCT02716883|Active Comparator|AMT|"This group (case group) received above mentioned routine antibiotic therapy followed by double-layer amniotic membrane transplantation 2-5 days after the start of medications and the second group (control group) only received routine antibacterial therapy.~The AM was trimmed in two layers to fit the corneal ulcer and was placed with its epithelium (basement membrane) side up, secured with 10/0 nylon sutures, supported by a therapeutic contact lens. If the patient underwent any tectonic procedure during the treatment such as keratoplasty, cyanoacrylate glue are documented."
2977003|NCT02716857|Experimental|Oxycodone extended-release|Egalet ADER oxycodone tablet
2977004|NCT02716857|Placebo Comparator|Placebo of Oxycodone extended-release|Egalet ADER oxycodone placebo tablet
2977005|NCT02716844|Experimental|Exercise Group,|Clinical Pilates exercise were given for 6 weeks, 3 days in a week
2977006|NCT02716844|No Intervention|Control Group|Nothing given to control group, told to continue their normal life for 6 weeks.
2977007|NCT02716831|Experimental|Counseling & Acceptance-based Therapy|Nutritional Counseling & Acceptance-based Therapy (N-CAAT) incorporates acceptance-based behavioral strategies and nutritional counseling designed to encourage willingness to tolerate distress and the ability to pursue chosen values in an adaptive manner despite distressing internal experiences. In addition to these skills, a principal focus of the treatment will be on identifying, practicing, and achieving behavioral goals, such as normalization of eating, reduction of maladaptive dietary restraint and restriction, and elimination of compensatory behaviors.
2977008|NCT02716831|Active Comparator|Cognitive Therapy for Eating Disorders|Participants in the Cognitive Behavioral Therapy for Eating Disorders (CBT) condition will receive 20-sessions of standard CBT for eating disorders based on the treatment approach developed by Dr. Christopher Fairburn and published in his book Cognitive Behavioral Therapy and Eating Disorders.
2977009|NCT02716818|Experimental|Chronocort®|Chronocort® will be provided as 5mg, 10mg and 20mg capsules for oral administration. The starting dose for each subject will be based on the subjects previous glucocorticoid therapy dose and then dose titrated to effect.
2977010|NCT02716818|Active Comparator|standard glucocorticoid therapy|Subjects in this arm will continue previous oral glucocorticoid therapy titrated to effect.
2977011|NCT02716805|Experimental|Cohort 1|Subjects will receive tremelimumab prior to and for 2 cycles post autologous stem cell transplant (ASCT) followed by up to 6 cycles of durvalumab.
2977012|NCT02716805|Experimental|Cohort 2|Subjects will receive tremelimumab prior to and for 2 cycles post autologous stem cell transplant (ASCT) followed by up to 6 cycles of durvalumab.
2977013|NCT02716805|Experimental|Cohort 3|Subjects will receive durvalumab + tremelimumab prior to and for 2 cycles post autologous stem cell transplant (ASCT) and up to 6 cycles of durvalumab.
2977014|NCT02716805|Experimental|Cohort 4|Subjects will receive durvalumab + tremelimumab prior to and for 2 cycles post autologous stem cell transplant (ASCT) and up to 6 cycles of durvalumab.
2977015|NCT02716792|Experimental|Ibandronate 15-Minute Infusion|Participants will receive ibandronate IV infusions over a 15-minute interval.
2977016|NCT02716792|Active Comparator|Ibandronate 60-Minute Infusion|Participants will receive ibandronate IV infusions over a 60-minute interval.
2977017|NCT02716779|Experimental|Pegylated Interferon (PEG-IFN) alfa-2a|Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
2977018|NCT02716779|Placebo Comparator|Placebo|Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
2977019|NCT02716779|Experimental|Ribavirin|Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
2977020|NCT02716766|Experimental|SECOX|Sorafenib 400 mg twice daily from Day 1 to 14, Capecitabine 850 mg/m2 twice daily from Day 1 to 7, Oxaliplatin 85 mg/m2 on Day 1
2977021|NCT02716766|Active Comparator|Sorafenib|Sorafenib 400 mg twice daily from Day 1 to 14
2977022|NCT02716753|Experimental|Seminal plasma|Half of the amount of seminal plasma received after preparation of the spermatozoa used for IVF will be deposited around the external cervical opening
2977023|NCT02716753|Placebo Comparator|Physiological NaCL solution|An amount of physiological NaCL solution equal to half of the amount of seminal plasma received after preparation of the spermatozoa used for IVF will be deposited around the external cervical opening
2977024|NCT02716740|Experimental|Leucine-enriched amino acid : 2.16g/day|Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (2.16g/day)
2977027|NCT02716727|Active Comparator|Ultrapak, Ultradent cord|The knitted cord is used for physical displacement of gingival tissue. Cord is placed in the gingival sulcus and left in place for at least 4 minutes to achieve gingival displacement.
2977028|NCT02716714|Active Comparator|ingenol mebutate gel 0.015%|Applied on face and scalp for three days.
2977029|NCT02716714|Active Comparator|ingenol mebutate gel 0.05%|Applied on trunk and extremities for two days.
2977030|NCT02716701|Experimental|Exercise Group|Subjects will wear a wristband activity tracker to monitor their physical activity and will be asked to increase their activity level, with a goal of at least doubling their average daily activity (steps)
2977031|NCT02716701|Active Comparator|Control Group|Subjects will wear a wristband activity tracker to monitor their physical activity and will not be encouraged to increase their activity level
2977032|NCT02716688|Experimental|Radiotherapy and S-1 arm|Radiotherapy will be delivered with a daily fraction of 1.8-2.0Gy to a total dose of 54-60Gy. Preplanned concurrent S-1 (70mg/m²/day) will be administered on Day 1 for 14 days, every 3 weeks. After CCRT, maintenance S-1 will be given up to four cycles.
2977033|NCT02716675|Experimental|Group 1: Low-Dose VRC01|Participants will receive an intravenous (IV) infusion of 10 mg/kg of VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
2977034|NCT02716675|Experimental|Group 2: High-Dose VRC01|Participants will receive an IV infusion of 30 mg/kg of VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
2977035|NCT02716675|Placebo Comparator|Group 3: VRC01 Placebo|Participants will receive an IV infusion of placebo for VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
2977036|NCT02716662|Experimental|Open Label|Axona
2977037|NCT02716649||All participants|No intervention
2977038|NCT02716636|No Intervention|Fast placement|Placement of the tenaculum quickly and without avoiding ratchet
2977039|NCT02716636|Experimental|Slow placement of the tenaculum|Placement of the tenaculum over a 7-10 second time frame and not allowing the tenaculum to ratchet audibly.
2977040|NCT02716623|Experimental|CR Diet and Exercise|Participants will be asked to follow specific diet intervention and exercise regimen.
2977041|NCT02716610|Experimental|INH 69 U (low)|single 69 U dose administration of Dance inhaled human insulin using a low-concentration formulation (300 U/mL)
2977042|NCT02716610|Experimental|INH 69 U (high)|single 69 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)
2977043|NCT02716610|Experimental|INH 139 U|single 139 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL) This arm was repeated in order to evaluate intra-subject variability.
2977044|NCT02716610|Experimental|INH 208 U|single 208 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)
2977045|NCT02716610|Active Comparator|LIS 18 U|single 18 U dose administration of subcutaneous insulin lispro using a 100 U/mL formulation This arm was repeated in order to evaluate intra-subject variability.
2977046|NCT02716597|Experimental|25% Albumin|25% albumin 75 grams IV over 1 hour once.
2977047|NCT02716597|Placebo Comparator|Placebo|0.9% normal saline 200mL IV over 1 hour once.
2977048|NCT02716584|Experimental|Physical exercise|Participants participate in brisk walking exercises.
2977049|NCT02716584|Active Comparator|Stretching exercise|Participants participate in non-aerobic, non-Yoga stretching exercises
2977050|NCT02716571|Other|Healthy Donors|Healthy Donors will given white blood cell and plasma
2977051|NCT02716558|Experimental|Moisture tolerant resin sealant|Moisture resistant sealant (wet bond sealant)
2977052|NCT02716558|Active Comparator|ART sealant|Glass inomer based sealant
2977053|NCT02716545|Experimental|Endoscopic Intervention Group|Endoscopic therapy
2977054|NCT02716532|Other|Peptamen AF|over 7 days
2977055|NCT02716519|Experimental|Santyl|Collagenase ointment applied topically once per day for up to six weeks
2977056|NCT02716519|Active Comparator|Standard Card|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
2977057|NCT02716506||Symptomatic POP|POP surgery in year 2015
2977058|NCT02716493|Experimental|Telerehabilitation group|Patients with unresectable thoracic neoplasia receiving chemotherapy treatment
2977059|NCT02716480|Experimental|Mobility Coaching|"45 patients undergoing bariatric surgery received a monthly mobility coaching session of 20 to 30 min by phone during 6 months."
2977060|NCT02716480|Experimental|Diet Coaching|"45 patients undergoing bariatric surgery received a monthly diet coaching session of 20 to 30 min by phone during 6 months."
2977061|NCT02716467|Experimental|intercessory prayer group|Patients in the experimental group receive prayer of intercession during radiotherapy treatment.
2977062|NCT02716467|Active Comparator|Radiotherapy Treatment|Patients in the radiotherapy group not receive prayer of intercession during radiotherapy treatment.
2977063|NCT02716454|Experimental|Early Surgery - ES|Early laparoscopic ileocaecal resection
2977064|NCT02716454|No Intervention|Step-up therapy - STUP|Treatment with step-up conservative approach according to good clinical practice.
2977065|NCT02716441||Radio-opaque Tissue Markers|Patients undergoing rotator cuff repair with implantation of radio-opaque tissue markers
2977066|NCT02716428|Experimental|Cohort 1|12 weeks of Faldaprevir plus TD-6450 plus Ribavirin
2977067|NCT02716428|Experimental|Cohort 2|12 weeks of Faldaprevir plus TD-6450
2977068|NCT02716415|Active Comparator|Calmoseptine Ointment|Calmoseptine Ointment as part of a structured skin care regimen.
2977069|NCT02716415|Active Comparator|Destin Maximum Strength 40% Zinc|Destin Maximum Strength 40% Zinc as part of a structured skin care regimen.
2977070|NCT02716402|Other|Cyanotic congenital heart disease|Patients who previously have been examined with cerebral MRI and V/Q SPECT/CT will be re-examined with cerebral MRI and V/Q SPECT/CT
2977071|NCT02716389|Other|Mask on|
2977072|NCT02716389|Other|Mask off|
2977073|NCT02716376|Experimental|Otovent®|Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
2977074|NCT02716376|No Intervention|No treatment|Observation: No treatment.
2977138|NCT02715908|Experimental|LBEC0101|Etanercept 50mg
2977075|NCT02716363|Experimental|Device : Rotablator|We compare in-hospital and long-term efficacy or safety of elective Rotational Atherectomy versus bailout Rotational Atherectomy and low-volume operator versus high-volume operator in patients with severe calcified lesions treated.
2977076|NCT02716350|Experimental|B-GOS|powder, 3.5g/day
2977077|NCT02716350|Placebo Comparator|Maltodextrin|powder, 3.5g/day
2977078|NCT02716337|Other|Intervention group|In the intervention group VLBW infants were fed target fortified human milk Growth and safety were compared to a historical group of VLBW infants fed with standard fortified human milk
2977079|NCT02716324|Active Comparator|ADHD Portal|In this arm, the ADHD Portal will be used alone as an electronic communication tool.The ADHD portal is considered standard of care at our institution for communicating information between clinicians, teachers, and parents.
2977080|NCT02716324|Experimental|ADHD Portal plus Care Manager|In this arm, the ADHD Portal will be combined with the Care Manager. Clinicians, teachers, and parents will use the ADHD Portal as in the ADHD Portal arm. In addition, clinicians, teachers, parents, and any external mental health providers will interact with a Care Manager, who will have access to information contained in the ADHD Portal.
2977081|NCT02716311|Other|Afatinib|Afatinib 40 mg/d until progression
2977082|NCT02716311|Experimental|Afatinib + cetuximab|Afatinib 40 mg/d until progression + cetuximab 500 mg/m² every 2 weeks during 6 months (beginning at D15 at 250 mg/m²)
2977083|NCT02716298|Active Comparator|fanfilcon A|Study participants are randomized to wear fanfilcon A lens during the crossover study
2977084|NCT02716298|Active Comparator|lotrafilcon B|Study participants are randomized to wear lotrafilcon B lens during the crossover study.
2977085|NCT02716285|Experimental|Tempocol-ColoPulse® (Peppermint oil)|Colon-targeted-delivery capsule containing 182mg of Peppermint Oil, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
2977086|NCT02716285|Experimental|Tempocol® (Peppermint oil)|Enteric-coated capsule containing 182mg of Peppermint Oil, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
2977087|NCT02716285|Placebo Comparator|Placebo|Capsule containing microcrystalline cellulose, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
2977088|NCT02716272|Experimental|MONOTHERAPY ARM|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
2977089|NCT02716272|Experimental|COMBINATION ARM|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
2977090|NCT02716259|Experimental|Scaling and root planing|Two sessions of scaling and root planing under local anesthesia and oral antiseptics (clorhexidine 0.12% rinse),
2977091|NCT02716259|Placebo Comparator|Supragingival prophylaxis|Two sessions of supragingival prophylaxis under local anesthesia and an oral rinse with no antiseptic properties.
2977092|NCT02716246|Experimental|Cohort 1 Low Dose|"Open-label, dose-escalation clinical trial of scAAV9.U1a.hSGSH injected intravenously through a peripheral limb vein~• Cohort 1 (Low Dose): 0.5 X 10^13 vg/kg (n=3 subjects)"
2977093|NCT02716246|Experimental|Cohort 2 Mid Dose|"Open-label, dose-escalation clinical trial of scAAV9.U1a.hSGSH injected intravenously through a peripheral limb vein~• Cohort 2 (Mid Dose): 1 X 10^13 vg/kg (n=3 subjects)"
2977094|NCT02716246|Experimental|Cohort 3 High Dose|"Open-label, dose-escalation clinical trial of scAAV9.U1a.hSGSH injected intravenously through a peripheral limb vein~• Cohort 3 (High Dose): 3 X 10^13 vg/kg (n=9-12 subjects)"
2977095|NCT02716233|Active Comparator|Arm 1|pegaspargase 2500 IU/m2 x 1: infusion of a conventional dose of pegaspargase during induction therapy: 2500 IU/m2x1
2977096|NCT02716233|Experimental|Arm 2|pegaspargase 1250 IU/m2 x 2: fractionation of the 2500 IU/m2 pegaspargase dose in two infusions of 1250 IU/m2 each
2977097|NCT02716220|Experimental|'Percutaneous Coronary Intervention' /Scaffold Implantation|PCI for enrolled subjects: implantation of the DREAMS 2G Drug-Eluting Coronary Scaffold System
2977098|NCT02716207|Experimental|Maximal tolerated dose with CyberKnife|SBRT will be delivered in 5 fractions within 1 to 2 weeks by the following schedule: Doses of 7 Gy, 7.5 Gy, 8 Gy, 8.5 Gy, 9 Gy, 9.5 Gy x 5 with BED10 in correspondence to 59.5 Gy, 65.6 Gy, 72 Gy, 78.6 Gy, 85.5 Gy, 92.6 Gy respectively while meeting with normal tissue constraints. A minimum of three patients will be included for each dosage level. And an interval is four weeks between each dose level. In case patient presents III/IV GI toxicity, three additional patients will be included at the same dose level. The Maximal Tolerated Dose will be defined as the dose for which at least 2 patients in 3, or at least 3 patients in 9, will present with a limiting toxicity.
2977099|NCT02716194|Experimental|Cohort 1 - Low dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
2977100|NCT02716194|Experimental|Cohort 2 - Medium dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
2977101|NCT02716194|Experimental|Cohort 3 - High dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
2977102|NCT02716181|Active Comparator|"Атопик phase 1"|"For the first phase of the study, subjects will be randomized to receive treatment with Атопик Soothing Cream."
2977103|NCT02716181|Placebo Comparator|Placebo - phase 1|For the first phase of the study, subjects will be randomized to receive treatment with Placebo Cream.
2977104|NCT02716181|Active Comparator|"Атопик phase 2"|"The second phase of the study is an open-label extension with all subjects receiving Атопик Soothing Cream."
2977105|NCT02716181|Placebo Comparator|Placebo - phase 2|"The second phase of the study is an open-label extension with all subjects receiving Атопик Soothing Cream."
2977106|NCT02716168|Experimental|Video consultation|Video consultation between cancer patient, general practitioner and oncologist at the start of chemotherapy treatment
2977107|NCT02716168|No Intervention|usual care|Usual care. The patients General Practitioner will receive standard discharge summary and ambulant notes from the oncologist specialist
2977108|NCT02716142|Experimental|Group A|rectal misoprostol 400 microgram
2977109|NCT02716142|Active Comparator|Group B|sublingual misoprostol 400 microgram
2977110|NCT02716129|Active Comparator|Group 1|Morphine group
2977111|NCT02716129|Active Comparator|Group 2|Morphine plus Nalbuphine group
2977112|NCT02716116|Experimental|Dose Escalation Cohort|AP32788 treatment for patients with advanced NSCLC.
2977113|NCT02716116|Experimental|Expansion Cohort 1|AP32788 treatment for NSCLC patients with epidermal growth factor receptor (EGFR) exon 20 activating insertions and no active, measurable central nervous system (CNS) metastases.
2977114|NCT02716116|Experimental|Expansion Cohort 2|AP32788 treatment for NSCLC patients with human epidermal growth factor receptor 2 (HER2) exon 20 activating insertions or point mutations and no active, measurable CNS metastases.
2977115|NCT02716116|Experimental|Expansion Cohort 3|AP32788 treatment for NSCLC patients with EGFR exon 20 activating insertions or HER2 exon 20 activating insertions or point mutations and active, measurable CNS metastases.
2977116|NCT02716116|Experimental|Expansion Cohort 4|AP32788 treatment for NSCLC patients with other targets against which AP32788 is active (examples include EGFR exon 19 deletions or exon 21 substitutions [with or without T790M mutations] and other uncommon EGFR activating mutations), with or without active, measurable CNS metastases.
2977117|NCT02716103||Initial Cohort: feasibility|Bone marrow collection and peripheral blood collection from ten patients with untreated AL amyloidosis will be evaluated to determine feasibility of isolating a plasma cell clone. An additional three teaspoons of bone marrow and 4 teaspoons of blood will be collected at the time of standard blood draw and bone marrow biopsy before receiving any treatment. There will be no extra procedures or visits specifically for this research.
2977118|NCT02716103||2nd Cohort - pre-treatment|If feasibility is determined with initial cohort, bone marrow collection and peripheral blood collection from 20 patients with untreated AL amyloidosis who are scheduled to undergo antineoplastic therapy will be evaluated to isolate a plasma cell clone. An additional 3 teaspoons of bone marrow and 4 teaspoons of blood will be collected at the time of standard blood draw and bone marrow biopsy before receiving therapy. For those who complete therapy and achieve complete response or very good partial response, subsequent samples of bone marrow and peripheral blood will be sent for minimal residual disease detection (based on the previously identified cancer clone) at 6 to 12 months post treatment.
2977119|NCT02716090|Experimental|Dalap Duo®|0.1% of adapalene and 2.5% and benzoyl peroxide gel cream. Apply the product on the areas affected by acne once a day in the evening for 84 days.
2977120|NCT02716090|Active Comparator|Epiduo®|0.1% of adapalene and 2.5% and benzoyl peroxide gel. Apply the product on the areas affected by acne once a day in the evening for 84 days.
2977121|NCT02716064|Experimental|TAP-CM Intervention|Patients in this arm will be encouraged to complete the Healthy Lifestyle App modules and use McMaster PHR to self manage their chronic disease. Participants will also be completing the health and life goals using the App. The TAPESTRY-CM reports generated will then be reviewed by the clinic huddle teams
2977122|NCT02716051|Experimental|MRI|Wholebody MRI with cardio-pulmonary synchronization At day 1 , at the afternoon, patient will undergo an MRI analysis.
2977123|NCT02716051|Active Comparator|PET|At day 1 , in the morning, patient will undergo an PET analysis
2977124|NCT02716038|Experimental|MPDL3280A, Carboplatin, Nab-paclitaxel|"Subjects with advanced or recurrent cancers receiving:~MPDL3280A every 21 days for up to 84 days~Carboplatin every 21 days for up to 84 days~Nab-paclitaxel every 7 days for up to 84 days"
2977125|NCT02716025||Case Group|
2977126|NCT02716025||Control Group|
2977127|NCT02716012|Experimental|MTL-CEBPA|
2977128|NCT02715999|Active Comparator|Quadratus Lumborum Block|Quadratus Lumborum block group (QL) patients will receive unilaterally Quadratus Lumborum block using Bupivacaine 0.2 %
2977129|NCT02715999|Active Comparator|Transversus abdominis plane block|Transversus abdominis plane block (TAP) patients will receive unilaterally TAP block using Bupivacaine 0.2 %
2977130|NCT02715986|Experimental|Severly depressed patients|Recruitment of twenty depressive subjects will be conducted within the hospital service adult psychiatry.These patients are referred for indication of ECT sessions for severe resistant depression. Four MRI evaluations (3T MRI examination) are programmed in such patients to analyze structural changes in the hippocampus.
2977131|NCT02715973|Experimental|Nutritional Supplement|"Diet Counseling (Energy=200 kcal/kg/day, (present weight) protein =3-4 gm/kg/day)~Nutritional supplement (Providing extra 40 kcal/kg/day)"
2977132|NCT02715973|Active Comparator|Standard nutritional treatment|"Diet counselling only (Energy=200 kcal/kg/day (present weight) protein =3-4 gm/kg/day).~Standard nutritional treatment"
2977133|NCT02715960|Experimental|single-arm|intervention: open registry, non-randomized, single-arm trial. Acitretin Capsules: 2.5 per piece.
2977134|NCT02715947|Experimental|single-arm|intervention: open registry, non-randomized, single-arm trial.Methotrexate:2.5mg per piece, oral.
2977135|NCT02715934|Experimental|Glucose to Goal|Three diabetes educators will be assigned to the Glucose to Goal/experimental arm. The educators will each identify two primary care practices of mid to large size to participate in the Glucose to Goal intervention. Patients will not be formally recruited or enrolled. Rather, information documented in the electronic medical record system will be extracted to evaluate patient-level outcomes. Based on a random sampling of mid to large size primary care practices in study communities, an estimated 2,200 patients with diabetes per study group will meet eligibility criteria for DSME referral.
2977136|NCT02715934|Other|Control Group|Two usual care diabetes educators will each identify three primary care practices of mid to large size to include in the control arm and participate in the usual care intervention. Uneven group assignment accounts for the amount of time (one day equivalent/per week) that the intervention diabetes educators will devote to each primary care practice versus the full-time availability of the usual care diabetes educators to see patients at the outpatient, hospital-based program. Like the experimental arm, an estimated 2,200 patients with diabetes will meet eligibility criteria for DSME referral. Patients will not be formally recruited or enrolled into the control arm; data will be extracted from the electronic medical record system to evaluate patient-level outcomes.
2977137|NCT02715921|Experimental|Cystic fibrosis patients|Receive tele-exercise training and undergo pulmonary function testing and exercise testing
2977142|NCT02715882|Experimental|1 injection of CBLB502 0.35 μg/kg|One subcutaneous injection of CBLB502 0.35 μg/kg (not more 30 μg/injection) or Placebo at Day 1 before tumor removal
2977143|NCT02715882|Experimental|1 injection of CBLB502 0.45 μg/kg|One subcutaneous injection of CBLB502 0.45 μg/kg (not more 40 μg /injection) or Placebo at Day 1 before tumor removal
2977144|NCT02715882|Experimental|2 injections of CBLB502 0.35 μg/kg|Two subcutaneous injections of CBLB502 0.35 μg/kg (not more 30 μg/injection) or Placebo at Day 1 and Day 4 before tumor removal
2977145|NCT02715882|Experimental|2 injections of CBLB502 0.45 μg/kg|Two subcutaneous injections of CBLB502 at 0.45 μg/kg (not more 40 μg /injection) or Placebo at Day 1 and Day 4 before tumor removal
2977146|NCT02715869|Active Comparator|A pharmacologic cardiac preconditioning|Sevoflurane as a pharmacologic preconditioner for the heart
2977147|NCT02715869|Active Comparator|B ischeamic preconditioning|ischemic preconditioning by inflation the cuff of blood pressure
2977148|NCT02715856|Other|Group 1 - Control Group|"About 2, 6, 12, and 24 weeks after surgery, participant has standard follow-up visits. At these visits, participant asked to perform different physical tasks. Physical therapist will observe one of the walking tests.~After each visit, participant completes a survey about their physical and emotional health as well as their pain. At the end of the study, participant completes a survey regarding the study."
2977149|NCT02715856|Experimental|Group 2 - Mobile Devices|"At a clinic visit before surgery, participant taught how to take photos of their surgical wounds and make videos using a mobile device.~About 2, 6, 12, and 24 weeks after surgery, participant has standard follow-up visits. At these visits, participant asked to perform different physical tasks. Physical therapist will observe one of the walking tests. After each visit, participant completes a survey about their physical and emotional health as well as their pain.~At weeks 3, 7, 13, and 25 participant uses a mobile device to send the study staff photos of their surgical wound and videos of their walking tests.~At the end of each follow-up visit, participant completes an electronic questionnaire about their quality of life. At the end of the study, participant completes a survey regarding the study and use of the mobile device.~A video conference held with physician at Weeks 3, 7, 13, and 25."
2977150|NCT02715830|Experimental|One Artery|In this arm after obtain the good result after the angioplasty of one artery the procedure stops
2977151|NCT02715830|Experimental|More than one artery|In this arm, after obtain a good result of the angioplasty of one artery, we continue trying one or two more arteries
2977152|NCT02715817|Active Comparator|Virtual Rehabilitation - VR|"A virtual rehabilitation program (G0) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The G0 treatment program consists of the following protocols: a) protocol 1 games (Balance Bubble Plus and Tennis); b) protocol 2 games (Rhythm Parade and Boxing)."
2977153|NCT02715817|Active Comparator|Conventional Therapeutic Exercises - CTE|A program of conventional therapeutic exercises (G1) for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The G1 treatment program consists of the following protocols: a) protocol 1: 30 minutes of upper limb PNF diagonal exercise (flexion-abduction-external rotation and extension-abduction-internal rotation), and 10 minutes of scapula PNF diagonal exercise (anterior and posterior elevation); b) protocol 2: 20 minutes of lower limb PNF diagonal exercise (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes of pelvis PNF diagonal exercise (anterior and posterior depression), and 10 minutes gait cycle training;
2977154|NCT02715817|Experimental|VR and CTE|In G2 program will be performed 20 minutes G0 protocol (1 or 2, used alternately between sessions a week) and 20 minutes G1 protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols.
2977155|NCT02715804|Experimental|PEGPH20 + nab-paclitaxel + gemcitabine|
2977156|NCT02715804|Active Comparator|Placebo + nab-paclitaxel + gemcitabine|
2977157|NCT02715791|Other|Usual Care|Patients randomized to the control group will receive usual care and upon the end of study will receive access to the Healthy Lifestyle App and the McMaster PHR
2977158|NCT02715791|Other|TAP-HC-DM|Patients randomized to the intervention group will get TAP-HC-DM intervention from time zero
2977159|NCT02715778||Adult Participants|
2977160|NCT02715778||Child Participants|
2977161|NCT02715765|Sham Comparator|Sham|The sham procedure involves only 40 sec direct current stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec.
2977162|NCT02715765|Experimental|Active tDCS|Current (2mA) is initiated in a ramp-like fashion over 10s from 0mA to 2mA using (SPONSTIM-25 25cm2 electrodes). The current is held constant for 20 min. Then the current is decreased in a ramp-like fashion over 10s from 2mA to 0mA.
2977163|NCT02715765|Experimental|Active tRNS|Current (2mA) is initiated in a ramp-like fashion over 10s from 0mA to 2mA using (SPONSTIM-25 25cm2 electrodes). Once at 2mA, an alternating current of 2mA with a 0mA offset is applied at random frequencies over a range of 0.1 to 100 Hz. This is performed for 20 minutes. Then the current is decreased in a ramp-like fashion over 10s from 2mA to 0mA.
2977164|NCT02715752||Herpes Simplex Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
2977165|NCT02715752||Human Papillomavirus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
2977166|NCT02715752||Epstein-Barr Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
2977167|NCT02715752||Cytomegalovirus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
2977168|NCT02715752||Varicella Zoster Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
2977169|NCT02715739||All participants|
2977170|NCT02715726|Experimental|Alirocumab + Placebo|Alirocumab subcutaneous (SC) injection plus ezetimibe placebo administered daily, orally. Background statin therapy (atorvastatin, rosuvastatin, or simvastatin) continued during the course of the trial
2977171|NCT02715726|Active Comparator|Placebo + Ezetimibe|Alirocumab placebo injection through SC administration plus ezetimibe administered daily, orally. Background statin therapy (atorvastatin, rosuvastatin, or simvastatin) continued during the course of the trial
2977172|NCT02715713||testosterone deficiency group|Men between the ages of 40 to 80-years-old with testosterone deficiency
2977265|NCT02715115|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
2977173|NCT02715713||prostate cancer group|Men between the ages of 40 to 80-years-old with prostate cancer that will result in testosterone deficiency due to surgical or pharmacological castration.
2977174|NCT02715700|Experimental|Maintenance Methadone and MK-1439|Participants receiving a stable methadone maintenance regimen for at least 2 weeks will receive the same formulation and dose of methadone at the study site from Day 1 through Day 7, and will then continue receiving their maintenance methadone at their usual clinic through the end of the study. Beginning on Day 2, participants will receive once daily MK-1439 tablet co-administered (within 5 minutes) with their methadone, for 5 days.
2977175|NCT02715687|Placebo Comparator|Placebo|Will receive 30 days treatment with oral placebo of 200mg
2977176|NCT02715687|Active Comparator|Interventional|Will receive 30 days treatment with oral Amiodarone of 200mg
2977177|NCT02715674|Placebo Comparator|control group|take 4lt/min oxygen with Plasti-med oxygen therapy mask
2977178|NCT02715674|Active Comparator|IS group|in postoperatively, patients will carry out Plasti-med TRIFLO 5 min per hour for 6 hours.
2977179|NCT02715674|Active Comparator|CPAP group|in postoperatively, patients will carry out 10 cmH2O noninvasive continuous positive airway pressure with BIPAP VISION 5 min per hour for 6 hours.
2977180|NCT02715661|Active Comparator|Coronary artery disease|those with a diagnosis of coronary artery disease having been hospitalized for a cardiac event. The intervention is six-month interval of exercise .
2977181|NCT02715661|Active Comparator|Metabolic Syndrome|Metabolic Syndrome patients are defined by having Systolic Blood Pressure (SBP)>130 and/or Diastolic Blood Pressure (DBP)>85 mmHg and any two of the following criteria: Abdominal obesity (waist circumference >102cm in males;>88cm in females), Fasting triglycerides > 1.695 mmol/L, Low HDL cholesterol: Males < 1.04 mmol/L; Females < 1.29 mmol/L, Fasting glucose >5.60 mmol/L. Participants will be assigned randomly into an exercise and a delayed exercise intervention, 6 months.
2977182|NCT02715661|Active Comparator|Health Control|Control individuals will have no diagnosis of cardiac, vascular, metabolic, inflammatory or neurological disease, and have not been on any medication for such conditions in the past 12 months. Participants will be assigned randomly into an exercise and a delayed exercise intervention, 6 months.
2977183|NCT02715648|No Intervention|No Phenazopyridine before cystoscopy|This group will not receive phenazopyridine prior to cystoscopy
2977184|NCT02715648|Experimental|Phenazopyridine before cystoscopy|This group will receive 200mg of phenazopyridine prior to cystoscopy
2977185|NCT02715635|Active Comparator|Nitrate-rich beetroot juice|"Biological: Typhoid vaccine The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution Other Name: Typhim Vi®~Dietary Supplement: Concentrate beetroot Juice 140 ml containing ~8 mmol of inorganic nitrate"
2977186|NCT02715635|Placebo Comparator|Nitrate-deplete beetroot juice|"Biological: Typhoid vaccine The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution Other Name: Typhim Vi®~Dietary Supplement: Concentrate beetroot Juice 140 ml which is nitrate-depleted"
2977187|NCT02715622||Open Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia open repair surgical procedure
2977188|NCT02715622||Laparoscopic Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia laparoscopic repair surgical procedure
2977189|NCT02715622||Robotic Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia robotic-assisted laparoscopic repair surgical procedure
2977190|NCT02715609|Experimental|DSF, Cu, Surgery, RT, TMZ|"DSF (dose level (DL) 1=125mg, DL 2=250mg, DL 3=375 mg, DL 4=500mg). DSF starts at DL 2 and escalated using the Time-to-Event Continual Reassessment Method~3 day lead-in of oral DSF once daily (QD) prior to surgery (optional)~2 mg Cu gluconate 3 times daily (TID) on days when DSF is given (optional pre-surgery)~Surgery performed per routine clinical care.~After surgery, evaluation to confirm the final pathological diagnosis as GBM (if not the patient will not continue with the 2nd part of the study).~RT 4-6 weeks following surgery at 60 Gy in 30 daily fractions.~TMZ from Day 1 of RT to the last day of RT at a daily oral dose for a maximum of 49 days as per standard clinical care.~DSF QD and Cu TID during chemoradiotherapy as per preoperative dose~4-6 weeks after completion of chemoradiotherapy, adjuvant TMZ may be administered for 6 cycles. TMZ on Days 1-5 of every 28-day cycle. Daily DSF of 500mg will be continued with adjuvant TMZ for up to 6 cycles."
2977191|NCT02715596|Experimental|Intervention A|2.7 g EPA supplementation in a 15 cc emulsion stick-pack
2977192|NCT02715596|Placebo Comparator|Intervention B|Placebo supplementation in a 15 cc emulsion stick-pack
2977193|NCT02715570|Experimental|Single dose - healthy volunteers|
2977194|NCT02715570|Experimental|Repeat dose - healthy volunteers|
2977195|NCT02715570|Experimental|Single dose - asthmatic patients|
2977196|NCT02715557|Experimental|Full Access to the relapse prevention program|The participants will receive access to the relapse prevention program throughout the entire 6-week trial period.
2977197|NCT02715557|Experimental|TAU|The participants will receive treatment as usual (TAU) for 6-weeks, and will receive access to the relapse prevention program after the completion of the 6 month follow-up.
2977198|NCT02715544|Experimental|Intervention group|The group will receive healthy lifestyle intervention
2977199|NCT02715544|Active Comparator|control group|Other: physical activity and dietary guidelines
2977200|NCT02715531|Experimental|Arm A (Hepatocellular Carcinoma [HCC], All subtypes)|Participants with advanced or metastatic and/or unresectable HCC who have received no prior treatment are non-randomized and will receive atezolizumab and bevacizumab, every 3 weeks (q3w), each cycle of 21 days, as long as participants are experiencing clinical benefit in the opinion of the investigator.
2977221|NCT02715414|Active Comparator|Multiple Family Group (MFG)|A multiple family group (MFG) is a 12-week, family-centered, group delivered intervention consists of six to eight families (caregiver/child dyads). Groups meet for approximately two hours per week, and sessions focus on targeting family-level factors that are associated with child problem behaviors. Specifically, eight of the 12 sessions are devoted to establishing rules (family organization, consistent discipline), responsibilities (inter-connectedness, expectancies), relationships (family warmth, within family support), respectful communication (family communication and conflict). An additional four sessions are focused on factors that impact the ability of families to incorporate new behaviors (family stress and social support).
2977266|NCT02715115|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water for Injection
2977201|NCT02715531|Experimental|Arm B (Gastric Cancer)|Participants with previously untreated human epidermal growth factor receptor 2 (HER2)-negative adenocarcinoma of the stomach or gastroesophageal junction (GEJ) are non-randomized and will receive atezolizumab, bevacizumab, and FOLFOX (oxaliplatin, leucovorin, and 5-fluorouracil [FU]), every 2 weeks (q2w), each cycle of 28 days, as long as participants are experiencing clinical benefit in the opinion of the investigator. Oxaliplatin will be administered for up to 8 cycles. After 6 months, at discretion of investigator, capecitabine may be administered as maintenance therapy without oxaliplatin instead of infusional 5-FU and leucovorin, and biologic therapy may be given every 3 weeks (q3w). In the event that a patient experiences unacceptable toxicity after replacement of infusional 5-FU and leucovorin with capecitabine, the patient may be allowed to switch back to 5-FU and leucovorin following investigator discussion with the Medical Monitor.
2977202|NCT02715531|Experimental|Arm C (Metastatic Pancreatic Cancer)|Participants with previously untreated metastatic pancreatic cancer are non-randomized and will receive atezolizumab q2w starting on Day 1, Cycle 1 (each cycle of 28 days). Administration of nab-paclitaxel followed by gemcitabine will occur on Days 1, 8, and 15 of each cycle (3-weeks-on/1-week-off schedule). Treatment consisting of atezolizumab with gemcitabine and nab-paclitaxel may be continued as long as participants are experiencing clinical benefit in the opinion of the investigator.
2977203|NCT02715531|Experimental|Arm E (Randomized Metastatic Esophageal Cancer)|Participants with squamous metastatic esophageal cancer (mEC) will be randomized (1:1) into Group E1 and Group E2. All participants with metastatic adenocarcinoma of esophageal carcinoma or GEJ Siewert Classification Type I will be enrolled into Group E3. In Groups E1 and E3, participants will receive atezolizumab and FOLFOX, q2w, each cycle of 28 days, as long as participants are experiencing clinical benefit in opinion of the investigator. Oxaliplatin will be administered for up to 8 cycles. In Group E2, participants will receive atezolizumab followed by cisplatin and 5-FU q3w. Cisplatin will be administered for up to 6 cycles. Treatment with atezolizumab in combination with 5-FU may be continued as long as participants experience clinical benefit in opinion of the investigator.
2977204|NCT02715531|Experimental|Arm F (Randomized HCC)|Participants with advanced or metastatic and/or unresectable HCC who have received no prior systemic treatment will be randomized (1:1) into Group F1 and Group F2. Participants will receive atezolizumab alone (Group F2) or combined with bevacizumab (Group F1) on a q3w schedule, with dosing on Day 1 of each 21 day Cycle. Treatment with atezolizumab with or without bevacizumab may be continued as long as participants are experiencing clinical benefit in the opinion of the investigator. Participants who are randomly assigned to Group F2 (atezolizumab monotherapy) and experience investigator-assessed unequivocal radiographic progression as per RECIST v1.1 will also be given the option to cross over to atezolizumab and bevacizumab combination therapy, provided they meet the criteria for crossover and Medical Monitor approval is obtained.
2977205|NCT02715518|Active Comparator|FFR-guided strategy arm|FFR measurement for non-IRA stenosis (>50% visual estimation) will be performed by continuous infusion of adenosine (140~180ug/kg/min) or intracoronary nicorandil (2mg bolus) injection. The FFR ≤ 0.80 will be targeted for PCI using 2nd generation drug-eluting stent. In case of non-IRA stenosis > 90%, we will judge FFR value of ≤ 0.80.
2977206|NCT02715518|Active Comparator|Angiography-guided strategy arm|"Non-IRA stenosis with > 50% stenosis will be the target of PCI using 2nd generation drug-eluting stent.~As for the angiography-guided strategy arm, PCI for non-IRA stenosis will be recommended during same procedure. However, exceptions can be made for complex lesions where the operator estimates that the revascularization procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a staged procedure during the same hospitalization."
2977207|NCT02715505|Experimental|HSC835|HSC835 is an expanded umbilical cord blood product used during single umbilical cord blood transplantation
2977208|NCT02715492|Active Comparator|Transarterial Chemoembolization|1st group: included 20 patients with HCC treated by TACE only.
2977209|NCT02715492|Experimental|TACE and LMWH|2nd group: included 20 patients with HCC treated by TACE and adjuvant dose of Low Molecular Weight Heparins (LMWH).
2977210|NCT02715479|Experimental|Treatment A|Single DTG tablet under fed conditions for a specified period
2977211|NCT02715479|Experimental|Treatment B|Two BMS955176 tablets under fed conditions for a specified period
2977212|NCT02715479|Experimental|Treatment C|Single DTG tablet and Two BMS955176 tablets under fed conditions for a specified period
2977213|NCT02715466|Experimental|Gelatine|Balanced gelatine solution
2977214|NCT02715466|Active Comparator|Electrolyte|Balanced electrolyte solution
2977215|NCT02715453|Experimental|Intervention on frailty|Intervention on frailty in addition to the usual care by the cardiologist. A multidisciplinary team (physicians, nurses and physiotherapists and nutritionists) will carry out the intervention on frailty
2977216|NCT02715453|No Intervention|Control|Conventional strategy consisting only of the usual care by the cardiologist
2977217|NCT02715440|Experimental|Immediate intervention|Gradual withdrawal of benzodiazepines or related drugs : 25% reduction of the benzodiazepines dose or related drugs every 2 weeks during nine weeks in order to stop the treatment .
2977218|NCT02715440|No Intervention|Delayed intervention|usual care without intervention
2977219|NCT02715427|Active Comparator|Conventional care|"Preoperative consultation Information support conventional perioperative No bowel preparation~Day before surgery Normal diet until midnight No carbohydrate loading Premedication with anxiolytic~Operative day Conventional general anaesthesia Classic management perfused volumes Conventional use of drains at the operative site Standard nasogastric drainage Conventional analgesia protocol~Postoperative time Mobilization from J1 Progressive refeeding Progressive removal of venous, arterial and urinary catheters. Gradual recovery of the usual treatment from J1 Breathe physiotherapy depending on the clinical course No stimulation of intestinal transit"
2977220|NCT02715427|Experimental|Enhanced recovery|"Preoperative consultation Specific information about the enhanced rehabilitation No bowel preparation Immunonutrition for the 7 preoperative days~Day before surgery Minimal preoperative fasting No premedication Carbohydrate loading~Operative day Optimized general anesthesia Reduced volumes perfused Limiting use of drains at the operative site Reduced doses of morphine Local anesthetic usage No standard use of nasogastric drainage~Postoperative time Stimulation mobilization from D0 Refeeding on demand  from D0 Early removal of venous, arterial and urinary catheters. J1 recovery from the majority of the usual treatment Breathe physiotherapy from D0 to D5 Ileus prevention by chewing gum"
2977222|NCT02715414|Experimental|MFG + Clinic Implementation Team|This condition consists of service providers, directors, and clinic staff who will create site-specific plans to enhance uptake and implementation of MFG. CITs address potential barriers to implementation and adjust the format and structure of MFG as needed in order to be implemented as part of clinic care.
2977223|NCT02715414|No Intervention|Standard Care|Standard Care consists of services including outpatient individual and family therapy, which are offered as part of clinic care.
2977224|NCT02715401|Experimental|Sequence 1|"T → R~T : HCP1303 R : HGP1201 + HIP1402"
2977225|NCT02715401|Experimental|Sequence 2|"R → T~T : HCP1303 R : HGP1201 + HIP1402"
2977226|NCT02715388|Experimental|Silicon oil removal 3D visualization|
2977227|NCT02715375|Experimental|Device: CREON2000A|Child with mild to moderate asthma maintains allergy medicines and has experimental device installed in home. Will child's use of asthma medicine decrease more than the child who lives with the Device: Sham CREON2000A?
2977228|NCT02715375|Sham Comparator|Device: Sham CREON2000A|Child with mild to moderate asthma maintains allergy medicines and has sham installed in home. What impact will the Device: Sham CREON2000A have and will the child's medical use parallel that of the child with the experimental Device: CREON2000A?
2977229|NCT02715362|Experimental|TAI-GPC3-CART cells|A single dose of GPC3-CART cells will be administered by transcatheter arterial infusion(TAI) mediated as one dose infusion. The dose is 1-10x106/kg GPC3-CAR positive T cells. The infusion will be scheduled to occur 2 days after a single dose of 1.5 grams/m2 of cyclophosphamide. Patients will undergo cannula--DSA radiography--CAR-T cells perfused into hepatic artery. The cells perfusion process would last 15min to 2 h, and the specific time depends on patent's tumor-burdened state.
2977230|NCT02715349|Experimental|Psychoeducation|3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
2977231|NCT02715349|No Intervention|Control|Family and patient do not receive psychoeducation, but still receive standard hospital services for schizophrenia.
2977232|NCT02715336|Experimental|Study group: High Responders|1000 units hCG
2977233|NCT02715336|No Intervention|Control group: High Responders|1000 units hCG
2977234|NCT02715336|Experimental|Study group: Normal Responders|5000 units hCG
2977235|NCT02715336|No Intervention|Control group: Normal Responders|5000 units hCG
2977236|NCT02715336|Experimental|Study group: Low Responders|10000 units hCG
2977237|NCT02715336|No Intervention|Control group: Low Responders|10000 units hCG
2977238|NCT02715297|Experimental|Arm A: SRT to the resection cavity|Postoperative stereotactic fractionated radiotherapy (SRT) to the resection cavity to a Total Dose of 46 Gy, 2 Gy single dose, or 36 Gy in 3 Gy single dose 5 fractions/week, depending on the volume and location of the treatment region.
2977239|NCT02715297|No Intervention|Arm B: Observation|Observation without adjuvant radiotherapy.
2977240|NCT02715284|Experimental|Part 1 - Dose Escalation|"Part 1 - Dose Escalation~Part 2 of the study will be conducted in two subparts:~In Part 2A, safety and tolerability of TSR-042 at fixed dose will be evaluated.~In Part 2B, clinical activity of TSR-042 will be evaluated."
2977241|NCT02715271||Retrospective cohort|Tuberculosis patients submitted to therapeutical surgery during the last 2-5 years.
2977242|NCT02715271||Prospective cohort|Tuberculosis patients prospectively submitted to therapeutical surgery.
2977243|NCT02715258|Active Comparator|Bexagliflozin tablets, 20 mgh|Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.
2977244|NCT02715258|Placebo Comparator|Placebo tablets|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
2977245|NCT02715245|Experimental|Experimental Group|Patients with multiple chronic disease referred to Mobile Rehabilitation and Physical therapy team (MRPTT) and Nurse-led case Management in the province of Almeria that comply the inclusion criteria; as well as their caregivers.
2977246|NCT02715245|No Intervention|Control Group|Patients with multiple chronic disease and their caregivers belonging to health centers or areas where there is no figure MRPTT or Nurse-led case Management to reach this population
2977247|NCT02715232|Experimental|Female-to-Males|Female-to-Male Transsexuals receiving Testosterone treatment
2977248|NCT02715232|Experimental|Male-to-Females|Male-to-Female Transsexuals receiving Estradiol and Anti-androgen treatment
2977249|NCT02715232|No Intervention|Female Controls|Female Controls receiving no intervention
2977250|NCT02715232|No Intervention|Male Controls|Male controls receiving no intervention
2977251|NCT02715219|Experimental|intervention group|Subjects in intervention group will be given an appointment date to attend the an Asthma Education Programme.
2977252|NCT02715219|No Intervention|control group|Subjects in control group will routinely go for the normal follow up in Respiratory Clinic without receive any intervention.
2977253|NCT02715206|Experimental|Control|middle schools not receiving keepin' it REAL; continue their own programs if any.
2977254|NCT02715206|Experimental|keepin' it REAL classic|middle schools will implement keepin' it REAL classic drug prevention curriculum
2977255|NCT02715206|Experimental|keepin' it REAL rural|middle schools will implement the keepin' it REAL rural curriculum
2977256|NCT02715193|Experimental|REMD-477 Treatment A|Administered as a single SC dose in subjects with Type 1 Diabetes
2977257|NCT02715193|Placebo Comparator|Matching placebo|Administered as a single SC dose in subjects with Type 1 Diabetes
2977258|NCT02715180|Other|Chest computed tomography|Low dose chest computed tomography during expiration and inspiration
2977259|NCT02715167|Active Comparator|Group Budesonide|Inhaled corticoids
2977260|NCT02715167|Placebo Comparator|Group Placebo|Placebo by inhalation
2977261|NCT02715154|Active Comparator|Dexmedetomidine 0.5 µg/kg/h|Solution containing 5 µg/mL of dexmedetomidine was continuously infused by 0.5 μg/kg in 10 min, followed with 0.1 ml/kg/hr continuous infusion until the closure of the abdominal.
2977262|NCT02715154|Placebo Comparator|Placebo|The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal.
2977263|NCT02715128|Active Comparator|real tDCS|anode over electrode position F3, cathode over F4, 20 min, 2mA intensity
2977268|NCT02715076|Experimental|Ambient Temp 19°C & Passive Insulation|Ambient Temperature 19°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
2977269|NCT02715076|Experimental|Ambient Temp 19°C & Forced-air Warming|Ambient Temperature 19°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
2977270|NCT02715076|Experimental|Ambient Temp 21°C & Passive Insulation|Ambient Temperature 21°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
2977271|NCT02715076|Experimental|Ambient Temp 21°C & Forced-air Warming|Ambient Temperature 21°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
2977272|NCT02715076|Experimental|Ambient Temp 23°C & Passive Insulation|Ambient Temperature 23°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
2977273|NCT02715076|Experimental|Ambient Temp 23°C & Forced-air Warming|Ambient Temperature 23°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
2977274|NCT02715063|Experimental|High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 300 kcal during adaptation (first 4 weeks) and 500 kcal after week number 4 until the end of training.
2977275|NCT02715063|Active Comparator|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 300 kcal during adaptation (first 4 weeks) at 20-30% of 1 one-rep max and 500 kcal after week number 4 until the end of training, at 40-60% of one-rep max.
2977276|NCT02715063|Active Comparator|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached. Exercise will be performed at three sessions per week.
2977277|NCT02715063|Placebo Comparator|Usual clinical care|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
2977278|NCT02715050|Experimental|Group A - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group A, received program 1 before strength training, and the same program 1 after training."
2977279|NCT02715050|Experimental|Group B - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 1 before strength training, and program 2 after training."
2977280|NCT02715050|Experimental|Group C - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group C, received program 2 before strength training, and program 1 after training."
2977281|NCT02715050|Experimental|Group D - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group D, received program 2 before strength training, and program 2 after training."
2977282|NCT02715037||Acute tonsillitis|Patients referred to the tertiary care center with severe acute tonsillitis but without peritonsillar cellulitis, infectious mononucleosis, or abscess formation.
2977283|NCT02715037||Peritonsillar cellulitis|Patients referred to the tertiary care center with severe acute tonsillitis and peritonsillar cellulitis but without abscess formation.
2977284|NCT02715037||Infectious mononucleosis|Patients referred to the tertiary care center with acute tonsillitis and biochemical or serological signs of infectious mononucleosis but without abscess formation.
2977285|NCT02715037||Controls|Patients treated for conditions not related to the throat and without signs or symptoms of recent throat disease.
2977286|NCT02715024|Experimental|Tamsulosin alone|
2977287|NCT02715024|Experimental|Tamsulosin + solifenacin|
2977288|NCT02715011|Experimental|Part 1: Dose Escalation|The first cohort of subjects will receive intravenous infusions of JNJ-63709178. Each subsequent cohort will receive intravenous infusions of JNJ-63709178 at an increased dose level. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered. Subjects will receive intravenous infusion of JNJ-63709178 every two weeks or more frequently. The cycle duration is 21-28 days. Ascending doses may be given initially to minimize or prevent cytokine release syndrome.
2977289|NCT02715011|Experimental|Part 2: Dose Expansion|Subjects will receive intravenous infusion of JNJ-63709178 at the recommended Phase 2 dose(s) (RP2D).
2977290|NCT02714998|Active Comparator|Methotrexate only|Single dose of systemic Methotrexate administered to 55 patients.
2977291|NCT02714998|Active Comparator|Salpingectomy only group|Laparoscopic unilateral salpingectomy performed to 61 patients.
2977292|NCT02714998|Active Comparator|Salpingectomy following Methotrexate|15 patients underwent laparoscopic unilateral salpingectomy following unsuccessful single dose of methotrexate administration.
2977293|NCT02714985||confirmed chikungunya cases|cases with confirmed chikungunya fever and included for follow-up as per protocol
2977294|NCT02714972|Active Comparator|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
2977295|NCT02714972|No Intervention|Predictive Low Glucose Suspend|The control algorithm will run passively and not dose additional insulin. If hypoglycemia is predicted, the system will suspend the pump.
2977296|NCT02714959|Experimental|Proleukin|Proleukin (subcutaneous injection) 1.5 MIU/day from day 1 to 5 at W1 3 MIU/day from day 1 to day 5 at W3, W6, and W9
2977297|NCT02714946|Active Comparator|LA Arm|Percutaneous Laser Ablation
2977298|NCT02714946|Active Comparator|RFA Arm|Percutaneous Radiofrequency Ablation
2977299|NCT02714933|Experimental|MRI sequence Advanced ZTE|
2977300|NCT02714920|Other|DNA Repair enzyme signature|Tumor biopsies and blood samples performed specifically to determine DNA Repair enzyme signature biomarkers profiles (CHEMRAD assay)
2977301|NCT02714907|Experimental|AF assessed from Cortrium C3 data|Atrial fibrillation assessed from Cortrium C3 device data
2977302|NCT02714907|Experimental|AF assessed from Holter data|Atrial fibrillation assessed from Holter data
2977303|NCT02714894||Clozapine Responders (Non-URS)|"Definition of non-URS~(1) ≥30% decrease in the PANSS positive subscale score, CGI-severity ≤3 and CGI-Improvement ≤2 after 12 weeks of treatment."
2977304|NCT02714894||Clozapine Non-Responders (URS)|"Definition of URS~Taking clozapine for ≥ 12 weeks, attaining a plasma clozapine level ≥350 ng/ml.~CGI-Severity score of ≥4 and score of ≥4 on 2 PANSS positivesymptom items."
2977305|NCT02714894||Healthy Controls|Healthy controls will be matched as closely as possible on age and gender with participants in the patient groups.
2977306|NCT02714881|Other|Tumor necrosis factor inhibitor|Subjects who are about to start on a tumor necrosis factor inhibitor (TNFi) as part of usual care will be recruited. They will have measurements including routine lipids, advanced lipoproteins, and coronary flow reserve (CFR) before and after their TNFi.
2977307|NCT02714868|Experimental|Project TEAM Intervention|Project TEAM is a manualized intervention co- facilitated by a disability advocate and a licensed professional. The intervention includes eight group sessions and two experiential learning field trips. In addition, young adults with disabilities serve as peer mentors on field trips and contact youth weekly to support attainment of goals. Project TEAM outcomes are to: increase youths' knowledge of environmental factors and modification strategies; reduce the impact of environmental barriers on participation; increase self-efficacy and self-determination; and increase participation in a personal activity goal in the area of education, employment, or community life.
2977308|NCT02714868|Active Comparator|Matched comparison|Youth with disabilities who are matched controls will receive their typical educational or therapeutic services. Youth will receive a stipend to participate in a preferred activity in the community; youth will document what they did and with whom they participated. Attempts to control for the impact of resources on participation and goal achievement.
2977309|NCT02714842|Experimental|Radiolabelled Diclofenac tablet A|Single dose of delayed release diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
2977310|NCT02714842|Experimental|Radiolabelled diclofenac tablet B|Single dose of delayed release diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
2977311|NCT02714842|Active Comparator|Voltaren|Single dose of enteric coated diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
2977312|NCT02714842|Experimental|Radiolabelled diclofenac tablet C|Single dose of delayed release diclofenac sodium (25 mg) tablet radiolabelled with 4 MBq 99mTc
2977313|NCT02714829|Experimental|Inject BMP|ExcelOS-inject containing rhBMP-2
2977314|NCT02714829|Active Comparator|ExcelOS-inject|ExcelOS-inject without rhBMP-2
2977315|NCT02714803|Experimental|Connective tissue massage group|Connective tissue massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
2977316|NCT02714803|Active Comparator|Classic massage group|Classic massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
2977317|NCT02714803|Sham Comparator|Sham massage group|Sham massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
2977318|NCT02714777||Pediatric population from 4 to 8 years-old|Description of the Autonomic nervous system activity (parasympathetic activity)
2977319|NCT02714751|No Intervention|Observational group|
2977320|NCT02714751|Other|Group after information intervention|Control group after daily information to healthcare team
2977321|NCT02714738|Experimental|Infraclavicular Block|The patient will be positioned supine. The operating limb may be positioned abducted or adducted by side depending on operator preference and patient factors. After standard preparation, the needle will be directed towards the target area using an in-plane, short-axis technique. Local anaesthetic (lidocaine 2% with epinephrine 1:200.000) will be injected posterior to the artery with the intention achieving the U shape, cranio-postero-caudal spread. Local anaesthetic will be deposited to the lateral and medial cords as well, if required. The total dose of the local anaesthetic will be 20-30 ml, as clinically indicated.
2977322|NCT02714738|Experimental|Axillary Brachial Plexus Block|The patient will be positioned supine with the operative upper limb extended, flexed at the elbow, rested on a pillow to expose the axilla. After standard preparation, the needle will be directed towards the target area using an in-plane, short-axis technique. All four nerves in the axillary region are being blocked. The local anesthetic (lidocaine 2% with epinephrine 1:200.000, 15-25 ml) will be divided among the four nerves as clinically indicated by the spread, but at least 3 ml applied to each nerve.
2977323|NCT02714725|Placebo Comparator|Control group (Group C)|During bypass, patients in this group will receive propofol infusion 50 - 70 mcg/kg/min plus normal saline infusion
2977324|NCT02714725|Active Comparator|Group Dexmedetomidine (Group DEX)|During bypass, patients in this group will receive propofol infusion 50 - 70 mcg/kg/min plus dexmedetomidine infusion 0.5 mcg/kg/hr
2977325|NCT02714712||HCV group (Peginterferon alfa-2a)|A total of 156 chronic HCV genotype 1 or 2 patients who received Peginterferon alfa-2a (Peg-IFN alfa-2a) plus ribavirin therapy were consecutively enrolled from the gastroenterological clinics.
2977326|NCT02714712||Control Group|There were 153 healthy controls negative for anti-HCV enrolled simultaneously from the database of Health Management Center.
2977327|NCT02714699|Experimental|diclofenac potassium|oral diclofenac potassium
2977328|NCT02714699|Active Comparator|hyoscine butyl bromide|oral hyoscine butyl bromide
2977329|NCT02714699|Placebo Comparator|placebo|oral placebo
2977396|NCT02714231|Active Comparator|hyoscine|oral hyoscine butyl bromide
2977330|NCT02714686|Experimental|Radio Mass Media Family Planning Campaign|Clusters receive a three-year mass media campaign on family planning in an attempt to reduce cognitive barriers to contraception
2977331|NCT02714686|No Intervention|Control group|
2977332|NCT02714673||ADELC|Cohort of patients on long term anticoagulation and undergoing a primary hip or knee replacement.
2977333|NCT02714673||CONTROL|Cohort of patients not on long term anticoagulation and undergoing a primary hip or knee replacement.
2977334|NCT02714660||Participants with Type 2 Diabetes|Adults with type 2 diabetes will be enrolled in this mixed methods observational study.
2977335|NCT02714647|Experimental|Experimental|"This group will perform the attention demanding activity (a variant of the Simon Task) with a focus on accuracy over speed prior to practicing the motor task. Participants will also have extended deadlines (750 ms) throughout the task to ensure an accuracy preference. Participants will then perform 50 trials of the simulated feeding task where they will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90°, and 135° around the start cup as fast as possible using the non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition where each trial will consist of 15 repetitions."
2977336|NCT02714647|Sham Comparator|Control|"This group will perform the attention demanding activity (a variant of the Simon Task) with a focus on speed over accuracy prior to practicing the motor task. Participants will also have short deadlines (250 ms) throughout the task to ensure a speed preference. Participants will then perform 50 trials of the simulated feeding task where they will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90°, and 135° around the start cup as fast as possible using the non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition where each trial will consist of 15 repetitions."
2977337|NCT02714634|Experimental|methotrexate + biologic group|"Methotrexate +~biologic chosen by investigator"
2977338|NCT02714634|Active Comparator|Triple therapy|Triple therapy using 3 conventional disease modifying drugs (DMARDs)
2977339|NCT02714621|No Intervention|Feasibility of MR-HIFU for painful gynaecological metastases|Investigating whether it would be possible to use the MRgHIFU system to treat recurrent gynaecological cancers.
2977340|NCT02714621|Experimental|Treatment using MR-HIFU of painful gynaecological metastases|Testing whether MRgHIFU could be an effective treatment for the symptoms of recurrent gynaecological cancers (pain and bleeding)
2977341|NCT02714608|Experimental|Ginsenoside H dripping pills|Drug: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
2977342|NCT02714608|Experimental|Ginsenoside H dripping pills+Placebo|Drug: Ginsenoside H dripping pills ,Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
2977343|NCT02714608|Placebo Comparator|Placebo|Drug: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
2977344|NCT02714595|Experimental|S-649266|Participants will receive S-649266 2 g administered intravenously over 3 hours, every 8 hours for 7-14 days
2977345|NCT02714595|Active Comparator|Best Available Therapy (BAT)|BAT will be chosen by the investigator and may include up to three antibacterial agents for carbapenem resistant Gram-negative bacteria, intravenously administered per country-specific guidelines for 7-14 days.
2977346|NCT02714582|Experimental|Bedside shift report|"The experimental group (nurses and patients) will:~develop a tailored BSR-intervention by use of co-design, diagnostic interviews, and pilot testing~use the tailored BSR-intervention, with participation of the patient, instead of the regular nurse shift report"
2977347|NCT02714582|No Intervention|No bedside shift report|The control group will not use bedside shift report, but will use the regular nurse shift report without participation of the patient
2977348|NCT02714569|Experimental|Part A: LY3202328|A single ascending dose of LY3202328 orally, in 2 periods while fasting, and up to one period while fed.
2977349|NCT02714569|Placebo Comparator|Part A: Placebo|A single ascending dose of placebo orally, in 1 period while fasting, and up to one period while fed.
2977350|NCT02714569|Experimental|Part B: LY3202328|A multiple ascending dose of LY3202328 at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
2977351|NCT02714569|Placebo Comparator|Part B: Placebo|A multiple ascending dose of placebo at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
2977352|NCT02714543|Experimental|aloevera group|aloevera juice twice daily for 3 months. aloevera gel one scoop to be applied 3-4 times daily for 3 months
2977353|NCT02714543|Active Comparator|steroid group|intralesional injection of hydrocortisone 100mg and injection hyaluronic acid 1500IU once a week for 6 weeks with Capsules SM Fibro once daily for 3 months.
2977354|NCT02714530|Experimental|Radiotherapy combined with erlotinib|Standard treatment 3 Gy x 10 to lung tumor and mediastinal lymph nodes and erlotinib given concomitantly, 150 mg p.o. daily from the day before radiation, until the last day of radiation.
2977355|NCT02714530|Active Comparator|Radiotherapy alone|Radiotherapy 3 Gy x 10 alone
2977356|NCT02714517|Experimental|hydrotherapy|patients receive daily conventional physiotherapy and three 30- minutes sessions of in- water exercises per week, for four weeks
2977357|NCT02714517|Active Comparator|controls|patients receive daily conventional physiotherapy and three 30- minutes sessions of on- land exercises per week, for four weeks
2977358|NCT02714504|No Intervention|observational|No anti-mold prophylaxis given on the basis of results of baseline presence of skin lesions
2977359|NCT02714504|Experimental|Anti-mold prophylaxis|Anti-mold prophylaxis with either voriconazole or posaconazole for patients with baseline skin lesions in the extremities positive for Fusarium spp.
2977360|NCT02714491|Active Comparator|Music|Erigo + Music: During each stepping verticalization session the patient receives auditory stimulation (earphones) with previously preferred music
2977361|NCT02714491|Active Comparator|Metronome|Erigo + Metronome: During each stepping verticalization session the patient receives auditory stimulation (earphones) with a metronome (rhythmic with the stepping movement)
2977362|NCT02714491|Active Comparator|Silence|Erigo + Silence: During each stepping verticalization session the patient does note receive any auditory stimulation.
2977363|NCT02714478|Experimental|treatment|"3 Equistasi devices will be placed during physiotherapy, 5 times per week, for 4 weeks"
2977364|NCT02714478|Placebo Comparator|controls|"3 placebo devices will be placed during physiotherapy, 5 times per week, for 4 weeks"
2977365|NCT02714465|Experimental|Hyperbaric oxygen therapy|All patients underwent radiosurgery with clinical and instrumental signs of cerebral radionecrosis
2977366|NCT02714452|Other|Intervention|Person-centred care
2977367|NCT02714452|No Intervention|Control|Conventional care
2977368|NCT02714439|Experimental|High-Resolution Microendoscopy|After standard colposcopy examination performed, participants undergo a high-resolution microendoscopy imaging procedure. Proflavine 0.01% is applied to the cervix, then high-resolution microendoscopy imaging procedure performed. Standard colposcopy procedure will then continue.
2977369|NCT02714426|Active Comparator|Testing only|In weeks 1 and 14, participants receive: Montreal Cognitive Assessment (MoCA), Wechsler Test of Adult Reading (WTAR), Functional Activities Questionnaire (FAQ), Older Americans Resources and Services (OARS) Complete Activities of Daily Living Scale, The Short Form (36) Health Survey (SF-36), Attention measures (Attention Network Test (ANT); Continuous Performance Test (CPT); Auditory Dual Task (ADT); Mind wandering; Cued Stroop)**, Positive and Negative Affect Scale (PANAS)**, Geriatric Depression Scale (GDS), Mindfulness Attention Awareness Scale (MAAS)**, Five Facet Mindfulness Questionnaire (FFMQ)**, Emotion Regulation Questionnaire (ERQ)**, State-Trait Anxiety Inventory (STAI)**, and Starkstein Apathy Scale (AS). **Asterisked measures given in whole or part in Weeks 2-13 as well.
2977370|NCT02714426|Experimental|Mindfulness-inspired Treatment/Testing|"Participants receive all of the measures in the active comparator Testing only condition in Weeks 1-14. In weeks 4-11, participants receive Mindfulness Inspired Treatment"
2977371|NCT02714413|Placebo Comparator|Sucrose 50g + placebo|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
2977372|NCT02714413|Experimental|Sucrose 50g + D-allulose 2.5 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
2977373|NCT02714413|Experimental|Sucrose 50g + D-allulose 5.0 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
2977374|NCT02714413|Experimental|Sucrose 50g + D-allulose 7.5 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
2977375|NCT02714413|Experimental|Sucrose 50g + D-allulose10.0 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
2977376|NCT02714400|Active Comparator|Venlafaxine|50mg of Venlafaxine before sleep
2977377|NCT02714400|Placebo Comparator|Placebo|One piece of placebo before sleep
2977378|NCT02714387||ICU patients|Patients with Non Traumatic Neuro-Vascular Diseases. Medical data concerning ICU stay will be collected.
2977379|NCT02714374|Experimental|GL-ONC1|Cohort 3, 5, 7, 8, 9
2977380|NCT02714361|Active Comparator|Vitamin D3 supplement|Participants will be asked to take 1 capsule of vitamin D3 supplement (1500 IU) (37.5ug) daily for a total duration of 8 weeks.
2977381|NCT02714361|Placebo Comparator|Placebo|Participants will be asked to take 1 capsule of placebo (65% olive oil) daily for a total duration of 8 weeks.
2977382|NCT02714322|Experimental|MYL-1401A (Adalimumab)|MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
2977383|NCT02714322|Active Comparator|Humira® (Adalimumab)|Humira® initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
2977384|NCT02714309|Experimental|Control Trial|A mixed macronutrient breakfast meal is consumed without additional protein, following a period of rest. An ad libitum lunch meal is subsequently consumed.
2977385|NCT02714309|Experimental|Exercise No Preload Trial|Following an exercise bout a mixed macronutrient breakfast meal is consumed without additional protein. An ad libitum lunch meal is subsequently consumed.
2977386|NCT02714309|Experimental|Exercise With Preload Trial|Following low/moderate intensity exercise bout, whey protein (20g) administered prior to consumption of mixed macronutrient breakfast meal. An ad libitum lunch meal is subsequently consumed.
2977387|NCT02714296|Active Comparator|Group Nutridrink 200ml|50 patients: two days before the investigation is assigned to a diet with the use of specialized clinical nutrition Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
2977388|NCT02714296|Active Comparator|Group Nutridrink compact protein|two days before the study is assigned diet with the addition of specialized clinical nutrition Nutridrinc compact protein 125 ml 2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
2977389|NCT02714296|No Intervention|Group control|only diet without receiving specialized nutrition
2977390|NCT02714283||Non-CF bronchiectasis patients|Complete national 2006-2014 Medicare data from Part A, B and D will be obtained from CMS. We will use bronchiectasis ICD-9 codes 494.0 and 494.1 to identify patients with bronchiectasis within Medicare. From this identified bronchiectasis cohort, we will exclude patients with cystic fibrosis (ICD-9 codes 277.00-277.09), HIV infection (042), and a history of organ transplant (V42.0, V42.1, V42.6, V42.7, V42.8).
2977391|NCT02714270|Active Comparator|modified partograph|routine modified partograph
2977392|NCT02714270|Active Comparator|paperless partograph|paperless partograph with no graph paper
2977393|NCT02714257|No Intervention|Enhanced Usual Care - control group|Participants will receive enhanced usual care by reviewing three printed pamphlets on fall risks and recommendation to exercise. In addition, to maximize patient safety, the investigators will communicate the baseline bone density results (measured by Dual-energy X-ray absorptiometry, DXA) to the patient's primary care provider, and any critical values of a baseline measure.
2977394|NCT02714257|Experimental|Enhanced Usual Care plus Exercise Coaching Intervention|Participants will receive the three printed pamphlets on fall risks and exercising in groups (same as the controls) plus: (1) an exercise program that includes strength, balance, and aerobic exercises; (2) an exercise coach that provides in-person and telephone support/feedbacks to enhance participation in the exercise program; and (3) regular progress reports sent by coaches by fax/Electronic Health Records every 4 months, to communicate the patient's progress.
2977395|NCT02714231|Experimental|diclofenac|oral diclofuhenac sodium
2977397|NCT02714218|Experimental|Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg IV|Specified dose on specified days
2977398|NCT02714218|Experimental|Ipilimumab 3 mg/kg IV + Nivolumab 1 mg/kg IV|Specified dose on specified days
2977399|NCT02714218|Experimental|Nivolumab 6 mg/kg IV + Ipilimumab 1 mg/kg|Specified dose on specified days
2977400|NCT02714205|Experimental|Transdermal Nitroglycerin|Daily transdermal nitroglycerin patch, starting at 0.2 mg/hr. Dose escalation up to 0.6 mg/hr.
2977401|NCT02714205|Placebo Comparator|Placebo|Daily transdermal placebo patch.
2977402|NCT02714192|Experimental|BCTT|Participants received an standardized exercise stress test within 7 days of concussive injury. Stress test is stopped when participant experiences any exacerbation of symptoms. Heart rate at time of symptom exacerbation is referred to as the threshold heart rate (THR). Stress test is known as the Buffalo Concussion Treadmill Test.
2977403|NCT02714192|No Intervention|No BCTT|All participants in the no intervention arm did not get assessed using the BCTT until they had fully recovered or when they had their second clinic visit fourteen days after their first visit.
2977404|NCT02714179|Active Comparator|Group Preemptive (Group PE),|Group I: i.V. paracetamol 1 g (100 ml) was given 30 min before induction of anesthesia.
2977405|NCT02714179|Active Comparator|Group Preventive (Group PV),|Group II: i.V. paracetamol 1 g (100 ml) was given before the end of surgery.
2977406|NCT02714166|Experimental|Sunscreen lotion Sun Protection Factor 50 (BAY987521)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
2977407|NCT02714166|Other|Ophthalmic Ointment|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
2977408|NCT02714153|Experimental|Bridge Occlusion Balloon|Bridge Balloon catheter is designed to be used for temporary vessel occlusion of the superior vena cava in applications including perioperative occlusion and emergency control of hemorrhage associated with vascular tears that may occur during lead extraction procedures.
2977409|NCT02714140|Experimental|Group A: More preferred Existing + Common|Group A participants will be offered the common option and 3 currently available testing options that are targeted at the distribution of preferences among participants.
2977410|NCT02714140|Experimental|Group B: More preferred Enhanced + Common|"Group B participants will be offered the common option and 3 preference-informed enhanced testing options, which include combinations of features that may not yet be available in the study area."
2977411|NCT02714140|Active Comparator|Group C: Less preferred + Common|Group C participants will be offered the common option and 3 predicted less-preferred options. With the common option being the best option in Group C, this group is effectively a non-PB-HCT comparison group.
2977412|NCT02714127||Cases|"Women (25-64 years old) with abnormal cytology results and/or (high risk) HPV infection refered for colposcopy, and hence possibly diagnosed with an (high risk) HPV infection and/or cervical (pre)cancerous lesions.~No clinical evaluations/interventions will be performed by our research group. Participants have an already scheduled colposcopy exam. However, this visit is not an extra investigation that the participants should undergo when participating in the study."
2977413|NCT02714127||Controls|"Healthy women (25-64 years old), falsely diagnosed with abnormal cytology and/or (high risk) HPV infection, but referred for colposcopy, are included as negative controls. Based on a specificity of 76.14% of the HPV type-specific PCR (polymerase chain reaction) used, an estimated 24 out of these 100 participants will be incorrectly scheduled for colposcopy and serve as the control group.~No clinical evaluations/interventions will be performed by our research group. Participants have an already scheduled colposcopy exam. However, this visit is not an extra investigation that the participants should undergo when participating in the study."
2977414|NCT02714114||Cases: HPV vaccinated group|"Women (18-26 years old) whom are previously vaccinated with the bivalent (Cervarix) or quadrivalent (Gardasil) prophylactic HPV vaccine.~No clinical evaluations will be performed."
2977415|NCT02714114||Controls: HPV unvaccinated group|"Women (18-26 years old) whom are not vaccinated with the bivalent (Cervarix) or quadrivalent (Gardasil) prophylactic HPV vaccine.~No clinical evaluations will be performed."
2977416|NCT02714101|Experimental|Equine assisted occupational therapy|Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
2977417|NCT02714088|Experimental|Intervention|Participants will undertake a high-intensity interval training intervention, completing two exercise sessions per week for 12 weeks. The exercise sessions will consist of 4 sets of 4-6 repetitions of 60s (45s high-intensity exercise, followed by 15s rest), interspersed with 3 minutes rest. During each exercise repetition participants will be encouraged to reach >90% of their maximal heart rate.
2977418|NCT02714088|No Intervention|Control|Participants will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet.
2977419|NCT02714075|Experimental|Iron fortified rice|Administration of iron fortified rice to all subjects; subjects will act as their own controls and each subject will receive all foreseen treatments/interventions.
2977420|NCT02714062|Placebo Comparator|Placebo|Days 1-56: Placebo
2977421|NCT02714062|Experimental|VI-0521 Mid Dose|"Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)~Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)"
2977422|NCT02714062|Experimental|VI-0521 Top Dose|"Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)~Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)~Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)~Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)"
2977423|NCT02714049|Experimental|flibanserin|Subjects meeting inclusion/exclusion criteria who respond to flibanserin will have a total of 20 weeks of open label drug
2977424|NCT02714049|Experimental|flibanserin and sex therapy|Subjects meeting inclusion/exclusion criteria who respond to flibanserin will have a total of 20 weeks of open label drug as well as 9 sex therapy visits
2977425|NCT02714036|Experimental|MN-166 (ibudilast)|MN-166 (ibudilast) 10 mg capsules administered orally. Fifty (50) mg b.i.d. (5 capsules) in the morning and 50 mg b.i.d. (5 capsules) evening will be administered for a total daily dose of 100 mg/d. Study drug dosing may vary based on individual tolerability.
2977426|NCT02714023|Active Comparator|Normal Saline|Patients were randomized to receive normal saline as an irrigation solution during appendectomy.
2977563|NCT02713139|Experimental|Colpistatin 5DT|
2977564|NCT02713139|Active Comparator|Gynecological Flagyl|
2977427|NCT02714023|Active Comparator|Sterile Water|Patients were randomized to receive sterile water as an irrigation solution during appendectomy.
2977428|NCT02714023|No Intervention|No irrigation used|Patients who do not receive any irrigation at time of operation.
2977429|NCT02714010|Experimental|Arm 1|Patients take EGFR-TKI alone till tumor progression
2977430|NCT02714010|Active Comparator|Arm 2|Patients take EGFR-TKI concurrent with whole brain radiotherapy (WBRT) till tumor progression, WBRT started within the first week of taking TKI
2977431|NCT02713997|No Intervention|Standard Care|Patients in the standard care arm will undergo the usual procedure of TPIAT with no ancillary therapies provided.
2977432|NCT02713997|Experimental|etanercept|Patients in the etanercept arm will undergo the usual procedure of TPIAT with additional therapy of etanercept.
2977433|NCT02713997|Experimental|alpha-1 antitrypsin|Patients in the alpha-1 antitrypsin arm will undergo the usual procedure of TPIAT with additional therapy of alpha-1 antitrypsin (Aralast NP)
2977434|NCT02713984|Experimental|HER2 positive cancers|Patients with relapsed and refractory cancer of HER2 expression will be treated with anti-HER2 CAR-T cells
2977435|NCT02713971|Experimental|Gamepad|Biofeedback rehabilitation with Gamepad system.
2977436|NCT02713971|Active Comparator|Control|Conventional physiotherapy.
2977437|NCT02713958|Experimental|Tele rehabilitation|Telerehabilitation:The subjects in the study group will receive two treatments in Telerehabilitation and one treatment in the clinic weekly . At home they will be asked practice daily active exercises with the Meditouch Ltd. system.
2977438|NCT02713958|Active Comparator|rehabilitation|Traditional Occupational Therapy:The subjects in this group will receive three treatments in the clinic every week. At home they will be asked to practice daily active exercises in the same level of difficulty and duration as the study group but without the Meditouch Ltd. system
2977439|NCT02713945|Experimental|Simvastatin|Simvastatin administrated orally at 10 mg once a day in the morning during the first month Simvastatin administrated orally at 20 mg once a day in the morning during the second month During months 3 to 12, the dose will be fixed at 20 mg per day for children aged 12 years and younger and 40 mg for adolescent older than 12 years.
2977440|NCT02713945|Placebo Comparator|Control|Placebo administrated orally once daily in the morning
2977441|NCT02713932||Transcatheter aortic valve implantation|
2977442|NCT02713919|Experimental|Intervention Group|Adapted German PRO-SELF© Plus Pain Control Program
2977443|NCT02713919|No Intervention|Control Group|No intervention
2977444|NCT02713906|Experimental|X-Ray Knee Guide group|Total knee arthroplasy using Materialise X-Ray Knee Guides
2977445|NCT02713893|Experimental|Econazole nitrate 1% plus Benzydamine HCl 0.12%|5 grams of Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream, once daily for 15 consecutive days
2977446|NCT02713893|Active Comparator|Placebo plus Econazole nitrate 1%|5 grams of Placebo plus Econazole nitrate 1% intravaginal cream, once daily for 15 consecutive days
2977447|NCT02713893|Active Comparator|Placebo plus Benzydamine HCl 0.12%|5 grams of Placebo plus Benzydamine HCl 0.12% intravaginal cream, once daily for 15 consecutive days.
2977448|NCT02713893|Placebo Comparator|Placebo|5 grams of Placebo intravaginal cream, once daily for 15 consecutive days.
2977449|NCT02713880||Observation|Patients with Transthyretin-Related Familial Amyloidotic Polyneuropathy or high-grade suspicion for Transthyretin-Related Familial Amyloidotic Polyneuropathy
2977450|NCT02713867|Experimental|Nivolumab 240 mg|Nivolumab 240 mg Every 2 Weeks
2977451|NCT02713867|Experimental|Nivolumab 480 mg|Nivolumab 480 mg Every 4 Weeks
2977452|NCT02713854|Experimental|Endometrial biopsy group|Women who have an endometrial biopsy 2-3 months prior to IVF
2977453|NCT02713841|Experimental|Inhaled insulin (LOM)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a low output mesh (aerosol particles sized 3.5-4.0 μm)
2977454|NCT02713841|Experimental|Inhaled insulin (MOM1)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a medium output mesh (aerosol particles sized 4.3-4.8 μm)
2977455|NCT02713841|Experimental|Inhaled insulin (MOM2)|repeat of single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a medium output mesh (aerosol particles sized 4.3-4.8 μm)
2977456|NCT02713841|Experimental|Inhaled insulin (HOM)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a high output mesh (aerosol particles sized 5.0-5.5 μm)
2977457|NCT02713841|Active Comparator|subcutaneous insulin lispro (LIS)|single 6 unit dose of insulin lispro administered subcutaneously
2977458|NCT02713828|Experimental|Phase I: Glembatumumab Vedotin|Glembatumumab vedotin once every three weeks (q3w) by 90-minute intravenous (IV) infusion, until disease progression or intolerance. The Dose-Limiting Toxicity (DLT) evaluation period for determination of the appropriateness of dose-escalation will be through the end of the second treatment cycle.
2977459|NCT02713828|Experimental|Phase II: Glembatumumab Vedotin|Glembatumumab vedotin once every three weeks (q3w) by 90-minute intravenous (IV) infusion, until disease progression or intolerance. The Maximum Tolerated Dose (MTD) determined in Phase I will be used in Phase II.
2977460|NCT02713815|Sham Comparator|control group|sham repetitive transcranial magnetic stimulation (rTMS) of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
2977461|NCT02713815|Active Comparator|rTMS group|Use randomized, prospective pseudo stimulus controlled clinical trial design, evaluation of repetitive transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
2977462|NCT02713815|Active Comparator|psychotherapy group|The main content of motivational-cognitive psychotherapy is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
2977463|NCT02713815|Active Comparator|rTMS+psychotherapy group|Combination therapy by using rTMS and motivational-cognitive psychotherapy
2977464|NCT02713802|Experimental|Test product|Propofol solution (1% [10 mg/mL]), via intravenous injection
2977465|NCT02713802|Active Comparator|Reference product|Propofol emulsion (1% [10 mg/mL]), via intravenous injection
2977466|NCT02713789|Active Comparator|hMaxi-K|Single Treatment/ two escalating dose levels (8000 µg and 16,000 µg injection). In each dose level, 11 participants will receive hMaxi-K and 6 will receive placebo (only one injection per each participant)
2977467|NCT02713789|Placebo Comparator|Placebo (PBS-20% sucrose)|PBS-20% sucrose administered during two single treatment dose levels (8000 µg and 16000 µg) by injection (only one injection per each participant)
2977468|NCT02713776|Experimental|Pasireotide|Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
2977469|NCT02713776|Placebo Comparator|Placebo|Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
2977470|NCT02713763|Experimental|Sunitinib|Sunitinib 37.5 mg/day
2977471|NCT02713750||HIV female adolescents|sexually active, HIV-infected female adolescents, 12-24 years old who are aware of their HIV status
2977472|NCT02713737|Experimental|HFNC group|HFNC: Heated humidified high-flow nasal cannula.
2977473|NCT02713737|Active Comparator|NIV group|NIV: Noninvasive ventilation.
2977474|NCT02713724|Active Comparator|DAPS-group|Physical exercise
2977475|NCT02713724|Active Comparator|Standard-group|Limited physical exercise
2977476|NCT02713711|No Intervention|control group|The control group plaques did not receive any treatment.
2977477|NCT02713711|Experimental|phototherapy group|Twelve sessions of phototherapy (UV-B) applied on psoriatic plaques according to individual initial evaluation of Minimal Erythema Dose (MED).
2977478|NCT02713711|Experimental|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L) applied on psoriatic plaques.
2977479|NCT02713711|Experimental|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments on the same conditions described above applied on psoriatic plaques.
2977480|NCT02713698||Propofol - adults not obese|Patients with 18 or more years presenting for inpatient nose and ear surgery.
2977481|NCT02713698||Propofol - obese|Patients with 18 or more years presenting for inpatient bariatric surgery.
2977482|NCT02713698||Propofol - elderly|Patients with 65 or more years presenting for urgent orthopaedic surgery.
2977483|NCT02713685|Experimental|Subarachnoid block|Subarachnoid block will be given in lateral position
2977484|NCT02713685|Active Comparator|Peripheral nerve block|Combined Femoral and Sciatic nerve block will be given using nerve stimulation technique
2977485|NCT02713672|Experimental|Intervention group|Psychiatric patients with a CYP2D6 or CYP2C19 PM or IM genotype, using antidepressants or antipsychotics metabolized by CYP2D6 or CYP2C19
2977486|NCT02713672|No Intervention|Control group|Psychiatric patients with a CYP2D6 or CYP2C19 EM genotype using antidepressants or antipsychotics
2977487|NCT02713659|Experimental|Early Literacy Promotion|Parents and children randomized to the Early Literacy Promotion arm.
2977488|NCT02713659|Active Comparator|Standard Literacy Promotion|Parents and children randomized to the Standard Literacy Promotion arm.
2977489|NCT02713633|Other|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
2977490|NCT02713633|Other|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
2977491|NCT02713620|Placebo Comparator|Healthy|"the Healthy group receiving three intramuscular injections of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, and 6"
2977492|NCT02713620|Active Comparator|HIV-Group1|"the Standard doses group receiving three intramuscular injections of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, and 6"
2977493|NCT02713620|Active Comparator|HIV-Group 2|"the Four doses group receiving four intramuscular doses of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, 2, and 6"
2977494|NCT02713620|Active Comparator|HIV-Group 3|"the Four double doses group receiving four intramuscular double doses (40 μg) of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, 2, and 6"
2977495|NCT02713607|Experimental|doxycycline|Given doxycycline and assessment of gut, blood and skin
2977496|NCT02713607|No Intervention|Control|Control subjects to assess if there is baseline difference in these micro-evironments.
2977497|NCT02713594|Placebo Comparator|Control|Counseling from WTQL
2977498|NCT02713594|Experimental|Incentive|Counseling from WTQL; Financial incentive to participate
2977499|NCT02713581||Women with proximal VTE|"Patients will correspond to cases of proximal venous thromboembolism. They will be recruited during consultations conducted for the chronic management of a history of proximal venous thromboembolism or thrombophilia following a recent history of proximal venous thromboembolism. Venous thromboembolism, outside of acute phase episodes, has good symptom stability over time; no difference is to be expected between patients with a chronic history of proximal venous thromboembolism and new patients coming in for a checkup. Note that these patients may or may not have a history of placental vascular disease.~Intervention: Blood sampling"
2977500|NCT02713581||Women with >1 healthy pregnancy|"This populations is composed of healthy, female, adult volunteers (<50 years in age) that have had at least 1 healthy pregnancy.~Intervention: Blood sampling"
2977501|NCT02713568|Active Comparator|Ultrasound|"During routine third trimester ultrasound scan between 30 weeks and 35 weeks +6 days of gestational age, all women with an apparently normal, live singleton pregnancy, planning to deliver at the investigator's hospital maternity, will be invited to participate in the study.~An Ultrasound scan to estimate the fetal weigth will be carried out during the 36th week of gestation."
2977565|NCT02713139|Active Comparator|Gino-Canesten 3|
2977502|NCT02713568|Experimental|Magnetic Resonance|"During routine third trimester ultrasound scan between 30 weeks and 35 weeks +6 days of gestational age, all women with an apparently normal, live singleton pregnancy, planning to deliver at the investigator's hospital maternity, will be invited to participate in the study.~A Magnetic Resonance examination to estimate the fetal weigth will be carried out during the 36th week of gestation."
2977503|NCT02713555|Experimental|Roux-en-Y Gastric Bypass group|Morbidly obese patients with type 2 diabetes mellitus will be examined before and after the Roux-en-Y Gastric Bypass procedure
2977504|NCT02713555|Experimental|Gastric sleeve group|Morbidly obese patient with type 2 diabetes Mellitus will be examined before and after the Gastric Sleeve procedure
2977505|NCT02713555|No Intervention|Method /control group|Healthy normal weight participants matched by age and gender to the intervention study will be examined with the same methods as the intervention groups and serve as participants in a method study and as a metabolic normal reference group.
2977506|NCT02713542|Experimental|Autologous Conditioned Plasma (ACP)|3 Intra-articular (IA) injections at 1 week intervals
2977507|NCT02713542|Placebo Comparator|Normal Saline (NS)|3 NS Intra-articular (IA) injections at 1 week intervals
2977508|NCT02713529|Experimental|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
2977509|NCT02713516|Experimental|Single Arm|The children in this study will have a single visit. During this visit the child and their parent will be introduced to the virtual reality (VR) system. The child will interact with the VR system and after they have finished, they will be asked questions about their experience with the VR system.
2977510|NCT02713503||Healthy Drivers|Driving Observation and VisionCoach
2977511|NCT02713490|Active Comparator|EXPAREL|Single dose of EXPAREL 266 mg in 20 mL admixed with bupivacaine HCl 0.5% in 20 mL and expanded in volume with 80 mL normal saline (total volume of 120 mL).
2977512|NCT02713490|Active Comparator|Bupivacaine|Bupivacaine HCl 0.5% in 20 mL expanded in volume with 100 mL normal saline (total volume of 120 mL).
2977513|NCT02713477|Experimental|Insulin glargine/ lixisenatide dose 1 Test 1|Test 1 will be administered thru subcutaneous (SC) injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
2977514|NCT02713477|Experimental|Insulin glargine/ lixisenatide dose 2 Test 2|Test 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
2977515|NCT02713477|Placebo Comparator|Placebo - Reference 1|Reference 1 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
2977516|NCT02713477|Other|Insulin glargine (Lantus) - Reference 2|Reference 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour pior to breakfast under fasted condition
2977517|NCT02713464|Active Comparator|maternal education|Phase IIa: Pregnant women attending antenatal clinics or postpartum in clinics or hospital who receive programmed maternal education about risks and care of newborn jaundice.
2977518|NCT02713464|No Intervention|Historic control|Phase I: (before-after design) Baseline prevalence of acute bilirubin encephalopathy before maternal education instituted.
2977519|NCT02713464|No Intervention|No intervention|Phase IIb: Opportunistic controls - infants of mothers who failed to receive education about risks and care of newborn jaundice.
2977520|NCT02713451|Active Comparator|Liberal Oxygenation (LO) group|A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 90 to 105 mmHg that will be checked on arterial blood gases (ABG). Between these measurements, SpO2 will be kept more or equal to 96 percent. Alarms will be set at 95 percent for SpO2.
2977521|NCT02713451|Experimental|Conservative Oxygenation (CO) group|A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 55 to 70 mmHg that will be checked on arterial blood gases. Between these measurements, SpO2 will be kept between 88 and 92 percent. Alarms will be set between 87 and 93 percent for SpO2.
2977522|NCT02713438|Experimental|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
2977523|NCT02713438|Experimental|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad, the child. The parent is actively participating in forming plans by the child.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
2977524|NCT02713438|Experimental|Collaborative Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad (child and parent). Physical activity may be performed jointly by both persons in the dyad.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
2977525|NCT02713438|Active Comparator|Education|The education group received extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participant, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
2977526|NCT02713425|Experimental|Single Arm - Entertaining Video Game|The children in this study will have a single visit. During this visit they will be introduced to the game. The child will then interact with the game and after they have finished, they will be asked questions about their experience with the game.
2977527|NCT02713412|Experimental|Glucose|75g glucose and 150mg C13-acetate in 300ml water
2977528|NCT02713412|Placebo Comparator|Control|300ml water
2977529|NCT02713399||Soft Contact Lenses|healthy subjects wearing soft contact lenses
2977530|NCT02713399||Rigid Contact Lenses|healthy subjects wearing rigid contact lenses
2977531|NCT02713386|Active Comparator|Arm I (paclitaxel and carboplatin)|See Detailed Description.
2977532|NCT02713386|Experimental|Arm II (ruxolitinib, paclitaxel, and carboplatin)|See Detailed Description.
3129359|NCT01692132||Prucalopride|
2977533|NCT02713373|Experimental|Arm I (cetuximab and pembrolizumab)|Patients receive cetuximab IV over 120 minutes on day 1 (days 1, 7, and 14 of course 1 only) and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity. Patients may continue pembrolizumab treatment for up to 1 year if they experience disease progression.
2977534|NCT02713360|Experimental|Cognitive therapy|The intervention consists of 3 steps. 1: Consultation with a nurse that aims of identifying what the anxiety consist of and how the patient experiences his or her life situation with an ICD. A plan is made to structure the treatment. 2: Participation in an individualized intervention based on anxiety type specific protocols. 3. The intervention is considered finalized if the patient has a HADS-A score under 8 two times in a row. The intervention group will receive usual care as well.
2977535|NCT02713360|No Intervention|Usual care|The control group will receive usual care which consists of control of ICD, disease control and treatment, and at one of the sites an offer of a group information meeting where experiences and events with ICD are discussed. The meeting takes place at Rigshospitalet every other month.
2977536|NCT02713347|Experimental|ADAPT Intervention|"The intervention includes 3 components:~nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.~social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.~collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist.~The nurse and social worker visits are in-person or by phone."
2977537|NCT02713347|No Intervention|Enhanced usual care|Patients in the control group will continue to receive care at the discretion of their providers, which may include referrals to and ongoing care from cardiology, pulmonary, palliative care, or mental health. They will also have the same amount of interaction with research assistants as the intervention patients, completing questionnaires and participating in study visits at the same frequency. Patients' providers will be given the results of baseline depression surveys if they screen positive for depression, and patients will be given an information sheet that outlines self-care for CHF or COPD.
2977538|NCT02713321||Health Home patients|The cohort is made up of patients with type 2 diabetes, insured by Medicaid, and eligible for participation in a Medicaid Health Home (either due to HIV infection, serious mental illness, substance abuse, or multiple chronic conditions). One group will include patients who participate in the Health Home program.
2977539|NCT02713321||non-Health Home patients|The second group will include patients who do not participate in the Health Home program, but have type 2 diabetes, are insured by Medicaid, and meet eligibility requirements for the Health Homes.
2977540|NCT02713308||Group1-CRT|Patients with RV-to-LV delay≥80ms, CRT standard programming (single-point)
2977541|NCT02713308||Group2-MPP|Patients with RV-to-LV delay<80ms, CRT programming with MPP (multi-point)
2977542|NCT02713295||Subjects with Moderate to Severe Plaque Psoriasis|Subjects with Moderate to Severe Plaque Psoriasis in Greece
2977543|NCT02713282|Experimental|Paliperidone palmitate 3 month formulation (PP3M)|Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq.) up to 525 mg eq. based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
2977544|NCT02713269|Experimental|Thermal Ablation + Stereotactic Spine Radiosurgery (SSRS)|"Participants undergo thermal ablation procedure to tumor tissue using a laser. Radiation treatment starts within 2 weeks of thermal ablation. Treatment delivered in 1 or 3 fractions per treating physician.~Symptom questionnaires completed at baseline and at follow up months 1, 3, 6, 9, 12, then every 6 months."
2977545|NCT02713256|Experimental|CFZ533 10mg/kg|CFZ533 intravenously over approximately one hour
2977546|NCT02713243|Experimental|LJN452 followed by placebo|Randomized patients in this arm will receive single oral dose of LJN452 daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of placebo daily for 14 days.
2977547|NCT02713243|Experimental|Placebo followed by LJN452|Randomized patients in this arm will receive single oral dose of placebo daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of LJN452 daily for 14 days.
2977548|NCT02713230|Active Comparator|EXPAREL 133 mg|EXPAREL (bupivacaine liposome injectable suspension) 133 mg in 10 mL expanded with 10 mL of normal saline for a total volume of 20 mL.
2977549|NCT02713230|Placebo Comparator|Placebo|Normal saline in 20 mL.
2977550|NCT02713217||Pre-Implementation Cohort|Eligible patients will be recruited and enrolled prior to implementation of the blended integrated care model in each study site. They will be exposed to care as usual in the CBOCs.
2977551|NCT02713217||Post-Implementation Cohort|"Eligible patients will be recruited and enrolled following implementation of the blended integrated care model in each study site. These participants are thus exposed to the intervention model."
2977552|NCT02713204|Experimental|Group 1|Participants in Group 1 will receive REGN910-3 dosing regimen 1
2977553|NCT02713204|Experimental|Group 2|Participants in Group 2 will receive REGN910-3 dosing regimen 2
2977554|NCT02713204|Active Comparator|Group 3|Participants in Group 3 will receive IAI
2977555|NCT02713191|Experimental|Dexmedetomidine|Dexmedetomidine + fentanyl before, and dexmedetomidine infusion during, procedure
2977556|NCT02713191|Active Comparator|Midazolam|Midazolam + fentanyl before, and matching saline infusion during, procedure
2977557|NCT02713178|Active Comparator|EXPAREL 133 mg|Single dose of 133 mg (10 mL) EXPAREL (bupivacaine liposome injectable suspension) expanded in volume with 10 mL of normal saline for a total volume of 20 mL.
2977558|NCT02713178|Active Comparator|EXPAREL 266 mg|Single dose of 266 mg (20 mL) EXPAREL (bupivacaine liposome injectable suspension).
2977559|NCT02713178|Placebo Comparator|Placebo|Normal saline (20 mL).
2977560|NCT02713165|Experimental|Raisins Enhanced Diet|Participants will be provide with a Raisin Enhanced Diet over a short term period of time.
2977561|NCT02713152||Patients with OAG|Patients with a diagnosis of Open Angle Glaucoma
2977562|NCT02713152||Controls|Controls without a diagnosis of Open Angle Glaucoma
2977566|NCT02713126|Placebo Comparator|Placebo|Subjects will undergo cardiac exercise training and receive oral placebo capsules three times per day for 12 weeks while wearing an accelerometer
2977567|NCT02713126|Active Comparator|Sodium Nitrite|Subjects will undergo cardiac exercise training and receive oral sodium nitrite capsules three times per day for 12 weeks while wearing an accelerometer
2977568|NCT02713113|Active Comparator|group 1|patients were given 1.5 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
2977569|NCT02713113|Active Comparator|group II|patients were given 2 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
2977570|NCT02713113|Active Comparator|group III|patients were given 4 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
2977571|NCT02713087|Active Comparator|Ephedrine|
2977572|NCT02713087|Active Comparator|Phenylephrine|
2977573|NCT02713074|Active Comparator|Group A|povidone-iodine group
2977574|NCT02713074|Active Comparator|Group B|Normal saline group
2977575|NCT02713061|Experimental|TAK-850 0.5 mL|TAK-850 0.5 mL (15 µg of hemagglutinin [HA] antigen per strain), subcutaneous injection, once on Day 1.
2977576|NCT02713048||Acute coronary syndrome culprit coronary lesion|
2977577|NCT02713048||Stable obstructive coronary artery disease|
2977578|NCT02713048||Non-obstructive coronary artery disease|
2977579|NCT02713035|No Intervention|Usual|Receive standard medical therapy for eczema
2977580|NCT02713035|Experimental|Treatment|Receive standard medical therapy for eczema plus behavioral self help intervention
2977581|NCT02713022||Breast Cancer|DEXA scan will be carried out 1 to 30 days prior to mastectomy. Patients will also complete the Godin Leisure Time Exercise Questionnaire (GLTEQ) and their waist to hip ratio will be measured.
2977582|NCT02713022||Prostate Cancer|DEXA scan will be carried out 1 to 30 days prior to radical prostatectomy. Patients will also complete the Godin Leisure Time Exercise Questionnaire (GLTEQ) and their waist to hip ratio will be measured.
2977583|NCT02713009|Experimental|Treatment 1|Pregnancy multivitamin + vitamin D daily from ~Week 12 gestation until delivery
2977584|NCT02713009|Placebo Comparator|Treatment 2|Pregnancy multivitamin + placebo daily from ~Week 12 gestation until delivery
2977585|NCT02712996|Active Comparator|Vyvanse|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
2977586|NCT02712996|Placebo Comparator|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
2977587|NCT02712983|Experimental|TIP dose regimen 1|Tobramycin inhalation powder (TIP)
2977588|NCT02712983|Experimental|TIP and placebo dose regimen 1|Tobramycin inhalation powder (TIP) and inhaled placebo
2977589|NCT02712983|Placebo Comparator|Placebo dose regimen 1|Inhaled placebo
2977590|NCT02712983|Experimental|TIP dose regimen 2|Tobramycin inhalation powder (TIP)
2977591|NCT02712983|Experimental|TIP and placebo dose regimen 2|Tobramycin inhalation powder (TIP) and inhaled placebo
2977592|NCT02712983|Placebo Comparator|Placebo dose regimen 2|Inhaled placebo
2977593|NCT02712983|Experimental|TIP dose regimen 3|Tobramycin inhalation powder (TIP)
2977594|NCT02712983|Experimental|TIP and placebo dose regimen 3|Tobramycin inhalation powder (TIP) and inhaled placebo
2977595|NCT02712983|Placebo Comparator|Placebo dose regimen 3|Inhaled placebo
2977596|NCT02712970||stage-I|Single pit in the midline, no lateral extension. Pit-picking technique will be performed.
2977597|NCT02712970||Stage-II|>1 pits in the midline, no lateral extension. Pit-picking and Bascom cleft lift techniques will be performed.
2977598|NCT02712970||Stage-III|Midline pit/pits plus lateral extension in one direction. Bascom cleft lift technique will be performed.
2977599|NCT02712970||Stage-IV|Midline pit/pits plus lateral extension in both directions. Rhomboid excision with the Limberg Flap will be performed.
2977600|NCT02712970||Stage-R|Recurrent PSD following any type of treatment. Other flap techniques such as V-Y advancement flap, Z-Plasty will be performed.
2977601|NCT02712957|Experimental|NEO6860|NEO6860 is provided as a powder in individual containers to be reconstituted as a suspension. In this arm patients will receive both NEO6860 and a placebo of naproxen.
2977602|NCT02712957|Placebo Comparator|Placebo|In this arm, patients will receive both placebo: oral liquid suspension (NEO6860 placebo) and capsule (naproxen placebo).
2977603|NCT02712957|Active Comparator|Naproxen|Naproxen is provided as over-encapsulated tablets using a commercially approved medication. In this arm patients will receive both naproxen and a placebo of NEO6860.
2977604|NCT02712944|Active Comparator|Testosterone|Testosterone intramuscular every 2 weeks
2977605|NCT02712944|Placebo Comparator|Saline|Saline intramuscular every 2 weeks
2977606|NCT02712918|Experimental|Brief Behavioral Activation Treatment for Depression|Behavioral treatment of depression. The study utilized the revised version of the Brief Behavioral Activation Treatment for Depression (BATD) protocol from 2011. The treatment was added to treatment as usual. Up to 10 sessions were administered.
2977607|NCT02712918|Placebo Comparator|Standard care|Standard CARE (SC) at the inpatient unit. Mandatory: Therapeutic conversations with psychiatrist, psychologist or M.D, milieu therapy. Optional: Psychosomatic physiotherapy, therapeutic groups, psychopharmacological treatment.
2977608|NCT02712905|Experimental|INCB059872|
2977609|NCT02712905|Experimental|INCB059872 in combination with other therapies|"Initial cohort dose of INCB059872 to evaluate different doses of INCB0599872 in combination with other therapies in the following treatment groups:~Combination with all-trans retinoic acid (ATRA) in subjects with relapsed/refractory AML.~Combination with azacitidine in subjects with newly diagnosed, treatment-naive AML~Combination with nivolumab in subjects with advanced SCLC previously progressed on platinum-based treatment.~Upon identification of the recommended dose(s) for each treatment combination, expansion cohorts of approximately 30 subjects in each treatment group may begin enrollment to further determine safety, tolerability, efficacy, PK, and PD of the selected dose(s)."
2977610|NCT02712866||Patients treated with vedolizumab|
2977611|NCT02712853||Autism Spectrum Disorder (ASD)|"Age at enrollment: 18 months to 6 years with established DSM-5 diagnosis of autism spectrum disorder. Exclusion criteria include:~wards of the state syndromic autism (attributed to a known genetic mutation) active periodontal infection active upper respiratory infection"
2977612|NCT02712853||Control|"Age 18 months to 6 years without autism spectrum disorder (may have typical development or developmental delay without autism - as defined by negative MCHAT-R or negative ADOS-II evaluation)~Exclusion criteria include:~wards of the state active periodontal infection active upper respiratory infection"
2977613|NCT02712840|Experimental|Freeze-All Protocol|Participants freezing all good quality embryos, with subsequent frozen embryo transfer of best quality blastocyst.
2977614|NCT02712840|Active Comparator|Fresh Protocol|Participants receiving fresh embryo transfer of best quality blastocyst and freezing of all good quality supernumerary embryos.
2977615|NCT02712827|Experimental|Progrip|The Progrip group is the intervention group. Patients will undergo laparoscopic total extraperitoneal repair of inguinal hernia. The surgeon will use a self-gripping mesh to repair the hernia. No fixation is required for the mesh.
2977616|NCT02712827|Active Comparator|Non-Progrip|"The Non-Progrip group is the control group.~Operation is performed under general anesthesia. A standard three-trocar technique is used: one infra-umbilical camera trocar (1cm) and two 5mm trocars placed at midline between the umbilicus and pubic bone (or one at the side of inguinal hernia). A laparoscope is inserted to the preperitoneal space through the incision. The space is insufflated with carbon dioxide. Dissection is performed, hernia content (if any) is reduced.~A non self-gripping synthetic mesh is placed. Fibrin glue is used for fixation."
2977617|NCT02712814||Hormonally mediated PVD|"The entire vestibule is tender~The pain began while taking hormonal contraceptive~Secondary PVD~On exam, atrophic vestibular tissue (dry and thin)"
2977618|NCT02712814||Congenital Neuroproliferative PVD|"The entire vestibule is tender~Primary PVD~There may be sensitivity to palpation of the umbilicus~Normal appearing vestibule"
2977619|NCT02712814||Acquired neuroproliferative PVD|"The entire vestibule is tender~Secondary PVD, The pain had begun after a severe allergic reaction or vaginitis.~Normal appearing vestibule"
2977620|NCT02712814||Hypertonic pelvic muscle dysfunction|"The pain is at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule~Pelvic floor muscles are tight and tender~Primary or Secondary PVD"
2977621|NCT02712814||Neuroproliferative +Hypertonic|"The entire vestibule is tender, but worse at 4-8 o'clock position of the vestibule~Primary PVD~There may be sensitivity to palpation of the umbilicus~Normal appearing vestibule~Pelvic floor muscles are tight and tender"
2977622|NCT02712814||Hormonally +Hypertonic|"The entire vestibule is tender, but worse at 4-8 o'clock position of the vestibule~The pain began while taking hormonal contraceptive~Secondary PVD~On exam, atrophic vestibular tissue (dry and thin)~Pelvic floor muscles are tight and tender"
2977623|NCT02712801|Experimental|Intervention group|Children will receive antiretroviral treatment (ART) until 6 weeks old after birth. For the first two weeks, Zidovudine (AZT), Lamivudine (3TC) and Nevirapine (NVP) will be used. When the child is 2 weeks old, the regimen will be adjusted and Nevirapine (NVP) will be replaced by Lopinavir/ritonavir (LPV/r). Early infant diagnosis and other relevant testing will be performed to monitor children's HIV infection status. If the child is not infected, ART will be stopped when he/she reaches 6 weeks old. Otherwise, the treatment will be continued.
2977624|NCT02712801|Active Comparator|Control group|Children will receive routine prevention of mother-to-child transmission of HIV services. Nevirapine (NVP) or Zidovudine (AZT) will be administrated to them until 6 weeks old after birth. Early infant diagnosis services will be provided when the child is 6 weeks old and repeated when 3 months old. Children with HIV infection will be referred to receive routine HIV infection treatment.
2977625|NCT02712788|Active Comparator|Milrinone|Milrinone will be administered intravenously at an initial rate of 0.75mCg/kg/min and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.
2977626|NCT02712788|Placebo Comparator|Placebo|Placebo (Normal Saline) will be administered intravenously and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.
2977627|NCT02712775|Experimental|Minocycline|Experimental group will receive an infusion of minocycline, the investigational drug, through a needle in a vein in the arm at the dose of 200 mg at 1 h prior to transplantation and 100 mg 12 h and 24 h after transplantation. In addition, the donated liver will be flushed with 200 mg minocycline 1 h prior to transplantation.
2977628|NCT02712775|Placebo Comparator|Saline|Placebo group will receive an infusion of saline, a placebo, through a needle in a vein in the arm according to the same schedule. In addition, the donated liver will be flushed with saline 1 h prior to transplantation.
2977629|NCT02712749|Experimental|Group A : Sound with Binaural Beats|"Acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz through generated by the software Gnaural in stereo option"
2977630|NCT02712749|Active Comparator|Group B : Sound without Binaural Beats|"Acoustic frequencies of 256 Hz in both ears to perceive one tone without beats generated by the software Gnaural in mono option"
2977631|NCT02712736|Other|Survey respondents|The patients who consent to participate will be sent home from the clinic with a survey to complete and return via mail in a provided addressed, stamped envelope. The survey consists of the Short Form-36 (SF-36), the Chronic Liver Disease Questionnaire (CLDQ), questions from the PROMIS SexFs v2.0, questions regarding perceived risk for liver transplant, cholangiocarcinoma, and colorectal carcinoma, as well as perceived overall life expectancy, and questions regarding complementary and alternative medicine use.
2977632|NCT02712723|Active Comparator|Placebo + Letrozole|Placebo randomized to 3 capsules/day 3 weeks on/1week off or 2 capsules/day continuous dosing + Letrozole 2.5 mg PO daily
2977633|NCT02712723|Experimental|Ribociclib 600 mg + Letrozole|Ribociclib 600 mg PO daily 21 days on/7 days off + Letrozole 2.5 mg PO daily
2977634|NCT02712723|Experimental|Ribociclib 400 mg + Letrozole|Ribociclib 400 mg continuous daily dosing + Letrozole 2.5 mg PO daily
2977635|NCT02712710|Experimental|wear a functional knee brace|20 subjects with symptomatic medial compartment knee OA, with grade 2 to 4 on Kellgren and Lawrence scale, and showing willing to wear a functional knee brace. All of the subjects received 4 weeks' rehabilitation treatment (3 times a week)
2977636|NCT02712710|No Intervention|no wear a functional knee brace|Another 20 subjects with comparable body height, weight, and sex. All of the subjects received 4 weeks' rehabilitation treatment (3 times a week)
2977637|NCT02712697|Experimental|WM Group|Shentong Granules, two packs, bid, P.O., 48weeks; Prednisone, 0.5-1mg/kg.d, P.O., eight to twelve weeks; then reduced to 30mg by reduce 5mg every two weeks; followed by the monthly reduction of 5mg, about 9-12 months
2977638|NCT02712697|Placebo Comparator|Hormone Group|Placebo ; Prednisone, 0.5-1mg/kg.d, P.O., eight to twelve weeks; then reduced to 30mg by reduce 5mg every two weeks; followed by the monthly reduction of 5mg, about 9-12 months
2977639|NCT02712671||Enrolled subjects|Subjects attending the Ian Charleson Centre and agreeing to be tested for latent, subclinical and active tuberculosis using Chest radiograph, Blood interferon gamma release assay, Tuberculin skin testing, Sputum induction for mycobacterial microscopy and culture with spirometry, and Mycobacterium tuberculosis polymerase chain reaction testing.
2977640|NCT02712658|Active Comparator|terbutaline|terbutaline is administered by injection (0.25-0.5 mg Bricanyl, AstraZeneca diluted in 9 ml isotonic saline)
2977641|NCT02712658|Placebo Comparator|Placebo|placebo is administered as isotonic saline (10 ml)
2977642|NCT02712619|Experimental|metformin 250mg|metformin 375/250 mg
2977643|NCT02712619|Experimental|metformin 1000mg|metformin 1000/1000 mg
2977644|NCT02712593|Experimental|Niagen™ 100|
2977645|NCT02712593|Experimental|Niagen™ 300|
2977646|NCT02712593|Experimental|Niagen™ 1000|
2977647|NCT02712593|Experimental|Placebo|
2977648|NCT02712580|Active Comparator|First investigational device|"official name of product: Wireless microcurrent Stimulation Wetling W 200 n=47 patients The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light."
2977649|NCT02712580|Active Comparator|Second investigational device|"official name of product: Wireless microcurrent Stimulation Wetling W 200 n=47 patients The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light."
2977650|NCT02712580|Placebo Comparator|ES Wetling W200 with white light|Placebo device - 'ES Wetling W200 Placebo with white light' n=47 patients The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
2977651|NCT02712580|Placebo Comparator|ES Wetling W200 with red light|Placebo device - 'ES Wetling W200 Placebo with red light' n=47 patients The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
2977652|NCT02712554|Experimental|Treatment A low dose CL-108|CL-108 tablets, 22.5mg hydrocodone, 975 mg APAP, 37.5 mg promethazine
2977653|NCT02712554|Experimental|Treatment B high dose CL-108|CL 108, 37.5 mg hydrocodone, 1625 mg APAP, 62.5 mg promethazine
2977654|NCT02712554|Active Comparator|Treatment C low dose M366|M366 tablets, 22.5 mg hydrocodone/975mg APAP
2977655|NCT02712554|Active Comparator|Treatment D high dose M366|M366 tablets, 37.5 mg hydrocodone, 1625 mg APAP
2977656|NCT02712554|Placebo Comparator|Treatment E|Placebo Tablets
2977657|NCT02712528|Active Comparator|remifentanil-based|remifentanil-based regimen consisting of remifentanil 0.75 mcg/kg/min and supplemental propofol for maintaining BIS 40-60
2977658|NCT02712528|Placebo Comparator|sevoflurane-sufentanil balanced|balanced sevoflurane (end-tidal 1.2-2.8 vol%) and sufentanil (0.015 mcg/kg/min) regimen
2977659|NCT02712515||Essential tremor|Participants in this group will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system, which is capable of recording during stimulation.
2977660|NCT02712515||Parkinson's disease|Participants in this group with Parkinson's disease will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system, which is capable of recording during stimulation.
2977661|NCT02712502||Study group (OG).|"50 patients c and acute exacerbation of chronic bacterial rhinosinusitis in the study group (OG).~The treatment regimen in the study group.~Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.~Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
2977662|NCT02712502||Control group (CG).|"50 patients c and acute exacerbation of chronic rhinosinusitis in the control group (CG).~The treatment regimen of the control group. Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
2977663|NCT02712489||No treatment|"All patients that participated to the therapeutic phase II trial of the Tat vaccine ISS T-003"
2977664|NCT02712476|Active Comparator|Mannitol,furosemide|Mannitol 0.5mg/kg and furosemide 0.5mg/kg IV is compared with mannitol 1mg/kg and furosemide 0.5mg/kg
2977665|NCT02712476|Placebo Comparator|Mannitol, placebo|Mannitol 0.5mg/kg and placebo is compared with mannitol+forosemide
2977666|NCT02712463||Participants with Schizophrenia|This is an observational study. Data will be collected from the medical records of participants diagnosed with schizophrenia and who had been on oral antipsychotics for at least one year and thereafter have been switched to Long Acting Injectable atypical antipsychotics for at least one year.
2977667|NCT02712450||Control group|"Patients included from January 2016 to August 2016~Before regulating doctors training course"
2977668|NCT02712450||Experimental group|"Patients included from January 2017 to August 2017~After regulating doctors training course"
2977669|NCT02712437|Experimental|PROSPECT|Participants who have received treatment for early stage breast cancer and who experience chronic insomnia as assessed by difficulty sleeping for >30 days with an insomnia severity index score of >14. Participants will complete baseline symptom questionnaires and actigraphy, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 6 weeks. Participants will then repeat questionnaires and actigraphy at 6 weeks and questionnaires at 12 weeks.
2977670|NCT02712424|Active Comparator|DAR-901|0.1 mL intradermal injection of 1 mg DAR-901
2977671|NCT02712424|Placebo Comparator|Placebo|0.1 mL intradermal injection of sterile saline for human use
2977672|NCT02712411|Experimental|Sequence 1|"T → R~T : HCP1303 R : HGP1201 + HIP1402"
2977673|NCT02712411|Experimental|Sequence 2|"R → T~T : HCP1303 R : HGP1201 + HIP1402"
2977674|NCT02712398|Experimental|Phasix™ ST|Subjects treated with Phasix™ ST mesh
2977675|NCT02712385|No Intervention|Control - usual care|Usual post-TIA/minor stroke care as per current healthcare system protocol will be given to patients in control group and details will be recorded.
2977676|NCT02712385|Active Comparator|Manual|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual'.
2977677|NCT02712385|Active Comparator|Manual + pedometer, 1|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual' and a pedometer with telephone follow-up from a General Practitioner.
2977678|NCT02712385|Active Comparator|Manual + pedometer, 2|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual' and a pedometer with telephone follow-up from a Stroke nurse.
2977679|NCT02712372|Experimental|Part 1, Dose Level 1|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
2977680|NCT02712372|Experimental|Part 1, Dose Level 2|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
2977681|NCT02712372|Experimental|Part 1, Dose Level 3|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
2977682|NCT02712372|Experimental|Part 1, Dose Level 4|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
2977683|NCT02712372|Experimental|Part 1, Dose Level 5|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
2977684|NCT02712372|Experimental|Part 1, Dose Level 6|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
2977685|NCT02712372|Experimental|Part 2, Dose Level 1|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
2977686|NCT02712372|Experimental|Part 2, Dose Level 2|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
2977687|NCT02712372|Experimental|Part 2, Dose Level 3|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
2977688|NCT02712372|Placebo Comparator|AZD4831 Placebo|"Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.~Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12"
2977689|NCT02712359|Other|Havrix_dose Group|Subjects with approximately 8 years and 10 years post vaccination with the last received vaccine dose of the complete series (2 doses) and the partial series (1 dose) of Havrix. Thus, the study has two population: one with the complete series of Havrix (2 doses) and the partial series completion (1 dose).
2977690|NCT02712346|Experimental|Treatment|Ambrisentan 5 mg PO daily
2977691|NCT02712346|Placebo Comparator|Placebo|One inactive pill PO daily
2977692|NCT02712333|Experimental|Air purifiers|Participants in this group received an intervention of true air purifiers placed in the center of the room.
2977693|NCT02712333|Sham Comparator|Control|Participants in this group received an intervention of sham air purifiers, which were under the same conditions as the true purifiers except the filter gauze in them were removed.
2977694|NCT02712320|Experimental|LMIS 50 mg|50 mg leuprolide mesylate administered subcutaneously, when given as two separate injections 6 months apart (Month 12 and Month 18 from the initiation of Protocol FP01C-13-001)
2977695|NCT02712307|Experimental|5 days|Phenoxymethylpenicillin 800 mg x 4 for 5 days
2977696|NCT02712307|Active Comparator|10 days|Phenoxymethylpenicillin 1000 mg x 3 for 10 days
2977697|NCT02712294|No Intervention|Control Group (GC)|The GC received standard ambulatory care, including routine exams and drug therapy. All patients were reassessed after the 2 month protocol.
2977698|NCT02712294|Experimental|NMES Group (GE)|Receiving the usual care and guidance on their illness, underwent 30 minute NMES sessions twice a week for two months using an electrostimulator. Specifically, 5 cm adhesive surface electrodes in four alternate channels on the Rectus Femoris (two channels the right and two on the left) were used to deliver two-phase symmetrical currents, with a rectangular pulse wave at a frequency of 35 Hz and pulse duration of 250 μ. The time of ascent and descent was one second, contraction time was four seconds and relaxation was eight seconds.
2977699|NCT02712281|Experimental|Autism MEAL Plan|Parents of eligible children who are randomized to the Autism Managing Eating Aversions and Limited variety (MEAL) Plan will participate in group-based parent training sessions (4 parents per group).
2977700|NCT02712281|Active Comparator|Parent Education|Parents of eligible children who are randomized to the Parent Education Arm will receive group-based parent education (PE). Each group includes 4 parents.
2977701|NCT02712268|Other|After introduction of the checklist|Review of medications of all consecutive admitted patients during the study period using a checklist
2977702|NCT02712255|Experimental|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
2977703|NCT02712255|Experimental|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad, the patient. The partner is actively participating in forming plans by the patient.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning"
2977704|NCT02712255|Experimental|Collaborative Planning|Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad (the patient and the partner). Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
2977705|NCT02712255|Active Comparator|Education|The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participant, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
2977706|NCT02712242|Experimental|Platelet Rich Fibrin|PRF was laid directly on the palatal wound immediately after harvesting the tissue graft and stabilized
2977707|NCT02712242|Active Comparator|Butyl cyanoacrylate|Butyl cyanoacrylate was directly applied on the palatal wound after harvesting the tissue graft
2977708|NCT02712242|Placebo Comparator|Wet Gauze|Wet Gauze was placed for 1 minute on the palatal wound after harvesting the tissue graft
2977709|NCT02712229|Experimental|CONNECT Intervention|At clinics randomized to the CONNECT intervention, oncology nurses will be selected by a nurse advisory panel to receive standardized primary palliative care training. A multi-step deployment strategy will be employed to orient oncologists and implement CONNECT processes. CONNECT nurses will administer CONNECT to enrolled patients and caregivers. An intervention fidelity monitoring and maintenance plan will be implemented to ensure high quality and consistent delivery of the intervention.
2977710|NCT02712229|No Intervention|Usual Care Control|At clinics randomized to Usual Care, enrolled patients and caregivers will continue to receive supportive oncology care according to usual practice.
2977711|NCT02712216|Other|Trocar Insertion Sites|Insertion of a 21-gauge 3.5inch spinal needle perpendicular to the abdominal wall at each possible trocar site. The needle will be placed after the abdomen is insufflated under direct visualization with the laparoscopic camera. The needle will be inserted to the level of the peritoneum and a hemostat will be place on the needle at the level of the epidermis.
2977712|NCT02712203||12 months|MMR vaccine / MMRV vaccine : administration of the first dose at 12 months of age
2977713|NCT02712203||13 months|MMR vaccine / MMRV vaccine : administration of the first dose at 13 months of age
2977714|NCT02712203||14 months|MMR vaccine / MMRV vaccine : administration of the first dose at 14 months of age
2977715|NCT02712203||15 months or more|MMR vaccine / MMRV vaccine : administration of the first dose at 12 months of age or older
2977716|NCT02712190|Experimental|Low - High frequence sequence|High-Frequency non-invasive ventilation (HF-NIV) with 2 different settings, sequence of respiratory rate 250/min and respiratory rate 500/min
2977717|NCT02712190|Experimental|High - Low frequence sequence|High-Frequency non-invasive ventilation (HF-NIV) with 2 different settings, sequence of respiratory rate 500/min and respiratory rate 250/min
2977718|NCT02712177||Coadministration B_RV246|Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar).
2977719|NCT02712177||Coadministration B_RV234|Subjects in this group received 4CMenB vaccine at 2, 3 and 4 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar)..
2977720|NCT02712177||Coadministration B_MMRV12|Subjects in this group previously received three doses of 4CMenB and routine vaccine at 2, 4 and 6 months of age,respectively. They also received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine.
2977721|NCT02712177||Separate administration B246_RV357|Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age; routine infant vaccinations (Infanrix Hexa+Prevenar) were administered at 3, 5 and 7 months of age.
2977722|NCT02712177||Separate administration B12_MMRV13|Subjects in this group previously received three doses of 4CMenB and routine vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age. They also received a booster (fourth) dose of 4CMenB at 12 months of age and one dose of MMRV vaccine at 13 months of age.
2977723|NCT02712177||RV only RV234|Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 3 and 4 months of age.
2977724|NCT02712177||RV only RV246|Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age.
2977725|NCT02712164|Experimental|Experimental: Modified NPWT dressing|In the experimental group, a microporous silver-impregnated foam with a thin silicone contact layer (Mepilex Ag) will be applied. A macroporous foam layer (V.A.C. GranuFoam) and an occlusive dressing (V.A.C. Drape) will then be applied to cover the foam, plus 3-5cm border of intact skin. The occlusive dressing will then be pinched and a 2cm hole will be cut to apply the SensaT.R.A.C. Pad that supplies pressure from the NPWT unit. NPWT will be applied at 125mmHg throughout treatment using KCI's InfoV.A.C. Therapy Unit. The donor site dressing will be replaced on postoperative day 5-7 and a new occlusive dressing (Tegaderm) will be applied.
2977726|NCT02712164|Active Comparator|Control: Tegaderm|In the control group, the donor sites will be dressed with an occlusive dressing only (Tegaderm). The donor site dressings will be replaced on postoperative day 5-7 and a new occlusive dressing (Tegaderm) will be applied.
2977727|NCT02712151|Active Comparator|Abdominal Wall Block with Ropivacaine 0.2%|Patients will receive bilateral transversus abdominis plane and rectus sheath blocks via ultrasound guidance. A total of 1.0ml/kg distributed between the four blocks (0.4+0.4+0.1+0.1) of 0.2% Ropivacaine (max 50ml) will be injected, as a one time single shot injection, into the fours sites. Surgical infiltration of the four port sites will receive 0.4ml/kg of sterile saline.
2977728|NCT02712151|Active Comparator|Surgical Infiltration with Ropivacaine 0.5%|Patients will receive surgical infiltration of local anesthetic into the 4 laparoscopic port sites. A total of 0.4 ml/kg (0.1+0.1+0.1+0.1) of 0.5% Ropivacaine, divided between the four port sites (max 20 ml), will be used. A total of 1ml/kg, divided between the TAP (0.4ml/kg on each side) and RS (0.1ml/kg on each side), of sterile saline will be used for the nerve blocks.
2977729|NCT02712125|Active Comparator|isosorbide mononitrate|Received 20 mg isosorbid mononitrate (IMN) (Effox, Mina Pharma Co, Egypt; under license of Schwartz Pharma, Germany) vaginally once daily until delivery
2977730|NCT02712125|Placebo Comparator|Control|Received placebo vaginal tablets once daily until delivery
2977731|NCT02712112|Experimental|Intermittent dosing arm|one-week on and one-week off schedule(Imatinib Mesylate, 400 mg once daily, oral)
2977732|NCT02712112|Sham Comparator|Continuous dosing arm|continuous dosing without off-treatment schedule(Imatinib Mesylate, 400 mg once daily, oral)
2977733|NCT02712086|No Intervention|usual dietary management|Control group: usual dietary management Following the intervention, the stomach of patients underwent many changes
2978286|NCT02708602||β2AR Arg16Gly (AG group)|People with β2AR Arg16Gly genotype.
2977734|NCT02712086|Experimental|care of with usual dietary protein supplementation|Intervention group: Usual dietary management with protein supplementation (30g) in addition to the usual inputs
2977735|NCT02712073||patients undergoing colonoscopy|
2977736|NCT02712060||EDS patients|Patients with the diagnosis of Ehlers-Danlos syndrome
2977737|NCT02712060||controls|Patients/Subjects without the diagnosis of Ehlers-Danlos syndrome
2977738|NCT02712047|Experimental|Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg|Subjects will receive FF/VI 100/25 mcg each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
2977739|NCT02712047|Placebo Comparator|Placebo|Subjects will receive placebo each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
2977740|NCT02712034|Placebo Comparator|Medication-assisted treatment (MAT)|Patients will receive standard medication-assisted treatment (MAT) as prescribed by their health care provider.
2977741|NCT02712034|Experimental|MAT + A-CHESS|Patients in the MAT + A-CHESS arm will receive MAT as described plus the A-CHESS recovery support system via a smartphone.
2977742|NCT02712021|Experimental|Cerebral Palsy-Study group|The intervention consisted of wearing a lycra suit, with shoulder, trunk and pelvis coverage, for more than 4 hours per day for 6 months. The motor function assessments will be performed without the Lycra suit, whereas the static balance assessments were performed with and without the suit.
2977743|NCT02712021|Active Comparator|Cerebral Palsy-Control Group|Children with clinical characteristics similar to the study group; they will be assessed using the same protocol but with no use of lycra garments
2977744|NCT02712008|Experimental|Group 1|Participants in Group 1 will receive REGN910-3 dosing regimen 1
2977745|NCT02712008|Experimental|Group 2|Participants in Group 2 will receive REGN910-3 dosing regimen 2
2977746|NCT02712008|Active Comparator|Group 3|Participants in Group 3 will receive IAI
2977747|NCT02711995|Experimental|RenuGel|Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
2977748|NCT02711995|Active Comparator|Botulinum toxin|Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
2977749|NCT02711982|Active Comparator|Optic nerve decompression|Optic canal and optic nerve sheath decompression within 5 days from trauma occur.
2977750|NCT02711982|Active Comparator|methylprednisolone|a maximum daily dose of 1 g of methylprednisolone
2977751|NCT02711969|Experimental|Apatinib mesylate|
2977752|NCT02711956|Experimental|DE and DC - ZEN003694 in Combination with Enzalutamide|"Dose Escalation (DE) and Dose Confirmation (DC): ZEN003694 will be administered orally once daily with enzalutamide in 28-day cycles, enrolling mCRPC patients.~Patients are either enzalutamide-naïve with prior progression on abiraterone by Prostate Cancer Working Group 2 (PCWG2) criteria or are currently receiving enzalutamide who have experienced prostate-specific antigen (PSA) progression by PCWG2 criteria in the absence of radiographic and/or clinical progression. For the latter, patients may or may not have experienced prior progression on abiraterone."
2977753|NCT02711917|Experimental|SP1- sevoflurane MAC 0.5|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.5. Propofol infusion is started to keep BIS between 40-60.
2977754|NCT02711917|Experimental|SP2- Sevoflurane MAC 0.75|In this group, patient of age 40-60 years, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen.Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.75. Propofol infusion is started to keep BIS between 40-60.
2977755|NCT02711917|Experimental|SP3 -Sevoflurane MAC 1.0|In this group, patient of age 40-60 years, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 1.0. Propofol infusion is started to keep BIS between 40-60.
2977756|NCT02711917|Experimental|SP4- Sevoflurane MAC 0.5|In this group, patient above 60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Propofol infusion is started to keep BIS between 40-60.
2977757|NCT02711917|Experimental|SP5- Sevoflurane MAC 0.75|In this group, patient above 60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.75. Propofol infusion is started to keep BIS between 40-60.
2977758|NCT02711917|Experimental|SE1- Sevoflurane MAC 0.5|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
2977759|NCT02711917|Experimental|SE2- Sevoflurane 0.75|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
2977785|NCT02711748|Experimental|PEA|In case of bradycardia. The patient unconscious, not breathing, the ECG - bradycardia 30 / min - no pulse. Pulseless electrical activity
2979469|NCT02700620|Experimental|Treatment group|Internet-delivered CBT
2977760|NCT02711917|Experimental|SE3- Sevoflurane MAC 1.0|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
2977761|NCT02711904|Active Comparator|Extubation U|Remifentanil concentration between 2 - 3 ng/ml.
2977762|NCT02711904|Experimental|Extubation T|Remifentanil concentration between 3 - 4 ng/ml
2977763|NCT02711891|Experimental|5% Loperamide gel|Participants received 5% loperamide gel (0.2gm equivalent to 10 mg) applied following a single surgilance to the 5th digit. The loperamide gel was applied 10 minutes following the first lance, rubbed in for one minute within an 8 mm mold surrounding the lance site. The mold was removed and the gel was covered with a transparent occlusive dressing and left in place for 30 minutes. The forearm was also swabbed with the loperamide gel which was left in place for 30 minutes. The placebo gel contained the same ingredients without the loperamide. The loperamide gel formulation includes: Loperamide 5%, Propylene Glycol; Ethanol (190 proof USP); Ethyl acetate; and Klucel HF 1%.
2977764|NCT02711891|Placebo Comparator|Placebo gel|Participants received placebo gel (0.2gm) applied following a single surgilance to the 5th digit. The placebo gel was applied 10 minutes following the first lance, rubbed in for one minute within an 8 mm mold surrounding the lance site. The mold was removed and the gel was covered with a transparent occlusive dressing and left in place for 30 minutes. The forearm was also swabbed with the placebo gel which was left in place for 30 minutes. .The placebo gel contained the same ingredients without the loperamide. The placebo gel formulation includes: Propylene Glycol; Ethanol (190 proof USP); Ethyl acetate; and Klucel HF 1%.
2977765|NCT02711878|Experimental|Let's Move Program|Participants in this group will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes in their home while wearing a heart rate monitor and a pedometer. Participants will then enter a maintenance exercise period for 65 weeks.
2977766|NCT02711878|Active Comparator|Let's Flex Program|Participants in this group will be asked to stretch five times per week for twelve weeks for a minimum of thirty minutes in their home. Participants will then enter a maintenance exercise period for 65 weeks.
2977767|NCT02711865||MK-0646|Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice treated with the IGF1R antibody MK-0646. The drug will be administered twice weekly, via IP injection at a dose of 500 microgram per animal.
2977768|NCT02711865||Control|Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice who receive no other treatment.
2977769|NCT02711852|Experimental|Drug: Duvelisib (IPI-145)|Subjects will begin taking the same dose from their previous duvelisib study. All doses are taken by mouth twice daily (BID). Two dose reductions are allowed per subject, but doses may not be less than 10 mg.
2977770|NCT02711839|Placebo Comparator|Control Group|Commercial diabetic formula
2977771|NCT02711839|Experimental|Treatment Group|White sweet potato formula
2977772|NCT02711826|Active Comparator|Maintenance CNI based immunosuppression therapy group|Standard of care
2977773|NCT02711826|Experimental|Polyclonal Regulatory T Cells group|"Subjects to receive polyTregs (400 ± 100 x 10^6). After polyTreg infusion, eligible subjects will start Mammalian Target of Rapamycin (mTOR) inhibitor.~Target tacrolimus trough levels prior to conversion to everolimus are 4-11 μg/dl, which falls within standard of care. For eligible participants in polyTregs and darTregs groups, the tacrolimus dose will be reduced by 50% when everolimus is initiated. Tacrolimus will be discontinued 4 weeks after initiation of everolimus therapy.~Everolimus, a mTOR inhibitor immunosuppressant, will be initiated at a dose of 1.5 mg orally twice daily and titrated, as needed. Participants will begin everolimus with target trough levels of 3-8μg/L for 4 weeks while still taking tacrolimus. Everolimus target trough levels will be 6-10 μg/L when tacrolimus is discontinued."
2977774|NCT02711826|Experimental|Donor-Alloantigen-Reactive Regulatory T Cells group|"Subjects to receive darTregs (400 ± 100 x 10^6). After darTregs infusion, eligible subjects will start Mammalian Target of Rapamycin (mTOR) inhibitor.~Target tacrolimus trough levels prior to conversion to everolimus are 4-11 μg/dl, which falls within standard of care. For eligible participants in polyTregs and darTregs groups, the tacrolimus dose will be reduced by 50% when everolimus is initiated. Tacrolimus will be discontinued 4 weeks after initiation of everolimus therapy.~Everolimus, a mTOR inhibitor immunosuppressant, will be initiated at a dose of 1.5 mg orally twice daily and titrated, as needed. Participants will begin everolimus with target trough levels of 3-8μg/L for 4 weeks while still taking tacrolimus. Everolimus target trough levels will be 6-10 μg/L when tacrolimus is discontinued."
2977775|NCT02711813|Placebo Comparator|Placebo|Placebo to TAB08
2977776|NCT02711813|Experimental|TAB08 Dose 1|
2977777|NCT02711813|Experimental|TAB08 Dose 2|
2977778|NCT02711800|Experimental|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by Dr. Patrick Seed from the department of pediatrics. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The intervention duration is 30 days.
2977779|NCT02711787|Experimental|Experimental group|Robotic device Gloreha (Gloreha, Idrogenet, Italy) and traditional rehabilitation, 60-minute session for 3 consecutive weeks (3 days/week).
2977780|NCT02711787|Active Comparator|Control group|Physiotherapy, occupational therapy and traditional rehabilitation, 60-minute session for 3 consecutive weeks (3 days/week).
2977781|NCT02711761|Experimental|15 cm|The depth of guide wire will be 15 cm from puncture site of skin prior to tissue dilation during central venous catheterization
2977782|NCT02711761|Experimental|17.5 cm|The depth of guide wire will be 17.5 cm from puncture site of skin prior to tissue dilation during central venous catheterization
2977783|NCT02711761|Active Comparator|20 cm|The depth of guide wire will be 20 cm from puncture site of skin prior to tissue dilation during central venous catheterization
2977784|NCT02711748|Experimental|Bradycardia|Treatment In case of bradycardia. The patient unconscious, breathing preserved in ECG - bradycardia 40 / min with pulse.
2978287|NCT02708602||β2AR Gly16Gly (GG group)|People with β2AR Gly16Gly genotype.
2977786|NCT02711735|Active Comparator|RUTI® vaccine|Intervention: Patients randomized to receive RUTI® vaccine will receive one injection of RUTI® vaccine in their right or left deltoid muscle.
2977787|NCT02711735|Placebo Comparator|Matching RUTI® Placebo|Intervention: Patients randomized to receive Placebo will receive one injection of Placebo in their right or left deltoid muscle.
2977788|NCT02711722|Active Comparator|PScli1|Patients are ventilated in Pressure support (PS) according to the Clinical settings for 30min.
2977789|NCT02711722|Active Comparator|NAVAcli|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to match to respiratory muscle unloading reached with PScli1. Patients are ventilated in NAVAcli for 30min.
2977790|NCT02711722|Active Comparator|NAVA40%|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to target 40% muscle unloading based on the Neuro-Ventilatory Efficiency (NVE) measurement. Patients are ventilated in NAVA40% for 30min.
2977791|NCT02711722|Active Comparator|NAVA60%|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to target 60% muscle unloading based on the Neuro-Ventilatory Efficiency (NVE) measurement. Patients are ventilated in NAVA60% for 30min.
2977792|NCT02711722|Active Comparator|PScli2|Patients return to PS ventilation, according to the Clinical settings as in PScli1 for 30min.
2977793|NCT02711709|Other|Intra-abdominal sepsis|Frailty measurements. Modified Minnesota Leisure Time Activities. Computed tomography morphometrics. Mobility Monitors.
2977794|NCT02711696|Active Comparator|A, GCED cohort|GCED, Gluten Contamination Elimination Diet
2977795|NCT02711696|No Intervention|B, time cohort|Cohort B consisted of patients on long term follow-up that accepted a repeated biopsies 60 or more months later the first control biopsy.
2977796|NCT02711683||DL-3-n-butylphthalide group|using DL-3-n-butylphthalide treatment in patients with mild to moderate AD already receiving donepezil
2977797|NCT02711683||donepezil group|only using donepezil treatment in patients with mild to moderate AD
2977798|NCT02711670|Experimental|thiazide|Stone formers History of calcium containing kidney stones, hypercalciuria on previous urine tests, no kidney disease, not pregnant/lactating
2977799|NCT02711657|Experimental|Fibrocyte measurement and lung function test|All participants has a peripheral blood sample taken, where fibrocytes are measured using flowcytometry. Further peripheral blood mononuclear cells (PBMC) are isolated and cultured. All, except healthy controls, have their lung function measured.
2977800|NCT02711644|Experimental|Supportive Lifestyle Counselling|Two supportive lifestyle counselling sessions with Registered Dietitian from study entry to 34 weeks.gestation.
2977801|NCT02711644|Active Comparator|Standard Lifestyle Counselling|Two standard counselling sessions with Registered Dietitian from study entry to 34 weeks gestation
2977802|NCT02711631|No Intervention|Control: Standard therapy|Participants in this arm of the study will receive standard therapy.
2977803|NCT02711631|Experimental|MedBIKE|Participants in this arm will be using the new MedBIKE system as their method of rehabilitation.
2977804|NCT02711618|Experimental|UltraShape Contour I V3 treatment|Up to 60 healthy adult volunteers seeking noninvasive fat reduction, male and females at up to four sites, age of 18 to 60, with BMI above 28
2977805|NCT02711605|Experimental|Unilateral UltraShape treatment|One side of the chest (left or right breast) will be treated with the UltraShape focused ultrasound device, while the opposite will serve as an untreated control.
2977806|NCT02711605|Experimental|Bilateral UltraShape treatment|Both sides of the chest (right and left breasts) will be treated with the UltraShape focused ultrasound device.
2977807|NCT02711592|Other|Genetic Panel for Analgesics|Genetic testing for analgesics prior to surgery will be conducted. The subject will receive postoperative analgesia based on test results.
2977808|NCT02711579|Experimental|Celecoxib for electroencephalography|Electroencephalography will be performed before and after celecoxib administration
2977809|NCT02711579|Placebo Comparator|Placebo for electroencephalography|Electroencephalography will be performed before and after placebo administration
2977810|NCT02711579|Experimental|Celecoxib for motor evoked potential|Motor evoked potential will be measured before and after celecoxib administration
2977811|NCT02711579|Placebo Comparator|Placebo for motor evoked potential|Motor evoked potential will be measured before and after placebo administration
2977812|NCT02711566|Active Comparator|Sensorimotor training|"Patients in this arm were assigned to the 'Physioassistant: Haptic training' intervention. The treatments were delivered through a planar robotic manipulandum, specifically designed for motor learning studies and robot-assisted rehabilitation.~All participating centers used the exact same apparatus and experimental set-up."
2977813|NCT02711566|Experimental|Haptic training|Patients in this arm were assigned to the 'Physioassistant: Sensorimotor training' intervention. The treatments were delivered through a planar robotic manipulandum, specifically designed for motor learning studies and robot-assisted rehabilitation. All participating centers used the exact same apparatus and experimental set-up.
2977814|NCT02711553|Experimental|Ramucirumab|"A1: Ramucirumab plus cisplatin and gemcitabine intravenously (IV) on Days 1 and 8, every 21 days.~A2: Placebo plus cisplatin and gemcitabine IV on Days 1 and 8, every 21 days."
2977815|NCT02711553|Experimental|Merestinib|"B1: Merestinib orally each day, plus cisplatin and gemcitabine IV on Days 1 and 8, every 21 days.~B2: Placebo orally each day, plus cisplatin and gemcitabine IV on Days 1 and 8, every 21 days."
2977816|NCT02711540||Pre-TAVI Balloon Aortic Valvuloplasty|This is the cohort of patients in the study who did receive Balloon Aortic Valvuloplasty (BAV) prior to TAVI implantation
2977817|NCT02711540||No Pre-TAVI Balloon Aortic Valvuloplasty|This is the cohort of patients in the study who did not receive Balloon Aortic Valvuloplasty (BAV) prior to TAVI implantation
2977818|NCT02711527|Active Comparator|Acupunture group A|"The subjects will receive acupuncture treatment twice weekly for 3 weeks (6 treatments in total) Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation , all needles will be retained for 30 minutes."
2977819|NCT02711527|Active Comparator|Acupunture group B|"The subjects will receive acupuncture treatment twice weekly for 3 weeks (6 treatments in total). Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes."
2977926|NCT02710851|Placebo Comparator|Hepatitis E vaccine,Hecolin®|Participants in this arm would receive Hepatitis E vaccine,Hecolin®
2977820|NCT02711501|Experimental|Laser irradiation|laser-assisted surgery with the following parameters: Wavelength:810 nanometer, power: 3 W, pulse mode,pulse length 100 µs, pulse interval 200 µs
2977821|NCT02711501|Experimental|blade|conventional surgery by blade
2977822|NCT02711488|Experimental|Intervention group|Combine primary prevention activities at the school level with secondary prevention at the household level
2977823|NCT02711488|No Intervention|Control group|No intervention
2977824|NCT02711462|Other|Cohort 1|Subjects will receive 2mg of PF 06687234 or placebo via the SC route
2977825|NCT02711462|Other|Cohort 2|Subjects will receive 20mg PF 06687234 or placebo via the SC route
2977826|NCT02711462|Other|Cohort 3|This is an optional cohort that may be added anytime during the study. In this cohort, subjects will receive PF 06687234 or placebo via the SC route
2977827|NCT02711462|Other|Cohort 4|Subjects will receive 40mg of PF 06687234 or placebo via the SC route
2977828|NCT02711462|Other|Cohort 5|Subjects will receive 80mg of PF 06687234 or placebo via the SC route
2977829|NCT02711462|Other|Cohort 6|Subjects receive a single dose of PF 06687234 or placebo via the IV route
2977830|NCT02711462|Other|Cohort 7|This is an optional cohort where Japanese subjects will receive PF 06687234 or placebo via the SC route
2977831|NCT02711462|Other|Cohort 8|Subjects in this cohort may receive 20 mg of PF 06687234 or placebo via the SC route every week with a total of 5 doses
2977832|NCT02711462|Other|Cohort 9|Subjects in this cohort may receive 40 mg of PF 06687234 or placebo via the SC route every two weeks with a total of 3 doses
2977833|NCT02711462|Other|Cohort 10|This is an optional cohort. The maximum dose tested in the multiple dose cohort will not exceed the highest dose tested in the single dose cohorts
2977834|NCT02711462|Other|Cohort 11|This is an optional cohort. The maximum dose tested in the multiple dose cohort will not exceed the highest dose tested in the single dose cohorts
2977835|NCT02711449|Experimental|Methylprednisolone|125 mg Methylprednisolone intravenously approximately 30 minutes prior to skin incision
2977836|NCT02711449|Placebo Comparator|Placebo|0.9% Saline intravenously approximately 30 minutes prior to skin incision
2977837|NCT02711436|Active Comparator|Computed Tomography Scan|To determine the presence of periosteal or orbital abscess, intracranial abscess and dural venous sinus thrombosis that are imaged properly with Computed Tomography scan.
2977838|NCT02711436|Active Comparator|Fast Magnetic Resonance Imaging|To determine the presence of periosteal or orbital abscess, intracranial abscess and dural venous sinus thrombosis that are imaged properly with T1/T2-weighted MRI.
2977839|NCT02711423|Experimental|Part I (Dose Escalation): Gantenerumab|Participants will receive a single SC dose of gantenerumab on Day 1.
2977840|NCT02711423|Placebo Comparator|Part I (Dose Escalation): Placebo|Participants will receive a single SC dose of matching placebo on Day 1.
2977841|NCT02711423|Experimental|Part II (PK Extension): Gantenerumab|Participants will receive a single SC dose of gantenerumab on Day 1. The dose range will be determined by safety and tolerability data collected from Part I.
2977842|NCT02711397||Celiac patients|Celiac patients following a GFD for at least one year prior to the inclusion in the study.
2977843|NCT02711397||Positive controls|Healthy children and adults on an unrestricted gluten containing diet.
2977844|NCT02711397||Negative controls|Healthy infants who were exclusively fed with infant formula specifically labelled as gluten-free.
2977845|NCT02711371||Cannabis Dependence|Cannabis dependent individuals according to DSM 4 criteria, aged 18-40 years
2977846|NCT02711371||Healthy|Healthy controls, socio-demographically matched
2977847|NCT02711358|Experimental|indomethacin|indomethacin suppositories
2977848|NCT02711358|Placebo Comparator|placebo|placebo suppositories
2977849|NCT02711345|Experimental|Escalation|
2977850|NCT02711345|Experimental|Expansion Group 1|
2977851|NCT02711345|Experimental|Expansion Group 2|
2977852|NCT02711345|Experimental|Expansion Group 3|
2977853|NCT02711345|Experimental|Expansion Group 4|
2977854|NCT02711332||Degree of Haemolysis|Each subject will have four capillary blood sampling on different fingers. A reference venous blood sampling will be conducted.
2977855|NCT02711319|Active Comparator|active (real) rTMS (ACTIVE GROUP)|"The patients were randomly distributed in two study groups: real or sham rTMS group.~For real rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes."
2977856|NCT02711319|Sham Comparator|sham rTMS (SHAM GROUP)|For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2).
2977857|NCT02711306|Experimental|GMN diet first, than PN diet|Randomized, cross-over, controlled feeding trial with a 2 week washout between alternative diets, subjects were assigned to receive GMN or PN diet for 4 weeks after a 2-weeks run-in period
2977858|NCT02711306|Experimental|PN diet first, than GMN diet|Randomized, cross-over, controlled feeding trial with a 2 week washout between alternative diets, subjects were assigned to receive GMN or PN diet for 4 weeks after a 2-weeks run-in period
2977859|NCT02711293|Experimental|ART home delivery + enhanced nutrition counseling|Community health workers visit participants at home (maintaining patients' prior clinic visit frequency) to deliver antiretroviral therapy (ART) and to provide standard plus enhanced nutrition counseling.
2977860|NCT02711293|Experimental|ART home delivery + no enhanced nutrition counseling|Community health workers visit participants at home (maintaining patients' prior clinic visit frequency) to deliver antiretroviral therapy (ART) and to provide standard counseling.
2977861|NCT02711293|Experimental|No ART home delivery + enhanced nutrition counseling|Community health workers visit participants at home to provide enhanced nutrition counseling. Participants will not receive ART home delivery.
2977862|NCT02711293|No Intervention|Standard of care|Participants in this arm receive facility-based ART care and no enhanced nutrition counseling. They receive community health worker visits as per the standard of care in Dar es Salaam.
2977863|NCT02711280|Experimental|Sevoflurane General anesthesia|Anesthesia was induced with 8% sevoflurane with 8L/min oxygen. Anesthesia was maintained with 1-3% sevoflurane in oxygen/air mixture.
2977968|NCT02710604|Active Comparator|CMX157 10mg versus TDF|CMX157, 10mg tablet, 28 days versus TDF 300mg tablet, 28 days
2977864|NCT02711280|Experimental|Propofol General anesthesia|Anesthesia was induced with propofol 4mg/kg. Anesthesia was maintained with propofol 7-12mg/kg/h.
2977865|NCT02711267|Experimental|Phase 1: Optimization Study|6 subjects will be included in this study, each with 3 application sites on the arm and 3 on the leg. 2 dOFM probes (OFM Probe) will be implanted per site resulting in 12 dOFM probes per subject (operated by OFM pump). On each the arm and the leg the proximal and distal site of the 3 adjacent sites will be treated by 5% Zovirax® cream. The central site on arm and leg will be left untreated in order to test a potential lateral carry-over of acyclovir from one application site to the other. Blood samples will be taken to test for uptake into the blood stream and redistribution to other application sites.
2977866|NCT02711267|Experimental|Phase 2: Formulation Study|6 subjects will be included in this study, each with 3 application sites on the arm and 3 on the leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. Different topical 5% acyclovir formulations currently available on the market will be tested. One application site on the arm and one on the leg will be used for U.S. Zovirax® cream 5% application. The remaining two application sites on the arm and the remaining 2 on the leg will be used to randomly administer two of the remaining formulations (5% Aciclostad cream, 5% Aciclovir cream 1A Pharma, 5% Zovirax® cream (Austria), 5% Zovirax Cold Sore Cream) according to an application pattern.
2977867|NCT02711267|Experimental|Phase 3: Pilot BE study|4 subjects will be included in the pilot BE study with 3 application sites on each leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. One reference drug product (R) and one test drug product (T) will be applied on the application sites in order to test for BE between duplicate sites with R applied, and to test for non-BE between application sites with R and T applied.
2977868|NCT02711267|Experimental|Phase 4: Main BE Study|20 subjects will be included in the pilot BE study with 3 application sites on each leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. One reference drug (R) and one test drug (T) will be applied on the application sites in order to test for BE between duplicate sites with R applied and to test for non-BE between application sites with R and T applied.
2977869|NCT02711254|Experimental|Phantom System|Patients will be treated with the Phantom Knee System device
2977870|NCT02711241|Active Comparator|Dipyrone|
2977871|NCT02711241|Active Comparator|Papaverine|
2977872|NCT02711228|Experimental|Subcutaneous Immune Globulin (Human) (Hizentra)|Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.
2977873|NCT02711202|Active Comparator|Sirolimus|Patients received two applications of anti-CD52 MabCampath (Alemtuzumab), a single dose of anti-TNF-α Remicade (Infliximab) monoclonal antibodies in the early posttransplant period. First 14 days patients received tacrolimus monotherapy, at post-operative day (POD) 14, they were randomized to sirolimus monotherapy.
2977874|NCT02711202|Active Comparator|Tacrolimus|Patients received two applications of anti-CD52 MabCampath (Alemtuzumab), a single dose of anti-TNF-α Remicade (Infliximab) monoclonal antibodies in the early posttransplant period. First 14 days patients received tacrolimus monotherapy, at POD 14, they were randomized to tacrolimus monotherapy.
2977875|NCT02711189|Placebo Comparator|Placebo|Within Subject Design
2977876|NCT02711189|Active Comparator|Oxytocin|Intranasal oxytocin will be delivered on twice daily basis in this crossover trial.
2977877|NCT02711176|Experimental|Tavanex & Nexium & Tinafas|"Patients will receive Nexium (Esomeprazole) 40 mg daily and Tinafas (Tinidazole) 1 g daily and Tavanex (Levofloxacin) 500 mg daily for 14 days"
2977878|NCT02711176|Active Comparator|Lanzol & Klacid &Iramox|Patients will receive Lanzol (lansoprazole) 30 mg twice daily and Klacid (clarithromycin) 500 mg twice daily and Iramox (amoxicillin) 1 g twice daily for 14 days
2977879|NCT02711163|Experimental|Extensively hydrolyzed formula|Feeding extensively hydrolyzed formula
2977880|NCT02711163|Placebo Comparator|Amino acid formula|Feeding amino acid formula
2977881|NCT02711150|Experimental|EPD Measurements|"Intervention:~PLL Length Measured through US will be done with the subject placed on the Epidural Positioning Device."
2977882|NCT02711150|Active Comparator|Flexed Position Measurements|"Intervention:~PLL Length Measured through US will be done with the subject placed in a flexed lumbar spine position."
2977883|NCT02711137|Experimental|INCB057643|
2977884|NCT02711137|Experimental|INCB057643 + Standard of Care (SOC) agents|
2977885|NCT02711124||Group with hemoglobin A1c < 7|There will be no intervention administered to the group. The group will be observed for platelet function pre- and postoperatively.
2977886|NCT02711124||Group with hemoglobin A1c ≥ 7%|There will be no intervention administered to the group. The group will be observed for platelet function pre- and postoperatively.
2977887|NCT02711111|Experimental|orthodontic bone anchor|new bone anchor device, which creates anterior traction on the upper jaw. Placed on the chin-region intra-orally.
2977888|NCT02711111|Active Comparator|face mask protraction|control group, conventional treatment method. Face mask creates anterior traction on the upper jaw
2977889|NCT02711098|Active Comparator|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5 ° C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5 ° C for 24 hours.
2977890|NCT02711098|Placebo Comparator|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5 ° C for 48 hours.
2977891|NCT02711085||Acute trauma|Those within the first 3 weeks of a non-catastrophic injury affecting the musculoskeletal system, including but not limited to whiplash or other road-traffic collisions, sports injuries, work-related injuries, sprains, strains, slips and falls and non-displaced fractures that don't require surgical correction.
2977892|NCT02711072|Placebo Comparator|control group|
2977893|NCT02711072|Active Comparator|infiltration group|
2977894|NCT02711059|Active Comparator|parathyroidectomy|change in insulin resistance
2977895|NCT02711059|No Intervention|control|the study participant will be examined parallel with the active comparator
2977896|NCT02711046|Experimental|single stage nasolabial flap|single staged nasolabial flap as an interpositional material after surgical resection of fibrous band in oral submucous fibrosis
2979470|NCT02700620|No Intervention|Control group|Waitlist control
2977897|NCT02711033|Experimental|Laparoscopic-assisted total gastrectomy|Patients including in the laparoscopic-assisted total gastrectomy (LATG) group will undergo LATG with spleen-preserving splenic hilum lymph nodes dissection.
2977898|NCT02711033|Active Comparator|Open total gastrectomy|Patients who are included in the open total gastrectomy (OTG) group will OTG with spleen-preserving splenic hilum lymph nodes dissection.
2977899|NCT02711020|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy delivered in individual format.
2977900|NCT02711020|Experimental|Personal Construct Therapy|Personal Constructs Therapy delivered in individual format.
2977901|NCT02711007|Experimental|apatinib|apatinib 750mg tablet or 500mg tablet by mouth, Qd half an hour after dinner
2977902|NCT02710994|Experimental|CDFR0209, Then Losec|Subjects first received CDFR0209 each morning in a fasting state for 7 days. After a washout period of 14 days, they then received Losec 40 mg in a fasting state each morning for 7 days.
2977903|NCT02710994|Experimental|Losec, Then CDFR0209|Subjects first received Losec 40 mg each morning in a fasting state for 7 days. After a washout period of 14 days, they then received CDFR0209 in a fasting state each morning for 7 days.
2977904|NCT02710981|Active Comparator|Clomiphene citrate only|women with prior 5 ovulatory cycles of Clomiphene citrate induction, but without conception (clomiphene citrate failure), with thin endometrium (<8mm) in at least 3 cycles.
2977905|NCT02710981|Experimental|Sildenafil vaginal gel and Clomiphene|Women who did not conceive on the Clomiphene citrate only cycle (41 women) were given Clomiphene citrate 100 mg/ day starting from day of the cycle for 5 days, with the addition to sildenafil vaginal gel 5 gm twice daily starting from day 8 of the cycle until day of HCG injection.
2977906|NCT02710968|Experimental|11540KE and Balt Goldbal 2 balloon|"Patients meeting inclusion criteria will receive fetoscopic tracheal occlusion using the fetoscopy sheath 11540 KE and the Balt Goldbal2 detachable balloon.~Participants with an O/E LHR 25% (severe group) will have FETO completed at 27 weeks + 0 days to 29 weeks + 6 days gestation. Balloon removal is 4-5 weeks after that.~Participants with an O/E LHR 25 - <30% (less severe group) will have FETO completed at 30 weeks + 0 days to 31 weeks + 6 days gestation. Balloon removal is 3 - 4 weeks after that."
2977907|NCT02710955|Experimental|Thickened infant formula|
2977908|NCT02710942|Experimental|SPHERE intervention|It is a comprehensive self-guided Internet-based cognitive-behavioral therapy (CBT) that includes three components: (1) the myWHI diary. (2) 30 multi-media learning topics that the user is encouraged to go through in a sequential way. The topics contain education information and teach strategies to cope better with their headaches.
2977909|NCT02710942|Experimental|PRISM intervention|It is a targeted self-guided Internet-based CBT intervention. PRISM was built upon the myWHI diary, an electronic headache diary. PRISM helps users discover their headache triggers by analyzing the inputted diary data using association rule mining. Once one or multiple headache triggers are identified the application uses an algorithm to provide the user with a few personalized recommendations to help them to cope with these triggers. The algorithm is based on the opinion of clinical experts (e.g., medical health professionals, psychologists). The user chooses recommendations to follow and sets goals in the application to follow them. To support the process, the application checks in with users about their goals and tracks goal completion.
2977910|NCT02710942|No Intervention|Usual care|Participants can continue doing what they usually do to deal with their migraines.
2977911|NCT02710929||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-IV criteria
2977912|NCT02710929||TD group|Typically development controls without lifetime diagnosis with ADHD
2977913|NCT02710916|Sham Comparator|perimetric glaucoma patients|
2977914|NCT02710916|Active Comparator|preperimetric glaucoma patients|
2977915|NCT02710916|Sham Comparator|perimetric glaucoma control patients|
2977916|NCT02710903|Experimental|Healthy with Dominant IL28B and IL29|Stent-induced biofilm overgrowth model will be used in dominant IL28B and IL29 allelic with probing depths (PD) ≤4mm, no evidence of inter proximal clinical attachment loss (CAL), and <20% of sites with bleeding on probing (BOP).
2977917|NCT02710903|Experimental|Periodontal Disease with Dominant IL28B and IL29|Stent-induced biofilm overgrowth model will be used in dominant IL28B and IL29 allelic with the presence of at least four periodontal sites with PD ≥ 5mm, evidence of interproximal CAL, and ≥20% of sites with BOP.
2977918|NCT02710903|Experimental|Healthy with IL28B and/or IL29 SNP variants|Stent-induced biofilm overgrowth model will be used in IL28B or IL29 SNP variants with PD ≤4mm, no evidence of interproximal CAL, and <20% of sites with BOP.
2977919|NCT02710903|Experimental|Periodontal Disease with IL28B and/or IL29 SNP variants|Stent-induced biofilm overgrowth model will be used in IL28B or IL29 SNP variants with the presence of at least four periodontal sites with PD ≥ 5mm, evidence of interproximal CAL, and ≥20% of sites with BOP.
2977920|NCT02710890|Experimental|Lacosamide|Up to 2 age-based Cohorts with Cohort 1 including at least 40 subjects who are >=8 to <17 years and Cohort 2 including at least 20 subjects who are >=4 to <8 years. Within Cohort 1, at least 20 subjects will be >=12 to <17 years of age and at least 20 subjects will be >=8 to <12 years of age. A Data Monitoring Committee (DMC) will review the safety and tolerability data for each Cohort to make the following recommendations: the progression of the current Cohort, including iv infusion durations to be evaluated, and progression to initiate enrollment in the next Cohort (Cohort 2) and whether to initiate the assessment of safety in younger pediatric subjects (>=1 month to <4 years of age)
2977921|NCT02710877|Experimental|Programmed Intermittent bolus (PIEB)|Intervention: epidural analgesia through administration of a mixture of levobupivacaine 0,0625% and sufentanil 4 mcg. Intermittent bolus of 10 ml mixture every 75 minutes. Patient controlled bolus of 5 ml same mixture, lock-out 15 minutes.
2977922|NCT02710877|Active Comparator|Manuale epidural bolus (TOP-UP)|Intervention: manual epidural bolus of 15 ml levobupivacaine 0,0625% and sufentanil 5 mcg on maternal request.
2977923|NCT02710851|Experimental|low dosage HPV Vaccine(1:1)|Participants in this arm would receive low dosage HPV vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
2977924|NCT02710851|Experimental|low dosage HPV Vaccine(1:2)|Participants in this arm would receive low dosage HPV vaccine with virus-like particles type 6 and 11 at 1:2 ratio.
2977925|NCT02710851|Experimental|high dosage HPV Vaccine(1:1)|Participants in this arm would receive high dosage HPV vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
2978288|NCT02708602||β2AR Gln27Gln (CC group)|People with β2AR Gln16Gln genotype.
2977927|NCT02710838|Experimental|Cancer group|All patients receive the infrared endoscopy after injecting indocyanine green（ICG） intravenously.
2977928|NCT02710838|Other|Non-cancer group|All patients receive the infrared endoscopy after injecting ICG intravenously.
2977929|NCT02710825|Experimental|Osteopathic treatment|
2977930|NCT02710825|Placebo Comparator|Simulated osteopathic treatment|
2977931|NCT02710812||Rectum sparing group|"Patients who have all of the following requirements:~Major or complete clinical response at restaging after 7-8 weeks from the end of neoadjuvant therapy, confirmed at second restaging (after 11-12 weeks from the end of neoadjuvant therapy);~Written informed consent (after 2nd restaging).~Note: They will be subject to wait-and-see approach only patients with cCR."
2977932|NCT02710799|Active Comparator|Control|Referrals will be evaluated through the state's protocols
2977933|NCT02710799|Experimental|Intervention|Referrals will be evaluated through the state's protocols associated with telephone-based teleconsultations.
2977934|NCT02710786||Gastric bypass|Patients undergoing gastric bypass
2977935|NCT02710773|Experimental|Backward Walking Treadmill Training|The subjects will perform a backward walking training on treadmill device
2977936|NCT02710773|Active Comparator|Treadmill training|The subjects will perform a walking training on treadmill device
2977937|NCT02710760|No Intervention|Control|Households in the control group receive no special treatment.
2977938|NCT02710760|Experimental|Adoption Encouragement Treatment|"Households in the Adoption Encouragement Treatment group were visited between March and April 2015 and offered child nutrition focused adoption encouragement. Both the male household head and the primary female caregiver were invited to attend these meetings (though the household head is the primary target), where the nutritional benefits of Quality Protein Maize (QPM) adoption for children were emphasized along with the agronomic properties. In addition, the fact that only small amounts of QPM are necessary to nourish children was highlighted and small seed bag sizes were offered. During the adoption encouragement visit, we offered the option to order up to three 2 kg bags of QPM for free."
2977939|NCT02710760|Experimental|Consumption Encouragement Treatment|In addition to receiving the Adoption Encouragement Treatment, households in the Consumption Encouragement Treatment group received additional information, targeted to the caregiver, and tools for separating Quality Protein Maize and targeting it to young children in the household in August 2015. They will additionally receive further guidance in February 2016.
2977940|NCT02710747|Experimental|Genetic Group|Dose (mg/week) = [5.6044 - 0.02614 × Age [in years] + 0.0087 × Height [cm] + 0.0128 × Weight [kg] - 0.8677 × VKORC1 A/G -1.6974 × VKORC1 A/A - 0.5211 × CYP2C9 *1/*2 - 0.9357 × CYP2C9 *1/*3 - 1.0616 × CYP2C9 *2/*2 - 1.9206 × CYP2C9*2/*3 - 2.3312 × CYP2C9 *3/*3 - 0.1092 × Asian race - 0.5503 × amiodarone ]2
2977941|NCT02710747|No Intervention|Control Group|Dose for the first three days after operation will be 4.5mg/d.
2977942|NCT02710734|Experimental|CRT|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then chemoradiation followed by TURBT#3
2977943|NCT02710734|Experimental|Surveillance|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then active surveillance
2977944|NCT02710734|Experimental|Intravesicle therapy|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then intravesicle therapy followed by TURBT#3
2977945|NCT02710734|Experimental|Radical Cystectomy|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then cystectomy
2977946|NCT02710721|Experimental|Fasting|60h-modified fasting (36h before and 24h after chemotherapy)
2977947|NCT02710721|Active Comparator|Control|mediterranean diet
2977948|NCT02710708|Experimental|Ethinyl Estradiol 20 (EE20)/DRSP (YAZ, BAY86-5300)|Chinese women between 18 and 45 years old inclusive (smokers not older than 35 years old) requesting oral contraception who have no contraindication to YAZ will be recruited for the study. Women who underwent surgical or medical abortions will also be recruited.
2977949|NCT02710695|Active Comparator|Control|This group will receive a 10 minute discussion
2977950|NCT02710695|Active Comparator|Intervention|This group will receive a 10 minute standardized discussion
2977951|NCT02710682|Active Comparator|Mini-open surgery|Surgery
2977952|NCT02710682|Experimental|Ultrasound-guided Tendon fenestration|Tendon fenestration
2977953|NCT02710669|Experimental|(R)-propafenone|Single intravenous dose of (R)-propafenone (2mg/kg) infused over 10 minutes
2977954|NCT02710669|Active Comparator|(S)-Propafenone|Single intravenous dose of (S)-propafenone (2mg/kg) infused over 10 minutes
2977955|NCT02710669|Placebo Comparator|Placebo|Placebo (normal saline) is infused over 10 minutes
2977956|NCT02710656|Experimental|Drug Coated Balloon (DCB) - Legflow®|Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting Legflow® balloon.
2977957|NCT02710656|Active Comparator|Standard PTA - POBA|Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug eluting balloon (POBA, plain old balloon angioplasty).
2977958|NCT02710643|No Intervention|MRD - BEFORE RT|Patients who had negative baseline Bcl-2 in PB and BM will not undergo further treatment after radiotherapy; they will not repeat Bcl-2 during subsequent follow-up visits.
2977959|NCT02710643|No Intervention|MRD + BEFORE RT AND MRD - AFTER RT|Patients who had positive baseline Bcl-2 in PB and / or BM and become negative after local radiotherapy will not undergo further treatment.
2977960|NCT02710643|Experimental|MRD + BEFORE RT AND MRD + AFTER RT|"Patients who had positive baseline Bcl-2 in PB and / or BM and remain positive after local radiotherapy get Ofatumumab (8 weekly infusion of 1000 mg total dose).~Patients Bcl-2 negativized either after radiotherapy or after Ofatumumab, who became Bcl-2 positive during the follow-up monitoring will be treated/retreated with Ofatumumab 8 weekly infusions at the conventional dose of 1000 mg; Bcl-2 monitoring will be continued subsequently according to the program.In case of persistent positive PCR after Ofatumumab the treatment will not be repeated."
2977961|NCT02710630|Active Comparator|Dabigatran etexilate capsule|
2977962|NCT02710630|Experimental|Dabigatran etexilate tablet A1|
2977963|NCT02710630|Experimental|Dabigatran etexilate tablet B1|
2977964|NCT02710630|Experimental|Dabigatran etexilate tablet C1|
2977965|NCT02710630|Experimental|Dabigatran etexilate tablet D1|
2977966|NCT02710630|Experimental|Dabigatran etexilate tablet E1|
2977967|NCT02710604|Active Comparator|CMX157 5mg versus TDF|CMX157, 5mg tablet, 28 days versus TDF(tenofovir disoproxil fumerate) 300mg tablet, 28 days
2977969|NCT02710604|Active Comparator|CMX157 25mg versus TDF|CMX157, 25mg tablet, 28 days versus TDF 300mg tablet, 28 days
2977970|NCT02710604|Active Comparator|CMX157 50mg versus TDF|CMX157, 50mg tablet, 28 days versus TDF 300mg tablet, 28 days
2977971|NCT02710604|Active Comparator|CMX157 100mg versus TDF|CMX157, 100mg tablet, 28 days versus TDF 300mg tablet, 28 days
2977972|NCT02710591|Experimental|Rimeporide|"Multiple oral doses of rimeporide ranging from 50 to 300 mg will be administered three times a day (TID) for a total of 4 weeks. 4 ascending dose levels will be studied sequentially in ascending order. Rimeporide is provided as hard gel 25 mg or 50 mg capsules.~Each patient will participate in only 1 dose cohort. 5 patients are expected to be recruited in each cohort through all participating sites."
2977973|NCT02710578|Active Comparator|Alcohol|Alcohol
2977974|NCT02710578|Placebo Comparator|Placebo|Tonic water
2977975|NCT02710565|Other|Cohort|"Participants who are scheduled to have an endo bronchial ultrasound (EBUS) trans bronchial needle aspiration (TBNA) will provide additional samples. These samples will then be sent to Imperial College London to see whether a cell line can be grown.~If growth is successful then the samples will be returned to our pathology department to see if grading is possible and then to compare these results with the previous diagnostic samples.~The cell line samples will not be used for patient diagnosis."
2977976|NCT02710552|Active Comparator|Three antihypertensive Drugs|Patients will be treated with Tripliam, that is a commercially available fixed low-dose combination of three antihypertensive drugs, that is 5 mg/daily perindopril, 1,25 mg/daily indapamide and 5 mg/day amlodipine
2977977|NCT02710552|Active Comparator|Two antihypertensive drugs|Patients will be treated with Reaptan, that is a commercially available fixed high-dose combination of two antihypertensive drugs, that is 10 mg/daily perindopril and 5 mg/day amlodipine
2977978|NCT02710539|Active Comparator|Free combination|Perindopril 10 mg/daily, indapamide 2,5 mg/daily, and amlodipine 10 mg/daily will be given according to a free combination strategy
2977979|NCT02710539|Active Comparator|Tripliam|fixed combination of perindopril 10 mg/daily, indapamide 2,5 mg/daily, amlodipine 10 mg/daily
2977980|NCT02710526|Experimental|32 mg CAM2038 weekly|Group 1, 32 mg of CAM2038 subcutaneous weekly injection at multiple injection sites
2977981|NCT02710526|Experimental|128 mg CAM2038 monthly injection|Group 2: 128 mg of CAM2038 subcutaneous monthly injection in the buttocks
2977982|NCT02710513|Experimental|Beta-glucans|2 months run-in period (Mediterranean Diet-based dietary scheme including a daily supply of 100 g of normal pasta) + 2 months intervention period (Mediterranean Diet-based dietary scheme including a daily supply of 100 g of functional pasta providing 3 g of beta-glucans/day)
2977983|NCT02710500|Experimental|Cohort 1 (Low Dose)|"Three (n=3) dysferlin deficiency subjects will receive bilateral injections with one extensor digitorum brevis muscle (EDB) receiving the rAAVrh74.MHCK7.DYSF.DV and the other side receiving saline alone.Subjects will receive a total dose of 2 x 10^12 in one muscle.~Intervention Drug: rAAVrh.MHCK7.DYSF.DV"
2977984|NCT02710500|Experimental|Cohort 2 (High Dose)|"Three (n=3) dysferlin deficiency subjects will receive bilateral injections with one extensor digitorum brevis muscle (EDB) receiving the rAAVrh74.MHCK7.DYSF.DV and the other side receiving saline alone.Subjects will receive a total dose of 6 x 10^12 vg in one muscle.~Intervention Drug: rAAVrh74.MHCK7.DYSF.DV"
2977985|NCT02710487|Experimental|REM Sleep Awakening (REMSA)|The investigators will actively awaken each subject from nocturnal REM sleep in a sleep laboratory setting, in the hour preceding her/his habitual wake time.
2977986|NCT02710487|Experimental|NREM Sleep Awakening (NREMSA)|Awakening from the NREM sleep stage N2 will be the control intervention.
2977987|NCT02710474|Active Comparator|Standard Care|Preterm infants will receive current Standard Care (SC) in the NICU.
2977988|NCT02710474|Experimental|Intervention|Preterm infants will receive Family Nurture Intervention (FNI) in addition to current Standard Care (SC) in the NICU. Specifically, staff will support the parents and facilitate contact between mother and infant during the NICU stay.
2977989|NCT02710474|Active Comparator|Term Controls|Full term infants will receive current Standard Care (SC) in the NICU. Term Controls (TC)
2977990|NCT02710461|Experimental|Subjects with abdominal obesity|Intervention with grape pomace and pomegranate pomace
2977991|NCT02710448|Experimental|Metformin|Metformin in patients with renal failure
2977992|NCT02710435||Arm 1 - Prospective|Includes eligible subjects in the prospective arm who undergo baseline testing followed by the Neovasc Reducer System implant procedure
2977993|NCT02710435||Arm 2 - COSIRA|Includes subjects who were previously enrolled and treated with the Neovasc Reducer System during the COSIRA study and agree to participate in this long term follow up study
2977994|NCT02710435||Arm 3 - CE Mark|"Includes subjects who received a Neovasc Reducer System under CE Mark (unrelated to the COSIRA study), and agree to participate in this long term follow up study~Arm 3 has been closed to enrollment-June 2017"
2977995|NCT02710422|Experimental|Arm 1 - Amniotic Membrane Placement|Participants who receive the human amniotic membrane placement after robotic assisted radical prostatectomy (RARP). Participants will also undergo PSA measurement and complete the EPIC 26 and Sexual History Inventory for Men (SHIM) psychosocial questionnaires at protocol-defined intervals.
2977996|NCT02710422|Other|Arm 2 - No Amniotic Membrane Placement|Participants who do not receive human amniotic membrane placement after robotic assisted radical prostatectomy (RARP). Participants will also undergo PSA measurement and complete the EPIC 26 and Sexual History Inventory for Men (SHIM) psychosocial questionnaires at protocol-defined intervals.
2977997|NCT02710409|Experimental|Quadrivalent influenza vaccine|
2977998|NCT02710409|Active Comparator|Trivalent influenza vaccine A|Active Comparator A
2977999|NCT02710409|Active Comparator|Trivalent influenza vaccine B|Active Comparator B
2978000|NCT02710396|Experimental|Cohort 1|Subjects will receive single agent pembrolizumab 200 mg IV will be administered every 3 weeks for up to 2 years.
2978001|NCT02710396|Experimental|Cohort 2|Subjects will receive pembrolizumab 200 mg IV every 3 weeks for up to 2 years with 2 cycles of nab-paclitaxel and carboplatin administered with cycles 1 and 2.
2978002|NCT02710396|Experimental|Cohort 3|Subject will receive pembrolizumab 200 mg IV every 3 weeks for up to 2 years with 2 cycles of pemetrexed and carboplatin administered with cycles 1 and 2.
2978003|NCT02710383||Observation|Patients at 2 months with a cystic fibrosis disease or high-grade suspicion for a cystic fibrosis disease
2985181|NCT02662114||Tresiba®|
2978004|NCT02710370||Controls|Patients who meet criteria for gastric bypass surgery, and do not have a documented history of Type 1 or Type 2 Diabetes.
2978005|NCT02710370||Participants with Type 2 Diabetes|Patients who meet criteria for gastric bypass surgery, and have a documented history of Type 2 Diabetes.
2978006|NCT02710357|Active Comparator|Mandibular complete denture|Participants allocated to this group will not receive any additional treatment. When needed, retreatment or any adjustment/repair in the dentures will be performed accordingly. Participants will receive regular maintenance for their dentures, including adjustments for the elimination of sore areas, denture relining and repair of fractures, when needed, until the end of the follow-up period.
2978007|NCT02710357|Experimental|Single-implant mandibular overdenture|Participants allocated to this group will have an implant placed in the mandibular midline and after 4 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
2978008|NCT02710344|No Intervention|Usual Care|Usual care at community mental health care provider
2978009|NCT02710344|Experimental|Telehealth|Usual care at community mental health care provider PLUS psychiatric telehealth program with remote monitoring.
2978010|NCT02710331|Experimental|Active THC and Placebo Ethanol|
2978011|NCT02710331|Experimental|Active THC and Active Ethanol|
2978012|NCT02710331|Experimental|Placebo THC and Active Ethanol|
2978013|NCT02710331|Placebo Comparator|Placebo THC and Placebo Ethanol|
2978014|NCT02710318|Experimental|Immunization Alert on|Children with visits seen when the immunization alert is on
2978015|NCT02710318|No Intervention|Immunization Alert off|Children with visits seen when the alert is off
2978016|NCT02710305|Active Comparator|Group A|oral hyoscine butyl bromide tablets plus lidocaine cream
2978017|NCT02710305|Placebo Comparator|Group B|oral placebo tablets plus placebo cream
2978018|NCT02710292|Other|DT1, then TE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.
2978019|NCT02710292|Other|TE, then DT1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.
2978020|NCT02710279|Other|Depressive patients|Depressive patients with or without story of suicidal behavior will pass the TSST and will have a psychological assessment to complete with a questionnaire on their smartphone
2978021|NCT02710266|Placebo Comparator|Placebo group|hepatectomy without Gabexate Mesilate
2978022|NCT02710266|Experimental|Preoperative Gabexate Mesilate group|Gabexate Mesilate administered from the preoperative day
2978023|NCT02710266|Experimental|Intraoperative Gabexate Mesilate group|Gabexate Mesilate administered from the operative day
2978024|NCT02710253|Experimental|Salvage Radiation Therapy|"Radiation treatment utilized in this trial consists of standard doses to 50 Gy in 4 fractions with stereotactic radiation or 60-70 Gy in 10 fractions (6-7 Gy/fraction,) or 20-30 Gy in 5 fractions or 20-30 Gy in 5 fractions or 30-45 Gy in 10-15 fractions with conventional external beam radiation.~Low dose radiation allowed on the other tumors. This will consist of a single dose of radiation on the last day of higher dose of radiation in which the primary tumor is being treated. This low dose radiation will use a range of doses (from 200cGy-30cGy).~Patients may receive additional radiation therapy consisting of either stereotactic body radiation therapy (SBRT) or conventionally fractionated radiation after the 2nd imaging evaluation as long as at least stable disease is noted."
2978025|NCT02710227||liver cirrhosis|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
2978026|NCT02710227||control|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
2978027|NCT02710214|Experimental|Duavee|1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
2978028|NCT02710214|Placebo Comparator|Placebo|Placebo pill daily for 8 weeks.
2978029|NCT02710201|No Intervention|Control|No feedback on progress of other participants.
2978030|NCT02710201|Experimental|Descriptive Social Norm|Average physical activity of other participants in study conveyed to this group.
2978031|NCT02710201|Experimental|Descriptive-plus-Injunctive Social Norm|Average physical activity of other participants in study and message of approval or disapproval (depending on how one is faring compared to others) conveyed to this group.
2978032|NCT02710188|Experimental|HTL0009936 modified release (MR) Formulation|Intervention: 5 different modified release formulations of HTL0009936, as a single dose
2978033|NCT02710188|Active Comparator|HTL00009936 immediate release (IR) fasted|Intervention: 1 immediate release formulation of HTL0009936, as a single dose in the fasted state
2978034|NCT02710162|Experimental|Screening|Participants enrolled will have the following test: Micro Mouth Pressure Meter, reflexive cough testing (with capsaicin used in blocks), lingual strength and endurance trials using the Iowa Oral Performance Instrument, Electrical Impedance Myography of the tongue, Pulmonary Function Testing, and a Videofluoroscopic Swallowing Study. In addition, the patient will complete the following surveys: Swallowing Related Quality of Life Questionnaire (SWAL-QOL), Eating Assessment Tool-10 (EAT-10), Functional Oral Intake Scale (FOIS), Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS), and the Communicative Effectiveness Survey (CES).
2978035|NCT02710149|Experimental|B Cell Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD20-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
2978036|NCT02710136|Experimental|Glycerinated CR Allergenic Extract|"Complete Arm Title: Glycerinated German Cockroach Allergenic Extract.~Cockroach sensitive subjects are exposed to cockroach nasal allergen (NAC) intranasally at at increasing doses per protocol. The NAC aim is pursuit of optimal dose range as determined by tolerability and eliciting a threshold of nasal symptoms."
2978060|NCT02709980|Active Comparator|Cognitive Behavior Therapy for Insomnia|6 sessions of cognitive behavioral therapy for insomnia (CBT-I).
2978061|NCT02709967|Active Comparator|Material support|Writing materials
2978062|NCT02709967|Experimental|Economic support|Writing materials and economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9).
2978037|NCT02710123|Experimental|Aerobic Exercise|Participants will receive an exercise prescription based on their heart rate threshold (HRT) for symptom exacerbation during the Buffalo Concussion Treadmill Test (BCTT). The script will ask the participant to exercise one a day for 20 minutes at 80% of HRT. Participants will wear a smart watch to monitor their frequency, actual time and HR during exercise. Treatment will continue until participant is fully recovered from their concussion. Intervention: Sub-Threshold exercise prescription
2978038|NCT02710123|Placebo Comparator|Stretching Exercise|Participants will receive a prescription for stretching exercises that they will be asked to do daily. Participants will wear a smart watch to monitor their frequency, actual time and HR during exercise. Treatment will continue until participant is fully recovered from their concussion. Intervention: Structured stretching exercise prescription.
2978039|NCT02710110|Experimental|Active Respiratory Trainer|Participants enrolled in this arm will be given the PowerLung trainer. The adjustable spring allows for discrete and calibrated changes to the valve, which in turn blocks air until sufficient inspiratory or expiratory pressure is applied by an individual. In addition, the Micro Mouth Pressure Meter, Pulmonary Function testing, videofluoroscopic swallowing study (VFSS), Swallowing Quality of Life Questionnaire (SWAL-QOL), Iowa Oral Pressure Instrument (IOPI), and capsaicin for use in the reflexive cough test.
2978040|NCT02710110|Sham Comparator|Sham Trainer|Participants enrolled in this arm will be given the PowerLung trainer; however, the adjustable spring allows for discrete and calibrated changes to the valve and these will not have any resistance. In addition, the Micro Mouth Pressure Meter, Pulmonary Function testing, videofluoroscopic swallowing study (VFSS), Swallowing Quality of Life Questionnaire (SWAL-QOL), Iowa Oral Pressure Instrument (IOPI), and capsaicin for use in the reflexive cough test.
2978041|NCT02710097|Experimental|Active THC and Placebo Ethanol|
2978042|NCT02710097|Experimental|Active THC and Active Ethanol|
2978043|NCT02710097|Experimental|Placebo THC and Active Ethanol|
2978044|NCT02710097|Placebo Comparator|Placebo THC and Placebo Ethanol|
2978045|NCT02710084|Experimental|Oxytocin|The first phase of the study will follow a double-blind, placebo-controlled design. Participants randomized to the experimental group will receive intranasal oxytocin in doses of 24 IU, two times daily, for a total of 48 IU. Doses may be reduced by 8 IU/day if safety concerns emerge. During the second phase of the study, all participants will receive oxytocin, in identical doses.
2978046|NCT02710084|Placebo Comparator|Saline|During the first phase, patients randomized to the placebo group will receive intranasal saline solution in doses of 24 IU two times daily, for a total of 48 IU. During the second phase of the study, all participants will receive oxytocin, in identical doses.
2978047|NCT02710071|Active Comparator|Nebivolol 5mg for 2 weeks then 10 mg|Nebivolol 5 mg for 2 weeks followed by nebivolol 10 mg for 4 weeks
2978048|NCT02710071|Active Comparator|HCTZ 12.5 mg for 2 weeks then 25 mg|Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks
2978049|NCT02710058||Arab American Women with Breast Cancer|We conducted a study using an evaluation assessment survey to assess the impact of the AMBER support groups on quality of life parameters, compliance with treatment appointments, and patient/family support. After reviewing preliminary results, we identified several recurrent themes, such as the need for health information, discrepancies around the extent of family support and disease disclosure, and an overall satisfaction with the support groups. To further examine these themes, we are initiating a qualitative research study using an in-depth interview guide. A trained interviewer bilingual in Arabic and English will conduct 10-15 in-depth interviews, to saturation, with AMBER's support group participants over a 6 month period.
2978050|NCT02710045|Active Comparator|MV at 9 months|"All vaccines given as per normal Gambia schedule until 9 months of age, including third dose of diphtheria-tetanus-whole cell pertussis (DTP3), hepatitis B vaccine (HBV) and oral polio vaccine (OPV) at four months of age.~At 9 months of age given a single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid. Yellow fever vaccine (YF) and OPV administered at 11 months of age. Given a standard MV challenge at 18 months of age."
2978051|NCT02710045|Active Comparator|DTP + MV at 9 months|DTP3 dose withheld and given HBV and OPV at four months of age. At 9 months of age given a single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid, and i.m. DTP (Serum Institute of India Ltd.) in the thigh. Yellow fever vaccine (YF) and OPV administered at 11 months of age. Given a standard MV challenge at 18 months of age.
2978052|NCT02710045|Active Comparator|DTP at 9 months|DTP3 dose withheld and given HBV and OPV at four months of age. At 9 months of age given i.m. DTP (Serum Institute of India Ltd.) in the thigh. MV, OPV and YF administered at 11 months of age. Given a standard MV challenge at 18 months of age.
2978053|NCT02710032|Experimental|Intervention|Social Network-Based Adherence Intervention
2978054|NCT02710032|No Intervention|Control|Control
2978055|NCT02710019|Experimental|Psychoeducational video games|Group 1 will play the Back to Reality video games series: (1) Harry's Journey which delivers experiential knowledge about psychiatric symptoms and substance use; (2) Harry's Journal which catalogs 12 symptoms associated with psychosis and (3) the PathwaysToCare Map which displays the mental health and addictions services located in Hamilton.
2978056|NCT02710019|Other|Control video games (Group 2)|The control video games are a mix of mini-games, such as word search, quiz, and memory video games. The control games will not provide any education about mental health and addictions issues
2978057|NCT02710006|Experimental|SonoHysteroAVC|Three-dimensional sonohysterography is the first point for uterine cavity volume estimation, and it is going to be performed in all participants. The investigators are going to fill the uterine cavity twice by saline solution during single sonohysterography procedure, and acquise the volumetric datasets of uterus for offline analysis. The 3D dataset containing the entire uterine cavity will by analyzed using a personal computer and/or the ultrasound machine with specific softwere.
2978058|NCT02709993|Experimental|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
2978059|NCT02709980|Placebo Comparator|Sleep Education|6 sessions of sleep education.
2978120|NCT02709655|Placebo Comparator|Placebo|
2978063|NCT02709967|Experimental|Combined intervention|Writing materials, economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9) and community dialogue (youth club meetings, community and parent meetings)
2978064|NCT02709954|Experimental|Active THC and Placebo Ethanol|
2978065|NCT02709954|Experimental|Active THC and Active Ethanol|
2978066|NCT02709954|Experimental|Placebo THC and Active Ethanol|
2978067|NCT02709954|Placebo Comparator|Placebo THC and Placebo Ethanol|
2978068|NCT02709941|Active Comparator|IMST Training Group|Subjects in inspiratory muscle strength training group will complete 30 breaths against a resistance set at 75% of Maximal Inspiratory Pressure (PI Max) everyday for period of 6 weeks.
2978069|NCT02709941|Placebo Comparator|Placebo Training Group|Subjects in placebo training group will complete 30 breaths against a resistance set at 15% of Maximal Inspiratory Pressure (PI Max) everyday for period of 6 weeks.
2978070|NCT02709928|Experimental|TD-0714|Capsule formulation
2978071|NCT02709928|Placebo Comparator|Placebo|Capsule formulation
2978072|NCT02709915|Experimental|Breakfast Diet (Bdiet)|The Bdiet will consist in 3 meals with distribution of calories: breakfast 50%, lunch 33% and dinner 17%.
2978073|NCT02709915|Active Comparator|6 small meals diet (6Mdiet)|The 6Mdiet will consist on 6 meals (breakfast, lunch and dinner and 3 snacks) with distribution of calories: breakfast 15%, lunch 25%, dinner 30% and 10% each of the three snacks.
2978074|NCT02709902|Experimental|Adapalene/BP gel, 0.3%/2.5%|Topical, once daily, for 84 days.
2978075|NCT02709902|Active Comparator|EPIDUO® FORTE|Topical, once daily, for 84 days.
2978076|NCT02709902|Placebo Comparator|Placebo|Topical, once daily, for 84 days.
2978077|NCT02709889|Experimental|Rovalpituzumab tesirine|Rovalpituzumab tesirine 0.2-0.4 mg/kg will be administered intravenously on Day 1 of each 6-week cycle.
2978078|NCT02709876|Experimental|Stem Cells|Intravitreal Injection of bone marrow derived CD34+, CD133+, CD271+ stem cells.
2978079|NCT02709863|Active Comparator|Sevoflurane|1-1.5 minimum alveolar concentration (MAC), inhalation route, during operation
2978080|NCT02709863|Active Comparator|Desflurane|1-1.5 minimum alveolar concentration (MAC), inhalation route, during operation
2978081|NCT02709863|Active Comparator|Propofol|6-10 mg/kg/h, iv infusion, during operation
2978082|NCT02709850|Experimental|Cohorts A to D|Single dose by subcutaneous (SC) injection
2978083|NCT02709850|Experimental|Cohort EE|Multiple doses by subcutaneous (SC) injection
2978084|NCT02709850|Experimental|Cohort AA to DD, and FF|Multiple doses by subcutaneous (SC) injection
2978085|NCT02709837|Active Comparator|Poorly cooked meat-Good chewing|Meat cooked 10min at 75°C, chewing without appliance
2978086|NCT02709837|Active Comparator|Highly cooked meat-Good chewing|Meat cooked 45min at 90°C, chewing without appliance
2978087|NCT02709837|Active Comparator|Poorly cooked meat-Bad chewing|Meat cooked 10min at 75°C, chewing with appliance
2978088|NCT02709837|Active Comparator|Highly cooked meat-Bad chewing|Meat cooked 45min at 90°C, chewing with appliance
2978089|NCT02709824|Active Comparator|Chlorhexidine gluconate with ADS|Chlorhexidine 0.12% plus Anti-Discoloration System Mouthwash
2978090|NCT02709824|Active Comparator|Chlorhexidine gluconate without ADS|Chlorhexidine 0.12% Mouthwash
2978091|NCT02709811|Experimental|electrochemotherapy|
2978092|NCT02709798|Experimental|Shenfu Injection|80ml Shenfu Injection + 70ml 5% glucose injection), ivdrip, 30 minutes before PCI and 1-5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
2978093|NCT02709798|Placebo Comparator|5% Glucose Injection|150 ml 5% glucose injection, ivdrip, 30 minutes before PCI and 1-5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
2978094|NCT02709785|Experimental|Group 1|25 subjects with plaque and gingival inflammation
2978095|NCT02709785|Experimental|Group 2|25 subjects with plaque and gingival inflammation
2978096|NCT02709785|Placebo Comparator|Group 3|25 subjects with plaque and gingival inflammation
2978097|NCT02709772|Active Comparator|Provider Alert|This arm is the intervention arm. This arm will receive the Electronic Record Alert.
2978098|NCT02709772|No Intervention|No Provider Alert|This arm is the control arm.
2978099|NCT02709759|Active Comparator|MI|Motivational interviewing focused on reducing alcohol use, delivered by videoconferencing.
2978100|NCT02709759|Active Comparator|BA|Brief Advice to reduce drinking delivered by videoconferencing
2978101|NCT02709759|Active Comparator|MI + ITM|Motivational intervention to reduce drinking, delivered by videoconferencing, plus Interactive text messaging around alcohol use
2978102|NCT02709759|Active Comparator|BA + ITM|Brief Advice to reduce drinking, delivered by videoconferencing, plus Interactive text messaging around alcohol use
2978103|NCT02709759|Active Comparator|MI + ITM + EI|Participants in this arm receive MI delivered by videoconferencing and ITM over 9 months rather than 1
2978104|NCT02709759|Active Comparator|BA + ITM + EI|Participants in this arm receive BA delivered by videoconferencing and ITM over 9 months rather than 1
2978105|NCT02709759|Active Comparator|BA + EI|Participants in this arm receive BA delivered by videoconferencing over 9 months rather than 1
2978106|NCT02709759|Active Comparator|MI + EI|Participants in this arm receive MI delivered by videoconferencing over 9 months rather than 1
2978107|NCT02709746|Experimental|Vortioxetine 10 mg/day|
2978108|NCT02709746|Experimental|Vortioxetine 20 mg/day|
2978109|NCT02709746|Active Comparator|Fluoxetine 20 mg/day,|
2978110|NCT02709746|Placebo Comparator|Placebo|
2978111|NCT02709733|Experimental|VR Motivation Training|Weekly training sessions with a VR motivation treatment 1 hour per week for 8 weeks.
2978112|NCT02709720|Experimental|1|2 cycles of metronomic Vinorelbine 50 mg + cisplatin, followed by 2 cycles of Vinorelbine 30 mg + cisplatin concomitant with radiotherapy
2978113|NCT02709707||Patients with diabetes|
2978114|NCT02709681||SCD patients|Patients followed in 32 Italian Centers.
2978115|NCT02709668|Placebo Comparator|placebo|gel cap with placebo
2978116|NCT02709668|Experimental|enlyte|gel cap of B vitamins brand Enlyte
2978117|NCT02709655|Experimental|Vortioxetine 10 mg/day|
2978118|NCT02709655|Experimental|Vortioxetine 20 mg/day|
2978119|NCT02709655|Active Comparator|Fluoxetine 20 mg/day,|
2978121|NCT02709642|No Intervention|Control|Control Participants will complete weekly weigh-ins and receive emails about how their current weight compares to their baseline weight.
2978122|NCT02709642|Experimental|Deposit Contract|The deposit contract group will also complete weekly weigh-ins and receive emails about how their current weight compares to their baseline weight. In addition, the deposit contract group will be asked to make a deposit of at least $100 each 10-week period over the course of one year (50 weeks). Each week, they will recoup 1/10 of their 10-week deposit if they are within two pounds of their baseline weight or lower. If they are more than two pounds above their baseline weight, they will forfeit 1/10 of their 10-week deposit. The money they forfeited for that week will go into a collective pool to be divided up at the end of each 10-week period by all deposit contract participants who successfully maintained their weight loss at the end of the 10-week period.
2978123|NCT02709629|Experimental|Individualized and adaptive computerised cognitive training|Training in this group is individualized using a computer algorithm which assigns tasks (from a pool of 33 training tasks) on the basis of cognitive strengths and weaknesses as determined by the training program. In addition, task difficulty is adaptive and responsive to performance level. Participants are able to see feedback on their progress each training session in the form of a session-score. A range of behavior change techniques are used throughout the training period (delivered via scheduled monitoring phone calls, and email contact with participants) to support the compliance and adherence of participants. These include a range of motivation and confidence building strategies, based on a theoretical framework. Participants are required to train for approx. 30 min., 3 times per week, for 8 weeks.
2978124|NCT02709629|Active Comparator|Active control|"Training in this group is generic, and tasks (from the same pool of 33 training tasks) are randomly selected by the training program. In addition, task difficulty is fixed, such that irrespective of performance, each time a participant is presented with a given task, the level of difficulty returns to the basic level. Participants in this arm do not receive feedback on their progress at the end of each training session. The same protocol of behavior change techniques is used in this intervention arm.~Participants are also required to train for approx. 30 min., 3 times per week, for 8 weeks."
2978125|NCT02709616|Experimental|Personalized cellular vaccine|DC and PMBC based cellular vaccine
2978126|NCT02709603|Experimental|Group A|oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
2978127|NCT02709603|Placebo Comparator|Group B|oral 2 tablets (PLACEBO) 30 minutes before the procedure
2978128|NCT02709590|Experimental|Group A|oral diclofenac potassium plus lidocaine anesthetic cream placed into their cervix immediately before HSG
2978129|NCT02709590|Placebo Comparator|Group B|oral placebo tablets plus placebo cream placed into their cervix immediately before HSG
2978130|NCT02709577|Experimental|EndoBarrier Gastrointestinal Liner|Subjects randomized and implanted with the EndoBarrier Gastrointestinal liner; subjects will be implanted for 24 weeks to 52 weeks and evaluated for study endpoints.
2978131|NCT02709577|Experimental|Sham: endoscopy and standard of care|Subjects randomized to sham arm received an upper GI examination and were evaluated for study endpoints.
2978132|NCT02709564|Placebo Comparator|Group A|400 mg placebo
2978133|NCT02709564|Active Comparator|Group B|400 microgram misoprostol
2978134|NCT02709551|Experimental|HRV-Bfb|HRV biofeedback, training about 30 minutes/day
2978135|NCT02709551|Experimental|MBI|Mindfulness based intervention, training about 30 minutes/day
2978136|NCT02709551|Other|MBI_HRV-Bfb|Mindfulness based HRV biofeedback. Wait list control group for the interventions HRV-Bfb and MBI, after the main phase intervention with combined method.
2978137|NCT02709538|Experimental|GSP 301 NS|
2978138|NCT02709538|Placebo Comparator|GSP 301 Placebo NS pH 3.7|
2978139|NCT02709538|Placebo Comparator|GSP 301 Placebo NS pH 7|
2978140|NCT02709525|Experimental|hyaluronic acid|Immediately after the extractions, one socket was randomly filled with 1% hyaluronic acid gel.
2978141|NCT02709525|Placebo Comparator|Blood clot|Immediately after the extractions, the other side socket was naturally filled with blood clot.
2978142|NCT02709512|Experimental|Drug: ADI-PEG 20 plus Pem Cis|"Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study~In Combination With:~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous"
2978143|NCT02709512|Placebo Comparator|Drug: Placebo plus Pem Cis|"Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study~In Combination With:~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous"
2978144|NCT02709499|Sham Comparator|0J LLLT|The intervention will be made with the machine off.
2978145|NCT02709499|Experimental|6J LLLT|The Laser radiation will be made with 4J by spot
2978146|NCT02709486|Experimental|Low dose|Investigational product
2978147|NCT02709486|Experimental|High dose|Investigational product
2978148|NCT02709486|Placebo Comparator|Placebo|Investigational product
2978149|NCT02709473|Active Comparator|propofol|Propofol arm includes patients that induction of general anesthesia started with propofol and followed by remifentanil and rocuronium administration
2978150|NCT02709473|Active Comparator|remifentanil|Remifentanil arm include patients that induction of general anesthesia started with remifentanil and followed by propofol and rocuronium administration
2978151|NCT02709460|Experimental|Lateral occlusion|Women included in this arm is randomized to lateral occlusion of the uterine artery
2978152|NCT02709460|Active Comparator|cervical occlusion|Women included in this arm is randomized to occlusion of the uterine artery at cervical entry
2978153|NCT02709447|Experimental|Date SMART|Group based prevention
2978154|NCT02709447|Active Comparator|Health Promotion|Group based prevention
2978155|NCT02709434|Active Comparator|Intervention group|Patients with quiescent IBD who are randomized to receive the active intervention of the psychoeducational programme
2978156|NCT02709434|Placebo Comparator|Control group|Randomized to standard care
2978184|NCT02709278|Experimental|Group 2D: close to or higher than standard aerosol BCG|9 volunteers receiving BCG Bulgaria (InterVax) at the optimal dose identified from preliminary results obtained from Groups 2B and 2C by the aerosol inhaled route and intradermal saline placebo, followed by bronchoscopy.
3002983|NCT02543489|Other|Flex IM Rod|
2978157|NCT02709421||Indomethacin Group|"All the patients with high risks of PEP received administration of one single dose of 100mg rectal indomethacin after ERCP.~Patients were considered high risk of PEP if they met one of the following criteria: clinical suspicion of sphincter of Oddi dysfunction, a history of PEP, pancreatic sphincterotomy, precut sphincterotomy, ≥8 cannulation attempts, cannulation time≥10 minutes; pneumatic dilatation of an intact biliary sphincter, ≥3 inadvertent pancreatic duct cannulation, opacification of pancreatic acini, or the acquisition of a cytologic specimen from the pancreatic duct with the use of a brush or forceps."
2978158|NCT02709408||Carbapenem-resistant Enterobacteriaceae|Patients with complicated intrabdominal infections, pneumonia, complicated urinary tract infection and bloodstream infection due to carbapenem-resistant Enterobacteriaceae
2978159|NCT02709408||Carbapenem-resistant A. baumannii|Patients with bloodstream infections due to carbapenem-resistant Acinetobacter baumannii
2978160|NCT02709408||Susceptible Enterobacteriaceae|Patients with complicated intrabdominal infections, pneumonia, complicated urinary tract infection and bloodstream infection due to carbapenem-susceptible Enterobacteriaceae matched to carbapenem-resistant ones by centre, type of ward, infection type, acquisition and previous duration of hospitalisation.
2978161|NCT02709408||Admitted control patients|Patients without infection due to Enterobacteriaceae matched to carbapenem-resistant Enterobacteriaceae cases according to centre, ward and previous length of hospitalisation.
2978162|NCT02709395|Experimental|Navina Smart|Navina Smart will be used, during 4 weeks, for transanal irrigation (TAI).
2978163|NCT02709382|Experimental|FEP-TAZ|Cefepime and Tazobactam combination; IV infusion over a period of 90 minutes Healthy subjects, Mild and Moderate RI: 4 g (2 g FEP and 2 g TAZ) Severe RI and patients on HD: 2 g (1 g FEP and 1 g TAZ)
2978164|NCT02709369|Experimental|Active HIRREM|This is a single site, single-arm, open-label, developmental study. Participants are recruited to receive eight to twenty sessions of High-resolution, relational, resonance-based electroencephalic mirroring (HIRREM), in addition to their usual care.
2978165|NCT02709356|Experimental|Alzheimer's disease|"Patients with mild Alzheimer's disease.~1-month of 60-40 MCT oil and 1-month of C8 MCT oil (order of the two intervention are randomized)"
2978166|NCT02709356|Experimental|Controls|"Healthy elderly people~1-month of 60-40 MCT oil and 1-month of C8 MCT oil (order of the two intervention are randomized)"
2978167|NCT02709343|Experimental|Bone-marrow derived MSCs|4 doses of Allogeneic bone-marrow derived MSCs (2x106 cells/kg) given intravenously twice weekly for 2 weeks
2978168|NCT02709343|Placebo Comparator|Placebo|Placebo product manufactured to look like MSCs
2978169|NCT02709330|Experimental|Lunasin regimen|"The Lunasin regimen consists of:~LunaRich X Capsules (12 capsules per day)~Reliv NOW - a mixture of 'vitamins, minerals and super-powered antioxidants' (3 scoops per day)~Pro-Vantage - a mixture of 'soy protein, medium chain triglycerides, creatine, CoQ10 and supercharged amino acids' (2 scoops per day)~It will be suggested that patients open the LunaRich X capsules and mix the contents of these as well as the other 2 ingredients in water to make a shake. If patients do not tolerate advancing to the next dosage, they will be asked to drop back to the highest dosage they could tolerate."
2978170|NCT02709330|Active Comparator|Historical controls|For each enrolled participant, matched historical controls will be identified from the PatientsLikeMe database. Participants will be matched according to their ALSFRS-R progression rate before they start on the Lunasin regimen (estimated by assuming their score was normal at 48 on the date of symptom onset).
2978171|NCT02709317|Active Comparator|Standard Care|In this arm, veterans receive the care that they would receive had they not enrolled in the research. No one will receive less than standard care.
2978172|NCT02709317|Experimental|Prevention Intervention|An adaptive monitoring intervention, delivered through text messages and brief telephone calls, that can provide extended prevention services for veterans engaging in risky alcohol use. After a veteran receives a BI for risky drinking, we will monitor alcohol use for 4 weeks. Veterans who reduce alcohol use to safe levels will be placed in a monitoring track, which consists of tailored text messages and brief monthly telephone contacts. Conversely, veterans who continue to use alcohol at hazardous levels will be placed in a track that provides tailored text messages and more frequent telephone calls. These calls provide further prevention/intervention services to help the veteran reduce alcohol use. These services address motivational issues and identify more effective ways to cope with stress and other factors that trigger unsafe alcohol use. Information on the veteran's progress is used to guide the content of subsequent text messages and prevention interventions.
2978173|NCT02709304|Placebo Comparator|Standard Gel|Standard gel not containing local anesthetic used to insert urinary catheters.
2978174|NCT02709304|Experimental|Lidocaine Gel|lidocaine containing gel uses to insert urinary catheters
2978175|NCT02709291|Other|Community Health Workers|Community health workers will complete a 5-day interventionist training to deliver a behavioral parent training intervention.
2978176|NCT02709291|Other|Parent-Child Dyads|Parents and children will receive a behavioral parent training intervention delivered by community health workers.
2978177|NCT02709278|Other|Group 1A: low dose aerosol BCG SSI|3 volunteers receiving BCG SSI at a dose of 1 x 10^3 cfu by the aerosol inhaled route, followed by bronchoscopy.
2978178|NCT02709278|Other|Group 1B: medium dose aerosol BCG SSI|3 volunteers receiving BCG SSI at a dose of 1 x 10^4 cfu by the aerosol inhaled route, followed by bronchoscopy.
2978179|NCT02709278|Experimental|Group 1C: standard dose aerosol BCG SSI|12 volunteers receiving BCG SSI at a dose of 1 x 10^5 cfu by the aerosol inhaled route and intradermal saline placebo, followed by bronchoscopy.
2978180|NCT02709278|Experimental|Group 1D: standard dose intradermal BCG SSI|12 volunteers receiving BCG SSI at a dose of 1 x 10^5 cfu by the intradermal route and aerosol inhaled saline placebo, followed by bronchoscopy and punch biopsy at the intradermal injection site.
2978181|NCT02709278|Other|Group 2A: lower than standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10^4 cfu by the aerosol inhaled route, followed by bronchoscopy.
2978182|NCT02709278|Other|Group 2B: close to the standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10^5 cfu by the aerosol route, followed by bronchoscopy.
2978183|NCT02709278|Other|Group 2C: higher than standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10^6 cfu by the aerosol inhaled route, followed by bronchoscopy.
2978246|NCT02708888|Experimental|Trunk training|Exercises: Core stability training
2978185|NCT02709278|Experimental|Group 2E: close to or higher than standard intradermal BCG|12 volunteers receiving BCG Bulgaria (InterVax) at the optimal dose identified from preliminary results obtained from Groups 2B and 2C by the intradermal route and aerosol inhaled saline placebo, followed by bronchoscopy and punch biopsy at the intradermal injection site.
2978186|NCT02709265|Experimental|Cohort 1|amikacin/fosfomycin (30/12 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
2978187|NCT02709265|Experimental|Cohort 2|amikacin/fosfomycin (60/24 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
2978188|NCT02709265|Experimental|Cohort 3|amikacin/fosfomycin (90/36 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
2978189|NCT02709265|Experimental|Cohort 4|amikacin/fosfomycin (90/36 mg) delivered via the PARI LC Sprint Nebulizer (single dose)
2978190|NCT02709265|Experimental|Cohort 5|amikacin/fosfomycin (Dose and Nebulizer to be chosen based on results from Cohorts 1 - 4)
2978191|NCT02709252|Experimental|Cohort|Only one cohort is included with comparisons of two different hemodynamic parameters
2978192|NCT02709239|Active Comparator|DHA 200mg|Participants will receive 200mg DHA to take per day. Participants will be asked to take four capsules containing 50mg DHA each.
2978193|NCT02709239|Experimental|DHA 800mg|Participants will receive 800mg DHA to take per day. Participants will be asked to take four capsules containing 200mg DHA each.
2978194|NCT02709226|Experimental|I|Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned reirradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
2978195|NCT02709213||Patients with CT-diagnosed acute colitis|Patients with symptomatic colitis (fever and/or pain and/or diarrhea) proven by computed tomography
2978196|NCT02709200||Dexmedetomidine|Patients that received dexmedetomidine during open heart surgery.
2978197|NCT02709200||No dexmedetomidine|Patients that didn't receive dexmedetomidine during open heart surgery.
2978198|NCT02709187|Experimental|RT group|combination dose of Candesartan and Rosuvastatin and DP-R208 in order
2978199|NCT02709187|Experimental|TR group|DP-R208 and combination dose of Candesartan and Rosuvastatin in order
2978200|NCT02709174||pregnant with pulmonary embolism|Pregnant women who underwent diagnostic imaging to evaluate for suspected PE at our institution
2978201|NCT02709174||pregnant without pulmonary embolism|Pregnant women who underwent diagnostic imaging to evaluate for suspected PE at our institution
2978202|NCT02709161|Experimental|real-time fMRI neurofeedback: Amygdala|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
2978203|NCT02709161|Active Comparator|real-time fMRI neurofeedback: HIPS|HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
2978204|NCT02709148|Experimental|chronic brain recording|This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.
2978205|NCT02709135||Pre-hospital HEART Score|All subjects included in this quality surveillance study will have had a HEART score, including POC troponin calculated by paramedics prior to arrival at the emergency department.
2978206|NCT02709122|Experimental|With Tension pneumothorax|evaluation of the patient with the existing tension pneumothorax during a simulated CPR - breathing
2978207|NCT02709122|Experimental|Without Tension pneumothorax|evaluation of the patient without the existing tension pneumothorax during a simulated CPR - breathing
2978208|NCT02709109|Experimental|VX-371 + Saline , then Saline|Participants receive VX-371 + Saline during Treatment Period 1 followed by Saline during Treatment Period 2. A washout period of 28 Days will be maintained between the two treatment periods. All subjects must be receiving stable treatment with Orkambi before the first dose of study drug and throughout the duration of the study.
2978209|NCT02709109|Experimental|Saline, then VX-371 + Saline|Participants receive Saline during Treatment Period 1 followed by VX-371 + Saline during Treatment Period 2. A washout period of 28 Days will be maintained between the two treatment periods. All subjects must be receiving stable treatment with Orkambi before the first dose of study drug and throughout the duration of the study.
2978210|NCT02709109|Experimental|VX-371 + Placebo, then Placebo|Participants receive VX-371 + placebo (saline) during Treatment Period 1 followed by placebo (saline) during Treatment Period 2. A washout period of 28 Days will be maintained between the two treatment periods. All subjects must be receiving stable treatment with Orkambi before the first dose of study drug and throughout the duration of the study.
2978211|NCT02709109|Experimental|Placebo, then VX-371 + Placebo|Participants receive placebo (saline) during Treatment Period 1 followed by VX-371 + placebo (saline) during Treatment Period 2. A washout period of 28 Days will be maintained between the two treatment periods. All subjects must be receiving stable treatment with Orkambi before the first dose of study drug and throughout the duration of the study.
2978212|NCT02709096|Experimental|BPX-01, 1% Topical Gel|BPX-01, 1% Topical Gel; applied once daily to the face for four weeks.
2978213|NCT02709096|Placebo Comparator|BPX-01, Vehicle Gel|BPX-01, Vehicle Gel; applied once daily to the face for four weeks.
2978214|NCT02709083|Experimental|Treatment-dasatinib, nilotinib, imatinib|Patients receive dasatinib orally (PO) once a day (QD) or nilotinib PO twice a day (BID) at the discretion of the treating hematologist. Patients achieving either a 1 log reduction at 3 months or a 2 log reduction at 6 months in their breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) transcript levels may switch to imatinib mesylate PO QD.
2978215|NCT02709070|Active Comparator|resection|Resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. The investigators performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
2978216|NCT02709070|Experimental|highly-purified CTL|Peripheral blood (20-30mL) for manufacturing the individualized highly-purified CTL agent was collected from the respective participants who were randomized to the immunotherapy group before starting treatment. The highly-purified CTL agent was prepared at a central manufacturing facility. Participants in the immunotherapy group received a number up to 5×10E9 of the highly-purified CTL agent intravenously over 60 minutes without any premedication and then were observed for at least 30 minutes. Participants were scheduled to receive highly-purified CTL: 4-6 treatments at a frequency of once two-week during 6 months after receiving resection, followed by 6-9 treatments during 6 months to 2 years after receiving resection.
2978217|NCT02709057|Active Comparator|Life-style intervention 1|Life-style intervention in participants with low genetic risk score: The 3-year lifestyle intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
2978218|NCT02709057|Active Comparator|Life-style intervention 2|Life-style intervention in participants with high genetic risk score: The 3-year lifestyle intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
2978219|NCT02709057|No Intervention|Control 1|No intervention in participants with low genetic risk score
2978220|NCT02709057|No Intervention|Control 2|No intervention in participants with high genetic risk score
2978221|NCT02709044|Experimental|Ringer lactate 20 mL/kg|This group of subjects will receive a bolus of 20 ml / kg of Ringer's solution for infusion within first hour of the diagnosis
2978222|NCT02709044|Experimental|Ringer lactate 40 ml/kg|This group of subjects will receive a bolus of 40 ml / kg of Ringer's solution for infusion within first hour of the diagnosis
2978223|NCT02709031|Active Comparator|Cicletanine|Patients will take escalating doses of cicletanine
2978224|NCT02709031|Experimental|Cicletanine + magnesium|Patients will take escalating doses of cicletanine; patients will in addition take magnesium
2978225|NCT02709018|Experimental|Losartan|Losartan flexibly dosed from 25-100 mg per day over 10 weeks
2978226|NCT02709018|Placebo Comparator|Placebo|Placebo flexibly dosed from 25-100 mg per day over 10 weeks
2978227|NCT02709005|Experimental|5% Monolaurin Vaginal Gel|80 subjects will receive 5% Monolaurin Gel twice daily for three successive days for a total of 6 doses
2978228|NCT02709005|Placebo Comparator|Vehicle Placebo|40 subjects will receive placebo Gel twice daily for three successive days for a total of 6 doses
2978229|NCT02708992|Experimental|Cefixime/Azithromycin|Eight participants will receive three oral doses of 800 mg cefixime (q 8 hours) on Day 1, followed by three oral doses of 800 mg cefixime (q 8 hours)+ one oral dose of 1000 mg azithromycin (with first dose of cefixime) on day 10
2978230|NCT02708979|Active Comparator|University Exam Period|This visit takes place the week before an exam at the university assuming that this will induce a stress response. Measurements (see description elsewhere) are being taken within 1-2 weeks prior to an university exam.
2978231|NCT02708979|Placebo Comparator|University Non-exam Period|This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period. Measurements (see description elsewhere) are being taken in a control-period without exams (at least 4 weeks after and 4 weeks prior to an exam)
2978232|NCT02708966|Experimental|Gymnema Sylvestre|Patients with IGT
2978233|NCT02708966|Placebo Comparator|Placebo|Patients with IGT
2978234|NCT02708953|Experimental|Treatment (thoracic manipulation)|Patients in the initial manipulation group will attend physical therapy two sessions per week for 3 weeks for a total of 6 sessions. Each treatment session will last for a total of 15 minutes. After the initial manipulation group receives 3 weeks of treatment they will wait for 1-week, be retested, and then crossover into the other group.
2978235|NCT02708953|Active Comparator|Wait-list (thoracic manipulation)|When individuals are assigned to the wait-list control group they will serve as the control for 3 weeks while the initial manipulation group receives treatment. After serving as the wait-list control condition for 3 weeks, this group will then return for testing and will receive the manipulation package as described below at 4 weeks.
2978236|NCT02708940|Active Comparator|Usual care|Control arm - these patients will get usual care as part of the PHP and IOP programs at UCLA. They will not receive mobile support messages.
2978237|NCT02708940|Active Comparator|Participatory technology development|Intervention - Patients will have access to a website that allows them to co-create mobile support messages with their therapist to support their care as part of the PHP and IOP programs at UCLA.
2978238|NCT02708927|Experimental|patient|MS diagnosis according to McDonald criteria (Polman et al., 2005). Relapsing-remitting MS (RRMS) according to Lublin et al. (1996);
2978239|NCT02708927|Experimental|Control|healthy subject
2978240|NCT02708914|Other|UB-851|
2978241|NCT02708914|Other|Eprex then UB-851|
2978242|NCT02708901|Active Comparator|GI Vivomixx®|25 children with GI symptoms
2978243|NCT02708901|Placebo Comparator|GI Placebo|25 children with GI symptoms
2978244|NCT02708901|Active Comparator|NGI Vivomixx®|25 children without GI symptoms
2978245|NCT02708901|Placebo Comparator|NGI placebo|25 children without GI symptoms
2978247|NCT02708888|Sham Comparator|Cognitive exercises|Exercises: The RevArte Visual Search Test (RVST) of Lafosse et al (2013) and the Visuospatial Neglect Test Battery (VNTB) of Vaes et al. (2015)
2978248|NCT02708875|Experimental|Mixed Meal Challenge|Participants will consume a liquid mixed meal (300 calories - fat, carbohydrate, and protein) for monitoring changes in glucose metabolism, plasma insulin and microvascular responses in skeletal muscle over 2 hours.
2978249|NCT02708875|Active Comparator|Glucose Challenge|Participants will consume a glucose challenge (50g glucose) for monitoring changes in glucose metabolism, plasma insulin and microvascular responses in skeletal muscle over 2 hours.
2978250|NCT02708862|Experimental|Simple Mask|Simple mask at 60 L/min for 3 minutes
2978251|NCT02708862|Experimental|Non-rebreather at 15 L/min|Non-rebreather at 60 L/min
2978252|NCT02708862|Experimental|Non-rebreather at 60 L/min|Non-rebreather at 60 L/min for 3 minutes
2978253|NCT02708862|Experimental|Bag valve mask at 15 L/min|Bag valve mask at 15 L/min for 3 minutes
2978254|NCT02708849|Experimental|Ketamine plus lamotrigine|
2978255|NCT02708849|Placebo Comparator|ketamine plus placebo|
2978256|NCT02708836|Active Comparator|ETT only|Endotracheal tube intubation after induction of anesthesia. Ventilation with ETT until emergence.
2978257|NCT02708836|Experimental|Combined ETT/LMA technique|Placement of LMA after induction of anesthesia. Intubation of trachea with ETT via LMA with fiberoptic bronchoscope. Ventilation with ETT throughout case. Removal of ETT while deeply anesthetized. Ventilation with LMA until emergence.
2978258|NCT02708810|Other|80 Gy Radiation & Unframed Virtual Cone|80 Gy Virtual Cone Radiosurgery unframed (face mask)
2978259|NCT02708797|Other|Migraine with aura Patients|Patients with migraine with aura will be studied 30 days after the pre inclusion visit with both magnetic resonance imaging and Transcranial Doppler.
2978260|NCT02708797|Other|Controls|Control group with healthy volunteers will be studied 30 days after the pre inclusion visit with both magnetic resonance imaging and Transcranial Doppler.
2978261|NCT02708784||Pompe disease|Patients will perform muscle strength measurement with dynamometer and MR-imaging. After 8 months the investigations will be repeated.
2978262|NCT02708784||Myotonic Dystrophy|Patients will perform muscle strength measurement with dynamometer and MR-imaging. The investigations will not be repeated after 8 months.
2978263|NCT02708784||Healthy controls|Patients will perform muscle strength measurement with dynamometer and MR-imaging. The investigations will not be repeated after 8 months.
2978264|NCT02708771|Experimental|Intervention|4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
2978265|NCT02708771|Placebo Comparator|Control|Capsules of similar appearance and flavor without active drug
2978266|NCT02708758|Active Comparator|Treatment group|Medical nutrition therapy plus self monitoring capillary glucose levels and if necessary drug therapy (metformin or insulin) when goals are not met.
2978267|NCT02708758|No Intervention|Routine care group|Prenatal routine care without medical nutrition therapy and without self monitoring capillary glucose levels and drug therapy specific for GDM.
2978268|NCT02708745|Placebo Comparator|Placebo Arm|Parent participants will receive a placebo survey about their attitudes toward common child health topics before their child's health supervision visit.
2978269|NCT02708745|Experimental|Intervention Arm|Parent participants will also receive the intervention survey about their attitudes toward childhood vaccines before their child's health supervision visit.
2978270|NCT02708732||DLBCL Participants|A cohort of approximately 100 patients in first remission with DLBCL will complete questionnaires through a 15-minute postal or online survey.
2978271|NCT02708719|Other|Pulmonary rehabilitation|multimodal pulmonary Rehabilitation program (3 weeks Duration)
2978272|NCT02708706|Experimental|physical therapy and hyaluronic acid|patient received ultrasound-guided hyaluronic acid and normal saline injection as well as physical therapy.
2978273|NCT02708706|Active Comparator|physical therapy only|patient received physical therapy only.
2978274|NCT02708693|Experimental|experimental: steroid injection and splinting|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine) and a customized volar thermoplastic wrist splint
2978275|NCT02708693|Active Comparator|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
2978276|NCT02708680|Active Comparator|Entinostat plus Atezolizumab|Patients in this arm will receive entinostat at the RP2D in combination with atezolizumab
2978277|NCT02708680|Placebo Comparator|Placebo plus Atezolizumab|Patients in this arm will receive placebo in combination with atezolizumab
2978278|NCT02708654|Experimental|Intervention|Participants will be (1) given an electronic pill bottle for their diuretic and a Bluetooth scale; (2) asked to provide the coordinator with name and contact information of a family member or friend to serve as a support partner; (3) will be assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence and registering a weight measurement; and, (4) will determine their preferences for Way to Health platform communication methods during the study.(5) Research coordinators to remotely monitor weight gain thresholds and add alert into the participant's electronic health record for verified weight gain
2978279|NCT02708654|No Intervention|Control|Participants will receive usual care.
2978280|NCT02708641|Experimental|AML patients|pembrolizumab 200 mg given IV once every three weeks
2978281|NCT02708628|Active Comparator|Patients using contractubex|Scar excision will be performed in second c-section for 60 patients and these patients will use prophylactic topical scar gel containing extract of allium cepae, allantoin and heparin two times in a day.
2978282|NCT02708628|Active Comparator|Patients not using contractubex|Scar excision will be performed in second c-section for 60 patients and these patients will not use prophylactic topical scar gel containing extract of allium cepae, allantoin and heparin.
2978283|NCT02708615|Other|Vertical rotation|Vertical insertion and 90 degree rotation of speculum in vagina
2978284|NCT02708615|Other|Straight horizontal insertion|Straight horizontal insertion of speculum with no rotation in vagina
2978285|NCT02708602||β2AR Arg16Arg (AA group)|People with β2AR Arg16Arg genotype.
2978289|NCT02708602||β2AR Gln27Glu (CG group)|People with β2AR Gln27Glu genotype.
2978290|NCT02708602||β2AR Glu27Glu (GG group)|People with β2AR Glu27Glu genotype.
2978291|NCT02708589|Active Comparator|probiotic|the probiotics capsules contain 7 strains of friendly bacteria (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, and Lactobacillus bulgaricus) and prebiotic (fructooligosaccharide).
2978292|NCT02708589|Placebo Comparator|Placebo|Placebo capsules have identical appearance to probiotic capsules and contain Maltodextrin.
2978293|NCT02708576|Experimental|NGM313|Administration of active NGM313
2978294|NCT02708576|Placebo Comparator|Placebo|Administration of placebo comparator
2978295|NCT02708563|Experimental|Immediate intubation|These infants will have immediate endotracheal suctioning after delivery. They will then have resuscitation per Neonatal Resuscitation Program guidelines.
2978296|NCT02708563|Experimental|Immediate resuscitation|These infants will have immediate resuscitation per the Neonatal Resuscitation Program guidelines without endotracheal suctioning.
2978297|NCT02708550|Experimental|Participatory Organizational Intervention|Participatory intervention (workshops) with workers, consultants and leaders. The workshops will find solutions for increased use of assistive devices
2978298|NCT02708550|No Intervention|Control|This group will go through the same baseline and follow-up tests as the intervention group, but will not receive any intervention.
2978299|NCT02708537||PRGF in candidates for sperm donors|Prospective study of 58 candidates for sperm donors clinic IVI Bilbao.
2978300|NCT02708524|Experimental|Senofilcon C Wearers|Senofilcon C Wearers will wear the Senofilcon C Contact Lenses as daily wear for 30 (-2/+6) days.
2978301|NCT02708524|Active Comparator|Comfilcon A Wearers|Comfilcon A Wearers will wear the Comfilcon A Contact Lens as daily wear for 30 (-2/+6) days.
2978302|NCT02708524|Active Comparator|Lotrafilcon B Wearers|Lotrafilcon B Wearers will wear the Lotrafilcon B Contact Lens as daily wear for 30 (-2/+6) days.
2978303|NCT02708524|Active Comparator|Samfilcon A Wearers|Samfilcon A Wearers will wear the Samfilcon A Contact Lens as daily wear for 30 (-2/+6) days.
2978304|NCT02708511|Experimental|Diagnostic (Cu 64 DOTA-B-Fab)|Patients receive copper Cu 64-DOTA-B-Fab IV followed by PET/CT 60 minutes post-injection and 24 hours post-injection
2978305|NCT02708498|Experimental|Kronoberg Educational Intervention|The educational intervention is provided to staff at ten nursing homes.
2978306|NCT02708498|No Intervention|Skåne Control|The control group consists of an equal number of participants. This group receives no intervention.
2978307|NCT02708498|Experimental|Skåne Educational Intervention|The educational intervention is provided to staff at ten nursing homes.
2978308|NCT02708498|No Intervention|Kronoberg Control|The control group consists of an equal number of participants. This group receives no intervention.
2978309|NCT02708485|No Intervention|Control group|No intervention
2978310|NCT02708485|Experimental|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
2978311|NCT02708472|Experimental|Open-label|"Subjects who qualify will receive daily active synchronized Transcranial Magnetic Stimulation (sTMS) treatments. Treatment will be initiated on Day 1 of the study. Subjects will come to the clinic for 5 daily treatment sessions for a total of 4 treatment weeks (20 treatment sessions). Treatment will be discontinued at the end of Week 4. Subjects will be clinically evaluated for safety and efficacy at the end of each of the four weekly treatment courses.~At the end of Week 4, subjects who have not met the endpoint of 50% reduction in Hamilton Anxiety Rating Scale (HAM-A) score will be eligible to be considered for 2 additional weeks of daily treatment in an extended phase (for a total of 30 treatment sessions)."
2978312|NCT02708459|Active Comparator|Control|Control group where postoperative analgesia will be maintained by Morphine intravenous boluses (2 mg) if Visual analogue scale (VAS) scale more than 4.
2978313|NCT02708459|Active Comparator|Bupevecaine group|Postoperative analgesia will be maintained by 20 ml Bupevecaine (0.25%) boluses in surgically inserted TAP catheter each 8 hours for 48 hours with rescue analgesia intravenous morphine (2mg) if VAS more than 4
2978314|NCT02708459|Active Comparator|Dex group|catheter will surgically inserted in Transversus abdominus plane (TAP) plane before wound closure Postoperative analgesia will be maintained by Dexmedetomedine 0.4 mg/kg plus Bupevecaine 0.25 20 ml boluses each 8 hours for 48 hours in surgically inserted TAP catheter with rescue analgesia intravenous morphine (2mg) if VAS more 4
2978315|NCT02708446|Active Comparator|Sublingual misoprostol|200mg mifepristone + 400mcg sublingual misoprostol q3h
2978316|NCT02708446|Active Comparator|Buccal misoprostol|200mg mifepristone + 400mcg buccal misoprostol q3h
2978317|NCT02708433|Active Comparator|Buffered 1% lidocaine|"In week one each subject would receive either anesthetic (Buffered 1% lidocaine with 1/100,000 Epinephrine) or (Non-Buffered 2% lidocaine with 1/100,000 Epinephrine) to block the inferior alveolar, lingual, buccal nerves.~In week two the alternate anesthetic would be administered.~Mandibular molar and canine tested for pulpal anesthesia"
2978318|NCT02708433|Active Comparator|Non-Buffered lidocaine|"In week two each subject would receive the alternate anesthetic (Buffered 1% lidocaine with 1/100,000 Epinephrine) or (Non-Buffered 2% lidocaine with 1/100,000 Epinephrine) to block the inferior alveolar, lingual, buccal nerves.~Mandibular molar and canine tested for pulpal anesthesia"
2978319|NCT02708420|Other|Glidescope intubation|This standard GlideScope (GS) technique involves a midline laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
2978320|NCT02708420|Other|Macintosh Laryngoscope|This standard technique involves laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
2978321|NCT02708407|Experimental|Peritoneal Dialysis Group|These participants will continue to receive standard HF care and Peritoneal Dialysis with a single daily exchange of icodextrin.
2978322|NCT02708407|No Intervention|Control Group|These participants will continue to receive standard HF care.
2978323|NCT02708394|Experimental|olanzapine|Atypical antipsychotic
2978324|NCT02708394|Placebo Comparator|placebo|Placebo comparator
2978325|NCT02708381||Senior Adult Cancer Patients|Cancer patient population 70 years and older, eligible for screening.
3015242|NCT02460965||Healthy participants|
2978326|NCT02708368||Patients on dialysis|16 patients on dialysis with a sex ratio 1:1; 8 patients on hemodialysis and 8 patients on hemodiafiltration
2978327|NCT02708368||Healthy Subjects|16 healthy subjects with a sex ratio 1:1
2978328|NCT02708355|Experimental|Esomeprazole 20 mg once daily|Esomeprazole 20 mg administered orally in the morning and placebo administered orally in the evening
2978329|NCT02708355|Experimental|Esomeprazole 20 mg twice daily|Esomeprazole 20 mg administered orally in the morning and esomeprazole 20 mg administered orally in the evening
2978330|NCT02708355|Placebo Comparator|Placebo|Placebo administered orally in the morning and placebo administered orally in the evening
2978331|NCT02708329|Active Comparator|CTO coronary angioplasty +T-provisional stenting|Coronary angioplasty using T-provisional stenting in patients with bifurcational lesion in Chronic total occlusion segment.
2978332|NCT02708329|Experimental|CTO coronary angioplasty + Mini-crush stenting|Coronary angioplasty using Mini-crush stenting in patients with bifurcational lesion in Chronic total occlusion segment.
2978333|NCT02708316||schizophrenia group|schizophrenia patients in the group
2978334|NCT02708316||control group|healthy population
2978335|NCT02708303||Foregut Surgery|Foregut surgery includes conditions of the esophagus, stomach and proximal small intestine. More specifically foregut surgery includes surgery for gastroesophageal reflux disease, hiatal hernias, and paraesophageal hernias.
2978336|NCT02708290||Participants who engage with MITA at least 3 days/week|All participants are encouraged to engage with MITA exercises on a daily basis. However this routine is not enforced. As a results, some participants engage with MITA more often than others. At the end of the study we plan to compare participants who engaged with the MITA software at least 3 days/week to those who engaged with MITA less than twice a week.
2978337|NCT02708290||Participants who engage with MITA less than twice a week|All participants are encouraged to engage with MITA exercises on a daily basis. However this routine is not enforced. As a results, some participants engage with MITA more often than others. At the end of the study we plan to compare participants who engaged with the MITA software at least 3 days/week to those who engaged with MITA less than twice a week.
2978338|NCT02708290||Participants who enter the study before the age of 4|"There is a broad consensus that early intervention has the greatest chance of positive impact on an individual with ASD. All participants are encouraged to enter the study as early as possible. On the other hand, there are no contraindications to cognitive exercises. Many parents of teenagers with low functioning ASD expressed satisfaction with their kids engagement with MITA. One parent noted that his boy with low functioning autism turns into smart kid for an hour. He stops acting out and, the sporadic fires in his brain stop and he turns into cognitively thinking kid. At the end of the study we plan to compare participants who entered the study before the age of four to those who entered the study after they reached the age of 7."
2978339|NCT02708290||Participants who enter the study after the age of 7|
2978340|NCT02708290||Participants who continued MITA exercises for over 2 years|"There is a broad consensus that prolonged intervention has the greatest chance of positive impact on an individual with ASD. MITA provides unlimited adaptive puzzles good for years of daily exercises. We encourage all participants to keep exercising with MITA. MITA is completely free and there is no reason to ever stop brain training.~At the end of the study we plan to compare participants who engaged with MITA exercises for over 2 years to those who quit the study in less than three months."
2978341|NCT02708290||Participants who quit MITA exercises in less than 3 months|
2978342|NCT02708277|Experimental|Group A|At the end of the procedure the surgery loop-shaped intrauterine contraceptive device (IUCD) was placed in the uterine cavity.
2978343|NCT02708277|Experimental|Group B|At the end of the procedure the surgery an intrauterine balloon (Cook Medical) was placed in the uterine cavity.
2978344|NCT02708264|Experimental|Cervical Pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 36th week of pregnancy (or earlier if indicated)
2978345|NCT02708264|No Intervention|No intervention|No pessary No pessary will be used. Subjects will receive standard obstetrical management
2978346|NCT02708251|Experimental|glyceryl trinitrate cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine. 1 mL glyceryl trinitrate cream will be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
2978347|NCT02708251|Experimental|lidocaine cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine. 1 mL lidocaine creamwill be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
2978348|NCT02708251|Placebo Comparator|placebo cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine.1 mL placebo cream will be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
2978349|NCT02708238|Experimental|Group A|All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
2978350|NCT02708238|Active Comparator|Group B|All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
2978351|NCT02708238|Active Comparator|Group C|All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 15 drops two times per day of a commercially available solution
2978352|NCT02708225|Experimental|interventional - with a medical clown|will perform pulmonary function test without the presence of a clown and an hour later will re-do the test with a medical clown present
2978353|NCT02708225|No Intervention|non interventional|will perform pulmonary function test without the presence of a clown and an hour later will re-do the test without a medical clown present
2978388|NCT02707965|Active Comparator|Sequence 2|This is a crossover study with 4 treatment periods consisting of 2 Test periods(generic drug) and 2 Reference periods (brand name drug). Each treatment period lasts about 2 weeks, and patients will be randomized into one of the two sequences. All drugs are administered orally, and dosage will depend on a patient.
2978576|NCT02706704|Active Comparator|Systemic|Subcutaneous injection of 40 mg adalimumab (Humira) given every 2 weeks.
2978354|NCT02708212|Active Comparator|EGD-colonoscopy group|In this group, patients receiving an EGD followed by a colonoscopy during a same-day bidirectional endoscopy. Patients receive moderate conscious sedation with fentanyl and midazolam for the procedures. Gastric polypectomy will be provided when gastric polyps are found during an EGD study. Colon polypectomy will be provided when colon polyps are found during a colonoscopy study. Patients' heart rate, respiratory rate, blood pressure, and oxygen saturation will be recorded every 60 seconds during the endoscopic examinations. Patients' tolerability to EGD and colonoscopy examinations will be scaled by patients and endoscopists after the completion of the examinations. Aldrete scores are recorded15 minutes and 25 minutes after entering the recovery room. The recovery time will also be recorded.
2978355|NCT02708212|Active Comparator|Colonoscopy-EGD group|In this study group, patients receive a colonoscopy followed by an EGD during a same-day bidirectional endoscopy. Patients receive moderate conscious sedation with fentanyl and midazolam for the procedures. Colon polypectomy will be provided when colon polyps are found during a colonoscopy study. Gastric polypectomy will be provided when gastric polyps are found during an EGD study. Patients' heart rate, respiratory rate, blood pressure, and oxygen saturation will be recorded every 60 seconds during the endoscopic examinations. Patients' tolerability to colonoscopy and EGD examinations will be scaled by patients and endoscopists after the completion of the examinations. Aldrete scores are recorded15 minutes and 25 minutes after entering the recovery room. The recovery time will also be recorded.
2978356|NCT02708186|Experimental|Nelotanserin|Nelotanserin 80 mg
2978357|NCT02708186|Placebo Comparator|Placebo|Placebo
2978358|NCT02708173|Experimental|One dose Vaccine in aged 18-60 years old|One dose of Quadrivalent Influenza Virus Vaccine will be given in aged 18-60 years old.
2978359|NCT02708173|Experimental|One dose Vaccine in aged 3-17 years old|One dose of Quadrivalent Influenza Virus Vaccine will be given in aged 3-17 years old.
2978360|NCT02708160|Placebo Comparator|Fluoride Free toothpaste|Fluoride free (0%), silica based toothpaste
2978361|NCT02708160|Experimental|1.1% Fluoride toothpaste|Prevident 5000 Plus, silica based toothpaste
2978362|NCT02708160|Active Comparator|0.243% Fluoride Toothpaste|silica based fluoride toothpaste
2978363|NCT02708147|Sham Comparator|Conventional treatment|"Conventional treatment means that there will be only contact with physician/paediatrician and maybe drugs prescription.~Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after."
2978364|NCT02708147|Experimental|Physiotheraphy + Conventional treatment|Apart Conventional treatment a Physiotherapy protocol (techniques and education) will be performed on 5 sessions and evaluations will be made after each session as well as on baseline and on the 3th, 5th and 21st days and an interview 30 days after.
2978365|NCT02708134||Pediatric Cardiac Arrests|Pediatric cardiac arrests requiring chest compressions for at least 1 minute managed at clinical centers identified as part of standard clinical operations.
2978366|NCT02708121|Experimental|Intervention arm|Participant receives intervention to motivate weight loss treatment initiation and access to weight loss treatment.
2978367|NCT02708121|Active Comparator|Comparator Arm|Participant receives access to weight loss treatment alone.
2978368|NCT02708108|Experimental|Obesity Intervention|Personalized 28-day Dietary Intervention and Activity and Exercise Intervention with the goal to reduce fat gain and lean muscle loss while inducing an overall negative energy balance.
2978369|NCT02708095|Experimental|Dose 1 Baricitinib|Baricitinib given orally once a day for 24 weeks.
2978370|NCT02708095|Experimental|Dose 2 Baricitinib|Baricitinib given orally once a day for 24 weeks.
2978371|NCT02708095|Placebo Comparator|Placebo|Placebo given orally once a day for 24 weeks.
2978372|NCT02708082||Glaucoma|Early, moderate or advanced glaucoma, glaucoma suspects or pre-perimetric glaucoma will perform OCT scanning and HFA perimetry
2978373|NCT02708069|Other|e-Unstuck condition|Parents in the e-Unstuck condition will be asked to complete each of the e-Unstuck modules (one per week) over the course of the nine-week intervention, in addition to reading the UOT manual.
2978374|NCT02708069|Other|In-Person condition|Parents participating in the in-person condition will be asked to attend two in-person trainings (approximately 125 and 100 minutes respectively) on the Unstuck and On Target (UOT) curriculum, in addition to reading the UOT manual.
2978375|NCT02708056|Other|Sugammadex, Bridion|Drug were given intravenously by a anesthesiologist at the end of surgery
2978376|NCT02708043|Other|F-LMA group|LMA were placed to 814 patients for adenoidectomy surgery. Researchers evaluated flexible laryngeal mask airway use during pediatric adenoidectomies in terms of patient safety, comfort, complications and surgeon satisfaction levels.
2978377|NCT02708030|Active Comparator|Ketogenic Diet|Ketogenic diet (KD) will be administered by the non-fasting protocol. The child will be admitted to the hospital, and KD will be started in 1:1 ratio. The ratio will increased every 48hours to a maximum of 4:1 or ketosis (urinary ketones 40-80mg/dL) is attained. The child will thereafter be discharged and followed up on Out patient basis.
2978378|NCT02708030|Experimental|Modified Atkins Diet|Modified Atkins Diet (MAD) will be administered on out patient basis. Parents of children will be advised to monitor for seizure frequency and ketosis at home.
2978379|NCT02708030|Experimental|Low Glycemic Index Therapy|Low Glycemic Index Therapy (LGIT) will be administered on out patient basis. Parents of children will be advised to monitor for seizure frequency and ketosis at home.
2978380|NCT02708017|Active Comparator|S-TAP block|ultrasound guided bilateral subcostal TAP block
2978381|NCT02708017|Active Comparator|P-TAP block|ultrasound guided bilateral Posterior TAP block
2978382|NCT02708004|Experimental|ACT-132577|3 different dose levels
2978383|NCT02708004|Placebo Comparator|Placebo|Matching active drug
2978384|NCT02707991|No Intervention|Enhanced Usual Care|Usual clinic appointment process plus receipt of the Centers for Disease Control and Prevention (CDC) Hepatitis C Fact Sheet
2978385|NCT02707991|Experimental|Nurse Case Management|Nurse-initiated hepatitis C clinic referral, strengths-based education, patient navigation, appointment reminders, and care coordination of HIV/hepatitis C drug-drug interaction prevention
2978386|NCT02707978|Experimental|Experimental F 18 T807|
2978387|NCT02707965|Active Comparator|Sequence 1|This is a crossover study with 4 treatment periods consisting of 2 Test periods(generic drug) and 2 Reference periods (brand name drug). Each treatment period lasts about 2 weeks, and patients will be randomized into one of the two sequences. All drugs are administered orally, and dosage will depend on a patient.
2978389|NCT02707952|Experimental|Arm A|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) for 8 weeks in HCV genotype(GT)1 -infected, DAA treatment-naïve participants without cirrhosis.
2978390|NCT02707952|Active Comparator|Arm B|Ombitasvir (25 mg)/paritaprevir (150 mg)/ritonavir (100mg) (OBV/PTV/r) QD for 12 weeks in HCV GT1 infected, DAA treatment-naïve participants without cirrhosis.
2978391|NCT02707952|Experimental|Arm C|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120mg) QD for 12 weeks in HCV GT1- or GT2-infected participants with compensated cirrhosis, HCV GT3-, 4-, 5- and 6-infected participants (with compensated cirrhosis or without cirrhosis), HCV GT1- and GT2-infected participants who had failed prior DAA treatments (with compensated cirrhosis or without cirrhosis), and HCV GT1- or GT2-infected participants with severe renal impairment and compensated cirrhosis.
2978392|NCT02707952|Experimental|Arm D|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in GT1- or GT2-infected participants with severe renal impairment and without cirrhosis.
2978393|NCT02707939||Autism Spectrum Disorder|Patients with a diagnosis of autism spectrum disorder
2978394|NCT02707939||Controls|Patients with no developmental diagnoses
2978395|NCT02707913|Experimental|BF-Amlodipine Tablet 10mg|During the study session, healthy subjects will be administered a single dose of BF-Amlodipine Tablet 10mg after an overnight fast of approximately 10 hours
2978396|NCT02707913|Active Comparator|Norvasc Tablet 10mg|During the study session, healthy subjects will be administered a single dose of Norvasc Tablet 10mg after an overnight fast of approximately 10 hours
2978397|NCT02707900|Experimental|Vorinostat + AGS-004|"Vorinostat (VOR) 400 mg PO - two paired doses at Step 2 (Enrollment) - Only participants demonstrating an in vivo response to the 2nd of the paired VOR doses will proceed to the AGS-004 manufacturing and treatment in Steps 3 through 7.~Step 4 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal (ID) injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 10-7 viable cells. AGS-004 will be administered every 3 weeks for 4 doses."
2978398|NCT02707887|Placebo Comparator|Treatment as Usual|Patients are offered substance use group therapy including relapse prevention. They are also provided medical consultation on an ongoing basis as needed.
2978399|NCT02707887|Active Comparator|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT) involves the discussion of the treatment rationale, identification of values and goals in various life areas and activities in line with chosen life areas, and training for patients to identify their cycle of negative mood and behavior using forms to track their daily goals.
2978400|NCT02707887|Active Comparator|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
2978401|NCT02707874|Active Comparator|CI 0.2% ropivacaine|"Patients in Group Continuous Infusion (CI) will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine.~• All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required.~2) Oral patient controlled analgesia (PCA) using oxycodone or hydromorphone. Patients under 70 years of age will receive either 10 mg of oxycodone or 2 mg of hydromorphone 2 hourly as needed, and patients 70 years of age or older will receive 5 mg of oxycodone or 1 mg of hydromorphone 2 hourly as needed.~3) Oral acetaminophen 1,000 mg 6 hourly."
2978402|NCT02707874|Active Comparator|PIB 0.2% ropivacaine|"Patients in Group programmed intermittent boluses (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine.~• All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required.~2) Oral patient controlled analgesia (PCA) using oxycodone or hydromorphone. Patients under 70 years of age will receive either 10 mg of oxycodone or 2 mg of hydromorphone 2 hourly as needed, and patients 70 years of age or older will receive 5 mg of oxycodone or 1 mg of hydromorphone 2 hourly as needed.~3) Oral acetaminophen 1,000 mg 6 hourly."
2978403|NCT02707861|Experimental|Cohort 1|"IV ibalizumab (combined with optimized background regimen):~800 mg once every two weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial~OR~2000 mg once every four weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial~Administered for 48 weeks, or until ibalizumab becomes commercially available"
2978404|NCT02707861|Experimental|Cohort 2|"IV ibalizumab (combined with optimized background regimen):~800 mg once every two weeks for qualifying patients who have never received ibalizumab~Administered for 48 weeks, or until ibalizumab becomes commercially available"
2978405|NCT02707835|Active Comparator|control group|self massage, skin care education, manual lymph drainage exercise, compression garment
2978406|NCT02707835|Active Comparator|manual lymph drainage group|manual lymph drainage by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
2978407|NCT02707835|Experimental|experimental group|epidermis fascia taping by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
2978408|NCT02707822||kidney or liver transplantation|Renal or liver transplant recipients with tacrolimus as immunosuppressive drugs.
2978409|NCT02707809|No Intervention|Control|Routine anesthesia care for kidney transplant
2978410|NCT02707809|Experimental|Dexmedetomidine|Routine anesthesia care for kidney transplant and perioperative intravenous infusion of dexmedetomidine
2978411|NCT02707796|Experimental|Hemicolectomy|Oxygen reserve index and partial oxygen pressure will be noted for patients undergoing hemicolectomy
2978412|NCT02707783||Bioresorbable vascular scaffold (BVS) implantation|Patients with un/stable angina that require coronary revascularization undergoing the BVS implantation
2978413|NCT02707770|Experimental|Ambulatory oxygen|Patient will use ambulatory oxygen during pulmonary rehabilitation programme (flow rate determined at the initial assessment to a maximum flow rate of 6 litres per minute)
2978414|NCT02707770|Placebo Comparator|Room air|Patient will breath on room air during pulmonary rehabilitation programme
2978415|NCT02707757|Active Comparator|Iron sucrose|Iron sucrose 200mg for 5 doses
2978416|NCT02707757|Active Comparator|Neorecormon|Incremental increase in dose along following parameters: 1000-2000-3000-4000-6000-8000-12000
2978417|NCT02707744||sinus rhythm|patients with heart failure and sinus rhythm
2978418|NCT02707744||atrial fibrillation|patients with heart failure and atrial fibrillation
2978419|NCT02707731|Experimental|Hydrokinesiotherapy in preterm|Salivary cortisol samples, pain applying the Neonatal Infant Pain Scale Scale, heart rate, respiratory rate and oxygen saturation were collected before and after hydrokinesiotherapy
2978420|NCT02707705|Experimental|: Auricular Acupuncture (needle patch) group A|Needle patch: Patients receiving the auricular acupuncture protocol with needles inserted on adhesive tape.
2978421|NCT02707705|Placebo Comparator|Needle-free patch: group P.|Patients who received the auricular acupuncture protocol with adhesive tape without needles.
2978422|NCT02707705|No Intervention|No intervention: group C|Patients without any device or intervention.
2978423|NCT02707692|Other|Placebo, Flu, Pneumovax|"Each subject will take Influenza (Fluarix®, GSK), Pneumococcal (Pneumovax®23, Merck), and placebo. Randomization will determine the order in which the subjects receive the injections. There are six potential study arms, one for each order in which someone could receive the injections:~Arm 1: Placebo, Flu, Pneumovax"
2978424|NCT02707692|Other|Arm 2: Placebo, Pneumovax, Flu|Arm 2: Placebo, Pneumovax, Flu
2978425|NCT02707692|Other|Arm 3: Flu, Placebo, Pneumovax|Arm 3: Flu, Placebo, Pneumovax
2978426|NCT02707692|Other|Arm 4: Pneumovax, Placebo, Flu|Arm 4: Pneumovax, Placebo, Flu
2978427|NCT02707692|Other|Arm 5: Pneumovax, Flu, Placebo|Arm 5: Pneumovax, Flu, Placebo
2978428|NCT02707692|Other|Arm 6: Flu, Pneumovax, Placebo|Arm 6: Flu, Pneumovax, Placebo
2978429|NCT02707679|Other|Effects of Mulligan's Mobilization|The patients in this arm (n=18) received two techniques pertaining to Mulligan's Mobilization with movement approach (Mulligan's Straight Leg-Raise with Traction and Tibial Gliding) along with an exercise therapy. Patients received 4 sessions of treatment twice a week for a period of 2 weeks and followed up in accordance with a 6-week-home exercise program. Primary outcomes: pain severity, knee range of motion, hamstring flexibility, and physical performance (10-step stair climbing test, timed up and go test), Kujala Patellofemoral Pain Scoring and Y-Balance test were assessed before the treatment, 45 minutes after the initial treatment, at the end of the 4-session-treatment during 2-week period and 6 weeks later.
2978430|NCT02707679|Other|Effects of Kinesiotaping|Patients in this arm were applied kinesiotaping on quadriceps and hamstring muscle along with an exercise therapy. Patients received 4 sessions of treatment twice a week for a period of 2 weeks and followed up in accordance with a 6-week-home exercise program. The same assessment parameters was conducted on this arm too.
2978431|NCT02707666|Experimental|Pembrolizumab+Surgery+Chemotherapy|Neoadjuvant pembrolizumab, followed by surgery, followed by adjuvant pemetrexed and cisplatin
2978432|NCT02707653|Other|Miso|Misoprostol 400 s/l
2978433|NCT02707640|Placebo Comparator|Matching Placebo|
2978434|NCT02707640|Experimental|N-Acetylcysteine|
2978435|NCT02707640|Other|Pirfenidone|Background therapy
2978436|NCT02707627|Experimental|Intervention Group|Participants who have been allocated to the intervention group will receive laser therapy + standard scar management (SSM) for the treatment of their hypertrophic burn scars. SSM will be administered according to standard clinical practice at our institution over the duration of the trial. In addition, each participant will receive three sessions of laser therapy scheduled at two month intervals that will be carried out by a single burn surgeon.
2978437|NCT02707627|Active Comparator|Control Group|Participants who have been allocated to the control group will receive SSM alone for the treatment of their burn scars over the duration of the study. The type of scar treatment that participants receive is based on standard clinical practices at our institution and will not be affected by their enrollment in this study.
2978438|NCT02707614||Robotic vs open prostastectomy|One group is operated by open prostatectomy the other by robotic assistance
2978439|NCT02707601|Experimental|E/C/F/TAF + LDV/SOF|"Part 1: Participants will switch from 2 nucleoside reverse transcriptase inhibitors (NRTI) plus a third agent to E/C/F/TAF.~Part 2: After 8 weeks of E/C/F/TAF treatment, the participants will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study."
2978440|NCT02707601|Experimental|F/R/TAF + LDV/SOF|"Part 1: Participants will switch from 2 NRTI plus a third agent to F/R/TAF.~Part 2: After 8 weeks of F/R/TAF treatment, the participants will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study."
2978441|NCT02707588|Experimental|Pembrolizumab and radiotherapy|200 mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy
2978442|NCT02707588|Active Comparator|Cetuximab and radiotherapy|Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.
2978443|NCT02707575|Experimental|Ranibizumab|Intravitreal Ranibizumab
2978444|NCT02707562|Experimental|GLPG1837 dose 1, GLPG1837 dose 2, GLPG1837 dose 3|GLPG1837 twice daily oral dosing - morning and evening, for 4 weeks
2978445|NCT02707549|Active Comparator|Normal Saline Group|the patients included in this group will receive normal saline solution (0.9% sodium chloride) during surgery and in the first 24 hours after ICU admission.
2978446|NCT02707549|Experimental|Balanced Crystalloid Solution Group|the patients included in this group will receive balanced crystalloid solution during surgery and in the first 24 hours after ICU admission.
2978447|NCT02707536|No Intervention|No socket grafting|Extraction with normal socket healing
2978448|NCT02707536|Active Comparator|Socket grafting with platelet rich fibrin (PRF) alone|Extraction with socket grafting with platelet rich fibrin (PRF) alone.
2978449|NCT02707536|Active Comparator|Socket grafting with bone grafting alone|Extraction with socket grafting using bone graft (xenograft).
2978450|NCT02707536|Active Comparator|Socket grafting with PRF and bone grafting|Extraction with socket grafting using PRF combined with bone graft (xenograft).
2978451|NCT02707523|Placebo Comparator|Control|Placebo controlled (normal saline) daily for 3 days
2978452|NCT02707523|Active Comparator|Azithromycin (10 mg/kg)|10 mg/kg IV Azithromycin daily for 3 days
2978453|NCT02707523|Active Comparator|Azithromycin (20 mg/kg)|20 mg/kg IV Azithromycin daily for 3 days
2978512|NCT02707081|Active Comparator|Intraperitoneal instillation group|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure with intravenous normal saline in a volume equivalent to that used in intravenous lidocaine group as placebo to ensure blinding.
2978549|NCT02706860|Experimental|"80 mg atorvastatin for 2 days regimen"|80 mg atorvastatin/ day for 2 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
2978454|NCT02707510|Experimental|Intervention Arm|Patients in the intervention group will be provided with all programmatic materials (including copies of power point presentations, copies of reading texts, and audio CDs) and classes will be held in group format, with a maximum of 9 participants per group. Classes will meet weekly, in a group, and at a set time. All classes will be facilitated jointly by the two Co-PIs. All participants will complete surveys before class, during class, at the end of class, 1 month after the end of class, 6 months after the end of class and 1 year after the end of the class. Additionally, those randomized to the intervention group will be asked to attend a 1 time focus group 1 week after the end of the class.
2978455|NCT02707510|No Intervention|Control Arm|Patients in the control group will be asked to complete surveys at: baseline, 6 weeks after baseline (T1), and 1 month after T1. After T1, the control group will off study and will be permitted to attend the next available GRACE course.
2978456|NCT02707497|Experimental|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
2978457|NCT02707497|Placebo Comparator|control|The control group will not use any platelet-increased drugs.
2978458|NCT02707484|Experimental|Thalidomide Group（100mg）|
2978459|NCT02707484|Experimental|Thalidomide Group（50mg）|
2978460|NCT02707484|Placebo Comparator|placebo -controlled Group|
2978461|NCT02707471|Experimental|SM-AET|a self-management intervention for enhancing skills to improve adherence and reduce symptom interference (SM-AET) (active intervention group)
2978462|NCT02707471|Other|general health education Intervention|general health education Intervention (control group)
2978463|NCT02707458|Experimental|Single arm|All subjects will receive probucol, starting with a fixed dose of 600 mg daily following the evening meal. The variable plasma concentrations achieved and the resulting modification in concentration of CSF apoE will suggest an ideal range of plasma concentrations for use of the drug as an inducer of increased availability of apoE in the CSF. The known dose-proportionality of the drug in plasma will then be used to estimate an ideal individualized dose for each participant. The effects of such individualized dosage will be tested over 1 year of follow-up observations, searching for treatment effects on CSF apoE and for evidence of other treatment effects, particularly including adverse effects.
2978464|NCT02707445|Experimental|GENIUS|All comer patients who had undergone percutaneous coronary intervention with administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months
2978465|NCT02707432|Experimental|Time 1 (T1) Intervention Group|"This group will be the first to receive the adapted intervention, Heart Matters (adapted from the PREMIER intervention). The intervention will be 12 months long."
2978466|NCT02707432|Experimental|Time 2 (T2) Intervention Group|"This delayed intervention group will receive the adapted intervention, Heart Matters, six months after the T1 Intervention group. The intervention will be 12 months long."
2978467|NCT02707419|Experimental|Experimental group|Video of the exercises and conventional physiotherapy. 45 minutes twice a day, 5 days a week for 2 weeks.
2978468|NCT02707419|Active Comparator|Control group|Video of nature scenes and conventional physiotherapy. 45 minutes twice a day, 5 days a week for 2 weeks.
2978469|NCT02707406|Experimental|NEOX®CORD 1K|Intervention Other: hct/p human cell or tissue product: NEOX®CORD 1K Intervention other: human tissue application of of NEOX®CORD 1K on subject wound
2978470|NCT02707406|Active Comparator|Standard of Care|Intervention Other: standard of care alone Other intervention of Standard dressing with a non-adherent wound contact layer, a classic foam pad or gauze for moderately draining wounds, a secondary bandage, and institution of an investigator-approved off-loading device
2978471|NCT02707393|Experimental|single arm|Fludarabine intravenous - daily dose: 40mg/sqm on day -7, -6, -5, -4; Thiotepa intravenous - daily dose: 2 x 5mg/kg on day -3; Melphalan intravenous - daily dose: 140/mg/sqm on day - 2; ATG intravenous - dose according to local standards on day -3, -2, -1; bone marrow or peripheral blood stem cells of an HLA identical sibling or matched unrelated donor on day 0; GvHD propyhlaxis with Mycophenolate Mofetil and Cyclosporine A
2978472|NCT02707380|Active Comparator|Group 1 Resistance Training Group|Participants will perform 3 exercises, one of which will be a series of 7 muscle-strengthening exercises using body weight resistance and elastic resistance bands + 36 sessions of a standard cardiac rehabilitation program consisting of monitored exercise, nutritional guidance, and heart-healthy lifestyle education three times weekly.
2978473|NCT02707380|Active Comparator|Group 2 Standard of Care|Participants will perform 3 exercises that do not include the 7 muscle-strengthening exercises + 36 sessions of a standard cardiac rehabilitation program consisting of monitored exercise, nutritional guidance, and heart-healthy lifestyle education three times weekly.
2978474|NCT02707367|Experimental|Recovery Roadmap (RR)|Participants from programs randomized to the RR condition will receive 6-month access to the Recovery Roadmap online tool.
2978475|NCT02707367|Active Comparator|Illness Management and Recovery (IMR)|Participants from programs randomized to the IMR condition will receive Illness Management and Recovery (IMR) mental health counseling practices.
2978476|NCT02707354|Experimental|Probe based confocal laser endomicroscopy (Cellvizio)|intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console.
2978477|NCT02707341||Psoriasis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
2978478|NCT02707328|Experimental|A|"Chemotherapy:~Gemcitabine 1000 mg/m2 and Abraxane 125 mg/m2 weekly x3 of 28 day cycle~Radiation:~20-55 GY over 5 fractions~Dosing schedule: 3 cycles of chemotherapy, followed by CyberKnife, followed by 3 additional cycles of chemotherapy."
2978479|NCT02707315|Experimental|A|"Chemotherapy:~Gemcitabine 1000 mg/m2 weekly x 3 on 28 day cycle~Radiation:~25 Gy over 5 fractions~Surgery:~surgical resection of pancreas~treatment plan:~1 cycle of chemotherapy, followed by stereotactic radiosurgery, followed by an additional 6 cycles of chemotherapy or surgical resection"
2978513|NCT02707081|Active Comparator|Intravenous injection group|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery and 100 ml of saline intraperitoneally as placebo to ensure blinding
2978550|NCT02706860|Experimental|"40 mg atorvastatin for 5-9 days preoperative regime"|40 mg atorvastatin/ day for 5-9 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
2978480|NCT02707302|Experimental|Iodophor-impregnated adhesive drapes|"In the iodophor-impregnated adhesive drapes group, routine disinfection will be carried out and bacteria samples will be harvested 1 cm from the wound site using sterilized swabs prior to use of the surgical adhesive drapes, and again at the end of surgery before skin suturing, for preoperative bacterial culture. The packaging of the 3M™ iodophor-impregnated adhesive drapes will be opened and the aseptic adhesive drapes unfolded until the stop instruction. The adhesive drapes will then be pasted to the surgical wound and smoothed using an aseptic cloth, taking care to avoid air bubbles."
2978481|NCT02707302|Experimental|Iodophor-free adhesive drapes|Patients in the iodophor-free adhesive drapes group will undergo the same procedures, but with iodophor-free drapes.
2978482|NCT02707276|Experimental|Active LFMS|Active Low Field Magnetic Stimulation three 20 minute treatments, once per day for five consecutive days
2978483|NCT02707276|Sham Comparator|Sham LFMS|Sham Low Field Magnetic Stimulation three 20 minute treatments, once per day for five consecutive days
2978484|NCT02707263|Active Comparator|Intravenous continuous infusion of heparin (IV UFH)|Heparin will be administered intravenously.
2978485|NCT02707263|Active Comparator|Subcutaneous heparin|Heparin will be subcutaneously administered.
2978486|NCT02707250|Placebo Comparator|Placebo|Oblique subcostal tap block with normal sterile saline ,20 ml, bilateral, single shot,24h
2978487|NCT02707250|Active Comparator|Bupivacaine|Oblique subcostal tap block with bupivacaine 0,25% ,20 ml, bilateral, single shot,24h
2978488|NCT02707250|Active Comparator|Pethidine|Oblique subcostal tap block with pethidine 1% ,10 ml,bilateral,single shot,24h
2978489|NCT02707250|Active Comparator|Pethidine Local Infiltration (L.I.)|Local infiltration of pethidine 1% at trocar insertion sites, 5ml /site, 24h compared with Tap Block with pethidine 1%
2978490|NCT02707237|Other|Verbal counseling|Parents with threatened delivery will receive verbal counseling only
2978491|NCT02707237|Other|Verbal, pictorial, written counseling|Parents with threatened delivery will receive verbal counseling supplemented with pictorial and written information
2978492|NCT02707224|Experimental|Group A|combination dose of Candesartan cilexetil and Rosuvastatin and DP-R208 in order
2978493|NCT02707224|Experimental|Group B|DP-R208 and combination dose of Candesartan cilexetil and Rosuvastatin in order
2978494|NCT02707211|Experimental|Anti-oxLDL IgM antibodies|administration Anti-oxLDL IgM antibodies
2978495|NCT02707198|No Intervention|Group A|Will receive prescribed antibiotics and will not receive kefir. Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
2978496|NCT02707198|Active Comparator|Group B|Will receive prescribed antibiotics and will receive kefir only during hospital stay. Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
2978497|NCT02707198|Active Comparator|Group C|Will receive prescribed antibiotics and will receive kefir during hospital stay and for the duration of the prescribed antibiotic regimen for up to a total of 30 days . Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
2978498|NCT02707185|Other|Physicians|"Physician in training:~All internal medicine (IM), emergency medicine (EM), anesthesia (A), surgery (S) residents and all hospital ICU nurses."
2978499|NCT02707185|Other|Nurses|Nurses in Training
2978500|NCT02707172|Experimental|Intervention|"Subject was first exposed to 1000 microgram of diethylhexyl phthalate on both hands, and was asked to perform the intervention, handwashing with soap, by a standardized hand washing technique.~Then the subjects in this arms are crossover to receive placebo, handwashing with water only."
2978501|NCT02707172|Placebo Comparator|Placebo|"Subject was exposed to 1000 microgram of diethylhexyl phthalate on both hands, and was asked to perform the placebo, handwashing with water, by a standardized hand washing technique.~Then the subjects in this arms are crossover to perform the intervention, handwashing with soap."
2978502|NCT02707159|Experimental|Nab paclitaxel / gemcitabine|Patients will receive 125 mg per m2 nab-paclitaxel and 1000 mg per m2 on days 1, 8 and 15 followed by one week of rest before new treatment cycle.
2978503|NCT02707146|Experimental|Tablet in the waiting room|"Patients in the intervention arm will be met in the waiting room prior to their primary care visit and will use the Visit Planner tool application on the tablet"
2978504|NCT02707146|Active Comparator|Health Education Handout|Patients in the control arm will be met in the waiting room prior to their primary care visit and will be given an educational pamphlet on health lifestyle to review
2978505|NCT02707120|Experimental|PRGF-Endoret eye-drops|
2978506|NCT02707120|Active Comparator|Artificial tears eye-drops|
2978507|NCT02707107|Active Comparator|3 g of zidebactam (1 g q8h) and 6 g of cefepime (2 g q8h) or 6|administered as IV infusions every q8h, over a period of 60 minutes.
2978508|NCT02707107|Placebo Comparator|Placebo|administered as IV infusions every q8h, over a period of 60 minutes.
2978509|NCT02707094|Other|Usual Care (Medication + Exercise)|Usual Care: Participants will receive guidance on over-the-counter and prescribed pain medications to use to treat their chronic low back pain symptoms. The Research Coordinator (RC) will provide instructions for low back pain stretching and strengthening exercises. The Licensed Provider (LP) will determine if any exercises should be excluded based on their physical limitations. Participants enrolled in the usual care treatment arm will track the frequency of their back stretching and strengthening exercise sessions on the Pain Medication & Exercise Diary. For the purpose of this study, treatment compliance will be met if participants complete the exercises a minimum of three times per week.
2978510|NCT02707094|Experimental|Biomodulator + Usual Care|Biomodulator + Usual Care treatment group: Usual care, as described above, will be provided to all participants randomly allocated to this treatment group, in addition to treatment with the Biomodulator three times per week x 4 weeks. The licensed provider will review medication and treatment logs, prescribe pain medications as indicated, and assess for treatment side effects. In addition to treatment with the Biomodulator, the participant will perform back stretching and core strengthening exercises for a minimum of three times per week as instructed and will be told to use their prescribed pain medications as needed to self-treat their low back pain symptoms (as previously described above).
2978511|NCT02707081|Placebo Comparator|Placebo control group|Saline was given both intraperitoneally and intravenously during caesarean section
2978575|NCT02706704|Active Comparator|Intravitreal|Intravitreal injection of 1.5mg/0.03ml adalimumab given at zero, 2 weeks, and then every 4 weeks.
2978514|NCT02707068|Experimental|QOLITI|"Intervention group receives the QOLITI (Quality Of LIfe Tool for IBD) manual immediately to work with over the course of several weeks along with 3 x 30 minutes of telephone support by a trained healthcare professional. Telephone calls will occur at two, four and six weeks post-randomisation.~Participants will be invited to discuss their experiences after the end of the actual study. These interviews are no obligatory part of the QOLITI study."
2978515|NCT02707068|No Intervention|Waitlist Control group (WLC)|Waitlist control group waits until after the study finishes to receive the same manual, but without telephone support sessions.
2978516|NCT02707055|Experimental|Active Drug|Ghrelin Receptor Inverse Agonist
2978517|NCT02707055|Other|Placebo|Placebo
2978518|NCT02707055|Other|MI-VF|Motivational Interviewing with Video
2978519|NCT02707055|Other|Counseling|Counseling support
2978520|NCT02707042|Experimental|B|Research sampling and testing will occur at 10 timepoints before, during, and after a 5-day oral course of once-daily azithromycin. 500 mg will be taken orally on day 1, then 250 mg every 24 hours from day 2 to day 5 inclusive, preferably at the same time every day.
2978521|NCT02707042|Experimental|A|Research sampling and testing will occur at 10 timepoints before, during, and after a 7-day therapeutic oral course of twice daily amoxicillin. 500 mg will be taken orally every 12 hours, preferably at the same time every day, within 1 hour of finishing a meal, for a total of 21 doses.
2978522|NCT02707016|Other|High dose sevoflurane|"Inhaled sevoflurane 8% during induction of general anesthesia (from the start of gas administration to the insertion of a laryngeal mask).~After laryngeal mask insertion, sevoflurane will be reduced to 4%. Caudal block with L-bupivacaine 0.25% will be performed in all children.~After caudal block, sevoflurane will be reduced to 0.75 MAC according to age of the child and maintained until the end of surgery After surgery, PAED and pain scales will be administered every 15 minutes up to 2 hours after surgery."
2978523|NCT02707016|Other|Low dose sevoflurane|"Inhaled sevoflurane 5% during induction of general anesthesia (from the start of gas administration to the insertion of a laryngeal mask).~After laryngeal mask insertion, sevoflurane will be reduced to 4%. Caudal block with L-bupivacaine 0.25% will be performed in all children.~After caudal block, sevoflurane will be reduced to 0.75 MAC according to age of the child and maintained until the end of surgery After surgery, PAED and pain scales will be administered every 15 minutes up to 2 hours after surgery."
2978524|NCT02707003||AZ PACU|Observation of standard of care with capnography blinded
2978525|NCT02707003||TWH PACU|Observation of standard of care with capnography blinded
2978526|NCT02706990|Other|Physica KR|Patients who have received a Physica KR total knee implant.
2978527|NCT02706990|Other|Physica PS|Patients who have received a Physica PS total knee implant.
2978528|NCT02706977|Experimental|Diabetes Group - Low Dose Sinemet CR|Participants with diabetes mellitus type-2 and electroretinogram (ERG) delays will receive low dose Sinemet CR twice daily for two weeks.
2978529|NCT02706977|Experimental|Diabetes Group - High Dose Sinemet CR|Participants with diabetes mellitus type-2 and electroretinogram (ERG) delays will receive high dose Sinemet CR twice daily for two weeks.
2978530|NCT02706977|Other|Diabetes Group - No Electroretinogram (ERG) Delays|Participants with diabetes mellitus type-2 who do not have electroretinogram (ERG) delays. Participants in this group will have one baseline visit only.
2978531|NCT02706977|Other|Age-Matched Controls|Participants will serve as age-matched controls for participants with diabetes. This group will participate in the baseline, week 2, and week 4 visits only.
2978532|NCT02706964|Experimental|Proactive imaging|All enrolled subjects will under go a single whole-body Positron emission tomography/x-ray computed tomography (PET/CT) scan and a diagnostic-quality x-ray computed tomography (CT) scan with contrast acquired in the same imaging session; and a single brain magnetic resonance imaging (MRI) scan with contrast to be completed in separate imaging session but within 2 weeks of the PET/CT scan. Imaging will take place within 7 months after enrollment.
2978533|NCT02706951|Experimental|ABT-494 Dose A|ABT-494 Dose A once daily for 240 weeks
2978534|NCT02706951|Experimental|ABT-494 Dose B|ABT-494 Dose B once daily for 240 weeks
2978535|NCT02706951|Active Comparator|Methotrexate followed by ABT-494 Dose B|Methotrexate for 14 weeks followed by ABT-494 Dose B for 226 weeks
2978536|NCT02706951|Active Comparator|Methotrexate followed by ABT-494 Dose A|Methotrexate for 14 weeks followed by ABT-494 Dose A for 226 weeks
2978537|NCT02706938|Other|Head of bed elevation - Control|Participants will sleep with head of bed raised with standard 20 cm-height wooden blocks during a first period of 6 weeks. After a washout 2 week period, participants will sleep in a bed without inclination for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
2978538|NCT02706938|Other|Control - Head of bed elevation|Participants will sleep in a bed without inclination during a first period of 6 weeks. After a washout 2 week period, participants will sleep with head of bed raised with standard 20 cm-height wooden blocks for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
2978539|NCT02706925|Experimental|BI 443651|
2978540|NCT02706925|Placebo Comparator|Placebo|
2978541|NCT02706912|Experimental|VOTA Group|All enrolled subjects are in this arm. After pre-assessment subjects have an 8-week waiting period, after which a mid-assessment takes place. Subject then participate in VOTA therapy for 8 weeks, followed by a post-assessment . The pre-/mid-assessment difference is used to control for spontaneous recovery. The mid-/post-assessment difference is used to ascertain efficacy.
2978542|NCT02706899|Experimental|33A + azacitidine|Vadastuximab talirine plus azacitidine
2978543|NCT02706899|Active Comparator|Placebo + azacitidine|placebo plus azacitidine
2978544|NCT02706886|Active Comparator|ALN-GO1|
2978545|NCT02706886|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
2978546|NCT02706873|Experimental|ABT-494 Dose B|ABT-494 Dose B once daily monotherapy and Methotrexate matching placebo orally once weekly.
2978547|NCT02706873|Active Comparator|Methotrexate|Methotrexate orally once weekly and ABT-494 matching placebo orally once daily.
2978548|NCT02706873|Experimental|ABT-494 Dose A|ABT-494 Dose A once daily monotherapy and Methotrexate matching placebo orally once weekly.
2978647|NCT02706184|Experimental|Intervention|Patients receive E. coli Nissle suspension
2978551|NCT02706860|Experimental|"80 mg atorvastatin for 5-9 days preoperative regime"|80 mg atorvastatin/ day for 5-9 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
2978552|NCT02706847|Experimental|ABT-494 Dose A|ABT-494 Dose A once daily for 240 weeks
2978553|NCT02706847|Experimental|ABT-494 Dose B|ABT-494 Dose B once daily for 240 weeks
2978554|NCT02706847|Placebo Comparator|Placebo followed by ABT-494 Dose B|Placebo once daily for 12 weeks followed by ABT-494 Dose B for 228 weeks
2978555|NCT02706847|Placebo Comparator|Placebo followed by ABT-494 Dose A|Placebo once daily for 12 weeks followed by ABT-494 Dose A for 228 weeks
2978556|NCT02706834|Experimental|Cohort1|Non-Japanese participants will be assigned to receive placebo during one of the first through fourth intervention periods and will receive TAK-828 during the remaining 3 periods. Participants will receive TAK-828 0.1 milligram (mg) or matching placebo, solution, orally, once on Day 1 of first intervention period (4 days), followed by 7 days washout period, and then TAK-828 3 mg or matching placebo, solution, orally, once on Day 1 of second intervention period (4 days), followed by 7 days wash-out period, and then TAK-828 20 mg or matching placebo, solution, orally, once on Day 1 of third intervention period (4 days), followed by 7 days wash-out period, and then TAK-828 100 mg solution, orally, once on Day 1 of fourth intervention period (4 days). A fifth interventional period (4 days) may be conducted in either Cohort 1 or 2 with TAK-828 dose to be determined (DTBD) based on results from previous periods. Interventional Period 1-4 doses will be given after a fast of at least 8 hours.
2978557|NCT02706834|Experimental|Cohort2|Non-Japanese participants will be assigned to receive placebo during one of the first through fourth intervention periods and will receive TAK-828 during the remaining 3 periods. Participants will receive TAK-828 0.5 mg or matching placebo, solution, orally, once on Day 1 of first intervention period (4 days), followed by 7 days washout period, and then TAK-828 10 mg or matching placebo, solution, orally, once on Day 1 of second intervention period (4 days), followed by 7 days wash-out period, and then TAK-828 40 mg or matching placebo, solution, orally, once on Day 1 of third intervention period (4 days), followed by 7 days wash-out period, and then TAK-828 200 mg solution, orally, once on Day 1 of fourth intervention period (4 days). A fifth interventional period (4 days) is planned to be conducted in either Cohort 1 or 2 with TAK-828 dose to be determined (DTBD) based on results from previous periods. Interventional Period 1-4 doses be given after a fast of at least 8 hours.
2978558|NCT02706834|Experimental|Cohort3|Japanese participants will be assigned to receive placebo during one of the first through third intervention periods and will receive TAK-828 during the remaining two periods. Participants will receive TAK-828 3 milligram (mg) or matching placebo, solution, orally, once on Day 1 of first intervention period (4 days), followed by 7 days washout period, and then TAK-828 20 mg or matching placebo, solution, orally, once on Day 1 of second intervention period (4 days), followed by 7 days wash-out period, and then TAK-828 100 mg or matching placebo, solution, orally, once on Day 1 of third intervention period (4 days). Interventional Period 1-3 doses will be given after a fast of at least 8 hours.
2978559|NCT02706821|Active Comparator|Treatment sequence 1|PLE (persimmon leaf extract) once a day during 8 weeks cross-over to placebo once a day during 8 weeks.
2978560|NCT02706821|Active Comparator|Treatment sequence 2|Placebo once a day during 8 weeks cross-over to PLE once a day during 8 weeks.
2978561|NCT02706808|Experimental|resistance starch for CKD|- Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo
2978562|NCT02706808|Experimental|cross-over period|intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
2978563|NCT02706795|Experimental|Dose A|DaxibotulinumtoxinA
2978564|NCT02706795|Experimental|Dose B|DaxibotulinumtoxinA
2978565|NCT02706795|Experimental|Dose C|DaxibotulinumtoxinA
2978566|NCT02706782|Experimental|TAI-meso-CART|A single dose of meso-CART cells will be administered by vascular interventional mediated as one dose infusions. The dose is 1-10x106/kg meso-CAR positive T cells. The infusion will be scheduled to occur 2 days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures. Patients will undergo cannula--DSA radiography--CAR-T cells perfusion. The cells perfusion process would lasts 15min to 2 h, and the specific time depends on patent's tumor-burdened state.
2978567|NCT02706769|Active Comparator|Paracetamol|Participants will take blinded Paracetamol (as they were taking before entering the study)
2978568|NCT02706769|Placebo Comparator|Placebo|Participants will take blinded Paracetamol
2978569|NCT02706756|Experimental|Education, exercise and manual therapy|"One group will receive education and advice, manual therapy that is applied toward the impairments of the subject, a prescription of progressive rehabilitation exercises designed to strengthen weakened muscle groups and stretch joint movements that demonstrate range of motion limitations. Treatment is based on clinical presentation and identification of impairments by the treating clinician. Subjects will be seen twice weekly for 4 to 6 weeks, depending on the progression.~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
2978570|NCT02706756|Active Comparator|Education and exercise|"Group will receive a prescriptive intervention designed to strengthen the hip and surrounding regions as well as improve flexibility of the lower extremity. This group will not receive additional physiotherapy management but will be schedule bi-weekly to review the home exercises and to receive appropriate educational support.~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
2978571|NCT02706756|Placebo Comparator|Supervised neglect|"Group will receive supervised neglect. We will monitor this group for changes or emergent situations but no formal care will be provided.~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
2978572|NCT02706730|Experimental|OTO-104|12 mg dexamethasone
2978573|NCT02706717|Active Comparator|Visbiome Extra Strength|
2978574|NCT02706717|Placebo Comparator|Placebo for Visbiome Extra Strength|
2978648|NCT02706184|Placebo Comparator|Control|Patients receive placebo
2978577|NCT02706691|Experimental|BGJ398 (infigratinib) Dosing|Patients receive BGJ398 (125 mg) by mouth once daily on a three weeks on, one week off schedule. Courses repeat every 28 days until disease progression or unacceptable toxicity.
2978578|NCT02706678|Experimental|Tacrolimus sustained-release capsule group|Oral
2978579|NCT02706652||patients|screening patients
2978580|NCT02706626|Experimental|Brigatinib|Experimental: Brigatinib until progressive disease, unacceptable toxicity, withdrawal of consent
2978581|NCT02706613|Other|Face to Face Pulmonary Rehabilitaton|6 week incremental pulmonary rehabilitation (PR) programme. Participants will attend 12 sessions over the 6 week period. The components of the PR programme will include an exercise programme. Education sessions will also be provided and include anatomy of the lungs and what is COPD, anxiety and depression, self management, managing breathlessness, medications and treatments, managing exacerbations of COPD and chest infections, clearing sputum and the Active Cycle of Breathing Technique, nutrition, pacing, smoking cessation. Participants on the face to face arm will also be instructed to carry out the pulmonary rehabilitation exercises an additional three times a week at home.
2978582|NCT02706613|Active Comparator|Online Pulmonary Rehabilitation|Those randomised to receive the online programme will be given log-in details and a password, and instructions to begin the 6 week programme at home. The online programme mirrors the conventional face-to-face PR programme and the exercise and educational components are given by means of instructional videos. Participants will be instructed to exercise five times a week. Participants in the online arm will receive during the PR course telephone contact to record any adverse or serious adverse events.
2978583|NCT02706600|Other|Written Self Management|The HealthQuest written self management plan was produced in 2013. It is a one page document which contains a written self management plan which can be individualised for the patient. It consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate.
2978584|NCT02706600|Active Comparator|Online Self Management|"myCOPD is a system that can be accessed by patients using any device that can connect to the internet and can operate in any internet browser. It contains: Educational information, Inhaler technique videos explaining the correct technique required to use different inhaler devices licensed for use in people with COPD.~Medication and symptom diaries. Appointment diary, pulmonary rehabilitation videos to promote and support exercises that can be done in the home.~Oxygen Alert Card - Users can create their own oxygen alert card online A 5 Day local weather and pollution reports - Feed for reports come from the met office and DEFRA.~A Self management plan, which consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate. The action plan is populated automatically with the information input by the patients."
2978585|NCT02706587|Experimental|Neuromuscular electrical stimulation|NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
2978586|NCT02706587|Sham Comparator|Sham Control|No electrostimulation
2978587|NCT02706574||Isolated Traumatic Brain Injury|This group will present to our Level 1 Trauma Center with a Traumatic Brain Injury and no other associated injuries. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
2978588|NCT02706574||Isolated Body Trauma|This group will present to our Level 1 Trauma Center as a trauma patient with no injury to their head. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
2978589|NCT02706574||Combined Traumatic Brain Injury and Body Trauma|This group will present to our Level 1 Trauma Center as a trauma patient that had injuries to both their head and body. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
2978590|NCT02706574||Healthy, Uninjured Controls|This group will consist of subjects that have not been exposed to any major trauma in the previous 12 months. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
2978591|NCT02706561|Experimental|Standard care plus the ACT intervention (ACT-ED)|SC + ACT-ED-Group A uses Acceptance and Commitment Therapy (ACT). In this group, men focus on: long-term goals of rehabilitation; acceptance of the frustration related to ED; identifying and overcoming barriers; and committing to an erectile rehabilitation program. All participants will be asked to complete a set of questionnaires (baseline). The participants can complete it using your personal computer, one of MSKCC computers, in-person or over the phone. The questionnaires will take about 45-60 minutes to complete. You will also complete the same set of questionnaires at 6, 12, 18, and 24 months following study entry. In both groups, the participant will receive three in-person sessions or phone (30-45 minutes), six brief telephone sessions (5-10 minutes), and six monthly phone calls (5-10 minutes)
2978592|NCT02706561|Experimental|SC plus nurse Enhanced Monitoring and Education (EME)|SC + EME-Group B uses enhanced monitoring and education. This group focuses on answering questions about the rehabilitation program, manage technical issues related to injections, and the dose titration of injection medication. Participants in this group will also receive education on the side effects and impact of prostate cancer surgery, and strategies for restarting sexual activity. All participants will be asked to complete a set of questionnaires (baseline). You can complete it using your personal computer, one of MSKCC computers, in-person or over the phone. The questionnaires will take about 45-60 minutes to complete. The participant will also complete the same set of questionnaires at 6, 12, 18, and 24 months following study entry. In both groups, the participant will receive three in-person sessions or phone (30-45 minutes), six brief telephone sessions (5-10 minutes), and six monthly phone calls (5-10 minutes).
2978593|NCT02706548|Experimental|Occupational Therapy Intervention Group|Thirty-minute intervention in which the participant and interventionist discuss past medication taking performance, medication-related goals, and strategies to meet goals. Intervention is enhanced with motivational interviewing and therapeutic use of self.
2978594|NCT02706548|Active Comparator|Standard Care Intervention Group|Thirty-minute educational intervention in which the participant and interventionist review a pamphlet on adherence to medication.
2978651|NCT02706171|Experimental|C: Non-resectable|"Radiation- CyberKnife:~50 Gy over 5 fractions"
2978595|NCT02706535|Experimental|Part 1 Cohort 1|Subjects will receive a single dose of GSK525762 10 mg on Day 1 followed by 200 mg Itraconazole two times a day (BID) on Day 3. On Day 4 to Day 6 inclusive subjects will receive a single dose of itraconazole 200 mg in the morning. On Day 7 subjects will receive a single dose of GSK525762 5 mg one hour after receiving 200 mg dose of itraconazole. On day 8 and 9 subjects will receive a single dose of 200 mg itraconazole in the morning.
2978596|NCT02706535|Experimental|Part 1 Cohort 2|Subjects will receive a single dose of GSK525762 10 mg on day 1 followed by 200 mg Itraconazole BID on day 3. On day 4 to day 6 inclusive subjects will receive a single dose of itraconazole 200 mg in the morning. On day 7 subjects will receive a single dose of GSK525762 5 mg or GSK525762 10 mg one hour after receiving 200 mg dose of itraconazole. On day 8 and 9 subjects will receive a single dose of 200 mg itraconazole in the morning.
2978597|NCT02706535|Experimental|Part 2|Subjects will receive a single dose of GSK525762 10 mg on day 1. From day 3 to 17 inclusive, subjects will receive a single dose of 600 mg rifampicin in fasting conditions. On day 18 subjects will receive single dose of GSK525762 either 20 or 30 mg along with 600 mg dose of rifampicin. On day 19 subjects will receive a single dose of rifampicin 600 mg.
2978598|NCT02706522|Experimental|Allocated to Carbohydrated group|"Patients was administered in hospital~Randomization~Patient was allocated to Carbohydrated group~Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal."
2978599|NCT02706522|Placebo Comparator|Allocated to Placebo group|"Patients was administered in hospital~Randomization~Patient was allocated to Placebo group~Patients received 400 mL of water 12 hours before anesthesia and 400 mL 2 hours before anesthesia."
2978600|NCT02706509|Active Comparator|oral tramadol|Patients will receive oral Tramadol 50 mg capsules (n=50)' . After an hour, Jaydess intrauterine device will be inserted.
2978601|NCT02706509|Sham Comparator|verbal anesthesia|'verbal anesthesia' (n=50) After an hour, Jaydess intrauterine device will be inserted
2978602|NCT02706496||young adults (20-35yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
2978603|NCT02706496||middle age(45-60yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
2978604|NCT02706496||elderly(65-74yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
2978605|NCT02706483|Experimental|Plecanatide|Plecanatide 6.0 mg tablets
2978606|NCT02706470|Experimental|Cyclosporin A|Patients allocated to Cyclosporin A group will receive oral Cyclosporin A in a dose of 50 mg three times a day for 20-30 days in early pregnancy.
2978607|NCT02706470|Active Comparator|Dydrogesterone|Patients allocated to dydrogesterone group will receive oral dydrogesterone in a dose of 10 mg three times a day for 30 days in early pregnancy.
2978608|NCT02706457||cohort 2012 - 2014|all patients admitted for > 48 hours on the Intensive Care Unit in 2012, 2013 and 2014
2978609|NCT02706444|Active Comparator|Conventional Balloon Angioplasty|Conventional balloon angioplasty. After fistulogram, full expansion of conventional balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram
2978610|NCT02706444|Active Comparator|Drug-Coated Balloon Angioplasty|Drug-coated balloon angioplasty. After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram
2978611|NCT02706431|No Intervention|Normoventilation|The patients will be normoventilated before anesthesia
2978612|NCT02706431|Experimental|Hyperventilation|Prior to anesthesia, the patients will hyperventilate during 2 mins or until symptoms from the central nervous system (e.g. dizziness).
2978613|NCT02706418|Other|Clinical Massage Therapy|
2978614|NCT02706405|Experimental|Group I (JCAR014, durvalumab)|Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 28 (may occur as early as day 21) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
2978615|NCT02706405|Experimental|Group II (durvalumab, JCAR014)|Patients receive durvalumab IV over 60 minutes on days -1 and -28 (may occur as early as day 21), and JCAR014 IV over 20-30 minutes on day 0. Patients may receive durvalumab IV over 60 minutes every 4 weeks for up to 11 doses in the absence of disease progression or unacceptable toxicity.
2978616|NCT02706392|Experimental|Treatment (ROR1 CAR-specific autologous T-lymphocytes)|Patients receive chemotherapy comprising fludarabine phosphate and cyclophosphamide as determined by the referring physician in consultation with the protocol PI. Beginning within 36-96 hours after completion of lymphodepleting chemotherapy, patients receive ROR1 CAR-specific autologous T-lymphocytes IV over 20-30 minutes. Patients may receive a second infusion of ROR1 CAR-specific autologous T-lymphocytes with or without additional cytoreductive therapy at the same (for those that received the highest cell dose) or up to the next highest dose level and there is persistent disease, there were no toxicities attributed to the first infusion, and the patient is at least 21 days from the first T cell infusion.
2978617|NCT02706379|Experimental|Local cerebral oxygen saturation|use NIRS technical to detect local cerebral oxygen saturation of both sides of brain
2978649|NCT02706171|Experimental|A: pre-operative|"Radiation- CyberKnife:~35-40 Gy over 5 fractions~Surgery:~Surgical resection of sarcoma"
2978650|NCT02706171|Experimental|B: Post-operative|"Radiation- CyberKnife:~40 Gy over 5 fractions"
2980164|NCT02695797|No Intervention|Control|No immunotherapy.
2978618|NCT02706353|Experimental|APX005M + Pembrolizumab|"Dose Escalation Phase:~Starting dose level of APX005M is 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses. Tumor site chosen based on volume to be injected.~All participants receive Pembrolizumab at 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.~Dose Expansion Phase:~Starting dose level of APX005M is maximum tolerated dose from Dose Escalation Phase.~Participants receive same dosage of Pembrolizumab as in Dose Escalation Phase."
2978619|NCT02706340||Vaginal delivery|Women who have had a copper IUD placed within 10 minutes of a vaginal delivery of at least 34 weeks 0 days gestation.
2978620|NCT02706340||Cesarean delivery|Women who have had a copper IUD placed within 10 minutes of a cesarean delivery of at least 34 weeks 0 days gestation.
2978621|NCT02706327|Experimental|CAD/CAM|8-week follow-up with CAD/CAM insole and home based exercise program
2978622|NCT02706327|Experimental|Semi-custom|8-week follow-up with semi-custom insole and home based exercise program
2978623|NCT02706327|Placebo Comparator|Control|8-week follow-up with placebo insole and home based exercise program
2978624|NCT02706314||Critically ill patients with CIP|Critically ill patients with a Sequential Organ Failure Assessment (SOFA)-Score >7 with CIP
2978625|NCT02706314||Critically ill patients without CIP|Critically ill patients with a Sequential Organ Failure Assessment (SOFA)-Score >7 without CIP
2978626|NCT02706314||Healthy volunteers|Healthy volunteers with neither critical illness nor CIP
2978627|NCT02706301|Experimental|Telephone-Based Coping Skills Training (CST)|The CST condition will receive 5 sessions of a cognitive behavior theory-based protocol that teaches coping skills (e.g., relaxation, activity pacing/planning, cognitive restructuring) relevant to managing pain as well as psychological distress.
2978628|NCT02706301|No Intervention|Standard care control|The standard care control condition will receive resources and referrals related to survivorship health. This information will be provided to the participant during their initial survivorship care consult.
2978629|NCT02706288|Experimental|Weight loss with diet with exercise|Persons with obesity with blood glucose concentrations higher than recommended and a moderate to high amount of fat in the liver (people with metabolically abnormal obesity) will be tested before and after 7-10% weight loss. Following baseline testing, participants will be placed on a caloric-restricted plant-based very-low-fat (PB) diet and an exercise program until 7-10% weight loss is achieved; they will then be re-tested so that pre- and post-intervention outcomes can be compared.
2978630|NCT02706275|Experimental|Warming Group|External warming via forced air warming
2978631|NCT02706275|No Intervention|Control Group|Standard of care body temperature management
2978632|NCT02706262|No Intervention|Metabolically normal lean - Baseline testing only|"Metabolically normal lean - Lean individuals that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.~Dietary intervention - None."
2978633|NCT02706262|No Intervention|Metabolically normal obese - Baseline testing only|"Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.~Dietary intervention - None."
2978634|NCT02706262|Experimental|Metabolically abnormal obese - Mediterranean diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.~Dietary intervention - A nutritionally balanced diet that includes fruits, vegetables, fish, beans, whole grains, and olive oil with approximately 50% of daily calories coming from complex carbohydrates, 30% of calories from fat, and 20% of calories from protein."
2978635|NCT02706262|Experimental|Metabolically abnormal obese - Low carbohydrate ketogenic diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.~Dietary intervention - A very-low-carbohydrate, adequate protein, high-fat diet containing 20 grams of carbohydrate or less per day (about 5% of calories), derived mainly from vegetables."
2978636|NCT02706262|Experimental|Metabolically abnormal obese - Plant-based very-low-fat diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.~Dietary intervention - A plant-based diet high in complex carbohydrates and low in fat, protein, and sodium, with approximately 70% of daily calories from carbohydrates, 15% from fat, and 15% from protein."
2978637|NCT02706249|Active Comparator|A: Standard Dose Enoxaparin|"Participants will receive Enoxaparin 40 mg subcutaneously once daily. On study Enoxaparin will be administered for up 14 days during hospitalization.~After the day 14 assessment, treatment arms will be un-blinded in order to appropriately schedule a bilateral lower extremity ultrasound for participants enrolled onto Arm A at day 17."
2978638|NCT02706249|Active Comparator|B: Weight Adjusted Enoxaparin|"Participants will receive Enoxaparin at 1mg/kg subcutaneously once daily with maximum dose of 100 mg daily. Participants who weigh more than 100kg will be capped at 100mg.~On study Enoxaparin will be administered for up 14 days during hospitalization."
2978639|NCT02706236|Active Comparator|Intervention Arm|Pancreatic enzyme replacement (Pancrelipase) with meals and snacks daily, for 4 weeks.
2978640|NCT02706236|Placebo Comparator|Placebo Arm|Lactose placebo tablets with meals and snacks, for 4 weeks.
2978641|NCT02706223|Experimental|Pharmacist Led|This arm involved subjects following pathway of care and treatment delivery delivered by community pharmacists
2978642|NCT02706223|Experimental|Nurse Led|This arm involved subjects following the conventional pathway of care and treatment delivery delivered by specialist secondary care nurses
2978643|NCT02706210||vascular cognitive disorders pre-dementia (VCD-P)|
2978644|NCT02706210||amnestic mild cognitive impairment (aMCI)|
2978645|NCT02706197|Experimental|IA No treatment except SOC surgery|Placement of OxyChip will be through a minimally invasive procedure (needle injection) and removal will be at the time of surgical resection. In Phase IA, patients will not have any cancer therapy prior to removal of the OxyChip and duration of implantation is typically less than 4 weeks but may be up to 52 weeks.
2978646|NCT02706197|Experimental|IB SOC adjuvant therapy and SOC surgery|Placement of OxyChip will be through a minimally invasive procedure (needle injection) and removal will be at the time of surgical resection. In Phase IB, patients will have standard of care neoadjuvant systemic therapy or pre-operative radiation therapy during the time that the OxyChip is within the tumor, which is typically 6 weeks but may be up to 52 weeks.
2981833|NCT02684357|Placebo Comparator|Placebo|
2978652|NCT02706158|Experimental|supplement and balanced diet|"Woman at high risk of pre-eclampsia:~supplements. 1500 mg Calcium and 1200 IU Vitamin D for 2 months. balanced diet."
2978653|NCT02706158|No Intervention|women without nutrition or supplement intervention|usual follow-up in the gynecology out patient clinic, without nutrition or supplement intervention.
2978654|NCT02706145|Experimental|Intervention Group (West Louisville)|This group will be exposed to the social norming campaign via traditional, mass, and social media over the three-year intervention period.
2978655|NCT02706145|No Intervention|Control Group (East Nashville)|This group will serve as the control group, and measures of social norms and attitudes toward violence will be compared between this group and the intervention group.
2978656|NCT02706132|Experimental|The MSCs group|The group of patients receive allogeneic MSCs therapies.
2978657|NCT02706119|Experimental|Glargine insulin|Single dose glargine insulin (basal component) + regular insulin within total parenteral nutrition (TPN) reservoir (prandial component). 50% of the total calculated dose of insulin is administered subcutaneously as single dose subcutaneous glargine insulin; remaining 50% of the total calculated dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Intravenous glargine insulin, and regular insulin added to TPN bag
2978658|NCT02706119|Active Comparator|Regular insulin|Regular insulin added to TPN bag (basal + prandial component). The calculated total dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Regular insulin added to TPN bag
2978659|NCT02706106|Experimental|Knee brace with a hole|Patients will be prepared to receive the device of knee brace with a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
2978660|NCT02706106|Placebo Comparator|Knee brace without a hole|Patients will be prepared to receive the device of knee brace without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
2978661|NCT02706093|Other|High Intensity Interval Training #1|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
2978662|NCT02706093|Other|Moderate intensity continuous training|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
2978663|NCT02706093|Other|High Intensity Interval Training #2|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
2978664|NCT02706093|Other|High Intensity Interval Training #3|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
2978665|NCT02706080||Antithrombotic agents|We propose to realize a single-center prospective registry of patient under Antithrombotic agent who came to the emergency unit for any reason.
2978666|NCT02706067|Experimental|Orlistat|Participants will receive intermittent orlistat for up to 4 years, with the dose determined according to body weight changes.
2978667|NCT02706054|Placebo Comparator|C-group|patients receiving an IM saline injection near the nerve root (periradicular)
2978668|NCT02706054|Experimental|M-group|patients receiving an IM Meloxicam injection near the nerve root (periradicular)
2978669|NCT02706041|Active Comparator|Definitive closure laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
2978670|NCT02706041|Other|Damage control laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
2978671|NCT02706028|Active Comparator|ultrasound group|Patients in the ultrasound group received underwater US therapy to both hands and wrists for 7 minutes with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
2978672|NCT02706028|Sham Comparator|control group|The control group received sham treatment (the ULTRON home OE-302® device was not turned on) during 10 sessions for 7 minutes per session.
2978673|NCT02706015|Experimental|Cefaliv® & Placebo|Dihydroergotamine mesylate+ dipyrone sodium + caffeine
2978674|NCT02706015|Active Comparator|Neosaldina® & Placebo|Isometheptene mucate + dipyrone sodium + anhydrous caffeine
2978675|NCT02706002|Active Comparator|hip prosthesis under fluoroscopy|implantation of femoral stem of hip prosthesis in this group of patients are under fluoroscopic guidance for stem size and stem alignment and last rap before original stem implantation will be checked for alignment , lateral and vertical offsets parameters.
2978676|NCT02706002|Sham Comparator|hip prosthesis without fluoroscopy|in this group of patients rasping of femoral canal during hip prosthesis is made via anatomic landmarks which confirmed by to senior surgeons and than original stem implanted.
2978677|NCT02705989|Placebo Comparator|Single Ascending Dose (SAD)|Single ascending dose of BMS-986195 or Placebo matching BMS-986195
2978678|NCT02705989|Placebo Comparator|Multiple Ascending Dose(MAD)|Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195
2978679|NCT02705989|Placebo Comparator|Japanese-Multiple Ascending Dose(MAD)|Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195 in subjects with Japanese heritage
2978680|NCT02705989|Experimental|Relative Bioavailability with Food Effects (Open Label)|
2978681|NCT02705976|Active Comparator|self-managing warfarin|self-managing warfarin patients who are educated in dosing warfarin to achieve target INR value
2978682|NCT02705976|Experimental|algorithm-suggested warfarin dosing|algorithm-suggested warfarin dosing, where the participants are provided with a dosage suggestion of their warfarin dosage (calculated dose) to achieve target INR
2978715|NCT02705729|Active Comparator|Ketac Universal|Simplified glass ionomer tooth filling
3032771|NCT02343120|Experimental|BGB-3111|
2978683|NCT02705963|Experimental|Oral Contraceptive / Trametinib|In treatment period 1 of the PK Phase patients will take the Oral Contraceptive once daily from Days 1-5. Period 2 of the PK Phase starts on Day 6 when patients take both the Oral Contraceptive and trametinib once daily from Days 6 to 21. Patients may continue dosing with trametinib only once daily from Day 22 onwards (post PK Phase).
2978684|NCT02705950|Active Comparator|intrathecal baclofen bolus|In ITB bolus group: An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level. A 50 µg.
2978685|NCT02705950|Placebo Comparator|placebo|In the placebo group: 1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
2978686|NCT02705937|Experimental|Dairy product|The product will be taken for 14 days
2978687|NCT02705937|Active Comparator|Aequasyal mouth spray medical device|The spray will be taken for 14 days
2978688|NCT02705924|Experimental|Psychoeducational intervention|group participating to the first psychoeducational intervention: it consists in a week-end session in a SPA center including several conferences about HBOC familial risk, cancer prevention, prophylactic possibilities (surgery), recommendations about nutrition and physical activity a risk modulators, assisted medical procreation and embryo selection, social support...). Besides conferences, Moreno role games and group sharing are organized under the supervision of a psychotherapist.
2978689|NCT02705924|Other|Waiting list|delayed intervention: group participating to the second psychoeducational intervention (6 months later). Intervention is same as in the intervention arm but it is delayed. Because questionnaires are completed before this second intervention in both arms and allocation to arms are randomized, it represents an adequate control group.
2978690|NCT02705911|Experimental|Isometric Handgrip training|Participants are asked to perform daily 4 x 2 minute contractions with alternating hands , separated with 1 minute rest period using a ZonaHealth device;
2978691|NCT02705911|Active Comparator|Aerobic endurance training|Participants are asked to perform at least 150 minutes extra of moderate aerobic exercise per week
2978692|NCT02705911|No Intervention|Control|Participants are asked to continue with their daily routine and not to perform extra exercise.
2978693|NCT02705898|Experimental|LPA+Fitbit|A 12-week LPA+Fitbit intervention for depressed women in intensive alcohol treatment. This will include: 1) a single in-person physical activity (PA) counseling orientation session; 2) 6 brief, phone-based PA counseling sessions focused on increasing PA and strategically using bouts of PA to cope with affect and alcohol cravings; 3) use of the Fitbit fitness tracker for physical activity goal-setting and daily self-monitoring; and 4) weekly supportive messages delivered by email.
2978694|NCT02705898|Active Comparator|Health Education Contact Control (HEC)|The HEC condition will include: 1) an in-person orientation session, 2) 6 telephone-delivered health education sessions, and 3) weekly health-related e-mails. A variety of health and lifestyle topics will be addressed including the following: Session 1 (week 1) - Nutrition—What to Eat and What Not to Eat; Session 2 (week 2) - Sleep Problems and Sleep Hygiene; Session 3 (week 4) - Alcohol Use among Women; Session 4 (week 6) - Relaxation training; Session 5 (week 8) - Time Management and Assertiveness; and Session 6 (week 10) - Being a Smart Patient when Coordinating your Healthcare.
2978695|NCT02705885|Experimental|Gingipain IgY|Participants consume lozenges containing IgY against gingipains of Porphyromonas gingivalis
2978696|NCT02705885|Placebo Comparator|Placebo IgY|Participants consume lozenges containing placebo IgY
2978697|NCT02705872|Experimental|Programmed intermittent boluses|Epidural analgesia performed with programmed intermittent boluses.
2978698|NCT02705872|Active Comparator|Continuous perfusion|Epidural analgesia performed with a continuous perfusion.
2978699|NCT02705859|Other|Single Arm|"This study is a Phase Ib/II open label, single arm, adaptive multi-centre trial.~Patients with HER2-positive, metastatic or incurable recurrent breast cancer, following disease progression during, or after, treatment with at least one systemic treatment regimen in the metastatic or recurrent setting, will be treated with copanlisib (at 30, 45 or 60 mg flat dosing IV weekly - depending on the maximum tolerated dose (MTD) determined in the Phase Ib part of the study) plus trastuzumab (4 mg/kg IV Cycle 1 Day 1 and then 2 mg/kg IV weekly starting from day 8)."
2978700|NCT02705846||BRCA1 mutation carriers|Men with a known pathogenic germline BRCA1 mutation
2978701|NCT02705846||BRCA2 mutation carriers|Men with a known pathogenic germline BRCA2 mutation
2978702|NCT02705846||BRCA1 controls|Men known not to carry a pathogenic germline BRCA1 mutation
2978703|NCT02705846||BRCA2 controls|Men known not to carry a pathogenic germline BRCA2 mutation
2978704|NCT02705833||Population with R/M SCCHN|Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) patients diagnosed between 01July2013 and 30June2014, alive or deceased, at the time of data collection
2978705|NCT02705820|Experimental|single arm study|experimental treatment with maintenance pembrolizumab
2978706|NCT02705807|Experimental|FLOLAN arm|Subjects will receive the existing FLOLAN treatment (i.e., FLOLAN injection prepared with the currently marketed diluent) for a run-in period of a maximum of 4 weeks, the thermostable formulation of FLOLAN injection (i.e., FLOLAN injection prepared with the reformulated diluent) for a 4-week treatment period and there will be a one-week follow-up visit.
2978707|NCT02705781|Experimental|General|One arm study: smARTrack Feeding Tube System.
2978708|NCT02705768|No Intervention|Healthy control|Twenty five (25) healthy individuals of same age group will serve as the control group. Control subjects will be evaluated at baseline only.
2978709|NCT02705768|Experimental|Carbamazepine group|Twenty five (25) patients recruited in this group will receive Tab. Carbamazepine. Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
2978710|NCT02705768|Experimental|Oxcarbazepine group|Twenty five (25) patients recruited in this group will receive Tab. Oxcarbazepine. Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
2978711|NCT02705755|Experimental|TD-9855: Part A|Subjects will receive placebo and escalating single doses of TD-9855
2978712|NCT02705755|Experimental|TD-9855: Part B|Subjects will receive a single dose of TD-9855 or placebo
2978713|NCT02705755|Experimental|TD-9855: Part C|Subjects will receive once daily doses of TD-9855 for up to 5 months as part of an optional outpatient open-label extension arm.
2978714|NCT02705742|Other|stem cells group|mesenchymal stem cells only
3038431|NCT02304887||Senosumab|
2978716|NCT02705729|Active Comparator|Ketac Molar Quick|Glass ionomer tooth filling
2978717|NCT02705716|Experimental|Test Dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste containing 0.454% weight by weight (w/w) stannous fluoride (1100 parts per million [ppm] fluoride). Participants will then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute.
2978718|NCT02705716|Placebo Comparator|Control Dentifrice|Participants will be instructed to apply a full brush head of toothpaste containing 0.76% sodium monofluorophosphate (1000ppm fluoride) to a dry toothbrush. Participants will then brush the whole mouth thoroughly for at least 1 minute.
2978719|NCT02705703|Experimental|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
2978720|NCT02705677||Rett syndrome|This is a biobanking project for individuals with mutations in MECP2 or meeting diagnostic criteria for classic (typical) or variant (atypical) Rett syndrome in order to identify other genetic factors such as X-chromosome inactivation or genetic background that may explain the variations noted in these individuals, including those with the same MECP2 mutation. No interventions are anticipated.
2978721|NCT02705677||MECP2 Duplication disorder|This is a biobanking project for individuals with MECP2 duplications to understand the difference in the size of the duplication and the potential impact of other genes in the duplicated segment. No interventions are anticipated.
2978722|NCT02705677||Rett-related disorders|This is a biobanking project for individuals with mutations in MECP2, CDKL5, and FOXG1 to understand the interplay of mutations in these individuals and the resultant phenotypic expression; for example, individuals with mutations in MECP2 but not meeting diagnostic criteria for Rett syndrome or individuals with mutations in CDKL5 or FOXG1 who may or may not meet diagnostic criteria for atypical Rett syndrome. No interventions are anticipated.
2978723|NCT02705664|Experimental|Loceryl NL|Amorolfine hydrochloride NL 5% to be applied once weekly for 7 weeks on all affected toenails of one foot
2978724|NCT02705664|Active Comparator|Urea Ointment + Bifonazole Cream|"On the opposite foot:~Urea 40% ointment to be applied once a day under occlusion for 2-3 weeks depending on the achievement of optimal diseased toenail plates removal)~Bifonazole 1% cream to be applied for 4 weeks on affected toenails (after the maximum 3-week treatment period with Urea ointment)"
2978725|NCT02705651|Experimental|Somatostatin-Analog|A long acting somatostatin analog will be applied.
2978726|NCT02705651|No Intervention|No treatment|This arm will be be the observational control according to the endpoints of the study. No intervention will be made.
2978727|NCT02705638|Experimental|Rituximab and Lenalidomide|All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15, as well as Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
2978728|NCT02705625|Experimental|MIV-711:1|MIV-711 for a total of 26 w
2978729|NCT02705625|Experimental|MIV-711:2|MIV-711 for a total of 26 w
2978730|NCT02705625|Placebo Comparator|Placebo|Placebo for a total of 26 w
2978731|NCT02705612|Other|control group|Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy.
2978732|NCT02705612|Experimental|experimental group|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as the patients in control group. Patients also receive nimotuzumab during the external radiotherapy.
2978733|NCT02705586|Experimental|only one arm - open label study|
2978734|NCT02705573|Experimental|Mannitol 20%|Mannitol 1g/ kg BW
2978735|NCT02705573|Placebo Comparator|Nacl 0.9%|NaCl 0.9% 5ml/ kg BW
2978736|NCT02705560|Experimental|Cow´s milk (3.9% fat, pasteurized)|Cow´s milk (3.9% fat, pasteurized) Single dose, 600 ml milk
2978737|NCT02705560|Experimental|Hard, yellow cheese|"Hard, yellow cheese Single dose, 100 g cheese~+ 500 ml water"
2978738|NCT02705560|Active Comparator|Soy based drink|Soy based drink Single dose, 600 ml soy drink (soy drink + plant based cream)
2978739|NCT02705547|Experimental|Rosuvastatin (Crestor)|This is an open-label study of Rosuvastatin (Crestor) in patients with FRDA. Study subjects will receive 10 mg of Rosuvastatin daily for 3 months.
2978740|NCT02705534|Experimental|Treatment|Subjects will receive sofosbuvir, ledipasvir and ribavirin
2978741|NCT02705521|No Intervention|Treatment as usual group|Patients will attend physiotherapy on a weekly basis for assessment (standard physiotherapy). They will be assessed for progression and be provided with a home exercise program. Range of motion in their shoulder will be collected on a weekly basis using the MIRA technology. Patients will be required to complete an exercise diary documenting the exercises performed as well as duration and frequency.
2978742|NCT02705521|Experimental|Treatment as usual plus Exergames group|Patients will attend physiotherapy on a weekly basis for assessment (standard physiotherapy). Rather than use a home exercise program patients will be provided with a laptop computer and kinect sensor. they will use the new technology to play 'Exergames' each program will be tailored to the patients progress and patients can play the system as often as they wish. Patients will be required to complete an exercise diary documenting the exercises performed as well as duration and frequency.
2978743|NCT02705508|Experimental|PEG group|Treatment PEG dosages were as follows: days 1 and 8,30min intravenous infusion of 1000mg/m2 gemcitabine;day1,4h intravenous infusion of 100mg/m2 etoposide,day1-3,deep intramuscular injection of 2500U/m2 Pegaspargase at three different sites.The regimen was repeated every 3 weeks.Stage IE/IIE patients underwent four cycles induction chemotherapy, followed by involved-field radiotherapy after got CR, PR or SD. Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved-field radiation (IFRT) dose was 50-56 Gy.Stage IIIE/IVE patients were given for a maximum of six cycles.
2978744|NCT02705495|Active Comparator|acupuncture|12 acupuncture treatments according to a standardized protocol, plus recommendation for use of cranberry products
2978745|NCT02705495|Other|Control|Recommendation for use of cranberry products only
2978746|NCT02705482|Experimental|Arm A: MEDI0562 and durvalumab|MEDI0562 and durvalumab
2978747|NCT02705482|Experimental|Arm B: MEDI0562 and tremelimumab|MEDI0562 and tremelimumab
2978748|NCT02705469|Experimental|Dose Escalation and Dose Confirmation - ZEN003694 Single Agent|ZEN003694 will be administered orally as a single agent once daily in 28-day cycles, enrolling mCRPC patients.
2978749|NCT02705456|Experimental|HA-Tooth Paste|"Tooth Brushing HA~Cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite twice daily over the duration of the study (24 weeks).~Professional caries prevention by professional supragingival tooth cleaning and the subsequent application of a 1% chlorhexidine gel once every 4 weeks over the duration of the study (24 weeks)."
2978750|NCT02705456|Active Comparator|FL-Tooth Paste|"Tooth Brushing FL~Cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste twice daily over the duration of the study (24 weeks).~Professional caries prevention by professional supragingival tooth cleaning and the subsequent application of a 1% chlorhexidine gel once every 4 weeks over the duration of the study (24 weeks)."
2978751|NCT02705443||Tissue w/ Thermographic Anomaly|"Visibly undamaged tissue with anomaly identified by the thermographic image~No intervention~Standard of care"
2978752|NCT02705443||Tissue w/o Thermographic Anomaly|"Visibly undamaged tissue with no anomaly identified by the thermographic image~No intervention~Standard of care"
2978753|NCT02705443||Tissue w/ Visible Anomaly|"Visibly damaged tissue~No intervention~Standard of care"
2978754|NCT02705430|No Intervention|A|Group A will continue their actual therapy (control).
2978755|NCT02705430|Experimental|B|Group B will continue their standard therapy with additional stress management application only using a mobile phone (Eco Fusion Mentally) for 3 months of the study
2978756|NCT02705430|Experimental|C|Group C will continue their standard therapy with additional life style program using a mobile phone (Eco Mentally and NewMe) for 3 months of the study
2978757|NCT02705430|Experimental|D|Group D will continue their standard therapy plus additional life style program using a mobile phone with additional supplemental EPA and DHA capsules of 2 g/day to be taken daily for the 3 months of the study
2978758|NCT02705417||Group A|Patients in whom selection of vascular access relied upon physical examination and medical history, during pre-operative surgical assessment
2978759|NCT02705417||Group B|Patients who underwent vascular mapping using color Doppler Ultrasonography in addition to physical examination and history during pre-operative evaluation.
2978760|NCT02705378|Active Comparator|Polyethylene glycol|17g power qday; reconstituted in water for naso/orogastric tube administration
2978761|NCT02705378|Experimental|naloxegol|25mg qday; crushed pill reconstituted in water for naso/orogastric tube administration
2978762|NCT02705365|Experimental|Patient Navigation|Patients assigned to the patient navigator (PN) arm will be sent a letter about the program with lung screening educational materials. The PN will educate eligible patients about lung screening, explore barriers to screening, coordinate scheduling an appointment with a provider, and possibly attend the visit with the patient. The PN will further coordinate scheduling the CT scan, help the patient obtain the test, and access any required follow-up. The PN will assess the patient's interest in quitting smoking and if so, offer and help to connect the smoker to existing cessation resources in the community and provide follow-up contacts to monitor adherence to treatments.
2978763|NCT02705365|Active Comparator|Usual Care|The control group will receive usual care during the 1-year study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results as well as smoking cessation guidance.
2978764|NCT02705352|Experimental|5-Fluorouracil|Antimetabolite will be injected 2 weeks after periocular reconstruction with full thickness skin graft. Injection will be repeated every 2 weeks for a total of up to 4 injections.
2978765|NCT02705352|Placebo Comparator|Normal saline|Normal saline will be injected 2 weeks after periocular reconstruction with full thickness skin graft. Injection will be repeated every 2 weeks for a total of up to 4 injections.
2978766|NCT02705339|Experimental|Arm 1: Rociletinib|"Rociletinib is an oral drug which will be administered on an outpatient basis at a dose of 500 mg twice per day during each 28-day cycle.~After completion of cycle 1, patients who tolerate the 500 mg twice per day dose without significant adverse effect may increase dosing to 625 mg twice per day at the discretion of the investigator"
2978767|NCT02705326|Experimental|Opti-Speech|Speech treatment will be guided by Opti-Speech's visual feedback of tongue movement during speech
2978768|NCT02705300|Experimental|Chemotherapy plus tocotrienol|"Every 2 weeks: irinotecan 165 mg/m2 iv, oxaliplatin 85 mg/m2 iv, calcium folinate 200 mg/m2 iv, and 5-fluorouracil 3200 mg/m2 as a 46 hour infusion.~Daily: Tocotrienol 300 mg x 3 daily"
2978769|NCT02705300|Placebo Comparator|Chemotherapy plus placebo|"Every 2 weeks: irinotecan 165 mg/m2 iv, oxaliplatin 85 mg/m2 iv, calcium folinate 200 mg/m2 iv, and 5-fluorouracil 3200 mg/m2 as a 46 hour infusion.~Daily: Placebo x 3 daily"
2978770|NCT02705287||Vitamin D dynamics-pregnant|Pregnant women recruited to measure Vitamin D dynamics during pregnancy.
2978771|NCT02705287||Vitamin D dynamics-nonpregnant|Non-pregnant women recruited to measure Vitamin D dynamics.
2978772|NCT02705287||Delivery-placental transfer|Pregnant women planning to deliver by scheduled c-section who will be dosed with vitamin D3 in late gestation (week 36-38).
2978773|NCT02705287||Delivery-Vitamin D|Pregnant women will be dosed with vitamin D3 at term when they come in for their pre-surgical appointments prior to their scheduled c-section
2978774|NCT02705287||Delivery-25(OH) Vitamin D|Pregnant women will be dosed with 25(OH)D3 when they come in for their pre-surgical appointments
2978775|NCT02705274|Active Comparator|Prompt Panretinal Photocoagulation|PRP= Panretinal Photocoagulation. PRP alone.
2978776|NCT02705274|Experimental|Bevacizumab with deferred PRP|Bevacizumab = Anti vascular endothelial growth factor. PRP= Panretinal photocoagulation. Intravitreal anti-VEGF with PRP only if indicated.
2978777|NCT02705261|Experimental|Cognitive-behavior therapy|Cognitive-behavior therapy to teach parents the skills to help their children. Participants will have access to the program as often as they wish and have the post assessment at week 12.
2978778|NCT02705248||Group A|(Group A) case group: 40 pregnant females at 6- 13wks presenting with a history of recurrent pregnancy loss (two or more failed clinical pregnancies as documented by ultrasonography or histopathology examination according to the American Society of Reproductive Medicine) (ASRM, 2008).
2978779|NCT02705248||Group B|control group: 40 pregnant females at 6- 13wks with no history of abortion.
2978780|NCT02705222|Active Comparator|D&C group|Women will undergo D&C
2978781|NCT02705222|Active Comparator|Hysteroscopy group|Women will undergo hysteroscopy
2978782|NCT02705209|Active Comparator|Treatment|
2978783|NCT02705209|Placebo Comparator|Control|
2978784|NCT02705196|Experimental|Intratumoral LOAd703 Injection|"Patients will receive Gemcitabine intravenously at a dose of 1000mg/m2 + nab-paclitaxel 125 mg/m2 as per hospital standards. One cycle will be one dose of Gemcitabine +nab-paclitaxel given on days 1, 8, and 15 of a 28 day cycle. LOAd703 will be given every other week for 6 doses starting on day 15 of the first cycle of chemotherapy.~In Phase I patients will be assigned to the following doses:~Dose level 1: 5 X 10^10 viral particles per treatment Dose level 2: 1 X 10^11 viral particles per treatment Dose level 3: 5 X 10^11 viral particles per treatment In Phase IIa, patients will be dosed according to the schedule as specified above however the dose of LOAd703 will be fixed and based on the outcome of the Phase I component of the study."
2978785|NCT02705183|Active Comparator|A: Surgery & Post-operative radiotherapy|Surgery & Post-operative radiotherapy
2978786|NCT02705183|No Intervention|B: Surgery only|Surgery only
2978787|NCT02705170||left ventricle dilatation|The subjects of the investigation will be patients with recent diagnosis of unknown left ventricle dilatation. These subjects received coronary artery angiography as exam suggested by guidelines to discriminate the cause of left ventricle dilatation. In subjects without documentation of coronary artery lesions, the Authors will assess the index of microvascular resistance.
2978788|NCT02705157||Bone metastasis of the long bone|Patients with bone metastases of the long bone(s) receiving surgical stabilisation of a pathologic or impending fracture or receiving radiotherapy for a painful metastasis.
2978789|NCT02705144||biopsies from lung tissue affected by emphysema|analysis of the number of stem cell niches
2978790|NCT02705144||biopsies from lung tissue affected by interstitial fibrosis|analysis of the number of stem cell niches
2978791|NCT02705144||biopsies from normal appearance lung tissue|analysis of the number of stem cell niches
2978792|NCT02705131|Experimental|Balance Chiropractic Therapy(BCT)|patients are in the sitting position and receive the Balance Chiropractic Therapy(BCT) .1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.The patients will received BCT 1 time every other day, 20min each time. a total of 10 times in 20 days.
2978793|NCT02705131|Active Comparator|Traction Therapy(TT)|patients will receive the Traction Therapy(TT):The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
2978794|NCT02705118|Experimental|Automatic registration arm|"Automatic registration for fusion imaging of US and MRI will be performed.~Automatic Imaging fusion of ultrasonography and MRI"
2978795|NCT02705118|Active Comparator|Manual registration arm|"Manual registration for fusion imaging of US and MRI will be performed.~Manual Imaging fusion of ultrasonography and MRI"
2978796|NCT02705105|Experimental|Mogamulizumab + Nivolumab|"During parts 1 and 2, mogamulizumab and nivolumab are administered at appropriate intervals.~Part 1 (Dose Escalation Part): During cohort 1 to 2, mogamulizumab and nivolumab are administered in combination.~Part 2 (Expansion Part): Patients will be treated with maximum tolerated dose established in the dose escalation part for each combination."
2978797|NCT02705092|Experimental|Subliminal priming with subliminal reward stimuli|"This intervention consisted of five presentations [three cycles of mosaic (displayed for 117 ms each), physical exertion words as subliminal priming (displayed for 17 ms), and positive words as subliminal reward (displayed for 17 ms)].~These were set to 1 package. 1 package is 24 times per 5 seconds presented in the animation (Animation of Skateboarding) for approximately 2 min."
2978798|NCT02705092|Experimental|Subliminal priming with supraliminal reward stimuli|"This intervention consisted of four presentations [two cycles of mosaic (displayed for 117 ms each), physical exertion words as subliminal prime (displayed for 17 ms), and positive words as supraliminal reward (displayed for 150 ms)].~These were set to 1 package. 1 package is 24 times per 5 seconds presented in the animation (Animation of Skateboarding) for approximately 2 min."
2978799|NCT02705066|Placebo Comparator|Placebo (Cellulose)|
2978800|NCT02705066|Experimental|Cognizin 250 mg/day|
2978801|NCT02705066|Experimental|Cognizin 500 mg/day|
2978802|NCT02705053|Active Comparator|Sensor-Augmented Pump Open-Loop Care (Week 2)|The subjects' Sensor-Augmented Pump Open-Loop Care for the second week of the study before any adjustments to pump settings, using a CGM and Insulin Pump.
2978803|NCT02705053|Experimental|Closed-Loop Control System with Zone MPC and HMS|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on CGM glucose levels. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device. Algorithmic adjustment of carbohydrate ratios prior to closed-loop initiation, and continued basal rate and carbohydrate ratio algorithmic optimization during closed-loop use will occur.
2978804|NCT02705040||Normal|bone mineral density T>=-1.0
2978805|NCT02705040||Osteopenia|bone mineral density -1.0>T>=-2.5
2978806|NCT02705040||Osteoporosis|bone mineral density T<-2.5
2978807|NCT02705027|Active Comparator|Standard|"After randomization one half of the patients receive a Freka®-Trilumina probe, which is inserted in nasogastric route an then pushed  using a small forceps which is inserted through the endoscope into the small intestine."
2978808|NCT02705027|Experimental|Freka®-EasyIn|The other half of the patients will receive a Freka®-EasyIn probe which is directly placed in the small intestine inserted over the endoscope, after endoscopy was initially pushed - as far as possible - into the small intestine.
2978809|NCT02705014|Experimental|treatment group|patients were administered with pulsatile gonadotropin-releasing hormone (GnRH )therapy for 12 months at an interval of 90 minutes.The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L.
2978838|NCT02704793|Experimental|Bilateral 1 Hz Cerebellar rTMS|Patients will be treated with 900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere for 5 consecutive days.
2979110|NCT02703051|Experimental|GMI-1271 with Filgrastim|GMI-1271 with Filgrastim
2978810|NCT02704988|Active Comparator|Colon Cancer - Carnoy|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
2978811|NCT02704988|Active Comparator|Colon Cancer - GEWF|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
2978812|NCT02704988|Active Comparator|Rectal Cancer - Carnoy|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
2978813|NCT02704988|Active Comparator|Rectal Cancer - GEWF|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
2978814|NCT02704975|Experimental|Rehabilitation and Dry Needling|Standard Rehabilitation Protocol following shoulder stabilization surgery and Dry Needling to the Shoulder girdle 1 time a week for 4 weeks between weeks 4 and 8 post operatively
2978815|NCT02704975|Active Comparator|Rehabilitation|Standard Rehabilitation Protocol following shoulder stabilization surgery alone
2978816|NCT02704962|Experimental|trifluoperazine plus olanzapine|trifluoperazine 5mg/day + olanzapine 5mg/day
2978817|NCT02704962|Active Comparator|full-dose olanzapine|olanzapine 10mg/day
2978818|NCT02704949|Experimental|Low-dose|The intervention is to use 1/4 fluoroscopy dose while the ureteroscopy is being performed
2978819|NCT02704949|Active Comparator|Full-dose|The intervention is to use full fluoroscopy dose while the ureteroscopy is being performed
2978820|NCT02704936||Male donor|42 samples of semen from male donor attached to a donation program Normal sperm count as WHO 2010.
2978821|NCT02704936||IUI positive pregnancy|42 samples of semen from a program attached to patients for insemination Male indication Normal / slightly abnormal sperm count or infertility source unknown and have obtained positive pregnancy in any of the first 4 treatments IUI
2978822|NCT02704936||IUI unsuccessful pregnancy|42 samples of semen from a program attached to patients for insemination Male indication Normal / slightly abnormal sperm count or infertility source unknown and after undergoing maximum 4 cycles have unsuccessfully IUI indication of IVF / ICSI.
2978823|NCT02704923|Active Comparator|Atropine|
2978824|NCT02704923|Placebo Comparator|Placebo|
2978825|NCT02704910|Placebo Comparator|Voluntary subject|Patient without parkinson disease, without deep brain stimulation
2978826|NCT02704910|Active Comparator|Patients|Subthalamic stimulation
2978827|NCT02704897|Experimental|Intervention Arm|"Wound assessment tool - delivered via a smartphone. A link will be sent to participants on discharge, which can be accessed at any point should they have concerns about their wound.~They will also be sent the tool at 3 additional time-points."
2978828|NCT02704897|No Intervention|Control Arm|Normal Post-operative Care
2978829|NCT02704884|Experimental|probiotic soy milk|consume a diet containing 200 ml/day probiotic soy milk in intervention group
2978830|NCT02704884|Active Comparator|soy milk|200 ml/day soy milk in the control condition
2978831|NCT02704858|Experimental|NEO100|Intranasal delivery of NEO100 (perillyl alcohol) four times a day, escalation up to four different doses to determine maximum tolerated dose. Followed by treatment of total of 25 patients at maximum tolerated dose
2978832|NCT02704845||Ankylosing Spondylitis|
2978833|NCT02704845||Chronic non-specific low back pain|
2978834|NCT02704832|No Intervention|Arm A|"Arm A Standard oncological care: patients will be treated according to daily oncological practices as defined for each type of cancer, in the Management protocol of Oncology written and validated by a group of expert oncologists. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months."
2978835|NCT02704832|Experimental|Arm B|"Arm B Geriatrician Intervention: patients will be treated according to the same Management protocol of Oncology than patients in the arm Standard oncological care.~Before the beginning of the medical treatment, a comprehensive geriatric assessment will be performed by the geriatrician and the nurse that will define a plan of geriatric management care, according to the Management protocol of Geriatrics.~The nurse, under the supervision of a geriatrician, will monitor implemented geriatric interventions. Phone follow-up will be performed every month for 6 months and at 9 months or during any change of situation according to a pre-established phone call plan. A full geriatric assessment by the geriatrician and the nurse will be performed at 6 and 12 months."
2978836|NCT02704819|Experimental|Non-specialist doctor +DSS|"Patients allocated to +DSS group will receive the following intervention:~V1: appointment with a non-specialist doctor with the support of the DSS~V2: appointment with an overseeing expert~V3: DSS Customised Vestibular Physiotherapy~V4: follow-up visit with the overseeing expert"
2978837|NCT02704819|Active Comparator|Non-specialist doctor -DSS|"Patients allocated to -DSS group will receive the following intervention:~V1: appointment with a non-specialist doctor without the support of the DSS~V2: appointment with an overseeing expert~V3: Standard Physiotherapy Practice~V4: follow-up visit with the overseeing expert"
3041936|NCT02281019||Other indications|
2978839|NCT02704793|Sham Comparator|Sham (electrical stimulation)|Sham treatment will be performed with the same protocol using a small device placed on the TMS coil (not visible to the patients) producing electrical stimulation (less than 3 mili amperes), to simulate the sensation of real TMS.
2978840|NCT02704780|Active Comparator|400 Microgram Misoprostol|Misoprostol 400 micro-gram dissolved in 20 mL normal saline will be injected in the umbilical vein in the first group
2978841|NCT02704780|Active Comparator|800 Microgram Misoprostol|Misoprostol 800 micro-gram dissolved in 20 mL normal saline will be injected in umbilical cord of the second group
2978842|NCT02704767|Placebo Comparator|TarceP|Tarceva with Placebo
2978843|NCT02704767|Experimental|TarceA|Tarceva with Apatinib
2978844|NCT02704754|Experimental|suvorexant|10 to 20 mg to be administered before bedtime
2978845|NCT02704754|Placebo Comparator|Placebo pill|A pill without active ingredients
2978846|NCT02704741|Experimental|all subjects|"Eligible subjects will undergo 3 treatments in 4±1 weeks interval on the Vagina (External/Vulva and Internal/Vagina) with the CO2RE device according to study protocol.~Subject will return for to 5 follow-up (FU) visits: 1 week ± 2 days post first treatment visit and 1, 3, 6 and 12 months after last (third) treatment (± 2 weeks).~Methodology described in protocol to evaluate efficacy of treatments will be carried out at each visit at the clinic."
2978847|NCT02704728|Experimental|Thetanix|In Part A, 8 subjects will receive a single dose and in Part B, 8 subjects will receive twice daily doses for 7.5 days (a total of 15 doses). Each dose consists of three capsules
2978848|NCT02704728|Placebo Comparator|Placebo|In Part A, 2 subjects will receive a single dose and in Part B, 2 subjects will receive twice daily doses for 7.5 days (a total of 15 doses). Each dose consists of three capsules.
2978849|NCT02704715|Other|general anesthesia,orbital operation|"diagnosed as orbital disease and ocular tumor~over 16 years old~orbital operation under general anesthesia"
2978850|NCT02704702|Other|Sequence 1 (ABC)|"Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment C)~There will be a washout of at least 7 days between the each period."
2978851|NCT02704702|Other|Sequence 2 (ACB)|"Period 1(Treatment A) → Period 2(Treatment C) → Period 3(Treatment B)~There will be a washout of at least 7 days between the each period."
2978852|NCT02704702|Other|Sequence 3 (BAC)|"Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment 3)~There will be a washout of at least 7 days between the each period."
2978853|NCT02704702|Other|Sequence 4 (BCA)|"Period 1(Treatment B) → Period 2(Treatment C) → Period 3(Treatment A)~There will be a washout of at least 7 days between the each period."
2978854|NCT02704702|Other|Sequence 5 (CAB)|"Period 1(Treatment C) → Period 2(Treatment A) → Period 3(Treatment B)~There will be a washout of at least 7 days between the each period."
2978855|NCT02704702|Other|Sequence 6 (CBA)|"Period 1(Treatment C) → Period 2(Treatment B) → Period 3(Treatment A)~There will be a washout of at least 7 days between the each period."
2978856|NCT02704689|Experimental|AccuLIF|
2978857|NCT02704676||control patients|normal pregnant women, 3rd trimester
2978858|NCT02704676||mild pre-eclampsia|patients with albuminuria +1 and blood pressure >140/90 and <160/110
2978859|NCT02704676||sever pre-eclampsia|patients diagnosed as sever pre-eclampsia according to criteria done by ACOG
2978860|NCT02704663|Experimental|Transumbilical route|Transumbilical removal of benign adnexal masses via laparoscopy.
2978861|NCT02704663|Active Comparator|Lateral abdominal route|Lateral transabdominal removal of benign adnexal masses via laparoscopy.
2978862|NCT02704650|Experimental|Vaginal fluid of healthy patient|vaginal fluid sample from healthy patients
2978863|NCT02704650|Experimental|Vaginal fluid of ovary cancer patients|vaginal fluid sample from patients with ovary cancer
2978864|NCT02704637|Experimental|HS-1000 recording|Each non-invasive recording session with the HS-1000 device will be done for 10 consecutive uninterrupted minutes. Patients will be recorded once daily for the duration of their time in ICU or for up to 14 days total. In the case the PI or a member of the study team positively confirms vasospasm based on clinical assessment or follow-up care during the monitoring period, the patient will be recorded twice daily for up to 14 consecutive days or for their duration in the ICU.
2978865|NCT02704624|Active Comparator|Vitamin D|Tablets with 50000UI cholecalciferol (vitamin D3) will be administered, weekly, for six months.
2978866|NCT02704624|Placebo Comparator|Placebo|The patients selected to the placebo group will receive inert content tablets without therapeutic effect, weekly, for six months.
2978867|NCT02704611|Active Comparator|Group I|Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week).
2978868|NCT02704611|Sham Comparator|Group II|Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec.
2978869|NCT02704598|Active Comparator|Rivaroxaban|Patients with deep venous thrombosis using Rivaroxaban for 6 months, and then will be evaluated with DUPLEX SCAN to assess the recanalization rate, and also the clinical signs and symptoms.
2978870|NCT02704598|Active Comparator|Warfarin|Patients with deep venous thrombosis using Warfarin for 6 months, and then will be evaluated wiht DUPLEX SCAN to assess the recanalization rate, and also the clinical signs and symptoms.
2978871|NCT02704585|Other|Nellcor|Connection to Nellcor pulse oximeter for measuring oxygen saturation after birth
2978872|NCT02704585|Other|Masimo|Connection to Masimo pulse oximeter for measuring oxygen saturation after birth
2978873|NCT02704572|Experimental|6months to 2years after shingles|Patients will be vaccinated with Zostavax from 6 months to 2 years after zoster illness.
2978874|NCT02704572|Active Comparator|2years to 5years after shingles|Patients will be vaccinated with Zostavax from 2 years to 5 years after zoster illness.
2978875|NCT02704559|Experimental|Study effect of DWC20156 on DWC20155 PK|To study effect of DWC20156 on DWC20155 PK
2978876|NCT02704559|Experimental|Study effect of DWC20155 on DWC20156 PK|To study effect of DWC20155 on DWC20156 PK
2978877|NCT02704546|Experimental|Methylphenidate|In experimental days taking MPH, subjects will take 20mg Ritalin® (Novartis AG) in two tablets of 10mg, by swallow 1 hour prior to performing the physical test.
3051738|NCT02215798||Cymbalta|
2978878|NCT02704546|Placebo Comparator|Placebo|In experimental days with placebo subjects will be asked to ingest 2 capsules identical to Ritalin® capsules, by swallow 1 hour prior to performing the physical test.
2978879|NCT02704533|Experimental|Optimization Phase - Group A|"n=6; three times 9x10^5 PfSPZ Vaccine on Days 0, 7 and 28 by DVI. Group A will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.~If >75% efficacious, the treatment will be simplified to two times 1.35x10^6 PfSPZ Vaccine on Days 0 and 7 (Group B1).~If <75% efficacious, the treatment will be increased to three times 1.35x10^6 PfSPZ Vaccine on Days 0, 7 and 28 (Group B2)"
2978880|NCT02704533|Experimental|Optimization Phase - Group B1|"n=6; two times 1.35x10^6 PfSPZ Vaccine on Days 0 and 7 by DVI. Group B1 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.~If >75% efficacious, the treatment will be simplified to one injection 2.7x10^6 PfSPZ Vaccine (Group C1).~If <75% efficacious, the treatment will be increased to two times 2.7x10^6 PfSPZ Vaccine on Days 0 and 7 (Group C2)."
2978881|NCT02704533|Experimental|Optimization Phase - Group B2|"n=6; three times 1.35x10^6 PfSPZ Vaccine on Days 0, 7 and 28 by DVI. Group B2 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.~If >75% efficacious, the treatment will be simplified to two times 2.7x10^6 PfSPZ Vaccine on Days 0 and 7 (Group C2).~If <75% efficacious, the treatment will be increased to three times 2.7x10^6 PfSPZ Vaccine on Days 0, 7 and 28 (Group C3)."
2978882|NCT02704533|Experimental|Optimization Phase - Group C1|"n=6; one time 2.7x10^6 PfSPZ Vaccine by DVI. Group C1 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.~If Group C1 gets vaccinated, study will proceed to verification phase after completion."
2978883|NCT02704533|Experimental|Optimization Phase - Group C2|"n=6; two times 2.7x10^6 PfSPZ Vaccine by DVI. Group C2 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.~If Group C2 gets vaccinated, study will proceed to verification phase after completion."
2978884|NCT02704533|Experimental|Optimization Phase - Group C3|"n=6; three times 2.7x10^6 PfSPZ Vaccine by DVI. Group C3 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.~In case C3 shows <75% efficacy, verification phase will not be done."
2978885|NCT02704533|Experimental|PfSPZ Challenge (7G8) dose finding - Group D1|"n=3, one dose of 800 PfSPZ Challenge (7G8) by DVI.~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
2978886|NCT02704533|Experimental|PfSPZ Challenge (7G8) dose finding - Group D2|"n=3, one dose of 1,600 PfSPZ Challenge (7G8) by DVI.~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
2978887|NCT02704533|Experimental|PfSPZ Challenge (7G8) dose finding - Group D3|"n=3, one dose of 3,200 PfSPZ Challenge (7G8) by DVI.~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
2978888|NCT02704533|Experimental|Verification Phase - Group V1|"n=12; optimal regimen from phase 1 - shortest, well tolerated safe schedule that provides >75% protection (5/6) against homologous CHMI (V1).~Optimal & maximum regimens will be compared in this phase. The maximum regimen is a 3-dose regimen (Day 0, 7, 28) with highest well-tolerated PfSPZ Vaccine dose/injection (V2).~Efficacy will be determined by repeat CHMI 3 and 8 weeks after last immunization. Inoculation of 2 CHMIs will be done about 35 days (5 weeks) apart.~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered in one of 2 sequences (NF54-7G8 or 7G8-NF54). Allocation to the 2 sequences will be double blind, random, at a 1:1 ratio and nested within the intervention groups (V1 and V2 PfSPZ Vaccine and placebo (P1 and P2)). CHMI will be done at a dose of 3,200 PfSPZ unless the dose escalation study of PfSPZ Challenge (7G8) indicates that a different dose would be preferable for 7G8."
2978889|NCT02704533|Experimental|Verification Phase - Group V2|"n=12; maximum regimen from the phase 1 - 3-dose regimen (Day 0, 7 and 28) with highest well-tolerated PfSPZ Vaccine dose per injection (V2).~Optimal & maximum regimens will be compared in this phase. The optimal regimen (shortest, well tolerated and safe schedule) that provides >75% protection (5/6) against homologous CHMI (V1).~In case that shortest efficacious regimen during phase 1 is C3, 12 volunteers will be vaccinated and 6 volunteers will receive NS during this phase. In this case optimal regimen equals maximum regimen (3 x 2.7x10^6 PfSPZ). Group V2/P2 will not be immunized.~Efficacy will be determined by repeat CHMI 3 and 8 weeks after last immunization. Inoculation of 2 CHMIs will be done about 35 days (5 weeks) apart.~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
2978890|NCT02704533|Placebo Comparator|Verification Phase - Group P1|"n=6; normal saline as placebo. This group will follow the regimen selected for Group V1.~Efficacy of the vaccination regimen will be determined by CHMI which will be done by repeat CHMI three and eight weeks after the last immunization. Inoculation of the two CHMIs will be done approximately 35 days (5 weeks) apart.~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
2978891|NCT02704533|Placebo Comparator|Verification Phase - Group P2|"n=6; NS as placebo. This group will follow the regimen selected for Group V2.~In case that shortest efficacious regimen during phase 1 is C3, 12 volunteers will be vaccinated and 6 volunteers will receive NS during this phase. In this case optimal regimen equals maximum regimen (3 x 2.7x10^6 PfSPZ). Group V2/P2 will not be immunized.~Efficacy will be determined by repeat CHMI 3 and 8 weeks after the last immunization. Inoculation of the 2 CHMIs will be done about 35 days (5 weeks) apart.~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
2978892|NCT02704520|Other|Control arm|Patients in the control arm will undergo surgery and then receive a course of chemotherapy (CAPOX [capecitabine and oxaliplatin] or FOLFOX [5-fluorouracil, oxaliplatin, folinic acid], or single agent capecitabine or 5-fluorouracil) and follow-up assessments as standard i.e. standard clinical practice
2978893|NCT02704520|Experimental|Intervention arm|Patients in the intervention arm will be split into one of two groups according to their response to chemoradiotherapy. Patients who show a good response (mrTRG I&II) will be offered deferral of surgery and receive the standard course of chemotherapy. Patients who show a poor response (mrTRG III-V) will receive 12 weeks of chemotherapy (CAPOX [capecitabine and oxaliplatin] or FOLFOX [5-fluorouracil, oxaliplatin, folinic acid], or single agent capecitabine or 5-fluorouracil), undergo repeat restaging, and then continue to surgery or defer surgery. Depending on chemotherapy regimen received patients may then receive a further 12 weeks of chemotherapy.
2978894|NCT02704507|Experimental|Topical steroid|Topical retinoid plus topical steroid applied daily to half of the face for 4 weeks, followed by 4 weeks of topical tretinoin. Patients will be randomized to which side receives the topical steroid.
2978895|NCT02704507|Placebo Comparator|Topical emollient|Topical retinoid plus topical emollient applied daily to the opposite half of the face for 4 weeks, followed by 4 weeks of topical tretinoin.
2978896|NCT02704494|Experimental|Resveratrol|Resveratrol + Losartan
2978897|NCT02704494|Placebo Comparator|Placebo|Placebo + Losartan
2978898|NCT02704481|Experimental|Mifepristone-misoprostol|Women randomized to receive 200 mg mifepristone to take on Day 1, 800 mcg buccal misoprostol to take 24-48 hours after later, and four placebo misoprostol pills to take a further 3-12 hours later.
2978899|NCT02704481|Experimental|Misoprostol-misoprostol|Women randomized to receive a placebo mifepristone pill to take on Day 1 and two doses of 800 mcg buccal misoprostol, the first of which should be taken 24-48 hours after the placebo and the second of which should be taken 3-12 hours after the first misoprostol dose.
2978900|NCT02704468||CAVI and FGF-21|renal transplant patients for more than 1 month measured FGF-21 and CAVI
2978901|NCT02704429|Experimental|PRN1008|Part A: Open-label PRN1008, 12 weeks; 12 week follow up; Part B: Open-label PRN1008, 24 weeks;4 weeks follow up
2978902|NCT02704416|No Intervention|Control arm|Control arm - continued implanted cardioverter defibrillator therapy
2978903|NCT02704416|Active Comparator|Intervention Arm|ablation of areas of fragmented signal in the right ventricular outflow tract plus continued implanted cardioverter defibrillator therapy
2978904|NCT02704416|Other|Single Cross Over Arm|these patients were initially assigned to the control arm of the study. When these patients met the primary outcome of the study it is allowed for these patients to be included in the intervention arm and/or to start quinidine
2978905|NCT02704403|Experimental|120 mg Elafibranor|Coated tablets dosed at 120mg Elafibranor; oral administration; one tablet per day before breakfast with a glass of water
2978906|NCT02704403|Placebo Comparator|Placebo|Coated placebo tablets; oral administration; one tablet per day before breakfast with a glass of water
2978907|NCT02704390|Experimental|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate oral capsule will be administered once daily in the morning for 24 months.
2978908|NCT02704377|Experimental|Supportive care (quality of life, supportive care preferences)|Participants complete questionnaires about quality of life and preferences for supportive care treatment, wear accelerometerundergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week, and undergo a single Dual X-ray Absorptiometry (iDXA) scan over 10 minutes. Other interventions include: Laboratory Biomarker Analysis, Quality-of-Life Assessments, and othe Questionnaire Administration.
2978909|NCT02704364|Experimental|NGM282 Dose 1|NGM282 Dose 1
2978910|NCT02704364|Experimental|NGM282 Dose 2|NGM282 Dose 2
2978911|NCT02704364|Active Comparator|Placebo|Placebo
2978912|NCT02704351||Sugammadex group|sugammadex to reverse neuromuscular blockade following cardiac surgery
2978913|NCT02704338|Experimental|Regulatory T cells|CD4(cluster of differentiation)+CD25+CD127- T cells isolated from peripheral blood mononuclear cells were be expanded with GMP(Good Manufacturing Practice) anti-CD3/CD28 coated beads in the presence of IL-2 and all-trans retinoid acid.
2978914|NCT02704325|Experimental|GALGT2 Viral Vector|Dose: 1E12 vg (total dose) (n=3) of rAAVrh74.MCK.GALGT2 vs Placebo (Saline). All participants will receive rAAVrh74.MCK.GALGT2 in the right or the left EDB muscle and receive Saline in the opposite EDB muscles. The investigator will not know which side will receive rAAVrh74.MCK.GALGT2 vs Saline until after the trial is over. At the end of the trial the investigator will be unblinded.
2978915|NCT02704325|Experimental|Saline|Dose: 1E12 vg (total dose) (n=3) of rAAVrh74.MCK.GALGT2 vs Placebo (Saline). All participants will receive rAAVrh74.MCK.GALGT2 in the right or the left EDB muscle and receive Saline in the opposite EDB muscles. The investigator will not know which side will receive rAAVrh74.MCK.GALGT2 vs Saline until after the trial is over. At the end of the trial the investigator will be unblinded.
2978916|NCT02704312|Experimental|Radiotherapy techniques|Quantitative Physics: dosimetric comparison of doses in target volumes and organs at risk. The technique used is that of which the dose on the organs at risk is as low as possible, and whose dose to the target volume is the closest possible to the prescribed dose (100% of the prescribed dose)
2978917|NCT02704299|Experimental|Autologous T cells-Based Immunotherapy|Surgery Chemotherapy Autologous T cells-Based Immunotherapy
2978918|NCT02704286|Sham Comparator|Generic Osteoarthritis Risk Information|Participants in this arm received generic osteoarthritis information that was not personalized.
2978919|NCT02704286|Experimental|Personalized Osteoarthritis Risk|Participants in this arm obtained their personalized osteoarthritis risk from the internet-based Osteoarthritis Risk Calculator.
2978920|NCT02704260|Experimental|GENETIC ANALISYS|GENETIC ANALYSIS AND RESEARCH OF GENETIC BLOOD SAMPLE
2978921|NCT02704247|Experimental|Testing CARDIOSPACE System|Healthy volunteers have to test CARDIOSPACE System
2978922|NCT02704234|Experimental|Active Acupuncture|Active Acupuncture 2 times per week for 5 weeks
2978923|NCT02704234|Placebo Comparator|Placebo|Placebo Acupuncture 2 times per week for 5 weeks
2978924|NCT02704221|Active Comparator|Behavioral Parent Training (BPT)|The control group will include 10 participants who will 1) wear Fitbit activity trackers daily for 12 weeks and 2) attend 12 weekly BPT training sessions.
2978925|NCT02704221|Experimental|BPT + Contingency Management (BPT+CM)|The experimental group will include 10 participants who will 1) wear Fitbit activity trackers daily for 12 weeks, 2) attend 12 weekly BPT training sessions, and 3) receive monetary rewards for achieving weekly step-count goals.
2978956|NCT02703987|Active Comparator|Group II|Non-fermented infant milk formula
2978926|NCT02704208|Experimental|Behavioral: Thrive With Me Intervention|Participants randomized to the TWM Intervention will gain access to a website for 150 days. The TWM website includes: peer-to-peer support through a private social network and optimized gaming features; daily SMS communication for medication reminders and mood tracking; medication adherence monitoring; and tailored HIV informational content.
2978927|NCT02704208|Placebo Comparator|Behavioral: Thrive With Me Control|Participants randomized to the TWM Control group will receive HIV related content through a weekly web link. The web links will be static pages (not interactive) with information aimed at improving overall wellbeing while living with HIV, but not focused on improving ART medication adherence.
2978928|NCT02704195|Active Comparator|Chronic Subthalamic nucleus stimulation|This arm is the reference, with the best stimulation parameters
2978929|NCT02704195|Experimental|Unilateral reduction of stimulation|30% unilateral reduction of Subthalamic nucleus stimulation
2978930|NCT02704182|Active Comparator|Real tDCS|Direct current stimulation using anodal electrode, 25 patients received real anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
2978931|NCT02704182|Sham Comparator|Sham tDCS|Sham direct current stimulation, 25 patients received sham anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
2978932|NCT02704169|Experimental|Spatially registered endoscopy for H&N cancer|
2978933|NCT02704156|Experimental|Five-fraction SBRT|Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive five-fraction SBRT/cyberknife as the initial treatment
2978934|NCT02704143|Experimental|Combination of Cyberknife with S-1|Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.
2978935|NCT02704130|Experimental|TAE + MWA combination therapy|In patients randomized to receive the experimental therapy, transarterial embolization (TAE) treatments will be initiated within one week of randomization. Blunt embolization will be performed with LC beads with a maximum size of 700 µm. Microwave ablation (MWA) will be performed up to one month following randomization. The LC beads will be admixed with 8-15 mL of contrast and injected into the arterial branch at a rate of 1-2 mL/min. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request.
2978936|NCT02704130|Active Comparator|MWA monotherapy|Microwave ablation (MWA) will be performed up to one month following randomization. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request. All operative MWAs will be performed in a laparoscopic or robot-assisted laparoscopic setting. All ablations will be guided by intraoperative ultrasound. Ablations will be performed with a 2.45-GHz generator with a 1.8-mm-diameter transcutaneous antenna.
2978937|NCT02704117|Experimental|Active tDCS|Cathodal transcranial direct current stimulation (tDCS) applied over the pre-supplementary motor area (pSMA), weekdays for approximately six weeks
2978938|NCT02704104|Experimental|AC5 Topical Hemostatic Device|The intervention in this arm is the application of a topical hemostatic agent (AC5) to a freshly excised skin lesion
2978939|NCT02704104|Placebo Comparator|Control|The intervention in this arm is the application of saline (Control) to a freshly excised skin lesion
2978940|NCT02704091|Active Comparator|Smecta|2 sachets, three times a day (TID), during 5 to 9 days
2978941|NCT02704091|Placebo Comparator|Smecta placebo|2 sachets of placebo, TID, during 5 to 9 days
2978942|NCT02704078|Active Comparator|EBUS-TBNA|Mediastinal lymph node aspiration shall be performed transtracheally.
2978943|NCT02704078|Experimental|EUS-B-FNA|Mediastinal lymph node aspiration shall be performed transesophageally
2978944|NCT02704065||Recurrent AA amyloidosis|Renal transplant recipients with biopsy-confirmed AA amyloidosis in the renal allograft
2978945|NCT02704065||Control group 1|Renal transplant recipients whose primary diseases are amyloidosis with no clinical or laboratory signs of recurrence in the renal allograft
2978946|NCT02704065||Control group 2|Renal transplant recipients whose primary diseases are other than amyloidosis
2978947|NCT02704052|Active Comparator|Standard enoxaparin dose|We will identify a convenience sample of surgical patients placed on enoxaparin prophylaxis at their attending surgeon's discretion—the proposed research will not dictate the initial enoxaparin dose magnitude or frequency. However, we will identify patients already on enoxaparin, evaluate peak and trough steady state aFXa levels, and adjust patient's dose if necessary based on steady state aFXa levels. Eligible patients will have enoxaparin prophylaxis started within 36 after surgery at their surgeon's discretion. Steady state peak and trough aFXa levels will be drawn at 4 and 12 hours, respectively, after the third enoxaparin dose. Goal peak aFXa levels will be 0.2-0.4 IU/mL for twice daily dosing and 0.3-0.5 IU/mL for once daily dosing.
2978948|NCT02704052|Experimental|Real time enoxaparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time enoxaparin dose adjustment and will receive followup steady state peak and trough aFXa levels. aFXa monitoring will be discontinued when in range peak levels are obtained, when enoxaparin prophylaxis is discontinued at surgeon discretion, or when the patient is discharged. Patients may be continued on enoxaparin prophylaxis after discharge per attending surgeon discretion but aFXa levels will not be followed in the outpatient environment.
2978949|NCT02704026||Inflammatory Bowel Disease|Patients 6-18 of age at the time of enrolment who have IBD at any stage of disease activity, on any or no treatment
2978950|NCT02704026||Control|Age- and sex-matched healthy controls
2978951|NCT02704013|Other|Intervention|Patients with overactive bladder will receive anticholinergic therapy: oral oxybutynin in daily dose 0.2-0.5 mg/kg divided in two daily doses for 3 to 6 months depending on treatment outcome assessed 3 months after start of intervention.
2978952|NCT02704000|No Intervention|Control|No interventions - only baseline and endline assessments to be conducted at children's home.
2978953|NCT02704000|Experimental|Home visits by CDAs|Intervention: Behavioral: Home visiting program (Jamaica curriculum) Children in this intervention arm will be visited twice a months by trained child development agents (CDAs). CDAs will implement the Jamaica curriculum intervention during the home visits..
2978954|NCT02704000|Experimental|Home visits by CHWs|Intervention: Behavioral: Home visiting program (Jamaica curriculum) Children in this intervention arm will be visited twice a months by trained community health workers (CHWs) trained on delivering the intervention. CHWs will implement the Jamaica curriculum intervention during the home visits..
2978955|NCT02703987|Experimental|Group I|Fermented infant milk formula
3074550|NCT02063893||giving high vaccine|
2978957|NCT02703974|Experimental|Early handwashing station + nudge|This arm will include 5 randomly selected schools that will have had handwashing stations built after the baseline observation (Phase I), and nudges built after Phase II data collection.
2978958|NCT02703974|Experimental|Late handwashing station + nudge|This arm will include 5 randomly selected schools that will have had handwashing stations and nudges built at the same time, after Phase II data collection.
2978959|NCT02703974|Active Comparator|Early handwashing station + education|This arm will include 5 randomly selected schools that will have had handwashing stations built after the baseline observation (Phase I), and will receive a Hand hygiene education-based program, after Phase II data collection is complete.
2978960|NCT02703974|Active Comparator|Late handwashing station + education|This arm will include 5 randomly selected schools that will have had handwashing stations built after Phase II data collection is complete, when the Hand hygiene education-based program will commence.
2978961|NCT02703961|Experimental|experimental|"concurrent and adjuvant chemotherapy with cisplatin and docetaxel combined radical radiotherapy.~During external beam radiotherapy: cisplatin 60mg/m2, d1,d22; docetaxel 60mg/m2, d1,d22.~After external beam radiotherapy: cisplatin 75mg/m2, d43,d64;~The patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy.~docetaxel 75mg/m2, d43,d64."
2978962|NCT02703961|Other|control|"standard chemoradiotherapy with weekly cisplatin.~Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29.~Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy."
2978963|NCT02703948|Other|Restylane Silk with Lidocaine|
2978964|NCT02703935|Experimental|health talk and adventure-based training|Participate will join a four-day adventure-based training programme, which contains education talks, workshop and adventure-based training activities. The programme will be implemented on four different days within six months in a day camp training centre. The integrated programme will be implemented in small group with maximum 12 participants in one group. Health education talks and workshop will be implemented in between adventure-based training activities in day camp centre, which will be conducted by healthcare professionals working in a local university.
2978965|NCT02703935|Placebo Comparator|Placebo Control|Participants will receive an amount of time and attention that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
2978966|NCT02703922|Other|GCA suspicion|A first screening is performed using color Doppler ultrasound. In case of negative results, patients undergo TAB.
2978967|NCT02703909|Experimental|moderate NMB + 10 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate neuromuscular block (NMB) which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
2978968|NCT02703909|Active Comparator|moderate NMB + 15 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate NMB which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 15 mm Hg pressure. This arm represents the usual operating conditions for this type of surgery at the University hospital.
2978969|NCT02703909|Experimental|deep NMB + 10 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 10 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
2978970|NCT02703909|Experimental|deep NMB + 15 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 15 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
2978971|NCT02703896|Placebo Comparator|Group C (placebo)|"Drug intervention Two doses of Placebo at 8.00 pm and then at 6.00 am~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)"
2978972|NCT02703896|Active Comparator|Either PPIs or H2RAs|"Drug Intervention Two doses at 8.00 pm and then at 6.00 am~Group L (lansoprazole 15 mg)~Group E(esomeprazole 20 mg)~Group P (pantoprazole 20 mg)~Group R (rabeprazole 10 mg)~Group O (omeprazole 20 mg)~Group T (cimetidine 200 mg)~Group F (famotidine 20 mg)~Group N (nizatidine 150 mg)~Group Z (ranitidine 150 mg)~Group S (lafutidine 10 mg)"
2978973|NCT02703896|Active Comparator|Either PPIs or H2RAs+prokinetics|"Drug intervention Two doses at 8.00 pm and then at 6.00 am~Group L D (lansoprazole 15 mg+ domperidone 10 mg)~Group EM (esomeprazole 20 mg+metoclopramide 10 mg)~Group PD (pantoprazole 20 mg+domperidone 10)~Group RM (rabeprazole 10 mg+metoclopramide 10 mg)~Group OD (omeprazole 20 mg+domperidone 10)~Group TD (cimetidine 200 mg+domperidone 10)~Group FM (famotidine 20 mg+metoclopramide 10 mg)~Group NM (nizatidine 150 mg+metoclopramide 10 mg)~Group ZD (ranitidine 150 mg+ domperidone 10 mg)~Group SD (lafutidine 10 mg+domperidone 10 mg)"
2978974|NCT02703896|Active Comparator|Either PPIs or H2RAs+Prokinetic|Drug intervention Two doses at 8.00 pm and then at 6.00 am Group OM (omeprazole 20 mg +metoclopramide 10 mg) Group SM (lafutidine 10 mg + metoclopramide 10 mg )
2978975|NCT02703896|Other|Intervention Orogastric intubation|After general anesthesia, an oro-gastric tube was inserted through another endotracheal tube placed in upper esophagus into the stomach for aspiration of gastric contents.
2978976|NCT02703883|Experimental|Body Weight Support|Treatment protocol consisted of 18 training sessions on the BWST, three times a week, every session included three sets of six minutes of locomotion with rest intervals of 2 min of rest.
2978977|NCT02703870|Active Comparator|Verum tDCS|Verum group receiving complete treatment of tDCS
2978978|NCT02703870|Sham Comparator|sham tDCS|Sham group receiving sham tDCS
2978979|NCT02703870|Active Comparator|real VRT|Real Vision Restoration Training
2978980|NCT02703844|Active Comparator|Active|Participants will be receiving an active Caloric Vestibular Stimulation treatment for a duration of 12 weeks, 7 days a week, twice daily for 20 minutes.
2979760|NCT02698514|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
2978981|NCT02703844|Sham Comparator|Placebo|"Participants will be receiving a Sham Caloric Vestibular Stimulation treatment for a duration of 12 weeks in the same manner as the active arm: 7 days a week, twice daily for 20 minutes.~Individuals allocated to this arm will be later crossed over, in unblinded fashion. to the active arm if the treatment shows evidence of efficacy and safety."
2978982|NCT02703831|Active Comparator|Dual attending|Two attending spine surgeons during the critical portions of the surgery
2978983|NCT02703831|Placebo Comparator|Single attending|One spine attending and an assistant during the critical portions of the surgery, The assistant can be a spine fellow, a resident or a physician's assistant.
2978984|NCT02703818|Experimental|Senza|Spinal Cord Stimulation for UEP
2978985|NCT02703805|Experimental|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors.
2978986|NCT02703805|Active Comparator|Standard YMCA membership|A 12 week standard YMCA membership.
2978987|NCT02703792||Care home staff|Care home staff working in the homes in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
2978988|NCT02703792||NHS staff|GPs supporting residents living in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
2978989|NCT02703792||Service user representatives|Service or carers of an older person with dementia attending and Age UK carers group
2978990|NCT02703792||Relatives of residents|Relatives of residents living in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
2978991|NCT02703779|Active Comparator|Stem cell collection without in-vivo purging with Bortezomib|"Standard of Care Stem cell collection without in-vivo purging with Bortezomib. Standard of Care drugs Granulocyte colony-stimulating factor (G-CSF) +/- Mozobil (the latter if needed).~NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B"
2978992|NCT02703779|Experimental|Stem cell collection with in-vivo purging with Bortezomib|"Bortezomib will be given subcutaneously (SQ) at 1.3 mg/m2 on day -11 and day -8 followed by Granulocyte colony-stimulating factor (G-CSF) given SQ on day -4 thru day -1 and continued until the collection is completed. Mozobil will be given if needed.~There must be at least 72 hours between each dose of bortezomib. NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B"
2978993|NCT02703766|Active Comparator|Lean|"Lean individuals are defined as having body fat content less or equal to 25% in men and less than 35% for women.~Overfeeding induced weight gain and subsequent weight loss"
2978994|NCT02703766|Experimental|Obese|"obese individuals are defined as having body fat content more than 25% in men and more than 35% for women.~Overfeeding induced weight gain and subsequent weight loss"
2978995|NCT02703753|Experimental|Intervention group|The intervention is an integral and multidisciplinary lifestyle intervention consisting of a healthy diet, appropriate physical activity and, if applicable, smoking cessation, customised to the needs of the women.
2978996|NCT02703753|No Intervention|Control group|The control group will receive usual care, including standard lifestyle advices during consultation with the GP, midwife, obstetrician or at the child well being centre. Furthermore, the control group will receive 1 recipe for a healthy meal per week.
2978997|NCT02703740|Experimental|HA 20 mg/mL|
2978998|NCT02703740|Experimental|HA 24 mg/mL|
2978999|NCT02703727||OAC|Patients on oral anticoagulation therapy (OAC) will receive a pharmacists led medication review with a focus on anticoagulation therapy (extended polymedication check)
2979000|NCT02703714|Experimental|Treatment|Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive sargramostim SC on days 1-14 of courses 1-2 or 2-3. Treatment repeats every 21 days for up to 2 courses for sargramostim and for up to 35 courses (24 months) for pembrolizumab in the absence of disease or unaccepted toxicity.
2979001|NCT02703701||Usual Care|Group enrolled during normal emergency department operating procedures (without a physician present at triage).
2979002|NCT02703701||Physician at Triage|Group enrolled while a physician is present at triage.
2979003|NCT02703688|Experimental|Healthy Homes|Behavioral Intervention
2979004|NCT02703688|Active Comparator|Usual Care|Counseling session delivered by pediatrician
2979005|NCT02703675|Experimental|adult healthy volunteer|Adult healthy volunteers will be recruited from staff in Dept. Neurology, medical students. They will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours.
2979006|NCT02703675|Experimental|adult normothermic patient|"Adult normothermic patients will be recruited from Neurocritical Care ICU in The Ohio State University Wexner Medical Center.~They will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours."
2979007|NCT02703675|Experimental|adult sick febrile patient|"Adult sick febrile patients will be enrolled from Neurocritical Care ICU in The Ohio State University Wexner Medical Center.~Five of the patients will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours.~Other five patients will received 2 rounds of cooling process each 2 hours long"
2979008|NCT02703662|Active Comparator|Strattice biologic mesh|Strattice mesh is made of noncross-linked porcine dermis, which is used to support abdominal wall reconstruction.
2979009|NCT02703662|Experimental|Permacol biologic mesh|Permacol mesh is made of cross-linked porcine dermis, which is used to support abdominal wall reconstruction.
2979010|NCT02703649|Experimental|Single dose|Single 20 mg dose of Letrozole on day 3 of the menstrual cycle.
2979011|NCT02703649|Active Comparator|Daily dose|Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
2979012|NCT02703636|Other|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
2979041|NCT02703506|Active Comparator|Control|"The control group: individualized session of physical therapy (TENS and exercise).~Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises ."
2979272|NCT02701920||Newborns and surgical delivery|Well term newborn infants following birth by cesarean section.
2979013|NCT02703623|Experimental|Grp1 and 2A: ARN-509 + Abiraterone + Prednisone|"Group 1: All participants receive ARN-509, Abiraterone, and Prednisone. Participants take 4 tablets of abiraterone acetate and 4 capsules of ARN-509 by mouth every day while on study. Participants also take 1 tablet of prednisone by mouth 2 times every day while on study. Each study cycle is 21 days.~After 8 weeks of receiving treatment, blood drawn for biomarker testing. Result of this biomarker test determines whether participant continues the study in next two groups.~Group 2A: Participants continue taking ARN-509, Abiraterone, and Prednisone as they did while in Group 1."
2979014|NCT02703623|Experimental|Grp 2B: ARN-509 + Abiraterone + Prednisone + Ipilimumab|"Group 2B: Participants take 4 tablets of Abiraterone Acetate and 4 capsules of ARN-509 by mouth every day while on study. Participants also take 1 tablet of Prednisone by mouth 2 times every day while on study. Ipilimumab given by vein Day 1 of Cycles 4, 5, 6, and 7.~Each study cycle is 21 days."
2979015|NCT02703623|Experimental|Grp 3: ARN-509+Abiraterone+Pred+Cabazitaxel+Carbo|"Group 3: Participants take 4 tablets of Abiraterone Acetate and 4 capsules of ARN-509 by mouth every day while on study. Participants also take 1 tablet of Prednisone by mouth 2 times every day while on study. Participants also receive Cabazitaxel and Carboplatin by vein on Day 1 of Cycles 4, 5, 6, and 7.~Each study cycle is 21 days."
2979016|NCT02703623|Experimental|Grp 4: ARN-509 + Abiraterone + Prednisone|After treatment in Groups 2 and 3 is complete, participants assigned to Group 4 and go back to only taking ARN-509, Abiraterone, and Prednisone.
2979017|NCT02703610|Active Comparator|Oxycodone/acetaminophen|Oxycodone/acetaminophen (5 mg/325 mg)
2979018|NCT02703610|Active Comparator|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen (400 mg/500 mg)
2979019|NCT02703597|Experimental|Focus Group|"Participants complete baseline survey. Baseline survey includes questions related to smoking behavior and attitude toward smoking, as well as demographic questions.~If eligible, participants take part in audio recorded focus group. Participants engage in group discussions that work to improve upon the online health programs."
2979020|NCT02703597|Experimental|ASPIRE Group|"A Smoking Prevention Interactive Experience (ASPIRE) Group contains participants with and without intent to smoke. Participants engage in four 40-minute sessions of ASPIRE spread over a period of 4 weeks. During ASPIRE use, participants face a laptop computer and individually watch videos and engage in computer-based activities related to the negative effects of smoking.~After 2 sessions and following the last session of the intervention, participants complete psychosocial surveys and social network surveys. Also, baseline survey again completed."
2979021|NCT02703597|Experimental|GSA-ASPIRE Group|"GSA-ASPIRE Group contains participants with and without intent to smoke. Participants engage in four 45-minute sessions of ASPIRE conducted over a period of four weeks. However, during each session, after every 9 minutes of ASPIRE use, participants engage in a 3-minute game-based social activities (GSA), for a total of 5 GSAs. During ASPIRE use, participants watch videos and engage in computer-based activities on the same computer screen. Also, participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSA activities contain games about the effects of smoking.~After 2 sessions and following the last session of the intervention, participants complete psychosocial surveys and social network surveys. Also, baseline survey again completed."
2979022|NCT02703584|Experimental|Double trigger|Triggering of ovulation with GnRH agonist ( Suprefact 0.5mg) + hCG ( Pregnyl 10,000IU)
2979023|NCT02703584|Placebo Comparator|control|Triggering of ovulation with hCH ( Pregnyl 10,000IU) + Placebo
2979024|NCT02703571|Experimental|Advanced or metastatic pancreatic cancer|Patients in the Phase II portion of the study who have advanced or metastatic pancreatic cancer
2979025|NCT02703571|Experimental|KRAS-mutant colorectal cancer|Patients in the Phase II portion of the study who have KRAS-mutant colorectal cancer
2979026|NCT02703558|No Intervention|No dye|Participants will not receive a preoperative or intraoperative dye prior to their intraoperative concomitant cystoscopy.
2979027|NCT02703558|Active Comparator|Phenazopyridine|Participants will receive a single 200mg oral dose of phenazopyridine with a sip of water 30 minutes prior to their surgery which involves an intraoperative concomitant cystoscopy.
2979028|NCT02703558|Active Comparator|Fluorescein|Participants will receive 0.25cc of 10% intravenous sodium fluorescein administered by anesthesia during their surgery, immediately prior to their intraoperative concomitant cystoscopy.
2979029|NCT02703545||Peutz-Jeghers syndrome|
2979030|NCT02703545||Familial pancreas cancer|"at least 2 close relatives affected with pancreas cancer on same side of family~first degree relative and 1 second degree relative(1st degree link) or~first degree relatives or~1 first degree relative and 2 or more second degree relatives"
2979031|NCT02703545||Germline mutation Carrier 10 % risk|BRCA2 mutation carrier with family history of pancreas cancer or, PALB2 mutation carrier or, FAMMM (p16/CDKN2A) mutation carrier
2979032|NCT02703545||Germline mutation carrier 5 % risk|BRCA1 mutation carrier with family history of pancreas cancer or, HNPCC (Lynch Syndrome) with family history of pancreas cancer or, ATM gene mutation
2979033|NCT02703545||Hereditary pancreatitis|PRSS1, PRSS2, CTRC gene mutations
2979034|NCT02703532|Experimental|Stroke Survivors|"Participants who have survived a stroke will receive constraint-induced movement therapy (CIMT) while their caregiver participates in an educational program.~The caregiver of the stroke survivor may be randomized to receive CARE-CITE education or traditional education."
2979035|NCT02703532|Experimental|CARE-CITE Education Program Carepartners|Caregivers (someone who assists in the care of stroke survivors) will participate in online CARE-CITE education while their partner (stroke survivor) receives therapy.
2979036|NCT02703532|Active Comparator|Traditional Education Carepartners|Caregivers (someone who assists in the care of stroke survivors) will participate in traditional education while their partner (stroke survivor) receives therapy.
2979037|NCT02703519|No Intervention|1 cesarean section|control group
2979038|NCT02703519|No Intervention|2 cesarean sections|control group
2979039|NCT02703519|Experimental|resection of uterine scar tissue|2 cesarean sections with resection of uterine scar tissue from first cesarean section
2979040|NCT02703506|Experimental|Experimental. Pain Education Program|Ten group sessions of treatment with a patient education pain for chronic neck pain (biopsychosocial approach). The group sessions of 60-120 minutes twice a week with a maximum of 10 participants.
2979106|NCT02703077|Active Comparator|2: ERCP + Balloon Dilation|This group after the diagnosis of difficult bile duct stones, will be submitted to Balloon dilation of the papilla
2979042|NCT02703493|Experimental|Cohort 1|Patients will receive 6 weeks of Intensity-Modulated Radiation Therapy (IMRT) (standard of care) followed by the dose escalated stereotactic radiosurgery (SRS Boost). Cohort 1 will receive 8 Gy in a single fraction, cohort 2 will receive 10 Gy in a single fraction and cohort 3 will receive 10 Gy split into two fractions.
2979043|NCT02703480|Experimental|All Study Participants - d-PTFE|The proposed study design is a randomized controlled trial, split mouth design, to compare the two different vertical augmentation procedures: Titanium mesh (Ti-mesh) technique and Guided Bone Regeneration (GBR) technique with a high-density polytetrafluoroethylene (d-PTFE) membrane.
2979044|NCT02703480|Experimental|All Study Participants - Ti-mesh|The proposed study design is a randomized controlled trial, split mouth design, to compare the two different vertical augmentation procedures: Titanium mesh (Ti-mesh) technique and Guided Bone Regeneration (GBR) technique with a high-density polytetrafluoroethylene (d-PTFE) membrane
2979045|NCT02703467||Healthy|Healthy subjects will have no significant medical history and no previous history of asthma or other serious illnesses. They should be non-smokers. The investigators willl measure spirometry and ensure that the values lie within the normal predicted range.
2979046|NCT02703467||Asthmatics|Patients diagnosed as having asthma will be recruited from Royal Brompton Hospital Asthma Clinics. These patients will have a range of severity of asthma ranging from mild-moderate to severe asthma patients. The diagnosis of asthma is ascertained as described in the inclusion criteria.
2979047|NCT02703454|Experimental|FIRM-only|Subjects in this arm will be treated with FIRM-guided conventional RF ablation without pulmonary vein isolation (PVI).
2979048|NCT02703454|Active Comparator|Conventional|Subjects in this arm will undergo conventional RF ablation with confirmation of PVI.
2979049|NCT02703441|Experimental|Intervention: Tablet computer|Patients from the local municipality, planned to be discharged to a rehabilitation stay at the municipality training centre receive a tablet computer. The patient will be introduced to the tablet and informed about the nutritional and mobilisation intervention based on his/her individual needs and preferences. The patient and the research assistant will jointly prepare an individual plan for nutrition and physical activity The patient uses the tablet for ordering meals, registering dietary intake, viewing his/her instruction videos for the activity programme and registering physical activity during hospital admission and at the training centre up to 6 weeks after discharge from hospital.
2979050|NCT02703441|No Intervention|Control group|Patients in the control group receive usual care during their hospital stay and after discharge at the municipality training centre. Data are recorded at baseline and 6 and 12 weeks after discharge.
2979051|NCT02703415|Active Comparator|Bupivacaine|caudal Bupivacaine
2979052|NCT02703415|Active Comparator|Tramadol|caudal Tramadol
2979053|NCT02703402|Experimental|Exercise protocol|Will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA
2979054|NCT02703402|Experimental|Manual of exercises|Treatment Group: will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises.
2979055|NCT02703389|Experimental|Video|An innovative video will be developed to explain the nature of non-severe acute otitis media and the rationale for watchful waiting and antimicrobial stewardship. This video will be viewed at recruitment and will be available online for further viewing later.
2979056|NCT02703389|Active Comparator|Pamphlet|Informative pamphlet containing the same information as the video.
2979057|NCT02703389|No Intervention|No intervention|This is the reference standard currently.
2979058|NCT02703376|Other|Patients after esophageal surgery|Oral Prednisone for 12 weeks
2979059|NCT02703363|Experimental|Minocycline with TAU|
2979060|NCT02703363|Experimental|Celecoxib with TAU|
2979061|NCT02703363|Experimental|Minocycline and celecoxib with TAU|
2979062|NCT02703363|Active Comparator|Placebo with TAU|
2979063|NCT02703350|Experimental|LY900014 (Part A)|Individualized doses of LY900014 administered by injection under the skin once in each of 3 periods
2979064|NCT02703350|Active Comparator|Insulin Lispro - Reference (Part A)|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
2979065|NCT02703350|Experimental|LY900014 (Part B)|Individualized doses of LY900014 administered by injection under the skin with each meal for 14 days
2979066|NCT02703350|Active Comparator|Insulin Lispro - Reference (Part B)|Individualized doses of insulin lispro reference formulation administered by injection under the skin with each meal for 14 days
2979067|NCT02703337|Experimental|LY900014 (Part A)|Individualized doses of LY900014 administered by injection under the skin once in each of 3 periods
2979068|NCT02703337|Active Comparator|Insulin Lispro - Reference (Part A)|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
2979069|NCT02703337|Experimental|LY900014 (Part B)|Individualized doses of LY900014 administered by injection under the skin with each meal for 14 days
2979070|NCT02703337|Active Comparator|Insulin Lispro - Reference (Part B)|Individualized doses of insulin lispro reference formulation administered by injection under the skin with each meal for 14 days
2979071|NCT02703324|Experimental|LY900014|LY900014 delivered via an insulin pump as a continuous infusion under the skin, with intermittent bolus doses during meals for two 3-day periods
2979072|NCT02703324|Active Comparator|Insulin Lispro - Reference|Insulin lispro reference formulation delivered via an insulin pump as a continuous infusion under the skin, with intermittent bolus doses during meals for two 3-day periods
2979073|NCT02703311|Other|Cardioband procedure|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
2979074|NCT02703298|Experimental|TRX-818|
2979075|NCT02703285|Experimental|questionnaire|task of the participants in the study to determine the chest sound based on specific sounds
2979107|NCT02703064|Experimental|Furocyst|Furocyst 500mg capsule, BD
2979108|NCT02703051|Experimental|GMI-1271|GMI-1271
2979109|NCT02703051|Active Comparator|Filgrastim|Filgrastim
2979076|NCT02703272|Experimental|Part 1: Ibrutinib|The first 2 participants enrolled in each age group (1-5 years, 6-11 years and 12-17 years) will receive starting dose of Ibrutinib 240 milligram per square meter (mg/m^2) for the first cycle, followed by dose escalation at the start of Cycle 2 as long as all pharmacokinetic assessments are within the expected range and there are no safety concerns. For participants being treated at 240 mg/m^2 dose level during the first cycle, the maximum dose should not exceed a total of 420 mg/day. All participants will receive rituximab, ifosfamide, carboplatin, etoposide and dexamethasone (RICE) or ituximab, vincristine, ifosfamide, carboplatin, idarubicin and dexamethasone (RVICI) background therapy (investigator's choice), during treatment phase. Participants with PR or better only will receive Ibrutinib for 3 cycles or until PD, unacceptable toxicity or until initiating antilymphoma therapy or a conditioning regimen for stem cell transplantation during post-treatment phase.
2979077|NCT02703272|Experimental|Part 2: Ibrutinib|Participants will either receive ibrutinib and RICE/RVICI background therapy or RICE/RVICI background therapy alone, until 3 cycles are completed or until PD or unacceptable toxicity during the treatment phase. Participants who received ibrutinib and RICE/RVICI background therapy and with PR or better only will receive ibrutinib alone for 3 cycles during post-treatment phase.
2979078|NCT02703259|Active Comparator|Gabapentin|"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen, celecoxib, and gabapentin x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:~Gabapentin 600 mg (two capsules of gabapetin 300 mg); Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (two capsules of celecoxib 200 mg) = Total 3 tablets, 4 capsules"
2979079|NCT02703259|Placebo Comparator|Control|"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen and celecoxib x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:~Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (four capsules of celecoxib 100 mg) = Total total 3 tablets, 4 capsules"
2979080|NCT02703246|Active Comparator|abdominal morcellation|Women randomized to this group will undergo abdominal morcellation.
2979081|NCT02703246|Active Comparator|vaginal morcellation|Women randomized to this group will undergo vaginal morcellation.
2979082|NCT02703233|Active Comparator|Nitrous Oxide|Patients receive nitrous oxide via mask.
2979083|NCT02703233|Placebo Comparator|Placebo (Oxygen)|Patients receive oxygen via mask.
2979084|NCT02703220|Experimental|Hyperoxia|Determine the effect of sustained hyperoxia overnight vs room air overnight on ventilatory control during sleep, including the apneic threshold, carbon-dioxide reserve and chemosensitivity measured via pressure support ventilation (PSV) during (non-rapid eye movement sleep) NREM sleep.
2979085|NCT02703220|Experimental|Acetazolamide (ACZ)|Determine the effect of acetazolamide on cerebrovascular responsiveness to CO2 during wake and sleep. Participants will receive oral ACZ therapy for 7 days prior to the experimental night, on the night of the study and the subsequent night when polysomnography (PSG) will be performed.
2979086|NCT02703220|Experimental|Finasteride|Determine the effect of oral finasteride therapy vs placebo for 1 month on SDB and the AT and chemosensitivity during NREM sleep.
2979087|NCT02703207|Active Comparator|Positive airway pressure therapy|Control group patients will receive standard care with PAP- positive airway pressure.
2979088|NCT02703207|No Intervention|COPD|The COPD control group will be patients with moderate-to-severe COPD alone per the GOLD criteria.
2979089|NCT02703207|No Intervention|OSA and comorbid COPD|Eligible elderly (age >/=60yrs) Veterans with moderate to severe Overlap Syndrome.
2979090|NCT02703194|Experimental|Prednisone|Prednisone mono-therapy
2979091|NCT02703194|Experimental|Prednisone and Leflunomide|Prednisone and Leflunomide combination therapy
2979092|NCT02703181|Experimental|Cohort 1(600 mg Epelsiban or placebo[every 8 hours])|Each subject will receive 200 mg of epelsiban administered TID (every 8 hours) (total daily dose of 600 mg) or a matching placebo administered every 8 hours.
2979093|NCT02703168||Immediate loading|Patients were allocated to treatment group in the core study. Immediate loading was defined as follows: Implant(s) will be restored with a temporary restoration on the day of surgery
2979094|NCT02703168||Early loading|Patients were allocated to treatment group in the core study. Early loading was defined as follows: Healing caps will be placed on the implant(s) immediately after surgery. A provisional restoration will be placed between day 28 to day 34 post surgery
2979095|NCT02703155|Other|Home Oral Glucose tolerance test kit|Providing children with Cystic Fibrosis between 10 and 17 years of age with Home Oral glucose tolerance test kit to screen Cystic fibrosis related Diabetes.
2979096|NCT02703142||Patients after esophagectomy|Endoscopic examinations are performed at 1, 8, and 15 postoperative days. Endoscopic examination is added when abnormal findings are demonstrated.
2979097|NCT02703129|Experimental|Nutritional intervention|Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
2979098|NCT02703116|Experimental|Alcohol Use BI|Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.
2979099|NCT02703116|Active Comparator|Nutrition Intervention|Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).
2979100|NCT02703103|Experimental|Standard cardiopulmonary resuscitation|standard CPR (30:2) according to European Resuscitation Council 2015 guidelines for cardiopulmonary resuscitation.
2979101|NCT02703103|Experimental|asynchronous cardiopulmonary resuscitation|asynchronuos CPR according to European Resuscitation Council 2015 guidelines for cardiopulmonary resuscitation.
2979102|NCT02703090|Placebo Comparator|Placebo|Normal saline infusion
2979103|NCT02703090|Active Comparator|Drug lower dose|Remifentanil infusion
2979104|NCT02703090|Active Comparator|Drug higher dose|Remifentanil infusion
2979105|NCT02703077|Active Comparator|1: ERCP + Spyglass + EHL|This group after the diagnosis of difficult bile duct stones, will be submitted to spyglass cholangioscopy + EHL (electrohydraulic lithotripsy)
3108701|NCT01832207|Sham Comparator|Placebo|
2979111|NCT02703038||Cardiogenic shock|Patient with cardiogenic shock table defined by the combination of a low cardiac output even as the filling pressures are normal or high, originally of hypoperfusion and organ suffering.
2979112|NCT02703025|Experimental|GCB 70 administered group|Green coffee bean extract capsule 500mg, BD
2979113|NCT02703012|Experimental|Adjustment of ventilator settings by EIT|Individual Adjustment of Ventilator settings using an algorithm based on electrical impedance tomography.
2979114|NCT02702999|Active Comparator|Routine third trimester care|Routine third trimester care with clinically-indicated ultrasound (control)
2979115|NCT02702999|Experimental|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
2979116|NCT02702986|Experimental|imILT of pancreatic cancer|10 patients suffering from LAPC will be submitted to immunostimulating interstitial laser thermotherapy (imILT) in a single-arm setting
2979117|NCT02702973||Observe the fundus characteristics|Observe the fundus characteristics after high doses of interferonα-2b therapy in patients with melanomas of the skin.
2979118|NCT02702960|Experimental|part. liver transplant and BMT|"Patients receive living related donor partial liver transplantation performed according to standard practices. Patients will be maintained on tacrolimus, MMF, and prednisone after liver transplantation.~Upon recovery, patient must undergo eligibility screening for bone marrow transplantation (BMT).~If eligible, patients will begin:~Antithymocyte globulin (ATG): Day -16 to Day -14; fludarabine: Days -6 to Day -2 low-dose cyclophosphamide: Day -6 and -5. Tacrolimus, mycophenolate mofetil (MMF), and prednisone: day -7 and day -6. Total body irradiation on Day -1 Bone marrow infusion on Day 0. High dose cyclophosphamide plus MESNA: Day 3 and 4th Filgrastim, tacrolimus,MMF, and prednisone: Day 5 until neutrophil counts recover.~Patients followed up through post transplant day 60, then weekly following discharge."
2979119|NCT02702947|Experimental|Prunus Domestica|Prunus domestica extract capsules, 100mg, BD
2979120|NCT02702934|Experimental|High-amylose rusks|Test meal with 100g of carbohydrates coming from high-amylose rusks
2979121|NCT02702934|Active Comparator|Control rusks|Test meal with 100g of carbohydrates coming from regular rusks used as control
2979122|NCT02702921|Active Comparator|Surgeon's 'standard of care' stapler|Surgeon's current standard of care stapler
2979123|NCT02702921|Experimental|Ethicon Powered Vascular Stapler|Ethicon Powered Vascular Stapler
2979124|NCT02702908||mPC|Prostate cancer patients with bone metastases (mPC)
2979125|NCT02702908||mCRPC|Patients with castration-resistant prostate cancer with bone metastases (mCRPC)
2979126|NCT02702895||Phase 1|Former ASPIRE participants
2979127|NCT02702895||Phase 2 HOPE participants|Former HOPE participants
2979128|NCT02702895||Phase 2 Male Partners|Male partners of HOPE participants
2979129|NCT02702882|Other|Fenugreek seeds extract 500 mg|Fenugreek seeds extract ( Furosap) one caps once a day
2979130|NCT02702869||uCL±A|Children with unilateral cleft lip with/without cleft alveolus but intact secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form).
2979131|NCT02702869||uCL+P|Children with unilateral cleft lip with/without cleft alveolus and with cleft secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form) and severity of palate (submucous, Veau-I, Veau-II, Veau-III, or Veau-IV).
2979132|NCT02702869||bCL±A|Children with bilateral cleft lip with/without cleft alveolus but intact secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form).
2979133|NCT02702869||bCL+P|Children with unilateral cleft lip with/without cleft alveolus and with cleft secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form) and severity of palate (submucous, Veau-I, Veau-II, Veau-III, or Veau-IV).
2979134|NCT02702869||CP|Children with cleft secondary palate. Subgroup analysis by severity (submucous, Veau-I, Veau-II, Veau-III, or Veau-IV).
2979135|NCT02702856||Men screened for prostate cancer|
2979136|NCT02702843|Active Comparator|Xenon Light|Laparoscopic cholecystectomy with Xenon Light
2979137|NCT02702843|Experimental|Near infrared light|Laparoscopic cholecystectomy with Near infrared light
2979138|NCT02702830||Diagnostic (MRI and CPET)|Patients undergo CPET using a one-way breathing mask in 2 separate days 1-2 weeks apart. Patients also undergo MRI before and within 60 seconds after exercising.
2979139|NCT02702817|Active Comparator|naproxen|naproxen sodium tablets 220 mg twice daily for two years
2979140|NCT02702817|Placebo Comparator|placebo|tablets identical in appearance to naproxen tablets twice daily for two years
2979141|NCT02702804|Experimental|High Intensity Interval Training|Participants will attend two sessions per week for the 6 week intervention. Each session will consist of 6-10 sets of 60 second high intensity intervals interspersed with 60 seconds recovery. The workload during each interval will be set at 80-90% of peak power achieved during the VO2peak test. This is predicted to elicit 85-95% heart rate reserve in the participants. After each interval the participant's heart rate and rate of perceived exertion (RPE) will be collected. After each session a researcher will complete an Adverse Event form to record if an event occurred or not. Additionally the participant will complete a physical activity enjoyment (Perceived activity enjoyment scale) after one session per week.
2979142|NCT02702791|Experimental|Intervention|Telecoaching - feasible goal setting and feedback to enhance patient's motivation and commitment - in addition to pulmonary rehabilitation.
2979143|NCT02702791|Other|Usual care|includes only general advices regarding physical activity.
2979144|NCT02702778|Active Comparator|4mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 4mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
2979145|NCT02702778|Active Comparator|7mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 7mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
2979146|NCT02702778|Active Comparator|10mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 10mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
2979147|NCT02702765|Experimental|Wilsons disease|All patients will receive all interventions (galactose elimination capacity test , ultrasound, fibroscan, continuous reaction time test and functional hepatic nitrogen clearance ), except liver biopsy.
2979148|NCT02702752|Other|DYNASDY|The study considers changes in SDF-1α levels in response to treatment of cardiac disease (myocardial infarction, heart failure or atrial fibrillation). SDF-1α levels will be measured at the acute stages of the disease, after stabilization and at longer term as detailed below. Levels of SDF-1α will be correlated to the outcome of disease.
2979149|NCT02702752|Active Comparator|Control group|A control group of 20 subjects without cardiac disease (including hypertension), diabetes, hypercholesterolemia, and malignant disease.
2979150|NCT02702739|Active Comparator|Group I (<65 years)|Group I treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
2979151|NCT02702739|Active Comparator|Group II (>65 years)|Group II treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
2979152|NCT02702726|No Intervention|Congee and juice only|Control breakfast providing 50g carbohydrate
2979153|NCT02702726|Active Comparator|Congee and juice with coconut gel|Control breakfast, plus 25g coconut oleogel (solid)
2979154|NCT02702726|Active Comparator|Congee and juice with coconut oil|Control breakfast, plus 25g coconut oil (liquid)
2979155|NCT02702726|Active Comparator|Congee and juice with sunflower gel|Control breakfast, plus 25g sunflower oleogel (solid)
2979156|NCT02702726|Active Comparator|Congee and juice with sunflower oil|Control breakfast, plus 25g sunflower oil (liquid)
2979157|NCT02702713|Active Comparator|Dairy BEF + egg placebo + bakery placebo|200 subjects consuming every day for 12 weeks: 1 portion of Dairy BEF + 1 portion of Egg placebo + 1 portion of Bakery placebo
2979158|NCT02702713|Active Comparator|Egg BEF + dairy placebo + bakery placebo|200 subjects consuming every day for 12 weeks: 1 portion of Egg BEF + 1 portion of Dairy placebo + 1 portion of Bakery placebo
2979159|NCT02702713|Active Comparator|Bakery BEF + dairy placebo + egg placebo|200 subjects consuming every day for 12 weeks: 1 portion of Bakery BEF + 1 portion of Dairy placebo + 1 portion of Egg placebo
2979160|NCT02702713|Placebo Comparator|All placebo|200 subjects consuming every day for 12 weeks: 1 portion of Egg placebo + 1 portion of Dairy placebo + 1 portion of Bakery placebo
2979161|NCT02702700|Experimental|Lipoplatin/Visudyne-mediated photodynamic therapy|200 mg/m2 Lipoplatin™ will be delivered as iv perfusion. Then, intrapleural photo-induction will be realized through a classical video-assisted thoracoscopic (VATS) approach using 3 mg/m2 Visudyne® activated at 689 nm. At the end of the procedure, the patients will receive chemical pleurodesis by VATS as per standard-of-care treatment for malignant pleural effusion.
2979162|NCT02702687|Experimental|PEF Feedback|This group will have 9 visits across 15 months.
2979163|NCT02702687|Active Comparator|Control Feedback|This group will have 9 visits across 15 months.
2979164|NCT02702674|Active Comparator|propranolol plus oxytocin|121 patients who will receive a capsule containing 20 mg propranolol (propranolol plus oxytocin) administrated orally before beginning induction and repeated after 8 hours if no sufficient uterine contractions reached.
2979165|NCT02702674|Placebo Comparator|placebo plus oxytocin|121 control patients who will receive a similar capsule as a placebo (oxytocin plus placebo) before beginning induction.
2979166|NCT02702661|Experimental|Procedure - FICB|Fascia Iliaca Block following Hip Arthroscopy - Drug - Levobupivacaine 0.125% - 40ml
2979167|NCT02702661|Active Comparator|Procedure - LAI|Local Anaesthetic Infiltration following Hip Arthroscopy - Drug - Levobupivacaine 0.125% - 40ml
2979168|NCT02702648|Experimental|AC-082, Single Ascending Dose|Subjects receive AC-082 at different single dose levels in a sequential manner, starting from 10 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each subject can participate in only one dose level
2979169|NCT02702648|Placebo Comparator|Placebo, Single Ascending Dose|Subjects receive a single dose of the matched placebo
2979170|NCT02702648|Experimental|AC-082, Multiple Ascending Dose|Subjects receive AC-082 at different dose levels for 4 consecutive days in a sequential manner (dose levels and duration to be adapted according to the results of the single ascending dose cohorts). Each subject can participate in only one dose level
2979171|NCT02702648|Placebo Comparator|Placebo, Multiple Ascending Dose|Subjects receive the matched placebo for 4 days
2979172|NCT02702635|Experimental|All Subjects|All recruited subjects
2979173|NCT02702609|Experimental|Moldable beta-TCP grafting system|Device: easy-graft CLASSIC (beta-Tricalcium Phosphate)
2979174|NCT02702609|Active Comparator|Allograft|Device: Freeze-Dried Bone Allograft (FDBA) with collagen plug
2979175|NCT02702596|Experimental|MBIC + DEF|Measurement-Based Integrated Care with Depression Education Fotonovela
2979176|NCT02702596|Experimental|MBIC + SE|Measurement-Based Integrated Care + Standard Education
2979177|NCT02702570|Other|CASA intervention|Each participant serves as his/her own control. Measures administered before and after an intervention.
2979178|NCT02702557|Other|Elastic Band Exercises|Unsupervised Elastic band exercises performed once a day until the patient is discharged from the hospital. One exercise for the upper extremity (row exercise level 1-3) and one exercise for the lower extremity (knee extension level 1-3). The two exercises are both performed as 3 sets of 10 repetitions.
2979179|NCT02702544|Experimental|neutral position|the patient is in the neutral position, located on his back on a flat surface
2979180|NCT02702544|Experimental|legs raised for 20 degrees|patient is placed on a flat surface, legs raised for 20 degrees, supported around ankles
2979181|NCT02702544|Experimental|legs raised for 30 degrees|patient is placed on a flat surface, legs raised for 30 degrees, supported around ankles
2979182|NCT02702544|Experimental|legs raised for 45 degrees|patient is placed on a flat surface, legs raised for 45 degrees, supported around ankles
2979183|NCT02702544|Experimental|legs raised for 60 degrees|patient is placed on a flat surface, legs raised for 60 degrees, supported around ankles
2979184|NCT02702531|Experimental|FloShield|FloShield Air Laparoscopic Cleaning and Defogging System used during laparoscopic surgery
2979185|NCT02702531|Experimental|Water + Povidone-iodine Solution|Clearify Visualization with Water + Povidone-iodine Solutionused during laparoscopic surgery
2979186|NCT02702518|Active Comparator|rhDNase I|rhDNase I 0.1% eye drops 4 times a day for 8 weeks
2979187|NCT02702518|Placebo Comparator|Vehicle|Drug vehicle eye drops 4 times a day for 8 weeks
2979273|NCT02701920||Newborns needing stabilisation|Newborn infants requiring resuscitation or stabilisation following birth.
2979188|NCT02702505|Experimental|NeoMTA|The new formulation of MTA (does not contain bismuth oxide) will be used in one tooth receiving a pulpotomy to determine if the color of the tooth changes over time. The new formulation has received the Food and Drug Administrations 510(k) substantial equivalence clearance for Class II dental materials and is equivalent to its MTA predicate (ProRoot, Dentsply Tulsa Dental, Tulsa, OK, USA).19
2979189|NCT02702505|Other|ProRoot MTA|Control group. This group will receive the old formulation of MTA in the pulpotomy and the tooth will receive a full coverage stainless steel crown restoration.
2979190|NCT02702492|Experimental|KPT-9274|oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle.
2979191|NCT02702492|Experimental|KPT-9274 & Niacin Extended Release (ER)|500 mg niacin ER co-administered with each dose of oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle.
2979192|NCT02702466|Experimental|Immediate SPA Therapy|6 day immediate SPA treatment (soon after randomization) and written information with physical exercises adapted to their pathology and also a program of healthcare at the USB key
2979193|NCT02702466|Active Comparator|Late SPA Therapy|Written information with physical exercises adapted to their pathology and a program of healthcare at the USB key and late 6 day SPA treatment
2979194|NCT02702453|Experimental|Development and Testing|Develop an online interactive, tailored intervention to address the needs of men and partners interested in sexual recovery after treatment for localized prostate cancer during the first 6 months after treatment. The intervention will undergo content testing through 4 focus groups with prostate cancer survivors and partners and usability testing with 5 survivors and partners
2979195|NCT02702427|Experimental|ARM 1|Patients with Adenovirus or CMV infection after HSCT and no reduction of viral disease or stable disease with 10E6 viral copies within 2 weeks of antiviral treatment will receive a single infusion of virus-specific T-Cells
2979196|NCT02702414|Experimental|Prior Systemic Therapy|Participants with previously systemically treated HCC receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stop pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stop after receiving 35 trial treatments may be eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they meet the criteria for re-treatment.
2979197|NCT02702414|Experimental|Systemic Therapy Naive|Participants with HCC who had not received treatment for systemic disease receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stop pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stop after receiving 35 trial treatments may be eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they meet the criteria for re-treatment.
2979198|NCT02702401|Experimental|Pembrolizumab+Best Supportive Care|Participants receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC.
2979199|NCT02702401|Placebo Comparator|Placebo+Best Supportive Care|Participants receive a placebo IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC.
2979200|NCT02702388|Experimental|24 mg Lenvatinib|Participants will receive 24 mg once daily (QD) as the starting dose. Dose reductions will occur in succession based on the previous dose level (24, 20, 14, 10, or 8 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
2979201|NCT02702388|Experimental|18 mg Lenvatinib|Participants will receive 18mg QD as the starting dose. Dose reductions will occur in succession based on the previous dose level (18,14, 10, 8, or 4 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 18, 14, 10, 8 mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
2979202|NCT02702362|Active Comparator|anodal stimulation|"Patients received anodal tDCS (on the precuneus ) every day for 5 days (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after each tDCS.~A final CRS-R is performed 5 days after the end of the session to assess the potential long term effects of the tDCS."
2979203|NCT02702362|Sham Comparator|sham stimulation|Patients received sham tDCS (5 secondes of stimulation) every day for 5 days. A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed 5 days after the end of the session.
2979204|NCT02702349|Other|1|penicillin test and challenge
2979205|NCT02702336|Experimental|EYTO-Kids Intervention Group|Adolescents will receive 16h of training (2h healthy lifestyle training, social marketing and communication, 6h to design activities, 2h session together with all intervention high-schools, 6h to practice and standardize activities) and 4h (1h/activity) to implement 4 activities in schools. The scholars will receive 4 activities designed by adolescents, focusing on: 1) increasing fruit consumption, 2) increasing vegetable consumption, 3) increasing physical activity practice and to reduce sedentary lifestyles and, 4) decreasing sugary drinks and fast-food consumption.
2979206|NCT02702336|No Intervention|Control Group|The control group will not receive any kind of intervention (only the assessment).
2979207|NCT02702323|Experimental|Apatinib & TACE|Apatinib 500mg tablet by mouth per day, until disease progression, combined with TACE therapy one times every 4-6 weeks.
2979208|NCT02702323|Active Comparator|TACE|TACE therapy one times every 4-6 weeks.
2979209|NCT02702310||Quality of Life/ Grading Skin Findings|Patients' baseline quality of life is established by completion of an initial questionnaire, and skin lesion burden is quantified by physical examination using a recommended system . Following the standard of care radiation therapy, patients' completion of questionnaire, and physical examination is repeated for continued assessment.
2979210|NCT02702297||Single arm|daily multimodal monitoring during pregnancy after PPROM, Analysis of neonatal routine parameters and histologic examination of placenta
2979211|NCT02702284|Other|Adequate health literacy, control|This group of subjects will be referred to clinic staff for assistance with the advance directives (AD) and will not receive assistance from a research assistant. In addition, the research assistance will ask questions regarding the information received for the AD.
2979212|NCT02702284|Experimental|Adequate health literacy, intervention|The subjects in this group will hear a research assistant review the advance directive and be offered an opportunity to watch a video about advance directives.
2979213|NCT02702284|Other|Limited health literacy, control|This group of subjects will be referred to clinic staff for assistance with the advance directives (AD) and will not receive assistance from a research assistant. In addition, the research assistance will ask questions regarding the information received for the AD.
2979214|NCT02702284|Experimental|Limited health literacy, intervention|The subjects in this group will hear a research assistant review the advance directive and be offered an opportunity to watch a video about advance directives.
2979215|NCT02702271|Experimental|WATCHMAN FLX|WATCHMAN FLX implant: This is a single arm study
2979216|NCT02702258|Experimental|MB-BP|This is the primary intervention tested in this single arm trial.
2979217|NCT02702245|Placebo Comparator|Placebo comparator: Control|OGTT without thylakoids.
2979218|NCT02702245|Experimental|Experimental: Thylakoids 5 g|Intervention type: Dietary supplement. Supplement: thylakoid powder, dose 5 g. Intervention: OGTT at one occasion.
2979219|NCT02702245|Experimental|Experimental: Thylakoids 10 g|Intervention type: Dietary supplement. Supplement: thylakoid powder, dose 10 g. Intervention: OGTT at one occasion.
2979220|NCT02702232||Parkinson's disease|Patients with PD will be recruited consecutively from a neurology clinic. A group of sex- and age-matched normal subjects with be recruited from the public. These patients will be evaluated by ultrasonography for shoulder.
2979221|NCT02702232||Normal|Normal controls who will be evaluated by ultrasonography for shoulder
2979222|NCT02702219|Experimental|Dynamic streching|Mobility training of the hamstrings muscles to be performed every day
2979223|NCT02702219|Active Comparator|Static stretching|Static stretching of the hamstrings muscles to be performed every day
2979224|NCT02702206|Experimental|corticosteroids SASD injection|under US guidance 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
2979225|NCT02702206|Experimental|hyaluronic acid (ARTZ) SASD injection|under US guidance 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
2979226|NCT02702206|Placebo Comparator|normal saline SASD injection|under US guidance 2.5ml normal saline and 0.5ml distilled water and 1ml 1% lidocaine
2979227|NCT02702193|Experimental|SET-R/Healthy Home|SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers.
2979228|NCT02702193|No Intervention|TAU|Treatment as usual - the usual outpatient substance abuse or mental health services received by the mothers with no additional services provided by the study team.
2979229|NCT02702180|Experimental|molgramostim continuously|Inhalation of molgramostim nebuliser solution (rhGM-CSF) 300 mcg once daily for 24 weeks
2979230|NCT02702180|Experimental|molgramostim intermittently|Inhalation of molgramostim nebuliser solution (rhGM-CSF) 300 mcg for seven days and placebo nebuliser solution for seven days for 24 weeks (12 cycles)
2979231|NCT02702180|Placebo Comparator|placebo|Inhalation of placebo nebuliser solution once daily for 24 weeks
2979232|NCT02702167|Experimental|High-frequency rTMS|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
2979233|NCT02702167|Experimental|Low-frequency rTMS|1 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
2979234|NCT02702167|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
2979235|NCT02702154|Experimental|High-frequency rTMS|20 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
2979236|NCT02702154|Experimental|Low-frequency rTMS|1 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
2979237|NCT02702154|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
2979238|NCT02702141|Experimental|SGN-CD19B|
2979239|NCT02702128|Active Comparator|Tranexamic acid|1g of Tranexamic acid on 1hour and 1g of tranexamic acid on 8 hours
2979240|NCT02702128|Placebo Comparator|saline solution|30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
2979241|NCT02702115|Experimental|Cohort 1: SB-318: Starting Dose|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
2979242|NCT02702115|Experimental|Cohort 2: SB-318 at Next Ascending Dose|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
2979243|NCT02702102|Experimental|11C-PBR28 PET scans|Participants will receive one IV injection of up to 20 millicuries of 11C-PBR28.
2979244|NCT02702089||IAPE|Intersphincteric AP excision
2979245|NCT02702089||HP|Hartmann's procedure
2979246|NCT02702076|Experimental|Apomorphine|This arm will be treated with continuous subcutaneous infusion of apomorphine. The infusion will start with 1 mg/hr during the waking day (approximately 16 hours). The flow rate will be adjusted on a weekly basis, and may be increased with 0.5 to 1.0 mg/hr per discretion of the investigator, aiming at the disappearance of visual hallucinations. The duration of treatment is 4 weeks.
2979247|NCT02702076|Placebo Comparator|Placebo|This arm will be treated with continuous subcutaneous infusion of placebo. The infusion will start with 1 mg/hr during the waking day (approximately 16 hours). The flow rate will be adjusted on a weekly basis, and may be increased with 0.5 to 1.0 mg/hr per discretion of the investigator aiming at the disappearance of visual hallucinations. The duration of treatment is 4 weeks.
2979274|NCT02701920||Parental feedback|Parental feedback of babies recruited into HeartLight will be sought.
2979275|NCT02701920||Healthcare provider feedback|Healthcare professionals caring for babies recruited into HeartLight will have their feedback on the device sought.
2979306|NCT02701712|Experimental|Magnetic resonance - guided radiation therapy (MRgRT)|Magnetic resonance (MR) - guided radiation therapy
2984392|NCT02667548||patients receiving PCI|patients receiving PCI
2979248|NCT02702063|Other|TTE vs. EC + calibration group|"50 Patients undergoing routine transthoracic echocardiography at laboratory for transthoracic echocardiography at the department of cardiology of Medical University Vienna will be enrolled following informed consent. Non-inclusion criteria are inability to understand study procedure and age under 18 years old.~Patients with any grade of aortic regurgitation, congenital heart disease with intracardiac shunt (left-right shunt or right-left shunt) or arrhythmia (atrial fibrillation) or withdrawing consent during study procedure will be excluded. In addition, patients with intraabdominal (IAH), intracranial (ICH) hypertension or any disease of the hip joint, will not be included into the trial."
2979249|NCT02702063|Other|Right heart catheterisation|Twenty five patients undergoing routine right heart catheterization (RHC) at the department of cardiology for the evaluation of suspected pulmonary hypertension or heart failure will be included in this trial. EC measurements will be obtained during RHC, and a TTE (for measuring LVOT-area) will be performed immediately before undergoing RHC. Inclusion and exclusion criteria are similar as described above.
2979250|NCT02702063|Other|Passive leg raising test|"50 Patients undergoing routine transthoracic echocardiography at laboratory for transthoracic echocardiography at the department of cardiology of Medical University Vienna will be enrolled following informed consent. Non-inclusion criteria are inability to understand study procedure and age under 18 years old.~Patients with any grade of aortic regurgitation, congenital heart disease with intracardiac shunt (left-right shunt or right-left shunt) or arrhythmia (atrial fibrillation) or withdrawing consent during study procedure will be excluded. In addition, patients with intraabdominal (IAH), intracranial (ICH) hypertension or any disease of the hip joint, will not be included into the trial.~SV and CO will be measured using TTE and EC. Patient's legs will then be raised by 45degree, and SV and CO measurements will be repeated after 1 minute. Changes in SV and CO observed with both methods will be compared."
2979251|NCT02702050|Active Comparator|Conventional treatment group|Conventional treatment group will receive an educational session before commencement of the program. Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises will be provided within a 6-week period (i.e., two sessions per week) to all subjects. No mechanical stimulation will be given.
2979252|NCT02702050|Experimental|Mechanical stimulation group|A 10 minute mechanical stimulation program - 'Mechanical stimulation (LPG system; Cellu M6 Integral I), will be provided after each of the twelve sessions of conventional treatment.
2979253|NCT02702037|Experimental|Intervention|"The participants will be supported to perform the sit-to-stand exercise at least four times per day during 12 weeks (7 days/week).~The participants will also be offered an oral protein-rich supplement (125 ml, 18 g protein (24% of RDI), 300 kcal) twice a day in conjunction with two of the four sit-to-stand exercises during 12 weeks (7 days/week)."
2979254|NCT02702037|No Intervention|Control|Standard care
2979255|NCT02702011|Experimental|empagliflozin low dose|
2979256|NCT02702011|Experimental|empagliflozin medium dose|
2979257|NCT02702011|Experimental|empagliflozin high dose|
2979258|NCT02702011|Placebo Comparator|placebo|
2979259|NCT02701998|Experimental|mHealth-Enhance Physical Activity Intervention|Tech-PAI participants will be given 3 goals: 1) to increase their average baseline daily walking exercise by 30 minutes at week 12; 2) to increase their average baseline daily steps by 4,000 at week 12; and 3) to get up and walk for at least 2 minutes after every 60 minutes of sitting. Participants will receive instruction on how to gradually and safely increase their bout-related walking exercise and steps over the 12 week period. In addition to goal setting, Tech-PAI participants will receive a commercially available activity tracker and accompanying that provides real-time monitoring of steps, activity minutes, and issues a text-based prompt after 60 minutes of sitting to get up and move. Also, participants will receive a weekly e-mail feedback message from research staff on goal progress and will be asked to view weekly Internet-based video lessons that will provide behavioral strategies to increase MPA and steps and decrease SB during the first 6 weeks of the intervention period.
2979260|NCT02701998|Active Comparator|Physical Activity Intervention|PAI participants will be given the same goals as Tech-PAI intervention participants and receive a pedometer and related print materials to assist them in recording and increasing daily steps and bout-related MPA (but no activity tracker, access to video-based skills training lessons, or weekly feedback).
2979261|NCT02701985|Placebo Comparator|Placebo|Matching-placebo capsules will be administered orally, 2 times a day, for up to 12 weeks.
2979262|NCT02701985|Experimental|RO5459072|RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day, for up to 12 weeks.
2979263|NCT02701972|Experimental|Control and Test|Pre-implantation and Post-implantation of BACE device
2979264|NCT02701959|Placebo Comparator|Low nitrate lettuce|50g of low nitrate lettuce (placebo) on single occasions
2979265|NCT02701959|Active Comparator|High nitrate lettuce|50g of high nitrate lettuce (intervention) on single occasions
2979266|NCT02701946|Experimental|Modified Robert Jones bandage|Modified Robert Jones bandage is defined as a three-layers of thick cotton wool and two-layers of elastic bandages. The wool layers are put on firmly and overlapped the previous one by half at each turn. The elastic layers were pulled snugly with more tension distally than proximally. Before wrapping in each turn, the elastic bandage was stretched approximately 2 and 1.5 inches at below and above tibial tuberosity level, respectively. The whole bandage attains a thickness of about two inches and extends above the ankle joint to six inches above the knee joint. Before applying this bandage, the sterile gauze pads were placed over the wound and followed by WebrilTM padding (Covidien, Mansfield, MA, US).
2979267|NCT02701946|Placebo Comparator|Non compressive dressing|Non-compressive dressing is made by placing the sterile gauze pads over the wound and covering with the hypoallergenic self-adhesive, non-woven fabric tape.
2979268|NCT02701933|Other|Ketamine-Saline|Each participant receives both ketamine and placebo (saline) in randomised order in a repeated-measures design. In this arm, ketamine is administered on the first assessment and placebo (saline) is administered on the second assessment.
2979269|NCT02701933|Other|Saline-Ketamine|Each participant receives both ketamine and placebo (saline) in randomised order in a repeated-measures design. In this arm, placebo (saline) is administered on the first assessment and ketamine is administered on the second assessment.
2979270|NCT02701920||NICU infants and hat|Newborn infants of any gestation on the neonatal intensive care unit (NICU).
2979271|NCT02701920||NICU infants and sensor|Newborn infants of any gestation requiring heart rate monitoring on the neonatal intensive care unit.
2979276|NCT02701907|Other|breast cancer|In this study, we aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. We will focus our analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
2979277|NCT02701907|Other|non-small cell lung cancer|"In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies.~The investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed"
2979278|NCT02701907|Other|kidney cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
2979279|NCT02701907|Other|colorectal cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
2979280|NCT02701907|Other|ovarian cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
2979281|NCT02701907|Other|skin cutaneous melanoma|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
2979282|NCT02701881|Experimental|Long stenting group|
2979283|NCT02701881|Active Comparator|Short stenting group|
2979284|NCT02701868||Phase 1|Up to 40 individuals will be recruited to participate in focus groups at Pennington Biomedical Research Center. Approximately six focus groups (each with 5-10 participants) will be conducted at the PBRC Demonstration Kitchen over the course of approximately 3 months.
2979285|NCT02701868||Phase 2|Up to 150 individuals who did not participate in Whoa Baby Phase 1 will be recruited to test the efficacy of the revised instructions on infant overfeeding in comparison with the instructions currently provided on the packaging.
2979286|NCT02701855||Hypertension and progressive MCI|50 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
2979287|NCT02701855||Hypertension and stable MCI|50 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
2979288|NCT02701855||Hypertension, without MCI|60 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
2979289|NCT02701842|Experimental|Validity|ImPACT Online a computerized test will be administered to subjects. They will also receive a battery of paper and pencil neuropsychological tests.
2979290|NCT02701842|Active Comparator|Test/Re-Test|ImPACT Online will be administered at 2 time points.
2979291|NCT02701829|Experimental|Health Fairs (HF)|Drivers will undergo U&C Health Fair follow-up either Regular or Urgent Follow-up: Timeline is determined by health status, with regular follow-up continuing for at least two weeks and urgent follow-up continuing for at least a month
2979292|NCT02701829|Experimental|HF + text messaging + home BP monitoring|Drivers will receive: U&C HF follow-up, Mobile text messaging intervention w/ interactive 2- way messaging to encourage BP management for nine months A home BP monitoring equipment with instructions to self-monitor BP for nine months
2979293|NCT02701829|Experimental|HF +Tech + social network support (SNS).|"Drivers will receive:~U&C HF follow-up, Mobile text messaging intervention w/ interactive 2- way messaging to encourage BP management for nine months and home BP monitoring equipment with instructions to self-monitor BP for nine months A social network support intervention in which selected family/peers encourage drivers to maintain healthy behaviors for nine months"
2979294|NCT02701816||K-INNOVA|Patients with femoropopliteal artery disease undergoing endovascular therapy using Innova stent (Boston Scientific).
2979295|NCT02701777|Active Comparator|STDP|paired stimulation will be given to the brain so that the messages are received at the spinal cord at the correct time.
2979296|NCT02701777|Active Comparator|STDP+ Seromycin/ Placebo|a single dose of 100mg of Seromycin will be given in a pill form by mouth and then paired stimulation will be applied to the brain so that the messages are received at the spinal cord at the correct time.
2979297|NCT02701777|Active Comparator|STDP+Dextromethorphan/ Placebo|a single dose of 150mg of Dextromethorphan will be given in a pill form by mouth and then paired stimulation (STDP) will be applied to the brain so that the messages are received at the spinal cord at the correct time.
2979298|NCT02701777|Active Comparator|Training +STDP|motor training exercises will be done repetitively and then stimulation (STDP) to the brain will be applied.
2979299|NCT02701777|Active Comparator|Training|motor training exercises will be done repetitively
2979300|NCT02701777|Active Comparator|Training + Seromycin+STDP/ Sham STDP|Motor Training will be completed, then a single dose of 100 mg of Seromycin will be administered in pill form, and then stimulation or sham stimulation will be applied to the brain
2979301|NCT02701777|Active Comparator|Sham STDP|fake stimulation will be given to the brain so that the messages are received at the spinal cord at the correct time.
2979302|NCT02701764|Experimental|Pregabalin|Pregabalin 150 mg twice a day starting 1 day prior to LASIK and continuing for 14 days total.
2979303|NCT02701764|Placebo Comparator|Placebo|Placebo pill twice a day starting 1 day prior to LASIK and continuing for 14 days total.
2979304|NCT02701751|Other|Exercise session|Subjects will exercise at a moderate intensity for 60 minutes. There are no different arms in this study.
2979305|NCT02701738|Experimental|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
2979307|NCT02701699|Experimental|18-F-FAZA Scan|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
2979308|NCT02701686|Experimental|quit immediately (QI)|Subjects in the QI group will receive a smoking cessation booklet plus a brief intervention using the AWARD model: (a) Ask about smoking history, (b) Warn about the high risk, (c) Advise to quit now, as quitting can greatly reduce risks, (d) Refer smokers to a smoking cessation clinic, and (e) Do it again: repeat the intervention during each telephone follow-up. The whole intervention will be limited to less than 1 min or slightly longer if necessary. For the subsequent telephone follow-ups at 1, 3, 6 and 12 months, the counsellor will congratulate to the subjects who successfully quit smoking, while deliver the same brief intervention as a booster for those who continue to smoke.
2979309|NCT02701686|Experimental|cut down to quit (CDTQ)|Subjects in the CDTQ group will also receive the smoking cessation booklet plus a brief intervention using the AWARD model. Instead of asking them to quit immediately, they will be advised gradually cutting down on their cigarette consumption. Also, the subjects will be provided with an education card that contains reduction strategies and a suggested plan to reduce smoking. For the subsequent telephone follow-ups at 1, 3, 6 and 12 months, the nurse counsellor will repeat the warning message that one out of two smokers will be killed by smoking, and remind the subjects of their next reduction target. The counsellor will congratulate subjects who quit or reduce smoking on their success. When subjects fail to quit or reduce their cigarette consumption, the counsellor will reinforce the health hazards of continued smoking and the benefits of quitting, and encourage them to try again immediately or in the near future.
2979310|NCT02701673|Experimental|Belinostat/Gem/Bu/Mel + AutoSCT|"Busulfan test dose administered by vein on Day -10. Test dose of 32 mg/m2 based on actual body weight. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -8. Doses on Days -6 and -5 subsequently adjusted to target an area under curve (AUC) of 4,000 microMol.min-1.~Caphosol oral rinses 30 mL four times a day used from Day -8. Oral Glutamine, 15 g swished, gargled and swallowed four times a day starting on Day -8.~Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1. Starting dose of Belinostat 100 mg/ m2/day by vein on Day -9 through Day -2. Azacitidine 15 mg/m2/day by vein on Day -9 through Day -2. Participants with cluster of differentiation antigen 20 (CD20+) tumors receive Rituximab 375 mg/m2 by vein on Day -9.~Gemcitabine 75 mg/m2 by vein administered as a loading dose followed by prolonged infusion on Days -8 and -3.~Melphalan 60 mg/m2/d by vein on Day -2. Stem cell transplant by vein given on Day 0."
2979311|NCT02701660|Experimental|electronic medication dispenser|An Automatic Tablet Dispensing and Packaging System is used to repack all solid oral prescription medications for each participant into unit-of-dose pouches. Every participant receives a roll with pouches for 14-28 days loaded into a dispenser installed at their homes. The electronic medication dispenser is a remote controlled, electronic medication management aid reminding the patients with acoustic alerts to take their medication.
2979312|NCT02701647|Experimental|25-Hz rTMS|Participants will receive 4s train of 25-Hz repetitive Transcranial magnetic stimulation pulses with 50s inter-train intervals. Participant will receive a total of 600 rTMS pulses in 6 minutes for each hemisphere and a total of 1200 pulses followed by 30 minutes of treadmill training.
2979313|NCT02701647|Experimental|1-Hz rTMS|Participants will receive a total of 600 1-Hz repetitive Transcranial magnetic stimulation pulses in 10 minutes for each hemisphere and a total of 1200 pulses followed by 30 minutes of treadmill training.
2979314|NCT02701647|Sham Comparator|Sham rTMS|Sham repetitive Transcranial magnetic stimulation will be applied over the same site as for real rTMS , however, with the cables of the coil disconnected. Another figure-of-eight coil using the same stimulation parameters (intensity, time, and frequency) as 25-Hz group will be placed posterior to the subject's neck with the handle pointing backward to produce the same clicking sound effect as 25-Hz group. Sham rTMS will be followed by 30 minutes of treadmill training.
2979315|NCT02701634|Experimental|Entospletinib|Entospletinib for 48 weeks in combination with systemic corticosteroids as first-line therapy
2979316|NCT02701634|Placebo Comparator|Placebo|Placebo to match entospletinib for 48 weeks in combination with systemic corticosteroids as first-line therapy
2979317|NCT02701634|Experimental|Open-Label Extension|After Week 48, all participants will have the option to receive entospletinib for an additional 96 weeks in the open-label extension phase, while continuing treatment with systemic corticosteroids as first-line therapy.
2979318|NCT02701621|Active Comparator|MIRT Group|Individuals underwent Multidisciplinary Intensive Rehabilitation Treatment. It consists of 4 weeks of physical therapy in a hospital setting with four daily sessions for five days and one hour of physical exercise on the sixth day.The duration of each session is about one hour. The first session comprises cardiovascular warm-up activities, relaxation and muscle-stretching. The second session includes aerobic exercises and the use of different devices: a stabilometric platform, treadmill plus, crossover, cycloergometer. The third is a session of occupational therapy. The last session includes one hour of speech therapy. The rehabilitation program can also include: robotic-assisted walking training, virtual reality training and meetings with a Psychologist.
2979319|NCT02701621|Experimental|MIRT-AT|"Patients underwent land-based therapy in association with aquatic therapy, three times per week for four weeks.~The land-based activities included the second and the third session of MIRT.~The water sessions were divided in 3 phases:~i) Warm Up Exercises. This phase lasted 10 minutes and comprised walking performances.~ii) Central session Training. This phase lasted 30-45 minutes and comprised trunk mobility exercises in standing position and sitting on a floating device, static and dynamic exercises. The successive balance training exercises comprised: maintaining balance with closed eyes; balance control with one leg resting on a step; postural control changing the support base.~iii) Cool-down. This phase lasted 5 minutes and comprised general stretching exercises and gentle walking."
2979320|NCT02701608|Experimental|Oral switch treatment|Oral switch to the combination of levofloxacin and rifampicin
2979321|NCT02701608|Active Comparator|Conventional IV treatment according to european guidelines|Conventional IV treatment of staphylococci IE (European guidelines 2015)
2979322|NCT02701595|Experimental|Oral switch treatment|Oral switch to amoxicillin
2979323|NCT02701595|Active Comparator|Conventional IV treatment according to european guidelines|Conventional IV treatment of streptococci/enterococci IE (European guidelines 2015)
2979386|NCT02701192||Coccygectomy Treatment|Patients undergoing coccygectomy surgical procedure.
2979387|NCT02701179|Active Comparator|1 % Lignocaine|1 % Lignocaine administered for topical anaesthesia during bronchoscopy procedure
2979324|NCT02701582|Experimental|FloTrac Sensor|Anesthesiologist will be able to see the dynamic indicators, and will be given a study algorithm to follow, based on the trending data, for the duration of the surgery. Anesthesiologist may choose to discontinue the study algorithm at any time based on his or her best clinical judgment. Clinical judgment can and must always override the study protocol if discrepancy exists. If this occurs, the patient would be considered to fail the protocol, and be considered in a separate group in data analysis.
2979325|NCT02701582|Active Comparator|Control Group|FloTrac will be connected to the monitor, the anesthesiologist will not be able to see the monitor although the data will be collected and stored for analysis. Anesthesiologist will be asked to choose from the same drug and fluid options used in the GDT group (phenylephrine, epinephrine, normal saline, albumin, Voluven), but to be used in accordance with their best clinical judgment without the aid of FloTrac data. If a discrepancy exists, the attending anesthesiologist may choose to use other therapies not included in the GDT protocol, in accordance with their best clinical judgment. If this happens, the subject would be considered to fail the protocol, and be considered in a separate group in data analysis.
2979326|NCT02701569|Experimental|Rebound exercise|Repeated jumping on a mini trampoline was performed with feet slightly apart
2979327|NCT02701569|No Intervention|Control|No exercise was administered but participants continued with routine medical care
2979328|NCT02701556|Experimental|B&L NNR06 Multi-Purpose Solution|B & L investigational NNR06 used as a rub care regimen (Test)
2979329|NCT02701556|Active Comparator|COMPLETE MPS|B&L Multi-Purpose Solution as a rub care regimen (Control)
2979330|NCT02701543|Active Comparator|Ranger Drug Eluting Balloon|Intervention with Over the Wire (OTW) Percutaneous transluminal angioplasty (PTA )balloon catheter with a semi-compliant balloon coated with a formulation of 2μg/mm2 paclitaxel and acetyl tri-n-butyl citrate (ATBC) as carrier substance
2979331|NCT02701543|Active Comparator|In Pact Drug Eluting Balloon|Intervention with Over the Wire (OTW) peripheral balloon catheter. The balloon surface is coated with a formulation of 3μg/mm2 paclitaxel and urea as carrier substance.
2979332|NCT02701530|Experimental|Targeted smoking cessation|"Smoking cessation program tailored in cooperation with the target group; smokers with low education.~Peer-based anti-relapse strategy. Recruitment strategy: peer-driven, written invitations and posters."
2979333|NCT02701530|No Intervention|Control|No smoking cessation program.
2979334|NCT02701517|Active Comparator|Cyclosporine + METHOTREXATE|MTX days +1, +3, +6 and +11 followed by folinic acid rescue. All patients will receive CSA from day -7.
2979335|NCT02701517|Experimental|Cyclosporine + CAMPATH-1H|CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.
2979336|NCT02701504||Sleep apnea group|The patients who are found to have sleep apnea based on the results of the portable sleep study
2979337|NCT02701504||Non sleep apnea group|The patients who are found to have no sleep apnea based on the results of the portable sleep study
2979338|NCT02701491|Experimental|Ginger|Ginger
2979339|NCT02701491|Placebo Comparator|Placebo|Placebo-no intervention
2979340|NCT02701478|Other|N2O exposure|"There is only one arm in this study. All patients under General Anesthesia are exposed to 4 different doses or concentrations of inhaled N2O that is combined with the anesthetic desflurane. Each patient will be submitted to the standard nociceptive stimulus when inhaled N2O is at 0, 50, 25, and finally back to 0%. ANI and NoL Indices variations between before stimulus and after stimulus at each N2O concentration will be assessed and compared. This will allow to demonstrate an analgesic effect (less variations of ANI and NoL) when inhaled N2O is high (50%) testifying for the analgesic effect of this gas N2O."
2979341|NCT02701465|Experimental|Intervention group|The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.
2979342|NCT02701465|Active Comparator|Control group|The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
2979343|NCT02701452|Experimental|COAGO|All patients undergoing antagonist protocol and at high risk of OHSS (estradiol level ≥ 3000 pg/mL and/or more than 20 follicles ≥ 11mm on the day of triggering) were triggered by GnRH agonist.
2979344|NCT02701439||HIV-infected|"Enrollment of 740 HIV-infected adults with suspicion of pulmonary TB.~Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:~Abbreviated demographic and clinical evaluation~TB history and evaluation~Obtain three sputum samples - one early morning sample and two spot samples~HIV testing (and CD4 if positive)~Chest radiograph~Small membrane filtration intervention"
2979345|NCT02701439||HIV negative|"Enrollment of 350 HIV negative adults with suspicion of pulmonary TB.~Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:~Abbreviated demographic and clinical evaluation~TB history and evaluation~Obtain three sputum samples - one early morning sample and two spot samples~HIV testing (and CD4 if positive)~Chest radiograph~Small membrane filtration intervention"
2979346|NCT02701426|Experimental|participant|agree to participate to the program combining physical activity and nutritional counseling
2979347|NCT02701426|No Intervention|no participant|disagree to participate to the program
2979348|NCT02701413|Experimental|ApexM Device|The ApexM Device (InControl Medical) is a cylindrical inflatable instrument with electrodes on the dorsal and ventral sides. It is a battery operated, non-implanted device which will be inserted into the vagina and will stimulate the pelvic floor muscles. This device has been shown to be safe and effective for clinical use. Stimulation will alternate between 13 and 50Hz. The initial intensity will be set by the clinician at the patient's initial visit and will be increased in a standard fashion over the duration of the trial.
2979349|NCT02701413|Sham Comparator|Sham Device|The ApexM Device will be identical in every way but the electrical stimulation will be disabled. The device will still turn on and inflate to fit the contours of the vagina.
2979388|NCT02701179|Active Comparator|2 % Lignocaine|2 % Lignocaine administered for topical anaesthesia during bronchoscopy procedure
2979389|NCT02701166|Experimental|Bezafibrate|Bezalip retard 400mg tablet
2979390|NCT02701166|Placebo Comparator|Placebo|Placebo 400mg tablet
2979350|NCT02701400|Experimental|Arm I (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving disease control may restart treatment upon evidence of progressive disease, with or without confirmation.
2979351|NCT02701400|Active Comparator|Arm II (RT, tremelimumab, durvalumab)|Patients undergo stereotactic body radiation therapy (SBRT) or hypofractionated radiation therapy daily for 5 days over 1 week or for 3 fractions every other day for 1 week and then receive the same treatment as in Arm I.
2979352|NCT02701387|Experimental|AnyRidge Implant|Experimental implant (Megagen AnyRidge dental implant) placed in a healed edentulous site to replace a missing tooth.
2979353|NCT02701387|Active Comparator|EZ Plus Implant|Comparative implant (Megagen EZ Plus dental implant) placed in a healed edentulous site to replace a missing tooth.
2979354|NCT02701374|Experimental|1:TRK-700|high dose
2979355|NCT02701374|Experimental|2:TRK-700|low dose
2979356|NCT02701374|Placebo Comparator|3:Placebo|Placebo
2979357|NCT02701361|Active Comparator|Education group|A care condition in which an educational program relevant to critical illness is presented in a web-based format similar to the other arms. Telephone calls will be used to answer questions and assist with web content.
2979358|NCT02701361|Experimental|Standard mindfulness|Receives audiovisual mindfulness content via internet plus 1 call per week from a trained mindfulness expert.
2979359|NCT02701361|Experimental|Mobile mindfulness|Receives audiovisual mindfulness content via web-app. Will receive at least 1 call from a trained mindfulness expert, though up to 4 total calls based on symptoms / request.
2979360|NCT02701335|Experimental|Experimental group|Neural mobilization and standardized exercise . 12 sessions over 4 weeks (3 sessions per week).
2979361|NCT02701335|Active Comparator|Control group|Gloreha device and standardized exercise. 12 sessions over 4 weeks (3 sessions per week).
2979362|NCT02701322|Experimental|Medical Clown|the study group will be accompanied by a medical clown from the arrival to the premise, through the actual examination and after exiting the exam room. The medical clown will explain about the upcoming examination and will induce a less stressed atmosphere. After the examination the clown will close the session for the patient.
2979363|NCT02701322|No Intervention|Control|The control group will do the same videofluoroscopic procedure but without a medical clown.
2979364|NCT02701309||Non-invasive Iron detection|Children between 9months and 5years will be recruited for a non-invasive iron measurement on the lower lip. This study is focusing on the feasability of a non-invasive detection method. There is no intervention planed. The device is tested once for 3-5 Minutes.
2979365|NCT02701296|Experimental|Posterior capsular injection|Ultrasound guided posterior capsular injection of ropivacaine with epinephrine
2979366|NCT02701296|Active Comparator|Tibial nerve block|Ultrasound selective tibial nerve block of ropivacaine
2979367|NCT02701283|Experimental|Medtronic Transcatheter Aortic Valve Replacement Systems|Treatment of Aortic Stenosis with the Medtronic CoreValve System Transcatheter Aortic Valve Implantation (TAVI) device or the Medtronic Corevalve Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
2979368|NCT02701283|Active Comparator|Surgical Aortic Valve Replacement (SAVR)|Treatment of Aortic Stenosis with commercial Surgical Aortic Valve Replacement (SAVR)
2979369|NCT02701270|Experimental|Experimental Dietary Fibre 1|
2979370|NCT02701270|Experimental|Experimental Dietary Fibre 2|
2979371|NCT02701270|Active Comparator|Polydextrose|
2979372|NCT02701270|Active Comparator|Dextrose control|
2979373|NCT02701257|Active Comparator|iPhone bionic pancreas - Lilly glucagon|iPhone based bionic pancreas using insulin lispro and Lilly glucagon. These visits will be conducted separately from the infusion set sub-study visits.
2979374|NCT02701257|Experimental|iLet bionic pancreas - Lilly glucagon|iLet Bionic Pancreas using using insulin lispro and Lilly glucagon. These visits will be conducted separately from the infusion set sub-study visits.
2979375|NCT02701257|Experimental|iLet bionic pancreas - Xerisol glucagon|iLet Bionic Pancreas using using insulin lispro and Xeris Xerisol glucagon. These visits will be conducted separately from the infusion set sub-study visits.
2979376|NCT02701257|Experimental|iLet infusion set|The infusion set sub-study will be testing just the experimental iLet infusion set in a crossover with the contact detach infusion set. These visits will be conducted separately from the iPhone and iLet bionic pancreas visits.
2979377|NCT02701257|Active Comparator|Contact Detach infusion set|The infusion set sub-study will be testing just the experimental iLet infusion set in a crossover with the contact detach infusion set. These visits will be conducted separately from the iPhone and iLet bionic pancreas visits.
2979378|NCT02701244||Permanent Breast Seed Implant (PBSI)|Women with eligible early stage breast cancer who received a permanent breast seed implant status post lumpectomy
2979379|NCT02701231|Sham Comparator|Sham control|Subjects will receive one cycle of treatment of sham low-frequency rotating magnetic therapy system plus systemic anti-tumor therapy after randomization
2979380|NCT02701231|Experimental|Low-frequency Rotating Magnetic Therapy|Subjects will receive one cycle of treatment of low-frequency rotating magnetic therapy system plus systemic anti-tumor therapy after randomization
2979381|NCT02701218|Experimental|Single cycle|single cycle of canalith repositioning procedure
2979382|NCT02701218|Experimental|multiple cycles of CRP|multiple cycles of canalith repositioning procedure CRP will be stopped if 1) no nystagmus and vertigo in all positions 2) complications exited 3) stable nystagmus in the 2 last cycles
2979383|NCT02701205|Experimental|etanercept|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®) 50mg twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week from Week 12 to Week 24
2979384|NCT02701205|Experimental|etanercept (half dose)|One vial of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®） 25mg and one vial of placebo twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week from Week 12 to Week 24
2979385|NCT02701205|Placebo Comparator|Placebo|Two vials of Placebo twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®) 25mg twice a week from Week 12 to Week 24
2979391|NCT02701153|Experimental|Treatment (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy on Monday-Friday for 5 days. Beginning 2-12 weeks after completion of radiation therapy, patients undergo surgery.
2979392|NCT02701140|Active Comparator|Ticagrelor|Ticagrelor will be given in a loading dose of 180 mg followed by a dose of 90 mg twice daily.
2979393|NCT02701140|Active Comparator|Clopidogrel|Clopidogrel will be given in a loading dose of 600 mg followed by a dose of 75 mg once a day.
2979394|NCT02701127|Active Comparator|Niacinamide 1 gram|Oral niacinamide, 1 gram daily
2979395|NCT02701127|Active Comparator|Niacinamide 3 grams|Oral niacinamide, 3 grams daily
2979396|NCT02701127|Placebo Comparator|Placebo|Oral placebo pill
2979397|NCT02701114|Active Comparator|Proximal|Proximal Adductor Canal Block
2979398|NCT02701114|Active Comparator|Distal|Distal Adductor Canal Block
2979399|NCT02701101|Experimental|Use of SEM scanner daily|Use of SEM scanner daily to assess presence or absence of a Pressure Ulcer
2979400|NCT02701101|Active Comparator|Standard of Care|Use of current gold standard tools for Pressure Ulcer diagnosis Skin and Risk Assessments
2979401|NCT02701088|Experimental|Concomitant chemotherapy and radiotherapy|Chemoradiotherapy with two cycles of 5FU and Mitomycin-C plus radiotherapy by SIB-IMRT (for simultaneous integrated boost intensity modulated radiation therapy) day 1 to day 50 in 36 fractions
2979402|NCT02701075|Experimental|MC5-A Scrambler Therapy|MC5-A Scrambler Therapy is an electroanalgesia device that interferes with pain signal transmission by using nerve fibers as a passive means to convey a no pain message to the central nervous system. Electrodes are placed on dermatomes that correspond to the area of pain. Patient is treated for 30 minutes and given up to 10 treatment sessions.
2979403|NCT02701075|Sham Comparator|MC5-A Scrambler Therapy Sham Device|The MC5-A Scrambler Therapy Device will be used as an active sham device in this randomized double blind study. Participants assigned to this arm will not receive active therapy.
2979404|NCT02701062|Other|LAA Exclusion with AtriClip®|LAA Exclusion with AtriClip®: AtriClip® is used per label and is not experimental.
2979405|NCT02701062|Active Comparator|Medical Management|Medical Management: Standard of Care Oral Anticoagulation Therapy at the discretion of the Investigator.
2979406|NCT02701049|Other|SO/GI Collection|Methods to collect SO/GI information in the ED
2979407|NCT02701036||sporadic adult onset ataxia|SAOA denotes the non-hereditary degenerative adult-onset ataxia disorders that are distinct from multiple system atrophy (MSA). SAOA is a group of ataxia of unknown etiology characterized by a slowly progressive cerebellar syndrome starting around the age of 50 years. Possibly is accompanied by signs of mild autonomic dysfunction that do not meet the criteria of severe autonomic failure required for a diagnosis of MSA.
2979408|NCT02701036||cerebellar multiple system atrophy|Multiple system atrophy of cerebellar type is a cerebellar syndrome with sporadic onset developing in midlife, with autonomic features of otherwise unexplained bladder dysfunction with or without erectile dysfunction in males, orthostatic hypotension and atrophy of the cerebellum, brainstem, and middle cerebellar peduncles.
2979409|NCT02701010|Active Comparator|Group 1|Structured training and leaflet
2979410|NCT02701010|Active Comparator|Group 2|Structured training
2979411|NCT02701010|Active Comparator|Group 3|Leaflet
2979412|NCT02701010|Sham Comparator|Group 4|Control group
2979413|NCT02700997|Experimental|Vascular clip|Application of a clip to dissolvable sutures.
2979414|NCT02700984|Experimental|CyPass Micro-Stent + Cataract Surgery|Subjects who received the CyPass Micro-Stent at the conclusion of their cataract surgery (COMPASS trial)
2979415|NCT02700984|Active Comparator|Cataract Surgery Only|Subjects who did not receive the CyPass Micro-Stent at the conclusion of their cataract surgery (COMPASS Trial)
2979416|NCT02700971|Experimental|Cutaneous Biopsy for microarray analysis|To determine whether outcomes improve as a function of anti-tumor immunity which may enable the use of this technique as a predictive biomarker of treatment response.
2979417|NCT02700958|Experimental|Remote ischemic preconditioning|Remote Ischemic Preconditioning (RIPC) is performed by inflating blood pressure cuff for 5-minutes at 200 mmHg, or if patients systolic blood pressure is higher than 200 mmHg 20 mmHg above systolic pressure, alternated with 5-minute deflation for 4 times.
2979418|NCT02700958|Sham Comparator|SHAM remote ischemic preconditioning|SHAM Remote Ischemic Preconditioning (RIPC-SHAM) is accomplished by alternating 4 cycles of 5-minute inflation with 5-minute deflation. Blood pressure cuff will be inflated to 10-20 mmHg. RIPC-SHAM is performed with standard blood pressure cuff on upper-arm.
2979419|NCT02700945|Active Comparator|Reveal LINQ™ Insertable Cardiac Monitor|Subjects randomized to the Reveal LINQ™ Insertable Cardiac Monitor arm will be continuously monitored via the inserted Reveal LINQ™ device.
2979420|NCT02700945|No Intervention|Control Arm|Subjects randomized to the control arm will be followed per site specific standard of care.
2979421|NCT02700932|Experimental|PicoWay laser treatment|3 wavelength tattoo treatment with picosecond laser (PicoWay)
2979422|NCT02700919|Experimental|Regimen 1|Drug: BCT197 Dose 1, Day 1 to Day 5
2979423|NCT02700919|Experimental|Regimen 2|Drug: BCT197 Dose 2, Day 1 to Day 5
2979424|NCT02700919|Placebo Comparator|Regimen 3|Placebo Day 1 to Day 5
2979425|NCT02700906|Active Comparator|Corticosteroid injection|For corticosteroid injection, triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
2979426|NCT02700906|Active Comparator|Lidocaine injection|For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.
2979427|NCT02700893|Experimental|Atropine + propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants < 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
2979428|NCT02700893|Active Comparator|Atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants < 1000g 0.2 µg/kg for infants > 1000g
2979429|NCT02700880||Heart failure patients with LifeVest|Subjects with ischemic cardiomyopathy and heart failure (including NYHA II, III, IV and an ejection fraction ≤ 35%) who wear a medically prescribed ZOLL LifeVest Wearable Defibrillator
2979430|NCT02700867|Experimental|Proximal tibia|Assumption of intraosseous access into the proximal tibia. Simulation of continous resuscitation was carried out using a system of chest compression LifeLine ARM.
2979431|NCT02700867|Experimental|Proximal humerus|Assumption of intraosseous access into the proximal humerus. Simulation of continous resuscitation was carried out using a system of chest compression LifeLine ARM.
2979432|NCT02700854|Experimental|5% carbon-dioxide inhalation|5% carbon-dioxide will be administered through patient circuits to asphyxiated, cooled, mechanically ventilated newborns at risk for hypocapnia
2979433|NCT02700841|Experimental|Arm I (vaccines, CD34 transplant, DLI)|ARM I: Patients receive XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 SC every 2 weeks for 3 doses before transplant and on days 1, 15, and 30 and tetanus and influenza vaccines IM with the 3rd dose vaccine dose before transplant. Patients receive conditioning regimen comprising high-dose melphalan IV on day -2 and undergo autologous CD34 HSCT on day 0. Patients also receive autologous DLI IV on day 2.
2979434|NCT02700841|Active Comparator|Arm II (vaccines, stem cell transplant)|Patients receive XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 subcutaneously and tetanus and influenza vaccines as in Arm I. Patients receive high-dose melphalan IV on day -2 and undergo AHSCT on day 0.
2979435|NCT02700828|Active Comparator|Hydrocortisone|Hydrocortisone is the pharmaceutical term for cortisol, the principal glucocorticoid secreted by the adrenal gland
2979436|NCT02700828|Placebo Comparator|Placebo|Isotonic sodium chloride is an aqueous solution of 0.9 percent sodium chloride which is isotonic with the blood and tissue fluid
2979437|NCT02700815|Experimental|Diclofenac and capsaicin|Fixed dose combination
2979438|NCT02700815|Active Comparator|Diclofenac|
2979439|NCT02700815|Active Comparator|Capsaicin|
2979440|NCT02700815|Placebo Comparator|Placebo|
2979441|NCT02700802|Experimental|Feed1st: Face-to-face provider delivered referral|In this arm of the study, caregivers will receive usual care and a brief face-to-face referral to the Feed1st program delivered by the provider.
2979442|NCT02700802|Experimental|Feed1st: Text message delivered referral|In this arm of the study, caregivers will receive usual care and an automated brief text message referral to the Feed1st program from the health care provider. The text message referral will align as closely as possible with the face-to-face referral.
2979443|NCT02700802|No Intervention|Standard of Care|Usual care includes passive delivery of information from nursing staff about all available food options in the hospital including the self-serve food pantries in the standard Caregiver FYI Admissions Packet.
2979444|NCT02700789||Pregnant women|Women with a positive urinary pregnancy test following in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) treatment will be invited to attend for an additional transvaginal ultrasound scan at 33-34 days gestation. This will be conducted by a single investigator with experience in early pregnancy ultrasound using a Voluson E8 machine with a high frequency (5-9MHz and 9-12MHz) transvaginal probe and following standard operating procedures.
2979445|NCT02700776||COHORT I-BIRADS 1 or 2,|Phlebotomy - Blood sampling for GP88 and MM. Occurs at months 0 and 6-12.
2979446|NCT02700776||COHORT II -BIRADS 3|Phlebotomy - Blood sampling for GP88 and MM. Occurs at months 0, 3-6, and 6-12.
2979447|NCT02700776||COHORT III-BIRADS 4-6|SOC Tissue Biopsy. Occurs at months 0, 3-6, and 6-12.
2979448|NCT02700763|Experimental|[18F]dabrafenib molecular imaging|A [18F]dabrafenib PET scan will be performed at baseline (7 days or less before the start of treatment with oral dabrafenib).
2979449|NCT02700750|Other|OCT exam|OCT exam No Arm No Intervention
2979450|NCT02700737|Active Comparator|Group A|"Interventional cardiologists presented with limited dataset including only information that is available from imaging parameters currently recommended by clinical practice guidelines."
2979451|NCT02700737|Experimental|Group B|Interventional cardiologists presented with the full dataset, including imaging parameters currently recommended by clinical practice guidelines and image-based simulation modelling.
2979452|NCT02700724|Other|Observation|Patients will not undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Surgery will commence after 12 months of observation or sooner if cystoscopic evidence of disease progression or patient desire.
2979453|NCT02700724|Other|Immediate Surgery|Patients will undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Repeated surgery will be offered for additional recurrences.
2979454|NCT02700711|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance.
2979455|NCT02700711|Experimental|Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on placebo and methylphenidate during duloxetine maintenance.
2979456|NCT02700698||Healthy lean|Healthy lean women, 25-35 years
2979457|NCT02700698||Obese IR|Obese, insulin resistant women, 25-35 years
2979458|NCT02700685|Experimental|Pycnogenol|"Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks.~Subjects < 30 kg body weight: 20 mg Pycnogenol/day Subjects >= 30 kg body weight: 40 mg Pycnogenol/day"
2979459|NCT02700685|Placebo Comparator|Placebo|Placebo treatment (identical capsules containing excipients only)
2979460|NCT02700685|Active Comparator|Methylphenidate|Standard pharmaceutical treatment for ADHD, slow release. Subjects < 30 kg body weight: 20 mg methylphenidate once per day Subjects >= 30 kg body weight: 30 mg methylphenidate once per day
2979461|NCT02700672||Institutionalized older adults|Observational study
2979462|NCT02700672||Non-institutionalized older adults|Observational study
2979463|NCT02700659||UC monitoring patients|"Patients undergoing investigative cystoscopy for the detection of urothelial carcinoma as part of a standard-of-care schedule of investigations.~All patients will have urine samples taken and analyzed for NMP22 ELISA, NMP22 BladderChek, urine cytology and Cxbladder.~No results for any tests under evaluation in this study are provided to the clinician for diagnostic purposes."
2979464|NCT02700646|No Intervention|standard care|Standard care comparison
2979465|NCT02700646|Experimental|inpatient|Inpatient recommendations to parents regarding infant motor activities
2979466|NCT02700646|Experimental|inpatient/outpatient|Inpatient and outpatient recommendations to parents regarding infant motor activities
2979467|NCT02700633||Those with pacemaker at discharge|Landmark analysis of early mortality dependant on pacemaker status at discharge
2979468|NCT02700633||Those without pacemaker at discharge|Landmark analysis of early mortality dependant on pacemaker status at discharge
2979471|NCT02700607|Placebo Comparator|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
2979472|NCT02700607|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
2979473|NCT02700594|Active Comparator|Hip mobilization|Prone posterior-to-anterior Grade IV hip joint mobilization: The subject will be placed in prone on a treatment table. The intervening physical therapist will place the heel of his hand on the greater trochanter of the femur on the involved side provide rhythmic anterior-directed force. The subject will receive 3 bouts of 30 seconds of continuous mobilizations with 10 seconds rest in between bouts. For the prone posterior-to-anterior Grade IV hip joint mobilization, the intervening therapist will perform all 3 bouts in the same position.
2979474|NCT02700594|Active Comparator|Spine mobilization|Prone unilateral posterior-to-anterior Grade IV lumbar spinal joint mobilization: The subject will be placed in prone on the treatment table. The intervening physical therapist will place his thumbs on the transverse process, on the affected side, of the L3, L4 or L5 vertebrae and provide a rhythmic anterior-directed force. Prone unilateral posterior-to-anterior Grade IV lumbar spinal joint mobilization, the intervening therapist will perform 1 bout on each of L3, L4 and L5 for a total of 3 bouts
2979475|NCT02700581|Active Comparator|low PEEP conventional ventilation|PEEP 2 mmHg tidal volume 10ml/kg
2979476|NCT02700581|Experimental|moderate PEEP conventional ventilation|PEEP 7 mmHg tidal volume 10ml/kg
2979477|NCT02700581|Experimental|low PEEP protective ventilation|PEEP 2 mmHg with tidal volume 6 ml/kg
2979478|NCT02700581|Experimental|moderate PEEP protective ventilation|PEEP 7 mmHg tidal volume 6ml/kg
2979479|NCT02700568|Experimental|axitinib|Patients will receive axitinib.
2979480|NCT02700542|Active Comparator|Intervention|"Participants randomly assigned to the intervention group will receive the Integrated Pest Management (IPM) treatment 2-4 weeks of completion of the baseline assessment.The IPM protocol for this research will focus on pest control in the bathrooms and kitchen and will include an assessment of the pest problem, thorough cleaning, patching of small holes, identification and referral of any necessary large repairs, and targeted application of safe pesticides as needed. In cases of severe infestation, a second treatment visit might be required in the home.~In addition to the intervention, the family will be provided with basic information about good pest-control practices, such as appropriate food storage, and be given a set of food storage containers."
2979481|NCT02700542|Placebo Comparator|Control|Participants randomly assigned to the control group will be offered the equivalent intervention, information, and food storage containers after completion of their 12-month assessment.
2979482|NCT02700529|Experimental|ubenimex|ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
2979483|NCT02700529|Placebo Comparator|placebo|matched placebo capsules TID, administered orally for a total of 24 weeks
2979484|NCT02700516||Recurrent GN|Renal transplant recipients with biopsy-confirmed recurrent primary glomerulonephritis.
2979485|NCT02700516||Non-recurrent GN|Renal transplant recipients with non-recurrent primary glomerulonephritis.
2979486|NCT02700516||Non-GN|Renal transplant recipients with etiologies other than primary glomerulonephritis.
2979487|NCT02700503|Experimental|Intervention|Participants will be enrolled in the ENCOURAGE 2.0 family-based diabetes prevention intervention that was designed through our work in Aims 1 and 2 of the study. It is this modified population-level ENCOURAGE 2.0 family-based diabetes prevention intervention that will be studied.
2979488|NCT02700490|Active Comparator|Specialist|Assessment and treatment of common mental disorders by a clinical psychologist in primary care facilities.
2979489|NCT02700490|Experimental|Enhanced Usual Care|Assessment and treatment of common mental disorders by a general practitioner and nurse practitioner, who have been trained in the WHO mhGap manual, in primary care facilities.
2979490|NCT02700477|Active Comparator|Fenugreek seed extract|Fenugreek seeds extract 500 mg capsule twice a day for 12 weeks
2979491|NCT02700477|Placebo Comparator|Placebo|Placebo capsule containing Dicalcium Phosphate 500mg, BD
2979492|NCT02700464|Experimental|Bladder EpiCheck Urine Test|Bladder EpiCheck Urine Test
2979493|NCT02700464|Active Comparator|Gold Standard|Cystoscopy and pathology
2979494|NCT02700451|Placebo Comparator|Intravenous (IV) Placebo|IV Placebo arm
2979495|NCT02700451|Experimental|IV Ketorolac|IV Ketorolac arm
2979496|NCT02700451|Experimental|IV Acetaminophen|IV Acetaminophen arm
2979497|NCT02700438|Active Comparator|Glyceryl trinitrate ointment|Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were purchased from pharmacies. The dosage for all the patients was 375 mg of ointment (containing 1.5 mg of glyceryl trinitrate), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
2979498|NCT02700438|Experimental|Urgent PC Neuromodulation System®|The Urgent PC Neuromodulation System® (Uroplasty, Minnetonka, MN, USA) was used for percutaneous posterior tibial nerve stimulation. Subjects underwent one 30-min session 2 days per week for 8 consecutive weeks in an outpatient clinic. Patients were placed in the supine position without anesthesia. PPTNS was delivered using a needle electrode that was inserted 3-4cm cephalad and 2 cm posterior to the medial malleolus at a 60º angle towards the ankle joint to a depth of approximately 0.5-1cm. Successful placement was confirmed by the presence of electric sensation 5 cm above and below the insertion site or a digital plantar flexion. PPTNS was undertaken at the highest amplification (0-20 mA) at a frequency of 20 Hz, causing neither a motor response nor pain.
2979499|NCT02700425|Active Comparator|His Bundle Pacing|Subjects will be randomized to the HB lead position with their cardiac resynchronization therapy (CRT) pacemaker. HB lead pacing will be performed with the Medtronic SelectSecure™, Model 3830 lead. Delivery of the lead utilizes a deflectable sheath, the Medtronic SelectSite™, Model C304. Both devices are FDA approved for the purpose of HB pacing. It is the only device available which is presently FDA approved for selective HB pacing.
2979500|NCT02700425|Active Comparator|Coronary Sinus Pacing|Subjects will be randomized to the CS lead position with their cardiac resynchronization therapy (CRT) pacemaker. CS lead and CRT device generator selected for implant will be left to the discretion of the operator. Only FDA approved CS leads and CRT generators will be utilized in the study. There are five present manufacturers of CS leads and CRT generators: Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical.
2979501|NCT02700412|Experimental|5 mg/kg/day|The titration of CBD will start with a dose of 5 mg/kg/day given in two divided doses and titrated by 5 mg/kg/2 weeks up to 25 mg/kg/day; in some patients additional titration by 5mg/kg/day every 2 weeks up to 50mg/kg/day may be instituted at the discretion of the PI upon discussion with the Co-PI.
2979502|NCT02700399|Other|Erigo® First|"Erigo® 0 - 60 degrees - Wash out period (min 30 minutes, max 120 minutes) - Traditional Tilt table 0 - 60 degrees~Step frequency on Erigo® = 48"
2979503|NCT02700399|Other|Traditional first|"Traditional Tilt table 0 - 60 degrees - Wash out period (min 30 minutes, max 120 minutes) - Erigo® 0 - 60 degrees~Step frequency on Erigo® = 48"
2979504|NCT02700386|Experimental|Adjuvant Hypofractionated Radiation|"Adjuvant Hypofractionated Radiation (4005 cGy) will last 3-4 weeks with 15 treatments, +/- 4 additional fractions as a boost. Radiation should commence within 180 days of the date of primary surgery. Four additional fractions (a boost or conedown) to areas deemed to be at particularly high risk of recurrence may be added at the end of the radiation course. Fraction size for the boost treatment will continue at 267 cGy for an additional 1068 cGy in four fractions."
2979505|NCT02700373|Experimental|PDC-APB|"PDC-APB Intra-Muscular (IM)~One single dose will be administered with an inpatient direct observational period of 24 hours following the dose, followed by outpatient follow-up for a total of 28 days. After Day 28, the subject will continue to be followed up for study related AE assessments thru Week 24."
2979506|NCT02700373|Placebo Comparator|Placebo|"Placebo~One single dose will be administered with an inpatient direct observational period of 24 hours following the dose, followed by outpatient follow-up for a total of 28 days. After Day 28, the subject will continue to be followed up for study related AE assessments thru Week 24."
2979507|NCT02700360|Experimental|Part 1(1,000mg dose): group 1|period 1: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, after high-fat diet intake; period 2: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, on an empty stomach; cross-over period: 7 days
2979508|NCT02700360|Experimental|Part 1(1,000mg dose): group 2|period 1: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, on an empty stomach; period 2: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, after high-fat diet intake; cross-over period: 7 days
2979509|NCT02700360|Experimental|Part 2(500mg dose): group 3|period 1: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, after high-fat diet intake; period 2: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, on an empty stomach; cross-over period: 7 days
2979510|NCT02700360|Experimental|Part 2(500mg dose): group 4|period 1: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, on an empty stomach; period 2: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, after high-fat diet intake; cross-over period: 7 days
2979511|NCT02700360|Experimental|Part 2(2,000mg dose): group 5|period 1: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, after high-fat diet intake; period 2: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, on an empty stomach; cross-over period: 7 days
2979512|NCT02700360|Experimental|Part 2(2,000mg dose): group 6|period 1: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, on an empty stomach; period 2: EC-18 2,000 mg(500 mg/cap, 4 capsule) once daily, after high-fat diet intake; cross-over period: 7 days
2979513|NCT02700347|Experimental|Low dose pyrazinamide|Day 0: Pyrazinamide 10mg/kg, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 10mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
2979514|NCT02700347|Experimental|Standard dose pyrazinamide|Day 0: Pyrazinamide 25mg/kg single dose, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 25mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
2979515|NCT02700347|Experimental|High dose pyrazinamide|Day 0: Pyrazinamide 35mg/kg single dose, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 35mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
2979516|NCT02700334|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
2979517|NCT02700334|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
2979518|NCT02700321|Experimental|High Flow nasal cannula oxygen (HFNC)|"Patients randomized in HFNC group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ®/Airvo® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction."
2979519|NCT02700321|Active Comparator|STANDARD high flow Face Mask (HFFM)|"Patients randomized in Standard face mask group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction."
2979520|NCT02700308|Active Comparator|Conventional vertebroplasty|Conventional vertebroplasty (device's trade at the discretion of the investigator)
2979521|NCT02700308|Experimental|Kyphoplasty|Vertebroplasty with balloon placement and inflation prior to cement injection (device's trade at the discretion of the investigator)
2979522|NCT02700295||Orthokeratology contact lens group|
2979523|NCT02700282|Experimental|Cystic Fibrosis children|"Children with Cystic Fibrosis will experience lung function measurement while backpack carrying.~Aerobic Capacities will also be assessed during treadmill gait."
2979524|NCT02700282|Active Comparator|Healthy Children|"Healthy Children will experience lung function measurement while backpack carrying.~Aerobic Capacities will also be assessed during treadmill gait."
2979525|NCT02700256||Patients undergoing a procedure|Patients will be asked to complete a baseline survey after enrollment. After surgery, enrollees who opt for the email/online access will receive an email upon discharge with a link to the WebCore site. Email will be sent at 9 am on postoperative day (POD) 2 to the email address the patient provided at consent. On post-operative days 2 through 6 the patient will be asked to complete a symptom inventory, they will receive an email with a link to the WebCore website, where they will be able to complete that day's survey. Enrollees who opt for the automated phone calls will complete their surveys via Interactive Voice Response (IVR), which will be automatically set-up to call the patient at 9 am on POD 2. Patients will complete phone surveys daily for 5 days. If the first phone call does not connect to the patient, a second phone call will be made at 10:00am. If the second call is unsuccessful a third & final call for that day will be placed at 11:00am.
2979526|NCT02700243|Experimental|Fitbit|Participants receive a Fitbit and are followed over the course of one year, completing surveys and exercise tests.
2979527|NCT02700243|No Intervention|Usual Care|Participants receive usual care over the course of one year and are offered a Fitbit in the second year. Followed to assess use of Fitbit and health outcomes.
2979528|NCT02700230|Experimental|Treatment (MV-NIS)|Patients receive MV-NIS intratumorally on day 1. Patients also undergo SPECT/CT at baseline and at 3 and 8 days after MV-NIS. Patients may also undergo SPECT/CT at 15 and 28 days, and at 6 weeks based on whether there is uptake on prior imaging studies.
2979529|NCT02700217|Experimental|Spinal Anaesthesia|2.5ml of heavy 0.5% Bupivacaine, 400mg of Diamorphine (Spinal Anaesthesia) & IV infusion of Remifentanil 0.2-0.3ug/kg/min, Propofol 2-3mg/kg and 0.2 mg/kg of Cistracurium (General Anaesthesia)
2979530|NCT02700217|Active Comparator|Rectus Sheath Injection|50ml of 0.25% I-Bupivacaine max 2mg/kg (IV block Anaesthesia) injected into rectus sheath bilaterally & IV infusion of Remifentanil 0.2-0.3ug/kg/min, Propofol 2-3mg/kg and 0.2 mg/kg of Cistracurium (General Anaesthesia)
2979531|NCT02700204|Experimental|PicoWay 532nm fractional treatment|subjects will receive one treatment for peri auricular and/or Buttocks by 532nm hand-piece
2979532|NCT02700204|Experimental|PicoWay 1064nm fractional treatment|subjects will receive one treatment for peri auricular and/or Buttocks by 1064nm hand-piece
2979533|NCT02700191|No Intervention|Control|For subjects in the Control arm, the parameters measured by the (µ-Cor) µ-Cor system will not be analysed or made available to the investigator.
2979534|NCT02700191|Experimental|uCor|For subjects in the Interventional arm, all of the parameters measured by the (µ-Cor) µ-Cor system will be available to the investigator and will remain blinded to the subjects. The investigator will use µ-Cor information to aid in therapy adjustment decisions during the study period.
2979535|NCT02700178|Experimental|Biofeedback|Participants will be asked to participate in all or a subset of daily activities for wheelchair users. The intervention will consist of visual and/or auditory cues to guide their movement while performing the tasks during one to two sessions.
2979536|NCT02700165|Experimental|Fat Reduction|The treatments are designed to see if the fat, on the submandibular submental (chin), can be reduced.
2979537|NCT02700152|Experimental|all subjects|"Eligible subjects will receive 3 treatments, 2 weeks interval, with the UltraShape device according to the study protocol and user manual.~The subject will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment, for total expected study duration of 16 weeks"
2979538|NCT02700139|Experimental|Aspheric lens|An aspheric lens which is supposed to slow myopic progression in children by unique asphericity (proprietary information)
2979539|NCT02700139|No Intervention|Single vision spheric/toric lenses|Control: single vision spheric/toric lenses
2979540|NCT02700126||undergoing propofol based TIVA for clip|This study is an observational study performed in adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm. We will collect data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions. Data collection will be established with just observing and recording values displayed in screens of monitoring devices, and reviewing patient charts.
2979541|NCT02700113||ASD|There is only one group; minimally verbal individuals with Autism Spectrum Disorder aged 4 to 17 years.
2979542|NCT02700100|Experimental|Pulmonary Valved Conduit (PV-001)|Bioabsorbable Pulmonary Valved Conduit (PV-001) implantation through open surgery.
2979543|NCT02700087|Placebo Comparator|H2 blocker versus placebo|"The patient will then be randomly placed in the control group (placebo) or the intervention group (ranitidine 2mg/kg every 12 hours or famotidine 0.5 mg/kg daily).~Patients will stay on medication for a minimum of 6 months, or until symptoms resolve. Patients will be seen in follow up at 1, 2, 3, 4, 5, 6, 8 and 10 months. At which time I-GERQ, ASQ and weights will be taken. The primary outcome measure will be the time for the ASQ score to drop to normal on ranitidine or famotidine versus placebo."
2979544|NCT02700087|Active Comparator|Treatment arm|Patients who develop severe airway symptoms while they are in the H2 blocker versus placebo arm will then cross over to the treatment arm of the study. These patients will exit randomization and be unblinded. These patients will all be given H2 blockers, and the effects of the H2 blockers will be monitored and studied. Alternatively, patients' families may also elect to undergo surgery to treat laryngomalacia.
2979545|NCT02700074||Minimally Verbal|Minimally verbal adolescents with Autism Spectrum Disorder
2979546|NCT02700074||Verbal Impaired|Language impaired adolescents with ASD
2979547|NCT02700074||Verbal Normal|Language normal adolescents with ASD
2979548|NCT02700074||Typically Developing|Typically developing adolescent controls
2979549|NCT02700061|Experimental|Induced Constraint Therapy - ICT|Physical rehabilitation with Induced Constraint Therapy as part of the occupational therapy. Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
2979550|NCT02700061|Experimental|Robotic occupational therapy|Physical rehabilitation with Robotic occupational therapy. Robotic Occupational Therapy three times a week for twelve weeks.
2979551|NCT02700048|Placebo Comparator|Placebo|3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
2979552|NCT02700048|Experimental|Treatment with intra-nasal Naloxone|3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
2979553|NCT02700035|Experimental|BZDDD Prevention Program Intervention|We will employ an experimental randomized block (RB) design; blocked on reservation where 300 families will be assigned to the intervention condition (Bii-Zin-Da-De-Dah (Listening to One Another) 14 week family based prevention program). The first 4 weeks of the program are oriented towards the Anishinabe cultural traditions and the traditional Anishinabe family. Weeks 5 through 8 focus on identifying feelings and how to manage negative feelings such as anger and sadness in positive ways. The last 6 weeks of the program focus on outside influences and how to build positive support systems. Prior to the intervention we will complete a pre-test with families in the experimental group. Following the program, we will complete post-tests and 6 month follow-ups for a period of 36 months.
2979554|NCT02700035|No Intervention|BZDDD Prevention Program Control|We will employ a randomized block (RB) design; blocked on reservation, 300 families will be randomly assigned to the control condition. We will complete pre-tests, post-tests, and 6 month follow-ups for 36 months.
2979728|NCT02698761|No Intervention|Standard of Care|Patient will receive standard of care. Subject will have an actiwatch to compare activity and sleep habits. Nursing staff will be aware of study presence but will not receive any specific instruction for the patient.
2979555|NCT02700022|Experimental|Alisertib combined with R-EPOCH|Dose escalation will take place within cohorts. Subjects will receive alisertib tablets twice daily in combination with R-EPOCH chemotherapy on days 1 through 5 of each 21-day cycle. The treatment will be given in 6 cycles. The first 3 patients to be enrolled will receive a 20 milligram (mg) dose of alisertib. The dose of alisertib will be increased or decreased as more subjects enter the study. Each dose level will be evaluated for safety and tolerability before the next higher dose is given. The dose levels will be modified until the maximum tolerated dose (MTD) is reached. Once the MTD has been established, enrollment into that cohort will continue with up to a maximum of 24 patients total enrolled into the study.
2979556|NCT02700009|Experimental|Computer-assisted CBT (CCBT)|12 weeks of CCBT for depression
2979557|NCT02700009|Active Comparator|Treatment as Usual (TAU)|Treatment as usual by primary care physicians
2979558|NCT02699996|Experimental|Arm I (PSST program)|"PHASE 1: Participants (providers, survivors, and caregivers) complete a 60 minute interview to help adapt PSST to focus on AYA self-management of care.~PHASE 2: Patients complete the adapted PSST peer mentoring intervention comprising a videoconference or phone call with the peer mentor followed by secure text messaging weekly for 4 weeks and then monthly for 2 months."
2979559|NCT02699996|Active Comparator|Arm II (brochures, general health tips)|"PHASE 1: Participants (providers, survivors, and caregivers) complete a 60 minute interview to help adapt PSST to focus on AYA self-management of care.~PHASE 2: Patients receive tailored survivorship educational materials from the Children's Oncology Group patient education Health Links as well as a brochure with self-management strategies entitled: Moving Into Adult Health Care: A Guide for Young Adults With and Without Disabilities via email or postal mail. Patients also receive general health tips (e.g., exercise and nutrition recommendations) via text message weekly for 4 weeks and then monthly for 2 months."
2979560|NCT02699983|Experimental|Group I (SparkPeople program)|Patients receive one 30-minute session with the research assistant for training on how to use the SparkPeople website, and may request additional training if needed. Patients are instructed to self-monitor their diet at least weekly using SparkPeople and physical activity levels daily using the Fitbit monitoring device, which integrates with the SparkPeople program. Patients receive weekly motivational reminders to log into the website for 3 months via email, text, or phone, based on patient preference (active phase). Patients then enter the maintenance phase for an additional 3 months without reminders.
2979561|NCT02699983|Active Comparator|Group II (wait list)|Patients receive the weight loss handout and a Fitbit health monitoring device and proceed with their usual life. After 6 months, patients receive the SparkPeople treatment as in Group I.
2979562|NCT02699970||Selected features|
2979563|NCT02699957||Atrial Fibrillation|Those patients with the condition of atrial fibrillation.
2979564|NCT02699944|Experimental|CRT sub-optimal responder|Subjects who have had CRT for at least 6 months and who have not responded as well as they could, in their cardiologists opinion. Subjects' ejection fraction are still <50% despite CRT. A ECG Vest Optimization protocol will be utilized as one aspect to determine the best CRT programming for each individual subject.
2979565|NCT02699931|Experimental|Electric3D|3D electric toothbrush (Oral-B) with orthodontic head.
2979566|NCT02699931|Active Comparator|Manual|Manual orthodontic toothbrush (Oral-B).
2979567|NCT02699918|Experimental|screening oxymetry|nocturnal oxymetry to screen for sleep apnea
2979568|NCT02699905||Sepsis|Patients with the diagnosis of sepsis or septic shock
2979569|NCT02699905||Control|Healthy control with no evidence of active infection, or recent infection in the past 4 weeks.
2979570|NCT02699892||Rheumatoid arthritis participants|Participants who were on rituximab for rheumatoid arthritis and who will continue receiving rituximab treatment (at the discretion of treating physician) according to previous approved indication will be observed for a period of 72 weeks.
2979571|NCT02699879||Pirfenidone|Participants will receive pirfenidone orally according to the physician discretion.
2979572|NCT02699866|Experimental|BLT Implant Ø 2.9 mm|The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.
2979573|NCT02699853|Experimental|Arm I (RRC)|Patients undergo RRC at day 0.
2979574|NCT02699853|Experimental|Arm II (ORC)|Patients undergo ORC at day 0.
2979575|NCT02699840||Menactra Study Group 1|Participant aged 2 through 11 years at vaccination
2979576|NCT02699840||Menactra Study Group 2|Participant aged 12 through 17 years at vaccination
2979577|NCT02699840||Menactra Study Group 3|Participant aged 18 through 55 years at vaccination
2979578|NCT02699827|Active Comparator|Magnesium sulphate group|Patients will receive epidural levobupivacaine hydrochloride + magnesium sulphate
2979579|NCT02699827|Placebo Comparator|Placebo group|Patients will receive epidural levobupivacaine hydrochloride + saline 0.9%
2979580|NCT02699814|Experimental|H3 Parent/Child Dyads|A child is eligible for the H3 partnered evaluation if he or she is: 1) between the ages of 0.0-16.99 years; 2) speaks Spanish or English; 3) screens positive for a developmental delay or mental health problem. For children in the intervention groups, the additional eligibility criteria are: 1) referral to the H3 care program by a pediatrician based on clinical judgment; and 2) no prior history of receiving any H3 services in the past year.
2979581|NCT02699801|Active Comparator|Propofol|Patients received propofol for post-operative sedation
2979582|NCT02699801|Active Comparator|Dexmedetomidine|Patients received dexmedetomidine for post-operative sedation
2979583|NCT02699788|Experimental|Multifunction Cardiogram|non-invasive computerized, multiphase, resting electrocardiogram analysis device
2979584|NCT02699775||Chronic spastic stroke patients|Chronic spastic stroke patients treated regularly with botulinum toxin injection in lower limb muscles
2979585|NCT02699762|Experimental|experimental group|self rehabilitation of upper limb in experimental group + BTI + usual physiotherapy
2979586|NCT02699762|No Intervention|control group|BTI + usual physiotherapy
2979599|NCT02699710|Experimental|Part 1: GDC-0853, Rabeprazole (Fasting State)|Participants will receive single dose of GDC-0853 (200 milligrams [mg]) in a crossover design as either the capsule or tablet formulation in the fasted state with the final fixed treatment consisting of the tablet formulation administered in the fasted state after prior administration of rabeprazole (20 mg twice daily [BID]) for 3 days.
2979758|NCT02698527|Active Comparator|Non-Buffered Lidocaine|Vulvar biopsy conducted using non-buffered lidocaine as anesthesia
2985182|NCT02662101|Experimental|Single arm, exsalt application|
2979587|NCT02699749|Experimental|TAK-931|"TAK-931 30 mg, capsules, orally, QD or BID on Days 1-14 of each 21-day treatment cycle in dosing schedule A followed by dosing schedule B, C, D, E and F. In dosing schedules B through F, starting doses and dosing escalations will vary depending on the dosing data obtained from dosing in the previous schedule.~Dose escalation of TAK-931 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data. 3-4 dose cohorts are expected for each dosing schedule.~If the PK from the early cohorts support twice-daily (BID) dosing, then study drug administration in subsequent cohorts may transition to a BID dosing schedule."
2979588|NCT02699736||Cohort I|Enrolled from August 1994. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2979589|NCT02699736||Cohort II|Enrolled from January 1996. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2979590|NCT02699736||Cohort III|Enrolled from February 1997. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2979591|NCT02699736||Cohort IV|Enrolled from March 1999. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). The eligibility criteria of a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion has been removed for patients joining the study in 1999 and beyond, since the intention of the study is to include most patients eligible for antiretroviral therapy. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2979592|NCT02699736||Cohort V|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2979593|NCT02699736||Cohort VI|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2979594|NCT02699736||Cohort VII|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2979595|NCT02699736||Cohort VIII|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2979596|NCT02699736||Cohort IX|Enrolled from December 2011. Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2979597|NCT02699736||Cohort X|All patients should be consecutive patients (except those already enrolled in EuroSIDA), or patients who had a scheduled visit (i.e. those who made an appointment >2 weeks prior to their visit) in the outpatient clinic regardless of cluster of differentiation 4 (CD4) cell count and ART status). Enroll patients of 16 years or older and positive for antibodies against hepatitis C virus (regardless of HCV-RNA status, fibrosis stage and prior treatment against hepatitis C). For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2979598|NCT02699723|Experimental|Treatment (arsenic trioxide, itraconazole)|Patients receive arsenic trioxide PO and itraconazole PO daily for 50 days, followed by maintenance therapy consisting of 2 weeks off treatment and then 2 weeks on treatment for up to 6 months in the absence of disease progression or unacceptable toxicity.
2979668|NCT02699216|Experimental|Phase 1 Active Treatment|Subjects will undergo 8 treatments, approximately 11 minutes, to the enrolled eyes daily for three consecutive days, with an active device. They will receive no treatments on day 4 and 5.
2979600|NCT02699710|Experimental|Part 2: GDC-0853, Rabeprazole (Fasting or Fed State)|Participants will receive single dose of GDC-0853 (200 mg) tablet formulation in the fasted or fed state in a crossover design with the final fixed treatment consisting of the tablet formulation administered in the fed state after prior administration of rabeprazole (20 mg BID) for 3 days.
2979601|NCT02699710|Experimental|Part 3: GDC-0853, Methotrexate|Participants will receive single dose of methotrexate (7.5 mg) under fasting conditions on Day 1 (5 mg folic acid will be administered the following day [Day 2]) and then GDC-0853 (200 mg) tablet formulation twice daily (BID) under fasting conditions (an overnight fast for the morning dose and a 2 hour fast for the evening dose) from Days 15 to 20 after washout period from Days 2 to 14. On Day 21, participants will receive single dose of methotrexate (7.5 mg) with single dose of GDC-0853 (200 mg) tablet formulation under fasting conditions, and folic acid (5 mg) will be administered on Day 22.
2979602|NCT02699697|Experimental|ARM I (palliative radiation therapy)|Patients undergo 1 fraction of EBRT over 30 minutes.
2979603|NCT02699697|Experimental|ARM II (palliative radiation therapy)|Patients undergo 2 fractions of EBRT over 30 minutes. The 2 fractions will be separated by 3-7 days.
2979604|NCT02699684|Other|AOHG, then AOA|Lotrafilcon B contact lenses with EOBO-41 worn first, followed by lotrafilcon B contact lenses worn second. Both products worn bilaterally (in both eyes) for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.
2979605|NCT02699684|Other|AOA, then AOHG|Lotrafilcon B contact lenses worn first, followed by lotrafilcon B contact lenses with EOBO-41 worn second. Both products worn bilaterally for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.
2979606|NCT02699671||acute myocardial infarction|
2979607|NCT02699658|Experimental|levofloxacin in healthy|
2979608|NCT02699645|Experimental|Triple Pill (active treatment)|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;
2979609|NCT02699645|Placebo Comparator|Placebo|received via blinded study capsules
2979610|NCT02699619|Active Comparator|2 Hansson pins without plate|Patients with undisplaced femoral neck fractures operated with 2 isolated Hansson pins.
2979611|NCT02699619|Active Comparator|3 Hansson pins interlocked in a plate|Patients with undisplaced femoral neck fractures operated with 3 Hansson pins interlocked in plate (Pinloc).
2979612|NCT02699606|Experimental|Erdafitinib|Participants will receive a 8 milligram (mg) starting dose once daily with option to up-titrate to 9 mg on a 28-day cycle. The dose of study drug may be modified, delayed, or terminated based on guidelines provided in the protocol.
2979613|NCT02699593|Experimental|Test / Control Sequence|Subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality.
2979614|NCT02699593|Active Comparator|Control / Test Sequence|Subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality.
2979615|NCT02699580|Experimental|Biodegradable collagen implant|Both eyes are needed to correct strabismus. One eye is randomly selected for the placement of biodegradable collagen implant.
2979616|NCT02699580|Active Comparator|Without biodegradable collagen implant|Strabismus surgery is done without placing of biodegradable collagen implant in the other eye.
2979617|NCT02699567||Lean AA|Subjects with a BMI<=25 kg/m2 and carriers of a CD36 gene variation associated with low CD36 expression levels
2979618|NCT02699567||Obese AA|Subjects with a BMI>29.9 kg/m2 and carriers of a CD36 gene variation associated with low CD36 expression levels
2979619|NCT02699567||Lean GG|Subjects with a BMI<=25 kg/m2 and carriers of a CD36 gene variation associated with high CD36 expression levels
2979620|NCT02699567||Obese GG|Subjects with a BMI>29.9 kg/m2 and carriers of a CD36 gene variation associated with high CD36 expression levels
2979621|NCT02699554||Orthopaedic surgery|
2979622|NCT02699541|Experimental|Intervention group|Intervention group participants will receive the educational intervention based on the Information, Motivational, Behavioral change model.
2979623|NCT02699541|No Intervention|Control group|Control group participants will receive usual care treatment and referral to diabetes educational consultation if required.
2979624|NCT02699515|Experimental|MSB0011359C (M7824)|
2979625|NCT02699502|Experimental|patients with osteoporotic hip fractures|The intervention includes matching an appropriate drug to patients with hip fractures. All the relevant parameters regarding the patients with osteoporotic hip fractures will be reviewed (age, kidney function, previous treatment) and an appropriate anti osteoporosis medication will be determined. A recommendation regarding treatment will be sent to the local regulatory authorities, which will send the approved recommendation the the family physician.
2979626|NCT02699489|Experimental|Laparoscopic donor nephrectomy arm|This group will undergo laparoscopic donor nephrectomy
2979627|NCT02699489|Active Comparator|Open donor nephrectomy arm|This group will undergo open donor nephrectomy
2979628|NCT02699476|Active Comparator|Individual + Computer A|Daily activities involve playing one hour of computer games (e.g., hangman, boggle, word scramble, chess; computer cognitive training A (CCA)), and two (2) 90 minute individual training sessions interacting one-on-one with a trainer in a variety of cognitive tasks including attention, memory, and comprehension of information.
2979629|NCT02699476|Experimental|Individual + Computer B|Daily activities involve playing an alternative set of computer games (computer cognitive training B (CCB)), and two (2) 90 minute individual training sessions interacting one-on-one with a trainer in a variety of cognitive tasks including attention, memory, and comprehension of information.
2979630|NCT02699476|Active Comparator|Group + Computer B|Daily activities involve group and individual cognitive therapy discussions on health, nutrition, and other topics and computer cognitive training B (CCB).
2979631|NCT02699463|Active Comparator|Continous Positive Airway Pressure|Participants in this group will use CPAP therapy, nightly, for the 3 month duration of the trial
2979632|NCT02699463|Placebo Comparator|Control Group|Participants will receive standard care (Sleep hygiene counseling) during the study.
2979724|NCT02698813|Experimental|UCMSCs-HA|Multipoint of Transdermal injection into the wrinkles. Injectable filler agent composed of umbilical cord mesenchymal stem cells (UCMSCs) and hyaluronic acid (HA).
2979633|NCT02699450|Active Comparator|Arm A: 0.3 mg Ranibizumab|Participants will receive 0.3 milligrams (mg) ranibizumab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
2979634|NCT02699450|Experimental|Arm B: 1.5 mg RO6867461|Participants will receive 1.5 mg RO6867461 every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
2979635|NCT02699450|Experimental|Arm C: 6 mg RO6867461|Participants will receive 6 mg RO6867461 every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
2979636|NCT02699437||Pregnant women with preeclampsia|Testing for antiphospholipid antibodies (anticardiolipin antibodies and lupus anticoagulant) will be performed in pregnant women with preeclampsia.
2979637|NCT02699424|Other|Radiotherapy|
2979638|NCT02699411|Active Comparator|dry needling|Dry needling on the vastus is performed in patients undergoing ACL fortnight after the intervention and then evaluated. REL dry needling while supplies last twenty insertions before treatment, at midnight, a week and five weeks.
2979639|NCT02699411|Active Comparator|Stability and propioception|Proprioception and stability exercises in patients undergoing ACL fortnight after the intervention and then evaluates performed before treatment, at midnight, a week and five weeks.
2979640|NCT02699398|Experimental|VR-based therapy|3 weeks of home-based treatment for motor training using a virtual reality rehabilitation setup.
2979641|NCT02699398|Active Comparator|Control|3 weeks of home-based occupational therapy for motor training.
2979642|NCT02699385|Experimental|Oral Rehydration Therapy (ORT) + Domperidone|Each participants will initiate ORT in the physician's office and domperidone 0.25 milligram per kilogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
2979643|NCT02699385|Experimental|Oral Rehydration Therapy + Placebo|Each participants will initiate ORT in the physician's office and placebo oral suspension thrice daily for up to 7 days.
2979644|NCT02699372|Placebo Comparator|Placebo|Healthy volunteers will receive the placebo equivalent to RO6889450 as oral capsules.
2979645|NCT02699372|Experimental|RO6889450: Part 1 Single Ascending Dose (SAD)|Participants will undergo a series of screening visits prior to treatment and 4 weeks follow-up. Healthy volunteers will be enrolled in up to 7 dose groups (5 milligram [mg] to 450 mg) and will receive single oral dose of RO6889450 in the morning of the Day 1.
2979646|NCT02699372|Experimental|RO6889450: Part 2 Multiple Ascending Dose (MAD)|The starting dose for Part 2 MAD will be determined by analysis of safety and pharmacokinetic data of Part 1 SAD. All participants will receive RO6889450 orally for 14 days.
2979647|NCT02699359|Experimental|HS-1000 recording|Study participants will receive HS-1000 ICP readings for a continuous 16 minute interval in a 30 degree supine position. Recordings will be obtained in one session. When possible, these recordings will be obtained at their initial examination and all follow-up visits. Sports Medicine staff will coordinate the HS-1000 device earplug insertion and recordings so as not to interfere with, nor marginally delay the patient's normal, routine clinical evaluation.
2979648|NCT02699346|Experimental|HS-1000 recording|Eligible patients and healthy subjects will be enrolled into the study and HS-1000 headset portion of the device will be placed in their ears. HS-1000 monitoring intervals will last from 20 minutes continuously. Following completion of data collection, HS-1000 will be removed.
2979649|NCT02699333||Microscopic colitis cases|Patients found to have microscopic colitis based on colonic biopsies.
2979650|NCT02699333||Controls|Patients who meet eligibility requirements but do not have microscopic colitis on biopsy.
2979651|NCT02699320||"Asymptomatic"|"Asymptomatic meaning patients showed well tolerance to parenteral nutrient (PN) administration and there were no complications occurred within two months (n=7);"
2979652|NCT02699320||CLABSI|with central catheter-related blood stream infections (CLABSI) meaning patients had fever, increased neutrophils, documented positive catheter blood culture but exclude other source of infection (n=5)
2979653|NCT02699320||PNALD|with parenteral nutrient associated liver disease (PNALD), meaning SBS patients showed elevated liver enzymes and bilirubin (n=14).
2979654|NCT02699320||healthy controls|Seven healthy infants who had added complementary were served as controls (n=7).
2979655|NCT02699307|Experimental|Intervention|OT-led counseling based on home activity pattern
2979656|NCT02699294|Experimental|Contract-relax PNF stretch|A contract-relax PNF stretching techniques of the pectoralis minor muscle including latent trigger points will be applied by Group 1 after a single intervention of manual pressure release will be performed according to the techniques describe by Simons et al. (1999).
2979657|NCT02699294|Experimental|Z-stretch|The Z- stretch of the pectoralis minor muscle including latent trigger points will be applied by Group 2 after a single intervention of manual pressure release will be performed according to the techniques describe by Simons et al. (1999).
2979658|NCT02699294|Experimental|Manual pressure release|The single intervention of manual pressure release will be only applied to Group 3 according to the techniques describe by Simons et al. (1999).
2979659|NCT02699294|No Intervention|Control|This is a control group.
2979660|NCT02699281|Experimental|Ultra-micronized Palmitoylethanolamide|Ultra-micronized Palmitoylethanolamide 600 mg twice a day
2979661|NCT02699281|Placebo Comparator|Placebo|Placebo tab twice a day
2979662|NCT02699268||Infants (term borns and preterm borns)|Intervention: simultaneous lung function measurement using VoluSense Pediatrics and a mask-based method with an ultrasonic flowmeter (EcoMedics Exhalyzer)
2979663|NCT02699242|Experimental|Simulator arm|In the Simulation arm group the subjects will be trained on the virtual reality bronchoscopic simulator (ORSIM simulator) for up to 60 minutes as active intervention, before they undertake the 2nd Fiber optic intubations.
2979664|NCT02699242|No Intervention|Control arms|The control arm will be exposed only to the didactic teaching. The subjects will not undergo simulator training before undergoing 2nd fiber optic intubations.
2979665|NCT02699229||Malignant|Tissue sample
2979666|NCT02699229||Benign|Tissue sample
2979667|NCT02699229||Normal|Tissue Sample
2979669|NCT02699216|Placebo Comparator|Phase 1 Sham Treatment|Subjects will undergo 8 sham treatments, approximately 11 minutes, with a non-functional device to the enrolled eyes daily for three consecutive days during week 1, with no treatments on day 4 and 5. Followed by 8 active treatments, for approximately 11 minutes, for three consecutive days, with an active device during week 2, with no treatments on day 4 and 5.
2979670|NCT02699216|Experimental|Phase 2 Open Label|Subjects will undergo 8 treatments, approximately 11 minutes, to the enrolled eyes daily for three consecutive days, with an active device. They will receive no treatments on day 4 and 5.
2979671|NCT02699203|Experimental|High-carbohydrate meal|High carbohydrate breakfast meal consisting of oatmeal and berries.
2979672|NCT02699203|Experimental|Low-carbohydrate meal|Low carbohydrate breakfast meal consisting of eggs and avocado.
2979673|NCT02699190|Active Comparator|Standard Clinical Care followed by WGS|"Subjects will continue to receive standard clinical care according to existing algorithms based on MRI pattern recognition and will receive clinically indicated testing as considered appropriate by the expert clinician. This may include further clinical diagnostic testing as ordered by a neurologist or geneticist with specialized experience in leukodystrophy. The diagnostic testing must not include NGS (WES or WGS), though enzymatic assays, analytic testing, or sequencing by single or targeted panels will be permitted.~Crossover to Experimental Arm will occur if no diagnosis has been achieved within four (4) months of study enrollment."
2979674|NCT02699190|Experimental|Immediate WGS|Participants will undergo immediate WGS-based testing in a CLIA/CAP-certified laboratory. This testing will include tiered analysis of leukodystrophy associated genes, as defined by those disorders characterized by experts as resulting in leukodystrophies or genetic leukoencephalopathies. These results will be filtered for structural and copy number variations, and followed-up with comprehensive analysis of novel genes in coding regions if participants remain unsolved.
2979675|NCT02699177||Suspected PCD but negative|"CBF measurements:~Patients with suspected PCD will have their nasal cavity photographed using a Sony-video camera that will record the reflected light of a green LED bulb.Ciliary beat frequency (CBF) will be calculated by interferometry using a program developed by the PI.~Patients will undergo a nasal brush biopsies. The fresh biopsies will be analyzed by high-speed video microscopy to calculate CBF.~The two methods will be compared."
2979676|NCT02699177||Suspected PCD but positive|"CBF measurements:~Patients with suspected PCD will have their nasal cavity photographed using a Sony-video camera that will record the reflected light of a green LED bulb.Ciliary beat frequency (CBF) will be calculated by interferometry using a program developed by the PI.~Patients will undergo a nasal brush biopsies. The fresh biopsies will be analyzed by high-speed video microscopy to calculate CBF.~The two methods will be compared."
2979677|NCT02699164|Experimental|combine group|"Conventional physiotherapy applied 15 sessions of treatment. In addition to conventional physiotherapy non-surgical spinal decompression therapy applied.~First 10 sessions of treatment non-surgical decompression therapy applied and last 5 sessions spinal stabilization exercise applied."
2979678|NCT02699164|Experimental|conventional physiotherapy|conventional physiotherapy applied 15 sessions of treatment. Conventional physiotherapy consisted hotpack, Transcutaneal Electric Nerve Stimulation(TENS) and Ultrasound Currents. Spinal stabilization exercises applied last five sessions of therapy.
2979679|NCT02699138|Experimental|Trazodone|To determine effect of trazodone on quality of sleep as measured by apnea hypopnea index in subjects with obstructive sleep apnea and PTSD on routine overnight polysomnogram.
2979680|NCT02699138|Placebo Comparator|Placebo|To compare placebo outcomes against administration of trazodone
2979681|NCT02699125|Placebo Comparator|guanfacine|Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.
2979682|NCT02699125|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
2979683|NCT02699099|Experimental|Coad group|Children randomized to receive Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and YF vaccine and a combined measles and rubella vaccine at 9 months of age. Children will receive a booster dose of SB257049 vaccine 18 months post Dose 3 (i.e. at 27 months of age)
2979684|NCT02699099|Experimental|RTS,S group|Children randomized to receive Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and YF vaccine and a combined measles and rubella vaccine at 10.5 months of age. Children will receive a booster dose of SB257049 vaccine 18 months post Dose 3 (i.e. at 27 months of age)
2979685|NCT02699099|Experimental|Control group|Children randomized to receive Vitamin A at 6 months of age and YF vaccine and a combined measles and rubella vaccine at 9 months of age. These children will receive SB257049 vaccine at 10.5, 11.5 and 12.5 months of age plus a booster dose 17.5 months post Dose 3 (i.e. at 30 months of age), so they can benefit from the same protection as children from the Coad and the RTS,S groups
2979686|NCT02699086|Experimental|2 PDC-1421 Capsule|2 PDC-1421 Capsule trice daily, p.o. after meal for 56 days
2979687|NCT02699086|Experimental|1 PDC-1421 Capsule plus 1 placebo|1 PDC-1421 Capsule plus 1 placebo trice daily, p.o. after meal for 56 days
2979688|NCT02699086|Placebo Comparator|2 placebo|2 placebo trice daily, p.o. after meal for 56 days
2979689|NCT02699073|Experimental|Regorafenib|dose of regorafenib : 160mg once daily
2979690|NCT02699047|Experimental|Fish oil|3.6 g/day of the encapsulated fish oil (2 capsules/day) providing 1.55 g/d of the n-3 polyunsaturated fatty acids (EPA and DHA) during 9 weeks
2979691|NCT02699047|Placebo Comparator|Control group|3.2 g/day of the olive oil (2 capsules/day) without n-3 polyunsaturated fatty acids
2979692|NCT02699034|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device ( Vision-MR ablation catheter )
2979693|NCT02699008|Active Comparator|HPR-Ticagrelor row|ACS patients aftergoing PCI treated with clopidogrel and aspirin were included. in the 3-5th day after prescription of clopidogrel, platelet function were tested simultaneously by three methods: Light transmittance aggregometry（LTA）, Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA>50%;MAADP>47mm;CTP2Y<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
2979725|NCT02698813|Active Comparator|Control|Procedure: Transdermal injection of hyaluronic acid only.
2979726|NCT02698800|Experimental|Blue blocking (BB)|Wearing of BB lenses.
2979727|NCT02698800|Placebo Comparator|Clear|Wearing of clear lenses
2979694|NCT02699008|Active Comparator|HPR-Clopidogrel row|Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA>50%;MAADP>47mm;CTP2Y<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
2979695|NCT02699008|Active Comparator|unHPR row|Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA>50%;MAADP>47mm;CTP2Y<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
2979696|NCT02698995|Placebo Comparator|Group A|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+1 ml saline=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
2979697|NCT02698995|Active Comparator|Group B|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+2 mg dexamethasone=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
2979698|NCT02698995|Active Comparator|Group C|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+4 mg dexamethasone=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
2979699|NCT02698982|Experimental|Monitoring|Elderly scheduled for moderate risk surgery Depth of anesthesia monitoring and Continuous non invasive blood pressure monitoring accessible to the anesthesia provider.
2979700|NCT02698982|Sham Comparator|Sham|Elderly scheduled for moderate risk surgery Depth of anesthesia monitoring and Continuous non invasive blood pressure monitoring blinded to the anesthesia provider
2979701|NCT02698982|No Intervention|Control|elderly non scheduled for surgery
2979702|NCT02698969|Experimental|Sugammadex|patients enrolled who will receive sugammadex 2 mg*kg-1 at the end of surgery
2979703|NCT02698969|Active Comparator|Nestigmine, Atropine|patients enrolled who will receive neostigmine 50 mcg*kg-1 and atropine 15 mcg*kg-1 at the end of surgery
2979704|NCT02698943||Study Group|Participants who underwent phacoemulsification surgery and implantation of the Envista MX-60 IOL
2979705|NCT02698930|Experimental|dexmedetomidine group|
2979706|NCT02698930|Placebo Comparator|Control group|
2979707|NCT02698917|Active Comparator|Group 1|Low normal PaCO2, low normal PaO2, low normal MAP
2979708|NCT02698917|Active Comparator|Group 2|High normal PaCO2, low normal PaO2, low normal MAP
2979709|NCT02698917|Active Comparator|Group 3|Low normal PaCO2, high normal PaO2, low normal MAP
2979710|NCT02698917|Active Comparator|Group 4|High normal PaCO2, high normal PaO2, low normal MAP
2979711|NCT02698917|Active Comparator|Group 5|Low normal PaCO2, low normal PaO2, high normal MAP
2979712|NCT02698917|Active Comparator|Group 6|High normal PaCO2, low normal PaO2, high normal MAP
2979713|NCT02698917|Active Comparator|Group 7|Low normal PaCO2, high normal PaO2, high normal MAP
2979714|NCT02698917|Active Comparator|Group 8|High normal PaCO2, high normal PaO2, high normal MAP
2979715|NCT02698904|Experimental|Guided Relaxation Technique|Forced Vital Capacity (FVC), Forced Expiratory Volume in the First Second (FEV1), FEV1/FVC, Heart Rate Variability (HRV), airway resistance (kPa/l/s), before and after an 11 minutes, one-session, guided relaxation technique Following 30-40 minutes questionnaire, 5 minutes heart rate (HR) and oxygen saturation (SpO2) recording, 11 minutes relaxation technique (listening via headphone to audio recording. In the meanwhile, heart rate and saturation are recording) to be completed by second heart rate (HR) and oxygen saturation (SpO2) recording. Entire procedure 60-80 minutes.
2979716|NCT02698904|Sham Comparator|Documentary movie|"Forced Vital Capacity (FVC), Forced Expiratory Volume in the First Second (FEV1), FEV1/FVC, Heart Rate Variability (HRV), airway resistance (kPa/l/s), before and after an 11 minutes documentary movie.~Following 30-40 minutes questionnaire, 5 minutes heart rate (HR) and oxygen saturation (SpO2) recording, 11 minutes documentary movie (listening via headphone. In the meanwhile, heart rate and saturation are recording) to be completed by second heart rate (HR) and oxygen saturation (SpO2) recording. Entire procedure 60-80 minutes."
2979717|NCT02698891|Experimental|Neulasta|"After the screening procedures confirm participation in the research study:~Completion of 4 cycles of dose dense Adjuvant Doxorubicin Cyclophosphamide (AC)~Paclitaxel via IV, once every 2 week x 4 cycles~Neulasta™ (Pegfilgrastim) will be administered in Paclitaxel cycles, if:~The patient experiences a prior episode of fever and neutropenia.~If the patient has an active infection this decision will be at provider discretion.~If Neulasta™(Pegfilgrastim) is administered in any Paclitaxel cycle for a given patient, it will be then administered for all future cycles."
2979718|NCT02698878|Active Comparator|Control Group|Control Group consisting of six healthy male subjects wearing only the HEPHAISTOS ORTHOSIS for lower leg unloading (60 days).
2979719|NCT02698878|Experimental|Intervention Group|Intervention group consisting of seven healthy mal subjects, wearing the HEPHAISTOS orthosis for lower leg unloading (60 days), plus receiving lupin protein every day and performing a neuromuscular electrical stimulation training twice a day.
2979720|NCT02698852|Experimental|BuMA Supreme group|Totally 1000 subjects combined the 220 subjects from randomized controlled trial(RCT) group
2979721|NCT02698839|Experimental|BuMA Supreme group|This group contains 319 subjects. Among them, 220 subjects will be implanted with regular specifications and 99 subjects with narrower, wider or longer ones.
2979722|NCT02698839|Active Comparator|BuMA™ group|This group contains 220 subjects.
2979723|NCT02698826|Experimental|Adult patients resuscitated from cardiac arrest|Rapid FiO2 optimization protocol
2979759|NCT02698527|Experimental|Buffered Lidocaine|Vulvar biopsy conducted using buffered lidocaine as anesthesia
2979729|NCT02698761|Experimental|Comprehensive Care Plan|Patient will abide by the comprehensive care plan and sign an agreement stating compliance. Subject will have an actiwatch to compare activity and sleep habits. Nursing staff will be notified of study and support patient's compliance with study procedures.
2979730|NCT02698748|Experimental|Chloroquine|Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
2979731|NCT02698748|Placebo Comparator|Placebo|Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain.
2979732|NCT02698735|Experimental|Gentamicin|Gentamicin antibiotic
2979733|NCT02698735|Placebo Comparator|Placebo|Vehicle control
2979734|NCT02698722|No Intervention|Control|This group will receive verbal education about dialytic and non-dialytic therapies via a standardized script.
2979735|NCT02698722|Experimental|Intervention|This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
2979736|NCT02698709||Healthy corneas (C)|Corneas of normal candidates to refractive surgery who did not develop any sign of corneal ectasia after laser in situ keratomileusis during a two year follow-up period were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
2979737|NCT02698709||Overt keratoconus (Kc)|Whether both eyes manifested classic Kc-suggestive topographic features, such as corneal steepness higher than 47.20 diopters (D), superior-inferior asymmetry higher than 1.40 D and thinnest pachymetric reading lower than 500 micrometers. Such eyes were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
2979738|NCT02698709||Forme fruste keratoconus (FFKc)|Whether only one eye manifested classic Kc-suggestive topographic features, such as corneal steepness higher than 47.20 diopters (D), superior-inferior asymmetry higher than 1.40 D and thinnest pachymetric reading lower than 500 micrometers, and the fellow eye seemed unaffected. Such unaffected eyes were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
2979739|NCT02698696|Experimental|ECo program|Objective: to inform the patient about cognitive impairments and their repercussions; to train the patient in problem-solving skills through exercises; to implement strategies in daily life Duration: three months Frequency: two one-hour individual sessions and one hour of at-home training per week Modalities: pen and paper exercises, tools (tokens, cards, maps, chessboard) Modules: Psychoeducation, Attention, Memory, Executive Functions, Functional Impairments
2979740|NCT02698696|Experimental|CRT program|Objective: problem-solving skills training through exercises, in order to use strategies in daily life Duration: three months Frequency: two one-hour individual sessions and one hour of at-home training per week Modalities: pen and paper exercises Modules: Cognitive Flexibility, Working Memory, Planning
2979741|NCT02698696|Active Comparator|Supportive psychotherapy|Individual psychotherapy sessions focussing on autonomy in daily life, management of mood disorders' cognitive and functional impact, social skills, and the regulation of sleep and daily activities.
2979742|NCT02698683||malnourished|low zinc, low albumin, anthropometric measures lower than percentile 5 lymphocyte count
2979743|NCT02698683||well nourished|normal zinc, normal albumin, anthropometric measures higher than percentile 5 lymphocyte count
2979744|NCT02698657|Experimental|ASP5094 Dose Escalation|Three sequential cohorts will receive increasing intravenous doses of ASP5094. After all subjects in a cohort have completed study procedures the overall safety and tolerability of the dose will be determined after evaluation of the safety data. If there are no events which meet the stopping criteria, the next sequential cohort will begin enrollment while the current subjects continue through the third dose and the remainder of the study.
2979745|NCT02698657|Placebo Comparator|Placebo Dose Escalation|Three sequential cohorts will receive increasing intravenous doses of Placebo. After all subjects in a cohort have completed study procedures the overall safety and tolerability of the dose will be determined after evaluation of the safety data. If there are no events which meet the stopping criteria, the next sequential cohort will begin enrollment while the current subjects continue through the third dose and the remainder of the study.
2979746|NCT02698644|Experimental|isoamyl2cyanoacrylate|Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
2979747|NCT02698631|Active Comparator|Conventional AF ablation.|A standard radiofrequency AF ablation procedure will be carried out without LGE information.
2979748|NCT02698631|Experimental|LGE-MRI guided AF ablation.|Fibrosis information obtained from post-processed LGE-MRI will be used to guide AF ablation procedures.
2979749|NCT02698618|Experimental|Ticagrelor|A loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours)
2979750|NCT02698618|Active Comparator|Clopidogrel|A loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg
2979751|NCT02698605|Experimental|Usability test study of the MirrorPath|This study was a one-arm study and all subjects used the device and received usability test.
2979752|NCT02698592|Active Comparator|CelsiusTMDS® 8 mm catheter|50 patients underwent ablation with CelsiusTMDS® 8 mm catheter.
2979753|NCT02698592|Active Comparator|Thermocool® 3.5 mm irrigated catheter|50 patients underwent ablation with Thermocool® 3.5 mm catheter of irrigated tip.
2979754|NCT02698592|Experimental|Thermocool® SF catheter|50 patients underwent ablation with Thermocool® SF catheter.
2979755|NCT02698579||Subjects treated with Lenti-D|Subjects who have received Lenti-D Drug Product in Study ALD-102 (bluebird bio-sponsored clinical trial) and who meet the eligibility criteria for the study LTF-304
2979756|NCT02698566|Experimental|Ranibizumab PFS|Healthcare professionals (HCPs) will administer ITV injections of ranibizumab 0.5 mg delivered via PFS to enrolled patients (1 injection to each patient) on Day 1.
2979757|NCT02698553|Experimental|Bupropion XL once daily|Healthy subjects will receive Bupropion XL 150milligram (mg) once daily for 5 days (Day 1 to Day 5) and then Bupropion XL 300 mg once daily from Day 6 to Day 14.
2979761|NCT02698514|Experimental|Desflurane|Anesthesia was maintained with desflurane.
2979762|NCT02698501|Experimental|MEDI9929|MEDI9929 is a human monoclonal antibody immunoglobulin IgG2λ directed against TSLP. MEDI9929 binds with human TSLP and prevents its interaction with thymic stromal lymphopoietin receptor (TSLPR).
2979763|NCT02698501|Placebo Comparator|Placebo|Apart from the active substance, the placebo is otherwise identical to IMP.
2979764|NCT02698488|Active Comparator|Embryo Selection by Morphology|Embryos will be morphologically evaluated according to the number and regularity of blastomeres and fragmentation degree. Only embryo culture media of good quality embryos (embryos with ≥6 cells with no fragmentation) will be included in the study
2979765|NCT02698488|Active Comparator|Embryo Selection by Morphology and Mass Spectroscopy|Embryos will be morphologically evaluated according to the number and regularity of blastomeres and fragmentation degree. Only embryo culture media of good quality embryos (embryos with ≥6 cells with no fragmentation) will be included in the study. After dilution, embryo culture media will be analyzed by electrospray ionization quadrupole time-of-flight (ESI-QTOF) MS. The spectra will be collected in the negative ion mode. Abundance of ions in each spectrum will be further analyzed.
2979766|NCT02698475|Experimental|Ustekinumab Group|Participants will receive 1 of the following dose levels depending on their weight: participants weighing less than (<) 60 kg will receive Ustekinumab 0.75 milligram per kilogram (mg/kg); participants weighing greater than or equal to (>=) 60 kg to less than or equal to (<=) 100 kg will receive ustekinumab 45 mg; participants weighing >100 kg will receive ustekinumab 90 mg, at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants who enter the long-term extension (LTE) period will continue receiving ustekinumab every 12 weeks (q12w) beginning at Week 56 up to Week 248.
2979767|NCT02698462|Other|FIT and Questionnaire|Six thousand persons eligible for the national CRC screening program will be selected. They will be selected from four areas that are considered representative of the Netherlands. All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
2979768|NCT02698449|Experimental|cognitive rehabilitation + transcranial stimulation|specific cognitive rehabilitation combined to transcranial direct current stimulation
2979769|NCT02698449|Experimental|cognitive rehabilitation + stimulation sham|specific cognitive rehabilitation combined to transcranial direct current stimulation sham
2979770|NCT02698449|Experimental|placebo rehab + transcranial stimulation|nonspecific cognitive rehabilitation (placebo rehab) combined to transcranial direct current stimulation
2979771|NCT02698449|Experimental|placebo rehab + stimulation sham|nonspecific cognitive rehabilitation (placebo rehab) combined to transcranial direct current stimulation sham
2979772|NCT02698436|Experimental|Acne Mask|"The light therapy acne device is applied to the face once in the evening for a duration of 10 minutes. The cleanser is used twice daily, once in the morning and once in the evening.~Other Names: Cleanser is marketed while the device is not marketed"
2979773|NCT02698436|Active Comparator|2.5% Benzoyl Peroxide Treatment|"Cleanser and 2.5% Benzoyl Peroxide Treatment Both the cleanser and the 2.5% Benzoyl Peroxide Treatment are applied twice daily, once in the morning and once in the evening.~Other names: Both products are marketed"
2979774|NCT02698423|Experimental|Cobas HPV DNA test|Women will be invited to perform HPV self-testing with the Cobas HPV DNA test at home.
2979775|NCT02698423|Active Comparator|Papanicolau test|Women will be invited to come to the hospital to undergo a Papanicolau test (Pap test), which will be performed by the clinician.
2979776|NCT02698410|Experimental|Lanreotide (Autogel formulation) and Temozolomide|"Lanreotide ATG 120 mg every 28 days, deep subcutaneous injection for a maximum of 48 weeks, for a total number of 12 injections.~Temozolomide 250 mg hard capsules, for 5 consecutive days every 28 days, oral route, for a maximum of 48 weeks."
2979777|NCT02698371|Active Comparator|G1-Control: Futurabond®DC-SE|"Activation of the SingleDose blister FBDC DC (between thumb and forefinger and press on the part of the blister marked press here in blue). This injects Liquid 1 into Liquid 2 in the dispensing bay in a 1:1 ratio. Pierce the foil of the dispensing bay with the Single Tim, enlarge the hole with a circular movement and stir well to create a homogeneous mixture.~Futurabond DC will be applied as thickness to the enamel/dentine and rub into the tooth surface for 20s; Drying of the adhesive layer for at least 5s with an air syringe; This adhesive layer will be light-cured with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2, during 10s."
2979778|NCT02698371|Active Comparator|G2-Control: Futurabond®DC pre-etching|Etch with 36% phosphoric acid, during 30s in enamel structures. Remove the 36% phosphoric acid with water during 1 minute (m). The remove of water excess will be done with weak air spray, not to dry the dentine completely. The dentine surface must slightly remain wet. Application of FBDC as an all-in-one self-etch adhesive approach simultaneously in dentin and enamel structures.
2979779|NCT02698371|Experimental|G3: Futurabond® U - ER|"Application in enamel and dentin as an etch-and-rinse approach. Etching of the dental hard tissue phosphoric acid (during 15s in dentin and 30s in enamel structures; Aspirate the acid-etch agent, rinse with water for approx. 1 min. Dry off excess moisture with a gentle stream of air. Activating Futurabond U SingleDose (blister between thumb and forefinger and, by pressing on the area marked press here, allow the liquid contained in the blister to flow into the mixing and dispensing chamber. Position the enclosed Single Tim applicator in the centre of the coloured circle in order to pierce through the film of the mixing and dispensing chamber. By stirring thoroughly with the applicator, create a homogeneous streak-free mixture of the two liquids).~FU adhesive will be homogeneously applied to all cavity surfaces and rub in for 20s using the Single Tim; This adhesive layer will be light-cured with a light emitting diode unit, with an intensity of 1000mW/cm2 during 10s."
2979809|NCT02698189|Experimental|Dose B MK-8628 DLBCL Cohort|Participants with DLBCL (up to 14) will receive Dose B of MK-8628 for 21 consecutive days in Cycle 1. Dose limiting toxicity (DLT) will be used to establish the recommended dose after Cycle 1. Participants will continue receiving MK-8628 at an assigned/adjusted dose level for continuous 21-day cycles up to 7 months.
2979965|NCT02697071|Experimental|Ketamine|Patients will receive 0.2mg/kg ketamine intravenously over one minute.
2979780|NCT02698371|Experimental|G4: Futurabond® U - SE|"application in enamel and dentin as an self-etch approach; Activating Futurabond U SingleDose (blister between thumb and forefinger and, by pressing on the area marked press here, allow the liquid contained in the blister to flow into the mixing and dispensing chamber. Position the enclosed Single Tim applicator in the centre of the coloured circle in order to pierce through the film of the mixing and dispensing chamber. Expand the opening to its maximum size using a circular motion. By stirring thoroughly with the applicator, create a homogeneous, streak-free mixture of the two liquids).~FU adhesive will be homogeneously apply to all cavity surfaces and rub in for 20 s using the Single Tim; Dry off the adhesive layer with dry, oil-free air for at least 5 s in order to remove any solvents. This adhesive layer will be light-cured with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2, during 10 seconds."
2979781|NCT02698371|Experimental|G5: Adhese® Universal - ER|"application in enamel and dentin as an etch-and-rinse approach; Etching of the dental hard tissue phosphoric acid (during 15 seconds in dentin and 30 seconds in enamel structures; Aspirate the acid-etch agent, rinse with water for approx. 1 minute. Dry off excess moisture with a gentle stream of air. Keep dentin dry, do not over dry; Starting with the enamel, thoroughly coat the tooth surfaces (enamel and dentin) to be treated with AU; Adhesive will be scrubbed into the tooth surface for at least 20 seconds. Adhesive will be dispersed with compressed air until a glossy, immobile film layer results.~Light-curing for 10 s with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2."
2979782|NCT02698371|Experimental|G6: Adhese® Universal - SE|"application in enamel and dentin as an self-etch approach; Starting with the enamel, thoroughly coat the tooth surfaces (enamel and dentin) to be treated with AU; Adhesive will be scrubbed into the tooth surface for at least 20 seconds. Adhesive will be dispersed with compressed air until a glossy, immobile film layer results.~Light-curing for 10 s with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2."
2979783|NCT02698358||K-EPIC|Patients with femoropopliteal artery disease undergoing endovascular therapy using Epic stent (Boston Scientific).
2979784|NCT02698345||K-POP|Patients with isolated popliteal artery disease undergoing endovascular therapy using drug-eluting balloon (In.PACT Admiral, Medtronic)
2979785|NCT02698332|Active Comparator|Algorithm for UTI|Practices in this groups receives a diagnostic algorithm for UTI by post
2979786|NCT02698332|No Intervention|Control|Practices in this group does not receive anything in addition to instructions in the observational registration.
2979787|NCT02698319|No Intervention|Conventional Triage|Conventional triage using Danish Emergency Process Triage (DEPT).
2979788|NCT02698319|Experimental|Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm is used as triage form in the ED. The Copenhagen Triage Algorithm consists of a few vital parameters and a clinical assessment from the ED nurse.
2979789|NCT02698306|Experimental|Dexamethasone|Dexamethasone: Dexametasone 4mg tablet every 8/8hs for 3 days
2979790|NCT02698306|Active Comparator|Diclofenac Sodium|Diclofenac Sodium: Diclofenac Sodium 50 mg tablet every 8/8 hs for 3 days
2979791|NCT02698293|Experimental|Cohort 1|
2979792|NCT02698293|Experimental|Cohort 2|
2979793|NCT02698293|Experimental|Cohort 3|
2979794|NCT02698280|Experimental|Treatment|Patients are treated with bevacizumab and nimustine. Every 6 weeks is defined as one therapeutic cycle. Adverse effect is evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.03). Hematologic toxicity is evaluated every 2 weeks. Liver function, renal function, and electrolytes are assessed every 4-6 weeks. Platelet should be no less than 100*10^9/L and neutrophil count should be no less than 1.5*10^9/L.
2979795|NCT02698267|Experimental|BIIB074|Administered orally on Day 1 and Day 11
2979796|NCT02698254|Experimental|Re-Irradiation Therapy (RRT) to Brain - Children|"Participants may receive up to 6 weeks of radiation therapy. Dose of radiation decided by participant's radiation oncologist.~Quality of life and symptom questionnaires completed at baseline, and at months 1, 3, 5, 7, 9, 11, 13, 16, 19, 22, and 25 after radiation therapy."
2979797|NCT02698254|Experimental|Re-Irradiation Therapy (RRT) to Brain - Adults|"Participants may receive up to 6 weeks of radiation therapy. Dose of radiation decided by participant's radiation oncologist.~Quality of life and symptom questionnaires completed at baseline, and at months 1, 3, 5, 7, 9, 11, 13, 16, 19, 22, and 25 after radiation therapy."
2979798|NCT02698241||Diagnostic & Medication Management|Enrolled subjects will be managed using integrated device diagnostics combined with a clinical medication plan.
2979799|NCT02698228|Sham Comparator|Standard of Care|Intravenous injection of 0.1mg/kg of morphine. Injection of 5cc of 0.9% normal saline into the subcutaneous tissue of the thigh.
2979800|NCT02698228|Active Comparator|Femoral nerve block|Intravenous injection of 0.1mg/kg of morphine. Injection of 20cc of 0.5% bupivacaine into the fascia iliaca space using standard anatomic landmarks.
2979801|NCT02698228|Active Comparator|Ultra-sound guided femoral nerve block|Intravenous injection of 0.1mg/kg of morphine.Injection of 20cc of 0.5% bupivacaine around their femoral nerve under direct ultrasound guidance
2979802|NCT02698215|Experimental|Varenicline plus Naltrexone|VAR (1 mg twice daily) + NTX (50 mg once daily)
2979803|NCT02698215|Placebo Comparator|Varenicline|VAR (1 mg twice daily)
2979804|NCT02698202|Experimental|Digital Breast Tomosynthesis|to the experimental arm will be offered twice screening examination: standard 2D mammography + Digital Breast Tomosynthesis
2979805|NCT02698202|No Intervention|standard mammography|to the control arm the usual 2D standard mammography exam will be offered
2979806|NCT02698189|Experimental|Dose A MK-8628 AML Cohort|Participants with AML (up to 14) will receive Dose A of MK-8628 for 21 consecutive days in Cycle 1. Dose limiting toxicity (DLT) will be used to establish the recommended dose after Cycle 1. Participants will continue receiving MK-8628 at an assigned/adjusted dose level for continuous 21-day cycles up to 7 months.
2979807|NCT02698189|Experimental|Dose B MK-8628 AML Cohort|Participants with AML (up to 14) will receive Dose B of MK-8628 for 21 consecutive days in Cycle 1. Dose limiting toxicity (DLT) will be used to establish the recommended dose after Cycle 1. Participants will continue receiving MK-8628 at an assigned/adjusted dose level for continuous 21-day cycles up to 7 months.
2979808|NCT02698189|Experimental|Dose A MK-8628 DLBCL Cohort|Participants with DLBCL (up to 14) will receive Dose A of MK-8628 for 21 consecutive days in Cycle 1. Dose limiting toxicity (DLT) will be used to establish the recommended dose after Cycle 1. Participants will continue receiving MK-8628 at an assigned/adjusted dose level for continuous 21-day cycles up to 7 months.
2979810|NCT02698176|Experimental|MK-8628 Dose Level 1|Participants (up to 14) in Part A will receive MK-8628 Dose Level 1. Dose limiting toxicity (DLT) will be used to establish the recommended Phase 2 dose (RP2D) during the first cycle. Participants will continue receiving MK-8628 at an assigned/adjusted dose level for continuous cycles up to 24 months.
2979811|NCT02698176|Experimental|MK-8628 Dose Level 2|Participants (up to 14) in Part A will receive MK-8628 Dose Level 2. Dose limiting toxicity (DLT) will be used to establish the RP2D during the first cycle. Participants will continue receiving MK-8628 at an assigned/adjusted dose level for continuous cycles up to 24 months.
2979812|NCT02698176|Experimental|MK-8628 Dose Level 3|Participants (up to 14) in Part A will receive MK-8628 Dose Level 3. Dose limiting toxicity (DLT) will be used to establish the RP2D during the first cycle. Participants will continue receiving MK-8628 at an assigned/adjusted dose level for continuous cycles up to 24 months.
2979813|NCT02698176|Experimental|NMC Cohort|Participants (up to 30) in Part B will receive MK-8628 at one dose level below the dose currently being administered in Part A of the study. Once the RP2D from Part A is established, participants in Part B will receive MK-8628 at the RP2D. Participants will continue receiving MK-8628 at an assigned/adjusted dose level for continuous cycles up to 24 months.
2979814|NCT02698163|Active Comparator|Gutta Percha|For all the patients in the control arm of the study, standard treatment of care procedures will be given. Root canal therapy will be given according to the vertical obturation technique. The root canals will be filled with standard root canal filler material: gutta percha at the apical third up to and including the coronal third. The tooth will be restored with a crown for posterior teeth, or a composite filling for anterior teeth.
2979815|NCT02698163|Experimental|Nanodiamond reinforced Gutta Percha|For all the patients in the treatment arm of the study, standard treatment of care procedures will be given. Root canal therapy will be given according to the vertical obturation technique. The difference between the two arms will be the root canal filler material used. The root canals for the treatment arm of the study will be filled with gutta percha at the apical third, Nanodiamond gutta percha (NDGP) in the middle third, and again with gutta percha at the coronal third. The tooth will be restored with a crown for posterior teeth, or a composite filling for anterior teeth.
2979816|NCT02698150||Remote monitoring|Active group of patients undergoing daily remote monitoring using sensors and wearables
2979817|NCT02698150||Control|Control group of patients undergoing standard follow up wth no remote monitoring
2979818|NCT02698124||Decitabine|"Decitabine 20mg/m2 will be given IV daily on Days 1-5 in 28-day cycles. Treatment should be given for at least 4 cycles in the absence of unacceptable toxicity or disease progression requiring alternative therapy.~Beyond 4 cycles, treatment should continue as long as the subject continues to benefit based on investigator's judgment of no definitive progression."
2979819|NCT02698111|Experimental|Donafeinib|donafenib 200mg,bid
2979820|NCT02698098||Compulsory Drug Detention Center|Conventional drug treatment in Malaysia and Southeast Asia including detention for an average of 2 years, including educational and job skills programs and physical education. Medical therapies for treating substance use disorders, such as opioid-agonist treatment (OAT), are unavailable.
2979821|NCT02698098||Voluntary Treatment Center|Voluntary drug treatment facilities, called 'Cure and Care' centers in Malaysia, that provide methadone maintenance therapy in addition to psychosocial interventions, recreational programming, and vocational training, among other activities.
2979822|NCT02698085|Experimental|Intervention Goup|Actual Diacutaneous Fibrolysis
2979823|NCT02698085|Sham Comparator|Placebo Group|Sham Diacutaneous Fibrolysis
2979824|NCT02698072|Experimental|Exercise and dry needling|"24 therapeutic exercise sessions (twice a week) of a land-based therapeutic exercise program consisting of aerobic exercise (20-25 min warm-up), lower limbs muscle strengthening (20-25 min) and lower limbs muscles stretching (10-15 min).~6 dry needling sessions (once a week) at all the pain points of the involved symptomatic lower limb/s using Hong's fast-in and fast-out technique with multiple rapid needle insertion."
2979825|NCT02698072|Active Comparator|Exercise and sham dry needling|"24 therapeutic exercise sessions (twice a week) of a land-based therapeutic exercise program consisting of aerobic exercise (20-25 min warm-up), lower limbs muscle strengthening (20-25 min) and lower limbs muscles stretching (10-15 min).~6 sham dry needling sessions (once a week) at all the pain points of the involved symptomatic lower limb/s using a park sham device consists of a base with a hole in the centre and sticky tape on the bottom. From the top of the base extends a double tube, continuing the central hole in the base."
2979826|NCT02698059|Experimental|Treated|iNAP® Sleep Therapy System Treatment
2979827|NCT02698059|No Intervention|Baseline/Control|Self-controlled, pre-treatment baseline
2979828|NCT02698046|Experimental|Ferrous sulfate|
2979829|NCT02698046|Placebo Comparator|Placebo|
2979830|NCT02698033|Experimental|Peanut Flour|Double-blind food challenge with peanut flour
2979831|NCT02698033|Placebo Comparator|Oat Flour|Double-blind food challenge with oat flour
2979832|NCT02698020|No Intervention|Control|High level of supplemental inspired oxygen
2979833|NCT02698020|Experimental|Room-air|Supplemental oxygen only provided if oxygen saturation below target
2979834|NCT02698007|No Intervention|without lma|standard fiberoptic bronchoscopy without lma
2979835|NCT02698007|Experimental|with lma|fiberoptic bronchoscopy with the use of lma
2979836|NCT02697994|Experimental|Sterile Water Injection|Participants randomised to the intervention group received 4 intracutaneous injections of 0.1 ml sterile water into the skin surrounding the Michaelis rhomboid over the sacral area.
2979837|NCT02697994|Placebo Comparator|Dry Injection|Participants in the control group received 4 dry injections in the same region using an insulin needle .
2979838|NCT02697981|Experimental|intervention group|Pregnant post bariatric surgery women will receive nutritional counseling from a specialist dietitian, to ensure a healthy balanced diet including adequate daily servings from all food groups, intake of essential nutrient during pregnancy such as iron and folic acid and limitation of high-sugar and fatty foods. Patients will also be advised concerning eating at scheduled times (e.g., 4-6 times daily), supplements, preference of water. Advice concerning healthy cooking methods will also be given, as well as advised to avoid soft drinks, drinking during meals, grazing and emotional eating, and fast foods. Subject of lifestyle in general - encouraged to incorporate suitable physical activity on most days, refraining from alcohol, and smoking. intervention: nutrition counseling
2979839|NCT02697981|No Intervention|control group|The control group is comprised of healthy pregnant women, of similar age, smoking behavior and background. No treatment will be given, just follow-up data collection.
2979840|NCT02697968|Experimental|Electroacupuncture|
2979841|NCT02697955|Experimental|Bupivacaine-epinephrine|10 mL of 5 mg/mL bupivacaine with 5 μg/mL epinephrine = 50 mg bupivacaine and 50 μg epinephrine
2979842|NCT02697955|Placebo Comparator|Placebo|10 ml normal saline water (sodium chloride solution, 0,9%)
2979843|NCT02697942|No Intervention|Standard of care|Participants randomized to the standard of care arm will not receive any intervention.
2979844|NCT02697942|Experimental|Cognitive training (CT)|"Participants randomized to the CT arm will be given a tablet with connection to Lumosity®, which is a web-based brain game. Participants will use the tablets to play brain games at each dialysis session."
2979845|NCT02697942|Active Comparator|Exercise training (ET)|Participants randomized to ET arm will be given a stationary foot peddler. This foot peddler will be situated at a comfortable distance from the dialysis chair so that the patient can comfortably reach the peddler. Participants will use the foot peddlers at each dialysis session.
2979846|NCT02697929|Active Comparator|sugammadex|at the end of surgery administration of 2 mg/kg of sugammadex after the third T2 twitch at Train of Four (TOF) stimulation
2979847|NCT02697929|Active Comparator|neostigmine|at the end of surgery administration of 50 mcg/kg of neostigmine after the third T2 twitch at Train of Four (TOF) stimulation
2979848|NCT02697916|Active Comparator|ASA 81mg|aspirin 81mg
2979849|NCT02697916|Active Comparator|ASA 325mg|aspirin 325mg
2979850|NCT02697903|Experimental|9 elite weightlifters|"age: 21 ± 0.5 years, body mass: 80 ± 20 kg, height 175 ± 8.1 cm (mean ± SD). They received Natural Pomegranate Juice supplementation during and 48h following the first weightlifting training session."
2979851|NCT02697903|Placebo Comparator|9elite weightlifters|"age: 21 ± 0.5 years, body mass: 80 ± 20 kg, height 175 ± 8.1 cm (mean ± SD). They received Placebo Juice supplementation during and 48h following the second weightlifting training session."
2979852|NCT02697890|Active Comparator|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|"Interventions:~Procedure: Ridge preservation procedure"
2979853|NCT02697890|Experimental|FDBA (MinerOss®) + Mucograft® seal|"Interventions:~Device: Mucograft® seal Procedure: Ridge preservation procedure"
2979854|NCT02697877||Patients with known or suspected coronary artery disease.|Patients with known or suspected coronary artery disease undergoing clinically ordered stress cardiac magnetic resonance imaging.
2979855|NCT02697864|Experimental|48.8 mgA tafamidis free acid tablet|
2979856|NCT02697864|Experimental|58 mgA tafamidis free acid tablet|
2979857|NCT02697864|Experimental|4 soft gel capsules of 20 mg tafamidis meglumine|
2979858|NCT02697851|Experimental|Group 1|Microgynon 30® for 21 days, Followed by Microgynon 30® for 21 days plus Evotaz® for 14 days, Followed by Evotaz® for 14 days
2979859|NCT02697851|Experimental|Group 2|Evotaz® for 14 days followed by 7 days wash-out, Followed by Microgynon 30® for 21 days plus Evotaz® for 14 days, Followed by Microgynon 30® for 14 days (participants may chose to complete a 21 day pack). The total duration of the study is 57 days (+screening and follow up visits) and patients will have 3 intensive pharmacokinetic days on days 14, 35 and 56
2979860|NCT02697838|Experimental|control group|Apatinib Mesylate Tablets (850 mg qd p.o.) and Paclitaxel (80mg/m2 i.v. d1, d8, d15, q28d)
2979861|NCT02697825|Other|changes in eye|Changes in both intraocular pressure and optic nerve sheath diameter will be correlated in robotic surgeries to find out any statistical relation existing between two.
2979862|NCT02697812|Experimental|slow sternal retraction|sternal retraction (which is required for exposure of the heart during coronary artery bypass graft surgery) will be performed gradually over 15 minutes
2979863|NCT02697812|No Intervention|standard sternal retraction|sternal retraction will be performed as per standard practice (sternum opened rapidly over 30 sec.)
2979864|NCT02697799|Experimental|High-level recruitment strategy|Subjects in this group will receive pre-consent messaging and a consent form with a high-level recruitment strategy for research participation in the parent study. The consent form will provide information on the first page, under the header that describes the purpose of the study, as well as in the consent sections describing the cost to participate in the study.
2979865|NCT02697799|Experimental|Mid-level recruitment strategy|Subjects in this group will receive pre-consent messaging and a consent form with a mid-level recruitment strategy for research participation in the parent study. The consent form will provide information on the first page, under the header that describes the purpose of the study, as well as in the consent sections describing the cost to participate in the study.
2979866|NCT02697799|No Intervention|No modified recruitment strategy|Subjects in this group will receive consent form without a modified recruitment strategy for research participation in the parent study.
2979867|NCT02697786|Active Comparator|AVR preformed with full sternotomy|"30 patients, 7 days before and after surgery mini mental test and measurement of visual evoked cerebral blood flow response (VEFR) will be done.~Transcranial doppler measurements 1. beginning of the surgery, 2.after sternotomy, 3.during aortic cannulation,4.during CPB,5. during de-airing, 6. opening of the clamp on the aorta, 7. after CPB removal before chest closure. Prolonged de airing if needed"
2979868|NCT02697786|Experimental|AVR preformed with minimal invasive sternotomy|"30 patients, 7 days before and after surgery mini mental test and measurement of visual evoked cerebral blood flow response (VEFR) will be done.~Transcranial doppler measurements 1. beginning of the surgery, 2.after sternotomy, 3.during aortic cannulation,4.during CPB,5. during de-airing, 6. opening of the clamp on the aorta, 7. after CPB removal before chest closure. Prolonged de airing if needed"
2979869|NCT02697773|Placebo Comparator|Placebo|placebo administered subcutaneously at day 0 and week 8
2979870|NCT02697773|Experimental|Tanezumab 2.5 mg|tanezumab 2.5 mg administered subcutaneously at day 0 and week 8
2979871|NCT02697773|Experimental|Tanezumab 2.5mg/5mg|tanezumab 2.5 mg administered subcutaneously at day 0 and tanezumab 5 mg administered subcutaneously at week 8
2979872|NCT02697747||Ultrasound education|Training in the use of ultrasound to identify the L3-L4 interspace
2979873|NCT02697734|Experimental|osilodrostat Group|Participants are randomized in a 2:1 ratio to treatment with study drug (osilodrostat or placebo, respectively),
2979938|NCT02697240|Experimental|Intravenous citrulline|Intravenous citrulline at a bolus dose over 5 minutes and then a continuous rate for the next 23 hours.
2979874|NCT02697734|Placebo Comparator|osilodrostat Placebo Group|Participants are randomized in a 2:1 ratio to treatment with study drug (osilodrostat or placebo, respectively)
2979875|NCT02697721|Experimental|Powerful Tools for Caregivers|A 6-week psycho-educational program
2979876|NCT02697721|Other|Control group, delayed intervention|Control group with delayed intervention
2979877|NCT02697708|Placebo Comparator|Control Diet|Control (no additional potassium added to diet): Arm will consist of a 16 day balance period with a basal diet set at ~2340mg K/day; based on average American intake.
2979878|NCT02697708|Active Comparator|Potassium Supplement Diet|Potassium gluconate: Arm will consist of a 16 day balance period with the basal (control) diet plus the addition of 1000mg of K/day from potassium gluconate (12 tablets).
2979879|NCT02697708|Experimental|Potato Diet|Potato diet: Arm will consist of a 16 day balance period with a basal (control) diet with an addition of 1000mg of K/day from white potatoes.
2979880|NCT02697708|Experimental|French fries Diet|French fry diet: Arm will consist of a 16 day balance period with a basal (control) diet with an addition of 1000mg K/day from French fries.
2979881|NCT02697695||laparoscopic sleeve gastrectomy|patients who underwent laparoscopic sleeve gastrectomy (LSG) due to obesity and/or metabolic syndrome
2979882|NCT02697695||laparoscopic Roux-en-Y- gastric bypass|patients who underwent laparoscopic Roux-en-Y- gastric bypass (LRYGB) due to obesity and/or metabolic syndrome
2979883|NCT02697695||laparoscopic omega-loop gastric bypass|patients who underwent laparoscopic omega-loop gastric bypass (LOLGB) due to obesity and/or metabolic syndrome
2979884|NCT02697682|Experimental|Intervention|All patients are recieving the treatment.
2979885|NCT02697656|Active Comparator|Treatment as usual + self-help|Interdisciplinary treatment as usual at the outpatient pain clinic + an additional self-help binder with resources about pain management and employment advice.
2979886|NCT02697656|Experimental|Treatment as usual + IPS|Individual job support (IPS) as an integrated part of the interdisciplinary treatment at the outpatient pain clinic.
2979887|NCT02697643|Experimental|BHCDS-based recommendations|The Experimental condition will use the BH-CDS tool and receive tailored recommendations in addition to treatment as usual.
2979888|NCT02697643|Placebo Comparator|Non-tailored recommendations|The Control condition will use the BH-CDS tool and receive non-tailored recommendations in addition to treatment as usual.
2979889|NCT02697630|Experimental|Pembrolizumab and Entinostat|
2979890|NCT02697617|Placebo Comparator|Placebo Arm|Subject will be on placebo
2979891|NCT02697617|Active Comparator|Pioglitazone Arm|Subject will be on pioglitazone
2979892|NCT02697591|Experimental|INCAGN01876|
2979893|NCT02697565|Experimental|Train-the-Trainers Arm|Intervention Arm receives the Healthy Caregivers- Healthy Children Toolkit (healthy lifestyle role modeling intervention) via a nutritional gate keeper. The toolkit reinforces center health and activity policy standards.
2979894|NCT02697565|Other|Attention Control Arm|Control Arm that receives an attention control safety curriculum.
2979895|NCT02697552|Experimental|HBI-8000|HBI-8000 at the assigned dose twice weekly.
2979896|NCT02697539|Placebo Comparator|AmF/SnF2 group|Patients in this arm were adviced to use a standart dentifrice over the course of the study (AmF/SnF2, Meridol®, GABA, Lörrach, Germany).
2979897|NCT02697539|Active Comparator|mHA group|Patients in this arm were adviced to use the new dentifrice over the course of the study (mHA, BioRepair®, Wolff, Bielefeld, Germany).
2979898|NCT02697526|Other|Terumo|Patients in this arm will receive Terumo after catheterization
2979899|NCT02697526|Other|Tensoplast|Patients in this arm will receive Tensoplast after catheterization
2979900|NCT02697513|No Intervention|Before Period|Collection of patient-related data without interventions being made
2979901|NCT02697513|Active Comparator|After Period|Implementation of a simple infection management protocol as well as a 'Sepsis First Aid' kit to assist in the management of patients with acute infection
2979902|NCT02697487||No Treatment|This is a longitudinal observational study involving individuals who are depressed, depressed with other comorbidities and non-depressed individuals. The primary aim of this study is to describe the longitudinal course of illness and real world treatment outcomes for depressed patients receiving routine care from their providers. Health outcomes and biospecimens along with the functional and economic burden of depression will be characterized and compared amongst three groups: (1) depressed patients, (2) depressed patients with comorbid illnesses, and (3) non-depressed patients.
2979903|NCT02697474|Experimental|Hexaxim® Group|Subjects that received Hexaxim® in Study A3L12
2979904|NCT02697474|Experimental|Infanrix® hexa Group|Subjects that received Infanrix® hexa in Study A3L12
2979905|NCT02697461|Experimental|Intrinsic Foot Arm|In arm 1, a randomized control trial will be used in the investigation of validity and reliability comparing multisegmented foot motion, clinical joint physiological and accessory motion, and morphologic foot measurements, and the effect of intrinsic foot strengthening on multisegmented foot function.
2979906|NCT02697461|Experimental|Joint Mobilization Arm|In arm 2, the investigation of group differences in clinical and laboratory measures of multisegmented foot motion and kinetics will use a case control design. A randomized controlled trial will be conducted in the study investigating joint mobilization, with the researcher performing the assessments and the provider performing the treatments blinded to group allocation
2979907|NCT02697448|Active Comparator|propofol|Participants receiving propofol as anesthetic for cardiac ablation.
2979908|NCT02697448|Active Comparator|sevoflurane|Participants receiving sevoflurane as anesthetic for cardiac ablation.
2979909|NCT02697435|Experimental|Patient-Centered Care|Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain.
2979910|NCT02697435|Placebo Comparator|Imaging-Directed Care|Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
2979911|NCT02697422|Experimental|Peer health coach intervention group|Eligible participants will be randomly assigned to receive a home-visit peer health coach intervention to promote health outcomes and behavior change among Veterans with multiple cardiovascular disease (CVD) risk factors.
2979964|NCT02697071|Placebo Comparator|Placebo Control|Patients will receive an equivalent volume of normal saline intravenously.
2979912|NCT02697422|No Intervention|Control group|Participants who meet the same eligibility criteria as participants in the intervention group will be randomly assigned to receive no intervention. Participants will continue to receive their regular, usual primary care.
2979913|NCT02697409|Experimental|Intervention group|The intervention group receives two school-based modules taking less than two hours each delivered by medical students in the schools.
2979914|NCT02697409|No Intervention|Control group|
2979915|NCT02697396||with text messaging reminder system|Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
2979916|NCT02697396||without text messaging reminder system|Participants in this arm will receive no additional vaccination reminders. However, the study staff will ask and record if the participant's pediatrician provides appointment reminder cards, emails and/or calls prior to each scheduled vaccination as captured in the Outcomes Survey.
2979917|NCT02697383|Experimental|Ixazomib (MLN9708) and Dexamethasone|Patients with high risk SMM will be enrolled on the pilot study and treated with 2 drug combination (Cycles 1-12 Ixazomib at 4 mg weekly on days 1, 8 and 15, and dexamethasone on days 1, 8, 15 and 22 of 28 day cycle); the dexamethasone dose will be 40 mg/week the first 4 cycles, thereafter 20 mg/week.
2979918|NCT02697370|Other|Pharmacokinetic based factor VIII dosage|Patient's routine prophylactic factor VIII concentrate infusion will be given in the morning and the exact time (hours and minutes) and dose recorded. There is no wash out so the date, time and dose of the previous 2 prophylactic doses must be accurately known. Samples will be collected that afternoon, the following morning and the following afternoon. Samples can be taken at any convenient time but the exact time must be recorded. Factor VIII levels will be measured and this pharmacokinetic data will be used to calculate the dose of factor VIII (to be infused on alternate days) required to maintain a predicted factor VIII ≥1.5 IU/dL at all times(this will be rounded up to the nearest full 250 IU vial)
2979919|NCT02697357||Caregivers|This study is a pilot, single-arm intervention of Emotion Regulation Therapy for Cancer Caregivers (ERT-C). We plan to recruit a pilot sample 32 consented (24 evaluable) caregivers of patients diagnosed with cancer and measure their distress, anxiety, and other psychological outcomes at baseline. Caregivers will be consented into an 8-session ERT-C therapy (approximately 12 - 16 weeks).
2979920|NCT02697344|Experimental|Treatment (AT-101, lenalidomide, and dexamethasone)|Patients receive R-(-)-gossypol acetic acid PO QD on days 1-21. Beginning in course 2, patients also receive lenalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, and 15 of courses 2-12. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
2979921|NCT02697331|Active Comparator|progesterone|65 patients will receive progesterone tablet 100mg twice daily
2979922|NCT02697331|Placebo Comparator|Placebo|65 patients will receive placebo
2979923|NCT02697318|Other|Professional Administration|Instillation of Timolol maleate 0.5% ophthalmic solution (or participant's own glaucoma medication) administered by a professional, using the standard clinical method.
2979924|NCT02697318|Other|Self-Administration (new method)|Instillation of Timolol maleate 0.5% ophthalmic solution (or participant's own glaucoma medication) self-administered by the participant, using the new proposed method.
2979925|NCT02697305|Experimental|IV BCAA test|IV application of BCAA solution
2979926|NCT02697305|Experimental|ORAL BCAA test|At once oral ingestion of BCAA capsules
2979927|NCT02697305|Placebo Comparator|ORAL PLACEBO test|At once oral ingestion of placebo capsules
2979928|NCT02697292|Placebo Comparator|Placebo/Normal Saline Group|"Patients will maintain their stable dose of antiepileptic medications while receiving placebo. The dose will be based on ideal weight not to exceed 80 grams. Patients will receive placebo daily for 1 day [week 1 day 1], then they will receive placebo daily for 1 day [week 1 day 2]. Once every 2 weeks patients will receive placebo for 4 weeks [week 3 and 5] for 2 infusions. After completion of all 4 infusions all patients will be again evaluated at Mayo Clinic [week 6] and unblinded. The placebo group will then receive IVIG in an open label fashion in their homes through Option Care.~Option Care will administer IVIG (0.5g/kg not exceeding 80 gr) 1 day [week 7 day 1] then IVIG (1g/kg not exceeding 80 gr) for 1 day [week 7 day 2], then once every 2 weeks for 4 weeks (0.6g/kg IVIG) [week 9 and 11]. Patients will be evaluated at Mayo Clinic [week 12]. All will receive monthly telephone calls for one year after their last study infusion."
2979929|NCT02697292|Active Comparator|Intravenous Immunoglobulin (IVIG) (Gamunex-C) Group|Patients will maintain their stable dose of antiepileptic medications while receiving IVIG. The IVIG dose will be determined based on ideal weight with a dose not to exceed 80 grams. Patients will receive IVIG (0.5g/kg) daily for 1 day [week 1 day 1], then they will receive IVIG (1g/kg not exceeding 80 gr) daily for 1 day [week 1 day 2]. Patients will also receive 500 ml normal saline before and after the higher dose infusion of 1g/kg. Then once every 2 weeks patients will receive 0.6g/kg IVIG for 4 weeks [week 3 and 5] for 2 infusions. After completion of all 4 infusions all patients will be again evaluated at Mayo Clinic [week 6]. All patients will receive monthly telephone calls for one year after their last study infusion.
2979930|NCT02697279|Active Comparator|Traditional Incision and Drainage|Treatment of a simple cutaneous abscess with traditional incision and drainage with or without packing, decision made at the discretion of the provider.
2979931|NCT02697279|Experimental|Loop drainage|Treatment of a simple cutaneous abscess with incision and drainage using the loop drainage technique.
2979932|NCT02697266||Post-call anesthesiologists|Attending anesthesiologists, and Anesthesiology residents
2979933|NCT02697266||Regular-shift anesthesiologists|Attending anesthesiologists, and Anesthesiology residents
2979934|NCT02697253|Experimental|Successful drug|Participants who lost more than 30% body weight at 2 years post-roux-en-y bypass surgery will receive infusion of Exendin 9-39 prior to an intake test.
2979935|NCT02697253|Experimental|Unsuccessful drug|Participants who lost less than 15% body weight at 2 years post-roux-en-y bypass surgery will receive infusion of Exendin 9-39 prior to an intake test.
2979936|NCT02697253|Placebo Comparator|Success placebo|Participants who lost more than 30% body weight at 2 years post-roux-en-y bypass surgery will receive placebo infusion prior to an intake test.
2979937|NCT02697253|Placebo Comparator|Unsuccess placebo|Participants who lost less than 15% body weight at 2 years post-roux-en-y bypass surgery will receive placebo infusion prior to an intake test.
2985741|NCT02658344|Placebo Comparator|Saline solution|Sodium chloride
2979939|NCT02697227|Experimental|Behavior Activation Treatment (BATS) in IRS+ Smokers|"High reward sensitivity smokers (IRS+) complete 8, 45-minute individual treatment sessions. Treatment consists of 15 minutes of Standard Cessation Counseling (SC) strategies as well as 30 minutes of Behavioral Activation (BA) strategies. BA strategies focus on encouraging participant to structure a variety of reinforcing activities to promote a more rewarding smoke-free lifestyle through daily activity monitoring, assessment of values and life goals to facilitate choice of rewarding activities, scheduling of specific activities related to quit preparation and abstinence, and weekly homework assignments.~Participants receive nicotine replacement therapy (NRT) 21 mg patch for 8 weeks, initiated on the scheduled quit day (just prior to Visit 4)."
2979940|NCT02697227|Experimental|Behavior Activation Treatment (BATS) in IRS- Smokers|"Low reward sensitivity smokers (IRS-) complete 8, 45-minute individual treatment sessions. Treatment consists of 15 minutes of Standard Cessation Counseling (SC) strategies as well as 30 minutes of Behavioral Activation (BA) strategies. BA strategies focus on encouraging participant to structure a variety of reinforcing activities to promote a more rewarding smoke-free lifestyle through daily activity monitoring, assessment of values and life goals to facilitate choice of rewarding activities, scheduling of specific activities related to quit preparation and abstinence, and weekly homework assignments.~Participants receive nicotine replacement therapy (NRT) 21 mg patch for 8 weeks, initiated on the scheduled quit day (just prior to Visit 4)."
2979941|NCT02697227|Active Comparator|Standard Cessation Counseling (SC) in IRS+ Smokers|"High reward sensitivity smokers (IRS+) receive 8, 45-minute individual behavioral treatment sessions. Sessions initially consist of 15 minutes of behavioral treatment strategies for smoking cessation. Treatment involves preparation for quitting, identification of high risk situations for smoking, development of coping skills and direct support before and after the quit date, motivational intervention 91 for keeping or resetting a quit date, management of withdrawal symptoms, stress management, relaxation, relapse prevention, and medication compliance.~Participants receive nicotine replacement therapy (NRT) 21 mg patch for 8 weeks, initiated on the scheduled quit day (just prior to Visit 4)."
2979942|NCT02697227|Active Comparator|Standard Cessation Counseling (SC) in IRS- Smokers|"Low reward sensitivity smokers (IRS-) receive 8, 45-minute individual behavioral treatment sessions. Sessions initially consist of 15 minutes of behavioral treatment strategies for smoking cessation. Treatment involves preparation for quitting, identification of high risk situations for smoking, development of coping skills and direct support before and after the quit date, motivational intervention 91 for keeping or resetting a quit date, management of withdrawal symptoms, stress management, relaxation, relapse prevention, and medication compliance.~Participants receive nicotine replacement therapy (NRT) 21 mg patch for 8 weeks, initiated on the scheduled quit day (just prior to Visit 4)."
2979943|NCT02697214|Active Comparator|Apple Watch|Apple Watch heart rate monitoring device.
2979944|NCT02697214|Active Comparator|Fitbit Charge HR|Fitbit Charge HR heart rate monitoring device.
2979945|NCT02697214|Active Comparator|Mio Fuse|Mio Fuse heart rate monitoring device.
2979946|NCT02697214|Active Comparator|Basis Peak|Basis Peak heart rate monitoring device.
2979947|NCT02697201|Experimental|Intralipid Infusion, then Saline|Participants in this arm will first receive a lipid infusion. Then 4 weeks later the saline infusion.
2979948|NCT02697201|Sham Comparator|Saline Infusion, then Intralipid|Participants in this arm will first receive a saline infusion. Then 4 weeks later the lipid infusion.
2979949|NCT02697188|Experimental|Testosterone undecanoate|Period 2 - 200 mg T (as TU) QD Period 3 - 200 mg T (as TU) BID (100 mg/dose) Period 4 - 400 mg T (as TU) BID (200 mg/dose)
2979950|NCT02697188|Active Comparator|Testosterone enanthate|Period 1 - 400 mg T (as TE) QD Period 5 - 800 mg T (as TE) BID (400 mg/dose)
2979951|NCT02697175|Experimental|Live Video-Colposcopy|Women are able to observe their colposcopic examination in real-time watching a flat screen in front of them
2979952|NCT02697175|Active Comparator|No Live Video-Colposcopy|Women are not able to observe their colposcopic examination in real-time
2979953|NCT02697162|Experimental|Antiseptic-coated catheter|Hydrophilic intermittent urinary catheter coated with octenidine chloride
2979954|NCT02697162|Placebo Comparator|Hydrophilic catheter|Hydrophilic intermittent urinary catheter
2979955|NCT02697149||intervention|patients undergoing nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography
2979956|NCT02697149||control|patients undergoing standard endoscopic retrograde cholangiopancreatography
2979957|NCT02697136|Experimental|CER-001|CER-001 infusion; 9 weekly infusions followed by 20 biweekly infusions
2979958|NCT02697136|Placebo Comparator|Placebo|Saline infusion; 9 weekly infusions followed by 20 biweekly infusions
2979959|NCT02697123||antepartum and postpartum|This prospective, observational cohort study was designed to assess the incidence of VTE in patients hospitalized for Cesarean Section, Vaginal delivery or any antepartum indication.
2979960|NCT02697110|Experimental|A: Edutainment based intervention|This group receives the usual routine immunization at 6, 10, 14 weeks and 9 months and an Edutainment intervention package of limited group (i.e., 3-5 women) drama based video session (Edutainment) followed by a Question and Answer session with mothers on early brain development, parenting skills, communication and negotiating skills at 6 weeks. Mothers will be encouraged to train fathers and other caregivers at home with reinforcement of key messages at subsequent clinic visits. Key messages will be delivered through the use of flip charts at 14 weeks and given to mothers as take home for use in engaging the fathers partners and other caregivers for their child. Reinforcement of key messages at subsequent visits will be through the use of videos and flip chart.
2979961|NCT02697110|No Intervention|B|This group receives routine immunization care (usually includes group health talk) at 6, 10, 14 weeks and 9 months.
2979962|NCT02697097||Control Arm Group|Participants aged 18-30, Male and Female (10 participants each). Control group must have normal range of movement and no evidence of femoro-acetabular impingement (FAI) on clinical examination (negative impingement test, no symptoms). Other exclusions for Control Group include previous surgery to hip joint/s, history of arthritis, family history of FAI, patients who have had symptoms of hip pain in the preceding 1 year or may have other conditions which may affect the hip joint or hip muscle strength including neurological conditions or muscular dystrophy.
2979963|NCT02697097||FAI Arm Comparison Group|Participants aged 18-30, Male and Female (10 participants each). Participants with femoro-acetabular impingement as diagnosed clinically and on radiological imaging for the comparison group (MRI).
2986623|NCT02652416|Experimental|MD part (high dose)|Chinese, Japanese both
2979966|NCT02697058|Experimental|Part 1: Safety and PK|BAX2398 in combination with 5-FU/calcium levofolinate
2979967|NCT02697058|Experimental|Part 2: Safety, PK, Efficacy|BAX2398 in combination with 5-FU/calcium levofolinate
2979968|NCT02697058|Active Comparator|Part 2: 5-FU/calcium levofolinate alone|5-FU/calcium levofolinate
2979969|NCT02697045|Other|ARIPIPRAZOLE|ABILIFY MAINTENA 400 MG LAI
2979970|NCT02697032|Experimental|Patients|At day 0 before start with bicalutamide, a FDHT-PET/CT will be performed, and one after 6 weeks (i.e. 2 weeks after steady-state). The second FDHT-PET will be performed to determine if this scan can be used as a biomarker for early response. Patients will be treated with bicalutamide until progression or unacceptable toxicity is encountered.
2979971|NCT02697019|Experimental|Internet-delivered ERITA|
2979972|NCT02696993|Experimental|Nivolumab + Stereotactic Radiosurgery (SRS)|"Phase I: Nivolumab administered initially at 3 mg/kg by vein every 2 weeks. Stereotactic Radiosurgery (SRS) performed once, at dosage prescribed by treating physician. SRS performed optimally the day after the first administration of Nivolumab, but may occur within the first two weeks.~Neurocognitive exam completed at baseline and 1 month after radiation treatment."
2979973|NCT02696993|Experimental|Nivolumab + Whole Brain Radiation Therapy (WBRT)|"Phase I: Nivolumab administered initially at 3 mg/kg by vein every 2 weeks. WBRT delivered to the whole brain 5 days a week. Participants treated to a total dose of 30 Gy in 10 fractions. WBRT performed optimally the day after the first administration of nivolumab, but may occur within the first two weeks.~Neurocognitive exam completed at baseline and 1 month after radiation treatment."
2979974|NCT02696993|Experimental|Nivolumab + Ipilimumab and Stereotactic Radiosurgery (SRS)|"Phase II: Nivolumab administered by vein every two weeks at the maximum tolerated dose from Phase I. Ipilimumab 1 mg/kg by vein every 6 weeks. SRS performed optimally the day after the first administration of Ipilimumab , but may occur within the first two weeks.~Neurocognitive exam completed at baseline and 1 month after radiation treatment."
2979975|NCT02696993|Experimental|Nivolumab+Ipilimumab and Whole Brain Radiation Therapy (WBRT)|"Phase II: Nivolumab administered by vein every two weeks at the maximum tolerated dose from Phase I. Ipilimumab 1 mg/kg by vein every 6 weeks. WBRT delivered to the whole brain 5 days a week. Participants treated to a total dose of 30 Gy in 10 fractions. WBRT performed optimally the day after the first administration of nivolumab, but may occur within the first two weeks.~Neurocognitive exam completed at baseline and 1 month after radiation treatment."
2979976|NCT02696980|Experimental|Rescue|Intervention: Positive expiratory pressure (PEEP) 10 will be applied after the administration of methacholine
2979977|NCT02696980|Experimental|Prophylaxis|Intervention: Positive expiratory pressure (PEEP) 10 will be applied during the administration of methacholine
2979978|NCT02696980|Placebo Comparator|No PEEP|Intervention: Positive expiratory pressure (PEEP) 0 will be applied during the administration of methacholine
2979979|NCT02696967|Experimental|CLR325|Patients will be assigned to one of the 2 treatment arms in fixed randomization ratio. Patients randomized to this arm , will receive single dose of CLR325 (i.v.) in double blind manner.
2979980|NCT02696967|Placebo Comparator|Placebo|Patients will be assigned to one of the 2 treatment arms in fixed randomization ratio. Patients randomized to this arm , will receive single dose of placebo (i.v.) in double blind manner.
2979981|NCT02696954|Experimental|Group A|
2979982|NCT02696954|Experimental|Group B|
2979983|NCT02696941|Experimental|Metformin|Participants with insulin resistance who have not yet started any diabetic medication will be recruited and will be prescribed metformin at standard clinical doses.
2979984|NCT02696941|Experimental|SGLT2|Participants with poorly controlled type 2 Diabetes (T2DM) who have been recommended to start an SGLT2 inhibitor will be recruited.
2979985|NCT02696928|Other|Artemeter-Lumefantrine (combination therapy)|"33 patients~(standard of care)"
2979986|NCT02696928|Active Comparator|Artemeter-Lumefantrine and Primaquine (combination therapy)|33 patients
2979987|NCT02696928|Experimental|Artemeter-Lumefantrine and MB (combination therapy)|33 patients
2979988|NCT02696915|Placebo Comparator|Placebo|Patients received ultrasound guided fascia iliaca compartment block using 40 ml of saline 0.9%. Then intrathecal medications will be administered.
2979989|NCT02696915|Active Comparator|Bupivacaine|Patients received ultrasound guided fascia iliaca compartment block using 40 ml of 0.25% bupivacaine. Then intrathecal medications will be administered.
2979990|NCT02696902|Active Comparator|MEDI3902|
2979991|NCT02696902|Placebo Comparator|Placebo|
2979992|NCT02696889|Experimental|ROSE Protocol|Patients with POF choosing to enroll will be provided informed consent for Rejuvenation of Premature Ovarian Failure With Stem Cells (ROSE). They will undergo diagnosis and screening confirming POF including History and Physical Exams, Labs and Diagnostic Procedures. Following final approval and under anesthesia, bone marrow aspiration with separation of the bone marrow derived stem cell fraction will be performed. Diagnostic laparoscopy will allow for assessment of pelvic anatomy; biopsy of the right ovary and subsequent injection of the bone marrow derived stem cells into the right ovary.
2979993|NCT02696876|Active Comparator|Control group|Patients in this group will received conventional microfracture treatment as indicated for isolated cartilage defects and defined by the inclusion criteria.
2979994|NCT02696876|Experimental|Intervention group|Patients in this group will also receive microfracture for the treatment of isolated cartilage defects in combination with arthroscopic synovial brushing to access and release synovial MSCs into the joint space.
2979995|NCT02696863||filling a questionnaire and interview|"The questionnaire is tracking occupational carcinogens. It consists of 30 questions , fills an average of 3 minutes and includes three response categories: yes, no and do not know. A questionnaire will be added social and professional issues.~Interviews will be conducted with the patient to identify obstacles and facilitating elements"
2979996|NCT02696850|Experimental|Budesonide|"The study intervention will be budesonide powder (0.5 mg/capsule). Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.~Each study bottle will contain 60 capsules of Budesonide and will be assigned with a number from 1-80."
2980029|NCT02696642|Experimental|Anetumab ravtansine [mild impaired]|Subjects with mild hepatic impairment (Child-Pugh Class A and eGFR [estimated glomerular filtration rate] ≥60 mL/min/1.73 m2)
2979997|NCT02696850|Placebo Comparator|Saline Alone|Each study bottle will contain 60 capsules of placebo, which is lactose monohydrate and will be supplied in clear plastic capsules identical to the budesonide capsules. Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.
2979998|NCT02696837|Active Comparator|ETT & Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Endotracheal Intubation and Muscle Relaxant
2979999|NCT02696837|Active Comparator|ETT & No Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Endotracheal Intubation and No Muscle Relaxant
2980000|NCT02696837|Active Comparator|Proseal LMA & No Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Proseal Laryngeal Mask Airway and NO Muscle Relaxant
2980001|NCT02696837|Active Comparator|Proseal LMA & Subparalytic Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Proseal Laryngeal Mask Airway and subparalytic dose Muscle Relaxant
2980002|NCT02696824|Experimental|CBT-AD|Those assigned to the CBT-AD [cognitive behavioral therapy for adherence and depression) condition, will have up to 8 additional sessions delivered by the study clinic nurse. Additionally, those assigned to CBT-AD will have the procedures available to those assigned to ETAU.
2980003|NCT02696824|No Intervention|ETAU|"Participants in both conditions receive usual care plus the following procedures below.~All participant will have the benefit of the psychosocial assessment, and the clinic nurse will provide feedback to the participant and to their clinic doctor about their depression. Additionally, all participants will undergo standard of care second line treatment adherence counseling in the clinic . The clinic doctor will not be restricted in terms of referral or treatment of depression for their patient with respect to antidepressant medications or other interventions available."
2980004|NCT02696811|Placebo Comparator|Oat biscuits|Participants will eat 3 oat biscuits per day for 6 weeks
2980005|NCT02696811|Experimental|White Carrots|Participants will eat 100g (cooked weight) of white carrots per day for 6 weeks
2980006|NCT02696798|Experimental|Q2W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52."
2980007|NCT02696798|Experimental|Q4W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52."
2980008|NCT02696798|Placebo Comparator|Placebo|"Double Blind Period: Placebo given SC Q2W to week 14.~Extended Treatment Period: Starting dose of 160 mg ixekizumab given SC at week 16 followed by 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52."
2980009|NCT02696785|Experimental|Q2W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52."
2980010|NCT02696785|Experimental|Q4W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52."
2980011|NCT02696785|Placebo Comparator|Placebo|"Double Blind Period: Placebo given SC Q2W to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52."
2980012|NCT02696785|Active Comparator|Adalimumab|"Double Blind Period: 40 mg Adalimumab given SC Q2W to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 20 to week 52."
2980013|NCT02696772|Experimental|Energy balance|Intervention day diet containing 100% of estimated energy requirements
2980014|NCT02696772|Experimental|Energy restriction|Intervention day diet containing 25% of estimated energy requirements
2980015|NCT02696759|Other|Blood & Fecal Collection|Subjects receiving neoadjuvant chemotherapy for advanced breast cancer will be asked to complete questionnaires, provide two blood samples, and provide 2 fecal samples while receiving standard of care neoadjuvant chemotherapy
2980016|NCT02696746||Pain related conditions|Subjects with painful or painless conditions (observational study, no interventions)
2980017|NCT02696733|Experimental|UG - ONB|Patients with the bladder tumor located on the lateral wall, with the high risk of adductor muscles contraction during TURBT under spinal anesthesia.
2980018|NCT02696720|Experimental|Lidocaine|During a period of six weeks, a lidocaine patch will be applied around the wound (cut in two parts, 1cm above and below the wound, without direct contact with the scar) for a total of twelve hours per day, during night time.
2980019|NCT02696720|Sham Comparator|Sham|During a period of six weeks, a visually identical patch (sham) will be applied around the wound (cut in two parts, 1cm above and below the wound, without direct contact with the scar) for a total of twelve hours per day, during night time.
2980020|NCT02696707|Active Comparator|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
2980021|NCT02696707|Active Comparator|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
2980022|NCT02696694||P25-P75|serum progesterone between 25 and 75 percentile
2980023|NCT02696694||<P25 ó >P75|serum progesterone <25 or >75 percentile
2980024|NCT02696681|Experimental|Cognitive Behavioral Therapy|Integrating CBT for any substance use or mental health problems with CBT for adherence/self-care
2980025|NCT02696668|Active Comparator|modified FaME|Participants in the modified FaME group will receive a 16 weeks falls rehabilitation programme which will be tailored and progressed according to their abilities and their needs by the physiotherapist / instructor providing the rehabilitation at the hospital.
2980026|NCT02696668|Experimental|Multisensory|Participants in the multisensory group will receive balance exercises training which will be tailored and progressed to their abilities and needs.
2980027|NCT02696655|Experimental|liver transplant patients|Patients will use a behavioural intervention to assess its usability
2980028|NCT02696642|Experimental|Anetumab ravtansine [hepatic control]|Subjects with adequate hepatic and renal function (controls)
2980119|NCT02696070|Other|Sham of Provant|Sham of Provant
2980030|NCT02696642|Experimental|Anetumab ravtansine [moderate impaired1]|Subjects with moderate hepatic impairment (Child-Pugh Class B and and eGFR ≥60 mL/min/1.73 m2)
2980031|NCT02696642|Experimental|Anetumab ravtansine [moderate impaired2]|Moderate renal function impairment will be assessed by eGFR <60 and ≥30 mL/min per 1.73 m2
2980032|NCT02696629||Education and follow up|Participants who refuse or fail to have PAP treatment or Oral appliance or other treatments for sleep apnea. They also refuse or have counter-indication for surgical treatment. The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
2980033|NCT02696629||Upper airway surgery|Participants who undergo uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery.
2980034|NCT02696629||Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
2980035|NCT02696616|Experimental|BI 655088|
2980036|NCT02696616|Placebo Comparator|Placebo|
2980037|NCT02696603|Experimental|Participants with Parkinson disease|People who report a diagnosis of Parkinson disease. Participants are invited via the Parkinson mPower mobile application to complete the following behavioral interventions: Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, and Participant open-response writing.
2980038|NCT02696603|Experimental|Participants without Parkinson disease|People who do not report a diagnosis of Parkinson disease. Participants are invited via the Parkinson mPower mobile application to complete the following behavioral interventions: Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, and Participant open-response writing.
2980039|NCT02696590|Experimental|MS patients injectable Vitamin D3|MS patients who received injectable form of Vitamin D3, received 600.000 IU Intramuscular vitamin D3 injection, in two weeks; 300.000 IU at the study entry and 300.000 IU in second week
2980040|NCT02696590|Experimental|MS patients orally Vitamin D3|received the same total dose of 600 000 IU D3 in two weeks, in the form of twelve pearls, each containing 50 000 IU D3 as follows: the first pearl was delivered at study entry, followed by one pearl each day for another 11 Days.
2980041|NCT02696590|Active Comparator|Healthy groups Injectable Vitamin D3|who received injectable form of Vitamin D3, received 600.000 IU Intramuscular vitamin D3 injection, in two weeks; 300.000 IU at the study entry and 300.000 IU in second week
2980042|NCT02696590|Active Comparator|Healthy groups Vitamin D3 orally|received the same total dose of 600 000 IU D3 in two weeks, in the form of twelve pearls, each containing 50 000 IU D3 as follows: the first pearl was delivered at study entry, followed by one pearl each day for another 11 Days.
2980043|NCT02696577|Active Comparator|Low dose aspirin|Received aspirin 81mg once daily for 6 weeks
2980044|NCT02696577|Active Comparator|Low dose aspirin plus omega 3 group|Received aspirin 81mg and omega 3 once daily for 6 weeks.
2980045|NCT02696564|Active Comparator|Losartan|At randomization participants will start with a dose of 50mg (one capsule) once a day for 2 weeks. If this dose is well tolerated and systolic BP is >90 mm Hg and diastolic BP is > 60 mm Hg, the dose will be increased to 100 mg (2 capsules) once a day for the remaining 46 weeks.
2980046|NCT02696564|Placebo Comparator|placebo|At randomization participants will start with a dose of one capsule (inactive) once a day for 2 weeks. After two weeks, if systolic BP is >90 mm Hg and diastolic BP is > 60 mm Hg, the dose will be increased to 2 capsules once a day for the remaining 46 weeks.
2980047|NCT02696551|Experimental|Interventional hospital|Interventional hospital, which will receive 3-month medical education
2980048|NCT02696551|No Intervention|Non-interventional hospital|Non-interventional hospital, which will not receive 3-month medical education.
2980049|NCT02696538|Experimental|Experimental|All participants included in this group and will complete all three outcomes assessment
2980050|NCT02696512|Experimental|IBRF ACP/MCP Group 1|The Treatment group will be receiving a combination of pharmaceuticals (polypharmacy using FDA-approved products) and nutraceuticals (Nutraceutical supplementation) and median nerve stimulation (MNS)
2980051|NCT02696512|Other|Standard of Care Group 2|Standard of Care only
2980052|NCT02696499|Experimental|PA101B|
2980053|NCT02696499|Placebo Comparator|Placebo|
2980054|NCT02696486|Experimental|Exercise Training|
2980055|NCT02696473|Experimental|High Carrot Dose|The volunteer will eat 250g carrot for breakfast with 2 slices of bread and 10g butter
2980056|NCT02696473|Experimental|Low Carrot Dose|The volunteer will eat 100g of carrot for breakfast with 2 slices of bread and 10g butter
2980057|NCT02696460|Active Comparator|N2O/O2 analgesia|Wound debridement under analgesia with N2O/O2 premix.
2980058|NCT02696460|Active Comparator|Lidocaine/Prilocaine analgesia|Wound debridement under analgesia with eutectic mixture of 5% lidocaine/prilocaine.
2980059|NCT02696447||Cancer treated by radiotherapy|Patient with a solid cancer (all locations) treated with radiation therapy and/or brachytherapy as curative intent
2980060|NCT02696434|Active Comparator|PBO NTX + BUP|Placebo naltrexone + buprenorphine
2980061|NCT02696434|Experimental|NTX + BUP|Naltrexone + buprenorphine
2980062|NCT02696421||Non diabetic, non obese|
2980063|NCT02696408|Experimental|Laser treatment|preventive treatment performed by nurses of mucositis by laser treating daily by scanning the entire oral cavity for 2 minutes with a power of 250 mW associated with mouthwashes several times a day (standard preventive treatment of mucositis)
2980064|NCT02696408|Placebo Comparator|laser-off|daily laser-off session performed by nurses associated with mouthwashes several times a day (standard preventive treatment of mucositis)
2980065|NCT02696395|Active Comparator|DePuy Tri-Lock®|Total hip replacement with DePuy Tri-Lock® femoral stem and Deltamotion® acetabular component. The surgery will be conducted using a postero-lateral approach followed by post operative rehabilitation as per standard care.
2980066|NCT02696395|Active Comparator|DePuy Corail®|Total hip replacement with DePuy Corail® femoral stem and Deltamotion® acetabular component. The surgery will be conducted using a postero-lateral approach followed by post operative rehabilitation as per standard care.
2980067|NCT02696382|Active Comparator|Usual Care (UC)|"Participants in the Usual Care (UC) group will receive standard, low-intensity physical therapy following discharge from acute hospitalization."
2980120|NCT02696070|Other|Active Treatment|Active Provant Treatment
2986624|NCT02652416|Experimental|Placebo (SRD part)|placebo
2980068|NCT02696382|Experimental|Progressive High Intensity Therapy|"Participants in the Progressive High Intensity Therapy (PHIT) group will receive high intensity physical therapy following discharge from acute hospitalization."
2980069|NCT02696369|Experimental|2% Lidocaine HCL:Epinephrine inj.|2% Lidocaine HCL with epinephrine 1:200,000
2980070|NCT02696369|Active Comparator|2% Lidocaine HCL:Epinephrine inj. (3M)|2% Lidocaine HCl with epinephrine 1:80,000
2980071|NCT02696356|Experimental|Cohort 1|0.1mg GRN-1201
2980072|NCT02696356|Active Comparator|Cohort 2|1.0mg GRN-1201
2980073|NCT02696356|Experimental|Cohort 3|3.0mg GRN-1201
2980074|NCT02696343|Experimental|EPI experimental|Preterm infants randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
2980075|NCT02696343|Sham Comparator|EPI control|Preterm infants randomized to receive the Sham (blind pacifier) during tube feedings.
2980076|NCT02696330|Active Comparator|clopidogrel|50 patients undergoing ICSI
2980077|NCT02696330|Active Comparator|enoxaparin|50 patients undergoing ICSI
2980078|NCT02696330|Placebo Comparator|placebo|50 patients undergoing ICSI
2980079|NCT02696317|Other|AO1D, then AO|Senofilcon A contact lenses with HydraLuxe™, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
2980080|NCT02696317|Other|AO, then AO1D|Senofilcon A contact lenses, followed by senofilcon A contact lenses with HydraLuxe™. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
2980081|NCT02696304|Other|TBI for childhood leukemia|Patients with a metabolic syndrom who received TBI.
2980082|NCT02696304|Other|No TBI for childhood leukemia|Patients with a metabolic syndrom without previousTBI
2980083|NCT02696291|Experimental|Cohort 1 - 30 mg|Subjects receiving UV-4B 30 mg oral solution or placebo
2980084|NCT02696291|Experimental|Cohort 2 - 75 mg|Subjects receiving UV-4B 75 mg oral solution or placebo
2980085|NCT02696291|Experimental|Cohort 3 - 150 mg|Subjects receiving UV-4B 150 mg oral solution or placebo
2980086|NCT02696291|Experimental|Cohort 4 - X mg (dose to be determined)|Subjects receiving UV-4B X mg (dose to be determined) oral solution or placebo
2980087|NCT02696291|Experimental|Cohort 5 - Y mg (dose to be determined)|Subjects receiving UV-4B Y mg (dose to be determined) oral solution or placebo
2980088|NCT02696278|Experimental|Hummus and vegetables|Children will receive a lesson about vegetables and hummus and vegetables as part of their daily snack.
2980089|NCT02696278|Experimental|Vegetables only|Children will receive a lesson about vegetables and vegetables as part of their daily snack.
2980090|NCT02696265|Active Comparator|CFAE guided ablation|CFAE/spatiotemporal dispersion guided ablation: CFAE mapping and ablation during AF aimed at restoring sinus rhythm during ablation.
2980091|NCT02696265|Active Comparator|PVI guided ablation|PVI guided ablation: wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals.
2980092|NCT02696252||CGM Users|
2980093|NCT02696239|Active Comparator|V-lock suture|V-lock absorbable Wound Closure Device, by Covidien
2980094|NCT02696239|Active Comparator|Vicryl suture|Vicryl suture by Ethicon
2980095|NCT02696239|Active Comparator|Lapra-Ty II|Lapra-Ty II, Absorbable Suture Clip, by Ethicon
2980096|NCT02696226|Experimental|SAVR Warfarin Arm|Warfarin arm-(target INR of 2-3)
2980097|NCT02696226|Experimental|TAVR Warfarin and Clopidogrel Arm|Warfarin (target INR of 2-3) and Clopidogrel (75mg/day) arm
2980098|NCT02696226|Experimental|SAVR Aspirin Arm|Aspirin arm (81mg/day)
2980099|NCT02696226|Experimental|TAVR Aspirin and Clopidogrel Arm|Aspirin (81mg/day) and Clopidogrel (75mg/day) arm
2980100|NCT02696213|Experimental|SCOOT Immediate|This group will receive SCOOT immediately
2980101|NCT02696213|Other|SCOOT Delayed|This group will receive SCOOT after 6 weeks
2980102|NCT02696200|Experimental|Subjects Wearing the Q Collar|Subjects wearing the Q collar throughout the football season
2980103|NCT02696200|No Intervention|Subjects Not Wearing the Q Collar|Control group of subjects not wearing the q collar
2980104|NCT02696187|Experimental|KOLwebben|Patients in the experimental group will be introduced to KOL-webben during their ordinary visits to the primary care center. All patients will receive a pedometer
2980105|NCT02696187|No Intervention|Control group|Other than receiving a pedometer the patients in the control group will not receive any intervention.
2980106|NCT02696174|Experimental|Health Microinsurance Scheme|Households owning the HMI package, entitling them to visit and receive treatment from the selected primary care clinic
2980107|NCT02696174|No Intervention|Out-Of-Pocket|Households who visit the selected primary care clinic, but pay by Out-Of-Pocket
2980108|NCT02696161|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
2980109|NCT02696161|Placebo Comparator|5% dextrose|5% dextrose for hydrodissection
2980110|NCT02696148|Experimental|Liraglutide|
2980111|NCT02696148|Placebo Comparator|Placebo|
2980112|NCT02696135||Hypertrophic cardiomyopathy|Individuals with an unexplained maximal left ventricle wall thickness ≥15 mm on echocardiography and/or cardiac magnetic resonance imaging or or ≥13 mm for individuals with family history of HCM, in the absence of other cardiac or systemic diseases capable of producing that magnitude of cardiac hypertrophy.
2980113|NCT02696122|Experimental|Local Group|Local infiltration under general anesthesia via laryngeal mask
2980114|NCT02696122|Experimental|Spinal Group|Spinal anesthesia with 15 mg of 0.5% hyperbaric bupivacaine
2980115|NCT02696109|Experimental|Cornerstone|Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
2980116|NCT02696109|Active Comparator|Treatment as Usual|Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.
2980117|NCT02696096|Other|All Participants|FMRI Suboxone
2980118|NCT02696083|Experimental|Active Treatment|
2980121|NCT02696057|Active Comparator|Manual technics|Manual technics was consisted of soft tissue technics, muscle energy technics, joint mobilization.
2980122|NCT02696057|Active Comparator|Exercise|Spinal stabilization exercises were applied all the patients in this group accompanied by physiotherapist.
2980123|NCT02696044|Experimental|Participants aged 0 months to 3 years|Participants will receive 4 grams of triheptanoin per kilogram of body weight daily.
2980124|NCT02696044|Experimental|Participants aged 4 to 6 years|Participants will receive 3 grams of triheptanoin per kilogram of body weight daily.
2980125|NCT02696044|Experimental|Participants aged 7 to 9 years|Participants will receive 2.5 grams of triheptanoin per kilogram of body weight daily.
2980126|NCT02696044|Experimental|Participants aged 10 to 14 years|Participants will receive 2 grams of triheptanoin per kilogram of body weight daily.
2980127|NCT02696044|Experimental|Participants aged 15 to 20 years|Participants will receive 1.5 grams of triheptanoin per kilogram of body weight daily.
2980128|NCT02696044|Experimental|Participants aged 21 years and older|Participants will receive 1.2 grams of triheptanoin per kilogram of body weight daily.
2980129|NCT02696031|Experimental|Secukinumab|Secukinumab 150 mg s.c.
2980130|NCT02696031|Placebo Comparator|Placebo|Placebo s.c.
2980131|NCT02696031|Experimental|Experimental|Secukinumab 150 mg s.c. no load
2980132|NCT02696018||Critically ill patients|Ultrasonography in critically ill patients in weaning from mechanical ventilation
2980133|NCT02696005||Group I|15 patients who will continue participation in Exercise- Based Cardiac Rehabilitation Programme after completion initial 3-months period.
2980134|NCT02696005||Group II|15 patients who will stop participation in Exercise- Based Cardiac Rehabilitation Programme after the initial 3-months period.
2980135|NCT02695992|Active Comparator|Metoprolol|Metoprolol, extended release tablets. 100 mg daily
2980136|NCT02695992|Active Comparator|Diltiazem|Diltiazem, extended release tablets. 360 mg daily
2980137|NCT02695979||Patients undergoing OLT|Patients aged 18-70 with end-stage liver disease undergoing orthotopic liver transplantation (OLT).
2980138|NCT02695940|Active Comparator|LEO 124249 ointment 30 mg/g|Drug LEO 124249 ointment 30 mg/g twice daily application for 6 weeks, maximum of 1.44 g ointment per day
2980139|NCT02695940|Placebo Comparator|LEO 124249 ointment vehicle|LEO 124249 ointment vehicle twice daily application for 6 weeks, maximum of 1.44 g ointment per day
2980140|NCT02695927|Experimental|Chronic|Crossover study on the benefits of computer rehabilitation glasses on chronic sufferers of hemispatial neglect
2980141|NCT02695927|Experimental|Acute|Randomized, controlled study on the benefits of computer rehabilitation glasses on acute sufferers of hemispatial neglect
2980142|NCT02695927|Experimental|Optimization|Study to identify optimal operating parameters of computer rehabilitation glasses
2980143|NCT02695927|Active Comparator|Duration|Study to determine duration of effect of computer rehabilitation glasses
2980144|NCT02695914||Control group|Conventional treatment methods will be given to cases in control group.
2980145|NCT02695914||Experiment group|On the base of control group, Compound Qingre Granule will be added to in experiment group.
2980146|NCT02695901|Experimental|Chlorhexidine gluconate (0,12%)|Subjects will rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%).
2980147|NCT02695901|Experimental|M. alternifolia oil (Nanoparticle solution)|Subjects will rinse twice daily with 15 ml mouthrinse containing nanoparticles of M. alternifolia oil (0.3%).
2980148|NCT02695888|Experimental|Risky driving prevention|Web-based behavioral intervention to promote teen driver attention to the roadway, addressing mobile technology and passengers.
2980149|NCT02695888|Experimental|Control group|Web-based behavioral intervention for healthy lifestyles.
2980150|NCT02695875|Experimental|Aquatic therapy|Aquatic therapy is the experimental group. This therapy will take place in a warm pool which is located in Rialta's Sports Complex. Aquatic therapy session will be conducted by the main researcher with the help of an assistant. Because the number of patients (n=17), they will be subdivided into two subgroups of 8 and 9 people respectively in order to ensure the safety and care of patients. The intervention will last for one hour: Warming (15 minutes); exercises to train the static and dynamic balance (25 minutes); stretching (10 minutes); relaxation (10 minutes). Over 12 weeks of treatment, difficulty in performing exercises to train balance will increase progressively.
2980151|NCT02695875|Other|Land-based therapy|"The description is the same as aquatic therapy. The difference is land-based therapy sessions will be made at Faculty of Physiotherapy at University of A Coruña."
2980152|NCT02695862|Experimental|Bolus Terlipressin|Injection terlipressin after 2 mg bolus it will be given 2 mg QID
2980153|NCT02695862|Active Comparator|Terlipressin continuous(4mg/24hours)|Injection terlipressin after 2 mg bolus it will be given 4 mg over 24 hours,and dose will be titrated as per HVPG (Hepatic Venous Pressure Gradient)
2980154|NCT02695849||NSCLC Participants|Participants with non-squamous NSCLC will be enrolled in this study.
2980155|NCT02695836|Active Comparator|Standard feedback|Facilities in this arm will receive an initial face-to-face dissemination workshop that includes feedback of research data on modifiable aspects of their microsystem context but no goal setting.
2980156|NCT02695836|Experimental|Basic assisted feedback|In addition to the face-to-face dissemination workshop, facilities in this arm will receive a face-to-face goal setting workshop focused on modifiable areas of their microsystem context and two virtual support workshops at six month intervals.
2980157|NCT02695836|Experimental|Enhanced assisted feedback|In addition to the face-to-face dissemination workshop, facilities in this arm will receive an additional face-to-face goal setting workshop focused on modifiable areas of their microsystem context, two additional face-to-face support workshops at six month intervals plus on-demand email and telephone support.
2980158|NCT02695823|Experimental|Patients undergoing liver transplantation|
2980159|NCT02695810|Experimental|Dapagliflozin|Dapagliflozin, 10 mg per day
2980160|NCT02695810|Active Comparator|Metformin|Metformin, 2 x 850 mg per day
2980161|NCT02695810|Active Comparator|Exercise|Exercise, interval training
2980162|NCT02695810|No Intervention|Control|No intervention
2980163|NCT02695797|Experimental|Immunotherapy|Intravenous immunoglobulin (IVIG) and oral prednisolone. IVIG and oral prednisolone are administered simultaneously: IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day).
2980165|NCT02695784|Experimental|Probiotic continuation|This Group will Continue probiotics Beyond 34 weeks corrected Gestational agent standard practice
2980166|NCT02695784|No Intervention|Standard treatment Group|This group will continue current standard practice of stopping probiotics at 34 weeks corrected gestational age
2980167|NCT02695771|Experimental|Mitomycin C|Mitomycin C 40 mg in 40 mL of 0.9% sodium chloride intravesicular immediately following TURBT one time.
2980168|NCT02695771|Active Comparator|Gemcitabine|Gemcitabine 2 grams in 100 mL of 0.9% sodium chloride intravesicular immediately following TURBT one time.
2980169|NCT02695771|No Intervention|No intervention|Patients randomized to this arm will receive no intervention intravesicular immediately following TURBT one time.
2980170|NCT02695758|Active Comparator|interscalene brachial plexus block|Direct interscalene nerve block injection via brachial plexus
2980171|NCT02695758|Active Comparator|Bupivacaine extended-release liposome injection|Infiltration of local anesthetic/analgesic, Bupivacaine extended-release liposome injection (Exparel) + Diluted in 40cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues.
2980172|NCT02695745|Experimental|V116517|V116517 aqueous suspension; 300 mg
2980173|NCT02695745|Active Comparator|Celecoxib|Celecoxib capsules; 400 mg (2 capsules of 200 mg each)
2980174|NCT02695745|Placebo Comparator|Placebo|Placebo
2980175|NCT02695732|Experimental|Carvedilol|Carvedilol，6.25mg-12.5mg/d,oral,6-36 months
2980176|NCT02695732|Active Comparator|endoscopy|endoscopy，every 4 weeks until eradication of varices
2980177|NCT02695719|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
2980178|NCT02695719|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
2980179|NCT02695706|Experimental|Laboratoires Mercurochrome Reparador|A group of patients will be treated with a new restorative skin cream consists of hyperoxygenation essential fatty acids (60% linoleic acid) which does not contain preservatives (parabens) or known allergens.
2980180|NCT02695693|Experimental|TeachTown|Students in kindergarten-through-second-grade autism support classrooms in this arm receive access to TeachTown, an online academic and pre-academic intervention designed for students with autism. Their teachers also receive coaching in the use of TeachTown, as well as coaching in other evidence-based practices for students with autism, including discrete trial training, pivotal response training, and teaching in functional routines
2980181|NCT02695693|Active Comparator|Control|Teachers in kindergarten-through-second-grade autism support classrooms in this arm receive coaching in evidence-based practices for students with autism, including discrete trial training, pivotal response training, and teaching in functional routines
2980182|NCT02695680||Lung SBRT|Respiratory motion causes significant geometric and dosimetric errors in the administration of lung stereotactic radiotherapy (SBRT). The purpose of this study is to create and validate patient-specific motion models of the thoracic anatomy with high spatial and temporal resolution. These models will be used to develop novel four-dimensional (4D=3D+time) techniques for radiotherapy treatment planning and real-time motion-adaptive dose delivery.
2980183|NCT02695667||OSAS subjects|CPAP Referral OSAS
2980184|NCT02695667||Risk-Free subjects|paired normal control subjects
2980185|NCT02695654||Chronic pain in knee osteoarthritis|Ultrasound guided single shot Adductor canal block with 0,25% Levobupivacaine 14 ml and 100 mcg Clonidine
2980186|NCT02695641|Experimental|Stage 1 - Low dose administration|Ten hemodialysis patients will receive IV infusion treatment with 1.25mg bevacizumab and undergo serial blood draws on Days 0, 1, 3, 6, 10, 15, 22, and 29 during dialysis sessions. ELISA will be performed to evaluate drug serum concentration and corresponding plasma free VEGF-A levels (pg/ml). The safety and pharmacokinetic/dynamic (PK/PD) data will be analysed and ≥50% VEGF-A suppression retained from baseline by Day 15 will be considered successful. If target outcomes are met in stage 1, the study will be terminated, otherwise the study will progress to stage 2.
2980187|NCT02695641|Experimental|Stage 2 - Dose escalation|If outcomes are not met in stage 1, Ten additional hemodialysis patients will receive IV infusion treatment with 2.50mg bevacizumab treatment. They will undergo serial blood draws on Days 0, 1, 3, 6, 10, 15, 22, and 29 during dialysis sessions. ELISA will be performed to evaluate drug serum concentration and corresponding plasma free VEGF-A levels (pg/ml). The safety and PK/PD data will be analysed and ≥50% VEGF-A suppression retained from baseline by Day 15 will be considered successful. If target outcome is not met, the study will be terminated.
2980188|NCT02695628|Experimental|Diagnostic (18F-fluoromisonidazole, PET/CT, embolization)|Patients undergo transcatheter arterial embolization. Patients also receive 18F-fluoromisonidazole IV and undergo PET/CT scans 4 weeks prior to embolization treatment and in the 20 hours following completion of treatment.
2980189|NCT02695602|Experimental|Microdebrider-Assisted Inferior Turbinoplasty (MAIT)|Turbinoplasty using microdebrider turbinate blade (2.9mm inferior turbinate blade, Medtronic, 5000 Hz)
2980190|NCT02695602|Experimental|Submucous Resection (SMR)|Turbinoplasty using non-powered instruments
2980191|NCT02695576|Experimental|Surgery|Lumbar fusion surgery Physiotherapy Cognitive behavioral therapy
2980192|NCT02695576|Active Comparator|Non-surgery|Physiotherapy Cognitive behavioral therapy
2980193|NCT02695563|No Intervention|controls|The patients will be not treated with vaginal lactoferrin
2980194|NCT02695563|Active Comparator|Lactoferrin|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 4 hours prior to mid-trimester genetic amniocentesis.
2980195|NCT02695550|Experimental|CT-707|ALK-positive non-small cell lung cancer resistant to Crizotinib treatment
2980196|NCT02695537|Experimental|5 mg/kg/day|In some patients additional titration by 5 mg/kg/day every 2 weeks up to 50 mg/kg/day may be instituted at the discretion of the PI upon discussion with the Co-PI
2980197|NCT02695524|Active Comparator|Strengthening exercises|Side lying external rotation, prone horizontal abduction , Scapular punch, Knee Push, Full can, D1 Diagonal, three times a week, 8 weeks, 3x10 repetitions
2980198|NCT02695524|Experimental|Neuromuscular exercises|Towel slide, Scapular Clock, PNF scapular, Inferior Glide modified, Scapular Orientation Exercise, protraction and retraction of scapula, three times a week, 8 weeks, 3x10 repetitions
2980199|NCT02695511|Experimental|25% CR|25% caloric restriction
2980200|NCT02695511|No Intervention|CO (control)|healthy lifestyle recommendation
2980201|NCT02695498|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a standardized course in mindfulness mediation and yoga.
2980202|NCT02695498|Experimental|Migraine/stress Education|This course will educate participants about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
2980203|NCT02695485|Other|sensate flap|the donor nerve harvested with the flap
2980204|NCT02695472|Placebo Comparator|Placebo Arm|One Placebo tablet, twice daily
2980205|NCT02695472|Experimental|40 Milligrams NSI-189, total dose daily|One 40 Milligrams NSI-189 tablet and 1 placebo tablet per day
2980206|NCT02695472|Experimental|80 Milligrams NSI-189, total dose daily|One 40 Milligrams NSI-189 tablet twice per day
2980207|NCT02695459|Experimental|cisplatinum and everolimus|Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
2980208|NCT02695446|Other|Oral ER Minocycline - Up to 2mg/kg|Oral extended release minocycline - up to 2mg/kg once a day for 30 days.
2980209|NCT02695433|Experimental|Active treatment (AT) diet plan|1 Avocado 7 days/week (5-7 days is acceptable) over a 12 week period
2980210|NCT02695433|Placebo Comparator|Control (CT) diet plan|at least 1 serving of a low fat, low fiber, high glycemic carbohydrate and eliminate avocado 7 days / week (5-7 days is acceptable) over a 12 week period
2980211|NCT02695420|Experimental|25 mg Omecamtiv Mecarbil|25 mg Omecamtiv Mecarbil BID
2980212|NCT02695420|Placebo Comparator|Placebo|Placebo BID
2980213|NCT02695420|Experimental|37. 5 mg Omecamtiv Mecarbil|37.5 mg Omecamtiv Mecarbil BID Target Dose
2980214|NCT02695420|Experimental|50 mg Omecamtiv Mecarbil|50 mg Omecamtiv Mecarbil BID Target Dose
2980215|NCT02695407|Experimental|3 days cannulation|radial artery cannula removed after 3 days
2980216|NCT02695407|Experimental|5 days cannulation|radial artery cannula removed after 5 days
2980217|NCT02695394||MS / CIS|
2980218|NCT02695394||Healthy controls|
2980219|NCT02695381|Experimental|Etodolac-lidocaine Topical Patch|Therapy with experimental drug
2980220|NCT02695381|Placebo Comparator|Placebo|Therapy with placebo
2980221|NCT02695368|Experimental|Exposed patients: Plasma-filter on|"Those operated with Novaerus NV800 on for at least 2 Days prior to index surgery. This Group will also in the analysis be sub-grouped according to measurements prior to study start into:~regular operating theater~ultra-Clean operating theaters"
2980222|NCT02695368|Experimental|Unexposed patients: Plasma-filter off|Those with Novaerus NV800 off for at least 2 Days prior to index surgery
2980223|NCT02695368|Experimental|Mixed patients: Plasma-filter on or off|Those receiving multiple surgeries in different theaters with Novaerus NV800 on or off status will belong to a mixed Group.
2980224|NCT02695355|Experimental|ADHD medication effects|Single dose methylphenidate (Ritalin tablets); 10 mg for ages 8-13; 15 mg for ages 13-17
2980225|NCT02695342|Experimental|Home balance exercise program|The home-based exercise program will be tailored to address the underlying balance deficits in COPD and individualized according to each participant's ability. Physiotherapists will teach the program in four home visits over the first 6 weeks of the study; in the event of an exacerbation, a fifth visit will be provided to modify the program. Participants will be given an exercise DVD (with portable player), and will be instructed to perform the program 3 times/week for 6 months. Therapists will provide bi-monthly telephone support.
2980226|NCT02695329|Active Comparator|Vanguard with KneeAlign 2|Having total knee arthroplasty surgery with the use of a navigation system KneeAlign 2.
2980227|NCT02695329|No Intervention|Vanguard without KneeAlign 2|Having total knee arthroplasty surgery with the use of conventional surgical instruments, and without a navigation system KneeAlign 2.
2980228|NCT02695316|Other|Migrant Women|Focus Group Discussion in native Language with n=20
2980229|NCT02695316|Other|Health Care Professionals|Focus Group Discussion with n=20 Health Care Professionals
2980230|NCT02695316|Other|Interpreters|One-to-one Interviews with n=4 intercultural Interpreters
2980231|NCT02695316|Other|Telephone Interpreting Protocols|Retrospective quantitative analysis of n=50 Telephone Interpreting Protocols (questionnairs)
2980232|NCT02695303|Experimental|BAY 987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2980233|NCT02695290|Experimental|Afatinib|
2980234|NCT02695277|Experimental|Hybrid Procedure|Endoscopic epicardial surgical ablation (first stage) combined with endocardial catheter ablation (second stage) performed between 91 and 180 days post index procedure.
2980235|NCT02695277|Active Comparator|Catheter Procedure|Standard catheter ablation with pulmonary vein (PV) isolation (minimum lesion set) and optional additional lesions (index procedure). When required due to AF recurrence, ablation may be repeated within 6 months after the index-procedure according to clinical indications and consistent with the Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) Consensus Statement
2980236|NCT02695264|Experimental|HS-1000 recording|ICP readings will be recorded from both the invasive and HeadSense non-invasive ICP monitor for an aggregate of 30 minutes. During the recording sessions, a webcam will take periodic snapshots of the ICP monitor and/or bedside monitor picturing the ICP values and other clinical parameters that are displayed on screen, with a focus on blood pressure and heart rate (HR). Recording sessions will be done until an aggregate of at least 30 minutes of data are collected, depending on the patient's clinical condition. Recording sessions may be repeated over several days until the 30 minute target is reached.
2980237|NCT02695251|Experimental|Low AGE meal|Renal functional parameters are measured at baseline and after a low AGE (eggs) meal
2980238|NCT02695251|Experimental|High AGE meal|Renal functional parameters are measured at baseline and after a high (mixed nuggets) AGE (eggs) meal
2980239|NCT02695238|Experimental|prophylactic manual rotation group|During persistent occipital posterior presentation during the second stage of labor, prophylactic manual rotation will be performed.
2980240|NCT02695238|No Intervention|No prophylactic manual rotation group|During persistent occipital posterior presentation during the second stage of labor, expectant management for delevery will be performed
2980279|NCT02694874|Experimental|Rosiglitazone|Participants will receive rosiglitazone 0.045mg/kg/dose twice daily dosing, for 4 days
2980241|NCT02695225|Other|Lay-led tobacco abstinence|Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
2980242|NCT02695225|Other|Lay-led promotion of Ohio Quit Line|Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
2980243|NCT02695212|Experimental|Apremilast ( open label)|"Investigational Product: Apremilast~Doses: Period A:~10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6~Period B:~30mg Twice per day, day #7 through week #24~Period C:~Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral"
2980244|NCT02695199|Experimental|laparoscopic varicocelectomy|laparoscopic Doppler ultrasound assisted laparoscopic varicocelectomy group
2980245|NCT02695199|Sham Comparator|microscopic varicocelectomy|conventional Microscopic Subinguinal varicocelectomy group
2980246|NCT02695186||A/IM alone|Patients with intestinal metaplasia who undergo gastroscopy and blood sample analysis
2980247|NCT02695186||B/IM and MS|Patients with intestinal metaplasia and metabolic syndrome who undergo gastroscopy and blood sample analysis
2980248|NCT02695186||C/Healthy controls|Healthy controls without intestinal metaplasia or metabolic syndrome who undergo gastroscopy and blood sample analysis
2980249|NCT02695160|Experimental|Cohort 1|SB-FIX: Low Dose
2980250|NCT02695160|Experimental|Cohort 2|SB-FIX: Medium Dose
2980251|NCT02695160|Experimental|Cohort 3|SB-FIX: High Dose
2980252|NCT02695147||TAVI via Subclavian approach|Any TAVI procedure using any valve type performed via the subclavian approach
2980253|NCT02695147||TAVI via Direct Aortic approach|Any TAVI procedure using any valve type performed via the direct aortic approach
2980254|NCT02695134|Other|Intervention Group|This group will receive 6 Healing Touch treatments over 3 weeks
2980255|NCT02695134|No Intervention|Control Group[|This group will continue with their usual medical treatments but receive NO Healing Touch
2980256|NCT02695108|Experimental|classical approach for neck pain|patients in this arm received classical approaches for neck pain. Cervical manual therapy was performed on patients in this arm and they were also instructed to to perform cervical endurance, strength and stretching exercises. Rehabilitation period was lasted for 6 weeks. Pain, quality of life and scapular kinematics were assessed before and after rehabilitation program.
2980257|NCT02695108|Experimental|scapular exercise on neck pain|patients in this arm received cervical manual therapy and cervical exercises too. Apart from cervical manual therapy and cervical exercises,patients also performed scapular stabilization exercise targeting trapezius, serratus anterior and rhomboid muscles. Rehabilitation period was lasted for 6 weeks. The same assessment parameters was conducted on this arm too.
2980258|NCT02695069|Experimental|All Participants|A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
2980259|NCT02695043|Experimental|MMPET Group|This group of subjects will be comprised of a subset of culturally diverse patients admitted to the Bellevue the Traumatic Brain Injury Unit at Bellevue. Treatment will focus on improving awareness and comprehension of TBI and its long-term consequences, fostering increased trust in the TBI rehabilitation team, and conveying the importance of continued TBI follow up to maximize recovery.
2980260|NCT02695043|Active Comparator|Control Group|The Control Group will be comprised of equally diverse subset of patients who will receive Standard of Care Treatment.
2980261|NCT02695017|Experimental|Iso inertial|Subjects should do 12 exercise repetition with Iso inertial machine
2980262|NCT02695017|Experimental|Conventional machine|Subjects should do 12 exercise repetition with conventional machine
2980263|NCT02695004|Experimental|Donepezil 35 mg|Donepezil 35 mg or placebo
2980264|NCT02695004|Experimental|Donepezil 70 mg|Donepezil 70 mg or placebo
2980265|NCT02695004|Experimental|Donepezil140 mg|Donepezil 140 mg or placebo
2980266|NCT02695004|Experimental|Donepezil 210 mg|Donepezil 210 mg or placebo
2980267|NCT02695004|Experimental|Donepezil 280 mg|Donepezil 280 mg or placebo
2980268|NCT02694991|Experimental|OMT Group|Osteopathic Manipulative Treatment 15 minutes once a day for 8 days
2980269|NCT02694991|No Intervention|Control Group|No intervention, only usual care
2980270|NCT02694978|Experimental|Ferumoxytol|Participants received an IV infusion of ferumoxytol 510 milligram (mg) diluted (17 milliliter [mL]) in 233 mL 0.9% sodium chloride injection, United States Pharmacopeia (USP) (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.020 g.
2980271|NCT02694978|Active Comparator|FCM|Participants received an IV infusion of FCM 750 mg diluted (15 mL) in 235 mL 0.9% sodium chloride injection, USP (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.500 g.
2980272|NCT02694952|Active Comparator|FAV-Africa|FAV-Africa infusion at enrollment, and then at two and six hours after enrollment, if necessary. To be given as unblinded rescue dose at twelve hours if fourth dose of antivenom necessary.
2980273|NCT02694952|Experimental|EchiTabPlus-ICP|EchiTabPlus-ICP infusion at enrollment, and then at two and six hours after enrollment, if necessary.
2980274|NCT02694939|Experimental|STAND|Receives STAND intervention delivered in community mental health setting.
2980275|NCT02694939|Active Comparator|Usual Care|Receives usual care from community therapists.
2980276|NCT02694926|Other|adrenal insufficiency|
2980277|NCT02694900|Experimental|Resuscitation on the flor|2 min asynchronous cardiopulmonary resuscitation. The patient lies on the floor
2980278|NCT02694900|Experimental|Resuscitation on the stretcher|2 min asynchronous cardiopulmonary resuscitation. The patient lies on a stretcher
2986625|NCT02652416|Placebo Comparator|Placebo (MD part)|placebo
2980280|NCT02694874|Placebo Comparator|Placebo|Participants will receive placebo (grounded placebo powder) at a dose of 0.045mg/kg/dose twice daily for 4 days
2980281|NCT02694861||Registry Group|Patients previously enrolled in the ANGINA RELIEF Registry who are eligible for a 1-year, prospective follow-up (date of ANGINA RELIEF Registry TMR procedure performed within 12-18 month follow-up window).
2980282|NCT02694861||Prospective Group|A group of up to 100 new, prospectively enrolled patients from active centers that receive TMR with the CardioGenesis Laser System and complete a 30-day and 1-year follow-up.
2980283|NCT02694848|Other|Salvianolate injection group|Salvianolate injection,intravenously infusion,0.2g/time,once a day;other routine treatment according to the condition of the disease
2980284|NCT02694848|Active Comparator|Aspirin group|Aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
2980285|NCT02694848|Experimental|Salvianolate injection and aspirin group|Salvianolate injection,intravenously infusion,0.2g/time,once a day;aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
2980286|NCT02694822|Experimental|AGEN1884|anti-CTLA-4 antibody
2980287|NCT02694809|Experimental|Arm I (conjugated estrogens/bazedoxifene)|Patients receive conjugated estrogens/bazedoxifene orally (PO) once daily (QD) for 28 +/- 7 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
2980288|NCT02694809|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 28 +/- 7 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
2980289|NCT02694796|Experimental|Intervention|The 'Physical activity program after a balneotherapy' intervention involves providing a workshop during a balneotherapy about physical activity and use of automated physical activity program including website, mobile app and connected devices, and after the balneotherapy, the access to the automated program during 12 months.
2980290|NCT02694796|No Intervention|Control|Patients included in the control arm will receive a booklet including informations about physical activity recommendations and practice.
2980291|NCT02694783|Other|Donors|This arm will include HLA-matched 1st degree relatives who will undergo leukapheresis to provide donor cells for generation of PyVST cell product
2980292|NCT02694783|Experimental|Treatment|Open label treatement arm.
2980293|NCT02694770|Experimental|Neihulizumab|Patients will receive a total of 4 doses of Neihulizumab (AbGn-168H) on Day 1 (Week 0), Day 8 (Week 1), Day 15 (Week 2), and Day 22 (Week 3) by 1-hour i.v. infusion.
2980294|NCT02694770|Active Comparator|"Conventional Treatment"|Patients will receive a 2nd line therapy for aGvHD at the discretion of attending physician according to the standard practice at the study center. Currently there is no treatment for sr-aGvHD is approved in USA or Europe. There is no Standard treatment of this disease is recommended by American Society for Blood and Marrow Transplantation (ASBMT). Therefore, the study is designed to allow any established institutional practice for off-label use of a commercially available product for patients in the Conventional Treatment arm. Patients in this arm may receive treatments provided in ASBMT guidance such as ATG, TNF-alpha inhibitors (such as Etanercept and infliximab), pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis, methotrexate, basiliximab, daclizumab, inolimomab, denileukin diftitox, alemtuzumab, ATG+ etanercept, Dacliz + etanercept, Dacliz+ infliximab, and Dacliz/inflix/horse ATG.
2980295|NCT02694757|Experimental|Ostom-i device|Subjects will receive an Ostom-i device which will be worn over the ostomy bag underneath the subject's clothing. Output will be monitored daily by the Ostom-i application.
2980296|NCT02694744|Experimental|Group 1 - Dosing Without Food|Patiromer dosing without food
2980297|NCT02694744|Active Comparator|Group 2 - Dosing With Food|Patiromer dosing with food
2980298|NCT02694731|Experimental|Mobile application intervention|Participants receive a mobile app with a 5-week mindful eating program and ongoing tools for coping with cravings
2980299|NCT02694718|Experimental|Capecitabine+Oxaliplatin|Eligible participants received capecitabine 1000 milligrams per square meter (mg/m^2) on Days 1-14, and 825 mg/m^2 on Days 22-35 and 43-56 twice a day (bid) orally, along with oxaliplatin as a 2-hour intravenous (iv) infusion of 130 mg/m^2/once a day (d) on Day 1 and 50 mg/m^2/d on Days 22, 29, 43 and 50 prior to radiotherapy. Participants received radiation therapy having a fraction dose of 1.8 gray (Gy)/day, 5 days a week, for five consecutive weeks starting on Day 22 of the treatment period. Participants, who completed the treatment period, underwent surgery at Week 14.
2980300|NCT02694705|Experimental|CPAP|3 minutes of preoxygenation with a portable ventilator providing Continuous Positive Airway Pressure (CPAP) at 5 cmH20 and an FiO2 of 100%.
2980301|NCT02694705|Experimental|BVM|3 minutes of preoxygenation with a bag-valve-mask (BVM) device and oxygen flow rate of 15 litres / minute.
2980302|NCT02694705|Experimental|NRM|3 minutes of preoxygenation with a non-rebreather mask (NRM) device and oxygen flow rate of 15 litres / minute.
2980303|NCT02694692||Follow-up|No further interventions are planned for this trial and the three pain management interventions from the original study (NCT01561457) will remain our comparison groups (Kangaroo Mother Care alone, Sucrose alone, and Kangaroo Mother Care & Sucrose). All participants will be invited to back to the IWK Health Centre to receive their Vaccinations at 2, 6, 12 and 18 month time points as well as for their Neurodevelopment assessment at 18 corrected age (BSID-III).
2980304|NCT02694679|No Intervention|Random 0|The CBNH intervention will be delivered to 0% of population targeted households in the village.
2980305|NCT02694679|Active Comparator|Random 5|The CBNH intervention will be delivered to a random 5% of targeted households in the village.
2980306|NCT02694679|Active Comparator|Random 10|The CBNH intervention will be delivered to a random 10% of targeted households in the village.
2980307|NCT02694679|Active Comparator|Random 20|The CBNH intervention will be delivered to a random 20% of targeted households in the village.
2980308|NCT02694679|Active Comparator|Random 30|The CBNH intervention will be delivered to a random 30% of targeted households in the village.
2980309|NCT02694679|Active Comparator|Random 50|The CBNH intervention will be delivered to a random 50% of targeted households in the village.
2980310|NCT02694679|Active Comparator|Random 75|The CBNH intervention will be delivered to a random 75% of targeted households in the village.
2980311|NCT02694679|Active Comparator|Random 100|The CBNH intervention will be delivered to a random 100% of targeted households in the village.
2986724|NCT02651688|Placebo Comparator|Placebo|Placebo
2980312|NCT02694679|No Intervention|Friendship 0|CBNH 0% of population targeted
2980313|NCT02694679|Experimental|Friendship 5|The CBNH intervention will be delivered to 5% of households identified through friendship nomination.
2980314|NCT02694679|Experimental|Friendship 10|The CBNH intervention will be delivered to 10% of households identified through friendship nomination.
2980315|NCT02694679|Experimental|Friendship 20|The CBNH intervention will be delivered to 20% of households identified through friendship nomination.
2980316|NCT02694679|Experimental|Friendship 30|The CBNH intervention will be delivered to 30% of households identified through friendship nomination.
2980317|NCT02694679|Experimental|Friendship 50|The CBNH intervention will be delivered to 50% of households identified through friendship nomination.
2980318|NCT02694679|Experimental|Friendship 75|The CBNH intervention will be delivered to 75% of households identified through friendship nomination.
2980319|NCT02694679|Experimental|Friendship 100|The CBNH intervention will be delivered to 100% of households identified through friendship nomination.
2980320|NCT02694666|Experimental|Vibration training group|The vibration group will receive 8-week controlled whole-body vibration training as the intervention on the Galileo Med L device
2980321|NCT02694666|Placebo Comparator|Placebo training group|The placebo group will receive 8-week placebo training on the Galileo Med L device
2980322|NCT02694653|Active Comparator|Drug Arm|Acetaminophen 1000 mg in 100 mL normal saline IV administered 30 minutes prior to c/section incision to infuse within 15 minutes
2980323|NCT02694653|Placebo Comparator|Placebo Arm|100 mL normal saline IV administered 30 minutes prior to c/section incision to infuse within 15 minutes
2980324|NCT02694640|Experimental|Reach Plus|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff."
2980325|NCT02694640|Experimental|Reach Plus Phone|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
2980326|NCT02694640|Experimental|Reach Plus Message|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
2980327|NCT02694627|Experimental|Intervention|See intervention description
2980328|NCT02694627|No Intervention|Control|Participants randomized into the control arm are surveyed at the same time points as intervention participants, but do not receive any intervention.
2980329|NCT02694614|Experimental|smartphone-assisted dietary coaching|
2980330|NCT02694601|Experimental|Healthy adults|
2980331|NCT02694588|Active Comparator|Infliximab|5 mg/kg body weight, week 0/2/6, then every 8 weeks
2980332|NCT02694588|Active Comparator|Vedolizumab|300 mg, week 0/2/6, then every 8 weeks
2980333|NCT02694575||Other|Other - currently on other treatment (i.e., non-incretin based therapies)
2980334|NCT02694575||GLP-1|Currently on GLP-1 analogue therapy
2980335|NCT02694575||DPP-4|Currently on DPP-4 inhibitor therapy
2980336|NCT02694562|Experimental|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg)
2980337|NCT02694549|Experimental|CaveoVasc|
2980338|NCT02694536|Experimental|Erlotinib + Gemcitabine|Participants will receive erlotinib in combination with standard of care chemotherapy (gemcitabine) until disease progression, unacceptable toxicity, or withdrawal for any reason.
2980339|NCT02694523|Experimental|ABBV-066|
2980340|NCT02694523|Active Comparator|Adalimumab|
2980341|NCT02694510|Active Comparator|Light-protection|Light-protection of TPN solutions. TPN bags and infusion sets will be protected from light by aluminum foils throughout the study period.
2980342|NCT02694510|Active Comparator|Light-exposure|TPN bags and infusion sets will be exposed to light throughout the study period.
2980343|NCT02694484|Other|Healthy volunteers|For healthy volunteers corresponding to the inclusion criteria it will be taken them Blood and stool samples : a blood sample during the inclusion visit and if they are seropositive for the CMV, it will be taken them another blood sample and they will give a stool sample for the following visit
2980344|NCT02694471|Experimental|Old group|16 old participants (55-65 years) were included in physical inactivity or bed rest with supervised recovery intervent and underwent 14-day of bed rest. Bed rest was followed by 28-day recovery. During the bed rest participants will remain 24-hour horizontal with all daily activities performed lying in a bed. No social isolation will be forced. During the recovery participants will 3-times weekly per 75 minutes perform guided exercises to achieve baseline level.
2980345|NCT02694471|Active Comparator|Young group|7 young participants (18-30 years) were included in physical inactivity or bed rest with supervised recovery intervent and underwent 14-day of bed rest. Bed rest was followed by 28-day recovery. During the bed rest participants will remain 24-hour horizontal with all daily activities performed lying in a bed. No social isolation will be forced. During the recovery participants will 3-times weekly per 75 minutes perform guided exercises to achieve baseline level.
2980346|NCT02694458|Experimental|Modeling arm|Early vancomycin monitoring and bayesian dosage adjustment
2980347|NCT02694458|Sham Comparator|Control arm|Usual vancomycin dose and monitoring strategy
2980348|NCT02694432|Active Comparator|GOALS|Participants will use for approximately four months an online platform, GOALS, consisting of weekly lessons designed to enhance blood pressure control. Recommended lifestyle changes for hypertension, including a low-sodium diet, physical activity, weight loss (if appropriate) and behavioral self-management skills will be offered. Attention to medication adherence and pharmacist support as well as that of a dedicated online health coach and ongoing collaboration with the primary care physician are also provided.
2980349|NCT02694432|Experimental|Minding GOALS|Participants in this arm will also use the GOALS standard tools for blood pressure control. To further maximize success, they will receive additional online behavioral training throughout the 4-month intervention that focuses on mind-body approaches. Weekly topics, for example, will include meditation lessons, mindfulness-based stress reduction and mindfulness-based eating awareness.
2980350|NCT02694419||obese/PCO|Women with PCOS who are overweight\obese with BMI ≥ 25 kg/m2.
2980351|NCT02694419||normal weight/PCO|Women with PCOS who are normal weight with BMI < 25 kg/m2.
2980352|NCT02694419||Obese/fertile|Fertile regularly menstruating women with at least one previous spontaneous pregnancy who are overweight\obese with BMI ≥ 25 kg/m2.
2980353|NCT02694419||normal weight/fertile|Fertile regularly menstruating women with at least one previous spontaneous pregnancy who are normal weight with BMI < 25 kg/m2.
2980354|NCT02694393|Experimental|sodium nitrite|Inhalation of 46 or 80 mg of sodium nitrite twice daily for four weeks
2980355|NCT02694380||Head and Neck|Subjects with head and neck cancer receiving radiation therapy.
2980356|NCT02694380||Prostate|Subjects with prostate cancer receiving radiation therapy.
2980357|NCT02694380||Breast|Subjects with breast cancer receiving radiation therapy.
2980358|NCT02694380||Lung|Subjects with lung cancer receiving radiation therapy.
2980359|NCT02694367||Recurrent miscarriage group|Women with previous history of RM, defined as two or more consecutive miscarriages
2980360|NCT02694367||Control group|Women with no history of RM
2980361|NCT02694354|Experimental|BI 685509|
2980362|NCT02694354|Placebo Comparator|Placebo|matching placebo
2980363|NCT02694341|Active Comparator|Bakri Balloon with abdominal traction stitch|bakri balloon will be inserted with abdominal traction stitch
2980364|NCT02694341|Experimental|Bakri Balloon without abdominal traction stitch|bakri balloon will be inserted with no performance of abdominal traction stitch
2980365|NCT02694328|Experimental|ALKS 3831|Administered as a coated bilayer tablet
2980366|NCT02694328|Active Comparator|Olanzapine|Administered as a coated bilayer tablet
2980367|NCT02694315||Induction of labor|200 women all are primigravida between 37-42 weeks gestation to whom induction of labor will be carried out in the casualty of Ain Shams University Maternity Hospital. All participants will have an assessment of the cervix by both Bishop score system and transvaginal measurement of cervical length.
2980368|NCT02694302|Experimental|Walkbot|Walkbot(robot assisted gait training) 30 minutes and conventional physical therapy 30 minutes each per day to be administered 5 times a week for 3 weeks.
2980369|NCT02694302|Active Comparator|Conventional physical therapy|Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.
2980370|NCT02694289|Other|Metformin|Continue Metformin while admitted to hospital
2980371|NCT02694289|Other|Subcutaneous (sliding scale) Insulin|Discontinue Metformin upon admission and be placed on sliding scale subcutaneous insulin treatment while admitted to hospital
2980372|NCT02694276|Experimental|Internet-based cognitive behavior therapy|10 sessions of ICBT during 10 weeks.
2980373|NCT02694263|Experimental|Canagliflozin + Metformin|Canagliflozin + metformin (using the participant's current dose, or dose recommended by the study clinician). An initial dose of 100mg once daily of Canagliflozin will be prescribed, and this will be titrated up to a maximum of 300mg once daily.
2980374|NCT02694263|Active Comparator|Repaglinide + Metformin|Repaglinide + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). An initial dose of 0.5mg once daily where no prior treatment has been given will be prescribed. However, where prior treatment has been in place, an initial dose of 1-2mg once daily will be started and this will be titrated up to a maximum dose of 4mg daily.
2980375|NCT02694263|Active Comparator|Pioglitazone + Metformin|Piogliazone + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). For example, Pioglitazone dose will initially be 15mg or 30mg once daily. If the response is inadequate, the maximum daily dosage will be increased to 45mg once daily.
2980376|NCT02694263|Active Comparator|Gliclazide + Metformin|Gliclazide + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). For example, Gliclazide dose will initially be 40-80 mg once daily, up to maximum dose of 160mg twice daily..
2980377|NCT02694263|Active Comparator|Glimepiride + Metformin|Glimepiride + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). Glimepiride will initially be administered as 1mg once daily, up to a maximum dose of 4mg once daily.
2980378|NCT02694250|Other|DTRAX Cervical Cervical Cage with DTRAX Bone Screw|
2980379|NCT02694237|Active Comparator|Verbal|This group will only receive a verbal discussion based on the same script used for all three groups. This is the control group.
2980380|NCT02694237|Active Comparator|Verbal + Model|This group will receive a verbal discussion aided with an anatomic model intervention that group participants will be able to touch throughout the discussion.
2980381|NCT02694237|Active Comparator|Verbal + Video|This group will receive a verbal discussion aided with a knee anatomy video intervention that will be played on silent an orated by an interviewer.
2980382|NCT02694224|Experimental|vismodegib plus chemotherapy|Vismodegib 150 mg orally during paclitaxel and then dose dense epirubicin + cyclophosphamide (EC) therapy (see active comparator arm)
2980383|NCT02694224|Active Comparator|chemotherapy|Paclitaxel 80 mg/m2 weekly on days 1, 8 and 15 each 21 days x 12 doses and then dose dense E (90 mg/m2) plus cyclophosphamide (CPA) 600 mg/m2 each 2 weeks x 4 doses
2980384|NCT02694211|Experimental|Intervention group ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
2980385|NCT02694211|No Intervention|Control group|No intervention, business as usual
2980386|NCT02694185|Experimental|Experimental Group|This group will undergo the intervention as described in the protocol
2980387|NCT02694185|No Intervention|Control Group|This group will not receive the intervention, they will receive usual care
2980388|NCT02694172|No Intervention|Lean non diabetic|Lean and healthy subjects receiving no intervention
2980389|NCT02694172|Experimental|Overweight non diabetic|fiber rich cereal bars, two bars a day for 4 weeks
2980390|NCT02694172|Experimental|Overweight diabetic|fiber rich cereal bars, two bars a day for 4 weeks
2980391|NCT02694146|Experimental|PRP (platelet rich plasma)|"37 patients with coxarthrosis are treated with 6ml of PRP (platelet rich plasma), obtained from blood extracted from patients in the 20 minutes prior to infiltration thereof.~For PRP administration:~The injection should be performed at room temperature.~The administration should be carried out under aseptic conditions.~The patient will be placed in the supine position and the administration will be performed by an anterolateral approach.~The PRP is injected into the synovial space."
2980392|NCT02694146|Active Comparator|Hylan G-F 20 (Synvisc-One ®)|"37 patients with coxarthrosis are treated with a pre-filled syringe of hyaluronic acid 60mg / 6ml (Synvisc-One ®).~It is necessary to remove synovial fluid before injecting Hylan G-F 20.~The injection should be performed at room temperature.~The administration should be carried out under aseptic conditions.~The patient will be placed in the supine position and the administration will be performed by an anterolateral approach.~The Hylan G-F 20 is injected into the synovial space.~After injecting Hylan G-F 20 the patient should stand 5 minutes."
2980393|NCT02694133|Experimental|Aphasia group|Aphasia
2980394|NCT02694120||colonoscopy population|
2980395|NCT02694107|Experimental|Proprioceptive exercises|Proprioceptive exercises performed 3 sessions per week for 4weeks
2980396|NCT02694107|No Intervention|Control|Without any exercises
2980397|NCT02694094||Adults on Chronic ketogenic diets|Adults who have been on Modified Atkins or ketogenic diets for over 1 year
2980398|NCT02694094||Adults naive to ketogenic diets|Adults who have never been on Modified Atkins or ketogenic diets
2980399|NCT02694081|Experimental|Uncut Roux-en-Y Reconstruction|Uncut Roux-en-Y Reconstruction will be used after laparoscopy-assisted distal gastrectomy for early gastric cancer.
2980400|NCT02694081|Active Comparator|Billroth II Reconstruction|Billroth II Reconstruction will be used after laparoscopy-assisted distal gastrectomy for early gastric cancer.
2980401|NCT02694068||Discovery for Aim One|2173 subjects will be involved in the discovery cohort. These subjects will have been treated for PD less than 6 months at enrollment.
2980402|NCT02694068||Replication for Aim One|1673 subjects will comprise the replication cohort. These subjects will have been treated with PD for longer than 6 months at enrollment.
2980403|NCT02694068||Discovery for Aim Two|824 subjects will be involved in the discovery cohort. These subjects will have been treated for PD less than 12 months at enrollment with at least one 12-month follow-up.
2980404|NCT02694068||Replication for Aim Two|538 subjects will comprise the replication cohort. These subjects will have been treated with PD for longer than 12 months at enrollment with at least one 12-month follow-up.
2980405|NCT02694055|Experimental|ProCCM|Villages assigned to the experimental arm will receive the following health system strengthening interventions: training of primary health centre staff, infrastructure improvements at primary health centre, removal of point-of-care user fees, and the presence of Community Health Workers providing proactive case detection in addition to iCCM (ProCCM).
2980406|NCT02694055|Active Comparator|iCCM|Villages assigned to the active comparator arm will receive the following health system strengthening interventions: training of primary health centre staff, infrastructure improvements at primary health centre, removal of point-of-care user fees, and the presence of Community Health Workers providing passive integrated Community Case Management (iCCM) exclusively at a fixed health post to patients who initiate their own care-seeking.
2980407|NCT02694042|Experimental|Mission is Remission® Group|Participants in this group will be given access to the Mission is Remission® web-based teaching and support site. They will also be emailed a link to complete online questionnaires at set time points throughout the study.
2980408|NCT02694042|No Intervention|Control Group|Participants in this group will continue to receive standard care without access to the Mission is Remission® website. They will also be emailed a link to complete online questionnaires. At the end of the 6 month study period, participants in this group will be given access to the study website.
2980409|NCT02694029|Active Comparator|Radiation with ABC|Active Breathing Coordinator to assist radiation therapy
2980410|NCT02694029|Active Comparator|Radiation with VisionRT|VisionRT-based deep inspiration breath-hold to assist radiation therapy
2980411|NCT02694016|Experimental|Remote ischemic preconditioning|Patient will undergo normal isolated aortic valve replacement surgery with a biological prosthesis and a preoperative lower leg remote ischemic preconditioning(RIPC) phase.
2980412|NCT02694016|No Intervention|Control group|Patient will undergo normal isolated aortic valve replacement surgery with a biological prosthesis
2980413|NCT02694003|Experimental|Intervention|The intervention arm will receive access to the BNBD-NDD Intervention.
2980414|NCT02694003|No Intervention|Usual Care|The usual care arm does not receive the BNBD-NDD intervention. This arm is free to access other resources while enrolled in the study. After the 6-month follow up time point, the usual care arm will be able to access the intervention.
2980415|NCT02693990|Experimental|Grade II (Atypical) Meningiomas, STR|Patient will be treated at the starting dose of Intensity Modulated Proton Therapy (IMPT) which is pre-determined.
2980416|NCT02693990|Experimental|Grade III (Malignant) Meningiomas, GTR|Patient will be treated at a pre determined dose of Intensity Modulated Proton Therapy (IMPT) for the specific cohort.
2980417|NCT02693990|Experimental|Grade III (Malignant) Meningiomas, STR|Patient will be treated at a pre determined dose of Intensity Modulated Proton Therapy (IMPT) for the specific cohort.
2980418|NCT02693964||Postmenopausal women with T1D|Postmenopausal between 45-70 years of age and having T1D for at least 10 years
2980419|NCT02693964||Postmenopausal women without diabetes|Postmenopausal between 45-70 years of age without diabetes
2980420|NCT02693951|Experimental|the prophylactic use of antibiotics group|Half an hour before endoscopic treatment, cefotiam 2.0g intravenous
2980421|NCT02693951|No Intervention|Control|Routine endoscopic examination and treatment. Antibiotics are not used before endoscopic treatment
2980422|NCT02693938|Experimental|luteal phase clamp|Luteal euglycemic clamp administered during luteal phase of menstrual cycle.
2980423|NCT02693938|Active Comparator|follicular phase clamp|Follicular euglycemic clamp administered during follicular phase of menstrual cycle.
2980670|NCT02692209|Experimental|FFDM Plus DBT|FFDM Plus DBT images are being evaluated as compared to FFDM alone
2980424|NCT02693912||acute lung injury|Patients with a diagnosis of acute lung injury (ALI) under mechanical ventilation.Patients will underwent bronchoscopy for bronchoalveolar lavage fluid.
2980425|NCT02693912||control|Patient under mechanical ventilation without any lung diseases. Patients will underwent bronchoscopy for bronchoalveolar lavage fluid.
2980426|NCT02693886||A group|Experience of endoscopist: >2000 cases
2980427|NCT02693886||B group|Experience of endoscopist:between 1000 and 2000 cases
2980428|NCT02693886||C group|Experience of endoscopist:between 500 and 1000 cases
2980429|NCT02693886||D group|Experience of endoscopist:<500 cases
2980430|NCT02693873|Other|Single Arm Study:|All participants will receive GLA:D Canada, an education and neuromuscular exercise program
2980431|NCT02693860|Experimental|huJ591 followed by 89Zr-J591|Subjects will receive two infusions of unlabeled huJ591 on days 1 and 15 (+/- 1 day). 89Zr-J591 will be administered on day 22 (+/- 1 day) and 5-8 days later. PET/CT will be performed followed by repeat imaging of the prostate. Radical prostatectomy with or without lymph node dissection is performed 2 to 4 weeks after the second dose of J591.
2980432|NCT02693834|Experimental|Ankle foot Orthosis|Participants will be assigned to practice with Posterior Leaf spring AFO for a week, then they will be assigned to practice with Double adjustable AFO for another week.
2980433|NCT02693821|Experimental|Gabapentin|300mg of Gabapentin per day (two doses), orally during 30 days
2980434|NCT02693821|Placebo Comparator|Placebo|300mg of Placebo per day (two doses), orally during 30 days
2980435|NCT02693808|Active Comparator|Autologous fat injection|Patients have undergone lateral orbital wall decompression on both sides. Temporal hollowing after surgery will be treated with injection on one side with autologous fat and the other side with long-lasting hyaluronic acid.
2980436|NCT02693808|Active Comparator|Hyaluronic acid injection|Patients have undergone lateral orbital wall decompression on both sides. Temporal hollowing after surgery will be treated with injection on one side with autologous fat and the other side with long-lasting hyaluronic acid.
2980437|NCT02693795|Experimental|Baduanjin exercise group|"The participants randomized to Baduanjin exercise will collectively practice at cardiac rehabilitation centre in Guangdong Provincial Hospital of Chinese Medicine. A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Each Baduanjin exercise session lasts 45 minutes and continues twice per week for 12 weeks."
2980438|NCT02693795|Active Comparator|usual exercise control group|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
2980439|NCT02693782|Placebo Comparator|Placebo|15 g/day maltodextrin in 3 portions of 5 g.
2980440|NCT02693782|Active Comparator|Fibre supplement|15 g/day Wheat Bran Extract in 3 portions of 5 g.
2980441|NCT02693769|Experimental|fluticasone/formoterol BAI|To compare the efficacy of fluticasone/formoterol BAI 125/5 μg (2 puffs b.i.d.)
2980442|NCT02693769|Active Comparator|Ultibro Breezhaler|Ultibro Breezhaler 85/43 µg (1 puff o.d.)
2980443|NCT02693756|No Intervention|Control|Participants will be allowed to perform all usual activities but should refrain from performing the motor imagery exercises.
2980444|NCT02693756|Experimental|Motor imagery|"The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:~Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks."
2980445|NCT02693743|Active Comparator|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) will be delivered to the left PFC, deﬁned as a location 6 cm (cm) anterior to the right hand motor thumb area. A research nurse will deliver the treatments. rTMS will be delivered with a ﬁgure-eight coil at 120% motor threshold, 10 Hertz (Hz), 5 s (s) train duration, 20 s intertrain interval for 50 min (6000 pulses) 3 times daily for 3 days (total 9 sessions, 54,000 stimuli).
2980446|NCT02693743|Sham Comparator|Sham rTMS|Parameters for sham Repetitive Transcranial Magnetic Stimulation (rTMS) are identical to those for active stimulation except that aluminum plate blocks the propagation of a magnetic field. The sound and physical sensation is the same as with the active coil while been biologically inactive.
2980447|NCT02693730||Healthy Control|Does not have diagnosis of irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) and is otherwise healthy and able to participate as defined by the exclusionary criteria.
2980448|NCT02693730||Irritable Bowel Syndrome (IBS)|Diagnosed with IBS and meets the Rome III criteria, in the absence of red flag signs (i.e., unexplained weight loss, bloody stool, fever, anemia)
2980449|NCT02693730||Ulcerative Colitis (UC)|Clinically and histologically confirmed diagnosis of ulcerative colitis
2980450|NCT02693717|Experimental|MTAP-deficient (MTAP-/-) Bladder Cancer (Cohort 1)|"Pemetrexed 500 mg/m2 administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle.~5 daily doses of Folic acid 400 µg taken during the 7-day period preceding the first dose of Pemetrexed; and dosing continues during the full course of therapy, and for 3 weeks after the last dose of Pemetrexed.~Vitamin B12 1000 μg administered as an intramuscular injection approximately 1 to 2 weeks prior to first dose of Pemetrexed and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy.~Dexamethasone (4 mg of oral or equivalent) given twice daily should be taken on the day of, and two days after each dose of Pemetrexed, for rash prophylaxis unless medically contraindicated.~Dexamethasone 10 mg administered as an intravenous infusion on Day 1 of each 21-Day cycle."
2980505|NCT02693444|Active Comparator|Subacromial Lidocaine Injection|Both of your shoulders will be examined and evaluated (shoulder survey). Following the exam, you will be randomized (assigned by chance, similar to a coin toss) to receive a 10cc (2 teaspoon) subacromial injection of lidocaine, will be given under ultrasound (using sound waves) guidance to your affected shoulder. A repeat shoulder exam will be performed and recorded
2980669|NCT02692222||PPV|This study will track changes in PPV and CO before and after of volume expansion, which goal is to change the cardiac output.
2980715|NCT02691975|Experimental|SHR3680|Tablet
2980451|NCT02693717|Experimental|MTAP-normal (MTAPwt) Bladder Cancer (Cohort 2)|"Pemetrexed 500 mg/m2 administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle.~5 daily doses of Folic acid 400 µg taken during the 7-day period preceding the first dose of Pemetrexed; and dosing continues during the full course of therapy, and for 3 weeks after the last dose of Pemetrexed.~Vitamin B12 1000 μg administered as an intramuscular injection approximately 1 to 2 weeks prior to first dose of Pemetrexed and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy.~Dexamethasone (4 mg of oral or equivalent) given twice daily should be taken on the day of, and two days after each dose of Pemetrexed, for rash prophylaxis unless medically contraindicated.~Dexamethasone 10 mg administered as an intravenous infusion on Day 1 of each 21-Day cycle."
2980452|NCT02693704|Experimental|Normal hearing|People showing no hearing loss (< 20 dB HL). Introduction of speech signal via the DAI of two hearing aids Phonak Naida IX SP.
2980453|NCT02693704|Experimental|Moderate hearing impaired|"Patients showing moderate hearing loss (40-60 dB HL).~Introduction of speech signal via the DAI of two hearing aids among:~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
2980454|NCT02693704|Experimental|Severe hearing impaired|"Patients showing severe hearing loss (60-80 dB HL).~Introduction of speech signal via the DAI of two hearing aids among:~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
2980455|NCT02693704|Experimental|Profound hearing impaired|"Patients showing profound hearing loss (> 80 dB HL).~Introduction of speech signal via the DAI of two hearing aids among:~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
2980456|NCT02693691|Experimental|CardioMEMS HF System|Subjects will collect pulmonary artery pressure measurements daily which will be used by health care professionals to adjust cardiac medications.
2980457|NCT02693678|Experimental|Massage|10 min massage therapy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
2980458|NCT02693678|Experimental|Diathermy|10 min diathermy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
2980459|NCT02693678|Sham Comparator|Sham diathermy|10 min sham diathermy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
2980460|NCT02693665|Experimental|FACE-TC Intervention|Adolescent/family dyads randomized to the experimental condition receive Family Centered Advance Care Planning for Teens with Cancer (FACE-TC) intervention - 3 sessions scheduled one week apart of approximately 60 minutes duration each. Session 1 - Lyon Advance Care Planning Survey-Adolescent & Surrogate versions. Session 2 - Respecting Choices Interview facilitated by trained/certified facilitator with adolescent and family. Focuses on patient's understanding of their illness, possible complications, goals of care and treatment preferences in 3 bad outcome situations; and the Session 3 - Five Wishes an advance directive.
2980461|NCT02693665|No Intervention|Treatment As Usual (TAU)|Adolescent/family dyads randomized to the treatment as usual (TAU) condition receive written information on advance care planning, but no active intervention.
2980462|NCT02693652|Experimental|CVI-HBV-002 (20ug, 3 shots)|"HBV surface antigen 20ug/dose~Intramuscular injection at 0, 1, 2 month"
2980463|NCT02693652|Experimental|CVI-HBV-002 (20ug, 6 shots)|"HBV surface antigen 20ug/dose~Intramuscular injection at 0, 1, 2, 3, 4, 5 month"
2980464|NCT02693652|Experimental|CVI-HBV-002 (40ug, 3 shots)|"HBV surface antigen 40ug/dose~Intramuscular injection at 0, 1, 2 month"
2980465|NCT02693652|Experimental|CVI-HBV-002 (40ug, 6 shots)|"HBV surface antigen 40ug/dose~Intramuscular injection at 0, 1, 2, 3, 4, 5 month"
2980466|NCT02693639||liver transplantation grafts|
2980467|NCT02693626|Experimental|intensive cessation message|"Participants who allocate to this intervention group will receive regular, personalized text messages providing smoking cessation advice, support, and distraction. A quit day will be negotiated with each participant, and one to five messages will be sent per day for the time leading up to the quit day and the following 12 weeks.~One to three messages will be sent per week until the end of the 24 week follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points."
2980468|NCT02693626|No Intervention|No cessation message intervention|Control group participants only will receive one text message every week, thanking them for being in the study, providing study center contact details, and reminding them of the time until their free month at the end of follow up. Another one to two messages will be sent per week until the end of the 24 week. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points.
2980542|NCT02693197|Experimental|Cohort 6:T-817MA|Healthy subjects matched to subjects in Cohort 5
2980543|NCT02693184||Fragility Fracture Case|Men and women, age >65 years with a fragility fracture (defined as a fracture sustained after a fall from a standing height or less).
2980469|NCT02693626|Experimental|Not intensive cessation message|"Participants who allocate to this intervention group will receive regular, personalized text messages providing smoking cessation advice, support, and distraction. A quit day will be negotiated with each participant, and one to five messages will be sent per week for the time leading up to the quit day and the following 12 weeks.~One to three messages will be sent per week until the end of the 24 week follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points."
2980470|NCT02693613|Experimental|Group 1|Treatment arm includes 4 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® without a time lag, single dose of ASP1517 + Kremezin® with a time lag (1 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (1 h after ASP1517 administration)
2980471|NCT02693613|Experimental|Group 2|Treatment arm includes 3 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® with a time lag (2 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (2 h after ASP1517 administration)
2980472|NCT02693600|Active Comparator|Partial Trapeziectomy (PT)|Patients with Osteoarthritis of the trapeziometacarpal joint determined by the classification of Eaton-Littler (stages II-III) treated with with ligamentoplasty and partial trapeziectomy.
2980473|NCT02693600|Active Comparator|Total Trapeziectomy (TT)|Patients with Osteoarthritis of the trapeziometacarpal joint determined by the classification of Eaton-Littler (stages II-III) treated with ligamentoplasty and total trapeziectomy.
2980474|NCT02693587||Misodel group in Holbæk|Misodel for induction of labour in Holbæk
2980475|NCT02693587||Angusta group in Roskilde and Næstved|Angusta for induction of labour in Roskilde and Næstved
2980476|NCT02693574|Active Comparator|Clarithromycin|Clarithromycin 500 mg Tablets and Esomeprazole 20 mg Capsule And Amoxicillin 1000 mg,Tablets by mouth every 12 hours for 14 days
2980477|NCT02693574|Experimental|Levofloxacin|Levofloxacin 500 mg coated tablets and Esomeprazole 20 mg Capsule and Amoxicillin 1000 mg Tablets by mouth every 12 hours for 14 days
2980478|NCT02693561|Active Comparator|Deep Breathing Exercises|Technical Deep Breathing.
2980479|NCT02693561|Active Comparator|Self-Help Book|Reading the self-help book.
2980480|NCT02693561|Active Comparator|Deep Breathing Exercises and Book|"Technical Deep Breathing and Reading the self-help book.~Reading the self-help book and will be trained by the physical therapist to perform deep breathing."
2980481|NCT02693561|No Intervention|Control|Not suffer any intervention
2980482|NCT02693548||Familial hypercholesterolaemia patients|Index cases with genetic diagnosis of FH and their relatives over 15 years old with a genetic diagnosis of FH.
2980483|NCT02693548||Unaffected relatives|Relatives of FH patients without FH (genetically defined)
2980484|NCT02693535|Other|Group 1 (VEGFR)|Participants receive axitinib - dosage, frequency and duration per label VEGFR mutation, amplification or overexpression)
2980485|NCT02693535|Other|Group 2 (Bcr-abl, SRC, LYN, LCK)|Participants receive bosutinib- dosage, frequency and duration per label Bcr-abl, SRC, LYN, LCK mutations
2980486|NCT02693535|Other|Group 3 (ALK, ROS1, MET)|Participants receive crizotinib - dosage, frequency and duration per label ALK, ROS1, MET mutations
2980487|NCT02693535|Other|Group 4 (CDKN2A, CDK4, CDK6)|Participants receive palbociclib - dosage, frequency and duration per label CDKN2A, CDK4, CDK6 amplifications
2980488|NCT02693535|Other|Group 5(CSF1R,PDGFR,VEGFR)|Participants receive sunitinib - dosage, frequency and duration per label CSF1R, PDGFR, VEGFR
2980489|NCT02693535|Other|Group 6 (mTOR, TSC)|Participants receive temsirolimus - dosage, frequency and duration per label mTOR, TSC mutations
2980490|NCT02693535|Other|Group 8 (ERBB2)|Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label (ERBB2 amplifications)
2980491|NCT02693535|Other|Group 9 (BRAFV600E)|Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label BRAFV600E mutations
2980492|NCT02693535|Other|Group 11 (KRAS, NRAS and BRAF)|Participants receive cetuximab - dosage, frequency and duration per label KRAS, NRAS and BRAF wildtype
2980493|NCT02693535|Other|Group 12 (Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, YES1)|Participants receive dasatinib- dosage, frequency and duration per label Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, YES1 mutations
2980494|NCT02693535|Other|Group 13 (RET,VEGFR1/2/3,KIT,PDGFRβ,RAF-1,BRAF|Participants receive regorafenib- dosage, frequency and duration per label RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFRβ, RAF-1, BRAF mutations/amplifications
2980495|NCT02693535|Other|Group 14 (BRCA1/BRCA2; ATM)|Participants receive olaparib- dosage, frequency and duration per label Germline or somatic BRCA1/BRCA2 inactivating mutations; ATM mutations or deletions
2980496|NCT02693535|Other|Group 15 (POLE/POLD1;high mutational load)|Participants receive pembrolizumab- dosage, frequency and duration per label Note: high mutational load defined per protocol
2980497|NCT02693535|Other|Group 16 (MSIH, high mutational load and others)|Participants receive nivolumab and ipilimumab- dosage, frequency and duration per label Note: high mutational load defined per protocol, there are other targets not listed here due to character limits
2980498|NCT02693522|Experimental|somatropin|Subcutaneous injection
2980499|NCT02693522|Active Comparator|Eutropin|Subcutaneous injection
2980500|NCT02693483|Active Comparator|povidone iodine|153 cases undergoing cesarean sections will have preoperative vaginal cleansing with 10% povidone iodine
2980501|NCT02693483|No Intervention|no vaginal cleansing|153 cases undergoing cesarean sections
2980502|NCT02693470|Other|single-arm study|"50 patients with severe psoriasis who received Stelara(ustekinumab) at 0 and 1 month. The investigators check microparticles level at baseline and 4 months later.~50 patients without psoriasis: the microparticles are checked at baseline."
2980503|NCT02693457|Active Comparator|Drain|Intra-articular drain will be placed at closure of randomized knee for 24 hours
2980504|NCT02693457|Experimental|No Drain|No intra-articular will be placed in the contralateral knee of the same patient. A placebo drain will be placed so patient is unaware of which knee contains working drain.
2980544|NCT02693171||Dinutuximab administered for 5 cycles|High-risk neuroblastoma patient treated with Unituxin as standard of care
2980716|NCT02691962|Experimental|XenMatrix AB|Subjects treated with XenMatrix AB
2980506|NCT02693444|Placebo Comparator|Subacromial Saline Injection|Both of your shoulders will be examined and evaluated (shoulder survey). Following the exam, you will be randomized (assigned by chance, similar to a coin toss) to receive a 10cc (2 teaspoon) subacromial injection of saline, will be given under ultrasound (using sound waves) guidance to your affected shoulder. A repeat shoulder exam will be performed and recorded
2980507|NCT02693418|Experimental|Acidform Gel, Group A|Administration of a single vaginal dose of Acidform gel (5 g)
2980508|NCT02693418|Experimental|Acidform Gel, Group B|Administration of a single vaginal dose of Acidform gel (4 g)
2980509|NCT02693418|Experimental|Acidform Gel, Group C|Administration of a single vaginal dose of Acidform gel (3 g)
2980510|NCT02693418|Placebo Comparator|Placebo Gel, Group D|Administration of a single dose of hydroxyethylcellulose (HEC) placebo gel (4 g)
2980511|NCT02693418|No Intervention|No intervention, Group E|No vaginal product administered
2980512|NCT02693405|Experimental|child and adult survivors of brain tumor|"Executive functions and social cognition will be assessed using cognitive (Stroop task, Modified Card Sorting Task, Digit spans) and behavioral (BRIEF for childrens and BRIEF-A for adults) tests.~Quality of life will be assessed by questionaires (SF-36, QLQC30-BN20 for adults and Peds-Ql for childrens)"
2980513|NCT02693405|Experimental|healthy controls|"Executive functions and social cognition will be assessed using cognitive (Stroop task, Modified Card Sorting Task, Digit spans) and behavioral (BRIEF for childrens and BRIEF-A for adults) tests.~Quality of life will be assessed by questionaires (SF-36, QLQC30-BN20 for adults and Peds-Ql for childrens)"
2980514|NCT02693392|Active Comparator|Control|One hundred type-2 diabetes patients with standard oral hypoglycemic drugs (metformin +/- sulfonylurea) will be recruited and followed up without add-on fenugreek extract.
2980515|NCT02693392|Experimental|Fenugreek|One hundred type-2 diabetes patients with standard oral hypoglycemic drugs (metformin +/- sulfonylurea) will be recruited and followed up with add-on fenugreek extract.
2980516|NCT02693379|Experimental|D-VIA|HPV high risk-positive (16, 18, 45, 31, 33, 35, 39, 51, 52, 56, 58, 59, 66, 68) women had a cervical examination using acetic acid (VIA) application and visual inspection.
2980517|NCT02693366|Experimental|Autologous Cell Transplantation|We are conducting a prospective, non-randomized, single-center longitudinal study in five patients with progressive chronic kidney disease and estimated clearance between 40 and 20 ml / min. Patients will be followed by clinical and laboratory examination for 3 months prior to the procedure. These previous results serve as a control for comparison with a second time when the same patients receive treatment with stem cells being subsequently followed up for 9 months a total of one year of clinical follow-up.
2980518|NCT02693353||Study Group|Patients with diagnosed epiretinal membrane undergoing cataract surgery.
2980519|NCT02693353||Control Group|Patients without epiretinal membrane undergoing cataract surgery.
2980520|NCT02693327||Mental illness group|Participants in this group will provide biological samples to include both stool and blood samples.
2980521|NCT02693327||Non-mental illness group|Participants in this group will provide biological samples to include both stool and blood samples.
2980522|NCT02693314|Experimental|Jarro-Dophilus EPS® Group|Jarro-Dophilus EPS® (5 billion CFU/capsule) probiotic formulation capsule for 28 days
2980523|NCT02693314|Experimental|Jarro-Dophilus EPS® High Potency Group|Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule) probiotic formulation capsule for 28 days
2980524|NCT02693314|Placebo Comparator|Placebo Group|Placebo capsule for 28 days
2980525|NCT02693301|No Intervention|Control|
2980526|NCT02693301|Experimental|Experimental|A two month intervention program 3 days/week will be carried out. The session will last ~60 minutes, and will consist of a combined training (aerobic training ~30 min, and strength ~30 min of 7 whole body exercises (3 sets x 10 repetitions at 70-80% of their maximum).
2980527|NCT02693288|No Intervention|Ultrasound-guided nerve block|
2980528|NCT02693288|Experimental|Local infiltration anesthesia|Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaine 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
2980529|NCT02693275|Other|Quotient® System iPad Test|The Quotient® System iPad Test is a test specifically designed to provide clinicians with objective measures in ability to maintain seated stillness, sustained attention to a monotonous task and inhibiting incorrect impulsive responses. The attention task with motion analyses provides a number of objective measures for detailed assessment of the subject's movements and attentiveness.
2980530|NCT02693262|Experimental|CLS Mode on Biotronik CRT-D|All 15 patients will be randomized to this group. Their device will be set in the CLS mode for 1 week.
2980531|NCT02693262|Active Comparator|Accelerometer Mode on Biotronik CRT-D|All 15 patients will be randomized to this group. Their device will be set in the accelerometer rate responsive mode for 1 week.
2980532|NCT02693236|Experimental|adenovirus-transfected autologous DC vaccine plus CIK cells|
2980533|NCT02693210|Active Comparator|Group A: Methotrexate|Participants will receive methotrexate at dosage >=10 milligrams per week (mg/week) orally as determined by the investigator. They also receive placebo infusion on days 1 and 15 in place of rituximab and on Days 3 and 17 in place of cyclophosphamide.
2980534|NCT02693210|Experimental|Group B: Rituximab Monotherapy|Participants will receive 1 g intravenous infusions of rituximab on Days 1 and 15. They also receive Weekly placebo orally instead of methotrexate and placebo infusion in place of cyclophosphamide on Days 3 and 17.
2980535|NCT02693210|Experimental|Group C: Rituximab and Cyclophosphamide|Participants will receive 1g IV infusion of rituximab on Days 1 and 15 and 750 mg infusion of Cyclophosphamide on Days 3 and 17. They also receive weekly oral placebo in place of methotrexate.
2980536|NCT02693210|Experimental|Group D: Methotrexate and Rituximab|Participants will receive >=10 mg/week methotrexate orally along with 2 times 1 gram (g) rituximab IV infusions on Days 1 and 15. Participants will also receive placebo infusions on Days 3 and 17 in place of cyclophosphamide.
2980537|NCT02693197|Experimental|Cohort 1:T-817MA|Mild hepatic impairment subjects
2980538|NCT02693197|Experimental|Cohort 2:T-817MA|Healthy subjects matched to subjects in Cohort 1
2980539|NCT02693197|Experimental|Cohort 3:T-817MA|Moderate hepatic impairment subjects
2980540|NCT02693197|Experimental|Cohort 4:T-817MA|Healthy subjects matched to subjects in Cohort 3
2980541|NCT02693197|Experimental|Cohort 5 :T-817MA|Severe hepatic impairment subjects
2980545|NCT02693145|No Intervention|standard of care (SOC) arm|Individuals found to be out of HIV medical care will receive standard of care to re-engage. This will not include use of disease intervention specialist to locate and recruit back to HIV medical care or use of the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention.
2980546|NCT02693145|Experimental|Intervention arm|Individuals randomized to the intervention arm will receive field services to locate, contact, and provide assistance to access HIV medical care. Intervention may include use of disease intervention specialist to locate and recruit back to HIV medical care or use of the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention.
2980547|NCT02693132|Experimental|Supervised (SUP-PA)|Weight loss intervention that focuses on supervised physical activity and involves an energy restricted diet. Physical activity will be supervised by trained staff.
2980548|NCT02693132|Experimental|Unsupervised (UNSUP-PA)|Weight loss intervention that focuses on unsupervised physical activity (identical dose to SUP-PA) and involves an energy restricted diet (identical diet to SUP-PA). Physical activity will be self-monitored but no activity tracker will be used as an intervention tool.
2980549|NCT02693132|Experimental|Step-based (STEP)|Weight loss intervention that focuses on unsupervised physical activity prescribed as steps/day and involves an energy restricted diet (identical diet to SUP-PA and UNSUP-PA). Physical activity will be self-monitored and a pedometer will be used to track steps/day.
2980550|NCT02693119|Experimental|Group 1|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the left eye (OS) and one drop of vehicle topical ophthalmic solution
2980551|NCT02693119|Experimental|Group 2|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the right eye (OD) and one drop of vehicle topical ophthalmic solution
2980552|NCT02693119|Experimental|Group 3|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU)
2980553|NCT02693119|Experimental|OLE|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU)
2980554|NCT02693106|Experimental|Healthy adults|
2980555|NCT02693093|Placebo Comparator|placebo|TID Day for 28 Days
2980556|NCT02693093|Experimental|100 mg NI-03|TID Day for 28 Days
2980557|NCT02693093|Experimental|200 mg NI-03|TID Day for 28 Days
2980558|NCT02693093|Experimental|300 mg NI-03|TID Day for 28 Days
2980559|NCT02693080|Experimental|Diagnostic (CT perfusion imaging)|Patients undergo CT perfusion imaging of the lungs at baseline, within 48 hours of first SABR, and at 2-4 months after completion of SABR.
2980560|NCT02693067|Experimental|PV-10|Intralesional rose bengal disodium (PV-10) to one or more neuroendocrine tumor metastases to the liver
2980561|NCT02693054|Experimental|Hybrid Fractional Laser Treatment|Halo (1470nm and 2940 nm) laser
2980562|NCT02693041|Active Comparator|PROBIOTIC in low-risk women|In low-risk women, probiotic group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
2980563|NCT02693041|Placebo Comparator|PLACEBO in low-risk women|In low-risk women, placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
2980564|NCT02693041|Active Comparator|PROBIOTIC in women with a prior PTB|In women with a prior preterm birth (PTB), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
2980565|NCT02693041|Placebo Comparator|PLACEBO in women with a prior PTB|In women with a prior preterm birth (PTB), placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
2980566|NCT02693041|Active Comparator|PROBIOTIC in women with a prior PE|In women with a prior preeclampsia (PE), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
2980567|NCT02693041|Placebo Comparator|PLACEBO in women with a prior PE|In women with a prior preeclampsia (PE), placebo Group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
2980568|NCT02693028|Active Comparator|probiotic lozenge|Two probiotic lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
2980569|NCT02693028|Active Comparator|Probiotic capsule|Two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
2980570|NCT02693028|Active Comparator|Probiotic chewing gum|The probiotic chewing gum should be chewed on for about 10 minutes. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
2980571|NCT02693028|Placebo Comparator|Placebo lozenge|Two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
2980572|NCT02693028|Placebo Comparator|Placebo capsule|Two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
2980573|NCT02693002|Active Comparator|Hormone replacement therapy|Estradiol/norethindrone acetate 1mg/0.5 mg by mouth oral daily for 12 weeks
2980574|NCT02693002|Placebo Comparator|Placebo|Inert ingredients by mouth oral daily for 12 weeks
2980575|NCT02692976|Experimental|Myeloid dendritic cells (mDC) vaccinations|Patients will be vaccinated intranodally three times biweekly with mDC (5x 106 cells; n=7, arm A). DC will be loaded with major histocompatibility complex (MHC) class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA and loaded with keyhole limpet hemocyanin (KLH) as an immune control.
2980608|NCT02692690|Experimental|before-after|TENS stimulation neck and thigh
2987478|NCT02646527|No Intervention|SPC|standard palliative care
2980576|NCT02692976|Experimental|Plasmacytoid dendritic cells (pDC) vaccinations|Patients will be vaccinated intranodally three times biweekly with pDC (3x 106 cells; n=7, arm B). DC will be loaded with MHC class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA.
2980577|NCT02692976|Experimental|mDC and pDC vaccinations|Patients will be vaccinated intranodally three times biweekly with the combination of mDC and pDC (5x 106 mDC/ 3x 106 pDC; n=7, arm C). DC will be loaded with MHC class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA and loaded with KLH (mDC only) as an immune control.
2980578|NCT02692963|Experimental|BCG vaccination|
2980579|NCT02692963|No Intervention|Control|
2980580|NCT02692950|Other|Dialysis Patients|Honor My Decisions Advance Care Planning Videos, self-recorded by a patient using a computer application, followed immediately by a post-video questionnaire and a follow-up questionnaire 2-4 weeks later.
2980581|NCT02692937|Experimental|Surgery and exercise|Neurolysis of peripheral nerves in the back of the head and/or neck. Traditional neck-specific exercise program including five individual treatments sessions within 3 months plus home program over 9 months.
2980582|NCT02692937|Active Comparator|Exercise, Active Comparator|Traditional neck-specific exercise program including five individual treatments sessions within 3 months plus home program over 9 months.
2980583|NCT02692859|Experimental|Vaccine(Chengdu Olymvax Biopharmaceuticals Inc.)|Hib conjugate vaccine
2980584|NCT02692859|Active Comparator|Vaccine (Walvax Biotechnology Co., LTD.)|Hib conjugate vaccine
2980585|NCT02692833||AKI Patients|Patients who develop acute kidney injury within the first 5 days following their cardiac surgical operation.
2980586|NCT02692833||Non-AKI patients|Patients who do not develop acute kidney injury within the first 5 days following their cardiac surgical operation.
2980587|NCT02692820|Experimental|Probiotic|Those who provide consent will be randomised to receive once daily for the remainder of their pregnancy capsules of probiotics (containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 (each at 2.5 x 109 colony forming units (CFUs)). The product contains freeze-dried bacteria and excipients in a gelatin capsule.
2980588|NCT02692820|Placebo Comparator|Placebo|Those who provide consent will be randomised to receive once daily for the remainder of their pregnancy capsules of the placebo containing excipients alone in a gelatin capsule
2980589|NCT02692807|Active Comparator|Hip arthroscopy surgical procedures (HIPARTI Study)|Surgery is performed under general anaesthesia. Traction and joint access is controlled by fluoroscopy. A diagnostic round in the central and peripheral compartment is performed. Labrum, cartilage, and other possible conditions are looked for and findings are documented. Any labral, chondral and bony pathology (cam or pincer) is treated. Labrum may be debrided, sutured, detached and refixed if needed to treat a pincer lesion. Labrum is secured with suture anchors. Pincer and cam resection is performed using an arthroscopic burr. Cartilage lesions maybe left untreated or treated with debridement or microfracture.
2980590|NCT02692807|Placebo Comparator|Sham surgery (HIPARTI Study)|The same arthroscopic procedures as stated above are preformed, but no surgical interventions related to Cam, Pincer, or labral tear are performed, only diagnostic round in the central and peripheral compartment is performed. Labrum, cartilage, and other possible conditions are looked for and findings are documented.
2980591|NCT02692807|Active Comparator|Prospective Cohort (HARP Study)|Those that are not willing to be included in the RCT (HIPARTI Study), will be asked if they are willing to be included in the prospective cohort, or ongoing in countries were ONLY the surgery is performed (Australia). They will sign an informed concent and will undergo surgical interventions as part of usual care. Outcomes collected and follow-ups will be the same as for the RCT (HIPARTI).
2980592|NCT02692781|Experimental|Dose Cohort 1|20mg MOD-6031 / Placebo
2980593|NCT02692781|Experimental|Dose Cohort 2|50mg MOD-6031 / Placebo
2980594|NCT02692781|Experimental|Dose Cohort 3|100mg MOD-6031 / Placebo
2980595|NCT02692781|Experimental|Dose Cohort 4|150mg MOD-6031 / Placebo
2980596|NCT02692781|Experimental|Dose Cohort 5|200mg MOD-6031 / Placebo
2980597|NCT02692768|Active Comparator|Live Music Therapy|Live sedative guitar playing within a limited chord progression will be utilized. Added to this music will be vocal and verbal therapeutic suggestion for active listening, focused breathing, muscle relaxation, and guided imagery. Patients will choose from one of three nature scene options for the guided imagery in order to include patient preference of content. This treatment group will experience this music intervention live, including patient-centered interaction with the music therapist and education for repeated use of the routine on recording.
2980598|NCT02692768|Active Comparator|Recorded Music Therapy|Recorded sedative guitar playing within a limited chord progression will be utilized. Added to this music will be vocal and verbal therapeutic suggestion for active listening, focused breathing, muscle relaxation, and guided imagery. Patients will choose from one of three nature scene options for the guided imagery in order to include patient preference of content. This treatment group will be given a recording of their chosen music relaxation routine for use throughout the study process.
2980599|NCT02692768|Active Comparator|Control|This group will receive standard of care with no music therapy intervention
2980600|NCT02692755|Other|Single ARM|
2980601|NCT02692742|Experimental|Myelo001|Myelo001 100 mg QD
2980602|NCT02692742|Placebo Comparator|Placebo|Matching Placebo QD
2980603|NCT02692729|Experimental|supraumbilical transverse|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis. Above the panniculus, the fatty tissues are not particularly thick. A transverse opening of the aponeurosis and of the parietal peritoneum was done. Then the approach to the lower uterine segment was easy. A Ricard retractor was put in place.
2980604|NCT02692729|Active Comparator|pfannenstiel|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
2980605|NCT02692716|Experimental|Oral semaglutide|
2980606|NCT02692716|Placebo Comparator|Placebo|
2980607|NCT02692703|Experimental|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
2980609|NCT02692677|Experimental|JNJ-42756493|Each participant will receive a single oral dose of 12 milligram (mg) of unlabeled JNJ-42756493 admixed with 14C JNJ-42756493 at Pre-dose,0.5,1,2,3,4,8,12 hour post-dose(pd) on Day 1;24,36 h pd on Day 2;48 h pd on Day 3,72 h pd on Day 4; 96 h pd on Day 5;192 h pd on Day 9,216 h pd on Day 10,240 h pd on Day 11,264 h pd on Day 12,288 h pd on Day 13 and 312 h pd on Day 14
2980610|NCT02692651|Active Comparator|Fidaxomicin|Fidaxomicin 200 mg PO BID for 10 days or until the end of the duration of concomitant antibiotic exposure, whichever is longer.
2980611|NCT02692651|Active Comparator|Vancomycin|Vancomycin 125 mg PO QID for 10 days or until the end of the duration of concomitant antibiotic exposure, whichever is longer.
2980612|NCT02692638|Experimental|Early laparoscopic enterolysis|Patient randomized to the early laparoscopy arm will undergo diagnostic laparoscopy within 24 hours of admission (depending on surgeon and operating room availability). Standard laparoscopy will be performed including supine positioning, sequential compression devices, and appropriate pre-incision antibiotics. Trocar placement will be at the surgeon's discretion and as appropriate for the patient's previous incisions. The necessity for conversion will be left to the discretion of the attending surgeon. Post operative management will conform to the standards of care. Nasogastric tubes will not be routinely placed.
2980613|NCT02692638|Active Comparator|trial of nonoperative management|Patients randomized to the trial of nonoperative management arm will undergo standard therapy including nil per os (NPO), nasogastric decompression only if actively vomiting, intravenous fluids while awaiting return of bowel function. Patients who do not achieve return of bowel function within 72 hours of admission will undergo attempted laparoscopic enterolysis with the understanding that conversion to open procedure may be necessary.
2980614|NCT02692625|Experimental|Group A|"Group A (test group): This group consist of 80 children receiving the probiotic lozenges.~The Probiotic lozenges used in the trial is a non-commercial product provided by BioGaia AB, Lund, Sweden. The Probiotic lozenges consist of a minimum of 200 million live L. reuteri (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 (L. reuteri Prodentis®). The probiotic lozenge is used twice daily for two months."
2980615|NCT02692625|Placebo Comparator|Group B|"Group B (control group): This group consist of 80 children receiving the placebo lozenges.~The placebo lozenges used in the trial is non-commercial product provided by BioGaia AB, Lund, Sweden.The placebo lozenges is used twice daily for two months."
2980616|NCT02692612||Young|
2980617|NCT02692612||Middle-Aged|
2980618|NCT02692612||Old|
2980619|NCT02692599|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~Intervention: investigational live attenuated mumps vaccine;"
2980620|NCT02692599|Active Comparator|Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;~Intervention: control live attenuated mumps vaccine;"
2980621|NCT02692586|Experimental|FlowTriever System|
2980622|NCT02692573|Experimental|prone|Prone positioned after delivery
2980623|NCT02692573|Active Comparator|supine|Supine positioned after delivery
2980624|NCT02692560|Experimental|I-STAND|Participants randomly assigned to the I-STAND intervention group will receive 2 in-person health coaching sessions and 4 biweekly phone-based health coaching sessions. They will receive a wristband that gives a mild vibration after 20 minutes of inactivity and will be encouraged to stand if possible after each inactivity alert. Participants may also choose to receive biweekly email reminders in the weeks between coaching calls. They will also receive a workbook with content around reducing sitting time.
2980625|NCT02692560|Active Comparator|Healthy Living|Participants randomly assigned to the Healthy Living enhanced usual care control group will receive 1 in-person health coaching session and 5 biweekly check-in letters by mail. They will receive a workbook with general healthy living topics that are not expected to impact sitting time. All content is taken from Kaiser Permanente Washington's website and is available to all members. Participants will select topics of interest and review them on their own with no further health coaching.
2980626|NCT02692547|Other|Hybrid-logic closed loop system|All patients get to wear the pump. only 1 arm. There is no comparator in this study, as all patients wear the pump.
2980627|NCT02692534||Cocaine negative|Patients with preoperative urine cocaine negative results
2980628|NCT02692534||Cocaine positive|Patients with preoperative urine cocaine positive results
2980629|NCT02692495||Body odor|individuals self-reporting recurrent episodes of uncontrollable body odor with or without halitosis
2980630|NCT02692495||Halitosis|individuals with extra-oral halitosis, not complaining of body odors
2980631|NCT02692482|Experimental|polyurethane foam|Hydrocellular polyurethane foam multilayer dressing shaped for the sacral area
2980632|NCT02692482|Active Comparator|standard care|
2980633|NCT02692469|Active Comparator|Duodenal Switch Surgical Intervention|a DS procedure involves creating a sleeve gastrectomy with preservation of the pylorus, and creation of a Roux limb with a short common channel
2980634|NCT02692469|Experimental|Single Anastomosis Duodenal-Ileal Bypass|The SADI defers from the DS in that after the duodenum is separated from the stomach, preserving the pylorus, a loop of bowel 200 cm from the ileo-cecal valve is anastomosed with the pylorus, thus requiring only one anastomosis
2980635|NCT02692456|Active Comparator|Double needle celiac neurolysis (DNCN)|Patients were subjected to CT guided celiac neurolysis using 2 needle antero-crural technique on each side with patient in prone position and both needles will be lateral to the aorta
2980636|NCT02692456|Placebo Comparator|Single needle celiac neurolysis (SNCN)|Patients were subjected to CT guided celiac neurolysis using a single needle antero-crural approach from left side to be just in the front of the aorta near the origin of celiac trunk with patient in lateral position with his left side up then after the injection the patient were kept to his right side up for more homogenous spread of the dye.
2980637|NCT02692443||SVR Survivors|Through the SVR and SVR II studies vital status has been followed annually for the entire SVR cohort. As of June 2014 352 subjects are alive, 18 of whom have undergone cardiac transplantation, and 18 have undergone biventricular conversion leaving 334 transplant-free survivors with single ventricle physiology. Each patient enrolled to this ancillary study from the parent SVR study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to the already scheduled parent study follow-up procedures.
2980668|NCT02692235|Other|carnitine & leucine|24 weeks of l-carnitine-l-tartrate in combination with l-leucine supplementation
2989019|NCT02636140|Experimental|Light|Randomized amount and color of light
2980638|NCT02692443||Healthy Controls|In addition to the SVR survivors, investigators plan to enroll 100 age- and gender-matched healthy controls. Healthy controls enrolled for participation in this ancillary study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to completing the Neurodevelopmental Testing Battery that is already part of the parent SVR study and completed by SVR Survivors as part of their SVR follow-up appointments.
2980639|NCT02692417|Experimental|Posterior Tibial Nerve Stimulation Group|Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over their posterior tibial nerve, that is in the area of the ankle, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
2980640|NCT02692417|Experimental|Dorsal Genital Nerve Stimulation Group|Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over the dorsal genital nerve, that is above and/or on the lateral side of the clitoris, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
2980641|NCT02692404||Hospital Birth|Healthy nulliparous participants, planning spontaneous vaginal or induced vaginal delivery, and planning delivery at a hospital woman-care birth center (Magee-Womens Hospital of UPMC) will be consented to participate in the study at their 3rd trimester clinic visit. Participants and their newborns will be followed for a period of 3 months postpartum. They will be planning to utilize labor epidural analgesia for pain control during labor.
2980642|NCT02692404||Midwife Center Birth|Healthy nulliparous participants, planning vaginal delivery under the primary care of a nurse midwife (The Midwife Center for Birth and Womens Health, or UPMC-Mercy) will be consented to participate in the study at their 3rd trimester clinic visit. Participants and their newborns will be followed for a period of 3 months postpartum. They will be planning to avoid labor epidural analgesia for pain control during labor.
2980643|NCT02692391|Placebo Comparator|Placebo|6 doses, Q8hrs for a total period of 48 hours
2980644|NCT02692391|Active Comparator|Indomethacin suppository|Loading dose :100mg Maintenance dose: 50 mg, Q8hrs for a total period of 48 hours (5 doses)
2980645|NCT02692378|Active Comparator|Treatment|"Standard haemodialysis treatment thrice weekly (using a standard dialysate containing bicarbonate at a concentration of 35mmols/L) with the addition of oral sodium bicarbonate 500mg capsules for 12 weeks (weeks 5-16 of the study).~The dosage will be titrated to individual blood levels. Starting dose will be 1g twice daily and if predialysis bicarbonate levels remain <22mmols/L the dose will be increased by 0.5g twice daily each week. The maximum dose would be 3g twice daily.~The oral sodium bicarbonate may be withheld on dialysis days, when bicarbonate will be supplemented through the dialysate. This will be assessed on a case by case basis."
2980646|NCT02692378|No Intervention|Control|Standard haemodialysis treatment thrice weekly using a standard dialysate containing bicarbonate at a concentration of 35mmols/L.
2980647|NCT02692365|Experimental|Calcium channels|Magnetic Resonance assessment Hemodynamics + + infusion of manganese chloride
2980648|NCT02692365|Experimental|Tumor perfusion|Magnetic Resonance + hemodynamic + infusion of gadolinium
2980649|NCT02692352|Experimental|Experimental|8 sessions of Goal Management Training
2980650|NCT02692352|Active Comparator|Active control group|8 sessions of Brain Health Workshop
2980651|NCT02692339||Lenalidomide/Dexamethasone|Standard of Care doses for relapsed/refractory multiple myeloma
2980652|NCT02692326|Experimental|Intervention: Cyclic parenteral nutrition Cohort|All newborn who were included in the study to receive cyclic parenteral nutrition (within 24 hours). The parenteral nutrition was stopped for one hour the first day until 4 hours in preterm infants and 6 hours in term neonates.
2980653|NCT02692326|No Intervention|Control: Continuous parenteral nutrition|All newborn who were included in the study to receive continuous parenteral nutrition (24 hours). The parenteral nutrition was given by a central line in 24 hours with a basal flow
2980654|NCT02692313|Placebo Comparator|Saline infusion|Hyperinsulinemic euglycemic glucose clamp with saline infusion
2980655|NCT02692313|Experimental|Epinephrine infusion-0.015ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.015 ug/kg/min
2980656|NCT02692313|Experimental|Epinephrine infusion-0.03 ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.03 ug/kg/min
2980657|NCT02692313|Experimental|Epinephrine infusion-0.06 ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.06 ug/kg/min
2980658|NCT02692300|No Intervention|Control Group|Patients will undergo standard anesthesia as per standard of care in this patient population.
2980659|NCT02692300|Experimental|EEG-Guided Group|Practitioners will attempt to follow the EEG-Guided protocol to limit the incidence of EEG burst suppression by modifying administration of anesthesia. The EEG-guided protocol is suggestive rather than prescriptive, and practitioners will exercise judgment depending on the clinical situation.
2980660|NCT02692287|Other|Use of the PPH Butterfly|The PPH Butterfly will be inserted into the vagina of a healthy postnatal woman
2980661|NCT02692274||Primary Health care clinics|A survey of 100 primary Health care clinics was carried out
2980662|NCT02692274||Pregnant and breast feeding women|208 patients were recruited from nine clinics that participated in the survey for evaluation of the accuracy of results produced by the HIV rapid test.
2980663|NCT02692261|Active Comparator|Hyalossᵀᴹ matrix|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution used for maxillary sinus augmentation
2980664|NCT02692261|Active Comparator|Apatos alone xenograft|Each sinus was filled with 1 gr xenograft (with or without Hyaluronic Acide) for maxillary sinus augmentation
2980665|NCT02692248|Experimental|Ibrutinib -R-GEMOX-Dexa|"Subjects will receive Ibrutinib with R-GEMOX-Dexa followed by Ibrutinib maintenance according to:~Induction phase:~Rituximab 375 mg/m2 IV day 1~Gemcitabine 1000 mg/msq IV on day 1 or 2 (at investigator discretion).~Oxaliplatine 100 mg/msq on day 1 or 2 (after Gemcitabine administration);~Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3.~Ibrutinib 560 mg daily for 14 days.~Responding patients will receive 2 (if CR) or 4 (if PR) additional cycles every 14 days.Patients with SD and ABC profile will receive 4 additional cycles.~Maintenance phase: Responding patients will receive Ibrutinib 560 mg daily - Continuous cycles until a maximum of 2 years, disease progression or unacceptable toxicity."
2980666|NCT02692235|Experimental|carnitine|24 weeks l-carnitine-l-tartrate supplementation
2980667|NCT02692235|Placebo Comparator|leucine|24 weeks l-leucine supplementation
2989430|NCT02633319|No Intervention|Control|6-month wait-list control group
2980671|NCT02692209|Active Comparator|Full Field Digital Mammography|Fujifilm FFDM alone images are being evaluated as compared to FFDM + DBT
2980672|NCT02692196|Experimental|Neurofeedback Training|Neurofeedback training - neurofeedback of fronto-limbic functional connectivity.
2980673|NCT02692196|Sham Comparator|Sham Control|Sham training - feedback that is not related with fronts-limbic connectivity (motor connectivity)
2980674|NCT02692183||Parkinson Disease (PD) tremor patients|Patients with PD before and after MRI guided Focused ultrasound thalamotomy
2980675|NCT02692183||Essential tremor (ET) patients|Patients with ET before and after MRIFocused ultrasound guided thalamotomy
2980676|NCT02692170|Experimental|CVI-HBV-001 (5 μg)|"HBV surface antigen 5 μg/dose~Intramuscular injection at 0, 1, 6th month"
2980677|NCT02692170|Experimental|CVI-HBV-001 (10 μg)|"HBV surface antigen 10 μg/dose~Intramuscular injection at 0, 1, 6th month"
2980678|NCT02692170|Experimental|CVI-HBV-001 (20 μg)|"HBV surface antigen 20 μg/dose~Intramuscular injection at 0, 1, 6th month"
2980679|NCT02692170|Experimental|CVI-HBV-001 (40 μg)|"HBV surface antigen 40 μg/dose~Intramuscular injection at 0, 1, 6th month"
2980680|NCT02692170|Active Comparator|Conventional Hepatitis B vaccine (20 μg)|"HBV surface antigen 20 μg/dose~Intramuscular injection at 0, 1, 6th month"
2980681|NCT02692157|Placebo Comparator|Placebo|Placebo Comparator: Placebo - During this arm, Placebo medication will be administered orally each evening at 8pm.
2980682|NCT02692157|Active Comparator|NT-814 50 mg|Active Comparator: NT-814 50 mg - During this arm, 50 mg NT-814 will be administered orally each evening at 8pm.
2980683|NCT02692157|Active Comparator|NT-814 100 mg|Active Comparator: NT-814 100 mg - During this arm, 100 mg NT-814 will be administered orally each evening at 8pm.
2980684|NCT02692157|Active Comparator|NT-814 200 mg|Active Comparator: NT-814 200 mg - During this arm, 200 mg NT-814 will be administered orally each evening at 8pm.
2980685|NCT02692144|Experimental|Test-cluster|56g of optimized savory cluster made through a proprietary process with slowly digestible carbohydrates and fiber
2980686|NCT02692144|Placebo Comparator|Control-cluster|56g of control cluster made from general baking process with typical ingredients commonly used in commercially available energy snacks or bars
2980687|NCT02692144|Placebo Comparator|White-bread|47g of white bread containing equivalent amount of available carbohydrate in 56g of optimized savory cluster
2980688|NCT02692131||Speckle strain|All adult patients undergoing on pump CABG Surgery.
2980689|NCT02692131||Tissue doppler strain|All adult patients undergoing on pump CABG Surgery
2980690|NCT02692118||sepsis|Patients with septic shock admitted to ICU
2980691|NCT02692105|Active Comparator|Low dose rate brachytherapy|Device: Radiation Low dose rate prostate brachytherapy is delivered under anaesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.
2980692|NCT02692105|Experimental|High dose rate brachytherapy|"Device: Radiation High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anaesthesia, but no follow-up imaging visit is required.~HDR brachytherapy is also accomplished as an out-patient."
2980693|NCT02692092||Total Arthroplasty Patients|Any patient who has received a total hip or total knee arthroplasty at a healtheast acute care hospital.
2980694|NCT02692079|Experimental|T-PRF+Allograft|The defects were debrided and root planed with ultrasonic instrumentation and area-specific curets. All sites were washed with sterile salin solution and bleeding control was performed. Test group sites were treated with T-PRF+allograft
2980695|NCT02692079|Experimental|Allograft|The defects were debrided and root planed with ultrasonic instrumentation and area-specific curets. All sites were washed with sterile salin solution and bleeding control was performed. Control group sites were treated with only allograft
2980696|NCT02692066||Healthy Controls|Healthy Children ages 6 months-21 years who have not received varicella vaccine and who do not have prior varicella or zoster will receive Varivax. We will then measure 1) markers of humoral immunity at baseline and 4 weeks post vaccination and 2) markers of cell mediated immunity at baseline, 1 week, and 4 weeks post vaccination
2980697|NCT02692066||Children with Chronic Liver Disease|Children with chronic liver disease ages 6 months-21 years who have not received varicella vaccine and who do not have prior varicella or zoster will receive Varivax. We will then measure 1) varicella DNA in the blood and saliva at enrollment, 1 week, 2 weeks, 3 weeks, 4 weeks post vaccination 2)markers of humoral immunity at baseline and 4 weeks post vaccination and 3) markers of cell mediated immunity at baseline, 1 week, and 4 weeks post vaccination
2980698|NCT02692053|Experimental|Patients with septic shock|
2980699|NCT02692053|Other|Blood samples from a historical cohort of healthy volunteers|
2980700|NCT02692040|Experimental|1.5 mg|1.5 mg G3215 single dose, subcutaneous
2980701|NCT02692040|Experimental|4 mg|4 mg G3215 single dose, subcutaneous
2980702|NCT02692040|Experimental|8 mg|8 mg G3215 single dose, subcutaneous
2980703|NCT02692040|Experimental|10 mg|10 mg G3215 single dose, subcutaneous
2980704|NCT02692040|Experimental|12 mg|12 mg G3215 single dose, subcutaneous
2980705|NCT02692040|Experimental|16 mg|16 mg G3215 single dose, subcutaneous
2980706|NCT02692040|Experimental|32 mg|32 mg G3215 single dose, subcutaneous
2980707|NCT02692040|Placebo Comparator|Placebo|0.9% saline
2980708|NCT02692027|Active Comparator|Standard of care|Standard of care in Lesotho. ART-initiation after at least two clinic visits for pre-ART counseling and monthly follow-up visits at the clinic thereafter.
2980709|NCT02692027|Experimental|Same-day ART initiation with less frequent follow-up visits|Proposition of same-day ART initiation with less frequent follow-up visits thereafter.
2980710|NCT02692014||coronary heart disease|2,400 patients who are diagnosed with CHD and have received more than 2 times of coronary angiography within 12-24 months.
2980711|NCT02692001|No Intervention|Current MealTrain menu|This is the current menu being employed for food ordering in the pediatric inpatient wards.
2980712|NCT02692001|Experimental|Intervention MealTrain menu|The intervention menu included child-friendly labeling (attractive characters, fun food names and traffic light system) to encourage healthier choices.
2980713|NCT02691988|Experimental|ICS withdrawal|Guided ICS withdrawal combined with optimization of bronchodilator treatment
2980714|NCT02691988|Active Comparator|Usual care|Optimization of bronchodilator treatment
2980717|NCT02691949|Experimental|Mycophenolate mofetil standard|mycophenolate mofetil 250mg 2# twice per day (BID)
2980718|NCT02691949|Experimental|Mycophenolate sodium low|mycophenolate mofetil 250mg 1# twice per day (BID)
2980719|NCT02691936|Experimental|CO2 fractionated vaginal laser|Postmenopausal women will undergo treatment intravaginally with the fractional microablative CO2 laser system MonaLisa Touch vaginal laser protocol x 3 time points at baseline, 6 weeks and 3 months.
2980720|NCT02691936|Active Comparator|Estrogens, Conjugated (USP)|The women in the vaginal estrogen group will be prescribed and asked to administer the conjugated estrogen cream 0.5 g of cream equivalent to 0.625 mg of conjugated estrogen.
2980721|NCT02691923|Active Comparator|Fluorescein|Fluorescein administered IV at 5mg/kg approximately 30 minutes prior to the beginning of the tumor resection. A second injection may occur if the fluorescein fluorescence is dissipated substantially during the course of the procedure.
2980722|NCT02691923|Experimental|Fluorescein + ALA|"Fluorescein administered IV at 5mg/kg approximately 30 minutes prior to the beginning of the tumor resection. A second injection may occur if the fluorescein fluorescence is dissipated substantially during the course of the procedure.~ALA administered orally at 20mg/kg approximately 3 hours before surgery."
2980723|NCT02691910|Active Comparator|CONCURRENT CHLOROQUINE+PRIMAQUINE|"The infected individuals were treated with the standard chloroquine (CQ)+primaquine(PQ) regimen to malaria caused by Plasmodium vivax.~Chloroquine (tablet containing 150mg of base) - it was given on days 0 (10mg/kg), 1 (7.5mg/kg) and 2 (7.5mg/kg). Total dose, 25 mg base/kg.~Primaquine - it was given once a day (0.5 mg/kg) for seven days, starting on day 0 of CQ treatment. Total dose, 3.5mg/kg The medications were administered under direct observation and the patient was monitored for vomiting for 60 minutes."
2980724|NCT02691910|Experimental|CHLOROQUINE|"The infected individuals were initially treated with chloroquine (CQ) alone and the primaquine(PQ) was introduced on day 28.~Chloroquine (tablet containing 150mg of base) - it was given on days 0 (10mg/kg), 1 (7.5mg/kg) and 2 (7.5mg/kg). Total dose, 25 mg base/kg.~Primaquine - it was given once a day (0.5 mg/kg) for seven days, starting on day 28 of CQ treatment. Total dose, 3.5mg/kg.~The medications were administered under direct observation and the patient was monitored for vomiting for 60 minutes."
2980725|NCT02691897|Experimental|Melatonin|Melatonin 3mg once daily at bedtime
2980726|NCT02691897|Placebo Comparator|Placebo|Placebo 1 tablet once daily at bedtime
2980727|NCT02691884||Patients before/after Pressure Exertion|100 pregnant patients at term in low risk pregnancies, undergoing a routine cardiotocography, will experience different amounts of manual pressure on their abdomen. The amount of pressure applied will be recorded and the fetal heart rate will be compared before and at the time of maternal abdominal pressure.
2980728|NCT02691871|Experimental|Apatinib + Docetaxel|Low, medium or high dose of Apatinib (days 3-19, q3w) and Docetaxel (60 mg/m2, day 1, q3w)
2980729|NCT02691858|Experimental|Hydrocortisone|Hydrocortisone IV 10 mg/kg with Resuscitation before attempting reduction, single dose with Resuscitation before attempting reduction
2980730|NCT02691858|Placebo Comparator|Saline|Saline IV 100 ml with Resuscitation before attempting reduction, single dose with Resuscitation before attempting reduction
2980731|NCT02691845|Other|BA|Brief advice to exercise. This serves as a control condition.
2980732|NCT02691845|Active Comparator|BA + SHE + HE|Brief advice to exercise + supervised & home-based exercise + health education
2980733|NCT02691845|Experimental|BA + SHE + CBEX|Brief advice to exercise + supervised & home-based exercise + cognitive-behavioral sessions focused on increasing and maintaining exercise
2980734|NCT02691832|Experimental|research arm|"the trial contains one group which will undergo the described protocol three times:~connected to rectal thermistor and to the double sensor~connected to rectal thermistor, double sensor and cooling system of Icetron Technologies Ltd.~connected to rectal thermistor and to the double sensor integrated into a helmet."
2980735|NCT02691806|Experimental|research arm|Each of the 14 participants will undergo the same 2 days experimental protocol, separated by at least 2 days rest.
2980736|NCT02691793|Experimental|sunitinib|sunitinib 50 mg will be administered orally daily
2980737|NCT02691780|Experimental|Sorafenib|Sorafenib 200mg bid will be administered orally daily every 3weeks
2980738|NCT02691767|Experimental|pazopanib|pazopanib 800 mg will be administered orally daily every 3weeks
2980739|NCT02691754|Experimental|free paracetamol|the General Practitioners can prescribe paracetamol for free (covered by NHS). Patients can receive monthly dose at the local hospital
2980740|NCT02691754|No Intervention|standard drug prescription|"Paracetamol is not included in the list of drugs than can be prescribed in charge of National Health System by General Practitioners.~The General Practitioners can prescribe other drugs or recommend paracetamol payed by the patient (out of pocket) at the chemistry."
2980741|NCT02691728|Experimental|Treatment Arm|12 Week treatment with LDV/SOF FDC
2980742|NCT02691715|Experimental|Endometrial saline plus curettage|5 cc saline infused to the endometrial cavity and aspirated. Then routine endometrial curettage performed for same participant.
2980743|NCT02691715|Active Comparator|Endometrial curettage|Only routine endometrial curettage performed
2980744|NCT02691702|Experimental|Multiple Doses - Part A|Multiple ascending doses administered in the morning to healthy adult subjects in a parallel study design
2980745|NCT02691702|Experimental|Multiple Dose - Part B|Multiple ascending doses administered in the evening to healthy adult subjects in a parallel study design
2980746|NCT02691702|Experimental|Multiple Doses - Elderly|Multiple ascending doses administered to elderly subjects
2980747|NCT02691689|Other|Patients with ASD or VSD and PAH|
2980748|NCT02691676|Experimental|Plasmalyte|Arm 1: Plasmalyte in 5% glucose infusion solution (PL), manufactured by Baxter Healthcare as slightly alkalizing (Na+ 140; K+ 5.0; Mg2+ 1.5; Cl- 98; acetate 27; gluconate 23)
2980749|NCT02691676|Active Comparator|Ringerfundin|Arm 2: Ringerfundin infusion solution (RF), manufactured by B. Braun as acid-base neutral (Na+ 145; K+ 4.0; Mg2+ 1.0; Ca2+ 2.5; Cl- 127; acetate 24; malate 5.0).
2980750|NCT02691663|Active Comparator|Oral bicarbonate supplementation group|0.3 meq/kg/day NaHCO3 capsules
2980751|NCT02691663|Placebo Comparator|Placebo group|Methylcellulose capsules
2980752|NCT02691650||polytrauma patients|Patients with severe traumatic injury, admitted to the emergency unit. Serum cholinesterase activity measurement using 10 µl whole blood, otherwise obtained through routine blood gas analysis upon arrival to the hospital.
2980753|NCT02691650||burns patients|Patients with burns trauma, admitted to the emergency unit. Serum cholinesterase activity measurement using 10 µl whole blood, otherwise obtained through routine blood gas analysis upon arrival to the hospital.
2980754|NCT02691637||H. pylori eradication group|Patients who have had H. pylori infection. After diagnosis of H. pylori infection, the patients who subsequently received successful H. pylori eradication treatment according to appropriate indication.
2980755|NCT02691637||Control Group|Patients who still have H. pylori infection. The patients of control group do not have successful H. pylori eradication result or do not received eradication treatment for any reason.
2980756|NCT02691624||sentinel lymph node biopsy|Patients of the group is diagnosed with breast cancer and receive lymphoscintigraphy before operation, and will receive sentinel lymph node biopsy
2980757|NCT02691624||axillary lymph node dissection|Patients of the group is diagnosed with breast cancer and receive lymphoscintigraphy before operation, and will receive axillary lymph node dissection
2980758|NCT02691611||Alpha-1 Antitrypsin|All AATD patients who will start treatment with alpha-1 antitrypsin augmentation therapy
2980759|NCT02691611||Healthy Control|Healthy controls with no lung diseases
2980760|NCT02691598|Experimental|Group A|Dexmedetomidine Hydrochloride 4ug/ml；0.05ml/kg.h infusion for 24hours
2980761|NCT02691598|Placebo Comparator|Group B|Normal Saline 0.05ml/kg.h infusion for 24hours
2980762|NCT02691585|Experimental|Music intervention group 1|Raga 1 will be given
2980763|NCT02691585|Experimental|Music intervention group 2|Raga 2 will be given
2980764|NCT02691585|Experimental|Music intervention group 3|Raga 3 will be given
2980765|NCT02691585|No Intervention|Control Group 4|No raga. Just collection of electrophysiological parameters will be done.
2980766|NCT02691572|Active Comparator|Wound Infiltration|Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). At the end of surgery, 30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing. Sham procedure will be performed after surgery. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.
2980767|NCT02691572|Experimental|Transversus abdominis plane block|Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). After completion of surgery, bilateral ultrasound-guided TAP block will be performed using 20 mL bupivacaine 0.25% on each side. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.
2980768|NCT02691559|Active Comparator|maternal inflammation group|Amniotic fluid analysis by blood gas device: evaluate the possible association between maternal inflammation and amniotic fluid pH two groups will be designed. One group will consist of infants born to mothers with infection/inflammation whereas the control group will consist of infants born to mothers without infection/inflammation. In all deliveries amniotic fluid will be taken and will be analyzed by blood gas device.
2980769|NCT02691559|Active Comparator|normal pregnancy group|Amniotic fluid analysis by blood gas device: The control group will consist of infants born to mothers without infection/inflammation. In all deliveries amniotic fluid will be taken and will be analyzed by blood gas device.
2980770|NCT02691546||Subjects aged 75 years or older|
2980771|NCT02691533|Experimental|ω3 PUFA(10% Omegavan 100 ml)|
2980772|NCT02691533|Experimental|ω6 PUFA (20% Intralipid 50 ml)|
2980773|NCT02691533|Placebo Comparator|Placebo Arm|No Lipid Emulsion will be given in this arm
2980774|NCT02691520||Taiwan Participants with Treatment Resistant Depression|Taiwan participants with Depression will be followed up to 8 years for incidence and duration of treatment resistant depression.
2980775|NCT02691507|Active Comparator|Positive Control|Marketed - EpiCeram(R) Skin Barrier Emulsion: Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin.
2980776|NCT02691507|Experimental|Experimental|Not Yet Marketed - 1% Colloidal Oatmeal Balm: Apply at least once per night or more if needed.
2980777|NCT02691494|Placebo Comparator|Placebo|Placebo
2980778|NCT02691494|Experimental|Elagolix+Estradiol/Norethindrone Acetate|Experimental
2980779|NCT02691494|Experimental|Elagolix|Experimental
2980780|NCT02691481|Active Comparator|Oatmeal breakfast|consuming 200 kcal of plain cooked oatmeal for breakfast
2980781|NCT02691481|Active Comparator|Glucerna formula|consuming 200 kcal of Glucerna shake for breakfast
2980782|NCT02691481|Active Comparator|Ultra Glucose Control formula|consuming 200 kcal of Ultra Glucose Control shake for breakfast
2980783|NCT02691468|Active Comparator|PVC DLT|"After the induction of general anesthesia, a left sided PVC DLT was placed by the anesthesiologist using direct laryngoscopy. Tube position was confirmed with fiberotic bronchoscope.~The first set of measurements tracheal distance(from tracheal carina to proximal tip of DLT) and bronchial distance(from bronchial carina to distal tip of DLT) measured by bronchoscope is taken in supine position .~The second set of measurements is taken in lateral position after position change.~The displacement of PVC DLT is calculated from difference in tracheal distance between supine and lateral position."
2980784|NCT02691468|Active Comparator|silicon DLT|"After the induction of general anesthesia, a left sided silicon DLT was placed by the anesthesiologist using direct laryngoscopy. Tube position was confirmed with fiberotic bronchoscope.~The first set of measurements tracheal distance(from tracheal carina to proximal tip of DLT) and bronchial distance(from bronchial carina to distal tip of DLT) measured by bronchoscope is taken in supine position .~The second set of measurements is taken in lateral position after position change.~The displacement of silicon DLT is calculated from difference in tracheal distance between supine and lateral position."
2980785|NCT02691455|Active Comparator|Second Aqueous Shunt|"Second Aqueous Shunt~Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used."
2980786|NCT02691455|Active Comparator|Transscleral Cyclophotocoagulation|Transscleral Diode Laser Cyclophotocoagulation
2980787|NCT02691442|Active Comparator|Ropivacaine 0.75%|The investigators administer 5 milliliters of Ropivacaine 0.75% in the inter scalene space
2980788|NCT02691442|Active Comparator|Levobupivacaine 0.5%|The investigators administer 5ml of Levobupivacaine 0.5% in the inter scalene space
2980789|NCT02691442|Active Comparator|Levobupivacaine 0.5% + epinephrin|The investigators administer 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in the inter scalene space
2980790|NCT02691429|Active Comparator|acai dye (Euterpe oleracea) 10%|"Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).~Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in"
2980791|NCT02691429|Active Comparator|acai dye (Euterpe oleracea) 25%|"Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).~Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in"
2980792|NCT02691416|Experimental|propofol postconditioning|1.2mg/L propofol
2980793|NCT02691416|Experimental|sevoflurane|0.5%-2% sevoflurane
2980794|NCT02691403|Sham Comparator|Placebo QL block|30 ml single shot QL block with saline 0.9%
2980795|NCT02691403|Active Comparator|Active QL block|30 ml single shot QL block with 0.25% levo-bupivacaine
2980796|NCT02691390|Experimental|study group|alcoholics - dTMS group
2980797|NCT02691390|Sham Comparator|control group|alcoholics - sham group
2980798|NCT02691377|Experimental|Acupuncture group|Participants will receive acupuncture for 8 weeks. In particular, acupuncture will be performed three times a week in earlier 4 weeks and twice a week in later 4 weeks.
2980799|NCT02691377|Sham Comparator|Sham Acupuncture group|Participants will receive sham acupuncture for 8 weeks. The procedure is the same as the acupuncture arm.
2980800|NCT02691364||Healthy|Healthy women
2980801|NCT02691364||Preeclamptic|Pregnant women with preeclampsia
2980802|NCT02691351||non-Hodgkin T-cell Lymphoma|
2980803|NCT02691338||patients undergoing thrombectomy|40 anesthetized patients undergoing intra-arterial catheterization for thrombectomy after CVA. The patients will be recruited at the Rambam Health Center, Haifa, Israel. The patients will be monitored during the procedure ~ 1 hour (in the angio-suit) and for 1-4 hours after the procedure (in the intensive care unit) for a total of 2-5 hours monitoring.
2980804|NCT02691338||Control (patients after CVA)|10 patients after stroke that are treated conventionally (with no mechanical or pharmacological intervention). These patients will be monitored for 2 to 5 hours to validate the sensitivity of the system for stroke recognition.
2980805|NCT02691338||Control - healthy individuals|10 health individuals under general anesthesia. They will be monitored for 2 to 5 hours to validate the sensitivity to anaesthesia effects on EEG.
2980806|NCT02691325|Experimental|Part A (Sequence 1) - Placebo, GSK2269557 200 mcg|Subjects will receive a single dose of GSK2269557 matching placebo (one inhalation) in treatment period 1, and single dose of GSK2269557 200 microgram (mcg) (2 inhalations of GSK2269557 100 mcg) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
2980807|NCT02691325|Experimental|Part A (Sequence 2) - GSK2269557 100 mcg, Placebo|Subjects will receive a single dose of GSK2269557 100 mcg (one inhalation) in treatment period 1, and single dose of GSK2269557 matching placebo (two inhalations) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
2980808|NCT02691325|Experimental|Part A (Sequence 3) - GSK2269557 100 mcg, GSK2269557 200 mcg|Subjects will receive a single dose of GSK2269557 100 mcg (one inhalation) in treatment period 1, and single dose of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
2980809|NCT02691325|Experimental|Part B- GSK2269557 200 mcg|Subjects will receive repeated doses of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) once daily via the ELLIPTA DPI for 10 days. Doses of GSK2269557 may be modified based on emerging data from Part A.
2980810|NCT02691325|Experimental|Part B- GSK2269557 matching Placebo|Subjects will receive repeated doses of GSK2269557 matching Placebo (2 inhalations) once daily via the ELLIPTA DPI for 10 days.
2980811|NCT02691325|Experimental|Part C- GSK2269557 200 mcg with and without activated charcoal|Subjects will receive a single dose of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) via the ELLIPTA DPI with activated charcoal in one treatment period and without ingestion of activated charcoal in another treatment period. The washout period between each dosing day will be at least 14 days. Dose of GSK2269557 may be modified based on emerging data from Part A.
2980812|NCT02691312||Type 1 diabetes (T1D)|Pediatric patients with type 1 diabetes (T1D) will have an eye exam using the Digital Retinography System (DRS) taking non-mydriatic fundus images. If the test is positive or inconclusive, subjects will be notified and referred to an ophthalmologist for a dilated retinal exam. A chart review and questionnaire will be completed to evaluate for risk factors predisposing subjects to diabetic retinopathy.
2980813|NCT02691299|Active Comparator|Treatment Arm|All subjects will receive study treatment in 4-week cycles: Fruquintinib, QD, 5mg with best supportive care for 3 consecutive weeks, and then one week off. Tumor assessment will be performed every 4 weeks in the first 2 cycles, and every 8 weeks since the 3rd cycle, until disease progression or death. Subsequent anti-neoplastic treatment and survival status will be followed up after disease progression.
2980814|NCT02691299|Placebo Comparator|Control Arm|All subjects will receive study treatment in 4-week cycles: Placebo, QD, 5mg with best supportive care for 3 consecutive weeks, and then one week off. Tumor assessment will be performed every 4 weeks in the first 2 cycles, and every 8 weeks since the 3rd cycle, until disease progression or death. Subsequent anti-neoplastic treatment and survival status will be followed up after disease
2980815|NCT02691286||Cardiogenic Shock STEMI|Patients admitted to the hospital with the diagnosis with STEMI complicated with cardiogenic shock
2980816|NCT02691286||No Cardiogenic Shock STEMI|Patients admitted to the hospital with the diagnosis with STEMI without cardiogenic shock
2980817|NCT02691273|Experimental|breathing technique|this arm includes learning breathing technique using the patient's smartphone.
2980818|NCT02691260|No Intervention|no incentives|Participants do not receive financial incentives.
2980819|NCT02691260|Active Comparator|incentives for dietary self-monitoring|Participants receive financial incentives for dietary self-monitoring.
2980820|NCT02691260|Active Comparator|incentives for interim weight loss|Participants receive financial incentives for interim weight loss.
2980821|NCT02691260|Experimental|incentives for both|Participants receive incentives for dietary self-monitoring and interim weight loss.
2980822|NCT02691247|Experimental|CLBS03 Low Dose|A single infusion of CLBS03 Low Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP (United States Pharmacopoeia) infusion solution.
2980823|NCT02691247|Experimental|CLBS03 High Dose|A single infusion of CLBS03 High Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP infusion solution.
2980824|NCT02691247|Placebo Comparator|Placebo|A single infusion of placebo, consisting of the infusion solution only
2980825|NCT02691234|Experimental|Extracorporeal Shockwave Therapy and debridement|The treatment will be performed as an outpatient care procedure with no anesthesia. Patients will undergo wound debridement and cleansing before each treatment. The transducer device will be positioned against the lesion area and shockwaves will be delivered at a gradually increasing energy, with a maximum energy level of 0.09mJ/mm2
2980826|NCT02691234|Active Comparator|debridement and cleansing.|The standard treatment to the control group and the treatment group will be performed as an outpatient care procedure with no anesthesia. Patients will undergo wound debridement and cleansing. The physician will treat the patient in regard to his medical state: antibiotic medication if needed, dressing and off loading with Orthotic devices
2980827|NCT02691221|Other|Participants with previous suicide attempt or ideation|Participants will complete daily tasks assigned for completion through a downloaded application on their mobile device and completing six 2-hour long outcome assessment sessions including rater-lead scales over the course of six months.
2980828|NCT02691208|Experimental|Group I Kinesiotherapy|women with pain treated with a predefinided exercises protocol of 30 minutes.
2980829|NCT02691208|Experimental|Group II Acupuncture|women with pain treated with a predefinided exercises protocol of 30 minutes followed by 30 minutes of acupuncture, used in predefined points
2980830|NCT02691195|Placebo Comparator|group control|group control :Before induction of intravenous anesthesia, patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
2980831|NCT02691195|Experimental|group SPB|group SPB:Before induction of intravenous anesthesia, patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
2980832|NCT02691182|Experimental|Open-label treatment with SPN-810|Subjects aged 6-12 years will be treated with SPN-810 starting day 1 of Visit 1 of the study. The subjects will be given a choice of extending their participation in the study every 6-month period for up to 36 months. The clinician will be able to adjust the dose of SPN-810 throughout the study based on subject's response and tolerability.
2980833|NCT02691169|Experimental|18F-DCFPyL Injection|The subjects will receive the 18F-DCFPyL Injection (less than or equal to 9 mCi (333 MBq)) at visits 2 and 3.
2980834|NCT02691156||Premature Infants|Premature infants GA 24 to ≤34 wks at risk for hyperbilirubinemia will have BBC, ETCOc, and COHbc measured during 0-7 days of life.
2980835|NCT02691143|Experimental|Manipulation plus Tape|"The Tape Group will have TheraBand® Kinesiology Tape, an elastic therapeutic tape (ETT), applied immediately following cervical manipulation from a licensed chiropractor. The taping protocol will be applied by the investigator and consist of a Y strip applied at 25% tension running superior to inferior from the hair line to T1-2 and a horizontal I strip applied at 50% tension at the site of pain."
2980836|NCT02691143|No Intervention|Manipulation Only|The control group will receive manipulation from a licensed chiropractor only
2980837|NCT02691130|Experimental|A: M-001 0.5mg & H5N1 influenza vaccine|"Biological/Vaccine: Two Multimeric-001 administrations followed by H5N1 influenza vaccine~Two administrations of non adjuvanted M-001, 0.5mg followed by 3mcg Alum/H5N1 influenza vaccine at intervals of 19-23 days"
2980838|NCT02691130|Experimental|B: M-001 1.0mg & H5N1 influenza vaccine|"Biological/Vaccine: Two Multimeric-001 administrations followed by H5N1 influenza vaccine~Two administrations of non adjuvanted M-001, 1.0mg followed by 3mcg Alum/H5N1 influenza vaccine at intervals of 19-23 days"
2980839|NCT02691130|Placebo Comparator|C: Saline & H5N1 influenza vaccine|"Biological/Vaccine: Two saline administrations followed by H5N1 influenza vaccine~Two administrations of saline followed by 3mcg Alum/H5N1 influenza vaccinated intervals of 19-23 days"
2980840|NCT02691117|Experimental|Garlic concentrate|Garlic gel concentrate- once a day topical application
2980841|NCT02691104|Experimental|Intervention|"Use of the app and Fitbit alongside 5-7 week pulmonary rehabilitation programme (plus goal-setting help from physiotherapist), and then app and Fitbit plus intermittent contact with physiotherapist for 8 weeks after pulmonary rehabilitation~NB Randomisation is being deployed to test the practicality / acceptability of randomising for a larger RCT. It is not being used to assess the efficacy of the intervention in the current study"
2980842|NCT02691104|Other|Control|"Attend 5-7 week pulmonary rehabilitation programme (usual care) and wear blinded Fitbit during pulmonary rehabilitation and for 8 weeks afterwards~NB Randomisation is being deployed to test the practicality / acceptability of randomising for a larger RCT. It is not being used to assess the efficacy of the intervention in the current study"
2980843|NCT02691078|Experimental|Adult patients with neuroendocrine tumors|
2980844|NCT02691065|Experimental|Integrase Inhibitor|Switch from protease inhibitor-based regimen to raltegravir-based regimen
2980845|NCT02691065|No Intervention|Protease inhibitor|Continuation of protease-inhibitor based regimen
2980846|NCT02691052||Pts receiving nab-paclitaxel/gemcitabine|Patients with metastatic pancreatic cancer undergoing a firstline therapy with nab-paclitaxel and gemcitabine will be asked to fill in an EORTC QLQ-C30 questionnaire and an additional questionnaire on worries about quality of life impairments every 4 weeks. No further intervention.
2980847|NCT02691026|Experimental|Pembrolizumab|200 mg pembrolizumab, i.v. infusion every 3 weeks for up to 10 cycles
2980848|NCT02691013|Placebo Comparator|Placebo|Patients will receive a Placebo tablet every evening.
2980849|NCT02691013|Active Comparator|Ramelteon|Patients will receive Ramelteon 8mg every evening.
2980850|NCT02691000|Experimental|Bright White Light (BWL) Litebook|Participants will be instructed to use the BWL Litebook for an hour every day for 8 weeks.
2980851|NCT02691000|Placebo Comparator|Dim Red Light (DRL) Litebook|Participants will be instructed to use the DRL (comparison condition) Litebook for an hour every day for 8 weeks.
2980852|NCT02690987|Experimental|Overweight/obese subjects|Overweight/obese volunteers with BMI 28.0-50.0 kg/m2, otherwise healthy. This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design.
2980853|NCT02690987|Experimental|Ex-smokers|"Abstinent tobacco dependent individuals who score at least moderately on tobacco dependence as measured retrospectively using the Fagerström Test for Nicotine Dependence (FTND), and who have been in stable tobacco abstinence for at least 6 weeks.~This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design."
2980854|NCT02690987|Experimental|Ex-alcohol dependent subjects|"Abstinent alcohol dependent individuals who score at least moderately alcohol dependent as measured retrospectively using the Severity of Alcohol Dependence Questionnaire (SADQ), and who have been abstinent for at least 6 weeks.~This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design."
2980855|NCT02690974|Other|LCZ696 (sacubitril / valsartan)|All patients will be initiated on LCZ696 at 24.3 mg sacubitril / 25.7 mg valsartan that can be up-titrated to LCZ696 48.6 mg sacubitril / 51.4 mg valsartan bid after 2-4 weeks and then up-titrated again to 97.2 mg sacubitril / 102.8 mg valsartan bid after another 2 - 4 weeks.
2980856|NCT02690961|Experimental|Kukoamine B Mesilate 0.06mg/kg|Dose Escalation: Kukoamine B Mesilate 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
2980857|NCT02690961|Experimental|Kukoamine B Mesilate 0.12mg/kg|Dose Escalation: Kukoamine B Mesilate 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
2980858|NCT02690961|Experimental|Kukoamine B Mesilate 0.24mg/kg|Dose Escalation: Kukoamine B Mesilate 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
2980859|NCT02690961|Experimental|Placebo 0.06mg/kg|Dose Escalation: placebo 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
2980860|NCT02690961|Experimental|Placebo 0.12mg/kg|Dose Escalation: placebo 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
2980861|NCT02690961|Experimental|Placebo 0.24mg/kg|Dose Escalation: placebo 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
2980862|NCT02690948|Experimental|Pembrolizumab Monotherapy|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles are every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
2980863|NCT02690948|Experimental|Pembrolizumab plus Vismodegib Combination Therapy|Patients receive pembrolizumab IV over 30 minutes on day 1 and take vismodegib 150 mg by mouth daily. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
2980864|NCT02690935|Experimental|2LALERG|"Interleukin 1: 17 CH Interleukin 4: 17-27 CH Interleukin 5: 17 CH Interleukin 6: 17 CH Interleukin 10: 17 CH Interleukin 12: 9 CH Interleukin 13: 17 CH Tumor Necrosis Factor Alpha: 17 CH Transforming Growth Factor Beta: 5 CH Pulmo histaminum: 15 CH SNA-HLA-II: 18 CH~Impregnated on lactose saccharose globules (380 mg/capsule)"
2980865|NCT02690935|Placebo Comparator|Placebo|Non-impregnated lactose saccharose globules (380 mg/capsule)
2980866|NCT02690922|Experimental|ph+ ALL with dasatinib|patients in the arm are newly diagnosed ph+ ALL,the patient first receive dexamethasone as pretreatment,then dasatinib and prednisone are used as inductive treatment,and methotrexate to consolidate the therapy.
2980867|NCT02690909|Experimental|Redy™ Renal Denervation System|Renal Denervation System
2980868|NCT02690896|Experimental|UCF Behavioral Intervention Group|The intervention group will be the UCF Caregiver Support. Participants will receive a 90 minute group session, once a week, for a period of 6 consecutive weeks.
2980869|NCT02690896|Active Comparator|Community Comparison Group|Comparison group members will come from potential local support groups include, but are not limited to, the support group at the Faith Assembly of God church, the caregiver support group at the First Baptist Church of Orlando, and the caregiver support group at the Alzheimer's and Dementia Resource Center.
2980870|NCT02690883|Active Comparator|Lispro|Patients are treated with Glargine (Lantus, Sanofi-Aventis), the dosage is initiated according to the previous treatment plan and weight of the patients, injection before bed time, titration following FPG <7.2mmol/L and >4.4mmol/L.
2980871|NCT02690883|Experimental|Exenatide|Patients are treated with Glargine (Lantus, Sanofi-Aventis), the dosage is initiated according to the previous treatment plan and weight of the patients, injection before bed time, titration following FPG <7.2mmol/L and >4.4mmol/L.
2980872|NCT02690870|Experimental|tamoxifen|All patients will have serum hormone examination and be monitored by transvaginal ultrasound for ovaries on the day 3 of the menses（D3）.Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from D3 for 5 days.All patients will check serum E2 and be monitored by transvaginal ultrasound for the mean follicular diameter and endometrial thickness on the day 8 of the cycle. The investigators will add HMG and GnRH-ant according to follicular diameter,E2 and LH. Human chorionic gonadotropin(hCG) (5000-10000 IU IM) will be given when one follicle measured at least 18 mm is found. IVF or ICSI will be performed 34-36 h after hCG administration. All patients will receive luteal phase support with progesterone 60 mg im qd for 2 weeks.
2980873|NCT02690870|Active Comparator|clomiphene|All patients will have serum hormone examination and be monitored by transvaginal ultrasound for ovaries on the day 3 of the menses（D3）.Patients in clomiphene group will take 100 mg of CC oral tablets daily from D3 for 5 days.All patients will have sexual hormone determination and be monitored by transvaginal ultrasound for the mean follicular diameter and endometrial thickness on the day 8 of the cycle.The investigators will add HMG and GnRH-ant according to follicular diameter,E2 and LH. Human chorionic gonadotropin(hCG) (5000-10000 IU IM) will be given when one follicle measured at least 18 mm is found. IVF or ICSI will be performed 34-36 h after hCG injection. All patients will receive luteal phase support with progesterone 60 mg im qd for 2 weeks.
2980874|NCT02690857|Experimental|Docosahexaenoic acid|"Each capsule of DHA contains 100 mg DHA in triglycerides from algal oil, 0.125 mg alpha-tocopherol and 0.125 mg ascorbic acid.~Subjects receive an orally and daily ingestion of DHA capsules (5mg/kg for 15 days followed by 10 mg/kg for another 15 days without interruption between the 2 periods)."
2980994|NCT02689999|Experimental|Dexrabeprazole 10 mg Enteric-Coated Tablets|Dexrabeprazole 10 mg Enteric-Coated Tablets / once daily
2980875|NCT02690857|Placebo Comparator|Sunflower oil|Placebo capsules contain the same quantities of antioxidants and triglycerides of sunflower oil. Subjects receive an orally and daily ingestion of placebo capsules for 28 days.
2980876|NCT02690844|Active Comparator|Clonazepam|Clonazepam (Klonopin®) treatment arm - 1 mg clonazepam (Klonopin® tablet) TID, dissolved in mouth for 3 minutes then expectorated
2980877|NCT02690844|Placebo Comparator|Mucolox® alone|Mucolox® only - 5mL Mucolox® TID, swished around mouth for 3 minutes then expectorated
2980878|NCT02690844|Experimental|Mucolox® and clonazepam|Mucolox® and clonazepam - 1mg Clonazepam/5mL Mucolox® TID, swished around mouth for 3 minutes then expectorated.
2980879|NCT02690831|Active Comparator|Inspiratory Muscle training (IMT)|"The IMT program consisted of supervised and domiciliary exercises:~- The supervised exercises was performed in the presence of physiotherapist. This consisted of 30 min 2 days for 6 weeks using the threshold device (Powerbreathe classic level 1, Gaiam Ltd; Southam, Warwickshire, UK). This program involve 5 sets of 5 repetitions with 30 seconds rest between each one. The load of the training was distributed as follow:~First week: 30% Maximum Inspiratory Pressure (MIP)~Second week: 40% MIP~Third week: 50% MIP~Fourth week: 50% MIP~Fifth week: 60% MIP~Sixth week: 60% MIP~- The domiciliary exercises consisted of Yoga Breathing Exercises (Pranayama) that combines the inspiration and expiration through one or both nostrils, and requires the activation of chest and abdomen."
2980880|NCT02690831|Experimental|IMT + Manual Therapy and Motor Control Exercise|"The protocol for this group is identical to the previous group with the sole difference that is added a manual therapy (MT) and a motor control exercises (MCE). The MT protocol was performed for 15min, whereas the MCE was 10min. Below it described both protocols:~- MT:~Upper cervical region mobilization in flexion~Lower cervical postero-anterior mobilization + maintained traction~Costovertebral joint postero-anterior mobilization~Thrust dorsal~Cervical postero-anterior mobilization~- MCE:~Isometric contraction of the deep neck flexors.~Isometric contraction of the neck extensors.~Neural self-mobilization.~Cervical retraction with theraband.~Sphinx.~Scapular adduction exercises in prone.~Scapular adduction exercises in sitting position with theraband."
2980881|NCT02690818|Experimental|Behavioral intervention arm|"Regularly scheduled medication reminder text messages~Daily LTBI text messages without the option to text back. The messages will read, This is a reminder to take your medication.~Standard of care: Monthly reminder call and clinic visit"
2980882|NCT02690818|No Intervention|Control group receiving standard care|Standard of care: Monthly reminder call and clinic visit
2980883|NCT02690805||Breast cancer patients receiving neoadjuvant chemotherapy|One arm: Combined MRI-SMM Imaging
2980884|NCT02690792|Placebo Comparator|NAFLD/NASH - Placebo|"In NAFLD/NASH Group: Identically appearing Placebo capsules given as double-blinded, randomized intervention as a comparator to Vitamin E intervention.~Dosage: Placebo capsules. Two capsules by mouth each morning and two capsules by mouth each evening for 4 months."
2980885|NCT02690792|Active Comparator|NAFLD/NASH - Vitamin E|"In NAFLD/NASH Group: Vitamin E capsules given as double-blinded, randomized intervention as a comparator to Placebo capsules intervention.~Dosage: Vitamin E 200 IU/capsule. Two capsules by mouth each morning and two capsules by mouth each evening for 4 months."
2980886|NCT02690779|Experimental|Patients watching educational video|The educational intervention will consist of a 2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration. This video will be posted on YouTube. Group 1 will consist of 30 subjects who will be instructed to view this video prior to beginning their colonoscopy preparation. Information to access the YouTube video will be provided to the patients by endoscopy nurse assessment staff when contacting the patients as per standard practice to review appointment scheduling and procedure-day logistics.
2980887|NCT02690779|Sham Comparator|Patients not watching educational video|Group 2 will consist of 30 subjects who will not receive instructions to view the video. They will be given routine care instructions for bowel prep.
2980888|NCT02690766|Other|Physical Activity Group|The Success Study's Standard Behavioral Weight Change Intervention consists of 75 minute group sessions held monthly which include 30 minutes of physical activity with a licensed Physical Activity Instructor. Web Lessons that include information on Physical Activity, Nutrition and Healthy Behaviors will also be provided to participants on the study's website.
2980889|NCT02690753|Experimental|Tailored repositioning + Standardised incontinence care + TAP|A protocol tailored to individual risk factors will be applied to patients at risk.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
2980890|NCT02690753|Experimental|Standard repositioning + Standardised incontinence care + TAP|Instead of developing and using a tailored pressure ulcer prevention protocol, patients will receive standard care.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
2980891|NCT02690753|No Intervention|Usual care|Instead of developing and using a tailored pressure ulcer prevention protocol, patients will receive standard care. Instead of using comfort Shield® barrier cream cloths, incontinence care will be given to patients using the standard procedure on the ward. Instead of using the turn and position system, patients will be turned according to the standard procedure on the ward.
2980892|NCT02690740|Experimental|open label|"test/retest of a titrated quantitative CPT (TqCPT) with outcomes: CPT-scoring system and correlation with digital photo analysis.~in all patients: 1 Arm = CPT test/re-test, no comparator~No intervention of a new drug (CPT-solution registered (ALK- Abelló, Hørsholm, Denmark));"
2980893|NCT02690727|Experimental|RP6530 in fast condition|A single dose of RP6530 following fast condition
2980894|NCT02690727|Experimental|RP6530 in fed condition|A single dose of RP6530 following fed condition
2980895|NCT02690701|Experimental|Secukinumab|Eligible patients will receive secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 48 inclusive
2980896|NCT02690701|Placebo Comparator|Placebo|Eligible patients will receive placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8. Beginning with the Week 12 dose, patients will be switched to treatment with secukinumab 300 mg and will dose once weekly at Weeks 12, 13, 14, 15 and 16 followed by monthly dosing through Week 48 inclusive.
2980995|NCT02689986|Experimental|Treatment arm|Bendamustine, Rituximab
2980897|NCT02690688||Pneumoperitoneum|Patients scheduled for laparoscopic (minimal invasive) abdominal surgery supported by pneumoperitoneum. Hemodynamic monitoring will be performed using Vigileo® monitor, Edwards Lifescience
2980898|NCT02690688||Open Surgery|Patients scheduled for conventional (open) abdominal surgery. Hemodynamic monitoring will be performed using Vigileo® monitor, Edwards Lifescience
2980899|NCT02690675|Experimental|Intervention high-iron fortified milk|This group received a high dose of iron by formula milk (1.2mg/100mL) between 6 and 12 months of age.
2980900|NCT02690675|Experimental|Intervention low-iron fortified milk|This group received a low dose of iron by formula milk (0.4mg/100mL) between 6 and 12 months of age.
2980901|NCT02690662|Experimental|Obese with kidney stones|Hypocaloric diet for 3 months
2980902|NCT02690649|Experimental|Health Messaging (Non-Procedural)|PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.
2980903|NCT02690649|No Intervention|No Health Messaging|No PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.
2980904|NCT02690636|Active Comparator|Conventional|The patients will receive adjuvant radiotherapy conventionally fractionated 5000 cgy fractionated by 200cgy daily fractions, five fractions per week over 5 weeks with an additional 200cgy daily for five days as boost for patients with breast conservative surgery.
2980905|NCT02690636|Experimental|Hypofractionated|The patients will receive adjuvant radiotherapy hypofractionated 266cgy daily fractions, five fractions per week for total 16 fractions and an additional five daily fractions will be added as boost for patients with breast conservative surgery.
2980906|NCT02690623|Experimental|Pediatric hospitalist program|As currently planned, hospitalist services will involve an in-house hospitalist at all hours. The attending hospitalist on each hospitalist service will make morning rounds on weekdays and be present supervising the residents or providing care throughout the day. A different hospitalist will cover at night. On weekends, one hospitalist will cover up to 2 services each day. None will work for more than 25 hours at a stretch.
2980907|NCT02690623|Active Comparator|General Pediatric Inpatient Services|The attending pediatrician on each service conducts daily morning rounds on weekdays, supervises the students and house staff and is available to the residents by phone or in person during the day. On some afternoons the attending physician may be responsible for supervising care in a pediatric clinic. On weeknights, an on-call pediatrician is available to the residents by phone. On weekends two on-call pediatricians make rounds, supervise the residents, and take call from home for the 4 services. Each service usually maintains 10-20 patients at a time and generally accepts 8-12 new admissions per admitting day. This approach on the General Pediatric Services will not be changed materially as hospitalists assume responsibility for one or more of the 4 services.
2980908|NCT02690610|Experimental|Patients with mediastinal lesions|EBUS TBNA of mediastinal lesions or lymph nodes
2980909|NCT02690597|Other|Patient|"State-trait anxiety inventory Y-A form (STAI Y-A form)~Anxiety visual analog scale evaluation(A-AVS)."
2980910|NCT02690584|Experimental|Metacognitive therapy|Metacognitive therapy, one 45-60 min session weekly during 10 weeks.
2980911|NCT02690571|Sham Comparator|Filtered air exposure|One hour exposure to filtered air during intermittent exercise in controlled chamber, 6 hours after exposure bronchoscopy is performed.
2980912|NCT02690571|Experimental|Biodiesel exhaust exposure|One hour exposure to biodiesel exhaust (generated at same running conditions as earlier studies with diesel exhaust at approximate particle matter concentration 300 mcg/m3) during intermittent exercise in controlled chamber. Six hours after exposure bronchoscopy is performed.
2980913|NCT02690558|Experimental|pembrolizumab, gemcitabine and cisplatin|There is one arm in this study. Subjects will receive Pembrolizumab 200mg IV on day 1 in combination with cisplatin 35mg/m2 and gemcitabine 1000mg/m2 on day 1 and day 8 every 3 weeks for 4 cycles over 12 weeks.
2980914|NCT02690545|Experimental|ATLCAR.CD30 cells|"Phase Ib: In adults, and separately, in children, two doses will be investigated 1x10^8 cells/m2 and 2x10^8 cells/m^2. The study team will run two independent dose-escalation sequences, one for adults and another one for children. The study team plans to use the 3+3 design and start with a low dose of 1x10^8 cells/m2. If there are no DLT in first 3 patients, the study team will go up to the dose of 2 x 10^8 cells/m2. If there is toxicity in 1/3 patients in the initial cohort, the study team would expand to enroll up to 6 patients. If there are dose limiting toxicities (DLT) at the dose of 2 x 10^8 cells/m^2, the study team will initially decrease the dose to an intermediate dose of 1.5 x 10^8 cells/m^.~Phase II: The study team planning to enroll 25 patients to contribute data. Sequential boundary will be used to monitor DLT rate."
2980915|NCT02690532||High risk group|Children who are at high risk for developing celiac disease (siblings diagnosed with celiac disease).
2980916|NCT02690532||Non-celiac group|Children who are self-diagnosed with non-celiac gluten sensitivity.
2980917|NCT02690532||Control Group|Healthy control group (matched for age and gender).
2980918|NCT02690519|Experimental|GLPG1837 dose 1 and GLPG1837 dose 2|GLPG1837 twice daily oral dosing - morning and evening, for 4 weeks
2980919|NCT02690506|Placebo Comparator|Group C|Oral placebo pill was administered 2 hours before anesthesia
2980920|NCT02690506|Active Comparator|Group P|Oral pregabalin 150 mg was administered 2 hours before anesthesia
2980921|NCT02690493|Active Comparator|Acupuncture Only|Patients will be treated with acupuncture only.
2980922|NCT02690493|Active Comparator|Functional Taping Only|Patients will be treated with taping only.
2980923|NCT02690493|Experimental|Acupuncture and Functional Taping|Patients will be treated with both acupuncture and taping at the same session.
2980924|NCT02690480|Experimental|PD-0332991(Palbociclib)+fulvestrant(FaslodexTM)|Fulvestrant 500mg, on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days) in combination with Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
2980925|NCT02690480|Active Comparator|Placebo+fulvestrant(FaslodexTM)|Fulvestrant 500mg on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days) in combination with Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
2980926|NCT02690467|Experimental|Insupen G34x3,5mm|Needle for insulin pen 3,5 mm long and with a diameter of 34 gauge
2980927|NCT02690467|Active Comparator|Insupen G32x4mm|Needle for insulin pen 4 mm long and with a diameter of 32 gauge
2981026|NCT02689791|Experimental|Resistant Starch Type 4|Resistant Wheat Starch Muffins
2980928|NCT02690441|Experimental|CBT augmented with physical exercise|Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of physical exercise pre-treatment, and 10 weeks of physical exercise alongside CBT. Both treatment and physical exercise is administered individually.
2980929|NCT02690441|Active Comparator|CBT and placebo control|Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of placebo control (15 minutes telephone follow-up call each week) pre-treatment, and 10 weeks of attention placebo alongside CBT. Both treatment and placebo control is administered individually.
2980930|NCT02690428|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
2980931|NCT02690415||Antibiotics Given|Patients who's treating physician prescribed antibiotics following incision and drainage of their abscess.
2980932|NCT02690415||Antibiotics Not Given|Patients who's treating physician did not prescribed antibiotics following incision and drainage of their abscess.
2980933|NCT02690402|Experimental|adapted physical activity|a personalized care will be offered in terms of adapted physical activity
2980934|NCT02690389|No Intervention|Control|standard procedure is used
2980935|NCT02690389|Sham Comparator|Flumazenil only group|flumazenil is given
2980936|NCT02690389|Active Comparator|control with acupuncture|control with acupuncture
2980937|NCT02690389|Active Comparator|control with acupuncture and flumazenil|control with acupuncture and flumazenil
2980938|NCT02690376|Other|Magnetic Assisted Capsule Endoscopy|There is only one arm and its does not reach criteria for other options
2980939|NCT02690350|Experimental|Cohort 1 U3-1784 2.5 mg/kg|U3-1784 (2.5 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
2980940|NCT02690350|Experimental|Cohort 2 U3-1784 3.75 mg/kg|U3-1784 (3.75 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
2980941|NCT02690350|Experimental|Cohort 3 U3-1784 5.6 mg/kg|U3-1784 (5.6 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
2980942|NCT02690337|Experimental|DS-1123|This study will follow a modified Continual Reassessment Method (mCRM) + Escalation with Overdose Control (EWOC),design with a starting intravenous (IV) dose of 0.1 mg/kg.
2980943|NCT02690324|Experimental|Major depressive disorder|DSM-5 major depressive disorder HAMD-17 > 16
2980944|NCT02690324|Active Comparator|panic disorder|DSM-5 panic disorder PDSS>7
2980945|NCT02690324|Active Comparator|normal control|age >20, healthy adults HAMD-17<17 PDSS<7
2980946|NCT02690311|Sham Comparator|LED with bluelight|Two types of smartphone were used. One type had a conventional LED display with the full range of blue light. The LED in the other type newly developed by Samsung Display was suppressed for the blue light portion of the spectrum (wavelength 450 ~ 470 nm). The smartphones were indistinguishable from each other with the naked eye, because other wavelengths mimicked blue light in the suppressed LED.
2980947|NCT02690311|Experimental|LED without bluelight|Two types of smartphone were used. One type had a conventional LED display with the full range of blue light. The LED in the other type newly developed by Samsung Display was suppressed for the blue light portion of the spectrum (wavelength 450 ~ 470 nm). The smartphones were indistinguishable from each other with the naked eye, because other wavelengths mimicked blue light in the suppressed LED.
2980948|NCT02690285|Other|Part 1: glutathione transferase zeta 1 (GSTZ1) haplotyping|The participants will have blood collection and cheek cell collection after signing the informed consent, to determine GSTZ1 haplotype.
2980949|NCT02690285|Experimental|Part 2: Dichloroacetate (DCA) Kinetics|Eight study participants will be administered oral Dichloroacetate (DCA) 25 mg/kg daily for 5 days. On the fifth day frequent blood samples will be obtain over the following 24 hours. Study participants will complete a DCA kinetic study on day 5, at the Clinical Research Clinic (CRC).
2980950|NCT02690272|Experimental|Psychic processes|Quantitative and qualitative approche of the psychic process for patients awaiting kidney transplant
2980951|NCT02690259|Experimental|Sentinel node procedure|Enrolling all eligible endometrial cancer patient to the Sentinel node concept using indocyanine green.
2980952|NCT02690246||patients with HHT|patients with Hereditary Haemorrhagic Telangiectasia
2980953|NCT02690246||control cohort|indirectly only as a control cohort in questionnaire of affected persons
2980954|NCT02690220|Other|Implantation of a surgical mesh|"Women with a symptomatic genital descensus: at least stage II (ICS-classification according Pelvic Organ Prolapse Quantification System (POP-Q system)). This applies to primary as well as recurrent intervention.~Standard method to implant the TiLOOP® PRO A surgical mesh transvaginally."
2980955|NCT02690207|Experimental|HZ/su Group|Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
2980956|NCT02690194|No Intervention|Control|"Pre-procedure~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PROCEDURE~Post-procedure -Rate pain level of procedure"
2980957|NCT02690194|Placebo Comparator|Placebo Group|"Pre-Placebo therapy~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PLACEBO THERAPY SESSION~Post-Placebo therapy/Pre-procedure~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PROCEDURE~Post-procedure -Rate pain level of procedure"
2980958|NCT02690194|Experimental|Experimental (Buddhify) Group|"Pre-Buddhify therapy~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~BUDDHIFY THERAPY SESSION~Post-Buddhify therapy/Pre-procedure~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PROCEDURE~Post-procedure -Rate pain level of procedure"
2980959|NCT02690181|Experimental|GBS NoAdj/GBS NoAdj|Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
2980960|NCT02690181|Experimental|GBS Alum/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
2980961|NCT02690181|Experimental|GBS MF59 Full/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
2980993|NCT02690012|Active Comparator|Drug Magnesium citrate|Participants will be given standard dose levels of Magnesium citrate according to the level of magnesium in blood.
2980962|NCT02690181|Experimental|GBS MF59 Half/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
2980963|NCT02690181|Experimental|Placebo/GBS NoAdj|Subjects who had received placebo in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
2980964|NCT02690181|Experimental|Naive/GBS NoAdj|Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
2980965|NCT02690168||Healthy Men|
2980966|NCT02690155||Rivaroxaban|NVAF patients who were initiated on rivaroxaban for stroke prevention
2980967|NCT02690155||VKA (Vitamin K antagonist)|NVAF patients who were initiated on VKA for stroke prevention
2980968|NCT02690142|Experimental|ABY-035 i.v.|Part A: SAD (single ascending dose) including five different dose cohorts. ABY-035 given as intravenous injections. 6 ABY-035 and 2 placebo in each cohort.
2980969|NCT02690142|Experimental|ABY-035 s.c.|Part B: Bioavailability study where 6 subjects will receive ABY-035 as a single subcutaneous injection.
2980970|NCT02690142|Experimental|ABY-035 i.v. in psoriasis patients|Part C: Up to 12 psoriasis patients will receive ABY-035 as a single intravenous injection.
2980971|NCT02690142|Experimental|ABY-035 s.c. in psoriasis patients|Part D: Up to 18 patients will receive 3 or 7 biweekly doses of ABY-035 as s.c. injections
2980972|NCT02690129|Active Comparator|Group I (Progesterone Group)|"Complete bed rest as an in/or out- patient, according to patient's preference for first 48-72 hours.~Vaginal progesterone treatment as single daily dose of natural micronized progesterone (Prontogest ® 200 mg) at bedtime for 15 days.~If needed, a pain killer as Indomethacin 50 mg/ rectally twice daily up to control of uterine colic .~Complete abstaining from sexual activity or strenuous effort. Additionally, Rh-ve women with established viable fetuses and continue bleeding will be given a shot of anti-D immunoglobulin 300 ugm/IM ; after 12 weeks' gestation or if undergo surgical evacuation."
2980973|NCT02690129|Placebo Comparator|Group II ( Control group)|Will follow the same plan of management without progesterone support.
2980974|NCT02690116|Experimental|Qigong/Tai Chi Easy|The Qigong/Tai Chi Easy (QG/TCE) intervention has been standardized, manualized, and has a formal training program for instructors from the Institute of Integral Qigong and Tai Chi (IIQTC).
2980975|NCT02690116|Sham Comparator|Sham Qigong|This active control group uses a gentle movement intervention, with similar types of movements with the same energy expenditure, but without the meditative states and breath focus as QG/TCE (validated in the pilot study using the Meditative Movement Inventory).
2980976|NCT02690116|Active Comparator|Educational Support|The Recovery Support Group will consist of a classroom-style intervention, designed to educate, engage interaction, and maintain participation and attention over 8 weeks. This group will include readings/discussions specific to breast cancer, and social interaction facilitation.
2980977|NCT02690103|Active Comparator|Group 1|Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months. In addition, they are given ribavirin according to their body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
2980978|NCT02690103|Experimental|Group 2|Patients are treated with Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose.
2980979|NCT02690090||enoxaparin|enoxaparin prophylaxis as directed by treating Intensivist
2980980|NCT02690077|Active Comparator|Method 1 by Preference 1|Delivery through the Family-Centered Cesarean for patients with known Family-Centered preference.
2980981|NCT02690077|Active Comparator|Method 1 by Preference 2|Delivery through the Family-Centered Cesarean for patients with known Traditional Cesarean preference.
2980982|NCT02690077|Active Comparator|Method 2 by Preference 1|Delivery through the Traditional Cesarean for patients with known Family-Centered preference.
2980983|NCT02690077|Active Comparator|Method 2 by Preference 2|Delivery through the Traditional Cesarean for patients with known Traditional Cesarean preference.
2980984|NCT02690064|Experimental|Acute Antioxidant Treatment|Following an overnight fast, blood samples, flow-mediated dilation, lung function, and exercise capacity (VO2 peak) (post only) will be performed at baseline and 2 hours following either a single dose oral antioxidant cocktail (1000 mg Vitamin C, 600 IU vitamin E, 600 mg Alpha Lipoic Acid) or placebo on two days separated by at least 72 hours.
2980985|NCT02690064|Experimental|Chronic Antioxidant Treatment|Following the completion of Arm 1, blood samples, flow-mediated dilation, lung function, and exercise capacity (VO2 peak) will be performed, only in patients with CF, at baseline, 4 weeks, 8 weeks, and 12 weeks following an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg)taken once a day.
2980986|NCT02690051|Experimental|BeSmooth Peripheral Stent system|Patients treated with the BeSmooth Peripheral Stent System
2980987|NCT02690038|Experimental|Intervention Arm 1: Treatment|"Baseline Ig < 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks).~Baseline Ig > or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks)."
2980988|NCT02690038|Active Comparator|Intervention Arm 2: Control|"Baseline Ig < 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks).~Baseline Ig > or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks)."
2980989|NCT02690025|Experimental|ZP1848 High dose|s.c. administration of high dose
2980990|NCT02690025|Experimental|ZP1848 Medium dose|s.c. administration of medium dose
2980991|NCT02690025|Experimental|ZP1848 Low dose|s.c. administration of low dose
2980992|NCT02690012|Active Comparator|Drug Magnesium oxide|Participants will be given standard dose levels of Magnesium oxide according to the level of magnesium in blood.
2980996|NCT02689973|Experimental|Self-efficacy|The self-efficacy intervention protocol included following behavior change techniques (BCT; Michie et al., 2011): barrier identification, prompting focus on past success, and prompting self-talk. Applications of all BCT included references to self-efficacy beliefs. The intervention was integrated into health promotion-nutrition education program (8h). The intervention was applied twice (the baseline and 2-month follow-up).
2980997|NCT02689973|Experimental|Planning|"The following BCT were included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning.~The intervention was integrated into health promotion-nutrition education program (8h). The intervention was applied twice (the baseline and 2-month follow-up)."
2980998|NCT02689973|Experimental|Combined planning+self-efficacy|This condition included all BCT applied in the planning and self-efficacy arms. The intervention was integrated into health promotion-nutrition education program. The intervention was applied twice (the baseline and 2-month follow-up).
2980999|NCT02689973|Active Comparator|Education|The education group received extended physical activity education program. The physical activity education was integrated into health promotion-nutrition education program.The education program was applied twice (the baseline and 2-month follow-up).
2981000|NCT02689960|Other|vaginal administration first|Intervention first visit: vaginal administration of 100mg prednisone suppository, Intervention second visit: rectal administration of 100mg prednisone suppository
2981001|NCT02689960|Other|rectal administration first|Intervention first visit: rectal administration of 100mg prednisone suppository, Intervention second visit: vaginal administration 100mg prednisone suppository
2981002|NCT02689947|Experimental|Restylane Silk|open label no placebo control
2981003|NCT02689934|Experimental|Lactoflorene colesterolo|Red Yeast Rice titrated in 10 mg monacolin K per daily dose plus Bifidobacterium longum 50 mg, powder form, 1 packet per day
2981004|NCT02689934|Placebo Comparator|Placebo Lactoflorene colesterolo|placebo, powder form, 1 packet per day
2981005|NCT02689921|Experimental|Neoadjuvant Biological Therapy|"Subjects will receive an aromatase inhibitor for the duration of the study [exemestane (tablet, oral, 25 mg/day), letrozole (tablet, oral, 2.5 mg/day) or anastrozole (tablet, oral, 1 mg/day)]. Premenopausal subjects will receive leuprolide acetate (11.25 mg, intramuscular injection, 3-month intervals).~Pertuzumab will be given by intravenous infusion in 3-week cycles until disease progression (Cycle 1 Day 0: 840 mg, infused over 60-90 minutes; subsequent cycles: 420 mg, infused over 30-60 minutes).~Trastuzumab will be given by intravenous infusion in 3-week cycles until disease progression (Cycle 1 Day 0: 8 mg/kg, infused over 60-90 minutes; subsequent cycles: 6 mg/kg, infused over 30-60 minutes)"
2981006|NCT02689908|Other|The patients underwent thorax CT|The patients refered to radiology service underwent thorax computed tomography without contrast material for the evaluation of various complaints such as dyspnea, hemoptysis and pulmonary infections.
2981007|NCT02689895|Other|Intervention|Research assistants visit participants at home, and send SMS texts on scheduled days for 3 months to encourage adherence to ART. Pill charts, visit charts and text charts are completed. this is called modified directly administered anti-retroviral therapy (mDAART). In addition to the intervention, participants receive standard care at their usual clinic which comprises 3 monthly doctor reviews and adherence counseling at each review visit.
2981008|NCT02689895|No Intervention|Control|Participants get usual care at their clinic, which comprises 3 monthly doctor review visits and adherence counseling at each visit.
2981009|NCT02689882|Experimental|pharmacokinetic study|Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
2981010|NCT02689869|Experimental|Ibrutinib and GA 101|"Initial therapy 6 cycles of Ibrutinib:~Ibrutinib 560 mg once daily every day until start of maintenance for a total of 24 weeks.~1000 mg of GA101 I.V. on days d 1, 8, 15 of cycle 1 and on day 1 of cycles 2-6 (21 day cycles).~Maintenance with another 24 months of ibrutinib plus GA101 in patients with clinical remission after the last induction cycle:~Ibrutinib 560 mg once daily every day. GA101 at a dose of 1000 mg I.V. every 2 months for a total of 24 months. The total duration of ibrutinib plus obinutuzumab therapy will therefore be 30 months.~In patients remaining MRD positive at 30 months without clinical progression, single agent ibrutinib therapy is continued for another 12 months."
2981011|NCT02689856|Placebo Comparator|Vehicle cream|Placebo control base cream
2981012|NCT02689856|Experimental|3% hydrocortisone|3% Hydrocortisone acetate cream
2981013|NCT02689856|Experimental|0.5% hydrocortisone|0.5% Hydrocortisone acetate cream
2981014|NCT02689856|Experimental|5% lidocaine|5% Lidocaine hydrochloride cream
2981015|NCT02689856|Experimental|1% lidocaine|1% Lidocaine hydrochloride cream
2981016|NCT02689856|Experimental|3% Hydro 5% Lido|Hydrocortisone acetate and lidocaine hydrochloride at 3% and 5% cream
2981017|NCT02689856|Experimental|0.5% Hydro 1% Lido|Hydrocortisone acetate and lidocaine hydrochloride at 0.5% and 1% cream
2981018|NCT02689843|Active Comparator|Cyproterone compound + Spironolactone|Cyproterone compound (Cyproterone acetate 2mg+Ethinyl estradiol 35 mcg) once daily + Spironolactone 50 mg twice daily
2981019|NCT02689843|Active Comparator|Metformin|Metformin 1500 mg daily
2981020|NCT02689843|Active Comparator|Pioglitazone|Pioglitazone 30 mg daily
2981021|NCT02689830|Experimental|Bead Block microspheres|Prostate embolization
2981022|NCT02689817|Experimental|Monitoring patch, no display|Participants in this condition will receive a padded bandage that monitors pressure over time. In this arm, healthcare providers will not be able to view the pressure data collected.
2981023|NCT02689804|Other|Normal-BMI|Women with normal BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
2981024|NCT02689804|Other|Obese-BMI|Women with obese BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
2981025|NCT02689791|No Intervention|Control (SWF)|Standard Wheat Flour (SWF) Muffins
2981027|NCT02689778|Experimental|Pirfenidone|Oral pirfenidone 600 mg with breakfast and 1200 mg with dinner for 12 months.
2981028|NCT02689778|Placebo Comparator|Placebo|Oral placebo with breakfast and with dinner for 12 months.
2981029|NCT02689765|Experimental|Anthocyanins|Volunteers will be randomised double blinded into 'Anthocyanins' groups(n=60 per group)and given twice daily two capsules of either 80 grams of Anthocyanins, which corresponds a mixture of fresh blue berries and blackcurrants.The total duration of this trial was 24wk.
2981030|NCT02689765|Placebo Comparator|Control|A daily intake of 320mg Placebo to instead of treatment of Anthocyanins.
2981031|NCT02689752|Experimental|fruquintinib|fruquintinib suspension, 5 mg （100 mCi）oral taken once
2981032|NCT02689739||Obese Pregnant cohort|Women will be consented to participate and then separated into a study group of obese women (BMI >/= 30).
2981033|NCT02689739||Non-obese Pregnant cohort|This will be the control group of non-obese women (BMI <30).
2981034|NCT02689726|Experimental|GTL001 + Aldara, 5% imiquimod cream|2 doses, 6 weeks apart, GTL001 will be adjuvanted with Aldara, 5% imiquimod cream, applied to the injection site 15 minutes and 24 hours after each vaccination
2981035|NCT02689713|Experimental|Topical Voriconazole Study Drug Group|Subjects between 18 and 60 years old who have sustained a burn wound of less than 30% total body surface area, or traumatic wounds requiring skin graft will have the Topical Voriconazole study drug placed on graft site.
2981036|NCT02689713|Placebo Comparator|Topical Sterile Water Placebo Group|Subjects between 18 and 60 years old who have sustained a burn wound of less than 30% total body surface area, or traumatic wounds requiring skin graft will have the Topical Sterile Water Placebo placed on graft site.
2981037|NCT02689700||HCMV antibody-transfer|Materno-fetal HCMV antibody-Transfer form 24-41 weeks of gestation
2981038|NCT02689700||VZV antibody-transfer|Materno-fetal VZV antibody-Transfer form 24-41 weeks of gestation
2981039|NCT02689687|Experimental|Intervention|All participants will be (1) given an electronic pill bottle for their diuretic and a Bluetooth scale; (2) asked to provide the coordinator with name and contact information of a family member or friend to serve as a support partner; (3) will be assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence and registering a weight measurement; and, (4) will determine their preferences for Way to Health platform communication methods during the study.
2981040|NCT02689661||Obese participants|Obese participants recruited from the University of Michigan Investigational Weight Management Clinic. Subjects in this group complete the five surveys, undergo extensive metabolic phenotyping, and a comprehensive neuropathy assessment at study entry and again at 2 years.
2981041|NCT02689661||Lean participants|Healthy lean age and gender matched controls recruited via the umclinicaltrials.org complete the five surveys, complete an oral glucose tolerance test and cholesterol panel, as well as the complete comprehensive neuropathy assessment.
2981042|NCT02689635|Active Comparator|Sodium Restricted Diet|Low Salt (cardiac) diet
2981043|NCT02689635|Active Comparator|Regular Diet|Non-Cardiac diet
2981044|NCT02689622|Experimental|Evaluation of disease prognostic factors|Research of disease-related factors, research of comorbidities, geriatric assessment (Mini Mental Status Examination (MMSE), Geriatric Depression Scale-15, Mini Nutritional Assessment, Short Physical Performance Battery, grip strength, Fried criteria, Activities of Daily Living (ADL), Instrumental-ADL, G8, self-reported health status, quality of life Quality of Life Questionnaire-C30, Elderly Cancer Patients-14, EQ5D) at inclusion. At 3 months ADL and physical performance. Grade 3/4 toxicities and serious adverse events will be assessed during 6 months after inclusion (using NCI-COMMON TERMINOLOGY CRITERIA version 2.0) whatever treatment type (chemotherapy, supportive care).
2981045|NCT02689609||Single arm|All patients will receive intensity-modulated radiation therapy (IMRT) with or without adjunct chemotherapy as standard of care. They will have baseline pre-treatment and post-IMRT serum thyroid function test at least yearly after IMRT.
2981046|NCT02689596|Active Comparator|OT|Oxytocin
2981047|NCT02689596|Placebo Comparator|Placebo|Placebo
2981048|NCT02689583|Experimental|Successful treatment|The patients with H. pylori infection have successful treatment based on the results from antibiotic susceptibility testing，CYP2C19 gene polymorphism，drug resistance gene sequencing and 16SrRNA sequencing.
2981049|NCT02689583|Experimental|refractory infection|The patients with H. pylori infection have failed treatment based on the results from antibiotic susceptibility testing，CYP2C19 gene polymorphism，drug resistance gene sequencing and 16SrRNA sequencing.
2981050|NCT02689570||type 1 diabetic patients|Adult T1DM patients, aged 18-75 years, regularly attending the out-patient diabetes clinic of the Antwerp University Hospital are recruited starting from June 2011. Patients had to have a diabetes duration of ≥5 years and be in general good health to be included. Exclusion criteria were a history of a major adverse cardiovascular event (myocardial infarction, stroke), other cardiovascular complaints, pregnancy or a glomerular filtration rate ≤30 ml/min/1.73 m2.
2981051|NCT02689557|Other|measures of the volumes|Measures of the volumes of the lower limbs. A measure to rest, a measure of effort (walk) and a measure recovery. Intervention.
2981052|NCT02689544|Experimental|static stretching|Group of 15 volunteers (gSS)
2981053|NCT02689544|Experimental|dynamic stretching|Group of 15 volunteers (gDS)
2981054|NCT02689544|Other|control|Group of 15 volunteers (gC)
2981055|NCT02689531||High-Risk (Adult =>18 years old)|"Treated with one or more of the following respiratory modalities for at least 12 continuous hours, either currently or within the prior 7 days:~Invasive mechanical ventilation~Noninvasive ventilation (BiPAP or CPAP for any indication other than obstructive sleep apnea)~High-flow, supplemental oxygen therapy via nasal cannula. Only include systems that using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM.~High flow supplemental oxygen therapy delivering at least 50% FiO2 via aerosol facemask or tracheostomy collar (mask). Only include systems using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM.~Supplemental oxygen therapy delivered via either partial or non-rebreather face mask"
2981056|NCT02689531||Other-ICU/Standard Risk|Patients do not fulfill high-risk criteria, but, are receiving an antibiotic for treatment of lower respiratory tract infection or undifferentiated sepsis.
2981090|NCT02689258|Experimental|Part A Cohort D|400 mg of HTX-011B by infiltration
2981091|NCT02689258|Experimental|Part A Cohort E|600 mg of HTX-011B by infiltration
2981057|NCT02689531||High-Risk (Pediatric ≥120 days old and <18 years old)|"Currently treated with one or more of the following respiratory modalities for at least 24 hours:~Invasive mechanical ventilation via endotracheal intubation~New initiation of mechanical ventilation, BiPAP or CPAP via tracheostomy~Noninvasive ventilation (BiPAP or CPAP for any indication other than obstructive sleep apnea)~High-flow, supplemental oxygen therapy delivering at least 1.5LMP with 100% FiO2 via nasal cannula when delivered using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM~High flow supplemental oxygen therapy delivering at least 50% FiO2 via aerosol facemask or tracheostomy collar (mask) when delivered using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM~Supplemental oxygen therapy delivered via either partial or non-rebreather face mask"
2981058|NCT02689531||High-Risk (Pediatric <120 days old)|Currently treated with mechanical ventilation via endotracheal intubation for at least 5 days
2981059|NCT02689518|Other|Treatment - On-Label|On-label intravitreal aflibercept (Eylea) injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks (2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months
2981060|NCT02689505|Experimental|BI 836880|
2981061|NCT02689453|Experimental|1A|IL-15 for 10 doses over two weeks followed byalemtuzumab for 4 weeks
2981062|NCT02689453|Experimental|1B|IL-15 for 10 doses over two weeks followed by alemtuzumab for 4 weeks at the maximum tolerateddose (MTD)
2981063|NCT02689440|Experimental|Dasatinib + Venetoclax|"Participants take Dasatinib tablets by mouth one (1) time each day for up to 15 years.~After receiving Dasatinib for 3 months, participants begin to take Venetoclax by mouth every day with Dasatinib for up to 3 years.~If participant joined the study after April 1, 2018, participant receives Dasatinib alone for 3 months and then Dasatinib in combination with Venetoclax."
2981064|NCT02689440|Experimental|Dasatinib|"Participants take Dasatinib tablets by mouth one (1) time each day for up to 15 years.~If participant joined the study before April 1, 2018, participant receives Dasatinib alone.~If participant joined the study after April 1, 2018, participant receives Dasatinib alone for 3 months and then Dasatinib in combination with Venetoclax."
2981065|NCT02689427|Experimental|Enzalutamide + Paclitaxel|"Participants receive Enzalutamide by mouth every day for 12 study cycles. Each cycle is 7 days (1 week).~On Day 1 of each cycle, participants receive Paclitaxel by vein over about 2 hours."
2981066|NCT02689414|Experimental|Remote ischaemic preconditioning|Four episodes of 5 minutes of ischaemia are performed. Between all the episodes there is a 5-minute period of reperfusion.
2981067|NCT02689414|Sham Comparator|Control to RIPC|Four episodes of 5 minutes during which the pressure in the cuff is equal to venous pressure are performed. Between all the episodes there is a 5-minute pause.
2981068|NCT02689401|Experimental|Ferumoxtyol (Feraheme) with MRI|Patients will undergo a pre-contrast MRI followed by a pre determined dose of of IV Ferumoxyto. Post-contrast MRI imaging will be performed immediately following Ferumoxytol infusion and 48 hours after Ferumoxytol administration with subsequent image analysis.
2981069|NCT02689388|Active Comparator|General Anesthesia with nerve block|Femoral Nerve Block
2981070|NCT02689388|No Intervention|General Anesthesia no nerve block|No femoral Nerve Block
2981071|NCT02689375|Experimental|Patients to receive spinal cord stimulator|
2981072|NCT02689362|Experimental|Evogliptin 2.5mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 2.5 mg. The participants randomized to this group will receive 1 tablet daily of EVO 2.5 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
2981073|NCT02689362|Experimental|Evogliptin 5.0mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 5.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 5.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
2981074|NCT02689362|Experimental|Evogliptin 10.0mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 10.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 10.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
2981075|NCT02689362|Active Comparator|Sitagliptin 100mg+Placebo Evogliptin|SITA at a daily oral dose of 100 mg. The participants randomized to this group will receive 1 tablet daily of SITA 100 mg + 1 tablet of EVO placebo for 12 weeks.
2981076|NCT02689349|Experimental|Esteem Implant|Implantation of Esteem
2981077|NCT02689336|Experimental|Erlotinib and Temozolomide|"Erlotinib is an oral drug that will be administered on an outpatient basis at a dose of 85 mg/m^2/dose once a day continuously (every day of a 28-day cycle)~Temozolomide is an oral drug that will be administered on an outpatient basis at a dose of 180mg/m2/dose once a day on Days 1-5 of a 28-day cycle."
2981078|NCT02689323|Experimental|Open label|Participants will undergo 5 sessions of active rTMS
2981079|NCT02689310|Other|Standard Care - Stage III Pressure Ulcers|Patients with a stage III pressure ulcer who are randomized into this arm will be given standard treatment (hydrogel, collegense, and silver alginate dressings).
2981080|NCT02689310|Experimental|Honey Treatment - Stage III Pressure Ulcers|Patients with a stage III pressure ulcer who are randomized into this treatment arm will be given leptospermum scoparium honey dressings for treatment of their wound.
2981081|NCT02689310|Other|Standard Care - Stage IV Pressure Ulcers|Patients with a stage IV pressure ulcer who are randomized into this arm will be given standard treatment (hydrogel, collegense, and silver alginate dressings).
2981082|NCT02689310|Experimental|Honey Treatment - Stage IV Pressure Ulcers|Patients with a stage IV pressure ulcer who are randomized into this treatment arm will be given leptospermum scoparium honey dressings for treatment of their wound.
2981083|NCT02689297|Other|group A|Mouthwash (chlorine dioxide 12ml two times per day, for three weeks)
2981084|NCT02689297|Other|group B|Small toothbrush for tongue cleaning two times per day for three weeks
2981085|NCT02689284|Experimental|Dose Escalation Phase|Determine the MTD or MAD (if no MTD is defined) of escalating doses of margetuximab administered in combination with pembrolizumab
2981086|NCT02689284|Experimental|Dose Expansion Phase|Determine safety and activity of margetuximab and pembrolizumab combination dose (as determined from the Dose Escalation Phase)
2981087|NCT02689258|Experimental|Part A Cohort A|200 mg of HTX-011A by infiltration
2981088|NCT02689258|Placebo Comparator|Part A Cohort B|Saline Solution by infiltration
2981089|NCT02689258|Experimental|Part A Cohort C|200 mg of HTX-011B by infiltration
2981092|NCT02689258|Experimental|Part B Cohort A|Subjects will be enrolled in Part B following completion of enrollment in Part A to evaluate HTX-011 and HTX-002, with or without saline solution.
2981093|NCT02689258|Experimental|Part C Cohort A|Subjects will be enrolled in Part C following completion of Part B to evaluate 400 mg HTX-011B via instillation, bupivacaine HCl 100 mg via injection and saline placebo via injection
2981094|NCT02689258|Experimental|Part D Cohort A|Up to 300 mg of HTX-011B
2981095|NCT02689258|Placebo Comparator|Part D Cohort B|Saline Solution
2981096|NCT02689245|Experimental|Tenofovir + Fecal Microbiota Transplantation (FMT)|
2981097|NCT02689245|Active Comparator|Tenofovir|
2981098|NCT02689232|Experimental|Thromboelastography (TEG) level|
2981099|NCT02689232|Active Comparator|Coagulation Profile|
2981100|NCT02689219|Experimental|CD30 positive|Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
2981101|NCT02689219|Experimental|CD30 negative/unknown|Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
2981102|NCT02689206|Experimental|GSK1278863 10 mg|Subject will receive 10 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
2981103|NCT02689206|Experimental|GSK1278863 15 mg|Subject will receive 15 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
2981104|NCT02689206|Experimental|GSK1278863 25 mg|Subject will receive 25 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
2981105|NCT02689206|Experimental|GSK1278863 30 mg|Subject will receive 30 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
2981106|NCT02689206|Placebo Comparator|Placebo|Subject will receive GSK1278863 matching placebo three-times weekly for 4 weeks (up to 29 days).
2981107|NCT02689193||Salmonella|Patients for whom blood cultures grew Salmonella species.
2981108|NCT02689193||No pathogen|Patients for whom blood cultures did not grow a pathogen and no pathogen was detected using other routine care diagnostics (e.g. malaria with the use of a malaria rapid test).
2981109|NCT02689193||Another pathogen|Patients for whom blood cultures grew with another pathogen or a pathogen was detected using other routine care diagnostics (e.g. malaria with the use of malaria rapid test).
2981110|NCT02689193||Healthy controls|Healthy controls. Patients without fever but from whom blood is drawn for another reason (e.g. check of cholesterol).
2981111|NCT02689180|Placebo Comparator|Withdraw of furosemide|Withdraw of of 40 or 80 mg of furosemide per day
2981112|NCT02689180|Active Comparator|Maintenance of furosemide|Maintenance of 40 or 80 mg of furosemide per day
2981113|NCT02689167|Active Comparator|Arm A 4/6|"Sunitinib 37.5 mg/day; regimen 4/6 (Marketing Authorisation Indication) 4 weeks on  alternating with 2 weeks off "
2981114|NCT02689167|Experimental|Arm B 2/3|"Sunitinib 50 mg/day; regimen 2/3 (experimental arm) 2 weeks on  alternating with 1 week off "
2981115|NCT02689154|Experimental|W8Loss2Go App|Subjects will complete all stages of W8Loss2Go mHealth intervention.
2981116|NCT02689141|Experimental|Bendamustine + Ofatumumab + Ibrutinib|Bendamustine: 70mg/m² i.v. Ofatumumab: 1000 mg i.v. Ibrutinib: 420 mg po
2981117|NCT02689115||Clinical activity|Patients with rheumatoid arthritis who met the criteria established by the American College of RheumatologyDisease Activity Score 28 (DAS28) > 3.6.
2981118|NCT02689115||Clinical remission|Patients with rheumatoid arthritis with Disease Activity Score 28 (DAS28) < 2.4.
2981119|NCT02689102||ILD patients|ILD patients scheduled for diagnostic bronchoscopy with biopsy and/or broncho-alveolar lavage will undergo additional imagaing with probe based optical techniques.
2981120|NCT02689089|Other|3HP|The interrupted time series design aims to collect data at multiple time points before (standard regimen) and after the introduction of the new 3HP regimen (interruption) to detect if a significant increase in the number of completions has occurred with the new regimen
2981121|NCT02689076|Experimental|HIE Notification plus Care Coordination|VA provider notification of non-VA hospitalization via electronic health information exchange (HIE) plus post-hospital geriatric care transitions intervention
2981122|NCT02689076|Active Comparator|HIE Notification alone|VA provider notification of non-VA hospitalization via electronic health information exchange (HIE) followed by usual post-hospital care
2981123|NCT02689063|Experimental|Maxigesic IV|intravenous acetaminophen1000 mg + intravenous ibuprofen 300 mg/100 ml solution for infusion, 100 mL, every 6 hours for 48 hours
2981124|NCT02689063|Active Comparator|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL. every 6 hours for 48 hours
2981125|NCT02689063|Active Comparator|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL every 6 hours for 48 hours
2981126|NCT02689063|Placebo Comparator|Placebo IV|Placebo IV- 100 mL saline for infusion, 100mL every 6 hours for 48 hours
2981127|NCT02689050||Patients with lymphadenopathy|Patients ≥ 18 years of age, with (suspected) NSCLC or suspected sarcoidosis, and at least one suspected mediastinal/hilar lesion that are scheduled for standard diagnostic endosonographic workup will undergo additional needle based confocal laser endomicroscopy (nCLE) measurements of suspected lesions.
2981128|NCT02689037|Experimental|stenting+medical treatment|Patients in PTAS+MT group will receive Percutaneous transluminal angioplasty and stenting and medical treatment (aspirin 100mg daily and clopidogrel 75mg daily)
2981129|NCT02689037|Active Comparator|Aspirin plus clopidogrel|Patients in aspirin plus clopidogrel group will receive aspirin 100mg daily and clopidogrel 75mg daily for 90 days.
2981130|NCT02689024|Experimental|Continuous FICB with local anesthetics|"With ultrasound guidance, a Fascia Iliaca Compartment Block will be administered and a catheter left in the compartment underneath the iliac fascia. This catheter will remain in place until two days after surgery.~Initial pain treatment in the Emergency Department will be with 40 mL bupivacaine 0.25% or equipotent dosages of levobupivacaine or ropivacaine. Thereafter, until removal of the catheter, pain is treated by titrating local anesthetics according to pain scores."
2981163|NCT02688764|Experimental|PA21 (Velphoro®)|"PA21 (Velphoro®), chewable tablets 500 mg iron~PA21 (Velphoro®), chewable tablets 250 mg iron~PA21 (Velphoro®), powder for oral suspension 500 mg iron~PA21 (Velphoro®), powder for oral suspension 250 mg iron~PA21 (Velphoro®), powder for oral suspension 125 mg iron"
2981131|NCT02689024|Active Comparator|Traditional care with systemic analgesia|"Traditional care (usual care) will be on the discretion of the treating physician or hospital protocols and will comprise of systemic opioids such as fentanyl or morphine.~Usually, these opioids are combined with several other drugs, such as: paracetamol, NSAIDs (diclofenac or ibuprofen or naproxen) or dipyrone. (Inter)national guidelines advice morphine as first line agent in elderly patients with hip fractures, as longer acting analgesics are usually required."
2981132|NCT02689011|Experimental|Group F|Femoral nerve Block Group
2981133|NCT02689011|Active Comparator|Group E|Epidural Group
2981134|NCT02688998|Active Comparator|Venous access PORT or PICC|Participants will receive a central line placement either a PORT or a PICC prior to the initiation of chemotherapy.
2981135|NCT02688998|No Intervention|No intervention|Participants will only receive a central line if required once chemotherapy has been initiated.
2981136|NCT02688985|Experimental|RMS Cohort Arm 1: Ocrelizumab + LP at Weeks 1 and 12|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 12.
2981137|NCT02688985|Experimental|RMS Cohort Arm 2: Ocrelizumab + LP at Weeks 1 and 24|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 24.
2981138|NCT02688985|Experimental|RMS Cohort Arm 3: Ocrelizumab + LP at Weeks 1 and 52|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 52.
2981139|NCT02688985|Experimental|RMS Cohort Arm 4: Ocrelizumab + LP at Week -12 and Week 1|Ocrelizumab treatment will be delayed for 12 weeks from pre-treatment baseline. Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP at Week -12 (pre-treatment baseline) and a second LP before the start of dosing (Week 1, treatment baseline).
2981140|NCT02688985|Experimental|PPMS Cohort: Ocrelizumab + LP at Weeks 1 and 52|Participants with PPMS will receive ocrelizumab 600 mg as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 52.
2981141|NCT02688972|Experimental|cold water immersion|
2981142|NCT02688972|Other|control|13 volunteers
2981143|NCT02688959|Experimental|Tai Chi|Participants in this arm will attend 50-minute classes 2 times per week for 8 weeks. The course will emphasize experiential learning with 2 weeks of introductory sessions on gait, posture, and tai chi principles followed by instruction in the 24-form Yang style sequence. Students will be given a video to aid learning outside of class, and maintenance of practice post-intervention.
2981144|NCT02688959|Active Comparator|Exercise|Participants in the exercise arm will attend 50-minute classes 2 times per week for 8 weeks. The course will emphasize cardio-aerobic fitness training. Students will be given a video to aid practice outside of class, and maintenance of practice post-intervention.
2981145|NCT02688959|No Intervention|Control|Participants in the control arm will not attend a class and not be given a video.
2981146|NCT02688933|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine, 300 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting self-measured plasma glucose (SMPG) levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
2981147|NCT02688933|Active Comparator|Lantus|Lantus (Insulin glargine, 100 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting SMPG levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
2981148|NCT02688920||With T2DM|Subjects with type 2 diabetes.
2981149|NCT02688920||Without T2DM|Subjects without type 2 diabetes
2981150|NCT02688907|Experimental|AZD1775|AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.
2981151|NCT02688894||Small cell lung cancers|To provide molecular characteristics of Small cell lung cancers to proceed SUKSES trial, To assess success rate of molecular profiling of Small cell lung cancers
2981152|NCT02688881|Experimental|sirolimus|sirolimus 1mg will be administered orally daily
2981153|NCT02688855|Experimental|Investigational Group|Standard Rigid Fixation + Active OL1000 device
2981154|NCT02688855|Sham Comparator|Control Group|Standard Rigid Fixation + Sham OL1000 device
2981155|NCT02688842|Experimental|treatment group|Implantation of the released specification (38mm) of FirehawkTM rapamycin target-eluting coronary stent systems
2981156|NCT02688829|Experimental|treatment group|Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
2981157|NCT02688816||Women undergoing cervical cancer screening|"HIV-infected women will undergo a cervical cancer screening examination using the VIA method. A digital photograph of the cervix will also be taken to aide visual screening. This is known as digital cervicography, and it is currently standard of care within cervical cancer screening clinics in Zambia.~Cervical samples will be collected for molecular testing using Xpert HPV, and OncoE6. Cervical biopsy samples will also be obtained for confirmatory histopathologic diagnosis."
2981158|NCT02688803|Active Comparator|Dose dense AC-P|Dose dense AC-P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)
2981159|NCT02688803|Active Comparator|Dose dense AC|Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)
2981160|NCT02688803|Active Comparator|FEC-D|FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
2981161|NCT02688777|Experimental|Immediate Backward Walking Training|Individuals will participate in 18 sessions of Backward Walking training immediately following baseline assessment.
2981162|NCT02688777|Active Comparator|Delayed Backward Walking Training|Individuals will participate in 18 sessions of Backward Walking training at 1-year post-strokeD
2981164|NCT02688764|Active Comparator|Calcium Acetate (Phoslyra®)|Calcium Acetate (Phoslyra®) - Oral Solution: 667 mg calcium acetate per 5 mL.
2981165|NCT02688738|No Intervention|Control|Standard of care
2981166|NCT02688738|Active Comparator|Treatment|Oral doxycycline
2981167|NCT02688725|Experimental|Ultrasound|post mastectomy ultrasound
2981168|NCT02688712|Experimental|LY2157299 + Chemoradiation + Surgery|Patients will receive a 14 day course of LY2157299. On day 15 patients will begin chemoradiation treatment with Capecitabine or Fluorouracil. On day 29, patients will undergo another fourteen day course of LY2157299 concurrent with their ongoing chemoradiation treatment. Six to ten weeks after completing their neoadjuvant therapy, patient will undergo a tumor specific mesorectal excision as per standard of care.
2981169|NCT02688699|Experimental|EndoClot|spraying of Endoclot powder after EMR or ESD
2981170|NCT02688699|No Intervention|control|
2981171|NCT02688660||ADAPT Study Population|This cohort will be subjects from the ADAPT study who had an acute MRI scan which has been uploaded into the ADAPT database from all participating sites.
2981172|NCT02688660||Follow-Up MRI|This cohort will include patients from ADAPT sites who choose to participate in this option and obtain a follow-up MRI approximately 1 year after the TBI.
2981173|NCT02688660||Healthy Controls|This cohort will have one MRI to be used in comparison of the above cohorts.
2981174|NCT02688647|Experimental|KD025 Daily|Four 100mg capsules (400 mg) KD025 once daily (QD). Subjects should take 4 capsules with their morning meal or within 5 minutes of completing a meal.
2981175|NCT02688647|Other|Standard of Care|Standard of Care (SOC) which is a treatment/drug determined by each subject's prescribing physician.
2981176|NCT02688634||Treatment|Participants in this group are randomize to receive post-operative antibiotic of Amoxicillin x7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period. They will be evaluated for infection, fistula formation, and dehiscence upon discharge and at 30-day follow-up based on standards of care.
2981177|NCT02688634||Non-Treatment|Participants in this group will be randomize to no post-operative antibiotic. They will be evaluated for infection, fistula formation, and dehiscence upon discharge and at 30-day follow-up based on standards of care.
2981178|NCT02688621|Active Comparator|Internet only|Participants will be required to attend a weekly Internet chat session with your group members and one of the behavioral weight control therapists. Participants will learn the principles of managing eating and exercise behaviors in weekly, hour-long chat sessions and by completing weekly lessons. Participants are asked to self-monitor foods and exercise through the use of a smartphone ap. Participants will wear a tracking device that monitors steps. All participants will be contacted via e-mail individually, by their group leader who will monitor their progress and offer advice and encouragement. Meetings are weekly for 24 weeks and monthly for 12 months.
2981179|NCT02688621|Experimental|Internet + Incentives|Participants are given the same intervention as described for the internet only group, with the exception that they will have the opportunity to earn financial incentives. Financial incentives will be based on participants weight loss, and compliance with certain weight loss behaviors including meeting exercise goals, self-monitoring foods consumed, and daily weighing and reporting.
2981180|NCT02688608|Experimental|Pembrolizumab|200 milligrams of Pembrolizumab will be given intravenously every 3 weeks.
2981181|NCT02688595|Experimental|Seldinger|Use a 23 gauge introducer needle for ultrasound-guided central venous catheterization
2981182|NCT02688595|Experimental|Modified Seldinger|Use a 22 gauge Angiocath Plus catheter for ultrasound-guided central venous catheterization
2981183|NCT02688582|Experimental|TCI group|Patients who receive cefepime based on TCI for a maximum of 5 days with a target concentration of cefepime of 16 mg/L.
2981184|NCT02688569|Experimental|CBT-CWP|Participants in this condition will receive Cognitive Behavioral Therapy for Chronic Widespread Pain (CBT-CWP)
2981185|NCT02688569|No Intervention|Control|Participants in the Control condition will not receive CBT-CWP. They will however, continue completing the weekly assessments.
2981186|NCT02688556|Experimental|OTX-101 0.09%|0.09% cyclosporine nanomicellar ophthalmic solution
2981187|NCT02688556|Placebo Comparator|Vehicle|vehicle of OTX-101
2981188|NCT02688543|Experimental|RF treatment|Patients treated with radio frequency of the genicular nerves
2981189|NCT02688530|Placebo Comparator|0mg IV Dexamethasone|0mg IV Dexamethasone
2981190|NCT02688530|Experimental|4mg IV Dexamethasone|4mg IV Dexamethasone
2981191|NCT02688530|Experimental|6mg IV Dexamethasone|6mg IV Dexamethasone
2981192|NCT02688530|Experimental|8mg IV Dexamethasone|8mg IV Dexamethasone
2981193|NCT02688517|Other|Ancillary-Correlative (genomic analysis)|Previously collected tissue samples are analyzed for the presence of mutations via next generation sequencing. Patients may also undergo collection of blood samples for analysis of circulating cell-free DNA and circulating tumor cells.
2981194|NCT02688504||serious road accidents|Drivers involved in serious road accidents (hospitalization > 24 hours)
2981195|NCT02688504||non-serious road accidents|drivers involved in non-serious road accidents (hospitalization < 24 hours).
2981196|NCT02688491|Experimental|A (Intervention group,sunitinib)|Beginning 4-12 weeks following radical nephrectomy, patients receive sunitinib malate PO QD for 4 weeks
2981197|NCT02688491|No Intervention|B(observation group)|Patients with radical nephrectomy are observed without intervention
2981198|NCT02688478|Active Comparator|Filtered air|Exposure for 3 hours to filtered air followed by subject specific inhaled allergen challenge
2981199|NCT02688478|Experimental|Phthalate|Exposure for 3 hours to dibutyl phthalate followed by subject specific inhaled allergen challenge
2981200|NCT02688465|Experimental|Apomorphine pump|
2981201|NCT02688452|Active Comparator|Group 1|Young Healthy Adults
2981202|NCT02688452|Active Comparator|Group 2|Young Healthy Adults
2981203|NCT02688439|Active Comparator|Leg in a neutral position|Sciatic nerve block, with leg kept in a neutral position after anesthesia (control group)
2981204|NCT02688439|Experimental|Leg raised 30°|Sciatic nerve block, with leg raised 30° by placing the back of the foot over a support placed on the OR table and maintained in that position for 15 min
2981205|NCT02688439|Experimental|Distal tourniquet placed on the lower part of the leg|Sciatic nerve block, and distal tourniquet placed on the lower part of the leg (upper part of the tourniquet being about 4-6 inches from the ankle) with the leg in a neutral position.
2981206|NCT02688426|Sham Comparator|0J LLLT|The sham treatment is performed in the same way as treatment with LBP, however, with the apparatus switched off
2981207|NCT02688426|Experimental|6J LLLT|The Laser radiation will be made with 6J by spot.
2981208|NCT02688413|Experimental|MindMotionPRO|MindMotionPRO exercises in addition to standard practice for upper limb rehabilitation
2981209|NCT02688413|Active Comparator|Self-Directed Prescribed Exercises|Self-Directed Prescribed Exercises in addition to standard practice for upper limb rehabilitation
2981210|NCT02688400|Experimental|Diacerein|One placebo capsule once daily in the morning (breakfast) and one diacerein 50 mg capsule once daily in the evening (dinner) for the first month, then diacerein capsules twice daily with meals in the morning (breakfast) and the evening (dinner).
2981211|NCT02688400|Active Comparator|Celecoxib|One celecoxib 200 mg capsule once daily in the morning (breakfast) and one placebo capsule once daily in the evening (dinner).
2981212|NCT02688387|Experimental|Part 1|Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC1, FDC2, FDC3 and FDC4, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDC and reference formulations contains 10 mg ambrisentan and 40 mg tadalafil. Each dosing period will be separated by 7 days wash out period.
2981213|NCT02688387|Experimental|Part 2|Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC5, FDC6, FDC7 and FDC8, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDCs and reference formulations contains 10 mg ambrisentan and 40mg Tadalafil. OR Subjects will receive single dose of two FDCs from Part 1 in fed and fasted state. Each dosing period will be separated by 7 days wash out period.
2981214|NCT02688387|Experimental|Part 3|Enrolled subjects will receive single oral dose of 2 FDCs from Part 2 in fed and fasted state. The FDCs contains 10 mg ambrisentan and 40 mg Tadalafil. Each dosing period will be separated by 7 days wash out period.
2981215|NCT02688374|Other|Treatment A:Treatment B:Treatment C|Participants will be administered with Treatment A(Nicorette 2 mg coated mint gum) followed by Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
2981216|NCT02688374|Other|Treatment B:Treatment C:Treatment A|Participants will be administered with Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment A(Nicorette 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
2981217|NCT02688374|Other|Treatment C:Treatment A:Treatment B|Participants will be administered with Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment A(Nicorette 2 mg coated mint gum) followed by Treatment B (Nicotinell 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
2981218|NCT02688374|Other|Treatment A: Treatment C:Treatment B|Participants will be administered with Treatment A (Nicorette 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment B (Nicotinell 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
2981219|NCT02688374|Other|Treatment B:Treatment A: Treatment C|Participants will be administered with Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment A (Nicorette 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
2981220|NCT02688374|Other|Treatment C:Treatment B:Treatment A|Participants will be administered with Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment A (Nicorette 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
2981221|NCT02688361|Experimental|Fluimucil® (reference) then Acetylcysteine (test) 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference) following a wash out period of at least a week then administration of by 10ml of 2% oral solution of Acetylcysteine (test).
2981222|NCT02688361|Experimental|Acetylcysteine (test) 2% solution then Fluimucil® (reference)|Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test) following a wash out period of at least a week then administration of by 10ml of 2% oral solution of Fluimucil® (reference).
2981223|NCT02688348|Other|Ancillary-Correlative (late toxicity and QOL)|Patients complete the EORTC QLQ-BLM-C30 at baseline, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter after completion of chemo-radiotherapy.
2981224|NCT02688335|Experimental|Cloud9 Snoring Treatment|Snoring participants will be instructed to use the device as much as possible for 2 weeks.
2981225|NCT02688322|Experimental|2 g q12 of sulbactam, 1 h infusion|2 g of sulbactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 1 h every 12 h.
2981226|NCT02688309|Experimental|Clinic Patients|"Patients from the clinic will be considered for enrollment if they are receiving an intraocular injection of a steroid as part of standard care for macular edema or progressive fibrosis.~Clinic patients who are receiving an intraocular injection of steroid (Ozurdex) as part of standard care who agree to participate will have an anterior chamber (AC) tap just prior to the intraocular injection of steroid and a second AC tap at a follow up visit 6 ± 2 weeks after the steroid injection."
2981227|NCT02688309|Placebo Comparator|OR Patients|Patients undergoing surgery for one of the following conditions: (1) Proliferative Diabetic Retinopathy, (2) rhegmatogenous retinal detachment with PVR, (3) rhegmatogenous retinal detachment without PVR, (4) macular pucker, (5) macular hole. Surgical patients who agree to participate will have an anterior chamber (AC) tap at the beginning of surgery.
2981228|NCT02688296||Pilon Fractures|Patients who are implanted with Fibulock and have a Pilon fracture
2981229|NCT02688296||High Risk Patients|Patients who are implanted with Fibulock and are at high risk of complications from ankle surgery due to conditions such as diabetes, advanced age or osteoporosis
2981230|NCT02688296||Otherwise Healthy Patients|Patients implanted with Fibulock who are healthy other than their ankle fracture
2981231|NCT02688283|Experimental|Test-cluster|56g of optimized savory cluster made through a proprietary process with slowly digestible carbohydrates and fiber
2989465|NCT02633020|Experimental|AMG 714 8 mg/kg|AMG 714 IV every two weeks
2981232|NCT02688283|Placebo Comparator|Control-cluster|56g of control cluster made from general baking process with typical ingredients commonly used in commercially available energy snacks or bars
2981233|NCT02688283|Placebo Comparator|White-bread|45g of white bread containing equivalent amount of available carbohydrate in 56g of optimized savory cluster
2981234|NCT02688270|Experimental|Vascana® (0.9% nitroglycerin cream)|
2981235|NCT02688270|Placebo Comparator|Vehicle cream|
2981236|NCT02688244|Active Comparator|Irrigation|Irrigation of the area with at least 300ml normal saline using the power suction/irrigator
2981237|NCT02688244|Active Comparator|No irrigation|Only suction with the power suction/irrigator without saline attached
2981238|NCT02688231|Experimental|High intensity group|
2981239|NCT02688231|Experimental|Low intensity group|
2981240|NCT02688231|Active Comparator|Control group - conventional treatment|
2981241|NCT02688218|Experimental|Aerobic First, Resistance Second|Subjects will complete three 15 minute periods of aerobic exercise, with 10 minute recovery between each period. This will be followed by 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises.
2981242|NCT02688218|Experimental|Resistance First, Aerobic Second|Subjects will complete 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises. This will be followed by three 15 minute periods of aerobic exercise, with 10 minute recovery between each period.
2981243|NCT02688205||Shoulder pain group|The participants receive Cyriax's functional examination after history taking, and will be examined by ultrasound in one week.
2981244|NCT02688205||Without shoulder pain group|The participants receive Cyriax's functional examination after history taking, and will be examined by ultrasound in one week.
2981245|NCT02688192|Active Comparator|Arm I (TLC FIT)|"Assessment including~Wear an electronic accelerometer~Quality of life assessment~Physical fitness evaluation~Participate in a fitness program which includes:~8 group meetings over 90 minutes weekly~Behavioral internet based intervention engage in private social support messaging within the app and Facebook private groups and mobile app"
2981246|NCT02688192|Active Comparator|Arm II (WLC)|"Assessment including~Wear an electronic accelerometer~Quality of life assessment~Physical fitness evaluation~After waiting 6 months they will begin the fitness program as described in Arm I"
2981247|NCT02688179||Cardiac surgery patients|
2981248|NCT02688166||Breast Cancer|Breast cancer patients who are undergoing internal mammary lymph node radiation
2981249|NCT02688166||Lung Cancer|Non-surgical Stage III non-small cell lung cancer patients undergoing mediastinal nodal irradiation with curative intent using concurrent chemotherapy
2981250|NCT02688153|Active Comparator|EDWARDS INTUITY|EDWARDS INTUITY Valve System, Model 8300A
2981251|NCT02688153|Active Comparator|Stented aortic bioprostheses|Stented aortic bioprostheses
2981252|NCT02688140|Experimental|Arm A|"Induction therapy: Patients receive idarubicin i.v. over 20 minutes on day 1 and 3, oral tretinoin twice daily on day 1-28 (max. up to day 60) and arsenic trioxide i.v. over 2 hours on day 5-28 (max. up to day 60).~In case of morphological CR and regenerated blood counts, consolidation therapy should be started within 2-4 weeks after documented CR.~Consolidation therapy: Patients receive oral tretinoin twice daily on day 1-14. Treatment with tretinoin repeats every 4 weeks for up to 7 courses. Patients also receive arsenic trioxide i.v. over 2 hours on days 1-5 in week 1-4. Treatment with arsenic trioxide repeats every 8 weeks for up to 4 courses."
2981253|NCT02688140|Active Comparator|Arm B (standard chemotherapy)|"Induction therapy: Patients receive idarubicin i.v. over 20 minutes on day 1,3,5 and 7 and oral tretinoin twice daily on day 1-28 (max. up to day 60). In case of morphological CR and regenerated blood counts, consolidation therapy should be started within 2-4 weeks after documented CR~Consolidation therapy: Patients receive oral tretinoin twice daily on day 1-45, idarubicin i.v. over 20 minutes on day 1-4 and day 31, cytarabine i.v. over 3 hours on day 1-4, over 8 hours on day 31-35, mitoxantrone i.v. over 30 minutes on day 16-20.~Maintenance therapy (only for PML-RARa negative patients): Patients receive oral mercaptopurine once daily and methotrexate i.m./p.o. once weekly for 3 months. Treatment with mercaptopurine and methotrexate repeats every 3 months for 7 courses. After completion of course 1 of mercaptopurine and methotrexate, patients receive oral tretinoin once daily on days 1-15. Treatment with tretinoin repeats every 3 months for 6 courses"
2981254|NCT02688127|Experimental|tranexamic acid group|tranexamic acid given as 1 gram intravenous dose dilute in 500 cc of ringer lactate 20 minute before cesarean section
2981255|NCT02688127|Placebo Comparator|placebo group|the control group will receive 500 cc of ringer lactate 20 minute before cesarean section
2981256|NCT02688114|Experimental|Barrett's Esophagus Treatment|All participants are in the treatment arm. Patients with Barrett's esophagus will undergo baseline surveillance endoscopy, be treated with radiofrequency ablation, and undergo follow up endoscopy 1, follow up endoscopy 2, and follow up endoscopy 3.
2981257|NCT02688101|Experimental|DpC|DpC capsules, administered orally
2981258|NCT02688088|Active Comparator|Drug Cocktail|Single dose of drug cocktail (caffeine, warfarin, dextromethorphan, and midazolam) administered orally on Day 1 of Period 1.
2981259|NCT02688088|Experimental|Abemaciclib + Drug Cocktail|Abemaciclib administered orally every 12 hours on Days 1 - 12 of Period 2 with a single dose of drug cocktail administered orally on Day 8 of Period 2.
2981260|NCT02688088|Experimental|Abemaciclib - Period 3|Abemaciclib administered orally every 12 hours on Days 13 to 28 of Period 3. Participants may continue to receive abemaciclib until discontinuation criteria are met.
2981261|NCT02688088|Experimental|Abemaciclib - Period 4|Abemaciclib administered orally every 12 hours on Days 1 to 28 of Period 4. Participants may continue to receive abemaciclib until discontinuation criteria are met.
2981262|NCT02688075||Canagliflozin Plus or Minus(+/-) Other Antihyperglycemic Agent|Participants who are receiving Canagliflozin +/- other antihyperglycemic agent (AHA) as per usual clinical practice will be observed for effectiveness, safety and PRO.
2981263|NCT02688062|Experimental|NeuroRegen Scaffold with BMMCs transplantation|
2981264|NCT02688062|Experimental|Surgical intradural decompression and adhesiolysis|
2981265|NCT02688049|Experimental|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients receive NeuroRegen scaffold with mesenchymal stem cells transplantation after spinal cord injury.
2981299|NCT02687815|Experimental|vitamin D3|Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily
2981266|NCT02688049|Experimental|NeuroRegen scaffold/neural stem cells transplantation|Patients receive NeuroRegen scaffold with neural stem cells transplantation after spinal cord injury.
2981267|NCT02688036|Experimental|hypofractionated CRT|hypofractionated concurrent chemoradiotherapy
2981268|NCT02688036|Active Comparator|conventionally fractionated CRT|conventionally fractionated concurrent chemoradiotherapy
2981269|NCT02688023|Experimental|single-arm Irinotecan-Oxaliplatin-5-Fluorouracil/leucovorin|Irinotecan,oxaliplatin and 5-fluorouracil/leucovorin(5-fluorouracil/leucovorin can be substituted with Capecitabine or S-1)
2981270|NCT02688010|No Intervention|Control|No specific noise reduction strategies to restrict noise exposure less than 45 dB combined with either continuous bright light or continuous near darkness or unstructured combination of the two during the hospitalization.
2981271|NCT02688010|Experimental|Noise reduction and cycled light|Reduced noise exposure (sound levels <45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
2981272|NCT02687997|Experimental|Diagnostic|Patients enrolled in lung cancer screening subjected to a sleep study.
2981273|NCT02687997|No Intervention|Contro|Patients enrolled in lung cancer screening not included in the diagnostic intervention arm
2981274|NCT02687984|Experimental|RBP-7000 PLGH A|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 21 kDa PLGH polymer.
2981275|NCT02687984|Experimental|RBP-7000 PLGH B|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 29 kDa PLGH polymer.
2981276|NCT02687984|Active Comparator|RBP-7000 PLGH C|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 26 kDa PLGH polymer. This intermediate molecular weight treatment serves as the reference treatment.
2981277|NCT02687971|Active Comparator|Thermotherapy alone|"Local heat will be applied using a Localized Current Field radio-frequency generating device manufactured by Thermo-Med Technologies, Inc. A wand with 2 electrodes is connected to the main housing by a thin wire. The electrodes are applied to the skin. We will use electrodes 6 mm long, separated by 4 mm. One single session at the site of the lesion(s) at 50°C for 30 applications will be used. Depending on the size of the lesion, more than one application may be administered."
2981278|NCT02687971|Experimental|Thermotherapy plus Miltefosine|"In addition to receiving one single session of thermotherapy as described above, subjects will receive oral miltefosine two or three capsules a day, which is the equivalent of 100 to 150mg respectively for 21 days. Miltefosine capsules will be taken after breakfast, lunch and dinner, in other words, after food.~The daily dose of miltefosine will depend on the weight of each patient. According to dosage instructions if the patient is taking the miltefosine twice a day, it must be taken in the morning and night (dose of 100mg/Kg/day). Whereas if the patient is taking miltefosine three times a day, it must be taken in the morning, noon and night (dose of 150mg/Kg/day)."
2981279|NCT02687958|Experimental|A Everolimus 10mg (every cycle) until PD|Patients with stable disease, partial response or complete response after 4- 6 cycles of induction chemotherapy with Cisplatin or Carboplatin plus Etoposide or alternative first line chemotherapy according with local practice will receive maintenance therapy with Everolimus 10mg every cycle (28days) until PD or unacceptable toxicity.
2981280|NCT02687958|No Intervention|B Observational|Patients in this arm will meet observation criteria
2981281|NCT02687945|Active Comparator|Outpatient physiotherapy|two weeks of in-home physiotherapy following total hip replacement followed by two months of outpatient physiotherapy with 2-3 weekly sessions
2981282|NCT02687945|Active Comparator|No outpatient physiotherapy|two weeks of in-home physiotherapy following total hip replacement followed by two months of self-guided physiotherapy exercises
2981283|NCT02687932|Experimental|LCZ696|LCZ696 for 12 months
2981284|NCT02687932|Active Comparator|Valsartan|Valsartan for 12 months
2981285|NCT02687919|Experimental|Modified Paleo Diet Intervention (MPDI)|Consumed a modified Paleo diet, described as nine cups of vegetables and some fruits, meat protein including organ meat, and complete abstinence from products containing gluten (wheat, barley, rye, etc.), dairy, potatoes, and legumes (beans, lentils, peanuts, soy, etc.)
2981286|NCT02687919|No Intervention|Usual Care|Typical physician recommendations for MS.
2981287|NCT02687906|Experimental|Single dose IV meropenem-vaborbactam|"Vabomere (meropenem-vaborbactam) for IV injection will be administered as a single dose diluted in normal saline infused IV over 3 hours~Starting dose for Cohort 1 (ages 12-18 years) is 40mg/kg meropenem and 40mg/kg vaborbactam, or 2g meropenem 2g vaborbactam for subjects ≥50kg in weight. Following completion of each cohort an independent DSMB will assess the PK, safety and tolerability data to determine the subsequent cohort's dose"
2981288|NCT02687893|Experimental|Aerobic Exercise Week|Subjects will complete 45 minutes of aerobic exercise twice during a 7 day period. Exercise will be graded based on the participant's relative capacity determined at the screening visit. Each exercise session will be followed by 60 minutes of monitored resting recovery.
2981289|NCT02687893|Experimental|Resistance Exercise Week|Subjects will complete 45 minutes of anaerobic exercise twice during a 7 day period. Each exercise session will be followed by 60 minutes of monitored resting recovery.
2981290|NCT02687893|No Intervention|No Exercise Week|Subjects will perform no exercise during this week.
2981291|NCT02687880||All Subjects|"All subjects will undergo a surgical procedure (Testicular biopsy) to harvest their testicular tissue. In most cases, this will be done as part of their routine care but it is possible the subject may elect to have the procedure as part of a research only biopsy."
2981292|NCT02687867||Dabigatran|Non-valvular atrial fibrillation patients who were initiated on dabigatran for stroke prevention.
2981293|NCT02687867||Vitamin K antagonist|Non-valvular atrial fibrillation patients who were initiated on VKA for stroke prevention.
2981294|NCT02687854||Apixaban|Non-valvular atrial fibrillation patients who were initiated on apixaban for stroke prevention
2981295|NCT02687854||Vitamin K antagonist|Non-valvular atrial fibrillation patients who were initiated on Vitamin K antagonist for stroke prevention
2981296|NCT02687841|Experimental|AST-120 and PTX|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days Pentapentoxifylline 400mg QD for 10 days
2981297|NCT02687841|Active Comparator|PTX|Pentapentoxifylline 400mg QD for 10 days
2981298|NCT02687828||Subjects receiving adalimumab|The subjects who are prescribed adalimumab for intestinal Behcet's disease (BD) in accordance with the approved Korean label.
2981300|NCT02687815|Placebo Comparator|placebo|placebo formulations will be in gel cap form and identical to the active drug
2981301|NCT02687802||Mechanical ventilation|Patients under mechanical ventilation for more than 24h
2981302|NCT02687789|Experimental|Medical Device: WO3191|The vaginal suppository is used for the reduction and/or inhibition of vaginal biofilms that were shown to be related to recurrent bacterial vaginosis.
2981303|NCT02687789|Active Comparator|Medical Device: Vagisan® Lactic Acid|It is used for the maintenance and restoration of a natural pH level in the vagina. The acidification of the vaginal milieu with lactic acid promotes the growth of typical vaginal flora (lactic acid bacteria) and is unfavourable for the growth of pathogens in the vagina. Vagisan® Lactic Acid is used in the post-treatment of bacterial vaginosis.
2981304|NCT02687763|Experimental|Open Label|Open Label. Two 0.5-mL doses of ProQuad® will be given by intramuscular injection at least 30 days but no more than 365 days apart..
2981305|NCT02687750|Experimental|MRI|"Eppendorf tubes containing 10% fluorine-19 diluted in agar were taped to the upper thigh of participants. Investigational device was used to image the phantom with Magnetic resonance imaging (MRI). Imaging was performed for anatomical (proton) and fluorine (agent detection). Total scan time was under 1 hour.~Objectives:~Verify RF coil functionality~Obtain preliminary detection threshold limits using a human coil loading"
2981306|NCT02687737|Experimental|Exercise|The participants will have the following tests performed: Maximum Expiratory Pressure (MEP), insertion of a fine-wire electromyography (EMG) electrode into the mid-line base of the tongue, will complete swallowing tasks and breathing tasks under Videofluoroscopy (fluoroscopy on only during the actual task)
2981307|NCT02687724|Active Comparator|Standard treatment as per SmPC|Patients will receive standard loading dose of GLM of 200/100 mgs at WKS 0 & 2. They will then receive 100mgs/ 50mgs depending on their weight as per SmPC. Patients will report their modified partial mayo score and SHS score every 4 weeks (PRO) and provide it to the investigator site via a web based application.
2981308|NCT02687724|Experimental|Intervention Arm|Patients will receive standard loading dose of GLM of 200/100 mgs at WKS 0 & 2. As with Group 1, Patients will report their modified partial mayo and SHS score every four weeks ( the window for this will be +/- one week) and provide it to the investigator site via a web based application. In addition FCP, GLM DL and ADA shall be measured every four weeks.
2981309|NCT02687698|Experimental|Ketogenic diet|Patients will be suggested to follow a ketogenic diet for 8 weeks.
2981310|NCT02687698|No Intervention|Control|Usual diet.
2981311|NCT02687685|Experimental|Skin to skin contact immediate|At birth, the baby will be placed and dried on the breast of his mother where thermoregulation manoeuvres will be applied and once the cord clamping procedure has taken place; the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least one hour or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, it will be allowed again after these interventions. During immediate SSC, mother and baby receive continuous monitoring by the health staff
2981312|NCT02687685|Active Comparator|skin to skin contact early|At birth, the baby will be dried and placed on the abdomen and chest of his mother where thermoregulation manoeuvres are applied once there is an indication that the cord clamp procedure has been completed. At this time the baby will go to the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby who has 60 minutes of life, will proceed with the initiation of SSC for at least one hour or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC the mother and baby will receive monitoring by health personnel
2981313|NCT02687672|Experimental|Stem Cell Transplantation|Injection of leukapheresis-derived, purified, autologous CD34+and CD133+ stem cells
2981314|NCT02687672|Experimental|Stem Cells|Injection of bone marrow-derived, purified, autologous CD34+and CD133+ stem cells.
2981315|NCT02687659|Experimental|Study group using TEMIS system|using TEMIS system during physical exercises: walking, biking, running
2981316|NCT02687646|Experimental|Allogeneic Mesenchymal Cells|All patients will receive Adult Allogeneic Mesenchymal Cell from adipose tissue. It is not considered ethical the inclusion of a control group.
2981317|NCT02687633|Experimental|Treatment Group|The Treatment Group begins the JASPER intervention immediately upon enrollment in the study.
2981318|NCT02687633|Active Comparator|Delayed Treatment Group|The Delayed treatment group receives the same JASPER intervention as the Treatment Group, but after 6 months of receiving services in the community as usual.
2981319|NCT02687620||AS patients receiving Anti-TNF treatment|Three hundred and fifty consecutive AS patients fulfilling the modified New York criteria for the classification of AS (5), and with a new anti-TNF agent prescription (either for the first time or switched) in the last two weeks period will be included. Treatment with anti-TNF agents will be in accordance with the regulations of Turkish Social Security Agency (SGK) on the initiation and continuation of anti-TNF agents in AS, as well as ASAS/EULAR recommendations for the management of AS (29, 30).
2981320|NCT02687607||WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 80 years requiring treatment for single ruptured intracranial aneurysms.
2981321|NCT02687594||single group|sucroferric oxyhydroxide
2981322|NCT02687581|Experimental|12-hour IO-therapy Glasses|wear IO-therapy glasses for 12-hour
2981323|NCT02687581|Active Comparator|6-hour patching|wear the eye patch for 6-hour
2981324|NCT02687555|Experimental|Intervention|Computerized Cognitive Bias Modification of Appraisals (CBM-App), developed from that used by Woud et al. (2012,2013). The intervention comprises 8 sessions completed over a period of 2 weeks. The training takes place while participants are also receiving specialized inpatient treatment for PTSD at the Clinic for Psychosomatic Medicine and Psychotherapy, LWL University Clinic of Ruhr University of Bochum.
2981325|NCT02687555|Sham Comparator|Control|Computerized Peripheral Vision Task (PVT), developed from that used by Calkins et al. (2015). The intervention comprises 8 sessions completed over a period of 2 weeks. The training takes place while participants are also receiving specialized inpatient treatment for PTSD at the Clinic for Psychosomatic Medicine and Psychotherapy, LWL University Clinic of Ruhr University of Bochum.
2981326|NCT02687542|Placebo Comparator|Placebo|Placebo
2981327|NCT02687542|Experimental|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose level (1 mg QD)
2981328|NCT02687542|Experimental|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
2981329|NCT02687542|Experimental|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751 higher middle dose 2 (7 mg QD)
2981330|NCT02687542|Experimental|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
2981331|NCT02687529||Low Risk|Tested with CST001
2981332|NCT02687529||Known Risk|Tested with CST001
2981333|NCT02687516|Experimental|Family-based behavioral social facilitation therapy.|The FBSFT condition includes 17 weekly family-based treatment sessions at the hospital obesity clinic followed by monthly follow-up sessions with their local nurse and follow-up sessions at the hospital every third month for 2 years.The treatment targets both child and parent life-style; eating habits, physical activity, sedentary activity and sleep habits. Behavior modification techniques are systematically employed; such as self-monitoring, goal setting, reward systems, problem solving and stimulus control. In addition, FBSFT focuses on facilitating lifestyle change across different settings (family, friends, school and community) and harnessing social support for healthy habits, which is considered important for long-term weight control.
2981334|NCT02687516|Active Comparator|Treatment as usual|The TAU condition involves an assessment day with the multidisciplinary team (pediatrician, dietician, physical therapist and psychologist) at the hospital obesity clinic. Further a session with the nurse at the hospital clinic making a plan for behavioral lifestyle changes followed by monthly follow-up sessions with their local nurse and follow-up sessions at the hospital clinic every third month for 12 months. After 12 months they will be offered treatment by family-based behavioral social facilitation therapy (as in the other treatment arm).
2981335|NCT02687503|Other|Daily dose of probiotic|All children enrolled into the study will receive a daily dose of probiotic
2981336|NCT02687490|Experimental|Abraxane|Abraxane: 125 mg/m2, D1, D8, D15 every 28 days
2981337|NCT02687477|Sham Comparator|Sham procedure|Patients in the sham group will take sham procedure like PADN.
2981338|NCT02687477|Experimental|Pulmonary Arterial Denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
2981339|NCT02687464|Experimental|Non-operative treatment group|IV fluids, minimum 12 hrs IV antibiotics, minimum 12 hrs clear PO fluids only, regular clinical review. Discharge within 24 hrs after randomization, if study criteria met. If stable but not adequate improvement for discharge, non-operative management continues. If not improved by 48 hrs, appendectomy will be done. Discharge home once vital signs are within normal limits, light oral diet tolerated, adequate oral pain relief and mobile. Total 10 days of antibiotics (IV and oral) following randomization will be given. Antibiotics used vary between centers and will be current standard of care in that center; improving study feasibility and increased generalization of results.
2981340|NCT02687464|Active Comparator|Appendectomy group|Laproscopic appendectomy within 18 hrs of randomization. IV antibiotics given from time of randomization and continued post-operatively per the standardized treatment regimen: children with visibly normal appendix or non-perforated acute appendicitis will receive no further antibiotics; children with perforated appendicitis will continue IV antibiotics for a minimum of 3 days and then per local practice. The type of antibiotics used in each center will be identical to those used in the non-operative treatment group.
2981341|NCT02687451|Experimental|Oxymorphone HCl Open-Label Phase|Oxymorphone HCl Immediate Release Oral Liquid and Oxymorphone HCl Injection; open-label, single-dose, dose selection phase.
2981342|NCT02687451|Experimental|Oxymorphone HCl Multiple-Dose Phase|Oxymorphone HCl Immediate Release Oral Liquid and Oxymorphone HCl Injection; placebo controlled, randomized, double-blinded multiple-dose phase.
2981343|NCT02687451|Placebo Comparator|Placebo|Sodium Chloride 0.9% solution; comparator for multiple-dose phase.
2981344|NCT02687438|Experimental|Treatment|Steroid-releasing sinus implant placement following ethmoidectomy in addition to post-op standard of care (i.e. debridement, irrigation, and topical steroids)
2981345|NCT02687425|Experimental|pioglitazone|The patients under the long-term treatment of imatinib mesylate acquire pioglitazone additionally.
2981346|NCT02687412|Experimental|Fast-track Surgery|"Pre-operative: pre-operative assessment, counseling and FT management education; preoperative nutritional drink up to 4 h prior to surgery; mechanical bowl preparation should not be used; patients are not received mechanical bowel preparation, only oral intestinal cleaner 12 h pre-operation can be accepted, but no need of liquid stool; antimicrobial prophylaxis and skin preparation; preoperative treatment with carbohydrates (patients without diabetes).~Intraoperative : fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia; avoiding hypothermia, keeping the intra-operative lowtemperature at 36 ±0.5 degree centigrade; antiemetics at end of anaesthesia.~Post-operative : Postoperative glycaemic control; postoperative nausea and vomiting (PONV) control; early postoperative diet(3-6 h after surgery, patients resumed a liquid diet, 12 h after surgery patients began to take solid diet)."
2981347|NCT02687412|Other|Traditional surgery|"pre-operative assessment：pre-operative fasting at least 8h, oral bowel preparation or, Antimicrobial prophylaxis and skin preparation or mechanical bowl until liquid stool Intraoperative: keeping the intra-operative lowtemperature at 34.7±0.6 degree centigrade.~Post-operative: 6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust"
2981348|NCT02687399|Experimental|TT-173|It will be sprayed using this syringe and a nozzle tip couplet to it one time over the surgical lesion surfaces on the exposed tissues of the knee
2981349|NCT02687399|Placebo Comparator|placebo|It will be sprayed over the surgical lesion surfaces on the exposed tissues of the knee
2981350|NCT02687386|Experimental|Mitoxantrone packaged EDV|Mitoxantrone packaged EDV (EnGeneIC Dream Vector)
2981351|NCT02687373|Experimental|Part 1: Grp 1A - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination."
2981352|NCT02687373|Placebo Comparator|Part 1: Grp 1A - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination."
2981437|NCT02687087|Placebo Comparator|RIX-Placebo|Physiological Saline (sodium chloride 0.9% (w/v)
2981353|NCT02687373|Experimental|Part 1: Grp 1B - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2981354|NCT02687373|Placebo Comparator|Part 1: Grp 1B - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2981355|NCT02687373|Experimental|Part 1: Grp 1C - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2981356|NCT02687373|Placebo Comparator|Part 1: Grp 1C - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2981357|NCT02687373|Experimental|Part 1: Grp 2A - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 1.35 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns."
2981358|NCT02687373|Placebo Comparator|Part 1: Grp 2A - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns."
2981359|NCT02687373|Experimental|Part 1: Grp 2B - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 2.7 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns."
2981360|NCT02687373|Placebo Comparator|Part 1: Grp 2B - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns."
2981361|NCT02687373|Experimental|Part 1: Grp 2C - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
2981362|NCT02687373|Placebo Comparator|Part 1: Grp 2C - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
2981363|NCT02687373|Experimental|Part 1: Grp 2D - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2981364|NCT02687373|Placebo Comparator|Part 1: Grp 2D - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2981365|NCT02687373|Experimental|Part 1: Grp 2E - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2981366|NCT02687373|Placebo Comparator|Part 1: Grp 2E - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2981367|NCT02687373|Experimental|Part 1: Grp 3A - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 1.35 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
2981368|NCT02687373|Placebo Comparator|Part 1: Grp 3A - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
2981369|NCT02687373|Experimental|Part 1: Grp 3B - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 2.7 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns."
2981370|NCT02687373|Placebo Comparator|Part 1: Grp 3B - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns."
2981371|NCT02687373|Experimental|Part 1: Grp 3C - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns."
2981395|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 1|Participants will wear the control (standard) infusion set for 1 week, then the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4).
2981372|NCT02687373|Placebo Comparator|Part 1: Grp 3C - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns."
2981373|NCT02687373|Experimental|Part 1: Grp 3D - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2981374|NCT02687373|Placebo Comparator|Part 1: Grp 3D - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2981375|NCT02687373|Experimental|Part 1: Grp 3E - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2981376|NCT02687373|Placebo Comparator|Part 1: Grp 3E - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2981377|NCT02687373|Experimental|Part 2: Group 1 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.~N=104; the highest dose that is determined to be safe and well tolerated in the Part 1 trial, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 1.8 x 10^6 PfSPZ per dose."
2981378|NCT02687373|Experimental|Part 2: Group 2 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.~N=104; the second highest dose, which is half of the highest dose, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 9.0 x 10^5 PfSPZ per dose."
2981379|NCT02687373|Experimental|Part 2: Group 3 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.~N=104; a lower dose (half of the second highest dose) administered in 3 doses by DVI at 0, 8, 16 weeks. Likely dosage will be 4.5x 10^5 PfSPZ per dose."
2981380|NCT02687373|Placebo Comparator|Part 2: Group 4 - Normal Saline|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.~N=104; a placebo arm, will receive normal saline by DVI, 3 times at 8 week intervals."
2981381|NCT02687360|Active Comparator|Active rTMS treatment|This arm will receive real rTMS pulses and thus stimulation of the prefrontal cortex including the anterior cortex.
2981382|NCT02687360|Sham Comparator|Sham rTMS treatment|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
2981383|NCT02687347|Experimental|study arm|low dose methadone (1-10mg daily)
2981384|NCT02687347|Active Comparator|control arm|low dose morphine (1-10 mg/day)
2981385|NCT02687334||Standard general anesthesia induction|Patients scheduled for elective surgery at the First Hospital of China Medical University will be recruited for the study beginning in February 2016.We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia
2981386|NCT02687321||Advanced ovarian cancer patients|Patient with histologically confirmed advanced (FIGO III and IV) epithelial ovarian, fallopian tube or primary peritoneal carcinoma with complete remission after first line treatment are included into the study. The patient is regularly followed up every 3-4 months, blood sample collection is performed to determinate tumor marker found in blood, elevated by the presence of cancer recurrence. In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
2981387|NCT02687308|Active Comparator|1Retrograde radical prostatectomy RRP|This opem surgical prostatectomy techniques described by Patrick Walsh is made through prostatic dissection, from apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
2981388|NCT02687308|Experimental|2Anterograde radical prostatectomy RRP2A|This opem surgical prostatectomy techniques dissect the prostate, bladder neck and the neurovascular bundle, in an antegrade way, from bladder neck to the apex. With careful bladder neck dissection and preservation, careful nervesparing procedures with meticulous retroprostatic dissection of the posterior layer of Denonvilliers' fascia, and urethrovesical anastomosis performed through a monofilament running suture.
2981389|NCT02687295|Placebo Comparator|Control group|Control group subjects received the same diet restriction intervention as treatment group. However, their food products did not contain any active component.
2981390|NCT02687295|Active Comparator|Thylakoid group|Thylakoid group subjects received the same diet restriction intervention as the control group. However, their food products did contain an active component in the form of thylakoid powder.
2981391|NCT02687269|Experimental|Ranolazine|The patients undergoing elective and complete CABG revascularization performed by the same surgeon, will be randomized in two different groups to receive, in the three days before surgery, Ranolazine at a dose of 375 mg twice daily.
2981392|NCT02687269|Placebo Comparator|Placebo|The patients undergoing elective and complete CABG revascularization performed by the same surgeon, will be randomized in two different groups to receive, in the three days before surgery, placebo twice daily.
2981393|NCT02687256|Experimental|Protocol 1: Standard then Extended Set|Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then will repeat the cycle for a total of 4 weeks.
2981394|NCT02687256|Experimental|Protocol 1: Extended then Standard Set|Participants will wear the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.
2981396|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 2|Participants will wear the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4), then the control (standard) infusion set (week 5).
2981397|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 3|Participants will wear the Extended Wear infusion set with heparin at 80 IU (week 1), 120 IU (week 2), and 200 IU (week 3), then the control (standard) infusion set (week 4), then the Extended Wear infusion set with heparin at 40 IU (week 5).
2981398|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 4|Participants will wear the Extended Wear infusion set with heparin at 120 IU (week 1), and 200 IU (week 2), then the control (standard) infusion set (week 3), then the Extended Wear infusion set with heparin at 40 IU (week 4), and 80 IU (week 5).
2981399|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 5|Participants will wear the Extended Wear infusion set with heparin at 200 IU (week 1), then the control (standard) infusion set (week 2), then the Extended Wear infusion set with heparin at 40 IU (week 3), 80 IU (week 4), and 80 IU (week 5).
2981400|NCT02687256|Experimental|Protocol 2 (Part 2): Standard then Extended Set|Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then will repeat the cycle for a total of 4 weeks.
2981401|NCT02687256|Experimental|Protocol 2 (Part 1): Extended then Standard Set|Participants will wear the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.
2981402|NCT02687243|Experimental|Interactive Virtual Application|Online application
2981403|NCT02687243|No Intervention|Standard of Care|No intervention and Hospital Standard of Care
2981404|NCT02687230|Experimental|Cohort 1|Subjects receive 3 mg of MVT-2163 without the addition of prior MVT-5873.
2981405|NCT02687230|Experimental|Cohort 2|Subjects receive 17 mg of MVT-5873 followed by 3 mg of MVT-2163.
2981406|NCT02687230|Experimental|Cohort 3|Subjects receive 47 mg of MVT-5873 followed by 3 mg of MVT-2163.
2981407|NCT02687217|No Intervention|Group A: Control|Group A: Control- Received no supplemental oxygen throughout the surgery and received oxygen at 4l/min. in 2hrs postoperatively
2981408|NCT02687217|Experimental|Group B: Test|Group B: Test- Received hyperoxygenation more than or equal to 50% throughout the surgery and received oxygen at 6l/min. upto 2 hrs postoperatively.
2981409|NCT02687204|Active Comparator|Enoxaparin prophylaxis|All enrolled patients will receive twice daily enoxaparin prophylaxis. Patients with identified out of range peak anti-Xa levels will receive real time dose adjustment and will be considered as the experimental arm.
2981410|NCT02687204|Experimental|Real time dose adjustment|Patients with identified out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment
2981411|NCT02687191|Experimental|PF-05230907 (Cohort 1)|PF-05230907 IV bolus injection
2981412|NCT02687191|Experimental|PF-05230907 (Cohort 2)|PF-05230907 IV bolus injection
2981413|NCT02687191|Experimental|PF-05230907 (Cohort 3)|PF-05230907 IV bolus injection
2981414|NCT02687191|Experimental|PF-05230907 (Cohort 4)|PF-05230907 IV bolus injection
2981415|NCT02687191|Experimental|PF-05230907 (Cohort 5)|PF-05230907 IV bolus injection
2981416|NCT02687191|Experimental|PF-05230907 (Cohort 6)|PF-05230907 IV bolus injection
2981417|NCT02687191|Experimental|PF-05230907 (Cohort 7)|PF-05230907 IV bolus injection
2981418|NCT02687191|Experimental|PF-05230907 (Cohort 8)|PF-05230907 IV bolus injection
2981419|NCT02687191|Experimental|PF-05230907 (Cohort 9)|PF-05230907 IV bolus injection
2981420|NCT02687191|Experimental|PF-05230907 (Cohort 10)|PF-05230907 IV bolus injection
2981421|NCT02687191|Experimental|PF-05230907 (Cohort 11)|PF-05230907 IV bolus injection
2981422|NCT02687191|Experimental|PF-05230907 (Cohort 12)|PF-05230907 IV bolus injection
2981423|NCT02687191|Experimental|PF-05230907 (Cohort 13)|PF-05230907 IV bolus injection
2981424|NCT02687191|Experimental|PF-05230907 (Cohort 14)|PF-05230907 IV bolus injection
2981425|NCT02687191|Experimental|PF-05230907 (Cohort 15)|PF-05230907 IV bolus injection
2981426|NCT02687178|Active Comparator|Canrenone 50 mg|Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage.
2981427|NCT02687178|Active Comparator|Canrenone 100 mg|Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage.
2981428|NCT02687165|Active Comparator|Milnacipran augmented by D-cycloserine|participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving D-cycloserine in addition to Milnacipran
2981429|NCT02687165|Placebo Comparator|Milnacipran augmented by Placebo|participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving placebo in addition to Milnacipran
2981430|NCT02687152|Experimental|Arginase inhibition|N-hydroxyl-nor-L-arginine, i.a. 0.1 mg/min for 120 min
2981431|NCT02687139|Experimental|18F-DCFPyL PET/CT|
2981432|NCT02687126|Other|Pediatric Cardiac Surgical Patients|Central Venous Catheterization
2981433|NCT02687113|Other|CT/US fusion|"patients undergo routine conventional feasibility planning ultrasound, and clinical decision of RFA feasibility is made based on conventional planning ultrasound.~Then additional planning ultrasound using CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging."
2981434|NCT02687100|Experimental|Beclomethasone|Patients will receive beclomethasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning. The solution will be aspirated 15 minutes after the instillation.
2981435|NCT02687100|Placebo Comparator|Placebo|Patients will receive 8 mL of saline without any drug.
2981436|NCT02687087|Experimental|Visco-ease|Visco-ease is a suspension of multilamellar vesicles comprising lipids in ratios which mimic the lipidic composition of endogenous extra-alveolar lamellar bodies. Visco-ease is suspended in physiological saline (0.9% NaCl) to provide a final dose concentration of 19.6 mg/mL. Visco-ease is a white to off-white turbid suspension. The device under evaluation in this clinical investigation is Visco-ease at a concentration of 19.6 mg/mL.
2981438|NCT02687074|Experimental|Intubation rate on 28 days|patients with respiratory failure treat with HFNC or NIV and intubation rate on 28 days
2981439|NCT02687061||Chronic hepatitis B|Patients diagnosed with chronic hepatitis B
2981440|NCT02687061||Chronic hepatitis C|Patients diagnosed with chronic hepatitis C
2981441|NCT02687048|Active Comparator|EX protocol|Participants will receive a revised version of the Otago exercise program (OEP) - an individualized home-based exercise program; a trained physiotherapist will make 5 home visits throughout the 12-week intervention. The participants will be expected to complete the home exercises as prescribed three times per week. The exercises are for strength and balance and are gradually progressed over the course of the study to meet the individual's abilities.
2981442|NCT02687048|Experimental|EX Plus protocol|"These participants will receive mindful meditation coaching via 6 one-hour small group sessions with an experienced meditation instructor. They will also be expected to practice mindful meditation at home following online audio recordings (free of charge from University of California, Los Angeles; http://marc.ucla.edu/body.cfm?id=22) and written instructions a minimum of five times per week for 30 minutes. Participants will complete a meditation log to record their practice.~These participants will also receive the same revised version of the Otago exercise program; a trained physiotherapist will make 5 home visits throughout the 12-week intervention. The participants will be expected to complete the home exercises as prescribed three times per week."
2981443|NCT02687035|Experimental|SAPIEN 3|Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system
2981444|NCT02687022|Experimental|Myopia (Peramis)|Peramis aberrometry: 30 consecutive LASIK candidates with myopia and regular astigmatism who agree to participate in the study will have up to 4 aberrometry scans acquired consecutively using the Peramis (test) aberrometer.
2981445|NCT02687022|Active Comparator|Myopia (iDesign)|iDesign aberrometry: The same 30 consecutive LASIK candidates scanned in the Myopia (Peramis) arm will also have up to 4 aberrometry scans acquired consecutively using the iDesign aberrometer (control) aberrometer. The order of scans (Peramis and iDesign) will be randomised.
2981446|NCT02687022|Experimental|Irregular astigmatism (Peramis)|Peramis aberrometry: 30 consecutive cases with stage II-III keratoconus or post corneal transplantation cases with irregular astigmatism will have up to 4 aberrometry scans acquired consecutively using the Peramis (test) aberrometer
2981447|NCT02687022|Active Comparator|Irregular astigmatism (iDesign)|iDesign aberrometry: 30 consecutive cases with stage II-III keratoconus or post corneal transplantation cases with irregular astigmatism will also have up to 4 aberrometry scans acquired consecutively using the iDesign aberrometer (control) aberrometer. The order of scans (Peramis and iDesign) will be randomised.
2981448|NCT02687009|Experimental|Niclosamide|
2981449|NCT02686996|Active Comparator|Intervention|Each participant will be given a daily oral dose 2 g of carnosine (2 tablets twice daily) for 14 weeks
2981450|NCT02686996|Placebo Comparator|Control|Each participant will be given a daily oral dose 2 g of identical placebo tablets ( 2 tablets twice daily) for 14 weeks
2981451|NCT02686983|Experimental|Active|Betamethasone and local anesthetic.
2981452|NCT02686983|Placebo Comparator|Placebo|Saline with local anesthetic.
2981453|NCT02686957||women closed|"This cohort will include women who underwent repair for obstetric fistula at three fistula repair hospitals in Guinea and who had a closed fistula at hospital discharge.~no intervention will be done."
2981454|NCT02686944|Experimental|Intuvax (ilixadencel)|"Intuvax (ilixadencel) will be administered 2 or 3 times. First injection Day 1 (pat 1-12), second injection 14 days after the first vaccination (pat 1-12), third injection 28 days after the second vaccination (only pat 7-12).~Max 10 000 000 allogeneic dendritic cells/ml per injection."
2981455|NCT02686931||Control|Control: Normal developmental children with orthopedic disease
2981456|NCT02686931||Experimental|Experimental: Developmental delayed children
2981457|NCT02686918|Experimental|consultation by Advanced Practice Nurse.|During consultations, patients will be seen successively by Advanced Practice Nurse and referent oncologist.
2981458|NCT02686905|Experimental|Topical vitamin patch|Dietary Supplement: PatchMD Vitamin D3/Calcium Patch Dietary Supplement: PatchMD Multivitamin Patch Dietary Supplement: PatchMD B12 Energy Plus Patch
2981459|NCT02686905|Experimental|Oral vitamins|Dietary Supplement: Chewable Multivitamin with Iron Dietary Supplement: Chewable Calcium Dietary Supplement: Quick Dissolve B12
2981460|NCT02686892||Group|Spanish territory population of 46,439,864 inhabitants
2981461|NCT02686892||Cohort|Incident cases diagnosed with IBD over 12 months in the Spanish territory
2981462|NCT02686879|No Intervention|Natural progession|Following the natural progression of axial growth and refractive error.
2981463|NCT02686879|Experimental|Anisohyperopes - intervention eye|The more hyperopic eye will be fitted with a centre-near multifocal contact lens
2981464|NCT02686879|Experimental|Hyperopes|Both eyes will be fitted with centre-near multifocal contact lenses.
2981465|NCT02686879|Experimental|Anisohyperopes - fellow eye|The less hyperopic eye will be fitted with a single vision contact lens if required.
2981466|NCT02686866|Experimental|Body composition measurement|All patients will undergo body composition measurement with dual-energy X-ray absorptiometry and bioelectrical impedance analysis methods. Hand grip strength will also be performed.
2981467|NCT02686853|Experimental|Intrathecal administration group|
2981468|NCT02686840|Experimental|sublingual misoprostol|Group A (100 patients): will be treated with sublingual misoprostol
2981469|NCT02686840|Active Comparator|vaginal misoprostol|Group B (100 patients): will be treated with vaginal misoprostol
2981470|NCT02686827|Experimental|Paricalcitol (Vitamin D3)|paricalcitol, (Zemplar® 5 μg/ml Abbvie), will be administered via the subcutaneous route 4 times at 0.5 ml (registered dose of 5 μg/ml, thus 2.5 μg per sub-cutaneous injection). The minimum time interval between two injections is 4 days, which is a significantly lower frequency than the prescribed maximum of 3 times a week or every other day.
2981471|NCT02686827|Active Comparator|Placebo|Placebo, the same constituents as Zemplar (propylene glycol 30% (v/v) alcohol 20% (v/v)) but no paricalcitol, same dosage as verum-arm.
2981472|NCT02686814|Experimental|MDT-2215|17mm MDT-2215 aortic valve bioprosthesis
2981473|NCT02686788|Experimental|TMP001|600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
2981550|NCT02686242||general anesthesia|patients receive general anesthesia
2981474|NCT02686775|Experimental|Patient coach|Standard care and patient coach. 5 face-to-face sessions of approximately 1-2 hours duration and 3 phone calls from inclusion to one month after end of first line treatment. Deviations from this schedule might depend on the treatment modules and on the wishes and needs of the patient. Several patients will continue directly into palliative care and the coach will thus support this transition.
2981475|NCT02686775|Active Comparator|Standard treatment|Standard care.
2981476|NCT02686762|Active Comparator|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
2981477|NCT02686762|Active Comparator|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
2981478|NCT02686762|Placebo Comparator|Matching Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
2981479|NCT02686749|Active Comparator|AF catheter Ablation|Pulmonary Vein Isolation catheter ablation for treatment of AF. AF catheter ablation is an FDA approved treatment for AF
2981480|NCT02686749|Active Comparator|FDA approved anti arrhythmic drug|FDA approved anti arrhythmic drug for the treatment of AF will be based on treating physicians' preference in accordance to guidelines.
2981481|NCT02686736|Other|Internet-based educational intervention|The Internet-based educational intervention will include four educational sessions that will be provided during a four-week period. The follow up will last three-months.
2981482|NCT02686736|No Intervention|Control group|In the control group, teens will continue the usual school provided sexual education and will be invited to answer the internet-based self-applied questionnaire at the same time as the intervention group.
2981483|NCT02686723|Experimental|ACL injury|Subjects who has ACL injury repaired and who were allowed to return to sport
2981484|NCT02686723|Active Comparator|Healthy subjects|Subjects who has never been injured in ACL and who practice sports with cutting task (soccer, handball)
2981485|NCT02686710|Active Comparator|VIMA|Patiens receiving volatile induction and maitenance of anesthesia
2981486|NCT02686710|Active Comparator|TIVA|Patiens receiving total intravenous anesthesia based on propofol
2981487|NCT02686710|Active Comparator|Combi|Patiens receiving total intravenous induction and volatile anesthesia
2981488|NCT02686697|Experimental|L-Carnosine|oral doses of 2000mg for 4 weeks total - 2 weeks medication phase only, and then 2 weeks combined treatment with cognitive training.
2981489|NCT02686697|Placebo Comparator|Placebo|matching placebo
2981490|NCT02686684||Dimethyl Fumarate|MS patients who started treatment with dimethyl fumarate
2981491|NCT02686684||Healthy Control|
2981492|NCT02686658|Experimental|Dose Group 1|Zimura Dose Administration 1
2981493|NCT02686658|Experimental|Dose Group 2|Zimura Dose Administration 2
2981494|NCT02686658|Sham Comparator|Dose Group 3|Sham Administration 1
2981495|NCT02686658|Experimental|Dose Group 4|Zimura Dose Administration 3
2981496|NCT02686658|Experimental|Dose Group 5|Zimura Dose Administration 4
2981497|NCT02686658|Sham Comparator|Dose Group 6|Sham Administration 2
2981498|NCT02686645|Experimental|Fecal Microbiota Therapy|Vancomycin 125 mg po qid for 7 days or metronidazole 500 mg po tid for 7 days pre-treatment. Loperamide 4 mg po after morning prep and 2 mg post treatment. The route of administration fecal microbiota will be by retention enema via a rectal tube.
2981499|NCT02686632|Experimental|Palate Brushing|"In this group the intervention is palatal brushing, performed by the participants following each meal for a period of 6 months. This will be performed using the provided toothbrush (device). The results will determine if brushing the palate in an efficient intervention for reducing the microbial count and inflammation associated with denture stomatitis."
2981500|NCT02686632|No Intervention|Regular Oral Hygiene|The participants in this study arm will not be prescribed or allocated any intervention. The participants will be asked to continue with the regular hygiene and denture maintenance practices for the duration of the trial.
2981501|NCT02686619|Active Comparator|Mycophenolate Mofetil + Cyclosporine|Participants will receive mycophenoate mofetil, daclizumab, cyclosporine, and corticosteroids (prednisolone) for 3 to 12 months.
2981502|NCT02686619|Experimental|Mycophenolate Mofetil + Sirolimus|Participants will receive mycophenoate mofetil, daclizumab, and corticosteroids (prednisolone) for 3 to 12 months. Participants will also receive cyclosporine which will be replaced with sirolimus at later stage of the study.
2981503|NCT02686606|Experimental|Vital 1.5|200ml orally over 30 minutes
2981504|NCT02686606|Active Comparator|Ensure Plus|200ml orally over 30 minutes
2981505|NCT02686606|Experimental|Elemental 028|200ml orally over 30 minutes
2981506|NCT02686606|Active Comparator|water|200ml orally over 30 minutes
2981507|NCT02686593|Other|Clofarabine, AraC, mitoxantrone (CLAM)|This is the single arm with the intervention using Clofarabine, AraC, Mitoxantrone
2981508|NCT02686580|Experimental|Collagen paste|Injection of Permacol Collagen paste into the fistula tract.
2981509|NCT02686567|Active Comparator|with TDT|with TDT
2981510|NCT02686567|Active Comparator|without TDT|without TDT
2981511|NCT02686554||AD patients|
2981512|NCT02686554||AD patients immunized|
2981513|NCT02686528|Experimental|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
2981514|NCT02686528|Active Comparator|Hip Precautions|Patients will receive the following hip precautions: no hip flexion past 90º, no crossing the legs, and no twisting at the waist for the first six weeks after surgery.
2981515|NCT02686515|Active Comparator|Single-task balance training group|Participants in the single-task training group will participate in 12-session programs administered for 60 minutes each session, 3 times per week for 4 weeks. They will start walking on a treadmill with a self-selected comfortable speed for 5 minutes of warm-up and then receive an individually-progressed program of balance training aimed at improving standing balance and walking abilities.
2981551|NCT02686216|Experimental|F-18 THK-5351|F-18 THK-5351 imaging
2981765|NCT02684760|Experimental|Cohort 2: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
2981516|NCT02686515|Experimental|Dual-task balance training group|Participants in the dual-task training group will also participate in a 12-session program conducted 60 minutes per session, 3 days a week, for a total of 4 weeks. They will perform a cognitive task or motor task concurrently with the balance/gait task. The framework of progressive balance exercises in the dual-task training group will be progressed from simple to more complex tasks as outlined for the single-task training group. In addition, a variety of added tasks will be progressively integrated into the dual-task balance training program.
2981517|NCT02686502|No Intervention|Mode 1|Current guidelines. Subjects attending the examinations and the tests but not participating the individualized intervention. The subjects will receive general guidance on healthy exercise and diet.
2981518|NCT02686502|Active Comparator|Mode 2|Individualized lifestyle intervention. Exercise intervention will be based on submaximal ergometer test (estimated VO2max), clinical status, personal goals and preferences. Intervention also includes diet counseling, multiprofessional team support, peer support and use of mobile health applications.
2981519|NCT02686502|Active Comparator|Mode 3|Highly individual lifestyle intervention. In addition to Mode 2 arm intervention optimal intensity zones and volumes for individual exercise training will be determined based on advanced cardiopulmonary exercise test.
2981520|NCT02686489|Experimental|Heated humidification (HH)|Addition of water vapor (molecular water) to the inspired gas of spontaneously breathing tracheostomy patients.
2981521|NCT02686489|Active Comparator|Cool bland aerosol (LVN)|Addition of particulate water to the inspired gas of spontaneously breathing tracheostomy patients.
2981522|NCT02686476|Active Comparator|Empagliflozin dose group|Patient Receive Standard of Care with Empagliflozen
2981523|NCT02686476|No Intervention|Standard dose group|Standard care for Type 2 Diabetes Mellitus upgraded without Empagliflozin
2981524|NCT02686463|Experimental|the laparoscopy group|Patients who are randomized to the laparoscopy group.
2981525|NCT02686463|Experimental|the laparotomy group|Patients who are randomized to the laparotomy group.
2981526|NCT02686437|Experimental|Increasing Tension|"The kinesiology tape will be applied to the shoulder complex to influence proper activation of the rotator cuff muscles, specifically the supraspinatus and infraspinatus. The clinician applied the tape in an I strip from the vertebral border of the scapula to the lesser tubercle of the humerus. Over the course of the 4 weeks of care, the tension of the Intervention Group's tape will systemically increase based on the following timelines:~Week 1: 0% tension Week 2: 25% tension Week 3: 50% tension Week 4: 75% tension"
2981527|NCT02686437|Sham Comparator|Control Tension|"The kinesiology tape will be applied to the shoulder complex to influence proper activation of the rotator cuff muscles, specifically the supraspinatus and infraspinatus. The clinician applied the tape in an I strip from the vertebral border of the scapula to the greater tuberosity of the humerus. Over the course of the 4 weeks of care, the tension of the Control Group's tape will remain at 0% tension"
2981528|NCT02686411||Participant in Palliative Care Unit (PCU)|"Participants complete 2 questionnaires after being transferred to the PCU.~Two (2) weekdays after completion of first set of questionnaires, 2 more questionnaires completed."
2981529|NCT02686411||Caregiver of Participant in Palliative Care Unit (PCU)|"Caregiver of participant complete 2 questionnaires after participant transferred to the PCU.~Two (2) weekdays after completion of first set of questionnaires, 2 questionnaires completed."
2981530|NCT02686398|Active Comparator|Fluad|88 CKD patients were vaccinated with Fluad.
2981531|NCT02686398|Active Comparator|Agrippal|86 CKD patients were vaccinated with Agrippal.
2981532|NCT02686385|Experimental|Prednisolone + N-Acetylcysteine|Prednisolone for 20 days with NAC (N-Acetylcysteine) NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
2981533|NCT02686385|Active Comparator|N-Acetylcysteine|NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
2981534|NCT02686372|Experimental|HBV/TCR-T cell|Biological: HBV antigen specific TCR redirected T cell infusion.
2981535|NCT02686359|Experimental|Burning Mouth Syndrome Patients|saliva, blood and urinary samples
2981536|NCT02686359|Active Comparator|controls|saliva, blood and urinary samples
2981537|NCT02686346|Experimental|BV-ICE|"Phase I:~4 cycles of treatment, every 21 days: Brentuximab Vedotin (BV) + Etoposide- Carboplatine - Ifosfamide (ICE) = BV-ICE for cycles 1 to 3 and BV alone at cycle 4;~Phase II:~4 cycles of treatment, every 21 days: BV-ICE for cycles 1 to 3, BV alone at cycle 4"
2981538|NCT02686333|Experimental|Meditation Intervention Arm|10-15 minute meditation practices (brief silent meditations, guided meditations, body scans, gentle arm movement exercises). Before each session, the interventionist will perform a brief check in, and may discuss the patient's experience with them for 1-2 minutes after the intervention. Patients will be encouraged to practice the techniques at home between sessions. Patients will also be offered literature on mental health promotion.
2981539|NCT02686333|No Intervention|Control Group (No Meditation Exposure)|Patients randomized to the control group will be offered literature on mental health promotion and Treatment as Usual in the dialysis setting.
2981540|NCT02686320||Rheumatoid arthritis >65 years old|
2981541|NCT02686320||Rheumatoid arthritis <50 years old|
2981542|NCT02686307||ICD Implant|All patients receiving a dual chamber ICD
2981543|NCT02686294|Experimental|T-R|First period : administration of test drug Second period : administration of reference drug
2981544|NCT02686294|Experimental|R-T|First period : administration of reference drug Second period : administration of test drug
2981545|NCT02686281|Experimental|Cohort A (Part A)|"Single ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Other: Placebo"
2981546|NCT02686281|Experimental|Cohort B (Part A)|"Single ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Other: Placebo~The dose administered in Part A (fed) was based on the outcome of Part A (fasted)."
2981547|NCT02686268||Individuals diagnosed with known positive C9ORF72 ALS|Individuals diagnosed with known positive C9ORF72 ALS
2981548|NCT02686255||Children 0-18 months post heart surgery|complete blood count for all children 0-18 months going through cardiac surgery
2981549|NCT02686242||spinal anesthesia|patients receive spinal anesthesia before general anesthesia
2981552|NCT02686203|Experimental|B-Cure Laser Pro and needles|"Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).~The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment."
2981553|NCT02686190|Experimental|Luxtherapy|Luxtherapy exposition
2981554|NCT02686190|No Intervention|Not luxtherapy|Not luxtherapy exposition
2981555|NCT02686177|Experimental|1: Liraglutide|Liraglutide 1,2 mg once daily subcutaneous injection for 1 month (4 weeks)
2981556|NCT02686177|Active Comparator|2: Add on oral antidiabetic medication|Metformin or sulfonylurea depending on monotherapy
2981557|NCT02686164|Experimental|Lenvatinib + midazolam|Participants with histologically confirmed unresectable or refractory solid tumors.
2981558|NCT02686151|Active Comparator|letrozole|2.5mg/tablet(Jiangsu Hengrui Medicine Co., Ltd. products), orally taken 5mg once a day for 5 days
2981559|NCT02686151|Other|Polygeline Injection|500ml and 0.9% Sodium Chloride Injection (250ml) with dexamethasone 1mg intravenous injection，once a day for 2 days
2981560|NCT02686138|Experimental|50mg BID|Tenapanor, 50mg BID (100mg total)
2981561|NCT02686138|Placebo Comparator|Placebo|Placebo
2981562|NCT02686099|Experimental|SternaLock 360|Sternal closure performed with SternaLock 360 as a primary closure system
2981563|NCT02686099|Active Comparator|Wire Cerclage|Sternal closure performed with standard wire cerclage as a primary closure system
2981564|NCT02686086|Placebo Comparator|Standard hospital jet nebuliser|"Patients admitted to hospital with an acute exacerbation of COPD and prescribed nebulised bronchodilator therapy (combined short-acting salbutamol 2.5mg and ipratropium 0.5mg) will receive their prescribed medication via a standard hospital jet nebuliser.~Spirometry, lung volume measurement and symptom score (Borg breathlessness scale) will be recorded pre-nebulisation and at one hour post-nebulisation."
2981565|NCT02686086|Active Comparator|Vibrating mesh nebuliser|Patients admitted to hospital with an acute exacerbation of COPD and prescribed nebulised bronchodilator therapy (combined short-acting salbutamol 2.5mg and ipratropium 0.5mg) will receive their prescribed medication via a vibrating mesh nebuliser (Aerogen Solo) rather than the standard hospital nebuliser Spirometry, lung volume measurement and symptom score (Borg breathlessness scale) will be recorded pre-nebulisation and at one hour post-nebulisation.
2981566|NCT02686073||Group A|Underweight participants whose body mass index is less than 18.5 kg/m2
2981567|NCT02686073||Group B|Control group, in which the participants belong to the normal body mass index range , from 18.5 to 29.9 kg/m2
2981568|NCT02686073||Group C|Obese participants whose body mass index is more than or equal to 30 kg/m2.
2981569|NCT02686060|Experimental|in-line filters|0.2 micron positively charged PALL Corporation filters for parenteral nutrition (Posidyne® NEO Intravenous Filter Set) and 1.2 micro IV in-line filters used for lipid administration (Lipipor™ NEO Filters for Neonatal Parenteral Nutrition)
2981570|NCT02686060|No Intervention|without in-line filters.|
2981571|NCT02686047|Experimental|the HYAJOINT Plus group|the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
2981572|NCT02686047|Active Comparator|The Synvisc-One group|The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
2981573|NCT02686034|Active Comparator|gammaCore-S|Treatment of up to 5 migraine attacks with the Active gammaCore-S non-invasive vagus nerve stimulator device which delivers a mild electrical signal in the vicinity of the vagus nerve
2981574|NCT02686034|Sham Comparator|gammaCore-S Sham|Treatment of up to 5 migraine attacks with the Sham gammaCore-S non-invasive vagus nerve stimulator device which delivers a mild electrical signal in the vicinity of the vagus nerve
2981575|NCT02686021|Experimental|Metamizole and Ibuprofen|all patients (n=42) will receive metamizol and ibuprofen in one session. In the other session half will receive metamizol and placebo (n=21) and the other half will receive ibuprofen and placebo. The order will be randomized (balanced).
2981576|NCT02686021|Active Comparator|Metamizole and Placebo|"This is one of the two comparators for the Arm Metamizol and Ibuprofen. n=21"
2981577|NCT02686021|Active Comparator|Ibuprofen and Placebo|"This is the second of the two comparators for the Arm Metamizol and Ibuprofen. n=21"
2981578|NCT02686008|Experimental|HPV negative tumors|10 patients with HPV negative tumors: Non-oropharyngeal tumors or p16 negative and HPV negative oropharyngeal tumors
2981579|NCT02686008|Experimental|HPV positive tumors|10 patients with HPV positive tumors: p16 positive and HPV positive tumors
2981580|NCT02685995|Active Comparator|Palindrome TDC|
2981581|NCT02685995|Active Comparator|VectorFlow TDC|
2981582|NCT02685982|Experimental|Rhythmic Sensory Stimulation|Participants in this group will undertake 30 minutes of daily Rhythmic Sensory Stimulation, for 5 day per week, for a total of 5 weeks. The stimulation consists of specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range. The intervention is conducted at the participant's home using a portable device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit. This device is a low-voltage consumer product device that has built in low frequency (subwoofer-type) speakers. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration that is synchronized with the relaxing musical track.
2981583|NCT02685969||18F-Flutemetamol & 18F-FDG PET scans|All study participants will be assessed by PET scan with 18F-Flutemetamol & 18F-FDG PET scans.
2981584|NCT02685956||Vela Sentosa SA HSV1/2 PCR Test|Male and female subjects of any age with sample collected from a lesion and submitted to a clinical laboratory for the purpose of testing for the presence of HSV1 or HSV2 and diagnosing HSV infection.
2981585|NCT02685943|Experimental|CAMS treatment|Psychotherapy using the Collaborative Assessment and Management of Suicidality framework
2981586|NCT02685943|Active Comparator|Treatment as usual|Ordinary treatment for suicidal patients
2981587|NCT02685930||Pneumonia without ICU stewardship involvement|Patients receiving >24 hours of invasive mechanical ventilation for pneumonia-related respiratory failure. Antibiotic choice and duration of therapy will not be influenced by the dedicated ICU stewardship team.
2981652|NCT02685462|Experimental|Cenicriviroc|"Subjects in Group 1 and Group 2 will receive Cenicriviroc on Days 3-12.~Subjects in Group 3 will receive Cenicriviroc on Days 2-12."
2983599|NCT02672787|Active Comparator|ED usual care plus education|ED usual care plus education
2981588|NCT02685930||Pneumonia with ICU stewardship involvement|Patients receiving >24 hours of invasive mechanical ventilation for pneumonia-related respiratory failure. Recommendations for antibiotic choice and duration of therapy will be provided by the dedicated ICU stewardship team (consisting of pulmonary fellows and ICU pharmacists)
2981589|NCT02685917|Experimental|Microfracture with Collagen Augmentation in HTO|Two groups, either collagen augmentation or not. Firstly, all patients underwent an arthroscopic examination and microfracture for bone marrow. Collagen augmentation included Cartifill insertion after arthroscopic microfracture.
2981590|NCT02685917|Active Comparator|Microfracture without Collagen Augmentation in HTO|Two groups, either collagen augmentation or not. Firstly, all patients underwent an arthroscopic examination and microfracture for bone marrow. Collagen augmentation included Cartifill insertion after arthroscopic microfracture.
2981591|NCT02685904|Experimental|ENIA11|25 mg of ENIA11 subcutaneously administered twice weekly
2981592|NCT02685904|Placebo Comparator|Placebo|25 mg of Placebo subcutaneously administered twice weekly
2981593|NCT02685891|Active Comparator|playing tones|During slow-wave sleep short tones (50ms, 50dB) will be played
2981594|NCT02685891|Sham Comparator|Playing no tones|During slow-wave sleep no tones will be played
2981595|NCT02685865|Active Comparator|FCSEM Stent|WON is first identified using EUS and punctured using a 19 gauge needle. 10 ml of fluid is aspirated and sent for gram stain and culture with sensitivities. Using a catheter-based stent delivery system with a 15mm AXIOS stent mounted onto it is inserted into the echoendoscope, and introduced into the WON cavity so that the stent lies within both the WON and enteric lumen. The stent is then deployed so that one flange of the stent is located within the WON cavity and the other flange is located within the enteric lumen.
2981596|NCT02685865|Active Comparator|Plastic Stents|WON is first identified using EUS, and punctured using a 19 gauge needle. 10 ml of the WON fluid is aspirated and sent for gram stain and culture with sensitivities. A 0.025 or 0.035 inch guidewire is inserted into the WON through the fine needle aspiration (FNA) needle. A transmural tract is created using an Endoscopic Retrograde Cholangiopancreatography(ERCP) catheter (with the use of a needle knife catheter ± cautery if needed), and then dilated using a 12-13.5-15mm Controlled Radial Expansion (CRE) balloon to a maximum size of 15mm if technically possible. Two or three 7 French plastic stents are inserted through the transmural tract into the WON cavity.
2981597|NCT02685852|Active Comparator|Arm 1: Exenatide (5mcg)|Exenatide at a dose of 5 mcg
2981598|NCT02685852|Active Comparator|Arm 2: Exenatide (5mcg) + Acarbose (25mg)|Exenatide (5mcg) + Acarbose (25mg)
2981599|NCT02685852|Placebo Comparator|Arm 3: Placebo|Placebo
2981600|NCT02685839|Active Comparator|Traditional rehabilitation|"Each subject will do traditional rehabilitation work two times per week and one hour at a time~, lasting 24 weeks."
2981601|NCT02685839|Experimental|Power rehabilitation|Each subject will do Power rehabilitation work with motion tracking and biofeedback recording two times per week and one hour at a time, lasting 24 weeks.
2981602|NCT02685826|Experimental|Durvalumab 1500mg, Lenalidomide 25mg, Dexamethasone 40mg|"Durva+Len+Dex Cohort A for high risk transplant non-eligible NDMM subjects~Intravenous (IV) durvalumab (Durva) at 1500 mg on Day 1 of a 28-day cycle,~Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance [CrCl] value) on Days 1 to 21 of each 28-day treatment cycle~Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15,and 22 of each 28-day cycle."
2981603|NCT02685826|Experimental|Durva 1500mg, Len 25mg, Dex 40mg- up to 12 cycles|"Cohort B for ≥65 years old TNE NDMM non high risk subjects~Intravenous durvalumab at 1500 mg on Day 1 of a 28-day cycle,~Oral LEN 25 mg/day (adjust per the CrCl value) on Days 1 to 21 of each 28-day treatment cycle,~Oral dex 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15,and 22 of each 28-day cycle (for up to 12 cycles"
2981604|NCT02685826|Experimental|Durvalumab 1500mg, Lenalidomide 10mg|"Cohort C for high risk post-transplant NDMM subjects~Intravenous durvalumab at 1500 mg on Day 1 of a 28-day cycle~Oral Lenalidomide (LEN) 10 mg/day on Days 1 to 21 of each 28-day treatment cycle"
2981605|NCT02685813||Pregnant women in Denmark|Pregnant women in Denmark participating in prenatal screening. This counts for approximately 50000 pregnancies/year and covers >95% of all pregnancies nationally.
2981606|NCT02685787|Experimental|Psychosocial Intervention|Every caregiver in this arm will be assigned to a permanent counselor.
2981607|NCT02685787|Active Comparator|Educational Intervention on AD|The caregiver enrolled in this arm will not be assigned to a counselor but will participate to group sessions on AD education.
2981608|NCT02685774|Other|RT group|R: Reference drug(Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T) T: Test drug(CKD-395 0.25/500mg 2T)
2981609|NCT02685774|Other|TR group|T: Test drug(CKD-395 0.25/500mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T)
2981610|NCT02685761|No Intervention|Low Transverse|Patients in this arm will undergo their cesarean section using the standard low transverse skin incision location
2981611|NCT02685761|Experimental|Midline Vertical|Patients in this arm will undergo their cesarean section using a midline vertical skin incision
2981612|NCT02685761|Experimental|High Transverse|Patients in this arm will undergo their cesarean section using a high transverse skin incision, above the pannus
2981613|NCT02685748|Experimental|Aspirin & pantoprazole|"Aspirin 1000 mg/pd per os in two doses~Pantoprazole 40 mg/pd per os in two doses for gastric protection"
2981614|NCT02685748|Placebo Comparator|Placebo|"Two pills in the morning and two in the evening~All pills (aspirin, pantoprazole an placebo) will be the same looking- in the same capsules."
2981615|NCT02685735|Active Comparator|Gabapentin|Subjects will be randomized, stratifying for norepinephrine serotonin reuptake inhibitor (NSRI) use, to equal number to receive gabapentin or placebo pills. Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
2981616|NCT02685735|Placebo Comparator|Placebo|Subjects will be randomized, stratifying for norepinephrine serotonin reuptake inhibitor (NSRI) use, to equal number to receive gabapentin or placebo pills. Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards.
2981653|NCT02685462|Active Comparator|Group 3 (Simvastatin)|Group 3 (12 subjects) will receive Simvastatin on Days 1 and 12.
2981766|NCT02684760|Experimental|Cohort 3: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
2981617|NCT02685722|Experimental|UC-MSCs Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.treatment period and follow-up period.In accordance with chronic wound criteria for the patient,By producing the principle of random number,Were randomly divided into UC-MSCs Gel group or Gel group,The researchers according to the situation of wound healing time and decided to use the secondary treatment,to observe the clinical efficacy and safety.
2981618|NCT02685722|Experimental|Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.treatment period and follow-up period.In accordance with chronic wound criteria for the patient,By producing the principle of random number,Were randomly divided into UC-MSCs Gel group or Gel group,The researchers according to the situation of wound healing time and decided to use the secondary treatment,to observe the clinical efficacy and safety.
2981619|NCT02685709|Experimental|Run-in phase|Oral octreotide capsules
2981620|NCT02685709|Experimental|RCT phase - Oral|Oral octreotide capsules
2981621|NCT02685709|Active Comparator|RCT phase - Injectables|Injectable somatostatin analogs (octreotide or lanreotide)
2981622|NCT02685709|Experimental|Combination phase (sub-study)|Octreotide capsules plus cabergoline
2981623|NCT02685696|Experimental|Alexis O Retractor|Group 1 received the Alexis-O-Retractor at thet time of first Caesarean Section
2981624|NCT02685696|Active Comparator|Metal Retractor|Group 2 received the traditional self retaining metal Retractor at thet time of first Caesarean Section
2981625|NCT02685683|Experimental|GED-0301 Induction (160mg) followed by intermittent 160 mg|"GED-0301 160 mg by mouth (PO) daily (QD) for 12 weeks, followed by alternating GED 0301 160 mg QD for 4 weeks and no IP for 4 week, up to Week 100"
2981626|NCT02685670|Experimental|Mixed CD19CAR transfer|All subjects will be infused with αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T cells in equal number
2981627|NCT02685657|Experimental|AC followed by Docetaxel with Selumetinib|Doxorubicin 60 mg/m2 and Cyclophosphamide 600 mg/m2 as a single IV infusion on day 1 of every 3 week cycle then 75 mg/m2 of Docetaxel given as a single IV infusion on day 1 of every 3 week cycle, 75 mg of SELUMETINIB twice a day PO on days 1-21 of every 3 week cycle
2981628|NCT02685657|Active Comparator|AC followed by Docetaxel|Doxorubicin 60 mg/m2 and Cyclophosphamide 600 mg/m2 as a single IV infusion on day 1 of every 3 week cycle then 75 mg/m2 of Docetaxel given as a single IV infusion on day 1 of every 3 week cycle
2981629|NCT02685644||Laparoscopic removal|Patients with endometrioma who will undergo laparoscopic removal of cysts.
2981630|NCT02685631||Observational/data registry collection|Patients receiving Yttrium-90 resin microspheres as part of care
2981631|NCT02685618|Experimental|Iloprost + M1006B offset by -10 mmHg|"Administration of 1 ng/kg/min Ilomedin® as a 48h continuous i.v infusion. Administration of blood pressure modules M1006B: offset by -10 mmHg~Intervention: Drug: Iloprost + M1006B offset -10mmHg"
2981632|NCT02685618|Experimental|Iloprost + M1006B, No offset|"Administration of 1 ng/kg/min Ilomedin® as a 48h continuous i.v infusion Administration of blood pressure modules M1006B: No offset~Intervention: Drug: Iloprost + M1006B, No offset"
2981633|NCT02685618|Placebo Comparator|Placebo + M1006B offset by -10 mmHg|"Double dummy 0.9% saline as a 48h continuous i.v infusion. Administration of blood pressure modules M1006B: offset by -10 mmHg~Intervention: Drug: Placebo + M1006B offset -10mmHg"
2981634|NCT02685618|Placebo Comparator|Placebo + M1006B, No offset|"Double dummy 0.9% saline as a 48h continuous i.v infusion Administration of blood pressure modules M1006B: No offset~Intervention: Drug: Placebo + M1006B, No offset"
2981635|NCT02685605|Experimental|Experimental Arm (A)|Standard surgery plus intraoperative radiotherapy (20-30 Gy) followed by radiochemotherapy (EBRT: 60 Gy, 75 mg/m2/d temozolomide) and adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
2981636|NCT02685605|Active Comparator|Control Arm (B)|Standard surgery followed by radiochemotherapy (EBRT: 60 Gy, 75 mg/m2/d temozolomide) and adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
2981637|NCT02685592|Experimental|Lentigo maligna patients|All the participants with histologically confirmed lentigo maligna will receive photodynamic therapy three times with 2 weeks' intervals. The borderline of treatment area is delineated with Wood's lamp and hyperspectral imaging system using 5 millimeter margins. Before applying the 5-aminolevulinic acid nanoemulsion (BF-200 ALA, Ameluz®) light sensitizing gel the skin of treatment area is prepared with fractional ablative CO2-laser to enhance absorption. Ameluz® is spread as a 1 millimeter thick layer on the skin. After light sensitizer absorption the treatment area is illuminated with artificial red light (Aktilite CL128 lamp) using a light dose of 90 J/cm2. Finally 4 weeks after the last PDT treatment LM is excised surgically using 5 mm margins.
2981638|NCT02685566|Experimental|FFDM Plus DBT|Breast Images with FFDM and DBT
2981639|NCT02685566|Active Comparator|Full-Field Digital Mammography|Breast Images with FFDM alone
2981640|NCT02685553|Experimental|1|Use of NIR
2981641|NCT02685514|Experimental|HIFU Graves|Applying the High intensity Focused Ultrasound treatment to the relapsed Graves' disease Patients.
2981642|NCT02685501||Combat women soldiers|Women soldiers in combat units
2981643|NCT02685501||Non combat women soldiers|Women soldiers in non-combat units
2981644|NCT02685488|Active Comparator|Transcranial Ultrasound Power|Transcranial Ultrasound Power
2981645|NCT02685488|Sham Comparator|Transcranial Ultrasound Sham|Transcranial Ultrasound Sham. Unknown to both participants and experimenters, the ultrasound will not stimulate.
2981646|NCT02685475||Diabetic patients|Patients received ultrasound-guided axillary brachial plexus blocks (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
2981647|NCT02685475||Non-diabetic patients|Patients received ultrasound-guided axillary brachial plexus blocks (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
2981648|NCT02685462|Active Comparator|Group 1 (Rosuvastatin)|Group 1 (12 subjects) will receive Rosuvastatin on Days 1 and 13.
2981649|NCT02685462|Active Comparator|Group 1 (Digoxin)|Group 1 (12 subjects) will receive Digoxin on Days 1 and 13.
2981650|NCT02685462|Active Comparator|Group 1 (Caffeine)|Group 1 (12 subjects) will receive Caffeine on Days 1 and 13.
2981651|NCT02685462|Active Comparator|Group 2 (Atorvastatin)|Group 2 (12 subjects) will receive Atorvastatin on Days 1 and 13.
2981654|NCT02685449|Placebo Comparator|group A|"On the first study day, insulin bolus was not given before a standardized pure protein meal. On the second day, pre-breakfast insulin was given as a square-wave bolus before the same standardized pure protein meal.~The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
2981655|NCT02685449|Active Comparator|group B|"On the first study day, pre-breakfast insulin was given as a square-wave bolus before a standardized pure protein meal. On the second day, insulin bolus was not given before the same standardized pure protein meal.~The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
2981656|NCT02685436|Other|omeprazole and domperidone|wheezy infants with GERD will receive 12 weeks of domperidone (0.2mg/kg/day t.d.s.) and omeprazole (10 mg/once/day).
2981657|NCT02685423|Experimental|Visual Deprivation - 10 days|10 days of visual deprivation followed by vision training
2981658|NCT02685423|Active Comparator|Vision Training Only|Vision training without visual deprivation
2981659|NCT02685410|Experimental|One Night Stan Pilot Testing Group|The pilot testing of the One Nigh Stan prototype intervention will utilize 20 young black women aged 18-24 as participants.
2981660|NCT02685397|Active Comparator|LHRH agonist + Enzalutamide|Subjects will receive LHRH agonist in combination with the new generation of hormonal therapy (enzalutamide, 40mg)
2981661|NCT02685397|Experimental|LHRH agonist + Enzalutamide + SBRT|Subjects will receive LHRH agonist in combination with the new generation of hormone therapy (enzalutamide, 40mg) plus the additional SBRT treatment
2981662|NCT02685384||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
2981663|NCT02685384||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
2981664|NCT02685371||Breathing effort type|Current known criteria for constrictive pericarditis will be test under: 1- spontaneous breathing 2- Breathing with a negative pressure of -15 to - 30 cm of water 3- Breathing with a negative pressure of more than - 30 cm of water.
2981665|NCT02685358|Experimental|Clinician-Supported PTSD Coach|Clinician-supported PTSD Coach is primary care-based treatment. In this treatment a primary care mental health clinician guides patients in using the PTSD Coach mobile app to learn about PTSD symptoms, treatment options, and strategies to cope with common PTSD-related concerns. It consisted of 4 brief sessions over 8 weeks.
2981666|NCT02685358|Active Comparator|Primary Care Mental Health Integrated Care as Usual|Existing primary care mental health integrated treatment will serve as the comparison condition
2981667|NCT02685345|Experimental|DS-8500a 25 mg QD|DS-8500a 25 mg tablets, orally, once daily (QD) for up to 28 days
2981668|NCT02685345|Experimental|DS-8500a 75 mg QD|DS-8500a 75 mg tablets, orally, once daily (QD) for up to 28 days
2981669|NCT02685345|Placebo Comparator|placebo|placebo tablets, orally, once daily for up to 28 days
2981670|NCT02685332|Experimental|Stereotactic Radiation|Single Fraction Stereotactic Radiation. Cohort 1: 22.5 Gy Cohort 2: 25 Gy Cohort 3: 27.5 Gy Cohort 4: 30 Gy
2981671|NCT02685319|Experimental|muscle biopsy|a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
2981672|NCT02685306|Active Comparator|Taxane|Taxane (Paclitaxel) weekly on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
2981673|NCT02685306|Experimental|Bavituximab plus Taxane|Bavituximab 3 mg/kg weekly PLUS Taxane (Paclitaxel) on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
2981674|NCT02685293|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
2981675|NCT02685293|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
2981676|NCT02685280|Experimental|DBS for psychiatric disorders patients|Patients on deep brain stimulation for either obsessive-compulsive disorder or major depression, undergoing rechargeable neurostimulator implantation as intervention
2981677|NCT02685267|Active Comparator|Docetaxel/Prednisone|Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout
2981678|NCT02685267|Active Comparator|Docetaxel/Prednisone + Enzalutamide|Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout plus Enzalutamide 160 mg daily throughout. Subjects will continue enzalutamide until PD after 10 cycles of docetaxel.
2981679|NCT02685254|Experimental|Initial group therapy|'Structural skills training group' - Start up with weekly structured skills training group for 14 weeks supplemented by homework training
2981680|NCT02685254|Other|Initial control condition|Treatment as usual/clinical management the first 15 weeks pending deferred start of group therapy (partially cross-over)
2981681|NCT02685241||General population|General population
2981682|NCT02685228|Experimental|decitabine & gemcitabine|"This group was treated by low dose decitabine combinated with gemcitabine regimen. decitabine: 5mg/m2 d1-d5; gemcitabine: 1.0g/m2,d8,d15,d22. 28days for one cycle.~every 28days for one cycle"
2981683|NCT02685228|Active Comparator|gemcitabine|This group was treated by gemcitabine only. Gemcitabine: 1.0g/m2, d8,d15,d22; 28 days for one cycle. every 28days for one cycle
2981684|NCT02685202|Experimental|Mandibular advancement splint|An oral appliance which is standard of care in treating mild or moderate obstructive sleep apnea by repositioning the mandible in a forward position
2981685|NCT02685189||0.75 mg/kg Previous exposure to stannsoporfin|Previous exposure 0.75 mg/kg
2981686|NCT02685189||1.5 mg/kg Previous exposure to stannsoporfin|Previous exposure 1.5 mg/kg
2981687|NCT02685176|Experimental|No Heat|No active heating will be provided post cooling
2981688|NCT02685176|Experimental|Head|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, Vancouver) will be applied to the head following cooling
2981689|NCT02685176|Experimental|Torso|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, Vancouver) will be applied to the torso following cooling
2981690|NCT02685163|Experimental|Antioxidant Ice-cream|Natural antioxidant Ice-cream
2981691|NCT02685163|Placebo Comparator|Control Ice-cream|Natural control ice-cream
2981692|NCT02685150|Experimental|Functional dyspepsia|Participants are to undergo Endoscopic Tri-Modal Imaging, Omeprazole test and Analysis of gastric juice and those who fulfill with Rome III criteria for functional dyspepsia are to be classified into this group.
2981693|NCT02685150|Experimental|Acid reflux disease|Participants are to undergo Endoscopic Tri-Modal Imaging, Omeprazole test and Analysis of gastric juice. Participants with acid reflux are to confirmed by Omeprazole test, one kind of proton-pump inhibitor (PPI) tests.
2981694|NCT02685150|Experimental|Bile reflux disease|Participants are to undergo Endoscopic Tri-Modal Imaging and Analysis of gastric juice. Participants with bile reflux are to be confirmed by Analysis of gastric juice.
2981695|NCT02685150|Experimental|Health volunteers|Health volunteers for routine checkup. Participants are to undergo Endoscopic Tri-Modal Imaging as well as Analysis of gastric juice and those who show no abnormal findings are to be classified into this group.
2981696|NCT02685137|Experimental|Active drug-Stannsoporfin|"Stannsoporfin, single dose 4.5mg/kg administered Intramuscular (parental injection in the thigh) for treatment of jaundice~20 mg/mL 1.5 mL/vial"
2981697|NCT02685137|Sham Comparator|Reference Therapy-Sham|Sham Injection, no injection followed by a Band-Aid to thigh
2981698|NCT02685124|Experimental|Bahia orange juice|250 ml twice daily for 7 days
2981699|NCT02685124|Experimental|Cara Cara orange juice|250 ml twice daily for 7 days
2981700|NCT02685124|Placebo Comparator|Isocaloric control drink|250 ml twice daily for 7 days
2981701|NCT02685111|Active Comparator|A. Pegfilgrastim|D2 once a cycle pegfilgrastim arm
2981702|NCT02685111|Experimental|B. Filgrastim|Intermittent Every Other Days of 5 Shot (D3-11) filgrastim arm
2981703|NCT02685098|Experimental|Day 3|BKA performed at 3 days post allogeneic bone marrow derived mesenchymal stem cells injection.
2981704|NCT02685098|Experimental|Day 7|BKA performed at 7 days post allogeneic bone marrow derived mesenchymal stem cells injection.
2981705|NCT02685098|Experimental|Day 14|BKA performed at 14 days post allogeneic bone marrow derived mesenchymal stem cells injection.
2981706|NCT02685098|Experimental|Day 21|BKA performed at 21 days post allogeneic bone marrow derived mesenchymal stem cells injection.
2981707|NCT02685085|Experimental|Misoprostol|in this group misoprostol 25 ug will be administrated for induction of labor every 6 hours
2981708|NCT02685085|Experimental|Foley's catheter|In this group foley's catheter 30 cc will be used for induction of labor
2981709|NCT02685085|Experimental|Combined|Both misoprostol 25 ug and foley's catheter will be used for induction
2981710|NCT02685072|Experimental|TNP + Progesterone|Transdermal Nicotine Patch + Progesterone (200 mgs BID)
2981711|NCT02685072|Placebo Comparator|TNP + Placebo|Transdermal Nicotine Patch + Placebo (for Progesterone)
2981712|NCT02685059|Experimental|MEDI4736|part 1: MEDI4736 (with half dose as monotherapy for the first two weeks) part 2: MEDI4736 1.5 g total for 20 weeks
2981713|NCT02685059|Placebo Comparator|Placebo|part 1: Placebo (for the first two weeks) part 2: Placebo for 20 weeks
2981714|NCT02685059|Active Comparator|Taxane|Nab-Paclitaxel 125 mg/m² weekly for 12 weeks
2981715|NCT02685059|Active Comparator|Epirubicin|Epirubicin 90 mg/m² 2-weekly for 8 weeks
2981716|NCT02685059|Active Comparator|Cyclophosphamide|Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
2981717|NCT02685046|Experimental|Intervention|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
2981718|NCT02685033|Experimental|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
2981719|NCT02685033|Active Comparator|Comparator|Patients will receive an antibiotic consistent with Standard of Care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment will be 4-6 weeks.
2981720|NCT02685020|Experimental|Group 1A|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
2981721|NCT02685020|Placebo Comparator|Group 1B|Participants will receive placebo at weeks 0, 12, 24 and 48.
2981722|NCT02685020|Experimental|Group 2A|Participants will receive Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) at Week 0, 12 and 24.
2981723|NCT02685020|Placebo Comparator|Group 2B|Participants will receive placebo at weeks 0, 12 and 24.
2981724|NCT02685020|Experimental|Group 3A|Participants will receive Ad26.Mos.HIV vaccine at Week 0; followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) at Week 8 and 24.
2981725|NCT02685020|Placebo Comparator|Group 3B|Participants will receive placebo at weeks 0, 8 and 24.
2981726|NCT02685007||Inpatients|Inpatients planned for laparoscopic surgery, in the field of gynecology, urology and visceral surgery will be documented from of surgery until date of discharge from hospital
2981727|NCT02684994|Other|Cognitive Processing Therapy|Cognitive Processing Therapy
2981728|NCT02684981||Cohort A - VKA to Pradaxa switcher|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
2981729|NCT02684981||Cohort B - newly assigned to treatment|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
2981730|NCT02684968|Experimental|Colorectal Surgery with QL block having anesthetic|Bilateral QL catheter with local anesthetic infusion + intravenous patient controlled narcotic medication
2981731|NCT02684968|Placebo Comparator|Colorectal Surgery with QL block having saline|Bilateral QL catheter with normal saline infusion + intravenous patient controlled narcotic medication
2981732|NCT02684955||Cerebral spectroscopy + pupillometry|During CPR, rSO2 will be monitored continuously as well as quantitative measurements of the pupillary light reaction every 5 minutes.
2981733|NCT02684942|Active Comparator|Meperidine,Fentanyl,Meperidine,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and third fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and fourth fraction of brachytherapy.
2981734|NCT02684942|Active Comparator|Fentanyl,Meperidine,Fentanyl,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and fourth fraction of brachytherapy. And injection fentanyl 1 umg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and third fraction of brachytherapy.
2981735|NCT02684942|Active Comparator|Meperidine,Meperidine,Fentanyl,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and second fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at third and fourth fraction of brachytherapy.
2981736|NCT02684942|Active Comparator|Fentanyl,Fentanyl,Meperidine,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at third and fourth fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and second fraction.
2981737|NCT02684942|Active Comparator|Meperidine,Fentanyl,Fentanyl,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and fourth fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score more than 4 at second and third fraction of brachytherapy.
2981738|NCT02684942|Active Comparator|Fentanyl,Meperidine,Meperidine,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and third fractionof brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and fourth fraction of brachytherapy.
2981739|NCT02684929|Experimental|vegan|Vegan subjects interveinted with oral capsules of BCAA, 15 (women) or 20 (men) grams daily for 3 months
2981740|NCT02684929|Active Comparator|omnivor|Omnivorous subjects iterveined with oral capsules of BCAA, 15 (women) or 20 (men) grams daily for 3 months
2981741|NCT02684916|Experimental|Chiropractic treatment|Visit with active treatment.
2981742|NCT02684916|Placebo Comparator|Placebo|Visit without active treatment.
2981743|NCT02684903|No Intervention|Services As Usual (SAU)|Participants receive all the usual services provided by DHS- Children's Services.
2981744|NCT02684903|Experimental|Parent Child Interaction Therapy (PCIT)|Participants receive Parent Child Interaction Therapy (PCIT). PCIT is designed to improve child functioning by interrupting patterns of harsh, coercive interaction and enhancing parents' warm, positive parenting, autonomy support, and competent child management skills.
2981745|NCT02684890||Tinnitus patients|Patients with tinnitus lasting over 3 months
2981746|NCT02684890||Non-tinnitus patients|Patients without tinnitus
2981747|NCT02684877||Intensive care survivors|Observational study
2981748|NCT02684851|Placebo Comparator|Placebo|Inactive
2981749|NCT02684851|Active Comparator|Tranexamic|Tranexamic acid: anti-fibrinolytic agents
2981750|NCT02684825|Experimental|Continuous plus standard cardiac monitoring|Continuous cardiac monitoring by Reveal LINQTM- LNQ11 Internal Loop Recorder (ILR) plus standard cardiac monitoring
2981751|NCT02684825|No Intervention|Standard cardiac monitoring|Routine cardiac monitoring with follow-up at the same frequency, but with no Implantable Loop Recorder
2981752|NCT02684812|Active Comparator|Tranexamic Acid|Eligible subjects are randomly assigned to immediate administration of TXA (1 g i.v.) after a diagnosis of SAH, as confirmed by CT-scan of the brain, continued by continuous infusion of 1 g per 8 hours to a maximum of 24 hours after start of medication. A maximum of 4 g TXA (1 g bolus + 3x 1 g continuous infusion) can be administered to one patient.
2981753|NCT02684812|No Intervention|Control|Standard care
2981754|NCT02684799|Experimental|Part 1 Group 1 (Cenicriviroc)|Part 1 Group 1 (12 subjects) will receive CVC 150 mg on Days 1, 7 and 13.
2981755|NCT02684799|Active Comparator|Part 1 Group 1 (Omeprazole)|Part 1 Group 1 (12 subjects) will receive Omeprazole 20 mg from Days 2-7, and Omeprazole 40 mg from Days 8-13.
2981756|NCT02684799|Experimental|Part 1 Group 2 (Cenicriviroc)|Part 1 Group 2 (12 subjects) will receive CVC 150 mg on Days 1, 5, 9 and 13.
2981757|NCT02684799|Active Comparator|Part 1 Group 2 (Famotidine)|Part 1 Group 2 (12 subjects) will receive Famotidine 40 mg on Days 5, 9 and 13.
2981758|NCT02684799|Experimental|Part 2 (Cenicriviroc)|Part 2 (24 subjects) will receive Cenicriviroc from Days 1-10 and Days 11-20.
2981759|NCT02684799|Active Comparator|Part 2 (Omeprazole)|Part 2 (24 subjects) will receive Omeprazole from Days 11-20.
2981760|NCT02684786|Experimental|Prior right heart catheterization|Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status.
2981761|NCT02684786|Experimental|Scheduled for right heart catheterization|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
2981762|NCT02684773||Incentre Nocturnal Hemodialysis|These are patients who converted to incentre nocturnal hemodialysis (8 hours/session, 3 sessions/week) from conventional hemodialysis (4 hours/session, 3 sessions/week) at the inception of this study and are eligible for the long-term follow-up phase of the study.
2981763|NCT02684773||Conventional Hemodialysis|These are patients treated with conventional hemodialysis (4 hours/session, 3 session/week) who elected to remain on this dialysis schedule at the inception of this study and are eligible for the long term follow-up phase of the study.
2981764|NCT02684760|Experimental|Cohort 1: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
2981794|NCT02684604||Fertile women|44 fertile women
2981767|NCT02684760|Experimental|Cohort 4: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
2981768|NCT02684760|Experimental|Cohort 5: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
2981769|NCT02684760|Experimental|Cohort 6: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
2981770|NCT02684747|Experimental|Treatment - Autologous Transfusion|Participants will be randomized to the treatment group (autologous transfusion)
2981771|NCT02684747|Placebo Comparator|Control - Normal Saline (Placebo)|Participants will either be randomized to the control group (saline transfusion)
2981772|NCT02684734||Patients on no immunosuppressant|This includes patients on no medication or mesalamine.
2981773|NCT02684734||Patients on immunosuppressants|This includes patients on biologics, azathioprine (AZA), 6-mercaptopurine (6-MP), or corticosteroid. These patients will be sub-analyzed to: a) Patients on one immunosuppressive therapy with AZA, 6-MP, biologic or corticosteroid; b) Patients on combination therapy with AZA or 6-MP and biologic; c) Patients on triple therapy with corticosteroid, AZA or 6-MP, and biologic; d) Patients on corticosteroid and one other immunosuppressive therapy such as AZA, 6-MP, or biologic.
2981774|NCT02684721|No Intervention|Control group|Patients in the control group receive usual care as a minimum. This includes 3-5 days of hospitalisation where the anticoagulant treatment is initiated. The patient and the relatives receive general information about the disease and the course of treatment, the medication and future prevention of embolism. In the year following discharge the patient is booked for a check-up of their anticoagulant treatment with a physician or a nurse as required.
2981775|NCT02684721|Experimental|Exercise group|8-week home-base exercise programme: Patients in the intervention group receive the same usual care as patients in the control group. In addition the patients participate in an 8 week home-based exercise programme, including follow-up telephone calls with the physiotherapist after 1 week, 2 weeks and 4 weeks. Briefly put, the patients are required to exercise for a minimum of 3 times per week for 30-60 minutes, and with 3-4 intervals of approximately 1 minute at a high intensity level. Total exercise time and intervals increase during the 8 week programme. The patients can choose whatever type of exercise they prefer, and they are generally encouraged to choose something they already do, or something that they have previously had positive experiences doing.
2981776|NCT02684708|Active Comparator|COPDAC-28|cyclophosphamide, vincristine, prednisone, dacarbazine; cyclophosphamide 500 mg/m2, per infusion on day 1 + 8; vincristine 1.5 mg/m2 intravenously (capping dose 2 mg) on day 1 + 8 and prednisone 40 mg/m2/day by mouth divided into 3 doses (capping dose 80 mg/day) on day 1 - 15 and dacarbazine 250 mg/m2 infusion on day 1 - 3
2981777|NCT02684708|Experimental|DECOPDAC-21|patients with intermediate and advanced stages will be randomized after the induction therapy to receive either COPDAC-28 standard consolidation or the intensified DECOPDAC-21. cyclophosphamide dose augmented to 625 mg/m2 and adminstered per infusion on day 1 and day 2; vincristine dose not changed; prednisone 40 mg/m2/day by mouth on day 1 - 8 (no capping dose prescribed), i.e. dose-reduction; dacarbazine dose not changed; etoposide infusion100 mg/m2/day on day 1 - 3 and doxorubicine 25 mg/m2 per infusion on day 1as additional drugs in comparison to active comparator; cycle is administered as 21 days instead of 28 days-cycle for intensification
2981778|NCT02684695||Group A|Patients with enthesitis-related arthritis
2981779|NCT02684695||Group B|Patients with other forms of juvenile idiopathic arthritis (extended oligoarticular JIA and polyarticular JIA)
2981780|NCT02684682|Other|12h Group|Intervention 'Frequency of mechanical control of plaque (12h)'
2981781|NCT02684682|Other|24h Group|Intervention 'Frequency of mechanical control of plaque (24h)'
2981782|NCT02684682|Other|48h Group|Intervention 'Frequency of mechanical control of plaque (48h)'
2981783|NCT02684669|Experimental|High-dose naloxone|naloxone 4 mg/ml i.v. infusion, total 3.25 mg/kg, target controlled infusion with three infusion rates (0.25 mg/kg; 0.75 mg/kg; 2.25 mg/kg) each of 25 min duration.
2981784|NCT02684669|Placebo Comparator|Normal saline|0.9% physiological saline, i.v. infusion, total 0.81 ml/kg, target controlled infusion with three infusion rates (0.06 ml/kg; 0.19 ml/kg; 0.56 ml/kg) each of 25 min duration.
2981785|NCT02684656|Active Comparator|Hemodialysis|Intervention: Patients will be switch to hemodialysis and basal plasma oxalate levels as well as oxalate removal by hemodialysis will be determined after two weeks of treatment.
2981786|NCT02684656|Active Comparator|Hemodiafiltration|Intervention: Patients will be switch back to hemodiafiltration and basal plasma oxalate levels as well as oxalate removal by hemodiafiltration will be determined after two weeks of treatment.
2981787|NCT02684643|Experimental|enhanced individualised therapy|Patients' dialysis dosage, medication as well as dietary plan will be modified.
2981788|NCT02684643|Experimental|non-enhanced individualised therapy|Patients' medication as well as dietary plan will be modified without alteration of dialysis dosage.
2981789|NCT02684643|Experimental|regular intervention|Phosphate binders and calcitriol will be prescribed and adjusted without altering patients' diet habit.
2981790|NCT02684630|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
2981791|NCT02684630|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
2981792|NCT02684617|Experimental|Pembrolizumab and Dinaciclib|During the Dose Evaluation phase of the study, 12 participants will receive an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7mg/m^2 on Cycle 1 Day 1 and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants will then receive an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14mg/m^2 on Day 1 and infusion of dinaciclib 14mg/m^2 alone on Day 8 on Cycles 2 through 35. The study design will be revised based on the number of DLTs in Cycle 1 and Cycle 2. If ≤4 DLTs occur, 30 participants per disease type will be enrolled in the Signal Detection Phase. If >5 DLTs occur, a lower dose will be evaluated in up to 24 additional participants.
2981793|NCT02684604||unexplained infertility patients|44 patients diagnosed to have unexplained infertility
2981795|NCT02684591|Experimental|Aramchol 600 mg orally daily|"Total 600 mg Aramchol (200 mg/tablet and 400 mg/tablet) per day once a day orally for 12 weeks.~Intervention: Aramchol"
2981796|NCT02684591|Placebo Comparator|Placebo|Placebo in the form of a tablet; Two bottles will be given to patient and they will take two pills, once a day orally for 12 weeks.
2981797|NCT02684578|Experimental|Metformin|This arm will be receiving the study drug, Metformin, for the duration of the 18 month study. They will begin this drug on a low dose of Metformin, increasing the dosage in a step-wise fashion to avoid unwanted gastrointestinal discomfort, a common side effect when patients begin taking Metformin. During the 18 month study, subjects assigned to this arm will have 3 follow-up exams after the initial enrollment exam, at 6 month intervals.
2981798|NCT02684578|No Intervention|Observe|This arm will maintain standard of care for dry AMD, which is observation. During the 18 month study, subjects assigned to this arm will have 3 follow-up exams after the initial enrollment exam, at 6 month intervals.
2981799|NCT02684565|Active Comparator|BCAA High Protein supplement|Subjects will be randomly assigned to take high BCAA protein a day for 4 weeks after a 2-week washout will switch to the other arm.
2981800|NCT02684565|Active Comparator|BCAA Low Protein Supplement|Subjects will be randomly assigned to take low BCAA protein a day for 4 weeks after a 2-week washout will switch to the other arm.
2981801|NCT02684552|Experimental|Non invasive ventilation|Patients perform physical test with non invasive ventilation
2981802|NCT02684552|Active Comparator|Oxygen|Patients perform physical test with oxygen with mask
2981803|NCT02684539|Experimental|tilt table Erigo®|observation of physiological parameters, tilting table with onset of syncope
2981804|NCT02684526|Active Comparator|Eovist Contrast agent|To determine if Eovist contrast agent induces a transient abnormal sensation at first pass, which prevents patients from holding their breath at end of arterial phase liver MRI scans.
2981805|NCT02684526|Active Comparator|Non Eovist Contrast agents|To determine if using non-Eovist contrast agents produce the same abnormal sensation at first pass, which prevents patients from holding their breath at end of arterial phase liver MRI scans. Determine if this event is exclusive to Eovist contrast.
2981806|NCT02684513|Active Comparator|Oral Carbohydrate Beverage Group|Subjects assigned to this group will receive 710 mL of a preoperative beverage the evening prior to surgery and 355 mL the morning of surgery.
2981807|NCT02684513|Active Comparator|Rehydration Beverage Group|Subjects assigned to this group will receive 710 mL of re-hydration beverage the evening prior to surgery and 355 mL the morning of surgery.
2981808|NCT02684513|No Intervention|Fasted Controls|Subjects assigned to this group will fast for ≥8 hours prior to surgery.
2981809|NCT02684500||aneurysmal subarachnoid hemorrhage|Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) using abdominal ultrasound in order to evaluate the potential additional risk of non-occlusive mesenteric ischemia (NOMI) and non occlusive bowel necrosis (NOBN) for a aneurysmal subarachnoid hemorrhage in subjects undergoing hypertensive therapy for cerebral vasospasm in SAH, to justify the withholding of enteral nutrition.
2981810|NCT02684487|Active Comparator|vitamin D3|Patients will be given single dose of vitamin D3 within 24 hours of new-onset severe sepsis, followed by weekly doses of vitD3 (25,000 IU) up to 90 days to assess clinical outcomes and key biomarkers.
2981811|NCT02684487|Sham Comparator|Placebo|Patients will be given placebo intervention within 24 hours of new onset severe sepsis followed by or placebo for up to 90 days to assess clinical outcomes and key biomarkers.
2981812|NCT02684461|Active Comparator|Arm A: Sequential Consolidation|Completion of four cycles of Sequential Consolidation of Pembrolizumab 200mg every 21 days and then four cycles Nab-paclitaxel 100 mg/mg2 on day 1 and day 8 every 21 days
2981813|NCT02684461|Active Comparator|Arm B: Sequential Consolidation|Completion of 4 cycles of Sequential Consolidation of Nab-paclitexel 100 mg/m2 on day 1 and day 8 every 21 days and then Pembrolizumab 200 mg every 21
2981814|NCT02684461|Experimental|Arm C: Concurrent Consolidation|Concurrent Consolidation of Nab paclitaxel 100 mg/m2 on day 1 and day 8 plus Pembrolizumab 200 m5 on day 1 every 21 days for four cycles
2981815|NCT02684448||Robotic-Assisted Inguinal Hernia Repair|Subjects who have undergone robotic-assisted (da Vinci) inguinal hernia repair from the initiation of robotic-assisted hernia repair at site through December 2015.
2981816|NCT02684448||Open Inguinal Hernia Repair|Subjects who have undergone open inguinal hernia repair from the day prior to initiation of robotic-assisted hernia repair through 5 years prior to initiation.
2981817|NCT02684435|Experimental|Perflutren lipid microsphere|Activate by shaking for 45 seconds using VIALMIX. Use activated product within 5 minutes. Infusion: The recommended infusion dose for activated perflutren is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute per P.I. approval
2981818|NCT02684422||Cystic Fibrosis with MRSA infection|"Cystic Fibrosis patients that are admitted to the hospital for IV therapy targeting MRSA will give a sputum sample and complete symptom diaries at the beginning and end of therapy. There will be no intervention administered.~Inclusion criteria are ability to produce sputum and having a chronic i.e. > 2 years of positive respiratory cultures, MRSA CF lung infection."
2981819|NCT02684409|Experimental|PROT-CL-NP101-015.01|
2981820|NCT02684396|Experimental|Cohort 1: TAK-648 0.05 mg|TAK-648 0.05 mg, solution, orally, once on Day 1.
2981821|NCT02684396|Experimental|Cohort 2: TAK-648 0.15 mg|TAK-648 0.15 mg, solution, orally, once on Day 1.
2981822|NCT02684396|Experimental|Cohort 3: TAK-648 0.35 mg|TAK-648 0.35 mg, solution, orally, once on Day 1.
2981823|NCT02684396|Experimental|Cohort 4: TAK-648 0.7 mg|TAK-648 0.7 mg, solution, orally, once on Day 1.
2981824|NCT02684396|Experimental|Cohort 5: TAK-648 0.85 mg|TAK-648 0.85 mg, solution, orally, once on Day 1.
2981825|NCT02684396|Placebo Comparator|Cohort 1-5: Placebo|TAK-648 placebo-matching solution, orally, once on Day 1.
2981826|NCT02684383|Experimental|rDEN3∆30 vaccine|Participants will receive the rDEN3∆30 vaccine at Day 0.
2981827|NCT02684383|Placebo Comparator|Placebo|Participants will receive placebo at Day 0.
2981828|NCT02684370|Experimental|ABBV-066|
2981829|NCT02684370|Active Comparator|Ustekinumab|
2981830|NCT02684370|Placebo Comparator|Placebo|
2981831|NCT02684357|Experimental|ABBV-066|
2981832|NCT02684357|Active Comparator|Ustekinumab|
2981834|NCT02684344|Experimental|Tamsulosin Group|"Subjects will receive:~0.4mg tamsulosin by mouth nightly for 3 doses prior to the day of surgery and for 2 doses following surgery~education about signs and symptoms of urinary retention"
2981835|NCT02684344|Active Comparator|Education Group|"Subjects will receive:~1) education about signs and symptoms of urinary retention"
2981836|NCT02684331||T2DM|
2981837|NCT02684318|Experimental|Dose Level 1|PM01183 + olaparib PM01183: 1 mg/m² IV olaparib 100 mg BID
2981838|NCT02684318|Experimental|Dose Level 2|PM01183 + olaparib PM01183: 1 mg/m² IV olaparib 150 mg BID
2981839|NCT02684318|Experimental|Dose Level 3|PM01183 + olaparib PM01183: 1.5 mg/m² IV olaparib 200 mg BID
2981840|NCT02684318|Experimental|Dose Level 4|PM01183 + olaparib PM01183: 1.5 mg/m² IV olaparib 250 mg BID
2981841|NCT02684318|Experimental|Dose Level 5|PM01183 + olaparib PM01183: 2 mg/m² IV olaparib 250 mg BID
2981842|NCT02684318|Experimental|Dose Level 6|PM01183 + olaparib PM01183: 2 mg/m² IV olaparib 300 mg BID
2981843|NCT02684318|Experimental|Dose Level 7|PM01183 + olaparib PM01183 3 mg/m² IV olaparib 300 mg BID
2981844|NCT02684305|Experimental|Administration of Propess|"All women who failed induction of labor using vaginal insert slow release of dinoprostone 10 mg (Propess), defined as bishop score ≤ 7 24 hours after propess insertion will be randomized to one of the following treatment arms:~1.Administration of Propess for additional 24 hours."
2981845|NCT02684305|Experimental|Intravenous oxytocin infusion + balloon|"All women who failed induction of labor using vaginal insert slow release of dinoprostone 10 mg (Propess), defined as bishop score ≤ 7 24 hours after propess insertion will be randomized to one of the following treatment arms:~2. Intravenous oxytocin infusion combined with intracervical balloon administration, inflated with 60cc of saline."
2981846|NCT02684292|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 3-week cycle for up to 35 cycles.
2981847|NCT02684292|Active Comparator|Brentuximab vedotin|Participants receive BV 1.8 mg/kg (maximum 180 mg per dose) IV on Day 1 of each 3-week cycle for up to 35 cycles.
2981848|NCT02684279|Experimental|Dasotraline|4, 6, 8 mg flexibly dosed
2981849|NCT02684266|Experimental|SHR6390|Each subject will receive a single dose of SHR6390 and then repeat doses following a 3 week/1 week off regimen
2981850|NCT02684253|Experimental|Nivolumab 3mg/kg IV every 2 weeks|Nivolumab 3mg/kg IV every 2 weeks
2981851|NCT02684253|Experimental|Stereotactic Body Radiotherapy & Nivolumab|"Image Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Nivolumab).~Nivolumab 3mg/kg IV starting day 1 and then every 2 weeks thereafter. Treatment with Nivolumab will continue until progression or unacceptable toxicity."
2981852|NCT02684240|Experimental|Nitazoxanide|Participants with drug-sensitive tuberculous randomized to the NTZ arm will receive nitazoxanide 1000 mg po twice daily for 14 days. After this time point, participants will be switched to WHO standard tuberculosis therapy with isoniazid, rifampin, pyrazinamide and ethambutol.
2981853|NCT02684240|Other|Control|Participants with drug-sensitive tuberculosis randomized to the standard therapy arm will receive WHO standard tuberculosis therapy involving isoniazid 300 mg po daily, rifampin 600 mg po daily, pyrazinamide 25 mg/kg po daily and ethambutol 15 mg/kg po daily.
2981854|NCT02684227|Experimental|Part A: Enzalutamide, Carboplatin + Paclitaxel|Safety Lead-in Phase (Part A): Combination of Enzalutamide (160 mg Daily Orally) & standard intravenous (IV) Carboplatin (AUC= 5) and Paclitaxel (175 mg/m^2) on Day 1 every 21 day cycle for 6-9 cycles.
2981855|NCT02684227|Experimental|Part B: Enzalutamide, Carboplatin + Paclitaxel|Phase II (Part B): Induction treatment single agent Enzalutamide at dose found in Part A daily orally for 28 days, then initiated on combination therapy of enzalutamide, paclitaxel, and carboplatin at dose levels for each drug as found in Part A, on day 1 every 21 days for 6-9 cycles.
2981856|NCT02684214|Experimental|Food secure families|high and marginal household food security
2981857|NCT02684214|Experimental|Food insecure families|low and very low household food security
2981858|NCT02684201|Experimental|Boston Scientific cord stimulator lead|"A Boston Scientific Stimulator Lead (PMA P030017) will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance."
2981859|NCT02684188|No Intervention|Standard hospital discharge services|Patients received standard discharge planning; the baseline and return to baseline groups were combined to form a single standard discharge group
2981860|NCT02684188|Experimental|Enhanced rural discharge and transition|Enhanced rural discharge and transition involved conducting a functional needs assessment before discharge. Identified needs were shared with a Local Community Transition Coordinator (LCTC). Needs include such patient centered issues as housing, transportation, emotional support, support for completing daily chores, and assistance in securing local follow-up appointments. Once a patient returned home, the LCTC conduct a review of discharge orders to insure a patient can meet those recommendations. Then the LCTC worked with the patient to develop and implement a transition plan that linked the patient to local resources he or she can use to address needs. The LCTC also provided direct supports. This plan was implemented over the course of the first 30 days after discharge.
2981861|NCT02684175|Active Comparator|In-Person CI Counseling Session|Participants (n=6) randomized to receive an in-person CI counseling session will receive what normally occurs with patients pursuing cochlear implantation. The counseling will last 30-45 minutes and consists 5 key components: an explanation of the patient's hearing testing results, a discussion of the impact of hearing loss on the patient's life, treatment options for hearing loss including hearing aid amplification and cochlear implantation, an explanation of how CIs function and the necessary steps in candidacy and rehabilitation, and an outline of the expected outcomes following cochlear implantation.
2981862|NCT02684175|Experimental|Remote CI Counseling Session|Participants (n=6) randomized to receive a remote CI counseling session will be receiving the counseling session remotely. The participants will be counseled remotely by the audiologist located in Lexington, KY via the telemedicine system (intervention). This counseling will last 30-45 minutes and consists 5 key components: an explanation of the patient's hearing testing results, a discussion of the impact of hearing loss on the patient's life, treatment options for hearing loss including hearing aid amplification and cochlear implantation, explanation of how CIs function and the necessary steps in candidacy and rehabilitation, and an outline of the expected outcomes following cochlear implantation.
2981863|NCT02684162|Experimental|Minimal Residual Disease (MRD) Group|"Participants receive subcutaneous (SC) SGI-110 daily for the first 5 days of each 28-day cycle. Participants may receive up to 12 cycles of SGI-110.~On Day 6 of Cycles 2, 4, and 6, participants receive a donor lymphocyte infusion by vein over about 10-30 minutes."
2981864|NCT02684162|Experimental|Morphological Relapse for AML and MDS Group|"Participants receive subcutaneous (SC) SGI-110 daily for the first 5 days of each 28-day cycle. Participants may receive up to 12 cycles of SGI-110.~On Day 6 of Cycles 2, 4, and 6, participants receive a donor lymphocyte infusion by vein over about 10-30 minutes."
2981865|NCT02684162|Experimental|High Risk AML and MDS Group|"Participants receive subcutaneous (SC) SGI-110 daily for the first 5 days of each 28-day cycle. Participants receive up to 12 cycles of SGI-110.~On Day 6 of Cycles 2, 4, and 6, participants receive a donor lymphocyte infusion by vein over about 10-30 minutes."
2981866|NCT02684149|Experimental|A|Relational touch before the first arterial puncture and the second arterial puncture without relational touch
2981867|NCT02684149|Experimental|B|First arterial puncture without relational touch and relational touch before the second arterial puncture
2981868|NCT02684136|Experimental|suvorexant|9 nights of 20 mg suvorexant
2981869|NCT02684136|Placebo Comparator|placebo|9 nights placebo
2981870|NCT02684123|Active Comparator|Apremilast|Apremilast 30mg twice daily
2981871|NCT02684123|Placebo Comparator|Placebo|Placebo pills twice daily
2981872|NCT02684097|Active Comparator|Tralokinumab|Tralokinumab subcutaneous injection every two weeks for 24 weeks
2981873|NCT02684097|Placebo Comparator|Placebo|Saline subcutaneous injection every two weeks for 24 weeks.
2981874|NCT02684084|Active Comparator|Combination group (RBZ+DEX)|30 eyes will receive an intravitreal Lucentis (0.5 mg) injection followed by Ozurdex implant (0.7 mg) injection within 0 to 8 days.
2981875|NCT02684084|Active Comparator|Monotherapy group (DEX only)|30 eyes will receive Ozurdex implant (0.7 mg) injection only
2981876|NCT02684071|Experimental|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
2981877|NCT02684058|Experimental|HGG cohort: Dabrafenib and trametinib|HGG cohort: All patients in the HGG cohort will receive DRB+TMT
2981878|NCT02684058|Active Comparator|LGG cohort: Carboplatin with vincristine|LGG cohort: Patients randomized 2:1 to either DRB+TMT or active comparator chemotherapy.
2981879|NCT02684058|Experimental|LGG cohort: Dabrafenib and trametinib|LGG cohort: Patients randomized 2:1 to either DRB+TMT or active comparator chemotherapy.
2981880|NCT02684032|Experimental|Letrozole Cohort|Letrozole combination cohort in dose escalation
2981881|NCT02684032|Experimental|Fulvestrant cohort|Fulvestrant combination cohort in dose escalation
2981882|NCT02684032|Experimental|ARM A|Gedatolisib + palbociclib + letrozole in dose expansion
2981883|NCT02684032|Experimental|ARM B|Gedatolisib + palbociclib + fulvestrant in dose expansion
2981884|NCT02684032|Experimental|ARM C|Gedatolisib + palbociclib + fulvestrant in dose expansion
2981885|NCT02684019|Active Comparator|Dexmedetomidine|1microgram/kilogram loading dose followed by 0.5 microgram/kilogram/hour IV
2981886|NCT02684019|Active Comparator|Magnesium sulphate|40milligram/kilogram loading dose followed by 10milligram/kilogram/hour IV
2981887|NCT02684019|No Intervention|Propofol|0.5-1.5 mg/kg followed by 3mg/kg guided by BIS
2981888|NCT02684019|No Intervention|Bispectral index|Keep reading between 60-70
2981889|NCT02684006|Experimental|Avelumab in combination with axitinib|Avelumab administered at 10 mg/kg IV every two weeks in combination with axitinib, 5 mg PO BID.
2981890|NCT02684006|Active Comparator|Sunitinib|Sunitinib given at 50 mg PO QD on schedule 4/2
2981891|NCT02683993|Experimental|Stone breaking|Lithotripsy will be performed using the Lumenis Pulse 120H holmium laser system with low frequency parameters.
2981892|NCT02683993|Experimental|Stone dusting|Lithotripsy will be performed using the Lumenis Pulse 120H holmium laser system with high frequency parameters.
2981893|NCT02683980|Experimental|Ablation of the prostate|ablation of the prostate will be performed using the study device: Lumenis Pulse P120H Holmium Laser
2981894|NCT02683967|Active Comparator|Acupuncture|These patients received acupuncture during the follicular development phase and on the day of egg collection.
2981895|NCT02683967|No Intervention|Control|Patients received standard care, no acupuncture.
2981896|NCT02683954||endometriosis|30 women with laparoscopically diagnosed endometriosis. This group will be categorized into 3 sub-groups according to the BMI: i) Lean: BMI <25.0 kg/m2. ii) Overweight: BMI ≥25.0 kg/m2 but less than 30 kg/m2. iii) Obese: BMI ≥30 kg/m2.
2981897|NCT02683954||control|30 women without any laparoscopically detected pelvic endometriotic pathology. This group will be categorized into 3 sub-groups according to the BMI: i) Lean: BMI <25.0 kg/m2. ii) Overweight: BMI ≥25.0 kg/m2 but less than 30 kg/m2. iii) Obese: BMI ≥30 kg/m2.
2981898|NCT02683941|Experimental|Lanreotide (Autogel formulation)|120mg every 28 days until disease progression
2981899|NCT02683941|Placebo Comparator|Placebo|120mg every 28 days until disease progression, then patient may enter open-label treatment with Lanreotide
2981900|NCT02683928|Experimental|GBR 830|GBR 830 administered as IV infusion
2981901|NCT02683928|Placebo Comparator|Placebo|Placebo administered as IV infusion
2981902|NCT02683915||Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
2981903|NCT02683915||Non-cooled group|Infants in the non-cooled group received the current standard of care and will be placed under radiant heaters or in incubators, which are servo-controlled according to the abdominal skin temperature to maintain the rectal temperature at 37.0± 0.2°C.
2981904|NCT02683902|Active Comparator|Active tDCS + Diet|The participants will receive active tDCS treatment every day for 5 days per week, a total of 20 sessions. They will also be prescribed a hypocaloric dietary during these 4-week treatment.
2981978|NCT02683382|No Intervention|No treatment|Part 3 of the study: other eye is a control eye with no treatment for 45 days.
2981905|NCT02683902|Sham Comparator|Sham tDCS + Diet|The participants will receive sham tDCS treatment every day for 5 days per week, a total of 20 sessions. They will also be prescribed a hypocaloric dietary during these 4-week treatment.
2981906|NCT02683889|Experimental|One arm|One arm will receive acthar to measure rate of recurrence of FSGS after transplant. There are no other arms. We do have previous data that FSGS recurs in 23% of kidney transplants.
2981907|NCT02683876||Subjects with malodor|individuals with self-reported odor issues suspected to be associated with microbial imbalance on or inside the body and inefficient metabolism as evidenced from other laboratory tests
2981908|NCT02683876||Healthy control|individuals not complaining of uncontrollable or unpredictable malodor episodes
2981909|NCT02683863|Other|Group 1|"There will be 4 CSF sampling groups at the Week 6 visit for PK assessment:~1. Four subject for CSF samples 3 hours after dosing"
2981910|NCT02683863|Other|Group 2|2. Four subjects for CSF samples 5 hours after dosing
2981911|NCT02683863|Other|Group 3|3. Four subjects for CSF samples 7 hours after dosing
2981912|NCT02683863|Other|Group 4|4. Four subjects for predose CSF samples
2981913|NCT02683850|Experimental|Omega-3 SPM|"Intervention: Study participants will be instructed to take 3 Omega-3 SPM™ softgel supplements in the morning and 3 Omega-3 SPM™ soft gel supplements in the evening for two weeks.~At weeks two participants whose PROMIS-43 Pain Intensity score indicates a reduction in pain levels weeks, will take 2 Omega-3 SPM™ soft gel supplements in the morning and 2 in the evening for the remaining 2 weeks of the study.~Participants whose PROMIS-43 Pain Intensity score remained the same after two weeks, or increased will take 4 Omega-3 SPM™ soft gel supplements in the morning and 4 SPM™ softgels in the evening for the remaining two weeks of the study."
2981914|NCT02683837|Active Comparator|Standard practice|"Remifentanil infusion guided by usual clinical signs (heart rate, blood pressure).~Pupillometry blindly recorded. Anesthesia maintenance with sevoflurane."
2981915|NCT02683837|Experimental|Pupillometry|Remifentanil infusion guided by changes in pupillary diameter. Anesthesia maintenance with sevoflurane.
2981916|NCT02683824|Experimental|pancreatic cancer patients|Patients receive [18F]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
2981917|NCT02683824|Experimental|healthy patients|Patients receive [18F]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
2981918|NCT02683811|Experimental|Intervention group|Diario della Salute (DDS-2), a school-based program aimed to promote psychological well-being and to prevent cigarette smoking, alcohol abuse, unhealthy eating habits, physical inactivity in preadolescents aged 11-13 years. The program is composed by 5 highly standardised interactive units led by previously trained teachers during school hours (15 hours total). Units focus on emotional and social issues related to adolescent developmental tasks. The goal is to promote the adolescent emotional and social skills.
2981919|NCT02683811|No Intervention|Control group|No intervention aimed at preventing cigarette smoking, alcohol abuse, unhealthy eating habits, physical inactivity and promoting emotional and social well-being is administered at school by teachers.
2981920|NCT02683798|Active Comparator|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
2981921|NCT02683798|Experimental|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
2981922|NCT02683785|Experimental|GSK3196165|Subjects will receive a total of 8 doses of GSK3196165 over a 12-week treatment period.
2981923|NCT02683785|Placebo Comparator|Placebo|Subjects will receive a total of 8 doses of placebo over a 12-week treatment period.
2981924|NCT02683772|Active Comparator|Group A|Astral device will be set using iVAPS with manual EPAP
2981925|NCT02683772|Experimental|Group B|Astral device will be set using iVAPS with AutoEPAP
2981926|NCT02683759|Active Comparator|Treatment Arm|Patients will receive 5-Aminosalicyclic acid as per their current treatment regimen and will also take Bio-enhanced curcumin twice daily after meals as per the following regimen:
2981927|NCT02683759|Placebo Comparator|Control Arm|Patients will receive 5-Aminosalicyclic acid as per their current treatment regimen and will also take a placebo pill twice daily after meals
2981928|NCT02683746|Experimental|Albiglutide active LAI plus Placebo lyophilized DCC PI|Subjects will receive 30 milligrams (mg) of albiglutide liquid drug product via auto injector and matching placebo via lyophilized DCC pen injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
2981929|NCT02683746|Experimental|Albiglutide lyophilized DCC PI plus Placebo LAI|Subjects will receive 30mg of albiglutide lyophilized drug product via DCC pen injector and matching placebo via auto injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
2981930|NCT02683733|Active Comparator|Treatment Arm|"Patients will receive 5-Aminosalicylic acid as per their current treatment regimen and will also take Bio-enhanced curcumin twice daily after meals as per the following regimen:~Starting dose: 50 mg BID of Bio-enhanced Curcumin Soft Gelatin Capsule Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
2981931|NCT02683733|Placebo Comparator|Control Arm|Patients will receive 5-Aminosalicylic acid as per their current treatment regimen and will also take a placebo pill twice daily after meals
2981932|NCT02683720|Experimental|ONS1|new product
2981933|NCT02683720|Active Comparator|ONS2|usual care
2981934|NCT02683707|Experimental|PCI without IV opiate|IV midazolam and Local Anesthetic, with removal of IV fentanyl from peri-procedural analgesia (which is otherwise routinely given)
2981935|NCT02683707|Active Comparator|PCI with IV opiate|IV midazolam and Local Anesthetic and IV fentanyl for peri-procedural analgesia
2981936|NCT02683694|Other|study arm|iOCT is performed
2981937|NCT02683668|Experimental|Handihaler-Tiotropium 18 mcg untrained|Patients receiving Handihaler who have not been trained (real-life use) for over 3 months on its use. Here the investigators want to see that if patients have on-going symptoms but are on Handihaler-Tiotropium 18mcg what is happening PRIOR to proper inhaler technique training - that is their 'real-life' use of the inhaler - to their lung function (large and small airways) and also symptoms or exercise limitation (determined by CAT score) will already be recorded as entry criteria
2981938|NCT02683668|Experimental|Handihaler-Tiotropium 18 mcg trained|Patients will be trained in their use of Handihaler-Tiotropium and asked to take 18 mcg once daily for 14 days to see if their (i) airway lung function and or (ii) clinical symptoms improve. Here the investigators want to see what happens AFTER proper inhaler technique training on large and small airways lung function and also symptoms or exercise limitation (determined by CAT score)
2981939|NCT02683668|Experimental|Respimat-Tiotropium 5 mcg trained|Patients will be switched to trained Respimat Tiotropium 5 mcg once daily for 14 days to see if their (i) airway lung function and or (ii) clinical symptoms improve. Here the investigators want to see what happens AFTER this efficient device Respimat (trained) compared to PREVIOUS device Handihaler (trained) on large and small airways lung function and also symptoms or exercise limitation (determined by CAT score). The investigators want to see if the properties of the Respimat device with deeper lung deposition (slow velocity and small particles) can improve small airway measures (and indeed large airway measures) that might also be related to an improvement in symptoms.
2981940|NCT02683655|Experimental|Apatinib 500mg qd p.o.|Apatinib Mesylate Tablets 500 mg qd p.o. after the failure of chemotherapy or radiotherapy
2981941|NCT02683655|Experimental|Apatinib 750mg qd p.o.|Apatinib Mesylate Tablets 750 mg qd p.o. after the failure of chemotherapy or radiotherapy
2981942|NCT02683629|Experimental|NTCELL|NTCELL Implantation
2981943|NCT02683629|Sham Comparator|Sham Surgery|Sham Surgery
2981944|NCT02683616|Experimental|OSA + T2DM|CPAP treatment
2981945|NCT02683616|Experimental|OSA no T2DM|CPAP treatment
2981946|NCT02683616|No Intervention|T2DM no OSA|Standard care
2981947|NCT02683616|No Intervention|Healthy controls no ÓSA|no intervention
2981948|NCT02683603|Active Comparator|aerosolised (AS) colistin group|"the intervention was: AS colistin and imipenem. the drug administered was colimycin (colistin) powder 1 million units (MU) by a flakon (Sanofi Winthrop Industry) at the dosage of 4 million units (MU) for 30 minutes 3 times per day for at least 14 days in addition to IV imipenem 1 g three times per day. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland). Inhaled colimycin® requires specific settings of the ventilator to limit turbulence inspiratory flow. The adjustment consisted in a volume controlled mode with a Tidal volume <8 ml / kg, respiratory rate at 12 cycles / min, I / E: 1/1 and an end inspiratory break > 20%."
2981949|NCT02683603|Active Comparator|intravenous (IV) colistin goup|"the intervention was: IV colistin and imipenem. the intravenous (IV) colistin goup received IV colimycin (colistin) as a loading dose of 9 MU during 60 minutes followed by 4.5 million units 2 times per day in addition to IV imipenem 1 g three times per day."
2981950|NCT02683590|Experimental|sternum by a ceramic implant|The replacement of the sternum by a ceramic implant
2981951|NCT02683577|Experimental|Telotristat etiprate 500 mg|1 single oral dose (2 x 250-mg tablets)
2981952|NCT02683564|Experimental|BOW015|Infliximab-EPIRUS, 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks thereafter up to Week 46.
2981953|NCT02683564|Active Comparator|Remicade|Remicade (infliximab) , 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks thereafter up to Week 46.
2981954|NCT02683551||Ligasure|Patients underwent to Sutureless Thyroidectomy with Ligasure SmallJaw
2981955|NCT02683551||Harmonic|Patients underwent to Sutureless Thyroidectomy with Harmonic FOCUS
2981956|NCT02683538|Experimental|Separable cluster electrode|radiofrequency ablation (RFA) using separable cluster electrode in switching monopolar mode.
2981957|NCT02683525|Experimental|Sitagliptin|Sitagliptin 600 mg q 12 hours PO starting on Day -1 before transplant to be administered between 8:00 am and 10:00 am then given every 12 hours (total 32 doses) through day +14.
2981958|NCT02683499|Experimental|Ultrasonic tips|Prepared surfaces will be finished with ultrasonic tips
2981959|NCT02683499|No Intervention|Conventional|Prepared surfaces will be finished with ordinary burs
2981960|NCT02683486|Experimental|Activities of daily living on iO2t|Patients will complete simulated activities of daily living on intelligent oxygen therapy (an auto-titrating oxygen system)
2981961|NCT02683486|Active Comparator|Activities of daily living on LTOT|Patients will complete activities of daily living on their usual long-term oxygen therapy.
2981962|NCT02683473||Infants|Infants aged 1-3 months
2981963|NCT02683460|Experimental|patella resurfacing group|Procedure: Patellar component Resurfacing with onlay technique
2981964|NCT02683460|Active Comparator|patella retention|Procedure: patellar retention Trimming of osteophytes when appropriate
2981965|NCT02683447||CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
2981966|NCT02683434|Experimental|KT|Kinesio Taping Application
2981967|NCT02683434|No Intervention|CONTROL|
2981968|NCT02683421|Other|Cohort 1|Healthy Volunteers: 50 mcg tilmanocept with 2 mCi Tc 99m
2981969|NCT02683421|Other|Cohort 2|Healthy Volunteers: 200 mcg tilmanocept with 2 mCi Tc 99m
2981970|NCT02683421|Experimental|Cohort 3|RA Group: 50 mcg tilmanocept with 2 mCi Tc 99m
2981971|NCT02683421|Experimental|Cohort 4|RA group:200 mcg tilmanocept with 2 mCi Tc 99m
2981972|NCT02683408|Experimental|diosmiplex|diosmiplex 630 mg BID administered orally
2981973|NCT02683408|Placebo Comparator|placebo|placebo BID administrered orally
2981974|NCT02683395|Experimental|Treatment Group A|Open label, sequential PLX51107 dose escalation in approximately 30 solid tumor subjects.
2981975|NCT02683395|Experimental|Treatment Group B|Open label, sequential PLX51107 dose escalation in approximately 30 subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
2981976|NCT02683382|Experimental|Moisturizing Eye Product (product in development)|Moisturizing eye product in liquid form (medical device product in development). Part 1 of the study: Administered to both eyes 4 times/day for 1 day. Part 2: to one eye 4 times/day for 9 days. Part 3: to one eye 4 times/day for 45 days. Parts 2 & 3: treatment eyes randomized.
2981977|NCT02683382|Active Comparator|Moisturizing Eye Product, Comparison|Moisturizing eye product in liquid form (medical device CE-marked). Part 2 of the study: Administered to one eye 4 times/day for 9 days. Treatment eyes randomized.
2981979|NCT02683369|Experimental|Iron Supplement|Participants will consume one tablet of Blood Builder®/Iron Response®, once per day, every day, for 8 weeks.
2981980|NCT02683356|Active Comparator|OCT-guided PCI|OCT before and after Stent implantation
2981981|NCT02683356|Active Comparator|Angiography-guided PCI|OCT after Stent implantation
2981982|NCT02683343||carpal tunnel syndrome|No intervention
2981983|NCT02683343||normals|no intervention
2981984|NCT02683330|Experimental|Mindfulness-based intervention (MBI)|Participants randomly assigned to the MBI group will receive 8 sessions over an 8-week period. The sessions will last 1 hour and will be held via video-conference through Skype, an online application.
2981985|NCT02683330|No Intervention|Wait-list control (WLC)|Participants randomly assigned to the WLC group will be discouraged from any new mindfulness related activities during the trial. The WLC group will be offered the opportunity to take part in the MBI at the end of the 20-week follow-up.
2981986|NCT02683317|Experimental|DHA group|Experimental group will receive 75 mg of docosahexaenoic acid per kilo of baseline weight in one dose per day, administered by enteral feeding throughout 14 days.
2981987|NCT02683317|Sham Comparator|Control group|"Control group will receive sunflower oil, the excipient of the DHA in our intervention.~They will receive it once a day, administered by enteral feeding throughout 14 days."
2981988|NCT02683304|Experimental|The study population|The study population consists of consecutive headache patients (visual analogue scale > 3) presenting at the emergency department of the Nîmes University Hospital
2981989|NCT02683291|Active Comparator|Tacrolimus + Mycophenolate|"The investigators wil be used tacrolimus (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8ng/ml at the third month and then 3-7ng/ml from the third month to the 12th month) and mycophenolate sodium 720 mg twice daily. A dose reduction of mycophenolate sodium to 720 mg/day will be accepted due to possible side effects of the drug.~Prednisone 30 mg/day in the first month. Induction therapy consisted of basiliximab or thymoglobulin if panel reactivity class I greater than 50 %"
2981990|NCT02683291|Experimental|Tacrolimus + Sirolimus|"The investigators will be used tacrolimus (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8 ng/ml at the third month and then 3-7 ng/ml from the third month to the 12th month) and sirolimus 2 mg/day (adjusted serum levels at 4-8 ng/ml throughout the study period).~Prednisone 30 mg/day in the first month. Induction therapy consisted of basiliximab or thymoglobulin if panel reactivity class I greater than 50 %"
2981991|NCT02683278|Experimental|Cognitive-Behavioral Therapy|Group-based cognitive-behavioral manualized treatment
2981992|NCT02683278|Experimental|Mindfulness-acceptance Therapy|Group-based mindfulness-acceptance manualized treatment
2981993|NCT02683278|Active Comparator|Education|Group-based manualized pain education
2981994|NCT02683265|Experimental|Aptensio XR|Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg Aptensio XR)
2981995|NCT02683265|Placebo Comparator|Placebo comparator|Placebo capsules
2981996|NCT02683252|Experimental|Normal patients|Patients with normal bone appearance on conventional MR images
2981997|NCT02683252|Experimental|Carpal osteonecrosis|Patients presenting signal anomalies compatible with osteonecrosis of the carpal bones on conventional MR images (hypointensity on T1 weighted sequences, no contrast enhancement).
2981998|NCT02683252|Experimental|Femoral head osteonecrosis|Patients presenting signal anomalies compatible with osteonecrosis of the femoral head on conventional MR images (fat containing signal anomalies with geographic contours in the femoral epiphysis).
2981999|NCT02683252|Experimental|Pseudarthrosis|Patients presenting a non consolidated macroscopic bone fracture for over 6 months (clinical history and imaging findings).
2982000|NCT02683252|Experimental|Compartment syndrome|Patients with a confirmed compartment syndrome on intra-compartment pressure assessement
2982001|NCT02683239|Experimental|Fasinumab dosing regimen 1|Sub-study only
2982002|NCT02683239|Experimental|Fasinumab dosing regimen 2|
2982003|NCT02683239|Experimental|Fasinumab dosing regimen 3|
2982004|NCT02683239|Experimental|Fasinumab dosing regimen 4|
2982005|NCT02683239|Experimental|Placebo|
2982006|NCT02683226|Experimental|metformin and alogliptin|Vipdomet 12.5 mg/1000 mg tablets
2982007|NCT02683226|Experimental|pioglitasone and alogliptin|Incresync 12,5 mg/30 mg tablets
2982008|NCT02683213|Active Comparator|Fluoxetine|One capsule Fluoxetine 20mg once daily for 6 months.
2982009|NCT02683213|Placebo Comparator|Placebo|One matching capsule placebo once daily for 6 months.
2982010|NCT02683200|Experimental|Treatment (MRI-guided Tri-60Co teletherapy SBRT)|Patients undergo MRI-guided Tri-60Co teletherapy SBRT 3-5 fractions over 1-2 weeks.
2982011|NCT02683187|Active Comparator|Sitagliptin|The infusion procedures performed during study visits 2 and 3 are identical except that the oral medicine Sitagliptin will only be administered at one of the two visits, with order of Sitagliptin administration determined at random by study staff. In this arm, Sitagliptin will be administered.
2982012|NCT02683187|Placebo Comparator|Non-Sitagliptin|The infusion procedures performed during study visits 2 and 3 are identical except that the oral medicine Sitagliptin will only be administered at one of the two visits, with order of Sitagliptin administration determined at random by study staff. In this arm, placebo will be administered
2982013|NCT02683174|Experimental|Single study arm|All enrolled patients will be fitted with a novel ambulatory patch (ZIO®Patch), which continuously records heartbeats for up to 14 days. Brain natriuretic peptide (BNP) and hs-troponin I at 0 and 3 hours post ED attendance
2982014|NCT02683161|Other|Open-label trial|All participants will attend approximately 6 study sessions pre-surgery and approximately 6 study sessions post-surgery, during which they will be provided three intervention components aimed at smoking cessation: a medication (varenicline) that has been FDA approved for smoking cessation, contingency management for biological evidence of nonsmoking, and behavioral counseling.
2982015|NCT02683148|Experimental|Arm 1: DHEA Dose Level 1|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
2982016|NCT02683148|Experimental|Arm 2: DHEA Dose Level 2|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
2982017|NCT02683148|Experimental|Arm 3: DHEA Dose Level 3|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
2989466|NCT02633020|Placebo Comparator|Placebo|Placebo IV every two weeks
2982018|NCT02683148|Experimental|Arm 4: DHEA Phase II|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
2982019|NCT02683135|Active Comparator|High-carbohydrate diet|
2982020|NCT02683135|Experimental|Low-carbohydrate diet|
2982021|NCT02683135|Experimental|Low-carbohydrate diet with post-meal walking|
2982022|NCT02683109|Experimental|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
2982023|NCT02683109|Active Comparator|Free combination tiotropium + olodaterol|
2982024|NCT02683096||SGA Infants|
2982025|NCT02683096||Failed Hearing Screen Infants|
2982026|NCT02683083|Experimental|[131I]-SGMIB Anti-HER2 VHH1|
2982027|NCT02683070|Experimental|The PNB group|Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) will be performed after the completion of surgery before extubation.
2982028|NCT02683070|Active Comparator|The TRAM group|Intravenous tramadol of 1.5mg/kg will be administrated after the completion of surgery before extubation.
2982029|NCT02683057||IPAQ HIgh|Excessive physical activity:IPAQ quantifying the activity physical according vigorous intensity activities at least 3 days per week adding a minimum total physical activity of at least 1500MET-minutes / week or 7 or more days any combination of walking, moderate intensity or vigorous intensity activities a total minimum of physical activity of at least 3,000 MET-minutes / week
2982030|NCT02683057||IPAQ Moderate|Ideal Physical activity: IPAQ quantifying the activity physical according 3 days or more of vigorous intensity physical activity at least 20 minutes per day or 5 or more days of moderate intensity and / or walk at least 30 minutes per day or 5 or more days of any combination of walking, moderate-intensity activity and activity vigorous intensity for a total minimum of physical activity of at least 600 MET-minutes / week.
2982031|NCT02683057||IPAQ Low|IPAQ quantifying the activity physical according Insufficient physical activity: Individuals who can not put on the criteria of the above categories.
2982032|NCT02683044|Experimental|Li-ESWT 5 weeks|Consists of five sessions of Low-Intensity Extracorporeal Shock Wave Therapy , one per week, with 3000 pulses at 0,15 mg/mm2, at a frequency of 4 Hz. The distribution of the shocks will be 2000 pulses to the body of the penis and 1000 pulses at its base. Total duration: 5 weeks.
2982033|NCT02683044|Active Comparator|Li-ESWT 3 weeks|Consists of six sessions of Low-Intensity Extracorporeal Shock Wave Therapy , two per week, with 1500 pulses each one at 0.1 mJ/mm2, at a frequency of 4 Hz. The distribution of the shocks will be 900 pulses to the body of the penis and 600 pulses at its base. Total duration: 3 weeks.
2982034|NCT02683031|No Intervention|Without Ca2+ ionophore|Patients with previous incomplete ICSI cycle due to fertilization arrest were counseled to underwent a subsequent conventional ICSI cycle.
2982035|NCT02683031|Experimental|With Ca2+ ionophore|Patients with previous incomplete ICSI cycle due to fertilization arrest were counseled to underwent a subsequent ICSI cycle combined with artificial oocyte activation using Ca2+ ionophore.
2982036|NCT02683018|Active Comparator|Smoked Cannabis High CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 Smoked Cannabis High CBD/low THC cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
2982037|NCT02683018|Placebo Comparator|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
2982038|NCT02683005|Experimental|Ledipasvir/Sofosbuvir|Hepatitis C treatment will be initiated with ledipasvir (400 mg) and sofosbuvir (90mg) fixed dose combination, one pill, once daily for 12 weeks.
2982039|NCT02682992|Experimental|Low Level Laser Therapy|Patients meeting the eligibility criteria will be enrolled to receive prophylactic LLLT in addition to standard of care measures for oral mucositis or other toxicity of therapy. The radiation and chemotherapy dose, schedule, modality, technique, and any required adjustments will not be influenced by this protocol and will follow standard existing institutional practices.
2982040|NCT02682979||Geriatric patients|100 consecutive geriatric patients admitted in the Emergency Department of the Brugmann Hospital, Horta site, from 01/04/2015.
2982041|NCT02682966||PMI|Postoperative Myocardial injury, postoperative troponin levels ≥ 60 ng/L
2982042|NCT02682966||Control|postoperative troponin levels < 60 ng/L
2982043|NCT02682953|Experimental|Hyperbaric oxygen therapy|Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
2982044|NCT02682940|Other|Usual Care Patients on MDI or CSII|Usual care patients on multiple daily injections of insulin (MDI) or insulin pumps (CSII) will be their own controls against baseline and will use the Vigilant Diabetes Management Application in conjunction with a wireless blood glucose meter for three months.
2982045|NCT02682927|Experimental|ZX008 - 0.8 mg/kg/day|ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
2982046|NCT02682927|Experimental|ZX008 - 0.2 mg/kg/day|ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
2982047|NCT02682927|Placebo Comparator|Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses with food.
2982048|NCT02682901|Active Comparator|Cycloset (Bromocriptine-QR)|Subjects will be randomized in a 1:1 ratio to receive UDT (usual diabetes therapy) plus bromocriptine-QR. Following randomization subjects will be titrated to the maximum tolerated dose of the study drug over a four-week period. During these first 4 weeks, the daily dose of the study drug will be titrated up by one tablet (0.8 mg bromocriptine-QR) per day on a weekly basis until a maximal tolerated dose of at least two tablets (1.6 mg/day bromocriptine-QR) and no more than four tablets (3.2 mg/per day b-QR) is achieved. Subjects will be maintained at their maximum tolerated dose of between two to four tablets per day (1.6 to 3.2 mg bromocriptine-QR per day) for the duration of the study. Subjects will be seen at 4 weeks after randomization, at 12 weeks after randomization, and then at study end (week 24 or early termination).
2982123|NCT02682511|Experimental|Patients with dcSSc|Patients with dcSSc will be randomized to receive either oral ifetroban or oral placebo daily for 365 days
2982124|NCT02682511|Experimental|Patients with SSc-PAH|Patients with SSc-PAH will be randomized to receive either oral ifetroban or oral placebo daily for 365 days
2989500|NCT02632786|Placebo Comparator|Placebo|Placebo
2982049|NCT02682901|Placebo Comparator|Placebo|Subjects will be randomized in a 1:1 ratio to receive UDT (usual diabetes therapy) plus placebo. Following randomization subjects will be titrated to the maximum tolerated dose of the study drug over a four-week period. During these first 4 weeks, the daily dose of the study drug will be titrated up by one tablet (1 matching placebo tablet) per day on a weekly basis until a maximal tolerated dose of at least two tablets (2 placebo tablets) and no more than four tablets (4 placebo tablets) is achieved. Subjects will be maintained at their maximum tolerated dose of between two to four tablets per day (2 to 4 placebo tablets) for the duration of the study. Subjects will be seen at 4 weeks after randomization, at 12 weeks after randomization, and then at study end (week 24 or early termination).
2982050|NCT02682888|Experimental|high trait anxiety group|experiment 1: identified according to scores of the trait anxiety scale.
2982051|NCT02682888|Experimental|low trait anxiety group|experiment 1: identified according to scores of the trait anxiety scale.
2982052|NCT02682888|Experimental|oxytocin group|experiment 2: intranasal administration of oxytocin
2982053|NCT02682888|Placebo Comparator|placebo control group|experiment 2: intranasal administration of placebo
2982054|NCT02682862|Experimental|Spiolto Respimat|olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg 2 puffs OD (once daily) for 2-4 weeks. Participants then enter washout period and receive alternative treatment arm
2982055|NCT02682862|Active Comparator|Striverdi Respimat|olodaterol 2.5mcg 2 puffs OD (once daily) for 2-4 weeks. Participants then enter washout period and receive alternative treatment arm
2982056|NCT02682849||Retrospective cohort|
2982057|NCT02682849||Prospective PleuralFlow cohort|
2982058|NCT02682836|Experimental|single arm|Walk with Ease physical activity intervention
2982059|NCT02682823|Experimental|Group 1: AI-1000 G2 Self-Administration|Participants with RA will perform self-injection of tocilizumab with the AI-1000 G2 device. Visit 1 will be conducted for administration training, while Visits 2 and 3 will be conducted for use/performance evaluation.
2982060|NCT02682823|Experimental|Group 2: AI-1000 G2 Administration by CG|CGs will perform injection of tocilizumab to participants with RA using the AI-1000 G2 device. Visit 1 will be conducted for administration training, while Visits 2 and 3 will be conducted for use/performance evaluation.
2982061|NCT02682823|Experimental|Group 3: AI-1000 G2 Administration by HCP|HCPs will perform injection of tocilizumab to participants with RA using the AI-1000 G2 device. Because enrolled HCPs must be professionally qualified to deliver SC injections, no administration training will be provided. Visits 2 and 3 will be conducted for use/performance evaluation.
2982062|NCT02682810|Active Comparator|DNA PCR HIV diagnostic test|SOC or control arm through existing PMTCT program, with DBS samples sent to an off-site laboratory for DNA PCR testing.
2982063|NCT02682810|Experimental|Alere Q POC nucleic acid-based platform|POC test to provide same-day diagnosis
2982064|NCT02682797||1|At all study visits a complete ophthalmic examination, visual acuity and refractive error, Spectralis OCT, Cirrus OCT, Topcon OCT, PS-OCT, Optomap Fundus photography will be performed.
2982065|NCT02682784|Experimental|Oxytocin/Cocaine User|Individuals who meet criteria for cocaine use disorder and are randomized to oxytocin.
2982066|NCT02682784|Active Comparator|Placebo/Cocaine User|Individuals who meet criteria for cocaine use disorder and are randomized to placebo.
2982067|NCT02682784|Experimental|Oxytocin/Control|Healthy controls who are randomized to oxytocin.
2982068|NCT02682784|Active Comparator|Placebo/Control|Healthy controls who are randomized to placebo.
2982069|NCT02682771|Active Comparator|Control|Individuals were treated with Conventional Respiratory Physiotherapy (CRP), twice in immediate postoperative day and three times in first postoperative day.
2982070|NCT02682771|Experimental|Bilevel positive airway pressure|Individuals were treated with positive pressure, in the BIPAP mode (bilevel positive airway pressure, with inspiratory pressure:12 cmH20 and expiratory pressure: 8 cmH20) twice in the immediate postoperative day and three times in first postoperative day, in sessions 1 hour each
2982071|NCT02682771|Experimental|Load inspiratory breathing exercises|Individuals were treat with PowerBreathe, a device for inspiratory muscle, with 40% maximal inspiratory pressure, measured at preoperative, twice in the immediate postoperative day and three times in first postoperative day, in sessions 1 hour each.
2982072|NCT02682758|Other|Patients of normal weight|Patients undergoing routine xenon-based general anaesthesia for surgery with a body mass index of less than 30.
2982073|NCT02682758|Other|Obese patients|Patients undergoing routine xenon-based general anaesthesia for surgery with a body mass index equal to or more than 30.
2982074|NCT02682745|Experimental|R-T1-T2|First period: administration of reference drug, Second period: administration of test drug l, Third period : administration of test drug ll
2982075|NCT02682745|Experimental|R-T2-T1|First period : administration of reference drug, Second period : administration of test drug ll, Third period : administration of test drug l
2982076|NCT02682745|Experimental|T1-T2-R|First period : administration of test drug l, Second period : administration of test drug ll, Third period : administration of reference drug
2982077|NCT02682745|Experimental|T1-R-T2|First period : administration of test drug l, Second period : administration of reference drug, Third period : administration of test drug ll
2982078|NCT02682745|Experimental|T2-R-T1|First period : administration of test drug ll, Second period : administration of reference drug, Third period : administration of test drug l
2982079|NCT02682745|Experimental|T2-T1-R|First period : administration of test drug ll, Second period : administration of test drug l, Third period : administration of reference drug
2982080|NCT02682732|Experimental|FDG-PET/CT|(Fluorodeoxyglucose positron-emission tomography) FDG-PET/CT guided bone marrow sampling will be performed at diagnosis and at the end of induction chemotherapy (like cytarabine and daunorubicin). Then, patients will be followed to assess their response, and imaging-guided bone marrow sampling will be repeated in the likely event of disease relapse.
2982125|NCT02682498|Active Comparator|EXPAREL® Bupivacaine Liposome Suspension|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-Liposomal Bupivicaine will be administered at the end of the surgery. A new sustained-release local anesthetic solution (Bupivacaine Liposome Injectable Suspension) will be injected into the soft tissues around the join after surgery. Exparel is a novel-composition of bupivacine in which the drug is dissolved into liposomes which release it slowly over a period of 72 hours.
2982081|NCT02682719|Experimental|Valsartan/Sacubitril (LCZ696)|"Valsartan/Sacubitril (LCZ696) plus placebo to Valsartan. Standard dosing regime: LCZ696 100mg twice daily for two weeks then increased to 200mg twice daily for the remainder of the study.~Lower dosing regimen (for patients not taking an ARB or ACE inhibitor, subjects previously taking low doses of these agents and for subjects with a systolic BP of ≥100mm to 110mmHg at screening or baseline): LCZ696 50mg twice daily for two weeks then increased to 100mg twice daily for two weeks then further increased to 200mg twice daily for the remainder of the study."
2982082|NCT02682719|Active Comparator|Valsartan|"Valsartan plus placebo to Valsartan/Sacubitril (LCZ696). Standard dosing regime: Valsartan 80mg twice daily for two weeks then increased to 160mg twice daily for the remainder of the study.~Lower dosing regimen (for patients not taking an ARB or ACE inhibitor, subjects previously taking low doses of these agents and for subjects with a systolic BP of ≥100mm to 110mmHg at screening or baseline): Valsartan 40mg twice daily for two weeks then increased to 80mg twice daily for two weeks then further increased to 160mg twice daily for the remainder of the study."
2982083|NCT02682693|Experimental|Denosumab|Denosumab every 4 weeks for 6 cycles.
2982084|NCT02682693|Experimental|nab-Paclitaxel weekly|nab-Paclitaxel weekly for 12 weeks. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab. Patients with triple-negative tumors receive Carboplatin in parallel to nab-paclitaxel.
2982085|NCT02682693|Experimental|nab-paclitaxel 2 of 3 weeks|nab-Paclitaxel day 1,8 q22 for 12 weeks. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab. Patients with triple-negative tumors receive Carboplatin weekly in parallel to nab-paclitaxel.
2982086|NCT02682693|Experimental|EC every two weeks or every three weeks|Epirubicin and Cyclophosphamide 600mg/m² for 4 times. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab.
2982087|NCT02682680|Experimental|Colesevelam|Colesevelam 3.75 g daily (tablets or oral suspension) for 24 weeks
2982088|NCT02682680|Active Comparator|Ezetimibe|Ezetimibe 10 mg once daily for 24 weeks
2982089|NCT02682667||1/Cohort 1|Patients with cancer or a premalignant condition
2982090|NCT02682654|Experimental|Ankle/Knee brace|Dr. Scholl's Prototype Ankle or Knee Brace
2982091|NCT02682641|Experimental|IBRUTINIB + RITUXIMAB|"Subjects will receive the ibrutinib in combination with rituximab according to the following schedule:~Ibrutinib 560 mg daily po until disease progression or unacceptable toxicity. In case of sustained negative MRD (at least for 6 months) after 2 years of continuous therapy, ibrutinib will be discontinued.~Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1). Rituximab 375 mg/m2 iv, day one of every cycle 3, 5, 7 and 9."
2982092|NCT02682628|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2982093|NCT02682615||requirement of norepinephrine|requirement of norepinephrine <0,1 µg/kgKG/min versus ≥0,1 µg/kgKG/min
2982094|NCT02682602||Diseased/Implanted Hip|Subjects will have a diseased hip which requires replacement, which will be implanted with either DePuy Synthes Summit/Pinnacle total hip arthroplasty (THA) or the Corail/Pinnacle THA.
2982095|NCT02682602||Normal Hip|Subjects will have a normal hip.
2982096|NCT02682589|Active Comparator|Open surgery|Patients undergo open CME. A standard midline incision carefully protected is made through the abdominal wall and the abdominal cavity is explored. A colectomy with CME is performed with the removal of the afflicted colon and its accessory lymphovascular supply at their origins by resecting the colon and mesocolon in an intact envelope of visceral peritoneum and mesenteric fascia.
2982097|NCT02682589|Experimental|Laparoscopic surgery|Patients undergo laparoscopic CME. A small infraumbilical incision is made through the abdominal skin and the abdominal cavity is insufflated with carbon dioxide to allow access and visualization. The abdominal cavity is explored. A colectomy with CME is performed using laparoscopic-assisted techniques. A 6-8cm midline auxiliary incision is made for specimen extraction and anastomosis.
2982098|NCT02682576|Experimental|Brachial artery ultrasound imaging|Brachial artery ultrasound imaging is a non-invasive procedure for detecting endothelial dysfunction by measuring the flow-mediated dilation of the brachial artery using high resolution continuous electrocardiogram-gated B-mode (2D) ultrasound imaging during reactive hyperemia.
2982099|NCT02682563|Experimental|Dapagliflozin 10mg once daily|Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.
2982100|NCT02682563|Active Comparator|Gliclazide modified release 30mg once daily|Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.
2982101|NCT02682550||Ctrl|healthy volunteers, sex- and age matched Blood drawing at one time point: 20 ml
2982102|NCT02682550||PT|"polytrauma patients fulfilling the following criteria:~injury severity score ≥25~age ≥ 18 Blood drawing at admission to the emergency room, 8 h, 24h, 48 h, 120 h and 240 h post trauma: 20 ml"
2982103|NCT02682537||Female, BMI: 14,00-16,49 kg/m²|Age: 18 - 100 Years
2982104|NCT02682537||Female, BMI: 16,50-18,49 kg/m²|Age: 18 - 100 years
2982105|NCT02682537||Female, BMI: 18,50-19,99 kg/m²|Age: 18 - 100 years
2982106|NCT02682537||Female, BMI: 20,00-24,99 kg/m²|Age: 18 - 100 years
2982107|NCT02682537||Female, BMI: 25,00-29,99 kg/m²|Age: 18 - 100 years
2982108|NCT02682537||Female, BMI: 30,00-34,99 kg/m²|Age: 18 - 100 years
2982109|NCT02682537||Female, BMI: 35,00-39,99 kg/m²|Age: 18 - 100 years
2982110|NCT02682537||Female, BMI: 40,00-44,99 kg/m²|Age: 18 - 100 years
2982111|NCT02682537||Female, BMI: 45,00-49,99 kg/m²|Age: 18 - 100 years
2982112|NCT02682537||Male, BMI: 14,00-16,49 kg/m²|Age: 18 - 100 years
2982113|NCT02682537||Male, BMI: 16,50-18,49 kg/m²|Age: 18 - 100 years
2982114|NCT02682537||Male, BMI: 18,50-19,99 kg/m²|Age: 18 - 100 years
2982115|NCT02682537||Male, BMI: 20,00-24,99 kg/m²|Age: 18 - 100 years
2982116|NCT02682537||Male, BMI: 25,00-29,99 kg/m²|Age: 18 - 100 years
2982117|NCT02682537||Male, BMI: 30,00-34,99 kg/m²|Age: 18 - 100 years
2982118|NCT02682537||Male, BMI: 35,00-39,99 kg/m²|Age: 18 - 100 years
2982119|NCT02682537||Male, BMI: 40,00-44,99 kg/m²|Age: 18 - 100 years
2982120|NCT02682537||Male, BMI: 45,00-49,99 kg/m²|Age: 18 - 100 years
2982121|NCT02682524|Active Comparator|test|
2982122|NCT02682524|Active Comparator|reference|
2982126|NCT02682498|Active Comparator|Standard periarticular joint injection|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
2982127|NCT02682485|Experimental|Cipro, metronidazole, neomycin combo|As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with a direct topical antibiotics solution composed of metronidazole, ciprofloxacin and neomycin.
2982128|NCT02682485|Placebo Comparator|Saline|As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with direct topical saline.
2982129|NCT02682472|Experimental|SettleIN|SettleIN - Adjustment to care programme intervention
2982130|NCT02682459|Experimental|Lisinopril|Patients will receive, in addition to standard immunosuppressive therapy, lisinopril starting with 5 mg/day, then progressively up-titrated to reach the maximum tolerable dose (target dose) for 18 months.
2982131|NCT02682459|No Intervention|No intervention|Patients will receive only the standard immunosuppressive therapy.
2982132|NCT02682446||Negative H. pylori group|The participants revealed negative findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
2982133|NCT02682446||Previous H. pylori infection group|The participants revealed positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
2982134|NCT02682446||Eradicated H. pylori group|The participants revealed to success for H. pylori eradication in those who were positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
2982135|NCT02682446||Persistent H. pylori group|The participants revealed to fail in H. pylori eradication in those who were positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
2982136|NCT02682433|Experimental|diagnostic hysteroscopy|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, and in the same position, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
2982137|NCT02682433|Experimental|diagnostic sonar test|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, and in the same positionabdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
2982138|NCT02682420|Other|endoAVF|
2982139|NCT02682407|Experimental|OMS721|Administration of OMS721.
2982140|NCT02682407|Other|Vehicle (D5W)|Administration of Vehicle (D5W).
2982141|NCT02682381|Experimental|A|0.025 mg/kg/day of teduglutide for 24 weeks
2982142|NCT02682381|Experimental|B|0.05 mg/kg/day of teduglutide for 24 weeks
2982143|NCT02682381|Active Comparator|C|Observational cohort for the 24-week treatment period and 4 week follow-up. The subjects in the standard of care group will follow the same visit schedule as the randomized subjects.
2982144|NCT02682368|Experimental|POCUSS Trial-1 Acute Biliary Disease|Patients with suspected biliary pathology which will undergo POCUS. The results will be compared to the subsequent findings by imagistic means or at time of surgery.
2982145|NCT02682368|Experimental|POCUSS Trial-2 Acute Diverticulitis|Patients with suspected diverticulitis will undergo POCUS. The results will be compared to the subsequent findings by imagistic means or at time of surgery.
2982146|NCT02682368|Active Comparator|Radiology Report|Departmental imaging and reports.
2982147|NCT02682368|Active Comparator|Surgical diagnostic|Intraoperative findings of patients that undergo emergency surgery.
2982148|NCT02682355||Study cohort|Patients receiving IV polymyxin B for treatment of pneumonia and/or bloodstream infection
2982149|NCT02682342||Healthy Subjects|Healthy subjects meeting inclusion criteria will be administered a 75 g glucose solution one time (orally). Subjects will be ages 21-70 years with no evidence of diabetes, hypertension, metabolic syndrome, or high cholesterol at the time of screening. Potential subjects with a history of atherosclerotic disease, chronic renal insufficiency (plasma creatinine > 1.5 men, > 1.5 women), liver enzymes > 2.5x normal, pregnant at the time of screening will be excluded
2982150|NCT02682329|Active Comparator|CP 10% + HP 40%|Carbamide Peroxide 10% + Hydrogen Peroxide 40% were administered to each patient on this group. CP at home and HP at office
2982151|NCT02682329|Active Comparator|CP 15% + HP 40%|Carbamide Peroxide 15% + Hydrogen Peroxide 40% were administered to each patient on this group.CP at home and HP at office
2982152|NCT02682329|Active Comparator|CP 20% + HP 40%|Carbamide Peroxide 20% + Hydrogen Peroxide 40% were administered to each patient on this group.CP at home and HP at office
2982153|NCT02682329|Active Comparator|HP 10% + HP 40%|Hydrogen Peroxide 10% + Hydrogen Peroxide 40% were administered to each patient on this group. HP at Home and HP at office
2982154|NCT02682316|Active Comparator|usual standard dry gauze used for wound management|Patients who are randomized to the standard dry gauze arm will have the standard dry gauze placed at time of wound closure. Their dressing will be removed on post-operative day 2 as per routine departmental practice.
2982305|NCT02681289|Experimental|physiotherapy group|Early goal directed neuromotor therapy applied by physiotherapist
2982155|NCT02682316|Experimental|Prevena Negative Pressure Wound Therapy System (NPWT)|Patients who are randomized to the Prevena Therapy System arm will have the Prevena Incision Management System device placed at time of wound closure. The device will be removed on day of discharge from the hospital or post-operative day 7, whichever comes first.
2982156|NCT02682303|Experimental|elastic bandage|In this study, Idealplast C® (6cm*2.5m) was used.
2982157|NCT02682303|Placebo Comparator|Non-standardized tape (NST)|In the NST group, Pretape Cramer® (100% cotton, 1.25cm*10m) was used.
2982158|NCT02682290|Other|rheological measurement of sputum|"patients with COPD and patient with cystic fibrosis will perform a spontaneous expectoration.~Then all participants will have an induced expectoration with hypertonic salin solution."
2982159|NCT02682277|Active Comparator|Medical device polyglucosamine|2 times daily 2 polyglucosamine tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity
2982160|NCT02682277|Placebo Comparator|Placebo|2 times daily 2 placebo tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity
2982161|NCT02682264|Experimental|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) Cream, 1%, applied twice daily to whole face (about 1 gram) and affected areas of trunk (if applicable) for up to an additional 9 months. Over the course of the study, treatment on the face and/or trunk may be discontinued if/when acne clears and re-started if/when acne worsens, according to the assessment of the investigator for each respective treatment area.
2982162|NCT02682251|Experimental|Heart Failure Patients with CRT-CIED|PHR Messaging to notify patient of device transmitted information (i.e. percentage LV pacing)
2982163|NCT02682238|Experimental|BBI-4000, 15%|15% BBI-4000 (sofpironium bromide) topical gel
2982164|NCT02682238|Placebo Comparator|Vehicle|Vehicle (placebo) gel
2982165|NCT02682225|Experimental|Sequence 1: Qualification Session|Participants will receive Treatment A (intravenous placebo and intranasal placebo concurrently) on Day 1 and Treatment B (0.5 milligram per kilogram (mg/kg) of intravenous racemic ketamine and intranasal placebo concurrently) on Day 2.
2982166|NCT02682225|Experimental|Sequence 2: Qualification Session|Participants will receive Treatment B (0.5 mg/kg of intravenous racemic ketamine and intranasal placebo concurrently) on Day 1 and Treatment A (intravenous placebo and intranasal placebo concurrently) on Day 2.
2982167|NCT02682225|Experimental|Sequence 3: Treatment Phase|Participants in Sequence 3 will receive Treatment A (intravenous placebo and intranasal placebo) on Day 1 of period 1, Treatment D (intravenous placebo and intranasal 112 milligram (mg) of esketamine as 4 devices, each with 28 mg esketamine) on Day 1 of period 2, Treatment B (0.5 mg/kg of intravenous racemic ketamine and intranasal placebo) on Day 1 of period 3, Treatment C (intravenous placebo and intranasal 84 mg esketamine as 3 devices, each with 28 mg esketamine followed by 1 device with placebo) on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
2982168|NCT02682225|Experimental|Sequence 4: Treatment Phase|Participants in Sequence 4 will receive Treatment B on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment C on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
2982169|NCT02682225|Experimental|Sequence 5: Treatment Phase|Participants in Sequence 5 will receive Treatment C on Day 1 of period 1, Treatment B on Day 1 of period 2, Treatment D on Day 1 of period 3, Treatment A on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
2982170|NCT02682225|Experimental|Sequence 6: Treatment Phase|Participants in Sequence 6 will receive Treatment D on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment B on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
2982171|NCT02682212|Experimental|Physiotherapy intervention|Intensive pelvic floor muscle training (PFMT) given by a physiotherapist with vaginal/rectal pressure feedback once a week for 12 weeks.
2982172|NCT02682212|No Intervention|No intervention|Standard care
2982173|NCT02682199||Whole Brain Radiation|Patients scheduled to receive whole brain radiation with or without chemotherapy/targeted therapy.
2982174|NCT02682186|No Intervention|Control group (1)|The PECS Blocks are not (1) performed.
2982175|NCT02682186|Experimental|PECS group (2)|The PECS Blocks are performed (2): A single injection of Ropivacaine after dilution with sodium chloride 0.9% per fascial plane and per side.
2982176|NCT02682173|Active Comparator|Laparoscopic gastric bypass|MR Abdomen in morbidly obese patients receiving gastric bypass
2982177|NCT02682173|Active Comparator|Laparoscopic sleeve gastrectomy|MR Abdomen morbidly obese patients receiving sleeve gastrectomy
2982178|NCT02682160|Other|Use of Protein Assistant|patients can use the Protein Assistant during 2 months to evaluate the quantity of protein's intake.
2982179|NCT02682147|No Intervention|Hypoxia study group|40 subjects will recruited to study normoxia compared to hypoxia and normoxia compared to hyperoxia. 20M and 20F subjects will be evaluated in each group under normoxia with low dose non-contrast CT at total lung capacity (TLC) and 20% vital capacity (VC) and then with contrast using dual energy CT to evaluate heterogeneity of perfused blood volume (PBV). Following the normixia scans, in 40 of the subjects hypoxia will be induced by breathing an inspired FIO2 of 15%. or hyperoxia will be induced by breathing an inspired FIO2 of 100%. During hypoxia or hyperoxia the non-contrast and PBV scans mentioned under normoxia will be repeated.
2982180|NCT02682147|No Intervention|Hyperoxia Study Group|40 subjects will recruited to study normoxia compared to hypoxia and normoxia compared to hyperoxia. 20M and 20F subjects will be evaluated in each group under normoxia with low dose non-contrast CT at TLC and 20% vital capacity (VC) and then with contrast using dual energy CT to evaluate heterogeneity of perfused blood volume (PBV). Following the normixia scans, in 40 of the subjects hypoxia will be induced by breathing an fraction of inspired oxygen FIO2 of 15%. or hyperoxia will be induced by breathing an inspired FIO2 of 100%. During hypoxia or hyperoxia the non-contrast and PBV scans mentioned under normoxia will be repeated.
2982181|NCT02682147|Experimental|PAV Study Group|40 subjects (20M and 20F) will be studied with non-contrast imaging at TLC and 20%VC and with contrast using DECT to assess PBV as above. Following these baseline studies, the subject will be taken to the clinical research unit and administered of 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
2982182|NCT02682134|Experimental|"Xylocaine X"|Patients received xylocaine gel as lubricant on endotracheal tube
2982183|NCT02682134|Experimental|"Dexamethasone D"|Patients were given dexamethasone 8 mg intravenously
2982184|NCT02682134|Experimental|"xylocaine and dexamethasone XD"|Patients were given both xylocaine gel and dexamethasone 8 mg intravenously
2982185|NCT02682121|Placebo Comparator|Placebo|Patients on placebo.
2982186|NCT02682121|Active Comparator|Active drug|Patients on Metformin, 850mg twice daily for 6mos.
2982187|NCT02682108|Other|Diffusion-weighted imaging|Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
2982188|NCT02682095||Patients: achieved BP control|Patients who have achieved blood pressure control (≤140/90 mmHg)
2982189|NCT02682095||Patients: not achieved BP control|Patients who have not achieved blood pressure control (>140/90 mmHg)
2982190|NCT02682095||Individual interviews|Hypertensive patients who have considered changing lifestyle regarding one or more of the areas of tobacco, alcohol, diet, physical activity or stress.
2982191|NCT02682095||Focus-group interviews|Hypertensive patients
2982192|NCT02682082|Experimental|Neurolysis without Bupivacaine|Experimental Group: Endoscopic ultrasound guided celiac plexus Neurolysis without Bupivacaine so only with Absolute Alcohol 20 mL
2982193|NCT02682082|Active Comparator|Neurolysis with Bupivacaine|Endoscopic ultrasound guided celiac plexus Neurolysis with Bupivacaine (0.5% Bupivicaine 20mL + Absolute Alcohol 20 mL)
2982194|NCT02682069|Experimental|All patients|There is one arm to this study and all patients will undergo the same procedures. The test of this technology is on a per wound basis where bacteria will fluoresce red and samples will be obtained from the discrete red locations. Microbiology results indicating the presence or absence of bacteria will be correlated to the fluorescence signal in the fluorescent images.
2982195|NCT02682056|Other|Single Study Arm|Children and adolescents with diabetes will have blood glucose levels tested using microneedle patches, intravenous (IV) catheter draw, and lancet.
2982196|NCT02682043|Experimental|Toy car|The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.
2982197|NCT02682030|Active Comparator|Treatment group A|Subjects randomized to group A will be fitted for and issued a mechanical High Frequency Chest Compression Device (HFCC) device for home use. Subjects will be instructed to use the HFCC device 2-3 times per day for 15-30 minutes each. Subjects will be instructed to keep a device usage, concomitant medication, and adverse event diary.
2982198|NCT02682030|Active Comparator|Treatment group B- HFCC and Cough Assist|Subjects randomized to group B will be fitted for and issued a mechanical High Frequency Chest Compression Device (HFCC) device and will also be issued a cough assist device. Subjects will be instructed in the use of both devices. The HFCC device should be utilized 2-3 times per day for 15-30 minutes each followed by a session with the cough assist. Subjects will be instructed to keep a device usage, concomitant medication, and adverse event diary.
2982199|NCT02682017|Placebo Comparator|Treatment 1|Pork meat from pigs feed with a standard feed
2982200|NCT02682017|Experimental|Treatment 2|Pork meat from pigs fed a feed with a Laminarin/fucoidan mix
2982201|NCT02682004||Women with postpartum depression|
2982202|NCT02682004||Women without postpartum depression|
2982203|NCT02681991|Experimental|test|Renamezin capsule 2g, tid, PO
2982204|NCT02681978|Active Comparator|Ivabradine group|Ivabradine 5 mg twice daily + standard medical therapy
2982205|NCT02681978|Other|Control group|Standard medical therapy
2982206|NCT02681965|Experimental|LEAN|Participants randomized to the weight loss program will initially receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity. Written instructions in the LEAN book will include recording daily diet and exercise in the logs. At the end of the study, participants will return, via a stamped addressed envelope, the logs to the study office so compliance can be assessed.
2982207|NCT02681965|No Intervention|Waitlist Control|Participants randomized to the waitlist control study arm will be mailed the six-month questionnaires, which will include reporting of weight. On return of the 6-month questionnaires each woman will be provided with the entire weight loss program packet.
2982208|NCT02681952|Active Comparator|Renamezin->Kremezin|
2982209|NCT02681952|Active Comparator|Kremezin->Renamezin|
2982210|NCT02681939|Experimental|Tulsi|One capsule of Tulsi (Ocimum sanctum) orally, every morning and evening in empty stomach for 60 days regularly.
2982211|NCT02681939|No Intervention|No Tulsi|No intervention
2982212|NCT02681926||Average force group|A recent tool, called VISITAG, has been developed (and approved by EMEA) for Biosense Webster Navistar Smart Touch catheter in order to allow collection of ablation points with pre-determined characteristics, such as stability of catheter during ablation, mean contact force, drop in impedance. In the Average Force group, the operators decided to use the mean contact force as target parameter indicating a good lesion.
2982213|NCT02681926||Force Time Integral group|In the Force Time Integral (FTI) group, the operators decided to use the FTI as target parameter indicating a good lesion.
2982214|NCT02681913|No Intervention|standard cardioplegia|"Delivery of cardioplegic solutions will be according to the standard protocol (Amphia hospital, Breda, the Netherlands). Oxygenated blood and cardioplegic maintenance solution is delivered in a 20:1 ratio. Cardioplegic solutions will be administered at 20-minutes intervals. The flow of the cardioplegia must be at 300 ml/min, the duration is approximately 1 minute.~The cardioplegic maintenance solution consists of a 500 ml normal saline (0.9% NaCl) infusion bag. Potassiumchloride (20 mmol) and magnesiumsulphate (1000 mg) is added according to standard protocol.~This arms receives standard intermittent 20:1 diluted warm blood cardioplegic solution.~Intervention: n/a"
2982306|NCT02681289|Experimental|family group|Early goal directed neuromotor therapy applied by family
2982415|NCT02680535|Experimental|AuroShell particle infusion|Single intravenous infusion of AuroShell particles 12 to 36 hours prior to ultrasound-guided laser irradiation using a FDA cleared laser and an interstitial optical fiber.
2982215|NCT02681913|Experimental|adenosine enriched cardioplegia|"Delivery of cardioplegic solutions will be according to the standard protocol (Amphia hospital, Breda, the Netherlands). Oxygenated blood and cardioplegic maintenance solution is delivered in a 20:1 ratio. Cardioplegic solutions will be administered at 20-minutes intervals. The flow of the cardioplegia must be at 300 ml/min, the duration is approximately 1 minute.~The cardioplegic maintenance solution consists of a 1000 mg = 500 ml adenosine infusion bag (2 mg/ml). Potassiumchloride (20 mmol) and magnesiumsulphate (1000 mg) is added according to standard protocol.~This arms receives adenosine enriched, intermittent 20:1 diluted warm blood cardioplegic solution.~Intervention: Drug: Adenosine"
2982216|NCT02681900|Experimental|Self-affirmation|Participants in the self-affirmation arm write about their most important value, reasons why is important and an example of when they enacted that value. This is the Self-affirmation manipulation task as described in the intervention.
2982217|NCT02681900|Active Comparator|Control|Participants in this arm complete a control equivalent of the self-affirmation task, where they write about their least important value, reasons why is may be important to someone else and an example of when another person may have enacted that value. This is the Control task as described in the intervention.
2982218|NCT02681887|Placebo Comparator|Placebo|Placebo tablet identical to Circadin by mouth each day before bedtime for 12 weeks
2982219|NCT02681887|Experimental|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
2982220|NCT02681874|Experimental|Group A (Treatment Arm)|The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Sessions are 90 minutes. Groups consist of a maximum of five parents. Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions. Parent Leaders receive a week-long leadership training to deliver the program and will be supervised by the PI who is a licensed clinical psychologist.
2982221|NCT02681874|Active Comparator|Group B (Control Arm)|Parents in the control condition will receive the Smart and Secure Children (SSC) program's written handouts. Handouts include didactic curriculum content and instruct parents to write goals and document goal progress.
2982222|NCT02681861|Experimental|Part 1: ASP6294 Single Ascending Intravenous Doses|A dose escalation design will be implemented. Successive cohorts of patients (8 participants/cohort) will each be started on a fixed dose of ASP6294 or Placebo intravenously. If no dose limiting toxicities are observed escalation to the next higher dose is planned approximately every 3 weeks. Within the planned dose range, a dose lower than the next planned dose may be tested, or a dose level may be repeated, depending on emerging safety, tolerability and/or other relevant data, such as available pharmacokinetic and pharmacodynamic data of previous dose levels.
2982223|NCT02681861|Experimental|Part 2: ASP6294 Single Ascending Subcutaneous Doses|A dose escalation design will be implemented. Successive cohorts of patients (8 participants/cohort) will each be started on a fixed dose of ASP6294 or Placebo subcutaneously. The subcutaneous cohorts may be done in parallel with part 1, using doses which have been proven to be safe and tolerable. Within the planned dose range, a dose lower than the next planned dose may be tested, or a dose level may be repeated, depending on emerging safety, tolerability and/or other relevant data, such as available pharmacokinetic and pharmacodynamic data of previous dose levels.
2982224|NCT02681835|Experimental|Position 1|Standard position during intubation. Intubator is behind head of the victim, propped up on both elbows
2982225|NCT02681835|Experimental|Position 2|Intubator is behind head of the victim, lies on the left side
2982226|NCT02681835|Experimental|Position 3|Intubator stands astride the victims, intubated using the face-to-face
2982227|NCT02681822||Healthy young subjects|Healthy young Chinese Han subjects aged 18-30
2982228|NCT02681809|Experimental|Ocriplasmin 0.0625mg|
2982229|NCT02681809|Experimental|Ocriplasmin 0.125mg|
2982230|NCT02681809|Sham Comparator|Sham injection|
2982231|NCT02681796|Experimental|Study: Bupivacaine Epidural + standard of care pain regimen|-The study group will receive a T6 to T8 level epidural catheter in addition to the standardized pain regimen. Epidurals used in this study will contain a 0.125% bupivacaine-only infusion
2982232|NCT02681796|No Intervention|Control: Standard of care pain regimen|-The control group will receive a standardized pain regimen including an opioid patient controlled analgesia (PCA), IV acetaminophen, and IV ketorolac per surgeon's preference
2982233|NCT02681783|Active Comparator|neovascular AMD group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
2982234|NCT02681783|Experimental|CSR group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
2982235|NCT02681783|Experimental|iPCV group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
2982236|NCT02681783|No Intervention|cataract patients|Patients diagnosed with cataracts requiring cataract surgery will serve as study controls. No intervention will be applied to these patients.
2982237|NCT02681757|Active Comparator|Control- triple antibiotic ointment|triple antibiotic ointment (TAO) impregnated Adaptic gauze, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
2982238|NCT02681757|Experimental|Variable- mepitel Ag|mepitel Ag, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
2982239|NCT02681744|No Intervention|Control Group|These participants will be instructed to maintain their habits during 24 weeks. Before and after the aforementioned period, they will be asked to perform body composition and strength assessments, using DXA and isokinetic dynamometer, respectively.
2982307|NCT02681276|Experimental|Irrigation with 3% NaOCl|After informed consent the patient was randomly assigned to have the root canal treatment performed with a 3 % NaOCl irrigation during instrumentation. If the patient's first visit was on an uneven date the concentration of the irrigant was 3 %.
2982240|NCT02681744|Experimental|Experimental group|Participants from the experimental group will assign to the resistance training program undergo physician screening at rest and under cardiopulmonary exercise test conditions before starting the program. Following a three-week familiarization process, participants undergo one repetition maximum (1-RM) testing for each of the exercises of the training program. This procedure intended to determine exercise load and will be systematically repeated in four-week intervals. Volunteers will train thrice per week during 24 weeks. The training program will involve the following exercises: chest press, lat pulldown, knee extension, hamstrings curl, leg press, hip abduction.
2982241|NCT02681718|Experimental|Community Health Worker education|During a six-month intervention period, the CHWs will conduct six home-based visitations and provide individualized diabetes education using an intensive diabetes lifestyle curriculum called Diabetes Learning Circle (DLC), developed and used by the Sinai Diabetes Education Program. At each visit, lasting for approximately one hour, the participants will be motivated to set SMART behavioral goals for diabetes self-management. At each visit after the initial visit, CHWs will follow-up with each participant to check their progress on their behavioral SMART goals. In addition, the CHWs will conduct intermittent phone calls (at least one monthly) and home visits as needed.
2982242|NCT02681718|Experimental|Cell phone text messaging|The participants in the text messaging group will receive weekly text messages through CareMessage. Each participant will receive 3-4 text messages per week for 6 months.
2982243|NCT02681718|No Intervention|Control|The participants in the control group will receive education as determined by the hospital's diabetes educator, dietitian, physician, or the participant's managed care provider. No additional education will be provided by the research team.
2982244|NCT02681705|Experimental|Study Treatment|All subjects will undergo routine surgical staging of their tumor. Treatment must begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with Temozolomide. Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation therapy are combined as Temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles.
2982245|NCT02681692|Active Comparator|MEI colonoscopy Group|Patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system
2982246|NCT02681692|No Intervention|Standard colonoscopy Group|Patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) without the assistance of magnetic scope navigation system
2982247|NCT02681692|Active Comparator|MEI colon model Group|"Colonoscopist would be randomized to perform colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part.~All force variation data would be recorded by a image storage device."
2982248|NCT02681692|No Intervention|Standard colon model Group|Colonoscopist would be randomized to perform conventional colonoscopy on a colon model without an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
2982249|NCT02681679|Experimental|0.1% bromfenac ophthalmic solution|Patients received 0.1% bromfenac ophthalmic solution twice a day for 3 days before surgery.
2982250|NCT02681679|Placebo Comparator|control physiological normal saline|Patients received control physiological normal saline twice a day for 3 days before surgery.
2982251|NCT02681666|Active Comparator|FODMAPs CONTROL arm|Dietary intervention in this cohort with irritable bowel syndrome will be administered a low Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols diet by a dietician.
2982252|NCT02681666|Experimental|MB-IBS-EAT INTERVENTION STUDY arm|Irritable Bowel Syndrome eating awareness training intervention will be started in a comprehensive 8 weekly sessions of Mindfulness eating training.
2982253|NCT02681653|Active Comparator|Statin|Atorvastatin, 40 mg for 7 days in patients of septic shock admitted to ICU
2982254|NCT02681653|Placebo Comparator|Placebo|Matched placebo, 40 mg for 7 days in patients of septic shock admitted to ICU
2982255|NCT02681640|Experimental|uPAR PET|One injection of 68Ga-NOTA-AE105 followed by Positron Emission Tomography (PET/CT scan) to evaluate possible axillary lymph node metastatic lesions
2982256|NCT02681627|Active Comparator|endometrial scratch|Patient will be randomised to the intervention arm which is the luteal phase endometrial scratch
2982257|NCT02681627|Sham Comparator|touching cervix|Patient will have a speculum examination and cleaning of the cervix with cotton tip with saline but no scratch
2982258|NCT02681614|Experimental|Uronav|"Participants will undergo a Uronav guided biopsy with Magnetic Resonance Imaging confirmation~o All biopsies will be completed in the outpatient setting in the ambulatory OR prior to routine prostate brachytherapy under general anesthesia."
2982259|NCT02681601|Active Comparator|Diet + Nutrawell Powder with Fish Oil|Subjects will be evaluated by a registered dietitian with a diet prescription (55% carbohydrate, 30% fat and 15% protein) including Nutrawell powder with fish oil.
2982260|NCT02681601|Active Comparator|Dietary Intervention Only|Subjects will be evaluated by a registered dietitian with a diet prescription (55% carbohydrate, 30% fat and 15% protein) not including servings of Nutrawell powder with fish oil.
2982261|NCT02681588|Experimental|Obese group|
2982262|NCT02681588|Active Comparator|Normal Weight group|
2982263|NCT02681575|Experimental|Cog-Fun A|Metacognitive-Functional occupational therapy intervention (Cog-Fun - A) includes enhancing self awareness in occupational context, acquiring executive strategies and skills and implementation across multiple occupational domains.
2982264|NCT02681562|Experimental|Olaparib triple negative|Olaparib short administration in triple negative breast cancer
2982265|NCT02681562|Experimental|Olaparib BRCA mutated|Olaparib short administration in BRCA mutated patients
2982266|NCT02681549|Experimental|pembrolizumab plus bevacizumab|
2982308|NCT02681276|Active Comparator|Irrigation with 0.5% NaOCl|After informed consent the patient was randomly assigned to have the root canal treatment performed with a 0.5 % NaOCl irrigation during instrumentation. If the patient's first visit was on an even date the concentration of the irrigant was 0.5 %.
2983600|NCT02672787|Experimental|Intervention|Subjects will receive the ED-based behavioral intervention
2982267|NCT02681536|Experimental|Minidose long protocol|Down-regulation started on day 20 of the previous cycle by GnRH agonist triptorelin (0.5 µg Decapeptyl; Ferring). On the second day of menstruation, when down regulation was confirmed (as evidenced by endometrial thickness <5 mm and/or E2 levels <50 pg/mL) using transvaginal sonography (TVS) by Voluson 730 Pro (GE, Fairfield, CT) apparatus, gonadotropin (Merional; IBSA) was commenced at an initial dose of 300-450 IU/day for the first 5 days followed by individual adjustment in Gn dose according to ovarian response and the dose of Decapeptyl 50µg/day was continued until day of HCG administration.
2982268|NCT02681536|Experimental|microdose flare protocol|OCPs drospirenone /ethinyl estradiol (Yasmin, BAYER) for not less than 21 days before starting ovarian stimulation, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by HMG IM daily (Merional, 75 IU, IBSA) 3 days later. Then the same cycle adjustment was done as the minidose long protocol.
2982269|NCT02681523|Experimental|Single arm study|3 x 3 weekly cycles at the recommended dose of eribulin as the ready to use solution, 1.23 mg/m2, administered intravenously over 2-5 minutes on days 1 and 8 of every 21 day cycle. This will then be followed by 9 weeks of AI treatment, to be followed again by 3 x 3 weekly cycles of eribulin and 9 weeks AI treatment. Patients will remain on treatment for up to 9 months, or until disease progression or unacceptable toxicities, whichever is sooner.
2982270|NCT02681510|Experimental|Three drug intervention|varenicline, nicotine patch and nicotine lozenge for 12 weeks
2982271|NCT02681484|Experimental|Hypertensive|Patients diagnosed with hypertension (I10, either on drug therapy or verified by 24h blood pressure measurements) administered to anthroposophic speech therapy (intervention).
2982272|NCT02681484|Active Comparator|Normotensive|Patients diagnosed with tension headache (G 44.2) or anxiety disorders (F41) administered to anthroposophic speech therapy (intervention).
2982273|NCT02681471|Active Comparator|Monopolar TURP|Patients in Group M (Monopolar) were used monopolar resectoscope (Karl Storz, Tottling, Germany) and 5% Mannitol as an irrigation fluid.
2982274|NCT02681471|Active Comparator|Bipolar TURP|Patients in Group B (Bipolar) were used bipolar resectoscope TURis (OLYMPUS, Tokyo, Japan) and 0,9% Sodium chloride as an irrigation fluid.
2982275|NCT02681458||Drug Users|Case group that consisted of drug users with fungal infections
2982276|NCT02681458||Non-drug Users|Control group that consisted of non drug users with fungal infections
2982277|NCT02681445||Group 1 Healthy Non Smokers|No TB Symptoms No TB History Negative Mantoux test Normal Chest X-ray Non-Smoker
2982278|NCT02681445||Group-2 Smokers|No TB History No TB Symptoms No TB History Negative Mantoux test Smoker 10 + Cigarettes/day
2982279|NCT02681445||HIV Positive|"No TB Symptoms No TB History Negative Mantoux test Normal Chest X-ray HIV Positive~CD4 count >200"
2982280|NCT02681445||TB Suspect Group|WHO Screening Recommendation Protocls Unexplained Cough Sputum production Fever Weight Loss or loss of appetite Night Sweats
2982281|NCT02681445||Lower Respiratory Track Infection|TB Lab test Negative Ab Normal Chest X-ray HIV Negative
2982282|NCT02681432|Experimental|HIPEC|Primary ovarian cancer FIGO stage II, III or IV or recurrent
2982283|NCT02681432|Active Comparator|No HIPEC|Primary ovarian cancer FIGO stage II, III or IV or recurrent
2982284|NCT02681419|Active Comparator|Needle fenestration|Needle fenestration
2982285|NCT02681419|Active Comparator|Suture wick|suture wick using 10-0 vicryl
2982286|NCT02681406|No Intervention|Treatment as Usual|Participants randomized to this condition will continue their schedules and treatments as they had been and just come in to see research staff for research visits.
2982287|NCT02681406|Experimental|Telephone Monitoring and Counseling|TMC - participants receive brief (20 minute) telephone counseling once weekly, then biweekly, etc for 12 months.
2982288|NCT02681406|Experimental|ACHESS|Participants are signed up for an addiction based smart phone application that connects them in an anonymous fashion to a social network of other people in the study who are also struggling with alcohol addiction and sober living.
2982289|NCT02681406|Experimental|TMC + ACHESS|Participants in this arm receive both interventions - the telephone counseling plus the ACHESS phone application.
2982290|NCT02681393|Experimental|Brochure and Telephone Support|Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
2982291|NCT02681393|Active Comparator|Brochure Only|Participants will receive the Aerobic Exercise After Stroke educational brochure only.
2982292|NCT02681380|Experimental|Relation learning|Participants of this group will benefit form a specific learning on relation, Balint like. They will have 7 sessions during 3 months.
2982293|NCT02681380|Placebo Comparator|Control group|Participants of this group will have no learning related to relation with patient.
2982294|NCT02681367|No Intervention|fresh embryo transfer|Patient with RIF underwent ICSI cycle followed by Day 5 fresh embryo transfer.
2982295|NCT02681367|Experimental|Freeze all|Patient with RIF. All of them underwent ICSI cycle, all their embryos were cryopreserved at Day 5 and transferred in a consecutive natural cycle.
2982296|NCT02681354|Experimental|A additional BioRescue training|Using a playful rehabilitation, BioRescue
2982297|NCT02681354|No Intervention|Regular training|
2982298|NCT02681328||Afirma GEC|single molecular test GEC of collected tissue
2982299|NCT02681328||ThyroSeq v.2|single molecular test ThyroSeq v.2 of collected tissue
2982300|NCT02681328||Afirma GSC|single molecular test GSC of collected tissue
2982301|NCT02681328||ThyroSeq v.3|single molecular test ThyroSeq v.3 of collected tissue
2982302|NCT02681315|Experimental|6 liter/min group|Infants will be extubated to a HHHFNC (Fisher and Paykel Healthcare , Auckland, New Zealand) at ﬂow rate of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
2982303|NCT02681315|Active Comparator|3 liter/min group|Infants will be extubated to HHHFNC (Fisher and Paykel Healthcare , Auckland, New Zealand) a ﬂow rate of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
2982304|NCT02681302|Experimental|All Participants|"Ipilimumab 1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22~Nivolumab 3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26"
2982376|NCT02680769|Placebo Comparator|Placebo|placebo group
2982309|NCT02681263|Experimental|Temocillin|"Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.~Total antibiotic treatment between 10 and 14 days according to local guidelines (up to 21 days in immunosuppressed patients)."
2982310|NCT02681250|Experimental|Titanium-zirconium|Patients receiving titanium-zirconium implants
2982311|NCT02681250|Active Comparator|Titanium|Patients receiving titanium implants
2982312|NCT02681237|Experimental|Cediranib and Olaparib|"Cediranib will be given by mouth, at a dose of 20 mg, once a day, everyday.~Olaparib will given by mouth, at a dose of 300 mg, twice a day, every day."
2982313|NCT02681224|Active Comparator|Active Product with Occlusion|TR987 Gel with Silon Bandage
2982314|NCT02681224|Active Comparator|Active Product without Occlusion|TR987 without Silon Bandage
2982315|NCT02681224|Placebo Comparator|Placebo Gel with Occlusion|Placebo Gel with Silon Bandage
2982316|NCT02681224|Placebo Comparator|Placebo Gel without Occlusion|Placebo Gel without Silon Bandage
2982317|NCT02681211|Experimental|Auricular Acupuncture|If assigned to the auricular acupuncture arm, efficacious ear points will be located by a needle contact test and/or an electrical point finder which emits an acoustic alarm when a change in electrical resistance is detected signifying a potential active auricular acupoint.
2982318|NCT02681211|Active Comparator|Medication and Fluid|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
2982319|NCT02681198|Experimental|Lofexidine and paroxetine|Lofexidine in the presence of paroxetine
2982320|NCT02681185|Experimental|Interventional Group|The recruited participants will be provided access to Virtual Care suite via internet and telephone communication.
2982321|NCT02681185|Active Comparator|Standard of Care|The recruited participants will receive the standard of diabetes care as offered by the services in their community.
2982322|NCT02681172|Experimental|Neuraceq (florbetaben 18F) PET scan|"A single dose of 300 Megabecquerels (8.1 millicuries) Neuraceq will be administered per subject.~The applied florbetaben radioactive dose will be ± 20%."
2982323|NCT02681146|Experimental|Group1|Educational advice + physiotherapist treatment
2982324|NCT02681146|Experimental|Group2|Educational advice + physiotherapist treatment
2982325|NCT02681146|Experimental|Group3|Educational advice + physiotherapist treatment
2982326|NCT02681146|Experimental|Group4|Educational advice + physiotherapist treatment
2982327|NCT02681146|Experimental|Group5|Educational advice + physiotherapist treatment
2982328|NCT02681146|Experimental|Group6|Educational advice + physiotherapist treatment
2982329|NCT02681146|Experimental|Group7|Educational advice + physiotherapist treatment
2982330|NCT02681146|Experimental|Group8|Educational advice + physiotherapist treatment
2982331|NCT02681133||patients with knee pain|
2982332|NCT02681120||High risk/BMI > 30|Women at elevated risk for breast cancer will have imaging (MRI and mammogram) pre-bariatric surgery and 1 year post-bariatric surgery, and blood and tissue collection (blood draw and biopsy) pre-bariatric surgery, 2 weeks post-bariatric surgery, and 1 year post-bariatric surgery.
2982333|NCT02681120||Women with normal BMI|Deidentified samples that were donated to the IU Komen Tissue Bank will be used for comparison to the high risk/BMI > 30 cohort.
2982334|NCT02681107|Experimental|Single Arm|Single cohort to receive Accelerated Partial Breast Irradiation (APBI) 27Gy in 5 fractions
2982335|NCT02681094|Active Comparator|Saxagliptin+Dapagliflozin+Metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin
2982336|NCT02681094|Active Comparator|Dapagliflozin+Saxagliptin placebo+Metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Dapagliflozin and Saxagliptin Placebo
2982337|NCT02681094|Active Comparator|Saxagliptin+Dapagliflozin placebo+metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin placebo
2982338|NCT02681081|Other|Control|For sessions 2 through 4, maintain normal eating patterns.
2982339|NCT02681081|Active Comparator|Glucose Administration|For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
2982340|NCT02681081|Active Comparator|Intermittent Fasting|For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
2982341|NCT02681055|Experimental|open label arm|All 40 subjects will receive MN-001 for the first 4 weeks. At Week 4 subjects will increase their dosage frequency for remaining 8 weeks. Subjects will receive MN-001 for a total of 12 weeks.
2982342|NCT02681042|Experimental|SentreHeart Lariat|Left atrial appendage closure with SentreHeart Lariat device
2982343|NCT02681029|Experimental|Blastocyst transplantation|The infertile women who underwent intra- uterus transferring of blastocyst from thawed cleavage embryo
2982344|NCT02681029|Placebo Comparator|Control|The infertile women who underwent intra- uterus transferring of thawed cleavage embryo.
2982345|NCT02681016|Experimental|"Sirolimus-eluting stent Calypso"|"Commercially approved coronary stent system Calypso (Angioline, Russia) Coating - Sirolimus(rapamicine) Stent diameters: 2.0, 2.25, 2.5, 2.75, 3.0, 3.5, 4.0, 4.5 mm. Stent lengths: 8, 13, 15, 18, 23, 28, 33, 38 mm."
2982346|NCT02681016|Active Comparator|"Everolimus-eluting stent Xience Prime"|Commercially approved XIENCE PRIME, (Abbott Vascular, USA) Coating - Everolimus with concentration Stent diameters: 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm. Stent lengths: 8, 12, 15, 18, 23, 28, 33, 38 mm.
2982347|NCT02680990|Active Comparator|Exercise Education|Distribution of exercise education materials
2982348|NCT02680990|Experimental|Band Together|A strength-training and walking program with or without an exercise partner throughout neoadjuvant therapy.
2982377|NCT02680756|Experimental|Oral ferric iron compound|30 mg capsules to be taken orally twice a day for 52 weeks
2982378|NCT02680756|Active Comparator|Intravenous iron|Administered as per the local summary of product characteristics (SPC)
2982416|NCT02680522|Active Comparator|Control Group|composed of healthy volunteers who underwent training with virtual reality. Exercises with game through virtual reality
2983027|NCT02676648|Experimental|Experimental: Condition 8|1) core program; 3) text messages; 4) diet-appropriate food and cookbooks
2982349|NCT02680977|Experimental|MP-Equivalent; MP-Low; MP+DDCI|"MP-Equivalent: Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI (for example 100mg of Madopar corresponds to 500mg of Levodopa in MP).~MP-Low: Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI (for example 100mg of Madopar corresponds to 350mg of Levodopa in MP) MP+DDCI: Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI (for example 100mg of Madopar corresponds to 100mg of Levodopa in MP plus 25mg of Benserazide)"
2982350|NCT02680977|Active Comparator|LD+DDCI; LD-DDCI|"LD+DDCI: Levodopa plus Benserazide (dispersible formulation). The dose is calculated as 3.5mg per kg of body weight.~LD-DDCI: Levodopa without any dopa decarboxylase inhibitor (galenic formulation). The dose is 5-fold than LD+DDCI."
2982351|NCT02680977|Placebo Comparator|Placebo|Powder of groundnuts
2982352|NCT02680951|Experimental|Dose Level 1|"Study participants #1 - #6 receive dose level 1 of dasatinib (60/mg/m2/day) in addition to the standard treatment, for up to 2 courses. Each treatment course is 29 days.~Treatment course 1 consists of:~Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5~Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5~Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5~Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines~Dasatinib orally, once daily on days 6-29~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
2982353|NCT02680951|Experimental|Dose Level 2|"Study participants # 7 - # 12 receive dose level 2 of dasatinib (80/mg/m2/day) in addition to the standard treatment (up to 2 courses), if the participants receiving Dose Level 1 did not experience intolerable side effects. Each treatment course is 29 days.~Treatment course 1 consists of:~Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5~Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5~Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5~Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines~Dasatinib orally, once daily on days 6-29~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
2982354|NCT02680951|Experimental|Dose Level 3|"Study participants # 13 - # 18 receive dose level 3 of dasatinib (100/mg/m2/day) in addition to the standard treatment (up to 2 courses), if the participants receiving Dose Level 2 did not experience intolerable side effects. Each treatment course is 29 days.~Treatment course 1 consists of:~Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5~Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5~Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5~Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines~Dasatinib orally, once daily on days 6-29~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
2982355|NCT02680938|Active Comparator|oxytocin group|10 units of oxytocin will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.
2982356|NCT02680938|Placebo Comparator|control group|1 mL normal saline will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.
2982357|NCT02680925|Placebo Comparator|Conventional ventilation group|Mechanical ventilation is maintained with tidal volume (TV) of 10 ml/kg without PEEP during two-lung ventilation and TV of 8 ml/kg without PEEP during one-lung ventilation. Alveolar recruitment is performed 3 times; after intubation, before one-lung ventilation and after lung resection.
2982358|NCT02680925|Active Comparator|Lung protective ventilation group|Mechanical ventilation is maintained with tidal volume (TV) of 6 ml/kg with PEEP 6 cmH2O during two-lung ventilation and TV of 4 ml/kg PEEP 6 cmH2O during one-lung ventilation. Alveolar recruitment is performed 3 times; after intubation, before one-lung ventilation and after lung resection.
2982359|NCT02680912|Experimental|Warm needle acupuncture|"Warm needle acupuncture (wenzhen; 温针) is where moxa cones are placed on the handle of the needle, after the needle has been inserted. Once lit, heat transmits along the shaft of the needle to the acupuncture point.~Moxa refers to the herb mugwort (Artemisia vulgaris) that is burnt to warm specific parts of the body, including acupuncture points."
2982360|NCT02680912|Active Comparator|Basic needle acupuncture|Basic needle acupuncture is the use of acupuncture needles alone, without other methods of stimulation.
2982361|NCT02680899|Experimental|Curricular Intervention|The intervention is a novel science education curriculum in mental health and addiction called My Mind, My Body.
2982362|NCT02680886||Novosyn® Quick|Skin closure using rapid absorbable suture material
2982363|NCT02680873|Other|SASI bypass|sleeve gastrectomy done and gastro-ileum anastomosis 2.5 meter from the ileocecal valve . the anastomosis is less than 3cmm in diameter . the concept to push undigested food early to the ileum to stimulate intestinal hormones secretion to control diabetes .
2982364|NCT02680847|Experimental|ALO-02|One arm, open label, active
2982365|NCT02680834|Experimental|Dual Action Pneumatic Compression Device|ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks.
2982366|NCT02680834|Active Comparator|Multi-layer bandaging|PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks.
2982367|NCT02680821|Other|Isolated ACL-revision|The standard operation with an isolated Anterior cruciate ligament.
2982368|NCT02680821|Other|Combined ACL and ALL surgery|An operation with an Anterior cruciate ligament combined with an anterolateral ligament.
2982369|NCT02680808|Experimental|midazolam with F901318|Pharmacokinetic profile of midazolam 2 mg orally when given after dosing with F901318 to steady state.
2982370|NCT02680795|Experimental|Wild Type UGT1A1|"Cohort A:~Wild Type UGT1A1, Belinostat IV"
2982371|NCT02680795|Experimental|Heterozygous UGT1A1*28|"Cohort B:~Heterozygous UGT1A1, Belinostat IV"
2982372|NCT02680795|Experimental|Homozygous UGT1A1*28|"Cohort C:~Homozygous UGT1A1, Belinostat IV"
2982373|NCT02680782|Experimental|X4P-001 QD|Subjects will receive study drug in two dosing periods. In this arm subjects will receive drug once daily in the first period, followed by twice daily in the second dosing period.
2982374|NCT02680782|Experimental|X4P-001 BID|Subjects will receive study drug in two dosing periods. In this arm subjects will receive drug twice daily in the first period, followed by once daily in the second dosing period.
2982375|NCT02680769|Experimental|Magnesium|300 mg of citrate Mg/daily
2982379|NCT02680743|Experimental|Intervention Group|"Patients who fail newborn hearing screen will be screened for CMV by saliva PCR. If positive they will be referred for early hearing screen follow-up and early intervention.~They will also receive a consult with PEdiatric Infectious Disease to evaluate need for treatment.~Intervention:Education of parents to pursue prompt hearing screening."
2982380|NCT02680730|Experimental|Intervention only|Participants will be included in 1 pre-intervention and 2 post-assessment measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 60 minutes per day, for 5 consecutive days.
2982381|NCT02680730|Experimental|Intervention + Stability|Participants will be included in 2 pre-intervention and 2 post-assessment measures. The additional pre-intervention assessment will allow for assessment of stability of measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 60 minutes per day, for 5 consecutive days.
2982382|NCT02680717|Active Comparator|Treatment 1|Calcipotriene 0.005% ointment
2982383|NCT02680717|Active Comparator|Treatment 2|Clobetasol 0.05% ointment
2982384|NCT02680717|Active Comparator|Treatment 3|Tacrolimus 0.1% ointment
2982385|NCT02680704|Other|PEEP Titration Arm|PEEP titrated mechanical ventilation
2982386|NCT02680691|Experimental|Robot, then conventional training|Robot assisted gait training 4 weeks after conventional gait training
2982387|NCT02680691|Active Comparator|Conventional, then robot training|Conventional gait training 4 weeks after robot assisted gait training
2982388|NCT02680678|Active Comparator|Colloid preload|20 patients each patient receives 7 ml/kg of gelatin solution (gelofusin) 15 minutes before spinal anesthesia.
2982389|NCT02680678|Active Comparator|Colloid Co-load|20 patients each patient receives 7 ml/kg of gelatin solution (gelofusin) beginning with spinal anesthesia.
2982390|NCT02680678|Active Comparator|Crystalloid Preload|20 patients each patient receives 20 ml/kg of Ringer's lactate solution 15 minutes before spinal anesthesia.
2982391|NCT02680678|Active Comparator|Crystalloid Co-load|20 patients each patient receives 20 ml/kg of Ringer's lactate solution beginning with spinal anesthesia.
2982392|NCT02680652||CVID|Patients with a diagnosis of Common Variable Immune Deficiency
2982393|NCT02680652||Healthy Controls|age matched healthy controls
2982394|NCT02680639|Active Comparator|optimal EPAP determination|On the BiPAP Synchrony ventilator the EPAP (and IPAP) will be automatically adjusted by the ventilator to find optimal EPAP that abolishes EFL. Peak-to-Peak pressure oscillations will be set at 2.5 cmH2O (centimeters of water)
2982395|NCT02680639|Experimental|Optimized EPAP w/ no peak-to-peak|On the BiPAP Synchrony ventilator the EPAP (and IPAP) will be set at optimal pressure as determined by the Auto EPAP. Peak-to-Peak pressure oscillations will be set at 0 cmH2O (centimeters of water)
2982396|NCT02680639|Experimental|Optimized EPAP w/ max peak-to-peak|On the BiPAP Synchrony ventilator EPAP (and IPAP) will be set at optimal pressure as determined by the Auto EPAP. Peak-to-Peak pressure oscillations will be set at 5 cmH2O (centimeters of water)
2982397|NCT02680639|Experimental|non-optimized EPAP w/ no peak-to-peak|On the BiPAP Synchrony ventilator EPAP will be set at 4cmH2O and IPAP will be set at 10cmH2O (centimeters of water). Peak-to-Peak pressure oscillations will be set at 0 cmH2O (centimeters of water).
2982398|NCT02680626|Experimental|Magnesium|Participants in this arm will receive magnesium sulfate + ropivacaine in their bilateral transversus abdominis plane blocks
2982399|NCT02680626|Active Comparator|Non-magnesium|Participants in this arm will receive saline + ropivacaine in their bilateral transversus abdominis plane blocks
2982400|NCT02680613|Experimental|Motivational SMS|This arm will receive 15 motivational SMS about cervical cancer and screening.
2982401|NCT02680613|Experimental|Travel Voucher|This arm will receive a voucher covering return transport from the screening clinic. This arm will also receive identical 15 motivational SMS about cervical cancer and screening as the Motivational SMS arm.
2982402|NCT02680613|No Intervention|Control|This arm will receive standard sensitization during study period (church announcements, screening promotion by key community leaders and posters in community, as well as sensitization by the research assistants conducting the door-to-door household recruitment) during the study and follow-up period. They will also receive one SMS message with the location of screening services during the study period. At the conclusion of the study, participants in the arm will receive identical motivational SMS as the other two arms.
2982403|NCT02680600|Experimental|Study arm|"Cefepime dosing~Blood sampling~Urine sampling~Determination of renal markers~Population pharmacokinetic modeling~Covariate screening~Monte Carlo simulations"
2982404|NCT02680587|Placebo Comparator|Observational (no SBRT)|Evaluating men with oligometastatic prostate cancer lesions randomized to observation
2982405|NCT02680587|Experimental|SBRT|Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT).
2982406|NCT02680587|Experimental|DCFPyL-PET/MRI|DCFPyL-PET/MRI or -PT/CT Estimate the proportion of DCFPyL-PET/MRI or -PET/CT positive sites that are positive for new or progressive metastatic disease by bone scan at 6-months from SBRT and vice versa
2982407|NCT02680574|Experimental|vadadustat|
2982408|NCT02680574|Active Comparator|darbepoetin alfa|
2982409|NCT02680561|Experimental|Treatment A: Fp MDPI|Single inhalation dose of Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
2982410|NCT02680561|Experimental|Treatment B: FS MDPI|Single inhalation dose of Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler (FS MDPI) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
2982411|NCT02680561|Active Comparator|Treatment C: Comparator|Single inhalation dose of fluticasone propionate/salmeterol (ADVAIR DISKUS) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
2982412|NCT02680548|Active Comparator|0.9% saline (salt water)|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.9% saline injection per nerve (20cc max)
2982413|NCT02680548|Active Comparator|local anesthetic (freezing)|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.25% bupivacaine per nerve (20cc max)
2982414|NCT02680548|Active Comparator|local anesthetic (freezing) and steroid|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.25% bupivacaine and 4mg/cc methylprednisolone per nerve (20cc max)
2983028|NCT02676635|Experimental|Ergonomics Training Only|Participants in this arm receive Ergonomics training only
2982417|NCT02680522|Experimental|Parkinson's Group|composed of patients with Parkinson's disease and who underwent training with virtual reality. exercises with game through virtual reality
2982418|NCT02680509|Experimental|All|All patient will undergo a unilateral sympathicotomy R3. After this left and right will be compared
2982419|NCT02680496|Experimental|Lokomat - Treadmill - Overground|Walking order: lokomat walking, treadmill walking, overground walking
2982420|NCT02680496|Experimental|Lokomat - Overground - Treadmill|Walking order: lokomat walking, overground walking, treadmill walking
2982421|NCT02680496|Experimental|Treadmill - Lokomat - Overground|Walking order: treadmill walking, lokomat walking, overground walking
2982422|NCT02680496|Experimental|Treadmill - Overground - Lokomat|Walking order: treadmill walking, overground walking, lokomat walking
2982423|NCT02680496|Experimental|Overground - Lokomat - Treadmill|Walking order: overground walking, lokomat walking, treadmill walking
2982424|NCT02680496|Experimental|Overground - Treadmill - Lokomat|Walking order: overground walking, treadmill walking, lokomat walking
2982425|NCT02680483||AF cohort|AF consecutive patients
2982426|NCT02680470|Experimental|Virtual Observed Therapy|Intervention = Virtual observed therapy of participants taking TB therapy
2982427|NCT02680457|Active Comparator|Insulin Degludec|Patients with Type 2 Diabetes mellitus
2982428|NCT02680457|Active Comparator|Insulin Glargine|Patients with Type 2 Diabetes mellitus
2982429|NCT02680444|Experimental|Reappraisal-Only Intervention|Participants were instructed to independently practice the Self-Administered Reappraisal-Only Exercise in the evening for five days. First, participants recalled a negative event from that day and then followed the positive reappraisal instructions available online. This involved thinking about how one could grow, learn or benefit from the negative event in any way possible.
2982430|NCT02680444|Experimental|Mindful-Reappraisal Intervention|Participants were instructed to independently practice the Self-Administered Mindful-Reappraisal Exercise in the evening for five days. First, participants recalled a negative event from that day and then followed the Mindful-Reappraisal instructions available online. This involved thinking about the negative event in an objective, non-judgmental way, then following the Reappraisal-Only instructions, and closing off with a brief mindfulness breathing technique.
2982431|NCT02680444|Active Comparator|Event Recall Active Control|Participants were instructed to independently practice the Self-Administered Event Recall Exercise in the evening for five days. In this condition, participants were only instructed to recall a negative event from that day with no reappraisal exercise.
2982432|NCT02680431||Neurofibromatosis 1|10 mL venous blood sample taken from patients with type 1 neurofibromatosis
2982433|NCT02680431||Control|10 mL venous blood sample taken from age- and gender-matched healthy controls
2982434|NCT02680418|Experimental|Single dose (Dose level 1)|FDL169 (Dose level 1) administered as a single dose
2982435|NCT02680418|Experimental|Single dose (Dose level 2)|FDL169 (Dose level 2) administered as a single dose
2982436|NCT02680418|Experimental|Single dose (Dose level 3)|FDL169 (Dose level 3) administered as a single dose
2982437|NCT02680418|Experimental|Single dose (Dose level 4)|FDL169 (Dose level 4) administered as a single dose
2982438|NCT02680418|Experimental|Single dose (Dose level 5)|FDL169 (Dose level 5) administered as a single dose
2982439|NCT02680418|Experimental|Multiple dose|Repeat doses of FDL169 to be administered at a dose level to be determined
2982440|NCT02680405||Atopic Dermatitis|Subjects with Atopic Dermatitis will have blood draw, skin biopsies and tape stripping
2982441|NCT02680405||Non Atopic Dermatitis|Subjects with no Atopic Dermatitis will have blood draw, skin biopsies and tape stripping
2982442|NCT02680392|Experimental|Pulsed and Continuous Radiofrequency|In this group of patients undergoing total knee arthroplasty (allocation of patients is randomized), Pulsed radiofrequency (PRF) is applied to the saphenous nerve of the knee, associated to Continuous Radiofrequency (TRF) applied to the genicular nerves of the knee . A sham catheter is inserted in the mid-tigh to simulate a continuous adductor canal block, and connected to an infusion of normal saline (assessor and patient blinded to the treatment)
2982443|NCT02680392|Active Comparator|Continuous adductor canal block|"Continuous Adductor Canal Block~Continuous adductor canal block is performed in this group of patients, with a catheter infusing ropivacaine 0.2% in the first 48 hours after surgery.~The solutions bags are labelled in order to make assessor and patients, blinded to the treatment (Ropivacaine vs Normal Saline)"
2982444|NCT02680379|Experimental|Minocycline, then Minocycline/Lovastatin|Participants will take minocycline then a combined treatment of minocycline/lovastatin for 3 months.
2982445|NCT02680379|Experimental|Lovastatin, then Minocycline/Lovastatin|Participants will lovastatin then a combined treatment of minocycline/lovastatin for 3 months
2982446|NCT02680366|Experimental|collagen/ABMNC scaffold|collagen/ABMNC scaffold covered on Foley catheter balloon inserted after hysteroscopic adhesiolysis
2982447|NCT02680366|Active Comparator|Foley catheter balloon|Foley catheter balloon inserted after hysteroscopic adhesiolysis
2982448|NCT02680353|Active Comparator|Study group|Patients received bilateral superficial cervical plexus block before operation
2982449|NCT02680353|No Intervention|Control group|Patients received no intervention before operation
2982450|NCT02680314|Active Comparator|Single Dose|single dose of misoprostol
2982451|NCT02680314|Active Comparator|Multiple Dose|multiple doses of misoprostol
2982452|NCT02680301|Other|Ointment Right/Cream Left|Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on right side and 0.1% triamcinolone CREAM with wet-wrap dressing on left side of bilateral flare of atopic dermatitis twice daily as instructed.
2982453|NCT02680301|Other|Ointment Left/Cream Right|Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on left side and 0.1% triamcinolone CREAM with wet-wrap dressing on right side of bilateral flare of atopic dermatitis twice daily as instructed.
2982454|NCT02680288|Placebo Comparator|Oral Placebo|Oral inert treatment
2982455|NCT02680288|Experimental|Active Treatment, Low-Dose|Lorcaserin 10 mg, single dose
2982456|NCT02680288|Experimental|Active Treatment, High-Dose|Lorcaserin 20 mg, single dose
2982484|NCT02680158|Experimental|Extranasal : Intranasal : Sham|Randomized sequence number 3: Oculeve Intranasal Lacrimal Neurostimulator applied extranasally, intranasally, and applied intranasally with the Oculeve Sham device.
2989593|NCT02632331|Experimental|Fasted dosing preceding group|
2982457|NCT02680275|Experimental|Doxycycline,Dead Sea Peloid Gel,placebo|"Group -1 stage: Doxycycline 100mg 2 times per day 10 days; followed by Dead Sea Peloid Gel , 60 ml per day fo 12 days, intravaginally~Group -1 stage: Doxycycline 100mg 2 times per day 10 days; followed by placebo gel, 60 ml per day fo 12 days, intravaginally"
2982458|NCT02680262|Experimental|Intervention group 1|HPV self-sampling kit mailed directly
2982459|NCT02680262|Experimental|Intervention group 2|HPV self-sampling kit on demand
2982460|NCT02680262|Experimental|Intervention group 3|second reminder
2982461|NCT02680249|Experimental|CTP-656 Fed, low fat|Single dose of CTP-656 150 mg administered after a low-fat breakfast
2982462|NCT02680249|Experimental|CTP-656 Fasted|Single dose of CTP-656 150 mg administered fasted
2982463|NCT02680249|Experimental|CTP-656 Fed, high fat|Single dose of CTP-656 150 mg administered after a moderate-fat breakfast
2982464|NCT02680236||Breast Cancer Patients|"This pilot study proposes to explore the effect of art therapy on breast cancer patients' perception of pain, and its impact on daily functioning by offering four sessions of individual art therapy, spaced between one to three weeks apart.~The study will be open to breast cancer patients over the age of 18, who have been assessed by the Royal Marsden (RM) Pain Team, and who report having persistent post treatment pain of at least moderate intensity for the preceding two weeks despite having been optimally treated for their pain already, and who fulfil the inclusion criteria."
2982465|NCT02680223|Active Comparator|Precision tinted lenses|Precision tinted lenses will be provided for one month.
2982466|NCT02680223|Sham Comparator|Non-beneficial tinted lenses|Tinted lenses at a colour different from but not easily distinguishable from the precision tinted will be provided for one month.
2982467|NCT02680210|Other|cognitive measures and questionnaires|the material of the study will consist of cognitive measures and questionnaires in order to (1) compare the cognitive performances and behavioral manifestations between patients with TBI and volunteers without neurological disorders and (2) to analyze the links between cognitive and behavioural measures in the TBI population
2982468|NCT02680197|Experimental|CHF5259 12.5 μg total daily dose|"CHF5259 or Placebo administration:~Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 6.25μg + 1 puff of CHF5259 DPI matched placebo twice a day~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
2982469|NCT02680197|Experimental|CHF5259 25 μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 6.25μg + 1 puff of CHF5259 DPI 6.25μg twice a day~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
2982470|NCT02680197|Experimental|CHF5259 50 μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 12.5 μg + 1 puff of CHF5259 DPI 12.5 μg twice a day~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
2982471|NCT02680197|Experimental|CHF5259 100μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment :1 puff of CHF5259 DPI 25 μg + 1 puff of CHF5259 DPI 25 μg twice a day~Interventions :~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
2982472|NCT02680197|Placebo Comparator|CHF5259 matched Placebo BID|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 2 puffs of CHF5259 DPI matched placebo twice a day~Interventions :~Day 1 : pre-dose spirometry, serial spirometry, haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
2982473|NCT02680184|Experimental|CMP-001 1 mg plus pembrolizumab|Experimental CMP-001 in combination with pembrolizumab. CMP-001 administered intratumorally
2982474|NCT02680184|Experimental|CMP-001 3 mg plus pembrolizumab|Experimental CMP-001 in combination with pembrolizumab. CMP-001 administered intratumorally
2982475|NCT02680184|Experimental|CMP-001 5 mg plus pembrolizumab|Experimental CMP-001 in combination with pembrolizumab. CMP-001 administered intratumorally
2982476|NCT02680184|Experimental|CMP-001 7.5 mg plus pembrolizumab|Experimental CMP-001 in combination with pembrolizumab. CMP-001 administered intratumorally
2982477|NCT02680184|Experimental|CMP-001 10 mg plus pembrolizumab|Experimental CMP-001 in combination with pembrolizumab. CMP-001 administered intratumorally
2982478|NCT02680184|Experimental|Part 1 Dose Expansion CMP-001 plus pembrolizumab|Experimental CMP-001 in combination with pembrolizumab. CMP-001 administered intratumorally
2982479|NCT02680184|Experimental|CMP-001 Part 2 Monotherapy and Part 2 Crossover to Combination|Experimental CMP-001 administered intratumorally Experimental CMP-001 in combination with pembrolizumab
2982480|NCT02680171|Experimental|Prism adaptation treatment|Prism Goggles with ten-degree rightward deviating prism lenses will be used to implement prism adaptation treatment, in addition to standard care.
2982481|NCT02680171|Sham Comparator|Sham prism adaptation treatment|Non-Shifting Goggles (sham) will be worn by patients in the control condition. These goggles do not shift the patients visual field.
2982482|NCT02680158|Experimental|Intranasal : Extranasal : Sham|Randomized sequence number 1: Oculeve Intranasal Lacrimal Neurostimulator applied intranasally, extranasally and intranasally with the Oculeve Sham device.
2982483|NCT02680158|Experimental|Intranasal : Sham : Extranasal|Randomized sequence number 2: Oculeve Intranasal Lacrimal Neurostimulator applied intranasally, Oculeve Sham device applied intranasally, and extranasally with the Oculeve Intranasal Lacrimal Neurostimulator.
2982485|NCT02680158|Experimental|Extranasal : Sham : Intranasal|Randomized sequence number 4: Oculeve Intranasal Lacrimal Neurostimulator applied extranasally, intranasally with the Oculeve Sham device, and intranasally with the Oculeve Intranasal Lacrimal Neurostimulator.
2982486|NCT02680158|Experimental|Sham : Intranasal : Extranasal|Randomized sequence number 5: Oculeve Sham device, Oculeve Intranasal Lacrimal Neurostimulator applied intranasally and extranasally.
2982487|NCT02680158|Experimental|Sham : Extranasal : Intranasal|Randomized sequence number 6: Oculeve Sham device, Oculeve Intranasal Lacrimal Neurostimulator applied extranasally and intranasally.
2982488|NCT02680145|Experimental|Preoperative Pessary Use|All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse
2982489|NCT02680132|Experimental|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
2982490|NCT02680132|Active Comparator|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
2982491|NCT02680119|Experimental|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
2982492|NCT02680119|Active Comparator|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
2982493|NCT02680106|Experimental|SPINNER|All patients in this arm will be treated with the SPINNER dressing.
2982494|NCT02680106|Active Comparator|JELONET|All patients in this arm will be treated with JELONET dressing, regarded as the standard of current care for split-skin donor-site wounds.
2982495|NCT02680093||Cervical length in pregnant women.|"Pregnant Women beyond the date of birth in conservative monitoring and prenatal follow-up. will be followed while coming to routine monitoring.~physiological parameter of cervical length will be measured as the differential predictor to determine their due date."
2982496|NCT02680080|Active Comparator|Positive control group|"subjects will receive a single 400 mg tablet of Moxifloxacin - the most commonly used positive control in thorough QTc (TQT) studies. Subjects will be continuously recorded by a Holter monitor for 24 hours"
2982497|NCT02680080|Active Comparator|Grapefruit group|subjects will drink one liter of fresh pink-grapefruit juice as fast as possible. The pink-grapefruit juice will be squeezed in the morning of the experiment in the cardiology department. ECG will be performed immediately pre dose and at 1, 2, 3, 4, 6, 8, 12, 24 after fresh pink-grapefruit juice administration. In addition, subjects will be continuously recorded by a Holter monitor for 24 hours
2982498|NCT02680067|Experimental|Developmental arm - Healthy or rheumatoid arthritis subjects|Subjects in the developmental arm will have a minimum of two study visits to determine the optimal conditions for visualizing lymphatic transport in the upper extremities. Concentrations of 0.1 mg/ml of Indocyanine Green (ICG) will be injected intradermally into the web spaces of the hands in both upper extremities. Multispectral video and still images will be recorded using the MultiSpectral Imaging System (MSImager). An ultrasound of the upper extremities may be performed after the ICG fluorescence is observed. The exam will help identify the location of the lymphatic vessels and nodes in the areas fluoresced.
2982499|NCT02680067|Experimental|Clearance arm - Healthy individuals|Subjects in the clearance arm will have an initial study visit that involves injections of 0.1 mg/ml of Indocyanine Green (ICG) intradermally into the web spaces of the hands in both upper extremities. Multispectral video and still images will be recorded using the MultiSpectral Imaging System (MSImager). Follow up imaging sessions will occur weekly for three weeks for a minimum of four study visits total.
2982500|NCT02680054|Active Comparator|Arm 1 (usual treatment)|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given at the same time as the insulin for the carbohydrate content BEFORE the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
2982501|NCT02680054|Active Comparator|Arm 2|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given one hour after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
2982502|NCT02680054|Active Comparator|Arm 3|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given two hours after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
2982503|NCT02680041|Experimental|18F-fluciclovine PET CT|Single intravenous administration of 18F-fluciclovine PET CT.
2982504|NCT02680028|Active Comparator|Standard length intramedullary nail|220mm intramedullary nail
2982505|NCT02680028|Experimental|Short length intramedullary nail|175mm intramedullary nail
2982506|NCT02680015|Experimental|Experimental Group|Immediate enrollment in the PEERS group.
2982507|NCT02680015|No Intervention|Waitlist Group|Research measures while waiting for PEERS; will receive PEERS within one year.
2982508|NCT02680002|Experimental|7.5 mcg H5N1 (monobulk) Plus MF59 (monobulk)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long-term as monobulk inactivated
2982509|NCT02680002|Experimental|15 mcg H5N1 (monobulk) Plus MF59 (monobulk)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long-term as monobulk MF59 adjuvant
2982510|NCT02680002|Experimental|7.5 mcg H5N1 (monobulk) Plus MF59 (vials)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
2982511|NCT02680002|Experimental|15 mcg H5N1 (monobulk) Plus MF59 (vials)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
2982512|NCT02680002|Experimental|90 mcg H5N1 (monobulk) without MF59|Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59
2982513|NCT02680002|Experimental|90 mcg H5N1 (vials) without MF59|Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59
2982514|NCT02679989|Experimental|Intermittent Energy Restriction|Weight loss intervention: Intermittent Energy Restriction
2982515|NCT02679989|Active Comparator|Continuous Energy Restriction|Weight loss intervention: Continuous Energy Restriction
2982657|NCT02679040|Experimental|Immediate Mammary Reconstruction|Chemotherapy, radiation therapy, mastectomy with immediate mammary reconstruction
2989594|NCT02632331|Experimental|Fed dosing preceding group|
2982516|NCT02679976|Experimental|Study Lens (etafilcon A) for Multifocal|All Subjects in this study will wear the same contact lenses. However subjects wil be stratified as Hyperopes or Myopes using a 1:1 allocation. The study lens will be worn for a period of approximately 4 hours to allow lenses to settle on the eyes.
2982517|NCT02679963|Experimental|Maintenance Olaparib|Olaparib (experimental arm): 600 mg daily (2 doses of 300 mg (2*2 tablets of 150 mg) taken approximately 12 hours apart) po, administered until disease progression or toxicity requiring its interruption. Olaparib has to be started no later than 6 weeks after the last administration of induction chemotherapy, and no later than 3 weeks after the CT scan confirming response to induction chemotherapy
2982518|NCT02679963|Placebo Comparator|Placebo|Placebo (control arm): 2 doses of 300 mg per day (2*2 tablets of 150 mg) taken approximately 12 hours apart
2982519|NCT02679950||Initial diagnosis|The initial diagnosis only cohort will include 3 patients with germ cell tumor (GCT) who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department. One prospective blood and one tissue sample will be collected from each patient in this cohort. Tissue samples will come from the orchiectomy or virgin retro-peritoneal lymph node dissection (RPLND) that was done at initial diagnosis.
2982520|NCT02679950||Late relapse|"The late relapse cohort will include 3 patients with late relapse germ cell tumor (GCT) who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department. One prospective blood and two tissue samples will be collected from each patient in this cohort. Tissue samples will come from the orchiectomy or virgin retro-peritoneal lymph node dissection (RPLND) that was done at initial diagnosis and the other will come from the site of late relapse.~Patients in this cohort will have biopsies at the site of late relapse as part of their routine cancer treatment. No biopsies will be performed specifically for the purposes of this study. Tissue from the site of late relapse will also be requested from the Pathology Department."
2982521|NCT02679937|Experimental|Fit4Duty|6-week weight gain prevention group
2982522|NCT02679937|Active Comparator|Nutrition Education|Two, 50 minute educational videos.
2982523|NCT02679924|Experimental|Restylane Silk|Micro-injections of Restylane® Silk Hyaluronic Acid filler for correction of mid to low cheek fine lines and wrinkles.
2982524|NCT02679924|Sham Comparator|Sham Comparator|Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
2982525|NCT02679911|Experimental|Loceryl NL|Amorolfine hydrochloride NL 5% to be applied once weekly for 12 weeks on all affected toenails of one foot
2982526|NCT02679911|Active Comparator|Ciclopirox NL|Ciclopirox NL 8% to be applied once daily for 12 weeks on all affected toenails of the opposite foot
2982527|NCT02679898|No Intervention|Lean Control|This arm involves not making any changes to the subject's lifestyle at the moment of the start of the intervention and for 6 weeks.
2982528|NCT02679898|No Intervention|Overweight/Obese Control|This arm involves not making any changes to the subject's lifestyle at the moment of the start of the intervention and for 6 weeks.
2982529|NCT02679898|Experimental|Unloaded-Whole Body Vibration (WBVT)|Lower-body exercise training on a vibration platform
2982530|NCT02679898|Experimental|Loaded-Whole Body Vibration (WBVT)|Externally loaded lower-body exercise training on a vibration platform
2982531|NCT02679872||VATS team 1|Video-assisted thoracoscopic surgery team, from institution/hospital 1.
2982532|NCT02679872||VATS team 2|Video-assisted thoracoscopic surgery team, from institution/hospital 2.
2982533|NCT02679872||VATS team 3|Video-assisted thoracoscopic surgery team, from institution/hospital 3.
2982534|NCT02679872||VATS team 4|Video-assisted thoracoscopic surgery team, from institution/hospital 4.
2982535|NCT02679859|Experimental|B-type natriuretic guided medical therapy optimisation|B-type natriuretic guided medical therapy optimisation
2982536|NCT02679859|No Intervention|Normal medical management|
2982537|NCT02679846|Experimental|Standardized protocol of AEDs withdrawal|The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
2982538|NCT02679846|No Intervention|Current practice|Centers will continue their current practice
2982539|NCT02679833|Placebo Comparator|Placebo|A toothpaste, with the same matrix, all components, and appearance like the active arm but not containing vitamin B12.
2982540|NCT02679833|Active Comparator|Cyanocobalamin|A toothpaste with cyanocobalamin 100 µg cyanocobalamin per 1 g.
2982541|NCT02679820|Experimental|PostPlacental IUD insertion|Copper T intrauterine device will be inserted immediately following delivery of the placenta in cases of cesarean section deliveries.
2982542|NCT02679820|No Intervention|Control|IUD will be offered as a method of contraception after puerperium
2982543|NCT02679807|Active Comparator|Bifidobacterium lactis Bl-04|2*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier
2982544|NCT02679807|Placebo Comparator|Placebo|sucrose
2982545|NCT02679794|Experimental|Egg consumption|Consuming sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
2982546|NCT02679794|Placebo Comparator|Control|Consuming sautéed vegetables and 3g canola oil without eggs
2982547|NCT02679781|Active Comparator|oral sedation|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
2982548|NCT02679781|Active Comparator|nasal sedation|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
2982549|NCT02679768|Active Comparator|Standard|Electronical monitoring and assessment
2982550|NCT02679768|Experimental|Circadian Reinforcement Therapy|Electronical monitoring and assessment plus psychoeducation on zeitgeber and sleep
2982551|NCT02679755|Experimental|Experimental arm|Palbociclib plus Letrozole
2982552|NCT02679742|Experimental|β-hydroxymethylbutyrate|β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program
2982553|NCT02679742|Placebo Comparator|Placebo|Maltodextrin 3 grams once a day combined with a resistance training program
2982554|NCT02679729|Experimental|Part A, Dose Level 1|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
2982658|NCT02679027|Active Comparator|Easy intubation|Intubation difficulty score <5
2982659|NCT02679027|Active Comparator|Difficult intubation|Intubation difficulty score >5
2982555|NCT02679729|Experimental|Part A, Dose Level 2|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
2982556|NCT02679729|Experimental|Part A, Dose Level 3|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
2982557|NCT02679729|Experimental|Part A, Dose Level 4|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
2982558|NCT02679729|Experimental|Part A, Dose Level 5|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
2982559|NCT02679729|Experimental|Part A, Dose Level 6|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
2982560|NCT02679729|Experimental|Part A, Dose Level 7|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
2982561|NCT02679729|Experimental|Part B, Dose Level 1|Subjects will receive a single dose of IV AZD5634 and after a washout period of 14 days the same subjects will receive a single dose of inhaled AZD5634
2982562|NCT02679716|Other|study group|MRI of the cerebral arteries ist performed
2982563|NCT02679703|Experimental|High voltage|The applied parameters of high voltage electrical stimulation are medium voltage of 100 volts, an increase in the course of the session, frequency of 10 Hz, with application in the donor areas of thigh or scalp for 40 minutes, 25% above of level engine daily until complete epithelialization, and removal of the dressing type rayon.
2982564|NCT02679703|Experimental|Neuromuscular transcutaneous electrical stimulation (TENS)|10 Hz, 40 min, 200 μs and 25% above of motor level
2982565|NCT02679703|Experimental|Control Group|There will be no intervention
2982566|NCT02679690|Experimental|Patients with Heart Failure|Patients with heart failure receiving standard dietary sodium education and then color-coded cue card education and intervention.
2982567|NCT02679677|Sham Comparator|Control|Whole body vibration training as sham procedure (5Hz) 3 times a week, 3x2 minutes, for 6 weeks.
2982568|NCT02679677|Experimental|Intervention|Whole body vibration training (12 Hz up to 30 Hz) 3 times a week, 3x2 minutes, for 6 weeks.
2982569|NCT02679664|Experimental|Treatment group|20 mg tablet of rosuvastatin PO once-a-day starting at the time of randomization until the completion of follow-up at 6 months.
2982570|NCT02679664|No Intervention|Control group|Standard medical care only. No rosuvastatin group.
2982571|NCT02679651||Control group|Healthy Adults without foot pain
2982572|NCT02679651||DIsease group|Adults diagnosed with fat pat atrophy and report symptoms of foot pain and have participated in clinical trial to treat fat pad atrophy.
2982573|NCT02679638||Kaplan Hospital|Breast cancer survivors recruited at the Kaplan Medical Center
2982574|NCT02679638||Rambam Hospital|Breast cancer survivors recruited at the Rambam Medical Center
2982575|NCT02679638||Sheba|Breast cancer survivors recruited at the Sheba Medical Center
2982576|NCT02679638||Barzilai|Breast cancer survivors recruited at the Barzilai Medical Center
2982577|NCT02679599|Other|Cardiac rehabilitation as usual|Participants will receive cardiac rehabilitation as usual (i.e., as offered in the clinical setting).
2982578|NCT02679599|Experimental|Cardiac rehabilitation plus B-MOBILE-CARDIAC smartphone app|Participants will receive cardiac rehabilitation as usual, plus access to the B-MOBILE-CARDIAC smartphone application through 4 weeks post-rehabilitation.
2982579|NCT02679586|Experimental|Diffusion weighted MRI Group|"All patients will receive a double baseline diffusion weighted MRI (performed on the same day as the Baseline MRI).~Patients participating in Part I will receive another MRI approximately 1 week (day 8-11) after the first dose of Chemotherapy (chemotherapy will be determined by the treating physician and is not assigned as part of this trial).~Patients participating in Part II will receive a single MRI 1-2 weeks after the first dose of Chemotherapy A (chemotherapy will be determined by the treating physician and is not assigned as part of this trial). A second MRI will be repeated within 2 weeks prior to the start of Chemotherapy B."
2982580|NCT02679573|Experimental|Delafloxacin|IV delafloxacin with potential to switch to oral delafloxacin
2982581|NCT02679573|Active Comparator|Moxifloxacin/Linezolid|IV moxifloxacin with potential to switch to oral moxifloxacin, and potential to switch moxifloxacin to IV linezolid for confirmed MRSA
2982582|NCT02679560|Active Comparator|Liposomal Bupivacaine|In patients with femur or hip fractures, a fascia iliaca compartment block using liposomal bupivacaine will be administered
2982583|NCT02679560|Placebo Comparator|Ropivacaine HCL|In patients with femur or hip fractures, a fascia iliaca block using using 0.2% ropivacaine will be administered
2982584|NCT02679547||Appendicitis|The patients with appendicitis
2982585|NCT02679547||Control|The participants without appendicitis
2982586|NCT02679534|Experimental|hand massage|"Patients will receive a 20 minute hand massage by a trained nurse in addition to the standard ICU care. Before administering the massage, a favorable environment will be created that promotes calmness such as dampening the light, reducing the alarm intensity, closing the curtains and the door and posting the notice do not disturb, and a comfortable positioning of the patient will be ensured. The interventionist will hold each hand for 5-10 seconds, and apply 5-10 ml of unscented hypoallergenic cream to both hands and wrists. Then, she will perform massage using moderate pressure, and the stroking and kneading techniques during ten minutes on the palm and back of each hand."
2982587|NCT02679534|Active Comparator|hand holding|The active control group will receive hand holding by the same trained nurse in addition to standard ICU care. The same hand hygiene and environmental adjustments will be made as for those receiving massage. Patients will have their hands held for 5-10 seconds and unscented hypoallergenic cream applied to both hands. Then, the interventionist will hold each of the patients' hand in her hand for ten minutes without performing any tissue manipulation. The hand holding procedure will last for a total of 20 minutes.
2982660|NCT02679014|Placebo Comparator|Placebo|Participants will receive placebo capsules (2 capsules) twice daily for 28 days.
2984162|NCT02669056|Experimental|preterm babies|preterm babies (less than 28 weeks)
2982588|NCT02679534|Other|rest group|The passive control group will have a 20 minutes rest period including the same environmental adjustments as the massage and hand holding groups in addition to the standard care administered in the ICU. The standard care includes the pharmacological and non-pharmacological treatments used to promote recovery and symptom relief. In the study ICU, cardiac surgery patients are automatically prescribed a pain management protocol that includes the regular administration of morphine, unless extraordinary patient circumstances require different prescriptions. Patients might equally receive breakthrough doses of analgesia in addition to regular opioids. Of the existing non-pharmacological interventions, repositioning and back rubs are commonly employed in the study ICU to provide patient comfort.
2982589|NCT02679521|Active Comparator|rESWT|Radial extracorporeal shock wave therapy (rESWT).
2982590|NCT02679521|Placebo Comparator|Placebo|Placebo treatment.
2982591|NCT02679508|Experimental|Vonoprazan group|Vonoprazan 20 mg administered orally once daily in the healing phase + vonoprazan 10 mg (as the initial dose and adjusted to vonoprazan 10 mg or 20 mg) administered orally once daily in the maintenance phase
2982592|NCT02679508|Active Comparator|Lansoprazole group|Lansoprazole 30 mg administered orally once daily in the healing phase + lansoprazole 15 mg (as the initial dose and adjusted to lansoprazole 15 mg or 30 mg) administered orally once daily in the maintenance phase
2982593|NCT02679495|Active Comparator|Lifestyle intervention|A better lifestyle that are supposed to prevent gastric cancer occurrence are advised to patients. Measures includes dietary change and cessation of smoking and alcohol abuse. Behavioural and cognitive strategies from investigators are performed to patients to ensure adherence to established intervention.
2982594|NCT02679495|No Intervention|No intervention|No meassures are taken to change life style of enrolled patients.
2982595|NCT02679482||Selective laser trabeculoplasty (SLT)|Patients who underwent to Selective laser trabeculoplasty
2982596|NCT02679482||Pattern laser trabeculoplasty (PLT)|Patients who underwent to Pattern laser trabeculoplasty
2982597|NCT02679469|Experimental|Nalmefene hydrochloride 10 mg|nalmefene 10 mg tablet
2982598|NCT02679456|Active Comparator|Treatment Group 1 (Fluconazole)|Fluconazole
2982599|NCT02679456|Experimental|Treatment Group 2: (SCY-078)|Dose regimen 1
2982600|NCT02679456|Experimental|Treatment Group 3 (SCY-078)|Dose regimen 2
2982601|NCT02679443|No Intervention|Delayed Arm|Participants are started on folate and vitamin B12 supplementation for 5-7 days prior to initiation of chemotherapy
2982602|NCT02679443|Experimental|Immediate Arm|Participants are started on folate and vitamin B12 supplementation simultaneously with chemotherapy (within 24 hours of initiation of chemotherapy)
2982603|NCT02679430|Other|Prostate Arterial Embolization|"Intervention: Patients will undergo prostatic artery embolization.~The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms."
2982604|NCT02679417|Active Comparator|aerobic exercise|Each participant reach a minimum of 50 minutes of some form of aerobic exercise including running on a treadmill 5 to 7 days per week for 12 weeks under the supervision of fitness center trainers.
2982605|NCT02679417|Active Comparator|resistant exercise|Each participant reach a minimum of 50 minutes of some form of strength training involving repetitions of a resistance training exercise for each major muscle group at an intensity for at least 60% of a one-repetition max, 5 to 7 days per week for 12 weeks under the supervision of fitness center trainers.
2982606|NCT02679391||A|69 consecutive operated patients by general surgeons at Capio S:t Görans Hospital 2011. All post weight loss. , 96% female, BMI by the time of operation 26, mean age 41 (SD 9.5). Their mean weight loss in BMI units: 17.8 (SD 5.12).
2982607|NCT02679391||B|70 consecutive operated patients by plastic surgeons at Karolinska University Hospital 2010-2012. All post weight loss. 86% female, BMI by the time of oepration 26, mean age 38.6 (SD 11.4). Their mean weight loss in BMI units: 17.4 (SD 4.8).
2982608|NCT02679391||C|70 consecutive operated patients by general surgeons at Capio S:t Görans Hospital 2013-2014. All post weight loss. 90% female, BMI by the time of operation 26, mean age 46.8 (SD 10.1). Their mean weight loss in BMI units: 16.3 (SD 5.11)
2982609|NCT02679378||ClearSight™ System|To assess the ability of the ClearSight™ System to detect malignant tissue less than or equal to 1 mm of margins of excised breast specimen in breast conserving surgery when compared to histopathological assessment.
2982610|NCT02679365|Experimental|group a|This arm will have lower segment cesarean section done with double locking technique for closure of Rectus Sheath.
2982611|NCT02679365|Active Comparator|group b|This arm will have lower segment cesarean section done with continuous non-locking technique for closure of rectus sheath.
2982612|NCT02679352|Experimental|SMR stemless|Patients requiring a primary anatomic or reverse shoulder arthroplasty, due to symptomatic painful degenerative joint diseases with good bone stock
2982613|NCT02679339|Experimental|CNTX-2022 (lidocaine gel, 40%)|Application of 1mL CTNX-2022 (40% Anhydrous Lidocaine Gel) topically applied to 300cm squared outlined area once daily (in the morning) for 8 days at the study site.
2982614|NCT02679339|Placebo Comparator|Placebo|Application of 1mL placebo topically applied to 300cm squared outlined area once daily (in the morning) for 8 days at the study site.
2982615|NCT02679326|Experimental|study group|will receive stretching guidance and high level active Ultrasound
2982616|NCT02679326|Placebo Comparator|control group|will receive stretching guidance and very low level of Ultrasound
2982617|NCT02679313|Experimental|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit).
2982661|NCT02679014|Experimental|RO5459072|Participants will receive RO5459072 100 milligrams (mg) capsules (2*50 mg capsules) twice daily for 28 days.
2982662|NCT02679001||RA participants treated with a TNF inhibitor or TCZ|Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling will be observed.
2982618|NCT02679300|Experimental|Virtual reality group|During a single intervention session, participants will perform 2 sets of 2 minutes of pelvic tilt exercises using serious games. These serious games have to be controlled by pelvic tilts. Patients will perform the exercises in a standing position in front a TV-screen, on which the games will be displayed. Wireless motion sensors will be mounted to the patient's spine and pelvis to track the movements of the pelvis.
2982619|NCT02679300|Active Comparator|Control group|During a single session intervention, participants will perform 2 sets of 2 minutes of pelvic tilt exercises without a serious game. Patients will perform the exercises in a standing position. The number of repetitions and the tempo of the pelvic tilts will be indicated using a metronome.
2982620|NCT02679287|Experimental|Group A|Order of intervention will be 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d)
2982621|NCT02679287|Experimental|Group B|Order of intervention will be 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP
2982622|NCT02679274|Placebo Comparator|Placebo|Placebo injection (saline) to be received on weeks 0, 1, 4, 5, 8 and 9.
2982623|NCT02679274|Experimental|Testosterone|Testosterone Enanthate injections (25mg/injection females; 100mg/injection males) to be received on weeks 0, 1, 4, 5, 8 and 9.
2982624|NCT02679261|Experimental|Atorvastatin|Oral administration Atorvastatin 20 mg per day
2982625|NCT02679261|Placebo Comparator|Control|Oral administration of Placebo
2982626|NCT02679248|Experimental|Neo40 Daily®|
2982627|NCT02679248|Experimental|Placebo|
2982628|NCT02679235|Experimental|Triheptanoin|Triheptanoin suppementation 1g/kg body weight for 28 days (dose gradually increased each week, starting at, 0.25, 0.5, 0.75 and then 1 g) separated in 4 doses (with eah meal and before night)
2982629|NCT02679222|Experimental|Supplementation|Oral intake of one of the supplements: 20 g of coconut oil or 10 g of coconut oil + 10 g of MCT 60-40 or 20 g MCT 60-40 or 10 g coconut oil + 10 g tricaprylin or 20 g tricaprylin or 10 g coconut oil + 10 g triheptanoate or 20 g triheptanoate
2982630|NCT02679209|Experimental|Bone allograft|commercially available demineralized bone matrix putty allograft will be used to fill in the defect after opening a periodontal flap
2982631|NCT02679209|Experimental|Amnion chorion membrane|Amnion chorion commercially available allograft bioresorbable membrane as a guided tissue regeneration technique will be used to in the defect after opening a periodontal flap
2982632|NCT02679196|Experimental|KA2237|Open label treatment with KA2237
2982633|NCT02679183|Placebo Comparator|Control 0|No Intervention. This group received Premature Milk Formula. This group did not receive any Medically-Graded Honey.
2982634|NCT02679183|Experimental|Group 1|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 5 gram/day) for 2 weeks
2982635|NCT02679183|Experimental|Group 2|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 10 gram/day) for 2 weeks
2982636|NCT02679183|Experimental|Group 3|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 15 gram/day) for 2 weeks
2982637|NCT02679170||Routine clinical practice group (NSCLC ALK+)|Patients diagnosed and treated following routine clinical practice, for their NSCLC ALK+
2982638|NCT02679144|Experimental|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 twice daily on each day of study.
2982639|NCT02679131|Experimental|Cohort A|Normal Renal function, Belinostat IV, Dose A
2982640|NCT02679131|Experimental|Cohort B|Mild Impairment, Belinostat IV, Dose A
2982641|NCT02679131|Experimental|Cohort C|Moderate Impairment, Belinostat IV, Dose B
2982642|NCT02679131|Experimental|Cohort D|Severe Impairment, Belinostat IV, Dose B
2982643|NCT02679118|Experimental|Sentire|The patients will undergo their laparoscopic gastric bypass, during the operative period at pre-defined time points, a small amount of gas from the abdomen will be withdrawn and analyzed for the device. The laparoscopic gastric bypass will proceed without interference or effect from the device.
2982644|NCT02679105|Placebo Comparator|ALK diluent|Human albumin
2982645|NCT02679105|Active Comparator|ALK Alutard birch or 5-grasses|Grass pollen suspension or birch pollen suspension
2982646|NCT02679092|Active Comparator|Dilapan (14wks 0days-15wks, 6days)|The clinician will place 1 to 2 osmotic cervical dilators (Dilapan-S) (4mm x 65mm) the day before the participant's procedure.
2982647|NCT02679092|Active Comparator|Dilapan (16wks 0days-18wks, 6days)|The clinician will place 3 to 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
2982648|NCT02679092|Experimental|Mifepristone (14wks 0days-15wks, 6days)|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
2982649|NCT02679092|Experimental|Mifepristone (16wks 0days-18wks, 6days)|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
2982650|NCT02679079|Placebo Comparator|Placebo|Administered once daily for 6 weeks
2982651|NCT02679079|Experimental|Dose Group 1|Administered once daily for 6 weeks
2982652|NCT02679079|Experimental|Dose Group 2|Administered once daily for 6 weeks
2982653|NCT02679066|Active Comparator|Sugar-tong splint|Patients are placed in a sugar-tong splint for immobilization of the distal radius fracture.
2982654|NCT02679066|Active Comparator|Short Forearm Cast|Patients are placed in a short forearm cast, with bivalve, for immobilization of the distal radius fracture.
2982655|NCT02679053|Experimental|Exercise (IG)|Aerobic exercise three times per week on indoor bicycles at 60 to 75% of maximal heartrate aiming at a weekly total of 17.5kcal/kg bodyweight for 6 consecutive weeks. The exercise will take place under supervision. At the end of every week physical fitness is evaluated by the queens step test.No other activities with moderate or high intensity are allowed throughout the intervention time.
2982656|NCT02679053|Placebo Comparator|Control (CG)|Basic stretching and mobilisation program 3 times per week each for approx. 40 minutes, also under supervision for 6 consecutive weeks. At the end of every week physical fitness is evaluated by the queens step test.At the end of every week physical fitness is evaluated by the queens step test.No other activities with moderate or high intensity are allowed throughout the intervention time.
2982663|NCT02678988|Experimental|A1: Tocilizumab AI followed by PFS-NSD in abdomen|Participants will receive two single doses of 162 milligrams (mg) tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2), in abdomen.
2982664|NCT02678988|Experimental|A2: Tocilizumab AI followed by PFS-NSD in thigh|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2) in thigh.
2982665|NCT02678988|Experimental|A3: Tocilizumab AI followed by PFS-NSD in upper arm|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2), in upper arm.
2982666|NCT02678988|Experimental|B1: Tocilizumab PFS-NSD followed by AI in abdomen|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in abdomen.
2982667|NCT02678988|Experimental|B2: Tocilizumab PFS-NSD followed by AI in thigh|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in thigh.
2982668|NCT02678988|Experimental|B3: Tocilizumab PFS-NSD followed by AI in upper arm|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in thigh.
2982669|NCT02678975|Active Comparator|Control|Alkylating chemotherapy
2982670|NCT02678975|Experimental|Experimental|Alkylating chemotherapy + disulfiram + copper
2982671|NCT02678962|Active Comparator|SN6AD1 group|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
2982672|NCT02678962|Active Comparator|SBL-3 group|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
2982673|NCT02678962|Active Comparator|LS-313 MF30 group|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
2982674|NCT02678962|Active Comparator|AT LISA tri 839 MP group|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
2982675|NCT02678962|Active Comparator|ART group|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
2982676|NCT02678962|Active Comparator|LS-313 MF30T group|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
2982677|NCT02678949|Experimental|Inhaled Fluticasone 50 mcg/twice day|Group 2; Inhaled fluticasone. 50 mcg/twice day for a period of 4 weeks.
2982678|NCT02678949|Experimental|Inhaled Fluticasone 100 mcg/twice day|Group 3;Inhaled fluticasone. 100 mcg/twice day for a period of 4 weeks
2982679|NCT02678949|Experimental|Inhaled Albuterol|Group 2 and group 3, inhaled albuterol one dose of 400 mcg.
2982680|NCT02678936|Experimental|PRP|The operation will be performed with application of platelet rich plasma
2982681|NCT02678936|No Intervention|non-PRP|The operation will be performed without addition of platelet-rich plasma
2982682|NCT02678923|Experimental|MDCO-216|20 mg/kg of MDCO-216 administered intravenously (IV) as a 360 milliliter (mL) infusion over 2 hours on Days 1, 8, 15, 22, and 29
2982683|NCT02678923|Placebo Comparator|Placebo|360 mL of placebo (0.9% sodium chloride [NaCl] solution) infusion, IV, over 2 hours on Days 1, 8, 15, 22, and 29
2982684|NCT02678910|Experimental|Ovarian Cryopreservation|Removal of the ovary for cryopreservation is an investigational procedure. 100% of the tissue will be used for the participant's future use.
2982685|NCT02678897|No Intervention|Pain management in early pregnancy MTOP|Patients in early pregnancy (pregnancy weeks <9weeks) undergoing medical termination of pregnancy gets Ibuprofen (tbl 600mg 3 times a day) and Paracetamol (tbl 1000mg 3 times a day).
2982686|NCT02678897|Experimental|Patient controlled analgesia (PCA)|"Pregnancy weeks 9-20. All patients get baselineanalgesics: Ibuprofein 600mg and Paracetamol 1000mg both x3 a day.~Patients get pain medication (Oxynorm) via PCA"
2982687|NCT02678897|Active Comparator|Oxynorm on-demand|"Pregnancy weeks 9-20. All patients get baselineanalgesics: Ibuprofein 600mg and Paracetamol 1000mg both x3 a day.~Patients get extra pain medication (Oxynorm) on-demad from the nurse."
2982688|NCT02678884|Experimental|HNSCC Patients receiving RT|
2982689|NCT02678871|Other|All study participants|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the LOTUS heart valve system and LAA closure with the WATCHMAN device in the same setting. Dual antiplatelet therapy (clopidogrel and acetylsalicylic acid) will be prescribed for 6 months followed acetylsalicylic acid indefinitely. Follow-up will be performed after 1 month, 6 months and 1 year.
2982690|NCT02678858|Experimental|Integrated Social Cognitive and Behavioral Skills Therapy|The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) shall target expressive and interactional behavior skills together with those social cognitive domains (facial and prosodic affect recognition, social perception, theory-of-mind) known to be most impaired (Savla, 2012) and most closely associated with functional outcome (Fett, 2012) in schizophrenia.
2982691|NCT02678858|Active Comparator|Neurocognitive Remediation Therapy|The Neurocognitive Remediation Therapy (NCRT) shall target impairments in attention, memory, and executive functions as an active comparator to the ISST.
2982692|NCT02678845|Experimental|Treatment according to the Collabri model|Participants in this group will recive treatment according to the Collabri model which is a Danish model for collaborative care between primary and secondary care for depression, social phobia, generalized anxiety and panic disorder
2982693|NCT02678845|No Intervention|Treatment as usual|Control group. Participants in this group will recive treatment as usual. This means that participants will recive treatment corresponding to what their GP normally would offer as treatment. E.g. this could be refferal to a psychologist or psychiatrist and/or medicine.
2982694|NCT02678832||Cancer patients|
2982695|NCT02678832||Physicians|
2982696|NCT02678832||Oncology nurses|
2982697|NCT02678819|Experimental|Digital Aid|The digital cognitive aid is designed as a smartphone app. Intervention : cognitive aid during anesthesia and intensive care crises management.
2982698|NCT02678819|No Intervention|No digital aid|Anesthesia and intensive care crises managed without any cognitive aid.
2982830|NCT02677922|Experimental|Subcutaneous (SC) azacitidine|Subjects with either an IDH1 or IDH2 mutation will receive azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.
2982699|NCT02678806|Experimental|Postoperative radiotherapy group|Patients hospitalized in Affiliated Tumor Hospital of Guangxi Medical University from 1st November 2017, who were diagnosed as BCLC-A stage hepatocellular carcinoma, accepted hepatocellular carcinoma resection, pathologically confirmed as narrow margin (the closest distance from margin to tumor capsule < 1cm) and microvascular invasion was found in tumor capsule and adjacent tissues junction were selected and received margin postoperative radiotherapy.
2982700|NCT02678806|Active Comparator|Postoperative TACE group|
2982701|NCT02678793|Other|Subjects who have completed Study 4975-MN-202 will be eligible|Subjects who have completed Study 4975-MN-202 will be eligible to receive open-label treatment with CNTX-4975 200 μg in Study 4975-MN-203 if they meet the inclusion/exclusion criteria.
2982702|NCT02678780|Experimental|Cohort A|"Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO (World Health Organization) classification neuroendocrine tumors of the pancreas after progression to a previous targeted agent.~Treatment: Dosing schedule of 24 mg once a day of Lenvatinib (two 10-mg capsules + one 4-mg capsule)"
2982703|NCT02678780|Experimental|Cohort B|Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO (World Health Organization) classification neuroendocrine tumors of gastrointestinal tract after progression to somatostatin analogues Treatment: Dosing schedule of 24 mg once a day of Lenvatinib (two 10-mg capsules + one 4-mg capsule)
2982704|NCT02678767|Experimental|HIV+ with neurocognitive disorder|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
2982705|NCT02678767|Active Comparator|HIV+ without neurocognitive impairment|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
2982706|NCT02678767|Active Comparator|HIV- without neurocognitive impairment|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
2982707|NCT02678741|Active Comparator|No clinical response|No clinical response (PD de novo) after a minimum of 3 months on CPI monotherapy
2982708|NCT02678741|Active Comparator|Develop PD|Develop PD after initial clinical response to CPI monotherapy
2982709|NCT02678741|Active Comparator|Stable Disease|Stable disease for at least 6 months on CPI monotherapy
2982710|NCT02678728|Experimental|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia for 24hrs
2982711|NCT02678728|Placebo Comparator|Normal saline|IV loading and infusion of same volume of normal saline after induction of anesthesia for 24hrs
2982712|NCT02678715|Experimental|Sequence SB-CA-SM|Solubrux®+ Customized Appliance + Somatics®
2982713|NCT02678715|Experimental|Sequence SB-SM-CA|Solubrux®+Somatics®+Customized Appliance
2982714|NCT02678715|Experimental|Sequence CA-SB-SM|Customized Appliance+Solubrux®+Somatics®
2982715|NCT02678715|Experimental|Sequence CA-SM-SB|Customized Appliance+Somatics®+Solubrux®
2982716|NCT02678715|Experimental|Sequence SM-SB-CA|Somatics®+Solubrux®+Customized Appliance
2982717|NCT02678715|Experimental|Sequence SM-CA-SB|Somatics®+ Customized Appliance+Solubrux®
2982718|NCT02678702|Experimental|CBT-I|Behavioral intervention: CBT-I
2982719|NCT02678702|Active Comparator|Treatment as usual|Intervention: Control group receiving treatment as usual
2982720|NCT02678689|Experimental|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|An age-appropriate dose of BMN 190 administered via intracerebroventricular (ICV) infusion every other week (qow) for a duration of 144 weeks.
2982721|NCT02678676||Pioglitazone|Participants who previously received pioglitazone in the PROactive study (NCT00174993).
2982722|NCT02678676||Placebo|Participants who previously received Pioglitazone-matching placebo in the PROactive study (NCT00174993).
2982723|NCT02678663|Experimental|Injection-assisted cold snare polypectomy (I-CSP)|Polyps in this group will be resected with the cold snare technique after pre-lift of the lesion with a submucosal injection of methylene blue-tinted normal saline solution. The polyp and a small rim of normal tissue will be then snared closely and removed in a single piece without the use of electrocautery.
2982724|NCT02678663|Active Comparator|Endoscopic mucosal resection (EMR).|"Polyps in this group will be removed in a single piece by using an inject-and-cut EMR technique. Methylene blue-tinted normal saline solution will be injected into the submucosal space followed by the application of snare cautery for lesion resection."
2982725|NCT02678650|Experimental|volatile anesthetics group|10min after intubation, begin to sevoflurane wash-in / wash-out operation: sevoflurane administration was interrupted for at least 10 min, by washout with a high fresh gas flow (10 l/min) to achieve a MAC value below 0.2. Following the interruption, sevoflurane was again washed in with a high fresh gas flow (6 l/min) to achieve 1 MAC end-tidal concentration as soon as possible, and repeated twice periods of 10 minutes. Discontinuation of the halogenated agent for at 15 minutes during the last wash out time.
2982726|NCT02678650|Placebo Comparator|propofol intravenous anesthesia group|propofol infusion 3-5μg / kg / h
2982727|NCT02678624|Experimental|Treatment according to the Collabri model|Participants in this group will recive treatment according to the Collabri model which is a Danish model for collaborative care between primary and secondary care for depression, social phobia, generalized anxiety and panic disorder
2982728|NCT02678624|No Intervention|Treatment as usual|Control group. Participants in this group will recive treatment as usual. This means that participants will recive treatment corresponding to what their GP normally would offer as treatment. E.g. this could be refferal to a psychologist or psychiatrist and/or medicine.
2982729|NCT02678611|Experimental|Basis 250|
2982730|NCT02678611|Experimental|Basis 500|
2982731|NCT02678611|Placebo Comparator|Placebo|
2982732|NCT02678598||Micafungin group|
2982733|NCT02678585|Active Comparator|Nalbuphine|53 patients received intravenous regional lidocaine plus Nalbuphine
2982734|NCT02678585|Other|Control group|53 patients received intravenous regional lidocaine
2982735|NCT02678572|Experimental|Melphalan/PHP|3 mg/kg ideal body weight of melphalan for infusion administered directly to the liver via percutaneous hepatic perfusion (PHP) over 30 minutes followed by a 30 minute washout. Treatment cycles are to be repeated every 6-8 weeks until disease progression.
2982736|NCT02678572|Active Comparator|BAC - TACE|1 of 4 options under BAC: TACE (transarterial chemoembolization)
2982737|NCT02678572|Active Comparator|BAC - Dacarbazine|1 of 4 options under BAC: Systemic Dacarbazine.
2982738|NCT02678572|Active Comparator|BAC - Ipilimumab|1 of 4 options under BAC: Systemic Ipilimumab
2982739|NCT02678572|Active Comparator|BAC - Pembrolizumab|1 of 4 options under BAC: Systemic Pembrolizumab
2982740|NCT02678559|Experimental|TEE monitory system|comparison between TEE and mini-invasive monitoring systems in accuracy of measurement of stroke volume variation during ARM.
2982741|NCT02678559|Experimental|mini-invasive monitoring system|comparison between TEE and mini-invasive monitoring systems in accuracy of measurement of stroke volume variation during ARM.
2982742|NCT02678546||patients in outpatients departments|patients from outpatients departments in teaching hospital
2982743|NCT02678546||General|participants from center of continuing education in China Medical University
2982744|NCT02678533|Experimental|Fanconi anemia|G-CSF and Plerixafor
2982745|NCT02678520|Experimental|3-D conformal radiation therapy|"Intervention: Radiation therapy delivered to a total dose of 6600 centigray (cGy) at 200 cGy/fraction (fx) once daily using a 3-D conformal radiation technique (3-D CRT). The volume of radiation will encompass the prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement. Hormonal therapy will be required for patients with high risk disease (both the adjuvant and salvage groups). For patients with low risk disease, hormonal therapy will be as per standard of care. Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months. Hormonal therapy regimen will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg sc once every 3 months x 2 injections) or Lupron (22.5 mg im once every 3 months x 2 injections) to start on day 1 once the subject has been enrolled to the clinical trial."
2982746|NCT02678520|Active Comparator|Intensity modulated radiation therapy|"Intervention: Radiation therapy delivered to a total dose of 6600 centigray (cGy) at 200 cGy/fraction (fx) once daily using intensity modulated radiation therapy (IMRT). The volume of radiation will encompass the prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement. Hormonal therapy will be required for patients with high risk disease (both the adjuvant and salvage groups). For patients with low risk disease, hormonal therapy will be as per standard of care. Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months. Hormonal therapy regimen will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg sc once every 3 months x 2 injections) or Lupron (22.5 mg im once every 3 months x 2 injections) to start on day 1 once the subject has been enrolled to the clinical trial."
2982747|NCT02678507||Patients with chronic pain on opioids|
2982748|NCT02678494|Experimental|Neurofeedback training|Neurofeedback training: self-administered at home for 3 months. 3-5 sessions per week initially, then at least once a week. Each session consists of 5-6 blocks of 5 minute training.
2982749|NCT02678481|Experimental|MR-targeted biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MR imaging two targeted biopsy cores will be taken.
2982750|NCT02678481|Experimental|TRUS-guided biopsy|Patients of arm B receive a saturation TRUS-guided prostate biopsy.
2982751|NCT02678468||high-risk group|children with birth history of pre-term, low birth weight children with develop delay
2982752|NCT02678468||normal group|children with normal birth history and normal development
2982753|NCT02678455|Experimental|TV005 vaccine|Participants will receive one dose of TV005 vaccine at study entry (Day 0).
2982754|NCT02678455|Placebo Comparator|Placebo|Participants will receive one dose of placebo at study entry (Day 0).
2982755|NCT02678442|Active Comparator|FNB first, then FNA|In an endoscopic ultrasound-guided procedure, Shark Core Fine Needle Biopsy (FNB) will be performed first, followed by Fine Needle Aspiration (FNA).
2982756|NCT02678442|Active Comparator|FNA first, then FNB|In an endoscopic ultrasound-guided procedure, Fine Needle Aspiration (FNA) will be performed first, followed by Shark Core Fine Needle Biopsy (FNB).
2982757|NCT02678429|Active Comparator|DBS programming, standard of care|DBS settings determined from the standard Neurologist symptomatic response, first
2982758|NCT02678429|Experimental|DBS progamming from Atlas|DBS settings determined from the a functional atlas only,first
2982759|NCT02678416|Experimental|IV Acetaminophen/Placebo tablets|Acetaminophen, 100 mL of 1,000 mg/100 mL will be administered IV (15 minute infusion) and 2 placebo tablets will be administered orally
2982760|NCT02678416|Experimental|IV Placebo/Acetaminophen tablets|An IV placebo 100 mL (15 minute infusion of saline) and 2 acetaminophen tablets (500 mg/tablet) will be administered orally
2982761|NCT02678416|Placebo Comparator|IV Placebo/Placebo tablets|An IV placebo 100 mL (15 minute infusion of saline) and 2 placebo tablets will be administered orally
2982762|NCT02678416|Active Comparator|IV Morphine/Placebo tablets|An IV morphine (0.1 mg/kg) in 100 mL saline (15 minute infusion of saline) and 2 placebo tablets will be administered orally
2982763|NCT02678403|Experimental|1 - TENS group|The treatment will consist of Transcutaneous electrical nerve stimulation (TENS): stimulation of the leg (frequency of 10 Hz, Biphasic, with a pulse width of 200 µs, maximal intensity below motor threshold), 45 minutes per day, in the morning before the exercise rehabilitation programme, for 3 weeks, 5 days per week.
2982764|NCT02678403|Sham Comparator|2 - SHAM group|SHAM Transcutaneous electrical nerve stimulation (TENS) : the stimulation placebo will be delivered according to the same modalities as for the TENS group but with a voltage level that vanishes automatically after 10 seconds of stimulation.
2982765|NCT02678390|Experimental|Healthy women|"30 g of MCT per day for five days with two evaluation of the glucose/ketone/lipid metabolism (4-hour visit with repeated blood sampling) at the beginning and at the end of the sudy.~30 g of MCT per day in combination with 30 minutes of aerobic exercise (70% to 80% HRMax) per day for five days with two evaluation of the glucose/ketone/lipid metabolism (4-hour visit with repeated blood sampling) at the beginning and at the end of the sudy."
2990444|NCT02626663||MAHA|other microangiopathic hemolytic anemias
2982766|NCT02678390|Experimental|Women with prediabetes|"30 g of MCT per day for five days with two evaluation of the glucose/ketone/lipid metabolism (4-hour visit with repeated blood sampling) at the beginning and at the end of the sudy.~30 g of MCT per day in combination with 30 minutes of aerobic exercise (70% to 80% HRMax) per day for five days with two evaluation of the glucose/ketone/lipid metabolism (4-hour visit with repeated blood sampling) at the beginning and at the end of the sudy."
2982767|NCT02678377|Active Comparator|OnabotulinumtoxinA injections|100 units of OnabotulinumtoxinA (Botox®) injected into the detrusor (large muscle of the bladder) at the time of sling surgery.
2982768|NCT02678377|Sham Comparator|Saline injections|100 units of saline injected into the detrusor (large muscle of the bladder) at the time of sling surgery.
2982769|NCT02678364|Placebo Comparator|Control egg group|Two or less control (non-biofortified) eggs per week
2982770|NCT02678364|Active Comparator|Vitamin D3-eggs group|Seven vitamin D3-biofortified eggs per week
2982771|NCT02678364|Active Comparator|25-Hydroxyvitamin D-eggs group|7 25-hydroxyvitamin D-biofortified eggs per week
2982772|NCT02678351|Experimental|Diagnostic (68Ga-PSMA PET/MRI)|Patients receive 68Ga-PSMA IV. Patients then undergo PET/MRI after 45 minutes of administration of radiopharmaceutical injection.
2982773|NCT02678338|Experimental|Hu5F9-G4|Dose Escalation: CD47 blocking antibody Hu5F9-G4
2982774|NCT02678325|Active Comparator|Standardized normal protein enteral nutrition formula|Standardized enteral nutrition formula with a caloric density of 1.2 kcal/ml and protein percentage 20% of the total caloric intake
2982775|NCT02678325|Experimental|Standardized high protein enteral nutrition formula|Standardized enteral nutrition formula with a caloric density of 1.2 kcal/ml and protein percentage 33% of the total caloric intake
2982776|NCT02678312|Experimental|Part 1: LCZ696 open label|LCZ696 open label either 1) 0.8 mg/kg or 2) 3.1 mg/kg or both. After LCZ696 PK assessment, patients will be maintained on open-label Enalapril or standard of care for heart failure treatment, if patient consents to participate in Part 2.
2982777|NCT02678312|Active Comparator|Part 2: Enalapril|The target dose for enalapril is 0.2 mg/kg bid (0.4 mg/kg total daily dose) with a maximum dose of 10 mg bid (20 mg total daily dose).
2982778|NCT02678312|Experimental|Part 2:LCZ696|LCZ696 3.125 mg granules and adult formulation (50, 100, 200 mg) can be given based on patient weight.
2982779|NCT02678299|Experimental|Treatment|
2982780|NCT02678286|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
2982781|NCT02678286|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
2982782|NCT02678273|Experimental|Intervention group|Intervention
2982783|NCT02678273|No Intervention|Control group|Standard care when patient is in the hospital. At discharge, patients may be referred to community services as deemed necessary by the hospital team. This is not restricted.
2982784|NCT02678260|Experimental|PDR001|PDR001 will be administered i.v. every two weeks until a patient experiences unacceptable toxicity, progressive disease as per irRC and/or treatment is discontinued at the discretion of the investigator or the patient. The treatment period will begin on Cycle 1 Day 1. For the purpose of scheduling and evaluations, a treatment cycle will consist of 28 days. During the study, cohorts of patients will be treated with PDR001 until the maximum tolerated dose (MTD) is reached or a lower recommended dose (RD) is established.
2982785|NCT02678247|Active Comparator|NU-FlexSIV Socket|The Northwestern University Flexible Sub-Ischial Vacuum Socket is a novel socket design for transfemoral amputees.
2982786|NCT02678247|Active Comparator|IC Socket|The Ischial Containment Socket is the standard of care socket design for transfemoral amputees.
2982787|NCT02678234|Experimental|Theraflu Aktiv powder for oral solution|Participants in this arm will receive a single dose (1 sachet) of Theraflu Aktiv powder for oral solution
2982788|NCT02678234|No Intervention|No Treatment|Participants in this arm will not receive any medication
2982789|NCT02678221|Active Comparator|Sildenafil citrate with Aspirin|will receive sildenafil citrate 20mg ̸ 8hours plus low dose aspirin 150mg/day
2982790|NCT02678221|Other|placebo with Aspirin|will receive placebo plus low dose aspirin 150mg/day
2982791|NCT02678208|Active Comparator|Tranexamic acid|received tranexamic acid containing 1 g/10mL tranexamic acid diluted with 20 mL of 5% glucose over a 5 minute period
2982792|NCT02678208|Other|placebo|received 30 mL of 5% glucose over the same period of time.
2982793|NCT02678195|Experimental|3 days amoxicillin + 2 days placebo|3 days amoxicillin DT + 2 days placebo DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age).
2982794|NCT02678195|Active Comparator|5 days amoxicillin|5 days amoxicillin DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age).
2982795|NCT02678182|No Intervention|A1: Surveillance|Patients in this Arm will follow current UK standard of care for this setting and will be reviewed every 4 weeks
2982796|NCT02678182|Experimental|Arm A2: Capecitabine Maintenance|1250 mg/M2/DAY on days 1-21
2982797|NCT02678182|Experimental|Arm A3: MEDI4736 (Durvalumab)|IV treatment on day 1 +15, on a 28 day cycle.
2982798|NCT02678182|Active Comparator|Arm B1: Trastuzumab Maintenance|6mg/kg on day 1 every 21 days
2982799|NCT02678182|Experimental|Arm A4: Rucaparib|600mg PO twice daily
2982800|NCT02678169||Penumbra Aspiration System|Penumbra Aspiration System with the ADAPT technique
2982801|NCT02678156||LYoplant ONlay|Primary objective of the study is the generation of clinical data in patients receiving Lyoplant® Onlay for dura repair to assess its safety.
2982831|NCT02677896|Experimental|Enzalutamide plus androgen deprivation therapy (ADT)|Subjects will receive enzalutamide once daily. ADT (either bilateral orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) will be maintained during study treatment as per standard of care (SOC) and provided by the site's pharmacy stock.
2982832|NCT02677896|Placebo Comparator|Placebo plus androgen deprivation therapy (ADT)|Subjects will receive matching placebo once daily. ADT (either bilateral orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) will be maintained during study treatment as per standard of care (SOC) and provided by the site's pharmacy stock.
2984163|NCT02669056|Other|term babies|term babies with blood test prescription
2982802|NCT02678143|Experimental|Recipients|"The recipient of one antigen mismatch unrelated HSCT will begin the preparative regimen on Day -7. Alemtuzumab on Days -7, -6, -5, -4, and -3, cyclophosphamide on Days -4 and -3, and 300 cGy of total body irradiation (TBI) on Day -2.~The recipient of haplo-SCT will begin the preparative regimen on Day -7. Alemtuzumab on Days -7, -6, -5, -4, and -3, fludarabine on Days -7, -6, -5, -4, and -3, cyclophosphamide on Days -4 and -3, and 400 cGy of TBI on Day -2.~For both types of HSCT, the frozen peripheral blood stem cells will be thawed and infused on Day 0 per institutional guidelines. GVHD prophylaxis will consist of cyclophosphamide on Days +3 and + 4, mycophenolate mofetil (MMF) three times a day on Days +5 through +35 then tapered off over 1 week provided there is no evidence of GVHD, and sirolimus starting on Day +5 and continuing for one year. Sirolimus can be tapered at one year only if donor T-cell chimerism reaches more than 50% in the absence of GVHD."
2982803|NCT02678130|Active Comparator|InterFuse Group|Patients are randomized based on last digit (odd) of social security number to be treated with an InterFuse T device
2982804|NCT02678130|Active Comparator|Control Group: Standard of care TLIF|treated with a standard of care TLIF (Transforaminal Lumbar Interbody Fusion) device (e.g. Stryker's AVS Unilif)
2982805|NCT02678117|Active Comparator|Pregabalin & placebo|: will receive single dose oral Pregabalin 300 mg one hour preoperative and 200 ml of normal saline over 20 min.
2982806|NCT02678117|Active Comparator|Magnesium sulphate & Placebo|will receive preoperative single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline and a placebo capsule similar to pregabalin 300 mg.
2982807|NCT02678117|Active Comparator|Pregabalin & Magnesium sulphate|: will receive single dose oral pregabalin 300mg one hour preoperative and single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline.
2982808|NCT02678117|Placebo Comparator|Placebo|will receive placebo medications at the same time and route of administration of other groups.
2982809|NCT02678104|Experimental|Chlorhexidine mouth wash|Tooth extraction. The patients will start using Chlorhexidine mouthwash on 2nd day of extraction twice daily for 7 days.
2982810|NCT02678104|Experimental|Manuka Honey|intra-alveolar application of Manuka Honey after tooth extraction.
2982811|NCT02678091|Experimental|Patients|Patients with an orbital mass
2982812|NCT02678065|Experimental|InPact Admiral|Patients treated with the InPact Admiral balloon for popliteal lesions
2982813|NCT02678052||Cohort 1: No Chronic Disease|Pregnant women without a current diagnosis of any chronic disease with no exposure to any biological agent and at any time from first day of last menstrual period (LMP) will be observed for up to 1 year.
2982814|NCT02678052||Cohort 2: UC/CD Prospective Cohort|Pregnant women with current diagnosis of UC or CD with exposure to Entyvio or other biologic agents during pregnancy at any dose, and at any time from first day of LMP will be observed for up to 1 year.
2982815|NCT02678039|Experimental|Fluoroscopy|"Real-time fluoroscopic X-ray guidance to confirm placement of an epidural catheter in the spinal epidural space at the desired location.~Following epidural catheter placement, 1/8% bupivacaine is infused at 4ml/hr into the epidural catheter during and after surgery for pain control."
2982816|NCT02678039|Active Comparator|Traditional|"The traditional approach for placement of an epidural catheter is used with indirect indicators of placement including palpation of spine and 'loss-of-resistance' to fluid injection.~Following epidural catheter placement, 1/8% bupivacaine is infused at 4ml/hr into the epidural catheter during and after surgery for pain control."
2982817|NCT02678026|Experimental|Cervical Pessary|"Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early).~Women will receive pessary soon after UIC"
2982818|NCT02678026|No Intervention|No intervention|No treatment
2982819|NCT02678013|Experimental|Radiofrequency ablation(RFA)|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
2982820|NCT02678013|Active Comparator|RFA+CTL|RFA was performed the same as RFA Arm.Peripheral blood (20-30mL) for manufacturing the individualized highly-purified CTL agent was collected from the respective patients who were randomized to the immunotherapy group before starting treatment. The highly-purified CTL agent was prepared at a central manufacturing facility. Patients in the immunotherapy group received 5*10E9 of the highly-purified CTL agent intravenously over 60 minutes without any premedication and then were observed for at least 30 minutes. They were scheduled to receive highly-purified CTL: 4-6 treatments at a frequency of once two-week during 6 months after receiving RFA, followed by 6-9 treatments during 6 months to 2 years after receiving RFA.
2982821|NCT02678000|Experimental|LHW090|"For Part 1, patients will receive 3 doses of LHW090 once daily with escalating doses every 4 days for a total 12 days of treatment.~For Part 2, patients will receive LHW090 once daily for 4 weeks."
2982822|NCT02678000|Placebo Comparator|Placebo|For Part 1, patients will receive matching placebo once daily for 12 days. For Part 2, patients will receive matching placebo once daily for 4 weeks.
2982823|NCT02677987|Experimental|Intervention light|30 minutes of intervention systematic light exposure daily for 4 weeks.
2982824|NCT02677987|Active Comparator|Comparison light|30 minutes of comparison systematic light exposure daily for 4 weeks.
2982825|NCT02677974||On-X Aortic Heart Valve replacement|Patients with On-X Aortic Valve maintained on low dose warfarin anticoagulation with an INR target of 1.5 to 2.0, with or without home monitoring.
2982826|NCT02677948|Experimental|Pacritinib and Ibrutinib|"Phase I: Patients will receive Pacritinib 100-200 mg twice daily along with Ibrutinib 420mg/day.~Phase II Lead-In: Pacritinib at MTD daily continuous x 2 months followed by Pacritinib at MTD twice daily along with Ibrutinib 420mg/day."
2982827|NCT02677935|Experimental|Intervention|community support program
2982828|NCT02677922|Experimental|Oral AG-120 + Subcutaneous (SC) azacitidine|Subjects with an IDH1 mutation will receive AG-120 at the RP2D orally QD on Days 1-28 of each 28-day cycle + azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.
2982829|NCT02677922|Experimental|Oral AG-221 + Subcutaneous (SC) azacitidine|Subjects with an IDH2 mutation will receive AG-221 at the RP2D orally QD on Days 1-28 of each 28-day cycle + azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.
2982833|NCT02677883|Experimental|Arm I: Manometry-guided thoracentesis|Intervention Group - Patients undergo fine needle- aspiration, called therapeutic thoracentesis, to drain fluid accumulated around the lung. Unlike Arm II, the intervention group will have their pleural pressure monitored during the procedure.
2982834|NCT02677883|Active Comparator|Arm II: Symptom-guided thoracentesis|Comparison Group - Patients undergo symptom-guided thoracentesis, the current standard-of-care is to drain fluid until 1) it is all gone or 2) a symptom occurs that indicates the lung may take longer to fully re-expand and drainage should be stopped.
2982835|NCT02677870|Other|Diet treatment|In part 1 of the study, patients will not receive any medication. Each patient will DIET treatment alone. They will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week. Based on these diaries, average weekly Phe intake and Phe tolerance will be calculated and recorded.
2982836|NCT02677870|Active Comparator|Standard dose saproterin dihydrochloride|"Study numbers will be randomized into standard-dose saproterin dihydrochloride (Kuvan) or high-dose saproterin dihydrochloride (Kuvan)  groups (treatment group A or treatment group B). Both groups will receive a trial of both standard and high dose saproterin dihydrochloride before the end of the study. Standard-dose saproterin dihydrochloride will be 20mg/kg (rounded up to the nearest 100mg) provided in the form of 100mg tablets. Dosing of the tablets will be unidentifiable to patients. Medication will be given orally once daily."
2982837|NCT02677870|Experimental|High dose saproterin dihydrochloride|"Study numbers will be randomized into standard-dose saproterin or high-dose saproterin groups (treatment group A or treatment group B). Both groups will receive a trial of both standard and high dose saproterin dihydrochloride before the end of the study. Goal high-dose saproterin dihydrochloride dosing will be 40mg/kg (rounded up to the nearest 500mg), provided in the form of pre-packaged 500mg packets of powder. Labeled dosing on these packets will be covered by the investigational drug pharmacy and unidentifiable to patients. Dosing of the tablets will be unidentifiable to patients. Medication will be given orally once daily."
2982838|NCT02677857|Active Comparator|Lifestyle|Participants will be educated on the relationship between MVPA and improved health outcomes, including weight management, and cancer survivorship. The goal will be to increase MVPA to > 40 min/day 5 times/wk As participants will be overweight/obese, inactive, and coming into the program with different levels of baseline fitness and time since last cancer treatment, participants will shape their MVPA to meet the targeted goals. Initially, participants will be encouraged to complete MVPA > 10 min/day 5 times/wk, and then progressively increase MVPA by 5 min/day every week until reaching the intervention goal (week 7 of the 12 week intervention). Participants will be encouraged to do brisk walking and be allowed to accumulate time spent being physically active by engaging in multiple short bouts (i.e., > 10 min in length). Any MVPA in bouts of > 10 min in length will be counted towards the MVPA goal. Participants will self-monitor their MVPA using the Polar® Loop tracking system.
2982839|NCT02677857|Active Comparator|Lifestyle + SB|Participants will receive everything that is described in Lifestyle. Additionally, they will be educated on the relationship between SB and weight management, and cancer survivorship risk. The goal will be to reduce sedentary time by > 2 hrs/day or > 14 hrs/wk. Participants will shape towards the goal. Baseline measures will be used as the starting point from where to calculate the 2 hrs/day reduction, providing participants with a total SB goal per day. For example, if baseline measures indicate that a participant has a mean daily SB amount of 9.75 hrs, the participant's SB goal will be 7.75 hrs/day. To achieve that goal, participants will reduce SB by 20 minutes a day, starting week 2, with a decrease of an additional 20 minutes/day occurring weekly until the SB goal is achieved (week 7 of the 12 week intervention. Participants will self-monitor their SB using the Polar® Loop tracking system.
2982840|NCT02677857|No Intervention|Newsletter|Participants in this condition will receive standard care and every month they will receive a newsletter that provides information and tips about healthy eating and activity behaviors. This newsletter will include information on myPlate,28 activity guidelines,29 reading food labels, healthy recipes, and seasonal activity suggestions.
2982841|NCT02677844|Experimental|Abemaciclib|200 - 600 mg single increasing oral dose of abemaciclib on Day 1 of up to 3 study periods.
2982842|NCT02677844|Placebo Comparator|Placebo|Single oral dose of placebo on Day 1 of 1 study period.
2982843|NCT02677844|Active Comparator|Loperamide|Cohort 2, only. 8 mg Loperamide given orally once in 1 of 4 study periods.
2982844|NCT02677844|Experimental|Loperamide + Abemaciclib|Cohort 2, only. 8 mg Loperamide co-administered with abemaciclib given orally once in up to 1 of 4 study periods.
2982845|NCT02677844|Active Comparator|Loperamide + Placebo|Cohort 2, only. 8 mg Loperamide co-administered with placebo given orally once in up to 1 of 4 study periods.
2982846|NCT02677818||experimental group|The risk of bleeding adverse reactions when FVIII below the normal level.
2982847|NCT02677818||control group|The risk of bleeding adverse reactions when FVIII in normal level.
2982848|NCT02677805|Experimental|Botulinum toxin A|Botulinum Toxin A will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into glabellar area.
2982849|NCT02677805|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1 divided in five 0.1 mL injections into the glabellar area.
2982850|NCT02677792|Experimental|Behavioral Family Intervention (BFI)|
2982851|NCT02677779|Experimental|CO2 laser|Ulcer debridement with laser-CO2 (DEKA SmartXide2 c80-El.En, Florence Italy)
2982852|NCT02677779|Active Comparator|Traditional surgery|Ulcer debridement with traditional surgery
2982853|NCT02677766|Experimental|Intervention|Intervention of Occupational therapy consists of implementing plans of action focused on the occupational needs chosen by patients through COPM
2982854|NCT02677766|Active Comparator|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
2982855|NCT02677753|Active Comparator|Fluoroscopy guided PNE|Fluoroscopy will be utilized to assist with placement and/or confirm correct placement of lead wires.
2982856|NCT02677753|No Intervention|PNE without fluoroscopic guidance|No fluoroscopy will be used during or after the placement of the lead wires.
2982952|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part B)|One cycle of olaratumab alone (administered IV on Days 1 and 8). For all subsequent cycles, olaratumab and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.
2982857|NCT02677740|Experimental|Inhibitory rTMS (1 Hz)|Subjects are exposed to a 20-min inhibitory rTMS intervention that transiently suppresses the excitability of cortical structures beneath the site of stimulation. Subjects undergo MRI and MRS both before and right after the rTMS intervention. One week before the MRI/MRS acquisitions, neurophysiological parameters are also measured before and right after the rTMS intervention.
2982858|NCT02677740|Experimental|Excitatory rTMS (5 Hz)|Subjects are exposed to a 20-min excitatory rTMS intervention that transiently increases the net excitability of cortical structures beneath the site of stimulation. Subjects undergo MRI and MRS both before and right after the rTMS intervention. One week before the MRI/MRS acquisitions, neurophysiological parameters are also measured before and right after the rTMS intervention.
2982859|NCT02677714|Experimental|Patients with breast cancer receiving chemotherapy|"Patients with early stage breast cancer receiving 4 cycles of doxorubicin-based chemotherapy (doxorubicin:60 mg/m² and cyclophosphamide: 600 mg/m²) at about 2 week intervals followed by paclitaxel.~Patients will undergo 99mTc-rhAnnexin V-128 scans at 60 min and 2 hrs and a Cardiac Magnetic Resonance Imaging at baseline, after the 2nd cycle of chemotherapy, after the 4th cycle of chemotherapy and 12 weeks after the last cycle of chemotherapy."
2982860|NCT02677701|Active Comparator|azithromycin|azithromycin 500mg tablet over-encapsulated to match placebo in appearance, taken by mouth thrice weekly for 6 weeks
2982861|NCT02677701|Placebo Comparator|placebo|encapsulated placebo taken by mouth thrice weekly for 6 weeks
2982862|NCT02677688|Experimental|Autologous EBV specific CTL infusion|
2982863|NCT02677675|Experimental|Intervention (reminder module)|"A reminder module which included standardized weekly SMS medication reminders (sent at 9am every Monday); SMS reminder 3 days prior to scheduled clinic appointments (individualized and sent at lunch time), and an average of 90sec lunch hour telephone call reminders a day prior to scheduled clinic appointment (in addition to standard care - routine adherence counselling) was delivered consistently for 24 weeks to respondents in the intervention group by two trained PLHIV (research assistants)"
2982864|NCT02677675|No Intervention|Control (standard care)|Control group received standard care only (routine adherence counselling and paper-based appointment scheduling)
2982865|NCT02677662|Sham Comparator|Filtered air exposure|2 hour exposure to filtered air during intermittent exercise or rest.
2982866|NCT02677662|Experimental|Diesel exhaust exposure|2 hour exposure to dilute diesel exhaust (approximate PM10 (particulate matter<10um) concentration 300 mcg/m3) during intermittent exercise or rest.
2982867|NCT02677649|Active Comparator|cranberry|30 grams/day freeze dried whole cranberry powder added to a basal diet comprising meats, dairy products, simple sugars, and stevia
2982868|NCT02677649|Placebo Comparator|placebo|30 grams/day placebo powder [made with maltodextrin (CPC Maltrin M-180), citric acid, artificial cranberry flavor (Lorann oils), fructose, red color (Lorann oils), and grape shade] added to a basal diet comprising meats, dairy products, simple sugars, and stevia
2982869|NCT02677636|Experimental|MSRD-100|MSRD-100 is a topical gel with an active ingredient in a vehicle. Excipients are purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. Application is twice daily for 28 days.
2982870|NCT02677636|Placebo Comparator|Placebo Comparator|The vehicle is a topical gel and contains excipients of the formulation: purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. It does not contain the active ingredient MSRD-100. Application is twice daily for 28 days.
2982871|NCT02677623|Experimental|A- Pyridium|"Method of administration: oral~Dose: 200 mg PO with small sip of water~Known adverse events: yellow discoloration of skin or sclera, 1-10% central nervous system effects including headache and dizziness, GI effect of cramping, < 1% acute renal failure, methemoglobinemia, hemolytic anemia, hepatitis, rash, skin pigmentation, vertigo, stomach cramps~Contraindications: to be used in caution in patients with renal impairment Cr Cl < 50ml/minute and in patients who are receiving nitric oxide, prilocaine and sodium nitrite as it can cause methemoglobinemia"
2982872|NCT02677623|Experimental|B- Sodium Fluorescein|"Method of administration: intravenous~Dose: 25 mg~Known adverse events: nausea, vomiting, flushing or rash, hypersensitivity and anaphylactic reactions can occur following injection and immediate treatment with epinephrine should be available, skin and urine discoloration (urine may appear bright yellow for 24-36 hours), extravasation may cause skin sloughing, toxic neuritis and phlebitis, nausea, rare cardiac arrest and seizure,~Contraindications: use with caution in patients with history of hypersensitivity, allergies or asthma"
2982873|NCT02677623|Experimental|C- Mannitol|"Method of administration: irrigant during cystoscopy~Dose: 300cc during cystoscopy to visualize the ureters~Known adverse events: dysuria, polyuria, hyponatremia with excess absorption, potential increased risk of urinary tract infection~Contraindications when used as a genitourinary irrigation solution: anuria"
2982874|NCT02677623|Experimental|Control- Normal saline|"Method of administration: irrigant during cystoscopy~Dose: 300cc~Known adverse events: no known significant adverse events~Contraindications: none"
2982875|NCT02677610|Experimental|MSRD-100|MSRD-100 is a topical gel with an active ingredient in a vehicle. Excipients are purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. Application is twice daily for 28 days.
2982876|NCT02677610|Placebo Comparator|Vehicle|The vehicle is a topical gel and contains excipients of the formulation: purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. It does not contain the active ingredient MSRD-100. Application is twice daily for 28 days.
2982877|NCT02677597|Experimental|Cisplatin Combined With S-1|Cisplatin 75mg/m2 ivgtt d1 S-1 BSA＜1.5 50mg bid，BSA≥1.5 60mg bid po d1-14
2982878|NCT02677597|Experimental|Cisplatin Combined With Paclitaxel|Cisplatin 75mg/m2 ivgtt d1 Paclitaxel 175mg/m2 d1 ivgtt 3h
2982879|NCT02677584|Active Comparator|Prophylactic caffeine citrate|Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
2982957|NCT02677103|Experimental|RSWT group|The RSWT was delivered at 2 Hz with 2000 shock waves and the energy level of 0.26mJ/mm2 in calcific tendinitis of shoulder. RSWT will be performed once per week, and will be continued for 3 weeks.
2982880|NCT02677584|Active Comparator|Therapeutic caffeine citrate|Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
2982881|NCT02677571|Experimental|PVB|51 patients receiving US guided homolateral paravertebral thoracic block with 30ml of 0.25% levobupivacaine, before general anesthesia (TCI-TIVA).
2982882|NCT02677571|Experimental|PECS|51 patients receiving US guided pectorals nerve block with 30ml of 0.25% levobupivacaine, before general anesthesia (TCI-TIVA).
2982883|NCT02677558||CFOP obese|"Transthoracic Echocardiography in pregnant women with a gestational age of greater or equal 36 weeks who have a BMI of greater or equal 40kg/m2 at the time point of inclusion into the study.~Exclusion criteria: cardiac disease, on any cardiovascular drugs, pre-eclampsia or eclampsia."
2982884|NCT02677558||CFOP control|"Transthoracic Echocardiography pregnant women with a gestational age of greater or equal 36 weeks who have a BMI of less or equal 30kg/m2 at the time point of inclusion into the study.~Exclusion criteria: cardiac disease, on any cardiovascular drugs, pre-eclampsia or eclampsia"
2982885|NCT02677545|Experimental|Ticagrelor & Aspirin|Participants will receive a loading dose of 180 mg ticagrelor 1-3 days before stenting followed by a maintenance dose of 90 mg twice daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.
2982886|NCT02677545|Active Comparator|Clopidogrel & Aspirin|Participants will receive a loading dose of 300 mg clopidogrel 1-3 days before stenting followed by a maintenance dose of 75 mg once daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.
2982887|NCT02677532|Active Comparator|Epidural infusion|Thoracic epidural bolus of 10 ml levobupivacaine 0.25% plus sufentanil 0.15 mcg/kg before end of surgery, followed by continuous epidural infusion of 0.12% levobupivacaine plus 0.4 mcg/ml at 5 ml/h infusion rate for 48 hours.
2982888|NCT02677532|Experimental|Wound infusion plus morphine bolus|Intravenous slow bolus of 10 mg morphine, wound infiltration with 10 ml levobupivacaine 0.5%, followed by pre-peritoneal continuous wound infusion of levobupivacaine 0.25% at 4 ml/h infusion rate for 48 hours.
2982889|NCT02677519|Experimental|10 mg Aptensio XR|10 mg methylphenidate, extended release
2982890|NCT02677519|Experimental|15 mg Aptensio XR|15 mg methylphenidate, extended release
2982891|NCT02677519|Experimental|20 mg Aptensio XR|20 mg methylphenidate, extended release once daily
2982892|NCT02677519|Experimental|30 mg Aptensio XR|30 mg methylphenidate, extended release
2982893|NCT02677519|Experimental|40 mg Aptensio XR|40 mg methylphenidate, extended release
2982894|NCT02677519|Experimental|50 mg Aptensio XR|50 mg methylphenidate, extended release
2982895|NCT02677519|Experimental|60 mg Aptensio XR|60 mg methylphenidate, extended release
2982896|NCT02677506|Experimental|Supraclavicular|Supraclavicular brachial plexus block will be done.
2982897|NCT02677506|Active Comparator|Infraclavicular|Infraclavicular brachial plexus block block will be done.
2982898|NCT02677493|Experimental|IL-YANG Quadrivalent Influenza Vaccine|The QIV is included both B strain (Yamagata, Victoria).
2982899|NCT02677493|Active Comparator|IL-YANG Flu Vaccine Prefilled Syringe|This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.
2982900|NCT02677493|Active Comparator|IL-YANG Trivalent Influenza Vaccine|This TIV is included the B/Victoria strain.
2982901|NCT02677480|Active Comparator|Test group, probiotic tablets and gel|Test group, probiotic tablets and gel: tablets with probiotic bacteria (10exp8/tablet) and pH-rising components and gel (with probiotic bacteria and pH-rising components) in trays on the teeth once a week.
2982902|NCT02677480|Placebo Comparator|Placebo group, placebo tablets and gel|Placebo group, placebo tablets and gel: placebo tablets without probiotic bacteria and pH-rising components and gel (with no probiotic bacteria but with pH-rising components) in trays on the teeth once a week.
2982903|NCT02677467||Spontaneous epistaxis|A participant enroll if their age is over 18 with spontaneous epistaxis and their cause of visiting ER is spontaneous epistaxis. Exclusion criteria is that they needs immediately treatment for hypertensive urgency. And, they don't want to participate in this investigation. Investigators examine their blood-pressure variability and cardiovascular risk throughout their blood sample analysis.
2982904|NCT02677467||Bleeding of wound|A participant enroll if their age is over 18 with bleeding of wound and their cause of visiting ER is to bleed on wound. Exclusion criteria is that their wounds' condition is serious or their pain is much severe. And, they don't want to participate in this investigation. Investigators examine their blood-pressure variability and cardiovascular risk throughout their blood sample analysis.
2982905|NCT02677454|Experimental|Flash Glucose Monitor|"Each patient with Type 1 diabetes will have a subcutaneous tissue FGM sensor inserted. The sensor will produce a maximum of 1440 tissue fluid glucose measurements per 24 hours and 20160 measurements during the 14 day study. The FGM data (Abbott Freestyle Libre) will be compared to the time-matched reference blood glucose measurements.~Each ambulatory patient will sample capillary blood with the HemoCue meter and measure the concentration of glucose 6 to 10 times per day for 14 days. The concentration of finger-stick capillary blood glucose will be measured using the self-monitoring blood glucose (SMBG) hemocue meter in their daily living. The subjects will record SMBG, in a written diary. Subjects will dose insulin according to their routine methods throughout the 14 day study."
2982906|NCT02677441|Experimental|Conservative management|Conservative management includes a sling for 10 days, followed by specific standardized validated rehabilitation that includes range of motion recovery and progressive reinforcement.
2982907|NCT02677441|Active Comparator|Surgery|Surgical fixation of ACJD with coracoclavicular and acromioclavicular fixation, followed by specific standardized validated rehabilitation that includes range of motion recovery and progressive reinforcement.
2982953|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part B)|One cycle of olaratumab alone (administered IV on Days 1 and 8). For all subsequent cycles, olaratumab administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 though 5. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.
2982954|NCT02677116|Experimental|Olaratumab + Doxirubicin (Part C)|Olaratumab administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.
2982908|NCT02677428|Experimental|Remotely Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
2982909|NCT02677428|Active Comparator|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation & Pension-related information: (a) the Veterans Benefits Administration (VBA) website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C&P office where issues pertaining to an individual Veteran's specific application are addressed.
2982910|NCT02677415|Other|Local anesthesia|local anesthesia and spontaneous breathing will be maintained.
2982911|NCT02677415|Other|General anesthesia|Intravenous anesthetics and controlled ventilation will be used .
2982912|NCT02677402|Experimental|cold water immersion|Participants immersed their lower limbs in water of ~12°C
2982913|NCT02677402|Experimental|contrast water therapy|Participants immersed their lower limbs in water : alternated every 2 min between ~12°C and ~35°C for CWT
2982914|NCT02677402|Experimental|thermo neutral immersion|Participants immersed their lower limbs in water of ~35°C
2982915|NCT02677389|Experimental|Arm I (Enhanced SCP)|See Detailed Description
2982916|NCT02677389|Active Comparator|Arm II (SCP)|"Participants receive a standard SCP, comprised of a treatment and follow up recommendations, including basic physical activity guidance, copy of the USDA Dietary Guidelines for Americans, as well as standardized emails with wellness tips and information on stress management provided from the American Heart Association's website on Healthy Habits at 1, 2, 4, and 8 weeks. Specific topics in emails include positive self-talk, daily relaxation breathing techniques, better sleep, and ways to find pleasure."
2982917|NCT02677363|Experimental|Older adults|Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
2982918|NCT02677350|Experimental|Pilot|Twenty (20) subjects will be treated with 20 million (2 x 10^7) Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs) total divided into 10 injections of 2 million cells/cm of tract in 0.5 ml volume (for total volume of 5 ml per visit) at 4 week intervals for a maximum of 4 treatment sessions based on the discretion of the endoscopist at the time of injection.
2982919|NCT02677337|No Intervention|No intervention|
2982920|NCT02677337|Other|Educational Program|chart abstraction will be conducted post education intervention component.
2982921|NCT02677324|Experimental|ABT199|ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles
2982922|NCT02677311|Other|Cases|Participants who will receive gonadotoxic chemoradiation therapies to include the alkylating agents, heavy metals and plant alkaloids as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.
2982923|NCT02677311|Other|Controls|Participants who will receive chemoradiation therapies presumed to be low risk for gonadotoxicity as determined by the literature and the patient's oncolologist as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.
2982924|NCT02677298|Experimental|Botulinum toxin A|Botulinum Toxin A (Clostridium botulinum toxin type A) will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into the glabellar area.
2982925|NCT02677298|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1. divided in five 0.1 mL i.m. injections into the glabellar area.
2982926|NCT02677285||Skin graft|The bioimpedance measurement is done with a purpose built patch that has electrodes in contact with the wound and reference electrodes.
2982927|NCT02677285||Operation wound|The bioimpedance measurement is done with commercial electrodes places in healthy skin surrounding the wound.
2982928|NCT02677259|Experimental|Estradiol + Standard Luteal Phase Support|"17-beta estradiol 3 mg PO/PV BID from day of oocyte retrieval until 6 weeks gestation~Micronized progesterone 200 mg PV TID from day of oocyte retrieval until 10 weeks gestation"
2982929|NCT02677259|Active Comparator|Standard Luteal Phase Support|1. Micronized progesterone 200 mg PV TID from day of oocyte retrieval until 10 weeks gestation
2982930|NCT02677246|Experimental|Denosumab|Phase 1, 3+3 design with inter-patient dose escalation from 1mg/kg/dose to 2mg/kg/dose, and possibility of a dose de-escalation of 0.5mg/kg/dose, A modification of 3+3 design is implemented to take into account the achievement of bone resorption blockade by Denosumab. CTX is a biologic marker of bone resorption. Provided a decrease of CTX blood level will be observed under the lower limit (2,5th percentile) for age and sex, or under 20% of the pre-treatment level, there will be no reason to continue escalating the dose. This modified 3+3 design prevents exposure of children to dose escalations that would not be needed regarding the medical and biological aims of this trial.
2982955|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part C)|Olaratumab and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.
2983025|NCT02676648|Experimental|Experimental: Condition 6|1) core program; 2) breath meter; 3) text messages
2982931|NCT02677233||preeclamptic group|"Blood pressure: greater than or equal to 140 mmHg systolic or greater than or equal to 90 mmHg diastolic on two occasions at least 4 hours apart after 20 weeks of gestation (Roberts et al., 2013).~Proteinuria: protein/creatinine ratio greater than or equal to 0.3~In the absence of proteinuria, a new-onset hypertension with new onset of the following:~thrombocytopenia: platelet count less than 100.000/microliter~renal insufficiency: serum creatinine greater than 1.1 mg/dl~impaired liver function: elevated concentration of liver transaminases~pulmonary edema~cerebral or visual symptoms~Severe right upper quadrant or epigastric pain unresponsive to medication."
2982932|NCT02677233||non preeclamptic group|All are normotensive with blood pressure <140/90 with no proteinuria.
2982933|NCT02677220|Experimental|Surgical|Subjects to be implanted with the CI532 cochlear implant in one ear
2982934|NCT02677207|Experimental|JNJ-39393406|2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.
2982935|NCT02677207|Placebo Comparator|Placebo|2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.
2982936|NCT02677194|Experimental|Exposition LED|The patient is his own witness. This is a randomization for the allocation of treatments (LED parameters) on 6 mini-zones of 1,5x1,5 cm at the level of forearm. Dermabrasion by fractional laser CO2 ablative, evaluation of the pain on every zone by VAS post-act : exposition to LED 590nm (4 or 12sec) or 630nm(4min30 or 15 min) or 830 nm (6 or 12 min).
2982937|NCT02677194|Other|Control|Device without any LED exposition : This is a randomization for the allocation of treatments (LED parameters) on 6 mini-zones of 1,5x1,5 cm at the level of forearm or control (1 mini-zone)
2982938|NCT02677181|Experimental|ATG combined regimen|"ATG combined regimen for prophylaxis of GVHD, includes ATG, MMF(Mycophenolate mofetil ),CsA (cyclosporin A) and MTX (methotrexate).~All recipients in this arm received ATG, CsA, mycophenolate mofetil, and short-term methotrexate for GVHD prophylaxis. ATG (Thymoglobuline, rabbit) was used on 2.5 mg/kg/d from days -4 to -3). CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11."
2982939|NCT02677181|Active Comparator|no-ATG|regimen for prophylaxis of GVHD without ATG. The regimen includes MMF,CsA and MTX.CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11.
2982940|NCT02677168|Experimental|cNEP|Subjects with OSA will be treated with cNEP (continuous negative external pressure) at home for three weeks
2982941|NCT02677155|Experimental|Intranodal immunotherapy and anti-PD1|"Induction phase: 3 cycles of sequential intranodal immunotherapy (SIIT), every second week:~Radiotherapy 8 Gy single dose day 2, Rituximab 5 mg intranodal day 1 and 3, Autologous dendritic cells 1x 10 e8 intranodal day 4 and 5, GM-CSF 50 ug subcutaneously day 4 and 5, Pembrolizumab 200 mg intravenous day 5,~Consolidation phase:~Pembrolizumab 200 mg intravenous every third week for 8 cycles"
2982942|NCT02677142|Active Comparator|Attention Control Group (CG)|Behavioural: CG: Social Skills Activities: Participants in this arm will experience an 8-week manualized intervention program with activities and games. Sessions will NOT be designed around a specific social skill and activities and games will NOT have a specific focus. Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
2982943|NCT02677142|Experimental|Experimental Group (EG)|Behavioral: Structured social skills training program, SSIP. Participants in this arm will experience an 8-week manualized intervention program that addresses six major social skills, one per session, starting with easier skills (Social Initiation and Friendship Making, Cooperation) and moving towards more complex skills (Managing Teasing and Bullying, Conflict Resolution, Empathy, and Assertion). Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
2982944|NCT02677129|Experimental|home-based exercise intervention|"home-based exercise intervention:~Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems."
2982945|NCT02677129|No Intervention|Waiting control group|The wait list control group receives usual care over the study period. Usual care depends on the hospital guidelines as well as oncologists' and physicians' consideration.
2982946|NCT02677116|Experimental|Olaratumab Alone (Part A)|Olaratumab administered intravenously (IV) on Days 1 and 8 for one cycle (21 days).
2982947|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part A)|One cycle of olaratumab alone (administered IV on Days 1 and 8). For all subsequent cycles, olaratumab administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.
2982948|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part A)|One cycle of olaratumab alone (administered IV on Days 1 and 8). For all subsequent cycles, olaratumab and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.
2982949|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part A)|One cycle of olaratumab alone (administered IV on Days 1 and 8). For all subsequent cycles, olaratumab administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 though 5. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.
2982950|NCT02677116|Experimental|Olaratumab Alone (Part B)|Olaratumab administered intravenously (IV) on Days 1 and 8 for one cycle (21 days).
2982951|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part B)|One cycle of olaratumab alone (administered IV on Days 1 and 8). For all subsequent cycles, olaratumab administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.
2982956|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part C)|Olaratumab administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 though 5. All cycles are 21 days. Treatment will cease when discontinuation criterion is met.
2982958|NCT02677103|Experimental|USNP group|All needle punctures will be guided by ultrasound (US). The puncture needle is a 3.8cm 22# needle attached on a 5ml syringe. Before puncture, the skin of the puncture site will be sterilized with better iodine, and the transducer will be covered with a sterilized plastic bag. After injecting 3cc 1% Xylocain in the subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back-and-forth puncture about 10-20 times (depending on the size of the plaques) within the calcific plaques will be performed. The needle tract will be monitored by ultrasound to make sure the needle penetrated through the calcific plaque, but does not penetrate the rotator cuff.
2982959|NCT02677103|Experimental|RSWT plus USNP|In this group, each subject will receive radial shock wave therapy after ultrasound-guided needle puncture, as described in the previous paragraphs
2982960|NCT02677090|Placebo Comparator|Placebo|Placebo
2982961|NCT02677090|Active Comparator|Dose 1 - Promitor®|Investigational product Dose 1
2982962|NCT02677090|Active Comparator|Dose 2 - Promitor®|Investigational product Dose 2
2982963|NCT02677090|Active Comparator|Dose 3 - Promitor®|Investigational product Dose 3
2982964|NCT02677077||Czech Republic|Approximately 230 participants with RRMS receiving commercial natalizumab in Czech Republic
2982965|NCT02677077||Belgium|Approximately 70 participants with RRMS receiving commercial natalizumab in Belgium
2982966|NCT02677064||patients with acute leukemia (AML or ALL)|
2982967|NCT02677051|Placebo Comparator|Placebo|About 15 subjects will be randomized into this arm, receiving pills with an inactive placebo.
2982968|NCT02677051|Experimental|Sulforaphane|"About 30 subjects will be randomized into this arm, receiving pills with glucoraphanin rich broccoli seed powder containing active myrosinase resulting in sulforaphane once ingested Doses will be weight dependent with each pill resulting in ~ 50 µmol sulforaphane.~Body weight Dose of sulforaphane 34 kg ~ 50 µmol 68 kg ~ 100 µmol 102 kg ~ 150 µmol"
2982969|NCT02677038|Experimental|Olaparib|Participants receive Olaparib tablets in a dose of 300 mg orally (p.o.) twice daily. Treatment continues until progression, intolerable toxicity or as per participant's preference. Each treatment cycle is 28 days long.
2982970|NCT02677025|Experimental|Young Women's Health CoOp (YWHC)|This is an adapted behavioral intervention for young women in Cape Town South Africa who dropped out of school, who use alcohol and other drugs and are at risk for HIV.
2982971|NCT02677025|Active Comparator|HIV Counseling/Testing|Provide age and gender appropriate standard HIV counseling and testing.
2982972|NCT02677012|Experimental|REVOLVE™ Tissue Process Group|Tissue is washed with a medical solution and spun at low speed to clean the fatty tissue and separate the fat tissue from other substances before it is transplanted.
2982973|NCT02677012|Experimental|PureGraft™ Tissue Process Group|System of filters used to wash fatty tissue with a medical solution and separate out unwanted substances before it is transplanted.
2982974|NCT02677012|Experimental|Coleman Technique Tissue Process Group|Fatty tissue is placed in a centrifuge. Tissue spun at high speed in order to separate the different substances in the tissue. Once the spinning is done, fat cells collected and transplanted.
2982975|NCT02676986|Active Comparator|Cohort I (ER positive cohort)|Approximately 180 patients with ER positive breast cancer will be randomised 2:1 in favour of enzalutamide to receive enzalutamide plus exemestane or exemestane alone.
2982976|NCT02676986|Active Comparator|Cohort II (AR positive, TNBC cohort)|55 patients with AR positive, TNBC will receive single agent treatment with enzalutamide.
2982977|NCT02676973|Active Comparator|Sacral Colpopexy|Sacral Colpopexy performed via open, robotic, or laparoscopic procedure.
2982978|NCT02676973|Active Comparator|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair: Sacrospinous Ligament Suspension (SSLS) and Uterosacral Ligament Suspension (USLS)
2982979|NCT02676973|Active Comparator|Apical Transvaginal Mesh Repair|Uphold™ LITE or Elevate™-AA (Anterior & Apical)
2982980|NCT02676947|Experimental|Open Label|Intravenous Tocilizumab 8mg/kg monthly (up to a maximum dose 800mg) for 6 months
2982981|NCT02676934|Experimental|Et group|applying end tidal concentration as a control target for delivery of sevoflurane
2982982|NCT02676934|No Intervention|FGF group|using Fresh gas control for sevoflurane delivery
2982983|NCT02676921||GROUP 1|Ten samples of sinus membrane where harvested from fifteen patients during a surgical nasal approach for treatment of chronic rhinosinusitis.
2982984|NCT02676908|No Intervention|4 weeks & EVLT|After endovenous laser therapy and avulsions, patients will wear compression socks for four weeks (usual care)
2982985|NCT02676908|No Intervention|4 weeks & RFA|After radiofrequency ablation therapy and avulsions, patients will wear compression socks for four weeks (usual care)
2982986|NCT02676908|Experimental|2 weeks & EVLT|After endovenous laser therapy and avulsions, patients will wear compression socks for two weeks (trial group)
2982987|NCT02676908|Experimental|2 weeks & RFA|After radiofrequency ablation therapy and avulsions, patients will wear compression socks for two weeks (trial group)
2982988|NCT02676895|Experimental|Group A - S. sonnei vaccine 25 μg|2 injections of S. sonnei vaccine 25 μg
2982989|NCT02676895|Experimental|Group B - S. sonnei vaccine 100 μg|2 injections of S. sonnei vaccine 100 μg
2982990|NCT02676895|Active Comparator|Group C - Control vaccines|2 injections of control vaccines (Menveo and Boostrix)
2982991|NCT02676882|Other|EnBrace HR|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks
2982992|NCT02676869|Experimental|IMP321 dose escalation|IMP321 administered fortnightly in addition to SOC pembrolizumab.
2982993|NCT02676856|Experimental|CR group|For the patients in CR group(CR status of AML at microtransplantation), the conditioning regimen is high-dose (HD) Ara-C. Hematopoietic stem cell microtransplantation will be given to these patients with long-term course.
2982994|NCT02676856|Experimental|Non-CR group|For the patients in Non-CR group (PR or NR status of AML at microtransplantation), the conditioning regimens include: IAC or HD Ara-C. Hematopoietic stem cell microtransplantation will be given to these patients with short-term course.
2982995|NCT02676843|Experimental|18F-AV-1451|Subjects will receive 18F-AV-1451 by injection, and undergo a Positron Emission Tomography (PET) scan, which will then be qualitatively analyzed to examine tau deposition in the brain.
2982996|NCT02676830|Experimental|K-312|
2983026|NCT02676648|Experimental|Experimental: Condition 7|1) core program; 2) breath meter; 3) diet-appropriate food and cookbooks
2982997|NCT02676817||Group 1|Group 1 (n=70) = UC in remission regardless of the medication that allowed remission nor taken by the patient (Mayo' sub-score 0 or 1) and who require colonoscopy regardless of the study according to current guidelines (screening for dysplasia, monitoring during treatment etc).
2982998|NCT02676817||Group 2|Group 2 (n=30) = Active UC (Mayo' sub-score 2 or 3) requiring adalimumab and for whom a rectosigmoidoscopy will be performed 8 to 12 weeks after starting therapy, according to current French guidelines and routine practice. Eight weeks after the treatment is the minimum time necessary to evaluate the effects of this treatment according the current practice in France. Then, investigators chose in our study to assess the effects in the group 2 at 8 weeks. All the 30 patients in group 2 will receive adalimumab and they will be anti-TNF naïve patients.
2982999|NCT02676804|Experimental|High-intensity aerobic exercise|Subjects will participate in a 16 week high-intensity aerobic exercise program.
2983000|NCT02676791|Experimental|A (Povidone-Iodine)|Esophageal washout will be performed via a nasogastric tube with approx. 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) during esophageal resection.
2983001|NCT02676791|No Intervention|B (Control)|Esophageal resection will be performed without esophageal washout.
2983002|NCT02676778|Experimental|E7777|Participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) will receive 9 μg/kg/day of E7777, administered by intravenous drip infusion in 60 minutes (± 10 min) for Days 1 through 5 of each cycle in maximum of 8 cycles. Every cycle consists of 3 weeks.
2983003|NCT02676765|Experimental|Allergen|Subjects will be administered either Timothy Grass or Short Ragweed sublingual allergen tablets, depending on their individual allergic sensitization.
2983004|NCT02676765|Placebo Comparator|Placebo|Subjects will be administered placebo sublingual tablets
2983005|NCT02676752||Skin/soft tissue elasticity assessment|Participants will be evaluated for LEF status using the HN-LEF Grading Criteria and neck range of motion using the Cervical Range of Motion Device. Participants also complete study questionnaires, including VHNSS and LSIDS-H&N. Participants undergo ultrasound shear wave elastography over 20-25 minutes. Participants' cancer disease and treatment information will be gathered from their medical records.
2983006|NCT02676739|Placebo Comparator|Placebo|Capsule with no active medical ingredients to be taken orally once a day for 12 weeks.
2983007|NCT02676739|Active Comparator|Adderall XR 10mg|10mg Adderall XR capsule to be taken orally once a day for 12 weeks.
2983008|NCT02676739|Active Comparator|Adderall XR 20mg|20mg Adderall XR capsule to be taken orally once a day for 12 weeks.
2983009|NCT02676726|Experimental|Extraperitoneal|Patients who where randomized to extraperitoneal laparoscopic aortic lymphadenectomy.
2983010|NCT02676726|Active Comparator|Transperitoneal|Patients who where randomized to transperitoneal laparoscopic aortic lymphadenectomy.
2983011|NCT02676713|Experimental|TCM Sequential Treatment|"After conservative surgery, patients start to take pre-ovulation decoction for 14 days. Each menstrual period 2～5 days, patients start to take pre-ovulation decoction. If ultrasonography found ovulation, change to take post-ovulation decoction. If having taken 14 days, ultrasonography found LUFS or no follicle develop maturity, change to take post-ovulation decoction. Taking post-ovulation decoction for 14 days, or continue to next time menstruation. Taking medication for six menstrual cycles.~Pre-ovulation decoction is HuoXueXiaoYi decoction, and post-ovulation decoction is BuShenZhuYun decoction. 2 bags each time, 2 times a day, fused with hot water, 1 hour after dinner.~All drugs are tcm formula granules, manufactured by Jiangyin Tianjiang Pharmaceutical Co. ltd"
2983012|NCT02676713|Placebo Comparator|Placebo|"After conservative surgery, patients start to take pre-ovulation decoction(placebo) for 14 days. Each menstrual period 2～5 days, patients start to take pre-ovulation decoction. If ultrasonography found ovulation, change to take post-ovulation decoction. If having taken 14 days, ultrasonography found luteinized unruptured follicle syndrome (LUFS) or no follicle develop maturity, change to take post-ovulation decoction. Taking post-ovulation decoction(placebo) for 14 days, or continue to next time menstruation. Taking medication for six menstrual cycles. 2 bags each time, 2 times a day, fused with hot water, 1 hour after dinner.~Pre-ovulation decoction and post-ovulation decoction is placebo, manufactured by Jiangyin Tianjiang Pharmaceutical Co. ltd"
2983013|NCT02676700|Active Comparator|Pelvic floor muscle training and Kaatsu|"Participants are instructed in the PFMT program by primary investigator and instructed in Kaatsu training by a research nurse. The Kaatsu training is performed 4 times a week before PFMT. The program includes 2 x 15 knee extensions with partly occlusion of the blood supply to the thigh. Training level is >12 RM. Training is performed sitting on a chair and rubber bands are used to increase resistance. Training adherence and bother with the training is reported in a training diary. At week 6 the research nurse adjusts the training program.~The PFMT program includes three sets of 10 contractions with an intensity of >12 RM and is to be performed 4 times a week.~Training adherence and any bother with the training is reported in a training diary."
2983014|NCT02676700|Active Comparator|pelvic floor muscle training|"Participants perform the same PFMT program as the intervention group. The PFMT program includes three sets of 10 contractions with an intensity of >12 RM and is to be performed 4 times a week.~Training adherence and any bother with the training is reported in a training diary."
2983015|NCT02676687|Active Comparator|total resection|Removing the parenchyma until signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
2983016|NCT02676687|Experimental|supratotal resection|Extended removing the parenchyma at least 1cm beyond signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
2983017|NCT02676674|Experimental|Intervention|Three topical applications of 100,000 units of vitamin D3 in a newly formulated ointment will be applied to the upper arms over three weeks.
2983018|NCT02676661||no peri-implant disease|The subjects who did not suffer from peri-implant disease.
2983019|NCT02676661||peri-implant disease|The subjects who suffered from peri-implant disease.
2983020|NCT02676648|Experimental|Experimental: Condition 1|1) core program; 2) breath meter; 3) text messages; 4) diet-appropriate food and cookbooks
2983021|NCT02676648|Experimental|Experimental: Condition 2|1) core program
2983022|NCT02676648|Experimental|Experimental: Condition 3|1) core program; 2) breath meter
2983023|NCT02676648|Experimental|Experimental: Condition 4|1) core program; 2) text messages
2983024|NCT02676648|Experimental|Experimental: Condition 5|1) core program; 2) diet-appropriate food and cookbooks
2992997|NCT02609646||vancomycin|patients treated with vancomycin
2983029|NCT02676635|Experimental|Ergonomics and Safety Voice Training|Participants in this arm receive training on both Ergonomic principles and Safety Voice training
2983030|NCT02676635|No Intervention|Control Group|Participants in this arm will receive no additional Ergonomics or Safety Voice training
2983031|NCT02676622|Experimental|Stem-cell mobilization and Leukapheresis|"Stem-cell mobilisation will be achieved using Cyclophosphamide (CY) 4g/m² (2g/m2 on 2 consecutive days) followed 5 days later by filgrastim (G-CSF) 10 mg/kg injection. This will be done daily until the day before the last day of leukapheresis. The PBSCs will be harvested usually between day +9 and +11 of completing CY.~Leukapheresis will be performed to a target cell dose of 3-8 x106 CD34+ cells/kg Approximately 1 month later patients will undergo HSCT"
2983032|NCT02676609|Active Comparator|Use of smart phone application (device glucal)|"Before each meal patient will enter in the application food intakes. Automated carbohydrate and meal insulin dose computing according to individual meal insulin/carbohydrate ratio.~During the first month, then during the second month they'll use as usual their traintement and meal without the apllication"
2983033|NCT02676609|Active Comparator|Use of smart phone application (second month)|"During the first month they'll use as usual their traintement and meal without the apllication ,then during the second month they'll use the apllicatioin.~Before each meal patient will enter in the application food intakes. Automated carbohydrate and meal insulin dose computing according to individual meal insulin/carbohydrate ratio."
2983034|NCT02676596|Other|Cohort 1|Japanese and Non-Japanese subjects receiving K-312 50 mg QD
2983035|NCT02676596|Other|Cohort 2|Japanese and Non-Japanese subjects receiving K-312 100 mg QD
2983036|NCT02676596|Other|Cohort 3|Japanese and Non-Japanese subjects receiving K-312 200 mg QD
2983037|NCT02676596|Other|Cohort 4|Japanese and Non-Japanese subjects receiving K-312 400 mg QD
2983038|NCT02676596|Other|Cohort 5|Japanese and Non-Japanese subjects receiving K-312 25 mg QD
2983039|NCT02676596|Other|Cohort 6|Japanese and Non-Japanese subjects receiving K-312 10 mg QD
2983040|NCT02676583|Active Comparator|Billateral tonsil fossa closure|tonsillectomy
2983041|NCT02676583|Active Comparator|No closure of tonsil fossa|tonsillectomy
2983042|NCT02676583|Active Comparator|Unilateral tonsil fossa closure|tonsillectomy
2983043|NCT02676557||LASIK|
2983044|NCT02676544|Experimental|Embosphere microspheres|Embospheres are calibrated microspheres which will be percutaneously delivered intra-arterially via a microcatheter under fluoroscopic guidance to occlude the prostatic arteries.
2983045|NCT02676531|Experimental|Walking Meditation|"Walking Meditation program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking while listening to the sound Budd and Dha and squeeze rubber balls according to the sound in order to practice mindfulness while walking. In phase 1 (week 1-6), Walking Meditation will be conducted at initial moderate intensity (41-50% heart rate reserve) 3 sets, 10 minutes per set and rest 3 minutes between set In phase 2 (week 7-12), the training intensity will be increased to ultimate moderate intensity (51-60% heart rate reserve) 3 sets, 15 minutes per set and rest 3 minutes between set. In both phases of the training, the frequency of Walking Meditation training is three times a week."
2983046|NCT02676531|No Intervention|No Walking meditation|keep regular activities, sedentary life style.
2983047|NCT02676518||polycystic ovary syndrome women|PCOS women diagnosed by Rotterdam criteria visiting the Gynecologic Unit at King Chulalongkorn Memorial Hospital and meet the inclusion criteria and no exclusion criteria of the study
2983048|NCT02676505||1|"Group (I)(Coached group):~It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds."
2983049|NCT02676505||2|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth.
2983050|NCT02676492||Tic Disorder|Boys with a diagnosis of Tourette Syndrome (TS) or chronic tic disorder (CTD) aged 11-14 years
2983051|NCT02676492||Control|Boys aged 11-14 years without a diagnosis of TS/CTD (i.e. typically developing)
2983052|NCT02676479|Experimental|Uterine Lavage Group|"The study will involve up to 30 pairs of male and female sexually intimate partners who are carriers for a genetic disease (e.g Sickle Cell Disease or Thalassemia) and at high risk of transmitting the gene.~The female partner will be superovulated to mature multiple oocytes which can be fertilized, inseminated with her partner's sperm through intra-uterine insemination (IUI). Four to six days after IUI, the female partner will undergo a non-surgical uterine lavage procedure (Previvo Uterine Lavage System™, CA, U.S.A.) to recover preimplantation embryos."
2983053|NCT02676466|Experimental|Omega-3 fish oil|This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.
2983054|NCT02676466|Experimental|Losartan|This group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.
2983055|NCT02676466|Placebo Comparator|Placebo corn oil + cellulose based|This group will receive a placebo which will be matching to both the omega-3 fish oil and losartan which will be administered at doses corresponding to doses administered for omega-3 fish oil and losartan throughout the 12 month study.
2983128|NCT02676011|Placebo Comparator|Group D|IM normal saline 1 ml normal 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
2983129|NCT02675998|Experimental|3mg BID|Tenapanor, 3mg BID (6mg total)
2983056|NCT02676466|Experimental|Omega-3 fish oil + losartan|"This group will receive both the Losartan and Omega-3 fish oil. Losartan will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.~Omega-3 fish oil will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month."
2983057|NCT02676466|Placebo Comparator|Placebo corn oil|This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.
2983058|NCT02676466|Placebo Comparator|Placebo cellulose based|This group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan.
2983059|NCT02676453|Experimental|Intervention|Dental hygienist support
2983060|NCT02676453|No Intervention|control|Care as usal
2983061|NCT02676440|Other|Treatment|Toothpaste containing 1.11% Fluoride as Sodium Monofluorophosphate and Zinc Citrate Trihydrate Serum containing 0.17% Fluoride as Sodium Monofluorophosphate and Zinc Sulphate Heptahydrate
2983062|NCT02676440|Other|Comparator|Silica toothpaste 1350ppm F as Sodium Fluoride
2983063|NCT02676414|Other|Education program|"Group of patients participating in the interactive hypertension education program of the DHL© My blood pressure - OK!"
2983064|NCT02676414|No Intervention|Controls|"Group of patients not participating in the interactive hypertension education program of the DHL© My blood pressure - OK! (usual care)"
2983065|NCT02676401|Experimental|MT-3995 Low|
2983066|NCT02676401|Experimental|MT-3995 Middle|
2983067|NCT02676401|Experimental|MT-3995 High|
2983068|NCT02676388|Experimental|Freeze-dried, Capsulized FMT|Patients included will receive bowel lavage and subsequent Freeze-dried, Capsulized FMT, and then will be followed up for 3 months.
2983069|NCT02676388|Experimental|Fresh FMT|Patients included will receive bowel lavage and subsequent Fresh FMT, and then will be followed up for 3 months.
2983070|NCT02676375|Other|Standard Monotherapy|Treatment as usual starting with one smoking cessation medication plus group therapy.
2983071|NCT02676375|Experimental|Combination Extended Treatment|Extended treatment with multiple standard medications plus group therapy.
2983072|NCT02676375|Experimental|Combination Extended Treatment + Home Visits/Calls|Extended treatment with multiple standard medications plus group therapy plus home visits.
2983073|NCT02676362|Experimental|the first day|Gingival crevicular fluid collection with filter paper the length of sampling time in seconds: 5., 10., 30.
2983074|NCT02676362|Experimental|the 2nd day|Gingival crevicular fluid collection with filter paper the length of sampling time in seconds: 10., 30., 5.
2983075|NCT02676362|Experimental|the 3rd day|Gingival crevicular fluid collection with filter paper the length of sampling time in second: 30., 5., 10.
2983076|NCT02676349|Experimental|Arm B|Neoadjuvant chemotherapy with mFolfirinox regimen + concomitant chemoradiotherapy + surgery + adjuvant chemotherapy
2983077|NCT02676349|Active Comparator|Arm A|Neoadjuvant chemotherapy with mFolfirinox regimen + surgery + adjuvant chemotherapy
2983078|NCT02676336|Active Comparator|Violet™ Iodine|3mg molecular iodine (I2) daily
2983079|NCT02676336|Placebo Comparator|Placebo|3mg placebo daily
2983080|NCT02676336|Active Comparator|Cross-over|Subjects on placebo will be offered 3 months of active post-treatment
2983081|NCT02676323|Experimental|Treatment|Participants will be given panobinostat in combination with fludarabine and cytarabine. Treatment consists of one course of therapy given over 12 days. Participants will also receive intrathecal triples and leucovorin
2983082|NCT02676310|Experimental|Cohort 1: Bimatoprost 0.3% (Formulation B)|0.25 mL of bimatoprost 0.3% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
2983083|NCT02676310|Experimental|Cohort 2: Bimatoprost 1% (Formulation A)|0.25 mL of bimatoprost 1% (Formulation A) applied onto pre-specified area on the scalp once daily for 28 days.
2983084|NCT02676310|Experimental|Cohort 2: Bimatoprost 1% (Formulation B)|0.25 mL of bimatoprost 1% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
2983085|NCT02676310|Experimental|Cohort 3: Bimatoprost 1% (Formulation B)|1 mL of bimatoprost 1% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
2983086|NCT02676310|Experimental|Cohort 4: Bimatoprost 3% (Formulation B)|1 mL of bimatoprost 3% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
2983087|NCT02676297|Experimental|Test product A|tiotropium
2983088|NCT02676297|Experimental|Test product B|tiotropium
2983089|NCT02676297|Active Comparator|reference product|tiotropium
2983090|NCT02676284|Experimental|Durolane SJ|single dose injection
2983091|NCT02676258|Experimental|Si-Hy soft contact lens|olifilon B daily disposable soft contact lens
2983092|NCT02676258|Active Comparator|Vistakon soft contact lens|narafilcon A daily disposable soft contact lens
2983093|NCT02676245|Experimental|Viewing NBS + DBS Educational Movies|Group A: pregnant women who will view the NBS and residual specimen movies and printed materials during one visit between 30 and 40 weeks gestation.
2983094|NCT02676245|Experimental|Viewing NBS Educational Movie only|Group B: pregnant women who will view the NBS movie only and printed materials at one visit between 30 and 40 weeks. The movies will be presented on a tablet PC.
2983095|NCT02676245|No Intervention|No Educational Interventions|Control Group: pregnant women who will receive no experimental intervention during pregnancy or the postpartum period but will receive whatever information is routinely provided by their OB clinic and/or delivery center.
2983130|NCT02675998|Experimental|10mg BID|Tenapanor, 10mg BID (20mg total)
2983131|NCT02675998|Experimental|Dose Titration|Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question
2983132|NCT02675998|Placebo Comparator|Placebo|Placebo
2983096|NCT02676232|Experimental|Intervention|Participants in this arm will follow DARWeb: an online psychosocial intervention for children with recurrent abdominal pain and their parents. This is composed by 7 units for parents and 7 units for children, that have been developed from the cognitive-behavioral model, including setting goals, relaxation and distraction techniques, changing maladaptive thoughts and assertive communication training. The team under the program only contact with families for sending reminders and to answer potential technical problems or doubts
2983097|NCT02676232|No Intervention|Control|Participants allocated in this arm will not receive intervention. However, they will be invited to participate once the families allocated to the experimental group complete the program.
2983098|NCT02676219|Experimental|RS01|oral care product containing containing sodium monofluorophosphate and sodium fluoride
2983099|NCT02676219|Placebo Comparator|Water|Water
2983100|NCT02676206|Experimental|Music intervention|Subjects will have headphones placed on 1 minute prior to procedural sedation. Classical music will be played until the subject is fully awake.
2983101|NCT02676206|No Intervention|Non intervention|Subjects will have headphones placed on 1 minute prior to procedural sedation. No music will be played. The headphones will be removed when the subject is fully awake.
2983102|NCT02676193|Experimental|Australian Packs|The intervention to be administered to participants randomized to this group is the purchase of their US brand of cigarettes packaged using standard Australian marketing for three months.
2983103|NCT02676193|Experimental|Plain Packs|The intervention to be administered to participants randomized to this group is the purchase of their US brand of cigarettes packaged using plain packaging for three months. Plain packaging will indicate participants brand and will not have any brand-related images or labels.
2983104|NCT02676193|No Intervention|American Packs|Participants assigned the nonintervention group will purchase their US brand of cigarettes in the standard American packaging for three months.
2983105|NCT02676167|Other|Intervention|
2983106|NCT02676154|Other|Fesoterodine|Open-Label
2983107|NCT02676128|Experimental|Mobile Health ART Adherence Application (mARTAA)|mARTAA will use a smartphone-delivered application developed by Twine Health, Inc.
2983108|NCT02676128|Active Comparator|Face-to-Face ART Adherence Intervention|A single face-to-face ART adherence intervention will be administered.
2983109|NCT02676115|Active Comparator|Control Group|Standard Post Operative Skin Care
2983110|NCT02676115|Experimental|Treatment Group|Medipore Tape will be applied to ACL reconstruction Incision
2983111|NCT02676102|Active Comparator|Control Group|Participant will watch an educational video produced in partnership with the community of black men including customers, employers and owners of BOBs.
2983112|NCT02676102|Active Comparator|Targeted Intervention|Participants will watch an educational video produced in partnership with the community of black men including customers, employees, and owners of BOBs. Video production was informed by entertainment education models and produced with experts including an Academy Award winning filmmaker.
2983113|NCT02676102|Active Comparator|Tailored Intervention|Participants will watch videos with content individualized to participant's pre-intervention ODBI scores representing their organ donation beliefs
2983114|NCT02676089|Experimental|CHF 5993 200/6/12.5 µg|"Treatment A:~CHF 5993 200/6/12.5 µg: 2 inhalations bid Total daily dose: 800/24/50 µg BDP/FF/GB"
2983115|NCT02676089|Active Comparator|CHF 1535 200/6 µg|"Treatment B:~CHF 1535 200/6 µg: 2 inhalations bid Total daily dose: 800/24 µg BDP/FF"
2983116|NCT02676089|Active Comparator|CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg|"Treatment C (open-label arm):~CHF 1535 200/6 µg: 2 inhalations bid~+ Tiotropium Respimat 2.5 µg: 2 inhalations od Total daily dose: 800/24 µg BDP/FF + 5 µg Tio"
2983117|NCT02676076|Experimental|CHF 5993 100/6/12.5 µg|"Treatment A:~CHF 5993 100/6/12.5 µg: 2 inhalations bid Total daily dose: 400/24/50 µg BDP/FF/GB"
2983118|NCT02676076|Active Comparator|CHF 1535 100/6 µg|"Treatment B :~CHF 1535 100/6 µg: 2 inhalations bid Total daily dose: 400/24 µg BDP/FF"
2983119|NCT02676063||neonatal Hypoxic Ischemic encephalopathy|moderate or severe HIE among term and late preterm newborn
2983120|NCT02676050|Experimental|Imaging agents and imaging devices|All participants in Cohort 1 will be dosed on one occasion with the optical imaging agents and Cohort 2 can be dosed twice per agent. The final dosage will be <100ug per agent. The agents will be delivered using a novel delivery catheter and imaged with a novel imaging fibre and microendoscopy system.
2983121|NCT02676024|No Intervention|Control|Resuscitation teams will participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR without being provided cognitive aids. Participants in this group will be allowed to use any cognitive aid that they happen to keep with them and would normally use in their practice, for example, flash cards or smart phone apps.
2983122|NCT02676024|Experimental|Knowledge-based cognitive aid|"Resuscitation teams participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR. However, they will be trained in using a knowledge-based cognitive aid, which will be used by a dedicated team member (the cognitive aid reader)."
2983123|NCT02676024|Experimental|Cognitive aids with roles defined (CARD)|Resuscitation teams participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR. Participants will be trained to use the cognitive aids with roles defined (CARD) system. However, they will not be given knowledge-based cognitive aids and there will be no dedicated cognitive aid reader in the team.
2983124|NCT02676024|Experimental|Integrated cognitive aids|Participants will be trained to use the cognitive aids with roles defined (CARD) system and also in the use of a protocol-based cognitive aid, which will be used by a dedicated cognitive aid reader.
2983125|NCT02676011|Active Comparator|Group A|Intramuscular (IM) atropine (0.01 mg/kg) (1 ml) 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
2983126|NCT02676011|Active Comparator|Group B|1 ml normal saline IM 30 minutes before induction of anesthesia, intravenously (IV) atropine (0.01 mg/kg) in 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
2983127|NCT02676011|Active Comparator|Group C|IM normal saline 1 ml normal 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and 1mg/kg atropine mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
2983133|NCT02675985|Experimental|Intervention arm|Early intensive physical therapy will be the intervention arm. There is not a control group.
2983134|NCT02675972||patient with poor outcome|modified Rankin scale≥3
2983135|NCT02675972||patients with favorable outcome|modified Rankin scale<3
2983136|NCT02675959|Experimental|Defibrotide prophylaxis|defibrotide will be given prior to and during myeloablative immunotherapy conditioning (MAIC) followed by familial haploidentical (FHI) allogeneic stem cell transplantation (AlloSCT) with CD34 enrichment and t-cell addback in patients with high-risk sickle cell disease to reduced the risk and rate of the development of sinusoidal obstructive syndrome (SOS).
2983137|NCT02675946|Experimental|CGX1321 alone and with pembrolizumab|"Dose Escalation Phase: Ascending doses of CGX1321 once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle~Dose Expansion Phase: Patients will receive CGX1321, at the MTD (identified in the Dose Escalation Phase), once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle.~Phase 1b: Patients will receive 9 mg or 12 mg CGX1321, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle)."
2983138|NCT02675933|No Intervention|Standard of Care|"The control arm participants will receive only a satisfaction survey once disposition is determined by the physician provider. The satisfaction survey will be collected by the research associated and kept in a protected location, along with all other study materials.~All patients will receive standard of care, which at this institution is the help of Child Life Specialists, when they are available and requested by the physician. Physicians will be instructed to request Child Life Specialists with the same discretion as with all patients."
2983139|NCT02675933|Active Comparator|Questionnaire|"Participants who are randomized to the questionnaire arm will receive a patient-centered questionnaire at the beginning of their visit. This single page document will ask questions about their child including, but not limited to, diagnoses, suggestions for distraction, sensory issues that may affect their visit, and method to best administer medications. The research associate will ask them to fill it out to the best of their ability and will collect the questionnaire prior to a physician provider seeing the patient. At least one physician provider must review the questionnaire prior to seeing the patient.~Once disposition is determined, the satisfaction survey will be distributed by the research associate along with an envelope for the parent to seal their survey within."
2983140|NCT02675920||High risk group of HCC|"known high risk group of HCC according to AASLD guideline. And patients whose risk index is equal to or higher than 2.33.~Risk Index = 1.65 (if the prothrombin activity is <=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is <=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus [HCV] or hepatitis B surface antigen [HBsAg] is positive).~Patients undergo ultrasonography and LDCT using non-ionic monomer iodinated CT contrast media biannually and the interval between ultrasound and LDCT is within 30 days."
2983141|NCT02675907|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
2983142|NCT02675907|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
2983143|NCT02675894|Active Comparator|RFA with cooled-wet electrode|RFA is performed using three cool-wet electrodes in switching bipolar mode under the fused US guidance.
2983144|NCT02675894|Active Comparator|RFA with separable clustered electrode|RFA using separable clustered electrode in switching monopolar mode under the fused US guidance
2983145|NCT02675881|Active Comparator|RFA DSM|Eligible patients who undergo RFA using DSM and separable clustered electrodes.
2983146|NCT02675881|No Intervention|RFA SSM|Historical control group consisted of patients underwent RFA in our institution with single switching mode (SSM) and single/ or multiple clustered electrodes.
2983147|NCT02675868|Experimental|Norepinephrine|The noradrenaline group: a group of 10 subjects that will receive noradrenaline 0.05 μg/kg/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
2983148|NCT02675868|Active Comparator|Vasopressins|The vasopressin group: a group of 10 subjects that will receive vasopressin 0.04 IU/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
2983149|NCT02675868|Active Comparator|Phenylephrine|The phenylephrine group: a group of 10 subjects that will receive phenylephrine 0.5 μg/kg/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
2983150|NCT02675868|Placebo Comparator|Placebo|The placebo group: a group of 10 subjects that will receive NaCl 0.9% infusion for 5 hours, starting 60 minutes before endotoxin administration.
2983151|NCT02675855|Experimental|GrafixPRIME®|GrafixPRIME® is cryopreserved human placental membrane Patients will be fitted with off-loading devices
2983152|NCT02675855|Active Comparator|Active Comparator|Wound cover, Dressing Application Patients will be fitted with off-loading devices
2983153|NCT02675842|Active Comparator|Smoked Cannabis High CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
2983154|NCT02675842|Placebo Comparator|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
2983155|NCT02675829|Experimental|Lung cancers, HER2 mutant|
2983156|NCT02675829|Experimental|Lung cancers, HER2 amplified|
2983157|NCT02675829|Experimental|Bladder and urinary tract cancers, HER2 amplified|
2983158|NCT02675829|Experimental|Other solid tumor cancers, HER2 amplified|
2983159|NCT02675816|Other|Inspire® (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System.
2983160|NCT02675803|Experimental|VAY736|VAY736 active
2983161|NCT02675803|Placebo Comparator|Placebo|VAY736 placebo
2983162|NCT02675790|Active Comparator|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
2983163|NCT02675790|Active Comparator|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
2983194|NCT02675608||Year 2 Group 1|They are between 18-64 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; do not have diabetes.
2984164|NCT02669043|Experimental|Ketamine|All participants receive open-label ketamine
2983164|NCT02675777|Experimental|Quality Improvement Intervention|"Quality improvement intervention: 4 months during which a practice facilitator supports the clinic in implementing routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs (see Intervention) as part of behavioral health integration."
2983165|NCT02675777|No Intervention|Usual Care|Care received after 2/2016 but before active implementation begins, which includes passive access to tools in the EHR and 2 months of preparation in each clinic (team building and local pretesting by a local implementation team supported by the external practice facilitator).
2983166|NCT02675764|Experimental|Experimental|The experimental group receives the wrist subthreshold vibrotactile stimulation during therapy.
2983167|NCT02675764|Active Comparator|Placebo|"The control group will wear the vibration device with no vibration.~Both groups cannot feel the vibration since the vibration intensity is set below the perceptible level.~The vibration device is a generic, commercially-available, vibrator, not particularly used for this peripheral skin stimulation purpose."
2983168|NCT02675751|Experimental|wavefront-guided PRK with iDesign|wavefront-guided PRK for treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser
2983169|NCT02675725||Post cardiac surgery|Patients after cardiac surgery with signs of decreased organ perfusion and the need of fluid therapy.
2983170|NCT02675712||Adults with acute mood disorders|Adults aged over 18 diagnosed with an acute episode of a mood disorder using DSM-V criteria
2983171|NCT02675699|Experimental|Optimisation + HENRY|
2983172|NCT02675699|Active Comparator|HENRY as standard|
2983173|NCT02675673|Active Comparator|GJ-Tube arm|Patients randomized to his arm would usually have a small tube is inserted through the nose into the stomach first, so that air can be used to fill the stomach to make it visible on X-ray. A fine needle is then used to inject freezing medicine (local anesthetic) into the skin of the abdomen. Using an x-ray machine for guidance, a puncture is made into the stomach through the frozen skin. The feeding tube is placed through this puncture into the stomach and the tube tip is placed in the small bowel. Once the GJ-tube has been inserted, the tube in the nose is removed.
2983174|NCT02675673|Active Comparator|G-Tube arm|Patients who are randomized to this arm will usually have a small tube is inserted through the nose into the stomach first, so that air can be used to fill the stomach to make it visible on X-ray. A fine needle is then used to inject freezing medicine (local anesthetic) into the skin of the abdomen. Using an x-ray machine for guidance, a puncture is made through the frozen skin. A small guiding tube or catheter is placed through this puncture into the stomach, and is advanced up the esophagus and out of the mouth. The feeding tube is then pulled into the mouth, down the esophagus, and positioned through the abdomen with its inside tip in the stomach.
2983175|NCT02675660|Experimental|L-Homoarginine|125 mg of L-homoarginine
2983176|NCT02675660|Placebo Comparator|Placebo|placebo capsules
2983177|NCT02675647|Experimental|Intervention group|"Obese patients, randomized to receive an initial IV bolus of Heparin, before beginning of the cardiopulmonary bypass, at the dosage of 340 UI/kg based on ideal body weight of the obese patients.~The objective is to obtain an ACT target ≥ 400 s before the beginning of CPB. If necessary, additional boluses of heparin are administered at the dose of 100 UI/kg based on ideal body weight, to maintain this target during the CPB."
2983178|NCT02675647|Active Comparator|Control group|"Obese patients, randomized to receive an initial IV bolus of Heparin, before beginning of the cardiopulmonary bypass, at the usual dosage of 300 UI/kg based on total body weight of the obese patients.~The objective is to obtain an ACT target ≥ 400 s before the beginning of CPB. If necessary, additional boluses of heparin are administered at the dose of 100 UI/kg based on total body weight, to maintain this target during the CPB."
2983179|NCT02675634|Experimental|Test A, Test B, Subjects own product|The subjects first test Coloplast Test A, followed by Coloplast Test B and finally Subjects own product
2983180|NCT02675634|Experimental|Test A, Subjects own product, Test B|The subjects first test Coloplast Test A, followed by Subjects own product, and finally Coloplast Test B
2983181|NCT02675634|Experimental|Test B, Test A, Subjects own product|The subjects first test Coloplast Test B, followed by Coloplast Test A and finally Subjects own product
2983182|NCT02675634|Experimental|Test B, Subjects own product, Test A|The subjects first test Coloplast Test B, followed by Subjects own product, and finally Coloplast Test A
2983183|NCT02675634|Experimental|Subjects own product, Test A, Test B|The subjects first test Subjects own product, followed by Test A, and finally Coloplast Test B
2983184|NCT02675634|Experimental|Subjects own product, Test B, Test A|The subjects first test Subjects own product, followed by Test B, and finally Coloplast Test A
2983185|NCT02675621|Placebo Comparator|Control|Mix 1 flavored still beverage
2983186|NCT02675621|Active Comparator|Phenolic beverage 1|Mix 2 flavored still beverage with a high dose phenolic extract
2983187|NCT02675621|Active Comparator|Phenolic beverage 2|Mix 3 flavored still beverage with a high dose phenolic extract1 and a fruit extract
2983188|NCT02675621|Active Comparator|Phenolic beverage 3|Mix 4 flavored still beverage with a low dose phenolic extract3 and a fruit extract
2983189|NCT02675608||Year 1 Group 1|They are between 18-65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; have no history of immunodeficiency or weakened immunologic function; do not have diabetes; and do not have chronic HIV or hepatitis B or C infection.
2983190|NCT02675608||Year 1 Group 2|They are ≥65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; have no history of immunodeficiency or weakened immunologic function; do not have diabetes; and do not have chronic HIV or hepatitis B or C infection.
2983191|NCT02675608||Year 1 Group 3|They are between 18-65 years of age, are currently diabetic, and meet the criteria listed above for not diabetic subjects in Group 1, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
2983192|NCT02675608||Year 1 Group 4|They are ≥65 years of age, are currently diabetic, and meet the criteria listed above for non-diabetic subjects in Group 2, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
2983193|NCT02675608||Year 1 Group 5|They are between 35-50 years of age, meet the criteria listed above for non-diabetic subjects in Group 1, with the exception of chronic HIV with or without hepatitis B or C infection, and have current medical history of CD4 T-cell counts 300-800.
2983195|NCT02675608||Year 2 Group 2|They are ≥65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; do not have diabetes.
2983196|NCT02675608||Year 2 Group 3|If they are between 18-64 years of age, are currently diabetic, and meet the criteria listed above for not diabetic subjects in Group 1, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
2983197|NCT02675608||Year 2 Group 4|If they are ≥65 years of age, are currently diabetic, and meet the criteria listed above for non-diabetic subjects in Group 2, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
2983198|NCT02675582|Placebo Comparator|Control|Mix 1 flavored still beverage
2983199|NCT02675582|Experimental|Herbal beverage 1|Mix 2 flavored still beverage with a botanical extract(1)
2983200|NCT02675582|Experimental|Herbal Beverage 2|Mix 3 flavored still beverage with a botanical extract(2)
2983201|NCT02675582|Experimental|Combined Herbal Beverage|Mix 4 flavored still beverage with 2 botanical extracts (1,2)
2983202|NCT02675569|Active Comparator|Catheter|Catheter is a method of vascular access for hemodialysis. It consists of a long, thin plastic tube and may be either tunnelled or non-tunnelled.
2983203|NCT02675569|Experimental|Fistula|Fistula is a type of vascular access strategy for hemodialysis in which a direct connection of an artery to a vein is created. It is intended to provide an access with good blood flow that can last for decades.
2983204|NCT02675556|Experimental|Allogeneic hMSCs|Forty (40) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
2983205|NCT02675556|Placebo Comparator|Placebo|Forty (40) subjects will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
2983206|NCT02675556|Experimental|Pilot - Allogeneic hMSCs|Eight (8) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
2983207|NCT02675543|Experimental|Standard silicone oil|after vitreous removal, the vitreous chamber was filled with standard silicone oil (PDMS)
2983208|NCT02675543|Experimental|Heavy silicone oil|after vitreous removal, the vitreous chamber was filled with heavy silicone oil (Densiron 68)
2983209|NCT02675530|Experimental|healthy control|Healthy controls will receive electrophysiological assessments before and after NMDA antagonist administration.
2983210|NCT02675517||Spiolto Respimat|COPD patients requiring a fixed combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved SmPC and GOLD guidelines
2983211|NCT02675491|Experimental|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
2983212|NCT02675478|Experimental|AC220|This study will follow a mCRM (modified continual reassessment method) + EWOC (Escalation with Overdose Control) design.
2983213|NCT02675465|Experimental|ATB200|In Stage 1, safety, tolerability, and PK will be evaluated following sequential single ascending doses of intravenously infused ATB200 for 3 dosing periods.
2983214|NCT02675465|Experimental|ATB200 + AT2221|In Stage 2, safety, tolerability, and PK will be evaluated following single- and multiple-ascending dose combinations of ATB200 co-administered with AT2221 (Miglustat) In Stage 3, long term safety and efficacy will be assessed following 24 month treatment of ATB200 co-administered with AT2221 (Miglustat)
2983215|NCT02675452|Experimental|AMG 176 - Part 1a|Part 1a - dose exploration of the intervention, AMG 176
2983216|NCT02675452|Other|AMG 176 - Part 1b|Part 1b dose exploration. The intervention is AMG 176
2983217|NCT02675452|Other|AMG 176 - Part 2|Part 2 Combination therapy The intervention is AMG 176
2983218|NCT02675452|Experimental|AMG 176 - Part 3|Part 3 - Dose exploration. The intervention is AMG 176
2983219|NCT02675439|Experimental|Dose escalation monotherapy|ADU-S100 administered intratumorally on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxicity, progressive disease and/or treatment is discontinued; starting dose 50 micrograms
2983220|NCT02675439|Experimental|Dose escalation combination|ADU-S100 administered intratumorally on Days 1 and 8 of each 21-day cycle (starting dose 200 micrograms) and ipilimumab, i.v., (3 mg/kg) on day 1 of each 21-day cycle for the first 4 cycles. Dosing is continued until unacceptable toxicity, progressive disease and/or treatment is discontinued
2983221|NCT02675426|Placebo Comparator|Placebo followed by ABT-494 Dose A|Placebo once daily for 12 weeks (Period 1) followed by ABT-494 Dose A once daily for up to 5 years (Period 2)
2983222|NCT02675426|Placebo Comparator|Placebo followed by ABT-494 Dose B|Placebo once daily for 12 weeks (Period 1) followed by ABT-494 Dose B once daily for up to 5 years (Period 2)
2983223|NCT02675426|Experimental|ABT-494 Dose A|ABT-494 Dose A once daily for 12 weeks (Period 1) and up to an additional 5 years (Period 2)
2983224|NCT02675426|Experimental|ABT-494 Dose B|ABT-494 Dose B once daily for 12 weeks (Period 1) and up to an additional 5 years (Period 2)
2983225|NCT02675413|Experimental|Dimethyl Fumarate|Open label dimethyl fumarate (Tecfidera) at the US approved dose of 120mg BID for 7 days and then 240mg BID thereafter for 12 months.
2983226|NCT02675400|Active Comparator|Medication Arm|Vyvanse Arm: 3-week open-label titration beginning at 20 mg Vyvanse (a class II drug), and be increased weekly during the titration period until an optimal response is obtained and then continue for 5 weeks. Optimal response is defined as a clinician Clinical Global Impression-Improvement score (CGI-I) ≤ 2 with minimal associated adverse events. Fathers will remain on optimal dose through the course of the study. In cases of poor tolerability or loss of efficacy the dose can be changed. If an optimal response is not achieved a trial with a long acting methylphenidate will be initiated based upon the Texas algorithm for stimulant medication. The study physician will be available by phone 24 hours/day; participants will be instructed to call with any safety concerns.
2983227|NCT02675400|Active Comparator|Behavioral Parent Training Arm|"Behavioral Parent Training (BPT) Arm: Fathers in the BPT group will receive weekly parent training sessions based on the Barkley manual, Defiant Children, Third Edition. The child participants will also come to several sessions at the clinician's and supervisor's discretion."
2983228|NCT02675387|Active Comparator|Traditional Group|Children will be administered buccal infiltration anesthesia using a 21mm needle and 1.8ml of 2%Lidocaine
2983513|NCT02673476|Experimental|ALS-008176|ALS-008176 tablets
2983229|NCT02675387|Experimental|Buzzy|Children will be administered buccal infiltration anesthesia using a 21mm needle and 1.8ml of 2%Lidocaine after sensitizing the area with a vibrating device
2983230|NCT02675374|Experimental|Treatment group|24 patients
2983231|NCT02675374|Placebo Comparator|Control group|24 patients
2983232|NCT02675361|Experimental|Intervention group: transition program|Participants come from two clinics and will be randomly allocated to this group. Participants will go through a transition program which will last for 2 years. The intervention will be performed by specialist nurses.
2983233|NCT02675361|No Intervention|Comparison group|"Participants allocated to this group will receive usual care, which includes follow-up visits according to the complexity of the congenital heart disease. Usual care can vary across clinics, however, they all include meeting with a nurse and a physician.~This is established as a comparison group since there is the risk of contamination in this group."
2983234|NCT02675361|No Intervention|Control group|"Participants in this group will receive usual care. Follow-up visits will depend on the complexity of the disease.~Five clinis comprise this section of the study and will be part of an longitudinal, observational study, which investigators will use as a control group."
2983235|NCT02675348|Experimental|Dietary Supplement: Beef Protein|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.~Intervention will last for 10 weeks. Participants will ingest 20g of beef protein powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
2983236|NCT02675348|Experimental|Dietary Supplement: Whey Protein|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.~Intervention will last for 10 weeks. Participants will ingest 20g of whey protein powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
2983237|NCT02675348|Active Comparator|Dietary Supplement: CHO|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.~Intervention will last for 10 weeks. Participants will ingest 20g of maltodextrin powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
2983238|NCT02675335|Active Comparator|Sitagliptin|Sitagliptin tablets, 100mg per day, 12 weeks treatment
2983239|NCT02675335|Placebo Comparator|Placebo|Placebo tablets, 1 tablet per day, 12 weeks treatment
2983240|NCT02675322|Experimental|Danlou Tablets|Danlou tablets (4.5 g oral dose taken once daily) for 90 days
2983241|NCT02675322|Placebo Comparator|placebo|matching placebo for 90 days
2983242|NCT02675309|Experimental|MT-8554, rosuvastatin and simvastatin|Subjects will be administered a single dose of rosuvastatin followed on Day 4 by a single dose of simvastatin. MT-8554 will be administered from Days 6 to 12 with co-administration of rosuvastatin and simvastatin on Days 9 and 12, respectively.
2983243|NCT02675283|Other|coeliac disease point of care test|Patients will be consented for a finger prick point of care test, Simtomax, at the pharmacy.
2983244|NCT02675270|Experimental|Phonological, Orthographic, Untrained|
2983245|NCT02675270|Experimental|Semantic, Lexical, Untrained|
2983246|NCT02675257|Experimental|Cognitive-behavioural group treatment|"Five group sessions of diabetes-Specific cognitive-behavioural group treatment for diabetes patients with depressive symptoms and/or diabetes distress and suboptimal glycaemic control.~Interventions:~Diabetes-related affective problems analysis~Goal setting towards improvement of glycaemic control~Diabetes-specific problem-solving therapy~Interventions to increase diabetes treatment motivation~Activation of personal and social resources~Reduction of barriers to self-care/glycaemic control~Cognitive restructuring of diabetes-related problems~Goal definition regarding self-care/glycaemia/well-being"
2983247|NCT02675257|Active Comparator|Treatment-as-usual|"Standard diabetes education.~Interventions:~Health care and specific topics (e. g. blood pressure)~Healthy foods, cooking recommendations, recipes~Sports, activities and exercise~Foot care: exercises, care & control, injuries, neuropathy~Diabetes complications~Social aspects of living with diabetes"
2983248|NCT02675244|Active Comparator|MVS Alone|Participants will undergo mitral valve surgery alone.
2983249|NCT02675244|Active Comparator|MVS + TV Annuloplasty|Patients will undergo mitral valve surgery and tricuspid valve annuloplasty.
2983250|NCT02675231|Experimental|Abemaciclib + Trastuzumab + Fulvestrant|Abemaciclib given orally every 12 hours (Q12H) of a 21-day cycle; plus trastuzumab intravenous (IV) infusion on Day 1 of the cycle then a maintenance dose IV infusion on Day 1 of each subsequent cycle; plus fulvestrant intramuscularly (IM) on day 1, 15 and 29 and then once every 4 weeks thereafter.
2983251|NCT02675231|Experimental|Abemaciclib + Trastuzumab|Abemaciclib given orally Q12H of a 21-day cycle; plus trastuzumab IV infusion on Day 1 of the cycle then a maintenance dose IV infusion on Day 1 of each subsequent cycle.
2983252|NCT02675231|Active Comparator|Trastuzumab + Standard of Care Chemotherapy|Trastuzumab IV infusion on Day 1 of a 21-day cycle then a maintenance dose IV infusion on Day 1 of each subsequent cycle plus standard of care single agent chemotherapy of physician's choice administered according to product label.
2983253|NCT02675218||Patients with rheumatoid arthritis.|Rheumatoid arthritis diagnosis according to ACR (American College of Radiology)/EULAR 2010 classification criteria.
2983254|NCT02675205|Active Comparator|clopidogrel-aspirin|clopidogrel: 75mg and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery.
2983255|NCT02675205|Experimental|ticagrelor-aspirin|Ticagrelor: 90 mg bid and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery
2983256|NCT02675192||Proof cohort : muscular assessment|"Clinical examination : Body weight, BMI, cardiac frequency, muscular examination,...~Blood appraisal : glycaemia, lipidic appraisal, leptin, albumin, coagulation, metabolome and epigenetic tests,...~Urinary collection : metabolome tests~Maximal voluntary quadriceps strength (MVC)~Checking muscle functional skills~Muscular biopsy"
2983257|NCT02675179|Experimental|EOS + Spiral CT pelvimetry|Women with an indication of pelvimetry will be included in this study. They will be their own control because they will benefit from the two methods of diagnosis : EOS new technique, and spiral CT (usual technique).
2983258|NCT02675166||Pediatric cancer young adult survivors|544 patients alive and that are min 18 years old, included in the ARCERRA population register, for a primary cancer (not leukemia), diagnosed between 15 years old, between January the 1st 1993, and December the 31st 1999, in Rhône-Alpes.
2983259|NCT02675153|Experimental|Sirolimus|Subjects receive a continuous dosing schedule of oral sirolimus 2mg daily for six months and follow-up for at least one year.
2983260|NCT02675140|Experimental|ZENTEL|Children in intervention group 1 was received 400 mg single-dose albendazole administration, by mouth, for once.
2983261|NCT02675140|Experimental|ZENTEL and Vitamin A Soft Capsules|Children in intervention group 2 was received a 200,000 IU vitamin A capsule combined 400 mg single-dose albendazole once initially, by mouth.
2983262|NCT02675140|No Intervention|No drug adminitrated|Children in this Group were received no intervention as control group
2983263|NCT02675127|Experimental|A Test|Test drug (Daktavira, European Egyptian Pharmaceutical Industries)1 tablet contains 60 mg Daclatasvir
2983264|NCT02675127|Active Comparator|B Reference|Reference drug (Daklinza, (Bristol-Myers Squibb Pharma, UK)) 1 tablet contains 60 mg Daclatasvir
2983265|NCT02675114|Active Comparator|Surgical aortic valve replacement (SAVR)|
2983266|NCT02675114|Experimental|Edwards SAPIEN 3 THV|
2983267|NCT02675101|Active Comparator|Whole nuts|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume a combination of whole almonds and walnut pieces, a total of 110 g per day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Walnuts and almonds will be provided to participants for the duration of the study.
2983268|NCT02675101|Experimental|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume 29 potato crisps per day, which is approximately 18 g olestra/day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Fat free Pringles will be provided to participants for the duration of the study.
2983269|NCT02675101|Placebo Comparator|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume 29 potato crisps per day, which is approximately 17.4 g oil/day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Original Pringles will be provided to participants for the duration of the study.
2983270|NCT02675088|Experimental|high-dose TRT|high-dose thoracic radiotherapy X-ray RT
2983271|NCT02675088|Active Comparator|standard-dose TRT|standard-dose thoracic radiotherapy XRT
2983272|NCT02675075||Veterans With ALS|This Cohort Study will admit all eligible, interested Veterans diagnosed with ALS who meet the inclusion criteria.
2983273|NCT02675049|Placebo Comparator|0.9% saline|Patients were assigned to receive 0.9% saline intranasally 45 min before surgery using a computer-generated random number table.
2983274|NCT02675049|Experimental|dexmedetomidine 1 µg.kg-1|Patients were assigned to receive 1µg.kg-1dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
2983275|NCT02675049|Experimental|dexmedetomidine 1.5 µg.kg-1|Patients were assigned to receive 1.5µg.kg-1 dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
2983276|NCT02675049|Experimental|dexmedetomidine 2 µg.kg-1|Patients were assigned to receive 2µg.kg-1 dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
2983277|NCT02675036|Experimental|Primary canine tooth|Extraction of primary canine tooth
2983278|NCT02675036|Experimental|Primary canine and primary molar teeth|Extraction of primary canine and primary first molar teeth
2983279|NCT02675023|Experimental|Auto-injector (AI)|M923 administered via AI
2983280|NCT02675023|Experimental|Prefilled syringe (PFS)|M923 administered via PFS
2983281|NCT02675010|Other|ENDOSCOPIC GASTRIC BIOPSIES|ENDOSCOPIC BIOPSEIS TAKEN FROM BOTH ANTRUM AND CORPUS FOR H PYLORI DETECTION
2983282|NCT02674997||Study participants|Participants with Hemophila A
2983283|NCT02674984|Active Comparator|Combination Probiotic BB-12 with LGG|
2983284|NCT02674984|Placebo Comparator|Maldextrin|Placebo
2983285|NCT02674971|Active Comparator|INCREASE|This condition will be instructed to make food consumption decisions based solely upon the ED of a food. The goal of the ED condition will be to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) per day.
2983286|NCT02674971|Active Comparator|COMBINATION|This condition will be identical to the INCREASE condition, except it will also have a goal regarding the number of high-ED foods to consume and substituting low-ED foods for high-ED foods. Thus, this condition will have ED goals to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) and no more than 2 foods ≥ 3.0 kcal/g (i.e., crackers, chips, cookies, hard cheeses, hot dogs, salad dressings, etc.) per day. Foods with an ED >1.0 kcal/g but < 3.0 kcal/g will be unlimited; however, lower ED foods will be strongly encouraged. Furthermore, additions to beverages (i.e., sugar, cream) will count toward the > 3.0 kcal/g goal if the additions meet that ED criteria.
2983287|NCT02674958|Active Comparator|Aspirin|Aspirin 325mg orally bolus followed by 162mg orally daily during alcohol septal ablation for hypertrophic obstructive cardiomyopathy until day 7.
2983288|NCT02674958|No Intervention|No aspirin|No aspirin allowed during alcohol septal ablation for hypertrophic obstructive cardiomyopathy until day 7.
2983289|NCT02674945|Experimental|Wireless Activity tracker: Fitbit|Patients with brain tumor(s) will be give a wireless activity tracker (fitbit flex) to use during treatment. They will complete quality of life surveys and a sleep survey.
2983290|NCT02674932|Experimental|Signature Strengths|"Patients will complete the Values in Action Youth Survey (VIA-Youth) and will receive a list of his/her top character strengths (signature strengths). The patient will then participate in the Identifying and Using Signature Strengths Intervention."
2983291|NCT02674932|Active Comparator|Coping Skills + Memory Aid|Patients will complete the VIA-Youth but will not receive any results. The patient will then participate in the Identifying and Writing Down Coping Skills Intervention.
2983292|NCT02674932|Other|Coping Skills (Treatment as Usual)|Patients will complete the VIA-Youth but will not receive any results. After completing the VIA-Youth, the study team member and patient will have a treatment-as-usual discussion about coping skills. (This is equivalent to treatment as usual that is already provided on the psychiatric unit—doctors and nurses on the unit already have this a discussion about coping skills with patients).
2983293|NCT02674919|Experimental|Nordic Hamstring|The Nordic Hamstring group performs a progressive strengthening program (Mjolsnes et al., 2004) comprising of the Nordic Hamstring exercise during a period of 10 weeks. The training load increases from one session per week in week 1 to 3 sessions per week in week 3-10. Number of sets and repetitions progressively increase from 2 to 3 and 5 to 12, respectively. The exercise program is performed in the end of a regular football training session.
2983294|NCT02674919|Other|Control|The control group are asked not to perform the exercise or any other specific strength training for the hamstring muscles and to continue to play football as usual.
2983295|NCT02674906|Active Comparator|citrate|A quantity of 20 ml ACD-A per 100 ml of collected blood is used to prevent coagulation in the cell savage process. Pre-prepared ACD-A solutions is available (composition of ACD-A solution used: 22.0 g sodium citrate dehydrate, 24.5 g glucose monohydrate, 8.0 g citric acid monohydrate per 1000 ml of water
2983296|NCT02674906|Active Comparator|heparin|A heparinised saline solution of 25,000 IU of heparin per 1 litre of intravenous normal saline (0.9% NaCl) solution is used with a dosage of 20 ml of solution per 100 ml of collected blood. This type of solution is not commercially available and is made locally. This solution is used in the cell salvage process to prevent coagulation.
2983297|NCT02674893|Experimental|type 2 diabetics treated with GLP1 analogue|
2983298|NCT02674893|Active Comparator|Type 2 diabetics not treated with incretins|
2983299|NCT02674893|Other|Healthy subjects|
2983300|NCT02674880|Experimental|HMW-HA|HMW-HA (Yabro - 5 ml of saline containing 0.3% hyaluronic acid sodium salt) via nebulizer b.i.d.
2983301|NCT02674880|Placebo Comparator|Placebo|5 ml of saline via nebulizer b.i.d.
2983302|NCT02674867|Experimental|Early treatment group|"Vertically-HIV-1-infected children, between 5 and 17-year-of-age, who started cART before 6 months-of-age (early treatment group) with an initial virologic success (HIV-1 RNA <400 copies / mL reached no later than 24 months after the start of cART), whatever the later evolution of the viremia."
2983303|NCT02674867|Other|Late treatment group|"Vertically-HIV-1-infected children, between 5 and 17-year-of-age, who started cART after 24 months-of-age (late treatment group) with an initial virologic success (HIV-1 RNA <400 copies / mL reached no later than 24 months after the start of cART), whatever the later evolution of the viremia."
2983304|NCT02674854|Experimental|PG324 Ophthalmic Solution|1 drop daily (evening) both eyes
2983305|NCT02674854|Active Comparator|Netarsudil (AR-13324) ophthalmic solution|1 drop daily (evening) both eyes
2983306|NCT02674854|Active Comparator|Latanoprost ophthalmic solution|1 drop daily (evening) both eyes
2983307|NCT02674841|Experimental|Feedback group|Receives live feedback on TUT and pulling force during exercises.
2983308|NCT02674841|Active Comparator|Control group|Receives no feedback on TUT but on pulling force during exercises.
2983309|NCT02674828|Experimental|Reinforcement treatment|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
2983310|NCT02674828|Active Comparator|Standard Treatment|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it >2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
2983311|NCT02674815|Experimental|Intervention|Patients within this arm will perform two weeks of high intensity interval training prior to colorectal/thoracic surgery. Exercise intensity will be 100% of the peak power output (PPO) during maximal cardiopulmonary exercise testing. Patients will exercise for 15 seconds at 100% PPO and rest for 15 seconds (passive) for 30 minutes or until exhaustion. This will be performed 5 days a week for 2 weeks.
2983312|NCT02674802||Retrospective study|People who has successfully eradicated helicobacter pylori more than six months detected helicobacter pylori by the C-urea breath test in order to evaluate the reinfection.
2983313|NCT02674802||Prospective study|People who has infected helicobacter pylori received regular eradication therapy after the 4 weeks, 8 weeks and 6 months detected helicobacter pylori by the C-urea breath test in order to prospect the reinfection .
2983314|NCT02674789|Experimental|Exercise day|Behavioral intervention: 90min bike ergometer test at 70% of VO2max. Blood samples are collected at set time points (08:30, 11:00, 12:30, 13:30, 15:00, 16:00 and 18:30). Blood samples are analyzed on the pHOx analyzer for their ionized magnesium concentration. And on the Dimension Vista 1500 from Siemens for their total magnesium concentration.
2983315|NCT02674789|No Intervention|Non exercise day (Rest day)|No exercise protocol. Estimating daily variation of magnesium concentration. Blood samples are collected at set time points (08:30, 11:00, 12:30, 13:30, 15:00, 16:00 and 18:30). Blood samples are analyzed on the pHOx analyzer for their ionized magnesium concentration. And on the Dimension Vista 1500 from Siemens for their total magnesium concentration.
2983316|NCT02674776|Experimental|HuZhen Capsule|The main elements of HuZhen Capsule include Polygonum cuspidatum, Ligustrum lucidum etc.
2983317|NCT02674776|Placebo Comparator|Placebo Capsule|Placebo appearance, content color and taste should be consistent with HuZhen Capsule.
2983318|NCT02674763|Experimental|Dose Escalation Schedule A|IMGN779 administered on days 1 and 15 of a 28-day cycle
2983319|NCT02674763|Experimental|Dose Escalation Schedule B|IMGN779 administered on days 1, 8, 15 and 22 of a 28-day cycle
2983320|NCT02674763|Experimental|Dose Escalation Schedule C|IMGN779 administered on days 1 and 8 of a 21-day cycle
2983321|NCT02674763|Experimental|Dose Expansion Cohort|Patients with Relapsed AML; IMGN779 administered at dose and schedule selected as the putative RP2D.
2983322|NCT02674750|Experimental|CUDC-907|RR-DLBCL, including with MYC alterations detected by FISH or by >=40% MYC by IHC
2983323|NCT02674737|Experimental|Dexmedetomidine,tramadol and flurbiprofen|Both sedative and analgesic(dexmedetomidine, tramadol and flurbiprofen) are applied to this group of patients.
2983324|NCT02674737|Active Comparator|Tramadol and flurbiprofen|Only routine analgesic(tramadol and flurbiprofen) are applied to this group of patients.
2983325|NCT02674724|Experimental|Gym Group|With gym equipments, twice per week for 12 weeks.
2983326|NCT02674724|Active Comparator|Free Weights Group|With dumbbells, elastics, twice per week for 12 weeks.
2983327|NCT02674724|Placebo Comparator|Control Group|The control group will be instructed to perform stretching exercises at home in the same 12-week period, according to an illustrated booklet.
2983328|NCT02674711|Experimental|Educational Video|Evidence-based video: Best Advice for People Taking Opioid Medication
2983329|NCT02674711|No Intervention|Usual Care|Usual care education provided at time of pre-operative appointment.
2983330|NCT02674698|Other|VA Integrated Service Networks Group 1|Access to the CNH Dashboard Step 1
2983331|NCT02674698|Other|VA Integrated Service Networks Group 2|Access to the CNH Dashboard Step 2
2983332|NCT02674698|Other|VA Integrated Service Networks Group 3|Access to the CNH Dashboard Step 3
2983333|NCT02674698|Other|VA Integrated Service Networks Group 4|Access to the CNH Dashboard Step 4
2983334|NCT02674672|Experimental|VenaTech Retrievable arm|VenaTech Retrievable arm
2983335|NCT02674659|Experimental|Control group|Patients after coronary bypass surgery who undergo conventional cardiac rehabilitation program (aerobic training only)
2983336|NCT02674659|Experimental|Intervention group|Patients after coronary bypass surgery who undergo conventional cardiac rehabilitation program plus resistance training (aerobic and resistance training as well)
2983337|NCT02674646|Experimental|Group A: Verum Acupuncture|Group A: Verum Acupuncture (Needle Acupuncture) Needlepoints Bilateral PC 6, S 36, L 8, L 9 Unilateral R4, R 6 Acupuncture will be applied for approx. 20 min. with 10 needlepoints. Standard radiotherapy
2983338|NCT02674646|Sham Comparator|Group B: Sham Acupuncture|Group B: Sham Acupuncture (Needle Acupuncture) Needlepoints 8 needles in the medioaxillary line below the 6th rib, bilateral 2 needles unilateral Sham-acupuncture will be applied for approx. 20 min. with 10 needlepoints. Standard radiotherapy
2983339|NCT02674633|Active Comparator|EVO Multitasking|EVO Multitasking is a digital intervention that requires the subject to navigate a character through a game-like space, while collecting objects, in a fixed period of time.
2983340|NCT02674633|Active Comparator|EVO Words|EVO Words is a digital intervention that requires the subject to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time.
2983341|NCT02674620|No Intervention|Conservative|Standard conservative care of concussion
2983342|NCT02674620|Experimental|Treadmill|Aerobic exercise treatment for concussion
2983343|NCT02674607|Experimental|patients|thirty children with beta thalassemia major will receive oral spirulina (tablets=500 mg) for 3 months with a dose of 250 mg/kg/day (maximum dose 4 gm)
2983344|NCT02674607|No Intervention|controls|thirty healthy children of matched age and sex
2983345|NCT02674594||Patient treated with Dabigatran|
2983346|NCT02674594||Patient treated with Rivaroxaban|
2983347|NCT02674594||Patient treated with Apixaban|
2983348|NCT02674594||Patient treated with Warfarin|
2983349|NCT02674581|Experimental|Healthy Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
2983350|NCT02674581|Experimental|Mild Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
2983351|NCT02674581|Experimental|Moderate Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
2983352|NCT02674581|Experimental|Severe Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
2983353|NCT02674581|Experimental|End Stage Renal Disease Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
2983354|NCT02674568|Experimental|Rovalpituzumab tesirine|Subjects will be dosed with rovalpituzumab tesirine intravenously on Day 1 of each 6 week cycle for 2 cycles follow by end of treatment visit and long term follow-ups. Eligible subjects may qualify for retreatment (additional treatment).
2983355|NCT02674555|Experimental|ASP8273|Two Parts - Part A: 14C-radio labeled; Part B: non radio labeled (optional)
2983356|NCT02674529|Active Comparator|Antidepressant Treatment|20mg of escitalopram will be taken over an 8-week period, starting with 10mg for the first week.
2983357|NCT02674529|Placebo Comparator|Placebo|A placebo pill will be taken over an 8-week period.
2983358|NCT02674516|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo 3 sessions of anodal bilateral transcranial direct stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC) on three consecutive days. tDCS will be delivered by a battery-driven, constant-current stimulator connected to three saline-soaked surface sponge electrodes. Two anodal electrodes (25cm2) will be placed over the DLPFC bilaterally and one cathodal electrode (35cm2) will be placed at the back of the neck. Scalp electrodes will be positioned over the F3 and F4 according to the 10-20 EEG international system. A current of 2mA (1mA at each DLPFC site) will be applied for 20 minutes and the current will be ramped up and down at the beginning and end of the stimulation period.
2983359|NCT02674516|Sham Comparator|Sham stimulation|The sham transcranial direct current stimulation condition will involve the same placement of the electrodes, current intensity, and ramp time as the real tDCS condition, but stimulation will only last for 30 seconds.
2983360|NCT02674503|Experimental|Intensive|MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay.
2983361|NCT02674503|Placebo Comparator|Friendly visit|"UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive."
2983362|NCT02674490|Experimental|A-tDCS & SALT|A-tDCS (1 mA) plus Speech and Language Treatment (SALT) for 15 sessions (20-minutes per each 45-minute treatment session) over the course of 3 weeks. The electrical current will be administered to a pre-specified region of the brain. The stimulation will be delivered at an intensity of 1mA for a maximum of 20 minutes. SALT will be a computer-delivered naming + picture matching task .
2983363|NCT02674490|Sham Comparator|Sham-tDCS & SALT|Sham-tDCS plus SALT for 15 sessions (20-minutes per each 45-minute treatment session) over the course of 3 weeks. Current will be administered in a ramp-like fashion, but after the ramping, the intensity will drop to 0 mA. SALT will be a computer delivered oral naming + picture naming task.
2983364|NCT02674477|Experimental|Therapeutic Education System (TES)|Participants will have the opportunity to use the TES program while hospitalized, at specific, monitored times, and can also use it when discharged by using their specific login information. They can use it as much or as little as they like. They will continue with treatment as usual during and after hospitalization, as well.
2983365|NCT02674477|Other|Treatment as Usual (TAU)|Participants will have the typical treatment during and after their hospitalizations, without additional intervention.
2983366|NCT02674464|Active Comparator|Standard of Care Plus|The standard of care plus arm will include audit and feedback of blood pressure control rates at the provider level along with web-based training about: 1) barriers to blood pressure and cardiovascular disease (CVD) risk factors management in at-risk patient populations; 2) strategies to address healthcare disparities in clinical settings; and 3) appropriate blood pressure (BP) measurement techniques for all clinical staff. The Hopkins research team will help clinics develop audit and feedback mechanisms if they are lacking and will provide all blood pressure measurement and web-based training.
2983367|NCT02674464|Experimental|Collaborative Care/Stepped Care (CC/SC)|The CC/SC arm includes: -BP training -Audit and feedback dashboard, data stratified by race, ethnicity, payor status -A 4 hour workshop for organizational leaders in quality improvement and disparities reduction, with follow up meetings for problem-solving and support, and web-based, patient-centered communication skills training program for providers and staff -Support and guidance in establishing collaborative care model (CCM): team-based care targeting health behaviors and medication adherence. The primary care provider (PCP), care manager, CHW, and specialists in: medication management, psychosocial/behavioral, and self-management will make up the CCM team -Community health workers (CHW) working on contextualized patient interactions focused on problem-solving skills and patient self-management. CHWs will visit their patients in their homes and communities -Provider access to on-call specialists for help with patients who do not achieve BP control under the CC/SC
2983368|NCT02674451|Active Comparator|RIPC|Participants will receive remote ischemic preconditioning within one hour of coronary angiography. This involves blood pressure cuff inflation to 200mmHG for three-5 minute periods, each separated by 5 minute intervals.
2983369|NCT02674451|Sham Comparator|Controls|Participants will have routine blood pressure measurements will be obtained.
2983370|NCT02674438|Experimental|Active Intervention|"Two components to the intervention: (1) clinical algorithm for prognostication, and (2) post-discharge follow-up in the RAPID-HF clinic~Intervention #1 - Clinical algorithm: the EHMRG 7-day and EHMRG30-ST risk scores, which will be used to categorize patients as high, intermediate, or low risk. The clinical algorithm will be used to guide clinicians to decide on admission to hospital, observation, or emergency department discharge.~Intervention #2 - Referral to RAPID-HF (Rapid Ambulatory Program for Investigation and Diagnosis of HF) transitional care clinic: visit to RAPID-HF within 48 hours of discharge. Care provided in RAPID-HF by cardiologist + nurse for up to 30 days from date of discharge."
2983371|NCT02674438|No Intervention|Control|Usual care without access to the EHMRG/EHMRG30-ST scoring system, decision algorithm, or RAPID-HF clinic.
2983372|NCT02674425||Young adults (18-40)|Healthy adult volunteers, aged between 18 and 40, with no prior/current eye problems or family history of genetic eye diseases and good general health.
2983373|NCT02674425||Older adults (50-70)|Healthy adult volunteers, aged between 50 and 70, with no prior/current eye problems or family history of genetic eye diseases and good general health.
2983374|NCT02674412|Experimental|Buspirone then Placebo|Buspirone 10 mg PO TID for two weeks, followed by a washout period for two weeks and placebo for two weeks
2983375|NCT02674412|Experimental|Placebo then Buspirone|Placebo Tablet TID for two weeks, followed by a washout period for two weeks and Buspirone 10mg TID for two weeks.
2983376|NCT02674399|Experimental|JointStem|autologous adipose tissue derived mesenchymal stem cells (AdMSC)
2983377|NCT02674399|Active Comparator|Synvisc-One|hyaluronic acid
2983378|NCT02674386|Other|Cohort 1|long-term observational study of subjects from tanezumab parent study
2983379|NCT02674373||Localized gastric cancer|resectable tumor receiving a curative intent treatment.
2983380|NCT02674373||advanced gastric cancer|unresectable tumor treated with palliative chemotherapy
2983381|NCT02674360|Active Comparator|SDM Online Training|The intervention consists of a SDM training for oncologists, which is conducted in the form of a web-based SDM online Training (intervention group I). During training, the oncologists are guided to use decision aids for breast and colon cancer patients in their consultations, which were developed and evaluated in a previous project. The SDM training has the same duration (one session à 120 minutes) in both intervention groups. Doctors in the intervention group receive decision aids for breast cancer and colorectal cancer patients during training. The training contents are based on an already developed, evaluated and published SDM manual. The SDM online training works on the modeling principle.
2983382|NCT02674360|Active Comparator|Face-to-Face SDM Training|The intervention consists of a SDM training for oncologists, which is conducted in the form of an individualized, context-based SDM individual face-to-face training at the workplace of the participants (intervention group II). During training, the oncologists are guided to use decision aids for breast and colon cancer patients in their consultations, which were developed and evaluated in a previous project. The SDM training has the same duration (one session à 120 minutes) in both intervention groups. Doctors in the intervention group receive decision aids for breast cancer and colorectal cancer patients during training. The training contents are based on an already developed, evaluated and published SDM manual. The individual training works on the coaching principle.
2983383|NCT02674360|No Intervention|Control Group|The Control Group receives no SDM Training. All participants of the Control Group will be offered to participate in the SDM Online Training after T2.
2983514|NCT02673463|Experimental|Spironolactone|Spironolactone 25 mg once daily for 2 years
2983384|NCT02674347|Experimental|Cohort 1: 3 g or 6 g of Zidebactam|"Cohort 1 (Zidebactam): 3 g of Zidebactam (1 g every 8 hours [q8h]) (n=8) IV infusions administered over 60 minutes.~Cohort 2 (Zidebactam or placebo): 6 g of Zidebactam (2 g q8h) (n=8) IV infusions administered over 60 minutes."
2983385|NCT02674347|Placebo Comparator|Placebo|"Cohort 1: Placebo every 8 hours [q8h] (n=2) IV infusions administered over 60 minutes.~Cohort 2: Placebo every q8h (n=2) IV infusions administered over 60 minutes."
2983386|NCT02674334|Active Comparator|NIRS Monitored Not Treated|Anesthesiologist blinded to Near Infrared Spectroscopy (NIRS)
2983387|NCT02674334|Active Comparator|NIRS Monitored and Treated|Anesthesiologist treats based on Near Infrared Spectroscopy (NIRS)
2983388|NCT02674321|Experimental|SD-809|• SD-809 tablets taken once or twice daily for 8 weeks, includes a dose titration period and a maintenance period.
2983389|NCT02674308||Vedolizumab|
2983390|NCT02674308||Other Biologic Agents|
2983391|NCT02674295|Experimental|Cohort 1|50 milligram (mg) of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration.
2983392|NCT02674295|Experimental|Cohort 2|20 mg of intravenous esketamine in 30 milliliter (mL), fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
2983393|NCT02674282|Experimental|ACL-injured|ACL injured professional soccer players submitted to ACL reconstruction.
2983394|NCT02674282|No Intervention|Control|Healthy professional soccer players
2983395|NCT02674269|Experimental|300 IU of BotuGelTM (60ml)|One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
2983396|NCT02674269|Experimental|400 IU of BotuGelTM (60ml)|One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
2983397|NCT02674269|Placebo Comparator|TC-3 Gel|One intravesical instillation of 60 ml TC-3 gel
2983398|NCT02674256|Active Comparator|CRH injection|Intervention: intravenous injection of CRH 100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together then the solution will be injected IV over the course of 1 minute
2983399|NCT02674256|Placebo Comparator|placebo injection|"Intervention: intravenous saline injection~1mL of saline will be injected intravenously over the course of 1 minute"
2983400|NCT02674243|Experimental|Iodopovidone group|Patients who will be randomized for using iodopovidone solution for pleurodesis.
2983401|NCT02674243|Active Comparator|Talc group|Patients who will be randomized for using Talc for pleurodesis.
2983402|NCT02674230||Extreme obesity|BMI ≥35kg/m2
2983403|NCT02674230||Obesity|BMI 24-34.9kg/m2
2983404|NCT02674230||Normal subjects|BMI <24kg/m2. No systemic disease, including hypertension, diabetes, liver cirrhosis, chronic kidney disease, and psychiatric disease.
2983405|NCT02674217|Experimental|Multiple sclerosis autografted patients|Individuals with a relapsing-remitting (RRMS) course, secondary progressive (SPMS), primary progressive (PPMS) or progressive relapsing (PRMS) were included. Patients should have a Karnofsky performance status (18) above 70% and a EDSS score (1) of 6 or below. The study is approved by the Etichs Committee of the Clinica RUIZ and all patients signed a consent form after being fully informed about procedure an possible complications. Patients included will de treated with Hematopoietic stem cell transplantation
2983406|NCT02674204|Experimental|Study Agent|One atorvastatin 20 mg oral capsule per day
2983407|NCT02674204|Placebo Comparator|Control|One matching placebo daily
2983408|NCT02674191|Experimental|Group 1|Device: mini-plates supported molar intrusion (Stryker, Leibinger, GmbH& Co., Freiburg, Germany) for molar intrusion using miniplates to treat hyperdivergent adolescence Procedure/Surgery: Application of ULTRACARE benzocaine 20%, topical anesthesia (Ultradent Products, Inc) Procedure/Surgery: Administration of , Mepivacaine-l local anesthesia Procedure/Surgery: BETADINE povidone-iodine 10% a local disinfectant Drug: (150g Clindamycin/tds) for 1 week Postoperative antibiotic Drug: (Cataflam 25mg), are prescribed post-operatively an analgesic
2983409|NCT02674191|No Intervention|Group 2|hyperdivergent adolescence with no intervention
2983410|NCT02674178|Active Comparator|Age <35|< 35 years old included 201 women who are further subdivided according o FSH/LH ratio into G1A (201 patients) with FSH/LH ratio <2 and G1B (37 patients) with FSH/LH ratio ≥2.
2983411|NCT02674178|Active Comparator|Age ≥ 35|. Group 2 ≥ 35 years old included 34 women who are further subdivided according o FSH/LH ratio into G2A (25 patients) with FSH/LH ratio <2 and G2B (9 patients) with FSH/LH ratio ≥2
2983412|NCT02674165|Experimental|Intervention|"The pregnancy prevention intervention to be tested is an adaptation of Becoming a Responsible Teen (BART), an evidence-based (proven to work by research) HIV prevention curriculum designed primarily for African American adolescents, ages 14-18, in community-based settings.~The culturally-adapted version HART consists of nine sessions, lasting about 2 hours each, and includes interactive group discussions and role plays that are -performed by adolescents. Unlike BART, one PTSD awareness session has been added to address what happens to people who have been exposed to mental trauma and natural disasters."
2983413|NCT02674165|No Intervention|Control or nutrition|Nutrition/fitness curriculum will teach students about ingredients in food that are good for the body and will keep it in good health
2983414|NCT02674152|Experimental|BI 836880|
2983415|NCT02674139|Active Comparator|IUD insertion 6 Weeks after delivery|Subjects randomized to interval placement will have their Copper T 380A IUD placed in the office at six weeks postpartum or later
2983416|NCT02674139|Experimental|Immediate Post-placental insertion|Subjects randomized to receive the Copper T 380A IUD within 10 minutes of delivery of the placenta during caesarean section.
2983417|NCT02674126|Placebo Comparator|Control group|Control group
2983418|NCT02674126|Active Comparator|Maternal sound group|Maternal sound
2983419|NCT02674113|Active Comparator|regional anesthesia bupivacaine|regional anesthesia (a single shot fascia iliaca block using bupivacaine) prior to hip arthroscopy
2983420|NCT02674113|Placebo Comparator|regional anesthesia placebo|subcutaneous injection procedure placebo (0.9% sodium chloride in water)
2983421|NCT02674087||Expectant women|
2983422|NCT02674074|Experimental|measurement of corneal temperature by infrared thermography|
2983423|NCT02674061|Experimental|Cohort A: Pembrolizumab|Participants who have received 0 to 2 prior lines for treating ROC (or 1-3 total prior lines counting the front line) will receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for up to approximately 2 years.
2983424|NCT02674061|Experimental|Cohort B: Pembrolizumab|Participants who have received 3 to 5 prior lines for treating ROC (or 4-6 total prior lines counting the front line) will receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to approximately 2 years.
2983425|NCT02674035|Active Comparator|Device: 2-0 monofilament nylon suture|Plication of the anterior rectus sheath (correction of diastasis of the rectus abdominis muscles) was performed in two layers with Device 2-0 monofilament nylon suture (control group). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
2983426|NCT02674035|Active Comparator|Device: Single layer 2-0 monofilament|Single layer with a Device 2-0 monofilament nylon suture (correction of diastasis of the rectus abdominis muscles) (group I). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
2983427|NCT02674035|Active Comparator|Device: Barbed suture Quill Nylon 1|Using a continuous Device Barbed suture Quill Nylon 1 (correction of diastasis of the rectus abdominis muscles) (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
2983428|NCT02674022|Active Comparator|Mothers of Children with ASD|Initial treatment with standard prenatal supplement in mothers with abnormal homocysteine levels; additional treatment with optimized prenatal supplement in mothers not responding adequately to initial treatment.
2983429|NCT02674022|Active Comparator|Mothers of Typically Developing Children|Initial treatment with standard prenatal supplement in mothers with abnormal homocysteine levels; additional treatment with optimized prenatal supplement in mothers not responding adequately to initial treatment.
2983430|NCT02674009||laBCC Participants|Participants with laBCC who received at least one dose of Vismodegib in routine clinical practice for 32 months (between 02 Aug 2013 and 31 Mar 2016).
2983431|NCT02673996||Postural Tachycardia Syndrome (POTS)|Patients with postural tachycardia syndrome; patients will receive both IV phenylephrine and IV isoproterenol
2983432|NCT02673996||Healthy (control) Subjects|Healthy volunteers that are gender and age-matched (by groups) to the POTS patients; healthy subjects will receive both IV phenylephrine and IV isoproterenol
2983433|NCT02673983|Experimental|Patients undergoing endoscopic full-thickness biopsy|
2983434|NCT02673970||observational arm|From start treatment till date of death or date of cure, the patient will be followed for survival and adverse events on pembrolizumab
2983435|NCT02673957||Blood pressure cuff protocol|All participants receive a baseline control blood test, and all participants receive the blood pressure cuff inflation protocol and blood sampling following the cuff protocol.
2983436|NCT02673944|Experimental|Peritron+|Patients will undergo a routine urodynamic evaluation, the Peritron+ will be used in conjunction with a water-based urodynamic catheter
2983437|NCT02673931|Experimental|GLP-1|"270 patients will be randomized to GLP-1, that will be administered as follows:~248.5 mL of isotonic sodium chloride added 1.5 mL of 20% human albumin added 25 microg Byetta (Lilly, Exenatide).~The study drug infusion is initiated immediately before open heart surgery and ended after 6 hours and 15 minutes. A set dose of 17.4 microg will be given."
2983438|NCT02673931|Placebo Comparator|Placebo|"20% Human Albumin is given as placebo. 270 patients will be randomized to placebo, that will be administered as follows:~248.5 mL of isotonic sodium chloride added 1.5 mL of 20% human albumin.~The placebo infusion is initiated immediately before open heart surgery and ended after 6 hours and 15 minutes at the same rate as the study drug."
2983439|NCT02673931|Experimental|Restrictive Oxygenation|"The intervention is FiO2 of 50%, given as 'Conoxia (AGA, oxygen)'. 270 patients will be randomized to a FiO2 of 50% as long as the arterial O2 saturation (Sa02) remains above 91% during cardiopulmonary bypass, when weaning from and the following hour after weaning from cardiopulmonary bypass. The oxygenation strategy is discontinued and the patient is treated at the discretion of the attending physician after~a maximum of 1 hours of intervention or~the patient is slid from the operating table to a hospital bed for transfer to the intensive care unit, whichever comes first."
2983440|NCT02673931|Active Comparator|Liberal Oxygenation|"The intervention is a FiO2 of 100%, given as 'Conoxia (AGA, oxygen)'. 270 patients will be randomized to a FiO2 of 100% during cardiopulmonary bypass, when weaning from and the following hour after weaning from cardiopulmonary bypass. The oxygenation strategy is discontinued and the patient is treated at the discretion of the attending physician after~a maximum of 1 hours of intervention or~the patient is slid from the operating table to a hospital bed for transfer to the intensive care unit, whichever comes first."
2983441|NCT02673918|Experimental|Home-based rehabilitation|Home-based upper-body rehabilitation with online support
2983442|NCT02673905|Experimental|N-TEC (tissue engineered product)|N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membrane for 2 weeks to allow the cells to produce extracellular matrix containing cartilage specific Proteins. The IMP is implanted in the knee joint and secured by sutures.
2983443|NCT02673905|Experimental|N-CAM (tissue engineered product)|N-Cell activated Matrix (CAM) is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membrane for 2 days only to allow the cells to adhere. The IMP is implanted in the knee joint and secured by sutures.
2983444|NCT02673892|Experimental|PODS|The PODS intervention is administered during the discharge process which includes discharge teaching. In the acute settings, discharge teaching is provided by a nurse navigator, resident physician, or other members of the care team. In the rehabilitation setting, discharge teaching is provided by a multi-disciplinary team. PODS is used as a useful add-on to the usual discharge teaching process. The PODS form used during the study will be a fillable pdf. Members of the healthcare team will fill it out electronically, then print it out and give the paper to the patient. After the discharge teaching is finished, patients take the completed PODS home with them as a post-discharge reference and guide.
2983515|NCT02673463|Placebo Comparator|Placebo|Matched placebo once daily for 2 years
2983516|NCT02673437||Rivaroxaban group|Patients who have been prescribed rivaroxaban and antiplatelet therapy for the prevention of atherothrombotic events following ACS.
2983445|NCT02673892|No Intervention|Usual Care|Patients randomized to this arm will receive usual discharge care. At UHN, this involves receiving a discharge summary with information pertaining to hospital course including investigations performed and medications used, as well as follow-up care suggested. It is intended to be, unlike PODS, a document for the primary care physician seeing the patient after discharge to refer to. As to discharge instructions provided for the patient, there is no standard procedure and sometimes follow-up instructions are included for the patient. Patient education may or may not be provided to the patient verbally by their nurse, resident, physician, or pharmacist. Moreover, follow-up with the primary care physician may be set up prior to or following discharge with the nurse navigator.
2983446|NCT02673879|Active Comparator|Pericardiocentesis with Alteplase|Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase.
2983447|NCT02673879|Other|Conventional Pericardiocentesis|Conventional pericardiocentesis when indicated.
2983448|NCT02673866|Experimental|DS-1971a 400 mg TID|DS-1971a 400 mg three times per day (TID)
2983449|NCT02673866|Experimental|DS1971a 400 mg BID|DS1971a 400 mg twice per day (BID)
2983450|NCT02673866|Experimental|DS1971a 100 mg BID|DS1971a 100 mg BID
2983451|NCT02673866|Placebo Comparator|Placebo|Placebo
2983452|NCT02673866|Active Comparator|Pregabalin|Pregabalin
2983453|NCT02673840|Experimental|Ketotifen|
2983454|NCT02673840|Placebo Comparator|Placebo|
2983455|NCT02673827|No Intervention|Group control|Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
2983456|NCT02673827|Experimental|experimental group|"Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation.~They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation."
2983457|NCT02673814|Experimental|Arm A (durvalumab)|10 mg/kg durvalumab alone every two weeks
2983458|NCT02673814|Experimental|Arm B (bavituximab + durvalumab)|3 mg/kg bavituximab weekly in combination with 10 mg/kg durvalumab every two weeks
2983459|NCT02673814|Experimental|Arm C (bavituximab + durvalumab)|3 mg/kg bavituximab in combination with 10 mg/kg durvalumab both every two weeks
2983460|NCT02673801||Patient referred to orthopedic clinic|Orthopedic assessment in the outpatient clinic as well as a new algorithm (using patient-reported symptoms and radiographic evaluation) will be applied
2983461|NCT02673775|Placebo Comparator|Clean Air|Subjects will be exposed to clean air for 3 hours.
2983462|NCT02673775|Experimental|Ozone|Subjects will be exposed to 0.2 ppm ozone for 3 hours.
2983463|NCT02673762||Normal glucose metabolism|Normal fasting blood glucose, 2 hour post prandial glucose, hemoglobin A1c and HOMA IR
2983464|NCT02673762||Pre-diabetes|Abnormal glucose tolerance tests and/or insulin resistance with fating blood glucose and hemoglobin A1c below type II diabetes levels
2983465|NCT02673762||Type II diabetes|Hemoglobin A1c 6.5% or greater, fasting blood glucose >125 mg/dl or 2 hour post-prandial blood glucose 200 mg/ml or greater
2983466|NCT02673749|Experimental|RP-G28 Dose 1|
2983467|NCT02673749|Experimental|RP-G28 Dose 2|
2983468|NCT02673749|Placebo Comparator|Placebo|
2983469|NCT02673736|Experimental|PLX73086|"Part 1: Open-label, sequential PLX73086 dose escalation in approximately 36 solid tumors subjects.~Part 2: Extension cohort at the recommended phase 2 dose (RP2D) of PLX73086 in approximately 30 subjects with histologically confirmed, unresectable, locally advanced or refractory TGCT (including metastatic disease)."
2983470|NCT02673723|Experimental|Dezocine|Dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
2983471|NCT02673723|Placebo Comparator|Controlled|The same amount of saline is given for 10 seconds after surface anesthesia
2983472|NCT02673710||Participants with metastatic colorectal cancer|Participants diagnosed with mCRC treated in first line with a combination of bevacizumab and chemotherapy for whom it is decided to continue the administration of bevacizumab beyond progression while changing CTR will be included in this study
2983473|NCT02673697|Experimental|Perceval|The Perceval sutureless aortic heart valve (Perceval valve) is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The Perceval valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
2983474|NCT02673697|Active Comparator|other Stented biological valves|The comparator will be other commercially approved standard biological sutured stented valves, both bovine and porcine. The choice of the comparator tissue valve will be at the discretion of the participating investigators.
2983475|NCT02673684|Sham Comparator|Sham NSS|In this arm, the subject will receive the standard-of-care with regard to his pain management (which may or may not include opioids such as morphine). Additionally, the subject will receive a sham Neuro-Stim System device that will only be active for five minutes. Identical to the active device in placement, labeling, and packaging. It will remain on the subject's ear for 5 days at which point the subject may discard the device.
2983476|NCT02673684|Experimental|NSS|In this arm, the patient will receive the standard-of-care with regard to his pain management (which may or may not include opioids such as morphine). Additionally, the subject will receive an active Neuro-Stim System that generates electrical impulses that stimulate the neurovascular bundles in the ear. It will remain on subject's ear for 5 days at which point the subject may discard the device.
2983477|NCT02673671|Experimental|Subjects with a Post-operative ileus|Record myoelectric activity in patients with a post-operative ileus.
2983478|NCT02673671|Experimental|Subjects without a Post-operative ileus|Record myoelectric activity in patients without a post-operative ileus.
2983517|NCT02673437||Alternative dual antiplatelet therapy|Patients who have been prescribed alternative dual antiplatelet therapy for the secondary prevention of atherothrombotic events following ACS
2983518|NCT02673424|Active Comparator|FFR-guided stenting|Percutaneous coronaryintervention using drug-eluting stent(s) will be performed by FFR-guided strategy.
2983479|NCT02673658|Active Comparator|Motor + problem solving|This method focuses on spontaneous movement (rather than facilitated movement). Self-initiated, functionally directed movement is emphasized. Intervention includes guidance and cues, which gently call the child's attention to the support surface, and a set-up of the environment for small increments of movement so that the child can solve a movement problem. Passive movements are not used. Each small increment of movement to advance sitting skill or other motor skills is paired with a specific object or toy that challenges a cognitive concept for spatial problem solving. In this approach, the parent will adjust toys and supports to encourage changes of position from sitting, to transitions in and out of sitting to crawling or standing, but will not assist the child physically.
2983480|NCT02673658|Active Comparator|Body weight support training|In this approach, infants will be supported physically by their parents to take steps, sit, crawl, or reach, in practice sessions focused simply on the motor skill. Toys or problem solving will not be part of this intervention, but the child will be assisted (lifted by the parent) through movement to improve strength and learn specific movements and new positions. The child will be able to perform as much of the movement as possible, but the parents will initiate the activity if the child does not initiate, and the parent will lift the child passively through the task if the child is unable to move.
2983481|NCT02673645|No Intervention|Control group|These youth will receive standard mathematics instruction and support, but not the intensive tutoring offered through the intervention.
2983482|NCT02673645|Experimental|SAGA Innovations|These youth will receive the intensive mathematics tutoring by SAGA Innovations, with students randomized to tutors.
2983483|NCT02673619|Experimental|Umeclidinium once daily (QD) 1.85%|Subjects will apply UMEC topically once daily (2microliter [µL]/centimeter [cm]^2) to both the hands (palm and fingers) using graduated syringe at night before bedtime for 28 days. Randomization will be 4:1 (UMEC 1.85%: vehicle)
2983484|NCT02673619|Placebo Comparator|Vehicle QD|subjects will apply vehicle topical once daily (2µL/cm^2) to both the hands (palm and fingers) using graduated syringe at night before bedtime for 28 days.
2983485|NCT02673593|Placebo Comparator|Placebo|Taken orally as a single dose (Cohorts 1 - 4) Taken orally as a multiple daily dose for 28 days (Cohorts 5 - 7)
2983486|NCT02673593|Experimental|DS102 100mg Single Dose|Taken orally once by Cohort 1
2983487|NCT02673593|Experimental|DS102 500mg Single Dose|Single Dose taken orally on three separate occasions by Cohort 2 (second and third dose assessing food effect)
2983488|NCT02673593|Experimental|DS102 1000mg Single Dose|Taken orally once by Cohort 3
2983489|NCT02673593|Experimental|DS102 2000mg Single Dose|Taken orally once by Cohort 4
2983490|NCT02673593|Experimental|DS102 500mg Multiple Dose|Taken orally once a day for 28 days by Cohort 5
2983491|NCT02673593|Experimental|DS102 1000mg Multiple Dose|Taken orally once a day for 28 days by Cohort 6
2983492|NCT02673593|Experimental|DS102 2000mg Multiple Dose|Taken orally once a day for 28 days by Cohort 7
2983493|NCT02673580|Other|Open Access telePRO|Intervention: In open access, contact to the outpatient clinic is initiated by the patient by filling in a PRO questionnaire.
2983494|NCT02673580|Other|Standard telePRO|No intervention: In standard telePRO, outpatient follow-up activity is determined by a clinician and patients receive a questionnaire at fixed intervals.
2983495|NCT02673567|Experimental|TEV-48125 - 1|Dose Regimen 1
2983496|NCT02673567|Experimental|TEV-48125 - 2|Dose Regimen 2
2983497|NCT02673567|Experimental|TEV-48125 - 3|Dose Regimen 3
2983498|NCT02673567|Placebo Comparator|Placebo|Matching Placebo
2983499|NCT02673554|Experimental|Oral glucose tolerance test|An oral glucose challenge (75 g)
2983500|NCT02673554|Active Comparator|GIP Bolus|Hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l) with two repeated intravenous bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
2983501|NCT02673554|Active Comparator|GIP Infusion|Hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
2983502|NCT02673541|Active Comparator|AXIOS™ stent|1. Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Repeat endoscopy will be performed for stent removal at or before 60 days at the discretion of the attending gastroenterologist
2983503|NCT02673541|Active Comparator|double pigtail stents|2. Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Routine repeat treating gastroenterologist for stent removal will not be necessary, but left to the discretion of the attending gastroenterologist.
2983504|NCT02673528||Directly underwent TLA|Patients with the diagnosis who underwent directly total laparoscopic appendectomy
2983505|NCT02673528||Lap Assisted App|Patients with the diagnosis of acute appendicitis who underwent a successful laparoscopic assisted appendectomy
2983506|NCT02673528||Advanced to TLA|Patients with the diagnosis of acute appendicitis in whom laparoscopic assisted appendectomy attempted; however, because it fail advanced to total laparoscopic appendectomy.
2983507|NCT02673515|Active Comparator|Alternate day fasting|"Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum feed day with a 100% restriction fast day)."
2983508|NCT02673515|No Intervention|control group|control group
2983509|NCT02673502|Experimental|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
2983510|NCT02673502|Experimental|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery.
2983511|NCT02673489|Experimental|Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV)|Oral dosing of DCV 60 mg tablet once daily + SOF 400 mg tablet once daily + RBV 1000-1200 mg tablet per day (weight based) for 24 weeks.
2983512|NCT02673476|Placebo Comparator|Placebo|Identical Placebo Comparator
2983519|NCT02673424|Active Comparator|IVUS-guided stenting|Percutaneous coronaryintervention using drug-eluting stent(s) will be performed by IVUS-guided strategy.
2983520|NCT02673398|Experimental|Treatment (neratinib)|Patients receive neratinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2983521|NCT02673385||Brazelton scale|Procurement across Brazelton scale
2983522|NCT02673385||No test|usual care
2983523|NCT02673372|Active Comparator|Morphine Group|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg.
2983524|NCT02673372|Experimental|Ketamine Group|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min)
2983525|NCT02673359|Active Comparator|Progesterone group|Vaginal progesterone suppositories will be given
2983526|NCT02673359|Active Comparator|Cerclage group|Cervical cerclage will be performed.
2983527|NCT02673346||employees|YKHC employees
2983528|NCT02673333|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
2983529|NCT02673320|Experimental|Early surgery|Early surgery within 48 hours
2983530|NCT02673320|Other|Delayed surgery|Delayed surgery at 15 days
2983531|NCT02673307|No Intervention|Controle|The volunteer does not chew gum during the study period
2983532|NCT02673307|Experimental|Chewing gum|The volunteer chews gum during the first 45 min after ingestion of 250 ml water
2983533|NCT02673294|Experimental|intervention (6-12 months)|Participants with a chronicity between 6-12 months
2983534|NCT02673294|Experimental|Intervention (12-24 months)|Participants with a chronicity between 12-24 months
2983535|NCT02673294|Experimental|Intervention (>24 months)|Participants with a chronicity >24 months
2983536|NCT02673281|Experimental|Walnut shake|"All subjects will have 2 5-day visits to the BIDMC clinical research center, one where they will receive active milkshake containing 48g of walnuts daily in a single morning meal instead of breakfast, and another where they will receive a placebo milkshake without nuts"
2983537|NCT02673281|Placebo Comparator|Placebo shake|"All subjects will have 2 5-day visits to the BIDMC clinical research center, one where they will receive active milkshake containing 48g of walnuts daily in a single morning meal instead of breakfast, and another where they will receive a placebo milkshake without nuts"
2983538|NCT02673268|Experimental|Patients with breast cancer|
2983539|NCT02673255|Experimental|Sanofi Pasteur (Tenivac)|Tetanus and Diphtheria (Td) Vaccine, Manufacturer: Sanofi Pasteur (Tenivac), Dose: 0.5 mL, Route: Intramuscular (IM) in the deltoid muscle, Frequency: Every 90 days, Duration: 5 doses, 1 year.
2983540|NCT02673255|Experimental|MassBiologics|Tetanus and Diphtheria (Td) Vaccine, Manufacturer: MassBiologics, Dose: 0.5 mL, Route: Intramuscular (IM) in the deltoid muscle, Frequency: Every 90 days, Duration: 5 doses, 1 year.
2983541|NCT02673242|No Intervention|Control|No treatment other than medical
2983542|NCT02673242|Experimental|Intervention|Inspiratory muscle training
2983543|NCT02673229|Active Comparator|Collagenase Santyl|Applied topically (2 mm thickness once daily)
2983544|NCT02673229|Sham Comparator|Bacitracin|Applied topically (2 mm thickness) once daily
2983545|NCT02673216||Spontaneous abortion|Women attending for suspected spontaneous abortion
2983546|NCT02673216||Normal pregnant women|Normal pregnant women attending for nuchal translucency scan
2983547|NCT02673203|Active Comparator|Lean Healthy Control|(BMI <25 kg/m2)
2983548|NCT02673203|Active Comparator|Obese non-diabetic subject|BMI > 30 kg/m2
2983549|NCT02673203|Active Comparator|Obese T2DM (Type 2 Diabetes)|T2DM subjects who will be age and BMI-matched to obese, non-diabetic subjects
2983550|NCT02673203|Active Comparator|T1DM (Type 1 Diabetes)|T1DM subjects who will be age and BMI matched to control, non-diabetic subjects
2983551|NCT02673177|Experimental|Robot-assisted total mesorectal excision|Robot-assisted total mesorectal excision (RTME) for rectal cancer. Two different RTME procedures were chose to personalized patients. Generally, when the tumor located within 5-15cm from the anal verge, low anterior resection (LAR) was employed, and tumor located below 5cm, abdominoperineal resection (APR) was applied usually.
2983552|NCT02673177|Active Comparator|Laparoscopic total mesorectal excision|Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer was performed. The Urinary, sexual function and sphincter- preservation outcomes were evaluated.
2983553|NCT02673164|Active Comparator|CSCC_ASC|Cardiology Stem Cell Centre_adipose derived stem cells (CSCC_ASC)
2983554|NCT02673164|Placebo Comparator|Placebo|Saline
2983555|NCT02673151|Experimental|Diagnostic (68Ga-PSMA PET/CT)|Patients receive gallium Ga 68-labeled PSMA ligand Glu-urea-Lys(Ahx)-HBED-CC IV. Beginning 45-60 minutes later, patients under whole body (skull base to mid-thighs) PET/CT scan.
2983556|NCT02673138|Active Comparator|Basal interruption|Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit
2983557|NCT02673138|Experimental|Basal interruption with canagliflozin|Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit
2983558|NCT02673125|Experimental|Double embryo transfer|Patients with both MitoGrade normal and Mitograde elevated PGS normal embryos will have two embryos replaced- one Mitograde normal and one Mitograde elevated.
2983559|NCT02673112|Experimental|STEP-mhc + LS|Subjects will be asked to perform exercise at 80% of the heart rate threshold determined using the Balke protocol for 5 minutes greater than their measured minutes of MVPA/day at baseline (Subthreshold exercise program). They will also be given a light stretching protocol (5 stretches). The exercise intervention will last for 6 weeks and will be supported by weekly health coaching.
2983560|NCT02673112|Active Comparator|LS alone|Subjects will be given a light stretching program alone (5 stretches). The exercise program will last for 6 weeks.
2983561|NCT02673099|Other|HDF online|All patients were started on HF (high-flux) hemodialysis. After 6 months they were then treated by HDF online.
2983562|NCT02673086|Active Comparator|coracoid approach|Patients in this group will be randomized to receive an coracoid approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
2983563|NCT02673086|Active Comparator|retroclavicular approach|Patients in this group will be randomized to receive an retroclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
2995366|NCT02594033|Experimental|3.5 mm needle|
2983564|NCT02673073|Placebo Comparator|Control_Education|All patients will receive patient's information/education booklet on the heart failure including life style modification.
2983565|NCT02673073|Experimental|Intervention_Diary|All patients will receive patient's information/education booklet on the heart failure including life style modification. In addition, patients also receive a patient's diary for self-recording of 6 parameters: body weight, blood pressure, heart rate, number of remaining pills, degree of pitting edema, and degree of dyspnea.
2983566|NCT02673060|Experimental|dose escalation of MBC-11|MBC-11 was administered in 5 consecutively recruited cohort in dose 0.5 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg,10 mg/kg accordingly. The dose escalation is aimed at determining the maximum tolerated dose (MTD)
2983567|NCT02673047||Botox®|Patients prescribed botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence associated with neurogenic detrusor overactivity or overactive bladder as per standard of care in clinical practice.
2983568|NCT02673021|Experimental|Microwave Ablation|Microwave Ablation
2983569|NCT02673008|Experimental|MRD-directed DLI|For patients with MRD+ and without grade II/>II aGVHD by day +60 post-transplantation, DLI was given once by day +60 and was then administered based on MRD and GVHD status. If patients were MRD negative, DLI was not given again; if patients were MRD positive and without GVHD, DLI was given monthly until GVHD occurred or MRD became negative or for a total of four times. For patients with NR or PR pre-transplantation and with MRD negative by day +60 post-transplantation, DLI was given once by day +90 regardless of MRD, and was then administered when MRD became positive. For patients with CR pre-transplantation and with MRD negative post-transplantation, DLI was not given unless MRD became positive.
2983570|NCT02672995|Experimental|Single arm dose-escalation|"Fractionated stereotactic radiosurgery:~Group 1: tumors 1.5~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break.~Concurrent bevacizumab:~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab."
2983571|NCT02672982|Experimental|new combined NUTPSY treatment|2-month combined nutrition and psychosocial intervention
2983572|NCT02672982|Active Comparator|standard NUT treatment|2-month of standard nutritional treatment only
2983573|NCT02672969|Experimental|Smoke evacuation uses|Smoke evacuation uses means using RapidVac Smoke Evacuator with electrosurgical unit during coagulation and cutting surgery. (Experimental group)
2983574|NCT02672969|No Intervention|no smoke evacuation uses|No smoke evacuation uses means using only the regular electrosurgical unit during coagulation and cutting surgery. (Control group)
2983575|NCT02672956|Experimental|Supraumbilical entry group|Umbilical port will be insert to supra umbilical area.
2983576|NCT02672956|Experimental|Intraumbilical entry group|Umbilical port will be insert to intra umbilical area.
2983577|NCT02672956|Experimental|Infraumbilical group|Umbilical port will be insert to infra umbilical area.
2983578|NCT02672943|No Intervention|Normal|30 normal volunteers with age, sex and BMI-match as control group
2983579|NCT02672943|Active Comparator|treatment group|The Rehabilitation treatment group will receive rehabilitation training once per day, 3 days per week, for 12 weeks. The duration of each session is about 1 hour. Participants will first receive relaxation exercises, positioning and self-stretch exercises (emphasizing on spinal mobility and flexor muscle groups of limbs and trunk) for 15 minutes. Then they will have balance training for 20 minutes. The investigators will use goal-directed tasks, such as different types of ball games, for balance training. At the end, participants will receive walking exercise for 20 minutes, and cool down exercises for 5 minutes.
2983580|NCT02672943|Sham Comparator|non-treatment group|The group will not receive non-rehabilitation treatment, before and after the 12 weeks non-rehabilitation training, should accept MRI and Clinical assessments.
2983581|NCT02672917|Experimental|MVT-5873 Monotherapy Dose Escalation|Initial to maximum tolerated dose
2983582|NCT02672917|Experimental|MVT-5873 Combination Dose Escalation|Escalating dose in combination with a standard of care chemotherapy
2983583|NCT02672904|Active Comparator|CO2 laser|Patients undergoing endoscopic treatment with CO2 laser
2983584|NCT02672904|Active Comparator|KTP laser|Patients undergoing endoscopic treatment with KTP laser
2983585|NCT02672891|Experimental|Device|condom balloon catheter which is composed of a latex condom (SURE natural latex condom, Shanghai) and a 16-20 F, 2 ways silicon coated Foley catheter (Egypt). The catheter was introduced inside the condom and tied over tightly several times with a silk suture, to prevent air escape.
2983586|NCT02672878|Experimental|BVS implantation in patients with ISR|
2983587|NCT02672865|Experimental|HIPEC|The administration of hyperthermic intraperitoneal chemotherapy (HIPEC), using a warm solution of two chemotherapy medications (mitomycin and cisplatin) to bathe the internal surfaces of the abdomen in an attempt to kill any microscopic cancer cells that might be present on these surfaces.
2983588|NCT02672852|Experimental|ABBV-066|
2983589|NCT02672852|Placebo Comparator|Placebo|
2983590|NCT02672839|Experimental|Period 1 Treatment A|Healthy subjects will receive a single dose orally of LGD-6972 capsules fasted
2983591|NCT02672839|Experimental|Period 1 Treatment B|Healthy subjects will receive a single dose orally of LGD-6972 solution fasted
2983592|NCT02672839|Experimental|Period 2 Treatment A|Healthy subjects will receive a single dose orally of LGD-6972 capsules fasted
2983593|NCT02672839|Experimental|Period 2 Treatment B|Healthy subjects will receive a single dose orally of LGD-6972 solution fasted
2983594|NCT02672826|Experimental|adipose tissue surgery|The adipose tissue surgery (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated.
2983595|NCT02672813|Experimental|Pectoral Nerve I and II block|Under Ultrasound guidance, Pectoral nerve I block is given for every breast surgery using 10ml of 0.25 % Ropivacaine ( without added preservatives). Similarly Pectoral nerve II block is also given using 20 ml of 0.25% Ropivacaine ( without added preservative) in same group of patient.
2983596|NCT02672813|No Intervention|No block|Pectoral nerve block is not given in this group of patients undergoing breast surgery
2983597|NCT02672800|Experimental|Writing intervention|
2983598|NCT02672800|No Intervention|Control|
2983601|NCT02672774|Other|Gastric cancer|Consecutive patients with gastric cancer will be examined using magnification endoscopy with narrow band imaging and probe based confocal laser endomicroscopy.
2983602|NCT02672774|Other|Colorectal cancer|Consecutive patients with colorectal cancer will be examined using magnification endoscopy with narrow band imaging and probe based confocal laser endomicroscopy.
2983603|NCT02672761|Experimental|MBSR|Subjects enrol and complete a standardized and licensed meditation program developed by Jon Kabat-Zinn. The program includes a weekly 200 min group session, daily meditation training from 20-40 min and one 4 h retreat within the study period. The individual daily and overall training volume is noted in min.
2983604|NCT02672761|Experimental|MBT|Subjects while being on the waiting list for MBSR are allocated to a web-based training program (MBT- My Brain Training) for working, episodic and general memory functions. The individual daily and overall training volume is noted in min.
2983605|NCT02672761|Active Comparator|Wellness|Subjects while being on the waiting list for MBSR are allocated to a free accessable wellness program including sessions in a computerized chair delivering Shiatzu massage and relaxation music. The individual daily and overall training volume is noted in min.
2983606|NCT02672761|Placebo Comparator|Control|Subjects while being on the waiting list for MBSR are requested to do no special program for stress reduction or memory improvement. The individual daily and overall training volume of sports or recreational activity is noted in min.
2983607|NCT02672748|Experimental|Gardening|Receiving two years of technical, labor and financial support in starting, growing, and harvesting from a home food garden.
2983608|NCT02672748|No Intervention|Control|The control families receive a garden as a delayed intervention after two years.
2983609|NCT02672735|Experimental|Corrective Exercise Program|Participants in the Corrective Exercise Program (CEP) group (n = 28) will be given a four-week corrective exercise programming intervention.
2983610|NCT02672735|No Intervention|Control|The participants in the Control (CON) group (n = 28) will have their four-week corrective exercise programming intervention deferred for 4 weeks, and as such, will serve as the comparative group for the CEP group.
2983611|NCT02672722|Experimental|Healthy Test Subjects|We will be using the drug Definity that is an approved medication for cardiac contrast enhanced ultrasound to measure the changes in kidney blood flow with exercise in healthy subjects.
2983612|NCT02672709|Experimental|Anticoagulation|Apixaban will be prescribed at the dose of 2.5 mg twice per day for nine days.
2983613|NCT02672696|Experimental|FluoroMap group|"Adult patients with a proximal femoral fracture eligible for intramedullary nailing with a Gamma 3 nail (Stryker Inc).~In this group, the surgeon will use the FluoroMap 3D reconstruction system (Stryker Inc) with the standard fluoroscopy to help him place the cephalic screw in the femoral head."
2983614|NCT02672696|No Intervention|Test group|"Adult patients with a proximal femoral fracture eligible for intramedullary nailing with a Gamma 3 nail (Stryker Inc).~In this group, the surgeon will use only the standard fluoroscopy to help him visualize the position of the cephalic screw in the femoral head."
2983615|NCT02672670|Experimental|Coping-oriented supportive programme|Coping-oriented supportive programme: education of the SCI disease information, learning from role model by watching a well-established DVD, discussion about how to break down stressors and used appropriate coping strategies (problem-solving training, cognitive re-constructing, relaxation exercises, and activity scheduling) to manage the stressors relating to SCI. Social skills training and ways of maintaining and improving social support will also be discussed and practiced in the COSP.
2983616|NCT02672670|Active Comparator|A didactic group|Usual rehabilitation care--routine inpatient rehabilitation care and brief education in groups (structured by both the rehabilitation nurses and the researcher), which will consist of similar professional contacts as the intervention (COSP) group, and thus can balance between the two study groups for the effect of social contacts and attention to SCI patients during group sessions. The intervention in the comparison group will be conducted by a rehabilitation nurse in the SCI wards. The knowledge/didactic education presented to the patients in the comparison group will be the basic health education and relevant information provided by the rehabilitation nurses in their routine care (mainly including knowledge of SCI, nutritional needs, skin care, bowel and bladder training, and other physical and psychological care of patients with SCI provided by the inpatient rehabilitation wards).
2983617|NCT02672644|Experimental|Emervel Classic|Subjects treated with Emervel Classic (moderate NLFs; WSRS = 3/3). Subjects receiving bilateral treatment of NLFs following approved product labeling.
2983618|NCT02672644|Experimental|Emervel Deep|Subjects treated with Emervel Deep (severe NLFs; WSRS = 4/4). Subjects receiving bilateral treatment of NLFs following approved product labeling.
2983619|NCT02672631||Median Nerve injury hand|Participants will be randomly called; and that 10 participants which had unilateral median nerve transection totally and repaired primely in our clinic at 2014. In the sample, correlations between physical examination (Tinnel Test, motor strength assessment (Medical Research Council (MRC) Scale), static two-point discrimination test (S2PD), Semmes-Weinstein (SW) monofilament test, the Disability of the Arm, Shoulder and Hand (DASH) test), ENMG with the DTI results will be assessed.
2983620|NCT02672631||Healthy Hand|Control group will be taken from patients other hand which had not injured before. And we will compare with first group's results.
2983621|NCT02672618||chronic heart failure|18-85years old,having symptoms of heart failure,New York Heart Association（NYHA） class II or above American College of Cardiology/American Heart Association（ACC/AHA） class B, C, including hypertensive heart disease, rheumatic heart disease, ischemic cardiomyopathy and idiopathic cardiomyopathy
2983622|NCT02672618||normalCardiac function|18-85years old,no symptoms of heart failure,NYHA class I or above ACC/AHA class A, including controled hypertension,stability coronary heart disease and rheumatic heart disease
2983623|NCT02672618||healthy volunteers|18-85years old,Without basic cardiovascular diseases
2983624|NCT02672605|No Intervention|Control|Participant completes a survey measuring abortion stigma prior to receiving the mandatory Pennsylvania State consent for their abortion.
2983625|NCT02672605|Experimental|Investigational|Participant completes a survey measuring abortion stigma after receiving the mandatory Pennsylvania State consent for their abortion.
2983626|NCT02672592|Active Comparator|Anakinra|Anakinra//Kineret® 100mg s.c. bid
2983627|NCT02672592|Placebo Comparator|Placebo|Sodium Chloride 0.9% s.c. bid
2995367|NCT02594033|Active Comparator|4 mm needle|
2983628|NCT02672579||Children 4-7 years|Pediatric subjects between the ages of 4 and 7 who have had pruritus for 6 weeks or longer will complete surveys to assess the severity of pruritus.
2983629|NCT02672579||Children 8-17 years|Pediatric subjects between the ages of 8 and 17 who have had pruritus for 6 weeks or longer will complete surveys to assess the severity of pruritus.
2983630|NCT02672579||Parents|Parents of pediatric subjects between the ages of 4-17 years with chronic pruritus (for 6 weeks or longer) will complete surveys to assess their perception of their child's severity of pruritus.
2983631|NCT02672579||Clinicians|Clinicians treating pediatric subjects between the ages of 4-17 years with chronic pruritus (for 6 weeks or longer) will complete surveys to assess their perception of the child's severity of pruritus.
2983632|NCT02672566|Experimental|Experimental group : enoxaparin|Experimental group will take enoxaparin (4000 Ui / Day) and will benefit from the usual care.
2983633|NCT02672566|Active Comparator|Control group|The control group will only benefit from the usual care.
2983634|NCT02672553|Active Comparator|EDWARDS INTUITY|EDWARDS INTUITY Valve System, Model 8300A
2983635|NCT02672553|Active Comparator|Stented Aortic Bioprostheses|Stented Aortic Bioprostheses
2983636|NCT02672540|Experimental|SANGUINATE 320 mg/kg|Two-hour infusion of SANGUINATE on Day 1 and Day 2
2983637|NCT02672540|Placebo Comparator|Normal Saline|Two-hour infusion of Normal Saline and Day 1 and Day 2
2983638|NCT02672527|Experimental|TRA|"At Day 1 (D1), premedication with dexamethasone (20 mg) and a 5-HT3 receptor antagonist anti-emetic agent will be intravenously administered 30 minutes prior to trabectedin administration. Trabectedin will be administered through a central venous catheter at a starting dose of 1.5 mg/m² over 24 hours, diluted in at least 500 mL of normal saline solution or of glucose 5% injectable solution.~Each treatment cycle will last 21 days. Treatment duration: the treatment might be pursued until disease progression according to RECIST 1.1, or patient refusal, or toxicities.~In case of disease progression, the further treatments will be based on investigator's judgement."
2983639|NCT02672527|No Intervention|BSC|"Treatment:~Patients will receive the best supportive care (BSC) in order to alleviate their symptoms and improve their Quality of Life (QoL).~Antineoplastic agents (including surgery, radiotherapy, thermotherapy, chemotherapy, immunotherapy, hormonal treatment or antibodies-based treatments) are prohibited.~Treatment duration: the treatment might be pursued until disease progression according to RECIST 1.1, or patient refusal.~In case of disease progression, a treatment with trabectedin will be proposed (cross-over). In case of patient refusal, the further treatments will be based on investigator's judgement."
2983640|NCT02672514|Active Comparator|MiECC|"Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the minimally invasive extracorporeal circulation system (MiECC). MiECC has been developed based on the concept of a closed total CPB circuit. The basic elements are a centrifugal pump, a membrane oxygenator and an arterial filter. The priming volume compared to CECC could be reduced. The complete circuit is heparin-coated for maximizing the biocompatibility.~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation."
2983641|NCT02672514|Active Comparator|CECC|"Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the conventional extracorporeal circulation system (CECC). The CECC is an opened circulation system. The basic elements are a membrane oxygenator, a centrifugal pump, an open perfusion system containing the venous hard shell cardiotomy reservoir and the arterial line filter.~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation, leading to a reduction of the priming volume. The CECC flow was set as required in order to maintain a mean arterial pressure (MAP) between 50 and 75 mmHg."
2983642|NCT02672501|Experimental|anti-CD19-CAR-T cells|patients receive chemotherapy(CF, cyclophosphamide and Fludarabine) on day -6 to day -1, then infusied with anti-CD19-CAR-T cells transduced with lentivirus on day 0 in the absence of disease progression or unacceptable toxicity.
2983643|NCT02672488|Experimental|Sorafenib and Metformin|Sorafenib 400μg tablet by mouth and Metformin 500mg tablet by mouth with meal, twice per day
2983644|NCT02672488|Active Comparator|Sorafenib Alone|Sorafenib 400μg tablet by mouth, twice per day
2983645|NCT02672475|Experimental|Treatment (Paclitaxel, Galunisertib)|Patients receive Paclitaxel IV on days 1, 8, and 15. Patients also receive GalunisertibPO BID on days 1-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2983646|NCT02672462|Experimental|Renal denervation|
2983647|NCT02672449|Experimental|External beam radiotherapy|A total of 65 consecutive newly diagnosed prostate cancer patients with 2013 NCCN high risk category will be consecutively enrolled in a prospective phase II trial on Carbon Ions Boost Followed by Pelvic Photon Radiotherapy .
2983648|NCT02672436|Experimental|ENERGI-F703|ENERGI-F703, topical application, 2 times daily for 12 weeks
2983649|NCT02672436|Placebo Comparator|Placebo|ENERGI-F703 matched vehicle, topical application, 2 times daily for 12 weeks
2983650|NCT02672423|Experimental|Abemaciclib Part A|Reference formulation (R) = 3 x 50 mg abemaciclib capsules, Test formulation (T150) = 150 mg abemaciclib tablet administered orally on Day 1 in each of 2 periods.
2983651|NCT02672423|Experimental|Abemaciclib Part B|R = 3 x 50 mg abemaciclib capsules, T150 = 150 mg abemaciclib tablet, Test Formulation 50 (T50) = 3 x 50 mg abemaciclib tablets administered orally on Day 1 in each of 3 periods.
2983652|NCT02672423|Experimental|Abemaciclib Part C|T150 Fed and T150 Fasted = 150 mg abemaciclib tablet with a high-fat meal (T150 Fed) and then without a high-fat meal (T150 Fasted) on Day 1 in each of 2 periods administered orally.
2983653|NCT02672397|Experimental|Hispanic Intervention|Hispanic subjects that receive additional epidural education [44 patients]
2983654|NCT02672397|No Intervention|Hispanic Control|Hispanic subjects that receive standard of care [44 patients]
2983655|NCT02672397|Experimental|Non-Hispanic Intervention|Non-Hispanic subjects that receive additional epidural education [44 patients]
2983656|NCT02672397|No Intervention|Non-Hispanic Control|Non-Hispanic subjects that receive standard of care [44 patients].
2983687|NCT02672189|Experimental|EVA-Online self-management group|The content of the self-management CBT/Relaxation program is the same as the guided version of the program as described above, but without weekly guidance by a trained therapist. The women allocated to the self-management intervention will work through the program independently.
2983657|NCT02672384|Experimental|patients in ICU|"Dental examination will be performed to diagnose CP based on the Centre for Diseases Control definition.~A point of care P. gingivalis test (Denka Seiken Co (Japan) ) on saliva and detection of antibodies against P. gingivalis in sera will be performed.~In case of discrepancies between both diagnoses methods, RT-PCR for identification of P. gingivalis and other pathogens will be performed on samples of periodontal pocket performed in routine."
2983658|NCT02672371|Experimental|active eMNS|Subjects with receive active eMNS for 20 minutes.
2983659|NCT02672371|Sham Comparator|sham eMNS|Subjects with receive sham eMNS for 20 minutes.
2983660|NCT02672358|Experimental|Dabrafenib +Trametinib|Oral Dabrafenib plus Oral Trametinib
2983661|NCT02672345||Sevoflurane Group|Group of patients receiving sevorane during extracorporeal circulation period.
2983662|NCT02672345||Not Sevoflurane Group|Group of patients who did not receive the sevorane during extracorporeal circulation period.
2983663|NCT02672332|Experimental|SB204 4%|SB204 4% topically once daily
2983664|NCT02672332|Placebo Comparator|Vehicle Gel|Vehicle Gel topically once daily
2983665|NCT02672319|Experimental|EUS-guided glue injection|Gastroesophageal varices > 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
2983666|NCT02672319|No Intervention|Historical control|A historical control group of HCC patients with gastroesophageal variceal bleeding who underwent conventional cyanoacrylate injection by OGD for index variceal bleeding based on de-identified data from an existing prospective GI bleed database from 2009-2013 would also be included to allow a more meaningful interpretation of the rebleeding rate from gastroesophageal varices from this study.
2983667|NCT02672306|Experimental|UCMSCs|Subjects with Alzheimer's Disease Intervention: UCMSCs
2983668|NCT02672306|Placebo Comparator|Placebo|Subjects with Alzheimer's Disease Intervention: Placebo (normal saline)
2983669|NCT02672293|Experimental|Phosphate|500 mg of oral phosphate is administered after an overnight fast.
2983670|NCT02672280|Experimental|Medical Collagen Membrane with MSC|Applications of medical collagen membrane with umbilical cord derived mesenchymal stem cells (MSC).
2983671|NCT02672280|Active Comparator|Medical Collagen Membrane|Application of medical collagen membrane only.
2983672|NCT02672267|Experimental|Stem Cells|Experimental: Stem Cells ALLOGENEIC LOW OXYGEN MESENCHYMAL BONE MARROW CELLS Intervention: Biological: Stem cells
2983673|NCT02672267|Placebo Comparator|Placebo|Lactated Ringer's Solution
2983674|NCT02672254||Shams|Samples without any type of treatment
2983675|NCT02672254||Samples with 1 treatment|These samples will be treated with only one therapy: chemical agents such as cisplatin or other metallic compounds, or with superficial radiotherapy. These results will help us understand the effectiveness of each treatment by itself on cSCC cells.
2983676|NCT02672254||Samples with 2 treatments|These samples will be treated with both, chemical agents followed by superficial radiotherapy. These results will provide us information concerning the effectiveness of both treatments, wich is expected to be enhanced by the concomitant effects.
2983677|NCT02672241|Experimental|radio-chemotherapy plus nimotuzumab|Radiotherapy: The total radiation dose is 52.2Gy (1.8Gy fractions). Chemotherapy: Nimotuzumab, given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression. Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation therapy are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles.
2983678|NCT02672228|Experimental|MalariaSense device|This study will involve the evaluation of a medical diagnostic device. All participants enrolled in the study will be assessed for malaria using MalariSense Technology and will aslo get rapid diagnostic tests (RDTs), microscopy, PCR
2983679|NCT02672215|Experimental|tailored group|Received a web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting.
2983680|NCT02672215|Active Comparator|generic group|Received a web-based intervention containing generic information and tips to reduce and/or interrupt workplace sitting.
2983681|NCT02672215|No Intervention|control group|A waitlist control condition and received the generic intervention after completing all measurements
2983682|NCT02672202|Active Comparator|Duloxetine|Treatment
2983683|NCT02672202|Active Comparator|Pregabalin|Treatment
2983684|NCT02672202|Placebo Comparator|Placebo|
2983685|NCT02672189|No Intervention|Waiting list control group|Women in the waiting list control group will receive usual care. They will complete questionnaires during a period of 6 months. After completion of the last questionnaire they will be offered the opportunity to follow the EVA-Online program.
2983686|NCT02672189|Experimental|EVA-Online guided group|"The CBT/Relaxation program (EVA-Online) consists of 6 online sessions intended to be completed weekly over a 6 week period. The program comprises the following elements: (1) information and advice about symptoms (e.g., hot flushes, night sweats and sexual functioning); (2) monitoring and modifying precipitants; (3) relaxation and stress reduction; (4) cognitive restructuring of unhelpful thoughts and (5) encouraging helpful behavioral strategies (e.g., pacing activities). Throughout the program women will be asked to spend an hour a week to read the session and fill in the assignments and to spend 30 minutes per day on homework exercises (eg, filling in a hot flush/night sweats diary, practicing relaxation techniques).~Participating women will first undergo a 30 minute phone interview with a trained therapist before they start the online program. The same therapist will provide weekly feedback and support."
2983716|NCT02671955|Experimental|Part 4: Dose Expansion|Participants with advanced solid tumors will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
2996258|NCT02588001|Experimental|Enzalutamide Group|
2983688|NCT02672176|Sham Comparator|Usual Care-Chronic Disease Management|Usual Care through Chronic Disease Management: The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
2983689|NCT02672176|Active Comparator|P2E2T2 Program|The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (2, 3). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org).
2983690|NCT02672163|Experimental|AACD-Therapy group|6 patients are recruited to the AADC-therapy group. Autologous atrial appendage derived cells (AADCs) are harvested from the appendage tissue removed during the venal cannulation of bypass. The cells and their extracellular matrix are placed with tissue clue to Cormatrix-sheet and further on top of the myocardium in the area of infarction scar. The procedure is done simultaneously with CABG surgery. The patients will be carefully monitored after the operations and cardiac MRI and echocardiogram will be performed previously to surgery as well as during the follow ups.
2983691|NCT02672163|Active Comparator|Control group|20 patients are recruited to form the control group. They are patients scheduled for elective CABG surgery and they meet the same inclusion and exclusion criteria as the therapy group. There patients are followed as the hospital protocol with out any additional imagination or blood tests.
2983692|NCT02672150|No Intervention|Control|During the Baseline Control data is collected in all 36 sites at the agency, staff, and youth level on the 6 months prior to the interventions in Arms 2 & 3 to document what practice was before the study.
2983693|NCT02672150|Active Comparator|Core|"In the second phase (after baseline) all 36 sites receive a Core condition that includes five interventions: (1) JJ-TRIALS Orientation Meetings, (2) Needs Assessment, (3) Behavioral Health Training, (4) Site Feedback Report, (5) Goal Achievement Training, (6) Monthly Site Check-ins, and (7) Quarterly Reports. As part of Goal Achievement Training, sites receive assistance in using their Site Feedback Reports to select goals to meet their local needs. Sites are trained on using Data-Driven Decision Making (DDDM) to inform decisions (e.g., selecting a goal, monitoring progress) and enlisting DDDM templates and tools (developed as part of the project) to plan and implement proposed changes.~these principles to their improvement efforts during the implementation phase."
2983694|NCT02672150|Experimental|Enhanced|While the core intervention and DDDM are expected to facilitate change, organizations may need additional support to apply these principles to their improvement efforts during the implementation phase. In the third phase (after Core), 1/2 of the sites are randomly assigned to an Enhanced condition that provides continuing support for the use of DDDM tools by adding research staff facilitation of DDDM over a 12-month period and formalized Local Change Teams (LCTs) featuring representation from the JJ agency and a local BH provider, with meetings facilitated by research staff).
2983695|NCT02672137|Experimental|knowledge translation|knowledge translation 12-month multi-facet intensive knowledge translation measures that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
2983696|NCT02672137|No Intervention|Usual care|no intervention
2983697|NCT02672111|Experimental|CAM2038 (buprenorphine FluidCrystal®)q1w|CAM2038 q1w(buprenorphine FluidCrystal®) : SC injection depot for once weekly administration) (50 mg/mL) at doses of 8, 16, 24 and 32 mg (buprenorphine base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).
2983698|NCT02672111|Experimental|CAM2038(buprenorphine FluidCrystal®) q4w|CAM2038 q4w ( buprenorphine FluidCrystal®): SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (buprenorphine base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).
2983699|NCT02672098|Experimental|HIPEC|A procedure in which the internal parts of your abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
2983700|NCT02672085|Experimental|PRP infiltration|Supraspinatus interstitial lesion needling and infiltration with PRP
2983701|NCT02672085|Active Comparator|Needling|Supraspinatus interstitial lesion needling and infiltration with NaCl
2983702|NCT02672072||Control group|5-day specific training with dedicated scenario done by an ICU expert simulation team after the period of the study
2983703|NCT02672072||Simulation group|5-day specific training with dedicated scenario done by an ICU expert simulation team
2983704|NCT02672059||Peripheral Neuropathy|Patients with peripheral neuropathy (observational study, no interventions)
2983705|NCT02672046||Patients with knee injuries|Patients referred to assessment at the Clinic of Sports Injuries
2983706|NCT02672033|Experimental|Treatment (hypofractionated IMRT, pleurectomy/decortication)|Patients undergo 5 fractions of accelerated hypofractionated IMRT over 1 week with simultaneous integrated boost to gross disease. Patients then undergo pleurectomy/decortication within 14 days after completion of IMRT.
2983707|NCT02672020|Experimental|patients with adrenal tumor|
2983708|NCT02672007|Other|Included patients|All included patients will have respiratory rates measured by a research assistant using a criterion standard approach, by the SensiumVitals device and by the ward staff.
2983709|NCT02671994|Experimental|A (experimental group)|Oncologic treatment decision based on G8 screening followed by geriatric assessment and subsequent MDT, if needed, in addition to standard assessment (ECOG Performance Status + clinical assessment).
2983710|NCT02671994|No Intervention|B (control group)|Oncologic treatment decision based on standard assessment (ECOG Performance Status + clinical assessment).
2983711|NCT02671968|Experimental|CGM group|
2983712|NCT02671968|No Intervention|Control group|
2983713|NCT02671955|Experimental|Part 1: Dose Escalation|Participants with advanced solid tumors will receive intravenous infusions of JNJ-61610588 until disease progression. Dose escalation will continue until the maximum tolerated dose is reached.
2983714|NCT02671955|Experimental|Part 2: Biomarker Evaluation|Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at or below the recommended Phase 2 dose (RP2D) until disease progression.
2983715|NCT02671955|Experimental|Part 3: Dose Expansion|Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
2996612|NCT02585635||Clinicians|Haemophilia physicians
2983717|NCT02671942|Active Comparator|roflumilast:250μg|Drug: Roflumilast Roflumilast tablets Roflumilast 250 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
2983718|NCT02671942|Active Comparator|roflumilast:375μg|Drug: Roflumilast Roflumilast tablets Roflumilast 375 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
2983719|NCT02671942|Active Comparator|roflumilast:500μg|Drug: Roflumilast Roflumilast tablets Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
2983720|NCT02671942|Placebo Comparator|placebo|Drug: placebo placebo tablets placebo tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
2983721|NCT02671929|Experimental|self-help program + feedback|Patients in this arm receive access to the internet-based self-help program and get feedback on their progress in the program.
2983722|NCT02671929|Active Comparator|self-help program|Patients in this arm receive access to the internet-based self-help program and don't get any therapeutic feedback
2983723|NCT02671916||all patients|questionnaire for patients with ICU stay at least 5 days or longer without interruption at the ICU
2983724|NCT02671903|Active Comparator|Pacemaker: AV optimised, His pacing|Subjects will remain in this arm for 6 months before being crossed-over. See below intervention details.
2983725|NCT02671903|No Intervention|No pacing|Subjects will remain in this arm for 6 months before being crossed-over. The pacemaker will be programmed to VVI 30 bpm. Dynamic AV delay will be programmed off throughout the study.
2983726|NCT02671890|Experimental|Arm I (gemcitabine hydrochloride and disulfiram)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and disulfiram PO every other day or daily on days 1-28 or days 1-35.
2983727|NCT02671890|Placebo Comparator|Arm II (gemcitabine hydrochloride and placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and placebo PO every other day or daily on days 1-28 or days 1-35.
2983728|NCT02671864|Other|1: incretin-based therapy|Patients with incretin-based therapy
2983729|NCT02671864|Other|2: other antidiabetic|Patients with other antidiabetic
2983730|NCT02671851||Thoracic paravertebral blocks (TPVBs)|Patients received bilateral single injection ultrasound-guided TPVBs at the level of T3-T4 with 20 mL bupivacaine 0.375% as an adjunct to general anaesthesia. IV metamizole sodium and paracetamol were rescue analgesics.
2983731|NCT02671851||IV metamizole sodium, paracetamol|Patients received only standardized general anaesthesia. IV metamizole sodium and paracetamol were rescue analgesics.
2983732|NCT02671838|Other|Musculoskeletal ultrasound program|Participants will receive the musculoskeletal ultrasound program
2983733|NCT02671838|No Intervention|Control|Participants will not be receiving the musculoskeletal ultrasound program.
2983734|NCT02671825|Experimental|PUR0217a|PUR0200 formulation 1
2983735|NCT02671825|Experimental|PUR0228a|PUR0200 formulation 2
2983736|NCT02671825|Experimental|PUR0228b|PUR0200 formulation 3
2983737|NCT02671825|Experimental|PUR0228c|PUR0200 formulation 4
2983738|NCT02671825|Experimental|PUR0230c|PUR0200 formulation 5
2983739|NCT02671825|Active Comparator|Reference Product 1|Reference Product formulation with active charcoal
2983740|NCT02671825|Active Comparator|Reference Product 2|Reference Product without active charcoal
2983741|NCT02671799|Experimental|VenTouch System Implant|The VenTouch System is indicated for patients who have moderately severe or severe functional mitral regurgitation (grade 3 or 4 MR).
2983742|NCT02671786|Experimental|Intervention Arm|"Intervention area: Provision of community based health care to severely malnourished children 6 months age in 16 tribal villages by trained semi-literate village health workers.~Treatment of severely malnourished children through MAHAN RUTF & MAHAN Vit-Min mix~Growth monitoring of all children below the age of 5 years~Treatment of associated diseases like Diarrhea, Pneumonia, Malaria, etc.~Management of resistant or relapsed severely malnourished cases by pediatrician.~Intensive behavior change communication of parents of children below the age of 5 years for proper nutrition.~Dose: 46 gms of proteins/kg/day & 100170 calories/kg/day with gradual escalation with micro nutrient supplementation Route: Oral Frequency: 4 times a day Duration: 12 weeks"
2983743|NCT02671786|No Intervention|Control Arm|Control area: In control area, the V.H.W. and supervisor records weight of all under 5 children. They also collect data related to birth, deaths and verbal autopsy.
2983744|NCT02671773||BTS Step 2 Asthmatic patients|Group of 20 asthmatic patients on British Thoracic Society (BTS) treatment step 2 - regular low dose inhaled corticosteroids (dose of <400 micrograms/day BDP equivalent)
2983745|NCT02671773||BTS Step 4 Asthmatic patients on treatment with fluticasone|Group of 15 asthmatic patients on British Thoracic Society (BTS) treatment step 4 - high dose inhaled fluticasone (dose of >500 micrograms/day)
2983746|NCT02671773||BTS Step 4 Asthmatic patients on treatment with budesonide|Group of 15 asthmatic patients on British Thoracic Society (BTS) treatment step 4 - high dose inhaled budesonide (dose of >800 micrograms/day)
2983747|NCT02671760|Experimental|Treatment|SM-1
2983748|NCT02671760|Active Comparator|Comparator|2-drug combination
2983749|NCT02671760|Placebo Comparator|Placebo|Placebo
2983750|NCT02671747|Experimental|Pilot workshop|Participants attend intervention. No control arm
2983751|NCT02671734|No Intervention|control|Subjects in this arm received the standard consent form to read and underwent standard discussions with the procedurist prior to the procedure.
2983752|NCT02671734|Active Comparator|intervention|Subjects in this arm viewed a video detailing key elements of informed consent. Subjects in this arm also received the standard consent form to read and underwent standard discussions with the procedurist prior to the procedure.
2983753|NCT02671721|No Intervention|Conventional Strategy|Patients will receive usual and prudent PEEP and tidal volume settings.
2983754|NCT02671721|Experimental|Maximal Compliance Strategy|PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.
2983755|NCT02671721|Experimental|Transpulmonary Pressure Strategy|Personal PEEP titration using transpulmonary pressures obtained from a naso/orogastric tube containing an esophageal balloon port
2984224|NCT02668601||Non-GDM Exposed|Children not exposed to gestational diabetes in utero
2983756|NCT02671708|Experimental|IDA+BUCY|For intermediate-risk AML undergoing auto-HSCT，IDA+BUCY conditioning regimen was IDA 15mg/m2/day on days -12 and -10；BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
2983757|NCT02671708|Active Comparator|BUCY|"For intermediate-risk AML undergoing auto-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days~-3 and -2."
2983758|NCT02671695|Experimental|Group 1|chelation therapy plus Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months
2983759|NCT02671695|Experimental|Group 2|chelation therapy plus Amlodipine in a dose of 5 mg/day orally for 3 months
2983760|NCT02671682||Immunoadsorption|Immunoadsorption on 5 consecutive days with protein A columns and 2,5-fold patient's plasma volume
2983761|NCT02671682||Plasmapheresis|Plasmapheresis on 5 consecutive days with 2l plasma exchange
2983762|NCT02671669|Active Comparator|Usual Care (UC)|
2983763|NCT02671669|Active Comparator|Movn application (MVN)|
2983764|NCT02671630|No Intervention|Control group|Patients receive only usual hospital care
2983765|NCT02671630|Experimental|Experimental group|Patients receive only usual hospital care and community-based computerized cognitive training program
2983766|NCT02671617|No Intervention|Control|Control: This group of patients will receive 'current best practice' as per UK NHS recommendations for their specific cancer management prior to surgery.
2983767|NCT02671617|Experimental|High intensity interval training|"Exercise: Participants in this group will attend 3-4 times per week to complete HIIT training during the period from diagnosis to surgery.~High intensity interval training (HIIT)"
2983768|NCT02671591|Experimental|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP. The control condition is a one-hour, theory-based, one-to-one session that will help YBMSM think more about using condoms consistently and correctly with every sex partner.
2983769|NCT02671591|Active Comparator|control|"This condition will include the provision of free condoms and lubricants - selected from a buffet of condoms and lubricants designed to offer men a broad selection of high quality products that can optimize the fit and feel of condoms during sex."
2983770|NCT02671578|Experimental|Nitrous oxide|Nitrous oxide sedation
2983771|NCT02671565||Hyaluronic acid (HA) injection users|Patients with at least one procedure claim for intra‐articular administration of hyaluronic acid (procedure codes: J7320, J7322, J7325, Q4084, J7317, Q4083, J7321, Q4085, J7323, Q4086, J7324, J7327, J7326) within 90 days after their first specialist (physical medicine, physical therapy, orthopedic surgeon, rheumatologist or orthopedic) visit will be considered as HA users.
2983772|NCT02671565||Corticosteroids (CS) injections users|Patients with at least one procedure claim for intra‐articular administration of corticosteroids (procedure codes: J1020, J1030, J1040, J1094, J1100, J2920, J2930, J0702, J0704, J3300, J3301, J3302, J3303, J1700, J1710, J1720, J2650, J2920, J2930) within 90 days after their first specialist (physical medicine, physical therapy, orthopedic surgeon, rheumatologist or orthopedic) visit will be considered as CS users.
2983773|NCT02671565||HA non-users|Patients who do not have any claims for procedural or surgical intervention including HA and CS injections in first 90 days after their first specialist visit will be considered as HA non-users
2983774|NCT02671552|Experimental|Diagnostic (contrast-enhanced ultrasound)|Patients receive perflutren protein-type A microspheres IV and then undergo contrast-enhanced ultrasound imaging the morning prior to cryosurgery and at 3-4 months post treatment during Magnetic Resonance Imaging (MRI) or computed tomography (CT) follow up.
2983775|NCT02671539|Experimental|open label injection of rAAV2.REP1|This is an open label, single arm interventional trial with subretinal injection of rAAV2.REP1 and fellow eye comparison
2983776|NCT02671526|Experimental|Computerized Plasticity-based Adaptive Cognitive Training|
2983777|NCT02671513|Experimental|SHR6390|Each subject will receive a single dose of SHR6390 and then repeat doses following a 3 week/1 week off regimen.
2983778|NCT02671500|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
2983779|NCT02671487|Experimental|Mind-Body Skills Groups|Mind-body skills groups will be administered for 2 hours once a week for 10 weeks and then once a month for 10 months.
2983780|NCT02671487|No Intervention|Wait List Control|No intervention will be administered. Students will have the opportunity to receive the intervention at the end of the study.
2983781|NCT02671461|Experimental|BMS-986141 0.8mg|BMS-986141 0.8mg orally (tablets) and Aspirin (ASA) 75 to 162 mg orally (tablets)
2983782|NCT02671461|Experimental|BMS-986141 4.8mg|BMS-986141 4.8mg orally (tablets) and ASA 75 to 162 mg orally (tablets)
2983783|NCT02671461|Placebo Comparator|Placebo|Placebo orally (tablets) and ASA 75 to 162 mg orally (tablets)
2983784|NCT02671448||Homebound After Stem Cell Transplantation|The primary research outputs and measurements are the instruments/surveys, assessments, and video diaries to be completed by the patients, their caregivers and the healthcare providers during the time of the home transplantation care.
2983785|NCT02671435|Experimental|Part 1 -Dose escalation with 5 dose escalation cohorts|Durvalumab and IPH2201
2983786|NCT02671435|Experimental|Part 2 - Dose expansion with 4 dose expansion cohorts|Durvalumab and IPH2201
2983787|NCT02671435|Experimental|Part 3 -Dose Exploration with 6 dose exploration cohorts.|Durvalumab and IPH2201 and standard of standard of care systemic therapy in CRC.
2983788|NCT02671409|Placebo Comparator|Control group|The exercise program will be drawn from the recommendations of the American College of Physicians and the American Pain Society for the treatment of low back pain. The exercise protocol consist of: Strengthening the abdominal muscles and erector spinae: will be three sets of 15 repetitions for each exercise with rest time between 2 minutes series; - Proprioceptive Neuromuscular Facilitation (PNF). The PNF technique will be the contract-relax the hamstrings by 6/2. Stretching the erector muscles of the spine, iliopsos, hamstrings, quadriceps and sural triceps: will be three three repetitions, with 30 seconds support time each stretch and rest time between sets 1 minute.
2983827|NCT02671188|Placebo Comparator|Placebo|Subjects will be administered normal saline (0.9% sodium chloride) intravenously over the period of approximately 2 hours on Day 1, Day 15 and Day 29 (total of 3 doses) in a clinical facility with regular monitoring of vital signs. Monitoring of vital signs will continue for a minimum of 2 hours after completion of Infusion.
2983828|NCT02671175|Active Comparator|dihydroartemisinin-piperaquine|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrollment)
2983789|NCT02671409|Experimental|MOB Group|Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
2983790|NCT02671396|Experimental|Virtual reality based intervention|Virtual reality based balance training
2983791|NCT02671396|Active Comparator|Conventional intervention|Conventional balance training
2983792|NCT02671383|Active Comparator|Darunavir|Darunavir/Ritonavir 400/100mg once daily
2983793|NCT02671383|Active Comparator|Lopinavir|Lopinavir/Ritonavir 400/100mg twice daily
2983794|NCT02671357||ERAMIP|Minimally invasive pancreaticoduodenectomy (MIP) with stented pancreatic-gastrostomy & Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES). All patients are submitted to an ERAS trajectory
2983795|NCT02671344||IAD group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation IAD group 'Determination of gene profiles using arrays semen'
2983796|NCT02671344||FIV group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation FIV group of gene profiles using arrays semen'
2983797|NCT02671344||ICSI group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation 'Determination of gene profiles using arrays semen'
2983798|NCT02671318|Active Comparator|Drug conversion to sirolimus|Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
2983799|NCT02671318|Active Comparator|Maintenance of the current regimen|Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
2983800|NCT02671305|Experimental|placental circulation intact|preterm newborns assisted bedside with placental circulation intact
2983801|NCT02671305|Active Comparator|cord milking|preterm newborns who receive cord milking before assistance performed in a routine setting
2983802|NCT02671292|Experimental|Interpersonal Psychotherapy (IPT-WG)|IPT-WG targets the difficult social functioning and stressful events that are associated with loss of control eating and that are highly relevant to the adolescent children of military personnel.
2983803|NCT02671292|Active Comparator|Health Education (HE)|HE improves knowledge on various health topics including, alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence.
2983804|NCT02671279|Other|Low calorie diet|Dietary intervention group
2983805|NCT02671266|Experimental|Oxytocin, Then Placebo|Participants will first receive a nasal spray containing the hormone oxytocin (24 IU, 3 puffs per nostril). After a one-week washout period, participants will come back to the clinic and receive a placebo nasal spray (containing all of the same ingredients as the oxytocin spray minus the active oxytocin ingredient).
2983806|NCT02671266|Experimental|Placebo, Then Oxytocin|Participants will first receive a placebo nasal spray containing a matching formulation as the oxytocin spray (without the active oxytocin ingredient). After a one-week washout period, participants will come back to the clinic and receive an oxytocin nasal spray (24 IU, 3 puffs per nostril).
2983807|NCT02671240||- Patients with behavioral addiction|
2983808|NCT02671240||- Patients with no behavioral addiction|
2983809|NCT02671227|Active Comparator|intrathecal bupivacaine + Mg sulfate|intrathecal bupivacaine 15 mg + intrathecal Mg sulfate 50 mg. in gynecologic laparoscopic surgeries.
2983810|NCT02671227|Active Comparator|intrathecal bupivacaine|intrathecal bupivacaine 15 mg in gynecologic laparoscopic surgeries.
2983811|NCT02671214|Placebo Comparator|Control|100 g high fibre flour
2983812|NCT02671214|Active Comparator|Active 1|85 g high fibre flour + 15 g legume flour
2983813|NCT02671214|Active Comparator|Active 2|98 g high fibre flour + 2 g guar gum
2983814|NCT02671214|Active Comparator|Active 3|88 g high fibre flour + 2 g guar gum + 10 g legume flour
2983815|NCT02671214|Active Comparator|Active 4|83 g high fibre flour + 2 g guar gum + 15 g legume flour
2983816|NCT02671214|Active Comparator|Active 5|96 g high fibre flour + 4 g guar gum
2983817|NCT02671214|Active Comparator|Active 6|86 g high fibre flour + 4 g guar gum + 10 g legume flour
2983818|NCT02671214|Active Comparator|Active 7|81 g high fibre flour + 4 g guar gum + 15 g legume flour
2983819|NCT02671214|Active Comparator|Active 8|94 g high fibre flour + 6 g guar gum
2983820|NCT02671214|Active Comparator|Active 9|98 g high fibre flour + 2 g konjac mannan
2983821|NCT02671214|Active Comparator|Active 10|96 g high fibre flour + 4 g konjac mannan
2983822|NCT02671214|Active Comparator|Active 11|100 g low fibre flour
2983823|NCT02671201||Group A|Theoretical training will be scheduled for 2 hours with lectures in basics of emergency ultrasound. After the theoretical education the students will obtain a bedside-teaching on intensive care unit for 4 hours.
2983824|NCT02671201||Group B|Theoretical training will be scheduled for 3 hours and included lectures in echocardiography, lung ultrasound and abdominal ultrasound. After the theoretical education the students will obtain a bedside-teaching on intensive care unit for 3 hours.
2983825|NCT02671201||Group C|Theoretical training will be scheduled for 3 hours and included lectures in echocardiography, lung ultrasound and abdominal ultrasound.
2983826|NCT02671188|Experimental|GSK3050002 100 mg/mL|Subjects will be administered GSK3050002 intravenously (IV) over the period of approximately 2 hours on Day 1, Day 15 and Day 29 (total of 3 doses) in a clinical facility with regular monitoring of vital signs. Monitoring of vital signs will continue for a minimum of 2 hours after completion of Infusion. On Day 1, loading dose of GSK3050002 10 milligrams per kilogram (mg/kg) will be administered intravenously, followed by maintenance doses of 5mg/kg IV administered at Day 15 and Day 29. Each subject will receive a cumulative dose of 20 mg/kg.
2983949|NCT02670434|Active Comparator|Livalo® Immediate Release IR|Immediate Release Livalo®
2983829|NCT02671175|Placebo Comparator|dihydroartemisinin-piperaquine Placebo|Placebo comparator (matching tablets containing no active ingredients)
2983830|NCT02671162|Placebo Comparator|Wheat|Placebo capsule/ 2 capsule 3 times per day
2983831|NCT02671162|Active Comparator|Fumaria|Fumaria capsule (0.5 mg Fumaria parviflora L.) / 2 capsule 3 times per day.
2983832|NCT02671149|Experimental|Drink water|Participants will receive two 150ml drinks of water during the dehydration protocol
2983833|NCT02671149|No Intervention|Drink nothing|Participants will drink nothing during the dehydration protocol
2983834|NCT02671136|Other|CWC with HBO|Conventional Wound Therapies (CWC) with adjunctive Hyperbaric Oxygen Therapy
2983835|NCT02671136|Other|CWC without HBO|Conventional Wound Therapies (CWC) without adjunctive Hyperbaric Oxygen Therapy
2983836|NCT02671123|Active Comparator|Coronary PCI with OCT with Co-Registration|Coronary stenting will be performed with OCT guidance as per local practice. Pre and post stenting procedure will be performed with OCT guidance with the use of the Co-Registration software tool after stent implanted.
2983837|NCT02671123|Placebo Comparator|Coronary PCI with OCT without Co-Registration|"Coronary stenting will be performed with OCT guidance as per local practice. Pre and post stenting procedure will be performed with OCT guidance without the use of the Co-Registration software tool after stent implanted.~I"
2983838|NCT02671110|Experimental|Transforming Your Life|The TYL program emphasized: 1) helping participants develop and maintain healthy habits and disrupt unhealthy habits, 2) enabling participants to create a personal food and exercise environment that increases exposure to healthy eating and physical activity and encourages automatic responding to goal-related cues, and 3) facilitating participants' weight loss motivation.
2983839|NCT02671110|Active Comparator|Diabetes Prevention program|The DPP recommends that participants set a weight loss reduction goal of 7% or more of their baseline body weight, reduce consumption of high fat foods as a means to reduce caloric intake, and engage in brisk walking or other moderate intensity physical activity for 150 minutes per week. Sessions include information on changing energy intake and energy output through diet and exercise, and addressing psychological, social, environmental, and motivational challenges to health behavior change.
2983840|NCT02671097|Experimental|BAY1841788 (ODM-201) + Rosuvastatin|All subjects will receive a single dose BAY1841788 (ODM-201) (600 mg) followed by multiple doses BAY1841788 (ODM-201) (600 mg BID) as well as 2 times a single dose rosuvastatin (5 mg), once alone and once in combination with BAY1841788 (ODM-201).
2983841|NCT02671084|Experimental|Sevoflurane Group|Sevoflurane Group called group A patients will receive sevoflurane. The patients of group A will receive facial mask properly attached to your face, inspiratory fraction of sevoflurane 3%, with therapeutic target of 1.2% expired fraction into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. This procedure is sufficient to induce the pre anesthetic conditioning in the group exposed to sevoflurane. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.
2983842|NCT02671084|No Intervention|Control Group|Control Group called group B patients who will not receive sevoflurane. The patient of group B will receive facial mask properly attached to your face into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.
2983843|NCT02671058|Active Comparator|Cortenema|Hydrocortisone retention enema (Cortenema) administered rectally as a single dose; each dose unit delivers 100 mg of hydrocortisone per 60 mL.
2983844|NCT02671058|Experimental|Hydrocortisone acetate|Hydrocortisone acetate suppository 90 mg administered rectally as a single dose with the Sephure Rectal Suppository Applicator
2983845|NCT02671045||A - Genomic profile by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and an actionable target has been identified and the patient/physician agree to receive the targeted therapy
2983846|NCT02671045||B - Genomic profiling by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and an actionable target has been identified. However, the patient does not receive the targeted therapy.
2983847|NCT02671045||C - Genomic profiling by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and no actionable target has been identified.
2983848|NCT02671045||D - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target has been identified and the patient/physician agrees to receive the targeted therapy.
2983849|NCT02671045||E - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target has been identified. However, the patient does not receive targeted therapy.
2983850|NCT02671045||F - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target NOT has been identified.
2983851|NCT02671045||G - No genomic profiling|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has not been sent for genomic profiling.
2983852|NCT02671032|Experimental|Implantation with Nucleus CI532 cochlear implant|All participants will receive the same treatment - Implantation with Nucleus CI532 cochlear implant.
2983853|NCT02671019|Experimental|Internet-based treatment|A five-module Internet-based treatment program for harmful alcohol use (including therapist support) based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
2983854|NCT02671019|Active Comparator|Face-to-face treatment|Same treatment content as in the Internet-based treatment delivered via face-to-face treatment sessions in specialized addiction treatment.
2983855|NCT02671006||Patients|Patients with an active Chronic Urticaria according to the EAACI criteria will be included. The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
2983856|NCT02671006||Volunteers|Volunteers must no have history of immediate allergy (patients under medical follow up for melanoma in remission for at least 3 months, age (+/- 5 years) and sex matched). Controls should have no history of atopy, urticaria or immediate allergy declared (rhinitis, urticaria, asthma) at the time of the test. The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
2983857|NCT02670993|Experimental|Control group : Singing sessions.|Patients will participate to singing working sessions. They will continue to take their usual treatments during the study period.
2983858|NCT02670993|Active Comparator|Control group : Painting sessions.|Patients will continue to participate to painting work sessions, and to take their usual treatments during the study.
2983859|NCT02670980|Experimental|Retina Implant|Intelligent Retinal Implant System
2983860|NCT02670954|Experimental|Dexmedetomidine,tramadol and flurbiprofen|Both routine analgesic and sedation(dexmedetomidine,tramadol and flurbiprofen) are applied for this group of patients.
2983861|NCT02670954|Active Comparator|Tramadol and flurbiprofen|Only routine analgesic(Tramadol and flurbiprofen) is applied for this group of patients.
2983862|NCT02670941|Experimental|Ginger|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
2983863|NCT02670941|Experimental|Lavender|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
2983864|NCT02670941|Experimental|Orange|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
2983865|NCT02670941|Placebo Comparator|Jojoba|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
2983866|NCT02670928|Active Comparator|Active group of patients|Active group of patients undergo program of active lifestyle management (healthy nutrition, physical exercises, psychological counselling and classes on diabetes) in first 12 weeks of the study.
2983867|NCT02670928|Experimental|Control group of patients|Control group pf patients is being monitored for the same criteria as active group but does not take part in the lifestyle change management program.
2983868|NCT02670915|Experimental|Meal-time faster-acting insulin aspart and insulin degludec|
2983869|NCT02670915|Active Comparator|Meal-time NovoRapid® (insulin aspart) and insulin degludec|
2983870|NCT02670915|Experimental|Post-meal faster-acting insulin aspart and insulin degludec|
2983871|NCT02670902|Experimental|Critical Time Intervention-Residential|CTI-R is a 9-month, assertive outreach and linkage program.
2983872|NCT02670902|Active Comparator|Enhanced Usual Discharge-Residential|The enhanced usual discharge condition includes usual discharge services plus three telephone recovery check-up calls post-discharge.
2983873|NCT02670889|Experimental|Treatment with AHA|Study day using acetohydroxamic acid (with experimental drug) Safety labs will be collected prior to administering acetohydroxamic acid (AHA, experimental drug) to participants. The investigators will give the participant one dose of the AHA (dose: 60 mg/kg). 1 hour after taking the AHA, the participant will receive a single dose of Isotopic Intravenous [13C]-Urea through a different IV which will be inserted into the opposite arm and removed after the administration of the isotope. Over the next 4 hours, the investigators will collect blood samples to measure safety labs and various biomarkers. Urine samples will also be collected.
2983874|NCT02670889|Other|Baseline Measurements without AHA (Study Drug)|Study day without the use of acetohydroxamic acid (no experimental drug) Procedures are identical except for the administration of AHA, which will not occur.
2983875|NCT02670876|Experimental|Anti-bullying intervention|An anti-bullying intervention target to perpetrators of school bullying was conducted. The program consisted of 8 sessions over 4 weeks and was conducted by a board-certified psychiatrist and a therapist with previous training in psychosocial treatments. The intervention was based on cognitive-behavioral therapy (CBT) principles and addressed various factors that have been associated with perpetrators of school bullying, including impulse control, perspective taking (empathy), and the enhancement of communication skills.
2983876|NCT02670863|Experimental|Experimental Infant Formula|Experimental Infant Formula containing a prebiotic
2983877|NCT02670863|Active Comparator|Standard Infant Formula|Standard bovine milk-based term infant formula
2983878|NCT02670850|No Intervention|Control group|Patients received only routine hospital care
2983879|NCT02670850|Experimental|Intervention group|Patients received regular hospital routine care and model-based intervention program
2983880|NCT02670837|Experimental|Graft from HCT donor|Cells are harvested from a donor using Cellutome, then transferred via Adaptic dressing to the recipient's wound with up to 3 donor harvest sites/treated wound sites on day 0.
2983881|NCT02670837|Experimental|Self donor from intact skin patch|Cells are harvested from the subject using Cellutome, then transferred via Adaptic dressing to that subject's wound with up to 3 harvest sites/treated wound sites on day 0.
2983882|NCT02670824|Experimental|CN-105 Active Drug|"The CN-105 drug administered via IV at an escalating scale of mg/kg.~A1-0.01 mg/kg A2-0.03 mg/kg A3-0.1 mg/kg A4-0.3 mg/kg A5-1.0 mg/kg B1-1.0 mg/kg"
2983883|NCT02670824|Placebo Comparator|Placebo|Normal Saline
2983884|NCT02670811|Experimental|Intervention|Daily consumption of 150 mL of fermented milk with Lactococcus lactis for 8 weeks
2983885|NCT02670811|Placebo Comparator|Placebo|Daily consumption of 150 mL of artificially acidified milk
2983886|NCT02670798|No Intervention|Control|Standard of care hematologic management in the operating room
2983887|NCT02670798|Experimental|Study|Standard of care hematologic management plus additional monitoring with the intervention of Thromboelastography laboratory testing and use of a thromboelastography-guided transfusion protocol.
2983888|NCT02670785|Experimental|Estradiol Vaginal Capsule 0.003 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
2983889|NCT02670785|Experimental|Estradiol Vaginal Capsule 0.01 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
2983890|NCT02670785|Experimental|Estradiol Vaginal Capsule 0.02 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
2983891|NCT02670785|Placebo Comparator|Placebo|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
2983892|NCT02670772|Active Comparator|Stavudine|Stavudine 20mg twice daily for 96 weeks
2983893|NCT02670772|Active Comparator|Tenofovir Disoproxil Fumarate|Tenofovir 300mg once daily for 96 weeks
2983894|NCT02670759|Experimental|Paravertebral analgesia|A paravertebral nerve block will be performed under ultrasound guidance by the anaesthesiologist prior to the induction of general anesthesia. A catheter will be inserted and a continuous infusion of bupivacaine will be administered.
2983895|NCT02670759|Active Comparator|Intercostal analgesia|An intercostal nerve block using a single dose of bupivacaine will be performed by the surgeon at the end of surgery before skin closure.
2983896|NCT02670746||Nab-paclitaxel in combination with gemcitabine (AG)|The objective is to prospectively assess the use and treatment outcomes of nab-paclitaxel plus gemcitabine in pancreatic ductal adenocarcinoma. In all cases, the decision to treat the patient with nab-paclitaxel in combination with gemcitabine was already made prior to the decision to enter the subject into the study. Treatment will be according to routine clinical practice and based on recommendations as per Summary of Product Characteristics (SPC).
2983897|NCT02670733||high responsiveness of ICP to PEEP|After increasing positive end-expiratory pressure (PEEP) from 5 cmH2O to 15 cmH2O, intracranial pressure (ICP) increases above the median for the study population.
2983898|NCT02670733||low responsiveness of ICP to PEEP|After increasing positive end-expiratory pressure (PEEP) from 5 cmH2O to 15 cmH2O, the level of intracranial pressure (ICP) increases below the median for the study population.
2983899|NCT02670720|Experimental|avoralstat|Five avoralstat capsules (100 mg) to be taken three times daily by mouth
2983900|NCT02670707|Experimental|"Cytarabine (experimental) arm"|
2983901|NCT02670707|Experimental|"Vinblastine/prednisone (standard) arm"|
2983902|NCT02670694||Rett Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Rett Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
2983903|NCT02670694||Angelman's Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Angelman's Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
2983904|NCT02670694||Prader-Willi Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Prader-Willi Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
2983905|NCT02670694||Control|Siblings of RTT, AS and PW subjects will serve as control subjects.
2983906|NCT02670681|Active Comparator|Aerobic Exercise Mild Intensity|The subjects engage in aerobic exercise training (8 weeks) of mild intensity (continuous). The intensity is controlled by a corresponding heart rate at anaerobic threshold.
2983907|NCT02670681|Active Comparator|Aerobic Exercise Moderate Intensity|The subjects engage in aerobic exercise training (8 weeks) of moderate intensity (continuous). The intensity is controlled by a corresponding heart rate between anaerobic threshold and respiratory compensation point.
2983908|NCT02670681|Active Comparator|Aerobic Exercise High Intensity|The subjects engage in aerobic exercise (8 weeks) of high intensity interval training. The intensity is controlled by a corresponding heart rate above respiratory compensation point.
2983909|NCT02670668|Experimental|Mutation analysis- NACwith PCR|consisting of 50 patients undergoing NACwith pathological compete response
2983910|NCT02670668|Experimental|Mutation analysis-NAC with SD/PD.|consisting of 50 patients undergoing NAC with SD/PD
2983911|NCT02670655|Experimental|Group A (short-time iontophoresis group)|Group A was treated with iontophoresis-assisted AFL-PDT with a short incubation time (2 h)
2983912|NCT02670655|Active Comparator|Group B (short-time conventional group)|Group B was treated with conventional AFL-PDT with a short incubation time (2 h)
2983913|NCT02670655|Active Comparator|Group C (long-time conventional group)|Group C was treated with conventional AFL-PDT with a standard incubation time (3 h)
2983914|NCT02670642|Experimental|On demand 20 mg esomeprazole|On demand treatment with 20-mg esomeprazole once daily when needed
2983915|NCT02670642|Active Comparator|Continuous 20 mg esomeprazole|Continuous treatment with 20 mg esomeprazole once daily
2984119|NCT02669420|Experimental|extra amniotic misoprostol|misoprostol dissolved in warm saline , become dissolute misoprostol saline solution(200 microgram every 4 hours)
2983916|NCT02670629|Active Comparator|Anatomic Closed Reduction + Short Cast|"Patients in this group were treated by performing a closed anatomic reduction under anesthesia by using sedatives and then placing the child in a short arm cast for 6 weeks. The follow up was done at week 1, 3, 6 and 10 with new X rays in each consult.~The intervention in this control group was performing a closed anatomic reduction under anesthesia."
2983917|NCT02670629|Experimental|Partial reduction overriding position|"Patients in this group were only given oral medications, the fracture was not reduced, instead it was left with a partial reduction with overriding position placed in a short arm cast for 6 weeks. The follow up was done at week 1, 3, 6 and 10 with new X rays in each consult.~The intervention in this control group was not performing a closed anatomic reduction under anesthesia."
2983918|NCT02670616|Experimental|ibrutinib in combination with r-CHOP|Ibrutinib560 mg daily on day 1-21 per each cycle ,Rituximab375 mg/m2, Cyclophosphamide750 mg/m2, doxorubicin 50 mg/m2, vincristine1.4 mg/m2 on day 1; Prednisolone 100mg per day on day 1-5 ,cycle length: 21 days ,Six cycles of treatment
2983919|NCT02670603|Experimental|Experimental arm|In experimental arm, each patient painted EVONAIL® solution on nails and periungual areas once a day till developing onycholysis grade 2 or more.
2983920|NCT02670603|Other|Control arm|"In control arm, each patient painted EVONAIL® solution on nails and periungual area twice a day after developing onycholysis grade 2.~This study design allowed cross-over. Therefore, this control arm would give EVONAIL® solution after developing onlycholysis grade 2 in spite of control arm."
2983921|NCT02670590|Experimental|NAFLD|diet
2983922|NCT02670577||stage I or II HR-positive, HER2-negative|"Histologically proven invasive stage I and II breast cancer and Hormone Receptor positive & HER2 negative~& Axillary lymph node status: 0-3 involved"
2983923|NCT02670577||HER2+|"Histologically proven invasive T1a or T1b breast cancer~& Hormone receptor negative or positive~& HER2 positive~& Axillary lymph node status: 0-1 involved"
2983924|NCT02670577||Triple Negative|"Histologically proven invasive T1a or T1b breast cancer~& Hormone receptor negative~& HER2 negative~& Axillary lymph node status: 0-1 involved"
2983925|NCT02670577||Neoadjuvant|Stage I or II patients receiving neoadjuvant therapy.
2983926|NCT02670564|Experimental|Total body irradiation (TBI)|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
2983927|NCT02670564|Experimental|Busulfan|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
2983928|NCT02670564|Experimental|Treosulfan|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
2983929|NCT02670551|Experimental|Cariprazine 3.0 mg dose|3.0 milligram dose of cariprazine, one per day, oral administration
2983930|NCT02670551|Experimental|Cariprazine 1.5 mg dose|1.5 milligram dose of cariprazine, one per day, oral administration
2983931|NCT02670551|Placebo Comparator|Placebo|Dose-matched placebo, one per day, oral administration
2983932|NCT02670538|Experimental|Cariprazine 3.0 mg dose|3.0 milligram dose of cariprazine, one per day, oral administration
2983933|NCT02670538|Experimental|Cariprazine 1.5 mg dose|1.5 milligram dose of cariprazine, one per day, oral administration
2983934|NCT02670538|Placebo Comparator|Placebo|Dose-matched placebo, one per day, oral administration
2983935|NCT02670525|Experimental|Relapsed/Refractory leukemia|"Cohort 1: Relapsed/refractory leukemia~Acute lymphoblastic leukemia, first or greater relapse~Acute myeloid leukemia, first or greater relapse~Leukemia refractory to induction chemotherapy~Other recurrent leukemia~Myelodysplastic syndrome (MDS), first or greater relapse, or refractory to initial therapy~After the screening procedures confirms patient eligibility:~Leukemia Profiling will be performed~Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation."
2983936|NCT02670525|Experimental|New diagnosis|"Cohort 2: New diagnosis~Acute myeloid leukemia, new diagnosis (excluding acute promyelocytic leukemia (APL))~New diagnosis infant MLL-rearranged ALL or low hypodiploid (<40 chromosomes) ALL~Rare leukemia- e.g., JMML, leukemia of ambiguous lineage~Secondary leukemia~Myelodysplastic syndrome (MDS) not eligible for stem cell transplant~After the screening procedures confirms eligibility:~Leukemia Profiling will be performed~Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation."
2983937|NCT02670512|Experimental|Telehome Monitoring|Patients in this arm will use the telehome monitoring device (a mobile tablet) to support them with their peritoneal dialysis (communication, treatment tracking, supply tracking, appointment reminders, educational content).
2983938|NCT02670512|No Intervention|Standard of Care|Patients in this arm use the standard of care for peritoneal dialysis, which is simple telephone communication and using pen and paper log to track their treatments and supplies.
2983939|NCT02670499|Experimental|GAP-FLEX|Study Device will be used up to 6 times per day for up to 6 minutes to aid in the recovery and improve the degree of flexion from TKR
2983940|NCT02670499|Active Comparator|CPM|Control Device will be used up to 2 hours per day for up to 3 times per day to aid in the recovery and improve the degree of flexion from TKR and be compared to the Study Device
2983941|NCT02670486|No Intervention|standard of care|Usual urodynamics with no intervention.
2983942|NCT02670486|Active Comparator|Audiovisual intervention|Audiovisual stimulus during urodynamic testing.
2983943|NCT02670473|No Intervention|enfilcon A (habitual)|Participants are habitual wearers of enfilcon A lens and refitted with fanfilcon A lens.
2983944|NCT02670473|Experimental|fanfilcon A (test)|Participants are habitual wearers of enfilcon A lens and refitted with fanfilcon A lens.
2983945|NCT02670460|Experimental|Temporary diaphragmatic pacing|There is no comparator for this study. Single site and all patients are in the treatment allocated group of temporary diaphragmatic pacing with the LIVE Catheter which is inserted via the left subclavian vein.
2983946|NCT02670447||First episode of psychosis patients|Patients with schizophrenia will be studied in this clinical trial, and that have never received anti-psychotic treatment. They will perform an MRI.
2983947|NCT02670434|Experimental|NK-104-CR|Controlled release NK-104
2983948|NCT02670434|Placebo Comparator|Placebo|Livalo Placebo
2983950|NCT02670421|Active Comparator|Face to face Heart SMART program|Stress management program presented in a face to face meeting of 90-100 minutes with daily printed program instructions to follow over the next 12 weeks, accompanied by reading from a book entitled The Mayo Clinic Guide to Stress Free Living.
2983951|NCT02670421|Active Comparator|Online Heart SMART program|Stress management program in the form of 10- minute videos completed weekly by participant on-line for 12 weeks, accompanied by reading from a book entitled The Mayo Clinic Guide to Stress Free Living.
2983952|NCT02670395|Experimental|JNJ-54416076|Participants will receive single dose of JNJ-54416076 (in ascending dose) in Part 1 and 2 doses of JNJ-54416076 (one dose in the fasted state and an identical dose in the fed state) in Part 2. The dose selected for Part 2 will be selected based on the preliminary safety and PK data in Part 1.
2983953|NCT02670395|Experimental|Placebo|Participants will receive single dose of placebo in Part 1.
2983954|NCT02670382|Experimental|EPA intervention|Subjects randomized to receive 3000 mg EPA/day, provided as EPA 750 mg/capsule will be instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
2983955|NCT02670382|Experimental|DHA intervention|Subjects randomized to 3000 mg DHA/day provided as DHA 750 mg/capsule will instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
2983956|NCT02670382|Placebo Comparator|Placebo|3000 mg high oleic acid sunflower oil/day; 750 mg high oleic acid sunflower oil/capsule; subjects instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
2983957|NCT02670369|Experimental|Sitting time prompt|All participants will receive a prompting device (one-arm intervention).
2983958|NCT02670356|Experimental|Fish oil|fish oil, 1500 mg/day, EPA:DHA ratio of 4:1, each capsule containing 750 mg total EPA+DHA, 2 capsules/day for 10 weeks
2983959|NCT02670356|Experimental|krill oil|krill oil, 300 mg/day, each capsule containing 74 mg total EPA+DHA , 1 capsule/day for 10 weeks
2983960|NCT02670343|Experimental|Oral Testosterone Undecanoate|A single dose of oral testosterone undecanoate equivalent to 200 mg of testosterone in the form of two soft gelatin capsules containing 158 mg of testosterone undecanoate will be administered to each subject.
2983961|NCT02670330|Experimental|Experimental: ZORBLISA (SD-101 cream )|All subjects will apply ZORBLISA (SD-101-6.0%) cream topically, once a day to the entire body for a period of up to 1440 days (48 months).
2983962|NCT02670317|Experimental|G CHOP 21 + Ibrutinib|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
2983963|NCT02670304|Experimental|letrozole|letrozole for the first day after ovum picked up at least for 5 days.
2983964|NCT02670304|Active Comparator|aspirin|asprin for the first day after ovum picked up at least for 5 days.
2983965|NCT02670291|Active Comparator|active cTBS|Determination of resting motor threshold (RMT); Coil position: temporoparietal cortices halfway between T3/P3 and T4/P4 (EEG 10/20 system); active cTBS (80% of RMT);
2983966|NCT02670291|Sham Comparator|Sham cTBS|Determination of resting motor threshold (RMT); Coil position: temporoparietal cortices halfway between T3/P3 and T4/P4 (EEG 10/20 system); sham cTBS;
2983967|NCT02670278||US-Washington, Idaho|healthy breastfeeding women and their infants
2983968|NCT02670278||US-California|healthy breastfeeding women and their infants
2983969|NCT02670278||Sweden|healthy breastfeeding women and their infants
2983970|NCT02670278||Spain|healthy breastfeeding women and their infants
2983971|NCT02670278||Peru|healthy breastfeeding women and their infants
2983972|NCT02670278||Kenya|healthy breastfeeding women and their infants
2983973|NCT02670278||Ethiopia-rural|healthy breastfeeding women and their infants
2983974|NCT02670278||Ethiopia-urban|healthy breastfeeding women and their infants
2983975|NCT02670278||The Gambia-rural|healthy breastfeeding women and their infants
2983976|NCT02670278||The Gambia-urban|healthy breastfeeding women and their infants
2983977|NCT02670278||Ghana|healthy breastfeeding women and their infants
2983978|NCT02670265|Active Comparator|Parenteral nutrition|Active Comparator: Olimel peri 2.5% ® 1l/d (700 kcal/d) (Baxter GmbH, Unterschleißheim, Germany)
2983979|NCT02670265|Placebo Comparator|Isotonic fluid|Isotonic fluid 1l/d (E153, Berlin-Chemie AG, Berlin, Germany)
2983980|NCT02670252|Experimental|BUCY|For standard-risk ALL undergoing HLA-matched allo-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
2983981|NCT02670252|Active Comparator|TBICY|For standard-risk ALL undergoing HLA-matched allo-HSCT，TBICY conditioning regimen was 4.5 Gy TBI/day on days -5 and -4；CY 60 mg/kg/day on days -3 and -2.
2983982|NCT02670239||EVLP group|All lungs from brain dead donors that were considered at high-risk for transplantation and underwent EVLP in the Turin lung transplantation program
2983983|NCT02670226|Other|Case group|The intervention, specific to the study, is to take samples at baseline on patients with Amyotrophic Lateral Sclerosis
2983984|NCT02670226|Other|Control group|The intervention, specific to the study, is to take samples at baseline on patients without neurological disease
2983985|NCT02670213||NovoThirteen®|
2983986|NCT02670200|Experimental|intervention arm / verum arm|Participants can work on ten modules specialized cognitive behavior treatments to learn and deal with mindfulness, acceptance and commitment. They should learn to handle their emotions, to accept the situation and to get in an active future. The participants can direct contact a psychotherapist via email, Chat or Skype/tokbox. The modules based on Cognitive Behavior Therapy.
2983987|NCT02670200|Active Comparator|non-intervention arm / control group|Participants can work on six modules with information und education goals for learning something about their possibilities to become a better mood, better psychovegetative or psychosocial situation as cancer patient. This modules are based on Cognitive Behavior Therapy. The non-intervention arm will only allow contact to the platform, no direct contact to a psychotherapist (in opposite to the intervention arm) is available.
2983988|NCT02670187|Experimental|GLS-5300|GLS-5300 at 0.67 mg DNA/dose
2983989|NCT02670187|Experimental|GLS-5300 at 2 mg DNA/dose|GLS-5300 at 2 mg DNA/dose
2983990|NCT02670187|Experimental|GLS-5300 at 6 mg DNA/dose|GLS-5300 at 6 mg DNA/dose
2984120|NCT02669420|Experimental|vaginal misoprostol|misoprostol tablet soaked with distilled water and inserted in the posterior fornix of the vagina( 200 microgram every 4 hours)
2983991|NCT02670174|Active Comparator|Traditional training|A home exercise program consisting of rotator cuff and scapular muscle training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
2983992|NCT02670174|Experimental|Separate kinetic chain training|A home exercise program consisting of traditional training exercises as well as separate exercises focusing on core and lower limb training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
2983993|NCT02670174|Experimental|Integrated kinetic chain training|A home exercise program consisting of traditional training exercises while integrating core and lower limb training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
2983994|NCT02670161|Active Comparator|Treatment A (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
2983995|NCT02670161|Active Comparator|Treatment B (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
2983996|NCT02670161|Active Comparator|Treatment C (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
2983997|NCT02670148|Experimental|Chiropractic Care (CC)|Participants in the CC group will receive evaluation and treatment (chiropractic manipulative therapy) from a doctor of chiropractic over a 4 week period.
2983998|NCT02670148|No Intervention|Waitlist control group (WC)|Participants allocated to the waitlist control group will not receive any chiropractic treatment during the active study period. These individuals will be scheduled for one additional study visit following allocation. This final study visit will be scheduled 4 weeks after allocation (± 7 days). WC participants are not restricted from receiving any other healthcare during study participation. However, participants in the WC group will be asked not to receive any chiropractic care or spinal manipulation by any other provider during the 4 week intervention period. After WC participants complete the final study visit, they will be offered chiropractic care. This treatment will not be part of the study and no data will be collected at these visits.
2983999|NCT02670135|Placebo Comparator|triclosan free toothpaste|Control toothpaste with no triclosan ingredients in a 1450 ppm sodium fluoride/silica base - matching placebo
2984000|NCT02670135|Active Comparator|Triclosan containing toothpaste|Active formula containing 0.3% triclosan in a1450 ppm sodium fluoride/silica base
2984001|NCT02670122||Patients with non resectable HCC|DEB-TACE with doxorubicin eluting 100 µ microspheres
2984002|NCT02670109|Experimental|Unique|"Patients will receive a high dose chemotherapy regimen, consisting in the administration of three medications: Carmustine (BCNU) 300mg/m2, Cyclophosphamide 80mg/kg, and carboplatin 1400/m2.~Then they will undergo an Autologous Hematopoietic Stem Cell Transplantation."
2984003|NCT02670096|Experimental|Reference therapy|"Baseline evaluation of subjects without acetazolamide administration~Follow up evaluation of subjects one hour after acetazolamide administration"
2984004|NCT02670083|Experimental|Crenezumab|Participants will receive IV infusion of crenezumab q4w for 100 weeks.
2984005|NCT02670083|Placebo Comparator|Placebo|Participants will receive placebo q4w for 100 weeks.
2984006|NCT02670070|Active Comparator|Coadministration of G+R|Coadministration of gemigliptin 50mg and rosuvastatin 20mg
2984007|NCT02670070|Experimental|Combination G/R|Combination of gemigliptin 50mg / rosuvastatin 20mg
2984008|NCT02670057|Experimental|Transnasal SPG block|
2984009|NCT02670044|Experimental|1) Phase Ib Dose-Escalation, Arm A (Venetoclax + Cobimetinib)|Venetoclax in combination with cobimetinib
2984010|NCT02670044|Experimental|2) Phase Ib Dose-Escalation, Arm B (Venetoclax + Idasanutlin)|Venetoclax in combination with idasanutlin
2984011|NCT02670044|Experimental|3) Phase II Expansion, Arm A (Venetoclax + Cobimetinib)|Venetoclax in combination with cobimetinib
2984012|NCT02670044|Experimental|4) Phase II Expansion, Arm B (Venetoclax + Idasanutlin)|Venetoclax in combination with idasanutlin
2984013|NCT02670031||Newly Diagnosed Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
2984121|NCT02669407|Experimental|Regional nerve anesthesia|Regional nerve anesthesia of splanchnic nerve
2984225|NCT02668588|Experimental|LF-PB 30 mg|extended release of octreotide
2984014|NCT02670031||Well-Controlled Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
2984015|NCT02670031||Resistant Essential Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
2984016|NCT02670018|Active Comparator|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg * 2 tablets
2984017|NCT02670018|Experimental|C|Combination of gemigliptin 25mg/metformin HCl extended release 1000mg * 2 tablets
2984018|NCT02670005||FFR-PCI group|patients with ST-segment elevation myocardial infarction (STEMI) who received fractional flow reserve (FFR)-guided selective percutaneous coronary intervention (PCI)
2984019|NCT02670005||angiography-PCI group|patients with STEMI who received angiography-guided selective PCI
2984020|NCT02669992|Experimental|Stapled anastomosis|Stapled anastomosis by the use of commercially available linear stapler device
2984021|NCT02669992|Active Comparator|Hand-sewn anastomosis|Hand-sewn by the use of a resorbable monofilament suture
2984022|NCT02669992|Experimental|Abdominal wall mesh closure|Closure by the use of a mesh low-weight net device
2984023|NCT02669992|Active Comparator|Abdominal wall suture closure|Closure by the use of slowly absorbing monofilament suture
2984024|NCT02669979|Experimental|Intervention|"Intervention in the research groups is professional oral care with tooth brush, ordinary fluoridated tooth paste (1100-1450 ppm NaF), and repeated oral care instruction to participants and staff (contact person) , supra gingival depuration if necessary. The group receive treatment each month."
2984025|NCT02669979|No Intervention|Control|Care as usual. Common oral hygiene help administered by nursing staff.
2984026|NCT02669966|Experimental|Study Arm|Donor candidates with their intended recipients who meet criteria will be enrolled into this, the sole arm of our study. Donor-recipient pairs will be screened to meet criteria, and will proceed to kidney transplantation and post-transplant monitoring
2984027|NCT02669953||AMD patients previously teated with Lucentis|"Adults ≥ 50 years; Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS; Willingness and ability to comply with regular visits; Signed informed consent form;~The patient can take his medicine in the prescribed manner. The prescribed drugs do not constitute an exclusion criteria."
2984028|NCT02669953||treatment naive AMD patients|Adults ≥ 50 years; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
2984029|NCT02669953||DME patients previously teated with Lucentis|Adults ≥ 50 years; Patients who have been treated with ranibizumab due to DME for up to one year; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
2984030|NCT02669953||treatment naive DME patients|Adults ≥ 50 years; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
2984031|NCT02669940||Genotype 1 Chronic Hepatitis C|Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with the interferon-free ABBVIE REGIMEN ± Ribavirin (RBV) according to standard of care and in line with the current local label
2984032|NCT02669914|Experimental|Cohort 1: Non-small cell lung cancer w/o corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
2984033|NCT02669914|Experimental|Cohort 2: Epithelial origin solid tumors w/o corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
2984034|NCT02669914|Experimental|Cohort 3: NSCLC or non-NSCLC w/corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
2984035|NCT02669901|Other|Patients with opioid substance abuse disorders|All participants will receive Naloxone autoinjector as a preventative tool for accidental opioid overdose
2984036|NCT02669888|Experimental|Indigo naturalis ointment|"Form: ointment~Dose: each gram of ointment contains 200µg of indirubin~Dosing schedule: apply 0.5g of ointment per 10 x 10 dermatitis lesion twice daily"
2984037|NCT02669888|Placebo Comparator|Placebo|"Form: ointment~Dose: vehicle~Dosing schedule: apply 0.5g of ointment per 10 x 10 dermatitis lesion twice daily"
2984038|NCT02669875|Active Comparator|Serelaxin|IV infusion of serelaxin (RLX030) for 2 hours
2984039|NCT02669875|Placebo Comparator|Placebo|IV infusion of placebo (20mM sodium acetate pH5) matched to serelaxin for 2 hours
2984040|NCT02669862|Experimental|A-101 Solution 40|A-101 Solution 40% administered once per week
2984041|NCT02669862|Experimental|A-101 Solution 45|A-101 Solution 45% administered once per week
2984042|NCT02669862|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once per week
2984043|NCT02669849|Experimental|9-mg VX-210|a single 9-mg dose of VX-210 in fibrin sealant
2984044|NCT02669849|Experimental|Placebo|a placebo (buffer solution) in fibrin sealant
2984045|NCT02669836|Experimental|Posterior fossa decompression surgery|The bone is surgically removed from the suboccipital region of the skull and Cervical 1 lamina so the constricting epidural band can be resected
2984046|NCT02669836|Experimental|Dural augmentation surgery|The bone is removed from the suboccipital region of the skull and Cervical 1 lamina so the constricting epidural band can be resected. Then, the dura is opened. Microsurgical dissection is performed and the dura is sewn closed.
2984047|NCT02669823||Children <15y|no intervention
2984048|NCT02669823||Adults >=15y|no intervention
2984049|NCT02669810|Experimental|PROTHERACYTES|The interventional investigators will perform the ProtheraCytes® endocardiac injections using the HELIX® catheter introduced via the femoral route up to the left ventricle cavity.
2984050|NCT02669810|Active Comparator|Standard of Care|Patients will undergo standard of care procedure (PTCA Percutaneous Transluminal Coronary Angioplasty and stent(s) implantations)
2984226|NCT02668588|Placebo Comparator|Placebo|extended release of placebo
2984051|NCT02669797|Experimental|Arm 1: Education + EMI|Arm 1 includes: (1) 5-2-1-0 messages delivered during yearly well-child visits; (2) in-home visits and food preparation activities focusing on family meal quality (i.e., dietary quality, interpersonal quality) and quantity (i.e., frequency of family meals) for 12 weeks; (3) tailored ecological momentary intervention (EMI) texts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 24 weeks; and (4) a 12-week maintenance phase with EMI tips delivered on high stress days, based on EMA measures taken at baseline and 9 months.
2984052|NCT02669797|Experimental|Arm 2: Education + EMI + Video Feedback|Arm 2 includes: (1) 5-2-1-0 messages delivered during yearly well-child visits; (2) in-home visits and food preparation activities focusing on family meal quality (i.e., dietary quality, interpersonal quality) and quantity (i.e., family meal frequency) for 12 weeks; (3) tailored EMI texts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 24 weeks; (4) feedback on video-recorded family meals every other week delivered via an in-home visit with a dietitian and behavioral health provider for the same 24 weeks as the EMI family meal tips; and (5) a 12-week maintenance phase with EMI tips delivered on high stress days only, based on EMA measures taken at baseline and 9 months; video feedback home visits will be reduced to once per month.
2984053|NCT02669797|Active Comparator|Arm 3: Attention Control|Arm 3 includes: (1) 5-2-1-0 messages delivered during yearly well-child visits; (2) general child health messages (e.g., immunizations, child safety, school readiness) that will be delivered to the attention control arm in a similar manner and frequency as the experimental arms for 36 weeks. For example, general child health tips via text messages or video-clips via email will be sent weekly; and (3) a 12-week maintenance phase with general child health tips delivered once a month.
2984054|NCT02669784|Active Comparator|Contrast|"CTA of the chest: 40 mL of intravenous contrast (omnipaque) at a rate of 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds.~CTA of the chest and abdomen or CTA of the chest, abdomen and pelvis: 50 mL of intravenous contrast at a rate 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds."
2984055|NCT02669784|No Intervention|Comparison With Prior CTA|The images obtained with the low volume dose contrast will be compared to the images obtained on the same patient within the last 2 years. The prior study will have been performed with a dose of 100 mL of intravenous contrast (omnipaque).
2984056|NCT02669771||Enzalutamide group|oral
2984057|NCT02669758|Experimental|ALKS 3831|Administered as a coated bilayer tablet.
2984058|NCT02669745||Women of Chinese Descent|Females of Chinese descent, aged 18 year to 70 year, diagnosed with Stage 1 or Stage 2 (excluding those involving more than 3 lymph nodes) breast cancer.
2984059|NCT02669732|Experimental|DS-8500a 75 mg once daily (QD)|tablets, orally, once daily for up to 28 days
2984060|NCT02669732|Placebo Comparator|Placebo|tablets, orally, once daily for up to 28 days
2984061|NCT02669719|Experimental|chemotherapy followed dendritic cells|pemetrexed and carboplatin chemotherapy followed dendritic cells infusion from Cycle 3
2984062|NCT02669719|Active Comparator|chemotherapy|pemetrexed and carboplatin chemotherapy only
2984063|NCT02669706||IV pentamidine|Pentamidine 4mg/kg IV every month (maximum 300mg)
2984064|NCT02669693|Placebo Comparator|bread without olives|Intervention (no olives): Subjects will consume a meal of 109 g white bread and 200 of ml water, and post-prandial blood glucose measured over a 3 hour period.
2984065|NCT02669693|Active Comparator|bread with olives|Intervention (olives 100 g): Subjects will consume a meal of 109 g white bread, 100 g of olives and 200 of ml water, and post-prandial blood glucose measured over a 3 hour period.
2984066|NCT02669680|Experimental|G-CSF + Standard therapy|Standard care of acute-on-chronic liver failure and application of G-CSF
2984067|NCT02669680|Active Comparator|Standard therapy|Standard care of acute-on-chronic liver failure
2984068|NCT02669667|Experimental|Cohort 1|single dose of MEDI9314 or placebo
2984069|NCT02669667|Experimental|Cohort 2|single dose of MEDI9314 or placebo
2984070|NCT02669667|Experimental|Cohort 3|single dose of MEDI9314 or placebo
2984071|NCT02669667|Experimental|Cohort 4|single dose of MEDI9314 or placebo
2984072|NCT02669667|Experimental|Japanese Cohort|single dose of MEDI9314 or placebo
2984073|NCT02669667|Experimental|Cohort 5|single dose of MEDI9314 or placebo
2984074|NCT02669654|Experimental|Day-care management of Severe Pneumonia|management in Day-care clinic
2984075|NCT02669654|No Intervention|Existing Treatment Centre (ETC)|Severe Pneumonia management in Existing Treatment Centre
2984076|NCT02669641|Experimental|Steatosis|Patients with diagnosed steatosis in treatment with combination Silimarin, Phyllanthus Niruri and Choline
2984077|NCT02669628||Surgical technique|Laparoscopic ovarian cystectomy
2984078|NCT02669628||Alcohol sclerotherapy|US-aspiration and alcohol sclerosis
2984079|NCT02669615|Experimental|Melphalan HCl for injection (propylene glycol free)|Patients will receive 200 mg/m2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).
2984080|NCT02669602||No intervention|No Intervention
2984081|NCT02669589|Active Comparator|heparin anticoagulation|"Systemic anticoagulation of the continuous renal replacement therapy with heparin.~Dose will be titrated to maintain aPTT (activated partial thromboplastin time) between 45-60s)"
2984082|NCT02669589|Experimental|citrate anticoagulation|"Regional anticoagulation of the continuous renal replacement therapy with citrate.~Target posthemofilter ionized calcium level: 0.25-0.35 mmol/l"
2984083|NCT02669576|Experimental|Mind body medicine day care clinic|Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
2984084|NCT02669576|Other|Usual care|Patients continue usual care by their practitioner
2984158|NCT02669082|Experimental|Ramelteon 8 mg|Ramelteon 8 mg, tablet, orally, once daily at bedtime for 8 weeks.
2984159|NCT02669069|Active Comparator|PS1|
2984160|NCT02669069|Active Comparator|PS2|
2984085|NCT02669563|Experimental|Stage 1|"Subjects (n = 4 to 10) will be injected once with 20 mCi of [13N]ammonia and receive a 20 minute PET scan. They will then be injected once with 6.5 mCi of one of the two new drugs under study, [18F]4F-MHPG or [18F]3F-PHPG, and receive a 60 minute PET scan.~On a second visit to the clinic, subjects will be injected once with 6.5 mCi of [18F]3F-PHPG or [18F]4F-MHPG (whichever was not used for the first visit) and receive a 60 minute PET scan."
2984086|NCT02669563|Experimental|Stage 2|"Subjects (n = 20 to 26) will be injected with 20 mCi of [13N]ammonia and receive a 20 minute PET scan.~They will then be injected once with 6.5 mCi of [18F]4F-MHPG or [18F]3F-PHPG (whichever was chosen based on Stage 1 of the study) and receive a 60 minute PET scan. On a second visit to the clinic, subjects will be injected once with 20 mCi of [11C]HED and receive a 40 minute scan."
2984087|NCT02669550|Experimental|Fiberoptic bronchoscope|In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
2984088|NCT02669550|Experimental|Disposcope endoscope|In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
2984089|NCT02669537|Experimental|GOPRO resident|Residents will use the gopro during a vaginal procedure, review the case with the attending after, and perform a 2nd case of the same type. The VVSI and GRS will be used to assess any changes in surgical skill
2984090|NCT02669537|No Intervention|Control Resident|Residents will use standard surgical education practices, direct instruction from attending, surgical atlas, online videos. They will perform 2 cases of the same type and the difference in VVSI and GRS will be assessed
2984091|NCT02669537|Experimental|GOPRO medical student|Medical students will be allowed to watch the surgery on an iPad with the GoPro app. Their assessment of the educational value of the surgery will be assessed at the end of the procedure. They will also take a pre and post-test focusing on surgical instruments and steps used in the procedure.
2984092|NCT02669537|No Intervention|Control Medical Student|Medical students will be taught using standard practices, i.e instruction by residents/attendings. Their assessment of the educational value of the surgery will be assessed at the end of the procedure. They will also take a pre and post-test focusing on surgical instruments and steps used in the procedure.
2984093|NCT02669524|Active Comparator|T2D + OGTT + LY2409021|Type 2 diabetes patients + 50 oral glucose tolerance test 4 hours + the human antagonist of the glucagon receptor.
2984094|NCT02669524|Placebo Comparator|T2D + OGTT + placebo|Type 2 diabetes patients + 50 oral glucose tolerance test 4 hours + placebo comparator to the human antagonist of the glucagon receptor.
2984095|NCT02669524|Active Comparator|T2D + IIGI + LY2409021|Type 2 diabetes patients + isoglycaemic iv glucose infusion + the human antagonist of the glucagon receptor.
2984096|NCT02669524|Placebo Comparator|T2D + IIGI + placebo|Type 2 diabetes patients + isoglycaemic iv glucose infusion + placebo comparator to the human antagonist of the glucagon receptor.
2984097|NCT02669524|Active Comparator|T2D + MEAL + LY2409021|Type 2 diabetes patients + Standardised liquid meal + the human antagonist of the glucagon receptor.
2984098|NCT02669524|Placebo Comparator|T2D + MEAL + placebo|Type 2 diabetes patients + Standardised liquid meal + placebo comparator to the human antagonist of the glucagon receptor.
2984099|NCT02669524|Active Comparator|CTRL + OGTT + LY2409021|Healthy controls + 50 oral glucose tolerance test 4 hours + the human antagonist of the glucagon receptor.
2984100|NCT02669524|Placebo Comparator|CTRL + OGTT + placebo|Healthy controls + 50 oral glucose tolerance test 4 hours + placebo comparator of the human antagonist of the glucagon receptor.
2984101|NCT02669524|Active Comparator|CTRL + IIGI + LY2409021|Healthy controls + isoglycaemic iv glucose infusion + the human antagonist of the glucagon receptor.
2984102|NCT02669524|Placebo Comparator|CTRL + IIGI + placebo|Healthy controls + isoglycaemic iv glucose infusion + placebo comparator the human antagonist of the glucagon receptor.
2984103|NCT02669524|Active Comparator|CTRL + MEAL + LY2409021|Healthy controls + Standardised liquid meal + the human antagonist of the glucagon receptor.
2984104|NCT02669524|Placebo Comparator|CTRL + MEAL + placebo|Healthy controls + Standardised liquid meal + placebo comparator of the human antagonist of the glucagon receptor.
2984105|NCT02669511|Other|PQR309|A single arm study with PQR309, a phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), 60mg/80mg given once a day, orally.
2984106|NCT02669498|Active Comparator|Surgery with fallopian tube removal|Patients receiving routine fallopian tube removal during pelvic surgery after randomization.
2984107|NCT02669498|No Intervention|Surgery without fallopian tube removal|Fallopian tubes are not removed during pelvic surgery after randomization.
2984108|NCT02669485|Experimental|ICG|Administering indocyanine green during surgery and the use of ICG fluorescence imaging to assess bowel perfusion during surgery
2984109|NCT02669472|Experimental|F&V Intervention|Housing complexes randomized to the intervention arm received a multicomponent intervention comprised of a year-round, discount, mobile fresh fruit and vegetable market ('Fresh To You') that was paired with nutrition education interventions including educational newsletters, recipe cards, campaigns, taste-testings and videos in both English and Spanish.
2984110|NCT02669472|Experimental|Control Intervention|Housing complexes randomized to the comparison arm received a year-long intervention on physical activity and stress reduction including educational campaigns and materials in both English and Spanish.and a YMCA membership for those who joined the campaigns.
2984111|NCT02669459|Active Comparator|LLETZ|LLETZ (Large Loop excision of the transformation zone) treatment conform current guidelines, which is also the current gold standard in the Netherlands
2984112|NCT02669459|Other|Imiquimod 5% cream|intervention group
2984113|NCT02669446||Ectoin containing Lozenges|treatment with Ectoin containing lozenges
2984114|NCT02669446||Hyaluronic acid containing lozenges|treatment with hyaluronic acid containing lozenges
2984115|NCT02669446||Saline solution for gargling|Subjects in were requested to gargle with salt water
2984116|NCT02669433|Experimental|RVT-101 35 mg|RVT-101 35 mg once daily
2984117|NCT02669433|Experimental|RVT-101 70 mg|RVT-101 70 mg once daily
2984118|NCT02669433|Placebo Comparator|Placebo|Placebo
2984122|NCT02669394|Experimental|Resistance Training (RT)|The RT program will be a twice-weekly program. A pressurized air system and free weights will be used to provide the training stimulus. The pressurized air system exercises will consist of biceps curls, triceps extension, seated row, latissmus dorsi pull downs, leg press, hamstring curls, and calf raises. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form.
2984123|NCT02669394|Active Comparator|Stretching and Relaxation (CON)|The CON program will be a twice-weekly program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
2984124|NCT02669381|Other|Experimental: phenylalanine intake|Dietary supplement: phenylalanine intake
2984125|NCT02669368|Active Comparator|Standard dose Rocuronium|Pretreatment of saline 100ml then giving Rocuronium 0.6 mg/kg at induction of anesthesia.
2984126|NCT02669368|Active Comparator|Low dose Rocuronium|Pretreatment of saline 100ml then giving Rocuronium 0.45 mg/kg at induction of anesthesia.
2984127|NCT02669368|Active Comparator|Low dose Rocuronium + Magnesium Sulfate|Pretreatment of Magnesium sulfate 30 mg/kg then giving Rocuronium 0.45 mg/kg at induction of anesthesia.
2984128|NCT02669342|Active Comparator|Group A: Sharklet Catheter for 2 weeks first|"Arm A will have catheters inserted according to the schedule below:~Sharklet catheter inserted for 2 weeks~Standard catheter inserted for 2 weeks~Sharklet catheter inserted for 4 weeks~Standard catheter inserted for 4 weeks"
2984129|NCT02669342|Active Comparator|Group B: Sharklet Catheter for 4 weeks first|"Arm B will have catheters inserted according to the schedule below:~Sharklet catheter inserted for 4 weeks~Standard catheter inserted for 4 weeks~Sharklet catheter inserted for 2 weeks~Standard catheter inserted for 2 weeks"
2984130|NCT02669329|Experimental|Fat Reduction|The treatments are designed to see if the fat, on the upper arm, can be reduced.
2984131|NCT02669303|Experimental|platelet-rich plasma group|Autologous platelet-rich plasma subacromial injection
2984132|NCT02669303|Active Comparator|Methylprednisolone group|Methylprednisolone subacromial injection
2984133|NCT02669290|Experimental|Guided|Guided LV lead placement for CRT.
2984134|NCT02669290|Active Comparator|Non-Guided|Non-guided LV lead placement for CRT.
2984135|NCT02669277|No Intervention|group A|no platelet enhancing therapy
2984136|NCT02669277|Active Comparator|group B|Standard IVIG single dose 1.0 gm /kg/dose
2984137|NCT02669277|Experimental|group C|minipool IVIG product single dose 1.0 gm /kg/dose
2984138|NCT02669264|Experimental|ADCT-402|"Weekly administration - Patients will receive an IV infusion of ADCT-402, on Days 1, 8, and 15 of each 3-week (21-day) cycle.~3-week administration - Patients will receive an IV infusion of ADCT-402, on Day 1 of each 3-week (21-day) cycle.~The dose escalation will be conducted according to a 3+3 design.~In Part 2 (expansion), all patients will be assigned to the recommended dose and/or schedule of ADCT-402 identified in Part 1 by the Dose Escalation Steering Committee."
2984139|NCT02669251|Experimental|Phase 1b|Phase Ib dose escalation
2984140|NCT02669251|Experimental|Phase 2|MTD po bid on days 1-28
2984141|NCT02669238|Experimental|Implant|Subcutaneous insertion of an progestative implant containing 68mg of etonogestrel
2984142|NCT02669238|Active Comparator|Oral treatment|Continuous oral administration of second generation monophasic oestro-progestative (ethinyl-oestradiol)
2984143|NCT02669225|Experimental|Rested|RW PET/MR Scanning Sessions
2984144|NCT02669225|Experimental|Sleep|SD PET/MR Scanning Sessions
2984145|NCT02669199|Experimental|MSCs|The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
2984146|NCT02669186|Experimental|'Bupivacaine + Fentanyl' (Opioid Group)|Group 1 (opioid group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
2984147|NCT02669186|Active Comparator|Bupivacaine (Local Anesthetic Group)|Group 2 (local anesthetic group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
2984148|NCT02669173|Experimental|Treatment: Capecitabine + Bevacizumab|Capecitabine, PO dose to be determined by phase 1 dose escalation, cycle length 28 days. Treated with Bevacizumab, IV, 10 mg/kg days 1, 15 every 28 days, until progression.
2984149|NCT02669160|Experimental|Experimental|Group of communicating CP children receiving a 30 minutes daily session of verticalization with a motorized orthosis reproducing walking movement (PS Innowalk)
2984150|NCT02669160|Other|Control|Group of communicating CP children receiving a 30 minutes daily session of verticalization with their conventional passive stander.
2984151|NCT02669134|Active Comparator|SonR optimization|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV"
2984152|NCT02669134|Placebo Comparator|Fixed settings|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming device programming: sensed AV delay of 125 ms, VV delay of 0 ms (simultaneous); SonR CRT Optimization programmed Off)."
2984153|NCT02669121|Experimental|NoV GI.1/GII.4 Bivalent VLP Vaccine|NoV GI.1/GII.4 bivalent virus-like particle (VLP) vaccine intramuscularly (IM), once, on Day 1.
2984154|NCT02669121|Placebo Comparator|Placebo|NoV vaccine placebo-matching solution, intramuscularly (IM), once, on Day 1.
2984155|NCT02669108|Other|PET/MRI of the Testis|PET/MRI of the testis will be performed upon the patient achieving azoospermia (following the vasectomy), or 25 ejaculations and following proven azoospermia (via standard of care semen analysis).
2984156|NCT02669095|Experimental|Arm 1 (Test Lens)|Subjects will be dispensed the Investigational Contact Lenses (Test) to be worn as daily wear.
2984157|NCT02669095|Active Comparator|Arm 2 (Control Lens)|Subjects will be dispensed the Marketed Contact Lenses (Control) to be worn as daily wear.
2984161|NCT02669069|Active Comparator|PS3|
2984165|NCT02669030|Experimental|Suvorexant|suvorexant 10mg/day, 15mg/day or 20mg/day augmentation of FDA-approved antidepressant treatment
2984166|NCT02669030|Placebo Comparator|Placebo|no augmentation of FDA-approved antidepressant treatment
2984167|NCT02669017|Experimental|ADCT-402|"In Part 1 (dose escalation) patients will receive an IV infusion of ADCT-402, at escalating doses. Part 1 will continue until the maximum tolerated dose is determined.~In Part 2 (expansion), patients will be assigned to the recommended dose level(s) and schedule(s) of ADCT-402 identified in Part 1 by the Dose Escalation Steering Committee."
2984168|NCT02669004|Active Comparator|Intermittent bolus epidural morphine|"Patients who received epidural morphine with patient- controlled intermittent bolus epidural analgesia (PCIEA) represented Group 1. Epidural catheter was inserted by surgeon under direct visualization at the midpoint of the incision and advanced 5-6 cm cephalad to thoracic 4-5 before surgical closure.~Patients received morphine 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion."
2984169|NCT02669004|Active Comparator|Continuous epidural morphine|epidural morphine with patient- controlled continuous epidural analgesia (PCCEA) represented Group 2. Infusion the following initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
2984170|NCT02668991||Cohort 1|It will consist of planned 100 children and adults with Autism Spectrum Disorder (ASD) aged 6 years and older with no requirements regarding concurrent therapies or treatments.
2984171|NCT02668991||Cohort 2|It will consist of planned 50 children and adults aged 6 and older who, as part of their standard care, happen to be beginning a behavioral intervention within 2 weeks after the baseline visit of the study. This intervention can be an applied behavior analysis (ABA) program or similar or a social skills program or a school-based autism program and must be intended to last at least throughout the duration of the study.
2984172|NCT02668991||Cohort 3|It will consist of planned 30 normally developing children and adults. These participants will only have a single visit wherein they will undergo a single session with the task battery and biosensors. There should be 5 participants aged 6-9 years, 5 aged 10-12 years, 5 aged 13-17 years, and 5 aged 18 years and older. This cohort should approximate the male:female ratio in Cohorts 1 & 2, with approximately 1 female for every 5 males.
2984173|NCT02668978|Experimental|Hemopatch™|Hemopatch™ sealing hemostat
2984174|NCT02668978|Active Comparator|Control|Standard surgical technique
2984175|NCT02668965|No Intervention|control|intrauterine infusion with standard embryo culture media 10 microliters before embryo transfer
2984176|NCT02668965|Experimental|intrauterine hCG|intrauterine infusion with hCG (500 IU) 10 microliters before embryo transfer
2984177|NCT02668952|Active Comparator|Normal Saline group|0.9% Normal Saline (0.9% Sodium Chloride) injection intravenously as needed. The amount administered (dosage, frequency, and duration) will be left to the clinical judgment of the attending physicians, and will follow usual patterns of use in cardiac surgery patients.
2984178|NCT02668952|Experimental|Isolyte group|Isolyte S (B Braun, Irvine CA) injection intravenously as needed. The amount administered (dosage, frequency, and duration) will be left to the clinical judgment of the attending physicians, and will follow usual patterns of use in cardiac surgery patients. Isolyte S is a prepackaged solution containing sodium chloride 0.53%, sodium gluconate 0.5%, sodium acetate trihydrate 0.37%, potassium chloride 0.037%, and magnesium chloride hexahydrate 0.03% w/v.
2984179|NCT02668926|Experimental|Lisdexamfetamine, d-amphetamine, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
2984180|NCT02668926|Experimental|d-amphetamine, Placebo, Lisdexamfetamine|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
2984181|NCT02668926|Experimental|Placebo, Lisdexamfetamine, d-amphetamine|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
2984182|NCT02668913|Experimental|Diagnostic Analysis|This arm will be subject to Caris Molecular profiling.
2984183|NCT02668900|Experimental|Decision support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
2984184|NCT02668900|No Intervention|Usual care|The control group will not receive the decision support intervention prior to consultation with the physician.
2984185|NCT02668874|Active Comparator|Isolite® technique|The Isolite® technique differs in that it utilizes a flexible plastic dental adapter to separate the teeth from the cheek and tongue. The resident dentist will show the child the Isolite® before it is placed in the mouth. The resident with whom the child is scheduled will then apply the sealants.
2984186|NCT02668874|Active Comparator|cotton roll technique|The resident dentist with whom the child is scheduled with apply the sealants after the cotton roll technique has been placed.
2984187|NCT02668861|Experimental|Vitamin D+Budesonide Nasal Spray|Vitamin D 4000IU/day for 8 weeks + Budesonide Nasal Spray 128ug/d for 8 week
2984188|NCT02668861|Placebo Comparator|placebo+Budesonide Nasal Spray|Placebo for 8 weeks + Budesonide Nasal Spray128ug/d for 8 week
2984189|NCT02668848|Experimental|urine monitoring group|Patients of urine monitoring group will be checked for urine specific gravity (USG) once between 6a.m. to 12 m.d. in the first 5 days after admission. Patients will be advised to have water according to the level of USG.
2984190|NCT02668835||Cohort 1|Idiopathic Parkinson's Disease as defined by the UK brain bank criteria and history of resting tremor.
2984191|NCT02668835||Cohort 2|Essential Tremor with history of resting tremor. Diagnosis made by a movement disorder specialist
2984329|NCT02667964|Other|Healthy controls|Spiroergometry
2984192|NCT02668822|Experimental|ENG 125 μg + E2 300 μg (MK-8342B)|Participants received up to 4 cycles of etonogestrel-17β estradiol (ENG-E2) at a daily dose of 125 μg/300 μg via vaginal ring. Each cycle consisted of 21 days of MK-8342B vaginal ring use followed by 7 ring-free days.
2984193|NCT02668822|Placebo Comparator|Placebo|Participants received up to 4 cycles of placebo via vaginal ring. Each cycle consisted of 21 days of placebo vaginal ring use followed by 7 ring-free days.
2984194|NCT02668809|Experimental|Experimental Group 1|consent, oral health assessment, questionnaires, Educational Program, clinical exam, microbiological sampling, monitoring adherence.
2984195|NCT02668809|Experimental|Experimental group 2|Consent, oral health assessment, questionnaires, Educational Program, clinical exam, microbiological sampling, monitoring adherence, varnish application
2984196|NCT02668809|Placebo Comparator|Control Group|Consent,clinical exam, microbiological sampling, questionnaires
2984197|NCT02668796|Experimental|Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
2984198|NCT02668796|Active Comparator|Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)|apply using the given applicator
2984199|NCT02668796|Placebo Comparator|Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
2984200|NCT02668783|Experimental|ENG-E2 125 μg/300 μg|Participants will receive 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
2984201|NCT02668783|Placebo Comparator|Placebo|Participants will receive 4 cycles (or 6 cycles if also participating in the extension) of placebo. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
2984202|NCT02668770|Experimental|Dose Escalation Group: MGN1703 + Ipilimumab|"Participants receive MGN1703 on Days 1, 8, and 15 of all cycles as an injection under the skin. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.~Each cycle is 21 days long. Participants receive a total of 4 treatment cycles for a total of 12 weeks on treatment."
2984203|NCT02668770|Experimental|MTD Group: MGN1703 (subcutaneously) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy and cutaneous or subcutaneous manifestations.~MGN1703 given subcutaneously at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.~Each cycle is 21 days long."
2984204|NCT02668770|Experimental|MTD Group: MGN1703 (intratumoral injection) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy and cutaneous or or subcutaneous manifestations.~MGN1703 given by intratumoral injection at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.~Each cycle is 21 days long."
2984205|NCT02668770|Experimental|MTD Post XRT Group: MGN1703 (subcutaneously) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy treated with radiation (XRT) within the past 2 weeks.~MGN1703 given subcutaneously at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.~Each cycle is 21 days long."
2984206|NCT02668757|Other|HeartHab application arm|Patients in the HeartHab application arm will receive the mobile application during study period.
2984207|NCT02668744|Experimental|Intervention|TX Sprouts
2984208|NCT02668744|Placebo Comparator|Control|Delayed Intervention
2984209|NCT02668718|Other|Adjuvant radiotherapy|Patients who were randomized to adjuvant radiotherapy following radical prostatectomy
2984210|NCT02668718|No Intervention|Watchful waiting|Patients who were randomized to watchful waiting following radical prostatectomy
2984211|NCT02668705|No Intervention|Human RA|A sham research informed consent form will be explained by a research assistant
2984212|NCT02668705|Experimental|ECA|A sham research informed consent form will be explained by an ECA (embodied conversational agent as presented on a touch screen computer)
2984213|NCT02668705|Experimental|ECA + Human RA|A sham research informed consent form will be explained by an ECA and then questions will be answered by a research assistant
2984214|NCT02668692|Experimental|LEO 80185 gel|
2984215|NCT02668692|Active Comparator|Dovobet ® ointment|
2984216|NCT02668679|Active Comparator|Children and their parents with the presence of Dream Doctors|The DD will use various methods for entertaining the child and alleviate stress . The parents and the children will be given anxiety and satisfaction questionnaires. The children and parents will perform Pre-Pulse inhibition (PPI) test and GSR. In addition, stress hormones will be assessed (cortisol, epinephrine, and norepinephrine) and the following physical indices will be measured: blood pressure, pulse, saturation and body temperature. The amount of drugs given for deep sedation will be evaluated.
2984217|NCT02668679|Placebo Comparator|Children and their parents without the presence of DD|No DD during the gastroscopy. The parents and the children will be given anxiety and satisfaction questionnaires. The children and parents will perform Pre-Pulse inhibition (PPI) test and GSR. In addition, stress hormones will be assessed (cortisol, epinephrine, and norepinephrine) and the following physical indices will be measured: blood pressure, pulse, saturation and body temperature. The amount of drugs given for deep sedation will be evaluated.
2984218|NCT02668666|Experimental|Investigational Treatment|"71 subjects will be enrolled to determine progression-free survival (PFS) in subjects with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anti-cancer therapies.~Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.~Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously)."
2984219|NCT02668653|Experimental|Chemotherapy plus quizartinib|"Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by the experimental drug quizartinib~Consolidation: up to 4 cycles of cytarabine followed by the experimental drug quizartinib and/or hematopoeitic stem cell transplant~Maintenance: up to 12 cycles with the experimental drug quizartinib"
2984220|NCT02668653|Active Comparator|Chemotherapy plus placebo|"Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by placebo~Consolidation: up to 4 cycles of cytarabine followed by placebo and/or hematopoeitic stem cell transplant~Maintenance: up to 12 cycles with placebo"
2984221|NCT02668640||Participants with RA receiving Adalimumab|This group contains participants in China with RA receiving adalimumab
2984222|NCT02668614|Experimental|WR-22 model microwave sensor|
2984223|NCT02668601||GDM Exposed|Children exposed to gestational diabetes in utero
2984227|NCT02668575|No Intervention|Usual Care|Patients randomized to the control arm of this study will continue to receive the standard of high-quality CF care provided to all patients at the UPMC CF Center.
2984228|NCT02668575|Experimental|Supportive Care Intervention|Patients randomized to the intervention arm will receive a protocolized supportive care intervention from a palliative care nurse practitioner.
2984229|NCT02668562|Experimental|Early CABG|Patients to undergo early CABG
2984230|NCT02668562|Active Comparator|Delayed CABG|Patients to undergo delayed CABG
2984231|NCT02668549||Patients with Opioid dispensings|Patients receiving two or more opioid dispensings within 18 months
2984232|NCT02668549||Patients with Diuretic dispensings (neg control)|Patients receiving two or more Diuretics dispensings within 18 months will serve as negative control
2984233|NCT02668536|Experimental|UV Filter + BNP|A UV filtering agent and bioadhesive nanoparticles (BNPs) will comprise the experimental condition in this study. Participants will have 5 sites on their torso where they will have these placed.
2984234|NCT02668536|Sham Comparator|BNP only|A placebo bioadhesive nanoparticles (BNPs) (strips with no UV filtering) will comprise the sham comparison in this study. Participants will have 5 sites on their torso where they will have these placed.
2984235|NCT02668536|Active Comparator|Standard|As the active comparator, participants will have 5 sites on their torso where they will have standard sunscreen applied.
2984236|NCT02668536|No Intervention|Control|Participants will have 5 sites on their torso where no agent will be applied.
2984237|NCT02668523|Experimental|Raindrop|A single arm study to evaluate the effectiveness of a 2mm Raindrop Near Vision Inlay for the treatment of presbyopia in pseudophakic subjects. This corneal inlay is placed under a LASIK flap or in a corneal pocket, and is designed to change the anterior curvature of the cornea, resulting in the ability to reduce spectacle dependency for near and intermediate tasks.
2984238|NCT02668510|Experimental|Platelet Rich Plasma Injection Group|shockwave therapy within standard of care using Ossatron system with intervention injection of platelet rich plasma (PRP) using Arthex system, into the plantar fascia at the calcaneal origin
2984239|NCT02668510|Placebo Comparator|Placebo injection group|shockwave therapy with placebo normal saline injection
2984240|NCT02668497|Experimental|BoNT-A in de-novo Parkinson's disease patients|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined by biomechanical analysis of tremulous movements for tremor therapy in both upper extremity every 12 weeks over 72 weeks. BoNT-A dose will range from 50-300 U per arm
2984241|NCT02668497|Experimental|BoNT-A in L-dopa Parkinson's disease patients|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined by biomechanical analysis of tremulous movements for tremor therapy in both upper extremity every 12 weeks over 72 weeks. BoNT-A dose will range from 50-300 U per arm
2984242|NCT02668484|Experimental|repositionable valve prosthesis|Lotus
2984243|NCT02668484|Active Comparator|balloon-expandable valve prosthesis|Sapien
2984244|NCT02668471|Experimental|Ultrasound guided|Radial artery catheters will be placed with the assistance of bedside ultrasound.
2984245|NCT02668471|Active Comparator|traditional method|Radial artery catheters will be placed by the palpation technique only.
2984246|NCT02668458|Experimental|NIV|NIV group, preoxygenation by NIV: pressure support set for an exhaled tidal volume of 6-8 ml / kg of ideal body weight, PEEP of 5 cm H2O and FiO2 at 100%.
2984247|NCT02668458|Active Comparator|HFNC|High-flow nasal canula oxygen therapy. NHFC group, preoxygenation by NHFC: oxygen flow rate of 60 L / min and 100% FiO2
2984248|NCT02668445|Experimental|Low carbohydrate|Subjects will eat a low carbohydrate diet
2984249|NCT02668445|Experimental|High carbohydrate|Subjects will eat a high carbohydrate diet
2984250|NCT02668432|Experimental|Partial Load|All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive <4g IV or < 8g PO. The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).
2984251|NCT02668432|Active Comparator|Full Load|All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive (≥ 5g IV or ≥10g PO +/- 20%). The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).
2984252|NCT02668419|Active Comparator|Usual Care|Patients in this group were subject to regular Physical Therapy Sessions in the hospital and each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise.
2984253|NCT02668419|Experimental|Neuromuscular Electrical Stimulator|Lower limb muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min. Heart rate, blood pressure, respiratory rate and pulse oximetry were monitored throughout the sessions, in all patients.
2984254|NCT02668406||Burkholderia pseudomallei|Patients for whom blood cultures grew Burkholderia pseudomallei
2984330|NCT02667964|Other|Patients with T2DM|Spiroergometry
2984331|NCT02667964|Other|Patients with T1DM|Spiroergometry
2984255|NCT02668406||No pathogen|Patients for whom blood cultures did not grow a pathogen, but have other body site grown with Burkholderia pseudomallei, or are suspected of melioidosis
2984256|NCT02668406||Another pathogen|Patients for whom blood cultures grew another pathogen
2984257|NCT02668393|Other|Level 0|Nintedanib low dose with docetaxel
2984258|NCT02668393|Other|Level 1|Nintedanib medium dose with docetaxel
2984259|NCT02668393|Other|Level 2|Nintedanib high dose with docetaxel
2984260|NCT02668393|Other|Level 3|Nintedanib continuous high dose with docetaxel
2984261|NCT02668380||Apatinib|Apatinib Tablets: 850 mg,po, once daily , 28 days for a cycle
2984262|NCT02668367|Active Comparator|BTA-C585 oral capsules|100 mg capsules; Multiple ascending doses (MAD) from 100 mg to 600 mg
2984263|NCT02668367|Placebo Comparator|BTA-C585 matching placebo|BTA-C585 Matching placebo capsules; single doses
2984264|NCT02668341||psoriasis patients in Denmark|non-interventional survey study in psoriasis patients in daily practice care
2984265|NCT02668341||psoriasis patients in United Kingdom|non-interventional survey study in psoriasis patients in daily practice care
2984266|NCT02668341||psoriasis patients in Spain|non-interventional survey study in psoriasis patients in daily practice care
2984267|NCT02668341||psoriasis patients in Poland|non-interventional survey study in psoriasis patients in daily practice care
2984268|NCT02668341||psoriasis patients in Germany|non-interventional survey study in psoriasis patients in daily practice care
2984269|NCT02668328|Experimental|Behavioral Intervention|The proposed study involves a 2-phase randomized clinical trial in adults with recently diagnosed T2D. Participants will be randomized to a wait-list Control group, BI, or Tailored-BI. In Phase 1, wait-list Control participants will receive 6 months of standard care; BI and Tailored-BI participants will receive 6 months of Active Intervention. In Phase 2, wait-list Control group participants will cross-over to the delayed Tailored-BI, and the BI and Tailored-BI participants will enter a 6-month observation phase to examine maintenance effects of the intervention.
2984270|NCT02668315|Experimental|Cohort 1|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 1.0-4.9 x 10E5/kg and TNC superior or equal to 2.0 x 10E7/kg
2984271|NCT02668315|Experimental|Cohort 2|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 0.5-4.9 x 10E5/kg and TNC superior or equal to 1.5 x 10E7/kg
2984272|NCT02668315|Experimental|Cohort 3|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 0.25-4.9 x 10E5/kg and TNC superior or equal to 1.25 x 10E7/kg
2984273|NCT02668302|Experimental|Treatment|Steroid-releasing sinus implant placement following ethmoidectomy in addition to post-op standard of care (i.e. debridement, irrigation, and topical steroids)
2984274|NCT02668302|Active Comparator|Control|Post-op standard of care (i.e. debridement, irrigation, and topical steroids)
2984275|NCT02668289|Other|interventional|consent, screening, xrays, PVS impressions, photographs, CBCT, anesthesia, extraction, clinical measurements
2984276|NCT02668276|Placebo Comparator|Standard NCCN counseling|National Comprehensive Cancer Network (NCCN) counseling uses recommendations based on currently-accepted approaches to cancer treatment.
2984277|NCT02668276|Experimental|Standard NCCN counseling and Oncotype DX results|National Comprehensive Cancer Network (NCCN) counseling uses recommendations based on currently-accepted approaches to cancer treatment. The result provided by the Oncotype DX prostate test is called a Genomic Prostate Score (GPS). The GPS provides important information about how aggressive a man's cancer is based on the biology of the man's individual tumor.
2984278|NCT02668263|Active Comparator|Surgery and Drain|Group 1 will be allocated to receive a drain intra-operatively.
2984279|NCT02668263|Other|Surgery alone|Group 2 will not receive a drain and no further intervention.
2984280|NCT02668263|Experimental|Surgery and quilting sutures|Group 3 will not receive a drain but will receive quilting sutures
2984281|NCT02668250|Experimental|Experimental group : OPTI-AGED|The OPTI-AGED group will receive a combined optimization strategy of anesthesia concerning hemodynamic, ventilation, and depth of anesthesia.
2984282|NCT02668250|Active Comparator|Control Group :|The control group will not benefit from the OPTI-AGED intervention but patients will receive the usual care.
2984283|NCT02668237|Experimental|Experimental group|The intervention for this group will be the use of a OptiPAC. A molecular technique and urinary tests will be performed to test a panel of infectious agents : the results will allow the children to benefit from an adapted treatment.
2984284|NCT02668237|Active Comparator|Control Group|The children will benefit from the usual care : an antibiotic prevention treatment.
2984285|NCT02668224|Experimental|Vibrasens : Test group|Training programme: vibration training 3/week from Day 1 to Day 60 + Usual activities from day 60 to Day 75.
2984286|NCT02668224|Active Comparator|Control group|Control: Usual activities from day 1 to Day 75.
2984287|NCT02668211|Other|PROFEMUR Preserve RSA|Single cohort of subjects prospectively implanted with PROFEMUR® Preserve Classic femoral components
2984288|NCT02668198|Active Comparator|High definition white light|"All procedures will be performed by using a high-definition colonoscope (Olympus CFH190) with the near focus mode capability.~This is the standard endoscopic imaging technique."
2984289|NCT02668198|Active Comparator|White light with near focus|"For the 190 systems, the polyp was examined in standard focus and near focus modes, which provided in-focus images up to 2 mm from the optical lens, thus allowing true optical, in-focus zoom.~Near focus is used to help examine for any residual polyps."
2984290|NCT02668198|Active Comparator|Narrow band imaging|Narrow band imaging
2984291|NCT02668198|Active Comparator|Narrow band imaging with near focus|Narrow band imaging with near focus.
2984292|NCT02668185|Experimental|Active drug|NK3R antagonist - AZD4901 - 40mg bd - for 4 weeks
2984293|NCT02668185|Placebo Comparator|Placebo|Placebo - 40mg bd - for 4 weeks
2984294|NCT02668172|Experimental|Pasireotide LAR 60 mg monotherapy week 12|"After enrollment, acromegaly patients on combination treatment will half their regular weekly dose of pegvisomant (PEGV) for 12 weeks (run-in period).~When insuline-like growth factor 1 (IGF‐I) remains within the age adjusted normal limits after 12 weeks, PEGV and the LA-SSA (Octreotide Long Acting Release (LAR) or Lanreotide Autogel) with Pegvisomant (PEGV) are discontinued and patients are switched to pasireotide LAR 60 mg for 12 weeks."
2984295|NCT02668172|Experimental|Pasireotide LAR 60 mg and Pegvisomant week 12|When IGF-I rises above the adjusted normal limits after 12 weeks (run-in period), these subjects will switch their LA-SSA to Pasireotide LAR 60 mg every 4 weeks and continue with the reduced PEGV dose of the run-in period, for the remaining 12 weeks.
2984296|NCT02668172|Experimental|Pasireotide LAR 60 mg and Pegvisomant week 24|"Between week 12 and 24 dose adaptations of PEGV are not permitted unless IGF-I drops below the age adjusted normal limits, then the dose of PEGV will be decreased stepwise with 20 mg weekly until IGF-I is within the age adjusted normal limits.~At week 24, efficacy will be assessed, as the number of patients with a normal IGF-I in the two different groups; the combination Pasireotide LAR 60 mg / PEG V dose and monotherapy Pasireotide LAR 60 mg.~From week 24 patients will continue with Pasireotide LAR 60 mg monotherapy, or Pasireotide LAR will be combined with 50% of the original dose of PEGV, or with an increasing dose of PEGV every 8 weeks depending on the treatment arm."
2984297|NCT02668159|Experimental|Fish peptide|
2984298|NCT02668159|Experimental|Vitamin D|
2984299|NCT02668159|Experimental|Fish peptide + Vitamin D|
2984300|NCT02668159|Placebo Comparator|Control|
2984301|NCT02668146|Experimental|perampanel|Perampanel administration
2984302|NCT02668146|Placebo Comparator|placebo|Placebo administered to subjects.
2984303|NCT02668133|Active Comparator|lipid-based nutrient supplement SQ-LNS|"• Small quantity lipid nutrient supplement SQ-LNS containing 6 mg iron and 8 mg zinc per 20 g sachet (per day) 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc delivered orally in sugar solution~1 mg isotopically enriched 68Zn intravenously"
2984304|NCT02668133|Experimental|lipid-based nutrient supplement SQ-LNS with phytase|"• Small quantity lipid nutrient supplement SQ-LNS containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration ~500 FTU/20 g SQ-LNS added during manufacturing 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc delivered orally in sugar solution~1 mg isotopically enriched 68Zn intravenously"
2984305|NCT02668120||Cases|Patients with chronic histiocytic intervillositis during pregnancy followed at University Hospital of Lille. Alkaline phosphatase assay was performed during pregnancy and is documented in the medical record. The cases are included retrospectively.
2984306|NCT02668120||Low-risk pregnancy|Patients with a low risk pregnancy followed at University Hospital of Lille and recruited prospectively in prenatal consultation. These patients have no pathological obstetric history.
2984307|NCT02668120||High-risk pregnancy|Patients with severe pregnancy complication (IUGR, Preeclampsia or Death in Utero), but without chronic intervillositis, and hospitalized in the maternal-fetal pathology department of the University Hospital of Lille. They are recruited prospectively.
2984308|NCT02668107|Active Comparator|Intervention Group (Hammock positioning)|Babies in the intervention group (IG), will be positioned supine in a hammock in the incubator, with the appropriate postural adjustments.
2984309|NCT02668107|No Intervention|Control Group|Those selected for the control group (CG) will be placed in the incubator following the service routine.
2984310|NCT02668094|Active Comparator|Group L|Lidocaine 40mg was given intravenously before injection of propofol
2984311|NCT02668094|Active Comparator|Group LP|Pregabalin 75 mg was given orally 2 hour before surgery
2984312|NCT02668094|Active Comparator|Group HP|Pregabalin 150 mg was given orally 2 hour before surgery
2984313|NCT02668081|Experimental|Endoscopic papillary balloon dilation|For EPBD group, after selective cannulation of the common bile duct by the catheter, cholangiography will be performed to confirm the diagnosis of bile duct pathology. A 0.025-0.035-inch guidewire will then be inserted into the bile duct through the catheter. A dilating balloon (The controlled radial expansion (CRE) balloon dilation catheter, CRE balloon 5.5 cm (centimeter) in length, 1-1.2 cm/1.2-1.5 cm/1.5-2.0 cm in diameter) will be passed via the pre-positioned guidewire into the bile duct. Using fluoroscopic and endoscopic guidance, the balloon will be inflated with contrast medium up to the optimal size and duration (normally 5min (minutes)) after the waist on the balloon disappeared according to the patients' condition and tolerance.
2984314|NCT02668081|Active Comparator|Endoscopic sphincterotomy|"For EST group,endoscopic sphincterotomy(EST) will be done as large as possible with a pull type sphincterotome (The TRUEtome, Biliary sphincterotomy sphincterotome, Single-use sphincterotome CleverCut2V)~Other interventions: surgical intervention, endoscopic stenting, percutaneous transhepatic cholangiogram with balloon dilation"
2984315|NCT02668068|Active Comparator|Control Group|Large volume whole-lung lavage (WLL) only
2984316|NCT02668068|Experimental|Experimental Group|Combined large volume WLL with clinical grade umbilical cord mesenchymal stem cells transplantation
2984317|NCT02668055|Experimental|TB4|Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells in wound, stick with wound edge skin suture, with vaseline gauze bandaging, controlled side not adding slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitutes
2984318|NCT02668042|Experimental|liveness tissue skin|
2984319|NCT02668029|Experimental|oxygen|oxygen administered through a nasal cannula at a personalized, fixed flow
2984320|NCT02668029|Placebo Comparator|medical air|Medical air administered through a nasal cannula at the same flow
2984321|NCT02668016|Experimental|Atorvastatin 20mg Daily|Atorvastatin 20mg daily for 1 month
2984322|NCT02668016|Placebo Comparator|Placebo|Placebo daily for 1 month
2984323|NCT02668016|No Intervention|No Treatment|No Atorvastatin or placebo for 1 month
2984324|NCT02668003|Experimental|Cognitive Behavioural Therapy|Brief Cognitive Behavioural Therapy delivered by telephone
2984325|NCT02668003|No Intervention|Treatment as usual|The group allocated to usual care will receive no additional intervention - this will reflect the fact there is no specific intervention provided to patients currently for the prevention of CWP. Participants in this group will receive usual care and there will be no restriction on what this can involve. CBT is not readily available within the NHS and is generally restricted to persons who have developed specific conditions rather than persons at risk of those conditions.
2984326|NCT02667990|Experimental|orthopaedic stilettoe|orthopaedic stilettoe will be compared to standard stilettoe and comfy trainer
2984327|NCT02667977|Active Comparator|Group 1|These patients will receive Dextrose 5% and 0.9 NS in their maintenance IV fluids
2984328|NCT02667977|Active Comparator|Group 2|These patients will receive Dextrose 5% and 0.45 NS in their maintenance IV fluids
2984332|NCT02667951|No Intervention|Control group|The control group received general information on dementia care and follow-up phone calls simply to maintain contact, but without any training for developing a behavioral problem-management plan and strategies.
2984333|NCT02667951|Experimental|Intervention group|An individualized home-based caregiver-training program for managing behavioral problems, with referrals to community services and telephone consultation, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
2984334|NCT02667938|Experimental|Treatment 1|HCP1303 capsule 5/0.2mg + HCP1303 capsule 5/0.4mg placebo+ HGP1201 placebo
2984335|NCT02667938|Experimental|Treatment 2|HCP1303 capsule 5/0.2mg placebo+ HCP1303 capsule 5/0.4mg + HGP1201 placebo
2984336|NCT02667938|Active Comparator|Active Comparator|HCP1303 capsule 5/0.2mg placebo+ HCP1303 capsule 5/0.4mg placebo+ HGP1201
2984337|NCT02667925|Experimental|Intervention arm|Patients will receive an intraperitoneal chemotherapy (cisplatin) combined to a radiotracer (nanocis) in order to assess the intraperitoneal distribution of the chemotherapy
2984338|NCT02667912|Experimental|Distal renal denervation|Endovascular radiofrequency ablation of renal nerves in 6-8 separate points located in segmental branches and distal part of the main trunk of renal artery
2984339|NCT02667912|Active Comparator|Conventional renal denervation|Endovascular radiofrequency ablation of renal nerves in 6-8 separate points equally distributed within the main trunk of renal artery
2984340|NCT02667899|Active Comparator|DBS group|Besides routine treatment, Doc patients in this group will accepted deep brain stimulation treatment.
2984341|NCT02667899|Active Comparator|TMS group|Besides routine treatment, Doc patients in this group will accepted transcranial magnetic stimulation treatment.
2984342|NCT02667899|Placebo Comparator|Control group|This Doc patients will accepted routine treatment.
2984343|NCT02667886|Experimental|Part A|X4P-001 + axitinib dose escalation
2984344|NCT02667886|Experimental|Part B|"Randomized assignment to one of two regimens:~X4P-001 at the Part A maximum tolerated dose (MTD), in combination with axitinib~X4P-001 at 0.5x Part A MTD, in combination with axitinib"
2984345|NCT02667886|Experimental|Part C|X4P-001 monotherapy
2984346|NCT02667873|Experimental|SL-801|The study medication, SL-801 consists of tablets to be administered orally. The initial planned schedule involves administration daily on Days 1 through Day 4 and Days 8 through Day 11 of each cycle of therapy. A cycle of therapy is 21 days. The scheduled starting dose is 5 mg.
2984347|NCT02667860|Experimental|Intracorporeal anastomosis|Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.
2984348|NCT02667860|Active Comparator|Extracorporeal anastomosis|A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Rel Stapler
2984349|NCT02667847||Preoperative patients|Preoperative patients were asked to verbally rate their anxiety 1=on a scale from 0-10 and 2=using the new smiley scale
2984350|NCT02667834|Experimental|Social Cognition and Interaction Training (SCIT)|SCIT Social cognition and interaction training program.
2984351|NCT02667834|Active Comparator|Therapeutic education program (ETP)|Therapeutic education program
2984352|NCT02667821|Experimental|Intervention group|Participants included in the experimental arm will be adults aged 18 years and older with chronic/recurrent neck pain Grade II who have been prescribed cervical manipulation for treatment of their condition. Each participant will undergo three separate test maneuvers consistent with prior work completed at the St. Joseph's Healthcare Hamilton Brain Body Institute. Each participant will begin with neutral cervical spine as a standard natural control, followed by block randomization between maximum voluntary rotation of the cervical spine and one cervical manipulation. Please see Intervention section for a detailed description.
2984353|NCT02667808||Focus Group|Participants with HIV and receiving antiretroviral therapy (ART) will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
2984354|NCT02667808||Questionnaire|Participants with HIV will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
2984355|NCT02667795|Experimental|Monitored walking based exercise|Participants will be given a personalised daily exercise target. Participants will be given an activity tracker (a Fitbit ZipTM). The participants will be asked to wear the device all day to monitor their activity. Once a day the participants will be asked to complete the walking target they have been given at completion of their baseline assessment. This target should be completed in one go. The walking programme will last a minimum of 2 weeks and a maximum duration of 4 weeks. The length of time will depend on the length of time between recruitment and when the participant is scheduled to have their surgery.
2984356|NCT02667795|No Intervention|Control|No intervention
2984357|NCT02667782|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is developed by Jon Kabat-Zinn in 1979 (Kabat-Zinn, 1990). It is an eight-week Program that includes practices such as gentle mindful movement (awareness of the body), a body scan (to systematically nurture awareness of the body region by region), and sitting meditation (awareness of the breath to include the four foundations of mindfulness, namely, body, feeling tone, mental state, and mental content) (Cullen, 2011).
2984358|NCT02667782|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT), developed by Zindel Segal, Mark Williams and John Teasdale, employs a cognitive theoretical framework (Cullen, 2011; Segal, Williams, & Teasdale, 2002). It is also delivered as an eight-session group treatment. The first four sessions teach the fundamental concepts and skills of the practice of mindfulness. The remaining four sessions teach the individual how to notice his/her own thoughts and the impact of such thoughts on his/her own physical and emotional experiences.
2984359|NCT02667769|Other|Fasting day without any food|Complete fasting: On a fast day under this Protocol no solid food may be eaten unless it is solid, medically prescribed part of a bedtime snack just before falling asleep (which must sometimes be to prevent nocturnal hypoglycaemia with injection of basal insulin before going to sleep) , Otherwise, the patient have ad libitum access to mineral water and unsweetened tea (possibly a fluid intake restriction should be considered for other diseases).
2984360|NCT02667769|Other|Fasting day with calorie- & carbohydrate-free food|During a fasting day for this protocol, patients may calories in unlimited quantity and (with calorie-free dressing) Take carb food like tomatoes, cucumbers, lettuce to be, both during meal periods and in between, if desired.
2984361|NCT02667743|Experimental|Paclitaxel Micelles for Injection + Cisplatin|"In the First Period, 230 mg/m2 of Paclitaxel Micelles for Injection was intravenously administrated for three hours without special infusion device, then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment.~In the Second Period, 300 mg/㎡ of Paclitaxel Micelles for Injection was intravenously administrated for three hours without special infusion device to patients whose minimum neutrophil ≥1.0 × 109 /L and minimum platelet count ≥80 × 109 /L and with no hematologic toxicity of grade II to IV occurred in the First Period. Then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment."
2984362|NCT02667743|Active Comparator|Paclitaxel Injection + Cisplatin|175 mg/m2 of conventional Paclitaxel Injection was intravenously administrated for three hours, then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment.
2984363|NCT02667730|Placebo Comparator|Physiotherapy only|This group will receive non-pharmacological advice and physiotherapy only
2984364|NCT02667730|Experimental|Acetaminophen + physiotherapy|This group will receive acetaminophen 500mg 4 times daily for 7 days in addition to standardized physiotherapy
2984365|NCT02667730|Experimental|Naproxen + physiotherapy|This group will receive naproxen 500mg twice daily for 7 days in addition to standardized physiotherapy
2984366|NCT02667730|Experimental|Celecoxib + physiotherapy|This group will receive celecoxib 100mg twice daily for 7 days in addition to standardized physiotherapy
2984367|NCT02667717|Experimental|Experimental group : Mirror Therapy|Experimental group will perform mirror therapies during 16 weeks, added to the usual care. Therapy mirror sessions will take place at hospital units but also at home.
2984368|NCT02667717|Active Comparator|Control group : Usual care|The control group will benefit from the usual care during 16 weeks. No mirror therapies will be performed to this group.
2984369|NCT02667704|Experimental|Nintedanib|
2984370|NCT02667704|Experimental|Bosentan|
2984371|NCT02667691|Experimental|SODB Dimpless-caloric restriction|This arm receives daily two capsules of SODB Dimpless 40mg containing 480 UI of superoxide dismutase (SOD), associated with a moderate caloric restriction.
2984372|NCT02667691|Placebo Comparator|Placebo-caloric restriction|This arm receives daily two capsules Placebo containing excipients only, associated with a moderate caloric restriction.
2984373|NCT02667678|Experimental|Cohort HIVOL, patients infected by HIV|Patients enrolled in HIVOL cohort (study performed between 2011 and 2013) will be contacted to participate to HIVOL-2. The intervention will be blood and urinary samples, with the use of iohexol (Omnipaque®) to have an idea on renal plasmatic clearance.
2984374|NCT02667665||Alzheimer's Disease Dementia|
2984375|NCT02667665||non-Dementia|
2984376|NCT02667652|Active Comparator|short biliarypancreatic limb|short biliarypancreatic limb
2984377|NCT02667652|Active Comparator|long biliarypancreatic limb|long biliarypancreatic limb
2984378|NCT02667639|Active Comparator|Treatment|A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.
2984379|NCT02667639|Placebo Comparator|Placebo|A single 0.9% sodium chloride injection will be administered subcutaneously.
2984380|NCT02667626|Experimental|SCPR Intervention|"Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information, including resource lists of helpful websites, followed by regular reproductive health prompts and study adherence reminders for 24 weeks.~Healthcare providers of young breast cancer participants randomized to the intervention arm will receive their patient's SCPR and access to the same additional web-based educational reproductive health information as their patient, including resource lists of helpful websites."
2984381|NCT02667626|Active Comparator|Control|"Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders. At completion of the 24 weeks of follow up, they will have access to their SCPR.~Healthcare providers of young breast cancer participants randomized to the waitlist control arm will receive access to the same web-based resources as their patient."
2984382|NCT02667613|Experimental|HABIT-ILE|HABIT-ILE (Hand and arm bimanual intensive therapy including lower extremities) will be applied over 2 weeks.
2984383|NCT02667613|Active Comparator|Control|A two weeks period of usual customary care.
2984384|NCT02667600||Cesarean Section Group|Patients undergoing cesarean section
2984385|NCT02667587|Experimental|Nivolumab + Temozolomide + Radiotherapy|Nivolumab: specified dose on specified days; IV (intravenous) infusion Temozolomide: 75 mg (milligram)/meter squared daily during Radiotherapy, 4 week treatment break, 150 mg/meter squared Day 1-5 for Cycle 1 and increased to 200 mg/meter squared Day 1-5 for Cycle2-Cycle 6 as tolerated; orally (additional cycles may be permitted with approval of sponsor) Radiotherapy: 2 gray units (joule of radiation energy per kilogram) 5 times per week for 6 weeks
2984386|NCT02667587|Placebo Comparator|Nivolumab placebo + Temozolomide + Radiotherapy|Nivolumab Placebo: specified dose on specified days; IV infusion Temozolomide: 75 mg/meter squared daily during Radiotherapy, 4 week treatment break, 150 mg/meter squared Day 1-5 for Cycle 1 and increased to 200 mg/meter squared Day 1-5 for Cycle2-Cycle 6 as tolerated; orally (additional cycles may be permitted with approval of sponsor) Radiotherapy: 2 gray units 5x/week x 6 weeks
2984387|NCT02667574|Other|open-label|Enrolled patients will receive continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg per administration (in accordance with the product SmPC). One cycle of therapy will be defined as 28 days of treatment. The treatment will be renewed once a month depending on the product tolerance
2984388|NCT02667561|Experimental|Testosterone gel 1% 2.2 mg|Testosterone gel 1% Topical use 2.2 mg (220 mg of gel) once daily duration of treatment: 28 days
2984389|NCT02667561|Experimental|Testosterone gel 1% 4.4 mg|Testosterone gel 1% Topical use 4.4 mg (440 mg of gel) once daily duration of treatment: 28 days
2984390|NCT02667561|Experimental|Testosterone gel 1% 8.8 mg|Testosterone gel 1% Topical use 8.8 mg (880 mg of gel) once daily duration of treatment: 28 days
2984391|NCT02667561|Placebo Comparator|Placebo of Testosterone Gel 1%|Placebo of Testosterone Gel 1% Topical use Approximately 550 mg of gel Once daily duration of treatment: 28 days
2984393|NCT02667535|Experimental|Isosorbide Mononitrate 2.0% healthy|Isosorbide Mononitrate gel 2.0% - 2g Anorectal usage Once daily Healthy volunteers
2984394|NCT02667535|Experimental|Isosorbide Mononitrate 0.5% anal fissure|Isosorbide Mononitrate gel 0.5% - 2g Anorectal usage Once daily Participants with anal fissure
2984395|NCT02667535|Experimental|Isosorbide Mononitrate 1.0% anal fissure|Isosorbide Mononitrate gel 1.0% - 2g Anorectal usage Once daily Participants with anal fissure
2984396|NCT02667535|Experimental|Isosorbide Mononitrate 2.0% anal fissure|Isosorbide Mononitrate gel 2.0% - 2g Anorectal usage Once daily Participants with anal fissure
2984397|NCT02667522|Experimental|Parenting Intervention|Parenting Intervention: Parent-Child Interaction Therapy (PCIT)
2984398|NCT02667522|No Intervention|Waitlist Control|Waitlist Control Condition
2984399|NCT02667496|Experimental|Leukine|"Administered SC in treatment cycles up to 24 weeks~Florbetapir administered for PET scans to examine baseline brain imaging pathology and changes on treatment."
2984400|NCT02667496|Placebo Comparator|Placebo|"Administered SC in treatment cycles up to 24 weeks~Florbetapir administered for PET scans to examine baseline brain imaging pathology and changes on treatment."
2984401|NCT02667483|Experimental|DS-5141b|"DS-5141b, Subcutaneous injection~Part 1: DS-5141b will be injected subcutaneously once a week for 2 weeks at the following dose levels. Dose escalation will be performed. DS-5141b will be administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.~Level 1: 0.1 mg/kg~Level 2: 0.5 mg/kg~Level 3: 2.0 mg/kg~Level 4: 6.0 mg/kg~Part 2: Two doses of DS-5141b will be selected based on the results obtained in Part 1. Each selected dose will be administered subcutaneously once a week for 12 weeks.~Part 2-Extension: Two doses, 2.0 mg/kg or 6.0 mg/kg, of DS-5141b will be administered subcutaneously once a week for 48 weeks."
2984402|NCT02667470|Experimental|Solifenacin|
2984403|NCT02667457|Experimental|Patients|"Patients with asymptomatic carotid atherosclerotic plaque with evidence of 50% or more carotid stenosis in one or more carotid arteries on carotid ultrasound within 2 years.~Patients will undergo carotid ultrasound and 99mTc-rhAnnexin V-128 SPECT/CT imaging."
2984404|NCT02667457|Experimental|Healthy participants|"Healthy participants with no significant carotid artery disease on carotid ultrasound.~Participants will undergo carotid ultrasound and 99mTc-rhAnnexin V-128 SPECT/CT imaging."
2984405|NCT02667444|Experimental|SB204 4%|SB204 4% topically once daily
2984406|NCT02667444|Placebo Comparator|Vehicle Gel|Vehicle Gel topically once daily
2984407|NCT02667418|Other|Fidaxomicin|Standard 10-day fidaxomicin treatment for Clostridium difficile
2984408|NCT02667418|Other|Vancomycin T/P|Standard 10-day vancomycin treatment followed by taper and pulse vancomycin treatment for Clostridium difficile
2984409|NCT02667418|Other|Vancomycin|Standard 10-day vancomycin treatment for Clostridium difficile
2984410|NCT02667405|Experimental|Whirlpool|Immersion in Whirlpool during therapy
2984411|NCT02667405|Active Comparator|Hot Pack|Hot Pack Application during therapy.
2984412|NCT02667392|Experimental|Biofeedback Group|Participants will wear a pressure-sensitive insole inside the shoe of their paretic limb. An auditory tone will sound when participants have provided sufficient load to active the pressure-sensitive in-sole.
2984413|NCT02667392|Active Comparator|Verbal Feedback Group|Participants will receive verbal feedback from a physical therapist regarding the amount of loading they are exerting on their paretic limb.
2984414|NCT02667379|Other|Diagnostic skin testing|Diagnostic skin testing with cat dander samples on volar forearms.
2984415|NCT02667366|Experimental|Tel-PT|Tel-PT receives a manualized short-term CBT. Treatment consists of one initial face-to-face appointment and 8-12 subsequent telephone sessions between patient and licensed therapist. Each telephone contact lasts between 20 and 30 minutes and take place on a weekly and later biweekly basis.
2984416|NCT02667366|Active Comparator|TAU and text messages|Control Group receives treatment as usual and additionally weekly text messages containing general information about depression.
2984417|NCT02667353|Other|electroconvulsive therapy|only one arm in this study: patients who are treated with electroconvulsive therapy and have been given anesthesia with etomidate and succinylcholine
2984418|NCT02667340|Experimental|Superstarch|Supplementation with Superstarch before a simulated soccer game
2984419|NCT02667340|Placebo Comparator|Placebo|Supplementation with placebo before simulated soccer game.
2984420|NCT02667327|Active Comparator|Granexin gel plus Standard of Care|Granexin gel is comprised of 100 μM aCT1 peptide plus hydroxyethyl cellulose.
2984421|NCT02667327|Placebo Comparator|Vehicle gel plus Standard of Care|Vehicle gel is hydroxyethyl cellulose without active pharmaceutical ingredient.
2984422|NCT02667327|No Intervention|Standard of Care|Standard of Care includes cleaning and irrigating ulcer, non-surgical debridement, pain management, ulcer dressing, off-loading, and nutritional assessment.
2984423|NCT02667314|Experimental|Jigsaw Puzzle Group|Jigsaw puzzles & Cognitive health counseling
2984424|NCT02667314|Active Comparator|Cognitive Health Counseling Group|Cognitive health counseling only
2984425|NCT02667301|Experimental|EMG, TAS and tympanometry|"All treatments were performed by the same group of professionals. EMG needle administration by an ENT specialist with 30+ year experience, EMG recording by a neurologist with 20+ year experience. Tympanic cavity Air exchange Sensor (TAS) recording is done by an experienced technician. The following are done to all patients:~The patient is subjected to tympanometry test on the specific ear,~The patient is subjected to TAS test on the specific ear while sipping water and signals from ear and nasal cavity recorded,~The patient is hooked up to EMG instrument and TAS test equipment simultaneously and signals are recorded by both instruments for a duration of 150-300 seconds while the patient is at rest without sipping water. The patient is allowed to swallow during the test."
2984426|NCT02667288|Experimental|A-101 Solution|A-101 Solution 40% administered once
2984427|NCT02667275|Experimental|A-101 Solution|A-101 Solution 40% administered once
2984428|NCT02667275|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once
2984429|NCT02667262||Extended Release and/or Long-Acting Opioids|
2984430|NCT02667249||check list|clinical pathway using a paper based check-list
2984431|NCT02667249||integrated clinical pathway|clinical pathway in form of a clinical pathway integrated into the paper based medical treatment and nursing documentation
2984432|NCT02667236|Active Comparator|A-101 Solution|A-101 Solution 40% administered once
2984433|NCT02667236|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once
2984434|NCT02667223|Experimental|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
2984435|NCT02667223|Active Comparator|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered subcutaneously to healthy volunteers
2984436|NCT02667223|Experimental|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
2984437|NCT02667223|Experimental|Cohort 5: bococizumab 450 mg + rHUPH20|bococizumab 450 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
2984438|NCT02667223|Experimental|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg co-mixed with rHuPH20 and administered subcutaneously to subjects with hypercholesterolemia receiving a statin
2984439|NCT02667210||No shopping behavior|
2984440|NCT02667210||Minimal shopping behavior|
2984441|NCT02667210||Marked shopping behavior|
2984442|NCT02667210||Extensive shopping behavior|
2984443|NCT02667197||Opioid overdose and poisoning|
2984444|NCT02667184|Experimental|Low FODMAP Oral Nutrition Supplement 1|Low FODMAP Oral Nutrition Supplement
2984445|NCT02667184|Experimental|Low FODMAP Oral Nutrition Supplement 2|Low FODMAP Oral Nutrition Supplement
2984446|NCT02667184|Experimental|Low FODMAP Oral Nutrition Supplement 3|Low FODMAP Oral Nutrition Supplement
2984447|NCT02667184|Experimental|FOS Supplement|Supplement containing fructooligosaccharides
2984448|NCT02667171|Active Comparator|Control group|The control group will receive standardized conventional supervised COPD rehabilitation, delivered in groups. Rehabilitation contains exercise training and education sessions twice a week for a duration of 8-12 weeks.
2984449|NCT02667171|Experimental|Online COPD rehabilitation|Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks.
2984450|NCT02667158||No shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
2984451|NCT02667158||Minimal shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
2984452|NCT02667158||Marked shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
2984453|NCT02667158||Extensive shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
2984454|NCT02667145|Experimental|Intervention|Self care program focusing on the assistive device, For 4 weeks (1 to week lasting 90 minutes).
2984455|NCT02667145|No Intervention|Control group|receive only a brochure with orientations of joint protection.
2984456|NCT02667132||medical treatment|In this study, patient's data will be retrospectively obtained by recording the data in patients' files and electronic records. The data includes the determined parameters by the study group of GM and the data will be recorded in an excel file that includes specific columns of the following entries: patients' age, diagnosis, secondary disease, diagnosis methods, treatments, recurrence, the risk factors that may cause the disease (smoking, using oral contraceptive, breast infection etc.). antibiotic, immunosuppressive drugs, methotrexate
2984457|NCT02667132||surgical treatment|lumpectomy, mastectomy, abscess drainage
2984458|NCT02667132||surgical+medical treatment|first medical, after surgical treatment or first surgical, after medical treatment
2984459|NCT02667119|Experimental|Prolonged Exposure + Contingency Management|Standard services plus Prolonged Exposure and Contingency Management
2984460|NCT02667119|Active Comparator|Standard Care|Standard substance abuse treatment services
2984461|NCT02667106|Experimental|Single-dose, open label RX0041-2|Active Drug
2984462|NCT02667080|Active Comparator|Ejaculate 1|Semen sample after 2-7 days of sexual abstinence
2984463|NCT02667080|Active Comparator|Ejaculate 2|Semen sample after 2 hours of sexual abstinence
2984464|NCT02667067|Other|Ant cervical discectomy & fusion (ACDF)|
2984465|NCT02667067|Experimental|Simplify Disc|Simplify Disc
2984466|NCT02667054|Active Comparator|Active 4%|One dose of 4mL of RX0041 4% for one day in the mucous membrane prior to a diagnostic or surgical procedure.
2984467|NCT02667054|Placebo Comparator|Placebo|One dose of 4mL of RX0041 placebo for one day in the mucous membrane prior to a diagnostic or surgical procedure.
2984468|NCT02667054|Active Comparator|Active 8%|One dose of 4mL of RX0041 8% for one day in the mucous membrane prior to a diagnostic or surgical procedure.
2984469|NCT02667041|Experimental|rTMS treatment (Monophasic vs. biphasic)|Safety and efficacy
2984470|NCT02667041|Active Comparator|EEG/ERP biomarkers|Investigation of pre- and post-treatment cognitive biomarkers
2984471|NCT02667041|Active Comparator|Blood biomarkers|Investigation of pre- and post-treatment protein biomarkers
2984472|NCT02667028||patients receiving PCI|patients receiving percutaneous coronary intervention(PCI)
2984473|NCT02667015|Experimental|Anxiety Sensitivity Intervention|Group receives the 3-week, 6-session Anxiety Sensitivity Intervention. This is a 6-session psychotherapy occurring twice weekly (60-90 minutes) for three weeks. This psychotherapeutic treatment is focused on reducing anxiety sensitivity and includes many components, but primarily consists of psychoeducation about the relationship between anxiety and substance use disorders, interoceptive exposures, in vivo exposures, and cognitive challenging.
2984474|NCT02667015|No Intervention|Control Group|Receives only treatment as usual
2984475|NCT02667002|Experimental|Bilateral Abdominal Sacral Hysteropexy|Bilateral abdominal sacral hysteropexy will be perform in 10 patients. One month after patients will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
2984476|NCT02667002|Experimental|Classic Abdominal Sacral Hysteropexy|Conventional abdominal sacral hysteropexy will be perform in 10 patients. One month after patients will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
2984509|NCT02666846|Placebo Comparator|Cohort 3: SPR300 Placebo gel|Cohort 3: SPR300 matching placebo gel
2984477|NCT02667002|Active Comparator|Women with no uterovaginal prolapsed|Ten nulliparous participants with no uterovaginal prolapsed will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
2984478|NCT02666989|Active Comparator|open placebo|8 weeks of open placebo treatment
2984479|NCT02666989|No Intervention|waitlist group|4 weeks of waiting list followed by 4 weeks of open placebo treatment
2984480|NCT02666976|Experimental|ilaprazole group|ilaprazole 20mg once daily for 4 weeks.
2984481|NCT02666963|Experimental|RTA 901 10 mg or 40 mg or Placebo|RTA 901 capsules (10 mg or 40 mg) or placebo taken orally in a single dose. Group 1: RTA 901 10 mg or matching placebo Group 2: RTA 901 20 mg or matching placebo Group 3: RTA 901 ≤ 40 mg or matching placebo Group 4: RTA 901 ≤ 80 mg or matching placebo Group 5: RTA 901 ≤ 160 mg or matching placebo Group 6: RTA 901 ≤ 320 mg or matching placebo Group 7: RTA 901 ≤ 640 mg or matching placebo Dose selection will be based on the safety, tolerability and available pharmacokinetics observed in prior study groups.
2984482|NCT02666963|Experimental|RTA 901 Dose TBD or Placebo|RTA 901 capsules, Dose TBD mg or placebo taken orally once daily for 14 days. Group 8: RTA 901 X mg or matching placebo Group 9: RTA 901 ≤Y mg or matching placebo Group 10: RTA 901 ≤Z mg or matching placebo The actual doses for Arm 2 will be selected based on the safety and available pharmacokinetic data obtained from Arm 1.
2984483|NCT02666950|Experimental|Arm B (cytarabine and WEE1 inhibitor AZD1775|Patients receive cytarabine and WEE1 inhibitor AZD1775 as in Arm A.
2984484|NCT02666950|Experimental|Arm C (WEE inhibitor AZD1775)|Patients receive WEE inhibitor AZD1775 PO daily on days 1-5, 8-12, 15-19, and 22-26.
2984485|NCT02666937||ICU-patients (prospective)|Critically ill patients (18 years and older) on mechanically ventilation who have an arterial line and require bloodgasanalysis for medical reasons
2984486|NCT02666937||Emergency Department (prospective)|Patients (18 years and older), who are presented to the Emergency Department, and require bloodgasanalysis for medical reasons
2984487|NCT02666937||Pulmonary department (prospective)|Patients (18 years and older) who visit the outpatient clinic of the pulmonary department for different pulmonary functional test and require bloodgasanalysis for medical reasons
2984488|NCT02666937||Pulmonary department (retrospective)|Patients (18 years and older) who visited the outpatient clinic of the pulmonary department in the past of the VU medical centre in Amsterdam or the Medical Centre Alkmaar for different pulmonary functional test and required bloodgasanalysis for medical reasons
2984489|NCT02666924|Experimental|Cooking class|The addition of diabetes cooking educational classes to standard diabetes education classes. Cooking classes are a series of four, four-hour sessions. These cooking classes will be led by a registered dietitian, a registered nurse and a chinese chef. Conducted in Mandarin or Cantonese. The cooking education focus is culturally specific teaching for Chinese-Canadian persons living with diabetes.
2984490|NCT02666924|Active Comparator|Control|Type 2 diabetes educational classes, consisting of two sessions, one week apart, four-hour classes. These classes are taught by a registered dietitian and nurse, in Mandarin or Cantonese.
2984491|NCT02666911|Experimental|4D Ultrasound|4D ultrasound imaging of the carpal tunnel. 20 healthy volunteers between the ages of 18 and 80, who have no history of carpal tunnel syndrome or wrist injury. The same patients will be imaged with both 2D and 4D transducers.
2984492|NCT02666911|Active Comparator|2D ultrasound|2D ultrasound imaging of the carpal tunnel. 20 healthy volunteers between the ages of 18 and 80, who have no history of carpal tunnel syndrome or wrist injury.The same patients will be imaged with both 2D and 4D transducers.
2984493|NCT02666898|Experimental|Obinutuzumab and Ibrutinib CLL treatment|"3 parts~PART 1: 6 cycles of GA101 + Ibrutinib 420mg PO/ 28 days:~GA101:~C 1 D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v C 2 to 6 :D1 1000 mg i.v~Ibrutinib:~D3 Month 1 to Day 30 Month 15: 420mg daily PO~PART 2: 4 cycles / 28 days~After evaluation at D1 month 9:~patients in CR with BM MRD < 10-4, Ibrutinib 420mg daily~patients with BM MRD >10-4 or PR 4 courses of GA101 + FC/ 28-day + Ibrutinib PO until M16 Cycle 1 to 4 - GA101: 1000 mg i.v on day 1~Fludarabine : 40 mg/m² per os, days 2-4, / 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, / 28 days~Ibrutinib 420mg/day PO~PART 3 (only in GAI-FC+Ibru arm) :~After evaluation at D1 of M16:~patients CR with BM MRD< 10-4, treatment stopped~patients CR with BM MRD >10-4, Ibrutinib continued until PD or PB MRD becomes negative."
2984494|NCT02666885|Experimental|Integration of PET/MRI in radiotherapy|Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
2984495|NCT02666872|Experimental|Motivational interviewing on vaccination|An educational strategy based on motivational interviewing of approximately 15 minutes to promote vaccination, in maternity ward.
2984496|NCT02666872|No Intervention|Brochure about vaccines for infants|Parents in the control group only received a brochure about vaccines for infants. This brochure is given to all fathers and mothers giving birth to the CHUS, participating or not at our study.
2984497|NCT02666859|Experimental|Unilateral Transradial Amputation|This group includes people with a unilateral transradial amputation. Potential subjects must use a body-powered or myoelectric prosthetic device. This group will be exposed to virtual reality therapy and non-virtual reality therapy.
2984498|NCT02666859|Experimental|Unilateral Transhumeral Amputation|This group includes people with a unilateral transhumeral amputation. Potential subjects must use a body-powered or myoelectric prosthetic device. This group will be exposed to virtual reality therapy and non-virtual reality therapy.
2984499|NCT02666846|Experimental|Cohort 1: TIB200 gel 10%|Cohort 1: Ibuprofen, TIB200 gel (10%, w/w)
2984500|NCT02666846|Active Comparator|Cohort 1: Nurofen gel 10%|Cohort 1: Ibuprofen, Nurofen Max Strength gel (10%, w/w)
2984501|NCT02666846|Active Comparator|Cohort 1: Nurofen tablets|Cohort 1: Ibuprofen, Nurofen oral tablets (2 x 400 mg)
2984502|NCT02666846|Placebo Comparator|Cohort 1: TIB200 Placebo gel|Cohort 1: TIB200 matching placebo gel
2984503|NCT02666846|Active Comparator|Cohort 2: DCF100 gel 2%|Cohort 2: Diclofenac, DCF100 gel (2% w/w)
2984504|NCT02666846|Experimental|Cohort 2: DCF100 gel 4%|Cohort 2: Diclofenac, DCF100 gel (4% w/w)
2984505|NCT02666846|Active Comparator|Cohort 2: Voltaren gel 2%|Cohort 2: Diclofenac, Voltaren Emulgel (2%)
2984506|NCT02666846|Active Comparator|Cohort 2: Voltarol oral tablet|Cohort 2: Diclofenac, Voltarol oral tablet (50 mg)
2984507|NCT02666846|Placebo Comparator|Cohort 2: DCF100 Placebo gel|Cohort 2: DCF100 matching placebo gel
2984508|NCT02666846|Active Comparator|Cohort 3: SPR300 gel (15%:7%)|Cohort 3: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)
2984510|NCT02666820|Active Comparator|Large balloon dilatation|Patients underwent clearance of common bile duct stones using a papillary large balloon dilatation.
2984511|NCT02666820|Active Comparator|Mechanical lithotripsy|Patients underwent clearance of common bile duct stones using a mechanical lithotripsy.
2984512|NCT02666807|Experimental|Ginger|Ginger (Zingiber officinale Roscoe) 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
2984513|NCT02666807|Placebo Comparator|Placebo|Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks Placebo twice daily
2984514|NCT02666794|Active Comparator|Puncture epidural|Women in labor the epidural group will receive epidural bupivacaine with vasoconstrictor 0.125% 10 ml plus 10 micrograms sufentanil, followed by the placement of the epidural catheter
2984515|NCT02666794|Active Comparator|Puncture combined spinal-epidural|The mothers of the combined spinal-epidural analgesia group will receive intrathecal hyperbaric bupivacaine solution 0.5% 2.5 mg plus 5.0 micrograms of sufentanil and plus 60 micrograms of morphine, followed by placement of an epidural catheter to the catheter through technical needle
2984516|NCT02666781||Pilot Group|Postoperative surgical Patients with or without Obstructive Sleep Apnea
2984517|NCT02666768|Experimental|gamma interferon-1b|Gamma interferon-1b 100 mcg SC 3 times weekly for 12 months
2984518|NCT02666742|Experimental|Apixaban|Participants will be asked to take 5 milligrams by mouth twice per day.
2984519|NCT02666742|Active Comparator|Aspirin|Participants will be asked to take 81 milligrams by mouth once per day.
2984520|NCT02666729||AF Ablation Procedure|Patients with AF who are schedule for a first time pulmonary vein isolation (PVI) for AF using the TactiCath catheter. Patients will have four pulmonary veins ablated during procedure. The researcher will perform AF Ablation with contact force information on two veins. The research will perform AF Ablation without contact force information on the other two veins.
2984521|NCT02666703|Experimental|Study (CytoSorb)|In the study group (20 patients) the CytoSorb filter will be installed in the CPB in a parallel circuit. An additional roller pump will drive the blood through the filter with a constant flow of 400 ml/min (max flow).
2984522|NCT02666703|No Intervention|Control|In the control group (20 patients) no filter will be installed on the CPB.
2984523|NCT02666703|Active Comparator|Corticosteroid|In the corticosteroid group (20 patients), 1 gram of methylprednisolone will be added in the priming solution of CPB machine. No filter will be installed on the CPB.
2984524|NCT02666690|Experimental|Patients with metastatic cancer treated with anti angiogenics|
2984525|NCT02666664|Experimental|ETC-1002|ETC-1002 180 mg/day
2984526|NCT02666664|Placebo Comparator|Placebo|Placebo control
2984527|NCT02666651|Experimental|Test group|Administration of oral tolvaptan (15-60mg PO titration) during admission for decompensated heart failure
2984528|NCT02666651|Other|Control group|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority
2984529|NCT02666638|Active Comparator|Control Volunteers|MRI on up to a 7T scanner without contrast.
2984530|NCT02666638|Experimental|Clinical Patients|MRI on up to a 7T scanner without contrast.+ 10 minutes of research development imaging added onto their clinical MRI scans.
2984531|NCT02666625||Patients treated for cancer in childhood|
2984532|NCT02666612|Other|Patients with metastatic cancer|
2984533|NCT02666599|Experimental|18F-FDG PET/CT|18F-FDG radiotracer All patients will undergo a 18F-FDG PET/CT and a surgery with probe detection of β+''
2984534|NCT02666586|Placebo Comparator|Control smoothie|Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
2984535|NCT02666586|Experimental|Faba Bean powder smoothie|Breakfast smoothie with 32 g whole faba bean powder.
2984536|NCT02666586|Experimental|Faba bean protein concentrate smoothie|Breakfast smoothie with 32 g faba bean protein concentrate.
2984537|NCT02666586|Experimental|Faba bean starch smoothie|Breakfast smoothie with 33 g faba bean starch.
2984538|NCT02666586|Experimental|Faba bean protein isolate smoothie|Breakfast smoothie with 32 g faba bean protein isolate.
2984539|NCT02666573|Experimental|Photodynamic therapy protocol|In addition to scaling and root debridement, test sites received PDT according to manufacturer's instructions.
2984540|NCT02666573|Other|SRP|Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
2984541|NCT02666560|Active Comparator|Auditory cueing at self paced cadence|Participants performed a functional task with auditory cueing set at self paced cadence.
2984542|NCT02666560|Experimental|Cueing at 20% above self paced cadence|Participants performed a functional task with auditory cueing set at 20% above self paced cadence whilst performing a functional task.
2984543|NCT02666547|Other|68Ga-NODAGA-RGD,18F-FDG,18F-FET PET/CTs|Active Comparator: 68Ga-NODAGA-RGD radiotracer All patients will undergo a 68Ga-NODAGA-RGD PET/CT, a 18F-FDG PET/CT or a 18F-FET PET/CT
2984544|NCT02666534|Experimental|AFL-PDT|Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)
2984545|NCT02666534|Active Comparator|MAL-PDT|Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)
2984546|NCT02666508|Active Comparator|Plaque identifying toothpaste|A 30 day supply of daily syringes containing a plaque identifying toothpaste with targetol
2984547|NCT02666508|Active Comparator|Non-plaque identifying toothpaste|A 30 day supply of daily syringes containing an identical non plaque identifying toothpaste without targetol
2984604|NCT02666092||Fish allergy|"51 subjects presenting allergic manifestations after digestive, cutaneous, or respiratory contact with fish will be recruited.~Interventions will include:~A questionnaire on domestic exposure to fish, and on the characteristics of clinical manifestations~A detection of anti-Anisakis and anti-fish antibodies"
2984605|NCT02666092||Control|"51 subjects presenting no allergic manifestations after contact with fish.~Interventions will include:~A questionnaire on domestic exposure to fish~A detection of anti-Anisakis and anti-fish antibodies"
2984548|NCT02666482|Experimental|Stop Smoking SF Web App - baseline|"Online Study 1 will test the data gathering aspects of the proposed web app using a baseline, usual care intervention consisting of a static smoking cessation guide, the Guía para Dejar de Fumar, tested in printed form in the Muñoz et al. (1997) study. The print version of the guide yielded an 11% quit rate at 3 months. The investigators will utilize the content of the guide as the main element of the baseline app, so it will serve to estimate baseline utilization and quit rates when this already tested intervention is provided in a web app format. Participants can join the study online by going to: https://stopsmokingsf.org"
2984549|NCT02666469|Active Comparator|Group A Hyperbaric Oxygen Therapy and Exercise Program|Group A: Hyperbaric Oxygen Therapy (HBOT) and Exercise with HBOT sessions for 90 minutes, once daily, 5 times a week for 8 consecutive weeks. HBOT will be provided with 100% oxygen at 2.0 ATA. Patients will exercise in the multiplace hyperbaric chamber while receiving hyperbaric oxygen.
2984550|NCT02666469|Active Comparator|Group B Exercise Program|Group B: Exercise Program in the hyperbaric medical unit without exposure to HBOT
2984551|NCT02666456||Cross-sectional cohort|Patients with chronic peripheral neuropathic pain
2984552|NCT02666456||Longitudinal cohort|Painless patients before and after potential chronic neuropathic pain-inducing interventions (chemotherapy, Operation)
2984553|NCT02666443|Placebo Comparator|Control (C)|Control intervention (no dexamethasone)
2984554|NCT02666443|Experimental|Peri-neural (N)|Peri-neural Dexamethasone 1 mg
2984555|NCT02666443|Experimental|Intravenous|Intravenous Dexamethasone 1 mg
2984556|NCT02666430|Experimental|Mylan's insulin glargine|Patients will be administered either Mylan insulin glargine or Lantus® subcutaneously, once daily in combination with lispro and titrated based on blood glucose readings per standard of care for a total of thirty-six (36) weeks, split into three cycles of twelve (12) weeks each.
2984557|NCT02666430|Active Comparator|Lantus®|Patients will be administered either Mylan insulin glargine or Lantus® subcutaneously, once daily in combination with lispro and titrated based on blood glucose readings per standard of care for a total of thirty-six (36) weeks, split into three cycles of twelve (12) weeks each.
2984558|NCT02666417|Active Comparator|MNP+iron and test meal|"The MNP contains 400 μg Vitamin A, 5 μgVitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as FeFum and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g)~Iron compound added to the test meal: Test meal A will contain 2.5 mg 57Fe as ferrous fumarate and 2.5 mg of iron as NaFeEDTA (given as 1.5 mg 56Fe and 1 mg 58Fe). Test meal B will contain 5 mg iron in form of FeSO₄ (3 mg 56Fe and 2 mg 54Fe)."
2984559|NCT02666417|Active Comparator|MNP+iron+GOS and test meal|"The MNP contains 400 μg Vitamin A, 5 μgVitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g)~Iron compound added to the test meal: Test meal A will contain 2.5 mg 57Fe as ferrous fumarate and 2.5 mg of iron as NaFeEDTA (given as 1.5 mg 56Fe and 1 mg 58Fe). Test meal B will contain 5 mg iron in form of FeSO₄ (3 mg 56Fe and 2 mg 54Fe)."
2984560|NCT02666404|Experimental|Volume Resuscitation|We would like to establish new endpoints for guidance of volume resuscitation by implementing new measurements (body impedance, renal resistive index).
2984561|NCT02666391|Experimental|UCMSCs|Intracoronary infusion of umbilical cord mesenchymal stem cells (UCMSCs)
2984562|NCT02666391|No Intervention|controls|Standard medical treatment without umbilical cord mesenchymal stem cells (UCMSCs) infusion
2984563|NCT02666378|Experimental|CMR/ECHO|"Prior to starting chemotherapy treatment, then participant will undergo the following procedures:~Cardiac Magnetic Resonance Imaging (CMR)~Echocardiogram (ECHO)~Each imaging procedure will be repeated at predetermined times during the protocol"
2984564|NCT02666365|Active Comparator|Bolus infusion of Cefazolin|Subjects undergoing a ventral hernia repair in this arm of the study will receive the surgical prophylactic, cefazolin, in a bolus infusion
2984565|NCT02666365|Active Comparator|Continuous Infusion of Cefazolin|Subjects undergoing a ventral hernia repair in this arm of the study will receive the surgical prophylactic, cefazolin, in a continuous infusion
2984566|NCT02666352|Experimental|Moderate HI Participants|On Day 1 of Part 1, participants will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
2984567|NCT02666352|Experimental|Severe HI Participants|On Day 1 of Part 2, participants will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
2984568|NCT02666352|Experimental|Healthy Participants|Following completion of enrollment of all participants with HI in Parts 1 and 2, participants with normal hepatic function will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
2984569|NCT02666339|Experimental|Hortitherapy group|Hortitherapy + Usual care
2984570|NCT02666339|Active Comparator|Control group|Usual care
2984571|NCT02666326|No Intervention|Conventional diagnostic strategy|"Standard Diagnostics for suspected myocardial infarction, including standard biochemical analysis: min. two measurements of high sensitive troponin T with an interval of minimum 3 hours.~A normal value of high sensitive cardiac troponin-T in both blood samples rules out AMI and the patients can be discharged immediately if no other conditions are suspected."
2984572|NCT02666326|Experimental|Accelerated diagnostic strategy|'Accelerated, combined biomarker rule-out strategy for MI'. Copeptin measurement in a prehospital blood sample combined with high sensitive cardiac troponin T measurement in the first blood sample upon hospital admission, A normal value of both copeptin and cardiac troponin rules out AMI and the patients can be discharged immediately if no other conditions are suspected.
2984573|NCT02666300|Experimental|TaperGuard ETT|tracheal intubation with the TaperGuard ETT，the ETT cuff is Taper-shangped.
2984606|NCT02666079|Experimental|Treatment arm|Wide local excision (WLE) for breast cancer with intra-operative use of the LightPath® Imaging System.
2984607|NCT02666053|Experimental|Treatment A|Single BMS-663068 tablet under fasted conditions
2984608|NCT02666053|Experimental|Treatment B|Single BMS-663068 tablet with a high fat meal
2984574|NCT02666287|Experimental|Sequence 1|"Each subject will receive all the 9 treatment regimens in the following order: A,G/B/F/C,H/E/D,I with a washout period of 7 days between each treatment period administered via the ELLIPTA inhaler. Where Treatment A= BAT/FF 900/300 microgram (mcg) (3 inhalations of 300/100 mcg).~Treatment B= BAT 900 mcg (3 inhalations of 300 mcg) concurrently with FF (lactose) 300 mcg (3 inhalations of 100 mcg) from separate inhalers.~Treatment C= BAT 900 mcg (3 inhalations of 300 mcg). Treatment D= FF (lactose) 300 mcg (3 inhalations of 100 mcg). Treatment E= FF (magnesium stearate [MgSt]) 300 mcg (3 inhalations of 100 mcg). Treatment F= FF/VI 300/75 mcg (3 inhalations of 100 mcg/25 mcg). Treatment G= 7-day repeat doses: BAT/FF 300/100 mcg (1 inhalation). Treatment H= 7-day repeat doses: BAT 300 mcg (1 inhalation). Treatment I= 7-day repeat doses: FF (lactose) 100 mcg (1 inhalation)."
2984575|NCT02666287|Experimental|Sequence 2|Each subject will receive all the 9 treatment regimens in the following order: B/C,H/A,G/D,I/F/E with a washout period of 7 days between each treatment period.
2984576|NCT02666287|Experimental|Sequence 3|Each subject will receive all the 9 treatment regimens in the following order: C,H/D,I/B/E/A,G/F with a washout period of 7 days between each treatment period.
2984577|NCT02666287|Experimental|Sequence 4|Each subject will receive all the 9 treatment regimens in the following order: D,I/E/C,H/F/B/A,G with a washout period of 7 days between each treatment period.
2984578|NCT02666287|Experimental|Sequence 5|Each subject will receive all the 9 treatment regimens in the following order: E/F/D,I/A,G/C,H/B with a washout period of 7 days between each treatment period.
2984579|NCT02666287|Experimental|Sequence 6|Each subject will receive all the 9 treatment regimens in the following order: F/A,G/E/B/D,I/C,H with a washout period of 7 days between each treatment period.
2984580|NCT02666274||RK Group|participants colonised with Klebsiella spp. resistant to either 3GC or carbapenems (RK cohort of index carriers of Resistant Klebsiella)
2984581|NCT02666261||Breast Cancer Pathology Samples|Data on the epidemiology and HER2 testing of breast cancer will be collected from pathology routine diagnostics.
2984582|NCT02666235|Active Comparator|Remote ischaemic conditioning|Intermittent inflation of a forearm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a curtain.
2984583|NCT02666235|Sham Comparator|Control group|Sham intervention: Arm cuff placement but without inflation during a 40 minute period. A curtain will obscure the patient from the clinical team during this time. Arm cuff placement, no inflation.
2984584|NCT02666196|Experimental|DAA-I 6mg|Subjects given solid compound in vials containing 6mg per vial
2984585|NCT02666196|Experimental|DAA-I 50mg|Subjects given solid compound in vials containing 50mg per vial
2984586|NCT02666196|Experimental|DAA-I 110mg|Subjects given solid compound in vials containing 110mg per vial
2984587|NCT02666196|Placebo Comparator|Placebo|Subjects given 25ml placebo dissolved in 200ml water
2984588|NCT02666183|Experimental|Closer|"The full intervention (Closer) is a tested intervention that uses videoconferencing technology (WebEx) for delivery and delivers the highest dose of the intervention. This arm of the intervention will deliver personalized information to the DCG (aimed at enhancing self-efficacy) and emotional support via nurse coaching as well as the opportunity for the DCG to talk with the oncologist and patient in real time during a minimum of four patient-oncologist office visits over a 4-month period (at least once/month). For patients who have more than one oncologist-patient meeting/month, the study will use the videoconference technology to allow the DCG to join as many of the join in as many of the oncologist-patient office visits as desired."
2984589|NCT02666183|Active Comparator|Video-C Only|"This arm will involve the delivery of information solely via the use of videoconference technology during the patient-oncologist-DCG visit. There is always the possibility that the DCG will receive emotional support from the oncologist during the office visit (as would potentially occur during a face-to-face meeting) - but this will not be delivered systematically as in the Closer intervention. As with the Closer intervention, the DCG will be able to participate in the patient-oncologist visit in real time during a minimum of four office visits over the 4-month study period (total dose ~5 hours). The procedure for these meetings will be the same as outlined for Closer but will not involve having the nurse involved in the videoconference sessions with the oncologist, patient, and DCG."
2984590|NCT02666183|Active Comparator|Web-Only|"This group will be provided access to a website that will provide the following major links: a) Caregiving Resources (links to National Family Caregiver Association, etc.), b)Resources for DCGs (links to the Caregiving from a Distance, etc.), c) Cancer Information (links to National Cancer Institute, etc.). DCGs will be told that the study team will track usage of the website in order to assess which areas of the website are used most frequently. Any questions or concerns regarding use of the website can be sent online to the study's technical site, and the support staff will respond within 24 hours. As is current practice, DCGs can call an oncology nurse or oncologist to ask specific questions. Web-Only will deliver the lowest dose of the intervention."
2984591|NCT02666170|Experimental|therapy with alpha-lipoic acid daily for six months|
2984592|NCT02666157|Active Comparator|Dabigatran|oral dabigatran etexilate capsule 110 or 150 mg (110 mg in specific population) bid for entire study period
2984593|NCT02666157|Active Comparator|Rivaroxaban|oral rivaroxaban film-coated tablet 15 or 20 mg (10 or 15 mg in specific population) qd for entire study period
2984594|NCT02666157|Active Comparator|Apixaban|oral apixaban 5 mg (2.5 mg in specific population) bid for entire study period
2984595|NCT02666144||Glaucoma|
2984596|NCT02666144||Normal|
2984597|NCT02666131|Active Comparator|Granexin gel plus Standard of Care|Granexin gel is comprised of 100 μM aCT1 peptide plus hydroxyethyl cellulose.
2984598|NCT02666131|Placebo Comparator|Vehicle gel plus Standard of Care|Vehicle gel is hydroxyethyl cellulose without active pharmaceutical ingredient.
2984599|NCT02666118|Active Comparator|Preemptive Interscalene Block - Single Shot|
2984600|NCT02666118|Active Comparator|Postoperative Interscalene Block - Single Shot|
2984601|NCT02666118|Active Comparator|Preemptive Interscalene Block - Cathether|
2984602|NCT02666118|Active Comparator|Postoperative Interscalene Block - Catheter|
2984603|NCT02666105|Experimental|Exemestane Therapy|
2984609|NCT02666053|Experimental|Treatment C|Single BMS-663068 tablet after a single famotidine tablet under fasted conditions
2996657|NCT02585414||85 healthy subjects with no history of DES|
2984610|NCT02666040|Experimental|U - ULTRAPRO|Inguinal Hernia Surgery with ULTRAPRO® meshes, a new ULTRAPRO® mesh will be implanted in patients in the group (AG). The surgery will be evaluated in terms of procedure, detecting the mode of admission to hospital, the duration of surgery, anesthesia volume and type used, composition of the surgical equipment.
2984611|NCT02666040|Active Comparator|P - Prolene|"Inguinal Hernia Surgery with Prolene® meshes, the conventional mesh in polypropylene Prolene® will be implanted in patients in the control group (CG). The surgery will be evaluated in terms of procedure, detecting the mode of admission to hospital, the duration of surgery, anesthesia volume and type used, composition of the surgical equipment."
2984612|NCT02666027|Experimental|FIVA ON|The FIVA will be turned on for cases randomized to an even number. The ON light will be covered by tape. Routine induction and maintenance of anesthesia and rate and manner of delivery of IV fluid will be administered at the discretion by the anesthesiologist. The FIVA monitor will only monitor the first IV fluid bag since the study will be unblinded once the FIVA monitor alarm is triggered. When the IV bag is empty and the FIVA alarm is triggered, the anesthesiologist will turn off the FIVA and change the IV bag. The following will be recorded by the anesthesiologist: Type of surgical procedure; Duration of surgery; Presence of air in the IV; Number of false alarms triggered by the FIVA during the procedure; VAS assessment of ease of use of the FIVA; Loudness of audial alarm of the FIVA.
2984613|NCT02666027|Placebo Comparator|FIVA OFF|The FIVA will be off for cases randomized to odd numbers. The indicator lights will be covered by tape. Routine induction and maintenance of anesthesia and rate/manner of delivery of IV fluid will be administered at the discretion of the anesthesiologist. The IV bag may run dry with or without being noticed by the anesthesiologist. When they detect the empty bag, it will be changed after the removal of the FIVA. The anesthesiologist will record the presence or absence of air in the IV tubing following the termination of the study. The following will be recorded by the anesthesiologist: Type of surgery; Duration of surgery; Presence of air in the IV; Number of false alarms triggered by the FIVA device; VAS assessment of ease of use of the FIVA; Assessment of audial alarm of the FIVA.
2984614|NCT02666014|Active Comparator|Sugammadex group|"Sugammadex 2 mg/Kg will be administrated as a single dose via intravenous injection upon completion of surgery and guided by peripheral nerve stimulation.~The drug is to be diluted with normal saline to make up to 5 ml volume to maintain blinding."
2984615|NCT02666014|Active Comparator|Neostigmine group|"Neostigmine 0.040 mg/Kg, along with Atropine 0.015 mg/kg, diluted in normal saline to make up 5 ml total volume to maintain blinding.~Neostigmine 0.040 mg/Kg, along with Atropine 0.015 mg/kg will be administrated as a single dose via intravenous injection upon completion of surgery and guided by peripheral nerve stimulation for reversal of neuromuscular blockade produced during surgery.~Atropine sulfate-diphenoxylate hydrochloride combination will be an adjuvant drug to balance muscarinic side effects of Neostigmine, when Neostigmine is administered."
2984616|NCT02666001|Experimental|Part 1 (BMS-663068+methadone)|Effect of multiple doses of BMS-663068, 600mg ER on the exposure of methadone
2984617|NCT02666001|Experimental|Part 2 (BMS-663068+buprenorphine and norbuprene)|Effect of multiple doses of BMS-663068, 600mg ER on the exposure of buprenorphine and norbuprenorphine
2984618|NCT02665988|Experimental|Real tDCS|Those receiving experimental treatment will receive real tDCS during 20-minute periods over the course of 10 sessions. The treatment will be delivered by trained clinical personnel.
2984619|NCT02665988|Placebo Comparator|Sham tDCS|Those receiving sham tDCS will receive active tDCS during 20-minute periods over the course of 10 sessions. The treatment will be delivered by trained clinical personnel.
2984620|NCT02665975|Experimental|Experimental group: iCBT|CBT-based internet-intervention for tinnitus The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
2984621|NCT02665975|Active Comparator|Face-to-face clinical tinnitus care|Receive individual face-to-face tinnitus care, and follow-up appointments as required.
2984622|NCT02665936|Active Comparator|group L|Epidural levobupivacaine 0.125% (Chirocaine) in normal saline in a total volume of 10 ml will be administered epidurally in active stage of labor
2984623|NCT02665936|Active Comparator|group LD4|Epidural levobupivacaine 0.125%(Chirocaine) in normal saline combined with dexamethasone 4 mg in a total volume 10 ml
2984624|NCT02665936|Active Comparator|group LD8|Epidural levobupivacaine 0.125%(Chirocaine) in normal saline combined with dexamethasone 8 mg in a total volume 10 ml
2984625|NCT02665923||Newborn (gastric emptying)|30 healthy newborns who will be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying. Follow up of these newborns at two later time intervals will be performed (between ages 4-6 months, and 9-12 months).
2984626|NCT02665923||Newborn|Patients will undergo one ultrasound prior to their elective procedure after induction of general anesthesia to assess antral volume.
2984627|NCT02665923||Infants (1-12mos)|Patients will undergo one ultrasound prior to their elective procedure after induction of general anesthesia to assess antral volume.
2984628|NCT02665923||Children (2-7yrs)|Patients will undergo one ultrasound prior to their elective procedure after induction of general anesthesia to assess antral volume.
2984629|NCT02665923||Older children and adolescents (≥7yrs)|Patients will undergo one ultrasound prior to their elective procedure after induction of general anesthesia to assess antral volume.
2984630|NCT02665910|Experimental|SHR0302|Multiple ascending doses (2, 5, 10, 25 mg), oral tablets
2984631|NCT02665910|Placebo Comparator|SHR0302 placebo comparator|Multiple ascending doses (2, 5, 10, 25 mg), oral tablets (matching corresponding study medication)
2984632|NCT02665897||Eclampsia|pregnant women with eclampsia will be diagnosed by the occurrence of seizures on top of preeclampsia.
2984633|NCT02665897||severe preeclampsia|pregnant women with severe preeclampsia will be diagnosed according to blood pressure ≥160/110 mmHg with proteinuria detection by boiling method +3,+4.
2984634|NCT02665897||healthy|matched normotensive pregnant women.
2984635|NCT02665884||Glaucoma EX-PRESS|Glaucoma patients who underwent glaucoma surgery between the years 2014-2015 and had diurnal intraocular pressure measurements over 24 hours.
2984636|NCT02665884||Control Group|Glaucoma patients who had been treated with anti-glaucoma drops and had diurnal intraocular pressure measurements over 24 hours.
2996658|NCT02585414||255 subjects with DES|
2984637|NCT02665871|Experimental|one dose of Influenza Vaccine in aged 18 years and older|One dose of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in aged 18 years and older
2984638|NCT02665871|Experimental|One dose of Influenza Vaccine in aged 3-17 year|One dose of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in aged 3-17 years
2984639|NCT02665871|Placebo Comparator|placebo in aged 18 years and older|placebo in 10 subjects aged 18 years and older on day 0
2984640|NCT02665871|Placebo Comparator|placebo in aged 3-17 years|placebo in 10 subjects aged 3-17 years on day 0
2984641|NCT02665858|Active Comparator|IIH Patients|Patients diagnosed with Idiopathic Intracranial Hypertension who undergo OCT imaging
2984642|NCT02665858|Active Comparator|Control Group|Patients diagnosed with headache with ruled out Idiopathic Intracranial Hypertension who undergo OCT imaging
2984643|NCT02665845|Experimental|5-ASA group|Patients will receive corticosteroids with optimized 5-ASA.
2984644|NCT02665845|Active Comparator|Control group|Patients will receive corticosteroids alone.
2984645|NCT02665832|Experimental|AB|Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin) followed by DWJ1351
2984646|NCT02665832|Experimental|BA|DWJ1351 followed by Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)
2984647|NCT02665819||Pediatric cancer women survivors|Women diagnosed for a cancer between 01/01/87 and 31/12/99 before the age of 15 years old living in Rhône-Alpes, will incur a blood taking for DNA tests (hormone tests) to see their fertility capacity.
2984648|NCT02665806|Experimental|Ciclesonide|
2984649|NCT02665806|Active Comparator|Fluticasone|
2984650|NCT02665793|Experimental|DBPCFC to peanut cookie, then single-dose DBPCFC x 2|"Patients will undergo 3 sets of double-blind, placebo-controlled food challenge (DBPCFC):~DBPCFC to incremental doses of peanut (or placebo) baked into a cookie biscuit~DBPCFC to a single dose of peanut (or placebo) equivalent to 1 dosing interval below that to which that patient reacted at the baseline DBPCFC to gain entry to the study, on two separate occasions"
2984651|NCT02665793|Experimental|Single dose DBPCFC x 2, then DBPCFC to peanut cookie|"Patients will undergo 3 sets of double-blind, placebo-controlled food challenge (DBPCFC):~DBPCFC to a single dose of peanut (or placebo) equivalent to 1 dosing interval below that to which that patient reacted at the baseline DBPCFC to gain entry to the study, on two separate occasions~DBPCFC to incremental doses of peanut (or placebo) baked into a cookie biscuit"
2984652|NCT02665780|Experimental|Treatment|Periodontal debridement, tongue cleaning, mouth rinsing with 20ml Cetylpyridium Chloride daily for 24 weeks
2984653|NCT02665767|No Intervention|On-site sonography|The subjects(n=15) performed ultrasonography for the identification of the appendix under mentoring by an onsite expert.
2984654|NCT02665767|Active Comparator|Smartphone-based Telesonography|The subjects(n=15) performed ultrasonography for the identification of the appendix under mentoring by an offsite expert.
2984655|NCT02665754|Experimental|Active group|In active group, extract of causal allergen will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
2984656|NCT02665754|Placebo Comparator|Placebo group|In placebo group, normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
2984657|NCT02665741|Other|Control|No distal colonoscope attachment will be used in this arm
2984658|NCT02665741|Experimental|Olympus transparent cap|The Olympus transparent cap will be attached to the distal end of colonoscope prior to starting the procedure
2984659|NCT02665741|Experimental|Medivators Endocuff|The Medivators Endocuff will be attached to the distal end of colonoscope prior to starting the procedure
2984660|NCT02665728|Experimental|BLI400|BLI400 Laxative
2984661|NCT02665715|Experimental|Low carbohydrate/Standard carbohydrate|10 Roux-en-Y gastric bypass operated subjects are tested two days with mixed-meal tests. Each studytest day consist of both breakfast and lunch.
2984662|NCT02665715|Experimental|Standard carbohydrate/Low carbohydrate|10 Roux-en-Y gastric bypass operated subjects are tested two days with mixed-meal tests. Each studytest day consist of both breakfast and lunch.
2984663|NCT02665702|Experimental|Endostar Combined With NVB and DDP|Endostar15mg/m2 NVB25 mg/m2 DDP75 mg/m2
2984664|NCT02665689|Active Comparator|Regular Glycemic Control|Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen. Patients randomized into this group will be controlled by their general practitioner or private diabetologist (usual care). The glycemic control (blood measurements of HbA1c) will be performed at trial site (Department of diabetology, endocrinology and nutritional medicine) every 3 months. The site will not influence or change the diabetes medication given by general physician and serves as an observer only to monitor the diabetic control.
2984665|NCT02665689|Experimental|Intensified Glycemic Control|"Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen.~Patients randomized into this group will be controlled at the trial site (Department of diabetology, endocrinology and nutritional medicine) during first year monthly, in the second study year every 3 months. The individual HbA1c will be targeted according to the general status reflecting other risk factors for the vasculopathy (e.g. BMI, smoking, blood pressure, lipid status). All effort will be done to reach the target blood pressure ≤ 140/90 mmHg and blood triglyceride level < 140 mg/dl: Further the patients will be educated to improve their eating habits in regard to reduce the carbohydrate intake."
2984666|NCT02665663|Other|healthy volunteers|"Constitution of a control group consisting of 20 healthy volunteers, matched for age and sex to establish a normal pressure force of the language depending on the age and sex value"
2984667|NCT02665663|Other|Patients with Amyotrophic Lateral Sclerosis|Constitution of a group of 20 patients with Amyotrophic Lateral Sclerosis (ALS), included at diagnosis of the disease on clinical and electromyographic arguments addressed in speech pathology consultation without a complaint swallowing.
2984668|NCT02665663|Other|patients with Amyotrophic Lateral Sclerosis and swallowi|Constitution of a group of 20 patients with Amyotrophic Lateral Sclerosis ( ALS) and swallowing disorders clinically objectified in the ENT consultation.
2984669|NCT02665650|Experimental|AFM13 + Pembrolizumab|Participants receive AFM13 in escalating doses intravenously (IV) for up to 25 weeks, pembrolizumab as a fixed dose intravenously (IV) for up to 52 weeks.
2984670|NCT02665637|Active Comparator|CT-P6|Trastuzumab
2984671|NCT02665637|Active Comparator|US-licensed Herceptin|Trastuzumab
2984672|NCT02665624|Active Comparator|Stewed apricot juice + senna group|68 patients received 250 ml of Senna solution (containing 500 mg sennoside A+B calcium) (X-M solution, Yenisehir Pharmaceuticals, Turkey) at 6 PM on the day before colonoscopy, and at 6 AM on the day of the procedure. Additional one liter of stewed apricot juice (made with dried apricot) were told to be drunken until 2 h before colonoscopy.
2984673|NCT02665624|Active Comparator|senna alone group|60 patients received 250 ml of Senna solution (containing 500 mg sennoside A+B calcium) (X-M solution, Yenisehir Pharmaceuticals, Turkey) at 6 PM on the day before colonoscopy, and at 6 AM on the day of the procedure. 1 patient was dropped out due to obstructive sigmoid colon cancer.
2984674|NCT02665611|Experimental|intervention group|"intervention for improvement of treatment adherence Intervention group- This group will be followed by the MOMA call center (By the MOMA nures every couple weeks and by the study coordinatore and the treating Doctor at special visits as the study required.) The group will be monitored according to number of parameters, including treatment Adherence."
2984675|NCT02665611|Experimental|control group|"treatment as usual Control group- Treatment will continue as usual by the Doctor.(This group will allso be followed by the Study Coordinator at the same visits as the Intervention group.The group will be monitored according to number of parameters, including treatment Adherence."
2984676|NCT02665585|Experimental|C-Guard carotid stent|Carotid stenting procedure by C-Guard stent implantation (InspireMD, Boston, MA, USA)
2984677|NCT02665585|Active Comparator|Wallstent carotid stent|Carotid stenting procedure by Wallstent implantation (BostonScientific, Marlborough, MA, USA)
2984678|NCT02665572|No Intervention|renal transplant without bladder recycling|the patients allocated to this arm and met inclusion criteria will undergo renal transplant without prior recycling of the bladder
2984679|NCT02665572|Active Comparator|renal transplantation with bladder recycling|the patients allocated in this arm will undergo bladder recycling prior to renal transplantation
2984680|NCT02665559||Hypogonadism group|a cross-sectional and prospective study, in HIV-infected men less than 50 years old, with HIV-RNA ≤ 50 cop/mL under ART who had never presented AIDS
2984681|NCT02665546||Case|Patients with diagnosis of LCH based on histopathological or clinical and radiological findings.
2984682|NCT02665546||Controls|Current or ex smokers matched with cases for age, gender and smoking history.
2984683|NCT02665533|Active Comparator|Dexamethasone|Dexamethasone 8 mg, one capsule single preoperative dose.
2984684|NCT02665533|Experimental|Diclofenac Sodium associated with Codeine|Diclofenac Sodium 50 mg associated with Codeine 50 mg, one capsule single preoperative dose.
2984685|NCT02665520|Active Comparator|stem cells injection in penis|Treatment Injection of adipose derived cells into penis experimental;randomised
2984686|NCT02665520|No Intervention|controled arm|
2984687|NCT02665507|Active Comparator|LLLI|Subjects from this group will receive 6 biweekly physiotherapy treatment and in addition LLLI (low level laser irradiation) treatment performed with Gallium-Aluminium-Arsenide 808 nm laser ( GaAlAs 808nm laser ).
2984688|NCT02665507|Sham Comparator|Sham|Subjects from this group will receive 6 biweekly physiotherapy treatment and in addition sham LLLI treatment
2984689|NCT02665481|Experimental|MBSR|Mindfulness-Based Stress Reduction consists of a brief introductory meeting, eight weekly 2.5-hour classes, and a retreat, followed by monthly booster sessions for approximately 15 months. Content includes instruction in mindfulness meditation practices, gentle mindful movement, and exercises to enhance mindfulness in everyday life.
2984690|NCT02665481|Experimental|Exercise|The exercise protocol is optimal for improving aerobic fitness and insulin sensitivity in older adults, as well as improving strength and balance and reducing indices of frailty.It consists of classes twice weekly for 6 months, building up to 1.5 hr, under the direct supervision of trained exercise instructors, followed by once weekly classes for 12 months.
2984691|NCT02665481|Experimental|MBSR + Exercise|"This condition will receive both MBSR and exercise as described above. Participants in this condition will come in once weekly to receive MBSR and twice weekly to receive exercise classes, with at-home exercise the other two days as well as daily, at-home mindfulness practice. After the initial classes participants will also attend additional weekly or monthly sessions until completion of the study.~Note that at each site a pilot group is undergoing MBSR + Exercise (not randomized, separate from the RCT)."
2984692|NCT02665481|Active Comparator|Health Education|Health Education is a group-based intervention that increases health-related knowledge and action. Health Education improves chronic disease management.Health Education consists of ten weekly 2.5-hour classes, followed by monthly classes for approximately 15 months.
2984693|NCT02665468|Other|Arm 1: SAI|Supported adoption intervention
2984694|NCT02665468|Active Comparator|Arm 2: General wellness information|General wellness information
2984695|NCT02665455|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
2984696|NCT02665442|Experimental|Stylet|This group will receive an Esophageal stylet; EsoSure during the ablation procedure in attempt of moving the esophagus away from the ablation site.
2984697|NCT02665442|No Intervention|Non-Stylet|This group will receive the ablation procedure without any modifications or interventions. No esophageal stylet will be used in this group.
2984698|NCT02665429|No Intervention|Control|Providers who are subject only to the routine implementation of clinical practice guidelines without additional experimental intervention
2984699|NCT02665429|Experimental|Intervention|"Providers who are subject to routine clinical practice guideline implementation AND receive provider's own individual prescribing data profile intervention (Individual prescribing data profile and self-assessment)"
2984700|NCT02665416|Experimental|Part I (Dose Escalation): Selicrelumab, Vanucizumab|Participants will receive a fixed dose of vanucizumab, 2 grams via IV infusion on Days 1 and 15 of every 28-day cycle. Selicrelumab will be given SC, or potentially IV, in ascending dose levels on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment will continue as long as the participant experiences clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (expected 9 months).
2984737|NCT02665169|Experimental|Exercise intervention group|Supervised exercise intervention of 12 months. One Taiji and one gym training per week for first six months followed by 6 months free independent use of municipal facilities, including gym, swimming hall and weight room. Written and oral health counselling provided.
2985183|NCT02662088||Laparoscopic-lavage|Patients with colonic diverticulitis submitted to laparoscopic lavage
2984701|NCT02665416|Experimental|Part II (Expansion): Selicrelumab, Bevacizumab|Bevacizumab will be administered via IV infusion on days 1 and 15 of every 28-day cycle. Selicrelumab will be given SC after the Bevacizumab infusion at the dose determined in the Part I of the study on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment will continue as long as the participant experiences clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part II of the study (expected 15 months).
2984702|NCT02665403|Experimental|play intervention|30 minutes of hospital play interventions
2984703|NCT02665403|Placebo Comparator|control|usual care
2984704|NCT02665390|Experimental|treatment|Patients who are medically inoperable peripheral lung cancer will enroll in this study.They will receive percutaneous cryoablation and follow-up according to schedule.
2984705|NCT02665377|Active Comparator|ANP|Infusion of h-ANP at dose of 50ng/kg/min fore 5 days, starting at the induction of anesthesia.
2984706|NCT02665377|Placebo Comparator|Placebo|Infusion of NaCl at the same volyme as for ANP for 5 days.
2984707|NCT02665364|Experimental|IFN-Kinoid|IFN-Kinoid + ISA 51
2984708|NCT02665364|Placebo Comparator|Placebo|Placebo + ISA 51
2984709|NCT02665351|Active Comparator|Peramivir 300mg Q12H|Peramivir 300 mg, administered intravenously, twice daily (every 12 hours)
2984710|NCT02665351|Active Comparator|Peramivir 600mg Q24H|Peramivir 600 mg, administered intravenously, once daily (every 24 hrs)
2984711|NCT02665338|Sham Comparator|Sham rTMS|The sham TMS system will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
2984712|NCT02665338|Active Comparator|Active rTMS|Stimulation frequency for all active subjects: 10 Hertz - Pulse train duration (on time) 5 seconds, Inter-train interval (off time) 10 seconds (15 second cycle time), Power (intensity) level 100% rMT, Total 60 trains, 15 minutes, Total pulses 3000.
2984713|NCT02665325||TSHsuppressive therapy group|TSH-suppressive therapy group: newly diagnosed differentiated thyroid carcinoma and undergone thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
2984714|NCT02665325||Negative control group|Healthy volunteers (normal T3,T4,FT3,FT4,TSH, TG-ab,TPO-ab,TG) are recruited to match the patients with age, gender, education level, ect.
2984715|NCT02665325||Positive control group|Newly diagnosed nodular goiter and undergone thyroidectomy according to the China thyroid association guidelines for the management of thyroid nodule and thyroid cnacer; followed by L-T4 replacement therapy 6/12 months.
2984716|NCT02665286|Placebo Comparator|Placebo|Naproxen 500mg tablets taken twice per day + placebo. Placebo dose will be either 1 capsule orally twice per day or 1 or 2 capsules orally, thrice per day Naproxen 500mg po BID x 10 days #20 + Placebo
2984717|NCT02665286|Active Comparator|Orphenadrine|Naproxen 500mg, orally twice per day + orphenadrine 100mg, orally twice per day for 10 days Naproxen 500mg po BID x 10 days #20 + Orphenadrine
2984718|NCT02665286|Active Comparator|Methocarbamol|Naproxen 500mg tablets, orally twice per day + methocarbamol 750mg, orally as 1 or 2 tabs, thrice per day Naproxen 500mg po BID x 10 days #20 + Methocarbamol
2984719|NCT02665273|Experimental|Greater occipital nerve block|Bilateral greater occipital nerve block with 3cc of 0.5% bupivacaine, delivered using fan technique
2984720|NCT02665273|Sham Comparator|Sham|Bilateral intradermal injection of 0.5cc of 0.5% bupivacaine, delivered superficially to the area overlying the greater occipital nerve
2984721|NCT02665260|Active Comparator|Cantharidin with occlusion|Cantharidin 0.7% topical with occlusion
2984722|NCT02665260|Experimental|Cantharidin without occlusion|Cantharidin 0.7% topical without occlusion
2984723|NCT02665260|Placebo Comparator|Placebo with occlusion|Placebo topical with occlusion
2984724|NCT02665260|Placebo Comparator|Placebo without occlusion|Placebo topical without occlusion
2984725|NCT02665247|Experimental|C-SIP|Participants assigned to the C-SIP group will attend sessions where information about sleep is presented. In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.
2984726|NCT02665247|Other|Control Session|Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
2984727|NCT02665234|Active Comparator|Tavilermide Ophthalmic Solution|1% Tavilermide Ophthalmic Solution
2984728|NCT02665234|Placebo Comparator|Vehicle Ophthalmic Solution|Placebo Ophthalmic Solution
2984729|NCT02665221|Placebo Comparator|Control group|
2984730|NCT02665221|Experimental|Treatment group|
2984731|NCT02665208|Active Comparator|Treatment As Usual (TAU)|Participants will receive informational pamphlets and information for a 1800 quit line, and a prescription for a nicotine replacement therapy (NRT) for 7 Days
2984732|NCT02665208|Active Comparator|Nicotine Replacement Therapies|Participants will receive a prescription for a nicotine replacement therapy (NRT) for 7 Days.
2984733|NCT02665208|Active Comparator|Text Message Intervention|Participants will receive up to 5 messages a day with message content informed by principles of cognitive behavioral therapy using software developed and maintained by the National Cancer Institute.
2984734|NCT02665195||Prospective Registry of Multiplex Testing|This is a prospective ascertainment study that will obtain medical information and biospecimens from two different types of families: 1) Families transmitting sequence variants in non-BRCA predisposition genes that are either functionally deleterious or likely to be functionally deleterious based upon the interpretation of the laboratory that performed the testing on the Index Participant (Initial PROMPT enrollee), and 2) Families transmitting variants of uncertain significance (usually rare missense variants) in non- BRCA predisposition genes. Attempts will be made to collect a biospecimen and a completed risk factor questionnaire from each participant.
2984735|NCT02665182|Experimental|Up-positioning of the testes|Patients receive standard medical therapy and supportive therapy
2984736|NCT02665182|No Intervention|Medical therapy only|Patients receive standard medical therapy only
2984738|NCT02665169|Active Comparator|Control group|Control group, without any induced exercise intervention. Written and oral health counselling provided.
2984739|NCT02665156|Experimental|Robotic Stapled orthotopic neobladder|Intracorporeal stapled neobladder using robotic staplers: Partly stapled orthotopic neobladder: robotic staplers applied to create the neobladder neck and to suture the left side of the posterior aspect of neobladder. Right side of the posterior aspect of neobladder and the anterior aspect of the neobladder hand sewn.
2984740|NCT02665143|Experimental|Nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. Based on the phase I dose, in the randomized phase II, the combination will be compared with chemotherapy+placebo. Nintedanib or placebo will be added at day 8 and continued until end of cycle .
2984741|NCT02665143|Active Comparator|Placebo and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. Nintedanib or placebo will be added at day 8 and continued until end of cycle.
2984742|NCT02665130|Active Comparator|Tai-Chi group|Tai-Chi exercise plus Indacaterol 150ug/day
2984743|NCT02665130|Placebo Comparator|Pulmonary rehabilitation group|Conventional exercise plus Indacaterol 150ug/day
2984744|NCT02665117|Active Comparator|KMgCit + Chlorthalidone|After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KMgCit for 4 months.
2984745|NCT02665117|Active Comparator|KCl + Chlorthalidone|After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KCl for 4 months.
2984746|NCT02665104||patients without neurological symptoms|carotid endarterectomy patients who dont'have any neurological symptoms after carotid clamping
2984747|NCT02665104||patients with neurological symptoms|carotid endarterectomy patients who have new neurological symptoms after carotid clamping
2984748|NCT02665091|Experimental|Peer Education Group|Group was self compared after the intervention
2984749|NCT02665078||Thoracoscopic Ultrasound|Patients who undergo lobectomy or an anatomical segmental resection for malignant lung tumors will be enrolled in the study. After lung resection, the lung will be evaluated by XLTF-UC180 for localization of the tumor. The ultrasound probe will be put on the lung surface in several different directions to obtain the cross section with maximum diameter. The ultrasound image with size measurement of the tumor will be recorded using an ultrasound scanner (EU-Y0008, OLYMPUS MEDICALSYSTEMS CORP., Tokyo, Japan). After ultrasound evaluation, the specimen will be delivered directory to the pathology laboratory and the actual tumor size and histological diagnosis will be determined. In addition, we will evaluate the differences between US image and pathological morphology using HE slides of lung tumor.
2984750|NCT02665065|Experimental|Iomab-B|Iomab-B in conjunction with a Reduced Intensity Conditioning (RIC) regimen containing Fludarabine and low-dose Total Body Irradiation (TBI) prior to allogeneic HCT
2984751|NCT02665065|Active Comparator|Conventional Care|Defined as Investigator's choice of salvage chemotherapy with any combination of the following agents: Azacitidine (not allowed as a single agent), Carboplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Daunorubicin, Decitabine (not allowed as a single agent with the exception of patients with documented TP53 mutations who have not previously received 10-day regimens of single agent decitabine), Doxorubicin, Enasidenib, Etoposide, Fludarabine, Gemtuzumab ozogamicin, Idarubicin, L-Asparaginase, Midostaurin (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Mitoxantrone, Sorafenib (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Thioguanine, Topotecan, Venetoclax (in combination with a hypomethylating agent). Chemotherapy agents not listed above may be administered after providing clinical justification and receiving medical monitor approval prior to initiation of treatment.
2984752|NCT02665052|Experimental|Home-Based BATRAC|Home-based BATRAC training will consist of 45 minutes of high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
2984753|NCT02665052|Experimental|Lab-based BATRAC plus TTT|Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and rest periods followed by 15 minutes of therapist guided transition to task training (TTT).
2984754|NCT02665052|Placebo Comparator|Delayed Entry Usual Care|Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions. They will also receive weekly phone calls to record general activity level. After serving as a control, this group will be entered into their randomized active intervention group of either lab-based BATRAC + TTT training, or Lab-based Robot+ TTT.
2984755|NCT02665039|Experimental|Vinflunine + gemcitabine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:~280 mg/m2 in patients with GFR 40-60 ml/min~250 mg/m2 in patients aged >80 years and/or GFR 30-40 ml/min~Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2"
2984756|NCT02665039|Active Comparator|Carboplatin + gemcitabine|"Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5~Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2"
2984757|NCT02665026|Experimental|stoma closure at different times|choose different times to do stoma closure after surgery for rectal cancer
2984758|NCT02665013|Experimental|Tailored|Participants will complete surveys at each intervention time point. Based on survey responses, they will receive vaccine information on the study website tailored to their vaccine concerns and values
2984759|NCT02665013|Placebo Comparator|Untailored|Participants will complete surveys at each intervention time point and receive vaccine information on the study website. The vaccine information will NOT be tailored to their concerns and values.
2984760|NCT02665013|No Intervention|Usual Care|Participants will complete surveys at each intervention time point. They will receive vaccine information sheets that are provided in the well child visits at enrollment in the study.
2984789|NCT02664870||Hip Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy (with or without periacetabular osteotomy (PAO)) or arthroplasty
2984761|NCT02665000|Experimental|Study arm: Structured training programme|"The participants in study arm will undergo 5 days training program in laparoscopic appendectomy using the Box and Wet Trainer as intervention. Each training session will take up to 2 hours. The participant will then be exposed to the standard training in current practice over 5 supervised cases of laparoscopic appendectomy.~After the above training, they will be required to perform another 5 cases of laparoscopic appendectomy as performing surgeon under supervision by a trained surgeon. The operation will be recorded and graded based on a validated GOALS scoring system 6. The Primary Outcome will be the difference of the GOALS results between the 2 groups. Secondary outcomes will include OSAT score, patient outcome, residents' feedback score as well as conversion rates to open surgery."
2984762|NCT02665000|No Intervention|Control arm: non-training|"Participant in study arm will not receive any additional training during the training week. The participant will then be exposed to the standard training in current practice over 5 supervised cases of laparoscopic appendectomy.~They will be required to perform another 5 cases of laparoscopic appendectomy as performing surgeon under supervision by a trained surgeon. The operation will be recorded and then graded based on a validated GOALS scoring system 6"
2984763|NCT02664987||Patients receiving cancer pain treatment|
2984764|NCT02664974|Experimental|HEN group|Home Enteral Nutrition
2984765|NCT02664974|Active Comparator|Control group|Dietary Counseling
2984766|NCT02664961|Experimental|TRC105 and/or bevacizumab|All subjects will begin by receiving single agent TRC105 weekly. In the case of a complete response to single agent TRC105, subjects will continue to receive single agent TRC105 for at least 3 months following complete response. In the case of a partial response (without a complete response) to single agent TRC105, bevacizumab every two weeks will be added. In the absence of a partial or complete response to single agent TRC105, subjects will receive single agent bevacizumab every two weeks. In the absence of a complete response to single agent bevacizumab, or for subjects who have documented disease progression on a prior bevacizumab containing regimen, subjects will receive TRC105 weekly and bevacizumab every two weeks.
2984767|NCT02664948|Experimental|Intervention group|Early geriatric follow-up after discharge from hospital in the patient's home
2984768|NCT02664948|No Intervention|Control group|Usual care with follow-up home-visits conducted by home care and the GP after discharge, if they consider it as necessary
2984769|NCT02664935|Experimental|Arm A: AZD4547|AZD4547 - FGFR Inhibitor Route & Formulation: Oral, Tablets Strengths: 20 & 80mg Trial Dose & Schedule: 80 mg BD, Continuous dosing, 21 day cycle
2984770|NCT02664935|Experimental|Arm B: AZD2014|AZD2014 - MTORC1/2 Inhibitor Route & Formulation: Oral, Tablets Strengths: 25mg Trial Dose & Schedule: 125 mg BD, Intermittent dosing (2 continuous days in 7), 28 day cycle.
2984771|NCT02664935|Experimental|Arm C: Palbociclib|Palbociclib - CDK4/6 Inhibitor Route & Formulation: Oral, Capsules Strengths: 75, 100 & 125mg Trial Dose & Schedule: 125 mg OD, Intermittent dosing (21 days on, 7 days off), 28 day cycle.
2984772|NCT02664935|Experimental|Arm D: Crizotinib|Crizotinib - ALK Inhibitor Route & Formulation: Oral, Capsules Strengths: 200 & 250mg Trial Dose & Schedule: 250 mg BD, Continuous dosing, 21 day cycle.
2984773|NCT02664935|Experimental|Arm E: Selumetinib & Docetaxel|"AZD6244 (Selumetinib) - MEK Inhibitor Route & Formulation: Oral, Capsules Strengths: 25mg Trial Dose & Schedule: 75 mg BD, Continuous dosing, 21 day cycle.~Docetaxel - Chemotherapy Route & Formulation: IV infusion over 30-60 minutes, concentrate for solution for infusion.~Trial Dose & Schedule: 75 mg/m2, 3-weekly, 21 day cycle."
2984774|NCT02664935|Experimental|Arm F: AZD5363|AZD5363 - AKT Inhibitor Route & Formulation: Oral, Tablets Strengths: 80 & 200mg Trial Dose & Schedule: 480 mg BD, Intermittent dosing (4 days on, 3 days off), 28 day cycles.
2984775|NCT02664935|Experimental|Arm G: AZD9291|AZD9291 - EGFRM+ and T790M+ Inhibitor Route & Formulation: Oral, Tablets Strengths: 80mg Trial Dose & Schedule: 80 md OD, Continuous dosing, 21 day cycles
2984776|NCT02664935|Experimental|Arm NA Cohort NA1: MEDI4736|MEDI4736 - Anti-PDL1 Route & Formulation: IV Infusion, Lyophilized powder for solution for infusion Strengths: Vial containing 200mg Trial Dose & Schedule: 10 mg/kg IV, 2-weekly.
2984777|NCT02664922|Experimental|Sedation - Group 1|Sedation - monitored anesthesia with propofol.
2984778|NCT02664922|Experimental|Sedation - Group 2|Sedation - monitored anesthesia with ketamine + propofol
2984779|NCT02664922|Experimental|Sedation - Group 3|Sedation - monitored anesthesia with remifentanil + propofol
2984780|NCT02664922|Experimental|General Anesthesia - Group 1|General anesthesia (GA) with Sevoflurane + O2
2984781|NCT02664909|Experimental|Tranexamic Acid|Patients will receive 1 gram of topically applied tranexamic acid into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. 1 gram of tranexamic acid will be mixed with normal saline to a total volume of 50 cc, half of which will be delivered intra-articularly and half of which will be delivered in the subfascial space.
2984782|NCT02664909|Placebo Comparator|Placebo|Patients will receive 50 cc of topically applied normal saline into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. Half of this 50 cc dose of normal saline will be delivered intra-articularly and half will be delivered in the subfascial space.
2984783|NCT02664896||Knee Osteoarthritis Cohort|Subjects with knee osteoarthritis will be asked to participate in the knee osteoarthritis testing session. This group will participate in 1 three hour testing session.
2984784|NCT02664896||Healthy Subject Cohort|Healthy subjects will be asked to participate in the healthy control testing session. This group will participate in 1 two hour testing session.
2984785|NCT02664883||Group I (no cancer or hematuria)|Patients with no evidence of cancer and no hematuria undergo collection of blood and urine samples at baseline and 2 months for analysis via the Flow Cytometry MDSC Clinical Assay
2984786|NCT02664883||Group II (localized RCC)|Patients diagnosed with localized renal cell carcinoma undergo collection of blood and urine samples at baseline and after nephrectomy for analysis via the Flow Cytometry MDSC Clinical Assay. Patients also undergo CT or MRI within 30 days after nephrectomy.
2984787|NCT02664883||Group III (metastatic RCC)|Patients diagnosed with metastatic renal cell carcinoma undergo collection of samples prior to baseline and then after 4 months of systemic treatment for analysis via the Flow Cytometry MDSC Clinical Assay. Patients also undergo CT or MRI after completion of 4 months of systemic treatment.
2984788|NCT02664870||Shoulder Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy or arthroplasty
2984790|NCT02664870||Knee Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy or arthroplasty
2984791|NCT02664857|Active Comparator|vitamin D|After per orally vitamin D supplementation during 12 weeks, serum Vitamin D level will evaluate with laboratory testing. 600 IU vitamin D will apply to 30 subject during 12 weeks. At first day end end of the 12 weeks serum vitamin D level will analyse with laboratory testing.End of the 12 weeks, the children will be perform dental treatment under general anaesthesia. Postoperative pain, anxiety and sedation will evaluate.
2984792|NCT02664857|Sham Comparator|Placebo|Grup P will not take vitamin D during 12 weeks. This group just only will follow by researchers.At first day end end of the 12 weeks serum vitamin D level will analyse with laboratory testing.End of the 12 weeks, the children will be perform dental treatment under general anaesthesia. Postoperative pain, anxiety and sedation will evaluate.
2984793|NCT02664844|Experimental|Obese adolescent|
2984794|NCT02664818||Heart failure|Hospitalized patients with primary discharge diagnosis of heart failure and who were aged 18 years or older.
2984795|NCT02664805|Active Comparator|LEO 124249 ointment|Twice daily cutaneous application for 8 weeks
2984796|NCT02664805|Placebo Comparator|LEO 124249 ointment vehicle|Twice daily cutaneous application for 8 weeks
2984797|NCT02664792|Experimental|Diagnosis or suspicion of non-small cell lung carcinoma|SUS patients with diagnosis or suspicion of non-small cell lung carcinoma with an indication for mediastinoscopy
2984798|NCT02664779|Experimental|Arrhythmia diagnosis with the 10 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias.
2984799|NCT02664779|Active Comparator|Arrhythmia diagnosis with the 6 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias
2984800|NCT02664779|Active Comparator|Arrhythmia diagnosis with the 4 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias
2984801|NCT02664766|No Intervention|Control condition|Control condition with no intervention. Participants will be recording their daily alcohol consumption. No lifestyle modification during this period.
2984802|NCT02664766|Experimental|Exercise training program|Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week.
2984803|NCT02664753|Experimental|L-Carnitine group|"Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.~Intervention: 56 days of weight-adjusted L-Carnitine treatment"
2984804|NCT02664753|Placebo Comparator|Placebo then open group|"Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).~Intervention: 10 days of intravenous placebo (isotonic saline)"
2984805|NCT02664740|Experimental|Phage therapy|"Patients randomized to this arm will have phage therapy.~Intervention: Topical anti-Staphylococcus bacteriophage therapy"
2984806|NCT02664740|Placebo Comparator|Placebo|"Patients randomized to this arm will have placebo therapy anologous to that of the experimental arm.~Intervention: Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy"
2984807|NCT02664727|Experimental|Heavy drinkers|The effects of acute exercise in heavy drinkers. Participants will cycle on ergometer for 30 min at 50-60% of Heart Rate Reserve (HRR).
2984808|NCT02664727|Experimental|Alcoholic patients|The effects of acute exercise in alcoholic patients. Participants will cycle on ergometer for 30 min at 55-60% of Heart Rate maximal (HRmax).
2984809|NCT02664714|Active Comparator|PFMT Individualized|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s) 4(5s/10s), 5(5s/5s), 6(5s/5s), 7(6s/6s),8(6s/6s), 9(8s/8s) 10(8s/8s), 11(10s/10s),12(10s/10s)
2984810|NCT02664714|Experimental|PFMT individualized with group|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s)
2984811|NCT02664714|Active Comparator|12 group PFMT|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s)
2984812|NCT02664701|Active Comparator|Individual supportive therapy|"Patients randomized to this arm will have individual supportive therapy.~Intervention: Baseline evaluation with a psychiatrist~Intervention: Individual supportive therapy~Intervention: Evaluations with a psychiatrist"
2984813|NCT02664701|Experimental|Cognitive behavioural group therapy|"Patients randomized to this arm will have cognitive behavioural therapy.~Intervention: Baseline evaluation with a psychiatrist~Intervention: Cognitive behavioural group therapy~Intervention: Evaluations with a psychiatrist"
2984814|NCT02664688|Experimental|Lumbar stabilization exercises|Home exercise program to perform daily for 6 months
2984815|NCT02664688|Active Comparator|Flexor Exercises|Home exercise program to perform daily for 6 months
2984816|NCT02664675||Periimplantitis|"patients formerly treated with a non surgical procedure without antibiotics with at least one functional dental implant with at least on pocket deeper than 5 mm with bleeding on probing and radiographical alveolar bone loss.~These patient will be treated by open flap debridement nd the granulation tissue xill be harvested for analysis."
2984817|NCT02664675||Periodontitis|patients formerly treated with a non surgical procedure without antibiotics for a generalized severe chronic periodontitis (in accord to Armitage 2009) and needing a resective surgical procedure (periodontal pockets deeper than 5 mm with bleeding on probing) These patient will be treated by open flap debridement nd the granulation tissue xill be harvested for analysis.
2984818|NCT02664675||Healthy patient|healthy patients needing crown lengthening allowing collection of gingival explants
2984819|NCT02664662|Experimental|tailored education|Tailored rehabilitated education is which fit for each breast cancer patients after surgery in clinic. We design three of tailored books for experimental group. Each patients will be tailored by three principles. First, the educated times and hours are depended on patients physical function and learning ability. Second, the material is depended on each patient's life experience. Finally, the educated content is depended on patient's operation method.
2984820|NCT02664662|No Intervention|standard education|Only provide one paper of post operation and give education of rehabilitated exercise
2984821|NCT02664649|Experimental|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight <60 kg, serum creatinine ≥1.5 mg/dL [133 μMol/L].~- Also, subjects with severe renal insufficiency [calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min] will take apixaban 2.5 mg tablets orally twice daily"
2984822|NCT02664649|Active Comparator|Standard of care|VKA or Antiplatelet therapy
2984823|NCT02664636|Experimental|The study population|"The study population consists of patients 20 and 75 years of age who have had a supra-tentorial ischemic or hemorrhagic stroke. The study covers consulting or hospitalized patients at the neurological rehabilitation service (NHS) of Grau du Roi Medical Center, part of the Nîmes University Hospital. Most patients originate from a 2-4 week stay in the neurological acute care, cardiac or polyvalent departments of the University Hospitals of Montpellier or Nîmes.~Intervention: Physiotherapy~Intervention: Occupational therapy~Intervention: Functional near-infrared spectroscopy"
2984824|NCT02664623|Experimental|Dietary advice sheet|"Patients in this arm will receive a dietary advice sheet at the beginning of the study.~Intervention: Dietary advice sheet"
2984825|NCT02664623|Experimental|Dietary advice sheet + consults with dietician|"In addition to receiving a dietary advice sheet at the beginning of the study, patients randomized to this arm will have individual consultations with a dietician at inclusion, month 1 and month 3.~Intervention: Dietary advice sheet Intervention: Individual dietary consultations"
2984826|NCT02664610|No Intervention|No text messages, hypertensive|Participants who have high blood pressure, who are randomized to health information (do not receive text messages).
2984827|NCT02664610|Experimental|Text messages, hypertensive|Participants who have high blood pressure, who are randomized to receive text messages.
2984828|NCT02664597|Sham Comparator|Standard strategy|In control group, the complex adnexal mass will be managed according to the standard strategy and treatment plan routinely used by the multidisciplinary team.
2984829|NCT02664597|Experimental|ADNEXMR SCORING|In the intervention group, patients will undergo a pelvic MR imaging as routinely performed, including morphological sequences and functional sequences. Prospectively, the radiologist will classify the mass using ADNEXMR SCORING system and the patient will be managed according to the score.
2984830|NCT02664584||Cross-sectional cohort|Cohort who took part in the cross-sectional study (n=5186)
2984831|NCT02664584||Cross-sectional cohort + follow-up|Cohort who took part in both the cross-sectional and follow-up study (planned n=500 (on-going))
2984832|NCT02664571|Other|ACA with isolated hemosiderosis|"This group is composed of patients with amyloid cerebral angiopathy (ACA) with isolated hemosiderosis.~Intervention: Pet scan with FBB~Intervention: MRI scan~Intervention: APO E genotyping"
2984833|NCT02664571|Other|ACA with lobar hematoma(s)|"This group is composed of patients with amyloid cerebral angiopathy (ACA) with lobar hematoma(s).~Intervention: Pet scan with FBB~Intervention: MRI scan~Intervention: APO E genotyping"
2984834|NCT02664571|Other|Alzheimer's without ACA|"This group is composed of Alzheimer's type dementia without MRI signs in favor of amyloid cerebral angiopathy (ACA).~Intervention: Pet scan with FBB~Intervention: MRI scan~Intervention: APO E genotyping"
2984835|NCT02664571|Other|Healthy volunteers|"This group is composed of healthy volunteers.~Intervention: Pet scan with FBB~Intervention: MRI scan~Intervention: APO E genotyping"
2984836|NCT02664558|Experimental|ubenimex|ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
2984837|NCT02664558|Placebo Comparator|placebo|placebo capsules TID, administered orally for a total of 24 weeks
2984838|NCT02664545|Experimental|Bridge-Enhanced ACL Repair (BEAR)|The BEAR technique involves surgically placing a sponge (the BEAR scaffold) between the torn ends of the ACL, providing a scaffold for the ligament ends to grow into.
2984839|NCT02664545|Active Comparator|Tendon Graft|ACL reconstruction is when a tendon graft (either two hamstring tendons from the back of the knee or bone-patellar tendon-bone graft from the front of the knee) is taken and used to replace the torn ACL.
2984958|NCT02663674|Experimental|Group 2|400 mg of Fluconazole (2 capsules of 200 mg) administered orally once daily for 42 days starting on Day 1. N=500
2985184|NCT02662075|Experimental|E-cigarette/tobacco Smoking Exposure|
2985742|NCT02658318||Pierre Robin Syndrome (PRS)|Cleft palate patients with the Pierre Robin Syndrome.
2984840|NCT02664532|Experimental|Miller group|In Miller group, no 3 Miller blade was used for laryngoscopy by paraglossal technique. While intubating, the endotracheal tube (ETT) was directed underneath the laryngoscope blade without allowing it to go lateral to the blade. The curvature of the ETT automatically brings the tip towards the vocal cords as it was advanced. After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
2984841|NCT02664532|Other|Macintosh group|In Macintosh group, the curved blade was introduced to lift the base of the epiglottis to visualize larynx and then trachea intubated conventionally.After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
2984842|NCT02664519|Experimental|Exercise training followed by no exercise training|CKD subjects will be randomized to exercise training (to squeeze a tennis ball repeatedly for at least 30 min/day) or no exercise training for 28 days. Procedures in baseline visit will be repeated followed by cross over to alternate group for 28 days followed by repeat of baseline procedures.
2984843|NCT02664519|Experimental|No exercise training followed by exercise training|CKD subjects will be randomized to exercise training (to squeeze a tennis ball repeatedly for at least 30 min/day) or no exercise training for 28 days. Procedures in baseline visit will be repeated followed by cross over to alternate group for 28 days followed by repeat of baseline procedures.
2984844|NCT02664519|No Intervention|Normal Control|Control subjects without CKD will undergo baseline assessment as above.
2984845|NCT02664506|Experimental|Word repetition after a tiem delay|People with Aphasia and Short-Term Memory impairment will receive a behavioral treatment: Word repetition after a time delay. This is the intervention: repetition of words after a 5 or 10 second delay.
2984846|NCT02664493|Experimental|SPT group|"The patients who will show borderline change in 2-week protocol biopsy with stable graft function will be included in this study.~Methylprednisolone 0.5 g daily for 3 days will be administered in (Steroid pulse therapy) SPT group."
2984847|NCT02664493|No Intervention|non-SPT group|"The patients who will show borderline change in 2-week protocol biopsy with stable graft function will be included in this study.~Steroid pulse therapy (SPT) will not be applied and no additional treatment will be added in non-SPT group"
2984848|NCT02664480||study group|Reproductive age women with polycystic ovary syndrome and irregular menses (Salivary Alpha-amylase Levels of 3rd and 24th day of menstrual cyclus)
2984849|NCT02664480||control group|Reproductive age women with regular menses (Salivary Alpha-amylase level of 3rd and 24th day of menstrual cyclus)
2984850|NCT02664467|Experimental|Bright light therapy (BLT)|Bright light therapy (10'000 lux) for 30 minutes after wake-up using Philips EnergyUp EnergyLight HF3419/01
2984851|NCT02664467|Placebo Comparator|Placebo dim light|Placebo dim light (50 lux) for 30 minutes after wake-up using Philips EnergyUp EnergyLight HF3419/01
2984852|NCT02664454|Experimental|Systematic nurse-led GA|Interactive educational seminar for GPs and nurses, and focused on geriatric assessment in primary care combined with Systematic nurse-led GA and dedicated hotline for GPs seeking geriatric advice
2984853|NCT02664454|Experimental|GP-led GA on a case-by-case basis, as decided by the GP|Interactive educational seminar for GPs, and focused on Geriatric assessment in primary care combined with a GP-led GA on a case-by-case basis, as decided by the GP, and a dedicated hotline for GPs seeking geriatric advice
2984854|NCT02664454|No Intervention|No intervention|No educational seminar Usual care
2984855|NCT02664441|Active Comparator|Exenatide once weekly extended-release|Injections of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (Bydureon®) for 36 weeks in randomized intervention followed by 18 weeks open label exenatide once weekly extended-release.
2984856|NCT02664441|Placebo Comparator|Matching placebo|Weekly injections of placebo for 36 weeks followed by 18 weeks open label exenatide once weekly extended-release.
2984857|NCT02664428|Active Comparator|PREBIOIL TEST|Product tests prepared with olives flour, buckwheat flour, pea flour, chestnut flour, oil chemical leavening agents, salt, sucrose. Baked
2984858|NCT02664428|Placebo Comparator|CONTROL|Product control prepared with wheat flour, oil, chemical leavening agents, salt, sucrose. Baked
2984859|NCT02664415|Experimental|VRC01|Participants will receive an intravenous (IV) infusion of 40 mg/kg of VRC01 at Week 0 and every 3 weeks until Week 24 or until criteria for resumption of ART are met.
2984860|NCT02664415|Placebo Comparator|Placebo for VRC01|Participants will receive an IV infusion of placebo at Week 0 and every 3 weeks until Week 24 or until criteria for resumption of ART are met.
2984861|NCT02664389|Experimental|Genetic analysis of patient with early-onset breast cancer|Sequencing of 200 selected genes in patient with early-onset breast cancer without genomic alterations of BRCA1, BRCA2 or TP53
2984862|NCT02664389|Experimental|Genetic analysis of patient with early-onset ovarian cancer|Sequencing of 200 selected genes in patient with early-onset ovarian cancer without genomic alterations of BRCA1, BRCA2
2984863|NCT02664389|Experimental|Genetic analysis of patient with pediatric cancer|Sequencing of 200 selected genes in patient with pediatric cancer without genomic alteration of TP53
2984864|NCT02664389|Experimental|Genetic analysis of patient with early-onset colorectal cancer|Sequencing of 200 selected genes in patient with early-onset colorectal cancer without genomic alteration of APC, MUTYH, SMAD4, BMPR1A, PTEN or STK11 in case of adenomatous polyposis or hamartoma presentation or without genomic alteration of MSH2, MLH1 or MSH6 in case of HNPCC presentation
2984865|NCT02664389|Experimental|Genetic analysis of patient with multiple primary tumors|Sequencing of 200 selected genes in patient with Multiple primary malignant tumors without syndromic presentation
2984866|NCT02664376||Geriatric ward population|Every patient aged over 65 admitted in the unit 83 of the Geriatry Department, CHU Brugmann Hospital, undergoes a global geriatric evaluation at the end of its hospitalisation stay, including sarcopenia detection.
2984867|NCT02664363|Experimental|EGFRvIII CAR T cells|Dose escalation cohorts for 4 dose levels will be considered: #1: 4.5 x 10^6/kg, #2: 1.5 x 10^7/kg, #3: 4.5 x 10^7/kg, and #4: 1.5 x 10^8/kg. Starting at dose level 1, cohorts of 3-6 subjects will be accrued at each dose level.
2984959|NCT02663661|Other|Autoantibody negative subjects|Subjects who are relatives of persons with T1DM and have tested negative for autoantibodies will have a Metabolic Challenge Admission followed by a CGM home test.
2984960|NCT02663661|Other|One autoantibody subjects|Subjects who are relatives of persons with T1DM and have tested positive for one autoantibody will have a Metabolic Challenge Admission followed by a CGM home test..
2984868|NCT02664350|Experimental|Genotype Arm|Participants in this arm will have genotyping performed for CYP2D6 variants. Based on the CYP2D6 the treating physicians will be provided with an interpretation of genotype results, and a recommendation will be provided by a pharmacist on the UF Health Personalized Medicine team through one-on-one consultation with the physician for the type of pain medication. These participants will also be genotyped for OPRM1 variants at the end of the study which is performed for research purposes only. In addition, they will fill out the following questionnaires Brief Pain Inventory-Short Form (BPI-SF) and M.D. Anderson Symptom Inventory (MDASI).
2984869|NCT02664350|Active Comparator|Traditional Arm|Participants in this arm will have genotyping for CYP2D6 and OPRM1, however this information will not be provided to the physicians for treatment of the analgesic therapy but will be used for research purposes only. In addition, they will fill out the following questionnaires Brief Pain Inventory-Short Form (BPI-SF) and M.D. Anderson Symptom Inventory (MDASI).
2984870|NCT02664337|Experimental|Decision tool|"A decision tool will be provided to participants who currently or previously have had one of the following 12 musculoskeletal conditions: hip arthritis, knee arthritis, ankle arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus."
2984871|NCT02664337|Active Comparator|Standard treatment information|"Standard treatment information will be provided to participants who currently or previously have had one of the following 12 musculoskeletal conditions: hip arthritis, knee arthritis, ankle arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus."
2984872|NCT02664311|Placebo Comparator|Conventional Ventilation|Patients receiving conventional ventilation for the duration of this study
2984873|NCT02664311|Active Comparator|Jet Ventilation|Patients receiving Jet ventilation while under general anesthesia and during mapping and ablation in the left atrium
2984874|NCT02664285|Other|closure of subcutaneous tissue|in diabetic patients, the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section.
2984875|NCT02664285|Other|No closure of subcutaneous tissue|in diabetic patients, the subcutaneous fat will not sutured after cesarean section.
2984876|NCT02664259|Experimental|UTB-VBN-EBUS group|Bronchoscopes with a 3.0-mm distal end diameter and a 1.7-mm working channel diameter are used (BF-Y0058;Olympus).The EBUS probe is confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
2984877|NCT02664259|Active Comparator|UTB-VBN-EBUS-X-ray group|Bronchoscopes with a 3.0-mm distal end diameter and a 1.7-mm working channel diameter are used (BF-Y0058;Olympus).The EBUS probe is confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained under fluoroscopic guidance.
2984878|NCT02664233|Experimental|Connected group|Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
2984879|NCT02664233|No Intervention|Usual diabetes education and care|Participants will receive standard diabetes education and care; each of the recruiting clinics offers diabetes self-management education programs.
2984880|NCT02664220|Experimental|Povidone-iodine irrigation|
2984881|NCT02664220|Active Comparator|No irrigation|
2984882|NCT02664207|Experimental|Fetal Surgery in Women with ex|"Fetal myelomeningocele repair surgery will be offered to pregnant women meeting the criteria for surgery (as set by the MOMS trial) with the exception of the following:~a BMI greater than 35 (but less than or equal to 40 kg/m2)~(minor) Fetal structural abnormality~(well-controlled) Diabetes~Previous preterm delivery (followed by a full term delivery)~Maternal red cell alloimmunization (must NOT be associated with fetal disease, OR fetus must have negative red cell antigen status as determined by amniocentesis).~Intervention: Open Fetal Repair of Myelomeningocele"
2984883|NCT02664194|Active Comparator|Control Group|Primary percutaneous coronary intervention only
2984884|NCT02664194|Experimental|03 Hours Hypothermia Group - Proteus® Cooling System|03 hours of intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters using Proteus® Cooling System.
2984885|NCT02664194|Experimental|01 Hour Hypothermia Group - Proteus® Cooling System|01 hour of intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters using Proteus® Cooling System.
2984886|NCT02664181|Experimental|Oral THU/decitabine + Nivolumab|Oral THU ~10 mg/kg, followed by oral decitabine ~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days. This drug combination is administered with Nivolumab 3mg/kg IV Q2 weeks until progression
2984887|NCT02664181|Active Comparator|Nivolumab|Nivolumab 3mg/kg IV Q2 weeks until progression; This is the standard of care for patients with NSCLC who have progressed on prior chemotherapy.
2984888|NCT02664168|Active Comparator|Aquacel Ag Surgical Dressing|
2984889|NCT02664168|Active Comparator|Single-Use Negative Pressure Wound Therapy (PICO)|
2984890|NCT02664155|Experimental|DOA : Direct Oral Anticoagulants|"The experimental group receiving DOA regimens: patients will be secondarily randomly assigned within DOAs group between:~Apixaban (Eliquis® tablet) 10 mg bid for 7 days then 2.5 mg bid for 3 months~Rivaroxaban (Xarelto® tablet) 15 mg bid for 21 days then 15 mg od for 3 months."
2984891|NCT02664155|Active Comparator|SOC : Standard Of Care|The control group receiving the standard of care (SOC), i.e. heparins/VKA regimen. Patients will receive the current recommended therapy: subcutaneous or intravenous UFH/VKA in case of severe renal insufficiency and subcutaneous LMWH/VKA in case of moderate renal insufficiency for at least 5 days. VKA will begin concomitantly and continue for 3 months.
2984961|NCT02663661|Other|Two or more autoantibody subjects|Subjects who are relatives of persons with T1DM and have tested positive for two or more autoantibodies will have a Metabolic Challenge Admission followed by a CGM home test..
2984962|NCT02663635|Other|Single Arm|
2985217|NCT02661854|Experimental|MM09 Mannosylated 10.000 sublingual|10.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
2984892|NCT02664142|Experimental|BIS Group|"BIS monitor will be used during the GA monitoring, the BIS value will be known to the anaesthetist (investigator)~GA induction (Phase 1):~inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or~intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)~anaesthesia (Phase 2, Phase 3):~hypnotic component: titration of Sevorane concentration, with the aim of achieving the BIS values of 40-60%, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)~analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)~relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) Patients in this group will be administered anaesthetic, in order to achieve and maintain the required general anaesthesia."
2984893|NCT02664142|Experimental|Non-BIS Group|"BIS monitor will be used during the GA monitoring, however the BIS value will not be known to the anaesthetist (investigator)~GA induction (Phase 1):~inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or~intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)~anaesthesia (Phase 2, Phase 3):~hypnotic component: titration of Sevorane concentration, with the aim of achieving the MAC value appropriate for the age of the child, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)~analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)~relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) Patients in this group will be administered anaesthetic, in order to achieve and maintain the required general anaesthesia."
2984894|NCT02664129|Experimental|Experimental group with video|30 patients will watch the video of them in acute decompensation phase
2984895|NCT02664129|Sham Comparator|Control group without video|30 patients will not watch the video of them in acute decompensation phase, they pass a standard interview with psychometric scales
2984896|NCT02664116|Experimental|Cambia|Diclofenac postassium powder for oral solution and placebo injection
2984897|NCT02664116|Active Comparator|ketorolac|ketorolac intramuscular injection and placebo oral solution
2984898|NCT02664103|Experimental|SAR439281(Cohort 1)|Regimen 1: one full-dose tablet containing capecitabine and cyclophosphamide, given BID without interruption
2984899|NCT02664103|Experimental|SAR439281(Cohort 2)|Regimen 2: two tablets containing capecitabine and cyclophosphamide, given OD without interruption
2984900|NCT02664103|Experimental|SAR439281(Cohort 3)|Regimen 3: one tablet containing capecitabine and cyclophosphamide, given OD without interruption
2984901|NCT02664077|Experimental|Group 1: Regorafenib|Patients receive regorafenib orally once daily for 21 days of a 28 day cycle for a total of 26 cycles.
2984902|NCT02664077|Placebo Comparator|Group 2: Placebo|Patients receive placebo orally once daily for 21 days of a 28 day cycle for a total of 26 cycles.
2984903|NCT02664064|Experimental|online Diabetes Prevention Program|Participants will receive access to a 12-month online diabetes prevention program modeled after the CDC DPP curriculum. Participants receive online curriculum, access to a live health coach, interactive group message forums, and connected weight and activity monitoring devices.
2984904|NCT02664064|No Intervention|Matched Control|A de-identified dataset of control subjects matched on age, gender, prediabetes diagnosis, body mass index, comorbidities and socioeconomic status will be cultivated for comparison to the active intervention arm.
2984905|NCT02664051|Placebo Comparator|placebo|mannitol
2984906|NCT02664051|Active Comparator|disodium cromoglycate|disodium cromoglycate
2984907|NCT02664038|Experimental|CRT+IDC|Cognitive Remediation Therapy for 13 weeks plus Individual Drug Counseling
2984908|NCT02664038|Active Comparator|Computer Game Play+IDC|Computer arcade games for 13 weeks plus Individual Drug Counseling
2984909|NCT02664025|Active Comparator|simulation group|Interns will carry out 10 VE on a simulator
2984910|NCT02664025|No Intervention|Control group|Interns who will not perform any simulated VE
2984911|NCT02664012|Active Comparator|Own Brand Menthol Cigarette|Own Brand Menthol Cigarette
2984912|NCT02664012|Experimental|Electronic Menthol Cigarette #1|VUSE® (menthol flavor, 14 mg nicotine)
2984913|NCT02664012|Experimental|Electronic Menthol Cigarette #2|VUSE® (menthol flavor, 29 mg nicotine)
2984914|NCT02664012|Experimental|Electronic Menthol Cigarette #3|VUSE® (menthol flavor, 36 mg nicotine)
2984915|NCT02664012|Active Comparator|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
2984916|NCT02663999|Experimental|diazepam nasal spray (AB)|Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses. The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).
2984917|NCT02663999|Experimental|diazepam nasal spray (BA)|Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses. The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).
2984918|NCT02663986|Experimental|Organizational Skills Training (OST) Intervention|"To improve children's organizational functioning, OST focuses on four key skills.~Tracking Assignments~Managing Materials~Time Management~Task Planning"
2984919|NCT02663960|Experimental|fixed citrate doses protocol|Fixed citrate doses protocol: Anticoagulant Citrate Dextrose Solution ( Na+ 224, citrate 113, bicarbonate 203mmol/l, Fresenius Kabi, Italy) was administered in the prefilter ahead of the blood pump, which was set to meet a circuit citrate concentration of 4 mmol/l (duration: the maximum time is 72 hrs).
2984920|NCT02663960|Active Comparator|adjusted citrate doses protocol|Adjusted citrate doses protocol: Anticoagulant Citrate Dextrose Solution ( Na+ 224, citrate 113, bicarbonate 203mmol/l, Fresenius Kabi, Italy) was administered in the prefilter ahead of the blood pump, which the starting infusion rate be set 2.5 % of blood flow ( dosage range: 160-250ml/h) and then be adjusted to obtain postfilter ionized calcium levels of less than 0.40 mmol/l (duration: the maximum time is 72 hrs. )
2984921|NCT02663947||ultrasound group|ultrasonographic measure for optic nerve sheath diameter
2984963|NCT02663622|Experimental|Prophylaxis (CD24Fc)|CD24Fc (480 mg (day -1), 240 mg (day +14) and 240 mg (day +28)) + Tacrolimus (begin on day -3. IV [0.03mg/kg/day] or PO [0.045mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/m2/dose once daily on Day 1 after HCT, and at a dose of 10 mg/m2/dose on days 3, 6, and 11 after HCT)
2985218|NCT02661854|Experimental|MM09 Mannosylated 30.000 sublingual|30.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
2984922|NCT02663934|Experimental|Exercise (EXS)|All EXS sessions will be at an exercise facility at the WUSTL medical campus. Sessions will be offered weekdays. Each session will start with range of motion exercises. Participants will follow an individualized exercise training prescription based on baseline cardiovascular testing. Individual aerobic exercise intensity is based on % of maximum heart rate achieved during the baseline cardiorespiratory fitness test. The target exercise HR will start at 50% and progress to 85% HR reserve. During aerobic exercise, a battery-operated HR monitor will monitor HR. Exercise intensity & duration will be increased as the participant acclimates to the exercise prescription. Adaptation is determined when a given exercise intensity yields a lower HR than prior sessions conducted at the same intensity.
2984923|NCT02663934|Active Comparator|Social Interaction Stretching (SIS)|This group will serve as a control group against which to gauge the effects of aerobic and resistance training on cognitive function. Participants in this group will follow the same schedule and format as the EXS group. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program. These SIS participants will receive instructions on stretching, range of motion, limbering, and toning; but the intensity will be far less than that achieved in the EXS classes. Activities will focus on flexibility enhancement. As the participant's level of flexibility increases, stretches with increasing levels of difficulty will be incorporated into the program.
2984924|NCT02663921|Experimental|Healthy volunteers|Healthy volunteers without cutaneous disorders associated with pigmentary changes
2984925|NCT02663908|Experimental|Degarelix|
2984926|NCT02663908|Active Comparator|Leuprolide|
2984927|NCT02663895|Experimental|Oral treprostinil|Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated for 12 months
2984928|NCT02663882|Experimental|smoking-related self control task|self control practice - smoking related task
2984929|NCT02663882|Active Comparator|Non-smoking-related self control task|self control practice - non-smoking related task
2984930|NCT02663869||HIV Aging-Young|200 patients
2984931|NCT02663869||HIV Aging-Old|200 patients
2984932|NCT02663869||controls|1200 patients
2984933|NCT02663843|Experimental|i-gel airway|I-gel inserted for the low skill fibreoptic intubation technique
2984934|NCT02663843|Experimental|air-Q airway|Air-Q inserted for the low skill fibreoptic intubation technique
2984935|NCT02663830|Experimental|(Sildenafil & clomiphene citrate group)|105 Patients will receive 25 mg sildenafil citrate 6 hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
2984936|NCT02663830|Active Comparator|clomiphene only|105 patients will receive only clomiphene citrate 100mg/day (day 2 to 6) orally (2 tablets at same time daily).
2984937|NCT02663817|Experimental|Group 1 - 3DCRT, VMAT, or IMRT|Study participants being treated according to the standard of care with either three-dimensional conformal radiotherapy (3DCRT), intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT). Several CT scans will be performed for each enrolled subject: one before the radiotherapy course for patient treatment planning purposes (as part of the standard of care), one during the radiotherapy treatment course (between fraction 10 and 20 for 3DCT, IMRT or VMAT patients), and one at follow up visit or at least 6 weeks post-radiotherapy treatment (whichever comes first).
2984938|NCT02663817|Experimental|Group 2 - SBRT|Study participants being treated according to the standard of care with Stereotactic Body Radiotherapy (SBRT). Several CT scans will be performed for each enrolled subject: one before the radiotherapy course for patient treatment planning purposes (as part of the standard of care), one during the radiotherapy treatment course (after fraction 3 for SBRT patients), and one at follow up visit or at least 6 weeks post-radiotherapy treatment (whichever comes first).
2984939|NCT02663804|Active Comparator|Implant design 1|Journey II, BCS, Smith&Nephew
2984940|NCT02663804|Active Comparator|Implant design 2|Persona, Zimmer
2984941|NCT02663804|Active Comparator|Implant design 3|Unity, Corin
2984942|NCT02663778|Active Comparator|Standard|The standard arm consists of strength, endurance and flexibility exercises 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
2984943|NCT02663778|Experimental|Standard-plus|The standard-plus arm consists of strength, endurance and flexibility exercises plus task specific timing and coordination exercises to improve gait 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
2984944|NCT02663752|Other|Deferasirox|All patients are already on commercial deferasirox before entering the study.
2984945|NCT02663739||Aortic Dissection|Treating patients with acute complicated Stanford Type B aortic dissection with the Zenith® TXD
2984946|NCT02663726|Experimental|Yoga intervention group|10 weekly 75-min sessions of specialised yoga plus written advice about physical activity for older adults
2984947|NCT02663726|Active Comparator|Waiting list control group|Usual care plus written advice about physical activity for older adults
2984948|NCT02663713|Experimental|Ticagrelor|Ticagrelor 60 mg twice daily
2984949|NCT02663713|Active Comparator|Clopidogrel|Clopidogrel 75 mg once daily
2984950|NCT02663700|Experimental|1.8x10^6 sporozoites 2 doses|To be completed after safety data from Cohorts 1 and 2 are reviewed. Vaccination with 1.8x10^6 sporozoites on study weeks 3 and 11. n=8
2984951|NCT02663700|Experimental|2.7x10^6 sporozoites 2 doses|To be completed after safety data from Cohort 3 is reviewed. Vaccination with 1.8x10^6 sporozoites on study weeks 5 and 13. n=8
2984952|NCT02663700|Experimental|2.7x10^6 sporozoites 3 doses|Subjects to be assigned 1:1 to either PfSPZ vaccine (pending safety data from cohort 4) or placebo. Subjects will be administered the intervention on a 0, 8, and 16 week schedule (study days 1, 57, and 113). n=80
2984953|NCT02663700|Experimental|4.5x10^5 sporozoites 2 doses|Initial vaccination arm. Vaccination with 4.5x10^5 sporozoites on study weeks 1 and 9. n=8
2984954|NCT02663700|Experimental|9x10^5 sporozoites 2 doses|Initial vaccination arm. Vaccination with 9x10^5 sporozoites on study weeks 1 and 9. n=8
2984955|NCT02663687|Experimental|Treatment 1- 4|Treatment A: 9 Subjects will receive dose level I of SHP623 intravenously (IV). B: 9 Subjects will receive dose level I of SHP623 subcutaneously(SC).
2984956|NCT02663687|Placebo Comparator|Placebo|3 Subjects will receive placebo for each cohort
2984957|NCT02663674|Placebo Comparator|Group 1|A single dose of Fluconazole placebo (2 capsules) administered orally once daily for 42 days starting on Day 1. N=500
2984964|NCT02663622|Placebo Comparator|GVHD Prophylaxis|Placebo + Tacrolimus (begin on day -3. IV [0.03mg/kg/day] or PO [0.045mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/m2/dose once daily on Day 1 after HCT, and at a dose of 10 mg/m2/dose on days 3, 6, and 11 after HCT)
2984965|NCT02663596|Experimental|Vancomycin|Patients with vancomycin mixed in the CRRT solution(s)
2984966|NCT02663583||Intensity-Modulated Proton Therapy or( IMPT) Group|"Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.~Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.~Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits."
2984967|NCT02663583||TransOral Robotic Surgery (TORS) Group|"Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months.~Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months.~Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits."
2984968|NCT02663570|Experimental|open|therapy with melatonin 2 mg daily for six months
2984969|NCT02663557||non-hypertension with lower BPV|patients meeting to flowing two criteria: 1. mean SBP<140 mmHg; 2. Systolic blood pressure-coefficient variation (SBP-CV) < Median SBP-CV
2984970|NCT02663557||non-hypertension with higher BPV|patients meeting to flowing two criteria: 1. mean SBP< 140 mmHg; 2. SBP-CV > Median SBP-CV
2984971|NCT02663557||hypertension with lower BPV|patients meeting to flowing two criteria: 1. mean SBP> 140 mmHg; 2. SBP-CV < Median SBP-CV
2984972|NCT02663557||hypertension with higher BPV|patients meeting to flowing two criteria: 1. mean SBP> 140 mmHg; 2. SBP-CV > Median SBP-CV
2984973|NCT02663544|Active Comparator|Limited dairy diet|Three 8 oz. servings per week of non-fat milk. Participants will otherwise eat their usual diet, but will be asked not to consume any dairy products not provided by the study.
2984974|NCT02663544|Experimental|Low-fat dairy diet|3.3 daily servings of non-fat and low-fat dairy products in the form of fluid milk, cheese and yogurt. Participants will otherwise eat their usual diet, and will be asked not to consume any dairy products not provided by the study.
2984975|NCT02663544|Experimental|Full-fat dairy diet|3.3 daily servings of full-fat dairy products in the form of fluid milk, cheese and yogurt. Participants will otherwise eat their usual diet, and will be asked not to consume any dairy products not provided by the study.
2984976|NCT02663531|Experimental|Mild cognitive impairment|Patients with mild cognitive impairment
2984977|NCT02663531|Experimental|Alzheimer Disease|Patients with Alzheimer Disease
2984978|NCT02663531|Experimental|Healthy|Healthy volunteers
2984979|NCT02663518|Experimental|TTI-621 Escalation Phase|The Escalation Phase will include multiple doses of TTI-621
2984980|NCT02663518|Experimental|Indolent B-Cell Lymphoma|Monotherapy expansion cohort with TTI-621
2984981|NCT02663518|Experimental|Aggressive B-Cell Lymphoma|Monotherapy expansion cohort with TTI-621
2984982|NCT02663518|Experimental|T-Cell Lymphoma|Monotherapy expansion cohort with TTI-621
2984983|NCT02663518|Experimental|Hodgkin Lymphoma|Monotherapy expansion cohort with TTI-621
2984984|NCT02663518|Experimental|Chronic Lymphocytic Leukemia|Monotherapy expansion cohort with TTI-621
2984985|NCT02663518|Experimental|Acute Lymphoblastic Leukemia|Monotherapy expansion cohort with TTI-621
2984986|NCT02663518|Experimental|Multiple Myeloma|Monotherapy expansion cohort with TTI-621
2984987|NCT02663518|Experimental|Acute Myeloid Leukemia|Monotherapy expansion cohort with TTI-621
2984988|NCT02663518|Experimental|Myelodysplastic Syndrome|Monotherapy expansion cohort with TTI-621
2984989|NCT02663518|Experimental|Myeloproliferative Neoplasms|Monotherapy expansion cohort with TTI-621
2984990|NCT02663518|Experimental|Small Cell Lung Cancer|Monotherapy expansion cohort with TTI-621
2984991|NCT02663518|Experimental|Rituximab Combination|Combination therapy expansion cohort with TTI-621 plus Rituximab for CD20 positive malignancies
2984992|NCT02663518|Experimental|Nivolumab Combination|Combination therapy expansion cohort with TTI-621 plus Nivolumab for Hodgkin Lymphoma
2984993|NCT02663518|Experimental|Cutaneous T-Cell Lymphoma (CTCL)|Monotherapy expansion cohort with TTI-621
2984994|NCT02663518|Experimental|Peripheral T-Cell Lymphoma (PTCL)|Monotherapy expansion cohort with TTI-621
2984995|NCT02663505||Group 1|Patients receiving either elective or emergency surgery.
2984996|NCT02663492|Experimental|TEAS group|Patients with transcutaneous electrical acupoint stimulation (TEAS) group receive electrical stimulation of acupoints including Dazhui (DU14), Geshu (BL17), Zusanli (ST36), Sanyinjiao (SP6), and Hegu (LI4).
2984997|NCT02663492|Active Comparator|Medication group|On the basis of routine nursing care, patients need to take Sanguisorba officinalis L., named Diyu Shengbai Pian (a Traditional Chinese Medicine) 3 times per day.
2984998|NCT02663492|No Intervention|Control group|The patients of control group receive routine nursing care, including (1) to be observed the changes in patient condition, (2) to eat high-calories, high-protein, high-vitamin, easy-to-digest foods during chemotherapy, (3) to be treated by psychological care, (4) to be prevented against the occurrence of phlebiti, and (5) to use Ondansetron and Omeprazole as direction.
2984999|NCT02663479|Experimental|Cardiopressin|A 5 capsule proprietary blend of herbal extracts and nutrients
2985000|NCT02663479|Placebo Comparator|Placebo|A 5 capsule placebo matched in color and size to the Experimental supplement
2985001|NCT02663466||Recurrent Group|Patients with clinically confirmed recurrence of sacrococcygeal pilonidal sinus following Limberg flap surgery were eligible (recurrent group, RG). They were evaluated for erroneous off-midline closures as an exposure variable.
2985002|NCT02663466||Nonrecurrent Group|Patients who underwent same surgery from the January 2008 to July 2015 but have not had recurrence in the five-year follow-up period (non-recurrent group, NRG) were accepted eligible. They were evaluated for erroneous off-midline closures as an exposure variable.
2985028|NCT02663219|Experimental|Intervention|The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.
2985029|NCT02663219|No Intervention|Control|Standard of care
2985003|NCT02663453|Experimental|study group|multicomponent lipid emulsion composed of 30% soybean oil, 30% MCTs, 25% olive oil and 15% fish oil (SMOF lipid) was administered at a dose of 1gm/kg/day within 24 hours after birth; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.The macronutrients and micronutrients were provided using the same products in both groups.
2985004|NCT02663453|Active Comparator|control group|pure soybean oil lipid emulsion(intralipid) was administered at a dose of 1gm/kg/day within 24 hours after birth; lipid dosage was increased by an increment of 0.5gm/kg/day until the maximal dose of 3.5gm/kg/day was reached.The macronutrients and micronutrients were provided using the same products in both groups.
2985005|NCT02663440|Experimental|IMRT|Hypofractionated IMRT With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor
2985006|NCT02663427|Experimental|PG(-) and Hp(-) Group|PG negative （pepsinogen（PG）Ⅰ > 70ng/ml or PGⅠ/PGⅡ >7.0）and Hp (helicobacter pylori) negative. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
2985007|NCT02663427|Experimental|PG(-) and Hp(+) Group|PG negative and Hp positive. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
2985008|NCT02663427|Experimental|PG(+) and Hp(-) Group|PG positive (PGⅠ ≤ 70ng/ml and PGⅠ/PGⅡ≤7.0) and Hp negative. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
2985009|NCT02663427|Experimental|PG(+) and Hp(+) Group|PG positive and Hp positive. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
2985010|NCT02663414|Experimental|Atlas device|Each patient in this arm will receive the Atlas Knee System device on the medial side of the symptomatic knee.
2985011|NCT02663401|No Intervention|Control|Control situation in campus cafeterias where no labelling of food is proposed
2985012|NCT02663401|Experimental|Front-of-pack labelling (5-CNL)|Introduction of the 5-CNL front-of-pack nutrition label on shelf display tags for every food and beverage sold in the campus cafeteria. Communication campaigns accompanying the introduction of the label
2985013|NCT02663375||ACURATE TA™ Transapical Aortic Biorposthesis|Patients implanted with ACURATE TA™ Transapical Aortic Biorposthesis and Delivery System
2985014|NCT02663349|Experimental|Supported SCIT|Social Cognition and Interaction Training is a manualized intervention that focuses on emotion recognition training, perspective taking, and strategies to avoid jumping to conclusions. One hour group sessions will be offered twice a week for 12 weeks. In addition, one hour of individual training will be provided weekly by an instructor.
2985015|NCT02663336||CKD patients|Patients with chronic kidney disease, with diagnosed arterial hypertension and normal blood pressure during office blood pressure measurement. Comparison of ambulatory blood pressure (ABPM) with office blood pressure measurements (OBPM).
2985016|NCT02663323|Experimental|MeRes100 - BRS|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System
2985017|NCT02663310|Experimental|Surgery with Rehabilitation|Surgically removed cysts, and collected intracystic fluids and cerebrospinal fluid for histological and molecular analyses. Samples will be collected during the surgery and will be cryo-protected for further analyses. All subjects will enroll for intensive rehabilitation 60 days after surgery.
2985018|NCT02663310|Active Comparator|Rehabilitation|All subjects will enroll for intensive rehabilitation everyday as instruction.
2985019|NCT02663297|Experimental|ATLCAR.CD30 cells|"Three dose levels of ATLCAR.CD30 cells will be evaluated. Using the modified continual reassessment method (CRM), initial cohort of size two will be enrolled at each dose level after that subjects are enrolled one at a time until a minimum of 12 patients is treated. Each patient will receive one injection according to the dosing schedules listed below. Investigators will start with the lowest cell dose (2X10^7 cells/m^2) given to patients in one of our previous trials employing CAR-T cells including the CD28 costimulatory endodomain, and investigators will escalate the cell dose to the highest cell dose (2X10^8/m^2) given in the same trial.~Note: Initially, only adults will be enrolled during the dose escalation phase of the study. Once a dose level has been tested in at least 2 adults without the occurrence of dose limiting toxicities (DLTs), children may then be enrolled on that dose level according to the CRM."
2985020|NCT02663284|Experimental|Perineural block|Perineural block with Ropivacaine 0.5%
2985021|NCT02663271|Experimental|Optune+Pulsed Bevacizumab|The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI.
2985022|NCT02663271|Other|Historical Controls|Historical controls treated with continuous bevacizumab alone or in combination with standard chemotherapy will be compared with the Optune arm. Information will be collected: Bevacizumab or additional chemotherapy, physical examination and quality of life questionnaires performed and brain MRI.
2985023|NCT02663258|Experimental|Pembrolizumab arm|All participants treated with Pembrolizumab, 200mg iv, 3weekly
2985024|NCT02663245|Experimental|Intervention 1|Diabetes specific consultation + multicomponent intervention aimed at professionals and patients
2985025|NCT02663245|Experimental|Intervention 2|Multicomponent intervention aimed at professionals and patients minus the diabetes specific consultation.
2985026|NCT02663245|No Intervention|Control group|No intervention. Data of the control groups will be retrieved from the SIDIAP.
2985027|NCT02663232||Metastatic melanoma|Participants with metastatic melanoma who attend their physicians during the 18-month recruitment period and have valid biological samples available for BRAF mutation testing will be included in the study. There will be no intervention in this study.
2985030|NCT02663206|Other|Botulinum toxin injection|"Drug/Device: Botulinum toxin injection; Endoscopic Botulinum toxin (BTX) injection at lower esophagus; Upper endoscopy with Botulinum toxin injection.~The procedure will be performed as an outpatient basis by an endoscopist. Sedation can be in form of conscious sedation, monitored anesthesia care or general anesthesia. An upper endoscope will be inserted into the patient's mouth and advanced into lower esophagus. Botulinum toxin (Botox@) 100 units 8-10 (25 units/mL) will be injected in 1-ml portion in each of four quadrants about 1 cm above the Z-line (the LES region).~At 1 month follow-up, patients who do not response to the first botox injection (Eckardt score > 3) will receive the second botox injection.~At 3-month follow-up, POEM will be offered as a rescue therapy to both non-responders (Eckardt score > 3 at 3-month follow-up after the procedure) and relapsers (Eckardt score ≤ 3 at 3-month follow-up but becomes > 3 during the follow-up)"
2985031|NCT02663206|Other|peroral endoscopic myotomy|"Procedure/Surgery: peroral endoscopic myotomy.~The procedure will be performed by an endoscopist (gastroenterologist or surgeon). General anesthesia will be started and upper endoscope will be inserted into the patient's mouth and advanced into the stomach. Endoscopic myotomy will be performed. Mucosal entry will then be closed using endoscopic clips or endoscopic suturing.~All patients will recover from their procedures according to standard practice. They will remain nothing per oral (NPO) the night after the procedure and started on intravenous proton pump inhibitors. A gastrografin esophagram will be obtained the next day and if no evidence of leak, the diet will be advanced to a soft diet for two weeks. The patients will be evaluated by study coordinator/PI on a daily basis during their hospitalization."
2985032|NCT02663193||Enzalutamide Group|Participants who are receiving enzalutamide in a clinical practice setting will be observed for tolerability and quality of life.
2985033|NCT02663193||Abiraterone Acetate plus Prednisone group|Participants who are receiving abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
2985034|NCT02663180|Experimental|Intervention group|they will be enrolled in an educational program and video contact.
2985035|NCT02663180|No Intervention|Control group|No intervention
2985036|NCT02663167|Experimental|Internet-delivered Cognitive-Behavioral Therapy|
2985037|NCT02663154|Experimental|Aromatherapy|Aromatherapy inhaler (QueaseEASE, Soothing Scents Inc, Enterprise, AL) applied to nauseous post surgical paediatric patients in the postanesthetic care unit
2985038|NCT02663154|Placebo Comparator|Placebo|Saline inhaler applied to nauseous post surgical paediatric patients in the postanesthetic care unit
2985039|NCT02663141|Experimental|Losartan|Oral losartan 50 mg daily for 6 months
2985040|NCT02663141|Placebo Comparator|Placebo|Oral placebo daily for 6 months
2985041|NCT02663128|Experimental|Lanabecestat Reference Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
2985042|NCT02663128|Experimental|Lanabecestat Test Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
2985043|NCT02663128|Experimental|Lanabecestat Test Non Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
2985044|NCT02663115||Arm 1|Patients (age 40 - 70 years) with severe therapy-refractory heart failure caused by ischemic or dilatative myocardiopathy with indication for left ventricular assist device (LVAD) therapy
2985045|NCT02663115||Arm 2|Patients (age 40-70 years) with the indication for elective bypass surgery and normal left ventricular function (EF>50%)
2985046|NCT02663102||Fluarix Tetra Group|Subjects aged 3 years and above who will receive Fluarix Tetra as per locally approved PI (which is not part of the drug use investigation).
2985047|NCT02663089|Experimental|[14C]-GSK961081 IV+GSK961081 inhalation; [14C]-GSK961081 oral|On Day 1 of Treatment Period 1, after an overnight fast of at least 8 hours, each subject will receive [14C] GSK961081 4 micrograms (mcg) by IV infusion over 1 hour. Within 5 minutes after the start of infusion, subjects will take 1200 mcg non-radiolabelled GSK961081 by inhalation. After Treatment Period 1, there will be a washout of at least 2 weeks. On Day 1 of Treatment Period 2, after an overnight fast of at least 8 hours, each subject will take 200 mcg [14C]-GSK961081 as an oral solution.
2985048|NCT02663076||VKA - Vitamin K antagonist group|VKAs used in correspondence with the national guidelines for therapy of NVAF in Germany, Austria and Switzerland
2985049|NCT02663076||Rivaroxaban group|Rivaroxaban used in correspondence with the national guidelines for therapy of NVAF in Germany, Austria and Switzerland
2985050|NCT02663076||noAC group|noAC used in correspondence with the national guidelines for therapy of NVAF in Germany, Austria and Switzerland
2985051|NCT02663063|Experimental|SSP treatment group|Case on SSP treatment
2985052|NCT02663063|Sham Comparator|Non-SSP treatment group|Sham SSP treatment
2985053|NCT02663050|Experimental|Kinesio taping group|only Kinesio taping treatment group
2985054|NCT02663050|Active Comparator|NSAID treatment group|only NSAIDs taking group
2985055|NCT02663050|Active Comparator|Combination treatment group|NSAIDs plus Kinesio taping group
2985056|NCT02663037||1|"Subjects will be recruited from a pool of elderly patients who present to the Emergency Department.~To be eligible for participation in the study, patients must meet ALL of the following criteria:~Age ≥ 55 years old~Triaged as P2 or P3 in the Emergency Department~Singapore citizen or Permanent Resident~Provision of Informed consent~Not previously already enrolled in this study"
2985057|NCT02663024|Experimental|Arm 1|0.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
2985058|NCT02663024|Experimental|Arm 2|1.0 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
2985059|NCT02663024|Experimental|Arm 3|1.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
2985060|NCT02663024|Active Comparator|Arm 4|0.5mg/kg, iv, weekly infusion of idursulfase for 24 weeks
2985061|NCT02663011||5YR boy|
2985062|NCT02663011||5YR girl|
2985063|NCT02663011||4YR boy|
2985064|NCT02663011||4YR girl|
2985065|NCT02663011||3YR boy|
2985066|NCT02662985|Active Comparator|Group 1|"In Treatment Period-1:~Patients in this group will be administered secukinumab with 12 weeks of treatment from baseline.~In Treatment Period-2:~Patients will continue to receive the same active dose of secukinumab every 4 weeks until Week 24~In Treatment Period 3 (extension period):~the extension period is to allow responder patients the possibility to continue open-label secukinumab treatment up to Week 52"
2985146|NCT02662387|Active Comparator|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
2985067|NCT02662985|Placebo Comparator|Group 2|"In Treatment Period-1:~Patients will receive placebo at baseline and same time points as secukinumab until Week 8.~In Treatment Period-2:~Patients will commence open-label secukinumab every 4 weeks from Week 12, as follows, based on their clinical characteristics at Week 12~In Treatment Period-3:~Open-label secukinumab will continue to be assigned to patients"
2985068|NCT02662972|Experimental|Botulinum Toxin|The patients will be injected with 25 IU of Botulinum Toxin Type A towards the sphenopalatine ganglion in the affected side (ipsilateral to the pain)
2985069|NCT02662959|Experimental|Irinotecan|In the experimental arm, patients receive single agent of irinotecan as third line treatment in metastatic gastric cancer.
2985070|NCT02662946|Experimental|ICG- angiography|"Colonic resection margins and colo-rectal anastomosis are intraoperatively assessed using fluorescence angiography to evaluate colonic perfusion. If perfusion at the resection margin is judged insufficient the colon is re-resected to obtain a satisfactory perfusion"
2985071|NCT02662946|Active Comparator|No angiography|Subjective measures are employed to determine anastomotic perfusion
2985072|NCT02662933|Experimental|Bedside Assessment Measures|"The study intervention consists of a bedside functional assessment to be administered to eligible, consented subjects who are hospitalized with a new diagnosis of AML or are undergoing workup for suspected AML diagnosis. All subjects will be enrolled within 5 days of admission to the hospital for known or suspected AML or within 5 days of new confirmed diagnosis of AML obtained during a hospitalization for other indications. All measures will be performed by a trained examiner during a face to face interview.~Bedside assessment measures will be repeated once for subjects who complete induction chemotherapy within 2-8 weeks post discharge from initial hospitalization."
2985073|NCT02662907|Experimental|Aspirators Group|"Participants receive modified barium swallow at baseline and after 8 weeks of using the expiratory muscle strength training (EMST) device. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.~Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.~Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device."
2985074|NCT02662907|Other|Non-Aspirators Group|Participants receive modified barium swallow at baseline. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline and at 12 months.
2985075|NCT02662894|Experimental|Valsartan 160mg + Rosuvastatin 20mg|Fixed-dose combination of valsartan (160mg) + rosuvastatin (20 mg), oral, once daily.
2985076|NCT02662894|Experimental|Valsartan 320mg + Rosuvastatin 20mg|Fixed-dose combination of valsartan (320 mg) + rosuvastatin (20 mg), oral, once daily.
2985077|NCT02662894|Active Comparator|Diovan® 160mg + Crestor® 20mg|Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
2985078|NCT02662894|Active Comparator|Diovan® 320mg + Crestor® 20mg|Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
2985079|NCT02662855|Active Comparator|Control|WHO-recommended therapies, mainly symptomatic and supportive treatments. Briefly: body fluid management (intravenous or oral, depending on patient status), balanced nutrition (including glucose, electrolytes, vitamin, et al.), preventing intravascular volume depletion, correcting profound electrolyte abnormalities, avoiding the complications of shock, defervesce, anti-diarrheal, acesodyne, anti-anxiety. For patients with positive Plasmodium detection or bacterial infection, apply artemether-lumefantrine or antibiotics respectively. Details refer to 'Manual for the care and management of patients in Ebola Care Units/Community Care Centres, Interim emergency guidance' and 'Clinical Management of Patients with Viral Haemorrhagic Fever: A Pocket Guide for the Front-line Health Worker' by WHO.
2985080|NCT02662855|Experimental|Treatment|WHO-recommended therapies plus oral administration of Favipiravir
2985081|NCT02662842||FlowSmart Infusion set, then current set|Subjects will use the FlowSmart Infusion Set for a period of 9 to 11 days, then switch to their current infusion set for another period of 9 to 11 days. Subjects must use at least 3 sets during each Study Period then - Subjects will use their current infusion set for a period of 9 to 11 days, then switch to the FlowSmart infusion set for another period of 9 to 11 days. Subjects must use at least 3 sets during each Study Period.
2985082|NCT02662829|Experimental|Community-based intervention (CBI)|"Nurse training and mentorship in TB prevention using clinical algorithm based on national guidelines.~Health education using a treatment literacy curriculum for parents and guardians.~Community outreach by trained village health workers."
2985083|NCT02662829|Active Comparator|Standard of Care (SOC)|At SOC clinics, patients will receive usual care for management of contact tracing, screening, and IPT provision. Childhood TB in Lesotho is managed by nurses in health centers. Per national guidelines, TB patients are asked to bring in child contacts, who are screened using a simple symptom questionnaire. Children who screen negative are assessed for IPT eligibility. Absent contra-indications (eg, active hepatitis, regular alcohol consumption, peripheral neuropathy), nurses counsel children and guardians on IPT benefits, potential side effects, and importance of adherence. Children requiring chest x-rays or gastric lavage and HIV-infected children under age 1 are referred to the hospital. After initiation, patients and guardians return to the clinic monthly for monitoring for side effects, TB symptoms, adherence, and 30-day supply of isoniazid. If adherence problems are noted, the nurse counsels patient and guardian as appropriate.
2985084|NCT02662816|Experimental|glutathion|The study will validate the detection and the quantification of glutathione in muscle and liver using 1H MRS
2985085|NCT02662803|Experimental|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
2985086|NCT02662803|Placebo Comparator|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
2985087|NCT02662790|Experimental|Preterm|
2985088|NCT02662777||Eso-SPONGE® vacuum treatment|leakage after esophagectomy and gastrectomy, perforation of the esophagus
2985089|NCT02662764|Experimental|Zalviso™ 15 mcg|Zalviso™(sufentanil sublingual tablet system) 15 mcg
2985090|NCT02662751|Active Comparator|Routine Imaging|"Patients randomized to this arm will have routine post-stroke/TIA imaging assessments.~Intervention: Routine Imaging Assessment"
2985091|NCT02662751|Experimental|LDWBA first|"Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.~Intervention: LDWBA first followed by Routine Imaging Assessment if required."
2985092|NCT02662738|Active Comparator|A wheat product|A wheat product (containing 2% 13C-universally-labeled wheat) with natural fruit extract added.
2985093|NCT02662738|Placebo Comparator|Control|A wheat product (containing 2% 13C-universally-labeled wheat) without natural fruit extract added.
2985094|NCT02662738|Other|Glucose solution|A solution of 50g glucose of which 2% 13C-universally-labeled glucose (2%) and unlabeled glucose (98%) in 250 mL water.
2985095|NCT02662725|Experimental|ipilimumab + Stereotactic Radiosurgery|ipilimumab combined with a Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases
2985096|NCT02662712|Experimental|Part 1: Single Dose Escalation|The single dose escalation phase of the study will consist of 6 dosing sessions (Sessions I to VI) evaluated in 2 panels (Panels 1 and 2). The dose of JNJ-56136379 will be consecutively escalated over 5 levels, alternating between the 2 panels. Panel 1 will receive 3 single doses (SD1, SD3 and SD3fed) in Sessions I, III and V, respectively. Panel 2 will receive 3 single doses (SD2, SD4 and SD5) in Sessions II, IV and VI, respectively. There will be a washout period of at least 14 days between consecutive JNJ-56136379/placebo dosing in each individual participant.
2985097|NCT02662712|Experimental|Part 1: Multiple dose session|After completion of the fifth single dose session another panel of healthy participant (panel 3) receive multiple doses of JNJ-56136379 at one dose level (MDx) or placebo for 12 or 19 consecutive days (Session VII) in fed or fasted conditions.
2985098|NCT02662712|Experimental|Part 2: Multiple dose escalation|Multiple dose levels will be given in Panel 4 in Session VIII (European sites), Sessions IX and X (European and/or Asian sites) Session XI (Asian sites) for 28 consecutive days in fed conditions. Optional Sessions A-B-C (Panel 4) used for further dose evaluations at European and/or Asian sites. Per session, participants will receive JNJ 56136379 or placebo. Dose progression to the next multiple dose level may be adapted based on the emerging safety and PK outcome of the previous dosing levels.
2985099|NCT02662686|Active Comparator|Control|Embryo selection for transfer will be based initially on chromosomally normal embryos and secondly on embryo morphology criteria (specific of IVF lab, as standard practice).
2985100|NCT02662686|Experimental|MitoScore|Embryo selection for transfer will be based initially on chromosomal normality and secondly on the MitoScore value, trying to transfer chromosomally normal embryos which contain the lowest number of mitochondrial DNA copies.
2985101|NCT02662673|Other|Localized prostate cancer, Focal treatment.|
2985102|NCT02662660|Experimental|Port-sites infiltration:Bupivacaine0,25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port. Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
2985103|NCT02662660|Experimental|Epidural analgesia:Levobupivacaine0.125%|"Epidural analgesia consists in the placement of a thoracic epidural catheter inserted at the level T6-T7 and administration of a continuous perfusion of Levobupivacaine 0.125% 6ml/h.~Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours."
2985104|NCT02662660|Active Comparator|Metamizole and Acetaminophen iv|Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
2985105|NCT02662647|Experimental|DCAG plus HLI|Patient will be treated with decitabine and modified CAG regimen followed by HLA haploidentical peripheral mononuclear blood cells infusion.
2985106|NCT02662647|Experimental|DCAG|Patient will be treated with decitabine combining modified CAG regimen without other treatments.
2985107|NCT02662634|Experimental|Sequential, no radiation|"AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin Area Under Curve (AUC) 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G)."
2985108|NCT02662634|Experimental|Concurrent, no radiation|"AGS-003-LNG dosing initiated concurrently or subsequent to 3rd cycle of platinum doublet chemotherapy & radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses will then be administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells.~Platinum-doublet chemotherapy can be any of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G)."
2985109|NCT02662634|Experimental|Sequential, radiation|"AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G).~Radiation therapy per PI"
2985147|NCT02662387|Experimental|HFNC and external nasal dilator (END)|high flow nasal cannula and external nasal dilator
2985148|NCT02662374|Active Comparator|Control|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid
2985110|NCT02662634|Experimental|Concurrent, radiation|"AGS-003-LNG dosing initiated concurrently during or subsequent to the 3rd cycle (3-week cycle) of platinum doublet chemotherapy & radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells.~Platinum-doublet chemotherapy choice of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G).~Radiation therapy per PI."
2985111|NCT02662621|Other|ill patient|Patient with a cancer disease
2985112|NCT02662621|Other|Healthy volunter|Subject without any cancer pathology
2985113|NCT02662608|Experimental|Brontictuzumab|1.5 mg/Kg of Brontictuzumab single agent intravenously every three weeks.
2985114|NCT02662595|No Intervention|Control|
2985115|NCT02662595|Active Comparator|Text message|Subjects in this arm will receive a text message reminder in due time for measles vaccination.
2985116|NCT02662595|Active Comparator|Text message and voice call|Subjects in this arm will receive a voice call in addition to a text message reminder in due time for measles vaccination.
2985117|NCT02662582|Experimental|CK-2127107, then Placebo|Participants will first receive CK-2127107 for 14 days. After a washout period of 14 days, participants will then receive matching Placebo for 14 days.
2985118|NCT02662582|Experimental|Placebo, then CK-212710|Participants will first receive Placebo for 14 days. After a washout period of 14 days, participants will then receive matching CK-2127107 for 14 days.
2985119|NCT02662569|Active Comparator|Evolocumab Q2 weeks and atorvastatin|Evolocumab 140 mg SC every two weeks and atorvastatin 20 mg PO every day
2985120|NCT02662569|Active Comparator|Evolocumab QM and atorvastatin|Evolocumab 420 mg SC every month and atorvastatin 20 mg PO every day
2985121|NCT02662569|Placebo Comparator|Placebo Q2 weeks and atorvastatin|Placebo SC every two weeks and atorvastatin 20 mg PO QD
2985122|NCT02662569|Placebo Comparator|Placebo QM and atorvastatin|Placebo SC every month and atorvastatin 20 mg PO every day
2985123|NCT02662556|Experimental|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg
2985124|NCT02662543||Hospitalized AGE patients|Children less than 18-years-old hospitalized due to acute gastroenteritis to seven Estonian hospitals participating in this study
2985125|NCT02662530|Active Comparator|Botulinum toxin type A clinical|Initial and optimization of BoNT-A injection parameters will be conducted by clinical visual assessment
2985126|NCT02662530|Active Comparator|Botulinum toxin type A kinematic|Initial and optimization of BoNT-A injection parameters will be conducted by kinematic assessment
2985127|NCT02662504|Experimental|multimodal treatment + intrapleural PDT|"surgery of the MPM: extended pleurectomy/decortication (eP/D)~intra-operative (intrapleural) photodynamic therapy (PDT). Briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.~then:~prophylactic chest radiotherapy of surgical scars to prevent tumor seeding (3 x 7 Gray)~adjuvant standard chemotherapy by (cis)platin 75 mg/m2 and pemetrexed 500 mg/m2 up to 6 cycles (1 cycle every 3 weeks), with oral folic acid (400 μg daily) and vitamin B12 (1000 μg Q9W) supplementation"
2985128|NCT02662491|Experimental|vitamin D and calcium|daily oral vitamin D(3) (2000 IU) and calcium (600 mg) for 6 months
2985129|NCT02662491|Experimental|Calcium supplement|daily oral calcium (600 mg) for 6 months
2985130|NCT02662491|Experimental|vitamin D supplement|daily oral vitamin D(3) (2000 IU) for 6 months
2985131|NCT02662491|Placebo Comparator|Placebo|daily placebo tablet for 6 months
2985132|NCT02662478||primary gastric GIST|Consisted of all consecutive cases of primary gastric stromal tumors (PGST) that underwent laparoscopic surgery (LS).
2985133|NCT02662465|Experimental|mucositis grade 1, laser 660|Group 1 will include patients with oral mucositis grade 1. Sera used wavelength of 660nm, power 100mW and lluencia of 4 J / cm².
2985134|NCT02662465|Experimental|mucositis grade 2, laser 660|Group 2 included patients with oral mucositis grade 2. Sera used with a wavelength of 660nm, power 100mW and lluencia of 8 J / cm².
2985135|NCT02662465|Experimental|mucositis grade 3, laser 790|Group 3 included patients with oral mucositis grade 3 Sera used laser diode AsGaAl operating in continuous mode, with a wavelength of 790 nm, power of 100mW and fluency of 8 J / cm².
2985136|NCT02662452|Experimental|GLPG2222 single dose|Single dose of GLPG2222 oral suspension
2985137|NCT02662452|Placebo Comparator|Placebo single dose|Single dose of placebo oral suspension
2985138|NCT02662452|Experimental|GLPG2222 multiple doses|Multiple doses of GLPG2222 oral suspension
2985139|NCT02662452|Placebo Comparator|Placebo multiple doses|Multiple doses of placebo oral suspension
2985140|NCT02662439|Experimental|BCM group|The patients are measured by Body Composition Monitor (BCM) and both the patient and the physician know the results and adjust the diuretic therapy accordingly.
2985141|NCT02662439|Placebo Comparator|Control group|The patients are measured by Body Composition Monitor (BCM) but neither the patient nor the physician know the results, the physician adjusts the diuretic therapy as usual, according to the protocols.
2985142|NCT02662426|Experimental|Drugs for experimental group|Lingdancao granules, 4 packs per time (3g/pack), three times per day; analogous oseltamivir phosphate capsule, 1 capsule per time, twice per day.Drugs must be used on the day of fever and last for five days continuously.
2985143|NCT02662426|Active Comparator|Drugs for positive control group|Oseltamivir phosphate capsule (tamiflu), 1 capsule per time (75mg), twice per day; analogous Lingdancao granules, 4 packs per time, three times per day.Drugs must be used on the day of fever and last for five days continuously.
2985144|NCT02662426|Placebo Comparator|Drugs for placebo control group|Analogous Lingdancao granules, 4 packs per time, three times per day, analogous oseltamivir phosphate capsule, 1 capsule per time, twice per day.Drugs must be used on the day of fever and last for five days continuously.
2985145|NCT02662400|Experimental|MNCs GROUP|Patients with Type 2 Diabetes mellitus
2985180|NCT02662127|Experimental|SIGVARIS®. Class 2 - RAL: 23-32|Graduated elastic compression stockings
2985149|NCT02662374|Experimental|Group 1|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid Extra soft toothbrush, brushing with saline bd
2985150|NCT02662374|Experimental|Group 2|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid Supersaturated Calcium Phosphate Spray, 5ml qid
2985151|NCT02662361||no peri-implant disease|The subjects who did not suffer from peri-implant disease.
2985152|NCT02662361||peri-implant disease|The subjects who suffered from peri-implant disease.
2985153|NCT02662348|Experimental|Interleukin-2 Transfusion|Patients receive low-dose Recombinant Human Interleukin-2 SC daily beginning 3 days before the first HER2Bi armed T cell infusions infusion.
2985154|NCT02662348|Experimental|T Cells Transfusion|Patients receive HER2Bi-Armed T Cells IV weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
2985155|NCT02662335|Experimental|Arm I (computer-assisted cognitive training)|Patients complete a computerized working memory training program (Cogmed) over 35 minutes a day, 5 times a week for 6 weeks.
2985156|NCT02662335|Active Comparator|Arm II (wait-list)|Patients undergo standard follow-up care for 6 weeks. Following standard follow-up care, patients may complete Cogmed as in the Intervention Group in weeks 7-13.
2985157|NCT02662322|Experimental|HYPNOSIS|hypnotic communication, confusion procedure during peripheral intravenous catheterization
2985158|NCT02662322|Active Comparator|NOCEBO|negative connotation communication during peripheral intravenous catheterization
2985159|NCT02662322|Placebo Comparator|NEUTRAL|neutral connotation communication during peripheral intravenous catheterization
2985160|NCT02662309|Experimental|MPDL3280A|Patients receive 2x 3-weekly cycles of MPDL3280A (one infusion on the first day of each cycle) prior to cystectomy surgery.
2985161|NCT02662296|Experimental|Treatment (ibrutinib or idelalisib)|Patients receive ibrutinib PO QD on days 1-28 or idelalisib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2985162|NCT02662283|Active Comparator|Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
2985163|NCT02662283|Experimental|Reh-acteoside|Oral take reh-acteoside (0.4g bid) for 8 weeks
2985164|NCT02662283|Experimental|Reh-acteoside+Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) and reh-acteoside (0.4g bid) for 8 weeks
2985165|NCT02662270||Cases|Patients with a fibromyalgia diagnosis established according to the American College of Rheumatology current criteria by a trained physician.
2985166|NCT02662270||Controls|Healthy subjects paired by age and gender to the subjects in the cases group.
2985167|NCT02662257|Active Comparator|Sevoflurane group|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
2985168|NCT02662257|Experimental|Propofol group|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
2985169|NCT02662244|Experimental|Yag Laser Treatment Of Basal Cell Carcinoma|Study participants will be treated with long-pulsed 1064 nm Nd:YAG laser at the investigator's discretion based on the clinical endpoint (slight contraction and greying of the skin surface), the tumor characteristics, and the patient's skin phototype.
2985170|NCT02662218||Patients with superficial wounds|A cohort of 50 patients with superficial wounds of any etiology (see inclusion criteria), who need advanced wound care treatment in any case, will be observed over a period of 14 days; the exact duration for each patient depends upon the investigator's assessment. The observation consists of an initial visit, at least one dressing change after max. 7 days and a final visit. Patients will be treated with the CE-marked wound care product. This product is already in general use in the Netherlands and Germany. It is a sterile, bacteria-binding, super-absorbent wound dressing. Apart from the predefined study visits, daily dressing changes in accordance with daily clinical practice are possible.
2985171|NCT02662205|Active Comparator|Traditional Group|Traditional process psychotherapy group
2985172|NCT02662205|Experimental|Yoga Therapy Group|Psychotherapy group integrating yoga and process dialogue
2985173|NCT02662205|Active Comparator|Yoga Class|Yin yoga class
2985174|NCT02662192|Experimental|Intervention|Exercise + health education + auditory rehabilitation 10 weeks of exercise, interactive health education, socialization and auditory rehabilitation program
2985175|NCT02662192|Active Comparator|Auditory rehabilitation alone|"auditory rehabilitation alone~1 hour of group auditory rehabilitation once a week for 10 weeks"
2985176|NCT02662179||Elderly patients with solid tumors|The group will include elderly patients with a malignant solid tumor: ovary cancer, breast cancer, digestive cancer (colo-rectal, pancreas), lung cancer or urinary tract cancer (including bladder cancer).
2985177|NCT02662166|Experimental|MRI and biomarkers in bladder cancer|Utilization of MR-imaging and biomarkers to stage bladder cancer and in estimation of chemosensitivity
2985178|NCT02662153||ER/LA Opioid Cohort|
2985179|NCT02662140|Experimental|Mobile Health Application Group|"emobile health application will enhance the existing evidence informed curriculum of a Multiple Family Group model (called 4 Rs and 2 Ss for Strengthening Families Model) for families with children who have disruptive behavior disorders. This mobile application consists of two primary components that will support engagement and integration of the model's core concepts in family life. The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the Do process."
2985185|NCT02662062|Experimental|Pembrolizumab|Pembrolizumab to be administered via IV 200mg 3 weekly commenced concurrently with chemoradiotherapy, and continuing until 12 week cystoscopy.
2985186|NCT02662036|Active Comparator|Group 1: Bupivicaine|-TAP block of 30 cc of 0.25% bupivicaine
2985187|NCT02662036|Experimental|Group 2: Liposomal bupivacaine|-TAP block of 266 mg/30 cc liposomal bupivacaine
2985188|NCT02662023|Experimental|Bolus|ropivacaine 0.2% administration as repeated, scheduled (one/3 h) bolus doses (24 mL) x 6 h
2985189|NCT02662023|Active Comparator|Basal|ropivacaine 0.2% administration as a continuous basal infusion (8 mL/h) x 6 h
2985190|NCT02661997|Experimental|Tai Chi Intervention|All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
2985191|NCT02661997|Active Comparator|Wellness Intervention|The investigators will utilize a wellness education program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. The Wellness condition will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives.) Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. The project coordinator for this study will provide the didactic lessons.
2985192|NCT02661984||Healthy (no pulmonary disease)|Healthy children 4 - 6 years old with no pulmonary disease and not exhibiting respiratory illness or sinusitis.
2985193|NCT02661984||Asthmatic (physician diagnosed)|Asthmatic children 4 - 6 years old not exhibiting acute asthma symptoms, respiratory illness or sinusitis.
2985194|NCT02661971|Active Comparator|FLOT alone|"Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT~Docetaxel 50 mg/m², d1~Oxaliplatin 85 mg/m², d1~Calciumfolinat 200 mg/m², d1~5-Fluorouracil 2600 mg/m², d1"
2985195|NCT02661971|Experimental|FLOT + Ramucirumab|"Pre-operative therapy with FLOT + ramucirumab followed by surgical resection followed by post-operative therapy with FLOT + ramucirumab~Ramucirumab 8mg/kg, d1~Docetaxel 50 mg/m², d1~Oxaliplatin 85 mg/m², d1~Calciumfolinat 200 mg/m², d1~5-Fluorouracil 2600 mg/m², d1"
2985196|NCT02661958|Experimental|S6G5T-3|topical cream
2985197|NCT02661958|Experimental|S6G5T-1|topical cream
2985198|NCT02661958|Active Comparator|S6G5T-5|topical cream
2985199|NCT02661958|Active Comparator|S6G5T-7|topical cream
2985200|NCT02661958|Active Comparator|S6G5T-6|topical cream
2985201|NCT02661958|Placebo Comparator|S6G5T-8|topical cream
2985202|NCT02661945|Experimental|Near focus with narrow band imaging|Near focus with narrow band imaging is used for marking the tumor margin.
2985203|NCT02661945|No Intervention|Indigo carmin|After indigo carmine was sprayed over the lesion, marking is performed.
2985204|NCT02661932|Experimental|Letrozole associated COS|"Breast cancer patients undergo fertility preservation with letrozole associated COS for oocyte collection.~Letrozole is administered orally (5mg/day) during the entire stimulation protocol until ovulation triggering."
2985205|NCT02661919|Experimental|Emfit mattress sensor|
2985206|NCT02661906|Experimental|SKY Pre|Sudarshan Kriya Yoga is provided to all the enrolled participants. The baseline characteristics of patient is compared with that of their characteristics after yoga intervention. All the participants were provided with yoga training for 6 days and then asked to perform the SKY at home daily till 12 week. The questionnaire on anxiety, depression and quality of life were administered at the baseline and at the end of 6 days of yoga. Biochemical parameters such as HbA1c, lipid profile, fasting glucose and post meal glucose were measured at baseline and after 12 week of intervention.
2985207|NCT02661906|No Intervention|SKY post|The enrolled participants were provided with SKY intervention and their pre and post data were recorded.
2985208|NCT02661893|Experimental|JNJ-42847922 and Rifampin|A single oral dose of 40 milligram (mg) (=2*20 mg) dose of JNJ-42847922 on Day 1; A single oral dose of 40 mg (=2*20 mg) dose of JNJ-42847922 dosed with one oral dose of rifampin 600 mg (2*300 mg) on Day 5; A single oral dose of 40 mg (=2*20 mg) dose of JNJ-42847922 dosed on Day 12, following once daily dosing of rifampin with an oral dose of rifampin 600 mg (2*300 mg) on Days 5-12.
2985209|NCT02661880|Experimental|listening to preferred music choices|All patients will be invited to complete the McGill Quality of Life Questionnaire - Revised (McGill QOL-R) upon admission to the unit. The Questionnaire will not be part of the permanent medical record and the participants will remain anonymous. Afterwards participants will be asked if they would like to listen to music during their stay in the hospital. Music will be selected according to their choices from an i-Tunes playlist. Participants will be invited to listen to music at their own discretion. Prior to discharge from the hospital or after 3 days all willing participants will be again invited to complete the McGill QOL-R questionnaire.
2985210|NCT02661867||VD|Vaginal delivery group - women who gave birth of offspring through the vagina without the use of special instruments such as forceps or a vacuum extractor (instrumental vaginal delivery)
2985211|NCT02661867||CS|Cesarean section group - women delivered by surgical procedure in which one or more incisions are made through a mother's abdomen and uterus to deliver a baby. Cesarean section is performed when a vaginal delivery would put the baby's or mother's life or health at risk.
2985212|NCT02661854|Experimental|MM09 Mannosylated 5.000 subcutaneous|5.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
2985213|NCT02661854|Experimental|MM09 Mannosylated 10.000 subcutaneous|10.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
2985214|NCT02661854|Experimental|MM09 Mannosylated 30.000 subcutaneous|30.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
2985215|NCT02661854|Experimental|MM09 Mannosylated 50.000 subcutaneous|50.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
2985216|NCT02661854|Experimental|MM09 Mannosylated 5.000 sublingual|5.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
2985219|NCT02661854|Experimental|MM09 Mannosylated 50.000 sublingual|50.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
2985220|NCT02661854|Placebo Comparator|Placebo Sublingual Placebo subcutaneous|Sublingual and subcutaneous placebo.
2985221|NCT02661841|Experimental|LI-Guided Therapy|One hundred and fifty chronic heart failure patients treated based on guidelines and LI-Guided Therapy.
2985222|NCT02661841|Active Comparator|Control|One hundred and fifty chronic heart failure patients treated based on guidelines only.
2985223|NCT02661828|Active Comparator|Taper A Regimen|Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a Two-Week Taper Regimen to discontinue their medication.
2985224|NCT02661828|Active Comparator|Taper B Regimen|Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a One-Week Taper Regimen to discontinue their medication.
2985225|NCT02661815|Experimental|Phase 1 Expansion Cohort A|Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
2985226|NCT02661815|Experimental|Phase 1 Expansion Cohort B|Paclitaxel 70mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
2985227|NCT02661815|Experimental|Phase 1 Expansion Cohort C|Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Bevacizumab 10mg/kg days 1 and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
2985228|NCT02661802|Experimental|Oxygen Supplementation|Two six-minute walk tests, one with oxygen supplementation and another without were performed on different days. During the test with oxygen supplementation the delivery was continuous by mask at 40% and technician walked behind the patient with the oxygen source.
2985229|NCT02661789|Active Comparator|GnRHa|Goserelin 3.6 mg implant
2985230|NCT02661789|Placebo Comparator|Placebo|Injection of saline
2985231|NCT02661763||Schoolchildren in Zambia|Schoolchildren in grades 7-12 in fifteen randomly selected schools in Lusaka area
2985232|NCT02661750||Step 1|Patients who had inadequate preparations for colonoscopy with a standard dose of bowel cleansing agent.
2985233|NCT02661750||Step 2|Patients who had inadequate preparations for colonoscopy with a step 1 dose of bowel cleansing agent.
2985234|NCT02661750||Step 3|Patients who had inadequate preparations for colonoscopy with a step 2 dose of bowel cleansing agent.
2985235|NCT02661750||Step 4|Patients who had inadequate preparations for colonoscopy with a step 3 dose of bowel cleansing agent.
2985236|NCT02661750||Step 5|Patients who had inadequate preparations for colonoscopy with a step 4 dose of bowel cleansing agent.
2985237|NCT02661724|Experimental|Take Charge Burn - Pain (TCBR-Pain)|The TCBR-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress.
2985238|NCT02661724|No Intervention|Education attention control|The attention group receives an educational materials that is matched to the TCBR-Pain intervention in terms of session length and time on the web-based program. The web-based Education attention condition includes 7 sessions delivered over 7 weeks. The Education Attention Control is education materials commonly employed in rehabilitation centers and has been successfully used in several studies as a comparison to active rehabilitation interventions
2985239|NCT02661711|Experimental|Aflibercept (Eylea)|All patients recruited to the study will receive 3 loading intravitreal injections of Aflibercept (Eylea) at monthly intervals followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow-up will occur when there is evidence of OCT stability in the view of the investigator i.e. there is no further reduction in macular fluid compared to the previous visit. All patients will receive 5 injections before considering them non-responders.
2985240|NCT02661698|Placebo Comparator|Placebo 1|"Placebo~All participants will be given a placebo for the first visit. The other 3 arms will be randomised in a counterbalanced order."
2985241|NCT02661698|Placebo Comparator|Placebo 2|Placebo
2985242|NCT02661698|Active Comparator|DHA rich oil|Omega-3 oil: DHA enriched
2985243|NCT02661698|Active Comparator|EPA rich oil|Omega-3 oil: EPA enriched
2985244|NCT02661685|Experimental|autologous IKDC-like cell|Received autologous IKDC-like cells
2985245|NCT02661672|Experimental|Patients with Brain Hemorrhage|Subjects will receive best medical management for ICH plus they will receive the MIES surgery and use of the Apollo or Artemis System for clot evacuation.
2985246|NCT02661659|Other|Weekly Vaccination|Maintenance multipeptide vaccine (S-588210) administered every week
2985247|NCT02661659|Other|Every other Week Vaccination|Maintenance multipeptide vaccine (S-588210) administered every other week
2985248|NCT02661646||Advanced Pneumatic Compression Group|All study participants will receive treatment using an advanced pneumatic compression device.
2985249|NCT02661633||Population Pool|The Population Pool will consist of contact and non-contact athletes recruited at each site participating in the study. The athlete's in this pool will be tested with the study device pre-season and post-season each. The BrainScope Battery consists of 3 components to collect brain electrical activity, a cognitive assessment and a balance/sway measurement.
2985250|NCT02661633||Injured/Control Pool|Injured/Control Pool consisting of athletes who are injured during the season and matched control athletes.The athlete's in this pool will be tested with the study device at time of injury and 3 follow-up time points. The BrainScope Battery consists of 3 components to collect brain electrical activity, a cognitive assessment and a balance/sway measurement. In addition, the injured and matched control athletes will receive advanced MRI neuroimaging.
2985251|NCT02661607|Other|Point of care echocardiography after central venous catheter|Point of care echocardiography plus chest radiography
2985252|NCT02661594|Experimental|ABCD|A: APD421 5 mg followed by B: APD421 40 mg; C: Moxifloxacin 400 mg; D: Placebo.
2985253|NCT02661594|Experimental|BDAC|B: APD421 40 mg; D: Placebo. A: APD421 5 mg C: Moxifloxacin 400 mg;
2985254|NCT02661594|Experimental|CADB|C: Moxifloxacin 400 mg A: APD421 5 mg D: Placebo B: APD421 40 mg
2985255|NCT02661594|Active Comparator|DCBA|D: Placebo C: Moxifloxacin 400 mg B: APD421 40 mg A: APD421 5 mg
2985370|NCT02660827|Experimental|Hybrid closed loop|All subjects will be wearing the MMT-670G insulin pump, using it with the closed loop algorithm
2985256|NCT02661581|Experimental|Peer Support|Peer support intervention group: During the first 3 months of DSME, participants in the DSMS intervention group will be invited to attend 6 lifestyle change sessions delivered a 2-person peer leader team and conducted bi-weekly. Immediately following the 3 months of DSME, participants are invited to attend 9 months of weekly DSMS sessions (60-minutes per session) delivered by a Peer Leader. These sessions are designed to sustain the self-management gains achieved in the 3 months of DSME.
2985257|NCT02661581|No Intervention|Wait-list Control|Immediately following the 6 bi-weekly DSME sessions, participants randomized to the Wait-list control group will have completed their participation in the study.
2985258|NCT02661568||Population with condition and with exposure|
2985259|NCT02661555|Experimental|Aerobic exercise|Aerobic exercise two times per week for 24 weeks.
2985260|NCT02661555|No Intervention|Habitual lifestyle|Habitual lifestyle the first 24 weeks. Will be offered the same exercise intervention after 24 weeks.
2985261|NCT02661542|Experimental|Phase 1: Lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2985262|NCT02661542|Experimental|Phase 1: 1.5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2985263|NCT02661542|Experimental|Phase 1: 2.25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2985264|NCT02661542|Experimental|Phase 1: 3.375x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2985265|NCT02661542|Experimental|Phase 1: 5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2985266|NCT02661542|Experimental|Phase 1: 7.5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2985267|NCT02661542|Experimental|Phase 1: 11.25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2985268|NCT02661542|Experimental|Phase 1: 16.875x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2985269|NCT02661542|Experimental|Phase 1: 25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2985270|NCT02661542|Experimental|Phase 2a: FF-10502-01 at MTD in Pancreatic Cancer|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2985271|NCT02661542|Experimental|Phase 2a: FF-10502-01 at MTD in Solid Tumors|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2985272|NCT02661529|Active Comparator|Transesophageal Echocardiogram|Patients undergoing an Transesophageal Echocardiogram (TEE) for diagnostic purposes to detect a cardiac shunt abnormality, using Saline/Air Mixture and Saline/Blood Mixture for vessel contrast
2985273|NCT02661529|Active Comparator|Transthoracic Echocardiogram|Patients undergoing an Transthoracic Echocardiogram (TTE) for diagnostic purposes to detect a cardiac shunt abnormality, using Saline/Air Mixture and Saline/Blood Mixture for vessel contrast
2985274|NCT02661516||Vitamin K Antagonists|Vitamin K Antagonists dose as specified
2985275|NCT02661503|Active Comparator|BEACOPP|4 or 6 cycles of BEACOPP (21-day cycles) Bleomycin (B) Etoposide (E) Doxorubicin (A) Cyclophosphamide (C) Vincristine (O) Procarbazin (P) Prednisone (P). If FDG-PET is negative after two cycles patients will be given a total of four cycles. If FDG-PET is positive after two cycles patients will bev given a total of six cycles.
2985276|NCT02661503|Experimental|BRECADD|4 or 6 cycles of BRECADD (21.day cycles) Brentuximab Vedotin (BR) Etoposide (E) Cyclophosphamide (C) Doxorubicin (A) Dacarbazine (D) Dexamethasone (D). If FDG-PET is negative after two cycles patients will be given a total of four cycles. If FDG-PET is positive after two cycles patients will be given a total of six cycles.
2985277|NCT02661490|Experimental|Arm 1: NoV Vaccine Formulation A _1-Dose|Participants ≥ 60 years of age, 1-dose regimen: norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1/GII.4 bivalent virus-like particle (VLP) vaccine Formulation A, IM, on Day 29.
2985278|NCT02661490|Experimental|Arm 2: NoV Vaccine Formulation A _2-Dose|Participants ≥ 60 years of age, 2-dose regimen: norovirus GI.1/GII.4 bivalent VLP vaccine Formulation A, IM, on Days 1 and 29.
2985279|NCT02661490|Experimental|Arm 3: NoV Vaccine Formulation B_1-Dose|Participants ≥ 60 years of age, 1-dose regimen: norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1/GII.4 bivalent VLP vaccine Formulation B, IM, on Day 29.
2985280|NCT02661490|Experimental|Arm 4: NoV Vaccine Formulation B_2-Dose|Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1/GII.4 bivalent VLP vaccine Formulation B, IM, on Days 1 and 29.
2985281|NCT02661490|Experimental|Arm 5: NoV Vaccine Formulation A_1-Dose|Participants 18 to 49 years of age, 1-dose regimen: norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1/GII.4 bivalent VLP vaccine Formulation A, IM, on Day 29.
2985282|NCT02661477|Other|pegylated interferon + placebo|Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection will receive subcutaneous pIFNα2a (pegylated interferon alfa 2, Pegasys, 180 ug s.c. injection once a week, two times ). Washout period is 8 weeks. When the same patient gets next rhinovirus infection, he/she will receive subcutaneous placebo (0,9% NaCl) injection once a week, two times.
2985283|NCT02661477|Other|placebo + pegylated interferon|Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection will receive will receivesubcutaneous placebo(0,9% NaCl) injection once a week, two times. Washout period is 8 weeks. When the same patient gets next rhinovirus infection, he/she will subcutaneous pIFNα2a (pegylated interferon alfa 2, Pegasys, 180 ug s.c. injection once a week, two times ).
2985284|NCT02661464|Experimental|Exposed to Ad26.ZEBOV and/or MVA-BN Filo|Safety Data will be collected from participants who received Ad26.ZEBOV and/or MVA-BN-Filo in Phase 1, 2 or 3 clinical studies in 6-month intervals up to 60 months after prime vaccination, including the duration in the participant's original study (Cohort 1). Female participants who became pregnant with estimated conception within 28 days after vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV will be followed to the end of their pregnancy for pregnancy outcomes (Cohort 2). After the end of pregnancy, female participants will continue to be followed in Cohort 1. Safety Data for live born children to female participants will be followed up to 60 months after birth (Cohort 3).
2985285|NCT02661451|Experimental|TAVR (with SAPIEN 3 THV) and OHFT|Transcatheter heart valve and Optimal Heart Failure Therapy
2985286|NCT02661451|Active Comparator|OHFT|Optimal Heart Failure Therapy
2985287|NCT02661438|Other|Placebo to Ciprofloxacin DPI|Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
2985288|NCT02661425||Standard of Care|
2985289|NCT02661425||EnteraGam|
2985290|NCT02661386|Other|Manometry Device|"During the last 10 minutes of subjects waking up from anesthesia, the motility procedure will be performed."
2985291|NCT02661373|Experimental|Treatment Arm|Participants will receive SJ733, an investigational drug developed at St. Jude Children's Research Hospital, and cobicistat.
2985292|NCT02661360|Experimental|Starting condition of swaddled|
2985293|NCT02661360|Experimental|Starting Condition of Unswaddled|
2985294|NCT02661347|Active Comparator|Active comparator: tDCS & Risperidone|In the active arm, active tDCS will be applied using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator at a current of 2 milliampere (mA) for 20 minutes, twice a day for five consecutive days, for a total of 10 sessions.
2985295|NCT02661347|Sham Comparator|Sham comparator: tDCS & Risperidone|In the sham arm, active tDCS will be applied using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator at a current of 2mA for 1 minute, twice a day for five consecutive days, for a total of 10 sessions.
2985296|NCT02661334|Placebo Comparator|Placebo|30g white rice flour
2985297|NCT02661334|Experimental|Low dose|5g/day Creatine Monohydrate (25g white rice flour) for 28 days
2985298|NCT02661334|Experimental|Loading dose|Creatine Monohydrate 20g/day (10g white rice flour) for 7 days, followed by maintenance dose of Creatine Monohydrate 5g/day (25g white rice flour) for the remaining 21 days
2985299|NCT02661334|Experimental|High dose|High dose of Creatine Monohydrate 20g/day (10g white rice flour) for the entire 28 day period
2985300|NCT02661308|Experimental|Systematic bright light exposure|Systematic bright light exposure for 30 min. for 4 weeks
2985301|NCT02661308|Active Comparator|Systematic dim light exposure|Systematic dim light exposure for 30 min. for 4 weeks
2985302|NCT02661295|Other|Ferric Citrate|Ferric citrate at a starting dose of 2 tablets with each meal will be given to all participants.
2985303|NCT02661282|Experimental|Group 1 - Recurrent Glioblastoma - Dose Escal.|"Phase I: Following leukapheresis, first group of participants receive the lowest dose level of CMV CTLs. Each new group receives a higher dose of the study drugs than the group before it, if no intolerable side effects were seen. This continues until the highest tolerable dose of CMV CTLs is found. Starting dose level of CMV CTLs is 5 x10^6. Participants on dose escalation receive up to 4 doses of CMV-T cells and dose dense temozolomide, but no intrapatient dose escalation permitted.~Temozolomide administered orally once per day for 21 consecutive days (days 1-21) of a 42-day cycle. Starting dose for the first cycle is 100 mg/m2/day.~Cycles of dose dense Temozolomide can be continued beyond the 4th dose if participant is receiving benefit from therapy, for up to 12 cycles."
2985304|NCT02661282|Experimental|Group 2 - Recurrent Glioblastoma + Surgery - Dose Expan.|"Phase II: Following leukapheresis, participants begin treatment with 21 days of dose dense Temozolomide at a dose of 100 mg/m2/day. On day 22 participant undergoes adoptive CMV-specific T cell transfer (first dose at MFD or MTD of CMV-specific T cells).~Surgery for resection of recurrent disease scheduled on day 30. In the post-surgery phase, subsequent cycles of dose dense Temozolomide and CMV-specific T cells on Day 22, administered for a total of 3 cycles, at the MFD or MTD determined during dose escalation component. Cycles defined as every 42 days.~Participants receive a total of 3 cycles of dose dense Temozolomide followed by fixed doses of CMV-specific T cell infusion in the post-surgical phase, after which they remain on dose dense Temozolomide until tumor progression, as long as there are no unacceptable toxicities, for up to 12 cycles."
2985305|NCT02661282|Experimental|Group 3- Newly Diag.Glioblastoma Post Radiation + Temozolomide|"Phase II: Following leukapheresis, participants begin treatment with 21 days of dose dense Temozolomide at a dose of 100 mg/m2/day.~On day 22 participant undergoes adoptive CMV-specific T cell transfer (first dose at MFD or MTD of CMV-specific T cells).~Participants then receive an additional 3 cycles of dose dense Temozolomide followed by CMV-specific T cell infusion, at fixed dose of CMV-specific T cells (MFD or MTD determined in dose escalation). Cycles defined as every 42 days (first 4 cycles).~After a total of 4 cycles of dose dense Temozolomide followed by CMV specific T cell infusion, participants then continue on standard dose Temozolomide (200 mg/m2 days 1-5 every 28 days) (i.e., 28-day cycles starting in cycle 5) for 12 cycles or until tumor progression."
2985306|NCT02661269||Septic patients|Septic patients with fluid overload (fluid balance + 4 L)
2985307|NCT02661269||Post-cardiac surgery patients|Patients after cardiac surgery, at arrival on ICU.
2985429|NCT02660424|Experimental|VX-150, placebo|Sequence 1: VX-150 in Treatment Period 1→washout→ placebo in Treatment Period 2
2985308|NCT02661256|Active Comparator|on NCPAP|"Once consented, each participant underwent a video fluoroscopic swallow study (VFSS) while NCPAP was administered via a RAM cannula® (intervention). With the NCPAP turned on each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow), a total of 20 swallows were recorded. These swallows were termed on NCPAP swallows. The swallows were assessed in real time for any swallowing dysfunction."
2985309|NCT02661256|Active Comparator|Off NCPAP|"Immediately following the on NCPAP condition, an additional 20 swallows were recorded under VFSS with the NCPAP turned off (intervention). These swallows were termed off NCPAP swallows."
2985310|NCT02661243|Other|Dentate Sjogren's syndrome arm|30 human adults affected by SS with the need of replacement of missing premolars or molars in the upper or lower jaw. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
2985311|NCT02661243|Other|Dentate healthy controls arm|30 healthy human adults with the need of replacement of missing premolars or molars in the upper or lower jaw. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
2985312|NCT02661243|Other|Edentulous Sjogren's syndrome arm|30 human edentulous adults affected by SS with the need of stabilization of the dentures. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
2985313|NCT02661243|Other|Edentulous healthy controls arm|30 healthy human edentulous adults with the need of stabilization of the dentures. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
2985314|NCT02661230|Experimental|COGNIPLUS|Exercise-Gaming
2985315|NCT02661217|Other|Pre-discharge treatment initiation|Patients randomized to Pre-discharge treatment initiation could receive first dose of LCZ696 at any point after the investigator deemed the patient to be stable for at least 24 h, relatively to the ongoing acute HF-therapy.
2985316|NCT02661217|Other|Post-discharge treatment initiation|Patients randomized to Post-discharge treatment initiation could receive the first LCZ696 dose at any point between the day after discharge and up to 14 days after Discharge.
2985317|NCT02661204||Population A|Consecutive women in the age range 20 to 40 years, with a strong family history of breast cancer or a predisposing gene mutation such as BRCA1 or BRCA2, referring to our department for breast evaluation with ultrasound, will be invited to participate to the study. During the interview, before imaging examination, women will be questioned about family history as well as other relevant personal information (e.g. previous surgery or biopsy for benign breast disease).
2985318|NCT02661204||Population B|Consecutive women with a new breast cancer diagnosis and undergoing pre-operative MRI examination for local staging will be invited to participate to the study. ABUS will be performed within two weeks before the scheduled surgery.
2985319|NCT02661204||Population C|Consecutive women with BI-RADS 3 and 4 lesions detected in a routine breast imaging examination will be invited to participate to the study. ABUS will be performed just after the routine HH-US examination.
2985320|NCT02661204||Population D|Consecutive women undergoing breast MRI examination for the evaluation of breast implants integrity will be invited to participate to the study. ABUS will be performed just after the breast MRI.
2985321|NCT02661191|Other|asthma severity and disease exacerbation|intramuscular cholecalciferol 100,000 IU, followed by oral cholecalciferol 5000 IU weekly plus 400 IU daily for one year
2985322|NCT02661178|Experimental|emodepside (BAY 44-4400)|Up to 10 cohorts with single ascending dose
2985323|NCT02661178|Placebo Comparator|placebo of emodepside (BAY 44-4400)|Up to 10 cohorts with single ascending dose
2985324|NCT02661152|Experimental|Radio-/Chemoradiotherapy + nimorazole|Hypoxia profile guided non-responder (less hypoxic tumour) to nimorazole but receiving the drug, which is normal standard radiotherapy of HNSCC in Denmark.
2985325|NCT02661152|No Intervention|Radio-/Chemoradiotherapy|Hypoxia profile guided non-responder (less hypoxic tumour) to nimorazole and not receiving the drug, that is normally part of standard radiotherapy of HNSCC in Denmark.
2985326|NCT02661126|Experimental|Moderate RI Participants|Participants with an estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73m2 to <60 mL/min/1.73m2 take two MK-3682B FDC tablets on Day 1 after fasting for 10 hours.
2985327|NCT02661126|Experimental|Severe RI Participants|Participants with an eGFR of ≥15 mL/min/1.73m2 to <30 mL/min/1.73m2 take two MK-3682B FDC tablets on Day 1 after fasting for 10 hours.
2985328|NCT02661126|Experimental|Healthy Participants|Healthy participants (creatinine clearance [CLcr] ≥80 mL/min) take two MK-362B FDC tablets on Day 1 after fasting for 10 hours.
2985329|NCT02661113|Experimental|Dasatinib Plus RT + TMZ|Dasatinib (Sprycel) with Radiotherapy (RT) and 6 weeks of concomitant Temozolomide (TMZ)
2985330|NCT02661100|Experimental|CDX-1401 + Poly-ICLC + Pembrolizumab followed by Pembrolizumab|Patients receive CDX-1401, Poly-ICLC and Pembrolizumab for 4 cycles (Q 3 weeks) followed by Pembrolizumab alone (Q 3 weeks) until disease progression.
2985331|NCT02661087|Experimental|Bipolar energy|Hysteroscopic resection of symptomatic sub mucosal myomas with the use of bipolar energy
2985332|NCT02661087|Active Comparator|Monopolar energy|Hysteroscopic resection of symptomatic sub mucosal myomas with the use of monopolar energy
2985333|NCT02661074||Fishermen|"Fisherman followed by the Service de Santé des Gens de Mer of Boulogne-sur-Mer, France (occupational exposure to fish).~A questionnaire will be completed."
2985334|NCT02661074||Fish processing factories|"Workers of fish processing factories who are followed by the Service de Santé au Travail (ASTIL) of Boulogne-sur-Mer, France (occupational exposure to fish).~A questionnaire will be completed."
2985335|NCT02661074||Control|"Workers who are followed by the Service de Santé au Travail (ASTIL) of Boulogne-sur-Mer, France, but do not work in fish processing factories.~A questionnaire will be completed."
2985336|NCT02661061|Experimental|Ketamine|Trial Interventions: participants will receive four two-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
2985337|NCT02661061|Active Comparator|Midazolam|Trial Interventions: participants will receive four two-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
2985338|NCT02661048|Experimental|Open label|Non-randomized, open label clinical trial that intends to treat 10 subjects with refractory ventricular tachycardia with the CyberHeart system using standard radiosurgical techniques.
2985430|NCT02660424|Experimental|placebo, VX-150|Sequence 2: placebo in Treatment Period 1→washout→ VX-150 in Treatment Period 2
2985339|NCT02661035|Experimental|Reduced Intensity Conditioning|Non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related or unrelated donor stem cell infusion
2985340|NCT02661022|Experimental|SL-401/Pomalidomide/ Dexamethasone|SL-401 in combination with Pomalidomide and Dexamethasone
2985341|NCT02661009||Plasma and tissue matching|
2985342|NCT02661009||predicting clinical efficacy|
2985343|NCT02660983|Placebo Comparator|Placebo|Participants will receive donepezil matching placebo,once daily in the evening during the double blind period. Participants, who have completed the double-blind phase and want to continue the study participation, can be enrolled in the 24-week open-label extension phase.
2985344|NCT02660983|Experimental|Donepezil|Participants will receive donepezil 5 mg, once daily in the evening during the titration phase and then the dose will be increased to 10 mg at Week 4 during the double blind period. Participants, who have completed the double-blind phase and want to continue the study participation, can be enrolled in the 24-week open-label extension phase. During the maintenance period, dose reduction to 5 mg/day will be permitted only when 10 mg/day is intolerable due to adverse events.
2985345|NCT02660970|Active Comparator|Acupressure|Children will have to wear a 'seasickness-band', which has the effect of acupressure
2985346|NCT02660970|Placebo Comparator|Placebo-band|Children will have to wear a 'placebo-wristband'
2985347|NCT02660970|Active Comparator|Iberogast|Children will have to take Iberogast drops
2985348|NCT02660970|Placebo Comparator|Placebo-drops|Children will have to take placebo-drops
2985349|NCT02660957|Experimental|self-determination smoking cessation|Subjects in the intervention group will be allowed to select their own schedules of quitting after discussing their situation with the counsellor (quit immediately (QI), or quit progressively (QP) with the ultimate goal of completing cessation over an acceptable period). Subjects in the intervention group will receive a self-help quitting leaflet published by the Hong Kong Council on Smoking and Health plus a series of brief interventions using the AWARD model.
2985350|NCT02660957|Placebo Comparator|health life|Subjects in the placebo control group will receive a smoking cessation leaflet published by the Hong Kong Council on Smoking and Health (COSH), as will the intervention group. Moreover, subjects in the placebo control group will undergo a similar schedule of telephone follow-up as those in the intervention group. They will receive a 'placebo' intervention with a 'placebo booster' of the same duration on increasing physical activity and fruit and vegetable intake.
2985351|NCT02660944|Experimental|RSLV-132|10 mg/kg RSLV-132
2985352|NCT02660944|Placebo Comparator|Placebo|Saline placebo
2985353|NCT02660931|Experimental|AKI Risk Notification|Patients randomized to this arm will be eligible for an acute kidney injury risk notification, if their calculated risk exceeds the threshold during their inpatient encounter.
2985354|NCT02660931|No Intervention|Usual Care|These patients will receive usual clinical care, with no acute kidney injury risk notification.
2985355|NCT02660918|Experimental|Treatment|Women undergoing endometrial ablation that meet the eligibility criterial will receive a standardized paracervical injection of Bupivacaine 20 mL 0.25% at the completion of the procedure.
2985356|NCT02660918|Placebo Comparator|Control|Women undergoing endometrial ablation that meet the eligibility criterial will receive an equal volume standardized paracervical injection of Normal Saline at the completion of the procedure.
2985357|NCT02660905|Experimental|Active Treatment|E/C/F/TAF Ledipasvir-Sofosbuvir/TAF
2985358|NCT02660892|Experimental|Protein Intake|Threonine intake - Dietary supplement
2985359|NCT02660879|Placebo Comparator|Written Education|These patients were video taped before they had any inhaler education using their own inhalers. They were then given written educational materials, and given 5 minutes to read these materials. They were then re-taped for their inhaler technique.
2985360|NCT02660879|Experimental|Online Video Education|These patients were video taped before they had any inhaler education using their own inhalers. They were then given online video education located at use-inhalers.com, and were asked to complete the education (took on average 5 minutes). They were then re-taped for their inhaler technique.
2985361|NCT02660866|Placebo Comparator|SMT+APT+Placebo|"Standard Medical Therapy (SMT): Presence of any two of the listed classes of agents [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), statin therapy and beta-blocker drugs] + ability to perform at least 15 min of home walking a day, at least 3 times/week, at ≥20 steps/min~Background Antiplatelet Therapy (APT) :At least one aspirin dose within 5 days prior to randomization at 325 mg dose in aspirin naïve patients (0-5 days of prior aspirin use) or at least one aspirin dose within 5 days prior to randomization at 81 mg dose in patients on chronic (>5 days of prior use) aspirin therapy."
2985362|NCT02660866|Active Comparator|SMT+APT+Vorapaxar|"Standard Medical Therapy (SMT): Presence of any two of the listed classes of agents [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), statin therapy and beta-blocker drugs] + ability to perform at least 15 min of home walking a day, at least 3 times/week, at ≥20 steps/min~Background Antiplatelet Therapy (APT) :At least one aspirin dose within 5 days prior to randomization at 325 mg dose in aspirin naïve patients (0-5 days of prior aspirin use) or at least one aspirin dose within 5 days prior to randomization at 81 mg dose in patients on chronic (>5 days of prior use) aspirin therapy.~Vorapaxar: Vorapaxar 2.08mg/day"
2985363|NCT02660853||Severe Asthma|Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines
2985364|NCT02660840|Experimental|0.5 mg Test, then 0.5 mg reference|14 Subjects will receive a 0.5 mg single dose of two different pharmaceutical formulations (first test, then reference)
2985365|NCT02660840|Experimental|0.5 mg reference, then 0.5 mg Test|14 Subjects will receive a 0.5 mg single dose of two different pharmaceutical formulations (first reference, then test)
2985366|NCT02660840|Experimental|1 mg Test, then 1 mg reference|14 Subjects will receive a 1 mg single dose of two different pharmaceutical formulations (first test, then reference)
2985367|NCT02660840|Experimental|1 mg reference, then 1 mg Test|14 Subjects will receive a 1 mg single dose of two different pharmaceutical formulations (first reference, then test)
2985368|NCT02660840|Experimental|5 mg Test, then 5 mg reference|14 Subjects will receive a 5 mg single dose of two different pharmaceutical formulations (first test, then reference)
2985369|NCT02660840|Experimental|5 mg reference, then 5 mg Test|14 Subjects will receive a 5 mg single dose of two different pharmaceutical formulations (first reference, then test)
2985371|NCT02660814|Placebo Comparator|Healthy periodontium without obesity|"GCF samples were taken at baseline~Intervention: Gingival crevicular fluid collection"
2985372|NCT02660814|Active Comparator|Chronic periodontitis without obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions)"
2985373|NCT02660814|Placebo Comparator|Healthy periodontium with obesity|"GCF samples were taken at baseline~Intervention: Gingival crevicular fluid collection"
2985374|NCT02660814|Active Comparator|Chronic periodontitis with obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions)"
2985375|NCT02660801|Experimental|Participants without chronic back pain|Twenty-five healthy participants (without chronic nonspecific back pain) will participate in two experimental sessions. During the first session, each participant will received either a spinal manipulation of a spinal mobilization of their thoracic spine preceded and followed by the assessment of their thoracic spine stiffness. The second session (24 to 48h after) will be identical but with the other experimental condition (spinal manipulation or spinal mobilization).
2985376|NCT02660801|Experimental|Participants with chronic back pain|Twenty-five participants with chronic nonspecific back pain will participate in two experimental sessions. During the first session, each participant will received either a spinal manipulation of a spinal mobilization of their thoracic spine preceded and followed by the assessment of their thoracic spine stiffness. The second session (24 to 48h after) will be identical but with the other experimental condition (spinal manipulation or spinal mobilization).
2985377|NCT02660788|Active Comparator|Control Arm|Mail
2985378|NCT02660788|Experimental|Family Physician Reminder Letter Arm|Mail
2985379|NCT02660775|Experimental|schizophrenia|this project is to assess relevance of ClaCoS in schizophrenia compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
2985380|NCT02660775|Experimental|autism|this project is to assess relevance of ClaCoS in autism compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
2985381|NCT02660775|Placebo Comparator|healthy controls|this project is to assess relevance of ClaCoS in autism compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
2985382|NCT02660762|Experimental|Modified MRCUKALLⅫ/ECOGE2993 Regimen|"All patients received phase 1 of induction therapy, which consisted of daunorubicin,vincristine,Pegaspargase,prednisone and methotrexate (intrathecally).Patients went on to phase 2 at the end of phase 1.Phase 2 therapy consisted of cyclophosphamide,cytarabine,6-Mercaptopurine and methotrexate intrathecally. After Induction therapy, all patients received intensification therapy with high-dose methotrexate followed by Pegaspargase. After intensification therapy,patients received consolidation(cytarabine, etoposide,Pegaspargase,dexamethasone,vincristine,cyclophosphamide,daunorubicin,thioguanine)and maintenance therapy(vincristine,6-mercaptopurine,methotrexate~,prednisone). Intrathecal methotrexate and intrathecal cytarabine were given as CNS prophylaxis."
2985383|NCT02660736|Experimental|Regimen AB|"Subjects will be receive Regimen A treatment in Session 1 followed by Regimen B treatment in Session 2.~Regimen A: 50 mg Albiglutide Liquid Auto-injector + Placebo lyophilized DCC Pen injector.~Regimen B: 50 mg Albiglutide lyophilized DCC Pen injector + Placebo Liquid Auto-injector.~A minimum of an 8-week washout period between study treatment administration of Session 1 and Session 2."
2985384|NCT02660736|Experimental|Regimen BA|"Subjects will be receive Regimen B treatment in Session 1 followed by Regimen A treatment in Session 2.~Regimen A: 50 mg Albiglutide Liquid Auto-injector + Placebo lyophilized DCC Pen injector.~Regimen B: 50 mg Albiglutide lyophilized DCC Pen injector + Placebo Liquid Auto-injector.~A minimum of an 8-week washout period between study treatment administration of Session 1 and Session 2."
2985385|NCT02660723|Other|Healthy Volunteers|A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
2985386|NCT02660710|Experimental|R-CHOP|We will enroll 40 adult patients age 18-60 years (20 HIV-infected with CD4 count ≥ 100 cells/µL, 20 HIV-uninfected) who will receive a maximum of 6-8 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) over 18-24 weeks
2985387|NCT02660697|Active Comparator|Test - Extraction site development group|In the test group 29 healthy patients presenting 33 single rooted teeth scheduled for extraction with Extraction Defect Sounding (EDS) Class 3-4 type buccal bony dehiscences were included. 29 maxillary single rooted teeth and 4 single rooted teeth in the mandible (27 incisors, 2 canines and 4 premolars) were removed and treated by the novel extraction site development method. Pre- and postoperative ConeBeam Computer Tomography (CBCT) data were collected for further analysis.
2985388|NCT02660697|No Intervention|Control - Spontaneous healing group|In the control group. pre- and postextraction CBCT data sets of 14 patients with 21 extracted teeth were collected. 11 maxillary single rooted teeth and 10 single rooted teeth in the mandible (13 incisors, 2 canines and 6 premolars) were extracted and left for spontaneous healing.
2985389|NCT02660684|Experimental|Prograf + MTX|
2985390|NCT02660684|Active Comparator|Cyclosporine + MTX (historical control)|
2985391|NCT02660671|Active Comparator|Usual care|Email outreach
2985392|NCT02660671|Experimental|Active choice|Email outreach + active choice
2985393|NCT02660671|Experimental|Financial incentive + Active choice|Email outreach + active choice + financial incentive
2985394|NCT02660658|Other|Intrathecal dexmedetomidine|"Up-down sequential allocation~The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance"
2985395|NCT02660645||Blue Light Cystoscopy with Cysview®|Bladder cancer patients who have undergone Blue light cystoscopy with Hexaminolevulinate hydrochloride (Cysview®) 100mg in 50 milliliters (mL) reconstituted solution instilled intravesically into bladder prior to cystoscopy in operating room (OR). Retention time: 1-3 hours. The Karl Storz D-Light C Photodynamic Diagnostic (PDD) system is used for the cystoscopy procedure at the OR examination.
2985396|NCT02660632|Placebo Comparator|Thoracic epidural analgesia (TEA)|Patients who will be subjected for midline laparotomy, will receive epidural analgesia through an inserted thoracic epidural catheter before induction of general anesthesia
2985397|NCT02660632|Active Comparator|Rectus sheath catheter block|After insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected on each side, then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
2985398|NCT02660619||Low-risk patients|These will be patients with a prescription for opioids for chronic pain for at least 30 days, recruited from university-affiliated pain and rehabilitation medicine clinics that routinely employ precautions to avoid prescribing such medication to individuals seeking it for non-therapeutic reasons
2985399|NCT02660619||High-risk patients|These patients will be in treatment for addiction to opioids and have (or have had) a prescription of opioids to treat pain.
2985400|NCT02660606||Group 1: Opioid abusers|
2985401|NCT02660606||Group 2: Abusers of other substances|
2985402|NCT02660606||Group 3: Non-opioid abusers|
2985403|NCT02660606||Group 4: Non-opioid users|
2985404|NCT02660593|Experimental|SanGrow|Patients will be given SanGrow Decoction 150 ml per day for 3 months.
2985405|NCT02660580|Experimental|MSB11022|
2985406|NCT02660580|Active Comparator|Humira®|
2985407|NCT02660567|Experimental|Amr Maneuver|Active management of third stage plus Amr's maneuver
2985408|NCT02660567|No Intervention|Active management alone|Active management of third stage alone
2985409|NCT02660554|No Intervention|Usual care|In the usual care arm, antibiotic therapy against methicillin resistant Staphylococcus aureus (MRSA) will be given at the discretion of the care team. If bacterial cultures are negative for MRSA at 72 hours, the treating physician will be prompted to discontinue MRSA therapy.
2985410|NCT02660554|Experimental|Polymerase Chain Reaction|In subjects randomized to the polymerase chain reaction (PCR) arm, antibiotic therapy against methicillin resistant Staphylococcus aureus (MRSA) will be determined by the results of the PCR test. In subjects who are clinically stable, results from the PCR must be available prior to the administration of MRSA therapy. Subjects with a positive MRSA PCR will be administered MRSA therapy. In subjects with a negative MRSA PCR, MRSA therapy will be withheld. In subjects randomized to the automated PCR arm who are clinically unstable, empiric MRSA therapy will be allowed until the PCR is completed. In these cases of unstable subjects, empiric MRSA therapy will be discontinued if the PCR is negative.
2985411|NCT02660541|Active Comparator|Betafoam|Brand name: Betafoam® This is a medicated device (dressing) consisting of 3% povidone iodine.
2985412|NCT02660541|Active Comparator|Allevyn Silver dressing|Brand name: Allevyn® Silver
2985413|NCT02660528|Experimental|Tocilizumab|Tocilizumab 162 mg sc q2weeks x 4 doses
2985414|NCT02660515|Active Comparator|ORIF|The operation has to be performed within 3 weeks after the initial trauma. According to the current standard, antibiotic prophylaxis (Cefazoline, 1000 milligram intravenous) will be administered thirty minutes preoperatively. The distal radius will be approached according to Henry, which beholds an incision between the tendon of the flexor carpi radialis and the arteria radialis. After the fracture site is exposed, the fracture will be reduced and an appropriate volar locking plate will be positioned. The type and brand of the plate are at discretion of the treating surgeon. When a dorsal approach is deemed necessary the distal radius will be approached between the third and fourth dorsal extensor tendon compartments. To evaluate the quality of articular reduction, fluoroscopic images will be obtained. Wound closure will be performed using standard techniques.
2985415|NCT02660515|Active Comparator|ORIF with additional wrist arthroscopy|Surgery will be performed by a certified trauma surgeon, with experience in wrist arthroscopy. A delay of minimal 5 days before performing arthroscopy is mandatory to enable visualisation due to the organisation of the hematoma. During wrist arthroscopy, the forearm will be positioned upright and in neutral position, the elbow flexed by 90° and axial traction of 4-6 kg will be performed. Four portal entrees are created by superficial stab incisions and blunt preparation through the joint capsule; one midcarpal radiair and one midcarpal ulnar portal and the 3-4 and 6-R portal. A shaver is used for removal of fracture haematoma and osteocartilaginous debris. Cartilage damage will be graded using the Outerbridge classification system. With the 1 mm hook probe assessment of the quality of reduction and ligamentous injuries (TFCC, scapholunate and lunotriquetral) will be performed. Wound closure will be performed using standard techniques.
2985416|NCT02660502|Experimental|BioChaperone insulin lispro 0.1 U/kg|
2985417|NCT02660502|Experimental|BioChaperone insulin lispro 0.2 U/kg|
2985418|NCT02660502|Experimental|BioChaperone insulin lispro 0.4 U/kg|
2985419|NCT02660502|Active Comparator|Humalog®|
2985420|NCT02660489|Experimental|OC459 (CRTH2 antagonist)|OC459 50mg once daily for 5 weeks
2985421|NCT02660489|Placebo Comparator|Placebo|Placebo tablet once daily for 5 weeks
2985422|NCT02660476||QUDOS 1|Aims to recruit 1,700 diabetic patients (including 200 with type 1 diabetes mellitus (independent of healthcare setting)) attending the hospitals and primary care
2985423|NCT02660476||QUDOS 2|To further characterise 500 patients, from the total 1500 patients with T2DM recruited in QUDOS 1, who accept to continue with QUDOS 2 (a more detailed study and assessment).
2985424|NCT02660450|Experimental|Prescription for Workload|Prescription from 65% VO2max for 5 min of exercise
2985425|NCT02660450|Experimental|Prescription for Heart Rate|Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
2985426|NCT02660450|Experimental|Prescription Self Selected|Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
2985427|NCT02660437|Active Comparator|Effect of PR in MCI-group|Evaluation of the acute effect of a 3-week Pulmonary Rehabilitation (PR) program in cognitive function of MCI-Group using SMMSE, ACE-R, MoCA, TICS and Stroop test clinical instruments in reference to potential changes in pCO2 oscillation patterns (post-PR). Intervention: Pulmonary Rehabilitation program; 12 sessions of exercise training/breathing techniques.
2985428|NCT02660437|Placebo Comparator|Effect of PR in control-group|"Evaluation of the acute effect of a 3-week Pulmonary Rehabilitation (PR) program in cognitive function of control-group using SMMSE, ACE-R, MoCA, TICS and Stroop test clinical instruments in reference to potential changes in pCO2 oscillation patterns (post-PR).~Intervention: Pulmonary Rehabilitation program; 12 sessions of exercise training/breathing techniques."
2985431|NCT02660411|Active Comparator|Sevoflurane group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol and rocuronium.~Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
2985432|NCT02660411|Experimental|Propofol group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol and rocuronium.~Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
2985433|NCT02660398|No Intervention|Controls|Our control group will consist of an observational cohort of 40 patients in whom we will make quantitative assessments of the Train-of-four ratio (TOF ratio). This is done using the TOF-Watch SX monitor. The monitor will be calibrated after induction of general anesthesia, measurement of the TOF ratio will be obtained at time of extubation and again at the time of arrival to the Post Anesthesia Care Unit (PACU).
2985434|NCT02660398|Other|Intervention|The intervention consists of a protocol for intraoperative management of neuromuscular blockade with rocuronium and reversal with neostigmine. A train-of-four count of 4 at the thumb will be confirmed prior to administration of an adjusted dose of neostigmine. TOF ratio is measured in the same manner as for the Control group, it is done using the TOF-Watch SX monitor. The monitor will be calibrated after induction of general anesthesia, measurement of the TOF ratio will be obtained at time of extubation and again at the time of arrival to the Post Anesthesia Care Unit (PACU).
2985435|NCT02660385|Experimental|Cognitive Behavioral Therapy|Cognitive behavioral therapy for insomnia (CBT-I) will be provided in a group format, led by an interventionist. CBT-I includes strategies for modifying thoughts and behaviors about sleep. Participants will be instructed on and practice methods for modifying their thoughts and behaviors about sleep and insomnia. Participants will participate in four sessions, conducted every other week for 8 weeks. They will receive a call from the interventionist on intervening weeks.
2985436|NCT02660385|Active Comparator|Heart Failure Self-Management Education|Heart Failure Self-management education is an intervention that will be provided by a nurse in a group format. This includes standard components, such as education about fluid and sodium management, heart failure medications, diet and physical activity. Participants will participate in four sessions, conducted every other week for 8 weeks. They will receive a call from the interventionist on intervening weeks.
2985437|NCT02660372|Experimental|Imonogas|Imonogas 120 mg, 1 capsule three times daily for 8 weeks
2985438|NCT02660372|Active Comparator|Espumisan|Espumisan 40 mg, 2 capsules four times daily for 8 weeks
2985439|NCT02660359|Experimental|600 U Dysport® Group|
2985440|NCT02660359|Placebo Comparator|600 U Dysport® Placebo Group|
2985441|NCT02660359|Experimental|800 U Dysport® Group|
2985442|NCT02660359|Placebo Comparator|800 U Dysport® Placebo Group|
2985443|NCT02660346|Active Comparator|Group A - Daptomycin or Vancomycin|Standard of Therapy of physician's choice, usually daptomycin 6-8 mg/kg IVPB daily or vancomycin IVPB adjusted dose per site protocol with a goal vancomycin trough level: 15-20 mcg/mL.
2985444|NCT02660346|Experimental|Group B - Daptomycin with Ceftaroline|Daptomycin (6-8 mg/kg/day IVPB daily) with Ceftaroline (600 mg IVPB q8hr) to start within 72hrs of hospital admission. Daptomycin will be renally adjusted per package insert. Ceftaroline will be renally adjusted per institutional renal dosing recommendations for Q8h.
2985445|NCT02660333|Placebo Comparator|Placebo|Maltodextrin
2985446|NCT02660333|Active Comparator|Prebiotic|Fructooligosaccharide
2985447|NCT02660333|Active Comparator|Synbiotic|Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
2985448|NCT02660320|Active Comparator|Dermabrasion|Dermabrasion using dermaroller: The dermaroller is applied on the treated areas, this dermabrasion technique is based on micro holes performed using 540 micro needles (200µm depth) which should allow the penetration of the suspension cells or hyaluronic acid alone. Twelve passages will be performed on the treated area in order to achieve 60% of coverage.
2985449|NCT02660320|Placebo Comparator|Laser|To prepare the graft recipient site, the upper layer of epidermis is removed by superficial dermabrasion using Erbium or CO2 ablative laser. The test area is ready to receive suspension cells when the dermis will appeared. The cells suspension will be applied on the wound.
2985450|NCT02660307|Experimental|PROGRESS group|this group received the intervention based in meditation in the first 8 weeks. They were instructed to practice at least 5 times a week for up to half an hour a day. During the second 8 week period this group were left to manage their practice on their own.
2985451|NCT02660307|Other|control group|this group received no intervention in the first 8 weeks. During the second 8 week period, this group received the same intervention based in meditation that received PROGRESS group.
2985452|NCT02660294|Experimental|Platlet rich plasma|For those with endometrial thickness less than 7 mm intrauterine injection of platlet rich plasma (PRP) for enhancing endometrial thickness and receptivity
2985453|NCT02660294|No Intervention|Hormone replacement therapy|Oral intake of estradiol valerate for those with endometrial thickness less than 7 mm will improve endometrial receptivity
2985454|NCT02660281|Other|Full Intensity TBI-based Conditioning|Total Body Irradiation 1200 cGy of 150 cGy over 4 or 5 days, days -5 or -4 to -1 Fludarabine 30 mg/m2/day x 3 days, days -6, -5, -4 Stem Cell Infusion, day 0 Post- Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Mesna 50 mg/kg/day x 2 days, days +3 and +4
2985532|NCT02659774|Experimental|Group A|Health talk + workshop (Motivational intervention) + booklet + Short Message Service (SMS)
2985533|NCT02659774|Placebo Comparator|Group B|Face to Face counseling (Motivational intervention) + Booklet + SMS
2985455|NCT02660281|Other|Full Intensity Chemo-Only Conditioning|Fludarabine 25 mg/m2/day x 5 days, days -6, -5, -4, -3, -2 Busulfan 130 mg/m2/day x 4 days, days -6, -5, -4, -3 Pre-Stem Cell Infusion Cyclophosphamide 14.5 mg/kg/day x 2 days, days -3 and -2 Pre-Stem Cell Infusion Mesna 14.5 mg/kg/day x 2 days, days -3 and -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell Infusion Mesna 50 mg/kg/day x 2 days, days +3 and +4
2985456|NCT02660281|Other|Reduced Intensity Conditioning|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Melphalan 140 mg/m2/day x 1 day, day -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell InfusionMesna 50 mg/kg/day x 2 days, days +3 and +4
2985457|NCT02660281|Other|Non-Myeloablative Conditioning|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Pre-Stem Cell Infusion Cyclophosphamide 14.5 mg/kg/day x 2 days, days -3 and -2 Pre-Stem Cell InfusionMesna 14.5 mg/kg/day x 2 days, days -3 and -2 Total Body Irradiation 200 cGy, day -1 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, day +3 and +4 Post-Stem Cell Infusion Mesna 50 mg/kg/day x 2 days, day +3 and +4
2985458|NCT02660281|Other|Reduced Intensity Conditioning with Addition of Thiotepa|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Thiotepa 8 mg/kg, day -3 Melphalan 140 mg/m2/day x 1 day, day -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell InfusionMesna 50 mg/kg/day x 2 days, days +3 and +4
2985459|NCT02660268|Experimental|Clinical pathway|Patients in the experimental group will be followed according to the clinical pathway
2985460|NCT02660268|No Intervention|Control|Patients in the control group will receive standard care
2985461|NCT02660242|No Intervention|Control|No basal insulin adjustment, no carbohydrate intake (until glucose drops <70 mg/dL).
2985462|NCT02660242|Active Comparator|Basal insulin reduction|Basal insulin reduction to 50% five minutes before the start of exercise.
2985463|NCT02660242|Active Comparator|Glucose Tabs|Dextrose tabs orally (20 grams) five minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
2985464|NCT02660242|Experimental|G-Pen Mini™ (glucagon injection)|Glucagon (150 µg) five minutes before the start of exercise (SQ-abdomen).
2985465|NCT02660229|Experimental|Oxycodone Hydrochloride|Brand Name: OxyNorm® Generic name: Oxycodone hydrochloride
2985466|NCT02660229|Active Comparator|Morphine Sulphate|Brand name: BC Morphine sulfate Generic name: Morphine sulfate
2985467|NCT02660203|Experimental|forced expiration|2 daily sessions of forced expiration on ipsilateral decubitus from day 1 after surgery until chest tube removal
2985468|NCT02660203|No Intervention|control|No session of forced expiration
2985469|NCT02660190|Experimental|PDD|PDD at flexible cystoscopy
2985470|NCT02660190|Experimental|WL|WL only at flexible cystoscopy
2985471|NCT02660177|Experimental|metamizole|single IV metamizole (10mg/kg) administration
2985472|NCT02660164||Cohort A: High-Risk of Concussion|Middle school, high school and college athletes of either gender participating in sports where high-risk of concussion is anticipated: football, soccer, lacrosse, hockey, basketball, ice hockey, field hockey, rugby, cheerleading, boxing, and gymnastics.
2985473|NCT02660164||Cohort B: Low-Risk of Concussion|Middle school, high school and college athletes of either gender participating in sports where low-risk of concussion is anticipated: swimming, track, volleyball, baseball, softball and golf.
2985474|NCT02660151|Experimental|Treatment A-B|Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.
2985475|NCT02660151|Experimental|Treatment B-A|Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.
2985476|NCT02660138|Experimental|600 U Dysport® Group|
2985477|NCT02660138|Placebo Comparator|600 U Dysport® Placebo Group|
2985478|NCT02660138|Experimental|800 U Dysport® Group|
2985479|NCT02660138|Placebo Comparator|800 U Dysport® Placebo Group|
2985480|NCT02660125|Active Comparator|endometrial scratch injury|endometrial scratch done before ICSI cycle
2985481|NCT02660125|No Intervention|control|IcSI cycle without prior endometrial injury
2985482|NCT02660112|Experimental|(+)-Epicatechin|Total daily dose 75mg (+)-Epicatechin; 25mg cap three times per day by mouth for 24 weeks
2985483|NCT02660099|Experimental|Internet-delivered CBT|12 weeks of internet-delivered cognitive behavior therapy provided through a secure internet platform and online clinician contact
2985484|NCT02660086|Experimental|Personalized feedback|Emails and letters providing personalized nutrition feedback about food choices and health, social norms, and financial incentives for healthy food choices
2985485|NCT02660086|No Intervention|Control|Monthly letters with general nutrition information
2985486|NCT02660073|Experimental|NMES+FES group|NMES+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of surface NMES and ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks +3 weeks for measurements.
2985487|NCT02660073|Experimental|Control+FES group|Control+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of passive leg extension/flexion with no ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks+3 weeks for measurements.
2985488|NCT02660060|Experimental|Pramipexole Dexa Medica|Each tablet contains 0.25 mg pramipexole dihydrochloride monohydrate. An oral single dose of the tablet was administered at the first day of each treatment period.
2985489|NCT02660060|Active Comparator|Pramipexole Boehringer Ingelheim Pharma|Each tablet contains 0.25 mg pramipexole dihydrochloride monohydrate. An oral single dose of the tablet was administered at the first day of each treatment period.
2985534|NCT02659774|Placebo Comparator|Group C|Phone counseling (Motivational intervention) + Health talk + booklet + SMS
2985535|NCT02659774|Placebo Comparator|Group D|Phone counseling (Motivational intervention) + booklet + SMS
2985536|NCT02659761|Experimental|dolutegravir/abacavir/lamivudine|All study subjects will receive triumeq (600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine) single tablet that will be taken orally, once daily, during 96 weeks
2985490|NCT02660047|Active Comparator|Liraglutide|"Liraglutide: Solution for subcutaneous injection 6 mg/ml; Flexpen 3 ml.~Dose: s.c. 0,6 mg (0,1 mL) once daily. After 1 week, the dose will be increased to 1,2 mg (0,2 mL) once daily. If tolerated, after 1 week, dose will be increased to 1.8 mg (0,3 mL) once daily. In case of a hypoglycaemic episode, the dosage of oral blood glucose lowering medicaments will be adjusted first. If hypoglycaemia persists, Liraglutide / Liraglutide placebo will be adjusted on the basis of clinical parameters.~Duration: 26 weeks"
2985491|NCT02660047|Placebo Comparator|Liraglutide - Placebo|"Liraglutide placebo: Solution for injection; Flexpen 3 ml.~Dose: same as Liraglutide~Duration: 26 weeks"
2985492|NCT02660034|Experimental|Phase 1A|Approximately 50 subjects for the dose escalation until maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) determination
2985493|NCT02660034|Experimental|Phase 1B|Approximately 180 subjects for expansion in eight selected arms with nine cohorts.
2985494|NCT02660008|Experimental|ZP4207|ZP4207 (peptide analogue of human glucagon) Planned doses: 0.1, 0.3, 0.6, 1.0 mg s.c.
2985495|NCT02660008|Active Comparator|GlucaGen|GlucaGen (native glucagon) Planned doses: 0.5, 1.0 mg s.c.
2985496|NCT02659943|Experimental|Cohort 1|Dose escalation for patients who never had an alloHSCT
2985497|NCT02659943|Experimental|Cohort 2|Closed: Dose escalation for patients who have had an alloHSCT
2985498|NCT02659930|Experimental|1/Group 1|pomalidomide and liposomal doxorubicin in patients with KS requiring systemic therapy
2985499|NCT02659930|Experimental|3/Group 2|pomalidomide with liposomal doxorubicin in patients with advanced KS or KS and concurrent KSHV associated MCD or KICS
2985500|NCT02659930|Experimental|2/Group I|Pomalidomide and liposomal doxorubicin, given at the highest tolerated dose to patients with KS requiring systemic therapy
2985501|NCT02659917|Active Comparator|Ketac Molar® (3M/ESPE) - Glass ionomer|Pit and fissure sealing using conventional glass-ionomer cement
2985502|NCT02659917|Experimental|Maxxion® (FGM) - Glass ionomer cement|Pit and fissure sealing using conventional glass-ionomer cement
2985503|NCT02659917|Active Comparator|Ketac Molar® (3M/ESPE) - Glass ionomer -|Restoration using conventional glass-ionomer cement
2985504|NCT02659917|Experimental|Maxxion® (FGM) - Glass ionomer cement -|Restoration using conventional glass-ionomer cement
2985505|NCT02659904|Active Comparator|Less than 2 mm|Palatal mucosa thickness was measured from baseline to 1, 3 and 6 months after graft harvesting Intervention: Less than 2 mm remaining palatal tissue thickness
2985506|NCT02659904|Active Comparator|2 mm or more|Palatal mucosa thickness was measured from baseline to 1, 3 and 6 months after graft harvesting Intervention: 2 mm or more remaining palatal tissue thickness
2985507|NCT02659891|Active Comparator|Group 1 (Treatment)|Intravenous immune globulin (IVIg; Privigen®) 1g/kg monthly for 2 months with immunosuppression reduction.
2985508|NCT02659891|Placebo Comparator|Group 2 (Control)|Placebo infusion monthly for 2 months with immunosuppression reduction
2985509|NCT02659865|Placebo Comparator|Part A: Placebo|Single oral dose of placebo administered in one of three study periods
2985510|NCT02659865|Experimental|Part A: LY3039478 new formulation|Escalating single oral dose of LY3039478 administered in two of three study periods
2985511|NCT02659865|Experimental|Part B: LY3039478 original formulation|Single oral dose of LY3039478 administered in one of two study periods
2985512|NCT02659865|Experimental|Part B: LY3039478 new formulation|Single oral dose of LY3039478 administered in one of two study periods
2985513|NCT02659852|Experimental|Side by side group|
2985514|NCT02659852|Active Comparator|Stent in stent group|
2985515|NCT02659839||Cancer patients admitted to the ICU|Patients with cancer admitted to the ICU. No intervention will be administered.
2985516|NCT02659826|Experimental|anodal tsDCS and gait training|Volunteers will be submitted to anodal transcutaneous spinal cord stimulation and gait training
2985517|NCT02659826|Experimental|cathodal tsDCS and gait training|Volunteers will be submitted to cathodal transcutaneous spinal cord stimulation and gait training
2985518|NCT02659826|Sham Comparator|sham tsDCS and gait training|Volunteers will be submitted to sham transcutaneous spinal cord stimulation and gait training
2985519|NCT02659826|Experimental|High frequency rTMS and gait training|Volunteers will be submitted to high frequency transcranial magnetic stimulation and gait training
2985520|NCT02659826|Experimental|Low frequency rTMS and gait training|Volunteers will be submitted to low frequency transcranial magnetic stimulation and gait training
2985521|NCT02659826|Sham Comparator|sham rTMS and gait training|Volunteers will be submitted to sham transcranial magnetic stimulation and gait training
2985522|NCT02659813|Experimental|Firewire|Experimental Group 1. Novel orthodontic archwire.
2985523|NCT02659813|Experimental|CNiTi|Experimental Group 2. Current best available orthodontic archwire
2985524|NCT02659800|Placebo Comparator|Arm A1 (placebo)|"Patients receive placebo IM once weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Laboratory Biomarker Analysis Correlative Studies"
2985525|NCT02659800|Experimental|Arm A2 (CYT107 at 10 ug/kg)|"Patients receive glycosylated recombinant human interleukin-7 at 10 ug/kg IM once weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Laboratory Biomarker Analysis Correlative Studies"
2985526|NCT02659800|Experimental|Arm A3 (CYT107 at 20 ug/kg)|"Patients receive glycosylated recombinant human interleukin-7 at 20 ug/kg IM once weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Laboratory Biomarker Analysis Correlative Studies"
2985527|NCT02659800|Experimental|Arm B1 (CYT107 at 10 ug/kg)|"Patients receive glycosylated recombinant human interleukin-7 as in Arm A2. Patients also on Dexamethasone >0.75mg daily~Laboratory Biomarker Analysis Correlative Studies"
2985528|NCT02659800|Experimental|Arm B2 (CYT107 at 20 ug/kg)|"Patients receive glycosylated recombinant human interleukin-7 as in Arm A3. Patients also on Dexamethasone >0.75mg daily~Laboratory Biomarker Analysis Correlative Studies"
2985529|NCT02659787|Active Comparator|Low dose buprenorphine|Subjects all receive placebo, 0.2 mg buprenorphine, and 0.4 mg buprenorphine in crossover design
2985530|NCT02659787|Active Comparator|Higher dose buprenorphine|Subjects all receive placebo, 0.2 mg buprenorphine, and 0.4 mg buprenorphine in crossover design
2985531|NCT02659787|Placebo Comparator|Placebo|Subjects all receive placebo, 0.2 mg buprenorphine, and 0.4 mg buprenorphine in crossover design
2985537|NCT02659748|Experimental|Milk fat|A 21-day low-fat (E%) experimental diet including milk fat with macronutrient and fatty acid class profiles differing only in type of fat and, thus, the proportion of single (bioactive) fatty acids.
2985538|NCT02659748|Experimental|Control Fat|A 21-day low-fat experimental diet. Eucaloric diet to Arm #1 with macronutrient and fatty acid class profiles differing only in type of fat and, thus, the proportion of single fatty acids. A control fat is used to replace dairy fats.
2985539|NCT02659735|Experimental|Panel 1: Treatment ADBC|Participants will receive Treatment A (600 milligram [mg] JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 1; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 2; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 3; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
2985540|NCT02659735|Experimental|Panel 1: Treatment BACD|Participants will receive Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 1; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 2; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 3; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
2985541|NCT02659735|Experimental|Panel I: Treatment CBDA|Participants will receive Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 1; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 2; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 3; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
2985542|NCT02659735|Experimental|Panel I: Treatment DCAB|Participants will receive Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 1; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 2; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 3; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
2985543|NCT02659735|Experimental|Panel 2: Treatment EFG|Participants will receive Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 1; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 2; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
2985544|NCT02659735|Experimental|Panel 2: Treatment FGE|Participants will receive Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 1; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 2; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
2985545|NCT02659735|Experimental|Panel 2: Treatment GEF|Participants will receive Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 1; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 2; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
2985546|NCT02659735|Experimental|Panel 2: Treatment GFE|Participants will receive Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 1; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 2; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
2985547|NCT02659735|Experimental|Panel 2: Treatment FEG|Participants will receive Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 1; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 2; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
2985548|NCT02659735|Experimental|Panel 2: Treatment EGF|Participants will receive Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 1; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 2; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
2985549|NCT02659709|Other|Glaucoma Smartphone Application|Glaucoma patients will test a glaucoma smartphone application (app) on smart phones or tablets then complete 20 item questionnaire providing demographic information, effectiveness and ease of use with the application.
2985550|NCT02659683|Experimental|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
2985551|NCT02659683|Active Comparator|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
2985580|NCT02659423||Alternative programs BIC 3|"Bystander Intervention Components Clusters will include at least a component of Green Dot.~E.g. Comparisons will be made across schools that have alternative program versus those that do not. (BIC 3)"
2985552|NCT02659657|Experimental|Interleukin-2 interventions|Patients with standard risk hematologic malignancies undergoing an unmodified haploidentical HCT will be eligible. Once patients achieved neutrophil engraftment will be given IL-2, 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days).
2985553|NCT02659644|Experimental|Oral citrulline|
2985554|NCT02659631|Experimental|PF-06671008|
2985555|NCT02659618||Severe Persistent Asthma|All subjects will have severe persistent asthma diagnosed by a doctor.
2985556|NCT02659605|Experimental|Delayed cord clamping above the perineum|
2985557|NCT02659605|Active Comparator|Delayed cord clamping below the perineum|
2985558|NCT02659592|Experimental|infertile cancer survivors|infertile cancer survivors who seek to conceive and had frozen ovarian tissue when diagnosed years before
2985559|NCT02659579|Experimental|The Reader Organisation's Shared Reading Programme|In the Reader Organisation's Shared Reading Programme, parents and children will attend The Reader Organisation's weekly shared reading programme for 8 weeks. The programme consists of two different modules. Parents will attend 'Magical Storytimes' with their children, in which a collection of shared book reading sessions are led by a project worker. Parents will also attend sessions on their own ('Stories for you and Yours') in which they will be informed how to choose books and read interactively with their child.
2985560|NCT02659579|Active Comparator|Shared Reading control|In the Shared Reading control parents and children will attend a weekly shared reading group at a library for 8 weeks where parents/children will read in a shared reading group which will be coordinated by a group facilitator.
2985561|NCT02659553||mild steatosis|5% - 30% of hepatocytes have fatty infiltration
2985562|NCT02659553||moderate steatosis|30% - 60% of hepatocytes have fatty infiltration
2985563|NCT02659553||No steatosis|No or less than 5% of hepatocytes have fatty infiltration
2985564|NCT02659540|Experimental|Cohort A|Subjects in Cohort A will initially receive a conventional total radiotherapy palliative dose of 30 Gy delivered over 2 weeks in 10 fractions of 3 Gy each.
2985565|NCT02659540|Experimental|Cohort B|Subjects in Cohort B will receive the high-dose hypofractionated radiotherapy for which treatment of a target lesion will comprise a total palliative dose of 27 Gy delivered over 2 weeks in 3 fractions of 9 Gy each.
2985566|NCT02659527|Active Comparator|standardized needle biopsy|"All enrolled patients are examined by means of dual tracer PET / MRI. Images will be interpreted by 4 designated readers. The readers are blinded of the respective results among each other. A consensus of the two principal readers of nuclear medicine and radiology will serve as reference for the guided needle biopsy. Additionally the readers are blinded to any result of the pathological workout until the recruitment of the last patient is finished.~According to the randomization, the standardized 12 core TRUS-guided biopsy is performed without knowledge of imaging findings by the urologist. If the biopsy is negative patients will have an additional image-guided biopsy with 4 more cores samples. After a positive biopsy the subjects be treated according to normal clinical practice."
2985567|NCT02659527|Experimental|image-guided biopsy|"All enrolled patients are examined by means of dual tracer PET / MRI. Images will be interpreted by 4 designated readers. The readers are blinded of the respective results among each other. A consensus of the two principal readers of nuclear medicine and radiology will serve as reference for the guided needle biopsy. Additionally the readers are blinded to any result of the pathological workout until the recruitment of the last patient is finished.~Patients will have a standardized 12 core TRUS-guided biopsy without knowledge of imaging findings by the urologist. Patients randomized in this arm will have an additional image-guided biopsy with 4 more cores samples. After a positive biopsy the subjects be treated according to normal clinical practice."
2985568|NCT02659514|Experimental|Poziotinib, oral tablets|
2985569|NCT02659501|Active Comparator|Bupivacaine with epinephrine injections|Patients in the control arm of the study will be treated intra-operatively with standard of care, 0.5% bupivacaine and epinephrine injection (1:200,000), with 50 mg delivered into each breast pocket to perform a field block of the breast pocket (see below). Postoperatively, these patients will be treated with standard postoperative pain control, including narcotics as needed, such as morphine sulfate and hydrocodone/acetaminophen, and muscle relaxants, such as diazepam.
2985570|NCT02659501|Experimental|Liposomal bupivacaine|Patients in the experimental arm of the study will be treated intra-operatively with 1.33% liposomal bupivacaine, with 133 mg delivered to perform a field block of each breast pocket. Postoperatively, these patients will be treated with standard postoperative pain control, including narcotics as needed, such as morphine sulfate and hydrocodone/acetaminophen, and muscle relaxants, such as diazepam.
2985571|NCT02659488|Other|Lisdexamfetamine|During the Treatment Phase, subjects will be evaluated after 1, 2, 3, 4, 6, 8, 10, and 12 weeks (see Figure 2). The morning after completing the first fMRI scan, LDX will be started at 30 mg q AM (Baseline). After 1 week, LDX will then be increased to 50 mg q AM (Visit 1); after another week, LDX will be increased to 70 mg q AM (Visit 2). A single downward dose titration to 50 mg is allowed during week 3 if 70 mg/d is not tolerated. LDX dose at week 4 (50 or 70 mg/d) will be maintained for the next 8 weeks. Patients who do not tolerate 50 or 70 mg/day will be terminated. For patients who complete the 12-week treatment phase, LDX will be stopped at week 12 visit.
2985572|NCT02659475|Experimental|PHEN/TPM ER (Qsymia®)|PHEN/TPM ER (Qsymia®)
2985573|NCT02659462||patients post Fontan palliation for single ventricular hear|Cardio Pulmonary Exercise Testing
2985574|NCT02659462||Subjects post surgical correction of congenital heart disease|Cardio Pulmonary Exercise Testing
2985575|NCT02659462||Healthy patients|Cardio Pulmonary Exercise Testing
2985576|NCT02659436|Active Comparator|Verbal-linguistic CBT|Participants will receive 4 sessions of verbal cognitive restructuring and exposure therapy delivered in an individual therapy format.
2985577|NCT02659436|Experimental|Imagery-based CBT|Participants will receive 4 sessions of imagery-based cognitive work and behavioural experiments delivered in an individual therapy format.
2985578|NCT02659423||Green Dot BIC 1|"Bystander Intervention Components Clusters will include at least a component of Green Dot.~E.g. Comparisons will be made across schools that have Green Dot versus those that don't have Green Dot. (BIC 1)"
2985579|NCT02659423||Online BIC 2|"Bystander Intervention Components Clusters will include at least a component of online bystander training.~E.g. Comparisons will be made across schools that have online bystander training versus those that do not. (BIC 2)"
2998447|NCT02573558||PPF|patients who received propofol during the operation
2985581|NCT02659410|Experimental|Heat stress|4h exposure to heat stress alone or in combination with different solvents. Solvent concentrations are equal to their TLV. Heat conditions are 21, 25 and 30°C (WBGT). Inhalation exposure for all solvents and demal exposure for toluene.
2985582|NCT02659397|Experimental|ETC-1002 + Atorvastatin|ETC-1002 180 mg treatment, oral once daily added-on to Atorvastatin 80 mg once daily
2985583|NCT02659397|Placebo Comparator|Placebo + Atorvastatin|Placebo treatment, oral once daily added-on to Atorvastatin 80 mg once daily
2985584|NCT02659384|Experimental|Bevacizumab|Bevacizumab monotherapy treatment in arm 1 will be discontinued upon RECIST documented progression or upon treatment withdrawal, whichever occurs first. Patients will cross-over to the combination of bevacizumab and atezolizumab upon progression as long as they meet cross-over criteria.
2985585|NCT02659384|Experimental|atezolizumab + placebo|The randomized treatment regimen (atezolizumab + placebo) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients will cross over to the combination of atezolizumab and bevacizumab upon treatment failure as long as they meet cross-over criteria.
2985586|NCT02659384|Experimental|atezolizumab + acetylsalicylic acid|The randomized treatment regimen (atezolizumab + acetylsalicylic acid) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients will cross over to the combination of atezolizumab and bevacizumab upon treatment failure as long as they meet cross-over criteria.
2985587|NCT02659384|Experimental|atezolizumab + bevacizumab + placebo|The randomized treatment regimen (atezolizumab + bevacizumab + placebo) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients then go off protocol treatment and further treatment is left to the investigator's decision.
2985588|NCT02659384|Experimental|atezolizumab + bevacizumab + acetylsalicylic acid|The randomized treatment regimen (atezolizumab + bevacizumab + acetylsalicylic acid) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients then go off protocol treatment and further treatment is left to the investigator's decision.
2985589|NCT02659371|Experimental|Low energy diet|Low energy diet (800 kcal/d) for eight weeks, following 4 weeks on reintroduction supplying 1200 kcal/d.
2985590|NCT02659358||Biosensor + Patient Reported Outcomes (PRO)|Participants will wear a biosensor (Fitbit Charge HR®) continuously for a period of 15 days and respond to PROMIS questionnaires. This is not a chemotherapy or treatment-intervention trial.
2985591|NCT02659345|Experimental|Art Therapy|The art therapy intervention will be executed by an art therapist at the Cancer Center. The same art therapy practices that are utilized in daily practice will be employed in this study. The intervention will include assessment of patient's needs and goals in addition to utilization of various art modalities. Sessions will conclude with processing of the art and supportive counseling as appropriate. Pilot testing of the intervention has been performed informally at Maroone Cancer Center with positive feedback provided by patients and their support systems to the physicians, nurses, and art therapist. Change in pain, emotional distress, depression, adn anxiety will be measured by the emotions thermometer.
2985592|NCT02659332|Experimental|TURBT|Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of1ms)
2985593|NCT02659319|Experimental|Family Lifestyle (FL; n = 117)|This arm includes the Family Food & Lifestyle intervention (FL). Parents and children meet for 12 weekly, 90-minute psychoeducational groups in children's schools. They meet separately for 45 minutes and then conjointly for 45 minutes.
2985594|NCT02659319|Experimental|FL + Family Dynamics (FL+FD; n = 88)|This arm includes the Family Food & Lifestyle + Family Dynamics interventions (FL+FD). Parents and children meet separately for the full 90-minute psychoeducation sessions. The first 45 minutes are devoted to the Family Food & Lifestyle intervention and the second 45 minutes to the Family Dynamics intervention.
2985595|NCT02659319|Experimental|FL + Peer Group (FL+PG; n = 124)|This arm includes the Family Food & Lifestyle intervention plus the 12-session, Peer Group intervention.
2985596|NCT02659319|Experimental|FL + FD + Peer Group (FL+FD+PG; n = 130)|This arm includes the Family Food & Lifestyle intervention plus the Family Dynamics Intervention plus the Peer Group intervention.
2985597|NCT02659319|No Intervention|Control (n = 82)|Non-intervention control group
2985598|NCT02659306|Experimental|Metformin|Assessment will be done at the baseline, during and after 12 week of metformin use.
2985599|NCT02659293|Active Comparator|Lenalidomide (Control)|Treatment with lenalidomide only
2985600|NCT02659293|Experimental|Experimental Combination Regimen|Experimental arm using a combination of Carfilzomib, Lenalidomide and Dexamethasone
2985601|NCT02659280|Active Comparator|Standard of Care Therapy|Home Health or Outpatient Physical therapy services (a minimum of 1x/week).
2985602|NCT02659280|Experimental|Adjunct Therapy|"Home Health or Outpatient Physical therapy services (a minimum of 1x/week) with an adjunct Home Exercise Program given up to 1x/wk via Store and Forward tele-health through the Hudl Technique app."
2985603|NCT02659267|Experimental|Interventions Group=|Group of change behavior including physical activity and healthy eating habits promotion.
2985604|NCT02659267|No Intervention|Control Group=|Group that will not receive the VAMOS program as intervention, only participate in the Health Academy Program Activities.
2985605|NCT02659254|Experimental|Firesorb Implantation|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）in patients with coronary artery lesions.
2985606|NCT02659241|Experimental|AZD1775|Participants first take AZD1775 capsules 1 time each day on Days 1-5. Depending on when tumor reduction surgery is scheduled, participant may continue taking the study drug on Days 8-12, 15-19, and 22-26.
2985607|NCT02659228|Placebo Comparator|Control 1 (negative control)|Individuals with a diagnosis of UWS without neural markers of consciousness
2985608|NCT02659228|Active Comparator|Control 2 (positive control)|Individuals with a diagnosis of MCS, who are behaviourally responsive and who present neural markers of consciousness
2985609|NCT02659228|Experimental|Target Population|Individuals with a clinical diagnosis of UWS, but who possess some neurophysiological signatures of conscious awareness
2985610|NCT02659215|Experimental|Hyalofast with BMAC|A hyaluronan-based scaffold (Hyalofast®) is utilized together with autologous bone marrow aspirate concentrate (BMAC) in a one-step arthroscopic/mini-arthrotomic procedure.
2985643|NCT02658955|No Intervention|Large stitch|Cohort of patients operated previously with large stitch technique
2985743|NCT02658318||non-PRS|Cleft palate patients without the Pierre Robin Syndrome.
2985611|NCT02659215|Active Comparator|Microfracture|Microfracture is an arthroscopic surgical technique involving placement of microfracture penetrations within the cartilage defect to provide stem cells and growth factors from the bone marrow to aid cartilage repair.
2985612|NCT02659202|Experimental|Precision Spinal Cord Stimulator System|Intervention:the precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads lead extensions, each packaged as a separate kit.
2985613|NCT02659176|Active Comparator|Transperineal repair with PIS|transperineal repair of anterior rectocele with limited internal sphincterotomy
2985614|NCT02659176|Active Comparator|Transperineal repair without PIS|transperineal repair of anterior rectocele only
2985615|NCT02659163|Experimental|intervention|Intervention subjects will receive feedback on their health behaviors along with clinical recommendations.
2985616|NCT02659163|Active Comparator|control|Control subjects will receive feedback on their health behaviors for self-guided care.
2985617|NCT02659150|Other|Open-Label tocilizumab|tocilizumab will be given to rheumatoid arthritis patients at a dose of 162 mg subcutaneously a week
2985618|NCT02659124|Other|Standard of Care plus AmnioFix|All patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face.
2985619|NCT02659111|Experimental|High-intensity physical exercise, HIFE|
2985620|NCT02659111|Active Comparator|Physical training advice|
2985621|NCT02659098|Experimental|Open-Label Safety Run-in Phase: Treatment Group|Participants will receive CNTO 2476 3.0 x 10^5 cells in 50 microliter (mcL). CNTO 2476 will be delivered using the custom-designed Delivery System.
2985622|NCT02659085|Active Comparator|Electroconvulsive Therapy (ECT)|ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly. Each participating clinic decides for each patient whether the treatment is given uni- or bilateral, as well as the exact stimulation parameters. Choice of anesthetic drug (e.g. thiopental of propofol) and muscle relaxant is done by local anesthesiologist. The procedure differs in no way from how a given patient would have been treated if he or she were not included in the study.
2985623|NCT02659085|Experimental|Ketamine IV Infusion|Ketamin intra venous infusions of racemic ketamine (0.5mg/kg), delivered over a period of 40 minutes thrice weekly, as ECT (Monday, Wednesday and Friday).
2985624|NCT02659059|Experimental|Nivolumab+Ipilimumab|"Part 1~Specified Dose on Specified Days"
2985625|NCT02659059|Experimental|Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy|"Part 2~Specified Dose on Specified Days"
2985626|NCT02659046||FH30|Patients treated by Pirkanmaa physician-staffed emergency medical service (EMS) unit
2985627|NCT02659046||FH10|Patients treated by Helsinki and Uusimaa physician-staffed emergency medical service (EMS) unit
2985628|NCT02659033|Active Comparator|ceftriaxone|healthy volunteer who receive ceftriaxone
2985629|NCT02659033|Active Comparator|cefotaxime|healthy volunteer who receive cefotaxime
2985630|NCT02659020|Experimental|Olaratumab + Gemcitabine + Docetaxel (Dose Escalation)|Olaratumab intravenously (IV) on day 1 and day 8 of each cycle (1 cycle = 21 days) with gemcitabine IV on day 1 and 8 and docetaxel IV on day 8. Participants may continue to receive treatment until discontinuation criteria are met.
2985631|NCT02659020|Experimental|Olaratumab + Gemcitabine + Docetaxel|Olaratumab IV on day 1 and day 8 of each cycle (1 cycle = 21 days) with gemcitabine IV on day 1 and 8 and docetaxel IV on day 8. Participants may continue to receive treatment until discontinuation criteria are met.
2985632|NCT02659020|Placebo Comparator|Placebo + Gemcitabine + Docetaxel|Placebo IV on day 1 and day 8 of each cycle (1 cycle = 21 days) with gemcitabine IV on day 1 and 8 and docetaxel IV on day 8. Participants may continue to receive treatment until discontinuation criteria are met.
2985633|NCT02659007|Experimental|yoga|yoga, 2 times a week for 8 weeks
2985634|NCT02658994|Experimental|THPP+|As part of THPP+, the intervention will continue from the 6th month postnatal through 36 months postnatal and so will consist of an additional 30 months of lower intensity services that are unique to THPP+. The THPP+ will also include additional group sessions to be held every other month for a total of 18 over the intervention duration. The content will be a continuation of the previous THPP sessions with continuing emphasis on self-care as well as the baby's health and development.
2985635|NCT02658994|Active Comparator|Enhanced Usual Care|Women in the control clusters who were depressed prenatally have been receiving Enhanced Usual Care (EUC). At the time of the screening, women, their Lady Health Workers, and their local primary health care facility were informed of the diagnosis, and women were given an information sheet about depression and how to access care. There are no new EUC protocols put in place post-partum as part of the THPP+.
2985636|NCT02658981|Experimental|A1 Anti-LAG-3|"Patients receive Anti-LAG-3 monoclonal antibody BMS-986016 IV over 60 minutes and on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Pharmacological Study~Laboratory Biomarker Analysis"
2985637|NCT02658981|Experimental|A2 Anti-CD137 (Urelumab)|"Patients receive Anti-CD137 (Urelumab) IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity~Pharmacological Study~Laboratory Biomarker Analysis"
2985638|NCT02658981|Experimental|B1 Anti-LAG3 + Anti-PD-1 (nivolumab)|"Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes and anti-LAG-3 monoclonal antibody BMS-986016 IV on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Pharmacological Study~Laboratory Biomarker Analysis"
2985639|NCT02658981|Experimental|B2 Anti-CD137 + Anti-PD-1|"Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes on days 1 and 15 and Anti-CD137 (urelumab) IV on day 1. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Pharmacological Study~Laboratory Biomarker Analysis"
2985640|NCT02658981|Experimental|Intratumoral Studies|Patients pre-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 (Arm A1), or urelumab (Arm A2), or nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B (B1)), or nivolumab and urelumab as in Part B (B2). Within 45 days of surgical resection, patients post-operatively receive drug from one of the four arms.
2985641|NCT02658968|Experimental|Betalutin|10 MBq/kg b.w., in escalated doses with lilotomab pre-dosing
2985642|NCT02658955|Experimental|Short stitch|Patients in which abdominal wall is closed by short stitch technique
2985739|NCT02658357|Experimental|900 mg|Three, 300 mg Risperidone Implants
2985644|NCT02658942|Active Comparator|Ureteroscopy|Intervention: Flexible ureteroscopy for removal of lower calyceal stones using holmium:YAG laser lithotripsy
2985645|NCT02658942|Active Comparator|Shockwave lithotripsy|Intervention: Shockwave lithotripsy for lithotripsy of lower calyceal stones using Siemens Lithostar Lithotriptor
2985646|NCT02658929|Experimental|bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
2985647|NCT02658916|Experimental|Panel 1: BIIB092|BIIB092 administered by intravenous (IV) injection, once every four weeks
2985648|NCT02658916|Experimental|Panel 2: BIIB092|BIIB092 administered by intravenous (IV) injection, once every four weeks
2985649|NCT02658916|Experimental|Panel 3: BIIB092|BIIB092 administered by intravenous (IV) injection, once every four weeks
2985650|NCT02658916|Experimental|Panel 4: BIIB092 (Expansion Panel)|BIIB092 administered by intravenous (IV) injection, once every four weeks.
2985651|NCT02658903|Experimental|Study arm with Oxys-Cathter|The study group is treated with a modified urinary catheter, which delivers electromagnetic therapy to prevent and treat bacterial colonization during the study period. The intervention is the insertion of the study urinary catheter (foley) into the bladder.
2985652|NCT02658903|Other|Control-arm with commercial catheter|The control group is treated with a commercial urinary catheter. The intervention is the insertion of the control urinary catheter (foley) into the bladder,
2985653|NCT02658890|Experimental|Combination Therapy (Dose Escalation)|BMS 986205 + Nivolumab specified dose at specified intervals.
2985654|NCT02658890|Experimental|Combination Therapy (Dose Expansion)|BMS 986205 + Nivolumab specified dose at specified intervals.
2985655|NCT02658890|Experimental|Combination Therapy 2 (Dose Expansion)|BMS 986205 + both Nivolumab and ipilimumab specified dose at specified intervals
2985656|NCT02658877|Experimental|Omalizumab|
2985657|NCT02658877|Placebo Comparator|Placebo|
2985658|NCT02658864|Experimental|10-mg group|Twelve healthy subjects were administered a single oral dose of 10 mg lafutidine tablets in fasted state.
2985659|NCT02658864|Experimental|20-mg group|Twelve healthy subjects were administered a single oral dose of 20 mg lafutidine tablets in fasted state.
2985660|NCT02658864|Experimental|40-mg group|Twelve healthy subjects were administered a single oral dose of 40 mg lafutidine tablets in fasted state.
2985661|NCT02658851|Experimental|J-Plasma|Enrolled participants will have their PLND performed using J-Plasma® for dissection and sealing of lymphatic channels.
2985662|NCT02658838|Experimental|full amount low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with full amount low molecular weight heparin until they leave hospital.
2985663|NCT02658838|Experimental|half amount low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with half amount low molecular weight heparin until they leave hospital.
2985664|NCT02658838|Experimental|No low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with no low molecular weight heparin.
2985665|NCT02658825|Experimental|Panel 1: Dose level 1|Participants will receive either treatment A (JNJ-63623872, 2400 milligram (mg) tablet orally once on Day 1) or treatment B [(placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1].
2985666|NCT02658825|Experimental|Panel 1: Dose level 2|Participants will receive either treatment C (JNJ-63623872, 3000 mg tablet orally once on Day 1) or treatment D [placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1].
2985667|NCT02658825|Experimental|Panel 2: Treatment EFG|Participants will receive treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 1; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 2; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
2985668|NCT02658825|Experimental|Panel 2: Treatment FGE|Participants will receive treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 1; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 2; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
2985669|NCT02658825|Experimental|Panel 2: Treatment GEF|Participants will receive treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 1; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 2; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 3. A washout period of 5 days will be maintained between each treatment period.
2985670|NCT02658825|Experimental|Panel 2: Treatment GFE|Participants will receive treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 1; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 2; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
2985671|NCT02658825|Experimental|Panel 2: Treatment FEG|Participants will receive treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 1; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 2; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
2985672|NCT02658825|Experimental|Panel 2: Treatment EGF|Participants will receive treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 1; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 2; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 3. A washout period of 5 days will be maintained between each treatment period.
2985673|NCT02658812|Experimental|Talimogene Laherparepvec (T-VEC)|"Talimogene laherparepvec given via intra-tumoral injection at visible locally recurrent breast cancer site and skin metastases at an initial dose of 10^6 PFU/mL .~Second talimogene laherparepvec dose administered 10^8 PFU/mL on Day 22, and talimogene laherparepvec administered every 2 weeks after the second course with same dose with the maximum dose of 4.0 mL for each course."
2985674|NCT02658799|Experimental|diclofenac potassium|"Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium) was administered from 2 to 4 months, then diclofenac potassium therapy was reinstituted (b.i.d.) from 4 to 6 months.~To promote compliance, each patient was recalled monthly."
2985675|NCT02658799|Active Comparator|placebo|"or placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of placebo was undertaken from baseline to 2 months, no drug (placebo) was administered from 2 to 4 months, then diclofenac potassium therapy was reinstituted (b.i.d.) from 4 to 6 months.~To promote compliance, each patient was recalled monthly."
2985676|NCT02658786||Hepatitis B patients|Biopsy proven Hepatitis B virus infected cases will be followed for the period of 5 years
2985677|NCT02658786||Hepatitis C patients|Biopsy proven Hepatitis C virus infected cases will be followed for the period of 5 years
2985678|NCT02658786||Non Alcoholic Fatty liver Disease patients|Biopsy proven Non Alcoholic Fatty liver Disease patients cases will be followed for the period of 5 years
2985679|NCT02658773|Active Comparator|lidocaine-Prilocaine cream|lidocaine-Prilocaine anesthetic cream placed into their cervix prior to having the IUD inserted
2985680|NCT02658773|Placebo Comparator|placebo cream|an inert placebo cream placed into their cervix
2985681|NCT02658760|Experimental|Bupivacaine|30cc of 0.25% bupivacaine
2985682|NCT02658760|Active Comparator|Dexmedetomidine and bupivacaine|30cc of 0.25% bupivacaine and 2mg/kg dexmedetomidine
2985683|NCT02658747||Cohort Docetaxel|Participants initiated on docetaxel for the treatment of relapsed non-small cell lung cancer (NSCLC)
2985684|NCT02658734|Experimental|Trastuzumab emtansine|
2985685|NCT02658721|Experimental|lidocaine+adjunct tramadol|In the first group (LDC+TRA group), IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation.
2985686|NCT02658721|Experimental|lidocaine+systemic tramadol|In the second group (LDC+SysTRA group), IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation.
2985687|NCT02658721|Active Comparator|lidocaine|In the third group (LDC group), IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL.
2985688|NCT02658708|Experimental|Arm 1: Bright blue-green light|Complete the MEQ at screening, the day before 2nd cycle of chemo, and on the day of 3rd cycle of chemo, -21 day light intervention at home for 30 min once a day during 2nd cycle of chemo, Scores of ≤41 (evening types) on MEQ will have light delivered within 30 minutes of waking for 21 consecutive mornings. Score of ≥59 (morning types) on MEQ will have light delivered between 1900-2000 hours for 21 consecutive evenings. Light therapy will be self-administered using a light visor cap. On 2 randomly selected days ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter, Continuous ambulatory PSG for 24 hours at the participant's home before and after the light intervention, Complete the fatigue and sleep log on a daily basis and two visual analog scales (VAS) (diurnal fatigue and daytime sleepiness) within half an hour upon awakening, at 1200 hours, 1600 hours, 2000 hours, and within half an hour before going to bed
2985689|NCT02658708|Active Comparator|Arm 2: Dim red light|Complete the MEQ at screening, the day before 2nd cycle of chemo, and on the day of 3rd cycle of chemo, 21 day light intervention at home for 30 min once a day during 2nd cycle of chemo, Scores of ≤41 (evening types) on MEQ will have light delivered within 30 minutes of waking for 21 consecutive mornings. Score of ≥59 (morning types) on MEQ will have light delivered between 1900-2000 hours for 21 consecutive evenings. Light therapy will be self-administered using a light visor cap. On 2 days randomly selected days ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter, Continuous ambulatory PSG for 24 hours at the participant's home before and after the light intervention, Complete the fatigue and sleep log on a daily basis and two visual analog scales (VAS) (diurnal fatigue and daytime sleepiness) within half an hour upon awakening, at 1200 hours, 1600 hours, 2000 hours, and within half an hour before going to bed
2985690|NCT02658695||Group 1|The distance between the fundal endometrial surface and air bubbles (air bubbles depth) <10 mm.
2985691|NCT02658695||Group 2|The distance between the fundal endometrial surface and air bubbles (air bubbles depth) >10 mm.
2985692|NCT02658682|Experimental|ABM +|Attention Bias Modification
2985693|NCT02658682|Sham Comparator|ABM -|Sham Attention Bias Modification
2985694|NCT02658669|Experimental|Cognitive-Behavioral Therapy for Insomnia|6-week manualized treatment designed to improve symptoms of chronic insomnia.
2985695|NCT02658669|Active Comparator|Sleep Education|6-week manualized treatment designed to provide information regarding traumatic brain injury and its relationship to sleep disturbance, which incorporates training in sleep hygiene to help improve nighttime sleep and daytime functioning.
2985696|NCT02658656|Active Comparator|Exoskeleton + SOC|Patient will receive exoskeletal-assisted walking device for in home use for 4 months
2985697|NCT02658656|No Intervention|SOC|Patient will receive standard of care (wheelchair use)
2985698|NCT02658643|Experimental|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
2985699|NCT02658643|Active Comparator|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
2985700|NCT02658630|Experimental|Device: Robot + TTT Exercise|All participants will be enrolled in this group to receive the same 60 minute study intervention consisting of wrist and shoulder-elbow robot training and TTT arm exercises.
2985701|NCT02658617||patients|20 patients were enrolled. Subjects were investigated with magnetic resonance spectroscopy (MRS), functional magnetic resonance imaging (fMRI) and also underwent a psychodiagnostic assessment (evaluating the severity of depression: Hamilton Depression Rating Scale and Beck Depression Inventory; measuring hopelessness: Beck Hopelessness Scale; measuring Alexithymia: Toronto Alexithymia Scale; measuring self-perception: Body Perception Questionnaire). 1-2 days after the imaging patients started the treatment with duloxetine: 30mg for the first three days, then 60-90mg.
2985740|NCT02658344|Experimental|Jointstem|Autologous Adipose Tissue derived MSCs
2985702|NCT02658617||healthy controls|Subjects were investigated with magnetic resonance spectroscopy (MRS), functional magnetic resonance imaging (fMRI) and also underwent a psychodiagnostic assessment (evaluating the severity of depression: Hamilton Depression Rating Scale and Beck Depression Inventory; measuring hopelessness: Beck Hopelessness Scale; measuring Alexithymia: Toronto Alexithymia Scale; measuring self-perception: Body Perception Questionnaire).
2985703|NCT02658604||Home visit by pharmacist|Patients of participating pharmacies age 65 or older, who are on 5 or more chronic prescription medications, and who have a need for, and agree to, a home visit by a pharmacist for a medication review.
2985704|NCT02658591|Active Comparator|Control|Crackers with no faba bean fraction
2985705|NCT02658591|Experimental|Faba bean protein concentrate|Crackers with added faba bean protein concentrate
2985706|NCT02658591|Experimental|Faba bean protein isolate|Crackers with added faba bean protein isolate
2985707|NCT02658591|Experimental|Faba bean flour|Crackers with added faba bean flour
2985708|NCT02658591|Experimental|Faba bean starch|Crackers with added faba bean starch
2985709|NCT02658578|Active Comparator|Active PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
2985710|NCT02658578|Placebo Comparator|Sham PNS|In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
2985711|NCT02658565|No Intervention|Low-risk for nodal involvement|No lymphadenectomy recommended
2985712|NCT02658565|Experimental|High-risk for nodal involvement|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
2985713|NCT02658552|Experimental|HIFU treatment|To collect the data after HIFU treatment
2985714|NCT02658526||control|children without anesthesia / surgery
2985715|NCT02658526||anesthesia|children with anesthesia for diagnostic reason
2985716|NCT02658526||surgery|children with anesthesia / surgery
2985717|NCT02658513||All Patients|"All patients will undergo both of the following interventions:~Lancet blood sampling Standard intravenous blood sampling"
2985718|NCT02658500|Experimental|Infant Formula|200 newborns just consume the infant formula from 0-42 days to six months age.
2985719|NCT02658500|Other|Breast Milk|100 newborns were just fed with breast milk from after birth to six months age.
2985720|NCT02658487|Experimental|Treatment (vosaroxin, cytarabine)|Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
2985721|NCT02658474|Experimental|ACT-group|Group based Acceptance and Commitment Therapy. The patients will attend to three sessions which last for three days. Between the sessions the patients will train at home on ACT related topics. The whole intervention will last for three months.
2985722|NCT02658474|No Intervention|Primary care|Treatment in a primary care setting.
2985723|NCT02658461||Trastuzumab IV Infusion|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via IV infusion.
2985724|NCT02658461||Trastuzumab SC Single-Use Injection Device|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC single-use injection device.
2985725|NCT02658461||Trastuzumab SC Vial/Syringe|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC vial/syringe.
2985726|NCT02658448|Experimental|GTx-024 3 mg|GTx-024 softgel capsules will be administered once daily to a total dose of 3 mg for up to 12 weeks.
2985727|NCT02658435|Experimental|Tafenoquine 300 milligram (mg) single dose|Participants will receive single dose of TQ (2 tablets of 150mg) after standard meal. Participant will be randomized in a 2:1 ratio to 300mg TQ (n=300) or matched-placebo (n=150).
2985728|NCT02658435|Placebo Comparator|Matched Placebo 300mg single dose|Participants will receive single dose of matched placebo (2 tablets of 150mg) after standard meal. Participant will be randomized in a 2:1 ratio to 300mg TQ (n=300) or matched-placebo (n=150).
2985729|NCT02658422|Experimental|Sequence A-B (Test Montelukast then Reference Montelukast)|Subjects will receive Treatment A- Test montelukast sodium 10 mg tablets (GW483100) in Treatment Period 1 and then Treatment B - Reference montelukast sodium 10 mg tablets (innovator product) in Treatment Period 2.
2985730|NCT02658422|Experimental|Sequence B-A (Reference Montelukast then Test Montelukast)|Subjects will receive Treatment B- Reference montelukast sodium 10 mg tablets (innovator product) in Treatment Period 1 and then Treatment A Test montelukast sodium 10 mg tablets (GW483100) in Treatment Period 2.
2985731|NCT02658409|Experimental|GC3106(quadrivalent)|0.5ml, intramuscular, a single dosing
2985732|NCT02658409|Active Comparator|Fluarix™tetra Syringe Inj.(Quadrivalent)|0.5ml,intramuscular,a single dosing
2985733|NCT02658396|Experimental|GO-203-2C|"Patients who fulfill eligibility criteria will be entered into the trial to receive Bortezomib and GO-203-2C.~After the screening procedures confirm participation in the research study:~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have multiple myeloma, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.~Bortezomib~GO-203-2C"
2985734|NCT02658383|Experimental|Cleaner cookstove received after visit 2|This arm receives the cleaner cookstove earlier in the study (after visit 2 which is approximately after 6 months)
2985735|NCT02658383|Experimental|Cleaner cookstove received after visit 4|This arm receives the cleaner cookstove later in the study (thus acting as a control arm until after visit 4 which is after approximately 1 yr and 6 months)
2985736|NCT02658370|Experimental|animated home-based exercises (Wii-fit)|using the Wii game console by Nintendo
2985737|NCT02658370|Active Comparator|conventional home-based exercise program|by using a compilation with 31 exercises especially for rheumatoid arthritis patients
2985738|NCT02658357|Experimental|600 mg|Two, 300 mg Risperidone Implants
2985744|NCT02658305||transoral group|orthognathic patients that were treated with a transoral surgical approach
2985745|NCT02658305||transbuccal group|orthognathic patients that were treated with a transbuccal surgical approach
2985746|NCT02658292|Active Comparator|NAFT900|NAFT900 (Naftifine hydrochloride foam, 3%)
2985747|NCT02658292|Placebo Comparator|Vehicle|Vehicle Foam
2985748|NCT02658279|Experimental|Pembrolizumab (MK-3475)|Pembrolizumab (MK-3475) will be administered intravenously at a fixed dose of 200mg every 3 weeks until disease progression. Patients will be followed with DCE perfusion MRI done at baseline and every 9 weeks (+/- 7 days). Patients will be allowed to stay on treatment if increase in tumor size is believed to be due to pseudoprogression. Patients who undergo surgery for tumor management will have tissue collected for collateral studies. All collected tissue will be stored in the Pathology Core Tissue bank at MSK.
2985749|NCT02658266|Experimental|Resistance training|Home based resistance training 12 weeks home based resistance training 3 times per week, 10-12 reps, 2 sets
2985750|NCT02658266|No Intervention|Control group|No instructed exercise training. Continue with habitual physical activity.
2985751|NCT02658253|Experimental|Group A1:Primvac 20 µg +alhydrogel|"Group A1: 3 European volunteers 0.5 ml intramuscular injection: 20 µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56"
2985752|NCT02658253|Experimental|Group A2:Primvac 20 µg +GLA-SE|Group A2: 3 European volunteers 0.5 ml intramuscular injection:20 µg Primvac+ 2.5 µg GLA-SE Vaccination schedule: D0, D28 and D56
2985753|NCT02658253|Experimental|Group B1:Primvac 50 µg +alhydrogel|"Group B1: 6 European volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56"
2985754|NCT02658253|Experimental|Group B2:Primvac 50 µg +GLA-SE|Group B2: 6 European volunteers 0.5 ml intramuscular injection:50 µg Primvac+ 2.5 µg GLA-SE Vaccination schedule: D0, D28 and D56
2985755|NCT02658253|Experimental|Group C1:Primvac 50 µg +alhydrogel|"Group C1: 10 African volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56"
2985756|NCT02658253|Experimental|Group C2: Primvac 50 µg +GLA-SE|"Group C2: 10 African volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 2.5 µg GLA-SE~Vaccination schedule: D0, D28 and D56"
2985757|NCT02658253|Placebo Comparator|Group C3: Placebo|"Group C3: 5 African volunteers 0.5 ml intramuscular injection: NaCl 0.9% (placebo)~Vaccination schedule: D0, D28 and D56"
2985758|NCT02658253|Experimental|Group D1:Primvac 100 µg +alhydrogel|"Group D1: 10 African volunteers 0.6 ml intramuscular injection: 100µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56"
2985759|NCT02658253|Experimental|Group D2: Primvac 100 µg +GLA-SE|"Group D2: 10 African volunteers 0.6 ml intramuscular injection: 100 µg Primvac+ 2.56 µg GLA-SE~Vaccination schedule: D0, D28 and D56"
2985760|NCT02658253|Placebo Comparator|Group D3: placebo|"Group D3: 5 African volunteers 0.6 ml intramuscular injection: NaCl 0.9% (placebo)~Vaccination schedule: D0, D28 and D56"
2985761|NCT02658240|Active Comparator|Compartment Block|Fascia iliaca compartment block (FICB) with ropivacaine and epinephrine after surgery
2985762|NCT02658240|Active Comparator|Infiltration|Periarticular infiltration with ropivacaine and epinephrine prior to closing the incision
2985763|NCT02658214|Experimental|Cohort 1|ovarian/peritoneal/fallopian tube cancer and squamous cell carcinoma of the head and neck (SCCHN)
2985764|NCT02658214|Experimental|Cohort 2|Small-cell lung cancer (SCLC)
2985765|NCT02658214|Experimental|Cohort 3|Triple-negative breast cancer (TNBC)
2985766|NCT02658214|Experimental|Cohort 4|Triple-negative breast cancer (TNBC)
2985767|NCT02658214|Experimental|Cohort 5|Gastric/gastro-esophageal junction (GEJ)
2985768|NCT02658214|Experimental|Cohort 6|Pancreatic ductal adenocarcinoma (PDAC)
2985769|NCT02658214|Experimental|Cohort 7|Esophageal squamous cell carcinoma (ESCC)
2985770|NCT02658201|Other|MRI group|Ultrafast MRI
2985771|NCT02658188|Experimental|ASP8825 group|
2985772|NCT02658175|Experimental|Volanesorsen|
2985773|NCT02658162|Experimental|SANGUINATE|Two (2) infusions of SANGUINATE
2985774|NCT02658162|Placebo Comparator|Normal Saline|Two (2) infusions of Normal Saline
2985775|NCT02658149|Experimental|Psoas Compartment Block|After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
2985776|NCT02658149|Active Comparator|Periarticular Local Anesthetic|"An anesthetic cocktail of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues."
2985777|NCT02658136|Other|1 arm study: CCT estimated right ventricular function.|
2985778|NCT02658123|Active Comparator|Group A: Standard of care|"Standard of care pre-operative education~Standard of care home health visits~Standard of care follow-up post-operative visits with surgeon and CWOCN~At 30-days post hospital discharge, the participant will:~See the physician~Turn in Patient Data Collection Form~Turn in Healthcare Utilization Form~Complete The City of Hope QOL Survey for Ostomy Patients~Ostomy assessment with a CWOCN, including photo of ostomy site"
2985779|NCT02658123|Experimental|Group B: Phone call|"Standard of care pre-operative education~Standard of care home health visits~Standard of care follow-up post-operative visits with surgeon and CWOCN~Telephone call 48-72 hours post-discharge from CWOCN/PA to evaluate tolerability to foods/fluids, activity level, screen for red-flags, review/assess for medication, reviewing pouching of ostomy, review patient's ability to obtain supplies, provide continued education, discuss proper use of durable medical equipment/frequency of pouch changes, and complete Patient Assessment Form.~At 30-days post hospital discharge, the participant will:~See the physician~Turn in Patient Data Collection Form~Turn in Healthcare Utilization Form~Complete The City of Hope QOL Survey for Ostomy Patients~Ostomy assessment with a CWOCN, including photo of ostomy site"
2985780|NCT02658110|Sham Comparator|Non Protein Trial|Mixed Macronutrient Breakfast Meal and Mixed Macronutrient Lunch Meal served without additional whey protein
2985781|NCT02658110|Experimental|Preload Trial|Whey protein (20g) administered 15 minutes prior to Mixed Macronutrient Breakfast Meal
2985782|NCT02658110|Experimental|With Meal Trial|Whey protein (20g) administered alongside Mixed Macronutrient Breakfast Meal
2985783|NCT02658110|Experimental|Post Meal Trial|Whey protein (20g) administered 15 minutes after Mixed Macronutrient Breakfast Meal
2985784|NCT02658097|Experimental|Single Fraction Radiation Therapy (SFRT) + pembrolizumab|200mg Pembrolizumab by IV infusion on day 1 of each 3 week cycle. 8Gy will be given in a single fraction on the first day of treatment
2985785|NCT02658097|Active Comparator|Pembrolizumab|200mg Pembrolizumab by IV infusion on day 1 of each 3 week cycle.
2985786|NCT02658084|Experimental|Phase 1: T-DM1 + Vinorelbine|One cycle of Trastuzumab Emtansine (T-DM1)/Vinorelbine combination treatment is defined as 21-days (i.e. 3 weeks). The recommended (starting) dose of trastuzumab emtansine is 3.6 mg/kg given as an intravenous infusion on Day 1 of every 21-day cycle. The starting dose of Vinorelbine is 22.5 mg/m2 given as a direct intravenous push over 6-10 minutes on day 1 and day 8 of every 3-week (i.e. 21-day) cycle. Participants will be treated until documented disease progression or other criteria for discontinuation. Approximately 15 to 21 patients will be needed to establish the recommended phase II dose (RP2D).
2985787|NCT02658084|Experimental|Phase 2: T-DM1 + RP2D Vinorelbine|One cycle of trastuzumab emtansine (T-DM1)/vinorelbine combination treatment is defined as 21-days (i.e. 3 weeks). Participants will receive the recommended Phase 2 Dose (RPSD) of Vinorelbine with the fixed dose (3.6 mg/kg) of Trastuzumab Emtansine. Participants will be treated until documented disease progression or other criteria for discontinuation. Up to 35 patients will be treated at the RP2D (MTD) including 6 patients treated at RP2D in phase I.
2985788|NCT02658058|Active Comparator|Landmark technique|As intervention, patients in this group are administered landmark guided midline spinal anesthesia.
2985789|NCT02658058|Experimental|Ultrasound-guided paramedian technique|As intervention, patients in this group are administered spinal anesthesia based on preprocedural ultrasound-guided paramedian technique using parasagittal oblique view
2985790|NCT02658058|Experimental|Ultrasound-guided midline technique|As intervention, patients in this group are administered spinal anesthesia based on preprocedural ultrasound-guided midline technique using transverse median view
2985791|NCT02658045||Normal healthy volunteers|Measurement of oxygen saturation simultaneously by standard oximeter and Oxitone oximeter in healthy volunteers during 6 min walking test
2985792|NCT02658045||COPD patients|Measurement of oxygen saturation simultaneously by standard oximeter and Oxitone oximeter in COPD patients during 6 min walking test
2985793|NCT02658032|Other|Standard Care/No Bio Feedback|This arm will consist of those first randomized to be enrolled in the standard care arm and then those enrolled in the non bio feedback arm.
2985794|NCT02658032|Other|Standard Care/ Bio Feedback|This arm will consist of those first randomized to be enrolled in the standard care arm and then those enrolled in the bio feedback arm.
2985795|NCT02658032|Other|Personalized Care/ No Bio Feedback|This arm will consist of those first randomized to be enrolled in the personalized care arm and then those enrolled in the non bio feedback arm.
2985796|NCT02658032|Experimental|Personalized Care/ Bio Feedback|This arm will consist of those first randomized to be enrolled in the personalized care arm and then those enrolled in the bio feedback arm.
2985797|NCT02658019|Experimental|Phase II Pembrolizumab|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first. Optional tumor tissue collection (if available) at screening for PD-L1 expression. Optional peripheral blood sample collection (if serum available) for biomarkers.
2985798|NCT02658006||Cardiac surgical patients|Adult patients having a cardiac surgery at the Montreal Heart Institute
2985799|NCT02657993|Experimental|Hypnosis|The hypnosis intervention involves three, face-to-face, hypnosis sessions delivered by doctoral-level psychology professionals
2985800|NCT02657993|Active Comparator|Attention Control (Non-Hypnosis)|The attention control intervention is matched to the hypnosis intervention in terms of the amount of professional time received by patients.
2985801|NCT02657980|Experimental|YBand(YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 5 days a week for 2 weeks (total of 10 applications)
2985802|NCT02657980|Sham Comparator|Sham-Yband(YDT-201N)|sham-tDCS application 5 days a week for 2 weeks (total of 10 applications)
2985803|NCT02657954|Experimental|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training
2985804|NCT02657954|Active Comparator|Holistic Cognitive Education (HCE)|Holistic Cognitive Education
2985805|NCT02657941|Experimental|Motivational group|psycho-education program inspired by motivational interviewing and behavioral psychotherapy
2985806|NCT02657941|Active Comparator|educational group|exclusively informative psycho-education program
2985807|NCT02657928|Experimental|Treatment (ribociclib and letrozole)|Patients receive ribociclib PO daily and letrozole PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2985808|NCT02657915|Placebo Comparator|Placebo|This was a follow-up study with no investigational product administered. Subjects in the placebo arm had received at least 1 dose of placebo in RENEW.
2985809|NCT02657915|Experimental|BIIB033 100mg/Kg|This was a follow-up study with no investigational product administered. Subjects in the BIIB033 arm had received at least 1 dose of 100 mg/kg BIIB033 in RENEW.
2985810|NCT02657902||Gamma 3 Nail|Fractures that were treated with a Gamma 3 nail
2985811|NCT02657902||Gamma 3 Nail + U-Blade|Fractures that were treated with a Gamma 3 nail and additional with antirotation U-blade lag screws.
2985812|NCT02657889|Experimental|niraparib plus pembrolizumab|"Phase 1: Dose-escalation: ascending doses of niraparib up to 300mg/day orally (PO) on Days 1-21 and pembrolizumab 200mg intravenously (IV) on Day 1 of each 21-day cycle~Phase 2: niraparib (recommended Phase 2 dose) in combination with pembrolizumab 200mg IV on Day 1 of each 21-day cycle"
2985813|NCT02657876|Experimental|ExpressGraft-C9T1 skin tissue|
2985814|NCT02657863||Healthy volunteer|Normal volunteers will be enrolled and informed consent obtained per study guidelines as described. Urine and plasma will be collected from each of 30 subjects with no prior history of prostate or other cancers.
2985815|NCT02657863||Prostate cancer patients being treat with radiation therapy|Prostate cancer patients will be enrolled and informed consent obtained per study guidelines as described. We will collect urine and plasma samples from 25 consecutive men being treated with radiation therapy for high-risk prostate cancer prior to the onset of therapy.
2985935|NCT02656992|Sham Comparator|Control group|Control group was prescribed at 10% of baseline maximal inspiratory pressure, and remained at this level during all training sessions for 8 weeks.
2985816|NCT02657863||Prostate cancer patients being treated with radiation therapy|Prostate cancer patients will be enrolled and informed consent obtained per study guidelines as described. We will collect urine and plasma samples from 5 consecutive men being treated with radiation therapy for high-risk prostate cancer prior to initiation of androgen deprivation (week 0), again prior to initiation of radiotherapy (week 8), at the end of radiation therapy (week 16) and at 6 months and 12 months after the conclusion of radiation therapy.
2985817|NCT02657850||control cohort - study subject self-reporting|Participants who have another cancer (not head and neck cancer) and undergoing treatment will self-report their dysphagia symptoms.
2985818|NCT02657850||study cohort - study subject self-reporting|Participants who have head and neck cancer and undergoing treatment will self-report their dysphagia symptoms.
2985819|NCT02657850||study cohort - provider reporting|Participants who have head and neck cancer and undergoing treatment will have their dysphagia symptoms reported by the provider.
2985820|NCT02657837||Cystic Fibrosis|Children 2.5 to 18 years old with confirmed diagnosis of cystic fibrosis
2985821|NCT02657837||Children with other respiratory disease|Children 2.5 to 18 years old with confirmed diagnosis of respiratory disease including but not limited to asthma, transplant, and sickle cell anemia.
2985822|NCT02657837||Healthy Children|Children and adults 2.5 to 30 years old with no history of chronic disease
2985823|NCT02657824||measuring ejection fraction|ejection fraction in an acute dyspneic patients
2985824|NCT02657811|Active Comparator|Bench Incubation|These embryos will be randomized to the bench incubator.
2985825|NCT02657811|Active Comparator|Time Lapse Incubation|These embryos will be randomized to the Time Lapse Incubator.
2985826|NCT02657811|Active Comparator|Time Lapse Incubation - Modified|These embryos will be randomized to the bench incubator.
2985827|NCT02657798||Depressed patients taking sertraline|Patients with depression who have been randomised to the sertraline arm in the PANDA trial
2985828|NCT02657798||Depressed patients taking placebo|Patients with depression who have been randomised to the placebo arm in the PANDA trial
2985829|NCT02657798||Healthy controls|Healthy participants with no history of depression
2985830|NCT02657785|Experimental|R-IDARAM plus intrathecal chemotherapy|Patients will be treated with systemic R-IDARAM plus intrathecal immunochemotherapy
2985831|NCT02657759|Experimental|CARDICHOL|Food supplement formula in shape of pill called CARDICHOL. 2 pills daily during 12 weeks (from visit V1 to visit V4). One pill immediately before, after or during breakfast and lunch.
2985832|NCT02657759|Placebo Comparator|Placebo|"placebo with the same characteristics, appearance, packaging, and composition as the active formula, except for active ingredients replaced by dicalcium phosphate and flavouring substances.~2 pills daily during 12 weeks (from visit V1 to visit V4). One pill immediately before, after or during breakfast and lunch."
2985833|NCT02657746|No Intervention|usual care|Usual care comprises existing services for hypertension control in the community without any additional training
2985834|NCT02657746|Experimental|multi-component interventions|: The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
2985835|NCT02657733|Other|Healthy volunteers|Respiration rate will be measured using several medical devices: Radical-7, Capnostream20p and Nellcor Bedside Respiratory Patient Monitoring System
2985836|NCT02657720|Other|Healthy volunteers|Respiration rate will be measured using several medical devices: Radical-7, Capnostream20p and PTAF2 (flow meter)
2985837|NCT02657707|Experimental|Single-arm, open label|To evaluate the safety and effectiveness of MicroVention, Inc. Roadsaver™ Carotid Stent System used in conjunction with the Nanoparasol® embolic protection system for the treatment of carotid artery stenosis in patients with elevated risk for adverse events following carotid endarterectomy.
2985838|NCT02657694||Sofosbuvir+Ledipasvir|Following patients treating with Sofosbuvir+Ledipasvir
2985839|NCT02657694||Sofosbuvir+Daclatasvir|Following patients treating with Sofosbuvir+Daclatasvir
2985840|NCT02657694||Sofosbuvir+Velpatasvir|Following patients treating with Sofosbuvir+Velpatasvir
2985841|NCT02657681|Experimental|tSMS|30 min of tSMS, one session per day, for 9 days over 2 weeks
2985842|NCT02657681|Placebo Comparator|sham|30 min of sham, one session per day, for 9 days over 2 weeks
2985843|NCT02657668|Experimental|Treatment Group|Emotion focused therapy: EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
2985844|NCT02657668|No Intervention|Control Group|Control group: For control group interactions to be effective in therapeutic outcomes, the psycho-educational group was assigned as control group. The Psycho-educational group was conducted in four sessions (without pretest and posttest sessions). They became familiar with etiology and role of psychological factors in IBS, without any psychotherapy. Eight members were removed (because of being absent more than three sessions).
2985845|NCT02657655|Experimental|Kinesia 360 Users|Parkinson's patients will be monitored continuously using wearable Kinesia 360 sensors.
2985846|NCT02657642||Cohort 1 (exposed)|cohort 1: patients who will receive the OMAGE-P transitional care in geriatric or internal medicine departement of the Eaubonne Hospital
2985847|NCT02657642||Cohort 2 (non exposed)|Cohort 2: : patients included in the usual care arm of the OMAGE RCT study in 2007-2008
2985848|NCT02657629|Active Comparator|Continuous Feeding Regimen|Enteral feedings given as combination of continuous nocturnal feedings and intermittent bolus daytime feedings.
2985849|NCT02657629|Active Comparator|Intermittent Bolus Feeding Regimen|Enteral feedings given as intermittent bolus feedings for entire 24 hour period.
2985996|NCT02656524||Cohort1/Regorafenib|All patients with at least 1 treatment with regorafenib
2998656|NCT02572193|Experimental|Active case|POEM procedure
2985850|NCT02657616||No anticoagulation with VKA/NOAC|No prescriptions of vitamin-k-antagonists/novel anticoagulants in all observational period; No prescriptions of low molecular weight heparins/Clopidogrel during observation period to the extent of more than 30 days.
2985851|NCT02657616||Anticoagulation with vitamin-k-antagonists|The patient should be treated stable during the observation period with vitamin-k-antagonists (at least one prescription per half-year). The patient should be not been around on other anticoagulants during the observation period. This means that no prescriptions of novel anticoagulants and not more than 30 days should be observable prescriptions of low molecular weight heparins/Clopidogrel per year.
2985852|NCT02657616||Anticoagulation with novel oral anticoagulants|The patient should be treated stable during the observation period with a novel anticoagulant (at least one prescription per half-year). This means that no vitamin-k-antagonists prescriptions and not more than 30 days should be observable prescriptions of low molecular weight heparins/Clopidogrel per year from the start of the observation period.
2985853|NCT02657603|Active Comparator|LAX insertion of catheter|Lidocaine 10mg/ml, 15 ml injected into the adductor canal
2985854|NCT02657603|Active Comparator|SAX insertion of catheter|Lidocaine 10mg/ml, 15 ml injected into the contralateral adductor canal
2985855|NCT02657564|Other|Polyethylene glycol (PEG)|3-L polyethylene glycol (PEG) is provided for colonoscopy preparation. Patients receive blood tests for renal function and electrolytes before and after colonoscopy.
2985856|NCT02657551|Experimental|Regorafenib|Regorafenib tablets orally, once daily at predetermined dosage for 21 days per cycle
2985857|NCT02657538|Active Comparator|Near infrared transillumination|Near infrared transillumination is applied for initial enamel caries lesion detection.
2985858|NCT02657538|Active Comparator|Visual caries detection + BW|visual caries detection + bite wing radiography (BW): considered as gold standard in caries diagnostics.
2985859|NCT02657512|Experimental|Arm A|"Period  rivaroxaban alone~Washout period (at least 6 days)~Period  rivaroxaban and activated charcoal 2 hours after rivaroxaban administration~Washout period (at least 6 days)~Period   rivaroxaban and activated charcoal 5 hours after rivaroxaban administration"
2985860|NCT02657512|Experimental|Arm B|". Period  rivaroxaban and activated charcoal 5 hours after rivaroxaban administration~Washout period (at least 6 days)~Period  rivaroxaban alone~Washout period (at least 6 days)~Period   rivaroxaban and activated charcoal 8 hours after rivaroxaban administration"
2985861|NCT02657512|Experimental|Arm C|". Period  rivaroxaban and activated charcoal 2 hours after rivaroxaban administration~Washout period (at least 6 days)~Period   rivaroxaban and activated charcoal 8 hours after rivaroxaban administration~Washout period (at least 6 days)~Period  rivaroxaban alone"
2985862|NCT02657499||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
2985863|NCT02657499||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
2985864|NCT02657486|Experimental|BGJ398|BGJ398 will be administered at a dose of 125 mg orally once daily on a three weeks on, one week off schedule.
2985865|NCT02657473|Active Comparator|TIS 300mg once daily|Tobramycin inhalation solution (TIS) 300mg once daily for a period of 12 months
2985866|NCT02657473|Placebo Comparator|Placebo once daily|Saline 0.9% inhalation solution 300mg once daily for a period of 12 months
2985867|NCT02657460|Experimental|MTX-ATMPs|methotrexate-autologous tumor derived microparticles
2985868|NCT02657460|Sham Comparator|cisplatin|Cisplatin is a traditional treatment for lung cancer
2985869|NCT02657447|Experimental|Arm 1: Betalutin with lilotomab dose 1|Betalutin 15 MBq/kg b.w. with lilotomab pre-dosing
2985870|NCT02657447|Experimental|Arm 2: Betalutin with lilotomab dose 2|Betalutin 15MBq/kg b.w. with lilotomab pre-dosing
2985871|NCT02657434|Experimental|Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed|Participants will receive intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experience clinical benefit during the induction phase will begin maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
2985872|NCT02657434|Active Comparator|Arm B (Carboplatin or Cisplatin + Pemetrexed)|Participants will receive IV infusion of 500 mg/m^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who do not experience disease progression during the induction phase will begin maintenance therapy. Participants will receive IV infusion of 500 mg/m^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
2985873|NCT02657408|Experimental|BI 1026706|
2985874|NCT02657408|Experimental|Placebo|
2985875|NCT02657395|Experimental|PriMatrix|Use of PriMatrix as a substitute for a subepithelial connective tissue graft under a coronal positioned flap for root coverage.
2985876|NCT02657382|Experimental|Heart Rate Variability (HRV) Biofeedback (BF)|Participants with coronary artery disease randomized to this group will complete myocardial blood flow (MBF) imaging and mental stress tests. Participants in this group will also participate in heart rate variability (HRV) biofeedback (BF) during the first six weeks of the study.
2985877|NCT02657382|Experimental|Waitlist Control|Participants with coronary artery disease randomized to this group will complete myocardial blood flow (MBF) imaging and mental stress tests.Participants in this group will receive the heart rate variability (HRV) biofeedback (BF) intervention between the week 6 and week 12 study visits.
2985878|NCT02657369|Experimental|Lenvatinib|Participants will receive lenvatinib 24 milligrams (mg) (2 10-mg capsules and one 4-mg capsule) once daily by oral administration at approximately the same time each morning for up to approximately 24 months.
2985879|NCT02657356|Placebo Comparator|Placebo capsules|Placebo capsules will be administered orally once a day for 24 weeks.
2986383|NCT02654054|Experimental|Elagolix + Estradiol/Norethindrone Acetate|Experimental
2985880|NCT02657356|Experimental|Bardoxolone methyl capsules|Bardoxolone methyl capsules will be administered orally once a day for 24 weeks. Starting dosage is 5 mg and will dose-escalate to 10 mg at Week 4, unless contraindicated clinically.
2985881|NCT02657343|Experimental|Cohort A|Ribociclib will be given orally once day (day 5-18) at a pre-determine dose for two weeks of a 21 day cycle. T-DM1 will be given as IV infusions on Day 1 of a 3 week cycle at a pre-determined dose over pre-determined period of time.
2985882|NCT02657343|Experimental|Cohort B|Ribociclib will be given orally once day continuously for a 21-day cycle of treatment (except at Dose Level -2, when Ribociclib is given Days 1-14 of a 21 day cycle). Trastuzumab will be given as IV infusions over a pre-determined period of time and dose.
2985883|NCT02657343|Experimental|Cohort C|Ribociclib will be given orally once a day continuously for a 28-day cycle of treatment (except at Dose Level -1, when Ribociclib is given Days 1-21 of a 28 day cycle). Trastuzumab will be given as IV infusions over a pre-determined period of time and dose. Fulvestrant will be dosed approximately every 28 days as per standard of care.
2985884|NCT02657330|Experimental|SBP-101|SBP-101 is administered as a subcutaneous injection once daily, Monday through Friday for 3 weeks (total of 15 doses) followed by a 5-week rest period (3 weeks on, 5 weeks off = 1 treatment cycle). Dose escalation in phase 1a will continue until the maximum tolerated dose is determined.
2985885|NCT02657317|Experimental|FORT-A|"has been labeled FORT-A. FORT-A is provided on an outpatient basis and includes 12 daily group pain management and physical therapy sessions spanning three weeks. Group interventions are supplemented by individual psychotherapy, biofeedback, and case staffings. CBT sessions were decreased in favor of CAM components. FORT-A participants will receive 270 minutes (4½ hours) of intervention a day for 12 days over 3 weeks."
2985886|NCT02657317|Active Comparator|VA Treatment As Usual|"Treatment As Usual (TAU) represents usual VA Care based on as usual appointments and referrals from VA providers. TAU can include active medical interventions, psychosocial intervention, and other rehabilitation strategies."
2985887|NCT02657304|Experimental|Coaching group|PPC + Coaching
2985888|NCT02657304|Active Comparator|Control group|PPC
2985889|NCT02657291|Experimental|Costoclavicular|Ultrasound-guided infraclavicular block using Ropivacaine 0.5% 35 mL using the costoclavicular approach
2985890|NCT02657291|Active Comparator|Paracoracoid|Ultrasound-guided infraclavicular block using Ropivacaine 0.5% 35 mL using the paracoracoid or standard approach
2985891|NCT02657278|Other|Symptomatic Peripheral arterial disease|Patients scheduled to undergo surgery or angioplasty of the iliofemoral segment for intermittent claudication.
2985892|NCT02657265|Experimental|SpineJack® system|Spine fracture management
2985893|NCT02657265|Active Comparator|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
2985894|NCT02657252|Active Comparator|Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
2985895|NCT02657252|Active Comparator|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
2985896|NCT02657239|Experimental|MOVE UP Intervention|Subjects will participate in a healthy lifestyle weight management intervention focused on healthy eating and increasing physical activity
2985897|NCT02657226||Intensive Monitoring of Renal Function|Urine output measurements recorded at least every 2 hours within the first 48 hours of ICU admission and serum creatinine measurements recorded daily for 3 days following ICU admission.
2985898|NCT02657226||Less-Intensive Monitoring of Renal Function|Urine output measurements with gaps of more than 3 hours recorded during the first 48 hours of ICU admission and fewer than 3 days of serum creatinine measurements after ICU admission.
2985899|NCT02657213|Experimental|Minimed 640G with smartguard activated|"Group SmartGuard On: Patients will be equipped with a sensor augmented pump (SAP) therapy Minimed 640G insulin pump with SmartGuard activation"
2985900|NCT02657213|Active Comparator|Minimed 640G with smartguard off|"Group SmartGuard Off Patients will be equipped with a sensor augmented pump (SAP) therapy Minimed 640 insulin pump without SmartGuard activation"
2985901|NCT02657187|Experimental|rocuronium 1|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.24mg per muscle mass(kg).
2985902|NCT02657187|Experimental|rocuronium 2|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.32mg per muscle mass(kg).
2985903|NCT02657187|Experimental|rocuronium 3|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.40mg per muscle mass(kg).
2985904|NCT02657187|Experimental|rocuronium 4|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.48mg per muscle mass(kg).
2985905|NCT02657174|Experimental|G1- experimental active comparator group|G1 - (Experimental) 40 third molars surgeries will be performed in a conventional manner. At the end of surgery low level laser in auricular acupuncture points will be applied for prevention of inflammation and pain in a split-mouth design.
2985906|NCT02657174|Placebo Comparator|G2- control group|G2 - (Control) 40 third molars surgeries will be performed in the conventional manner, identically to the G1. At the end of surgery low level laser device off in auricular acupuncture points will be applied. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1, with split-mouth design.
2985907|NCT02657161|Active Comparator|Group A|"Comparator vaccine RABIPUR®~Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14"
2985908|NCT02657161|Experimental|Group B|"PIKA Rabies vaccine~Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14"
2985909|NCT02657161|Experimental|Group C|"PIKA Rabies vaccine with an accelerated regimen~Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose)"
2985997|NCT02656511|Experimental|Dolutegravir+Emtricitabine/Tenofovir|Dolutegravir 50 mg PO daily plus Emtricitabine 200 mg/Tenofovir alafenamide 25 mg
2986384|NCT02654054|Placebo Comparator|Placebo|Placebo
2985910|NCT02657148||Immediate postpartum Nexplanon|Participants who choose to enroll in the immediate postpartum Nexplanon arm will have a etonogestrel contraceptive implant (68 mg) (Nexplanon) placed in the immediate postpartum period (2-4 days following delivery), prior to hospital discharge.
2985911|NCT02657148||Control|Participants who choose to enroll in the control arm will receive standard postpartum contraceptive care: condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at > 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time > 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time > 6 weeks after delivery.
2985912|NCT02657135|Experimental|History of Traumatic Brain Injury|All participants have a history of TBI. At study outcome participants are provided treatment recommendations that are the result of a consensus meeting of all physician investigators. Follow up care is not provided by this clinical trial.
2985913|NCT02657122|Experimental|TD-1473 for SAD|6 of out 8 subjects per cohort will be randomized to receive TD-1473
2985914|NCT02657122|Placebo Comparator|Placebo for SAD|2 of out 8 subjects per cohort will be randomized to receive placebo
2985915|NCT02657122|Experimental|TD-1473 for MAD|6 of out 8 subjects per cohort will be randomized to receive TD-1473
2985916|NCT02657122|Placebo Comparator|Placebo for MAD|2 of out 8 subjects per cohort will be randomized to receive placebo
2985917|NCT02657109|Active Comparator|Control|Participants are submitted to cardiac rehabilitation protocol of the hospital where it will be conducted the study, which consists in respiratory exercises of 3 series Inspirations Maximum Sustained for 10 reps, 3 sets of 20 repetitions metabolic exercises with dorsiflexion and plantar flexion and ankle and wrist extension and fingers of the upper limbs. Assessment of heart rate varibility and oxidative stress carried out before the heart valve replacement surgery , the first day of postoperative and on the fifth postoperative day
2985918|NCT02657109|Active Comparator|Early mobilization|Participants performed exercise in cycle ergometer of lower Limbs, pedaling for 20 consecutive minutes at a moderate level with Heart Rate Assessment and the Borg scale to evaluate the Voluntary Comfort. Assessment of heart rate varibility and oxidative stress carried out before the heart valve replacement surgery , the first day of oepratório post and on the fifth postoperative day
2985919|NCT02657096|Experimental|Hybenx treatment|Both quadrants included maxillary teeth 11-16 and 21-26. Each selected subject underwent randomly, without anaesthesia, at the same time and after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional SRP + desiccant (Hybenx). In the maxillary quadrant assigned to SRP + hybenx treatment, hybenx was applied, after SRP, on the marginal gingiva with a 30-second incubation period and then thoroughly rinsed away through abundant irrigation with a sterile saline solution.
2985920|NCT02657096|Sham Comparator|Scaling and Root Planing|The contra-lateral quadrants were treated as conventional Scaling and Root Planing (SRP) alone.
2985921|NCT02657083|Experimental|Glucose control using DreaMed MD-AID|In this group the subjects use a closed loop system (DreaMed Substance Administration Device) that combines glucose monitoring system (S.C wired sensor, named Sof® Sensor™ or Enlite® Sensor™), which provides real-time interstitial glucose values, with a modern insulin pump (MiniMed® Paradigm® Veo™, Medtronic) and computer algorithm, which directs insulin delivery in response to glucose sensor data.
2985922|NCT02657083|Active Comparator|Glucose control using SAP|In this group the subjects use a standard treatment (Sensor Augmented Pump), characterised by glucose monitoring system (S.C wired sensor, named Sof® Sensor™ or Enlite® Sensor™) which provides real-time interstitial glucose values and a modern insulin pump (MiniMed® Paradigm® Veo™, Medtronic) without computer algorithm decisions.
2985923|NCT02657070|Experimental|Experimental Group|Virtual reality based therapy with augmented visuomotor feedback.
2985924|NCT02657070|Active Comparator|Control Group|Virtual reality based therapy without augmentation.
2985925|NCT02657057|Experimental|Transcutaneous Tibial Nerve Stimulation|TENS SNS therapy is performed as follows; patient is asked to sit with legs slightly bent and an adhesive electrode is attached transcutaneously 5cm cephalic to either the right or left medial malleolus (subject choice). A surface electrode is placed on the medial surface of the ipsilateral calcaneum and both electrodes are connected to a low voltage electronic stimulator. The current is then set to the highest level tolerable to the subject (0-20 mA) and subject undergoes therapy for 30 minutes and 12 weeks (once-a-week session). Data are completed at baseline, after half therapy and after 12 weeks therapy.
2985926|NCT02657057|Active Comparator|Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; patient is asked to sit with legs slightly bent. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial surface of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage electrical stimulator. The current is then set to the highest level tolerable to the subject (0-20 mA) and the subject undergoes therapy for 30 minutes and 12 weeks (once-a-week session). Data are completed at baseline, after half therapy and after 12 weeks therapy.
2985927|NCT02657044|Active Comparator|EMR|In the EMR-arm, endoscopic resection will be performed using the (p)EMR technique.
2985928|NCT02657044|Active Comparator|ESD|In the ESD-arm, endoscopic resection will be performed using the (h)ESD technique.
2985929|NCT02657031|Active Comparator|Control Arm|This arm uses standard of care treatment of prochlorperazine 10 mg IV along with diphenhydramine 25 mg IV plus Normal Sailine 500 cc bolus
2985930|NCT02657031|Experimental|Study Arm|This arm uses stud drug regime of Ketamine 0.3 mg/kg along with Ondansetron 4 mg IV plus Normal Saline 500 cc bolus.
2985931|NCT02657018|Experimental|Intervention|MOBIGAME group
2985932|NCT02657018|Active Comparator|Control|Lifestyle counseling group
2985933|NCT02657005|Experimental|TK216 treatment|Dose escalation and expansion cohorts to determine dose-limiting toxicities, maximally tolerated dose, preliminary efficacy, and recommended phase 2 dose.
2985934|NCT02656992|Experimental|High-IMT group|Intervention group receive supervised training sessions three times per week for 8 weeks. Each sessions lasted 21 minutes and comprised seven cycles of 2 minutes of breathing on an inspiratory threshold device followed by 1 minute of rest. High-IMT was performed at the maximal load tolerable for each 2-minute work interval and was progressively increased over the training period.
2985936|NCT02656979|Other|Blood flow pre&post IOP lowering|After measurement of blood flow with MRI and measurements of ocular parameters the patient receives the IOP lowering eye drop latanoprost once daily in one eye for approximately one week and then the measurements are are repeated in the same manner.
2985937|NCT02656979|No Intervention|Blood flow|The subjects will do blood flow measurements with MRI and measurements of ocular parameters only once. No intervention with IOP lowering drops.
2985938|NCT02656966|Active Comparator|Auricular acupuncture + standard therapy|Patients, who will wish acupuncture, will receive this intervention, in addition to standard therapy
2985939|NCT02656966|No Intervention|Standard therapy alone|Patients who do not wish acupuncture will be asked if they will fill in the study questionnaire
2985940|NCT02656953|Experimental|VDU lenses|VDU lenses provide a clear vision of the intermediate zone at a distance of approximately 70 centimeters, which is closer than distant vision at a distance of more than 2 meters (e.g. driving), but further than near vision at a distance of 40 centimeters (e.g. reading), so the computer screen is seen clear without the need for excessive focusing effort or bad postures. In this study Zeiss® Officelens Plus lenses with a Silhouette® frame were used.
2985941|NCT02656953|Active Comparator|Progressive lenses|Progressive lenses or multifocal lenses provide a continuous range of focal power between near and far distances.Progressive lenses have some lens power for the intermediate zone as well, but this zone might not be large enough for comfortable and ergonomic computer work. In this study Zeiss® Multifocal Precision Plus lenses with a Silhouette® frame were used.
2985942|NCT02656940|Experimental|Group 1 - diet rich in n-3 and n-6 PUFA|"Assigned intervention: The dietary intervention was conducted by 60 days. Were prescribed normocaloric diets with similar macronutrient composition, varying only the type of lipids offered.~Group 1 received diet rich in n-3 and n-6 polyunsaturated fatty acids (PUFA). The volunteers were asked to consume daily a mixture of virgin olive oil and soybean oil, totaling 35.2g to 52.8g, and 2 g of fish oil."
2985943|NCT02656940|Experimental|Group 2 - diet rich in MUFA|"Assigned intervention: The dietary intervention was conducted by 60 days. Were prescribed normocaloric diets with similar macronutrient composition, varying only the type of lipids offered.~Group 2 received diet rich in monounsaturated fatty acids (MUFA). The volunteers were asked to consume daily virgin olive oil, totaling 35.2g to 50.6g, and 1 capsule of 1g of soybean oil."
2985944|NCT02656940|Experimental|Group 3 - Placebo group|Placebo group was instructed to keep their eating habits and consuming 1 sachet of 2g of soybean oil and 1 capsule of 1g of soybean oil by day.
2985945|NCT02656927|Experimental|Yoga Condition|
2985946|NCT02656927|Placebo Comparator|Wait-list Control Condition|
2985947|NCT02656914|Experimental|Irlanda-2-Association|Take 10 mL every 12 hours (2x/day), oral route.
2985948|NCT02656914|Placebo Comparator|Placebo|Take 10 mL every 12 hours (2x/day), oral route.
2985949|NCT02656901|Active Comparator|Auto Total endovenous anesthesia|The closed loop delivering as already approved by ClinicalTrials.gov Identifier: NCT00392158
2985950|NCT02656901|Sham Comparator|Manual Desflurane anesthesia|The anesthesia will be maintained with desflurane to target the BIS of 50.
2985951|NCT02656901|Sham Comparator|Manual sevoflurane anesthesia|The anesthesia will be maintained with sevoflurane to target the BIS of 50.
2985952|NCT02656901|Sham Comparator|Manual total endovenous anestesia|In ManualTIVA group, the anesthesia will be maintained with propofol to target the BIS of 50
2985953|NCT02656888|Experimental|Irlanda-1-Association|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
2985954|NCT02656888|Placebo Comparator|Placebo|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
2985955|NCT02656875|Experimental|TRV130|"For clinician-administered bolus dosing, TRV130 initial dose is administered and supplemental dosing is available, if clinically indicated. Subsequent doses may be administered every 1 to 3 hours as needed.~For PCA dosing, the TRV130 regimen consists of a loading dose, a demand dose, and a lockout interval."
2985956|NCT02656849|Experimental|BAY 1000394|"After the screening procedures confirm eligibility to participate in the research study:~Each treatment cycle lasts 4 weeks.~Participants will take the study drug orally at predetermined times and dosage per cycle."
2985957|NCT02656823|Other|ANKYLOS C/X 6.6 mm implants|ANKYLOS C/X 6.6 mm implants
2985958|NCT02656810|Experimental|Sequence A|Single subcutaneous injection of two teriparatide products (PF708 and Forteo)
2985959|NCT02656810|Experimental|Sequence B|Single subcutaneous injection of two teriparatide products (Forteo and PF708)
2985960|NCT02656797|Experimental|AM-B|Topical Amphotericin-B 0.4% liposomal gel
2985961|NCT02656797|Placebo Comparator|Placebo|Placebo gel preparation
2985962|NCT02656784|Experimental|Trial-Based Cognitive Therapy (TBCT)|"Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach, based on the work of Franz Kafka The Trial and developed by Professor Irismar Reis de Oliveira at Federal University of Bahia, Brazil. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All individuals in the group will be submitted to MRI"
2985963|NCT02656784|Experimental|Behavioral Therapy (ERP)|The Behavioral Therapy is an intervention of first choice for treatment of OCD , which employs the technique of Exposure and Response Prevention (ERP) , considered the gold standard to the disorder. The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All individuals in the group will be submitted to MRI
2985964|NCT02656784|No Intervention|Control Group|The control group consisted of individuals without OCD, matched with the experimental group in terms of gender,age and education. In this group are not included in individuals in psychotherapeutic care and with a history of neurological or psychiatric disorder; however, all them will be submitted to MRI .
2985998|NCT02656498|Experimental|Cognitively Healthy Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
2985999|NCT02656498|Experimental|MCI Subjects|MCI Subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
2985965|NCT02656771|Active Comparator|Echo Bi-Metric THA stem|"Uncemented titanium alloy press-fit stem with a proximal plasma spray porous titanium coating designed for bone ingrowth and the distal part of the stem has a roughened titanium surface for bone on-growth.~It is a relatively new implant that is now in routine clinical use. The stem uses many of the features of the known and used Integral® and Bi-Metric® hip stems while integrating new design features to further enhance clinical performance such as a reduced neck geometry to allow for increased ROM and decreased risk of neck impingement, a polished neck designed to reduce debris should impingement occur and a polished bullet-shape distal tip to reduce distal stresses."
2985966|NCT02656771|No Intervention|Bi-Metric Porous Primary THA stem|"Uncemented titanium alloy press-fit stem with a proximal plasma spray porous titanium coating designed for bone ingrowth and the distal part of the stem has a roughened titanium surface for bone on-growth.~It was introduced in 1984 and have shown good clinical results and excellent stem survival in register studies"
2985967|NCT02656758|Experimental|Executive function training|the experimental group will receive 12 sessions of intensive Executive function training weekly immediately
2985968|NCT02656758|Other|the waitlist group|the waitlist group will wait 12 weeks before receiving intensive executive function training for comparison.
2985969|NCT02656745|Experimental|Mobile Smoking Cessation Solution|Subjects download & use the mobile application.
2985970|NCT02656732|Experimental|coronally advanced flap with amnion chorion membrane|coronally advanced flap was reflected and amnion chorion allograft membrane was placed under the flap as a guided tissue regeneration barrier.
2985971|NCT02656732|Active Comparator|subepithelial connective tissue graft|coronally advanced flap was reflected and subepithelial connective tissue graft was harvested from the palate and placed under the flap.
2985972|NCT02656719|Experimental|Ultrasound|Ultrasound guided percutaneous tracheostomy
2985973|NCT02656719|Active Comparator|Bronchoscopy|Bronchoscopy guided percutaneous tracheostomy
2985974|NCT02656706|Experimental|Adjuvant treatment|Ipilumumab:1mg/kg q6weeks (1 dose per cycle, 4 planned treatments over 6 months total) Nivolumab:3mg/kg q2weeks (3 doses per cycle, 12 planned treatments over 6 months total)
2985975|NCT02656693|Experimental|Online Program Only|Patients will use an online weight management program called BMIQ, with minimal additional support.
2985976|NCT02656693|Experimental|Combined Intervention|Patients will use an online weight management program called BMIQ, but will also receive additional monitoring and support from a population health manager who works with their primary care practices.
2985977|NCT02656693|No Intervention|Usual Care|Patients will continue receiving usual care but will also be mailed some general written information about weight management (very minimal intervention.)
2985978|NCT02656680|Experimental|FB+Friends|Facebook-delivered weight loss intervention allowing participants to invite their friends who are also interested in losing weight.
2985979|NCT02656680|Active Comparator|FB Only|Facebook-delivered weight loss intervention including only study participants.
2985980|NCT02656667|Experimental|neuromuscular electrical stimulation|conventional pulmonary rehabilitation including exercise training on treadmill and neuromuscular electrical stimulation with a medical device for quadriceps muscle strengthening
2985981|NCT02656667|Experimental|cycle ergometer training|conventional pulmonary rehabilitation including exercise training on treadmill and quadriceps strenghthening on cycle-ergometer
2985982|NCT02656641|No Intervention|Control|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will not complete any scales during other sessions.
2985983|NCT02656641|Experimental|Continuous Client Feedback|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will then complete symptoms scales, specifically the Patient Health Questionnaire-9 and Generalized Anxiety Disorder 7-Item Scale before each other session. The treating clinician will review and discuss their results and at the beginning of each session.
2985984|NCT02656641|Experimental|Continuous Self Feedback|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will then complete symptoms scales, specifically the Patient Health Questionnaire-9 and Generalized Anxiety Disorder 7-Item Scale before each other session. The treating clinician will not have access to these results.
2985985|NCT02656628||Fractures of humerus femur tibia|Dynamic Locking Screw 3.7mm and 5.0mm
2985986|NCT02656615|Experimental|Abiraterone|Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
2985987|NCT02656602|No Intervention|Nurse Counseling|A trained endoscopy nurse provided patients with all information on their scheduled colonoscopy.
2985988|NCT02656602|Experimental|Computer Assisted Instruction|The computer assisted instruction consisted of a platform using video mimicking the patient journey with voice-over supported by photo's, 3D animation and instructive texts. The video was presented in short clips, maximal 45 seconds, to maintain the focus of patient. Patient interaction was ascertained by mandatory mouse-click after each item in the CAI.All elements of informed consent for colonoscopy (risks, alternatives) were included.
2985989|NCT02656589||Herceptin probable sensitive group|Plasma microRNAs will be collected using microRNA extraction kit according to manufacturer's instructions; and their expression levels are analyzed by quantitative polymerase chain reaction (qPCR).According to microRNAs - herceptin predictive model(reported by our team), the patients will be considered as Herceptin probable sensitive group
2985990|NCT02656589||Herceptin probable resistant group|Plasma microRNAs will be collected using microRNA extraction kit according to manufacturer's instructions; and their expression levels are analyzed by quantitative polymerase chain reaction (qPCR).According to microRNAs - herceptin predictive model(reported by our team), the patients will be considered as Herceptin probable resistant group
2985991|NCT02656576|Other|patient with suspected lesions of the tonsillar region|patients will have a tonsil biopsy and a smear
2985992|NCT02656563|Experimental|Radium 223 Arm|Radium 223 Dichloride (Xofigo®)
2985993|NCT02656563|No Intervention|Non Treatment Arm|Control Arm
2985994|NCT02656550|Experimental|Uterine Transplant|Women will undergo uterine transplantation after IVF. Donor uterus will be from either a living donor or cadaveric.
2985995|NCT02656537|Experimental|EnSite™ HD Grid Catheter AF/AT Mapping|
2986047|NCT02656160|Active Comparator|Dalfampridine|
2986000|NCT02656498|Experimental|AD Subjects|AD Subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
2986001|NCT02656498|Experimental|Subjects with other neurodegenerative disease|Subjects with other neurodegenerative disease will receive an IV injection, [18F]THK-5351 at baseline.
2986002|NCT02656485|Experimental|Dose I|B244 Dose 1 (dose level [cells/mL] 20,000,000,000)
2986003|NCT02656485|Experimental|Dose II|B244 Dose 2 (dose level [cells/mL] 40,000,000,000)
2986004|NCT02656485|Experimental|Dose III|B244 Dose 3 (dose level [cells/mL] 80,000,000,000)
2986005|NCT02656485|Placebo Comparator|Placebo|Placebo to Match B244
2986006|NCT02656472|Active Comparator|Tranexamic Acid Arm|TXA arm will include 10 subjects who will receive TXA for duration of surgery.
2986007|NCT02656472|Active Comparator|Epsilon Aminocaproic Acid Arm|EACA arm will include 10 subjects who will receive EACA for the duration of surgery.
2986008|NCT02656433|Placebo Comparator|Placebo Group|Receive treatment with physiotherapy
2986009|NCT02656433|Experimental|Experimental or tRNS Group|Receive treatment with physiotherapy plus Transcranial Random Noise Stimulation (tRNS)
2986010|NCT02656420|Placebo Comparator|Placebo|Beverage (100 mL) containing pineapple juice, lime juice and water. Nightly for 10 days.
2986011|NCT02656420|Experimental|High Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (600 micromole) and sulforaphane-rich (40 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
2986012|NCT02656420|Experimental|Medium Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (300 micromole) and sulforaphane-rich (20 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
2986013|NCT02656420|Experimental|Low Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (120 micromole) and sulforaphane-rich (8 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
2986014|NCT02656407|Experimental|Ultrasensitive Doppler|Intraoperative ultrasensitive Doppler acquisitions by using an ultrasound device for functional area detection
2986015|NCT02656394|Active Comparator|GL101|GL101 topical gel
2986016|NCT02656394|Placebo Comparator|Placebo|Placebo topical gel
2986017|NCT02656368|Experimental|Interventional, open label, Safety/Efficacy Study|SEBORRHEAMEDIS Face Cream Interventional 30
2986018|NCT02656355|No Intervention|Stage 1:Healthy people|To establish baseline and reliability.
2986019|NCT02656355|No Intervention|Stage 2:Healthy people|To establish stage 3 training protocol.
2986020|NCT02656355|No Intervention|Stage 2:PD people|To establish stage 3 training protocol.
2986021|NCT02656355|Experimental|Stage 3:PD APA training group|Weight shift training and APA feedback.
2986022|NCT02656355|Experimental|Stage 3:PD Balance training group|Weight shift training without APA feedback.
2986023|NCT02656355|No Intervention|Stage 3:PD Control group|Control group
2986024|NCT02656342|Experimental|250 mg DCS|64 patients receive 250 mg D-Cycloserine two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
2986025|NCT02656342|Experimental|100 mg D-Cycloserine|64 patients receive 100 mg D-Cycloserine two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
2986026|NCT02656342|Active Comparator|Placebo|32 patients receive placebo two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
2986027|NCT02656329|Experimental|Arm 1- Iobenguane I-123 Injection|Iobenguane I-123 Injection. AdreView-guided ICD. Patients will receive a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.
2986028|NCT02656329|Experimental|Arm 2 - Implantable Cardioverter Defibrillator|Standard of care
2986029|NCT02656316|Experimental|Active tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
2986030|NCT02656316|Sham Comparator|Sham tDCS|The Sham tDCS - an inactive stimulation.
2986031|NCT02656303|Experimental|Ublituximab + TGR-1202|Ublituximab IV treatment + TGR-1202 oral daily dose
2986032|NCT02656290|Experimental|AModel 11000A for PVR|Pulmonary valve replacement
2986033|NCT02656277|Experimental|Decision tool|The decision tool includes a questionnaire and statistical model used to determine how patient preference regarding shoulder pain, physical limitations, physical therapy, recovery period, prognosis, and cost impact choice of surgical versus non-surgical intervention.
2986034|NCT02656277|Active Comparator|Information on Shoulder Dislocation|Subjects in this arm will receive the standard of care information available to patients to make this treatment decision.
2986035|NCT02656251|Active Comparator|0.12% Clorhexidine with alcohol|0.12% Clorhexidine with alcohol, 15ml every 12 hour for 4 days
2986036|NCT02656251|Experimental|0.12% Clorhexidine without alcohol|0.12% Clorhexidine without alcohol, 15ml every 12 hour for 4 days
2986037|NCT02656251|Placebo Comparator|control|placebo 15ml every 12 hour for 4 days
2986038|NCT02656225|Experimental|Ejiao compound|The participants in experimental group receive Ejiao compound (20ml, twice daily) orally for 4 weeks.
2986039|NCT02656225|Active Comparator|Niferex|The participants in control group receive Polysaccharide Iron Complex(Niferex)(150mg per tablet, once daily) orally after breakfast over 4 weeks.
2986040|NCT02656212|Experimental|(+)-epicatechin 30mg|10 subjects will be randomized to a 30mg dose of synthetic (+)-epicatechin
2986041|NCT02656212|Placebo Comparator|placebo|5 subjects will be randomized to a placebo
2986042|NCT02656199||Main Cohort|all patients enrolled will have an ultrasound of their diaphragm performed once they are on a pressure support trial. Intervention: Diaphragm Ultrasound
2986043|NCT02656186|Experimental|Single-arm pretest-posttest|In this study, the subjects served as their own controls. Subjects who were eligible based on inclusion criteria first entered into a 2-week pre-intervention period, during which they received nutrition counseling to keep their routine dietary habits. This was followed by an intervention period, during which an oral nutritional supplement was used over a period of 2 weeks.
2986044|NCT02656173|Experimental|Mirabegron group|Oral
2986045|NCT02656173|Experimental|Placebo group|Oral
2986046|NCT02656160|Placebo Comparator|Placebo|
2986048|NCT02656147|Experimental|Experimental: 1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
2986049|NCT02656147|Experimental|Experimental: 2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
2986050|NCT02656147|Experimental|Experimental: 3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
2986051|NCT02656121|Experimental|Vitamin D|1st subgroup will be treated with vitamin D together with standard treatment of PCOS
2986052|NCT02656121|Placebo Comparator|placebo|2nd subgroup will be treated with standard anti-PCOS drug therapy and placebo
2986053|NCT02656108|Experimental|omiited controlled cord traction|neither controlled cord traction nor fundal pressure will be applied. The placenta will be delivered physiologically and signs of placental separation will be awaited
2986054|NCT02656108|Active Comparator|controlled cord traction|the cord will be held in one hand and the other hand will be placed just above the woman's pubic boneto stabilize the uterus during cord traction
2986055|NCT02656082|Experimental|Etanercept|Intradermal injection of etanercept. The dosage is determined based on discoid lesion radius. Weekly injection up to 12 weeks.
2986056|NCT02656069|Other|G-Pen first, then Lilly Glucagon|A single 1 mg subcutaneous (SC) injection of G-Pen™ (glucagon injection) with a 7-28 day wash-out, followed by a single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin])
2986057|NCT02656069|Other|Lilly Glucagon first, then G-Pen|A single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin]) with a 7-28 day wash-out, followed by a single 1 mg SC injection of G-Pen™ (glucagon injection)
2986058|NCT02656056|Experimental|Lean Adults|Adults with a BMI between 21-25 will consume 8 oz of the fermented soybean beverage, twice daily.
2986059|NCT02656056|Experimental|Obese Adults|Adults with a BMI between 32-37 will consume 8 oz of the fermented soybean beverage, twice daily.
2986060|NCT02656043|Active Comparator|XPF-005|Active treatment: XPF-005 Gel
2986061|NCT02656043|Placebo Comparator|Vehicle gel|Placebo: XPF-005 Vehicle Gel
2986062|NCT02656030|Experimental|semispinalis cervicis resisted exercise|semispinalis cervicis resisted exercise 2 times/week, 6 weeks duration
2986063|NCT02656030|Experimental|cranio-cervical flexion exercise|cranio-cervical flexion exercise 2 times/week, 6 weeks duration
2986064|NCT02656030|Active Comparator|usual care|Usual care 2 times/week, 6 weeks duration
2986065|NCT02656017|Experimental|Metformin|"Participants will be started on 500 mg of metformin once daily, with the following scheduled dose titrations:~Increase to 500mg twice daily at week 2~Increase to 1000mg qAM, 500mg qPM at week 4~Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months).~Increased titrations based on tolerability"
2986066|NCT02656017|Placebo Comparator|Placebo|"Participants will be started on 500 mg of placebo once daily, with the following scheduled dose titrations:~Increase to 500mg twice daily at week 2~Increase to 1000mg qAM, 500mg qPM at week 4~Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months).~Increased titrations based on tolerability"
2986067|NCT02656004|Experimental|Essential Eucalyptus Oil|Using a disposable face mask was inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus.
2986068|NCT02656004|Experimental|Control|In the control session the procedure was the same. Using a disposable face mask was inhale for ten minutes fresh air. Inhalation of the fresh air occurred immediately after the 20 minute rest period in the session Control.
2986069|NCT02655991|Experimental|Telephone Case Monitoring|Telephone care management augmenting treatment as usual
2986070|NCT02655991|Active Comparator|Treatment as Usual|Case management, psychotherapy, and pharmacotherapy as usual
2986071|NCT02655978||Healthy Volunteers|These participants will not have any psychiatric disorder as assessed by a structured clinical interview for psychiatric disorders.
2986072|NCT02655978||Medically Treatment-Responsive BD|This group will be composed of participants who have BDI or BDII and have most recently been depressed but are currently in remission with evidence-based treatments for bipolar disorder
2986073|NCT02655978||Treatment-Refractory BD|This group will be composed of participants who have BDI or BDII, are currently depressed with their current episode lasting at least 12 months and not responding to 4 adequate evidence-based treatments for BDI or BDII and who have failed, been intolerant to, or were unwilling to try electroconvulsive therapy (ECT).
2986074|NCT02655965|Experimental|Ropivacaine + Clonidine|"A pecs block of Ropivacaine 3.5 mg/ml and Clonidine 5 µg/ml will be injected to the patients prior surgery. 10 ml of the drug combination will be injected between pectoral muscles and 20 ml of the drug combination will be injected between the muscles pectoralis minor and serratus anterior.~After surgery, subjects in both arms will receive one dose of Paracetamol (1g) and Diclofenac (75 mg) and one dose 0.05 mg/kg Piritramide as well as PCIA (Patient Controlled Intravenous Analgesia)-Piritramide for 24 hrs post-surgery."
2986075|NCT02655965|Placebo Comparator|Sodium Chloride|"A pecs block of Placebo (Sodium Chloride 0.9%) will be injected to the patients prior surgery. 10 ml of the Sodium chloride solution will be injected between pectoral muscles and 20 ml of the Sodium chloride solution will be injected between the muscles pectoralis minor and serratus anterior).~After surgery, subjects in both arms will receive one dose of Paracetamol (1g) and Diclofenac (75 mg) and one dose 0.05 mg/kg Piritramide as well as PCIA (Patient Controlled Intravenous Analgesia)-Piritramide for 24 hrs post-surgery."
2986076|NCT02655952|Experimental|Foxy-5|"Slow infusion of lyophilised and reconstituted Foxy-5 three times weekly for three weeks.~There will be a maximum of 8 dose cohorts. Cohorts 1-4 will be conducted in the United Kingdom and Denmark whereas cohorts 5-8 will only be conducted in Denmark. As doses in cohort 1 and 2 have been investigated in the previous phase I study, cohorts 1+2 and 3 can be run in parallel with dose escalation approved by the DSMB at all times.~DK+UK: Cohort 1: 0.8 mg/kg DK+UK: Cohort 2: 1.3 mg/kg DK+UK: Cohort 3: 1.8 mg/kg DK+UK: Cohort 4: 2.3 mg/kg DK only: Cohort 5: 3.0 mg/kg DK only: Cohort 6: 4.0 mg/kg DK only: Cohort 7: 5.3 mg/kg DK only: Cohort 8: 7.0 mg/kg"
2986077|NCT02655939|Active Comparator|Reflex Plus|Reflex Plus TM, Sachets to be taken once in a day Before breakfast for the study duration
2986078|NCT02655939|Placebo Comparator|Placebo|Placebo Sachets to be taken once in a day Before breakfast for the study duration
2986079|NCT02655926|Active Comparator|STN Arm|Participants would only have STN deep brain stimulation switched at optimal settings for that participant on for 12 weeks.
2986080|NCT02655926|Active Comparator|VC/VS Arm|Participants would only have VC/VS deep brain stimulation switched on at optimal settings for that participant for 12 weeks.
2986081|NCT02655913|Experimental|vitamin C+ mEHT+ supportive care|"Patients will be allocated into 3 Vitamin C infusion dosage groups:~1g/kg.d,1.2g/kg.d,1.5g/kg.d;3 times a week for 8 weeks(25 infusions);concurrent with Modulated Electro-Hyperthermia (mEHT): 150W x 60 min/session,3 times a week for 8 weeks (25 sessions);together with supportive care."
2986082|NCT02655913|Placebo Comparator|Supportive care|Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
2986083|NCT02655874|Experimental|Six-monthly influenza vaccine|Standard dose trivalent inactivated seasonal influenza vaccine will be administered at day 1 and 180
2986084|NCT02655874|Active Comparator|Annual influenza vaccine|Standard dose trivalent inactivated seasonal influenza vaccine will be administered at day 1 and an active-comparator (Tetanus-diphtheria-pertussis) at day 180
2986085|NCT02655861||Ichthyosis|
2986086|NCT02655848|Active Comparator|@ Cuff repair with LHB tenodesis|In case of pathologic changes of the long Head Biceps tendon, a tenodesis is performed in adjunct to performing an arthroscopic rotator cuff repair.
2986087|NCT02655848|Active Comparator|@ cuff repair with LHB tenotomy|In case of pathologic changes of the long Head Biceps tendon, a tenotomy is performed in adjunct to performing an arthroscopic rotator cuff repair.
2986088|NCT02655835|Experimental|Internet Mindfulness Meditation Intervention|Six-week internet mindfulness meditation training program including handouts and daily guided meditations
2986089|NCT02655835|Experimental|Access|Written information handouts on mindfulness meditation and access to guided daily meditations
2986090|NCT02655822|Experimental|Cohort 1|CPI-444
2986091|NCT02655822|Experimental|Cohort 2|CPI-444
2986092|NCT02655822|Experimental|Cohort 3|CPI-444
2986093|NCT02655822|Experimental|Cohort 4|CPI-444 + atezolizumab
2986094|NCT02655822|Experimental|Cohort 5|CPI-444
2986095|NCT02655809|Other|Physica KR|Patients who have received a Physica KR total knee implant.
2986096|NCT02655796|Experimental|Moderate/High Risk|Participants assessed as moderate/high risk of falling according to the CDC Algorithm for Fall Risk Assessment
2986097|NCT02655796|Experimental|Low Risk|Participants assessed as low risk of falling according to the CDC Algorithm for Fall Risk Assessment
2986098|NCT02655783|Active Comparator|control|normal saline, 250 ml/h, until expulsion of placental
2986099|NCT02655783|Experimental|intervention|normal saline + 5% dextrose, 250 ml/h, until expulsion of placental
2986100|NCT02655770|Active Comparator|Liraglutide arm|Patients will be treated with liraglutide (up to 1.8 mg s.c. once daily). Total treatment period will be 18 weeks.
2986101|NCT02655770|Placebo Comparator|Placebo arm|Patients will be treated with placebo (up to equal to 1.8 mg drug dose s.c. once daily). Total treatment period will be 18 weeks. The study will be placebo-controlled with placebo as an add-on to conventional diabetes treatment. Thus, no patient will receive a sub-standard treatment.
2986102|NCT02655757|Active Comparator|Sitagliptin|Sitagliptin 100mg QD
2986103|NCT02655757|Placebo Comparator|Placebo|Placebo
2986104|NCT02655744||newly-diagnosed patients with primary CNS lymphoma|
2986105|NCT02655731|Other|Treatment|PVI with HeartLight
2986106|NCT02655718|Other|Patients with ACS|Patients with ACS who underwent coronary angiography within 72 hours from the onset of disease. In identifying nonobstructive coronary atherosclerosis , patients underwent cardiac contrast MRI.
2986107|NCT02655705|Active Comparator|Cyclosporine A|Cyclosporine 200 mg/day (male) and 150 mg/day (female) orally, divided twice daily for 16 weeks
2986108|NCT02655705|Active Comparator|Methotrexate|Methotrexate was started with 10 mg/week orally as a single dose, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
2986109|NCT02655692|Placebo Comparator|Placebo|Saline dose
2986110|NCT02655692|Experimental|Low Dose Ketamine|Low Dose Ketamine (.20 mg/kg)
2986111|NCT02655692|Experimental|High Dose Ketamine|High Dose Ketamine (.50 mg/kg)
2986112|NCT02655679|Experimental|Dose 1|VTP-38543 administered topically every 12 hours
2986113|NCT02655679|Experimental|Dose 2|VTP-38543 administered topically every 12 hours
2986114|NCT02655679|Experimental|Dose 3|VTP-38543 administered topically every 12 hours
2986115|NCT02655679|Placebo Comparator|Vehicle 1|Vehicle matching VTP-38543 administered topically every 12 hours
2986116|NCT02655679|Placebo Comparator|Vehicle 2|Vehicle matching VTP-38543 administered topically every 12 hours
2986117|NCT02655653|Experimental|Epsilon-aminocaproic acid (EACA)|Epsilon-aminocaproic acid administered following anesthetic induction: EACA was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr.
2986118|NCT02655653|Experimental|Tranexamic acid (TA)|Tranexamic Acid administered following induction: TA was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion.
2986119|NCT02655640||Lupus|Characteristics of patients with Systemic Lupus Erythematosus. No interventions will be administered. Patients will be asked to complete questionnaires.
2986120|NCT02655640||Scleroderma|Characteristics of patients with Systemic Sclerosis. No interventions will be administered. Patients will be asked to complete questionnaires.
2986121|NCT02655627|Experimental|Group A|Usual Care Group: A brochure which emphasis the importance of physical activity and exercise in Type 2 DM will be given to the patients in this group after the evaluation.
2986122|NCT02655627|Experimental|Group B|Supervised Clinical Exercise Training Group: Patients in this group will continue group exercise training includes aerobic and resistance training, 1 hour in a day, 3 times in a week for 8 weeks with the supervision of a researcher physiotherapist.
2986123|NCT02655627|Experimental|Group C|Internet Based Exercise Training Group. the patients to this group will be a member of the web site named www.diyabetvehareket.com. The participation of the patients will be provided with the videos directing them to 1 hour in a day, 3 times in a week for 8 week both aerobic and resistance exercise training from the researcher physiotherapist.
2986214|NCT02655081|Experimental|Dietary supplement|Subjects will receive high arginine nutritional supplement (Nestle's Impact AR), prior to cystectomy
2986124|NCT02655614|Experimental|SAD Stage: GDC-0134|Participants in multiple cohorts and treatment periods will receive single doses of GDC-0134 oral capsules under fed/fasting conditions. To study the effect of proton pump inhibitor (PPI) medication rabeprazole on PK properties of GDC-0134, few participants may receive rabeprazole 20 milligrams (mg).
2986125|NCT02655614|Placebo Comparator|SAD Stage: Placebo|Participants in multiple cohorts and treatment periods will receive placebo matching to GDC-0134 under fed/fasting conditions. Few participants may receive rabeprazole 20 mg.
2986126|NCT02655614|Experimental|MAD Stage: GDC-0134|Participants will receive multiple doses of GDC-0134 for 28 days. To study the interactions between GDC-0134 and other drugs, some participants may receive single doses of midazolam and caffeine at various time points.
2986127|NCT02655614|Placebo Comparator|MAD Stage: Placebo|Participants will receive placebo matching to GDC-0134 for 28 days. To study the interactions between GDC-0134 and other drugs, some participants may receive single doses of midazolam and caffeine at various time points.
2986128|NCT02655614|Other|Open-Label Safety Expansion (OSE)|Participants will receive GDC-0134 at a dose determined by the corresponding MAD cohort.
2986129|NCT02655601|Experimental|Radiation Therapy, TMZ and BMX-001|Patients will receive standard of care radiation therapy plus temozolomide (TMZ). BMX-001 will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks. A total of 80 subjects will receive BMX-001 in this phase.
2986130|NCT02655601|Active Comparator|Radiation Therapy and TMZ|In this arm, one-half of the study subjects will not receive BMX-001 but will undergo all components of standard therapy (radiation therapy plus temozolomide [TMZ]). A total of 80 subjects will be in this study arm.
2986131|NCT02655588|Experimental|ImbPST|"ImbPST Arm: Participants in this arm will interact with imbPST program which provides a simulated therapy session based on the Problem Solving Treatment-Primary Care (PST-PC) treatment manual used in depression clinical trials . imbPST via a virtual therapist (presented via audio and video) provides programmed instructions on the steps and skills of problem solving, emotional support, and tailored feedback to the user's input."
2986132|NCT02655588|No Intervention|Control Group|Control Arm: Participants in this group will not receive any treatment for their depression and their depressive symptoms will be monitored for 6 to 9 weeks
2986133|NCT02655575|Experimental|BI + VR + CBT|"Brief Intervention (BI) consists of an individual clinical examination, education/information and advice about being active Vestibular Rehabilitation (VR) includes active exercises that provokes dizziness, Balance exercises and body awareness exercises in a group format.~Cognitive Behavioral Therapy (CBT) includes conversation and reflection about factors that may be a barrier to Activity and participation"
2986134|NCT02655575|Active Comparator|BI + phone calls|Brief Intervention (BI) consists of an individual clinical examination, education/information and advice about being active Phone Calls as follow-up at week 2 and 6 to reassure
2986135|NCT02655562|Experimental|biomarker treatment arm|Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO＜25ppb were given placebo (p.o., 10mg, qd).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
2986136|NCT02655562|Placebo Comparator|standard treatment arm|Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO＜25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
2986137|NCT02655549|Experimental|Cohort 1 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
2986138|NCT02655549|Experimental|Cohort 2 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
2986139|NCT02655549|Experimental|Cohort 3 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
2986140|NCT02655536|Experimental|bevacizumab plus erlotinib|bevacizumab 15mg/kg every 3 weeks plus erlotinib 150mg per day
2986141|NCT02655536|Active Comparator|erlotinib|erlotinib 150mg per day
2986142|NCT02655523|Active Comparator|Bupivacaine+Triamcinolone|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL 40 mg of triamcinolone.
2986143|NCT02655523|Active Comparator|Bupivacaine+Dexamethasone|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL 4 mg of dexamethasone.
2986144|NCT02655523|Placebo Comparator|Bupivacaine+Saline|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL of preservative free normal saline.
2986145|NCT02655510|Experimental|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg.
2986146|NCT02655497|Experimental|Cognitive Training|Cognitive training intervention. The intervention includes seven 2-hour group sessions interspersed with four individual 45-minute sessions for a total of 17 hours of intervention over an 8-week period. The experimental group will receive real-world strategy training, a cognitive strategy based approach that trains people to improve their level of independence on meaningful activities of daily life with which they are having difficulty.
2986147|NCT02655497|Active Comparator|Psychosocial education|The intervention includes seven 2-hour group sessions interspersed with four individual 45-minute sessions for a total of 17 hours of intervention over an 8-week period. The control group will receive brain-health education.
2986148|NCT02655484|Other|COPD patients|Oxygen was delivered to the face mask by a tube at a constant rate (5L/min) to keep the fingertip oxygen saturation at 90% or above. Ventilatory assistance was delivered using a BiPAP® Vision® ventilator (Respironics, Murrysville, Pennsylvania, USA) in BiPAP mode applied via a tightly fitting full face mask (Curative, Suzhou, China). A symptom-limited cycle exercise test was performed while assisted by non-invasive ventilation (NIV). All measurements were recorded at inspiratory pressure of 14 cmH2O, expiratory pressure of 4 cmH2O during rest and exercise. Breathing pattern, mean exhalation flow, mean plateau exhalation valve flow, the mean inspiratory fraction of CO2 (tidal FiCO2) reinsufflated from the circuit between the mask and the exhalation valve was measured for each breath.
3001006|NCT02556268|Experimental|Riociguat and TRIUMEQ|
2986149|NCT02655471|Experimental|HTLV-1 plus Tropical Spastic paraparesis|"Patients with recent onset of Tropical Spastic paraparesis due HTLV-1 will receive combination of Raltegravir and Zidovudine during 48 weeks"
2986150|NCT02655458|Experimental|autologous PBMC reconstitution, Elotuzumab, Lenalidomide|Max number of cycles is 12. Elotuzumab will be administered IV 20 mg/kg on Day 1 of each cycle. Lenalidomide dosing will start with cycle 4 at 10 mg orally daily days 1-21.
2986151|NCT02655445|Active Comparator|Mini-craniotomy|"Intervention: Bone flap > 30mm and replaced, placement of Jackson-Pratt drain~A linear incision located over the biggest bulk of the hematoma is made. Dura is opened and a wide opening of the pseudomembrane is done. A closed system subdural drain (Jackson-Pratt catheter) is inserted after irrigation until clear liquid return"
2986152|NCT02655445|Active Comparator|Twist Drill Craniostomy|"Intervention: twist drill burr hole <5mm, placement of Integra basket-type drain~A stab incision to the scalp is made, at the approximate location of the thickest diameter of hematoma. The twist-drill hole <5mm is placed obliquely to the surface of the skull, at an angle of about 45° until perforation of the dura. No irrigation is performed. A basket-type drain (Integra) is placed in the subdural space and tunneled underneath the skin"
2986153|NCT02655445|Active Comparator|Burr Hole Craniostomy|"Intervention: 2 Burr Holes >5mm and <30mm, placement of Jackson-Pratt drain~First burr hole at the site of maximal diameter, second anterior and superior to that point. The scalp incisions are so planned that they can be incorporated into a craniotomy if necessary. Visible membranes are opened with a sharp hook until the pia is visualized. Gentle irrigation is performed and continued until the returning liquid is clear. Two burr holes are placed to facilitate drainage. A closed system subdural drain (Jackson-Pratt catheter) is inserted after irrigation until clear liquid return"
2986154|NCT02655432||Spot photoscreener|Automated vision screener: Spot Vision Screener VS 100, Welch-Allyn. This photoscreener is a portable device, using an infrared light. It is built to detect amblyogenic risk factors. First of all, the spot photoscreener produces a sounds which attracts the child's attention and helps him shift his gaze towards the device, held at 1 meter in front him. The spot then evaluates for refractive errors, anisocoria, strabismus, ptosis and media opacity. The ophthalmologic evaluation consists of the measure of the visual acuity, ocular alignment, anterior and posterior segment. The patient will be cyclopleged with cycloplegic drops and will be refracted to obtain a cyclopleged refraction. This will determine his refractive error.
2986155|NCT02655419|Experimental|ATM-AVI + Metronidazole|Aztreonam-avibactam + metronidazole
2986156|NCT02655406|Active Comparator|Compression stockings|Patients randomised to group A will be asked to wear compression stockings for 1 week
2986157|NCT02655406|No Intervention|No compression|Patients randomised to group B will be provided with bandages to wear for 24 hours only, with no further compression afterwards
2986158|NCT02655393|Experimental|AMAZ-02 250 mg single dose|single dose of AMAZ-02 soft gel capsules at 250 mg dose, n=8 subjects (6 Active, 2 Placebo)
2986159|NCT02655393|Experimental|AMAZ-02 500 mg single dose|single dose of AMAZ-02 soft gel capsules at 500 mg dose, n=8 subjects (6 Active, 2 Placebo)
2986160|NCT02655393|Experimental|AMAZ-02 1000 mg single dose|single dose of AMAZ-02 soft gel capsules at 1000 mg dose, n=8 subjects (6 Active, 2 Placebo)
2986161|NCT02655393|Experimental|AMAZ-02 2000 mg single dose|single dose of AMAZ-02 soft gel capsules at 2000 mg dose, n=8 subjects (6 Active, 2 Placebo)
2986162|NCT02655393|Experimental|AMAZ-02 500 mg single dose-Food Effect|single dose of AMAZ-02 admixed in yoghurt at 500 mg dose, n=8 subjects (6 Active, 2 Placebo)
2986163|NCT02655393|Experimental|AMAZ-02 1000 mg single dose-Food Effect|single dose of AMAZ-02 admixed in yoghurt at 1000 mg dose, n=8 subjects (6 Active, 2 Placebo)
2986164|NCT02655393|Experimental|AMAZ-02 250 mg multiple dose|Repeated 28 day dosing of AMAZ-02 soft gel capsules at 250 mg dose, n=12 subjects (9 Active, 3 Placebo)
2986165|NCT02655393|Experimental|AMAZ-02 500 mg multiple 28 day dose|Repeated 28 day dosing of AMAZ-02 soft gel capsules at 500 mg dose, n=12 subjects (9 Active, 3 Placebo)
2986166|NCT02655393|Experimental|AMAZ-02 1000 mg multiple 28 day dose|Repeated 28 day dosing of AMAZ-02 soft gel capsules at 1000 mg dose, n=12 subjects (9 Active, 3 Placebo)
2986167|NCT02655380|Experimental|ketamine 1|Anesthesia induction with ketamine 1 mg followed by remifentanil.
2986168|NCT02655380|Experimental|ketamine 2|Anesthesia induction with ketamine 2 mg followed by remifentanil.
2986169|NCT02655367|Experimental|Milled followed by flaked oats|Participant consumes test meal consisting of porridge made from milled oats on study day 1, followed by porridge made from flaked oats on study day 2
2986170|NCT02655367|Experimental|Flaked followed by milled oats|Participant consumes test meal consisting of porridge made from flaked oats on study day 1, followed by porridge made from milled oats on study day 2
2986171|NCT02655354|Experimental|Intervention|The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.
2986172|NCT02655354|No Intervention|Usual Care|Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.
2986173|NCT02655341||Consecutive STEMI Patients|All patients with AMI referred for primary PCI in a single centre
2986174|NCT02655328|Experimental|athlete under asthma treatment|athlete suffering from asthma blood sample urine sample
2986175|NCT02655315|Active Comparator|DEFERIPRONE|Half of participants will receive the deferiprone (DFP) to 15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
2986176|NCT02655315|Placebo Comparator|PLACEBO|Half of participants will receive the placebo twice daily morning and evening. The treatment lasts nine months.
2986177|NCT02655302|Other|Bacterial exacerbations|Patients with at least 10^7 UFC/ml bacteria in their sputum during their first COPD exacerbation.
2986178|NCT02655302|Other|Non-bacterial exacerbations|Patients without detected bacteria or below 10^7 UFC/ml in sputum during their first COPD exacerbation.
2986179|NCT02655289|Experimental|Modulated TENS|
2986180|NCT02655289|Placebo Comparator|Placebo TENS|
2986725|NCT02651688|Experimental|12.5 mg Enclomiphene Citrate|12.5 mg Enclomiphene Citrate
2986181|NCT02655276|Experimental|100 mg microencapsulated Glycine and then Placebo tablets|100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d. for the first three weeks and then Placebo t.i.d. from Biotiki® for the second three weeks.
2986182|NCT02655276|Experimental|Placebo tablets and then 100 mg microencapsulated Glycine|Placebo t.i.d. from Biotiki® for the first three weeks and then 100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d. for the second three weeks.
2986183|NCT02655263|No Intervention|Control|12 hours of fasting
2986184|NCT02655263|Experimental|GH infusion|12 hours of fasting
2986185|NCT02655263|Experimental|GH and ketone bodies infusion|12 hours of fasting
2986186|NCT02655237|Experimental|TAK-385 40 mg|TAK-385 40 mg administered orally once daily before breakfast + leuprorelin placebo administered subcutaneously once every 4 weeks at site visit
2986187|NCT02655237|Active Comparator|Leuprorelin 1.88 mg|TAK-385 40 mg placebo administered orally once daily before breakfast + leuprorelin 1.88 mg administered subcutaneously once every 4 weeks at site visit
2986188|NCT02655237|Active Comparator|Leuprorelin 3.75 mg|TAK-385 40 mg placebo administered orally once daily before breakfast + leuprorelin 3.75 mg administered subcutaneously once every 4 weeks at site visit
2986189|NCT02655224|Experimental|TAK-385 40 mg|TAK-385 placebo administered orally once daily before breakfast + TAK-385 40 mg administered orally once daily before breakfast
2986190|NCT02655224|Placebo Comparator|TAK-385 placebo|TAK-385 placebo administered orally once daily before breakfast + TAK-385 placebo administered orally once daily before breakfast
2986191|NCT02655211|Active Comparator|CO2-CO2-Med|Participants will receive two blocks of CO2 laser treatment, followed by one block of usual care.
2986192|NCT02655211|Active Comparator|Med-CO2-CO2|Participants will receive one block of usual care, followed by two blocks of CO2 laser therapy.
2986193|NCT02655211|Active Comparator|CO2-Med-CO2|Participants will receive one block of CO2 laser therapy, one block of usual care, and finally one more block of CO2 laser therapy.
2986194|NCT02655211|Active Comparator|PDL-PDL-MED|Participants will receive two blocks of PDL laser therapy, followed by one block of usual care.
2986195|NCT02655211|Active Comparator|Med-PDL-PDL|Participants will receive one block of usual care, followed by two blocks of PDL laser therapy.
2986196|NCT02655211|Active Comparator|PDL-Med-PDL|Participants will receive one block of PDL laser therapy, followed by one block of usual care, followed by one block of PDL laser therapy.
2986197|NCT02655211|Active Comparator|PDL-CO2-Med|Participants will receive one block of PDL laser therapy, followed by one block of CO2 laser therapy, followed by one block of usual care.
2986198|NCT02655211|Active Comparator|CO2-PDL-Med|Participants will receive one block of CO2 laser therapy, followed by one block of PDL laser therapy, followed by one block of usual care.
2986199|NCT02655211|Active Comparator|Med-PDL-CO2|Participants will receive one block of usual care, followed by one block of PDL laser therapy, followed by one block of CO2 laser therapy.
2986200|NCT02655211|Active Comparator|Med-CO2-PDL|Participants will receive one block of usual care, followed by one block of CO2 laser therapy, followed by one block of PDL laser therapy.
2986201|NCT02655211|Active Comparator|PDL-Med-CO2|Participants will receive one block of PDL laser therapy, followed by one block of usual care, followed by one block of CO2 laser therapy.
2986202|NCT02655211|Active Comparator|CO2-Med-PDL|Participants will receive one block of CO2 laser therapy, followed by one block of usual care, followed by one block of PDL laser therapy.
2986203|NCT02655198|Experimental|fenfluramine|"Experimental : one armed open label study :~Add-on fenfluramine in refractory Lennox Gastaut patients. Starting dose 0.2mg/kg/day. In non-responders (<50% seizure frequency decrease), dose will be uptitrated every 4 weeks from 0,2 to 0,4 and max 0,8 mg/kg/day (max 30 mg). Total duration study and max exposure to the drug 20 weeks"
2986204|NCT02655185||Heart failure|
2986205|NCT02655172|Experimental|Patients|patients suffering schizophrenic disorders and who will perform cognitive tasks + PANSS+ IQ
2986206|NCT02655172|Active Comparator|Control group|healthy patients who will perform cognitive tasks
2986207|NCT02655159||Abraxane® treatment in patients with metastatic breast cancer|Patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease during the past 3 years (2012-2014) and who give their consent to data collection.
2986208|NCT02655146|Experimental|GnRHa protocol|All subjects are artificially preparing endometrium starting on day 3-5 of the cycle with oral E2 (Progynova) 4-10mg/day at least 14 days. After ultrasound and hormone tests, progesterone 100mg/day intramuscular injection is allocated with E2.In the meanwhile, if the subjects have a fail history of hormonal artificially preparing endometrium, such as an early ovulation, a singal dose of triptorelin 3.75mg would be intramuscular injected before E2 was used as a pretreatment. Then a maximum of two embryos are transferred when endometrium is perfectly prepared. All subjects receive routine luteal phase support with E2 and progesterone .A single dose of Triptorelin 0.1mg is administrated on the 3rd day after embryo implanted with routine luteal phase support.
2986209|NCT02655146|Other|routine luteal phase protocol|All subjects are artificially preparing endometrium starting on day 3-5 of the cycle with oral E2 4-10mg/day at least 14 days. After ultrasound and hormone tests, progesterone 100mg/day intramuscular injection is allocated with E2. In the meanwhile, if the subjects have a fail history of hormonal artificially preparing endometrium, such as an early ovulation, a singal dose of triptorelin 3.75mg would be intramuscular injected before E2 was used as a pretreatment. Then a maximum of two embryos are transferred when endometrium is perfectly prepared. All subjects receive routine luteal phase support with E2 and progesterone .
2986210|NCT02655133|Active Comparator|Pentaglobin®|Patients will receive Immunoglobulins IgGAM (Pentaglobin®) at dosage of 250 mg/kg IV (5 mL/kg) per day (rate of 0.4 mL/kg/h), for 72 hours. Microcirculation will be monitored with sublingual microcirculation device (Cytocam®) and Near InfraRed Specrotcopy (NIRS, Hutchinson®).
2986211|NCT02655133|Placebo Comparator|Physiologic Solution|Patients will receive physiologic solution (NaCl 0.9%) at a dosage of 5 ml/Kg per day for 72 hours. Microcirculation will be monitored with sublingual microcirculation device (Cytocam®) and Near InfraRed Specrotcopy (NIRS, Hutchinson®)
2986212|NCT02655120|Experimental|Bone Marrow +BMP7|The drilling is completed by a joint supply of autologous marrow unconcentrated and recombinant BMP7 (OP1)
2986213|NCT02655120|Placebo Comparator|Drilling|Group I: a simple drill is practiced
2986215|NCT02655068|Other|Computed Tomography (CT)|"Patients who undergo primary surgery will have their first study imaging surveillance at 3 months (+/- 30 days) post-surgery. CT surveillance will continue at 6,9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
2986216|NCT02655068|Other|PET/CT|"Patients who undergo primary radiotherapy will have their first study imaging surveillance at 6 months (+/- 30 days) post radiotherapy. The Positron Emission Tomography - Computed Tomography (PET/CT)surveillance will continue at 9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
2986217|NCT02655055|Experimental|Intervention|high frequency voluntary apheresis blood donation (i.e. 20 - 26 donations in one year period)
2986218|NCT02655055|No Intervention|Control|no voluntary (or paid) apheresis blood donation (whole blood donation allowed during one year period)
2986219|NCT02655042||RCT-01|Participants in previous clinical trial that received blinded injection of RCT-01
2986220|NCT02655042||Placebo|Participants in previous clinical trial that received blinded injection of placebo
2986221|NCT02655016|Experimental|Niraparib|Administered once daily continuously during a 28 day cycle.
2986222|NCT02655016|Placebo Comparator|Placebo|Administered once daily continuously over a 28 day cycle
2986223|NCT02655003|Experimental|INH (Intervention Nursing Homes)|TIME consists of a manual based multicomponent program which includes a rigorous assessment, the treatment, and the evaluation of NPS. The staff, physicians and nursing home managers in the intervention nursing homes will receive a one-day education program. Three nurses from each unit will receive further education including practical and theoretical training for three hours.
2986224|NCT02655003|Active Comparator|CNH (Control Nursing Homes)|A brief two hours education-only intervention about dementia and NPS will be given to the staff in for the control nursing homes (CNH). The staff and physicians in the control nursing homes continue practice as usual.
2986225|NCT02654990|Experimental|Arm A - 20mg PAN TIW|20mg panobinostat three times a week, 2 weeks on/1week of in combination with s.c. bortezomib and p.o. dexamethasone
2986226|NCT02654990|Experimental|Arm B - 20mg PAN BIW|20mg panobinostat twice a week, 2 weeks on/1 week off in combination with s.c. bortezomib and p.o. dexamethasone
2986227|NCT02654990|Experimental|Arm C - 10mg PAN TIW|10mg panobinostat three times a week 2 weeks on/1 week off in combination with s.c. bortezomib and p.o. dexamethasone
2986228|NCT02654977|Experimental|Metreleptin|Metreleptin open-label
2986229|NCT02654964|Experimental|Treatment Arm|"A Drug Combination Treatment will be determined through High Throughput Screening. The classes of drugs this combination therapy will be comprised from are:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent"
2986230|NCT02654951|Experimental|Visual + Force Feedback|Participants will complete a set of trials while receiving visual feedback only. After finishing, participants will continue to a new set of trials while receiving force feedback only.
2986231|NCT02654951|Experimental|Force + Visual Feedback|Participants will complete a set of trials while receiving force feedback only. After finishing, participants will continue to a new set of trials while receiving visual feedback only.
2986232|NCT02654938|Experimental|Mobilan (M-VM3)|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 2) treated with Investigational Drug Product
2986233|NCT02654938|Placebo Comparator|Placebo|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 2) treated with Placebo (Glucose 5%)
2986234|NCT02654925||Young Men|men 21-40 years of age
2986235|NCT02654925||Young Women|women 21-40 years of age; young women will be premenopausal and eumenorrheic, not on hormonal contraceptive therapy.
2986236|NCT02654925||Older Men|men 55-100 years of age
2986237|NCT02654925||Older Women|women 55-100 years of age; older women will be postmenopausal who are at least 12 months past the final menstrual period (FMP).
2986238|NCT02654912|Experimental|Reactive Focal Drug Administration|This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
2986239|NCT02654912|No Intervention|Reactive Focal Test and Treat|This is the current standard of care in Southern Province and is described by a reactive response to passively detected index case of malaria. The reactive response consists of testing all individuals within a defined radius of each RDT-confirmed incident malaria case with an RDT and treating all positive individuals with artemether-lumefantrine (AL).
2986240|NCT02654899|Experimental|Part 1_Cohort 1_Active;|Single ascending dose of PF-06815345
2986241|NCT02654899|Placebo Comparator|Part 1_Cohort 1_Placebo;|Single dose of placebo
2986242|NCT02654899|Experimental|Part 1_Cohort 2_Active|Single ascending dose of PF-06815345
2986243|NCT02654899|Placebo Comparator|Part 1_Cohort 2_Placebo|Single dose of placebo
2986244|NCT02654899|Experimental|Part 2|Single dose of solid dosage formulation (test) versus liquid dosage formulation (reference) of PF-06815345
2986245|NCT02654886|Experimental|Resistance Exercise Training|Participants will be given a regimen of resistance training after a 2 month observation period. Participants will be trained for 6 months (total= 72 training sessions). Two muscle groups (limbs) would be included in the resistance-training program. Participants will also be initiated with Respiratory muscle strength training using pressure-threshold respiratory trainers.
2986246|NCT02654873||Benign|Benign pathology specimens with macroscopically
2986247|NCT02654873||Suspicious|Suspicious group includes the conditions such as increasing of the gallbladder wall thickness, having calcifications or polyps in the gallbladder.
2986248|NCT02654873||Malign|Malign group includes the conditions such as detecting mass or irregularities in the gallbladder wall.
2986249|NCT02654860|Experimental|60 mg Paracetamol 3% (2 mL)|60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
2986250|NCT02654860|Experimental|90 mg Paracetamol 3% (3 mL)|90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
2986251|NCT02654860|Experimental|120 mg Paracetamol 3% (4mL)|120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
2986252|NCT02654860|Placebo Comparator|Phase II Only: Saline solution 0.9%|Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
2986253|NCT02654847|Active Comparator|Norepinephrine 3 micrograms/mL|1mL of a solution of norepinephrine, containing 3 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
2986254|NCT02654847|Active Comparator|Norepinephrine 4 micrograms/mL|1mL of a solution of norepinephrine, containing 4 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
2986255|NCT02654847|Active Comparator|Norepinephrine 5 micrograms/mL|1mL of a solution of norepinephrine, containing 5 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
2986256|NCT02654847|Active Comparator|Norepinephrine 6 micrograms/mL|1mL of a solution of norepinephrine, containing 6 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
2986257|NCT02654847|Active Comparator|Norepinephrine 7 micrograms/mL|1mL of a solution of norepinephrine, containing 7 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
2986258|NCT02654847|Active Comparator|Norepinephrine 8 micrograms/mL|1mL of a solution of norepinephrine, containing 8 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
2986259|NCT02654834||Pediatric Operating Room (OR) Staff|OR Staff exposed to nitrous oxide, and other volatile anesthetics
2986260|NCT02654834||Pediatric Intensive Care Unit (ICU) Staff|ICU Staff unexposed to any volatile anesthetics
2986261|NCT02654821|Experimental|TCR treatment|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
2986262|NCT02654808|Active Comparator|Standard trocar/ IAP 15 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the standard trocar insufflator at an intra-abdominal pressure (IAP) of 15 mmHg.
2986263|NCT02654808|Active Comparator|Standard trocar/ IAP 10 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the standard trocar insufflator at an intra-abdominal pressure (IAP) of 10 mmHg.
2986264|NCT02654808|Active Comparator|AirSeal trocar/ IAP 15 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the AirSeal trocar insufflator at an intra-abdominal pressure (IAP) of 15 mmHg.
2986265|NCT02654808|Active Comparator|AirSeal trocar/ IAP 10 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the AirSeal trocar insufflator at an intra-abdominal pressure (IAP) of 10 mmHg.
2986266|NCT02654795|Placebo Comparator|Patients without stroke|This group will consists of patients scheduled for atrial fibrillation ablation without history of stroke.
2986267|NCT02654795|Experimental|Patients with history of stroke|This group will consists of patients after ischemic stroke and history of atrial fibrillation.
2986268|NCT02654782|Active Comparator|Lactated Ringer's|Subjects randomized to Lactated Ringer's for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.
2986269|NCT02654782|Active Comparator|5% Human Albumin|Subjects randomized to 5% human albumin for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.
2986270|NCT02654769|Active Comparator|Active Comparator Picato®|Picato® (ingenol mebutate) gel, 0.05% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
2986271|NCT02654769|Experimental|Generic Ingenol Mebutate|Generic ingenol mebutate gel, 0.05% [Test]
2986272|NCT02654769|Placebo Comparator|Vehicle Foam|Vehicle gel of the test product
2986273|NCT02654743|Experimental|SF|"Sulforaphane (SF) will be administered in an approximate dosage of 1 µmol SF/lb (2.2 kg µmol/kg) body weight. This dosage roughly approximates the dosage that was used in the Singh et al, (2014; PNAS) clinical trial of sulforaphane in male adolescents and adults with autism. The sulforaphane will be supplied as glucoraphanin (GR)-enriched broccoli seed extract tablets (manufacturing details follow). Each active tablet will contain 125 mg broccoli seed extract (containing 37 µmol GR, which is equivalent to about 15 µmol SF), 50 mg dried broccoli sprouts (a source of myrosinase, the enzyme that converts GR to SF), 15 mg ascorbic acid, 55.90 mg microcrystalline cellulose, and other minor GRAS excipients used for tablet forming.~The total dose per day will depend of study participants' body weight."
2986274|NCT02654730|Experimental|G6PD deficient 0.25 mg/kg PQ + DHAP|
2986275|NCT02654730|Experimental|G6PD deficient 0.4 mg/kg PQ + DHAP|
2986276|NCT02654730|Active Comparator|G6PD deficient DHAP only|
2986277|NCT02654730|Active Comparator|G6PD normal 0.25 mg/kg PQ + DHAP|
2986278|NCT02654730|Active Comparator|G6PD normal 0.4 mg/kg PQ + DHAP|
2986279|NCT02654717|Experimental|DFD-07 cream|DFD-07 cream applied twice daily
2986280|NCT02654717|Placebo Comparator|Placebo cream|Placebo cream applied twice daily
2986281|NCT02654704||Healthy Young Adults|Healthy young adults aged 18-25. Vaccination in all cohorts/groups.
2986282|NCT02654704||Asthma Young Adults|Young adults aged 18-25 with asthma. Vaccination in all cohorts/groups.
2986283|NCT02654704||Immunocompromised Young Adults|"Young adults aged 18-25 that are immunocompromised (e.g. following treatment for leukemia).~Vaccination in all cohorts/groups."
2986284|NCT02654704||Healthy Older Adults|Healthy older adults aged 55+ Vaccination in all cohorts/groups.
2986285|NCT02654704||Asthma Older Adults|Older adults 55+ with asthma. Vaccination in all cohorts/groups.
2986726|NCT02651688|Experimental|25 mg Enclomiphene Citrate|25 mg Enclomiphene Citrate
2986286|NCT02654704||Immunocompromised Older Adults|"Older adults aged 55+ that are immunocompromised (e.g. following treatment for leukemia).~Vaccination in all cohorts/groups."
2986287|NCT02654678|Experimental|Enalapril Orodispersible Minitablets|Individually adapted dose of enalapril consisting of 1 to maximum 4 enalapril ODMTs of 0.25 mg and/or 1 mg and/or other prescribed treatment of heart failure.
2986288|NCT02654665|Experimental|Liraglutide|Liraglutide will be administered once daily by subcutaneous injection at a starting dose of 0.6 mg, increasing at 0.6 mg/week increments to a maximum of 3.0 mg over the next 6 weeks, as tolerated.
2986289|NCT02654665|Active Comparator|Bariatric Surgery|Subjects will have outcomes measured within 28 days before surgery. Post-operative management and frequency of follow-up visits will be decided by the bariatric surgeon. Study visits for biochemical and endothelial function testing; MRI and liver biopsy and / or fibroscan will follow the same schedule as that of the lifestyle and liraglutide arms. Target weight loss for the first 26 weeks post-surgery is at least 30% of excess body weight.
2986290|NCT02654665|Active Comparator|Diet modification and exercise|Exercise will be used to induce and maintain weight loss in a 26-week Weight Management Program. Each subject will follow an aerobic exercise prescription of moderate intensity (60-75% maximum heart rate) to expend 2000-3000 kcal/week, lasting 30-60 minutes each session (over 5-7 sessions). Subjects will be instructed by sports trainers, compliance reviewed and adjusted if necessary to maintain the targeted total energy expenditure to produce weight loss of at least 7% over 26 weeks.
2986291|NCT02654652|Experimental|Symbiotic|Patients will receive twice a day the symbiotic product during seven days after surgical treatment
2986292|NCT02654652|Placebo Comparator|Maltodextrin|Patients will receive twice a day the placebo product during seven days after surgical treatment
2986293|NCT02654639|Experimental|TAS-102 and Bevacizumab|Oral TAS-102 and intravenous Bevacizumab.
2986294|NCT02654626|Experimental|KBP-7072: Cohort 1|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
2986295|NCT02654626|Experimental|KBP-7072: Cohort 2|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
2986296|NCT02654626|Experimental|KBP-7072: Cohort 3|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
2986297|NCT02654626|Experimental|KBP-7072: Cohort 4|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
2986298|NCT02654613|Active Comparator|Quality Improvement Intervention|In intervention clinics, staff will follow QI methodology to undertake a detailed assessment of their HIV-TB care and to prioritize the steps to improve treatment outcomes. A senior nurse will be identified to be the QI champion and will be trained by the study team to fulfil this role. The QI champion in the clinic then provides peer-leadership, mentorship and support for the implementation of the prioritized changes until the checklist is complete and all integrated HIV-TB service components meet the required standard.
2986299|NCT02654613|No Intervention|Control Standard of Care|The control arm will continue with the usual support that is received for HIV-TB service integration
2986300|NCT02654587|Experimental|OSE2101|OSE2101 will be administered as a 1 mL-subcutaneous injection on Day 1 every three weeks for six cycles, then every two months for the remainder of year one and finally every three months until unequivocal Recist 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal. OSE2101 dose will be 5 mg of peptide (0.5 mg for each peptide).
2986301|NCT02654587|Active Comparator|Docetaxel or Pemetrexed|"Patients receiving docetaxel: Docetaxel 75 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of a 21-day cycle.~Patients receiving pemetrexed: Pemetrexed, 500 mg/m2, will be administered by intravenous infusion over 10 minutes on Day 1 of a 21-day cycle."
2986302|NCT02654574|Experimental|Face-to-face collection followed by collection by phone|Reference procedure i.e IADL collected during a face-to-face interview at the Memory Clinic, followed by the collection of IADL by phone, one month later.
2986303|NCT02654574|Experimental|Collection by phone followed by face-to-face collection|Collection of IADL by phone, followed by the collection of the IADL questionnaire using the reference procedure i.e IADL collected during a face-to-face interview at the Memory Clinic, one month later.
2986304|NCT02654561|Placebo Comparator|Saline|
2986305|NCT02654561|Experimental|Heparin|If severe sepsis with suspected DIC is diagnosed, the Heparin sodium(2ml:12500 units) will be administered intravenously continuously for 24 hours. The course of treatment will last 7 days or until the death or discharge.
2986306|NCT02654548|Experimental|PCOS women and babies|Sebum output using Sebutape on post-partum PCOS women and new born babies.
2986307|NCT02654548|Active Comparator|Non-PCOS women and babies|Sebum output using Sebutape on post-partum non-PCOS women and new born babies.
2986308|NCT02654522|Experimental|Filler|Each subject will have one product in one forearm and another product in the other. Products: JUVEDERM Ultra Plus (24 mg/mL of HA) and VOLUMA (20 mg/mL of HA). Subjects will be randomized as to which forearm will receive which product. In one forearm, subject will receive four injections of the assigned HA filler (0.2mL). HA injections will be placed along a line from the wrist to the antecubital fossa. The initial 0.2mL HA injection will be placed in the deep dermis 5 cm from the wrist and the subsequent three 0.2mL HA injections will be place in 5 cm increments in the deep dermis along the line noted above. Same process will be used on the contralateral forearm using the other HA filler.1-3 hours post injection, these 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
2986309|NCT02654522|No Intervention|Scale Validation|"One forearm of one of three subjects will be randomized to the scale control forearm. The opposite forearm of this subject as well as the forearms of the two remaining subjects will receive treatment in this study. The forearm that has been designated as the scale control forearm will be injected with VOLUMA in a straight line into the mid-dermis in the following manner: 0.05ml of VOLUMA will be injected 5 cm proximal to the wrist, 0.1ml of VOLUMA will be injected 10 cm proximal to the wrist, 0.15ml of VOLUMA will be injected 15 cm proximal to the wrist and 0.2ml of VOLUMA will be injected 20 cm proximal to the wrist. The remaining randomized forearms (the non-injected forearm from the subject above and the forearms from the two additional subjects) will be injected in a similar fashion to the control forearm as noted above; however, the dose at each location will be randomized. Control subject will receive no Hylenex until after pertinent data is collected for the study."
2986353|NCT02654223|Experimental|MG56 Mannosylated 100 subcutaneous|100 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
3001074|NCT02555709|Experimental|VTP-43742 Dose 8|psoriatic patients
2986310|NCT02654509|Experimental|EEE vaccine|Eastern Equine Encephalitis Vaccine will be administered as primary doses of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area and booster doses of 0.1 mL given intradermally in the volar aspect of the forearm. The primary series will be administered on Days 0 and 26-35 with a booster at 6 months. Titers will be collected 28-35 days after the second primary vaccine is < 1:40, the subject will receive a booster dose 28- 90 days of obtaining the titer result.
2986311|NCT02654496||Group 1 (Successful weight loss)|3-5 years post Roux-en-Y gastric bypass patients who had successful weight loss
2986312|NCT02654496||Group 2 (Suboptimal weight loss)|3-5 years post Roux-en-Y gastric bypass patients who had suboptimal weight loss
2986313|NCT02654496||Group 3 (Control group)|A control group who has not had Roux-en-Y gastric bypass surgery and are of similar age, gender, body mass index as the gastric bypass groups.
2986314|NCT02654483|Experimental|5 mg VPD-737|5 mg tablets of VPD-737 to be taken daily by mouth for 56 days
2986315|NCT02654483|Placebo Comparator|Placebo|Placebo tablets to be taken daily by mouth for 56 days
2986316|NCT02654457||Women with Breast Cancer #1|IVD Study
2986317|NCT02654457||Women with Breast Cancer #2|IVD Study
2986318|NCT02654457||Women with Breast Cancer #3|IVD Study
2986319|NCT02654444||GenASIs HiPath IHC #1|Expression of HER2 antibody. Semi-Quantitative value
2986320|NCT02654444||GenASIs HiPath IHC #2|Expression of HER2 antibody. Semi-Quantitative value
2986321|NCT02654444||GenASIs HiPath IHC #3|Expression of HER2 antibody. Semi-Quantitative value
2986322|NCT02654431||Breast Cancer patients|Breast cancer patients
2986323|NCT02654431||women with breast cancer|women with breast cancer
2986324|NCT02654431||Cancer patients|Cancer patients
2986325|NCT02654418|Experimental|SIC 8000, 10 mL ampoules|Procedure/Surgery: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size) with SIC 8000 injectate solution.
2986326|NCT02654418|Active Comparator|reference comparator|Procedure/Surgery: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size) with Reference Comparator Injectate solution (site standard of care injectate solution).
2986327|NCT02654405|Experimental|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
2986328|NCT02654405|Placebo Comparator|Placebo|Placebo capsule with 2 mg of sodium butyrate for making taste or odor, (9 mg/day)
2986329|NCT02654392|Placebo Comparator|placebo|This group will receive isoenergetic carbohydrate (corn syrup) supplement daily for 5 weeks
2986330|NCT02654392|Other|Polyunsaturated fatty acid group|This group will receive a plant essential fatty acid food supplement, Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, & Pumpkin oils, containing a 2.5:1 omega-6 to omega-3 ratio (1.5 g per 70kg body mass plus an additional 0.5 g on exercise days)
2986331|NCT02654379||Cohort|Cohort consisting of participants who are in the center to receive an infusion for rituximab for a non-oncology indication.
2986332|NCT02654366|Experimental|Community Supported Risk Reduction Group|Six weekly sessions will be scheduled during daytime and evening hours to accommodate the daily schedules of BNEP registrants and their CSPs. Each session meets for 60 minutes. Groups will consist of 5-6 BNEP registrant-CSP dyads (10-12 individuals). While BNEP registrants and CSPs attending the group together will receive an attendance incentive, BNEP registrants attending without a CSP will not earn one. The group leader will follow a manual that includes a structured outline. The group manual content combines risk reduction / treatment readiness and community outreach approaches. Following the introduction, each group session is divided into two components: 1) Risk Reduction and Treatment Readiness (30 min) and 2) Community Outreach skills (20 min).
2986333|NCT02654353|Other|Group A: stepwise ablation|Stepwise ablation of persistent atrial fibrillation (conventional treatment arm) In this arm, patients will be treated with the conventional stepwiese ablation approach
2986334|NCT02654353|Active Comparator|Group B: sequential substrate ablation|Sequential substrate ablation of persistent atrial fibrillation (novel procedure) In this arm, patients will undergo an ablation procedure that consist of PVI, cardioversion, linear ablation and atrial fibrillation re-induction after blocked lines, followed by electrogram-guided ablation
2986335|NCT02654340||Observation|Patients with tuberous sclerosis complex or high-grade suspicion for tuberous sclerosis complex
2986336|NCT02654327|No Intervention|Standard Care|Standard care with conventional lung protective mechanical ventilation
2986337|NCT02654327|Experimental|ECCO2R to enable lower tidal volume mechanical ventilation|VV-ECCO2R to enable lower tidal volume mechanical ventilation (target tidal volume of ≤ 3ml/kg predicted body weight and a Pplat ≤ 25cmH20)
2986338|NCT02654314|Experimental|Melatonin|5 mg Melatonin nightly, beginning within 24 hours of admission
2986339|NCT02654314|Placebo Comparator|Cellulose Microcrystylline|Blue capsule matching the melatonin arm
2986340|NCT02654301|Placebo Comparator|Control group|sucrose drink (Control, sucrose 50g + deionized water 100g)
2986341|NCT02654301|Active Comparator|5 g xylose group|5 g xylose (Test 1, sucrose : xylose = 10:1),
2986342|NCT02654301|Active Comparator|3.33 g xylose group|3.33 g xylose (Test 2, sucrose : xylose = 15:1)
2986343|NCT02654301|Active Comparator|2.5 g xylose group|2.5 g xylose (Test 3, sucrose : xylose = 20:1)
2986344|NCT02654288||single arm|The pancreatic cancer patients without history of chemotherapy who will receive gemcitabine-based chemotherapy will be recruited and the sera IgG4 and IL-10 will be detected before and after chemotherapy.
2986345|NCT02654275|Active Comparator|Proprioceptive Intervention|Strength training on a non-stable surface
2986346|NCT02654275|No Intervention|No Proprioceptive Intervention|Conventional strength training
2986347|NCT02654249|Other|THD and mucopexy|Patients will undergo to transanal hemorrhoidal dearterialization with mucopexy (THD)‪ under generla anesthesia.
2986348|NCT02654249|Active Comparator|Ligasure hemorroidectomy|Patients will undergo to Ligasure™ hemorroidectomy under generla anesthesia.
2986349|NCT02654236|Placebo Comparator|Placebo|Heavy Drinkers on placebo
2986350|NCT02654236|Experimental|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 4 weeks.
2986351|NCT02654236|No Intervention|Non-drinking Controls|Non-drinking healthy controls
2986352|NCT02654223|Experimental|MG56 Mannosylated 60 subcutaneous|60 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
2986354|NCT02654223|Experimental|MG56 Mannosylated 300 subcutaneous|300 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
2986355|NCT02654223|Experimental|MG56 Mannosylated 500 subcutaneous|500 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
2986356|NCT02654223|Experimental|MG56 Mannosylated 60 sublingual|60 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
2986357|NCT02654223|Experimental|MG56 Mannosylated 100 sublingual|100 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
2986358|NCT02654223|Experimental|MG56 Mannosylated 300 sublingual|300 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
2986359|NCT02654223|Experimental|MG56 Mannosylated 500 sublingual|500 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
2986360|NCT02654223|Placebo Comparator|Placebo Sublingual Placebo subcutaneous|Sublingual and subcutaneous placebo.
2986361|NCT02654197||H.pylori positive children|Healthy children, 6-12 years old, will undergo screening for H. pylori infection by measuring anti-H. pylori and CagA IgG antibodies in the serum. The status of H. pylori infection will be confirmed using breath test (UBT). Children will be classified as i) H. pylori negative, if they test negative on UBT ii) H. pylori positive- CagA negative, if they test positive on UBT, but lack serum CagA IgG antibodies iii) H. pylori positive- CagA positive, if they are positive for H. pylori on UBT and CagA IgG antibodies.
2986362|NCT02654197||H.Pylori negative children|Healthy children, 6-12 years old, will undergo screening for H. pylori infection by measuring anti-H. pylori and CagA IgG antibodies in the serum. The status of H. pylori infection will be confirmed using breath test (UBT). Children will be classified as i) H. pylori negative, if they test negative on UBT ii) H. pylori positive- CagA negative, if they test positive on UBT, but lack serum CagA IgG antibodies iii) H. pylori positive- CagA positive, if they are positive for H. pylori on UBT and CagA IgG antibodies.
2986363|NCT02654184|Active Comparator|Supine group|Anesthesia induction with sevoflurane for the patient while he is in supine position.
2986364|NCT02654184|Active Comparator|Right lateral group|Anesthesia induction with sevoflurane for the patient while he is in right lateral position position.
2986365|NCT02654171|Experimental|AK0529|Subjects will receive single or multiple doses of AK0529 at different dose levels within different cohorts.
2986366|NCT02654171|Placebo Comparator|Placebo|Patients who are randomized to the control arm within each cohort will receive the corresponding placebo to AK0529.
2986367|NCT02654158||Low-dose of Fuganlin Oral Liquid|"oral~less than 1 years old: 5mL each time and three times a day~1~3 years old: 10mL each time and three times a day~4~6 years old: 10mL each time and four times a day~7~12 years old: 10mL each time and five times a day"
2986368|NCT02654158||High-dose of Fuganlin Oral Liquid|"oral~less than 1 years old: 10mL each time and three times a day~1~3 years old: 20mL each time and three times a day~4~6 years old: 20mL each time and four times a day~7~12 years old: 20mL each time and five times a day"
2986369|NCT02654145|Experimental|Omalizumab switch to mepolizumab 100mg SC every 4 weeks|Subjects with severe eosinophilic asthma who are receiving omalizumab will enter a run-in period for a minimum of one week and a up to 4 weeks. Subjects will remain on their current maintenance therapy throughout the run-in period, including omalizumab. At Visit 2 (week 0) subjects will discontinue omalizumab treatment and will be switched to receiving mepolizumab 100 mg SC every 4 weeks for 28 weeks. Except for omalizumab, subjects will remain on their current maintenance therapy throughout the open-label treatment period. Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
2986370|NCT02654132|Experimental|Elotuzumab Arm|"Biological:Elotuzumab (BMS-901608; HuLuc63)~Solution, Intravenous(IV),10 mg/kg(Cycles 1 and 2 weekly, on Days 1,8,15,22)~Solution, Intravenous(IV),20 mg/kg(Cycle 3 and Beyond: Day 1)~Drug: Pomalidomide~•Capsules,Oral,4 mg,once daily, on Days 1-21~Other Name: Pomalyst~Drug: Dexamethasone~Subjects ≤ 75 years old:~•Tablets, Oral,28 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Tablets, Oral,40 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)~Subjects > 75 years old:~•Tablets, Oral,8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Tablets, Oral, 20 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)~Other Names:~Decadron,Dexamethasone ,Intensol,Dexpak,Taperpak"
2986371|NCT02654132|Active Comparator|Control Arm|"Drug: Pomalidomide~• Capsules, Oral, 4 mg, once daily, on Days 1-21 Other Name: Pomalyst~Drug: Dexamethasone~Subjects ≤ 75 years old:~• Tablets, Oral, 40 mg, weekly on Days 1, 8, 15 and 22~Subjects > 75 years old:~• Tablets, Oral, 20 mg, weekly on Days 1, 8, 15 and 22,~Other Names:~Decadron~Dexamethasone Intensol~Dexpak~Taperpak"
2986372|NCT02654119|Experimental|Treatment (cyclophosphamide, paclitaxel, trastuzumab)|"SYSTEMIC THERAPY: Patients receive cyclophosphamide IV over 1 hour, paclitaxel IV over 3 hours, and trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE TRASTUZUMAB THERAPY: Beginning in course 6, patients receive trastuzumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity.~Patients may undergo radiation therapy at the discretion of the radiation oncologist and medical oncologist and patients with estrogen/progesterone receptor positive tumors receive hormonal therapy as determined by the medical oncologist per standard NCCN guidelines."
2986373|NCT02654106|Experimental|Refractory Brain Metastases|Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases
2986374|NCT02654093|Experimental|Group A|A → B → C / A: Cholecalciferol, B: Raloxifene, C: Cholecalciferol+Raloxifene
2986375|NCT02654093|Experimental|Group B|A → C → B
2986376|NCT02654093|Experimental|Group C|B → A → C
2986377|NCT02654093|Experimental|Group D|B → C → A
2986378|NCT02654093|Experimental|Group E|C → A → B
2986379|NCT02654093|Experimental|Group F|C → B → A
2986380|NCT02654080|Experimental|Group 1: Vaccine|Participants will receive the HIV-1 nef/tat/vif, env pDNA vaccine at Day 0 and Months 1 and 3. They will receive the rVSV HIV envC vaccine boost at Months 6 and 9.
2986381|NCT02654080|Placebo Comparator|Group 2: Placebo|Participants will receive placebo vaccine at Day 0 and Months 1, 3, 6, and 9.
2986382|NCT02654054|Experimental|Elagolix|Experimental
2986385|NCT02654041|Experimental|Hypothyroxinemia induced patients|Combined T3 and Methimazole treatment will be administered. This experimental treatment will be administered adjunct to standard oncological treatment for newly-diagnosed GBM patients e.g. radiation followed by Temozolomide.
2986386|NCT02654028|Experimental|Autotransfusion group|These group of patients will receive autotransfusion before liver resection.
2986387|NCT02654028|Active Comparator|Control group|These group of patients will not receive autotransfusion before or after liver resection.
2986388|NCT02654015|Experimental|Medical Management plus Apollo MIES|Subjects will receive best medical management for ICH plus they will receive the MIES surgery and use of the Apollo System for clot evacuation.
2986389|NCT02654002|Experimental|GS-9674|"Part A: Participants will receive a single dose of GS-9674 during Period 1 and multiple doses of GS-9674 during Period 2.~Part B: Based on the safety and available PK and PD data from cohorts in Part A and Part C (if applicable), participants will receive up to 600 mg of GS-9674 once daily or twice a day.~Part C: Based on the safety and available PK and PD data from cohorts in Part A and Part B (if applicable), participants will receive up to 300 mg of GS-9674 once daily."
2986390|NCT02654002|Experimental|Placebo|"Part A: Participants will receive a single dose of GS-9674 placebo during Period 1 and multiple doses of GS-9674 placebo during Period 2.~Part B: Based on the safety and available PK and PD data from cohorts in Part A and Part C (if applicable), participants will receive GS-9674 placebo once daily or twice a day.~Part C: Based on the safety and available PK and PD data from cohorts in Part A and Part B (if applicable), participants will GS-9674 placebo once daily."
2986391|NCT02653989|Experimental|MDV9300|
2986392|NCT02653976|Experimental|SP-02L (darinaparsin for injection)|
2986393|NCT02653963|No Intervention|Conventional AGV|A limbus-based conjunctival peritomy was created 4mm posterior to the limbus and Tenon's capsule was dissected. The AGV Plate was secured to the sclera 8 mm posterior to the limbus. The tube was trimmed to an appropriate length and inserted into the anterior chamber through a corneoscleral track. The tube was fixed to the episclera with a 10-0 nylon mattress suture. A donor sclera was fashioned to cover the exposed part of the tube and was secured to the sclera using 10-0 nylon sutures. The conjunctiva and Tenon were closed using 10-0 nylon suture.
2986394|NCT02653963|Experimental|Triamcinolone adjuctival AGV|Subtenon Periplate 10 mg triamcinolone acetonide around the AGV plate after fixation of AGV Plate to the sclera
2986395|NCT02653950|Active Comparator|Traditional|a control arm of patients undergoing traditional septoplasty for DNS
2986396|NCT02653950|Experimental|Endoscopic|patients undergoing endoscopic septoplasty.
2986397|NCT02653937|Experimental|Kampo medicine|7.5g per day of Tsumura's shigyakusan ( Tsumura & Co ) was administered to each of 110 cases.
2986398|NCT02653924|Active Comparator|silk suture|silk suture
2986399|NCT02653924|Active Comparator|vicryl suture|vicryl suture
2986400|NCT02653924|Active Comparator|nylon suture|nylon suture
2986401|NCT02653924|Active Comparator|polypropylene suture|polypropylene suture
2986402|NCT02653911|Experimental|acupuncture group|"Bilateral ST25, EX-CA1, CV4 and SP6 will be selected for treatment. After routine sterilization of the local skin, bilateral ST25, EX-CA1, CV4 and SP 6 will be inserted by the needles (0.30 mm in diameter, 40 mm in length) to a depth of 25-30 mm to the abdominal muscle layer with the manipulation of lifting, thrusting and rotating until de qi. Each session will last for 30 minutes, and the manipulation of lifting, thrusting and rotating evenly three times will be used for CV 4 and SP 6 every 10 minutes. If the date of treatment is during the menstrual circle, the treatment will be continued as usual. Participants will be treated three times a week for 12 weeks with 36 sessions."
2986403|NCT02653911|Sham Comparator|Sham-acupuncture group|The sham ST25, EX-CA1, CV4 and SP 6, which are 1 cun (25 mm) outward to ST25, EX-CA1, CV4 and SP 6, will be inserted to 2-3 mm with needles with a diameter of 0.30 mm and a length of 13 mm. The needles will be inserted without de qi or any manipulation. The treatment sessions will be the same as those in the acupuncture group.
2986404|NCT02653898|Active Comparator|Focused Screening and Treatment + ITU|Approved antimalarial based on the malaria species identified on the monthly follow ups, following national treatment guidelines in Cambodia AND Insecticide Treated Uniform with 40% Permethrin; DHA-PIP or Artesunate + Mefloquine based on the malaria species, single dose Primaquine 15 mg in subjects with P.f uncomplicated malaria or Primaquine 45 mg weekly x 8 weeks in G6PD-deficient volunteers, or Primaquine 15 mg daily for 14 days in G6PD-normal volunteers.
2986405|NCT02653898|Active Comparator|Focused Screening and Treatment + sITU|Approved antimalarial based on the malaria species identified at the monthly follow up and following national treatment guidelines in Cambodia AND sham treated uniform. DHA-PIP or Artesunate + Mefloquine based on the malaria species, single dose Primaquine 15 mg in subjects with P.f uncomplicated malaria or Primaquine 45 mg weekly x 8 weeks in G6PD-deficient volunteers, or Primaquine 15 mg daily for 14 days in G6PD-normal volunteers.
2986406|NCT02653898|Active Comparator|Monthly Malaria Prophylaxis + ITU|Monthly DHA-PIP + weekly Primaquine 22.5 mg for 3 months; All subjects will also receive insecticide treated uniforms with 40% Permethrin
2986407|NCT02653898|Active Comparator|Monthly Malaria Prophylaxis + sITU|Monthly DHA-PIP + weekly Primaquine 22.5 mg for 3 months; All subjects will also receive sham treated uniforms
2986408|NCT02653872|Experimental|AZD7986 (alone) Treatment period 1|AZD7986 (15 mg/mL) 25 mg dosage administered alone
2986409|NCT02653872|Active Comparator|Verapamil (with AZD7986) Treatment period 2|Daily administration of verapamil (240 mg, extended release formulation) on Days 1 to 10 plus administration of single dose AZD7986 (25 mg) on Day 5
2986410|NCT02653872|Active Comparator|Itraconazole (with AZD7986) Treatment Period 3|Itraconazole (200 mg, oral solution formulation 10 mg/mL) administered twice on Day 1 and then daily Days 2 to 11 plus single dose AZD7986 (25 mg, tbc) on Day 6
2986411|NCT02653872|Active Comparator|Diltiazem (with AZD7986) Treatment period 3|Diltiazem (360 mg, extended release formulation) administered Days 1 to 13 plus single dose AZD7986 (25 mg) on Day 8
2986412|NCT02653833|Experimental|Healthy Controls (HC)|Healthy men currently taking no medications will be asked to perform graded hand-grip exercise while a contrast enhanced ultrasound (CEU) probe is placed over their forearm to measure blood flow. This is repeated at baseline and shortly after taking beetroot juice extract.
2986443|NCT02653625|Experimental|Open-label|One tablet of Cenicriviroc 150 mg once daily with food in the morning for 24 weeks
2986444|NCT02653612|Experimental|Experimental Arm|This cohort will receive the contrast agent
2986413|NCT02653833|Experimental|Becker Muscular Dystrophy (BMD)|"currently taking no medications will be asked to perform graded hand-grip exercise while a contrast enhanced ultrasound (CEU) probe is placed over their forearm to measure blood flow. Using a lower body negative pressure (LBNP) chamber, the subjects are tested for impaired exercise induced vasodilation to the skeletal muscle or functional sympatholysis. This is repeated at baseline and shortly after taking beetroot juice extract."
2986414|NCT02653820|Experimental|Chemotherapy patients|Chemotherapy patients will receive reflexology treatment
2986415|NCT02653807|Experimental|mobilization with movement|MWM at the talocrural joint during active weight bearing ankle dorsiflexion with the belt
2986416|NCT02653807|Active Comparator|osteopathic mobilization|passive mobilization of the talo-crural joint
2986417|NCT02653781|Experimental|Realistic simulation; Performance|Student participation in the study will happen on demand by enrollment in activities of dialogue-exhibition (workshop) on realistic simulation in the context of patient safety. Check the performance of students in face of simulation workshop for test realistic simulation.
2986418|NCT02653781|Other|theoretical-practical classes|Will be to give a theoretical-practical classes for students of control group the provision of similar opportunities
2986419|NCT02653768|Experimental|STEP-KOA|This is a stepped exercise program. It begins with an internet-based exercise training program (STEP 1). After three months, participants are assessed to see if they have achieved clinically meaningful improvement in key osteoarthritis outcomes. If so, they remain at STEP 1. If not, they move on to STEP 2, which adds telephone-based coaching. Participants are assessed again three months later. Those that still have not achieved clinically relevant improvement move on to STEP 3, which adds a series of in-person physical therapy visits.
2986420|NCT02653768|Active Comparator|Arthritis Education (AE)|"Participants in the AE control group will receive low literacy educational materials via mail every two weeks. Because STEP-KOA is a multi-component intervention, with participants receiving different numbers of Steps, it is not possible to implement a control condition that will mirror the exact intervention dose received by all participants in the STEP-KOA group. However, AE will achieve the goal of providing an active, OA-related control condition."
2986421|NCT02653755|Active Comparator|Ineligible for omission of RT|Prosigna confirms intermediate- or high-risk score. Participants with intermediate- or high-risk scores will be ineligible for omission of radiotherapy (RT). Some patients with low-risk scores may elect to receive RT.
2986422|NCT02653755|Active Comparator|Eligible for omission of RT|Prosigna confirms low risk score. Participant will be eligible for omission of therapy and chooses to do so. Patient will receive adjuvant endocrine therapy.
2986423|NCT02653742|Experimental|Ketorolac|Ketorolac 1mg/kg sublingual, in the form of Ketorolac Tromethamine solution for intravenous/intramuscular use.
2986424|NCT02653742|Experimental|Fentanyl|Fentanyl 2mcg/kg intranasal, in the form of Fentanyl Citrate solution for intravenous/intramuscular use.
2986425|NCT02653742|Experimental|Ketorolac and Fentanyl|Ketorolac 1mg/kg sublingual, in the form of Ketorolac Tromethamine solution for intravenous/intramuscular use and Fentanyl 2mcg/kg intranasal, in the form of Fentanyl Citrate solution for intravenous/intramuscular use.
2986426|NCT02653729|Experimental|Espidone, Olepra, Donu & C.B.T|Espidone tablet 2 mg and Donu 10 mg by mouth twice a day and Olepra tablet 5 mg by mouth at night and C.B.T 6 session program 45 minutes session after every 15 days
2986427|NCT02653729|Active Comparator|Espidone, Olepra & Donu|Espidone tablet 2 mg and Donu 10 mg by mouth twice a day Olepra tablet 5 mg by mouth at night
2986428|NCT02653716|Active Comparator|Case Management|CM
2986429|NCT02653716|Experimental|New Orleans Intervention Model|NIM
2986430|NCT02653703|Placebo Comparator|Vehicle, topical ethanol 96%|Exposure: 10 % topical trans-cinnamaldehyde [CAS Number: 14371-10-9] Vehicle: 96% ethanol
2986431|NCT02653703|Experimental|Topical L-menthol 40%|Exposure: 10 % trans-cinnamaldehyde [CAS Number: 14371-10-9] Intervention: 40% l-menthol [CAS Number: 2216-51-5] Vehicle: 96% ethanol
2986432|NCT02653677|Active Comparator|commercial bread, wheat flour|Intake of the specific kind of bread
2986433|NCT02653677|Experimental|wheat, organic flour|Intake of the specific kind of bread
2986434|NCT02653677|Experimental|wheat, supermarket flour|Intake of the specific kind of bread
2986435|NCT02653677|Experimental|einkorn, organic flour|intake of the specific kind of bread
2986436|NCT02653664|Experimental|Condition #1: PsychoEducation|Condition #1 will include 8 90-minute group sessions that will educate the subject about chronic pain, discuss the impact of pain, and inform the subject of different ways to manage it in hopes of decreasing pain and its impact on the subject's life. Participants in this condition will be given pre-recorded audio recordings of the content of the sessions to listen to.
2986437|NCT02653664|Experimental|Condition #2:Self-Hypnosis Training|In condition #2, the facilitator will perform a standard hypnotic short induction followed by therapeutic suggestions, including post-hypnotic suggestions. Participants will relax in a comfortable position with their eyes closed and will simply listen to the clinician read a standardized hypnotic script that will include an induction followed by suggestions for decreased pain and improvement in co-morbid symptoms (e.g., improved mood and optimism, relaxation, sleep quality).
2986438|NCT02653664|Experimental|Condition #3: Mindfulness Meditation|In condition #3, the facilitator will teach participants Vipassana meditation, which is the specific form of mindfulness meditation (MM) typically implemented in mindfulness research. The emphasis is placed upon developing focused attention on an object of awareness, such as the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. Time will also be devoted to problem solving around any difficulties with MM practice.
2986439|NCT02653651|Active Comparator|Ketamine|Ketamine infused at 0.1 mg/kg/hour
2986440|NCT02653651|Experimental|Lidocaine|Lidocaine infused at 1 mg/kg/hour
2986441|NCT02653651|Placebo Comparator|Placebo|An equal volume of saline
2986442|NCT02653638|Experimental|Drug|"Control-Hypercapnic Trials: Three stepwise CO2 elevations will be applied to the patient by adding fractional concentration of inspired CO2 (FICO2) at 2%, 4%, and 6% each time, balanced with room air. The end tidal CO2 (PetCO2) will be elevated and maintained constant for three minutes at each target level. Breath-by-breath changes in minute ventilation (VE) and PetCO2 will be measured.~Drug-Indomethacin: Healthy volunteers, indomethacin suspension will be orally administered at 1.2 mg/kg. After drug administration, the patient will rest quietly for 90 minutes."
2986445|NCT02653599|Experimental|TTP273 300 mg daily (150 mg BID)|Two 75 mg tablets of TTP273 administered orally twice daily for 12 weeks
2986446|NCT02653599|Experimental|TTP273 150 mg daily|Two 75mg tablets of TTP273 administered orally once daily and two placebo tablets administered orally once daily for 12 weeks
2986447|NCT02653599|Placebo Comparator|Placebo|Two matching placebo tablets administered orally twice daily for 12 weeks
2986448|NCT02653586|Experimental|"program In Favor of Resilience Self"|"The program In Favor of Resilience Self was delivered to adolescence aged 15-17, over 2 months. The program contained nine weekly, 90-min lessons that focus on enhancing self- resilience, self-esteem, self-image, body image. All students completed a self-report questionnaire at baseline, conclusion and 3 months after program conclusion."
2986449|NCT02653586|No Intervention|control group|The control group didn't receive the intervention program, instead they received a lecture on wised nutrition. In addition the control group completed the same self-report questionnaire as the intervention group at baseline, conclusion and 3 months after program.
2986450|NCT02653573|Experimental|Intervention|Telephone health coaching over 3 months with supporting education materials.
2986451|NCT02653560|Experimental|Potassium magnesium Citrate (KMgCit) arm|Potassium magnesium citrate will be prepared by mixing potassium citrate, magnesium citrate and/or citric acid by Meta Pharm Development. The content of each sachet will be dissolved in 250 ml water and will be drunk with breakfast and again with dinner during the KMgCit Phase, to deliver 40 meq K, 20 meq Mg and 74 meq citrate per day for 4 weeks
2986452|NCT02653560|Experimental|Potassium citrate arm|A special sachet formulation containing 20 meq K/sachet will be made for the study by Meta Pharm Development. The contents of a sachet will be added to 250 ml water and drunk with breakfast and dinner, to deliver 40 meq K (as citrate) per day during the Potassium Citrate Phase for 4 weeks.
2986453|NCT02653560|Experimental|Potassium chloride arm|Potassium chloride will contain 20 meq KCl per sachet. During the Potassium Chloride Phase, subjects will dissolve the content of each sachet in 250 ml water and ingest it with breakfast and again with dinner, to deliver 40 meq K (as chloride) per day for 4 weeks
2986454|NCT02653560|Placebo Comparator|Placebo|Placebo will comprise microcrystalline cellulose, equivalent in volume in each sachet as other test products. During the Placebo Phase, subjects will dissolve the entire content of a sachet in 250 ml water and drink it with breakfast and again with dinner for 4 weeks.
2986455|NCT02653547|Experimental|standard multisite four weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation; complete treatment of four weeks
2986456|NCT02653547|Experimental|high-frequency multisite four weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and high-frequency temporoparietal (bilateral) stimulation; complete treatment of four weeks
2986457|NCT02653547|Experimental|standard multisite two weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation; discontinuation after two weeks
2986458|NCT02653547|Experimental|high-frequency multisite two weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and high-frequency temporoparietal (bilateral) stimulation; discontinuation after two weeks
2986459|NCT02653534|Experimental|Intervention Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
2986460|NCT02653534|No Intervention|Control|Routine visits by government health workers
2986461|NCT02653521|Experimental|adaptive radiation therapy (ART)|40 patients treated with ART, using dose adaptation method to match the change of PTV and movement of OARs and achieve an optimal dose distribution using online CBCT images.
2986462|NCT02653521|No Intervention|the control group|40 patients treated with original plan for full treatment course.
2986463|NCT02653508|Experimental|Diet and Activity|60 overweight and obese adolescents aged 13-15 years old took part in the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. The activity intervention included a 45 minutes, three-day per week supervised training programme, while the nutritional education comprised of a supplementary 15 minutes of group-based sessions that could be also attended by the parents. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
2986464|NCT02653508|Experimental|Activity|60 overweight and obese adolescents aged 13-15 years old took part in the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. The activity intervention included a 45 minutes, three-day per week supervised training programme, that could be also attended by the parents. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
2986465|NCT02653508|No Intervention|Control|61 overweight and obese adolescents aged 13-15 years old were the control group of the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
2986466|NCT02653495|Experimental|Influenza vaccine in metabolic syndrome|Influenza vaccine
2986467|NCT02653495|Experimental|Influenza vaccine in healthy controls|Influenza vaccine
2986468|NCT02653482|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg daily
2986469|NCT02653482|Placebo Comparator|Dapagliflozin matching placebo|Dapagliflozin matching placebo 10 mg daily
2986470|NCT02653469||Augmented ventilation with fluid loading|This is an observational study and as a diagnostic intervention, subjects in the study would receive mechanical ventilation with augmented tidal volume of 12ml/kg for 2min. Augmented ventilation is performed when the patient's PPV is within grey zone (9-13%). The investigators perform this procedure to every patients and do not assigh this intervention to the subjects of the study. Then, 6ml/kg of ballanced crystalloid loading will be infused to every patient.
2986471|NCT02653456|Experimental|RA-308 Excimer Laser and DABRA Catheter|Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions that cannot be crossed with standard guidewires. The catheter and laser are a system, and cannot be used separately.
2986472|NCT02653443|Experimental|Day 6|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
3001075|NCT02555709|Experimental|VTP-43742 Dose 9|psoriatic patients
2986473|NCT02653443|Experimental|Day 7|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
2986474|NCT02653430|Experimental|Bariatric Surgery|Sleeve Gastrectomy
2986475|NCT02653417|Experimental|Regimen 1|RAD1901 5 mg
2986476|NCT02653417|Experimental|Regimen 2|RAD1901 10 mg
2986477|NCT02653417|Experimental|Regimen 3|RAD1901 20 mg
2986478|NCT02653417|Placebo Comparator|Regimen 4|Placebo
2986479|NCT02653404||Cases|"A blood sample necessary to perform QFT-GIT will be taken, together with other routine blood samples, from children with following diagnosis:~latent tuberculous infection: active TB contact, TST positive, lack of clinical and RX signs of active-TB~active TB: clinical and radiologic evidences of active-TB, positivity to microbial tests to BK~not infected: patients evaluated as TB contacts, with negative TST and negative clinical/radiological/microbial results for TB."
2986480|NCT02653391|Placebo Comparator|Elamipretide 1.0% Ophthalmic Solution and Vehicle Control|Each subject will receive one drop of elamipretide 1.0% ophthalmic solution in the randomly selected study eye BID and one drop of vehicle ophthalmic solution BID in the fellow control eye.
2986481|NCT02653391|Placebo Comparator|Elamipretide 3.0% Ophthalmic Solution and Vehicle Control|Each subject will receive one drop of elamipretide 3.0% ophthalmic solution or placebo in the randomly selected study eyes BID
2986482|NCT02653378|Active Comparator|DIET ARM|A 25% energy depletion (daily for 3 days) induced by reducing the amount of energy intake that would otherwise keep the individual in energy balance.
2986483|NCT02653378|Active Comparator|EX ARM|A 25% energy depletion (daily for 3 days) induced by performing aerobic exercise at 50% of V02max.
2986484|NCT02653365||Non-invasive ventilation|All patients eligible for inclusion in the study were treated with Non-invasive ventilation.
2986485|NCT02653352|No Intervention|Control|The control group received two one-hour general sessions on health issues and printed general advices regarding healthy diets.
2986486|NCT02653352|Experimental|Lifestyle modification|Intervention was focused on the reduction in consumption of sugar-sweetened carbonated beverages by students. During seven months of one school year, a healthy lifestyle education programme was implemented using simple messages encouraging water consumption instead of sugar-sweetened carbonated beverages. Education was delivered via classroom activities; banners were hung promoting water consumption, and water bottles with the logo of the campaign were given to children and schoolteachers.
2986487|NCT02653339|Experimental|Qufeng Shengshi Fang and Loratadine|Qufeng Shengshi Fang is a traditional Chinese medicine form 8 kinds of herbs. Loratadine is the second generation antihistamines, after converted into its active metabolite Carrie period (carebastine), its antihistamines and allergy effect has been demonstrated in vitro and in vivo tests, also received data from clinical trials.
2986488|NCT02653339|Active Comparator|Loratadine|Loratadine (INN) is a second-generation H1 histamine antagonist drug used to treat allergies. In structure, it is closely related to tricyclic antidepressants, such as imipramine, and is distantly related to the atypical antipsychotic quetiapine.Loratadine is marketed by Schering-Plough[needs update] under several trade names (e.g., Claritin) and also by Shionogi in Japan. It is available as a generic drug and is marketed for its nonsedating properties. In a version named Claritin-D or Clarinase, it is combined with pseudoephedrine, a decongestant; this makes it useful for colds, as well as allergies but adds potential side effects of insomnia, anxiety, and nervousness.
2986489|NCT02653326|Experimental|Telerehabilitation|In addition to routine care, patients in this arm will receive a telerehabilitation strategy comprised by a portable EKG monitor and a smartphone application.
2986490|NCT02653326|Active Comparator|Routine Care|Patients allocated to routine care will receive care as enforced by current practice guidelines. This care included nutritional counseling, depression screening, drug therapy for the management of comorbidities and physical exercise without telemonitoring.
2986491|NCT02653313|Experimental|ParvOryx|ParvOryx given intravenously on four consecutive days (day 1 to 4) and intrametastatic six to thirteen days thereafter (day 7, 10 or 14).
2986492|NCT02653300|Experimental|Oral Insulin|treatment
2986493|NCT02653287|Experimental|Intervention|The experimental intervention is a unique combination of four individual counseling sessions based in motivational interviewing and six group educational sessions focusing on physical activity, dietary behavior and behavioral strategies. The individual sessions will provide a tailored personalized intervention including problem-solving and goal setting for increasing physical activity, and following a healthy diet. Healthy Lifestyle Coaches (RN or MPH) will be responsible for conducting the individual and group sessions for a caseload of participants. There are no drugs involved in the intervention.
2986494|NCT02653287|Active Comparator|Control|The control group intervention will receive six group educational sessions focusing on SLE disease management. A nurse practitioner will be responsible for conducting the group sessions.Control arm participants will also receive four individual phone calls checking in with participants regarding questions about the study or from the group sessions, each lasting approximately 10-15 minutes.
2986495|NCT02653274|Active Comparator|OATS PORRIDGE|Oats breakfast porridge
2986496|NCT02653274|Active Comparator|RYE PORRIDGE|Rye breakfast porridge
2986497|NCT02653274|Active Comparator|FINGER (RAGI) MILLET PORRIDGE|Finger (ragi) millet breakfast porridge
2986498|NCT02653274|Active Comparator|PEARL (BAJRA) MILLET PORRIDGE|Pearl (bajra) millet breakfast porridge
2986499|NCT02653261|Experimental|Tranexamic Acid|Tranexamic Acid (TXA): bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
2986500|NCT02653261|Placebo Comparator|Placebo|An equal volume of saline
2986501|NCT02653248|Experimental|Cohort 1|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 8Gy. Total Dose: 40Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
2986502|NCT02653248|Experimental|Cohort 2|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 9Gy. Total Dose: 45 Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
2986538|NCT02653014|Experimental|Cohort 5|Subjects with mild to moderate renal impairment will receive multiple dose of KBP-5074
2986503|NCT02653248|Experimental|Cohort 3|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 10Gy. Total Dose: 50Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
2986504|NCT02653235|Active Comparator|Typhoid vaccination|Salmonella typhi vaccination
2986505|NCT02653235|Placebo Comparator|Placebo|0.9% sodium chloride
2986506|NCT02653222|Experimental|Renal sympathicolysis|"The patient will have:~Ambulatory Blood Pressure Monitoring~Magnetic Resonance Angiography~Blood test~Renal sympathicolysis~Ambulatory Blood Pressure Monitoring~Magnetic Resonance Angiography"
2986507|NCT02653209|Experimental|Sitagliptin - DPP4i|
2986508|NCT02653209|Experimental|Canagliflozin - SGLT2i|
2986509|NCT02653209|Experimental|Pioglitazone - TZD|
2986510|NCT02653196|Experimental|Allogeneic Hematopoietic Stem Cell Transplant|"Matched Unrelated Donor HSCT (minimum 9/10 human leukocyte antigen [HLA] match) OR Matched Related Donor HSCT (10/10 HLA match). Conditioning regimen begins 12 days prior to stem cell infusion and includes the following drugs:~Keratinocyte Growth Factor Alemtuzumab Thiotepa Etoposide Melphalan Fludarabine Tacrolimus (Cyclosporine A may be substituted for Tacrolimus) Mycophenolate mofetil"
2986511|NCT02653183|Active Comparator|Device Aquacel Surgical|Aquacel Surgical is a sterile, one piece post-operative dressing from ConvaTec.
2986512|NCT02653183|Experimental|Device Mepilex Border Post-Op|Post-operative all-in-one self-adherent soft silicone coated foam dressing.
2986513|NCT02653170|No Intervention|Usual Care|Patients in this group will receive the hospitals' usual transitional care approach.
2986514|NCT02653170|Experimental|SCM|"One intervention is provided:~1. SCM (Stroke Case manager): a trained social worker who provides in-home case management services."
2986515|NCT02653170|Experimental|SCM and VSSP|"Two interventions are provided:~SCM (Stroke Case manager): a trained social worker who provides in-home case management services. Plus:~VSSP (Virtual Stroke Support Portal): Access and training in the use of the VSSP: a purpose-built, online, patient-centered information and support resource."
2986516|NCT02653157||Burn patients with VAT or VAP with MDR-GNB|Adult patients with burn and/or inhalation injury requiring intubation
2986517|NCT02653144|Experimental|dexmedetomidine and ropivacaine group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with Ropivacaine 0.5% 20ml + 75mcg of dexmedetomidine
2986518|NCT02653144|Experimental|dexamethasone and ropivacaine group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with. Ropivacaine 0.5% 20ml + 4mg dexamethasone
2986519|NCT02653144|Active Comparator|ropivacaine only group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with Ropivacaine 0.5% 20ml (acting as control)
2986520|NCT02653131|Experimental|DPP-4|The administration of the DPP-4 inhibitor in the form of a pill once per day
2986521|NCT02653131|No Intervention|NO DPP|no therapy
2986522|NCT02653118||Cohort 1: V503 in the Base Study|Participants received the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543). No study vaccination will be administered in study V503-021.
2986523|NCT02653118||Cohort 2: GARDASIL in the Base Study|Participants received GARDASIL (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543) and were offered the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) at the conclusion of the base study. V503 vaccination was voluntary and not a condition for inclusion in Cohort 2. No study vaccination will be administered in study V503-021.
2986524|NCT02653105|Experimental|OLFM4|Patient have a blood test every 6 months at the same time of the clinical exam planned in the following. The OLFM4 will be dose in the blood sample and the rate of OLFM4 compared to the result of imaging.
2986525|NCT02653092|Active Comparator|Aim 1|"Reproduction of the reproductive phenotype of obesity in Normal Weight Women (NWW) by:~infusing insulin and free fatty acids (FFAs) in short term experiments and measuring gonadotropin pulsatility and pituitary GnRH response; and~inducing a chronic model of the reprometabolic syndrome by administering a eucaloric diet that is relatively high in pro-inflammatory omega-6 fatty acids and low in anti-inflammatory omega-3 fatty acids (high fat diet; HFD) for one month while monitoring gonadotropin pulsatility and daily urinary reproductive hormone excretion."
2986526|NCT02653092|Experimental|Aim 2|Assessment of the gluco-regulatory and anti-lipolytic actions of insulin with a 2-stage, Hyperinsulinemic, Euglycemic Clamp (HEC) to evaluate both suppression of lipolysis and hepatic glucose production.
2986527|NCT02653079||Study Cohort|Blood draw and Questionaire from patients suffering from chronic inflammatory diseases of the joints, namely painful shoulder syndrome (periarthritis humeroscapularis), painful elbow syndrome (Epicondylopathia humeri), benign achillodynia, and benign calcaneodynia with an - planned local low dose radiation therapy (LDRT) at the Department of Radiation Oncology, Universitätsklinikum Erlangen.
2986528|NCT02653066|No Intervention|Control|Participant is recruited via usual avenues including flyers and physician referral. This includes participants who received a HealtheRx with advertisement for phone survey but did not call in based on advertisement.
2986529|NCT02653066|Experimental|Intervention with consent form|After completing survey, participant in HealtheRx+ group receives $5 bill with their survey check and blank registry consent form.
2986530|NCT02653066|Experimental|Intervention with return of consent form|After returning signed consent form, participant in HealtheRx++ group is mailed $5 bill.
2986531|NCT02653040|Experimental|Dynamic lighting|Indoor lighting with low-lux no-blue wavelengths at night.
2986532|NCT02653040|No Intervention|Treatment as usual|Characterized by full white light with little variation through a day cyclus.
2986533|NCT02653027|Experimental|Lumacaftor Ivacaftor|Subjects will get an OGTT before and after starting the combination therapy lumacaftor-ivacaftor.
2986534|NCT02653014|Experimental|Cohort 1|Healthy Volunteers will receive multiple dose of KBP-5074
2986535|NCT02653014|Experimental|Cohort 2|Healthy Volunteers will receive multiple dose of KBP-5074
2986536|NCT02653014|Experimental|Cohort 3|Healthy Volunteers will receive multiple dose of KBP-5074
2986537|NCT02653014|Experimental|Cohort 4|Healthy Volunteers will receive multiple dose of KBP-5074
2986539|NCT02653014|Experimental|Cohort 6|Subjects with mild to moderate renal impairment will receive multiple dose of KBP-5074
2986540|NCT02653001|Experimental|Experimental arm|Stool sample collection: Stool samples collected from study participants will be introduced into the colon model to enhance our understanding of the colonic bacterial ecosystem in response to various food components, drugs or biological therapies, and/or to allow investigation the impact of the bacterial ecosystem itself on these added components
2986541|NCT02652988|Active Comparator|Active-tDCs|17 patients will receive Active-tDCS intervention (2mA, 30 min) at home.
2986542|NCT02652988|Sham Comparator|Sham-tDCS|17 patients will receive Sham-tDCS intervention (2mA, 30 min) at home.
2986543|NCT02652975|Experimental|Category 1|Examination of participants prior to chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
2986544|NCT02652975|Experimental|Category 2|Examination of participants immediately after chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
2986545|NCT02652975|Experimental|Category 3|Examination of participants one year after chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
2986546|NCT02652962|Experimental|Gelesis200 x 2, 10 min|3 x 0.70g Gelesis200 capsules administered 10 minutes before each of 2 meals (breakfast, lunch).
2986547|NCT02652962|Experimental|Gelesis200 x 2, 30 min|3 x 0.70g Gelesis200 capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
2986548|NCT02652962|Placebo Comparator|Placebo x 2, 10 min|3 x Placebo capsules administered 10 minutes before each of 2 meals (breakfast, lunch).
2986549|NCT02652962|Placebo Comparator|Placebo x 2, 30 min|3 x Placebo capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
2986550|NCT02652962|Experimental|Gelesis200 x 3, 10 min|3 x 0.70g Gelesis200 capsules administered 10 minutes before each of 3 meals (breakfast, lunch, dinner).
2986551|NCT02652962|Experimental|Gelesis200 x 3, 30 min|3 x 0.70g Gelesis200 capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
2986552|NCT02652962|Placebo Comparator|Placebo x 3, 10 min|3 x Placebo capsules administered 10 minutes before each of 3 meals (breakfast, lunch, dinner).
2986553|NCT02652962|Placebo Comparator|Placebo x 3, 30 min|3 x Placebo capsules administered 30 minutes before each of 3 meals (breakfast, lunch, dinner).
2986554|NCT02652949|Experimental|Valiant Evo Thoracic Stent Graft|Subjects treated with the Valiant Evo Thoracic Stent Graft, via implantation by the Valiant Evo Thoracic Stent Graft System
2986555|NCT02652936|Experimental|AF-130 capsule|AF-130 oral capsules administered as a single dose or once daily for 7 days
2986556|NCT02652936|Placebo Comparator|AF-130 matching placebo capsule|Oral placebo capsules to match AF-130 administered as a single dose or once daily for 7 days
2986557|NCT02652923|Experimental|Part 1 - volunteers|Subdermal low (1.0 ml) or high (2.0 ml) dose injection of the ultrasound contrast agent Sonazoid divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock) around a 2 cm in diameter region in the mid-upper outer quadrant of the left breast, followed a week later by the other dose injected in the same fashion into the right breast.
2986558|NCT02652923|Experimental|Part 2 - patients|Subdermal injection of the ultrasound contrast agent of Sonazoid divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock) around the breast cancer. Subjects will receive an injection of either a low (1.0 ml) or a high (2.0 ml) dose of Sonazoid depending on the outcome of the Part 1 safety and tolerability study.
2986559|NCT02652910|Experimental|IL-2 programmed CD19.CAR-T cells|Administrated with IL-2 programmed CD19.CAR-T cells on day 0,1,2 in the lympho-depleted patients
2986560|NCT02652910|Experimental|IL-7/IL-15 programmed CD19.CAR-T cells|Administrated with IL-7/IL-15 programmed CD19.CAR-T cells on day 0,1,2 in the lympho-depleted patients
2986561|NCT02652897||Exposure to glioma resection surgery|Patients undergoing elective glioma resection
2986562|NCT02652897||Exposure to colon resection surgery|Patients undergoing elective colon cancer resection
2986563|NCT02652884|Experimental|Group 1|will receive single dose intramuscular corticosteroid deltoid deposit (as phosphate and betamethasone acetate, 2 mL) for immediate postintubation.
2986564|NCT02652884|Placebo Comparator|Group 2|will receive 2 ml saline 0.9% NaCl in deltoid immediately postintubation.
2986565|NCT02652871|Experimental|LY2510924 + Idarubicin + Cytarabine|"Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients. On Day 8, LY2510924 administered after bone marrow aspiration and/or biopsy is performed.~Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase.~Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients > 60 years of age Idarubicin given for 2 days.~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days.~Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age < 60 years). In patients > 60 years of age Cytarabine given for 3 days only.~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days."
2986566|NCT02652858|Experimental|Pulse wave's speed observational arm|Whole patients for who the pulse wave's speed are measured during a cardiopulmonary bypass during cardiac surgery
2986567|NCT02652845|Experimental|Intervention-Wellness Engagement Program|"The group assigned to the intervention arm will receive treatment as described below for a twelve week period:~Weekly lessons related to healthy eating and physical activity Biweekly check-in calls with a trained peer support coach Access to neighborhood wide physical activity and nutritional education events"
2986568|NCT02652845|No Intervention|Delayed treatment control group|The delayed treatment control group will not receive the intervention for measurement purposes; however the intervention as described will be administered to this group upon conclusion of the 12 week period for the intervention group.
2986569|NCT02652832|Active Comparator|Depression Electroconvulsive therapy|40 patients with major depression receiving a mean of 12 sessions of Electroconvulsive therapy
2986570|NCT02652832|Active Comparator|Depression active repetitive transcranial magnetic stimulation|40 patients with major depression receiving a mean 4 weeks of 1 Hz repetitive transcranial magnetic stimulation applied over the right dorsolateral prefrontal cortex - DLPFC
2986571|NCT02652832|Sham Comparator|Depression sham repetitive transcranial magnetic stimulation|40 patients with major depression receiving a mean 4 weeks of sham 1 Hz repetitive transcranial magnetic stimulation applied over the right dorsolateral prefrontal cortex - DLPFC
2986572|NCT02652832|Active Comparator|Schizophrenia active transcranial magnetic stimulati|40 patients with schizophrenia and predominant negative symptoms receiving 20 sessions of intermittent theta burst simulation (iTBS) applied over the left dorsolateral prefrontal cortex - DLPFC
2986573|NCT02652832|Sham Comparator|Schizophrenia sham transcranial magnetic stimulation|patients with schizophrenia and predominant negative symptoms receiving 20 sessions of sham intermittent theta burst simulation (iTBS) applied over the left dorsolateral prefrontal cortex - DLPFC
2986574|NCT02652832|Active Comparator|Schizophrenia active transcranial Direct Current Stimulation|40 patients with schizophrenia and auditory verbal hallucinations receiving 10 sessions of transcranial Direct current stimulation (tDCS) applied with the anode over the left dorsolateral prefrontal cortex - DLPFC- and the cathode over the left temporoparietal junction
2986575|NCT02652832|Sham Comparator|Schizophrenia sham transcranial Direct Current Stimulation|40 patients with schizophrenia and auditory verbal hallucinations receiving 10 sessions of sham transcranial Direct current stimulation (tDCS) applied with the anode over the left dorsolateral prefrontal cortex - DLPFC- and the cathode over the left temporoparietal junction
2986576|NCT02652832|No Intervention|Healthy volunteers|80 healthy volunteers receiving no stimulation
2986577|NCT02652819|Experimental|FG-4592|Intervention is investigational treatment FG-4592
2986578|NCT02652819|Placebo Comparator|Placebo|Double blinded placebo control
2986579|NCT02652806|Experimental|FG-4592|Intervention is investigational treatment FG-4592
2986580|NCT02652806|Active Comparator|EPO|Intervention is subject's current dose of Li Xue Bao (epoetin alfa)
2986581|NCT02652793|Experimental|Experimental|All participants will switch their current antiretroviral regimen to a boosted atazanavir and lamivudine once daily.
2986582|NCT02652780|Experimental|GS010-treated Eyes|Each subject will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Subjects will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
2986583|NCT02652780|Sham Comparator|Sham-treated Eyes|Each subject will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
2986584|NCT02652767|Experimental|GS010-treated Eyes|Each subject will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Subjects will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
2986585|NCT02652767|Sham Comparator|Sham-treated Eyes|Each subject will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
2986586|NCT02652754|Other|Granexin® gel plus standard-of-care|Granexin® gel will be applied topically to diabetic foot ulcer(s) on Day 0 (baseline), Day 3, and Day 7. In addition, standard-of-care treatment will be applied to the ulcer(s) at Screening, Day 0, Day 3, and Day 7.
2986587|NCT02652741|Experimental|Drug administration|Enalapril Orodispersible Minitablet (ODMT), 0.25 mg or 1 mg, administered 1x/day or 2x/day for up to 8 weeks
2986588|NCT02652728|Experimental|Drug administration|Enalapril Orodispersible Minitablet (ODMT), 0.25 mg or 1 mg, administered 1x/day or 2x/day for up to 8 weeks
2986589|NCT02652715|Experimental|Basic science (Salvia hispanica seed)|Patients receive Salvia hispanica seed PO QD for 12 weeks.
2986590|NCT02652702|Experimental|Circular Stapler-assisted Colostomy|Using Circular Stapler-assisted Technique to Finish Colostomy after colorectal carcinoma surgery when patient need permanent sigmoid stoma.
2986591|NCT02652702|Experimental|Hand-stitching Colostomy|Using Conventional Hand-stitching Technique to Finish Colostomy after colorectal carcinoma surgery when patient need permanent sigmoid stoma.
2986592|NCT02652689|Experimental|Diagnostic ultrasound|Recording Doppler ultrasound signals noninvasively from the right chest wall
2986593|NCT02652676|Experimental|Reversible Pulmonary Artery Banding|"The addition of afterload Reversible Pulmonary Artery Banding to a normal-functioning right ventricle (in the setting of end-stage dilated cardiomyopathy) shifts the inter-ventricular septum toward the midline, thus significantly improving left ventricular geometry and function. It permits the infant or young child to operate from a much improved position on Starling's curve with gradual resolution of congestive heart failure and the potential for lethal ventricular dysrhythmia. An abundance of progenitor myocytes known to exist within the myocardium of this patient age group may then contribute to permanent left ventricular restoration."
2986594|NCT02652663||ECA-MRI group|ECA-MRI group (patients who underwent conventional MRI using extracellular contrast agent [ECA])
2986595|NCT02652663||Gd-EOB-MRI group|Gd-EOB-MRI group (patients who underwent gadoxetic acid-enhanced MRI)
2986596|NCT02652650|Experimental|Ethinylestradiol/Norethindrone|During the first oral contraceptive (OC) cycle participants will receive ethinylestradiol/norethindrone 35 microgram (mcg)/1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in). During the second OC cycle (from Day 29 to Day 56), participants will receive ethinylestradiol/norethindrone 35 mcg/1 mg alone qd for 21 days on Days 29 to 49 (Cycle II: OC alone, reference). During the third OC cycle (from Day 57 to Day 84), participants will receive ethinylestradiol/norethindrone 35 mcg/1 mg qd for 21 days on Days 57 to 77 and in addition JNJ-63623872, 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test).
2986597|NCT02652637|Experimental|Mechanical and oral antibiotic bowel preparation|Mechanical bowel preparation using PEG, neomycin 2g p.o. (single-dose), and metronidazole 2g p.o. (single dose) are given the day before surgery.
2986598|NCT02652637|No Intervention|No bowel preparation|No mechanical bowel preparation or oral antibiotics.
2986599|NCT02652624|Experimental|B/F/TAF|"Participants will switch to B/F/TAF FDC and receive treatment for 48 weeks.~Following Week 48, participants in countries where B/F/TAF is not available may have the option to receive B/F/TAF for up to 48 additional weeks."
2986600|NCT02652624|Active Comparator|Baseline Regimen|"Participants will remain on their baseline regimen of E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF for 48 weeks.~Following Week 48, participants in countries where B/F/TAF is not available may have the option to receive B/F/TAF for up to 48 additional weeks."
2986601|NCT02652611|Experimental|Screw Removal|Patients enrolled in the SI screw removal treatment group will undergo the surgery 5-9 months after the initial SI screw stabilization surgery. The surgeon will remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
2986602|NCT02652611|Experimental|Non-screw Removal|Patients enrolled in the Non-SI screw removal treatment group will not undergo surgical intervention to for removal of their SI screws. remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If complications arise and/or the patient requires screw removal surgery, crossover will be allowed and recorded within study follow0up forms.
2986603|NCT02652598|Experimental|Open-Label|Each patient will receive a two-week specified dosing amount of tolcapone (100mg TID on Day 1; 200mg TID on Days 2-14). The patient will be instructed to take the study drug three times daily. Tolcapone will be tapered after Day 14 to avoid potential withdrawal reactions.
2986604|NCT02652585|Active Comparator|Naltrexone|"1 capsule naltrexone 25 mg per day, oral use, day 1 to day 3;~1 capsule naltrexone 50 mg per day, oral use, day 4 to day 28"
2986605|NCT02652585|Placebo Comparator|Placebo|1 capsule placebo, oral use, day 1 to day 28
2986606|NCT02652572|Experimental|Granexin® gel plus standard-of-care|Granexin® gel will be applied topically to diabetic foot ulcer(s) on Day 0 (baseline), Day 3, and Day 7. In addition, standard-of-care treatment will be applied to the ulcer(s) at Screening, Day 0, Day 3, and Day 7.
2986607|NCT02652559|Experimental|Home initiation|Home initiation of long-term NIV will be compared with standard in-hospital initiation. NIV at home will be titrated by a specialised nurse of our home mechanical ventilation centre (HMV) on transcutaneously measured gas exchange and respiratory electromyography and will be adjusted with the use of telemedicine.
2986608|NCT02652559|Active Comparator|Inhospital initiation|Inhospital initiation of NIV is standard care and in the study will be set as the control arm.
2986609|NCT02652546|Active Comparator|A|CC-11050 200mg (2 capsules) BID with food
2986610|NCT02652546|Placebo Comparator|B|Placebo (2 capsules) BID with food
2986611|NCT02652520|Experimental|Kidney transplantation|HEMO2Life® use in organ preservation solution. Grafts removed and transplanted locally within the 6 kidney transplant centers participating in the study will be preserved with Hemo2life.
2986612|NCT02652507|Other|Anesthesia for MRI|"All patients will receive the same drugs.~A loading dose of dexmedetomidine of 2 mcg/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h. Bolus dose 2 mg/kg of ketamine will be given after the initial set of research images have been taken."
2986613|NCT02652494||Patients receiving Apremilast per daily clinical practice|Dutch patients receiving Apremilast according to daily clinical practice
2986614|NCT02652481|Other|open label - 1 arm|prospective, non-randomized, confirmatory study
2986615|NCT02652468|Experimental|Peripheral Blood Stem Cell Transplant|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over approximately 30 minutes on days -5 to -2, and mesna IV over 24 hours and cyclophosphamide IV over approximately 2 hours on days -5 and -4. Patients also undergo total nodal irradiation on day -1.~TRANSPLANT: Patients undergo TCR alpha-beta/CD19 depleted hematopoietic stem cell transplant on day 0. If the graft contains less than 4 x 10^6 CD34+ cells/kg patient BW, patients may receive a second graft on day 1.~GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO BID on days -1 to 30, tacrolimus PO or IV on days 2-180 with a taper beginning on day 90 (given only if graft TCR alpha-beta+ cell content is over 1 x 10^5 cells/kg ideal BW of the patient), and rituximab IV on day 2 (given only if graft B cell content exceeds 1 x 10^5 cells/kg ideal BW of the patient)."
2986616|NCT02652455|Experimental|PD-1, CD137 and Adoptive Cell Therapy|"Combination Therapy and Immunotherapy as described in intervention descriptions.~Nivolumab Treatment: The first 6 participants will not have pre-treatment with nivolumab and instead will be scheduled for the removal of their tumor sample for tumor Infiltrating lymphocytes (TIL) growth in the lab. The second 6 participants will receive treatment with nivolumab prior to removal of tumor sample for TIL growth; about 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.~Surgery to remove tumor for growth of TIL followed by: TIL growth process; lymphodepleting chemotherapy with cyclophosphamide and fludarabine; TIL infusion; Interleukin-2 treatment."
2986617|NCT02652442|Active Comparator|vestibular rehabilitation|"Gaze stability exercises include adaptation and substitution exercises. Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Substitution exercises specifically attempt to facilitate use of alternative strategies, rather than teaching the specific strategies. Participants will perform brief periods of gaze stability exercises 3 times daily.~In addition, participants will perform balance and gait exercises to improve postural stability and mobility and will be provided a written home exercise program."
2986618|NCT02652442|Experimental|centrifugation|"Participants will be rotated in a darkened rotary chair booth with 1 ear positioned 7-8 cm off-axis and the other ear positioned on-axis. Following a 5-minute rest period, the procedure will be repeated with the opposite ear positioned off-axis. Participants will receive 10 sessions in a 4-week period.~In addition, participants will perform balance and gait exercises to improve postural stability and mobility and will be provided a written home exercise program."
2986619|NCT02652429|Experimental|Inhaled Nitric Oxide (iNO)|Pulsed iNO 75 mcg/kg IBW/hour
2986620|NCT02652416|Experimental|SRD part (low dose)|Chinese, Japanese both
2986621|NCT02652416|Experimental|SRD part (medium dose)|Chinese, Japanese both
2986622|NCT02652416|Experimental|SRD part (high dose)|Chinese, Japanese both
2986626|NCT02652403|Active Comparator|Complete conventional dentures|Complete dentures fabricated by conventional technique.
2986627|NCT02652403|Active Comparator|Complete simplified dentures|Complete dentures fabricated by simplified technique
2986628|NCT02652390|Experimental|Methylprednisolone 80 mg|Local injection of 80 mg Methylprednisolone into the carpal tunnel
2986629|NCT02652390|Experimental|Methylprednisolone 40 mg|Local injection of 40 mg Methylprednisolone into the carpal tunnel
2986630|NCT02652390|Placebo Comparator|Placebo|Local injection of saline into the carpal tunnel
2986631|NCT02652377|Experimental|EDP-494 SAD Cohorts|EDP-494, oral 50 mg, 100mg, 200mg, 400mg and 800 mg, capsules, once daily in one single administration
2986632|NCT02652377|Experimental|EDP-494 MAD/POC Cohorts|EDP-494, oral 200mg, 400mg and 800 mg, capsules, once daily for 14 days
2986633|NCT02652377|Placebo Comparator|EDP-494 SAD Placebo Cohort|
2986634|NCT02652377|Placebo Comparator|EDP-494 MAD/POC Placebo Cohort|
2986635|NCT02652351|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
2986636|NCT02652338|Active Comparator|MNC-01|potassium, magnesium, and vitamins (MNC-01)
2986637|NCT02652338|Placebo Comparator|Placebo|cellulose, microcrystalline [NF], HPMC E15,
2986638|NCT02652325|Active Comparator|povidone-iodine|
2986639|NCT02652325|Active Comparator|3M Skin and Nasal Antiseptic 5% Povidone-Iodine USP swabs|
2986640|NCT02652325|Placebo Comparator|Saline|
2986641|NCT02652312|Active Comparator|Group 'D'|"Dexmedetomidine group Patients received dexmedetomidine (2 ml diluted in 18 ml of saline) IV in a dose of 1 mcg/kg over 10 minutes. A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour was infused.~Ondansetron: 0.15 mg/kg intravenous preoperative. Fentanyl: 1.5 μg/kg intraoperative Propofol: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia.~Atracurium: 0.5 mg/kg IV. Desflurane: 1 MAC concentration. Diclofenac sodium: 1 mg/kg for postoperative analgesia."
2986642|NCT02652312|Placebo Comparator|Group 'P'|"Placebo group Patients received similar volume of normal saline as the bolus and maintenance infusion as group D.~Ondansetron: 0.15 mg/kg intravenous preoperative. Fentanyl: 1.5 μg/kg intraoperative Propofol: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia.~Atracurium: 0.5 mg/kg IV. Desflurane: 1 MAC concentration. Diclofenac sodium: 1 mg/kg for postoperative analgesia."
2986643|NCT02652299||Early Rheumatoid Arthritis group|Following informed written consent, 20 patients with early RA will be enrolled from Odense University Hospital (OUH) during a 12 month period
2986644|NCT02652299||Longstanding Rheumatoid Arthritis group|Following informed written consent, 20 patients with longstanding RA will be enrolled from Odense University Hospital (OUH) during a 12 month period
2986645|NCT02652299||Control group: Synovial tissue and peripheral blood|20 Non-RA patients who are referred to arthroscopy in a joint of the hand at OUH Department of Orthopedics, Section of hand surgery, are asked to participate by the surgeon at the first ambulatory consultation. Following informed written consent, MRI of hand, a blood sample and synovial biopsies, will be used as control for synovial and plasma fibrocyte levels. The synovial biopsies will be obtained during the planned arthroscopy.
2986646|NCT02652286|Other|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
2986647|NCT02652273|Experimental|Abatacept|Abatacept 125mg administered via subcutaneous injection once a week for 24 weeks
2986648|NCT02652260|Experimental|Immediate Switch to MK-1439A|Participants on a baseline regimen of ATRIPLA^TM for at least 12 weeks prior to screening will be switched to blinded MK-1439A orally, once daily for 12 weeks, followed by open-label MK-1439A orally, once daily for an additional 12 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label MK-1439A for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label MK-1439A, with a maximum total duration of treatment of 228 weeks.
2986649|NCT02652260|Experimental|Deferred Switch to MK-1439A|Participants will continue on their ongoing ATRIPLA^TM regimen orally, once daily for 12 weeks, followed by open-label MK-1439A orally, once daily for 24 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label MK-1439A for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label MK-1439A, with a maximum total duration of treatment of 228 weeks.
2986650|NCT02652247|Experimental|ventilated trauma patients with pneumonia|ventilated trauma patients with pneumonia
2986651|NCT02652247|Experimental|ventilated trauma patients without pneumonia|ventilated trauma patients without pneumonia
2986652|NCT02652247|Experimental|ventilated surgical ICU patients with pneumonia|ventilated surgical ICU patients with pneumonia
2986653|NCT02652247|Experimental|ventilated surgical ICU patients without pneumonia|ventilated surgical ICU patients without pneumonia
2986654|NCT02652234|Experimental|Endostar-subcutaneous injection/Chemotherapy|
2986655|NCT02652221|Experimental|Study cohort|Acoustic Radiation Force Imaging
2986656|NCT02652208|Active Comparator|Online decision aid|This group will receive the access to an online decision aid that covers the main treatment options for stable chest discomfort.
2986657|NCT02652208|Active Comparator|Video decision aid|This group will receive the DVD and booklet decision aid describing stable chest discomfort and the main treatment options including medical therapy and stents.
2986658|NCT02652195|Placebo Comparator|Placebo|Each participant will be studied using fMRI following self-administration of placebo.
2986659|NCT02652195|Experimental|Oxytocin|Each participant will be studied using fMRI following self-administration of oxytocin.
2986660|NCT02652182||1|patients with acute ST (S- and T-wave)-segment elevation myocardial infarction who received emergent percutaneous coronary intervention in Huai'an first people's hospital
2986661|NCT02652182||2|patients with acute ST(S- and T-wave)-segment elevation myocardial infarction who received emergent percutaneous coronary intervention in Nanjing Drum Tower hospital
2986662|NCT02652169|Experimental|Study arm 1 - PRF plus amikacin and teicoplanin|PRF mixed with amikacin and teicoplanin is sprayed on the patients' ulcer
2986663|NCT02652169|Experimental|Study arm 2 - PRF plus normal saline|PRF mixed with normal saline is sprayed on the patients' ulcer
2986664|NCT02652169|Experimental|Study arm 3 - PRF mixed with PHMB plus Macrogolol|PRF mixed with polyhexanide and macrogolol is sprayed on the patients' ulcer
2986665|NCT02652169|Active Comparator|Study arm 4 - Acticoat 7|A silver gauze (Acticoat 7®) is applied to the patients' ulcer
2986666|NCT02652156|Active Comparator|Single Injection of Bupivacaine|Subjects will undergo post-operative pain relief treatment with a single injection of Bupivacaine, a local anesthetic injected into the transversus abdominis plane.
2986667|NCT02652156|Active Comparator|Single Injection of Exparel®|Subjects will undergo post-operative pain relief treatment with a single injection of Exparel®, a liposomal form of bupivacaine, into the transversus abdominis plane
2986668|NCT02652156|Active Comparator|Continuous infusion of Ropivacaine|Subjects will be treated with a continuous infusion of the local anesthetic Ropivacaine with the ON-Q® pump
2986669|NCT02652143|Experimental|sibling oocytes in vivo|randomized oocytes assigned to in vivo culture
2986670|NCT02652143|Active Comparator|sibling oocyte in vitro|randomized oocytes assigned to in vitro culture
2986671|NCT02652091||Interferon beta-1b|Patients diagnosed with relapse-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are injecting Betaseron via the Betaconnect device.
2986672|NCT02652078|Sham Comparator|Control|Sham treatment in identical format to treatment arm but without shockwave production
2986673|NCT02652078|Experimental|Shockwave|Active shockwave treatment to calf muscle bulk
2986674|NCT02652065|Active Comparator|Healthy skin|"Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on healthy skin.~The skin blood flow in response to these molecules will be followed by laser Doppler recordings."
2986675|NCT02652065|Experimental|Psoriasis plaque|"Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on a psoriasis plaque (on the patient's back).~The skin blood flow in response to these molecules will be followed by laser Doppler recordings."
2986676|NCT02652052|Other|Group 1: Observational|Observational only
2986677|NCT02652052|Experimental|Group 2: Dasatinib & Quercetin|Interventional: The drugs dasatinib and quercetin will be used in this arm
2986678|NCT02652039||cancer patients|
2986679|NCT02652026|Experimental|Treatment Group|The Treatment Group (TG) received full mouth debridement, which consisted of scaling and root planing (SRP), was done in a single visit using an ultrasonic scaler (SATELEC P5 Newtron, Acteon, Merignac, France) and Gracey curettes (Hu- Friedy, Chicago, USA).Also received Oral Hygienic Instructions
2986680|NCT02652026|Active Comparator|Control Group|The Control Group (CG) received periodontal prophylaxis at baseline, by removal of supragingival deposits (plaque and calculus) with ultrasonic scaler. Also received Oral Hygienic Instructions
2986681|NCT02652013|Experimental|40 patients with multiple sclerosis|The study sample will consist of 40 patients with multiple sclerosis. MS patients and control subjects will be recruited on the Rennes (Centre Hospitalier Universitaire and Pôle de Médecine Physique et de Réadaptation Saint-Hélier) and Angers sites (Centre Hospitalier Universitaire) participating in COGNISEP project
2986682|NCT02652013|Other|40 healthy subjects|All the performance of the 40 MS patients will be compared to 40 control subjects matched in age, gender and sociocultural level. Subjects with a history of neurological and psychiatric condition or substance abuse will be excluded from the study. Control subjects will receive an honorary as a token for their time.
2986683|NCT02651987|Experimental|Lanreotide Autogel®|One subcutaneous (SC) injection of lanreotide Autogel® 120mg every 14 days until disease progression or death or unacceptable toxicity or tolerability.
2986684|NCT02651974|Active Comparator|Control condition|A control invitation letter similar to the previous standard (non-incentive) invitation with slight wording and grammatical improvements will be mailed to patients randomly assigned to this group.
2986685|NCT02651974|Active Comparator|Cost condition|A control invitation letter with the addition of one line informing participants of the average value of the KIT procedure will be mailed to patients randomly assigned to this group.
2986686|NCT02651974|Active Comparator|Cost/Future condition|An invitation letter with the average value of the KIT procedure and a sentence assuring participants that should a follow-up test be requested, it will also be provided free of charge will be mailed to patients randomly assigned to this group.
2986687|NCT02651961|Active Comparator|One stage exchange|One stage exchange of the chronically infected implant
2986688|NCT02651961|Active Comparator|Two stage exchange|Two stage exchange of the chronically infected implant
2986689|NCT02651948|Experimental|Transperineal prostate biopsy (TPB)|Transperineal prostate biopsy MRI-guided
2986690|NCT02651948|Active Comparator|Transrectal prostate biopsy (TRB)|Transrectal prostate biopsy echo-guided
2986691|NCT02651935|Experimental|Intellivent ASV|Patients in this arm will be ventilated with Intellivent ASV. Intellivent ASV is an automatic close loop ventilation mode. FiO2 setting will be automatically adjusted according to patients SpO2 and minute volume will be automatically adjusted according to patients EtCO2.
2986692|NCT02651935|No Intervention|PCV+PSV|PCV+PSV is a conventional ventilation strategy of pressure controlled ventilation PCV) and pressure support ventilation (PSV).In this arm, FiO2, pressure control levels, respiratory frequency and all the ventilator settings will be manually adjusted by the physicians in charge.
2986693|NCT02651909||Rivaroxaban Cohort|Evidence of Rivaroxaban use with-in the last 48hours Participating subjects will not undergo any procedures associated with this study except data collection and minimal blood sampling of which results will not be become part of the medical record and no clinical decisions will be made using the results of research lab results. Blood samples are for TEG analysis and for Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
2986694|NCT02651909||Control cohort not taking Rivaroxaban|Not taking Rivaroxaban - matched to Rivaroxaban group by age gender, type of injury or illness requiring urgent surgery Participating subjects will not undergo any procedures associated with this study except data collection and minimal blood sampling of which results will not be become part of the medical record and no clinical decisions will be made using the results of research lab results. Blood samples are for TEG analysis and for Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
2986695|NCT02651896||HypoIGRT|"Low Risk (T1-T2a, Gleason score 6, and PSA < 10 ng/mL)~Intermediate Risk (T1-T2c, Gleason 7, and PSA 10-20 ng/mL)~High Risk (T3 - 4 , Gleason 8-10, and/or PSA > 20 ng/mL) Neoadjuvant hormone therapy is allowed on groups 2 and 3"
3001076|NCT02555709|Experimental|VTP-43742 Dose 10|psoriatic patients
2986696|NCT02651883|Active Comparator|Screening invitation (with education)|Participants will receive a phone call providing (i) education on cervical cancer, and (ii) assistance scheduling an appointment for free cervical cancer screening at a study-affiliated clinic.
2986697|NCT02651883|Experimental|Self-collection for HPV testing|Participants in the intervention arm will receive a kit to self-collect a sample and return it for HPV testing. Participants will then receive a phone call providing their HPV results plus (i) education on cervical cancer, and (ii) assistance scheduling an appointment for free cervical cancer screening at a study-affiliated clinic, if desired.
2986698|NCT02651870|Experimental|Candesartan 16mg + Amlodipine 5mg|Candesartan 16mg + Amlodipine 5mg, po, q.d.
2986699|NCT02651870|Experimental|Candesartan 16mg + Amlodipine 10mg|Candesartan 16mg + Amlodipine 10mg, po, q.d.
2986700|NCT02651870|Active Comparator|Candesartan 16mg|Candesartan 16mg, po, q.d.
2986701|NCT02651857|Experimental|Endoscopy exploratory single arm|
2986702|NCT02651844|Experimental|Mifepristone|Tablets of Mifepristone 200 mg p.o. once a day during 14 days between biopsy and surgery after confirming inclusion criteria
2986703|NCT02651831||1A: Content Validation|"Up to 4 focus groups of 6-10 cancer patients each will be conducted each lasting approximately 90 mins. An additional 10 to 15 patients will undergo individual semi-structured interviews each lasting around 60 minutes.~10-12 expert clinicians experienced in treating patients with ICMs or managing ICM toxicities will participate in a survey, and group or individual interviews."
2986704|NCT02651831||1B: Face Validity|Patients who have been and are being treated with ICMs to complete draft questionnaire (FACT-ICM). Some patients who were involved in the first round of interviews will be re-interviewed, and interview naïve patients will also be included.
2986705|NCT02651831||2A: To measure test-retest reliability|Patients to complete FACT-ICM at at two time points separated by 5 to 14 days.
2986706|NCT02651831||2B: To confirm construct validity|To evaluate discriminative properties of FACT-ICM, scores will be compared between pre-defined groups of patients where differences are expected.
2986707|NCT02651831||2C: To determine responsiveness and MCID|"Responsiveness testing: Patients will complete FACT-ICM within a week of starting treatment, then while on treatment and within 30 days after end of treatment (EOT) with ICMs.~MCID testing: In addition to the FACT-ICM score, patients undergoing serial assessment for responsiveness will also indicate how much better or worse they are using a 5-point rating scale."
2986708|NCT02651805|Experimental|Mechanical Insufflation-Exsufflation Group|Patients will receive usual care except suctioning or cough augmentation techniques+Mechanical Insufflation-Exsufflation
2986709|NCT02651805|Active Comparator|Usual Care Group|Patients will receive the usual care provided by the hospital, all interventions to control respiratory secretion will be verified in patient chart
2986710|NCT02651792|Active Comparator|ketamine- propofol|IV Ketamine 1mg/kg + Propofol 1.2 mg/kg will be given for sedation.
2986711|NCT02651792|Active Comparator|pethidine- propofol|1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
2986712|NCT02651779|Active Comparator|Closed reduction and plasterimmobilisation|The control group will be treated with closed reduction and cast immobilization. This will take place under local anaesthesia by means of a haematoma block with 20 cc Lidocaine 1%. Closed reduction will be preferably performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilizing wrist and hand in the reduced position. Additional radiographs will be performed to verify the success of the reduction. After this has been confirmed, the wrist will be immobilized initially in a split plaster and later changed into a circular cast for five to six weeks immobilization in total.
2986713|NCT02651779|Other|Open reduction and internal plate fixation|The surgery will be performed by a certified trauma surgeon. According to the current standard treatment protocol, antibiotic prophylaxis will be administered thirty minutes preoperatively. The distal radius will be approached according to Henry, which beholds an incision between the tendon of the flexor carpi radialis muscle and the radial artery. After the fracture site is exposed, the fracture will be reduced and provisionally fixed under fluoroscopy with K-Wires/reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Fracture reduction and screw placement will be confirmed by radiographic images. Additionally, fixation can be supported by a dorsal plate or radial column plate. This will be at discretion of the surgeon and depends on the fracture configuration and the position of the fragments. Wound closure will be performed at the discretion of the surgeon using standard techniques.
2986714|NCT02651766|No Intervention|Waiting List control group|No treatment within the study period, were allowed to continue physiotherapy and medication. Were offered the treatment after finishing the study
2986715|NCT02651766|Experimental|Cupping massage treatment|Received the 5 cupping treatments, application twice a week on the upper back and neck
2986716|NCT02651753|Experimental|A|"Period 1: Reference drug (Lipitor+ Lipidil supra), 2 tablets administered under fed conditions.~Period 2: Test drug(CKD-337), 1 capsule administered under fed conditions."
2986717|NCT02651753|Experimental|B|Period 1: Test drug(CKD-337), 1 capsule administered under fed conditions. Period 2: Reference drug (Lipitor+ Lipidil supra), 2 tablets administered under fed conditions.
2986718|NCT02651740|Experimental|Combining therapy|taking rifaximin for 3 days and then receiving fecal microbiota transplantation with donor stool through enteral nutrition tube
2986719|NCT02651727|Experimental|Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine|Part B, Cohort 1- IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1
2986720|NCT02651727|Experimental|Part B, Cohort 2- VS-4718, nab-paclitaxel, gemcitabine|Part B, Cohort 2- IV treatment for the first 2 cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15), followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3
2986721|NCT02651727|Experimental|Part A- VS-4718, nab-paclitaxel, gemcitabine|Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.
2986722|NCT02651714|Placebo Comparator|Placebo|Oral
2986723|NCT02651714|Experimental|Tradipitant|Oral
2986727|NCT02651675|Experimental|AAV directed hLDLR gene therapy|Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy
2986728|NCT02651662|Experimental|Open label (REGN2810)|Experimental cohorts will consist of multiple dose levels of REGN2810 administered intravenously (IV) every 2 weeks (Q2W)
2986729|NCT02651662|Experimental|Open label (REGN2810 and REGN1979)|Experimental cohorts will consist of a single dose level of REGN2810 administered intravenously (IV) and multiple dose levels of REGN1979 administered intravenously (IV)
2986730|NCT02651649|Experimental|Parturients with FGR/OSA who use CPAP|Subjects who meet criteria for FGR and OSA will be referred to a pulmonologist for referral for Continuous Positive Airway Pressure (CPAP). Women who agree with CPAP and comply with therapy will be compared to women who do not wear CPAP (eg. non-compliance).
2986731|NCT02651649|No Intervention|Parturients with FGR/OSA and no CPAP|Subjects who meet criteria for FGR and OSA will be referred to a pulmonologist for referral for CPAP. Women who agree with CPAP and comply with therapy will be compared to women who do not wear CPAP (eg. non-compliance).
2986732|NCT02651636|Experimental|Open label|Therapy with alpha-lipoic acid (800 mg), myoinositol (2000 mg) and folic acid (400 mcg) daily for six months
2986733|NCT02651623|Experimental|Sertraline|Maximum dose of 400 mg/day (200 mg BID given at approximately 12 hours apart) sertraline, dose titrated from a starting single dose (QD) of 50 mg in the morning on Day 1 followed by BID doses administered on Days 2 through 14 (Day 14 morning dose only) will be administered
2986734|NCT02651623|Active Comparator|Moxifloxacin|400 mg single dose of moxifloxacin (Avelox®) administered on Day 14
2986735|NCT02651623|Placebo Comparator|Drug - Placebo|placebo - placebo administered on Days 1 through 14
2986736|NCT02651610|Active Comparator|Taxane|Docetaxel on Day 1 of 21-day cycles OR Paclitaxel on Days 1, 8, and 15 of 28-day cycles
2986737|NCT02651610|Experimental|Bavituximab plus taxane|Bavituximab 3 mg/kg weekly PLUS Docetaxel on Day 1 of 21-day cycles OR Paclitaxel on Days 1, 8, and 15 of 28-day cycles
2986738|NCT02651597|Experimental|Low Viscous|Low Viscous Beta Glucan Oatmeal
2986739|NCT02651597|Experimental|Medium Viscous|Medium Viscous Beta Glucan Oatmeal
2986740|NCT02651597|Experimental|High Viscous|High Viscous Beta Glucan Oatmeal
2986741|NCT02651584|Experimental|Group 1: SL BPN tablets + placebo subcutaneous (SC) injections|"SL BPN: 2 mg/0.5 mg or 8 mg/2 mg BPN/naloxone tablets administered daily, at doses of 8 mg/2 mg to 32 mg/8 mg per day.~CAM2038 placebo: 0.16, 0.32, 0.48 and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w).~Following randomization, subjects will undergo initiation of BPN with either SL BPN or SC CAM2038 q1w and participate in weekly visits for 12 weeks (Phase 1). After Week 12, subjects will be transitioned to Phase 2 with monthly visits. During Phase 2, subjects in Group 1 will continue treatment with monthly dispensing of daily SL BPN treatment and monthly placebo SC injections, and subjects in Group 2 (receiving CAM2038 q1w) will be transferred to monthly injections of CAM2038 q4w and monthly dispensing of daily SL placebo."
2986742|NCT02651584|Experimental|Group 2: CAM2038 SC injections + SL placebo tablets|"CAM2038 q1w: BPN FluidCrystal® SC injection depot for once weekly administration (50 mg/mL) at doses of 8, 16, 24 and 32 mg (BPN base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).~CAM2038 q4w: BPN FluidCrystal® SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (BPN base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).~SL placebo: tablets matching 2 mg/0.5 mg and 8 mg/2 mg SL BPN doses, administered daily~Following randomization, subjects will undergo initiation of BPN with either SL BPN or SC CAM2038 q1w and participate in weekly visits for 12 weeks (Phase 1). After Week 12, subjects will be transitioned to Phase 2 with monthly visits. During Phase 2, subjects in Group 1 will continue treatment with monthly dispensing of daily SL BPN treatment and monthly placebo SC injections, and subjects in Group 2 (receiving CAM2038 q1w) will be transferred to monthly injections of CAM2038 q4w and monthly dispensing of daily SL placebo."
2986743|NCT02651558|Experimental|OBPM 2015-MD-0022 - CHEST|Cohort of 30 patients undergoing general anesthesia, monitored by optical signals at the chest
2986744|NCT02651558|Experimental|OBPM 2015-MD-0022 - CHEST & FINGER|Cohort of 10 patients undergoing general anesthesia, monitored by optical signals at the chest and at the fingertip
2986745|NCT02651558|Experimental|OBPM 2015-MD-0022 - FINGER|Cohort of 30 patients undergoing general anesthesia, monitored by optical signals at the fingertip
2986746|NCT02651545||Relapsing MS patients|Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.
2986747|NCT02651545||Healthy Controls|A sample of 30 healthy control volunteers, matched on demographics with the treated group will be enrolled.
2986748|NCT02651532||IBS + Confocal Laser Endomicroscopy|Outpatients with irritable bowel syndrome according to Roma III classification: recurrent abdominal pain or discomfort, at least 3 days per month, in the last 3 months and symptoms begin at least 6 months before diagnosis, associated with 2 or more of: improvement with defecation, start associated with changes in the bowel frequency, start associated with changes in stool consistency. Absence of alarm symptoms: gastrointestinal bleeding, weight loss, anemia, night-time symptoms, fever, family history of colorectal cancer or celiac disease, elevated erythrocyte sedimentation rate, positive fecal occult blood test.
2986749|NCT02651532||Control + Confocal Laser Endomicroscopy|Outpatients without IBS symptoms, undergoing colonoscopy for colorectal cancer screening
2986750|NCT02651519|Sham Comparator|Control|All patients undergoing breast cancer operation will be the treatment intervention with general anesthesia as an adjunct to stellate-ganglion block with saline.
2986751|NCT02651519|Experimental|stellate-ganglion block|All patients undergoing breast cancer operation will be the treatment intervention with general anesthesia as an adjunct to stellate-ganglion block with 0.25% ropivacaine hydrochloride.
2986752|NCT02651506|Experimental|Electromagnetic Navigation Bronchoscopy|
2986753|NCT02651506|Active Comparator|Transthoracic Needle Biopsy|
2986754|NCT02651493|Active Comparator|Down syndrome|photographs of individuals less than 18 yo with Down syndrome
2986755|NCT02651493|Active Comparator|Control group|photographs of individuals less than 18 yo with a genetic referral (not Down syndrome) or a healthy sibling to a child with Down syndrome
2986756|NCT02651480|Experimental|Vegan Group|Participants in the intervention group will follow a low-fat, plant-based diet for 14 weeks, and will attend nutrition classes in the form of a weekly support group.
2986757|NCT02651480|Active Comparator|Control Group|The control group will follow an unrestricted diet with no instruction.
2986758|NCT02651467|Experimental|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the experimental oral rinse 1 (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
2986759|NCT02651467|Experimental|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the experimental oral rinse 2 (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
2986760|NCT02651467|Placebo Comparator|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the placebo oral rinse (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
2986761|NCT02651454|Experimental|Daesiho-tang|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
2986762|NCT02651454|Experimental|Jowiseungcheung-tang|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
2986763|NCT02651454|Placebo Comparator|Placebo|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
2986764|NCT02651441|Experimental|D-CIK|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines,patients will receive 3 cycles of D-CIK treatment.
2986765|NCT02651441|Active Comparator|Chemotherapy|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines, patients will just regularly follow up.
2986766|NCT02651428|Experimental|Neutrolin arm|Neutrolin: Neutrolin will be added to the central venous catheter after dialysis as a lock solution
2986767|NCT02651428|Active Comparator|Heparin arm|Heparin: Heparin will be added to the central venous catheter after dialysis as a lock solution
2986768|NCT02651415|Experimental|Regorafenib and Perindopril|Phase II, open label, single arm trial of patient with refractory mCRC treated with regorafenib (10 mg/day) and perindopril (4 mg/day). There will be no stratification in this study.
2986769|NCT02651402|Active Comparator|FRIENDS for Life Train-the-Trainer|Therapists implement FRIENDS (a CBT protocol for students with anxiety) in the school setting, while supported by their supervisor assigned to the Train-the-Trainer (TT) implementation strategy (supervisors participate in training workshops on conducting supervision with active therapists).
2986770|NCT02651402|Experimental|Adapted FRIENDS Train-the-Trainer|Therapists implement an adapted version of FRIENDS (aFRIENDS) in the school setting while supported by their supervisor assigned to the TT strategy.
2986771|NCT02651402|Experimental|Adapted FRIENDS Train-the-Trainer Plus|Therapists implement aFRIENDS in the school setting while supported by their supervisor assigned to the Train-the-Trainer Plus (TT+) implementation strategy (supervisors participate in training workshops and receive further/on-going consultation on conducting supervision with active therapists).
2986772|NCT02651376|Experimental|Conventional plus AAIT|Participants received conventional treatment (anti-opportunistic infections and ART) plus a dose (3 times of MNCs) of AAIT.
2986773|NCT02651363||Patients treated with Dolocordralan|
2986774|NCT02651350|Experimental|Methylprednisolone|Participants will receive methylprednisolone from week 0 through week 48 study visit in combination with standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) in the first 12 weeks. Participants will then be followed until week 72 study visit.
2986775|NCT02651350|Active Comparator|Standard Treatment|Participants will only receive standard treatment (namely,routine liver protection drugs) including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72 study visit.
2986776|NCT02651337|Experimental|Drainage with Alivio in-line Flusher|Volume of saline needed to drain CSF using the Alivio in-line Flusher historically compared with volume of saline needed to drain CSF using a standard syringe
2986777|NCT02651324|Experimental|Treatment Group|A ketamine bolus of 0.5mg/kg will be given and then the ketamine infusion of 0.2 mg/kg/hr will be initiated prior to incision. Intra-operative opioids will be at the discretion of the attending anesthesiologist. Postoperative management will include continuation of the study drug as well as a standardized morphine patient-controlled analgesia (PCA) and acetaminophen 15 mg/kg IV every 6 hours. On postoperative day 1, patients are started on ketorolac 0.5 mg/kg up to 15 mg IV q8h. On postoperative day 2 they are transitioned to ibuprofen 10 mg/kg up to 600 mg. The ketamine infusion will continue for 48 hours post operatively at which point the PCA is discontinued and patients are transitioned to oral pain medications (Roxicet or Lortab and Flexeril) as per the current protocol.
2986778|NCT02651324|Placebo Comparator|Placebo|A placebo (saline) will be given in place of ketamine
2986779|NCT02651311|Experimental|Block|"ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg.~Fentanyl in postanesthesia care unit(PACU), Ibuprofen in ward when pain scale (FLACC) is equal to or more than 4."
2986780|NCT02651311|Placebo Comparator|No block|Fentanyl in PACU, Ibuprofen in ward when pain scale (FLACC) is equal to or more than 4.
2986781|NCT02651298|Experimental|Fractional CO2-laser|3 treatments with fractional co2-laser
2986782|NCT02651298|No Intervention|Untreated control|untreated control side of caesarean section scar
2986783|NCT02651285|Experimental|G-CSF|The embryos obtained with IVF in patients included iin this arm will be incubated after fertilization with medium supplemented with G-CSF
2986784|NCT02651285|Placebo Comparator|CONTROL|The embryos obtained by women undergoing IVF included in this arm will be incubated with a standard medium for IVF, and utilized as control group.
2986785|NCT02651272|Experimental|macitentan|10mg macitentan tablets, taken once daily (QD), by mouth (PO), for the treatment period lasting 16 weeks.
2986855|NCT02650674|Experimental|Product E: NP-0152|Cereal product Kellogg's Trésor Duo Choco - Low in SDS
2986786|NCT02651259|Experimental|Cohort 1 (pregnant women enrolled in the second trimester)|Participants will receive 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
2986787|NCT02651259|Experimental|Cohort 2 (pregnant women enrolled in the third trimester)|Participants will receive 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
2986788|NCT02651220|Experimental|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w|
2986789|NCT02651220|Active Comparator|Epiduo® Forte Gel 0.3%/2.5% w/w|
2986790|NCT02651220|Placebo Comparator|Placebo (vehicle) Topical Gel|
2986791|NCT02651207||local anaesthetic spray group|women will either chose the above, ethyl chloride spray prior to having their contraceptive implant fitted or the below injection. This comes in a canister and a maximum of 5 spray for 5 seconds will be applied topically to the skin at the site of the contraceptive implant insertion
2986792|NCT02651207||local anaesthetic injection group|women will either chose ethyl chloride spray prior to having their contraceptive implant fitted or the injection, subcutaneous 1% lidocaine, usually a dose of about 1-2 mls to the area skin where the contraceptive implant is to be inserted.
2986793|NCT02651194|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
2986794|NCT02651181|Experimental|Closed Loop System|
2986795|NCT02651168|Other|aflibercept|aflibercept treatment aflibercept, 40 mg/mL Solution for Intravitreal Injection
2986796|NCT02651155|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
2986797|NCT02651155|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
2986798|NCT02651142|Experimental|SLNB with para-SLN dissection|patients received sentinel lymph node biopsy with para-sentinel lymph node dissection
2986799|NCT02651142|Experimental|SLNB without para-SLN dissection|patients received sentinel lymph node biopsy without para-sentinel lymph node dissection
2986800|NCT02651116|Experimental|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
2986801|NCT02651116|Placebo Comparator|Placebo|10 mL of Placebo
2986802|NCT02651103||Posterior spinal fusion|Patients undergoing spinal fusion surgery
2986803|NCT02651090|Experimental|sonazoid|treatment arm with sonazoid
2986804|NCT02651077||Case Group|38 women with severe and deep endometriosis, aged 18 to 45 years old and hospitalized at Nantes University Hospital for surgical indication of endometriosis lesions ablation.
2986805|NCT02651077||Control Group|38 women aged 18 to 45 years old without suggestive signs of endometriosis
2986806|NCT02651064|Experimental|HIP|Received a 30% rebate on targeted fruits and vegetables (TFV) purchased using SNAP benefits in participating retailers. TFV earning the rebate included fresh, canned, frozen, and dried fruits and vegetables without added sugars, fats, oils, or salt, excluding white potatoes, mature legumes (dried beans and peas), and 100% juice.
2986807|NCT02651064|No Intervention|Non-HIP|Received SNAP benefits as usual.
2986808|NCT02651051|Sham Comparator|High Fat Breakfast Meal|High fat breakfast meal served without addition of whey protein isolate
2986809|NCT02651051|Experimental|High Fat Breakfast Meal + Whey Protein|High fat breakfast meal served with addition of whey protein isolate
2986810|NCT02651038|Experimental|Micafungin|Micafungin is administered per clinical need and the pharmacokinetic parameters are analyzed
2986811|NCT02651025|Experimental|Resistance Exercise Program|Patients included in intervention group will submit to resistance exercise training during hemodialysis, three times a week, for twelve weeks. This program includes exercises for the upper and lower limbs.
2986812|NCT02651025|No Intervention|Passive Stretching Program|Patients included in control group will submit to passive stretching program of lower limbs, during hemodialysis, three times a week, for twelve weeks.
2986813|NCT02650999|Experimental|Single Arm|
2986814|NCT02650986|Experimental|Treatment (cyclophosphamide, of NY-ESO-1 TCR/dnTGFbetaRII)|Patients receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients then receive NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL with TGFbDNRII-transduced autologous TILs infusion on day 0.
2986815|NCT02650973|Experimental|Sequence A|3 doses of CHS-1701 or Neulasta, random order
2986816|NCT02650973|Experimental|Sequence B|3 doses of CHS-1701 or Neulasta, random order
2986817|NCT02650973|Experimental|Sequence C|3 doses of CHS-1701 or Neulasta, random order
2986818|NCT02650947|Experimental|Sucralose|Subjects in this group ate capsule filled with sucralose 200 mg for 4 weeks (week 1-4) and measured oral glucose tolerance test (OGTT), acute insulin response (AIR), and gut microbe examination at week 4.
2986819|NCT02650947|Placebo Comparator|Placebo|Subjects ate empty capsule (placebo) for 4 weeks (week 1-4) and measured OGTT, AIR, and gut microbe examination at week 4.
2986820|NCT02650934||Adverse remodelling|EF below 40% following MI and remain below 40% after reperfusion
2986821|NCT02650934||not adverse remodelling|EF below 40% following MI and remodelling after reperfusion or EF above 40 % following MI
2986822|NCT02650921|Experimental|Restylane Lyft with Lidocaine|
2986823|NCT02650921|No Intervention|No Intervention|
2986824|NCT02650895|Experimental|CD24Fc|
2986825|NCT02650895|Placebo Comparator|Saline|
2986826|NCT02650882|Placebo Comparator|placebo|Placebo group (PG) Nine athletes who maintained their regular sporting activities and were submitted to the IMT program for 12 weeks with a fixed load at 15% MIP, placebo protocol.
2986827|NCT02650882|Experimental|Experimental|Experimental group (EG) Ten athletes who maintained their regular sporting activities and were submitted to the IMT program for 12 weeks with a progressive load at 60%, 70% and 80 % of MIP.
2986828|NCT02650869|Experimental|Standard care + Breast milk+ Probiotics|The study group will be fed with probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU) dissolved with 6 ml of milk then give 3 ml (3 billion probiotics) once daily with breast milk from first feeding.
2986829|NCT02650869|Active Comparator|Standard care|The control group will be given standard care without the addition of probiotics
2986856|NCT02650674|Experimental|Glucose reference|Glucose solution performed on three occasions
2987135|NCT02648607|Experimental|Customised Orthosis|Customised Dynamic Elastomeric Fabric Orthosis (DEFO)
2986830|NCT02650856|Experimental|Group 1 Tranexamic acid|"A dosis of 2 gr of tranexamic acid (1000mg/10mL X-GEN pharmaceuticals inc.) diluted in 80mL of physiologic solution and will be divided in two applications.~First application: 40mL of the solution previously prepared is applied over the surgical site and it will be left for five minutes then drained out completely by suction.~Second application: The rest of 40mL of solution previously prepared is applied after placing the final TKR components (femoral, tibial and patellar), over the surgical site and leaving it without draining it by suction."
2986831|NCT02650856|Active Comparator|Group 2 Platelet rich plasma|"A final volumen of 16 ml of platelet rich plasma is obtained from the forearm vein of the patient and will be divided in two applications.~First application: 8 mL of PRP are applied over the surgical site and are left for five minutes then drained out completely by suction.~Second application: The rest of the 8 mL are applied after placing the final TKR cemented components (femoral, tibial and patellar), over the surgical site and leaving it without draining."
2986832|NCT02650843||Patients with parkinsonism|Patients with parkinsonism that are referred for DAT SPECT imaging in Turku University Hospital, Finland or Helsinki University Hospital, Finland
2986833|NCT02650830||1) Normal control|metabolically healthy with no obesity
2986834|NCT02650830||2) prediabetes|defined in 'inclusion criteria'
2986835|NCT02650830||3) type 2 diabetes|defined in 'inclusion criteria'
2986836|NCT02650817|Experimental|Elacestrant (formerly RAD1901)|
2986837|NCT02650804|Experimental|BPM31510 plus gemcitabine|"BPM31510 Nanosuspension Injection (40 mg/mL) will be administered IV over 144 hours at the starting dose of 110 mg/kg. Each patient will receive 2 consecutive 72-hour infusions per week (Tuesday-Friday and Friday-Monday). The patient will be subsequently treated with gemcitabine IV once weekly at a starting dose of 1000 mg/m2.~Cycle 1 of combination therapy is 6 weeks in duration for patients with BPM31510 administered twice weekly on Tuesdays and Fridays for 6 weeks and gemcitabine administered on Mondays, Days 21, 28 and 35. Cycles 2-12 are 4 weeks in duration with BPM31510 administered twice weekly on Tuesdays and Fridays for 4 weeks and gemcitabine administered on Mondays, Days 7, 14 and 21."
2986838|NCT02650791|No Intervention|Prophylactic Platelet Transfusions|Patients allocated to the prophylactic platelet transfusion group will receive a platelet transfusion when the measured platelet count is less than 10 x 109/L.
2986839|NCT02650791|Experimental|Prophylactic Tranexamic Acid|Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral dose of Tranexamic Acid 1 gram three times daily. Tranexamic Acid will start when Platelet count is less than 50 x 109/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions
2986840|NCT02650752|Experimental|Lapatinib in Tandem With Capecitabine|A minimum of one patient at each dose level will be enrolled. Patients will receive a 4 week treatment cycle consisting of lapatinib 3 day on/11 day off in tandem with capecitabine 7 day on/7 day off with lapatinib. Both drugs will be administered orally as outpatient. Safety, toxicity, and DLT will be assessed weekly during the cycle 1 (first 4 weeks). Each patient will be monitored during cycle 1 prior to enrolling the next patient to the next higher dose level. Dose escalation will take place if no DLT or less than two occurrences of grade 2 toxicity (except those listed below) is observed within a given patient. In the event that a second instance of separate grade 2 toxicity (except those listed below) is noted, the cohort will be expanded to 3 patients at the same dose level and the study will revert to the standard 3+3 design with 3 patients per cohort. There will be no intra-patient dose escalation.
2986841|NCT02650739||SS-OCTdetermined group|Eyes with macular hole surgery that the postoperative prone positioning was discontinued after detecting a closure by SS-OCT
2986842|NCT02650739||Control group|Eyes with macular hole surgery that the halting of the prone position was determined by the surgeon
2986843|NCT02650726|Placebo Comparator|control group|The participants in this group are instructed to consume placebo capsules every day during the trial period.
2986844|NCT02650726|Experimental|treatment group|The participants in this group are instructed to consume anthocyanin capsules every day during the trial period.
2986845|NCT02650713|Experimental|Dose-Escalation (Part IA): RO6958688 + Atezolizumab|Each treatment cycle is 21 days in duration. Participants will be administered RO6958688 weekly (QW) or every 3 weeks (Q3W) at escalated doses in combination with a fixed dose of atezolizumab Q3W until recommended dose and schedule for RO6958688 is determined. On Day 1 of each cycle, when both atezolizumab and RO6958688 are administered, atezolizumab will be administered first, followed by RO6958688 at least half an hour after the end of the atezolizumab infusion.
2986846|NCT02650713|Experimental|Dose/Schedule Finding (Part IB): RO6958688 + Atezolizumab|The first cohort (cohort A) will compare the QW vs. Q3W schedules at a flat dose of RO6958688 in combination with atezolizumab Q3W. For the step up dosing schedule, the late cycle Maximum-Tolerated Dose (MTD) will be estimated by an intra-patient dose escalation design cohort B. In this cohort, the RO6958688 dose will be escalated up to 275% of the previous dose until the Dose-Limiting Toxicities (DLT) criteria for that dose level are met. also explore two additional RO6958688 step-up dose regimens (cohort C1 and C2) in combination with atezolizumab Q3W, in a randomized schedule comparison expansion. These randomized cohorts will start in parallel to the step up cohort B.
2986847|NCT02650713|Experimental|Expansion Part (Part II): RO6958688 + Atezolizumab|Participants will receive RO6958688 (at dose and schedule determined in the dose-escalation part) in combination with a fixed dose of atezolizumab Q3W until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent.
2986848|NCT02650700|Experimental|Chemotherapy plus spleen radiotherapy|Chemotherapy plus spleen radiotherapy are performed, simultaneously, to the subjects with advanced lung cancer who experienced chemotherapy induced thrombocytopenia (≧grade II CIT). The intervention is spleen radiotherapy.
2986849|NCT02650700|Other|Chemotherapy alone|Chemotherapy is performed to the subjects with advanced lung cancer who experienced chemotherapy induced thrombocytopenia (≧grade II CIT). When severe CIT (≧grade III) occurs, the subjects should receive chemotherapy plus spleen radiotherapy. The intervention is spleen radiotherapy.
2986850|NCT02650687||Elective Non Cardiac Surgical Patients|65 years of age and older
2986851|NCT02650674|Experimental|Product A: NP-0148|Cereal product belVita Milk & Cereals - High in SDS
2986852|NCT02650674|Experimental|Product B: NP-0149|Cereal product belVita Honey & Nuts - High in SDS
2986853|NCT02650674|Experimental|Product C: NP-0150|Cereal product belVita Mixed Berry - High in SDS
2986854|NCT02650674|Experimental|Product D: NP-0151|Cereal product Kellogg's Corn Flakes - Low in SDS - Low in fat
2986857|NCT02650661|Experimental|Online program & Health coaching|"This group is provided with Online health management program, Health coaching and Workshop."
2986858|NCT02650661|Experimental|Online program|"This group is provided with Online health management program."
2986859|NCT02650661|Active Comparator|Enhanced Usual Care|"This group is provided with Standard health educational booklet."
2986860|NCT02650648|Experimental|Humanized Anti-GD2 Antibody Hu3F8|This is a phase I study to assess the safety and feasibility of combining HLA-mismatched (KIR ligand incompatible) NK cells with hu3F8 in high-risk NB patients. Following chemotherapy, patients will be treated in sequential groups with a minimum of 3 patients/ dose of NK cells. Three dose levels of NK cells, starting at dose level 1, will be evaluated in this treatment protocol. The goal dose for each dose level is the high boundary (e.g. 9.9x10^6/kg in level 1; 14.9x10^6/kg in level 2, etc), but a range is provided to allow for cases where the goal dose cannot be achieved.
2986861|NCT02650635|Experimental|Treatment (CTX, pegfilgrastim, TLR8 agonist VTX-2337)|Patients receive cyclophosphamide IV over 30 minutes on day 1, pegfilgrastim SC on day 2, and TLR8 agonist VTX-2337 SC on day -6 of course 1 only and on days 9 and 16. Patients achieving CR, PR, or SD may continue therapy every 21 days for 3 additional courses. Treatment may then continue in the absence of disease progression or unacceptable toxicity.
2986862|NCT02650622||Cohort 1-Newborns aged 1-2 days|No intervention will be applied specifically for this cohort. Blood samples will be collected from this cohort by piggybacking the state-mandated newborn screening test.
2986863|NCT02650622||Cohort 2-Children aged 0-18 years|No intervention will be applied specifically for this cohort. Blood samples will be collected from this cohort by piggybacking the blood draw of patient's standard of care.
2986864|NCT02650622||Cohort 3-Diseased childrens and families|Blood samples will be collected from this cohort by piggybacking the blood draw of patient's standard of care. Skin biopsy will be performed on the proband children with the agreement from parents or guardians.
2986865|NCT02650609|Experimental|Methylprednisolone|"Methylprednisolone will be supplied as powder and stored in capsules containing 16 mg with lactose as excipient.~Capsules will be administered orally in the morning, during breakfast with a glass of water.~Dose is adapted according to the weight of the patient (1mg/kg):~<60 kg: 3 pills of 16 mg/day~60-80kg: 4 pills of 16 mg/day~>80kg: 5 pills of 16 mg/day The duration of the treatment is 21 days."
2986866|NCT02650609|Placebo Comparator|Placebo|"Placebo capsules will only contain lactose. Capsules will be administered orally in the morning, during breakfast with a glass of water.~Dose is adapted according to the weight of the patient (1mg/kg):~<60 kg: 3 pills of 16 mg/day~60-80kg: 4 pills of 16 mg/day~>80kg: 5 pills of 16 mg/day The duration of the treatment is 21 days."
2986867|NCT02650596|Experimental|GLP-1 group|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 3 months. After admission, the patients were treated with 0.6 mg liraglutide once daily for 1 week, then 1.2 mg liraglutide for another 1 week, and then 1.8 mg liraglutide to the end.
2986868|NCT02650596|Placebo Comparator|Control group|drug: placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: 3 months. After admission, the patients were treated with 0.6 mg placebo once daily for 1 week, then 1.2 mg placebo for another 1 week, and then 1.8 mg placebo to the end.
2986869|NCT02650583|Experimental|Supportive care (Enhancing Connections Program)|Patients participate in Enhancing Connections Program comprising of anchoring patients to help their child, adding to listening skills, building on listening skills, being a detective of their child's coping, and celebrating success for 5 sessions. Patients also receive workbook which includes text from the sessions, handouts, and at-home assignments to be completed between sessions.
2986870|NCT02650570||Head/Neck Cancer|Subjects diagnosed with advanced (stages III or IV), persistent (recurrence within 6 months) or recurrent head and neck squamous cell carcinoma (HNSCC)
2986871|NCT02650570||Healthy Control|Healthy controls age matched to the Head/Neck cancer group.
2986872|NCT02650557||CSF group|consecutive patients with angiographically documented CSF
2986873|NCT02650557||control group|age- and gender-matched control subjects
2986874|NCT02650544|Experimental|mirtazapine|Mirtazapine arm will be orally administered with mirtazapine 15mg, QD, consecutive medication for 8 weeks; along with palliative chemotherapy regimen decided by investigators.
2986875|NCT02650544|Placebo Comparator|Placebo|Placebo arm will be orally administered with placebo 15mg, QD, consecutive medication for 8 weeks; along with palliative chemotherapy regimen decided by investigators.
2986876|NCT02650518|No Intervention|Control|Subject receives the standard of care that is provided by the primary team taking up his/her case.
2986877|NCT02650518|Experimental|Catheter change+Short-course Antibiotics|
2986878|NCT02650505|Experimental|LEO 43204|LEO 43204 will be applied topically to the skin under open conditions 10 times
2986879|NCT02650505|Placebo Comparator|LEO 43204 vehicle|LEO 43204 vehicle will be applied topically to the skin under open conditions 10 times
2986880|NCT02650492|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
2986881|NCT02650479|Other|IV exenatide - pilot study|IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
2986882|NCT02650479|Experimental|Treatment Group A - core study|IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
2986883|NCT02650479|Experimental|Treatment Group B - core study|IV infusion of placebo over 6 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
2986884|NCT02650479|Experimental|Treatment Group C - core study|IV infusion of placebo over 6 hours and a single oral dose of 400 mg moxifloxacin within 1 min of start of infusion, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
2986915|NCT02650232|Other|Patients with heart failure|We will evaluate in this group (50 - 80 y + Heart failure) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
2986916|NCT02650219||gaucher disease type 1|"Inclusion criteria:~Adult patients >= 18 years old~Gaucher disease type 1, proved by low betaglucosidase, with or without treatment~Patients must have read, understood and signed informed consent. intervention : genetic analyses"
2986917|NCT02650219||Control|healthy subjects intervention: genetic analyses
2987042|NCT02649205||Chronic kidney disease (pre-dialysis)|Observational study: Supplemented protein-restricted diet
2986885|NCT02650466|Experimental|Nanopulse treatment|The study will be a single center, open label, non-randomized clinical trial that will provide efficacy data for the treatment of common warts by the Nanopulse system in terms of efficacy and cosmetic outcome with 1 - 4 application (treatment) sessions. All subjects will receive a minimum number of applications per discrete skin wart lesion. Up to 4 warts per subject will be treated with the Nanopulse device. The wart will be debulked to the point of pinpoint bleeding prior to the initial application. The subject will return after 1 week for an evaluation visit and at 4 weeks for a second treatment and 2 additional monthly treatments if warranted. If the subject is declared clinically clear at any of the application visits, they will be placed into follow up. The minimum number of treatments per wart is one and the maximum is 4. They will return at the 12 week point post last visit for final assessment and evaluation.
2986886|NCT02650440|Experimental|Novel Protocol|Progressive decrease of speed and guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.0 km/h.
2986887|NCT02650440|Experimental|Standard Protocol|Progressive increase of speed and decrease of guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.9 km/h.
2986888|NCT02650427|Experimental|DPPIV Inhibition|The study will include 3 weeks administration (± 7 days) of sitagliptin as monotherapy (taken orally). The study will use 3 doses: the first five patients will receive 100 mg/day, the next five 200 mg/day and the last five patients 600 mg/day. During this time, arrangements will be made for surgical resection, as per the standard of care treatment of patients. Blood samples will be obtained for immunology studies. The study will end one week after surgery. Patients will continue their treatment for HCC as prescribed by the clinician.
2986889|NCT02650414|Experimental|CART22 cells|"Subjects <50kg will receive 0.2-1 x 107 CART22 cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x106 CART22 cells/kg~Day 2, 30% fraction: 0.6-3x106 CART22 cells/kg~Day 3, 60% fraction: 1.2-6x106 CART22 cells/kg~Subjects ≥50kg will receive 1-5x108 CART22 cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x107~Day 2, 30% fraction: 0.3-1.5x108~Day 3, 60% fraction: 0.6-3x108"
2986890|NCT02650401|Active Comparator|Extracranial solid tumors harboring NTRK1/2/3,|"ROS1, ALK non-gene fusion molecular alterations~Oral entrectinib (RXDX-101)"
2986891|NCT02650401|Active Comparator|CNS tumors harboring- NTRK1/2/3, ROS1, ALK|"molecular alterations, including gene fusions~Oral entrectinib (RXDX-101)"
2986892|NCT02650401|Active Comparator|Neuroblastoma|Oral entrectinib (RXDX-101)
2986893|NCT02650401|Active Comparator|Non-neuroblastoma, extracranial solid tumors|"harboring - NTRK1/2/3, ROS1, ALK gene fusions~Oral entrectinib (RXDX-101)"
2986894|NCT02650401|Active Comparator|Any patient unable to swallow capsules|"who otherwise meet all other eligibility criteria~Oral entrectinib (RXDX-101)"
2986895|NCT02650388|Other|Post TAVI neurocognitive outcome|"TAVI with CoreValve will be done for all the patients and outcome will be assessed as Cognitive fuction, quality of life, Gait speed, Hand grip strength, Activities of daily living (ADL), Instrumental activities of daily living (IADL), Short- Form Mini Nutritional assessment (SF-MNA), Serum albumin level, Hemoglobin level, BMI, Montreal cognitive Assessment (MOCA), EQ-5D-3L-questionnaire, Ferreans and Powers Quality of life Index (QLI), MOCA, RBANS, Wisconsin test, Stroop test, Fluency test, Subjective Eyeball test, Serial Transcranial Doppler (TCD) during TAVI. Finally, Hungarian frailty score will be deduced."
2986896|NCT02650375|Experimental|Metatinib Tromethamine|
2986897|NCT02650362|Experimental|spinal cord stimulation|
2986898|NCT02650349|Experimental|spinal cord stimulation|The Vectris® SureScan® MRI lead will be connected to a RestoreSensor® SureScan® MRI neurostimulator.
2986899|NCT02650336||CIN proup|The occurrence of CIN was defined as an increase in serum creatinine of 0.5 mg/dL above the baseline value within 48-72 h after PCI. Follow-up SCr and BUN levels were measured 1, 2, and 3 days after the procedure.
2986900|NCT02650336||control group|The occurrence of CIN was defined as an increase in serum creatinine of 0.5 mg/dL above the baseline value within 48-72 h after PCI. Follow-up SCr and BUN levels were measured 1, 2, and 3 days after the procedure.
2986901|NCT02650310|No Intervention|Conventional transfer|This arm is the control group (conventional embryo transfer protocol) where there is no intervention.
2986902|NCT02650310|Experimental|Thermostable device transfer|This arm is the study group: embryo transfer protocol using a new thermostable device.
2986903|NCT02650297|Experimental|CDT and pneumatic compression pump|combined decongestive therapy consists of the pressure of bandage, manual lymphatic drainage, and exercises that increase the flow of lymph and skin care are used. Intermittent pneumatic pump is not as a part of CDT, but it can be used as an adjunct method. This device according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk.
2986904|NCT02650297|No Intervention|not CDT and pneumatic compression pump|Patients in the control group received no treatment for lymphedema but were placed on the waiting list for CDT as soon as possible after the 8 weeks follow-up period.
2986905|NCT02650284|Other|Bicompartmental Knee Replacement (BKR)|Receiving Restoris MCK Multicompartmental Knee System for Bicompartmental Knee Replacement (BKR). Surgery performed using Stryker's robotic-arm assisted surgery system Mako
2986906|NCT02650284|Other|Total Knee Replacement (TKR)|Receiving Stryker Triathlon Primary Total Knee System for Total Knee Replacement. Surgery performed using conventional instrumentation or navigation.
2986907|NCT02650271|Experimental|Entecavir|Patients will be received entecavir (10 mg/d) after 3 days of liver resection.
2986908|NCT02650271|Active Comparator|Lamivudine|Patients will be received lamivudine (100 mg/d) after 3 days of liver resection.
2986909|NCT02650258||Young Adult|80 Adults 21-40 years of age: 10 Male and 10 Female in each 5 year increment (21-25, 26-30, 31-35, 36-40).
2986910|NCT02650258||Middle Aged Adults|80 Adults 41-60 years of age: 10 Male and 10 Female in each 5 year increment (41-45, 46-50, 51-55, 56-60).
2986911|NCT02650258||Older Adults|100 Adults 61-85 years of age: 10 Male and 10 Female in each 5 year increment (61-65, 56-69, 70-75, 76-80, 81-85).
2986912|NCT02650245|Experimental|Moderate protein and 10gm lactulose|40% of daily recommended intake of protein based on weight
2986913|NCT02650232|Other|Young Healthy Volunteers|We will evaluate in this group (18 - 40 y) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
2986914|NCT02650232|Other|Old Healthy Volunteers|We will evaluate in this group (50 - 80 y) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
2986918|NCT02650206|Experimental|Liraglutide group|"Drug with diet control intervention: Subjects assigned to this group receive blinded pens containing liraglutide (commonly known as Victoza), manufactured by Novo Nordisk. Subjects will inject 0.6 mg daily into abdomen during the first week of the study, and if tolerated, will increase dose to 1.2 mg the second week of the study, and then up to 1.8 mg daily from the third week until the end of the 12-week study. Any adverse symptoms as well as fasting blood glucose will be monitored weekly for safety.~Subjects, with the guidance of the study's dietitian, will remain weight-stable for the first four weeks of the study, and then will be allowed to lose weight for the remaining eight weeks of the study."
2986919|NCT02650206|Placebo Comparator|Placebo group|"Diet control-only intervention: Subjects assigned to this group receive blinded pens containing placebo (normal saline) instead of liraglutide (commonly known as Victoza). Subjects will inject 0.6 mg of placebo daily during the first week of the study, will increase to 1.2 mg the second week of the study, and then up to 1.8 mg daily from the third week until the end of the 12-week study. Any adverse symptoms as well as fasting blood glucose will be monitored weekly for safety.~Subjects, with the guidance of the study's dietitian, will remain weight-stable for the first four weeks of the study, and then will be allowed to lose weight for the remaining eight weeks of the study."
2986920|NCT02650193|Experimental|HSP-130|"Cycle 0:~Regimen A: HSP 130, 3 mg, single SC injection in the deltoid region (n = 6) Regimen B: HSP 130, 6 mg, single SC injection in the deltoid region (n = 6)~Cycles 1-4:~Regimen B (n = 12): HSP 130, 6 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4.~Potential Regimen A (n = 12): 3 mg with background chemotherapy: Inclusion of this cohort will be based on assessment of comparability between Regimens A and B in Cycle 0 for ANC and CD34+ as defined above. If performed, this regimen will be HSP 130, 3 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4, as appropriate.~Conditional Regimen C (12 mg):This cohort will not be initiated until data from cycle 0 for 3 mg and 6 mg and Cycles 1-4 for 6 mg has been reviewed and analyzed."
2986921|NCT02650180|Other|Soberlink Cellular Device|Soberlink Cellular Device: a Breath Alcohol Analyzer
2986922|NCT02650167|Experimental|Colostrum|
2986923|NCT02650167|Experimental|Witness|
2986924|NCT02650154||Pre-ketamine group|Blood samples are taken prior to the administration of ketamine.
2986925|NCT02650154||Post-ketamine group|Blood samples are taken several hours after the administration of ketamine.
2986926|NCT02650141|Experimental|ziyinxiehuo Granules|Children of ziyinxiehuo granules group will be treated with chinese herbal granules,3 times a day, for 6 months.
2986927|NCT02650141|Active Comparator|zishenqinggan Granules|Children of zishenqinggan granules group will be treated with chinese herbal granules, 3 times a day, for 6 months.
2986928|NCT02650128|Experimental|Lithoplasty System|Shockwave Coronary Rx Lithoplasty® System is a lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic de novo coronary arteries prior to stent placement
2986929|NCT02650102|Experimental|antipsychotics|This group was treated with one of 5 antipsychotics(risperidone/olanzapine/aripiprazole/quetiapine/ziprasidone) randomly.
2986930|NCT02650102|No Intervention|health control|This group was treated with no invention
2986931|NCT02650089|Experimental|Resistance Exercise Low intensity|The 40% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
2986932|NCT02650089|Experimental|Resistance Exercise High intensity|The 80% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 8 repetitions were performed for each exercise, with an interval of 90 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
2986933|NCT02650089|Other|Control|In the control session, the participants remained seated in a comfortable chair in the same environment of the resistance exercise sessions.
2986934|NCT02650076|Experimental|Healthy|
2986935|NCT02650063|Experimental|DE-117 ophthalmic solution|
2986936|NCT02650050|Experimental|Micropulsed laser photocoagulation|
2986937|NCT02650050|Sham Comparator|Sham micropulsed laser photocoagulation|
2986938|NCT02650024|Experimental|Immediate (IMM)|"30 HCV mono-infected individuals will be enrolled into IMM.~Intervention:~Step 1: ledipasvir and sofosbuvir (90mg/400mg, single oral tablet, once daily for 12 weeks) Step 2: No treatment for 12 weeks Step 3: Placebo for ledipasvir and sofosbuvir (single oral tablet, once daily, for 12 weeks Step 4: No treatment for remaining follow-up period.~Duration: Subjects will remain on study drug regimen or placebo until week 36.~Administration: Appropriate dose of ledipasvir and sofosbuvir and placebo for ledipasvir and sofosbuvir can be administered at any time of the day, with or without food. The drug should be taken as close to the same time of day as possible."
2986939|NCT02650024|Experimental|Delayed (DEL)|"30 HCV mono-infected individuals will be enrolled into DEL.~Intervention:~Step 1: Placebo for ledipasvir and sofosbuvir (single oral tablet, once daily, for 12 weeks Step 2: No treatment for 12 weeks Step 3: ledipasvir and sofosbuvir (90mg/400mg, single oral tablet, once daily for 12 weeks) Step 4: No treatment for remaining follow-up period.~Duration: Subjects will remain on study drug regimen or placebo until week 36.~Administration: Appropriate dose of ledipasvir and sofosbuvir and placebo for ledipasvir and sofosbuvir can be administered at any time of the day, with or without food. The drug should be taken as close to the same time of day as possible."
2986940|NCT02650024|Experimental|Co-Infected Group|"12 HIV/HCV co-infected individuals will be enrolled into the Co-Infected group.~Intervention:~Step 1: ledipasvir and sofosbuvir (90mg/400mg, single oral tablet, once daily for 12 weeks) Step 2: No treatment for remaining follow-up period.~Duration: Subjects will remain on study drug regimen until week 12.~Administration: Appropriate dose of ledipasvir and sofosbuvir can be administered at any time of the day, with or without food. The drug should be taken as close to the same time of day as possible."
2986941|NCT02650011||ACLF cohort|Patients who have chronic liver disease and admitted for acute deterioration of liver function
2986942|NCT02649998|Active Comparator|Group 1|Each patient will initially receive a 40 mg bolus of IV furosemide (10 mg/mL) and a 2 mL bolus of IV saline placebo, followed by IV saline placebo 6 mL/h
3001077|NCT02555709|Experimental|VTP-43742 Dose 11|psoriatic patients
2986943|NCT02649998|Active Comparator|Group 2|Each patient will initially receive a bolus of IV saline placebo and a 2 mL bolus of IV isosorbide dinitrate (1 mg/mL), followed by IV isosorbide dinitrate 6 mL/h
2986944|NCT02649998|Active Comparator|Group 3|Each patient will initially receive a 40 mg bolus of IV furosemide (10 mg/mL) and a 2 mL bolus of IV isosorbide dinitrate (1 mg/mL), followed by IV isosorbide dinitrate 6 mL/h
2986945|NCT02649985|Experimental|Relapsing Remitting Multiple Sclerosis|"Subjects meeting the definition for RRMS by the International Panel Criteria, who are active, as defined by at least one MS relapse in the past 12 months, or at least one gadolinium enhancing lesion on a MRI within 3 months of enrollment.~The study will be performed in two phases. In the early pilot phase, 8 subjects with multiple sclerosis will undergo both [C-11]PBR28 PET scan and [F-18]PBR06 PET scan. At the end of this phase, a formal interim analysis will be performed and if imaging characteristics of [F-18]PBR06 are found non-inferior to or better than [C-11]PBR28, the rest of the study will be completed using [F-18]PBR06. On the other hand, if [F-18]PBR06 is found to be inferior to [C-11]PBR28, the rest of the study will be pursued using [C-11]PBR28."
2986946|NCT02649985|Experimental|Secondary Progressive Multiple Sclerosis|"Subjects meeting the definition for SPMS by International Panel Criteria and who have demonstrated deterioration in EDSS score in last 1 year~The study will be performed in two phases. In the early pilot phase, 8 subjects with multiple sclerosis will undergo both [C-11]PBR28 PET scan and [F-18]PBR06 PET scan. At the end of this phase, a formal interim analysis will be performed and if imaging characteristics of [F-18]PBR06 are found non-inferior to or better than [C-11]PBR28, the rest of the study will be completed using [F-18]PBR06. On the other hand, if [F-18]PBR06 is found to be inferior to [C-11]PBR28, the rest of the study will be pursued using [C-11]PBR28."
2986947|NCT02649985|Active Comparator|Alzheimer's Disease|"Subjects meeting the definition for probable AD based on NINDS-ADRDA criteria. In terms of severity of disease, the investigators will select subjects with mild AD, as defined by Mini-Mental Status Examination (MMSE) score of 20-26~The study will be performed in two phases. In the early pilot phase, 8 subjects with multiple sclerosis will undergo both [C-11]PBR28 PET scan and [F-18]PBR06 PET scan. At the end of this phase, a formal interim analysis will be performed and if imaging characteristics of [F-18]PBR06 are found non-inferior to or better than [C-11]PBR28, the rest of the study will be completed using [F-18]PBR06. On the other hand, if [F-18]PBR06 is found to be inferior to [C-11]PBR28, the rest of the study will be pursued using [C-11]PBR28."
2986948|NCT02649985|Other|Healthy Control|"This group will serve as non disease population.~The study will be performed in two phases. In the early pilot phase, 8 subjects with multiple sclerosis will undergo both [C-11]PBR28 PET scan and [F-18]PBR06 PET scan. At the end of this phase, a formal interim analysis will be performed and if imaging characteristics of [F-18]PBR06 are found non-inferior to or better than [C-11]PBR28, the rest of the study will be completed using [F-18]PBR06. On the other hand, if [F-18]PBR06 is found to be inferior to [C-11]PBR28, the rest of the study will be pursued using [C-11]PBR28."
2986949|NCT02649972|Experimental|Cobimetinib|This is an open-label, single-center, phase II study exploring the efficacy and safety of single-agent Cobimetinib in patients with histiocytic disorders whose tumors are 1) BRAFV600 wildtype or 2) BRAFV600E mutant and are intolerant to, or unable to access, BRAF inhibitors.
2986950|NCT02649959|Experimental|Open Label|CM-AT
2986951|NCT02649933||Watch PAt 200|obese pregnant women, pregnancy between 12 and 15 weeks
2986952|NCT02649920|Experimental|Cervical ripening balloon|Prospective
2986953|NCT02649920|Active Comparator|Dinoprostone|Retrospective
2986954|NCT02649907|Experimental|Weight loss|3 months weight loss intervention by behavioral intervention
2986955|NCT02649894|Experimental|investigation product|investigation product
2986956|NCT02649894|Active Comparator|Approved indwelling catheter|Approved indwelling catheter
2986957|NCT02649881||isolated heart from heart transplantation|
2986958|NCT02649868|Experimental|1|Treatment of hepatic tumors using bead embolization.
2986959|NCT02649855|Experimental|A/Sequential docetaxel followed by PROSTVAC|Standard ADT followed by simultaneous docetaxel + prostvac
2986960|NCT02649855|Experimental|B/ Combined docetaxel with PROSTVAC|Standard ADT followed by sequential docetaxel + prostvac
2986961|NCT02649855|Experimental|C/ PROSTVAC prior to docetaxel|Standard ADT followed by prostvac, then docetaxel
2986962|NCT02649842|Active Comparator|ZCT450|Approved toric intraocular lens, Model ZCT450
2986963|NCT02649842|Active Comparator|ZCT525|Approved toric intraocular lens, Model ZCT525
2986964|NCT02649842|Active Comparator|ZCT600|Approved toric intraocular lens, Model ZCT600
2986965|NCT02649829|Experimental|Single Arm|dendritic cell vaccination plus chemotherapy
2986966|NCT02649803|Other|community hospital|"During the study, subjects who diagnosed as asthma according to Guideline for the diagnosis and optimal management of asthma in children will be assigned to the nearest community hospital or Shanghai Children's Medical Center, and receive 12 months standard treatment, prescribed by the investigators according to Guideline for the diagnosis and optimal management of asthma in children. The patient's caregiver will be instructed to install asthma APP at their smart phone to follow up."
2986967|NCT02649790|Experimental|KPT-8602|"Relapsed/Refractory Multiple Myeloma (RRMM) - CLOSED TO ENROLLMENT~Metastatic Colorectal Cancer (CRC) - CLOSED TO ENROLLMENT~Relapsed/Refractory Metastatic Castration Resistance Prostate Cancer (mCRPC) - CLOSED TO ENROLLMENT~Higher Risk Myelodysplastic Syndrome (MDS) - OPEN TO ENROLLMENT~Starting dose for CRC, mCRPC, MDS is 20 mg of KPT-8602"
2986968|NCT02649764|Experimental|LY2606368 + Fludarabine + Cytarabine|"Initial cycle (cycle 1) considered Induction Phase. A cycle is defined as 28 days. Based on response, patients may be eligible for additional cycles beyond cycle 1.~Induction and Consolidation Phase Dose of Fludarabine: 30 mg/m2 by vein over 2 hours for 4 days.~Induction and Consolidation Phase Dose of Cytarabine: 1.0 gram/m2 continuous infusion daily for 4 days.~Induction Phase Starting Dose of LY2606368: 20 mg/m2 by vein daily for 3 days (days 1, 3, 4).~Consolidation Phase Starting Dose of LY2606368: Maximum tolerated dose (MTD) from Induction Phase.~LY2606368 administered on days 1, 3 and 4 in initial cohorts and escalated eventually to be administered on days 1, 2, 3, 4 and 5.~Consolidation therapy may continue for 3 additional cycles."
2986969|NCT02649751|Experimental|Group 1|"200 mg roscovitine (8) or placebo (4) once daily for 4 cycles of 7 days (4 days on and 3 days off)"
2986970|NCT02649751|Experimental|Group 2|"400 mg roscovitine (8) or placebo (4) once daily for 4 cycles of 7 days (4 days on and 3 days off)"
2986971|NCT02649751|Experimental|Group 3|"400 mg roscovitine (8) or (4) placebo twice daily for cycles of 7 days (4 days on and 3 days off)"
2986972|NCT02649738|Experimental|Corneal tissue inlay|The treated cornea will be implanted with a thin disc of preserved corneal tissue
2986973|NCT02649712|Active Comparator|Unilateral stent|Patients undergo placement of unilateral biliary stent on day 1.
2986974|NCT02649712|Active Comparator|Bilateral stents|Patients undergo placement of bilateral biliary stents on day 1.
2986975|NCT02649699|Other|Additional 3D MRI scans|Participating patients will receive additional 3D MRI scans during pre and post RT planning for their primary brain tumors.
2986976|NCT02649686|Experimental|Durvalumab plus Trastuzumab|Durvalumab q3w until PD Trastuzumab q3w x 6
2986977|NCT02649673|Experimental|LCL161+topotecan+Pegylated GCSF (PEG-GCSF)|"Dose Escalation: Groups of 3-6 patients per dose level (DL) will initiate treatment in escalating doses until the maximum tolerated dose (MTD) is reached. MTD is defined as the highest combination of doses that results in dose-limiting toxicities for 2 of 6 patients per dosing group.~LCL161: orally, on Days 1, 8, 15 of each 21-day cycle. Maximum dose not to exceed 1200 mg/week.~topotecan: orally, for first 5 days of each 21-day cycle. Maximum dose not to exceed 2.3 mg/m2 per day.~Pegylated GCSF (PEG-GCSF) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.~Dose Expansion: 24 additional patients will be treated at the MTD in 2 cohorts (SCLC-12 patients; ovarian cancer-12 patients)"
2986978|NCT02649647|Active Comparator|Conventional Resection|Patients receive conventional resection with standard proximal excision margin. The sigmoid colon is anastomosed to the rectum or anus.
2986979|NCT02649647|Experimental|Proximally Extended Resection|Patients receive proximally extended resection. The whole sigmoid colon and rectum proximal to the tumor is removed, and the descending colon is anastomosed to the rectum or anus.
2986980|NCT02649634|Experimental|Motivational Interviewing|Two 45-60 minute motivational interviewing sessions focusing on exploring and resolving ambivalence towards change.
2986981|NCT02649634|Active Comparator|Attention Control|Two 45-60 minute semi-structured interviews, acting as a pseudo-intervention, ascertaining information relevant to health history, weight history, diet history, as well as dietary and physical activity habits.
2986982|NCT02649621|Experimental|Amniotic Membrane Extract Eye Drop recipient|patients with limbal stem cell Deficiency who receive amniotic membrane transplantation and amniotic membrane extract eye drop as eye drop.
2986983|NCT02649608|Experimental|Lu AE04621|"Cohort 1: 3 patients with Parkinson's Disease~Before initiation of cohort 2-8, dosages will be decided at a dosing conference prior to each cohort. Dose levels can be increased, maintained or reduced both between cohorts but also within same cohort. In each cohort 3 patients with Parkinson's Disease will be included~In addition, 3 extra cohorts 9 to 11 are additional cohorts that might be used, if necessary to address the study objectives. Then up to 33 patients can be enrolled."
2986984|NCT02649595|Other|Red Cross respite care|A 2 week free stay at a Red Cross respite center after hospitalization.
2986985|NCT02649595|No Intervention|Streets/communal programmes|Homeless being discharged from hospital to the streets and communal programmes.
2986986|NCT02649582|Experimental|Single Arm|Dendritic cell vaccine plus temozolomide chemotherapy
2986987|NCT02649569||Observational (continuous activity monitoring, questionnaires)|Patients wear an activity monitor throughout and up 4 weeks after completion of radiation therapy. Patients who are willing may continue to wear the monitor through routine follow up appointments. Patients also complete questionnaires at evaluations, which take place prior to radiotherapy initiation, weekly during radiotherapy, and then 2 and 4 weeks after the completion of radiotherapy.
2986988|NCT02649556|Experimental|THS 2.2|Ad libitum use of THS 2.2
2986989|NCT02649556|Active Comparator|CC|Ad libitum use of CC
2986990|NCT02649543|Active Comparator|Primary Closure|Primary Closure is made after surgery.
2986991|NCT02649543|Active Comparator|Delayed Primary Closure|Delayed Primary Closure is made after at least 7 days.
2986992|NCT02649543|Active Comparator|Vacuum Assisted Closure|Vacuum Assisted Device is used in the wound.
2986993|NCT02649530|Experimental|WNT974|Patients will receive 10 mg of WNT974 daily by mouth.
2986994|NCT02649517|Other|chronic inflammation|All patients will be held PCI to exclude ischemic heart failure decompensation. Also, all patients will be performed endomyocardial biopsy.
2986995|NCT02649504|Active Comparator|R+3D, MMF|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study. Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study. Mycophenolate mofetil (MMF) will be given starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
2986996|NCT02649504|Placebo Comparator|R+3D, Placebo|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study. Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study. Placebo will be given starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
2986997|NCT02649478|Experimental|Fluticasone / Salmeterol|"fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura lever operated multidose inhaler (LOMI) inhaler device twice a day by inhalation throughout the study"
2986998|NCT02649478|Active Comparator|Advair Diskus 100/50|Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study
2986999|NCT02649478|Placebo Comparator|placebo inhaler|placebo inhaled powder twice a day by inhalation throughout the study
2987000|NCT02649465|Active Comparator|SGLT2 inhibitor|N=20 SGLT2 inhibitor dosage (Tofogliflozin): a dose of 20mg once daily for 48 weeks.
2987001|NCT02649465|Active Comparator|Sulfonylurea|N=20 Sulfonylurea (Glimepiride): an initial dose of 0.5 mg once daily for 48 weeks.
2987002|NCT02649452|Experimental|vibration|Flexibility test of Active Chest Flexibility and Shoulder Reach Flexibility tests will be performed before and after the experiment to determine their improvement in the flexibility of the pectoral muscles. After measuring the flexibility, two stretching exercises of one-arm doorway stretch and office chest stretch will be performed. it will be done twice, 30 second each with 10 second rest in between. After exercise, this group had to undergo vibration exercise by using whole body vibration machine.
2987003|NCT02649452|Active Comparator|Exercises|Flexibility test of Active Chest Flexibility and Shoulder Reach Flexibility tests will be performed before and after the experiment to determine their improvement in the flexibility of the pectoral muscles. After measuring the flexibility, two stretching exercises of one-arm doorway stretch and office chest stretch will be performed. it will be done twice, 30 second each with 10 second rest in between
2987004|NCT02649439|Experimental|A/PROSTVAC treatment|PROSTVAC treatment for 6 months with an additional optional year of maintenance for eligible patients
2987005|NCT02649439|Experimental|B/ Delayed PROSTVAC treatment|Surveillance for 6 month followed by PROSTVAC treatment for 6 months with an additional year of maintenance for eligible patients
2987006|NCT02649426|Experimental|Ultrasound Renal Denervation|Subjects in the TRIO or SOLO cohorts that are randomized to treatment, will receive renal denervation following a renal angiogram
2987007|NCT02649426|Sham Comparator|Sham Procedure|For subjects in TRIO or SOLO cohorts that randomize to the sham procedure, the diagnostic renal angiogram intervention will be considered the sham procedure.
2987008|NCT02649413|Experimental|Early response to prednisone treatment|intervention -children that will have a remission in 8 days (response) will get an adjusted steroids dose treatment.children that have a remission between 9-28 days will get a regular steroid dose.
2987009|NCT02649400||Diastolic Heart Failure|Women with diastolic heart failure and previous coronary artery disease
2987010|NCT02649387|Experimental|Treatment (ibrutinib)|"Patients receive ibrutinib PO QD on days 1-28. Treatment repeats every 4 weeks* for up to 36 courses in the absence of disease progression or unacceptable toxicity.~Note: *The last course may last up to 56 days to accommodate the study drug discontinuation visit."
2987011|NCT02649374|No Intervention|Gestational diabetes mellitus|women diagnosed with GDM during pregnancy, either treated by diet or pharmacological therapy
2987012|NCT02649374|Active Comparator|No GDM, Dietary Modifications|Women without GDM, will be advised and monitored for dietary, Exercise and lifestyle modifications
2987013|NCT02649374|No Intervention|No GDM, free diet|Women without GDM, for whom diet. exercise are continued regulary without any modifications
2987014|NCT02649361|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2987015|NCT02649361|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2987016|NCT02649348|Other|prehabilitation|To do preoperative exercise and bind abdominal binder over 5 days before operation.
2987017|NCT02649348|No Intervention|Comparator|Don't do any exercise or bind abdominal binder before operation.
2987018|NCT02649335|Active Comparator|Propranolol|Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study.
2987019|NCT02649335|Active Comparator|Endoscopic variceal ligation (EVL)|Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy (SMT) .
2987020|NCT02649322|Experimental|Group A|Participants in Group A will receive 0.25 mL of 1% plain lidocaine delivered by the J-tip injector at the regional block site prior to introduction of the needle for the nerve block procedure.
2987021|NCT02649322|Active Comparator|Group B|Participants in Group B will receive 2 mL of 1% plain lidocaine injected by syringe and 25 gauge needle at the regional block site prior to introduction of the needle for the nerve block procedure.
2987022|NCT02649309|Experimental|RIPre + RIPost|Intervention: RIPre 200 mmHg + RIPost 200 mmHg
2987023|NCT02649309|Experimental|RIPre + Sham|Intervention: RIPre 200 mmHg + Sham 10 mmHg
2987024|NCT02649309|Experimental|Sham + RIPost|Intervention: Sham 10 mmHg + RIPost 200 mmHg
2987025|NCT02649309|Sham Comparator|Sham + Sham|Intervention: Sham 10 mmHg + Sham 10 mmHg
2987026|NCT02649296|Other|Treatment with Skanlab Bodywave|Treatment with Skanlab Bodywave twice a week for four weeks at the affected knee.
2987027|NCT02649296|No Intervention|No treatment|Treatment with Skanlab Bodywave without function twice a week for four weeks.
2987028|NCT02649283|Other|Breast symmetrisation with OrbiSymm|Standard surgical intervention of up to 30 patients including placement of the OrbiSymm device
2987029|NCT02649283|Other|Breast symmetrisation without device|Standard surgical intervention of up to 30 patients without the Orbix device; only routine reduction/symmetrisation intervention
2987030|NCT02649270|Experimental|Group1|10 Psoriasis patients,T1h 0.2mg/kg,only single dose administration at week 1.
2987031|NCT02649270|Experimental|Group2|10 Psoriasis patients,T1h 0.4mg/kg ,first administration at week 1 and continous administration from fifth week for 9 weeks.
2987032|NCT02649270|Experimental|Group3|10 Psoriasis patients,T1h 0.8mg/kg,first administration at week 1 and continous administration from fifth week for 9 weeks.
2987033|NCT02649270|Experimental|Group4|10 Psoriasis patients,T1h 1.6mg/kg,first administration at week 1 and biweekly from fifth week for 9 weeks.
2987034|NCT02649257|Experimental|MC 6125 AS IOL + CTR|All patients received the same procedure: cataract surgery with phakoemulsification, implantation of a capsular tension ring (CTR13/11) and implantation of an intraocular lens (MC 6125 AS).
2987035|NCT02649244|Experimental|The Family Caregiver Training Program|The experimental group received a 2 hour intervention training on activities of daily throughout the early, middle, and late stages of dementia including communication, eating/feeding, nutrition, bathing, grooming, dressing, toileting, and transferring.
2987036|NCT02649244|No Intervention|Standard Care|The control group received a 1 1/2 hour training, however the information was based on what has been deemed standard care by the Alzheimer's Association.
2987037|NCT02649231|Experimental|Ketamine+Psychological Therapy|Ketamine with psychological therapy
2987038|NCT02649231|Active Comparator|Ketamine+Education|ketamine with alcohol education
2987039|NCT02649231|Active Comparator|Placebo+Psychological Therapy|placebo with psychological therapy
2987040|NCT02649231|Placebo Comparator|Placebo+Education|placebo with simple alcohol education
2987041|NCT02649218|Experimental|Arm 1|QGE031 every 4 weeks x 13 treatments
2987043|NCT02649192|Active Comparator|Influenza Virus Vaccine Plus Vitamins A and D|Participants receive influenza virus vaccine and Vitamins A and D supplement on Day 0 and Day 28.
2987044|NCT02649192|Placebo Comparator|Influenza Virus Vaccine Plus Placebo|Participants receive influenza virus vaccine and matched placebo on Day 0 and Day 28.
2987045|NCT02649179|Experimental|local infiltration with ropivacaine|patients were to receive 0.75% ropivacaine
2987046|NCT02649179|Placebo Comparator|local infiltration with 0.9% saline|patients were to receive placebo
2987047|NCT02649166|Experimental|Deep brain stimulation|All participants will undergo unilateral deep brain stimulation (DBS) implantation for essential tremor. Medtronic Activa PC+S devices will be used because these are capable of recording brain signals, as well as delivering DBS. Participants will receive continuous (open-loop) and closed-loop deep brain stimulation interventions, which will be compared for efficacy.
2987048|NCT02649153|Experimental|smoked plum|Patients will receive smoked plum (3 piece each time, three times per day) starting in the first day after resection until flatus.
2987049|NCT02649153|Active Comparator|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
2987050|NCT02649153|No Intervention|empty control|This group patients will not receive gum chewing or smoked plum.
2987051|NCT02649140|No Intervention|Group 1|Group1 is control group and participants do not need intervention.
2987052|NCT02649140|Experimental|Group 2|Group 2 is vinegar Group and participants in this group are asked to drink 15ml vinegar(Ninghuafu, Sanxi, China)after dinner at noon and evening respectively for a period of four weeks.
2987053|NCT02649127|Experimental|Imaginal Therapy Only|The imaginal exercise of exposure therapy will be manualized (Rothbaum, Foa & Hembree, 2007) and adapted with the permission of Dr. Foa for combat-related stress disorders (Peterson, Cigrang & Riggs, 2008). While traditional exposure therapy includes both imaginal exposure and in vivo exposure, this study will use only the imaginal exposure components. Participants will meet with a therapist the first week of treatment and every-other week for a total of five appointments over eight weeks. During the second session, the therapist will help the participant make an approximately 20-minute voice tape recording of their traumatic experience which they will listen to 5-days/week. A new recording will be made with the therapist during sessions 3 and 4 also, for a total of three tapes.
2987054|NCT02649127|Experimental|Exercise Only|The aerobic exercise regimen will be standardized according to the American College of Sports Medicine recommendations: frequency of a minimum of 5 sessions per week, at a vigorous intensity [>60% of oxygen uptake reserve (VO2R)], time of 20-25 minutes per exercise session. To determine the exercise heart rate intensity, the Karvonen formula for heart rate reserve will be used. The mode of exercise will be purposeful walking or jogging. The goal of the exercise is not training, but rather to keep the participant's heart rate >60% of their individually-determined heart rate reserve.
2987055|NCT02649127|Experimental|Imaginal Therapy & Exercise Combined|Participants will meet with a therapist the first week of treatment and every-other week for a total of five appointments over eight weeks. During the second session, the therapist will help the participant make an approximately 20-minute voice tape recording of their traumatic experience which they will listen to 5-days/week. A new recording will be made with the therapist during sessions 3 and 4 also, for a total of three tapes. Participants will exercise listening to their tape at least 5-times/week outside of scheduled unit Physical Training. Participants will wear the heart rate monitor to record their exercise activity.
2987056|NCT02649127|Active Comparator|Nurse-led Self-Care|The Self-Care Group will use written materials that outline the benefits of thinking about problems the individual is facing as well as the benefits of exercise, however doing the two activities together will not be advocated as part of the material. A fact sheet prepared by the National Center for PTSD, Returning from the War Zone: A Guide for Military Personnel as well as a list of coping strategies and self-care behaviors adapted from the National Center for PTSD guide, Self-Care and Self-Help Following Disasters, will be used to guide the discussion. The research nurse will meet with the participant five times over 8-weeks at weeks 1, 2, 4, 6, and 8 to encourage use of the self-care fact sheet and assess the participant for safety.
2987057|NCT02649114|Active Comparator|Cognitive-Behavioural Therapy|This version of CBT is based on techniques employed in evidence-based approaches to a transdiagnostic sample. The programme includes; individualized formulation, taking into account different maintaining factors across cases (e.g., nutritional and/or emotional drivers for binging); agenda setting; homework; change in diet (particularly to improve carbohydrate intake); diary-keeping; exposure; behavioral experiments; cognitive restructuring; and surveys. The behavioral change is maintained as a focus, along with changes in mood and cognitions.
2987058|NCT02649114|Experimental|Compassion-Focused Therapy|There are four main treatment elements to the program. Two of these are linked to the experience of being a therapy group. This involves patients providing compassionate support to other group members.The third treatment element involves compassionate mind training which mainly focuses on activating the soothing system via imagery and related practical exercises.The final element of the program aims to help patients improve their ability to use their wider social network to access support.
2987059|NCT02649101|Experimental|thalidomide plus chemotherapy|thalidomide tablet 100mg qn po
2987060|NCT02649101|Active Comparator|chemotherapy|Physician's choice chemotherapy. No constraints of the choice of chemotherapy drugs and regimens.
2987061|NCT02649075|Active Comparator|SBI 10 g BID|Serum-derived Bovine Immunoglobulin / Protein Isolate (SBI) 10.0 grams twice per day
2987062|NCT02649075|Placebo Comparator|Placebo BID|Placebo w/control protein
2987063|NCT02649062|Experimental|NGM282 Dose 1|NGM282
2987064|NCT02649062|Experimental|NGM282 Dose 2|NGM282
2987065|NCT02649062|Placebo Comparator|Placebo|Placebo
2987066|NCT02649049||Patients with NAFLD|Patients with NAFLD are the cases.
2987067|NCT02649049||control group|Healthy people without NAFLD are controls.
2987068|NCT02649036||Emergency call population|Citizens over 18 years old from the Capital Region of Denmark with a first time emergency call within a two-year study period (1/12-2011-30/11-2013)
2987069|NCT02649036||Background population|Citizens over 18 years old from the Capital Region of Denmark with no emergency call within a two-year study period (1/12-2011-30/11-2013)
2987070|NCT02649023||A: Patients with deep venous thrombosis|"All patients will be screened for deep venous thrombosis on postoperative day 3. Patients with a positive finding will be grouped in arm A"
2987071|NCT02649023||B: Patients without deep venous thrombosis|"All patients will be screened for deep venous thrombosis on postoperative day 3. Patients with a negative finding will be grouped in arm B"
2987072|NCT02649010|Active Comparator|Group A|Subjects will be randomly assigned to 2 groups (Group A & Group B) that will determine when they will be participating in the in-clinic YSI frequent sample testing.
2987073|NCT02649010|Active Comparator|Group B|Subjects will be randomly assigned to 2 groups (Group A & Group B) that will determine when they will be participating in the in-clinic YSI frequent sample testing.
2987074|NCT02648997|Experimental|Nivolumab Immunotherapy|Nivolumab will be administered very 2 weeks at a pre-determined dose.
2987075|NCT02648984|Other|Patient group|Patients with ventricular septal defect
2987076|NCT02648984|Other|Control group|Healthy control subjects
2987077|NCT02648971|Active Comparator|Single Portal Knee Arthroscopy|After randomization for each patient is complete, the website will document the name of the person who logged on to perform the randomization, the date and time of the log in, and the surgical group assignment for each patient. This randomization information will be forwarded to the operating room staff so that they can prepare for each study participant's surgical procedure. Patients in Group 1 will undergo knee arthroscopy using a single portal. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
2987078|NCT02648971|Active Comparator|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
2987079|NCT02648958|Placebo Comparator|Control group|The control group received saline instead of dexmedetomidine.
2987080|NCT02648958|Experimental|Dexmedetomidine group|The dexmedetomidine group received the dexmedetomidine.
2987081|NCT02648945|Active Comparator|high intensity exercise|"high intensity exercise on a treadmill according to Balke's Protocol.~high intensity of exercises for each group of 15 participants were set at 80-85% VO2 max (Schneider, S., et al., 2009). To determine the targeted HR for low and high intensity aerobic exercise for each participant, the needed VO2 max percentages were subbed into the Swain equation as follows: %VO2 max = (%HRmax - 37)/0.64 Exercise HR/HRmax = %HRmax~After rearrangement, it will be:~%HRmax = %VO2 max x 0.64 + 37 Exercise HR = %HRmax x HRmax During the experimental session, each participant performed physical exercise training on the treadmill according to Balke's Protocol. The reliability of this protocol was tested by Leddy, et. al. (2011)."
2987082|NCT02648945|Active Comparator|low intensity exercise|"low intensity exercise on a treadmill according to Balke's Protocol. low intensity of exercises for each group of 15 participants were set at 50-55% VO2 max (Schneider, S., et al., 2009). To determine the targeted HR for low and high intensity aerobic exercise for each participant, the needed VO2 max percentages were subbed into the Swain equation as follows: %VO2 max = (%HRmax - 37)/0.64 Exercise HR/HRmax = %HRmax~After rearrangement, it will be:~%HRmax = %VO2 max x 0.64 + 37 Exercise HR = %HRmax x HRmax During the experimental session, each participant performed physical exercise training on the treadmill according to Balke's Protocol. The reliability of this protocol was tested by Leddy, et. al. (2011)."
2987083|NCT02648932|Other|Haplo-Cord Search|If subject meets the inclusion criteria and consents, will undergo a haplo-cord transplant.
2987084|NCT02648932|Other|Matched Unrelated Donor Search (MUD)|If subject meets the inclusion criteria and consents, will undergo a MUD transplant.
2987085|NCT02648919|Experimental|Noni 6,000 mg/day|Noni extract 6,000 mg/day (4 capsules, 3 times per day)
2987086|NCT02648906|Experimental|Choline alfoscerate|"Drug: Choline alfoscerate and Donepezil~concomitant administration"
2987087|NCT02648906|Placebo Comparator|Placebo|Drug: Donepezil only
2987088|NCT02648893|Experimental|MBFC-Exp|The MBFC-Exp (four biofortified food crops - Experimental) arm will consume the biofortified multiple food crops basket.
2987089|NCT02648893|Active Comparator|MBFC-C|The MBFC-C (Multiple biofortified food crops - Control) arm will consume the non-biofortified (commercially available) four food crops basket.
2987090|NCT02648880|Experimental|Exercise Group|Participants will complete an exercise program in addition to standard care. Participants will start the exercise program within four weeks of their diagnosis and decision to undergo neoadjuvant treatment and continue until surgery. Participants will be encouraged to complete three sessions per week for at least eight weeks during neoadjuvant therapy. Exercise intensity, components, and time will be recorded for each exercise session. Participants will schedule their sessions with the exercise specialists administering the program, typically taking place between 8AM and 4PM, Monday through Friday.
2987091|NCT02648880|Active Comparator|Standard Care|Participants in the Standard Care group will receive no exercise intervention, but will continue to receive standard follow-ups, treatments and services from their oncology team.
2987092|NCT02648867|Experimental|Patients receiving PushCoach feedback|Patients will receive continuous maternal feedback from the PushCoach device, which includes both audio and visual feedback of fetal head movement during the second stage of labor
2987093|NCT02648867|Active Comparator|Patients blinded to PushCoach feedback|Patients will not receive continuous maternal feedback from the PushCoach device (it will be in place and collect data), but will receive normal feedback from the clinician during the second stage of labor.
2987094|NCT02648854|Other|Group 1|<Group 1> Period 1: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (Fasting condition) 7 days for wash out Period 2: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (High fat meal fed condition)
2987095|NCT02648854|Other|Group 2|<Group 2> Period 1: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (High fat meal fed condition) 7 days for wash out Period 2: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (Fasting condition)
2987096|NCT02648841|Active Comparator|Adjuvant Chemotherapy|The interventions of adjuvant chemotherapy group is 8 cycles of SOX(S-1+Oxaliplatin) chemotherapy to be given. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
2987134|NCT02648620|Experimental|SurVeil Drug Coated Balloon catheter|Paclitaxel Coated Balloon catheter for angioplasty
2987097|NCT02648841|Experimental|Adjuvant Chemo-radiotherapy|The interventions of adjuvant chemo-radiotherapy group is concurrent chemo-radiotherapy to be give after 4-6 cycles of chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral. Six cycles of SOX chemotherapy to be given. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
2987098|NCT02648828||Intern|Interns are in their first year of residency.
2987099|NCT02648828||Residents|Residents are in their 2nd or 3rd year of residency.
2987100|NCT02648828||Attendings|Attendings are physicians who have completed their residency.
2987101|NCT02648815|Active Comparator|Percutaneous catheter drainage group|Percutaneous catheter drainage (PCD) of necrotic tissue and pathological collections formed during acute pancreatitis
2987102|NCT02648815|Active Comparator|Abdominal paracentesis evacuation group|Abdominal paracentesis drainage (APD) of peritoneal fluid during acute pancreatitis
2987103|NCT02648802|Experimental|Cavity shaving and CM assessment|Standardized BCS with additional cavity shaving before CM assessment.
2987104|NCT02648802|Placebo Comparator|CM assessment|Standardized BCS with CM assessment.
2987105|NCT02648776||Estazolam|Exposure to sedative-hypnotic drugs; Patients who have taken estazolam for at least one week before the first date of enrollment
2987106|NCT02648776||Lorazepam|Exposure to sedative-hypnotic drugs; Patients who have taken lorazepam for at least one week before the first date of enrollment
2987107|NCT02648776||Diazepam|Exposure to sedative-hypnotic drugs; Patients who have taken Diazepam for at least one week before the first date of enrollment
2987108|NCT02648776||Alprazolam|Exposure to sedative-hypnotic drugs; Patients who have taken Alprazolam for at least one week before the first date of enrollment
2987109|NCT02648776||Flunitrazepam|Exposure to sedative-hypnotic drugs; Patients who have taken Flunitrazepam for at least one week before the first date of enrollment
2987110|NCT02648776||Zolpidem|Exposure to sedative-hypnotic drugs; Patients who have taken Zolpidem for at least one week before the first date of enrollment
2987111|NCT02648776||Zopiclone|Exposure to sedative-hypnotic drugs; Patients who have taken Zopiclone for at least one week before the first date of enrollment
2987112|NCT02648776||Control Group|Patients not taking any of the included or any other anxiety-hypnotic agents
2987113|NCT02648750|Experimental|Rehabilitation Assistant|Bridges stroke self-management programme. Delivered by rehabilitation assistants. Participants will receive a minimum of 4 sessions over a 4-6 week period.
2987114|NCT02648750|Active Comparator|Therapist|"Bridges stroke self-management programme. Delivered by registered stroke therapists (Occupational therapists or physiotherapists).~Participants will receive a minimum of 4 sessions over a 4-6 week period."
2987115|NCT02648737|Experimental|Cognitive Behavioural Therapy (CBT)|Patients who will receive CBT plus clinical monitoring will receive 10 weekly individual sessions (60-75 minutes), tailored to the preferences and needs of each patient. In each session, a registered psychologist will address specified aspects of (coping with) anxiety and related concerns with a specific focus on behaviour and thoughts associated with anxiety.
2987116|NCT02648737|Other|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status. Patients who receive clinical monitoring only will be given the option to receive CBT once the trial is completed.
2987117|NCT02648724|Experimental|Part 1: Dose-Escalation (Phase 1a)|Sym015 will be tested in four dose titration cohorts. A substitute or an additional dose level could potentially be evaluated.
2987118|NCT02648724|Experimental|Part 2: Basket Cohort (Phase 2a)|Patients with KRAS WT advanced solid tumor malignancies with MET-amplification will receive Sym015 at the RP2D.
2987119|NCT02648724|Experimental|Part 2: NSCLC Cohort (Phase 2a)|"Patients with KRAS WT NSCLC with METex14 mutation will receive Sym015 at the RP2D.~Note: Patients with malignancies other than NSCLC may be considered for entry to this cohort following discussion with the Sponsor's Medical Monitor(s)."
2987120|NCT02648711|Experimental|CRLX101 alone|Subjects will receive weekly infusion of CRLX101 alone. Starting dose is 12 mg/m^2 and the next dose level is 15 mg/m^2 (or 10 mg/m^2 if 12 mg/m^2 is not well tolerated. No other dose levels will be explored.
2987121|NCT02648711|Experimental|CRLX101 in combination with bevacizumab|Subjects receive weekly infusion of CRLX101 in combination with bi-weekly bevacizumab (10 mg/kg. The starting dose is 12 mg/m^2 and the next dose level is 15 mg/m^2. No other dose levels will be explored.
2987122|NCT02648711|Experimental|CRLX101 in combination with mFOLFOX6|Subjects receive weekly infusion of CRLX101 for 3 of every 4 weeks in combination with bi-weekly mFOLFOX6 (oxaliplatin 85 mg/m^2, leucovorin 400 mg/m^2 and 5FU 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous infusion). The starting dose is 12 mg/m^2 and the next dose level is 15 mg/m^2.
2987123|NCT02648698|Placebo Comparator|Experimental group|The positive patients of CD138 were randomly divided into two groups, patients in group 1 treated by antibiotic .Group 2 treated by vitamin C
2987124|NCT02648698|Placebo Comparator|Placebo group|The positive patients of CD138 were randomly divided into two groups, Patient in Group 2 treated by vitamin C
2987125|NCT02648685||normal glycaemic metabolism|100 subjects
2987126|NCT02648685||Type 2 Diabetes|300 subjects
2987127|NCT02648672|Experimental|BPN14770|A single oral dose of BPN14770.
2987128|NCT02648672|Placebo Comparator|Placebo|A single oral dose of placebo matching BPN14770
2987129|NCT02648659|Experimental|triple with clarithromycin|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Clarithromycin bid for 2 weeks
2987130|NCT02648659|Experimental|triple with metronidazole|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Metronidazole 500mg tid for 2 weeks
2987131|NCT02648659|Experimental|quadruple|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Clarithromycin 500mg bid, Metronidazole 500mg tid for 2 weeks
2987132|NCT02648646|Experimental|Single Arm - Intervention|Receives Otago Exercise Programme and Walk with Ease
2987133|NCT02648633|Experimental|Nivolumab & Valproate Following G.K.|Subjects will begin a valproate regimen prior to undergoing stereotactic radiosurgery (gamma knife) on a single lesion. Following the surgery, subjects will receive nivolumab every 2 weeks and daily valproate.
2987136|NCT02648594|Experimental|Intervention: Hook wire CT guided|"There is only one arm. When patient undergo surgery , the radiologist will place a CT-guided Hook wire in order to localize it in patient lung. The intervention consists to place a CT-guided hook wire in contact with the pulmonary nodule under local anesthesia.~Then, the thoracoscopy will be realised. Then, the surgery piece will be examined to confirm if the node is in the surgery piece"
2987137|NCT02648581|Experimental|Subcutaneous Ustekinumab|
2987138|NCT02648568|Active Comparator|Hypnosis plus relaxation|Ericksonian hypnosis, based on sensations when awakening partially during N3 ; Jacobson relaxation, based on flexion and relaxation of muscles (serves here as a control procedure)
2987139|NCT02648568|Active Comparator|Relaxation|Jacobson relaxation, based on flexion and relaxation of muscles (serves here as a control procedure)
2987140|NCT02648555|No Intervention|Standard follow-up (controls)|Given that depressive disorders may increase the risk of spontaneous abortions, antidepressants will be not discontinued. However, expectant mothers on paroxetine or sertraline, which have been reported to increase the incidence of cardiac malformations, will be switched to fluoxetine.
2987141|NCT02648555|Experimental|W+D protocol (lifestyle intervention)|Daily walking and dietary recommendations. Expectant mothers on paroxetine or sertraline will be switched to fluoxetine
2987142|NCT02648542|Active Comparator|CAS vs. tDCS|Assess the efficacy of compensatory auditory stimulation (CAS) versus transcranial direct current stimulation (tDCS)
2987143|NCT02648542|Sham Comparator|Combined CAS+tDCS vs. Sham|Assess the efficacy of combined compensatory auditory stimulation (CAS) + transcranial direct current stimulation (tDCS) versus sham stimulation
2987144|NCT02648529|Experimental|Patients with BCECTS|Patients with BCECTS on which MRI, fMRI and neuropsychological assessment will be performed
2987145|NCT02648529|Other|Healthy volunteers|Healthy volunteers on which MRI, fMRI and neuropsychological assessment will be performed
2987146|NCT02648516|Experimental|Conventional plus AAIT|Participants will receive ART plus a dose of allogenic adoptive immune transfusion (3 times of MNCs transfusions) from day 0 through the week 3 study visit.
2987147|NCT02648503|Experimental|Deep neuromuscular block|PTC=1-2
2987148|NCT02648503|Active Comparator|Moderate neuromuscular block|TOF=1-2
2987149|NCT02648490|Experimental|HLX07, in patients with solid cancers.|"Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive weekly infusion of assigned dose of HLX07. No intra-patient dose escalation is allowed.The proposed dose escalation sequence is 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg.~Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07, followed by dexamethasone 10 mg intravenous infusion for 10 minutes, and followed by diphenhydramine 30 mg intravenous infusion for 10 minutes. If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions."
2987150|NCT02648477|Experimental|Cohort 1 (pembrolizumab, doxorubicin hydrochloride)|"Patients receive pembrolizumab IV over 30 minutes on day 1 and doxorubicin hydrochloride IV on day 1. Treatment repeats every 3 weeks for 6 courses, and then continues for up to 24 months with pembrolizumab alone in the absence of disease progression or unacceptable toxicity.~Patients who stop pembrolizumab with stable disease or better may receive additional pembrolizumab therapy for up to 1 year if they progress after stopping study treatment."
2987151|NCT02648477|Experimental|Cohort 2 (pembrolizumab, anti-estrogen therapy)|"Patients receive pembrolizumab IV over 30 minutes on day 1 and an aromatase inhibitor (exemestane, anastrozole, or letrozole) PO QD on days 1-21. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity.~In both arms, patients who stop pembrolizumab with stable disease or better may receive additional pembrolizumab therapy for up to 1 year if they progress after stopping study treatment."
2987152|NCT02648464|Experimental|Hydroxychloroquine|Hydroxychloroquine 300 mg tablet by mouth daily for 6 months. Patients under the weight of 60 kg: hydroxychloroquine 300 mg tablet daily for 5 days per week for 6 months.
2987153|NCT02648464|Placebo Comparator|Placebo|Placebo tablet by mouth daily for 6 months. Patients under the weight of 60 kg: placebo tablet daily for 5 days per week for 6 months.
2987154|NCT02648451|Experimental|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES Rome for a period of 9 days
2987155|NCT02648438|Experimental|Treatment sequence 1|Treatment Period 1:AZD7594 Solution for infusion (150 μg intravenous formulation) Treatment Period 2:AZD7594 Inhalation powder (400 μg) by dry powder inhaler (DPI) Device 1 (monodose inhaler) Treatment Period 3:AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler) Treatment Period 4:AZD7594 Oral suspension (1200 μg oral formulation)
2987156|NCT02648438|Experimental|Treatment sequence 2|Treatment Period 1:AZD7594 Solution for infusion (150 μg intravenous formulation) Treatment Period 2:AZD7594 Inhalation powder (400 μg) by dry powder inhaler (DPI) Device 1 (monodose inhaler) Treatment Period 3:AZD7594 Pressurized inhalation suspension (400 μg) by pressurized metered-dose inhaler (pMDI) Treatment Period 4:AZD7594 Oral suspension (1200 μg oral formulation)
2987157|NCT02648425|Experimental|Regimen A / Amended Regimen A|"Regimen A: Cisplatin + 5-fluorouracil~Aslan001 daily in combination with:~Cisplatin 80 mg/m2 IV infusion for 1 day and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks for up to 6 cycles.~Or~Amended Regimen A: Cisplatin + 5-fluorouracil + leucovorin~Aslan001 daily in combination with:~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks for up to 6 cycles."
2987158|NCT02648425|Experimental|Regimen B|"Regimen B: Cisplatin + capecitabine~Aslan001 daily in combination with:~Cisplatin 60-80 mg/m2 IV infusion on Day 1 and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks for up to 6 cycles."
2987159|NCT02648412|Experimental|Ketamine sedation|"Procedure scheduled under ketamine sedation. Baseline pupillary diameter measurement in alert subjects. Injection of a bolus of 1 mg/kg of ketamine. Every minute, tetanic stimulations of incremental intensities (10-20-30-40-60 milliamps), during 5 seconds.~Pupillary diameter measurement before and after each stimulation. End of study period, beginning of procedure."
2987160|NCT02648399|Placebo Comparator|control group|only unilateral center lymph node dissection
2987161|NCT02648399|Experimental|experimental group|bilateral center lymph node dissection
2987162|NCT02648386|Sham Comparator|Laparoscopic surgery|Patients receive no interventions after rectal cancer treatment.
2987163|NCT02648386|Experimental|NeuroRegen scaffold transplantation|Patients receive NeuroRegen scaffold transplantation after rectal cancer treatment.
2987164|NCT02648386|Experimental|NeuroRegen scaffold/BMMCs transplantation|Patients receive autologous bone marrow mononuclear cells with NeuroRegen scaffold transplantation after rectal cancer treatment.
2987165|NCT02648386|Experimental|NeuroRegen scaffold/HUC-MSCs transplantation|Patients receive allogeneic human umbilical cord mesenchymal stem cells with NeuroRegen scaffold transplantation after rectal cancer treatment.
2987166|NCT02648373|Experimental|Education|Patients receive an educational video about low back pain based on the Consumer Reports Choosing Wisely recommendation for patients with back pain to avoid early imaging and remain as active as possible. After the video the evaluator and patient discussed key themes from the video and the patient was able to ask any questions. Previously scheduled physical therapy then began with treatment at the therapist's discretion.
2987167|NCT02648373|Active Comparator|Control|Previously scheduled physical therapy was provided with treatment at the therapist's discretion. No educational intervention was provided before beginning physical therapy
2987168|NCT02648360|Experimental|Text Messaging Intervention Arm|Participants will be enrolled in either a dietary or physical activity text messaging program. The dietary program will include nutritional education, reading nutrition labels, portion control, making lifestyle changes, finding social support, and identifying triggers. The physical activity program will provide information on the benefits of physical activity, exercise tips, and encouragement to live more active lifestyles. The programs have limited interactive capability; patients will be asked to respond to specific questions, but questions asked by the participants will be answered with an automated message asking them to contact their health care provider.
2987169|NCT02648347|Experimental|vadadustat|
2987170|NCT02648347|Active Comparator|darbepoetin alfa|
2987171|NCT02648334|Active Comparator|IN.PACT drug coated balloon|IN.PACT drug coated balloon
2987172|NCT02648334|Experimental|Lutonix drug coated balloon|Lutonix drug coated balloon
2987173|NCT02648321|Experimental|Motivational Interviewing|Motivational Interviewing
2987174|NCT02648321|Active Comparator|Health Education|Health Education
2987175|NCT02648282|Experimental|Cyclophosphamide, Pembrolizumab, GVAX, SBRT|
2987176|NCT02648269|Experimental|SEL-110|Single intravenous dose of SEL-110
2987177|NCT02648269|Experimental|SEL-212|Single intravenous dose of SEL-110 plus SEL-037 (pegsiticase)
2987178|NCT02648269|Experimental|SEL-037|Single intravenous dose of SEL-037 (pegsiticase)
2987179|NCT02648256|Experimental|Oropharyngeal rinse|"Polymerase Chain Reaction on Oropharyngeal rinse:~Dosage of Pneumocystis jiroveci will be performed on the broncho-alveolar lavage following the usual routine diagnosis.~Polymerase Chain Reaction will be performed on the broncho-alveolar lavage and the oropharyngeal rinse (not communicated to the clinician result) in the same series, in order to compare the results of the fungal quantification."
2987180|NCT02648243|No Intervention|Control|Patients will receive routine discharge instructions and medication information by the nurses and treating physicians at hospital discharge: Patients will not have any contact with the clinical pharmacists.
2987181|NCT02648243|No Intervention|Pharmacist delivered usual care at discharge|Patients will receive the usual counseling at discharge by the clinical pharmacists.
2987182|NCT02648243|Experimental|structured intervention at discharge and tailored follow up|The pharmacist will deliver a structured personalized discharge intervention in addition to 2 follow-up session (around 30 minutes each session) at 4 weeks of discharge and 8 weeks of discharge.
2987183|NCT02648230|Experimental|Pressure wire and Microcatheter|All subjects enrolled will have both an FFR done measured by a pressure wire (PW) and then again by a microcatheter (MC).
2987184|NCT02648217|Experimental|IDegAsp U100 BID|
2987185|NCT02648217|Active Comparator|BIAsp U100 BID|
2987186|NCT02648204|Experimental|Semaglutide 0.5 mg/Week|
2987187|NCT02648204|Experimental|Semaglutide 1.0 mg/Week|
2987188|NCT02648204|Active Comparator|Dulaglutide 0.75 mg/Week|
2987189|NCT02648204|Active Comparator|Dulaglutide 1.5 mg/Week|
2987190|NCT02648191|Experimental|Active stimulation|
2987191|NCT02648191|Sham Comparator|Inactive stimulation|
2987192|NCT02648178|Active Comparator|HALO G6|HALO cigalike model
2987193|NCT02648178|Active Comparator|HALO Triton|HALO tank model
2987194|NCT02648165|Experimental|ABM +|Attention Bias Modification
2987195|NCT02648165|Sham Comparator|ABM -|Sham Attention Bias Modification
2987196|NCT02648165|Experimental|ABM + and ACT|Attention Bias Modification followed by Group Acceptance and Commitment Therapy
2987197|NCT02648165|Sham Comparator|ABM - and ACT|Sham Attention Bias Modification followed by Group Acceptance and Commitment Therapy
2987198|NCT02648139|Experimental|Experimental dentifrice|Dentifrice containing the extract of Eugenia uniflora rip fruit. Each 10 ml of E. uniflora L. dentifrice comprises the following components: Hydroalcoholic extract of the ripe fruit of E. uniflora L. (3.0%), preservatives (parabens; 0.02 g), and dentifrice base (silicon dioxide, sodium lauryl sulfate, white dye, aromatic compounds, sodium saccharin, and Gangrez sodium salt; q.s.p.). Intervention protocol: three times per day (pea-like amount), for seven consecutive days.
2987199|NCT02648139|Active Comparator|Control Dentifrice|"Control dentifrice - Colgate total 12 (fluoride, 1500 ppm and triclosan, 0.3%)~Intervention protocol: three times per day (pea-like amount), for seven consecutive days."
2987200|NCT02648126|Other|Pure red cell aplasia participants|Group of participants with pure red cell aplasia and chronic kidney disease, that have resistance criteria to treatment with epoetin alfa produced by Bio-Manguinhos / Fiocruz. The Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation.
2987201|NCT02648113|Experimental|Restrictive transfusion strategy|Transfusions are withheld unless Hb is <= 8 g/dL, with a target Hb of 8 to 10 g /dL
2987202|NCT02648113|Experimental|Liberal transfusion strategy|Transfusions are allowed as soon as Hb <= 10 g/dL with a target of 11 g /dL.
2987203|NCT02648100||A|120 patients from Carte d'Identité des Tumeurs (CIT), Henri Mondor and Foch hospitals.
2987204|NCT02648100||B|510 cystectomy patients operated between 2005 and 2010 in Henri Mondor and Foch hospitals.
2987205|NCT02648100||C|188 patients treated by cystectomy and adjuvant chemotherapy for locally advanced bladder cancer from a national multicentric study.
2987206|NCT02648100||D|93 patients from the clinical trial GETUG 19 (UNICANCER)
2987207|NCT02648087|Other|With and without SDB|comparison of patients with and without sleep-disordered breathing
2987208|NCT02648074|Experimental|Allergic asthma|Bronchial asthma and sensitization to D. pteronyssinus allergen Interventions: Bronchial challenge with allergen; Eosinophil and linear bronchial smooth muscle cell co-culture formation.
2987209|NCT02648074|Active Comparator|Healthy subjects|"Healthy subjects without allergic and other chronic respiratory diseases (control group).~Interventions: Bronchial challenge with allergen; Eosinophil and linear bronchial smooth muscle cell co-culture formation."
2987210|NCT02648061||After cardiac arrest syndrome (ACAS)|adult patients after out-of-hospital cardiac arrest
2987211|NCT02648048|Experimental|Vismodegib and Pirfenidone|Participants being treated with pirfenidone, will receive vismodegib 150 milligrams (mg) once daily and pirfenidone up to 2403 mg daily orally for 24 weeks.
2987212|NCT02648035||Subcutaneous Tocilizumab|Participants receiving treatment for rheumatoid arthritis (RA) with subcutaneous Tocilizumab alone or in combination with conventional disease-modifying antirheumatic drugs (DMARDs) according to approved label.
2987213|NCT02648022|Experimental|Integrated Care|Consisted of brief mental health interventions and case management provided in a collaborative treatment environment.
2987214|NCT02648022|No Intervention|Usual Care|"The usual care group received standard of care required for HCV patients as currently performed in each clinic. All usual care patients were evaluated by their HCV Clinic treatment team, usually consisting of clinical nursing staff, the treating physician, and a clinic psychiatrist or psychologist"
2987215|NCT02648009|Other|Healthy Volunteers|"Arm 1~Group 1A: healthy male volunteers between 19 and 50 years of age.~Group 1B: healthy female volunteers between 19 and 50 years of age.~Group 1C: healthy male or female volunteers between 19 and 50 years of age, with the MRI scan performed twice~Group 1D: healthy male volunteers between 19 and 50 years of age.~Group 1E: healthy female volunteers between 19 and 50 years of age.~Group 1F: healthy male or female volunteers between 19 and 50 years of age, with the MRI scan performed twice"
2987216|NCT02648009|Other|Hypertension Hypertrophy Volunteers|"Arm 2~Group 2A: patients aged 30 to 75 with hypertension and hypertrophy~Group 2B: patients aged 30 to 75 with non-obstructive hypertrophic cardiomyopathy (HCM).~Group 2C: stable outpatients with NYHA class 1-3 heart failure who have evidence of elevated LV mass (LVH).~Group 2D: stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents.~Group 2E: patients aged 30 to 75 with hypertrophy~Group 2F: patients aged 30 to 75 with hypertrophic cardiomyopathy (HCM).~Group 2G: stable outpatients with NYHA class 1-3 heart failure who have evidence of elevated LV mass (LVH).~Group 2H: stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents."
2987217|NCT02647996||Conscious patients|"group: TBI patients awoken from comatose state with normal level of consciousness.~intervention: fMRI (resting state) and structural (DTI)"
2987218|NCT02647996||DOC patients|"group: TBI patients awoken from comatose state with abnormal level of consciousness~intervention: fMRI (resting state) and structural (DTI)"
2987219|NCT02647983|Experimental|Hyperpolarized Pyruvate (13C) Injection|Hyperpolarized Pyruvate (13C) Injection to be used a MRI contrast agent.
2987220|NCT02647970|Experimental|Group A|Dietary intervention
2987221|NCT02647970|Active Comparator|Group B|Dietary intervention
2987222|NCT02647957|Experimental|Group A|Hospital using Code Stroke
2987223|NCT02647957|No Intervention|Group B|Hospital not using Code Stroke
2987224|NCT02647944|Active Comparator|Liraglutide|Saxenda initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
2987225|NCT02647944|Placebo Comparator|Placebo|Placebo initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
2987226|NCT02647931|Experimental|Voice Therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia patients.
2987227|NCT02647918|Experimental|Group 1|Subjects with normal renal function
2987228|NCT02647918|Experimental|Group 2|Subjects with mild renal impairment
2987229|NCT02647918|Experimental|Group 3|Subjects with moderate renal impairment
2987230|NCT02647918|Experimental|Group 4|Subjects with severe renal impairment
2987231|NCT02647918|Experimental|Group 5|Subjects with ESRD requiring HD
2987232|NCT02647905|Experimental|Accuracy assessment, CGMS|To determine accuracy of the Senseonics Continuous Glucose Monitoring System measurements through approximately 90 days post-insertion. Manipulation of glucose levels during multiple clinic days
2987233|NCT02647892|Active Comparator|Arm A|10 mg/mL lidocaine; Frequency: 1
2987234|NCT02647892|Active Comparator|Arm B|9 mg/mL of 10% sodium bicarbonate-90% lidocaine; Frequency: 1
2987235|NCT02647892|Active Comparator|Arm C|7.5 mg/Ml of 25% sodium bicarbonate-75% lidocaine Frequency: 1
2987236|NCT02647892|Active Comparator|Arm D|5 mg/mL 50% sodium bicarbonate-50% lidocaine Frequency: 1
2987237|NCT02647879||Hepatitis C infected|All patients diagnosed with hepatitis C in Iceland
2987238|NCT02647866|Experimental|KHK4083|Subjects who qualify will receive IV infusion treatments of KHK4083 from Baseline to Week 48.
2987239|NCT02647866|Placebo Comparator|Placebo|Subjects will receive placebo IV infusion treatments from Baseline to Week 48.
2987240|NCT02647853|Experimental|TAT4 Gel concentration A|TAT4 Gel concentration A applied once daily to 50 cm2 for 14 days.
2987241|NCT02647853|Experimental|TAT4 Gel concentration B|TAT4 Gel concentration B applied once daily to 50 cm2 for 14 days.
2987242|NCT02647853|Placebo Comparator|Placebo|Placebo product once daily to 50 cm2 for 14 days.
2987243|NCT02647840|Other|Voice therapy|All participants will receive voice therapy based on the Estill model. This is very similar to our usual intervention.
2987244|NCT02647827|Active Comparator|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization.
2987245|NCT02647827|Active Comparator|Acupuncture + lifestyle management|Three treatment per week (4 weeks) and thereafter 2 times per week during 12 weeks.
2987246|NCT02647827|Active Comparator|Metformin + lifestyle management|Oral metformin 500 mg three times daily, in total 1500 mg per day.
2987247|NCT02647814|Experimental|Salud al Día|The participants in the intervention group will receive interactive text-messages with a link to support if needed for: clinic appointment reminders, follow-up on medicine and referral adherence, and illness care needs and use. Participants will additionally receive reminders for insurance renewal, food stamp applications, and health-promoting community events. Participants in this arm will complete a baseline survey when their infant is ≤ 2 months of age, a mid-point survey at 7-9 months, and a follow-up survey at by age 15 months.
2987248|NCT02647814|No Intervention|Usual Care|The participants in the usual care group will receive the clinic's usual care in terms of receiving no text messages. Participants in this arm will complete a baseline survey when their infant is ≤ 2 months of age, a mid-point survey at 7-9 months, and a follow-up survey at by age 15 months.
2987249|NCT02647801|Experimental|Mindfulness intervention|The experimental group comes to weekly laboratory meetings and practices mindfulness. Participants also fill out self-report questionnaires which assess self-control and mindfulness.
2987250|NCT02647801|No Intervention|Control group|The control group comes to weekly laboratory meetings and fills out self-report questionnaires which assess self-control and mindfulness. No mindfulness training is carried out.
2987251|NCT02647788|Active Comparator|Acetaminophen/Ibuprofen|Group 1: Acetaminophen 650 mg; Ibuprofen 400 mg
2987252|NCT02647788|Active Comparator|Acetaminophen/Codeine|Group 2: Acetaminophen 300mg, Codeine 30 mg
2987253|NCT02647775|Other|multi-port VATS|Multi-port VATS is an operative method
2987254|NCT02647775|Other|single-port VATS|Single-port VATS is an operative method
2987255|NCT02647762|Experimental|CF101 1mg|CF101 1mg, orally q12 hours
2987256|NCT02647762|Experimental|CF101 2mg|CF101 2mg, orally q12 hours
2987257|NCT02647762|Active Comparator|MTX once weekly|MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter.
2987258|NCT02647762|Placebo Comparator|Placebo|Placebo control , orally q12 hours
2987259|NCT02647749|Experimental|Group 1 : Cardiac rythm radiofrequency ablation|Prospective recruitment
2987260|NCT02647749|Experimental|Group 1: Implantation or programming of a pacemaker|Prospective recruitment
2987261|NCT02647749|Experimental|Group 1: Risk of serious arrhythmias or sudden death|Prospective recruitment
2987262|NCT02647749|Active Comparator|Group 2: Cardiac rythm radiofrequency ablation|Retrospective recruitment
2987263|NCT02647749|Active Comparator|Group 2 : Implantation or programming of a pacemaker|Retrospective recruitment
2987264|NCT02647749|Active Comparator|Group 2 : Risk of serious arrhythmias or sudden death|Retrospective recruitment
2987265|NCT02647736|Experimental|Copeptin values in normo- to hyperosmolar states|
2987266|NCT02647723|Experimental|Oral supplement for pregnant women|450 mg/daily of DHA beginning at 10-16 weeks of gestation through the end of pregnancy
2987267|NCT02647723|Placebo Comparator|Sugar pill|450 mg/daily of sugar pill beginning at 10-16 weeks of gestation through the end of pregnancy
2987268|NCT02647710|Experimental|PHAT Life Intervention|PHAT Life: Preventing HIV/AIDS Among Teens, is a uniquely-tailored intervention designed for recently-arrested juvenile offenders on probation. The program will teach teens about HIV/AIDS, sexually transmitted infections, and safer decision-making. PHAT Life draws on social learning theory and a Social-Personal Framework to address individual and social mechanisms related to HIV-risk, including emotion regulation, peer norms, partner communication, relationship characteristics, and HIV/AIDS/STI and substance use knowledge, attitudes, and beliefs.
2987269|NCT02647710|Active Comparator|Health Promotion Control|A health promotion program focusing on nutrition, physical activity, substance use, and sexual health.
2987270|NCT02647697|Experimental|Radiprodil|Subjects will receive a single dose of Radiprodil 30 mg in suspension form, orally via a syringe in the morning of Day 1.
2987271|NCT02647684|Experimental|Self- Direced Triple P|Self-directed Triple P workbook to be completed over 10 weeks. Over the course of the workbook parents will think about the changes they would like to make to their child's behaviour. They are taught strategies to enhance their relationship with their child, and promote desirable behaviours. They learn about options for managing problem behaviours and have the opportunity to decide if they would like to use any of these approaches with their child in a clear and consistent way. Parents have practice period to use the approaches they have learnt in weeks 1-3. By the end of week 6 they will have had practice in using their chosen positive parenting approaches, learnt to set goals and monitor their own behaviour when using these strategies. The final weeks aim to help parents identify times when the strategies may not be working and provide survival tips on what to do at these times.
2987272|NCT02647671|Experimental|Aquamin®|Experimental: Aquamin® (4 capsules per day) - 4 capsules; 2 to be taken in the morning and 2 in the evening
2987273|NCT02647671|Active Comparator|Calcium Carbonate|Active Comparator: Calcium Carbonate (4 capsules per day) - 4 capsules; 2 to be taken in the morning and 2 in the evening
2987274|NCT02647671|Placebo Comparator|Placebo|Placebo (Maltodextrin) - 4 capsules; 2 to be taken in the morning and 2 in the evening
2987275|NCT02647658|Experimental|GBC+PIPT|Guideline Based Care plus Psychologically Informed Physical Therapy
2987276|NCT02647658|Active Comparator|GBC|Guideline Based Care
2987277|NCT02647645|Active Comparator|Cognitive Training|Cognitive training Sham tDCS
2987278|NCT02647645|Experimental|Cognitive Training with tDCS|Cognitive training Active tDCS
2987279|NCT02647632|Experimental|16 weeks of treatment|Drug : Grazoprevir/Elbasvir + Sofosbuvir + Ribavirin during 16 weeks
2987280|NCT02647632|Experimental|24 weeks of treatment|Drug : Grazoprevir/Elbasvir + Sofosbuvir + Ribavirin during 24 weeks
2987281|NCT02647619|Active Comparator|Needle aponeurotomy|percutaneous transection or pretendinous palmar dupytren cord
2987282|NCT02647619|Active Comparator|Xiapex|Injection of 0.58 mg collagenase into pretendinous palmar dupytren cord
2987283|NCT02647606|Experimental|McGrath Group|MgGrath videolaryngoscope will be used for nasotracheal intubation with MILS
2987284|NCT02647606|Experimental|Pentax-AWS Group|Pentax-AWS videolaryngoscope will be used for nasotracheal intubation with MILS
2987285|NCT02647606|Experimental|Macintosh Laryngoscope Group|Macintosh Laryngoscope will be used for nasotracheal intubation with MILS
2987286|NCT02647593||gallstone hepatitis group,|gallstone hepatitis group (Among patients diagnosed as CBD stone who displayed above 400 IU/L of aminotransferase without cholangitis),
2987287|NCT02647593||control group|control group (Among patients diagnosed as CBD stone who showed the normal value of aminotransferase)
2987288|NCT02647567|Experimental|Caffeine Intake|The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
2987289|NCT02647567|Placebo Comparator|Placebo Intake|The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
2987290|NCT02647554|Experimental|Ulinastatin group|Ulinastain treatment group：400,000 IU ulinastatin will be reconstituted in 10 mL of 0.9% normal saline, and then dissolved in 100 mL of 0.9% normal saline every 8 hours for 10 days in a double-blind fashion.
2987291|NCT02647554|Placebo Comparator|Placebo group|Placebo control group：Matching with medication
2987292|NCT02647541|Experimental|Nutritional intervention|Consultation with a dietitian, including nutritional recommendations and supplementation.
2987293|NCT02647541|No Intervention|Standard therapy|No specific nutritional recommendations.
2987294|NCT02647528|Experimental|Treatment|Patients in this arm receive treatment
2987295|NCT02647528|Placebo Comparator|Placebo|Patients in this arm do not receive treatment
2987296|NCT02647515|Experimental|ranibizumab|
2987297|NCT02647502|Active Comparator|Continuous calorie restriction|Participants will be provided with a diet that includes approximately 78% of calories each day that would be needed to maintain current BMI.
2987298|NCT02647502|Experimental|Intermittent calorie restriction|Participants will be provided a diet that with a daily calorie intake required to maintain current BMI, except only 25% of this calorie intake will be provided for 2 days a week.
2987299|NCT02647502|Placebo Comparator|Control calorie intake|Participants will be assigned to consume enough calories each day required to maintain current BMI
2987300|NCT02647489|Experimental|1A - 20 µg PAMVAC + Alhydrogel|The study participant will get 20 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
2987301|NCT02647489|Experimental|2A - 20 µg PAMVAC + GLA-SE|The study participant will get 20 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
2987302|NCT02647489|Experimental|3A - 20 µg PAMVAC + GLA-LSQ|The study participant will get 20 µg of PAMVAC adjuvanted with GLA-LSQ administrated three times with each time 28 days interval (day 0-28-56)
2987303|NCT02647489|Experimental|4A - 50 µg PAMVAC + Alhydrogel|The study participant will get 50 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
2987304|NCT02647489|Experimental|5A - 50 µg PAMVAC + GLA-SE|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
2987305|NCT02647489|Experimental|6A - 50 µg PAMVAC + GLA-LSQ|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-LSQ administrated three times with each time 28 days interval (day 0-28-56)
2987306|NCT02647489|Experimental|1B - 50 µg PAMVAC + Alhydrogel|The study participant will get 50 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
2987307|NCT02647489|Experimental|2B - 50 µg PAMVAC + GLA-SE|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
2987308|NCT02647489|Experimental|3B - 100 µg PAMVAC + Alhydrogel|The study participant will get 100 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
2987309|NCT02647489|Experimental|4B - 100 µg PAMVAC + GLA-SE|The study participant will get 100 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
2987310|NCT02647489|Placebo Comparator|5B - Placebo|The study participant will get Placebo (physiological saline solution) administrated three times with each time 28 days interval (day 0-28-56)
2987311|NCT02647476|Experimental|Study group|Immunomodulating nutrition (Reconvan)
2987312|NCT02647476|Active Comparator|Control group|Standard nutrition (Peptisorb)
2987313|NCT02647463|Experimental|Attachment and Biobehavioral Catch-up|10-session intervention for parents and infants aimed at increasing parents' nurturance and following the lead, and reducing frightening behavior
2987314|NCT02647463|No Intervention|Waitlist Control|Waitlist Control
2987315|NCT02647450||GIANT Clinic Group|Patients are required to have been refereed to the GI and Nutrition team Clinic at the Royal Marsden Hospital. In the clinic they will be assessed for their symptoms using the Gastrointestinal Symptom Rating Scale (GSRS).
2987316|NCT02647437|Experimental|Levetiracetam, Then Placebo|2 weeks of levetiracetam administration (125 mg pill, bid), followed by a 1-2 week washout, then 2 weeks of placebo pill administration (bid).
2987317|NCT02647437|Experimental|Placebo, Then Levetiracetam|2 weeks of placebo pill administration (bid), followed by a 1-2 week washout, then 2 weeks of levetiracetam administration (125 mg pill, bid).
2987318|NCT02647424|Other|PCOS group|PCOS women with anovulation
2987319|NCT02647424|Other|Ovulatory group|Ovulatory group planned for intra-uterine insemination
2987320|NCT02647411||Projeto Boa Visão|Review of records between 1995 and 2000, in totality of 16.806 patients between 2 and 40 years old
2987321|NCT02647411||Projeto Olhar Brasil|Review of records between March and September 2014, in totality of 163 patients between 6 and 18 years old
2987322|NCT02647398|Experimental|A: Supervised combined training|INTERVENTION: Two supervised 75 min-vigorous aerobic training & strength training
2987323|NCT02647398|Active Comparator|B: Supervised strength training|ACTIVE COMPARATOR: Two supervised 45-minute sessions of strength training & Participants will be advised to comply with international recommendations of physical activity (150 min pf MVPA)
2987324|NCT02647385|Experimental|General Anesthesia|Interventions: include pain assessment, inflammatory response and opioid consumption.
2987362|NCT02647177||Pancreatic Cyst Group|Only the eligible participant in the study are considered for inclusion in this group.
2987325|NCT02647385|Experimental|General Anesthesia SAM and PEC I block|Interventions: include pain assessment, inflammatory response and opioid consumption.
2987326|NCT02647372|Experimental|Endocrinological approach|Parkinson patient submitted to DBS surgery target to globus pallidus nucleus or the subthalamic nucleus. Those patients will be endocrinological evaluation including metabolic measures, calorimetric parameters.
2987327|NCT02647372|Experimental|Neurological approach|Parkinson patient submitted to DBS surgery target to globus pallidus nucleus or the subthalamic nucleus. Those patients will be neurological evaluation including UPDRS scale.
2987328|NCT02647359|Experimental|Ataluren|Ataluren taken orally at a dose of 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening.
2987329|NCT02647359|Placebo Comparator|Placebo|Matching placebo taken orally in the morning, at midday, and in the evening.
2987330|NCT02647333|Experimental|Omega-3 fatty acid|Omega-3 fatty acids for 8 weeks, dosage are 3 and 4 g/day for women and men, respectively.
2987331|NCT02647333|Experimental|Omega-6 fatty acid|Omega-6 fatty acids for 8 weeks, dosage are 20 and 27 g/day for women and men, respectively.
2987332|NCT02647320|Experimental|DS-8500a 25mg|One DS-8500a 25 mg tablet, 2 placebo tablets, and one placebo capsule in a once-daily oral dose
2987333|NCT02647320|Experimental|DS-8500a 50 mg|Two DS-8500a 25 mg tablets, 1 placebo tablet, and one placebo capsule in a once-daily oral dose
2987334|NCT02647320|Experimental|DS-8500a 75 mg|Three DS-8500a 25 mg tablets and one placebo capsule in a once-daily oral dose
2987335|NCT02647320|Placebo Comparator|Placebo|Three placebo tablets and one placebo capsule in a once-daily oral dose
2987336|NCT02647320|Active Comparator|Sitagliptin 100 mg|Three placebo tablets and one sitagliptin 100 mg over-capsule in a once-daily oral dose
2987337|NCT02647307|Experimental|DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg).
2987338|NCT02647294|Experimental|Polyunsaturated omega-3 fatty acids|Patients will receive n-3 fatty acids (Maxicor) 3,6 g/day.
2987339|NCT02647294|Placebo Comparator|Placebo|Patients will receive placebo (soya oil)
2987340|NCT02647281|Experimental|Part 1: GSK3389404 10 mg|Subjects will receive a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.
2987341|NCT02647281|Placebo Comparator|Part 1: Placebo|Subjects will receive a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.
2987342|NCT02647281|Experimental|Part 1: GSK3389404 30 mg|Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.
2987343|NCT02647281|Experimental|Part 1: GSK3389404 60 mg|Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.
2987344|NCT02647281|Experimental|Part 1: GSK3389404 120 mg|Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.
2987345|NCT02647281|Experimental|Part 2: GSK3389404 30 mg|Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.
2987346|NCT02647281|Placebo Comparator|Part 2: Placebo|Subjects will receive a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.
2987347|NCT02647281|Experimental|Part 2: GSK3389404 60 mg|Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.
2987348|NCT02647281|Experimental|Part 2: GSK3389404 120 mg|Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.
2987349|NCT02647268|No Intervention|Control (no oxytocin) pretreatment|The myometrial samples are bathed in physiological saline solution (PSS).
2987350|NCT02647268|Active Comparator|Magnesium Sulphate|The myometrial samples are bathed in a 3.5mM magnesium sulphate solution.
2987351|NCT02647268|Active Comparator|Magnesium Sulphate + oxytocin|The myometrial samples are bathed in a 3.5mM magnesium sulphate plus 10-5M oxytocin solution.
2987352|NCT02647255|Experimental|PE and methylprednisolone pulse|Plasma exchange(PE) and methylprednisolone pulse therapy: plasma exchange >7 within 3ws, Volume: 60ml/kg/course; Replacement fluid: 5% albumin or fresh frozen plasma and methylprednisolone pulse therapy Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.
2987353|NCT02647255|Active Comparator|Methylprednisolone pulse|Methylprednisolone pulse alone: methylprednisolone 7-15mg/kg/d 3 times on consecutive or alternate days Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.
2987354|NCT02647242|Experimental|Patients with parkinson's disease|
2987355|NCT02647229|Active Comparator|Isosmotic bowel cleansing preparation|Isosmotic solution ingested prior to colonoscopy
2987356|NCT02647229|Active Comparator|Colonic Hyrdrotherapy|Colonic hydrotherapy is an FDA approved method of colon cleansing using constant warm water lavage with a contained temperature and pressure controlled device administered by a trained technician.2 There
2987357|NCT02647216|Active Comparator|Mindfulness Based Cognitive Therapy (MBCT)|MBCT is a structured 8-week group intervention which integrates aspects of cognitive behavioral therapy (CBT) with components of the Mindfulness Based Stress Reduction (MBSR) program.
2987358|NCT02647216|Active Comparator|Treatment as Usual (TAU)|Subjects randomized to TAU will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study (for the TAU group) and outside of the study (for the MBCT group) will be assessed at the 3-month follow up (Visit 3).
2987359|NCT02647203|Experimental|High Fluoride Toothpaste|5,000 ppm fluoridated toothpaste, high concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
2987360|NCT02647203|Active Comparator|Standard Fluoride Toothpaste|1,450 ppm fluoridated toothpaste, low concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
2987361|NCT02647190|Experimental|Erwinia Chrysanthemi asparaginase|This is a phase I trial designed to assess the safety of IV Erwinia Chrysanthemi asparaginase during initial induction in patients aged 60 years or older with newly diagnosed Ph-negative ALL. A total of 12 patients will be accrued to the study.
2987363|NCT02647151|Active Comparator|METHYLAMINOLEVULINATE HYDROCHLORIDE|METHYLAMINOLEVULINATE HYDROCHLORIDE (MAL)cream 160mg/g. Intervention: Just one application of the product in the actinic keratosis lesions before the photodynamic therapy
2987364|NCT02647151|Experimental|AMINOLEVULINIC ACID HYDROCHLORIDE|AMINOLEVULINIC ACID HYDROCHLORIDE (ALA) gel 78mg/g. Intervention: Just one application of the product in the actinic keratosis lesions before the photodynamic therapy
2987365|NCT02647138|Experimental|Marpac White Noise|Subject will have white noise machine placed in room.
2987366|NCT02647125|Experimental|Huachansu Arm|Patients in this arm will receive a treatment of Huachansu combined with thoracic radiotherapy.
2987367|NCT02647125|Active Comparator|Control Arm|Patients in this arm will receive thoracic radiotherapy alone.
2987368|NCT02647112|Experimental|Bladder EpiCheck|Urine sample will be tested with the Bladder EpiCheck in conjunction with cystoscopy and cytology
2987369|NCT02647112|No Intervention|Practice of medicine|Practice of medicine including cystoscopy and cytology
2987370|NCT02647099|Active Comparator|Aspirin|One tablet acetylsalicylic acid (ASA) 160 mg, orally once daily for three years
2987371|NCT02647099|Placebo Comparator|Placebo|One tablet placebo orally once daily for three years
2987372|NCT02647086|Experimental|Period 1|Patients will receive selected Cytochrome P450 substrates (Midazolam, Omeprazole, Warfarin, Caffeine, Metoprololin) in period 1 (day 1)
2987373|NCT02647086|Experimental|Period 2|Patients will receive dupilumab starting in Period 2 (day 8) and continue weekly through day 50; Patients will receive selected Cytochrome P450 substrates (Midazolam, Omeprazole, Warfarin, Caffeine, Metoprolol) in period 2 (at day 36).
2987374|NCT02647073|Experimental|Mobile monitoring device arm|Canary 01 Mobile Vital Signs Monitoring Device
2987375|NCT02647060||idiopathic pulmonary hypertension|"diagnose as idiopathic pulmonary arterial hypertension~clinical stable over 3 months~able to walk and can do bicycle cardiopulmonary exercise testing"
2987376|NCT02647060||secondary pulmonary hypertension|"diagnose as pulmonary hypertension~clinical stable over 3 months~able to walk and can do bicycle cardiopulmonary exercise testing"
2987377|NCT02647047|Experimental|Spinal|Patients will receive spinal analgesia (morphine 0.2 mg) before general anesthesia for minor laparotomic liver resection.
2987378|NCT02647047|Active Comparator|Epidural|Patients will receive epidural analgesia (bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL + sufentanil 50 mcg/mL 1 mL) before general anesthesia for minor laparotomic liver resection.
2987379|NCT02647034||pulmonary hypertension|The two groups were defined by catheterization result. (no intervention)
2987380|NCT02647034||non-pulmonary hypertension|The two groups were defined by catheterization result. (no intervention)
2987381|NCT02647021|Active Comparator|Therapeutic Exercise|"Therapeutic Exercise Program (standard care) will include:~Neck range of motion and strengthening, and posture retraining.~Shoulder specific progressive resistance exercise program that focuses on spinal accessory nerve dysfunction and rehabilitation of trapezius muscle function."
2987382|NCT02647021|Experimental|Therapeutic + Lower Body Exercise|"The Therapeutic Exercise Program (standard care) will include:~Neck range of motion and strengthening, and posture retraining.~Shoulder specific progressive resistance exercise program that focuses on spinal accessory nerve dysfunction and rehabilitation of trapezius muscle function.~The Resistance Exercise component will target 6-8 muscle groups of the lower extremities and core including gluteal, quadriceps, hamstrings, abdominals, and gastrocnemius muscles. A progressive introduction of exercises will occur over the first 3 weeks.~a personalized program of lower extremity resistance exercises~core strengthening exercises"
2987383|NCT02647008|Experimental|ACTIVE TENS|ACTIVE TENS
2987384|NCT02647008|Placebo Comparator|PLACEBO|INACTIVE TENS
2987385|NCT02647008|No Intervention|CONTROL|NO TENS
2987386|NCT02646995|Experimental|Active|modified lipid formulation
2987387|NCT02646995|Active Comparator|Control|fish oil
2987388|NCT02646982|Experimental|Candesartan|Candesartan will be given orally once a day in a stepwise manner as follows: All participants will be initiated on 8 mg candesartan. The dose will be increased in 2 week increments to 16 mg and 32 mg as long as the systolic blood pressure (SBP) >110 mm Hg, diastolic blood pressure (DBP) >40 mm Hg and participant reports no symptoms of hypotension (dizziness or weakness). The highest achievable dose will be the Maximal Tolerated Dose (MTD) and the participant will receive this dose for the remaining duration of the study (participants will be treated for 1 year).
2987389|NCT02646982|Placebo Comparator|Placebo|Participants will receive a matched placebo once a day orally for 12 months.
2987390|NCT02646969|Active Comparator|Formula regimen 1|"Product Control from enrollment to transition phase 1 (blinded administration), followed by open label administration for 2 months.~Product Test 2 from transition phase 2 to 1 year old (open label) Commercial follow up formula from 1 year old"
2987391|NCT02646969|Active Comparator|Formula regimen 2|Product Test 1 from enrollment to transition phase 1 (blinded administration) Product Control for 2 months(open label) Product Test 2 from transition phase 2 to 1 year old (open label) Commercial follow up formula from 1 year old
2987392|NCT02646969|No Intervention|Reference group|Infants fed HM exclusively through at least 4 months of age. Once breastfeeding is over and if wished Infant will receive Product test 2 until 1 year old followed by the commercial follow-up formula
2987393|NCT02646956||Age Group-Children|Children between ages of 7 and 14
2987394|NCT02646956||Age Group-Adults|Healthy adults who are the parent of the children
2987395|NCT02646943||Cohort of patients with chronic chagas cardiomyopathy|"We have established a prospective cohort of 1,959 patients with chronic Chagas cardiomyopathy (CCC) to evaluate if a clinical prediction rule based on electrocardiogram (ECG), Brain Natriuretic Peptide (BNP) levels and other biomarkers can be useful in clinical practice.~The study is being conducted in 21 cities of the northern part of Minas Gerais state in Brazil, and includes a follow up of at least two years. The baseline evaluation included collection of socio-demographic information, social determinants of health, health-related behaviours, comorbidities, medicines in use, history of previous treatment for Chagas Disease (ChD), symptoms, functional class, quality of life, blood sample collection and ECG."
2987396|NCT02646930|Experimental|Incidence of CE|To determine rates of CE in women undergoing initial IVF and outcomes
2987397|NCT02646917|Experimental|SkinPenTreatment|3 SkinPen treatments to each patient, each one month apart.
2987398|NCT02646904|Experimental|Beclometasone Dipropionate (BDP)|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of Nasal Beclomethasone Dipropionate for 21 days.
2987399|NCT02646904|Active Comparator|CERCHIO 10 mg/ml OS|For Children < 12 years old 10 drops die (5 mg die) for 21 days. For Children > 12 years old 20 drops die (10 mg die) for 21 days.
2987400|NCT02646891|Experimental|A1 - Adult TV P2VP8 30 mcg|Group A 1 - Adults receiving low dose Trivalent P2VP8 (30 mcg)
2987401|NCT02646891|Placebo Comparator|A1 - Adult Placebo (30mcg)|Group A 1 - Adults receiving Placebo (for low dose 30 mcg group)
2987402|NCT02646891|Experimental|A2 - Adult TV P2VP8 90 mcg|Group A2 - Adults receiving higher dose Trivalent P2VP8 (90 mcg)
2987403|NCT02646891|Placebo Comparator|A2 - Adult Placebo (90 mcg)|Group A2 - Adults receiving Placebo (for higher dose 90 mcg group)
2987404|NCT02646891|Experimental|B1 - Toddler TV P2VP8 30 mcg|Group B1 - Toddlers receiving low dose Trivalent P2VP8 (30 mcg)
2987405|NCT02646891|Placebo Comparator|B1 - Toddler Placebo (30mcg)|Group B1 - Toddlers receiving Placebo (for low dose 30 mcg group)
2987406|NCT02646891|Experimental|B2 - Toddler TV P2VP8 90 mcg|Group B2 - Toddlers receiving low dose Trivalent P2VP8 (90 mcg)
2987407|NCT02646891|Placebo Comparator|B2 - Toddler Placebo (180mcg)|Group B2 - Toddlers receiving Placebo (for low dose 90 mcg group)
2987408|NCT02646891|Experimental|C1 - Infant TV P2VP8 15 mcg|Group C1 - Infants receiving Trivalent P2VP8 (15 mcg)
2987409|NCT02646891|Placebo Comparator|C1 - Infant Placebo (15 mcg)|Group C1 - Infants receiving Placebo (for 15 mcg group)
2987410|NCT02646891|Experimental|C2 - Infant TV P2VP8 30 mcg|Group C2 - Infants receivingTrivalent P2VP8 (30 mcg)
2987411|NCT02646891|Placebo Comparator|C2 - Infant Placebo (30mcg)|Group C2 - Infants receiving Placebo (for 30 mcg group)
2987412|NCT02646891|Experimental|C3 - Infant TV P2VP8 90 mcg|Group C3 - Infants receiving Trivalent P2VP8 (90 mcg)
2987413|NCT02646891|Placebo Comparator|C3 - Infant Placebo (90 mcg)|Group C3 - Infants receiving Placebo (for 90 mcg)
2987414|NCT02646891|Experimental|D - Infant TV P2VP8 15 mcg|Group D - Expanded group of infants receiving Trivalent P2VP8 (15 mcg)
2987415|NCT02646891|Experimental|D - Infant TV P2VP8 30 mcg|Group D - Expanded group of infants receiving Trivalent P2VP8 (30 mcg)
2987416|NCT02646891|Experimental|D - Infant TV P2VP8 90 mcg|Group D - Expanded group of infants receiving Trivalent P2VP8 (90 mcg)
2987417|NCT02646891|Placebo Comparator|D - Infant Placebo|Group D - Expanded group of infants receiving Placebo ( for 15 mcg, 30 mcg and 90 mcg groups)
2987418|NCT02646878|Other|Harmony 1 Sensor Group A|Subjects wearing Harmony 1 Sensor will be assigned this group which will participate in the in-clinic YSI frequent sample testing 90 minutes after sensor insertion.
2987419|NCT02646878|Other|Harmony 1 Sensor Group B|Subjects wearing Harmony 1 Sensor will be assigned this group which will participate in the in-clinic YSI frequent sample testing 12 hours after sensor insertion.
2987420|NCT02646865|Experimental|Self-Compassion Enhanced Cognitive-Behavioral Therapy|Group Cognitive-Behavioral Therapy for social anxiety enhanced with exercises targeting self-compassion
2987421|NCT02646865|Active Comparator|Cognitive-Behavioral Therapy|Standard Group Cognitive-Behavioral Therapy for social anxiety
2987422|NCT02646852|Experimental|DFP-13318|"Stage 1: intravenous infusion once every 3 weeks~Stage 2: intravenous infusion once every 4 weeks"
2987423|NCT02646839|Experimental|KIR Favorable Transplant|To assess in a multi-center setting whether the disease-free survival (DFS) at one-year post-HCT for children with high-risk ALL, AML and MDS can be improved following favorably KIR-mismatched haplo-HCT using a graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells from CliniMacs TCR alpha-beta-Biotin system
2987424|NCT02646826|Placebo Comparator|Placebo|Subjects are treated with placebo tablets.
2987425|NCT02646826|Experimental|Paxerol - Dose Level 1|Subjects are treated with the first dose level of Paxerol.
2987426|NCT02646826|Experimental|Paxerol - Dose Level 2|Subjects are treated with the second dose level of Paxerol.
2987427|NCT02646826|Experimental|Paxerol - Dose Level 3|Subjects are treated with the third dose level of Paxerol.
2987428|NCT02646813|Active Comparator|Intraluminal Placement|These patients will have the Arndt endobronchial blocker placed within the endotracheal tube for lung isolation during their thoracic surgery. The observer will measure time required to place blocker correctly prior to surgery.
2987429|NCT02646813|Experimental|Extraluminal Placement|These patients will have the Arndt endobronchial blocker placed outside of the endotracheal tube for lung isolation during their thoracic surgery. The investigator will measure the time required for placement.
2987430|NCT02646800|Experimental|Micafungin group|
2987431|NCT02646787|Experimental|Active Virtual Reality|The subject is actively engaged in using virtual reality during a painful burn wound care session.
2987432|NCT02646787|Experimental|Passive Virtual Reality|The subject is passively engaged in using virtual reality during a painful burn wound care session.
2987433|NCT02646787|No Intervention|Control|No intervention during the subject's standard wound care session
2987434|NCT02646774|Experimental|Micafungin group|Injection
2987435|NCT02646761|Experimental|Rehabilitation with InterACTION|After total knee arthroplasty, subjects will undergo physical therapy 1 time per week supplemented by home exercise program with InterACTION device.
2987436|NCT02646761|Other|Standard Physical Therapy|After total knee arthroplasty, subjects will undergo standard of care physical therapy 2 times per week with standard home exercise program.
2987437|NCT02646748|Experimental|pembrolizumab + itacitinib|"Part 1a Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.~Part 1b Group A-1 and Group A-2 will evaluate the MTD or PAD of itacitinib in combination with pembrolizumab in subjects with select solid tumors."
2987438|NCT02646748|Experimental|pembrolizumab + INCB050465|"Part 1a Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.~Part 1b Group B-1 and Group B-2 will evaluate the MTD or PAD of INCB050465 in combination with pembrolizumab in subjects with select solid tumors.~Part 2 will evaluate the combination of INCB050465 in combination with pembrolizumab in subjects with small cell lung cancer, non-small lung cancer and urothelial cancer."
2987439|NCT02646735|Experimental|Fulvestrant|Fulvestrant 500 mg
2987440|NCT02646735|Active Comparator|Exemestane|Exemestane 25mg
2987441|NCT02646722||No pain|patients show no pain on rocuronium injection
2987442|NCT02646722||mild pain|patients move a hand only on rocuronium injection
2987443|NCT02646722||moderate pain|patients move a arm on rocuronium injection
2987444|NCT02646722||severe pain|patients show generalized movement because of pain
2987445|NCT02646709|Experimental|Ketamine 1|Ketamine 1 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
2987446|NCT02646709|Experimental|Ketamine 1.5|Ketamine 1.5 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
2987447|NCT02646709|Experimental|Ketamine 2|Ketamine 2 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
2987448|NCT02646696||Children with Autism Spectrum Disorder|Boys between the age of 4 to 11 years old with Autism Spectrum disorder will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
2987449|NCT02646696||Typically Developing Children|typically developing boys between the age of 4 to 11 years will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
2987450|NCT02646683|Other|Early Crohn's disease|VEDOLIZUMAB 300 mg at week 0,2,6, (10), 14, 22, 30, 38, 46
2987451|NCT02646683|Other|Late Crohn's disease|VEDOLIZUMAB 300 mg at week 0,2,6, (10), 14, 22, 30, 38, 46
2987452|NCT02646670|Active Comparator|Ranibizumab|- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml . This group will be five about patients about any age, with diabetic macular edema randomly chosen
2987453|NCT02646670|Active Comparator|Aflibercept|- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml. This group will be about five patients about any age, with diabetic macular edema randomly chosen
2987454|NCT02646670|Active Comparator|Ranibizumab and Aflibercept|- In this group will be held two applications of 0.1 ml Aflibercept(the first and the third doses) interspersed with one application of Ranibizumab 0.1 ml(the second dose). This group will be about five patients about any age, with diabetic macular edema randomly chosen
2987455|NCT02646670|Active Comparator|Aflibercept and Ranibizumab|- This group will be held two applications of Ranibizumab 0.1 ml(the first and the third doses) interspersed with one application of Aflibercept 0.1 ml(the second dose). This group will be five about patients about any age, with diabetic macular edema randomly chosen
2987456|NCT02646657|Other|Early UC|Patients with 'early UC' defined as disease duration < 4 years and no other treatments than aminosalicylates and/or corticosteroids
2987457|NCT02646657|Other|Late UC|Patients with 'late UC' defined as active disease despite treatment with immunosuppressives (IS) and/or anti-TNF. Patients wih intolerance to IS AND anti-TNF will also be allowed in the latter group.
2987458|NCT02646644||Metastasized intestinal NET|We will select the 18F- DOPA-PET scans conducted in the Universtiy Medical Center of Groningen (UMCG) of adult patients with a metastasized intestinal NET between February 2014 until November 2015. Only patients of whose clinical data are available within the UMCG are included.
2987459|NCT02646631|Experimental|Usual Treatment|
2987460|NCT02646631|Experimental|MORE|
2987461|NCT02646631|Active Comparator|MORE + MI|
2987462|NCT02646618|Active Comparator|Get Social|"Get Social participants will receive a weight loss intervention in a protected Twitter group. The intervention content will be structured to deliver in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet."
2987463|NCT02646618|Active Comparator|Traditional|Participants will attend weight loss groups weekly for 8 weeks, then biweekly for 16 weeks, then monthly between months 6 and 12. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
2987464|NCT02646605||patients initiating ART|HIV positive men and women initiating ART
2987465|NCT02646605||patients on established ART|HIV positive men and women on established ART
2987466|NCT02646592|Experimental|alfentanil|"Children under general anesthesia for elective surgery. Induction with sevoflurane or propofol according to the preference of the patient.~Maintenance with sevoflurane. 5 minutes before skin incision, first assessment of the pupillary pain index. Then injection of 10 µg/kg of alfentanil. After 5 minutes second assessment of pupillary pain index. End of study period, beginning of surgery."
2987467|NCT02646579|Experimental|Spinal and Peripheral Dry Needling|Participants will receive dry needling to the low back and painful areas in the leg.
2987468|NCT02646579|Active Comparator|Peripheral Dry Needling|Participants will receive dry needling to painful areas in the leg.
2987469|NCT02646566|Experimental|APD421 standard|Single (standard) dose IV APD421
2987470|NCT02646566|Experimental|APD421 high|Single (high) dose IV APD421
2987471|NCT02646566|Placebo Comparator|Placebo|Single IV placebo
2987472|NCT02646553||Children refered to the obesity clinic.|All children refered to the obesity clinic for examination and optionally treatment are invited.
2987473|NCT02646540|Experimental|Tolvaptan 30 mg and IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive 30 mg of tolvaptan concomitantly with their standard dose of diuretics.
2987474|NCT02646540|Active Comparator|Metolazone 5mg and IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive 5mg metolazone concomitantly with their standard dose of diuretics.
2987475|NCT02646540|Active Comparator|IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive two and a half (2.5) times their standard dose of diuretics.
2987476|NCT02646527|Experimental|DT+|Dignity Therapy is conducted with patients and partners
2987477|NCT02646527|Experimental|DT|Dignity Therapy is conducted only with patients
2987479|NCT02646514|Experimental|RFA with RF catheter (ELRA®) with stenting|
2987480|NCT02646514|Active Comparator|stenting|
2987481|NCT02646501|Experimental|group A+PSGB|(Antiarrhythmic drug + percutaneous stellate ganglion block) group
2987482|NCT02646501|Active Comparator|group A|Antiarrhythmic drug group
2987483|NCT02646488|Active Comparator|Cluster 1|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
2987484|NCT02646488|Active Comparator|Cluster 2|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
2987485|NCT02646488|Active Comparator|Cluster 3|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
2987486|NCT02646488|Active Comparator|Cluster 4|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
2987487|NCT02646475|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of three ascending doses of Angiotensin-(1-7). The doses are 4, 8, and 16 ng/kg/min. Each dose will be maintained for 10 minutes. The highest dose of Angiotensin-(1-7) will be maintained for an additional 120 minutes during the hyperinsulinemic-euglycemic clamp, for a total of 150 minutes of infusion.
2987488|NCT02646475|Placebo Comparator|Saline|Subjects will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will also be maintained for a total of 150 minutes.
2987489|NCT02646449|Active Comparator|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
2987490|NCT02646449|Placebo Comparator|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
2987491|NCT02646436|Other|HD treatment|Patients with absolute contraindication to the PD method - presence of recent abdominal surgery (less than 30 days); multiple previous abdominal surgery (more than two); presence of fibrosis or peritoneal adhesions; fungal peritonitis; severe respiratory insufficiency (FiO2> 70%); abdominal infections; severe hyperkalemia with changes characteristic in EKG; and acute pulmonary edema - will be treated with HD.
2987492|NCT02646436|Other|PD treatment|Patients stage 5 (creatinine clearance < 15 ml/min) requiring dialysis treatment immediately without absolute contraindication to the PD method will receive unplanned PD treatment. High volume PD (HVPD) will be used during the first 7 days of PD in order to achieve metabolic and fluid control. The procedure for acute PD has been published recently by our team . At this point, patients will be discharged from hospital and they will be treated by intermitent PD at the dialysis unit of the University Hospital.until their family be trained and home be prepared for the implementation of technique.
2987493|NCT02646423|Experimental|Prior CD Decision App (PCDDA)|Women who are randomized to PCDDA will be provided access to a tablet which they can use to view the Prior CD Decision App at their own pace. The research assistant will print a summary of the participant's predicted likelihood of a vaginal delivery (VBAC) if she undergoes a trial of labor (TOLAC), as well as her answers to the values clarification exercises, that she can review and share with whomever she chooses, including her provider.
2987494|NCT02646423|No Intervention|Usual Care - No App|Women randomized to the Usual Care - No App group will simply continue with usual care.
2987495|NCT02646410|Other|FPD+NDOT|Fixed-point delivery (FPD) combined with non directly observed treatment (NDOT)
2987496|NCT02646410|Other|FPD+DOT|Fixed-point delivery (FPD) combined with directly observed treatment (DOT)
2987497|NCT02646410|Other|DDD+NDOT|door-to-door delivery (DDD) combined with non directly observed treatment (NDOT)
2987498|NCT02646410|Other|DDD+DOT|door-to-door delivery (DDD) combined with directly observed treatment (NDOT)
2987499|NCT02646397|Experimental|Fosinopril,benidipine combination|254 CKD patients with HTN will take oral tablets of fosinopril (20 mg) plus benidipine (4/8 mg）once daily for 6 months.
2987500|NCT02646397|Experimental|Fosinopril,hydrochlorothiazide combination|254 CKD patients with HTN will take oral tablets of fosinopril (20 mg) plus hydrochlorothiazide (12.5/25 mg）once daily for 6 months.
2987501|NCT02646384|Experimental|Ovarian tissue cryopreservation|Children faced with a fertility threatening diagnosis or treatment plan will be offered ovarian tissue cryopreservation, particularly if pre menarchal and without other options to preserve fertility. Although considered experimental, there are over 120 live births worldwide using this technique
2987502|NCT02646371|Active Comparator|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
2987503|NCT02646371|Placebo Comparator|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
2987504|NCT02646358|Experimental|Cohort 1: Normal Renal Function|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
2987505|NCT02646358|Experimental|Cohort 2: Mild Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
2987506|NCT02646358|Experimental|Cohort 3: Moderate Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
2987507|NCT02646358|Experimental|Cohort 4: Severe Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
2987508|NCT02646358|Experimental|Cohort 5: End Stage Renal Disease|Vepoloxamer Injection, 50 mg/kg for 1 hour followed by 15 mg/kg/hr for 5 hours
2987509|NCT02646345||Pre Checklist|All surgical encounters before surgical checklist implementation
2987510|NCT02646345||Post Checklist|All surgical encounters after surgical checklist implementation
2987511|NCT02646332|Experimental|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
2987512|NCT02646332|Active Comparator|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
2987513|NCT02646319|Experimental|Treatment (nanoparticle albumin-bound rapamycin)|Patients receive nanoparticle albumin-bound rapamycin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
2987514|NCT02646306||Shoulder Impingement Syndrome|Execution of two tests in succession with the use of the shoulder proprioceptive rehabilitation tool (SRPT), each oriented to indicate a specific discriminative and integrative mode in the movement of the scapulothoracic. Will be required to each subject to perform recognition tasks that include both retraction movements of the hand, starting from a start position, and approaching movements of the hand, starting from an end position. First test: ability to integrate visual and proprioceptive informations. Second test: discriminative proprioceptive capacity of the subject, thus excluding the contribution of the view.
2987515|NCT02646306||Healthy Subjects|Execution of two tests in succession with the use of the shoulder proprioceptive rehabilitation tool (SRPT), each oriented to indicate a specific discriminative and integrative mode in the movement of the scapulothoracic. Will be required to each subject to perform recognition tasks that include both retraction movements of the hand, starting from a start position, and approaching movements of the hand, starting from an end position. First test: ability to integrate visual and proprioceptive informations. Second test: discriminative proprioceptive capacity of the subject, thus excluding the contribution of the view.
2987516|NCT02646280|Experimental|Massage therapy and contact experience|Traditional massage therapy consisting of different phases: surface touch, deep touch, static pressures, dynamic pressures and kneading associated with a preparation to the contact phase of the massage using the typical elements of neurocognitive rehabilitation such as motor imagery, dynamic state during which a person mentally simulates an action, and language, necessary to understand the way of perceiving and organizing sensory, cognitive and phenomenological informations by the patients and so to interpretate pain in a more articulate way.
2987517|NCT02646280|Active Comparator|Massage therapy|Traditional massage therapy consisting of different phases: surface touch, deep touch, static pressures, dynamic pressures and kneading.
2987518|NCT02646267|Experimental|standard intensity warfarin group|standard intensity warfarin group， target international normalised ratio(INR) was 2.1-3.0, warfarin baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range(2.1-3.0)
2987519|NCT02646267|Experimental|low intensity warfarin group|low intensity warfarin group， target international normalised ratio(INR) was 1.7-2.2, warfarin baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range(1.7-2.2)
2987520|NCT02646267|Active Comparator|dabigatran etexilate group|110mg dabigatran etexilate was administrated twice a day
2987521|NCT02646254|Active Comparator|blood cardioplegia|these patients received blood cardioplegia
2987522|NCT02646254|Active Comparator|del nido cardioplegia|these patients received del nido cardioplegia
2987523|NCT02646241|Experimental|unroofing biopsy|
2987524|NCT02646241|Active Comparator|EUS-FNB|
2987525|NCT02646228||molecular profiling, patient derived cells|
2987526|NCT02646215|Active Comparator|Inspiratory muscle training group|Threshold inspiratory muscle training
2987527|NCT02646215|No Intervention|Control group|No training
2987528|NCT02646202|Active Comparator|Sclerotherapy group|thirty patients treated by sclerotherapy for OV using ethanolamine oleate 5%.
2987529|NCT02646202|Active Comparator|Endoscopic band ligation group|thirty patients treated by endoscopic banding using the Euro-Ligator system.
2987530|NCT02646202|Experimental|Sclero-ligation (SL) group|thirty patients treated by intra variceal endoscopic sclerotherapy combined with band ligation.
2987531|NCT02646189|Experimental|REP 2139-Ca + immunotherapy|"REP 2139-Ca is the calcium chelate complex formulation of REP 2139.~Zadaxin is thymosin alpha 1~Pegasys is pegylated interferon alpha 2a~Patients initially receiving REP 2139-Ca with no Grade 3 adverse events at week 20 are eligible to transition to combination therapy with Zadaxin if serum HBV DNA is > 2000 copies / ml.~After 10 weeks of REP 2139-Ca / Zadaxin combination therapy, patients not experiencing a measurable improvement in serum antiviral response can further transition to combination therapy with REP 2139-Ca and Pegasys."
2987532|NCT02646163|Experimental|REP 2055|Treatment with REP 2055
2987533|NCT02646150||critical limb ischemia|
2987534|NCT02646137|Active Comparator|Transarterial chemoembolization (TACE)|treated by transarterial chemoembolization
2987535|NCT02646137|Experimental|Radiofrequency ablation with TACE|Radiofrequency ablation combined with TACE
2987536|NCT02646137|Experimental|Microwave ablation combined with TACE|Microwave ablation combined with TACE.
2987537|NCT02646124|Experimental|Diazepam|Naproxen +Diazepam
2987538|NCT02646124|Active Comparator|Placebo|Naproxen + Placebo
2987539|NCT02646111|Experimental|Genotype 1b without cirrhosis|12 weeks without Ribavirin
2987540|NCT02646111|Experimental|Genotype 1b with cirrhosis|12 weeks with Ribavirin
2987541|NCT02646111|Experimental|Genotype 1a without cirrhosis|12 weeks with Ribavirin
2987542|NCT02646111|Experimental|Genotype 1a with cirrhosis|24 weeks with Ribavirin
2987543|NCT02646098|Active Comparator|CD34+ cell selection|CD34+ cell selection applying CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany)
2987544|NCT02646098|No Intervention|No CD34+ cell selection|No CD34+ cell selection
2987545|NCT02646085|Experimental|Intervention|C11 Methionine positron emission tomography (PET/CT) studies will be performed as hybrid PET/CT examinations for attenuation correction and lesion localization. A bolus of 10 millicuries of C11 Methionine will be injected intravenously. Approximately 60 minutes following tracer injection, the patient will be positioned on a Siemens Biograph PET/CT scanner. A low milliampere CT of from the mid skull to mid thigh will be acquired first with while the patient is free breathing. PET will be acquired at 3 minutes per bed position using the 3D mode, approximately 6-7 bed positions. C11 Methionine PET/CT imaging will take less than 60 minutes.
2987546|NCT02646072|Active Comparator|Diabetes mellitus patients|Ketorolac tromethamine ophthalmic solution 0.45% four times a day for 3 days prior to cataract surgery
2987547|NCT02646072|No Intervention|Diabetes mellitus control patients|Topical refresh plus four times a day for 3 days prior to cataract surgery
2987548|NCT02646072|Active Comparator|Non diabetic patients|Ketorolac tromethamine ophthalmic solution 0.45% four times a day for 3 days prior to cataract surgery
2987549|NCT02646072|No Intervention|Non diabetic control patients|Topical refresh plus four times a day for 3 days prior to cataract surgery
2987550|NCT02646059|Experimental|Text group|Text messages containing reminds of blood donation information would be sent to donors in this group.
2987741|NCT02644642|Experimental|BB(Bronchial Blocker) group|disconnection technique will be applied
2987551|NCT02646059|Experimental|Telephone group|Investigators would give telephone calls to the donors in this group, ask the reasons why they stopped donating blood.
2987552|NCT02646059|No Intervention|Control group|No intervention will be giving to this group.
2987553|NCT02646046|Experimental|Combi lone-CPR|"Intervention group~: Newly developed method"
2987554|NCT02646046|Active Comparator|Conventional lone-CPR|Conventional CPR group
2987555|NCT02646033||robotic surgery|all those patients aged 40 - 60 years undergoing robotic surgeries, who does not have any ophthalmic complains.
2987556|NCT02646020|Experimental|Aprepitant and placebo|aprepitant 125mg d1, 80mg d3 and d5, along with placebo 5mg d1-d28;
2987557|NCT02646020|Active Comparator|desloratadine and placebo|placebo 125mg d1, 80mg d3 and d5, along with desloratadine 5mg d1-d28
2987558|NCT02646007|Experimental|BM-MSC|Bone marrow derived mesenchymal stromal/stem cells injection during decompressive surgery in patients with Kienböck's disease.
2987559|NCT02645994|Experimental|Target Controlled Infusion|Propofol is administered through a target controlled infusion pump based on Marsh model to achieve a BIS of 50 and manually adjusted to maintain BIS between 40 and 60
2987560|NCT02645994|Active Comparator|Closed Loop Anesthesia Delivery System|Propofol is administered through Closed Loop Anesthesia Delivery System which is titrated automatically to achieve a target BIS of 50 and maintain it between 40 and 60.
2987561|NCT02645981|Experimental|Donafenib|Drug:Donafenib; Dose:200mg,bid,po.
2987562|NCT02645981|Active Comparator|Sorafenib(Nexavar)|Drug:Sorafenib; Dose:400mg,bid,po.
2987563|NCT02645955||Control group, disease history|people who didn't have disease history of Maintenance Hemodialysis
2987564|NCT02645955||The MHD patient group, diseases history|Maintenance Hemodialysis Patients
2987565|NCT02645942|Experimental|Intervention group|L-carnitine 1400 mg daily for 8 weeks
2987566|NCT02645942|Placebo Comparator|Placebo group|Placebo
2987567|NCT02645916|Experimental|DSGOST|admission to Danggui-Sayuk-Ga-Osuyu-Saenggang-tang granule
2987568|NCT02645916|Placebo Comparator|Placebo|admission to placebo
2987569|NCT02645903|Active Comparator|transversus abdominis plane block|"Patients who received a tranversus abdominis plane block with ultrasound after standard general anesthesia represented Group 1.~The tranversus abdominis plane block was performed bilaterally by obtaining an image with real time ultrasound guidance with a 6-13 MHz linear probe.~The block was placed with a 22 G 80 mm needle while obtaining real-time images via an in-plane technique.~Two 20 mL syringes were prepared after preparing a local anesthetic concentration of 1.5 mg/kg of 0.5% bupivacaine to 40 mL with saline. These were administered to the left and right abdominal walls.~Postoperative analgesia was administered through a morphine the patient-controlled analgesia device."
2987570|NCT02645903|Placebo Comparator|nonblocked|Patients who received standard general anesthesia alone made up Group 2. Postoperative analgesia was administered through a morphine the patient-controlled analgesia device.
2987571|NCT02645890|Active Comparator|CKD-397|Tadalafil/ Tamsulosin Fixed dose combination
2987572|NCT02645890|Experimental|TD+TM|Tadalafil/ Tamsulosin Coadministration
2987573|NCT02645877||Prehospital care|All pre-hospital service data were collected from January 2005 to December 2014 from the Beijing Emergency Center and Beijing Red Cross Emergency Center, which oversee all pre-hospital care in Beijing. The major illnesses were classified into 34 disease spectrum categories according to the Medical Priority Dispatch System (MPDS) which total includes 34 diseases. Data on pre-hospital emergency demand and first aid-related time intervals were analyzed to determine trends over the period.
2987574|NCT02645864|Experimental|Apatinib and Irinotecan|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: apatinib 250 mg per day and irinotecan 150mg q2w. Cohort 2: apatinib 500 mg per day and irinotecan 150mg q2w. Cohort 3: apatinib 750 mg per day and irinotecan 150mg q2w.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event~Grade 3 non-hematologic toxicity including fever, nausea, vomiting, and diarrhea that continues despite optimal medical management) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If two (2) DLTs are experienced in any cohort, the study will stop and the dose of combination treatment in this cohort will be documented."
2987575|NCT02645851|Experimental|"PLR-induced SV changes based strategy"|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Stroke Volume (SV) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if SV changes ≥10%, or no administration otherwise. Measurement of beat-to-beat stroke volume by intraarterial pulse contour analysis using the PiCCO system (Pulsion, Germany) will be used to assess stroke volume changes. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
2987576|NCT02645851|Experimental|"PLR-induced PP changes based strategy"|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Pulse Pressure (PP) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if PP changes ≥10%, or no administration otherwise. We will perform measurement of intraarterial blood pressure using vascular pressure transducers (Edwards Life Science, USA). Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
2987577|NCT02645851|Other|Usual Care|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the fluid bolus will be administered without measurement of any predictive index of fluid responsiveness. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
2987578|NCT02645838|Experimental|Motivational interviewing group|"Structural motivational interviewing for one section (about 20 mins)，provided by family physician~Follow-up telephone call，provided by family physician"
2987579|NCT02645838|No Intervention|Brief advice group|Brief advice without motivational interviewing (about 5 mins), provided by family physician
2987610|NCT02645630|Active Comparator|Sham Cervical Manipulation|Patients assigned to this group will receive a sham cervical spine manipulation targeting the C3/C4 segment on both sides. No therapeuthic thrust will be applied.
2987611|NCT02645617|Experimental|Varnish|Dental varnish containing povidone iodine and sodium fluoride
2987580|NCT02645799|Active Comparator|LABR-312|"LABR-312 will be administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent. Target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.~Three (3) doses will be tested:~Group 1: Low dose -> 0.01 mg LABR-312 Group 2: Intermediate dose-> Up to 0.03 mg LABR-312 Group 3: High dose-> Up to 0.08 mg LABR-312 The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1 year post randomization.~OCT follow-up will be performed at 9 months."
2987581|NCT02645799|Placebo Comparator|saline|"Placebo will be administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent. Target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.~Three (3) doses will be tested:~Group 1: Low dose -> placebo (saline) equivalent to 0.01 mg LABR-312. Group 2: Intermediate dose-> placebo (saline) equivalent to up to 0.03 mg LABR-312 Group 3: High dose-> placebo (saline) equivalent to up to 0.08 mg LABR-312. The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1 year post randomization.~OCT follow-up will be performed at 9 months."
2987582|NCT02645786||Case|"Differentiated thyroid cancer group:~who received total- or near-total thyroidectomy, and thereafter regularly visited the endocrine out-patient department (OPD) of Chuncheon Sacred Heart Hospital.~1) age less than 45 years old when receiving total or near-total thyroidectomy, 2) serum level of TSH<0.1 mU/L in the intermediate recurrence-risk or TSH<0.3 mU/L in the low recurrence-risk group13, 14 over 2 years before study entry, 3) receiving TSH suppressive therapy for 5 to 9 years with fixed dose of LT4 more than 2 years before study entry, and 4) no history of structural heart disease, arrhythmia, or cardiac symptoms (palpitation, exertional dyspnea and chest discomfort) during therapy."
2987583|NCT02645786||Control|"Control group As each DTC patient was enrolled, control subjects were selected from patients who visited endocrinology department for thyroid nodule work-up. The control group had to meet the following criteria~1) the subject matched to a patient by age (±2 years), sex, and body mass index (BMI) (±2 kg/m2), 2) within the reference range of serum TSH (0.3-4.6 mU/L), 3) no history of structural heart disease, arrhythmia, or cardiac symptoms, 4) no history of comorbid diseases which affect thyroxine metabolism and cardiac structure, including hepatic or renal disease, anemia, and hypertension."
2987584|NCT02645773|Experimental|Pre-laser|non-ablative laser Laser Pre-wounding low dose laser Pre-wounding medium dose laser Pre-wounding high dose
2987585|NCT02645773|Experimental|Immediate-laser|non-ablative laser Laser low dose - immediate after wounding Laser medium dose - immediate after wounding Laser high dose - immediate after wounding
2987586|NCT02645773|Experimental|Post-laser|non-ablative laser Laser low dose - post wounding Laser medium dose - post wounding Laser medium dose - post wounding
2987587|NCT02645773|No Intervention|Control|Untreated control wound
2987588|NCT02645760|Active Comparator|Core stabilization exercise|7-weeks of core stabilization exercise
2987589|NCT02645760|Active Comparator|conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
2987590|NCT02645747||Group 1|The source population of this study is patients who suffer from visual impairment due to ME secondary to CRVO. In order to ensure the representativeness of the study population, the number of Belgian patients which started Eylea treatment during the brief period between the 1st of June 2014 and the 28th of February 2015 were taken into account. However, data of patients diagnosed with neovascular glaucoma secondary to CRVO will be excluded.
2987591|NCT02645734|Active Comparator|Injection intravitreous bevacizumab|Injection intravitreous bevacizumab at a dose 1.25mg
2987592|NCT02645734|Active Comparator|Injection ziv-aflibercept at dose of 1.25 mg|Injection ziv-aflibercept at dose of 1.25 mg
2987593|NCT02645734|Active Comparator|Injection ziv-aflibercept at dose of 2.5 mg|Injection ziv-aflibercept at dose of 2.5 mg
2987594|NCT02645721|Experimental|Extended self-help program with guidance|The program is a comprehensive CBT program lasting 12 weeks, with as many modules. The modules are quite extensive. A guide with basic education in psychotherapy assists and counsels participants online.
2987595|NCT02645721|Active Comparator|Briefer Self-help program, no guidance|This self-help program also lasts 12 weeks but contains only 9 modules; a pause occurs during the final weeks of the program for self-testing of acquired skills. The modules are quite brief. Participants receive no guidance.
2987596|NCT02645721|Other|Waiting list|Participants will be put on a waiting list. After 12 weeks on the waiting list, participants will receive access the the extended self-help program used in the experimental arm. However, participants will be offered a choice between three guidance options of varying intensity: proactive guidance, reactive guidance (only at participant request) or no guidance.
2987597|NCT02645708|Other|Retrograde Intrarenal Surgery (RIRS)|Patients in Group 1 undergo Retrograde Intrarenal Surgery
2987598|NCT02645708|Other|EPVL after RIRS|"Patients in Group 2 undergo external physical vibration lithecbole after Retrograde Intrarenal Surgery.~with the help of changing the position and direction of the extracorporeally physical vibration machine, the urinary stone was discharged from the urinary collecting system"
2987599|NCT02645695|Active Comparator|routine pulmonary rehabilitation|routine pulmonary rehabilitation consisted of position giving technique
2987600|NCT02645695|Active Comparator|chest wall vibration technique|chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours.
2987601|NCT02645682|Experimental|anti-infection CVC (Certofix®protect)|intervention group
2987602|NCT02645682|Active Comparator|normal CVC (Certofix®)|control group
2987603|NCT02645669|Experimental|Study site|Scaling and Root planing (SRP) was followed by placement of S boulardii-FOS mixture
2987604|NCT02645669|Placebo Comparator|Control site|Only Scaling and Root planing (SRP) was performed
2987605|NCT02645656|Experimental|Curcumin Arm|Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals.
2987606|NCT02645643|Experimental|intervention group|Medical students rolled into this group would accept education of medical humanities.
2987607|NCT02645643|No Intervention|control group|Medical students rolled into this group would not gain education of medical humanities.
2987608|NCT02645630|Experimental|Right Cervical Manipulation|Patients assigned to this group will receive a cervical spine manipulation targeting the C3/C4 segment on the right side.
2987609|NCT02645630|Experimental|Left Cervical Manipulation|Patients assigned to this group will receive a cervical spine manipulation targeting the C3/C4 segment on the left side.
2987612|NCT02645591|Experimental|Nerve Sparing RARP + AmnioFix®|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) plus placement of a 2x12 sheet of AmnioFix® to the neurovascular bundle.
2987613|NCT02645591|Active Comparator|Nerve Sparing RARP|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP)
2987614|NCT02645578|Experimental|RMNS group|Focus intervention: right median nerve stimulation plus standard management
2987615|NCT02645578|No Intervention|Control group|Standard management
2987616|NCT02645565|Active Comparator|Low dose Cyclophosphamide|Intravenous Cyclophosphamide therapy 500 mg intravenous 2 weekly for 3 months followed by azathioprine 2 mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.
2987617|NCT02645565|Active Comparator|High Dose Cyclophosphamide|Intravenous Cyclophosphamide therapy 750mg/m2 intravenous 4 weekly for 6 months followed by azathioprine 2mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.
2987618|NCT02645552|Experimental|Tranexamic acid|Focused intervention
2987619|NCT02645552|Placebo Comparator|Sodium chloride|Placebo control
2987620|NCT02645539|Experimental|Single Arm|All patients are treated with the intravascular ventricular assist system (iVAS).
2987621|NCT02645526|Experimental|KMC with woolen cap|In this group, the head of the patients will be covered with a woolen cap during KMC.
2987622|NCT02645526|No Intervention|KMC without woolen cap|In this group, the head of the patients will be uncovered during KMC.
2987623|NCT02645513|Experimental|Malaria-only text messages|Health workers at facilities in this arm receive twice-daily text message reminders for six months on key reminders related to malaria diagnosis and treatment.
2987624|NCT02645513|Experimental|Malaria, pneumonia, and diarrhea messages|Health workers at facilities in this arm receive twice-daily text message reminders for six months on key reminders related to diagnosis and treatment of malaria, pneumonia, and diarrhea
2987625|NCT02645513|Placebo Comparator|Control|No text message reminders to health workers, just the usual health system supports.
2987626|NCT02645500|Experimental|Physical activity message|"Participants will receive training on healthy living style focusing on positive psychology, physical activity and healthy diet, and health messages related to physical activity.~The training workshop include one core session and one booster session at one month.~Daily messages in relation to physical activity will be sent to the participants."
2987627|NCT02645500|Active Comparator|Healthy diet message|"Participants will receive training on healthy living style focusing on positive psychology, physical activity and healthy diet, and health messages related to healthy diet .~The training workshop include one core session and one booster session at one month.~Daily messages in relation to healthy diet will be sent to the participants."
2987628|NCT02645487|Experimental|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Dose-Escalation
2987629|NCT02645474|Active Comparator|Paravertebral block with ropivacaine|Patients are treated with an older technique (paravertebral block with ropivacaine), somehow established in treating pain after breast surgery. This technique has been shown to be effective but has an intrinsic risk of iatrogenic pneumothorax and is considered technically demanding.
2987630|NCT02645474|Experimental|PECS block with ropivacaine|Patients are treated with PECS block, which has been already adopted in common clinical practice as an alternative to paravertebral block for postoperative pain treatment after breast surgery. This technique is thought to be somehow simpler to perform and safer with regard to pneumothorax, however no studies have been done yet to statistically compare the two blocks with regard to safety and effectiveness.
2987631|NCT02645461|Active Comparator|Riluzole|Riluzole 50 mg twice daily in ALS patients
2987632|NCT02645461|Experimental|PEA plus Riluzole|Riluzole 50 mg twice daily plus Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily in ALS patients
2987633|NCT02645448|Other|Resistance Exercise Low intensity|"Day 1 (Control Session)~Day 2 (Resistance Exercise)~Day 3 (Duration of effect)"
2987634|NCT02645448|Other|Resistance Exercise High intensity|"Day 1 (Control Session)~Day 2 (Resistance Exercise)~Day 3 (Duration of effect)"
2987635|NCT02645435|Active Comparator|Hip direct anterior approach|Patients with hip arthritis
2987636|NCT02645435|Active Comparator|Lateral hip approach|Patients with hip arthritis
2987637|NCT02645409|Experimental|Partial nephrectomy|OTL38 will be given approximately 2 hours before surgery. Intraoperative fluorescent imaging will utilized in parallel with standard operating procedures for partial nephrectomy. Photographs of the surgery field and tumor (ex-vivo) will be taken under normal light and fluorescent light.
2987638|NCT02645409|Experimental|Radical nephrectomy|OTL38 will be given approximately 2 hours before surgery. Intraoperative fluorescent imaging will utilized in parallel with standard operating procedures for radical nephrectomy. Photographs of the surgery field and tumor (ex-vivo) will be taken under normal light and fluorescent light.
2987639|NCT02645383|Active Comparator|PASCAL group|Patients undergone PASCAL laser photocoagulation
2987640|NCT02645383|Active Comparator|Conventional group|Patients undergone conventional laser photocoagulation
2987641|NCT02645370|Active Comparator|Active Comparator:Topiramate|The treatment with TPM is initiated at a 50 mg daily dose and sequentially increase every 7 days, as tolerated, in 25 mg increments up to a target dose of 150 mg total/day.
2987642|NCT02645370|Experimental|Experimental:Danzhen|The treatment with Danzhen is 3 tablets triple daily.
2987643|NCT02645357|Experimental|computer reminders on clinical practice|on-screen, point-of-care computer reminders on clinical practice.
2987644|NCT02645357|Other|Control group|No on-screen, point-of-care computer reminders on clinical practice.
2987645|NCT02645344|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|Low frequency rTMS at 1 Hz was applied over P5 of the contralesional hemisphere in addition to conventional rehabilitation
2987646|NCT02645344|Experimental|rTMS combined with sensory cueing (SC)|Vibration cueing was emitted using a wristwatch device on the hemiplegic arm combined with low frequency rTMS in addition to conventional rehabilitation
2987647|NCT02645344|Active Comparator|Conventional rehabilitation|Physical therapy and occupational therapy
3001079|NCT02555683|Experimental|QAW039 Dose 1|QAW039 Dose 1 once daily
2987648|NCT02645331|Experimental|Remind-to-move|RTM involved a wristwatch device worn on more-affected arm which emitted sensory cueing continuously to remind the children to use the more-affected hand to engage in daily activities or complete bimanual tasks intensively, 5 hour per day, 5 days every week, for 3 consecutive weeks.
2987649|NCT02645331|Active Comparator|Modified constraint induced movement therapy (mCIMT)|children were encouraged to wear a customer-made volar resting splint that extended from below the elbow to the fingertips on their noninvolved hands for 5 hour daily except for toileting, writing and specific physical sports, for 3 weeks. Each child was supervised by one therapist to complete structured unimanual practice with the affected hand during the supervised session, 5 days every week, for 3 consecutive weeks.
2987650|NCT02645331|Placebo Comparator|Conventional rehabilitation|Conventional splinting, muscle strengthening, stretching, and neurodevelopmental facilitation techniques for 1hr daily, 2 day per week for 3 weeks.
2987651|NCT02645305|Experimental|Treatment|Autologous stromal vascular fraction (SVF) and platelet rich plasma (PRP) will be transfused into 20 COPD patients.
2987652|NCT02645292|Experimental|1 mile Walk using treadmill|Walking for 1 mile on treadmill (American Motion Fitness, 8800D) as fast as participant can, without any inclination
2987653|NCT02645292|Experimental|Stair Climbing|30 meters of vertical distance to be covered (14 flights of stairs with a total of 154 steps)
2987654|NCT02645279|Active Comparator|oral 30% glucose|oral 30% glucose total 200 mg/kg with 0.5-1 mL increments
2987655|NCT02645279|Active Comparator|IV midazolam|intravenous administration of midazolam 0.1 mg/kg
2987656|NCT02645266|Experimental|Aflibercept Injection [Eylea] group|Intervention: Subjects will be receiving a (2mg/ml) dose of VEGF-Trap, injected intravitreally at the start of every month, for the 4 months duration of the trial.
2987657|NCT02645253|Experimental|Cohort 1|AZD7594 inhalation powder (200 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
2987658|NCT02645253|Experimental|Cohort 2|AZD7594 inhalation powder (400 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
2987659|NCT02645253|Experimental|Cohort 3|1600 μg AZD7594 inhalation powder (4 x 400 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
2987660|NCT02645253|Experimental|Cohort 4|400 μg AZD7594 pressurized inhalation suspension (2 x 200 μg inhalations) or placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
2987661|NCT02645240|Experimental|Heparin injection|Injection of low molecular weight heparin in patients with acute mesenteric ischemia to assess outcome
2987662|NCT02645227|Active Comparator|Group 1|Open flap debridement (OFD)
2987663|NCT02645227|Active Comparator|Group 2|OFD with Platelet rich fibrin (PRF)
2987664|NCT02645227|Active Comparator|Group 3|OFD with PRF and 1.2% Rosuvastatin
2987665|NCT02645214|Placebo Comparator|Control scrubs (non-antiseptic)|subject will wear control scrubs for the duration of a 12-hour ICU shift
2987666|NCT02645214|Active Comparator|Antiseptic Impregnated Scrubs Type 1|subject will wear antiseptic impregnated scrubs-type 1 for the duration of a 12-hour ICU shift
2987667|NCT02645214|Active Comparator|Antiseptic Impregnated Scrubs Type 2|subject will wear antiseptic impregnated scrubs-type 2 for the duration of a 12-hour ICU shift
2987668|NCT02645201|Active Comparator|Probiotic|Children in probiotic group will receive chewable tablets containing 4x108 CFU of Gastrus. Subjects will take 1 tablet twice a day for 21 days
2987669|NCT02645201|Placebo Comparator|Placebo|Children in placebo group will receive placebo tablets of similar appearance and taste as Gastrus tablets. Subjects will take 1 placebo tablet twice a day for 21 days
2987670|NCT02645188|Experimental|Experimental|Cueing
2987671|NCT02645188|No Intervention|Control|
2987672|NCT02645175|Experimental|TW1025|TW1025 oral solution, 20ml, 3 times per day (daily dose: 60 ml)
2987673|NCT02645175|Placebo Comparator|Placebo|TW1025 oral solution matched placebo, 20ml, 3 times per day
2987674|NCT02645162|Experimental|Preschool|"This arm will receive the community-based preschool intervention.~The preschool sessions will include 2 groups per day (3 years 6months to 4 years 6 months in the morning session and 4 years 7 months to 5 year 6 months in the afternoon session at the time of enrolment)~Each session will last 3 hours for 5 days per week.~The expected CYL-to-child ratio will be 1:15; however, given the expected high level of local demand it may exceed to a maximum of 1:20 ratio."
2987675|NCT02645162|No Intervention|Control|The control group will receive standard services available in the community.
2987676|NCT02645149|Other|Standard therapy or clinical trial|Patients with BRAF and NRAS wild type tumour for whom there is no actionable genetic aberration in tumour tissue. These patients will receive trametinib based upon the known MAPK excess activity in the majority of melanomas that may be inhibited by a MEK inhibitor.
2987677|NCT02645149|Other|Matched targeted therapy|Patients with BRAF and NRAS wild type tumour for whom there is a targeted therapy available, will receive targeted drug matched to gene defect in tumour. If a patient cannot receive the matched targeted therapy because of the existence of one or more drug specific exclusion criteria, an alternative matched therapy may be assigned, or these patients will be treated per standard therapy / clinical trial arm.
2987678|NCT02645149|Other|Trametinib and / or supportive care|Patients with BRAF V600 and NRAS mutations will be treated with standard approved therapies or on clinical trials, and will be followed for clinical response and survival outcomes.
2987679|NCT02645136|Experimental|PILATES|Weekly Pilates sessions, guided by a specialized physiotherapist. The duration of the treatment was 10 weeks, and each session lasted 45 to 50 minutes. All subjects received instruction to perform specific daily home exercises.
2987680|NCT02645136|Active Comparator|PFMT and AES|For also 10 weeks, the participants went trough anal electrical stimulation (AES) associated with Pelvic Floor Muscle Training (PFMT), supervised by a specialized physiotherapist. All subjects received orientation to perform the same pelvic floor exercises at home.
2987681|NCT02645136|Placebo Comparator|Control|Control Group
2987682|NCT02645123|Experimental|Spinal mobilization|The individuals of the group received 5 treatments in total for 10 minutes that included: posterior to anterior spinal accessory mobilization passive physiological inter vertebral rotation The above was applied to the level that the MRI showed disc degeneration
2987683|NCT02645123|Sham Comparator|Sham Treatment|The investigator touched the skin overlying the low back statically for 10 minutes
3001080|NCT02555683|Experimental|QAW039 Dose 2|QAW039 Dose 2 once daily
2987684|NCT02645123|Active Comparator|Classic Physiotherapy|This group received static hamstring stretch for 5 minutes, TENS (2 channels biphasic pulse, 90Hz, 100μs pulse width) for 20 minutes and 15 minutes of Swedish type massage (effleurage, petrissage, kneading)
2987685|NCT02645110|Experimental|MC Hand soap|For bacterial removal trial: Hand washing with the tested soap following bacterial application
2987686|NCT02645110|Sham Comparator|Water|For bacterial removal trial: Hand washing with tap water alone following bacterial application
2987687|NCT02645097|Active Comparator|Proximal saphenous nerve block|The anesthesiologist will administer a saphenous proximal nerve block if specified in the randomization envelope.
2987688|NCT02645097|Active Comparator|Distal saphenous nerve block|The anesthesiologist will administer a saphenous distal nerve block if specified in the randomization envelope.
2987689|NCT02645084|Active Comparator|Intervention|Intervention: offering an online risk assessment questionnaire to CRC patients, to facilitate the detection of colorectal cancer patients with hereditary or familial colorectal cancer
2987690|NCT02645084|No Intervention|Control|Control: Hospital-based standard practice for the detection of colorectal cancer patients with hereditary or familial colorectal cancer, informed by the referral criteria that are being used in the intervention group
2987691|NCT02645071|Experimental|Physical activity|The experimental arm is a 15-20 min interactive session, which aims to reduce participants' sedentary behavior and increase physical activity by increasing their motivation, self-efficacy, and knowledge of different types of easy exercises.
2987692|NCT02645058|Experimental|RIRS (retrograde intrarenal surgery)|In the first arm (RIRS) the patients will be treated by a standard retrograde ureterorenoscopy and Holmium laser lithotripsy. Preoperative exams will be abdomen ultrasound and Xray (CT in case of stones > 15 mm), urine analysis and culture (according to all the more recent guidelines). Surgeries will be performed under general or spinal anesthesia, according to anesthesiologist evaluation. According with standard technique, ureteroscopy will be performed using both rigid and flexible ureteroscope. Lithotripsy will be performed by Holmium laser. Major stone fragments will be removed at the end of the procedure. Finally a double J ureteral stent will be push in specific cases depending on intraoperative findings (length of the procedure, macroscopic view of the ureter, residual stones etc.). RIRS will be an outpatients procedure with an hospital stay <23 hours. Some patients may require a longer hospital stay due to specific pre-operative diseases or intra/post-operative events.
2987693|NCT02645058|Experimental|ESWL (extracorporeal shockwaves lithotripsy)|In the second arm (ESWL) the patients will be treated by a standard extracorporeal shock waves lithotripsy (ESWL). Preoperative exams will be the same as first arm. No general or spinal anaesthesia will be used, but just intravenous medications if required. Ultrasound and/or X-Ray will be used to locate the stone. Power and number of shock waves will consist in 20-24 KV and 3000-3500 sw respectively, according to individual tolerance. ESWL will be an outpatients procedure with an hospital stay <23 hours. Some patients may require a longer hospital stay due to specific pre-operative diseases or intra/post-operative events.
2987694|NCT02645045||Dry eye|Patients with dry eye syndrome
2987695|NCT02645045||normal|Patients without dry eye
2987696|NCT02645032|Experimental|Test group|Two doses of Vi-DT (typhoid conjugate vaccine) will be administrated intramuscularly 4 weeks apart (Day 0 and Day 28).
2987697|NCT02645032|Active Comparator|Comparator group|"Biological/Vaccine:~One dose of Typhim Vi® will be administrated intramuscularly at 1st dose (Day 0).~One dose of VAXIGRIP® will be administrated intramuscularly at 2nd dose (Day 28)."
2987698|NCT02645019||Cuffed ETT or LMA|
2987699|NCT02645006|Experimental|Intervention arm- 3 session workshop|The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.
2987700|NCT02645006|Other|Control arm- 1 session workshop|The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention
2987701|NCT02644993|Experimental|Proton beam therapy|
2987702|NCT02644980|Experimental|Etomidate|The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
2987703|NCT02644980|Experimental|Propofol|The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
2987704|NCT02644967|Experimental|Arm 1|IMO-2125 intratumoral injection plus ipilimumab
2987705|NCT02644967|Experimental|Arm 2|IMO-2125 intratumoral injection plus pembrolizumab
2987706|NCT02644954|Active Comparator|Metformin|Topical coal tar and topical calcipotriol + oral metformin 850mg twice daily
2987707|NCT02644954|Placebo Comparator|Placebo|Topical coal tar and topical calcipotriol
2987708|NCT02644941|Experimental|Human Acellular Vessel (HAV)|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. It will be surgically implanted in the forearm or upper arm on Study Day 0.
2987709|NCT02644941|Active Comparator|ePTFE|The comparator (one of two commercially available 6mm ePTFE grafts) will be surgically implanted in the forearm or upper arm on Study Day 0.
2987710|NCT02644915|Experimental|study group|"Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion, ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg."
2987711|NCT02644915|Placebo Comparator|control group|"100ml 0.9%%NaCl solution,but without edaravone, will be treated at 10 minutes before kidney reperfusion, ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg."
2987712|NCT02644902|Experimental|Technology Arm|5 days training of health workers in THP through avatar assisted cascade training and supervision
2987713|NCT02644902|Active Comparator|Specialist Arm|5 days training and supervision of health workers in THP by specialists
2987714|NCT02644889||Patients advanced NSCLC EGFR mutated|This is an observational study, there is no intervention.
2987715|NCT02644876|Experimental|Penehyclidine group|Penehyclidine inhalation will be administered (penehyclidine hydrochloride 0.5 mg/0.5 ml + normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
2987716|NCT02644876|Placebo Comparator|Control group|Placebo inhalation will be administered by inhalation (water for injection 0.5 ml + normal saline 5.5 ml ) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
2987717|NCT02644863|Experimental|DC-CIK|After accepting chemotherapy according to guidelines,patients will receive 3 cycles of autologous DC-CIK treatment.
2987718|NCT02644863|Sham Comparator|Chemotherapy|After the Chemotherapy by Paclitaxel and Cisplatin, patients will just regularly follow up.
2987719|NCT02644837|Active Comparator|i-Gel and AuraGain|"In this arm of the crossover study, patients will undergo insertion of Ambu AuraGain laryngeal mask airway and iGel and will undergo initial management with the iGel. Primary and Secondary outcomes will be assessed. The initial device will be removed and subsequent Airway management will then be undertaken with the Ambu AuraGain and the same outcomes will be assessed.~Interventions with both devices will be~Insertion of the laryngeal mask airway~Assessment of ease of insertion~Ability to perform positive pressure ventilation~Measurement of OLP~Fibreoptic assessment with Ambu A-scope~Ability to insert nasogastric tube~Record number of manipulations~An assessment of device related trauma"
2987720|NCT02644837|Active Comparator|AuraGain and i-Gel|"In this arm of the crossover study, patients will undergo insertion of the Ambu AuraGain laryngeal mask airway and i-Gel and will undergo initial management with the Ambu AuraGain.. Primary and Secondary outcomes will be assessed. Airway management will then be undertaken with the iGel device and the same outcomes will be assessed.~Interventions with both devices will be~Insertion of the laryngeal mask airway~Assessment of ease of insertion~Ability to perform positive pressure ventilation~Measurement of OLP~Fibreoptic assessment with Ambu A-scope~Ability to insert nasogastric tube~Record number of manipulations~An assessment of device related trauma"
2987721|NCT02644824|Experimental|Biventricular Pacing (BiVp)|Consented infants with wide QRS randomized to receive standard of care and BiVp.
2987722|NCT02644824|No Intervention|Control (wide QRS)|Consented infants with wide QRS randomized to receive standard of care alone.
2987723|NCT02644824|No Intervention|Control (narrow QRS)|This is an observation control group. Consented infants with narrow QRS will enter control group 2 without randomization.
2987724|NCT02644811|Experimental|Group A - Miniscrews|"Topical anesthesia (buccal and palatal) followed by local anesthesia (buccal and palatal). Extraction of the maxillary first premolars.~Fixed appliance in the maxilla or maxilla and mandible.~Anchorage reinforcement with miniscrews (Spider Screw K1 short neck). Miniscrews are placed buccally between the maxillary second premolar and the first molar after topical anesthesia (buccal) and injection (buccal). Miniscrews are placed when space closure starts. Space closure is performed as en masse retraction. Miniscrew are immediately loaded with 150g Nickel Titanium coil springs."
2987725|NCT02644811|Active Comparator|Group B - Molarblock|"Topical anesthesia (buccal and palatal) followed by local anesthesia (buccal and palatal. Extraction of the maxillary first premolars.~Fixed appliance in the maxilla or maxilla and mandible.~Anchorage reinforcement with molarblocks - a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar. Molarblocks are installed from the beginning of leveling and alignment. Space closure is performed as en masse retraction with type one active tie-backs."
2987726|NCT02644798||ARDS patients|ARDS patients in Han nationality
2987727|NCT02644759|Experimental|Stem Cell Transplantation|Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
2987728|NCT02644746|Experimental|Acupuncture group|Acupuncture has a long time used for chronic pain including low back pain, sciatica, and other pain related to spina via stimulating specific acupuncture points.
2987729|NCT02644746|Placebo Comparator|Placebo needle group|The placebo needle using in this trial will be unpenetrated needles. Based on our previous research, the placebo needle is a valid control for acupuncture research and may eliminate the placebo effect of acupuncture.
2987730|NCT02644720|Experimental|multifocal intraocular lens group|
2987731|NCT02644720|Active Comparator|monofocal intraocular lens group|
2987732|NCT02644707|Experimental|L-selenomethionine|A group randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months
2987733|NCT02644707|Placebo Comparator|Placebo|A group randomized to receive placebo (control group) for 6 months
2987734|NCT02644694|Experimental|Dexamethasone Phosphate Ophthalmic Solution|Experimental: Dexamethasone Phosphate Ophthalmic Solution (40 mg/mL) delivered via the EyeGate II Drug Delivery System
2987735|NCT02644668|Experimental|Cohort 1/Ambulatory/CK-2127107/Placebo|18 ambulatory patients ≥ 12 years of age with Type III or Type IV SMA randomized 2:1 to CK-2127107 150 mg versus placebo single dose on Day 1 and then twice daily (BID) for remainder of 8 weeks
2987736|NCT02644668|Experimental|Cohort 1/Non-Ambulatory/CK-2127107/Placebo|18 non-ambulatory patients ≥ 12 years of age with Type II or Type III SMA randomized 2:1 to CK-2127107 150 mg versus placebo single dose on Day 1 and then twice daily (BID) for remainder of 8 weeks
2987737|NCT02644668|Experimental|Cohort 2/Ambulatory/CK-2127107/Placebo|18 ambulatory patients ≥ 12 years of age with Type III or Type IV SMA randomized 2:1 to CK-2127107 450 mg versus placebo single dose on Day 1 and then twice daily (BID) for remainder of 8 weeks
2987738|NCT02644668|Experimental|Cohort 2/Non-Ambulatory/CK-2127107/Placebo|18 non-ambulatory patients ≥ 12 years of age with Type II or Type III SMA randomized 2:1 to CK-2127107 450 mg versus placebo single dose on Day 1 and then twice daily (BID) for remainder of 8 weeks
2987739|NCT02644655|Experimental|CD19-specific chimeric antigen receptor|After pretreatment, cluster of differentiation antigen 19 (CD19)-specific chimeric antigen receptor will be transfused.
2987740|NCT02644642|Experimental|DLT(Double Lumen Tube) group|disconnection technique will be applied
2987742|NCT02644629|Active Comparator|Active IV|Will receive IV Ketamine, along with IN placebo.
2987743|NCT02644629|Active Comparator|Active IN|Will receive IN Ketamine, along with IV placebo.
2987744|NCT02644616|Active Comparator|trial group(tolvaptan group)|trial group (tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv,n=20)
2987745|NCT02644616|Placebo Comparator|control group|control group(placebo 15mg/d po(10 days) +torasemide 20mg/d iv,n=20)
2987746|NCT02644603|Experimental|Enhanced Recovery After Surgery|Patients underwent ERAS protocol
2987747|NCT02644603|No Intervention|Conventional Treatment|Patients underwent conventional treatment
2987748|NCT02644590|Experimental|Melatonin treatment|Adolescents with Type 1 Diabetes will undergo baseline 24 hour ambulatory blood pressure monitoring, followed by treatment with Melatonin for 3 weeks, using a single tablet at bed time, and repeat of the 24-hour blood pressure test following treatment period.
2987749|NCT02644577|Experimental|metformin group|Metformin 1000mg/day
2987750|NCT02644577|Placebo Comparator|placebo group|starch
2987751|NCT02644564||Ultrasonography|Patients will undergo structured clinical examination and ultrasonography of both shoulders on the day of inclusion. They also fill out an injury registration form, Oxford Shoulder Score and QuickDASH. Follow-up at 3, 6 and 12 months will be identical, but without ultrasonography and injury registration form.
2987752|NCT02644551|Experimental|CELEXT07|suspension that is applied topically to the infected nail(s) daily.
2987753|NCT02644551|Placebo Comparator|placebo|placebo is a suspension that simulates the physical properties of the experimental agent CELEXT07. It is applied topically to the infected nail(s) daily.
2987754|NCT02644551|Active Comparator|Penlac|Is a standard of care for the condition and is applied topically to the infected nail(s) daily.
2987755|NCT02644538|No Intervention|nucleot(s)ides treated|patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) are still using the original treatment for 72 weeks
2987756|NCT02644538|Active Comparator|PegIFN alfa-2a + nucleot(s)ides treated|patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir), then will add PegIFN alfa-2a to the original nucleot(s)ides for 48 weeks, then follow up for 24 weeks
2987757|NCT02644525|Experimental|1|Increasing doses of imatinib will be given to differentsubjects (each not to receive more than 1 dose), andmicrofilarial (MF) change following imatinib will becompared to blinded placebo-receiving subjects MFconcentrations.
2987758|NCT02644525|Placebo Comparator|2|Increasing doses of imatinib will be given to differentsubjects (each not to receive more than 1 dose), andmicrofilarial (MF) change following imatinib will becompared to blinded placebo-receiving subjects MFconcentrations.
2987759|NCT02644499|Active Comparator|Combination therapy|Combination of Methotrexate (up to 25 mg per week), Leflunomide (20 mg once a day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop) will be given as bridging therapy.
2987760|NCT02644499|Active Comparator|Monotherapy|Methotrexate (up to 25 mg once a week) for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop) will be given as bridging therapy.
2987761|NCT02644486|Experimental|A Group|
2987762|NCT02644486|Experimental|B Group|
2987763|NCT02644486|Active Comparator|C Group|
2987764|NCT02644473|Experimental|Tranexamic acid|Investigators will administer topical (1.5g) TXA during total knee arthroplasty and total hip arthroplasty
2987765|NCT02644473|Placebo Comparator|Control|
2987766|NCT02644460|Experimental|Stratum A|Appropriate dose RT will be administered in 30-33 fractions over approximately 6 weeks for Stratum A patients. Treatment with abemaciclib (LY2835219) will start on the same day as RT and continue twice daily during and after RT for a maximum treatment duration of 2 years. Investigators plan to treat a maximum of 4 cohorts of research participants (dosage levels 1, 2, 3, and 4) with escalating doses of abemaciclib (LY2835219) starting with dose level 1 (80% of adult dose). A cycle is defined as 28 days and the first 6 weeks of therapy will constitute the dose-limiting toxicity (DLT)-evaluation period. Participants must take abemaciclib by mouth as intact capsules.
2987767|NCT02644460|Experimental|Stratum B|Abemaciclib (LY2835219) will be administered orally on a twice daily basis continuously for 28 days, which defines one cycle. The maximum treatment duration will be 2 years. Investigators plan to treat a maximum of 4 cohorts of research participants (dosage levels 1, 2, 3, and 4) with escalating doses of abemaciclib starting with dose level 1 (80% of adult dose). Dose escalation will be independent of Stratum A escalation. A cycle is defined as 28 days and the first 4 weeks of therapy will constitute the DLT-evaluation period. Participants must take abemaciclib by mouth as intact capsules.
2987768|NCT02644447|Experimental|HUC-MSCs Transplantation|
2987769|NCT02644447|Experimental|HUC-MSCs with Injectable Collagen Scaffold Transplantation|
2987770|NCT02644434|Active Comparator|Conventional Strategy|Patients randomized to the conventional strategy group would undergo either jailed wire technique (diameter of side branch<2.5mm and ≥2.0mm) or provisional two-stent strategy (diameter of side branch≥2.5mm).
2987771|NCT02644434|Experimental|Intentional Strategy|Patients randomized to the intentional strategy group would undergo either jailed balloon technique (diameter of side branch<2.5mm and ≥2.0mm) or elective two-stent strategy (diameter of side branch≥2.5mm).
2987772|NCT02644421|Experimental|VVZ-149|"The following doses will be administered intravenously:~Loading Dose: 1.8 mg/kg VVZ-149 over 0.5 hours~Maintenance infusion: 1.3 mg/kg/hr VVZ-149 over 7.5 hours"
2987773|NCT02644421|Active Comparator|Lidocaine|"The following doses will be administered intravenously:~Lidocaine 4mg/kg LBM over 0.5 hours~Normal saline over 7.5 hours"
2987774|NCT02644421|Placebo Comparator|Placebo|Normal saline administered intravenously over 8 hours
2987775|NCT02644408|Experimental|Megestrol and chemoradiotherapy|"Megestrol（Yining）：160mg/d，po,5 weeks in total，oen week before chemoradiotherapy and one week after chemoradiotherapy.~chemoradiotherapy：chemotherapy and radiotherapy： 50Gy in total，2 Gy/d，5d/w."
2987776|NCT02644408|Active Comparator|chemoradiotherapy|chemoradiotherapy：chemotherapy and radiotherapy： 50Gy in total，2 Gy/d，5d/w.
2987777|NCT02644395|Active Comparator|Amlodipine|Current treatment of choice
2987778|NCT02644395|Experimental|Chlorthalidone|Testing new indication for approved drug
2987779|NCT02644382||Key Informant interviews|20 in-person or phone qualitative interviews with patients.
2987780|NCT02644382||Focus Groups|four qualitative focus groups of 6-10 women each.
2987781|NCT02644382||Physician Interviews|physician qualitative interviews over the telephone.
2987782|NCT02644369|Experimental|Pembrolizumab|Pembrolizumab will be given by intravenous infusion (IV, given by vein) at a dose of 200 mg, once every 3 weeks.
2987783|NCT02644356|Experimental|Online CE/CME course|Participant in taking the three course modules and completing pre- and post-course data collection.
2987784|NCT02644330|Active Comparator|surgical group|The patients in Group A (surgical group) underwent surgical repair with cardiopulmonary bypass
2987785|NCT02644330|Experimental|closure group|The patients in Group B (closure group) underwent minimally invasive transthoracic device closure.
2987786|NCT02644317|Experimental|with modified shoe inserts|wear the modified shoe inserts and shoes for balance test.
2987787|NCT02644317|No Intervention|without modified shoe inserts|only wear the shoes for balance test.
2987788|NCT02644304|Active Comparator|Clomiphene citrate plus cabergoline|This group will receive Clomiphene citrate 50 mg tablet twice daily from the second day of menses to the sixth day plus cabergoline 0.25 mg from second day every 3 days (4 doses only)
2987789|NCT02644304|Active Comparator|Clomiphene citrate plus placebo|This group will receive Clomiphene citrate 50 mg tablet twice daily from the second day of menses to the sixth day plus placebo tablets from second day every 3 days (4 doses only)
2987790|NCT02644291|Experimental|mebendazole|oral mebendazole as dose escalation (three groups), or l oral mebendazole at maximum dose for extended cohort. Given in 3 divided doses with meals as chewable 500 mg tablets based on calculated patient surface area.
2987791|NCT02644278|Experimental|VX984/PLD|dose-escalation study in subjects with solid tumors (Part A) followed by an expansion phase in subjects with recurrent or metastatic endometrial cancer who have progressed on a prior platinum regimen (Part B).
2987792|NCT02644252|Experimental|Performance status 0-1, Arm A|Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Tocotrienol 300 mg x 3 daily until progression.
2987793|NCT02644252|Experimental|Performance status 0-1, Arm B|Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Placebo 1 capsule x 3 daily until progression.
2987794|NCT02644252|Experimental|Performance status 2, Arm A|Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Tocotrienol 300 mg x 3 daily until progression
2987795|NCT02644252|Experimental|Performance status 2, Arm B|Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Placebo 1 capsule x 3 daily until progression
2987796|NCT02644239|Active Comparator|Group control|classical ketogenic diet
2987797|NCT02644239|Active Comparator|Group case|Group case: modified ketogenic diet to reduce at least 20% saturated fat, up> 50% of the acid supply monounsaturated, increasing> 50% polyunsaturated fatty acid content and a lower ratio w6 / w3 at least 50% compared to classic diet used by the control group
2987798|NCT02644226||Sevoflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using sevoflurane as maintenance agents.
2987799|NCT02644226||Desflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using desflurane as maintenance agents.
2987800|NCT02644213|Experimental|research arm|"12 young, healthy civilian volunteers will participate in this study. The experiment will take place in a dome room.~The experiment will be performed according to the protocol of using CAREN and MOTEK systems:~CAREN high (Computer Assisted Rehabilitation Environment) which screens virtual scene in the dome.~MOTEK (Motek Medical©, the Netherlands) which is a two track treadmill (for each leg) placed on a rotatable platform.~each subject will undergo the same experiment protocol."
2987801|NCT02644200|No Intervention|ORS|Controls treated with oral rehydration solution (standard therapy)
2987802|NCT02644200|Active Comparator|ORS+GT|Group treated with oral rehydration solution plus gelatin tannate
2987803|NCT02644187|Other|Left side first -Aktilite CL128|Randomized left side first with application of 5-aminolevulinic acid under occlusion during 3h. After that Aktilite CL128.
2987804|NCT02644187|Other|Right side first -Aktilite CL128|Randomized right side first with application of 5-aminolevulinic acid under occlusion during 3h. After that Aktilite CL128.
2987805|NCT02644187|Other|Left side first -BF-RhodoLED|Randomized left side first with application of 5-aminolevulinic acid under occlusion during 3h. After that BF-RhodoLED.
2987806|NCT02644187|Other|Right side first -BF-RhodoLED|Randomized right side first with application of 5-aminolevulinic acid under occlusion during 3h. After that BF-RhodoLED.
2987807|NCT02644161|Active Comparator|Combination acupuncture treatment (CAI)|Post stroke depression patients will receive Dense Cranial Electroacupuncture Stimulation (DCEAS) and body acupuncture. Patients will continue their existing antidepressant and rehabilitation therapy as usual.
2987808|NCT02644161|Sham Comparator|Least acupuncture stimulation (LAS)|Post stroke depression patients will receive Least acupuncture stimulation (LAS). Patients will continue their existing antidepressant and rehabilitation therapy as usual.
2987809|NCT02644148|Other|Conventional Roux-en-Y anastomosis|Conventional Roux-en-Y Gastrojejunostomy will be used after laparoscopic distal gastrectomy for early gastric cancer.
2987810|NCT02644148|Experimental|Uncut Roux-en-Y anastomosis|Uncut Roux-en-Y Gastrojejunostomy will be used after laparoscopic distal gastrectomy for early gastric cancer.
2987811|NCT02644135|Experimental|Halo Oral Spray|Based upon the preliminary studies that assessed the duration of the antimicrobial effects of Halo as reported in the preliminary studies and feasibility, subjects assigned to both study arms will be asked to spray the product intra-orally 3 times daily (Three sprays per use, total = 9 sprays per day).
2987812|NCT02644135|Placebo Comparator|Halo Placebo|The placebo will consist of purified sterile water without CPC - the active antiseptic. Subjects assigned to both study arms will be asked to spray the product intra-orally 3 times daily (Three sprays per use, total = 9 sprays per day).
2987910|NCT02643485||Study group|Patients undergoing forefoot reconstruction of hallux valgus or hallux rigidus
2987813|NCT02644122|Experimental|SF1126|SF1126 1110 mg/m2 administered intravenously (IV) twice per week (separated by at least three days) for the first four treatment cycles (28 days) and then once weekly for subsequent cycles.
2987814|NCT02644109|Experimental|Phytosterols|"Milk powder: subjects will be instructed to consume 22 g/day of the product, with 0.65 g of esterified phytosterols (0.39 g of free equivalent sterols). The product will be reconstituted with 200 ml of water at time of consumption, preferably at breakfast or tea time. The total amount of product will be provided at the beginning of the study (day 1), together with instructions, material for preparation, and storage.~Drinking yoghurt: the daily volume consumed will be 90 ml/day with 1.3 grs of esterified phytosterols (0.78 g of free equivalent phytosterols). Subjects will be instructed to consume this beverage with main meal (not later than 15 min after it. The product should be kept refrigerated. Products will be distributed to subjects on a weekly basis."
2987815|NCT02644109|Placebo Comparator|Placebo|"Milk powder: subjects will be instructed to consume 22 g/day of the product, without phytosterols. The product will be reconstituted with 200 ml of water at time of consumption, preferably at breakfast or tea time. The total amount of product will be provided at the beginning of the study (day 1), together with instructions, material for preparation, and storage.~Drinking yoghurt: the daily volume consumed will be 90 ml/day without phytosterols. Subjects will be instructed to consume this beverage with main meal (not later than 15 min after it. The product should be kept refrigerated. Products will be distributed to subjects on a weekly basis."
2987816|NCT02644096|No Intervention|conventional treatment|After surgery, patients with total hip replacement are only seen once 3 months after surgery, and they have no further contact with the hospital.
2987817|NCT02644096|Other|Intervention|counselling and support after discharge from hospital
2987818|NCT02644070|Experimental|alveolar bone preservation with mp3|Extraction sockets grafted with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy) with graft particle size between 600 and 1000 µm and a collagen membrane (Evolution, Osteobiol, Coazze, Italy) used to stabilize the biomaterial into the socket.
2987819|NCT02644070|Experimental|alveolar bone preservation with apatos|Extraction sockets grafted with cortical porcine bone with particle size between 600 and 1000 µm (Apatos, Osteobiol, Coazze, Italy ) and a collagen membrane (Evolution, Osteobiol, Coazze, Italy) used to stabilize the biomaterial into the socket.
2987820|NCT02644070|No Intervention|NO_graft|extraction sockets with spontaneous healing
2987821|NCT02644057|Active Comparator|M-group|Will be given milrinone as an intravenous infusion at 0.2-0.6 mcg/kg/min for a maximum period of 72 hours and adjusted based on creatinine clearance measured by cockcroft-gault equation. It would be titrated based on hemodynamic response , urine output and at the discretion of the treating physician
2987822|NCT02644057|Active Comparator|D-group|Will be given dobutamine as an intravenous infusion at a maximum rate of 20 mcg/kg/min depending on patient tolerance and would adjusted based on hemodynamic response, urine output and at the discretion of treating physician
2987823|NCT02644044|Experimental|Treatment|Treatment with IT methotrexate
2987824|NCT02644031|Experimental|Mtwo rotary system|( continuous rotation system)
2987825|NCT02644031|Experimental|safe-sider rotary system|(reciprocating system)
2987826|NCT02644031|Experimental|hand files|k-files
2987827|NCT02644018|Experimental|Ingavirin|Ingavirin (Imidazolyl ethanamide pentandioic acid), capsules 30 mg daily for 5 days. The contents of one capsule of Ingavirin, capsules 30 mg should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.
2987828|NCT02644018|Placebo Comparator|Placebo|Placebo, capsules daily for 5 days. The contents of one capsule of placebo should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.
2987829|NCT02643979|Experimental|Ketofol and Propofol|This arm receives a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.
2987830|NCT02643979|Active Comparator|Propofol only|This arm receives 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.
2987831|NCT02643966|Experimental|Whole breast ultrasound|All women will receive both 3D mammography and whole breast ultrasound for breast cancer screening; the order of interpretation will vary for each of two radiologists
2987832|NCT02643953|No Intervention|Control Group|This arm includes women who are eligible and give birth (including cases of fetal or infant death) in the intervention period in comparative health wards, who will not receive the interventions and who will continue to receive their usual pattern of utilization of maternity care.
2987833|NCT02643953|Experimental|Other|The intervention will need to be multi-faceted, and will consist of provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; conditional cash transfers to promote uptake of services and targeted community health education and advocacy activities
2987834|NCT02643927|Experimental|standard 8-weeks MBSR|8-week program
2987835|NCT02643927|Experimental|4-week shortened MBSR|Short 4 sessions intervention
2987836|NCT02643927|No Intervention|Control Group|control group: No intervention
2987837|NCT02643914|Experimental|Nicotine Cravings|
2987838|NCT02643901|Experimental|Ic-GW003 150ug/kg 4-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
2987839|NCT02643901|Experimental|Ic-GW003 300ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
2987840|NCT02643901|Experimental|Ic-GW003 500ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
2987841|NCT02643901|Experimental|Ic-GW003 650ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
2987842|NCT02643901|Experimental|Ic-GW003 850ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
2987843|NCT02643875|Sham Comparator|Ortho-k lens with normal compression factor|The eye wears ortho-k lens with normal compression factor to achieve plano (+/- 0.25D) correction.
2987844|NCT02643875|Active Comparator|Ortho-k lenses with increased compression factor|The eye wears ortho-k lenses with increased compression factor to achieve 1 diopter (+/- 0.25D) over correction.
2987845|NCT02643862|Active Comparator|xolair|Pts will be randomized to receive xolair at a 3 active:1 placebo ratio
2987911|NCT02643485||Control group|Healthy volunteers (Students)
2987846|NCT02643862|Placebo Comparator|Placebo|This is a placebo that looks similar to Xolair and is given as a subcutaneous shot, just like Xolair
2987847|NCT02643849|Experimental|Spanner|
2987848|NCT02643836|Experimental|Treatment PEMF|The investigators will recruit and enroll 76 patients (between 18 and 30 years of age) who have had persistent symptoms consistent with PCS for at least 4 weeks, but not more than 6 months, after the initial injury. The experimental group will contain 38 subjects. Each study subject will receive two hats, which contain the integrated PEMF device, this will be done to ensure continuity of treatment in case that one of the hats stops working due to the battery running out. The subjects will receive PEMF treatment for 15 minutes three times per day for 6 weeks. Upon enrollment and at the end of the 6-week treatment period, all subjects will undergo a comprehensive assessment that will include symptom inventories, neuropsychological tests, qEEG measurement and near-infrared spectroscopy. The investigators will conduct a 3-month follow-up to assess longer-term outcomes.
2987849|NCT02643836|Sham Comparator|Sham Treatment|The investigators will recruit and enroll 76 patients (between 18 and 30 years of age) who have had persistent symptoms consistent with PCS for at least 4 weeks, but not more than 6 months, after the initial injury. The sham group will contain 38 subjects. Each study subject will receive two hats, which contain a de-activated PEMF device, the device will still be blinking to show sham treatment activity. The sham subjects will receive the sham treatment for 15 minutes three times per day for 6 weeks. Upon enrollment and at the end of the 6-week treatment period, all subjects will undergo a comprehensive assessment that will include symptom inventories, neuropsychological tests, qEEG measurement and near-infrared spectroscopy. The investigators will conduct a 3-month follow-up to assess longer-term outcomes.
2987850|NCT02643823|Experimental|hUC-MSC + DMARDs|Patients will be treated in combination with hUC-MSC and DMARDs with a 12 months follow-up.
2987851|NCT02643823|Active Comparator|DMARDs|Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs) with a 12 months follow-up.
2987852|NCT02643810|Active Comparator|Interval training group|Patients to be randomized to the 'interval training group' will have exercise training sessions 3 times per week for a period of 12 weeks. During training, they will undergo interval exercise series composed of high-intensity intervals (80-90% of peak heart rate) and low-intensity intervals (50-70% of peak heart rate).
2987853|NCT02643810|Active Comparator|Continuous training group|Patients to be randomized to the 'continuous training group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo moderate continuous exercise training at 70-75% of peak heart rate.
2987854|NCT02643810|No Intervention|Usual care group|Patients to be randomized to the 'usual care group' will undergo standard care for 12 weeks.
2987855|NCT02643797|Experimental|Intervention Group: MA Health Coaching|"Patients in the intervention group will receive the MA Health Coaching intervention during their primary care visits, as well a follow-up calls to encourage/monitor progress and offer support."
2987856|NCT02643797|No Intervention|Usual Care|"Patients in this group will receive treatment as usual during their primary care visits."
2987857|NCT02643784|Experimental|Rosuvastatin|Rosuvastatin study drug will be supplied in tablets (10 mg), assigned dose to be taken orally, once daily by subjects randomized to receive rosuvastatin 20 mg(take rosuvastatin until 14th day).
2987858|NCT02643784|No Intervention|Control|Control group(don't take rosuvastatin until 14th day), as directed by the study physician.
2987859|NCT02643771|Experimental|Diabetic group|Subjects with Chronic Periodontitis and Type 2 Diabetes Mellitus treated with non surgical periodontal therapy (Full Mouth Scaling and Root Planing)
2987860|NCT02643771|Experimental|Nondiabetic group|Subjects with Chronic Periodontitis and without Type 2 Diabetes Mellitus treated with non surgical periodontal therapy (Full Mouth Scaling and Root Planing)
2987861|NCT02643758|Experimental|Bifocal soft contact lenses|Device: Bifocal soft contact lenses Use of bifocal contact lenses with nasally decentered optical zone to control the progression of myopia
2987862|NCT02643758|No Intervention|Single vision spectacles|Control: Single vision spectacles
2987863|NCT02643745|Experimental|Nephrology Intervention|Nephrology intervention before surgery:
2987864|NCT02643745|No Intervention|Standard of Care|No nephrology intervention before surgery (standard of care)
2987865|NCT02643732|Experimental|Methylphenidate|"Methylphenidate 10mg (one tablet) twice daily, increasing to 20mg (two tablets) twice daily following assessment 2 weeks into trial.~24 weeks duration"
2987866|NCT02643732|Placebo Comparator|Placebo|"Identical, over-encapsulated placebo tablets manufactured to be identical to the experimental tablets. One tablet twice daily, increased to two tablets twice daily following assessment 2 weeks into trial.~24 weeks duration."
2987867|NCT02643719|Active Comparator|Topiramate|
2987868|NCT02643719|Active Comparator|Behavioral intervention|
2987869|NCT02643719|Active Comparator|topiramate and behavioral intervention|
2987870|NCT02643719|Active Comparator|Standard of Care|
2987871|NCT02643706||CIN|CIN was defined as an absolute increase in serum creatinine concentration of at least 0.5 mg/dL (44.2umol/l) or a relative rise of at least 25% from baseline on the follow-up blood sample drawn 24 to 72 hours after the operation.
2987872|NCT02643706||Control|The enrolled patients without CIN.
2987873|NCT02643693|Experimental|Sequence 1 (P3L-VUSE-CC)|Each subject will use ad libitum P3L on Visit 2, VUSE on Visit 3 and CC on Visit 4.
2987874|NCT02643693|Experimental|Sequence 2 (P3L - CC - VUSE)|Each subject will use ad libitum P3L on Visit 2, CC on Visit 3 and VUSE on Visit 4.
2987875|NCT02643693|Experimental|Sequence 3 ( VUSE - CC - P3L)|Each subject will use ad libitum VUSE on Visit 2, CC on Visit 3 and P3L on Visit 4.
2987876|NCT02643693|Experimental|Sequence 4 (VUSE - P3L - CC)|Each subject will use ad libitum VUSE on Visit 2, P3L on Visit 3 and CC on Visit 4.
2987877|NCT02643693|Experimental|Sequence 5 (CC - P3L - VUSE)|Each subject will use ad libitum CC on Visit 2, P3L on Visit 3 and VUSE on Visit 4.
2987878|NCT02643693|Experimental|Sequence 6 (CC - VUSE - P3L)|Each subject will use ad libitum CC on Visit 2, VUSE on Visit 3 and P3L on Visit 4.
2987879|NCT02643680|Experimental|The novel biocellulose wound dressing|
2987880|NCT02643680|Active Comparator|Bactigras|
2988108|NCT02642237|Experimental|LPS-Fluenz|Healthy volunteers administered intravenously with endotoxin, followed by an intranasal inoculation with Fluenz, a live-attenuated influenza vaccin
3001081|NCT02555683|Placebo Comparator|Placebo|Placebo once daily
2987881|NCT02643667|Experimental|Phase I: Ibrutinib|"Ibrutinib: will be given by mouth daily~Blood samples for PSA and for immune assays will be collected at baseline, before RP, and after RP~Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib"
2987882|NCT02643667|Experimental|Phase II: Ibrutinib|"Ibrutinib: will be given by mouth daily~Blood samples for PSA and for immune assays will be collected at baseline, before RP, and after RP~Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib"
2987883|NCT02643654|Placebo Comparator|Placebo|The placebo product is manufactured following the same procedures and batch records used to manufacture the MABp1 drug product. The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
2987884|NCT02643654|Active Comparator|MABp1|MABp1 is a recombinant human IgG1 monoclonal antibody specific for human interleukin-1α (IL-1α). The entire MABp1 heavy and light chain sequences are identical to those found in naturally-occurring human IgG1κ, with the light and heavy chain variable regions being identical to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy individual. It is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
2987885|NCT02643641|Experimental|BM32-3|2 placebo injections will be given followed by 3 injections with 20 micrograms each of BM321, BM322, BM325 and BM326
2987886|NCT02643641|Experimental|BM32-4|1 placebo injections will be given followed by 4 injections with 20 micrograms each of BM321, BM322, BM325 and BM326
2987887|NCT02643641|Experimental|BM32-5|5 injections with 20 micrograms each of BM321, BM322, BM325 and BM326 will be given
2987888|NCT02643641|Placebo Comparator|Placebo|5 placebo injections (alhydrogel only) will be given
2987889|NCT02643628|Experimental|Microneedling Only|All eligible scars within the treatment areas on each side of the face will receive microneedling treatment. The device will be rolled in a horizontal direction with medium pressure. After every roll, the device will be lifted and positioned a few millimeters inferior to the previous starting point. Rolling will be repeated until the entire skin area has been treated. The device will then be reoriented vertically and rolling will be repeated in a vertical direction.
2987890|NCT02643628|Experimental|Microneedling and Bellafill|Subjects undergo microneedling as described for the Microneedling Only group. Then at Week 12, all eligible scars within the treatment areas on each side of the face will be treated with Bellafill (injected using a standard tunneling technique). A touch-up treatment is allowed at Month 1 after initial treatment, if additional treatment is required to achieve optimal correction.
2987891|NCT02643615|Experimental|VEP under TIVA|Patients undergoing prone spine surgery will receive an anesthesia regimen using propofol (TIVA) for maintenance
2987892|NCT02643615|Experimental|VEP under balanced anesthesia|Patients undergoing prone spine surgery will receive an anesthesia regimen using Desflurane as part of balanced general anesthesia
2987893|NCT02643602|Experimental|Bicarbonate and theophylline|Hydration with bicarbonate in addition to theophylline
2987894|NCT02643602|Active Comparator|Sodium and theophylline|Hydration with sodium chloride in addition to theophylline
2987895|NCT02643589|Experimental|ATG 7.5mg/kg|ATG 7.5mg/kg group refers to treatment with ATG in the total dose of 7.5mg/kg.
2987896|NCT02643589|Active Comparator|ATG 10mg/kg|ATG 10mg/kg group refers to treatment with ATG in the total dose of 10mg/kg.
2987897|NCT02643576|No Intervention|Control|Usual SNAP-like food benefits
2987898|NCT02643576|Experimental|Rewards|Usual SNAP-like food benefits, plus a modification to this food benefit program that entails a 30% bonus on eligible fruit and vegetable purchases (i.e. F&V bonus)
2987899|NCT02643576|Experimental|Restrictions|Usual SNAP-like food benefits, plus a modification that requires no sugar-sweetened beverages, candy, or sweet baked goods be purchased
2987900|NCT02643576|Experimental|Rewards plus restrictions|Usual SNAP-like food benefits, plus two modifications to this food benefit program: one modification includes a 30% bonus on eligible fruit and vegetable purchases and the other modification is that sugar-sweetened beverages, candy, or sweet baked goods are not allowed to be purchased (i.e. Bonus & Restriction)
2987901|NCT02643563|Experimental|Ropivacaine 0.5%|Low volume (5 ml) Interscalene Block with Ropivacaine 0.5%
2987902|NCT02643563|Active Comparator|Ropivacaine 1%|Low volume (5 ml) Interscalene Block with Ropivacaine 1%
2987903|NCT02643563|Active Comparator|Bupivacaine 0.5% + epinephrine 1:200,000|Low volume (5 ml) Interscalene Block with Bupivacaine 0.5% + epinephrine 1:200,000
2987904|NCT02643550|Experimental|IPH2201 (MONALIZUMAB) +CETUXIMAB|Dose escalation of IPH2201 (MONALIZUMAB) + CETUXIMAB
2987905|NCT02643537||Luxation erecta|All patients with Inferior shoulder dislocation in fixed abduction, also known as luxatio erecta humeri (LEH)
2987906|NCT02643524|Active Comparator|Nutrition and Exercise Counseling|CAM boot prescribed as standard of care Nutritional counseling provided Upper body exercise counseling provided Blood drawn for Albumin level at enrollment and final visit Height and weight measured at enrollment and final visit Patients in this arm compared with patients in control arm
2987907|NCT02643524|Active Comparator|Control|CAM boot prescribed as standard of care No nutritional or exercise counseling provided Blood drawn for Albumin level at enrollment and final visit Height and weight measured at enrollment and final visit
2987908|NCT02643511|Experimental|Prostate biopsy,Hemiablative focal Brachytherapy|This is a non-randomized, Phase II study examining the efficacy in terms of postimplant dosimetry (primary endpoint) as well as the secondary endpoints of QOL changes, toxicity, local control with post-treatment biopsy outcomes and comparison with historical whole-gland cohorts in men with early stage low volume prostate cancer treated with hemiablative focal brachytherapy
2987909|NCT02643498|Experimental|Stereotactic Body Radiotherapy (SBRT)|"Cohorts 1-3 After completion of induction chemotherapy, stereotactic body radiotherapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.~Cohorts 4-6 For cohort 4, dose prescription will start at 7 Gy x 6 fractions (42Gy, isoeffective to 11 Gy x 3), followed by 4.8 Gy x 12 (54Gy) and 4.5Gy x 15 (67.5Gy)."
2987912|NCT02643472|Other|Care Notebook|Parents of infants who were discharged from the Children's National NICU will be randomized to receive enhanced usual care by provision of a NICU care resource notebook. Parents will be notified about group assignment prior to discharge. Stratification will occur according to birth weight.
2987913|NCT02643472|Experimental|Care Notebook + Parent Navigator|Parents of infants who were discharged from the Children's National NICU will be randomized to receive a care notebook + Parent Navigation. Parents will be notified about group assignment prior to discharge. Stratification will occur according to the birth weight.
2987914|NCT02643459|No Intervention|Conventional|no suPAR measurement. Standard care.
2987915|NCT02643459|Experimental|suPAR|suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR. Since suPAR is measured on all patients regardless of disease the investigators cannot define a single intervention. A possible intervention depends on the clinical situation.
2987916|NCT02643446||G1: IPV+OPV, 1 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months of age, that is one month after the first dose of IPV and just before the first dose of OPV.
2987917|NCT02643446||G2: IPV+OPV, 1 m+7d followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the first dose of OPV.
2987918|NCT02643446||G3: IPV+OPV, 2 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 4 months of age, that is one month after the first dose of OPV and just before the second dose of OPV.
2987919|NCT02643446||G4: IPV+OPV, 3 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 5 months of age, that is one month after the second dose of OPV.
2987920|NCT02643446||G5: OPV, 3 m followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 5 months of age, that is one month after the third dose of OPV.
2987921|NCT02643446||G6: OPV, 1 m followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 3 months of age, that is one month after the first dose of OPV and just before the second dose of OPV.
2987922|NCT02643446||G7: OPV, 1 m+7d followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of OPV.
2987923|NCT02643446||G8: IPV+IPV, 1 m+7d followup|Using 2 dose IPV and 1 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of IPV.
2987924|NCT02643446||G9: IPV+IPV, 2 m followup|Using 2 doses of IPV and 1 doses of OPV at 2, 3,4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 4 months of age, that is one month after the second dose of IPV and just before the first dose of OPV.
2987925|NCT02643446||G10: IPV+OPV, 1 m and 3 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months of age, that is one month after the first dose of IPV and just before the first dose of OPV;the third sample at 5 months of age, that is one month after the second dose of OPV.
2987926|NCT02643446||G11: IPV+OPV, 1 m+7d and 2 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the first dose of OPV,the third sample at 4 months of age, that is one month after the first dose of OPV.
2987927|NCT02643446||G12: IPV+IPV,1 m+7d and 2 m followup|Using 2 dose IPV and 1 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of IPV,the third sample at 4 months of age, that is one month after the second dose of IPV.
2987928|NCT02643433|Experimental|MR and JE coadministration group|Infants aged 8 months are vaccinated measles-rubella combined vaccine (MR) and Japanese Encephalitis alive vaccine (JE) in different sites at same time.
2987929|NCT02643433|Active Comparator|MR administration alone group|Infants aged 8 months are vaccinated measles-rubella combined vaccine alone
2987930|NCT02643420|Experimental|SPI-2012|"SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6)~Supplied in prefilled single-use syringes for subcutaneous injection~Administered on Day 2 of each cycle"
2987931|NCT02643420|Active Comparator|Pegfilgrastim|"Pegfilgrastim (6 mg/0.6 mL) (Neulasta® [NDC 55513-190-01] manufactured by Amgen)~Single-dose subcutaneous injection administered on Day 2 of each cycle"
2987932|NCT02643407|Experimental|Docetaxel plus Nedaplatin|docetaxel 60mg/m2 and nedaplatin 80mg/m2, d1 every 3 weeks
2987933|NCT02643407|Active Comparator|Docetaxel plus Cisplatin|docetaxel 60mg/m2 and cisplatin 75mg/m2, d1 every 3 weeks
2987934|NCT02643394|Active Comparator|Oral Acetaminophen|Oral Acetaminophen 1-hour before surgery
2987935|NCT02643394|Active Comparator|Intravenous Acetaminophen|Intravenous Acetaminophen within 1-hour prior to anesthetic emergence
2987936|NCT02643381|Experimental|Etomidate|Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
2987937|NCT02643381|Experimental|Ketamine|Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
2987938|NCT02643368|Active Comparator|mOPV2 at 6 and 7 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 7 weeks of age
2987939|NCT02643368|Active Comparator|mOPV2 at 6 and 8 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 8 weeks of age
2987940|NCT02643368|Active Comparator|mOPV2 at 6 and 10 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 10 weeks of age
2988109|NCT02642237|Placebo Comparator|Placebo-Fluenz|Healthy volunteers administered intravenously with placebo, followed by an intranasal inoculation with Fluenz, a live-attenuated influenza vaccin
2987941|NCT02643368|Active Comparator|mOPV2 at 6 and 10 week of age and IPV at 6 weeks of age|Participants enrolled in this arm would receive a dose monovalent type 2 oral polio vaccine (mOPV2) at 6 and 10 weeks of age. In addition, the participants will also receive inactivated polio vaccine (IPV) at 6 weeks of age
2987942|NCT02643355|Experimental|Experimental - Olanzapine|Drug of interest in the study - Olanzapine
2987943|NCT02643355|Active Comparator|Standard of Care - Clonidine|Standard of care - clonidine
2987944|NCT02643342|No Intervention|Single-vision glasses|Subjects wearing single-vision glasses CR-39 of refractive index 1.56.
2987945|NCT02643342|Sham Comparator|Orthokeratology with normal compression factor|Subjects wearing orthokeratology lenses of normal compression factor about 0.50-0.75D.
2987946|NCT02643342|Active Comparator|Orthokeratology with increased compression factor|Subjects wearing orthokeratology lenses of increased compression factor about 1.50-1.75D.
2987947|NCT02643329|Experimental|BF-Gliclazide Tablet 80mg|During the study session, healthy male subjects will be administered a single oral dose of BF-Gliclazide Tablet 80 mg after an overnight fast of approximately 10 hours.
2987948|NCT02643329|Active Comparator|Diamicron 80mg Tablet|During the study session, healthy male subjects will be administered a single oral dose of Diamicron 80 mg Tablet after an overnight fast of approximately 10 hours.
2987949|NCT02643316|Active Comparator|Same day 4 L preparation of PEG|Receive 1 gallon (4 L) of Polyethylene Glycol (PEG) preparation on the morning of the colonoscopy.
2987950|NCT02643316|Active Comparator|Split dose 4 L preparation of of the PEG|Receive the split-dose regimen. Will take half (2 L) of the PEG preparation the evening before colonoscopy and half (2 L) of the PEG preparation on the morning of the procedure.
2987951|NCT02643303|Experimental|Phase 1, Cohort 1A|IV Durvalumab + IT/IM polyICLC
2987952|NCT02643303|Experimental|Phase 1, Cohort 1B|IV Durvalumab + IV Tremelimumab + IT/IM polyICLC
2987953|NCT02643303|Experimental|Phase 1, Cohort 1C|IV Durvalumab + IT Tremelimumab + IT/IM polyICLC
2987954|NCT02643303|Experimental|Phase 2 Cohort|Once the recommended combination doses of the triplet dosing regimen has been determined in Cohort 1C, subsequent subjects will be enrolled into Cohort 2 to receive the recommended combination doses of both checkpoint antibodies in combination with polyICLC.
2987955|NCT02643290|Other|Patients|Adult patients with low back pain secondary to an high degree scolisis are treated by fiting with a brace 2-4 hours a day and tracked for 6 months.
2987956|NCT02643277|Other|Conventional care|Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
2987957|NCT02643277|Experimental|Mobile phone text messaging|The intervention will receive text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring. The messages provide tips and suggestions, and positive reinforcement or encouragement, for improving lifestyle behaviors and compliance with therapy.
2987958|NCT02643264|Experimental|rTMS 10 Hz|Deep Repetitive Transcranial Magnetic Stimulation (rTMS, 10 Hz) of the insula ,15 stimulation sessions (1 daily, 5 days / week).
2987959|NCT02643264|Sham Comparator|rTMS Sham|Sham Repetitive Transcranial Magnetic Stimulation (rTMS, Sham),15 stimulation sessions (1 daily, 5 days / week).
2987960|NCT02643251|Experimental|Clonidine Hydrochloride Topical Gel,0.1%|Clonidine Hydrochloride Topical Gel,0.1%
2987961|NCT02643251|Placebo Comparator|Clonidine Hydrochloride Gel Comparator|Clonidine Hydrochloride Gel Comparator
2987962|NCT02643238|Experimental|Group A - Blind|Subjects will be trained to ambulate through a 40-foot obstacle course by the occupational therapy colleagues at Akron Children's Hospital after which they will be scored on their performance while using the BrainPort® system.
2987963|NCT02643238|Active Comparator|Group C - Control|Subjects will be trained to ambulate through a 40-foot obstacle course by the occupational therapy colleagues at Akron Children's Hospital after which they will be scored on their performance while using the BrainPort® system.
2987964|NCT02643225||pregnant women with gestational diabetes|case group
2987965|NCT02643225||non diabetic pregnant women|control group
2987966|NCT02643212|Placebo Comparator|Placebo|
2987967|NCT02643212|Experimental|Rivaroxaban|Rivaroxaban 10mg, 1 once a day
2987968|NCT02643186|Active Comparator|misoprostol group|preoperative vaginal misoprostol in decreasing blood loss in transabdominal myomectomy
2987969|NCT02643186|Active Comparator|uterine artery ligation group|bilateral uterine artery ligation in decreasing blood loss in transabdominal myomectomy
2987970|NCT02643173||Volatile|The investigators retrospectively reviewed and analyzed the electrical medical records of patients who underwent surgery for HCC under the general anesthesia using volatile anesthetics as maintenance agents.
2987971|NCT02643173||Intravenous|The investigators retrospectively reviewed and analyzed the electrical medical records of patients who underwent surgery for HCC under the general anesthesia using intravenous anesthetics as maintenance agents.
2987972|NCT02643160|Experimental|Functional Trunk Training Group|Functional Trunk Training which includes strengthening of trunk muscle and functional activities including trunk region.
2987973|NCT02643160|No Intervention|Control Group|No intervention, the continued their regular physical therapy
2987974|NCT02643147|Experimental|CA125 guided strategy|In this group loop diuretic (Furosemide) dosage will be guided by Carbohydrate Antigen 125 (CA125) plasma levels
2987975|NCT02643147|Active Comparator|Conventional strategy|Standard treatment strategy Therapy is based on established european guidelines
2987976|NCT02643134|Other|Group 1|Patients in Group 1 undergo extracorporeal shockwave lithotripsy(ESWL).
2987977|NCT02643134|Other|Group 2|Patients in Group 2 undergo external physical vibration lithecbole for the treatment after extracorporeal shockwave lithotripsy(ESWL).A multi-dimensional physical harmonic vibration inertial guidance technology
2988149|NCT02641886|Experimental|Jian Pi Yi Shen Hua Tan Granules group|Treat with the prescription of Jianpi Yishen Huatan Granules and conventional treatment of ischemic stroke.
2987978|NCT02643121||children with sepsis, SIRS|Data will be collected and analyzed from childrens with SIRS or septic state who will be admitted to the Department of Anesthesia and Intensive Care of the University Children´s Hospital Brno, Czech Republic. Infections, sepsis, severe sepsis, septic shock and multiple organ dysfunction syndrome (MODS) will be defined according to commonly used criteria - by International pediatric sepsis consensus conference.
2987979|NCT02643121||control group, healthy children|The samples children undergoing elective surgery will be used as a controls, i.e. samples from patients without signs of infection.
2987980|NCT02643108|Experimental|Lateral episiotomy|Lateral episiotomy (left or right) is performed by the attending physician or assisting midwife at crowning of the fetal head in operative vaginal delivery by vacuum extraction. Regular manual perineal support is applied.
2987981|NCT02643108|No Intervention|No episiotomy|No episiotomy is performed during operative vaginal delivery. The woman may tear spontaneously. Regular manual perineal support is applied.
2987982|NCT02643095|Experimental|Lens fitting/evaluation|This study will be done with subjects who already habitually wear scleral contact lenses. The study lens is made with a material that is already widely available and has a new design. It will be fit by the investigators and will be assessed and at one week and 1 month.
2987983|NCT02643082|Experimental|GFF MDI, 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
2987984|NCT02643082|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI)
2987985|NCT02643069|Experimental|Intervention Geriatric Program|A comprehensive management plan of the frail patients, covering both in-hospital and postdischarge time, according to the treating physicians (s) surgeon and the performance of a geriatrician . This management will consist of the therapeutic plan, access to geriatric levels of care, coordination with primary and social care, rehabilitation, and discharge plan.
2987986|NCT02643069|No Intervention|Usual clinical practice|A comprehensive management plan of the frail patients, covering both in-hospital and postdischarge time, agreed with the treating physicians (s) surgeon.
2987987|NCT02643056|Experimental|Panitumumab|6 mg/kg per administration
2987988|NCT02643043||UC Subjects|Subjects with confirmed metastatic urothelial cancer willing to participate in biospecimen collection (tissue and blood) for genetic studies.
2987989|NCT02643030|Experimental|normocapnia|Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
2987990|NCT02643030|Active Comparator|hypercapnia|Tidal volume (6ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg
2987991|NCT02643017|Placebo Comparator|normal saline|
2987992|NCT02643017|Experimental|Dex|
2987993|NCT02643004|Active Comparator|Senofilcon A|Participants were randomized to wear senofilcon A lens pair for one week during the crossover study.
2987994|NCT02643004|Active Comparator|Stenfilcon A|Participants were randomized to wear stenfilcon A lens pair for one week during the crossover study.
2987995|NCT02642991|Experimental|Study Test contact lens|Study Test Contact Lens
2987996|NCT02642991|Active Comparator|comfilcon A contact lens|Control Contact Lens
2987997|NCT02642978|Experimental|RSRCLM|robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).Three different liver resection procedures were chose to personalized patients. Generally, when the size of liver metastasis was ≤ 3 cm, a wedge resection was chose without Hilar vessels blocking. The segmentectomy was performed using the Glissonian approach when tumor size was among 3-5 cm, and Hilar vessels was blocked, if necessary. For resection of Couinaud's segments II and III, left lateral sectionectomy (LLS) was performed commonly. Intraoperative ultrasound can help us find intrahepatic pedicles and follow the proper resection line. When liver tumor size was more than 5 cm or more than 3 tumors with the size over 3cm, hemicolectomy was applied usually.
2987998|NCT02642978|Active Comparator|Open|Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis. The DFS and safety event were evaluated.
2987999|NCT02642965|Experimental|Treatment (CPX-351 and FLAG)|"COURSE 1: Patients receive cytarabine IT on day 0 and at day 28-30 or up to 7 days prior to day 1 of course 2, and liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5. Patients with CNS1 receive no further CNS-directed therapy in course 1. Patients with CNS2 disease may receive additional 4-6 doses of cytarabine IT twice weekly starting 48 hours after the third dose of liposome-encapsulated daunorubicin-cytarabine until CNS is clear at the discretion of the investigator. Patients meeting criteria for CR, CRp, and CRi may proceed to course 2.~COURSE 2: Beginning 28 days later, patients receive filgrastim SC on days 1-5 and then on day 15 until blood count recovery, and fludarabine phosphate IV over 30 minutes and high-dose cytarabine IV over 1-3 hours QD on days 1-5."
2988000|NCT02642952||Open-graft group|Patients treated for abdominal aortic aneurysm with open graft will be measured for central hemodynamics and arterial stiffness by non-invasive methods.
2988001|NCT02642952||Endograft group|Patients treated for abdominal aortic aneurysm with endograft will be measured for central hemodynamics and arterial stiffness by non-invasive methods.
2988002|NCT02642939|Experimental|mifepristone|mifepristone 300 mg capsule per day, orally in 28-day cycles
2988003|NCT02642926|Active Comparator|Monopolar endoscopic endometrial ablation|
2988004|NCT02642926|Experimental|Bipolar endoscopic endometrial ablation|
2988005|NCT02642913|Experimental|Enzalutamide without Sorafenib|Will get enzalutamide, at the dose approved by the FDA for prostate cancer. If this dose has serious side effects, a lower dose will be given to new patients as they take part in the study. At the end of this part of the study, the recommended dose of enzalutamide will be set for all patients on this study. More patients will then be treated with this dose.
2988006|NCT02642913|Experimental|Enzalutamide with Sorafenib|Will get enzalutamide and sorafenib. The first group of patients will get the recommended dose of enzalutamide with sorafenib by mouth either once or twice daily. The dose of sorafenib you receive will depend on when the patient starts the study. At the beginning of the study, patients will be treated with a lower dose of sorafenib. If this dose does not have serious side effects, a higher dose will be given to new patients as they take part in the study.
2988007|NCT02642900|Experimental|Nystatin 100.000 units|Patients were treated with a topical antifungal nystatin oral suspension(1000.000 units) 5mL every six hours/14 days. Patients were instructed to rinse the solution for 5 minutes and then to spit the solution out. Samples were collected on days 7, 14 and 30 after the end of treatment (follow-up).
2988008|NCT02642900|Active Comparator|Photodynamic Therapy|Patients used mouthwash with methylene blue 0.005% for 20 minutes (pre-irradiation time). The palatal mucosa was irradiated using a low level laser with the following settings: wavelength of 660 nm, energy density of 120 J/cm ², output power of 40 milliwatt, 2 minutes per point. PDT was performed in two sessions (one session per week). Samples were collected immediately after each clinical procedure and 30 days after the second procedure (follow-up).
2988009|NCT02642887|Experimental|The test group|This group included 30 recession defects treated with mTA + SCTG
2988010|NCT02642887|No Intervention|The control group|This group included 30 recession defects treated with cTT + SCTG
2988011|NCT02642874|Experimental|Methocarbamol|Methocarbamol twice daily
2988012|NCT02642874|Placebo Comparator|placebo|Calcium carbonate twice daily
2988013|NCT02642861|Active Comparator|Cyclobenzaprine|Cyclobenzaprine administration for 2 weeks
2988014|NCT02642861|Placebo Comparator|PLacebo|Calcium carbonate for 2 weeks
2988015|NCT02642848|Active Comparator|HTO with micro fracture|High tibial osteotomy(HTO) with micro fracture is an common treatment for the correction of malalignment of the knee treating osteoarthritis.
2988016|NCT02642848|Experimental|HTO with bone marrow stem cell|High tibial osteotomy(HTO) with transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone.
2988017|NCT02642848|Experimental|HTO with adipose derived stem cell|High tibial osteotomy(HTO) with autologous adipose-derived stromal vascular fraction transplantation using LipoSculptor collecting from abdominal fat tissue.
2988018|NCT02642809|Experimental|Arm 1: Pembrolizumab and Brachytherapy|"Brachytherapy dose=16 Gy delivered in 2 fractions of 8 Gy per fraction, separated by 7-10 days between fractions.~Pembrolizumab started within 1 week after completion of brachytherapy administered as an intravenous infusion over 30 minutes. It will be given every 3 weeks.~Standard of care endoscopic biopsy will take place at time of enrollment and 2-6 months (optional) after pembrolizumab initiation.~Research endoscopic biopsy for 8 consented patients will take place 1-2 weeks after initiation of brachytherapy.~Peripheral blood will be collected: Pre-brachytherapy, Post-brachytherapy but pre-pembrolizumab (on day 1), Day 22 after the start of pembrolizumab, 3, 6, and 12 months (+/- 2 weeks) after the start of pembrolizumab, and time of progression"
2988019|NCT02642796|No Intervention|Group I (control)|Patient controlled analgesia (epidural fentanyl): PCA only
2988020|NCT02642796|Experimental|group II|PCA plus lumbar plexus & sciatic nerve transcutaneous electric nerve stimulation (LS-TENS)
2988021|NCT02642796|Experimental|group III|PCA plus surgical wound transcutaneous electric nerve stimulation ( SW-TENS)
2988022|NCT02642783|Other|Descriptive analysis|panelists were asked to rate different sensory attributes for different laxative bowel cleansing solutions on a 15 cm line scale.
2988023|NCT02642783|Other|Acceptability test|panelists were asked to rate the acceptability of different laxative bowel cleansing solutions using the 9-point hedonic scale.
2988024|NCT02642757|Experimental|Brief intervention|AUDIT brief intervention
2988025|NCT02642757|Sham Comparator|Control group|Pamphlet on alcohol use
2988026|NCT02642744|Other|Attending nurse model|The attending nurse model of in-hospital care delivery aims to improve patient understanding, shared decision making, medication adherence, and reduce early readmissions after discharge to improve quality of life. On the inpatient stroke unit, the attending nurse will take ownership of essential aspects of an individual stroke patient's care, education, and transition out of the hospital. To further contribute to the patient's plan of care, the attending nurse will be present on daily teaching rounds.
2988027|NCT02642744|No Intervention|Conventional inpatient nursing care|Standard of care nursing care patients receive while inpatient
2988028|NCT02642731||Patients for elective TKA|patients with normal or near normal plasma creatinine who come for elective total knee arthroplasty
2988029|NCT02642718|Placebo Comparator|Placebo|In the operating room, the anesthesiologist administered 50 mL of 0.9% saline intravenously to patients in the control group 30 minutes before surgical incision
2988030|NCT02642718|Experimental|Ketorolac Tromethamine|In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision. (a single dose).
2988031|NCT02642705|Experimental|High intensity interval training N|High intensity interval training N: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a high intensity interval training protocol (1 min ON at 100% maximal power output, 1 min OFF), breathing ambient air (normoxia)
2988032|NCT02642705|Experimental|High intensity interval training H|High intensity interval training H: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a high intensity interval training protocol (1 min ON at 100% maximal power output, 1 min OFF), breathing hypoxic air (about 3 500 m of altitude)
2988033|NCT02642705|Active Comparator|Constant load exercise training N|Constant load exercise training N: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a constant load training protocol (50% maximal power output), breathing ambient air (normoxia)
2988034|NCT02642705|Experimental|Constant load exercise training H|Constant load exercise training H: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a constant load training protocol (50% maximal power output), breathing hypoxic air (about 3 500 m of altitude)
2988035|NCT02642705|Experimental|Hypoxic conditioning at rest|Hypoxic conditioning at rest : The intervention consists in 8-week conditioning period, 3 times a week, hypoxic breathing for one hour (about 4500 m of altitude) while seating quietly
2988036|NCT02642705|Sham Comparator|Normoxic conditioning at rest|Normoxic conditioning at rest : The intervention consists in 8-week conditioning period, 3 times a week, normoxic breathing for one hour (ambient air) while seating quietly
2988037|NCT02642692|Experimental|Patellar Tendon Graft|Kind of graft that will be used for acl reconstruction
2988038|NCT02642692|Experimental|Hamstring Graft|Kind of graft that will be used for acl reconstruction
2988039|NCT02642679|Experimental|Opticell Ag|Opticell Ag covered with a transparent occlusive dressing (Tegaderm) with evenly distributed perforations which permit a controlled leakage into a layer of cotton gauze pads placed directly over the Opticell Ag and occlusive dressing combination.
2988185|NCT02641600|Placebo Comparator|Placebo stockings|Placebo stockings (0 mmHg)
2988186|NCT02641587|Experimental|CHTP 1.2|Ad libitum use of the CHTP 1.2
2988040|NCT02642666|Experimental|Yoga intervention|While in the yoga intervention arm of the study participants will practice yoga at home and at school for six weeks with the goal of practicing yoga daily during that time period. Yoga classes will be held twice a week at school. On the days that the children do not practice yoga at school, they will practice yoga at home with the use of a children's yoga video that mirrors the yoga class that they attend at school.
2988041|NCT02642666|No Intervention|Normal school and home activities|While in the wait-list group the children will continue with their regular activities both at home and at school.
2988042|NCT02642653|Active Comparator|Lovastatin and PILI|Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with study medication Lovastatin.
2988043|NCT02642653|Placebo Comparator|Placebo and PILI|Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with placebo.
2988044|NCT02642640|Other|melatonin-placebo|subjects will receive melatonin first and placebo second
2988045|NCT02642640|Other|placebo-melatonin|subjects will receive placebo first and melatonin second
2988046|NCT02642627|Experimental|Bellafill Injections|Correctable acne scars will be individually identified and only scars that the Investigator determines to be correctable will receive study treatment. All eligible scars within the treatment area will be treated. Bellafill will be injected using a standard tunneling technique whereby the filler is injected in a retrograde manner utilizing several passes until the scar reaches a desired level of correction. A touch-up treatment is allowed if additional treatment is required to achieve optimal correction.
2988047|NCT02642614|Experimental|BI 1026706 low dose|
2988048|NCT02642614|Experimental|BI 1026706 medium|
2988049|NCT02642614|Experimental|BI 1026706 high dose|
2988050|NCT02642614|Placebo Comparator|Placebo|
2988051|NCT02642601|Experimental|indomethacin|one dose of indomethacin 100 mg rectal suppository;will be adminstrated1-2 hours before embryo transfer
2988052|NCT02642601|No Intervention|no medication|no indomethacine before embryo transfer
2988053|NCT02642588|Experimental|energy gel|women will be given 22 g of carbohydrates every 45-60 minutes for up to 8 hours or until delivery during the active phase of labor
2988054|NCT02642588|No Intervention|control|women will be given only clear liquids during labor
2988055|NCT02642562|No Intervention|Standard care|Participants in this arm will receive their usual care
2988056|NCT02642562|Experimental|Standard care plus IV iron infusion|"Iron to be administered as iron (III) isomaltoside 1000.~Infused over a minimum of 15 mins for doses up to and including 1000mg, and a minimum of 30 mins for doses >1000mg Body weight <50 kg: 20 mg/kg Hb ≥10 g/dL and body weight 50 to <70 kg: 1000 mg Hb ≥10 g/dL and body weight ≥70 kg: 20 mg/kg up to a max of 1500 mg Hb < 10 g/dL and body weight 50 to <70 kg: 20 mg/kg Hb < 10 g/dL and body weight ≥70 kg: 20 mg/kg up to a max of 2000 mg"
2988057|NCT02642549|Experimental|Girls for Health Intervention (G4H)|G4H will integrate proven girls' education strategies with innovative vocational interventions to build 1350 girls' career aspirations and academic achievement
2988058|NCT02642549|No Intervention|Control Condition|standard of care to support school attendance among girls (i.e., school tracking of attendance and reaching out to truant girls).
2988059|NCT02642536|Active Comparator|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
2988060|NCT02642536|Active Comparator|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
2988061|NCT02642523|Placebo Comparator|Saline Infusion|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
2988062|NCT02642523|Experimental|Insulin Clamp|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
2988063|NCT02642523|Experimental|BNP Infusion (Nesiritide)|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
2988064|NCT02642510|Experimental|DVD Structured Education|Participants in this group will watch an educational DVD in addition to standard teaching by nursing staff.
2988065|NCT02642510|Active Comparator|Standard Educational Teaching|Participants in this group will receive educational teaching by their assigned nursing staff.
2988066|NCT02642497|Active Comparator|local ketamine group|intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure, with closure of suction drain tube for 30 min. postoperatively.
2988067|NCT02642497|Placebo Comparator|control group|intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure, with closure of suction drain tube for 30 min. postoperatively.
2988068|NCT02642497|Active Comparator|systemic ketamine group|Intra-muscular injection of ketamine at a dose of 1 mg/kg before wound closure.
2988069|NCT02642484|Active Comparator|Gabapentin|Gabapentin twice daily
2988070|NCT02642484|Placebo Comparator|PLacebo|Calcium carbonate twice daily
2988071|NCT02642471|Experimental|Arm 1|patients with negative sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 1 or Arm 2 Arm 1: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 2: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
2988072|NCT02642471|No Intervention|Arm 2|patients with negative sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 1 or Arm 2 Arm 1: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 2: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
2988147|NCT02641912|Other|Mineral Water|"During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use."
2988073|NCT02642471|Experimental|Arm 3|patients with positive sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 3 or Arm 4 Arm 3: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 4: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
2988074|NCT02642471|No Intervention|Arm 4|patients with positive sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 3 or Arm 4 Arm 3: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 4: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
2988075|NCT02642458||trastuzumab plus chemotherapy|Treatment with trastuzumab plus chemotherapie as first line therapy, administered intravenously/subcutaneously in a three weekly frequency. Docetaxel is recommended as chemotherapy, however, any treatment choice or change in regimen is performed at the discretion of the treating physician.
2988076|NCT02642458||pertuzumab plus trastuzumab plus chemotherapy|Treatment with with pertuzumab plus trastuzumab plus chemotherapy as first line therapy, administered intravenously/subcutaneously in a three weekly frequency. Docetaxel is recommended as chemotherapy, however, any treatment choice or change in regimen is performed at the discretion of the treating physician.
2988077|NCT02642445|Experimental|Renal Sympathetic Denervation|Renal sympathetic Denervation are conducted from the adventitia of renal artery
2988078|NCT02642445|No Intervention|Control Group|Renal Sympathetic Denervation are not conducted in control group.
2988079|NCT02642432|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
2988080|NCT02642419|Experimental|Rivaroxaban|
2988081|NCT02642419|Experimental|Rivaroxaban and single antiplatelet drug|
2988082|NCT02642393|Experimental|Inosine|Inosine will be dosed by titrating the number of capsules taken daily to achieve an elevation of serum urate to trough levels of 7.1 to 8.0 mg/dL.
2988083|NCT02642393|Placebo Comparator|Placebo|Placebo will be dosed to match the capsule titrations of the inosine group.
2988084|NCT02642380|Experimental|4 cycles|Oral administration of dexamethasone 40 mg for four consecutive days every 14 days for 4 courses
2988085|NCT02642380|Active Comparator|1 cycle|Oral administration of dexamethasone 40 mg for four consecutive days
2988086|NCT02642367|Experimental|no use of stylet|Endotracheal intubation was performed 2 min after rocuronium injection without use of stylet with McGrath videolaryngoscope after endotracheal tube was rolled up circularly for 3 min
2988087|NCT02642367|Active Comparator|use of stylet|Endotracheal intubation was performed 2 min after rocuronium injection using a styletted endotracheal tube with McGrath videolaryngoscope
2988088|NCT02642354|Experimental|Study Test contact lens|Study Test Contact Lens
2988089|NCT02642354|Active Comparator|comfilcon A contact lens|Control Contact Lens
2988090|NCT02642341|Experimental|Study Test contact lens|Study Test Contact Lens
2988091|NCT02642341|Active Comparator|comfilcon A contact lens|Control Contact Lens
2988092|NCT02642328|Experimental|HIIT Training|Circuit training with strength and power. The chosen exercises were (random order): Sit-Ups, Mountain Climbers, Plank, Side Skater, Push Ups, Ground Support with Vertical Jump, Overhead Squat, Box Jump.Time total = 4 minutes
2988093|NCT02642328|Active Comparator|Control|Running aerobic exercise at 65% of VO2Max
2988094|NCT02642315|Other|open-label|"open-label single arm study~Horizant, 600 mg oral once daily at 5 pm for 360 days."
2988095|NCT02642302|Experimental|HIIT With 60 sec Rest|The experimental (1) group will be submitted at Six reps of 30 seconds of high intensity interval training (all out) with 60 seconds of interval rest for a total of 30 sessions of training. Dependents variables such as VO2Max and performance parameters are estimated before and after training sessions
2988096|NCT02642302|Experimental|HIIT With 120 sec Rest|The experimental (2) group will be submitted at Six reps of 30 seconds of high intensity interval training (all out) with 120 seconds of interval rest for a total of 30 sessions of training. Dependents variables such as VO2Max and performance parameters are estimated before and after training sessions
2988097|NCT02642302|Active Comparator|Control|Continuous exercise at 50-55% of VO2max with similar total work
2988098|NCT02642289|Experimental|Probiotic1: Lactobacillus acidophilus|Dietary Supplement: Probiotics 1. 8-week probiotic food-supplement intervention with Lactobacillus acidophilus (Daily intake: 24 millions)
2988099|NCT02642289|Placebo Comparator|Placebo|Inactivate substance
2988100|NCT02642289|Experimental|Probiotic2: Lactobacillus Rhamnosus GG ®|Dietary Supplement: Probiotics 2 8-week probiotic food-supplement intervention with Lactobacillus Rhamnosus (Daily intake: 24 millions)
2988101|NCT02642276|Active Comparator|Maximal walking group|Patients to be randomized to the 'maximal walking group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo an exercise training programme consisting of 60 minutes of repetitive interval muscle training/walking up to the point of pain-free walking distance.
2988102|NCT02642276|Active Comparator|Submaximal walking group|Patients to be randomized to the 'submaximal walking group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo an exercise training programme consisting of 60 minutes of repetitive interval muscle training/walking up to 2/3 of pain-free walking distance.
2988103|NCT02642276|No Intervention|Usual care group|Patients to be randomized to the 'usual care group' will undergo standard care for 12 weeks.
2988104|NCT02642263|No Intervention|Oxytocin|Oxytocin 20 IE in 500 ml G Na intravenous infusion over 6 hours (GlucoSalin 2:1; 2/3 glucose 5%+1/3 NaCl 0.9%), Sintetica-Bioren, Switzerland, after birth of the baby. For blinding purposes a 3ml NaCl 0.9% syringe is administered intravenously after birth of the baby as well.
2988105|NCT02642263|Experimental|Carbetocin|100 mcg of Carbetocin, Ferring, Switzerland, as iv administration after birth of the baby. For blinding purposes an intravenous infusion of 500 ml G Na (GlucoSalin 2:1; 2/3 glucose 5%+1/3 NaCl 0.9%) is administered over 6 hours.
2988106|NCT02642250|Experimental|Entoban Capsules|Entoban is the combination of Holarrhena antidysenterica, Berberis aristata, Symplocos racemosa, Querecus infectoria and Helicteres isora.
2988107|NCT02642250|Experimental|Metronidazole DS|Metronidazole DS(400 mg) is commonly used to treat diarrhea.It eliminates bacteria and other microorganisms that cause infections of the reproductive system, gastrointestinal tract, skin, vagina, and other areas of the body.
3002620|NCT02545829|Experimental|Sequence 2|HIP1302 → HGP1406
2988110|NCT02642224|Experimental|Social work intervention|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
2988111|NCT02642211|Active Comparator|phako|eyes receiving phakoemulsification for cataract surgery
2988112|NCT02642211|Active Comparator|MSICS|Eyes undergoing manual small incision cataract surgery
2988113|NCT02642185||Ablation|Patients that are primarily treated with microwave ablation of colorectal liver metastases
2988114|NCT02642185||Resection|Patients identified in the Swedish liver registry during the same time frame subjected to liver resection, propensity score matched to the ablation group
2988115|NCT02642172|Experimental|ITF (Inulin/OFS 75/25)|16 gram/day of ITF (Inulin/OFS 75/25)
2988116|NCT02642172|Placebo Comparator|placebo|16 gram/day of maltodextrin (placebo)
2988117|NCT02642159|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without other lipid modifying therapy (LMT) for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when non-high-density lipoprotein cholesterol (non-HDL-C) levels >=100 mg/dL (2.59 mmol/L) at Week 8.
2988118|NCT02642159|Active Comparator|Usual Care|Participants on usual care continued on insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without additional LMT or with either ezetimibe, fenofibrate, omega-3 fatty acids or nicotinic acid as per Investigator's judgment for 24 weeks.
2988119|NCT02642133|Other|Intervention|All patients were in the same arm - this is a cohort study where the group serves as their own control. Patients who did not undergo the procedure were not included in this outcomes study.
2988120|NCT02642120|Experimental|Receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
2988121|NCT02642120|No Intervention|Do not receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the control group.
2988122|NCT02642107|Experimental|Elective neck irradiation|Whole neck irradiation is given in the positive neck. Elective neck irradiation of Level II,III,Va lymph node area is given in negative neck, and Level IV,Vb and Supraclavicular fossa lymph node area were not irradiated in negative neck.
2988123|NCT02642107|Active Comparator|Whole neck irradiation|Whole neck irradiation is given regardless of the positive or negative neck.
2988124|NCT02642094|Experimental|The effect of short-term rapamycin treatment|Subjects will be given a low dose of rapamycin at 2 mg/day for 5-7 days of treatment. A surgical specimen will be taken 3-7 days after the last dose of rapamycin. The specimens will be evaluated for lesion size, nuclear grade, presence of necrosis in each patient's core biopsy and surgical specimens, as well as IHC (ImmunoHistoChemistry) for biomarkers including p16, COX2 (cyclooxygenase-2), and Ki-67. Specimens will also be tested for rapamycin treatment on the properties of mammary stem/progenitor cells as another biomarker for gauging the efficacy of rapamycin treatment.
2988125|NCT02642068||ADHD group|Drug-naïve adult ADHD Probands
2988126|NCT02642068||Sibling group|Unaffected Siblings of Drug-naïve Adult ADHD
2988127|NCT02642068||Control group|Age-, sex-, handedness-, and IQ-matched controls without lifetime ADHD or a family history of ADHD
2988128|NCT02642055|Experimental|Neuro+ Intervention|30 sessions (900 minutes) of Neuro+ Attention Training administered over 10 weeks.
2988129|NCT02642055|Active Comparator|Treatment as Usual|Continuation of current treatment for ADHD
2988130|NCT02642042|Experimental|Treatment (trametinib, docetaxel)|Patients receive trametinib PO on days 1-21. Patients also receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2988131|NCT02642029|Other|Psychosis patients|Patients with schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic features will undergo a single session each of excitatory TMS, inhibitory TMS, and sham TMS (in randomized order).
2988132|NCT02642029|Other|Healthy control participants|Individuals without major psychiatric illness will undergo a single session each of excitatory TMS, inhibitory TMS, and sham TMS (in randomized order).
2988133|NCT02642016|Experimental|CDX-0158|
2988134|NCT02642003|Experimental|GCSF+SMT|5-day course of GCSF (5 μg/kg/d) plus standard medical therapy for 6 months
2988135|NCT02642003|No Intervention|SMT|
2988136|NCT02641990|Experimental|Group 1|ITCA 650 20/60 mcg/day, ITCA placebo
2988137|NCT02641990|Experimental|Group 2|ITCA placebo, ITCA 650 20/60 mcg/day
2988138|NCT02641964||ARDS group|patients with acute necrotizing pancreatitis complicated by ARDS
2988139|NCT02641964||non-ARDS group|acute necrotizing pancreatitis patients without ARDS
2988140|NCT02641951|Placebo Comparator|Stellate ganglionic block|Ultrasound guided stellate ganglionic block
2988141|NCT02641951|Active Comparator|Pecs II block|Ultrasound guided Pecs II block
2988142|NCT02641938|Experimental|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
2988143|NCT02641938|Placebo Comparator|Normal Saline|IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
2988144|NCT02641925|Active Comparator|Omentum preserving|Omentum preserving: The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed.
2988145|NCT02641925|Experimental|Total omentectomy|Total omentectomy: Whole omentum will be removed.
2988146|NCT02641912|Experimental|Experimental Mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
2988148|NCT02641899|Experimental|Experimental Treatment|ITCA 650 20/60 mcg/day Acetaminophen 1000 mg Atorvastatin 40 mg Lisinopril 20 mg Warfarin 25 mg Digoxin 0.5 mg
2988150|NCT02641886|Placebo Comparator|the Placebo Group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin and conventional treatment of ischemic stroke.
2988151|NCT02641873|Experimental|BBI608 + FOLFIRI +Bevacizumab|
2988152|NCT02641860|Other|Mesenchymal progenitor cells Dosage 1|Mesenchymal progenitor cells low-dose group
2988153|NCT02641860|Other|Mesenchymal progenitor cells Dosage 2|Mesenchymal progenitor cells mid-dose group
2988154|NCT02641860|Other|Mesenchymal progenitor cells Dosage 3|Mesenchymal progenitor cells high-dose group
2988155|NCT02641847|Experimental|High risk group A|TA(E)C x 4 cycles to GP x 4 cycles (docetaxel + doxorubicin (epirubicin) + cyclophosphamide to gemcitabine + cisplatin), docetaxel: 75 mg/m2 IV on day 1; doxorubicin: 50 mg/m2 IV on day 1 or epirubicin 75 mg/m2 IV on day 1; cyclophosphamide: 500 mg/m2 IV on day 1; gemcitabine: 1250 mg/m2 IV on day 1 and 8; cisplatin: 75 mg/m2 IV on day 1, dosing interval is 21 days.
2988156|NCT02641847|Active Comparator|High risk group B|A(E)C x 4 cycles to T x 4 cycles (doxorubicin (epirubicin) + cyclophosphamide to docetaxel), doxorubicin: 60 mg/m2 IV on day 1 or epirubicin 90 mg/m2 IV on day 1; cyclophosphamide: 600 mg/m2 IV on day 1; docetaxel: 100 mg/m2 IV on day 1, dosing interval is 21 days.
2988157|NCT02641847|Other|Low risk group C|A(E)C x 4 cycles to T x 4 cycles (doxorubicin (epirubicin) + cyclophosphamide to docetaxel), doxorubicin: 60 mg/m2 IV on day 1 or epirubicin 90 mg/m2 IV on day 1; cyclophosphamide: 600 mg/m2 IV on day 1; docetaxel: 100 mg/m2 IV on day 1, dosing interval is 21 days.
2988158|NCT02641834|Experimental|Veg Group|Group that starts with the Vegetarian diet
2988159|NCT02641834|Active Comparator|Med group|Group that starts with the Mediterranean diet
2988160|NCT02641821|Experimental|Nifedipine GITS|
2988161|NCT02641808|Experimental|follicular flushing group|Monofollicular IVF therapy with follicular flushing up to five times after aspiration of the follicule at the time to the oocyte pick-up
2988162|NCT02641808|Active Comparator|aspiration group|Monofollicular IVF therapy with aspiration only at the time of the oozyte pick-up
2988163|NCT02641795|Experimental|Experimental|Minimally invasive robotic cochlear implantation with custom device
2988164|NCT02641782|Active Comparator|Standard Arm|Standard IL-2 i.v. together with antibody ch14.18, GM-CSF and retinoic acid
2988165|NCT02641782|Experimental|Experimental Arm|IL-2 s.c. together with antibody ch14.18, GM-CSF and retinoic acid
2988166|NCT02641769|Other|Stem Cell Transplantation|intervention with transplantation of autologous purified stem cells
2988167|NCT02641756|Experimental|Study Population|"This is a single arm study. The investigators will include 10 HIV positive patients under chronic CART (combined antiretroviral therapy).~The intervention will consist on treatment interruption after in depth sampling under CART"
2988168|NCT02641743|Experimental|Inslow|Each participant was requested to consume one of is energetic test meals (200 kcal per serving 200ml) Inslow at 7:00 AM.
2988169|NCT02641743|Placebo Comparator|standard balanced formula|Each participant was requested to consume one of is energetic test meals (200 kcal per serving 200ml) standard balanced formula at 7:00 AM.
2988170|NCT02641730|Experimental|Group 1|Participants will receive guselkumab 200 milligram (mg) at Week 0, 4, 12 and every 8 weeks thereafter through Week 60, and two syringes of placebo at Week 16 to maintain the blind.
2988171|NCT02641730|Experimental|Group 2|Participants will receive a syringe of guselkumab 100 mg and a syringe of placebo for guselkumab at Week 0, 4, 12 and every 8 weeks thereafter through Week 60, two syringes of placebo at Week 16 to maintain the blind.
2988172|NCT02641730|Experimental|Group 3|Participants will receive two syringes of placebo at Week 0, 4 and 12. At Week 16, placebo participants will be randomized in a 1:1 ratio to guselkumab mg arm (Group 3a) or 100 mg arm (Group 3b). Group 3a participants will receive guselkumab 200 mg at Week 16, 20 and every 8 weeks thereafter through Week 60. Group 3b participants will receive guselkumab 100 mg and a syringe of placebo at Week 16, 20 and every 8 weeks thereafter through Week 60.
2988173|NCT02641717|Experimental|All subjects|All patients enrolled in this study will self-collect a vaginal swab (experimental) then have a physician collected vaginal swab (gold standard)
2988174|NCT02641704||Multidisciplinary program|Multidisciplinary program designed and administered by the Competence- and Integration Center in Sonderborg Municipality
2988175|NCT02641691|Experimental|Arm 1: Radiation/Oxaliplatin/Leucovorin/5-FU|"Radiotherapy will consist of five fractions, delivered once daily, to a total dose of 25Gy at 5 Gy per fraction.~An optional concomitant boost may be delivered to the primary tumor of 1-2 Gy per day (30-35 Gy to tumor total). If a boost is given then the maximum allowed dose to small bowel is 25 Gy.~Chemotherapy should begin two weeks (9-12 working days) after completion of radiotherapy.~Oxaliplatin will be given intravenous (IV) over 2 hours on Day 1 every 14 days for a maximum of 8 cycles.~Leucovorin will be given IV over 2 hours on Day 1 every 14 days for a maximum of 8 cycles.~5-FU bolus will given IV push on Day 1 every 14 days for a maximum of 8 cycles.~5-FU infusion will be given continuous IV on Day 1 over 46 hours every 14 days for a maximum of 8 cycles~Alternatively, capecitabine/oxaliplatin (CAPE PO 1000 mg/m2 BID days 1-14 Q21 days, oxaliplatin IV 130 mg/m2 IV Q21 days on day 1) x 5 cycles over 15 weeks may be administered instead of FOLFOX"
2988176|NCT02641652|Active Comparator|Sertraline|sertraline, 25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial
2988177|NCT02641652|Placebo Comparator|Placebo|placebo
2988178|NCT02641639|Active Comparator|Fosbretabulin tromethamine|Physician's choice chemotherapy (weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) plus bevacizumab and CA4P
2988179|NCT02641639|Placebo Comparator|Placebo|Physician's choice chemotherapy (weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) plus bevacizumab and placebo
2988180|NCT02641626|Experimental|Urgent Coronary Angiography|Urgent Coronary Angiography: as soon as possible, when the patient is randomized.
2988181|NCT02641626|Active Comparator|Deferred coronariography|Deferred coronary angiography: after extubation if the patient has a good neurologic prognosis.
2988182|NCT02641613|Active Comparator|supraclavicular|patients receive a supraclavicular block for forearm or hand surgery with 30 ml of a mixture of ropivacaine 0.5 % and mepivacaine 1 %
2988183|NCT02641613|Experimental|retroclavicular block|patients receive a retroclavicular block for forearm or hand surgery with 30 ml of a mixture of ropivacaine 0.5 % and mepivacaine 1 %
2988184|NCT02641600|Active Comparator|Elastic stockings|Class 1 elastic stockings (18-21 mmHg)
3002721|NCT02545049|Placebo Comparator|Placebo|Matching placebo
2988187|NCT02641587|Active Comparator|CC|Ad libitum use of subject's own preferred non-menthol brand of CC
2988188|NCT02641574||previous 1|women who have had in their past one cesarean section
2988189|NCT02641574||previous 2|women who have had in their past 2 cesarean sections
2988190|NCT02641574||previous 3|women who have had in their past 3 cesarean sections
2988191|NCT02641574||previous 4|women who have had in their past 4 cesarean sections
2988192|NCT02641561|Placebo Comparator|A (NS+Placebo)|Normal Saline (intravenous during procedure) + Placebo (100mg suppository per rectum prior to procedure )
2988193|NCT02641561|Active Comparator|B (NS+IND)|Normal Saline (intravenous during procedure) + Indomethacin (100mg suppository per rectum prior to procedure )
2988194|NCT02641561|Active Comparator|C (LR+Placebo)|Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Placebo (100mg suppository per rectum prior to procedure)
2988195|NCT02641561|Experimental|D (LR+IND)|Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Indomethacin (100mg suppository per rectum prior to procedure)
2988196|NCT02641548|Experimental|Silicone sock+heel cream|Every evening a cream (Footmender, Auxilum Cura Innovatio, Dublin, Ireland, European Patent 2522342) is applied to the feet and a sock of silicone is used every night.
2988197|NCT02641548|Active Comparator|Heel cream|Every evening a cream (Footmender, Auxilum Cura Innovatio, Dublin, Ireland, European Patent 2522342) is applied to the feet
2988198|NCT02641535|Experimental|research arm|"12 healthy volunteers from the border guard of the police forces will participate in this study. The subjects will undergo 4 experiment days:~Recruitment , medical examination and VO2max test.~Acclimatization day by performing moderate exercise protocol under hot and humid climate.~3.2 days of performing moderate exercise under hot and humid conditions protocol, each day dressed with different protective garment:~Protective garment in current use + NBC mask.~The new BC membrane protective garment + NBC mask"
2988199|NCT02641522|Experimental|Post-Infusion|Single infusion of siltuximab (11 mg/kg)
2988200|NCT02641509|Experimental|NBI to perform the polipectomy|this arm will undergo polypectomy with the use of NBI to define the margins of the lesion
2988201|NCT02641509|Experimental|no NBI to perform the polypectomy|this arm will undergo polipectomy without the use of NBI to define the margins of the lesion
2988202|NCT02641496|Experimental|CBT-OSA|CBT-OSA is a new cognitive behavioral therapy which focuses on changing behaviors and thoughts to help individuals adjust to using a CPAP machine.
2988203|NCT02641496|Active Comparator|Sleep Education|The Sleep Education treatment will include information, facts, and videos on sleep, cardiovascular disease, PTSD, and proper sleep hygiene.
2988204|NCT02641483|Experimental|Colonic Motility|Study participants will act as their own controls, first providing data using their usual digital rectal stimulation intervention for bowel care, then providing data using electrical stimulation for bowel care.
2988205|NCT02641470|Experimental|DA9301|Orally administration of DA9301 (Vaccinium uliginosum extract) pills (1000 mg/day) for 4 weeks.
2988206|NCT02641470|Placebo Comparator|Placebo|Orally administration of placebo pills (1000 mg/day) for 4 weeks.
2988207|NCT02641457|Experimental|Aflibercept x Ranibizumab|12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and 12 eyes patients received an intraocular injection of 1.25mg ranibizumab
2988208|NCT02641444||Efavirenz|Receiving efavirenz as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
2988209|NCT02641444||Atazanavir|Receiving atazanavir as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
2988210|NCT02641444||Raltegravir|Receiving raltegravir as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
2988211|NCT02641444||Maraviroc|Receiving maraviroc as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
2988212|NCT02641431|Experimental|mapping/ablation|Epicardial substrate identification consisted in mapping the entire RV epicardial surface under baseline conditions and after ajmaline infusion (1mg/kg in 5 minutes).We obtained 3 groups of RV epicardial maps using CARTO3 system: 1) bipolar/unipolar voltage map, 2) local activation time map (LAT), and 3) potential duration map (PDM), in which abnormal long-duration bipolar electrograms were defined as low-frequency (up to 100 Hz) prolonged duration (> 200 ms) bipolar signals with delayed activity extending beyond the end of the QRS complex. Epicardial ablation was performed during sinus rhythm using a stepwise strategy in a descending order of abnormal potential duration as displayed on the map and beginning from the longest potentials.
2988213|NCT02641418|Other|Exercise|only 1 arm to trial
2988214|NCT02641405|Experimental|Equistasi|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.
2988215|NCT02641405|Placebo Comparator|Placebo|Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
2988216|NCT02641392|Experimental|GED-0301 (160 mg) followed by Placebo intermittent 160 mg|GED-0301 160 mg once daily (QD) for 12 weeks, followed by alternating Placebo (PBO) QD for 4 weeks with GED 0301 160 mg QD for 4 weeks, up to 208 weeks, if the subject previously received Placebo in the prior GED-0301 Study
2988217|NCT02641392|Experimental|Intermittent GED-0301 160 mg and placebo|Alternating GED-0301 160 mg once daily (QD) for 4 weeks with placebo (PBO) QD for 4 weeks, up to 208 weeks, depending on previous response in the prior GED-0301 study
2988218|NCT02641392|Experimental|Intermittent GED-0301 40 mg and placebo|Alternating PBO once daily (QD) for 4 weeks with GED-0301 40 mg QD for 4 weeks with, up to 208 weeks, depending on previous response in the prior GED-0301 study
2988219|NCT02641392|Experimental|Continuous GED-0301 40 mg|GED-0301 40 mg once daily (QD) for up to 208 weeks
2988220|NCT02641392|Experimental|Intermittent placebo and GED-0301 160 mg|Alternating PBO QD for 4 weeks with GED-0301 160 mg QD for 4 weeks, through Week 208
2988221|NCT02641379|Experimental|PEG-IFN 24 weeks|Participants will receive PEG-IFN (180 microgram [mcg]), subcutaneously (sc), once weekly for 24 weeks and Ribavirin 1000-1200 milligram per day (mg/day) (<75 kilogram (kg); >75 kg) for 24 weeks.
2988307|NCT02640807|Placebo Comparator|Control|Patients will receive Placebo (NaCl 0.9%) twice a week for 4 weeks
2988222|NCT02641379|Experimental|PEG-IFN 24/72 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) till week 24; if patient is still HCV RNA positive. Treatment will be stopped if participant is HCV RNA negative at week 24 -treatment with PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) till week 72
2988223|NCT02641379|Experimental|PEG-IFN 48 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly for 48 weeks and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) for 48 weeks.
2988224|NCT02641379|Experimental|PEG-IFN 72 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly for 72 weeks and Ribavirin 1000-1200 mg/day (<75 kg; > 75 kg) for 72 weeks.
2988225|NCT02641366||Tremor kinetics after DBS|This group have already undergone Deep Brain Stimulation (DBS) placement and will have measurements of tremor kinetics by using the electromagnetic tracking. The electromagnetic sensors will be placed on the arm and hand while the routine outpatient neurologic examinations are being performed. The testing will be performed with the DBS system in both the on and off settings.
2988226|NCT02641366||Tremor kinetics before and after DBS|This group will have measurements of tremor kinetics by using electromagnetic tracking prior to being scheduled to undergo Deep Brain Stimulation (DBS) placement. A total of two testing sessions will be performed: the first session will be performed during the routine preoperative visit, the second session will be performed during the routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
2988227|NCT02641353|Experimental|Treatment A - Apremilast 30 mg tablet fasted|A single oral dose of 30 mg apremilast tablet under fasted conditions.
2988228|NCT02641353|Experimental|Treatment B Apremilast 30 mg oral suspension fasted|A single oral dose of 30 mg apremilast oral suspension formulation (6 ml) under fasted conditions
2988229|NCT02641353|Experimental|Treatment C - Apremilast 30 mg oral suspension fed|A single oral dose of 30 mg apremilast oral suspension formulation (6 ml) under fed conditions
2988230|NCT02641340|Experimental|Cycle 1, Cohort 1|Fentanyl Sublingual Spray (FSS) low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
2988231|NCT02641340|Experimental|Cycle 1, Cohort 2|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
2988232|NCT02641340|Experimental|Cycle 1, Cohort 3|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
2988233|NCT02641340|Experimental|Cycle 1, Cohort 4|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
2988234|NCT02641340|Experimental|Cycle 2, Cohort 1|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
2988235|NCT02641340|Experimental|Cycle 2, Cohort 2|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
2988236|NCT02641340|Experimental|Cycle 2, Cohort 3|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
2988237|NCT02641340|Experimental|Cycle 2, Cohort 4|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
2988238|NCT02641340|Experimental|Cycle 3, Cohort 1|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
2988239|NCT02641340|Experimental|Cycle 3, Cohort 2|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
2988240|NCT02641340|Experimental|Cycle 3, Cohort 3|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
2988241|NCT02641340|Experimental|Cycle 3, Cohort 4|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
2988242|NCT02641327||Internal ward|Patients hospitalized in Internal Medicine unit with unstable blood pressure that need regulation/ stabilization of their blood pressure (e.g., CHF, post surgical, hypotension or Hypertension patients, patients with kidney failure, heart disease, stroke)
2988243|NCT02641327||ICU|Patients hospitalized in intensive care with arterial line that allow continuous blood pressure measurement
2988244|NCT02641314|Experimental|metronomic therapy|Treatment consists of eight alternating 28-day-cycles of propranolol, celecoxib, cyclophosphamide, vinblastine, etoposide (PCCVE) and of propranolol, celecoxib, cyclophosphamide, vinblastine (PCCV) followed by five cycles PCCV resulting in a total of 13 cycles (364 days of treatment)
2988245|NCT02641301|Experimental|Subjects Roux-en-Y-gastric bypass (RYGB)|Sustained release morphine sulfate, 30 mg
2988246|NCT02641301|Active Comparator|Control volunteers matched with RYGB|Sustained release morphine sulfate, 30 mg
2988247|NCT02641288|Experimental|Ropivacaine irrigation|Using a standard irrigation device, 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
2988248|NCT02641288|Placebo Comparator|Normal saline irrigation|Using a standard irrigation device, 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
2988249|NCT02641275|Experimental|Intervention|Structured self-management-training (incl. systemic analysis, coaching, teaching) in 4 sessions.
2988250|NCT02641275|No Intervention|Control group|no intervention other than existing support (see exclusion criteria). However, intervention will be offered and studied secondary as well (after 1 1/2 year of no intervention).
2988251|NCT02641249|No Intervention|No vibration|In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods.
2988252|NCT02641249|Experimental|Vibration|In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods.
2988768|NCT02637661||No coronary heart disease|To study the characteristics of earlobe crease
2988253|NCT02641236|Active Comparator|Gut Decontamination with vancopoly|"All eligible participants will be randomized to either Arm A: Gut Decontamination or Arm B: No Gut Decontamination.~Participants assigned to this arm will receive non-absorbable, oral vancomycin-polymyxin B as per our institutional standard practice."
2988254|NCT02641236|No Intervention|No Gut Decontamination|"All eligible participants will be randomized to either Arm A: Gut Decontamination or Arm B: No Gut Decontamination.~Participants assigned to this arm will not receive oral vancomycin-polymyxin B, but all other HSCT supportive care will be the same as for patients in Arm A."
2988255|NCT02641210|Experimental|Periodontal Treatment|The experimental group underwent nonsurgical periodontal therapy, performed by a single professional who performed the scaling and root planing procedures under local anesthesia using an ultrasonic device and Gracey and mini Gracey curettes, with Robson polishing brush and prophylactic paste. This therapy was performed in two sessions at seven day intervals, with no time limit, according to the needs of each periodontal condition. In each session, subjects received oral hygiene instruction (OHI) for use of toothbrushes for the modified Bass technique, dental floss and other complementary means (interdental brush, single tuft brush, electric toothbrush, etc.) when necessary. Supportive periodontal therapy was performed in 30, 60 and 90 days. Albendazole administration.
2988256|NCT02641210|No Intervention|No Periodontal Treatment|Individuals in the control group underwent only the polishing of tooth surfaces with Robson brush and prophylactic paste fine-grained and topical fluoride application. After 90 days, they were reassessed with the same parameters of clinical examination of the baseline.
2988257|NCT02641197|Experimental|AngioDefender|The AngioDefender device uses a novel, proprietary software algorithm to analyze pulse wave amplitude data collected before and after brachial artery occlusion by a standard upper arm pneumatic blood pressure cuff. The procedure is non-invasive and does not employ ultrasound.
2988258|NCT02641171||Entire Cohort|This is an observational/validation study and there is no intervention involved. Exhaled air samples, blood samples, and fecal samples will be obtained.
2988259|NCT02641158|Other|Control Group|
2988260|NCT02641158|Experimental|Care Facilitation Group|
2988261|NCT02641145|Experimental|Active AL cardiac amyloidosis|50 individuals with light chain systemic amyloidosis with active plasma cell dyscrasia and cardiac involvement will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of the heart at baseline, 6 months and 12 months after initiation of chemotherapy. 25 of these individuals will also undergo a N-13 ammonia PET scan of the heart following supine bicycle stress at baseline and at 6 months after initiation of chemotherapy.
2988262|NCT02641145|Active Comparator|Remission AL cardiac amyloidosis|25 individuals with light chain systemic amyloidosis with cardiac involvement and plasma cell dyscrasia in hematological remission (complete hematological remission or very good partial response-differential free light chain (dFLC)<40 mg/dL for > 1 year prior to enrollment) will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI scan of the heart at baseline.
2988263|NCT02641145|Experimental|Active AL Pre-CMP|25 individuals with light chain systemic amyloidosis with active plasma cell dyscrasia and without cardiac involvement will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of the heart at baseline. At 6 months they will undergo a research MRI of the heart and at 12 months they will have a clinical follow up.
2988264|NCT02641145|No Intervention|Multiple Myeloma Controls|25 individuals with diagnosis of multiple myeloma without concomitant amyloidosis by standard criteria will undergo urine and blood testing only.
2988265|NCT02641132|Experimental|Pterygium surgery: Head and body.|Application of Mitomycin C 0.02% after excision of the body and the head of the pterygium.
2988266|NCT02641132|Active Comparator|Pterygium surgery: Body.|Application of Mitomycin C 0.02% after excision of the body only of the pterygium.
2988267|NCT02641119||Albumin|Patients receiving any amount of 5% albumin during large volume resuscitation (defined as ≥ 60ml/kg in a single 24 hour period), as prescribed by treating clinician.
2988268|NCT02641119||Saline-only|Patients receiving only saline during large volume resuscitation (defined as ≥ 60ml/kg in a single 24 hour period), as prescribed by treating clinician
2988269|NCT02641106|Experimental|Video Directly Observed Therapy|VDOT arm participants use a smartphone to make a video recording of each weekly medication dose ingested using the VDOT mobile phone app. The VDOT app is programmed to send encrypted, time/date stamped videos to a HIPAA-compliant server as soon as the video recorder is stopped. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken. Dose 1 is observed in-person; doses 2-12 are observed via videos.
2988270|NCT02641106|Active Comparator|In-Person DOT|In-Person DOT arm participants follow standard-of-care procedures for monitoring ingestion of all medication doses. Participants take their first medication dose at the enrollment visit and return to the clinic once weekly to be observed taking the remaining 11 doses of medication until they complete the 12-dose regimen.
2988271|NCT02641093|Experimental|Pembrolizumab|Pembrolizumab in combination with standard of care surgery followed by radiation therapy with or without cisplatin
2988272|NCT02641080|Active Comparator|Aspirin|Participants randomized to aspirin alone will be advised to take a 325mg per day as their outpatient DVT/PE prophylaxis.
2988273|NCT02641080|Active Comparator|Aspirin with portable Compression Device|Participants randomized to the compression device group are asked to wear the compression devices for 20 hours a day for 2 weeks along with taking an 325mg aspirin per day as their outpatient DVT/PE prophylaxis.
2988274|NCT02641067|Experimental|Severe Renal Impairment|Participants with severe renal impairment receive a single oral dose of 100 mg doravirine
2988275|NCT02641067|Experimental|Healthy Matched Controls|Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine
2988276|NCT02641054|Experimental|CVXL-0107 then cross-over to placebo|"Study drug (CVXL-0107) 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of study drug on top of supraoptimal dose of levodopa.~Cross-over to placebo 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of placebo on top of supraoptimal dose of levodopa"
2988305|NCT02640807|Experimental|CYT107 high frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for 4 weeks
2988306|NCT02640807|Experimental|CYT107 low frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for the first week, followed by CYT107 and Placebo once a week for the three following weeks
2988277|NCT02641054|Placebo Comparator|Placebo then cross-over to CVXL-0107|"Placebo 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of placebo on top of supraoptimal dose of levodopa.~Cross-over to study drug (CVXL-0107) 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of study drug on top of supraoptimal dose of levodopa"
2988278|NCT02641041|Experimental|Cohort 1|A single IV dose of 10 mg/kg BIIB033 or placebo given on Day 1
2988279|NCT02641041|Experimental|Cohort 2|A single IV dose of 30 mg/kg BIIB033 or placebo given on Day 1
2988280|NCT02641041|Experimental|Cohort 3|One IV dose of 100 mg/kg BIIB033 or placebo given on Days 1 and 15
2988281|NCT02641028|Experimental|CERC-501|Administered orally once daily, 15mg daily, 8 days.
2988282|NCT02641028|Placebo Comparator|Placebo|Administered orally daily, 8 days.
2988283|NCT02641002|Experimental|Dose escalation of CC-90002|CC-90002 by intravenous (IV) infusion on a 28 day cycle
2988284|NCT02640989|Experimental|Group 1|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~Seasonal trivalent influenza vaccine, Anflu®"
2988285|NCT02640989|Experimental|Group 2|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~Seasonal trivalent influenza vaccine, VAXIGRIP"
2988286|NCT02640989|Active Comparator|Group 3|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~Seasonal trivalent influenza vaccine, Fluarix"
2988287|NCT02640976|Active Comparator|Poor responders|"This group will include women who underwent IVF/ICSI cycle and produced 4 oocytes or less.~intervention:~fixed daily morning dose of Human menopausal gonadotrophin (HMG) Merional® intra-muscular injection ,starting on cycle day 2 and will be maintained for 9-11 days according to each individual ovarian response,at a dose of (300 IU).~On cycle day 7, the GnRH antagonist Cetrorelix 0.25 mg Cetrotide® will be introduced as daily subcutaneous injections and continued till the day of ovulation triggering.~Finally, when at least 3 follicles will reach 17 mm in diameter, ovulation will be triggered by a single intra-muscular injection of 10,000 IU of Human chorionic gonadotrophin (hCG) Choriomon®."
2988288|NCT02640976|Active Comparator|Good responders|"This group will include women who produced (5 or more oocytes) after COH.~Intervention:~fixed daily morning dose of Human menopausal gonadotrophin (HMG) Merional® intra-muscular injection ,starting on cycle day 2 and will be maintained for 9-11 days according to each individual ovarian response,at a dose of (225 IU) for participants with AMH levels > 1.5 ng/ml and/or FSH levels ≤ 8 mIU/ml~On cycle day 7, the GnRH antagonist Cetrorelix 0.25 mg Cetrotide® will be introduced as daily subcutaneous injections and continued till the day of ovulation triggering.~When at least 3 follicles will reach 17 mm in diameter, ovulation will be triggered by a single intra-muscular injection of 10,000 IU of Human chorionic gonadotrophin (hCG) Choriomon®."
2988289|NCT02640963|Experimental|Intervention: the GrACE programme|The programme included several weight-bearing exercises (using body weight and dumbbells) and a range of seated, non-resisted upper- and lower-body dynamic and reaching movements. While developed for respite care older adults, the GrACE programme was slightly modified for the RAC setting; using reduced range of motion and resistance, and an extended conditioning/familiarisation phase. The conditioning phase lasted for three weeks and focus on the development of correct technique. After concluding the conditioning phase, participants started to use light dumbbells. Participants performed the exercises twice per week for 12 weeks. Training sessions lasted approximately 45 minutes, were separated by at least 48 hours and were delivered by an experienced allied health professional.
2988290|NCT02640963|Placebo Comparator|Control Group|All subjects assigned to the control group were given the option to engage in other activities that were offered by the facility during the 12-week intervention period. Activities were facility specific, and included Zumba aerobic exercise and walking, however no specific resistance exercises were offered.
2988291|NCT02640950|Experimental|Open-Label TMS|Active Transcranial Magnetic Stimulation
2988292|NCT02640937||Orthopaedic device related infections|"Inclusion Criteria:~infections after fracture fixation or prosthetic joint surgery~Affected bone or joint: Long bones of the lower extremity; hip joint, knee joint;~Bacterial growth of S. epidermidis at the site of interest~Written consent~Age: 18 and older"
2988293|NCT02640924|Experimental|Proton radiotherapy|Proton radiotherapy will be totally 66 cobalt gray equivalent (CGE) in 10 fractions and delivered once daily, 5 fractions per week, over 2 weeks for HCC more than 1 cm away from the alimentary tract.
2988294|NCT02640924|Experimental|Radiofrequency Ablation|Multiple-electrode radiofrequency with switch-controller system (ME-SWC RFA) can create a large coagulation necrosis volume and successful treat HCC sized more than 3 cm, extending to 8.5 cm. ME-SWC RFA system uses up to 3 electrodes parallel insertion to inside of the tumors with an equilateral triangular confirmation before initiation of ablation. The distances between electrodes are about 1.5-2 cm, estimated by ultrasound measuring. The switching machine is set on the auto-mode, and all electrodes work alternately and switching each other automatically after impendence surge.
2988295|NCT02640898|Active Comparator|FU-based chemoradiotherapy|patients will be treated with the INT0116 regimen.
2988296|NCT02640898|Experimental|docetaxel-based chemoradiotherapy|patients will be treated with modified DCF chemotherapy in combination with docetaxel-based chemoradiotherapy.
2988297|NCT02640885|Experimental|Foley's cather tamponade|Balloon tamponade with 2-way Foley's Cather was successfully used during cesarean section due to sever postpartum haemorrhage after failure of medical treatment.
2988298|NCT02640872||HAPPY Cohort|A elderly cohort for chronic diseases
2988299|NCT02640859||Normal cohort|Normal cohort for biobank
2988300|NCT02640846|Active Comparator|Levosimendan|Doser
2988301|NCT02640846|Active Comparator|Milrinone|Doser
2988302|NCT02640833|Experimental|Duvelisib+Venetoclax|
2988303|NCT02640820|Experimental|Sensitization Phase|Up to two doses of Sensitizing DPCP Ointment will be applied and subjects who exhibit a sensitization response will enter the Treatment Phase. Pharmacokinetics (PK) of Sensitizing DPCP Ointment will be measured in a subset of subjects. For PK, blood will be collected prior to application of the Sensitizing DPCP Ointment and again at 1, 2, and 24 hours after application.
2988304|NCT02640820|Experimental|Treatment Phase|In the Treatment Phase, subjects will receive doses of Treatment DPCP Ointment weekly for 10 weeks. Subjects who at the end of the Treatment Phase have exhibited partial clearance of warts may be given the option to continue with an additional 10 weekly treatments.
3004238|NCT02534896|Experimental|Sunpharma1505 1|
2988308|NCT02640794|Active Comparator|Aspirin +clopidogrel|Patients would be randomized within the month prior to the TAVI procedure to receive aspirin/acetylsalicylic acid (80-325 mg/d) + clopidogrel (75 mg/d)
2988309|NCT02640794|Active Comparator|Aspirin|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin/acetylsalicylic acid (80-325 mg/d)
2988310|NCT02640781|Experimental|covered stent|newly designed covered stent group
2988311|NCT02640781|Active Comparator|uncovered stent|currently used uncovered stent group
2988312|NCT02640768|Experimental|educational training|educational training
2988313|NCT02640768|No Intervention|no educational training|no educational training wards
2988314|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 Monotherapy|Arm will be comprised of [14C]AZD2014 followed by AZD2014 Monotherapy
2988315|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 + Fulvestrant|Arm will be comprised of [14C]AZD2014 followed by AZD2014 + Fulvestrant
2988316|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 + Paclitaxel|Arm will be comprised of [14C]AZD2014 followed by AZD2014 + Paclitaxel
2988317|NCT02640729|Experimental|Nelotanserin|Nelotanserin 40mg then nelotanserin 80 mg
2988318|NCT02640729|Placebo Comparator|Placebo|Placebo
2988319|NCT02640716|Active Comparator|training group|Intervention: Multi-domain adaptive internet-based training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. 5 x 30 minutes per week, for 7 weeks.
2988320|NCT02640716|Placebo Comparator|control group|Intervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 7 weeks.
2988321|NCT02640703|Active Comparator|morning vaccination|Vaccination with Infanrix + Prevenar 13 between 7 and 10 am
2988322|NCT02640703|Active Comparator|evening vaccination|Vaccination with Infanrix + Prevenar 13 between 7 and 10 pm
2988323|NCT02640690|Experimental|Trauma-Sensitive Yoga (TSY) Intervention|10-weekly 1-hour TSY Sessions
2988324|NCT02640690|Active Comparator|Cognitive Processing Therapy-Cognitive Intervention (CPT-C)|12-weekly 1.5 hour CPT-C Sessions
2988325|NCT02640677||Pregnant women exposed to 4CMenB|Pregnant women within the US who received at least 1 dose of 4CMenB vaccine within 30 days prior to LMP or at any time during pregnancy
2988326|NCT02640664|Experimental|Ranibizumab 0.1 mg|Ranibizumab 0.1 mg
2988327|NCT02640664|Experimental|Ranibizumab 0.2 mg|Ranibizumab 0.2 mg
2988328|NCT02640664|No Intervention|Laser therapy|Laser therapy
2988329|NCT02640651|Experimental|DC-Stimulator (PLUS version)|For tDCS stimulation, anodal stimulation of the right dorsolateral prefrontal cortex will be performed for twenty minutes at 2mA. The current will be applied by a battery-driven tDCS stimulator via a pair of saline-soaked sponge electrodes (25 cm2 surface). The anodal electrode will be placed on the scalp at the F4 position according to the international 10-20 EEG coordinate system. 20 minute tDCS sessions will be conducted ten times over a two week period
2988330|NCT02640638|Experimental|CenteringPregnancy group prenatal care|Pregnant women who were randomized to receive CenteringPregnancy group prenatal care
2988331|NCT02640638|No Intervention|Traditional individual prenatal care|Pregnant women who were randomized to receive traditional individual prenatal care
2988332|NCT02640625|Experimental|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
2988333|NCT02640612|Experimental|BI 695501|
2988334|NCT02640599|Experimental|Vestibular Rehabilitation + Areobic Exercise|
2988335|NCT02640599|Active Comparator|Vestibular Rehabilitation|
2988336|NCT02640586|Experimental|Assessing response with MRI|"Preoperative chemo-radiotherapy as standard treatment. Neoadjuvant therapy (long course intensity modulated radio-chemotherapy, GTV 50.6Gy, totally 22 fractions; Capecitabine 825mg/m2 /bid by oral administration).~Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.~All patients are scheduled to receive total mesorectal excision surgery 12-14 weeks after the completion of preoperative chemo-radiotherapy."
2988337|NCT02640573|Experimental|Hydroxurea|Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria.
2988338|NCT02640560||Children with food allergy|"Children with food allergy to nuts, hazelnuts, walnuts, shellfish and mollusks (1-14 years old).~The Parents of the cases children will compile a Food allergy questionnaire"
2988339|NCT02640560||Healthy Children|Healthy Children (1-14 years old) The Parents of the control children will compile a Control questionnaire
2988340|NCT02640547||Genotype 1 (GT1) participants treated without Ribavirin (W12)|GT1 participants receiving PTV/r+OBV+DSV for 12 weeks
2988341|NCT02640547||Genotype 1 (GT1) participants treated with Ribavirin (W12)|GT1 participants receiving PTV/r+OBV+DSV+RBV for 12 weeks
2988342|NCT02640547||Genotype 1 (GT1) participants treated with Ribavirin (W24)|GT1 participants receiving PTV/r+OBV+DSV+RBV for 24 weeks
2988343|NCT02640547||Genotype 4 (GT4) participants treated with Ribavirin (W12)|GT4 participants receiving PTV/r+OBV+RBV for 12 weeks
2988344|NCT02640547||Genotype 4 (GT4) participants treated with Ribavirin (W24)|GT4 participants receiving PTV/r+OBV+RBV for 24 weeks.
2988345|NCT02640534|Experimental|Enzalutamide + Metformin|Enzalutamide 160 mg od + metformin 850 mg bid until disease progression
2988346|NCT02640534|Active Comparator|Enzalutamide|Enzalutamide 160 mg od until disease progression
2988347|NCT02640521|No Intervention|Control Parents|
2988348|NCT02640521|Active Comparator|Treatment Parents|Chart reminders (paper or electronic medical records, depending on clinic wishes) to prompt providers to ask about in home smoking at every medical visit; establishing a New York State Quit line referral system in the pediatric practice; and amending the training curriculum for providers and the patient education materials that are part of a provider toolkit, to focus on the negative impact of second hand smoke (SHS) on their children,and specifically, asthma outcomes.
2988349|NCT02640508|Experimental|Combination Eribulin and lenvatinib|Eribulin will be given on days 1 and 8. Lenvatinib will be given daily in each 28 day cycle.
2988350|NCT02640495||Study subjects|Patients admitted with malaria, caused by Plasmodium falciparum, treated with parenteral artesunate.
2988351|NCT02640482|Experimental|Arm A DB Active Drug|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (double-blind [DB] treatment period)
2988352|NCT02640482|Experimental|Arm B DB Placebo|Placebo for ABT-493/ABT-530 QD for 12 weeks (DB treatment period)
2988353|NCT02640482|Experimental|Arm B OL Active Drug|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (open-label [OL] treatment period)
2988354|NCT02640469|Active Comparator|Chlorhexidine with water rinse|This is a traditional method of disinfection used at NYU Hospital for Joint Disease. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
2988355|NCT02640469|Experimental|Chlorhexidine without water rinse|This is an experimental method of disinfection. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
2988356|NCT02640469|Active Comparator|Chlorhexidine + sterillium hand rub|This is a standard method of disinfection used at NYU Hospital for Joint Disease. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
2988357|NCT02640456||Para- or retropharyngeal abscess|Patients with para- or retropharyngeal abscess.
2988358|NCT02640456||Neck abscess|Patients with neck abscess without relation to the pharynx or salivary glands.
2988359|NCT02640443|Experimental|Treatment|Treatment with sulfamethoxazole. Subjects will serve as their own control, by using the data from baseline and after treatment stop.
2988360|NCT02640430|Active Comparator|standard treatment|"Control group will be made of 20 COPD patients with severe and very severe airflow obstruction, mucus hypersecretion and reduced cough efficiency referred to standard pulmonary rehabilitation after acute exacerbation.~Control group will b treated with PEP-bottle over 10 daily sessions (20 minutes twice a day). Patients are asked to breath against a positive expiratory pressure determined by a column of water in a bottle (PEP Bolltle). PEP is one of the validated treatment used in the clearance of bronchial secretions in COPD patients.~All patients will receive regular treatment with inhaled bronchodilators and inhaled steroids according to current guidelines for their disease stage. Each patient will sign an informed consent form."
2988361|NCT02640430|Experimental|Free Aspire|"Experimental group will be made of 20 COPD patients with severe and very severe airflow obstruction , mucus hypersecretion , and reduced cough efficiency referred to standard pulmonary rehabilitation after acute exacerbation.~Patients are asked to use FREE ASPIRE Free Aspire is an electro-medical device which removes bronchopulmonary secretions noninvasively, without using a suction catheter and without generating airway pressure, positive or negative.~All patients will receive regular treatment with inhaled bronchodilators and inhaled steroids according to current guidelines for their disease stage. Each patient will sign an informed consent form."
2988362|NCT02640417|Experimental|Nucleotides + B12|Nucleotides + Vitamin B12 Dose: two capsules, three times per day + placebo corresponding to Group B treatment
2988363|NCT02640417|Active Comparator|B vitamins|Vitamin B1 + Vitamin B6 + Vitamin B12 Dose: one tablet, three times daily + placebo corresponding to Group A treatment
2988364|NCT02640404|Experimental|Menactra® Vaccine (9 to 23 Months)|Participants (infants and toddlers) received 2-dose series of study vaccine with 3-month interval (first dose at Day 0 and second dose 3 months after dose 1).
2988365|NCT02640404|Experimental|Menactra® Vaccine (2 to 55 Years)|Participants (children, adolescents and adults) received 1 dose of study vaccine at Day 0.
2988366|NCT02640391||Quiescent UC|Patients with quiscent UC who will undergo colonoscopy for surveillance or mucosal healing check up
2988367|NCT02640365|Experimental|GROUP A / GROUP B (two differents cohorts)|"GROUP A (Patients with unresectable advanced non-colorectal cancer ) - irinotecan + MM-398 dose escalation (3-18 patients)~Level 1 : initial DOUBLIRI dose 60/90 (0-3 patients)~MM-398 : 60mg/m²~Irinotecan (CPT-11) : 90mg/m²~Level 2: DOUBLIRI dose 80/90 (9 - 18 patients)~MM-398 : 80mg/m²~CPT-11: 90mg/m²~Level 3A: DOUBLIRI dose 60/120 (12-18 patients)~MM-398 : 60mg/m²~CPT-11: 120mg/m²~Level 3B: DOUBLIRI dose : 80/120 (12-18 patients)~MM-398 : 80mg/m²~CPT-11 : 120 mg/m²~GROUP B (Patients with unresectable metastatic colorectal cancer)- LV/5FU-bevacizumab+irinotecan+MM-398 dose Escalation (3-18 patients)~same level as group A + LV/5FU - bevacizumab regimen :~Bevacizumab : 5mg/kg(day (d) 1)~Leucovorin (LV) : 400mg/m² (d1)~5-fluorouracile infusion (5 FU) :2400mg/m² (d1,2)"
2988368|NCT02640352|Active Comparator|Probi Defendum|Dietary supplement (tablet) with probiotics
2988369|NCT02640352|Placebo Comparator|Placebo|Dietary supplement (tablet) without probiotics
2988370|NCT02640339||Parkinson Disease|Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually, with alpha-synuclein deposits in neurons which aggregate into Lewy bodies.
2988371|NCT02640339||Mutiple system atrophy|is a degenerative neurological disorder. MSA is associated with the degeneration of nerve cells in specific areas of the brain. This cell degeneration causes problems with movement, balance, and autonomic functions of the body such as bladder control or blood-pressure regulation. Neuronal death probably occurs as a consequence of alpha-synuclein aggregation in oligodendroglia.
2988372|NCT02640339||REM sleep behavior disorder|a sleep disorder in which you physically act out vivid, often unpleasant dreams with vocal sounds and sudden, often violent arm and leg movements
2988373|NCT02640339||dementia with Lewy bodies|"causes a progressive decline in mental abilities.~It may also cause visual hallucinations, which generally take the form of objects, people or animals that aren't there. This can lead to unusual behavior such as having conversations with deceased loved ones.~Another indicator of Lewy body dementia may be significant fluctuations in alertness and attention, which may include daytime drowsiness or periods of staring into space. And, like Parkinson's disease, Lewy body dementia can result in rigid muscles, slowed movement and tremors."
2988374|NCT02640339||Pure autonomic failure|Pure autonomic failure is dysfunction of many of the processes controlled by the autonomic nervous system, such as control of blood pressure•Blood pressure may decrease when people stand, and they may sweat less and may have eye problems, retain urine, become constipated, or lose control of bowel movements
2988375|NCT02640339||Healthy controls|Healthy normals with no neurological involvement
2988446|NCT02639936||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
2988873|NCT02637089||PD-non-MCI|Patients with Parkinson's disease, no mild cognitive impairment
2988376|NCT02640326|Active Comparator|Active Comparator|The catheterized arm will have Standard of care Foley urinary catheter insertion according to usual institutional care pathways in the operating room prior to surgery initiation. The urinary catheter will be assessed for removal on the morning of post-operative day 1, and patients will be monitored for urinary complications once catheter is removed until patient has successfully voided spontaneously within 8 +/- 2 hours.
2988377|NCT02640326|Experimental|Experimental Arm|The non-catheterized arm will have standard of care Foley urinary catheter insertion, with no Foley Urinary Catheter inserted prior to, during, or after surgery unless the patient is showing signs of urinary retention after surgery. Patient will be monitored for urinary complications starting in the recovery room until patient has successfully voided spontaneously within 8 +/- 2 hours
2988378|NCT02640313|Experimental|18F-choline PET-MR imaging|"Intervention: 18F-choline PET-MR imaging.~Drug: 18F-choline, dosis 4 MBq/kg body-weight (maximum 360 MBq), administered intravenously as a single dose.~Procedure: dynamic and static 18F-choline PET-MR."
2988379|NCT02640300|Experimental|Immediate discontinuation group|The antipsychotic drugs that patients took at baseline were prepared in unmarked capsules, with the dose adjusted to provide a 25% reduction weekly over the next 3 weeks. The dose tapering schedule was as follows: 3 capsules at baseline, 2 capsules at week 1, 1 capsule at week 2, and 0 capsules at week 3. All capsules contained placebo (i.e., the antipsychotic drugs were abruptly discontinued). Clozapine was gradually increased to 300 mg/day according to the following schedule: 12.5 mg/day at day 0 and increased by 25 mg/day to 300 mg/day at day 12, with this dose maintained for three weeks and thereafter adjusted according to clinical judgment. Concomitant medications were kept constant throughout the study period.
2988380|NCT02640300|Experimental|Gradual discontinuation group|The antipsychotic drugs that patients took at baseline were prepared in unmarked capsules, with the dose adjusted to provide a 25% reduction weekly over the next 3 weeks. The dose tapering schedule was as follows: 3 capsules at baseline, 2 capsules at week 1, 1 capsule at week 2, and 0 capsules (i.e., the antipsychotic drugs were discontinued) at week 3. Clozapine was gradually increased to 300 mg/day according to the following schedule: 12.5 mg/day at day 0 and increased by 25 mg/day to 300 mg/day at day 12, with this dose maintained for three weeks and thereafter adjusted according to clinical judgment. Concomitant medications were kept constant throughout the study period.
2988381|NCT02640287|Experimental|Waldenström macroglobulinemia|Patients with diagnosis of Waldenström macroglobulinemia
2988382|NCT02640287|Experimental|Others B-cell malignancies|Patients with diagnosis of Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma or Multiple Myeloma
2988383|NCT02640287|Other|Healthy subjects|Control healthy subjects without B-cell malignancy
2988384|NCT02640274|Experimental|Intervention group|The intervention is an individual nurse-led counselling programme in addition to usual care.
2988385|NCT02640274|Other|Control group|usual care
2988386|NCT02640261||Group 1|Single embryo transfer on day 5, according to standard embryo morphological criteria
2988387|NCT02640261||Group 2|Single embryo transfer on day 5, chosen on the basis of both embryo morphological criteria and levels of cytokines measured in the individual FF.
2988388|NCT02640248||Cuff ETT|
2988389|NCT02640235|Experimental|CELSTAT|Oxidized cellulose strip (CELSTAT), Single-use treatment, Intraoperative, direct application to target bleeding site
2988390|NCT02640235|Active Comparator|Surgicel Original|Oxidized regenerated cellulose strip (Surgicel Original), Single-use treatment, Intraoperative, direct application to target bleeding site
2988391|NCT02640222||AC-naive treated with VKA|AC-naive treated with VKA
2988392|NCT02640222||AC-naive treated with apixaban|AC-naive treated with apixaban
2988393|NCT02640222||AC-naive treated with dabigatran|AC-naive treated with dabigatran
2988394|NCT02640222||AC-naive treated with rivaroxaban|AC-naive treated with rivaroxaban
2988395|NCT02640222||AC-experienced treated with VKA|AC-experienced treated with VKA
2988396|NCT02640222||AC-experienced treated with apixaban|AC-experienced treated with apixaban
2988397|NCT02640222||AC-experienced treated with dabigatran|AC-experienced treated with dabigatran
2988398|NCT02640222||AC-experienced treated with rivaroxaban|AC-experienced treated with rivaroxaban
2988399|NCT02640209|Experimental|Arm 1|
2988400|NCT02640196|Placebo Comparator|Macintosh|The participants intubated the easy airway simulator with a double lumen tube using the Macintosh laryngoscope followed with intubating the difficult airway simulator
2988401|NCT02640196|Placebo Comparator|GlideScope|The participants intubated the easy airway simulator with a double lumen tube using the GlideScope laryngoscope followed with intubating the difficult airway simulator
2988402|NCT02640196|Active Comparator|Airtraq|The participants intubated the easy airway simulator with a double lumen tube using the Airtraq laryngoscope followed with intubating the difficult airway simulator
2988403|NCT02640196|Active Comparator|King Vision|The participants intubated the easy airway simulator with a double lumen tube using the King Vision followed with intubating the difficult airway simulator
2988404|NCT02640183|Experimental|Group A (EMLA)|3 mL EMLA® cream 5% will be applied in the endocervical canal 7 min before procedure, with a 5-mL needleless syringe. A subsequent application will be made with a swab at ectocervix level, using a vaginal speculum, which will be then withdrawn.
2988405|NCT02640183|Placebo Comparator|Group B (Placebo)|3 mL of ultrasonic gel will be applied in the endocervical canal 7 min before procedure, with a 5-mL needleless syringe. A subsequent application will be made with a swab at ectocervix level, using a vaginal speculum, which will be then withdrawn.
2988406|NCT02640157|Experimental|Arm A|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
2988407|NCT02640157|Active Comparator|Arm B|Sofosbuvir 400 mg once daily (QD) co-administered with daclatasvir 60 mg QD for 12 weeks.
2988408|NCT02640157|Experimental|Arm C|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
2988409|NCT02640144|Active Comparator|Treatment group|Randomized, patients that are going for knee arthroscopy for any indication including pain and cartilage damage or osteoarthritis. After surgery - will receive 3 injections of Sodium Hyaluronate 1% - ARTHREASE TM
2988410|NCT02640144|Placebo Comparator|Control group|Randomized, patients that are going for knee arthroscopy for any indication including pain and cartilage damage or osteoarthritis. After surgery - will receive 3 injections of BPS - Buffer Phosphate Solution - as a placebo
2988411|NCT02640131|Experimental|BSHR Intervention|"Couples will attend 30-minute clinic consultations with an Urologist and a Sexual Health Counsellor and receive session-specific chapters of the Kindness, Intimacy, Sexuality and Satisfaction manual over the course of the intervention.~The BSHR Intervention involves two complementary components; the bio-medical, and the psychosocial. The bio-medical component for both arms intervention includes an urologist consultation at a pre-operative appointment and 5 f/u appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.~The psychosocial component aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive sexual health counseling and manualized support."
2988412|NCT02640131|Active Comparator|Attention Control|"Survivorship Counseling: Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) and receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You Manual. The bio-medical component is the same in both arms.~The core topics discussed during over 7 counseling sessions include: preparation for immediate post-surgery recovery, Kegel exercises, nutrition and prostate cancer, exercise and prostate cancer, and maintaining healthy lifestyle change."
2988413|NCT02640118|Active Comparator|Pancreatectomised + Lixisenatide|"During the experimental day the patient will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a Lixisenatide-injection will be given subcutaneously"
2988414|NCT02640118|Placebo Comparator|Pancreatectomized + lixisenatide-placebo|"During the experimental day the patient will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a placebo-injection will be given subcutaneously."
2988415|NCT02640118|Active Comparator|Healthy + Lixisenatide|"During the experimental day the subject will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a Lixisenatide-injection will be given subcutaneously"
2988416|NCT02640118|Placebo Comparator|Healthy + lixisenatide-placebo|"During the experimental day the subject will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a placebo-injection will be given subcutaneously"
2988417|NCT02640105||Patient with Cluster headache|Prospective follow-up of patient with Cluster headache
2988418|NCT02640092|Experimental|[18F]GTP1|Participants will complete [18F]GTP1 PET imaging at four time points: Baseline, 6 months, 12 months and 18 months. For each [18F]GTP1 imaging session, the following procedure will be performed: a catheter will be placed for intravenous (IV) administration of [18F]GTP1. Participants will receive an IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie [mCi]) of [18F]GTP1.
2988419|NCT02640079|Experimental|Cognitive behavioral therapy|Cognitive behavioral therapy aimed at reducing pain catastrophizing.
2988420|NCT02640066|Experimental|acupuncture|acupuncture treatment with Supportive care
2988421|NCT02640066|No Intervention|standard treatment|Supportive care measures only
2988422|NCT02640053|Experimental|Arm I (topical cryotherapy, paclitaxel)|Patients apply bags filled with crushed ice to hands and feet for 15 minutes before, for 60 minutes during administration, and for 15 minutes after finishing administration of paclitaxel. Courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity.
2988423|NCT02640053|Active Comparator|Arm II (paclitaxel)|Patients receive paclitaxel IV over 60 minutes on weeks 1-12. Courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity.
2988424|NCT02640040|Experimental|combined surgery|combined surgery for enrolled patients with CPT(Congenital Pseudarthrosis of Tibia): sleeve resection of the pathological soft tissues, intramedullary rod fixation, packaged lilac bone autograft,and llizarov external fixation device installation.
2988425|NCT02640027|No Intervention|Treatment in the Clinic Only|Patients in Group A will receive their follow-up care entirely at the investigators institution
2988426|NCT02640027|Experimental|Treatment in the Clinic and at Home|Cast removal at home using a telemedicine tool
2988427|NCT02640014|Experimental|Study 1: Milk OIT follow up|Follow up on patient with severe milk allergy how have participated to milk OIT.
2988428|NCT02640014|No Intervention|Study 1: Follow up|Follow up on patient with severe milk allergy how have not participated to milk OIT.
2988429|NCT02639988||rheumatoid arthritis and type 2 diabetes|
2988430|NCT02639988||osteoarthritis and type 2 diabetes|
2988431|NCT02639975|Experimental|100 mg PBF-677|
2988432|NCT02639975|Experimental|200 mg PBF-677|
2988433|NCT02639975|Experimental|400 mg PBF-677|
2988434|NCT02639975|Experimental|600 mg PBF-677|
2988435|NCT02639975|Placebo Comparator|Placebo 100 mg|
2988436|NCT02639975|Placebo Comparator|Placebo 200 mg|
2988437|NCT02639975|Placebo Comparator|Placebo 400 mg|
2988438|NCT02639975|Placebo Comparator|Placebo 600 mg|
2988439|NCT02639962||NSTEMI|patients hospitalized with NSTEMI diagnosed according to the national Danish guidelines, and are scheduled to coronary angiography.
2988440|NCT02639962||patients with stable angina pectoris|Patients in this group have stable angina symptoms and had verified plaques by earlier CAG or Cardiac CT
2988441|NCT02639949|Experimental|Group CBT|
2988442|NCT02639949|Active Comparator|Standard Care|
2988443|NCT02639936||Immunocompetent controls|Control persons without immunodeficiency with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
2988444|NCT02639936||Solid organ transplant recipients|Patients after solid organ transplantation with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
2988445|NCT02639936||Stem cell transplant recipients|Patients after stem cell transplantation with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
2988617|NCT02638714|Experimental|Stem Cells|Intervention: Transplantation of autologous purified stem cells
2988447|NCT02639936||Patients with chronic renal failure|Patients with chronic renal failure with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
2988448|NCT02639936||Individuals with HIV infection|Individuals with HIV infection with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
2988449|NCT02639923||Minor head injury CCT pos. group|Tbi patients with acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.
2988450|NCT02639923||Minor head injury CCT neg. group|Tbi patients without acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.
2988451|NCT02639923||Control Group (healthy volunteers)|Volunteers without history, signs or symptoms of acute traumatic injuries. Volunteers consent to have 7ml peripheral blood to be drawn.
2988452|NCT02639910|Experimental|Two-Cohort|MOR00208 in combination with idelalisib or venetoclax
2988453|NCT02639871||healthy volunteers|31P-MR Spectroscopy and CEST for Validation of MRI/MRS methods
2988454|NCT02639871||HD presymptomatic individuals|General medical exam Clinical assessment with illness rating scales: Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS) and Total Functional Capacity (TFC), 31P-MR Spectroscopy and CEST
2988455|NCT02639871||early affected HD patients|General medical exam Clinical assessment with illness rating scales: UHDRS and TFC, 31P-MR Spectroscopy and CEST
2988456|NCT02639871||Controls|General medical exam Clinical assessment with illness rating scales: UHDRS and TFC, 31P-MR Spectroscopy and CEST
2988457|NCT02639858|Experimental|Docetaxel-PM|Docetaxel-PM 75mg/m2 IV infusion
2988458|NCT02639845||Patients Prescribed Eye Drops|Patients who are scheduled to receive prescription eye drops due to complications such as cataract surgery, glaucoma, retina surgery, or eye-related condition.
2988459|NCT02639819|Experimental|Treatment|Study drug
2988460|NCT02639806||Prospective - General Anesthetic|The prospective treatment group will have an anesthetic induction according to the anesthetic provider's preference that will include propofol and fentanyl as IV induction agents and rocuronium as a muscle paralytic. Maintenance of anesthesia for the treatment group will include sevoflurane with a target end tidal concentration of 1-1.5%, rocuronium as a paralytic as needed, opioids and any other standard medication deemed necessary by the provider.
2988461|NCT02639806||Retrospective - Local Anesthetic with Sedation|The retrospective group will have received local anesthetic from the surgeon using lidocaine injected subcutaneously and received sedation using fentanyl and midazolam as needed to achieve the desired level of sedation.
2988462|NCT02639793|Active Comparator|manual radiofrequency ablation|Radiofrequency catheter ablation using manual catheter manipulation will be used as an ablation technique.
2988463|NCT02639793|Active Comparator|magnet navigation ablation|Radiofrequency catheter ablation using remote magnet navigation will be used as an ablation technique.
2988464|NCT02639793|Active Comparator|cryoablation|Catheter ablation using cryoablation technique will be used as an ablation technique of atrial fibrillation.
2988465|NCT02639780||healthy young female|
2988466|NCT02639780||healthy young male|
2988467|NCT02639780||healthy older female|
2988468|NCT02639780||healthy older male|
2988469|NCT02639780||obese older female|
2988470|NCT02639780||obese older male|
2988471|NCT02639767|Experimental|pemetrexed/cisplatin with pleural IMRT|This is a single institution phase I study of pemetrexed/cisplatin given concurrently with pleural intensity modulated radiation therapy (IMRT) in patients with unresectable malignant pleural mesothelioma (MPM). All patients will receive pleural intensity modulated radiation therapy (IMRT). Patients will be enrolled in cohorts of 3-6 at each dose level of pemetrexed/cisplatin, and dose escalation will proceed in a standard 3+3 fashion until the maximum tolerated dose (MTD) is identified.
2988472|NCT02639754|Experimental|Social Network Leader Endorsement|Leaders of social networks randomized to this arm will be trained to endorse frequent HIV testing, compliance with medical guidelines, and effective ways to communicate these concepts to social network members.
2988473|NCT02639754|Active Comparator|Routine Counseling|Members of social networks randomized to this arm will receive HIV counseling at baseline sessions.
2988474|NCT02639741|Active Comparator|Oral Melatonin Tablet|Melatonin, Vitamin C and placebo tablet Preoperative single oral dose of melatonin (6 mg) or placebo tablet will be given one hour before the start of anesthesia.
2988475|NCT02639741|Active Comparator|Oral Vitamin C Tablet|Melatonin, Vitamin C and placebo tablet Preoperative single oral dose of vitamin C (2 gr) or placebo tablet will be given one hour before the start of anesthesia.
2988476|NCT02639741|Placebo Comparator|Oral Placebo Tablet|Preoperative single oral dose of placebo tablet will be given one hour before the start of anesthesia.
2988477|NCT02639728|Experimental|Regular coffee|Will receive a 4oz cup coffee, three times daily (at 8:00, 12:00, and 16:00 hours)and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
2988478|NCT02639728|Experimental|Decaffeinated coffee|Will receive a 4oz cup of decaffeinated coffee (at 8:00, 12:00, and 16:00 hours) and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
2988479|NCT02639728|Experimental|Warm water|Will receive a 4oz cup of warm water at 8:00, 12:00, and 16:00 hours) and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
2988480|NCT02639702|Experimental|Switch group|Participants will receive clozapine once daily at evening or bedtime throughout the study period. If a participant takes ≥200 mg of clozapine at a time other than evening/bedtime, half of this dose will be switched to an evening/bedtime regimen on day 0 (baseline), then another half dose will be switched on day 7 (week 1). Participants will receive placebo in place of the clozapine dose that was switched to evening/bedtime.
2988481|NCT02639702|No Intervention|Maintenance group|Participants will continue to take clozapine twice daily throughout the study period.
2988689|NCT02638155||No Food Addiction Group|Those participants with no identified food addiction
2988482|NCT02639689|Experimental|WALKAIDE|"A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device."
2988483|NCT02639676||Group 1: Infants born to mothers with preeclampsia|Infants with expected delivery at 26+0 weeks gestation or greater .
2988484|NCT02639676||Group 2: Infants born to mothers with normotensive pregnancies|Infants with expected delivery at 26+0 weeks gestation or greater.
2988485|NCT02639663|Experimental|women whom are interested in breastfeeding and have not begun.|"Post-partum primi and multiparous women Post-partum primipara and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~Control group: participants will not receive any device for breastfeeding pain control"
2988486|NCT02639663|Experimental|Post-partum women that have already begun breast feeding|2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
2988487|NCT02639650|Active Comparator|control group|etoposide, methotrexate ,actinomycin D,vincristine, cyclophosphamide(EMA-CO), two weeks a cycle
2988488|NCT02639650|Experimental|study group|paclitaxel + cisplatin or carboplatin，two weeks a cycle
2988489|NCT02639637|Other|Sitagliptin then Placebo|Subjects in this arm will receive sitagliptin 100 mg daily. After one week of treatment, subjects will report for study day #1. During the study day subjects will be given intra-aterial neuropeptide Y and enalaprilat. A four week washout of medications will occur after the study day. Subjects will then receive placebo for one week followed by study day #2.
2988490|NCT02639637|Other|Placebo then Sitagliptin|Subjects in this arm will receive placebo for one week. After this, subjects will report for study day #1. During the study day subjects will be given intra-aterial neuropeptide Y and enalaprilat. A four week washout of medications will occur after the study day. Subjects will then receive 100 mg of sitagliptin daily for one week followed by study day #2.
2988491|NCT02639637|Placebo Comparator|Sitagliptin then Placebo: Valsartan|Subjects in this arm will receive sitagliptin 100 mg/d for one week as well as valsartan 160 mg/d for one week. After this subjects will report for study day #1. During the study day, subjects will be given intra-arterial neuropeptide Y. A four week washout of medication will occur after the study day. Subjects will then receive placebo/d and valsartan 160 mg/d for one week followed by study day #2.
2988492|NCT02639637|Placebo Comparator|Placebo then Sitagliptin: Valsartan|Subjects in this arm will receive placebo/d for one week as well as valsartan 160 mg/d for one week. After this subjects will report for study day #1. During the study day, subjects will be given intra-arterial neuropeptide Y. A four week washout of medication will occur after the study day. Subjects will then receive sitagliptin 100mg/d and valsartan 160 mg/d for one week followed by study day #2.
2988493|NCT02639624|Experimental|Low bicarbonate dialysate First|Dialysis with low bicarbonate dialysate (expected normal for an adult ~24 mEq) for the first half of dialysis then switched over to normal bicarbonate dialysate for the second half.
2988494|NCT02639624|Active Comparator|Normal bicarbonate dialysate First|Dialysis with normal (37 mEq) for the first half of dialysis then switched over to low bicarbonate dialysate
2988495|NCT02639611|Active Comparator|Immediate Post Operative Acupuncture Treatment|
2988496|NCT02639611|Active Comparator|Acupuncture Treatment After 6 Weeks of Recovery|
2988497|NCT02639598|Experimental|flunarizine|"This study consisted of two periods: a prospective baseline screening period lasting up to 2 weeks (week -2 to week 0, T0), and a treatment period lasting 8 weeks after enrollment (weeks 0-8, T1-T4).~The treatment phase consisted of a 2-week titration period (T1) and a 6-week maintenance period (T2-T4). During the titration period, subjects were given 5 mg/day flunarizine once daily in the first week, followed by 10 mg/day flunarizine in divided doses (twice daily) in the second week. When subjects could not tolerate this target dose, the initial dose was continued through T4."
2988498|NCT02639598|Active Comparator|topiramate|"This study consisted of two periods: a prospective baseline screening period lasting up to 2 weeks (week -2 to week 0, T0), and a treatment period lasting 8 weeks after enrollment (weeks 0-8, T1-T4).~The treatment phase consisted of a 2-week titration period (T1) and a 6-week maintenance period (T2-T4). During the titration period, subjects were given 25 mg/day topiramate once daily in the first week, followed by 50 mg/day topiramate in divided doses (twice daily) in the second week. When subjects could not tolerate this target dose, the initial dose was continued through T4."
2988499|NCT02639585|Experimental|Treatment arm|Daclinza and Sunvepra
2988500|NCT02639572|Experimental|Siloss® bone graft|Based on the sequence, in the test site,Siloss® was placed.
2988501|NCT02639572|Placebo Comparator|Hydroxyapatitie Bone graf|Based on the sequence, the control site which was treated by Hydroxyapatite graft only.
2988502|NCT02639559|Experimental|Arm 1: Donors|-Donors will receive subcutaneous (SC) BL-8040 in the morning (Day 1) followed by leukapheresis approximately 180 minutes (up to 270 minutes) after the injection per institutional protocol. If the donor does not reach the collection goal for mobilization (≥ 5.0 x 10^6 CD34+ cells/kg), a second leukapheresis will be performed on Day 2 (24 hours ± 2 hours from the BL-8040 injection) in an effort to reach a total of ≥ 5 x 10^6 CD34+ cells/kg and at least ≥ 2 x 10^6 CD34+ cells/kg from the combined collections.
2988503|NCT02639559|Experimental|Arm 2: Recipients|-All or part of the leukapheresis product will be infused into the recipient per institutional guidelines. The day of the infusion will be considered Day 0; if the infusion occurs over multiple days, the final day of infusion will be considered Day 0
2988504|NCT02639546|Experimental|Cobimetinib - Dose-Escalation Stage|Participants will receive 0.6 milligrams per kilogram (mg/kg) cobimetinib by mouth once daily on Days 1 to 21 of each 28-day treatment cycle. The dose will be increased by up to approximately 33% of the preceding dose level for each successive cohort until maximum tolerated dose (MTD) or maximum administered dose (MAD) is determined. Once MTD or MAD has been identified in tablets, enrollment of participants using suspension will commence at a minimum of one dose level below MTD or MAD of the tablets.
2988690|NCT02638142||Continuous Furosemide Infusion|continuous intravenous furosemide infusion
2988505|NCT02639546|Experimental|Cobimetinib - Expansion Stage|During the expansion stage, participants will be enrolled in disease-specific cohorts and treated at or below the MTD or MAD determined during the dose-escalation stage for pediatric participants and at the recommended adult dose for participants greater than or equal to (>=) 18 years.
2988506|NCT02639533|Experimental|Pregabalin|Pregabalin 150 mg PO single dose
2988507|NCT02639533|Placebo Comparator|Placebo|Placebo (a pill of same physical characteristics as the one used for the experimental arm, containing starch) PO single dose
2988508|NCT02639520|Active Comparator|Group Canephron® N|Canephron® N & fosfomycin trometamol-placebo
2988509|NCT02639520|Active Comparator|Group Fosfomycin Trometamol|Canephron® N-placebo & fosfomycin trometamol
2988510|NCT02639494|Experimental|Self-Centering Guide Catheter|Subjects who provided written informed consent and an attempt is made to insert the Self-Centering Guide Catheter into the subject's femoral artery.
2988511|NCT02639481|Active Comparator|Control group standard physiotherapy|Patients will receive standard physiotherapy for 60 minutes, including the goal of verticalization and stimulation of the patient but without the use of the robotic Erigo®Pro device.
2988512|NCT02639481|Active Comparator|Erigo®Pro group without FES|Patients will receive 60 minutes of therapy with the robotic Erigo®Pro verticalization device but without functional electrical stimulation (FES) of the leg muscles.
2988513|NCT02639481|Active Comparator|Erigo®Pro group with FES|Patients will receive 60 minutes of therapy with the robotic Erigo®Pro verticalization device including functional electrical stimulation (FES) of the leg muscles.
2988514|NCT02639468|Experimental|Tomographie par impédance électrique|Tomographie par impédance électrique
2988515|NCT02639455|No Intervention|Athlete group|Participants wo regularly exercise and are student athletes.
2988516|NCT02639455|No Intervention|Non-exercise group|Participants who are not student athletes.
2988517|NCT02639455|Experimental|Exercise group|Participants are not student athletes but commit to modest exercise for 5 weeks as part of this study.
2988518|NCT02639442|Experimental|ClearRing™|subjects will undergo general/spinal/local block anesthesia and cystoscopy and/or x-ray evaluation. One to three implants will be transplanted into the patient prostate, followed by cystoscopy for results evaluation
2988519|NCT02639429|Experimental|Combined approach: Foley Balloon + Vaginal Misoprostol|These women will receive vaginal misoprostol per standard protocol at 25 micrograms every 4 hours. In addition, a 26 Fr-Foley balloon catheter will be inserted by routine clinical standards. The Foley will be inserted through the internal cervical os, filled with 60 mL of normal saline, and then pulled snugly against the internal os. The catheter of the Foley will be taped to the patient's inner thigh under gentle traction. If the Foley is unable to be placed, the patient will be reexamined in 1 hour and placement will be reattempted if Bishop's score is still 6 or less by the healthcare provider. When the Foley balloon had fallen out or had to be removed because 12 hours have passed since insertion as per protocol, further management of labor will be left at the discretion of the labor team.
2988520|NCT02639429|Active Comparator|Single approach: Vaginal Misoprostol only|These women will receive 25 micrograms of misoprostol per vagina every 4 hours. Once the cervix becomes favorable (Bishop score > 6), misoprostol administration will be discontinued. Further management will be left at the discretion of the labor team.
2988521|NCT02639416|Active Comparator|Standard management|Standard management consists of F-100 and/or ready-to-use therapeutic food (RUTF) according to usual practice for 14 days
2988522|NCT02639416|Experimental|Polymeric formula|Exclusive polymeric formula supplemented with micronutrients in equivalent volume to F-100 for 14 days
2988523|NCT02639416|Experimental|Elemental formula|Exclusive elemental formula supplemented with micronutrients in equivalent volume to F-100 for 14 days
2988524|NCT02639403|Experimental|RT for Obstructing Rectal Cancer|Conformal three-dimensional RT was planned (3D-RT) in patients with obstructing rectal cancer not amenable for curative resection
2988525|NCT02639390|Experimental|Robotic|The experimental group will receive 1-hour robotic training sessions, 3 times per week for a total of 12 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive the same dosage and schedule (1-hour sessions, 3 times/week, 12 total sessions) of conventional one-on-one therapy from an occupational therapist.
2988526|NCT02639390|Active Comparator|Conventional|Subjects will receive 24 hours of one-on-one treatment from an occupational therapist. The treatment schedule will parallel that given to the experimental group (1-hour sessions, 3 times/week).
2988527|NCT02639377|Experimental|Chlorhexidine gluconate|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
2988528|NCT02639377|Placebo Comparator|Placebo|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
2988529|NCT02639364|Active Comparator|conventional ventilation strategy|The conventional ventilation strategy use volume-controlled ventilation (VCV) or pressure-controlled ventilation (PCV) mode, combination with low tidal volume and adequate PEEP level.
2988530|NCT02639364|Experimental|BILEVEL-APRV protocol|According to our BILEVEL-APRV protocol, BILEVEL-APRV APRV mode with specific settings,combination with spontaneous breathing.
2988531|NCT02639351|Experimental|Arm 1|MenC-CRM/ Aluminium Hydroxide/ 12.5 ug LHD153R
2988532|NCT02639351|Experimental|Arm 2|MenC-CRM/ Aluminium Hydroxide/25 ug LHD153R
2988533|NCT02639351|Experimental|Arm 3|MenC-CRM/ Aluminium Hydroxide/ 50 ug LHD153R
2988534|NCT02639351|Experimental|Arm 4|MenC-CRM/ Aluminium Hydroxide/ 100 ug LHD153R
2988535|NCT02639351|Active Comparator|Arm 5|MenC-CRM/Aluminium Hydroxide
2988536|NCT02639338|Experimental|SOF/VEL/VOX|SOF/VEL/VOX tablet for 8 weeks
2988537|NCT02639338|Experimental|SOF/VEL|SOF/VEL tablet for 12 weeks
2988538|NCT02639286|Experimental|Study Drug|300 mg of study drug administered
2988539|NCT02639286|Placebo Comparator|Placebo|Placebo administered via SC
2988540|NCT02639273|Experimental|Drug|
2988541|NCT02639273|Placebo Comparator|Placebo|
2988542|NCT02639260|Experimental|Cohort A|3,000 mg/day
2988543|NCT02639260|Experimental|Cohort B|10000 mg/day
2988544|NCT02639247|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
2988545|NCT02639247|Experimental|SOF/VEL|SOF/VEL for 12 weeks
2988691|NCT02638142||Intermittent Furosemide Infusion|bolus intermittent intravenous furosemide infusion
2988546|NCT02639234|Experimental|Vigil™ + Nivolumab|Patients meeting study eligibility criteria will receive doublet therapy comprising of (i) Vigil™ 1 x 10^7 cells by intradermal injection every 2 weeks (for a minimum of 4 and a maximum of 12 doses) and (ii) nivolumab 3 mg/kg by intravenous infusion over 60 minutes every 2 weeks.
2988547|NCT02639221|Experimental|PXT002331|
2988548|NCT02639221|Placebo Comparator|Placebo|
2988549|NCT02639208|Experimental|PatientsLikeMe (PLM)|"After the screening procedures confirm eligibility.~Baseline Survey Assessment and PatientsLikeMe Introduction~Treatment Evaluation on PLM website at predetermined times per protocol~Final Survey"
2988550|NCT02639195||Treatment, retrospective|Retrospective analysis on patients treated with manual physical therapy in quality of life outcomes as measured by pre and post treatment questionnaires. Chart review.
2988551|NCT02639195||Untreated control|Prospective data collection via questionnaire of subjects with a history of small bowel obstruction in an observational manner. No treatment is performed.
2988552|NCT02639182|Experimental|AGS-16C3F|AGS-16C3F will be administered as a single 60-minute intravenous (IV) infusion once every 3 weeks.
2988553|NCT02639182|Active Comparator|Axitinib|Axitinib will be administered twice daily continuously, by mouth.
2988554|NCT02639169|Experimental|music|Apply live music through techniques music therapy in group experimental and evaluation through the visual analog scale (VAS) and numeric.
2988555|NCT02639169|No Intervention|Comparative|Apply the visual analog scale (VAS) and numeric.
2988556|NCT02639156|Experimental|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 ONS providing at least 300kcal/day will be changed onto an equivalent prescription of AYMES LONDON for a period of 9 days.
2988557|NCT02639143|Experimental|ticagrelor|Ticagrelor, 180 mg, oral administration. followed by 90 mg bid
2988558|NCT02639143|Active Comparator|Clopidogrel|Clopidogrel 600 mg loading dose taken orally, followed by 75 mg qd.
2988559|NCT02639130|Active Comparator|Vildagliptin|"After a screening examination, patients were treated with vildagliptin and participated in meal tests (day 9 and 10, respectively), in a crossover design. Between the two treatment periods, there was a ≥ 5 week wash-out period.~Experimental procedures: Meal test, determination of the rate of gastric emptying. On days 9 and 10 of treatment, the volunteers underwent a mixed meal (one scrambled egg, a slice of ham, 10 g of butter, two slices of toast, 20 g strawberry jam, and 200 ml of unsweetened tea) test in the morning after fasting overnight. 13C-octanoic acid (110 µl/100 mg) was used as label.~Meal tests were performed (days 9 and 10), without and with a high dose intravenous infusion of exendin [9-39]."
2988560|NCT02639130|Placebo Comparator|Placebo|"After a screening examination, patients were treated with placebo, and participated in meal tests (day 9 and 10, respectively), in a crossover design. Between the two treatment periods, there was a ≥ 5 week wash-out period.~Experimental procedures: Meal test, determination of the rate of gastric emptying. On days 9 and 10 of treatment, the volunteers underwent a mixed meal (one scrambled egg, a slice of ham, 10 g of butter, two slices of toast, 20 g strawberry jam, and 200 ml of unsweetened tea) test in the morning after fasting overnight. 13C-octanoic acid (110 µl/100 mg) was used as label.~Meal tests were performed (days 9 and 10), without and with a high dose intravenous infusion of exendin [9-39]."
2988561|NCT02639117|Other|Vismodegib|Vismodegib 150 mgs po qd. Open label.
2988562|NCT02639104|Experimental|Cervical postural related neck pain|Patients recruit in this group who has a neck pain without radiculopathy. If the patient examination shows neurologic deficits, this patient will exclude in this study. All patients will undergo lateral cervical spine spot radiography and serratus anterior needle electromyography. Cervical segmental angle measurements will be done in all patients.
2988563|NCT02639104|Sham Comparator|Control group|The healthy volunteers recruit in this group. All inviduals will undergo lateral cervical spot radiography and serratus anterior needle electromypography
2988564|NCT02639091|Experimental|BAY 94-9343 + Pemetrexed + Cisplatin|Investigating the combination of anetumab ravtansine (BAY 94-9343) with Pemetrexed (500 mg/m2) and Cisplatin (75 mg/m2) in Part 1 (dose escalation cohorts) and Part 2 (two MTD expansion cohorts)
2988565|NCT02639078|Experimental|TD-0714|One time dosing in capsule formulation
2988566|NCT02639078|Placebo Comparator|Placebo|Placebo comparator one time dosing in capsule formulation
2988567|NCT02639065|Experimental|Investigational Treatment|Durvalumab 1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
2988568|NCT02639052|Experimental|Botox|10 units of Botox intradermally injected into one forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
2988569|NCT02639052|Placebo Comparator|Saline|Saline vehicle intradermally injected into the other forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
2988570|NCT02639039|Active Comparator|Cortisone Injection|Fifty patients with GTPS will be randomized into a CI or TDN group. Treatment will be carried out at the 1st visit following consent according to SOC. Treatment will be administered according to standard of care for up to 6 weeks.
2988571|NCT02639039|Active Comparator|Trigger Point Dry Needling|Fifty patients with GTPS will be randomized into a CI or TDN group. Treatment will be carried out at the 1st visit following consent according to SOC. Treatment will be administered according to standard of care for up to 6 weeks.
2988572|NCT02639026|Experimental|Cohort 1|Subjects will receive 20 mg/kg MEDI4736 and 1 mg/kg tremelimumab in combination every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses. The total duration of therapy is 12 months. Cohort 1 tests 8 Gy x 3 fractions
2988573|NCT02639026|Experimental|Cohort 2|Subjects will receive 20 mg/kg MEDI4736 and 1 mg/kg tremelimumab in combination every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses. The total duration of therapy is 12 months. Cohort 2 tests 17 Gy x 1 fraction.
2988574|NCT02639013|Experimental|ttransducer technique|the nurses will measure intraabdominal pressure at each shift during the day by using transducer technique
2988575|NCT02639000|Experimental|Blastocyst|Embryo transfer of at maximum 2 embryos at blastocyst stage
2988576|NCT02639000|Active Comparator|Cleavage|Embryo transfer of at maximum 2 embryos at cleavage stage
2988765|NCT02637687|Experimental|Treatment|Open Label LOXO-101 (larotrectinib)
2988766|NCT02637674|Experimental|Uterus Transplantation|Women will undergo deceased donor uterine transplantation after IVF
2988577|NCT02638987|Experimental|Dry needling|After the second computer task, a single dry needling session will be performed with the subject lying on the non painful side. After palpation of a taut band and detection of MTrP 2 in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the MTrP and will move the needle up and down in multiple directions. When local twitch responses are elicited, this will be repeated until the local twitch responses are extinct.
2988578|NCT02638987|No Intervention|Rest|After the first computer task, participants will rest in sidelying position for 10 minutes.
2988579|NCT02638974|Experimental|Medical Skin Camouflage|This arm will use medical skin camouflage for 6 weeks
2988580|NCT02638974|No Intervention|Wait List Control|This arm will receive medical skin camouflage at the end of the study
2988581|NCT02638961|Placebo Comparator|Standard treatment|Only standard medical treatment
2988582|NCT02638961|Active Comparator|IMT group|Standard medical treatment associated to Inspiratory muscle training
2988583|NCT02638961|Active Comparator|FES group|Standard medical treatment associated to functional electrostimulation of both legs for 45 minutes a day, 2 days per week for a total of 12 weeks.
2988584|NCT02638961|Active Comparator|IMT+FES group|Standard medical treatment associated to combination of inspiratory muscle training and functional electrostimulation of both legs
2988585|NCT02638948|Placebo Comparator|Placebo|Placebo + Methotrexate dose as specified
2988586|NCT02638948|Experimental|Dose Level 1|BMS-986142 at dose level 1+ Methotrexate as specified
2988587|NCT02638948|Experimental|Dose Level 2|BMS-986142 at dose level 2 + Methotrexate as specified
2988588|NCT02638935|Other|BI-RADS 3|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
2988589|NCT02638935|Other|BI-RADS 4a|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
2988590|NCT02638935|Other|BI-RADS 4b|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
2988591|NCT02638935|Other|BI-RADS 4c|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
2988592|NCT02638922||no treatment|girls who never received estradiol treatment
2988593|NCT02638922||Estradiol treatment|girls who received estradiol treatment
2988594|NCT02638909|Experimental|ceritinib|Phase II, single-arm study of oral ceritinib in adult patients with ALK and ROS1 activated gastrointestinal malignancies
2988595|NCT02638896|Experimental|Dose reduction arm|AS patients who achieved remission will receive etanercept 50 mg subcutaneous injections every other weeks plus sulfasalazine (2g/d) oral administration till week24. Celecoxib will be the background therapy.
2988596|NCT02638896|Active Comparator|Dose maintenance arm|AS patients who achieved remission will receive etanercept 50 mg subcutaneous injections every weeks plus sulfasalazine (2g/d) oral administration till week24. Celecoxib will be the background therapy.
2988597|NCT02638896|Other|Etanercept discontinuation arm|AS patients who achieved remission will take sulfasalazine (2g/d) till week24. Celecoxib will be the background therapy.
2988598|NCT02638857|Sham Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization(TACE) treatment:patients will receive lipiodol,Mitomycin (MMC),Epirubicin（EADM） hepatic arterial infusion,3 cycles.
2988599|NCT02638857|Experimental|DC-PMAT cells|After accepting concurrent TACE treatment,patients will receive 3 cycles of Dendritic Cell -Precision Multiple Antigen T (DC-PMAT) cells treatment.
2988600|NCT02638831|Experimental|Ketorolac Tromethamine|Ketorolac 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
2988601|NCT02638831|Active Comparator|Ketoprofen|Ketoprofen gel 2.5% for external application. Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
2988602|NCT02638818||minimally invasive whipple|Surgical technique (minimally invasive vs open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
2988603|NCT02638818||traditional whipple|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
2988604|NCT02638805|Experimental|Group 1|ITCA 650 20/60 mcg/day
2988605|NCT02638805|Experimental|Group 2|ITCA 650 60 mcg/day
2988606|NCT02638792|Experimental|Internet-based exposure therapy|"The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images."
2988607|NCT02638792|Active Comparator|Internet-based stress management therapy|The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
2988608|NCT02638792|No Intervention|Waitlist|When the active treatment groups have finished treatment (W11), the WL group will be able to start active treatment and be assessed at post-treatment, and 4, 12 months later using the same questionnaires as the treatment group. The participants will be able to choose which treatment they receive i.e. no randomization.
2988609|NCT02638779|Experimental|Blood sampling|Blood sampling will be performed in all patients and healthy volunteers
2988610|NCT02638766|Other|Unique arm|Regorafenib 160mg once a day, frequency: 3 weeks on/1 week off in cycles of 28 days
2988611|NCT02638753|Active Comparator|Education|Patients will receive 4 sessions (1 hour each) of education on pain neurophysiology.
2988612|NCT02638753|Experimental|Education combined with hypnosis|Patients will receive 4 sessions (1 hour each) of education on pain neurophysiology combined with hypnosis.
2988613|NCT02638740|Active Comparator|SCALING AND ROOT PLANING (SRP)|Scaling and root planning with ultrasonic scalar
2988614|NCT02638740|Experimental|MUSTARD OIL AND SALT MASSAGE WITH SRP|Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
2988615|NCT02638727|Active Comparator|Drug Arm|This group treat with L-Citrulline (3 grams per day)
2988616|NCT02638727|Placebo Comparator|Placebo Arm|this group treat with placebi every day
2988618|NCT02638701|Experimental|Infliximab treatment|Administer infliximab intravenously to patients with DVB aneurysms (3 mg/kg at 0, 3 and 7 weeks, then at 8-week intervals x 7) for a total of 12-months. Patients will undergo MR imaging at 0, 12, and 24-month time points.
2988619|NCT02638688||2D ultrasound|2D-US measurements are the most accurate method for measuring fibroid volumes
2988620|NCT02638688||3D ultrasound|3D-US measurements are the most accurate method for measuring fibroid volumes
2988621|NCT02638688||postoperative|actual volume using change in water path measurements are the most accurate method for measuring fibroid volumes
2988622|NCT02638675|Experimental|Wellness program, accelerometer, incentives|During the intervention period (weeks 1 to 12), intervention participants will be eligible to earn daily reward points contingent on step count goal achievement. Intervention participants will earn 100 reward points (i.e. $1) for each day that specific step count goals are reached. During weeks 13 to 24, participants will no longer receive daily reward points for completing specific step count goals.
2988623|NCT02638675|Active Comparator|Wellness program and accelerometer|During the 24 week trial, control participants will receive no additional incentives when step count goals are reached.
2988624|NCT02638662||First time IVF patients. Observational|Those who are doing IVF for the first time.
2988625|NCT02638662||Donors Observational|Those who are doing IVF for the sole purpose of donating their eggs.
2988626|NCT02638662||2 or more IVF cycles Obervational|Those who have done IVF 2 or more times with no success.
2988627|NCT02638649||subjects who call 911 for dyspnea|All subjects who call 9-1-1 for difficulty breathing will have the potential to be enrolled in the study.
2988628|NCT02638636|Experimental|Internet-based exposure therapy|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.
2988629|NCT02638636|No Intervention|Waitlist|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment when the first group has finished (i.e. week 10).
2988630|NCT02638623|Active Comparator|Drug|Covered two liters of body temperature warmed lactated ringer's in the immediate preoperative setting of subjects undergoing total knee or total hip replacement
2988631|NCT02638623|Placebo Comparator|Placebo|Covered empty bag with no hydration supplement
2988632|NCT02638610|Experimental|Sensation measurement|patients with eyelid pathology going through eyelid surgery.
2988633|NCT02638597|Experimental|Gemfibrozil|Participants in this arm will receive smoking cessation counseling and will be provided gemfibrozil 600 mg twice daily by mouth for 9 weeks, starting one week prior to target quit date and ending with study completion
2988634|NCT02638597|Other|Waitlist|Participants in this arm will receive the smoking cessation counseling but will not receive medication. After completing the trial without medication, participants who continue to smoke and have a desire to quit may choose to enter the gemfibrozil arm.
2988635|NCT02638584|Experimental|Ilaprazole|Ilaprazole tab 10mg, 2 tablets once daily for 8 weeks.
2988636|NCT02638584|Active Comparator|Rabeprazole|Rabeprazole tab 20mg, 1 tablet once daily for 8 weeks.
2988637|NCT02638571|Sham Comparator|Usual education|Households in the control clusters (kebeles) will receive usual nutrition education from Health extension workers, about complementary foods, over 9 months.
2988638|NCT02638571|Experimental|Enhanced Education|Additional education sessions from Health extension workers (HEWs) trained on use of pulses for complementary foods (CF). HEWs provide nutrition education programs and counseling about pulse-cereal mix complementary foods, over 9 months.
2988639|NCT02638558|Experimental|written + oral explanation|patients will undergo both written and oral explanation for preparation with split dose
2988640|NCT02638558|Experimental|written explanation|patients will receive only a written explanation for preparation with split dose
2988641|NCT02638545|Experimental|dexmedetomidine|
2988642|NCT02638532|Other|Foot Fat Pad Grafting|All subject who enter into the study will undergo the fat pad grafting procedure to either the Heel or Forefoot based on the discretion of the PI, Co-investigator and the study subject.
2988643|NCT02638519|Other|Healthy Volunteers|Healthy volunteers will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
2988644|NCT02638519|Other|Alzheimer's Disease Participants|Alzheimer's disease participants will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
2988645|NCT02638506|Experimental|Intranasal Fentanyl|All patients will receive a 1.5 mcg⁄kg dose of fentanyl or an equivalent volume of similar looking placebo. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe.
2988646|NCT02638506|Placebo Comparator|Salinex|All patients will receive a 1.5 mcg⁄kg dose of fentanyl or an equivalent volume of similar looking placebo. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe.
2988647|NCT02638493||HIV positive TDF/FTC|8 HIV positive men taking TDF/FTC as treatment
2988648|NCT02638493||HIV negative|8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis
2988649|NCT02638493||HIV Positive TAF|8 HIV positive men taking TAF as treatment
2988650|NCT02638480|No Intervention|Control|The control subjects will be treated with only the current SOC including NSAIDs and physical therapy.
2988651|NCT02638480|Experimental|Experimental|The experimental subjects will be treated with current SOC and will also use a kneeMD splint 3 times a day for 20 minutes per session
2988767|NCT02637661||Initial AMI|To study the sensitivity, specificity, positive predictive value, and negative predictive value of different earlobe crease as risk factors of AMI
2988652|NCT02638467|Experimental|Bosutinib and Bone Marrow Transplant|Subjects will receive 400mg of bosutinib from day at least -45 to day -15 to assess the sensitivity of patient Chronic Myeloid Leukemia (CML) to this TKI. Patients will be transplanted with the aim to transplant > 3 x 106 CD34+ cells/kg Body Weight (BW) recipient from bone marrow or > 3 x 108 nucleated cells/kg BW recipient from bone marrow. Then, subjects will receive 400mg of bosutinib once daily from day +30 after transplant.
2988653|NCT02638454|Active Comparator|HL-YNG|"Healthy young sedentary males and females 20-30 yrs old~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
2988654|NCT02638454|Experimental|FL-OLD|"Functionally-limited older sedentary males and females without sarcopenia (70-85 yrs old)~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
2988655|NCT02638454|Experimental|SR-OLD|"Functionally-limited older sedentary males and females with clinically defined sarcopenia (70-85 yrs old)~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
2988656|NCT02638428|Experimental|Refractory/relapsed solid tumor or AML|Conventional chemotherapy (Ifosfamide carboplatin etoposide for solid tumor and fludarabine cytarabine for AML) with matched single-targeted agent (axitinib, crizotinib, dasatinib, erlotinib, everolimus, imatinib, pazopanib, ruxolitinib, sorafenib, vandetanib, vemurafenib, or trastuzumab) or multi-targeted receptor tyrosine kinase inhibitor (pazopanib or sorafenib) according to the result of CancerSCAN™
2988657|NCT02638415|Experimental|HVPG group|HVPG-guided therapy
2988658|NCT02638415|Other|non-HVPG group|routine therapy
2988659|NCT02638402||Stage I, II, III, IV ovarian cancer|Stage I, II, III, IV ovarian cancer receive treatment in National Taiwan University Hospital
2988660|NCT02638402||Stage I, II, III, IV endometrial cancer|Stage I, II, III, IV endometrial cancer receive treatment in National Taiwan University Hospital
2988661|NCT02638389|Experimental|Patients with vascular malformations|Patients with venous, lympathic or complex vascular malformations (KTS, PTEN, etc.) will receive sirolimus after completion of inclusion criteria
2988662|NCT02638376|Active Comparator|KXL treatment only|
2988663|NCT02638376|Active Comparator|KXL and topography-guided PRK|simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)
2988664|NCT02638350|Experimental|Intervention lung ultrasound|All patients will have strategy with lung ultrasoundlung ultrasound
2988665|NCT02638337|Experimental|Ospemifene|Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.
2988666|NCT02638337|Placebo Comparator|Placebo|Participants will take one tablet of matching placebo, orally, once a day for 12 weeks.
2988667|NCT02638324|Active Comparator|Renal nervous denervation.|Renal nervous denervation is performed to the patients who do not response properly to conventional therapy. The patients are randomised according to the waiting list principle.
2988668|NCT02638324|Active Comparator|Renal nervous denervation (delayed)|Renal nervous denervation is performed after six months on the waiting list
2988669|NCT02638298|Experimental|NPWT dressing|
2988670|NCT02638298|Placebo Comparator|Standard dry gauze dressing|
2988671|NCT02638285|Experimental|HCG group|HCG group
2988672|NCT02638285|Experimental|LH group|LH group
2988673|NCT02638285|Experimental|clomiphene citrate|clomiphene citrate
2988674|NCT02638272|Other|spine surgery|The objective was to compare the outcomes of radical debridement versus no debridement under different surgical procedures for the treatment of thoracic and lumbar tuberculosis.
2988675|NCT02638259|Experimental|50mg GP2015|Group 1 will receive treatment with 50mg GP2015 by subcutaneous injection every week up to 24 weeks (Treatment Period 1) after which patients achieving at least a moderate clinical response continue treatment with 50mg GP2015 subcutaneous injection every week up to 48 weeks (Treatment Period 2).
2988676|NCT02638259|Active Comparator|50mg EU-authorized Enbrel|Group 2 will receive treatment with 50mg EU-authorized Enbrel by subcutaneous injection every week up to 24 weeks (Treatment Period 1) after which patients achieving at least a moderate clinical response will be switched to 50 mg GP2015 subcutaneous injection every week up to 48 weeks (Treatment Period 2).
2988677|NCT02638246|Experimental|Contingent|Participants in this group received incentives contingent on meeting pre-specified daily blood-glucose testing adherence goals.
2988678|NCT02638246|Active Comparator|Noncontingent|Participants in this group received incentives independent of meeting pre-specified daily blood glucose testing adherence goals.
2988679|NCT02638233|Other|Sofosbuvir 400mg/Ledipasvir 90 mg|Subjects will receive sofosbuvir 400mg q.d p.o and ledipasvir 90 mg q.d p.o (FDC) for 8 weeks
2988680|NCT02638207|Experimental|0.5 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
2988681|NCT02638207|Experimental|1.0 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (1.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
2988682|NCT02638207|Experimental|2.0 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (2.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
2988683|NCT02638194|Active Comparator|Hookah Smoking Group|10 participants will smoke tobacco hookah for 2 hours
2988684|NCT02638194|Active Comparator|Hookah Secondhand Smoke Group|10 individuals will be exposed to secondhand hookah tobacco smoke for 2 hours
2988685|NCT02638181|Experimental|trabeculectomy|
2988686|NCT02638168|Active Comparator|Immediate Release Methylphenidate|With-in subjects trial. Subjects will be randomized to 0.3 mg/kg of Immediate Release Methylphenidate versus placebo over 3-weeks duration
2988687|NCT02638168|Placebo Comparator|Placebo|inert placebo ingredient
2988688|NCT02638155||Food Addiction Group|Those participants identified as having food addiction by the Yale Food Addiction Scale.
2988692|NCT02638129|Other|Lead-In: Naltrexone/Bupropion + Placebo|Naltrexone hydrochloride (HCl) 8 mg/bupropion HCl 90 mg extended release (ER) combination tablets, orally, once daily for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, once daily for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
2988693|NCT02638129|Other|Lead-In: Placebo + Naltrexone/Bupropion|Naltrexone/bupropion placebo-matching tablets, orally, once daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, once daily, for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
2988694|NCT02638129|Active Comparator|Naltrexone/Bupropion|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet, in the morning (AM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet in the AM and one in the evening (PM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
2988695|NCT02638129|Placebo Comparator|Placebo|Naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
2988696|NCT02638116|Experimental|Ibrutinib + Omeprazole|Participants will receive a dose of Ibrutinib 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7 and Omeprazole at a dose of 40 mg tablets orally once on Days 3 through 7.
2988697|NCT02638103|Experimental|TEV-48125 - 1|Dose Regimen 1
2988698|NCT02638103|Experimental|TEV-48125 - 2|Dose Regimen 2
2988699|NCT02638090|Experimental|Phase I Dose Escalation|"Level 1: Vorinostat 200mg by mouth (PO) Daily; Pembrolizumab 200 mg intravenously (IV) every (Q) 3 weeks.~Level 2: Vorinostat 400 mg PO Daily; Pembrolizumab 200 mg IV Q3 weeks"
2988700|NCT02638090|Experimental|Phase Ib Expansion|"Pembrolizumab plus Vorinostat.~Level 1: Maximum Tolerated Dose (MTD)"
2988701|NCT02638090|Active Comparator|Arm A: Pembrolizumab|"Pembrolizumab treatment only.~Level 1: Pembrolizumab 200 mg Q3 wks"
2988702|NCT02638090|Active Comparator|Arm B: Pembrolizumab plus Vorinostat|"Pembrolizumab plus Vorinostat treatment.~Level 1: MTD"
2988703|NCT02638077||Group 1|2000 DTC patients undergo the first-time thyroidectomy and identified as intermediate or high risk of recurrence will be recruited. Doctors can treat the patients based on disease conditions. Investigators will record data which are related to study endpoints.
2988704|NCT02638064|Experimental|Surgiflo injection|Injection of surgiflo in the pilonidal sinus cavity after curettage of its content
2988705|NCT02638051|Experimental|Study Group|Modulated Electro-Hyperthermia (mEHT): 150 Watt x 60 min/session every 2nd day for 4 weeks (14 sessions); TCM Herbal Decoction: Shi Pi Decoction administered orally twice a day (200 mL x 2) 30 min after breakfast and supper, for 4 weeks.
2988706|NCT02638051|Active Comparator|Control Group|IPCI: CDDP (30-60 mg) with 5FU (500-600 mg/sqm of body surface), both dissolved in 100 mL of normal saline, after abdominal paracentesis and catheterization with following closed drainage of the ascites up to small amount of remaining liquid. After IPCI, the catheter occluded. Administered biweekly during four weeks of the course, totally two times.
2988707|NCT02638038|Experimental|Oral INT 131 3 mg|Oral INT-131 Double blind study
2988708|NCT02638038|Experimental|Oral INT-131 1 mg|Oral INT-131 Double blind
2988709|NCT02638038|Placebo Comparator|Placebo|Oral placebo Double blind
2988710|NCT02638012|Experimental|HHT - Floseal|Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity.
2988711|NCT02638012|Active Comparator|HHT - Standard of Care|If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care).
2988712|NCT02637999|Experimental|MXB then PEG IFN|Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 48 weeks
2988713|NCT02637999|Experimental|MXB + PEG IFN then PEG IFN|Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks
2988714|NCT02637999|Active Comparator|PEG IFN|PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks
2988715|NCT02637986|Experimental|ARM A - suffered from one episode of UTI|Women who suffered from one episode of UTI during pregnancy before recruitment
2988716|NCT02637986|Placebo Comparator|ARM A - suffered from one episode of UTI - placebo|Women who suffered from one episode of UTI during pregnancy before recruitment
2988717|NCT02637986|Experimental|ARM B -suffered from more than one episode of UTI|women who suffered from more than one episode of UTI or one episode of pyelonephritis during pregnancy before recruitment
2988718|NCT02637986|Placebo Comparator|ARM B -suffered from more than one episode of UTI - placebo|women who suffered from more than one episode of UTI or one episode of pyelonephritis during pregnancy before recruitment
2988719|NCT02637973|Experimental|Empagliflozin|Empagliflozin, film-tablet, 25mg once daily
2988720|NCT02637973|Placebo Comparator|Placebo|Placebo, once daily
2988721|NCT02637960|Experimental|Fedovapagon 2 mg|One daily dose of 2 mg fedovapagon for 12 weeks
2988722|NCT02637960|Experimental|Placebo matched to fedovapagon|One daily dose of placebo (matched to fedovapagon) for 12 weeks
2988723|NCT02637947|Experimental|Magnetic navigation|Catheter ablation using magnetic navigation for ventricular tachycardia via remote magnetic navigation of a NaviStar RMT ThermoCool catheter, or other magnetically compatible catheter, via Stereotaxis's Niobe ES system.
2988724|NCT02637947|Active Comparator|Manual navigation|Catheter ablation using manual navigation for ventricular tachycardia via a manually navigated Thermocool catheter, or equivalent catheter.
2988725|NCT02637934|Experimental|Biodistribution|The Biodistribution cohort will include up to 10 patients who will undergo a series of vertex to mid-thigh biodistribution [18F]FTT PET/CT scans over a period of approximately 4 hours.
2988726|NCT02637934|Experimental|Dynamic|The Dynamic cohort will include up to 20 patients who will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh scans imaging post injection of [18F]FTT.
2988727|NCT02637921|Active Comparator|Hypoxic ambulatory|Participants ambulatory in normobaric hypoxia with standardised nutritional intake
2988728|NCT02637921|Experimental|Hypoxic Bed rest|Participants are on bed rest in normobaric hypoxia with standardised nutritional intake
2988729|NCT02637921|Active Comparator|Normoxic bed rest|Participants are on bed rest in normobaric normoxia with standardised nutritional intake
2988730|NCT02637908|Experimental|Mindfulness training|The mindfulness training (experimental condition) will receive 6-weeks of mindfulness training for parents provided in a group setting.
2988731|NCT02637908|No Intervention|Wait-list control|The wait-list control group will receive no intervention during the course of the study. The control group will be offered training following the completion of the study.
2988732|NCT02637895|Placebo Comparator|Placebo|Placebo pill once daily for 12 weeks of active treatment.
2988733|NCT02637895|Active Comparator|Vortioxetine|Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.
2988734|NCT02637882|Experimental|First intervention (ear plug)|"Other: ear plug~Other Name: eastnova ear plug"
2988735|NCT02637882|Other|Second intervention (eye mask)|"Other: eye mask~The patients will receive the second intervention (eye mask) in the second night (N2) from 9 pm to 6 am.~Other Name: Sleeping mask"
2988736|NCT02637882|Other|Ear plug and eye mask|The patients will receive the mixed intervention (eye mask) and (ear plug ) in the first night (N1) from 9 pm to 6 am.
2988737|NCT02637869||Control Group - non-intervention|Clinics that did not participate in the APM project
2988738|NCT02637869||Alternative Payment Model -intervention|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
2988739|NCT02637856|Experimental|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
2988740|NCT02637843|Active Comparator|Slender arm|Uses the terumo slender sheath for radial angiography or angioplasty
2988741|NCT02637843|No Intervention|Standard arm|Uses the terumo standard sheath (Routine) for radial angiography or angioplasty
2988742|NCT02637830|Experimental|Fluoride varnish and fluoride toothpaste|Application of fluoride varnish (Duraphat) at the begining of the study. Application of fluoride toothpaste (Crest) twice a day for 3 days.
2988743|NCT02637830|Placebo Comparator|placebo toothpaste|Application of placebo toothpaste twice a day for 3 days
2988744|NCT02637830|Active Comparator|Fluoride toothpaste|Application of fluoride toothpaste (Crest) twice a day for 3 days
2988745|NCT02637817||Control Group|Neonates with no evidence of brain lesions on conventional MRI.
2988746|NCT02637817||Patients Group|Neonates with PWML diagnosed by conventional MRI.
2988747|NCT02637804|Active Comparator|stenfilcon A vs narafilcon A (Group 1)|Participants are randomized to wear either stenfilcon A lens pair or narafilcon A lens pair, bilaterally, for 1 week during the cross over study.
2988748|NCT02637804|Active Comparator|stenfilcon A vs delefilcon A (Group 2)|Participants are randomized to wear either stenfilcon A lens pair or delefilcon A lens pair, bilaterally, for 1 week during the cross over study.
2988749|NCT02637791|Experimental|Intervention|The virtual glove in their homes for a period of 8 weeks and advised to try to build up to using the system for a maximum of 20 minutes 3 times a day for 8 weeks.
2988750|NCT02637791|No Intervention|Control|Usual care
2988751|NCT02637778|Experimental|Cardioprotective diet|The study participants receive defined personal nutrition counselling every two weeks and they get daily menu plans (with optimised nutrient profiles) over an entire period of 20 wks (follow-up 20 wks).
2988752|NCT02637778|Experimental|Cardioprotective diet + 3 g EPA+DHA/d|"The study participants receive defined personal nutrition counselling every two weeks and they get daily menu plans (with optimised nutrient profiles) over an entire period of 20 wks (follow-up 20 wks).~Participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)."
2988753|NCT02637765|No Intervention|Control Group|Usual Physical Activity
2988754|NCT02637765|Experimental|Intervention Group|8-week increased physical activity program
2988755|NCT02637752|Active Comparator|Lifestyle counseling|Intervention: Lifestyle counseling or nutrition/physical counselling
2988756|NCT02637752|No Intervention|No Intervention|To ensure that both groups benefited equally from the study, the control group received the counselling and the handouts at the end of the study.
2988757|NCT02637739|Experimental|Pregnancy of unknown location|pregnant women of at least 5 weeks by last menstrual period and transvaginal ultrasound did not revealed intra-uterine pregnancy or ectopic pregnancy Intervention: hysteroscope
2988758|NCT02637726|Experimental|TIVA0|Propofol : TIVA guided by clinical signs. Remifentanil
2988759|NCT02637726|Experimental|TIVA BIS|propofol : TIVA guided by EEG Monitoring. Remifentanil
2988760|NCT02637726|Experimental|TCI KBIS|Propofol : TCI Kataria guided by EEG Monitoring. Remifentanil.
2988761|NCT02637726|Experimental|TCI SBIS|Propofol : TCI Schnider guided by EEG Monitoring. Remifentanil.
2988762|NCT02637713||Radiofrequency energy to the LES|All patients that have undergone sleeve gastrectomy as treatment for obesity that have developed severe reflux symptoms. Will be treated with Stretta (FDA approved device for the management of GERD) and evaluated prospectively for resolution/improvement of reflux symptoms.
2988763|NCT02637700|Experimental|Intravenous Immunoglobulin|Patients with skin biopsy proven idiopathic Small Fiber Neuropathy in this arm will receive intravenous immunoglobulin.
2988764|NCT02637700|Placebo Comparator|Placebo (Saline 0.9%)|Patients with skin biopsy proven idiopathic Small Fiber Neuropathy in this arm will receive placebo (saline 0.9%).
2988769|NCT02637648|Experimental|Sodium oxbate|oral administration of sodium oxybate, 6-18ml per night, starting with 6ml in two nightly dosages of 1.5g each, increased by steps of 1.5g every second or third night until treatment response
2988770|NCT02637648|Placebo Comparator|Placebo|oral administration of placebo, 6-18ml per night, starting with 6ml in two nightly dosages
2988771|NCT02637635|Experimental|Breast reconstruction with implant|The patients will undergo breast reconstruction with an expander prosthesis.
2988772|NCT02637635|Experimental|Autologous fat transplantation|The patients will undergo lipofilling as a pre-treatment before they will undergo breast reconstruction with an expander prosthesis.
2988773|NCT02637622||Best-Worst Scaling (Case 2)|Preference elicitation survey using a best-worst scaling method.
2988774|NCT02637622||Discrete Choice Experiment|Preference elicitation survey using a discrete choice experiment method.
2988775|NCT02637609||Likert Scale|Priority elicitation survey using a Likert scale method.
2988776|NCT02637609||Best-Worst Scaling (Case 1)|Priority elicitation survey using a best-worst scaling method.
2988777|NCT02637596|Experimental|RFA group|Twenty-fourth consecutive patients with histologically proved pancreatic cancer [stage IIb (n=4), III (n=15), IV (n=5) ]underwent intraoperative RFA of primary tumor.
2988778|NCT02637583|Active Comparator|Sequential vaccination PCV13 and PPV23|PCV13 0.5 ml intramuscular injection once on day 0 PPV23 0.5 ml intramuscular injection once 6 months later
2988779|NCT02637583|Experimental|Simultaneous vaccination PCV13 and PPV23|PCV13 0.5ml intramuscular injection once on day 0 followed by PPV23 0.5ml intramuscular injection on day 0
2988780|NCT02637583|Active Comparator|Single vaccinationPPV23|PPV23 0.5ml intramuscular injection on day 0
2988781|NCT02637570|Experimental|Hibiscus tea|420 mg Hibiscus 2 hour after dinner with 1 glass of cool water every day
2988782|NCT02637570|Experimental|green tea|450 mg green tea 2 hour after dinner with 1 glass of cool water every day
2988783|NCT02637570|Placebo Comparator|control group|450 mg placebo (dextrose) 2 hour after dinner with 1 glass of cool water every day
2988784|NCT02637557|Placebo Comparator|Control|Matching placebo twice daily
2988785|NCT02637557|Experimental|500 mg IW-3718|500 mg IW-3718 twice daily
2988786|NCT02637557|Experimental|1000 mg IW-3718|1000 mg IW-3718 twice daily
2988787|NCT02637557|Experimental|1500 mg IW-3718|1500 mg IW-3718 twice daily
2988788|NCT02637544|Active Comparator|Verum|"Acupuncture therapy.~For this study arm following acupuncture points suitable for facial pain, according to traditional chinese medicine, were chosen:~F2, F3, F34, IT3, IT19, S7, T21 and temporomandibular joint ear acupuncture points. Only intervention is the acupuncture therapy."
2988789|NCT02637544|Placebo Comparator|Placebo|Placebo acupuncture therapy. For this study arm points outside of the meridians according to traditional chinese medicine, were chosen. Only intervention is the acupuncture therapy.
2988790|NCT02637531|Experimental|Part A/B: IPI-549 Dose Escalation|Participants receive IPI-549 orally (PO) once a day (QD) for Part A and twice a day (BID) in Part B until disease progression.
2988791|NCT02637531|Experimental|Part C: IPI-549 and nivolumab|Participants receive IPI-549 (dose determined from Part A/B) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2988792|NCT02637531|Experimental|Part D: IPI-549 Monotherapy|Participants receive IPI-549 (dose determined from Part A/B) orally until disease progression.
2988793|NCT02637531|Experimental|Part D Annex: IPI-549 and nivolumab|Participants receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2988794|NCT02637531|Experimental|Part E: NSCLC: IPI-549 and nivolumab|Participants with NSCLC receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2988795|NCT02637531|Experimental|Part E: Melanoma: IPI-549 and nivolumab|Participants with melanoma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2988796|NCT02637531|Experimental|Part E: SCCHN: IPI-549 and nivolumab|Participants with squamous cell cancer of the head and neck receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2988797|NCT02637531|Experimental|Part F: TNBC: IPI-549 and nivolumab|Participants with triple negative breast cancer receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2988798|NCT02637531|Experimental|Part G: ACC: IPI-549 and nivolumab|Participants with adrenocortical carcinoma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2988799|NCT02637531|Experimental|Part G: Mesothelioma: IPI-549 and nivolumab|Participants with mesothelioma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2988800|NCT02637518||Hospital Universitario de Getafe|"Assessment of frailty tools in elderly people~The Geriatric Department attends patients:~1800/year - acute unit. 800/year - Orthogeriatrics and Interconsultation Unit. 300/year - Day Hospital. 4000/year - Outpatient office. 1200/year - Domiciliary Care."
2988801|NCT02637518||Diabetes Frail Ltd.|Assessment of frailty tools in elderly people Has significant experience in managing research studies in older people.
2988802|NCT02637518||Università Cattólica del Sacro Cuore|"Assessment of frailty tools in elderly people~The Geriatric Unit is compounded by:~24 beds of Acute Care Ward 46 beds of Intensive Rehabilitation Unit 20 beds of Day Hospital Outpatient clinic"
2988803|NCT02637518||Gérontopole de Toulouse|"Assessment of frailty tools in elderly people~The Geriatric Unit is compounded by:~5 Acute Care Units - 100 beds. 3 Rehabilitation Unit - 75 beds. Long term care Unit - 140 beds. 2 Day Hospitals Outpatient Clinic"
2988804|NCT02637518||Jagiellonian University Medical College|Assessment of frailty tools in elderly people The Department of Internal Medicine and Gerontology is the largest centre in Poland limited to the Geriatric market.
2988838|NCT02637297|Experimental|Group I (immediate intervention group)|Participants undergo hypnotherapy session over 20-30 minutes using a standardized script for pain reduction that contains post-hypnotic suggestions for permanence of hypnotherapy benefits. The hypnotherapy session is recorded and the participant listens to the recording daily for 4 weeks.
2988874|NCT02637089||PD-MCI|Patients with Parkinson's disease with mild cognitive impairment
2988875|NCT02637089||MCI (non-PD-MCI)|Patients with mild cognitive impairment, no Parkinson's disease
2988805|NCT02637505|Active Comparator|Arthroscopic microfracture (MF)|"The AM group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. The cartilage is cut sharp forming a rim of 90 degrees. The calcified layer is removed using a curette before an arthroscopic awl is then used to perform multiple holes (microfractures) from the periphery towards the center. The microfractures are 3 - 4 mm apart and 2 - 4 mm deep into the subchondral bone. The correct and successful technique is confirmed by direct visualization: while reducing the fluid pump pressure, the release of marrow fat droplets and blood will be observed."
2988806|NCT02637505|Sham Comparator|Arthroscopic debridement (AD)|The AD group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. The lesion is stabilized, debriding all loose or marginally attached cartilage from the surrounding rim to form a stable edge of healthy cartilage around the defect using a ring curette, where cartilage slops down to the defect.
2988807|NCT02637492||ICCMI|Patient hospitalized for lower limb arterial disease and suspected to have critical ischaemia
2988808|NCT02637479|Experimental|Pituitary radiosurgery group|Subjects will receive a pituitary radiosurgery by GammaKnife® during a brief hospitalization associated with standards of care for pain according to recommendations (Standards, Options and Recommendations about drug analgesic treatments for nociceptive cancer pain in adults)
2988809|NCT02637479|Active Comparator|Control group|Subject will receive standards of care for pain according to recommendations (Standards, Options and Recommendations about drug analgesic treatments for nociceptive cancer pain in adults)
2988810|NCT02637466|Experimental|Vortioxetine|In cycle I of the study, participants will be randomized on to flexible-dose VTX (10-20 mg) versus. Vortioxetine starting dose will be 10 mg daily. Vortioxetine starting dose will be 10 mg daily with a dose escalation up to 20 mg daily at week #4. Study cycle II is an 8-week, open label treatment design for non-responders completing the Cycle I RCT. One treatment arm will continue VTX non-responders to 8 week VTX (10-20 mg/day) augmentation with cognitive behavioral therapy (10 sessions). The 2nd treatment arm will continue placebo non-responders who complete the RCT to VTX (10 to 20 mg/day). The third treatment arm will continue VTX responders/remitters who complete the RCT to open-label VTX for another 8-weeks to assess maintenance efficacy for up to 16 weeks.
2988811|NCT02637466|Placebo Comparator|Placebo|"In cycle I of the study, 80 eligible depressed women with breast cancer will be randomized into an 8-week, double-blind, placebo-controlled, flexible-dose vortioxetine (10-20 mg) treatment arm versus placebo arm.~Responders to placebo treatment will complete their study participation at the end of Cycle I, and will not proceed to Cycle II."
2988812|NCT02637453|Experimental|CPVI|Only circumferential pulmonary vein isolation(CPVI) was performed for these patients.
2988813|NCT02637453|Experimental|CPVI+ALA|Besides circumferential pulmonary vein isolation(CPVI), additional linear ablation(ALA) perpendicular to the pulmonary vein ostium was performed for these patients, ie. CPVI+ALA.
2988814|NCT02637440|No Intervention|Conservative|After the index primary PCI. The control group will receive best medical therapy and regular follow up and only PCI for recurrent angina with evidence of inducible ischaemia.
2988815|NCT02637440|Active Comparator|FFR guided|FFR group will undergo FFR at 4 weeks of the index primary PCI as OPD. If FFR is less than 0.8, then PCI will be performed
2988816|NCT02637440|Active Comparator|angiogram guided|The group will undergo PCI for all significant lesions more than 50
2988817|NCT02637427|Experimental|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg, range 10-20 cc/Kg, to a maximum of 5 units)
2988818|NCT02637427|No Intervention|No transfusion|No transfusions prior to the procedure
2988819|NCT02637414|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
2988820|NCT02637414|Experimental|Flourishing App Program|This group will receive the intervention Flourishing App Program and after that it will not receive any other intervention.
2988821|NCT02637401||Therapy group|Dialectical behaviour therapy: a psychological therpay involving 16 group sessions plus approximately 5 individual meetings over 4 months.
2988822|NCT02637388|Placebo Comparator|Placebo Comparator: Control Breakfast|Breakfast cereal and yoghurt only (placebo, negative control)
2988823|NCT02637388|Experimental|Experimental: beta-Glucan Breakfast|Breakfast cereal and yoghurt with the addition of 4g beta-glucan (14.7g Oatwell28 powder)
2988824|NCT02637375|Experimental|Therapy|Patients will receive ganetespib monotherapy for two weeks followed by twelve weeks of ganetespib/paclitaxel therapy followed by 4 bi-weekly doses of doxorubicin/cyclophosphamide therapy followed by surgery.
2988825|NCT02637362|Active Comparator|Ankle + Sham metatarsal|Ankle block + sham metatarsal block
2988826|NCT02637362|Active Comparator|Ankle + Metatarsal|Ankle block + metatarsal block
2988827|NCT02637362|Active Comparator|Metatarsal + sham ankle|Metatarsal block + sham ankle block
2988828|NCT02637349|Experimental|POST SCP|Patient receives Survivorship Care Plan (SCP) after active treatment ends. It will be discussed with the patient. SCP includes medical and psychosocial history, medical contact information, 5-year follow-up plan and educational materials.
2988829|NCT02637349|Active Comparator|POST TAU|Patient receives treatment as usual (TAU) after active treatment ends.
2988830|NCT02637336|Experimental|Acupuncture|acupuncture session were inserted, and maintained for 20 minutes in paragraph 6 of the channel the pericardium (Neiguan).
2988831|NCT02637336|Experimental|Aerobic Exercise|The aerobic exercise session was conducted through 20 minutes.
2988832|NCT02637336|Experimental|Aromatherapy|Eucalyptus essential oil was inhaled by volunteers for 20 minutes
2988833|NCT02637336|No Intervention|Control|In the control session the volunteers remained seated at rest for 20 minutes without performing therapy.
2988834|NCT02637323|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
2988835|NCT02637323|Active Comparator|TCA IR 40 mg|Commercially available triamcinolone acetonide, single 1 mL intra-articular (IA) injection Immediate-release formulation
2988836|NCT02637310|Experimental|N02RS1 1200mg|Combination of Broussonetia spp and Lonicera spp
2988837|NCT02637310|Placebo Comparator|Placebo|sugar pill
2988871|NCT02637115|Experimental|Killed Akk|This group corresponds to Akkermansia muciniphila that have been heat-killed. The initial quantity of bacteria before the heating procedure was of 10exp10 bacteria.
2988839|NCT02637297|Active Comparator|Group II (wait-list control group)|At week 5, participants undergo hypnotherapy session over 20-30 minutes using a standardized script for pain reduction that contains post-hypnotic suggestions for permanence of hypnotherapy benefits. The hypnotherapy session is recorded and the participant listens to the recording daily for 4 weeks.
2988840|NCT02637284|Experimental|Intervention 1a (cohort 1)|Single dose of 1 oral tablet of PCO-02 containing 1 mg of Bepecin (12 subjects)
2988841|NCT02637284|Experimental|Intervention 1a (cohort 2)|Single dose of 3 oral tablets of PCO-02 containing 1 mg of Bepecin (12 subjects)
2988842|NCT02637284|Experimental|Intervention 1a (cohort 3)|Single dose of 6 oral tablets of PCO-02 containing 1 mg of Bepecin (12 subjects)
2988843|NCT02637284|Placebo Comparator|Control group 1a (cohort 1)|Single dose of 1 oral tablet of PCO-03 as placebo (2 subjects)
2988844|NCT02637284|Placebo Comparator|Control group 1a (cohort 2)|Single dose of 3 oral tablets of PCO-03 as placebo (2 subjects)
2988845|NCT02637284|Placebo Comparator|Control group 1 a (cohort 3)|Single dose of 6 oral tablets of PCO-03 as placebo by mouth (2 subjects)
2988846|NCT02637284|Experimental|Intervention 1b|Multiple dose regime of 3 oral tablets of PCO-02 containing 1 mg Bepecin every 8 hours during 2 weeks (36 subjects)
2988847|NCT02637284|Placebo Comparator|Control group 1b|Multiple dose regime of 3 oral tablets of PCO-03 as placebo every 8 hours during 2 weeks (6 subjects)
2988848|NCT02637271|Experimental|Total Meal Replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
2988849|NCT02637271|Active Comparator|Typical Diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
2988850|NCT02637245||Patients with Diabetic Macular Edema|Patients with Diabetic Macular Edema. There will be no intervention in this cohort, only observation of standard of care.
2988851|NCT02637232||Mirvaso® / Onreltea TM|
2988852|NCT02637206|Experimental|Part 1 (Single Application)|All subjects will have two sets (left and right) of 4 semi-occlusive test patches applied to randomized test sites on their upper backs on Day 1. Test patches on left back will be for simple-patch test and those on right back will be for photo-patch test. Each set will consist of approximately 150 micro liter (0.15 mL) of the following study treatments: GSK2894512 0.5% cream, GSK2894512 1% cream, placebo (cream vehicle without the active ingredient) and an empty patch. The test patches will be applied for 24 hrs (photo-patch test) or 48 hrs (simple-patch test).
2988853|NCT02637206|Experimental|Part 2 (Repeat Application)|All subjects will have repeat applications of GSK2894512 0.5%, 1% cream and placebo twice a day for 7 days on both side (left and right, 3 in total) of their upper back (approximately 5 centimeter (cm) in diameter >10 cm away from another application area) under non-occlusive conditions and covered with gauze using adhesive. GSK2894512 0.5% and 1% cream and placebo will be randomized according to the randomization code in the same manner as Part 1.
2988854|NCT02637193|Experimental|Venlafaxine|Maximum dose of 450 mg/day (225 mg BID given at approximately 12 hours apart) Venlafaxine, dose titrated from a starting single dose (QD) of 75 mg venlafaxine in the morning of Days 1 and 2, followed by BID escalating doses administered on Days 3 through 10, followed by 450 mg/day (BID) on Days 11 through 13, and on Day 14 only the morning dose of 225 mg will be administered, then 3 days (Days 15, 16 and 17) of down titration
2988855|NCT02637193|Active Comparator|Moxifloxacin|400 mg single dose of moxifloxacin (Avelox®) administered on Day 14
2988856|NCT02637193|Placebo Comparator|Drug -- placebo|Placebo administered on Days 1 through 13 and on Days 15 to 17
2988857|NCT02637180||patients with low-energy fracture(s)|"The study will include patients from pre-defined groups of individuals (postmenopausal, perimenopausal, male, and steroid induced osteoporosis) who would be anyway eligible to receive treatment for their condition according to standard medical practice and Greek treatment guidelines.~Drug: anti-osteoporotic medication (bisphosphonates, denosumab, strontium ranelate, teriparatide, SERMs)"
2988858|NCT02637167|Active Comparator|Rifaximin|Rifaximin: one tablet (550 mg) morning and evening for three months
2988859|NCT02637167|Active Comparator|Saccharomyces boulardii|S. boulardii: two capsules (500 mg) morning and evening for three months
2988860|NCT02637167|No Intervention|Control group|The third group receives no intervention
2988861|NCT02637154|Active Comparator|Motivational Interviewing|With 30 patients Motivational Interviewing method will be used during each visit
2988862|NCT02637154|Active Comparator|Standard Education|With 30 patients Standard Education material will be used during each visit
2988863|NCT02637141|Experimental|AMG 714 150 mg|AMG 714 150 mg SC every two weeks
2988864|NCT02637141|Experimental|AMG 714 300 mg|AMG 714 300 mg SC every two weeks
2988865|NCT02637141|Placebo Comparator|Placebo|Placebo SC every two weeks
2988866|NCT02637128|Experimental|artemether-lumefantrine (AL)|"20mg artemether/120 mg lumefantrine per tablet, Coartem-D™; Novartis, Basel, Switzerland administered following manufacturer's prescribed weight-based dosing, twice daily for 3 days.~5-14 kg: 1 tablet; 15-24: 2 tablets; 25-34 kg: 3 tablets; >34 kg: 4 tablets per dose"
2988867|NCT02637128|Experimental|artesunate-amodiaquine (ASAQ)|25mg artesunate/67.5 mg amodiaquine or 50 mg artesunate/135mg amodiaquine per tablet, Coarsucam™; Sanofi-Aventis, Paris, France administered following manufacturer's prescribed weight-based dosing, once daily for 3 days 4.5-8.9 kg: 1 25mg/67.5 mg tablet; 9-17.9 kg: 1 50mg/135 mg tablet; 18-35.9 kg 2 50mg/135 tablets; >36 kg: 4 50mg/135mg tablets per dose
2988868|NCT02637115|Placebo Comparator|Placebo|Placebo corresponds to a solution of Phosphate buffer saline (PBS) and glycerol, that is the carrier used in the 3 other groups receiving the bacteria (active arms)
2988869|NCT02637115|Experimental|Live Akk 9|Live Akkermansia muciniphila (Akk) at the dose of 10exp9 live bacteria (one billion of live bacteria) per day
2988870|NCT02637115|Experimental|Live Akk 10|Live Akkermansia muciniphila (Akk) at the dose of 10exp10 live bacteria (ten billion of live bacteria) per day
2988872|NCT02637102||Patients undergoing cardiac or vascular surgery|
2988876|NCT02637089||HC (non-PD-non-MCI)|Healthy Controls (age-matched to patients)
2988877|NCT02637076|Experimental|narcolepsy with cataplexy|patients given single dose of Xyrem
2988878|NCT02637076|Experimental|health controls|healthy controls given a single dose of Xyrem
2988879|NCT02637063|Experimental|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
2988880|NCT02637063|Experimental|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
2988881|NCT02637063|Other|Usual care|No intervention beyond the participants' personal medical care.
2988882|NCT02637050||CTEPH Patients|Patients with confirmed diagnosis of CTEPH
2988883|NCT02637037|Experimental|Treatment A|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
2988884|NCT02637037|Active Comparator|Treatment B|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
2988885|NCT02637037|Experimental|Treatment C|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
2988886|NCT02637037|Active Comparator|Treatment D|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
2988887|NCT02637037|Experimental|Treatment E|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
2988888|NCT02637037|Active Comparator|Treatment F|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
2988889|NCT02637037|Experimental|Treatment G|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
2988890|NCT02637037|Active Comparator|Treatment H|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
2988891|NCT02637024|Experimental|APBI: 30 Gy|Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 30 Gy in 5 daily fractions of 6 Gy
2988892|NCT02637024|Experimental|APBI: 27.5 Gy|Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 27.5 Gy in 5 daily fractions of 5.5 Gy
2988893|NCT02636998||Normal weight|BMI <85th percentile
2988894|NCT02636998||Obese|BMI > 95th percentile
2988895|NCT02636972||Group 1|Mild or absent dysmenorrhoea and no other pelvic pain symptoms without contraceptive pill use.
2988896|NCT02636972||Group 2A|History of mild or absent dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).
2988897|NCT02636972||Group 2B|History of severe dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).
2988898|NCT02636972||Group 3|Severe dysmenorrhoea but without chronic pelvic pain and without contraceptive pill use.
2988899|NCT02636972||Group 4|Severe dysmenorrhoea but without chronic pelvic pain and with contraceptive pill use (Participants already using contraceptive pills).
2988900|NCT02636972||Group 5|Chronic pelvic pain and severe dysmenorrhoea without contraceptive pill use
2988901|NCT02636972||Group 6|Chronic pelvic pain and severe dysmenorrhoea with contraceptive pill use (Participants already using contraceptive pills).
2988902|NCT02636959|Active Comparator|high volume saline irrigation (HVSI)|High volume nasal spray, NeilMed® Sinus Rinse, is a high saline nasal rinse that is a safe, nonpharmacologic treatment. Randomized participants will be asked to use the rinse for one month (twice daily) by following the manufacturer's guidelines and use of the squeeze bottle provided. Preoperative and one month Postoperative sinus surgery, the participants will complete subjective questionnaires and at one-month after surgery, endoscopic sinonasal photos will be taken. These data will be used to assess the quality of postoperative improvements after treatment.
2988903|NCT02636959|Active Comparator|low volume saline irrigation (LVSI)|Low volume nasal spray, Salinex Rinse, is a low saline nasal rinse that is a safe, nonpharmacologic treatment. Randomized participants will be asked to use the rinse for one month (twice daily) by following the manufacturer's guidelines and use of the squeeze bottle provided. Preoperative and one month Postoperative sinus surgery, the participants will complete subjective questionnaires and at one-month after surgery, endoscopic sinonasal photos will be taken. These data will be used to assess the quality of postoperative improvements after treatment.
2988904|NCT02636946|Experimental|Bimatoprost SR|"Assigned primary eye: Sham selective laser trabeculoplasty (SLT) administered on Day 1 followed by Bimatoprost sustained release (SR) Dose A administered on Day 4, Weeks 16 and 32 in one eye.~Contralateral eye: SLT administered on Day 1 followed by Sham Bimatoprost SR administered on Day 4, Weeks 16 and 32 in one eye."
2988905|NCT02636946|Active Comparator|Selective Laser Trabeculoplasty (SLT)|"Assigned primary eye: SLT administered on Day 1 followed by Sham Bimatoprost SR administered on Day 4, Weeks 16 and 32 in one eye.~Contralateral eye: Sham selective laser trabeculoplasty (SLT) administered on Day 1 followed by Bimatoprost sustained release (SR) Dose A administered on Day 4, Weeks 16 and 32 in one eye."
2988906|NCT02636933||26 prematurely born children|Lung function assessment of 26 prematurely born children (of both sex and 3-5 years old) attending as outpatient clinic of Pediatric Allergology & Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR)
2988907|NCT02636933||26 full-term born children|Lung function assessment of a Control group of full-term born children (N=26), recruited by a collaborative Pediatricians network within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy.
2988908|NCT02636920|Other|TEP-CASES|"25 Case Patients will follow the Therapeutic Education to the Patient (TEP).~In addition the following procedures will be performed:~Pediatric Asthma Quality of Life Questionnaire (PAQLQ);~Children Asthma Control Test (C-ACT);~Pediatric Caregiver Asthma Quality of Life Questionnaire (PCAQLQ);~Functional respiratory tests: forced expiratory volume in one second (FEV1), forced expiratory flow between 25% and 75% (FEF 25-75), forced vital capacity (FVC) and Peak expiratory flow (PEF)"
2988982|NCT02636387|Placebo Comparator|Placebo|0.2 mg tablets, dose titrated to effect
2988909|NCT02636920|No Intervention|TEP-CONTROLS|"25 Control Patients will follow the usual care program:~The Pediatric Asthma Quality of Life Questionnaire (PAQLQ);~The Children Asthma Control Test (C-ACT);~the Pediatric Caregiver Asthma Quality of Life Questionnaire (PCAQLQ);~Functional respiratory tests: forced expiratory volume in one second (FEV1), forced expiratory flow between 25% and 75% (FEF 25-75), forced vital capacity (FVC) and Peak expiratory flow (PEF)"
2988910|NCT02636907|Experimental|BI 695501|
2988911|NCT02636894|Other|Restylane Silk|Restylane Silk
2988912|NCT02636881|Active Comparator|Autologous Chondrocyte Implantation|A diagnostic arthroscopy of the knee joint.The lesion is stabilized down to the subchondral bone, but not through it. Cartilage biopsy is taken from the medial femoral notch. The harvested cartilage is transported to the cell culture Laboratory and cultured for two weeks. The chondrocyte implantation: A mini-open arthrotomy is performed and the lesion is curetted down to subchondral bone, avoiding bleeding. The lesion is measured and a template of sterile aluminum foil is used to cut out a matching piece of collagen sheet which is used to contain the cells in the defect. The flap is sutured to the lesion and sealed with fibrin glue, leaving and opening at the upper part for injection of the cells. The last opening is then closed with a last stitch and fibrin glue.
2988913|NCT02636881|Sham Comparator|Arthroscopic Debridement|"The AD group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. Lose bodies are removed, any meniscal pathology is addressed. Inflamed synovium is debrided. The lesion is stabilized by debridement around the edges and down to the subchondral bone using a ring curette, but not through it. Microfracture or any other cartilage treatment will not be performed.~No intra-articular local anesthetics will be used due to the possible harmful effect on cartilage [41-43].~All the operating surgeons will receive proper training in the operative procedure before study start."
2988914|NCT02636868|Experimental|Aerosolized lucinactant (low dose)|Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.
2988915|NCT02636868|Experimental|Aerosolized lucinactant (high dose)|Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.
2988916|NCT02636868|Active Comparator|nasal CPAP|nCPAP alone
2988917|NCT02636842|Other|Location|Deltoid or Gluteal Muscle
2988918|NCT02636829|Experimental|Multiple Sclerosis patients|"Patients (Multiple Sclerosis, Rheumatoid Arthritis) will be recruited during specialized consultations or hospital admissions for monitoring their chronic disease at the University Hospital of Nimes and will be divided into two distinct groups.~Intervention: QALCIMUM questionnaire~Intervention: Determination of calcium intake by a dietician interview"
2988919|NCT02636829|Experimental|Rheumatoid Arthritis patients|"Patients (Multiple Sclerosis, Rheumatoid Arthritis) will be recruited during specialized consultations or hospital admissions for monitoring their chronic disease at the University Hospital of Nimes and will be divided into two distinct groups.~Intervention: QALCIMUM questionnaire~Intervention: Determination of calcium intake by a dietician interview"
2988920|NCT02636816|Experimental|Infusion|carbetocin is given slowly
2988921|NCT02636816|Active Comparator|Bolus|carbetocin is given quickly
2988922|NCT02636803|Experimental|oxfendazole 6 mg/kg|patients receive 6 mg/kg oxfendazole once
2988923|NCT02636803|Experimental|oxfendazole 30 mg/kg|patients receive 30 mg/kg oxfendazole once
2988924|NCT02636803|Experimental|oxfendazole 6 mg/kg 3 times|patients receive 6 mg/kg oxfendazole three times
2988925|NCT02636803|Active Comparator|albendazole 400 mg|patients receive 400 mg albendazole once
2988926|NCT02636790|Active Comparator|Surgery wait time (< 8 weeks)|Outcomes of patients with sinus surgery of less than 8 weeks.
2988927|NCT02636790|Active Comparator|Surgery wait time (> 1 year)|Outcomes of patients with sinus surgery of more than 1 year.
2988928|NCT02636764|Active Comparator|exercise group|An exercise protocol drawn up with the objective will be held to strengthen the musculature: flexor and extensor of the knee; extension, abduction, hip side rotator, using the weight and the elastic band.
2988929|NCT02636764|Placebo Comparator|exercise group + Ultrasound therapy|Apart from intervening in the exercise group, an ultrasound device is used .
2988930|NCT02636764|Experimental|exercise group + interferential current|Besides the intervention of the exercise group after the exercises will be applied to interferential current through the device. Will be positioned 4 electrodes (8x5 cm), two upper and two lower (forming a square) around the center of the knee.
2988931|NCT02636764|Experimental|exercise group + short-wave diathermy|Besides the intervention of the exercise group after the exercises will be applied diathermies short wave in continuous mode. For that will be used apparatus, 27.12 megahertz, by means of vulcanized rubber electrodes (12x17 cm) with gentle warming for 30 minutes.
2988932|NCT02636764|Experimental|exercise group + Low level laser therapy|Apart from intervening in the exercise group, will be applied to Low level laser therapy, through the laser unit, Class 3b, gallium-aluminum-arsenide, continuous mode, wavelength: 830 nanometer, power: 30 watts.
2988933|NCT02636751|Experimental|In-person prehabilitation group|The participants in this group will receive a 12-week rehabilitation program (2x/week) including, education, stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities, in addition to walking aid adjustment. General information about pain control, such as ice application and medication usage will also be provided
2988934|NCT02636751|Experimental|Tele-prehabilitation group|The participants in this group will receive a 12-week rehabilitation program (2x/week) including, education, stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities, in addition to walking aid adjustment using a telecommunication software (Reacts®, Facetime® or Skype®). General information about pain control, such as ice application and medication usage will also be provided.
2988935|NCT02636751|Active Comparator|Usual care group|The participants in this group will be provided with the hospital's usual documentation before total joint arthroplasties, consisting of information regarding the pre- and post-surgery course and medication.
2988936|NCT02636738|Experimental|experiment|Vela XL thulium laser, laser fiber and accessories
2988937|NCT02636725|Experimental|Axitinib + Pembrolizumab|Concurrent Axitinib and Pembrolizumab therapy, with Blood Draw and Tumor Specimen Collection for correlative studies.
2988983|NCT02636387|Experimental|Desmopressin|0.2mg tablets, dose titrated to effect after
3004239|NCT02534896|Experimental|Sunpharma1505 2|
2988938|NCT02636712||ImageReady™ System indication|"Subject must have the ImageReady™ System as their initial (de novo) pacing system implant~Subject has a Class I or II indication for implantation of a pacemaker according to the CSPE guidelines"
2988939|NCT02636699|Experimental|Viaskin Peanut 250mcg|
2988940|NCT02636699|Placebo Comparator|Placebo|
2988941|NCT02636673||Robotic-assisted sigmoid resection|Patient that have undergone robotic-assisted sigmoid resection for benign or malignant disease between 2010 and 2015
2988942|NCT02636673||Laparoscopic sigmoid resection|Patient that have undergone laparoscopic sigmoid resection for benign or malignant disease between 2010 and 2015
2988943|NCT02636647|Active Comparator|FMT|Fecal transplant via enema once
2988944|NCT02636647|No Intervention|No treatment|No transplant performed
2988945|NCT02636634|Other|diagnostic imaging strategy|PET-FET (positron emission tomography using 1-Fluoro-Ethyl-Tyrosine) and MSR (magnetic resonance spectroscopy) before biopsy
2988946|NCT02636621|Active Comparator|Brazilian Dental Appliance|The device increases the volume of the airway by mandibular traction.
2988947|NCT02636621|Placebo Comparator|Placebo|Oral device that does not change the volume of the airway
2988948|NCT02636608||Genotype 1 (GT1) participants treated with Ribavirin (W24)|GT1 participants receiving PTV/r+OBV+DSV+RBV for 24 weeks
2988949|NCT02636608||Genotype 1 (GT1) participants treated without Ribavirin (W12)|GT1 participants receiving PTV/r+OBV+DSV for 12 weeks
2988950|NCT02636608||Genotype 4 (GT4) participants treated with Ribavirin (W12)|GT4 participants receiving PTV/r+OBV+RBV for 12 weeks
2988951|NCT02636608||Genotype 4 (GT4) participants treated with Ribavirin (W24)|GT4 participants receiving PTV/r+OBV+RBV for 24 weeks
2988952|NCT02636608||Genotype 1 (GT1) participants treated with Ribavirin (W12)|GT1 participants receiving PTV/r+OBV+DSV+RBV for 12 weeks
2988953|NCT02636595|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
2988954|NCT02636582|Experimental|Arm I (nelipepimut-S plus GM-CSF vaccine)|Patients receive nelipepimut-S plus GM-CSF vaccine ID 2 vaccination 2 weeks apart prior to surgery.
2988955|NCT02636582|Experimental|Arm II (sargramostim)|Patients receive sargramostim ID 2 vaccinations 2 weeks apart prior to surgery.
2988956|NCT02636569|Active Comparator|topical DFMO+diclofenac twice daily|The topical medications, topical DFMO and diclofenac, will will be applied onto the skin of one arm, every day twice daily for 30 days. Enough medication will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The medications will come in a tube. The medications will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
2988957|NCT02636569|Placebo Comparator|placebo|The topical medication will will be applied onto the skin of one arm, twice daily for 30 days. Enough placebo will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The placebo will come in a tube. The placebo will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
2988958|NCT02636556|Experimental|chemoradiation|concurrent chemoradiation.
2988959|NCT02636543||Group 2a-patient|75 patients who attended a genetic counselling consultation.
2988960|NCT02636543||Group 2a-public|75 persons belonging to general population.
2988961|NCT02636543||Group 2b-patient|75 patients who attended a genetic counselling consultation (those patients are different than patients from group 2a-).
2988962|NCT02636543||Group 2b-public|75 persons belonging to general population (those persons are different than patients from group 2a).
2988963|NCT02636543||Group 2b-professional|75 genetic professionals.
2988964|NCT02636530|Experimental|Ground Reaction Forces|Participants will have an individualized exercise program that includes walking, jogging, stair climbing, and box jumping.
2988965|NCT02636530|Experimental|Joint Reaction Forces|Participants will have an individualized exercise program that includes weight lifting and aerobic rowing.
2988966|NCT02636517|Other|C. Difficile without IBD|Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile
2988967|NCT02636517|Other|C. Difficile with IBD|Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile with Inflammatory Bowel Disease
2988968|NCT02636491|Experimental|investigational device|"MD-Logic-Automated Insulin Delivery System, Version 01.05.02~The device is being used continuously over 60 hours for insulin therapy"
2988969|NCT02636491|Placebo Comparator|MiniMed Paradigm® Veo™ System|"sensor augmented insulin pump~The device is being used continuously over 60 hours for insulin therapy"
2988970|NCT02636478||reference group|therapy naive patients with a sleep related breathing disorder
2988971|NCT02636478||therapy group|patients with devices treating their sleep related breathing disorder
2988972|NCT02636465||obese healthy adults|persons with BMI> 30 kg/m2
2988973|NCT02636465||obese COPD patients|COPD-patients (GOLD I-IV Group A-D) with BMI> 30 kg/m2
2988974|NCT02636465||OHS-patients|patients with defined OHS: BMI>30 kg/m2 and sleep related breathing disease, no COPD
2988975|NCT02636439|Active Comparator|dietary, and aerobic exercise|"Intervention for diet-A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb.) weight loss per week.~Intervention for aerobic exercise-Based on initial evaluations and the stress testing results, (HR, VO2, RPE) an individual exercise prescription will be developed for aerobic training."
2988976|NCT02636439|Active Comparator|dietary, aerobic and resistance training|"Intervention for diet-A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb.) weight loss per week.~Intervention for aerobic exercise-Based on initial evaluations and the stress testing results, (HR, VO2, RPE) an individual exercise prescription will be developed for aerobic training.~Intervention for resistance training- Additional weight resistant exercise will be added to this arm."
2988977|NCT02636426|Experimental|sorafenib|In this phase I study patients are treated with high-dose, pulsatile sorafenib in escalating AUC0-12h cohorts.
2988978|NCT02636413|Experimental|LacTEST|0,45 g of gaxilose po, once, per diagnostic test performed.
2988979|NCT02636413|Active Comparator|Hydrogen Breath Test|25 to 50 g of lactose po, once, per diagnostic test performed.
2988980|NCT02636400|No Intervention|expectant|7 menstrual cycles of expectant management
2988981|NCT02636400|Experimental|postop IUI|4 IUI cycles within 7 menstrual cycles
2988984|NCT02636374|Experimental|Guided Imagery|Participants listened to a pregnancy-specific guided imagery recording on four separate occasions during their pregnancies. Perceived stress was measured immediately pre and post each listening session using the Perceived Stress Measure-9 (PSM-9).
2988985|NCT02636361|Experimental|LY900014 (A)|Formulation A: Single dose of LY900014 formulation administered subcutaneously (SC) in one of five periods
2988986|NCT02636361|Experimental|LY900014 (B)|Formulation B: Single dose of LY900014 formulation administered SC in one of five periods
2988987|NCT02636361|Experimental|LY900014 (C)|Formulation C: Single dose of LY900014 formulation administered SC in one of five periods
2988988|NCT02636361|Experimental|LY900014 (D)|Formulation D: Single dose of LY900014 formulation administered SC in one of five periods
2988989|NCT02636361|Active Comparator|Insulin Lispro|Reference formulation: Single dose of lispro administered SC in one of five periods
2988990|NCT02636348|Experimental|Calcium/Vitamin D Bar|Dietary supplement consumed as 2 calcium and vitamin D fortified snack bars per day
2988991|NCT02636348|Experimental|Calcium/Vitamin D Pill|Dietary supplement consumed as several capsules per day
2988992|NCT02636348|Placebo Comparator|Placebo Bar|Placebo consumed as 2 isocaloric, unfortified snack bars per day
2988993|NCT02636348|Placebo Comparator|Placebo Pill|Placebo consumed as several capsules per day
2988994|NCT02636335|Experimental|Bright Light|"8 a.m. study participants will be exposed to Bright Light (4500 lx) Phillips Energy Light HF3319 for 30 minutes prior and during a 30 minute lasting exercise test with self-chosen exercise intensity on a bicycle ergometer.~The light exposure and time-trial will be performed in three repetitive exercise sessions 48h apart."
2988995|NCT02636335|Experimental|Control|"8 a.m. study participants will be exposed to a Control Light Condition (230 lx) Phillips Energy Light HF3319 for 30 minutes prior and during a 30 minute lasting exercise test with self-chosen exercise intensity on a bicycle ergometer.~The light exposure and time-trial will be performed in three repetitive exercise sessions 48h apart."
2988996|NCT02636322|Experimental|Rituximab, Lenalidomide, and Ibrutinib + EPOCH or R-CHOP|"The selection of R-DA-EPOCH or R-CHOP made by the treating physician.~Smart Start: Rituximab by vein on Day 1. Ibrutinib by mouth 1 time every day. Lenalidomide by mouth 1 time every day on Days 1-10 of each cycle.~At completion of Smart Start Participants on R-EPOCH: Rituximab IV on Day 1. Ibrutinib by mouth 1 time every day. Lenalidomide by mouth 1 time every day on Days 1 - 10 of each cycle. Etoposide IV on Days 1 - 4 of each cycle. Prednisone by mouth 2 times each day on Days 1 - 5 of each cycle. Vincristine IV Days 1 - 4 of each cycle. Cyclophosphamide IV Day 5 of each cycle. Doxorubicin IV on Days 1 - 4 of each cycle.~At completion of Smart Start Participants on R-CHOP: Rituximab IV on Day 1. Cyclophosphamide IV on Day 1 of each cycle. Doxorubicin IV on Day 1 of each cycle. Vincristine IV on Day 1 of each cycle. Prednisone by mouth on Days 1 - 5 of each cycle."
2988997|NCT02636309|No Intervention|control group|control group only filled up the questionnaires. They didn't receive intervention
2988998|NCT02636309|Experimental|intervention group|physical therapy at work
2988999|NCT02636296|Experimental|Pilates|Group received 12 week of inspired-Pilates intervention (2 days/week, 60 minutes duration).
2989000|NCT02636296|Other|Control|Control group was oriented to maintain the habitual activities during 12 weeks
2989001|NCT02636283|Active Comparator|Entresto|oral route
2989002|NCT02636283|Placebo Comparator|Placebo group|Oral placebo
2989003|NCT02636270|Experimental|PAPP-A2 deficient patients|Patients deficient in PAPP-A2 with short stature will be treated with Increlex (rhIGF-1)
2989004|NCT02636257|Experimental|Recessive Spherical Headed Silicone Intubation|The silicone nasolacrimal intubation under nasal endoscopy can restore natural drainage pathway in tears and as an out-patient surgery, it is more simple,cheap and mini-invasive.Recessive Spherical Headed Silicone Intubation is safe,convenient and almost unpainful for no trauma.It has no facial scar and no damage for structure and function of lacrimal duct.Besides,silica gel is non-toxic and nonirritating.Nasal endoscopy handed by otorhinolaryngologist helps intraoperative visualization about anatomy of the nasal cavity,understanding and management of congenital nasolacrimal duct obstruction and is the only method that confirms the correct anatomic position of the catheterization and in real time,avoiding traditionally the blind raking-out wire by the ophthalmologist alone.Compare to the classic DCR,its short therapeutic effects are equal but more convenient and fewer time and money-cost.
2989005|NCT02636257|Other|Dacryocystorhinostomy|Nasolacrimal duct obstruction is common among patients with epiphora,which is seriously affect the quality of life. The treatment principle is to restore or rebuild the lacrimal duct drainage channel. The classic operation type is dacryocystorhinostomy(DCR), which is complex for face-section particularly.After surgery the lacrimal passage can't siphon the tear out physically any more so that it will effect the patients' life.Besides,the operating time,bleeding volume,hospitalization time and total cost for the surgery is higher.
2989006|NCT02636244|Experimental|SHAPE Gel|1% SHAPE Gel applied twice daily for 12 weeks.
2989007|NCT02636231|Active Comparator|IMRT and concurrent Endostar|"IMRT and concurrent Endostar (Endostatins) to treat locally recurrent NPC patients; Endostar is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.~IMRT is to give GTV 60Gy in 27 fractions."
2989008|NCT02636231|Experimental|IMRT alone|IMRT alone to treat locally recurrent NPC patients. IMRT is to give GTV 60Gy in 27 fractions.
2989009|NCT02636218|Active Comparator|0.9% NaCl control|Normal saline
2989010|NCT02636218|Experimental|Ketamine|Anesthetic
2989011|NCT02636205|Experimental|Armeo|Group receiving Armeo therapy
2989012|NCT02636192||Cohort 1|Cohort 1 included participants who were exposed to sodium-glucose co-transporter 2 (SGLT2) inhibitor (canagliflozin, dapagliflozin and empagliflozin).
2989013|NCT02636192||Cohort 2|Cohort 2 included participants who were exposed to other non-SGLT2 antihyperglycemic agents (AHA).
2989014|NCT02636179||448 children|Children aged 11-15 years from a historical cohort born after In Vitro Fertilization or Intracytoplasmic Sperm Injection at Hospital Saint Joseph of Marseille
2989015|NCT02636179||1344 children|Children aged 11-15 years born spontaneously schooling in the same geographic area as case
2989016|NCT02636166|Other|Pregnancy test|"Clearblue investigational Pregnancy test~Clearblue Marketed pregnancy test~Professional pregnancy test"
2989017|NCT02636153|Experimental|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
2989018|NCT02636153|Experimental|Restricted Phosphorus Diet|Diet containing 500mg of phosphorus per day
2989020|NCT02636127|Experimental|Systemic Sclerosis (SSc) patient|15 patients whose diagnosis of SSc is made according to the revised ACR/EULAR ( American College of Rheumatology ) criteria 2013 will be recruited and blood samples will be obtained
2989021|NCT02636127|Other|healthy patient|15 healthy patients will be recruited and blood samples will be obtained
2989022|NCT02636114|Active Comparator|scaling and root planing|this was an international study in which scaling and root planing was done in systemically healthy patients patients with chronic periodontitis
2989023|NCT02636114|No Intervention|control group|Scaling and planing was not done that no intervention is carried out in this group
2989024|NCT02636088|Experimental|Cetuximab|Cetuximab is administered once a week. The initial dose is 400 mg/m2 body surface area. First Cetuximab infusion should start day 15 in cycle 1.The subsequent weekly doses are 250 mg/m2.
2989025|NCT02636075||Upper 1/3 of thyroid tissue|
2989026|NCT02636075||Middle 1/3 of thyroid tissue|
2989027|NCT02636075||Lower 1/3 of thyroid tissue|
2989028|NCT02636075||Below thyroid tissue|
2989029|NCT02636062||Follow-up CAC > 0|All patients with CAC scores of zero > 5 years previous will be invited to enroll and undergo repeat CAC scanning. This group will include all patients that develop incident CAC.
2989030|NCT02636062||Follow-up CAC zero|All patients with CAC scores of zero > 5 years previous will be invited to enroll and undergo repeat CAC scanning. This group will include all patients who continue to have a CAC of zero.
2989031|NCT02636049|Experimental|Treatment Period: 6 mg Triferic IV over 3 hours|Each subject will receive a single 6 mg dose of Triferic administered as a continuous intravenous infusion over 3 hours. The Triferic IV dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 0.020 mg/mL. Administration of 300 mL IV at 100 mL/hr for 3 hours results in delivery of 6 mg of Triferic iron.
2989032|NCT02636049|Experimental|Treatment Period: 35 micrograms/kg IV push|Each subject will receive Triferic as 35 µg/kg body weight IV push over 30-60 seconds. The Triferic IV push dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 35 µg Triferic iron/kg body weight per subject in 4.5 mL.
2989033|NCT02636049|No Intervention|Baseline: diurnal variation of iron|Each subject will have blood drawn periodically to determine the diurnal variation of iron.
2989034|NCT02636036|Experimental|enadenotucirev and nivolumab|
2989035|NCT02636023|Experimental|SPhENo-Cardiograph / ECG|SPhENo-Cardiograph and ECG
2989036|NCT02636010|Experimental|MK-3475 Pembrolizumab|MK-3475 at a dose of 200 mg every three weeks for 1 year with a potential expansion of 1 additional year of treatment in case of clinical benefit and patient agreement
2989037|NCT02635997||patients on antiresorptive therapy|Ibandronate 150 mg per month + Vitamine D 400-800 IU and Calcium 500-1000 mg per day
2989038|NCT02635984|Placebo Comparator|Triplet Therapy Plus Placebo|All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
2989039|NCT02635984|Active Comparator|Triplet Therapy Plus Olanzapine|All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
2989040|NCT02635971|Experimental|TAI chemotherapy|Patients in this arm will receive transcatheter arterial infusion of chemotherapy with gemcitabine and oxaliplatin every 2 weeks, until progression of disease or adverse effects leading to treatment termination. Each 4-week period is one cycle of treatment.
2989041|NCT02635971|Active Comparator|Chemotherapy|Patients in this arm will receive intravenous chemotherapy with gemcitabine and oxaliplatin every 2 weeks, until progression of disease or adverse effects leading to treatment termination. Each 4-week period is one cycle of treatment.
2989042|NCT02635958||Group 1|BMI 18.5 to 24.9
2989043|NCT02635958||Group 2|BMI 25 to 29.9
2989044|NCT02635958||Group 3|BMI 30 to 34.9
2989045|NCT02635958||Group 4|BMI ≥ 35
2989046|NCT02635945|Experimental|PBF-680 10 mg|2 capsules: PBF-680, 5 mg capsules for oral administration (excipient: 76 mg microcrystalline cellulose).
2989047|NCT02635945|Placebo Comparator|Placebo|2 capsules: Placebo to PBF-680, as 95.12 mg microcrystalline cellulose capsules.
2989048|NCT02635932|Experimental|Functional Splint group|Patient will be using the functional splint during their activity daily life
2989049|NCT02635932|Active Comparator|Night Splint group|Patients will use the night splint during the sleep time
2989050|NCT02635919|Experimental|mSMART|Smokers in this group will have the mSMART application installed on their smartphones. The mSMART application will provide information about varenicline (Chantix) and reminders when it's time to take the medication.
2989051|NCT02635919|No Intervention|Control|Smokers in this group will not be given the mSMART application.
2989052|NCT02635906|Experimental|2 hours|after coronary arteriography or coronary angioplasty, will be removal the introducer and the patient will be in bed rest for two hours
2989053|NCT02635906|Active Comparator|4 hours|after coronary arteriography or coronary angioplasty, will be removal the introducer and the patient will be in bed rest for four hours
2989054|NCT02635893|Active Comparator|D-Cycloserine/Placebo + Stimulation|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation.
2989055|NCT02635893|Active Comparator|Training+Med/Placebo+Stimulation|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation followed by training.
2989056|NCT02635893|Active Comparator|Training+Med+Stimulation/Placebo Stim|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation or placebo stimulation followed by training.
2989057|NCT02635880|Experimental|Investigational Enlighten Device|Laser treatment for removal of benign pigmented lesions (BPLs) with Nd:YAG dual-wavelength, dual-pulse duration laser.
2989058|NCT02635867|Active Comparator|Indirect pulp capping therapy|Resin-modified calcium silicate - TheraCal LC Calcium hydroxide - Dycal Resin-based dentin bonding agent
2989059|NCT02635867|Active Comparator|Direct pulp capping therapy|Resin-modified calcium silicate - TheraCal LC Calcium hydroxide - Dycal
2989060|NCT02635854|Experimental|Test group|The test group (Septic choc group) includes 15 patients suffering from septic shock in intensive care unit.
2989061|NCT02635854|Other|Control group|The control group (Orthopedic surgery group) includes 15 patients recruited from the orthopedic surgical anesthesia consultation programmed for a prosthetic hip or knee pose.
2989062|NCT02635828|Experimental|Triple therapy PONV prophylaxis|At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis.
2989063|NCT02635815||Group I|twenty six patients with history of bleeding or had an attack of bleeding during one year follow-up. All underwent upper gastrointestinal endoscopy.
2989064|NCT02635815||Group II|thirty four patients without bleeding. All underwent upper gastrointestinal endoscopy.
2989065|NCT02635802|Experimental|Remifentanil|injection form concentration 20μg/ml loading dose 1.0-2.0μg/kg intravenous injection slowly,time ＞1min,then 5μg/kg·h pumping until the operation is finished.
2989066|NCT02635802|Experimental|Lidocaine|injection form concentration 10mg/ml loading dose 100-400mg local anesthesia
2989067|NCT02635802|Experimental|Remifentanil+Lidocaine|"injection form concentration 20μg/ml loading dose 1.0-2.0μg/kg intravenous injection slowly,time ＞1min,then 5μg/kg·h pumping until the operation is finished~+ injection form concentration 10mg/ml loading dose 100-400mg local anesthesia"
2989068|NCT02635789|Experimental|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
2989069|NCT02635789|Placebo Comparator|Placebo gel|Placebo gel is matched ingredient with NPC-12G gel
2989070|NCT02635776|Experimental|AR101 powder provided in capsules & sachets|Study product provided in pull-apart peanut protein capsules or sachets
2989071|NCT02635776|Placebo Comparator|Placebo powder provided in capsules & sachets|Placebo formulation in pull-apart capsules or sachets containing only inactive ingredients
2989072|NCT02635763|Other|PNBs1|Femoral nerve and the lateral cutaneous nerve block combined with general anesthesia
2989073|NCT02635763|Other|PNBs2|Lumbar plexus and sacral plexus nerve block combined with general anesthesia
2989074|NCT02635750|Experimental|BI 409306|
2989075|NCT02635750|Experimental|Donepezil low dose|
2989076|NCT02635750|Experimental|Donepezil high dose|
2989077|NCT02635737|Experimental|Sentimark device placement|Sentimark device placed in women having mastectomy surgery
2989078|NCT02635724|Experimental|Peramivir|Single dose 600 mg IV injection
2989079|NCT02635711|Experimental|Adapted Taekwondo training|An adapted TKD training regime which was developed by our research team [16] will be used in this study. This training programme is designed to train balance control, eye-hand coordination and facilitate skeletal development for children with DCD. The high-impact striking techniques (e.g., punching and blocking) incorporated in the programme may stimulate bone growth [15]. Subjects who are assigned to the TKD training group will attend a weekly 1-h session of TKD training that will be held at the University of Hong Kong for 12 weeks. All TKD training sessions will be conducted by a qualified World Taekwondo Federation black belt coach.
2989080|NCT02635711|Active Comparator|Control|Subjects who are assigned to the DCD-control group will receive no TKD training during the study period. Instead, they will participate in jogging exercise daily (one hour per day) for 12 weeks. Participants will be encouraged to jog to school or other places every day, as appropriate. Pedometers will be used to monitor their exercise level and enhance habitual physical activity. The pedometer count (steps per day) will be documented in a log book by the parents. Signed log books will be returned to our research personnel after the intervention period. In addition, children with DCD in this group will receive an adapted TKD training menu and 12 training/demonstration sessions immediately after the follow-up testing is completed.
2989081|NCT02635698|Experimental|Intervention group, Optifast|OPTIFAST, medically supervised weight-management program
2989082|NCT02635698|Active Comparator|Control group, Low-energy, low-fat|Food-based program, current standard of care for weight management
2989083|NCT02635685|Experimental|Intervention group|Intervention with Clinical Decision Support tool installed on units.
2989084|NCT02635685|No Intervention|Control group|Control group without intervention with Clinical Decision Support tool installed on units.
2989085|NCT02635672|Experimental|Dose escalation of BAY 1251152 / Arm 1|Investigating BAY 1251152 in a dose escalation cohort in patients with solid tumors and aggressive NHL
2989086|NCT02635659|Experimental|Encapsulated nutrients|The investigational product will be a shot of sterile water (80 ml) mixed with a total of 21.6 grams encapsulate consisting of 13 grams of sucrose (60% of the total) encapsulated whey protein (<5% of total). On top of the encapsulated sucrose, 6.44 grams of casein (30% of total) encapsulated in whey protein (<5% of total) will be mixed with the shot of water. The micro-beats of encapsulated sucrose and casein are 150 µm and the ratio active (sucrose and casein) : whey is 95:5%, this means that the shot of water contains 13 grams of encapsulated sucrose, 6.44 grams of encapsulated casein and 1.3 grams of whey protein required for the encapsulation.
2989087|NCT02635659|Placebo Comparator|Placebo|The placebo has the same nutrient composition (e.g. 13 grams of sucrose and 6.44 grams of casein) as the active and will be equicaloric, and will also be mixed with a shot of sterile water (80 ml). The main difference of the placebo is that this nutrient mixture will be immediately released in the stomach, instead of being delivered to the ileum (active). This immediate release of the nutrient mixture is possible by using a different micro-encapsulation technique.
2989088|NCT02635646|Experimental|Family and interdisciplinary approach|Family and interdisciplinary approach: Patients in this group will receive a Family and interdisciplinary approach that includes nutritional, physical activity and psychological counseling + metformin 850mg twice at day for 12 months
2989089|NCT02635646|Active Comparator|Individual approach|Iindividual approach: Patients in this group will receive individual approach that includes nutritional and physical activity counseling + metformin 850mg twice at day for 12 months
2989090|NCT02635633|Experimental|continuous thetaburst stimulation|Transcranial magnetic stimulation over the epileptogenic focus using a cTBS stimulation protocol.
2989128|NCT02635360|Experimental|Following chemoradiation|Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. After chemoradiation is complete, subjects will receive the study drug, pembrolizumab.
2989091|NCT02635620||e-cigarette group|Probands are smokers who intend to start vaping for the first time. The probands are recruited in e-cigarette shops. It is aimed to include 60 persons who start vaping. A baseline visit at the beginning will measure conventional lung function parameters, mannitol provocation, FeNO and exhaled CO. The measurement will be repeated after 3 months to evaluate changes in these parameters. In addition there will be questionnaires concerning smoking/vaping behaviour and health status at the beginning and after 1, 2 and 3 months.
2989092|NCT02635620||smoking cessation group|Probands are smokers who intend to quit smoking within a clinical conducted smoking cessation program. It is aimed to include 20 persons who stop smoking. Like in the e-cigarette group, a baseline visit at the beginning will measure conventional lung function parameters, mannitol provocation, FeNO and exhaled CO. The measurement will be repeated after 3 months to evaluate changes in these parameters. In addition there will be questionnaires concerning smoking behaviour and health status at the beginning and after 1, 2 and 3 months.
2989093|NCT02635607|Other|Fixed Protocol|Patients will start Follitropin beta stimulation on menstrual cycle day 3 and the daily dose will be fixed for the first 5 days of stimulation, a modification of the rFSH dose will be allowed from stimulation day 6 onward. Ganirelix will start fixedly on stimulation Day 5. rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed, and triptorelin trigger will be used as a replacement in case of OHSS high risk
2989094|NCT02635607|Other|Flexible protocol|Patients will start Follitropin beta stimulation on menstrual cycle day 3 and the daily dose will be fixed for the first 5 days of stimulation, a modification of the rFSH dose will be allowed from stimulation day 6 onward. Ganirelix will start flexibly by the promissory criterion in the flexible group. rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed, and triptorelin trigger will be used as a replacement in case of OHSS high risk
2989095|NCT02635594|Experimental|Carnipure® tartrate|1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate
2989096|NCT02635594|Placebo Comparator|Placebo|1000mg cellulose + 475mg L-tartaric acid
2989097|NCT02635581|Experimental|DELTA TT|
2989098|NCT02635555|Experimental|Adjusted Spinal Dose|"Patients in this group receive height and weight adjusted dose for spinal anesthesia.During surgery, phenylephrine/ephedrine is given to maintain blood pressure as necessary.~Episodes of hypotension will be treated with these vasopressors ."
2989099|NCT02635555|Active Comparator|Standard Spinal Dose|"Patients in this group receive a fixed standard dose for spinal anesthesia. During surgery, phenylephrine/ephedrine is given to maintain blood pressure as necessary.~Episodes of hypotension will be treated with these vasopressors ."
2989100|NCT02635542|Active Comparator|Group CIS|Continual neuromuscular blockade (standard therapy) during general anesthesia will be provided with cisatracurium (CIS), with 0.2mg/kg IV given as an initial dose and repeated dosing determined by neuromuscular blockade monitoring (peripheral nerve stimulator maintained at 1-2 twitches).
2989101|NCT02635542|Experimental|Group SUX|A single dose of neuromuscular blockade (experimental group) will be provided at the start of anesthesia with succinylcholine (SUX), with 1mg/kg IV given as an initial dose and no repeat dosing.
2989102|NCT02635529|Active Comparator|OFD + DFDBA|Intrabony defects treatment was carried out with OFD + DFDBA
2989103|NCT02635529|Active Comparator|OFD+DFDBA+AM|Intrabony defects treatment was carried out with OFD + DFDBA+ AM
2989104|NCT02635516|Experimental|Treatment|Only one arm was used and this arm received Near-Infrared Phototherapy.
2989105|NCT02635503|Experimental|transrectal specimen extraction|Laparoscopic colorectal resection with natural orifice specimen extraction will be performed for patients in this group.
2989106|NCT02635503|Active Comparator|Conventional laparoscopic surgery|Conventional laparoscopic surgery for colorectal cancer will be performed for patients in this group.
2989107|NCT02635490||prophylactic antibiotics|
2989108|NCT02635477|Experimental|Intervention Group|frail elderly patients discharged from a cardiovascular hospitalization; provided with an actigraphy device that displays an adaptive personalized daily step count goal and audible alerts to increase physical activity
2989109|NCT02635477|Experimental|Control Group|frail elderly patients discharged from a cardiovascular hospitalization; provided with a matching actigraphy device that has a blacked-out screen and does not display step count goals or provide audible alerts (functions in silent monitoring mode only)
2989110|NCT02635464|Experimental|hUC-MSCs+Injectable collagen scaffold+CABG|
2989111|NCT02635464|Active Comparator|hUC-MSCs+CABG|
2989112|NCT02635464|Active Comparator|CABG|
2989113|NCT02635451||study group|Study group included 20 pregnant women with PPROM and fulfilled the inclusion and exclusion criteria.
2989114|NCT02635451||control group|Control group also included 20 pregnant women without PPROM following every recorded case of PPROM and matched for gestational age.
2989115|NCT02635438|Experimental|Arm A|Test Product: Clotrimazole troche/ lozenges USP, 10 mg (Unique Pharmaceutical Laboratories, India) 10mg troche 5 times a day for 14 consecutive days
2989116|NCT02635438|Active Comparator|Arm B|Reference Product: Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) troche 5 times a day for 14 consecutive days
2989117|NCT02635425|Experimental|7 eggs collection|Aspiration of 7 eggs only
2989118|NCT02635425|Active Comparator|Full eggs collection|Aspiration of all eggs
2989119|NCT02635412|Placebo Comparator|Scheduled delivery at 34 weeks|Scheduled delivery at 34 weeks (range 33 weeks 5 days to 34 weeks 3 days)
2989120|NCT02635412|Active Comparator|Scheduled delivery at 36 weeks|Scheduled delivery at 36 weeks (range 35 weeks 5 days to 36 weeks 3 days)
2989121|NCT02635399|Placebo Comparator|conventional group|Conventional PPPD
2989122|NCT02635399|Experimental|DJ-pexy group|PPPD with additional DJ-pexy to anchor DJ to transverse colon
2989123|NCT02635386|Experimental|Exenatide once weekly (EQW )|EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks
2989124|NCT02635386|Experimental|Dapagliflozin (DAPA)|DAPA-10 mg oral pill once daily in am for 24 weeks
2989125|NCT02635386|Experimental|EQW plus DAPA|EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks
2989126|NCT02635386|Experimental|Dapagliflozin plus Glucophage (MET ER)|Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks
2989127|NCT02635386|Active Comparator|Phentermine /Topiramate (PHEN/ TRP) ER|Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks
2989129|NCT02635360|Experimental|Concurrent to chemoradiation|Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. While subjects are receiving chemotherapy and radiation, they will also receive the study drug, pembrolizumab.
2989130|NCT02635347|Experimental|Remote Ischemic Conditioning (RIC) group|Participants will receive RIC during transplant and the initial four post-transplant days. During transplant: first intervention after induction of anesthesia but before commencing surgery and the second at the conclusion of the procedure. After transplant: RIC applied daily during the first four consecutive postoperative days. Pneumatic tourniquet will be used to induce RIC
2989131|NCT02635334|Experimental|Montelukast 10 mg daily for 8 weeks|Study subjects will take montelukast 10 mg orally daily for 8 weeks
2989132|NCT02635334|Placebo Comparator|Placebo daily for 8 weeks|Study subjects will take placebo orally daily for 8 weeks
2989133|NCT02635321||Patients with LGMD 2T|Four patients over 18 years old with genetically verified LGMD 2T.
2989134|NCT02635308|Experimental|Experimental|"High-Intensity, Unilaterally-Biased Resistance training 3x/wk x 12wk MOVE"
2989135|NCT02635295|Experimental|Mobile cooperation|Nursing student - nurse teacher mobile cooperation during the clinical practicum.
2989136|NCT02635295|No Intervention|Standard cooperation|Nursing student - nurse teacher standard cooperation during the clinical practicum.
2989137|NCT02635282|Active Comparator|IN fentanyl and midazolam|group of patients who are randomized to receive intranasal fentanyl and midazolam
2989138|NCT02635282|Experimental|IN ketamine|group of patients who are randomized to receive intranasal ketamine
2989139|NCT02635269|Experimental|Sugar|The subjects exercise on the cycle-ergometer until exhaustion or for a maximum of 1 hour at an intensity that corresponds to 60-65% of VO2max.
2989140|NCT02635256|Experimental|Hypofractionated Radiosurgery|5 fractions with 7 Gy, total dose 35 Gy
2989141|NCT02635243|Experimental|SAR438544 dose 1|Single dose of SAR438544 given SC under fasting conditions and under induced hypoglycemia. Novolin^®R will be used to induce hypoglycemia.
2989142|NCT02635243|Active Comparator|Glucagon|Single dose of glucagon given SC under fasting conditions and under induced hypoglycemia. Novolin^®R will be used to induce hypoglycemia.
2989143|NCT02635243|Experimental|SAR438544 Optional Dose|Optional lower, intermediate, or higher dose of SAR438544 given SC under fasting conditions and under induced hypoglycemia. Novolin^®R will be used to induce hypoglycemia.
2989144|NCT02635230||Patients with chronic oral anticoagulation and P2Y12 inhibitor|Patients with chronic indication for chronic oral anticoagulation (OAC) because of a heart valve prosthesis and/or atrial fibrillation undergoing coronary revascularisation (by PCI or CABG) and requiring concomitant treatment with P2Y12 inhibitors.
2989145|NCT02635217|Experimental|Group A1|EGD performed before the Colonoscopy with Carbon Dioxide insufflation.
2989146|NCT02635217|Experimental|Group A2|EGD performed before the Colonoscopy with room air insufflation.
2989147|NCT02635217|Experimental|Group B1|Colonoscopy performed before the EGD with Carbon Dioxide insufflation.
2989148|NCT02635217|Experimental|Group B2|Colonoscopy performed before the EGD with room air insufflation.
2989149|NCT02635204|Experimental|DFD-06 Cream|DFD-06 Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
2989150|NCT02635204|Placebo Comparator|Vehicle Cream|Vehicle Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
2989151|NCT02635191|Experimental|Tailored Group|In tailored therapy, medications will be adjusted according to the antimicrobial susceptibility testing (including Clarithromycin sensitivity) and cytochrome P450 isoenzyme 2C19 genotype. 10 days regimen will be prescribed.
2989152|NCT02635191|Active Comparator|Standard group|In standard triple therapy, children will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) for 10 days.
2989153|NCT02635178|Experimental|Active|Cognitive Anxiety Sensitivity Treatment (CAST) is a computerized treatment designed to model the educational and behavioral techniques used in anxiety treatments. The psychoeducational component focuses on the nature of stress and its effects. CAST was designed to dispel myths concerning the immediate dangers of stress on cognitive processes. Individuals are taught that psychological arousal from stress is not dangerous and they may have developed a conditioned fear to these sensations, as indicated by their elevated levels of AS cognitive concerns. In addition to the psychoeducation, interoceptive exposure exercises will be introduced to correct the conditioned fear response. The program will demonstrate exercises that elicit sensations consistent with AS cognitive concerns.
2989154|NCT02635178|Placebo Comparator|Control|The Physical Health Education Training (PHET) control condition was designed to control for the effects of general education provided in the CAST condition. Participants will be presented with information regarding the importance and benefits of maintaining a healthy lifestyle. The program will discuss diet, alcohol and water consumption, exercise, sexual health, and sleep. PHET will instruct the participant how to monitor their daily health habits in order to achieve a healthy lifestyle. PHET will take approximately 45 minutes to complete. Based on the findings of Schmidt and colleagues (in press), this intervention does not appear to exert a strong effect on AS.
2989155|NCT02635165|Active Comparator|Surgical treatment with Stracos|The patient was placed in the lateral decubitus position. The procedure involved a curvilinear thoracic incision overlying the center of the fractured segments. The intercostal muscles were dissected off the rib on its superior aspect away from the fracture site, and the fracture was then reduced. The investigators then chose the most suitable Stracos, which is to be found in two available sizes, 6 or 9 claws, according to the length of the fracture. The clip chosen was molded according to the shape of the corresponding rib and the claws were crimped using special pliers on and around the fractured rib.The investigators treated only one rib out of two with Stracos, and as for displaced or comminuted fractures, the adjacent rib was wrapped using vicryl suture on the osteosynthesis rib.
2989156|NCT02635165|No Intervention|Medical treatment|
2989187|NCT02634905|Experimental|Individual session therapeutic education|The children included in the active arm will undergo, along with their parents (by child's age and wish), a structured individual TPE session between W0 and W2. This session will be conducted by the nurse trained in TPE. The session will be one hour long.
2989188|NCT02634905|No Intervention|Control|
2989189|NCT02634892|No Intervention|Standard of Care (SOC)|Patients receive usual or standard of care regarding management of early stage pressure ulcers
2989157|NCT02635152|Experimental|Interpretation Bias Modification (IBM)|"Treatment consists of eight brief sessions. In Task 1, participants read unique scenarios (You notice someone pointing in your direction). A sentence meant to resolve the ambiguity will appear (This person thinks they reco_nize you). After filling in the missing letter, the interpretation is reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is this person mocking you?). In Task 2, participants are shown a word denoting a threatening (mocking) or benign (cheerful) interpretation. Participants are presented with an ambiguous scenario (You hear people at a nearby table laughing) and asked to denote whether the word and the sentence are related. Participants will receive positive or negative feedback based on their response."
2989158|NCT02635152|Active Comparator|Progressive Muscle Relaxation (PMR)|Participants will receive eight brief sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release 10 different muscle groups.
2989159|NCT02635139|Experimental|Breakfast Skipping|Effect of breakfast skipping on metabolism
2989160|NCT02635139|Experimental|Dinner Skipping|Effect of dinner skipping on metabolism
2989161|NCT02635113|Experimental|PD Shoe|40 subjects will wear the shoe in order to test abnormal gait patterns that increase likelihood of falls and the effectiveness of a gait synchronized vibration system to plantar surface to reduce fall risk.
2989162|NCT02635100|Experimental|MNT Algorithm|All participants will be monitored using an existing (FDA approved) CPAP machine that has been modified to be externally controlled by a computer with the MNT algorithm, for titration.
2989163|NCT02635087||high risk group|"the miRNA tool predict this group of patients as high risk"
2989164|NCT02635074|Experimental|Treatment (ibrutinib, idarubicin, cytarabine)|"INDUCTION: Ibrutinib daily on days 1 to 21, idarubicin intravenously (IV) over 15 minutes on days 1 to 3 and cytarabine IV continuously on days 1 to 4.~CONSOLIDATION: Patients achieving CR or CRi may receive ibrutinib daily on days 1 to 21, idarubicin IV over 15 minutes on days 1 to 2 and cytarabine IV continuously on days 1 to 3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients maintaining a CR/CRi may receive ibrutinib daily on days 1 to 28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
2989165|NCT02635061|Experimental|ACY-241 in combination with nivolumab|
2989166|NCT02635048|Other|Group 1|Patients in Group 1 undergo mini percutaneous nephrolithotomy
2989167|NCT02635048|Other|Group 2|Patients in Group 2 undergo percutaneous nephrolithotomy
2989168|NCT02635035|Experimental|Lisdexamfetamine First|In this crossover study design, participants assigned to this group will receive Lisdexamfetamine first, then placebo second
2989169|NCT02635035|Experimental|Lisdexamfetamine Second|In this crossover study design, participants assigned to this group will receive placebo first, then Lisdexamfetamine second
2989170|NCT02635022||FLS|Patients with new hip fracture or newly identified vertebral fractures
2989171|NCT02635022||MMS|Patients prescribed with anti-osteoporosis medications but not fit FLS requirements
2989172|NCT02635009|Active Comparator|Arm I (PCI using 3DCRT)|Patients undergo PCI using 3DCRT daily for 2 weeks.
2989173|NCT02635009|Experimental|Arm II (PCI with HA using IMRT)|Patients undergo PCI with HA using IMRT daily for 2 weeks.
2989174|NCT02634983|Experimental|QVA149|Single daily dose of 110/50 μg QVA149 for 8-10 days.
2989175|NCT02634983|Placebo Comparator|Placebo|Single daily dose of matching placebo for 8-10 days.
2989176|NCT02634970|Experimental|Ranibizumab at 0.5 mg|Single arm, intravitreal injection
2989177|NCT02634957|Experimental|3 day absolute voice rest|participants would begin initiation of voice/speaking 3 days post phonomicrosurgery for benign vocal fold lesions
2989178|NCT02634957|Experimental|7 day absolute voice rest|participants would begin initiation of voice/speaking 7 days post phonomicrosurgery for benign vocal fold lesions
2989179|NCT02634944|Experimental|mTBI|mTBI (concussed) participants will be administered the VOMS after concussive event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
2989180|NCT02634944|Sham Comparator|Healthy Control|Healthy controls will be administered the VOMS tool. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
2989181|NCT02634944|Experimental|BLAST mTBI|Blast mTBI (concussed) participants will be administered the VOMS after concussive blast event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
2989182|NCT02634944|Experimental|BLUNT mTBI|Blunt mTBI (concussed) participants will be administered the VOMS after concussive blunt event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
2989183|NCT02634931|Experimental|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
2989184|NCT02634918||Ultrasound|3 groups of hemophilia patients - Those with > 20 bleeds into a joint, those with < 2 bleeds into a joint and those with no bleeds into a joint will be enrolled into the study
2989185|NCT02634918||those with < 2 bleeds into a joint and|3 groups of hemophilia patients Group I - Those with > 20 bleeds into a joint, Group II - those with < 2 bleeds into a joint and Group III - those with no bleeds into a joint will be enrolled into the study
2989186|NCT02634918||those with no bleeds into a joint will be enrolled into the st|3 groups of hemophilia patients Group I - Those with > 20 bleeds into a joint, Group II - those with < 2 bleeds into a joint and Group III - those with no bleeds into a joint will be enrolled into the study
2989190|NCT02634892|Experimental|SOC plus PRO-TECT|Patients receive usual or standard of care plus the addition of PRO-TECT.
2989191|NCT02634879|No Intervention|Control|Control Group
3004240|NCT02534896|Active Comparator|Reference1505|
2989192|NCT02634879|Active Comparator|Loss Aversion|Each physician in this arm will have access to funds prior to earning them.
2989193|NCT02634879|Active Comparator|Group Incentive|Each physician will receive 50% of their potential incentive based on group performance. Physicians will also receive information on the performance of physicians on key CI measures in their group.
2989194|NCT02634866||Group N|The subjects with no symptoms of HF and normal left ventricular diastolic function (no less than 40 subjects)
2989195|NCT02634866||Group D|The subjects with no symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
2989196|NCT02634866||Group D_HF|The subjects with symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
2989197|NCT02634853|Active Comparator|Tavilermide Ophthalmic Solution|1% Tavilermide Ophthalmic Solution
2989198|NCT02634853|Placebo Comparator|Vehicle Ophthalmic Solution|Placebo Ophthalmic Solution
2989199|NCT02634840|Experimental|Surgical intervention|"Patients receiving our modified bilateral sagittal split osteotomy procedure during orthognathic surgery, intervention arm in prospective cohort study"
2989200|NCT02634827|Experimental|Treatment (decitabine, midostaurin)|Patients receive decitabine intravenously (IV) over 1 hour on days 1-5 and midostaurin orally (PO) twice daily (BID) on days 8-21 of courses 1 and 2, and on days 1-28 of each subsequent course. Patients failing to achieve complete response (CR)/complete response with incomplete recovery (CRi)/partial response (PR)/morphologic leukemia-free state by end of course 2 receive midostaurin PO BID on days 1-28. Patients achieving CR/CRi/PR/morphologic leukemia-free state by end of course 8 may continue on current regimen. Patients failing to achieve a CR/CRi/PR/ morphologic leukemia-free state in bone marrow blasts by end of course 8 go to event monitoring. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
2989201|NCT02634814|Experimental|TENS and Therapeutic Exercise|Patients assigned to the TENS+Therapeutic Exercise (TE) group will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN), and 8 hours of TENS per day (150 pulses per second, 150 msec phase duration at a patient-percieved strong sensory intensity). Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program.
2989202|NCT02634814|Sham Comparator|Sham TENS and Therapeutic Exercise|"Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day. Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program."
2989203|NCT02634814|Active Comparator|Therapeutic Exercise Only|The role of the comparison group is to provide data on how traditional TE affects the outcome measures. The TE only group will allow us to assess how the addition of TENS to traditional TE will augment the effects of traditional TE. Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program.
2989204|NCT02634801|Experimental|Ixekizumab|"160 milligrams (mg) ixekizumab given as two subcutaneous injections (SC) followed by 80 mg ixekizumab given SC every 2 weeks until week 12 and then 80 mg ixekizumab given SC every 4 weeks until week 24.~Extension Period: At week 24, participants have the option to continue ixekizumab treatment for up to 36 weeks."
2989205|NCT02634801|Active Comparator|Fumaric Acid Esters|"Starting dose of 105 mg FAE given orally followed by 215 mg FAE given orally 1 to 3 times per day until week 24.~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks."
2989206|NCT02634801|Active Comparator|Methotrexate|"7.5 mg starting dose up to 30 mg MTX given orally once a week until week 24.~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks."
2989207|NCT02634788|Experimental|Buprenorphine 0.5 mg TID|Participants received buprenorphine 0.5 mg sublingual (under the tongue) spray three times daily (TID) for two days.
2989208|NCT02634788|Experimental|Buprenorphine 0.25 mg TID|Participants received buprenorphine 0.25 mg sublingual spray TID for two days.
2989209|NCT02634788|Experimental|Buprenorphine 0.125 mg TID|Participants received buprenorphine 0.125 mg sublingual spray TID for two days.
2989210|NCT02634788|Placebo Comparator|Placebo|Participants received placebo-matching buprenorphine sublingual spray TID for two days.
2989211|NCT02634775|Experimental|CKD - no dialysis|Change in treatment strategy: Start on dialysis, transplantation
2989212|NCT02634775|Experimental|Patients on PD|Change in treatment strategy: Change of PD prescription, start on HD, transplantation
2989213|NCT02634775|Experimental|Patients on HD|Change in treatment strategy: Change of HD prescription, transplantation
2989214|NCT02634749|Experimental|Nordic diet|The participant in the Nordic diet group will experience three interventions: a) a systematic introduction of taste portions, b) Protein reduced complementary foods (milk cereal drinks, porridge and baby milk with reduced protein content), and c) homemade and industry manufactured main meals with a predominance of Nordic ingredients.
2989215|NCT02634749|No Intervention|Regular diet|The participants will be given the current advice on infant feeding issued by the Swedish National Food Agency. They will also be given regular, commercially available milk cereal drinks, porridge, baby milk and industry manufactured main meals. No advice or recipes on meals will be given apart from the current recommendations.
2989216|NCT02634736|Experimental|Exergame plus usual treatment|Exergame programme plus usual falls prevention treatment including assessment and exercises (prescribed by the physiotherapists).
2989217|NCT02634736|No Intervention|Usual treatment|No exergame programme, just usual falls prevention treatment including assessment and exercises (prescribed by the physiotherapists).
2989218|NCT02634723||Previously Untreated Patients (PUPs)|PUPs in China with Moderate to Severe Hemophilia A
2989277|NCT02634307|Experimental|ALKS 8700|Oral capsules
2989431|NCT02633306|Experimental|Transcranial Magnetic Stimulation|transcranial magnetic stimulation
2989219|NCT02634710|Experimental|Hypofractionated Radiation Therapy|Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given every other day. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
2989220|NCT02634697|Experimental|3RP Intervention Group|"AF Patients will undergo the 3RP intervention which will comprise of the following:~i. One-one-one session: each subject will spend an hour with a clinician to set specific goals for the intervention. They will also answer questionnaires.~ii. ECG monitoring: Enrolled subjects may be monitored with an ECG at some point after the time of consent up to the day of the one-on-one session, and again after completing the 8 weeks.~iii. Weeks 1 - 8: subjects will meet with the clinician/staff member as a group once a week for 1.5 hours each where they will be taught a variety of techniques to elicit the relaxation response as well as other cognitive skills.~At the end of the 4th (mid-point) and 8th (last) weekly session, subjects will answer questionnaires.~iv. 6 month follow up: 3 months after the final 3RP session to answer questionnaires.~v. Subjects will be asked to keep track of their AF episodes during the course of the study."
2989221|NCT02634697|Active Comparator|3RP Waitlist Control Group|The Control Group will wait for 6 months (from the time the Intervention group starts the 3RP intervention) and then will undergo the same study procedures as the intervention group - except for the 6 month follow up.
2989222|NCT02634684|Active Comparator|dextroamphetamine|"Drug: Dexedrine, dextroamphetamine, d-amphetamine.~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
2989223|NCT02634684|Placebo Comparator|Placebo|"Drug: Dexedrine, dextroamphetamine, d-amphetamine~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
2989224|NCT02634671|Other|22Q11|24 patients with 22Q11DS to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
2989225|NCT02634671|Other|SCHIZOPHRENIA|24 patients with schizophrenia to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
2989226|NCT02634658|Experimental|Medical ICU Subjects|All Medical ICU subjects that meet eligibility criteria and are enrolled in the study will receive muscle Ultrasounds, Nerve Conduction Studies and Electromyography (EMG).
2989227|NCT02634658|Experimental|Neuro ICU Subjects|All Neuro ICU subjects that meet eligibility criteria and are enrolled in the study will receive Nerve Conduction Studies and Electromyography (EMG).
2989228|NCT02634645||Patients with Barrett's Esophagus|Patients with non-dysplastic Barrett's esophagus, patients with Barrett's related dysplasia which includes low-grade dysplasia, high-grade dysplasia and intramucosal cancer who will be evaluated and treated with endoscopic eradication therapies (EET).
2989229|NCT02634645||Patients with invasive esophageal cancer|Patients with invasive esophageal cancer who will be treated with surgery (esophagectomy), chemotherapy, radiation, and palliative treatment modalities.
2989230|NCT02634632|Experimental|Subjects with cancer|choose to write advance directives
2989231|NCT02634619|Active Comparator|Ventral Buccal Mucosa Graft Onlay|Standard of care method for repairing urethral strictures
2989232|NCT02634619|Active Comparator|Dorsal Buccal Mucosa Graft Onlay|Standard of care method for repairing urethral strictures
2989233|NCT02634606|Active Comparator|Gamma Delta Tocotrienols - Low Dose|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (63mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
2989234|NCT02634606|Active Comparator|Gamma Delta Tocotrienols - High Dose|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (127mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
2989235|NCT02634606|Placebo Comparator|Sugar Pill|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the Placebo arm of the study to evaluate the cholesterol suppressive actions of Placebo. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
2989236|NCT02634593|No Intervention|Control|Control
2989237|NCT02634593|Active Comparator|Low glycemin load snacks|Low glycemic load snacks, consumed during specific times
2989238|NCT02634580|Active Comparator|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
2989239|NCT02634580|Active Comparator|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.
2989240|NCT02634580|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
2989432|NCT02633293|Experimental|Inhaled Treprostinil|Open-label access
2989241|NCT02634580|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.
2989242|NCT02634567|No Intervention|Treatment as Usual|This group will not any training with the Cogmed training program.
2989243|NCT02634567|Experimental|Training Group|This group will receive intervention with the Cogmed training program and coach over a period of 5 weeks.
2989244|NCT02634541|Active Comparator|DMARD-naive|Sulfasalazine will be given as the initial therapy.
2989245|NCT02634541|Experimental|Post-sulfasalazine|Sulfasalazine contraindicated or not efficient, adalimumab will be given as the initial therapy.
2989246|NCT02634528|Experimental|Julphar Insulin N|Julphar Insulin N, human isophane insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/kg body weight
2989247|NCT02634528|Active Comparator|Huminsulin® Basal|Huminsulin® Basal, neutral protamine hagedorn (NPH), human isophane insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/kg body weight
2989248|NCT02634515|Experimental|Julphar Insulin R|Julphar Insulin R, soluble human insulin, biosimilar, 100 IU/mL, single subcutaneous injection of 0.3 IU/kg body weight
2989249|NCT02634515|Active Comparator|Huminsulin® Normal|Huminsulin® Normal, soluble human insulin, reference, 100 IU/mL, single subcutaneous injection of 0.3 IU/kg body weight
2989250|NCT02634502|Experimental|Treatment|Patients will receive radiofrequency ablation for liver metastatic lesions, as well as two weeks of oral S-1 treatment every three weeks, until progression of disease or adverse effects leading to termination of treatment. Each 3-week period is one cycle of treatment.
2989251|NCT02634489|Active Comparator|Tamsulosin HCl and Solifenacin Succinate|Participants will receive daily doses of tamsulosin HCL and Solifenacin Succinate (3 dose strengths) as single tablets.
2989252|NCT02634489|Active Comparator|EC905 (tamsulosin HCI and solifenacin succinate)|Participants will receive a fixed combination tablet (3 dose strengths).
2989253|NCT02634476|Experimental|cognitive bias modification training|Participants complete four sessions of the alcohol approach/avoidance task.
2989254|NCT02634476|Sham Comparator|sham training|Participants complete four sessions of the sham approach/avoidance task.
2989255|NCT02634463|Other|Antipsychotic Immunoassay Development Participants|No study agent will be administered as a part of this study. Participants must be on Aripiprazole or Olanzapine, or Paliperidone or Risperidone, orally, daily or long-acting injectable versions, as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for use in the development of antipsychotic immunoassays. Participants may also be on long acting injectable versions of the medication.
2989256|NCT02634450|No Intervention|Control|Current practice of Early Infant Diagnosis in Mozambique: using conventional system of collecting blood on Dried Blood Spot and sending it to central laboratory for PCR processing and receiving result by SMS printer.
2989257|NCT02634450|Active Comparator|Intervention|Point Of Care Device (Alere q) is used for Early Infant Diagnosis, with the sample collected and processed in the consultation room with the device
2989258|NCT02634437|Experimental|Normal Renal Function|Ulipristal acetate, 10 mg, oral administration
2989259|NCT02634437|Experimental|Moderate Renal Impairment|Ulipristal acetate, 10 mg, oral administration
2989260|NCT02634437|Experimental|Severe Renal Impairment|Ulipristal acetate, 10 mg, oral administration
2989261|NCT02634424|Experimental|MyPKFiT|Personalized prophylaxis : Treatment is adjustment according to PK modeling
2989262|NCT02634411|Experimental|8 days of effective antibiotic treatment|Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against PA of 8 days.
2989263|NCT02634411|Sham Comparator|15 days of effective antibiotic treatment|Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against PA of 15 days.
2989264|NCT02634398||Treated subjects|All subjects recruited and treated wiht the Axium neurostimulator
2989265|NCT02634385|No Intervention|Small Renal Mass|Patient's with a small renal mass will be undergoing embolization prior to laparoscopic partial nephrectomy.
2989266|NCT02634372|Experimental|EMDR Therapy|EMDR: 20 individual sessions 60 minutes each for 6 months
2989267|NCT02634372|Active Comparator|Supportive therapy|Supportive therapy: 20 individual sessions 60 minutes each for 6 months.
2989268|NCT02634359|Other|IVF Treatments- Frozen Embryo transfer|Consenting women that arrive to IVF clinic for frozen embryo transfer on spontaneous cycle Study Intervention: Ultrasound and Blood test to detect Ovulation. At home, HR, RR and movements will be contactlessly measured using EarlySense home device
2989269|NCT02634359|Other|IVF Treatments- Clinical Evaluation|"Consenting women that arrive for cycle evaluation or insemination on spontaneous cycle (infertile women).~Study Intervention: Ultrasound and Blood test to detect Ovulation At home, HR, RR and movements will be contactlessly measured using EarlySense home device"
2989270|NCT02634359|Other|No IVF|Healthy women volunteers with regular menstrual cycles - not using contraceptives Study Intervention: Ultrasound and Blood test to detect Ovulation At home, HR, RR and movements will be contactlessly measured using EarlySense home device
2989271|NCT02634346|Experimental|ALKS 3831|Administered as a coated bilayer tablet
2989272|NCT02634346|Active Comparator|Olanzapine|Administered as a coated bilayer tablet
2989273|NCT02634346|Placebo Comparator|Placebo|Administered as a coated bilayer tablet
2989274|NCT02634333|Sham Comparator|Observation (Prompt Sham)|Sham injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. Deferred aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
2989275|NCT02634333|Experimental|Prompt aflibercept|Aflibercept injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. More frequent aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
2989276|NCT02634320|Other|Aripiprazole Lauroxil|Intramuscular (IM) injection
2989278|NCT02634294|Experimental|Peg interferon alfa-2b|Pegylated Interferon α-2b (PEG INTRON®) , 1~1.5μg/kg qw, subcutaneous injection, 1 to 12 months, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
2989279|NCT02634281|Experimental|group A|Subjects in Group A will receive varenicline for six weeks .During this phase, subjects will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
2989280|NCT02634281|Active Comparator|group B|group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
2989281|NCT02634268|Active Comparator|Lifestyle intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
2989282|NCT02634268|No Intervention|Usual Care|Participants continue with usual diet and exercise activities as they desire
2989283|NCT02634255|Active Comparator|Rocuronium elective surgery|patients undergoing inguinal herniorrhaphy
2989284|NCT02634255|Experimental|Rocuronium emergency surgery|patients undergoing appendectomy
2989285|NCT02634242|Experimental|Si-Wu-Tang (SWT)|Subjects are recommended to drink 125 mL of SWT (n=30) for 6 continuous days per month during the following 6 months and vice versa with one month of washout period in between.
2989286|NCT02634242|Placebo Comparator|placebo|Subjects are recommended to drink 125 mL of Placebo (n=30) for 6 continuous days per month during the following 6 months and vice versa with one month of washout period in between.
2989287|NCT02634229||Diabetic family members|(i) probands negative for GCK/MODY2 , HNF1A/MODY3 genes and HNF4A/MODY1; (ii) dominant inheritance of diabetes (three consecutive affected generations, or two generations with at least 2 diabetic patients in a generation); (iii) Diagnosis of diabetes before age 40 years in at least 3 diabetic family members; (iv) negative testing for anti-GAD and IA2-antibodies; and (v) body mass index < 30 kg/m2 (to avoid inclusion of patients with insulin-resistant type 2 diabetes).
2989288|NCT02634229||Healthy relatives|Healthy subjects whose relationship is relevant for genetic analysis and necessary for the validation step (family cosegregation study)
2989289|NCT02634216|Experimental|Type 1 Diabetics using CGM|Type 1 diabetics using Continuous Glucose MonitoringCGM to take 500 mg daily of Capros supplement (250 mg twice a day) at lunch and dinner.
2989290|NCT02634203|Experimental|Balloon Pulmonary Angioplasty (BPA)|Non-operable patients with CTEPH allocated to BPA arm
2989291|NCT02634203|Active Comparator|Riociguat|Non-operable patients with CTEPH allocated to Riociguat arm
2989292|NCT02634190||Triple negative women|Women 30 years of age or older coming for routine cervical screening who tested triple negative at baseline with the interventions: Thinprep® LBC, HR HC2® HPV DNA and APTIMA® HPV Assay
2989293|NCT02634190||Women tested positive|Women who tested positive in any of the tests Thinprep® LBC, HR HC2® HPV DNA or APTIMA® HPV Assay will undergo colposcopy and be followed up over a ten year period and subjects who tested positive during the follow up assessment will be followed up over a ten year period and subjects who tested positive during the follow up assessment will be followed up over a 5 year period on a yearly basis
2989294|NCT02634177|Active Comparator|Assay-guided treatment (AGT)|Assay results will be provided to the treating investigator, who will use the results to guide pharmacotherapy of the subject's MDD treatment.
2989295|NCT02634177|Placebo Comparator|Treatment-as-usual (TAU)|The treating investigator will treat subjects of the TAU group without the knowledge of the pharmacogenetic testing results.
2989296|NCT02634164|No Intervention|control|"Control Treatment with Oral Glucose Tolerance Test:~Blood glucose and insulin will be obtained following the protocol of Eicher et al (4). Participants will ingest a Placebo (inert, calorie free, stevia sweetener) with blood collections at 0,2,4,6,8,10,30 prior to a standard 75 g glucose solution, followed by blood collections at 0,2,4,6,8,10,30,60,90,120 minutes post glucose ingestion. A total of 16 blood collections will be taken."
2989297|NCT02634164|Experimental|Leucine Supplement|Control Treatment with Oral Glucose Tolerance Test:
2989298|NCT02634164|Experimental|Isoleucine Supplement|Isoleucine Combined with Oral Glucose Tolerance Test:
2989299|NCT02634164|Experimental|Leucine and Isoleucine Supplement|Leucine and Isoleucine Combined with Oral Glucose Tolerance Test:
2989300|NCT02634151|Placebo Comparator|Placebo|Placebo treatment on stable background statin therapy
2989301|NCT02634151|Experimental|Gemcabene 600 mg QD|Gemcabene treatment on stable background statin therapy
2989302|NCT02634138|Experimental|Intervention|Revitive IX Neuromuscular Electrical Stimulation Device
2989303|NCT02634099|Other|hemoglobine monitoring|3 different techniques will be used for hemoglobine monitoring : hemocue, pulse co-oxymeter (SpHb) and blood measurement
2989304|NCT02634086||Percutaneous coronary intervention|Patients with triple-vessel coronary artery disease underwent percutaneous coronary intervention.
2989305|NCT02634086||Coronary artery bypass graft|Patients with triple-vessel coronary artery disease underwent coronary artery bypass graft.
2989306|NCT02634086||Optimal medication therapy|Patients with triple-vessel coronary artery disease underwent optimal medication therapy only.
2989307|NCT02634073|Experimental|Treatment A: Lamivudine 300 milligram(mg)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
2989308|NCT02634073|Experimental|Treatment B: Lamivudine 300 mg + Sorbitol 3.2 g (low dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 3.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
2989309|NCT02634073|Experimental|Treatment C: Lamivudine 300 mg + Sorbitol 10.2 g (medium dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 10.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
2989310|NCT02634073|Experimental|Treatment D: Lamivudine 300 mg + Sorbitol 13.4 g (high dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 13.4 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
2989428|NCT02633319|Experimental|Agricultural Training|Agrics: Initial 3-month agricultural training intervention with ongoing support afterwards.
2989311|NCT02634060|Experimental|Home Based Fecal Calprotectin|"IBDoc® at week 0, 4 and 8 using smartphone. All material will be provided by the third party The same stool sample of the home base faecal calprotectin will be brought to the hospital and used for ELISA faecal calprotectin measurement at week 0, 4 and 8 for UC patients and week 0 and 4 for CD patients.~IBDoc® results will be forwarded to the patient and the health care professional."
2989312|NCT02634047|Active Comparator|conventional technique|transesophageal echocardiography probe was inserted using a traditional blind insertion technique.
2989313|NCT02634047|Experimental|videolaryngoscope technique|transesophageal echocardiography probe was advanced into esophagus under direct vision using videolaryngoscope
2989314|NCT02634034|Experimental|NK-104-CR (8mg), Pitavastatin IR (4mg), Pitavastatin IR (8mg)|
2989315|NCT02634034|Experimental|Pitavastatin IR (4mg), Pitavastatin IR (8mg), NK-104-CR (8mg)|
2989316|NCT02634034|Experimental|Pitavastatin IR (8mg), NK-104-CR (8mg), Pitavastatin IR (4mg)|
2989317|NCT02634021|Active Comparator|dexmedetomidine group|dexmedetomidine 1 mcg/kg intravenous loading followed by dexmedetomidine continuous infusion at the rate of 0.5 mcg/kg/hr
2989318|NCT02634021|Experimental|midazolam group|midazolam 0.1 mg/kg intravenous loading followed by dexmedetomidine continuous infusion at the rate of 0.5 mcg/kg/hr
2989319|NCT02634008|Experimental|Cohort 1|Paritaprevir/ritonavir/ombitasvir (75mg/50mg/12.5mg) and dasabuvir (250mg) with or without ribavirin (1000-1200mg) daily taken orally for 8 weeks.
2989320|NCT02634008|Experimental|Cohort 2|Three tablets of glecaprevir/pibrentasvir (100mg/40mg) daily taken orally for 6 weeks
2989321|NCT02634008|Experimental|Cohort 3|Three tablets of glecaprevir/pibrentasvir (100mg/40mg) daily taken orally for 4 weeks
2989322|NCT02633995||preeclampsia|spinal anaesthesia will be given for cesarean section
2989323|NCT02633995||normotensive|spinal anaesthesia will be given for cesarean section
2989324|NCT02633969|Experimental|Indomethacin Capsules low dose|Indomethacin Capsules low dose twice daily for up to three days
2989325|NCT02633969|Experimental|Indomethacin Capsules high dose|Indomethacin Capsules high dose twice daily for up to three days
2989326|NCT02633956|Experimental|5 mg Obeticholic Acid|5 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
2989327|NCT02633956|Experimental|10 mg Obeticholic Acid|10 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
2989328|NCT02633956|Experimental|25 mg Obeticholic Acid|25 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
2989329|NCT02633956|Placebo Comparator|Placebo|One tablet daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
2989330|NCT02633943||Subjects with hemoglobinopathies|Subjects treated with ex vivo gene therapy product in a bluebird bio-sponsored clinical trial who agree to participate in this study
2989331|NCT02633930|Experimental|berberine quadruple therapy|Berberine 300 mg, three times daily for 14 days,lansoprazole 30 mg,amoxicillin 1000 mg, and Bismuth 220 mg by mouth, twice daily for 14 days.
2989332|NCT02633930|Active Comparator|clarithromycin quadruple therapy|Bismuth 220 mg, lansoprazole30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
2989333|NCT02633917|Experimental|Motor control exercises|One group should perform motor control exercises
2989334|NCT02633917|Active Comparator|Standard exercises|the other group should perform standard physiotherapy exercises
2989335|NCT02633904|Active Comparator|Osteotomy|Femoral osteotomy are applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
2989336|NCT02633904|Experimental|Non-osteotomy|Femoral osteotomy are not applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
2989337|NCT02633891|Experimental|Balance exercise program|Participants will attend weekly group training sessions and will keep an exercise log of home activity during a three month exercise program designed to improve balance. Balance exercises will be performed three times per week in a home-based training program.
2989338|NCT02633891|Active Comparator|standard care|Participants will meet in person on a weekly basis for a general education class regarding health and fall prevention but will not participate in an exercise class.
2989339|NCT02633878|Experimental|CHM+MP|Chinese herbal medicine+Micronized progesterone
2989340|NCT02633878|Placebo Comparator|MP Placebo+CHM Placebo|Micronized progesterone placebo+Chinese herbal medicine placebo
2989341|NCT02633878|Placebo Comparator|MP Placebo+CHM|Micronized progesterone placebo+Chinese herbal medicine
2989342|NCT02633878|Placebo Comparator|MP+CHM Placebo|Micronized progesterone+Chinese herbal medicine placebo
2989343|NCT02633852|Experimental|Aflibercept (EYLEA) 2mg /0.05 ml|Aflibercept (EYLEA) 2mg /0.05 ml
2989344|NCT02633839|Experimental|Adults who smoke|"Day -1, subjects begin pre-treatment of oral dose regimen of carbidopa every 8 hours.~Day 1, subjects receive a final dose of carbidopa and 1 hour later, a single dose of CVT-301."
2989345|NCT02633839|Experimental|Adults who don't smoke|"Day -1, subjects begin pre-treatment of oral dose regimen of carbidopa every 8 hours.~Day 1, subjects receive a final dose of carbidopa and 1 hour later, a single dose of CVT-301."
2989346|NCT02633826||kidney transplant recipients|kidney transplant recipients of an allograft from a living donor, no intervention
2989347|NCT02633813|Experimental|Naftifine hydrochloride 2%|A thin layer of sufficient quantity of Naftifine hydrochloride cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
2989348|NCT02633813|Active Comparator|Naftin® 2% (Naftifine hydrochloride 2%)|A thin layer of sufficient quantity of Naftifine hydrochloride cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
2989349|NCT02633813|Placebo Comparator|Placebo vehicle cream.|A thin layer of sufficient quantity of vehicle cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
2989350|NCT02633800|Experimental|Patritumab|All participants receive patritumab with cetuximab plus platinum-based therapy (cisplatin or carboplatin)
2989351|NCT02633800|Placebo Comparator|Placebo|All participants receive placebo with cetuximab plus platinum-based therapy (cisplatin or carboplatin)
2989352|NCT02633787|Experimental|Study Group|Participants received a booster dose of Menactra vaccine approximately four years earlier
2989353|NCT02633774|Active Comparator|Rhythm control group|1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation 2. check the echo, brain perfusion CT and K-MOCA on baseline 3. confirm a thrombus through the TEE 4. Cardioversion after 1 month 5. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines) 6. If AF recur, RFCA 7. check the brain perfusion CT, K-MOCA after 3M and 12M
2989354|NCT02633774|Active Comparator|Rate control group|1. No AAD, just anticoagulation 2. HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin) 3. check the echo, brain perfusion CT and K-MOCA on baseline 4. check the brain perfusion CT and K-MOCA after 3M and 12M 5. Without the treatment about antiarrythmia and rhythm control, diffication of rate control, the subject will be drop out for study.
2989355|NCT02633761|Active Comparator|Group 1|200mg mifepristone followed in 24 hours by repeated doses of 200mcg buccal misoprostol given every 3 hours
2989356|NCT02633761|Placebo Comparator|Group 2|placebo followed in 24 hours by 200mcg buccal misoprostol given every three hours.
2989357|NCT02633748|Other|Intervention|The twenty participants in the intervention arm will undergo a pre-assessment, post assessment, and a three month follow-up assessment. The pre and post assessments will ask participants to 1) fill out questionnaires to measure lifestyle, stress, meditations habits, and sleep impairment, 2) take a blood sample, 3) use a BodyMedia's Sensewear® armband for a week, and 4) provide salivary cortisol levels. The three month follow-up will repeat everything done if the first two assessments, excluding the blood sample. The intervention arm will also attend the weekly two and a half hour Mindfulness-Based Cancer Survivorship (MBSC) four-week program between the pre and post assessments.
2989358|NCT02633748|No Intervention|Control|The twenty participants in the control arm will undergo the same pre assessment as the intervention arm, receive a presentation on breathing exercises, and undergo the same post and three-month follow-up assessments. The control arm will also be offered the same Mindfulness-Based Cancer Survivorship program given to the intervention arm following the three month follow-up.
2989359|NCT02633735|No Intervention|control|Usual care
2989360|NCT02633735|Active Comparator|intervention|The appy-cds intervention is a point of care clinical decision support system designed to identify pediatric patients at risk for appendicitis using EHR and supplemental data. The appy-cds has multiple components, 1) presents risk prediction/stratification to provider, 2) provides recommendations consistent with standardized appendicitis care, 3) alerts for unnecessary exposure to ionizing radiation via a best practice alert. The intervention is administered to providers in this arm.
2989361|NCT02633722|Experimental|TRF-b|Participants are instructed to eat between 8am-5pm
2989362|NCT02633722|Experimental|TRF-d|Participants are instructed to eat only between 12-9pm
2989363|NCT02633722|No Intervention|Baseline|No lifestyle instruction given
2989364|NCT02633709|Placebo Comparator|Part 1: Single Ascending Dose: Placebo|Participants will receive a single dose of matching placebo orally on Day 1 of Part 1.
2989365|NCT02633709|Experimental|Part 1: Single Ascending Dose: RO7034067|Participants will receive a single ascending dose (SAD) of RO7034067 orally on Day 1 of Part 1.
2989366|NCT02633709|Experimental|Part 2: Food Effect: Fasted-Fed|This arm consists of two periods. In Period 1 participants will receive one oral dose of RO7034067 in the fasted state on Day 1. In Period 2 participants will receive one oral dose of RO7034067 in the fed state on Day 1.
2989367|NCT02633709|Experimental|Part 2: Food Effect: Fed-Fasted|This arm consists of two periods. In Period 1 participants will receive one oral dose of RO7034067 in the fed state on Day 1. In Period 2 participants will receive one oral dose of RO7034067 in the fasted state on Day 1.
2989368|NCT02633709|Experimental|Part 3: Itraconazole Interaction|In Period 1 a single oral dose of RO7034067 will be administered. After a wash-out period in Period 2 participants will be administered oral doses of itraconazole twice daily from Day 1 to Day 8. On Day 4 participants will receive a single oral dose of RO7034067 in the fed state in combination with itraconazole.
2989369|NCT02633696|Active Comparator|Legalón Sil i.v 350 mg|8 healthy volunteers received 1 vial of 350 mg iv of sylibin lyophilisate for solution for infusion (legalon sil) in two hours (single dose).
2989370|NCT02633696|Experimental|Silybin-phosphatidylcholine oral 360 mg|8 healthy volunteers received 9 capsules of 40 mg of sylibin each one (360 mg in total) orally.
2989371|NCT02633683|Experimental|HORIZANT 600 mg|HORIZANT 600 mg once daily
2989372|NCT02633670|Experimental|Hemopatch|The hemopatch is a promising new sealing synthetic hemostatic agent with a noval dual mechanism of action. The hemopatch is a polyethylene glycol coated (PEG coated) collagen patch. The PEG coating helps in rapid adhesion to the tissue surface while the collagen layer causes platelet activation and adhesion.
2989373|NCT02633670|Active Comparator|Standard technique|Standard hemostatic agents (floseal, tisseal).
2989374|NCT02633657|Experimental|HORIZANT 300 mg|HORIZANT 300 mg once daily
2989375|NCT02633644|Experimental|Treated with Harmony System|Implantation and activation of the Harmony endovascular neurostimulator
2989376|NCT02633631||Women seeking family planning services|Women seeking family planning and gynecological services will be enrolled in our study.
2989377|NCT02633618|Experimental|Analgecine|3ml, 2 times per day, continuous infusion for two weeks.
2989378|NCT02633618|Active Comparator|Neurotropin|3ml, 2 times per day, continuous infusion for two weeks.
2989379|NCT02633605||First Sense Breast Exam|
2989380|NCT02633592|Active Comparator|HRARM|Patients and healthy volunteers are subjected to position change ( LLP to SP) during pressure measurements with HR-ARM.
2989381|NCT02633592|Active Comparator|MRI Defecography|Patients and healthy volunteers are subjected to position change during MRI Defecography
2989382|NCT02633579|Active Comparator|Erythromycin lactobionate|40 mg erythromycin lactobionate was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %
2989383|NCT02633579|Active Comparator|Erythromycin lactobionate with atropine|40 mg erythromycin lactobionate was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %; Atropine sulfate was given as an i.v. bolus (15 µg/kg) followed by a continuous infusion of 15 µg/kg/h over 30 min
2989384|NCT02633579|Placebo Comparator|Atropine|"Atropine sulfate was given as an i.v. bolus (15 µg/kg) followed by a continuous infusion of 15 µg/kg/h over 30 min.~Infusion of saline as a placebo for erythromycin was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %"
2989429|NCT02633319|Experimental|Parenting and Agricultural Training|Village farmer groups receiving both Skilful Parenting and Agrics interventions.
2989385|NCT02633579|Placebo Comparator|Placebo|Infusion of saline was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %; also placebo for atropine was given as an i.v. bolus of saline followed by a continuous infusion over 30 min
2989386|NCT02633566|Active Comparator|Functional plantar orthoses|Functional plantar orthoses in polypropylene with Medial Heel Skive technique
2989387|NCT02633566|Placebo Comparator|Placebo plantar orthoses|Plantar orthoses made in Ethil Vinyl Acetate (22º Shore) without correction of the pronation
2989388|NCT02633553|Experimental|radiotherapy group|complete resection and adjuvant radiotherapy
2989389|NCT02633553|No Intervention|observation group|complete resection
2989390|NCT02633540|Experimental|IMRT Radiation|All subjects will be treated using IMRT with the standard fractionation for T1a glottic cancer at Fox Chase Cancer Center: 63 Gy in 28 fractions; 6 for T1a and 65.25 Gy in 29 fractions; 33 for T2a. Treatment will be followed by functional assessments performed at months 1,3,6,12,and 24.
2989391|NCT02633527|Placebo Comparator|Placebo|Subjects in this arm will be administered Placebo
2989392|NCT02633527|Experimental|SPN-810 ER Low Dose|Subjects in this arm will be administered low dose of SPN-812 ER
2989393|NCT02633527|Experimental|SPN-812 ER Low-Medium Dose|Subjects in this arm will be administered low-medium dose of SPN-812 ER
2989394|NCT02633527|Experimental|SPN-812 ER High-Medium Dose|Subjects in this arm will be administered high-medium dose of SPN-812 ER
2989395|NCT02633527|Experimental|SPN-812 ER High Dose|Subjects in this arm will be administered high dose of SPN-812 ER
2989396|NCT02633514|Experimental|Radiochemotherapy|adjuvant radiochemotherapy after incomplete resection
2989397|NCT02633514|Sham Comparator|radiotherapy|adjuvant radiotherapy after incomplete resection
2989398|NCT02633501|Experimental|Subset 1 Arm 1|One of two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI
2989399|NCT02633501|Experimental|Subset 1 Arm 2|Gadobenate dimeglumine (0.01 mmol/kg)-enhanced MRI then one of two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI
2989400|NCT02633501|Experimental|Subset 2 Arm 1|One of four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI
2989401|NCT02633501|Experimental|Subset 2 Arm 2|Gadobenate dimeglumine (0.01 mmol/kg)-enhanced MRI then one of four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI
2989402|NCT02633488|Placebo Comparator|Placebo|12 weeks of Placebo tablet 3 x daily
2989403|NCT02633488|Experimental|Metformin|12 weeks of Metformin tablet 850 mg 3 x daily
2989404|NCT02633475||CONTROL: women no miscarriage|Group of patients who referred to the Fourth Affiliated Hospital of Guangxi Medical University or Liuzhou Maternity and Child Healthcare Hospital, who have more than one successful pregnancy without miscarriage. Then the blood sample will be collected and the IL-10 Polymorphism will be analyzed.
2989405|NCT02633475||CASE: patients with IRM|Group of patients who referred to the Fourth Affiliated Hospital of Guangxi Medical University or Liuzhou Maternity and Child Healthcare Hospital, who have more than three consecutive miscarriages without clear cause (Idiopathic Recurrent Miscarriage, IRM). Then the blood sample will be collected and the IL-10 Polymorphism will be analyzed.
2989406|NCT02633462|Active Comparator|Test Group|Polycystic ovarian syndrome(PCOS) women who have periodontitis and treated with scaling and root planing(SRP) along with Myo-inositol supplementation
2989407|NCT02633462|Active Comparator|Control Group|Polycystic ovarian syndrome(PCOS) women who have periodontitis treated with Myo-inositol along with oral hygiene instructions.
2989408|NCT02633449|Experimental|cognitive behavioral therapy + tDCS|Group cognitive behavioral therapy combined with tDCS
2989409|NCT02633449|Active Comparator|cognitive behavioral therapy + sham-tDCS|Group cognitive behavioral therapy combined with sham-tDCS
2989410|NCT02633449|Placebo Comparator|cognitive behavioral therapy|Group cognitive behavioral therapy only
2989411|NCT02633436||cancer tissues|SLC1A5 expression of esophageal cancer tissues from patients
2989412|NCT02633436||paired adjacent tissues|SLC1A5 expression of paired adjacent esophageal tissues from patients
2989413|NCT02633423|Experimental|PEEP and CPAP|Patients will be ventilated with positive end-expiratory pressure(PEEP) before and after cardiopulmonary bypass(CPB); during CPB continous positive airway pressure(CPAP) will be adopted.
2989414|NCT02633423|Experimental|ZEEP and CPAP|Patients will be ventilated without PEEP(ZEEP) before and after cardiopulmonary bypass(CPB); during CPB continous positive airway pressure(CPAP) will be adopted.
2989415|NCT02633423|Experimental|PEEP and NO VM|Patients will be ventilated with positive end-expiratory pressure(PEEP) before and after cardiopulmonary bypass(CPB); during CPB no mechanical ventilation will be adopted(no VM)
2989416|NCT02633423|Placebo Comparator|ZEEP and NO VM|Patients will be ventilated without PEEP(ZEEP) before and after cardiopulmonary bypass(CPB); during CPB no mechanical ventilation will be adopted(no VM)
2989417|NCT02633410|Active Comparator|Transtibial|Transtibial technique used to create femoral tunnel
2989418|NCT02633410|Active Comparator|Anteromedial|Anteromedial technique used to create femoral tunnel
2989419|NCT02633397|Experimental|Riociguat|Treatment Arm
2989420|NCT02633397|Placebo Comparator|Placebo|Placebo Arm
2989421|NCT02633384|Experimental|SMOFlipid|infants subjected to corrective surgery for congenital abnormalities and needing prolonged PN using a new generation intravenous lipid emulsion
2989422|NCT02633384|Other|Lipofundin|infants subjected to corrective surgery for congenital abnormalities and needing prolonged PN using a current intravenous lipid emulsion
2989423|NCT02633371|Experimental|Oxybutynin|Oxybutynin 3% gel, 1 gram of product (56 mg oxybutynin) topically to each armpit daily for 4 weeks
2989424|NCT02633358|Experimental|Therapeutic hypothermia|Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling
2989425|NCT02633345|Experimental|Probiotic|The probiotic tablets contain Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2 at a dose of 1 * 109 CFU/tablet. The participants will take two tablets a day for four weeks.
2989426|NCT02633345|Placebo Comparator|Control|Placebo tablets. The participants will take two tablets a day for four weeks.
2989427|NCT02633319|Experimental|Parenting Training|Skilful Parenting: 12-week group-based parent intervention delivered by Investing in Children and Our Societies to caregivers who are members of farmer groups in participating villages.
2989433|NCT02633280||COPD-Untreated (Group 1)|In this Group will be enrolled patients of both sex and older than 40-years with COPD stage GOLD 2 and 3 that did not receive COPD treatment in the last 6 months (beta 2 agonists, corticosteroids, anticholinergics).
2989434|NCT02633280||COPD-uncontrolled (Group 2)|In this Group will be enrolled patients of both sex and older than 40-years with COPD stage GOLD 2 and 3 that receive a COPD treatment (e.g. beta 2 agonists, corticosteroids, anticholinergics) but with a post-bronchodilator FEV1< 80% and an FEV1/FVC < 0.7 or with 1-2 exacerbation/year
2989435|NCT02633280||Control subjects (Group 3)|In this Group will be enrolled patients of both sex and older than 40 years; (2) will be free from lung disease as determined by a physician; (3) will have a normal spirometry (FEV1> 85% and FEV1/FVC > 0.7)
2989436|NCT02633267|Experimental|Usual Vocational Services + CBT|This is the experimental intervention - Usual vocational services at a vocational services center plus additional cognitive behavioral therapy at vocational service center.
2989437|NCT02633267|Active Comparator|Usual Vocational Services|This is the care as usual intervention - Vocational services as usually delivered to service seeking clients
2989438|NCT02633254|Experimental|Single arm|Treatment group Magentic Resonance guided High Intensity Focused Ultrasound will be employed on uterine fibroids
2989439|NCT02633241|Other|Dexmedetomidine-Propofol arm|Patients in this cohort will receive a combination of Dexmedetomidine 1mcg/kg and Propofol100mcg/kg/minute to accomplish an MRI examination.
2989440|NCT02633215|Experimental|Active stimulation with motor training|2 hours of active peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
2989441|NCT02633215|Active Comparator|Sham stimulation with motor training|2 hours of sham peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
2989442|NCT02633202|Experimental|RT group|intensity modulated-radiotherapy (IMRT) alone: Patients receive intensity modulated-radiotherapy (IMRT) alone
2989443|NCT02633202|Active Comparator|CCRT group|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles
2989444|NCT02633189|Experimental|erlotinib and bevacizumab|
2989445|NCT02633189|Active Comparator|erlotinib|
2989446|NCT02633176|Active Comparator|cisplatin and docetaxel|"Induction chemotherapy: Patients receive cisplatin and docetaxel intravenously on day 1 repeated every 3 weeks for 6 cycles.~Concurrent chemoradiation: Patients who achieve complete response or partial response receive radiotherapy for primary and/or metastatic lesions with concurrent cisplatin 30mg/m^2 intravenously every week.~Maintenance treatment: Capecitabine will be given at a dose of 1000mg/m^2 orally twice a day starting on day 1 and continuing for days 1 to 14 of each 21 day cycle for at least 2 years or until progression."
2989447|NCT02633176|Experimental|cetuximab, cisplatin, and docetaxel|"Induction chemotherapy: Patients receive cetuximab 400mg/m^2 intravenously over at least 120 minutes on day 1 followed by 250 mg/m^2 intravenously over at least 60 minutes every week. Cisplatin and docetaxel will be administered intravenously on day 2 repeated every 3 weeks for 6 cycles.~Concurrent chemoradiation: Patients who achieve complete response or partial response receive radiotherapy for primary and/or metastatic lesions with concurrent cetuximab 250mg/m^2 intravenously followed by cisplatin 30mg/m^2 intravenously every week.~Maintenance treatment: Capecitabine will be given at a dose of 1000mg/m^2 orally twice a day starting on day 1 and continuing for days 1 to 14 of each 21 day cycle for at least 2 years or until progression."
2989448|NCT02633163|Experimental|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution
2989449|NCT02633163|Experimental|High Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal Stem Cells MSCs 5 x 10^6 cells/kg in Plasma-Lyte A solution
2989450|NCT02633163|Placebo Comparator|Plasma Lyte A Solution|Placebo Infusion (Plasma-Lyte A solution only)
2989451|NCT02633150|Experimental|Polyphenol|red grapes polyphenol supplementation on metabolic parameters in obese insulinoresistant subjects
2989452|NCT02633150|Placebo Comparator|Placebo|Placebo supplementation on metabolic parameters in obese insulinoresistant subjects
2989453|NCT02633137|Experimental|Chemotherapy|Lenalidomide + R-CHOP x 4 cycles R-HiDAC x 2 cycles R-Len maintenance x 6 months
2989454|NCT02633124|Experimental|Edelvaiss Multiline NEO|The Edelvaiss Multiline NEO design allows to position the access to the infusion line outside of the incubator, without increasing the residual volume and this device has been validated by the manufacturer as part of CE marking for a period of 21 days.
2989455|NCT02633124|Other|Standard Infusion Set|The infusion set used for the standard group is the infusion set usually used.
2989456|NCT02633111|Experimental|Patients with aggressive B-cell Non-Hodgkin lymphoma|This is a non-therapeutic protocol aimed to assess the ability of Adaptive clonoSEQ® MRD assay to detect clinical relapse in DLBCLwhen compared to conventional approaches for detecting relapse such as patient-reported symptoms, clinical exams, and CT scans.
2989457|NCT02633098|Experimental|Artesunate|Artesunate 200mg oral tablets once daily for 14 days.
2989458|NCT02633098|Placebo Comparator|Matching placebo|Matching placebo oral tablets once daily for 14 days.
2989459|NCT02633085||Fixed Bearing or Mobile Bearing UKA|
2989460|NCT02633059|Experimental|Treatment (ixazomib citrate, idasanutlin, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and idasanutlin PO QD on days 1-5 every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive dexamethasone PO on days 1, 8, 15, and 22 every 28 days for 12 courses at the discretion of the treating physician.
2989461|NCT02633046|Other|Acthar 80 U 3x/week Open Label Treatment Period|Starting at Week 0-23, open label treatment with Acthar 80 U 3x/week.
2989462|NCT02633046|Active Comparator|Acthar 80 U 2x/week|Starting at Week 26 for subjects who meet remission criteria at Week 23.
2989463|NCT02633046|Placebo Comparator|Placebo 80 U 2x/week|Starting at Week 26 for subjects who meet remission criteria at Week 23.
2989464|NCT02633046|Other|Acthar 80 U 3x/week Open Label Extension|Starting at Week 26 for subjects who do not achieve remission at Week 23, an additional 24 weeks of open label treatment with Acthar 80 U 3x/week will be available.
2989467|NCT02633007|Experimental|CVT-301 then Placebo (AB)|All subjects will receive both CVT-301 and placebo in two dosing periods separated by one day. Subjects will be randomized 1:1 into sequence AB or BA [CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)] and they will start pre-treatment of carbidopa (as Lodosyn®) administered every 8 hours until the completion of all study treatments.
2989468|NCT02633007|Experimental|Placebo then CVT-301 (BA)|All subjects will receive both CVT-301 and placebo in two dosing periods separated by one day. Subjects will be randomized 1:1 into sequence AB or BA [CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)] and they will start pre-treatment of carbidopa (as Lodosyn®) administered every 8 hours until the completion of all study treatments.
2989469|NCT02632981|Active Comparator|chronic periodontitis patients|gingival crevicular fluid and saliva collecion were taken before and after nonsurgical periodontal treatment
2989470|NCT02632981|Placebo Comparator|periodontally healthy controls|gingival crevicular fluid and saliva collection were taken at baseline after oral hygiene instructions
2989471|NCT02632968|Active Comparator|Pinhole surgery with orthodontic buttons|Pinhole surgery with orthodontic buttons The selected participants were assigned in test and control. In the test group orthodontic buttons were cemented on the bid-buccal region of the crown with dual cure GIC. After administration of LA, 2 to 3 pinhole incisions were made and a full thickness muco-periosteal tunnel was raised and collagen membrane was tucked in through the pinhole incisions. The sling sutures 5-0 mersilk were placed to hold the tunnel in an advanced location using orthodontic buttons as anchoring units. Inter-dental sutures with 6-0 mersilk were also placed for stabilization of the advanced gingival tissue.
2989472|NCT02632968|Active Comparator|Pinhole surgery without buttons|Pinhole surgery without orthodontic buttons The selected participants were assigned in test and control. In the control group, after administration of LA, 2 to 3 pinhole incisions were made and a full thickness muco-periosteal tunnel was raised and collagen membrane was tucked in through the pinhole incisions till the recession defects were covered. No sutures or orthodontic buttons were used in the control site.
2989473|NCT02632955|Experimental|Drug Eluting Balloon|After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
2989474|NCT02632955|Sham Comparator|Regular Angioplasty|After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
2989475|NCT02632942|Experimental|HAQ Criteria|"Obliteration of accessory vein which satisfy the HAQ criteria as below:~60% or greater diameter of the main AVF~50% diameter of AVF with at least one more av>40% in diameter.~50% in diameter and divides into branches of same size.~av likely to interfere with cannulation on physical examination.~>30% in diameter and associated with stenosis at site of origin."
2989476|NCT02632942|Active Comparator|Current Recommendation|Obliteration of accessory vein which satisfy the current recommendations only defined as accessory vein with a diameter greater than 25% of the AVF diameter.
2989477|NCT02632929||Diabetic Foot Ulcers at Amputation Risk|Patients at high risk for limb amputation from a diabetic foot ulcer will be treated with comprehensive, interdisciplinary approach (usual care) in combination with early application of advanced therapy; dehydrated human amniotic membrane allografts (AMNIOEXCEL®, Derma Science, Princeton, New Jersey).
2989478|NCT02632916|Active Comparator|Zoledronic Acid|Intravenous zoledronic acid 0.025mg/kg
2989479|NCT02632916|Experimental|Denosumab|Subcutaneous denosumab 1.0mg/kg
2989480|NCT02632903|Experimental|Intravenous Zoledronic Acid|Intravenous Zoledronic Acid 0.025mg/kg at baseline and 6 months
2989481|NCT02632890||Patients survey|Adult patients treated with abatacept for rheumatoid arthritis
2989482|NCT02632890||HCP survey|HCP with at least 1 patient taking abatacept
2989483|NCT02632890||Retrospective chart review study|Adult patients treated with abatacept for rheumatoid arthritis
2989484|NCT02632877|Experimental|Pirfenidone with MODD|"Active ingredients: Pirfenidone 8% with modified oxide diallyl disulfide (MODD) 0.016%.~Dosage form: gel. Dosage: standar finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency and duration: topically applied every eight hours for 6 months."
2989485|NCT02632877|Active Comparator|Ketanserin|"Active ingredients: Ketanserin 2%. Dosage form: gel. Dosage: standar finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency and duration: topically applied every 12 hours for 6 months."
2989486|NCT02632864|Experimental|Proton arm|Proton beam therapy
2989487|NCT02632851||Ectoin inhalation solution|treatment according to instructions for use
2989488|NCT02632851||Pari NaCl inhalation solution (0.9%)|treatment according to instructions for use
2989489|NCT02632838|Experimental|the mHealth Group|The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor on a daily basis at HOME and also will be asked to visit community health center once a week to receive the regular hypertension care for the 6-month period as usual.
2989490|NCT02632838|No Intervention|the Standard Follow-up Group|The standard follow-up group will receive regular hypertension care as usual which consists: nursing assessment, medication management, patient education, follow up and continuing care in the community health center
2989491|NCT02632825|Experimental|Nasal High Flow|NHF will be applied at 8 L/min (AIRVO 2) through (OPT 316) Optiflow nasal cannula interface without supplemental oxygen
2989492|NCT02632825|No Intervention|Control|Control is no NHF intervention
2989493|NCT02632812|Experimental|Rebamipide & Naproxen|Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg) for 7 days
2989494|NCT02632812|Placebo Comparator|Placebo & Naproxen|Sugar pill manufactured to mimic Rebamipide 100 mg effervescent granules (oral) Twice daily for 7 days
2989495|NCT02632799|Experimental|NHF small cannula|NHF 8 L/min (Airvo2) , Smaller cannula (neonatal, yellow)
2989496|NCT02632799|Experimental|NHF big cannula|NHF 8 L/min (Airvo2) , Bigger cannula (neonatal, purple)
2989497|NCT02632799|Experimental|Mask CPAP|CPAP 5cm H2O
2989498|NCT02632799|No Intervention|no intervention|control
2989499|NCT02632786|Experimental|NEOD001|Study Drug given IV every 28 days at 24mg/kg
2989501|NCT02632773|Experimental|Parent Learning Style 1|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
2989502|NCT02632773|Experimental|Parent Learning Style 2|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
2989503|NCT02632773|Other|Learning Style 1 (Parent)|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
2989504|NCT02632773|Other|Learning Style 2 (Parent)|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
2989505|NCT02632760|Active Comparator|ferric carboxymaltose|ferric carboxymaltose 1000 mg (or similar product) given Intravenously
2989506|NCT02632760|Placebo Comparator|Placebo|Placebo intravenous infusion
2989507|NCT02632747|Experimental|Sequence A|Empagliflozin followed by a wash-out followed by empagliflozin matching placebo on a background of open label ramipril.
2989508|NCT02632747|Experimental|Sequence B|Empagliflozin matching placebo followed a wash-out followed by empagliflozin on a background of open label ramipril.
2989509|NCT02632734|Experimental|CoreBone Cone device|Experimental: CoreBone Cone device After extraction intervention will include the placement of CoreBone Cone device derived from coral that its dimensions is 4-5mm width and 8-10mm height. One cone for each extraction socket.Its advantage is that it fits well the socket site.Measurements from models taken at different times will be analysed for bone loss. Changes in width and height of alveolar bone will be studied at 3 and 6 month. We predict that CoreBone Cones are more effective than particulate device.
2989510|NCT02632734|Experimental|CoreBone 500 device|After extraction intervention will include the placement of CoreBone500 device derived from coral that is particulate. 0.3-0.5cc for each extraction socket.Its advantage is that it fills well the socket site.Measurements from models taken at different times will be analysed for bone loss. Changes in width and height of alveolar bone will be studied at 3 and 6 month.
2989511|NCT02632721|Experimental|Dose Escalation Cohorts (Phase I)|Combination treatment of decitabine with escalating doses of BI 836858
2989512|NCT02632721|Experimental|Extension Cohorts (Phase I)|Combination treatment of decitabine with BI 836858 at MDT (Maximum Tolerated Dose)
2989513|NCT02632721|Experimental|Arm 1 (Phase II)|Combination treatment of decitabine with BI 836858 at R2PD (Recommended Phase II dose)
2989514|NCT02632721|Other|Arm 2 (Phase II)|Monotherapy treatment with decitabine (standard of care treatment)
2989515|NCT02632708|Experimental|AG-120 with cytarabine and daunorubicin|Daily AG-120 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, subjects may undergo a second induction cycle given as per institutional practice. Subjects who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-120. Subjects who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-120.
2989516|NCT02632708|Experimental|AG-120 with cytarabine and idarubicin|Daily AG-120 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, subjects may undergo a second induction cycle given as per institutional practice. Subjects who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-120. Subjects who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-120.
2989517|NCT02632708|Experimental|AG-221 with cytarabine and daunorubicin|Daily AG-221 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, subjects may undergo a second induction cycle given as per institutional practice. Subjects who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Subjects who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
2989518|NCT02632708|Experimental|AG-221 (starting on Day 8) with cytarabine and idarubicin|Daily AG-221 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, subjects may undergo a second induction cycle given as per institutional practice. Subjects who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Subjects who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
2989519|NCT02632708|Experimental|AG-221 (starting on Day 8) with cytarabine and daunorubicin|Daily AG-221 administered orally starting on Day 8 of induction cycle 1 in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, subjects may undergo a second induction cycle given as per institutional practice. Subjects who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Subjects who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
2989520|NCT02632708|Experimental|AG-221 with cytarabine and idarubicin|Daily AG-221 administered orally starting on Day 8 of induction cycle 1 in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, subjects may undergo a second induction cycle given as per institutional practice. Subjects who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Subjects who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
2989521|NCT02632695|Experimental|FOOTFIT Plus|The intervention consists of: 1) a prescribed, evidence-based, phased, non-exertive physical activity conditioning activities for lower leg function (CALF) movements that are to be performed daily at home; 2) a low-cost, tri-axial Bluetooth® enabled highly sensitive motion-sensing accelerometer and tracking device (BEAT) worn on the foot during CALF to capture frequency and intensity of foot movements; and 3) a Smartphone that receives foot movement data, provides automated educational/motivational messages, and reports and allows regular communication with the wound care provider on progress.
2989522|NCT02632695|Experimental|FOOTFIT|The intervention consists of: 1) a prescribed, evidence-based, phased, non-exertive physical activity conditioning activities for lower leg function (CALF) movements that are to be performed daily at home; 2) a low-cost, tri-axial Bluetooth® enabled highly sensitive motion-sensing accelerometer and tracking device (BEAT) worn on the foot during CALF to capture frequency and intensity of foot movements; and 3) a Smartphone that receives foot movement data, provides automated educational/motivational messages, and reports. There is not regular communication with the wound care provider on progress.
2989523|NCT02632669|Experimental|Hemi gland focal LDR brachytherapy|Hemi gland focal LDR brachytherapy using permanent iodine 125 seed implantation
2989524|NCT02632656||Patients with congestive heart failure|Patients with congestive heart failure (CHF) who are followed in the hospital or clinic setting, with optimization of medical therapy
2989525|NCT02632643|Experimental|lifestyle counseling|
2989526|NCT02632630|Active Comparator|Amino Acids w/Electrolytes in Dextrose|Peripheral parenteral nutrition (PPN)
2989527|NCT02632630|Active Comparator|Ensure product|Calorie and protein dense oral nutritional supplement for patients with elevated nutritional needs.
2989528|NCT02632630|Active Comparator|Crystalloid solutions|Standard care intravenous maintenance fluids.
2989529|NCT02632630|Active Comparator|Oral nutritional supplementation|Nutrient-enhanced drink products that provide macronutrients and micronutrients with the aim of increasing oral nutritional intake.
2989530|NCT02632617||CTA Group|Participants in CTA group will primarily receive computed tomographic angiography examination before surgery. Those with positive findings in CTA (≥50% diameter stenosis in main coronary artery) or uncertain diagnosis caused by motion artifact or calcium artifact are required to undergo ICA, and coronary artery bypass grafting (CABG) is recommended in patients with significant stenosis according to the ICA result. Participants with negative findings in CTA do not need further coronary artery evaluation, and CABG won't be performed during the surgery.
2989531|NCT02632617||ICA Group|Participants in ICA group will undergo ICA as guideline recommend before surgery, coronary artery bypass grafting (CABG) is recommended in patients with significant stenosis
2989532|NCT02632604|Active Comparator|Bottom-up to top-down cognitive training|Participants are given 20 hours of cognitive training with exercises that involve essentially bottom-up cognitive processes, followed by 20 hours of cognitive training with exercises that involve essentially top-down cognitive processes
2989533|NCT02632604|Active Comparator|Top-down to bottom-up cognitive training|Participants are given 20 hours of cognitive training with exercises that involve essentially top-down cognitive processes, followed by 20 hours of cognitive training with exercises that involve essentially bottom-up cognitive processes
2989534|NCT02632604|Placebo Comparator|Computer games|Participants are given 40 hours of computer games commonly found on the internet and which do not involve a high demand in cognitive functions (e.g. fishing game, pinball game, tetris, etc).
2989535|NCT02632578||HIV-positive|
2989536|NCT02632578||HIV-negative|
2989537|NCT02632565|Active Comparator|intra-articular 0.5% lidocaine|intra-articular 7 mL 0.5% lidocaine injection for 3 times with one week intervals
2989538|NCT02632565|Active Comparator|intra-articular saline|intra-articular 7 mL saline injection for 3 times with one week intervals
2989539|NCT02632552|Experimental|Technology-assisted care transition arm|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
2989540|NCT02632552|Active Comparator|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
2989541|NCT02632539|Active Comparator|subglottic secretion drainage|The conventional method which we use subglottic secretion drainage to clear subglottic secretion
2989542|NCT02632539|Experimental|Manual air-impingement operation|A method which we invented to clear subglottic secretion
2989543|NCT02632526|Experimental|AZD5718 amorphous form, treatment 1 (Part A)|Starting dose 25 mg/day, single ascending dose
2989544|NCT02632526|Experimental|AZD5718 amorphous form, treatment 2 (Part A)|Single dose of AZD5718 amorphous suspension
2989545|NCT02632526|Experimental|AZD5718 amorphous form, treatment 3 (Part A)|Single dose of AZD5718 amorphous suspension
2989546|NCT02632526|Experimental|AZD5718 amorphous form, treatment 4 (Part A)|Single dose of AZD5718 amorphous suspension
2989547|NCT02632526|Experimental|AZD5718 amorphous form, treatment 5 (Part A)|Single dose of AZD5718 amorphous suspension
2989548|NCT02632526|Experimental|AZD5718 amorphous form, treatment 6 (Part A)|Single dose of AZD5718 amorphous suspension
2989549|NCT02632526|Experimental|AZD5718, crystalline form, treatment 7 (Part A)|Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose
2989550|NCT02632526|Experimental|AZD5718 crystalline form, treatment 8 (Part A)|Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose
2989551|NCT02632526|Experimental|AZD5718 amorphous form, treatment 1 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
2989552|NCT02632526|Experimental|AZD5718 amorphous form, treatment 2 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
2989553|NCT02632526|Experimental|AZD5718 amorphous form, treatment 3 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
2989554|NCT02632526|Experimental|AZD5718 amorphous form, treatment 4 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
2989555|NCT02632526|Experimental|AZD5718 amorphous/crystalline form, repeat 1 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
2989556|NCT02632526|Experimental|AZD5718 amorphous/crystalline form, repeat 2 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
2989557|NCT02632526|Experimental|AZD5718 amorphous/crystalline, repeat 3 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
2989558|NCT02632526|Experimental|AZD5718 amorphous form, repeat 1 (Part B)|Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)
3005530|NCT02526394|Active Comparator|5|Boostrix + NeisVacC
2989559|NCT02632526|Experimental|AZD5718 amorphous form, repeat 2 (Part B)|Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)
2989560|NCT02632513|Experimental|continuous ultrasonic irrigation|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
2989561|NCT02632513|No Intervention|Syringe irrigation|In the syringe irrigation group, irrigation was done using 27 gauge syringe.
2989562|NCT02632500|Experimental|30 compressions and 2 seconds of pause|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 30 compressions and 2 seconds of pause protocol (30 chest compressions followed by 2 seconds of pause) on a manikin connected to the Personal Computer."
2989563|NCT02632500|Experimental|50 compressions and 5 seconds of pauses|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 50 compressions and 5 seconds of pause protocol (50 chest compressions followed by 5 seconds of pause) on a manikin connected to the Personal Computer."
2989564|NCT02632500|Experimental|100 compressions and 10 seconds of pause|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 100 compressions and 10 seconds of pause protocol (100 chest compressions followed by 10 seconds of pause) on a manikin connected to the Personal Computer."
2989565|NCT02632500|Experimental|hands-only|"After the randomization the participant will be asked to perform 8 minutes of CPR following the hands-only protocol (continuous chest compressions without any pauses) on a manikin connected to the Personal Computer."
2989566|NCT02632487|Active Comparator|Exercise|This group will receive 8 weeks of center-based exercise followed by recommendations to remain physically active.
2989567|NCT02632487|Experimental|Exercise + Non-Exercise Physical Activity (NEPA)|This group will receive 8 weeks of center-based exercise combined with behavioral counseling and a technology intervention designed to increase daily Exercise + Non-Exercise Physical Activity (NEPA).
2989568|NCT02632474|Experimental|Low-dose|Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)
2989569|NCT02632461|Experimental|Podcast (+Bite Counter)|Participants in this group will receive podcasts twice weekly in conjunction with using a wearable wrist device called a Bite Counter. The Bite Counter tracks the number of bites/calories per bite. (Podcasts plus Bite Counter)
2989570|NCT02632461|Active Comparator|Podcast (+Mobile App)|Participants in this group will receive podcasts twice weekly in conjunction with using a mobile application to track their diet. (Podcasts plus Mobile Diet Application)
2989571|NCT02632448|Experimental|Part A: LY2880070|Multiple oral doses of LY2880070 ranging from 10-400 milligrams (mg) per day (or higher), during 21-day cycles
2989572|NCT02632448|Experimental|Part A: LY2880070 with Gemcitabine|Multiple oral doses of LY2880070, and Gemcitabine administered intravenously on two or three days of each 21-day cycle
2989573|NCT02632448|Experimental|Part A: LY2880070 (Metabolism Phenotype)|Multiple oral doses of LY2880070 administered during 21 day cycles, to participants who are poor metabolizers
2989574|NCT02632448|Experimental|Part B: LY2880070 (Breast)|Multiple oral doses of LY2880070 ranging from 10-400 milligrams (mg) per day (or higher), during 21-day cycles
2989575|NCT02632448|Experimental|Part B: LY2880070 (Colorectal)|Multiple oral doses of LY2880070 ranging from 10-400 milligrams (mg) per day (or higher), during 21-day cycles
2989576|NCT02632448|Experimental|Part B: LY2880070 with Gemcitabine (Ovarian, Endometrial, STS)|Multiple oral doses of LY2880070, and Gemcitabine administered intravenously on two or three days of each 21-day cycle
2989577|NCT02632435|Other|Peripherally inserted central catheter|PICC line will be inserted for the delivery and duration of chemotherapy.
2989578|NCT02632435|Other|portacath|PORT will be inserted for the delivery and duration of chemotherapy and trastuzumab.
2989579|NCT02632422|Experimental|Non-ambulatory - dAIH|Non-ambulatory subjects will be randomly assigned to receive 10 sessions of daily acute intermittent hypoxia (dAIH) 10 treatment visits at a frequency of up to 5 days each week for 2 weeks.
2989580|NCT02632422|Sham Comparator|Non-ambulatory - dSHAM|Non-ambulatory subjects will be randomly assigned to receive 10 sessions of daily room air (dSHAM) 10 treatment visits at a frequency of up to 5 days each week for 2 weeks.
2989581|NCT02632422|Experimental|Ambulatory - dAIH+Walk|Ambulatory subjects will be randomly assigned to receive 10 sessions of daily acute intermittent hypoxia (dAIH) coupled with 60 minutes of walking practice at a frequency of up to 5 days each week for 2 weeks.
2989582|NCT02632422|Sham Comparator|Ambulatory - dSHAM+Walk|Ambulatory subjects will be randomly assigned to receive 10 sessions of daily room air (dSHAM) coupled with 60 minutes of walking practice at a frequency of up to 5 days each week for 2 weeks.
2989583|NCT02632422|Other|Ambulatory-Walk|Ambulatory subjects will be randomly assigned to 10 sessions of walking practice only for 5 consecutive sessions/week x 2 weeks.
2989584|NCT02632409|Experimental|Nivolumab|Nivolumab dose as specified
2989585|NCT02632409|Placebo Comparator|Placebo|Placebo dose as specified
2989586|NCT02632396|Experimental|Treatment (ixazomib, rituximab)|Beginning between 70-180 days after stem cell transplant, patients receive ixazomib PO on days 1, 8, and 15, and rituximab IV (or SC after first dose if deemed appropriate) on day 1 of courses 1, 3, 5, 7, and 9. Treatment repeats every 28 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
2989587|NCT02632383|Experimental|Test Group|"Intervention: Young with Diabetes - app The test group receives standard care and the mHealth app Young with Diabetes - app to support young people to self-manage their diabetes.~The young people's parents are also invited to download the app. The diabetes team (doctors, nurses and dieticians) also have the app and uses the app in their consultations with the young people."
2989588|NCT02632383|No Intervention|Control Group|The control group receives standard care
2989589|NCT02632370||Gliolan®|Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials. The formulation contains 1.5 g 5-aminolevulinic acid hydrochloride corresponding to 1.17 g of 5-aminolevulinic acid. The oral solution is intended for single (partial) use.
2989590|NCT02632357|Experimental|AS group|Subjects with ULNTT asymmetry > 10°
2989591|NCT02632357|No Intervention|S group|Subjects with ULNTT symmetry
2989592|NCT02632344|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Treatment will be administered on Day 1 of each cycle after all procedures/assessments have been completed
2989595|NCT02632318|Experimental|Light|Dawn simulation for 30 minutes prior to habitual wake time
2989596|NCT02632318|No Intervention|No light|Darkness for 30 minutes prior to habitual wake time
2989597|NCT02632305|Experimental|Treatment|"Eligible patients will receive nab-paclitaxel in combination with gemcitabine + cisplatin at the recommended phase II dose based on the phase I study completed in metastatic pancreas cancer patients.~The doses of study drugs will be as follows:~nab-Paclitaxel 100 mg/m2 day 1 and 8 every 21 days~Cisplatin 25 mg/m2 day 1 and 8 every 21 days~Gemcitabine 800 mg/m2 day 1 and 8 every 21 days~Nab-paclitaxel will be administered first followed by cisplatin and then gemcitabine on day 1 and 8 of each treatment cycle. Cycles will be 3 weeks in length (21 days)."
2989598|NCT02632292|Experimental|Absorb GT1|Bioresorbable everolimus-eluting scaffolds
2989599|NCT02632292|Active Comparator|Promus|Everolimus-eluting stents
2989600|NCT02632279|Experimental|TRP depleted|TRP depleted protein drink
2989601|NCT02632279|Placebo Comparator|Placebo|Balanced protein drink (+1.21g of TRP)
2989602|NCT02632266|Active Comparator|Powder HMF|Once patient has reached 80ml/kg/day of enteral feedings, 1 pack of powder HMF will be added to 50 ml of human or donor breast milk, then increased to a maximum of 2 packs for 50 ml following the unit feeding advancement protocol and this will be continued up until 48 hours prior to discharge.
2989603|NCT02632266|Active Comparator|Liquid HMF|Once patient has reached 80ml/kg/day of enteral feedings, researchers will add 1 packet (5 ml) of liquid HMF to 50 ml of human or donor breast milk, then increase to 2 packs to 50 ml following the unit feeding protocol and this will be continued up until 48 hours prior to discharge.
2989604|NCT02632253|Active Comparator|Moderate intensity continuous exercise|"Patients perform two weekly supervised MICE session on a cycling ergometer per week plus one self monitored 30-60 min MICE training of choice at home.~MICE is performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down)."
2989605|NCT02632253|Experimental|High intensity interval training|"High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min.~Additionally patients perform one self monitored 30-60 min MICE training of choice per week at home."
2989606|NCT02632240|Active Comparator|Control group|Surgery:The tunnel technique for covering gingival recession. Graft: connective tissue.
2989607|NCT02632240|Active Comparator|Study group|Surgery:The tunnel technique for covering gingival recession.Graft: xenogenic collagen matrix (Mucoderm).
2989608|NCT02632227||Hypovolemia|patients with hypovolemic signs including hypotension, decreased central venous pressure (less than 5mmHg), and decreased urine output
2989609|NCT02632214|Experimental|Deaf|Group of early profound deaf participants fMRI measure
2989610|NCT02632214|Experimental|Hearing signers|Group of hearing signer controls fMRI measure
2989611|NCT02632214|Sham Comparator|Hearing non signers|Group of hearing non signer controls fMRI measure
2989612|NCT02632201|Experimental|PIK-HER2 cells|PIK-HER2 cells treatment will be performed every 3 weeks with a total of three periods.
2989613|NCT02632201|Active Comparator|DC-PMAT|DC-PMAT treatment will be performed every 3 weeks with a total of three periods.
2989614|NCT02632188|Active Comparator|Postoperative routine treatment|Postoperative routine treatment according to the hospitals local routines
2989615|NCT02632188|Experimental|DC-PMAT treatment|On the basis of postoperative routine treatment, patients will receive 3 cycles of dendritic cell-precision multiple antigen T (DC-PMAT) cells treatment.
2989616|NCT02632175|Experimental|Subjects receiving Adalimumab|Subjects receiving Adalimumab up to 288 weeks
2989617|NCT02632162||cardiac surgery|active Group screening
2989618|NCT02632162||orthopedic surgery|control Group screening
2989619|NCT02632149|Experimental|Vagus nerve Stimulation is on|
2989620|NCT02632136|Active Comparator|TAP block group|"This group will receive 30 ml of 0.25% Bupivacine given as Transversus Abdominus Plane Block under direct Laparascopic view. The TAP block will be injected in the angle of Petit above the anterior superior iliac supine.~They will also receive normal saline injections at port sites, which will be injected before the ports are inserted. 15 ml of normal saline will be divided in aliquots of 7, 4 and 4 ml. 7 ml will be injected at sub-umblical port side and 4 ml each at the site of other two ports."
2989621|NCT02632136|Placebo Comparator|Peri-Portal block Group|"They will receive 0.5% Bupivacaine injections at port sites, which will be injected before the ports are inserted. 15 ml of 0.5% Bupivacaine will be divided in aliquots of 7, 4 and 4 ml. 7 ml will be injected at sub-umblical port side and 4 ml each at the site of other two ports.~This group will also receive 30 ml of Normal Saline Injection given as Transversus Abdominus Plane Block under direct Laparascopic view. The TAP block will be injected in the angle of Petit above the anterior superior iliac supine."
2989622|NCT02632123||Idiopathic pulmonary fibrosis|Patients newly diagnosed with idiopathic pulmonary fibrosis
2989623|NCT02632110|Experimental|ALA 25 min 10 Milliwatts (mW)|ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
2989624|NCT02632110|Experimental|MN + ALA 25 min 10 mW|Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
2989625|NCT02632110|Experimental|ALA 25 min 20 mW|ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
2989626|NCT02632110|Experimental|MN + ALA 25 min 20 mW|Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
2989627|NCT02632110|Experimental|ALA 60 min 10 mW|ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
2989628|NCT02632110|Experimental|MN + ALA 60 min 10 mW|Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
2989629|NCT02632110|Experimental|ALA 60 min 20 mW|ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
2989630|NCT02632110|Experimental|MN + ALA 60 min 20 mW|Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
2989631|NCT02632110|Placebo Comparator|VEH|Vehicle (VEH) PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
2989632|NCT02632110|Placebo Comparator|MN + VEH|Microneedle lesion preparation prior to Vehicle PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
2989633|NCT02632097|Experimental|Histoacryl|Intervention: Lichtenstein Hernioplasty with Histoacryl™(cyanoacrylate glue 0.5 ml) for mesh fixation (Optilene™ mesh 60 g/m2 (B. Braun))
2989634|NCT02632097|Experimental|Suture|Intervention: Lichtenstein Hernioplasty with Sutures (polypropylene 2/0) to fix the Optilene™ mesh 60 g/m2 (B. Braun)
2989635|NCT02632071|Active Comparator|80 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
2989636|NCT02632071|Active Comparator|120 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
2989637|NCT02632071|Active Comparator|180 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
2989638|NCT02632071|Active Comparator|240 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
2989639|NCT02632045|Experimental|Ribociclib (LEE-011)/Fulvestrant|LEE-011 is administered orally, 600mg, daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
2989640|NCT02632045|Placebo Comparator|Placebo/Fulvestrant|Placebo is administered orally, 600mg daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
2989641|NCT02632032|Other|Insulin therapy and diabetes education|Children and adolescents living with type 1 diabetes already on insulin therapy received collective diabetes education during a five days camp.
2989642|NCT02632019|Active Comparator|gemcitabine|Gemcitabine treatments will be performed once a week with a total of six times
2989643|NCT02632019|Experimental|Dendritic cell-precision T cell for neo-antigen|Dendritic cell-precision T cell for neo-antigen (DC-PNAT) combined with gemcitabine treatment: Gemcitabine: once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: once per 3 weeks with a total of three periods.
2989644|NCT02632006|Experimental|PIK-PD-1 cells|PIK-PD-1 cells treatment will be performed every 3 weeks with a total of three periods.
2989645|NCT02632006|Active Comparator|DC-PMAT|DC-PMAT cells treatment will be performed every 3 weeks with a total of three periods.
2989646|NCT02631980|Experimental|IV iron|Postoperative iv iron administration (Ferinject) upon arrival in after surgery recovery room
2989647|NCT02631980|Placebo Comparator|IV placebo|Postoperative iv placebo administration upon arrival in after surgery recovery room
2989648|NCT02631967|Experimental|Kono anastomosis|Patients receiving Kono anastomosis
2989649|NCT02631967|Experimental|Stapled side-to-side anastomosis|Patients receiving stapled side-to-side anastomosis
2989650|NCT02631954|Experimental|TR Group|Test drug: Vorico Injection 200mg(Voriconazole) Wash out: 7 days Reference drug: Vfend® IV 200mg
2989651|NCT02631954|Experimental|RT group|Reference drug: Vfend® IV 200mg Wash out: 7 days Test drug: Vorico Injection 200mg(Voriconazole)
2989652|NCT02631941|Experimental|Z7200|single dose (two inhalations)
2989653|NCT02631941|Active Comparator|Symbicort Turbohaler|single dose (two inhalations)
2989654|NCT02631941|Experimental|Z7200 with charcoal|single dose (two inhalations)
2989655|NCT02631941|Active Comparator|Symbicort Turbohaler with charcoal|single dose (two inhalations)
2989656|NCT02631941|Active Comparator|Symbicort Turbohaler replicate|single dose (two inhalations)
2989657|NCT02631928|Experimental|Julphar Insulin 30/70|human biphasic insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/ kg body weight
2989658|NCT02631928|Active Comparator|Huminsulin® Profil III|human biphasic insulin, reference, 100 IU/mL, single subcutaneous injection of 0.6 IU/ kg body weight
2989659|NCT02631902|Experimental|Exercise|Community-based exercise program
2989660|NCT02631902|Experimental|Exercise plus dietary intervention|Community-based exercise and dietary intervention program
2989661|NCT02631902|No Intervention|Control|Habitual physical activity and habitual dietary pattern
2989662|NCT02631889|Experimental|Transcollation technology|the use of transcollation technology for hilium dissection during Lung surgery
2989663|NCT02631889|Active Comparator|Traditional Electrocautery|The use of electrocautery for hilium dissection during lung surgery
2989664|NCT02631876|Experimental|Arm 1|IMGN853 administered at 6 mg/kg AIBW once every three weeks (Q3W)
2989665|NCT02631876|Experimental|Arm 2|Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan
2989666|NCT02631863|Experimental|ALA|Patients will receive 3 topical treatments of aminolaevulinic acid 500mg
2989667|NCT02631863|Placebo Comparator|Placebo|Patients will receive 3 topical treatments of placebo 500mg
2989668|NCT02631850|Active Comparator|Traditional CI Therapy|"Participants will receive a 35-hour dose of CI therapy. Treatment will consist of 35 therapist/client contact hours in the clinic, 10 weekdays, over 3 weeks. To promote carry-over of motor gains to daily activities, participants will complete: (1) a treatment contract, (2) daily self-report of arm use, and (3) problem-solving to overcome barriers to use of the more affected upper extremity. In addition, the client will agree to wear a padded restraint mitt on the less affected hand for the majority of waking hours to encourage use of the weaker hand for daily activities. Finally, the participant will agree to 30 minutes per day of individualized task-practice outside the clinic (in addition to training in the clinic) focused on functional activities catered towards accomplishing the person's therapeutic goals."
2989704|NCT02631616|Experimental|Treatment arm|Monthly injections of Somatostatin (Sandoatatin LAR - 30mg)
2989705|NCT02631603|Experimental|Placebo|Capsules of placebo will be taken for 3 months.
2989805|NCT02630966|Experimental|Group 2: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 10, 14, and 22.
3005531|NCT02526394|Active Comparator|6|Boostrix + Menitorix
2989669|NCT02631850|Active Comparator|Gaming CI Therapy|15 hours of progressive massed motor practice will occur through in-home video game play over 15 consecutive weekdays. Participants will play the game during times of their choosing. The participant will wear an activity monitor biofeedback device for the majority of waking hours. As with traditional CI therapy, the client will agree to an additional 30 minutes per day of individualized task-practice. Five therapist/client contact hours will occur in the clinic on approximate treatment days 1, 3, 6, and 11 and will focus on treatment elements that cannot be readily addressed through the game, such as problem-solving to help the participant carry over motor gains to daily life.
2989670|NCT02631850|Active Comparator|Gaming CI Therapy with Additional Contact via Video Conference|This group will receive treatment that is identical to Group 2, but will receive an additional 4 hours video conference consultation throughout the treatment period.
2989671|NCT02631850|Active Comparator|Traditional Occupational Therapy/Physical Therapy|Five therapist/client contact hours will occur on approximate treatment days 1, 3, 6, and 11 (same schedule as gaming CI therapy). 1 hour progressive resistance exercise to establish and progress an upper extremity home exercise program, 2 hours of neuromuscular reeducation, and 2 hours functional practice on ADLs with verbal encouragement to use the more affected upper extremity to the largest extent possible. Home practice consists of stretching exercises, designed to increase range of motion, prescribed twice daily. After completing their participation in the standard OT condition (6 months), participants will be crossed-over to a CI therapy gaming only condition. This condition will be identical to that described above, excluding therapist contact throughout the intervention. Rather, participants will receive a DVD explaining the intervention and guiding them through use of the system.
2989672|NCT02631837|Experimental|vNOTES hysterectomy|vaginal Natural Orifice Transluminal Endoscopic Surgery
2989673|NCT02631837|Active Comparator|LSC hysterectomy|Laparoscopic hysterectomy
2989674|NCT02631824|Active Comparator|Standard treatment|open reduction and internal fixation TFNA
2989675|NCT02631824|Experimental|Augmentation|open reduction and internal fixation TFNA Augmentation (Cement)
2989676|NCT02631811|Experimental|Supportive /palliative care intervention|patients will be supported by a multidisciplinary palliative specialist team
2989677|NCT02631811|No Intervention|usual medical follow up|patients will be supported by the support care team if asked by the oncologist
2989678|NCT02631798|Experimental|Dye staining|Food grade dye mucosal staining
2989679|NCT02631785|Experimental|Anxious group|Youth diagnosed with anxiety disorder will receive Cognitive Behavioral Therapy for reducing anxiety symptoms.
2989680|NCT02631785|No Intervention|Control group|Healthy youth will be recruited for comparison but their participant in the study will not include intervention.
2989681|NCT02631772|Experimental|Late Cohort, Arm 1|LDV/SOF monotherapy x 12 weeks
2989682|NCT02631772|Active Comparator|Late Cohort, Arm 2|LDV/SOF+ribavirin x 12 weeks
2989683|NCT02631759|Experimental|Lévétiracetam|52 patients will be recruited over 2 years in the experimental group
2989684|NCT02631759|Placebo Comparator|Placebo|52 patients will be recruited over 2 years in the control group
2989685|NCT02631746|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 46 courses in the absence of disease progression or unacceptable toxicity.
2989686|NCT02631733|Experimental|Treatment (liposomal irinotecan, veliparib)|Patients receive liposomal irinotecan IV over 90 minutes on days 1 and 15 and veliparib PO BID on days 5-12 and 19-25 or 3-12 and 17-25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Within 2-6 days prior to beginning liposomal irinotecan treatment, patients may optionally receive FMX IV and undergo MRI at baseline and 24 hours after FMX infusion.
2989687|NCT02631720||Adult Lung Transplant Recipients|Adult lung transplant recipients undergoing lung transplant at each of the participating centers.
2989688|NCT02631707|No Intervention|Control Standard Protein Diet|Control Arm Ministry of Health guidelines percentage energy from carbohydrate (50-55%), protein (10-15%) and fat (30%).
2989689|NCT02631707|Experimental|Intervention High Protein Diet|Intervention Arm Percentage energy from carbohydrate (40%), protein (30%) and fat (30%).
2989690|NCT02631694|Experimental|Fear reactivation with propranolol|
2989691|NCT02631694|Placebo Comparator|Fear reactivation with placebo|
2989692|NCT02631694|Placebo Comparator|No fear reactivation with propranolol|
2989693|NCT02631681|Experimental|Men with prostate cancer on androgen deprivation therapy|Group based supervised combined aerobic and resistance training for 12 weeks.
2989694|NCT02631668|Experimental|ferrous succinate and vitamin C|In this group, the patients received 100mg ferrous succinate and 200mg vitamin C three times per day for 3-4 months
2989695|NCT02631668|Active Comparator|ferrous succinate with normal dosage|In this group, the patients received 100mg ferrous succinate three times per day for 3-4 months
2989696|NCT02631668|Active Comparator|ferrous succinate with double dosage|In this group, the patients received 200mg ferrous succinate three times per day for 3-4 months
2989697|NCT02631655|Other|device 18FDOPA|impact of device 18F-FDOPA PET on treatment decisions
2989698|NCT02631642|Experimental|HMPL-689|Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.
2989699|NCT02631642|Placebo Comparator|HMPL-689 placebo|Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.
2989700|NCT02631629|Placebo Comparator|Non-fortified foods SA|Non-fortified foods (eggs, cheese, yoghurt, crips bread) (placebo), women of South Asian (SA) origin
2989701|NCT02631629|Placebo Comparator|Non-fortified foods CA|Non-fortified foods (eggs, cheese, yoghurt, crips bread) (placebo), women of Caucasian (CA) origin
2989702|NCT02631629|Active Comparator|Vitamin D fortified foods SA|Vitamin D fortified foods (eggs, cheese, yoghurt, crips bread), women of South Asian (SA) origin
2989703|NCT02631629|Active Comparator|Vitamin D fortified foods CA|Vitamin D fortified foods (eggs, cheese, yoghurt, crips bread), women of Caucasian (CA) origin
3005716|NCT02525276|Placebo Comparator|-training + HT|-training + HT
2989706|NCT02631603|Active Comparator|Prednisolone|"Oral prednisolone, anticipated dose:~first month after steroid pulse 0.5 mg/kg bw/d, second month 0.25 mg/kg bw/d, and third month 0.125 mg/kg bw/d in a single morning dose.~Individual capsules will be prepared using rounded dose."
2989707|NCT02631590|Experimental|Combination Therapy|Treatment Plan: Cisplatin (25 mg/m^2 ) + Gemcitabine (1000 mg/m^2) + copanlisib (60 mg) on days 1 and 8 with day 15 off to be administered on an every 21-days schedule.
2989708|NCT02631577|Experimental|Atezolizumab-G-lena|Dose escalation phase: Participants with relapsed or refractory FL will receive obinutuzumab (G) and lenalidomide (lena) during Cycle 1 (28-day cycle) and atezolizumab (MPDL3280A), obinutuzumab, and lenalidomide during Cycles 2-6, during induction treatment, followed by atezolizumab (MPDL3280A; monthly) and obinutuzumab (every other month [q2m]) for 24 months as well as lenalidomide for 12 months, during maintenance treatment. Expansion phase: Participants with previously untreated FL will receive same treatment regimen as described for dose escalation phase.
2989709|NCT02631551|Experimental|GSP 301 NS|
2989710|NCT02631551|Active Comparator|Olopatadine HCl NS|
2989711|NCT02631551|Active Comparator|Mometasone furoate NS|
2989712|NCT02631551|Placebo Comparator|GSP 301 Placebo NS|
2989713|NCT02631538|Placebo Comparator|Placebo|Subjects will receive belimumab placebo weekly subcutaneous injections to Week 52 and rituximab placebo infusions at Weeks 8 and 10.
2989714|NCT02631538|Experimental|Belimumab monotherapy|Subjects will receive 200 mg weekly subcutaneous injections of belimumab to Week 52 and placebo rituximab infusions at Weeks 8 and 10.
2989715|NCT02631538|Experimental|Belimumab and Rituximab co-administration therapy|Subjects will receive belimumab 200 mg SC weekly for 24 weeks followed by weekly placebo belimumab injections to Week 52 with rituximab 1000 mg intravenously at Weeks 8 and 10.
2989716|NCT02631538|Active Comparator|Rituximab monotherapy|Subjects will receive 1000 mg IV rituximab infusions at Weeks 8 and 10 and weekly subcutaneous injections of placebo belimumab to Week 52.
2989717|NCT02631525|Active Comparator|REM-PRO|Total intravenous anesthesia with remifentanil and propofol, target controlled infusion based on Minto's and Marsh's pharmacokinetic models.
2989718|NCT02631525|Active Comparator|REM-DES|Balanced anesthesia with remifentanil target controlled infusion based on Minto's pharmacokinetic model and desflurane.
2989719|NCT02631512|Other|Woulgan Gel|Primary dressing with Woulgan Gel with Soluble Beta-Glucan (SBG)
2989720|NCT02631512|Other|Intrasite Hydrogel|Primary dressing with Intrasite Hydrogel
2989721|NCT02631499|Experimental|Adjuvant TACE|TACE will be performed 4-6 weeks after hepatectomy in patients with preoperative CTC ≥2 Epirubicin, lipiodol and gelatin sponge articles are used in TACE.
2989722|NCT02631499|No Intervention|Control|no interventions were assigned after hepatectomy
2989723|NCT02631486|Experimental|Early|"The first group will use sling for comfort only. Active assisted exercises in closed chain and in safe zone are allowed in the first 4 weeks.~The rehabilitation stages will start from active assisted progressing to more active stages phases until full recovery. The whole program will last about 3 months."
2989724|NCT02631486|Active Comparator|Conservative|The second group will use a sling for 6 weeks. The rehabilitation stages will start with active assisted/closed chain movements with short levers, it will progress to more active stages phases until full recovery. The whole program will last about 3 months.
2989725|NCT02631473|Active Comparator|1st Stage-Group A|"Day 1: 50 mg NANO-efavirenz single dose~Days 4-21: 50 mg NANO-efavirenz OD (once daily)"
2989726|NCT02631473|Active Comparator|1st Stage-Group B|"Days 1-7: 400mg NANO-lopinavir BID (twice daily)~Days 8-21: Wash-out period~Days: 22-28: 200mg NANO-lopinavir BID plus 100mg Ritonavir (Norvir) BID"
2989727|NCT02631473|Active Comparator|2nd Stage-Group A-Group 1-Dose level 1|"21 Days: 300mg NANO-efavirenz OD~4 weeks: Wash-out period~21 days: 600mg Sustiva OD"
2989728|NCT02631473|Active Comparator|2nd Stage-Group A-Group 2-Dose level 2|"21 Days: 200mg NANO-efavirenz OD~4 weeks: Wash-out period~21 days: 400mg Sustiva OD"
2989729|NCT02631473|Active Comparator|2nd Stage-Group B-Arm 1|"7 days: Kaletra® (lopinavir400mg/ritonavir100mg) BD~2 weeks: Wash-out period~7 days: NANO-lopinavir (200mg +/- ritonavir®)"
2989730|NCT02631473|Active Comparator|2nd Stage-Group B-Arm 2|"7 days: NANO-lopinavir (200mg +/- ritonavir Norvir)~2 weeks: Wash-out period~7 days: Kaletra® (lopinavir400mg/ritonavir100mg) BD"
2989731|NCT02631460|Experimental|S1 and Carboplatin|S1 80-120 mg/d+Carboplatin AUC=5 Patients without progression received maintenance until disease progression with S1
2989732|NCT02631460|Active Comparator|pemetrexed and Carboplatin|pemetrexed 500 mg/m2+ Carboplatin AUC=5 Patients without progression received maintenance until disease progression with pemetrexed
2989733|NCT02631447|Experimental|Arm A: Combo Target/Combo Immuno|Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD; then Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD
2989734|NCT02631447|Experimental|Arm B: Como immuno/Combo Target|Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD; then Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD
2989735|NCT02631447|Experimental|Arm C: Sandwich|Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) for 8 weeks followed by Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD; then Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD
2989736|NCT02631434|Experimental|sit-to-stand|To perform a sit-to-stand test
2989737|NCT02631434|Active Comparator|six minute walking test|To perform a six minutes walking test
2989738|NCT02631421||Pulmonary Arterial Hypertension|Clinical diagnosis of pulmonary arterial hypertension
2989739|NCT02631421||Healthy subjects and patients with other causes of PH|Patients referred for right heart catheterization who do not have PAH
2989740|NCT02631408|No Intervention|Control Group|No additional treatment. Routine iv. antibiotic prophylaxis only.
2989741|NCT02631408|Experimental|Vancomycin Group|Vancomycin powder is applied before wound closure. Routine iv. prophylaxis stays unchanged
2989804|NCT02630966|Experimental|Group 1: Vedolizumab IV 300 mg + Placebo|Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 14, and 22, and vedolizumab placebo-matching, IV, once, at Week 10.
2989742|NCT02631395|Other|Training group|Six teams, consisting of 13 to 25 players each, were randomized into two groups throughout their competition season; the training Group (intervention Group) and the Control Group.The intervention group completed strength training exercises Three times a week the Whole competition season.
2989743|NCT02631395|Other|Control group|The three teams in the Control Group trained as normal throughout the season and participated in a comparable handball training program, but did not conduct any specific upper--body strength training
2989744|NCT02631382|Experimental|wet cupping : double cupping|wet cupping: (traditional cupping technique): cupping (suction) - Scarification - cupping (suction)
2989745|NCT02631382|Experimental|wet cupping: single cupping|wet cupping:(Asian cupping): Puncture by needles then cupping (suction):
2989746|NCT02631369|Experimental|inter- & intrarater reliability study|pre-study: inter- and intrarater reliability study in 30 healthy subjects, interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
2989747|NCT02631369|Experimental|cyclotorsion in forth nerve palsy|measurement of cyclotorsion on SLO-fundusphoto in 20 patients forth nerve palsy interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
2989748|NCT02631369|Experimental|cyclotorsion in healthy subjects|measurement of cyclotorsion on SLO-fundusphoto in 30 healthy subjects to be compared to patients with forth nerve palsy interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
2989749|NCT02631356|Placebo Comparator|Ringer's lactate solution|Infusion of Ringer's lactate solution (10ml/kg) in the control group
2989750|NCT02631356|Active Comparator|Succinylated gelatin|Infusion of Succinylated gelatin (10ml/kg) in the test group
2989751|NCT02631343|Experimental|Intervention KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
2989752|NCT02631343|Other|Control|Routine visits by government health workers
2989753|NCT02631330|Experimental|Falls prevention group|"Intervention group that will receive a monthly talk (individual or collective) of 30 minutes on the advantages of having a free fall hazards environment and multiple physical exercise component: balance,muscle strength and aerobic capacity and risk polypharmacy and abuse of drugs, especially benzodiazepines). In the same monthly meeting, subjects will be train Multicomponent physical activity program during 60 minutes. 15 minutes of gait and balance training; 15 minutes of endurance training; 30 minutes of aerobic training according Training Intervention in a Controlled Population of Frail Elderly (EMTIFE) study NCT02331459"
2989754|NCT02631330|No Intervention|Control group|Subjects will receive the same information provided at the beginning to Falls prevention group. They will not receive further information during the follow-up period.
2989755|NCT02631317||rt-PA|patients treated with rt-PA, followed strategies were used: advance hospital notification by EMS, stroke team notification, key performance indicators feedback form, standard informed consent procedures, performance of thrombolysis at CT-room.
2989756|NCT02631304||Patients undergoing cardiac surgery|Elderly patients scheduled to undergo elective cardiac surgery (coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery) with the use of cardiopulmonary bypass.
2989757|NCT02631291|Experimental|Lifestyle|Behavioral self-monitoring of daily physical activity, dietary, and sleep behaviors, for 12 weeks, into an electronic tablet.
2989758|NCT02631291|No Intervention|Usual Care|Participants randomized to this condition will receive the written education provided to all participants.
2989759|NCT02631291|Experimental|LIfestyle + coaching|Behavioral self-monitoring of daily physical activity, dietary, and sleep behaviors, for 12 weeks, into an electronic tablet; and behavioral self-monitoring + motivational interviewing lifestyle coaching.
2989760|NCT02631278|Other|single arm|Intraoperative radiofrequency ablation
2989761|NCT02631265|Active Comparator|Reduction of insulin basal rate at the time of exercise|
2989762|NCT02631265|Active Comparator|Reduction of insulin basal rate 20 minutes prior to exercise|
2989763|NCT02631265|Active Comparator|Reduction of insulin basal rate 40 minutes prior to exercise|
2989764|NCT02631252|Experimental|Open-label, Single-arm|"Hydroxychloroquine + Mitoxantrone + Etoposide~Hydroxychloroquine is given up to 21 days, started concurrently with both Mitoxantrone, administered by IVPB over 15 minutes each day for 5 days and Etoposide, administered intravenously over 2 hours each day for 5 days"
2989765|NCT02631239|Active Comparator|MESA|Methotrexate, etoposide, dexamethasone, Peg-asparaginase and sandwiched radiotherapy
2989766|NCT02631239|Experimental|ESA|Etoposide, dexamethasone, Peg-asparaginase and sandwiched radiotherapy
2989767|NCT02631226||Pregnant women colonized by resistant enterobacteria|
2989768|NCT02631200|Experimental|Advance care plan|Participants will be offered the opportunity to complete an advance care plan.
2989769|NCT02631200|No Intervention|Usual care|Participants will be offered usual care for 12 weeks (and only then be offered the opportunity to complete an advance care plan).
2989770|NCT02631187|Experimental|Balloon Eustachian Tuboplasty|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
2989771|NCT02631174|No Intervention|cohort 1|Cohort 1 (Aim 1) - 6 participants Cohort 1 will be comprised of 6 neonates (≤28 days of age) admitted to the CICU or NICU who are neither undergoing ECMO nor CPB. Cohort 1 will receive a single dose of ATIII by short 15 minute infusion.
2989772|NCT02631174|Active Comparator|cohort 2.1|"• Cohort 2.1 - 6 neonates undergoing ECMO.~Three participants will receive a single dose 15 minute infusion of hpATIII that is dose adjusted to account for additional circuit volume followed by a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume~Three participants will receive a single dose 15 minute infusion of hpATIII that is not dose adjusted to account for circuit volume followed by a single dose 15 minute infusion of hpATIII that is dose adjusted to account for additional circuit volume"
2989773|NCT02631174|Active Comparator|cohort 2.2|"• Cohort 2.2 - 12 neonates who will undergo open-heart surgery with CPB~Six participants will receive a single dose 15 minute infusion of ATIII that is dose adjusted to account for additional circuit volume.~Six participants will receive a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume"
2989774|NCT02631174|Active Comparator|cohort 2.3|"• Cohort 2.3 - 12 infants who will undergo open-heart surgery with CPB~Six participants will receive a single dose 15 minute infusion of ATIII that is dose adjusted to account for additional circuit volume.~Six participants will receive a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume"
2989775|NCT02631174|Active Comparator|cohort 3|Cohort 3 (Aim 3) - 6 participants Six participants (neonates or infants) who will undergo ECMO and receive ATIII as standard of care will be enrolled and have a baseline ATIII level measured within 6 hours of ATIII administration and repeated within 15 minutes of initiation of extracorporeal support. If post-support level is < 80% normal activity then an ATIII level will be repeated and participants will be assigned to one of two hpATIII dosing regimens in which one formula accounts for additional circuit volume and one formula does not account for additional circuit volume, as described in section 7.4. Upon completion and 120 hr follow up after the first dose, participants still having ATIII activity less than 80% will then receive a second dose
2989776|NCT02631161|Experimental|EQUIA forte|Dental non-carious cervical restorations are being restored with a glass hybrid restorative system (Medical product: EQUIA forte).
2989777|NCT02631161|Active Comparator|Filtek Supreme XT/Clearfil SE Bond|Dental non-carious cervical restorations are being restored with a composite resin based material/Adhesive combination (Medical product: Filtek Supreme XT/Clearfil SE Bond).
2989778|NCT02631148|Experimental|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 6 weeks
2989779|NCT02631148|Placebo Comparator|Placebo|Placebo tablet identical to Circadin by mouth each day before bedtime for 6 weeks
2989780|NCT02631135|Placebo Comparator|Group 1 (TIVA)|Only propofol (started as firstly 12 mg. kg-1 for the 30 minutes, the second 30 minutes 9 mg. kg-1) and remifentanil infusion (0.5 μg.kg-1)
2989781|NCT02631135|Active Comparator|Group 2 (TIVA+D)|Propofol started as firstly 12 mg. kg-1 for the 30 minutes, the second 30 minutes 9 mg. kg-1) and remifentanil infusion (0.5 μg.kg-1),and also dexmedetomidine infusion (started as 0.5 μg.kg-1 without making the loading dose and the dose change was not made during the operation)
2989782|NCT02631122|Active Comparator|Supraclavicular BPNB|Patients in this group will be randomized to receive an Ultrasound Guided Supraclavicular Brachial Plexus Nerve Block and outcomes will be measured over the perioperative and 1day time period.
2989783|NCT02631122|Active Comparator|Retroclavicular BNPB|Patients in this group will be randomized to receive an Ultrasound Guided Retroclavicular Brachial Plexus Nerve Block and outcomes will be measured over the perioperative and 1day time period.
2989784|NCT02631109|Experimental|L-DEP|Pegaspargase 2000U/m2 day5; doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered once on the first day of every week; methylprednisolone 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
2989785|NCT02631096|Experimental|0.2 mg/kg ARB-001467 or Placebo|HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.2 mg/kg versus placebo once a month for 3 months
2989786|NCT02631096|Experimental|0.4 mg/kg ARB-001467 or Placebo|HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
2989787|NCT02631096|Experimental|ARB-001467 or Placebo|HBeAg-positive subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
2989788|NCT02631096|Experimental|0.4 mg/kg ARB-001467|HBeAg-negative subjects receive ARB-001467 at. 0.4 mg/kg (open label) bi-weekly for 5 treatments and then subjects with HBsAg ≤1000 IU/mL AND ≥1.0 log10 decrease from baseline at Day 71 will continue monthly dosing through 48 weeks
2989789|NCT02631083|Experimental|Breakfast, lunch, snack and dinner (high GI)|Subjects will consume meals which are high glycemic index for breakfast (Honey stars cereal), lunch (glutinous rice meal) and snack (white bread and jam) in the whole body calorimeter. A take-away high glycemic index dinner will be provided.
2989790|NCT02631083|Experimental|Breakfast, lunch, snack and dinner (low GI)|Subjects will consume meals which are low glycemic index for breakfast (All bran cereal), lunch (basmati rice meal) and snack (multigrain bread and sugar-free jam) in the whole body calorimeter. A take-away low glycemic index dinner will be provided.
2989791|NCT02631070|Experimental|Experimental Arm - Luspatercept (ACE-536)|Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks
2989792|NCT02631070|Placebo Comparator|Control Arm: Placebo|Subcutaneous injection every 3 weeks
2989793|NCT02631057||Non-Valvular Atrial Fibrillation|
2989794|NCT02631057||acute ischemic stroke|
2989795|NCT02631044|Experimental|JCAR017 1-dose schedule|Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 1 intravenous (IV) injection
2989796|NCT02631044|Experimental|JCAR017 2-dose schedule|Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 2 intravenous (IV) injections
2989797|NCT02631031|Other|morning administration|administration of single oral dose valsartan (160 mg) in the morning
2989798|NCT02631031|Other|evening administration|administration of single oral dose valsartan (160 mg) in the evening
2989799|NCT02631018|Experimental|Physical Activity Enhanced Weight Loss Intervention|Participants will engage in 18 weight loss intervention group sessions over 6 months. Sessions will occur weekly for the first 3 months, and biweekly for the latter 3 months. Participants will receive a behavioral weight loss curriculum, calorie and physical activity recommendations. This arm, uniquely, will receive a culturally based physical activity component.
2989800|NCT02631018|Active Comparator|Standard Weight Loss Intervention|Participants will engage in 18 weight loss intervention group sessions over 6 months. Sessions will occur weekly for the first 3 months, and biweekly for the latter 3 months. Participants will receive a behavioral weight loss curriculum, calorie and physical activity recommendations.
2989801|NCT02631005|Experimental|Walk With Ease Participants|"Participants will receive a copy of the Walk With Ease workbook. This workbook provides guidance on walking safety and on how to start and maintain a regular walking program. It is designed to help participants increase their physical activity over a six-week period. Participants will complete self-reported outcomes questionnaires before and after completion of the program."
2989802|NCT02630992|Experimental|amoxicillin-clavulanate potassium|amoxicillin-clavulanate potassium (600 mg/221.5 mg/5 mL; 28:1) administered prior to February 25, 2016 at 90/3.2 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 1) or administered as of February 25, 2016 at 80/2.85 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 2)
2989803|NCT02630979||No treatment|Clinical and medical oncology physicians.
2989806|NCT02630953|Active Comparator|Original Tailored Intervention|This existing empirically supported Spanish-language PA intervention, which is based on Social Cognitive Theory and the Transtheoretical Model (TTM), emphasizes behavioral strategies for increasing PA levels (goal-setting, self-monitoring, problem-solving barriers, increasing social support, self-rewards for meeting PA goals).
2989807|NCT02630953|Experimental|Enhanced Tailored Intervention|We designed the Enhanced Tailored Intervention to build upon our previous research in order to outperform the original tailored intervention, in a cost effective, theoretically guided and data driven manner with potential for dissemination. Participants in the Enhanced Tailored Intervention will receive an interactive technology based intervention that: 1) addresses important SCT constructs for increasing PA that were not significantly changed in the original parent trial (enjoyment/outcome expectations and social support) and 2) provides greater accountability and interactivity for self-monitoring (through text messages), as requested by participants in the original parent trial.
2989808|NCT02630940||Idiopathic pulmonary fibrosis sufferers|Male or female idiopathic pulmonary fibrosis (IPF) sufferers over the age of 40, with a confirmed diagnosis of IPF against international guidelines. Patients are devoid of significant other medical, surgical or psychiatric illnesses that may affect respiratory symptoms or disease progression.
2989809|NCT02630927|Placebo Comparator|Part 1 Single-Ascending (SAD Phase)|A range of doses of AG519 will be tested based on the assessment of safety and tolerability. A single dose of AG-519 will be administered by mouth (orally).
2989810|NCT02630927|Placebo Comparator|Part 2 Multiple-Ascending (MAD Phase)|A range of doses of AG519 will be tested based on the assessment of safety and tolerability. AG519 will be administered by mouth (orally) each day for a period up to 14 days.
2989811|NCT02630927|Experimental|Part 3 Bioavailability & Food Effect|The dose to be assessed in Part 3 will be selected based on emerging safety, tolerability and PK/PD data from preceding cohorts in Part 1 and Part 2, which will be reviewed during a dose decision meeting.
2989812|NCT02630927|Experimental|Experimental Part 4 (Subjects of Japanese Origin)|Two dose levels of AG-519 will be tested based on the assessment of safety and tolerability in preceding cohorts in Part 1, Part 2, and Part 3
2989813|NCT02630927|Experimental|Experimental Part 5 Open-label Multiple-Ascending (MAD)|Up to two dose levels of AG-519 will be tested based on the assessment of safety and tolerability in preceding cohorts in Part 1, Part 2, and Part 3. AG519 will be administered by mouth (orally) each day for a period up to 14 days.
2989814|NCT02630914|Experimental|Intervention|All patients will have the hybrid procedure of ablation of atrial fibrillation.
2989815|NCT02630901|Experimental|PRX003|
2989816|NCT02630901|Placebo Comparator|Placebo|
2989817|NCT02630888|Active Comparator|Memantine|Patients randomized to this group will receive a dose of 15 mg / day of memantine during the first week (V0); all have the dose of memantine increased on the second week (V1) at the dose of 30 mg / day (in two divided doses of 15 mg).
2989818|NCT02630888|Placebo Comparator|Placebo|Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine.
2989819|NCT02630875|Active Comparator|A4250 1|Dose I
2989820|NCT02630875|Active Comparator|A4250 2|Dose 2
2989821|NCT02630875|Active Comparator|A4250 3|Dose 3
2989822|NCT02630875|Active Comparator|A4250 4|Dose 4
2989823|NCT02630875|Active Comparator|A4250 5|Dose 5
2989824|NCT02630875|Active Comparator|A4250 6|Dose 6
2989825|NCT02630862|Active Comparator|aspirin|acetylsalcylic acid 100 mg per day give orally for six months, starting the day of carotid endoartherectomy
2989826|NCT02630862|Active Comparator|aspirin plus dipyridamole|acetylsalicylic acid 25 mg plus dipyridamole extended release 200 mg, combined in a capsule, per day starting the day of carotid endoartherectomy
2989827|NCT02630849|Experimental|IMF group|intercostal muscle flap and pericostal no-compression suture of the intercostal space
2989828|NCT02630849|Active Comparator|IINB group|Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
2989829|NCT02630836|Experimental|XCEL-MT-OSTEO-BETA|Adult ex-vivo expanded mesenchymal stromal cells from allogeneic bone marrow, cryopreserved, to combine with fibrin glue and cancellous human bone tissue + endomedullary nailing
2989830|NCT02630836|Other|Standard treatment|Standard surgical treatment with isolated endomedullary nailing
2989831|NCT02630823|Experimental|Arm 1: MK-3475|"Patients will undergo endometrial biopsy followed by 2 doses of MK-3475 3 weeks apart. 3-4 weeks after the second dose of MK-3475, the standard of care surgical resection will take place, followed by standard of care adjuvant therapy. Tissue and blood will be collected at the time of surgical resection for immune analysis. For patients whose pathology confirms high-risk features and advanced stage, MK-3475 will be given every 3 weeks starting 4 -6 weeks after completion of adjuvant therapy for a maximum of 4 doses post-surgery.~MK-3475 will be given intravenously at a dose of 200 mg over the course of 30 minutes.~The standard of care chemotherapy will consist of 6 cycles of paclitaxel and carboplatin AUC 5 every 3 weeks for 6 cycles.~The decision to administer radiation therapy will be per the treating physician. If the patient does not receive radiation therapy, then the patient will start MK-3475 every 3 weeks x 4 doses after the completion of chemotherapy."
2989832|NCT02630810|Experimental|Early oral hydration|Early oral intake of 100 ml clear unsweetened water 1 hour following the Cesarean Section, then upon patient's desire, then starting semisolid, solid food when participant passed flatus.
2989833|NCT02630810|Active Comparator|Delayed oral hydration|Oral intake of 100 ml clear unsweetened water after 6 hours from the end of CS then upon patient's request,then starting semisolid, solid food when participant passed flatus.
2989834|NCT02630797|Placebo Comparator|Blueberry baseline|No blueberry products provided as part of the usual dietary intake
2989835|NCT02630797|Active Comparator|Blueberry Low|One blueberry product per day containing an equivalent of 0.75 cups of fresh blueberries provided as part of usual dietary intake for 42 days
2989836|NCT02630797|Active Comparator|Blueberry Medium|Two blueberry products per day containing an equivalent of 1.5 cups of fresh blueberries provided as part of usual dietary intake for 42 days
2989950|NCT02630134|Experimental|Baeta|These patients receive the Baeta device and take it home.
2989837|NCT02630797|Active Comparator|Blueberry High|Four blueberry products per day containing an equivalent of 3 cups of fresh blueberries provided as part of usual dietary intake for 42 days
2989838|NCT02630784|Experimental|Homecare ventilator|NIV with a dedicated ventilator for homecare, functioning with a turbine and with vented mask (exhalation by a calibrated leak)
2989839|NCT02630784|Active Comparator|ICU ventilator|NIV with a dedicated ICU ventilator, functioning with non-vented masks and an exhalation valve.
2989840|NCT02630771||PDAP only|Persistent dentoalveolar pain disorder patients who do not fit criteria for TMD. Pressure pain threshold before/during conditioned pain modulation.
2989841|NCT02630771||PDAP + TMD|Persistent dentoalveolar pain disorder patients who also fit criteria for TMD. Pressure pain threshold before/during conditioned pain modulation.
2989842|NCT02630771||Painfree controls|Painfree subjects. Pressure pain threshold before/during conditioned pain modulation.
2989843|NCT02630758|Experimental|Mindfulness-based Yoga|"Participants in the 12-week mindfulness-based yoga condition were guided by a gentle yoga DVD that included postures (asanas), pranayama (breathing exercises), and relaxation (meditation). Participants were asked to complete 60-75 minutes of the DVD twice per week and were encouraged to do more if they were interested.~Following the initial baseline assessment and randomization telephone interview, participants in the yoga group completed weekly 15-minute telephone sessions for the first month and bi-weekly telephone sessions for the second and third for a total of eight sessions over the 12 weeks. The mindfulness telephone sessions were modified from the Mindfulness-Based Stress Reduction."
2989844|NCT02630758|Active Comparator|Walking Control Group|"The 12-week walking control condition included twice-weekly home practice with a 65-minute walking DVD (Sansone, 2008) and eight telephone sessions with the telephone counselor.~Participants were asked to complete 60 minutes of the DVD (or other walking) twice weekly and encouraged to do more if they were interested.~Participants received telephone sessions on the same schedule as the yoga condition. The education sessions covered a variety of health and wellness related topics."
2989845|NCT02630745|Active Comparator|Immediate periodontal surgery (Group 1)|periodontal surgical procedure in the form of open flap debridement will be performed immediately( in which after debridement mucoperiosteal flaps will be repositioned and secured by using 3-0 non-absorbable black silk surgical suture) after obturation of the root canal system( using calcium hydroxide intracanal medicament placed with the help of 27 gauge endodontic syringe for 10 days and access cavity will be sealed with suitable sealer).
2989846|NCT02630745|Active Comparator|Delayed periodontal surgery (Group 2)|periodontal surgical procedure in the form of open flap debridement( in which after debridement mucoperiosteal flaps will be repositioned and secured by using 3-0 non-absorbable black silk surgical suture) will be performed 3 months after obturation of the root canal system ( using calcium hydroxide intracanal medicament placed with the help of 27 gauge endodontic syringe for 10 days and access cavity will be sealed with suitable sealer).
2989847|NCT02630732|Active Comparator|Brain School|Pain Neuroscience Education Program
2989848|NCT02630732|Active Comparator|Back School|Classical Back School
2989849|NCT02630719|Experimental|timolol eye drops|Treatment with timolol eye drops at the onset of an acute migraine headache
2989850|NCT02630719|Placebo Comparator|Placebo eye drop|Treatment with artificial eye drops at the onset of an acute migraine headache
2989851|NCT02630706|Experimental|Ertugliglozin 5 mg|Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks.
2989852|NCT02630706|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg administered orally once daily for 26 weeks.
2989853|NCT02630706|Placebo Comparator|Placebo|Placebo matching ertugliflozin administered orally once daily for 26 weeks.
2989854|NCT02630693|Active Comparator|Palbociclib (100mg)|Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
2989855|NCT02630693|Active Comparator|Palbociclib (125mg)|Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
2989856|NCT02630680||Colorectal diseases patients|
2989857|NCT02630667|Experimental|SLOW Carbohydrate|Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response.
2989858|NCT02630667|Experimental|MEDIUM Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response.
2989859|NCT02630667|Experimental|FAST Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response.
2989860|NCT02630667|Placebo Comparator|Non-Caloric Placebo|Non-caloric placebo consisting of artificial sweeteners
2989861|NCT02630654||GEP NETs|Patients with a suspected diagnosis of metastatic GEP NETs
2989862|NCT02630654||Healthy controls|Healthy controls matched by age and gender.
2989863|NCT02630641||Prostate cancer patients|
2989864|NCT02630628|Experimental|Tacrolimus|route: oral duration: 96 weeks
2989865|NCT02630628|Active Comparator|Mycophenolate Mofetil|route: oral duration: 96 weeks
2989866|NCT02630615||Cohort A (one-time blood sample)|"Blood samples will be collected from eligible patients only once at baseline. These samples will be immediately processed for CTCs and CTC derived xenografts.~For Cohorts A & B: Patients can participate in both cohorts simultaneously, or only one cohort per patient preference."
2989867|NCT02630615||Cohort B (multiple blood samples)|Blood samples will be collected from eligible patients at baseline just prior to initiation of therapy. Samples will also be collected on day 1 of every cycle of therapy for 4 cycles (typical cycles are 21 days for chemotherapy, 28 days for targeted therapy and 14 days for immune therapy). At the time of initiation of the treatment break, blood samples will be collected. During the treatment break, patients will be followed every 6-12 weeks with imaging studies, and we will collect blood samples at each visit. At the time of disease progression in the event patient goes on best supportive care, the last blood draw will be at the time of this decision as there will unlikely be any further imaging studies going forward. If a patient is found to have disease progression while on active therapy, the next blood draw will be on the first day of the next therapy and time point of subsequent blood draws will depend on the type of therapy the patient receives.
2989868|NCT02630615||Cohort C (healthy volunteers)|Blood samples will be collected from eligible health volunteers only once. These samples will be used to test the CTC chip system. Two tubes of peripheral blood will be collected and taken to the PI's lab for processing.
2989869|NCT02630602|Active Comparator|Functional goat cheese|The functional cheese is rich in conjugated linoleic acid (CLA) and omega-3. It was used for obese and overweight people, who need a special diet advice to control of lipid profile. 9,3% of polyunsaturated fatty acids 60 g per day during 12 weeks
2989870|NCT02630602|Placebo Comparator|Control cheese|Control cheese, not enriched with conjugated linoleic acid (CLA) and omega-3 4.1% of polyunsaturated fatty acids. 60 g per day during 12 weeks
2989871|NCT02630589|Experimental|ABI implantation|All 10 patients included in the study will be neurosurgically implanted with the ABI. This is open label, not blinded. The implant is permanent, but can be switched off.
2989872|NCT02630576|Experimental|Men - Left Hand|5 healthy male volunteers undergoing 4 types of neuromuscular stimulation protocols on the left hand
2989873|NCT02630576|Experimental|Men - Right Hand|5 healthy male volunteers undergoing 4 types of neuromuscular stimulation protocols on the right hand
2989874|NCT02630576|Experimental|Women - Left Hand|5 healthy female volunteers undergoing 4 types of neuromuscular stimulation protocols on the left hand
2989875|NCT02630576|Experimental|Women - Right Hand|5 healthy female volunteers undergoing 4 types of neuromuscular stimulation protocols on the right hand
2989876|NCT02630563|Experimental|Mycophenolate Mofetil+Corticosteroids+Cyclosporine|Part 1: Participants will receive mycophenolate mofetil. Part 2: Participants will receive mycophenolate mofetil along with cyclosporine and corticosteroids.
2989877|NCT02630550||Aortic Aneurysm Repair|The impact of large abdominal retractors and an abdominal aortic cross-clamp on the validity of the Cheetah NICOM's measurements will be evaluated in this group.
2989878|NCT02630550||Femoral Endarterectomy|The impact of the clamping of a large peripheral arterial vessel on the validity of the Cheetah NICOM's measurements will be evaluated in this group.
2989879|NCT02630524|Experimental|Low Carbohydrate Diet|
2989880|NCT02630524|Active Comparator|Standard Diet|
2989881|NCT02630511|Experimental|Mannitol - rest|Bronchial challenge following rest
2989882|NCT02630511|Experimental|Methacholine - rest|Bronchial challenge following rest
2989883|NCT02630511|Experimental|Placebo - rest|Bronchial challenge (placebo) following rest
2989884|NCT02630511|Experimental|Mannitol - exercise|Bronchial challenge following exercise
2989885|NCT02630511|Experimental|Placebo - exercise|Bronchial challenge (placebo) following exercise
2989886|NCT02630498|Experimental|study (first group)|The first group will include those who receive a single shot brachial plexus block with or without general anesthesia.
2989887|NCT02630498|No Intervention|Controlled (second group)|The second group will be the control group and include those patients who receive general anesthesia only, without any block whether due to the preference of patient or the surgeon.
2989888|NCT02630485|Experimental|Graceful Lifestyle Changes & MYO|"The 12-week lifestyle intervention will incorporate three lifestyle changes: a low-glycemic diet, increased exercise, and stress reduction through meditation and mindfulness.~In addition, this group will take myo-inositol (6 grams in juice or water every morning)."
2989889|NCT02630485|Experimental|Graceful Lifestyle Changes|"The 12-week lifestyle intervention will incorporate three lifestyle changes: a low-glycemic diet, increased exercise, and stress reduction through meditation and mindfulness.~In addition, this group will take a white powder placebo (6 grams in juice or water every morning)."
2989890|NCT02630485|Placebo Comparator|Letrozole & MYO|"The women assigned to the fertility medication group will be prescribed letrozole. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.~In addition, this group will take myo-inositol (6 grams in juice or water every morning)."
2989891|NCT02630485|Placebo Comparator|Letrozole|"The women assigned to the fertility medication group will be prescribed letrozole. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.~In addition, this group will take a white powder placebo (6 grams in juice or water every morning)."
2989892|NCT02630472|Experimental|Quinine Sulfate|"Each study participant randomized into the experimental arm will receive 28 tubes with 1mg/ml (6 mls total) of quinine sulfate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be supplied in light-protected tubes. Patients will apply 3 mls of quinine sulfate to each nostril twice per day. Thus the patients will be exposed to a maximum of 12mls or 12.0 mg of quinine per day.~The Investigational Drug Service (IDS) will prepare and record the distribution of the irrigant. The Clinical Research Coordinator or Clinical Research Nurse will pick up the solutions and will demonstrate the application to the subject. The application of the solution is exactly the same as if the study subject were to irrigate with regular saline as part of their daily regimen for chronic rhinosinusitis."
2989893|NCT02630472|Placebo Comparator|Placebo|"The placebo arm will be spiked with Sucrose Octaacetate which has a bitter taste, but does not stimulate sinonasal nitric oxide production.~Each study participant will receive 28 tubes with 0.5mg/ml sucrose octaacetate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be supplied in light-protected tubes.~The placebo arm will mirror the experimental arm exactly, except for the treatment solution contained in the vials."
2989894|NCT02630459|Experimental|AMG 334 Dose Level 1|Lowest dose of Active AMG 334 investigational product.
2989895|NCT02630459|Placebo Comparator|Placebo|AMG 334 Placebo Comparator
2989896|NCT02630459|Experimental|AMG 334 Dose Level 2|Middle dose of Active AMG 334 investigational product.
2989897|NCT02630459|Experimental|AMG 334 Dose Level 3|Highest dose of Active AMG 334 investigational product.
2989925|NCT02630303|Experimental|LED-RL Phototherapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to LED-RL phototherapy and two subjects randomized to mock therapy).~After either a maximally tolerated dose (MTD) has been established, or the study endpoint of 640 J/cm2 has been achieved, an additional 27 LED-RL phototherapy subjects (for a total of 30) and 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
2989898|NCT02630446|Experimental|in-home respite care program|During the respite care period, lasting at least five days, a trained or experienced care worker for persons with dementia takes over all caregiving tasks while the informal caregiver is absent. The care worker thus temporary moves into the house of the person with dementia. The care worker also writes down his/her observations in a diary as well as daily experiences and strategies on how to manage the difficult behaviors the caregivers listed before. So additionally to the provision of respite, this program also includes caregiver support and psycho-education. This support enables the caregiver to validate theirs perceptions, to learn how to deal with difficult behaviors and to feel understood by somebody.
2989899|NCT02630446|No Intervention|standard dementia care|Control group receiving all types of standard dementia care except in-home respite care of the Baluchon type.
2989900|NCT02630433|Experimental|Index cholecystectomy|Cholecystectomy within 48 hours after inclusion.
2989901|NCT02630433|Active Comparator|Scheduled cholecystectomy|Cholecystectomy 6 weeks after inclusion.
2989902|NCT02630420|Experimental|cetuximab and savolitinib|Following assessment in Part 1 of dose-limiting toxicity and maximum tolerated dose, this drug combination will be administered in Part 2 of the study to assess safety, tolerability, response rate, and progression-free survival.
2989903|NCT02630407|Experimental|Hyaluronic acid group|Single injection of 3 ml HA (product name: Hymovis, Fidia Spa, Padova, Italy) the day after ACL reconstruction (after drainage removal)
2989904|NCT02630407|Placebo Comparator|Placebo group|Single injection of 3 ml saline solution the day after ACL reconstruction (after drainage removal)
2989905|NCT02630394|Experimental|Azithromycin prophylaxis|Azithromycin will be supplied as a 250-mg tablet. Participants weighing less than 40 mg will be instructed to take 1 tablet 3 days a week (Monday, Wednesday, and Friday), and participants who weigh more than 40 kg will be instructed to take 2 tablets on the same 3 days per week.
2989906|NCT02630381|Experimental|Shock wave arm|Unfocused extracorporeal shock wave therapy will be applied on the distal radius on one site when the patient is receiving general anaesthesia for surgery on the lower extremity or spine.
2989907|NCT02630381|No Intervention|Contra-lateral arm|The distal radius and/or wrist that did not receive UESWT will not be treated
2989908|NCT02630368|Experimental|Experimental phase I dose escalating|"Prospective open-labeled phase I trial.~Combination of cyclophosphamide and JX-594 dose escalation. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 14"
2989909|NCT02630368|Experimental|Experimental group soft-tissue sarcoma|"Randomized non comparative phase II clinical trial : Arm 1.~Experimental phase II soft-tissue sarcoma :~Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 48"
2989910|NCT02630368|Experimental|Control group soft-tissue sarcoma|"Randomized non comparative phase II clinical trial : Arm 2.~Control-arm phase II soft-tissue sarcoma :~Patients will be treated by metronomic cyclophosphamide. Cyclophosphamide will be administered 50 mg twice daily orally, one week on/one week off. One cycle consits of 28 days.~Number of subjects : 24"
2989911|NCT02630368|Experimental|Experimental group breast cancer|"Single-arm phase II clinical trial.~Experimental phase II Group breast cancer :~Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 32"
2989912|NCT02630355|Sham Comparator|Control|Inflation of blood pressure cuff in lower limb to 40mmHg for four cycles of 5 minutes inflation and then deflation
2989913|NCT02630355|Active Comparator|Low Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for two cycles of 5 minute inflation and then deflation.
2989914|NCT02630355|Active Comparator|Standard Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for four cycles of 5 minute inflation and then deflation.
2989915|NCT02630355|Active Comparator|High Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for four cycles of 5 minute inflation and deflation on weekly basis for four consecutive weeks.
2989916|NCT02630342|Experimental|Group 1: preparation materials only|This group will receive preparation materials for a clinical MRI scan. These include links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan. Preparation for this group will occur only at home.
2989917|NCT02630342|Experimental|Group 2: Materials with review|This group will receive in preparation for a clinical MRI scan links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan. Preparation for this group will occur at home and include a visit with research team to review preparation materials with the research team
2989918|NCT02630342|Experimental|Group 3: Mock MRI scanner|This group will receive the same materials as training group 1. In addition they will attend the mock scanner where the research team will utilise a mock MRI scanner to practice lying down in a scanner, staying still , wearing headphones and watching a movie/video on the mirror system.
2989919|NCT02630342|No Intervention|Neuro-oncology retrospective controls|A retrospective control group of neuro-oncology patients from the 3 years prior to the study initiation. This group will be used to determine the age at which patients were able to complete a diagnostic MRI without GA
2989920|NCT02630342|Experimental|Neuro-oncology prospective|Child life specialist preparation will be provided to these patients. This preparation for Diagnostic MRI scanning in which utilise the Mock MRI scanner as preparation for the scan.
2989921|NCT02630329|Experimental|vNOTES adnexectomy|Vaginal Natural Orifice Transluminal Endoscopic Surgery
2989922|NCT02630329|Active Comparator|LSC adnexectomy|Laparoscopic adnexectomy
2989923|NCT02630316|Placebo Comparator|Placebo|Matching placebo inhaled using an ultrasonic nebulizer four times daily
2989924|NCT02630316|Active Comparator|Active Inhaled Treprostinil|Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled four times daily and titrated up to a maximum of 12 breaths four times daily
2989926|NCT02630303|Sham Comparator|Mock Therapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to LED-RL phototherapy and two subjects randomized to mock therapy).~After either a maximally tolerated dose (MTD) has been established, or the study endpoint of 640 J/cm2 has been achieved, an additional 27 LED-RL phototherapy subjects (for a total of 30) and 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
2989927|NCT02630290|Placebo Comparator|Ropivacaine|After a careful aspiration, 1 to 2 mL of normal saline is injected for a distribution in and around the brachial plexus. Additional needle tip repositioning and injections may be needed when the distribution is not attained. Then the study drug (0.5% ropivacaine in a total volume of 20 mL) will be injected with additional fine adjustment of the block needle under continuous ultrasound monitoring.
2989928|NCT02630290|Experimental|Ropivacaine + Dexmedetomidine|After skin infiltration with 1-2 mL of lidocaine 2%, a 21-gauge 90-mm spinal needle will be inserted into the brachial plexus sheath using in-plane technique. After a careful aspiration, 1 to 2 mL of normal saline is injected for a distribution in and around the brachial plexus. Additional needle repositioning and injections may be needed when the distribution is not attained. Then the study drug (0.5% ropivacaine plus 30 microg dexmedetomidine in a total volume of 20 mL) will be injected with additional fine adjustment of the block needle under realtime ultrasound monitoring.
2989929|NCT02630277|Experimental|Arm 1|1:1 Intravitreal Aflibercept Injection once every 4 weeks
2989930|NCT02630277|Experimental|Arm 2|Intravitreal of Aflibercept once every 4 weeks for 4 months then as needed (PRN)
2989931|NCT02630264|Experimental|Combination therapy|"E10A+chemotherapy group (360 subjects):~E10A (Endostatins) of 1.0×1012VP on day 1 and 6~Paclitaxel Injection 160mg/m2 on day 3~Cisplatin Injection 25mg/m2 on day 3, 4, and 5. Repeat every 21 days."
2989932|NCT02630264|Experimental|Chemotherapy|"Chemotherapy-alone group (180 subjects):~Paclitaxel Injection 160mg/m2 on day 1~Cisplatin Injection 25mg/m2 on day 1, 2, and 3. Repeat every 21 days"
2989933|NCT02630251|Experimental|GSK2820151 arm|An accelerated dose escalation phase will be utilized in order to minimize sub-optimal drug exposures, followed by a conventional 3+3 dose escalation phase to achieve MTD. Initially, one subject per dose cohort will be recruited (accelerated dose escalation phase) until the first instance of a >=Grade 2 drug related toxicity or dose-limiting toxicity (DLT). Further cohorts will be recruited in blocks of three subjects (3+3 dose escalation phase). Projected dose levels are 3 mg, 6 mg, 12 mg, 20 mg, 40 mg, 60 mg, 100 mg, 150 mg, 200 mg, and 300 mg. Additional subjects may be enrolled at previously cleared dose levels in order to obtain further data for PK and/or PD analysis. Once MTD is determined, additional subjects (18 subjects total at MTD) may be enrolled to collect additional safety data.
2989934|NCT02630238|Experimental|Branched-Chain Amino Acid group|The branched-chain amino acid group will be on a hypocaloric diet, exercise and receive 0.342g/kg of BCAA per day, partially accounted for through their diet with the rest provided by a BCAA supplement
2989935|NCT02630238|Placebo Comparator|Placebo Group|The placebo will be on a hypocaloric diet, exercise and receive isoenergetic beverage with carbohydrate instead of branched-chain amino acids
2989936|NCT02630225|Experimental|Intervention|"Participants in this arm will receive three intervention services in addition to treatment as usual services:~A brief intervention including a feedback session utilizing principles of Motivational Interviewing (MI).~Extended outreach services (6 months) using the Critical Time Intervention (CTI) approach.~Multi-agency attention."
2989937|NCT02630225|Other|Treatment as Usual|Participants in this arm will receive the usual care offered to victims of gun shot wounds.
2989938|NCT02630212||Control|Chinese Han people undergoing coronary angiography in Qilu Hospital in corresponding period whose coronary arteries narrowing less than 50 percent.
2989939|NCT02630212||Aortic dissection|Chinese Han people diagnosed with aortic dissection in Qilu Hospital
2989940|NCT02630199|Experimental|AZD6738 + paclitaxel|The PART A will be in combination with paclitaxel; the starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity. The PART B will be an independent parallel PK expansion cohort with cycle 0 of AZD6738 on D1, D8~D21 monotherapy followed by combination therapy with weekly paclitaxel from cycle 1.
2989941|NCT02630186|Experimental|Rociletinib and MPDL3280A|
2989942|NCT02630173|Experimental|Non vital teeth with apical radiolucency|Endodontic treatment was performed in non vital teeth with periapical radiolucency. Local anesthesia was provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation was done.Using 3 % sodium hypochlorite, canal negotiation was done & apical patency was achieved with #10 or #15K-files. Coronal flaring with # 2 and #3 Gates-Glidden drills was done.Calcium hydroxide was filled in the canals with the help of a lentulo spiral.At the second appointment,calcium hydroxide paste was removed and copious irrigation with 3% sodium hypochlorite was followed by 5.0 mL 17% ethylenediaminetetraacetic acid with a final rinse of 5.0 mL of 3% sodium hypochlorite. The canals were obturated with gutta-percha and ZOE sealer.
2989943|NCT02630173|Active Comparator|Vital teeth|Only scaling and root planing will be done in contralateral vital tooth with pocket depth >5mm .Non surgical periodontal treatment in the form of scaling and root planing was provided in minimum of two sessions using ultrasonic scaler (Satelec P5 Booster Suprasson) and hand instruments (Hu-friedy scalers and curettes).
2989944|NCT02630160|Active Comparator|Intraarticular Catheter with anesthesic|Intraarticular infusion with Bupivacaine Hydrochloride
2989945|NCT02630160|Placebo Comparator|Intraarticular Physiological Saline|Infusion of Physiological Saline [Flebobag Salina Fisiologica Grifols 0.9%] Sterile Solution by intraarticular catheter
2989946|NCT02630160|Active Comparator|Perifascial Catheter with anesthesic|Perifascial infusion with Bupivacaine Hydrochloride
2989947|NCT02630160|Placebo Comparator|Perifascial Physiological Saline|Infusion of Physiological Saline [Flebobag Salina Fisiologica Grifols 0.9%] Sterile Solution by Perifascial catheter
2989948|NCT02630147|Experimental|Night-vanilla|Intervention = exposition to vanilla scent A quantity of 2 ml of a saturated vanilla solution (2% vanillin) will be applied on premature pyjamas infant's, close to his face (on each shoulder and on the upper chest).
2989949|NCT02630147|No Intervention|Night-no vanilla|The only difference with the experimental arm is the absence of vanilla (usual, standard care)
3005717|NCT02525276|No Intervention|- training - HT|- training - HT
2989951|NCT02630121|Placebo Comparator|Placebo/Fluticasone Propionate|Placebo Spray 2 Sprays QHS Fluticasone Propionate 1 spray BID
2989952|NCT02630121|Active Comparator|Oxymetazoline Hydrochloride /Fluticasone Propionate|Oxymetazoline Hydrochloride 2 Sprays QHS Fluticasone Propionate 1 spray BID
2989953|NCT02630108|Experimental|Thermal Ablation & TACE|"Transarterial chemoembolization (TACE) is performed immediately following thermal ablation.~EADM, ultra-fluid lipiodol and gelatin sponge articles are used in TACE."
2989954|NCT02630108|Active Comparator|TACE alone|Only TACE is performed. EADM, ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
2989955|NCT02630095|Other|Control.|No anticoagulation，just routine follow up.
2989956|NCT02630095|Experimental|Anticoagulation|Nadroparin Calcium and Warfarin
2989957|NCT02630082|Other|Intervention|Circumcision and flexible sigmoidoscopy
2989958|NCT02630069|Experimental|CDP-choline+supportive psychotherapy|CDP-choline 500mg once a day for 12 weeks / Supportive psychotherapy 1 session/2 weeks for 12 weeks
2989959|NCT02630069|Placebo Comparator|Placebo+supportive psychotherapy|Placebo 500mg once a day for 12 weeks / Supportive psychotherapy 1 session/2 weeks for 12 weeks
2989960|NCT02630069|No Intervention|Healthy control|No intervention
2989961|NCT02630043|Experimental|Tolcapone and Oxaliplatin|"Subjects will receive oral tolcapone at their assigned dose level on each day of this 21-day cycle.~Oxaliplatin will be given at 100 mg/m2 IV on Day 1 of Cycle 2 through 5 and any subsequent 21-day cycle."
2989962|NCT02630030|Experimental|Ixazomib|Patients receive ixazomib PO 3 hours before surgery.
2989963|NCT02630017|Experimental|Drug condition|40 mg methylphenidate on one study day
2989964|NCT02630017|Placebo Comparator|Placebo condition|matching placebo on other study day
2989965|NCT02630004|Experimental|Melatonin|Melatonin oral gel 3%
2989966|NCT02630004|Placebo Comparator|Placebo|Placebo oral gel
2989967|NCT02629991|Experimental|Intranasal Oxytocin (IN-OXT)|Syntocinon (synthetic oxytocin) will be used in this protocol. Each subject will receive a dose of 16 IU BID (32 IU a day), and will be instructed to inhale 2 puffs per nostril (4 IU each) twice a day.
2989968|NCT02629991|Placebo Comparator|Matched Placebo|Each subject will receive a dose of 16 IU BID (32 IU a day), and will be instructed to inhale 2 puffs per nostril (4 IU each) twice a day.
2989969|NCT02629978|Experimental|radiofrequency ablation|In this group, patients willingly receive CT-guided percutaneous radiofrequency ablation procedures are selected according to the inclusion criteria as follows. After a series of preoperative evaluation and preoperative preparation，the procedures will be performed under the CT guidance. CT/MRI scans will be ordered after 24-48 hours to see if there are complications (such as haemorrhage, pneumothorax and pleural effusion). Regularly follow-up will be carried out for several years after RFA to assess the effectiveness and safety of RFA integratedly.
2989970|NCT02629965|Experimental|tiotropium + olodaterol|inhalation two puffs from the RESPIMAT inhaler, once a day, in the morning
2989971|NCT02629965|Active Comparator|tiotropium|inhalation two puffs from the RESPIMAT inhaler, once a day, in the morning
2989972|NCT02629952|Experimental|Blueberry Tea|3 cups of blueberry tea per day x 4 weeks
2989973|NCT02629952|No Intervention|No Treatment|No Treatment
2989974|NCT02629939|No Intervention|questionnaires|"Questionnaires will be distributed to families of heart patients to test the theoretical knowledge to perform CPR The questionnaires were distributed to internal, cardiology clinics and clinic T by a doctor, Paramedic or medical student. The family will be asked to fill out the questionnaire independently.~The questionnaires will be distributed in Hebrew, Arabic, Russian and English The research questionnaire will include questions about able to perform basic CPR"
2989975|NCT02629939|Experimental|to participate in a short course for learning CPR|": The investigators will offer patients and their relatives to participate in a short course for learning CPR.~Relatives will receive a prescription Containing a proposal for participation in the course~Prescription will be awarded in four places:~-.Family physicians as a suggestion during a routine visit / presentation of cardiac problem~Heart Rehabilitation Institute - cardionegev~Doctors internal medicine department as part of a patient's discharge letter with heart disease~Doctors in cardiology clinic The prescription will be accompanied by several minutes of explanation about the program and its importance The investigators consider the level of responsiveness and participation, find out which arm yielded the highest number of participants (actual turnout of the total prescriptions distributed) And how to expand their activities"
2989976|NCT02629926||Patients to receive GH replacement|30 patients will be recruited to the study who wishes to continue receiving growth hormone replacement, all of whom will receive NutorpinAq Recombinant growth hormone
2989977|NCT02629926||Patients who will not receive GH replacement|An additional 30 patients who elect not to receive growth hormone replacement will provide a parallel control data.
2989978|NCT02629913|Experimental|Intervention|mementor somnium
2989979|NCT02629913|Other|Waitlist|
2989980|NCT02629900|Experimental|Intermittent fasting group|Participants will restrict their daily food intake (time restricted feeding) to an 8-hour time period between 1200 to 2000 hours. During the remaining 16-hour intermittent fasting period (2000 to 1200 hours) participants will be allowed to drink zero calorie beverages (diet soda pop, black coffee, tea, water, etc) in order to maintain normal hydration. There will be no attempt to restrict food intake. Rather simply to restrict the time period each day when food is consumed.
2989981|NCT02629887|Active Comparator|Face Mask|Standard Face Mask with T piece resuscitator for neonatal resuscitation. Face mask placement per Neonatal Resuscitation Program resuscitation guideline.
2989982|NCT02629887|Active Comparator|Non-inflatable supraglottic airway|Use of non-inflating supraglottic airway with T-piece resuscitator instead of Standard Face Mask with T piece resuscitator for neonatal resuscitation, replacing standard of care face mask in Neonatal Resuscitation Program guideline.
2989983|NCT02629874|Active Comparator|EA-230 (30mg/kg)|Subjects will receive EA-230, 30 mg/kg
2989984|NCT02629874|Active Comparator|EA-230 (90mg/kg)|Subjects will receive EA-230, 90 mg/kg
2989985|NCT02629874|Active Comparator|EA-230 (180mg/kg)|Subjects will receive EA-230, 180 mg/kg
2989986|NCT02629874|Placebo Comparator|Placebo|subjects receive placebo
2989987|NCT02629861|Experimental|TEV-48125 - 1|Dose Regimen 1
2989988|NCT02629861|Experimental|TEV-48125 - 2|Dose Regimen 2
2989989|NCT02629861|Placebo Comparator|Placebo|Matching Placebo
2989990|NCT02629848|Experimental|Motesanib + Paclitaxel + Carboplatin|Motesanib 125 mg, (5 x 25 mg) tablets, orally, once daily and paclitaxel 200 mg/m^2, intravenous, once on Day 1 and carboplatin at a dose to achieve a target Area Under the Curve (AUC) of 6.0 mg/mL x minute, once on Day 1 of a 3 week Cycle for up to 6 Cycles. After 6 Cycles, motesanib 125 mg, tablets, orally, once daily alone until disease progression, drug intolerability, study withdrawal or death for up to 36 months.
2989991|NCT02629848|Placebo Comparator|Placebo + Paclitaxel + Carboplatin|Motesanib placebo-matching tablets, orally, once daily and paclitaxel 200 mg/m^2, intravenous, once on Day 1 and carboplatin at a dose to achieve a target AUC of 6.0 mg/mL x minute, once on Day 1 of a 3 week Cycle for up to 6 Cycles. After 6 Cycles, motesanib placebo-matching, tablets, orally, once daily alone until disease progression, drug intolerability, study withdrawal or death for up to 36 months.
2989992|NCT02629835|Active Comparator|Intravenous dexamethasone 8 mg|patients receiving intravenous 8 mg of dexamethasone in parallel to ultrasound guided axillary nerve block with a standardized local anesthetic solution
2989993|NCT02629835|Active Comparator|Perineural dexamethasone 8 mg|patient receiving perineural 8 mg of dexamethasone in a mixture with a standardized local anesthetic solution for ultrasound guided axillary block
2989994|NCT02629822|Experimental|HIV-1 Infected|Treatment-naïve HIV-1 infected participants with NNRTI transmitted resistance will be treated with open-label MK-1439A consisting of a single FDC tablet of MK-1439 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg, to be administered orally, once daily for up to 96 weeks. For some participants who continue into the study extension, study treatment will continue for an additional 96 weeks, approximately, through a total of approximately 192 weeks of treatment.
2989995|NCT02629809|Experimental|Fludarabine + Cyclophosphamide + Obinutuzumab|"Obinutuzumab Days 1, 2, 8, and 15 of Cycle 1, and Day 1 of Cycles 2-3. Fludarabine Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2-3. Cyclophosphamide Days 2-4 of Cycle 1, and Days 1-3 of Cycles 2-3. Ibrutinib every day during Cycles 1-3. Allopurinol 1 time each day on Days 1-7 of Cycle 1. Valacyclovir every day while on Ibrutinib and 3 months after last dose.~If complete response end of Cycle 3, Obinutuzumab and Ibrutinib given on schedule as described for Cycles 4-6. If no disease end of Cycle 6, Ibrutinib alone for Cycles 7-12. If disease end of Cycle 6, Obinutuzumab and Ibrutinib given for Cycles 7-12. If complete response end of Cycle 12, no further treatment. If disease end of Cycle 12, Ibrutinib alone per physician's decision.~If disease end of Cycle 3, Obinutuzumab and Ibrutinib given on schedule as described for Cycles 4-12. If disease end of Cycle 12, Ibrutinib given alone per physician's decision. If complete response end of Cycle 12, no further treatment."
2989996|NCT02629796||CIDP treated (IVIG)|patients with a diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) according to European criteria, treated with IVIG (intravenous immunoglobulin as a first line of treatment) as a usual treatment
2989997|NCT02629796||control|healthy subjects
2989998|NCT02629783|Experimental|Physiotherapy + Corticosteroid injection + Psychomotor therapy|Usual care + intervention
2989999|NCT02629783|Active Comparator|Physiotherapy + Corticosteroid injection|Usual care
2990000|NCT02629757|Experimental|β-elemene|β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles.
2990001|NCT02629744|Experimental|Etrolizumab|Participants will self-administer single SC dose of etrolizumab using prefilled auto-injector, into the abdomen or the anterior thigh.
2990002|NCT02629731|Experimental|ankle OA|inclusion criteria: 1) diagnosis of ankle OA or PTTD [non-control subjects only], 2) undergoing conservative care (i.e., prescribed a foot orthosis) and deemed not to be a surgical candidate, 3) between 18 and 80 years of age, and 4) ambulatory (able to walk at least 15 m) with the primary impediment to pain-free ambulation being ankle OA or PTTD
2990003|NCT02629731|Experimental|flat foot|inclusion criteria: 1) diagnosis of flat foot, 2) undergoing conservative care (i.e., prescribed a foot orthosis) and deemed not to be a surgical candidate, 3) between 18 and 80 years of age, and 4) ambulatory (able to walk at least 15 m)
2990004|NCT02629731|No Intervention|control|inclusion criteria: 1) between 18 and 80 years of age, and 2) ambulatory (able to walk at least 15 m)
2990005|NCT02629718|Experimental|A(NACT)|Neoadjuvant Chemotherapy followed by Radical Surgery
2990006|NCT02629718|Active Comparator|B(RS)|Radical Surgery alone
2990007|NCT02629705|Other|Group A|"Placebo intervention~Assessment block (3 days)~Washout-phase of 21-35 days~Carrageenan intervention~Assessment block (3 days)"
2990008|NCT02629705|Other|Group B|"Carrageenan intervention~Assessment block (3 days)~Washout-phase of 21-35 days~Placebo intervention~Assessment block (3 days)"
2990009|NCT02629692|Experimental|K0706|Part A of the study : Two arm,Placebo-Controlled,double blind - Completed on Nov 2016 Part B : Single arm,open-label,dose escalation - Ongoing (Initiated enrollment in April 2017)
2990010|NCT02629679||Males nonathletes|Boys non-involved in organized sport and exercising
2990011|NCT02629679||Females nonathletes|Girls non-involved in organized sport and exercising
2990012|NCT02629679||Males athletes|Athletic boys (involved in sports)
2990013|NCT02629679||Females athletes|Athletic girls (involved in sports)
2990014|NCT02629666|Active Comparator|Exercise Referral Scheme (ERS)|In the Exercise Referral Scheme (ERS) intervention participants will undergo a physical activity program of 16 weeks, with two sessions per week (60 minutes each session). Participants will be asked to perform the activity in a moderate to vigorous intensity (according to each individual's progression) during the central part of each session. Intensity will be estimated using the modified Borg Scale of Perceived Exertion (e.g. moderate intensity activity will be considered as a 4 to 6 and vigorous-intensity activity as a 7 to 9) or with training loads (i.e. ankle weights and dumbbells) corresponding to 70-80% of maximum, adjusted progressively during the training period. ERS programs will be based on a combination of aerobic, strength-based, balance and flexibility activities, with a specially trained PA specialist. These sessions will be always performed under the supervision of the same trainer. The PA intervention is adapted to the participants' functional status.
2990045|NCT02629471|Experimental|response time due to light flashs pulses|light flashing effects on response time to random target appearance
2990046|NCT02629458|Experimental|Patients requiring surgery|
2990047|NCT02629432||Cosyconet COPD Cohort|MRI and CT of the lung will be performed in a multi-centre cohort of 625 COPD-patients from the main COSYCONET cohort.
2990048|NCT02629419|Experimental|CAMB (Encochleated Amphotericin B)|Encochleated Amphotericin B (200 mg, 400 mg, 800 mg)
3008026|NCT02509364||Health control|Healthy volunteer
2990015|NCT02629666|Experimental|ERS + Self-management Strategies|"Participants will undergo the aforementioned Physical Activity program plus 11 sessions of Self-Management Strategies (SMS).~SMS start with a face-to-face session in an indoor primary-care facility. The next 6 sessions are further implemented in a group format. SMS are aimed at increasing self-efficacy in reducing sedentary behaviour and at adopting/maintaining an active behaviour as complement to a standard physical activity program (ERS). SMS group sessions will be conducted during week 3 to 11 of the ERS, after the PA sessions (6 sessions: 3 once a week, 3 once every second week). There will be 4 telephone contacts during the adherence phase, at week 15, 20, 25 and 30."
2990016|NCT02629666|No Intervention|Control group|Researchers will give to all participants during the first informative meeting (prior assessment) a written general booklet standardized across sites with WHO recommendation regarding PA regular practice for health. During the intervention, a health advice meeting with standardized topics about healthy lifestyle and feedback on some outcomes regarding their results will be held twice in the Primary Health Centre (at week 5, and at week 11). Researchers will send a letter or phone call prior to each follow up reminding the next assessment.
2990017|NCT02629653|Other|Single arm|The endovascular cooling system will be Zoll IVTM. This system consists of a control module (either CoolGard 3000 or Thermogard XP), a CoolGard start-up kit, and an ICY catheter (either IC-3585 AE or IC-3585)
2990018|NCT02629640||Research Participants|Medical history questionnaire; clinical assessment and review; participant follow-up; blood or buccal sample; post mortem examination.
2990019|NCT02629627|Experimental|cojugated ALC/Leucine+Metformin|Intervention with conjugated linoleic acid/Leucine + 500mg in individuals with METS
2990020|NCT02629627|Active Comparator|Metformin+placebo conjugatedALC/leucine|active comparator with Metformin 500mg + Placebo of ACL/Leucine in individuals with METS
2990021|NCT02629627|Placebo Comparator|Placebo of Metformin|Active comparator with ACL/Leucine + Placebo of Metformin in individuals with METS
2990022|NCT02629627|Placebo Comparator|ACL/Leu placebo|Placebo comparator with ACL/Leu placebo + Metformin placebo in individuals with METS
2990023|NCT02629614|Experimental|TAPS Stimulation|Temporal Afferent Patterned Stimulation (TAPS) is alternating bursts of TENS stimulation applied to the radial and median nerves of a subject's wrist using the Cala ONE device.
2990024|NCT02629614|Sham Comparator|Sham Stimulation|0 amplitude stimulation applied to the radial and median nerves of a subject's wrist using the Cala ONE device.
2990025|NCT02629601|Experimental|Active Rewards|Participant will receive the standard active rewards incentives.
2990026|NCT02629601|Active Comparator|Active Rewards Doubled|Participant will receive the standard active rewards doubled in magnitude.
2990027|NCT02629601|Active Comparator|Active Rewards & Lottery 1|Participant will receive the standard active rewards incentives plus a lottery 1 with a 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward.
2990028|NCT02629601|Active Comparator|Active Rewards & Lottery 1 & Broadcast|Participant will receive the standard active rewards incentives plus a lottery 1 with a 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward. Includes broadcasting winners (number) each week.
2990029|NCT02629601|Active Comparator|Active Rewards & Lottery 2 & Broadcast|Participant will receive the standard active rewards incentives plus a lottery 2 with a 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward. Includes broadcasting winners (number) each week.
2990030|NCT02629588||Persons in coma or vegetative state|People who survived TBI have a period of complete unconsciousness or coma with no awareness of themselves or their surroundings received multimodal or unimodal sensory stimulation.People in a coma are unaware and unresponsive, but not asleep as there is no sleep-wake cycle. While in a coma, people are unable to speak, follow commands or open their eyes. The person in coma may have a simple reflex in response to touch or pain, but essentially there is no meaningful response to external stimuli. There is an absence of awareness of self and the environment, even under conditions of vigorous external stimulation. Coma can last from hours to days, depending on the severity of the brain damage, and sometimes a person can remain in a comatose state for months and even years.
2990031|NCT02629562|Experimental|Arm 1|first dosing: single dose of 6mg of B12019 administered subcutaneously, second dosing: single dose of 6mg of Neulasta administered subcutaneously
2990032|NCT02629562|Experimental|Arm 2|first dosing: single dose of 6mg of Neulasta administered subcutaneously, second dosing: single dose of 6mg of B12019 administered subcutaneously
2990033|NCT02629549|Experimental|OTL38|Dosage calculated by weight of individual
2990034|NCT02629536|Experimental|Active-verum-NAC tablet|Intervention: Twice-daily administration of N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablets
2990035|NCT02629536|Placebo Comparator|Sham-placebo tablet|Intervention: Twice daily administration of sham/placebo tablet
2990036|NCT02629523|Experimental|Afatinib|Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
2990037|NCT02629510|Experimental|Tachosil|The group composed of patients whose surgical margin of cervix will be treated with Tachosil® after a loop electrosurgical excisional procedure (LEEP)
2990038|NCT02629510|No Intervention|No Tachosil|The group composed of patients whose surgical margin of cervix will NOT be treated with Tachosil® after a loop electrosurgical excisional procedure (LEEP)
2990039|NCT02629497|Experimental|Healthy subjects for Omega-6 protection|Platelets from healthy donors will be assessed for regulation by Primrose Oil (omega-6 fatty acid).
2990040|NCT02629497|Experimental|T2DM patients for Omega-6 protection|platelets from Type 2 diabetes mellitus (T2DM) patients will be assessed for regulation by Primrose Oil (omega-6 fatty acid).
2990041|NCT02629497|Active Comparator|Healthy control for Omega-3 protection|Platelets from healthy donors will be assessed for regulation by Fish Oil (omega-3 fatty acid).
2990042|NCT02629497|Active Comparator|T2DM for Omega-3 protection|platelets from Type 2 diabetes mellitus (T2DM) patients will be assessed for regulation by Fish Oil (omega-3 fatty acid).
2990043|NCT02629484|Active Comparator|Focused Cardiac Ultrasound|participants randomised to receive focused cardiac ultrasound prior to surgery for hip fracture
2990044|NCT02629484|No Intervention|Standard care (clinical assessment)|Participants randomised to standard care receive clinical assessment of the patient
2990164|NCT02628626|Placebo Comparator|Placebo|Patients in this arm will receive placebo for 4 weeks.
2990049|NCT02629406||Diabetes typ 1|Patients with typ 1diabetes with a duration of the disease between 10-20 years (HbA1C >65 mmol/l) and age 20-50 will be exposed to intermittent hypoxia.
2990050|NCT02629406||Healthy controls|Healthy controls, age 20-50 will be exposed to intermittent hypoxia.
2990051|NCT02629393|Experimental|ALXN1101|
2990052|NCT02629380|Experimental|Hyaluronic acid group|Single injection of 3 ml HA (Hymovis, Fidia Farmaceutici SpA, Padova, Italy) at the end of the arthroscopic meniscectomy
2990053|NCT02629380|Other|meniscectomy alone|Arthroscopic meniscectomy alone
2990054|NCT02629367|Active Comparator|Group 1|Vorapaxar 2.08 mg once daily
2990055|NCT02629367|Experimental|Group 2|Clopidogrel 75 mg per orem once daily + Vorapaxar 2.08 mg once daily
2990056|NCT02629367|Experimental|Group 3|Aspirin 81 mg per orem once daily + Vorapaxar 2.08 mg once daily
2990057|NCT02629367|Experimental|Group 4|Aspirin 81 mg per orem once daily + Clopidogrel 75 mg once daily + Vorapaxar 2.08 mg once daily
2990058|NCT02629354|Experimental|Ibuprofen and Caffeine|
2990059|NCT02629354|Active Comparator|Ibuprofen|
2990060|NCT02629341|Active Comparator|Functional yogurt powder|This arm will receive one daily serving of the functional yogurt which is enriched in Calcium, D, K, C vitamins, Zn, Mg, L-leucin and the Lactobacillus plantarum 3547 probiotic
2990061|NCT02629341|Placebo Comparator|Control yogurt powder|This arm will receive one daily serving of the control yogurt which consists of a regular yogurt not enriched
2990062|NCT02629328|Other|CardioCel|Treatment with CardioCel implant
2990063|NCT02629315|Active Comparator|10% neutral buffered formaldehyde|Specimens will be fixed for 24-48hours in 10% neutral buffered formaldehyde and then dissected for lymph nodes.
2990064|NCT02629315|Experimental|Carnoy's solution|Specimens will be fixed for 24-48hours in Carno'ys solution and then dissected for lymph nodes.
2990065|NCT02629302|Experimental|animal assisted therapy|"Standard therapy (speech therapy, occupational therapy and physiotherapy) that is done in the presence and with Integration of an animal."
2990066|NCT02629302|Active Comparator|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
2990067|NCT02629289|Other|Treatment A|HSP-130, 6 mg, single subcutaneous (SC) injection in the deltoid region
2990068|NCT02629289|Other|Treatment B|US-approved Neulasta, 6 mg, single SC injection in the deltoid region
2990069|NCT02629289|Other|Treatment C|EU-approved Neulasta, 6 mg, single SC injection in the deltoid region
2990070|NCT02629250|Placebo Comparator|SV maximization|Goal-directed fluid therapy with stroke volume maximization. Device: The Volume-View system from Edwards Co.
2990071|NCT02629250|Experimental|supernormal DO2|"Goal-directed fluid therapy with stroke volume maximization and supernormal oxygen delivery.~Device: The Volume-View system from Edwards Co."
2990072|NCT02629237|Experimental|Multifaceted education group|Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
2990073|NCT02629237|No Intervention|control group|Subjects will not be asked to watch education film and not participate in counseling session before and after surgery.
2990074|NCT02629224|Experimental|Renal impairment|
2990075|NCT02629224|Experimental|Haemodialysis|
2990076|NCT02629211|Experimental|NaviAid™ AB|NaviAid™ AB device procedure
2990077|NCT02629198||normal weight|Healthy men and women ages 25-40 and 55-75. BMI 18.5 to 25.0
2990078|NCT02629198||overweight|Healthy men and women ages 25-40 and 55-75. BMI 25.0 to 30.0
2990079|NCT02629198||obese|Healthy men and women ages 25-40 and 55-75. BMI over 30
2990080|NCT02629185||normal weight|BMI 18.5 to 25.0 Healthy men and women ages 25-40 and 55-75
2990081|NCT02629185||overweight|BMI 25.0 to 30.0 Healthy men and women ages 25-40 and 55-75
2990082|NCT02629185||obese|BMI over 30.0 Healthy men and women ages 25-40 and 55-75
2990083|NCT02629172||Chronic infection of hepatitis C virus (HCV) Genotype 1 (GT1)|Participants with confirmed chronic hepatitis C genotype 1, receiving paritaprevir/ritonavir/ombitasvir according to standard of care and in line with the current local label
2990084|NCT02629159|Placebo Comparator|Placebo followed by ABT-494|Placebo once every two weeks for subcutaneous injection and once daily for oral tablet for 26 weeks (Period 1) followed by ABT-494 once daily for up to 5 years (Period 2).
2990085|NCT02629159|Active Comparator|Adalimumab (ADA)|Subcutaneous injection once every two weeks
2990086|NCT02629159|Experimental|ABT-494|Once daily
2990087|NCT02629146|Experimental|Midazolam|Drug: Midazolam (experimental)
2990088|NCT02629146|Placebo Comparator|Isotonic saline|Drug: Isotonic saline (placebo)
2990089|NCT02629146|Active Comparator|Fentanyl|Drug: Fentanyl (active comparator)
2990090|NCT02629133|Experimental|SHE Program|"Participants received a 50 minute intervention on the computer immediately after their baseline assessment and a 15 minute booster session on the computer within 2 weeks after the intervention. There was also a 3 and 6 month follow-up after completion of the SHE program."
2990091|NCT02629133|No Intervention|Control Condition|Control condition consisted of a series of questions regarding television show preferences and viewing a brief series of videos of popular entertainers/shows, with subsequent requests for rating of subjective preference. Participants in this condition completed a baseline assessment as well as a television show booster and a follow-up assessment 3 and 6 months later.
2990092|NCT02629120|Other|MUD|Patient with Matched Unrelated Donor cells
2990093|NCT02629120|Other|Allo|Patient with Sibling Donor Cells
2990094|NCT02629094|Experimental|Treatment|Intervention: Eplerenone will be administered for 6 months as follows: 25 mg once daily for 1 week and then 50 mg once daily for the remainder of the study.
2990095|NCT02629081||Controls & Cases|Controls (participants without heartburn or other GERD symptoms undergoing standard upper endoscopy for the following: anemia, weight loss, diarrhea, and screening for esophageal varices) and Cases (participants with heartburn or other GERD symptoms undergoing standard endoscopy for heartburn or other GERD symptoms.)
2990096|NCT02629068|Experimental|PURPOSE|"Parents in the PURPOSE group will join a secret Facebook group for 2 months. Groups will be lead by 2 peer leaders and include 20 parent participants."
2990133|NCT02628847|Experimental|Drug|Sildenafil citrate 25mg once per day for 14 days starting day 5-9 post stroke while undergoing usual rehabilitation
2990097|NCT02629068|No Intervention|Treatment as Usual (TAU)|Treatment as Usual parents will be contacted after 8 weeks to complete follow-up interview. Will not receive PURPOSE intervention.
2990098|NCT02629055|Experimental|Respiratory EMG|Additional EMG measurements whilst on NIV will be used to guide the titration of NIV.
2990099|NCT02629055|No Intervention|Care as usual|NIV will be initiated according to standard care protocol.
2990100|NCT02629042|Active Comparator|Control|
2990101|NCT02629042|Experimental|Experimental|
2990102|NCT02629029|Other|Surgical - therapeutic free flap|patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will be imaged using two systems: (i) pre-operative CTA with IV contrast; (ii) intra-operative fluorescence endoscopy with ICG.
2990103|NCT02629016|Experimental|Mindfulness|Education and experiential exercises for mindfulness including movement, thoughts and meditation
2990104|NCT02629016|Active Comparator|Wellness|Education and experiential exercises for general wellness including sleep hygiene, goal setting and power poses.
2990105|NCT02629016|No Intervention|Waitlist|Students receive regular health class instruction without intervention.
2990106|NCT02629003|Active Comparator|[11C]Cimbi-36|"[11C]Cimbi-36~Maximum of 600 Mega Becquerel (MBq) or 1.5 micrograms, single dose intravenous (I.V.)"
2990107|NCT02629003|Active Comparator|[11C]Cimbi-36-5|"[11C]Cimbi-36-5~Maximum of 600 Mega Becquerel (MBq) or 1.5 micrograms, single dose intravenous (I.V.)"
2990108|NCT02628990|Experimental|1.6 g plant stanols|A yoghurt drink containing plant stanol ester (1.6 grams plant stanols), consumed with a meal daily for 4 weeks
2990109|NCT02628990|Experimental|2 g plant stanols|A yoghurt drink containing plant stanol ester (2 grams plant stanols), consumed with a meal daily for 4 weeks
2990110|NCT02628990|Experimental|1.6 g plant stanols and camelina oil|A yoghurt drink containing plant stanol ester (1.6 grams plant stanols) and camelina oil (2 g), consumed with a meal daily for 4 weeks
2990111|NCT02628990|Experimental|2 g plant stanols and camelina oil|A yoghurt drink containing plant stanol ester (2 grams plant stanols) and camelina oil (2 g), consumed with a meal daily for 4 weeks
2990112|NCT02628990|Placebo Comparator|Placebo|A placebo yoghurt drink, consumed with a meal daily for 4 weeks
2990113|NCT02628977|Experimental|OSA Health Education & Support Group|Participants randomly assigned to the intervention arm will receive OSA health education and social support from a trained Peer educator.
2990114|NCT02628977|Active Comparator|Attention Control Group|Participants in the attention control group will receive standard sleep literature, providing information about Obstructive Sleep Apnea and access to available sleep services.
2990115|NCT02628964|Active Comparator|4.5% e-cig|e-cigarettes with nicotine cartridges
2990116|NCT02628964|Placebo Comparator|0 mg e-cig|e-cigarettes with placebo cartridges (0mg).
2990117|NCT02628951|Experimental|Ramucirumab + Paclitaxel|"Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.~Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason."
2990118|NCT02628938|Experimental|Miswak extract mouth wash|50% mouthwash aqueous solution 5ml twice a day for 7 days
2990119|NCT02628938|Experimental|Miswak sticks|Sticks twice a day for 7 days
2990120|NCT02628938|Active Comparator|Chlorohexidine gluconate mouth wash|0.2% mouth wash aqueous solution (Oraxine ®) 5 ml twice a day for 7 days
2990121|NCT02628925||Recovery room|10 medical staff working in the recovery room
2990122|NCT02628925||Orthopedic ward|10 medical staff working on the orthopedic ward
2990123|NCT02628912||long-term survivors of HPV-related oropharyngeal cancer|This is a cross-sectional pilot study of long-term survivors of HPV-related oropharyngeal cancer treated with CTRT who are at least three years from treatment completion. This study consists of a onetime assessment of cardiopulmonary fitness, physical function status, measurement of lean body mass, endothelial function quality of life assessment, medical history and blood laboratory evaluation for traditional cardiac risk factors, endocrine derangement and inflammation.
2990124|NCT02628899|Other|Prospective TAVR Arm|200 patients prospectively undergoing transfemoral TAVR
2990125|NCT02628899|Other|Historical SAVR Controls|Historical controls will be selected from among patients at the same site who have undergone isolated bioprosthetic SAVR within the previous 36 months. TAVR patients will then be matched to SAVR patients using STS database variables to perform propensity matching, including (but not limited to) age, gender, race, ethnicity, STS score, and valve prosthesis size.
2990126|NCT02628899|Other|Low-Risk TAVR with Bicuspid Aortic Valve|The third arm of the trial will comprise a registry of TAVR in up to 100 low-risk patients with bicuspid aortic valve. The results from the registry arm will be analyzed independently.
2990127|NCT02628886|Experimental|maternal group|13-valent pneumococcal conjugate vaccine [Prevenar13®] (PCV13) vaccine, 0.5ml, once, stat, plus tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV13 at 8, 12 and 16 weeks according to normal EPI vaccination in country
2990128|NCT02628886|Placebo Comparator|control group|placebo sterile 0.9% sodium chloride, 0.5ml, once, stat plus tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV13 at 8, 12 and 16 weeks according to normal EPI vaccination in country
2990129|NCT02628886|Experimental|neonatal group|tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV 13 0.5ml at birth, 8 weeks and 16 weeks
2990130|NCT02628873|Experimental|Arm 1|HyCoSy procedure followed by HSG procedure
2990131|NCT02628873|Experimental|Arm 2|HSG procedure followed by HyCoSy procedure
2990132|NCT02628860|Experimental|Ferinject|"Ferinject to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50 Kg .~Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® must be diluted only in sterile 0.9% sodium chloride.~Strength/Packaging: 10 mL vials containing 500 mg iron as iron per vial."
3009065|NCT02502370|Experimental|Group 1 Arm B LV5FU2|
2990134|NCT02628847|Placebo Comparator|control|placebo capsule once per day for 14 days starting day 5-9 post stroke while undergoing usual rehabilitation
2990135|NCT02628834|Experimental|Fascial mobilization|First day intervention: Patients will take fascial mobilization techniques to management of plantar flexor spasticity
2990136|NCT02628834|Experimental|Stretching exercise|Second day intervention:Patients will take fascial mobilization techniques to management of plantar flexor spasticity
2990137|NCT02628834|No Intervention|Healthy Volunteers|Healthy individuals will only be evaluated with no intervention
2990138|NCT02628821||Preterm Infants treated with non-invasive ventilation|"Preterm Infants of less than 32 weeks of Gestational age treated with synchronized non-invasive ventilation (SNIPPV) to prevent intubation or extubation failure based in a prospective protocol:~nCPAP failure: Preterm infants supported with nCPAP that meet intubation criteria if they are in a stable situation.~Electively For extubation:~Preterm infants in which nCPAP extubation has previously failed or Prolonged mechanical ventilation (more than 15 days) with high respiratory parameters (PMAP > 10 cmH2O and FiO2>35%)."
2990139|NCT02628808||Autism Spectrum Disorder|For all patients included in the study, core assessment carried out by either collaborating partners consists of diagnosis using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Patients with profound intellectual disability or with a known medical cause of autism, such as neurocutaneous syndromes, Fragile X, metabolic disorders, extreme prematurity, congenital rubella and other prenatal or postnatal neurological infections or gross dysmorphology, will be excluded.
2990140|NCT02628808||controls|Age 6 to 40 Healthy individuals with or without idiopathic surgical or urological conditions (e.g. orthopaedic conditions, hernia repairs, renal malformations, pre- or post-circumcision, phimosis, balanitis, scoliosis, congenital hip dislocation, adenoid or tonsil removal, dental procedures such as wisdom tooth extraction, cosmetic procedures such as removal of skin tags or cleft lip repairs, non-head injuries such as fractures, drainage of subungual or perichondrial haematomata).
2990141|NCT02628795|Experimental|PRT + FM|Progressive resistance training + functional mobility training 3 d/wk x 16 wk
2990142|NCT02628795|Active Comparator|Usual Care|Post-surgical usual care including physical therapy
2990143|NCT02628782|Experimental|InSeal VCD|InSeal's Vascular Closure Device Use of the experimental VCD to close the access site of the artery
2990144|NCT02628769|Experimental|Solithromycin|28 day treatment of 400 mg Solithromycin taken once a day.
2990145|NCT02628769|Placebo Comparator|Placebo|28 day treatment with placebo taken once per day.
2990146|NCT02628756|Experimental|Endometrial injury|Hysteroscopic-guided endometrial injury (Karl Storz, Tuttlingen, Germany).
2990147|NCT02628743|Experimental|Olesoxime|"Participants who have consented to the dose increase will receive 10 milligrams per kilogram (mg/kg) suspension twice a day (BID) either orally or via a naso-gastric or gastrostomy tube with breakfast and dinner, preferably at the same time of the day throughout the study. If the drug administration does not coincide with one of the scheduled meals, a snack should be taken prior to drug administration. Preferably there should be at least 10 hours between the morning and evening dose. The total dose in this study will not exceed 2000 mg.~Participants who do not consent to the dose increase will continue with the previous dosage and receive a dose of 10 mg/kg suspension once a day orally or via a naso-gastric or gastronomy tube with the main meal, preferably at the same time of the day."
2990148|NCT02628730|Active Comparator|Ablation Index Group|PVI using radiofrequency ablation (RFA) guided by Ablation Index.
2990149|NCT02628730|Other|Reference Group (Contact Force Group)|That group will be formed by the 40 patients who underwent mandatory repeat EPS 8-10 weeks following contact force guided PVI in the PRESSURE study (ClinicalTrials.gov Identifier: NCT01942408). RFA ablation data from reference group (Contact Force Group) will be compared with those obtained from the Ablation Index Group.
2990150|NCT02628717||SOF/SMV|SOF/SMV 400mg/150mg QD 12-24 weeks
2990151|NCT02628717||SOF/DCV|SOF/DCV 400mg/60mg QD 12-24 weeks
2990152|NCT02628717||SOF/LDV|SOF/LDV 400mg/90mg QD 12-24 weeks
2990153|NCT02628717||treatment duration|12 - 24 weeks
2990154|NCT02628704|Experimental|Selinexor, carfilzomib and dexamethasone|60 mg of selinexor and and 20 mg of dexamethasone will be taken twice weekly. On days coinciding with carfilzomib administration, selinexor will be given between 30 minutes and 4 hours after the end of the carfilzomib infusion.
2990155|NCT02628704|Placebo Comparator|Placebo, carfilzomib and dexamethasone|Placebo (for 60 mg of selinexor) and and 20 mg of dexamethasone will be taken twice weekly. On days coinciding with carfilzomib administration, Placebo (for 60 mg of selinexor) will be given between 30 minutes and 4 hours after the end of the carfilzomib infusion.
2990156|NCT02628691||HCV coinfection with no-to-moderate fibrosis|
2990157|NCT02628678|Other|Fructooligosaccharide (FOS)|Subjects will be required to take 8 grams of FOS per day for a total of 10 days.
2990158|NCT02628665|Experimental|24 to 48 hours group|"photosensitizer(photofrin): 2mg/kg, Diomed Surgical Diode Laser:400mv/cm irridiation 750 seconds, 24 to 48 hours: The injection of photosensitizer(photofrin) 24 to 48 hours light irradiation power.~630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds."
2990159|NCT02628665|Active Comparator|48 to 72 hours group|"photosensitizer(photofrin): 2mg/kg, Diomed Surgical Diode Laser:400mv/cm irridiation 750 seconds, 48 to 72 hours: The injection of photosensitizer(photofrin) 48 to 72 hours light irradiation power.~630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds."
2990160|NCT02628652|Experimental|Gluco-Galacto-Oligosaccharide (GOS)|Subjects randomized to this treatment arm will ingest GOS once per day for a total of 14 days. One level of GOS will be taken during Phase I and 2 levels of GOS will be taken during Phase II.
2990161|NCT02628652|Experimental|Gluco-Oligosaccharide (GLOS)|Subjects randomized to this treatment arm will ingest GLOS once per day for a total of 14 days. One level of GLOS will be taken during Phase I and 2 levels of GLOS will be taken during Phase II.
2990162|NCT02628652|Active Comparator|FructoOligosaccharide (FOS)|Subjects randomized to this treatment arm will ingest FOS once per day for a total of 14 days. One level of FOS will be taken during Phase I and 2 levels of FOS will be taken during Phase II.
2990163|NCT02628639|Experimental|electroencephalography recording|Cerebral measurements from high-density electroencephalography after the presentation of personalized stimulations
3009066|NCT02502370|Active Comparator|Group 2 Arm C LV5FU2|
2990165|NCT02628626|Active Comparator|Colesevelam and Clonidine|Patients in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks.
2990166|NCT02628613|Active Comparator|Paclitaxel plus Carboplatin|Paclitaxel plus Carboplatin for 4 cycles, paclitaxel 80 mg/m2 IV on day 1, 8 and 15, carboplatin AUC 2 IV, on day 1 and 8, dosing interval is 21 days
2990167|NCT02628613|Experimental|Vinorelbine plus Epirubicin|Vinorelbine plus Epirubicin for 4 cycles, vinorelbine 25 mg/m2 IV on day 1 and 8, epirubicin 60 mg/m2 IV on day 1, and dosing interval is 21 days.
2990168|NCT02628600|Experimental|LAI|
2990169|NCT02628587|Experimental|Generic clopidogrel|Patients are assigned to take generic clopidogrel
2990170|NCT02628587|Active Comparator|Patent clopidogrel|Patients are assigned to take patent clopidogrel (Plavix)
2990171|NCT02628574|Experimental|TRX518 monotherapy (Parts A and B)|Subjects receive an assigned dose of TRX518 administered intravenously one time per week or one time per cycle on a 21-day cycle
2990172|NCT02628574|Experimental|TRX518 with gemcitabine (Part C)|Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with gemcitabine (dosed two times per cycle) on a 21-day cycle
2990173|NCT02628574|Experimental|TRX518 with pembrolizumab (Part D|Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with pembrolizumab (dosed one time per cycle) on a 21-day cycle
2990174|NCT02628574|Experimental|TRX518 with nivolumab (Part E)|Subjects receive an assigned dose of TRX518 (dosed two times per cycle) intravenously administered in combination with nivolumab (dosed two times per cycle) on a 28-day cycle
2990175|NCT02628561|Active Comparator|Active tdcs/M1|Anodal tDCS on primary motor cortex and CIMT (constraint induced movement therapy)
2990176|NCT02628561|Experimental|Active tdcs/Premotor|Anodal tDCS on premotor cortex and CIMT (constraint induced movement therapy)
2990177|NCT02628561|Sham Comparator|Sham tdcs|Sham tDCS and CIMT (constraint induced movement therapy)
2990178|NCT02628548|Experimental|Cognitive training program 1|This 8-week program will meet once per week for 1.5 hours. Participants will be trained in performing various cognition enhancing techniques at each class, and will practice these techniques both in class and at home each day for 45 minutes.
2990179|NCT02628548|Experimental|Cognitive training program 2|This 8-week program will meet once per week for 1.5 hours. Participants will be trained in performing various cognition enhancing techniques at each class, and will practice these techniques both in class and at home each day for 45 minutes.
2990180|NCT02628535|Experimental|MGD009|Orlotamab; Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein
2990181|NCT02628522|Experimental|ADRCs therapy|"Infiltration with 20mL Lidocaine 2% and Epinephrine 1:100 000. Liposuction will be done from the abdomen using Tulip cannulas. Fat will be processed with Celution system.~Isolated ADRCs will be administered in chronic anal fissures."
2990182|NCT02628509||cardiac devices|patients receiving mechanical circulatory support patients undergoing transaortic valve replacement
2990183|NCT02628496|Experimental|Arm 1: CLM|"On the day of surgery, participants will have placement of laser-safe endotracheal tube and a rigid laryngoscope will be introduced into the oral cavity to gain access to the laryngeal introitus and then placed into suspension (standard of care)~Fluorescein dye will be administered intravenously~Confocal laser probe will be introduced through the rigid laryngoscope and touched first on the lesion of concern and put into scanning mode in order to obtain photos and video footage of the lesions. The probe will then be placed on normal appearing vocal fold tissue to obtain a control sample.~The remainder of the procedure is standard excisional biopsy and KTP laser photoablation"
2990184|NCT02628483|Experimental|Ultimate Omega|5 capsules of Ultimate Omega fish oil daily in the morning with food
2990185|NCT02628483|Active Comparator|Meg-3|5 capsules of Meg-3 fish oil daily in the morning with food
2990186|NCT02628470|Experimental|group cervical manipulation|The patient is supine without a pillow and physiotherapist standing in the ipsilateral corner of the hand of the thrust.
2990187|NCT02628470|Placebo Comparator|Placebo group|Participants will receive a protocol of domiciliary cervical control exercises.
2990188|NCT02628470|Active Comparator|Group cervical mobilization|Oscillatory mobilization technique. With the patient in prone, the investigator applies an oscillatory motion in the most painful cervical segment for three minutes
2990189|NCT02628457||Mild Subgroup|patients with supraspinatus tendon retracted upto medial 1/3rd of humerus head and arthroscopic rotator cuff repair done by single row.
2990190|NCT02628457||Moderate Subgroup|patients with supraspinatus tendon retracted between medial 1/3rd of humerus head and glenoid,and arthroscopic rotator cuff repair done by single row.
2990191|NCT02628457||Severe subgroup|patients with supraspinatus tendon retracted beyond glenoid and arthroscopic rotator cuff repair done by single row
2990192|NCT02628444|Experimental|CYD Dengue vaccine group|Participants randomized to receive 3 doses of CYD Dengue vaccine
2990193|NCT02628444|Experimental|Placebo 1/CYD Dengue vaccine group|Participants randomized to receive a placebo followed by 2 doses of CYD Dengue vaccine
2990194|NCT02628444|Experimental|Placebo 2/CYD Dengue vaccine group|Participants randomized to receive 2 doses of placebo followed by 1 dose of CYD Dengue vaccine
2990195|NCT02628431||General anesthesia|Patients that will recieve general anesthesia for elective surgery
2990196|NCT02628431||Regional or neuraxial anesthesia|Patients that will revieve regional or neuraxial anesthesia for elective surgery
2990197|NCT02628418|Experimental|Gloreha Group|"The patients in the Gloreha Group underwent to following interventions:~General Rehabilitation~Specific hand rehabilitation by Gloreha device"
2990198|NCT02628418|Other|Control Group|"The patients in the Control Group underwent to following interventions:~General Rehabilitation~Specific hand rehabilitation performed by physiotherapist"
2990199|NCT02628405|Experimental|Treatment (R2-ICE)|Patients receive lenalidomide PO daily on days 1-14, rituximab IV on day 1, ifosfamide IV over 24 hours on day 2, carboplatin IV over 1-2 hours on day 2, and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CMR, PMR, or NMR may receive 2 more courses per physician discretion. After completion of 2 cycles of R2ICE treatment, patients achieving objective status of CMR, PMR or NMR may proceed to SCT during the event monitoring phase.
2990282|NCT02627872||COPD patients (GOLD I-II)|Participants with mild-to-moderate COPD (GOLD I-II)
2990200|NCT02628392|Experimental|DS-8500a 25 mg QD|DS-8500a 25 mg tablet once daily (QD), orally, for up to 12 weeks, and matching sitagliptin placebo capsule
2990201|NCT02628392|Experimental|DS-8500a 50 mg QD|DS-8500a 50 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule
2990202|NCT02628392|Experimental|DS-8500a 75 mg QD|DS-8500a 75 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule
2990203|NCT02628392|Placebo Comparator|placebo|placebo tablet and placebo capsule, orally, once daily for up to 12 weeks to match DS-8500a and sitagliptin, respectively.
2990204|NCT02628392|Active Comparator|Sitagliptin|capsule, orally, once daily for up to 12 weeks and matching DS-8500 placebo tablet
2990205|NCT02628379||Class 1, 2, or 3 alterations, with targeted therapy|Patients put on targeted therapies matched to specific genomic alterations.
2990206|NCT02628379||Site-specific therapy determined by tissue of origin testing|Patients put on therapy determined by tissue of origin testing (e.g., CancerTYPE ID)
2990207|NCT02628379||Empiric CUP therapy|Patients put on empiric treatment at physician discretion
2990208|NCT02628366|Experimental|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention arm will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the temperature should be lowered by a minimum of 0.5°C and a maximum of 0.9°C.
2990209|NCT02628366|No Intervention|Standard Fixed Dialysate Temperature|Dialysis centres in the control group will provide usual care, which is standard dialysis using a fixed dialysate temperature of 36.5°C
2990210|NCT02628353|Placebo Comparator|Placebo|control group
2990211|NCT02628353|Experimental|Phenolic compound|treated group
2990212|NCT02628327||Glaucoma subjects|Survey given to all glaucoma subjects agreening to study.
2990213|NCT02628314||Osteoarthritis|
2990214|NCT02628301|Active Comparator|Hypercaloric diet|Hypercaloric diet (1.6x REE) for 30 days
2990215|NCT02628301|Placebo Comparator|Normal diet|Normocaloric diet (1.0xREE)
2990216|NCT02628288|Active Comparator|PCI with Axxess device + AbsorB BVS|Bifurcation lesion will be treated percutaneously by performing coronary stenting with AXXESS device and additional Absorb BVS.
2990217|NCT02628288|Active Comparator|PCI with Modified T with Absorb BVS|Bifurcation lesion will be treated percutaneously by performing coronary stenting with a modified T stenting technique using Absorb BVS.
2990218|NCT02628275|No Intervention|Control|Continued inactivity
2990219|NCT02628275|Active Comparator|Moderate to vigorous physical activity|MVPA (55-90% of maximum heart rate) for 150 min/week (current recommendations)
2990220|NCT02628275|Active Comparator|Light physical activity|LPA (40-55% of maximum heart rate) for 150 min/week
2990221|NCT02628249|Experimental|Base protein|0.8 g/kg/d of protein provided as crystalline amino acid made after egg protein.
2990222|NCT02628249|Experimental|Sufficient protein|1.75 g/kg/d protein provided as crystalline amino acid made after egg protein.
2990223|NCT02628249|Experimental|Base + BCAA|Base protein intake + Branched chain amino acids
2990224|NCT02628249|Experimental|Base + EAA|Base protein intake + essential amino acids.
2990225|NCT02628249|Experimental|Base + NEAA|Base protein intake + non essential amino acids
2990226|NCT02628236|Experimental|ALA|20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment
2990227|NCT02628223|Active Comparator|180 degrees|180 degrees of Selective Laser Trabeculoplasty using Neodymium:Yttrium Aluminum Garnet (YAG) laser
2990228|NCT02628223|Active Comparator|360 degrees|360 degrees of Selective Laser Trabeculoplasty using Neodymium:Yttrium Aluminum Garnet (YAG) laser
2990229|NCT02628210|Other|map3® Cellular Allogeneic Bone Graft|Patients will receive map3® Cellular Allogeneic Bone Graft
2990230|NCT02628197|Active Comparator|CONTROL GROUP|34 osteopenic postmenopausal women with chronic periodontitis who received calcium (500mg) and vitamin D (250I.U.) supplementation twice a day for 6 months.Scaling and root planing was not done in this group.
2990231|NCT02628197|Active Comparator|TEST GROUP|34 osteopenic postmenopausal women with chronic periodontitis who received scaling and root planing along with calcium (500mg) and vitamin D (250I.U.) supplementation twice a day for 6 months.
2990232|NCT02628171|Other|Control|Participants will receive a controlled diet (base diet), typical of an American diet, with 0 g/day of cashew nuts (control).
2990233|NCT02628171|Active Comparator|Cashew|Participants will receive a controlled diet, typical of an American diet, with 42 g/day of cashew nuts (base diet with cashew nuts).
2990234|NCT02628145|Experimental|Resistance Training Intervention|The RT intervention will take place three times per week for approximately 12 weeks on non-consecutive days using 8-10 exercises for major muscle groups utilizing free weights and machines follow American College of Sports Medicine and National Strength and Conditioning Association guidelines for RT in older adults.
2990235|NCT02628145|Active Comparator|Active Control Group|The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
2990236|NCT02628132|Experimental|Durvalumab and Paclitaxel|After one cycle of paclitaxel, durvalumab will be given concurrently with paclitaxel. Once paclitaxel cycles are completed, durvalumab will be continued alone until disease progression or unacceptable toxicity.
2990237|NCT02628119|Experimental|Intra-procedural access flow|"Management of access dysfunction based on intra-procedure access flow monitoring.~Criteria for target access flow:~Within 90% of baseline access flow if known 180% increase from pre-intervention flow if access flow not known 600ml/min for thrombosed grafts and 500 ml/min for thrombosed arteriovenous fistula in case baseline access flow not known"
2990238|NCT02628119|Active Comparator|Standard Angioplasty|Intervention based on current standards of care i.e. 2 dimensional angiographic views.
2990239|NCT02628106|Experimental|Lipo-prostaglandin E1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days.
2990240|NCT02628093|Other|THUNDERBEAT|THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
2990540|NCT02625948|No Intervention|observation(spot sign -)|regular clinical treatment
2990241|NCT02628093|Other|LIGASURE|LIGASURE energy device will be used for dissection of tissue and ligation of vessels
2990242|NCT02628080|Experimental|Cohort 1|Atovaquone suspension, 750mg/5ml bd and 1000mg (6.25ml) bd for 7-17 days. Device: PET-CT, Device: DWI-MRI
2990243|NCT02628080|No Intervention|Cohort 2|Device: PET-CT, Device: DWI-MRI
2990244|NCT02628067|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously every 3 weeks (Q3W) for up to 35 administrations (approximately 2 years of treatment)
2990245|NCT02628054|Active Comparator|Typhoid Vaccine|Typhoid vaccination in single 0.5mL injections into the non-dominant deltoid muscle in the arm
2990246|NCT02628054|Placebo Comparator|Placebo|A single 0.5mL injection of 0.9% sodium chloride saline solution into the non-dominant deltoid muscle in the arm
2990247|NCT02628041|Active Comparator|Permanent Iodine-125 seed implant|Prostate brachytherapy using Iodine-125 seed implant to a prescription dose of 144 Gy delivered to the Target volume defined as Clinical Target volume (CTV)+ 0-3 mm margin.
2990248|NCT02628041|Experimental|High-dose-Rate Prostate brachytherapy|"Prostate brachytherapy implant using Iridium-192 to a prescription dose of 19 Gy delivered to the CTV in one fraction. Greater than 95% coverage of the CTV with the prescription dose is considered per protocol, 90-95% coverage is considered a minor deviation and, < 90% coverage is considered a major deviation.~Attempts should be made to achieve these other dosimetric values:~D90: 105-115%~V150 ≤ 35%~V200 ≤ 12%"
2990249|NCT02628028|Experimental|Part A Low Dose LY3337641|Given once a day for 4 weeks.
2990250|NCT02628028|Experimental|Part A Mid Dose LY3337641|Given once a day for 4 weeks.
2990251|NCT02628028|Experimental|Part A High Dose LY3337641|Given once a day for 4 weeks.
2990252|NCT02628028|Placebo Comparator|Part A Placebo|Given once a day for 4 weeks.
2990253|NCT02628028|Experimental|Part B Low Dose LY3337641|Given once a day for 12 weeks.
2990254|NCT02628028|Experimental|Part B Mid Dose LY3337641|Given once a day for 12 weeks.
2990255|NCT02628028|Experimental|Part B High Dose LY3337641|Given once a day for 12 weeks.
2990256|NCT02628028|Placebo Comparator|Part B Placebo|Given once a day for 12 weeks.
2990257|NCT02628015||preschool children preterm|born 2010 or 2011 Birthweight <1500g
2990258|NCT02628015||preschool children full-term|born 2010 or 2011 born after 38 weeks
2990259|NCT02628015||school children preterm|same children from the preschool group will be tested 2 years later again
2990260|NCT02628015||school children full-term|same children from the preschool group will be tested 2 years later again
2990261|NCT02628015||youths preterm|born 2001 or 2002 Birthweight <1500g
2990262|NCT02628015||youths full-term|born 2001 or 2002 born after 38 weeks
2990263|NCT02628015||adults preterm|Birthweight <1500g
2990264|NCT02628015||adults full-term|born after 38 weeks
2990265|NCT02628002|Experimental|Test arm|The subjects randomized to the anti-gravity treadmill arm will be instructed on the safe use of the Alter-G treadmill by the study staff. After this instruction, subjects will be exercised on the Alter-G anti-gravity treadmill using the conventional Bruce protocol with unweighting to 75% of their body weight to reach target heart rate. If the subject is unable to reach the target heart rate, they will be further unweighted to 50% of their body weight to enable the subject to reach target heart rate on the Bruce protocol. If the subject is still unable to reach target heart rate with 50% unweighting, the patient's subsequent SPECT images will be excluded from use in the research comparison to control subject images.
2990266|NCT02628002|Active Comparator|Control arm|The control arm subjects will undergo the conventional treadmill/regadenoson pharmacological stress SPECT. Consistent with standard practice, these patients will perform adjunctive low-intensity walk on a conventional treadmill prior to regadenoson and Tc-99m injection if tolerated.
2990267|NCT02627989||Diflucortolone valerate (Nerisona/Texmeten)|Adult patients with atopic dermatitis switching from diflucortolone-valerate fatty ointment to ointment (water/oil emulsion) during autumn/ winter (Nov to Feb) or spring/ summer (May to Aug)
2990268|NCT02627976|Active Comparator|breast edema vest|
2990269|NCT02627963|Experimental|Tivozanib hydrochloride|Patients randomized to this arm will receive the study drug, tivozanib hydrochloride.
2990270|NCT02627963|Active Comparator|Sorafenib|Patients randomized to this arm will receive the comparator drug, sorafenib.
2990271|NCT02627950|Active Comparator|Isotonic sodium chloride + Ticagrelor|46 patients with NaCl i.v. and 180 mg ticagrelor orally pre revascularization plus medical standard therapy
2990272|NCT02627950|Experimental|Morphinhydrochloricum + Ticagrelor|46 patients with 5 mg morphine i.v. and 180 mg ticagrelor pre revascularization plus medical standard therapy
2990273|NCT02627950|Experimental|Morphinhydrochloricum + Ticagrelor + Metoclopramide|46 patients with 5 mg morphine i.v. and 10 mg MCP i.v. and 180 mg ticagrelor pre revascularization plus medical standard therapy
2990274|NCT02627937||pediatric sleep apnea|The children were confirmed to have OSAHS by comprehensive polysomnography (PSG).
2990275|NCT02627924||subjects with Rheumatoid Arthritis|Subject has a diagnosis of RA as defined by the 1987 revised American College of Rheumatology (ACR) classification criteria and/or the ACR/the European League against Rheumatism (EULAR) 2010 classification criteria (any duration since diagnosis)
2990276|NCT02627911|Other|Usual System (open-loop)|"In open loop, the patient will be provided with its usual pump and a CGM. To estimate rest and physical activity in patients being sedentary situation ( Centers : Caen, Nancy & Strasbourg) or in situations of physical activity ( Centers : CHSF Marseille and Besancon ) , the usual system will be complemented by an accelerometer  ActiGraph  and a  ActiHeart  heart rate monitor."
2990277|NCT02627911|Experimental|DIABELOOP System (closed-loop)|In the closed loop, the patient's pump will be replaced by the Diabeloop system consisting of insulin pump Cellnovo driven by remote control augmented by Diabeloop software and connected to the CGM.
2990278|NCT02627898|Experimental|Green tea extract|Individuals with T2DM controlled with metformin or glibenclamide, or both; with no hypertension neither treated with insulim
2990279|NCT02627898|Placebo Comparator|Placebo|Individuals with T2DM controlled with metformin or glibenclamide, or both; with no hypertension neither treated with insulim
2990280|NCT02627885|Active Comparator|ICBT|Internet-based CBT for Parkinsons Disease with therapist contact added to standard medical treatment
2990281|NCT02627885|Other|SMT|Standard Medical Treatment for Parkinsons Disease only
3009067|NCT02502370|Experimental|Group 2 ARM D FOLFOX|
2990283|NCT02627872||Smoker Control Group|Actively smoking participants with normal lung function (do not have COPD)
2990284|NCT02627872||Healthy Never-smoker Control Group|Healthy participants that never have smoked
2990285|NCT02627859|Experimental|Durolane SJ|Durolane SJ intra-articular injection; device
2990286|NCT02627846|Active Comparator|EndoVenous Laser Ablation|EndoVenous Laser Ablation (EVLA) involves the delivery of laser light through a glass fibre placed into the lumen of a refluxing vein. This energy is converted into heat inducing a permanent, non-thrombotic occlusion.
2990287|NCT02627846|Active Comparator|MechanoChemical Ablation (ClariVein®)|Mechanochemical ablation (MOCA) is performed by a device called ClariVein® which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip.
2990288|NCT02627833||Subject Group|Patients suffering from Bronchiolitis Obliterans
2990289|NCT02627833||Control Group|Age and sex matched control group
2990290|NCT02627820|Experimental|Experimental Drug|Isis 420915/GSK 299872, an antisense oligonucleotide. Administered subcutaneously three times per week for the first week, and then weekly for 18 months. Each dose shall contain 300 mg of active drug.
2990291|NCT02627807|Experimental|Individualized CTV|Patients receive IMRT using individualized CTV based on disease extension risk atlas and computer-aided delineation. Gemcitabine and cisplatin induction chemotherapy or docetaxel and cisplatin induction chemotherapy and cisplatin 100mg/m² concurrent chemotherapy or cisplatin 80mg/m² concurrent chemotherapy are optional based on clinical classification.
2990292|NCT02627807|Active Comparator|Traditional CTV|Patients receive IMRT using traditional CTV. Gemcitabine and cisplatin induction chemotherapy or docetaxel and cisplatin induction chemotherapy and cisplatin 100mg/m² concurrent chemotherapy or cisplatin 80mg/m² concurrent chemotherapy are optional based on clinical classification.
2990293|NCT02627794|Experimental|Silastic Silicone & Restora™ Steroid eluting spacer|"Silastic Silicone spacers are actively being used as the standard of care.~Restora™ Steroid eluting spacer (experimental).~Each nostril will receive one each of above spacers."
2990294|NCT02627781||suspected appendicitis|This group includes all patients with suspected appendicitis, who are admitted to our University Hospital.
2990295|NCT02627768||Cohort 1: Ustekinumab Treatment|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy.
2990296|NCT02627768||Cohort 2: TNFi Treatment|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy.
2990297|NCT02627755|Active Comparator|Glide group|Device: Glidescope® use
2990298|NCT02627755|Experimental|Glide+aScope group|Device: combined use of two airway devices Glidescope® + aScope®
2990299|NCT02627742|Experimental|METANEB|Patients will receive standard care with the addition of therapy with The MetaNeb® System.
2990300|NCT02627729|Active Comparator|Linear cutter-Circular stapler J pouch|J pouch anal anastomosis after laparoscopic low anterior resection
2990301|NCT02627729|Active Comparator|Circular stapler Side-to-end anastomosis|side to end coloanal anastomosis after laparoscopic low anterior resection
2990302|NCT02627716|Experimental|SOS Intervention Group|Subjects benefit from the SOS Plan in addition to the usual follow-ups
2990303|NCT02627716|No Intervention|Control Group|Subjects receive no additional intervention (tracking the continuation of psychiatric care according to the standard care terms)
2990304|NCT02627690||Islet transplanted|patients who underwent islet transplantation
2990305|NCT02627690||non islet transplanted|patients who refused or were non selected for islet transplantation for a non nephrologic reason
2990306|NCT02627677|Experimental|Cohort A: ponatinib 30 mg QD|ponatinib 30 mg, taken orally once daily
2990307|NCT02627677|Experimental|Cohort B: ponatinib 15 mg QD|ponatinib 15 mg, taken orally once daily
2990308|NCT02627677|Active Comparator|Cohort C: nilotinib 400 mg BID|nilotinib 400 mg, taken orally twice daily
2990309|NCT02627664||observational study|natural history of non dopaminergic signs
2990310|NCT02627651|Experimental|brain injury|children post brain injury
2990311|NCT02627651|Active Comparator|controls|children typically developed age matched
2990312|NCT02627638|Other|Osteopathic treatment|
2990313|NCT02627625|Experimental|test product A|tiotropium
2990314|NCT02627625|Experimental|test product B|tiotropium
2990315|NCT02627625|Experimental|test product C|tiotropium
2990316|NCT02627625|Active Comparator|Commercial product D|tiotropium
2990317|NCT02627625|Active Comparator|commercial product E|tiotropium
2990318|NCT02627612|Experimental|TM RWB PLUS Pro Vetus|Research participants will receive an introductory email from the research team informing them that they were randomly assigned to this group and request that they voluntarily join TM RWB and receive mentorship from their matched and assigned mentor. In addition to TM RWB membership, research participants will also receive approximately four months of mentorship from a ProVetus mentor to assist them in further transitioning within the five domains.
2990319|NCT02627612|Active Comparator|TM RWB ONLY|Research participants will receive an introductory email from the research team informing them that they were randomly assigned to this arm and request that they voluntarily join TM RWB. Weekly emails will provide lists of voluntary physical/social activities available to all Chapter members. No participation is required in these activities.
2990320|NCT02627612|No Intervention|Control Group (Waitlist)|Research participants (recent Veterans) will be placed on a waitlist for approximately sixteen months. Based on their desires, the research participants in this group will have opportunity to belong to TM RWB plus receive approximately four months of mentorship from trained, peer-mentors (who are TM RWB volunteers).
2990349|NCT02627391|Active Comparator|Delayed surgery according to guidelines|Surgical aortic valve replacement
2990350|NCT02627378|Active Comparator|Extracorporeal Membrane Oxygenation|Patients received Extracorporeal Membrane Oxygenation (ECMO) support
3009103|NCT02502162|Experimental|LDN|Naltrexone HCL, 4.5 mg, Once a day.
2990321|NCT02627599||Chronic Obstructive Pulmonary Disease|"More than 12 million adults are diagnosed with COPD~COPD is the 3rd leading cause of death in the U.S.~Breathing difficulty is the major reason patients seek medical attention~COPD patients requiring hospitalization are associated with higher costs~Oximetry is an important tool for assessing need for Long-Term Oxygen Therapy~LTOT has been proven to improve survival and quality of life~Patients provided with a breath responsive variable bolus oxygen conserving device:~support increased activity~improve quality of life~increase functional capability~reduce portable oxygen source utilization~maintain and/or improve oxygen saturation"
2990322|NCT02627586|Active Comparator|Moderate intensity continuous exercise|Moderate intensity continuous exercise (MICE) is performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-85% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down). This group will perform MICE training three times per week. Cycling resistance will be adjusted weekly according to heart rate and Borg scale.
2990323|NCT02627586|Experimental|High-intensity interval training|"High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. Moderate intensity continuous exercise (MICE) is also performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-85% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down). This group performs two HIIT sessions and one MICE session per week.~In both training forms cycling resistance will be adjusted weekly according to heart rate and Borg scale."
2990324|NCT02627573|Experimental|Thymoglobulin|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -5 Busulfan 1 mg/kg po qid x 2 days Days -4 through -3 Thymoglobulin 2,5 mg/kg po qd x 2 days Days -1 through +30: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days -1 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration
2990325|NCT02627573|Experimental|PTCy|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
2990326|NCT02627560|Experimental|topical tranexamic acid|tranexamic acid to be smeared on surgical wounds before closure
2990327|NCT02627560|Placebo Comparator|placebo control|saline to be smeared on surgical wounds before closure
2990328|NCT02627547|Experimental|Experimental tests|2 sets of experimental tests; once, during a period of normal training and repeated following one week of de-training
2990329|NCT02627534|Active Comparator|Ultrasonic Debridement (UD)|Ultrasonic Debridement (UD) (n=20)
2990330|NCT02627534|Experimental|UD + Antimicrobial Photodynamic Therapy|Ultrasonic Debridement + aPDT (UD+aPDT) (n=20)
2990331|NCT02627521|Experimental|PRU Guided CABG|Timing of CABG surgery within 24 hours of reaching a normalized platelet function (NPF). NPF defined as a PRU value >235 or a PRU value between >170 and <235 for two consecutive days as documented by VerifyNow assay.
2990332|NCT02627521|Active Comparator|CABG per standard of care|Timing of CABG per standard of care
2990333|NCT02627508|Experimental|Pregnenolone (up to 500 mg per day)|"Twice daily intake of orally administered Pregnenolone will occur on a schedule as described below.~Weeks 1 and 2: 30mg twice daily (total 60mg per day)~Weeks 3 and 4: 60mg twice daily (total: 120mg per day)~Weeks 5 and 6: 90mg twice daily (total: 180mg per day)~Weeks 7 and 8: 150mg twice daily (total: 300mg per day)~Weeks 9 and 10: 210mg twice daily (total: 420mg per day)~Weeks 11 to 14: 250mg twice daily (total: 500mg per day)"
2990334|NCT02627508|Placebo Comparator|Placebo|Placebo
2990335|NCT02627495|Experimental|tDCS intervention (open label)|Subjects will undergo tDCS stimulation
2990336|NCT02627469|No Intervention|Control|Common oral hygiene help administered by nursing staff
2990337|NCT02627469|Experimental|Intervention|Extended professional oral hygiene care Electric toothbrush (Oral-B Professional Care 7000) 1100 ppm sodium fluoride dentifrice (Zendium Classic, Opus Health Care AB/Zendium)
2990338|NCT02627456|Experimental|1A|(n=5), will be asafety group.Subjects will receive1 dose of PfSPZVaccine (4.5x105)
2990339|NCT02627456|Experimental|1B|n=5), will be asafety group.Subjects will receive1 dose of PfSPZVaccine (9.0x105)via DVI. All 5subjects will receiveantimalarialtreatment withartesunate/amodiaquine (ASAQ) prior toPfSPZ Vaccine.Subjects will befollowed forapproximately 3months postvaccination.
2990340|NCT02627456|Experimental|1C|(n=30), will be thetargeted dose forthe primary PilotSafety Group.Subjects will receive3 doses of PfSPZVaccine (18x105)via DVI on Day 1,57, 113. 15 subjectswill receiveantimalarialtreatment withartesunate/amodiaquine (AS/AQ) priorto eachadministration ofPfSPZ Vaccine, while15 will not. All 30subjects will receiveantimalarialtreatment withASAQ prior to PfSPZChallenge.
2990341|NCT02627456|Experimental|1D|(n=15), will be theCHMI control group.Subjects will notreceive any PfSPZvaccinations but willserve as infectivitycontrols for CHMI.All 10 subjects willreceive antimalarialtreatment withASAQ prior to PfSPZ challenge
2990342|NCT02627443|Experimental|Arm I (carboplatin, gemcitabine hydrochloride, VX-970)|Patients receive carboplatin IV over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and ATR kinase inhibitor VX-970 IV over 60 minutes on days 2 and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2990343|NCT02627443|Active Comparator|Arm II (carboplatin, gemcitabine hydrochloride)|Patients receive carboplatin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2990344|NCT02627430|Experimental|Treatment (talazoparib and Hsp90 inhibitor AT13387)|Patients receive talazoparib PO QD on days 1-7 (course 0). Beginning in course 1, patients receive talazoparib PO QD on days 1-28 and HSP90 inhibitor AT13387 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2990345|NCT02627417|Experimental|Dapsone: (Disulone®)|Dapsone: Disulone® given orally at 100 mg per day
2990346|NCT02627417|Active Comparator|"Prednisone (Cortancyl®) alone and standard of care"|"Prednisone (Cortancyl®) alone at 1 mg/kg for 3 weeks followed by monitoring and standard of care (control arm)"
2990347|NCT02627404|Other|Main module|Blood sample
2990348|NCT02627391|Experimental|Early surgery|Surgical aortic valve replacement
2990351|NCT02627378|Placebo Comparator|Non Extracorporeal Membrane Oxygenation|Patients did not receive Extracorporeal Membrane Oxygenation (ECMO) support
2990352|NCT02627365|Experimental|Individualized, interactive SMS|Individualized, interactive SMS intervention plus Standard care. Messages sent automatically using the Text-IT system.
2990353|NCT02627365|No Intervention|Standard care|Standard care according to Kenyan guidelines, including clinic-based adherence education and counseling.
2990354|NCT02627352|Experimental|Transscleral Cyclophotocoagulation|Subjects undergo a Micropulse Transscleral Cyclophotocoagulation(TSCPC) laser surgery, where a diode laser is used to damage tissue of the ciliary body, the tissue inside the eye that produces aqueous, the clear fluid in the eye that maintains intraocular pressure. This causes it to produce less aqueous.
2990355|NCT02627339||Healthy controls|Healthy controls age 10 to 90 years
2990356|NCT02627326|Active Comparator|Group 1|Interventions done in 30 patients and included conventional endodontic treatment (ET) and periodontal surgery . After 3 months of completion of endodontic therapy without using 2%chlorhexidine gluconate gel intracanal medicament , periodontal surgery in the form of open flap debridement (OFD) was performed.
2990357|NCT02627326|Active Comparator|Group 2 Chlorhexidine|Interventions done in 30 patients and included intracanal medicament . After biomechanical preparation of root canal, 2%Chlorhexidine gluconate gel as an intracanal medicament was placed in root canal from pulp chamber to apex for 3 months (replacing every month). After 3 months,periodontal surgery in the form of open flap debridement (OFD) was performed in the respective tooth and medicament was changed and placed further for 3 months (replacing every month). Obturation was done after 3 months of OFD.
2990358|NCT02627313|Experimental|GammaPod|GammaPod tumour bed boost
2990359|NCT02627300|Experimental|Octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
2990360|NCT02627287|Experimental|DV3316 pen-injector|
2990361|NCT02627287|Active Comparator|FlexPen®|
2990362|NCT02627274|Experimental|Part A: RO6874281 Monotherapy|Dose Escalation: RO6874281 will be administered as an intravenous (IV) infusion. The starting dose regimen of RO6874281 as a single agent will be 5 milligrams (mg) once weekly (QW). Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 for a maximum of 24 months.
2990363|NCT02627274|Experimental|Part B: RO6874281 in Combination with Trastuzumab|"Dose Escalation: RO6874281 will be administered as an IV infusion. The starting dose regimen of RO6874281 in combination with trastuzumab will be 10 mg QW. The standard dose for trastuzumab will be a loading dose of 4 milligrams per kilogram (mg/kg) followed by a maintenance dose of 2 mg/kg from Cycle 2 in a QW regimen. Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 in combination with trastuzumab until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 in combination with trastuzumab for a maximum of 24 months.~Extension Phase: When the MTD and/or the OBD and/or the recommended dose for further development of RO6874281 is defined, participants will receive the MTD and/or the OBD and/or the recommended dose for further development of RO6874281."
2990364|NCT02627274|Experimental|Part C: RO6874281 in Combination with Cetuximab|"RO6874281 will be administered as an IV infusion. The starting dose regimen of RO6874281 in combination with cetuximab will be 5 mg QW. Cetuximab will be administered QW as a loading dose of 400 milligrams per square meter (mg/m^2) followed by a maintenance dose of 250 mg/m^2 from Cycle 2. Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 in combination with cetuximab until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 in combination with cetuximab for a maximum of 24 months.~Extension Phase: When the MTD and/or the OBD and/or the recommended dose for further development of RO6874281 is defined, participants will receive the MTD and/or the OBD and/or the recommended dose for further development of RO6874281."
2990365|NCT02627261||patients with multiple myeloma|blood samples and bone marrow aspirates will be collected in patients at different time point
2990366|NCT02627248|Experimental|Docetaxel, Epirubicin and Cyclophosphamide (TEC)|Six cycles of docetaxel (75 mg/m²), epirubicin (70 mg/m²) and cyclophosphamide (600 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be not be administrated.
2990367|NCT02627248|Experimental|Docetaxel, Epirubicin and Cyclophosphamide + Huaier (TEC+HE)|Six cycles of docetaxel (75 mg/m²), epirubicin (70 mg/m²) and cyclophosphamide (600 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be administrated from the first cycle of chemotherapy until time of definitive surgery.
2990368|NCT02627248|Experimental|Epirubicin and Docetaxel (ET)|Six cycles of epirubicin (70 mg/m²) and docetaxel (75 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be not be administrated.
2990369|NCT02627248|Experimental|Epirubicin and Docetaxel+Huaier (ET+HE)|Six cycles of epirubicin (70 mg/m²) and docetaxel (75 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be administrated from the first cycle of chemotherapy until time of definitive surgery.
2990370|NCT02627235|Experimental|DIAL Intervention|The physical activity intervention emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals), and includes daily IVR-system call feedback and monthly graphic-based feedback delivered in the mail. In addition, social support, outcome expectations and perceived physical activity enjoyment variables will be assessed at baseline, 30, 60, and 90 days. Responses will be used to select appropriate tailored feedback modules.
2990371|NCT02627235|Active Comparator|Wait List Control|Access to the intervention 12 weeks following baseline assessment.
2990372|NCT02627222|Active Comparator|Treatment|Daily consumption of two cassava-based meals prepared with pro-vitamin A rich biofortified cassava
2990373|NCT02627222|Placebo Comparator|Control|Daily consumption of two cassava-based meals prepared with common white cassava
2990374|NCT02627209|Active Comparator|serum angiotensin converting enzyme|spectrophotometric assay
2990375|NCT02627209|Active Comparator|serum lysozyme|radial immunodiffusion
2990443|NCT02626663||TTP|Thrombotic thrombocytopenic purpura
2990376|NCT02627196|Experimental|Device Arm|Subjects will receive Barostim Activation Therapy® with the implanted BAROSTIM NEO® System in addition to optimal guideline directed medical management.
2990377|NCT02627196|No Intervention|Guideline Directed Medical Management|Patients will be followed under optimal guideline directed medical management.
2990378|NCT02627183||Paroxysmal AF + catheter ablation|Subjects with paroxysmal Atrial Fibrillation (AF) undergoing catheter ablation.
2990379|NCT02627183||Permanent/persistent AF + exercise|Subjects with permanent or persistent Atrial Fibrillation (AF) undergoing exercise training two times weekly for 12 weeks as part of their involvement in the OPPORTUNITY Study (NCT02602457).
2990380|NCT02627170||Healthy adults group|Age 20 to 40 years of age and have myopia with a spherical equivalent (SE) between 0.00 and -11.00 diopters (D)
2990381|NCT02627157||myopia patients|20 to 40 years of age and have myopia with a spherical equivalent (SE) between 0.00 and -11.00 diopters (D)
2990382|NCT02627144||Advanced and/or Metastatic RCC participants|Participants with mRCC who are being treated with bevacizumab at the recommended dose of 10 milligram per kilogram (mg/kg) of body weight once every 2 weeks as an intravenous infusion, in combination with interferon alpha-2a at the recommended starting dose of 9 million international units (MIU) 3 times a week until disease progression will be observed. No diagnostic or therapeutic interventions will be given other than used in normal daily routine.
2990383|NCT02627131|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
2990384|NCT02627118|Experimental|Dialyzer Comparison|2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR followed by 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H
2990385|NCT02627105|Experimental|Beef group|Subjects in this group are asked to consume 4 or more servings of beef per week and to exclude all other red meats from their diet for the 6 month study.
2990386|NCT02627105|Other|Non-beef group|Subjects in this group are asked to avoid all red meats from their diet for the 6 month study.
2990387|NCT02627092|Experimental|Copper linen exposure|"Subjects will use copper linens during their hospital stay, consisting of copper hospital gowns, copper bed sheets (top and bottom sheets), and copper pillow covers.~A subset of 50 subjects from this arm will be recruited to provide three types of swabs to calculate the microbial burden on copper linens. Linen swabs, anatomical swabs and environmental swabs will be collected from subjects and subject hospital rooms will be collected to do bacteria counts."
2990388|NCT02627092|No Intervention|Non-copper linen exposure|"Subjects will not have exposure to copper linens during their hospital stay. They will use the usual hospital linens provided by hospital, not containing copper.~A subset of 50 subjects from this arm will be recruited to provide three types of swabs to calculate the microbial burden on copper linens. Linen swabs, anatomical swabs and environmental swabs will be collected from subjects and subject hospital rooms will be collected to do bacteria counts."
2990389|NCT02627079|Active Comparator|Cohort 1|"Cohort 1 will include 15 sedentary participants who have completed all cancer therapy except adjuvant hormonal therapy.~All participants will be provided a Fitbit. Participants will then be provided daily SMS text messaging tailored to their activity level for 12 weeks.."
2990390|NCT02627079|Active Comparator|Cohort 2|Cohort 2 will include 15 sedentary participants in active treatment. All participants will be provided a Fitbit. Participants will then be provided daily SMS text messaging tailored to their activity levels for 12 weeks.
2990391|NCT02627066|Active Comparator|Volume Control|This group of patients will receive a volume reduction protocol that includes two primary components: 1) persistent ultrafiltration to slowly reduce patient's post-dialysis weight; and 2) persistent dietary education focused on reducing intake of dietary sodium and phosphorus additives
2990392|NCT02627066|Active Comparator|Volume Control + Exercise|This group of patients will receive the volume control intervention in addition to intensive counseling to increase their physical activity levels.
2990393|NCT02627053|Experimental|rivaroxaban|
2990394|NCT02627040|Active Comparator|InterTan Intertrochanteric Nail|'Surgical fixation' of intertrochanteric fracture with a cephalomedullary nail with an InterTan device (two-integrated screws)
2990395|NCT02627040|Active Comparator|Gamma 3 Intertrochanteric Nail|'Surgical fixation' of intertrochanteric fracture with a cephalomedullary nail and Gamma 3 locking nail (single screw)
2990396|NCT02627027|Experimental|RT group|R: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T) T: Test drug(CKD-395 0.25/750 mg 2T)
2990397|NCT02627027|Experimental|TR group|T: Test drug(CKD-395 0.25/750 mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T)
2990398|NCT02627014|Experimental|INTERVENTION|Manual Therapy in temporomandibular joint and cervical region. Home physical therapy in temporomandibular joint and cervical region.
2990399|NCT02627014|Active Comparator|CONTROL|Manual therapy in cervical region Home physical therapy in cervical region
2990400|NCT02627001|Experimental|NuMask Intraoral Airway Device|A United States Army Combat Medic uses a single hand technique to hold a Nu-Mask Intraoral Airway Device on a cadaver while an Impact 731 ventilator delivers 10 standardized breaths with tidal volumes of 750 ml each.
2990401|NCT02627001|Active Comparator|Bag Valve Mask|A United States Army Combat Medic uses a single hand technique to hold a conventional bag valve mask on a cadaver while an Impact 731 ventilator delivers 10 standardized breaths with tidal volumes of 750 ml each.
2990402|NCT02626988|Experimental|Intervention|The intervention group will receive capacity building sessions on the 'Promotion of a biodiverse diet' and will include both Agriculture and Nutrition topics, in addition to access to routine health and nutrition checks, and agriculture extension as offered by commune and provincial staff as normal. 5 Sessions will be held in each village over 12 months.
2990403|NCT02626988|No Intervention|Control|The control group will continue to receive routine health check and nutrition education from health staff at commune health facilities. Access to agriculture extension services as offered by provincial staff will also continue as normal.
2990404|NCT02626975||ACL reconstruction ballooning|"ACL reconstruction with short hamstring tendon autograft~arm ballooning~arm no ballooning"
2990405|NCT02626962|Experimental|Nivolumab and Ipilimumab|Nivolumab and Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
2990406|NCT02626949|Experimental|MBSR Course|Mindfulness-Based Stress Reduction Course (MBSR) consisting of 8 weekly sessions, 2.5 hours each, and a 5 hour silent retreat during the 6th week of the program.
2990407|NCT02626949|Experimental|HEP Course|Health Enhancement Program (HEP) consisting of 8 weekly sessions, 2.5 hours each, and 1.5 hour monthly educational sessions after the 8 week intervention.
2990408|NCT02626936|Active Comparator|Dual-hormone CL with overestimation of meal size category|A large size standardized meal of 75g of carbohydrates will be provided to the patient and the meal size will be overestimated by one category, which will result in a meal insulin bolus for a meal of 95g of carbohydrates.
2990409|NCT02626936|Active Comparator|Dual-hormone CL with adequate estimation of meal size category|A large size standardized meal of 75g of carbohydrates will be provided to the patient and the meal size will be adequately estimated, which will result in a meal insulin bolus for a meal of 65g of carbohydrates.
2990410|NCT02626923||Patients on once daily Maraviroc|Maraviroc tablet 600 mg once daily 48 weeks
2990411|NCT02626910||Second Life: People with disabilities|People with disabilities recruited from the virtual world, Second life.
2990412|NCT02626910||Second Life: People without disabilities|People without disabilities recruited from the virtual world, Second life.
2990413|NCT02626910||Second Life: Clinicians|Clinicians recruited from the virtual world, Second life.
2990414|NCT02626910||Urban group|People with and without disabilities recruited from an Urban setting.
2990415|NCT02626897|Other|Sarcoidosis - GENEActiv device first|Six patients start with the GENEActiv wrist-worn accelerometer which is needed to be worn for a 7 day period. Participants then switch to the ActiGraph GT3X device for a 7 day period. At the end of this second period they complete a short exit questionnaire detailing their experience and their device preference.
2990416|NCT02626897|Other|Sarcoidosis - ActiGraph device first|Six patients start with the ActiGraph GT3X wrist-worn accelerometer which is needed to be worn for a 7 day period. Participants then switch to the GENEActiv device for a 7 day period. At the end of this second period they complete a short exit questionnaire detailing their experience and their device preference.
2990417|NCT02626884|Experimental|Ibrutinib|All patient receive ibrutinib at a dose of 560 mg/d for up to 20 21-day cycles
2990418|NCT02626858|Other|extra treatment planning CT-scan|Extra pre-operative CT-scan for treatment planning in RT
2990419|NCT02626845|Active Comparator|Rituximab Arm|All subjects in this arm will receive standard of care induction therapy, and then will receive two additional rituximab infusions at week 16 and week 32.
2990420|NCT02626845|Placebo Comparator|Placebo Arm|All subjects in this arm will receive standard of care induction therapy, and then will receive two additional placebo infusions at week 16 and week 32.
2990421|NCT02626832|Experimental|Healthy Control|This group is represented by healthy controls
2990422|NCT02626832|Experimental|Depression|This experimental group is represented by subjects with depression
2990423|NCT02626832|Experimental|Schizophrenia|This experimental group is represented by subjects with schizophrenia
2990424|NCT02626832|Experimental|Prodromal subjects|This experimental group is represented by subjects with prodromal symptoms for schizophrenia
2990425|NCT02626819|Experimental|Arm 1: Receiving MOVE! Toward Your Goals|Receiving MOVE! Toward Your Goals intervention (MTG tool, health coaching at baseline, follow-up health coaching calls, potential support of goals from primary care provider)
2990426|NCT02626819|Active Comparator|Arm 2: Receiving Enhanced Usual Care|Receiving Enhanced Usual Care (standard VA Health Living Messages handouts, potential support of weight management efforts from primary care provider)
2990427|NCT02626806||patients with hemodynamic significant CAD;|
2990428|NCT02626806||patients without hemodynamic significant CAD|
2990429|NCT02626793||Patients with ≤ 1 conventional, systemic pre-treatment|After failure (inadequate response/intolerance) to or contraindication for ≤ 1 conventional, systemic pre-treatment
2990430|NCT02626793||Patients with > 1 conventional, systemic pre-treatment|After failure (inadequate response/intolerance) to or contraindication for > 1 conventional, systemic pre-treatment
2990431|NCT02626780|Experimental|SVF Injection|Autologous adipose-derived SVF will be injected into a small (approximately 2x2cm) area of the scalp in men or women with androgenic alopecia.
2990432|NCT02626767|Experimental|Intervention|Participants were required to complete a high-intensity interval exercise training intervention, which took place three time per week for 10 weeks. The exercise sessions comprised of 4 to 7 repetitions of 45 s maximal effort exercise, based on boxing, dance, soccer and basketball drills), interspersed with 90-s rest. During each repetitions participants were encouraged to reach >90% of their individual maximal heart rate. Participants were asked to maintain their dietary habits throughout the intervention period.
2990433|NCT02626767|No Intervention|Control|Participants were asked to maintain their usual diet, physical education and physical activity habits during the intervention period and were not aware that an exercise intervention was taking place at other study sites.
2990434|NCT02626754|Experimental|Sunitinib|Sunitinib malate, 12.5mg/capsule, 50mg/day
2990435|NCT02626741|Experimental|meal replacement group|the participants receive a meal replacement plus life style modification
2990436|NCT02626741|Experimental|control group|the participants receive life style modification only.
2990437|NCT02626715|Active Comparator|Reduced-Intensity Conditioning|"Campath (alemtuzumab), Droxia (hydroxyurea), Fludara (fludarabine), Alkeran (melphalan), Thiotepa (triethylenethiophosphoramide)~Trade Name (generic name)"
2990438|NCT02626715|Active Comparator|Myeloablative Conditioning|"Campath (alemtuzumab), Thiotepa (triethylenethiophosphoramide) , Fludara (fludarabine), Busulfex (busulfan)~Trade Name (generic name)"
2990439|NCT02626689||β-thalassemia transfusion dependent subjects|Participants will complete 3 quality of life instruments (i.e. FACT-AN, the SF-36v2, and the TranQol) once every 3 weeks, in addition to a TranQol instrument on the day of a RBC transfusion. Continuous monitoring of Healthcare Resource Utilization will be conducted throughout the course of the study at each clinical visit.
2990440|NCT02626689||β-thalassemia Non Transfusion Dependent (NTD) subjects|Participants will complete 2 quality of life instruments (i.e. FACT-An and the the SF-36v2l) once every 3 weeks, in addition to completing the non-transfusion dependent Patient Recorded Outcome (PRO) tool on a daily basis. Continuous monitoring of Healthcare Resource Utilization will be conducted throughout the course of the study at each clinical visit.
2990441|NCT02626676|Experimental|Educational Programme Group|Stage 5D Chronic Kidney Disease Patients on high-efficiency hemodialysis programme - 4-hour sessions, 3 times a week will be followed up
2990442|NCT02626663||aHUS|atypical Hemolytic Uremic Syndrome
2990445|NCT02626650|Active Comparator|Check symptoms one has experienced|This is the baseline condition. When asked to indicate concussion symptoms (or most other kinds of symptoms for medical conditions), people usually place a check mark next to each symptom they have experienced.
2990446|NCT02626650|Experimental|Check symptoms one has not experienced|Participants place a check mark next to each symptom they have NOT experienced in the most recent sports season.
2990447|NCT02626650|Experimental|Uncheck symptoms one has experienced|To begin, all symptoms will be automatically checked. Participants are told to remove a check mark from each symptom they have experienced in the most recent sports season.
2990448|NCT02626650|Experimental|Uncheck symptoms one has not experienced.|To begin, all symptoms will be automatically checked. Participants are told to remove a check mark from each symptom they have NOT experienced in the most recent sports season.
2990449|NCT02626637|Experimental|Physical activity coaching|Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
2990450|NCT02626611|Placebo Comparator|Placebo|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
2990451|NCT02626611|Active Comparator|Low Dose Food|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
2990452|NCT02626611|Active Comparator|High Dose Food|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
2990453|NCT02626598||Treated patients|Patients treated with blended Belotero for etched-in fine lines of the cutaneous lip, and/or radial cheek area, and/or nasolabial folds, and/or melolabial folds, and/or forehead area will be evaluated with photographs, physician ratings, and patient improvement assessments.
2990454|NCT02626585|No Intervention|Control|Control group (n=20): Following removal of nasal cast on postoperative first week, no additional taping was applied to this group.
2990455|NCT02626585|Experimental|2-weeks of PRT|2-weeks of PRT (n=17): Following removal of nasal cast on postoperative first week, 2 weeks of additional postrhinoplasty taping was applied to this group (form 1st to 3rd week).
2990456|NCT02626585|Experimental|4-weeks of PRT|4-weeks of PRT (n=20): Following removal of nasal cast on postoperative first week, 4 weeks of additional postrhinoplasty taping was applied to this group (form 1st to 5th week).
2990457|NCT02626572|Experimental|S47445 5mg|
2990458|NCT02626572|Experimental|S47445 15mg|
2990459|NCT02626572|Experimental|S47445 50mg|
2990460|NCT02626572|Placebo Comparator|Placebo|
2990461|NCT02626546||Major surgical procedures|All patients selected to follow up
2990462|NCT02626533||Total knee arthroplasty patients|Patients undergoing total knee arthroplasty for osteoarthritis are enrolled in the study. Blood and joint fluid samples will be obtained from patients, and questionnaires will be administered to assess pain and stiffness.
2990463|NCT02626520|Experimental|Resectable, Low Risk|Systemic chemotherapy followed by definitive surgery without pre-operative or post-operative radiotherapy.
2990464|NCT02626520|Experimental|Locally Advanced|Systemic chemotherapy followed by chemoradiation, followed by definitive surgery
2990465|NCT02626507|Experimental|Gedatolisib ER+/HER2- Breast Cancer|"Gedatolisib at escalating doses of 180, 215 and 260 mg via a 3-6 dose-escalation scheme is administered once weekly on the first day for each of the four weeks during the four 4-week cycles.~Faslodex at 500 mg is administered IM into the buttocks slowly (over 1 - 2 minutes per injection) as two 5-mL injections, one in each buttock, on Days 1 and 15 of Cycle 1 and on Day 1 of the remaining three 4-week treatment cycles.~Palbociclib at 125 mg is administered PO with food daily on Days 1-21 for each of the four 4-week cycles~Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment."
2990466|NCT02626494|Experimental|Cocaine Group|n-AC and placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 4 doses of n-AC/placebo over 2 consecutive days (total dose=4800mg; individual dose=1200mg). Subjects will take the first 2 doses of n-AC/placebo 5 days after the screening assessment (one in the morning, one in the evening), and the last 2 dose 1h prior to scanning, with 12 hours dosing intervals in between. 14 days later n-AC/placebo will be administered analogously as described above. Preparation and blinding of n-AC and placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
2990467|NCT02626494|Active Comparator|Healthy Control Group|n-AC and placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 4 doses of n-AC/placebo over 2 consecutive days (total dose=4800mg; individual dose=1200mg). Subjects will take the first 2 doses of n-AC/placebo 5 days after the screening assessment (one in the morning, one in the evening), and the last 2 dose 1h prior to scanning, with 12 hours dosing intervals in between. 14 days later n-AC/placebo will be administered analogously as described above. Preparation and blinding of n-AC and placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
2990468|NCT02626481|Experimental|Daratumumab + Dexamethasone|patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
2990469|NCT02626468||Normal|Participants with no diagnosis of respiratory disease between the ages of 0 and 80
2990470|NCT02626468||COPD|Patients from different diagnostic groups between the ages of 0 and 80
3009104|NCT02502162|Placebo Comparator|Placebo|Sugar pill
2990471|NCT02626455|Experimental|Copanlisib + R-B or R-CHOP / Arm 1|Combination of copanlisib with standard immunochemotherapy (rituximab and bendamustine) [R-B] or rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone [R-CHOP] (safety run-in and phase III)
2990472|NCT02626455|Placebo Comparator|Placebo + R-B or R-CHOP / Arm 2|Combination of placebo and R-B or R-CHOP (phase III only)
2990473|NCT02626442|Experimental|Group Exercise Class|6 month group balance/exercise class, three days a week - up to one hour. Exercise program includes walking around a track, bodyweight/balance exercises, and an obstacle course.
2990474|NCT02626442|No Intervention|Testing|Subjects enrolled in other MERCE exercise and robotics interventions will receive balance/walking tests, MRI with famous name recognition task, and cognitive testing pre and post their intervention.
2990475|NCT02626429|Experimental|Active, Young Adult Famale|Participants will complete a bout of exercise and then consume a randomly assigned amino acid intake prior to measuring whole body 13CO2 excretion and phenylalanine oxidation.
2990476|NCT02626416|Experimental|telemedicine group|Congenital cataract patients use telemedicine to pursue and adjust the time of follow-up under non-clinical settings
2990477|NCT02626416|No Intervention|non-telemedicine group|Congenital cataract patients pursue and adjust the time of follow-up through outpatient visit in the hospital
2990478|NCT02626403|Active Comparator|anodal tDCS|Patients will receive anodal tDCS (bilateral fronto-parietal stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
2990479|NCT02626403|Sham Comparator|sham tDCS|Patients will receive sham tDCS (15 second of stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
2990480|NCT02626390|Experimental|Implicit Learning|Physiotherapy delivered based on implicit treatment guidance - achieved primarily by reducing the frequency of verbal coaching statements and promoting an external focus of attention.
2990481|NCT02626390|Active Comparator|Explicit Learning|Physiotherapy delivered based on explicit treatment guidance - achieved primarily by giving frequent verbal coaching statements and promoting an internal focus of attention.
2990482|NCT02626377|Experimental|Interventional arm|'Support provided by social worker'
2990483|NCT02626377|Other|Non-interventional arm|'Information booklet receipt'
2990484|NCT02626364|Experimental|Treatment|crenolanib 100mg PO TID
2990485|NCT02626351|Experimental|Receiving/ received QI intervention|A clinic which is presently receiving the Intensive Phase of the QI intervention, or is in the Maintenance Phase
2990486|NCT02626351|Active Comparator|Not yet received QI intervention|A clinic which has not yet received the QI intervention
2990487|NCT02626338|Experimental|Arm A|"Mitoxantrone~Cytarabine~Crenolanib"
2990488|NCT02626338|Experimental|Arm B|"Mitoxantrone~Etoposide~Cytarabine~Crenolanib"
2990489|NCT02626338|Experimental|Arm C|"Fludarabine~Cytarabine~G-CSF~Idarubicin~Crenolanib"
2990490|NCT02626312|Experimental|Advanced Cirrhosis Group|"Participant receives radiation therapy up to 5 days a week for a total of either 15 or 25 doses, based on decision of physician.~Participant may receive chemotherapy while on study based on decision of physician.~Symptom questionnaire completed at baseline, weekly during radiation treatment, and at follow up."
2990491|NCT02626312|Experimental|Low Functional Liver Volume Group|"Participant receives radiation therapy up to 5 days a week for a total of either 15 or 25 doses, based on decision of physician.~Participant may receive chemotherapy while on study based on decision of physician.~Symptom questionnaire completed at baseline, weekly during radiation treatment, and at follow up."
2990492|NCT02626312|Experimental|Prior Liver Directed Radiation Group|"Participant receives radiation therapy up to 5 days a week for a total of either 15 or 25 doses, based on decision of physician.~Participant may receive chemotherapy while on study based on decision of physician.~Symptom questionnaire completed at baseline, weekly during radiation treatment, and at follow up."
2990493|NCT02626299|Placebo Comparator|200 mg/day DHA|Participants will receive 2 placebo pills/day that do not contain DHA. Like the experimental group, they will be given a supplement of Docosahexaenoic acid - 200mg/day , a common amount in prenatal vitamins.
2990494|NCT02626299|Experimental|1000 mg/day DHA|The intervention includes Docosahexaenoic acid - 800mg/day per day provided in two 400 mg capsules. The intervention group as well as the active comparator group will be given 1-200 mg/capsule per day of DHA that is a common amount in prenatal vitamins.
2990495|NCT02626286|Other|HIV quarterly global care|HIV quarterly global care including i) data collection on health status, symptoms of sexually transmitted infections (STI) and sexual behavior, ii) a clinical examination, iii) STI diagnosis and treatment, iv) prevention counselling adapted for MSM, v) the provision of condoms and lubricants, and vi) HIV screening test at each quarterly visit for HIV-negative MSM or immediate support of HIV infection including antiretroviral therapy for HIV-positive MSM.
2990496|NCT02626273|Experimental|intervention group|an intervention group who will undergo the management program combining physical activity and restrictive diet at Tza Nou Medical House for 10 months
2990497|NCT02626273|Other|a control group|a control group who will not undergo any intervention
2990498|NCT02626260|Experimental|Cohort 1b|The subject test one adhesive strip on the peristomal area
2990499|NCT02626247|Active Comparator|Vitamin A + Long chain PUFA|The test product is a food supplement containing Vitamin A + Long chain Poly Unsaturated Fatty Acids (PUFA). It is presented as a hard shell capsule containing lipophylic nutrients.
2990500|NCT02626247|Placebo Comparator|Placebo|The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
2990501|NCT02626234|Experimental|INC280|
2990502|NCT02626221||Single|Single Cohort Study
2990503|NCT02626208|Experimental|Nestorone®/ Estradiol 75|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 75 ug/day of estradiol
2990504|NCT02626208|Experimental|Nestorone®/Estradiol 100|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 100 ug/day of estradiol
2990505|NCT02626208|Experimental|Nestorone®/ Estradiol 200|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 200 ug/day of estradiol
2990506|NCT02626195|Experimental|nutritional support program apply|Preoperative nutritional support program is given for 5 or more days preoperatively by nutritional support program.
2990507|NCT02626195|No Intervention|historical control group|Historical control group is that did not receiving
2990508|NCT02626182|Experimental|Sildenafil|Subjects will be randomized in a 3:1 (sildenafil:placebo) fashion. Subjects randomized to the treatment arm will receive sildenafil 20 mg p.o. t.i.d for 1 week followed by 40 mg p.o. t.i.d. for 11 weeks.
2990509|NCT02626182|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will receive placebo p.o. t.i.d for 1 week followed by 2 placebo tablets p.o. t.i.d. for 11 weeks.
2990510|NCT02626169|Active Comparator|Clopidogrel|Clopidogrel 75 mg once a day by mouth for 30 days
2990511|NCT02626169|Active Comparator|Ticagrelor|Ticagrelor 90 mg twice daily by mouth for 30 days
2990512|NCT02626156|Experimental|Cooling gel pack|A cooling pack will be applied to affected leg or foot skin where an ulcer has recently healed for 30 minutes three times a week (preventive maintenance). Patients will self monitor skin temperature of affected skin daily to detect elevation and will cool the affected skin daily for 5 consecutive days (bolus) if the skin temperature becomes elevated 2°F above the baseline.
2990513|NCT02626156|Active Comparator|Cooling cotton pack|A cooling cotton pack will be applied to affected leg or foot skin where an ulcer has recently healed for 30 minutes three times a week (preventive maintenance). Patients will self monitor skin temperature of affected skin daily to detect elevation and will cool the affected skin daily for 5 consecutive days (bolus) if the skin temperature becomes elevated 2°F above the baseline.
2990514|NCT02626143|Experimental|Investigational nutrient-rich whey protein formula|
2990515|NCT02626143|Active Comparator|Cow's milk based formula|
2990516|NCT02626143|No Intervention|Breast milk|
2990517|NCT02626130|Experimental|Arm A - Tremelimumab|"Participants receive Tremelimumab at 10mg/kg every month for 2 doses prior to surgery, metastasectomy, or repeated biopsy. Cytoreductive surgery, metastasectomy, or repeated biopsy occurs 4-6 weeks after the 2nd dose of Tremelimumab. After 4 weeks post-surgery or biopsy, participants continue to receive anti-CTLA-4 every 4 weeks for 3 doses and every 12 weeks after that until progression.~Tremelimumab administered intravenously at a dose of 10 mg/kg. Participants receive first dose at Week 1, second dose at Week 5. After surgery participants receive one dose of Tremelimumab every 4 weeks for 3 doses and every 12 weeks after that until progression . All participants have their primary kidney tumor removed 4-6 weeks after the 2nd dose of Tremelimumab."
2990518|NCT02626130|Experimental|Arm B - Cryoablation + Tremelimumab|"Participants receive Tremelimumab at 10mg/kg every month for 2 doses prior to surgery, metastasectomy, or repeated biopsy. Cytoreductive surgery, metastasectomy, or repeated biopsy occurs 4-6 weeks after the 2nd dose of Tremelimumab. After 4 weeks post-surgery or biopsy, participants continue to receive anti-CTLA-4 every 4 weeks for 3 doses and every 12 weeks after that until progression.~Participants additionally receive cryoablation of a metastasis 2-6 days prior to the first dose of tremelimumab.~Participants receive first dose at Week 1, second dose at Week 5. After surgery participants receive one dose of investigational product every 4 weeks for 3 doses and every 12 weeks after that until progression. All participants have their primary kidney tumor removed 4-6 weeks after the 2nd dose of Tremelimumab."
2990519|NCT02626117|Active Comparator|CAF+ SCTG+ laser depithelialisation|CAF + SCTG and Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium.
2990520|NCT02626117|Sham Comparator|CAF+SCTG+ sham laser depithelialisation|CAF+ SCTG+ sham LASER deepithelialisation was applied to remove the sulcular epithelium.
2990521|NCT02626104|Experimental|A - Lactoferrin|Bovine lactoferrin orally - 100 mg twice a day, for whole antibiotic treatment period.
2990522|NCT02626104|Placebo Comparator|B - Maltodextrin|Maltodextrin orally - 100 mg twice a day, for whole antibiotic treatment period.
2990523|NCT02626091|Experimental|Perfusion evaluation of anastomosis|During left-sided colonic resections, anastomosis perfusion will be estimated by the visual appreciation of the surgeon and the ICG fluorescence-based enhanced reality. These two approaches will be compared.
2990524|NCT02626078||observation and interview of residents|residents will be observed over lunch and an interview will be held with each resident after lunch
2990525|NCT02626065|Experimental|Nivolumab, patients with BRAF mutation|"Nivolumab (dose equal to 3mg/kg), 10 mg/ml solution for infusion. injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.~Blood sampling at different time"
2990526|NCT02626065|Experimental|Nivolumab, patients with BRAF wild type|"Nivolumab (dose equal to 3mg/kg), 10 mg/ml solution for infusion. injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.~Blood sampling at different time"
2990527|NCT02626026|Experimental|GS-4059 (Part A, Cohort 1, Treatment A)|Participants will receive GS-4059 20 mg (2 x 10 mg) once daily for 1 week.
2990528|NCT02626026|Experimental|GS-4059 (Part A, Cohort 1, Treatment B)|Participants will receive GS-4059 placebo (2 capsules) once daily for 1 week.
2990529|NCT02626026|Experimental|GS-4059 (Part A, Cohort 2, Treatment C)|Participants will receive GS-4059 10 mg (1 x 10 mg) twice daily for 1 week.
2990530|NCT02626026|Experimental|GS-4059 (Part A, Cohort 2, Treatment D)|Participants will receive GS-4059 (1 capsule) placebo twice daily for 1 week.
2990531|NCT02626026|Experimental|GS-4059 (Part B)|"Participants will receive GS-4059 20 mg (2 x 10 mg) or GS-4059 placebo (2 capsules) once daily for 4 weeks.~Based on safety, PK, and PD data from Part A, participants may receive an alternative dosing regimen of GS-4059 10 mg twice daily."
2990532|NCT02626000|Experimental|Phase 1b|Talimogene laherparepvec in combination with pembrolizumab
2990533|NCT02625987|Experimental|Continuous intradermic stitch|Closure was did with a continuous intradermic stitch.
2990534|NCT02625987|Sham Comparator|Separated stitches|Like comparator was used a closure with separated stitches.
2990535|NCT02625974|Experimental|Nifurtimox 60 days / Arm 1|Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)
2990536|NCT02625974|Placebo Comparator|Nifurtimox 30 days / Arm 2|Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)
2990537|NCT02625961|Experimental|Pembrolizumab|Participants receive pembrolizumab, 200 mg, intravenously, every 3 weeks (Q3W) for up to 24 months.
2990538|NCT02625948|Active Comparator|tranexamic acid|tranexamic acid
2990539|NCT02625948|Placebo Comparator|Placebo|0.9% NaCl
2990541|NCT02625922|Experimental|Serelaxin followed by Placebo|On Day 1 of treatment period 1, Serelaxin will be administered as a continuous i.v.infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
2990542|NCT02625922|Experimental|Placebo followed by Serelaxin|On Day 1 of treatment period 1, matching placebo will be administered as a continuous i.v.infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
2990543|NCT02625909|Experimental|Drug: SOF/VEL for 6 weeks|Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the short treatment duration arm (A) for 6 weeks.
2990544|NCT02625909|Experimental|Drug: SOF/VEL for 12 weeks|Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the standard treatment duration arm (B) for 12 weeks.
2990545|NCT02625896|Experimental|Intervention|A sequence of free fall manoeuvres performed using the human body: A free fall velocity reduction prior to main parachute deployment followed by a head high body attitude prior to main parachute extraction.
2990546|NCT02625896|No Intervention|Control|Normal main parachute extraction performed in a manner that is typical for the study participant.
2990547|NCT02625883||Survivors|Patients with out-of-Hospital resuscitation and return of spontaneous circulation. Structured interview for quality of life (questionnaire) one year after resuscitation.
2990548|NCT02625870|Experimental|Omega-3-Acid Ethyl Esters 90 Soft Capsules|
2990549|NCT02625870|Placebo Comparator|Corn Oil|
2990550|NCT02625857|Experimental|Dose Cohort 1A and 1B|JNJ-64041809 will be administered intravenously (IV) once every 21 days.
2990551|NCT02625857|Experimental|Dose Cohort 2A and 2B|JNJ-64041809 will be administered intravenously (IV) once every 21 days.
2990552|NCT02625844||Monopegylated Epoetin Beta|Health care personnel performing anemia management tasks for patients using monopegylated epoetin beta.
2990553|NCT02625844||Other Erythropoiesis Stimulating Agents (ESAs)|Health care personnel performing anemia management tasks for patients using other ESAs.
2990554|NCT02625831||SLE patients|"165 SLE patients. Subgroup : 77 with active lupus and 88 in disease remission. in the active subgroup : 36 with lupus nephritis and 41 without.~Biological analysis were performed."
2990555|NCT02625831||healthy patients|48 healthy patients. Biological analysis were performed.
2990556|NCT02625818||acute psychiatric condition|
2990557|NCT02625805|Experimental|Participants diagnosed with ADD/ADHD|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv) and Methylphenidate administration
2990558|NCT02625805|Experimental|Healthy participants|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv) and Methylphenidate administration
2990559|NCT02625792|Experimental|Endo-Clot(TM)|The intervention group
2990560|NCT02625779|Active Comparator|Valproate and Placebo|Valproate: 300mg/day for 8 weeks Placebo: for 8 weeks
2990561|NCT02625779|Experimental|Valproate and Cytidine-containing Drug|Valproate: 300mg/day for 8 weeks Cytidine-containing Drug: 2g/day for 8 weeks
2990562|NCT02625779|Experimental|Valproate and Creatine-containing Drug|Valproate: 300mg/day for 8 weeks Creatine-containing Drug: 3g/day for the first week 5g/day for week 2-8
2990563|NCT02625766|Experimental|Operative|Patients enrolled in the operative treatment group will undergo surgical intervention for their pelvic fracture. The surgeon will decide the best surgical technique as per standard of care for the patient's injury. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments to determine if the injury is healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
2990564|NCT02625766|Experimental|Non-operative|Patients enrolled in the non-operative treatment group will not undergo surgical intervention for their pelvic fracture. They will mobilize as per the surgeon's instructions according to standard of care of for this injury. X-rays will be taken at follow-up clinic appointments to determine if the injury is healing properly or if the pelvis has shifted and may warrant surgical intervention. If complications arise and/or surgery is required, crossover will be allowed and recorded within study follow-up forms.
2990565|NCT02625753|Active Comparator|Codeine plus paracetamol|Codeine plus paracetamol every 6 hours for 72 hours after photorefractive keratectomy.
2990566|NCT02625753|Placebo Comparator|placebo|Placebo every 6 hours for 72 hours after photorefractive keratectomy.
2990567|NCT02625740|Experimental|Study group|After crossing the lesion with a guidewire, patients will be treated with intravascular high intensity, low-frequency ultrasound followed by local administration of liquid mixture of Paclitaxel and Iopromide-370 with predetermined dosage of 1.0 µg/mm
2990568|NCT02625740|Active Comparator|Control group|After crossing the lesion with a guidewire, patients will be treated with drug eluting ballon angioplasty with the In.Pact Admiral ballon (Medtronic)
2990569|NCT02625727|Experimental|hyaluronic acid group|hyaluronic acid injection
2990570|NCT02625727|Active Comparator|hyaluronic acid and corticosteroid group|hyaluronic acid combined corticosteroid injection
2990571|NCT02625714|Other|A group|Renexin® → SID142
2990572|NCT02625714|Other|B group|SID142 → Renexin®
2990573|NCT02625701|Experimental|Goal-Directed-Therapy (GDT)|"Besides the basal infusion of crystalloids at 3-6 ml/kg/h, colloids (200 ml) or crystalloids (200 ml) are given over 10 min if the Pressure Pulse Variation (PVV) or Stroke Volume Variation (SVV) exceeds 10-12% with the aim to optimize cardiac output.~Otherwise, vasopressors can be used to achieve appropriate mean arterial pressure (MAP>70 mmHg, within ±20% of baseline).~Blood losses are replaced with colloids (1:1) or crystalloids (2:1)."
2990574|NCT02625701|Active Comparator|Restrictive strategy|"Crystalloids are given at a fixed rate of 3-6 ml/kg/h. Otherwise, vasopressors can be used to achieve appropriate MAP (>70 mmHg, within ±20% of baseline).~Blood losses are replaced with colloids (1:1) or crystalloids (2:1)."
2990575|NCT02625688|Placebo Comparator|Early cord clamping|Cord clamping will be applied after 30 seconds post delivery.
2990576|NCT02625688|Active Comparator|Delayed cord clamping|Cord clamping will be applied after 3 minutes post delivery.
3009275|NCT02501031|Experimental|Flaxseed (ground)|
2990577|NCT02625688|Active Comparator|Cord milking|The baby will be placed below the level of the placenta, between the mother's thighs (during a vaginal delivery) or at the side of the mother swaddled in sterile towels (during a caesarian delivery).
2990578|NCT02625662||iFSHD group|First recruitment group
2990579|NCT02625649||RYGB|RYGB-operated type 2 diabetic patients
2990580|NCT02625649||non-RYGB|non-RYGB-operated type 2 diabetic controls
2990581|NCT02625636|Experimental|SAR438544 dose 1|Single dose of SAR438544 given SC under fasting conditions
2990582|NCT02625636|Experimental|SAR438544 dose 2|Single dose of SAR438544 given SC under fasting conditions
2990583|NCT02625636|Experimental|SAR438544 dose 3|Single dose of SAR438544 given SC under fasting conditions
2990584|NCT02625636|Placebo Comparator|Placebo|Single dose of placebo given SC under fasting conditions
2990585|NCT02625636|Active Comparator|Glucagon|Single dose of glucagon given SC under fasting conditions
2990586|NCT02625636|Experimental|SAR438544 Optional Dose|Optional lower, intermediate, or higher dose of SAR438544 given SC under fasting conditions
2990587|NCT02625623|Experimental|Avelumab+Best Supportive Care (BSC)|
2990588|NCT02625623|Active Comparator|Physician's choice chemotherapy+BSC or BSC alone|"Physician's choice chemotherapy comprises of the following:~Paclitaxel or~Irinotecan~Subjects who are not deemed eligible to receive Paclitaxel or Irinotecan at the dose and schedule specified will receive BSC as per investigator discretion and visit the clinic once every 3 weeks."
2990589|NCT02625610|Experimental|Avelumab|"Induction Phase: Subjects will be administered with oxaliplatin and either 5-Fluorouracil (5-FU) or capecitabine for 12 weeks.~Maintenance Phase: Subjects will be administered with intravenous (IV) infusion of avelumab once every 2 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
2990590|NCT02625610|Active Comparator|Oxaliplatin-fluoropyrimidine doublet|"Induction Phase: Subjects will be administered with oxaliplatin and either 5-FU or capecitabine for 12 weeks.~Maintenance Phase: Subjects will continue the same regimen of oxaliplatin-fluoropyrimidine doublet chemotherapy (oxaliplatin + 5-FU/Leucovorin (LV) or oxaliplatin + capecitabine) as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation. Subjects who are not deemed eligible to receive further chemotherapy will receive best supportive care (BSC) alone with no active therapy."
2990591|NCT02625597|Experimental|Dental Materials|
2990592|NCT02625584|Other|Shared Reading Control|Reading Together - Shared Reading Control. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will not be trained to read with their child. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
2990593|NCT02625584|Experimental|Dialogic Reading|Reading Together - Dialogic Reading. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will be trained to read with their child using a dialogic reading style. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
2990594|NCT02625584|Experimental|Pausing for Reading|Reading Together - Pausing for Reading. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will be trained to read with their child using a style which involves pausing, recasting and open questioning. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
2990595|NCT02625571|Experimental|Intervention|
2990596|NCT02625558|Active Comparator|Riociguat|Active drug
2990597|NCT02625558|Placebo Comparator|Placebo|placebo
2990598|NCT02625545|Experimental|UroLift System procedure|All eligible,enrolled subjects will undergo a UroLift procedure
2990599|NCT02625532|Active Comparator|Follicular phase|Controlled ovarian stimulation starts during follicular phase on day 2-3 of the menstrual cycle
2990600|NCT02625532|Experimental|Luteal phase|Controlled ovarian stimulation starts during luteal phase on day 3 to 5 after first LH positive urine test
2990601|NCT02625519|Experimental|Urinary follicle-stimulating hormone|Controled Ovarian stimulation with urinary follicle-stimulating hormone
2990602|NCT02625519|Experimental|Recombinant follicle-stimulating hormone|Ovarian stimulation with recombinant follicle-stimulating hormone
2990603|NCT02625506|Placebo Comparator|Levobupivacaine|Patients will be subjected for radical mastectomy surgery and pectoral nerve block with levobupivacaine
2990604|NCT02625506|Active Comparator|Levobupivacaine and Tramadol|Patients will be subjected for radical mastectomy surgery and pectoral nerve block with levobupivacaine and tramadol
2990605|NCT02625493||study population|All patients who underwent elective coronary procedures belonged to the one group, they received standard care without any additional interventions, but were asked to fill in a questionnaire.
2990606|NCT02625480|Experimental|Single Arm|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR+ T cells/kg
2990607|NCT02625467|Experimental|Penetrating keratoplasty|Conventional penetrating keratoplasty technique
2990608|NCT02625467|Experimental|PALK|Pachymetry and Excimer laser assisted lamellar keratoplasty
2990609|NCT02625454|Experimental|Intravenous Acetaminophen|Subjects will receive 1000 mg of intravenous Acetaminophen q 6 hours, up to two doses and an oral placebo resembling oral acetaminophen
2990610|NCT02625454|Active Comparator|Oral Acetaminophen|Subjects will receive 1000 mg of oral Acetaminophen q 6 hours, up to two doses and an intravenous placebo resembling intravenous acetaminophen
2990611|NCT02625441|Experimental|Short anti-HER2 treatment|Pertuzumab 840 mg, i.v., then 420 mg i.v., 3-weekly for 3 cycles; Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles
2990612|NCT02625441|Active Comparator|Standard anti-HER2 treatment|Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles; Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
2990613|NCT02625428|Experimental|FC|biopsy to evaluate a recent rise in serum creatinine so called for cause biopsies
2990614|NCT02625428|Experimental|S|done at 4 months and 1 year after transplant mostly looking for subclinical rejection.
2990615|NCT02625415|Experimental|Vitamin B6|Topical application of B6 cream to the hand or/and feet 1-2 ml applied to the hand or /and feet three times a day for 4 weeks.
2990616|NCT02625415|Placebo Comparator|Placebo|Topical application of B6 Placebo cream to the hand or/and feet 1-2 ml applied to the hand or /and feet three times a day for 4 weeks.
2990617|NCT02625402|Experimental|Interactive decision aid|Group receiving brief interactive decision aid. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise
2990618|NCT02625402|Experimental|Video decision aid|Group receiving long video decision aids. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog
2990619|NCT02625389|Experimental|Embolization with Lipiodol Ultra Fluid and glue|
2990620|NCT02625376|Experimental|Trans-Resveratrol|capsule of 250 mg of resveratrol. two capsules daily : one in the morning and evening for 24 months
2990621|NCT02625376|Active Comparator|Resvega|"capsule composed of antioxydant, omega 3, carotenoid, 15 mg of resveratrol, zinc and copper.~two capsules daily : one in the morning and evening for 24 months"
2990622|NCT02625376|Placebo Comparator|Placebo|capsule of medium chain triglyceride. two capsules daily : one in the morning and evening for 24 months
2990623|NCT02625363|Experimental|Glucose Ref - Std|250 ml glucose solution with 50 gram available carbohydrate per serving, used as reference
2990624|NCT02625363|Experimental|Glucose Ref and 450 ml water|250 ml glucose solution with 50 gram available carbohydrate per serving. Sample was consumed with additional water intake @150 ml at 45, 75, and 105 minutes after meal consumption
2990625|NCT02625363|Experimental|White Bread with 250 ml water|White bread with 50 gram available carbohydrate was consumed with 250 ml water immediately after meal consumption
2990626|NCT02625363|Experimental|White Bread and 700 ml water|White bread with 50 gram available carbohydrate was consumed with 250 ml water immediately after meal consumption. Moreover, subjects given additional water intake @150 ml at 45, 75, and 105 minutes after meal consumption
2990627|NCT02625363|Experimental|White Bread with 125 ml water (twice)|Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes
2990628|NCT02625350|Experimental|Instant noodle without soup|Instant noodle with 50 gram available carbohydrate per serving; cooked with 500 ml of water for 6 minutes and drained
2990629|NCT02625350|Experimental|Instant noodle with soup|Instant noodle with 50 gram available carbohydrate per serving; cooked with 500 ml of water for 6 minutes, drained, and given additional 250 ml of water as soup
2990630|NCT02625350|Experimental|Glucose reference|250 ml glucose solution with 50 gram available carbohydrate per serving, used as reference
2990631|NCT02625337|Active Comparator|Pembrolizumab mono|Pembrolizumab monotherapy
2990632|NCT02625337|Experimental|Pembrolizumab with dabrafenib+trametinib short|Pembrolizumab combined with a short scheme of dabrafenib+trametinib
2990633|NCT02625337|Experimental|Pembrolizumab with dabrafenib+trametinib intermediate|Pembrolizumab combined with an intermediate scheme of dabrafenib+trametinib
2990634|NCT02625337|Experimental|Pembrolizumab with dabrafenib+trametinib long|Pembrolizumab combined with a long scheme of dabrafenib+trametinib
2990635|NCT02625324|Other|Endovasculair repair|Valiant Evo Thoracic Stent Graft System
2990636|NCT02625311|Experimental|MIS|Minimal invasive surgery for placement total knee prosthesis
2990637|NCT02625311|Active Comparator|conventional approach|"conventional open surgery for placement total knee prosthesis."
2990638|NCT02625298|Experimental|ProRoot MTA|Traumatized permanent teeth obturated with ProRoot MTA after root canal treatment
2990639|NCT02625298|Experimental|MTA+ Cercamed|Traumatized permanent teeth obturated with MTA+ Cerkamed after root canal treatment
2990640|NCT02625285||G6PD Deficient Volunteers|"Subjects with age ≥ 18 years~Male and female~Previously tested G6PD deficient at SMRU clinic"
2990641|NCT02625285||G6PD Intermediate or Heterozygous Volunteers|"Subjects with age ≥ 18 years~Female~Previously tested G6PD intermediate or heterozygous for G6PD variants at SMRU clinic"
2990642|NCT02625285||G6PD-Normal Volunteers|"Subjects with age ≥ 18 years~Male and female~Previously tested G6PD normal at SMRU clinic"
2990643|NCT02625272|Experimental|Group A|The novel hand-assisted laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were brought out through the hand-port incision at the beginning of the operation and divided extracorporeally.
2990644|NCT02625272|No Intervention|Group B|novel laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were divided at the beginning of the operation intracorporeally.
2990645|NCT02625272|No Intervention|Group C|the traditional laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer.
2990646|NCT02625259|Experimental|Part 1: TAK-117 9*100 mg + TAK-117 3*300 mg|TAK-117900 milligram (mg), capsules, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, tablets, orally, once on Day 15.
2990647|NCT02625259|Experimental|Part 1: TAK-117 3*300 mg + TAK-117 9*100 mg|TAK-117 900 mg tablets, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, capsules, orally, once on Day 15.
2990648|NCT02625259|Experimental|Part 2: TAK-117 Fasted + TAK-117 Fed|TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 15.
2990649|NCT02625259|Experimental|Part 2: TAK-117 Fed + TAK-117 Fasted|TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 15.
2990650|NCT02625259|Experimental|Part 3: TAK-117 + Lansoprazole|TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 1, followed by lansoprazole 30 mg, tablets or capsules, once daily from Day 10 to Day 15, followed by TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 15.
2990651|NCT02625246|Experimental|Group 1|3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion
2990652|NCT02625246|Experimental|Group 2|3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion
2990653|NCT02625233|Experimental|senofilcon C|Vistakon Investigational Contact Lens (Test)
2990654|NCT02625233|Active Comparator|comfilcon A|Marketed Monthly Wear Contact Lens (Control)
2990655|NCT02625220|Experimental|Prototype toric lens senofilcon A|Subjects will wear the senofilcon A prototype toric contact lens bilaterally for 6-8 days as a daily disposable modality.
2990656|NCT02625207|Experimental|Cohort 1|African-Americans with No CYP3A5*1 alleles (poor metabolizer)
2990657|NCT02625207|Experimental|Cohort 2|African-Americans with One CYP3A5*1 allele (intermediate metabolizer)
2990658|NCT02625207|Experimental|Cohort 3|African-Americans with Two CYP3A5*1 alleles (extensive metabolizer)
2990659|NCT02625207|Experimental|Cohort 4|Caucasians with No CYP3A5*1 alleles (poor metabolizer)
2990660|NCT02625194|Experimental|Oxygen|Oxygen is supplied through suction port in bronchoscope during bronchoscope-guided intubation.
2990661|NCT02625194|No Intervention|Control|Bronchoscope-guided intubation is performed without oxygen supply.
2990662|NCT02625181|Experimental|PONV clinical decision support system|Automated recommendations on PONV prophylaxis provided to anesthesia providers through the anesthesia information management system and email.
2990663|NCT02625168|Experimental|Afatinib|Afatinib 30 or 40 or 50mg daily orally after study recruitment until radiologically documented disease progression, intolerable side effects as judged by investigators or patient withdrawal.
2990664|NCT02625168|Experimental|Erlotinib|Erlotinib 150mg daily until radiologically documented disease progression, intolerable side effects as judged by investigators or patient withdrawal.
2990665|NCT02625155|Other|Standard of Care (SOC Arm)|Standard of Care UDT
2990666|NCT02625155|Other|Selective PGx Testing (Test Arm)|Standard of Care UDT with selective PGx testing
2990667|NCT02625142|Experimental|Family-centered rounds checklist|"During the post-intervention period, health care team members on two pediatric inpatient services received the Family-centered Rounds Checklist tool, as well as training in how to use the checklist in the delivery of effective family-centered rounds"
2990668|NCT02625142|No Intervention|Usual care|Two pediatric inpatient services were not provided the Family-centered rounds checklist tool, and delivered morning rounds in their usual manner. These services served as a control.
2990669|NCT02625129||Pharmacist-provided travel care|
2990670|NCT02625103|Experimental|Clozapine|treatment as usual: administration of clozapine between 9 and 12 pm. Blood sampling 10 -14 hours post drug administration
2990671|NCT02625090|Experimental|UCB0942|"UCB0942 400 mg bid or a tapered UCB0942 dose of 200 mg bid.~The Investigator will be allowed to increase or decrease the dose of UCB0942 to optimize tolerability and seizure control for each subject. Increases or decreases to the dose of UCB0942 should be made in steps not exceeding 200 mg/day per week; an exception is Taper Week 1 where a step of 800 mg/day to 500 mg/day is allowed. A faster decrease of the dose than 200 mg/day per week is allowed when it is clinically appropriate in the Investigator's medical judgment. Daily UCB0942 doses during this study may be 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid); intermediate doses will not be allowed except for tapering and titration unless agreed by the UCB Study Physician or PRA Medical Monitor. The dose of UCB0942 must always be administered as bid morning and evening doses, approximately 12 hours apart."
2990672|NCT02625077|Experimental|Laparoscopic valvuloplasty|Via laparoscopy, using three sutures a part of the esophagus is folded (similar to the way parts of a telescope slide in each other) into the stomach, creating a valve on the inside to prevent gastric acid to enter the esophagus.
2990673|NCT02625077|Active Comparator|Laparoscopic Toupet fundoplication|Via laparoscopy, the entire stomach is mobilized and folded around itself posteriorly, creating a partial (270 degrees) fundoplication.
2990674|NCT02625064||1: patient at High risk for ARDSp|Severe pneumonia and（PaO2/FIO2）＞300mmHg
2990675|NCT02625064||2: patient at High risk for ARDSexp|Severe sepsis and without ARDS
2990676|NCT02625064||3: mild ARDS|PaO2/FiO2=201～300 mmHg，and PEEP or CPAP≤5 cm
2990677|NCT02625064||4: moderate ARDS|PaO2/FIO2=101～200 mmHg，且PEEP≥5 cm H2O
2990678|NCT02625064||5: severe ARDS|PaO2/FIO2≤100 mmHg，且PEEP≥10 cm H2O
2990679|NCT02625051|Active Comparator|Ureteroscopy|Kidney stone of participants in this arm will be treated with ureteroscopy (URS). A ureteral stent will be inserted at the end of the procedure.
2990680|NCT02625051|Active Comparator|Percutaneous nephrolithotomy|Kidney stone of participants in this arm will be treated with percutaneous nephrolithotomy (PNL). A percutaneous nephrostomy tube will be inserted at the end of the procedure.
2990681|NCT02625038|Experimental|Interventional|3D-planned osteotomies with patient-specific guides
2990682|NCT02625025|Experimental|Low pression pneumoperitoneum|Patients undergoing Single Port Access Laparoscopy for benign adnexal pathology with use of Low Pression Pneumoperitoneum (8 mm Hg)
2990683|NCT02625025|Experimental|Standard pression pneumoperitoneum|Patients undergoing Single Port Access Laparoscopy for benign adnexal pathology with use of Standard Pression Pneumoperitoneum (12 mm Hg)
2990684|NCT02625012||Vitiligo|A serial of vitiligo patients under treatment with UVB-NB
2990685|NCT02624999|Experimental|Immunotherapy|Subjects in this arm will receive immunotherapy (AlloVax™: CRCL + AlloStim™) twice a week for 4 weeks and then every 4 weeks for an additional 12 weeks
2990686|NCT02624999|Active Comparator|Standard chemotherapy|Subjects in this arm will receive up to six three-week cycles of chemotherapy consisting of cisplatin on day 0 of the 3-week cycle at dose 80-100 mg/m2 IV followed by 1000 mg/m2 IV 5FU on days 1-4 of the cycle
2990687|NCT02624986|Experimental|Dose-Escalation Cohort (DLBCL Participants)|Participants will receive 'Regimen A', which includes escalating doses of idasanutlin in combination with a fixed dose of obinutuzumab (1000 milligrams [mg]) for 6 cycles (1 Cycle=28 days) until maximum tolerated dose (MTD) is achieved. Regimen A will be followed by treatment which includes idasanutlin in combination with fixed dose of rituximab (375 milligrams per square meter [mg/m^2]) for 6 cycles (1 Cycle=28 days) to determine the RP2D for this treatment.
2990723|NCT02624778|Experimental|LY3002813 Single dose 1|LY3002813 administered intravenously (IV) once
2990724|NCT02624778|Experimental|LY3002813 Single dose 2|LY3002813 administered IV once
2990688|NCT02624986|Experimental|Dose-Escalation Cohort (FL Participants)|Participants will receive 'Regimen A', which includes escalating doses of idasanutlin in combination with a fixed dose of obinutuzumab (1000 mg) for 6 cycles (1 Cycle=28 days) until MTD is achieved. Regimen A will be followed by Regimen B which includes obinutuzumab given alone in Cycle 1 and idasanutlin and obinutuzumab combination from Cycles 2-6 (1 Cycle=28 days) to determine the RP2D for this regimen.
2990689|NCT02624986|Experimental|Expansion Cohort: DLBCL Participants|Participants with DLBCL will receive 6 cycles (1 Cycle=28 days) of induction treatment with idasanutlin at the RP2D identified during the dose-escalation phase, in combination with rituximab. Induction treatment will be followed by post-induction consolidation treatment with rituximab and idasanutlin for 6 months.
2990690|NCT02624986|Experimental|Expansion Cohort: FL Participants|Participants will receive 6 cycles (1 Cycle=28 days) of induction treatment with idasanutlin at the RP2D identified during the dose-escalation phase, in combination with obinutuzumab. Participants will receive either 'Regimen A' or 'Regimen B' which will be determined at the end of the dose-escalation phase. Induction treatment will be followed by post-induction maintenance treatment with obinutuzumab and idasanutlin for a maximum of up to 24 months.
2990691|NCT02624973|Experimental|A|ER/PGR>50% TP53 wt
2990692|NCT02624973|Experimental|B|ER/PGR>50% TP53 mutated
2990693|NCT02624973|Experimental|C|ER/PGR<50% TP53 wt
2990694|NCT02624973|Experimental|D|ER/PGR<50% TP53 mutated
2990695|NCT02624973|Experimental|E|HER2+ TP53 wt
2990696|NCT02624973|Experimental|F|HER2+ TP53 mutated
2990697|NCT02624973|Experimental|G|Triple negative breast cancer TP53 wt
2990698|NCT02624973|Experimental|H|Triple negative breast cancer TP53 mutated
2990699|NCT02624960|Experimental|Accucinch Implant|Accucinch Implant procedure is completed
2990700|NCT02624947|Placebo Comparator|Treatment Group A|Formulation buffer (0.5mL injection)
2990701|NCT02624947|Active Comparator|Treatment Group|RSV F vaccine with adjuvant (0.5mL injection)
2990702|NCT02624908|Active Comparator|canagliflozin|Subjects randomized to this arm will start with 100 mg tablet and increase to 300 mg tablet at Visit 4 if well tolerated.
2990703|NCT02624908|Placebo Comparator|placebo|Subjects randomized to this arm will start with 100 mg tablet and increase to 300 mg tablet at Visit 4 if well tolerated.
2990704|NCT02624895||mCRC: Anti-EGFR MAbs + FOLFOX 1st line|• Adult (>= 18 years old) RAS wild-type metastatic colorectal cancer patients candidate to receive FOLFOX plus panitumumab or FOLFOX plus cetuximab as upfront treatment as per clinical practice.
2990705|NCT02624895||mCRC: Anti EGFR MAbs + FOLFIRI 1st line|Adults (>= 18 years old) RAS WIld Type metastatic colorectal cancer patients candidate to receive FOLFIRI plus panitumumab or FOLFIRI plus cetuximab as upfront treatment as per clinical practise
2990706|NCT02624882|Experimental|Positive rapid Group A Streptococcus (GAS) test|In case of positive rapid GAS test, patients will be treated by antibiotics: amoxicillin 50mg/kg/d during 10 days or cefpodoxime 8mg/kg/d during 10 days in case of betalactamine allergy
2990707|NCT02624882|Active Comparator|Negative rapid GAS test|If case of negative rapid GAS test, usual care: local antiseptic or surgical intervention
2990708|NCT02624869|Experimental|evolocumab (AMG 145)|Single arm all subjects receive evolocumab (AMG 145) every 4 weeks (QM)
2990709|NCT02624856|Experimental|Liposomal bupivacaine|Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
2990710|NCT02624856|Active Comparator|Standard bupivacaine plus dexamethasone|Bupivacaine 0.5% 10 mL plus 2 mg dexamethasone for quadriceps sparing femoral nerve block and bupivacaine 0.25% 20 mL plus 2 mg of dexamethasone for posterior knee compartment periarticular injection.
2990711|NCT02624843|Experimental|Benzyl Alcohol Lotion 5%|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
2990712|NCT02624843|Active Comparator|Ulesfia (Benzyl Alcohol Lotion 5%)|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
2990713|NCT02624843|Placebo Comparator|Vehicle Placebo Lotion 0%|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
2990714|NCT02624830|Experimental|Drug, Sulfonylurea|Sulfonylurea tablets (glibenclamide, other forms of sulfonylureas) were administered at the time of intervention (before November 1, 2006). The patients have been prospectively followed up. Sulfonylurea dose, insulin requirement, death of all causes, episodes of severe hypoglycemia, ketoacidosis, development of discoloured teeth and diarrhea have been recorded. For a small number of subjects, increment of insulin and C-peptide after either an oral or intravenous glucose load and/or response to intravenous glucagon have been tested.
2990715|NCT02624817|Experimental|Drug: Sulfonylurea|Sulfonylurea tablets (glibenclamide, other forms of sulfonylureas) were administered at the time of intervention (before November 1, 2006). The patients have been prospectively followed up. Sulfonylurea dose, insulin requirement, death of all causes, episodes of severe hypoglycemia, ketoacidosis, development of discoloured teeth and diarrhea have been recorded. For a small number of subjects, increment of insulin and C-peptide after either an oral or intravenous glucose load and/or response to glucagon have been tested.
2990716|NCT02624804|Experimental|Stem Cell Educator Therapy|"Patients will have apheresis performed and then have their own blood returned to them with the educated stem cells"
2990717|NCT02624791|Experimental|Lens sequence 1|"No contact lenses; 1-DAY ACUVUE® MOIST contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses"
2990718|NCT02624791|Experimental|Lens sequence 2|"No contact lenses; 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses;~1-DAY ACUVUE® MOIST contact lenses"
2990719|NCT02624791|Experimental|Lens sequence 3|"1-DAY ACUVUE® MOIST contact lenses; No contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses"
2990720|NCT02624791|Experimental|Lens sequence 4|"1-DAY ACUVUE® MOIST contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses; No contact lenses"
2990721|NCT02624791|Experimental|Lens sequence 5|"1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses;~1-DAY ACUVUE® MOIST contact lenses; No contact lenses"
2990722|NCT02624791|Experimental|Lens sequence 6|"1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses; No contact lenses;~1-DAY ACUVUE® MOIST contact lenses"
3009276|NCT02501031|No Intervention|Usual diet|
2990725|NCT02624778|Experimental|LY3002813 Single dose 3|LY3002813 administered IV once
2990726|NCT02624778|Experimental|LY3002813 Multiple dose 1 x 24 wks|LY3002813 administered IV for 24 wks
2990727|NCT02624778|Experimental|LY3002813 Multiple dose 2 x 24 wks|LY3002813 administered IV for 24 weeks
2990728|NCT02624778|Experimental|LY3002813 Multiple dose 3 x 72 wks|LY3002813 administered IV for 72 wks
2990729|NCT02624778|Experimental|LY3002813 Multiple dose 4 x 72 weeks|LY3002813 administered IV for 72 wks
2990730|NCT02624778|Placebo Comparator|Placebo given once|Placebo administered IV once
2990731|NCT02624778|Placebo Comparator|Placebo x 24 weeks|Placebo administered IV for 24 wks
2990732|NCT02624778|Placebo Comparator|Placebo x 72 weeks|Placebo administered IV for 72 wks
2990733|NCT02624765|Active Comparator|RCT A (1st arm): AF without hydrops|Atrial Flutter (AF) without hydrops: Treatment with Digoxin as monotherapy.
2990734|NCT02624765|Active Comparator|RCT A (2nd arm): AF without hydrops|Atrial Flutter (AF) without hydrops: Treatment with Sotalol as monotherapy.
2990735|NCT02624765|Active Comparator|RCT B (1st arm): SVT without hydrops|Supraventricular Tachycardia (SVT) without hydrops: Treatment with Digoxin as monotherapy.
2990736|NCT02624765|Active Comparator|RCT B (2nd arm): SVT without hydrops|Supraventricular Tachycardia (SVT) without hydrops: Treatment with Flecainide as monotherapy.
2990737|NCT02624765|Active Comparator|RCT C (1st arm): SVT with hydrops|Supraventricular Tachycardia (SVT) with hydrops: Treatment with Digoxin and Sotalol.
2990738|NCT02624765|Active Comparator|RCT C (2nd arm): SVT with hydrops|Supraventricular Tachycardia (SVT) with hydrops: Treatment with Digoxin and Flecainide.
2990739|NCT02624752|No Intervention|Standard of Care|"Standard of care could include liberalized diet consisting of 3 meals and snacks served daily or the standard oral nutrition supplementation (ONS) routinely used in the hospital, as prescribed by the medical team.These routine meals and snacks are the standard of care."
2990740|NCT02624752|Experimental|Ensure|Patients randomized to Enhanced Oral Nutritional Supplementation (ONS) will receive the standard of care hospital menu (3 meals and snacks per day) plus 2 cans of Ensure (or similar product) per day while in hospital and will continue 2 cans per day of Ensure when discharged home until they have been receiving the enhanced ONS for a total of 90 days.
2990741|NCT02624726|Experimental|FOLFIRI/Aflibercept|5 Fluorouracil/Leucovorin/Irinotecan/Aflibercept
2990742|NCT02624713|Other|obesity treatment|"Retrospective Random Controlled Research~The research group - families that have completed an intervention program of Active Maccabi ,within the past two to three years. The families will be requested to attend a follow-up meeting of all family members in which they will answer questionnaires. Approximately 66 families.~The control groups - families who did not participate in the program who have a child between the age 7-14 who has suffered from obesity/weight (over the past 2-3 years), . Approximately 66 families."
2990743|NCT02624700|Experimental|A: Pemetrexed + Sorafenib|All study participants will get the same study treatment. Each participant will be given pemetrexed intravenously which means by vein (IV) once every 21days.They will take sorafenib pills by mouth two times each day for 5 days starting on the pemetrexed treatment day. The treatment is Pemetrexed 375 mg/m2 IV Day 1 + Sorafenib 200mg PO twice each day on Days 1-5 of each 21-day cycle
2990744|NCT02624687|Active Comparator|Intervention|These subjects will participate in a behavioral intervention that will focus on reducing sedentary behavior and improving self-management of pain. This will include an initial, in-person behavioral intervention and then monthly follow-up calls. In addition, subjects will receive a sit-stand desk attachment and a wrist-worn activity prompter to aid in sedentary behavior reduction.
2990745|NCT02624687|Placebo Comparator|Control|These subjects will receive no intervention.
2990746|NCT02624674|Experimental|Multi-spectral Imaging Group|All subjects in this group will undergo baseline Near Infrared Spectroscopy (NIRS) measurement points with the Multi-spectral imaging device, baseline vascular studies (including ankle-brachial index (ABI), vascular doppler (arterial and venous), and toe pressures. At the one month mark (from baseline), NIR measurement point and vascular studies will again be performed. All measurements are incorporated into the routine wound care and will not require extra trips in hospital for wound care.
2990747|NCT02624661|Experimental|Glycerol injection|The patients will be injected with glycerol using a new neuronavigation-based technique in the trigeminal ganglion.
2990748|NCT02624648|Placebo Comparator|Placebo Group|"The effects of Placebo on sexual function, desire and depression in postmenopausal women.~The Female Sexual Function Index (FSFI) and the Female Intervention Efficacy Index Questionnaire (FIEI).~The Beck Depression Inventory II will be used to ward off depression"
2990749|NCT02624648|Experimental|Maca (Lepidium Meyenii Walp) Group|"The effects of Lepidium Meyenii Walp on sexual function, desire and depression in postmenopausal women.~The Female Sexual Function Index (FSFI) and the Female Intervention Efficacy Index Questionnaire (FIEI).~The Beck Depression Inventory II will be used to ward off depression"
2990750|NCT02624635|Active Comparator|Manual Therapy|The treatment for this group will be manual therapy.
2990751|NCT02624635|Experimental|Manual Therapy and Hip Strengthening|It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip.
2990752|NCT02624622|Active Comparator|CHW applies chlorhexidine|Intervention: Chlorhexidine gel 7.1% topical 3 gm applied to the umbilical cord stump in one application. The community health worker is given the chlorhexidine to apply to the umbilical cord stump within 24 hours of delivery of the newborn infant.
2990753|NCT02624622|Experimental|Mother applies chlorhexidine|Intervention: Chlorhexidine gel 7.1% topical 3 gm applied to the umbilical cord stump in one application. Mother is given the chlorhexidine during the first prenatal care visit to apply to the umbilical cord stump within 24 hours of delivery of the newborn infant.
2990754|NCT02624609|Placebo Comparator|Control without pomegranate juice|Control meal will be white bread and a glass of water containing the same amounts of sugars naturally present in the pomegranate juice.
2990755|NCT02624609|Experimental|Test with pomegranate juice|Test meal will be white bread with a glass of pomegranate juice
2990756|NCT02624596|Experimental|Ketamine|OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
2990757|NCT02624596|Active Comparator|Midazolam|OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
2990758|NCT02624557|Experimental|Moderate hepatic impairment group|Subjects with moderate hepatic impairment with Child-Pugh score 7 - 9
2990759|NCT02624557|Experimental|Severe hepatic impairment group|Subjects with severe hepatic impairment with Child-Pugh score 10 - 15
2990760|NCT02624557|Experimental|Matching healthy control group|Subjects with apparent normal liver function matched to the hepatic impairment subjects by sex, race, age, and weight.
2990761|NCT02624544|Experimental|Group A|Proton Pump Inhibitor esomeprazole 40 mg twice a day
2990762|NCT02624544|Active Comparator|Group B|desonide
2990763|NCT02624531|Other|fertility-sparing surgery|NACT with Taxane combined with cisplatin and Fertility-sparing Treatment Strategy
2990764|NCT02624518|Experimental|Diagnostic (68Ga-RM2 PET/MRI)|Patients receive 68Ga-RM2 IV and beginning 45 minutes later undergoing PET/MRI scan. The 68Ga-RM2 PET/MRI may be repeated at the completion of treatment to evaluate response to therapy, if requested by the treating physician. Imaging with PET/MRI is the intervention.
2990765|NCT02624505|Placebo Comparator|Placebo Product|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
2990766|NCT02624505|Active Comparator|90 mcg Reference Product|Drug : 90 mcg Reference Product One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
2990767|NCT02624505|Active Comparator|180 mcg Reference Product|Drug: 180 mcg Reference Product One actuation each from two different Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
2990768|NCT02624505|Experimental|90 mcg Test Product|Drug: 90 mcg Test Product One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols
2990769|NCT02624492|Experimental|BI 836826-GemOx|
2990770|NCT02624492|Active Comparator|R-GemOx|
2990771|NCT02624479|Experimental|Fast first|Sodium thiosulfate fast release formulation first, followed by medium and slow
2990772|NCT02624479|Experimental|Medium first|Sodium thiosulfate medium release formulation first, followed by slow and fast
2990773|NCT02624479|Experimental|Slow first|Sodium thiosulfate slow release formulation first, followed by fast and medium
2990774|NCT02624466||CKD - no dialysis|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
2990775|NCT02624466||Patients on PD|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, urine and PD fluid, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
2990776|NCT02624466||Patients on HD|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, urine and spent dialysate, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
2990777|NCT02624453|Experimental|IMMY LFA positive patients|HIV positive patients who will be positive for cryptococcal antigen (by the IMMY LFA test) would be consented for lumbar puncture in search of cryptococcal meningitis (CM). If CM is not confirmed, they would be prescribed pre-emptive fluconazole based therapy at 800mg/day for two weeks (placed on antiretroviral therapy two weeks after screening for cryptococcal antigen), then 400mg/day for 8 weeks and thereafter 200mg/day until CD4 counts increases beyond 200cells/ml. (CM confirmed cases will be referred to the ACTA trial ISRCTN45035509)
2990778|NCT02624453|Active Comparator|IMMY LFA negative patients|HIV positive patient who will be negative for cryptococcal antigen (by the IMMY LFA test) would not be consented for lumbar puncture, will be placed immediately on antiretroviral therapy immediately after screening for cryptococcal antigen and would not be placed on fluconazole pre-emptive therapy.
2990779|NCT02624440|Experimental|Clarithromycin|p.o. clarithromycin 250 mg twice daily for 180 days
2990780|NCT02624440|Experimental|Sulfamethoxazole/trimethoprim|p.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily for 180 days
2990781|NCT02624440|Experimental|Observation|Observation without prophylactic antibiotic treatment
2990782|NCT02624427|Experimental|Glaucoma Eyes|Measurement of intraocular pressure (IOP)
2990783|NCT02624427|Active Comparator|Healthy Eyes|age-matched healthy eyes as controls will undergo Measurement of intraocular pressure (IOP)
2990784|NCT02624414|Other|Anti TNF induction therapy 6-12 months|All subjects will be identified through The Royal Melbourne Hospital's IBD clinic, associated specialty clinics and the colonoscopy waiting list of The Royal Melbourne Hospital. The potential participants who have been commenced on Anti TNF induction therapy 6-12 months prior to commencement of the study will be identified. The potential participants identified in this way will be informed of the project at the time of contact and assessment; in some instances the potential participant will be informed of the project via telephone where subjects are remote. The potential participants will be provided an Ethically-approved information sheet at this time. Consent will be gained at the time of assessment.
2990785|NCT02624401|Experimental|Dexmedetomidine|Intravenous dexmedetomidine using target controlled infusion.
2990786|NCT02624401|Experimental|Propofol|Intravenous propofol using target controlled infusion.
2990787|NCT02624401|Experimental|S-ketamine|Intravenous S-ketamine using target controlled infusion.
2990788|NCT02624401|Experimental|Sevoflurane|Inhalational sevoflurane using target controlled inhalation.
2990789|NCT02624401|Placebo Comparator|Placebo|Intravenous saline.
2990790|NCT02624388|Experimental|Arm A: Genistein followed by Placebo|Genistein daily throughout chemotherapy cycles 1 and 2, and placebo daily during chemotherapy cycles 3 and 4
2990791|NCT02624388|Experimental|Arm B: Placebo followed by Genistein|Placebo daily throughout chemotherapy cycles 1 and 2, and genistein daily during chemotherapy cycles 3 and 4
2990792|NCT02624362|Experimental|Odor+ Positive belief|Participants receive 15 minute odor presentation (Phenylethyl Alcohol odor) accompanied by the suggestion that this odor improves asthma symptoms (therapeutic suggestion)
2990793|NCT02624362|Experimental|Odor + Negative belief|Participants receive 15 minute odor presentation (Phenylethyl Alcohol odor) accompanied by the suggestion that this odor worsens asthma symptoms (asthmogenic suggestion)
2990794|NCT02624349|Active Comparator|Transplant|Intervention: Quadravalent human papillomavirus vaccine 0.5ml intramuscular injection at 0, 2, and 6 months and/or post administration antibody titers as described in methods
2990795|NCT02624349|Active Comparator|Control|Intervention: Quadravalent human papillomavirus vaccine 0.5ml intramuscular injection at 0, 2, and 6 months and/or post administration antibody titers as described in methods
2990796|NCT02624336|Active Comparator|DTC1 mouth wash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
2990797|NCT02624336|Placebo Comparator|Oradex mouth wash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
2990798|NCT02624336|Placebo Comparator|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
2990799|NCT02624323|Experimental|Axillary catheterization|Real-time ultrasound-guided axillary vein catheterization, in plain technique.
2990800|NCT02624323|Experimental|Jugular catheterization|Real-time ultrasound-guided jugular vein catheterization, out of plain technique.
2990801|NCT02624310|Experimental|Droxidopa First, Placebo Second|Participants in this arm will receive droxidopa first, then cross over and receive placebo
2990802|NCT02624310|Experimental|Placebo First, Droxidopa Second|Participants in this arm will receive placebo first, then cross over and receive droxidopa
2990803|NCT02624297|No Intervention|Control Group|Healthy control group for comparisons with coronary artery disease groups.
2990804|NCT02624297|No Intervention|CAD without OSA - Control|Clinical follow-up.
2990805|NCT02624297|Experimental|CAD without OSA - Intervention|Aerobic exercise training.
2990806|NCT02624297|No Intervention|CAD with OSA - Control|Clinical follow-up.
2990807|NCT02624297|Experimental|CAD with OSA - Intervention|Aerobic exercise training.
2990808|NCT02624284|Sham Comparator|Sham dose|Participants in this arm will receive the sham transcranial direct current stimulation (tDCS) procedure. During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS.
2990809|NCT02624284|Experimental|1mA dose|Participants in this arm will receive the 1mA transcranial direct current stimulation (tDCS) procedure. A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).
2990810|NCT02624284|Experimental|2 mA dose|Participants in this arm will receive the 2 mA transcranial direct current stimulation (tDCS) procedure. A neuroConn DC-Stimulator Plus will apply a constant direct current (2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).
2990811|NCT02624271|Experimental|GastroPanel|GastroPanel test on blood samples
2990812|NCT02624258|Experimental|RNA CART19 cells|CD19 RNA redirected autologous T-cells (RNA CART19 cells)
2990813|NCT02624245|Experimental|Experimental: Conventional Physical Therapy|Strength, this arm will receive hip and knee muscle strengthening with and without weight bearing.
2990814|NCT02624245|Active Comparator|Movement control training|Movement control training, this arm will receive movement control training associated to muscle strengthening.
2990815|NCT02624232||Patients with anorectal malformations|"Participants are identified through relevant diagnostic codes in ICD-10(Q 42) and ICD-9(75.120, 75.121) in patients which underwent surgery for ARM in the years 1985-2005 are included if informed consent is obtained.~Relevant questionnaires regarding symptoms and QoL are completed before the following examinations:anorectal manometry, endoanal ultrasonography, pudendal nerve conduction velocity, colon transit time, Magnetic resonans(MR)-scan of the pelvis and uroflowmetry."
2990816|NCT02624219|Experimental|Group 1|N = 55 receive 7.5 mcg A/H5N8 + AS03 on Day 1, 22
2990817|NCT02624219|Experimental|Group 2|N = 55 receive 7.5 mcg A/H5N8 + MF59 on Day 1, 22
2990818|NCT02624219|Experimental|Group 3|N = 55 receive 15 mcg A/H5N8 unadjuvanted on Day 1, 22
2990819|NCT02624219|Experimental|Group 4|N = 55 receive 15 mcg A/H5N8 + AS03 on Day 1, 22
2990820|NCT02624219|Experimental|Group 5|N = 55 receive 15 mcg A/H5N8 + MF59 on Day 1, 22
2990821|NCT02624206|Active Comparator|Juice A|Half of the group to receive Juice A, a novel juice flavor.
2990822|NCT02624206|Active Comparator|Juice B|Half of the group to receive Juice B, a novel juice flavor different from Juice A.
2990823|NCT02624193|Experimental|MBSR Program|"MBSR Program:~The MBSR intervention is a nine-week program designed to cultivate mindfulness, a focused non-judgmental awareness of the present moment. It consists of eight 2-hour weekly sessions and one 3-hour retreat and the content includes three main components: 1) material related to mindfulness, meditation, yoga, and the mind-body connection; 2) experiential practice of mindful meditation (sitting, lying down, walking), gentle mindful yoga, and body scan during group meetings and encouragement of home practice; and 3) group discussion focused on problem-solving related to barriers to effective practice. HIV disease will not be discussed as a group topic, unless it is brought up by participants."
2990824|NCT02624193|Placebo Comparator|HT Program|"Healthy Topics Program:~The health education program Healthy Topics (HT) will serve as an attention control group. The HT program is focused on providing age-appropriate health information and education. There is minimal content overlap in the MBSR and HT programs regarding self-care and healthy eating; however, the style, structure, and content of the MBSR and HT programs are distinct. HT participants will receive no training in MBSR or meditation. Topics covered include physical activity, nutrition, managing weight, building health, personal care, understanding adolescence, tobacco, alcohol, and other drugs. HIV disease will not be discussed as a group topic, unless it is brought up by participants."
2990825|NCT02624180|Experimental|Colchicine|Colchicine 0.6 mg daily by mouth
2990826|NCT02624180|Placebo Comparator|Placebo|Placebo for colchicine 1 tablet by mouth daily
2990827|NCT02624167|Active Comparator|NW-3509A|Patients will start on NW-3509A 15 mg BID and be up-titrated to 20mg, and 25mg BID dependent on tolerability.
2990828|NCT02624167|Placebo Comparator|Placebo|Patients will receive matching placebo BID
2990865|NCT02623868|Experimental|Group 6|C-B-A (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
2990829|NCT02624141|Experimental|Epoetin Beta 30000 IU|Dosage at Initiation: Subcutaneous injection of 30000 IU epoetin beta administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks.
2990830|NCT02624128|Experimental|valproic acid plus cisplatin and cetuximab|
2990831|NCT02624102|Experimental|Cognitive therapy|Major depressive disorder treated with cognitive therapy (Trial Based Cognitive Therapy plus Drug).
2990832|NCT02624102|Experimental|Behavioral Therapy|Major depressive disorder treated with behavioral therapy (Behavioral Activation plus drug).
2990833|NCT02624102|Other|Antidepressants|Major depressive disorder treated only with antidepressants (Drug alone).
2990834|NCT02624089|Experimental|Ropivacaine Group|This group will receive nebulized ropivacaine 0.5% based on ideal body weight at a dose of 0.5 mg/kg with a maximum total dose of 30 mg. This will be administered once at the onset of pneuomoperitoneum during appendectomy.
2990835|NCT02624089|Placebo Comparator|Placebo group|This group will receive placebo (normal saline) based on ideal body weight at a dose of 0.5 mg/kg with a maximum total dose of 30 mg. This will be administered at the onset of pneuomoperitoneum during appendectomy.
2990836|NCT02624089|No Intervention|Non-enrolled group|This group will not receive either intervention (ropivicaine) or placebo (normal saline), but will have primary and secondary endpoints evaluated.
2990837|NCT02624076|Experimental|Acupuncture plus expectant management|
2990838|NCT02624076|Active Comparator|expectant management|
2990839|NCT02624063|Experimental|Daclatasvir + Sofosbuvir|Daclatasvir 60 mg tablet + Sofosbuvir 400 mg tablet oral dosing once daily for 12 weeks
2990840|NCT02624063|Experimental|Simeprevir + Sofosbuvir|Simeprevir 150 mg tablet + Sofosbuvir 400 mg tablet oral dosing once daily for 12 weeks
2990841|NCT02624050|Active Comparator|Methohexital|Methohexital will be administered intravenously as a general anesthetic at a dosage of 1.5mg per kg of patient body weight.
2990842|NCT02624050|Active Comparator|Propofol|Propofol will be administered intravenously as a general anesthetic at a dosage of 2.5mg per kg of patient body weight.
2990843|NCT02624037|Experimental|Individualized Dosage Precision IFX Dashboard|A clinician will select a dose and dosing frequency that is populated by a pharmacokinetic dashboard system that monitors and aims to dose patients to maintain a target trough infliximab concentration. Dosage and dosing frequency may vary from each patient.
2990844|NCT02624024||Acute chest pain or equivalent ischemic symptoms|acute chest pain or equivalent ischemic symptoms suggestive of acute coronary syndromes (ACS) or acute myocardial infarction (MI)
2990845|NCT02624011|Experimental|Physical inactivity|Study arm consisting of 7 days of habitual physical activity followed by 7 days of step reduction and exercise cessation.
2990846|NCT02623998|Experimental|Intervention|Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy
2990847|NCT02623998|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
2990848|NCT02623985|Experimental|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia which is rapid test.
2990849|NCT02623985|Experimental|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue which is rapid test.
2990850|NCT02623985|Experimental|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture which is gold standard.
2990851|NCT02623972|Experimental|Eribulin|"Eribulin-Administered via iv, at predetermined dosage and schedule per cycle~Two research breast biopsies~Adriamycin (doxorubicin) via iv a predetermined dosage and schedule per cycle~Cyclophosphamide (AC) via iv a predetermined dosage and schedule per cycle~Surgical Removal of the breasts (Mastectomy) and axillary lymph node dissection~Radiation Therapy~Endocrine Therapy (if applicable)~Optional 10 Patient-Optional DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans"
2990852|NCT02623959|Experimental|Indwelling Pleural Catheter (IPC) + Saline|"Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Saline in the catheter.~After the IPC is removed, participant is called one time each month by study staff to check on their status."
2990853|NCT02623959|Active Comparator|Indwelling Pleural Catheter (IPC) + Doxycycline|"Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Doxycycline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Doxycycline in the catheter.~After the IPC is removed, participant is called one time each month by study staff to check on their status"
2990854|NCT02623933|Experimental|MRI assisted HDR monotherapy|HDR monotherapy to the whole prostate gland (19Gy/1) with MRI assisted focal boost to intraprostatic nodule up to 22.5Gy
2990855|NCT02623920|Experimental|Brentuximab, Bendamustine, Rituximab|Brentuximab Vedotin in Combination with Bendamustine and Rituximab
2990856|NCT02623907||AS group|Severe AS patients, without severe AR
2990857|NCT02623907||AR|Severe AR patients, without severe AS
2990858|NCT02623881|Active Comparator|Cervical pessary|Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
2990859|NCT02623881|Active Comparator|Vaginal Progesterone|Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
2990860|NCT02623868|Experimental|Group 1|A-B-C (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
2990861|NCT02623868|Experimental|Group 2|B-C-A (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
2990862|NCT02623868|Experimental|Group 3|C-A-B (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
2990863|NCT02623868|Experimental|Group 4|A-C-B (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
2990864|NCT02623868|Experimental|Group 5|B-A-C (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
3012788|NCT02477332|Experimental|QGE031 Arm 1|
2990866|NCT02623855|Active Comparator|Park prescription|Park prescription, pedometry.
2990867|NCT02623855|Experimental|Park prescription and family outings|Park prescription, pedometry, case management and 3 weekly family outings.
2990868|NCT02623842|Experimental|Radiofrequency|
2990869|NCT02623829|Experimental|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered. The forehead will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml(2.5 units) and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml(5 units) each in addition to the lateral aspect of each corrugator with 0.05ml(2.5 units). The injections will be administered with a 30G needle perpendicular to the skin.
2990870|NCT02623829|Sham Comparator|Saline|1ml of normal saline will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml each in addition to the lateral aspect of each corrugator with 0.05ml. The injections will be administered with a 30G needle perpendicular to the skin.
2990871|NCT02623816|Experimental|Sub-optimal/optimal dosing|Patients will not change sub-optimal dosing regimen of omeprazole 20 mg for 6 weeks after which they will receive optimal dosing of omeprazole for 4 weeks. Rescue antacid use is permitted. Total duration of 10 weeks.
2990872|NCT02623816|No Intervention|Sub-optimal dosing|No change will be made to the sub-optimal dosing regimen of omeprazole 20 mg. Rescue antacid use is permitted. Total duration of 10 weeks.
2990873|NCT02623816|Experimental|Optimal dosing|Patients will be administered optimal dosing of Omeprazole 20 mg for 4 weeks starting at week 2. Rescue antacid use is permitted. Total duration of 6 weeks.
2990874|NCT02623803|Active Comparator|Treatment group|lidocaine infusion will be initiated at the time of anesthesia induction in the operating room. Dosage 1.5mg/kg/hour. Continuous infusion until patient meets discharge criteria in recovery room.
2990875|NCT02623803|Placebo Comparator|Control group|placebo infusion (D5W) will be initiated at the time of anesthesia induction in the operating room. Continuous infusion until patient meets discharge criteria in recovery room.
2990876|NCT02623790|Experimental|Test meal (butter)|Subjects will eat one test meal containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
2990877|NCT02623790|Experimental|Test meal (cheddar cheese)|Subjects will eat one test meal containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
2990878|NCT02623790|Experimental|Test meal (cream cheese)|Subjects will eat one test meal containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
2990879|NCT02623777|Experimental|AXOS as first intervention|AXOS as first intervention
2990880|NCT02623777|Experimental|SCFA as first intervention|SCFA as first intervention
2990881|NCT02623764||MCI due to Alzheimer´s disease|Individuals with MCI diagnosed with Alzheimer´s disease on the basis of cognitive decline and positive biomarkers by MRI and/or Cerebro Spinal Fluid (CSF) analysis. The intervention is donepezil in recommended doses, 5mg/day for a month and then 10mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
2990882|NCT02623764||Mild dementia due to Alzheimer´s disease|Individuals with mild dementia and diagnosed with Alzheimer´s disease on the basis of cognitive decline and positive biomarkers by MRI and/or CSF analysis. The intervention is donepezil in recommended doses, 5mg/day for a month and then 10mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
2990883|NCT02623764||Mild dementia due to Lewy body disease|Individuals with mild Lewy body dementia. The intervention is Exelon patches in recommended doses, 4.6mg/day for a month and then 9.5mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
2990884|NCT02623751|Experimental|KHK2375 PO and Exemestane PO|KHK2375 and Exemestane
2990885|NCT02623738|Placebo Comparator|Placebo ophthalmic solution|Eyedrop
2990886|NCT02623738|Experimental|DE-117 ophthalmic solution low|Eyedrop
2990887|NCT02623738|Experimental|DE-117 ophthalmic solution high|Eyedrop
2990888|NCT02623738|Active Comparator|Latanoprost ophthalmic solution 0.005%|Eyedrop
2990889|NCT02623725|Experimental|CYD Dengue Vaccine Booster|Participants from a previous CYD dengue vaccine study randomized to receive CYD dengue vaccine booster
2990890|NCT02623725|Experimental|Placebo Vaccine Group|Participants from a previous CYD dengue vaccine study randomized to receive a placebo vaccine
2990891|NCT02623712|Active Comparator|More Frequent CT Surveillance|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
2990892|NCT02623712|Active Comparator|Less Frequent CT Surveillance|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
2990893|NCT02623699|Experimental|Single Ascending Dose|Part A: Randomized single ascending dose
2990894|NCT02623699|Experimental|Multiple Ascending Dose|Part B: Randomized multiple ascending dose
2990895|NCT02623686|Experimental|Aroma group|"two massages delivered within a two day period~the patient will choose the essential oils used from blend A and blend B (if no choice is made, therapist will choose blend A and B alternately). One drop of the essential oil blend will be added to 5 mls of grapeseed base oil.~an Inhalation Patch with the same blend of oils as used in the massage will be left by the therapist for use on each of the two nights following the aromatherapy massage intervention. Its use will be explained to the patient and to the member of nursing staff. The Inhalation Patch will be applied to the patient's upper chest when it is time to sleep at approximately 11 pm and will be removed the following morning at approximately 6 am."
2990896|NCT02623686|No Intervention|Control Group|Normal Care
2990897|NCT02623673||bevacizumab plus dexamethasone 0.7mg|simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg
2990898|NCT02623660|Experimental|Experimental|This group will receive treatment from the ODIN1 device in conjunction with standard care and diagnostic device testing.
2990899|NCT02623660|Active Comparator|Control|This group will receive the standard care and the diagnostic device testing.
2990900|NCT02623647|Other|A single-arm, nonrandomized|stereotactic body radiotherapy SBRT, 40 Gy for 3 fractions
2990901|NCT02623634||observation|this study measure the cuff leak volume and cuff leak ratio according to the cuff leak test with different positions and waveform,, at the same time observe the patient general condition, vital signs, oxygen saturation, cuff leak test results under different conditions and the breathing machine parameters, the diameter of the airway, the use of sedatives and hormones, after extubation stridor and intubation is happening again, the use of NPPV after extubation, patient outcomes
2990902|NCT02623608|Experimental|High fat meal|Subjects eat a high fat breakfast (reference breakfast) at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h.
2990903|NCT02623608|Experimental|High fat meal + Active Ingredient 1|"Subjects eat the same high fat breakfast with the active ingredient 1 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
2990904|NCT02623608|Experimental|High fat meal + Active Ingredient 2|"Subjects eat the same high fat breakfast with the active ingredient 2 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
2990905|NCT02623608|Experimental|High fat meal + Active Ingredient 3|"Subjects eat the same high fat breakfast with the active ingredient 3 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
2990906|NCT02623608|Experimental|High fat meal + Active Ingredient 4|"Subjects eat the same high fat breakfast with the active ingredient 4 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
2990907|NCT02623595|Experimental|SBRT+GM-CSF|Metastasis lesion will be treated with a SBRT of 50Gy/5F from day 1 to day 5 in a cycle of 21 days.Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
2990908|NCT02623582|Experimental|Cohort 1|The first 3 subjects to receive RNA CART123 cells will receive up to 3 doses of RNA CART123 cells, with no lymphodepleting chemotherapy prior to infusion.
2990909|NCT02623582|Experimental|Cohort 2|"The remaining 12 subjects of the study will receive up to six IV doses of RNA CART123 cells.~Subjects in Cohort 2 may be given lymphodepleting chemotherapy 4 days (+/- 1 day) prior to the first CART123 cell infusion (if ALC> 500/uL).~Lymphodepleting chemotherapy may be repeated before the fourth dose of RNA CART123 cells (if ALC> 500/uL).~Lymphodepleting chemotherapy includes a single dose of cyclophosphamide (1g/m2) Weight used for dosing will be the weight obtained prior to the apheresis procedure Cell numbers are based on CAR+ cells with CAR expression determined by flow cytometry Based on the product release criteria, at least 20% of the total cells will be RNA CART123 cells.~Dosing will not be changed for changes in subject weight The indicated doses are +/- 20% to account for manufacturing variability."
2990910|NCT02623569|Experimental|Ivabradine|Ivabradine 5 mg twice a day for first 4 weeks and 7.5mg twice a day when positive ETT and HR（heard rate）＞60times/min or negative ETT and HR（heard rate）＞80times/min of subjects.
2990911|NCT02623569|Active Comparator|Atenolol|Atenolol 12.5 mg twice a day for first 4 weeks and 25mg twice a day when positive ETT and HR（heard rate）＞60times/min or negative ETT and HR （heard rate）＞80times/min of subjects.
2990912|NCT02623556|Experimental|TB subjects|"720 cases TB (Tuberculosis) subjects who meet the standard respectively are divided average into two groups through a randomized and blind method.~360 TB subjects are injected ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm. 360 TB subjects are injected ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h."
2990913|NCT02623556|Experimental|non-TB subjects with lung disease and suspected TB subjects|360 cases non-TB subjects with lung disease and suspected TB subjects,who meet the standard respectively are divided average into different groups through a randomized and blind method. 180 non-TB subjects with lung disease are injected ESAT6-CFP10(10ug/ml) in left arm and TB-PPD in right arm. 180 non-TB subjects with lung disease are injected ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm. The study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
2990914|NCT02623543|Experimental|OrthoK|OrthoK lenses will be prescribed for subjects randomly and followed for 2yrs throughout wearing the lenses. There will be an enrollment appointment, dispense appointment, 1-day, 1-week, 1-month, 6-month, 12-month, and 24-month follow-ups.
2990915|NCT02623543|Placebo Comparator|Control|Subjects in the randomly assigned control will continue to wear their glasses throughout the 2yr follow-up period. There will be an enrollment appointment, 6-month, 12-month, and 24-month follow-ups.
2990916|NCT02623530|Active Comparator|Control group|Control group: to implement educational intervention focusing on first aid for developing critical thinking (CT) skills and disposition, through the Problem Based Learning (PBL), not based on the Active Learning Model for Critical Thinking (MEAPC).
2990917|NCT02623530|Experimental|Experimental group|Experimental group: to implement educational intervention focusing on first aid for developing critical thinking (CT) skills and disposition, through the Problem Based Learning (PBL), based on the Active Learning Model for Critical Thinking (MEAPC).
2990918|NCT02623517||Enrolled Subjects|The Enrolled Subjects group will comprise of 75 individuals who will be followed for 12 months for their atrial fibrillation condition. Data will be collected from subjects' devices for 12 months, and any needed changes or additions to therapy will be done. (ie: ablation, pacemaker setting changes, medication control).
2990919|NCT02623517||Registry Subjects|The Registry Subjects group will comprise of screened patients who do not exhibit symptoms of atrial fibrillation at the time of screening. The already collected data from the patient's device during the screening visit will be kept and put into a registry.
2990920|NCT02623504|Experimental|Equetro|200-1200 mg of Equetro (carbamazepine) by mouth given in divided doses in the morning and in the evening. Dosage is titrated in 200 mg increments weekly as needed according to subject response.
2990921|NCT02623504|Placebo Comparator|Placebo|Placebo dosage to match the active Equetro treatment given in 2 daily doses in the morning and in the evening.
2990922|NCT02623491|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive 0.75 milligrams (mg) of JNJ-55375515 (starting dose) or Placebo on Day 1. Dose of the study medication will be escalated sequentially up to a maximum of 200 mg.
2990923|NCT02623491|Experimental|Part 2: Multiple Ascending Dose (MAD)|Participants will receive JNJ-55375515 (at doses determined based on the data from the SAD part) or Placebo from Day 1 to 10.
2990924|NCT02623478|Experimental|Insulin Lispro - Test Formulation|Novel formulation of insulin lispro delivered via an insulin pump as a continuous infusion under the skin, with intermittent bolus doses during meals for two 3-day periods
2990925|NCT02623478|Active Comparator|Insulin Lispro - Reference Formulation|Marketed formulation of insulin lispro delivered via an insulin pump as a continuous infusion under the skin, with intermittent bolus doses during meals for two 3-day periods
2990926|NCT02623465|Experimental|Part A:Insulin Lispro Test|Individualized doses of insulin lispro test formulation administered by injection under the skin once in each of 3 periods
2990927|NCT02623465|Active Comparator|Part A:Insulin Lispro Reference|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
2990928|NCT02623465|Experimental|Part B:Insulin Lispro Test|Individualized doses of insulin lispro test formulation administered by injection under the skin with each meal for 14 days
2990929|NCT02623465|Active Comparator|Part B:Insulin Lispro Reference|Individualized doses of insulin lispro reference formulation administered by injection under the skin with each meal for 14 days
2990930|NCT02623452|Experimental|Part A:Insulin Lispro Test|Individualized doses of Insulin Lispro test formulation administered by injection under the skin once in each of 3 periods
2990931|NCT02623452|Active Comparator|Part A:Insulin Lispro Reference|Individualized doses of Insulin Lispro reference formulation administered by injection under the skin once in each of 3 periods
2990932|NCT02623452|Experimental|Part B:Insulin Lispro Test|Individualized doses of Insulin Lispro test formulation administered by injection under the skin with each meal for 14 days
2990933|NCT02623452|Active Comparator|Part B:Insulin Lispro Reference|Individualized doses of Insulin Lispro reference formulation administered by injection under the skin with each meal for 14 days
2990934|NCT02623439|Experimental|cyclophosphamide post BMT|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
2990935|NCT02623426|Active Comparator|Dexamethasone intravitreal implant 0.7mg|"Eligible eye(s) treated at study visit M01 (week 0).~Retreatment required at study visit M03 (8 weeks) if re-treatment criteria met.~Retreatment permitted at later time points if retreatment criteria met.~Re-treatment criteria:~Central subfield thickness greater than 1.1X upper limit of normal (330 μm for Zeiss and Topcon SD OCT and 352 μm for Heidelberg OCT) and/or cystoid space(s) within 1 mm central subfield.~IOP of <25 mm Hg (treatment with ≤3 IOP-lowering agents permitted)~Minimum time between treatments: minimum target is 8 weeks after last injection but re-injection permitted as early as 51 days after last injection;"
2990936|NCT02623426|Active Comparator|Intravitreal methotrexate 400 µg in 0.1 mL|"Eligible eye(s) treated at study visit M01 (week 0).~Retreatment required at M02 (4 weeks) and M03 (8 weeks) if retreatment criteria met.~Retreatment permitted at later time points if retreatment criteria met.~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection."
2990937|NCT02623426|Active Comparator|Intravitreal ranibizumab 0.5 mg per 0.05 mL|"Eligible eye(s) treated at study visits M01 (week 0), M02 (4 weeks), and M03 (8 weeks).~Retreatment permitted at M04 (12 weeks) and at later time points if retreatment criteria met.~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection.~Re-treatment permitted at later time points if re-treatment criteria met."
2990938|NCT02623413||Sites implementing contact precautions|"Centers isolating for VRE may only participate if complying with the following standards:~Contact precautions triggered by the initial detection of VRE~Patients discharged as a VRE-carrier must be placed in contact isolation upon readmission~Termination of contact precautions after at least two consecutive VRE-negative consecutive fecal screening cultures~Resumption of contact isolation on first subsequent VRE-positive culture~Contact precautions must encompass the following measures:~Patients: Placement in single rooms. Cohorting is only permitted, in case of unavailability of single rooms~Staff and visitors: Wearing of gloves and gowns when entering the room.~Patients: Wearing of gloves and gowns when leaving the room."
2990939|NCT02623413||Sites not implementing contact precautions|Only VRE colonized or infected patients with urinary or fecal incontinence or diarrhea (defined as > 3 loose bowel movements/day), must be isolated in single rooms at any time during the study.
2990940|NCT02623400||Preterm infants and their parents|Preterm infants born before 34 weeks gestational age and/or with a birth weight lower than 1500g and their parents.
2990941|NCT02623387|Active Comparator|Standard Paravertebral Block|Patients receiving a conventional paravertebral block of dilute local anaesthetic (eg. 5ml of 0.5% bupivacaine or similar) administered using anatomical landmarks
2990942|NCT02623387|Active Comparator|Ultrasound Guided Paravertebral Block|Patients receiving paravertebral block of dilute local anaesthetic (eg. 5ml of 0.5% bupivacaine or similar) administered under ultrasound guidance
2990943|NCT02623374|Experimental|SH-CBT|This intervention will be a tailored CBT intervention adapted from the previously validated (Ayres, et al., 2012) self-help CBT intervention that comprises of a self-help booklet containing information, advice, a relaxation CD and daily diaries. This intervention lasts 4 weeks (approx. 4 hours per week) and the materials guide the individual through each chapter and exercise, including the homework set out for each chapter.
2990944|NCT02623374|No Intervention|No Treatment-Wait Control (NTWC)|Women will be offered no intervention but will complete questionnaires at the same assessment points as the intervention/treatment arm participant group (i.e. baseline (A0), 6 weeks (A1), 20 weeks (A2) post randomisation). They will be offered the SHCBT intervention off trial following the final assessment (i.e. A2).
2990945|NCT02623361|Placebo Comparator|Sham|
2990946|NCT02623361|Active Comparator|Fascia Iliaca Compartment Block|
2990947|NCT02623348|Experimental|pedometer|Patients will be given pedometers and instructions to increase physical activity based on pedometer output
2990948|NCT02623348|No Intervention|usual care|No intervention
2990949|NCT02623335|Experimental|QPL (question prompt list) brochure|Patients will be mailed the QPL (question prompt list) prior to their appointment with an enrolled surgeon.
2990950|NCT02623335|No Intervention|Usual care|The investigators have observed that usual care includes informed consent and a surgeon-directed deliberative phase in which surgeons present their own evaluation of the trade-offs and goals of the proposed intervention.
2990951|NCT02623322|Experimental|MHAA4549A: Dose Level 1|Participants will receive single-dose MHAA4549A by intravenous (IV) administration.
2990952|NCT02623322|Experimental|MHAA4549A: Dose Level 2|Participants will receive single-dose MHAA4549A by IV administration.
2990953|NCT02623322|Placebo Comparator|Placebo|Participants will receive single-dose placebo by IV administration.
2990954|NCT02623309|Experimental|HAPLO graft|"Conditioning regimen~Fludarabin : 30 mg/m2/day for 4 days: from D-5 à J-2.~Busulfan IV : 130 mg/m2/day for 2 days : drom D-4 to D-3. + 1 day of Thiotepa : 5mg/kg at D-6.~Prophylaxis regimen for GVHD~F CSA and MMF (starting day +5)~Additional immunosuppression: PT-HDCy (50 mg/kg/day) on days +3 and +4~Hematopoietic Stem Cell Graft PBSC graft will be preferred for a minimal targeted cell dose of 4 x 106 CD34+cells/kg GCSF (Neupogen ®) during 4 to 5 days (D-4 to D-1): SC 10 µg/kg/d."
2990955|NCT02623309|Active Comparator|MUD graft|"Conditioning regimen~Fludarabin : 30 mg/m2/day for 5 days: from D-6 to D-2.~Busulfan IV : 130 mg/m2/day for 2 days: from D-4 to D-3.~Prophylaxis regimen for GVHD~CSA and MMF will be used from day -1 after UD~Additional immunosuppression: Rabbit ATG (2.5 mg/kg/day) on days -3 and -2~Hematopoietic Stem Cell Graft PBSC graft will be preferred for a minimal targeted cell dose of 4 x 106 CD34+cells/kg"
2990956|NCT02623296|Experimental|GLPG1205 and single CYP450 substrate cocktail dose|Daily GLPG1205 administration from Day 1 to Day 12 Single GLPG1205 co-administration on Day 13 with CYP450 substrate cocktail
2990957|NCT02623296|Placebo Comparator|Placebo and single CYP450 substrate cocktail dose|Daily Placebo administration from Day 1 to Day 12 Single Placebo co-administration on Day 13 with CYP450 substrate cocktail
2990958|NCT02623270|Experimental|Noninvasive Ventilation|After induction of anesthesia, checking of ability to bag mask ventilating the patient, the manual bag ventilation will be replaced by a Noninvasive Ventilator, V60 (Philips)
2990959|NCT02623244||ovarian endometrioma|Women with ovarian endometrioma noted by ultrasonography.
2990960|NCT02623244||The control group|Women with age and body mass index matched and without ovarian endometrioma in ultrasonography
2990961|NCT02623231|Experimental|escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
2990962|NCT02623231|Placebo Comparator|placebo|Group number 2 will include 50 patients, who will receive Placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
2990963|NCT02623218|Experimental|TBI-ACUP|This group will receive the standard of care plus acupuncture treatments during the acute 10-day phase following a diagnosed TBI.
2990964|NCT02623218|Sham Comparator|TBI-SHAM|This group will receive the standard of care plus sham acupuncture treatments during the acute 10-day phase following a diagnosed TBI.
2990965|NCT02623218|Active Comparator|C-ACUP:|This group of participants without TBI will receive one acupuncture treatment and serve as a healthy control group.
2990966|NCT02623218|Sham Comparator|C-SHAM|This group of participants will receive one sham acupuncture treatment and serve as a healthy sham comparator group.
2990967|NCT02623205|Active Comparator|Escitalopram|Active Comparator: Escitalopram (Lexapro) 10mg Week 1, 20mg Weeks 2 and 3, and 30mg for Weeks 4 to 8 (or until 12 for patients close to remission)
2990968|NCT02623205|Placebo Comparator|Placebo|Lactose pill manufactured to mimic Escitalopram pill
2990969|NCT02623192||ARDS|
2990970|NCT02623179|Active Comparator|A-Culture and Sensitivity group|Diagnosis by Culture and Sensitivity group-Treatment based on the results of the FH C & S testing - Odd Numbers on randomization table
2990971|NCT02623179|Active Comparator|B-Diagnosis by Molecular Testing|Diagnosis by Molecular Testing-Treatment based on the results of the PathoGenius molecular testing - Even Numbers on randomization table
2990972|NCT02623153|Active Comparator|capecitabine and oxaliplatin|capecitabine of 1000 mg/m2, orally administered twice a day on days 1-14 and oxaliplatin at 130 mg/m2on day 1, as intravenous 2 h infusion
2990973|NCT02623153|Experimental|S1, oxaliplatin and docetaxel|S1 of 40 mg/m2, orally administered twice a day on days 1-14,oxaliplatin 130 mg/m2 and docetaxel 40 mg/m2on day 1 as intravenous
2990974|NCT02623140|Experimental|Biofreedom|Biofreedom stent treatment at index procedure
2990975|NCT02623140|Active Comparator|Orsiro|Orsiro stent treatment at index procedure
2990976|NCT02623127|Experimental|Sunitinib|Sunitinib will be administered orally at a dose of 50 mg once daily in 3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment.
2990977|NCT02623114|Experimental|Methylphenidate|ADHD patients with methylphenidate administration Generic names include concerta, metadata and penid. The initial dosage was fixed for 2 weeks and then adjusted according to the clinician's judgement. The patients visited the hospital at week 2,4,6,8,16,24, 9months, 12,15,18,21,24 months.
2990978|NCT02623114|Experimental|Atomoxetine|ADHD patients with atomoxetine administration Generic names include strattera. The initial dosage was fixed for 2 weeks and then adjusted according to the clinician's judgement. The patients visited the hospital at week 2,4,6,8,16,24, 9months, 12,15,18,21,24 months.
2990979|NCT02623101|Active Comparator|Standard of care procedure|"Clinical suspected basal cell carcinomas, of all subtypes, will be diagnosed by conventional 3mm punch biopsy of the most clinical suspicious part of the lesion. Punch biopsies will be performed under local anesthetics using 1% xylocaine/adrenaline. Hematoxylin/eosin stained sections of the punch biopsies will be evaluated by an experienced pathologist. Subjects will receive surgical excision according to subtype.~When there is any doubt by reflectance confocal microscopic diagnosis, a punch biopsy will also be obtained and the lesion will be excized when the biopsy reveals a basal cell carcinoma."
2990980|NCT02623101|Experimental|Reflectance confocal microscopy (RCM)|The Vivascope 1500 and Vivascope 3000 (handheld divice) will be used (CE certified, Lucid Technologies, Henrietta, NY, USA). Reflectance confocal microscopy (RCM) imaging will be performed on clinical suspected basal cell carcinomas, of all subtypes. When there are signs of a basal cell carcinoma imaged by RCM, subjects will receive surgical excision according to subtype. When there is any doubt by RCM diagnosis, a punch biopsy will also be obtained and the lesion will be excized when the biopsy reveals a basal cell carcinoma.
2990981|NCT02623088||PAP therapies|Patients with sleep apnea syndrome treated by CPAP after respiratory and vascular assessment and followed 5-7 years, as part of a clinical research.
2990982|NCT02623075|Experimental|Transplant recipients (Chimeric)|Adults who have received a kidney/stem cell transplant and have achieved chimerism will receive the IIV4 (influenza vaccine).
2990983|NCT02623075|Experimental|Transplant recipients (IS)|Adults who have received a kidney/stem cell transplant and are currently maintained on standard immunosuppressive therapy will receive the IIV4 (influenza vaccine).
2990984|NCT02623075|Active Comparator|Controls|Healthy adults who meet inclusion and exclusion criteria will receive the IIV4 (influenza vaccine).
2990985|NCT02623062|Active Comparator|Compound Sodium Alginate Oral Suspension sachets|Each patient will be instructed to take Compound Sodium Alginate Oral Suspension sachet or matching placebo as a 2x10ml sachets four times daily regimen. Prior to dosing, all patients will be instructed by the Investigator on how they will take the medication. Patients will be instructed to start taking their medication the day after their randomisation visit (Day 1) for seven days (20ml taken four times a day: 30 minutes after breakfast, 30 minutes after lunch, 30 minutes after dinner and immediately before lying down for bed. Shake well before use).
2990986|NCT02623062|Placebo Comparator|Matching placebo sachets|Each patient will be instructed to take Compound Sodium Alginate Oral Suspension sachet or matching placebo as a 2x10ml sachets four times daily regimen. Prior to dosing, all patients will be instructed by the Investigator on how they will take the medication. Patients will be instructed to start taking their medication the day after their randomisation visit (Day 1) for seven days (20ml taken four times a day: 30 minutes after breakfast, 30 minutes after lunch, 30 minutes after dinner and immediately before lying down for bed. Shake well before use).
2990987|NCT02623049||octogenarians patients - Apixaban|octogenarians patients who will be treated with Apixaban
2990988|NCT02623049||younger than 70 years patients - Apixaba|younger than 70 years patients who will be treated with Apixaba
2990989|NCT02623049||octogenarians patients - Rivaroxaban|octogenarians patients who will be treated with Rivaroxaban
2990990|NCT02623049||younger than 70 years patients - Rivaroxaban|younger than 70 years patients who will be treated with Rivaroxaban
2990991|NCT02623049||octogenarians patients - Dabigatran|octogenarians patients who will be treated with Dabigatran
2990992|NCT02623049||younger than 70 years patients - Dabigatran|younger than 70 years patients who will be treated with Dabigatran
2990993|NCT02623036|Active Comparator|Enalapril arm|Patients randomized to this group will receive equivalent dose enalapril to their current ACEI therapy and change the administration time to bedtime.
2990994|NCT02623036|Active Comparator|Lisinopril arm|Patients randomized to this group will receive equivalent dose lisinopril to their current ACEI therapy and change the administration time to bedtime.
2990995|NCT02623023|Experimental|Combigan group|Combigan will be administered twice a day on the day before the intraocular injection and once in the morning of the injection
2990996|NCT02623023|Placebo Comparator|Refresh tears|Refresh tears will be administered twice a day on the day before the intraocular injection and once in the morning of the injection
2990997|NCT02623010|Experimental|Single arm|Imbruvica (ibrutinib) will be given as maintenance treatment until relapse or toxicity to 30 elderly PCNSL patients after achieving response to first line treatment
2990998|NCT02622997|Active Comparator|Refrigerated|Sample taken and refrigerated immediately then stored in laboratory at -20oC until testing
2990999|NCT02622997|Experimental|Incubated at 25oC for 1 week|Sample taken and refrigerated immediately then incubated at 25oC for 1 week in laboratory then at -20oC until testing
2991000|NCT02622997|Experimental|Incubated at 25oC for 2 weeks|Sample taken and refrigerated immediately then incubated at 25oC for 2 weeks in laboratory then at -20oC until testing
2991001|NCT02622984|Experimental|RBIRT|Telehealth model or the remote administration of SBIRT, a short term, brief intervention and referral to treatment for alcohol abuse.
2991002|NCT02622984|Active Comparator|SBIRT|Face-to-face intervention and referral to treatment for alcohol abuse.
2991003|NCT02622971|Active Comparator|PBMT and Cryotherapy|Volunteers allocated in this group received phototherapy (PBMT - applied in six points of quadriceps) and cryotherapy (20 minutes in PRICE protocol) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
2991004|NCT02622971|Active Comparator|Cryotherapy and PBMT|Volunteers allocated in this group received cryotherapy (20 minutes in PRICE protocol) and phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
2991005|NCT02622971|Active Comparator|PBMT (active phototherapy)|Volunteers allocated in this group received active phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
2991006|NCT02622971|Placebo Comparator|PBMT (placebo phototherapy)|Volunteers allocated in this group received placebo phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol. The placebo PBMT device was identical to the active devices and displayed the same settings and emitted the same sound regardless of the comparator.
2991007|NCT02622971|Active Comparator|Cryotherapy|Volunteers allocated in this group cryotherapy (20 minutes in PRICE protocol) as a treatment three minutes and 24h, 48h and 72h after exercise protocol. Two flexible ice packs filled with ice cubes and water (with a volume of 1.15 liters each) were used in order to cover the entire quadriceps. Rubber belts were used to apply compression and to affix the packs tightly to the volunteers' quadriceps.
2991008|NCT02622958|Experimental|PH94B Nasal Spray|Water based solution of 16 ppm PH94B. Each nasal spray delivers .8 micrograms PH94B in 50 microliters
2991009|NCT02622958|Placebo Comparator|Placebo Nasal Spray|Water based solution, each nasal spray delivers 50 microliters of droplets.
2991010|NCT02622945|Experimental|Active tDCS plus Speech-Language Therapy|Active tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min. Language therapy will be oral and written naming. This is a cross-over study so all participants will receive this arm but the order will be randomized.
2991011|NCT02622945|Sham Comparator|Sham plus Speech-Language Therapy|Sham tDCS will be applied at the beginning of 45min speech-language therapy session. Language therapy will be oral and written naming. This is a cross-over study so all participants will receive this arm but the order will be randomized.
3012789|NCT02477332|Experimental|QGE031 Arm 2|
2991012|NCT02622932|Experimental|Anlotinib and 14C-labeled Anlotinib|each participant will be given a single dose of 14C-labeled gilteritinib.
2991013|NCT02622906|Placebo Comparator|Placebo|1 injection per month during 6 months of the placebo product
2991014|NCT02622906|Active Comparator|Pasireotide|1 injection per month during 6 months of the Pasireotide LP (60mg/injection)
2991015|NCT02622893|Active Comparator|Transperitoneal laparoscopic nephrectomy|Patients in this group underwent transperitoneal laparoscopic nephrectomy in 45-60º modified flank position after receiving epidural catheter in the sitting position before the surgery.
2991016|NCT02622893|Active Comparator|Retroperitoneal laparoscopic nephrectomy|Patients in this group underwent retroperitoneal laparoscopic nephrectomy in lateral decubitis position after receiving epidural catheter in the sitting position before the surgery.
2991017|NCT02622880|Active Comparator|: IMPACT|along 10 days before surgery
2991018|NCT02622880|Experimental|immunomodulatory supplement|along 10 days before surgery
2991019|NCT02622867|Experimental|Lactobacillus plantarum 3547|1 capsule/daily during 12 weeks with Lactobacillus plantarum 3547 (10x109 cfu/d). The capsule contains 77 mg probiotic Lp3547 and 390 mg maltodextrin
2991020|NCT02622867|Placebo Comparator|Maltodextrin|1 daily capsule of maltodextrin (425 mg) during 12 weeks
2991021|NCT02622854|Experimental|plasma exchange|plasma exchange, with 1.5 estimated plasma volume exchanged with albumin solution, using citrate anticoagulation, performed daily until triglycerides <=10 mmol/l
2991022|NCT02622854|Active Comparator|conservative treatment|infusion of 5% glucose and insulin, to maintain blood glucose at 5-8 mmol/l
2991023|NCT02622841|Experimental|BLEND|Combination of stereotactic bodyradiotherapy and surgical stabilization within 48 hours for the treatment of unstable spinal metastases.
2991024|NCT02622828|Other|Behavioural|Participant-identified community based activity
2991025|NCT02622815||Healthy blood donors|10,000 highly controlled blood donors in the age range 35-65 years
2991026|NCT02622815||Moli-sani subjects|A sample of 1,000 tumor cases have been identified so far and samples from these participants will be analyzed compared to 1,000 controls from randomly extracted from the Moli-sani cohort (parent cohort).
2991027|NCT02622815||Cancer patients|4,000 Patients with breast, lung, and gastrointestinal tumors.
2991028|NCT02622802|Experimental|ex-vivo placenta perfusion|ex vivo placenta perfusion study with exposure to paracetamol, erythromycin and azithromycin
2991029|NCT02622789||Controls|Age-matched Healthy Controls
2991030|NCT02622789||General Exercises|Low Back Pain Participants Receiving General Exercises
2991031|NCT02622789||Pilates Exercises|Low Back Pain Participants Receiving Pilates Exercises
2991032|NCT02622776|Other|Vaginal DNA Collection|Patients with a diagnosis of ovarian cancer or endometrial cancer who have not yet had surgery, chemotherapy or radiation may be able eligible to participate. Patients unaffected by cancer may be able to participate.
2991033|NCT02622763|Experimental|10 millions dose|a total of 10 millions tolerogenic dendritic cells
2991034|NCT02622763|Experimental|100 millions dose|a total of 100 millions tolerogenic dendritic cells
2991035|NCT02622750|Experimental|triple-branched stent graft|The triple-branched stent graft was a branched 1-piece graft and included a main stent graft and 3 sidearm stent grafts (Yuhengjia Science and Technology, Corp, Ltd, Beijing, China). The main stent graft and sidearm stent grafts were individually mounted on 4 catheters and restrained by 4 silk sutures .The triple-branched stent graft was inserted into the true lumens of the aortic arch and proximal descending aorta; the three vascular stent branches were then grafted into the corresponding true lumens of the aortic arch branch vessels followed by the sequential release of the vascular stent backbone and the branch stents in the left subclavian artery, the left common carotid artery, and the innominate artery.
2991036|NCT02622750|Active Comparator|four-branched Dacron graft|"A four-branched Dacron graft (Boston Scientific Inc, Boston, MA) and a stent graft (MicroPort Medical Co Ltd, Shanghai, China) were used in total arch replacement combined with stented elephant trunk (SET) implantation.The SET was inserted into the true lumen of the descending aorta.The proximal edge of the residual aorta was trimmed to match the proximal end of the stent graft.The anastomosis between the four-branched prosthetic graft and the distal aorta containing the intraluminal stented graft was carried out using open aortic technique."
2991037|NCT02622737|Experimental|Functional Training|Functional exercise training program
2991038|NCT02622737|Experimental|Stationary Bike|Stationary bike training program
2991039|NCT02622737|Experimental|Exergaming|Virtual Reality Exposure Therapy
2991040|NCT02622724|Experimental|FP-1201-lyo 10 μg|"FP-1201-lyo 10 μg (Interferon beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection."
2991041|NCT02622724|Placebo Comparator|FP-1201-lyo Placebo|"FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.~Investigational placebo product is lyophilisate for solution for injection which will be reconstituted in water for injection."
2991042|NCT02622711|Experimental|DI Dietary Intervention|Individualized dietary counselling to reduce body weight
2991043|NCT02622711|Experimental|PAI Physical Activity Intervention|Individualized physical activity counseling to reduce body weight
2991044|NCT02622711|Experimental|PADI Physical Activity+Diet Intervention|Individualized dietary and physical activity counseling to reduce body weight
2991045|NCT02622711|Experimental|LII Less Intensive Intervention|Materials and guidelines available to general public
2991046|NCT02622698|Placebo Comparator|Control|The patients in the control group did not receive any supplementation, and were directed to follow the dietary guidelines of their surgeon.
2991047|NCT02622698|Experimental|Treatment|Patients were instructed to consume one ounce (containing 16 grams of protein) of the supplement three times daily. No other modifications were made to the patient's diet. Patients were provided with a total of 60 doses, which would last 20 days if they consumed each dose as instructed.
2991048|NCT02622685|Experimental|DWP10292|"Drug: DWP10292 DWP10292 tablets, oral administration, multiple administration~Arms: DWP10292"
2991049|NCT02622685|Placebo Comparator|DWP10292 Placebo|"Drug: Placebo Placebo tablets, oral administration, multiple administrations~Arms: Placebo"
2991078|NCT02622503||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis receiving rituximab will be observed for treatment responses.
2991050|NCT02622685|Experimental|Ursodeoxycholic acid (UDCA)|"Drug: Ursodeoxycholic acid (UDCA) UDCA tablets, oral administration, multiple administrations~Arms: Ursodeoxycholic acid (UDCA)"
2991051|NCT02622685|Placebo Comparator|Ursodeoxycholic acid (UDCA) Placebo|"Drug: Placebo Placebo tablets, oral administration, multiple administrations~Arms: Placebo"
2991052|NCT02622672|Experimental|Placebo|glycerin.soy-lecithin, and water
2991053|NCT02622672|Experimental|Supplement|water-soluble Ubiquinol 100 mg/d
2991054|NCT02622659|Experimental|Fuganlin Oral Liquid|"Fuganlin Oral Liquid:oral~less than 1 years old: 5mL each time and three times a day~1~3 years old: 10mL each time and three times a day~4~6 years old: 10mL each time and four times a day~7~12 years old: 10mL each time and five times a day~Xiaoer Jiebiao Oral Liquid placebo:oral~1~2 years old: 5mL each time and twice a day~3~5 years old: 5mL each time and three times a day~6~14 years old: 10mL each time and twice a day"
2991055|NCT02622659|Active Comparator|Xiaoer Jiebiao Oral Liquid|"Xiaoer Jiebiao Oral Liquid:oral~1~2 years old: 5mL each time and twice a day~3~5 years old: 5mL each time and three times a day~6~14 years old: 10mL each time and twice a day~Fuganlin Oral Liquid placebo:oral~less than 1 years old: 5mL each time and three times a day~1~3 years old: 10mL each time and three times a day~4~6 years old: 10mL each time and four times a day~7~12 years old: 10mL each time and five times a day"
2991056|NCT02622646||Well controlled patients|Patients with an adequate disease control with the routine clinical practice (AJBR≤2, non-severe ABR≤5 and severe ABR≤2) (Ministerio de Sanidad, Servicios Sociales e Igualdad. Gobierno de España; 2012)
2991057|NCT02622646||Poor controlled patients|Patients with poor disease control, based on the international guidelines: AJBR>2, ABR>2 for severe BE or ABR >5 for non-severe BE
2991058|NCT02622633|Experimental|Stimulation|One week after implantation of the device, participants randomized in this arm will receive continuous magnetic stimulation of high frequency (50Hz) with epidural electrode for 12 weeks. And then, the epidural electrode will be turned off for more 12 weeks in a crossover fashion.
2991059|NCT02622633|Sham Comparator|Sham Stimulation|One week after implantation of the device, participants randomized in this arm will receive sham stimulation for 12 weeks and then continuous magnetic stimulation with epidural electrode of high frequency (50Hz) stimulation for more 12 weeks.
2991060|NCT02622620||Patients with glioma|Patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who receive concurrent chemoradiation (CCRT) with temozolomide
2991061|NCT02622607|Experimental|ZOL|Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 months for 12 months.
2991062|NCT02622607|No Intervention|Control|No investigational treatment
2991063|NCT02622594|Active Comparator|1|Treatment 1 will include microneedling performed prior to ALA application to their right face and ALA application only to the left face 60 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
2991064|NCT02622594|Active Comparator|2|Treatment 2 will include microneedling performed prior to ALA application to their left face and ALA application only to the right side of their face 60 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
2991065|NCT02622594|Active Comparator|3|Treatment 3 will include microneedling performed prior to ALA application to their right face and ALA application only to the left side of their face 30 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
2991066|NCT02622594|Active Comparator|4|Treatment 4 will include microneedling performed prior to ALA application to their left face and ALA application only to the right side of their face 30 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
2991067|NCT02622581||Non-squamous cell carcinoma|3,250 patients with non-squamous cell carcinoma will be tested for molecular alterations. (CRISP)
2991068|NCT02622581||Squamous cell carcinoma|1,750 patients with squamous cell carcinoma that possibly will be tested for molecular alterations. (CRISP)
2991069|NCT02622581||Non-squamous cell carcinoma (not tested)|Not tested for molecular alterations (CRISP-Satellite).
2991070|NCT02622568|Active Comparator|Cryotherapy and Veregen|Cryotherapy will be performed on the day of first clinic visit according to current standard of care in Children's Medical Center pediatric outpatient dermatology clinic, which consists of two freeze/thaw cycles for maximum of 10 seconds each. Sinecathecins 15% ointment will be prescribed and initiated immediately following the day of first clinic visit. Sinecathecins 15% ointment will be applied to verrucous lesions twice daily. Follow-up clinical visits will be required at 0 weeks, 6 weeks, and 12 weeks. Clinical photos will be taken at each visit. Verrucae will be measured at each visit using a standard ruler. Outcome measures will be numerical reduction in diameter of verruca.
2991071|NCT02622568|Experimental|Veregen only|Veregen ™or sinecathecins 15% ointment will be prescribed and initiated immediately following the day of first clinic visit. Veregen ™ or sinecathecins 15% ointment will be applied to verrucous lesions twice daily per current Children's Medical Center protocol. Follow-up clinical visits will be required at 0 weeks, 6 weeks, and 12 weeks. Clinical photos will be taken at each visit. Verrucae will be measured at each visit using a standard ruler. Outcome measures will be numerical reduction in diameter of verruca.
2991072|NCT02622555||Mirabegron treatment|Women with overactive bladder syndrome eligible for Mirabegron treatment
2991073|NCT02622542|Active Comparator|BMT Alone|Patients in this group will be managed with the best medical therapy (BMT) alone
2991074|NCT02622542|Experimental|BMT+TEVAR|Patients in this group will be managed with thoracic endovascular aortic repair (TEVAR) in addition to the best medical therapy (BMT)
2991075|NCT02622529||Screening through Questionnaires|All of the patients within this single existent Arm will receive the questionnaires.
2991076|NCT02622516|Active Comparator|Intervention Group (IG)|Participants in the intervention group subjects (IG) will receive physiotherapy treatment in vestibular rehabilitation based on multisensory exercises consisting of the group of therapeutic proposals that stimulation of the vestibular, proprioceptive and visual associated with manual therapy treatment proposed by the techniques cervical global pompage and classic massage therapy on neck and shoulder girdle .
2991077|NCT02622516|Experimental|Control Group (CG)|Participants in the control group subjects (CG) will receive physiotherapy treatment in vestibular rehabilitation based on Cawthorne and Cooksey Exercises, consisting of eye movements in different directions, slowly and quickly; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.
2991079|NCT02622490|Active Comparator|Low carb. one meal|Intervention: One meal of 750 kcal with 20 % of energy content from carbohydrates
2991080|NCT02622490|Active Comparator|Low Carb. 5 small meals|Intervention: Five meals every 30 minutes of 150 kcal/each with 20 % of energy content from carbohydrates.
2991081|NCT02622490|Active Comparator|High carb. one meal|Intervention: One meal of 750 kcal with 50 % of energy content from carbohydrates
2991082|NCT02622490|Experimental|High carb. 5 meals|Intervention: Five meals every 30 minutes of 150 kcal/each with 50 % of energy content from carbohydrates.
2991083|NCT02622477||Participants with idiopathic pulmonary fibrosis|Participants with idiopathic pulmonary fibrosis receiving Pirfenidone will be observed for treatment responses.
2991084|NCT02622464|Experimental|micro injection of SVF in vocal cords|micro injection of Stromal Vascular Fraction extracted from autologous adipose tissue in vocal cords
2991085|NCT02622451|Other|Youth Behavioral Intervention|Teen Intervene
2991086|NCT02622451|Other|Parent Education|Everyday Parenting
2991087|NCT02622438|Other|Course and follow up of patients affected by FSHD|
2991088|NCT02622425|Active Comparator|PD01|Carotenoid-producing Bacillus strain PD01
2991089|NCT02622425|Placebo Comparator|Placebo|Maltodextrin
2991090|NCT02622412|Experimental|Intervention Group|Patients randomised to the intervention group will get immediate access to the Multi-professional breathlessness service (MBS).
2991091|NCT02622412|Other|Control Group|Patients randomised to the control group will get delayed MBS intervention. They will receive standard care and get access to the service after a waiting time of eight weeks.
2991092|NCT02622399|Experimental|Project NOW|Participants in the intervention arm receive access to free mobile communications and a web-based informational platform supported by txtwire.
2991093|NCT02622399|No Intervention|Control|Participants in the control arm do not receive access to the txtwire platform.
2991094|NCT02622386|Experimental|Riboflavin|Riboflavin (Vitamin B2) 400 mg oral capsule taken once daily for 12 weeks, followed by 4 week washout period before crossover. At crossover, patients will no longer receive Riboflavin but matching placebo capsule for additional 12 weeks.
2991095|NCT02622386|Placebo Comparator|Placebo|Placebo oral capsule taken once daily for 12 weeks, followed by 4 week washout period before crossover. At crossover, patients will no longer receive placebo but 400 mg Riboflavin (Vitamin B2) capsule for additional 12 weeks.
2991096|NCT02622373||Birth Between 23-32 Weeks Gestation|Babies born between 23-32 weeks of gestational age will have their body composition determined using PEA POD Infant Body Composition System at 34 weeks, 36 weeks and 40 weeks of corrected age.
2991097|NCT02622373||Birth Between 34-36 Weeks Gestation|Babies born at 34 weeks and 36 weeks of gestational age will have their body composition measured using PEA POD Infant Body Composition System as soon as they are off parenteral nutrition and receiving full enteral nutrition.
2991098|NCT02622373||Birth at Term|Body composition will be measured using PEA POD Infant Body Composition System in this group will be obtained prior to discharge.
2991099|NCT02622360||Dyslexia|Individuals with confirmed dyslexia.
2991100|NCT02622360||Control|Healthy control subjects.
2991101|NCT02622334|Experimental|Part A|Participants will receive up to 3 multiple ascending dose levels with the starting dose of 0.1% RO5093151 (topical ocular instillation) and sequentially 0.5% and 1% RO5093151 doses or placebo (3:1, active:placebo) twice a day (BID) on Day 1 and once a day (QD) for 6 days.
2991102|NCT02622334|Experimental|Part B|Participants will receive highest feasible dose (HFD) or maximum tolerated dose (MTD) of RO5093151 from Part A or 0.005% latanoprost (topical ocular instillation) once daily for 7 days.
2991103|NCT02622321|Experimental|Arm A (Episodic Treatment): Emicizumab|Participants, who received episodic treatment with bypassing agents prior to study entry, will receive prophylactic emicizumab. Participants will continue to receive episodic bypassing agent therapy to treat breakthrough bleeds, with rFVIIa and/or activated prothrombin complex concentrate (aPCC).
2991104|NCT02622321|Active Comparator|Arm B (Episodic Treatment): No Emicizumab|Participants, who received episodic treatment with bypassing agents prior to study entry, will not receive emicizumab prophylaxis. These participants will have the opportunity to switch to emicizumab prophylaxis after at least 24 weeks on-study. Participants will continue to receive bypassing agent therapy to treat breakthrough bleeds, with rFVIIa and/or aPCC.
2991105|NCT02622321|Experimental|Arm C (Prophylactic Treatment): Emicizumab|Participants, who received prophylactic bypassing agents prior to study entry, will receive prophylactic emicizumab. Participants will continue to receive bypassing agent therapy to treat breakthrough bleeds, with rFVIIa and/or aPCC.
2991106|NCT02622321|Experimental|Arm D (Episodic or Prophylactic Treatment): Emicizumab|Participants who received episodic bypassing agents while participating in Study BH29768 but were unable to enroll in Arms A or B, or participants who received prophylactic bypassing agents but were unable to enroll in Arm C, will be enrolled in this arm to receive prophylactic emicizumab. Participants will continue to receive bypassing agent therapy to treat breakthrough bleeds, with rFVIIa and/or aPCC.
2991107|NCT02622308|Experimental|single-case design|"The study design will be a non-randomized clinical trial with single-subject baseline design (also called single-case baseline design) where each patients act as their own controls:~Observations (A) will be taken before and after a 8-week intervention period. We plan to introduce a 4-week INP-treatment period ('FlowOx™) (B) using the same outcome variables that were used as baseline measures. If the patient demonstrates improvements in outcome variables after the first treatment period (B1), the patient will be asked to continue INP therapy for another 4-week period, before a final assessment after a total of 8-week intervention period (B2) (A-B-B design)."
2991108|NCT02622295|Experimental|Acute gene regulation|Adaptations in gene regulation in response to single-session high-frequency active-resisted stance or single-session low-frequency active-resisted stance
2991109|NCT02622295|Experimental|16 Week Training Study|Adaptations in gene regulation, metabolic markers, and subject-report metrics in response to 16 weeks of high-frequency active-resisted stance training or 16 weeks of low-frequency active-resisted stance training
2991110|NCT02622282|Experimental|Experimental Group|Participants will receive text messages and telephone calls during the length of their participation. Participants will receive a handout with information on PAD and physical activity.
2991111|NCT02622282|Active Comparator|Control Group|Participants will receive a handout with information on PAD and physical activity.
2991112|NCT02622269|Experimental|Patient-regulated compression|Patient-regulated compression device
2991113|NCT02622269|Active Comparator|Standard compression|Standard compression device
2991114|NCT02622256|Experimental|Health System: HTN Intervention|Investigators will identify patients with known hypertension (ICD-9 code 401.9), from the Penn Data Store (PDS). Participants will be asked to complete 3 short surveys.
2991115|NCT02622256|No Intervention|Health System: HTN Control, survey only|Investigators will identify patients with known hypertension (ICD-9 code 401.9), from the Penn Data Store (PDS). Participants will be asked to complete 3 short surveys. Participants in this arm will be exposed to daily messages about heart health and asked to tweet about health.
2991116|NCT02622243|Experimental|tiotropium|2 inhalations of 2.5mcg/inhalation tiotropium from Respimat inhaler and 1 inhalation of placebo from Breezehaler 1 hour prior to methacholine challenge
2991117|NCT02622243|Experimental|glycopyrronium|1 inhalation of 50mcg glycopyrronium from Breezehaler and 2 inhalations from placebo Respimat inhaler 1 hour prior to methacholine challenge
2991118|NCT02622230|Experimental|Mianhuahua Flavonoids Tablets|Mianhuahua Flavonoids Tablets, oral administration
2991119|NCT02622230|Placebo Comparator|Placebo|Placebo, oral administration
2991120|NCT02622217|Experimental|Sleep deprived|Participants undergo a simulation session after an on call night
2991121|NCT02622217|No Intervention|Rested|Participants undergo a simulation session after a night of normal sleep at home
2991122|NCT02622204||high tibial osteotomy|patients undergoing knee osteoarthritis
2991123|NCT02622191|Experimental|Open-angle glaucoma|Participants with open-angle glaucoma and an abnormal visual field defect in one eye will be tested on spectral domain optical coherence tomography (SD-OCT)
2991124|NCT02622191|Experimental|Control|Participants without glaucoma and normal vision/eyes will be tested on spectral domain optical coherence tomography (SD-OCT)
2991125|NCT02622178|Experimental|Healthy Subjects|Healthy subjects will require intraocular pressure less than 22 mmHg, normal appearing optic discs and retinal nerve fiber layer, normal optical coherence technology (RNFL thickness) and normal visual field results in both eyes. Participants will be tested on optical coherence tomography testing and Diopsys visual evoked potential testing (VEP).
2991126|NCT02622178|Experimental|Glaucoma Suspects|Glaucoma suspects will require glaucomatous appearance of the optic discs and/or retinal nerve fiber layer in at least one eye, normal optical coherence technology (RNFL thickness) and normal visual field results in both eyes. Participants will be tested on optical coherence tomography testing and Diopsys visual evoked potential testing (VEP).
2991127|NCT02622178|Experimental|Glaucoma Patients|Glaucoma patients will have repeatable abnormal visual fields, glaucomatous optic disc appearance (those with cup to disc area ratio, rim thinning or Retinal Nerve Fiber Layer defects indicative of glaucoma) and/or repeatable intra-ocular pressure of 23 mm Hg or more, in at least one eye. Participants will be tested on optical coherence tomography testing and Diopsys visual evoked potential testing (VEP).
2991128|NCT02622165|Experimental|The REWARD serious game intervention|A mobile 4-week serious game intervention will be administered.
2991129|NCT02622165|No Intervention|Control group|School curriculum as usual
2991130|NCT02622152|Active Comparator|Right lateral position group|After weaning from mechanical ventilation in the postoperative Intensive Care Unit (ICU patient underwent Repositioning the patients for 30 minutes period on the supine position Repositioning the patients for 30 minutes period on the left lateral position Repositioning the patients for two-hours period on the right lateral position This period of repositioning in both groups repeated during the period of ICU stay
2991131|NCT02622152|Active Comparator|Routine hospital care group|After weaning from mechanical ventilation in the postoperative Intensive Care Unit (ICU patient underwent Repositioning the patients for two-hours period on supine position Repositioning the patients for two-hours period on the left lateral position Repositioning the patients for two-hours period on the right lateral position This period of repositioning in both groups repeated during the period of ICU stay
2991132|NCT02622139|Experimental|Multispectral Optoacoustic Tomography|Multispectral Optoacoustic Tomography (MSOT) for the evaluation of disease activity in inflammatory bowel diseases (IBD)
2991133|NCT02622126|Active Comparator|Normotensive pregnant women group|"Preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6% 130/0.4) (Voluven).~Sub arachnoid 10-12 mg hyperbaric bupivacaine Sub arachnoid 200 meg morphine Isotonic 0.9 sodium chloride (NaCl) solution ( 10 ml/kg) will be used as co loading during the duration of the operation Ephedrine 6 me intravenous will be used to treat severe hypotension (fall of > 20% of mean arterial pressure from baseline) Atropine 0.5 mg intravenous will be used to treat bradycardia (fall of >30% of heart rate from baseline or <50 beats /minute and when associated with hypotension)"
2991134|NCT02622126|Active Comparator|Mild preeclampsia pregnant women group|"Preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6% 130/0.4) (Voluven).~Sub arachnoid 10-12 mg hyperbaric bupivacaine Sub arachnoid 200 meg morphine Isotonic 0.9 sodium chloride (NaCl) solution (NaCl) solution ( 10 ml/kg) will be used as co loading during the duration of the operation Ephedrine 6 me intravenous will be used to treat severe hypotension (fall of > 20% of mean arterial pressure from baseline) Atropine 0.5 mg intravenous will be used to treat bradycardia (fall of >30% of heart rate from baseline or <50 beats /minute and when associated with hypotension)"
2991135|NCT02622113|Experimental|Canagliflozin (TA-7284) ＋insulin|
2991136|NCT02622100||Bioresorbable Vascular Scaffold|
2991137|NCT02622087|Experimental|Hormonal contraceptive|Women who receive one-session-treatment while they are on the hormonal contraceptive pill
2991138|NCT02622087|Experimental|Naturally cycling- high estradiol|Naturally cycling women who receive one-session-treatment during a period of high estradiol
2991139|NCT02622087|Experimental|Naturally cycling-low estradiol|Naturally cycling women who receive one-session-treatment during a period of low estradiol
2991140|NCT02622074|Experimental|Cohort A: KNp / KAC|Participants receive pembrolizumab (K) PLUS nab-paclitaxel (KNp) followed by pembrolizumab (K) PLUS doxorubicin (A) PLUS cyclophosphamide (C).
2991141|NCT02622074|Experimental|Cohort B: KNpCb / KAC Regimen 1|Participants receive Regimen 1 of pembrolizumab (K) PLUS nab-paclitaxel (KNp) PLUS carboplatin (Cb) followed by pembrolizumab (K) PLUS doxorubicin (A) PLUS cyclophosphamide (C).
2991142|NCT02622074|Experimental|Cohort C: KNpCb / KAC Regimen 2|Participants receive Regimen 2 of pembrolizumab (K) PLUS nab-paclitaxel (KNp) PLUS carboplatin (Cb) followed by pembrolizumab (K) PLUS doxorubicin (A) PLUS cyclophosphamide (C).
2991143|NCT02622074|Experimental|Cohort D: KNpCb / KAC Regimen 3|Participants receive Regimen 3 of pembrolizumab (K) PLUS nab-paclitaxel (KNp) PLUS carboplatin (Cb) followed by pembrolizumab (K) PLUS doxorubicin (A) PLUS cyclophosphamide (C).
2991144|NCT02622074|Experimental|Cohort E: KTCb / KAC Regimen 1|Participants receive Regimen 1 of pembrolizumab (K) PLUS paclitaxel (T) PLUS carboplatin (Cb), followed by pembrolizumab (K) PLUS doxorubicin (A) PLUS cyclophosphamide (C).
2991145|NCT02622074|Experimental|Cohort F: KTCb / KAC Regimen 2|Participants receive Regimen 2 of pembrolizumab (K) PLUS paclitaxel (T) PLUS carboplatin (Cb) followed by pembrolizumab (K) + doxorubicin (A) PLUS cyclophosphamide (C).
2991146|NCT02622061||PCD Subjects|Participants 5 and older with PCD.
2991147|NCT02622061||Healthy Subjects|Participants 5 and older without any pulmonary disease.
2991148|NCT02622048|Experimental|Stage 2 Parents experiencing psychosis|Parents all receive the self-directed Triple P Positive Parenting Programme
2991149|NCT02622022|Active Comparator|Morphine|18 patients treated with oral morphine hydrochloride linctus 5 mg 4 four times daily and as needed up to 4 times daily
2991150|NCT02622022|Placebo Comparator|Placebo|18 patients treated with oral linctus corresponding to 5 mg morphine hydrochloride, four times daily and as needed up to 4 times daily
2991151|NCT02622009||COPD I|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE I
2991152|NCT02622009||COPD II|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE II
2991153|NCT02622009||COPD III|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE III
2991154|NCT02622009||NONSMOKERS|BRONCHOSCOPIC PROCEDURE IN NONSMOKERS
2991155|NCT02622009||CURRENT OR EXSMOKERS|BRONCHOSCOPIC PROCEDURE IN CURRENT OR EXSMOKERS
2991156|NCT02621996|Experimental|Hammock group|PN who will be positioned in hammock inside the incubator will be with the high trunk to about the 30th, and will be used a roll of restraint in the neck by keeping a slight lordosis to avoid suffocation risks. In two days of placement, should remain about 8 hours in the hammock, being removed during cleaning procedures, diet and medical evaluation and then immediately replaced in the hammock. The alternation of decubitus (right side, supine and left lateral) should be performed whenever the child is manipulated for these procedures.
2991157|NCT02621996|Active Comparator|control group|"In the control group, the position will follow the routine procedure of the Hospital Barão de Lucena, consisting of the use of restraint nests U, made with rolled sheet placed on the mattress of the incubator and covered by another sheet. The control group incubators will also be inclined at 30 ° as routine service. During the 8 position, switching the supine will also be held, side left and side right after the baby handling to cleaning procedures, diet and medical evaluation."
2991158|NCT02621983|Active Comparator|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
2991159|NCT02621983|Active Comparator|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
2991160|NCT02621970|Experimental|IC plus CC plus IMRT plus AC|Induction chemotherapy: TP -- Docetaxel 75mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 2 cycles; Concurrent chemotherapy: PX -- Cisplatin 25 mg/m2, D1-3 and Xeloda 2000mg/m2, D1-14, every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy; Adjuvant chemotherapy: Xeloda 2500mg/m2, D1-14, every 3 weeks for 2 cycles
2991161|NCT02621970|Active Comparator|CC plus IMRT|Concurrent chemotherapy: Cisplatin 100 mg/m2, D1, every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
2991162|NCT02621957|Experimental|Female Healthy Volunteers|Healthy volunteer female subjects of non-childbearing potential will be administered pravastatin once on Day 1 during Period 1 (Day -1 to Day 4). During Period 2 (Days 5-28) GDC-0810 will be administered daily on Days 5-8. Pravastatin will be co-administered on Day 7.
2991163|NCT02621944|Experimental|Participants 1-10|"This group will receive a 0.5 mg/kg enteral dose of Melatonin. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Generalized Motor Assessment (GMA), Pharmacokinetics, and safety monitoring."
2991164|NCT02621944|Experimental|Participants 11-20|"This group will the Melatonin dose of 3 mg/kg enteral, only if the group Participants 1-10 has meet the safety goals. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Generalized Motor Assessment (GMA), Pharmacokinetics, and safety monitoring."
2991165|NCT02621944|Experimental|Participants 21-30|"This group will receive Melatonin dose of 5 mg/kg enterally, only if the group Participants 11-20 has meet the safety goals. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Generalized Motor Assessment (GMA), Pharmacokinetics, and safety monitoring."
2991166|NCT02621931|Experimental|TEV-48125 - 1|Dose Regimen 1
2991167|NCT02621931|Experimental|TEV-48125 - 2|Dose Regimen 2
2991168|NCT02621931|Placebo Comparator|Placebo|Matching Placebo
2991383|NCT02620436|No Intervention|Standard of Care|Existing mother shelters with no changes made, except to ensure that they can provide standard of care.
2991785|NCT02617667|Active Comparator|Restasis|Cyclosporine A 0.05% ophthalmic emulsion
2991169|NCT02621918|Experimental|Progressive Resistance Training (PRT)|For the progressive resistance training we use 11 exercises. The exercises for upper limbs were held in the waiting room before the hemodialysis session. Resistance exercise was carried out in two sets of 15-20 repetitions, the intensity were determined by the method of maximal repetitions, where series were run until exhaustion to momentary exercises (15-20 repetitions) with specific load. The load adjustments or volume were managed when necessary, but necessarily for every 4th week of training. The effort perception should be situated between 12 and 16 on the Borg scale (Borg and Noble, 1974), as proposed by The Life Options Rehabilitation Advisory Council: Exercise for the Patient Dialysis (1995).
2991170|NCT02621918|Experimental|Aerobic Exercise (AER)|Aerobic exercise was conducted with a mini ergometer cycling (Mini Bike E5 Acte Sports) attached to the patient chair. Patients exercised 50-60 minutes of continuous workout with increased load. The workload was adjusted when necessary, according to the perceived effort made by the patient. The scale of perceived exertion, Borg scale (Borg and Noble , 1974), was used in accordance with the proposed By The Life Options Rehabilitation Advisory Council: Exercise for the Patient Dialysis (1995), which defines the values of perceived exertion between 12 and 16.
2991171|NCT02621918|Placebo Comparator|NEPLA|The control group performed active mobilization of members, circumduction of cervical, scapular girdle and extremities, breathing exercises with no loads, set on three to five repetitions only and no stretch exercises. The exercises were performed during the hemodialysis session, three times per week and did not exceed 5 minutes.
2991172|NCT02621905|Active Comparator|Sporanox|100 mg
2991173|NCT02621905|Experimental|Lozanoc|50 mg
2991174|NCT02621892|Experimental|50mg BID|Tenapanor
2991175|NCT02621892|Placebo Comparator|Placebo|Placebo
2991176|NCT02621879|Experimental|Bilateral Gluteal Advancement Flap|Advancement of both gluteal muscles to the midline after release incisions in their fascia.
2991177|NCT02621866|Experimental|Active|UVA irradiation.
2991178|NCT02621866|Sham Comparator|Sham UVA irradiation|
2991179|NCT02621853|Other|MRI+RAMAN|Patients will undergo an MRI for assessment of the fat content of the liver. Then during surgery, their livers will be illuminated (for a few seconds) by Raman spectroscope (the device in question) to see if MRI findings correlate well with Raman spectroscopy findings.
2991180|NCT02621840|Experimental|Intervention|Patients in the intervention group will be mandated to complete the PAT with Dr. Koka. After scheduling the surgery with the surgical coordinator, intervention patients will be required to go directly to Dr. Koka's office, to complete all necessary pre-operative steps.
2991181|NCT02621840|No Intervention|Usual Care|Patients in the usual care group will be treated with the standard protocol that is currently utilized in the Wills Eye Hospital Cataract and Primary Eye Care (CPEC) Service. After scheduling the surgery with the surgical coordinator, the patient will be given pre-admission testing (PAT) paperwork to be completed. The patient schedules the PAT on his or her own with the primary care physician.The patient will be given the information for Dr. Koka's cardiology office if he or she has any problem getting the PAT done.
2991182|NCT02621827|Experimental|Non-pregnant, non-lactating (NPNL)|"NPNL women are age and parity matched to pregnant women. Each NPNL women is studied twice, approximately 3 months apart.~At each study period the participant receives (as the intervention) a single oral dose of stable isotope labeled 25(OH)D3."
2991183|NCT02621827|Experimental|Pregnant/Lactating|Pregnant women receive (as the intervention) a single oral dose of stable isotope labeled 25(OH)D3. The same women are followed-up in lactation to repeat the same protocol.
2991184|NCT02621814|Experimental|Experimental 1|Formula feeding
2991185|NCT02621814|Experimental|Experimental 2|Formula feeding
2991186|NCT02621801|Experimental|Intervention|Stress Management and Resiliency Training for Residents (SMART-R)
2991187|NCT02621801|Active Comparator|Waitlist Control|The control group will receive the same intervention (SMART-R) after the experimental group.
2991188|NCT02621788|Experimental|First Year Residents|Stress Management and Resiliency Training for Residents (SMART-R) delivered to first year residents in the departments of medicine and psychiatry at Massachusetts General Hospital
2991189|NCT02621775|Experimental|Computer-based stress management program|Immediate e-learning condition with minimal contact (n =40),
2991190|NCT02621775|Experimental|Stress management in face-to-face|Immediate treatment in face - to- face (n = 40)
2991191|NCT02621775|Other|Waiting list|Waiting list (n=40)
2991192|NCT02621762|Experimental|Mg first|Receives MgCl2 first, MgCl2 and Bicarbonate in second phase
2991193|NCT02621762|Experimental|Bicarbonate first|Receives Bicarbonate first, MgCl2 and Bicarbonate in second phase
2991194|NCT02621749|Active Comparator|CRRT group|the CRRT group receives continuous renal replacement therapy for acute kidney injury
2991195|NCT02621749|Active Comparator|IRRT group|the IRRT group receives intermittent renal replacement therapy after termination of CRRT.
2991196|NCT02621710||Minimally invasive hysterectomy|Patients undergoing scheduled minimally invasive hysterectomy (vaginal, laparoscopic, robotic) for benign condition
2991197|NCT02621710||Abdominal hysterectomy|Patients undergoing scheduled abdominal hysterectomy for benign condition
2991198|NCT02621697|Experimental|Cognitive motor training|Evaluate the effectiveness of a 12-week training based on dual-task (motor and cognitive) in institutionalized elderly.
2991199|NCT02621697|Active Comparator|Control Group|kinesiotherapeutic conventional treatment
2991200|NCT02621684|Experimental|Arm 1: Aerobics|"Complete baseline questionnaires either online or on paper~Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline~Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.~Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations.~Require physical evaluation and orientation to the WellAware gym~12 week walking program at the WellAware Center~required to check in with gym staff to check attendance~advised to walk at own pace for 3 days per week~15 minutes per day for the first 2 weeks~30 minutes per day for the next 2 weeks~50 minutes or more for remaining weeks"
2991226|NCT02621502|Experimental|Quinoa variety 2|1 dose of Quinoa Variety 2 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
2991201|NCT02621684|Experimental|Arm 2: Resistance training|"Complete baseline questionnaires either online or on paper~Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline~Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.~Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations.~Require physical evaluation and orientation to the WellAware gym~12 week weight lifting program at WellAware Center~exercise physiologists will work with each patient to develop a custom routine~exercise load will start at 60% of one-repetition maximum and progress from 8 to 12 repetitions~2-4 sets of repetition exercises will be performed to target upper & lower muscle groups~resistance load will be added by 5 pounds when patients can complete more than 12 repetitions"
2991202|NCT02621684|Active Comparator|Arm 3: Usual care|"Complete baseline questionnaires either online or on paper~Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline~Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.~Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations."
2991203|NCT02621671|Experimental|Arm 1: Cognitive Interviews|"Participants will complete several survey items, view 1 of 8 disease risk pictures (selected at random), and then complete further survey questions.~Participants will then be recorded giving their opinions on the remaining 7 disease risk pictures which depict the hypothetical risk of disease.~The entire visit will take no more than 90 minutes with no follow-up.~The first 10-20 participants will be randomized to this arm."
2991204|NCT02621671|Experimental|Arm 2: Experimental survey|"Participants will be randomly assigned by GfK's computer to one of the 12 experimental conditions.~After completing questions about information seeking and physical activity, the participants will read a short scenario that describes the purpose of a risk assessment tool and ask them to imagine that they had just entered their information into such a tool.~Participants will see whichever risk ladder corresponds to the experimental condition to which they were assigned.~The hypothetical display will be consistent with a display generated for an individual whose risk profile includes risk increasing and decreasing factors, but does not engage in the recommended amount of physical activity."
2991205|NCT02621658|Active Comparator|Clear Liquid Diet|Clear Liquid Diet the day before colonoscopy.
2991206|NCT02621658|Experimental|Full Liquid Diet|Full Liquid Diet the day before colonoscopy.
2991207|NCT02621645|Experimental|Early intervention|Intervention between 12.0 and 14.0 weeks. Early selective reduction of TRAP mass.
2991208|NCT02621645|Active Comparator|Late intervention|Intervention between 16.0 and 19.0 weeks. Late selective reduction of TRAP mass. This is the standard timing of the intervention. One of two possible techniques for late reduction is chosen by the treating physician.
2991209|NCT02621632|Other|Healthy subjects and patients|To done a novel compression system. 20 healthy subjects and 20 patients done a novel compression system termed Socknleg and a compression class III stocking as a comparator.The Socknleg compression system was developed by the investigator and produced by Sigvaris AG, St. Gallen, Switzerland.
2991210|NCT02621619|Experimental|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram IV acetaminophen in addition to 0.5 mg IV hydromorphone
2991211|NCT02621619|Placebo Comparator|Placebo + 0.5 mg IV hydromorphone|100 ml normal saline placebo in addition to 0.5 mg IV hydromorphone
2991212|NCT02621606|Experimental|Part I, Healthy Participants|Healthy participants will receive a single intravenous (IV) dose of ~370 megabecquerel (MBq) [11C]MK-6884 in Part I of the study
2991213|NCT02621606|Experimental|Part II, Healthy Elderly Participants|Healthy elderly participants will receive two separate IV doses of ~370 MBq [11C]MK-6884 in Part II of the study. Administration of the two doses will be separated by at least 3 hours
2991214|NCT02621606|Experimental|Part III, Participants with AD|Participants with AD will receive a single IV dose of ~370 MBq [11C]MK-6884 in Part III of the study
2991215|NCT02621593|Experimental|Treatment of dry eye secondary to MGD|Intervention: Treatment of dry eye symptoms secondary to MGD with the M22-IPL system
2991216|NCT02621580|No Intervention|Control|Patients with type 1 or type 2 diabetes mellitus (according to ADA or WHO guidelines) that have severe preproliferative or proliferative diabetic retinopathy and do not require laser or anti-VEGF treatment in at least one eye.
2991217|NCT02621580|Experimental|Treatment: Pan-Retinal Photocoagulation|Patients with type 1 or type 2 diabetes mellitus (according to ADA or WHO guidelines) that have severe preproliferative or proliferative diabetic retinopathy and require PRP laser in at least one eye.
2991218|NCT02621567|Experimental|Bright Light Therapy Group|Participants in this group will receive bright light therapy lamps and will be instructed to use them for 30 minutes every morning within an hour of waking up, everyday for 4 weeks.
2991219|NCT02621567|Placebo Comparator|Dim Light Group|Participants in this group will receive modified dim lamps and will be instructed to use them for 30 minutes every morning within an hour of waking up, everyday for 4 weeks.
2991220|NCT02621554|Experimental|resveratrol supplementation|Dietary Supplement: Resveratrol
2991221|NCT02621554|Placebo Comparator|placebo supplementation|Dietary Supplement: Placebo
2991222|NCT02621541|Experimental|Preoperative diagnosis|Preoperative diagnosis
2991223|NCT02621528|Other|CeraFlex occluder|The Lifetech CeraFlex™ study is a triple-arm study.
2991224|NCT02621515|Experimental|Nivolumab|All patients in this trial will receive treatment with nivolumab for 24 months. Treatment will be discontinued if confirmed disease progression has been demonstrated, if unacceptable toxicity or intercurrent illness prevents further treatment, and when informed consent is withdrawn. After discontinuation of treatment, follow-up will start. Duration of follow-up depends on survival of patients, with a maximum of 24 months. Therefore the end of this study is determined as 24 months after the last patient in this trial has started follow-up, has died, withdraws consent or is lost to follow-up for a different reason
2991225|NCT02621502|Experimental|Quinoa variety 1|1 dose of Quinoa Variety 1 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
2991418|NCT02620124|No Intervention|Natural cycle, control|Treatment cycles with normal luteal support with progesteron
2991479|NCT02619747|Active Comparator|Compound Sodium Alginate Oral Suspension sachet|Single dose of contents of two 10 ml sachets of Compound Sodium Alginate Oral Suspension
2991227|NCT02621502|Experimental|Quinoa variety 3|1 dose of Quinoa Variety 3 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
2991228|NCT02621502|Experimental|Quinoa variety 4|1 dose of Quinoa Variety 4 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
2991229|NCT02621502|Active Comparator|Anhydrous Glucose|1 dose of Anhydrous Glucose orally. . The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the control powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
2991230|NCT02621489|Experimental|Bydureon 2 mg Once Weekly|Patients randomised to Bydureon will be treated with Metformin 1g BID, and only receive 10U of Humulin kwickpen QD at bedtime, with no more up-titration of insulin during the study.
2991231|NCT02621489|Active Comparator|Humulin kwickpen|Patients randomised to the comparator group will be treated with Meformin 1g BID and Humulin kwickpen to reach a fP-glucose level of 6 mmol/l. For that reason patients will be instructed to increase the bedtime Insulin dose of 2-4U every third day until this goal is reached.
2991232|NCT02621476|Experimental|Standardized intervention|Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
2991233|NCT02621476|Experimental|Usual care|Usual care
2991234|NCT02621463|Experimental|Noninvasive Ventilation|Use of the Noninvasive Ventilator (V60, Philips). The ventilator mask will be placed on the patient's face according to their comfort using an elastomeric H-strap. CPAP of 8 cmH2O (pressure) will be the starting setting for the ventilator.
2991235|NCT02621450|Placebo Comparator|standart dialysate|dialysate sodium 140 mEq/L
2991236|NCT02621450|Other|low sodium dialysate|dialysate sodium will be reduced from 140 mEq/L to 137 mEq/L
2991237|NCT02621437|Experimental|Intervention group (osteopathy)|Patients will have three sessions of osteopathy and 6 phone questionnaires.
2991238|NCT02621437|Other|control group|Patients will have 6 phone questionnaires.
2991239|NCT02621424|Experimental|RTMS|repetitive transcranial magnetic stimulation
2991240|NCT02621424|Sham Comparator|sham|sham noise to block the sound of treatment
2991241|NCT02621411||Substance abuser group|After preoperative screen by application of ICG test cassette, this group of patients are found current use of the certain substance(s).
2991242|NCT02621411||Non-substance abuser group|After preoperative screen by application of ICG test cassette, this group of patients are not found use of any substance.
2991243|NCT02621398|Experimental|Treatment (paclitaxel, carboplatin, radiation, pembrolizumab)|Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Patients undergo 3D CRT or IMRT QD 5 days a week for 6 weeks. Beginning 2-6 weeks after, 2 weeks before the end, or at the start of chemotherapy and radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
2991244|NCT02621385|Experimental|Tradipitant|One dose of midazolam followed by tradipitant dosing for days 3-16. Midazolam is also given on day 16
2991245|NCT02621359|Experimental|Quadruple therapy|Nitazoxanide (500mg bid), Levofloxacin (500 mg once daily), Omeprazole (40 mg bid) and doxycyclin (100 mg twice daily) were prescribed for 14 days.
2991246|NCT02621346|Experimental|Imagery Group|The imagery group, will sit on the leg press and image completing 3 sets of leg press. The imagery group will be asked to fill out the Movement Imagery Questionnaire -revised as this gives us a measure of imagery ability. The imagery group will be given an imagery script prior to imaging. Weekly manipulation checks will be completed to ensure that participants are imagining what they are supposed to.
2991247|NCT02621346|Active Comparator|Maintenance Group|The maintenance group will continue to perform the leg press three times per week at 1/3rd of final strength assessment. This is the percentage of intensity recommended to maintain muscle mass and strength gains by the American College of Sports Medicine.
2991248|NCT02621346|Active Comparator|Control Group|Control group will come in 3 times per week for 20 minutes and complete 3 sets of 8-12 of a bicep curl 1/3 of predicted 1 RM
2991249|NCT02621333|Experimental|CIK combined chemotherapy group|autologous CIK combined chemotherapy group Drugs: platinum combined doublets; After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-indued killer cells are transfused into the vein of patients in one hour.
2991250|NCT02621333|Active Comparator|chemotherapy group|platinum combined doublets Drugs: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/ m2，D1-3 or carboplatin AUC=5, D1.
2991251|NCT02621320|Experimental|Vitamin D|alcohol-based (Ethanol 65%) Vitamin D3 (Vi-De 3®. WILD) solution 6000IU per day.
2991252|NCT02621320|Placebo Comparator|Placebo|Same alcohol-based solution (Ethanol 65%) as intervention product but without cholecalciferol
2991253|NCT02621307|Experimental|Salba|50g glucose 25g ground Salba (Salba Corporation Ltd, Buenos Aires, Argentina) 200ml water
2991254|NCT02621307|Experimental|Flax|50g glucose 31g ground Flax (Bob's Red Mill Natural Raw Whole Flaxseed) 200ml water
2991255|NCT02621307|Placebo Comparator|Control|50g glucose 200ml water
2991256|NCT02621294|Experimental|Measuring protein requirement|Measuring protein requirement of athletes by feeding different amount of protein in the form of amino acid mixture and measuring their oxidation through expired CO2
2991257|NCT02621281|Active Comparator|cold storage|In this randomized clinical trial, 200 kidney pairs from deceased donors will be included in the study, which will be randomly assigned, one kidney to machine perfusion and the other to cold storage. In machine perfusion group, patients will be analyzed by two subgroups based on pressure, resistance index and perfusion time duration.
2991419|NCT02620124|Experimental|Natural cycle, intervention|Treatment cycles with normal luteal support with progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days: Intervention is the additional 0.1 mg triptorelin as described in the previous sentence.
2991258|NCT02621281|Active Comparator|Kidney Transporter machines|In this randomized clinical trial, 200 kidney pairs from deceased donors will be included in the study, which will be randomly assigned, one kidney to machine perfusion and the other to cold storage. In machine perfusion group, patients will be analyzed by two subgroups based on pressure, resistance index and perfusion time duration.
2991259|NCT02621268|Experimental|Indocyanine Green|Dosage calculated by weight of individual, 5mg/kg.
2991260|NCT02621255|Active Comparator|General anesthesia|General Anesthesia: Effect of general anesthesia will compare with regional anesthesia without use of nonsteroid antiinflammatory drug usage. Propofol 2mg/kg and rocuronium will be administered to patients for anesthesia induction. Anesthesia maintenance will ensure with sevoflurane %2 and N2O/O2 %50/50 mixture.
2991261|NCT02621255|Active Comparator|bupivacaine|Regional Anesthesia: Effect of regional anesthesia will compare with general anesthesia without use of nonsteroid antiinflammatory drug usage. Combined epidural-spinal anesthesia will be performed to patients. %5 bupivacain and 20µg fentanyl will apply for spinal anesthesia. Anesthesia maintenance will ensure with bupivacain.
2991262|NCT02621242|Other|Cohort|All subjects will undergo all procedures
2991263|NCT02621229|Active Comparator|Low Calorie Refeeding|beginning at 1400 kcal/d and advanced 200 kcal every other day
2991264|NCT02621229|Experimental|High Calorie Refeeding|beginning with 2000 kcal and advanced 200 kcal/d
2991265|NCT02621190|No Intervention|A|patients without CTCs or AR-V7 negative CTCs are treated according to their physician's discretion
2991266|NCT02621190|Experimental|B|patients with AR-V7 positive CTCs are treated with cabazitaxel 25mg/m2 q3w
2991267|NCT02621177|Experimental|NBP607|Trivalent Inactivated Cell Culture-derived Influenza Vaccine
2991268|NCT02621177|Active Comparator|Agrippal S1|Trivalent Inactivated Egg-derived Influenza Vaccine
2991269|NCT02621164|Experimental|NBP607-QIV|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine
2991270|NCT02621164|Active Comparator|Agrippal S1|Trivalent Inactivated Egg-derived Influenza Vaccine
2991271|NCT02621151|Experimental|Pembrolizumab, Gemcitabine, and RT|"Lead-in single dose Pembrolizumab 200 mg, intravenously (IV)~Transurethral Resection of Bladder Tumor (TURBT) at pre-RT (maximal) and completion of therapy (diagnostic)~External Beam Radiation Therapy (EBRT) - 52 Gy in 20 fractions over 4 weeks (1 fraction = 2.6 Gy)~Gemcitabine 27 mg/m^2 IV twice weekly for 4 weeks concurrent with EBRT~Pembrolizumab 200 mg IV every 3 weeks for total 3 doses starting day 1 of EBRT"
2991272|NCT02621138||cerebral palsy|Age 6-12 years Gross Motor Function Classification System I-II
2991273|NCT02621138||control|Age 6-12 years
2991274|NCT02621125|Experimental|Fertilix|Fertilix supplementation
2991275|NCT02621125|Placebo Comparator|Placebo|Placebo
2991276|NCT02621112|Experimental|Intradermal HBVv with imiquimod|Intradermal hepatitis B vaccination with topical imiquimod pretreatment. Subjects to receive intradermal 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical imiquimod ointment pretreatment 5 minutes before injection at 0, 1, 3, 6 months
2991277|NCT02621112|Active Comparator|Intradermal HBVv with aqueous cream|Intradermal hepatitis B vaccination with topical aqueous cream. Subjects to receive intradermal 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical aqueous cream pretreatment 5 minutes before injection at 0, 1, 3, 6 months
2991278|NCT02621112|Active Comparator|Intramuscular HBVv with aqueous cream|Intramuscular hepatitis B vaccination with topical aqueous cream. Subjects to receive intramuscular 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical aqueous cream pretreatment 5 minutes before injection at 0, 1, 3, 6 months
2991279|NCT02621086|Experimental|Level 1|10g of Cellodextrin
2991280|NCT02621086|Experimental|Level 2|20g of Cellodextrin
2991281|NCT02621086|Experimental|Level 3|30g of Cellodextrin
2991282|NCT02621086|Experimental|Level 4|50g of Cellodextrin
2991283|NCT02621073|Active Comparator|VeraFlo with Prontosan|V.A.C. VeraFlo™ Therapy, the only NPWT system with an instillation feature which allows solution to dwell in the wound for thorough contact with the wound bed. The solution being instilled is Prontosan: Unlike other antiseptics, the antimicrobial efficacy of Prontosan® is not impaired in human wound fluid, human tissue or by high loads of blood or albumin. Furthermore, Prontosan® blocks the microbial attachment to surfaces and has been shown to effectively remove biofilms in vitro and in vivo (Hubner et al 2010).
2991284|NCT02621073|Active Comparator|V.A.C Ulta System|The V.A.C.Ulta™ Therapy System is an integrated wound therapy system that provides NPWT (negative pressure wound therapy), without instillation.
2991285|NCT02621060|Placebo Comparator|Placebo|1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
2991286|NCT02621060|Experimental|Chlorogenic acid|1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
2991287|NCT02621047|Experimental|Alectinib: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 milligrams (mg) on Day 1.
2991288|NCT02621047|Experimental|Alectinib: Severe Hepatic Impairment|Participants with severe hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 mg on Day 1.
2991289|NCT02621047|Experimental|Alectinib: Normal Hepatic Function|Participants with normal hepatic function will receive alectinib at a single oral dose of 300 mg on Day 1.
2991290|NCT02621034|Experimental|Control|K-file hand instrumentation
2991291|NCT02621034|Experimental|Reciproc|rotary reciprocating protocol
2991292|NCT02621034|Experimental|One shape|one shape continuous rotation protocol
2991293|NCT02621021|Experimental|1/ACT TIL|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin (IL-2)
2991294|NCT02621021|Experimental|2/ACT TIL+Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin (IL-2) + pembrolizumab
2991295|NCT02621021|Experimental|3/Retreatment|Standard dose pembrolizumab
2991296|NCT02621008|Experimental|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
2991420|NCT02620124|No Intervention|Hormone replacement cycle, control|Standard hormone replacement cycle with estrogen and progesteron
2991297|NCT02620995|Experimental|hypertensive patients|Hypertensive patients will receive a single oral dose of sildenafil citrate (100 mg) - acute protocol - and a chronic 30-day treatment with sildenafil citrate (50 mg twice daily) - chronic protocol. Penile and systemic microvascular function will be evaluated before and one hour after acute sildenafil administration and in the end of each treatment period.
2991298|NCT02620995|Sham Comparator|comparator group|Normotensive individuals age-matched to the hypertensive patients will receive only a single dose of sildenafil citrate (100 mg) - acute protocol. Penile and systemic microvascular function will be evaluated before and one hour after sildenafil administration.
2991299|NCT02620982|Experimental|ARIES Application|Low intensity Extracorporeal Shockwave Application utilizing the Dornier Aries
2991300|NCT02620969||Patients on haemodialysis|During a midweek session of a patient on haemodialysis, blood and dialysate sampling is performed at different time points.
2991301|NCT02620956|Active Comparator|obese nebulizer|would be used to inhale an aerosol with technetium labeled diethylenetriaminepente-acetic acid (99mTc - DTPA) with an activity of 1 mCi in a total dose volume with normal saline of 2,5 ml and heliox using a vibrating mesh inhaler.
2991302|NCT02620956|Experimental|asthmatic obese nebulizer|would be used to inhale an aerosol with technetium labeled diethylenetriaminepente-acetic acid (99mTc - DTPA) with an activity of 1 mCi in a total dose volume with normal saline of 2,5 ml and heliox using a vibrating mesh inhaler.
2991303|NCT02620943||Exposed Group|Pregnant mothers reporting inadequate (<4) dietary diversity during pregnancy
2991304|NCT02620943||Unexposed group|Pregnant mothers reporting adequate (>=4) dietary diversity during pregnancy
2991305|NCT02620904|Active Comparator|mifepristone|following informed consent women will be randomized and the mifepristone group will take 200 mg by mouth immediately prior to induction of labor for fetal demise on labor and delivery
2991306|NCT02620904|Placebo Comparator|placebo pill|following informed consent women will be randomized and the placebo group will take a placebo pill by mouth (similar in properties to the mifepristone group, but it will lack any active drug) immediately prior to induction of labor for fetal demise on labor and delivery
2991307|NCT02620891|Active Comparator|experimental group|Using helium oxygen mixture
2991308|NCT02620891|No Intervention|matched group|Using air oxygen mixture
2991309|NCT02620878|Experimental|AP|Experimental arm: A closed-loop control system (artificial pancreas) will be used during night and day for 72 hours (3 days) with the aim of automate insulin infusion by an insulin pump to control glucose level. AP is composed of a CGM device (Dexcom G4), an insulin pump (Accu Chek Spirit combo, Roche), and a model predictive control algorithm that is embedded in a smartphone and wirelessly linked to the CGM device and insulin pump. A remote monitoring will be ensured all the time the AP will be active and study team will be present in the camp.
2991310|NCT02620878|Active Comparator|SAP|Active Comparator: SAP teraphy (CGM + insulin pump) will be used for 72 hours during day and night (3 days).
2991311|NCT02620865|Experimental|Treatment (anti-CD3 x anti-EGFR BATs)|Patients receive one of the following standard chemotherapy regimens at the discretion of the treating physician: gemcitabine hydrochloride IV over 30 minutes; gemcitabine hydrochloride IV over 30 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes; oxaliplatin IV over 2 hours, fluorouracil IV over 46 hours and leucovorin calcium IV over 2 hours; or fluorouracil IV over 46 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV, and oxaliplatin IV over 2 hours. Approximately 2 weeks after standard chemotherapy completion, patients receive anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV over 5-30 minutes twice weekly for 4 weeks. Patients also receive aldesleukin SC and sargramostim SC on day -3 before the first anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells infusion and continuing twice weekly until the final infusion.
2991312|NCT02620852|Active Comparator|Annual Arm|Women in this arm will receive Athena standard of care mammography screening, including annual mammograms. They will complete a health questionnaire and receive screening advice based on a basic risk assessment.
2991313|NCT02620852|Experimental|Risk-Based Arm|Women in this arm will receive risk-based screening, where risk is calculated based on a model including personal history, family history, and genetic testing. All women in the risk-based arm complete a health questionnaire, provide a saliva sample for genetic testing, and receive screening advice based on a comprehensive risk assessment. Women in this arm will be tested for a panel of 9 genes related to breast cancer risk as well as a panel of SNPs, which can further modify risk. Women will be assigned a screening start date, screening stop date, and screening frequency.
2991314|NCT02620839|Experimental|Cohort 1A|Alpelisib: 200 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
2991315|NCT02620839|Experimental|Cohort 2A|Alpelisib: 250 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
2991316|NCT02620839|Experimental|Cohort 2B|Alpelisib: 250 mg/day, orally, days 1-21 Cisplatin: 35 mg/m^2, intravenously, days 1, 8, 15
2991317|NCT02620839|Experimental|Cohort 3A|Alpelisib: 300 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
2991318|NCT02620839|Experimental|Cohort 3B|Alpelisib: 300 mg/day, orally, days 1-21 Cisplatin: 35 mg/m^2, intravenously, days 1, 8, 15
2991319|NCT02620839|Experimental|Cohort 4A|Alpelisib: 350 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
2991320|NCT02620839|Experimental|Cohort 4B|Alpelisib: 350 mg/day, orally, days 1-21 Cisplatin: 35 mg/m^2, intravenously, days 1, 8, 15
2991321|NCT02620826|Experimental|Indirect pulp therapy|Primary molars will be treated with indirect pulp therapy using resin-modified glass ionomer (Vitrebond Plus).
2991322|NCT02620826|Active Comparator|Pulpotomy|Primary molars treated with MTA pulpotomy.
2991323|NCT02620813|No Intervention|No Acne|Healthy subjects without acne between the ages of 15-45
2991324|NCT02620813|Experimental|Acne Subjects on Topical Tretinoin Treatment|Subjects with acne before and after topical retinoid therapy
2991325|NCT02620813|Experimental|Acne Subjects on Systemic Isotretinoin Treatment|Subjects with acne before and after isotretinoin therapy
2991326|NCT02620800|Experimental|FABLOx|5 fluorouracil (5-FU ) (180 mg/m^2/day for 14 days), by continuous intravenous infusion (CIVI) via ambulatory pump, nab-paclitaxel (75 mg/m^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15, bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15, calcium leucovorin (20 mg/m^2) IV bolus on Days 1, 8, 15, and oxaliplatin (40 mg/m^2) as a 60-min IV infusion on Days 1, 8, and 15. First bevacizumab infusion is given over 90 minutes.
2991327|NCT02620787|Experimental|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 6 doses of oral tedizolid 200mg once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours.
2991328|NCT02620787|Active Comparator|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 to 6 doses of oral tedizolid 200mg once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours.
2991329|NCT02620774|Experimental|Diabetic Wound Infection|Participants with a documented history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 8 hours.
2991330|NCT02620774|Active Comparator|Healthy Volunteer|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid in the thigh by a microdialysis probe over 8 hours.
2991331|NCT02620761|Placebo Comparator|Control|Infants in the Placebo arm will receive 0.9% sodium chloride (0.1 ml/hr). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion (in this arm the placebo) will be increased to 0.2 ml/kg/hr. This rate will be continued throughout the remainder of the study.
2991332|NCT02620761|Experimental|Fenoldopam|Infants in the experimental arm will receive fenoldopam (60 ug/ml; 0.1 ml/hr to provide 0.1ug/kg/min). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion will be increased to 0.2 ml/kg/hr (0.2 ug/kg/min for infants receiving fenoldopam). This rate will be continued throughout the remainder of the study.
2991333|NCT02620748|Experimental|Tranexamic Acid|This arm will receive an injection of Tranexamic Acid
2991334|NCT02620748|Placebo Comparator|Saline|This arm will receive an injection of Saline Solution
2991335|NCT02620735|Active Comparator|Exercise Only|Participants receive 12-weeks PA training (1x/week - 60 min) group sessions with a CEP/RKin, and a progressively structured home-based exercise program based on the American College of Sports Medicine (ACSM) guidelines.It combines aerobic-resistance exercise with flexibility training, and progresses towards increased in intensity and improved fitness. The goal is at least 150 min/week of moderate-intensity aerobic activity. Participants are also asked to complete 3-5 additional home-based sessions of aerobic, and resistance activities each week. Initial intensity is based on the performance of the exercises during a group session and is self-monitored via the 10-point rating of perceived exertion, with a prescribed training zone of 4-7.
2991336|NCT02620735|Experimental|Exercise + iMOVE|Participants will receive the same exercise program at the Exercise Only group + 1) one-on-one telephone-based counselling (10 x 30-minute telephone: weeks 1, 2, 3, 4, 5, 6, 8, and 12 (during the exercise program) and at weeks 20,28 (post-exercise program booster sessions)); 2) supportive software on smart-phone devices (the HealthCoach program), 3) use of Fit-bit and corresponding software. The iMOVE intervention was designed to enhance sustained behavior change. The theoretical constructs employed are based on promoting motivation and establishing: a) exercise self-efficacy, b) social support for exercise and c) positive exercise-induced feelings during the acute intervention (12 weeks) and post-exercise program period (6 months).
2991337|NCT02620722|Experimental|LOP Measurement|Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument and the gold-standard technique with the handheld Doppler ultrasound.
2991338|NCT02620709|Experimental|Hula intervention|"Participants randomized to the intervention arm will receive the 6-month KaHOLO Program within 1 week of baseline data collection. The first 3 months of the KaHOLO was designed and standardized as a culturally-based PA, which includes 12 weeks of hula lessons. These hula lessons consist of two 60 minute classes per week over 12 weeks. Each hula lesson will consist of 15 participants, providing with the opportunity to engage in social support network.~The last three months of the program will be reduced to once a week sessions. One week will consist of hula lessons for 60 minutes. The remaining 3 weeks will consist of the intervention group meeting for 45 minutes with the community-peer educator."
2991339|NCT02620709|No Intervention|Wait-List Control|After baseline data collection and education, participants randomized to the wait-list control arm will not receive the KaHOLO Program while their counterparts who were randomized to the intervention arm are undergoing the intervention program. Thus, they will not receive the intervention for 6 months until after the intervention arm is completed and their 6 month follow-up data collection is completed. They will not receive any other intervention from us during the 6 month period but they will be instructed to continue with their routine medical care as usual.
2991340|NCT02620696|Experimental|Treatment 1|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide placebo daily from Days 1-42"
2991341|NCT02620696|Experimental|Treatment 2|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide 25 mg daily for 14 days (Days 15-28)~netazepide placebo daily from Days 1-14, and from Days 29-42"
2991342|NCT02620696|Experimental|Treatment 3|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide 25 mg daily for 14 days (Days 29-42)~netazepide placebo daily from Days 1-28"
2991343|NCT02620696|Experimental|Treatment 4|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide placebo daily from Days 1-28"
2991344|NCT02620696|Experimental|Treatment 5|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide 1 mg daily for 14 days (Days 15-28)~netazepide placebo daily from Days 1-14"
2991345|NCT02620696|Experimental|Treatment 6|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide 5 mg daily for 14 days (Days 15-28)~netazepide placebo daily from Days 1-14"
2991346|NCT02620683|Active Comparator|Buffered Lidocaine|"In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block.~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels"
2991382|NCT02620436|Experimental|Core Mother Shelter Model|Existing mother shelters will be renovated, and mother shelters will be built at intervention sites, to meet the Core Mother Shelter Model. This model includes ensuring a safe infrastructure with four walls, a roof, doors and windows that lock, a toilet, running water, and beds.
2991347|NCT02620683|Active Comparator|Non-buffered Lidocaine|"In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block. At least a week later injections would involve the alternate local anesthetic combination.~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels"
2991348|NCT02620670|Active Comparator|Individuals with obesity|Body mass index (BMI) is 30.0 to 39.9 kg / m2 and a waist circumference greater than 80 cm in women and 90 cm for men Physical activity of moderate intensity for 3 days
2991349|NCT02620670|Active Comparator|Individuals with normal weight|Body mass index BMI is 18.5 to 24.9 kg / m2 with lower waist circumference of 80 cm for women and 90 cm for men Physical activity of moderate intensity for 3 days
2991350|NCT02620657||Non interventional study|The patients with advanced NSCLC who have the medical records from Jan 1st 2014 to Dec 31st 2014 will be recruited .
2991351|NCT02620644|Other|G1 Diabetics with no retinpathy|Group 1 consists of diabetic patients free from diabetic retinopathy (45 eyes). OCT retinal GCC measurements.
2991352|NCT02620644|Other|G2 Non diabetics|Group consists of non-diabetic subjects, free from any ocular pathology(21 eyes).OCT retinal GCC measurements.
2991353|NCT02620631|Placebo Comparator|Placebo|Subjects receive intrathecal injection of saline at time of spinal anesthesia
2991354|NCT02620631|Experimental|Morphine|Subjects receive intrathecal injection of morphine sulfate 0.2mg at time of spinal anesthesia
2991355|NCT02620618|Experimental|Intravitreal Infliximab|Patients with refractory behcets uveitis.
2991356|NCT02620605|Active Comparator|Late administration of Cabirgoline 0.5 mg|Cabergoline 0.5mg (Dostinex®, Pfizer Australia Pty Ltd ) administrated once daily started on day of HCG triggering and continued for 8 days.
2991357|NCT02620605|Experimental|Early administration of Cabirgoline 0.5mg|Cabergoline 0.5mg(Dostinex®, Pfizer Australia Pty Ltd ) once daily stared once patients fulfilling the inclusion criteria at any day of cycle and continued for 8 days post HCG trigger.
2991358|NCT02620592|Active Comparator|ZYDPLA1 tablet|ZYDPLA1 tablets: Route of administration: Oral Dosage (Single Ascending Study): 1 mg, 5mg, 20mg, 50mg, 100mg, 200mg Multiple Ascending Study: 100mg, 200mg Food effect and Gender effect study: 200mg
2991359|NCT02620592|Placebo Comparator|Placebo|Placebo tablets: Route of administration: Oral Dosage (Single Ascending Study): 1 mg, 5mg, 20mg, 50mg, 100mg, 200mg Multiple Ascending Study: 100mg, 200mg Food effect and Gender effect study: 200mg
2991360|NCT02620579|Experimental|Personalized Pharmaceutical and Education|This group will have propranolol (Propranolol LA) 60 mg administered orally and receive the pain processing education modules as the combined intervention for this arm.
2991361|NCT02620579|Placebo Comparator|Placebo Pharmaceutical, General Education|This group will have the placebo pharmaceutical administered orally and receive general shoulder anatomy education modules as the interventions for this arm.
2991362|NCT02620579|Active Comparator|Placebo Pharmaceutical, Personalized Education|This group will have the placebo pharmaceutical administered orally and receive the pain processing education modules as the combined intervention for this arm.
2991363|NCT02620579|Active Comparator|Personalized Pharmaceutical, General Education|This group will have propranolol (Propranolol LA) 60 mg administered orally and receive general shoulder anatomy education modules as the interventions for this arm.
2991364|NCT02620566|Active Comparator|Bupivacain -Caudal|Single shot Caudal Block will receive Group C with 1ml per kg Bupivacain 0,25%.
2991365|NCT02620566|Active Comparator|Bupivacain- Local|Single shot Local Infiltration will receive Group L with 0,2ml per kg Bupivacain 0,25%.
2991366|NCT02620553|Experimental|Human Insulin|Oral Insulin at 2.5 mg, 7.5 mg, 22.5 mg, or 67.5 mg per day
2991367|NCT02620553|Placebo Comparator|Placebo|Oral Placebo
2991368|NCT02620514|No Intervention|Health-literacy Assessment|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants with low adherence will continue to one or more intervention groups that address needs based on the results of the survey.
2991369|NCT02620514|Experimental|Health-literacy Assessment + Education and Reminders|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants with then complete a 24-week intervention aimed to improve education about inflammatory bowel disease and scheduled nurse phone call reminders.
2991370|NCT02620514|Experimental|Health-literacy Assessment + Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive education about IBD.
2991371|NCT02620514|Experimental|Health-literacy Assessment + Medication Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive education regarding their medications.
2991372|NCT02620514|Experimental|Health-literacy Assessment + Financial Support|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive financial support for medications.
2991373|NCT02620501|Placebo Comparator|Placebo|Patients will receive 10cc of 1/2 normal saline to gargle prior to EGD
2991374|NCT02620501|Experimental|Experimental|Patients will receive 10cc of 2% topical lidocaine to gargle prior to EGD
2991375|NCT02620488|Active Comparator|Healthy Control|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
2991376|NCT02620488|Experimental|Sickle Cell Disease|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
2991377|NCT02620475|Active Comparator|Gold standard of care|The usual gold standard of wound treatment to prevent scarring is to cover the incision with a self adhesive gauze type dressing (Mepore) covered by paper tape.
2991378|NCT02620475|Experimental|SutureSafe dressings|SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.
2991379|NCT02620462|Experimental|Wearable sensor-based exercise training|The intervention group in addition to standard of care, will receive 6 weeks of sensor-based balance training that provides real-time visual feedback of lower extremities during exercise. The visual feedback is provided on computer screen.
2991380|NCT02620462|No Intervention|Control Group|The control group only receives standard of care.
2991381|NCT02620449|Experimental|single arm study|
2991384|NCT02620410|Other|Axonics SNM System|Axonics SNM Therapy for urinary control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments.
2991385|NCT02620384|Placebo Comparator|A|This group will receive all standard heart failure therapy and placebo pill.
2991386|NCT02620384|Active Comparator|B|This group will receive all standard heart failure therapy with addition of metolazone.
2991387|NCT02620371|Placebo Comparator|(bupivacaine)|30 patients were given preoperative ultrasound guided, modified pectoral block (pecs II block) with local anesthetic(0.25% bupivacaine)
2991388|NCT02620371|Active Comparator|(bupivacaine, ketamine)|30 patients were given preoperative ultrasound guided, modified pectoral block (pecs II block) with local anesthetic(0.25% bupivacaine plus ketamine 1 mg/kg) .
2991389|NCT02620358|Experimental|High Work of Breathing|"If patient has weaning criteria, a Spontaneous Breathing Trial (SBT) with T Tube for 2 hours will be done.~The patient will be extubated after the SBT if he has no criteria of SBT failure."
2991390|NCT02620358|Experimental|Low Work of Breathing|"If patient has weaning criteria a Spontaneous Breathing Trial (SBT) with Pressure Support Ventilation of 8 cmH2O for 30 minutes will be done.~The patient will be extubated after the SBT if he has no criteria of SBT failure."
2991391|NCT02620345|Experimental|Dydrogesterone M/ Women Pregnancy|"Reducing the size of fibroids with medication~Drug: Dydrogesterone M 15mg/Fibroids/Women Pregnancy~Dosage:~1tablet/24 hours/day/ (when seeing fibroids to 4 weeks after postpartum). Dydrogesterone 15mg/day Beta Carotene 4000 IU/day Ascorbic Acid 100 mg/day Cholecalciferol 400 IU/day Dl-Alpha Tocopheryl Acetate 11IU Thiamin Mononitrate 1.5 mg/day Riboflavin 1.7 mg/day Niacinamide 18 mg/day Pyridoxine Hydrochloride 2.6 mg/day Folic Acid 400 mcg/day Cyanocobalamin 4mcg/day Calcium Carbonate 150 mg/day Ferrous Fumarate 27 mg/day Zinc Oxide 25 mg/day~The lost in size of fibroids throughout pregnancy after 48 weeks."
2991392|NCT02620345|Experimental|Dydrogesterone M/ Reproductive Age|"Reducing the size of fibroids with medication~Drug: Dydrogesterone M 15mg/Fibroids/Reproductive Age~Dosage:~1tablet/24 hours/day/24 weeks ( from discovered fibroids through 24 weeks). Dydrogesterone 15mg/day Beta Carotene 4000 IU/day Ascorbic Acid 100 mg/day Cholecalciferol 400 IU/day Dl-Alpha Tocopheryl Acetate 11IU Thiamin Mononitrate 1.5 mg/day Riboflavin 1.7 mg/day Niacinamide 18 mg/day Pyridoxine Hydrochloride 2.6 mg/day Folic Acid 400 mcg/day Cyanocobalamin 4mcg/day Calcium Carbonate 150 mg/day Ferrous Fumarate 27 mg/day Zinc Oxide 25 mg/day~The lost in size of fibroids after 24 weeks."
2991393|NCT02620332|Placebo Comparator|Placebo injection|Water for injection
2991394|NCT02620332|Experimental|MultiPepT1De injection low dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
2991395|NCT02620332|Experimental|MultiPepT1De injection medium dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
2991396|NCT02620332|Experimental|MultiPepT1De injection high dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
2991397|NCT02620319|Experimental|biodegradable stent|endoscopic implantation of biodegradable airway stent, the SX-ELLA Stent DV Tracheal (DV Stent)
2991398|NCT02620306|Experimental|Fimasartan(A)|
2991399|NCT02620306|Experimental|Fimasartan(B)|
2991400|NCT02620306|Active Comparator|Losartan(A)|
2991401|NCT02620306|Active Comparator|Losartan(B)|
2991402|NCT02620293|Experimental|Eczema Emollient|Eczema Repair Emollient
2991403|NCT02620280|Active Comparator|Carbo-abrax, surgery, anthra|Patients will receive a combination of carboplatin and abraxane as neoadjuvant treatment. Definite surgery will be performed not later than 6 weeks after the last dose of neoadjuvant therapy. Four cycles of AC or EC or FEC will then be delivered as adjuvant chemotherapy
2991404|NCT02620280|Experimental|Carbo-abrax-MPDL3280A, surgery, anthra|Patients will receive a combination of carboplatin, abraxane and MPDL3280A as neoadjuvant treatment. Definite surgery will be performed not later than 6 weeks after the last dose of neoadjuvant therapy. Four cycles of AC or EC or FEC will then be delivered as adjuvant chemotherapy
2991405|NCT02620267|Experimental|tDCS Stimulation|Each subject will receive all three types of stimulation on separate days- anodal, cathodal, and sham stimulation
2991406|NCT02620241|Other|sitting position|infants are in a sitting position for 20 minutes
2991407|NCT02620228|Experimental|BIP Biopsy System|Biopsy system that enables real-time bioimpedance measurement from the tip of the biopsy needle.
2991408|NCT02620215|Experimental|Cervical Ripening Balloon|Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
2991409|NCT02620215|Active Comparator|Prostin|Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
2991410|NCT02620176|Experimental|Transcutaneous vagal nerve stimulation|Active vagal nerve stimulation to the left auricular branch of the vagus nerve.
2991411|NCT02620176|Placebo Comparator|Sham vagal nerve stimulation|Placebo vagal nerve stimulation stimulation. The stimulator is attached to the left ear, but rotated 180 degrees, so that it is not stimulating the auricular branch of the vagal nerve.
2991412|NCT02620163|Experimental|YH22162|YH22162 40/5/12.5 mg (telmisartan 40/amlodipine 5mg/chlorthalidone 12.5mg) for the first 2 weeks, then force titrated to YH22162(telmisartan 80mg/amlodipine 5mg/chlorthalidone 25mg) for the remaining 6weeks
2991413|NCT02620163|Active Comparator|telmisartan/amlodipine|Twynsta(telmisartan 40/amlodipine 5mg) for the first 2 weeks, then force titrated to Twynsta(telmisartan 80mg/amlodipine 5mg) for the remaining 6weeks
2991414|NCT02620150|Experimental|Experimental|CCBT plus Escitalopram, oral, for 10 weeks, once daily, starting at 10mg/day. Tapered up or down, based on tolerability and clinical response, to 20mg/day max.
2991415|NCT02620150|Placebo Comparator|Placebo|CCBT plus Placebo, oral, for 10 weeks, once daily, starting at 10mg/day. Tapered up or down, based on tolerability and clinical response, to 20mg/day max.
2991416|NCT02620137|Experimental|Multicentrum® 3 months|Patients maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 3 months
2991417|NCT02620137|Active Comparator|Multicentrum® 12 months|Patients maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 12 months
2991421|NCT02620124|Experimental|Hormone replacement cycle, intervention|Standard hormone replacement cycle with estrogen and progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days
2991422|NCT02620111|Experimental|Whey protein high leucine|Subjects are supplemented water in a fasted state for 180 minutes while the isotopic tracer 15Nphenylalanin is infused. Subjects are supplemented with whey protein high in leucine from 180 - 360 minutes while the isotopic tracer 15Nphenylalanin is infused.
2991423|NCT02620111|Active Comparator|Whey protein normal leucine|Subjects are supplemented water in a fasted state for 180 minutes while the isotopic tracer 15Nphenylalanin is infused. Subjects are supplemented with whey protein normal in leucine from 180 - 360 minutes while the isotopic tracer 15Nphenylalanin is infused.
2991424|NCT02620098|Experimental|Size Matters Handwriting Program|All participants were receiving educational support in the form of IEP and/or RtI tier 2 interventions, and were participating in a support classroom where those services where being delivered. The intervention group consisted of 23 kindergarten students comprising all students in two kindergarten support classrooms, one in each of two neighboring schools. All students in the group received the Size Matters Handwriting Program.
2991425|NCT02620098|No Intervention|Control|All participants were receiving educational support in the form of IEP and/or RtI tier 2 interventions, and were participating in a support classroom where those services where being delivered. The control group consisted of 12 kindergarteners comprising all students in a kindergarten support classroom at a third school. They received no additional interventions.
2991426|NCT02620085||Graves' disease|Patient had been diagnosed of Graves' disease and now under euthyroid status
2991427|NCT02620072|Experimental|oral insulin capsule (dose escalation using 2 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 67.5 mg rH-insulin crystals. Insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) contained in hard gelatine capsules given orally.
2991428|NCT02620072|Placebo Comparator|Placebo capsule|Daily administration of placebo capsules containing filling substance (microcrystalline cellulose).
2991429|NCT02620059|Experimental|Lifestyle Intervention|"Behavioral: Lifestyle Intervention These women will receive the Healthy Lifestyle Intervention. This intervention will have been delivered during 12 weeks, which will be Distance learning program (multimedia or internet). During the intervention (12 weeks) and follow up period, women will receive not only motivational messages through the Short Message System (SMS) but also a pedometer to record their steps.The intervention will focus on women increasing physical activity (walking) to 10'000 steps per day and receiving healthy eating guidelines.~This intervention curriculum will cover topics related to healthy eating, physical activity, and stress management during postpartum. General information about postpartum period will also be provided."
2991430|NCT02620059|No Intervention|Control|These women will receive general information via pamphlet about postpartum period and tips for stress management.
2991431|NCT02620046|Experimental|Group A: Vedolizumab SC 108 mg Q2W|"Participants from studies MLN0002SC-3027 and MLN0002SC-3031 who:~Completed the Maintenance Period (Week 52), or~Were not randomized into Maintenance Period and achieved response at Week 14 after having received a third vedolizumab IV infusion at Week 6 ."
2991432|NCT02620046|Experimental|Group B: Vedolizumab SC 108 mg QW|"Participants from studies MLN0002SC-3027 and MLN0002SC-3031 who withdrew early from the Maintenance Period due to treatment failure.~Participants from current study who experience treatment failure while on study."
2991433|NCT02620033|No Intervention|Standard Care|Those assigned to the standard care group will follow the routine pre- and post-operative care for patients whose undergoing radical prostatectomy.
2991434|NCT02620033|Active Comparator|Yoga therapy group|Those assigned to the yoga therapy group will be asked to participate in yoga session three times in a week for 6 weeks prior to the scheduled surgery and then re-initiated 3 weeks after the surgery for another 6 weeks. Each session will be approximately 60 - 75 minutes. These yoga session will be held at Nydia's Yoga Therapy Studio, located in San Antonio, TX, under the guidance of certified yoga instructor, Dr. Nydia Tijerina Darby, PT, DPT, MS, who's the owner of the studio and co-investigator of this study. The yoga exercise will be tailored to patient's comfort level.
2991435|NCT02620020|Experimental|Dosing regimen 1|Subcutaneous (SC) administration of Fasinumab and intravenous (IV) administration of placebo administered intravenously (IV) in accordance with dosing regimen 1
2991436|NCT02620020|Experimental|Dosing regimen 2|SC administration of Fasinumab and IV administration of placebo in accordance with dosing regimen 2
2991437|NCT02620020|Experimental|Dosing regimen 3|IV administration of Fasinumab and SC administration of placebo in accordance with dosing regimen 3
2991438|NCT02620020|Experimental|Dosing regimen 4|SC administration of placebo and IV administration of placebo in accordance with dosing regimen 4
2991439|NCT02620007|Experimental|Experimental arm|oral Ciprofloxacin 500 mg bid and oral Rifaximin 800 mg bid for 12 weeks
2991440|NCT02620007|Placebo Comparator|Control arm|a placebo of Ciprofloxacin bid and a placebo of Rifaximin bid for 12 weeks
2991441|NCT02619994|Active Comparator|Control Arm|"Regimen is the locally-used WHO-approved MDR-TB regimen in Korea based on 2014 Korean guideline of TB management.~Intensive phase regimen consists of four effective second-line anti-TB drugs (including injectables) and pyrazinamide.~Treatment duration: for at least 20 months"
2991442|NCT02619994|Experimental|Experimental Arm|"Regimen consists of only oral medication using delamanid, linezolid, levofloxacin, and pyrazinamide, for nine or twelve months depending on the time of sputum culture conversion to negative.~Delamanid (100 mg bid for the entire treatment period)~Linezolid (600mg/day for 2 months and 300mg/day afterwards until the end of treatment)~Levofloxacin (750 ~1000 mg/day)~Pyrazinamide (1000~ 2000 mg/day)"
2991443|NCT02619981|Active Comparator|Father present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , Father present
2991444|NCT02619981|Active Comparator|Mother Present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , Mother present
2991445|NCT02619981|Active Comparator|Both parents present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , both parents present
2991480|NCT02619747|Placebo Comparator|Matched placebo|Single dose of contents of two 10 ml sachets of matched placebo
2991446|NCT02619968|Experimental|Experimental group|"Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application.~Application of the tourniquet Will be held in conjunction with exercises for the experimental group.~Tennis ball: will initially be 3 sets, where one series with 10 grips, increasing 5 grips every week, 60 seconds rest every series.~Halter: are performed with load of 1 kg, 2 kg and 3 kg. Handgrip: they will be performed 3 sets of dynamic manual hold exercises in the intensity of 40% of MVC.~Home program: at home will be performed isometric exercises with tennis ball on the same frequency as in performing ambulatory without applying the tensiometer."
2991447|NCT02619968|Sham Comparator|Group control|Will be held the same isometric and isotonic concentric ambulatory and home with the same duration, frequency and intensity, except is not to apply the tourniquet.
2991448|NCT02619955||Rare iron overload with hepcidin deficiency|clinical, biological, and genetic analysis of rare iron overlaod phenotype (except C282Yhomozygisity), samples with DNA
2991449|NCT02619942|Active Comparator|D2 radical operation group|In D2 radical operation group(D2), the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes, which along the feeding vessels.
2991450|NCT02619942|Experimental|CME group|In complete mesocolic excision group (CME), in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodesmshould be entirely removed.
2991451|NCT02619916|Experimental|MBCT|Mindfulness-Based Cognitive Therapy
2991452|NCT02619916|Experimental|CBT|Cognitive Behavioral Therapy
2991453|NCT02619916|No Intervention|TAU|Treatment as usual
2991454|NCT02619903|No Intervention|COPD Control|Subjects with COPD that do not get the additional dental cleaning, only dental examination.
2991455|NCT02619903|Active Comparator|COPD Test|Subjects with COPD that do get the additional dental cleaning, as well as dental examination.
2991456|NCT02619903|No Intervention|Gastric ulcer Control|Subjects with gastric ulcer that do not get the additional dental cleaning, only dental examination.
2991457|NCT02619903|Active Comparator|Gastric ulcer Test|Subjects with gastric ulcer that do get the additional dental cleaning, as well as dental examination.
2991458|NCT02619890||Patients with glioma requiring treatment|Patients with glioma requiring treatment, who undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and perfusion (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent
2991459|NCT02619877|Experimental|ALLO-ASC-DFU|Allogeneic mesenchymal stem cells
2991460|NCT02619877|Active Comparator|Standard therapy|Standard therapy for patients with diabetic foot ulcer
2991461|NCT02619864|Experimental|AZD2014 plus temozolomide|Patients will receive single agent AZD2014 for 2 days immediately prior to surgery at a fixed dose of 125 mg bid po (i.e. on days -2, -1, and on morning of day 0 [day of surgery]). After recovery from surgery, patients will start the dose escalation (within 7-21 days after tumour resection).
2991462|NCT02619851|Experimental|ALLO-ASC-DFU|Allogeneic mesenchymal stem cells
2991463|NCT02619851|Active Comparator|Conventional Therapy|Typical therapy conducted for burn injury patients
2991464|NCT02619838||Aptus CCS 5.0 or/and 7.0 screws|Procedure/Surgery: Subtalar, Double or Triple Arthrodesis of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint of the foot with the Aptus CCS 5.0 or/and 7.0 screws
2991465|NCT02619825|Other|"Group 1 healthy volunteers"|Echography and Elastography To determine physiological standards across age classes of myocardial stiffness estimated by Elastography in ultrafast (estimated right ventricular stiffness [VD] and left ventricular [LV]). This will be done in groups of children without heart condition, age group (10 children per group, four age groups [0-1mois, 1 month-1 year 1 year-5 years, 5 years-15years]).
2991466|NCT02619825|Other|Group 2 Patients CMH primitive|Echography and Elastography To evaluate myocardial stiffness Elastography (RV and LV) on different groups of children (same age group) with Hypertrophic Cardiomyopathy (HCM) non obstructive primitive and examine correlations with the conventional parameters of systolic and diastolic function of both ventricles and with myocardial strain values.
2991467|NCT02619825|Other|Group 3 Patients primitive CMD:|Echography and Elastography To evaluate myocardial stiffness Elastography (RV and LV) on different groups of children (same age group) with Dilated Cardiomyopathy primitive and examine correlations with the conventional parameters of systolic and diastolic function of both ventricles and with myocardial strain values.
2991468|NCT02619812|Active Comparator|Group A: SBI + Placebo|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams + placebo twice per day
2991469|NCT02619812|Active Comparator|Group B: Colesevelam + Placebo|Colesevelam 1.875 g + Placebo twice per day
2991470|NCT02619812|Active Comparator|Group C: Colesevelam + SBI|Colesevelam 1.875 g + Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams twice per day
2991471|NCT02619812|Placebo Comparator|Group D: Double Placebo|Double placebo twice per day
2991472|NCT02619799|Active Comparator|GROUP A(MAGNESIUM GROUP)|MAGNESIUM GROUP received 50 mg(0.1 ml) of intrathecal magnesium sulphate diluted to 1 ml with 0.9% normal saline combined with 14-16 ml of epidural 0.75% ropivacaine as a part of combined spinal epidural technique at L2-L3/L3-L4 interspace.
2991473|NCT02619799|Active Comparator|GROUP B(MIDAZOLAM GROUP)|MIDAZOLAM GROUP received 1mg(0.2ml) of intrathecal midazolam diluted to 1ml with 0.9% normal saline combined with 14-16 ml of epidural 0.75% ropivacaine as a part of combined spinal epidural technique at L2-L3/L3-L4 interspace.
2991474|NCT02619786|Experimental|inhaled colistin|Inhaled colistin 75 mg mixed with normal saline up to 4 ml every 12 hours at least 5 days
2991475|NCT02619773|Experimental|Mupirocin dressing|"Mupirocin + island dressing applied to surgical incision until postoperative day 5.~Intervention: mupirocin ointment applied to extrication incision."
2991476|NCT02619773|No Intervention|Island dressing|Island dressing applied to surgical incision until postoperative day 2. This arm will not undergo any intervention.
2991477|NCT02619760|Active Comparator|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists , followed by 59-month clopidogrel monotherapy
2991478|NCT02619760|Active Comparator|12-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists with 11-month DAPT composed of aspirin and clopidogrel, followed by 48-month aspirin monotherapy
3012790|NCT02477332|Experimental|QGE031 Arm 3|
2991481|NCT02619734|No Intervention|Control|Conventional treatment established by the good clinical practice Patients received standard local care dressing method (compresses) to heal leg ulcers
2991482|NCT02619734|Experimental|Stem Cell Injection|Intramuscular implantation of Autologous bone marrow-derived mononuclear cells
2991483|NCT02619721|Experimental|Sacral Neuromodulation is on|Sacral Neuromodulation is on as soon as implantation
2991484|NCT02619721|Placebo Comparator|Sacral Neuromodulation is off|Sacral Neuromodulation is off after implantation
2991485|NCT02619708|No Intervention|Standard Preoperative Experience|The preoperative visit will be performed, as it would be normally. Patients will be given a description of the preoperative experience, they will be told what to expect, they will be given brochures detailing what will happen on the day of the surgery, and will be given the opportunity to ask questions. Patients will fill out questionnaires immediately preoperatively on the day of the procedure, on the day after the procedure, and 30-days after the operation (only for patients undergoing surgery for degenerative spine disease).
2991486|NCT02619708|Experimental|Immersive Preoperative Experience|The preoperative visit will be performed, as it would be normally, with the only addition of a 5-minute video for the patients randomized to the intervention group. Patients will be given a few minutes to watch the video, and will have the chance to ask questions. The video will include a simulated patient encounter (with actors not real patients) showcasing the preoperative experience of the patient, including getting checked in, meeting the nurses, surgeons, and the anesthesiologists. Patients will fill out questionnaires immediately preoperatively on the day of the procedure, on the day after the procedure, and 30-days after the operation (only for patients undergoing surgery for degenerative spine disease).
2991487|NCT02619695|Experimental|Ketoprofen|Interventional arm: ketoprofen gel 2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
2991488|NCT02619695|Placebo Comparator|Placebo|Placebo arm: placebo gel form of ketoprofen
2991489|NCT02619682|Experimental|Treatment (ixazomib citrate and lenalidomide)|Within 30-120 days after finishing autologous transplant, patients receive ixazomib citrate PO on days 1, 8 and 15. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-28. Treatment repeats for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients will continue to alternate between ixazomib citrate and lenalidomide every 2 courses for up to 24 months in the absence of disease progression or unacceptable toxicity.
2991490|NCT02619669|Experimental|TAK-228 followed by TAK-228 plus Letrozole|"Eligible subjects will have a research biopsy and baseline blood and urine studies done within two weeks prior to start of study treatment. Subjects will then be treated with TAK-228 for 10 days, and a repeat biopsy and pharmacokinetics will be done on day 11.~The subject will then be treated with the combination of TAK-228 and letrozole for an additional 110 days, before undergoing resection of the primary tumor. Subjects will be treated at the recommended Phase II dose of TAK-228 of 3 mg once daily, and a dose deescalation to 2 mg daily will be performed if dose-limiting toxicity is seen in 1/3 or more of the subjects at the first dose level. The maximum tolerated dose cohort will be expanded to include six to ten subjects."
2991491|NCT02619656|Experimental|Treatment|"Patients randomized to insufflation with CO2.~Intervention: CO2 Insufflation with CO2Efficient Endoscopic Insufflator on managed flow setting at 3.4 L/min"
2991492|NCT02619656|Active Comparator|Control|"Patients randomized to insufflation with ambient air.~Intervention: Ambient air insufflation with Evis Exera 111 CLV-190 on medium air flow setting 0.68 L/min"
2991493|NCT02619643|Experimental|Primed PAS 1A|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
2991494|NCT02619643|Experimental|Unprimed PAS 1B|A single session of active paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied.
2991495|NCT02619643|Sham Comparator|Sham PAS|A single session of sham paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied
2991496|NCT02619643|Experimental|Primed PAS 2A|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
2991497|NCT02619643|Experimental|Unprimed PAS 2B|A single session of active paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied.
2991498|NCT02619643|Experimental|Primed PAS 1C|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
2991499|NCT02619643|Experimental|Primed PAS 2C|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
2991500|NCT02619630|Experimental|High-Risk (HR) patients|Nelarabine during consolidation and maintenance
2991501|NCT02619617|Experimental|SOM230 0.9mg|cohort 2
2991502|NCT02619617|Experimental|SOM230 1.5 mg|cohort 1
2991503|NCT02619604|Other|Clinician education|
2991504|NCT02619591|Active Comparator|Ultrasound Imaging - Single View|Ultrasound performed on patient. A single view of each hemithorax with ultrasound was performed on patient
2991505|NCT02619591|Experimental|Ultrasound Imaging - Multiple Views|Ultrasound performed on patient. Multiple view of each hemithorax with ultrasound was performed on patient
2991506|NCT02619578|Other|TEAS Group|TEAS consisted of 30 min of stimulation (12-15 mA, 2/100 Hz) at the Hegu (L14) and Neiguan (PC6) before anesthesia. Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v. Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
2991507|NCT02619578|Other|Con Group|The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation. Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v. Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
2991508|NCT02619565|Other|Blood samples if evolution of the disease|blood samples at Day 0 and also if there is an evolution of the disease
2991574|NCT02619136|Experimental|Restrictive Transfusion Strategy|We will permit but not require red cell transfusions once a hemoglobin value falls below 80 g/L (required below 70 g/L) during the 30 days following randomization
2991509|NCT02619552||Anti-TNF (Remicade, Humira or Cimzia) for luminal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
2991510|NCT02619552||Anti-TNF (Remicade, Humira or Cimzia)for perianal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
2991511|NCT02619552||Steroid (Prednisone or budesonide) for luminal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
2991512|NCT02619539||Trauma patients|All patients having / suspected to have severe trauma injuries admitted to participating centers.
2991513|NCT02619526|Experimental|Nebivolol|Nebivolol 10mg, once a day
2991514|NCT02619526|Active Comparator|Carvedilol|Carvedilol 25mg, twice a day
2991515|NCT02619513|No Intervention|General anesthesia group(Group GA)|Group GA received general anesthesia only and intravenous analgesia pump.
2991516|NCT02619513|Experimental|TEB group(Group GE)|Group GE received continuous thoracic epidural block(TEB) combined with general anesthesia and postoperative continuous thoracic epidural analgesia, and only added ropivacaine in PVB as an postoperative adjuvant.
2991517|NCT02619513|Experimental|PVB without DEX group (Group GT)|Group GT received ultrasound-guided(Mindray M7 series) continuous thoracic paravertebral nerve block(PVB) combined with general anesthesia and continuous thoracic paravertebral nerve block patient-controlled analgesia, and only added ropivacaine in PVB as an postoperative adjuvant.
2991518|NCT02619513|Experimental|PVB with DEX group(Group GTD)|Group GTD received ultrasound-guided(Mindray M7 series) continuous thoracic paravertebral nerve block combined with general anesthesia and continuous thoracic paravertebral nerve block patient-controlled analgesia,but with dexmedetomidine 0.5μg/kg added to ropivacaine in PVB as an adjuvant.
2991519|NCT02619500|Experimental|Thrust Manipulation|Subjects in this arm will receive spinal thrust manipulation to both the cervical and thoracic spines.
2991520|NCT02619500|Active Comparator|Non-thrust Mobilizations|Subjects in this arm will receive spinal non-thrust mobilizations to both the cervical and thoracic spines
2991521|NCT02619487|Experimental|8-12 years old, parent receiving text|text message to parent only
2991522|NCT02619487|Active Comparator|13-18 years old, parent receiving text|text message to parent only
2991523|NCT02619487|Active Comparator|13-18 years, both receiving text|Text message to parent and adolescent
2991524|NCT02619487|No Intervention|No text|No text will be sent
2991525|NCT02619474|Experimental|Experimental|Patients who have been admitted to the 3F or 3M wards under the care of the clinical teaching unit (CTU) after the introduction of the new, labelled whiteboard.
2991526|NCT02619474|No Intervention|Control|Patients who have been admitted to the 3R surgical ward under the care of any of the nursing groups without the introduction of the new labelled whiteboard.
2991527|NCT02619461|Experimental|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes.
2991528|NCT02619461|No Intervention|Control|Resting
2991529|NCT02619448|Experimental|Chemotherapy with hypofractionated RT|Carboplatin AUC 2 + Paclitaxel 50 mg/m2 given weekly x 4 concurrently with radiation therapy (70 Gy in 20 fractions) over 4 weeks
2991530|NCT02619435|Experimental|regorafenib|
2991531|NCT02619422|Other|Intensivo|intensive cardiac rehabilitation program in less time
2991532|NCT02619422|No Intervention|Convencional|standard cardiac rehabilitation program
2991533|NCT02619409|Placebo Comparator|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
2991534|NCT02619409|Active Comparator|EPI25 group|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
2991535|NCT02619409|Active Comparator|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc.
2991536|NCT02619409|Active Comparator|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075 cc, and sterile saline 0.025%.
2991537|NCT02619409|Active Comparator|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc
2991538|NCT02619396|Active Comparator|"Group 20 W / LSI 4"|Patients elected to AF ablation and randomized to Combination 1 of RF power and LSI on LA posterior wall
2991539|NCT02619396|Active Comparator|"Group 40 W / LSI 4"|Patients elected to AF ablation and randomized to Combination 2 of RF power and LSI on LA posterior wall
2991540|NCT02619396|Active Comparator|"Group 20 W / LSI 5"|Patients elected to AF ablation and randomized to Combination 3 of RF power and LSI on LA posterior wall
2991541|NCT02619396|Active Comparator|"Group 40 W / LSI 5"|Patients elected to AF ablation and randomized to Combination 4 of RF power and LSI on LA posterior wall
2991542|NCT02619383|Experimental|HBOT|All patients were treated with 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
2991543|NCT02619370|Experimental|Intervention|Play 'My Gift of Grace,' a conversation card game for 4-6 players (the game consists of 20 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues); all game sessions will be audio recorded and transcribed.
2991544|NCT02619370|Active Comparator|Control|"Review and discuss a brochure on ACP called Advance Care Planning: Tips from the National Institute of Aging. Discussion will be prompted by the researcher asking participants to discuss the information they've just read with the group. However, there will not be a formal structure to this discussion."
2991545|NCT02619357|Experimental|Cohort 1|10 subjects diagnosed with COPD (GOLD stages 2 and 3). Subjects will wear multiple devices simultaneously (SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband and Garmin Vivofit 2 wristband) up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests.
2991546|NCT02619357|Experimental|Cohort 2|10 subjects diagnosed with asthma. Subjects will wear multiple devices simultaneously (SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband and Garmin Vivofit 2 wristband) up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests.
2991547|NCT02619331|Experimental|Atopic volunteers|Allergy tests will be performed in allergic patients with rhinoconjunctivitis and allergy test reading measured following two different methodologies. 1) test reading based on conventional wheal and flare measurement (wheal diameter in mm, CWFM), 2) test reading based on high speed laser doppler imaging (HS-LDI). Both type of tests reading will be compared.
2991548|NCT02619318|Experimental|The Balancing Everyday Life (BEL) intervention|The BEL was developed on the basis of previous research on lifestyle interventions made by our own group and other researchers [1, 2]. It is a group-based programme (5-8 participants) with 12 sessions, one session a week, and 2 booster sessions with two-week intervals. The themes for the group sessions are, e.g., activity balance, healthy living, work-related activities, and social activities. Each session contains a main group activity and a home assignment to be completed between sessions. The main group activity starts with analysing the present situation and proceeds with identifying desired goals and finding strategies for how to reach them. The home assignment is aimed at testing one of the proposed strategies. Self-analysis, setting goals, finding strategies and evaluating the outcome of tested strategies form a process for each session, but also for the BEL intervention as a whole.
2991549|NCT02619318|Active Comparator|Care as usual (standard occupational therapy)|Standard occupational therapy involves support to open-market employment and support in managing everyday life in general.
2991550|NCT02619305|Experimental|Immediate treatment|Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
2991551|NCT02619305|No Intervention|Delayed treatment|Participants will be social network ties of women receiving no intervention but who will be placed on a waitlist to receive the intervention after a 12-month delay.
2991552|NCT02619292|Experimental|Mindful Movement Program|"Mindfulness is moment-to-moment, present-centered, purposive non-judgmental awareness; Dance/movement therapy is a multidimensional approach that integrates body awareness, expression and acceptance to facilitate physical, emotional, cognitive, social and spiritual integration of individuals"
2991553|NCT02619279|Experimental|Immediate treatment|Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
2991554|NCT02619279|No Intervention|Delayed treatment|Participants' mothers will receive no intervention but will be placed on a waitlist to receive the intervention after a 12-month delay.
2991555|NCT02619266|Experimental|Acupuncture+Placebo|Acupuncture once daily for 7 days and Placebo tablet by mouth, twice a day for 7 days.
2991556|NCT02619266|Active Comparator|Megestrol Acetate+Sham acupuncture|Megestrol Acetate tablet 160mg by mouth, twice a day for 7 days and Sham Acupuncture once a day for 7 days .
2991557|NCT02619266|Placebo Comparator|Placebo+Sham acupuncture|Placebo tablet by mouth, twice a day for 7 days and Sham Acupuncture once a day for 7 days .
2991558|NCT02619253|Experimental|Dose Finding Cohort|Estimate the Recommended Phase 2 Dose (RP2D) in patients with advanced renal and urothelial cell carcinoma patients. Patients will be treated with oral vorinostat every day for 14 days, and with pembrolizumab at the fixed dose of 200 mg IV. Each cycle is every 21 days. Two dose levels of vorinostat will be tested in 2 patient cohorts according to the 3 + 3 standard design (100 and 200 mg).
2991559|NCT02619253|Experimental|Expansion Cohort|Once the Expansion Test Dose is identified, the Dose Expansion Phase will be opened and the combination will be tested in patients with advanced renal cell or urothelial cell carcinoma. Thirty patients with prior treatments will be enrolled in two expansion cohorts: 15 anti-PD1 naive patients and 15 anti-PD1 resistant patients (defined as patients with transient clinical response or without clinical response to prior immune-checkpoint inhibition).
2991560|NCT02619240||patients suspected of TB|patients suspected of TB requiring to undergo bronchoscopy as part of the investigation
2991561|NCT02619227|Experimental|Immediate treatment|Participants will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
2991562|NCT02619227|No Intervention|Delayed treatment|Participants will receive no intervention but will be placed on a waitlist to receive the intervention after a 12-month delay.
2991563|NCT02619214|Experimental|Oxygen 30%|Patient receives 1 hour of general anesthesia with a 30% oxygen concentration.
2991564|NCT02619214|Experimental|Oxygen 60%|Patient receives 1 hour of general anesthesia with a 60% oxygen concentration.
2991565|NCT02619201|Experimental|ondansetron|An intravenous dose of ondansetron ( 0.15mg /kg / doses ) Diluted in 20 ml of saline and administer intravenously in 5 minutes
2991566|NCT02619201|Active Comparator|metoclopramide|An intravenous dose of metoclopramide ( 0.15mg /kg / doses ) Diluted in 20 ml of saline and administer intravenously in 5 minutes
2991567|NCT02619188||Hyperemesis gravidarum|Hyperemesis gravidarum patients admitted to hospital PUQE-form inclusion (PUQE-score), Nutritional form inclusion, Blood sampling inclusion (Prealbumin analysis), Intervention at discharge : PUQE-form, Nutritional form and Blood sampling
2991568|NCT02619188||Control: Healthy pregnant women|Outpatients NOT subjected to severe nausea and emesis (PUQE-score <13). PUQE-form inclusion (PUQE-score), Nutritional form inclusion, Blood sampling inclusion (Prealbumin analysis).
2991569|NCT02619175|Experimental|BalanceTutor|"perturbation-based balance training while standing and walking on the BalanceTutor (MediTouch).~10-12 training sessions, 4-5 per week for 3 weeks. Each session will last 30 minutes."
2991570|NCT02619175|Active Comparator|Posturograph|"Balance and gait training without external perturbations. Voluntary weight shifting while standing on a computerized posturography (NeuroCom) and walking on a treadmill.~10-12 training sessions, 4-5 per week for 3 weeks. Each session will last 30 minutes."
2991571|NCT02619162|Experimental|Letrozole+Nintedanib|Letrozole+Nintedanib
2991572|NCT02619149|Active Comparator|Intervention|Piperacillin-tazobactam combination product
2991573|NCT02619149|Placebo Comparator|Control|Saline solution
2991648|NCT02618668|Active Comparator|Propofol|I.V propofol 2 mg/kg
2991575|NCT02619136|Active Comparator|Liberal Transfusion Strategy|We will transfuse at a transfusion threshold of 100 g/L for up to 30 days after randomization.
2991576|NCT02619123|Active Comparator|invitation to mammography screening|44-45 years old women in this arm are invited to attend for a mammography screening every 1 year. After the age of 50, all women will continue to be screened in the usual service screening programme.
2991577|NCT02619123|Experimental|invitation to tailored screening|44-45 years old women in this arm with a dense breast (3-4 categories in BI-RADS) at the baseline mammography are invited again after 1 year, while the lower-density group in the intervention arm are invited after 2 years. After the age of 50, all women will continue to be screened in the usual service screening programme.
2991578|NCT02619110|Other|backward walking treadmill training|The intervention group not only received four weeks of conventional physical therapy but also accepted additional four weeks of backward walking treadmill training at the same time
2991579|NCT02619110|Other|conventional physical therapy|The conventional physical therapy training focused on strengthening, postural control, functional mobility and forward gait training program but excluded backward walking training
2991580|NCT02619097|Experimental|0.08mg/kg|Pegol-sihematide injection, 0.08mg/kg, single-dose
2991581|NCT02619097|Experimental|0.2mg/kg|Pegol-sihematide injection, 0.2mg/kg, single-dose
2991582|NCT02619097|Experimental|0.33mg/kg|Pegol-sihematide injection, 0.33mg/kg, single-dose
2991583|NCT02619097|Experimental|0.5mg/kg|Pegol-sihematide injection, 0.5mg/kg, single-dose
2991584|NCT02619097|Experimental|0.7mg/kg|Pegol-sihematide injection, 0.7mg/kg, single-dose
2991585|NCT02619084|Experimental|STN DBS ON First|"The study will be performed according a randomized, double-blind, crossover design with two 3-month phases, during which the stimulation could be switched on or off, separated by a 1-month washout period, At the end of the second double-blind phase, a further open period of 6 months with stimulation switched on will follow."
2991586|NCT02619084|Experimental|STN DBS OFF First|"The study will be performed according a randomized, double-blind, crossover design with two 3-month phases, during which the stimulation could be switched on or off, separated by a 1-month washout period, At the end of the second double-blind phase, a further open period of 6 months with stimulation switched on will follow."
2991587|NCT02619071|Experimental|Refractory or relapsed acute myeloid leukemia|
2991588|NCT02619058|Experimental|Arm 1（NKT cells single low dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 1×10^9 on d1, 2×10^9 on d3, 4×10^9 on d29, 8×10^9 on d31.
2991589|NCT02619058|Experimental|Arm 2（NKT cells single high dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 5×10^9 on d1, 5×10^9 on d3, 5×10^9 on d29, 5×10^9 on d31.
2991590|NCT02619058|Experimental|Arm 3（NKT cells multiple dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 5×10^9 on d1, 5×10^9 on d3 of each 28 days-cycle, the dosing will be ended after 8 cycles.
2991591|NCT02619045|Other|Solid tumors|Patients with solid tumor starting a intra venous chemotherapy with 21 days cycles.
2991592|NCT02619032|Active Comparator|Remifentanil|Drug: Remifentanil (Ultiva). Intraoperative intravenous infusion of remifentanil 0.5-1 μg/kg/min for up to 1 h.
2991593|NCT02619032|Active Comparator|Fentanyl|Drug: Fentanyl (FNT). Intraoperative administration of fentanyl given as one single bolus dose of 50 μg at the time of induction of anesthesia.
2991594|NCT02619019|Active Comparator|Dexamethasone group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
2991595|NCT02619019|Active Comparator|Pethidine group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
2991596|NCT02619019|Placebo Comparator|Control group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
2991597|NCT02619006||Immediate Cord Clamping|Healthy term infants who were previously randomized or assigned at birth to the control group known as immediate cord clamping. The cord was clamped and cut within10 seconds after birth.
2991598|NCT02619006||Delayed Cord Clamping or Cord Milking|Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
2991599|NCT02618993|Placebo Comparator|Control group|Control group: Realization of the V3 block with a placebo in maxillofacial surgeries
2991600|NCT02618993|Experimental|Loco-regional anesthesia (LRA) group|Loco-regional anesthesia (LRA) group: Realization of the V3 block with Ropivacaine in maxillofacial surgeries
2991601|NCT02618980|Experimental|early endoscopy|endoscopic hemostasis
2991602|NCT02618980|No Intervention|without early endoscopy|Patients assigned to non-endoscopic treatment group receive high dose infusional PPI therapy. If UGI bleeding subsided after medical treatment alone, diagnostic EGD will be done under stable hemodynamic and 2 weeks after ACS to confirm UGI SRH. If the SRH is not located at UGI tract, the patients will be excluded. Troponin I or T and complete ECG will be checked every 8 hours within 24 hours of interventions. APACHE II score at intervention will be calculated for each patient.
2991603|NCT02618967|Placebo Comparator|Placebo Arm|7 dose levels of matching AMG 570 placebo administered as single dose subcutaneous in healthy volunteers.
2991604|NCT02618967|Active Comparator|AMG 570 Arm|7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.
2991605|NCT02618954|Other|Study patient|Articular ultrasound at each study follow-up
2991606|NCT02618941|Experimental|AFFITOPE® PD01A + Adjuvant|one injection of 75µg AFFITOPE® PD01A/adjuvanted
2991607|NCT02618941|No Intervention|Control|Untreated control group
2991608|NCT02618928||Hepatitis C Virus G1 or G4 Participants|Participants following all inclusion criteria
2991609|NCT02618915|Experimental|Dose 1|1.6 x 10^12 GC/kg DTX101(AAVrh10FIX)
2991610|NCT02618915|Experimental|Dose 2|3.0 x 10^12 GC/kg DTX101 (AAVrh10FIX)
2991611|NCT02618915|Experimental|Dose 3|5.0 x 10^12 GC/kg DTX101 (AAVrh10FIX)
2991612|NCT02618915|Experimental|Dose 4|1.0 x 10^13 GC/kg DTX101 (AAVrh10FIX)
2991649|NCT02618655||Fever，none definite diagnosis|Those who have fever，but the doctor can not make definite diagnoses with the diagnostic methods available.
3012791|NCT02477332|Experimental|QGE031 Arm 4|
2991613|NCT02618902|Experimental|tolerogenic dendritic cells (tolDC)|Each vaccine (5x106, 10x106 , or 15x106cells in 500 µL NaCl 0.9% solution supplemented with 5% human albumin) will be administered through intradermal injection at 5 sites (100 µL/site) in the subclavicular region (5-10 cm from the cervical lymph nodes). Injection sites will alternate between left and right sides.
2991614|NCT02618889|Active Comparator|CBT plus botox|Participants will be randomized to receive BoNT (onabotulinumtoxinA). Patients will undergo study assessments four weeks later. We will inject a total of 250 units of onabotulinumtoxinA, as the average optimal dose in cervical dystonia,11 using a 100:1 dilution with normal saline. The target muscles will be the ones deemed most active in the cervical region or in any of the affected limbs. If several limbs are affected, only up to two will be targeted in similar fashion, with a total dose not to exceed 400 units altogether (250 +150 units, if involvement is asymmetric or unilateral [leg and arm, respectively]; 200 + 200 units, if involvement is symmetric).
2991615|NCT02618889|Placebo Comparator|CBT plus placebo|Participants will be randomized to receive normal saline (placebo). We will inject a total of 250 units of normal saline, as this is the average optimal dose of onabotulinumtoxinA in cervical dystonia. The target muscles will be the ones deemed most active in the cervical region or in any of the affected limbs. If several limbs are affected, only up to two will be targeted in similar fashion, with a total dose not to exceed 400 units altogether (250 +150 units, if involvement is asymmetric or unilateral [leg and arm, respectively]; 200 + 200 units, if involvement is symmetric).
2991616|NCT02618876|Active Comparator|Nalbuphine group|30 children will be given Caudal Bupivacaine plus Nalbuphine.
2991617|NCT02618876|Other|Control group|30 children will be given Caudal Bupivacaine.
2991618|NCT02618863|Active Comparator|1 , cricoid pressure|30 male
2991619|NCT02618863|Active Comparator|2,cricoid pressure|30 female
2991620|NCT02618850|Other|Advanced CRC patients undergoing first-line chemotherapy|single cohort
2991621|NCT02618837|Active Comparator|Downstream strategy arm|downstream administration strategy of P2Y12 receptor blockers (prasugrel or ticagrelor)
2991622|NCT02618837|Active Comparator|Upstream strategy arm|upstream administration strategy (ticagrelor only)
2991623|NCT02618824|Active Comparator|HTK Solution|Hearts will be arrested with HTK solution during cardiac operation
2991624|NCT02618824|Active Comparator|HTK Solution + TWBC|Hearts will be arrested with HTK solution during cardiac operation and received terminal warm blood cardioplegia before aortic cross clamp removal.
2991625|NCT02618811||Group 1|not sarcopenic
2991626|NCT02618811||Group 2|sarcopenic
2991627|NCT02618811||Group 3|not myosteatotic
2991628|NCT02618811||Group 4|myosteatotic
2991629|NCT02618785|Experimental|Hyoscine|The experiment group receive Hyoscine 10 mg 2 tablets by mouth before hysterosalpingography procedure
2991630|NCT02618785|Placebo Comparator|Placebo|The control group receive placebo by mouth before hysterosalpingography procedure
2991631|NCT02618772|Placebo Comparator|Intranasal Saline|0.08ml/kg of saline to a maximum of 2ml intranasally with an atomizer MAD-300
2991632|NCT02618772|Active Comparator|Intranasal Midazolam|0.08ml/kg (0.4mg/kg of 5mg/ml IV solution) intranasal midazolam, to a maximum of 2ml (10mg), with an atomizer MAD-300
2991633|NCT02618759|Experimental|DSXS1505|To evaluate the therapeutic efficacy and safety of DSXS topical spray, 0.15%.
2991634|NCT02618759|Placebo Comparator|Placebo|Eligible patients will be randomized in a 1:1 ratio to Test or Placebo product.
2991635|NCT02618746|Experimental|Group A, Telerehabilitation|The 12-month home care/rehabilitative program will include the following components: a) individualized action plan; b) educational session on self management; c) physical exercise sessions to remote monitoring; d) access to the call centre; e) professional weekly calls by physiotherapists, dietician and physician with remote connection as a response to possible incidents; f) remote monitoring selectively and temporarily.
2991636|NCT02618746|Active Comparator|Group B, Hospital based Rehabilitation|Patients assigned to the hospital based program will visit the hospital twice weekly for 12 months in order to participate in a multidisciplinary rehabilitation program including exercise, physiotherapy dietary and psychological advice by the staff of the rehabilitation centre based at the University clinic.
2991637|NCT02618746|No Intervention|Group C, Usual care Group|The control group will follow the usual care not involving the initial 8-week rehabilitation program neither maintenance hospital rehabilitation sessions or home telemonitoring of vital signs.
2991638|NCT02618733|Experimental|Ticagrelor|Ticagrelor 90mg, twice a day
2991639|NCT02618733|Active Comparator|Clopidogrel|Clopidogrel 75mg, once a day
2991640|NCT02618720|Experimental|ornidazole|oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
2991641|NCT02618720|Placebo Comparator|placebo|oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
2991642|NCT02618707||Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
2991643|NCT02618694|Experimental|Group 1|patient had posterior retroperitoneoscopic adrenalectomy
2991644|NCT02618694|Active Comparator|Group 2|patient had Transperitoneal laparoscopic adrenalectomy
2991645|NCT02618681||AMI with earlobe crease|To observe the prognosis for AMI with earlobe crease
2991646|NCT02618681||AMI without earlobe crease|To observe the prognosis for AMI without earlobe crease
2991647|NCT02618668|Experimental|Ketamine / Propofol Admixture|Ketamine / Propofol Admixture: I.V propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+ 4 ml saline in a 20-ml syringe which resulted in 0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol.
2991650|NCT02618642|Active Comparator|Piler light + red filter|Radiation: Piler light phototherapy Piler light (polychromatic incoherent low-energy radiation) + red filter time of phototherapy treatment: 10 minutes for one session
2991651|NCT02618642|Active Comparator|Piler light + blue filter|Radiation: Piler light phototherapy Piler light (polychromatic incoherent low-energy radiation)+ blue filter time of phototherapy treatment: 10 minutes for one session
2991652|NCT02618642|Active Comparator|Piler light without a filter|Radiation: Piler light phototherapy Piler light (polychromatic incoherent low-energy radiation)without a filter time of phototherapy treatment: 10 minutes for one session
2991653|NCT02618629|Experimental|14C-Z-215|
2991654|NCT02618616|Experimental|ZPL-389|Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally OD for 12 weeks.
2991655|NCT02618616|Placebo Comparator|Placebo|Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.
2991656|NCT02618603|Experimental|BoNT-A treatment group|Ultrasound guided sub-acromial bursa injection with BoNT-A (100 u);
2991657|NCT02618603|Active Comparator|Triamcinolone acetonide treatment group|Ultrasound guided sub-acromial bursa injection with Triamcinolone acetonide (40mg)+1% Lidocaine 2 ml;
2991658|NCT02618577|Experimental|Edoxaban|"Edoxaban will be applied in NOAH at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:~Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein p inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole."
2991659|NCT02618577|Active Comparator|ASA or Placebo|Either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator
2991660|NCT02618564|Active Comparator|2 TABS QHS|Sennosides 2 tabs, taken two nights before the colonoscopy
2991661|NCT02618564|Active Comparator|3 TABS QHS|Sennosides 3 tabs, taken two nights before the colonoscopy
2991662|NCT02618564|Active Comparator|2 TABS AM|Sennosides 2 tabs, taken the morning before the colonoscopy
2991663|NCT02618564|Active Comparator|3 TABS AM|Sennosides 3 tabs, taken the morning before the colonoscopy
2991664|NCT02618564|Active Comparator|2 TABS AM & QHS|Sennosides 2 tabs taken the morning before and 2 tabs taken the evening before the colonoscopy.
2991665|NCT02618551|Experimental|Intervention|Patients will be treated by three bronchial thermoplasty sessions.
2991666|NCT02618525|Active Comparator|Supraorbital pressure|Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
2991667|NCT02618525|Active Comparator|Jaw thrust maneuver|Jaw thrust maneuver is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
2991668|NCT02618512|Experimental|SBC-103|Patients were administered 1 mg/kg by IV infusion once every other week (qow) for at least 12 weeks. After evaluation of 12-week safety, tolerability, and pharmacodynamic data in individual patients, the dose was increased to 3 mg/kg qow. Infusions were to be at least 10 days apart and were administered every 14 days ±5 days.
2991669|NCT02618499|Active Comparator|oxytocin inmediately at birth|Intervention: Timing of administration of postpartum Oxytocin. 10 international Units (IU) immediately at birth will be given intravenously (IV) to the mother.
2991670|NCT02618499|Experimental|oxytocin at 3 minutes|Intervention: Timing of administration of postpartum Oxytocin. 10 IU IV at 3 minutes immediately after the cord is clamped
2991671|NCT02618486|Experimental|Obese with CP|Procedure/Surgery Non surgical periodontal therapy Received OHE, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine rinse thrice a day
2991672|NCT02618486|Active Comparator|Non obese with CP|Procedure/Surgery Non surgical periodontal therapy Received OHE, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine rinse thrice a day
2991673|NCT02618473|No Intervention|seloken|"In seloken arm, patients performs the cardiac CT procedure regarding the national scan guidelines, ande receive 5-10 intravenous seloken, until heart rate below 60 beats pr minit is achieved."
2991674|NCT02618473|Experimental|non-seloken|"Patients randomized to non-seloken, do not receive any medication."
2991675|NCT02618460|Experimental|Whole Group|
2991676|NCT02618447|Experimental|Arm 1: 4D phase contrast MR scan|"Each patient will undergo a total of 3 MRI/MRA scans (lasting 30-60 minutes):~Scan 1: Baseline (pre-portal vein embolization (PRE))~Scan 2: Early after PVE (within 48 hours)~Scan 3: Late after PVE (at 3-8 weeks).~Scans 1 and 3: routine liver MR sequences with/without contrast (Gadoxetic acid, Eovist) and 4D phase contrast of the portal venous system. The 4D phase contrast sequence will be repeated twice at each time point, adding about 15-30 minutes to each scan.~Scan 2: 4D phase contrast sequences and imaging for localization."
2991677|NCT02618434|Experimental|Low dose SPN-810|Subjects will be treated with low dose of SPN-810
2991678|NCT02618434|Experimental|High dose SPN-810|Subjects will be treated with high dose of SPN-810
2991679|NCT02618434|Placebo Comparator|Placebo|Subjects will be treated with a Placebo
2991680|NCT02618408|Experimental|Low dose SPN-810|Subjects will be treated with low dose SPN-810
2991681|NCT02618408|Experimental|High dose SPN-810|Subjects will be treated with high dose SPN-810
2991682|NCT02618408|Placebo Comparator|Placebo|Subjects will be treated with a Placebo
2991683|NCT02618395|Experimental|Treatment A|
2991684|NCT02618395|Experimental|Treatment B|
2991685|NCT02618395|Experimental|Treatment C|
2991686|NCT02618382|Experimental|All subjects|Patients will undergo standard treatment of their chronic subdural hematoma with the addition of preoperative and postoperative oral tranexamic acid treatment. Patients will receive a dose of 1300mg orally three to four hours prior to surgery. They will then take 1300mg orally three times daily for three days or until discharge, whichever occurs first.
2991687|NCT02618369|Other|MR-HIFU treatment|"The interventional radiologist will locate the target lesion and mark the volume to be treated using MRI images.~The operator starts the treatment and monitors the progress of the treatment with MR thermal and dose maps to ensure adherence to treatment plan."
3012792|NCT02477332|Active Comparator|Omalizumab|
2991688|NCT02618356|Experimental|combined use Raltitrexed and S-1|"Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.~BSA(body surface area) S-1 dosage <1.25 m2 80 mg/d~1.25m2 — <1.5 m2 100 mg/d~1.5 m2 120 mg/d"
2991689|NCT02618343|Experimental|ISOPROPYL ALCOHOL AROMATHERAPY|Prehospital patients complaining of nausea randomized into the IPA Arm.
2991690|NCT02618343|Active Comparator|Ondansetron|Prehospital patients complaining of nausea randomized into the ondansetron arm.
2991691|NCT02618330|Experimental|retainer: 0.75-mm-thick film|
2991692|NCT02618330|Experimental|retainer: 1.00-mm-thick film|
2991693|NCT02618317|Active Comparator|Heparin Lock Solution|Patients on Heparin 1,000 U/ml locking solution, administered at the end of each dialysis session during a 15-week period .
2991694|NCT02618317|Experimental|Trissodium Citrate 30%|Patients on trissodium citrate 30% locking solution, administered at the end of each dialysis session during a 15-week period .
2991695|NCT02618317|Experimental|Minocycline-EDTA 30 mg/ml - 3 mg/ml|Patients on Minocycline 30 mg/ml/EDTA 3 mg/ml locking solution, administered at the end of each dialysis session during a 15-week period.
2991696|NCT02618304|Experimental|moderate to severe meibomian gland dysfunction|
2991697|NCT02618291|Experimental|Active Geriatric Evaluation (AGE tool)|The Active Geriatric Evaluation is a comprehensive assessment and management tool consisting of a 20-minute clinical screening instrument (Brief Assessment Tool, BAT) to identify 8 geriatric syndromes, and complementary diagnostic evaluations and propositions of management & treatment for each syndrome.
2991698|NCT02618291|Active Comparator|Usual care|"No specific intervention will be provided to the patients, except what family practitioners (FPs) usually do. In this regard, it is possible that some FPs might use structured interventions similar to the AGE tool. This will be neither encouraged nor discouraged. FPs in the usual care arm will be asked to perform one BAT after 2 years of follow-up, at the final patient visit."
2991699|NCT02618278|Experimental|Intervention|Patients randomised to the intervention arm will receive a individual, goal -orientated physiotherapy management package within 2 weeks G.P referral for physiotherapy.
2991700|NCT02618278|Active Comparator|Usual care|Patients randomised to usual care will receive the same individual, goal-orientated physiotherapy management as the intervention arm but at 6 weeks post G.P referral, as is usual care.
2991701|NCT02618265|Experimental|Mobile terminal|Stroke received mobile terminal management for secondary prevention administration, as the same time platelet reactivity modified drug selection was performed. Mobile application management conducts the control and regulation for anti hypertension, statin and antiplatelet therapy to increasing drug compliance.
2991702|NCT02618265|Active Comparator|traditional management|Stroke received traditional management for secondary prevention administration
2991703|NCT02618265|Active Comparator|website platform management|Stroke received website platform management for secondary prevention administration. Website platform management conducts the control and regulation for anti hypertension, statin and antiplatelet therapy to increasing drug compliance.
2991704|NCT02618252|Experimental|Zonare|108 patients are randomized to receive the intervention of using ultrasound machine (Zonare ZS3 machine) for IV cannulation. These patients will first undergo IV cannulation with assistance of the ultrasound machine.
2991705|NCT02618252|Experimental|Veinviewer|108 Patients are randomized to receive the Intervention of using the Veinviewer Flex machine for IV cannulation. These patients will first undergo IV cannulation with assistance of the Veinviewer Flex machine.
2991706|NCT02618239|Experimental|Healthy subjects|Bimuno Galacto-oligo-saccharide administration 2.7 g/d x 3 weeks
2991707|NCT02618226|Other|Optic nerve ultrasound|Optic nerve sheath diameter (ONSD) measurement will be performed in subjects with concomitant measurement of Intracranial Pressure (ICP) from an invasive ICP monitor. The operator measuring ONSD will be blinded to concomitant ICP.
2991708|NCT02618213|Active Comparator|Continous Positive Airway Pressure|CPAP is administered through a binasal tube fitted with a Benveniste gas jet administered with humified airflow. Start flow is 12-14 l/min and can be changed to maximum 15 or minimum 12 l/min. Oxygen can be supplied as needed to keep SpO2 (peripheral capillary Oxygen saturation) within acceptable limits.
2991709|NCT02618213|Active Comparator|High Flow Oxygenation Therapy|HFOT is administered by optiflow Junior ( Fisher&Paykal Healthcare® Auckland, New Zealand) Start flow 12-14 l/min. Oxygen can be supplied as needed to keep Sp02 within acceptable limits
2991710|NCT02618200|Experimental|3D prostate ultrasound|3D prostate ultrasound will be performed in patients the day before radical prostatectomy
2991711|NCT02618187|Experimental|Placebo Pre-Treat + Weekly Drug|Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
2991712|NCT02618187|Placebo Comparator|Placebo Pre-Treat + Daily placebo|Placebo pre-treatment, followed by once daily placebo for 8 weeks
2991713|NCT02618187|Experimental|Antibiotic Pre-Treat + Daily Drug|Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
2991714|NCT02618187|Experimental|Anitibiotic Pre-Treat + Weekly Drug|Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
2991715|NCT02618174|Placebo Comparator|Neutral Control Condition|Message about age of University of Birmingham
2991716|NCT02618174|Placebo Comparator|Food-based Control Condition|Message about variety of vegetables in the world
2991717|NCT02618174|Active Comparator|Health Condition|Message about the health benefits of eating vegetables
2991718|NCT02618174|Active Comparator|Descriptive Social Norm|Message suggesting most people eat plenty of vegetables
2991719|NCT02618174|Experimental|Liking Social Norm|Message suggesting most people like eating vegetables
2991720|NCT02618161|Experimental|Arm A|HDR Brachytherapy single dose of 15 Gy followed by EBRT of 46 Gy in 23 fractions and Androgen deprivation therapy 6 months to 3 years, (sequencing of HDR followed by EBRT)
2991721|NCT02618161|Active Comparator|ARM B|External Beam Radiotherapy (EBRT) of 46 Gy in 23 fractions, followed by single dose of HDR brachytherapy of 15 Gy boost and Androgen deprivation therapy 6 months to 3 years (timing of HDR Brachytherapy Treatment is changed compared to ARM A)
2991722|NCT02618148|Experimental|ESTROGEN HERBALS 21|"Used for women who wish to monthly menstruation~Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
2991723|NCT02618148|Experimental|ESTROGEN HERBALS 28|"Used for women who do not wish to monthly menstruation~Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
2991724|NCT02618135|Experimental|Intervention Group|10 child participants in the intervention group will take part in a total of 24 sessions spread over an 8-week period, and a final follow-up review 1 month after the completion of the training session. If sessions are missed during the 8-weeks period due to unforeseen circumstances (e.g. sickness, travel plans), arrangements will be made for participants to attend up to 5 BCI-based therapy sessions per week. All participants will have to complete a minimum of 20 sessions within the 8-weeks period for treatment efficacy.
2991725|NCT02618135|Other|Control Group|10 child participants in the control group will not receive BCI training during the first 8 weeks of their study participation; they will act as controls. At week 9, subjects in this group will go through the BCI training similar to the intervention group. If sessions are missed during the 8-weeks period due to unforeseen circumstances (e.g. sickness, travel plans), arrangements will be made for participants to attend up to 5 BCI-based therapy sessions per week. All participants will have to complete a minimum of 20 sessions within the 8-weeks period for treatment efficacy. They will take part in a total of 24 sessions spread over an 8-week period, followed by a final follow-up review 1 month after the completion of the training sessions.
2991726|NCT02618109|Other|Relapse Group|"Collection of blood samples will be done in newly diagnosed relapse of B-ALL children at the time of relapse diagnosis.~Children aged from 1 to 18 years at the time of first B-ALL relapse diagnosis."
2991727|NCT02618109|Other|Control Group|"Collection of blood samples will be done at the same stage of treatment as the relapse group has been collected.~Children aged from 1 to 18 years enrolled into FRALLE (protocol of treatment) or EORTC (European Organisation for Research and Treatment of Cancer) treatment protocols, treated for B-ALL and who are in complete molecular remission.~These control patients will be recruited at the same time from the beginning of B-ALL treatment as paired-relapsed control patients."
2991728|NCT02618096|Active Comparator|Oxytocin & Membrane sweeping|"Women assigned to Concurrent oxytocin with membrane sweeping had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, followed by oxytocin infusion the next day"
2991729|NCT02618096|Active Comparator|Oxytocin & Dinoprostone|"Women assigned to Concurrent oxytocin with dinoprostone vaginal insert: The 10mg dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening, followed by oxytocin infusion the next day"
2991730|NCT02618083|Experimental|retinal detachment|color Doppler ultrasound of the eye
2991731|NCT02618070|Experimental|Functional dyspepsia patient|Yogurt ingestion
2991732|NCT02618070|Experimental|Healthy|Yogurt ingestion
2991733|NCT02618057|Experimental|Steroid|Prednisolone, 1.0 mg/kg/day, PO, for 5 days Levofloxacin, 10mg/kg/day, IV, for 5days
2991734|NCT02618057|Active Comparator|Control|Levofloxacin, 10mg/kg/day, IV, for 5days
2991735|NCT02618044||Obese patients without preoperative GER|Obese patients selected for laparoscopic Roux-en-Y Gastric Bypass without preoperative GER at 24h-impedance pH monitoring (Group G-)
2991736|NCT02618044||Obese patients with preoperative GER|Obese patients selected for laparoscopic Roux-en-Y Gastric Bypass with preoperative GER at 24h-impedance pH monitoring (Group G+)
2991737|NCT02618031||Favorable CIS|Patients with a favorable CIS (fCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines.
2991738|NCT02618031||Poor CIS|Patients with a poor CIS (pCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines.
2991739|NCT02618018|Experimental|intraocular lens|AT TORBI 709M toric intraocular lens
2991740|NCT02618005|Experimental|LcS group|Consuming probiotic capsule
2991741|NCT02618005|No Intervention|Control group|
2991742|NCT02617992||EMR Surveillance|Patients who are referred for Endoscopic Mucosal Resection of Upper Gastrointestinal Lesions undertaking a surveillance visit will be included in this cohort.
2991743|NCT02617979|Experimental|Arm 1: SAFECARE at Home|"Patients randomized to the intervention arm will be assigned a username and password to access a SAFECARE at Home account via the internet. They will also be emailed a link to the site with their username and password.~The investigators have worked directly with SAFECARE at Home to create customized lessons for patients undergoing pancreatectomy. These lessons are comprehensive and encompass preoperative preparation as well as postoperative recovery and care. This includes videos, printed material, web-based material, and modules that focus on the pre-treatment, treatment, and follow-up care of patients undergoing surgery for pancreatic cancer.~All patients will receive standard pre- and post-operative instructions and care. This will include verbal education about the procedure by the surgeon as well as standard educational patient handouts, which are routinely provided preoperatively to pancreatectomy patients."
2991744|NCT02617979|No Intervention|Arm 2: Standard of Care|-All patients will receive standard pre- and post-operative instructions and care. This will include verbal education about the procedure by the surgeon as well as standard educational patient handouts, which are routinely provided preoperatively to pancreatectomy patients.
2991745|NCT02617953|Experimental|Active rTMS(A)|low frequency frontal and temporal repetitive transcranial magnetic stimulation
2991746|NCT02617953|Experimental|Active rTMS(B)|Temporal low frequency repetitive transcranial magnetic stimulation
2991747|NCT02617953|Sham Comparator|Sham condition(C)|low frequency frontal and temporal repetitive transcranial magnetic stimulation
2991748|NCT02617940|Experimental|fissure sealant|single placement of resin-based sealant on occlusal surface and oral hygiene orientation
2991749|NCT02617940|Placebo Comparator|oral hygiene orientation|single application of water on occlusal surface and oral hygiene orientation
2991750|NCT02617927||Vedolizumab Cohort|"Group 1a Mothers exposed to Vedolizumab at any time during pregnancy (and up to 3 months prior to last menstrual period [LMP], if this information is available).~Group 1b Infants born to Group 1a patients."
2991751|NCT02617927||Anti-TNF Agents Cohort|"Group 2a Patients with IBD who were exposed to anti-TNFs at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).~Group 2b Infants born to Group 2a patients."
2991752|NCT02617927||Conventional therapy only Cohort|"Patients with IBD who were exposed to conventional therapy only any time during pregnancy (and up to 3 months prior to LMP, if this information is available).~• Group 3b Infants born to Group 3a patients."
2991753|NCT02617901|Experimental|Recruited children|"Children aged below 16 years attending the Radiology Department for a left hand radiograph in order to assess bone age on the basis of clinical need. There will be one male and one female from each of five age groups (< 5 years; 5 to 7 years; 8 to 10 years; 11 to 13 years; 14 to 16 years).~Bone age will be assessed according to the Greulich & Pyle and TW3 methods by 3 observers on 2 separate occasions at least 4 weeks apart. Recruited children will have intervention in the form of a left hand DXA which will be anonymised and from which the same 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.~Radiographs and DXA will be read in random and varied order."
2991754|NCT02617888|Active Comparator|CCTA Breast Shields|Within female subset, randomization to wearing bismuth breast shield.
2991755|NCT02617888|No Intervention|CCTA No Breast Shields|Within female subset, randomization to wearing no bismuth breast shield (standard of care).
2991756|NCT02617888|No Intervention|Observational Arm|Non-females undergoing CTA and subjects undergoing cardiac catheterization and nuclear medicine testing.
2991757|NCT02617875|Active Comparator|Conventional EMS physician|The dispatching personnel will evaluate the emergency call severity and after exclusion of the life-threatening cases listed in a written procedure instruction, they will dispatch a conventional EMS physician, if this is the result of the randomization software.
2991758|NCT02617875|Other|Tele-EMS physician|The dispatching personnel will evaluate the emergency call severity and after exclusion of the life-threatening cases listed in a written procedure instruction, they will dispatch a tele-EMS physician, if this is the result of the randomization software.
2991759|NCT02617862|Experimental|PCI imaging system|
2991760|NCT02617849|Experimental|Pembrolizumab, Carboplatin, Paclitaxel|Carboplatin will be administered at AUC = 6, IV over 60 minutes every 3 weeks for up to 4 doses. Paclitaxel will be administered at 175mg/m2, IV over 3 hours every 3 weeks for up to 4 doses. Pembrolizumab will be administered at 200 mg, IV over 30 minutes every 3 weeks.
2991761|NCT02617823|No Intervention|semi-recumbent|rutine positioning at the hospital today
2991762|NCT02617823|Experimental|lateral position|experimental position to be evaluated against rutine
2991763|NCT02617810|Experimental|JNJ-42847922 Plus Midazolam Plus Warfarin|Participants will receive Treatment A (midazolam 4 milligram [mg] syrup once on Day 1 and warfarin 25 mg tablet once on Day 3) followed by Treatment B (JNJ-42847922 20 mg once daily from Day 1 to Day 9, midazolam 4 mg syrup once on Day 7 and warfarin 25 mg tablet once on Day 9). A washout period of 14 to 21 days will be maintained between each treatment period.
2991764|NCT02617797|Experimental|Radiofrequency|Experimental group: women with urinary incontinence are subjected to standard treatment cinesiotherapy perineal ( pelvic muscle exercises ) every day in home and one session per week in the clinic in beyond the RF application in the genital area once a week to total 5 sessions.
2991765|NCT02617797|Sham Comparator|Radiofrenquency Off|Control group: women with stress urinary incontinence will be submitted to the treatment of cinesioterapia standard perineal ( pelvic muscle exercises ) every day in home and one session per week in the clinic beyond the application of radiofrequency off in genital area once a week with the total of 5 sessions.
2991766|NCT02617784|Experimental|Regimen A: Oseltamivir with HD|Participants will receive 30 milligrams (mg) of oseltamivir via oral suspension approximately 1 hour after alternating HD sessions. Sessions will occur three times per week within the 6.5-week study period, and participants will receive a total of 9 doses of oseltamivir.
2991767|NCT02617784|Experimental|Regimen B: Oseltamivir with CAPD|Participants will receive 30 mg of oseltamivir via oral suspension once weekly after dialysis exchange. CAPD sessions will occur four times every 24 hours, and participants will receive a total of 6 doses of oseltamivir within the 6-week study period.
2991768|NCT02617771|Active Comparator|Vit D|Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year) from October to March
2991769|NCT02617771|No Intervention|Control|
2991770|NCT02617758|Experimental|Treatment AB|Participants will receive Treatment A (single application of DURAGESIC fentanyl transdermal system 100 microgram per hour (µg/h) dose) as Reference in Period 1; followed by Treatment B (single application of Fentanyl transdermal system [JNJ-35685-AAA-G021] 100 µg/h dose) as test in Period 2. A washout period of at least 8 days and no more than 14 days will be maintained between each treatment period.
2991771|NCT02617758|Experimental|Treatment BA|Participants will receive Treatment B [single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose] as test in Period 1; followed by Treatment A (single application of DURAGESIC fentanyl transdermal system 100 µg/h dose) as Reference in Period 2. A washout period of at least 8 days and no more than 14 days will be maintained between each treatment period.
2991772|NCT02617745|Experimental|Stupp protocol|Blood assessment of the platelet level every week during the radiotherapy phase and every cycle during the chemotherapy
2991773|NCT02617732|Experimental|Tianqi capsule|a Chinese patent medicine extracted form more than10 kinds of herbs, which was approved to treat type 2 diabetes by CDFA in 2002.
2991774|NCT02617732|Placebo Comparator|placebo|a capsule looks the same as Tianqi capsule, containing starch and other edible compositions.
2991775|NCT02617719||Primary care|Staff, patients aged 75 years and older and their carers associated with a single, participating United Kingdom primary care practice.
2991776|NCT02617706|Experimental|Transdermal Continuous Oxygen Therapy|EPIFLO® working study unit, all day, every day for 2 - 4 weeks + standard wound care
2991777|NCT02617706|No Intervention|Standard of care|standard wound care for 4 weeks
2991778|NCT02617693|Other|Standard of care|
2991779|NCT02617693|Experimental|Life style intervention|
2991780|NCT02617680|Experimental|desflurane - oxygen in air|The manufacturer recommended age-corrected end-tidal concentrations of desflurane in air should be set and achieved initially. Concentration of oxygen should be 50%.
2991781|NCT02617680|Experimental|desflurane - oxygen in nitric oxide|The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially.Concentration of oxygen should be 50%.
2991782|NCT02617667|Experimental|CyclASol Ophthalmic Solution 1|Cyclosporine A solution (dose-level 1) in vehicle
2991783|NCT02617667|Experimental|CyclASol Ophthalmic Solution 2|Cyclosporine A solution (dose-level 2) in vehicle
2991784|NCT02617667|Placebo Comparator|Placebo Ophthalmic Solution|Vehicle only
3012793|NCT02477332|Placebo Comparator|Placebo|
2991786|NCT02617654|Active Comparator|Liraglutide treatment|Liraglutide treatment in the dose of 1.8 mg daily for 52 weeks
2991787|NCT02617654|Placebo Comparator|Placebo treatment|Treatment with placebo once daily for 52 weeks
2991788|NCT02617641|Experimental|TAVIEenM@RCHE intervention|The experimental group will receive a web-based tailored nursing intervention. Between 3 and 4 sessions of 15 to 25 minutes each are completed within 4 weeks. A booster session is delivered at 8 weeks post randomization.
2991789|NCT02617641|Active Comparator|Publicly available websites|The control group will receive hyperlinks to four publicly available websites and one online booklet on the topic of walking.
2991790|NCT02617628|Active Comparator|Before Re-entry|Extended Release Naltrexone, 380 mg injection, 1x monthly for 4 months
2991791|NCT02617628|Active Comparator|After Re-entry|Extended Release Naltrexone, 380 mg injection, 1x monthly for 4 months
2991792|NCT02617615|Experimental|MB-110|oral hard-gel capsule formulation. One dose strength, 25 mg of MB-110, will be filled into the #00 hard-gel capsule.
2991793|NCT02617615|Placebo Comparator|Placebo|in the same #00 hard-gel capsules.
2991794|NCT02617602|Experimental|Goal directed therapy|Based on transpulmonary thermodilution, hemodynamic management will be implemented to achieve predefined goals
2991795|NCT02617602|Active Comparator|Control|Conventional therapy
2991796|NCT02617589|Experimental|Nivolumab + Radiotherapy Arm|Nivolumab IV infusion + Radiotherapy dose as specified
2991797|NCT02617589|Active Comparator|Temozolomide + Radiotherapy Arm|Temozolomide + Radiotherapy dose as specified
2991798|NCT02617576||Flavored contrast|This group of patients will have the choice to flavor their contrast.
2991799|NCT02617576||Unflavored contrast|This group of patients will drink the contrast without flavoring.
2991800|NCT02617563||Minimally invasive lumbar fusion|A single or double level instrumented fusion using minimally invasive PLIF, TLIF, MIDLF, DLIF, OLIF, ALIF procedures for the treatment of the degenerative lumbar spine.
2991801|NCT02617550|Experimental|Vericiguat + Nitroglycerin|Co-administration of vericiguat and nitroglycerin
2991802|NCT02617550|Placebo Comparator|Placebo + Nitroglycerin|Aministration of matching placebo and nitroglycerin.
2991803|NCT02617537|Experimental|BAY86-5300|Patients suffering from dysmenorrhea, treated with Yaz
2991804|NCT02617537|Placebo Comparator|Placebo|Patients suffering from dysmenorrhea,treated with placebo
2991805|NCT02617524|Experimental|Valve Medical Dedicated Sheath|Valve Medical Dedicated Sheath version 00
2991806|NCT02617511|Experimental|Omega-3 Supplementation|This groups will supplement their regular diet with 2.97 grams of combined omega-3 fatty acid (EPA/DHA) supplement in soft gel form on a daily basis for 12 weeks. This group will also complete a whole body progressive resistance training program 3 days per week for 12 weeks.
2991807|NCT02617511|Placebo Comparator|Placebo|This group will supplement their regular diet with 3.0 grams of a combined omega-3-6-9 supplement in soft gel form on a daily basis for 12 weeks. This group will also complete a whole body progressive resistance training program 3 days per week for 12 weeks.
2991808|NCT02617498|Active Comparator|harmonic scalpel|parenchymal liver transection was performed either by harmonic scalpel after demarcation of line of transection by intraoperative US and doppler. The clearly exposed vessels were ligated by 5/0 proline or clipped according to their size.
2991809|NCT02617498|Active Comparator|spray mode diathermy|parenchymal liver transection was performed either by spray mode diathermy after demarcation of line of transection by intraoperative US and doppler. The clearly exposed vessels were ligated by 5/0 proline or clipped according to their size.
2991810|NCT02617485|Experimental|MabionCD20®|"A course of MabionCD20® consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles.~Intervention: Drug: Rituximab"
2991811|NCT02617485|Active Comparator|MabThera®|"A course of MabThera® consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles.~Intervention: Drug: Rituximab"
2991812|NCT02617472|Experimental|Pelvic floor exercise|Pelvic floor exerciser, daily use
2991813|NCT02617459|Experimental|Levobetaxolol eye drops|Levobetaxolol eye drops 5ml/25mg per bottle
2991814|NCT02617459|Active Comparator|Betaxolol eye drops|Betaxolol eye drops 5ml/12.5mg per bottle
2991815|NCT02617446|Placebo Comparator|Placebo|i.v. infusion for 24 hours
2991816|NCT02617446|Active Comparator|treatment|The 2 doses of istaroxime (0.5 and 1.0 µg/kg/min) will be infused i. v. for 24 hours in comparison with placebo, in treatment of Chinese and Italian patients with Acute Decompensated Heart Failure.
2991817|NCT02617433|Experimental|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours.
2991818|NCT02617420||Intervention|All patients will be enrolled in one arm. These patients will have monitoring devices placed on their asthma controller and rescue medication, with data transmitted both to their smartphones and a dashboard accessed by their primary pediatric pulmonary provider.
2991819|NCT02617407|Experimental|Livionex®|Study patients assigned to this arm will use Livionex toothpaste for daily teeth brushing from day 1 to day 7. Study participants will be monitored up to 44 days after study enrollment.
2991820|NCT02617407|Active Comparator|PreviDent® 5000 plus|Study patients assigned to this arm will use PreviDent 5000 plus toothpaste for daily teeth brushing from day 1 to day 7. Study participants will be monitored up to 44 days after study enrollment.
2991821|NCT02617394|Active Comparator|Control group|
2991822|NCT02617394|Experimental|Study group|
2991823|NCT02617381|Experimental|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
2991824|NCT02617368||KC group|KC group included patients those were diagnosed and classified for moderate keratoconus according to the Amsler-Krumeich classification system
2991825|NCT02617368||Forme Fruste Keratoconus Group (FFKG)|Forme Fruste Keratoconus Group (FFKG) included patients diagnosed with FFK.
2991826|NCT02617368||Control Group (CG)|Control group(CG) was formed by refractive surgery candidates.
2991827|NCT02617355|Other|Prototype vs Covidien magnetic drape|New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax vs Covidien magnetic drape
2991852|NCT02617212|Active Comparator|Conventional treatment|Implant surgery. Three abutment dis-/reconnections.
3015443|NCT02459587|Experimental|CLF|Crisis Line Facilitation
2991828|NCT02617355|Other|Prototype vs 4 commercial drapes|"New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax vs 4 commercially available magnetic drapes:~Green Covidien Magnetic Drape Jac-Cell Medic Reusable Magnetic Pad DeRoyal Magnetic Pad size 10 x 16 DeRoyal Magnetic Pad size 20 x 16"
2991829|NCT02617342|Experimental|Robot-mediated Intervention|Families assigned to the robot condition will be asked to complete pre-test assessments and post testing as well as to participate in the robot intervention. The intervention will last for a 8-14 week period in which families will bring their child in 2-3 times a week on average for approximately 30 minutes until 24 treatment sessions have been completed. Children will receive one-on-one intervention with an interventionist facilitating the child's interactions with the robot.
2991830|NCT02617342|No Intervention|Treatment as Usual|Families assigned to the TAU condition will be asked to complete pre-test assessments and approximately 8-14 weeks later return to complete post-test assessments where the social emotions activity will be retested. During the 8-14 weeks between the testing assessments, families in the TAU condition will also receive a weekly email asking about their child's media use.
2991831|NCT02617329|Other|cervical flexion|Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
2991832|NCT02617329|Other|Extracorporeal shock wave therapy (ESWT)|The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group.
2991833|NCT02617316|Other|barefoot first|Ten runners carried on barefoot test first and then in-shoes.
2991834|NCT02617316|Other|in shoes first|Ten runners carried on in-shoes test first and then barefoot.
2991835|NCT02617303|Experimental|OTAGO'S program arm|Patients meeting the inclusion criteria will be randomly assigned to the experimental group. They will receive OTAGO'S exercise program during three months, followed by adherence phase. Falls and fractures will be quarterly followed during 15 months.
2991836|NCT02617303|Active Comparator|CONTROL GROUP|Patients meeting the inclusion criteria will be randomly assigned to the control group. Normal medical treatment will be provided by family physicians and nurses. Falls and fractures will be quarterly followed during 15 months.
2991837|NCT02617290|Experimental|Ticagrelor Arm|Ticagrelor is an oral antiplatelet agent which was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. It is available as round, yellow tablets (90 mg). The standard dose is 90 mg twice a day during the maintenance phase and 180 mg once for the loading dose. It is approved for duration of 12 month in ACS patients and will be used for duration of one month in the ALPHEUS Study.
2991838|NCT02617290|Active Comparator|Clopidogrel Arm|Clopidoprel is an oral antiplatelet agent which was approved for use in the European Union by the European Commission in 1997 and available as generic since 2007. The standard dose of clopidogrel is one 75 mg tablet once a day. The dosage for the loading dose is normally 300 mg but 600 mg is also used. Clopidogrel is the standard of care for PCI at the moment.
2991839|NCT02617277|Experimental|Dose Schedule A|In Schedule A, patients will receive MEDI4736 by intravenous on Day 1, and AZD1775 twice daily orally on Days 1-5 and Days 15-19 of a 28-day cycle. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the aZD1775 consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
2991840|NCT02617277|Experimental|Dose Schedule B|In Schedule B, patients will receive MEDI4736 by intravenous on Day 1, and AZD1775 twice daily orally on Days 15-17 and Days 22-24 of a 28-day cycle. In Schedule B there will be a 7-day AZD1775 lead-in to enable serial PK measurements prior to initiating MEDI4736 on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the aZD1775 consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
2991841|NCT02617277|Experimental|Dose Schedule C|In Schedule C, patients will receive MEDI4736 by intravenous on Day 1, and AZD1775 twice daily orally on Days 8-10, Days 15-17, and Days 22-24 of a 28-day cycle. In Schedule C there will be a 7-day AZD1775 lead-in to enable serial PK measurements prior to initiating MEDI4736 on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the aZD1775 consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
2991842|NCT02617277|Experimental|Dose Schedule D|In Schedule D, patients will receive MEDI4736 by intravenous on Day 1, and AZD1775 one time per day orally on Days 15-19, and Days 22-26 of a 28-day cycle. In Schedule D there will be a 9-day lead-in period with AZD1775 being dosed on Days -9 to -5 to enable serial PK measurements prior to initiating MEDI4736 on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the aZD1775 consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
2991843|NCT02617264|Experimental|Axillary lymph node FNA Biopsy|A carbon compound ink (SPOT) is injected to the axillary lymph node suspected to be infected with cancer
2991844|NCT02617251||neonatology patients|neonatology patients
2991845|NCT02617251||paediatric patients|paediatric patients
2991846|NCT02617238|Active Comparator|PWV group|"Cardiovascular risk management based on PWV will include altogether~the implementation of international guidelines,~the normalisation of blood pressure, and~the normalisation of arterial stiffness"
2991847|NCT02617238|No Intervention|Conventional group|These patients will be treated according to the 2007 (and then 2013) ESH-ESC Guidelines for the management of hypertension
2991848|NCT02617225||DHaAL Intervention|The group receives standard Ailment-free Life (DHaAL) DHaAL intervention
2991849|NCT02617225||DHaAL +CFSS Intervention|This group received the standard DHaAL intervention and additional support under another UNICEF program named Child Friendly School System (CFSS).
2991850|NCT02617225||Control|This group receive the standard / business-as-usual support from the Education Department, but does not receive DHaAL or CFSS Interventions.
2991851|NCT02617212|Experimental|Definitive abutment|Implant surgery. No abutment dis-/reconnections.
2991853|NCT02617199|Experimental|Epidural anesthesia|Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
2991854|NCT02617199|Active Comparator|intravenous analgesia|ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
2991855|NCT02617186|Active Comparator|Thoracoscopic Lobectomy|
2991856|NCT02617186|Active Comparator|Robotic Lobectomy|
2991857|NCT02617173|Experimental|Transcutaneous electrical nerve stimulation|Low current electrical stimulator
2991858|NCT02617160|Experimental|MD Logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
2991859|NCT02617160|Active Comparator|Control Group-Medical guided recommendations|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice
2991860|NCT02617134|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific chimeric antigen receptor targeting MUC1 antigen by infusion.
2991861|NCT02617121|Active Comparator|Gabapentin|oral gabapentin 300 mg 1 hours before induction of anesthesia
2991862|NCT02617121|Active Comparator|ramosetron|ramosetron 0.3 mg iv at end of surgery
2991863|NCT02617121|Active Comparator|Gabapentin and ramosetron|oral gabapentin 300 mg 1 hours before induction of anesthesia ramosetron 0.3 mg iv at end of surgery
2991864|NCT02617108|Experimental|Foley balloon|Foley balloon following TCRS: a Foley balloon with 4 ml of normal saline solution will be placed into the uterine cavity at the end of the operation for five days.
2991865|NCT02617108|No Intervention|control groups|control groups: women will not receive any therapy of the treatment (comparison group).
2991866|NCT02617095|Experimental|T2762|One drop of T2762 in each eye 3 to 6 times daily
2991867|NCT02617095|Active Comparator|Optive|One drop of Optive in each eye 3 to 6 times daily
2991868|NCT02617082||partial breast irradiation|
2991869|NCT02617069|Experimental|Group 1 (Cardiac surgery+botulinum toxin)|All patients underwent conventional cardiac surgery. After the main stage of the surgery botulinum toxin (50 U/1 mL) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right ganglionated plexi (GP); second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior pulmonary vein (PV) and left inferior PV (between the PVs and left atrial appendage (LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
2991870|NCT02617069|Active Comparator|Group 2 (Cardiac surgery+placebo)|All patients underwent conventional cardiac surgery. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
2991871|NCT02617056||Observational group|Subjects with dementia
2991872|NCT02617043|Experimental|HF-WBI|Hypofractionated whole breast irradiation for early breast cancer with prescription dose 40Gy in 15 fractions in 3 weeks. Tumor bed is simultaneously integrated boosted to 48Gy.
2991873|NCT02617017|Experimental|Buspirone|
2991874|NCT02617017|Placebo Comparator|Placebo|
2991875|NCT02616991|Experimental|Cohort|computed tomography venography
2991876|NCT02616965|Experimental|Treatment|Treatment consists of the combination of Romidepsin given 10mg/m2 or 14mg/m2 on days 1, 8 and 15 every 28 days and Brentuximab vedotin given 0.9mg/kg or 1.2mg/kg on days 1 and 15 every 28 days for 16 cycles.
2991877|NCT02616952|Experimental|Chinese herbal therapy group|Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks.
2991878|NCT02616952|Other|Pelvic floor muscle training group|Pelvic floor muscle training includes intensive exercises and home exercises. Intensive exercises are conducted in hospital once a week while home exercises are performed three times daily for 12 weeks.
2991879|NCT02616939||Patients with suspected cardiac disease|"Patients eligible for cardiac CT will be included with a focus on symptomatic patients with low-intermediate risk for obstructive coronary artery disease.~Patients will undergo Cardiac CT scanning (with the SpotLight CT)."
2991880|NCT02616926|Experimental|Hepatic resection|"Hepatic resection is performed as a primary treatment for hepatocellular carcinoma.~Intervention: Hepatic resection"
2991881|NCT02616926|Active Comparator|TACE + RFA|"TACE is performed as a primary treatment for hepatocellular carcinoma. RFA will be performed two weeks later if necessary.~Intervention: TACE; RFA"
2991882|NCT02616913|Experimental|R,R-monatin|150 mg single dose
2991883|NCT02616913|Active Comparator|Moxifloxacin|400 mg tablet single dose
2991884|NCT02616913|Placebo Comparator|Placebo|placebo single dose
2991885|NCT02616900|Experimental|eSight Eyewear|Main arm
2991886|NCT02616887||Vertebral metastases|Selected patients with spine metastases are treated with ablative single dose SBRT and VMAT technique in various solid tumors .
2991887|NCT02616874|Experimental|MVA.HIVconsv plus romidepsin|MVA.HIVconsv plus romidepsin
2991888|NCT02616861|Experimental|IW-1973|1973 Escalating Doses
2991889|NCT02616861|Placebo Comparator|Placebo|Matching Placebo
2991890|NCT02616848|Experimental|Everolimus, Eribulin|
2991891|NCT02616835|Experimental|theta-burst TMS|Theta-Burst protocol for transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
2991892|NCT02616835|Sham Comparator|sham theta-burst TMS|Sham protocol for theta-burst transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
2991893|NCT02616822|Experimental|trans-resveratrol|Used for trans-resveratrol substance 300 mg single dose
2991894|NCT02616822|Placebo Comparator|Placebo|Used for placebo substance single dose
2991895|NCT02616809|Experimental|Sitting|Participants will sit continuously for 8 hours in a simulated office environment
2991896|NCT02616809|Experimental|slow cycling|Participants will cycle at regular hourly intervals during an 8-hr simulated office environment
2991897|NCT02616809|Experimental|standing|Participants will change posture (from sitting to standing) during hourly intervals for an 8-hr period in a simulated office environment
2991898|NCT02616809|Experimental|slow walking|Participants will transition from sitting to slow walking on a treadmill desk at regular hourly intervals during an 8-hr period in a simulated office environment
2991899|NCT02616796|Experimental|Social gaze training|Appropriate social gaze behavior will be reinforced using the principles of Applied Behavior Analysis.
2991900|NCT02616796|No Intervention|No Training|Appropriate social gaze behavior will not be reinforced.
2991901|NCT02616783|Experimental|E/C/F/TAF|Participants will switch from tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or 3TC plus a third agent to E/C/F/TAF and will receive treatment for 48 weeks.
2991902|NCT02616783|Active Comparator|Remain current regimen|Participants will remain on current TDF and FTC (or FTC/TDF) or 3TC plus continuing third agent.
2991903|NCT02616770|Experimental|S1226 (4%)|S1226 (4%) dosed as single dose for 2 minutes
2991904|NCT02616770|Placebo Comparator|Saline (for 4%)|3 mL saline and medical air as single dose for 2 minutes
2991905|NCT02616770|Experimental|S1226 (8%)|S1226 (8%) dosed as single dose for 2 minutes
2991906|NCT02616770|Placebo Comparator|Saline (for 8 %)|3 mL saline and medical air as single dose for 2 minutes
2991907|NCT02616770|Experimental|S1226 (12%)|S1226 (12%) dosed as single dose for 2 minutes
2991908|NCT02616770|Placebo Comparator|Saline (for 12%)|3 mL saline and medical air as single dose
2991909|NCT02616757|Active Comparator|Simple Bone Cyst Patients|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline and once annually for 2 years.~There will also be optional blood samples taken o measure bone alkaline phosphatase."
2991910|NCT02616757|Active Comparator|Fracture patients|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline, after 3 months and at future follow-up visits as clinically indicated or at a one year follow-up visit.~There will also be optional blood samples taken to measure bone alkaline phosphatase."
2991911|NCT02616757|Placebo Comparator|Health volunteers|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline, after 3 months and at a one year follow-up visit.~There will also be optional blood samples taken to measure bone alkaline phosphatase."
2991912|NCT02616744|Experimental|Arm A: Ibandronic acid|Ibandronic acid 150 mg per os per month for two years
2991913|NCT02616744|Placebo Comparator|Arm B: Placebo|Placebo per os per month for two years
2991914|NCT02616731|Active Comparator|Tranexamic acid|
2991915|NCT02616731|Active Comparator|Diosmin|
2991916|NCT02616718|Experimental|Ventral incisional hernia|Repeated computed tomography scan of abdomen
2991917|NCT02616705||IgG4-related sclerosing cholangitis|Patients with IgG4-related sclerosing cholangitis (also called IgG4 associated cholangitis, IgG4 related cholangitis, or biliary IgG4-related disease)
2991918|NCT02616705||Controls|cholangiocarcinoma, PSC, and other patients with biliary strictures
2991919|NCT02616692||HCC patients / Cohort 1|Patient preferences associated with oral anti-cancer therapy (Sorafenib), repeated TACE, and HAIC and their perceptions regarding the respective treatment characteristics
2991920|NCT02616679||Cognitively Normal|Participants will be deemed cognitively normal based on criteria set forth by the National Alzheimer's Disease Coordinating Center/Alzheimer's Disease Centers (ADCC/ADC).
2991921|NCT02616679||Amnestic Mild Cognitive Impairment (aMCI)|Participants will be deemed aMCI based on criteria set forth by the National Alzheimer's Disease Coordinating Center/Alzheimer's Disease Centers (ADCC/ADC).
2991922|NCT02616666|Experimental|Dapagliflozin 10 mg|Patients will be randomized to receive either dapagliflozin or SOC. As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs). Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
2991923|NCT02616666|Active Comparator|Standard of Care (SOC)|Patients will be randomized to receive either dapagliflozin or SOC. As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs). Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
2991924|NCT02616653|Active Comparator|Sitting followed by lateral position|First half of participants will be assigned to have their L3-L4 intervertebral space located first in the sitting position followed by the lateral position using the palpation method confirmed by US. (L3-L4 location: Palpation method confirmed by US)
2991925|NCT02616653|Active Comparator|Lateral followed by sitting position|Second half of participants will be assigned to have their L3-L4 intervertebral space located first in the lateral position followed by the sitting position using the palpation method confirmed by US. (L3-L4 location: Palpation method confirmed by US)
2991926|NCT02616640|Experimental|Durvalumab monotherapy|Intravenous (IV) durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle
2991927|NCT02616640|Experimental|Durvalumab + pomalidomide (POM)|IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle and Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle
2991928|NCT02616640|Experimental|Durvalumab + pomalidomide (POM) + dexamethasone (dex)|IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle with Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle and Oral dex 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle
2991929|NCT02616627||chronic dialysis|Patient enrolled at the National Taiwan University Hospital Jinshan branch
2991930|NCT02616614|Active Comparator|Onexton gel|Clindamycin 1.2% and benzoyl peroxide 3.75% topical gel Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
2991931|NCT02616614|Experimental|Clindamycin/benzoyl peroxide gel|Generic clindamycin 1.2% and benzoyl peroxide 3.75% topical gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
2991932|NCT02616614|Placebo Comparator|Placebo|A vehicle gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
2991933|NCT02616601|Active Comparator|Carac Cream|Carac (fluorouracil) 0.5% topical cream applied to the designated treatment area (full face or balding scalp) identified by the investigator once daily for two weeks
2991934|NCT02616601|Experimental|Generic Fluorouracil Cream|Generic fluorouracil 0.5% topical cream applied to the designated treatment area (full face or balding scalp) identified by the investigator once daily for two weeks
2991935|NCT02616601|Placebo Comparator|Placebo|Vehicle cream applied to the designated treatment area (full face or balding scalp) identified by the investigator once daily for two weeks
2991936|NCT02616588|Experimental|Intervention Arm|All participants are enrolled into the intervention arm and receive the Veteran Patient Navigator and Social Work Intervention.
2991937|NCT02616575||Silver link|Patients enrolled in NTUH hospital and its Behui branch
2991938|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.04 mg/kg/week)|
2991939|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.08 mg/kg/week)|
2991940|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.16 mg/kg/week)|
2991941|NCT02616562|Active Comparator|Open labelled daily Norditropin® (0.034 mg/kg/day)|
2991942|NCT02616549|Experimental|Sudarshan Kriya Yoga|
2991943|NCT02616549|No Intervention|Waitlist Control|
2991944|NCT02616536|Active Comparator|Flipped classroom|The flipped classroom is new pedagogical method, which employs asynchronous video lectures and practice problems as homework and active, group-based problem solving activities in the classroom.
2991945|NCT02616536|Active Comparator|traditional classroom|The classroom lecture is a special form of communication in which voive, gesture. Movements, facial expression and eye contact can either complement or detract from the content. No matter what your topic, your delivery and manner of speaking immeasurably influence your student's' attentiveness and learning.
2991946|NCT02616523|Active Comparator|dexmedetomidine|The investigators will compare fentanyl consumption in participants undergoing laparoscopic intestine resection intra and postoperatively. Dexmedetomidine group will receive dexmedetomidine infusion 0,5 mcg/kg/h beside boluses of fentanyl.
2991947|NCT02616523|Active Comparator|lidocaine|Lidocaine group will receive lidocaine infusion 1,5 mg/kg/h during the laparoscopic intestine resection.
2991948|NCT02616523|Placebo Comparator|placebo|The placebo group will receive intravenous infusion of normal saline only.
2991949|NCT02616510||PCOS|Rotterdam criteria (at least 2 out of three criteria present) oligo-anovulation polycystic ovarian morphology hyperandrogenism
2991950|NCT02616510||POI|amenorrhea of at least 4 months prior to age 40 years, with follicle stimulating hormone (FSH) levels above 40 IU/L
2991951|NCT02616497|Active Comparator|Aspirin|100mg/day
2991952|NCT02616497|Active Comparator|Triflusal|300mg twice or 600mg once daily
2991953|NCT02616484|Active Comparator|Dichloroacetate, then Placebo|"This group will start on the Dichloroacetate (DCA) treatment which will last for 4 months. After 4 months a 1 month washout period will occur. After the 1 month the group will crossover to the placebo treatment for 4 months.~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens"
2991954|NCT02616484|Placebo Comparator|Placebo, then Dichloroacetate|"This group will start on the placebo treatment which will last for 4 months. After 4 months a 1 month washout period will occur. After the 1 month the group will crossover to the Dichloroacetate (DCA) treatment for 4 months.~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens"
2991955|NCT02616471|Experimental|High-fat cheese (HFC) group|"The subjects in the HFC group will be supplied with equal amounts of two types of regular/high fat cheeses. The cheeses are normal-fat Danbo (Riberhus, 25% fat, Arla, DK) and normal-fat Cheddar (Sharp Cheddar, 32% fat, Cabot, US).~No further dairy and cheese consumption is allowed"
2991956|NCT02616471|Experimental|Low-fat cheese (LFC) group|The subjects in the LFC group will be supplied with equal amounts of two types of reduced/low fat cheeses. The cheeses are reduced-fat Danbo(Cheasy, 13% fat, Arla, DK) and reduced-fat Cheddar (Sharp Light Cheddar, 16% fat, Cabot, US). No further dairy/cheese consumption is allowed.
2991957|NCT02616471|Active Comparator|No-cheese/carbohydrate group (CTR)|For subjects in the CTR group, cheese is replaced by simple and starchy carbohydrates in jam and white bread, which will be supplied by the department. The daily energy and sodium contents will be matched to those of the cheese in the HFC group. No dairy/cheese consumption is allowed.
2991958|NCT02616458|Experimental|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours. The research assistant provided and reviewed proper dosing instructions for acetaminophen and ibuprofen, and provided a prescription for antipyrine/benzocaine analgesic ear drops to each family to use as pain relief if their child did develop ear pain in the subsequent 12 months.
2991959|NCT02616458|Active Comparator|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
2991960|NCT02616445|Placebo Comparator|MAD Study|
2991961|NCT02616445|Placebo Comparator|Fed-Fasted|
2991962|NCT02616445|Experimental|CSF|
2992374|NCT02613689|Active Comparator|Control Group|Subjects will receive SMS support text messages
2991963|NCT02616432|Experimental|Tomosynthesis + FFDM|Women enrolled to DBT Arm will undergo manufacturer-defined DBT
2991964|NCT02616432|No Intervention|FFDM - Standard of Care for Screening|Women enrolled to the FFDM Arm will undergo bilateral digital mammogram with standard CC and MLO views acquired
2991965|NCT02616419|Experimental|Buzzy® device|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
2991966|NCT02616419|Active Comparator|Maxilene® (Lidocaine liposomal 4%)|Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
2991967|NCT02616406||Open repair|Repair group to be monitored with wearable activity monitors pre and post op.
2991968|NCT02616406||Laparoscopic group|Laparoscopic surgical repair group to be monitored with wearable activity monitors pre and post op.
2991969|NCT02616393|Experimental|Cohort A - Brain Metastases|Tesevatinib will be orally administered with a dose of 300 mg once daily to subjects with NSCLC who have progressed with BM
2991970|NCT02616393|Experimental|Cohort B - Leptomeningeal Metastases|Tesevatinib will be orally administered with a dose of 300 mg once daily to subjects with NSCLC who have progressed with LM
2991971|NCT02616393|Experimental|Cohort C - Brain Metastases at initial presentation|Tesevatinib will be orally administered with a dose of 300 mg once daily to subjects with NSCLC with BM at initial presentation
2991972|NCT02616380||Subjects with RA receiving Adalimumab|This group contains subjects in Taiwan with RA receiving adalimumab
2991973|NCT02616367|Experimental|liposomal bupivacaine Periarticular injection|Will consist of 100 mL (one syringe with 50 mL total: 40 mL 0.25% bupivacaine, 300 mcg epinephrine, 1 mL ketorolac, 2.5 mL morphine, 6.5 mL normal saline) (one syringe with 50 mL total: 20 mL liposomal bupivacaine 30 mL normal saline).
2991974|NCT02616367|Active Comparator|Ropivacaine Periarticular Injection|Will consist of 100 mL (1 mL ketorolac, 2.5 mL morphine, 28.95 mL normal saline, 300 mcg of epinephrine, and 200 mg ropivacaine
2991975|NCT02616354|Active Comparator|Group I|"Group I received intravenous imipenem/cilastatin 1 g every 8 h (q8h) or 0.5g every 6 h (q6h) with optimized two-step infusion therapy (OTIT; rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours) Group I is more informative than Group II from PK parameters(%T>MIC,AUC/MIC)."
2991976|NCT02616354|Placebo Comparator|Group II|"group II received intravenous imipenem/cilastatin 1g q8h or 0.5g q6h with extended infusion therapy (2-hours continuous infusion in a constant speed).~Group I is more informative than Group II from PK parameters(%T>MIC,AUC/MIC)."
2991977|NCT02616341|Experimental|Team ERP (T-ERP) Intervention|The ERP team intervention (T-ERP) consists of 25 sessions over 20 weeks with four components: (a) 3-4 pretherapy individual session with therapist, (b) 12 weekly group sessions (90-mins) led by a therapist and, (c) 10 individual coaching sessions with a case manager during weeks 2-11 of the group, and (d) 2 booster group sessions to reinforce relapse prevention
2991978|NCT02616341|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU) includes standard community treatment consisting of a personalized treatment plan and assistance with treatment referrals to available community resources
2991979|NCT02616328||Participants with confirmed rheumatoid arthritis|
2991980|NCT02616315|Placebo Comparator|Group A: Placebo|Naltrexone hydrochloride (HCl)/bupropion hydrochloride (HCl) placebo-matching tablet, orally, 1 tablet in the AM, daily, during Week 1, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 1 tablet in the AM and 1 in the PM, during Week 2, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 2 tablets in the AM and 1 in the PM, during Week 3, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 2 tablets in the AM and 2 in the PM, in Week 4 through Week 49. Participants must be re-titrated if off treatment for ≥1 week (≥7 days).
2991981|NCT02616315|Experimental|Group B: Naltrexone HCl/Bupropion HCl|Naltrexone HCl 8 mg/bupropion HCl 90 mg, tablet, orally, 1 tablet in the AM, daily, during Week 1, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 1 tablet in the AM and 1 in the PM, during Week 2, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 2 tablets in the AM and 1 in the PM, during Week 3, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 2 tablets in the AM and 2 in the PM, in Week 4 through Week 49. Participants must be re-titrated if off treatment for ≥1 week (≥7 days).
2991982|NCT02616302|Experimental|≤30 kg: Dexlansoprazole 15 mg|Dexlansoprazole 15 mg, capsules, once, daily, for 12 weeks. Participants weigh ≤30 kg.
2991983|NCT02616302|Experimental|≤30 kg: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, once, daily, for 12 weeks. Participants weigh ≤30 kg.
2991984|NCT02616302|Experimental|>30 kg: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, once, daily, for 12 weeks. Participants weigh >30 kg.
2991985|NCT02616302|Experimental|>30 kg: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, once, daily, for 12 weeks. Participants weigh >30 kg.
2991986|NCT02616289|Experimental|Emollient|Topical emollient (Sun Flower seed oil) in addition to routine standard of care for severe acute malnutrition.
2991987|NCT02616289|No Intervention|Control|Routine Standard of care only for severe acute malnutrition.
2991988|NCT02616276|Active Comparator|Control|Control breakfast
2991989|NCT02616276|Experimental|Intervention 1|High glycemic index breakfast
2991990|NCT02616276|Experimental|Intervention 2|Low glycemic index breakfast
2991991|NCT02616263|Experimental|Foot Intervention|The intervention is a progressive, home based exercise program aimed to increase ankle and foot plantarflexion muscle strength, increase ankle dorsiflexion and toe flexion range of motion, and to retrain individuals to dorsiflex the ankle while keeping the toes in a neutral position. A trained physical therapist with experience working with older adults with diabetes and foot specific complications will monitor and progress the exercise program assuring participant safety and maximizing exercise benefit.
2991992|NCT02616263|Active Comparator|Shoulder Intervention|Participants will be trained in a progressive home exercise program that includes passive stretching of end range shoulder flexion and external rotation and a tailored dose of active shoulder motion.
2992028|NCT02616042|Experimental|Centella asiatica|Participants received a dentifrice which contains Centella asiatica, dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime).
2991993|NCT02616250|Experimental|Brimonidine 0.33% gel / CD07805/47 (Br) + Ivermectin 1% cream|"Half group will receive once-daily Br 0.33% gel in the morning and once-daily IVM 1% cream in the evening for 12 weeks.~Half group will receive once-daily Br vehicle gel in the morning for the first 4 weeks and once-daily Br 0.33% gel in the morning for the following 8 weeks and once-daily IVM 1% cream in the evening for 12 weeks."
2991994|NCT02616250|Placebo Comparator|CD07805/47 (Br) placebo gel + CD5024 (IVM) placebo cream|Subjects will receive once-daily Br vehicle gel in the morning and once-daily IVM vehicle cream in the evening for 12 weeks.
2991995|NCT02616237|Experimental|Intervention Group|"Lifestyle Intervention: The interventions include participation in a private research group on Facebook for health education, self monitoring and social support. Participants will receive 12 weekly lessons related to nutrition, physical activity, Chinese food therapy, acupressure, weight loss. A registered nutritionist and a registered Chinese medicine practitioner will join the Facebook group as health partners. Both of them are also registered nurses.~Besides the Facebook contents, the participants will also receive government printed health information on healthy eating, physical activity, obesity and cancers."
2991996|NCT02616237|No Intervention|Control Group|The participants randomized into the Control Group will only receive government printed health information on healthy eating, physical activity, obesity and cancers.
2991997|NCT02616224||Participants with unresectable LA/mBC|
2991998|NCT02616198|Active Comparator|EquiaFil G-coat|EquiaFil G-coat combination was applied on one randomly selected cavity to be restored
2991999|NCT02616198|Active Comparator|EquiaFil Fuji Varnish|EquiaFil Fuji Varnish combination was applied on one randomly selected cavity to be restored
2992000|NCT02616198|Active Comparator|Riva SC G-coat|River SC G-coat combination was applied on one randomly selected cavity to be restored
2992001|NCT02616198|Active Comparator|Riva SC Fuji Varnish|River SC Fuji Varnish combination was applied on one randomly selected cavity to be restored
2992002|NCT02616185|Experimental|Dose Escalation|
2992003|NCT02616172|Experimental|Autologous bone marrow infusion|One time administration of autologous bone marrow mononuclear cells intravenously, minimum dose of 6 million cells per kg Total nucleated cells.
2992004|NCT02616159|Experimental|Oatmeal 1|40 g cereal
2992005|NCT02616159|Experimental|Oatmeal2|40 g cereal
2992006|NCT02616159|Experimental|Oatmeal 3|40 g cereal
2992007|NCT02616159|Placebo Comparator|Ready to eat cereal|32.2 g cereal
2992008|NCT02616159|Placebo Comparator|Hot cereal|28.8 g cereal
2992009|NCT02616146|Experimental|ENG-E2 125 μg/300 μg|Participants will receive up to 13 cycles of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
2992010|NCT02616146|Active Comparator|LNG-EE 150 μg/30 μg|Participants will receive up to 13 cycles of LNG-EE 150 μg/30 μg. Each cycle will consist of one tablet per day for 21 days, followed a 7-day tablet-free interval.
2992011|NCT02616120|Placebo Comparator|Placebo|placebo identified to SQJZ herbal mixtures, 29.375g, 2 times per day.for 12 weeks.
2992012|NCT02616120|Active Comparator|SQJZ herbal mixtures|SQJZ herbal mixtures 29.375g, 2 times per day.for 12 weeks.
2992013|NCT02616107|Experimental|Intervention|Family caregivers of breast cancer patients who consent to participate in the study have a 50/50 chance of being randomized to the intervention group and will receive the booklet, Managing Cancer Care: A Caregiver's Guide (MCC-CG) (N=18)
2992014|NCT02616107|Active Comparator|Control|Family caregivers of breast cancer patients who consent to participate in the study have a 50/50 chance of being randomized to the control group and will receive the Symptom Management Toolkit (N=17)
2992015|NCT02616094|Experimental|Treatment Seeking Alcohol Dependent Adults|Group consists of 100 treatment seeking alcohol dependent (AD) men and women (ages 18-60). AD subjects will complete either 8 weeks of outpatient treatment at the Yale Stress Center, or the first 4 weeks as inpatient treatment at the CNRU, followed by 4 weeks of outpatient treatment at the Yale Stress Center. While in outpatient treatment, AD subjects may be admitted to the CNRU or HRU for the 1-5 days prior to one or both of their scans, to ensure abstinence for their scans.
2992016|NCT02616094|Active Comparator|Social Drinking Controls|Group consists of demographically and handedness matched 50 socially drinking controls. Healthy controls will be moderate and binge/heavy social drinkers who will participate in a single MRI session after baseline assessments. Healthy controls may be admitted to the HRU overnight prior to their scan.
2992017|NCT02616094|Active Comparator|Prazosin/Placebo Group|This is a separate group of 60 treatment seeking AD subjects in a NIAAA-funded RCT of Prazosin vs placebo for alcohol dependence ( PI: Sinha, Hic protocol 0705002691, NCT00585780) to assess target primary and secondary predictors of alcohol treatment outcomes in the context of a currently ongoing RCT. AD subjects enrolled in the PZ/PL RCT will NOT be given drugs as part of this study. That study and intervention is listed elsewhere (NCT00585780). Subjects will participate in a baseline scan and a second scan between weeks 10-12 of the 12-week RCT with follow-ups. PZ/PL is only given to subjects enrolled in 0705002691, not the current protocol.
2992018|NCT02616081||Clean Intermittent Catheterization|
2992019|NCT02616081||Indwelling Catheter|
2992020|NCT02616081||Bladder Surgery|
2992021|NCT02616068|Experimental|transdermal patch & placebo|transdermal patch 100 mg once a day for 7 days and placebo (for loxoprofen sodium 60 mg tablet) by mouth, every 8 hours for 7 days
2992022|NCT02616068|Active Comparator|loxoprofen sodium & placebo|loxoprofen sodium 60 mg by mouth, every 8 hours for 7 days and placebo (for transdermal patch 100 mg) once a day for 7 days
2992023|NCT02616055|Experimental|50mg Daily|One 50mg tesevatinib tablet per day
2992024|NCT02616055|Experimental|100mg Daily|Two 50mg tesevatinib tablets per day
2992025|NCT02616055|Experimental|150mg M/Th|Three 50mg tesevatinib tablets every Monday and Thursday.
2992026|NCT02616055|Experimental|150mg MWF|Three 50mg tesevatinib tablets every Monday, Wednesday and Friday.
2992027|NCT02616042|Experimental|Centella asiatica and bamboo salt|Participants received a dentifrice which contains Centella asiatica, bamboo salt, dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime). All participants used the assigned dentifrices for 4 days in each trial cycle.
2992084|NCT02615639|Active Comparator|IFN-a-2a|IFN-a-2a 180ug subcutaneous injection， every week for 9 months.
2992029|NCT02616042|Placebo Comparator|Control dentifrice|Participants received a plain dentifrice which contains dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime).
2992030|NCT02616029|Experimental|E/C/F/TAF|Participants will switch from their current regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF FDC and will receive treatment for 48 weeks.
2992031|NCT02616016|Other|MRI guided High Intensity Focused Ultrasound Treatment|"Intervention Group The interventional radiologist will locate the target tissue and mark the volume to be treated using MRI images.~The operator starts the treatment and monitors the progress of the treatment with MR thermal and dose maps to ensure adherence to treatment plan.~An individual treatment sonication will last approximately 30 seconds."
2992032|NCT02616003|Other|Giant Obese Patients (BMI >65 kg/m2)|Patients with a BMI above 65 kg/m2 that need preoperative conditioning therapy (intervention 1: Liraglutide, intervention 2: aminosteril hepa 8%, intervention 3: Caloric diet with 800 kcal) for weight loss surgery to achieve technical operability.
2992033|NCT02615990|Experimental|Erigo Pro plus standard Physical Therapy|The Erigo device therapy is a combination of tilt table with robotic stepper device allowing for cyclic leg loading. It also includes Functional Electrical Stimulation to optimize active neuromuscular stimulation. It will be used once a day to replace one of the standard PT therapies. The exercise mimics walking beyond what regular range of motion provides. Patients will have 2 additional PT therapies 20 minutes of standard range of motion movements.
2992034|NCT02615990|Active Comparator|Standard Physical Therapy|Patients will have 3 standard Physcial Therapy session. Patients will have 2 additional PT therapies 20 minutes of standard range of motion movements.
2992035|NCT02615977|Experimental|Intervention|"In the verum treatment condition, i.e. Zooming Joystick Task, 90% of all alcohol-related pictures appear in the landscape format and hence are trained to be pushed away."
2992036|NCT02615977|Placebo Comparator|Placebo Intervention|In the placebo condition, i.e. Zooming Joystick Task (Placebo), alcohol picture are as often pushed away as pulled towards the subject.
2992037|NCT02615951|Other|Nutrient transporters study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of nutrient transporters expression
2992038|NCT02615951|Other|Chemokine receptors study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of chemokine receptors expression
2992039|NCT02615951|Other|Genes study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of genes expression
2992040|NCT02615951|Other|Protein surface study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of protein surface expression
2992041|NCT02615951|Other|Protein surface & genes data validation|"Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure for validation of the data from protein surface study and genes study arms analysis."
2992042|NCT02615938|Experimental|Start HCQ block Verum|During trial: Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.
2992043|NCT02615938|Placebo Comparator|Start HCQ block Placebo|At the beginning of the trial: Placebo for 4 weeks then Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.
2992044|NCT02615938|Experimental|Stop HCQ block Verum|Individual dose, usually Hydroxychloroquine Sulfate (HCQ, Quensyl) 6-10 mg/kg bw/d, p.o., one daily dose in the evening; the maximum daily dose is 400 mg. The dose, on which the patient is included into the trial, should be continued for 3 months. After therapy of 3 months the medication will be stopped. The patients will be followed up for additional 3 months.
2992045|NCT02615938|Placebo Comparator|Stop HCQ block Placebo|Patients will receive Placebo for 3 months and will be followed up for additional 3 months.
2992046|NCT02615925|Other|Psychiatry Consultation|Psychiatry Consultation, it is proposed by one of the investigators, patients that clinical data from this psychiatric examination, conducted as part of their usual care, are recorded as part of the research that their is proposed and explained. An information note is then distributed and not collected their opposition
2992047|NCT02615912|Other|Surfactant Exposure|PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5% Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5% Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5% Silwet* DA-63 (Momentive) 1.5% Sodium lauryl sulfate (Sigma Aldrich) 1.0% Water
2992048|NCT02615899|Active Comparator|Matched|Administer Targeted (specific) balance exercise interventions
2992049|NCT02615899|Active Comparator|Mismatched|Administer Untargeted (non-specific) balance exercise interventions
2992050|NCT02615886|Experimental|Observational Control|Randomized participants will be observed for diarrhea incidences throughout the 6 month trial with no intervention.
2992051|NCT02615886|Experimental|Rice Bran|Randomized participants will consume a measured dose of rice bran daily throughout the 6 month trial.
2992052|NCT02615873|Experimental|AP CD/LD|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
2992053|NCT02615860|Experimental|Topical 85% trichloroacetic acid (TCA)|AIN lesions are treated with trichloric acid
2992054|NCT02615860|Active Comparator|Surgical electrocautery (ECA)|AIN lesions are treated with electrocautery
2992055|NCT02615847|Experimental|Memantin arm|Memantinhydrochlorid, administered once per day during 12 month. Dosage is from 0-20 mg.
2992056|NCT02615834|No Intervention|Control group|
2992057|NCT02615834|Active Comparator|Study group|
2992058|NCT02615821|Experimental|Affective Mental Contrasting|"Before the goal formation or mental contrasting activities, participants will receive information about the affective benefits of exercising (e.g. regular physical activity has been shown to reduce stress, physical activity is enjoyable), and related research support including appropriate references. During the mental contrasting component of the activity the prompts will remain the same as the standard condition, with minor variations in questions in order to elicit affective judgements. Specifically, the affective condition will include the additional prompts Why might you find exercise to be enjoyable, pleasant, exciting, or fun? for eliciting outcomes, and Why might you find exercise to be unenjoyable, unpleasant, boring, or miserable? for eliciting obstacles."
2992059|NCT02615821|Active Comparator|Instrumental Mental Contrasting|"Before the goal formation or mental contrasting activities,participants will receive information about the instrumental benefits of exercising (e.g., regular physical activity reduces the risk of developing cancer) and related research support, again including appropriate references. During the mental contrasting component of the activity the prompts will remain the same as the standard condition, with minor variations in questions in order to elicit either instrumental judgements. Specifically, the instrumental conditions will include the prompts Why might you find exercise to be useful, advantageous, beneficial, or important? for eliciting outcomes, and Why might you find exercise to be unimportant, useless, inconvenient, or detrimental? for eliciting obstacles."
2992060|NCT02615821|Active Comparator|Standard Mental Contrasting|In the standard condition, the space where the affective and instrumental benefits of physical activity were listed in the instrumental and affective conditions, will be left blank in the standard condition, and no additional prompting questions will be given, allowing for the idiosyncratic identification of obstacles and outcome.
2992061|NCT02615808|Experimental|Oxygen saturation data visualization|During intervention periods staff in both units will have access to the data visualization tool in the electronic health record.
2992062|NCT02615808|No Intervention|Control|During control periods, the staff will not have access to the data visualization and will continue to use standard of care electronic health record and monitor data to understand oxygen status and trends.
2992063|NCT02615795|No Intervention|Control|Best practice
2992064|NCT02615795|Experimental|Intervention|Best practice + Tele Monitoring of physiological parameters (heart frequence, oxygen saturation, weight, FEV1), and answers to disease specific questions, using Tunstall monitoring device.
2992065|NCT02615782|Experimental|A group|"Period 1: CKD-397 1T single oral administration under fasting condition~Period 2: CKD-397 1T single oral administration under fed condition (high fat meals)"
2992066|NCT02615782|Experimental|B group|"Period 1: CKD-397 1T single oral administration under fed condition (high fat meals)~Period 2: CKD-397 1T single oral administration under fasting condition"
2992067|NCT02615769|Experimental|Invitation with focused information of spirometry|
2992068|NCT02615769|Active Comparator|Standard invitition|
2992069|NCT02615756|Experimental|Physical exercise|
2992070|NCT02615743|Experimental|Intervention Group|Caregivers of intervention arm participants will receive daily text message reminders about asthma controller medication use, as well as an electronic monitoring device to track the participant's medication usage for 60 days following hospital discharge. At the end of 30 days, participants will be able to opt out of daily text messages if they choose. All caregivers of participants will also complete a 30-minute survey at the time of enrollment and 2 brief telephone followups at 30 and 60 days.
2992071|NCT02615743|Other|Control Group|Caregivers of control arm participants will receive an electronic monitoring device to track their medication usage for 60 days following hospital discharge. At 30 days, caregivers of participants will be able to opt in to receive daily text message reminders about asthma medication use. Caregivers of all participants will also complete a 30-minute survey at the time of enrollment and 2 brief telephone followups at 30 and 60 days.
2992072|NCT02615730|Experimental|Paclitaxel & GSK2636771|Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily) in combination with a fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)
2992073|NCT02615717|Experimental|Attentional Bias Modification|In the ABM treatment condition, participants will have four 20-minute in-lab treatment conditions across two weeks. Within these Attention Bias Modification sessions, participants will be presented with a fixation cross for 500 ms. The fixation cross will then be replaced with a word pair consisting of either a threat/neutral pair or a neutral/neutral word for 500 ms, followed by a probe in the location of one of the two words (80% threat/neutral pairs, 20% neutral/neutral pairs; the target will always appear in the location of the neutral word).
2992074|NCT02615717|Active Comparator|Attentional Control Condition|Participants will have four 20-minute in-lab treatment conditions across two weeks. Within the Attention Bias Modification control sessions, participants will be presented with a fixation cross for 500 ms. The fixation cross will then be replaced with a word pair consisting of either a threat/neutral pair or a neutral/neutral word for 500 ms, followed by a probe in the location of one of the two words (80% threat/neutral pairs, 20% neutral/neutral pairs; the target appears in the location of the neutral word in 50% of the trials. Complete Stroop and 3-back task, etc.
2992075|NCT02615704||Active APP with MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using active APP with MEMS
2992076|NCT02615704||Active APP without MEMs|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using active APP without MEMS
2992077|NCT02615704||Control APP with MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using control APP with MEMS
2992078|NCT02615704||Control APP without MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using control APP without MEMS
2992079|NCT02615691|Experimental|Previously untreated patients (PUPs)|<6 years of age with severe hemophilia A (baseline Factor VIII (FVIII) level < 1%)
2992080|NCT02615678|Experimental|Acupuncture|Acupuncture including scalp needling will be applied to selected points based on literature
2992081|NCT02615639|Experimental|HPDC-T cells & entecavir|HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks , and entecavir(ETV) 0.5mg tablet by mouth, every night.
2992082|NCT02615639|Active Comparator|entecavir|entecavir 0.5mg tablet by mouth, every night.
2992083|NCT02615639|Experimental|HPDC-T cells & IFN-a-2a|HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks ,and IFN-a-2a 180ug subcutaneous injection， every week for 9 months.
3015444|NCT02459587|No Intervention|EUC|Enhanced Usual Care
2992085|NCT02615639|Experimental|HPDC-T cells & Telbivudine|HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks ,and Telbivudine 600mg tablet by mouth, every night.
2992086|NCT02615639|Active Comparator|Telbivudine|Telbivudine 600mg tablet by mouth, every night.
2992087|NCT02615626||Group 1|Periodontal healthy
2992088|NCT02615626||Group 2|Gingivitis, Non-surgical Periodontal Treatment
2992089|NCT02615626||Group 3|Chronic Periodontitis, Non-surgical Periodontal Treatment
2992090|NCT02615613|Experimental|High acceptability meal|A custard recipe was used as the high acceptability meal
2992091|NCT02615613|Experimental|Low acceptability meal|The regular custard recipe was reformulated to yield a low acceptability version
2992092|NCT02615600|Experimental|lf-tRNS|Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): <100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
2992093|NCT02615587||AF patients in Denmark / Cohort 1|"The base population of AF patients for diagnosis and health care utilization / resource use will be identified in the National Patient Registry. For a given period of time (2000-2013, both years inclusive) all patients with a hospital contact (admission, outpatient visit or ER visit) and for whom AF was the primary or secondary diagnosis code will be identified.~Further Data sources used:~Registry of Medicinal Product Statistics: for determining the individuals' use of prescription medicine DREAM database: for investigation of sickness benefit and productivity loss Statistics Denmark's databases: on social services from municipalities Cause of Death Registry: AF-patients or controls who died during the study period (2000-2013) Danish Civil Registry: used for identification of controls, holds information about age, gender"
2992094|NCT02615574|Experimental|αDC1 vaccine + CKM|all subjects enrolled in study
2992095|NCT02615561|Experimental|Phase 1 (Cure phase)|Efficacy and safety of the medical device Bepanthen Itch Relief Cream in children´s mild AD (responders will enter study phase 2)
2992096|NCT02615561|Experimental|Phase 2 (Care phase) / Arm 1|Efficacy and safety of the new cosmetic Bepanthen test product in maintaining healthy skin in the remission phase after cure of children´s mild AD
2992097|NCT02615561|Active Comparator|Phase 2 (Care phase) / Arm 2|Efficacy and safety of Stelatopia (cosmetic comparator) in maintaining healthy skin in the remission phase after cure of children´s mild AD
2992098|NCT02615548|Experimental|Community exercise class|Regular community exercise class is the intervention. It is an exercise class that incorporate PWR moves( UP,ROCK,STEP,TWIST) and cardiovascular training.
2992099|NCT02615548|Active Comparator|self-directed exercise activity|Self-directed exercise.
2992100|NCT02615535|Experimental|EEG neurofeedback-assisted meditation|EEG neurofeedback assisted meditation using the MUSE device and auditory feedback.
2992101|NCT02615535|Active Comparator|Non-EEG feedback-assisted meditation|Non-EEG neurofeedback assisted meditation. Subjects will have auditory instruction from the MUSE device without the EEG neurofeedback.
2992102|NCT02615496||Educational materials: Physicians|
2992103|NCT02615496||Educational materials: Patients|
2992104|NCT02615483|Experimental|Web-based platform|Access to a web-based platform
2992105|NCT02615483|No Intervention|Control|Conventional
2992106|NCT02615470|Experimental|Enhanced immunization delivery model|Pharmacist-technician pairs employed by community pharmacies that are assigned to this arm will receive a) immunization update training, b) training by immunization experts to enhance immunization delivery model and foster practice change at the beginning of 6-month and c) regular feedback and clinical support for the period of 6 months.
2992107|NCT02615470|Active Comparator|Immunization update|Pharmacist-technician pairs employed by community pharmacies that are assigned to the control arm will receive an immunization update training. They will not receive a training by immunization experts nor regular feedback and clinical support.
2992108|NCT02615457|Experimental|Arm I|Patients taking Huaier Granule for adjuvant treatment after the triple negative breast cancer has been surgically removed. The Huaier Granule (Qidong Gaitianli Medicines Co., Ltd.) should be given orally from the 3rd day after surgery up to 5 years after surgery or until study termination.
2992109|NCT02615457|No Intervention|Arm II|Patients not taking Huaier Granule after the triple negative breast cancer has been surgically removed.
2992110|NCT02615444|Experimental|Beta-glucan enriched oatcake|Oatcakes which have been enriched with beta-glucan. Each participant will consume 5 oatcakes daily in order to ingest 4g of oat-beta glucan.
2992111|NCT02615444|Placebo Comparator|Isocaloric control|Control: Wheat based snack, equicaloric and matched to intervention product for macronutrient content. Contains no oat-beta glucan. Each participant will consume 6.5 Krackawheats daily.
2992112|NCT02615431||MitraClip Intervention|the influence of MitraClip on Apnoea Asleep
2992113|NCT02615418|Active Comparator|Fully active treatement|
2992114|NCT02615418|Sham Comparator|partially active|first 2.5 weeks will receive sham treatment followed by active
2992115|NCT02615405|Experimental|EPA|3.5 g/day in Studies 1 & 2
2992116|NCT02615405|Active Comparator|DHA|1.75 g/day in Studies 1 & 2
2992117|NCT02615405|Placebo Comparator|Placebo capsules|oleic oil in Study 1
2992118|NCT02615392|Experimental|Park prescription|The participants in this group will receive a brief counseling on physical activity together with a park prescription that highlights the importance of engaging in at least 150 minutes of physical activity per week and the possibility of engaging in physical activity in the park. In addition, they are invited to join in a structured and supervised physical activity program in the park. The structured physical activity program will take place in public parks located in the participants' neighbourhood. Participants will receive text messages for reminder and registration purposes approximately once a week. Also, participants will receive a sheet to monitor their weekly physical activity, information about parks in their neighborhood, and a counseling phone call half-way through the study.
2992119|NCT02615392|No Intervention|Control|The participants in this group will not be given any park prescription or be invited to participate in the weekly program in the park. However, they will receive all the information materials provided to the experimental group after the study has ended.
2992120|NCT02615379|Experimental|Transdermal Continuous Oxygen Therapy|EPIFLO® working study unit, all day, every day for 2 weeks + standard wound care
2992121|NCT02615379|No Intervention|Standard of care|standard wound care for 2 weeks
3017778|NCT02444351|Experimental|botox group|
2992122|NCT02615366|Active Comparator|Tranexamic Acid|Tranexamic acid will be provided as an intravenous infusion (1g in 100mL 0.9% NaCl solution [1% TXA] at 5 ml/min) 20 minutes pre-operatively, followed by an additional intravenous dose of the same dosing parameters postoperatively. Oral tablet doses containing 1 g of TXA (2x 500mg tablets) per dose will be administered to the patient to be taken orally by the patient according to a standard regimen; the first tablet dose will be taken on the same day as the surgery, in the evening. The patient will then take one tablet dose three times a day for a total of five days following the surgery (one dose in the morning, one dose mid-day, and one dose in the afternoon) for a 6 day total regimen.
2992123|NCT02615366|Placebo Comparator|Placebo Control|Placebo control will be either 100 ml of 0.9% NaCl solution or tablets of similar appearance containing no medicinal ingredients; placebo will be administered according to the same regimen as the intervention group.
2992124|NCT02615353|Experimental|Lifestyle Intervention|6 months of a bi-weekly Nutrition Education, Physical Activity, and Behavioral Modification program
2992125|NCT02615353|Placebo Comparator|Usual Care Control|Medical screening and dietary counseling with a Endocrinologist and Registered Dietitian
2992126|NCT02615340|Active Comparator|Enteral melatonin 0.5 mg|Melatonin 0.5 mg from the 1mg/mL oral suspension qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration of 0.1 mg/mL; final volume in the oral syringe will be 5 mL)
2992127|NCT02615340|Active Comparator|Enteral melatonin 2 mg|Melatonin 2 mg from the 1mg/mL oral suspension qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration 0.4 mg/mL; final volume in the oral syringe will be 5 mL)
2992128|NCT02615340|Placebo Comparator|Enteral matched placebo|Melatonin 0 mg qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration 0 mg/mL; final volume in the oral syringe will be 5 mL)
2992129|NCT02615327|Experimental|Active Treatment 1|8g Polydextrose
2992130|NCT02615327|Experimental|Active Treatment 2|12 g Polydextrose
2992131|NCT02615327|Experimental|Active Treatment 3|16 g Polydextrose
2992132|NCT02615327|Placebo Comparator|Placebo|0 g Polydextrose
2992133|NCT02615314||BPPV without migraine|Two hundred and sixty-three patients with BPPV (2009-2014), confirmed by videonystagmography (VNG), were enrolled in the study. Patients' charts were reviewed. They were grouped as those with or without migraine. Distribution of gender, age, duration of symptoms and affected side were reviewed. Two hundred and thirty-one patients with no migraine were identified.
2992134|NCT02615314||BPPV with migraine|Thirty-two patients (11.4%) with migraine were identified. Diagnosis and classification of migraine and its differentiation from other type of headaches was based on third edition of International classification of headache disorders (ICHD-III beta) by international headache society (IHS). All patients with migraine had migrainous headache with or without aura and they all were diagnosed in our institution and followed by our neurology staff.
2992135|NCT02615301|Experimental|Salmon (HD+HK)|Tailor-made salmon with high levels of vitamin D3 and K1
2992136|NCT02615301|Experimental|Salmon (LD+HK)|Tailor-made salmon with low levels of vitamin D3 and high K1
2992137|NCT02615301|Experimental|Salmon (HD+LK)|Tailor-made salmon with high levels of vitamin D3 and low K1
2992138|NCT02615301|Experimental|Supplement (vitamin D + Calcium)|Supplement with vitamin D and Calcium
2992139|NCT02615288|Active Comparator|High Dose Vitamin D3 (10,000 IU daily)|
2992140|NCT02615288|Placebo Comparator|Low Dose Vitamin D3 (1000 IU daily)|
2992141|NCT02615275|Experimental|SECA mBCA Bioelectrical Impedance (BIA) Scale Analysis|"Eight-electrode BIA device (SECA mBCA) used to estimate body composition in a head and neck cancer patient population during radiation therapy by comparing it to routine imaging-derived estimates of body composition. Body composition assessed at baseline, weekly throughout RT during clinic visits, and after completion of treatment at the 10-12 week follow up.~Computed tomography (CT) or positron emission tomography (PET) scan performed at baseline, every week during radiation treatment (about 6-7 weeks), and at 10-12 weeks after completion of radiation therapy.~Symptom questionnaire completed at baseline, every week during radiation treatment (about 6-7 weeks), and at 10-12 weeks after completion of radiation therapy.~Radiation treatment administered per treating physician for 6-7 weeks."
2992142|NCT02615262|Experimental|Experimental|Dexamethasone 1 mg per 1 kg of body weight intravenously immediately after induction of anesthesia
2992143|NCT02615262|Placebo Comparator|Control|0.9% Sodium Chloride 0.25 ml per 1 kg of body weight intravenously immediately after induction of anesthesia
2992144|NCT02615249|Experimental|Metal Allergen Epicutaneous Patch|Application of patch test allergens to test for positive allergic responses.
2992145|NCT02615236|Experimental|PERINEAL ULTRASOUND|Perineal ultrasound with a bedside scanner by inserting a the probe into the perineum and reviewed in real-time
2992146|NCT02615236|Active Comparator|Clinical diagnosis|Diagnosis of OASIS will be clinically
2992147|NCT02615223|Experimental|Arm1|"Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.~Patients receive cryoablation therapy."
2992148|NCT02615223|Experimental|Arm2|Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
2992149|NCT02615210|No Intervention|Standard|Standard of care biopsies with optional SOC-directed biopsy afterwards
2992150|NCT02615210|Experimental|Study|SOC-directed biopsies using the SpyGlass System plus standard of care biopsies
2992151|NCT02615197|Active Comparator|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT) as described in the 2 DBT treatment manuals (Linehan, 1993; 2014).
2992152|NCT02615197|Experimental|Dialectical Behavior Therapy + DBT Prolonged Exposure protocol|Standard Dialectical Behavior Therapy (DBT) as described in the 2 DBT treatment manuals (Linehan, 1993; 2014) plus an adapted version of Prolonged Exposure therapy for PTSD.
2992153|NCT02615184|Experimental|Healing Period: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, orally, once, daily, for 8 to 12 weeks (healing of erosive esophagitis [EE] confirmed by endoscopy).
2992154|NCT02615184|Experimental|Healing Period: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, orally, once, daily, for 8 to 12 weeks (healing of EE confirmed by endoscopy).
2992479|NCT02613091|Experimental|Clemastine|This group will receive 8mg of clemastine daily.
2992155|NCT02615184|Experimental|Maintenance: Dexlansoprazole 30 mg|Participants in the Healing Period: Dexlansoprazole 60 mg treatment arm with healed EE confirmed by endoscopy will be re-randomized to receive dexlansoprazole 30 mg, capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
2992156|NCT02615184|Experimental|Maintenance: Dexlansoprazole 15 mg|Participants in the Healing Period: Dexlansoprazole 30 mg treatment arm with healed EE confirmed by endoscopy will be re-randomized to receive dexlansoprazole 15 mg, capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
2992157|NCT02615184|Placebo Comparator|Maintenance: Placebo|Participants who are eligible to enter the Maintenance of Healing period as confirmed by endoscopy will be re-randomized to receive placebo-matching capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
2992158|NCT02615171|Active Comparator|RELAX-AS|Participants will participate in a 6-month weight loss intervention which will include: fifteen 15-minute weight loss counseling visits lead by a weight loss clinician; handouts related to nutrition and exercise to read outside of the study visit; and use of the RELAX app developed by the study team. Participants will be instructed to use RELAX app daily for: diet and physical activity logging; monitoring stress level; receiving information to cope with stress; charts to see how they are doing over time; and receive feedback reports given to them and their PCP, which includes information about how they are doing toward their goals. We will also encourage participants to meet with their physician to discuss feedback reports. Weight loss clinicians and PCP will review participant's progress using the RELAX-web program.
2992159|NCT02615171|Active Comparator|DIET-AS|Participants will participate in a 6-month weight loss intervention which will include: fifteen 15-minute weight loss counseling visits lead by a weight loss clinician; handouts related to nutrition and exercise to read outside of the study visit; and use of a diet app. The app will be designed to help people stay on track with their weight loss goals. Participants will be instructed on to use it daily to track diet and physical activity.
2992160|NCT02615171|Active Comparator|DIET|Participants will participate in a 6-month weight loss intervention which will include a fifteen 15-minute weight loss counseling visits lead by a weight loss clinician and handouts related to nutrition and exercise to read outside of the study visit.
2992161|NCT02615158|Experimental|Maternal Physical Activity and Nutrition|A maternal intervention focusing on healthy diet and physical activity patterns for mothers.
2992162|NCT02615158|Experimental|Parenting|A toddler parenting intervention focusing on parenting, limit setting, and development strategies.
2992163|NCT02615158|Experimental|Child Safety|Attention control group. The parents received intervention to promote safety among toddlers.
2992164|NCT02615145||GT4 participants treated with Ribavirin|GT4 participants receiving Ombitasvir+Paritaprevir+Ritonavir+Ribavirin
2992165|NCT02615145||GT1 participants treated with Ribavirin|GT1 participants receiving Dasabuvir+ Ombitasvir+Paritaprevir+Ritonavir + Ribavirin
2992166|NCT02615145||Genotype 1 (GT1) participants treated without Ribavirin|GT1 participants receiving Dasabuvir+ Ombitasvir+Paritaprevir+Ritonavir
2992167|NCT02615145||Genotype 4 (GT4) participants treated without Ribavirin|GT4 participants receiving Ombitasvir+Paritaprevir+Ritonavir
2992168|NCT02615132|Experimental|Treatment Group|The study SLP will instruct the patient to use the ipad apps as intervention for at least one-hour per day, until they are admitted to outpatient SLP services or for a maximum of 8 weeks, whichever comes first. Throughout the telemedicine treatment phase, patients' progress will be monitored remotely by a study SLP through Apps/Skype/Facetime/Telephone consultation on a weekly basis.
2992169|NCT02615132|No Intervention|Control|Patients will be sent home with standard of care.
2992170|NCT02615119|Experimental|Anorexia nervosa|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
2992171|NCT02615119|Experimental|Generalized anxiety disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
2992172|NCT02615119|Experimental|Panic disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
2992173|NCT02615119|Experimental|Major depressive disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
2992174|NCT02615119|Experimental|Brain injury|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
2992175|NCT02615119|Active Comparator|Healthy comparison|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
2992176|NCT02615106|Experimental|Endostar Combined With Radiotherapy|Drug: Endostar Endostar 7.5 mg/m2/day, day 1-14 Radiation: 21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
2992177|NCT02615080|Active Comparator|CRD007|CRD007 (containing pemirolast sodium) tablets given twice daily for 14 weeks
2992178|NCT02615080|Placebo Comparator|Placebo|Matching placebo tablets given given twice daily for 14 weeks
2992179|NCT02615067|Experimental|99mTc-MIP-1404 Injection|20 ± 3 millicurie (mCi) intravenous (IV) injection of 99mTc-MIP-1404
2992180|NCT02615054||treated with trastuzmab no cardiac effects|
2992181|NCT02615054||treated with trastuzmab with cardiac effects|
2992182|NCT02615054||healthy volunteers no cancer treatment|
2992183|NCT02615041|Experimental|1 g by bolus injection|1 g of meropenem with bolus injection every 8 h regimen
2992184|NCT02615041|Experimental|1 g by 3 h infusion|1 g of meropenem with 3 h infusion every 8 h regimen
2992185|NCT02615041|Experimental|2 g by 3 hinfusion|2 g of meropenem with 3 h infusion every 8 h regimen
2992186|NCT02615028|Other|Closed eyes double-leg stance|Body relaxed with both arms naturally placed beside thighs, eyes closed for 40 seconds.
2992187|NCT02615015||ST elevation myocardial infarction patient cohort|Patients who suffered from ST elevation myocardial infarction since 2006, referred to the General Hospital of Vienna and received primary percutaneous coronary intervention.
2992188|NCT02615015||Healthy proband cohort|Age matched healthy individuals who voluntarily participate in the study.
2992189|NCT02615002|Experimental|piromelatine 5 mg|5 mg tablets once daily
2992190|NCT02615002|Experimental|piromelatine 20 mg|20 mg tablets once daily
2992191|NCT02615002|Experimental|piromelatine 50 mg|50 mg tablets once daily
2992192|NCT02615002|Placebo Comparator|Placebo|Placebo tablet once daily
2992302|NCT02614196|Experimental|Galcanezumab 240mg|Galcanezumab 240mg given by SC injection once a month for 6 months.
2992193|NCT02614989|Experimental|MRI guided Focused Ultrasound treatment|"MRI guided focused ultrasound thalamotomy~Patients will undergo unilateral thalmotomy using MRI guided Focused Ultrasound intervention for the treatment of the tremor"
2992194|NCT02614976|No Intervention|Control|No padding before application of blood pressure cuff
2992195|NCT02614976|Experimental|Padding|Padding before application of blood pressure cuff
2992196|NCT02614963|Experimental|Clostridium Butyricum group|Irritable bowel syndrome patients treated with Clostridium Butyricum
2992197|NCT02614963|Placebo Comparator|Placebo group|Irritable bowel syndrome patients treated with placebo
2992198|NCT02614950|Experimental|Treatment interuption|
2992199|NCT02614937|Experimental|Squalamine and ranibizumab to Week 10|"All eyes received an initial 10 week mandatory loading period of topical Squalamine Lactate Ophthalmic Solution, 0.2% therapy.~All eyes received mandatory intravitreal injections of ranibizumab 0.5mg at the conclusions of weeks 2 and 6.~Randomize at Week 10 to 2 different groups - Squalamine and No Squalamine, continue PRN ranibizumab in both groups"
2992200|NCT02614937|Experimental|Continue Squalamine, ranibizumab PRN|Continue use of Squalamine Lactate Ophthalmic Solution, 0.2% after Week 10; continue ranibizumab 0.5 mg IVT PRN
2992201|NCT02614937|Experimental|Stop Squalamine, ranibizumab PRN|Discontinue use of Squalamine Lactate Ophthalmic Solution, 0.2% after Week 10; continue ranibizumab 0.5 mg IVT PRN
2992202|NCT02614924|Other|Flexible fibre-optic scope|Randomly allocated to fibreoptic group
2992203|NCT02614924|Other|Pentax AWS videolaryngoscope|Randomly allocated Pentax AWS videolaryngoscope
2992204|NCT02614911||Sick patients|Biological sampling of blood for all patients. Biological sampling of saliva, biopsies (skin and endoscopic), feces, for some patients
2992205|NCT02614911||Healthy relatives|Biological sampling of blood for all healthy relatives
2992206|NCT02614898|Other|Clinical assessments & laboratory tests|Clinical assessments and laboratory tests for patients already taking an approved therapy Soliris® (eculizumab).
2992207|NCT02614885||Prophylactic Mastectomy|Females undergoing prophylactic mastectomy with RFA performed on the excised tissue.
2992208|NCT02614872|Experimental|GLASSIA®|Glassia® IV treatment additional to Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.
2992209|NCT02614872|No Intervention|Institution standard of care (SOC)|Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.
2992210|NCT02614859|Active Comparator|A|
2992211|NCT02614859|Experimental|B|
2992212|NCT02614846|Experimental|Hetrombopag Olamine|All the subjects receive 6 weeks Hetrombopag Olamine dosing, 5mg for the first 2 weeks, 2.5mg or 7.5mg for the last 4 weeks according to the PLT counting.
2992213|NCT02614833|Experimental|Paclitaxel + IMP321 at the RPTD|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks. Patient will receive weekly paclitaxel at Days 1, 8 and 15 with adjunctive treatment of study agent, either IMP321, on Days 2 and 16 of each 4-week cycle. After completion of the 6-cycle chemo-immunotherapy phase, responding or stable patients will receive study agent (IMP321) every 4 weeks during the maintenance phase for an additional period of up to 12 injections
2992214|NCT02614833|Active Comparator|Comparator: Paclitaxel + Placebo|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks. Patient will receive weekly paclitaxel at Days 1, 8 and 15 with adjunctive treatment of study agent, placebo, on Days 2 and 16 of each 4-week cycle. After completion of the 6-cycle chemo-immunotherapy phase, responding or stable patients will receive study agent (placebo) every 4 weeks during the maintenance phase for an additional period of up to 12 injections
2992215|NCT02614820|Experimental|treatment group|inflation of a blood pressure cuff on the bilateral thighs to 150 mm Hg for four 5-minute intervals
2992216|NCT02614820|Other|control group|inflation of a blood pressure cuff on the bilateral thighs to 40 mm Hg for four 5-minute intervals
2992217|NCT02614807|Experimental|Intervention|All recruited patients will receive a standard endorsement of lower fluid intake (<1.5 Litres/day) by a hypertension nurse and physician and an additional treatment consisting of a bottle (237 ml) of Nepro (a low sodium, low potassium content protein supplement) a day (supply for 4 weeks will be provided).
2992218|NCT02614794|Experimental|Tucatinib in combination with capecitabine & trastuzumab|Tucatinib in combination with capecitabine & trastuzumab
2992219|NCT02614794|Active Comparator|Placebo in combination with capecitabine & trastuzumab|Placebo in combination with capecitabine & trastuzumab
2992220|NCT02614768|Experimental|Glucose Sensor|Continuous subcutaneous glucose monitoring using four different CGM systems in parallel will be performed throughout the study. Insulin therapy will be performed by the subjects themselves, as under daily life conditions. For the hypoglycaemia experiment an increased insulin bolus will be administered with meals (180% of the subject's calculated mealtime dose).
2992221|NCT02614742|Active Comparator|SFX-01|300mg bid for up to 28 days.
2992222|NCT02614742|Placebo Comparator|Placebo|300mg placebo bid for up to 28 days
2992223|NCT02614729|Experimental|Energy Balance Comparison|"Participants will randomly consume 4 eucaloric diets for 7 consecutive days/treatment. Energy levels for all diets are established according to needs for energy balance.~Interventions:~Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN); Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN); High Protein-Beef, Even Distribution (HP-BEEF-EVEN); High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)"
2992224|NCT02614729|Experimental|Energy Restriction Comparison|"Participants will randomly consume 3 energy restriction diets (1250 kcal/day) for 7 consecutive days/treatment. Energy levels for all diets are established according to needs for energy restriction.~Interventions:~Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN); Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN); High Protein-Beef, Even Distribution (HP-BEEF-EVEN)"
2992225|NCT02614716|Experimental|LY3090106|LY3090106 given subcutaneously (SC) in escalating dose cohorts once every 2 or 4 weeks for 16 weeks.
2992226|NCT02614716|Placebo Comparator|Placebo|Placebo given subcutaneously (SC) once every 2 or 4 weeks for 16 weeks.
2992227|NCT02614703|Experimental|Chromoendoscopy using Acetic Acid 2.5%|Patient will have endoscopic examination of esophagus. Esophageal mucosa sprayed with 5cc solution of Acetic Acid 2.5% one time only. Esophageal mucosa examined again. Biopsies are obtained. Abnormal areas identified by Acetic Acid 2.5% will be submitted on separate containers for pathology review. If no abnormalities seen, random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
2992228|NCT02614703|Active Comparator|Standard random esophageal biopsies|Patient will have endoscopic examination of the esophagus. Esophageal mucosa will not be sprayed with Acetic Acid 2.5%. Random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
2992229|NCT02614690|Active Comparator|No split Cast of forearm fractures|"Patient will have a No split cast long arm cast applied after a closed reduction of forearm fractures. The cast will not be split. 20 patients will be randomized to this arm."
2992230|NCT02614690|Active Comparator|Univalve Split Cast of forearm fractures|"Patients will have a Univalve Split Cast long arm cast applied after undergoing closed reduction of of forearm fractures. This is a cast that is split on only one side of the cast. 20 patients will be randomized to this arm"
2992231|NCT02614690|Active Comparator|Bivalve Split Cast of forearm fractures|"Patients will have a Bivalve Split Cast long arm cast applied after they have undergone a closed reduction of of forearm fractures. This is a cast that will be split on both sides of the cast. 20 patients will be randomized to the bivalve split arm cast."
2992232|NCT02614664||Single ventricle|Patients with single ventricle physiology presenting for laparoscopic procedures.
2992233|NCT02614651|Experimental|The study population|"The study population consists of subjects with a concentric constriction of the visual field (retinitis pigmentosa, glaucoma) whose motor capacity allows the use of a computer keyboard with one hand. Subjects are recruited on a voluntary basis, from information disseminated to professionals in the rehabilitation of functional low vision and patient associations, in the Ophthalmology Service of the University Hospital of Nimes and within the ARAMAV Institute.~Intervention: Find visual comfort threshold related to light intensity~Intervention: Find the size of the visual field~Intervention: Effectiveness of brightness control~Intervention: Performance of color correction~Intervention: Vuzix Wrap 1200DX virtural reality glasses"
2992234|NCT02614638|Active Comparator|1st observational period (before experimental intervention)|"Patients in this arm are included during a first month of observation before the intervention is implemented.~Intervention: One month of department-wide observation"
2992235|NCT02614638|Experimental|2nd obs. period (during experimental intervention)|"Following a one-month wash-out period, patients in this arm are included during a second month of observation during which the intervention is implemented.~Intervention: Pharm Tech participates in department"
2992236|NCT02614625||Normal subjects|Patient with healthy, normal eyes
2992237|NCT02614625||Eyes with corneal disease|"Subjects that have any of the following conditions~Corneal dystrophy or degeneration~Corneal scarring~Corneal ulcer~Corneal injury~Keratoconus~Patients who had undergone corneal surgery~Patients with other corneal disease"
2992238|NCT02614625||Eyes with retinal disease|"Subjects that have any of the following conditions:~Diabetic macular edema~Cystoid macular edema~Age related macular degeneration~Retinal vascular disorders (e.g. retinal artery occlusion)~Epiretinal membrane~Choroidal nevus~Macular hole~Patients who had undergone retinal surgery~Patients with other retinal disease"
2992239|NCT02614625||Eyes with glaucoma|Eyes diagnosed with glaucoma of any type and any stage
2992240|NCT02614612|Experimental|Itacitinib (200 mg)|Itacitinib (200 mg) + prednisone or methylprednisolone (corticosteroids)
2992241|NCT02614612|Experimental|Itacitinib (300 mg)|Itacitinib (300 mg) + prednisone or methylprednisolone (corticosteroids)
2992242|NCT02614599|Experimental|BP22042013|This group of patients receive 2.000 kilocalories diet(60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
2992243|NCT02614599|Experimental|Low carbohydrate Diet|the second group of patients receive diet of 2.000 Kilo calories without rapidly absorbed carbohydrates and without proteins supplements
2992244|NCT02614586|Experimental|Placebo + TAK-058 + Ondansetron|TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 milligram (mg), solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally along with TAK-058 placebo-matching solution, orally, on Day 1 of third intervention period (2 days).
2992245|NCT02614586|Experimental|TAK-058 + Placebo + Ondansetron|TAK-058 150 mg, solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of third intervention period (2 days).
2992246|NCT02614586|Experimental|Ondansetron + Placebo + TAK-058|Ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
2992247|NCT02614586|Experimental|Placebo + Ondansetron + TAK-058|TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
2992248|NCT02614586|Experimental|TAK-058 + Ondansetron + Placebo|TAK-058 150 mg, solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
2992303|NCT02614196|Placebo Comparator|Placebo|Placebo given by SC injection once a month for 6 months.
2992304|NCT02614196|Experimental|Galcanezumab 120mg Maximum Extended Enrollment Cohort|Galcanezumab 240mg given as loading dose followed by galcanezumab 120mg once a month for 5 months by by subcutaneous (SC) injection.
2992249|NCT02614586|Experimental|Ondansetron + TAK-058 + Placebo|Ondansetron 16 mg, capsule, orally along with TAK-058 placebo-matching solution, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
2992250|NCT02614573|Experimental|The study population|The clinical phases of this study will be held in the nursing home (EHPAD; principal building + 2 annexes) of Pont-Saint-Esprit, located in France. Patients are elderly dependents treated by anti-vitamin K for more than 6 months.
2992251|NCT02614560|Experimental|Pre-allo (before stem cell transplant)|Pre-allo reduced intensity chemotherapy vadastuximab talirine (melphalan and fludarabine)
2992252|NCT02614560|Experimental|Post-allo (after stem cell transplant)|Post-allo vadastuximab talirine
2992253|NCT02614547|Active Comparator|SAGE-547|Intravenous
2992254|NCT02614547|Placebo Comparator|Placebo|Intravenous
2992255|NCT02614508|Experimental|Cohort A (buparlisib, ofatumumab)|Patients receive buparlisib PO QD on days 1-28 and ofatumumab IV on days 1, 8, 15, and 22 during of courses 1-2; and day 1 of courses 4-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2992256|NCT02614508|Experimental|Cohort B (buparlisib, ibrutinib)|Patients receive buparlisib as in Cohort A and ibrutinib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2992257|NCT02614495|Experimental|Sulfatinib|Sulfatinib 300mg once-daily
2992258|NCT02614482|Experimental|Fesoterodine 4mg|Fesoterodine 4 mg Po Die, dose could be increased to 8mg Po Die after 1 month and 4 months.
2992259|NCT02614469|Experimental|Group 1, Inosine with Food|Group 1 subjects will take inosine with food on day 1 after an overnight fast and will take a second dose of inosine without food on day 8 after an overnight fast.
2992260|NCT02614469|Experimental|Group 2, Inosine without Food|Group 2 subjects will take inosine without food on day 1 after an overnight fast and will take a second dose of inosine with food on day 8 after an overnight fast.
2992261|NCT02614456|Experimental|Interferon-gamma and nivolumab|"Interferon-gamma (IFN-γ): starting dose 50 mcg/m2 subcutaneously Nivolumab: 3 mg/kg intravenously~Induction phase: IFN-γ every other day alone for 1 week Combination phase: IFN-γ every other day & Nivolumab every 2 weeks for 3 months Single agent phase: Nivolumab every 3 weeks up to 1 year"
2992262|NCT02614443|Experimental|Depression Condition|Participants in this group will be offered the Space from Depression programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
2992263|NCT02614443|Experimental|Anxiety Condition|Participants in this group will be offered the Space from Anxiety programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
2992264|NCT02614443|Experimental|Stress Condition|Participants in this group will be offered the Space from Stress programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
2992265|NCT02614430|Active Comparator|Vocational training|Participants are randomized into the intervention group (training) where they are offered a training course of 4-9 weeks of physical training three times a week with a physiotherapist.
2992266|NCT02614430|No Intervention|Control|Participants are randomized into the control group where they are offered the standard treatment.
2992267|NCT02614417||Polysomnography|Patients undergo an one-night in-hospital polysomnography to diagnose sleep-disordered breathing
2992268|NCT02614404|Experimental|Imatinib|Dose escalation study of imatinib, 400mg/day, 600mg/day, 800mg/day, to determine the efficacy of each imatinib treatment in eliminating parasitemia along with the safety and tolerability of each treatment. Standard of care rescue drug is dihydroartemisinin-piperaquine.
2992269|NCT02614391|Experimental|Active distraction using a tablet|Children were admitted in a comfortable room with a parent and started to play with a videogame suitable for their age three minutes before procedure. They continued to play the videogame during venipuncture. The use of a computer tablet permitted to play with one hand only.
2992270|NCT02614391|Active Comparator|Passive distracion|Children were admitted in a comfortable room with a parent and received various kinds of passive distractions: nurses singing a song, reading a book, blowing bubbles and playing a puppet show. The technique that most engaged the child, was continued during procedure.
2992271|NCT02614378|Active Comparator|Subject receiving treatment|participant receiving air insufflation
2992272|NCT02614378|Placebo Comparator|Subject receiving placebo|participant not receiving air insufflation
2992273|NCT02614365|Experimental|Aerobic Exercise|6-month 3-time/week aerobic exercise, and a 12-month passive follow-up.
2992274|NCT02614365|Active Comparator|Stretch Exercise|6-month 3-time/week stretch exercise, and a 12-month passive follow-up.
2992275|NCT02614352|Experimental|AG1502|
2992276|NCT02614352|Active Comparator|Candesartan + Atorvastatin|
2992277|NCT02614339|Experimental|metformin|
2992278|NCT02614339|Active Comparator|control|
2992279|NCT02614326|Experimental|Memory Flexibility (MemFlex) Training|MemFlex training draws on cognitive bias modification and memory specificity training techniques (Raes et al., 2009; Dalgleish et al., 2014). MemFlex is primarily self-guided and aims to reduce autobiographical memory biases associated with depression. The training is presented over one face-to-face session and eight self-guided sessions. In the initial session, the researcher introduces cued-recall tasks used throughout the workbook, and guides the participant in completion of the tasks. When understanding of the basic principles is satisfactory, the researcher assists the participant to set a schedule for completion of the workbook over the following four weeks. The participant will receive a phone call at the beginning of week three to check progress, and clarify any difficulties.
2992305|NCT02614196|Experimental|Galcanezumab 240mg Maximum Extended Enrollment Cohort|Galcanezumab 240mg given by SC injection once a month for 6 months.
2992306|NCT02614196|Placebo Comparator|Placebo Maximum Extended Enrollment Cohort|Placebo given by SC injection once a month for 6 months.
2992307|NCT02614183|Experimental|Galcanezumab 120mg|Galcanezumab given by subcutaneous (SC) injection at 120mg dose once a month for 6 months. Participants received a loading dose of 240mg (2 injections of 120mg each) was administered at visit 3 only.
2992280|NCT02614326|Placebo Comparator|Psychoeducation|The psychoeducation condition will also complete an initial face-to-face session. This session will cover the symptoms and causes of depression, and the workbook will be introduced. The workbook will consist of eight self-guided sessions that the individual will be required to complete over four weeks. The workbook content will cover the presentation of depression and basic information on factors associated with depression, such as worry, procrastination, and sleep difficulties. Each session consists of psychological theories of the topic, followed by a series of questions about the material to ensure participant engagement. The participant will receive a phone call from a team member at the beginning of week three to check progress, and clarify any difficulties.
2992281|NCT02614313|Active Comparator|Fructose double-blind|Fructose during breath test, double-blind 35g
2992282|NCT02614313|Active Comparator|Fructose open|Fructose during breath test, open 35g
2992283|NCT02614313|Placebo Comparator|Sweet placebo double-blind|Assugrin during breath test double-blind
2992284|NCT02614313|Placebo Comparator|Neutral placebo double-blind|Water during breath test double-blind
2992285|NCT02614300|Active Comparator|Pulmonary Rehabilitation|These sessions will be individually designed and they will be a combination of global aerobic interval training using a cycloergometer. The aim is to achieve a training intensity of 80% HR or greater of the obtained during the ISWT. This intensity will be progressively increased during the firsts four weeks until achieving the target. The duration will be of about 45 minutes per session. Oxygen Saturation, HR and Borg scale for dyspnoea and fatigue will be measured before, during and at the end of the session in order to monitories the effort.
2992286|NCT02614300|Active Comparator|Chest Physiotherapy|"The ELTGOL technique (total slow expiration with glottis open in lateral decubitus) for airways clearance will be used in order to move respiratory secretions from the distal bronchial tree. It will be applied during 15 minutes each side (right and left lungs) assuming an approximate session length of 30 minutes. The patient could perform the cough technique when it's necessary."
2992287|NCT02614300|Active Comparator|Pulmonary Rehabilitation and Chest Physiotherapy|"This group will perform a combination of the two programs in the same session with a total duration of 1h and 15 minutes. The session will be divided in different parts: First, we will execute 15min of chest physiotherapy (7.5min for each side); second, the pulmonary rehabilitation session (45min) and finally, another 15min of chest physiotherapy (7.5min for each side). The patient will have a rest when it's necessary and we will continue with the session when there is a decrease of 2 points in the Borg scale.~Intensity of physiotherapy exercises and drainage techniques will be maintained similar to the PR and CP programs."
2992288|NCT02614300|No Intervention|Control Group|"For the control group, participants will attend educational sessions to improve patients' understanding and awareness of the respiratory diseases. These sessions will be performed at beginning and at 12 weeks by the physiotherapist and the pulmonologist.~The physiotherapist will also do monthly telephone calls for patient's monitoring."
2992289|NCT02614287|Experimental|Galcanezumab 120 mg|Galcanezumab 240mg given as loading dose at first dosing visit followed by 120 mg given by subcutaneous (SC) injection once a month for up to 11 months by auto injector or pre-filled syringe.
2992290|NCT02614287|Experimental|Galcanezumab 240 mg|Galcanezumab 240 mg given by SC injection once a month for up to 12 months by auto injector or pre-filled syringe.
2992291|NCT02614274|Experimental|Nutraceutical joint health formulation|A Proprietary Blend
2992292|NCT02614261|Experimental|Galcanezumab 120 mg|"Galcanezumab 120 mg given by subcutaneous (SC) injection once a month for 3 months.~Participants may be eligible for optional open label extension at the end of the double blind period with dose level 1 or dose level 2."
2992293|NCT02614261|Experimental|Galcanezumab 240 mg|"Galcanezumab 240 mg given by SC injection once a month for 3 months.~Participants may be eligible for optional open label extension at the end of the double blind period with dose level 1 or dose level 2."
2992294|NCT02614261|Placebo Comparator|Placebo|"Placebo given by SC injection once a month for 3 months.~Participants may be eligible for optional open label extension at the end of the double blind period with dose level 1 or dose level 2."
2992295|NCT02614248|Experimental|Coconut Oil|Participants in this group will receive a generous layer of organic, unrefined coconut oil applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding).
2992296|NCT02614248|Active Comparator|Standard of Care|Participants in this group will receive the standard of care for preventing and treating diaper dermatitis at Genesis. This includes no treatment until a diaper dermatitis appears. If diaper dermatitis appears, participants will receive a generous layer of Medline Remedy Phytoplex Z-Guard Skin Protectant applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding).
2992297|NCT02614235|Experimental|Pocket-ECG III System|After signing written informed consent, a Pocket-ECG III® system will be given to the patient. All participants will be monitored by the Pocket-ECG® system until a diagnosis is achieved or for a maximum of two months (whatever it happens first). Everyday daily reports sent via e-mail by the manufacturer company (MEDICALgorithmics© S.A.) will be reviewed by the investigator team; in case of a diagnosis event (according to prespecified diagnostic criteria from the European Society of Cardiology), appropriate treatment will be applied.
2992298|NCT02614235|Active Comparator|Conventional Holter|Every patient will be his/her own control. Conventional 24-hours Holter monitoring will be simulated using data obtained by the Pocket-ECG III® system in the first 24 hours, ignoring the registries of the rest of days. Two and Three 24-hours conventional Holter strategies will also be simulated analyzing data from first 24 hours and 1-2 additional days, respectively, chosen by means of a random number creation system which will identify the days of registry to be considered.
2992299|NCT02614222|Experimental|Peripheral Nerve Block with CAIG|The participants in this group (test group) will utilize the same procedure utilizing existing ultrasound equipment with the supplemental CAIG system.
2992300|NCT02614222|No Intervention|Peripheral Nerve Block without CAIG|The participants in the control group will receive the procedure with traditional ultrasound methods and equipment.
2992301|NCT02614196|Experimental|Galcanezumab 120mg|Galcanezumab 240mg given as loading dose followed by galcanezumab 120mg once a month for 5 months by by subcutaneous (SC) injection.
2992308|NCT02614183|Experimental|Galcanezumab 240mg|Galcanezumab 240mg given by SC injection once a month for 6 months.
2992309|NCT02614183|Placebo Comparator|Placebo|Placebo given by SC injection once a month for 6 months.
2992310|NCT02614157|Experimental|LLND+TME group|advanced rectal cancer patients after neoadjuvant chem-radiation with suspicious lateral lymph nodes involvement undergo lateral lymph node dissection and total mesorectal excision(LLND+TME)
2992311|NCT02614157|No Intervention|TME group|advanced rectal cancer patients after neoadjuvant chem-radiation with suspicious lateral lymph nodes involvement undergo total mesorectal excision (TME)solely, without LLND
2992312|NCT02614131|Experimental|LY2599666 (Part A)|LY2599666 given subcutaneously (SC) once.
2992313|NCT02614131|Placebo Comparator|Placebo (Part A)|Placebo matching LY2599666 given SC once.
2992314|NCT02614131|Experimental|LY2599666 (Part B)|LY2599666 given SC once weekly for 12 weeks (13 doses).
2992315|NCT02614131|Placebo Comparator|Placebo (Part B)|Placebo given SC once weekly for 12 weeks (13 doses).
2992316|NCT02614131|Experimental|Solanezumab (Part C)|Solanezumab given intravenously (IV) once weekly or once every 4 weeks for 12 weeks.
2992317|NCT02614131|Placebo Comparator|Placebo (Part C)|Placebo given IV once weekly or once every 4 weeks for 12 weeks.
2992318|NCT02614118|Active Comparator|Ketorolac tromethanine|10 mg oral Ketorolac tromethanine 45 minutes before root canal treatment
2992319|NCT02614118|Active Comparator|Acetaminphen & Ketorolac tromethamine|1000 mg Acetaminophen and 10 mg Ketorolac tromethamine oral 45 minutes before root canal treatment
2992320|NCT02614118|Placebo Comparator|Placebo|placebo 45 minutes before root canal treatment
2992321|NCT02614105|Experimental|Pelvic floor muscle training|Participants in the pelvic floor muscle training group will receive group exercise sessions (1 hour) at the physiotherapy out-patient department of the hospital once a week for 16 weeks with guidance from an experienced pelvic floor physiotherapist. The group exercise sessions will focus on pelvic floor muscle training, relaxation and breathing techniques. Participants in the pelvic floor muscle training group will also receive an individually adapted pelvic floor muscle training program for daily home use.
2992322|NCT02614105|Experimental|Cough-suppression|Participants in the cough-suppression group will receive a group education session with general information about cough-suppression therapy and advice about how to distinguish between unproductive and productive cough to enable them to perform airway clearance techniques when required. In addition, participants will receive one to two individual sessions (30-60 minutes) of cough-suppression therapy tailored to the individual needs based on symptoms and underlying disease activity
2992323|NCT02614105|Experimental|Control group|Participants in the group will receive guidance and instruction in terms of correct contraction of the pelvic floor muscles at clinical assessment. Control group participants will receive brief written information about pelvic floor muscle training and cough-suppression therapy, but no other form of regular follow-up or intervention throughout the intervention period.
2992324|NCT02614092|Experimental|Water based Activity+ Cognitive Training|water-based physical activity + classroom based cognitive training
2992325|NCT02614079|Experimental|DSSEP|DSSEP testing after SCS trial lead placement
2992326|NCT02614066|Experimental|Single Arm|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR+ T cells/kg
2992327|NCT02614040|Active Comparator|0.9% Saline|Patients in a month randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
2992328|NCT02614040|Active Comparator|Physiologically-balanced|Patients in a month randomized to physiologically-balanced isotonic fluid will receive physiologically-balanced isotonic crystalloid (Plasma-Lyte© A or Lactated Ringer's) whenever isotonic intravenous fluid administration is ordered by the treating provider.
2992329|NCT02614014|Experimental|Psychological intervention|Cognitive-behavior interventional program
2992330|NCT02614014|No Intervention|Control|No intervention
2992331|NCT02614001|Experimental|inspiratory muscle training, stroke rehabilitation|Inspiratory muscle training with a pressure threshold device (Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA) will be start at a resistance equal to 30% of their MIP or at a load which patient can tolerate, and then the loading will be gradually increased 2cm H2O per week or as symptom tolerated and according to the RPE scale. Each patient will receive regular post-stroke rehabilitation program.
2992332|NCT02614001|Other|control group|stroke rehabilitation.
2992333|NCT02613988|Other|MR imaging and standard treatment|Patients with glioblastoma undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and perfusion (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent) at pre-CCRT; 4 weeks after completion of the CCRT; and every 2 or 3 months during the adjuvant temozolomide therapy.
2992334|NCT02613975|Experimental|on positional device|patients who could not tolerate cpap will be provided with positional device for treatment of OSA which will vibrate when patients lie in prone position
2992335|NCT02613975|Experimental|patients on dental device|patients on dental devices but not optimally treated for OSA will be provided positional device for optimization of treatment for OSA, which will vibrate when patients lie in prone position
2992336|NCT02613962|Experimental|relapsed or refractory pediatric tumor|This is a prospective, international, multicentric clinical proof-of-concept study to stratify targeted therapies adapted to molecular profiling of relapsed or refractory pediatric tumors. The molecular screening will be done on a newly biopsied or resected tumor sample obtained at the time of relapse/progression, using high-throughput technologies, primarily WES and RNA Sequencing, and bioinformatics analysis.
2992337|NCT02613949|Active Comparator|12-week RINCE mode 1|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device at treatment mode 1
2992338|NCT02613949|Active Comparator|12-week RINCE mode 2|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device at treatment mode 2
2992339|NCT02613949|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
2992340|NCT02613936|Experimental|Active anodal tDCS + cognitive training|In this arm, 40 patients with mmTBI will undergo 10 sessions of active tDCS x 30 minutes combined with simultaneous cognitive training on consecutive weekdays.
2992341|NCT02613936|Sham Comparator|Placebo anodal tDCS + cognitive training|In this arm, 40 patients with mmTBI will undergo 10 sessions of placebo tDCS x 30 minutes combined with simultaneous cognitive training on consecutive weekdays.
2992342|NCT02613923|Experimental|GO! To Sleep|Participants in the intervention group will be provided with a code and website address to participate in this program. This program includes reminder emails and is 6 weeks in duration. Participants will be given a blood draw to measure biomarkers.
2992343|NCT02613923|Active Comparator|informational control|Participants in the control group will receive weekly emails with sleep information and the health benefits of sleep for 6 weeks.Participants will be given a blood draw to measure biomarkers.
2992344|NCT02613910|Experimental|Ofatumumab|t the Baseline (Bln) and wk 4 visits, Subjects will receive 40mg ofatumumab sc (Oft) (as two 20mg sc inj) and as 1 Oft 20mg sc inj every 4 wks from wk 8 through wk 56. Subjects will return to clinic 4 wks after the last dose for a follow-up (f/u) visit (wk 60). Antihistamine 10 mg and Acetaminophen/paracetamol (A/P) 1 grams(g) will be given 1-2 hours(h) before and 4 h after each dose of Oft. A/P 1 g will be supplied for self administration if needed. Prednisone/Prednisolone dose will continue to be tapered during core study period (CSP) by 1 dose level every 2 wks to <= 10 mg/day from Bln through wk 60. Upon completion of the CSP, subjects will enter Individualized f/u Period, where subjects will monitored every 12 wks for a minimum of 1 yr and for up to 2 yr, until CD19+ B-LC or IgG recover to lower limit of normal (LLN) or to the subject's Bln value from Study OPV116910 (if <LLN) or if study withdrawal criteria are met or for a maximum of 2 yr after the last dose of Oft.
2992345|NCT02613897|Active Comparator|Saxa/Dapa + Metn and/or Met+SU|Saxagliptin 5mg + Dapagliflozin 10mg plus metformin or metformin plus sulfonylurea.
2992346|NCT02613897|Active Comparator|Dapa + Met or Met + SU.|Dapagliflozin 10mg plus metformin or metformin plus sulfonylurea.
2992347|NCT02613897|Placebo Comparator|Placebo|Placebo for saxagliptin + placebo for dapagliflozin plus metformin or metformin plus sulfonylurea.
2992348|NCT02613884|Experimental|Treatment|All patients with a 25OHD level <30 ng/dL will be given 250,000 IU D3 (cholecalciferol) orally at one point in time and during CF clinic.
2992349|NCT02613871|Experimental|LDV/SOF|LDV/SOF FDC for 12 weeks
2992350|NCT02613845||Cardiac surgery|Study subjects are all patients who underwent cardiac surgery with cardiopulmonary bypass at the University Hospital Basel during the year 2013.
2992351|NCT02613832|Experimental|EPAP Group|The EPAP devices increase the alveolar pressure. This effect is obtained through valves that generate a resistance to airflow during expiration.
2992352|NCT02613832|Experimental|Breath Stacking Group|The Breath Stacking consists on the implementation of subsequent inspiratory efforts through a one way valve, which allows stacked volume of gas during each inspiration, until it reaches a maximum lung volume.
2992353|NCT02613819|Experimental|Stereotactic Ablative Body Radiotherapy|"Stereotactic Ablative Body Radiotherapy (SABR)~Treatment schedule 1: 26 Gray (Gy) in 1 fraction, for tumours of less than or equal to 4cm in size.~Treatment schedule 2: 42 Gray (Gy) in 3 fractions, for tumours of greater than 4cm in size"
2992354|NCT02613806|Experimental|D group (dexmedetomidine)|Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion with microperfusion pump at the beginning of the surgery,and continued till end of surgery.
2992355|NCT02613806|Active Comparator|C group (saline)|The patients received equal volume normal saline by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
2992356|NCT02613793||Preterm pre-eclampsia (cases)|Pregnant patients diagnosed with pre-eclampsia prior to 35 weeks gestation
2992357|NCT02613793||Pregnant patients (controls)|Age- and gestation-matched pregnant patients who are not suffering with pre-eclampsia, hypertensive disease or any other neuropsychiatric condition
2992358|NCT02613780|Active Comparator|Sequential group|Photorefractive keratectomy will be performed 12-18 months after participants had crosslinking
2992359|NCT02613780|Active Comparator|Simultaneous group|Photorefractive keratectomy and crosslinking will be performed on the same day
2992360|NCT02613767||Obese|"BMI >30 kg/m2, Protein meal,~L-[ring 13C6]Phenylalanine infusion"
2992361|NCT02613767||Overweight|"BMI >25 and < 30 kg/m2, Protein meal,~L-[ring 13C6]Phenylalanine infusion"
2992362|NCT02613767||Healthy-Weight|"BMI >18 and < 25 kg/m2, Protein meal,~L-[ring 13C6]Phenylalanine infusion"
2992363|NCT02613754|Experimental|Contingency Management|Contingency Management (CM+): This procedure is designed to reinforce treatment attendance, non-gambling behaviour, and study completion. Participants will earn points that will be recorded on vouchers that could be subsequently redeemed for gift cards at a variety of local businesses. Submission of evidence of gambling behaviour or non-attendance re-sets the point value for future vouchers to the starting level. This intervention is in addition to Treatment as Usual.
2992364|NCT02613754|Active Comparator|Treatment as Usual|Treatment as Usual (TAU): This is typically a semi-structured approach for delivering cognitive behavioural therapy addressing the participant's experiences, thoughts, and emotions relating to their gambling.
2992365|NCT02613741|Experimental|Intervention|12 weeks of lifestyle-based physical activity intervention
2992366|NCT02613741|No Intervention|Control|12 weeks of no intervention
2992367|NCT02613728|Active Comparator|Standard of Care Arm|Standard enhanced care following minimally invasive colorectal cancer surgery
2992368|NCT02613728|Experimental|Intervention (RecoverMI) Arm|Routine care with Accelerated Recovery Plan, Early Discharge, and Telemedicine following minimally invasive colorectal cancer surgery
2992369|NCT02613715|Experimental|Blackberry juice with 12% ethanol|250 ml of blackberry juice freshly prepared with 250 g fresh blackberries, 80 ml alcohol beverage (38%) and 17 g sugar.
2992370|NCT02613715|Experimental|Blackberry juice|250 ml of blackberry juice freshly prepared with 250 g fresh blackberries, 80 ml water and 17 g sugar.
2992371|NCT02613702|Experimental|Modified Free Gingival Graft|Twenty patients will receive the modified free gingival graft technique at the inferior incisors area. In this technique, the graft is covered by a flap, similarly to what is done in a connective tissue graft surgery.
2992372|NCT02613702|Active Comparator|Original Free Gingival Graft technique|Twenty patients will receive the original technique of free gingival graft at the inferior incisors area.
2992373|NCT02613689|Experimental|Scheduled Gradual Reduction (SGR)|Subjects will receive the Scheduled Gradual Reduction (SGR) intervention, as well as SMS support text messages.
3018434|NCT02439983|Experimental|Proprietary Nutritional Supplement|
2992375|NCT02613676|Experimental|TcB screening before discharge|Participants in this group will be screened for jaundice using the JM 105 transcutaneous device. The TcB value will be plotted on the Bhutani nomogram to assess the risk category. Infants who are categorised as high risk according to the nomogram will require blood sampling for TsB and assessment for need for phototherapy.
2992376|NCT02613676|Other|Standard care (visual inspection)|Participants in this group will be managed routinely according to the current standard of care where babies are assessed for jaundice by visual inspection. Babies in this group will require blood draw for TsB if there are visibly jaundiced
2992377|NCT02613663|Experimental|immediate implants with nanobone graft|Nano-hydroxyapatite bone graft fill the gap between immediate implant and labial bone wall.
2992378|NCT02613663|Active Comparator|immediate implants with autogenous bone graft|Autogenous graft fill the gap between immediate implant and labial bone wall.
2992379|NCT02613650|Experimental|MEK162 and mFOLFIRI, all patients|
2992380|NCT02613598|Experimental|Bortezomib and Ruxolitinib|Bortezomib on days 1, 4, 8, and 11 of a 21 day cycle in combination with Ruxolitinib (5, 10, 15, 20, or 25 mg) twice daily.
2992381|NCT02613585|Experimental|Permethrin Impregnated Clothing|Uniforms and work clothing (including pants, shorts, shirts, socks, and hats) treated with long-lasting permethrin by Insect Shield.
2992382|NCT02613585|No Intervention|Untreated Clothing|Uniforms and work clothing sent to Insect Shield, washed and refolded (no permethrin applied).
2992383|NCT02613572|Experimental|alpha lipoic acid (ALA) 600mg once daily x 5 days|All 15 patients recruited to the Phase I part will take escalating doses of alpha lipoic acid (ALA) open label. Each enrolled subject will take 600 mg of oral ALA once daily with a meal for 5 days. If well-tolerated, each subject will then take 800 mg of oral ALA once daily with a meal for 5 additional days. If 800 mg of oral ALA is well-tolerated, then subjects will then take 1200 mg of oral ALA once daily with a meal for 5 days.
2992384|NCT02613572|Experimental|alpha lipoic acid 800mg|once daily with meal x 5 days
2992385|NCT02613572|Experimental|alpha lipoic acid 1200mg|once daily x 5 days
2992386|NCT02613572|Placebo Comparator|Placebo 600mg|All 50 subjects in Phase II will be double blinded and randomized to either placebo or ALA. Each will take one 600mg capsule of ALA (or placebo) once daily with a meal for 2 weeks and then increase to two 600 mg capsules of ALA (or placebo) once daily with a meal for the
2992387|NCT02613572|Experimental|ALA 600 mg|once daily with a meal for 2 weeks
2992388|NCT02613572|Placebo Comparator|Placebo 1200mg|Two 600mg capsules once daily with a meal for the entire remainder of the 18 month period of the study
2992389|NCT02613572|Experimental|ALA 1200mg|Two 600mg capsules once daily with a meal for the entire remainder of the 18 month period of the study
2992390|NCT02613559|Experimental|TK001 0.1mg|Injection:single Intravitreal Injection
2992391|NCT02613559|Experimental|TK001 0.5mg|Injection:single Intravitreal Injection
2992392|NCT02613559|Experimental|TK001 1.0mg|Injection:single Intravitreal Injection
2992393|NCT02613559|Experimental|TK001 2.0mg|Biological: TK001 Injection:single Intravitreal Injection
2992394|NCT02613559|Experimental|TK001 2.5mg|Biological: TK001 Injection:single Intravitreal Injection
2992395|NCT02613559|Experimental|TK001 3.0mg|Injection:single Intravitreal Injection
2992396|NCT02613546|Experimental|Cognitive behavioral therapy (CBT)|"The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:~evaluation session;~sessions of psychoeducation about the CBT model~5 sessions of cognitive restructuring 2 sessions of preventing relapse"
2992397|NCT02613546|Other|Control|The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
2992398|NCT02613533|Experimental|Narrow Angle Glaucoma Study Group|Subjects will be given 10ml/kg of water over 15 min prior to surgery and Intra-ocular pressure measurement (IOP) is checked every 15 min before and after surgical procedure.
2992399|NCT02613520|Experimental|Group 1a (PfSPZ Vaccine)|18- 45 years; n=6; 3 doses of 9 x 10^5 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
2992400|NCT02613520|Placebo Comparator|Group 1a (normal saline)|18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
2992401|NCT02613520|Other|Group 1a (CHMI controls)|18- 45 years; n=3; volunteers will not receive any intervention, but will serve only as infectivity controls for the CHMI for Group 1a. Volunteers will be injected with PfSPZ Challenge (for CHMI).
2992402|NCT02613520|Experimental|Group 1b (PfSPZ Vaccine)|18- 45 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
2992403|NCT02613520|Placebo Comparator|Group 1b (normal saline)|18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
2992404|NCT02613520|Other|Group 1b (CHMI controls)|18- 45 years; n=3; volunteers will not receive any intervention, but will serve only as infectivity controls for the CHMI for Group 1b. Volunteers will be injected with PfSPZ Challenge (for CHMI).
2992405|NCT02613520|Experimental|Group 2a (PfSPZ Vaccine)|11-17 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
2992406|NCT02613520|Placebo Comparator|Group 2a (normal saline)|11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.
2992407|NCT02613520|Experimental|Group 2b (PfSPZ Vaccine)|11-17 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart.
2992408|NCT02613520|Placebo Comparator|Group 2b (normal saline)|11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.
2992409|NCT02613520|Experimental|Group 3a (PfSPZ Vaccine)|6-10 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
2992410|NCT02613520|Placebo Comparator|Group 3a (normal saline)|6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.
2992411|NCT02613520|Experimental|Group 3b (PfSPZ Vaccine)|6-10 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart.
2992412|NCT02613520|Placebo Comparator|Group 3b (normal saline)|6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.
2992413|NCT02613520|Experimental|Group 4a (PfSPZ Vaccine)|1-5 years; n=6; 3 doses of 4.5 x 10^5 PfSPZ Vaccine given 8 weeks apart.
2992414|NCT02613520|Placebo Comparator|Group 4a (normal saline)|1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.
2992415|NCT02613520|Experimental|Group 4b (PfSPZ Vaccine)|1-5 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
2992416|NCT02613520|Placebo Comparator|Group 4b (normal saline)|1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.
2992417|NCT02613520|Experimental|Group 5a (PfSPZ Vaccine)|6-11 months; n=3; 1 dose of 2.7 x 10^5 PfSPZ Vaccine.
2992418|NCT02613520|Experimental|Group 5b (PfSPZ Vaccine)|6-11 months; n=6; 3 doses of 4.5 x 10^5 PfSPZ Vaccine given 8 weeks apart.
2992419|NCT02613520|Placebo Comparator|Group 5b (normal saline)|6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.
2992420|NCT02613520|Experimental|Group 5c (PfSPZ Vaccine)|6-11 months; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
2992421|NCT02613520|Placebo Comparator|Group 5c (normal saline)|6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.
2992422|NCT02613507|Experimental|Arm A: Nivolumab|Nivolumab Intravenous infusion specified dose on specified days
2992423|NCT02613507|Active Comparator|Arm B: Docetaxel|Docetaxel Intravenous infusion specified dose on specified days
2992424|NCT02613494|Active Comparator|Hyoscine|Hyoscine hydrobromide
2992425|NCT02613494|Active Comparator|Glycopyrrolate|Glycopyrronium bromide
2992426|NCT02613494|Placebo Comparator|Placebo|Placebo
2992427|NCT02613481|Other|Poly-L-Lactic Acid (Sculptra) injection|Poly-L-Lactic Acid (Sculptra) injection for all enrolled subjects
2992428|NCT02613468|Placebo Comparator|Periodontally healthy|"Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.~Intervation: Collection of periodontal records and pregnancy parameters."
2992429|NCT02613468|Placebo Comparator|Periodontally diseased, untreated|"This group is comprised of individuals who do not accept treatment Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit were evaluated.~Birth weight was recorded at the end of pregnancy."
2992430|NCT02613468|Active Comparator|Periodontally diseased, treated|"This group is comprised of individuals who agree to treatment. Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit were evaluated.~Initial Periodontal Therapy is completed (calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.~Birth weight was recorded at the end of pregnancy. Intervation: Collection of periodontal records and pregnancy parameters."
2992431|NCT02613455|Active Comparator|Kenalog (triamcinolone )|Patients assigned to the corticosteroid arm will receive an intratendinous injection of 1cc Kenalog-40 (triamcinolone-40mg) + 2cc lidocaine 1% by an attending orthopaedic hand surgeon in clinic. They will be provided a home stretching regimen for lateral epicondylitis. They will be discouraged from using nonsteroidal anti-inflammatory drugs . No additional physical or occupational therapy will prescribed.
2992432|NCT02613455|Active Comparator|extracorporeal shock wave therapy|Following clearance, patients will be booked for ESWT in the operating room either Walter Reed National Military Medical Center (WRNMMC) or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24 kilovolts, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.
2992433|NCT02613429|Active Comparator|Cranial horizontal|identification of the airway by from the cranial end. Marking of the airway, including the cricothyroid membrane, on the skin, by starting the examination from the cranial end at the level of the thyroid catilage , horizontally and thereafter moving caudally
2992434|NCT02613429|Active Comparator|caudal longitudinal|identification of the airway from the distal end. Marking of the airway, including the cricothyroid membrane, on the skin, by starting the examination caudally, and then moving cranially
2992435|NCT02613416|Experimental|Denosumab|6 monthly subcutaneous injections of denosumab
2992436|NCT02613403|Experimental|[Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV|C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks.
2992437|NCT02613403|Experimental|[Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B|C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 24 weeks.
2992438|NCT02613403|Experimental|[Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV|C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks.
2992439|NCT02613403|Experimental|[Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B|C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 24 weeks.
2992440|NCT02613403|Experimental|[Part B] Prior DAA (GT1-6) or SOF/PR (GT3) Failure: MK-3682B|C or NC HCV participants previously failing any all-oral DAA regimen (GT1-6) or SOF/PR regimen (GT 3 only) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 16 weeks.
2992441|NCT02613390|Experimental|MRI-Based Image Guidance|"MRI images of the spine taken of anesthetized participant in the operative prone position. These images are exported into a computer navigation program, and used to help the doctor perform surgery.~Pain and symptom questionnaires completed at baseline and at follow up."
3018435|NCT02439970|Active Comparator|Treatment 1|BCV plus vGCV placebo
2992442|NCT02613377||Transfused critically ill children|Any infusion of RBC, plasma or platelets will be considered a transfusion.
2992443|NCT02613377||Non-transfused critically ill children|For each transfused patient (index patient), one matched non-transfused control will be identified and included in the control group. The matching will be conducted using four criteria in hierarchical order: gender; age ± 10%; baseline Hemoglobin level (± 15 g/L); and Pediatric Risk of Mortality III score (PRISM III score ± 10%).
2992444|NCT02613364|Experimental|Arm I (behavioral intervention-yoga)|Patients undergo the YOCAS intervention comprising 18 specific physical postures and mindfulness exercises focused on breathing and meditation and meet with the yoga instructor over 75 minutes 2 times a week for 4 weeks.
2992445|NCT02613364|Experimental|Arm II (cognitive intervention-CBT-I)|Patients undergo CBT-I intervention comprising sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention delivered by a health professional over 90 minutes once a week for 8 weeks.
2992446|NCT02613364|Active Comparator|Arm III (educational intervention)|"Patients attend survivorship health education sessions over 75 minutes 2 times a week for 4 weeks based on the American Society of Clinical Oncology cancer survivorship educational recommendations delivered by a community health educator. Patients also receive a booklet entitled, Cancer Survivorship Next Steps for Patients and Their Families."
2992447|NCT02613351|Experimental|scooting|incremental test to establish the relationship between leg and breathing heaviness with increasing demand (speed) during scooting
2992448|NCT02613338||DePuy Attune PS FB knee system|Patients implanted with a DePuy Attune posterior stabilizing fixed bearing knee system
2992449|NCT02613325|Experimental|Arm 1: fPAM imaging & Single cell PAM imaging|"fPAM imaging will be performed prior to scheduled excision. The time to excision will not be extended longer than 2 weeks for imaging purposes.~When the participant presents for imaging, the area of the thickest lesion depth will be determined by fPAM. The area of deepest thickness will be marked perpendicular to the longest axis of the lesions and a clinical photo will be taken and placed in the image storage database.~Surgical excision will be performed as standard of care and fPAM depth will be compared with histological examination.~To image CTCs in cutaneous blood vessels, a small cuticle area on a finger will be imaged (Single cell PAM imaging) and the most distal cutaneous metastasis or metastasis of largest diameter will be imaged"
2992450|NCT02613286|Experimental|Extrafascial Hysterectomy|Type A hysterectomy with 1 - 2cm of vaginal cuff plus level 1 pelvic lymph-node dissection according to Querleu and Morrow classification.
2992451|NCT02613286|Active Comparator|Modified radical hysterectomy|Type B2 hysterectomy with 1 - 2cm of vaginal cuff plus level 1 pelvic lymph-node dissection according to Querleu and Morrow classification.
2992452|NCT02613273|Experimental|Experimental: Arm 1 (Aerobic Exercise)|Arm 1 will engage in a periodized program consisting of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout. A physical assessment, physical function and strengths tests, questionnaires and diet diaries will be completed at baseline and 3 months.
2992453|NCT02613273|Experimental|Experimental: Arm 2 (Resist. Exercise)|Arm 2 will engage in a periodized program consisting of 3 resistance exercise sessions per week comprised of various loads and volumes. A physical assessment, physical function and strengths tests, questionnaires and diet diaries will be completed at baseline and 3 months.
2992454|NCT02613273|No Intervention|No Intervention: Arm 3 (Control)|Arm 3 will follow their usual exercise and lifestyle routine. A physical assessment, physical function and strengths tests, questionnaires and diet diaries will be completed at baseline and 3 months.
2992455|NCT02613260|No Intervention|Usual Care|Patients in this study arm will receive usual care from their primary care clinic.
2992456|NCT02613260|Experimental|FIT Outreach + Usual Care|Patients in this study arm will receive usual care at their primary care clinic and the intervention.
2992457|NCT02613247|Experimental|Immediate-start group|Hylan G-F 20 6 mL intra-articular knee injection
2992458|NCT02613247|Other|Delayed-start group|Washout control group which then becomes an experimental group (Hylan G-F 20 6 mL intra-articular knee injection) at 6 weeks post-enrolment
2992459|NCT02613234|Experimental|Experimental Group|Active Intervention on brain waves by cathode tDCS
2992460|NCT02613234|Sham Comparator|Control Group|Sham Intervention on brain waves by cathode tDCS
2992461|NCT02613221|Experimental|panitumumab + TAS-102 combination therapy|panitumumab + TAS-102 combination therapy
2992462|NCT02613208||Participants With Metastatic Breast Cancer|Participants with metastatic breast cancer receiving bevacizumab in combination with paclitaxel, will be observed for treatment responses for up to 18 months from the start of treatment.
2992463|NCT02613195|Experimental|Hydrogen-rich Celsior solution|Using aging liver grafts（≥60 years old)，lavaged and cold stored with hydrogen-rich Celsior solution for 2-4 hours.
2992464|NCT02613195|No Intervention|Celsior solution|Using aging liver/kidney grafts（≥60 years old）, lavaged and cold stored with common Celsior solution for 2-4 hours.
2992465|NCT02613182|Experimental|Open Label|Open Label Study Drug NEOD001
2992466|NCT02613169|Experimental|Isoniazid|Isoniazid (INH) ~10 mg/kg (7-15 mg/kg), will be administered once daily to infants in INH arm for 12 months.
2992467|NCT02613169|No Intervention|No Isoniazid|No INH will be administered to this arm.
2992468|NCT02613156||laparoscopic group|patients in the laparoscopic group underwent laparoscopic resection of recurrent HCC
2992469|NCT02613156||control group|patients in the control group underwent conventional open surgery
2992470|NCT02613143||Surgery|
2992471|NCT02613130|Experimental|Two-Step stannous fluoride toothpaste|Two-Step stannous fluoride toothpaste
2992472|NCT02613130|Active Comparator|Potassium nitrate toothpaste|Potassium nitrate toothpaste
2992473|NCT02613117|Other|potassium oxalate gel|potassium oxalate gel self applied
2992474|NCT02613117|Other|oxalate liquid, SnF2 paste|Potassium oxalate liquid professionally applied, Stannous fluoride paste self applied
2992475|NCT02613104|Experimental|Sad to Happy|emotion recognition modification - sad>happy
2992476|NCT02613104|Placebo Comparator|Sad control|emotion recognition modification - sad>happy control
2992477|NCT02613104|Experimental|Angry to Happy|emotion recognition modification - angry>happy
2992478|NCT02613104|Placebo Comparator|Angry control|emotion recognition modification - angry>happy control
3018436|NCT02439970|Active Comparator|Treatment 2|vGCV plus BCV placebo
2992480|NCT02613078|Experimental|Gut-Directed Hypnotherapy (GDH)|Gut-Directed Hypnotherapy on a daily basis (20 min each day, at least 4 times/week)
2992481|NCT02613078|Experimental|Probiotic (NS)|Nutritional supplement SymbioLact B once a day diluted in water or tea
2992482|NCT02613078|Active Comparator|Active Controls (AC)|AC group keeps a symptom dairy (self-monitoring)
2992483|NCT02613065|Experimental|Eggwhite protein shake|Participants drink a NOW Foods protein shake (~20% daily energy requirements) at the beginning of each of the three daily meals. Kcals/meal are dependent upon participant's baseline Resting Metabolic Rate value.
2992484|NCT02613065|Active Comparator|Maltodextrin carbohydrate shake|Participants drink a NOW Foods carbohydrate shake (~20% daily energy requirements) at the beginning of each of the three daily meals. Kcals/meal are dependent upon participant's baseline Resting Metabolic Rate value.
2992485|NCT02613052|Placebo Comparator|Agitated Normal Saline|Agitated saline is the current standard of care contrast agent used for bubble studies. 10 mL of agitated normal saline will be used for the bubble study.
2992486|NCT02613052|Active Comparator|Albumin only|10 mL of agitated 5% albumin will be used for the bubbly study.
2992487|NCT02613052|Experimental|Albumin and Propofol|7 mL of 5% albumin and 3 mL of propofol (10 mg/mL) will be agitated together and used for the bubble study.
2992488|NCT02613039|Other|female outpatient subjects|Patients requiring combined Oral Contraceptives therapy.
2992489|NCT02613026|Experimental|Combined therapy group|pirarubicin 50mg/m2, iv, d1; docetaxel 75mg/m2, div, d1. 21 days were a cycle of treatment, with a total of 4-8 cycles.
2992490|NCT02613026|Experimental|Sequential therapy group|cyclophosphamide 600mg/m2, iv, d1; Pirarubicin 60mg/m2, iv, d1, 21 days were a cycle of treatment, with a total of 4 cycles. Then followed by Docetaxel 75- 100mg/m2, div, d1, 21 days were a cycle of treatment, with a total of 4 cycles.
2992491|NCT02613013|Active Comparator|single LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris >0.1mm. and patency was determined by direct visualization of the posterior chamber.
2992492|NCT02613013|Experimental|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure
2992493|NCT02613000||All enrolled patients/Group A|500 consecutive adult patients will be enrolled in Part A (clinical data)
2992494|NCT02613000||Patients with blood and urine sampling/Group B|Patients with informed consent signed (anticipated 200 out of 500 patients) will participate in Part A (clinical data) and B (intestinal-specific biomarkers from blood and urine)
2992495|NCT02612987|Experimental|iCBT|
2992496|NCT02612974|Experimental|Group A|Hirudinaria granulosa and Qurse mafasil are given
2992497|NCT02612974|Active Comparator|Group B|Qurse mafasil only given
2992498|NCT02612961|Experimental|Saline Instillation|3mL normal saline from pink sodium chloride bullet instilled into tracheostomy immediately prior to suctioning.
2992499|NCT02612961|Sham Comparator|Placebo|Pretend to instill 3mL of normal saline using empty pink sodium chloride bullet immediately prior to suctioning.
2992500|NCT02612948|No Intervention|Standard Care|Standard care for delerium
2992501|NCT02612948|Active Comparator|Quetiapine|Quetiapine therapy was initiated at 12.5 mg twice daily a. After thefirst dose of quetiapine 12.5 mg, the regimen could then be adjusted by the rounding surgeon. If the surgeon felt benefit from receiving a higher dose of quetiapine the dose could then be increased. Quetiapine was discontinued if adverse events (torsades de pointes or other ventricular tachycardias) occurred. All patients receiving at least one dose of quetiapine were included in the final intention-to-treat analyses. All prescribing decisions were left to the discretion of the rounding surgeon and were not mandated as part of the study.
2992502|NCT02612922|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
2992503|NCT02612922|Placebo Comparator|Placebo|Two Placebo tablets orally twice daily (b.i.d.) for 5 days
2992504|NCT02612909|Placebo Comparator|Phosphate Buffered Saline (PBS)|Sterile Phosphate Buffered Saline (PBS); 0.5 mL by IM injection
2992505|NCT02612909|Experimental|Low Dose A/H5N1 vaccine|15 mcg HA/0.5 ml vaccine by IM injection
2992506|NCT02612909|Experimental|High Dose A/H5N1 vaccine|30 mcg HA/0.5 ml vaccine by IM injection
2992507|NCT02612896|Experimental|Elimination arm|"Both human and porcine interventions at four-monthly intervals in the first two study years, for a total of six iterations (only human interventions will be detailed here):~Human: Mass drug administration, praziquantel 10mg/kg, according to the list of WHO recommended anthelmintic drugs for use in preventive chemotherapy for taeniasis. And Health Education"
2992508|NCT02612896|Experimental|Control intervention arm|Human: yearly health education, for a total of five iterations. The intervention on the pig host will not be detailed here)
2992509|NCT02612883||Esophagus|Measuring of tissue perfusion of the esophagus
2992510|NCT02612883||Liver|Measuring of tissue perfusion of the liver
2992511|NCT02612883||Stomach|Measuring of tissue perfusion of the stomach
2992512|NCT02612883||Pancreas|Measuring of tissue perfusion of the pancreas
2992513|NCT02612883||Colon|Measuring of tissue perfusion of the colon
2992514|NCT02612870|Active Comparator|Sienna+ retro and Technetium 1|"Sienna+® is administered retro-mamillary 1 day before surgery for sentinel node marking.~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
2992555|NCT02612649||Ramosteron group|Female patients with diarrhea-predominant irritable bowel syndrome
2992515|NCT02612870|Active Comparator|Sienna+ peri and Technetium 1|"Sienna+® is administered peri-tumorally 1 day before surgery for sentinel node marking.~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
2992516|NCT02612870|Active Comparator|Sienna+ retro 4-6 and Technetium 1|"Sienna+® is administered retro-mamillary 4-6 days before surgery for sentinel node marking.~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
2992517|NCT02612870|Active Comparator|Sienna+ peri 4-6 and Technetium 1|"Sienna+® is administered peri-tumorally 4-6 days before surgery for sentinel node marking.~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
2992518|NCT02612857|Placebo Comparator|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
2992519|NCT02612857|Experimental|IMO-8400 Dose Group 1|IMO-8400 Dose Group 1 subcutaneous injections once a week for 24 weeks.
2992520|NCT02612857|Experimental|IMO-8400 Dose Group 2|IMO-8400 Dose Group 2 subcutaneous injections once a week for 24 weeks.
2992521|NCT02612844|Experimental|NNC0143-0406|
2992522|NCT02612844|Active Comparator|Insulin Aspart|
2992523|NCT02612831|Other|Early bariatric surgery|patient receive their procedure early (within 3 months)
2992524|NCT02612831|Other|Delayed bariatric surgery|Patient receive their procedure later (in 12 - 15 months), following a year of optimal medical treatment
2992525|NCT02612805|Experimental|Aerobic training group|This group perform aerobic hydrogymnastics.
2992526|NCT02612805|Active Comparator|Combined training group|This group perform combined hydrogymnastics.
2992527|NCT02612805|Placebo Comparator|Training placebo|This group perform stretching and relaxation in aquatic environment.
2992528|NCT02612792|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
2992529|NCT02612792|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
2992530|NCT02612792|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin for treating furcation defect
2992531|NCT02612779|Experimental|Elotuzumab + Pomalidamide + Low Dose Dexamethasone (EPd)|patients will receive treatment with elotuzumab in combination with pomalidomide and low-dose dexamethasone. Patients are eligible to receive Nivolumab at progression.
2992532|NCT02612779|Experimental|Elotuzumab + Nivolumab (EN)|Patients will receive treatment with a combination of elotuzumab and nivolumab
2992533|NCT02612766|Other|Single Arm|This is a single-arm interventional study, in which each patient gets 50 grams/day of pure, uncontaminated oats
2992534|NCT02612753|Experimental|Aphasics Patients|Patients which have difficulties to speak. Improvement of language for aphasics patients.
2992535|NCT02612753|Sham Comparator|Aphasics Patients control|Patients which have difficulties to speak will receive Sham tDCS +SLT for aphasics patients control
2992536|NCT02612740|Experimental|Test Group|The bone defect was filled with granules of deproteinized bovine bone (Bio-Oss, Geistlich Pharm, AG Wolhausen, Switzerland)
2992537|NCT02612740|No Intervention|Control Group|No filling material was used in the bone healing
2992538|NCT02612727|Active Comparator|Window tinting film for filtered sunlight phototherapy|Window tinting film
2992539|NCT02612727|Active Comparator|Conventional phototherapy|Infants will be randomized to conventional phototherapy (new arm)
2992540|NCT02612714|Other|medication status|Rosuvastatin 5 mg qd for 6 months, Quitted rosuvastatin for 6 months, Re-administrated rosuvastatin for 6 months
2992541|NCT02612701|Experimental|Cigarettes|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking two standard cigarettes
2992542|NCT02612701|Experimental|E-cigarettes (nicotine free e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking nicotine free e-cigarette liquid.
2992543|NCT02612701|Experimental|E-cigarettes (low nicotine e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking low concentration(4-6 mg/mL) e-cigarette liquid.
2992544|NCT02612701|Experimental|E-cigarettes (high nicotine e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking high concentration (18-24 mg/mL) e-cigarette liquid.
2992545|NCT02612688|Experimental|ACP Video Program|Facility asked to implement ACP Video Program
2992546|NCT02612688|No Intervention|Usual ACP procedures|Facility follows usual ACP procedures
2992547|NCT02612675|Active Comparator|Standard ONS|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption
2992548|NCT02612675|Experimental|Low Carbohydrate ONS|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption
2992549|NCT02612662|Experimental|Cohort 1|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
2992550|NCT02612662|Experimental|Cohort 2|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
2992551|NCT02612662|Experimental|Cohort 3|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
2992552|NCT02612662|Experimental|Cohort 4|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
2992553|NCT02612662|Experimental|Cohort 5|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
2992554|NCT02612662|Experimental|Cohort 6|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
3018437|NCT02439957|Active Comparator|Treatment 1|BCV plus vGCV placebo
2992556|NCT02612636|Active Comparator|ear plug and eye mask|"The patients will not receive the intervention in the first night (N1) from 9 pm to 6 am~The patients will receive the intervention (eye mask) in the second night (N2) from 9 pm to 6 am.~The patients will receive the intervention (ear plug) in the third night (N3) from 9 pm to 6 am.~The patients will receive the intervention (eye mask and ear plug) in the fourth night (N4) from 9 pm to 6 am."
2992557|NCT02612636|No Intervention|control|The researcher will assess and observe the patients who are receiving the routine hospital nursing care during the four nights.
2992558|NCT02612623|Experimental|Gefapixant 15 mg twice daily|Two 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks
2992559|NCT02612623|Experimental|Gefapixant 30 mg twice daily|Four 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks
2992560|NCT02612623|Experimental|Gefapixant 50 mg twice daily|One 50 mg gefapixant tablet administered by mouth twice daily for 8 weeks
2992561|NCT02612623|Experimental|Placebo to match gefapixant|Matching placebo tablets administered by mouth twice daily for 8 weeks
2992562|NCT02612610|Placebo Comparator|Placebo|Participants received one matching placebo tablet administered by mouth twice daily for 12 weeks.
2992563|NCT02612610|Experimental|Gefapixant 7.5 mg|Participants received one 7.5 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
2992564|NCT02612610|Experimental|Gefapixant 20 mg|Participants received one 20 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
2992565|NCT02612610|Experimental|Gefapixant 50 mg|Participants received one 50 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
2992566|NCT02612597|Experimental|Bedrest|4 days of bedrest
2992567|NCT02612597|Experimental|Exercise Training|6 weeks of aerobic endurance exercise training with 4 supervised sessions per week at an average intensity of 65 % of maximal heart rate
2992568|NCT02612584|Experimental|Pinhole soft contact lens|
2992569|NCT02612571||Wind instrument players|A wind instrument is defined as any instrument that contains a resonator, in which a column of air is set into resonation by the player blowing into a mouthpiece at one end of the resonator.
2992570|NCT02612571||Non-wind instrument players|A non-wind instrument is defined as any instrument that does not contain a resonator.
2992571|NCT02612558|Experimental|Fostamatinib 150 mg|Fostamatinib 150 mg bid (morning and evening) over the course of 24 weeks
2992572|NCT02612545|Active Comparator|ACT|Patients randomized to ACT will receive DHA-PPQ only
2992573|NCT02612545|Experimental|TACT|Patients randomized to TACT will receive DHA-PPQ plus MQ
2992574|NCT02612532|Experimental|LuCID|"Standardised exhaled volatile organic compound collection by ReCIVA breath sampler (http://www.owlstonenanotech.com/medical/products/reciva) for analysis of volatile organic compounds by Lonestar (http://www.owlstonenanotech.com/medical/products/lonestar)"
2992575|NCT02612519|Experimental|Alfapump - Substudy 1|Alfapump implantation
2992576|NCT02612519|Active Comparator|TIPS - Substudy 1|TIPS implantation
2992577|NCT02612519|Experimental|Alfapump - Substudy 2|Alfapump implantation
2992578|NCT02612519|No Intervention|Standard - Substudy 2|Standard treatment
2992579|NCT02612506|Experimental|Hepalatide|Hepalatide 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg
2992580|NCT02612506|Placebo Comparator|Placebo|Placebo 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg
2992581|NCT02612480|Experimental|Ticagrelor and acetylsalicylic acid|7 day treatment with ticagrelor 2x90mg after a loading dose of 180 mg and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg.
2992582|NCT02612480|Active Comparator|Clopidogrel and acetylsalicylic acid|7 day treatment with clopidogrel x75 mg after a loading dose of 300 mg and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg
2992583|NCT02612480|Placebo Comparator|Placebo and acetylsalicylic acid|7 day treatment with placebo and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg
2992584|NCT02612480|Placebo Comparator|Placebo|7 day treatment with 2 placebos
2992585|NCT02612467|Experimental|Stratified care|Patients are stratified into low, medium, high risk of poor outcome. Stratified care are delivered by special trained physiotherapists according to risk group
2992586|NCT02612467|Active Comparator|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
2992587|NCT02612454|Experimental|Age ≥6 months to <18 years|Participants aged ≥6 months to <18 years will receive dupilumab
2992588|NCT02612441|Experimental|1 real Acupuncture group-intervention|real Acupuncture Needles
2992589|NCT02612441|Sham Comparator|2 sham Acupuncture group|sham Acupuncture Needles
2992590|NCT02612428|Experimental|ELAD System|This group will receive treatment with ELAD plus standard of care therapy.
2992591|NCT02612428|Other|Standard of Care (Control)|This group will receive standard of care therapy as defined in the protocol.
2992592|NCT02612415|Experimental|High flow nasal cannula (HFNC)|Heated humidified high flow nasal cannula therapy delivered at 2 L/kg/min gas flow rate (for children older than 10 kg in weight, an additional 0.5 L/kg/min per kilogram over 10 kg). Any approved device can be used to deliver HFNC
2992593|NCT02612415|Active Comparator|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure delivered using any interface (hood, mask or prongs)
2992594|NCT02612402|Experimental|Learning algorithm|The app will be installed on the patients's phone. The app will measure the amount of activity performed. THE INTERVENTION IS THAT the Patients will receive daily messages, a learning algorithm will study the exercise response to each type of message and personalize the best message sequence for each patient.
2992595|NCT02612402|Active Comparator|control|The app will be installed on the patients's phone. The app will measure the amount of activity performed. THE INTERVENTION IS THAT THE Patients will receive a weekly reminder to exercise.
2992596|NCT02612389|Experimental|MM Intervention taught via DVD|Receive Meditative Movement training via DVD with pre and post interventional testing.
2992597|NCT02612389|No Intervention|MM Intervention Waitlist Control|Testing at same frequency as Meditative Movement interventional subjects.
2992694|NCT02611830|Placebo Comparator|Placebo (IV and SC) Maintenance Arm|"Open-label Induction: vedolizumab IV 300 mg, infusion, at Week 0 (Day 1) and Week 2 (Day 15)~Double-blind Maintenance:~placebo matching to vedolizumab IV infusion Q8W starting at Week 6 up to Week 46, and~placebo matching to vedolizumab SC injection Q2W starting at Week 6 up to Week 50."
2992598|NCT02612376||AD, DS, Mild Cognitive Impairment|Persons with age-related Mild Cognitive Impairment (MCI) or Alzheimer Disease (AD) according to clinical diagnosis, consistent with Alzheimer's Association (AA) and the National Institute on Aging (NIA) diagnostic criteria. Individuals with Down Syndrome (DS) according to clinical diagnosis, with cognitive ability sufficient to follow directions.
2992599|NCT02612376||Healthy Controls|"Non-DS community-dwelling controls~Non-pregnant mothers and fathers of DS individuals (controls)~An Informant (study partner) available to complete functional interviews/survey measures annually."
2992600|NCT02612363|Experimental|Early goal directed sedation group|"Dexmedetomidine for sedation in early goal directed sedation group~Analgesia~Dexmedetomidine start at 0.7ug/kg/hour~Dose range: 0.2- 0.7 u/kg/hour~Supplemental other sedatives at lowest effective dose Target Richmond Agitation-Sedation Scale score of -2 to +1 to achieve sedation goal in EGDS group"
2992601|NCT02612363|Placebo Comparator|Standard sedation|"Control drug for sedation in early goal directed sedation group~Analgesia~Control drug~Supplemental other sedatives at lowest effective dose for standard sedation Target Richmond Agitation-Sedation Scale score of -2 to +1 to achieve sedation goal"
2992602|NCT02612350||Increased Risk for Cancer Development|The group is to include at least 1000 individuals who are at high risk for the development of cancer. Risk is assessed through the completion of a clinical history questionnaire. Examples of such subjects include those with known hereditary cancer syndrome pathogenic variants without a diagnosis of cancer, with significant family history of breast, ovarian, colon, or lung cancer or melanoma, or another strong history of cancer but no prior molecular diagnosis, heavy smokers or those exposed to carcinogens and mutagens. The individuals who meet criteria for inclusion will undergo cell-free DNA isolation and circulating-tumor DNA (ctDNA) analysis for the detection of genetic mutations associated with the possible development of a malignancy.
2992603|NCT02612337|Experimental|OTO-104|12 mg dexamethasone
2992604|NCT02612337|Placebo Comparator|Placebo|
2992605|NCT02612324|Experimental|Pono Choices|Pono Choices: A Culturally Responsive Teen Pregnancy and STI Prevention Program for Middle School Youth in Hawaii. The program includes 9.5 hours of scripted lessons or modules.
2992606|NCT02612324|Active Comparator|Business as Usual|Middle school sexual health content or programs chosen by control group schools.
2992607|NCT02612311|Experimental|Ublituximab + TGR-1202|"Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions~TGR-1202: Fixed oral daily dose"
2992608|NCT02612311|Active Comparator|Obinutuzumab + Chlorambucil|"Obinutuzumab: IV infusion dose on Days 1, 8 and 15 in Cycle 1 followed by Day 1 infusion in Cycles 2 - 6~Chlorambucil: Oral dose on Days 1 and 15 of Cycles 1 - 6"
2992609|NCT02612311|Experimental|Ublituximab|- Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions
2992610|NCT02612311|Experimental|TGR-1202|- TGR-1202: Fixed oral daily dose
2992611|NCT02612298|Experimental|arotinolol|Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks
2992612|NCT02612298|Active Comparator|Metoprolol|Metoprolol succinate sustained-release tablet, oral, 23.75-71.25mg, qd for 12 weeks.
2992613|NCT02612285|Experimental|SNX-5422|Open-label administration of SNX‑5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), followed by a 7‑day drug‑free period. Each treatment cycle will be 28 days. Subjects will repeat this 28-day schedule until the cancer progresses or the subject is unable to tolerate SNX-5422.
2992614|NCT02612272|Active Comparator|Corticosteroid|"This arm will receive intra-articular betamethasone.~4cc of 1% lidocaine, 1cc of 0.9% normal saline and 1cc (6 mg) of betamethasone.~An 18 gauge needle connected to a syringe filled with the study drug will be administered. If there is no effusion, a 22 gauge needle with 6cc of the study drug will be injected into the administration site~Please see detailed description of study for further information."
2992615|NCT02612272|Experimental|Ketorolac|"This arm will receive intra articular ketorolac.~2cc (60 mg) of ketorolac and 4cc of 1% lidocaine~An 18 gauge needle connected to a syringe filled with the study drug will be administered. If there is no effusion, a 22 gauge needle with 6cc of the study drug will be injected into the administration site~Please see detailed description of study for further information."
2992616|NCT02612259|Experimental|TRYPTOPHAN|"tryptophan 3.5 mg / kg / day divided in 2 doses, one before breakfast and another one before dinner. Oral administration.~Total treatment duration for each patient is 6 months."
2992617|NCT02612259|Placebo Comparator|PLACEBO|"lactose capsules 3.5 mg / kg / day divided in 2 doses, one before breakfast and another one before dinner. Oral administration.~Total treatment duration for each patient is 6 months."
2992618|NCT02612246|Experimental|GLPG1972 single dose|Single oral dose of GLPG1972 solution - ascending doses
2992619|NCT02612246|Placebo Comparator|Placebo single dose|Single oral dose of placebo solution
2992620|NCT02612246|Experimental|GLPG1972 multiple doses|Multiple oral doses of GLPG1972 solution - ascending doses
2992621|NCT02612246|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo solution
2992622|NCT02612233|Active Comparator|Pregabalin|Pregabalin 150mg ON week 1 increased to Pregabalin 300mg ON weeks 2-11 then decrease to Pregabalin 150mg ON week 12 then STOP
2992623|NCT02612233|Active Comparator|Duloxetine|Duloxetine 30mg ON week 1 increase to Duloxetine 60mg weeks 2-11 then decrease to Duloxetine 30mg ON week 12 then STOP
2992624|NCT02612233|Placebo Comparator|Placebo|1 capsule ON week 1- increase to 2 capsules ON week 2-11 then decrease to 1 capsule ON week 12 then STOP.
2992625|NCT02612220|Experimental|Experimental Group|Complete hemostasis will be achieved using BioFoam® Surgical Matrix
2992626|NCT02612220|Active Comparator|Control Group|Complete hemostasis will be achieved without the use of topical agents, using conservative hemostasis
2992627|NCT02612194|Experimental|Cohort 1|c-MET high (> 50%), RON null (0-9%)
2992628|NCT02612194|Experimental|Cohort 2|c-MET + (10-100%), RON + (10-100%)
2992629|NCT02612194|Experimental|Cohort 3|c-MET null (0-9%), RON + (10-100%)
2992630|NCT02612181|Experimental|Dexmedetomidine group|Dexmedetomidine group: Dexmedetomidine infusion for dexmedetomidine group to the goal of sedation: Richmond agitation-sedation scale 0 to -2 Dexmedetomidine doses 0-0.7 mcg/kg/h
2992631|NCT02612181|Placebo Comparator|Control group|Control group: Placebo infusion for control group to the goal of sedation: Richmond agitation-sedation scale 0 to -2 Control drug doses 0-0.7 mcg/kg/h
2992727|NCT02611648|Experimental|HLD/ETO|Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
2992632|NCT02612168|Experimental|All patients|Each patient will have any pigmented lesions (PLs) which are due to be biopsied, two PLs not due for biopsy and one patch of healthy skin photographed. Each will be photographed using three cameras: A standard DSLR and two smartphones with a dermoscopic lens attachment. Photographic images will be analysed by Melanoma Image Analysis Algorithm (MIAA)
2992633|NCT02612155|Experimental|Intervention cell recipients|Experimental: infusions: infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have autologous nucleated cord blood cells available for infusion will receive up to two infusions. Outcomes will be measured at 22-26 months by neurodevelopment assessment
2992634|NCT02612155|Placebo Comparator|Placebo recipients|Control: infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have cord blood available for infusion will receive placebo (a mix of autologous cord blood red blood cells and plasma) infusions. Outcomes will be measured at 22-26 months by neurodevelopment assessment
2992635|NCT02612142|Experimental|aerobic exercise (AE)|Intervention type: Behavioral. Intervention name: Aerobic exercise Intervention description: 10 days of daily aerobic exercise (brisk walking, jogging); duration: 30 minutes per session; intensity: 65%-75% of age-predicted maximal heart rate. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
2992636|NCT02612142|Sham Comparator|stretching exercise (ST)|Intervention type: Behavioral. Intervention name: Stretching exercise Intervention description: 10 days of daily stretching exercise; duration: 30 minutes per session. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
2992637|NCT02612142|No Intervention|no intervention (NI)|No behavioral intervention. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
2992638|NCT02612129|Active Comparator|arimoclomol|arimoclomol capsules for oral administration (3 times daily). Doses:150-600 mg/day (based on weight)
2992639|NCT02612129|Placebo Comparator|Placebo|Matching placebo capsules
2992640|NCT02612116|Active Comparator|pulverized ticagrelor sublingually|Pulverized ticagrelor 180 mg (Brilique) administered sublingually
2992641|NCT02612116|Active Comparator|pulverized ticagrelor orally|Pulverized ticagrelor 180 mg (Brilique) administered orally
2992642|NCT02612116|Active Comparator|Integral ticagrelor orally|Ticagrelor 180 mg (Brilique) administered orally in integral tablets
2992643|NCT02612103||Active Crohns disease|Verified Crohns disease diagnosis according to clinical, endoscopic and histological standard criteria and Harvey Bradshaw index > 4.
2992644|NCT02612103||Crohns disease in remission|Verified Crohns disease diagnosis according to clinical, endoscopic and histological standard criteria and Harvey Bradshaw index ≤ 4.
2992645|NCT02612103||Active ulcerative colitis|Verified ulcerative colitis diagnosis according to clinical, endoscopic and histological standard criteria and Simple Clinical Colitis Activity Index > 3.
2992646|NCT02612103||Ulcerative colitis in remission|Verified ulcerative colitis diagnosis according to clinical, endoscopic and histological standard criteria and Simple Clinical Colitis Activity Index ≤ 3.
2992647|NCT02612103||Irritable bowel syndrome|Verified irritable bowel syndrome according to standard criteria.
2992648|NCT02612103||Healthy controls|No known chronic diseases which needs continuously medication.
2992649|NCT02612090|Active Comparator|Active Treatment Beverage|Strawberry
2992650|NCT02612090|Placebo Comparator|Placebo Treatment Beverage|Placebo Beverage
2992651|NCT02612077||Observational Chemotherapy/Bevacizumab|Observed patients receiving chemotherapy with concomitant bevacizumab
2992652|NCT02612064|Experimental|Stannous Fluoride dentifice|Participants will apply (under supervision) a pea-sized dose of experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm) to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted
2992653|NCT02612064|Other|Sodium Monofluorophosphate dentifrice|Participants will apply (under supervision) a pea-sized dose of dentifrice containing Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted.
2992654|NCT02612051|Experimental|Part A, Cohort 1: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
2992655|NCT02612051|Experimental|Part A, Cohort 2: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
2992656|NCT02612051|Experimental|Part A, Cohort 3: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
2992657|NCT02612051|Experimental|Part B, Cohort 4: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
2992658|NCT02612051|Experimental|Part B, Cohort 5: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
2992725|NCT02611648|No Intervention|standard HLD|Standard high-level disinfectant (metricide ortho-phthalaldehyde) currently performed at BIDMC (standard HLD)
3018438|NCT02439957|Active Comparator|Treatment 2|vGCV plus BCV placebo
2992659|NCT02612051|Experimental|Part B, Cohort 6: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
2992660|NCT02612051|Experimental|Part B, Cohort 7: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
2992661|NCT02612051|Experimental|Part C, Cohort 8: GSK3008348, IPF, PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per Part B) in two treatment periods. There will be washout period of 6 to 14 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in both periods.
2992662|NCT02612038|Experimental|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
2992663|NCT02612038|Sham Comparator|Sham expiratory resistance|Sham resistance will be added to the patient's respiratory circuit
2992664|NCT02612025|Experimental|Exercise group|Exercise training during intensive medical treatment
2992665|NCT02612025|No Intervention|Control group|Usual Care
2992666|NCT02612012||Axillary radiotherapy|
2992667|NCT02611999|No Intervention|Control|Physicians in this Arm received only a paper memo with a list of common imaging tests and procedures.
2992668|NCT02611999|Experimental|Single Price|Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
2992669|NCT02611999|Experimental|Paired Inside/Outside Prices|Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
2992670|NCT02611986|Experimental|McGrath MAC|tracheal intubation using the McGrath MAC
2992671|NCT02611986|Experimental|Macintosh Laryngoscope|tracheal intubation using the Macintosh Laryngoscope
2992672|NCT02611973|Experimental|HU without aspirin|
2992673|NCT02611973|Active Comparator|HU + aspirin maintenance|
2992674|NCT02611973|Other|HU + AAG|Observational arm
2992675|NCT02611960|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of each 3-week cycle until progressive disease (PD) or unacceptable toxicity or a maximum of up to 35 cycles.
2992676|NCT02611960|Active Comparator|Standard of Care Chemotherapy|Participants receive capecitabine 1000 mg/m^2 orally (PO) twice each day (BID) on Days 1-14 of each 3-week cycle OR gemcitabine 1250 mg/m^2 IV Days 1 and 8 of each 3-week cycle OR docetaxel 75 mg/m^2 IV on Day 1 of each 3-week cycle until PD or unacceptable toxicity.
2992677|NCT02611947||Healthy Volunteers|"Inclusion criteria:~Aged 18 or more.~Never smoked.~No respiratory infection in the 4 weeks before the begin of the study.~No history of pulmonary resection.~No active malignancy or malignancy of any organ system within the past 5 years."
2992678|NCT02611934|Experimental|Mild Therapeutic Hypothermia|OHCA survivors with diagnosed or suspected ACS
2992679|NCT02611934|No Intervention|no-Mild Therapeutic Hypothermia|OHCA survivors with diagnosed or suspected ACS
2992680|NCT02611921|Experimental|Crossover Group: Ketamine verses Placebo|"Phase 1: Two ascending doses of intranasal ketamine~Two week washout~Phase 2: Two doses of placebo"
2992681|NCT02611921|Experimental|Crossover Group: Placebo verses Ketamine|"Phase 1: Two doses of placebo~Two week washout~Phase 2: Two ascending doses of intranasal ketamine"
2992682|NCT02611908|Experimental|ibrutinib +obinutuzumab|
2992683|NCT02611895|Experimental|HIV DNA|Blood test : Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
2992684|NCT02611882|Experimental|preRP population|"Patients with high-risk prostate cancer pre-prostatectomy.~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
2992685|NCT02611882|Experimental|BCR population|"Patients with prostate cancer with biochemical recurrence.~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
2992686|NCT02611882|Experimental|CRCP population|"Patients with castrate persistent prostate cancer.~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
2992687|NCT02611869|Experimental|Cryoballoon|
2992688|NCT02611869|Active Comparator|RF ablation|
2992689|NCT02611856||monochorial-biamniotic pregnancies|
2992690|NCT02611843|Experimental|Peer-Supported Web CBT|Semi-structured brief sessions conducted weekly for the 12 weeks of study treatment by a certified peer support specialist. Sessions focus on helping participants use the skills they are learning in the Web CBT treatment in their daily lives. Web CBT consists of 24 brief (i.e., 20-minute) modules. Participants will be asked to complete two modules per week. Module topics include The Connection Between PTSD and Substance Use, Motivational Enhancement, Relaxation, Identifying, Evaluating and Challenging Automatic Thoughts, Functional Analyses of Substance Use, Substance Use Refusal Skills, Communication, Anger Management, Pain Management, and Insomnia.
2992691|NCT02611843|Experimental|Self-Managed Web CBT|Self-managed Web CBT consists of 24 brief (i.e., 20-minute) modules. Participants will be asked to complete two modules per week. Module topics include The Connection Between PTSD and Substance Use, Motivational Enhancement, Relaxation, Identifying, Evaluating and Challenging Automatic Thoughts, Functional Analyses of Substance Use, Substance Use Refusal Skills, Communication, Anger Management, Pain Management, and Insomnia.
2992692|NCT02611830|Experimental|Vedolizumab SC 108 mg Maintenance Arm|"Open-label Induction: vedolizumab IV 300 mg, infusion at Week 0 (Day 1) and Week 2 (Day 15)~Double-blind Maintenance:~vedolizumab SC 108 mg injection Q2W starting at Week 6 up to Week 50, and~matching placebo to vedolizumab IV infusion Q8W starting at Week 6 up to Week 46."
2992693|NCT02611830|Experimental|Vedolizumab IV 300 mg Maintenance Arm|"Open-label Induction: vedolizumab IV 300 mg, infusion at Week 0 (Day 1) and Week 2 (Day 15)~Double-blind Maintenance:~vedolizumab IV 300mg, infusion at Week 6 up to Week 50, and~matching placebo to vedolizumab IV infusion Q8W starting at Week 6 up to Week 46."
2992726|NCT02611648|Experimental|double HLD|Double the exposure time of the standard high level disinfectant (metricide ortho-phthalaldehyde)
2992695|NCT02611817|Experimental|Vedolizumab SC 108 mg Maintenance Arm|"Open-label Induction: vedolizumab IV 300 mg, infusion at Week 0 (Day 1) and Week 2 (Day 15)~Double-blind Maintenance: vedolizumab SC 108 mg injection once every 2 weeks (Q2W) starting at Week 6 up to Week 50"
2992696|NCT02611817|Placebo Comparator|Placebo SC Maintenance Arm|"Open-label Induction: vedolizumab IV 300 mg, infusion at Week 0 (Day 1) and Week 2 (Day 15)~Double-blind Maintenance: matching placebo to vedolizumab SC injection Q2W starting at Week 6 up to Week 50"
2992697|NCT02611804|Experimental|Diclofenac Sodium Gel, 3%|Diclofenac Sodium Gel, 3%, applied twice daily for 60 days
2992698|NCT02611804|Active Comparator|Solaraze®|Solaraze® (diclofenac sodium) Gel, 3%, applied twice daily for 60 days
2992699|NCT02611804|Placebo Comparator|Vehicle of Test Product|Vehicle of Test Product, Gel, applied twice daily for 60 days
2992700|NCT02611791|Experimental|Radiofrequency|Eight RF sessions were performed, with an interval of seven days between them. The application of Radiofrequency in the external genitalia.
2992701|NCT02611791|Sham Comparator|Radiofrenquency Off|Eight RF sessions were performed, with an interval of seven days between them. The application of Radiofrequency in the external genital which was turned off, but a water-soluble gel was used
2992702|NCT02611778|Experimental|FYB201|FYB201 is provided as single use vials and will be administered by intra‐vitreal injection.
2992703|NCT02611778|Active Comparator|Lucentis|Lucentis® is provided as single use vials and will be administered by intra‐vitreal injection.
2992704|NCT02611765|Experimental|Enhanced therapy|Benzathine penicillin G intramuscular 7.2 million units Three doses of 2.4 million units of intramuscular benzathine penicillin G administered weekly (a total of 7.2 million units)
2992705|NCT02611765|Active Comparator|Standard therapy|Benzathine penicillin G intramuscular 2.4 million units A single intramuscular injection of 2.4 million units of benzathine penicillin G
2992706|NCT02611752|Experimental|CAM2038 q1w, 24 mg|CAM2038 q1w 24 mg will be administered on the first day and then Hydromorphone 0mg, 6mg, 18mg will be subsequently administered on consecutive days after CAM2038 q1w 24 mg administration.
2992707|NCT02611752|Experimental|CAM2038 q1w, 32 mg|CAM2038 q1w 32 mg will be administered on the first day and then Hydromorphone 0mg, 6mg, 18mg will be subsequently administered on consecutive days after CAM2038 q1w 32 mg administration .
2992708|NCT02611752|No Intervention|Hydromorphone 0 mg|Hydromorphone 0 mg will be assigned to CAM2038 q1w 24 mg and 32 mg
2992709|NCT02611752|No Intervention|Hydromorphone 6 mg|Hydromorphone 6 mg will be assigned to CAM2038 q1w 24 mg and 32 mg
2992710|NCT02611752|No Intervention|Hydromorphone 18 mg|Hydromorphone 18 mg will be assigned to CAM2038 q1w 24 mg and 32 mg
2992711|NCT02611739|Experimental|Intervention Group|"Children in the experimental treatment condition will sit in front of the nurse and beside (or on the lap) of a parent. Medi-Port (humanoid robot) will be positioned beside the child (at eye-level) and will execute a pre-programmed series of behaviours to distract the child before, during, and after the SCP needle insertion. The nurse will insert the needle according to hospital procedures, using minimal distraction (e.g., What's on TV?). The estimated time for port procedures and completion of the needle insertion will range from 10-30 minutes. The total estimated time which includes the completion of surveys and questionnaires on the pain intensity of the SCP needle insertion procedure and acceptability of Medi-port will be approximately 1 hour. There will be no follow-up visits."
2992712|NCT02611739|Active Comparator|Control Group|"Following consent and randomization, children in the (control) usual care condition will sit in front of the nurse and beside (or on the lap) of a parent. Medi-Port (humanoid robot) will be positioned beside the child (at eye-level) and will execute a standard set of dancing movements only. The nurse will insert the needle according to hospital procedures, using minimal distraction (e.g., What's on TV?). The estimated time for port procedures and completion of the needle insertion will range from 10-30 minutes. The total estimated time which includes the completion of surveys and questionnaires on the pain intensity of the SCP needle insertion procedure and acceptability of Medi-port will be approximately 1 hour. There will be no follow-up visits."
2992713|NCT02611726|Active Comparator|Acupuncture treatment|Individualized acupuncture needle insertion according to traditional Chinese and Japanese medicine on top of standard medical care during In-Vitro-Fertilization. Acupuncture needles will be inserted to body surface points following traditional diagnosis (anamnesis, tongue, pulse and abdomen inspection) according to practitioner discretion.
2992714|NCT02611726|No Intervention|Control|Standard medical care during In-Vitro-Fertilization.
2992715|NCT02611713||Participants with Advanced Parkinson's Disease|Participants who along with their physicians have elected for treatment with Duodopa/Duopa and are prescribed according to the local product label and reimbursement guidelines for their participating countries.
2992716|NCT02611700|Experimental|experimental group|Nimotuzumab+TP(paclitaxel+cisplatin)
2992717|NCT02611700|Placebo Comparator|control group|Placebo + TP(paclitaxel+cisplatin)
2992718|NCT02611687|Experimental|pitolisant|tablet, oral, once a day.
2992719|NCT02611687|Placebo Comparator|placebo|tablet, oral, once a day.
2992720|NCT02611661|Other|Stratum 1: Observe|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~No further treatment just observation"
2992721|NCT02611661|Experimental|Stratum 2: Percutaneous ablation|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~Percutaneous ablation can be radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation"
2992722|NCT02611661|Experimental|Stratum 3: SBRT|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~The planned SBRT dose will be 30 Gy in 5 fractions of 6 Gy each. It is recommended that each fraction be separated by a minimum of 12 hours and a maximum of 8 days."
2992723|NCT02611661|Experimental|Stratum 4: SBRT + Percutaneous Ablation|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~Percutaneous ablation can be radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation~The planned SBRT dose will be 30 Gy in 5 fractions of 6 Gy each. It is recommended that each fraction be separated by a minimum of 12 hours and a maximum of 8 days."
2992724|NCT02611661|No Intervention|Stratum 5: Referral for systemic therapy|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~Referred for further systemic therapy and are not candidates for further locoregional therapy on study."
2992969|NCT02609815|Active Comparator|glimepiride/metformin|amaryl-Mex 1/500 mg x 2 tablets
2992728|NCT02611635||VKA treatment of AF / Cohort 1|A sample of about 200 patients with non-valvular atrial fibrillation who are treated with VKAs for at least three months at date of study inclusion
2992729|NCT02611635||NOAC treatment of AF / Cohort 2|A sample of about 200 patients with non-valvular atrial fibrillation who are treated with NOACs for at least three months at date of study inclusion
2992730|NCT02611622|Active Comparator|Arm 1: Control|"Participants will be presented with envelopes labeled with a unique block-randomization code and asked to pick one~Once the participant selects an envelope, the research coordinator will verify whether the code assigns the patient to the control or the intervention group, without the knowledge of the otolaryngologist who will be blinded to participant randomization at this point.~Participants in the control group will proceed to filling out Demographic Survey and Patient Satisfaction Survey~Once completed, they will be given the opportunity to discuss any further questions or concerns about their thyroid condition with their otolaryngologist"
2992731|NCT02611622|Experimental|Arm 2: LUMA ENT™|"Participants will be presented with envelopes labeled with a unique block-randomization code and asked to pick one~Once the participant selects an envelope, the research coordinator will verify whether the code assigns the patient to the control or the intervention group, without the knowledge of the otolaryngologist who will be blinded to participant randomization at this point.~Participants in the intervention group will proceed to viewing the LUMA ENT™ videos pertinent to their thyroid condition using either of the two iPADS (the videos should not last longer than 10 minutes)~Once video viewing is complete, participants will be given the opportunity to discuss any further questions or concerns about their thyroid condition with their otolaryngologist, especially as relates to questions that arise as a result of viewing the video~Subsequently, the participants will proceed to filling out Demographic Survey and Patient Satisfaction Survey"
2992732|NCT02611609|Experimental|Cohort 1|Low dose MultiStem
2992733|NCT02611609|Experimental|Cohort 2|High dose MultiStem
2992734|NCT02611609|Experimental|Cohort 3|Highest safe MultiStem dose (from Cohorts 1 and 2) or Placebo
2992735|NCT02611596|Experimental|Ranolazine|Subjects will take one 500mg tablet twice daily (500mg BID) for seven days and then increase to two 500mg tablets twice daily (1000mg BID) for the remainder of the study, for a total of 24 weeks. Subjects taking moderate CYP3A4 inhibitors will not participate in upward titration and will remain on 500mg tablet twice daily (500mg BID) for the duration of the trial.
2992736|NCT02611596|Placebo Comparator|Placebo|Subjects will take one placebo tablet (identical to the 500mg Ranolazine tablet) twice daily (500mg BID) for seven days and then increase to two 500mg tablets twice daily (1000mg BID) for the remainder of the study, for a total of 24 weeks. Subjects taking moderate CYP3A4 inhibitors will not participate in upward titration and will remain on 500mg tablet twice daily (500mg BID) for the duration of the trial.
2992737|NCT02611583|Active Comparator|Ibuprofen and TENS plus|Patients will receive 45 minutes of TENS therapy. All patients will receive ibuprofen.
2992738|NCT02611583|Placebo Comparator|Ibuprofen and Sham TENS plus|Patients will receive 45 minutes of sham TENS therapy. All patients will receive ibuprofen.
2992739|NCT02611570||LDCT and follow-up|LDCT(1.5 mSV) at enrollment. If subjects with positive result of LDCT, then subjects will be under surgery, resection or followed by every 3-12 months for their possible occurrence of lung cancer.The frequency of follow-up depends on their pathological status and changes of nodules.
2992740|NCT02611557|Other|Manual lymphatic drainage therapy|Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
2992741|NCT02611544|Active Comparator|Acceptance and Commitment Therapy|6 weeks, the ACT group will meet weekly for 2 hours at one of three facilities.
2992742|NCT02611544|Active Comparator|Survivorship Education|6 weeks, SE group will meet weekly for 2 hours at one of three facilities.
2992743|NCT02611544|Active Comparator|Enhanced Usual Care|"Continue to meet with their health care team + receive a variety of readings at each data collection point on coping with common survivorship concerns, including a booklet from the National Cancer Institute entitled Facing Forward: Life After Cancer Treatment."
2992744|NCT02611531|Experimental|Video Module Education (VME)|The RE will provide participants with a tablet device and will demonstrate how to access VME and complete the pre/post e-learning assessments. The RE will provide technical support but will neither participate directly in the education nor help with the self-assessments. The participants will first complete the pre-assessment e-learning tool on the tablet. They will then watch the video instruction that will provide a complete demonstration with verbal instructions on correct inhaler technique. Next the participants will complete the post-assessment e-learning tool. Based on participants' performance, they will be directed to further tailored video-instruction. The cycle of self-assessment and video instruction will continue until sufficient mastery has been achieved.
2992745|NCT02611531|Active Comparator|Teach-To-Goal (TTG)|Participants assigned to the TTG condition will be provided with an intensive, iterative education and evaluation strategy that consists of the following steps.
2992746|NCT02611518|Experimental|Panel 1|Participant will be administered a single oral dose of rosuvastatin 10 milligram (mg) on Day 1 and Day 14 and JNJ-54861911 at a dose of 25 mg once daily from Day 8 until Day 17.
2992747|NCT02611518|Experimental|Panel 2|Participant will be administered a single oral dose of metformin 500-mg on Day 1 and Day 14 and JNJ-54861911 at a dose of 25 mg once daily from Day 8 until Day 16.
2992748|NCT02611505|Experimental|Cohort 1|Participants with moderate hepatic impairment will receive esketamine solution (containing 14 milligram [mg] of esketamine base per 100 microliter [mcl]) by intranasal route into each nostril using nasal spray pump at 0 hour (h) on Day 1.
2992749|NCT02611505|Experimental|Cohort 2|Participants with mild hepatic impairment will receive esketamine solution (containing 14 mg of esketamine base per 100 mcl) by intranasal route into each nostril using nasal spray pump at 0h on Day 1.
2992750|NCT02611505|Experimental|Cohort 3|Participants with normal hepatic function and no evidence of liver damage will receive esketamine solution (containing 14 mg of esketamine base per 100 mcl) by intranasal route into each nostril using nasal spray pump at 0h on Day 1.
2992751|NCT02611492|Active Comparator|Intensive Arm (A)|"4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)~+ Post-SCT Maintenance"
2992752|NCT02611492|Experimental|Light Arm (B)|"4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)~+ Post-SCT Maintenance"
2992753|NCT02611466|Experimental|ASP7962|Participants receive 100 mg of ASP7962 orally twice daily for 4 weeks.
2992754|NCT02611466|Active Comparator|Naproxen|Participants receive 500 mg of naproxen orally twice daily for 4 weeks.
2992755|NCT02611466|Placebo Comparator|Placebo|Participants receive placebo orally twice daily for a period of 4 weeks.
2992756|NCT02611453|Experimental|Single arm|"All patients will undergo endoscopic retrograde cholangiopancreatography (ERCP) that is indicated for suspected or confirmed choledocholithiasis or biliary strictures. Air contrast cholangiography using carbon dioxide gas will be performed with standard fluoroscopy and digital subtraction fluoroscopic image capture followed by routine cholangiography using iodinated contrast and standard fluoroscopy. Carbon dioxide (CO2) is routinely used in ERCP procedures and would flow into the biliary tree of patients at the time of ERCP, irrespective of this study's interventions. Digital subtraction image capture is a commercially available setting on certain fluoroscopy units that optimizes resolution with air or CO2 used as a contrast medium."
2992757|NCT02611440|Experimental|Pharmacist Intervention|It will be a semi -structured interviews with patient and pharmacist over various time after the stroke (at Month0, M3, M6, M9) combined with patient's therapeutic follow-up from various healthcare professionals.
2992758|NCT02611440|No Intervention|Control|No pharmacist intervention planned.
2992759|NCT02611427|Active Comparator|Education/Self-efficacy|Booklet about physical activity, movement monitoring device, encouragement
2992760|NCT02611427|Active Comparator|Education|Booklet about physical activity
2992761|NCT02611414|Experimental|anodal tDCS|TDCS will be delivered with two saline-soaked sponge electrodes. The main electrode to anodal stimulation will be placed over the motor cortex, M1. The second electrode is neutral and will be placed on the skin overlying the supraorbital region The current will be delivered at the intensity of 2mA for 20 minutes. The procedure will be repeated at five consecutive days.
2992762|NCT02611414|Sham Comparator|Sham tDCS|Two electrodes are positioned at M1 and supra-orbital área. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes. The procedure will be repeated at five consecutive days.
2992763|NCT02611401|Experimental|Mindulness Based Intervention|intervention with group-based Mindfulness Based Intervention
2992764|NCT02611401|Active Comparator|Active Control|intervention with group-based Psychoeducation and Relaxation
2992765|NCT02611388|Experimental|2/10HZ TEAS pretreatment|Patients were given 30min of 2/10HZ TEAS before anesthesia
2992766|NCT02611388|Experimental|10/50HZ TEAS pretreatment|Patients were given 30min of 10/50HZ TEAS before anesthesia
2992767|NCT02611388|Sham Comparator|fake stimulation|Patients were only attached electrodes without electric current
2992768|NCT02611375|Experimental|tDCS + FTP group|This group of individuals with tetraplegia will receive transcranial direct current stimulation (tDCS) over the hand area of their primary motor cortex (M1). Stimulation at 2mA will be applied for 20 minutes while subjects complete a total of 1 hour of functional task practice (FTP) per session. (Only 20 minutes of functional task practice be be performed with stimulation on). 3 sessions will be completed per week for 4 weeks.
2992769|NCT02611375|Active Comparator|PNSS + FTP group|This group of individuals with tetraplegia will receive peripheral nerve somatosensory stimulation (PNSS) to the median nerve of the primary hand being trained. Stimulation will be set to elicit a sensory - not motor - response. Stimulation will be performed concurrently with the entire functional task practice (FTP) session. 3 sessions will be completed per week for 4 weeks.
2992770|NCT02611375|Active Comparator|sham tDCS + FTP group|This group of individuals with tetraplegia will receive sham transcranial direct current stimulation (tDCS) over the hand area of their primary motor cortex (M1) alongside functional task practice. Stimulation will be briefly turned on at the beginning of FTP and again after 20 minutes of practice in order to create a sham effect and maintain blinding of the participants. 3 sessions will be completed per week for 4 weeks.
2992771|NCT02611362|Experimental|Intervention|"The IMB Gaming Intervention is designed to improve information, motivation, and skills about adherence and HIV preventative behaviors throughout play. The mission of Viral Combat is: kill virus and build strength through taking medicine, learning HIV prevention information, and engaging with healthy characters in order to improve motivation and build skills. Wisepill openings translate into enhanced game play (i.e. nanobucks used to buy game enhancements). Participants will be told to take PrEP daily and phones and software will be coded to record and react to daily dosing. If a participant misses a dose, a message is sent from the Wisepill dispenser to study investigators' database on a secure server. Participants will get a game graphic with a supportive message such as Missing you: Get in the Game to their phones. Throughout the gaming intervention subjects will continue routine clinical care visits and HIV testing in the PrEP clinic."
2992772|NCT02611362|No Intervention|Comparison|This condition will be matched with the IMB Gaming Intervention for appeal, time and attention. Subjects in COMP will each receive smartphones with the same data service plan as the active arm. Smartphones given to participants in COMP will have a stylistically similar non-PrEP, non-IMB game designed by Mission Critical Studios (Dr. Nano X: Incredible Voyage Inside The Body, http://www.youtube.com/watch?v=lyHzSZFzU1Q ). This is the same game that Viral Combat is being adapted from. Therefore, the iPhone game in COMP will have a look and feel that is very similar to our intervention game but without IMB, PrEP, and HIV prevention related content. Participants will also receive a Wisepill device, which records pill dispenser openings, but there will be no dose related game enhancement or messaging. Similar to the Intervention group, participants will have routine clinical care visits in the PrEP clinic (or more frequently if needed for urgent care).
2992773|NCT02611336|Experimental|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 5 months
2992774|NCT02611323|Experimental|Dose-Escalation Cohort: FL|Participants with relapsed or refractory FL will receive 18 weeks of induction treatment with polatuzumab vedotin and venetoclax at escalating doses to identify the recommended Phase 2 dose (RP2D) for polatuzumab vedotin and venetoclax when combined with a fixed dose of obinutuzumab. Those who achieve CR, PR, or SD at the EOI will be eligible to receive a 24-month maintenance regimen consisting of 8 months of venetoclax and 24 months of obinutuzumab.
2992796|NCT02611154|Experimental|Intranasal Testosterone|All participants will be receiving intranasal testosterone and will follow the same study procedures.
2992797|NCT02611141|Other|Patient with Retromolar Gap|20 patients with a retromolar gap between the last erupted molar and the ascending ramus at the right lower mandible.
2992775|NCT02611323|Experimental|Dose-Escalation Cohort: DLBCL|Participants with relapsed or refractory DLBCL will receive 18 weeks of induction treatment. Venetoclax will be administered at escalating doses to identify the RP2D of venetoclax when combined with fixed doses of polatuzumab vedotin and rituximab. Those who achieve CR or PR at the EOI will be eligible to receive an 8-month consolidation regimen consisting of venetoclax and rituximab.
2992776|NCT02611323|Experimental|Expansion Cohort: FL|Participants with relapsed or refractory FL will receive 18 weeks of induction treatment with polatuzumab vedotin and venetoclax at the RP2D identified during the dose-escalation phase, in addition to obinutuzumab. Those who achieve CR, PR, or SD at the EOI will be eligible to receive a 24-month maintenance regimen consisting of 8 months of venetoclax and 24 months of obinutuzumab.
2992777|NCT02611323|Experimental|Expansion Cohort: DLBCL|Participants with relapsed or refractory DLBCL will receive 18 weeks of induction treatment. Venetoclax will be administered at the RP2D identified during the dose-escalation phase, in addition to polatuzumab vedotin and rituximab. Those who achieve CR or PR at the EOI will be eligible to receive an 8-month consolidation regimen consisting of venetoclax and rituximab.
2992778|NCT02611310||Participants with HER2-positive unresectable LA/mBC|
2992779|NCT02611297|Other|Transbronchial lung biopsy with cryoprobe|
2992780|NCT02611284|Experimental|Treatment Cohort (LISA)|All preterm infants born at < 32 WG between October 2013 and November 2014 who met inclusion criteria were managed by the new LISA technique.
2992781|NCT02611284|Other|Historical Cohort (INSURE)|The control group was collected from the period immediately before the study's initiation (from Jun 2012 to September 2013). This cohort was comprised of preterm infants of less than 32 WG who met the inclusion criteria.
2992782|NCT02611271||Piperacillin/Tazobactam|Critically ill patients teated with piperacillin/tazobactam undergoing renal replacement therapy and cytosorb absorption during sepsis
2992783|NCT02611271||Imipenem/Cilastatin|Critically ill patients teated with imipenem/cilastatin undergoing renal replacement therapy and cytosorb absorption during sepsis
2992784|NCT02611258|Experimental|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 5 months
2992785|NCT02611245|Experimental|Indocyanine green|This group of patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. Before systematic lymphadenectomy, four-point of ICG with 10mg was injected in normal lung tissue around the tumor. After 3-5 minutes, fluorescence and white-light images were collected and recorded in real-time. With the guidance of intraoperative images, all fluorescent lymph nodes were removed and sent to routine pathological confirmation.
2992786|NCT02611232|Active Comparator|Victoza®|Subjects with preclinical type 1 diabetes aged 18-30 years are treated with Victoza® (liraglutide)
2992787|NCT02611232|Placebo Comparator|Placebo|Subjects with preclinical type 1 diabetes aged 18-30 years are treated with placebo
2992788|NCT02611219|Experimental|Arm 1: Pediatric patients|"Patients will wear a Fitbit Flex during hospitalization~Completion of Demographic Data Form at baseline, discharge from hospital, and at the six week clinic visit~Assist in recording time out of bed using the SCT Daily Activity Log~Fill out (some with help of parents) applicable questionnaires: Child Health Ratings Inventories-General Health Module (5-12 years), General Health Module-Baseline Adolescent-Self Report (13-18 years), General Health Module-Follow Up Adolescent-Self Report (13-18 years) at baseline, discharge from hospital, and at six week clinic visit~Patients will be assessed using standard physical therapy assessment tools to determine functioning, muscle strength, endurance, and mobility: The Functional Independence Measure for Children and Manual Muscle Testing is done weekly, discharge from hospital, and at six week clinic visit. The 3-Minute Step Test is done at admission, discharge from hospital, and at six week clinic visit."
2992789|NCT02611219|Experimental|Arm 2: Parents of pediatric patients|"Parents will be considered participants as they will be completing study questionnaires.~Completion of Demographic Data Form at baseline~Assist in recording time out of bed using the SCT Daily Activity Log~Fill out applicable questionnaires: General Health Module-Baseline Parent Report -Adolescent (13-18 Years), General Health Module-Follow Up Parent Report-Adolescent (13-18 years), General Health Module-Baseline Parent Report-School Age (5-12 years), and General Health Module Follow Up Parent Report-School Age (5-12 years), HSCT Module-Follow UP Parent Report School Age (5-12 years), HSCT Module-Follow Up Parent Report Adolescent (13-18 years), HSCT Module-Follow Up Adolescent-Self Report (13-18 years), HSCT Module-Follow Child-Self Report (5-12 years) at baseline, discharge from hospital, and at six week clinic visit.~Assist child with Child Health Ratings Inventories-General Health Module (5-12 years) at baseline, discharge at hospital, and at six week clinic visit"
2992790|NCT02611206|Experimental|Open Label rTMS|All participants who qualify will undergo 6 weeks of open-label rTMS.
2992791|NCT02611193|Experimental|Manipulative treatment|Manipulative Treatment
2992792|NCT02611193|Sham Comparator|Simulated manipulative treatment|Simulated manipulative treatment
2992793|NCT02611180||Arm 1: Acute skin GVHD|"When clinically indicated, patients will undergo a skin biopsy to confirm a suspected diagnosis of acute or chronic GVHD, or to assess the status of their previously diagnosed acute or chronic GVHD. After the necessary samples are obtained for optimal medical care of the patient, two 6 mm punch biopsies (or four 4 mm punch biopsies) will be performed for research purposes, one (or two) of the affected area and one (or two) of a non-affected area (normal skin).~Patients who have clinical resolution of their acute or chronic GVHD will undergo one additional 6 mm punch biopsy (or two additional 4 mm punch biopsies) of the previously affected area. This additional biopsy should occur within 10 cm of the previous affected area sample.~With each skin biopsy, peripheral blood will be obtained by venipuncture or cannulation of an indwelling venous access device."
2992794|NCT02611180||Arm 2: Chronic skin GVHD|"When clinically indicated, patients will undergo a skin biopsy to confirm a suspected diagnosis of acute or chronic GVHD, or to assess the status of their previously diagnosed acute or chronic GVHD. After the necessary samples are obtained for optimal medical care of the patient, two 6 mm punch biopsies (or four 4 mm punch biopsies) will be performed for research purposes, one (or two) of the affected area and one (or two) of a non-affected area (normal skin).~Patients who have clinical resolution of their acute or chronic GVHD will undergo one additional 6 mm punch biopsy (or two additional 4 mm punch biopsies) of the previously affected area. This additional biopsy should occur within 10 cm of the previous affected area sample.~With each skin biopsy, peripheral blood will be obtained by venipuncture or cannulation of an indwelling venous access device."
2992795|NCT02611167|Experimental|Intravenous bone marrow-derived MSC transplantation|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
2992798|NCT02611141|Other|Patient without a Retromolar Gap|20 patients without a retromolar gap between the last erupted molar and the ascending ramus at the right lower mandible.
2992799|NCT02611128||Peripubertal girls|Peripubertal girls with varying androgen concentrations will have careful phenotype/genotype assessment, primarily to assess the relationship between urinary exosomal DENND1A.V2 and serum free testosterone concentrations.
2992800|NCT02611102|Experimental|MCT oil + Butter in Coffee|This group will be provided with MCT oil and butter to add to their daily coffee intake.
2992801|NCT02611102|Placebo Comparator|Low calorie coffee|This group will continue to drink their normal daily coffee with < 50kcal of creamer and/or sweetener.
2992802|NCT02611089||Radial dysplasia patients|Recruited participants will have 2-3 small tissue biopsy samples taken during 1-2 of their planned reconstructive surgical procedures for radial dysplasia, whilst under general anaesthesia in the operating theatre. Samples will be taken by scalpel or scissors, by the operating surgeon, from within the surgical site in the forearm and hand. The skin incision and deep dissection will have to be made as part of the normal course of reconstructive surgery, regardless of participation in this study.
2992803|NCT02611089||Control patients|Recruited participants will have 2-3 small tissue biopsy samples taken during their planned reconstructive surgery for hand trauma, whilst under general anaesthesia in the operating theatre. Samples will be taken by scalpel or scissors, by the operating surgeon, from within the surgical site in the forearm and hand. The skin incision and deep dissection will have to be made as part of the normal course of reconstructive surgery, regardless of participation in this study.
2992804|NCT02611076|Experimental|Stop Smoking for Good Intervention in Spanish|Study II: Stop Smoking for Good Intervention in Spanish (SS-SP) will comprise a series of 10 booklets distributed over 18 months, plus additional monthly contacts via 9 supportive pamphlets developed in Study I. Behavioral: Stop Smoking for Good Intervention in Spanish (SS-SP) Assessments will occur at six-month intervals, through 24 months.
2992805|NCT02611076|Active Comparator|Usual Care|Study II: Usual Care (UC) will comprise a single, Spanish-language, smoking cessation booklet developed by the National Cancer Institute (NCI). Behavioral: Usual care (UC) Assessments will occur at six-month intervals, through 24 months.
2992806|NCT02611063|Experimental|fostamatinib|Subjects will receive fostamatinib 100 mg qd, 150 mg qd, or 100 mg bid with dosage determined by the modified continual reassessment method. The treatment period begins at baseline 90 days after transplant and continues for up to 1 year after transplant. In patients with steroid-refractory cGVHD who are also included on this study, these subjects also receive fostamatinib 100mg qd, 150mg qd, or 100mg bid dosage determined by the modified continual reassessment method.
2992807|NCT02611050|Experimental|Option Grid|Patients randomized to the Option Grid arm will receive the Multi-vessel Coronary Artery Disease Option Grid at the time of enrollment. The treating physician will then discuss the patient diagnosis and treatment choice reviewing the Option Grid within the conversation to facilitate patient understanding and shared decision making
2992808|NCT02611050|Other|Usual Care|Patients randomized to usual care will discuss the patient diagnosis and treatment options typical to the physician's routine care.
2992809|NCT02611037|Experimental|Chemoperfusion + Questionnaire|"Transarterial Chemoperfusion treatment with cisplatin (35 mg/m^2), methotrexate (100 mg/m^2) and gemcitabine (1000 mg/m^2).~Patients undergo angiogram and transarterial chemoperfusion treatment in every 4 weeks (3-6 weeks interval allowed) when cisplatin, methotrexate and gemcitabine will be administered into the thoracic aorta and/or the internal mammary artery on the side of the disease.~Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire."
2992810|NCT02611024|Experimental|PM01183 Escalation Group|"PM01183 1.0 mg/m2 D1 60 min i.v. infusion q3wk~Irinotecan 75 mg/m2 D1-8 90 min. i.v. infusion q3wk"
2992811|NCT02611024|Experimental|Irinotecan Escalation Group|"PM01183 3.0 mg/m2 D1 60 min i.v. infusion q3wk~Irinotecan 15 mg/m2 D1-8 90 min. i.v. infusion q3wk"
2992812|NCT02611011||Women|Women seeking health services will perform the Congo Red Dot test (GV-005) individually by following the the test instructions
2992813|NCT02610985|Active Comparator|2-Dimensional laparoscopic hysterectomy|traditional 2-D laparoscopy
2992814|NCT02610985|Experimental|3-Dimensional laparoscopic hysterectomy|experimental 3-D laparoscopy
2992815|NCT02610972||CLINICALLY CONFIRMED PREECLAMPSIA|Women clinically diagnosed with preeclampsia (severe, mild or superimposed) during pregnancy will provide a urine sample in the postpartum period to determine the presence or absence of proteinuria using the Congo Red test GV-005.
2992816|NCT02610972||CLINICALLY HEALTHY|Women with a delivery of a healthy normal baby at term (induction of labor or an elective Caesarean Section) will provide a urine sample in the postpartum period to determine the presence or absence of proteinuria using the Congo Red test GV-005.
2992817|NCT02610959|Experimental|Intervention group|Intervention with cod 200 grams two times the week for four months.
2992818|NCT02610959|Experimental|Control group|Control group which will continue to eat their habitual diet.
2992819|NCT02610946|Placebo Comparator|Paper-based|Use of paper-based calenders, reminders, medication list, and blood pressure, fluid intake tracking methods in adolescent renal transplant care
2992820|NCT02610946|Experimental|Electronic application|Use of electronic apps (iphone or i-Pad mini) to determine whether it can improve compliance with transplant care and readiness to transition to adult care.
2992821|NCT02610933|No Intervention|Vitamin K antagonist|Vitamin K antagonist treatment targeting an international normalized ratio of 2 to 3 for 18 months
2992822|NCT02610933|Active Comparator|rivaroxaban|Rivaroxaban 10 mg tablet by mouth once daily for 18 months
2992823|NCT02610933|Active Comparator|rivaroxaban and vitamin K2|Rivaroxaban 10 mg tablet by mouth once daily and MK-7 2000 microgram tablet by mouth thrice weekly for 18 months
2992824|NCT02610920|Experimental|Iron-tracer Injection and Biopsy|Single injection of 30mg of iron sucrose followed by axillary ultrasound-guided biopsy of lymph node within 2 hours.
2992825|NCT02610907|Experimental|Cohort 01a|"This is a sub-study testing three patches consisting of an adhesive patch and a sleeve. The sleeve can contain one of three solutions:~Buffer Own output Simulated output (digestive enzymes)~All subjects will test the three solutions at the same time, hence the three patches with different solutions will be placed on the peristomal skin simultanously."
2992826|NCT02610894|Active Comparator|Treatment Group|An mHealth application [Postoperative Care at Home mHealth application (PoCAH)] accessed via iPad mini.
2992827|NCT02610894|Sham Comparator|Control Group|Access via iPad Mini of usual and standard discharge and care instructions.
2992828|NCT02610881|Experimental|Iron and Folic Acid (IFA)/Micronutrient Powders (MNP)|Participants will receive iron and folic acid (IFA) drops for one month followed by a two week washout period. Participants will then receive micronutrient powders (MNP) for one month. Mothers of participants will receive counseling on the benefits of iron intake, side effects of IFA, and preservation of IFA bottles and MNP sachets.
2992829|NCT02610881|Experimental|Micronutrient Powders (MNP)/Iron and Folic Acid (IFA)|Participants will receive micronutrient powders (MNP) for one month followed by a two week washout period. Participants will then receive iron and folic acid (IFA) drops for one month. Mothers of participants will receive counseling on the benefits of iron intake, side effects of IFA, and preservation of IFA bottles and MNP sachets.
2992830|NCT02610868|Experimental|MYOBLOC Injection|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections over the course of 1 year.
2992831|NCT02610855|Active Comparator|Spinal Fusion Surgery|The surgical participants recruited from the pediatric orthopaedic clinic and have severe scoliosis curves requiring posterior spinal fusion. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified before and one year after spinal fusion surgery.
2992832|NCT02610855|Active Comparator|Brace Treatment|The bracing participants have scoliosis curves that require treatment with a spinal brace for at least the next year. All braces will have monitors to record hours of brace wear, as is current standard of care. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified before bracing and after one year.
2992833|NCT02610855|Other|Control Arm|The control group are participants who do not have scoliosis. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified at baseline and one year after enrollment.
2992834|NCT02610842|Experimental|Handbook group|"Patients will receive a home based program named Hands on - a hand care guide in Systemic Sclerosis which includes a handbook with instructions about the disease and hand exercises. Patients will be asked to follow the program instructions and carry out the exercises daily during the following 12 weeks."
2992835|NCT02610829|Experimental|Gamma Tocopherol|Subjects will ingest 1400 mg gamma tocopherol, orally administered in 3 doses separated by 12 hours.
2992836|NCT02610816|Active Comparator|1FED|1-food elimination diet: Participants eliminate milk from the diet in Phase 1
2992837|NCT02610816|Active Comparator|4FED|4-food elimination diet: Participants eliminate milk, egg, wheat, soy from the diet in Phase 1
2992838|NCT02610816|Other|1FED Non-Responders (4FED)|Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy from the diet in Phase 2
2992839|NCT02610816|Other|4FED Non-Responders (SGC)|Participants that fail to respond to 4FED in Phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily in Phase 2
2992840|NCT02610803||Patients with ischemic stroke|Patients admitted with ischemic stroke from August 2008 to April 2011 (Retrospectively defined).
2992841|NCT02610790||Connected bracelet|Patients with a colorectal surgery planned will be included. Fifteen days before surgery, patients will have a connected bracelet permitting to quantify the number of steps and distance achieved each day before surgery.
2992842|NCT02610777|Active Comparator|Azacitidine|Azacitidine 75 milligram per square meter (mg/m^2), intravenously or subcutaneously, on Days 1 to 5, Days 8 and 9 in 28-day treatment cycles.
2992843|NCT02610777|Experimental|Azacitidine + Pevonedistat|Azacitidine 75 mg/m^2, intravenously or subcutaneously, on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m^2, 60-minute (±10) infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles.
2992844|NCT02610764|Experimental|Experimental diagnostic test|"Evaluation and enumeration of circulating Tumor cells from the blood with two different CTC-detection platforms: one established test (CellSearch) and one experimental test (ScreenCell).~Control diagnostic test: CT-Scan of the Chest and the Abdomen, Endoscopy and Endosonography, Clinical response and histo pathologic response. (% Of vital tumor Cells in the histologic specimen)."
2992845|NCT02610751||Smoking|No interventions were applied to this group. Measurements of female fetal testosterone, maternal cotinine and testosterone levels, newborn anogenital distance, second digit to fourth digit (2D:4D) finger length ratio, newborn length and birth weight are collected.
2992846|NCT02610751||Non-smoking|No interventions were applied to this group. Measurements of female fetal testosterone, maternal cotinine and testosterone levels, newborn anogenital distance, second digit to fourth digit (2D:4D) finger length ratio, newborn length and birth weight are collected.
2992847|NCT02610738|Experimental|Junior KICk-OFF education programme|Participants will attend an age appropriate self management programme (Junior KICk-OFF) designed to improve their knowledge and understanding of type 1 diabetes
2992848|NCT02610725|Other|Yoga class|A 30 minute online Hatha yoga video intervention will be administered to participants.Participants will only participate in one yoga class and complete follow-up questionnaires.
2992849|NCT02610712|Experimental|TRD patients|Treatment-Resistant (TRD) patients to receive intravenous ketamine at 0.5 mg/kg dose.
2992850|NCT02610699|Active Comparator|Smartphone otoscope/Conventional otoscope|Participating clinicians will use a smartphone otoscope for one month followed by a conventional otoscope for one month, alternating monthly, for a total of 6 months to examine children between 6 months and 18 years of age who have clinical signs of acute otitis media (AOM).
2992851|NCT02610699|Active Comparator|Conventional otoscope/Smartphone otoscope|Participating clinicians will use a conventional otoscope for one month followed by a smartphone otoscope for one month, alternating monthly, for a total of 6 months to examine children between 6 months and 18 years of age who have clinical signs of acute otitis media (AOM).
2992852|NCT02610686|Other|Chloroquine|Single treatment arm
2992853|NCT02610647|Other|Control group|"Subjects randomized to this group will have a tapping test with no sensory blocking.~Intervention: Tapping test"
2992854|NCT02610647|Experimental|Wrist anesthesia|"Subjects randomized to this group will have an axillary block / regional anesthesia followed by a tapping test.~Intervention: Wrist anesthesia~Intervention: Tapping test"
2992897|NCT02610322|Placebo Comparator|Control group|Usual diet: to receive a conventional lifestyle education on MetS.
2992855|NCT02610647|Experimental|Wrist anesthesia, masked|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear a blinding mask, and then will perform a tapping test.~Intervention: Wrist anesthesia~Intervention: Blinding mask~Intervention: Tapping test"
2992856|NCT02610647|Experimental|Wrist anesthesia, helmet|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear an anti-noise helmet, and then will perform a tapping test.~Intervention: Wrist anesthesia~Intervention: Anti-noise helmet~Intervention: Tapping test"
2992857|NCT02610647|Experimental|Wrist anesthesia, masked & helmet|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear a blinding mask, will wear an anti-noise helmet, and then will perform a tapping test.~Intervention: Wrist anesthesia~Intervention: Blinding mask~Intervention: Anti-noise helmet~Intervention: Tapping test"
2992858|NCT02610634||Parkinson's disease|People with Parkinson's disease (≥ 50 years old) who do not have dementia (MoCA ≥ 21).
2992859|NCT02610634||Older Adults|Aged-matched older adults (≥ 50 years old) who are cognitively intact (MoCA ≥26).
2992860|NCT02610621|Experimental|Lumpectomy without sentinel node biopsy|Subjects will undergo standard of care lumpectomy. A biopsy of the sentinel node will not be performed. After surgery, subjects will receive standard of care radiation on the affected breast and chemotherapy.
2992861|NCT02610608||Women undergoing ART|Observation of the incidence of venous and arterial thrombosis following ovarian stimulation
2992862|NCT02610595|Experimental|experimental group|Jianpixiaozhong particles and Wuse Dietotherapy
2992863|NCT02610582|Experimental|Single Arm|"dose escalation rAAVhCNGA3~low dose: ≤ 1x10e10 vgp (n=3)~intermediate dose: ≤ 5x10e10 vgp (n=3)~high dose: ≤ 1x10e11 vgp (n=3)"
2992864|NCT02610569|Active Comparator|standart endoscopy|Intervention: 2 standard endoscopy during anti-TNFalpha or vedolizumab treatment
2992865|NCT02610569|Experimental|PillCamCOLON (C2)|Intervention : 2 PillCamCOLON (C2) during anti-TNFalpha or vedolizumab treatment
2992866|NCT02610556|Experimental|TP plus IMRT|Concurrent chemotherapy: TP - Docetaxel 60mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
2992867|NCT02610556|Active Comparator|DDP plus IMRT|Concurrent chemotherapy: DDP - Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
2992868|NCT02610543|Experimental|UCB5857|UCB5857 once daily for 12 weeks
2992869|NCT02610543|Placebo Comparator|Placebo|Placebo once daily for 12 weeks
2992870|NCT02610530||Non-Surgery|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2 who have been on medical treatment for glycemic control.
2992871|NCT02610530||Surgery-A|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2. who underwent sleeve gastrectomy with ileal transposition
2992872|NCT02610530||Surgery-B|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2. who underwent sleeve gastrectomy with transit bipartition
2992873|NCT02610517|Other|Provider Training|Training providers to offer alcohol pharmacotherapy to at-risk drinkers interested in quitting or reducing their drinking as part of overall HIV care could be an important strategy to reduce hazardous alcohol use in this medically-ill population.
2992874|NCT02610517|Other|Patient Intervention|Determine the effectiveness of a computer-delivered brief intervention (CBI) for reducing hazardous drinking in the HIV clinical care setting at two intervention clinics: University of Alabama at Birmingham (UAB) and the University of Washington (UW).
2992875|NCT02610504|Experimental|Durolane 3ml|Single intra-articular injection into shoulder
2992876|NCT02610491|Placebo Comparator|Placebo|Cellulose
2992877|NCT02610491|Active Comparator|Hesperidin|Citrus peel extract
2992878|NCT02610452|Experimental|The study population|"The study population consists of adult patients treated in the Palliative Care Unit of the University Hospital of Nimes, regardless of their original condition. In 2013 the proportion of stays connected with diagnostics for cancer was 70.16%.~Intervention: Clown therapy"
2992879|NCT02610439||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
2992880|NCT02610426||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
2992881|NCT02610413||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
2992882|NCT02610400|Experimental|RACD+RAVC|"In this arm, subjects will receive both:~(i) reactive case detection (RACD) and (ii) additional reactive vector control (RAVC)"
2992883|NCT02610400|Experimental|RACD without RAVC|In this arm, subjects will receive RACD, however without the addition of RAVC.
2992884|NCT02610400|Experimental|TPE+RAVC|"In this arm, subjects will receive both:~(i) targeted parasite elimination (TPE) and (ii) RAVC."
2992885|NCT02610400|Experimental|TPE without RAVC|In this arm, subjects will receive TPE, however without the addition of RAVC.
2992886|NCT02610387|Active Comparator|Arm 1:tDCS|Transcranial direct current stimulation (tDCS) Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days
2992887|NCT02610387|Sham Comparator|Arm 2: Sham tDCS|Sham tDCS and simultaneous balance training(20 minutes) for 5 consecutive days
2992888|NCT02610374|Other|Cohort A|HIV-positive individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
2992889|NCT02610374|Other|Cohort B|HIV-negative high-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
2992890|NCT02610374|Other|Cohort C|HIV-negative low-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
2992891|NCT02610361|Experimental|BGB-283|
2992892|NCT02610348|Experimental|Group A|Toddlers vaccinated with Hexaxim®/Hexyon®/Hexacima® in study A3L12
2992893|NCT02610348|Experimental|Group B|Toddlers vaccinated with Infanrix hexa® in study A3L12
2992894|NCT02610335|Active Comparator|Control group (C)|Kyphosis reeducation + patient education + auto-reeducation at home
2992895|NCT02610335|Other|Test group (M)|Spinal mobility reeducation + patient education + auto-reeducation at home.
2992896|NCT02610322|Experimental|Whole soy group|Whole soy replacement diet: to incorporate 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods.
2992898|NCT02610309|Experimental|Family-Based Crisis Intervention|The Family-Based Crisis Intervention (FBCI) is a single-session intervention that takes place in the Emergency Department. Adolescents randomized to the experimental condition received a standard psychiatric evaluation followed by the experimental intervention. FBCI was administered by licensed psychiatric social workers who were trained in the intervention. The research clinician provided FBCI to the suicidal adolescent and his/her parent(s)/guardian(s) in a 60-90 minute session in which she helped the adolescent and family develop a joint crisis narrative of the problem and taught them cognitive-behavioral skill-building, therapeutic readiness, psycho-education about depression, and safety planning.
2992899|NCT02610309|No Intervention|Treatment As Usual|Treatment as usual included an emergency psychiatry evaluation (standard care).
2992900|NCT02610296|Active Comparator|QPI-1002|QPI-1002 Injection, single dose
2992901|NCT02610296|Placebo Comparator|Placebo|isotonic saline
2992902|NCT02610283|Active Comparator|QPI-1002|QPI-1002 Injection, single dose
2992903|NCT02610283|Placebo Comparator|Placebo|isotonic saline
2992904|NCT02610270|Experimental|2 Gums|Athletes that continued their usual training and diet, who took 2 gums of omega 3 (DHA 760 mg) during the experimental period.
2992905|NCT02610270|Experimental|3 Gums|Athletes that continued their usual training and diet, who took 3 gums of omega 3 (DHA 1140 mg) during the experimental period.
2992906|NCT02610270|No Intervention|Control|Athletes and coaches that continued their usual training and diet, but did not take any supplements during the experimental period.
2992907|NCT02610257|Active Comparator|Vibration Relevant|Vibration applied on the muscle belly after 'motor block' onset
2992908|NCT02610257|Active Comparator|Neutral Vibration Relevant|Vibration applied on a bony mark after 'motor block' onset
2992909|NCT02610257|Active Comparator|Neutral Vibration Non-Relevant|Vibration applied on a bony mark before 'motor block' onset
2992910|NCT02610257|Active Comparator|Vibration Non-Relevant|Vibration applied on the muscle belly after 'motor block' onset
2992911|NCT02610257|No Intervention|No Vibration|
2992912|NCT02610244|No Intervention|Treatment As Usual|Standard treatment as usual as directed by the physician.
2992913|NCT02610244|Experimental|Modified Cogmed Training|10 weeks of computerized training (3x weekly for 35-minutes each session) that targets thinking skills that are often impaired in individuals diagnosed with ADHD.
2992914|NCT02610231|Experimental|Istradefylline 20 mg or 40 mg|Treatment for 52 weeks
2992915|NCT02610218||histo-HER2+ gastric cancer patients|Histologically HER2 positive gastric cancer patients treated with HER2 targeted therapy. Interventions: peripheral blood samples of 12.5 mL for CTC and cfDNA analysis will be collected before targeted therapy, at the time that they achieve the optimal response and when they suffer progressive disease.
2992916|NCT02610218||histo-HER2- gastric cancer patients|Histologically HER2 negative gastric cancer patients treated with chemotherapy. Interventions: peripheral blood samples of 12.5 mL for CTC and cfDNA analysis will be collected before targeted therapy, at the time that they achieve the optimal response and when they suffer progressive disease.
2992917|NCT02610205||Caring touch interventions|The study was conducted as a mixed-methods design. A recruitment of potential study participants was made up from a list of incoming patients arriving at the emergency department following an MVA, and who upon medical examinations were given an injury severity score between 0-3 and subsequently discharged straight home. ISS is a 0-8 point scale rating injury severity, where a rating of 0 indicates no physical injury; 1-3 represents minor physical injuries. The patients were informed about the study by mail during the week after the MVA, and those interested in participating in the caring touch intervention were asked to contact the investigator and subsequently completed a written informed consent form during the first encounter with the therapist.
2992918|NCT02610179|Active Comparator|Standard Glucola GCT|A prospective cohort of 617 women who will undergo screening for gestational diabetes with the standard glucola GCT between 24 and 28 weeks gestational age.
2992919|NCT02610179|Experimental|Twizzlers challenge|At a later date, the same prospective cohort of 617 women Participants will receive their Twizzlers challenge between 24 and 28 weeks gestational age.
2992920|NCT02610166|Experimental|Game|Access to the game.
2992921|NCT02610166|Active Comparator|Usual Care|Control group.
2992922|NCT02610153||Cohort 1|Adult patients, diagnosed with no-valvular atrial fibrillation and who have recently initiated or are going to initiate VKA treatment, that attend the Cardiology Units
2992923|NCT02610140|Experimental|BAY 94-9343|Drug Anetumab ravtansine given Intravenously (IV)
2992924|NCT02610140|Active Comparator|Vinorelbine|Drug Vinorelbine given Intravenously
2992925|NCT02610127||OBIZUR - Prospective Participants|Participants enrolled and treated with Obizur after the prospective study start date
2992926|NCT02610127||OBIZUR - Retrospective Participants|Retrospective chart review of participants treated with OBIZUR from product approval date until prior to the prospective study start date
2992927|NCT02610114|Experimental|Z-Score and computer algorithm|
2992928|NCT02610114|Active Comparator|Z-Score|
2992929|NCT02610101|Active Comparator|Traditional SCD Diet|7 subjects will be randomized to a traditional SCD diet
2992930|NCT02610101|Active Comparator|Modified SCD Diet|"7 subjects will be randomized to a modified SCD diet, which includes oatmeal and rice"
2992931|NCT02610101|Active Comparator|Whole Foods Diet|"7 subjects will be randomized to a Whole foods diet without added sugars"
2992932|NCT02610088|Active Comparator|Dapagliflozin|Dapagliflozin will be started in patient with type 2 diabetes mellitus
2992933|NCT02610088|Active Comparator|Gliclazide|Gliclazide will be started in patient with type 2 diabetes mellitus
2992934|NCT02610075|Experimental|AZD1775|This is a single-arm study in which all patients will receive AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
2992935|NCT02610062|Experimental|Dose Escalation of AGS67E Schedule 1|Participants will receive AGS67E as an intravenous infusion once every three weeks (Q3) to determine a safe dose for future development.
2992936|NCT02610062|Experimental|Dose Escalation of AGS67E Schedule 2|Participants will receive AGS67E as an intravenous infusion once weekly for three weeks to determine a safe dose for future development.
2992968|NCT02609815|Experimental|gemigliptin/metformin|zemimet-SR 50/1000 mg x 1 tablet
2992937|NCT02610062|Experimental|Dose Expansion of AGS67E Schedule 1|Participants will receive AGS67E dose level deemed safe in the dose escalation part of the study once every three weeks (Q3).
2992938|NCT02610062|Experimental|Dose Expansion of AGS67E Schedule 2|Participants will receive AGS67E dose level deemed safe in the dose escalation part of the study once weekly for three weeks.
2992939|NCT02610049|Active Comparator|Control|Subjects will receive 8 sessions of Cognitive Processing Therapy.
2992940|NCT02610049|Experimental|Experimental|Subjects will receive 8 sessions of CPT + Art Therapy 8 sessions of individual therapy.
2992941|NCT02610049|Experimental|Experimental 2|Subject to receive 8 sessions of individual therapy for Art + CPT Cognitive Processing Therapy intervention pre-specified to be administered separately.
2992942|NCT02610036||neuropathic type 2 diabetic patients|the foot ulcer of 30 neuropathic and 30 neuroischemic type 2 diabetic patients
2992943|NCT02610036||neuroischemic type 2 diabetic patients|the foot ulcer of 30 neuropathic and 30 neuroischemic type 2 diabetic patients
2992944|NCT02610023||Observational (Willett FFQ, Fred Hutchinson FFQ, CCAT)|After consenting to participate in this study, participants will visit the Clinical Research Center (CRC) on 3 occasions. One of the three FFQ's will be completed at each visit and there will be 4 to 6 weeks between visits. Participants will also complete a blood draw and assessment of skin carotenoids at this CRC visit. Prior to each visit, participants will complete a 3-day diet record, a daily sun exposure diary, and a 3-day activity record.
2992945|NCT02610010|Experimental|IMRT alone|Intensity-modulated radiotherapy without cisplatin-based concurrent chemotherapy
2992946|NCT02610010|Active Comparator|IMRT plus concurrent chemotherapy|Intensity-modulated radiotherapy with cisplatin-based concurrent chemotherapy
2992947|NCT02609997|Experimental|Single-piece IOL Group|Age-related cataract patients receive in-the-bag implantation of a single-piece IOL
2992948|NCT02609997|Experimental|Three-piece IOL Group|Age-related cataract patients receive in-the-bag implantation of a three-piece IOL
2992949|NCT02609984|Experimental|Combination|CMB305 and atezolizumab
2992950|NCT02609984|Active Comparator|Control|Atezolizumab
2992951|NCT02609971|Experimental|Vibration group|The vibration group (Vibration at 50 Hz) will hold an exercise protocol on the vibration platform (model Power Plate® pro5 ™), which is to stay on on affected limb, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 50 Hz.
2992952|NCT02609971|No Intervention|Control group|The control group (No vibration) will hold an exercise protocol on the vibration platform, which is to stay on affected limb, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. The vibrating platform will remain off throughout intervention.
2992953|NCT02609958|Experimental|Treatment Arm A|Varlitinib (ASLAN001) tablets
2992954|NCT02609945|Experimental|CVT-427 (zolmitriptan inhalation powder)|"Periods 1-2: Subjects will receive Zomig oral tablet in Period 1 and Zomig nasal spray in Period 2, 1 hour apart.~Periods 3-6: Subjects will receive CVT-427 (dose levels (DL) 1, 2, 3 and 4), administered in ascending order provided that safety and tolerability data are observed to be adequate to allow dose escalation, approximately 24 hours after preceding DL."
2992955|NCT02609932|Other|SD or SS|In this study, IFN- γ-1b will be subcutaneously administered a total of 30 subjects in one of two cohorts; Single Dose (SD) or Steady State (SS) dosing. Dosing of IFN- γ-1b will be based upon the time subject became eligible and started study. In this non-randomized, open-label study, subjects will be enrolled on the SD cohort first, and once that cohort has been filled, enrollment to the SS cohort will begin. Although not required, subjects in the SD cohort may also volunteer to participate in the SS cohort if they still meet eligibility criteria. Separate consents will be used for the SD and SS cohorts. In the event not all the SD subjects choose to continue onto the SS cohort, we will plan to recruit new participants from our local campus community.
2992956|NCT02609906|Other|PhilosTM with augmentation (Depuy-Synthes)|The intervention group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes)
2992957|NCT02609906|Other|MultiLoc®-Nail (Depuy-Synthes)|The comparison group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes).
2992958|NCT02609893|Active Comparator|Modified Directly Observed Therapy|Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV-SOF) tablet (LDV 90mg/SOF 400mg) observed daily dosing (modified for non-observed Saturday and Sunday dosing) for 8 weeks
2992959|NCT02609893|Active Comparator|Unobserved Dosing|Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV-SOF) tablet (LDV 90mg/SOF 400mg) provided weekly (7 tablets) for unobserved daily dosing for 8 weeks
2992960|NCT02609880|Experimental|Cognitive Behavioral Therapy|This group will receive Cognitive Behavioral Therapy to optimize sleep, pain, and mood in women with gynecologic cancers. The therapy will be provided on a one-on-one basis, for 2 hours once a week for six weeks by a trained therapist with a master's degree in Clinical Psychology.
2992961|NCT02609880|Placebo Comparator|Psychoeducation|This group will receive Psychoeducation which is aimed at providing information, resources, and non-specific support related to adapting well to cancer. The education will be provided on a one-on-one basis, for 2 hours once a week for six weeks by a trained therapist with a master's degree in Clinical Psychology.
2992962|NCT02609867|Experimental|Flowise Cerebral Flow Diverter|Flowise Cerebral Flow Diverter (TaeWoong Medical Co., Ltd. Korea)
2992963|NCT02609854|Experimental|Sham Sustained Acoustic Medicine Device|Sham Sustained Acoustic Medicine device - the device is to be used 4 hours/day, ≥4 days per week for 8 weeks.
2992964|NCT02609854|Experimental|3 MHz Sustained Acoustic Medicine Device|3 MHz Sustained Acoustic Medicine device - the device is to be used 4 hours/day, ≥4 days per week for 8 weeks.
2992965|NCT02609841||Cardiac rhythm remote monitoring system|Subjects use non-invasive wearable BodyGuardian remote monitoring system throughout 12 days of study.
2992966|NCT02609828|Experimental|Arm 1|Tanezumab 20 mg subcutaneously
2992967|NCT02609828|Placebo Comparator|Arm 2|Placebo matched to active treatment subcutaneously
2992970|NCT02609802|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
2992971|NCT02609802|Experimental|Desflurane|Anesthesia was maintained with desflurane.
2992972|NCT02609789|Experimental|Part A: Dose 1|Drug JNJ-55920839 or Placebo administered IV infusion Dose 1.
2992973|NCT02609789|Experimental|Part A: Dose 2|Drug JNJ-55920839 or Placebo administered IV infusion Dose 2.
2992974|NCT02609789|Experimental|Part A: Dose 3|Drug JNJ-55920839 or Placebo administered IV infusion Dose 3.
2992975|NCT02609789|Experimental|Part A: Dose 4|Drug JNJ-55920839 or Placebo administered IV infusion Dose 4.
2992976|NCT02609789|Experimental|Part A: Dose 5|Drug JNJ-55920839 or Placebo administered IV infusion Dose 5.
2992977|NCT02609789|Experimental|Part A: Dose 6|Drug JNJ-55920839 or Placebo subcutaneous injection Dose 6.
2992978|NCT02609789|Experimental|Part B|Participants will receive 6 doses of JNJ-55920839 or placebo (every 2 weeks) as an IV infusion.
2992979|NCT02609776|Experimental|Part 1: Dose Escalation|The first cohort of participants will receive intravenous infusions of JNJ-61186372 at a dose of 140 milligram (mg). Each subsequent cohort will receive intravenous infusions of JNJ-61186372 at an increased dose level. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered. Participants will receive intravenous infusion of JNJ-61186372 once weekly during cycle 1 and once every 2 weeks during subsequent cycles. The duration of each treatment cycle is 28 days.
2992980|NCT02609776|Experimental|Part 2: Dose Expansion|Participants will receive intravenous infusion of JNJ-61186372 at the recommended Phase 2 dose (RP2D) regimen(s) once weekly during cycle 1 and once in 2 weeks for subsequent cycles. The duration of each treatment cycle is 28 days.
2992981|NCT02609750|Experimental|Structured care & workplace intervention|Through a flow chart the investigators in detail specify the medical and work place interventions (all according to evidence-based guidelines). Red, yellow and blue flags, and motivational factors are identified in a screening investigation. The aim of the screening is to individually tailor the rehabilitation interventions. Physiotherapy interventions are based on a bio-psychosocial and cognitive behavioural therapy perspective. Behavioural medicine treatment principles include careful examination and treatments such as advice to stay active, instructions, OMI, OMT, MDT. The investigators apply interventions based on ergonomics, motivational factors and work place changes according to Convergence Dialogue Meetings (CDM).
2992982|NCT02609750|Active Comparator|Treatment as Usual|Patients follows the PHCs standard schedule and procedures including the so called rehabilitation guarantee
2992983|NCT02609737|Experimental|68Ga-DOTA-JR11 and 177Lu-DOTA-JR11|Pts get a PET/CT study with approx.150-200 MBq of 68Ga-DOTA-JR11. Lesions with focal radiotracer uptake not explained by physiologic sstr2 expression will be interpreted as metastatic disease. If 68Ga-DOTA-JR11 uptake by metastases with a diameter of more than 2 cm is less than the physiologic radiotracer uptake by the liver, no further imaging & therapy will be performed as part of the study, as it is unlikely that pts with this low radiotracer uptake will benefit from PRRT (2). All other pts will undergo a dosimetric study with 1850 MBq (less than 100 μg peptide) of 177Lu-DOTA-JR11. Results of the dosimetry study, will determine the balance of activity of 177Lu-DOTA-JR11 that can be administered without exceeding the radiation dose limits. This activity will be split into 2 equal amounts to be delivered in 2 cycles, approximately 3 months apart. After each therapy cycle, pts will be followed clinically for 3 months.
2992984|NCT02609724|Experimental|Fluoroscopy-guided MLD|Information, skin care, compression therapy, exercises and fluoroscopy-guided MLD 3 weeks (15 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment
2992985|NCT02609724|Active Comparator|Traditional MLD|Information, skin care, compression therapy, exercises and traditional MLD 3 weeks (15 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment
2992986|NCT02609724|Placebo Comparator|Placebo MLD|Information, skin care, compression therapy, exercises and placebo MLD 3 weeks (15 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment
2992987|NCT02609698|Experimental|Coroflex ISAR 3 months DAPT|Patients who have received a Coroflex ISAR stent procedure to treat coronary arterial lesions, and administered the drug for 3 months
2992988|NCT02609698|Active Comparator|Coroflex ISAR 6 months DAPT|Patients who have received a Coroflex ISAR stent procedure to treat coronary arterial lesions, and administered the drug for 6 months
2992989|NCT02609685|Other|Active Surveillance|Active surveillance instead of standard of care immediate surgery. Patients will be closely monitored every six months until disease is stable for a two-year period and then annually thereafter.
2992990|NCT02609685|No Intervention|Immediate Surgery|"Patients who choose to get surgery immediately after diagnosis may choose to enroll in a questionnaire sub-study that will compare quality of life and anxiety scores to patients who enroll in the active surveillance study. This is considered no intervention because the protocol is not directing treatment. Surgery is the standard treatment for papillary thyroid microcarcinoma."
2992991|NCT02609672|Experimental|Exercise|The participants in this arm were asked to attend 3 group classes per week for 12 weeks taught by a certified exercise instructor. Four class times were offered per week. These classes included a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements were obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
2992992|NCT02609672|Other|No Exercise|The participants in this arm were asked to refrain from changing their physical activity over the 12 weeks and maintain any strategies typically used to manage knee and/or hip pain. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the no exercise group were offered a free exercise pass following completion of the study. Measurements were obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
2992993|NCT02609659|Experimental|3-DAA + RBV 600 mg|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) plus RBV (ribavirin [600 mg once daily]) for 12 weeks.
2992994|NCT02609646||linezolid|patients treated with linezolid
2992995|NCT02609646||meropenem|patients treated with meropenem
2992996|NCT02609646||piperacillin/tazobactam|patients treated with piperacillin/tazobactam
2992998|NCT02609633|Active Comparator|Control: Usual Care - Current Diabetes Management System (DMS)|Participants will perform self-monitoring of blood glucose (SMBG) for 6 months using the current DMS device. Follow-up office visits will be scheduled at Months 3 and 6 to review and discuss SMBG data and modify the type 1 diabetes (T1D) regimen as needed.
2992999|NCT02609633|Experimental|Interventional: Accu-Chek® CONNECT DMS|Participants will receive training on Day 1 with the Accu-Chek® CONNECT DMS and will thereafter perform SMBG for 6 months. Follow-up office visits will be scheduled at Months 3 and 6 to review and discuss SMBG data and modify the T1D regimen as needed.
2993000|NCT02609620|Experimental|Treatment|In the treatment group: The LunGuard Peristaltic Feeding Tube (PFT) will be positioned in the ICU and positioning will be verified by X-ray. Nutritional formula will be fed into the stomach via the feeding lumen of the PFT
2993001|NCT02609620|Active Comparator|Control|Patients in the control group will have a Convatec Levin Duodenal Tube inserted according to standard procedure, which is considered the gold standard.
2993002|NCT02609607|Placebo Comparator|Placebo|Every other day placement of a placebo rectal suppository for 4 weeks
2993003|NCT02609607|Experimental|Bisacodyl|Every other day placement of a bisacodyl 10 mg rectal suppository for 4 weeks
2993004|NCT02609594|Active Comparator|Standard of Care|Subjects randomized to this group will receive standard of care (multi-layer compression therapy).
2993005|NCT02609594|Experimental|Weekly application of Amnioband|Weekly application of Amnioband plus standard of care.
2993006|NCT02609594|Experimental|Biweekly application of Amnioband|Biweekly application of Amnioband plus standard of care.
2993007|NCT02609568||Control Group 1|Children with non-trauma complaints
2993008|NCT02609568||Control Group 2|Children with non TBI and musculoskeletal trauma
2993009|NCT02609568||Cases|Children admitted to hospital with moderate/severe isolatedTBI
2993010|NCT02609555|Experimental|TEM perineal Rectopexy|TEM perineal rectopexy: triple repair technique , Perineal rectopexy with a polyprolene mesh assisted by TEM technique, postanal repair to close the postanak space then finally anal cerclage to hold the rectum in place for one month.
2993011|NCT02609542||STOL group|"STOL children will be recruited in the neuropediatric unit at the GHICL in Lille. Children will be followed and we will determine if capacities of verbal memory of the children presenting STOL diagnosed at an early stage of their development (before 6 years) are predictive of the evolution of the disorder according to their cognitive profile and more specifically, their language profile as well as their tests performances. The participants' eye movements ( visual world paradigm or eye tracking) will be recorded in order to determine the interplay between linguistic and visual information processing.~Patients with a persistent STOL will be identified at the end of the follow up."
2993012|NCT02609542||Control group|Children with no language development disorder willing to participate in the study will be recruited at school. The participants' eye movements ( visual world paradigm or eye tracking) will be recorded in order to determine the interplay between linguistic and visual information processing.
2993013|NCT02609529|Experimental|SBI|Entergam 10 g/day PO
2993014|NCT02609529|Placebo Comparator|Placebo|Placebo 10 g/day PO
2993015|NCT02609516||Healthy|Patients without any of the pre-specified chronic diseases
2993016|NCT02609516||Multimorbid|Patients having any two or more of the pre-specified chronic diseases
2993017|NCT02609503|Experimental|Open label|Pembrolizumab
2993018|NCT02609503|Other|Radiation|Intensity Modulated Radiation Therapy (IMRT)
2993019|NCT02609490|Experimental|Treatment-Azilsartan|Azilsartan tabelts
2993020|NCT02609490|Active Comparator|Positive Control-olmesartan medoxomil|olmesartan medoxomil tablets
2993021|NCT02609477|Experimental|Istradefylline 40 mg|40 mg istradefylline (1 × 40 mg tablet + 3 × placebo tablets + 3 × placebo capsules)
2993022|NCT02609477|Experimental|Istradefylline 80 mg|80 mg istradefylline (2 × 40 mg tablets + 2 × placebo tablets + 3 × placebo capsules)
2993023|NCT02609477|Experimental|Istradefylline 160 mg|160 mg istradefylline (4 × 40 mg tablets + 3 × placebo capsules)
2993024|NCT02609477|Active Comparator|Phentermine 45 mg|45 mg phentermine (4 x placebo tablets + 3 × 15 mg phentermine hydrochloride capsules)
2993025|NCT02609477|Active Comparator|Phentermine 90 mg|90 mg phentermine (4 × placebo tablets + 3 × 30 mg phentermine hydrochloride capsules)
2993026|NCT02609477|Placebo Comparator|Placebo|Placebo (4 × placebo tablets + 3 × placebo capsules)
2993027|NCT02609464|Active Comparator|Inturrupted Knotte Sutures|
2993028|NCT02609464|Active Comparator|Barbed Sutures|
2993029|NCT02609451|Experimental|2 weeks|Ileostomy closure after 2 weeks
2993030|NCT02609451|Experimental|12 weeks|Ileostomy closure after 12 weeks
2993031|NCT02609438|Active Comparator|Short breaks|Participants instructed to stand/move for 1-2 minutes every half hour throughout the workday
2993032|NCT02609438|Active Comparator|Long breaks|Participants instructed to take two 15-minute activity breaks during each workday
2993033|NCT02609425|Other|STRATAFIX|Anastomosis of esophagus to stomach
2993034|NCT02609412|Experimental|Static compression of LMTRP|static compression of most sensitive LMTRP with the foam roll for 90 seconds
2993035|NCT02609412|Experimental|Dynamic self-myofascial release of calf|dynamic self-myofascial release rolling back and forth on the entire calf for 90 seconds with the foam roll
2993036|NCT02609412|Placebo Comparator|Placebo laser acupuncture of LMTRP|placebo laser acupuncture applied on most sensitive LMTRP of the calf, light and acoustic sounds provided, but laser remains switched off, 90 seconds
2993037|NCT02609399|Experimental|Oseltamivir|Subjects randomized to the oral treatment arm will receive 5 days of oral oseltamivir.
2993038|NCT02609399|Experimental|Peramivir|Subjects randomized to the IV treatment group will receive 1 dose of IV peramivir.
2993039|NCT02609386|Experimental|Regimen 1|IRX Regimen with IRX-2, cyclophosphamide, indomethacin, zinc-containing multivitamin, and omeprazole as neoadjuvant and adjuvant therapy.
2993040|NCT02609386|Active Comparator|Regimen 2|Regimen 1 but without IRX-2
2993041|NCT02609373|Other|Sleep intervention|Sleep intervention
2993042|NCT02609360|Active Comparator|0.9% NaCl|Circuit priming will be performed with 0.9% NaCl solution
2993043|NCT02609360|Active Comparator|Ringer Lactate|Circuit priming will be performed with Ringer Lactated
3020477|NCT02426060|Experimental|Imrecoxib&Warfarin|
2993044|NCT02609360|Experimental|Balanced Solution|Circuit priming will be performed with a Balanced Solution created by mixing 0.9% NaCl, Sodium bicarbonate (8.4%) and injectable sterile water, in order to obtain a solution with constant sodium concentration (140 mEq/l) and SID equal to patient's bicarbonate level.
2993045|NCT02609347|Experimental|Manual Therapy Group|Participants in the manual therapy group will receive 3 treatment sessions of joint mobilization based on the physical therapist's clinical decision making.
2993046|NCT02609347|Sham Comparator|Control Group|Participants in the control group will receive a sham manual therapy treatment consisting of soft tissue mobilization and Grade I mobilizations at the proximal tib/fib joint.
2993047|NCT02609334|Placebo Comparator|Placebo|Matching placebo tables are given as a single dose
2993048|NCT02609334|Active Comparator|CRD007 Low dose|"Low dose of CRD007 (pemirolast sodium) given as a single dose"
2993049|NCT02609334|Active Comparator|CRD007 High dose|"High dose CRD007 (pemirolast sodium) given as a single dose"
2993050|NCT02609321|Experimental|Thoracic Paravertebral Block|to identify the thoracic T3, a parallel line 2.5 cm from the spinous process is drawn and in this place the ultrasound sensor is placed. Ultrasonograph image identifies the transverse process, the intercostal cost-transverse ligament, the pleura and lung. We proceed to insert a needle between the two corresponding transverse processes and positions after passing the cost-ligament posterior intercostal and transverse to the parietal pleura. After negative aspiration for blood, 0.5% bupivacaine anesthetic is administered at doses of 1.5 mg/kg slowly. The volume is defined by the anesthesiologist. The injection of anesthetic is displayed, as well as confirmation of the correct location of the needle because the volume injected above pushes the pleura.
2993051|NCT02609321|Active Comparator|Surgical Wound Infiltration|before the close of the skin, it proceeds to infiltrate the subcutaneous tissue and skin with 0.5% bupivacaine at doses of 1.5 mg/kg, generating the widest possible dissemination of the bupivacaine in the surgical area.
2993052|NCT02609308|Active Comparator|Short leg cast|The patients in this group will be immobilize with a short leg cast for 14 days, and later they will be able to do physical rehabilitation and will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.
2993053|NCT02609308|Experimental|Platelet-rich plasma|In this group, the patients will be receive a single dose of autologous platelet-rich plasma, and will be immobilized with a short leg cast. Posteriorly, they will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.
2993054|NCT02609295|Placebo Comparator|Placebo|Individuals who consumed 1.2 g (two capsules) of medium-chain triglyceride (MCT) oil daily
2993055|NCT02609295|Experimental|ALA group|Individuals who consumed 1.2 g (two capsules) of perilla oil daily
2993056|NCT02609282|Experimental|Prompt group|Following an education session on the health benefits of breaking prolonged sitting, the prompt group will receive hourly prompts on their PC to stand. The prompts will be delivered by Microsoft Outlook and will run for a period of 10 weeks. The messages will be short in length, varied and centre around the key message of breaking prolonged sitting by standing.
2993057|NCT02609282|No Intervention|Control group|The control group will receive the same education session as the prompt group, but will receive no prompts on their PC.
2993058|NCT02609269||Decipher GRID Patients|Patients who have been tested with any of the Decipher suite of genomic solutions.
2993059|NCT02609256|Experimental|Stereotactic infarct tissue aspiration|Patients receive the stereotactic infarct tissue aspiration 24-48 hours after cerebral infarction beside medical therapy.
2993060|NCT02609256|Sham Comparator|Medical therapy|osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc;
2993061|NCT02609243|Active Comparator|intensive consulting, conventional diet|subjects receive 16 units of nutritional consulting, first 3 weeks of intervention phase are designed as a conventional hypocaloric low-fat diet referring to DGE guidelines (below 30 % fat), followed by 11 months of isocaloric-to-moderate-hypocaloric low-fat diet (below 30 kcal% fat ) - dietary intervention without supplement
2993062|NCT02609243|Active Comparator|conventional consulting, low-carb diet|subjects receive 8 units of nutritional consulting, first 3 weeks of intervention phase are designed as a very-low calory ketogenic (low-carb) diet (< 40 g CH / day), following 11 months are restricted to not more than 40 % energy intake by carbohydrates under isocaloric-to-moderate-hypocaloric conditions - dietary intervention without supplement
2993063|NCT02609243|Active Comparator|conventional consulting, conventional diet|subjects receive 8 units of nutritional consulting, first 3 weeks of intervention phase are designed as a conventional hypocaloric low-fat diet referring to DGE guidelines (below 30 % fat), followed by 11 months of isocaloric-to-moderate-hypocaloric low-fat diet (below 30 kcal% fat) - dietary intervention without supplement
2993064|NCT02609243|Active Comparator|intensive consulting, low-carb diet|subjects receive 16 units of nutritional consulting, first 3 weeks of intervention phase are designed as a very-low calory ketogenic (low-carb) diet (< 40 g CH / day), following 11 months are restricted to not more than 40 % energy intake by carbohydrates under isocaloric-to-moderate-hypocaloric conditions - dietary intervention without supplement
2993065|NCT02609230|Experimental|A|For the first arm (A), dose escalation will use the following single patient dose-escalation cohorts based on 'Design 4' proposed by Simon and colleagues: 125, 250, and 500 mg. every 3 weeks.
2993066|NCT02609230|Experimental|B|Following completion of Arm A dose escalation, subsequent cohorts will be tested in a minimum of 3 patients, the Arm B dose cohort will consist of dose levels administered every week (planned dosing of 250, 375, 500 and 625 mg).
2993067|NCT02609217||Multiparous|12 multiparous women and their partners, planned to undergo elective term cesarean section.
2993068|NCT02609217||Nulliparous|12 nulliparous women and their partners, planned to undergo elective term cesarean section.
2993069|NCT02609204|Experimental|Normal Eye Participants|People with normal eye and no history of eye diseases are being recruited for the study and tested on the Diopsys NOVA
2993070|NCT02609191|Experimental|The study population: first 30 patients|"The study population consists of adult patients referred to the Nuclear Medicine and Medical Biophysics Department of the Nîmes University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body exam using the Discovery A~Intervention: First whole body exam using the Stratos DR~Intervention: Second whole body exam using the Stratos DR"
2993071|NCT02609191|Experimental|The study population: last 20 patients|"The study population consists of adult patients referred to the Nuclear Medicine and Medical Biophysics Department of the Nîmes University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body exam using the Discovery A~Intervention: First whole body exam using the Stratos DR"
2993072|NCT02609178|Experimental|FGP design (FGP, AVR)|use functional generated path to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
2993073|NCT02609178|No Intervention|conventional design (CON)|use conventional method to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
2993074|NCT02609165|Active Comparator|study group|rhNGF 180 µg/ml eye drops solution
2993075|NCT02609165|Placebo Comparator|control group|vehicle eye drops solution
2993076|NCT02609152|Experimental|Continuous perfusion of esmolol|Intervention: Drug: Continuous perfusion of esmolol
2993077|NCT02609152|Placebo Comparator|Continuous perfusion of saline|Intervention: Continuous perfusion of saline
2993078|NCT02609139|Experimental|<=400mg Modified Release Tablets, Fasted|Up to 400 mg PF-06650833 modified release tablets administered under fasted conditions
2993079|NCT02609139|Experimental|100mg Modified Release Tablets, Fasted|100 mg PF-06650833 modified release tablets administered under fasted conditions
2993080|NCT02609139|Experimental|20mg Modified Release Tablets, Fasted|20 mg PF-06650833 modified release tablets administered under fasted conditions
2993081|NCT02609139|Experimental|<= 400mg Modified Release Tablets, Fed|Up to 400 mg PF-06650833 modified release tablets administered with high fat meal food intake
2993082|NCT02609139|Experimental|100mg Modifed Release Tablets, Fed|100 mg PF-06650833 modified release tablets administered with high fat meal food intake
2993083|NCT02609139|Experimental|20mg Modified Release Tablets, Fed|20 mg PF-06650833 modified release tablets administered with high fat meal food intake
2993084|NCT02609126|Experimental|EP-104IAR|15mg EP-104IAR in 4 mL carrier fluid
2993085|NCT02609126|Placebo Comparator|Vehicle|4 mL carrier fluid
2993086|NCT02609113|Active Comparator|Strong Magnetic Wristband|Magnetic wristband of 1,795 Gauss strength
2993087|NCT02609113|Placebo Comparator|Weaker Magnetic Wristband|Magnetic wristband of 5 Gauss strength.
2993088|NCT02609100|Active Comparator|Video Capsule Endoscopy|Randomization arm one is to video capsule endoscopy (VCE) a non-invasive procedure in which a patient swallows a disposable 1.0 X 2.5 cm 'pill' containing a camera electronically linked to equipment outside the patient which records images as it passes from the esophagus through the entire tract and is excreted in feces. It images the small intestine in areas beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. Its greatest use is in identifying points of bleeding and ulcers.
2993089|NCT02609100|Active Comparator|Next Day Colonoscopy|Randomization arm two is to colonoscopy, a test that allows the doctor to look at the inner lining of the large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.
2993090|NCT02609087|Experimental|Sevoflurane|adjust the end-tidal sevoflurane (sevofran inhaler, Hana pharmacy, Korea) concentration maintaining the 40 ~ 50 BIS (bispectral index) with 3 ng/ml of remifentanil using TCI (target controlled infusion) pump
2993091|NCT02609087|Experimental|Propofol|adjust propofol (FRESOFOL MCT INJ 2% (vial), Fresinus Kabi Korea) concentration maintaining the 40 ~ 50 BIS (bispectral index) with 3 ng/ml of remifentanil using TCI (target controlled infusion) pump
2993092|NCT02609074|Experimental|CPC/rhBMP-2|"All operations were done by doctors titled with associate chief physician or above. Procedures were performed under general anesthesia in a tertiary care medical center.~A minimally invasive internal fixation method had been applied in the surgeries. In brief, the patients with fracture were treated by reduction of fracture first of all, the correction of displacement, and the angle of the deformity, and the use of metal implants were fixed, and the collapse of the cancellous bone was filled with CPC/rhBMP-2 microffolds (product of Shanghai Rebone Biomaterials Co., Ltd, following the manufacturer's instruction), which was compacted and prevented from filling material into the joint cavity."
2993093|NCT02609074|Active Comparator|CPC|"All operations were done by doctors titled with associate chief physician or above. Procedures were performed under general anesthesia in a tertiary care medical center.~A minimally invasive internal fixation method had been applied in the surgeries. In brief, the patients with fracture were treated by reduction of fracture first of all, the correction of displacement, and the angle of the deformity, and the use of metal implants were fixed, and the collapse of the cancellous bone was filled with CPC paste (product of Shanghai Rebone Biomaterials Co., Ltd, following the manufacturer's instruction), which was compacted and prevented from filling material into the joint cavity."
2993094|NCT02609061|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
2993095|NCT02609061|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
2993096|NCT02609061|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate for treating furcation defect
2993097|NCT02609048|Placebo Comparator|Placebo Dose|Placebo Capsule Two Capsules Daily
2993098|NCT02609048|Experimental|Seladelpar / MBX-8025 50 mg Dose|MBX-8025 50 mg capsule One Capsule Daily
2993099|NCT02609048|Experimental|Seladelpar / MBX-8025 200 mg Dose|MBX-8025 100 mg capsules (2 taken once daily)
2993100|NCT02609035|Experimental|Intervention|Patients who are either appointment-based medication synchronization calls, refill ready calls, or refill reminder calls at the pharmacy who have been identified as missing at least one vaccination. These patients will receive a telephonic prompt to get a vaccination.
2993101|NCT02609035|No Intervention|Control|Patients who are either appointment-based medication synchronization calls, refill ready calls, or refill reminder calls at the pharmacy who have been identified as missing at least one vaccination. These patients will receive usual pharmacy care.
2993102|NCT02609022|Experimental|CV-MG01|The therapeutic vaccine candidate, CV-MG01 comprises two short synthetic peptides separately conjugated to a carrier protein for the potential treatment of myasthenia gravis
2993103|NCT02609022|Placebo Comparator|Placebo|Aluminium hydroxide adjuvant alone
2993104|NCT02609009|Experimental|Spinal Manipulation Therapy|Active chiropractic care for this RCT will consist of diversified technique prone, side posture and supine manipulations with soft-tissue therapy
2993105|NCT02609009|Other|Usual Medical Care|Control group patients will follow the usual medical visit scheduled according to their attending orthopaedists. Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises.
2993106|NCT02608996|Active Comparator|Subcutaneous BNP|Patients will receive gradually increasing doses (10-25 µg/kg) of subcutaneously administered nesiritide (BNP) twice daily for two days, to determine the feasibility, safety and blood pressure lowering effect of BNP so as to identify the optimal dose.
2993107|NCT02608996|Placebo Comparator|Subcutaneous placebo|Patients will receive subcutaneously administered placebo twice daily for two days for determination of the effect of BNP.
2993108|NCT02608983|Experimental|Treatment 1|
2993109|NCT02608983|Experimental|Treatment 2|
2993110|NCT02608983|Placebo Comparator|Treatment 3|
2993111|NCT02608970|Experimental|BMS-986177|BMS-986177 specified dose on specified days
2993112|NCT02608970|Other|Placebo|Placebo specified dose on specified days
2993113|NCT02608957|Experimental|Latella Knee Implant System|
2993114|NCT02608944|Experimental|MRI perfusion vs. PET Imaging perfusion|Adenosine Regadenoson O-15 labeled radioactive water MRI PET Imaging
2993115|NCT02608931|Experimental|Dranabinol Capsules|The initial dose will be 2.5 mg BID (5 mg/day), and the maximum dose will be 10 mg TID (30 mg/day).
2993116|NCT02608931|Placebo Comparator|Placebo Capsules|placebo
2993117|NCT02608918|Experimental|BMS-955176|BMS-955176 specified dose on specified days
2993118|NCT02608905|Experimental|Dapagliflozin|Dapagliflozin 5 mg daily by mouth for 2 weeks followed by 10 mg by mouth daily for 10 weeks
2993119|NCT02608905|Placebo Comparator|Placebo|Placebo tablets by mouth daily for 12 weeks
2993120|NCT02608892|Experimental|Intervention|BSweet2Babies video
2993121|NCT02608892|No Intervention|Control|Usual care
2993122|NCT02608879|Experimental|OMDP Group|Subjects randomized to this group will attend weekly visits and receive a full dental cleaning, as well as have their gums/tongue cleaned by a dental professional. Subjects will also receive standard of care oral hygiene instructions.
2993123|NCT02608879|Other|Control Group|Subjects assigned to the control group will receive standard of care oral health instructions and will come for bi-weekly treatment visits where they will have their teeth cleaned (brushed) by a dental professional.
2993124|NCT02608866|Experimental|SF-SSRS|Single-Fraction (SF) Stereotactic Spine Radiosurgery
2993125|NCT02608866|Experimental|MF-SSRS|Multiple-Fraction (MF) Stereotactic Spine Radiosurgery
2993126|NCT02608853||Liraglutide-like Cohort|
2993127|NCT02608853||LEADER™-like Cohort|
2993128|NCT02608840|Experimental|MCI auditory stimulation|MCI patients receiving auditory stimulation during sleep (crossover arm 1)
2993129|NCT02608840|Sham Comparator|MCI sham stimulation|Sham intervention: MCI patients sleeping with headphones but sounds not played (crossover arm 2)
2993130|NCT02608840|Experimental|Older adult auditory stimulation|healthy older adults receiving auditory stimulation during sleep (crossover arm 1)
2993131|NCT02608840|Sham Comparator|older adult sham stimulation|Sham intervention: healthy older adults sleeping with headphones but sounds not played (crossover arm 2)
2993132|NCT02608827|Active Comparator|Slow breathing group (GRL)|After randomization and have done aerobic exercise, patients allocated in this arm of the study, using the device-guided breathing - Slow breathing group (GRL), for 15 minutes during the experimental session.
2993133|NCT02608827|Placebo Comparator|Music group (GC)|After randomization and have done aerobic exercise, patients allocated in this study arm will hear slow music - Music group (GC), for 15 minutes during the experimental session.
2993134|NCT02608801||Patients from NoFRACT|Patients from NoFRACT who consent to participate in this sub-study, will be offered examination and treatment with anti-osteoporotic drugs cf. treatment algorithm in the main-study. I.e. if osteoporosis is present clinically or at DXA scan, treatment is started.
2993135|NCT02608788|Active Comparator|S.L.® & Difflam Forte ®|"1.5 mg/ml Benzydamine , S.L.® Spray Solution 2.5 mg and 3.0 mg/ml Benzydamine ,Difflam Forte ® 5.0 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
2993136|NCT02608788|Placebo Comparator|placebo ( for Acular® )|placebo(distilled water)spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
2993137|NCT02608788|Active Comparator|Acular® & S.L.®|"5％ Ketorolac Tromethamine , Acular® 8.0 mg and 1.5 mg/ml Benzydamine , S.L.® Spray Solution 2.5 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
2993138|NCT02608788|Experimental|Difflam Forte ® & Acular®|"3.0 mg/ml Benzydamine , Difflam Forte ® 5.0 mg and 5％ Ketorolac Tromethamine Acular® 8.0 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
2993139|NCT02608775|Experimental|Metrodoloris Medical System|Application of a skin electrode
2993140|NCT02608775|Active Comparator|Aisys® care station, Acertys|SPI calculated from photoplethysmography
2993141|NCT02608762||pediatric/adolescent patients with brain tumors|A prospectively recruited of newly-diagnosed pediatric/adolescent patients with brain tumors or head/neck cancers
2993142|NCT02608749|Experimental|IC|Integrated care (IC)
2993143|NCT02608749|Experimental|LEE|Lower extremity exercise (LEE)
2993144|NCT02608749|Experimental|HC|Home care (HC)
2993145|NCT02608736|Experimental|Valproic Acid|Valproic acid will be orally administered in a total dose of 1500mg per day (500mg, every 8 hours), for three months.
2993146|NCT02608736|Placebo Comparator|Placebo|Placebo will be orally administered in a total dose of three capsules per day (every 8 hours), for three months.
2993147|NCT02608723|Active Comparator|Standard shock waves device|3 sessions were applied: one per week.
2993148|NCT02608723|Active Comparator|Austere shock waves device|3 sessions were applied: one per week.
2993149|NCT02608723|Active Comparator|Sophisticated shock waves device|3 sessions were applied: one per week.
2993150|NCT02608710|Experimental|Single Dose|Single dose of RDEA3170 4.5 mg, RDEA3170 6 mg or RDEA3170 12 mg on Days 1, 5 and 9.
2993151|NCT02608710|Experimental|Multiple Dose|RDEA3170 12 mg once daily (qd)
2993152|NCT02608710|Experimental|Single Dose Food Effect|Since dose of RDEA3170 6 mg administered in fed or fasted state on Day 1 and Day 8.
2993153|NCT02608697|Experimental|Group 1: CAT-2054 or Placebo Dose 1|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 250 mg CAT-2054 or placebo QD and open label 40 mg atorvastatin tablet administered daily.
2993154|NCT02608697|Experimental|Group 2: CAT-2054 or Placebo Dose 2|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 400 mg CAT-2054 or placebo QD and open label 40 mg atorvastatin tablet administered daily.
2993155|NCT02608697|Experimental|Group 3: CAT-2054 or Placebo Dose 3|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 250 mg CAT-2054 or placebo BID and open label 40 mg atorvastatin tablet administered daily.
2993156|NCT02608697|Experimental|Group 4: CAT-2054 or Placebo Dose 4|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 400 mg CAT-2054 or placebo BID and open label 40 mg atorvastatin tablet administered daily.
2993157|NCT02608684|Experimental|Cisplatin+Gemcitabine+Pembrolizumab|"2 cycles of 750mg gemcitabine and 30mg cisplatin chemotherapy (standard of care) followed by 4 cycles of gemcitabine and cisplatin combined with pembrolizumab in 21-day treatment cycles.~Gemcitabine 750 mg/m2 every 3 weeks (Q3W) x 6 cycles IV infusion Day 1 and Day 8 of each 3 week cycle Standard of care~Cisplatin 30 mg/m2 Q3W x 6 cycles IV infusion Day 1 and Day 8 of each 3 week cycle after gemcitabine Standard of care~Pembrolizumab 200 mg Q3W starting with cycle 3 IV infusion Day 1 of each 3 week cycle after gemcitabine and cisplatin Experimental"
2993158|NCT02608671|No Intervention|Continuous skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
2993159|NCT02608671|Experimental|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
2993160|NCT02608658|Experimental|Interventional Arm|The experimental arm of this study will involve all patients in this study. Subjects will be evaluated in a clinical setting and undergo a brief healthcare questionnaire, blood work, and a breath test. Subjects will then take a medical food (EnteraGam) twice daily for 8 weeks total, after which they will be seen in clinic at 4 weeks for follow up and then at 8 weeks to repeat the healthcare questionnaire, breath tests, and blood draw.
2993161|NCT02608632|Experimental|Group 1 (RDN guided by HFS)|"Renal arteries were assessed for suitability of ablation by renal angiography. The real-time 3-dimensional aorta-renal artery maps were reconstructed with the use of navigation system and ablation catheter via femoral artery access. After that high-frequency stimulation (HFS) was used before the initial and after each radiofrequency (RF) delivery within the renal artery. RDN was considered to have been achieved when the sudden increase of blood pressure (> 15 mm Hg from invasive arterial monitoring) was eliminated in response to HFS.~RF ablations of 8-12 watts (impedance drop >10%) were applied discretely from the first distal main renal artery bifurcation all the way back to the ostium. The duration of each RF delivery was 60-120 sec, and up to 6 lesions (separated by > 5 mm) were performed both longitudinally and rotationally within each renal artery."
2993162|NCT02608632|Active Comparator|Group 2 (RDN as standard procedure)|"Renal arteries were assessed for suitability of ablation by renal angiography. The real-time 3-dimensional aorta-renal artery maps were reconstructed with the use of navigation system and ablation catheter via femoral artery access.~RF ablations of 8-12 watts (impedance drop >10%) were applied discretely from the first distal main renal artery bifurcation all the way back to the ostium. The duration of each RF delivery was 60-120 sec, and up to 6 lesions (separated by > 5 mm) were performed both longitudinally and rotationally within each renal artery. High-frequency stimulation (HFS) was performed before and after RDN to just to verify the response of BP"
2993163|NCT02608619||PET Imaging|This study will enroll patients who have a clinical diagnosis of a systemic histiocytic disorder, and who are scheduled to undergo confirmatory biopsies of the systemic lesions, that were identified by standard imaging modalities.
2993164|NCT02608606|No Intervention|oral administration of tacrolimus|Oral administration of tacrolimus (FK506) in the usal dose and measuring plasmatic levels at hours 0, 0.5, 1, 2, 3, 4 and 6. Measuring AUC.
2993165|NCT02608606|Active Comparator|sublingual administration of tacrolimus|sublingual administration of tacrolimus (FK506) in the dose that allows similar plasmatic level at time 0 compared with the oral administration, and measuring plasmatic levels at hours 0, 0.5, 1 , 2, 3 , 4 and 6. Measuring AUC.
2993166|NCT02608593||Implant reconstruction with Strattice|Women having immediate breast reconstruction with partial or total Strattice cover
2993167|NCT02608593||Implant reconstruction without Strattice|Women having immediate implant based breast reconstruction where no Strattice has been used
2993168|NCT02608580|Other|Patients with sicke cell disease|"Adult sickle cell disease patients will fill in a survey about the quality of their hospital care, in the transition period between the pediatric to an adult hospital care system.~Since filling in this survey is not part of the standard of care, this study has been defined as interventional."
2993169|NCT02608567||Preserved LV GLS|"Patients will be compared according to the level of LV global longitudinal strain (GLS) as derived from transthoracic echocardiography and speckle tracking analysis.~Two groups will be compared regarding outcome: preserved LV GLS vs. reduced LV GLS. The definition use for reduced LV GLS will be >-16%. An optimal threshold would also be calculated and derived from the pooled data."
2993170|NCT02608567||Reduced LV GLS|The definition use for reduced LV GLS will be >-16%. An optimal threshold would also be calculated and derived from the pooled data.
2993171|NCT02608554|Experimental|Taichi|The 24 forms of simplified TCC recommended as the popular health sport by the General Administration of Sport of China were applied.
2993172|NCT02608554|Active Comparator|Self-monitored exercise|Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise.
2993173|NCT02608541||Retrospective rib fracture fixation|patients presenting since 2006 with multiple rib fractures or flail chest, managed operatively or non-operatively
2993174|NCT02608541||Prospective rib fracture fixation|patients presenting from October 2015 to October 2017 with multiple rib fractures or flail chest, managed operatively or non-operatively
2993175|NCT02608502|Experimental|Treatment Group A|RSV-F Vaccine (0.5mL Injection)
2993176|NCT02608502|Placebo Comparator|Treatment Group B|Phosphate Buffer Placebo (0.5mL Injection)
2993177|NCT02608489|Active Comparator|Diqufosol|3% Diquafosol Tetrasodium Ophthalmic Solution
2993178|NCT02608489|Placebo Comparator|Hyaluronate|0.1% Sodium Hyaluronate Ophthalmic Solution
2993179|NCT02608476|Experimental|CB-03-01 cream|CB-03-01 cream, 1% applied twice daily for 12 weeks
2993180|NCT02608476|Placebo Comparator|Vehicle cream|Vehicle cream applied twice daily for 12 weeks
2993181|NCT02608463|Experimental|Neuropathic Pain|Subjects will complete the painDETECT Questionnaire at study entry and be assigned to this group with a score ≥13. They will receive be invited to participate in repetitive transcranial magnetic stimulation (rTMS).
2993182|NCT02608463|No Intervention|Non-neuropathic Pain|Subjects will complete the painDETECT Questionnaire at study entry and be assigned to this group with a score on the 1≥score≤12 on the PDQ. They will receive no study intervention.
2993183|NCT02608463|No Intervention|Control|Subjects will complete the painDETECT Questionnaire at study entry and be assigned to this group with a score = 0 on the PDQ. They will receive no study intervention.
2993184|NCT02608450|Experimental|CB-03-01 cream|CB-03-01 cream, 1% applied twice daily for 12 weeks
2993185|NCT02608450|Placebo Comparator|Vehicle cream|Vehicle cream applied twice daily for 12 weeks
2993186|NCT02608437|Experimental|SGI-110 and Ipilimumab|SGI-110 in combination with Ipilimumab
2993187|NCT02608424|Experimental|Foot Mechanical Stimulation|"Intervention: Foot Mechanical Stimulation (FMS) will be performed on enrolled patients every 72 hours (total 5 stimulation sessions) by a pressure-controlled mechanical stimulator (Gondola®, European Community (CE) marking n° 0476) .~The sites of the stimulation will be the tip of the hallux and the lower big toe first metatarsal joint plantar surface. The FMS procedure consists in the application of the patient's calibrated pressure for 6 seconds, over the selected sites. Each of the 2 cutaneous sites of both feet will be mechanically stimulated. The procedure will be automatically repeated for 4 times in every subject so that the overall time of stimulation will be approximately 2 minutes."
2993188|NCT02608411|Experimental|ARQ-197|ARQ-197 360 mg twice/day by mouth (PO), with meals, continuously as maintenance treatment until disease progression or unacceptable toxicity.
2993189|NCT02608398||overweight children at weight-loss camp|This is an observational study there is no intervention. The investigators will carry out metabolic profiling on a cohort of overweight or obese children who are attending a commercial weight loss camp for 2-5 weeks.
2993190|NCT02608385|Experimental|Dose Escalation Cohort|Patients will be enrolled to receive specific doses of radiation (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects. Enrollment will continue until best safe dose of SBRT is determined for each organ type.
2993191|NCT02608385|Experimental|Large Volume Tumors Cohort|Patients with large tumors will be enrolled and their tumors will be partially treated with (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects.
2993192|NCT02608385|Experimental|Oligometastatic Cohort|Patients with few tumors (4 or less) will be enrolled and their tumors treated with (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects.
2993193|NCT02608372|Experimental|Sequence A|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence LD-UP-CTR
2993194|NCT02608372|Experimental|Sequence B|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence LD-CTR-UP
2993195|NCT02608372|Experimental|Sequence C|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence UP-LD-CTR
2993196|NCT02608372|Experimental|Sequence D|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence UP-CTR-LD
2993197|NCT02608372|Experimental|Sequence E|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence CTR-LD-UP
2993198|NCT02608372|Experimental|Sequence F|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence CTR-UP-LD
2993199|NCT02608359||Abiraterone Acetate (Zytiga) Post-marketing Surveillance (PMS)|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
2993200|NCT02608346|Other|Blood sampling|
2993201|NCT02608333|Experimental|ESDM-12|ESDM -12 : 60 children will receive 12 hours a week of ESDM ( Early Start Denver Model)intervention delivered by trained therapists during 2 years.ESDM is a comprehensive relational, developmental and behavioral intervention.It's described in a manual for Professional and parents.
2993202|NCT02608333|Active Comparator|Control group|control group: 120 children will receive heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period
2993203|NCT02608320|Experimental|Treatment Sequence (ACB) Position (RLR)|Participants will receive treatment A (Duragesic 12.5 microgram per hour [mcg/h]) applied to right paraspinal side in period 1, then treatment C (aged JNJ- 35685-AAA-G016 12.5 mcg/h) applied to left paraspinal side in period 2 and then treatment B (New JNJ-35685- AAA-G016 12.5 mcg/h) applied to right paraspinal side in period 3.
2993204|NCT02608320|Experimental|Treatment Sequence (BAC) Position (RLR)|Participants will receive treatment B applied to right paraspinal side in period 1, then treatment A applied to left paraspinal side in period 2 and then treatment C applied to right paraspinal side in period 3.
2993205|NCT02608320|Experimental|Treatment Sequence (CBA) Position (RLR)|Participants will receive treatment C applied to right paraspinal side in period 1, then treatment B applied to left paraspinal side in period 2 and then treatment A applied to right paraspinal side in period 3.
2993206|NCT02608320|Experimental|Treatment Sequence (BCA) Position (RLR)|Participants will receive treatment B applied to right paraspinal side in period 1, then treatment C applied to left paraspinal side in period 2 and then treatment A applied to right paraspinal side in period 3.
2993207|NCT02608320|Experimental|Treatment Sequence (CAB) Position (RLR)|Participants will receive treatment C applied to right paraspinal side in period 1, then treatment A applied to left paraspinal side in period 2 and then treatment B applied to right paraspinal side in period 3.
2993208|NCT02608320|Experimental|Treatment Sequence (ABC) Position (RLR)|Participants will receive treatment A applied to right paraspinal side in period 1, then treatment B applied to left paraspinal side in period 2 and then treatment C applied to right paraspinal side in period 3.
2993209|NCT02608320|Experimental|Treatment Sequence (ACB) Position (LRL)|Participants will receive treatment A applied to left paraspinal side in period 1, then treatment C applied to right paraspinal side in period 2 and then treatment B applied to left paraspinal side in period 3.
2993210|NCT02608320|Experimental|Treatment Sequence (BAC) Position (LRL)|Participants will receive treatment B applied to left paraspinal side in period 1, then treatment A applied to right paraspinal side in period 2 and then treatment C applied to left paraspinal side in period 3.
2993211|NCT02608320|Experimental|Treatment Sequence (CBA) Position (LRL)|Participants will receive treatment C applied to left paraspinal side in period 1, then treatment B applied to right paraspinal side in period 2 and then treatment A applied to left paraspinal side in period 3.
2993212|NCT02608320|Experimental|Treatment Sequence (BCA) Position (LRL)|Participants will receive treatment B applied to left paraspinal side in period 1, then treatment C applied to right paraspinal side in period 2 and then treatment A applied to left paraspinal side in period 3.
2993213|NCT02608320|Experimental|Treatment Sequence (CAB) Position (LRL)|Participants will receive treatment C applied to left paraspinal side in period 1, then treatment A applied to right paraspinal side in period 2 and then treatment B applied to left paraspinal side in period 3.
2993214|NCT02608320|Experimental|Treatment Sequence (ABC) Position (LRL)|Participants will receive treatment A applied to left paraspinal side in period 1, then treatment B applied to right paraspinal side in period 2 and then treatment C applied to left paraspinal side in period 3.
2993215|NCT02608320|Experimental|Treatment Sequence (DFE) Position (RLR)|Participants will receive treatment D (Duragesic 100 mcg/h) applied to right paraspinal side in period 1, then treatment F (aged JNJ-35685-AAA-G021 100 mcg/h) applied to left paraspinal side in period 2 and then treatment E (new JNJ-35685-AAA-G021 100 mcg/h) applied to right paraspinal side in period 3.
2993216|NCT02608320|Experimental|Treatment Sequence (EDF) Position (RLR)|Participants will receive treatment E applied to right paraspinal side in period 1, then treatment D applied to left paraspinal side in period 2 and then treatment F applied to right paraspinal side in period 3.
2993217|NCT02608320|Experimental|Treatment Sequence (FED) Position (RLR)|Participants will receive treatment F applied to right paraspinal side in period 1, then treatment E applied to left paraspinal side in period 2 and then treatment D applied to right paraspinal side in period 3.
2993218|NCT02608320|Experimental|Treatment Sequence (EFD) Position (RLR)|Participants will receive treatment E applied to right paraspinal side in period 1, then treatment F applied to left paraspinal side in period 2 and then treatment D applied to right paraspinal side in period 3.
2993219|NCT02608320|Experimental|Treatment Sequence (FDE) Position (RLR)|Participants will receive treatment F applied to right paraspinal side in period 1, then treatment D applied to left paraspinal side in period 2 and then treatment E applied to right paraspinal side in period 3.
2993220|NCT02608320|Experimental|Treatment Sequence (DEF) Position (RLR)|Participants will receive treatment D applied to right paraspinal side in period 1, then treatment E applied to left paraspinal side in period 2 and then treatment F applied to right paraspinal side in period 3.
2993221|NCT02608320|Experimental|Treatment Sequence (DFE) Position (LRL)|Participants will receive treatment D applied to left paraspinal side in period 1, then treatment F applied to right paraspinal side in period 2 and then treatment E applied to left paraspinal side in period 3.
2993222|NCT02608320|Experimental|Treatment Sequence (EDF) Position (LRL)|Participants will receive treatment E applied to left paraspinal side in period 1, then treatment D applied to right paraspinal side in period 2 and then treatment F applied to left paraspinal side in period 3.
2993223|NCT02608320|Experimental|Treatment Sequence (FED) Position (LRL)|Participants will receive treatment F applied to left paraspinal side in period 1, then treatment E applied to right paraspinal side in period 2 and then treatment D applied to left paraspinal side in period 3.
2993224|NCT02608320|Experimental|Treatment Sequence (EFD) Position (LRL)|Participants will receive treatment E applied to left paraspinal side in period 1, then treatment F applied to right paraspinal side in period 2 and then treatment D applied to left paraspinal side in period 3.
2993225|NCT02608320|Experimental|Treatment Sequence (FDE) Position (LRL)|Participants will receive treatment F applied to left paraspinal side in period 1, then treatment D applied to right paraspinal side in period 2 and then treatment E applied to left paraspinal side in period 3.
2993226|NCT02608320|Experimental|Treatment Sequence (DEF) Position (LRL)|Participants will receive treatment D applied to left paraspinal side in period 1, then treatment E applied to right paraspinal side in period 2 and then treatment F applied to left paraspinal side in period 3.
2993227|NCT02608307||Participants|All patients, parents and health care providers who meet eligibility criteria and consent to participate in the study.
2993228|NCT02608294|Experimental|Experimental Group|Kinesio Taping Procedure application with 35% strain.
2993229|NCT02608294|Sham Comparator|Sham Group|Kinesio Taping Sham procedure application without strain.
2993230|NCT02608281|Other|CEDEM|diagnostic contrast enhanced Dual Energy mammograms after Iodine based contrast media administration compared to CE MRI
2993231|NCT02608268|Experimental|Dose escalation MBG453 alone|
2993232|NCT02608268|Experimental|Dose escalation MBG453 in combination with PDR001|
2993233|NCT02608268|Experimental|Dose Ranging group|
2993234|NCT02608268|Experimental|Dose Expansion of MBG453 alone|
2993235|NCT02608268|Experimental|Dose Expansion of MBG453 in combination with PDR001|
2993236|NCT02608255|Experimental|acute coronary syndromes|
2993237|NCT02608242|Experimental|YH22189|YH22189 FDC tablet of Yuhan Corporation
2993238|NCT02608242|Active Comparator|Twynsta 80/10mg|Telmisartan/Amlodipine 80/10mg (FDC)
2993239|NCT02608242|Active Comparator|Crestor 20mg|Rosuvastatin 20mg
2993310|NCT02607761|Active Comparator|Control 1|2 minutes video with same images but information on work-family balance.
2993240|NCT02608229|Experimental|Dose De-escalation: BVD-523/Nab-paclitaxel/Gemcitabine|"Treatment will be given in a 28-day cycle.~BVD-523 is an oral drug which will given at the protocol-dictated dose on a twice daily basis (at approximately 12-hour intervals).~Dose de-escalation patients will take BVD-523 at 600 mg twice daily on its own for two weeks before initiating Cycle 1 treatment with gemcitabine and nab-paclitaxel.~Nab-paclitaxel will be given at a dose of 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes.~Gemcitabine will be given at a dose of 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes.~Mandatory biopsy at baseline and baseline at end of 2 week BVD-523 lead in."
2993241|NCT02608229|Experimental|Dose Expansion: BVD-523/Nab-paclitaxel/Gemcitabine|"Treatment will be given in a 28-day cycle.~BVD-523 is an oral drug which will given at the protocol-dictated dose on a twice daily basis (at approximately 12-hour intervals).~Nab-paclitaxel will be given at a dose of 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes.~Gemcitabine will be given at a dose of 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes.~Mandatory biopsy at baseline and at end of cycle 2 (if deemed safe for participant and feasible to obtain)"
2993242|NCT02608216|Experimental|FLT PET/CT|All subjects will receive an [18F]FLT PET/CT scan.
2993243|NCT02608203|Experimental|patients with gastroenteropancreatic neuroendocrine tumors|
2993244|NCT02608190|Experimental|Active training|Patients will undergo active working memory training (see description of protocol).
2993245|NCT02608190|Active Comparator|Passive training|Patients will undergo passive working memory training (see description of protocol).
2993246|NCT02608177|Experimental|Linagliptin/Glipizide|Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
2993247|NCT02608177|Experimental|Glipizide/Linagliptin|Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
2993248|NCT02608164|Active Comparator|Vitamin D oral spray solution|An oral spray solution containing 3000IU (75micrograms) vitamin D3 per spray
2993249|NCT02608164|Active Comparator|Vitamin D capsules|A capsule containing 3000IU (75micrograms) vitamin D3 per capsule
2993250|NCT02608151|Active Comparator|Touch massage without oil|massage without oil
2993251|NCT02608151|Experimental|touch massage with oil|massage with an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil)
2993252|NCT02608138||1|Urinary iodine will be measured at one point in time in school children aged 6-12. A sample of salt used at home and schools will be collected to estimate iodine levels.
2993253|NCT02608125|Experimental|PRN1371|Drug: PRN1371
2993254|NCT02608112||Participants with Moderate to Severe RA|Participants with moderate or severe RA, naïve to TCZ treatment (IV or SC), and who have no contra-indication to TCZ SC therapy as per the local label are included.
2993255|NCT02608099|Active Comparator|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
2993256|NCT02608099|Experimental|Uninterrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
2993257|NCT02608086|Other|Control|"Flyer What can I do facing a crisis?"
2993258|NCT02608086|Experimental|Psychological First Aid|"Psychological First Aid according to an adapted protocol based on the WHO PFA Operation Guide 2012 Brochure Network and Services Flyer What can I do facing a crisis?."
2993259|NCT02608073|Experimental|Capecitabine + Cisplatin|Participants with metastatic nasopharyngeal cancer will receive combination treatment with capecitabine (1000 milligrams per meter square [mg/m^2] tablets twice daily [BID] orally) and cisplatin (100 mg/m^2/day intravenous [IV] infusion) for up to 8 cycles.
2993260|NCT02608060|Experimental|Epoetin Beta - 30000 IU|Dosage at Initiation: Subcutaneous injection of 30000 IU epoetin beta administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
2993261|NCT02608047||dengue patients|Dengue patients confirmed by Non-structural protein and RNA
2993262|NCT02608047||Healthy controls|Healthy population without any diseases
2993263|NCT02608034|Experimental|Part 1: Vemurafenib+Itraconazole|Part 1: Participants will receive vemurafenib orally BID up to Day 20 (Period A) followed by vemurafenib orally BID along with itraconazole orally once in the morning from Days 21 to 40 (Period B).\nPart 2: Participants will receive vemurafenib orally BID up to Day 20 (Period A) followed by vemurafenib orally BID along with rifampin orally once in the morning from Days 21 to 40 (Period B).
2993264|NCT02608021||Amnestic mild cognitive impairment|
2993265|NCT02608021||Cognitively normal|
2993266|NCT02608008||Data analysis|Periinterventional data analysis during structural heart procedures like transfemoral aortic valve implantation, MitraClip Implantations und PFO/ASD implantations with and without the use of EchoNavigator System Release II.
2993267|NCT02607995||low key intervention|for the whole group
2993268|NCT02607982|Experimental|Concurrent Chemoradiotherapy Arm|Radiotherapy was delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks. Concurrent paclitaxel (135mg/m², d1) and oxaliplatin (125mg/ m², d1) were administered on Days 1 and Day 29 of radiotherapy.
2993269|NCT02607969|Experimental|seen once every six weeks|Parents will be educated about home program and they will be asked to control once every six weeks.
2993270|NCT02607969|Experimental|seen once a week.|Parents will be educated about home program and they will be asked to control once a week.
2993271|NCT02607956|Experimental|Blinded Phase: B/F/TAF|B/F/TAF + DTG placebo + F/TAF placebo for at least 144 weeks
2993272|NCT02607956|Experimental|Blinded Phase: DTG+F/TAF|DTG+F/TAF + B/F/TAF placebo for at least 144 weeks
2993308|NCT02607761|Experimental|Intervention Group|2 minutes video with information and images on age-related fertility, infertility definitions, infertility risk factors, probabilities of fecundity according to age and cycle.
2993309|NCT02607761|No Intervention|Control|No intervention
2993311|NCT02607748|Experimental|18F-NaF PET and coronary CTA imaging|18F-NaF PET and coronary CTA imaging
2993273|NCT02607956|Experimental|Open-Label Phase|At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 48 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.
2993274|NCT02607943|Experimental|Insulin Glargine|subcutaneous long acting basal insulin (insulin glargine) with added short acting regular insulin to correct hyperglycemic events
2993275|NCT02607943|Active Comparator|Regular Insulin|short acting regular insulin pre-meal with added NPH at bed time if start eating
2993276|NCT02607930|Experimental|Blinded Phase: B/F/TAF|B/F/TAF + ABC/DTG/3TC placebo for at least 144 weeks
2993277|NCT02607930|Active Comparator|Blinded Phase: ABC/DTG/3TC|ABC/DTG/3TC + B/F/TAF placebo for at least 144 weeks
2993278|NCT02607930|Experimental|Open-Label Phase|At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 48 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.
2993279|NCT02607917|Experimental|Mass Media plus clinic intervention.|These geographic areas will receive the media plus clinic intervention over a two year period.
2993280|NCT02607917|Experimental|Media|These geographic areas will receive the media intervention over a two year period.
2993281|NCT02607917|No Intervention|No Intervention|Adjacent states will receive no intervention.
2993282|NCT02607904|Experimental|GWP42003-P|"Administered orally, twice daily (morning and evening), commencing with titration of 100 mg/mL GWP42003-P to 20 mg/kg/day over 10 days in a blinded manner (i.e., only participants taking placebo in the blinded phase will up-titrate; doses will remain unchanged for those taking GWP42003-P in the blinded phase).~Participants remain on the maintenance dose for the remainder of the 12-month treatment period. However, investigators may subsequently decrease or increase the participant's dose (to a maximum of 30 mg/kg/day) until the optimum dose is found.~Dosing is tapered (10% each day) for participants who do not immediately continue to use GWP42003-P once market authorization is granted, or for those who withdraw early."
2993283|NCT02607891|Experimental|STP + GWP42003-P|"Administered orally, twice daily (morning and evening; immediately after the participant's STP dose), commencing with up-titration of 100 mg/mL GWP42003-P to a maintenance dose of 20 mg/kg/day over 11 days.~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the open-label-extension (OLE) phase or who withdraw early.~STP Arm: Last patient completion anticipated August 2018"
2993284|NCT02607891|Placebo Comparator|STP + Placebo|"Administered orally, twice daily (morning and evening; immediately after the participant's STP dose), commencing with up-titration of placebo to an equivalent maintenance dose of 20 mg/kg/day over 11 days.~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.~STP Arm: Last patient out completion August 2018"
2993285|NCT02607891|Experimental|VPA + GWP42003-P|"Administered orally, twice daily (morning and evening; immediately after the participant's VPA dose), commencing with up-titration of 100 mg/mL GWP42003-P to a maintenance dose of 20 mg/kg/day over 11 days.~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.~VPA Arm: Last patient completion anticipated January 2018"
2993286|NCT02607891|Placebo Comparator|VPA + Placebo|"Administered orally, twice daily (morning and evening; immediately after the participant's VPA dose), commencing with up-titration of placebo to an equivalent maintenance dose of 20 mg/kg/day over 11 days.~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.~VPA Arm: Last patient completion anticipated January 2018"
2993287|NCT02607865|Experimental|Semaglutide 3 mg|
2993288|NCT02607865|Experimental|Semaglutide 7 mg|
2993289|NCT02607865|Experimental|Semaglutide 14 mg|
2993290|NCT02607865|Active Comparator|Sitagliptin 100 mg|
2993291|NCT02607852|Other|Arm A|Patients between the ages of 5-18 years. They will complete the 5-18 version of the BOQ on iPads or through the HTTPS Tonic link.
2993292|NCT02607852|Other|Arm B|Patients between the ages of 0-4 years. They will complete the 0-4 version of the BOQ and appropriate Pediatric Symptom Checklists (i.e. baby or preschool) on iPads or through the HTTPS Tonic link.
2993293|NCT02607839|Placebo Comparator|normal saline|normal saline intravenous infusion
2993294|NCT02607839|Active Comparator|glucose|glucose intravenous infusion
2993295|NCT02607826|Experimental|Intervention arm|
2993296|NCT02607826|No Intervention|Standard of Care|
2993297|NCT02607813|Experimental|Dose escalation LXH254|
2993298|NCT02607813|Experimental|Dose expansion LXH254: Group 1|
2993299|NCT02607813|Experimental|Dose expansion LXH254: Group 2|
2993300|NCT02607813|Experimental|Dose expansion LXH254: Group 3|
2993301|NCT02607813|Experimental|Dose expansion: LXH254 + PDR001|
2993302|NCT02607813|Experimental|Dose escalation LXH254 + PDR001|
2993303|NCT02607800|Experimental|SOF/VEL/VOX|SOF/VEL/VOX tablet for 8 weeks
2993304|NCT02607800|Active Comparator|SOF/VEL 12 weeks|SOF/VEL tablet for 12 weeks
2993305|NCT02607787|Experimental|Exercise Group|As well as usual care, this group receive a behavioural change session and intervention information regarding the exercise programme. The home-based walking and strengthening intervention is individually tailored for each participant. They receive a booklet, diary and pedometer to guide them as well as weekly phone calls for 12 weeks to monitor their progress.
2993306|NCT02607787|Other|Control Group|This group attends and participates in the same assessment outcomes as the intervention group and receives usual care for the duration of the study. However they are not given any exercise instructions and do not receive the intervention information until their final assessment at week 24. They are aware of their group allocation throughout the duration of the study.
2993307|NCT02607774|Experimental|Secukinumab|Secukinumab over 24 weeks
2993312|NCT02607735|Experimental|SOF/VEL/VOX (Primary Study)|SOF/VEL/VOX for 12 weeks
2993313|NCT02607735|Experimental|Placebo (Primary Study)|Placebo to match SOF/VEL/VOX for 12 weeks
2993314|NCT02607735|Experimental|SOF/VEL/VOX (Deferred Treatment Substudy)|SOF/VEL/VOX for 12 weeks for eligible participants initially randomized to receive placebo
2993315|NCT02607722||Nintedanib|Patients with IPF
2993316|NCT02607709|Placebo Comparator|Nephroureterektomy|scheduled to receive routine standard open or robot assisted nephroureterectomy without lymphadenectomy
2993317|NCT02607709|Experimental|Nephroureterektomy + Lymphadenectomy|scheduled to received mapped lymphadenectomy in conjugation with nephroureterectomy
2993318|NCT02607696|Experimental|Zolpidem 1.75 mg|Zolpidem Hemitartarate 1.75 mg Orodispersible Tablets Once daily
2993319|NCT02607696|Experimental|Zolpidem 3.50 mg|Zolpidem Hemitartarate 3.50 mg Orodispersible Tablets Once daily
2993320|NCT02607683|Experimental|XAF5 (concentration A: 0.1%)|Participants will apply XAF5 Ointment (concentration A: 0.1%) to the lower eyelids once daily.
2993321|NCT02607683|Experimental|XAF5 (concentration B: 0.035%)|Participants will apply XAF5 Ointment (concentration B: 0.035%) to the lower eyelids once daily.
2993322|NCT02607683|Placebo Comparator|Placebo|Participants will apply Placebo Ointment to the lower eyelids once daily.
2993323|NCT02607670|Experimental|TAT4 Gel|The participant will apply TAT4 Gel to the nasolabial fold area once daily.
2993324|NCT02607670|Placebo Comparator|Placebo|The participant will apply Placebo Gel to the nasolabial fold area once daily.
2993325|NCT02607657|Experimental|Eplerenone 25 mg|Eplerenone 25 mg Tablet Oral Once daily
2993326|NCT02607657|Experimental|Eplerenone 50 mg|Eplerenone 50 mg Tablet Oral Once daily
2993327|NCT02607657|Experimental|Eplerenone 100 mg|Eplerenone 100 mg (2 tablets of 50 mg) Tablet Oral Once daily
2993328|NCT02607657|Experimental|Eplerenone 50 mg x 2|Eplerenone 50 mg Tablet Oral Twice daily
2993329|NCT02607657|Experimental|Eplerenone 25 mg x 2|Eplerenone 25 mg Tablet Oral Twice daily
2993330|NCT02607644|Experimental|Laryngeal Tube (LT)|VBM Laryngeal Tube (Intervention)
2993331|NCT02607644|Active Comparator|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA)
2993332|NCT02607631|Experimental|Single arm|
2993333|NCT02607618|Experimental|iclaprim|iclaprim 80 mg intravenous every 12 hours
2993334|NCT02607618|Active Comparator|vancomycin|vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
2993335|NCT02607592|Experimental|Nadaplatin and Pemetrexed|nadaplatin 80mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
2993336|NCT02607592|Active Comparator|Cisplatin/Pemetrexed|cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
2993337|NCT02607579|Active Comparator|Ropivacaine|This group is given an adductor canal block with Ropivacaine which is the previous gold standard medication.
2993338|NCT02607579|Experimental|Exparel|This group is given an adductor canal block with Exparel which is believed to last longer and provide a better pain relief post-operatively.
2993339|NCT02607566|Experimental|Iyengar Yoga|Iyengar Yoga Intervention twice weekly for 60 minutes for 12 weeks.
2993340|NCT02607566|Active Comparator|Standard Exercise Program|professionally supervised program of aerobic exercise including use of an indoor walking track, treadmills, stationary bicycles and elliptical machines, held for 60 minutes twice weekly for 12 weeks
2993341|NCT02607553|Experimental|Experimental: G-202|G-202 administered by intravenous infusion on 3 consecutive days of a 28-day cycle
2993342|NCT02607540|Experimental|Two cycles PF-radiotherapy|"2 cycles cisplatin-5-fluorouracil: cisplatin: 75mg/m2 d1，29；5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.~radiotherapy： 50Gy，2 Gy/d，5d/w."
2993343|NCT02607540|Active Comparator|Four cycles PF-radiotherapy|"4 cycles cisplatin-5-fluorouracil: cisplatin: 75mg/m2 d1，29, 57, 85；5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.~radiotherapy： 50Gy，2 Gy/d，5d/w."
2993344|NCT02607527|Other|Device Implantation|Mitral Valve Iris Ring
2993345|NCT02607514|Experimental|immediate yoga arm|participants will immediately start the 8-week hyperthermic yoga intervention
2993346|NCT02607514|Other|delayed yoga arm|participants will wait 8-weeks to start the 8-week hyperthermic yoga intervention
2993347|NCT02607501|Other|eCLIPs BRS|Implant eCLIPs BRS at target aneurysm
2993348|NCT02607488|Placebo Comparator|Placebo|Patients will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.
2993349|NCT02607488|Active Comparator|Lidocaine 1%|"Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]"
2993350|NCT02607488|Active Comparator|Lidocaine 1.5%|Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1,5% solution which will be continued for 24 hours after surgery.
2993351|NCT02607488|Active Comparator|Lidocaine 2%|Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.
2993352|NCT02607475|Experimental|Robotic telesonography compared to conventional sonography|All participants will receive two imaging studies: (1) Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix), and (2) conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare).
2993353|NCT02607462|Experimental|PRP|Platelet-rich plasma taken made from centrifuged venous blood.
2993354|NCT02607462|Placebo Comparator|Saline|Sodium chloride 0.9% used as placebo.
2993355|NCT02607449|Experimental|A|Standard DOTS+ treatment regiment with FS-1 drug.
2993356|NCT02607449|Placebo Comparator|B|Standard DOTS+ treatment regiment with a placebo.
2993357|NCT02607436|Experimental|Sarpogrelate + Aspirin|Sarpogrelate as an active drug
2993358|NCT02607436|Active Comparator|Aspirin alone|Aspirin as an active comparator
2993394|NCT02607163|Placebo Comparator|control|saline, same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
2993359|NCT02607423|Experimental|Diagnostic (18F-FDG PET/CT)|"Patients undergo fludeoxyglucose F-18 PET/CT at baseline and after course 1 of chemotherapy. Patients undergo 1 of 3 chemotherapy regimens at the discretion of the investigator.~CHEMOTHERAPY REGIMEN 1: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, and 8. Patients also receive cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY REGIMEN 2: Patients receive docetaxel IV over 60 minutes and cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY REGIMEN 3: Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
2993360|NCT02607410|Active Comparator|sitagliptin|100mg every day of sitagliptin in patients that were previosly using metformin and glyburide
2993361|NCT02607410|Active Comparator|NPH insulin|NPH insulin will be applied bedtime every night in patients that awere previously using metformin and glyburide,The insulin dosage will be adjusted to fasting glycemia between 90 and 100 mg / dL
2993362|NCT02607384|Experimental|Vision problems|Children with refractive error will be prescribed eyeglass wearing, and children with convergence insufficiency will be given orthoptic exercises. Children with any other vision problem will be given a specialist referral to a pediatric eye specialist.
2993363|NCT02607371||Cohort 1 / VKA treatment|A sample of about 200 patients with nonvalvular atrial fibrillation who are treated with VKAs for at least three months at date of study inclusion
2993364|NCT02607371||Cohort 2 / NOAC treatment|A sample of about 200 patients with nonvalvular atrial fibrillation who are treated with NOACs for at least three months at date of study inclusion
2993365|NCT02607358||Clopidogrel|Clopidogrel non-responders (HOTPR) Blood sampling for HOTPR-testing
2993366|NCT02607358||Acetacylicacid|Acetcylicacid non-responders (HOTPR), Blood sampling for HOTPR-testing
2993367|NCT02607345|Active Comparator|Glucomedics®|25gr Glucomedics®
2993368|NCT02607345|Experimental|Zusto®|25gr Zusto®
2993369|NCT02607332|Experimental|Paclitaxel|paclitaxel 80mg/m2/day on a Cycle1Day1, Cycle1Day8,Cycle1Day15 off 1 week schedule
2993370|NCT02607319|Experimental|Low molecular weight heparin|Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution (Hibor; Laboratories Rovi Pharmaceuticals) for injection in pre-filled syringes.
2993371|NCT02607319|No Intervention|No intervention group|Control group receiving standard care.
2993372|NCT02607306|Experimental|Insulin degludec/liraglutide OD|
2993373|NCT02607306|Active Comparator|Insulin degludec OD|
2993374|NCT02607306|Active Comparator|Liraglutide OD|
2993375|NCT02607293||Subjects undergoing ART treatment with long GnRH-a or GnRH-ant|Subjects undergoing ART treatment with long GnRH-a protocol or GnRH-ant protocol + Gn + human chorionic gonadotropin (hCG) as per routine clinical practice. No visits or intervention(s) additional to the routine practice of the Investigators will be performed during this observational study.
2993376|NCT02607280|Experimental|DS-5565 group|DS-5565 15 mg (for moderate renal impairment) or 7,5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
2993377|NCT02607267||laparoscopic Roux en Y Gastric Bypass|patients undergoing LRYGB, being the first surgical treatment for severe obesity
2993378|NCT02607267||laparoscopic Sleeve Gastrectomy|patients undergoing LSG, being the first surgical treatment for severe obesity
2993379|NCT02607254|Experimental|Pregabalin|All patients will be initially treated with pregabalin. after 8 weeks of treatment, some will be randomized to continue on pregabalin if their pain is controlled.
2993380|NCT02607254|Placebo Comparator|Placebo|After finishing the treatment phase, some patients will be randomized to the placebo arm for the withdrawal phase.
2993381|NCT02607241|Active Comparator|BRS|"OCT-guided BRS implantation: implantation of a bioresorbable scaffold (BRS) under OCT guidance.~Note: Absorb™ from Abbott Vascular has been used as BRS until this product became unavailable in April 2017. Currently the recruitment is stopped due to this issue, until the use of another BRS gets final approval."
2993382|NCT02607241|Experimental|DCB-only|FFR-guided DCB-only PCI: PCI using DCB (SeQuent Please™, B Braun Melsungen GmBH) without stent implantation und FFR guidance
2993383|NCT02607228|Experimental|GS-5829 Dose Escalation|Participants who have progressed on either abiraterone and/or enzalutamide will be enrolled to receive increasing doses of GS-5829 to determine the MTD.
2993384|NCT02607228|Experimental|GS-5829 + Enzalutamide Dose Escalation|Following a two week lead-in with enzalutamide once daily, participants who have progressed on abiraterone will receive GS-5829 in combination with enzalutamide once daily. Based on observed pharmacokinetics (PK) interaction, toxicity, and tolerability observed in the single agent dose escalation, the dose of GS-5829 may be increased.
2993385|NCT02607228|Experimental|GS-5829 Dose Expansion (Group 1)|Participants will receive ≤ the MTD of GS-5829 (based on safety, pharmacodynamics (PD), and tolerability).
2993386|NCT02607228|Experimental|GS-5829 + Enzalutamide Dose Expansion (Group 2)|Participants will receive ≤ the MTD of GS-5829 plus enzalutamide (based on safety, PD, and tolerability).
2993387|NCT02607228|Experimental|GS-5829 + Enzalutamide Dose Expansion (Group 3)|Participants will receive GS-5829 plus enzalutamide (dose will be equivalent to the dose chosen for Group 2).
2993388|NCT02607215|Experimental|Vinorelbine Plus DDP|"Vinorelbine:25 mg/m2, D1, D8 every 21 days~DDP:75 mg/m2, D1 every 21 days"
2993389|NCT02607215|Active Comparator|Vinorelbine|Vinorelbine:30 mg/m2, D1, D8 every 21 days
2993390|NCT02607202|Experimental|Arm A|nab-paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration over 30 minutes without premedication, followed by gemcitabine 1000 mg/m2 on Days 1 and 8 by IV administration over 30 minutes. Treatment to be repeated Q21 days.
2993391|NCT02607202|Experimental|Arm B|nab-paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration over 30 minutes without premedication, followed by carboplatin AUC 2 on Day 1 and 8 by IV administration over 60 minutes. Treatment to be repeated Q21 days.
2993392|NCT02607176|Experimental|Heweizhixie capsule|Heweizhixie capsule, 0.33g/#, 3 #, Tid, Oral
2993393|NCT02607163|Experimental|dexmedetomidine|dexmedetomidine, 0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
2993395|NCT02607137|Experimental|Health Education|Health information related to physical activity
2993396|NCT02607124|Experimental|RB+ High Grade Glioma|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 600mg daily (DIPG); <21 yrs of age 350 mg/m2/day)
2993397|NCT02607124|Experimental|Non-Biopsied Diffuse Instrinsic Pontine Glioma|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 600mg daily (DIPG); <21 yrs of age 350 mg/m2/day)
2993398|NCT02607111|Experimental|open label|Dalteparin injected as a bolus into the arterial port of the hemodialysis machine every dialysis session for four weeks
2993399|NCT02607098||Males diagnosed with male-factor infertility|This study will recruit a convenience sample of 10 men and their partners seeking consultation from a fertility urologist following the detection of male-factor infertility.
2993400|NCT02607098||Female partners|This study will recruit a convenience sample of 10 men and their partners seeking consultation from a fertility urologist following the detection of male-factor infertility.
2993401|NCT02607072|Experimental|Aspirin 200 mg daily|Aspirin 200 mg daily
2993402|NCT02607072|Experimental|Aspirin 100 mg daily|Aspirin 100 mg daily
2993403|NCT02607072|Placebo Comparator|Placebo control|Placebo control
2993404|NCT02607046|No Intervention|Control|Standard Medical Care
2993405|NCT02607046|Experimental|Exercise|Exercise Training
2993406|NCT02607046|Experimental|NMES|Neuromuscular Electrical Stimulation
2993407|NCT02607046|Experimental|Exercise + NMES|Combined Exercise Training and Neuromuscular Electrical Stimulation
2993408|NCT02607033|Experimental|Exercise and Weight Loss|Individuals assigned to this group will be asked to complete both the exercise and weight loss intervention for six months
2993409|NCT02607033|Active Comparator|Exercise|Individuals assigned to this group will be asked to complete the exercise intervention for xic months
2993410|NCT02607020|Experimental|Physical exercise|
2993411|NCT02607020|Active Comparator|Relaxation|
2993412|NCT02607007|Experimental|2% M.F. Milk|Breakfast meal: 250 mL 2% M.F. milk, 75 g white toast, 23.2 g strawberry jam, 100 mL water
2993413|NCT02607007|Experimental|2% M.F. Plain Greek Yogurt|Breakfast meal: 175 g 2% plain Greek yogurt, 75 g white toast, 23.2 g strawberry jam, 100 mL + 75 mL water
2993414|NCT02607007|Experimental|31% M.F. Cheddar Cheese|Breakfast meal: 30 g 31% M.F. cheddar cheese, 75 g white toast, 27.0 g strawberry jam, 100 mL + 220 mL water
2993415|NCT02607007|Experimental|Soy Beverage|Breakfast meal: 250 mL soy beverage, 75 g white toast, 19.3 g strawberry jam, 100 mL water
2993416|NCT02607007|Experimental|Water (control)|Breakfast meal: 250 mL + 100 mL water
2993417|NCT02606994|Experimental|Oral Defense Toothpaste|The experimental group will brush with Oral Defense Toothpaste three times per day during the study
2993418|NCT02606994|Placebo Comparator|Crest Toothpaste/Magic Mouth Rinse|The placebo group will brush with Crest Toothpaste three times per day during the study. Participants in the placebo comparator group who require additional management of their oral mucositis pain will be provided Magic Mouth Rinse.
2993419|NCT02606981|Experimental|Chlorination|Device: Water chlorination by the Flogenic Primary drinking water source will be outfitted with automatic dosing device supplied with chlorine tablets. The device is called the Flogenic.
2993420|NCT02606981|Placebo Comparator|Control|Active control: Vitamin C dosing into water. Primary drinking water source will be outfitted with automatic dosing device supplied with vitamin C tablets. The device is not commercially available.
2993421|NCT02606955|Experimental|BIA REST|BIA DW assessment
2993422|NCT02606942||Dancers with knee injury|A cohort of dancers with reported knee injury. Questionnaires, physical exam, US of the knee
2993423|NCT02606942||Dancers with no knee injury|A cohort of dancers without reported knee injury. Questionnaires, physical exam, US of the knee
2993424|NCT02606942||Non-dancers athletes|A cohort of non-dancers athletes without knee injuries. Questionnaires, physical exam, US of the knee
2993425|NCT02606916|Experimental|SMART & S-1/DDP|Patients in experimental group receive daily simultaneous modulated accelerated radiotherapy combined with DDP and S-1.
2993426|NCT02606903|Experimental|BI 695501 prefilled syringe|
2993427|NCT02606903|Experimental|BI 695501 autoinjector|
2993428|NCT02606877|Experimental|Group 1|Treatment naïve to pirfenidone
2993429|NCT02606877|Experimental|Group 2|Treatment before with pirfenidone
2993430|NCT02606864|Experimental|BAYa2502 without food|Oral intake of a single 120 mg nifurtimox dose under fasted conditions
2993431|NCT02606864|Experimental|BAYa2502 with food|Oral intake of a single 120 mg nifurtimox dose under fed conditions after ingestion of a high calorie and high fat breakfast
2993432|NCT02606838|Experimental|Persons with Diabetes|Untrained Persons with Diabetes used the Styx Lancing Device System to obtain fingerstick and Alternate Site palm capillary blood.
2993433|NCT02606812|Experimental|Traditional-food|During the 3 months, a dish containing traditional food will be provided 5 days per week. The food will contain an average of 600 Kcal, ≤ 50 mg of cholesterol, ≥ 10 g of fiber, ≥ 130 g of vegetables, and ≤ de 200 mg of sodium. Each dish will be accompanied with 3 standard-sized corn tortillas.
2993434|NCT02606812|No Intervention|Control|Is the group who will intake the cafeteria fast food. The control group will receive habitually consumed fast food provided by the cafeteria of the campus at a similar caloric proportion.
2993435|NCT02606799|No Intervention|Standard Care|intensive care therapy according to international standards and following local SOPs, including fluid therapy, mechanical ventilation, catecholamine therapy and other pharmacotherapy as required
2993436|NCT02606799|Experimental|CytoSorb|all of the above, plus extracorporeal hemadsorption therapy (CytoSorbents Adsorber cartridge) using continuous veno-venous hemofiltration (citrate anticoagulation) CytoSorb cytokine elimination
2993437|NCT02606786|Experimental|stabilization exercises|Lumbopelvic stabilization exercises have been shown to decrease pain and disability in those with low back pain. The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
2993438|NCT02606773|Experimental|600 mg Novo C plus|Single dose of oral 600 mg Novo C plus dietary supplement (contains 600 mg ascorbic acid in liposomal formulation)
2993439|NCT02606773|Experimental|900 mg Novo C Plus|Single dose of 900 mg oral Novo C plus dietary supplement (contains 900 mg ascorbic acid in liposomal formulation)
2993440|NCT02606773|Active Comparator|500 mg intravenous vitamin C|Single dose of 500 mg intravenous ascorbic acid (Vitamin C 100 mg/ml injection; EGIS)
2993441|NCT02606773|Active Comparator|500 mg oral vitamin C|Single dose of 500 mg oral ascorbic acid (Cetebe 500 mg retard capsules; GlaxoSmithKline Consumer Healthcare - GSK Export)
2993442|NCT02606760|Experimental|P-3073|P-3073
2993443|NCT02606760|Placebo Comparator|vehicle of P-3073|vehicle of P-3073
2993444|NCT02606747||Diabetes mellitus with DPN|Aged from 40 to 80. Normal cognitive ability. Right handed. Able to walk without any other kinds of central nervous system disorder. Confirmed diabetes with DPN.
2993445|NCT02606747||Diabetes mellitus without DPN|Aged from 40 to 80. Normal cognitive ability. Right handed. Able to walk without any other kinds of central nervous system disorder. Confirmed diabetes without DPN.
2993446|NCT02606734|Other|Treatment Arm|All subjects enrolled in the trial will use the DyeVert System.
2993447|NCT02606721||Challenge Subjects|Male or female subjects aged 5 - 35 with suspected food allergy and an upcoming scheduled clinical food challenge
2993448|NCT02606708|Experimental|Accelerated intensity modulated radiation therapy (AIMRT)|All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.
2993449|NCT02606682|Experimental|NPT200-11 - Cohort 1, Dose 1|Single ascending dose of orally administered capsule(s) NPT200-11: 15 mg OR Single dose of orally administered placebo capsule(s) to match dose
2993450|NCT02606682|Experimental|NPT200-11 - Cohort 2, Dose 2|Single ascending dose of orally administered capsule(s) NPT200-11: 30 mg OR Single dose of orally administered placebo capsule(s) to match dose
2993451|NCT02606682|Experimental|NPT200-11 - Cohort 3, Dose 3|Single ascending dose of orally administered capsule(s) NPT200-11: 60 mg OR Single dose of orally administered placebo capsule(s) to match dose
2993452|NCT02606682|Experimental|NPT200-11 - Cohort 4, Dose 4|Single ascending dose of orally administered capsule(s) NPT200-11: 120 mg OR Single dose of orally administered placebo capsule(s) to match dose
2993453|NCT02606682|Experimental|NPT200-11 - Cohort 5 ,Dose 5|Single ascending dose of orally administered capsule(s) NPT200-11: 240 mg OR Single dose of orally administered placebo capsule(s) to match dose
2993454|NCT02606682|Experimental|NPT200-11 -Cohort 6, Dose 6|Single ascending dose of orally administered capsule(s) NPT200-11: 360 mg OR Single dose of orally administered placebo capsule(s) to match dose
2993455|NCT02606682|Experimental|NPT200-11 - Cohort 7, Dose 7|Single ascending dose of orally administered capsule(s) NPT200-11: 480 mg OR Single dose of orally administered placebo capsule(s) to match dose
2993456|NCT02606669|Experimental|Intermittent Fasting|"The intervention of interest here is the Intermittent Energy Restriction (IER) or the Intermittent Fasting approach, specifically, the 5:2 diet, where adherence to this dietary intervention consists of fasting for two consecutive days and consuming enough to meet energy requirements for the remaining five non-fasting days. In this study, fasting will be achieved by using a meal replacement product (Optifast®) supplemented by two scoops of protein powder (Propass®) and a multivitamin, making a total of 540kcal (54g protein, 60g carbohydrates) for each fasting day."
2993457|NCT02606669|No Intervention|Control|Diet and Physical Activity advice only. No treatment plan.
2993458|NCT02606643|Active Comparator|Group 1 Catheter to traction|"For the Tension arm (research related), slight tension will be placed on the catheter, which will then be taped to the patient's inner thigh. The tension will be assessed and retaped as needed every 30 minutes by the research and/or the nursing staff.~Only slight tension will be applied to those catheters assign to the tension group. The catheter will be taped to the inner thigh so there is no sag in the catheter from the urethra to the tape. There is no method or device to measure the tension placed on these catheters, if the patient moves her leg it can lessen or increase the tension, these are known factors."
2993459|NCT02606643|Active Comparator|Group 2 Catheter to no traction|"Foley catheter placed as SOC No traction applied"
2993460|NCT02606630|Experimental|ABT-555|ABT-555 will be administered at Visit 4 for Part 2 only
2993461|NCT02606617|Active Comparator|Mosapride|Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
2993462|NCT02606617|Placebo Comparator|Placebo|Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
2993463|NCT02606604|Experimental|FES Cycling|The intervention consists of electrical stimulation to five lower extremity muscle groups (quadricep, hamstring, anterior tibialis, gluteal, and gastrocnemius muscle groups) while cycling for 45 minutes, 3 times per week for 8 weeks. Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed).
2993464|NCT02606604|Active Comparator|Cycling Only|The intervention consists of lower extremity cycling for 45 minutes, 3 times per week for 8 weeks. Electrical stimulation will not be applied to any muscles. Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed.
2993465|NCT02606591|Experimental|Electroencephalograph (EEG) + Testing|Participants complete an electroencephalograph (EEG) cognitive tests, and provide a hair sample shortly after entering the study and again near the end of the school year. Hair sample tested to measure a stress hormone called cortisol.
2993466|NCT02606565|Experimental|Intervention arm: 4% chlorhexidine|Neonates randomized to the chlorhexidine arm will have umbilical stump cleansing with a single application of 4% chlorhexidine solution at birth
2993467|NCT02606565|No Intervention|Control arm: Dry cord care|Neonates randomized to the control arm will receive the current standard of cord care (dry cord care)
2993468|NCT02606552|Active Comparator|Dabigatran plus aspirin|Medical treatment with dabigatran plus aspirin after 3months triple therapy (Dabigatran plus DAPT (dual-antiplatelet therapy))
2993469|NCT02606552|Experimental|Dabigatran plus clopidogrel|medical treatment with dabigatran plus clopidogrel after 3months triple therapy (Dabigatran plus DAPT)
2993470|NCT02606552|Other|Amplazter Cardiac Plug (ACP)|Amplazter Cardiac Plug (ACP) device-using percutaneous left atrial appendage closure
2993510|NCT02606253|Active Comparator|Metolazone|Metolazone 5mg tablet orally twice daily for 48 hours.
2993511|NCT02606253|Experimental|Chlorothiazide|Chlorothiazide 500mg intravenous infusion over 30 minutes twice daily for 48 hours
2993512|NCT02606253|Experimental|Tolvaptan|Tolvaptan 30mg tablet orally once daily for 48 hours
2993471|NCT02606539|Active Comparator|surgery and methotrxate|The patient will be treated by total abdominal hystrectomy(after written consent laparatomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg alternating with calcium folinate 0.1 mg/kg until normalization of B-HCG
2993472|NCT02606539|Active Comparator|methotrxate|The patient will be treated by multiple courses of methotrexate( antifolate) 1mg/kg every 14 days each one alternating in every otherday with calcium folinate 0.1 mg/kg till normalization of B-HCG
2993473|NCT02606526|Experimental|Intervention arm: BCG at birth|Infants randomized to this arm will receive an intra-dermal administration of 0.05 ml of BCG vaccine within 24h of birth
2993474|NCT02606526|Active Comparator|Control arm: BCG at 14 weeks of age|Infants randomized to this arm will receive intra-dermal administration of 0.05 ml of BCG vaccine at 14 weeks of age
2993475|NCT02606513|Experimental|Comparison of CTU vs MRU|CTU is the primary test of choice for the evaluation of the UUT. The performance of MRU will be compared to that of CTU in the same patient population
2993476|NCT02606500|Experimental|Elonva 150 mcg|Elonva 150 mcg intramuscular daily obese
2993477|NCT02606500|Active Comparator|Elonva 100 mcg|Elonva 100 mcg intramuscular daily normal weight
2993478|NCT02606487||CF pulmonary exacerbation group|Patients with cystic fibrosis admitted for inpatient treatment of a pulmonary exacerbation
2993479|NCT02606461|Experimental|Selinexor 60mg|"Phase 2: 57 patients were randomized to selinexor or placebo in a 1:1allocation.~Phase 3: Approximately 222 patients will be randomized to selinexor (~148 patients) or placebo (~74 patients) in a 2:1 allocation."
2993480|NCT02606461|Placebo Comparator|Placebo|"Phase 2: Approximately 57 patients were randomized to selinexor or placebo in a 1:1 allocation.~Phase 3: Approximately 222 patients will be randomized to selinexor (~148 patients) or placebo (~74 patients) in a 2:1 allocation."
2993481|NCT02606448|Active Comparator|Femoral Nerve Block|Patients in this group received preoperative ultrasound guided femoral nerve blocks by senior anesthesiologist using ropivicaine.
2993482|NCT02606448|Experimental|Liposomal Bupivacaine|Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
2993483|NCT02606435|Experimental|thrombus aspiration with PCI|patient will receive manual thrombus aspiration with percutaneous coronary intervention (PCI)
2993484|NCT02606435|Active Comparator|PCI alone|patients will receive percutaneous coronary intervention (PCI) alone including stent implantation
2993485|NCT02606422|Experimental|Active tDCS plus Speech-Language Therapy|Active tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min.
2993486|NCT02606422|Sham Comparator|Sham plus Speech-Language Therapy|Sham tDCS will be applied at the beginning of 45min speech-language therapy session.
2993487|NCT02606409|Active Comparator|Dexmedetomidine|Dexmedetomidine intravenous sedation at 0.2-0.7 µg/kg/h for >24h.
2993488|NCT02606409|Active Comparator|Propofol|Propofol sedation at 10-70µg/kg/h for >24h.
2993489|NCT02606383|Experimental|Dapaconazole|Dapaconazole 2% Cream Topical
2993490|NCT02606383|Active Comparator|Ketoconazole|Ketoconazole 2% Cream Topical
2993491|NCT02606370|Experimental|Unstable shoes|Wearing unstable shoes during 1 month
2993492|NCT02606370|No Intervention|Control Group|Not Wearing unstable shoes
2993493|NCT02606357|Experimental|HOE901|HOE901 administered subcutaneously once a day in the evening, at dinner, or at bedtime with titration based on FPG levels
2993494|NCT02606344|Experimental|Intervention Group (IG)|Loans were provided to poor women who enrolled in the intervention group. A participatory learning and action curriculum was integrated into loan meetings, which took place every 2 weeks.
2993495|NCT02606344|No Intervention|Control Group (CG)|
2993496|NCT02606331|Experimental|Piezosurgery|In one half of the dental arch, piezosurgery will be performed for canine retraction, whereas in the other half ordinary canine retraction procedure will be followed.
2993497|NCT02606331|Experimental|ER:YAG Laser|In one half of the dental arch, ER:YAG laser irradiation will be performed for canine retraction, whereas in the other half ordinary canine retraction procedure will be followed.
2993498|NCT02606318|Experimental|Adjusted the challenge-skill balance|This group received 10-session occupational therapy with adjustment of challenge-skill balance.This intervention aimed at improving the skill level for the activity has started once the balance were balanced.
2993499|NCT02606318|Other|Non-adjusted the challenge-skill balance|This group received 10-session occupational therapy without adjustment of challenge-skill balance. That is conducted the therapy in the normal manner for the day care center.
2993500|NCT02606305|Experimental|Regimen A|Dose escalation and dose expansion with IMGN853 and bevacizumab
2993501|NCT02606305|Experimental|Regimen B|Dose Escalation with IMGN853 and carboplatin
2993502|NCT02606305|Experimental|Regimen C|Dose Escalation with IMGN853 and pegylated liposomal doxorubicin
2993503|NCT02606305|Experimental|Regimen D|Dose escalation and dose expansion with IMGN853 and pembrolizumab
2993504|NCT02606305|Experimental|Regimen E|Dose escalation and dose expansion with IMGN853 and bevacizumab+carboplatin
2993505|NCT02606292|Experimental|Arm 1: PAE assessment|-The PAE-EUS assessment will be performed in the operating room by the after induction of general anesthesia and following strict sterile technique while the patient is being positioned and prepped for esophageal surgery.
2993506|NCT02606279|Placebo Comparator|Placebo control|20 HIV-infected participants will be randomized into a blinded arm where they will receive 24 weeks of placebo therapy. During this time, they will undergo the same study procedures as the intervention arm.
2993507|NCT02606279|Experimental|Valsartan|20 HIV-infected participants will be randomized into a blinded arm where they receive 24 weeks of valsartan therapy. For those subjects randomized to the valsartan group, they will receive valsartan 40 mg by mouth daily for 2 weeks, then increase to 80 mg by mouth daily for the remaining 22 weeks. During this time, they will undergo the same study procedures as the placebo arm.
2993508|NCT02606266|Experimental|Valganciclovir|Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension), at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
2993509|NCT02606266|No Intervention|Control group|Control group with standard care who do not receive the investigational medicinal product
2993513|NCT02606240||Mild to Moderate ARDS on PRISMALUNG|Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device in patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS).
2993514|NCT02606227|Experimental|Experimental group:financial incentives|Vouchers for show up + Vouchers at increasing amount to reward tobacco abstinence
2993515|NCT02606227|Other|Control group:no financial intervention|Vouchers for show up only, no financial incentive for rewarding tobacco abstinence
2993516|NCT02606214|Experimental|Dose Level 1: 50 mg TBA-354|50 mg TBA-354 for 14 days (two 25 mg once daily)
2993517|NCT02606214|Placebo Comparator|Dose Level 1: Placebo|Placebo cohort for Dose Level 1
2993518|NCT02606214|Experimental|Dose Level 2: 100 mg TBA-354|100 mg TBA-354 for 14 days (one 100 mg tablet once daily)
2993519|NCT02606214|Placebo Comparator|Dose Level 2: Placebo|Placebo cohort for Dose Level 2
2993520|NCT02606214|Experimental|Dose Level 3: 200 mg TBA-354|200 mg TBA-354 for 14 days (two 100 mg once daily)
2993521|NCT02606214|Placebo Comparator|Dose Level 3: Placebo|Placebo cohort for Dose Level 3
2993522|NCT02606214|Experimental|Dose Formulation Comparison Cohort|"All subjects in this cohort will receive two doses of the active drug. The first dose in three subjects will be a 100 mg TBA-354 tablet, followed 14 days later by a 100 mg dose of the TBA-354 suspension formulation. The first dose in the other three subjects will be 100 mgs of the TBA-354 suspension formulation, followed 14 days later by a 100 mg TBA-354 tablet dose. Placebo formulations will not be used in the dose formulation comparison cohort.~Each dose will be administered orally with 200 ml of water after a minimum 8 hour overnight fast. Food will be given two hours after each dose."
2993523|NCT02606201|Experimental|IPSMA|Injection Peri Sphincter Myofibers Autologous
2993524|NCT02606188|Active Comparator|Modified High-flow nasal cannula therapy|Patients undergoing bronchoscopy are given Modified High-flow nasal cannula oxygen therapy all the time.
2993525|NCT02606188|Active Comparator|Nasal cnnnula therapy|Patients undergoing bronchoscopy are given nasal cannula oxygen therapy all the time.
2993526|NCT02606175|Other|Admitted for renal transplantation|"Patients who are hospitalised on the abdominal transplantation surgery ward at the University Hospitals of Leuven (UZLeuven) and undergo a kidney transplantation during this hospitalisation.~Intervention: taking questionnaires and tests at predefined timepoints:~at discharge: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire~1 month after kidney transplantation: BAASIS, medication knowledge test~3 months after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test~1 year after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire~2 years after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire"
2993527|NCT02606149|Active Comparator|Standard of information|Information on chemotherapy as done in routine practice following national and international guidelines
2993528|NCT02606149|Experimental|Truthful information on chemotherapy risks|Information on the potential role of anticancer chemotherapy in worsening life-threatening conditions
2993529|NCT02606136|Experimental|pamrevlumab (FG-3019)|Each subject will receive pamrevlumab (FG-3019) (35 mg/kg, every 2 weeks) for up to 156 weeks.
2993530|NCT02606123|Experimental|EPI-506|Part I: Ascending doses of EPI-506 administered orally to define the maximum tolerated dose.
2993531|NCT02606097|Experimental|regorafenib|regorafenib 160 mg daily, 3 weeks on/1 week off
2993532|NCT02606084|Experimental|Cohort 1|Participants with mild renal impairment (Measured Creatinine Clearance [CLCR,m] greater than or equal to >= 50 to 79 milliliter/minute [mL/min]) will self-administer esketamine 28 milligram (mg) intranasally on Day 1.
2993533|NCT02606084|Experimental|Cohort 2|Participants with moderate renal impairment (CLCR,m >=30 to 49 mL/min) will self-administer esketamine 28 mg intranasally on Day 1.
2993534|NCT02606084|Experimental|Cohort 3|Participants with severe renal impairment (CLCR,m less than [<] 30 mL/min), not on dialysis will self-administer esketamine 28 mg intranasally on Day 1.
2993535|NCT02606084|Experimental|Cohort 4|Participants with normal renal function and no evidence of kidney damage (CLCR,m >= 80 mL/min) will self-administer esketamine 28 mg intranasally on Day 1.
2993536|NCT02606058|No Intervention|Early cord clamping (Control Arm)|Immediate cord clamping (< 10 seconds after birth). The cord is clamped 6 cm from the umbilicus within ten seconds of delivery of the baby.
2993537|NCT02606058|Experimental|Deferred cord clamping|Deferred cord clamping. Investigator/Research personnel holds the baby as low as possible below the level of the introitus or placenta for 60 seconds and not to exceed 80 seconds, then clamps the cord about 6 cm from the umbilicus.
2993538|NCT02606045|Active Comparator|Group I|Subjects randomized to Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, tranexamic acid 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.
2993539|NCT02606045|Active Comparator|Group II|Group II will receive Arm B, tranexamic acid 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.
2993540|NCT02606032|Active Comparator|Metronidazole+doxycylcine+terbinafine|Metronidazole 500 mg BID, Doxycycline 100 mg BID, Terbinafine 250 mg once daily all for 14 days
2993541|NCT02606032|Placebo Comparator|Placebo|Placebo Metronidazole, Placebo Doxycycline, and Placebo Terbinafine all BID for 14 days
2993542|NCT02606006|Active Comparator|Non-AAT Group|Inpatients in this group will receive 3-5 brief afternoon physical therapy sessions over 3-5 successive days. None of the sessions will include use of a canine for AAT. This group will include the intervention of Standard of Care Physical Therapy
2993543|NCT02606006|Experimental|AAT Group|Inpatients in this group will receive 3-5 brief afternoon physical therapy sessions over 3-5 successive days. The session on the middle day will include use of a canine for AAT. This group will receive a behavioral intervention of Canine Animal-Assisted Therapy.
2993544|NCT02605993|Experimental|Cohort 1|"ALXN1210 1400 mg on Day 1, 1000 mg on Day 15 and Day 29 and every 4 weeks.~During the extension period, all patients switched to weight-based dosing as follows:~≥ 40 to < 60 kg: 3000 mg every 8 weeks~≥ 60 to < 100 kg: 3300 mg every 8 weeks~≥ 100 kg: 3600 mg every 8 weeks"
2993801|NCT02604355|Experimental|Healthy Participants (Study of Food Effect)|
2993545|NCT02605993|Experimental|Cohort 2|"ALXN1210 2000 mg on Day 1, 1600 mg on Day 22 and Day 43 and every 6 weeks.~During the extension period, all patients switched to weight-based dosing as follows:~≥ 40 to < 60 kg: 3000 mg every 8 weeks~≥ 60 to < 100 kg: 3300 mg every 8 weeks~≥ 100 kg: 3600 mg every 8 weeks"
2993546|NCT02605993|Experimental|Cohort 3|"ALXN1210 1600 mg on Day 1 and Day 15, 2400 mg on Day 29 and every 8 weeks.~During the extension period, all patients switched to weight-based dosing as follows:~≥ 40 to < 60 kg: 3000 mg every 8 weeks~≥ 60 to < 100 kg: 3300 mg every 8 weeks~≥ 100 kg: 3600 mg every 8 weeks"
2993547|NCT02605993|Experimental|Cohort 4|"ALXN1210 3000 mg on Day 1, 5400 mg on Day 29 and every 12 weeks.~During the extension period, all patients remained on the same dose regimen."
2993548|NCT02605980||Male|Community-dwelling healthy older adults over the age of 70 years. Must be ambulatory, with or without walking aids
2993549|NCT02605980||Female|Community-dwelling healthy older adults over the age of 70 years. Must be ambulatory, with or without walking aids
2993550|NCT02605967|Experimental|PDR001 - Investigational drug|anti-PD1 humanized monoclonal antibody
2993551|NCT02605967|Active Comparator|Chemotherapy|commonly used chemotherapy as per investigator's choice
2993552|NCT02605954|Experimental|E/C/F/TAF|Participants will switch to E/C/F/TAF FDC and receive treatment for 48 weeks.
2993553|NCT02605954|Active Comparator|ABC/3TC+3rd Agent|"Participants will maintain prior regimen of ABC/3TC plus a third antiretroviral agent for 24 weeks followed by a delayed switch to E/C/F/TAF FDC.~Note: the prior regimen is determined by the participant's clinician (prior to entry into the study) and will consist of one of the third antiretroviral agents listed."
2993554|NCT02605928|Experimental|BIP Needle|Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability. It measures bioimpedance and detects synovial fluid during inta-articular injection.
2993555|NCT02605915|Experimental|Cohort 1A: Atezolizumab/Trastuzumab/Pertuzumab|Participants will receive atezolizumab in combination with trastuzumab and pertuzumab every 3 weeks.
2993556|NCT02605915|Experimental|Cohort 1B: Atezolizumab/Trastuzumab emtansine 3.6 mg|Participants will receive atezolizumab in combination with trastuzumab emtansine (3.6 mg/kg) every 3 weeks.
2993557|NCT02605915|Experimental|Cohort 1C: Atezolizumab/Trastuzumab emtansine 3.0 mg|Participants will receive atezolimumab in combination with trastzumab emtansine (3.0 mg/kg) every 3 weeks.
2993558|NCT02605915|Experimental|Cohort 1D: Atezolizumab/Trastuzumab emtansine 2.4 mg|Participants will receive atezolimumab in combination with trastzumab emtansine (2.4 mg/kg) every 3 weeks.
2993559|NCT02605915|Experimental|Cohort 1E: Atezolizumab/ doxorubicin/ cyclophosphamide|Participants with HER2-negative breast cancer will receive atezolizumab (every 2 weeks) in combination with doxorubicin (every 2 weeks) and cyclophosphamide for four cycles. After the completion of four cycles of combination atezolizumab /doxorubicin / cyclophosphamide, atezolizumab will be continued as a single-agent at a dose of 1200 mg every 3 weeks.
2993560|NCT02605915|Experimental|Cohort 1F: Atezolizumab/Trastuzumab/Pertuzumab/ Docetaxel|Participants will receive atezolizumab in combination with trastuzumab, pertuzumab, and docetaxel every 3 weeks.
2993561|NCT02605915|Experimental|Cohort 2A: Atezolizumab/Trastuzumab/Pertuzumab|Participants will receive atezolizumab in combination with trastuzumab and pertuzumab every 3 weeks for 2 cycles, followed by docetaxel, carboplatin, trastuzumab and pertuzumab every 3 weeks for 6 cycles. Breast surgery will be performed no later than 6 weeks after neoadjuvant therapy. Upon the completion of surgery, participants will receive 12 cycles of single-agent trastuzumab every 3 weeks.
2993562|NCT02605915|Experimental|Cohort 2B: Atezolizumab/Trastuzumab emtansine|Participants will receive atezolizumab in combination with trastuzumab emtansine every 3 weeks for 2 cycles, followed by docetaxel, carboplatin, trastuzumab and pertuzumab every 3 weeks for 6 cycles. Breast surgery will be performed no later than 6 weeks after neoadjuvant therapy. Upon the completion of surgery, participants will receive 12 cycles of single-agent trastuzumab every 3 weeks.
2993563|NCT02605915|Experimental|Cohort 2C: Safety Expansion|Participants with HER2-positive metastatic breast cancer/unresectable locally advanced breast cancer who received prior treatment with trastuzumab and a taxane chemotherapy will receive atezolizumab in combination with trastuzumab emtansine at the dose determined from stage 1, every 3 weeks until disease progression, lack of clinical benefit, or unacceptable toxicity.
2993564|NCT02605915|Experimental|Cohort 2D: Safety Expansion|Participants with HER2-positive metastatic breast cancer recently progressed on an HP containing regimen will receive atezolimumab in combination with trastuzumab and pertuzumab every 3 weeks until disease progression, lack of clinical benefit, or unacceptable toxicity.
2993565|NCT02605902|Active Comparator|iCBIT|internet-delivered Comprehensive Behavioral Intervention for Tics (iCBIT) consisting of psychoeducation, habit reversal training (HRT), function-based assessment and intervention, and relaxation training
2993566|NCT02605902|Placebo Comparator|Control intervention/reference test|internet-delivered psychoeducation and relaxation training.
2993567|NCT02605902|Active Comparator|face-to-face CBIT-treatment|face-to-face CBIT-treatment
2993568|NCT02605889|Experimental|Group A|Laser acupuncture
2993569|NCT02605889|Sham Comparator|Group B|Simulation Laser acupuncture
2993570|NCT02605876|Experimental|Whole Body Vibration|Subjects will receive whole body vibration (30Hz, 2g) applied continuously for 1 minute. This exposure will be repeated 6 times with 2 minutes of rest between exposures.
2993571|NCT02605876|Experimental|Local Muscle Vibration|Subjects will receive local muscle vibration (30Hz, 2g) applied continuously for 1 minute. This exposure will be repeated 6 times with 2 minutes of rest between exposures.
2993572|NCT02605876|No Intervention|Control|Subjects will perform the same procedures as the experimental groups with the exception that no vibratory stimulus will be applied.
2993573|NCT02605863|Experimental|Intermediate Risk NMIBC|Enzalutamide 160mg by mouth daily for 12 months
2993574|NCT02605863|Experimental|High Risk NMIBC|Enzalutamide 160mg by mouth daily for 12 months
2993575|NCT02605850|Placebo Comparator|Ground beef patty + Water|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
2993576|NCT02605850|Active Comparator|Ground beef patty + Pomegranate Extract|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
2993577|NCT02605850|Active Comparator|Ground beef patty + Pomegranate Juice|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
2993578|NCT02605837|Experimental|OBS|Oral Bedesonide Suspension
2993579|NCT02605837|Placebo Comparator|Placebo|Placebo
2993580|NCT02605824|Experimental|20% n-acetylcystine (NAC)|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC delivered via nebulizer three times per day for seven days.
2993581|NCT02605824|Placebo Comparator|0.9% saline|Normal saline will be administered as the placebo agent via a nebulizer three times per day for seven days.
2993582|NCT02605811|Experimental|temozolomide|temozolomide oral 150mg/m2 d1-5/28d for 12 cycles
2993583|NCT02605811|Active Comparator|prophylaxis cranial radiotherapy|prophylaxis cranial radiotherapy,25-30Gy/10Fra
2993584|NCT02605798|Experimental|T test|Test drug (Elbanovir)1 tablet contains 400 mg Sofosbuvir
2993585|NCT02605798|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
2993586|NCT02605798|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
2993587|NCT02605785|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will received a Tau PET scan.
2993588|NCT02605772|Experimental|metformin+Saxagliptin|metformin 0.5g tablet Saxagliptin 5mg tablet metformin 0.5g three times a day for three months Saxagliptin 5mg one time a day for three months
2993589|NCT02605772|Experimental|acarbose+Saxagliptin|acarbose 50mg tablet Saxagliptin 5mg tablet Saxagliptin 5mg one time a day for three months acarbose 100mg three times a day for three months
2993590|NCT02605759|Experimental|CryoBalloon Focal Ablation System|CryoBalloon Focal Ablation for the treatment of esophageal squamous cell dysplasia
2993591|NCT02605746|Experimental|2-4 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 2-4 hours prior to craniotomy for tumor resection.
2993592|NCT02605746|Experimental|4-8 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 4-8 hours prior to craniotomy for tumor resection.
2993593|NCT02605746|Experimental|22-26 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 22-26 hours prior to craniotomy for tumor resection.
2993594|NCT02605720|Experimental|Dihydroartemisinin-piperaquine|
2993595|NCT02605707|Experimental|Intravenous stem cell transplantation|Intravenous transplantation of autologous endothelial progenitor cells plus conventional treatment include rehabilitation
2993596|NCT02605707|No Intervention|Conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
2993597|NCT02605694|Experimental|Arm 1|Duvelisib 25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity; and Rituximab (375 mg/m2) will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
2993598|NCT02605694|Active Comparator|Arm 2|"R-CHOP will be administered as follows:~IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~Cyclophosphamide (750 mg/m2)~Doxorubicin hydrochloride (50 mg/m2)~Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~Rituximab (375 mg/m2) Orally on Days 1-5 of Cycles 1-6 (21-day cycles)~Prednisone (100 mg) will be administered."
2993599|NCT02605681||Sepsis patients|Patients who diagnosed as sepsis
2993600|NCT02605681||Control healthy people|Healthy controls
2993601|NCT02605668|Experimental|Intensified Psychological Intervention|Intensified psychological intervention (Cognitive Behavioral Therapy), based on optimized extinction learning
2993602|NCT02605668|Active Comparator|Treatment As Usual|Standard intervention (Cognitive Behavioral Therapy) without optimized extinction learning
2993603|NCT02605655|Experimental|AMP-1915|Instant noodles contained AMP-1915 2 g/pc with meal, 1 pc/day for 3 months.
2993604|NCT02605655|Placebo Comparator|Placebo|Instant noodles with the same sharp and color as Experimental noodles with meal, 1 pc/day for 3 months.
2993605|NCT02605629|Experimental|CG428|Patients will self-administer the study product twice per day (morning, evening) for 6 months, for the efficacy assessment
2993606|NCT02605629|Placebo Comparator|Placebo|Patients will self-administer the study placebo twice per day (morning, evening) for 6 months, for the efficacy assessment
2993607|NCT02605616|Experimental|Active drug AZ compound|AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
2993608|NCT02605616|Placebo Comparator|Placebo|Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
2993609|NCT02605590|Experimental|1.25 mg|Part 1: single inhaled dose of 1.25 mg AIR-DNase followed by Part 2: once daily inhaled dose of 1.25 mg AIR DNase for 5 consecutive days.
2993610|NCT02605590|Experimental|2.5 mg|Part 1: single inhaled dose of 2.5 mg AIR-DNase followed by Part 2: once daily inhaled dose of 2.5 mg AIR DNase for 5 consecutive days.
2993611|NCT02605590|Experimental|5 mg|Part 1: single inhaled dose of 5 mg AIR-DNase followed by Part 2: once daily inhaled dose of 5 mg AIR DNase for 5 consecutive days.
2993612|NCT02605590|Placebo Comparator|Placebo|Placebo comparator for each of the dose levels, administered accordingly as single inhaled dose in Part 1 followed by once daily inhaled dose for 5 consecutive days in Part 2.
2993613|NCT02605577|Experimental|experimental group|"group of late preterm infants following new systemic nutritional management protocol during hospital stay,which including specific enteral and parenteral nutritional protocol and complication monitor, such as hyperglycemia,hypoglycemia,infection,hyperbilirubinemia and anemia(the intervention refers to thisnew systemic nutritional management protocol )"
2993614|NCT02605577|No Intervention|control group|group of late preterm infants using current nutritional management protocol during hospital stay
2993615|NCT02605564|Active Comparator|study Group A|Gluten free diet
2993616|NCT02605564|Placebo Comparator|Study Group B|No intervention
2993617|NCT02605551|Active Comparator|OMT Group|During the initial visit, the subject will have his BP recorded manually by the osteopathic physician in a standardized fashion. The subject will then undergo the OMT protocol and have his BP recorded again immediately afterwards. This will represent the conclusion of the initial visit. There will be 2 subsequent visits about 2-3 weeks apart that will be identical to this visit. Following the third visit, the next follow-up will be 2 months afterwards. However, the patient will only have his BP checked, and will not undergo an OMT treatment. The final visit will be another 2 months afterwards and will also be a simple BP check with no OMT treatment. The principles of lifestyle modification (diet/exercise/weight loss) will also be discussed at each visit.
2993618|NCT02605551|Placebo Comparator|Control Group|Patients in this arm will only receive lifestyle modification recommendations at each visit, along with a BP check. No antihypertensive medication changes will be made unless indicated by the guidelines.
2993619|NCT02605538|Active Comparator|Cystic Fibrosis|Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.
2993620|NCT02605538|Active Comparator|Healthy volunteers|Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.
2993621|NCT02605525|Experimental|SM101 12 mg/kg|Human soluble recombinant Fcγ Receptor IIB
2993622|NCT02605525|Experimental|SM101 24 mg/kg|Human soluble recombinant Fcγ Receptor IIB
2993623|NCT02605525|Placebo Comparator|Placebo|L-histidine-buffered saline with mannitol, sucrose, and polysorbate 2
2993624|NCT02605512|Other|Breast cancer patients with 3DCRT|Measures of subclinical functional and anatomical cardiac lesions and circulating biomarkers 'Subclinical cardiac lesions and biomarkers'
2993625|NCT02605499|Experimental|UV-C light disinfection|During intervention UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
2993626|NCT02605499|No Intervention|Control|During control period there will be standard discharge and daily room cleaning only, with no UV-C light disinfection.
2993627|NCT02605486|Experimental|Palbociclib in Combination with Bicalutamide|This is a non-randomized, open-label, phase I/II trial for patients with AR(+) MBC . There will be a dose finding phase I portion of the study to establish the recommended phase II dose (R2PD). This will be followed by a phase II where efficacy is evaluated. Patients with AR(+)ER(-) breast cancer treated on the phase I at the recommended phase II dose will be counted towards the primary endpoint analysis for the phase II study.
2993628|NCT02605473|Experimental|Decitabine + Peginterferon Alfa-2b|Decitabine starting dose of 10mg/m^2 given daily via intravenous infusion on days 1-5 of 28 day cycle. Peginterferon Alfa-2b starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
2993629|NCT02605460|Other|Unique|Patients will receive reduced BUCY 2 conditioning regimen, consisting in the administration of two medications: Busulfan and Cyclophosphamide Plus: CXCR4 Antagonist. Then they will undergo a Hematopoietic Stem Cell Transplantation (Autologous or Allogeneic)
2993630|NCT02605447|Experimental|SYNERGY stent + 3 month DAPT|Subject with implantation of at least one SYNERGY stent within the preceding 3 calendar days that takes the required dual antiplatelet therapy (3 months of P2Y12 inhibitor, 15 months of aspirin)
2993631|NCT02605434|Experimental|AP-CD/LD|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d and Placebo IR Carbidopa/ levodopa
2993632|NCT02605434|Active Comparator|SINEMET®|IR Carbidopa/ levodopa tablets 25/100 mg at least 4 times a day and placebo AP-CD/LD
2993633|NCT02605421|Experimental|Patients Treated for Neuroblastoma|Consolidation course #1 consists of thiotepa and cyclophosphamide followed by a PBSC rescue. Consolidation course #2 consists of melphalan, etoposide and carboplatin followed by a second PBSC rescue. Post infusion, patients will receive Granulocyte-Colony Stimulating Factor beginning on Day 0 of each consolidation course.
2993634|NCT02605408||Cataract surgery|Phacoemulsification and artificial IOL implantation with and without LenSx® laser system
2993635|NCT02605395|Experimental|Group A-Idiazole then Pariet|Subjects will receive a single oral dose of IDIAZOLE 20mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fed condition in treatment period 2.
2993636|NCT02605395|Experimental|Group B-Pariet then Idiazole|Subjects will receive a single oral dose of PARIET 20 mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of Idiazole 20mg DR tabs under fed condition in treatment period 2.
2993637|NCT02605382|Experimental|chlorhexidine gluconate|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
2993638|NCT02605382|Placebo Comparator|placebo|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
2993639|NCT02605369|Experimental|Intervention arm: An integrated package|Pregnant women in the intervention clusters will receive an integrated package consisting of peer support for facility based births by pregnancy buddies, mama kits and mobile phone messages. These components will all aim at mitigating the three delays and increasing the proportion of facility based births.
2993640|NCT02605369|No Intervention|Control arm: Standard of care|Pregnant women in the control clusters will continue to receive the standard of care for pregnant women according to Ugandan Ministry of Health guidelines
2993641|NCT02605356|Experimental|Radium-223 dichloride [Phase 1, dose 1]|Phase 1: Radium-223 dichloride; 30 kiloBecquerel (kBq)/kg body weight (33 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
2993642|NCT02605356|Experimental|Radium-223 dichloride [Phase 1, dose 2]|Phase 1: Radium-223 dichloride; 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
2993643|NCT02605356|Experimental|Radium-223 dichloride [Phase 1, dose 3]|Phase 1: Radium-223 dichloride; 80 kBq/kg body weight (88 kBq/kg after implementation of NIST update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
2993644|NCT02605356|Placebo Comparator|Placebo +SoC [Phase 2]|Phase 2: Matching placebo (isotonic saline) every 4 weeks for a total of 6 doses plus SoC (Standard of care) bortezomib/dexamethasone.
2993645|NCT02605356|Experimental|Radium-223 dichloride + SoC [Phase 2]|Phase 2: Phase 1b-selected dose of radium-223 dichloride every 4 weeks for 6 doses plus SOC bortezomib/dexamethasone
2993646|NCT02605343||NeuroIDgenetix-guided Pain Management|The medical provider for the NeuroIDgenetix-guided group will make post-operative pain management recommendations based on test results. Patient outcomes, narcotic consumption, opioid-related adverse effects, time to mobilization, number of adverse drug events and number of hospital and/or medical visits will be measured throughout the study.
2993647|NCT02605343||Historical Control|The retrospective chart review will utilize patient outcomes from patients meeting the study inclusion/exclusion criteria. The medical provider for the control group will not have received the NeuroIDgenetix Test Panel results and would have made post-operative pain management recommendations per standard of care.
2993648|NCT02605330||Fibrinogen plasma level in CABG|In all patients undergoing coronary artery bypass grafting (CABG) the investigators plan to measure the fibrinogen plasma level
2993649|NCT02605330||Fibrinogen plasma level in AVR|In all patients undergoing aortic valve replacement (AVR) the investigators plan to measure the fibrinogen plasma level
2993650|NCT02605330||Fibrinogen plasma level in AAR|In all patients undergoing aortic arch replacement (AAR) the investigators plan to measure the fibrinogen plasma level
2993651|NCT02605304|Experimental|Arm A: LDV/SOF + RBV|Ledipasvir/sofosbuvir + ribavirin for 12 weeks, followed by 24 weeks of post-treatment follow-up.
2993652|NCT02605304|Experimental|Arm B: LDV/SOF|Ledipasvir/sofosbuvir for 24 weeks, followed by 24 weeks of post-treatment follow-up.
2993653|NCT02605291|Experimental|Experimental arm 1|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
2993654|NCT02605291|Experimental|Experimental arm 2|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
2993655|NCT02605291|Experimental|Experimental arm 3|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
2993656|NCT02605278|Experimental|Clinical program for pain and depression|Structured program with integrated management for depression and chronic musculoskeletal pain with three main components: 1) Optimized care of major depression on the basis of a Clinical Guideline 2) Care Management, and 3) Group psychoeducational intervention.
2993657|NCT02605278|Active Comparator|Control|Care as usual
2993658|NCT02605265|Active Comparator|Capecitabine Alone|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 825mg/m2 bid Monday-Friday per week~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT~Adjuvant Chemotherapy:~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1; q3w, 5cycles"
2993659|NCT02605265|Experimental|Capecitabine with Irinotecan|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT~Adjuvant Chemotherapy:~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1; q3w, 5cycles"
2993660|NCT02605252|Experimental|CHB patients|Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg <1500 IU/ mL and Hepatitis B virus DNA not detectable, are to receive peginterferon alfa-2b 80 micrograms/week for 48 weeks.
2993661|NCT02605239|Experimental|bleaching teeth|Group of patients will be bleaching with 10% peroxide carbamide , and them will be assessed the impact on dental confidence , impact psychosocial and esthetic perception
2993662|NCT02605226|Experimental|Arm I|"Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.~Patients receive cryoablation therapy."
2993663|NCT02605226|Experimental|Arm II|Patients receive androgen ablation as in arm I. Patients receive external beam radiation therapy.
2993664|NCT02605213|Experimental|Vancomycin|Vancomyicn 250 mg every 6 hours for 12 weeks
2993665|NCT02605213|Placebo Comparator|Placebo|placebo every 6 hours for 12 weeks
2993666|NCT02605200|Other|Participants|Participants will complete tests of glucose tolerance and psychosocial assessments, and will undergo medical history screening. Those children identified with diabetes and/or abnormal glucose tolerance will receive both diabetes self-management education and psychosocial support from a pediatric Certified Diabetes Educator (CDE) and a psychologist, respectively.
2993667|NCT02605187|Active Comparator|No choice|No choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
2993668|NCT02605187|Experimental|Choice: low protocol|Choice given low dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
2993669|NCT02605187|Experimental|Choice: medium protocol|Choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
2993670|NCT02605187|Experimental|Choice: high protocol|Choice given high dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h gabapentin po one time dose
2993671|NCT02605174|Experimental|Lasmiditan 50 milligram (mg)|Oral tablet. Lasmiditan 50 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
2993672|NCT02605174|Experimental|Lasmiditan 100 mg|Oral tablet. Lasmiditan 100 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
2993802|NCT02604355|Experimental|Participants with Chronic Hepatitis B (Proof of mechanism)|
2993673|NCT02605174|Experimental|Lasmiditan 200 mg|Oral tablet. Lasmiditan 200 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
2993674|NCT02605174|Placebo Comparator|Placebo|Oral tablet. Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
2993675|NCT02605161||Parkinson's disease group|"patients diagnosed with Parkinson's disease by a movement disorder specialist from the deep brain stimulation program at The Ottawa Hospital, Civic Campus~to undergo pre-operative MRI with contrast"
2993676|NCT02605161||Control group|"patients diagnosed with either essential tremor or cervical dystonia by a movement disorder specialist from the deep brain stimulation program at The Ottawa Hospital, Civic Campus~to undergo pre-operative MRI with contrast"
2993677|NCT02605148|Experimental|Gluten free diet|Gluten free diet during 18 months. The subjects will be referred to a nutritionist every 6 months. Vitamin D 800 U Daily, Omega 3 fatty acids and probiotics as nutritional supplements.
2993678|NCT02605148|Active Comparator|Normal diet|Normal diet. Vitamin D 800 U Daily, Omega 3 fatty acids and probiotics as nutritional supplements.
2993679|NCT02605135||Continued Pessary Use|All participants will undergo clinical testing prior to placement of the pessary and the investigator will test their vaginal environment prior to pessary placement. Testing will consists of a vaginal swab and 10 mL of vaginal lavage at each study visit. The participant will then be followed, and repeat testing obtained at the standard clinical interval for pessary follow-up, every three months
2993680|NCT02605135||Discontinued Pessary Use|All participants will undergo clinical testing prior to placement of the pessary and the investigator will test their vaginal environment prior to pessary placement. Testing will consists of a vaginal swab (AIM 1) and 10 mL of vaginal lavage (Aim 2) at each study visit. The participant will then be followed, and repeat testing obtained at the standard clinical interval for pessary follow-up, every three months. Should the participant discontinue pessary use, we will additionally culture the microbes that are present on the pessary and compare those to the vaginal microbiota.
2993681|NCT02605122|Experimental|Solithromycin|Solithromycin will be administered orally, as capsules or as a suspension, or intravenously. Patients may receive intravenous therapy initially and switch to an oral formulation. Dosage is weight based and age based.
2993682|NCT02605122|Active Comparator|Standard of Care|Comparators will be selected according to subject age and are consistent with current recommendations for treatment of CABP in children. These include intravenous ceftriaxone, ampicillin, and amoxicillin and oral amoxicillin and amoxicillin-clavulanic acid. Azithromycin or erythromycin may be added as well.
2993683|NCT02605109||RiskMERS|Exposed to case-patients
2993684|NCT02605096|Experimental|MRI group|"This arm assess the use of MRI as the first line examination of suspected scaphoid fracture (replacing conventional plain x-ray).~Patients with negative findings will receive a splint and contact card to a specialist wrist clinic if the pain persists for ten to fourteen days after initial presentation.~Patients with positive findings will receive a plaster cast and undergo a CT scan (to evaluate displacement) and will be referred to the fracture clinic. Furthermore, if the CT scan confirms a displaced fracture, that might require surgery, the patient should be seen by a Hand Specialist at fracture clinic.~All patients enrolled in the pilot should undergo a 4-view plain x-ray 3 months after the initial ED/UCC presentation."
2993685|NCT02605096|Active Comparator|X-ray group|"This arm is the current standard of care pathway for the diagnosis of patients with suspected scaphoid fracture. This includes an initial clinical assessment on arrival to the Emergency Department of Urgent Care Centre followed by a plain x-ray (using a 4-view scaphoid protocol).~Patients with negative/positive findings for scaphoid fracture in the initial X-ray will be immobilised with a splint/plaster cast.~All patients will be referred to an initial fracture clinic and a proportion of patients are likely to require additional imaging scans (usually CT but also MRI) and follow-up appointments in the fracture clinic. All patients enrolled in the pilot should undergo a 4-view plain x-ray 3 months after the initial ED/UCC presentation."
2993686|NCT02605083|Experimental|eFT508|Escalation cohort
2993687|NCT02605070|Experimental|Infertility group|Patients referred will be evaluated to participate in the study and then asked to take part.In this visit,the normal protocol for infertility patients will be followed and at least 2 spermiograms and a blood test analyzing the following parameters:FSH, LH,Estradiol,Total testosterone,SHBG, Albumin,Calculation of bioavailable testosterone,Prolactin.If these tests have not been performed,a second baseline visit will be scheduled.Should the patient meet all the inclusion criteria and after the patient has signed an informed consent form agreeing to participate in the study,the physician will prescribe the medication and schedule visits.Before initiating the treatment, they will provide a semen sample.This sample will be sent to the Center for Reproductive Biology,where the sample will be subjected to epigenetic analysis.The patient will be given samples of Bravelle.It is administered subcutaneously.The dose will be 150 IU 3times a week for 3months
2993688|NCT02605070|No Intervention|Fertily group|"Patients who volunteer will be informed of the nature of the study and asked to sign the informed consent form. At least two spermiograms will be performed along with a blood test analyzing the following parameters:FSH,LH,Estradiol,Total testosterone,SHBG,Albumin,Estimation of bioavailable testosterone,Prolactin.~A second baseline visit will be scheduled to evaluate the test results and to check whether these subjects meet all the inclusion criteria for the control group. Those subjects will provide a semen sample which will be stored at -20º C.~Outpatient visit: week twelve: a physical exam will be carried out to identify any adverse reactions. A blood test and a semen sample will also be obtained."
2993689|NCT02605057|Experimental|LEO 80185 gel|LEO 80185 gel will be allocated to 7 different test sites on each subject
2993690|NCT02605057|Experimental|Dovobet Ointment|Dovobet Ointment will be allocated to 7 different test sites on each subject
2993691|NCT02605044|Experimental|Masitinib + FOLFIRI|masitinib + FOLFIRI
2993692|NCT02605044|Placebo Comparator|Placebo + FOLFIRI|Placebo + FOLFIRI
2993693|NCT02605005||GA|general anesthesia
2993694|NCT02605005||ISB|interscalene block
2993695|NCT02604992|Experimental|Group 1 (A,B,C)|With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment B, and then Treatment C.
2993696|NCT02604992|Experimental|Group 2 (B,C,A)|With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment C, and then Treatment A.
2993697|NCT02604992|Experimental|Group 3 (C,A,B)|With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment A, and then Treatment B.
2993698|NCT02604992|Experimental|Group 4 (C,B,A)|With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment B, and then Treatment A.
2993699|NCT02604992|Experimental|Group 5 (A,C,B)|With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment C, and then Treatment B.
2993700|NCT02604992|Experimental|Group 6 (B,A,C)|With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment A, and then Treatment C.
2993701|NCT02604966|Experimental|Artesunate (AS) group|P. falciparum infected patients randomly allocated to this arm will be treated with AS (50mg/tablet) 4 mg/kg body weight once daily for three days followed by DHA-PPQ (40mg of DHA +320mg of PPQ/tablet) once daily for three days.
2993702|NCT02604966|Active Comparator|DHA - PPQ group|P. falciparum infected patients randomly allocated to this arm will be treated with the combination DHA-PPQ (40mg of DHA +320mg of PPQ/tablet) once daily for three days.
2993703|NCT02604953||Ocular Hypertension patients|Ocular hypertension patients are recruited from the Wills Eye Hospital Glaucoma Service. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
2993704|NCT02604953||Healthy Controls|Healthy adults are recruited from staff, family and friends of Wills Eye Hospital Glaucoma Research Center. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
2993705|NCT02604953||Glaucoma patients|Glaucoma patients are recruited from the Wills Eye Hospital Glaucoma Service. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
2993706|NCT02604940|Experimental|dexmedetomidine|Experimental group will receive 1mcg/kg IV dexmedetomidine over 10 minutes intraoperatively at the beginning of surgical closure
2993707|NCT02604940|Active Comparator|Normal Saline|Control group will receive Normal saline over 15 minutes at the beginning of surgical closure
2993708|NCT02604927|Placebo Comparator|Placebo|800 mg of dextrose, four times per day, during 28 days.
2993709|NCT02604927|Experimental|Beta-alanine|800 mg of beta-alanine, four times per day, during 28 days.
2993710|NCT02604914|Experimental|ND0612L (LD/CD solution)|3 doses of the investigational ND0612L (LD/CD solution) for subcutaneous (SC) infusion 0.24ml per hour.
2993711|NCT02604914|Experimental|ND0612H (LD/CD solution)|3 doses of the investigational ND0612H (LD/CD solution) for subcutaneous (SC) infusion 0.64ml per hour.
2993712|NCT02604914|Active Comparator|LCIG (Levodopa-carbidopa intestinal gel)|Active Comparator: LCIG subjects who completed the ND0612H arm will be administered with 3 doses of LCIG, directly to the jejunum.
2993713|NCT02604901|Experimental|Screening and Brief Intervention (BI)|Screening and Brief Intervention (BI) at initial prescription fill and at each additional refill.
2993714|NCT02604901|Experimental|Pill Box (PB)|Pill Box (PB) and information about their medications at the initial fill and at each additional refill.
2993715|NCT02604901|Experimental|Brief Intervention + Pill Box (BI+PB)|Screening and Brief Intervention (BI) and Pill Box (PB) at initial prescription fill and at each additional refill.
2993716|NCT02604901|No Intervention|Standard Care (SC)|The Standard Care (SC) arm administered traditional dispensing and counseling by Rite Aid® pharmacists.
2993717|NCT02604888|Other|Volunteers|20 volunteers both men and women with an age between 18 and 70 years suffering from Alopecia Areata in several types apply on the scalp drops of the MEXIS/M6S PATENT - lotion against Alopecia
2993718|NCT02604875||observational|Blood samples will be taken for measuring copeptin levels in healthy subjects.
2993719|NCT02604862|Experimental|FIB ONE administration|All participants in this clinical study will be dosed on one occasion with FIB ONE. The final dosage will be 70 µg (± 40%)
2993720|NCT02604849||Received therapy desconolizacion against Klebsiella pneumoniae|
2993721|NCT02604849||Patients who do not receive the therapy|
2993722|NCT02604836|Experimental|Ibandronate|Participants will receive 150 milligrams (mg) of ibandronate as a film-coated tablet once-monthly.
2993723|NCT02604823|Experimental|Group A (Naïve Participants)|Participants who never received any HBV treatment, will receive peginterferon alfa-2a (180 micrograms [mcg]) subcutaneously once weekly for 48 weeks.
2993724|NCT02604823|Experimental|Group B (Conventional Interferon Pretreated Participants)|Participants who received conventional interferon treatment and had relapse or did not respond, will receive peginterferon alfa-2a (180 mcg) subcutaneously once weekly for 48 weeks.
2993725|NCT02604823|Experimental|Group C (Lamivudine Pretreated Participants)|Participants who received lamivudine and had relapse or did not respond, will receive peginterferon alfa-2a (180 mcg) subcutaneously once weekly for 48 weeks.
2993726|NCT02604810|Active Comparator|IGIV-C 10%|IV dose of Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified (Grifols)
2993727|NCT02604810|Experimental|IGSC 20%|Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (Grifols)
2993728|NCT02604797|Experimental|Nalbuphine|Nalbuphine group: nalbuphine 100 mg, ramosetron 0.3mg, background dose 1ml/h,patient-controlled analgesia(PCA) 1ml/time, lockout time 10 min, flurbiprofen axetil 50mg 6h after operation.
2993729|NCT02604797|Experimental|Sufentanil|Sufentanil group: sufentanil 100ug, ramosetron 0.3mg, background dose 1ml/h, PCA 1ml/time, lockout time 10 min, flurbiprofen axetil 50mg 6h after operation.
2993730|NCT02604784|Experimental|cohort A|Cohort A: For patients that have indication for systemic therapy with standard chemotherapy. This cohort has a phase II design; the Objective Response Rate (ORR) will be evaluated according to the RECIST criteria (version 1.1) after 2 and 3 cycles of PIPAC with Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m2 ) or Oxaliplatin (92 mg/m2) according to the primary cancer, in association with standard systemic chemotherapy.
2993731|NCT02604784|Experimental|cohort B|Cohort B: For patients that have not indication for systemic therapy with standard chemotherapy. This cohort has a phase I design; with a dose-escalation design the maximum tolerated doses and recommended doses of Cisplatin + Doxorubicin and Oxaliplatin (according to the pathology) administered through PIPAC in patients with peritoneal carcinomatosis will be evaluated.
2993732|NCT02604758|Experimental|Tidal Model|the psychiatric nursing approach based on the Tidal Model
2993880|NCT02603861|Active Comparator|Modafinil|200 mg modafinil administered orally in no more than one of the four periods.
2993733|NCT02604758|No Intervention|control group|The control group received routine treatment and follow-up in the Alcohol and Substance Addiction Treatment Clinic.
2993734|NCT02604745||Degenerative Mitral Regurgitation|This cohort includes patients that have had mitral valve surgery for Degenerative Mitral Regurgitation (Type II)
2993735|NCT02604732|Active Comparator|Patients who stop Aspirin|Patients need to stop Aspirin 1 week before the surgery
2993736|NCT02604732|Experimental|Patients who continue Aspirin|Patients will continue Aspirin
2993737|NCT02604719|Experimental|tanexamic acid and Ethamsylate|10 ml of the study drugs (1 gm Tranexamic acid and 1 gm Ethamsylate ) slowly (over 30-60 sec ) in the 2 minutes after birth
2993738|NCT02604719|Placebo Comparator|placebo|10 ml normal saline will be administered intravenously just after birth
2993739|NCT02604706|Experimental|NADA Acupuncture|NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
2993740|NCT02604706|Experimental|LP Acupuncture|The LP-acupuncture was delivered in two phases: (1) three treatments each week during the two first weeks; (2) two treatments each week for two weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. BC-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
2993741|NCT02604706|Active Comparator|Relaxation|Relaxation consisted of listening to soft music in a quiet room with dampened light and was delivered to match the amount and phases of the LP-acupuncture. Relaxation were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
2993742|NCT02604693||Chronic Beryllium Disease|Those that have been diagnosed with the disease. No interventions will be administered.
2993743|NCT02604693||Beryllium Sensitization|Those that have been diagnosed with beryllium sensitization and do not have chronic beryllium disease. No interventions will be administered.
2993744|NCT02604693||normal controls|Those that do not have chronic beryllium disease or beryllium sensitization. No interventions will be administered
2993745|NCT02604680|Experimental|BLI1100-1|Topical gel
2993746|NCT02604680|Experimental|BLI1100-2|Topical gel
2993747|NCT02604680|Experimental|BLI1100-3|Topical gel
2993748|NCT02604680|Experimental|BLI1100-4|Topical gel
2993749|NCT02604680|Placebo Comparator|Placebo|Topical gel
2993750|NCT02604667||Group 1: Cancer and Stroke|Patients with active solid tumor cancer and acute ischemic stroke. Will undergo blood tests and transcranial Doppler microemboli detection study.
2993751|NCT02604667||Group 2: Stroke and No Cancer|Patients with acute ischemic stroke and no cancer. Will undergo blood tests and transcranial Doppler microemboli detection study.
2993752|NCT02604667||Group 3: Cancer and No Stroke|Patients with active solid tumor cancer and no stroke. Will undergo blood tests and transcranial Doppler microemboli detection study.
2993753|NCT02604654|Experimental|Yiqitongluo group|Yiqitongluo granule 12g each time, 3 times a daily for 4 weeks.
2993754|NCT02604641|Placebo Comparator|Placebo group|0 mg CoQ10 daily
2993755|NCT02604641|Active Comparator|Quvital LD group|50 mg CoQ10 daily
2993756|NCT02604641|Active Comparator|Quvital HD group|150 mg CoQ10 daily
2993757|NCT02604628|No Intervention|Control|Patients will be treated as standard of care.
2993758|NCT02604628|Experimental|Antibiotic Stewardship Intervention|Patients will be treated as standard of care. The Antibiotic Stewardship Intervention will be targeted at the physicians treating the community-acquired pneumonia patients. The purpose of the intervention is to increase prescription concordance with the national guideline for community-acquired pneumonia.
2993759|NCT02604615|Experimental|Capecitabine-oxaliplatin 2 cycles|oxaliplatin：65mg/m2,d1,8,22,29,I.V; capecitabine: 625mg/m2, bid d1-5; q1w, po,5 weeks in total; radiotherapy:50Gy,2 Gy/d,5d/w.
2993760|NCT02604615|Active Comparator|Capecitabine-oxaliplatin 4 cycles|oxaliplatin:65mg/m2,d1,8,22, 29,43,50,64,71,I.V; capecitabine:625mg/m2,bid d1-5; q1w, po,10 weeks in total; radiotherapy:50Gy ,2 Gy/d,5d/w.
2993761|NCT02604602||PPH|
2993762|NCT02604602||non-PPH|
2993763|NCT02604589|Placebo Comparator|PCA only|Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
2993764|NCT02604589|Experimental|Bupivicaine 0.25% (LOW DOSE)|"Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.~Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter."
2993765|NCT02604589|Experimental|Bupivicaine 0.5% (HIGH DOSE)|"Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.~Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter."
2993766|NCT02604576|Experimental|Group 1|FDC Bromopride 10 mg and Simethicone 80 mg
2993767|NCT02604576|Active Comparator|Group 2|Bromopride 10 mg (Digesan ® - Sanofi Aventis)
2993803|NCT02604342|Experimental|Alectinib|Participants will receive oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
2993804|NCT02604342|Active Comparator|Premetrexed/Docetaxel|Participants will receive chemotherapy with either pemetrexed (500 milligrams per square meter [mg/m^2] of body surface area) or docetaxel (75 mg/m^2) intravenously.
2993805|NCT02604329|Experimental|intervention|"Radiation : use of Oncolase Digi therapy laser diode"
2993845|NCT02604069|Experimental|Continuous Glucose Monitor|Application of CGM for 6 days following free flap reconstruction in conjunction with clinical monitoring
2993768|NCT02604563||Arm 1: Geriatric assessments/peripheral blood draw/buccal swab|"Participants identified as having clonal hematopoiesis after analysis of their baseline blood draw will be asked to return every 6 months for repeat geriatric assessment and sample collection listed below.~Complete the self-administered geriatric assessments of Activities of Daily Living, Instrumental Activities of Daily Living (subscale of the OARS), Karnofsky Self-reported Performance Rating Scale, Number of Falls, Physical Health Section (subscale of the OARS), MOS Social Activity Survey, and Body Mass Index & Unintentional Weight Loss at baseline and every 6 months until death.~Cognitive assessment and Timed Up and Go will be performed by a member of the research team at baseline and every 6 months until death.~Peripheral blood draw will occur at baseline and no more than every 6 months until death.~Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death"
2993769|NCT02604550|Active Comparator|Femoral Nerve Block|Subjects undergoing anterior cruciate ligament (ACL) surgery will be randomized to receive 20 mL of ropivacaine 0.5% in the femoral nerve. Subjects will also receive standard of care Percocet 7.5/325 and naprosyn following surgery.
2993770|NCT02604550|Active Comparator|Adductor Canal Block|Subjects undergoing anterior cruciate ligament surgery will be randomized to receive 20 mL of ropivacaine 0.5% in the adductor canal. Subjects will also receive standard of care Percocet 7.5/325 and naprosyn following surgery.
2993771|NCT02604537|Active Comparator|Celestone|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml Celestone OR
2993772|NCT02604537|Experimental|Ketorolac|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of Ketoraloc
2993773|NCT02604524|Experimental|Closed-Loop Control (CLC) System|Subjects will use the Closed-Loop Control system in an attempt to maintain blood glucose in a certain range during the day and at night during the trial.
2993774|NCT02604524|Placebo Comparator|Sensor Augmented Pump Therapy Group|Subjects will manage their own glucose levels during the trial.
2993775|NCT02604511|Experimental|Ibrutinib|This is single arm, open label, Phase II, single center study designed to evaluate the safety and efficacy of ibrutinib in previously untreated WM patients. Treatment will be administered in 4-week cycles, and participants will receive treatment for up to 48 cycles. Treatment will be comprised of ibrutinib at 420 mg per day by oral administration.
2993776|NCT02604498|Experimental|Liver function impaired|Subject with Moderate Impaired Hepatic Function. Nemonoxacin Malate Capsules 500mg single dose oral.
2993777|NCT02604498|Experimental|Healthy Subjects|Healthy volunteers. Nemonoxacin Malate Capsules 500mg single dose oral.
2993778|NCT02604485|Other|Cohort|XOMA 358 dose level A, dose level B, dose level C, and dose level D.
2993779|NCT02604472||CCRT group|Locoregionally advanced nasopharyngeal carcinoma patients received concurrent chemoradiotherapy
2993780|NCT02604472||IC+CCRT group|Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and concurrent chemoradiotherapy
2993781|NCT02604459|Active Comparator|Usual general anesthesia care|"Subjects will have their general anesthetic management directed at the discretion of the anesthesia provider.~General anesthesia with be maintained with propofol, fentanyl, sevoflurane"
2993782|NCT02604459|Experimental|Optimized general anesthesia care|The subjects will have general anesthesia with propofol, fentanyl, sevoflurane. In addition the subjects will be monitored with a depth of anesthesia monitor (BIS) and a cerebral oximeter (Foresight). These additional monitors will be used to direct care. BP management: Systolic BP will be maintained within 20% of baseline systolic BP variables.
2993783|NCT02604446|Experimental|Tapentadol|depot Tapentadol in addition to usual pain treatment
2993784|NCT02604446|Active Comparator|Oxycodone|depot Oxycodone in addition to usual pain treatment
2993785|NCT02604446|Placebo Comparator|Placebo|depot glucose placebo in addition to usual pain treatment.
2993786|NCT02604433|Experimental|Luspatercept (ACE-536) plus Best Supportive Care (BSC)|Luspatercept, subcutaneous(ly) (SC) once every 21 days
2993787|NCT02604433|Placebo Comparator|Placebo plus Best Supportive Care (BSC)|normal saline solution subcutaneous(ly) (SC) once every 21 days
2993788|NCT02604420||Transplant, no TMA|Adult patients who undergo an allogeneic hematopoietic stem cell transplant but do not meet the criteria for a thrombotic microangiopathy in the one year follow up period. No interventions anticipated.
2993789|NCT02604420||Transplant, +TMA|Adult patients who undergo an allogeneic hematopoietic stem cell transplant and meet the criteria for a thrombotic microangiopathy in the one year follow up period. Possible interventions include observation, treatment of an underlying infection or GvHD, use of plasma exchange, or use of anti-complement therapy (eculizumab or other anti-complement drug). Eculizumab is used as a 900mg intravenous infusion over 35 minutes, given weekly for 4 weeks, then 1200mg every other week. Patients must be vaccinated against meningococcus 2 weeks before starting drug or, if that is not feasible because of the physician's assessment of the severity of the TMA, given prophylactic antibiotics for the 2 week period before immunization has taken hold.
2993790|NCT02604407|Experimental|SHP465 12.5 mg|Subjects will receive SHP465 12.5 mg
2993791|NCT02604407|Experimental|SHP465 37.5 mg|Subjects will receive SHP465 titrated up to 37.5 mg
2993792|NCT02604407|Placebo Comparator|Placebo|Subjects will receive matching placebo
2993793|NCT02604394|Active Comparator|Rheolytic Thrombectomy with PCI|"Rheolytic Thrombectomy (RT) will be performed with the The AngioJet rheolytic thrombectomy system (Medrad Interventional/Possis, Minneapolis, Minnesota).~The single-pass antrograde thrombectomy technique will be used."
2993794|NCT02604394|Sham Comparator|Conventional PCI|In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
2993795|NCT02604381|Experimental|Glucosamine Sulfate Potassium Chloride/Ginkgo Biloba Extract|2 capsules daily, immediately following a meal. 1 capsule in the morning, and 1 capsule in the evening, at approximately the same time each day.
2993796|NCT02604381|Placebo Comparator|Placebo|2 capsules daily, immediately following a meal. 1 capsule in the morning, and 1 capsule in the evening, at approximately the same time each day.
2993797|NCT02604368|Experimental|SC411|Omega-3 docosahexaenoic acid, soft gelatin capsule, once a day
2993798|NCT02604368|Placebo Comparator|Placebo|Soybean oil, soft gelatin capsule
2993799|NCT02604355|Experimental|Healthy Participants (Multiple-Ascending Dosing)|
2993800|NCT02604355|Experimental|Healthy Participants (Single-Ascending Dosing)|
2993806|NCT02604316|Experimental|Arabinoxylan|10 days of weight loss diet calculated as 100% RMR + 15g Arabinoxylan (Medium Chain Naxus, BioActor b.v., Netherlands) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40% carbohydrate
2993807|NCT02604316|No Intervention|Control- Non Arabinoxylan|10 days of weight loss diet calculated 100% RMR using a heterogeneous natural fibre for food ingredients, 30% protein, 30% fat, 40% CHO.
2993808|NCT02604316|Experimental|Beta-Glucan|10 days of weight loss diet calculated as 100% RMR AND 6g Beta-Glucan (Viscofibre, Naturex SA, France) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40%
2993809|NCT02604316|No Intervention|Control Non Beta glucan|10 days of weight loss diet calculated 100% RMR using a heterogeneous natural fibre for food ingredients, 30% protein, 30% fat, 40% CHO.
2993810|NCT02604290|Experimental|Kinesio Taping method|"The tape is applied depending on the physical examination:~Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.~Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.~Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers."
2993811|NCT02604290|Sham Comparator|Kinesio Taping sham|The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
2993812|NCT02604277|Experimental|Group Intervention Program|Patients diagnosed with Bipolar Disorder will receive therapy in a group setting of 4 to 12 male and female participants.
2993813|NCT02604264|Active Comparator|ClearGuard HD end cap|Treatment
2993814|NCT02604264|No Intervention|Standard hemodialysis end cap|Control
2993815|NCT02604251|Experimental|Treatment with KLOX BioPhotonic WoundGel System|One breast will be randomized to be treated with KLOX BioPhotonic WoundGel System.
2993816|NCT02604251|Active Comparator|Treatment with silicone sheets|The second breast will be randomized to be treated with silicone sheets.
2993817|NCT02604238|Experimental|Group A|"Administered a safe dose of Alteplase. All patients are treated with low molecular weight heparin ( LMWH ) according to the Guidelines ESC2014 heparin in addition it is administered a safe dose of Alteplase."
2993818|NCT02604238|No Intervention|Group B|All patients are treated with low molecular weight heparin ( LMWH ) according to the Guidelines ESC2014 heparin. It not added any treatment.
2993819|NCT02604225|Experimental|Penthrox|Methoxyflurane
2993820|NCT02604225|Placebo Comparator|Placebo|Saline 0.9%
2993821|NCT02604212|Experimental|ARC:520 Injection 1.0 mg/kg|Intravenous ARC-520 at 1.0 mg/kg, once every 4 weeks for 4 doses
2993822|NCT02604212|Placebo Comparator|Placebo|0.9% normal saline, once every 4 weeks for 4 doses
2993823|NCT02604212|Experimental|ARC-520 Injection 2.0 mg/kg|Intravenous ARC-520 at 2.0 mg/kg, once every 4 weeks for 4 doses
2993824|NCT02604199|Experimental|ARC-520 Injection 1mg/kg|Intravenous ARC-520 at 1.0 mg/kg, once every 4 weeks for 4 doses
2993825|NCT02604199|Placebo Comparator|Placebo|0,9% normal saline, once every 4 weeks for 4 doses
2993826|NCT02604199|Experimental|ARC-520 Injection 2mg/kg|Intravenous ARC-520 at 2.0 mg/kg, once every 4 weeks for 4 doses
2993827|NCT02604186|Experimental|Botulinum Toxin Injections|Botulinum Toxin injections at adductors and triceps surae
2993828|NCT02604186|Placebo Comparator|Placebo Injections|Placebo injections at adductors and triceps surae
2993829|NCT02604173|Experimental|Budesonide|Budesonide inhaler as experimental treatment along with placebo pill.
2993830|NCT02604173|Active Comparator|Acetazolamide|Acetazolimide pill as active comparator along with sham inhaler.
2993831|NCT02604173|Sham Comparator|Control|Sham inhaler as control for budesonide inhaler along with placebo pill as control for acetazolamide comparator.
2993832|NCT02604160|Experimental|LY3113593|Escalating doses of LY3113593 administered by slow intravenous (IV) infusion once every 2 weeks (Q2W) (days 1, 15, 29, and 43) or every 4 weeks (Q4W) on (day 1 and day 29) in each part.
2993833|NCT02604160|Placebo Comparator|Placebo|0.9% saline, administered by slow intravenous (IV) infusion once every Q2W (days 1, 15, 29, and 43) or Q4W (day 1 and 29) in each part.
2993834|NCT02604147|Sham Comparator|Simulated inspiratory muscle training|Inspiratory muscle training with load of 15% of maximal inspiratory pressure.
2993835|NCT02604147|Experimental|Inspiratory muscle training group|Inspiratory muscle training with initial load of 50% of maximal inspiratory pressure.
2993836|NCT02604134|Other|conventional treatment group|The child will receive a prophylaxis and fluoride varnish. Parents will fill out a parent and a child questionnaire.
2993837|NCT02604134|Other|Silver Nitrate group|The child will receive a prophylaxis, then silver nitrate and then fluoride varnish. Parents will fill out a parent and a child questionnaire.
2993838|NCT02604121|Experimental|transepithelial brushing|transepithelial brushing in liquid-based technology + biopsy
2993839|NCT02604108|Experimental|Physical Exercise|Physical Exercise: Participants will receive training and health messages on positive psychology and healthy living style focusing on physical activity.
2993840|NCT02604108|Experimental|Healthy Diet|Healthy Diet: Participants will receive training and health messages on positive psychology and healthy living style focusing on healthy diet.
2993841|NCT02604095|Experimental|Melatonin|Take one table at bedtime.
2993842|NCT02604082|Active Comparator|Vibocompression (VB)|Grup 1 - Vibrocompression: Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the thoracic compression during expiration
2993843|NCT02604082|Active Comparator|Hyperinflation (HMV)|Grup 2 - Hyperinflation with Mechanical ventilator: Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the increase in inspiratory pressure ventilator .
2993844|NCT02604082|Experimental|HMV+VB|Grup 3 - Hyperinflation with mechanical ventilator and vibrocompression:Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the thoracic compression during expiration and the increase in inspiratory pressure ventilator.
2994140|NCT02602171|Experimental|reverberation condition|Oldenburger Sentence test, localization test
2993846|NCT02604056|Active Comparator|Audit + Feedback|'Usual care' / standard quality improvement supports (including online Audit and Feedback reports for each prescriber in the home)
2993847|NCT02604056|Experimental|Audit + Feedback + Educational Outreach|'Active/full' intervention (featuring Educational Outreach offered to each prescriber and team members in the home)
2993848|NCT02604043|Experimental|supraglottic impendence/pH probe|
2993849|NCT02604030|Experimental|Upper limb function|Assessment of scapular kinematics during arm elevation, perceived function, quality of life, range of motion and muscle strength for shoulder complex after a rehabilitation program focused on upper limb.
2993850|NCT02604017|Experimental|ABT-493/ABT-530 for 12 weeks|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
2993851|NCT02604017|Experimental|ABT-493/ABT-530 for 8 weeks|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
2993852|NCT02604004|Active Comparator|Period 1|Epivir ® tablet 150-mg single dose (drug reference)
2993853|NCT02604004|Experimental|Period 2|Lamivudine 150-mg tablet single dose (drug test)
2993854|NCT02603978|No Intervention|Wait-list|This arm will receive no intervention for the first 6 months. At the conclusion of the 6-month period, this group will receive a brief alcohol intervention
2993855|NCT02603978|Active Comparator|Brief Alcohol Intervention|This arm will receive a brief (2-hour) alcohol intervention based on motivational interviewing
2993856|NCT02603978|Active Comparator|Bystander and Social Norms Intervention|This arm will receive a brief (2-hour) bystander and social norms intervention designed to increase healthy sexual behaviors
2993857|NCT02603978|Active Comparator|Combined Alcohol and Bystander Intervention|This arm will receive a combined (4-hour) alcohol and bystander/social norms intervention to target both alcohol and sexual behavior
2993858|NCT02603965|Experimental|Diagnostic (Cu 64 TP3805 PET/CT)|Patients receive copper Cu 64 TP3805 IV and undergo PET/CT at 30 minutes and 2 hours post-injection. Patients then undergo radical prostatectomy within 1 to 3 weeks after scans.
2993859|NCT02603952|Placebo Comparator|Placebo + Oseltamivir 75 mg|Participants will receive a single intravenous (IV) infusion of placebo (matched to MEDI8852) on Day 1 and oseltamivir 75 milligrams (mg) capsules orally twice a day (BID) from Day 1 to Day 5.
2993860|NCT02603952|Experimental|MEDI8852 750 mg + Oseltamivir 75 mg|Participants will receive a single IV infusion of MEDI8852 750 mg on Day 1 and oseltamivir 75 mg capsules orally BID from Day 1 to Day 5.
2993861|NCT02603952|Experimental|MEDI8852 3000 mg + Oseltamivir 75 mg|Participants will receive a single IV infusion of MEDI8852 3000 mg on Day 1 and oseltamivir 75 mg capsules orally BID from Day 1 to Day 5.
2993862|NCT02603952|Experimental|MEDI8852 3000 mg|Participants will receive a single IV infusion of MEDI8852 3000 mg on Day 1.
2993863|NCT02603939||Participants with Advanced Knee OA|People with advanced knee osteoarthritis requiring joint replacement surgery are being assessed for their pain responses before and after joint replacement surgery
2993864|NCT02603939||Participants with Early Knee OA|Participants with osteoarthritis with early disease who do not require joint replacement surgery are being assessed for pain
2993865|NCT02603926|Experimental|Allopregnanolone|Subjects will receive and intravenous infusion of Allopregnanolone at escalating doses of 2mg, 4mg, and 6mg once weekly over a three week period. The highest dose tolerated without sedation will be held stable for the remaining weekly infusions, for a total of 12 infusions.
2993866|NCT02603913||Normal pregnancy|Normal uncomplicated pregnancy
2993867|NCT02603913||Pre-eclampsia|"Hypertension (>140 mmHg systolic or >90 mmHg diastolic) developing after 20 weeks gestation and the coexistence of one or more of the following new onset conditions:~Proteinuria (>300 mg/day)~Other maternal organ dysfunction~renal insufficiency (creatinine >90 μmol/L)~liver involvement (elevated transaminases - and/or severe right upper quadrant or epigastric pain)~neurological complications (eclampsia, altered mental status, blindness, stroke, hyperreflexia when accompanied by clonus, severe headaches when accompanied by hyperreflexia, persistent visual scotomata)~hematological complications (thrombocytopenia, disseminated intravascular coagulation, hemolysis)~Uteroplacental dysfunction"
2993868|NCT02603913||Pregnancy induced hypertension|New onset of hypertension (>140 mmHg systolic or >90 mmHg diastolic) after 20 weeks gestation, without proteinuria, in a previously normotensive woman.
2993869|NCT02603913||Preterm birth|Babies born alive before 37 weeks of pregnancy are completed.
2993870|NCT02603913||Intra-uterine growth restriction|Moderate IUGR is an estimated fetal weight and / or abdominal circumference < 10th percentile for its gestational age Severe IUGR is an EFW (estimated fetal weight) and/ or AC (abdominal circumference) < 5th percentile for its gestational age
2993871|NCT02603900|Experimental|Adductor Canal Catheter|This group will receive ropivacaine 0.5% 15 ml for the adductor canal block under ultrasound guided nerve block. A multi-orifice catheter will be placed in the adductor canal and an infusion of ropivacaine 0.2% at 10 ml/hr will be continued for 72 hours.
2993872|NCT02603900|Experimental|Local Infiltration of Analgesia|Local infiltration using 20 ml of free bupivacaine solution (Marcaine 0.25% with epinephrine 1:200000, ) diluted with 40 ml of normal saline following implantation of the knee prosthesis, the solution will be injected into the vastus medialis (5 ml), medial retinaculum (5 ml), origin of MCL (5 ml) and LCL (5 ml), lateral portion of quadriceps tendon (5 ml), vastus lateralis (5 ml), and subcutaneous tissues especially along saphenous nerve distribution (30 ml). Postoperatively, a sham adductor canal catheter will be placed as in the ACC arm following stabilization in the PACU to infuse only normal saline with an initial bolus of 15 ml saline and infusion of saline at 10ml/hr for 72 hours.
2993873|NCT02603887|Experimental|Pembrolizumab|Pembrolizumab 200 mg administered as a single agent intravenous infusion every 3 weeks (one cycle=21 days) for up to 24 cycles.
2993874|NCT02603874|Experimental|Target Tape|Including target tape in the procedure
2993875|NCT02603874|No Intervention|Control|Without target tape in the procedure
2993876|NCT02603861|Placebo Comparator|Placebo|Placebo matching LY3154207 administered once orally in one of four periods.
2993877|NCT02603861|Experimental|LY3154207 - Dose 1|LY3154207 administered orally in no more than one of the four periods.
2993878|NCT02603861|Experimental|LY3154207 - Dose 2|LY3154207 administered orally in no more than one of the four periods.
2993879|NCT02603861|Experimental|LY3154207 - Dose 3|LY3154207 administered orally in no more than one of the four periods.
2994605|NCT02599077|Experimental|Dienogest|the patient handling with 2 mg dienogest / day.
2993881|NCT02603848|Experimental|Ibuprofen suspension|Ibuprofen suspension (Advil) will be administered orally at a dose of 10mg/kg every 6 hours for 72 hours post-surgery.
2993882|NCT02603848|Active Comparator|Morphine Sulfate suspension|Morphine sulfate suspension will be administered orally at a dose of 0.02 - 0.04 mg/kg every 6 hours for 72 hours post-surgery.
2993883|NCT02603835|Experimental|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
2993884|NCT02603822|Experimental|Healthy Volunteers|Subjects will receive a saccharide solution of 12C mannitol 100 mg, 13C mannitol 100 mg, and lactulose 1 g in 250ml of water at visits 2, 5, and 7 prior to permeability testing. The subjects will also receive Indomethacin capsules prior to visit 5.
2993885|NCT02603809|Experimental|ACT-132577 Dose 1|ACT-132577 Dose 1
2993886|NCT02603809|Experimental|ACT-132577 Dose 2|ACT-132577 Dose 2
2993887|NCT02603809|Experimental|ACT-132577 Dose 3|ACT-132577 Dose 3
2993888|NCT02603809|Experimental|ACT-132577 Dose 4|ACT-132577 Dose 4
2993889|NCT02603809|Active Comparator|Lisinopril 20 mg|20 mg
2993890|NCT02603809|Placebo Comparator|Placebo|Placebo
2993891|NCT02603796||Newborns requiring ncpap|3D scan of nares will be performed before and after administration of NCPAP for infants with Corrected Gestational Age greater than or equal to 24 weeks and less than or equal to 42 weeks.
2993892|NCT02603783|Active Comparator|Capsaicin|1,5 mg capsaicin in 30 minutes
2993893|NCT02603783|Placebo Comparator|Placebo|75 ml placebo (0,9 % saline) in 30 minutes
2993894|NCT02603770|Experimental|XueZhiKang (XZK)|XueZhiKang (XZK) 1200 mg
2993895|NCT02603770|Active Comparator|Lovastatin|Lovastatin 20 mg
2993896|NCT02603757|Active Comparator|Group A|Standard-dose of 2,000 IU Vitamin D3, daily
2993897|NCT02603757|Experimental|Group B|Higher-dose of 50,000 IU of Vitamin D3, weekly
2993898|NCT02603744|Experimental|5 million MSC|The patients with POF who underwent intraovarian injection of 5 million mesenchymal stem cells.
2993899|NCT02603744|Experimental|10 million MSC|The patients with POF who underwent intraovarian injection of 10 million mesenchymal stem cells.
2993900|NCT02603744|Experimental|15 million MSC|The patients with POF who underwent intraovarian injection of 15 million mesenchymal stem cells.
2993901|NCT02603718|Experimental|Standard physical therapy treatment with feedback|Standard physical therapy rehabilitation is administered to stroke patients. Attention level of the patient gathered with an EEG tool is measured, and provided to both therapist and patient on-line during one of the two treatments.
2993902|NCT02603718|Experimental|Standard physical therapy treatment without feedback|Standard physical therapy rehabilitation is administered to stroke patients. Attention level of the patient gathered with an EEG tool is measured but feedback is not provided.
2993903|NCT02603705|Experimental|Oxycodone extended-release|Egalet abuse-deterrent, extended-release oxycodone tablet
2993904|NCT02603692||Pediatric group (ages 8-17)|PROMIS pediatric domains for emotional distress (anxiety and depression), physical function (fatigue, pain interference, mobility and upper extremity), and peer relations
2993905|NCT02603692||Adult group (ages 18-35)|PROMIS adult domains. To reduce respondent burden, the multi-form design will be used which includes the short form of physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference and pain intensity.
2993906|NCT02603692||Parent/guardian proxy|Parent/guardian will complete the parental proxy PROMIS instruments based on corresponding child age (ages 5 to 17 years)
2993907|NCT02603679|Active Comparator|A: Weekly Paclitaxel|Patients receive weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for a 12-week period. Thereafter, treatment is switched to endocrine treatment in combination with palbociclib. Pre- or perimenopausal women and all men are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women); postmenopausal women receive an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during the second 12-week period
2993908|NCT02603679|Experimental|B: Tamoxifen + Palbociclib|Pre- or perimenopausal women and all men are treated with tamoxifen together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
2993909|NCT02603679|Experimental|B: Aromatase Inhibitor + Palbociclib|Postmenopausal women receive an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
2993910|NCT02603679|Experimental|B: Goserelin + Aromatase Inhibitor + Palbociclib|Pre- or perimenopausal women may be treated with goserelin and an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
2993911|NCT02603666|Other|Elastography|Fibroscan elastography device for evaluation of liver disease in CF patients.
2993912|NCT02603653|Experimental|Patients|Virtual radial task in 3D
2993913|NCT02603653|Experimental|Controls|Virtual radial task in 3D
2993914|NCT02603640|Experimental|epileptic patient|
2993915|NCT02603627||With lung cancer|Patients who have a new diagnosis of lung cancer will be invited to undergo spirometry to enable us to gather data on the prevalence of COPD in this group.
2993916|NCT02603627||Without lung cancer|Smokers who are referred to the smoking cessation clinic will be invited to undergo spirometry to ascertain the prevalence of COPD in this group.
2993917|NCT02603614|Experimental|Cenderitide|7 days of continuous, subcutaneous infusions of cenderitide starting at a dose of 5 ng/kg/min for 1 day, then escalating to a dose of 7.5 ng/kg/min for 3 days, followed by 10 ng/kg/min for a further 3 days.
2993918|NCT02603614|Placebo Comparator|Control|7 days of continuous, subcutaneous infusions of placebo.
2993919|NCT02603601|Active Comparator|Standard lifestyle intervention|The standard lifestyle intervention is a 1-hour individual nutritional counseling session with a registered dietician at BIDMC.
2993920|NCT02603601|Experimental|Mind-body lifestyle intervention|The mind-body lifestyle intervention is a 10-week mindfulness-based intervention that integrates mindfulness with traditional behavioral strategies to improve long-term weight maintenance.
2993921|NCT02603588|Experimental|active acupuncture|intervention: subjects in the active acupuncture group received active sphenopalatine ganglion acupuncture
2993922|NCT02603588|Sham Comparator|sham acupuncture|intervention: subjects in the sham acupuncture group received sham sphenopalatine ganglion acupuncture
2993923|NCT02603575|Experimental|Caspofungin and corticosteroids|patients treat with caspofungin and corticosteroids on the base of sulfanilamide
2993924|NCT02603575|Active Comparator|Caspofungin and no corticosteroids|patients treat with caspofungin on the base of sulfanilamide
2993925|NCT02603575|Active Comparator|corticosteroids and no caspofungin|patients treat with corticosteroids on the base of sulfanilamide
2993926|NCT02603575|Active Comparator|no corticosteroids and no caspofungin|patients treat with sulfanilamide only
2993927|NCT02603562|Experimental|ATYR1940|Intrapatient dose escalation ATYR1940: ATYR1940 will be administered as an IV infusion at doses of 0.3, 1.0, and 3.0 mg/kg for up to 12 Weeks. The dose level in this study will not exceed 3.0 mg/kg.
2993928|NCT02603562|Placebo Comparator|Placebo|An initial IV infusion of placebo will be supplied as normal saline, and administered over a 30-minute period at Week 1.
2993929|NCT02603549||Surgery or Blood Patch|
2993930|NCT02603536|Experimental|Vulnerable or pilot participant|"In addition to standard care, WelTel will send a weekly text message to participants in this arm for a one year period. Participants will be requested to respond to the outgoing message How are you? within 48 hours; they may respond that they are doing well or that they have a problem. A clinician will call to follow-up with all participants who respond indicating a problem or who do not respond within 48 hours."
2993931|NCT02603523|Experimental|Senior Dance|The intervention group will attend a single educational class on fall risk factors and prevention, and will participate in a 12-week, twice-weekly group-based program of Senior Dance. Each dance class will last for an hour, and the number of participants per class will range from 10 to 15. Senior Dance-certified instructors will lead the classes. The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups.
2993932|NCT02603523|No Intervention|Control group|Participants in the control group will attend the same educational class on fall risk factors and prevention that intervention group participants will receive, and will be instructed not to take part in any regular exercise programs such as supervised group exercise, Tai Chi, Yoga, or any dance activity during the study period. At the end of the study, they will be offered Senior Dance classes, twice a week, during 12 weeks.
2993933|NCT02603510|Experimental|SAR342434/Humalog|SAR342434 and Humalog will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.
2993934|NCT02603510|Experimental|Humalog/SAR342434|Humalog and SAR342434 will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.
2993935|NCT02603497|Experimental|Control (Subjects with normal renal function)|Oral
2993936|NCT02603497|Experimental|Mild renal impairment|Oral
2993937|NCT02603497|Experimental|Moderate renal impairment|Oral
2993938|NCT02603497|Experimental|Severe renal impairment|Oral
2993939|NCT02603471|Experimental|Text Messaging CBT (TXT-CBT)|This condition will receive CBT based text messaging (TXT-CBT). Those assigned to TXT-CBT will also be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have an initial meeting with a CBT clinician to review the Life-Steps concepts. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
2993940|NCT02603471|Active Comparator|Informational group|A pamphlet with information about HIV, the importance of ART adherence, and relapse prevention will be provided to participants in this condition.
2993941|NCT02603458|Placebo Comparator|Placebo|Group of enrolled subjects receiving two infusions of intravenous placebo (5% glucose solution)
2993942|NCT02603458|Experimental|NRX-1074 Dose Group|Group of enrolled subjects receiving two infusions of intravenous NRX-1074 (10 mg)
2993943|NCT02603445|Experimental|Follicular lymphoma (FL)|
2993944|NCT02603445|Experimental|Mantle cell lymphoma (MCL)|
2993945|NCT02603432|Experimental|Arm A|Avelumab plus Best Supportive Care (BSC)
2993946|NCT02603432|Other|Arm B|Best Supportive Care (BSC) alone
2993947|NCT02603419|Experimental|Lead-in phase-Cohort A|X1 mg IV every 2 weeks
2993948|NCT02603419|Experimental|Lead-in phase-Cohort B|X2 mg IV every 2 weeks
2993949|NCT02603419|Experimental|Lead-in phase-Cohort C|X3 mg IV every 3 weeks
2993950|NCT02603419|Experimental|Lead-in phase-Cohort D|X4 mg IV every 2 weeks
2993951|NCT02603419|Experimental|Lead-in phase-Cohort E|X5 mg IV every 2 weeks
2993952|NCT02603419|Experimental|Expansion phase|X1 mg IV every 2 weeks followed by X1 or X4 mg every 2 weeks
2993953|NCT02603406|Experimental|Group A|mechanical barrier disruption procedure + hrEPO manufactured by Dong-A pharmaceutics Multiple burrholes with local anesthesia after medication Drug: Erythropoietin 33,000u daily for 3 day via intravenous
2993954|NCT02603406|No Intervention|Group B|conventional medical therapy Drug: no-specific intervention
2993955|NCT02603393|Experimental|QVA149|
2993956|NCT02603393|Active Comparator|Tiotropium + salmeterol/fluticasone|
2993957|NCT02603380||Clinical staff|Clinicians in the Royal Infirmary of Edinburgh.
2993958|NCT02603380||Patients|Patients in intensive care units and general wards in the Royal Infirmary of Edinburgh.
2993959|NCT02603367|Experimental|Supportive care (COMFORT communication intervention)|"Participants receive the printed communication tool A Communication Guide for Caregivers, a guide developed from the COMFORT communication curriculum, a national training program for palliative care communication. After a 1 week period to review the material, participants undergo communication coaching with a research nurse by phone over approximately 1 hour."
2993960|NCT02603354|Active Comparator|3x12 m peroxide gel tooth bleaching 6%|bleaching with 6% hydrogen peroxide 3 times of 12 minutes session for in office bleaching teeth
2993961|NCT02603354|Experimental|1-36 m peroxide gel tooth bleaching 6%|bleaching with 6% hydrogen peroxide 1 time of 36 minutes session for in office bleaching teeth
2993962|NCT02603341|Active Comparator|Photon|Photon therapy: once a day, 5 days a week, for 5 to 7 weeks
2993963|NCT02603341|Active Comparator|Proton|Proton therapy: once a day, 5 days a week, for 5 to 7 weeks
2993964|NCT02603328|Active Comparator|Treatment|Atorvastatin 80mg OD (optimal dose). Treatment dose will be de-escalated to 40mg based on reported adverse events.
2993965|NCT02603328|Placebo Comparator|Placebo|Identically looking capsules containing no active ingredient
2993966|NCT02603302|Experimental|Locally advanced rectal cancer|"RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV + Chemotherapy with 5-FU~Surgery 8 weeks after the neoadjvuant treatment."
2993967|NCT02603289||Teen|< 17 years of age
2993968|NCT02603289||Adult|17 years of age or older
2993969|NCT02603289||Adult with Primer Aligners|17 years of age or older This group will get Primer Aligners
2993970|NCT02603276|Active Comparator|Plant sterols|Plant sterols 800 mg per dose, 1 liquid stick per day, per 8 weeks
2993971|NCT02603276|Active Comparator|Red Yeast Rice|Red Yeast Rice 200 mg containing 5 mg monacolin K per daily dose, 1 liquid stick per day, per 8 weeks
2993972|NCT02603276|Experimental|Red Yeast Rice plus Plant sterols|lant sterols 800 mg per dose + Red Yeast Rice 200 mg containing 5 mg monacolin K per daily dose, 1 liquid stick per day, per 8 weeks
2993973|NCT02603263||Workplace Restaurant Customers|"1 Group (Workplace Restaurant Customers) across 3 sites (data to be combined at end of study)~Study consists of three phases:~Pre Intervention~Intervention~Post Intervention~All phases lasted two weeks and included monitoring till receipts for meals (these were automatically generated and held on the tills electronically). The intervention phase consisted of posters being displayed in the restaurants, featuring a Social Norms Poster."
2993974|NCT02603250||Wicking|50% of the 132 children enrolled in the study will have their Hb measured using the wicking method of HemoCue® 201+ blood collection.
2993975|NCT02603250||Gravity|50% of the 132 children enrolled in the study will have their Hb measured using the gravity method of HemoCue® 201+ blood collection.
2993976|NCT02603237|Other|Glucose tolerance test|All participants will receive an oral standardized glucose tolerance test
2993977|NCT02603237|Other|Fat tolerance test|The same participants will receive an oral standardized fat load test
2993978|NCT02603224|Experimental|MRG-201|
2993979|NCT02603224|Placebo Comparator|Placebo|
2993980|NCT02603211||Women with Breast Tumors|Women with breast tumors.
2993981|NCT02603198|Active Comparator|mepivacaine chloridrato epinephrine|Side of operation that is going to receive anesthesia with 2% mepivacaine chloridrato with 1:100.000 epinephrine, maximum of 4 cartridges
2993982|NCT02603198|Active Comparator|mepivacaine chloridrato levonordefrin|Side of operation that is going to receive anesthesia with 2% mepivacaine chloridrato with 1:20.000 levonordefrin, maximum of 4 cartridges
2993983|NCT02603185|Experimental|Hemay007|"Part 1: Single ascending dose Group Hemay007 tablets will be taken orally once daily in doses of 0.2g, 0.6g,1.2g, 2g, 3g.~Part 2: Food effect group Hemay007 tablets will be taken orally in single dose with a high-fat, high-calorie meal or at overnight fasting.~Part 3: Multiple doses group Hemay007 tablets will be taken orally once daily in low, medium, high doses"
2993984|NCT02603185|Placebo Comparator|Placebo|"Part 1: Single ascending dose Group Placebo tablets will be taken orally once daily in doses of 0.2g, 0.6g,1.2g, 2g, 3g.~Part 3: Multiple doses group Placebo tablets will be taken orally once daily in low, medium, high doses"
2993985|NCT02603172|Experimental|Part A: Cohort 1|Subjects will receive a single dose of GSK3039294 (Dose level 1) on Day 1 and will remain in-house until Day 4. Wash-out will take place from Day 5 to Day 14. Subjects will receive Dose level 2 on Day 15 (Period 2).
2993986|NCT02603172|Experimental|Part A: Cohort 2|Subjects will receive a single dose of GSK3039294 (Dose level 3) on Day 1 and will remain in-house until Day 4. Wash-out will take place from Day 5 to Day 14. Subjects will receive Dose level 4 on Day 15 (Period 2).
2993987|NCT02603172|Experimental|Part B: Cohort 3a|Subjects will receive repeat dosing of GSK3039294 for a total of 21 days. The dose will be escalated every week throughout the study duration. Subjects will first receive a low dose given once daily. After 7 days, if well tolerated, the total daily dose will be increased and, GSK3039294 will be given, for example, as twice daily dosing for 7 days. At the end of this 7 day period and if previous dosing was well tolerated, the dose will be increased to a maximum daily dose that will not exceed pre-clinical safety exposure limits. On Day 4 and 5 GSK3039294 will be administered under fasted and fed conditions, respectively, to investigate the food effect on the PK.
2993988|NCT02603172|Experimental|Part B: Cohort 3b|Subjects will be enrolled in Cohort 3b only if required for further investigation. Subjects will receive GSK3039294 for 21 consecutive days and more than one dose level or regimen may be investigated, for example on the first 10 days the dose may be administered thrice daily, and on the last 11 days may be administered twice daily.
2993989|NCT02603172|Experimental|Part C: Cohort 4|Subjects will receive repeat dosing of GSK3039294 at the predicted optimal clinical dose determined from Part B for a total of 21 days.
2993990|NCT02603159|Experimental|Capecitabine-5 weeks-radiotherapy|Capecitabine 5 weeks : 625mg/m2, bid d1-5; q1w, po,5 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.
2993991|NCT02603159|Active Comparator|Capecitabine-10 weeks-radiotherapy|Capecitabine 10 weeks : 625mg/m2, bid d1-5; q1w, po,10 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.
2993992|NCT02603146|Experimental|Hydroxychloroquine Group|Subjects randomized to hydroxychloroquine (HCQ). Subjects will receive 200-400 mg of HCQ (1-2 pills), based upon ideal body weight (IBW), taken daily for 12 months.
2993993|NCT02603146|Placebo Comparator|Placebo Group|Subjects randomized to placebo HCQ. Subjects will receive 200 - 400 mg of HCQ placebo (1-2 pills), based upon IBW, taken daily for 12 months.
2994032|NCT02602912|Experimental|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is a spinal needle that has bioimpedance measurement capability.
2994033|NCT02602899|Experimental|PINS Deep Brain Stimulator|Deep Brain Stimulator is on,continuous stimulation to the brain,
2994034|NCT02602886|Experimental|Exposure and Response Prevention Therapy|
2993994|NCT02603133|Experimental|Cohort 1 - WISER 1-6|The intervention will begin for all NICUs, with baseline surveys as necessary pre-work. For those unable to attend, a link to the baseline survey will be emailed with site champion instructions to complete in groups at staff meetings and during shift change. Two weeks later, three randomly (random number generator) assigned NICUs (block 1) included in the first block webinar will then receive Module 1 of the intervention with Modules 2-6 being rolled out monthly. The second block of three NICUs starts approximately six-month later.
2993995|NCT02603133|Experimental|Cohort 2 - WISER 1-6|This second block of 3 NICUs will start approximately six-months after roll-out of group 1. At time point 0 this NICUs in this group will receive a lecture on safety culture, unrelated to the burnout intervention.
2993996|NCT02603120|Experimental|Blinded Phase: B/F/TAF|B/F/TAF + ABC/DTG/3TC placebo for at least 48 weeks
2993997|NCT02603120|Active Comparator|Blinded Phase: ABC/DTG/3TC|ABC/DTG/3TC + B/F/TAF placebo for at least 48 weeks
2993998|NCT02603120|Experimental|Open-Label Phase|At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.
2993999|NCT02603107|Experimental|B/F/TAF|"Randomized Phase: Participants will switch to B/F/TAF FDC and continue treatment for at least 48 weeks.~Extension Phase: After Week 48, participants in countries where B/F/TAF is not available may have the option to receive B/F/TAF for up to 96 additional weeks."
2994000|NCT02603107|Experimental|Current antiretroviral regimen|"Randomized Phase: Participants will remain on current antiretroviral regimen consisting of ritonavir boosted ATV (RTV+ATV), ritonavir boosted DRV (RTV+DRV), cobicistat boosted ATV (COBI+ATV or ATV/co), or cobicistat boosted DRV (COBI+DRV or DRV/co) plus either FTC/TDF or ABC/3TC for at least 48 weeks.~Extension Phase: After Week 48, participants in countries where B/F/TAF is not available may have the option to receive B/F/TAF for up to 96 additional weeks."
2994001|NCT02603094|Experimental|clear fluids until premedication|allowed to drink until premedication, aprox 30 minutes before anaesthesia induction. Fasting for solids and non-clear fluids is six hours.
2994002|NCT02603094|Active Comparator|2 hours fluid fasting|allowed to drink until 2 hour before scheduled anaesthesia induction clear fluid Ingestion. Fasting for solids and non-clear fluids is six hours.
2994003|NCT02603081|Placebo Comparator|Placebo|0 mg SPI-1005 bid po x 21d
2994004|NCT02603081|Active Comparator|Low dose|200 mg SPI-1005 bid po x 21d
2994005|NCT02603081|Active Comparator|Mid dose|400 mg SPI-1005 bid po x 21d
2994006|NCT02603081|Active Comparator|High dose|600 mg SPI-1005 bid po x 21d
2994007|NCT02603068|Experimental|Individual Maximum Tolerated Dose (iMTD)|Subjects are allowed to titrate oral treprostinil up to a maximum dose of 12 mg TID.
2994008|NCT02603068|Experimental|Fixed Dose (FD)|Subjects are allowed to titrate oral treprostinil up to a maximum dose of 1 mg TID.
2994009|NCT02603055|Experimental|30μg/0.5ml Hepatitis E vaccine|three doses, 30μg/0.5ml per dose
2994010|NCT02603055|Active Comparator|30μg/0.5ml Recombinant Hepatitis E vaccine|30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co., Ltd. three doses, 30μg/0.5ml per dose
2994011|NCT02603042||Observation|Patients at 2 months with Hypophosphatasia disease or high-grade suspicion for Hypophosphatasia disease
2994012|NCT02603029|Placebo Comparator|Placebo cream|Cream with 0% Silver fir wood extract (Belinal)
2994013|NCT02603029|Active Comparator|Belinal cream|Cream with 2% Silver fir wood extract (Belinal)
2994014|NCT02603016|Experimental|GLSE compound group|GLSE compound 2g each time by mouth,twice a day for 42 days.
2994015|NCT02603016|Experimental|Maitake mushroom extract compound group|Maitake mushroom extract compound 2 tables each time by mouth,twice a day for 42 days.
2994016|NCT02603016|Experimental|Ginseng compound group|Ginseng compound 2 tables each time by mouth,twice a day for 42 days.
2994017|NCT02603016|No Intervention|blank control group|Take nothing.
2994018|NCT02603003|Placebo Comparator|Cisplatin|Cisplatin
2994019|NCT02603003|Placebo Comparator|Pemetrexed|Pemetrexed
2994020|NCT02603003|Experimental|Jinfukang|Jinfukang
2994021|NCT02602990||Cerebral AVM treated with SQUID™|
2994022|NCT02602977|Experimental|multiple-dose RIPC|Multiple-dose Remote Ischemic Preconditioning. A group of 10 subjects that will receive 4 cycles of remote ischemic preconditioning of the upper limb per day in the 7 consecutive days before the endotoxemia experiment. The last dose will be applied 40 minutes before LPS administration.
2994023|NCT02602977|Experimental|single-dose RIPC|Single-dose Remote Ischemic Preconditioning. A group of 10 subjects that will receive a single RIPC dose, starting 40 minutes before LPS administration.
2994024|NCT02602977|Active Comparator|control group|Only LPS infusion. A group of 10 subjects that will be administered LPS without RIPC.
2994025|NCT02602964|Experimental|Deep neuromsucular block|Deep neuromuscular block and low pressure pneumoperitoneum
2994026|NCT02602964|No Intervention|Standard neuromuscular block|Standard neuromuscular block and low pressure pneumoperitoneum
2994027|NCT02602951|Experimental|Control|Pilot subjects
2994028|NCT02602951|Experimental|Patients|Patients with an intracranial disorder or needing a supraaortic trunk MRA
2994029|NCT02602938|Experimental|aspirin|"The included patients will be administered with aspirin (100mg) orally once a day in 28-day cycles.~The CTC was evaluated at baseline, and every 28 days for 2 months."
2994030|NCT02602925|Experimental|Dose decrease|Patients receive daily practice care, but doses of etanercept, adalimumab or ustekinumab will be lowered: intervals of drug-administration will be prolonged stepwise with tight control of disease activity and DLQI. First, the dose will be decreased to 66-70% of the normal dose (by interval prolongation with a factor 1.5). If patients remain in a state of low disease activity, the dose will be further reduced to 50% (by doubling the original interval). Each step will be analyzed after three months, or when the patient visits earlier due to complaints.
2994031|NCT02602925|Other|Usual care|Patients will continue treatment with the normal dose and treatment regimens will be based on usual daily practice care. Treatment decisions are made at the discretion of the treating physician.
2994139|NCT02602171|Experimental|dereverberation condition|Oldenburger Sentence test, localization test
2994035|NCT02602873||good efficacy|using therapeutic drug monitoring to adjust the dose of tacrolimus. patients can reach effective outcome.
2994036|NCT02602873||poor efficacy|using therapeutic drug monitoring to adjust the dose of tacrolimus. patients can not reach effective outcome.
2994037|NCT02602860|Experimental|Levetiracetam|"Cohort 1: Half of the subjects will receive LEV as a 5 minute iv infusion during the second Positron Emission Tomography (PET) scan, 60 minutes after the start of [11C]UCB-J administration.~Cohort 2: Half of the subjects will receive LEV as a 5 minute iv infusion during the first PET scan, 60 minutes after the start of [11C]UCB-J administration. The dose of LEV (500 mg to 2500 mg) or BRV (50 mg to 200 mg) will be decided based on the data obtained in Cohort 1. Subjects will return for a second PET imaging session (Visit 4), 7 to 28 days after completion of their first session (Visit 3) to enter the BRV arm."
2994038|NCT02602860|Experimental|Brivaracetam|"Cohort 1:Half of the subjects will receive BRV as a 5 minute iv infusion during the second Positron Emission Tomography (PET) scan, 60 minutes after the start of [11C]UCB-J administration.~Cohort 2:Half of the subjects will receive BRV as a 5 minute iv infusion during the first PET scan, 60 minutes after the start of [11C]UCB-J administration. The dose of BRV (50-200 mg) will be decided based on the data obtained in Cohort 1. Subjects will return for a second PET imaging session,7 to 28 days after completion of their first session to enter the LEV arm.~Cohort 3:void Cohort 4:Subjects will take oral BRV (25-100 mg bid) for 4 days and a single dose of BRV on Day 5. Pre-/post-block scans will be obtained at the first dose, one post-block scan after the last dose. Additional post-block scans may be obtained 8-10 and 28h or later after last dose; if last scan not needed, subject will return 7 to 28 days later for a post-block scan. Dose range for LEV in Cohort 4 will be 250 to <1500mg."
2994039|NCT02602847||Patients with alcoholic or hepatitis C virus related disease|cccDNA assay on liver biopsy in patients with liver transplantation for alcoholic disease or hepatitis C virus (HCV) related disease, without contact with HBV
2994040|NCT02602847||Hepatitis B core antibody positive donors|cccDNA assay on liver biopsy in patients who receive liver from hepatitis B core antibody positive donors
2994041|NCT02602847||HBV patients|cccDNA assay on liver biopsy in patient with liver transplantation for chronic hepatitis B, with or without HBV replication
2994042|NCT02602834|Experimental|HTx|Heart transplant recipients n=15
2994043|NCT02602834|Active Comparator|Control|Healthy controls n=5
2994044|NCT02602808||Severe acute pancreatitis group|Severe acute pancreatitis is characterised by persistent organ failure.
2994045|NCT02602808||Moderately severe acute pancreatitis|Moderately severe acute pancreatitis is characterised by the presence of transient organ failure or local or systemic complications in the absence of persistent organ failure.
2994046|NCT02602808||Mild acute pancreatitis|Mild acute pancreatitis is characterised by the absence of organ failure and the absence of local or systemic complications.
2994047|NCT02602795|Experimental|Distress Tolerance (DT)|Acceptance and Commitment Therapy based Distress Tolerance (DT) intervention to facilitate opioid detoxification delivered in six 50-minute individual telehealth sessions.
2994048|NCT02602795|Active Comparator|HIV/STI Intervention|Information Motivation Behavioral model based HIV/STI risk reduction intervention delivered in six 50-minute individual telehealth sessions.
2994049|NCT02602795|No Intervention|Treatment As Usual (TAU)|Traditional treatment given to patients who elect to transition to XR-NTX at the treatment sites.
2994050|NCT02602769||Cases of ROHHAD syndrome|"Children diagnosed with ROHHAD syndrome during the course of their clinical care by their physicians.~The following procedures will be performed in this group:~Body composition~Energy intake~Resting energy expenditure~Total energy expenditure~Mixed meal tolerance test."
2994051|NCT02602769||Control cohort|"Children matched for age- , sex- and BMI of the cases with ROHHAD syndrome.~The following procedures will be performed in this group:~Body composition~Energy intake~Resting energy expenditure~Total energy expenditure~Mixed meal tolerance test."
2994052|NCT02602756|Active Comparator|A|Protontherapy : 4 sessions of 13 Gy, total dosis 52 Gy
2994053|NCT02602756|Experimental|B|Protontherapy : 8 sessions of 6.5 Gy, total dosis 52 Gy
2994054|NCT02602743|Experimental|remifentanyl, ketamine|Experimental:Remifentanyl and ketamine Remifentanyl vial 2 mg, Ketamine vial 500mg/10 mlt by intravenous. 2 mg/kg ketamine and 0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
2994055|NCT02602743|Active Comparator|propofol, ketamine|"Active comparator:Propofol and ketamine Propofol injectable emulsion vial 200 mg/20 mlt, Ketamine vial 500mg/10 mlt by intravenous.~2 mg/kg ketamine and 1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started."
2994056|NCT02602730|Experimental|Break the Chain|Access during the evaluation study period to an Internet smoking cessation intervention that included digital coaching messages sent at prescribed times during the participant's quit process and as needed in response to participant questions or comments.
2994057|NCT02602730|Active Comparator|Clearing the Air PDF|"Control users were e-mailed a copy of the National Cancer Institute's PDF smoking cessation booklet, Clearing the Air."
2994058|NCT02602717|Experimental|thyroid cancer|
2994059|NCT02602704|Active Comparator|Bazedoxifene & Calcium/Vit D|"Enrollment: 57~Drug: Bazedoxifene 20 mg/day (Viviant)~Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)"
2994060|NCT02602704|Active Comparator|Calcium/Vit D|"Enrollment: 57~Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)"
2994061|NCT02602691|Active Comparator|Endomyocardial biopsy|Systematic endomyocardial biopsies performed according to a planned monitoring schedule in usual care for patients with a heart transplantation.
2994062|NCT02602691|Experimental|AlloMap® test|Noninvasive gene expression profiling blood test (AlloMap®) performed instead of endomyocardial biopsies when planned in the monitoring schedule for patients with a heart transplantation.
2994063|NCT02602678|Experimental|PRONE-Supine|We test the hypothesis that in infants with severe bronchiolitis, prone position reduces the work of breathing (WOB) and the intrinsic Positive End Expiratory Pressure (PEEP).
2994064|NCT02602678|Experimental|SUPINE - Prone|We test the hypothesis that in infants with severe bronchiolitis, prone position reduces the work of breathing (WOB) and the intrinsic Positive End Expiratory Pressure (PEEP).
2994065|NCT02602665|Experimental|Shallow catheter tip placement|Patients randomized to shallow tip placement will have the tip of the catheter placed approximately one vertebral body above to even with the carina.
2994066|NCT02602665|Experimental|Deep catheter tip placement|Patients randomized to deep tip placement will have the tip of the catheter placed 1.5 to 2.5 vertebral bodies below the carina.
2994067|NCT02602652|Experimental|a live attenuated chimeric JE vaccine|Children were received JE-CV as a booster dose after vaccinated with SA14-14-2 vaccine as a first dose regimen 12-24 months before.
2994068|NCT02602639|Experimental|Functional electrical stimulation rowing|Using an Odstock 4 channel neuromuscular stimulator with Concept 2 Rower
2994069|NCT02602613|Experimental|AMEND|
2994070|NCT02602600|Experimental|Liraglutide|Liraglutide up to 3.0 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks followed by 2 weeks of weight maintenance diet. Before initiating treatment participants will serve as their own controls for 4 weeks.
2994071|NCT02602587|Experimental|blood samples and bone marrow samples|The patients included in this study will be processed according to the standard treatment in force for their disease. This study does not in any way interfere with this treatment regimen, and is only based on additional samples of blood and bone marrow in acts planned in the prognostic or follow-up protocols. Treatment shall start within the 15 days following inclusion and first sampling.
2994072|NCT02602574||ERCP- induced acute pancreatitis|"All patients with indication for ERCP will be prepared for ERCP. One hour before and 4-6 hours after the procedure 10 mL of blood sample and urine sample will be collected.~24 hours after the procedure all patients will be taken 30 ml of heparinized peripheral venous blood and urine sample.~Upon clinical and laboratory confirmation of acute pancreatitis according to ESGE guidelines for post-ERCP pancreatitis, will be further monitored during hospitalization for evaluation of the severity of the disease."
2994073|NCT02602574||non -ERCP acute pancreatitis|"All patients with acute pancreatitis according to Atlanta criteria admitted through Emergency Department will be taken 30 ml of heparinized peripheral venous blood and urine sample upon 24 hours after the clinical symptoms have started. 10 mL of collected blood samples will be examined in the Department of Laboratory Medicine. Other 20 mL of blood samples will be sent to Department of Physiology and Immunology, School of Medicine where immunologic analysis will be performed.~This group of patients will be further monitored during hospitalization for evaluation of the severity of the disease. Severity of the disease will be assessed according to the Atlanta criteria."
2994074|NCT02602574||Control group|"Control group will consist of patients who underwent ERCP but didn't develop acute pancreatitis. One hour before and 4-6 hours after the procedure 10 mL of blood sample and urine sample will be collected.~24 hours after the procedure all patients will be taken 30 ml of heparinized peripheral venous blood and urine sample."
2994075|NCT02602561|Active Comparator|HMB|3 g HMB/day
2994076|NCT02602561|Placebo Comparator|Placebo|Placebo administered similar to the active comparator
2994077|NCT02602548||Open Shoulder Surgery|Culture
2994078|NCT02602548||Arthroscopic Shoulder Surgery|Culture
2994079|NCT02602535|Experimental|M.O.R.E.|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
2994080|NCT02602535|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
2994081|NCT02602522|Experimental|Experimental|The patients in this arm will be given 1 bag per time of Shandong Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the first menorrhea period. And then in the next menstrual cycle, the patients will in turn be given 1 bag per time of Sichuan Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the second menorrhea period.
2994082|NCT02602522|Active Comparator|controlled|The patients in this arm will be given 1 bag per time of Sichuan Danshen-Jiang-Fu Granule prepared, twice a day for 5 days before menorrhea and the first 2 days in the first menorrhea period. And then in the next menstrual cycle, the patients will in turn be given 1 bag per time of Shandong Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the second menorrhea period.
2994083|NCT02602509|Experimental|Celecoxib plus rifampicin group|Visit 1: Celecoxib 400mg Visit 2: Rifampicin 10mg/kg Visit 3: Celecoxib 400mg PLUS rifampicin 10mg/kg
2994084|NCT02602509|Experimental|Celecoxib plus pyrazinamide group|Visit 1: Celecoxib 400mg Visit 2: Pyrazinamide 25mg/kg Visit 3: Celecoxib 400mg PLUS pyrazinamide 25mg/kg
2994085|NCT02602496|Experimental|Control|3 servings of refined grains per day.
2994086|NCT02602496|Experimental|Fruits and Vegetables|5 servings of fruits and vegetable per day.
2994087|NCT02602496|Experimental|Whole Grain|3 servings of whole grains per day.
2994088|NCT02602496|Experimental|Whole Grain + Fruits and Vegetables|3 servings of whole grains per day and 5 servings of fruits and vegetable per day.
2994089|NCT02602483|Experimental|Triple combination|Powder for oral administration
2994090|NCT02602483|Active Comparator|Ibuprofen|Powder for oral administration
2994091|NCT02602483|Active Comparator|Magnesium + ascorbic acid|Powder for oral administration
2994092|NCT02602483|Placebo Comparator|Placebo|Powder for oral administration
2994093|NCT02602470||Rosacea treated patients|Patients using topical rosacea treatment
2994094|NCT02602457|Experimental|Moderate-intensity continuous exercise|Moderate-intensity continuous exercise training
2994095|NCT02602457|Experimental|High-Intensity Interval Training|High-Intensity Interval Training
2994096|NCT02602444||STEMI|ST-elevation myocardial infarction patients receiving 180 mg ticagrelor loading dose
2994097|NCT02602444||NSTEMI|non-ST-elevation myocardial infarction patients receiving 180 mg ticagrelor loading dose
2994098|NCT02602431|Active Comparator|Extra-oral laser irradiation|infra-red wave laser, 660nm, 100mW, and 107J/cm2
2994099|NCT02602431|Placebo Comparator|Extra-oral placebo|Laser point will be placed in region without irradiation on.
2994100|NCT02602431|Active Comparator|Intra-oral laser irradiation|red wave laser, 660nm, 100mW, and 107J/cm2
2994101|NCT02602431|Placebo Comparator|intra-oral placebo|Laser point will be placed in region without irradiation on.
2994102|NCT02602418|Experimental|HIV Positive participants|Intervention; 90 HIV positive participants will be trained. Half the participants will have the Adaptive WM Cogmed training, and half will have the non-adaptive WM Cogmed training.
2994103|NCT02602418|Other|Seronegative particpiants|Intervention; 90 seronegative participants will be trained. Half the participants will have the Adaptive WM Cogmed training, and half will have the non-adaptive WM Cogmed training.
3020657|NCT02424890|Active Comparator|Control Group|3 simulation sessions
2994104|NCT02602392|Experimental|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
2994105|NCT02602392|Active Comparator|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
2994106|NCT02602379||Tetanic stimulation|Single arm study. See Study description for a through description of the intervention.
2994107|NCT02602366|Other|Month 1|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
2994108|NCT02602366|Other|Month 2|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
2994109|NCT02602366|Other|Month 3|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
2994110|NCT02602366|Other|Month 4|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
2994111|NCT02602353|Experimental|Loxoprofen Pain Patch|One Active Pain Patch containing loxoprofen applied once daily for 3 days
2994112|NCT02602353|Placebo Comparator|Placebo Patch|One Placebo Patch applied once daily for 3 days
2994113|NCT02602353|Other|No Treatment|No Treatment for 3 days
2994114|NCT02602340|Experimental|Behavioral Activation therapy|Participants will complete 10, 90-minute sessions of Behavioral Activation therapy, conducted using a group format. Each group will include 8-12 participants. Behavioral Activation therapy seeks to target behaviors that might maintain or worsen the depression.
2994115|NCT02602327|Experimental|Tas-102 and radioembolization|Combination therapy with Tas-102 and radioembolization using 90Y resin microspheres
2994116|NCT02602314|Experimental|Imatinib + Nilotinib|
2994117|NCT02602314|Experimental|Nilotinib|
2994118|NCT02602301|Active Comparator|1|group A that included 109 women in whom labour was augmented by IV infusion of oxytocin using isotonic saline 0.9%,
2994119|NCT02602301|Active Comparator|2|group B that included 109 women in whom labour was augmented by IV infusion of oxytocin using glucose 5% .
2994120|NCT02602301|Placebo Comparator|3|Group C in which 109 women continued their labour course without any further augmentation.
2994121|NCT02602288|Experimental|AAR+Behavioral Intervention (EXP)|Ask Advise Refer (AAR): WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources. Telebased tobacco counseling: Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke. Mobile phone smoking cessation application: Smartphone based application to support smoking cessation efforts. Nicotine polacrilex: Over the counter nicotine replacement therapy in gum or lozenge form.
2994122|NCT02602288|Active Comparator|AAR+Attention Control Intervention (CTL)|Ask Advise Refer (AAR): WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources. Telebased nutrition counseling: Telephone counseling to promote nutritious eating practices in the family. Mobile phone nutrition application: Smartphone based application to support healthy eating habits
2994123|NCT02602275|Experimental|Neurexan®|0.6 mg / tablet, 3 tablets, 40-60 minutes before the second MRI Intervention: Drug: Neurexan®
2994124|NCT02602275|Placebo Comparator|Placebo|3 tablets, 40-60 minutes before the second MRI
2994125|NCT02602262||HIV D+/R+|HIV-infected individuals who accept an organ from an HIV-infected deceased donor
2994126|NCT02602262||HIV D-/R+|HIV-infected individuals who accept an organ from an HIV-uninfected deceased donor
2994127|NCT02602249|No Intervention|Experimental Group A(control group)|saline infusion and follow up
2994128|NCT02602249|Experimental|Experimental Group B|MUC1-gene-DC-CTL will be used against tumor cells.
2994129|NCT02602249|Experimental|Experimental Group C|MUC1-peptide-DC-CTL will be used against tumor cells.
2994130|NCT02602236|Experimental|AOS-C2000-B|A new 2-piece appliance composed with 2 parts : a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
2994131|NCT02602223|Experimental|Amnion chorion membrane|Amnion chorion membrane will be placed over bone graft after socket preservation on randomly assigned side of the mouth i.e., contra-lateral to the active comparator.
2994132|NCT02602223|Active Comparator|d-PTFE membrane|dense polytetrafluoroethylene membrane will be placed over bone graft after socket preservation on randomly assigned side of the mouth i.e., contra-lateral to the Experimental side
2994133|NCT02602210|Active Comparator|group A|Group A: treated with intravenous hydrocortisone in addition to standard therapy (= treatment group)
2994134|NCT02602210|Placebo Comparator|group B|Group B: IV treatment with NaCL 0.9% in addition to standard therapy (= placebo group)
2994135|NCT02602197|Active Comparator|Paracetamol|1 gr paracetamol received intravenously bolus 15 minutes after anesthetic induction and at the postoperative 6 th,12 th, 18 th and 24 th hours
2994136|NCT02602197|Active Comparator|Dexketoprofen|50 mg dexketoprofen received intravenous bolus 15 minutes after anesthetic induction and at the postoperative 8 th,16 th and 24 th hours.
2994137|NCT02602184|Experimental|AR/101|Topically treatment with AR/101+Standard of Care once daily for up to 21 days. Daily treatment will include application of AR/101 drug to the wound and coverage with dressing (SoC). Subjects who are scheduled for an elective abdominoplasty at the practice of the principal investigator will have superficial split thickness wounds created on their abdomen according to protocol about 4 weeks prior to their scheduled abdominoplasty. A total of 8 split thickness (5X5 cm, 0.0254 mm in thickness) wounds will be distributed on the abdomen between the umbilicus and the suprapubic hairline. 4 of the wounds will be treated with AR/101.
2994138|NCT02602184|Placebo Comparator|Placebo|Topically treatment with Placebo + Standard of Care once daily for up to 21 days. Daily treatment will include application of placebo control to the wound and coverage with dressing (SoC). Subjects who are scheduled for an elective abdominoplasty at the practice of the principal investigator will have superficial split thickness wounds created on their abdomen according to protocol about 4 weeks prior to their scheduled abdominoplasty. A total of 8 split thickness (5X5 cm, 0.0254 mm in thickness) wounds will be distributed on the abdomen between the umbilicus and the suprapubic hairline. 4 of the wounds will be treated with Placebo.
2994141|NCT02602158|Active Comparator|Octanoic acid (1-13C, 99%)|100 µL 13C Octanoic acid (Cambridge isotope laboratories)
2994142|NCT02602158|Active Comparator|TRIOCTANOIN (1,1,1-13C3, 99%)|100 µL 13C Trioctanoin (Cambridge isotope laboratories)
2994143|NCT02602145||Peripheral artery disease patients|Patients with peripheral artery disease that were treated with a stent as part of their standard of care. Patients who meet the inclusion criteria (i.e. already have an SFA stent) will be consented after their endovascular repair, and those who choose to participate in the study will be followed for six months. At six months a standard post-operative contrast-enhanced CTA of the lower extremities will be obtained to assess for restenosis.
2994144|NCT02602132|Experimental|Clamping group|Indwelling urinary catheter is clamped before removal and unclamped when the patient expresses his desire to urinate.
2994145|NCT02602132|No Intervention|Free drainage group|The urinary catheter will be removed without prior clamping.
2994146|NCT02602119|Experimental|OTL38|Dosage calculated by weight of individual
2994147|NCT02602106|Experimental|Intervention group|"The aquatic exercise program included a total of three 50-55 minutes session per week. Pregnant women started at 9 weeks and finished at 38-39 weeks.~Each session included 10 minutes of warm up and 10 minutes of cool down including an specific pelvic floor muscle training. The core section of the session included aerobic and strength moderate exercise in water during 25 to 30 minutes"
2994148|NCT02602106|No Intervention|Control group|Sedentary healthy pregnant women
2994149|NCT02602093|Active Comparator|Transforaminal Endoscopic Discectomy|Surgery: Patients will undergo Percutaneous Transforaminal Endoscopic Discectomy.
2994150|NCT02602093|Active Comparator|Open Microdiscectomy|Surgery: Patients will undergo conventional micro discectomy.
2994151|NCT02602080||FA patients under popliteal block + spinal + sedation|Foot and ankle patients under popliteal block+ spinal+ sedation
2994152|NCT02602080||TSA patients under brachial plexus block + general (LMA)|Total shoulder arthroscopy patients under brachial plexus block + general (LMA)
2994153|NCT02602080||TSA patients under brachial plexus block + sedation|Total shoulder arthroplasty patients under brachial plexus block + sedation
2994154|NCT02602067|Experimental|131I-Tenatumomab|"Diagnostic: each patient will receive one single i.v. infusion of 370 MBq±10% 131I-Tenatumomab in 10 ml of saline (conveyed by 10 ±10%, 20 ±10%, 40 ±10% mg of Tenatumomab). It will be administered as a short infusion in approximately 30 minutes (333 ° µl / min).~Therapeutic: each patient will receive one single i.v. infusion, escalating 131I-Tenatumomab dose starting at 2.5 GBq±10%,with escalation steps of 1 GBq, up to 5.5 GBq±10% in 10 ml of saline, (conveyed by 10 ±10% , 20 ±10%, 40 ±10% mg of Tenatumomab). It will be administered as a short infusion in approximately 30 minutes (333° µl / min)"
2994155|NCT02602054|Experimental|Surgical treatment|Implement surgical treatment for closure of patent ductus arteriosus
2994156|NCT02602054|Active Comparator|Control group|"- Indomethacin: Administer 1 full cycle (3 doses) of indomethacin (1 dose every 12 hours) for 2 days Dose 0.1 - 0.25 mg / kg~- Ibuprofen: Administer 1 full cycle (3 doses) of ibuprofen (1 dose every 24 hours) for 2 days Dose 05 - 10 mg / kg~- Acetaminophen: Administer 1 full cycle (12 doses) of acetaminophen (1 dose every 6 hours) for 3 days Dose 15 mg / kg"
2994157|NCT02602041||Patients with breast cancer and partners|We will invite 10 women with early stage breast cancer (BC) and their partners for a semi-structured interview.
2994158|NCT02602041||Patients with testicular cancer and partners|We will invite 10 men with disseminated testicular cancer (TC) and their partners for a semi-structured interview.
2994159|NCT02602028|Experimental|once daily dosage schema of colchicine|The once daily dosage group was prescribed as once daily at 08:00 a.m. (Total 1mg)
2994160|NCT02602028|Experimental|twice daily dosage schema of colchicine|Twice daily dosage group received the treatment twice daily at 08:00 a.m. and 08:00 p.m. (Total 1mg)
2994161|NCT02602002|Experimental|Active|Remifentanil 0.1 ug/kg/min to 0.10 ug/kg/min
2994162|NCT02602002|Placebo Comparator|Placebo|Saline (0.9%)
2994163|NCT02601989|Experimental|Tadalafil|Per oral intake of tadalafil 20 mg o.d. for six weeks
2994164|NCT02601989|Placebo Comparator|Placebo|Per oral intake of placebo
2994165|NCT02601976|Experimental|PegInterferon alfa-2a and Ribavirin|PegInterferon alfa-2a subcutaneously once weekly Ribavirin administered orally according to the body weight
2994166|NCT02601963|Experimental|FMX-103 1.5%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
2994167|NCT02601963|Experimental|FMX-103 3%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
2994168|NCT02601963|Placebo Comparator|Vehicle foam (0%)|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
2994169|NCT02601950|Experimental|Open-label Tazemetostat|All Cohorts [Cohort 1 - MRT, RTK, ATRT, or tumors with rhabdoid features, including small cell carcinoma of the ovary hypercalcemic type [SCCOHT], also known as malignant rhaboid tumor of the ovary [MRTO] Cohort 2 - Relapsed/refractory synovial sarcoma (SS18-SSX rea), Cohort 3 - Other INI1-negative tumors or any solid tumor with an EZH2 GOF mutation, Cohort 4 - Renal medullary carcinoma, Cohort 5 - Epithelioid sarcoma, Cohort 6 - Epithelioid sarcoma undergoing mandatory tumor biopsy and Cohort 7 - Poorly differentiated chordoma (or other chordoma with Sponsor approval)] will receive 800 mg oral Tazemetostat BID x 28 days
2994170|NCT02601937|Experimental|Open-label Tazemetostat|Level 1 (Starting Dose) Oral Tazemetostat 240 mg/m^2 BID; Level 2 Oral Tazemetostat 300 mg/m^2 BID; Level 3 Oral Tazemetostat 400 mg/m^2 BID; Level 4 Oral Tazemetostat 520 mg/m^2 BID; Level 5 Oral Tazemetostat 700 mg/m^2 BID; Level 6 Oral Tazemetostat 900 mg/m^2 BID; Level 7 Oral Tazemetostat 1200 mg/m^2 BID
2994171|NCT02601924|Active Comparator|Topical Pressure Massage Block injection|Topical pressure massage at site of alveolar nerve block injection.
2994172|NCT02601924|Active Comparator|Topical Anesthetic Gel Block injection|Topical anesthetic gel (20% Benzocain) at site of inferior alveolar nerve block injection.
2994173|NCT02601924|Active Comparator|Topical Pressure Massage Infiltration|Topical pressure massage at site of maxillary anterior infiltration
2994174|NCT02601924|Active Comparator|Topical Anesthetic Gel Infiltration|Topical anesthetic gel (20% Benzocain) at site of maxillary anterior infiltration
2994175|NCT02601911|Active Comparator|Ketorolac tromethanine|This group will receive a caplet including10 mg Ketorolac tromethamine 45 minutes before applying infra alveolar nerve block injection.
2994176|NCT02601911|Active Comparator|Acetaminophen|This group receive a caplet including10 mg Ketorolac tromethamine/ 1000 mg Acetaminophen, before applying the injection.
2994177|NCT02601911|Placebo Comparator|Placebo|This group receive a caplet including placebo, before applying the injection.
2994178|NCT02601898|Experimental|Lipoic acid|vaginal capsules of lipoic acid (10 mg, one capsule per day)
2994179|NCT02601898|Active Comparator|Progesterone|Vaginal soft gel of progesterone (200 mg, two capsules per day)
2994180|NCT02601885|Experimental|Group 2|Participants will receive multiple doses of ABT-555 or placebo
2994181|NCT02601885|Experimental|Group 3|Participants will receive multiple doses of ABT-555 or placebo
2994182|NCT02601885|Experimental|Group 1|Participants will receive multiple doses of ABT-555 or placebo
2994183|NCT02601859|Experimental|Phase 3|Administration of Lithium to 20 individuals with MCI (non-randomised) for 9 weeks. Lithium dose escalates from 100mg to 200mg to 400mg, then a 3 week wash out period, total study duration 12 weeks. Blood samples taken at regular intervals throughout trial and analysed for GSK-3 enzyme activity in blood.
2994184|NCT02601833|Experimental|Silver Diamine Fluoride|This arm will receive Silver Diamine Fluoride applied to their carious lesion, in lieu of restoration placement, with the goal of arresting caries.
2994185|NCT02601833|Active Comparator|Conventional Caries Management|Restorative dental care according to American Academy of Pediatric Dentistry guidelines. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
2994186|NCT02601807|Active Comparator|Active|Subjects given active ActiPatch device before or after crossover (randomised)
2994187|NCT02601807|Placebo Comparator|Placebo|Subjects given placebo ActiPatch device before or after crossover (randomised)
2994188|NCT02601794|Experimental|App-based Mindfulness Training|12 week mindfulness training delivered remotely through mobile app
2994189|NCT02601794|No Intervention|Waitlist Control|No intervention provided during study period. 12 week mindfulness training will be delivered through mobile app once all study assessments have been completed
2994190|NCT02601781|Experimental|Primary PCI (PPCI) with BVS|Primary percutaneous coronary intervention (PPCI) with bioresorbable vascular scaffold (BVS) implantation in STEMI patients. Following the arterial route, PPCI (performed according to the international guidelines) aims to recanalize an occluded coronary artery that is then maintained patent inserting an endovascular permanent prosthesis (stent). In this study we aim to assess the results following the use of a fully bioresorbable prosthesis (BVS) during PPCI using a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation). BVS has the theoretical advantage, as compared with a permanent stent, to disappear within 24-36 months from implantation restoring the native pristine vessel state.
2994191|NCT02601768||ASD II|Transcatheter closure of ASD II
2994192|NCT02601755|Experimental|iCanCope app and website|Intervention: Behavioral: iCanCope app and website
2994193|NCT02601755|Active Comparator|Attention control group|Intervention: Behavioral: Attention control group
2994194|NCT02601742|Active Comparator|Zinc group|Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
2994195|NCT02601742|Placebo Comparator|Placebo group|Pedialyte oral electrolyte solution, 330 ml per day for 7 days
2994196|NCT02601729||RT-CGM population|Prospective data collection during standardized clinical follow-up and from filled out questionnaires.
2994197|NCT02601729||Pump only population|Retrospective data collection on demographic and clinical characteristics.
2994198|NCT02601716|Experimental|Group 1|"Group 1 subjects (n=15) will receive 4 doses of PfSPZ Vaccine (4.5 x 10^5 PfSPZ/dose) every 2 days, followed by a single, boosting dose (same dose as before) given 16 weeks later, for a total PfSPZ dose = 22.5 x 10^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by heterologous CHMI (7G8) Pf parasites at 28 and 40 weeks after the first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 4 priming immunizations and the boost scheduled for Group 1. Participants not protected after the first CHMI will be invited to receive a booster vaccination (4.5 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week 40)."
2994199|NCT02601716|Experimental|Group 2|"Subjects (n=15) will receive 3 doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) every 8 weeks, total PfSPZ dose = 27 x 10^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by heterologous CHMI (7G8) Pf parasites at 28 and 40 weeks after first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 2. Participants not protected after the first CHMI will be invited to receive a booster vaccination (9.0 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week 40)."
2994200|NCT02601716|Experimental|Group 3|"Group 3 subjects (n=15) will receive 3 doses of PfSPZ Vaccine (18 x 10^5 PfSPZ/dose) every 8 weeks for a total PfSPZ dose of 54 x 10^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by CHMI with heterologous (7G8, NF135.C10) Pf parasites at 40 and 66 weeks after the first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 3. All participants will be invited to receive a booster vaccination (18 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week66)."
2994284|NCT02601222|Experimental|Runzao zhiyang capsule|Runzao zhiyang capsule: 4 pills each time, 3 times a day, oral， Urea Cream (topical application, apply to the affected area and gently rub) 2 times a day.
2994471|NCT02599922|Experimental|Middle dose|rAAV2tYF-PR1/7-hCNGB3 will be administered at the middle of three planned dose levels.
2994201|NCT02601716|Experimental|Group 4|"Subjects (n=15) will receive a single, priming dose of PfSPZ Vaccine (27 x 10^5 PfSPZ/dose), followed by 2 additional immunizations (9.0 x 10^5 PfSPZ per dose) every 8 weeks, total PfSPZ dose = 45 x 10^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by CHMI with heterologous 7G8 and NF135.C10 Pf parasites at 40 and 66 weeks, respectively, along with 8 infectivity controls at each CHMI. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 4. All participants will be invited to receive a booster vaccination (9.0x10^5 PfSPZ) 21 days prior to the second CHMI.~Subjects will be followed for 56 days beyond the final CHMI at (post-immunization week 66)."
2994202|NCT02601716|Other|Infectivity Controls, CHMI (7G8)|Infectivity controls (n=24) will not receive any PfSPZ Vaccine. They will serve as infectivity controls for CHMI for all groups. 8 infectivity controls will undergo CHMI with each of two CHMIs (at 28 and 40) for Groups 1 and 2, and 8 infectivity controls will undergo CHMI with the 40 week CHMI for Groups 3 and 4. All CHMI will be conducted by exposure to the bites of 5 mosquitoes infected with heterologous (7G8) Pf parasites. Subjects will be followed for 56 days beyond the last CHMI at week 40 at the UMB site.
2994203|NCT02601716|Other|Infectivity Controls, CHMI (NF135.C10)|Infectivity controls (n=8) will not receive any PfSPZ Vaccine. They will serve as infectivity controls for the second CHMI at week 66 for Groups 3 and 4. CHMI will be conducted by exposure to the bites of 3-5 mosquitoes infected with heterologous (NF135.C10) Pf parasites. Subjects will be followed for 56 days beyond the last CHMI at week 66 at the NMRC site.
2994204|NCT02601703|Experimental|Tacrolimus Ointment 0.1%|
2994205|NCT02601703|Active Comparator|Protopic® ointment, 0.1%|
2994206|NCT02601703|Placebo Comparator|Placebo of Tacrolimus Ointment|
2994207|NCT02601690||Blood Sampling|Participants allergic to one or more of cat, rye grass, ragweed or house dust mite.
2994208|NCT02601677|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
2994209|NCT02601677|Active Comparator|Standard Control|Fluoxetine
2994210|NCT02601664|Active Comparator|Combined Intervention|Combined intervention: pre-PCI intracoronary vasodilator and glycoprotein IIb/IIIa inhibitor administration, use of an EPD if technically feasible, and complete coverage of the lipid core plaque, if technically feasible
2994211|NCT02601664|Active Comparator|Conventional PCI|Conventional PCI
2994212|NCT02601651|Experimental|Lidocaine|Lignocaine group (Group A) will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.
2994213|NCT02601651|Placebo Comparator|Normal saline|Normal saline group (Group B) will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
2994214|NCT02601638|Experimental|Arm 1|"Demographics and Health History Questionnaire (5-10 minutes to complete)~Pre-Class Laryngectomy Survey (5-10 minutes to complete)~Attend a preoperative counseling session with a speech pathologist. It will take 30-60 minutes~Attend the Total Laryngectomy Preoperative Education Class. Participants will attend within 1-2 weeks of providing written consent and prior to their scheduled surgery. The preoperative education class will take one hour.~Complete the Day of Hospital Discharge Laryngectomy Survey at the time of discharge from the hospital (5-10 minutes to complete)~Perform the day of discharge practicum assessing the minimal competency skills for laryngectomy care prior to discharge from the hospital.~Complete the Laryngectomy Education Study Exit survey. Participants will perform an exit survey at the first clinic appointment after 30 days after hospital discharge (15-30 minutes to complete)"
2994215|NCT02601625|Experimental|Anifrolumab 300 mg SC injections|300 mg single dose anifrolumab delivered as 2 separate 1 mL SC injections administered serially
2994216|NCT02601625|Experimental|Anifrolumab 300 mg IV infusion|300 mg single dose anifrolumab delivered as an IV infusion over 30 minutes
2994217|NCT02601625|Experimental|Anifrolumab 600 mg SC infusion|600 mg single dose anifrolumab or placebo delivered as 4 mL SC by infusion pump
2994218|NCT02601625|Placebo Comparator|Placebo 300 mg SC injections|300 mg single dose placebo delivered as 2 separate 1 mL SC injections administered serially
2994219|NCT02601625|Placebo Comparator|Placebo 300 mg IV infusion|300 mg single dose placebo delivered as an IV infusion over 30 minutes
2994220|NCT02601625|Placebo Comparator|Placebo 600mg SC infusion|600 mg single dose placebo delivered as 4 mL SC by infusion pump
2994221|NCT02601612|Experimental|Group 1: D46cpΔM2-2 Vaccine|RSV-seropositive children will receive a single dose of 10^6 PFU D46cpΔM2-2 vaccine at study entry (day 0).
2994222|NCT02601612|Placebo Comparator|Group 1: Placebo|RSV-seropositive children will receive a single dose of placebo at study entry (day 0).
2994223|NCT02601612|Experimental|Group 2: D46cpΔM2-2 Vaccine|RSV-seronegative infants and children will receive a single dose of 10^5 PFU D46cpΔM2-2 vaccine at study entry (day 0).
2994224|NCT02601612|Placebo Comparator|Group 2: Placebo|RSV-seronegative infants and children will receive a single dose of placebo at study entry (day 0).
2994225|NCT02601599|Experimental|Intervention|Motivational interviewing The medical student will deliver a 15 minute consultation with the patient. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, educate the patient about effective behavioral and pharmacological cessation strategies, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy. Patients who elect to receive this consult with have a coloured sticker placed by the medical student on the medical chart requesting a consultation.
2994226|NCT02601599|No Intervention|Usual care|This group will not receive student contact, but may be counselled by the smoking cessation officer or other Connolly staff as per normal procedures.
2994227|NCT02601586|Experimental|PR oxycodone|"A titration phase of two weeks, in three steps:~Level 1 (from D1 to D5):~Oxycodone : 10 mg PR/day bid (5 mg PR/5 mg PR)~Levodopa placebo 100 mg/day bid (50 mg/50 mg)~Level 2 (from D6 to D10):~Oxycodone : 20 mg PR/day tid (10 mg/0 mg/10 mg)~Levodopa placebo: 150 mg/day tid (50 mg/50 mg/50 mg)~Level 3 (from D11to D15):~Oxycodone: 40 mg PR/day tid (20 mg/0 mg/20 mg)~Levodopa placebo: 200 mg/day tid (100 mg/50 mg/50 mg)~A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).~A withdrawal period:"
2994285|NCT02601222|Placebo Comparator|Runzaozhiyang capsule agent simulation|Runzaozhiyang capsule agent simulation:4 pills each time, 3 times a day, oral, Urea Cream (topical application, apply to the affected area and gently rub) 2 times a day.
3020658|NCT02424877|Experimental|SandRA|cell phone monitoring
2994228|NCT02601586|Active Comparator|levodopa|"A titration phase of two weeks, in three steps:~Level 1 (from D1 to D5):~Oxycodone placebo : 10 mg PR/day bid (5 mg PR/5 mg PR)~Levodopa 100 mg/day bid (50 mg/50 mg)~Level 2 (from D6 to D10):~Oxycodone placebo: 20 mg PR/day tid (10 mg/0 mg/10 mg)~Levodopa : 150 mg/day tid (50 mg/50 mg/50 mg)~Level 3 (from D11to D15):~Oxycodone placebo: 40 mg PR/day tid (20 mg/0 mg/20 mg)~Levodopa : 200 mg/day tid (100 mg/50 mg/50 mg)~A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).~A withdrawal period:"
2994229|NCT02601586|Placebo Comparator|Placebo|"A titration phase of two weeks, in three steps:~Level 1 (from D1 to D5):~Oxycodone placebo : 10 mg PR/day bid (5 mg PR/5 mg PR)~Levodopa placebo 100 mg/day bid (50 mg/50 mg)~Level 2 (from D6 to D10):~Oxycodone placebo: 20 mg PR/day tid (10 mg/0 mg/10 mg)~Levodopa placebo: 150 mg/day tid (50 mg/50 mg/50 mg)~Level 3 (from D11to D15):~Oxycodone placebo: 40 mg PR/day tid (20 mg/0 mg/20 mg)~Levodopa placebo: 200 mg/day tid (100 mg/50 mg/50 mg)~A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).~A withdrawal period:"
2994230|NCT02601573|Experimental|Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks|TN HCV GT3 participants will take 1 fixed-dose combination (FDC) tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg once-daily (q.d.) with RBV (200 mg capsules; weight-based dosing) twice-daily (b.i.d.) for 8 weeks.
2994231|NCT02601573|Experimental|Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks|TN HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.
2994232|NCT02601573|Experimental|Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.
2994233|NCT02601573|Experimental|Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. with RBV (200 mg capsules; weight-based dosing) b.i.d. for 12 weeks.
2994234|NCT02601573|Experimental|Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 16 weeks.
2994235|NCT02601560|Experimental|MEDI6012 24 mg IV|Participants received a single IV dose of 24 mg MEDI6012 on Day 1.
2994236|NCT02601560|Experimental|MEDI6012 80 mg IV|Participants received a single IV dose of 80 mg MEDI6012 on Day 1.
2994237|NCT02601560|Experimental|MEDI6012 240 mg IV|Participants received a single IV dose of 240 mg MEDI6012 on Day 1.
2994238|NCT02601560|Experimental|MEDI6012 800 mg IV|Participants received a single IV dose of 800 mg MEDI6012 on Day 1.
2994239|NCT02601560|Experimental|MEDI6012 80 mg SC|Participants received a single SC dose of 80 mg MEDI6012 on Day 1.
2994240|NCT02601560|Placebo Comparator|Placebo Intravenous (IV)|Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
2994241|NCT02601560|Experimental|MEDI6012 600 mg SC|Participants received a single SC dose of 600 mg MEDI6012 on Day 1.
2994242|NCT02601560|Placebo Comparator|Placebo Subcutaneous (SC)|Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.
2994243|NCT02601547|Experimental|intervention|"PET-FDG brain imaging and NPT should be performed at T0 (within the 15 days before chemotherapy), at Tf (within 1 month after chemotherapy termination), T+12 (Tf+12 months: within the first month after one year of achievement of chemotherapy). Several PET parameters should be calculated: minimal Standard Uptake Value (SUV), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.~NPT scores (3 values) should be correlated with the five better values on PET-FDG.~Each patient will be monitored along a time period of 18 months.~Duration of the study: one year to include the 15 patients with all the exams; 18 months follow-up for each; total of 30 months."
2994244|NCT02601534|Experimental|Zero-time Exercise (PA) group|"The intervention arm (PA group) aims to improve family communication and well-being, reduce sedentary behavior and increase physical activity. The programme includes a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months after the first session as well as biweekly/monthly mobile messages.~The holistic health session is not a part of the cRCT, it aims to collect one-year feedback from participants and provides additional health information to improve dietary habits."
2994245|NCT02601534|Placebo Comparator|Healthy Eating (HE) group|"The control arm (HE group) aims to improve family communication and well-being and enhance healthy eating habits. Participants are required to engage their family members in their activities. The programme includes a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months after the first session as well as biweekly/monthly mobile messages.~The holistic health session is not a part of the cRCT, it aims to collect one-year feedback from participants and provides additional health information to improve physical activity habit."
2994246|NCT02601521|Experimental|Internal coaching program|The internal coaching program uses a chronic disease management strategy to treat tobacco use and dependence. The program provides evidence-based treatment consisting of up to 12 months of services from a tobacco coach based at Partners HealthCare. The tobacco coach offers (1) repeated smoking cessation counseling delivered by proactive telephone calls, emails, and interactive voice response [automated phone calls] and (2) facilitated access to a new Partners HealthCare Inc., health insurance benefit that provides access to all FDA-approved smoking cessation medications without copay or prior approval.
2994247|NCT02601521|Active Comparator|External coaching program|The external coaching program consists of referral to the Massachusetts Tobacco Control Program's Smokers Helpline, a free program offering multi-session proactive telephone counseling for 3 months to individuals who are ready to quit smoking. Individuals in this arm also receive information about Partners HealthCare, Inc.'s new health insurance benefit that provides access to all FDA-approved smoking cessation medications without copay or prior approval.
2994248|NCT02601508|Active Comparator|Modarate Blockade Group|Neuromuscular blocking agent, cis-atracurium will be administered after skin incision and reversal agents, pyridostigmine & glycopyrrolate will be given for the recovery.
2994249|NCT02601508|Experimental|Deep Blockade Group|Neuromuscular blocking agent, rocuronium will be administered after skin incision and reversal agent, Sugammadex will be given for the recovery.
2994286|NCT02601209|Experimental|Arm I (sapanisertib)|Patients receive sapanisertib as in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3020659|NCT02424877|No Intervention|Control|conventional monitoring
2994250|NCT02601495||Women in a court diversion program|Women enrolled in the court diversion program in Tulsa, Oklahoma called Women in Recovery who report symptoms related to anxiety or depressive symptoms (Patient Health Questionnaire score ≥ 10 and/or Overall Anxiety Severity and Impairment Scale ≥ 8), problematic eating behavior(Eating Disorder Screen score ≥ 2), problems related to substance use (Drug Abuse Screening Test score > 2), or post traumatic stress disorder symptoms (PTSD Checklist score ≥ 30).
2994251|NCT02601482|Experimental|Control (CON)|No exercise intervention.
2994252|NCT02601482|Experimental|Normal Interval Walking (IW-60).|Sixty minutes with repeated cycles of 3 minutes of fast and 3 minutes of slow walking on a treadmill
2994253|NCT02601482|Experimental|Time-reduced Interval Walking (IW-45)|Forty-five minutes with repeated cycles of 3 minutes of fast and 1.5 minutes of slow walking on a treadmill
2994254|NCT02601469|Experimental|DSXS1503|administered twice daily for 28 days in patients with moderate to severe plaque psoriasis.
2994255|NCT02601443|Experimental|Cervical Pessary|"Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.~Cervical pessary has been tried as a simple, non-invasive alternative that might replace the above invasive cervical stitch operation to prevent preterm birth."
2994256|NCT02601443|No Intervention|Routine care (watch and wait)|
2994257|NCT02601430|Experimental|BOLD-MRI|Blood Oxygen Level Dependent (BOLD)-MRI assessment of limb perfusion before and after standard of care endovascular therapy.
2994258|NCT02601417|No Intervention|Control|Group which considers both blood culture and bile culture for antibiotics choice
2994259|NCT02601417|Experimental|Trial|Group which considers only blood culture and ignore bile culture for antibiotics choice. Patients in this arm would undergo bile culture but ignore the result when choosing antibiotics
2994260|NCT02601404||Bioresorbable Scaffold|Patients receiving percutaneous coronary intervention (PCI) for coronary artery disease using Absorb™(Abbott Vascular)
2994261|NCT02601391|Other|STEPPS within forensic services.|"Forensic inpatients attend the STEPPS-HI group. Consent will be obtained. Pre and post group psychometric questionnaires will be completed as well as each service user attending a short semi-structured interview following the conclusion of the group .~Primary nurse will fill in pre and post group questionnaires. Facilitators will complete short feedback forms each session and attend a focus group upon completion.~Psychology Assistants/Interns will collect records of self harm and violence/aggressive incidents for each service user as well as records of nursing observation level and leave status taken."
2994262|NCT02601378|Experimental|LXS196 as a single agent|About 68 patients will be enrolled in dose escalation and expansion
2994263|NCT02601378|Experimental|LXS196 in combination with HDM201|about 44 patients to be enrolled in dose escalation and expansion
2994264|NCT02601365|Experimental|Cohort 1|25mcg/m2 daily of iGM-CSF for 7 days
2994265|NCT02601365|Experimental|Cohort 2|50mcg/m2 daily of iGM-CSF for 7 days
2994266|NCT02601365|Experimental|Cohort 3|125mcg/m2 daily of iGM-CSF for 7 days
2994267|NCT02601365|Experimental|Cohort 4|250mcg/m2 daily (divided BID) of iGM-CSF for 7 days
2994268|NCT02601339||GM-IVH|Premature infants who developed germinal matrix-intraventricular hemorrhage. FDNIRS-DCS measures will be performed up to once a day if clinically feasible.
2994269|NCT02601339||Posthemorrhagic hydrocephalus (PHH)|"Premature infants with complications of hydrocephalus secondary to intraventricular hemorrhage and have the potential to receive endoscopic third ventriculostomy (ETV) with choroid plexus cauterization (CPC) and/or ventriculoperitoneal (VP) shunting for clinical treatment.~FDNIRS-DCS measures will be performed up to once a day if clinically feasible. Additional FDNIRS-DCS measures will be performed on the day of hydrocephalus treatment to monitor the treatment response if clinically feasible. These additional measures are limited to up to four times a day."
2994270|NCT02601339||Healthy Control (HC)|Premature infants without diagnosed brain injuries. FDNIRS-DCS measures will be performed up to once a day if clinically feasible.
2994271|NCT02601339||Ventriculomegaly Control (VC)|"Infants who have symptomatic hydrocephalus of any etiology except post-hemorrhagic etiology and have the potential to receive ETV/CPC and/or VP shunting for clinical treatment.~FDNIRS-DCS measures will be performed up to once a day if clinically feasible. Additional FDNIRS-DCS measures will be performed on the day of hydrocephalus treatment to monitor the treatment response if clinically feasible. These additional measures are limited to up to four times a day."
2994272|NCT02601326|Active Comparator|Laparoscopic ventral mesh Rectopexy|Fixation of the rectum to the sacrum using laparoscopy and mesh
2994273|NCT02601326|Active Comparator|delorme's procedure|excision of excess rectal mucosa under spinal anesthesia then plication of the rectal muscles with vicryl 2/0 sutures
2994274|NCT02601313|Experimental|KTE-C19|Experimental: Single Arm. A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion CAR transduced autologous T cells administered intravenously.
2994275|NCT02601300|Experimental|GED-0301 160 mg once daily (QD)|Patients will receive oral GED-0301 160 mg once daily (QD)for duration of 52 week treatment.
2994276|NCT02601287|Experimental|BOTOX® 100U|Botulinum Toxin Type A 100U into the detrusor muscle on Day 1 in patients with Overactive Bladder
2994277|NCT02601287|Experimental|BOTOX® 200U|Botulinum Toxin Type A 200U into the detrusor muscle on Day 1 in patients with Neurogenic Detrusor Overactivity
2994278|NCT02601274|Experimental|Single Group Assignment|Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 7 dose cohorts,including120mg/160mg/200mg/220mg/300mg/400mg/500mg, QD in the dose escalation stage .
2994279|NCT02601261||Patients with some access to internet during stay|
2994280|NCT02601261||Patients without access to internet during stay|
2994281|NCT02601248|Experimental|Theliatinib|Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 5 dose cohorts,including120mg/160mg/200mg/220mg/300mg, QD in the dose escalation stage .
2994282|NCT02601235|Experimental|Naridrin|Naridrin: 2 drops in each nostril once daily as prescription
2994283|NCT02601235|Active Comparator|0.05 % Oxymetazoline Hydrochloride|2 pumps in each nostril every 12 hours
2994472|NCT02599922|Experimental|Higher dose|rAAV2tYF-PR1/7-hCNGB3 will be administered at the highest of three planned dose levels.
2994287|NCT02601209|Experimental|Arm II (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm I.
2994288|NCT02601196|Other|Ulipristal acetate treatment|Women who receive UPA treatment before another IVF cycle.
2994289|NCT02601183||Ischemic stroke|The patients in the group are diagnosed as ischemic stroke by CT or MRA examination within 8h following stroke attack.
2994290|NCT02601183||Hemorrhagic stroke|The patients in the group are diagnosed as hemorrhagic stroke by CT or MRA examination within 8h following stroke attack.
2994291|NCT02601170|Experimental|PRP Group|single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)
2994292|NCT02601170|Active Comparator|HA Group|five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).
2994293|NCT02601157|Experimental|Orsiro SES/3-months DAPT|As an one of experimental arms in 2x2 factorial design, patients allocated to this group will be implanted with Orisro sirolimus-eluting stents for their coronary lesions, and then will be followed with 3-month dual antiplatelet therapy (DAPT) schedule.
2994294|NCT02601157|Active Comparator|Orsiro SES/1-year DAPT|As an one of comparator arms in 2x2 factorial design, patients allocated to this group will be implanted with Orisro sirolimus-eluting stents for their coronary lesions, and then will be followed with 1-year dual antiplatelet therapy (DAPT) schedule.
2994295|NCT02601157|Experimental|CX-ISAR/3-months DAPT|As an one of experimental arms in 2x2 factorial design, patients allocated to this group will be implanted with Coroflex ISAR (CX-ISAR) sirolimus-eluting stents for their coronary lesions, and then will be followed with 3-month dual antiplatelet therapy (DAPT) schedule.
2994296|NCT02601157|Active Comparator|CX-ISAR/1-year DAPT|As an one of comparator arms in 2x2 factorial design, patients allocated to this group will be implanted with Coroflex ISAR (CX-ISAR) sirolimus-eluting stents for their coronary lesions, and then will be followed with 1-year dual antiplatelet therapy (DAPT) schedule.
2994297|NCT02601144|Experimental|VFS|variable frequency deep brain stimulation (VFS)
2994298|NCT02601144|Active Comparator|HFS|high frequency deep brain stimulation (HFS)
2994299|NCT02601144|Active Comparator|LFS|low frequency deep brain stimulation (LFS)
2994300|NCT02601144|No Intervention|DBS off|deep brain stimulation off
2994301|NCT02601131||AML, ALL and MDS|Patients receiving intensive chemotherapy with diagnoses of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) or myelodysplastic syndromes (MDS).
2994302|NCT02601131||Autologous stem cell transplantation|Patients undergoing autologous stem cell transplantation
2994303|NCT02601131||Allogeneic stem cell transplantation|Patients undergoing allogeneic stem cell transplantation including both myeloablative conditioning (MAC) and the reduced-intensity conditioning (RIC)
2994304|NCT02601131||Platelet transfusion prophylaxis|Patients receiving platelet transfusion prophylaxis before the intervention, such as insertion of a central venous catheter or lumbar puncture
2994305|NCT02601131||Control|Patients with AML, ALL or MDS that have low PLC (10-20 billion/L) and is not relevant for platelet transfusion. Samples taken in the same manner as in the other groups. Control is needed to rule out other causes of variation of the PLC than the platelet transfusion and thereby strengthen the causality between a given transfusion and increased PLC.
2994306|NCT02601118|Experimental|training group|41 training students were pre-tested before education with Micro Expression Training Tool (METT) and Subtle Expression Training Tool (SETT) at baseline and then, took second METT and SETT tests after a 1-hour class about interpreting micro and subtle expressions.
2994307|NCT02601118|No Intervention|control group|41 control students were pre-tested before education with METT and SETT at baseline and then, took the second tests without attend the training class.
2994308|NCT02601105|Placebo Comparator|Placebo Vehicle Cream|Lipoderm® base served as the placebo vehicle control to be applied every night to demarcated 10 x 10 cm area containing stretch marks on randomly assigned side of abdomen for 12 weeks.
2994309|NCT02601105|Active Comparator|Centella Asiatica|An alcoholic extract of CA (verified by HPLC) mixed into a Lipoderm® base served as the treatment cream to be applied every night to demarcated 10 x 10 cm area containing stretch marks on the opposite side of the abdomen for 12 weeks.
2994310|NCT02601092|Experimental|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.~No drugs or devices will be used."
2994311|NCT02601092|Active Comparator|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.~No drugs or devices will be used."
2994312|NCT02601079|Active Comparator|Conventional biopsy|"4 out of 8 biopsies taken with a conventional biopsy forceps from the tumor tissue in the distal esophagus and cardia. The biopsies will be taken in random order blinded for the person performing the examination. 1 additional biopsy will be taken from the tumor tissue in order to be evaluated for appropriateness of further genetic analysis. Both type of biopsies will be taken from the same patient. In total 10 biopsies per patient."
2994313|NCT02601079|Active Comparator|Endodrill biopsy|"4 out of 8 biopsies taken with the Endodrill instrument from the tumor tissue in the distal esophagus and cardia. The biopsies will be taken in random order blinded for the person performing the examination. 1 additional biopsy will be taken from the tumor tissue in order to be evaluated for appropriateness of further genetic analysis. Both type of biopsies will be taken from the same patient. In total 10 biopsies per patient."
2994314|NCT02601066|Experimental|EPS and ECG holter monitor|Electrophysiological study (EPS) and ECG holter monitor implantation
2994315|NCT02601053|Active Comparator|Dull (boring) movie|Participants will be exposed to a dull (i.e. boring) movie followed by a scary (i.e. horrifying) movie.
2994316|NCT02601053|Experimental|Scary (horrifying) movie|Participants will be exposed to a scary (i.e. horrifying) movie followed by a to a dull (i.e. boring) movie.
2994317|NCT02601040|Experimental|Attenuated Hepatitis A Vaccine, H2 Strain|Health subjects received attenuated Hepatitis A vaccine intramuscularly in the deltoid region.
2994318|NCT02601040|Experimental|Inactivated Hepatitis A Vaccine, Lu8 Strain|Health subjects received inactivated Hepatitis A vaccine intramuscularly in the deltoid region.
2994319|NCT02601040|Placebo Comparator|Group A Meningococcal Polysaccharide vaccine|Health subjects received Group A Meningococcal Polysaccharide vaccine intramuscularly in the deltoid region.
2994320|NCT02601027|Placebo Comparator|Placebo|sham TAP catheter with saline infusion
2994321|NCT02601027|Experimental|TAP catheter|infusion of 0.125% bupivacaine through TAP catheter
2994322|NCT02601014|Experimental|Treatment (nivolumab and ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 60 minutes every 2 weeks for 36 weeks in the absence of disease progression or unacceptable toxicity.
2994323|NCT02601001|Placebo Comparator|Treatment group C|Placebo
2994324|NCT02601001|Active Comparator|Treatment group A|25 mg and 37.5 mg
2994325|NCT02601001|Active Comparator|Treatment group B|25 mg and 50 mg
2994326|NCT02600988|No Intervention|Group 1: Control|Control group is composed by the first 50 patients included in the study. Those patients will not receive the treatment. Evaluations and follow-up will be the same as in the other groups.
2994327|NCT02600988|Experimental|Group 2: 1000IU/day of Vitamine D|It is composed by the following 50 patients joining the study. They will take 1000 IU of vitamin D once a day.
2994328|NCT02600988|Experimental|Group 3: 5000IU/day of Vitamine D|It is composed by the last 50 patients joining the study. They will take 5000 IU of vitamin D once a day.
2994329|NCT02600975|Active Comparator|Group 1|10µg of R21 with AS01B on days 0, 28, and 56.
2994330|NCT02600975|Active Comparator|Group 2|50µg of R21 with AS01B on days 0, 28, and 56.
2994331|NCT02600962||STEMI|Patients discharged with STEMI
2994332|NCT02600962||NSTEMI|Patients discharged with NSTEMI
2994333|NCT02600949|Experimental|Cohort A: Peptide Vaccine|"Participants receive at least one line of chemotherapy prior to their first vaccination, as per treating physician.~Vaccine given on day 1, week 0, which will be at least 4 weeks after the end of their prior therapy.~Vaccine given in a total volume of up to 1.0ml/shot consisting of a peptide cocktail injected subcutaneously into two to three separate sites of the subject's thighs for a total of up to 1.0ml per vaccination per cocktail. If subject is prescribed two cocktails then up to four to six sites on the subject's thighs may be used, provided that each vaccine cocktail is administered into different thighs.~Participant called 2 times by study staff in the 6 months after last dose of vaccine and asked about any side effects experienced since the end-of-study visit."
2994334|NCT02600949|Experimental|Cohort B: Peptide Vaccine + Pembrolizumab|"Vaccine administered first followed by Pembrolizumab therapy.~Vaccine given in a total volume of up to 1.0ml/shot consisting of a peptide cocktail injected subcutaneously into two to three separate sites of the subject's thighs for a total of up to 1.0ml per vaccination per cocktail. If subject is prescribed two cocktails then up to four to six sites on the subject's thighs may be used, provided that each vaccine cocktail is administered into different thighs.~Pembrolizumab administered as a fixed dose of 200 mg infusion every three weeks over approximately 30 minutes until week 51.~Participant called 2 times by study staff in the 6 months after last dose of vaccine and asked about any side effects experienced since the end-of-study visit."
2994335|NCT02600936||Registry|A retrospective and prospectively maintained registry of patients who have undergone or will undergo vein stent placement for proximal venous outflow obstruction
2994336|NCT02600923|Experimental|Palbociclib + Letrozole|palbociclib and letrozole combination
2994337|NCT02600910||Manual Wheelchair User Cohort|"Physical Exam. Screening exam performed by a licensed physical therapist to confirm inclusion/exclusion criteria.~Assessment of Shoulder Function in Everyday Life. Shoulder motion & hand loading data will be collected over a few days, twice per yr for 3-5 yrs in home & community environment.~Magnetic Resonance Imaging (MRI) of Shoulders. Imaging will use standard clinical protocol once per yr for 3-5 yrs.~Shoulder Strength Testing. Once per yr for 3-5 yrs. Additional Variables. Updated demographic info will be collected yearly including but not limited to weight, chair type, health status, and job type."
2994338|NCT02600910||Matched Able-bodied Cohort|"Physical Exam. Screening exam performed by a licensed physical therapist to confirm inclusion/exclusion criteria.~Assessment of Shoulder Function in Everyday Life. Shoulder motion & hand loading data will be collected over a few days, twice per yr for 3-5 yrs in home & community environment.~Magnetic Resonance Imaging (MRI) of Shoulders. Imaging will use standard clinical protocol once per yr for 3-5 yrs.~Shoulder Strength Testing. Once per yr for 3-5 yrs. Additional Variables. Updated demographic info will be collected yearly including but not limited to weight, health status, and job type."
2994339|NCT02600897|Experimental|Dose-escalation Cohort: FL|Participants with R/R FL will receive 6 months of induction treatment with polatuzumab vedotin and lenalidomide at escalating doses to identify the recommended Phase 2 dose (RP2D) for polatuzumab vedotin and lenalidomide when combined with a fixed dose of obinutuzumab. Those who achieve CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 24-month maintenance regimen consisting of lenalidomide and obinutuzumab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).
2994340|NCT02600897|Experimental|Dose-escalation Cohort: DLBCL|Participants with R/R DLBCL will receive 6 months of induction treatment with fixed dose of polatuzumab vedotin and rituximab along with dose escalating lenalidomide. Lenalidomide will be administered at escalating doses to identify the recommended Phase 2 dose (RP2D) for lenalidomide. Those who achieve CR and PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 6-month consolidation regimen consisting of lenalidomide and rituximab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).
2994341|NCT02600897|Experimental|Expansion Cohort: FL|Participants with R/R FL who received induction treatment with polatuzumab vedotin and lenalidomide, in addition to obinutuzumab and achieved CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will receive a 24-months maintenance regimen consisting of lenalidomide and obinutuzumab for first 12 months followed by obinutuzumab treatment for next 12 months. Post-induction therapy will start 8 weeks after Cycle 6 Day 1.
2994693|NCT02598570|Experimental|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
2994342|NCT02600897|Experimental|Expansion Cohort: DLBCL|Participants with R/R DLBCL who received induction treatment with polatuzumab vedotin and lenalidomide in addition to rituximab and achieved CR or PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will receive a 6-month consolidation regimen consisting of lenalidomide and rituximab. Post-induction therapy will start 8 weeks after Cycle 6 Day 1.
2994343|NCT02600884|Experimental|Families Talking Together Plus (FTT+HPV)|Parents in the experimental group will attend a 1-hour intervention session, receive program materials to use with youth at home, and receive 2 booster phone calls post-intervention. Content of the experimental intervention includes parent-child sexual health communication and HPV vaccination navigation.
2994344|NCT02600884|Active Comparator|Brief motivational interviewing (BMI)|Parents in the brief motivational interviewing (BMI) group will attend a 1-hour intervention session, receive program materials to use with youth at home, and receive 2 booster phone calls post-intervention. Content of the control intervention includes obesity prevention strategies using motivational interviewing.
2994345|NCT02600871|Experimental|Provodine|"Provodine patients will have standard care including incision and drainage. The contents of 1 packet of Provodine applied with a Q-tip to the walls and floor of the abscess cavity. The contents of a 2nd packet will be applied to the surrounding skin within 5 cm around the incision.~Provodine patients will return within 48-72 hours for a follow-up visit, have the packing removed and the contents of the packet reapplied to the abscess cavity and surrounding skin.~Provodine patients will be instructed to cleanse the abscess at home by soaking in water once a day and patting the wound dry. They will wash their hands with soap and water, pat dry, and apply the contents of 1 packet of Provodine to dorsum and palmar aspects of hands and fingers and rub together for 1 minute. They will apply the contents of a 2nd packet to the abscess cavity, and a 3rd packet to the surrounding skin. They will be then rinse their hands with water, pat dry, and cover the wound with 4x4 gauze."
2994346|NCT02600871|Active Comparator|Standard Care|"Standard care patients will have standard care including incision and drainage.~Standard care patients will return within 48-72 hours for a follow-up visit and have the packing removed.~Standard care patients will be instructed to cleanse the abscess at home by soaking in water once a day and patting the wound dry. They will cover wound with 4x4 gauze and wash hands with soap and water for 1 minute."
2994347|NCT02600858|Experimental|"Training off medication"|"Participants will train on the upper limb feeding task before taking their first daily dose of standard dopamine medication for Parkinson's disease, i.e. while off dopamine replacement medication"
2994348|NCT02600858|Other|"Training on medication"|"Participants will train on the upper limb feeding task after taking their first daily dose of standard dopamine medication for Parkinson's disease, i.e. while on dopamine replacement medication"
2994349|NCT02600845|Experimental|ACCU-CHEK|All participants will utilize ACCU-CHEK Connect Diabetes Management System containing three primary components: ACCU-CHEK Aviva Connect Blood Glucose Monitoring System intended to be used for the quantitative measurement of glucose, ACCU-CHEK Connect Diabetes Management App indicated as an aid in the treatment of diabetes, and ACCU-CHEK Connect Online Diabetes Management System indicated for use by persons with diabetes or by healthcare professionals in the home or in healthcare facilities.
2994350|NCT02600832|Experimental|AABM Training|Immediately following screening, patients will be randomly assigned to receive 9 sessions of real AABM training (16 subjects each) taking place over three weeks.
2994351|NCT02600832|Sham Comparator|Sham Training|Immediately following screening, patients will be randomly assigned to receive 9 sessions of sham training (16 subjects each) taking place over three weeks.
2994352|NCT02600819|Experimental|E/C/F/TAF|Participants will switch their current antiretroviral regimen to E/C/F/TAF and receive treatment for 96 weeks.
2994353|NCT02600806|Other|Azithromycin/levofloxacin|Azithromycin or levofloxacin are given according to serum procalcitonin levels
2994354|NCT02600793|Experimental|Arm 1|Single dose IV ceftaroline will be administered
2994355|NCT02600780|Active Comparator|Allopurinol|Allopurinol 300mg Tablets once daily for 90 days
2994356|NCT02600780|Experimental|Febuxostat|Febuxostat 40mg Tablets once daily for 90 days
2994357|NCT02600767|Other|Artemether-Lumefantrine|Three days of standard treatment. This is a standard combination therapy for the treatment of P. falciparum malaria.
2994358|NCT02600754|Experimental|IT-PST|IT-PST refers to problem-solving therapy that will be tele-delivered by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More).
2994359|NCT02600754|Experimental|IT-SCM|IT-SCM refers to self-care management support that will be tele-delivered by trained lay advisers (TLAs) co-located in an aging-service agency (Meals on Wheels and More).
2994360|NCT02600754|No Intervention|Wait-list control (Usual Care or UC)|Participants who will serve as controls with telephone safety calls
2994361|NCT02600741||Study group 1|Caregivers randomized to this group will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period. Each patient will be paired with a caregiver and patients will continue their routine antipsychotic treatments prescribed by their treating physician.
2994362|NCT02600741||Study group 2|Caregivers randomized to this group will receive whatever caregiver support that is customarily available at the study site, if any. Each patient will be paired with a caregiver and patients will continue their routine antipsychotic treatments prescribed by their treating physician.
2994363|NCT02600728|Experimental|experimental group (EG)|The experimental training (ET) consisted of eight gait training sessions, twice a week, using the declarative memory cues strategy (DMCS).
2994364|NCT02600728|Active Comparator|control group (CG)|The control training (CT) consisted of a similar gait training without DMCS.
2994365|NCT02600715|Experimental|Active B&O suppository of belladonna|Receive the B&O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
2994366|NCT02600715|Placebo Comparator|Placebo suppository|Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
2994367|NCT02600702|No Intervention|usual care|quadricep exercise
2994368|NCT02600702|Experimental|Siriraj home base exercise|Knee exercise protocol for 12 position for 3 months with low-impact aerobic exercise
2994369|NCT02600702|Active Comparator|Modalities and exercise|Physical modalities for 6 weeks and Knee exercise protocol for 12 position for 3 months with low-impact aerobic exercise
2994370|NCT02600689|Experimental|Physical exercise training|Combined aerobic and resistance exercise for 30 or more minutes at least 3 times per week for 12 weeks using the Wii Fit Plus
2994371|NCT02600689|Active Comparator|Cognitive exercise training|Cognitive, brain-training, video gaming ~30 minutes per session, 3 times per week for 12 weeks
2994372|NCT02600676|Active Comparator|TENS, 10 weeks (active) 2 hours a day.|26 children.
2994373|NCT02600676|Placebo Comparator|TENS, 10 weeks (placebo) 2 hours a day.|26 children.
2994374|NCT02600663||acute back pain|
2994375|NCT02600650|Experimental|Experimental|Receive daily authentic Testosterone boosting supplement
2994376|NCT02600650|Placebo Comparator|Placebo|Receive daily placebo supplementation
2994377|NCT02600637|Experimental|MBSR|Mindfulness-based Stress Reduction program
2994378|NCT02600637|Active Comparator|Education|Educational group program
2994379|NCT02600624||Participants|Women who are in active labor and their newborn infants.
2994380|NCT02600611|Experimental|iclaprim|iclaprim 80 mg intravenous every 12 hours
2994381|NCT02600611|Active Comparator|vancomycin|vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
2994382|NCT02600598|Experimental|LEO 43204 Group A|Group A - Experimental LEO 43204, applied once daily for 3 consecutive days in patients with actinic keratosis
2994383|NCT02600598|Experimental|LEO 43204 Group B|Group B - Experimental LEO 43204, applied once daily for 3 consecutive days in patients with actinic keratosis
2994384|NCT02600585||Flublok|Recombinant influenza vaccine (RIV); Intramuscular injection of vaccine of recombinant uncleaved hemagglutinin (rHA0) derived from influenza A/H1N1, A/H3N2, and B viruses, as identified for the season by the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) in a total volume of 0.5 mL.
2994385|NCT02600585||Inactivated Influenza Vaccine|Injectable, inactivated, egg-based influenza vaccines (IIV); Intramuscular injection of vaccine (whether trivalent or quadrivalent) derived from influenza A/H1N1, A/H3N2, and B viruses, as identified for the season by the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) in a total volume of 0.5 mL.
2994386|NCT02600572|Experimental|Isometric exercise|Subjects performing the isometric exercises intervention
2994387|NCT02600572|Experimental|Eccentric exercise|Subjects performing the eccentric exercises intervention
2994388|NCT02600559|Experimental|0.1 mL OTO-201|Ciprofloxacin
2994389|NCT02600533|No Intervention|Standard care/control group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the standard of care group will be provided standard educational resources (booklet and DVD), with no additional instructions. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
2994390|NCT02600533|Experimental|Video viewing group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
2994391|NCT02600520|Active Comparator|Rosuvastatin Group|SRP followed by RSV gel LDD
2994392|NCT02600520|Active Comparator|Atorvastatin Group|SRP followed by ATV gel LDD
2994393|NCT02600520|Placebo Comparator|Placebo group|SRP followed by placebo gel LDD
2994394|NCT02600507|Experimental|40 mg ITI-007|40 mg ITI-007 administered orally as capsules once daily for 6 weeks
2994395|NCT02600507|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as capsules once daily for 6 weeks
2994396|NCT02600507|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
2994397|NCT02600494|Experimental|40 mg ITI-007|40 mg ITI-007 administered orally as capsules once daily for 6 weeks
2994398|NCT02600494|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as capsules once daily for 6 weeks
2994399|NCT02600494|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
2994400|NCT02600481|Experimental|low-pressure pneumoperitoneum group|Subjects assigned to the low-pressure pneumoperitoneum group will receive 7-10 mm Hg carbon dioxide pneumoperitoneum, and the expected duration is longer than 3 hours to complete robot-assisted surgeries in the Trendelenburg position;
2994401|NCT02600481|Active Comparator|standard-pressure pneumoperitoneum group|Subjects assigned to the standard-pressure pneumoperitoneum group will receive 12-16 mm Hg carbon dioxide pneumoperitoneum, which is expected lasted longer than 3 hours to complete robot-assisted surgeries in the Trendelenburg position;
2994402|NCT02600468||Patients who use ORENCIA|Patients who use ORENCIA for the approved indications and who at the start of treatment
2994403|NCT02600455||Patients who are treated with ORENCIA|Patients who are treated with ORENCIA according to the approved indications, and dosage and administration
2994404|NCT02600442||main and unique cohort|
2994405|NCT02600429|Experimental|RGN-259|It is a preservative-free, sterile eye drop solution containing Tβ4
2994406|NCT02600429|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4.
2994407|NCT02600416|Other|AV port reversal|Patients undergoing citrate CVVH.
2994408|NCT02600403||IOP between 22-32 mmHg|Forty four (44) patients with intraocular pressure between 22 and 32 millimeters (mmHg) of mercury will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
2994409|NCT02600403||IOP greater than 32 mmHg|Six (6) patients with intraocular pressure greater than 32 millimeters of mercury (mmHg) will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
2994410|NCT02600403||IOP less than 22 mmHg|Eleven (11) patients with stable intraocular pressure (less than 22 millimeters of mercury (mmHg)) on ophthalmic solutions (eye drops) will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
2994442|NCT02600130|Experimental|Cohort 1|Cohort 1 (10 subjects) Target dose 20 million Longeveron Mesenchymal Stem Cells (LMSCs) via peripheral intravenous infusion.
2994443|NCT02600130|Experimental|Cohort 2|Cohort 2 (10 subjects) Target dose 100 million Longeveron Mesenchymal Stem Cells (LMSCs)via peripheral intravenous infusion.
2994411|NCT02600390|Experimental|SANGUINATE™ (4-week)|This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 4-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.
2994412|NCT02600390|Experimental|SANGUINATE™ (6-week)|This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 6-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.
2994413|NCT02600351|Experimental|LDV/SOF 12 weeks, without cirrhosis|LDV/SOF for 12 weeks
2994414|NCT02600351|Experimental|LDV/SOF + RBV 12 weeks, without cirrhosis|LDV/SOF + RBV for 12 weeks
2994415|NCT02600351|Experimental|LDV/SOF + RBV 12 weeks, with compensated cirrhosis|LDV/SOF + RBV for 12 weeks
2994416|NCT02600351|Experimental|LDV/SOF 24 weeks, with compensated cirrhosis|LDV/SOF for 24 weeks
2994417|NCT02600325|Experimental|Treatment group|Grazoprevir/elbasvir single tablet regimen (100/50mg)
2994418|NCT02600312|Active Comparator|oXiris|Continuous renal replacement therapy with filter that adsorbs cytokines/toxins.
2994419|NCT02600312|No Intervention|ST150|Continuous renal replacement therapy with filter that does not adsorb cytokines/toxins.
2994420|NCT02600299|Experimental|Intervention Arm|On the basis of previous studies that evaluated PEG interventions for women with breast cancer, a structured program based on the Cognitive Behavioral Therapy (CBT) principles was developed. Patients in the PEG group will be involved in three sessions of psychoeducation. The PEG program is designed to cover the various aspects outlined by the IOM on quality cancer survivorship. This program is designed to take place on three individual days on a weekend. For each session, three major topics will be covered, with lectures and interactive workshop integrated. Sessions will be conducted by healthcare professionals who are experts/well-versed in their respective domains.
2994421|NCT02600299|Placebo Comparator|Usual Care|No active intervention provided.
2994422|NCT02600286|Experimental|1|"Arm (1) will be randomised to receive either :~5 mg/per os of EllaOne every day through 12 months.~10 mg/per os of EllaOne every day through 12 months.~EllaOne placebo/per os every day through 12 months."
2994423|NCT02600286|Experimental|2|"Arm (2) will be randomised to receive either :~5 mg/per os of EllaOne every day through 12 months.~10 mg/per os of EllaOne every day through 12 months.~EllaOne placebo/per os every day through 12 months."
2994424|NCT02600286|Experimental|3|"Arm (3) will be randomised to receive either :~5 mg/per os of EllaOne every day through 12 months.~10 mg/per os of EllaOne every day through 12 months.~EllaOne placebo/per os every day through 12 months."
2994425|NCT02600273|Active Comparator|Usual brand cigarettes|During one session, participants will smoke their usual brand cigarettes
2994426|NCT02600273|Experimental|Lower nicotine content cigarettes|During one session, participants will smoke SPECTRUM Research Cigarettes
2994427|NCT02600273|Experimental|Electronic cigarettes 1|During one session, participants will use an electronic cigarette with 0 mg/mL nicotine e-liquid
2994428|NCT02600273|Experimental|Electronic cigarettes 2|During one session, participants will use an electronic cigarette with 18 mg/mL nicotine e-liquid
2994429|NCT02600260|Other|enoxaparin|A prospective study that will evaluate all pregnant women admitted for clinical treatment and / or surgery through the application of a thromboprophylaxis protocol with risk assessment score.The patient in whom prophylaxis would be indicated are those with scores greater than or equal to 3. The drug to be used is enoxaparin and the dose to be used depends on the weight of the patient.It will be further assessed: adverse effects of treatment with enoxaparin, protocol failure in the group treated and untreated (without anticoagulation) and bleeding incidence in both groups.
2994430|NCT02600260|Other|no intervention|Pregnant women admitted in hospital for clinical treatment and/or delivery and that does not score for thromboprophylaxis.
2994431|NCT02600247|Experimental|Duloxetine group|"Experimental: Duloxetine group~Phase I (preemptive): 1day before operation (30mg for 1 day)~Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)~Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon"
2994432|NCT02600247|Active Comparator|routine pain control group|"Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
2994433|NCT02600234|Experimental|Treatment with Inter-Atrial Shunt Device|Once all study criteria have been met, if randomized to this arm, patients will receive the IASD implant.
2994434|NCT02600234|Placebo Comparator|Control|Once all study criteria have been met, if randomized to this arm, patients will not receive the implant. They will undergo an intracardiac echo only, with the option to crossover at 1 year.
2994435|NCT02600208|Experimental|Single Experimental Arm|Alpha Beta T cell depletion is performed for all PBSC grafts using the CliniMACs device
2994436|NCT02600195|Experimental|EPIQ sites|Use Evidence-based Practice for Improving Quality (EPIQ) method to develop and implement evidence-based practice changes to reduce hospital-acquired infection
2994437|NCT02600195|No Intervention|Control sites|Continue current practices
2994438|NCT02600182|Experimental|Bilevel Positive Airway Pressure (BiPAP)|The routine physical therapy will be performed in two groups (control and BiPAP). The BiPAP group will receive two daily sessions of 20 minutes, with positive expiratory pressure of 10cmH2O and inspiratory of 15cmH2O.
2994439|NCT02600182|No Intervention|Control|Routine physical therapy will be performed.
2994440|NCT02600169||Patients treated with pemprolizumab|All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma. Patients will be included from all 14 WIN-O (Werkgroep Immunologie Nederland voor Oncologie) centers in the Netherlands. Patients are at least 18 years of age.
2994441|NCT02600156|Experimental|Single arm study|MR guided focal laser ablation of prostate cancer using the Visualase Thermal Therapy System.
2994470|NCT02599922|Experimental|Lower dose|rAAV2tYF-PR1/7-hCNGB3 will be administered at the lowest of three planned dose levels.
2994444|NCT02600130|Placebo Comparator|Cohort 3|Cohort 3 (5 subjects) Placebo (Plasmalyte A and 1% human serum albumin (HSA)) via peripheral intravenous infusion.
2994445|NCT02600117|Other|Tenofovir disoproxil fumarate|300 mg, orally, once a day for 3 years or when sAg+ve seroconverts to sAb+ve whichever comes earlier
2994446|NCT02600104|Experimental|all subjects|will receive up to four (4) facial treatments in 3-8 weeks interval, with the PicoWayTM device-fractional hand piece 1064nm and/or 532nm according to the study protocol. Subjects will be followed by phone 7 days post first treatment by study staff, and will return for follow‐up (FU) visits at the clinic at: 6 weeks and 12 weeks following the last treatment.
2994447|NCT02600091|Experimental|MBCT Intervention|Participants in the Mindfulness-based Cognitive Therapy Intervention arm will receive an 8-week programme in mindfulness-based cognitive therapy
2994448|NCT02600091|No Intervention|Waiting List Control|The participants who are allocated to the waiting list control group will receive usual care. They will receive the MBCT intervention 3 months after the intervention group complete their MBCT programme.
2994449|NCT02600078|Active Comparator|Moderate Hypoxia|Subjects will be exposed to moderate hypoxia and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
2994450|NCT02600078|Sham Comparator|Sham|Subjects will be exposed to sham and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
2994451|NCT02600078|Active Comparator|Mild Hypoxia|Subjects will be exposed to mild hypoxia and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
2994452|NCT02600065||Study cohort|"All patients who are suffering from brain tumor of brain metastases and are willing to participate.~The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy."
2994453|NCT02600052|Experimental|GPNF|Patients will be submitted to aerobic training, with prior application of PNF technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.
2994454|NCT02600052|Active Comparator|GCONTROL|Patients will be submitted to aerobic training, with prior application of relax technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.
2994455|NCT02600039|Experimental|ELTGOL|
2994456|NCT02600039|Active Comparator|Acapella|
2994457|NCT02600026|Experimental|Video Camera: Intervention|DriveCam video event recorder with feedback
2994458|NCT02600026|Placebo Comparator|Video Camera: Monitoring|DriveCam video event recorder with no feedback
2994459|NCT02600000|Experimental|Sympathetic myocardial activity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the modulation of sympathetic myocardial activity of patients with HF
2994460|NCT02600000|Experimental|Maximal functional capacity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the maximal functional capacity of patients with HF
2994461|NCT02600000|Experimental|submaximal functional capacity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the submaximal functional capacity of patients with HF
2994462|NCT02600000|Experimental|Thickness and mobility of the diaphragm after IMT|Assess the impact of Inspiratory Muscle Training in combination with a cardiac rehabilitation program on the thickness and mobility of the diaphragm in patients with heart failure.
2994463|NCT02600000|Other|Accuracy of AVD-Glittre Test|Evaluate and establish a diagnostic value for the ADL-Glittre Test in adults with heart failure when compared with information from a pattern Gold, through the sensitivity and specificity values.
2994464|NCT02599987|Experimental|Inspiratory Muscle Training Group|Will use the breathing coach POWERbreathe® Classic Light. Participants will hold the workout three sets of 30 inspirations, 2 sessions per day, 7 days per week for 8 weeks. The training group will carry with IMT load of 50% of MIP. Weekly, patients attend the Cardiopulmonary Physical Therapy Laboratory for evaluation of MIP and load adjustment, performing a training session in the presence of the therapist, while other sessions will be held by the participant at home and registered in the diary training. The training took place with the patient sitting in chair with a back, with knees and hips flexed to 90 °, the participant will use a nose clip and the device coupled to the nozzle mouth, will be instructed to diaphragmatic breathing pattern.
2994465|NCT02599987|Sham Comparator|Sham Group|Will use the breathing coach POWERbreathe® Classic Light. Participants will hold the workout three sets of 30 inspirations, 2 sessions per day, 7 days per week for 8 weeks. The sham group will carry without load, but will be subjected to the same procedures in the experimental group (simulation of load adjustment in the Cardiopulmonary Physical Therapy Laboratory) to ensure blinding of the study, other sessions will be held by the participant at home and registered in the diary training. The training took place with the patient sitting in chair with a back, with knees and hips flexed to 90 °, the participant will use a nose clip and the device coupled to the nozzle mouth, will be instructed to diaphragmatic breathing pattern.
2994466|NCT02599961|Experimental|UX007 (Triheptanoin)|This is a single arm, open label study. All subjects will be on active treatment; no reference therapy or placebo will be administered.
2994467|NCT02599948||Patients hospitalised in ICU|Patients hospitalised in ICU
2994468|NCT02599935|Experimental|educational intervention and supplements|structured educational intervention and dietary supplements
2994469|NCT02599935|Active Comparator|usual interventions|Usual treatment without nutritional supplements or structured assessment
3020660|NCT02424864|Other|4D PET-CT|Other intervention: 4D PET-CT
2994473|NCT02599922|Experimental|Maximum tolerated dose|rAAV2tYF-PR1/7-hCNGB3 will be administered at the maximum tolerated dose identified from Groups 1, 2 and 3.
2994474|NCT02599896|Experimental|Group 1|5 mg/kg/IV on Day 0
2994475|NCT02599896|Experimental|Group 2|5 mg/kg SC on Day 0
2994476|NCT02599896|Experimental|Group 3|20 mg/kg IV on Day 0
2994477|NCT02599896|Experimental|Group 4|40 mg/kg IV on Day 0
2994478|NCT02599896|Experimental|Group 5|5 mg/kg SC on Day 0, Week 12 and Week 24
2994479|NCT02599896|Experimental|Group 6|20 mg/kg IV on Day 0, Week 12 and Week 24
2994480|NCT02599896|Experimental|Group 7|5 mg/kg SC on Day 0, Week 4
2994481|NCT02599896|Experimental|Group 8|20 mg/kg IV on Day 0, Week 4
2994482|NCT02599883|Experimental|MulticenterRecruitment|COPD phenotypization by Low-Dose Computed Tomography
2994483|NCT02599870|Experimental|NeuroIDgenetix Test Panel Intervention|The medical provider for the NeuroIDgenetix-guided group will make post-operative pain management recommendations based on test results. Patient outcomes, length of hospital stay and number of medical visits will be measured throughout the study.
2994484|NCT02599870|No Intervention|Control|The medical provider for the control group will not receive the NeuroIDgenetix Test Panel results and will make post-operative pain management recommendations based as usual. Patient outcomes, length of hospital stay and number of medical visits will be measured throughout the study.
2994485|NCT02599857|Experimental|CONCOR smartphone application|Use of CONCOR smartphone application
2994486|NCT02599857|No Intervention|Standard care (no CONCOR smartphone application)|No CONCOR smartphone application
2994487|NCT02599844||Sepsis with Severe AKI|"This group will have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI) which lead to classification of injury or failure. The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV)."
2994488|NCT02599844||Sepsis without AKI|This group will have a history of a pediatric admission with sepsis which lead to no classification of sepsis-related Acute Kidney Injury (sAKI). The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).
2994489|NCT02599831|Experimental|Electrical pudendal nerve stimulation|"Four sacrococcygeal points were selected. Two 0.40Х100 mm needles were inserted perpendicularly to a depth of 80-90 mm 1 cm bilateral to the sacrococcygeal joint, to produce a sensation referred to the root of the penis (perineum) or the anus. Two needles of 0.40Х100 or 125mm were inserted obliquely toward the ischiorectal fossa to a depth of 90 to 110 mm about 1 cm bilateral to the tip of the coccyx, to produce a sensation referred to the root of the penis (or the perineum).~Each two ipsilaterally needles were connected to one electrode from a G6805-2Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China), with a frequency of 2.5 Hz and an intensity (45~55 mA). EPNS was given for 60 min a time, 3 times per week for 8 weeks."
2994490|NCT02599831|Active Comparator|PFM training with Transanal ES|Electromyogram BF-assisted PFMT (using a nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co. Ltd, China) and following TES (using a neuromuscular stimulation therapy system (PHENIX USB4, Electronic Concept Lignon Innovation, France)) at a current intensity of < 60 mA (as high as possible within the patient's tolerance) and frequencies of 15 Hz and 85 Hz (alternate 3-minute periods of stimulation) were performed by a specially trained therapist, 20 minutes each time, respectively (a total of 40 minutes), 3 times a week for a total of 8 weeks. The patients were also required to conduct 30 maximal high-intensity PFM contractions for 2-6 seconds (with 2-6 seconds rest), 3 sessions every day at home for a total of 8 weeks.
2994491|NCT02599818|Experimental|NavSTAR|Participants in this arm will receive services from the NavSTAR Patient Navigation team. The Patient Navigator will work with patients for up to 3 months post-hospital discharge to resolve internal barriers (e.g., ambivalence about treatment; low motivation; competing life demands, etc.) and external barriers (e.g., lack of transportation; lack of ID card, etc.) to appropriate utilization and engagement in addiction treatment and medical care. Interventions include motivational interventions and patient navigation with proactive case management, tailored to participants' specific needs.
2994492|NCT02599818|No Intervention|TAU (Treatment as Usual)|Participants in this arm will receive usual care, which includes in-hospital services from a multidisciplinary substance use disorder consultation liaison team.
2994493|NCT02599805|Experimental|Natrox treatment group|In this group, all subjects will have the Natrox™ ODS will be applied to the ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. Dressings according to the standard practice guidelines will be used. Patients in this group will continue to receive treatment as described by the diabetic foot ulcer standard of care. The ulcer will be photographed at biweekly intervals for a period of 8 weeks to analyze ulcer surface area using a standardized digital imaging software.
2994494|NCT02599805|No Intervention|Control group|"All subjects in this group will receive the Diabetic foot ulcer standards of care which include:~Full medical assessment in all cases.~Surgical operation/Intervention where indicated.~Local treatment of the ulcer (debridement followed by ulcer care according to modern ulcer healing standards and management of diabetes.) The ulcer will be photographed at biweekly intervals for a period of 8 weeks to analyze ulcer surface area using a standardized digital imaging software."
2994495|NCT02599792|Experimental|CTP-656, 150 mg|Single Oral Dose
2994496|NCT02599792|Active Comparator|Kalydeco, 150 mg|Single oral dose
2994497|NCT02599792|Experimental|CTP-656, 75 mg or matching placebo|Subjects will be administered 75 mg CTP-656 for 7 days.
2994498|NCT02599792|Experimental|CTP-656, 150 mg or matching placebo|Subjects will be administered 150 mg CTP-656 for 7 days.
2994499|NCT02599792|Experimental|CTP-656, high dose or matching placebo|Subjects will be administered up to 300 mg CTP-656 for 7 days.
2994500|NCT02599779|Experimental|Treatment arm A|"Arm-A: Pembrolizumab will be started and Stereotactic Body Radiation Therapy will be given at the time of progression on pembrolizumab and pembrolizumab will be continued.~Pembrolizumab will continue until progression as per immune related response criteria (irRC)."
2994501|NCT02599779|Experimental|Treatment arm B|"Arm B: Pembrolizumab will be started. Stereotactic Body Radiation Therapy will be given before the 2nd course of pembrolizumab and pembrolizumab will be continued.~Pembrolizumab will continue until progression as per immune related response criteria (irRC)."
2994502|NCT02599766|Experimental|animal assisted therapy|"Standard therapy that is done in the presence and with integrating an animal."
2994503|NCT02599766|Active Comparator|standard therapy|"Standard therapy without the presence of an animal."
2994504|NCT02599753|Experimental|18F-DTBZ for Parkinson's Disease|The participants qualify for the study will return to the clinic at a later date and will have catheter(s) placed for i.v. administration of 18F- DTBZ for injection. The participants will receive a single i.v. bolus of 18F- DTBZ, followed by brain PET imaging of 10 minutes duration, approximately 80 minutes post-dose injection. Vital signs will be obtained prior to and immediately after the administration of 18F- DTBZ, and at the completion of the imaging session. Adverse events will be continuously monitored during the imaging session. The participants experience any adverse event will not be discharged until the event has resolved or stabilized.
2994505|NCT02599740|Placebo Comparator|Placebo|Rice only
2994506|NCT02599740|Active Comparator|Assumed active|Assumed key active consumed with rice
2994507|NCT02599740|Active Comparator|Natural fruit extract|Natural fruit extract consumed with rice
2994508|NCT02599727|Experimental|Active Isometric exercise|Subjects performing the isometric exercises intervention
2994509|NCT02599727|Active Comparator|No exercise|Subjects not performing the isometric exercises intervention
2994510|NCT02599714|Experimental|Triplet Combination|The experimental arm will be comprised of AZD2014 + palbociclib + fulvestrant.
2994511|NCT02599714|Active Comparator|Doublet Combination|The comparator will be comprised of Matching AZD2014 placebo + palbociclib + fulvestrant. (Part C Only)
2994512|NCT02599701|Placebo Comparator|Placebo|A single dose of placebo with exactly the same characteristics of the active drug at bedtime.
2994513|NCT02599701|Experimental|Gabapentin|A single dose of Gabapentin 300mg at bedtime.
2994514|NCT02599675|Experimental|Vitamin D3|Vitamin D3 capsules for 12 weeks (2000 IU daily, equivalent to 50 ug)
2994515|NCT02599675|Placebo Comparator|Placebo|Placebo capsules for 12 weeks (the number of daily capsules will match that of the vitamin D-group)
2994516|NCT02599662|Other|Group 1: 10 Gy Low-KV IORT|10 Gy Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
2994517|NCT02599662|Other|Group 2: 15 Gy Low-KV IORT|15 Gy Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
2994518|NCT02599662|Other|Group 3: 20 GY Low-KV IORT|20 GY Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
2994519|NCT02599649|Experimental|Low or Intermediate-1 MDS Group - Lirilumab|Lirilumab by vein over about 60 minutes 1 time each 28 day cycle.
2994520|NCT02599649|Experimental|Low or Intermediate-1 MDS Group - Nivolumab + Lirilumab|Nivolumab by vein over about 60 minutes every 2 weeks during Cycles 1-9. Lirilumab by vein over about 60 minutes 1 time each cycle. Cycle is 28 days.
2994521|NCT02599649|Experimental|High Risk MDS Group - Azacitidine + Lirilumab|Azacitidine by vein over about 60 minutes on Days 1-7 of each 28 day cycle. Lirilumab by vein over about 60 minutes on Day 7 of each 28 day cycle.
2994522|NCT02599649|Experimental|High Risk MDS Group - Azacitidine + Lirilumab + Nivolumab|Azacitidine by vein over about 60 minutes on Days 1-7 of each 28 day cycle. Lirilumab by vein over about 60 minutes on Day 7 of each 28 day cycle. On Days 7 and 21 of Cycles 1-9 and then on Day 7 of Cycles 10 and beyond, Nivolumab by vein over about 60 minutes.
2994523|NCT02599623|Experimental|Local anesthesia|Patient operated in local anesthesia, with a mesh repair in Lichtenstein if no bowel necrosis existed.
2994524|NCT02599623|Active Comparator|General anesthesia|Patient operated in general anesthesia, with a mesh repair in Lichtenstein if no bowel necrosis existed.
2994525|NCT02599610|Active Comparator|Digital vaginal examination|Patients assigned to this group will be followed-up with digital vaginal examinations as described in intervention protocol.
2994526|NCT02599610|Experimental|Transperineal ultrasound examination|Patients assigned to this group will be followed-up with transperineal ultrasound examinations as described in intervention protocol.
2994527|NCT02599597|Experimental|Therapist-assisted iCBT|Internet-delivered cognitive behavioral therapy (iCBT), containing physical activity and sleep management for preventing depressive relapse. Monthly depression screening with therapist feedback.
2994528|NCT02599597|Active Comparator|Monthly screening with feedback|Monthly depression screening with therapist feedback.
2994529|NCT02599597|No Intervention|Control|No intervention, follow-up along with all participants at 6 and 12-months.
2994530|NCT02599584|Experimental|precritical staff|4 min of precritical team staff for anticipation of risk and role attribution during the critical events if they occur. athe staff will take place after briefing of the scenario and before the start of the scenario.
2994531|NCT02599584|No Intervention|control|screening of normal labs results during 4 min, after briefing of the scenario and before the start of the scenario
2994532|NCT02599571|Other|Very low nicotine content cigarettes|Reduced nicotine content cigarettes.
2994533|NCT02599571|Other|Conventional nicotine content cigarettes|Conventional nicotine content cigarettes.
2994534|NCT02599558|Experimental|Cytosponge,Diet,EEsAI Pro,Phone call|Patients going through the six food elimination diet (clinically)for EoE, will be asked to participate. We will introduce 1 of the 6 foods previously eliminated for two weeks, than another for two weeks, at the end of 4 weeks the participant will return to swallow the cytosponge to monitor them through the diet, rather than multiple repeat Upper Endoscopies. The cytosponge is a 10 minute procedure done in the office. This will be sent for histology, <15 phf would be considered a responder. Results of the histology will help the investigator to direct the diet, which foods to add or take out of the diet.
2994535|NCT02599545||Maternal/VLBW Infant Pairs|One-hundred-fifty mother-VLBW infant pairs, a total of 300 participants, will be recruited for the final sample size of 120 pairs.
2994536|NCT02599532|Other|Nephrotic syndrome|Subjects with nephrotic syndrome will receive a single dose of apixaban 10 mg and will subsequently have blood drawn at 0, 0.5, 1, 3, 4, 6, 8, 24 hours after drug administration.
2994537|NCT02599532|Other|Non-nephrotic syndrome|Subjects without nephrotic syndrome will receive a single dose of apixaban 10 mg and will subsequently have blood drawn at 0, 0.5, 1, 3, 4, 6, 8, 24 hours after drug administration.
2994538|NCT02599506||breast cancer radiation therapy|Observation over a period of all treatment sessions for radiotherapy
2994539|NCT02599493|Experimental|Low dose|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
2994540|NCT02599493|Active Comparator|High dose|Patients will be randomly assigned to high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
2994541|NCT02599480|Active Comparator|mirabegron|Patients will be orally administererd with 50 mg of mirabegron once a day during 12 months.
2994542|NCT02599480|Placebo Comparator|Placebo|Patients will be orally administererd with a placebo once a day during 12 months.
2994543|NCT02599467|Experimental|case group 1: ALND|"Inclusion criteria: unilateral breast cancer surgery with Axillary lymph node dissection (ALND) during the last year and a half. Exclusion criteria: bilateral breast cancer, ipsilateral shoulder pathology, neuropathy.~Procedure: ULNT 1 and EMG recording."
2994544|NCT02599467|Experimental|case group 2: SLNB|"Inclusion criteria: unilateral breast cancer surgery with Sentinel Lymph Node Biopsy (SLNB) during the last year and a half. Exclusion criteria: bilateral breast cancer, ipsilateral shoulder pathology, neuropathy.~Procedure: ULNT 1 and EMG recording"
2994545|NCT02599467|Active Comparator|control group|"Matched by age and dominant arm to each case. Exclusion criteria: current painful conditions involving their neck or dominant upper-extremity, and chronic pain conditions or use of pain relievers.~Procedure: ULNT 1 and EMG recording."
2994546|NCT02599454|Experimental|atezolizumab + SBRT|"DOSE ESCALATION PHASE: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Within 24-48 hours after receiving atezolizumab, patients also undergo 4-5 fractions of stereotactic body radiation therapy over days 1-5 of course 3.~EXPANSION PHASE: Patients receive atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Within 24-48 hours after receiving atezolizumab, patients also undergo 4-5 fractions of stereotactic body radiation therapy over days 1-5 of course 3."
2994547|NCT02599441||Ankle fracture cases|
2994548|NCT02599415|Other|TL01 light treatment|routine treatment with a CE marked device that has been used for this disease for many years
2994549|NCT02599402|Experimental|Combination therapy: Nivolumab + Ipilimumab|Nivolumab + Ipilimumab specified dose on specified days
2994550|NCT02599402|Experimental|Monotherapy: Nivolumab|Nivolumab specified dose on specified days
2994551|NCT02599389|No Intervention|Standard balloon|Angioplasty with use of standard balloons
2994552|NCT02599389|Experimental|Drug-coated balloons|Angioplasty with use of drug-coated balloons
2994553|NCT02599389|Experimental|Drug-coated balloons and laser|Angioplasty with use of drug-coated balloons in association with Excimer Laser
2994554|NCT02599376|Active Comparator|BMI less than 30|The drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid
2994555|NCT02599376|Experimental|BMI more than 40|The drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid
2994556|NCT02599350||1|Patients receiving mechanical ventilation
2994557|NCT02599337|Experimental|sorafenib|Sorafenib is the test product.In period 1, period 2 and period 3, 12 of 36 Subjects were given Single oral dose (1 x 200 mg) sarofenib.
2994558|NCT02599337|Active Comparator|Nexavar|Nexavar is the reference product.In period 1, period 2 and period 3, 24 of 36 Subjects were given Single oral dose (1 x 200 mg) Nexavar .
2994559|NCT02599324|Experimental|Phase 1b/2: Renal Cell Carcinoma|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with everolimus to determine the Recommended Phase 2 Dose (RP2D) of ibrutinib.~Phase 2: Patients will receive ibrutinib at the RP2D determined in Phase 1b in combination with everolimus."
2994560|NCT02599324|Experimental|Phase 1b/2: Urothelial Carcinoma|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with paclitaxel to determine the RP2D of ibrutinib.~Phase 2: Subjects will receive paclitaxel at the RP2D determined in Phase 1b in combination with paclitaxel."
2994561|NCT02599324|Experimental|Phase 1b/2: Gastric Adenocarcinoma|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with docetaxel to determine the RP2D of ibrutinib.~Phase 2: Subjects will receive docetaxel at the RP2D determined in Phase 1b in combination with docetaxel."
2994562|NCT02599324|Experimental|Phase 1b/2: Colorectal Adenocarcinoma|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with cetuximab to determine RP2D of ibrutinib.~Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b in combination with cetuximab."
2994563|NCT02599311|Other|the efficacy|transvaginal synthetic mesh
2994564|NCT02599311|No Intervention|the recurrence rate|transvaginal synthetic mesh
2994565|NCT02599311|No Intervention|the quality of life|transvaginal synthetic mesh
2994566|NCT02599311|Other|the rate of the LUTS|We use Tolterodine to improve patients' LUTS
2994567|NCT02599298|Active Comparator|SGMT arm|Treatment of OSA requires a multidisciplinary approach, involving a sleep physician and paramedical staff with expertise in the management of sleep disorders. An initial medical assessment is needed to confirm the diagnosis of OSA, determine its severity and decide whether CPAP therapy is appropriate. As part of this evaluation, an objective overnight sleep study will be performed. This will be followed by an assessment, education, and counseling at the multidisciplinary therapy clinic.
2994604|NCT02599090|Experimental|4|Temozolomide + Higher Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Higher Dose Sorafenib
3022106|NCT02415517|No Intervention|Passive control group|No intervention
2994568|NCT02599298|No Intervention|Control arm|The patients will be treated according to the standard treatment for acute coronary syndrome in Singapore, which is largely in accordance with the recommendations of the American College of Cardiology and the American Heart Association. Management includes, but is not limited to, antiplatelet and lipid-lowering therapy, early coronary revascularization, and cardiac rehabilitation, with the recommendation to follow the current practice and the most recent international guidelines.
2994569|NCT02599285||Fixation|Patients with a trimalleolar AO Weber C fracture with open reduction and fixation of the posterior malleolar fragment.
2994570|NCT02599285||No Fixation|Patients with a trimalleolar AO Weber C fracture without open reduction and fixation of the posterior malleolar fragment.
2994571|NCT02599272|Other|Rice with vegetables but no added spice|Control session - rice with control vegetables (tomatoes and aubergines) - no mixed spices
2994572|NCT02599272|Active Comparator|Rice with vegetables and low spice|Dose 1 mixed spice session - rice with 6 g powdered mixed spices and 40 g polyphenol rich vegetables (onions, ginger and garlic)
2994573|NCT02599272|Active Comparator|Rice with vegetables and high spice|Dose 2 mixed spice session - rice with 12 g powdered mixed spices and 80 g polyphenol rich vegetables (onions, ginger and garlic)
2994574|NCT02599259|Experimental|1. Monitored (M+)|Group receiving treatment as usual (TAU) and using the AiCure platform for monitoring and intervention platform on a mobile device being tested when taking their daily anticoagulation medication.
2994575|NCT02599259|No Intervention|Unmonitored (M-)|No Intervention. Group receiving TAU and not issued mobile device with the AiCure platform.
2994576|NCT02599233||The study population|"The study population consists of adult surgery patients at the Nîmes University Hospital, with recruitment based on the operating theater program for a predefined six month period and for a predefined list of surgeries. The latter list of surgical acts was established according to the Medicalization of Information Systems Progam (PMSI) database. Patients are recruited either the day before or the day after surgery, in their respective departments.~Interventions:~In hospital pain evaluation~In hospital questionnaires~Telephone conctact at 3 months"
2994577|NCT02599207|Experimental|Matched related umbilical cord blood|Six subjects will receive an infusion of HLA matched sibling umbilical cord blood cells.
2994578|NCT02599207|Experimental|Mismatched related umbilical cord blood|Nine subjects will receive an infusion of HLA-mismatched (≥3/6 match) or matched sibling umbilical cord blood cells.
2994579|NCT02599194|Experimental|Diagnostic (18F-FSPG PET/CT)|Patients receive fluorine F 18 L-glutamate derivative BAY94-9392 IV and 60 minutes after injection, undergo 18F-FSPG PET/CT before and after the start of therapy.
2994580|NCT02599181|Experimental|WITH-Group: alcoholic skin disinfection|In the WITH-group, the skin is disinfected with an aerosolized alcoholic solution propanol-biphenol: Kodan, Schülke & Mayr, Zurich, Switzerland prior to perineural catheter removal.
2994581|NCT02599181|No Intervention|WITHOUT: no alcoholic skin desinfection|"In the WITHOUT-group, the skin is NOT disinfected prior to perineural catheter removal."
2994582|NCT02599168|Active Comparator|Dexmedetomidine group|Patients will receive a pre-induction loading dose of dexmedetomidine 1-µ/kg over 10 minutes followed by an intraoperative infusion of 0.5-µ/kg/hour . Over and above the use of study drug dexmedetomidine propofol administration will be controlled with Closed Loop Anaesthesia Delivery system to maintain a consistent anaesthetic depth (BIS 40-60) using bispectral index monitor in all the patients
2994583|NCT02599168|Placebo Comparator|Non-Dexmedetomidine group|Patients will receive a pre-induction loading dose of 0.9% saline solution over 10 minutes followed by an intraoperative infusion.Over and above the use of 0.9% saline solution propofol administration will be controlled with Closed Loop Anaesthesia Delivery system to maintain a consistent anaesthetic depth (BIS 40-60) using bispectral index monitor in all the patients
2994584|NCT02599155|Placebo Comparator|Crystalloid group|Crystalloid group receive only crystalloid for intravenous volume expansion. The same transfusion protocol is applied in both groups.
2994585|NCT02599155|Active Comparator|Colloid group|Colloid group receive colloid preferentially for intravenous volume expansion, until 30 ml/kg. The same transfusion protocol is applied in both groups.
2994586|NCT02599142|Active Comparator|Group A: Closed-face shells|Cranial radiotherapy using the control closed-face immobilisation shell.
2994587|NCT02599142|Experimental|Group B: open-face shell|Cranial radiotherapy using the experimental open-face immobilisation shell
2994588|NCT02599129|Experimental|Secukinumab|300 mg subcutaneous injections
2994589|NCT02599129|Placebo Comparator|Placebo|matching placebo subcutaneous injections
2994590|NCT02599116|Other|Microbiome cohort|"Pre-operative (baseline) bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires.~Six to twelve weeks following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires~Six to twelve months following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires"
2994591|NCT02599103|Placebo Comparator|fat-free milkshake|
2994592|NCT02599103|Active Comparator|Olive oil|
2994593|NCT02599103|Experimental|soybean oil|
2994594|NCT02599103|Experimental|fried soybean oil|
2994595|NCT02599103|Experimental|palm oil|
2994596|NCT02599103|Experimental|fried palm oil|
2994597|NCT02599103|Experimental|camellia oil|
2994598|NCT02599103|Experimental|fried camellia oil|
2994599|NCT02599103|Experimental|tallow|
2994600|NCT02599103|Experimental|fried tallow|
2994601|NCT02599090|Experimental|Dose Level 1|"Temozolomide + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle~Temozolomide 75mg/m^2 daily during radiation therapy, and 150mg/m^2 in the first cycle of adjuvant therapy. Dose Level 1 will receive sorafenib in the adjuvant phase (following radiation therapy) at the dose of 400mg BID in combination with standard dose temozolomide 150-200 mg/m^2 two days out of 28 day cycle. Radiotherapy 2.0 Grey (Gy)/day given daily 5 days per week for total of 60.0 Gy over 6 weeks."
2994602|NCT02599090|Experimental|2|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle + Higher Dose Sorafenib
2994603|NCT02599090|Experimental|3|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Lower Dose Sorafenib
2994606|NCT02599077|Active Comparator|Levonorgestrel + ethinylestradiol|The patient handling with levonorgestrel + ethinylestradiol (0,10 mg - 0,02 )
2994607|NCT02599064|Experimental|RXI-109|Intravitreal injections of RXI-109 in one eye given on Day 1 and at monthly intervals through Month 3 for a total of four doses
2994608|NCT02599051|Active Comparator|Monarc|Placement of a transobturator monarc sling for stress urinary incontinence
2994609|NCT02599051|Experimental|Mini-arc|Placement of a single incision mini-arc sling for stress urinary incontinence
2994610|NCT02599038|Experimental|Serine supplementation|Serine oral administration 20mg/kg/day
2994611|NCT02599025|No Intervention|Supine position|Children tested while lying down
2994612|NCT02599025|No Intervention|Standing position|Children tested while standing
2994613|NCT02599025|Experimental|Cycling supine postion|Children lying down with APT cycling system
2994614|NCT02599025|Experimental|Cycling standing postion|Children standing with Innowalk cycling system
2994615|NCT02599012|Experimental|Subjects|
2994616|NCT02598999|Experimental|Part I, SAD|Single administration of OSCN- or bLF or Placebo in healthy male volunteers
2994617|NCT02598999|Experimental|Part II, SAD and MAD|Single and multiple administrations of ALX-009 or Placebo in healthy male volunteers
2994618|NCT02598999|Experimental|Part III, MAD|Multiple administrations of OSCN- or bLF or Placebo in patients suffering from cystic fibrosis
2994619|NCT02598999|Experimental|Part IV, MAD|Multiple administrations of ALX-009 or Placebo in patients suffering from cystic fibrosis
2994620|NCT02598986|Placebo Comparator|white pita bread|Pita bread made of white wheat flour
2994621|NCT02598986|No Intervention|Whole grain pita bread|no macronutrient supplementation
2994622|NCT02598986|Experimental|Restored white pita bread|macronutrient supplementation
2994623|NCT02598986|Experimental|Fortified white pita bread|macronutrient supplementation 2
2994624|NCT02598973|Active Comparator|Exercise|aerobic walking
2994625|NCT02598973|No Intervention|No exercise|normal activity
2994626|NCT02598960|Experimental|Mono therapy - BMS-986156 (Dose Escalation)|BMS-986156 dose as specified
2994627|NCT02598960|Experimental|Combination therapy - BMS-986156 + Nivolumab (Dose Escalation)|BMS-986156 + Nivolumab dose as specified
2994628|NCT02598960|Experimental|Mono therapy - BMS-986156 (Dose Expansion)|BMS-986156 dose as specified
2994629|NCT02598960|Experimental|Combination therapy - BMS-986156 + Nivolumab (Dose Expansion)|BMS-986156 + Nivolumab dose as specified
2994630|NCT02598947|Experimental|Posterior shoulder tightness group|As well as receiving a strengthening program for the scapular and rotator cuff musculature, subjects allocated to the 'posterior shoulder tightness' treatment group will also receive specific manual therapy and home stretches to address stiffness of the posterior shoulder
2994631|NCT02598947|Sham Comparator|Posterior shoulder tightness sham group|The 'sham posterior shoulder tightness' group will receive the same strengthening program for the scapular and rotator cuff musculature, in addition they will receive home stretches and manual therapy of similar durations to the 'posterior shoulder tightness' group, but delivered to structures that have no known direct structural influence on the posterior shoulder
2994632|NCT02598934|Experimental|Ibandronate Group 1|Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly. Group 1 will receive a physician consultation after 4 months of treatment to review bone turnover test results.
2994633|NCT02598934|Experimental|Ibandronate Group 2|Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly. Group 2 will not receive a physician consultation.
2994634|NCT02598921|Other|Three dimensional ultrasound|Three dimensional ultrasound evaluated the uterine cavity for cavitary lesions
2994635|NCT02598921|Other|Office hysteroscopy|Office hystrescopy evaluated the uterine cavity for cavitary lesions
2994636|NCT02598908||NHS staff volunteer donors|Interested staff working within the Pathology Department at SWBH NHS Trust will be provided with written information regarding the proposed EQA scheme and the sample collection procedure. A consent form will be given to staff members, who will be asked to return the signed form within 1 week if they wish to participate. Each participating staff member will be assigned a unique patient identifier to allow for sample results to be anonymised.
2994637|NCT02598908||SWBH outpatient donors|A list of SWBH NHS Trust patient TPMT results will be gathered from the Pathology computer system (Telepath). Those with a TPMT activity of interest, measured in the past five years, will be contacted with the agreement of their hospital consultant. Information and consent forms will be sent to the patient either through the post or via their hospital consultant. Each participating patient will be assigned a unique patient identifier to allow for sample results to be anonymised.
2994638|NCT02598895|Experimental|Treatment (docetaxel, carboplatin)|Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 courses in the absence of disease progression or unacceptable toxicity.
2994639|NCT02598882|Active Comparator|treadmill|patients will be 30 minutes of activity on treadmill, before and after exercise the same shall be assessed as fatigue of quadriceps by surface electromyography
2994640|NCT02598882|Active Comparator|videogame|patients will be 30 minutes of activity with video games, before and after exercise the same shall be assessed as fatigue of quadriceps by surface electromyography
2994641|NCT02598869|Active Comparator|Intravitreal triamcinolone|subjects will receive intravitreal injection of 2mg /0.05 ml of preservative free triamcinolone acetonide ( otherwise known as triesence)
2994642|NCT02598869|Active Comparator|posterior subtenon triamcinolone|subjects will receive posterior subtenon injection of 40mg /1 ml of preserved triamcinolone acetonide ( otherwise known as kenalog)
2994643|NCT02598856|Experimental|Intranasal naloxone 1x|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
2994644|NCT02598856|Active Comparator|Intranasal naloxone 2x|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
2994645|NCT02598856|Active Comparator|Intravenous naloxone|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
2994646|NCT02598856|Active Comparator|Intramuscular naloxone|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
2994647|NCT02598843|Active Comparator|Standard treatment protocol|Cast immobilisation with 4 weeks in equinus cast (non-weight bearing) followed by 4 weeks in semi-equinus cast (non-weightbearing) and 2 weeks in neutral cast (full weightbearing). At this point, the cast is remove and patients mobilise fully weightbearing for a further 2 weeks out of cast, with 1.5cm heel raise. Commence physiotherapy at 10 weeks, when cast removed.
2994648|NCT02598843|Experimental|Accelerated rehabilitation|4 weeks in Ossur rebound walking boot with 2 heel wedges (3cm), 2 weeks in Ossur rebound walking boot with 1 heel wedge (1.5cm) and 2 weeks in Ossure rebound walking boot with no heel wedges (neutral position). Fully weightbearing throughout. Commence physiotherapy at 4 weeks.
2994649|NCT02598830|Experimental|Vitamin D3+str.training, COPD & Healthy|"Vitamin D3 capsules for 30 weeks:~weeks 1-2: 10000 IU/day (equivalent to 250 ug), accompanied by 1000 mg Ca2+~weeks 3-30: 2000 IU/day (equivalent to 50 ug), accompanied by 1000 mg Ca2+~Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner:~weeks 15-17, familiarization period~week 18, test period~weeks 19-28, intervention period~weeks 29-30, test period"
2994650|NCT02598830|Placebo Comparator|Placebo+str.training, COPD & Healthy|"Placebo capsules for 30 weeks (the number of capsules ingested each day match those of the vitamin D3 group)~Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner:~weeks 15-17, familiarization period~week 18, test period~weeks 19-28, intervention period~weeks 29-30, test period"
2994651|NCT02598817||Standard Infant Formula|Standard Infant Formula containing High Sn-2
2994652|NCT02598804|Experimental|Intervention group|"No single group but 2 groups :~Intervention group (5 educational workshop in addition to spa therapy)~Control group (Written information booklet in addition to spa therapy)"
2994653|NCT02598804|Other|control group|"No single group but 2 groups :~Intervention group (5 educational workshop in addition to spa therapy)~Control group (Written information booklet in addition to spa therapy)"
2994654|NCT02598791|Active Comparator|GIP|4 hour i.v. infusion of glucose-dependent insulinotropic polypeptide (4 pmol/kg/min)
2994655|NCT02598791|Active Comparator|GLP-1|4 hour i.v. infusion of glucagon-like peptide-1 (1 pmol/kg/min)
2994656|NCT02598791|Placebo Comparator|NaCl (placebo)|4 hour i.v. NaCl (placebo)
2994657|NCT02598791|Active Comparator|GIP + GLP-1|4 hour co-infusion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1
2994658|NCT02598778|Active Comparator|Chlorhexidine gluconate (.12%)|An oral rinse given to pediatric patients in routine practice within the standard of care.
2994659|NCT02598778|Active Comparator|Sodium fluoride oral rinse (.05%)|An oral rinse given to pediatric patients in routine practice within the standard of care.
2994660|NCT02598778|Active Comparator|Coconut oil|A food product. In previous studies it has shown positive effects on the reduction of oral plaque and gingivitis as an oral rinse.
2994661|NCT02598778|Placebo Comparator|Deionized water|Water that has had the majority of its ions removed.
2994662|NCT02598765|Active Comparator|Standard Trabeculectomy|Patients in the Standard Trabeculectomy arm will undergo regular trabeculectomy
2994663|NCT02598765|Experimental|Microtrabeculectomy|Patients in the Microtrabeculectomy arm will undergo microtrabeculectomy
2994664|NCT02598752||functional performance testing|This observational study will evaluate the feasibility and safety of functional performance testing in patients undergoing HCT. In addition to standard of care procedures, participants will undergo a CPET with a rest and stress echo, pulmonary function, and patient reported outcome questionnaires within 30 days of HCT.
2994665|NCT02598739|Experimental|Resistance exercise|"Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension."
2994666|NCT02598739|Other|Control group|Waiting list for the exercises.
2994667|NCT02598726|Experimental|Supportive care (curcumin, piperine)|Patients receive curcumin PO BID or TID and piperine extract (standardized) PO on days 1-7 in the absence of disease progression or unacceptable toxicity.
2994668|NCT02598713|Experimental|Aspiration Markers|Aspiration marker solution will be composed as following: Quinine 83 mg/L suspended in sterile water. After enrollment patients will be challenged with 5 mL of the study solution nebulized in the retropharyngeal space twice a day for two consecutive days.
2994669|NCT02598687|Other|treatment|treatment arm: TH-302 pre-treatment day 4 and weekly during treatment. 5 x carboplatin and paclitaxel, radiotherapy: 23 x 1.8Gy HX4 scans day 1 and day 8,surgery 6-10 weeks after chemo-radiotherapy
2994670|NCT02598674||Sepsis with Severe AKI|"This group will have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI) which lead to classification of injury or failure. The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV)."
2994671|NCT02598674||Control|This group will not have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI). The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).
2994672|NCT02598661|Experimental|Part 1: Imetelstat|Imetelstat will be administered at a starting dose of 7.5 milligram per kilogram (mg/kg) given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.
2994673|NCT02598661|Experimental|Part 2: Imetelstat|Imetelstat will be administered at a starting dose of 7.5 milligram per kilogram (mg/kg) given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.
2994674|NCT02598661|Placebo Comparator|Part 2: Placebo|Matching Placebo to Imetelstat will be administered.
2994675|NCT02598648|Other|ALI( acute lung injury)|Diagnostic criteria: 1.Acute onset；2.FiO2/ PaO2＜ 40.0 kPa (300mmHg, ALI); 3.Chest X-ray showed that the double lung texture increased, the increase of crude, fuzzy, visible diffuse patchy infiltration shadow with compensatory emphysema, for the most early performance; B. double lung field large sheet, asymmetric, edge fuzzy infiltration shadow, the most dense in the lung；4. Echocardiography, left atrial hypertension; 5.The gestational age >35 week, have maternal age cholestasis (severe), sepsis or meconium aspiration syndrome (MAS) understanding of history, and with the exception of the primary pulmonary surfactant (PS) lack of. FXR and RIPK3 were measured in neonate with ALI.
2994676|NCT02598648|Other|ARDS(respiratory distress syndrome)|"ARDS :Diagnostic criteria: 1.Acute onset；2.FiO2/ PaO2＜ 26.7 kPa (200mmHg, ARDS); 3.Chest X-ray showed that the double lung transparent brightness is generally lower, the glass sample, with bronchial inflatable sign, and even double lung field common density increased, the heart shadow is not clear, a white lung, as the most important performance；4. Echocardiography, left atrial hypertension; 5.The gestational age >35 week, have maternal age cholestasis (severe), sepsis or meconium aspiration syndrome (MAS) understanding of history, and with the exception of the primary pulmonary surfactant (PS) lack of；6.Need to use a ventilator.~FXR and RIPK3 were measured in neonate with ALI.were measured in another group neonate with ARDS"
2994677|NCT02598648|Other|control|Control group: Patients with mechanical ventilation due to external causes of the lung, no ALI-ARDS performance,FiO2/ PaO2＜ 40.0 kPa (300 mmHg), such as premature apnea or HIE. FXR and RIPK3 were measured in neonate with HIE
2994678|NCT02598635|Experimental|Cholecalciferol|A capsule of pulverized cholecalciferol 4800 U will be administered once a day for 16 weeks. At serum calcium levels > 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels > 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to < 10.6 mg/dL and/or <7.1 mg/dL respectively.
2994679|NCT02598635|Placebo Comparator|Placebo|An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks. At serum calcium levels > 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels > 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to < 10.6 mg/dL and/or <7.1 mg/dL respectively.
2994680|NCT02598622|Experimental|Acetyl-L-Carnitine only|The first 15 subjects participating in this study will receive Acetyl-L-Carnitine and pharmacokinetic testing will be done.
2994681|NCT02598622|Experimental|Acetyl-L-Carnitine or Placebo|Subjects 16-30 will be randomized to receive drug or placebo.
2994682|NCT02598609|Other|Cluster A|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster A. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 4 months. The intervention is implemented during 4 months. The length of the post interventional period is 12 months.
2994683|NCT02598609|Other|Cluster B|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster B. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 8 months. The intervention is implemented during 4 months. The length of the post interventional period is 8 months.
2994684|NCT02598609|Other|Cluster C|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster C. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 12 months. The intervention is implemented during 4 months. The length of the post interventional period is 4 months.
2994685|NCT02598596|Experimental|Pegloticase regimen <120 kg - Main Study|Subjects weighing <120 kg will receive a tolerizing dose of pegloticase 8 mg IV weekly for the first 3 weeks of dosing followed by an 8 mg IV dose every 2 weeks for a total of 10 doses.
2994686|NCT02598596|Experimental|Pegloticase regimen ≥120kg|Subjects weighing ≥ 120 kg will be sequentially assigned to 1 of 3 different loading doses (8, 12, and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses.
2994687|NCT02598596|Experimental|Pegloticase PK Sub-Study|Subjects weighing <120 kg and ≥120 kg will be assigned to 1 of 2 different loading doses (12 and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses. Subjects will have multiple blood sampled for PK levels over the 17 week dosing period.
2994688|NCT02598596|Experimental|Pegloticase Imaging Sub-Study|A subset of subjects participating in the Main Study and weighing <120 kg will have dual-energy computed tomography (DECT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) performed at Screen and at Week 17.
2994689|NCT02598596|Experimental|Pegloticase FDG-PET-CT Sub-Study|A subset of subjects participating in the Main Study and weighing <120 kg will have fluorodeoxyglucose-positron emission tomography (FDG-PET-CT) to evaluate carotid and aortic (chest) atherosclerosis at Screen and at Week 17.
2994690|NCT02598596|Experimental|Pegloticase and Azathioprine|Subjects weighing <120 kg will receive azathioprine (AZA) daily for a 2-week run-in period, followed by daily AZA plus pegloticase 8 mg IV every 2 weeks through Week 25 for a total of 13 doses.
2994691|NCT02598583|Experimental|Cohort 1|"Intravenous infusion of ALXN1210 as follows:~Induction phase: a) 400 mg on Day 1 and Day 8, 600 mg on Day 15; OR b) 600 mg on Day 1, 600 mg on Day 15~Maintenance phase: 900 mg on Day 29 and each month thereafter~On Day 477, the dose and dosing interval for all patients will change to an every 8 week, weight-based regimen as follows:~≥ 40 to <60 kg: 3000 mg every 8 weeks~≥ 60 to <100 kg: 3300 mg every 8 weeks~≥100 kg: 3600 mg every 8 weeks"
2994692|NCT02598583|Experimental|Cohort 2|"Intravenous infusion of ALXN1210 as follows:~Induction phase: 600 mg on Day 1, 900 mg on Day 15~Maintenance phase: 1800 mg on Day 29 and each month thereafter~On Day 477, the dose and dosing interval for all patients will change to an every 8 week, weight-based regimen as follows:~≥ 40 to <60 kg: 3000 mg every 8 weeks~≥ 60 to <100 kg: 3300 mg every 8 weeks~≥100 kg: 3600 mg every 8 weeks"
2994694|NCT02598557|Experimental|Arm I (exemestane)|Patients receive exemestane PO QD on days 1-7. Courses repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
2994695|NCT02598557|Experimental|Arm II (exemestane, placebo)|Patients receive exemestane PO QD on days 1, 3, and 5. Patients also receive placebo PO QD on days 2, 4, 6, and 7. Courses repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
2994696|NCT02598557|Experimental|Arm III (exemestane, placebo)|Patients receive exemestane PO QD on day 1 and placebo PO QD on days 2-7. Courses repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
2994697|NCT02598544|Other|lean men|
2994698|NCT02598544|Other|Obese men without type 2 diabetes|
2994699|NCT02598544|Other|Obese men with type 2 diabetes|
2994700|NCT02598531||Test Arm|Test Arm participants will be enrolled in the standard of care bariatric surgery program and will undergo surgical weight loss through Laparoscopic Sleeve Gastrectomy or Laparoscopic Gastric Bypass. Approximately 9-13 months post surgery, each participant will be evaluated to determine if he/she is still eligible for a total knee replacement or if their need has been removed. If still eligible, participants will be enrolled in the standard of care TKA program and will undergo a TKA procedure. Participants will complete nine (9) research visits over 3.5-4 years.
2994701|NCT02598531||Control Arm|Control Arm participants will be enrolled in the standard of care TKA program and complete six (6) research visits over 2.5-3 years. This group of participants will undergo a TKA procedure without any surgical weight loss intervention.
2994702|NCT02598518|Experimental|Integrating Combined Therapies|Integrating Combined Therapies (ICT) is a 10-session, manual-guided individual therapy. ICT has three phases designed to address substance use, psychiatric problems and their interactions. MET is the first phase (2 sessions) and is focused on assessment, feedback and securing motivation to address problems and take steps. CBT is the second phase (5 sessions) and incorporates patient education and functional analysis, develops coping skills, teaches methods to challenge beliefs, and activates alternative behaviors. TSF (3 sessions) is focused on maintaining recovery and engaging in community-based recovery activities. Although ICT has core components, its application is flexible to accommodate the unique needs and problems of individual patients (and their comorbidities).
2994703|NCT02598518|Active Comparator|Standard Care|Standard Care (SC) is the typical outpatient treatment that the patient would receive ordinarily at the identified addiction treatment program. SC service operates using the American Society of Addiction Medicine criteria (9 hours per week); group and individual sessions focused on motivation to address substance use, education about the consequences of substance use on major life areas, education about the disease concept and brain changes associated with addiction, exposure to information about social and family relationships and recovery, and relapse prevention skills.
2994704|NCT02598505|Experimental|Indacaterol|Inside this arm we also compare the effect of Carvedilol to the effect of Bisoprolol
2994705|NCT02598505|Placebo Comparator|Placebo|Inside this arm we also compare the effect of Carvedilol to the effect of Bisoprolol
2994706|NCT02598492||Imputation of SF to PF|Patients required invasive mechanical ventilation within 6 hours after intubation
2994707|NCT02598479||IPTLD and nutrition therapy|Patients presenting to the Arizona Center for Advanced Medicine for the treatment of cancer using Insulin Potentiation Low Dose Chemotherapy and Nutrition Therapy
2994708|NCT02598466||Abatacept|
2994709|NCT02598453|Experimental|Ibandronate IV|Participants will receive ibandronate 3 mg IV once every 3 months
2994710|NCT02598453|Experimental|Ibandronate Oral|Participants will receive ibandronate 150 milligrams (mg) tablet once monthly
2994711|NCT02598440|Experimental|Group A: Ibandronate Then Alendronate|Participants wil receive once-monthly oral ibandronate (150 mg tablet) for 3 months followed by and once-weekly oral alendronate (70 mg tablet) in crossover design for 12 weeks.
2994712|NCT02598440|Experimental|Group B: Alendronate Then Ibandronate|Participants will receive once-weekly oral alendronate (70 mg tablet) for 12 weeks followed by once-monthly oral ibandronate (150 mg tablet) for 3 months.
2994713|NCT02598427|Experimental|Intrathecal Pertuzumab and Trastuzumab|"Four cohorts will enroll in a dose escalation of pertuzumab and a consistent dose of trastuzumab. The cohorts will be assigned as follows:~Cohort: Intrathecal Dose:~10mg pertuzumab, 80mg trastuzumab~20mg pertuzumab, 80mg trastuzumab~40mg pertuzumab, 80mg trastuzumab~80mg pertuzumab, 80mg trastuzumab"
2994714|NCT02598414|Experimental|Bowel Anastomosis Under ICG Guidance|Patients undergo robotic colon/rectal resection and anastomosis with near-infrared ICG fluorescence imaging.
2994715|NCT02598414|Active Comparator|Standard Bowel Anastomosis|Patients undergo robotic colon/rectal resection and anastomosis without near-infrared ICG fluorescence imaging.
2994716|NCT02598388|Experimental|Part 1 (US Participants)|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.ZEBOV or placebo on Day 15.
2994717|NCT02598388|Experimental|Part 2 Group 1 (African Participants)|Participants will receive Ad26.ZEBOV or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 29.
2994718|NCT02598388|Experimental|Part 2 Group 2 (African Participants)|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.ZEBOV or placebo on Day 15.
2994719|NCT02598375||Children with feeding intolerance|Critically ill children having with respiratory or catecholamine support in PICU have the feeding intolerance at least for12 hours or more.
2994720|NCT02598375||Children without feeding intolerance|Critically ill children having with respiratory or catecholamine support in PICU have not the feeding intolerance signs at least for 12 hours or less
2994721|NCT02598362|Other|intravenous|Participants who are treated with ciprofloxacin intravenously, at discretion of the treating physician.
2994722|NCT02598362|Other|oral|Participants who are treated with ciprofloxacin via the oral route, at discretion of the treating physician.
2994776|NCT02597920||New AF patients / B|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
2994777|NCT02597907|Experimental|aprepitant plus palonosetron|aprepitant 80 mg palonosetron 0.075 mg
2994778|NCT02597907|Active Comparator|aprepitant plus ramosetron|aprepitant 80 mg ramosetron 0.3 mg
2994779|NCT02597894|Other|Prostate biopsy|Patients undergo two biopsies, the first at baseline before start of ADT and the second two months later during brachytherapy.
2994723|NCT02598349|Experimental|Proton Radiation with capecitabine|"The following will be performed in this group: Proton Radiation Therapy with concomitant oral chemotherapy, capecitabine taken on radiation treatment days for 6 weeks. A surgical resection will be performed between 8 and 16 weeks if radiographic studies suggest operability.~Additionally, a Functional Assessment of Cancer Therapy (FACT-Hep) questionnaire is to be filled out by participants at baseline, at week 4 and week 6, then 1 month after completion of treatment, then every 3 months for 1 year, and then every 6 months for 3 years. The FACT-Hep questionnaire is specific to those with gastrointestinal cancers focusing on hepatobiliary and pancreatic cancer."
2994724|NCT02598336|Other|Breathing Sequence|Simultaneous measurement using Structured Light Plethysmography and Pneumotachograph Spirometry during a period of tidal breathing followed by a forced respiratory manoeuvre. This sequence is repeated twice.
2994725|NCT02598336|Other|Agreement and repeatability Breathing Sequence|Simultaneous measurement using Structured Light Plethysmography and Pneumotachograph Spirometry during a period of tidal breathing. This sequence is repeated one further time at rest, and once further time after an exercise test to elevate respiratory rate.
2994726|NCT02598323|Experimental|patients with active singleton pregnancy between 16 and 26 SA|
2994727|NCT02598310|Experimental|nab-paclitaxel plus trastuzumab|Four cycles of nab-PTX 260 mg/m2 with trastuzumab 6 mg/kg (8 mg/kg as the loading dose). One year of adjuvant trastuzumab will be administrated. Anthracycline regimens may be administered by physician's choice for the case expected to have a high risk of recurrence based on the pathological findings of surgical specimen. Adjuvant endocrine therapy may be administrated for the case with weakly hormone-sensitive (1-9% of positive cells) tumor.
2994728|NCT02598297|Active Comparator|Ruxolitinib|Ruxolitinib 10 mg BID (Blinded)
2994729|NCT02598297|Placebo Comparator|Ruxolitinib Placebo|Placebo 10 mg BID (Blinded)
2994730|NCT02598284|Experimental|Point of Care (POC) Only|Clinics will receive facilitation to implement point-of-care (POC) quality improvement strategies to accelerate performance on ABCS clinical measures. All strategies will focus on aspects of the clinical encounter.
2994731|NCT02598284|Experimental|POC + Population Managment (PM)|Clinics will receive facilitation to implement point-of-care (POC) quality improvement strategies as well as population management (PM) strategies to accelerate performance on ABCS clinical measures. Strategies in this arm will occur both at the clinical encounter and strategies aimed at the time between clinical encounters.
2994732|NCT02598271||Low SCr|Patients with a serum creatinine below or equal to 1.3mg/dL
2994733|NCT02598271||High SCr|Patients with a serum creatinine above to 1.3mg/dL
2994734|NCT02598258|Experimental|Sauna + Cold Water Bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after , subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
2994735|NCT02598245|Active Comparator|TOT 8/4|"Transobturator sling (TOT) is placed according to the original description. Instead of a Metzenbaum Scissor which should guarantee the distance between the urethra and the sling a Hegar dilator sound of 4 mm diameter is used (Hegar 4). An additional Hegar dilator sound of 8 mm is placed in the urethra before tightening the sling and suturing the vaginal skin."
2994736|NCT02598245|Experimental|TOT 6/3|"Transobturator sling (TOT) is placed according to the original description. Instead of a Metzenbaum Scissor which should guarantee the distance between the urethra and the sling a Hegar dilator sound of 3 mm diameter is used (Hegar 3). An additional Hegar dilator Sound of 6 mm is placed in the urethra before tightening the sling and suturing the vaginal skin."
2994737|NCT02598232|Experimental|1,414nm Nd:YAG laser|It has high absorption coefficient in water and a short pulse width.
2994738|NCT02598219|Experimental|Pre-operative SN mapping with Nanocis|"1 'Pre-operative Sentinel Node (SN) mapping with Nanocis'~2- Intra-operative SN mapping with patent V blue dye, or Intra-operative SN mapping with indocyanin green for patients with known hypersensitivity, allergy to patent V blue dye~3- Full bilateral laparoscopic lymphadenectomy and Hysterectomy: If bilateral SN are detected, all positive SN are removed, then the surgeon proceeds to a total hysterectomy. If non SN are detected, or only unilateral SN are detected, the surgeon will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral lymphadenectomy with more enlarged dissection regardless the pathology."
2994739|NCT02598219|Other|B : Current initial staging protocols|Current French initial staging protocols
2994740|NCT02598206|Experimental|Experimental 1|"All subjects will receive 2 treatments in one of the indicated sequence orders:~A - B B - A"
2994741|NCT02598193|Experimental|Pirfenidone+Nintedanib|Participants with IPF will receive pirfenidone at 1602-2403 milligrams per day (mg/day) dose and nintedanib at the 200-300 mg/day dose up to 24 weeks.
2994742|NCT02598180|Experimental|VergenixTM Flowable Gel|VergenixTM Flowable Gel
2994743|NCT02598167||RRMS Population|Participants with a diagnosis of RRMS and being prescribed with a DMT for a period of at least 3 months according to standard local clinical practice will be included.
2994744|NCT02598154||Study population|The study population consists of patients whose age is between 20 and 75 years and who experienced a supra-tentorial ischemic or hemorrhagic stroke. The study covers inpatients or patients consultating in the neurological rehabilitation service (NHS) at the Grau du Roi Medical Center, Nîmes University Hospital.
2994745|NCT02598141|Other|Per-op biopsy around material|"Patients included in this study require biopsies for suspicion of infected osteo-articular materials (implants, protheses, nails, screw, plates).~Interventions:~Biological sampling grinding~Biological sampling with standard procedures"
2994746|NCT02598128|Experimental|RELiZORB|Treatment (RELiZORB)
2994747|NCT02598128|Placebo Comparator|Control|Placebo control
2994748|NCT02598115|No Intervention|Before collarborative pharmaceutical care|"All clusters start in this arm for 15 days. Following the start of the study, 1 randomly chosen cluster will switch to the experimental arm every 15 days.~Days 1 to 15: all clusters in the before arm Days 16 to 30: 1 cluster in the Collaborative Pharmaceutical Care arm Days 31 to 45: 2 clusters in the Collaborative Pharmaceutical Care arm Days 46 to 60: 3 clusters in the Collaborative Pharmaceutical Care arm Days 61 to 75: 4 clusters in the Collaborative Pharmaceutical Care arm Days 76 to 90: 5 clusters in the Collaborative Pharmaceutical Care arm Days 91 to 105: all 6 clusters in the Collaborative Pharmaceutical Care arm"
2995305|NCT02594358|Active Comparator|Caffeine 20 mg|Patching plus once daily caffeine for 12 weeks
2994749|NCT02598115|Experimental|After collarborative pharmaceutical care|"All clusters start in the No Intervention arm for 15 days. Following the start of the study, 1 randomly chosen cluster will switch to the experimental arm every 15 days.~Days 1 to 15: all clusters in the before arm Days 16 to 30: 1 cluster in the Collaborative Pharmaceutical Care arm Days 31 to 45: 2 clusters in the Collaborative Pharmaceutical Care arm Days 46 to 60: 3 clusters in the Collaborative Pharmaceutical Care arm Days 61 to 75: 4 clusters in the Collaborative Pharmaceutical Care arm Days 76 to 90: 5 clusters in the Collaborative Pharmaceutical Care arm Days 91 to 105: all 6 clusters in the Collaborative Pharmaceutical Care arm"
2994750|NCT02598102|Experimental|Diclofenac sodium|Oral diclofenac 75 mg one hour prior to stent removal
2994751|NCT02598102|Placebo Comparator|Placebo|Placebo one hour prior to stent removal
2994752|NCT02598089|Experimental|Trivalent Seasonal Influenza Vaccine|"0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains:~NYMC BX-51B reassortant of B/Massachusetts/2/2012~NYMC X‐179A reassortant of A/California/7/2009 (H1N1)~NYMC X-223A reassortant of H3/A/Texas/50/2012 (H3N2)"
2994753|NCT02598089|Placebo Comparator|Placebo|0.5 mL of Phosphate Buffered Saline
2994754|NCT02598076|Active Comparator|control|Group will receive standard treatment for psychogenic non-epileptic seizures. They will undergo an initial clinic visit with a neuropsychiatrist and neurologists. They will not undergo any subsequent motivational interview. Following the initial clinic visit, all subjects with ongoing seizures will either be scheduled for ongoing psychotherapy for treatment of PNES at Brigham and Women's Hospital or referred to a local psychotherapist according to their preference.
2994755|NCT02598076|Experimental|MI|"Group will receive an initial clinic visit with a neuropsychiatrist and neurologists, identical to the initial clinic visit for the control group. In addition they will receive 1 session of motivational interviewing immediately following the initial clinic visit. These patients will be questioned using standardized motivational interviewing techniques by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.~Following the initial clinic visit, all subjects with ongoing seizures will either be scheduled for ongoing psychotherapy for treatment of PNES at Brigham and Women's Hospital or referred to a local psychotherapist according to their preference (identical treatment in control and MI arms)."
2994756|NCT02598063|Active Comparator|ADV + Lamivudine|Participants will receive ADV and lamivudine tablets at a dose of 10 mg orally QD for first 12 weeks followed by ADV for 60 weeks.
2994757|NCT02598063|Experimental|Peginterferon alfa-2a + Lamivudine|Participants will receive peginterferon alfa-2a injection at a dose of 180 micrograms (mcg) once weekly (QW) and 100 milligrams (mg) lamivudine tablets orally once daily (QD) for first 12 weeks followed by peginterferon alfa-2a for 36 weeks.
2994758|NCT02598050||older surgical patients|Mini Cog
2994759|NCT02598037|Other|FTO gene polymorphism|test meal after fasting for 12 hours
2994760|NCT02598024|Experimental|Narrative Exposure Therapy (NET-R)|Revised Narrative Exposure Therapy (NET-R) is a 4-session manual-based treatment, each session lasting 60-90-minutes, and first three sessions delivered daily and the last session after a gap of 1-2 days
2994761|NCT02598024|Experimental|Control Focused Behavioural Treatment|CFBT is an intervention to facilitate natural recovery process by restoring sense of control over anxiety, fear, or distress. For this study in Nepal, a monitoring session will be added to the one-session group CFBT used by Basoglu and Salcioglu (2011), and the revised CFBT would be delivered to groups of 20-30 survivors. Each treatment session would be delivered within 1- 2 hours (90 minutes on average), at the interval of two weeks.
2994762|NCT02598024|No Intervention|Waiting List Control|The waiting list participants will receive the treatment of choice (NET-R or CBFT-R) after 3 months.
2994763|NCT02598011|Experimental|Toca 511/Toca FC at 170 mg/kg/day|"Toca 511: 4 mL administered by intracranial parenchymal injection into the walls of the resection cavity following tumor resection or, for those subjects who are not candidates for resection, via stereotactic injection into their tumor using a standard Nashold-type side cutting biopsy needle.~Toca FC: Approximately 4 to 6 weeks after tumor resection, subjects will begin temozolomide concurrent with radiation therapy. During concurrent chemoradiation at the start of the second and sixth week of concurrent chemoradiation and every 28 days thereafter, a 7-day course of oral Toca FC will be dosed at 170 mg/kg/day"
2994764|NCT02598011|Experimental|Toca 511/Toca FC at 220 mg/kg/day|"Toca 511: 4 mL administered by intracranial parenchymal injection into the walls of the resection cavity following tumor resection or, for those subjects who are not candidates for resection, via stereotactic injection into their tumor using a standard Nashold-type side cutting biopsy needle.~Toca FC: Approximately 4 to 6 weeks after tumor resection, subjects will begin temozolomide concurrent with radiation therapy. During concurrent chemoradiation at the start of the second and sixth week of concurrent chemoradiation and every 28 days thereafter, a 7-day course of oral Toca FC will be dosed at 220 mg/kg/day"
2994765|NCT02597998|Experimental|14C-BI 409306|14C-BI 409306 oral solution
2994766|NCT02597985|Active Comparator|Prehabilitation|Will receive 4 weeks of supervised exercised prescription before they undergo TAVR and will monitor and record, improvement if any, in the short-term physical performance battery score
2994767|NCT02597985|Placebo Comparator|Usual care|Will receive usual care
2994768|NCT02597972|Active Comparator|Open Reduction Internal Fixation Proximal Humerus|The patients randomized into the ORIF group will receive standard surgical treatment of their proximal humerus fracture with a proximal humeral locking plate.
2994769|NCT02597972|Active Comparator|Reverse Total Shoulder Arthroplasty|The patients randomized into the RTSA group will receive standard surgical treatment of their proximal humeral fracture with a Reverse Total Shoulder Arthroplasty.
2994770|NCT02597959||risk factors of musculoskeletal injuries|trainees for surgical assistants - determining the level of risk
2994771|NCT02597959||design wearable devices|Creating feedback mechanism to reduce surgical assistant musculoskeletal risk
2994772|NCT02597946|Experimental|all patients|Part A: all enrolled patients will receive afatinib monotherapy. Part B: all eligible patients will receive afatinib combined with weekly paclitaxel.
2994773|NCT02597933|Experimental|Nintedanib|patient receives capsules containing nintedanib twice a day
2994774|NCT02597933|Placebo Comparator|Placebo|patient receives capsules identical to those containing active drug
2994775|NCT02597920||Switch patients / A|Patients with non-valvular atrial fibirillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
2994780|NCT02597868|Active Comparator|Capecitabine|Capecitabine 1250mg per BSA by mouth twice per day for 14 days, per 21 days as a cycle, until disease progress or toxicity can not be tolerated.
2994781|NCT02597868|Experimental|endocrine therapy|endocrine therapy is be gived as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemotreatment,the medcine will be confirmed by the patient's past-treatment.
2994782|NCT02597855||Type 1 polypoidal choroidal vasculopathy|Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
2994783|NCT02597855||Type 2 polypoidal choroidal vasculopathy|Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
2994784|NCT02597842|Experimental|shuangxuezu|Patients were given 30min of TEAS before induction until the end of the operation at two acupoints.
2994785|NCT02597842|Experimental|neiguanxuezu|Patients were given TEAS at neiguan acupoint.
2994786|NCT02597842|Experimental|zusanlixuezu|Patients were given TEAS at Zusanli acupoint.
2994787|NCT02597842|Sham Comparator|duizhaozu|Patients were not given TEAS at two acupoints.
2994788|NCT02597829|Other|Open Label Certolizumab Pegol|Active Treatment
2994789|NCT02597816|Other|Three dimensional ultrasound|Infertile women with diagnosis of arcuate and septate uterus based on Hystro-salpingography were recruited. All women were examined by Three dimensional ultrasound on day 22 cycle to allow for better delineation of the uterine contour. The outer and inner fundal contours and the length of the fundal notch were examined by Three dimensional ultrasound in the mid-coronal view of the multi-planar and multi-slice display of the uterus. The final diagnosis of the anomalies was based on combined hysteroscopy/laparoscopy examination, the gold standard.
2994790|NCT02597803|Experimental|High Dose RGN-259|High dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
2994791|NCT02597803|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
2994792|NCT02597803|Experimental|Low Dose RGN-259|Low dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
2994793|NCT02597790||Group A (HIV/HCV coinfected)|
2994794|NCT02597790||Group B (HIV monoinfected)|
2994795|NCT02597777|Placebo Comparator|Side of face receiving placebo vehicle|One half of the face (left or right side) will be randomized to receive the placebo lotion. Subjects will be asked to apply a pea-sized amount of the lotion to half of the face at twice daily application for 4 weeks.
2994796|NCT02597777|Experimental|Side of face receiving AH8 lotion|One half of the face (left or right side) will be randomized to receive the 10% Acetyl Hexapeptide-8 containing (AH8) lotion. Subjects will be asked to apply a pea-size amount of the lotion to the half of the face twice daily application for 4 weeks.
2994797|NCT02597764|Active Comparator|Standard Urotherapy (SU)|Standard Urotherapy (SU): A non-invasive therapy combining cognitive, behavioral and physical therapy. The study team will explain the problem to the children and their parents and educate them on the following: proper voiding mechanics, sitting, standing positions, how and when to void, techniques on relaxing pelvic floor muscles, and avoiding straining. An assessment of bowel habits will be done and their diet and drinking/voiding habits will be modified to maintain proper hydration with timed voiding. Voiding diaries will be provided for the assessment of the bladder and bowel habits.
2994798|NCT02597764|Experimental|Standard Urotherapy (SU) + Diaphragmatic Beathing (DB)|"Standard Urotherapy (SU) with the addition of Diaphragmatic Breathing (DB):~A non-invasive breathing technique that is performed by a marked expansion of the abdomen (contracting diaphragm) rather than chest cavity during inspiration and tightening of the stomach muscles during expiration. Participants will lie on their back on a flat surface. Head is supported with a pillow and knees are bent forward supported by another pillow. Participants will place one hand on chest and the other on the abdomen, then start inhalation by moving their abdomen out against their hand, breathing in through their nose while keeping their chest and the other hand as still as possible. During expiration, the participants will tighten their abdominal muscles by forcing them inward and breathe out through pursed lips while keeping the hand on the chest as still as possible. Participants will be asked to perform this exercise for 10 minutes 3 times daily for 3 months."
2994799|NCT02597751|Experimental|Treatment Arm|Participants are randomized to treatment group. After the first MRI scan, participants are assessed by an independent occupational therapist (before and after intervention) and participate in 10 treatment sessions with a treating occupational therapist. Following the post-treatment assessment, participants have a second MRI scan. Twelve weeks later, participants have a third, follow-up scan.
2994800|NCT02597751|No Intervention|Waitlist control|"Participants are randomized to the waitlist control group. After the first MRI scan, participants wait for 12 weeks and then have a 2nd MRI scan. Participants then have 10 treatment sessions with an occupational therapist and are assessed by an independent occupational therapist before and after treatment. Participants then have a third MRI scan to examine brain changes associated with intervention."
2994801|NCT02597738|Experimental|Cohort A: Lung Cancer Group|Cohort A: Fresh tissue biopsy and blood collection A One time Fresh tissue biopsy of the patient's lung cancer (outside of their normal standard of care biopsy) will be collected for the research. Patients will also complete research blood sample collections every two to four weeks for one year.
2994802|NCT02597738|Experimental|Cohort B: Chronic inflammatory disease|Non-Smokers with chronic inflammatory diseases - A one time blood sample collection will be completed.
2994803|NCT02597738|Experimental|Cohort C: Smokers without lung cancer|Smokers without lung cancer - A one time blood sample collection will be completed.
2994804|NCT02597725||Urodynamics|There is no intervention in this study.
2994805|NCT02597712|Experimental|Treatment|Patients will take 25 mg YF476 once daily for 12 weeks
2994806|NCT02597712|Placebo Comparator|YF476 Placebo|Patients will take matching placebo once daily for 12 weeks
2994807|NCT02597699|Active Comparator|reference protocol|reference protocol : Sufentanil ® associated with Xylocaine ® in Procedure of foeticide
2994808|NCT02597699|Experimental|experimental protocol|experimental protocol : Ultiva ® associated wih a lethal reference agent, Xylocaine ® in Procedure of foeticide
2994809|NCT02597686|Experimental|SD-PB training|
2995306|NCT02594358|Active Comparator|Caffeine 40 mg|Patching plus once daily caffeine for 12 weeks
2994810|NCT02597673|No Intervention|Standard rehabilitation protocol|All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. The HEP sessions provide the participant with a self-management framework for returning to duty following PFPS rehabilitation. The exercises are quadriceps strengthening exercises. These exercises consist of stretching exercises of the quadriceps and hamstring muscles and a combination of open chain and closed chain exercises. The combined open and closed chain exercises are active straight leg raises, quadriceps straightening, step up, and squats.
2994811|NCT02597673|Experimental|Self-Managed NMES Program|Neuromuscular electrical stimulation (NMES). This group will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the HEP for 9 weeks; each 20-minute NMES session includes a 2-minute warm-up, a 15-minute work-out and a 3-minute cool down. NMES with the thigh garment will be used as the participant is performing the home exercises of stretching and combined open and closed chain exercises. Those in the NMES group will alternate HEP alone and NMES with HEP for a total of 62 sessions (31 sessions of NMES/HEP and 31 sessions HEP alone).
2994812|NCT02597673|Experimental|Self-Managed TENS Program|Transcutaneous electrical nerve stimulation (TENS). The TENS treatment groups will receive the battery-operated Kneehab® XP with lead wire TENS applicator system. The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks for a total of 31 TENS/HEP sessions and 31 HEP alone for a total of 62 sessions.
2994813|NCT02597673|Experimental|Combined NMES/TENS Program|The combined NMES/TENS treatment group will receive the Kneehab® XP with the conductive thigh garment and the lead wire TENS applicator. The same parameters for TENS and NMES will be used (described above). The NMES and the TENS protocol will be performed on alternating days. There will be a total of 31 NMES sessions with HEP and 31 TENS sessions with HEP for a total of 62 sessions.
2994814|NCT02597660|Active Comparator|Drug: Somatropin|Under ultrasound guidance, patients will receive an injection of somatropin (0.1mg in a volume of 0.2mL of bacteriostatic saline) into the area of tendinopathic lesion. A series of three injections will be delivered one week apart. Vials will be blinded.
2994815|NCT02597660|Placebo Comparator|Drug: Placebo|Under ultrasound guidance, patients will receive an injection of 0.2mL of bacteriostatic saline (which is an equivalent volume of diluent used in the active comparator arm) into the area of tendinopathic lesion. A series of three injections will be delivered one week apart. Vials will be blinded.
2994816|NCT02597647|Experimental|Live attenuated influenza vaccine|Healthy adult volunteers given intranasal FluMist (Live Attenuated Influenza vaccine). Subjects will undergo nasal swabs, nasopharyngeal washes, and nasal epithelial brushings at baseline, 1-2 weeks, and 4-6 weeks after LAIV.
2994817|NCT02597647|Placebo Comparator|Saline nasal spray|Healthy adult volunteers given intranasal saline nasal spray. Subjects will undergo nasal swabs, nasopharyngeal washes, and nasal epithelial brushings at baseline, 1-2 weeks, and 4-6 weeks after saline administration.
2994818|NCT02597634|Experimental|SST-0225|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
2994819|NCT02597634|Placebo Comparator|Placebo|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
2994820|NCT02597621||M/XDR|The M/XDR-cohort will consist of patients with a suspected infection with an M/XDR-TB strain.The suspicion will be held on behalf of molecular biological methods (i.e. GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The suspected cases will be confirmed by culture (n= 20). Empirically, less than 10% of the cases have an XDR-TB
2994821|NCT02597621||Susceptible|The non M/XDR-TB cohort will consist of patients with no suspected infection with an M/XDRTB strain. The suspicion will be out ruled on behalf of molecular biological methods (i.e.GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The non M/XDR-TB cases will be confirmed by culture (n= 20). Empirically, about 90% of these patients have no drug resistance against first line drugs.
2994822|NCT02597621||Healthy Controls|Healthy controls.
2994823|NCT02597608|Experimental|UPPR: Control|No interventions are provided.
2994824|NCT02597608|Experimental|UPPR: Livelihoods only|Livelihoods programmes offered by UPPR.
2994825|NCT02597608|Experimental|UPPR: Livelihoods plus nutrition|Livelihoods programmes offered by UPPR, plus nutrition programmes offered by UPPR.
2994826|NCT02597608|Experimental|CLP: Livelihoods only|Livelihoods programmes offered by CLP.
2994827|NCT02597608|Experimental|CLP: Livelihoods plus nutrition|Livelihoods programmes offered by CLP, plus nutrition programmes offered by CLP.
2994828|NCT02597608|Experimental|Shiree: Livelihoods only|Livelihoods programmes offered by Shiree.
2994829|NCT02597608|Experimental|Shiree: Livelihoods plus nutrition|Livelihoods programmes offered by Shiree, plus nutrition programmes offered by Shiree.
2994830|NCT02597595|Experimental|patients|thirty children with beta thalassemia major, with age range from 4-18 years, will receive oral spirulina (tablets=500 mg) for 3 months with a dose of 250 mg/kg/day (maximum dose 4 gm)
2994831|NCT02597595|No Intervention|controls|thirty healthy children of matched age and sex
2994859|NCT02597439|Placebo Comparator|Placebo|Subjects will be treated daily with placebo for six months. Placebo capsules will contain a 1:1 combination of coconut oil and medium chain triglycerides because these do not contain polyunsaturated fatty acids and have no impact on omega-3 fatty acid metabolism. Placebo capsules also contain the same amount of vitamin E as the omega-3 capsules and 1% fish oil to mimic flavour and taste.
2994992|NCT02596425|Experimental|Passive deflation|In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
2994832|NCT02597582|Active Comparator|Ligusure assisted neck dissection|"The study group patients were treated using the LigaSure vessel sealing system (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) for dissection and hemostasis throughout the whole procedures during neck dissection.~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours."
2994833|NCT02597582|Other|Conventional neck dissection|"The control group patients were treated using conventional cold instrument dissection, monopolar electrocautery hemostasis, and suture ligation during neck dissection.~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours."
2994834|NCT02597569||Historical Control|Patient participants will be recruited from an inpatient rehabilitation stroke unit prior to introducing CO-OP KT training to the stroke team. Patient participants will receive Usual Care from their stroke team.
2994835|NCT02597569||CO-OP KT Exposure group|Patient participants will be recruited from an inpatient rehabilitation stroke unit after the stroke team has been exposed to CO-OP KT training. Patient participants will receive Usual Care, augmented by CO-OP KT, from their stroke team.
2994836|NCT02597556|Active Comparator|Albendazole|Albendazole will be administered as a single 400mg chewable tablet at 0, 3, 6, 9, and 12 months.
2994837|NCT02597556|Placebo Comparator|Placebo|Matching Placebo will be administered as a single chewable tablet at 0, 3, 6, and 9 months. At month 12, all participants will receive a single 400mg Albendazole tablet.
2994838|NCT02597543|Experimental|Nonspecific allograft dysfunction|Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
2994839|NCT02597543|Experimental|Normal graft function|Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
2994840|NCT02597530|Experimental|Long-term stimulution group|According to ancient Chinese medical books, acupoints Hegu and Zusanli are chosen and identified.Patients in Long-term stimulation group received electrical stimulation with the 'disperse-dense' waves.TEAS will be administered 30 minutes prior to anesthesia and continued until the end of the surgery with dilatational wave(2-15HZ).All patients will remove electrodes on surgery over.
2994841|NCT02597530|Other|Short-term stimulution group|According to ancient Chinese medical books, acupoints Hegu and Zusanli are chosen and identified.The patients in Short-term stimulation group received electrical stimulation with the 'disperse-dense' waves.TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia with dilatational wave(2-15HZ).All patients will remove electrodes on surgery over.
2994842|NCT02597530|Placebo Comparator|Sham group|Patients in sham group will be pasted electrodes 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
2994843|NCT02597517||Intervention group|(Digital chromoendoscopy and magnification) Patients with functional dyspepsia and positive stool antigen test for H pylori in whom gastric body mucosal will be evaluated with digital chromoendoscopy (OE system) and magnification technology in addition to white light
2994844|NCT02597517||Control group|(Digital chromoendoscopy and magnification) Patients with functional dyspepsia and negative stool antigen test for H pylori in whom gastric mucosal body will be evaluated with digital chromoendoscopy (OE system) and magnification technology in addition to white light
2994845|NCT02597504|Active Comparator|Standardization|individuals assigned to this group will be healthy volunteers and will take the Quick Test.
2994846|NCT02597504|Experimental|Validity and Reliability|"Reliability:~Test-Retest~Validity:~Concurrent:Quick Test administered with ImPACT online Discriminant: Concussed patient administered Quick Test Construct: Determine agreement between Quick Test and and paper and pencil test."
2994847|NCT02597491|Active Comparator|4 wk assessment + TLC monthly|4 week assessment, 8 weeks of counseling, NRT, monthly follow-up (responders)
2994848|NCT02597491|Active Comparator|4 week assessment + TLC quarterly|4 week assessment, 8 weeks of counseling, NRT, quarterly follow-up (responders)
2994849|NCT02597491|Active Comparator|4 week assessment +TLC + MTM|4 week assessment, 4 weeks counseling, NRT, medication management (nonresponders)
2994850|NCT02597491|Active Comparator|8 week assessment + TLC monthly|8 week assessment, 8 weeks of counseling, NRT, monthly follow-up (responders)
2994851|NCT02597491|Active Comparator|8 week assessment + TLC quarterly|8 week assessment, 8 weeks of counseling, NRT, quarterly follow-up (responders)
2994852|NCT02597491|Active Comparator|8 week assessment + TLC + MTM|8 week assessment, 8 weeks counseling, NRT, medication management (nonresponders)
2994853|NCT02597478|Experimental|Low-Dose Fentanyl Spray Group|Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving low-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. Low-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
2994854|NCT02597478|Experimental|High-Dose Fentanyl Spray Group|Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving high-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. High-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
2994855|NCT02597465|Experimental|SPARC1507|
2994856|NCT02597465|Experimental|Chemotherapy|
2994857|NCT02597452|Other|intelligent Breast Exam, iBE|Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for participation.
2994858|NCT02597439|Active Comparator|Omega-3 fatty acids|Subjects will be treated daily with 1.2 gram omega-3 polyunsaturated fatty acids (720 mg eicosapentaenoic acid (EPA) and 480 mg Docosahexaenoic acid(DHA)) for six months.
2994900|NCT02597114|Experimental|AGT-181|AGT-181 (fusion protein of anti-human insulin receptor monoclonal antibody and alpha-L-iduronidase) administered once weekly x 26 weeks at same dose level as subject received in core study
2994860|NCT02597426||Patient|Nasopharyngeal carcinoma (NPC) patients who are disease free more than four years after definitive management with radiotherapy +/- chemotherapy who were treated with Intensity-Modulated Radiotherapy (IMRT), study will involve Collection of demographic data, endocrine assessment (Pituitary and Thyroid), Patient reported outcomes (Quality of Life Questionnaire), neurocognitive assessment (Behavioral rating scale) and audiology assessment (Assessment of hearing)
2994861|NCT02597426||Caregiver/Family member|Caregivers for patients who consent to participate. Study will involve Frontal Systems Behavior Scale- FrSBe (behavioral rating scale)
2994862|NCT02597413||Before group|Women in this group are included before the implementation of a strategy of systematic catheterization (they will not be catheterized).
2994863|NCT02597413||After group|"Women in this group are included after the implementation of a department-wide strategy of systematic catheterization.~Intervention: catheterization"
2994864|NCT02597400|Experimental|HMS5552 and Metformin|"All subjects will receive the following:~Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;~Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;~HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals."
2994865|NCT02597387|Experimental|Mitoxantrone HCL Liposome Injection|Each treatment cycle lasts for 28 days with 20mg/m2
2994866|NCT02597374|Experimental|Experimental|A 45 mn EEG for all the participants.
2994867|NCT02597361|Active Comparator|Irbesartan|Irbesartan: 150 or 300 mg o.d. for 2 years.The up-titration of irbesartan from 150 mg to 300 mg o.d. occurs during the first 8 weeks following randomization and will be driven by clinical, hemodynamic and biological (plasma creatinine and K) tolerability.
2994868|NCT02597361|Placebo Comparator|Placebo|Placebo once or twice per day for 2 years.
2994869|NCT02597348|Experimental|Liver Transplantation|Arm LT+C: patients will be treated by experimental liver transplantation preceding the non experimental standard chemotherapy (according to usual practices).
2994870|NCT02597348|No Intervention|No intervention|Arm C: patients will receive non experimental standard chemotherapy according to usual practices in the context of definitively unresectable CLM.
2994871|NCT02597335|Experimental|IDH1/IDH2|
2994872|NCT02597322|Experimental|AXITINIB|
2994873|NCT02597309|Active Comparator|Intervention Group|Subjects in this group will take canagliflozin in addition to their regular U-500 insulin dose and other antihyperglycemic medications. Canagliflozin dose will be titrated after 2 weeks from 100 mg once daily to 300 mg once daily. This dose will continue for 22 weeks.
2994874|NCT02597309|Placebo Comparator|Control Group|Subjects in this group will take a matched placebo in addition to their regular U-500 insulin dose and other antihyperglycemic medications for 2 weeks then another matched-placebo for 22 weeks.
2994875|NCT02597283|Experimental|Biguard stent system|PCI with Biguard sirolimus-eluting bifurcation stent system
2994876|NCT02597283|Active Comparator|Sirolimus-eluting stent system|PCI with regular sirolimus-eluting stent system
2994877|NCT02597270||Cohort 1|Brazilian participants with Genotype 1 HCV infection treatment naive participants or previously failed to double therapy (Peg-interferon-α and Ribavirin) will be included in the trial and will constitute the trial population.
2994878|NCT02597257|Placebo Comparator|Normal Saline|"normal saline~total 250 ml~once a week~4 times"
2994879|NCT02597257|Active Comparator|Lidocaine HCl|"lidocaine 3 mg/kg mixed in normal saline~total 250 ml~once a week~4 times"
2994880|NCT02597244|Experimental|Treatment group|Percutaneous Extraforaminotomy using BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea)
2994881|NCT02597231|Experimental|Melatonin Group|Patients in this group will receive melatonin 3mg orally at 9pm.
2994882|NCT02597231|Placebo Comparator|Placebo Group|Patient in this group will receive a matching placebo pill orally at 9pm.
2994883|NCT02597218||Patients following hepatectomy|"Patients following hepatectomy of any type, any gender. Roughly, we will describe: type of resection, presence of cancer,use of mechanical/pharmacological prophylaxis, major/minor bleedings ocurring during observation period.~Outcomes: Venous thromboembolism (VTE)[deep vein thrombosis (DVT) and pulmonary embolism (PE)] and portal thrombosis (PT)."
2994884|NCT02597205|Experimental|Mobile app|Multi-faceted intervention for physicians and patients respectively: physician-facing app and patient-facing messages
2994885|NCT02597192|Active Comparator|Active test group|probiotic oral hygiene products with Bacillus (PIP, Chrisal)
2994886|NCT02597192|Placebo Comparator|Placebo group|oral hygiene products without Bacillus
2994887|NCT02597179||Metastatic Breast Cancer, Young Breast Cancer|Patients with feasible biopsy site.
2994888|NCT02597166|Other|Ledipasvir/Sofosbuvir|Each tablet contains 90 mg ledipasvir and 400 mg sofosbuvir, given orally, once daily for 24 weeks.
2994889|NCT02597153|Experimental|Mitoxantrone HCL Liposome Injection|Each treatment cycle lasts for 28 days with 20mg/m2
2994890|NCT02597140|Experimental|Lidocaine group|Patients will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
2994891|NCT02597140|Placebo Comparator|Control group|Patients will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous normal saline infusion of 2 mg/kg/hr.
2994892|NCT02597127|Experimental|ALN-PCSSC 200 mg (bi-annual dosing)|ALN-PCSSC 200 milligram (mg) SC administration once at Day 1
2994893|NCT02597127|Experimental|ALN-PCSSC 300 mg (bi-annual dosing)|ALN-PCSSC 300 mg SC administration once at Day 1
2994894|NCT02597127|Experimental|ALN-PCSSC 500 mg (bi-annual dosing)|ALN-PCSSC 500 mg SC administration once at Day 1
2994895|NCT02597127|Placebo Comparator|Normal Saline (bi-annual dosing)|Saline SC administration once at Day 1
2994896|NCT02597127|Experimental|ALN-PCSSC 100 mg (quarterly dosing)|ALN-PCSSC 100 mg SC administration twice at Day 1 and Day 90
2994897|NCT02597127|Experimental|ALN-PCSSC 200 mg (quarterly dosing)|ALN-PCSSC 200 mg SC administration twice at Day 1 and Day 90
2994898|NCT02597127|Experimental|ALN-PCSSC 300 mg (quarterly dosing)|ALN-PCSSC 300 mg SC administration twice at Day 1 and Day 90
2994899|NCT02597127|Placebo Comparator|Normal Saline (quarterly dosing)|Saline SC administration twice at Day 1 and Day 90
2994991|NCT02596438||Asian Americans|Foreign born or children of foreign born Asian American from Hepatitis B endemic areas residing in Sacramento, CA.
2994901|NCT02597101|Placebo Comparator|Placebo|5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily
2994902|NCT02597101|Experimental|AZD9668|60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)
2994903|NCT02597075|Active Comparator|Arm A: with ST + PA|Standard therapy + structured Physical activity and pedometer
2994904|NCT02597075|Active Comparator|Arm B:|Standard therapy
2994905|NCT02597062|Experimental|Carfilzomib plus cyclophosphamide plus dexamethasone|20 mg/m2 day 1 of first cycle then escalated to 70 mg/m2 for all subsequent doses) given on days 1, 8, and 15 of a 28 day cycle plus weekly oral dexamethasone (< 70 years, 40 mg; ≥ 70 years 20mg) and cyclophosphamide 300 mg/m2 capped at 500 mg
2994906|NCT02597049|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) given subcutaneously (SC) once a week for 24 weeks.
2994907|NCT02597049|Experimental|0.75 mg Dulaglutide|0.75 mg dulaglutide given SC once a week for 24 weeks.
2994908|NCT02597049|Placebo Comparator|Placebo|Placebo given SC once a week for 24 weeks.
2994909|NCT02597036|Experimental|Part A LY3127804|Dose escalation of LY3127804 given intravenously (IV) every 2 weeks (Q2W) for 28 day cycle.
2994910|NCT02597036|Experimental|Part B LY3127804 + Ramucirumab Dose 1|Dose escalation of LY3127804 in combination with Ramucirumab given IV Q2W for 28 day cycle.
2994911|NCT02597036|Experimental|Part C LY3127804 + Ramucirumab Dose 2|LY3127804 in combination with Ramucirumab given IV Q2W for 28 day cycle.
2994912|NCT02597036|Experimental|Part D LY3127804 + Ramucirumab|LY3127804 and Ramucirumab given IV Q2W until participant qualifies for study discontinuation.
2994913|NCT02597036|Experimental|Part E LY3127804 + Ramucirumab + Paclitaxel|LY3127804 and Ramucirumab given IV Q2W and Paclitaxel given IV on day 1, 8, and 15 until participant qualifies for study discontinuation.
2994914|NCT02597023|Experimental|MitoQ|MitoQ, 20 mg per day for six weeks
2994915|NCT02597023|Placebo Comparator|Placebo|Placebo, inert excipient, one time per day for six weeks
2994916|NCT02597010|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
2994917|NCT02597010|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
2994918|NCT02596984|Experimental|caspofungin|Caspofungin will be administered according to the international recommendation.
2994919|NCT02596971|Experimental|Atezo-G-Benda (Safety Run-In and Expansion Phases)|Safety run-in phase: Participants with previously untreated or relapsed or refractory FL will receive obinutuzumab (G) and bendamustine during Cycle 1 (28-day cycle) and atezolizumab, obinutuzumab, and bendamustine during Cycles 2-6, during induction treatment, followed by atezolizumab (once monthly) and obinutuzumab (every other month [q2m]) for 24 months, during maintenance treatment. Expansion phase: Participants with previously untreated FL will receive same treatment regimen as described for safety run-in phase.
2994920|NCT02596971|Experimental|Atezo-G-CHOP (Safety Run-In Phase)|Safety run-in phase: Participants with previously untreated or relapsed or refractory FL will receive obinutuzumab and CHOP during Cycle 1 (21-day cycle) and atezolizumab, obinutuzumab, and CHOP during Cycles 2-6, during induction treatment, followed by atezolizumab (once monthly) and obinutuzumab (q2m) for 24 months, during maintenance treatment.
2994921|NCT02596971|Experimental|Atezo-R-CHOP (Expansion Phase)|Participants with previously untreated DLBCL will receive rituximab and CHOP during Cycle 1 (21-day cycle) and atezolizumab, rituximab, and CHOP during Cycles 2-8 (atezolizumab and rituximab for 8 cycles and CHOP for either 6 or 8 cycles, as determined by the investigator), during induction treatment, followed by atezolizumab from Cycles 9-25 during consolidation treatment.
2994922|NCT02596958||Bevacizumab|Patients will receive six 3-weeks cycle of IV bevacizumab along with platinum-based chemotherapy, followed by maintenance therapy of bevacizumab until progression (approximately 7 months).
2994923|NCT02596945||Peritoneal Dialysis participants|Participants who are on peritoneal dialysis and have been prescribed with methoxy polyethylene glycol were observed for a period of 9 months.
2994924|NCT02596932|Other|Tight control|"Intervention Standard Care:~Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level > 100mg/dL"
2994925|NCT02596932|Experimental|Less tight control|"Intervention:~Less Tight glucose control protocol: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose > 120 mg/dL"
2994926|NCT02596919|Other|No arms|No randomisation therefore no arms. All patients will receive the same research treatment.
2994927|NCT02596906|Experimental|tDCS+Training|This group will receive 20 minutes of tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks
2994928|NCT02596906|Sham Comparator|Sham tDCS+training|"This group will receive 20 minutes of sham tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks."
2994929|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by periodic 160 mg GED0301|GED-0301 160 mg once daily (QD) for 12 weeks; followed by placebo QD for 4 weeks; followed by alternating GED-0301 160 mg QD for 4 weeks and placebo QD for 4 weeks, until the the Week 52 Visit
2994930|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by periodic GED0301 40mg|GED-0301 160 mg once daily (QD) for 12 weeks; followed by placebo QD for 4 weeks; followed by alternating GED-0301 40 mg QD for 4 weeks and placebo QD for 4 weeks, until the Week 52 Visit
2994931|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by continuous GED0301 40mg|GED-0301 160 mg once daily (QD) for 12 weeks; followed by continuous GED-0301 40 mg QD, until the Week 52 Visit
2994932|NCT02596893|Experimental|Placebo|Placebo once daily (QD) until the Week 52 Visit
2994933|NCT02596880|Experimental|Treatment|Subjects will receive sofosbuvir, daclatasvir and ribavirin
2994934|NCT02596867|Experimental|open label single arm, drug propanolol|all subjects will receive the experimental drug
2994935|NCT02596854|Experimental|Neurological MRI|Images acquired for post processing with synthetic software. This is a crossover design where all subjects receive the same imaging scan, and comparison is done between the raw conventional scan and post-processed images using the research software.
2994936|NCT02596828|Experimental|RIST|
2995039|NCT02596191|Other|control group|Healthy volunteers
2995040|NCT02596178|Experimental|EIT Guided PEEP Therapy|
2994937|NCT02596815|Experimental|Median Nerve Neural Mobilization|15 minute Median Nerve Neural Mobilization sessions 3 times a week during 6 continuous weeks.The maximum degree of elbow extension applied in the Median Nerve neural mobilization procedure was determined through the use of a Universal Goniometer Device.
2994938|NCT02596815|Active Comparator|Waiting list control group|Patients assigned to a 6 week waiting list to receive treatment
2994939|NCT02596802|Experimental|FETO therapy|Intervention name: FETO therapy
2994940|NCT02596789|Other|state dependency TMS|TMS performed at rest and during a cognitive/emotional task
2994941|NCT02596776|Active Comparator|Fat biopsy|From each abdominal and thigh biopsy, between 0.5 - 3 g of tissue is obtained (often less from the thigh), which is used for immunohistochemistry and frozen for subsequent RNA or protein isolation.
2994942|NCT02596776|Experimental|Propranolol and Fat Biopsy|From each abdominal and thigh biopsy, tissue will be examined for gene expression, with a focus on genes believed to be involved in adipose beiging (PGC1α, UCP1, TMEM26, IL4, Metrnl, CPA3, Siglec 8, tyrosine hydroxylase, others), and with immunohistochemistry, with a focus on beige adipocytes, macrophages, eosinophils and mast cells.
2994943|NCT02596776|Active Comparator|Heavy Water and Fat Biopsy|The investigator will measure in vivo adipose lipolysis and triglyceride (TG) turnover in response to cold to physiologically demonstrate the impact of cold exposure on tissue function. The subjects will then be given 50 mL sterile containers of 70% 2H2O and consume two 50 mL vials per day during the remainder of the 5-week labeling period. Plasma and urine will be collected weekly so that body 2H2O can be measured.
2994944|NCT02596763|Other|Baclofen|Patient with current alcohol use disorder included by any baclofen prescriber located in the French region of Nord - Pas-de-Calais - Picardie.
2994945|NCT02596750|Active Comparator|Microneedle Pretreatment|One ventral forearm is randomized to receive pretreatment with microneedle rollers that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.
2994946|NCT02596750|Sham Comparator|Sham Microneedle Pretreatment|One ventral forearm is randomized to receive pretreatment with sham microneedle rollers (flat roller without any microneedles) that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.
2994947|NCT02596737|Other|workers|"Workers will fulfil a visual analog scale of Well-being regarding 3 main categories: Physically, Mentally, At Work."
2994948|NCT02596711|Experimental|Health Education (HE) Group|Participants receive general health education and handouts. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Counselor discusses a health topic (such as sleep, nutrition, and exercise) and how it relates to participant and their smoking. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
2994949|NCT02596711|Experimental|Culturally Tailored Smoking Cessation (CTSC) Group|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participant and counselor discuss how smoking and their culture may relate to each other. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
2994950|NCT02596711|Experimental|Culturally Tailored Smoking + Adherence Enhancement (AE) Group|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participants receive additional talks related to smoking cessation tailored to their culture. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
2994951|NCT02596698||Adolescents with Mood Disorders|Teens aged 13-18 with a diagnosis of a mood disorder.
2994952|NCT02596698||Adolescents with no Mental Health Diagnoses|13-18, no psychiatric d/o diagnosis
2994953|NCT02596685|Experimental|Arm A (electronic-cigarette)|"Patients receive nicotine-free and flavor-free electronic cigarettes and instructed to use them BID over a 2 hour period for 4 weeks.~Patients undergo a second bronchoscopy during week 5."
2994954|NCT02596685|Experimental|Arm B (control)|"Patients receive no intervention.~Patients undergo a second bronchoscopy during week 5."
2994955|NCT02596685|Experimental|Arm I (bronchoscopy of the left lung)|Patients undergo bronchoscopy of the left lung over 30-60 minutes.
2994956|NCT02596685|Experimental|Arm II (bronchoscopy of the right lung)|Patients undergo bronchoscopy of the right lung over 30-60 minutes.
2994957|NCT02596672|Experimental|Intervention|They will complete a 12-week peer-led walking programme. Participants will be paired together as walking partners and will be given a pedometer and step count logs for self-monitoring. The walking co-ordinators will facilitate walking groups two times a week in the local areas, lasting for 30 minutes. The nature of the walks will be tailored to the participants stated preferences of types of activity. Participants will also receive local walking route maps. After 12 weeks, the formal peer-led component will finish and participants will be encouraged to continue walking with their walking partners other activity programmes organised in the fold in order to maintain activity levels.
2994958|NCT02596672|No Intervention|Control|"Folds assigned to the control group will not receive any additional support to change their physical activity behaviour over the course of the intervention period.~At the six-month data collection point they will be offered a referral to a local walking group in their area or advice on beginning a self-directed walking programme (similar to Public Health Agency www.choosetolivebetter.com/content/getting-active). They will be asked to complete outcome measures at baseline and follow up time-points. Post-study a sample of control participants will be asked to attend a focus group, exploring their views on social activity as form of physical activity for older adults in folds."
2994959|NCT02596659|Experimental|The experimental group|Participants in the experimental group received radial extracorporeal shock wave therapy (rESWT) plus physical therapy for 3 weeks.
2994960|NCT02596659|Sham Comparator|The control group|Participants in the control group received sham shockwave therapy plus physical therapy for 3 weeks.
2994961|NCT02596646|Active Comparator|Group A|Early Precut
2994962|NCT02596646|Active Comparator|Group B|Prolonged cannulation attempts
2994963|NCT02596633|No Intervention|Treatment as Usual|Participants carry on with their usual care
2994964|NCT02596633|Active Comparator|Intervention|ACT self help book with telephone support calls; Telephone-support Acceptance and Commitment therapy (ACT)
2994965|NCT02596620|Experimental|Sequential therapy|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily, amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 5 days followed by esomeprazole (Nexium) (40 mg) twice daily, levofloxacin(Cravit)(500 mg), 1 tablet once daily and metronidazole (Flagyl)(250 mg) 2 tablets three times daily for 5 days
2994966|NCT02596620|Active Comparator|Triple therapy|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily; amoxicillin (Amolin)(500 mg) 2 tablets twice daily and levofloxacin(Cravit)(500 mg), 1 tablet once daily for 10 days
2994967|NCT02596594|Experimental|Port intervention|"The subcutaneous intraumbilical port-system will be implanted in IUGR patients with the cerebroplacental ratio less than 1 (cerebroplacental ratio= PI in the middle cerebral artery / PI umbilical artery) between 24/0 and 30/0 weeks of gestation.~The fetuses will receive AAs and glucose supplementation via a subcutaneously implanted intraumbilical perinatal port system till the delivery. Control by doppler and cardiotocogram"
2994968|NCT02596594|No Intervention|control|"IUGR patients with the cerebroplacental ratio less than 1 (CPR= PI middle cerebral artery / PI umbilical artery) between 24/0 and 30/0 weeks of gestation.~Control by doppler and cardiotocogram"
2994969|NCT02596581|No Intervention|diabetics with periodontally healthy group|Control group
2994970|NCT02596581|No Intervention|systemically and periodontally healthy group|Control group
2994971|NCT02596581|Active Comparator|diabetics with chronic periodontitis group|non-surgical periodontal treatment was performed
2994972|NCT02596581|Active Comparator|chronic periodontitis group|non-surgical periodontal treatment was performed
2994973|NCT02596568|Experimental|Active tDCS stimulation|Anodal tDCS will be applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
2994974|NCT02596568|Sham Comparator|Sham tDCS stimulation|tDCS electrodes will be applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor, however stimulation will never be turned on.
2994975|NCT02596555|Experimental|Dabigatran treatment|Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
2994976|NCT02596542|Experimental|Water temperature|
2994977|NCT02596529|Experimental|Fixation|Patients with a medium-sized posterior fragment which will be treated by open reduction and internal fixation of all fractured malleoli.
2994978|NCT02596529|Active Comparator|No fixation|Patients with a medium-sized posterior fragment which will be treated bij open reduction and internal fixation of lateral and medial malleolus alone. No fixation of the posterior malleolus take place.
2994979|NCT02596503|Experimental|Eribulin + Irinotecan|"Eribulin will be administered intravenously on days 1 and 8 of a 21-day cycle, while irinotecan will be administered orally on days 1-5. The oral antibiotic cefixime will be used to reduce irinotecan-associated diarrhea.~Eribulin dose will be assigned at time of enrollment using a 3+ 3 Phase 1 design (ranging from 0.8 - 1.4 mg/m2/dos). The dose of irinotecan will be fixed at 90 mg/m2/day x 5 days."
2994980|NCT02596490|Experimental|Phase 1: Couple-Based Mindfulness Disclosure Group|"Phase 1:~Couples participate in 2 guided meditation sessions. During the sessions, participants do deep breathing and visualization exercises then asked to review the exercises. Participants also asked for feedback about the instructions. Participants complete a written review about the program and a questionnaire about their general health and well-being. Each session will last about 60-90 minutes."
2994981|NCT02596490|Experimental|Phase 2: Couple-Based Mindfulness Disclosure Group|"Phase 2:~Participants complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires. After completing the last session, about 4 weeks later, participants complete the same questionnaires again. Participants also complete a program review.~Couples participate in 4 guided meditation sessions with a trained meditation instructor. Participants do deep breathing and visualization exercises. All meditation and discussion sessions videotaped.~Participants continue daily meditation practice and some other short exercises at home."
2994982|NCT02596490|Experimental|Phase 3: Couple-Based Mindfulness Disclosure Group|"Participant completes 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.~Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
2994983|NCT02596490|Experimental|Phase 3: Cancer-Related Discussion Program Group|"Participant completes 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.~Participant and partner take part in a discussion program, 1 discussion session each week for 4 weeks with a trained interventionist. These are one-on-one sessions. Issues discussed for couples coping with cancer. Each session will last about 60 minutes."
2994984|NCT02596490|Other|Phase 3: Attention Control (AC) Group|Participant completes 13 questionnaires at baseline and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.
2994985|NCT02596477|Experimental|Vepoloxamer - Low dose|Vepoloxamer injection administered intravenously 225 mg/kg over 3 hours
2994986|NCT02596477|Experimental|Vepoloxamer - High dose|Vepoloxamer injection administered intravenously 450 mg/kg over 3 hours
2994987|NCT02596477|Placebo Comparator|5% dextrose in water (D5W)|D5W administered intravenously over 3 hours
2994988|NCT02596451|Experimental|Diclofenac Sodium gel, 1%|apply gel to the target knee
2994989|NCT02596451|Active Comparator|Voltaren® Gel|apply gel to the target knee
2994990|NCT02596451|Placebo Comparator|Placebo|apply gel to the target knee
2994993|NCT02596425|Experimental|40 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.
2994994|NCT02596425|Experimental|60 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.
2994995|NCT02596412|Experimental|augmented reality (Mini-Docs) on tablet|• Cerebral-palsied children using the module with augmented reality (Mini-Docs) on tablet during TB injections in addition to regular drug techniques (experimental group)
2994996|NCT02596412|No Intervention|Control|Cerebral-palsied children with the usual pain care during TB injections, which combines drug techniques to distractibility techniques (control group)
2994997|NCT02596399|Experimental|DSTA4637S|
2994998|NCT02596399|Placebo Comparator|Placebo|
2994999|NCT02596386||potassium level in saliva|Each willing participant will undergo Sialometry
2995000|NCT02596386||blood test|blood will be drawn from the dialysis connections for Biochemistry for potassium level evaluation
2995001|NCT02596373|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks
2995002|NCT02596373|Active Comparator|Mitoxantrone Hydrochloride Injection|Mitoxantrone Hydrochloride Injection 14 mg/m2 will be infused intravenously once over 30 minutes in 150 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks
2995003|NCT02596360|Experimental|Dextromethorphan|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
2995004|NCT02596360|Placebo Comparator|Placebo|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
2995005|NCT02596347||Beryllium Sensitization (BeS)|Blood draw
2995006|NCT02596347||Chronic Beryllium Disease(CBD)|blood draw BAL
2995007|NCT02596334|Active Comparator|triple therapy|dolutegravir + abacavir + lamivudine (TRIUMEQ) : oral administration, one tablet daily during 48 weeks.
2995008|NCT02596334|Experimental|monotherapy|dolutegravir (TIVICAY) : 50 mg, oral administration, one tablet daily during 48 weeks.
2995009|NCT02596321|Experimental|Mitizax ALK HDM tablet|Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU)
2995010|NCT02596321|Placebo Comparator|Placebo tablet|Placebo tablet
2995011|NCT02596308|Experimental|15µg vaccine|15µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.
2995012|NCT02596308|Experimental|30µg vaccine|30µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.
2995013|NCT02596295||Mothers for term infants|Lactating mothers
2995014|NCT02596295||Mothers for preterm infants|Lactating mothers
2995015|NCT02596282|Active Comparator|Clinical Officer (CO),|COs were trained and provided neonatal male circumcision under topical anesthesia using the Mogen clamp
2995016|NCT02596282|Experimental|Nurse Midwife (NMW)|NMWs were trained and provided neonatal male circumcision under topical anesthesia using the Mogen clamp
2995017|NCT02596269|Experimental|Nefopam(NF) group|Received i.v. PCA with the same volume of solution containing 1250 µg fentanyl plus 120 mg of nefopam in normal saline (fentanyl 12.5 µg/ml and nefopam 1.2 mg/ml).
2995018|NCT02596269|Placebo Comparator|Saline(SF) group|Received i.v. PCA with 100 ml solution containing 1250 µg of fentanyl in normal saline (12.5 µg/ml),
2995019|NCT02596256|Experimental|control group|Apatinib Mesylate Tablets (500 mg qd p.o.) and Docetaxel (60mg/m2 i.v. d1 q21d)
2995020|NCT02596256|Active Comparator|contrast group|Docetaxel (60mg/m2, i.v. d1 q21d)
2995021|NCT02596243|Experimental|GX-188E|GX-188E + EP
2995022|NCT02596243|Placebo Comparator|placebo|Placebo + EP
2995023|NCT02596230||Patients with acute VTE|Patients will be enrolled for cross sectional characterization of baseline characteristics
2995024|NCT02596230||Dabigatran|Patients treated with dabigatran for acute VTE will be followed for one year
2995025|NCT02596230||vitamin K antagonist|Patients treated with VKA for acute VTE will be followed for one year
2995026|NCT02596217|Experimental|Stage 1 (low dose SC)|Low dose administered by subcutaneous (SC) injection
2995027|NCT02596217|Experimental|Stage 1 (medium dose SC)|Medium dose administered by subcutaneous (SC) injection
2995028|NCT02596217|Experimental|Stage 1 (high dose SC)|High dose administered by subcutaneous (SC) injection
2995029|NCT02596217|Experimental|Stage 2 (low dose IV)|Low dose administered by intraveneous (IV) infusion
2995030|NCT02596217|Experimental|Stage 2 (medium dose IV)|Medium dose administered by intraveneous (IV) infusion
2995031|NCT02596217|Experimental|Stage 2 (high dose IV)|High dose administered by intraveneous (IV) infusion
2995032|NCT02596217|Placebo Comparator|Placebo SC (Stage1)|Placebo administered by subcutaneous (SC) injection
2995033|NCT02596217|Placebo Comparator|Placebo IV (Stage2)|Placebo administered by intraveneous (IV) infusion
2995034|NCT02596204|Active Comparator|Data Upload|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. FitBit, pump and sensor (if applicable) data will be uploaded at least weekly. Subjects will continue to receive usual diabetes care. Phone calls and emails to the diabetes clinic will be initiated by the family.
2995035|NCT02596204|Experimental|Weekly Review|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. FitBit, pump and sensor (if applicable) data will be uploaded at least weekly. For subjects in the weekly review group, research staff (diabetes educator, nurse practitioner and/or physician) will review uploaded blood glucose, pump, and available sensor, activity and sleep data on a weekly basis. If glucose patterns are identified which suggest a change to diabetes management (ie insulin dose changes), the family will be contacted by text, email or telephone to review glucose patterns and to review staff recommendations.
2995036|NCT02596191|Experimental|patients with mild CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score between 1 and 10
2995037|NCT02596191|Experimental|patients with moderate CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score between 11 and 20
2995038|NCT02596191|Experimental|patients with severe CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score ≥21
2995041|NCT02596165|Experimental|Pulse wave analysis measurement|Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
2995042|NCT02596152|Experimental|Mini-trampoline|participants allocated to this group will participate in a 12-week mini-trampoline group instructed training twice a week.
2995043|NCT02596152|Active Comparator|Nordic Walking|participants allocated to this group will participate in a 12-week Nordic Walking group instructed training twice a week.
2995044|NCT02596139||Healthy people|
2995045|NCT02596126|Active Comparator|Treatment Prevention for Secondary CV|Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the ESC guidelines. Drugs and doses will be left at the discretion of the treating physicians..
2995046|NCT02596126|Experimental|Cardiovascular Polypill|Patients allocated to the experimental arm will receive a cardiovascular polypill containing aspirin 100 mg, atorvastatin (40 or 20 mg) and ramipril (2.5, 5 or 10 mg) taken orally once a day.
2995047|NCT02596113||Individuals without pathological findings during colonoscopy|In this group, sample would be collected from peripheral blood (plasma) and biopsy samples from normal colon mucosa
2995048|NCT02596113||Individuals with bigger than 1 cm adenomatous polys|In this group, sample would be collected from peripheral blood (plasma) and biopsy samples from the polyp which would be sent for histopathological evaluation to confirm its adenomatous elements.
2995049|NCT02596113||Individuals with colorectal cancer|In this group, sample would be collected from peripheral blood (plasma) and biopsy samples from colorectal cancer which would be sent for histopathological evaluation to confirm its cancerous elements.
2995050|NCT02596100|Experimental|Tablet|80mg immediate release tablet
2995051|NCT02596100|Experimental|Capsule|80mg immediate release capsule
2995052|NCT02596087|No Intervention|Normal Use of EHR|Sites will configure their EHR systems so that alerts will not be triggered for providers in the control arm if the patient does not have the condition on her/his problem list.
2995053|NCT02596087|Experimental|Intervention Arm|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. Each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
2995054|NCT02596074|Experimental|Omiganan (CLS001)|CLS001 topical gel, 2.5%
2995055|NCT02596074|Placebo Comparator|Vehicle|Vehicle topical gel
2995056|NCT02596061|No Intervention|Control|These participants are made aware of all smoking cessation services offered by the clinic, for example group counseling or individual counseling, but are not offered any rewards for participating in these activities.
2995057|NCT02596061|Experimental|Intervention-Rewards Only|Patients have access to a website where they can self-report smoking status, add virtual supporters, and submit journal entries. Patients receive incentives for completing these activities and for utilizing counseling services at the clinic. At the 2 mo. mark, these participants come to the clinic for a biochemical verification of their smoking status. Their rewards are contingent on successfully passing this verification test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
2995058|NCT02596061|Experimental|Intervention-Pre-Commitment|Patients have access to a website where they can self-report smoking status, add supporters, and submit journal entries. Patients receive incentives for these activities and for using clinic counseling services. At enrollment, patients are offered the chance to set aside some of their future rewards for a deposit contract that lasts for 4 mos. and starts 2 mos. after the rewards contract. If, at the end of 6 mos., the patients pass the second verification test, their rewards are returned to them. At the 2 mo. mark, patients come to the clinic for a biochemical verification of their smoking status. Rewards are contingent on passing this test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
2995059|NCT02596061|Experimental|Intervention-Commitment|Patients have access to a website where they can self-report smoking status, add virtual supporters, and submit journal entries. Patients receive incentives for these activities and for using clinic counseling services. After 2 mos., this group is offered the chance to set aside some of their rewards towards a deposit contract that lasts for 4 months. If, after the 4 mos., the patients pass the second cessation verification test, their rewards are returned to them. At the 2 mo. mark, these patients come to the clinic for a biochemical verification of their smoking status. Rewards are contingent on passing this test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
2995060|NCT02596048|Other|Iomeron|Patients will undergo a injection of Iomeron if they are scheduled to undergo an elective thoraco-abdominal aorta, carotid, pulmonary or peripheral MDCTA examination
2995061|NCT02596035|Experimental|Nivolumab|Nivolumab dose as specified
2995062|NCT02596022|Experimental|CI-581a|Administration of CI-581a followed 2 weeks later by CI-581b
2995063|NCT02596022|Active Comparator|CI-581b|Administration of CI-581b followed 2 weeks later by CI-581a
2995064|NCT02596009|Experimental|Breezhaler®|Each patient was required to inhale via Breezhaler® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
2995065|NCT02596009|Other|Ellipta®|Each patient were required to inhale via Ellipta® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
2995066|NCT02596009|Other|Handihaler®|Each patient were required to inhale via Handihaler® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
2995067|NCT02595996|Experimental|Treatment|Patients will be given propranolol in escalating doses
2995068|NCT02595983|Experimental|Revusiran (ALN-TTRSC)|
2995069|NCT02595970|Experimental|Secukinumab|Weekly sub cutaneous injections of 300 mg during the first month and then Monthly until Week 52 plus extension until 03/11/2016.
2995307|NCT02594345|Experimental|Intervention group|
2995070|NCT02595944|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
2995071|NCT02595944|No Intervention|Arm II (observation)|Patients are followed serially with imaging for 1 year.
2995072|NCT02595931|Experimental|Treatment(irinotecan hydrochloride,ATR kinase inhibitor M6620)|Patients receive irinotecan hydrochloride IV over 90 minutes and ATR kinase inhibitor M6620 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
2995073|NCT02595918|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes on days -56, -42, -28, and -14 in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on day 0.
2995074|NCT02595905|Active Comparator|Arm I (cisplatin and placebo)|Patients receive cisplatin IV over 1 hour on day 1 and placebo PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2995075|NCT02595905|Experimental|Arm II (cisplatin and veliparib)|Patients receive cisplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2995076|NCT02595892|Active Comparator|Arm I (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.
2995077|NCT02595892|Experimental|Arm II (gemcitabine, ATR kinase inhibitor M6620)|Patients receive gemcitabine hydrochloride as in Arm I and ATR kinase inhibitor M6620 IV over 60-90 minutes on days 2 and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2995078|NCT02595879|Experimental|Treatment (triapine, chemoradiation)|Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 3 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 2 hours on days 1 and 11 and PO on days 2-5, 8-10, 12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 90-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity.
2995079|NCT02595866|Experimental|Treatment (pembrolizumab and cART)|Patients receive pembrolizumab IV over 30 minutes on day 1. Patients continue receiving their recommended combination antiretroviral therapy orally daily. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2995080|NCT02595827|No Intervention|Universal|In this group, caretakers of children will receive the standard advice under current iCCM guidelines in DRC. Specifically, the CHW will advise that the child come back in 2-3 days.
2995081|NCT02595827|Active Comparator|Conditional|In this Conditional Advice group, caretakers will be given advice that is modified from the current iCCM guidelines. Specifically, the CHW will advise that the child come back in 2-3 days if the child's symptoms continue.
2995082|NCT02595801||Exposed|Exposure to surgery prior to completion of Early Development Instrument
2995083|NCT02595801||Reference|No exposure to surgery prior to completion of Early Development Instrument
2995084|NCT02595788||Supine position|Examination in the supine position
2995085|NCT02595788||Prone position|Change from supine to prone position
2995086|NCT02595775|Experimental|Round 1: Intervention arm|"Half of the endoscopists in Ontario will receive an individualized audit & feedback report.~Individualized A/F report."
2995087|NCT02595775|No Intervention|Round 1: Control|Half of the endoscopists in Ontario will NOT receive an individualized audit & feedback report.
2995088|NCT02595775|Other|Round 2: Month 12|"All endoscopists in Ontario will receive an individualized audit & feedback report at month 12.~Individualized A/F report"
2995089|NCT02595775|Other|Round 2: Poor performers|"In Round 2, selected 60 poorer performers will be randomly assigned to receive one of the following interventions at month 12:~A/F report plus a high intensity intervention~A/F report plus a low intensity intervention~A/F report alone"
2995090|NCT02595762||Participants With HER2-Positive Breast Cancer|Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/MBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.
2995091|NCT02595749|Experimental|Intranasal Oxytocin (40 IU)|Two 20 IU doses of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) will be administered to each participant. Doses will be separated by 2 hours. Each 20 IU dose transferred into two, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 10 minutes.
2995092|NCT02595749|Placebo Comparator|Saline Nasal Spray|Two doses of placebo (consisting of 2ml sterile saline [Ocean Nasal Spray Solution]) will be administered to each participant. Doses will be separated by 2 hours. Each placebo dose transferred into two, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 10 minutes.
2995093|NCT02595736|Placebo Comparator|Placebo (SC)|Single subcutaneous (SC) dose of placebo
2995094|NCT02595736|Experimental|LY3200327 (SC)|Single escalating subcutaneous (SC) dose of LY3200327
2995095|NCT02595736|Experimental|LY3200327 (IV)|Single intravenous (IV) dose of LY3200327
2995096|NCT02595736|Placebo Comparator|Placebo (IV)|Single intravenous (IV) dose of placebo
2995097|NCT02595723|Experimental|Phenytoin + Megestrol|Participants will take phenytoin (200mg BID) for four days and megestrol acetate (800mg/d) for three days following single day of only phenytoin. Declarative memory will be tested on Day 4.
2995098|NCT02595723|Experimental|Placebo + Megestrol|Participants will take placebo for four days and megestrol acetate (800mg/d) for three days following single day of only placebo. Declarative memory will be tested on Day 4.
2995099|NCT02595723|Placebo Comparator|Placebo + Placebo|Participants will take placebo for four days and placebo for three days following single day of only placebo. Declarative memory will be tested on Day 4.
2995100|NCT02595710||Biospecimen retention|Blood Collection Skin Punch Biopsy Collection Urine Sample Collection
2995160|NCT02595307|Experimental|Pamphlet|Participant group that will receive a written pamphlet outlining the risks of surgery as discussed in consultation.
2995101|NCT02595697|Experimental|J-EMT for Toddlers with Autism|The J-EMT intervention:(a) teach foundational social communicative behaviors, (b) teach related skills that predict long term language outcomes, (c) teach a range of communicative functions, (d) target specific spoken language skills as well as foundational skills, (e) incorporate instructional methods, contexts, and partners that increase social use of language in natural contexts, and (f) promote generalization and maintenance of newly learned skills to everyday activities and routines. In addition, because parents are essential partners for young children with ASD who are learning to communicate, studies are needed that (g) include parents and (h) specify the method and fidelity of parent instruction and fidelity and dosage with which parents use the trained strategies
2995102|NCT02595697|No Intervention|Business as Usual Control Group|All children, regardless of group assignment will participate in all assessments. Children randomized to the control group will not receive intervention, but will complete all other research procedures. Other treatments that all children receive in the community will be recorded with bi-monthly surveys.
2995103|NCT02595684|Experimental|Tadalafil|Tadalafil capsules
2995104|NCT02595684|Placebo Comparator|Placebo|Calcined magnesia capsules
2995105|NCT02595671|Active Comparator|Waiting Group|Patients will not receive a treatment during the actual intervention. This group will receive the digital super coach as an incentive at the end of the trial.
2995106|NCT02595671|Active Comparator|Conventional face to face PA & dietitian|Participants will receive both dietary and physical activity advice. The advice is provided my medical trained staff (eg. dieticia, physiotherapist) according to a standardised protocol. The number of consultations are respectively three and four for diet and physcial activity.
2995107|NCT02595671|Active Comparator|Digital Super Coach|Only receive coaching via digital super coach.
2995108|NCT02595671|Active Comparator|Digital Super Coach + minimal coaching|Receive digital super coach and only have a few appointments with a physical activity coach and a dietitian.
2995109|NCT02595658|Experimental|1|Carbohydrate only meal: Participants will consume a standardised carbohydrate meal (80 g of carbohydrates, 25 g protein, 0 g fat: meal composition, white rice, chicken, curry sauce; 420 kcal) and will self-administer (into the subcutaneous tissue of the abdomen, as per their regular routine) a rapid-acting insulin dose calculated as per the carbohydrate-counting ratio (e.g. 1 IU of insulin per 10 g of carbohydrates).
2995110|NCT02595658|Experimental|2|Participants will replicate Trial 1, but on this occasion the meal consumed will have an additional 50 g of fat (via addition of Ghee). This fat will be added to the sauce within the meal (80 g of carbohydrates, 25 g of protein, 50 g of fat; 735 Kcal). Participants will administer their rapid-acting insulin as per the carbohydrate counting method (i.e. the same IU of insulin as per Trial 1).
2995111|NCT02595658|Experimental|3|Trial 3) Participants will replicate Trial 2, but will administer a rapid-acting insulin dose that has been increased by 30%.
2995112|NCT02595658|Experimental|4|Participants will replicate Trial 2, but will administer an additional rapid-acting insulin dose of 30% 3 hrs post-meal.
2995113|NCT02595645|Experimental|Polypectomy and NGS|All patients which underwent screening colonoscopy and fulfilling the inclusion criteria are eligible. Polyps were biopsied and underwent histopathological and genetic analyses
2995114|NCT02595632||Healthy|Healthy subjects with no apparent lung disease and normal lung function testing.
2995115|NCT02595619|Experimental|RRT plus ECCO2R|
2995116|NCT02595606|Experimental|treatment group|treatment with 0.3% Sodium Hyaluronate, by five times a day, one or two drop each time
2995117|NCT02595606|No Intervention|control group|without treatment
2995118|NCT02595593|Active Comparator|Rib Fixation System|This group of subjects will receive a surgical rib plating procedure after trauma
2995119|NCT02595593|No Intervention|Critical Care and Pain Control|This group will receive critical care and pain control after trauma
2995120|NCT02595580|Experimental|GlucoPred|
2995121|NCT02595567|Other|ITPC|
2995122|NCT02595554|Active Comparator|Concurrent chemoirradiation (CCRT)|Concurrent chemoirradiation
2995123|NCT02595554|Experimental|NACT+Surgery|Neoadjuvant chemotherapy with Paclitaxel and Cisplatin (3 cycles), followed by radical surgery
2995124|NCT02595541|Active Comparator|milrinone group|milrinone
2995125|NCT02595541|Active Comparator|sildenafil and milrinone group|milrinone and sildenafil
2995126|NCT02595528|Experimental|AGN-199201 and AGN-190584 Vehicle|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
2995127|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose A|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
2995128|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose B|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
2995129|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose C|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
2995130|NCT02595515|Experimental|Chiropractic treatment|Manipulation and/or mobilisation. Intervention: Procedure: Chiropractic treatment.
2995131|NCT02595515|Placebo Comparator|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
2995132|NCT02595502|Active Comparator|Sequence 1: Test Control Test|Test/control/test using the Johnson & Johnson Vision Care (JJVC) Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each in between lenses for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.
2995133|NCT02595502|Active Comparator|Sequence 2: Control Test Control|Control/test/control using the JJVC Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.
2995134|NCT02595489|Experimental|Vitamin D3|Single-arm, dose-escalation starting at 2,000 IU of vitamin D3 daily for a 6 month period, followed by a 4,000 IU daily for at least 6 months thereafter. No placebo.
2995135|NCT02595476|Experimental|BIS 55|"Induction:~TCI propofol (6 µg/ml) - remifentanil (4 ng/ml) Atracurium IV (0.5 mg/kg)~Orotracheal Intubation~Remifentanil target decreased to 1 ng/ml~Propofol target adjustment to reach BIS 55~10 minutes steady state~Tetanic stimulation (ulnar nerve): 100 Hz, 60 milliamps, 5 seconds~Pupillary dilation recording (videopupillometer Algiscan)"
2995136|NCT02595476|Active Comparator|BIS 25|"Induction:~TCI propofol (6 µg/ml) - remifentanil (4 ng/ml) Atracurium IV (0.5 mg/kg)~Orotracheal Intubation~Remifentanil target decreased to 1 ng/ml~Propofol target adjustment to reach BIS 25~10 minutes steady state~Tetanic stimulation (ulnar nerve): 100 Hz, 60 milliamps, 5 seconds~Pupillary dilation recording (videopupillometer Algiscan)"
2995137|NCT02595463|Experimental|Lidocaine|Following intraoperative IV placement, a 1.5 mg/kg bolus does of lidocaine hydrochloride is given and is followed by a continuous infusion of 2 mg/kg/hr until discharge from the Phase 1 recovery period.
2995138|NCT02595463|Placebo Comparator|Placebo|Following intraoperative IV placement, a bolus of saline is given and is followed by a continuous infusion until discharge from the Phase 1 recovery period. The volume of the bolus and rate of infusion are equivalent to that which would have been given in the experimental arm.
2995139|NCT02595450||Erlotinib|Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
2995140|NCT02595437|Experimental|Triferic via IV Infusion|Patients will receive IV Triferic iron 0.07 mg/kg diluted in an appropriate amount of D5W administered as a 100 mL infusion into the venous return port of the blood lines during the time the patient is receiving dialysis.The rate of administration will be calculated as such that the entire amount will be administered over the course of the dialysis treatment.
2995141|NCT02595437|Experimental|Triferic via Hemodialysate|Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic via the hemodialysate over the course of the dialysis treatment.
2995142|NCT02595424|Experimental|Arm A (capecitabine, temozolomide)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2995143|NCT02595424|Active Comparator|Arm B (cisplatin, carboplatin, etoposide)|Patients receive cisplatin IV on days 1-3 or carboplatin IV on day 1. Patients also receive etoposide IV on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2995144|NCT02595398|Experimental|4mg CLS-TA Suprachoriodal Injection|Suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
2995145|NCT02595398|Sham Comparator|Sham Procedure|Matching suprachoroidal syringe with sham procedure
2995146|NCT02595385|Active Comparator|RAP|Retrograde Autologous Prime of the bypass circuit. To remove 500-900ML of fluid.
2995147|NCT02595385|Active Comparator|CS|Reinfusion of shed blood during the operation
2995148|NCT02595385|Active Comparator|RAP and CS|RAP and CS used in combination
2995149|NCT02595385|No Intervention|Control|No intervention
2995150|NCT02595372|Experimental|High dose omeprazole treatment|Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until surgery.
2995151|NCT02595359|Experimental|moxifloxacin intracameral|moxifloxacin injection given at conclusion of cataract intervention
2995152|NCT02595346|Experimental|hydroxychlorquine|hydroxychloroquine 200 mg twice a day for 6 months
2995153|NCT02595346|Placebo Comparator|control|placebo 2 pills a day for 6 months
2995154|NCT02595333|Experimental|Group SF1|primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
2995155|NCT02595333|Experimental|Group S1|primary cesarean section+postoperative analgesia with sufentanil group
2995156|NCT02595333|Experimental|Group SF2|repeated cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
2995157|NCT02595333|Experimental|Group S2|repeated cesarean section+postoperative analgesia with sufentanil group
2995158|NCT02595320|Experimental|Group A|capecitabine, 1500 mg, twice a day for 7 days on then 7 days off
2995159|NCT02595320|Active Comparator|Group B|capecitabine, 1250 mg/m2 OR 1000 mg/m2, twice a day for 14 days on then 7 days off
2995161|NCT02595307|No Intervention|No Pamphlet|Patient group that will not receive a written pamphlet outlining the risks of surgery as discussed in consultation.
2995162|NCT02595294|Experimental|Cervical Lateral Glide|"15 minutes Cervical Lateral Glide neural mobilization~5 times a week~During 6 weeks~Patient's adequate cervical spine linear alignment was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization."
2995163|NCT02595294|No Intervention|Waiting list control group|- Patients assigned to a 6 week waiting list to receive treatment
2995164|NCT02595281|Experimental|Study arm|
2995165|NCT02595268|Experimental|Pitavastatin Then JNJ-63623872|Participants will sequentially receive single oral dose of pitavastatin 1 milligram (mg) on Day 1, followed by JNJ-63623872 600 mg twice daily on Days 4 through 12 with a single oral dose of pitavastatin 1 mg administered in the morning of Day 9. All study drug intakes will be taken orally, under fed conditions (within approximately 10 minutes after completion of a meal).
2995166|NCT02595255||High risk|Conditioning therapy for bone marrow transplantation or pelvic irradiation. Fertility preservation is usually already proposed in this group of patients. No intervention.
2995167|NCT02595255||Moderate/low risk|"Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML, osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL, Wilms tumour, retinoblastoma.~This is the study group we will compare with high risk and no risk patients. No intervention"
2995168|NCT02595255||No risk|"Patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.~No intervention"
2995169|NCT02595242|Experimental|Mitoxantrone 12 mg/m2|Mitoxantrone Hydrochloride Liposome Injection 12 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
2995170|NCT02595242|Experimental|Mitoxantrone 16 mg/m2|Mitoxantrone Hydrochloride Liposome Injection 16 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
2995171|NCT02595242|Experimental|Mitoxantrone 20mg/m2|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
2995172|NCT02595229|Active Comparator|PQ (Pronator quadraus) repair|Following volar plate osteosynthesis the pronator quadratus muscle is sutured with 3 to 5 U-shaped stitches using a polyfilament absorbable synthetic suture.
2995173|NCT02595229|No Intervention|No PQ repair|Following volar plate osteosynthesis the pronator quadratus muscle is placed in its anatomical position without suture repair.
2995174|NCT02595216|Experimental|all subjects|"All subjects in this study will receive a single Profound system treatment to the submental area with the profound device; subjects will return to four follow- up visits: 1 week post treatment, 1, 3 and 6 months post treatment.~Prior to treatment, tissue will be treated with injected tumescence or local dermal infiltration solution according to the protocol."
2995175|NCT02595203|Experimental|Part A: Cohort 1|Participants receive a single intravenous (IV) dose of 240 mg/3.7 megabecquerel (MBq) of [14C-pos 1]-Debio 1450 BES solution.
2995176|NCT02595203|Experimental|Part A: Cohort 2|Participants receive a single oral dose of 240 mg/3.7 MBq of [14C-pos 1]-Debio 1450 BES solution.
2995177|NCT02595203|Experimental|Part B: Cohort 3|Participants receive a single oral dose of 240 mg Debio 1450/37 kilobecquerel (kBq) of [14C-pos 25]-Debio 1450 BES solution.
2995178|NCT02595190|Experimental|surgery group|sacral canal cyst microscopic tamponade treatment; resting state functional magnetic resonance imaging (rfMRI)
2995179|NCT02595190|Experimental|drug group|gabapentin + tramadol tablets; resting state functional magnetic resonance imaging (rfMRI)
2995180|NCT02595190|Placebo Comparator|control group|resting state functional magnetic resonance imaging (rfMRI)
2995181|NCT02595177|Experimental|Multifocal IOL|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, multifocal intraocular lens implantation in both eyes planning for emmetropia complete the intervention.
2995182|NCT02595177|Experimental|Monovision|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, a monofocal intraocular lens implantation planning for emmetropia in one eye (dominant) and a monofocal IOL planning for 1.50 D of myopia in the other eye (non-dominant) complete the intervention.
2995183|NCT02595177|Experimental|Hybrid Monovision|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, a monofocal intraocular lens implantation in the dominant eye and a multifocal IOL in the non-dominant eye complete the intervention.
2995184|NCT02595164||Impulsive subjects|Subjects exhibiting impulsive symptoms Behavioral Task
2995185|NCT02595164||Non-impulsive subjects|Subjects which do not exhibit impulsive symptoms Behavioral Task
2995186|NCT02595151||gastric intestinal metaplasia|Those fulfilling the criteria of GIM by CLE according to the study by Yuting Guo et al were included.
2995187|NCT02595151||normal gastric|diagnosed during routine colonoscopy procedures.
2995188|NCT02595138|Experimental|A|zoledronic acid received
2995189|NCT02595138|No Intervention|B|observation
2995190|NCT02595125|Sham Comparator|Conventional technique|Intrauterine device (IUD) insertion by the conventional technique
2995191|NCT02595125|Experimental|Direct technique|Intrauterine device (IUD) insertion by the direct technique
2995192|NCT02595112|Experimental|Patient undergoing otorhinolaryngologic surgery|Staphylococcus aureus carriage is measured in the vestibulum nasi and posterior nasal cavity. Posterior nasal cavity is measured during endoscopic procedure.
2995193|NCT02595099|Experimental|Mindfulness training|8 week programme of Mindfulness training
2995194|NCT02595086|Experimental|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy(LPPG) with D1+ lymphadenectomy is performed (exclude lymph node station No. 5) in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy. Extra-corporeal gastro-gastrostomy should be performed
2995230|NCT02594865|Active Comparator|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
2995231|NCT02594865|Active Comparator|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
2995232|NCT02594852|Experimental|Intervention (+ laser)|+ laser therapy
2995195|NCT02595086|Active Comparator|Laparoscopic DG|"Laparoscopic distal gastrectomy(LDG) with D1+ lymphadenectomy in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.~Anastomosis method (extra-corporeal or intra-) and reconstruction type (Billroth I (gastroduodenostomy), Billroth II, or Roux-en Y gastrojejunostomy) are optional according to the surgeon's preference"
2995196|NCT02595073|Experimental|DSXS topical product|DSXS Active treatment
2995197|NCT02595073|Placebo Comparator|Placebo topical product|Placebo treatment
2995198|NCT02595060|Experimental|150 mcg inhaled molgramostim|once daily inhaled molgramostim (rhGM-CSF) for 3 days
2995199|NCT02595060|Experimental|450 mcg inhaled molgramostim|once daily inhaled molgramostim (rhGM-CSF) for 3 days
2995200|NCT02595060|Placebo Comparator|inhaled placebo|once daily inhaled placebo for 3 days
2995201|NCT02595047|Experimental|tissue/ organ prefabrication|in vivo generation of autologous tissue for joint replacement
2995202|NCT02595034|Experimental|Clindamycin/BP Gel 1%5%|Clindamycin and Benzoyl Peroxide Gel 1%/5% applied twice daily (morning and evening) for 70 days (10 weeks).
2995203|NCT02595034|Active Comparator|BenzaClin® Topical Gel|BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel applied twice daily (morning and evening) for 70 days (10 weeks).
2995204|NCT02595034|Placebo Comparator|Placebo|Placebo (vehicle of the test product) applied twice daily (morning and evening) for 70 days (10 weeks).
2995205|NCT02595021|Experimental|Total or Subtotal Colectomy|all patients who underwent total colectomy(removal of the large intestine from ileum to the rectum. After it is removed, the end of the small intestine is sewn to the rectum) or subtotal colectomy(removal of transverse colon, descending colon, sigmoid colon to the rectum. After it is removed, the end of the ascending colon is sewn to the rectum)as part of optimal cytoreductive surgery
2995206|NCT02595021|Active Comparator|Other Bowel Resection|all patients who underwent partial intestinal resection as part of optimal cytoreductive surgery
2995207|NCT02595008|Experimental|DSXS topical product|treatment with DSXS twice daily for 28 days
2995208|NCT02594995|Experimental|NBP in thrombolysis group|NBP 25mg bid for 2 weeks administered after 24 hours after receiving recombinant plasminogenactivator(rt-PA) thrombolysis
2995209|NCT02594995|Experimental|NBP group|NBP 25mg bid for 2 weeks administered for the patients who do not receive rt-PA
2995210|NCT02594995|No Intervention|Control group|Control group not receiving rt-PA thrombolysis, receiving basic therapy for acute stroke, e.g. aspirin/clopidogrel and lipid-lowering therapy
2995211|NCT02594995|No Intervention|Control in thrombolysis group|Control group receiving rt-PA thrombolysis
2995212|NCT02594982|Other|intervention bundle|An intervention bundle consisting of optimized sedation, pain assessment and treatment, early mobilization and sleep.
2995213|NCT02594969|Active Comparator|Healthy Group|These subjects do not have atopic dermatitis and are considered healthy. They will participate in the bleach bath and the moisturizer application.
2995214|NCT02594969|Experimental|Atopic Dermatitis Group|These subjects have atopic dermatitis and are considered healthy. They will participate in the bleach bath and the moisturizer application.
2995215|NCT02594956|Active Comparator|With Nasogastric Decompression|This group will receive conventional care according to the protocol of the service in place with removal of the nasogastric tube the 3rd postoperative day if the flow is < 500ml / 24h, if not removal will take place on the 5th postoperative day.
2995216|NCT02594956|Experimental|Without Nasogastric decompression|The nasogastric tube will be take off at the end of the surgery, just after the extubation.
2995217|NCT02594943|Active Comparator|Conventional Biopsy|"4 out of 8 biopsies taken with a Boston Scientific Large capacity with needle biopsy forceps from the suspected tumor tissue in the stomach. They will be taken in random order blinded for the person performing the examination."
2995218|NCT02594943|Active Comparator|Endodrill Biopsy|"4 out of 8 biopsies taken with the Endodrill 1A instrument from the suspected tumor tissue in the stomach. They will be taken in random order blinded for the person performing the examination."
2995219|NCT02594930|Experimental|undirected and directed biopsy|Via an antero-lateral incision of the knee samples are taken without visual control; Afterwards an arthroscope is inserted and samples are taken from 5 defined regions of the knee (suprapatellar pouch, medial and lateral gutter, notch, Hoffa's fat pad)
2995220|NCT02594917||Test Group|The study population will include ten patients (ages 18-60 yrs) with confirmed mutations of the iron-sulfur cluster biogenesis complex of proteins and experiencing dyspnea, heart failure, or exercise intolerance.
2995221|NCT02594917||Control Group|It will also include ten additional patients (ages 18-60 yrs) who are unaffected first-degree family members of the above subjects.
2995222|NCT02594904|Experimental|G-6-PD normal group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
2995223|NCT02594904|Experimental|G-6-PD mild deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
2995224|NCT02594904|Experimental|G-6-PD moderate deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
2995225|NCT02594904|Experimental|G-6-PD sever deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
2995226|NCT02594891|Experimental|endoscopic retrograde biliary drainage|Patients will undergo endoscopic retrograde biliary drainage (ERBD) with 8.5 F plastic stent with proximal flap when bile duct stones were removed clearly with ERCP. The stent will be taken out with endoscopy three months later if not discharge self-driven.
2995227|NCT02594891|Placebo Comparator|endoscopic nasobiliary drainage|Patients will undergo endoscopic nasobiliary drainage (ENBD) when bile duct stones were removed clearly with ERCP. The nose bile duct will be pulled out 3-5 days later if no cholangitis occurrence.
2995228|NCT02594878|Experimental|Pamidronatdinatrium 3mg/ml|Pamidronatdinatrium 1 mg/kg max 60 mg for 3 days every 3 month in total of 3 series (0,3,6 month). First day first series 0,5mg/kg max 30 mg.
2995229|NCT02594878|Placebo Comparator|Natrium chloride 9 mg/ml|Natrium chloride 9 mg/ml volume equals experimental drug
2995233|NCT02594852|Placebo Comparator|Non-intervention (- laser)|- laser
2995234|NCT02594839|Experimental|MSCs|2 intravenous infusions of suspension of 200 000 000 MSCs each at interval of 7 days. Infusions will be repeated every 3 months for 1 year.
2995235|NCT02594839|Placebo Comparator|placebo|2 intravenous infusions of 400 mL saline each at interval of 7 days. Infusions will be repeated every 3 months for 1 year.
2995236|NCT02594826|Experimental|Culturally appropriate intervention|Culturally appropriate, church-based intervention focused on cervical cancer and navigation assistance.
2995237|NCT02594826|Active Comparator|General health education control|General health and cancer education on nutrition, regular check-ups, tobacco use, and cancer screening.
2995238|NCT02594800|Active Comparator|standard dose|Drug: Rosuvastatin rosuvastatin 10 mg daily for 52 weeks.
2995239|NCT02594800|Experimental|intensive dose|Drug: Rosuvastatin rosuvastatin 20 mg daily for 52 weeks.
2995240|NCT02594787|Active Comparator|Phosphorus|Intervention (500 mg of potassium phosphate) will be administered with 75 g glucose solution and diet induced thermogenesis will be measured afterwards
2995241|NCT02594787|Placebo Comparator|Placebo|Placebo (cellulose) will be administered with 75 g glucose solution and diet induced thermogenesis will be measured afterwards
2995242|NCT02594774|Experimental|Osteopathic treatment|Manipulative osteopathy (and standard medical treatment)
2995243|NCT02594774|No Intervention|Standard medical treatment|Standard medical treatment
2995244|NCT02594761|Experimental|Treatment A|Hercules: 8 mg/kg i.v. infusion over 90 minutes
2995245|NCT02594761|Active Comparator|Treatment B|Herceptin EU: 8 mg/kg i.v. infusion over 90 minutes
2995246|NCT02594761|Active Comparator|Treatment C|Herceptin US: 8 mg/kg i.v. infusion over 90 minutes
2995247|NCT02594748|Experimental|Experimental group|Intervention is administered to patients in this Arm. The intervention is self-management education based on the theory of planned behavior(TPB). The intervention of experimental group is individual guide and face to face education based on TPB.
2995248|NCT02594748|Active Comparator|Comparison group|The comparison group will receive routine care
2995249|NCT02594735|Other|open label|A patient's participation in this study will last approximately 24 weeks ( screening visit and 5 intervention visits) with possible extension to 48 weeks. At screening, participants will have a physical exam, muscle strength assessment, blood and urine collection, and chest x-ray; they will also be asked to complete several questionnaires. All participants will receive each week subcutaneous injection of Abatacept. During intervention phase of the trial, muscle strength testing, physical exam, disease activity measurements, blood and urine collection, and muscle MRI will be performed. Participants will also be asked to complete several questionnaires. Participants will be also monitored closely for for serious drug related side effects.
2995250|NCT02594722|Experimental|One single arm group|"COPD included in a pulmonary rehabilitation program~Intervention:~Investigators used a bedside cycloergometer with electrical stimulation. COPD perform 2 measure of oxygen uptake during exercise for compare aerobic capacities:~Functional Electrical Stimulation Cycling (FES-cycling)~Classic Cycloergometer endurance training with a sham electrical stimulation"
2995251|NCT02594709|Experimental|ONSM Multisession Radiosurgery|Multisession Radiosurgery
2995252|NCT02594696|Experimental|Proactive Psychiatry Consultation (PPC)|"The patient is linked to a psychiatrist and case manager at cancer diagnosis who deliver team-based, patient-centered care. The psychiatrist collaborates with the oncologist to guide cancer treatment. The psychiatrist and case manager proactively monitor patient symptoms and potential barriers to care and remain in communication with the patient, oncology team, and community-based providers for the duration of the intervention.~Patients complete study assessments at baseline, 4 +/- 2 weeks after baseline, and post-intervention (12 +/-2 weeks after baseline)~Oncologists provide feedback about the usefulness of the intervention (12 +/- 2 weeks after baseline)"
2995253|NCT02594683||Key Group of Interest|Exclusively formula fed subjects since 1 month of age
2995254|NCT02594683||Other-Fed Group|Mixed feeding of formula and breast milk
2995255|NCT02594683||Breastfeeding Group|Exclusively breastfeeding at least until 4 months of age
2995256|NCT02594670|Experimental|DU20 and HT7 combination|combination of two acupoints based on location and Heart meridian, including Baihui (DU20) and Shenmen(HT7).
2995257|NCT02594670|Other|DU20 and SP6 combination|combination of two acupoints based on location and Spleen meridian, including Baihui (DU20) and Sanyinjiao(SP6).
2995258|NCT02594670|Sham Comparator|DU20 and SA combination|combination of local acupoint Baihui (DU20) and a sham acupoint (SA) not belonging to any regular meridian or acupoint.
2995259|NCT02594657|Experimental|pedal rate ON 50 RPM|
2995260|NCT02594657|Experimental|pedal rate on 80 RPM|
2995261|NCT02594644|Experimental|10-minute Incubation with Microneedle Roller|10-minute topical aminolevulinic acid incubation group. Subjects randomized by binary randomization into each treatment group and undergo secondary binary randomization for microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
2995262|NCT02594644|Experimental|20-minute Incubation with Microneedle Roller|20-minute topical aminolevulinic acid incubation group. Subjects randomized by binary randomization into each treatment group and undergo secondary binary randomization for microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
2995263|NCT02594644|Sham Comparator|10-minute Incubation with Sham Microneedles|10-minute topical aminolevulinic acid incubation group. Binary randomization of subjects into treatment groups and secondary binary randomization for application of the microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
2995264|NCT02594644|Sham Comparator|20-minute Incubation with Sham Microneedles|20-minute topical aminolevulinic acid incubation group. Binary randomization of subjects into treatment groups and secondary binary randomization for application of the microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
2995265|NCT02594631|Active Comparator|ESWL Group|Patients in this arm will receive ESWL as treatment for acute calcular urinary retention
2995266|NCT02594631|Active Comparator|Endoscopy group|Patients in this arm will receive endoscopic treatment for acute calcular urinary retention
2995267|NCT02594605|Experimental|Platelet Rich Fibrin|Platelet Rich Fibrin was applied with conventional flap surgery for treatment of periodontal bone loss in test group.
2995304|NCT02594371|Active Comparator|IV paclitaxel|IV paclitaxel - supplied as Taxol or generic
2995268|NCT02594605|Active Comparator|Conventional Flap Surgery|Platelet Rich Fibrin was not applied to control groups. Only conventional flap surgery was applied to control groups.
2995269|NCT02594592||Younger Women|Younger Women (age ≤ 55 years),complete questionaire
2995270|NCT02594592||Younger Men|Younger Men (age ≤ 55 years),complete questionaire
2995271|NCT02594592||Older Men|Older Men (age > 55 years). complete questionaire
2995272|NCT02594592||Older Women|Older Women (age > 55 years),complete questionaire
2995273|NCT02594579|Active Comparator|Vitamin D|Dietary Supplement: Vitamin D3
2995274|NCT02594579|Placebo Comparator|Placebo|Dietary Supplement: Placebo
2995275|NCT02594566|Experimental|Research Subjects|A total of 3 injections of the vaccine (CyMVectin) will be given at Days 0, 28 (+4 days), and 56 (+4 days).
2995276|NCT02594553|Experimental|Intervention|All GPs working at the participating GP out-of-hours centres that are in the intervention group will use the GP-parent information-exchange tool (interactive booklet).
2995277|NCT02594553|No Intervention|Control|All GPs working at the participating GP out-of-hours centres that are in the control group will provide care as usual.
2995278|NCT02594540|Experimental|Feet Mechanical Stimulation|The feet mechanical stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland). Intervention: Device: Foot Mechanical Stimulation (GONDOLA)
2995279|NCT02594540|Sham Comparator|Sham Feet Mechanical Stimulation|The sham stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland). Intervention: Device: Foot Mechanical Stimulation (GONDOLA)
2995280|NCT02594527|Experimental|Volunteer-led physical activity sessions|Patient will receive volunteer-led physical activity sessions twice a day during admission.
2995281|NCT02594501|Experimental|COBRA PzF|Cobra PzF plus 14-day DAPT (dual antiplatelet therapy)
2995282|NCT02594501|Active Comparator|Drug Eluting Stent|standard FDA-approved DES (Xience/Promus or Resolute) plus 3 or 6-month DAPT (dual anti-platelet therapy)
2995283|NCT02594488|Active Comparator|Remote monitoring|Remote cardiac monitoring by the Reveal® LINQ implantable cardiac monitor
2995284|NCT02594488|No Intervention|Control arm|Follow-up at the same frequency, but with no implantable cardiac monitor
2995285|NCT02594475|Experimental|Left lateral position|Endoscopic retrograde cholangiopancreatography is performed in left lateral position in this group.
2995286|NCT02594475|Active Comparator|Prone position|Endoscopic retrograde cholangiopancreatography is performed in prone position in this group.
2995287|NCT02594462|Other|ENG-group|"Twenty-five women with homozygous sickle cell anemia (hemoglobin SS), aged between 18-40 years-old, who had at least one episode of sickle cell pain crisis in the last three months pre- enrollment; whom desire to use etonogestrel-releasing implant contraceptive without contraindications will be invited to inserted etonogestrel implant.~Etonogestrel implant is a single implant progestogen-only, with 4 cm in length and 2 mm diameter containing 68 mg etonogestrel (3- ketodesogestrel), the active metabolite of desogestrel, involved in a ethylene vinyl acetate membrane (Huber, 1998), which is released continuously in bloodstream for three years. It will be inserted subdermal, on the inner face of non-dominant arm between the first and seventh day of the menstrual cycle."
2995288|NCT02594449|Active Comparator|low concentration Benzalkonium Chloride|To use low concentration Benzalkonium Chloride Solution to gargle
2995289|NCT02594449|Active Comparator|high concentration Benzalkonium Chloride|To use high concentration Benzalkonium Chloride Solution to gargle
2995290|NCT02594449|Placebo Comparator|Normal Saline|To use Normal Saline to gargle
2995291|NCT02594436||Ingenol mebutate gel 0.015 percent|Topical treatment of face or scalp once daily for three consecutive days
2995292|NCT02594436||Ingenol mebutate gel 0.05 percent|Topical treatment of trunk or extremities once daily for two consecutive days
2995293|NCT02594423|Active Comparator|Fine needle Diathermy|Fine needle Diathermy(FND) will be applied under topical anaesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels.
2995294|NCT02594423|Active Comparator|Fine Needle Diathermy and Bevacizumab|Fine needle Diathermy(FND) will be applied under topical anaesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels. Patients will receive subconjunctival injections of bevacizumab in the conjunctiva near the limbus in the quadrant(s) affected (total volume of between 0.2 ml-0.3 ml of the 2.5 mg/0.1 ml solution). The subconjunctival injections will be administered after FND in the same treated quadrants.
2995295|NCT02594410|Experimental|Treatment|patients receiving renal artery stenting and anti-hypertension drug for renal artery atherosclerosis
2995296|NCT02594397|Experimental|acupoints combination 1|acupoints comination 1 includes the specific acupoint ST36 (Zusanli) and a local acupoint CV12 (Zhongwan).
2995297|NCT02594397|Active Comparator|acupoints combination 2|acupoints comination 2 includes the specific acupoint ST36 (Zusanli) and a distal acupoint PC6(Neiguan).
2995298|NCT02594397|Sham Comparator|sham acupoints combination|sham acupoints combination includes the specific acupoint ST36 (Zusanli) and a sham acupoint.
2995299|NCT02594384|Experimental|Continuous monotherapy|All patients will take LAM-002A two times daily by mouth every day until cancer progression or intolerability.
2995300|NCT02594384|Experimental|Intermittent monotherapy|All patients will receive LAM-002A at escalating dose levels two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
2995301|NCT02594384|Experimental|LAM-002A + rituximab|All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab 375 mg/m2 by vein every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions)
2995302|NCT02594384|Experimental|LAM-002A + atezolizumab|All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
2995303|NCT02594371|Experimental|Oraxol (paclitaxel + HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg capsules~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
2995308|NCT02594332|Experimental|Mepolizumab|100 mg SC every 4 weeks for 13 injections
2995309|NCT02594332|Experimental|Placebo|Amount of Placebo corresponding to mepolizumab dose SC every 4 weeks for 13 injections
2995310|NCT02594319|Active Comparator|Control|Daily reporting of fruit and vegetable consumption
2995311|NCT02594319|Experimental|Daily reward|Incentives for fruit and vegetable consumption delivered daily
2995312|NCT02594319|Experimental|Delayed reward|Incentives for fruit and vegetable consumption delivered in a lump sum at the end of the intervention
2995313|NCT02594306|Experimental|Non operation|Recording the event related potential of drug addicts when they receive the stimulus of Emotional pictures stimulation system.
2995314|NCT02594306|Experimental|Deep brain stimulation|Recording the event related potential after the deep brain stimulation operation.Recording the local field potential of drug addiction people when we conduct a test of adjacent contact stimulation in the deep brain stimulation operation. Recording the waveform of bilateral NAc/ALIC after puting the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule
2995315|NCT02594306|Active Comparator|Standard Control|Recording the event related potential of normal people when they receive the stimulus of emotional pictures stimulation system.
2995316|NCT02594293|No Intervention|Controlled Group|Discontinue the NA treatment and follow up for 96 weeks
2995317|NCT02594293|Experimental|Pegasys 24 weeks|Discontinue the NA treatment ,PegIFN alfa-2a 180 μg by week for 24 weeks and follow up for 72 weeks
2995318|NCT02594293|Experimental|Pegasys 48 weeks|Discontinue the NA treatment ,PegIFN alfa-2a 180 μg by week for 48 weeks and follow up for 48 weeks
2995319|NCT02594280||Selective Laser Trabeculoplasty (SLT)SLT|Monitor glaucoma patients that are scheduled to be treated with Selective Laser Trabeculoplasty (SLT) with VEP/PERG. The treatment is not dependent on the study.
2995320|NCT02594280||Trabecular stent bypass microsurgery|Monitor glaucoma patients that are scheduled to be treated with trabecular stent bypass microsurgery with VEP/PERG.The treatment is not dependent on the study.
2995321|NCT02594267|Experimental|Part 1: Dose Finding, Cohort 1|"Dose finding Phase Intervention: Folotyn (Pralatrexate Injection) CHOP: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone~The first cohort will begin with three patients with dose A of pralatrexate plus CHOP at full dose.~The second cohort will begin with three patients with dose B of pralatrexate plus CHOP at full dose.~The third cohort will begin with three patients with dose C of pralatrexate plus CHOP at full dose.~The fourth cohort will begin with three patients with dose D of pralatrexate plus CHOP at full dose.~The fifth cohort will begin with three patients with dose E of pralatrexate plus CHOP at full dose.~Part 2: Dose Expansion, Additional ten patients will be enrolled at the MTD or MAD (if the MTD is not reached) plus CHOP at full dose in this part of the study. Blood samples for PK analysis of pralatrexate will be collected at various intervals pre and post pralatrexate injection during cycle 1, Dose 1."
2995322|NCT02594254|Experimental|Study Arm 1|Subjects in Study Arm 1 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush.
2995323|NCT02594254|Experimental|Study Arm 2|Subjects in Study Arm 2 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush and custom dental trays.
2995324|NCT02594254|Experimental|Study Arm 3|Subjects in open-label Study Arm 3 will receive 4 ml of 1600 µM study drug administrations for a total of 7 consecutive days. Subjects will receive 4 C16G2 Gel administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the clinic for 6 consecutive days. Study drug will be administered via a manual brush and custom dental trays.
2995325|NCT02594254|Experimental|Study Arm 4|Subjects in open-label Study Arm 4 will receive 4 ml 800 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.
2995326|NCT02594254|Experimental|Study Arm 5|Subjects in open-label Study Arm 4 will receive 4 ml of 1600 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.
2995327|NCT02594254|Experimental|Study Arm 6|If initiated, subjects in Study Arm 6 will receive 4 ml of 1600 µM study drug over a 7 day study drug administration period. Subjects will receive 4 C16G2 Gel or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
2995328|NCT02594254|Experimental|Study Arm 7|If initiated, subjects in Study Arm 7 will receive 4 ml of 800 µM or 1600 µM study drug on a single day once a week or once a month for a total of 4 days of C16G2 Gel or placebo administration. Subjects will receive 4 study drug administrations on the day of dosing. Study drug will be administered via manual toothbrush and custom dental trays.
2995329|NCT02594241|Active Comparator|Methylprednisolone|Patients in this arm will be given an intravenous infusion of 125 mg Methylprednisolone (Solu-Medrol) immediately after induction of general anesthesia.
2995330|NCT02594241|Placebo Comparator|Physiological saline|Patients in this arm will be given an intravenous infusion of saline immediately after induction of general anesthesia.
2995331|NCT02594228|Experimental|Whey Protein and exercise training|Six meals per day of 20 grams of protein, two of which were whey protein and 4 days per week of exercise training..
2995332|NCT02594228|Experimental|Food Protein and exercise training|Six meals per day of 20 grams of protein, all of which were whole food protein and 4 days per week of exercise training.
2995333|NCT02594215|Experimental|Experimental|Experimental
2995334|NCT02594189|Other|1|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
2995335|NCT02594176|Experimental|Test Product|2.2 g FLEXISEQ® twice daily
2995336|NCT02594176|Placebo Comparator|Placebo|2.2 g placebo twice daily
2995364|NCT02594046|Placebo Comparator|placebo group|placebo group who apply a placebo on their scalp for 16 weeks
2995365|NCT02594033|Experimental|3 mm needle|
2995337|NCT02594163|Experimental|Brentuximab Vedotin|Subjects randomized to the brentuximab vedotin arm will receive IV infusions of brentuximab vedotin followed by bendamustine on day 1, and rituximab followed by bendamustine on day 2 of each 21 day cycle.
2995338|NCT02594163|Active Comparator|Rituximab,Bendamustine control|Subjects randomized to the control arm will receive IV infusions of rituximab on day 1 or day 2 and bendamustine on both days 1 and 2 of each 21 day cycle.
2995339|NCT02594150|No Intervention|usual care|Each FIT kit will include a tube in which to deposit the stool sample, directions on how to collect and mail the sample, a letter about colorectal cancer screening, a Labcorp requisition form, and a pre-paid return envelope.
2995340|NCT02594150|Experimental|unconditional fixed incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will also receive a financial incentive in the form of a gift card and a note explaining that this gift card is a token of our appreciation for completing the kit.
2995341|NCT02594150|Experimental|conditional fixed incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will receive a note stating that they will receive a financial incentive in the form of a gift card if they return their completed FIT within two months of receiving the FIT kit.
2995342|NCT02594150|Experimental|conditional lottery incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will receive a note stating that they will be entered in a 1/10 chance lottery to receive a financial incentive in the form of a gift card if they return their completed FIT within two months of receiving the FIT kit.
2995343|NCT02594137|Experimental|Without Watertight Duraplasty|"After standard craniectomy (12x15cm) and dural opening, the intervention, which is to not perform watertight duraplasty is carried out. The exposed brain parenchyma is covered with Surgicel. Usual closure is then performed."
2995344|NCT02594137|No Intervention|With Watertight Duraplasty|After standard craniectomy (12x15cm) and dural opening, watertight duraplasty with pericranium or an artificial graft is performed. Usual closure is then performed. This kind of duraplasty is performed by most neurosurgeons and this group will be used as a control.
2995345|NCT02594124|Experimental|Group 1|Participants transitioned from ISIS 396443-CS3B (NCT02193074)
2995346|NCT02594124|Experimental|Group 2|Participants transitioned from ISIS 396443-CS4 (NCT02292537)
2995347|NCT02594124|Experimental|Group 3|Participants transitioned from ISIS 396443-CS12 (NCT02052791)
2995348|NCT02594124|Experimental|Group 4|Participants transitioned from ISIS 396443-CS3A (NCT01839656)
2995349|NCT02594124|Experimental|Group 5|Participants transitioned from 232SM202 (NCT02462759)
2995350|NCT02594111|Active Comparator|Colchicine|Colchicine 1.8 mg PO over 1 hour
2995351|NCT02594111|Placebo Comparator|Placebo|Matching placebo
2995352|NCT02594098|Experimental|Secukinumab|Secukinumab (300 mg) via subcutaneous injection using 2 prefilled syringes
2995353|NCT02594098|Placebo Comparator|Placebo|Placebo via subcutaneous injection using 2 prefilled syringes
2995354|NCT02594085|Experimental|Patch 3/Patch4 + Patch1/patch2 + patch 5/patch 6|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 3 and Patch 4 Test period 2: Patch 1 and Patch 2 Test period 3: Patch 5 and Patch 6"
2995355|NCT02594085|Experimental|Patch 1/Patch2 + Patch3/patch4 + patch 5/patch 6|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
2995356|NCT02594085|Experimental|Patch 1/Patch2 + Patch5/patch 6 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
2995357|NCT02594085|Experimental|Patch 3/Patch4 + Patch5/patch6 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 3 and Patch 4 Test period 2: Patch 5 and Patch 6 Test period 3: Patch 1 and Patch 2"
2995358|NCT02594085|Experimental|Patch 5/Patch 6 + Patch 3/patch 4 + patch 1/patch 2|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 5 and Patch 6 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 1 and Patch 2"
2995359|NCT02594085|Experimental|Patch 5/Patch 6 + Patch1/patch2 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
2995360|NCT02594072|Experimental|SABR with androgen suppression|Stereotactic ablative radiotherapy (SABR) with a prescribed dose of 36.25 Gy in 5 fractions over 5 weeks (one treatment day per week). Zoladex ® for androgen suppression, taken for 6 months for patients with intermediate-risk prostate cancer, 18 months for patients with high-risk prostate cancer.
2995361|NCT02594072|Active Comparator|EBRT with androgen suppression|Conventional external beam radiation therapy (EBRT) with a prescribed dose of 73.68 Gy in 28 fractions (5 treatment days per week over 5.5 weeks). Zoladex ® for androgen suppression, taken for 6 months for patients with intermediate-risk prostate cancer, 18 months for patients with high-risk prostate cancer.
2995362|NCT02594059|Experimental|Pulmonary idiopathic fibrosis|Patients with pulmonary idiopathic fibrosis according to ATS/ERS 2011's criteria
2995363|NCT02594046|Experimental|stem cell group|stem cell group who apply 1.2 g of allogeneic human adipose derived stem cell component extract on their scalp for 16 weeks
2995368|NCT02594020|Other|dental bur versus air abrasion|1 tooth prepared with air abrasion versus one prepared tooth with dental bur
2995369|NCT02594020|Other|sono abrasion versus dental bur|1 tooth prepared with sono abrasion ans 1 tooth prepared with dental bur
2995370|NCT02594020|Other|air abrasion versus sono abrasion|1 tooth prepared with air abrasion versus 1 tooth prepared with sono abrasion
2995371|NCT02594007|Experimental|discharge home|SEEQ for 28 days. Cardiocom for 30 days
2995372|NCT02594007|Experimental|discharge to skilled nursing facility|SEEQ for 28 days, DocView for 30 days
2995373|NCT02593994||Onyx Drug Eluting Stent|
2995374|NCT02593981|Active Comparator|Fruit/Honey Drink|Fruit/Honey Drink (2 canisters) will be taken orally twice a day. Subjects will consume the drink on days 1 through 28.
2995375|NCT02593981|Placebo Comparator|Placebo|Placebo (2 canisters) will be taken orally twice a day. Subjects will consume the placebo drink on days 1 through 28.
2995376|NCT02593968|Experimental|Treatment|subject were treated 3 periods with Yallaferon®; each period has interval 10 days ; one period included Yallaferon application for every other day for 10 times
2995377|NCT02593968|Placebo Comparator|Plcaebo|subject were treated 3 periods with Yallaferon® Plcaebo; each period has interval 10 days; one period included Yallaferon application for every other day for 10 times
2995378|NCT02593955|Active Comparator|PD exercise group|Supervised exercise training, 3x per week for 16 weeks
2995379|NCT02593955|Active Comparator|PD sleep hygeine group|Tips for improved sleep hygiene, reading materials
2995380|NCT02593955|No Intervention|Healthy control|MRI sub-study only
2995381|NCT02593942|Experimental|group I|remifentanil
2995382|NCT02593942|Experimental|group II|remifentanil, propofol
2995383|NCT02593929|Experimental|ruxolitinib|Ruxolitinib will be taken orally for 14-21 days prior to surgery, every morning and every evening, and will be discontinued after the morning dose on the day of planned surgical resection.
2995384|NCT02593903|Experimental|Antibiotics Group|Patients randomized to this arm will receive prophylactic oral antibiotics following the surgery and catheter placement (Septra, 3 mg/kg/dose once daily), and will continue the medication for until the day before catheter removal 4-8 days post-operation.
2995385|NCT02593903|No Intervention|No Antibiotics Group|Patients randomized to this arm will receive regular clinical care without prophylactic antibiotics, including catheter placement/removal.
2995386|NCT02593890|Active Comparator|Intervention|Arm A: Participants will be fitted with the THEYA Recovery bra
2995387|NCT02593890|No Intervention|Control|Arm B: Participants will be recommended or fitted with current recommended bra used in each hospital by the Breast Care Nurse Specialist
2995388|NCT02593877|Experimental|VHA algorithm|Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) and VHA-guiding further resuscitation with blood products and procoagulant factors
2995389|NCT02593877|No Intervention|Control|Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) and conventional coagulation tests guiding further resuscitation with blood products and procoagulant factors
2995390|NCT02593864|Experimental|Variable-Stiffness Shoe|Subjects will wear a load-modifying variable-stiffness shoe for 6 months
2995391|NCT02593851|Experimental|Part 1: Cohort 1a|Participants (greater than or equal to [>=] 6 months and less than or equal to [<=] 24 months of age) will receive JNJ-53718678, 2 milligram per kilogram body weight (mg/kg) oral solution once daily on Day 1 to Day 7. Dose and/or dosing regimen may be adapted in subsequent cohorts based on the review of the safety/tolerability and full pharmacokinetic data from Cohort 1a.
2995392|NCT02593851|Experimental|Part 1: Cohort 1b|Participants (>= 6 months and <= 24 months of age) will receive total daily dose of 6 mg/kg JNJ-53718678 oral solution or placebo [either in once daily [qd] or twice daily [bid]) on Day 1 to Day 7.
2995393|NCT02593851|Experimental|Part 1: Cohort 1c|Participants (>= 6 months and <= 24 months of age) will receive total daily dose of 18 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
2995394|NCT02593851|Experimental|Part 1: Cohort 1d|Participants (>= 6 months and <= 24 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 1d is optional and may be included at the discretion of the sponsor.
2995395|NCT02593851|Experimental|Part 1: Cohort 1e|Participants (>= 6 months and <= 24 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 1e is optional and may be included at the discretion of the sponsor.
2995396|NCT02593851|Experimental|Part 1: Cohort 2a|Participants (>= 3 months and less than [<] 6 months of age) will receive total daily dose of 1.5 mg/kg JNJ-53718678 oral solution [either in a qd or a bid regimen] on Day 1 to Day 7.
2995397|NCT02593851|Experimental|Part 1: Cohort 2b|Participants (>=3 months and < 6 months of age) will receive total daily dose of 4.5 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
2995398|NCT02593851|Experimental|Part 1: Cohort 2c|Participants (>= 3 months and < 6 months of age) will receive total daily dose of 13.5 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7
2995399|NCT02593851|Experimental|Part 1: Cohort 2d|Participants (>= 3 months and < 6 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 2d is optional and may be included at the discretion of the sponsor.
2995400|NCT02593851|Experimental|Part 1: Cohort 2e|Participants (>= 3 months and < 6 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 2e is optional and may be included at the discretion of the sponsor.
2995401|NCT02593851|Experimental|Part 1: Cohort 3a|Participants (greater than (>) 1 month and < 3 months of age) will receive total daily dose of 1 mg/kg JNJ-53718678 oral solution [either in a qd or a bid regimen] on Day 1 to Day 7.
2995402|NCT02593851|Experimental|Part 1: Cohort 3b|Participants (> 1 month and < 3 months of age) will receive total daily dose of 3 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
2995403|NCT02593851|Experimental|Part 1: Cohort 3c|Participants (> 1 month and < 3 months of age) will receive total daily dose of 9 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
2996065|NCT02589457|Active Comparator|Viread® tablet|Tenofovir Disoproxil Fumarate
2995404|NCT02593851|Experimental|Part 1: Cohort 3d|Participants (> 1 month and < 3 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 3d is optional and may be included at the discretion of the sponsor.
2995405|NCT02593851|Experimental|Part 1: Cohort 3e|Participants (> 1 month and < 3 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 3e is optional and may be included at the discretion of the sponsor.
2995406|NCT02593851|Experimental|Part 2: Cohort f|Participants of all age groups will receive daily dose of JNJ-53718678 oral solution or placebo, either in a qd or a bid regimen on Days 1 to 7.
2995407|NCT02593838|Other|CTP and SPECT-MPI|Every patient enrolled will undergo CT-MPI and SPECT-MPI. The latter is clinically indicated,.
2995408|NCT02593825|Experimental|START-Play intervention|Intervention incorporating cognitive factors and focusing on self-initiated movement toward achievement of skill in sitting and reaching to increase problem-solving skills, which will then improve overall developmental outcomes. Visits to home by physical therapist twice weekly with parent training, for 3 months.
2995409|NCT02593825|Active Comparator|Business as Usual|Early motor intervention provided as standard treatment in the home for infants with motor dysfunction who are just beginning to sit. Dosage and content of intervention may vary from infant to infant and geographically.
2995410|NCT02593812|Experimental|"Training off medication"|"Participants will train on the postural stepping task before taking their first daily dose of standard Parkinson's medication (dopamine), i.e. while off dopamine replacement medication"
2995411|NCT02593812|Other|"Training on medication"|"Participants will train on the postural stepping task after taking their first daily dose of standard Parkinson's medication (dopamine), i.e. while on dopamine replacement medication"
2995412|NCT02593799||Patients with esophageal varices|"Esophageal varices were confirmed by endoscopy. They were divided into any grade and high-risk varices."
2995413|NCT02593799||Patients without esophageal varices|"Patients without esophageal varices were divided into patients without any grade or high-risk varices."
2995414|NCT02593786|Experimental|Nivolumab monotherapy|Nivolumab specified dose on specified days
2995415|NCT02593786|Experimental|Cohort Expansion|Nivolumab specified dose on specified days
2995416|NCT02593773|Experimental|interferon γ-1b|Subcutaneous (SC) doses of ACTIMMUNE® TIW for a total of 26 weeks.
2995417|NCT02593760|Active Comparator|Placebo + Ruxolitinib|Participants will receive placebo (PO QD) in combination with ruxolitinib (dose will depend on the participant's baseline platelet count) for up to 48 weeks.
2995418|NCT02593760|Experimental|Vismodegib + Ruxolitinib|Participants will receive vismodegib (150 mg PO QD) in combination with ruxolitinib (dose will depend on the participant's baseline platelet count) for up to 48 weeks.
2995419|NCT02593747|Experimental|Loratadine oral solution/syrup then Claritin peach syrup|Subjects received a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.
2995420|NCT02593747|Experimental|Claritin peach syrup then Loratadine oral solution/syrup|Subjects received a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.
2995421|NCT02593734|No Intervention|Control|No intervention
2995422|NCT02593734|Experimental|Experimental|The intervention is prescription and dispensing by a nurse of oral antipsychotic or antidepressant medication as clinically indicated. The mediations to be selected from include oral olanzapine, risperidone, amitryptaline or fluoxetine at doses prescribed by the treating psychiatrist.
2995423|NCT02593721|Experimental|Median Nerve Neural Mobilization|15 minute Median Nerve Neural Mobilization sessions 5 times a week (monday to Friday) during 6 continuous weeks The maximum degree of elbow extension applied in the Median Nerve neural mobilization procedure was determined through the use of a Universal Goniometer Device.
2995424|NCT02593721|Active Comparator|Ibuprofen|A single daily 400 mg dose of oral Ibuprofen that can be increased depending on patient tolerance to a maximum dose of 1200 mg/day equally divided in 3 oral intakes of the drug every 8 hours during 6 continuous weeks.
2995425|NCT02593708|Experimental|Cohort 0|"Neratinib: 80 mg, daily, oral~Paclitaxel: 80 mg/m2, weekly, intravenously~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
2995426|NCT02593708|Experimental|Cohort 1|"Neratinib: 120 mg, daily, oral~Paclitaxel: 80 mg/m2, weekly, intravenously~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
2995427|NCT02593708|Experimental|Cohort 2|"Neratinib: 160 mg, daily, oral~Paclitaxel: 80 mg/m2, weekly, intravenously~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
2995428|NCT02593708|Experimental|Cohort 3|"Neratinib: 200 mg, daily, oral~Paclitaxel: 80 mg/m2, weekly, intravenously~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
2995429|NCT02593695|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
2995430|NCT02593695|Active Comparator|Standard Control|Fluoxetine
2995431|NCT02593682|Experimental|Suvorexant Group|In this arm, subjects will receive 10 mg suvorexant 2 hours before a one-minute 35% CO2 challenge.
2995432|NCT02593682|Placebo Comparator|Placebo Group|In this arm, subjects will receive a placebo, compounded to look identical to the study drug, 2 hours before a one-minute 35% CO2 challenge.
2995433|NCT02593669|Experimental|Neutral IOL|Phacoemulsification cataract surgery is performed with neutral IOL implantation.
2995434|NCT02593669|Experimental|Blue-blocking IOL|Phacoemulsification cataract surgery is performed with blue-blocking IOL implantation.
2995435|NCT02593656|Experimental|High Protein|Ingestion of 2.0 grams of protein per kilogram of body weight per day combined with exercise training
2996066|NCT02589457|Experimental|CKD-390|Tenofovir Disoproxil Fumarate
2995436|NCT02593656|Active Comparator|Normal Protein|Ingestion of 1.0 gram of protein per kilogram of body weight per day combined with exercise training
2995437|NCT02593643|Experimental|ketamine+TAU - MDD|Ketamine + treatment as usual (TAU) in MDD inpatients with SI
2995438|NCT02593643|Active Comparator|midazolam + TAU - MDD|Midazolam + treatment as usual (TAU) in MDD inpatients with SI
2995439|NCT02593643|Experimental|ketamine + TAU - BD|Ketamine + treatment as usual (TAU) in BD inpatients with SI
2995440|NCT02593643|Active Comparator|midazolam + TAU - BD|Midazolam + treatment as usual (TAU) in BD inpatients with SI
2995441|NCT02593630|Experimental|Unicirc circumcision|Unicirc circumcision under topical anaesthetic, wound sealing with cyanoacrylate tissue adhesive
2995442|NCT02593617|Other|University students who use alcohol|In Addiction Profile Index, university students who use alcohol in last year.
2995443|NCT02593617|Other|University students who don't use alcohol|In Addiction Profile Index, university students who don't use alcohol in last year.
2995444|NCT02593617|Other|University students who use energy drinks|In energy drink consumption questionnaire, university students who use energy drinks in last year.
2995445|NCT02593617|Other|University students who don't use energy drinks|In energy drink consumption questionnaire, university students who don't use energy drinks in last year.
2995446|NCT02593617|Other|University students who use substance|In Addiction Profile Index, university students who use substance in last year.
2995447|NCT02593617|Other|University students who don't use substance|In Addiction Profile Index, university students who don't use substance in last year.
2995448|NCT02593591||Biomarker group|Advanced cancer undergoing genomic profiling
2995449|NCT02593578||Biomarker group|Advanced cancer undergoing genomic profiling
2995450|NCT02593565||Intervention|Woman, 18 years of age or older, currently pregnant, and have a diagnosis of vasculitis.
2995451|NCT02593552|Experimental|Video camera|DriveCam video event recorder with counseling feedback
2995452|NCT02593539|Experimental|GSK2269557 DPI 1000 mcg|Subjects will receive GSK2269557 1000 mcg once daily via dry powder inhaler (DPI) for 84 days
2995453|NCT02593526|No Intervention|No Diuretic and 37°C dialysate|Standard of care, no diuretic
2995454|NCT02593526|Experimental|No Diuretic and 35.5°C dialysate|Cool dialysate only, no diuretic
2995455|NCT02593526|Experimental|Diuretic and 37°C dialysate|Isothermic dialysate (37°C) and bumetanide (diuretic)
2995456|NCT02593526|Experimental|Diuretic and 35.5°C dialysate|Cool dialysate (35.5°C) and bumetanide (diuretic)
2995457|NCT02593513|Experimental|Daifert|The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
2995458|NCT02593513|Other|Control Group|The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
2995459|NCT02593500|Experimental|Pulmictan+Test (Treatment Sequence AB)|"Treatment period 1:~Budesonide 200 µg (Budesonida Pulmictan® 200 µg: reference product (A)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs)per treatment period under fasting conditions.~Treatment period 2:~Budesonide 200 µg (test product (B)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) per treatment period under fasting conditions."
2995460|NCT02593500|Experimental|Test+Pulmictan (treatment sequence BA)|"Treatment period 1:~Budesonide 200 µg (test product (B)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) under fasting conditions.~Treatment period 2:~Budesonide 200 µg (Budesonida Pulmictan® 200 µg: reference product (A)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) under fasting conditions."
2995461|NCT02593487|Experimental|Rosuvastatin 10mg/d group|rosuvastatin 10mg table by mouth, qd
2995462|NCT02593487|Active Comparator|Rosuvastatin 20mg/d group|rosuvastatin 20mg table by mouth, qd
2995463|NCT02593474|Other|Detoxification / induction|The detoxification / induction procedure consists of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses. Followed on day 8 by Vivitrol injection. Participants then receive a second injection 4 weeks after the first.
2995464|NCT02593461|Experimental|Diafert|The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
2995465|NCT02593461|Other|Control Group|The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
2995466|NCT02593448|Active Comparator|Propofol|"General anaesthesia with Propofol use. Maintenance of anaesthesia in group P will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60.~Intervention: NIRS during VOT on several timepoints."
2995467|NCT02593448|Experimental|Sevoflurane|"General anaesthesia with sevoflurane use. Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60.~Intervention: NIRS during VOT on several timepoints."
2995468|NCT02593435||No treatment|There will be two groups, one is breast cancer patient group, another group inlude the first-degree relatives and second degree relatives of patients with BRCA1/2 mutation. All volunteers should provid tissue(s) and blood for NGS test.
2995469|NCT02593422|Experimental|Expressive Writing|Writing about ovarian cancer: Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
2995470|NCT02593422|Active Comparator|Fact Writing (Control)|Writing about ovarian cancer: Participants will be asked to write about the facts of their experience with ovarian cancer
2995471|NCT02593409|Other|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
2995472|NCT02593396|Placebo Comparator|placebo|Placebo BD
2995473|NCT02593396|Experimental|Active|Bupropion hydrochloride sustained-release 150mg BD
2995474|NCT02593383|Experimental|Treat group 1|Group 1: 0.1% Adapalene + 1% Clindamycin Hydrochloride
2995475|NCT02593383|Experimental|Treatment group 2|Group 2: 0.1% Adapalene + 2% Clindamycin Hydrochloride
3024018|NCT02402621|Experimental|Model based analgesic group|fentanyl
2995476|NCT02593383|Experimental|Treatment group 3|Group 3: 0.05% Adapalene + 0.5% Clindamycin Hydrochloride
2995477|NCT02593383|Experimental|Treatment group 4|Group 4: 0.05% Adapalene + 1% Clindamycin Hydrochloride
2995478|NCT02593383|Placebo Comparator|Placebo group|Placebo Group: Blank Gel
2995479|NCT02593370|Experimental|Suprasacral Parallel Shift guided by US/MR image fusion|Use of ultrasound/MR image fusion guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).
2995480|NCT02593370|Active Comparator|Suprasacral Parallel Shift guided by US|Use of ultrasound guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).
2995481|NCT02593357|Experimental|COPD patients|measure of endothelial function with EndoPAT® in COPD patients
2995482|NCT02593344|Experimental|endopat|measure of endothelial function with endopat
2995483|NCT02593331|Placebo Comparator|Placebo|Participants will receive placebo matching to BFKB8488A.
2995484|NCT02593331|Experimental|BFKB8488A SC|Participants will receive single ascending SC dose of BFKB8488A in each dose escalation cohort.
2995485|NCT02593331|Experimental|BFKB8488A IV|Participants will receive single IV dose of BFKB8488A.
2995486|NCT02593318|Experimental|Part 1 - Oxaloacetate (OAA) 1 gram/day|Participants take 1 gram of OAA per day for period of 4 weeks
2995487|NCT02593318|Experimental|Part 2 - Oxaloacetate (OAA)2 gram/day|Participants take 2 grams of OAA per day for period of 4 weeks
2995488|NCT02593305|Experimental|Beetroot crystals (nitrate), then placebo|Participants will receive a nitrate rich beetroot powder (10g/day) for 4 weeks. After a washout period of 4 weeks, they will then receive the placebo (beetroot powder, no nitrate) for 4 weeks.
2995489|NCT02593305|Experimental|Placebo, then beetroot crystals (nitrate)|Participants will receive a beetroot powder placebo (no nitrate) for 4 weeks. After a 4 week washout period, they will receive the nitrate rich beetroot powder for 4 weeks.
2995490|NCT02593292|Active Comparator|PROSPERO group (intervention group)|
2995491|NCT02593292|Placebo Comparator|control group|
2995492|NCT02593279|Active Comparator|asthma with proximal or diffuse lung damage|
2995493|NCT02593279|Experimental|asthma with small airway prevailing damage|
2995494|NCT02593266|Experimental|Intervention Group|weekly sessions of PIP for depression.
2995495|NCT02593266|No Intervention|Waiting list control group|This is treatment as usual.
2995496|NCT02593253|Experimental|Intervention Audit and Feedback Bundle|Access to the electronic dashboard and weekly feedback rounds
2995497|NCT02593253|Active Comparator|Bi-weekly audit and feedback emails|Access to biweekly feedback emails with performance on selected quality measures (current practice).
2995498|NCT02593240|Experimental|Human Performance Institute©|
2995499|NCT02593240|Experimental|The iDiet® with Voucher|
2995500|NCT02593240|Experimental|The iDiet® with Food|
2995501|NCT02593240|No Intervention|Wait-listed control|These participants will be in the control sites and will participate in outcome assessments only for a six month period.
2995502|NCT02593227|Experimental|Low dose FRα vaccine|FRα peptide vaccine with GM-CSF adjuvant - single ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
2995503|NCT02593227|Experimental|High dose FRα vaccine|FRα peptide vaccine with GM-CSF adjuvant - triple ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
2995504|NCT02593227|Experimental|Low dose FRα vaccine + cyclophosphamide|Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
2995505|NCT02593227|Experimental|High dose FRα vaccine + cyclophosphamide|Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
2995506|NCT02593214|Experimental|Wondaleaf Arm|This is a single arm clinical trial, all subjects and their married couples were be recruited to the arm using investigational device Wondaleaf only.
2995507|NCT02593201|Experimental|Treatment|One extra week of antibiotic therapy
2995508|NCT02593201|Sham Comparator|Control|No extra antibiotics
2995509|NCT02593188||HYQVIA- Epoch 1|Participants receiving HYQVIA
2995510|NCT02593188||HYQVIA- Epoch 2|Participants with rHuPH antibody titers ≥160 (tested in Epoch 1)
2995511|NCT02593175|Experimental|Panitumumab + Carboplatin + Paclitaxel|"One week before Cycle 1 participants receive a single dose of Panitumumab by vein. About 1 week after the first Panitumumab dose, participants have an image-guided core biopsy and/or a fine needle aspiration (FNA) to remove breast tissue.~Participants then receive the study drug combination for 4 cycles. Each cycle is 21 days.~On Day 1, 8, and 15 of each cycle, participants receive Panitumumab 2.5 mg/kg by vein and Paclitaxel 80 mg/m2 by vein.~On Day 1 of each cycle Carboplatin AUC 4 received by vein."
2995512|NCT02593162|Experimental|Group 1|12 weeks of Faldaprevir plus low dose TD-6450 plus Ribavirin
2995513|NCT02593162|Experimental|Group 2|12 weeks of Faldaprevir plus high dose TD-6450 plus Ribavirin
2995514|NCT02593149|Experimental|Treatment|ClearGuard HD End Cap
2995515|NCT02593149|No Intervention|Control|Tego® connector with the Curos® for Tego disinfecting port protector
2995516|NCT02593136|Experimental|Home Fortification and Counseling|Participants aged 6 to 18 months will receive a daily supplement of vitamins and minerals in dry powder form to be taken once daily for up to nine months or up to 240 sachets. Participant caregivers will also receive improved young child feeding practices (IYCF) counseling from a front line worker.
2995517|NCT02593136|Experimental|Improved Child Feeding Practices (IYCF) Counseling|Participants ages 6 to 18 months will receive improved young child feeding practices (IYCF) counseling from a front line worker.
2995518|NCT02593123|Experimental|Arm I (MMF-15, sargramostim)|Patients receive mycophenolate mofetil PO or IV BID on days 1-15 and sargramostim SC from post-transplant day 4 until neutrophil engraftment.
2995519|NCT02593123|Experimental|Arm II (MMF-30, filgrastim)|Patients receive mycophenolate mofetil PO or IV BID on days 1-30 and sargramostim SC from post-transplant day 4 until neutrophil engraftment.
2995520|NCT02593110|Active Comparator|Telmisartan + Supervised Treadmill Exercise Therapy|Participants in this group will receive both daily telmisartan and supervised treadmill exercise three days weekly for six months.
2995521|NCT02593110|Active Comparator|"Telmisartan + No Exercise Control Group"|Participants in this group will receive daily telmisartan and attend weekly educational lectures at the medical center for six months.
2995522|NCT02593110|Active Comparator|Placebo + Supervised Treadmill Exercise Therapy|Participants randomized to this group will receive daily placebo and supervised treadmill exercise three times weekly for six months.
2995523|NCT02593110|Placebo Comparator|"Placebo + No Exercise Control Group"|Participants randomized to this group will receive daily placebo and health education lectures weekly for six months.
2995524|NCT02593097|Experimental|Metformin 500mg|Metformin 500mg twice a day
2995525|NCT02593097|Placebo Comparator|Matching placebo|Matching placebo twice a day
2995526|NCT02593084|Experimental|Higher Intensity Resistance Training|Participants will take part in a 12-week higher-intensity resistance training protocol.
2995527|NCT02593084|Active Comparator|Lower Intensity Resistance Training|Participants will take part in a 12-week lower-intensity resistance training protocol that will serve as the active comparator.
2995528|NCT02593071|Experimental|Treatment Group A|RSV-F Vaccine ( 0.5mL Injection)
2995529|NCT02593071|Placebo Comparator|Treatment Group B|Phosphate Buffer Placebo (0.5mL Injection)
2995530|NCT02593058|Experimental|PEPS+TAU|Eight one-hour weekly sessions of Positive Emotions Program for Schizophrenia (PEPS) + Treatment as Usual (TAU)
2995531|NCT02593058|Active Comparator|Treatment As Usual (TAU)|Treatment as usual - with no attempts to standardize this treatment as TAU is tailored to the patient's specific needs
2995532|NCT02593045|Experimental|IPH4102|
2995533|NCT02593032|Experimental|Randomized Treatment|Patients in the treatment group will begin receiving their medications in pre-filled trays from Friendship Pharmacy. Patients will receive 5 trays on a monthly basis in order to accommodate a 30-day, insurance-reimbursed fill schedule.
2995534|NCT02593032|No Intervention|Control Arm|Patients in the control arm will receive usual care and can continue using their existing pharmacy.
2995535|NCT02593019|Experimental|AZD1775|AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.
2995536|NCT02592993|Experimental|PicoWay treatment to all subjects|Subjects in this study will receive up to six (6) treatments in 3-8 weeks interval, with the PicoWay device-fractional handpiece 532nm and/or 1064nm according to the study protocol. Subjects will be followed by phone 7 days post first treatment by study staff, and will return for two follow‐up (FU) visits at the clinic at: 6 weeks and 12 weeks following the last treatment.
2995537|NCT02592980|Experimental|Traditional anticoagulation|For the Traditional Anticoagulation group, the physician will adjust the dose according to the current INR value based on current guidelines
2995538|NCT02592980|Experimental|Pharmacogenetic anticoagulation|For the Pharmacogenetic Anticoagulation group, the dose will be prescribed based on data from each patient applied in a pharmacogenetic algorithm. In some cases, used algorithm may provide a counter-intuitive dose, i.e., a dose that is not adequate for adjusting the current patient' INR (for example, a higher dose for a patient that already has a high INR). In these cases, the physician will adjust the dose following clinical criteria based on published guidelines
2995539|NCT02592967|Experimental|Cohort 1A and 1B|JNJ-64041757 will be administered intravenously (IV) once every 21 days.
2995540|NCT02592967|Experimental|Cohort 2A and 2B|JNJ-64041757 will be administered intravenously (IV) once every 21 days.
2995541|NCT02592954|Experimental|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
2995542|NCT02592954|Placebo Comparator|Jojoba oil|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
2995543|NCT02592928||Lleida Health Sector|"Lleida (168k inhabitants and 21 Primary Care centers). Primary Care centers from this health sector~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
2995544|NCT02592928||Vic Health Sector|"Vic (49k inhabitants and 11 Primary Care Centers). Primary Care centers from this health sector~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
2995545|NCT02592928||AISBE Health Sector|"Atenció Integral en Salut Barcelona Esquerra (AISBE) (540k inhabitants and 19 Primary Care centers). Primary Care centers from this health sector~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
2995546|NCT02592915|Experimental|Test Group|Patients randomized in the Test Group will receive the clonidine hydrochloride
2995547|NCT02592915|Placebo Comparator|Control Group|Patients randomized in the Control Group will receive the Placebo
2995548|NCT02592902|Active Comparator|Recurrent respiratory papillomatosis|Patients with recurrent respiratory papillomatosis (RRP) - surgical collection of histology specimen from the vocal cords and rear laryngeal commissure, performance of immunohistochemical analysis - proof of pepsin, HPV 6 and 11, herpes simplex virus (HSV) type 2, chlamydia trachomasis, and assessment of the dysplasia.
2995549|NCT02592902|Active Comparator|Laryngeal cyst - control group|Patients with laryngeal cyst - surgical collection of a histology specimen from the vocal cords and rear laryngeal commissure, performance of immunohistochemical analysis - proof of pepsin and HPV 6 and 11, herpes simplex virus (HSV) type 2 and chlamydia trachomasis.
2995550|NCT02592889|No Intervention|CONTROL|OPTIMIZED MEDICAL TREATMENT
2995551|NCT02592889|Active Comparator|DEVICE|MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM + OPTIMIZED MEDICAL TREATMENT
2995552|NCT02592876|Experimental|19A+RICE|Denintuzumab mafodotin plus rituximab, ifosfamide, carboplatin, and etoposide
2995553|NCT02592876|Active Comparator|RICE|Rituximab, ifosfamide, carboplatin, and etoposide
2995554|NCT02592863|Experimental|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
2995555|NCT02592863|Placebo Comparator|Placebo|Patients will take placebo 3 times per day for 12 weeks
2995556|NCT02592850|Experimental|Osteopathic Manipulative Treatment|Active manipulative treatment.
2995557|NCT02592850|Sham Comparator|Sham Osteopathic Manipulative Treatment|Sham manipulative treatment.
2995558|NCT02592837|Experimental|Flex 19G EBUS-TBNA|Mediastinal and hilar lymph node sampling using the flexible 19G EBUS-TBNA needle
2995559|NCT02592837|Active Comparator|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 21G EBUS-TBNA needle
2995560|NCT02592824|Active Comparator|Intravenous glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
2995561|NCT02592824|Placebo Comparator|Intravenous saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
2995562|NCT02592811|Active Comparator|ESLBD|"Endoscopic Sphincterotomy plus Large Balloon Dilatation +/- lithotripsy~ERCP with deep cancellation of BDS~Endoscopic large sphincterotomy~Large Balloon Dilatation of Oddi Sphincter: with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)~Stone extraction with dormia basket or extraction balloon~Mechanical Lithotripsy if needed"
2995563|NCT02592811|Active Comparator|CONV|"Conventional treatment associating Endoscopic Sphincterotomy +/- Mechanical Lithotripsy (ES+/-LM)~ERCP with deep cancellation of BDS~Endoscopic large sphincterotomy~Stone extraction with dormia basket or extraction balloon~Mechanical Lithotripsy if needed"
2995564|NCT02592798|Experimental|Abatacept|"Abatacept intravenous injection every 28 days~Adults will use the weight-tiered dose: < 60 kg: 500 mg, 60 to 100 kg: 750 mg, > 100 kg: 1000 mg~Pediatric patients 6 to 17 years who weigh < 75 kg will receive:10 mg/kg"
2995565|NCT02592798|Other|Placebo|Normal saline or D5W (5% Dextrose in Water)
2995566|NCT02592785|Experimental|BAY1163877|Cohort 1: Safety, tolerability and PK of 600 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 21 days after start of study treatment Cohort 2: Safety, tolerability and PK of 800 mg dose given twice daily
2995567|NCT02592772|Experimental|Reduced Nicotine Non-Menthol (RNC)|Study participants will be randomized from their own brand of menthol cigarettes to the reduced nicotine non menthol cigarettes (RNC: NRC 200; 0.07 mg nicotine yield cigarettes without menthol) during the 6 week experimental phase.
2995568|NCT02592772|Experimental|Reduced Nicotine Menthol (RNC-Men)|Study participants will be randomized from their own brand of menthol cigarettes to the reduced nicotine menthol cigarettes (RNC-Men: NRC 201; 0.07 mg reduced nicotine content menthol cigarettes) during the 6 week experimental phase.
2995569|NCT02592772|Experimental|Conventional Nicotine Non-Menthol (CN)|Study participants will be randomized from their own brand of menthol cigarettes to the regular/conventional nicotine non menthol cigarettes (CN: NRC 600; 0.8 mg nicotine content) during the 6 week experimental phase.
2995570|NCT02592759|Experimental|Smart Glove Group|The subjects will be treated with conventional occupational therapy for 30 minutes and smart glove treatment for 30 minutes. 5 treatments per week will be conducted a total of 2 weeks.
2995571|NCT02592759|No Intervention|Homework group|The subjects will be treated with conventional occupational therapy for 30 minutes and upper extremity rehabilitation homework which means the self training at bedside, for 30 minutes. 5 treatments per week will be conducted a total of 2 weeks.
2995572|NCT02592746|Experimental|Palbociclib + Exemestane + GnRH agonist|
2995573|NCT02592746|Active Comparator|Capecitabine|
2995574|NCT02592733||Historical Cohort|Patients who have undergone infrarenal endovascular repair at each centre in the past.
2995575|NCT02592733||Prospective Cohort|Patients undergoing infrarenal endovascular repair in the study using CYDAR in addition to the local angiography equipment.
2995576|NCT02592720|Experimental|Cocktail plus FFR guided group|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
2995577|NCT02592720|Placebo Comparator|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
2995578|NCT02592707|Experimental|177Lu-OPS201|177Lu-OPS201 will be administered in 3 cycles at intervals of 8 weeks
2995579|NCT02592694|Experimental|Cocktail with thrombus aspiration|Intracoronary cocktail (tirofiban, bivalirudin, tenecteplase) injection combined with thrombus aspiration
2995580|NCT02592694|Active Comparator|Thrombus aspiration|Thrombus aspiration alone
2995581|NCT02592681|Experimental|verum acupuncture|Participants will receive real needle insertion. The needles will be left in the acupoint for 20 min, with a manual rotation at a ten-min interval. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian).
2995582|NCT02592681|Active Comparator|acupressure|Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Duration of each session will be 15 min.
2995583|NCT02592681|Sham Comparator|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan).
2995584|NCT02592668|Experimental|Active stimulation|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function. The total estimated time for the intervention is 66 weeks.
2995585|NCT02592655|Active Comparator|Pneumatic Tourniquet|All participants randomly allocated to receive all interventions. Pneumatic Tourniquet: The Automatic Tourniquet System (ATS) 1500 by Zimmer (formerly Aspen Labs) is a pneumatic tourniquet that is typically used in surgical settings, and is representative of best outcome under the ideal circumstances of a controlled environment. The 10 cm (4 inch) wide cylindrical cuff was used for all participants.
2995586|NCT02592655|Active Comparator|Windlass Tourniquet|Windlass Tourniquet with a 3.8 cm (1.5 inch) wide strap is representative of the typical use device in civilian prehospital and military combat environments. In accordance with current prehospital guidelines: If distal perfusion is observed after One Windlass Tourniquet is applied then a second windlass tourniquet will be applied immediately proximal to the first windlass tourniquet so that the participant has Two Windlass Tourniquets applied.
2995629|NCT02592434|Experimental|CP-690,550|Treatment arm: Tofacitinib tablets or solution, according to subjects' body weights
2995587|NCT02592655|Experimental|Tourniquet Tape 10 cm|Tourniquet Tape 10 cm wide is a highly elastic transparent occlusive tape that is expected to create sufficient circumferential pressure to occlude arterial blood flow when tightly wrapped around a limb. The tape should be applied in mostly overlapping layers. The final wrap should be applied without tension to prevent the elastic tension from causing the tape to unwind itself.
2995588|NCT02592655|Experimental|Tourniquet Tape 5 cm|Tourniquet Tape 5 cm wide is a highly elastic transparent occlusive tape that is expected to create sufficient circumferential pressure to occlude arterial blood flow when tightly wrapped around a limb. The tape should be applied in mostly overlapping layers. The final wrap should be applied without tension to prevent the elastic tension from causing the tape to unwind itself.
2995589|NCT02592642|Experimental|Group 1|Self-management Program, Workbook, Video, Pedometer
2995590|NCT02592642|Active Comparator|Group 2|Instructional Workbook, Video, and Pedometer
2995591|NCT02592642|Experimental|Group a|Para-spinal TENS
2995592|NCT02592642|Placebo Comparator|Group b|Para-spinal Placebo TENS
2995593|NCT02592642|Experimental|Group c|Prototype Spinal Stenosis Belt
2995594|NCT02592642|Sham Comparator|Group d|Sham spinal stenosis belt
2995595|NCT02592629|Active Comparator|no topical or subcutaneous anesthetic|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine
2995596|NCT02592629|Active Comparator|subcutaneous lidocaine|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after 2 ml or 1% lidocaine by subcutaneous injection
2995597|NCT02592629|Active Comparator|topical ethyl chloride|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after applying ethyl chloride spray for 3 seconds
2995598|NCT02592616|Experimental|CON|Control (CON).
2995599|NCT02592616|Experimental|CW|Continuous Walking (CW).
2995600|NCT02592616|Experimental|IW|Interval Walking (IW).
2995601|NCT02592603|Active Comparator|Endocuff-assisted Colonoscopy|Endocuff-assisted Colonoscopy with the ARC Endocuff-vision® attached at the distal tip of the scope.
2995602|NCT02592603|No Intervention|Standard Colonoscopy|Standard Colonoscopy without any additional device
2995603|NCT02592590|Experimental|Group A|
2995604|NCT02592590|Experimental|Group B|
2995605|NCT02592590|Experimental|Group C|
2995606|NCT02592590|Active Comparator|Group D|
2995607|NCT02592577|Experimental|Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T|
2995608|NCT02592564|Experimental|Psychological treatment|Psychological treatment during 9 weeks.
2995609|NCT02592551|Experimental|MEDI4736|8 patients will receive an infusion of MEDI4736 (15 mg/kg intravenously, once), one to six weeks prior to surgical resection.
2995610|NCT02592551|Active Comparator|MEDI4736 + Tremelimumab|8 patients will receive an infusion of MEDI4736 (1500 mg intravenously, once) + tremelimumab (75mg intravenously, once), one to six weeks prior to surgical resection.
2995611|NCT02592551|Placebo Comparator|Untreated arm (control)|Untreated arm (control)
2995612|NCT02592538|Experimental|RFA+stent+S-1|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement, and be treated with S-1 began within 1 month after RFA.
2995613|NCT02592538|Placebo Comparator|RFA+stent|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will only receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement
2995614|NCT02592525|Experimental|Cluster A|IP-SDM training for health professionals (intervention at 4 months)
2995615|NCT02592525|Experimental|Cluster B|IP-SDM training for health professionals (intervention at 11 months)
2995616|NCT02592525|Experimental|Cluster C|IP-SDM training for health professionals (intervention at 18 months)
2995617|NCT02592525|Experimental|Cluster D|IP-SDM training for health professionals (intervention at 25 months)
2995618|NCT02592512||NIV-NAVA|4 hour NIV-NAVA, followed by 4 hour NIV-PS/PC
2995619|NCT02592512||NIV-PS/PC|4 hour NIV-PS/PC, followed by 4 hour NIV-NAVA
2995620|NCT02592499|Experimental|HM III|Patients randomized to mechanical circulatory support will be treated with the HeartMate III (HM III) left ventricular assist device system.
2995621|NCT02592499|Active Comparator|OMM, Optimal Medical Management|"Patients randomized to OMM will be treated according to international guidelines.~ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J. 2012 Jul;33(14):1787-84"
2995622|NCT02592486|Active Comparator|Simultaneous administration group|The subjects receive injections of pneumococcal vaccine and influenza vaccine simultaneously. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016 season.
2995623|NCT02592486|Active Comparator|Sequential administration group|The subjects receive injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016.
2995624|NCT02592473|Experimental|Embozene Microspheres|Embozene Microspheres are spherical particles consisting of a hydrogel core and a poly nanocoat that will be used during study procedure, Prostatic Artery Embolization (PAE) to reduce or eliminate bloodflow to the prostate.
2995625|NCT02592460|Experimental|poor-polyamines diet|
2995626|NCT02592460|Active Comparator|high-polyamines diet|
2995627|NCT02592447|Experimental|Cognitive Behavior Therapy (CBT)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions.
2995628|NCT02592447|Other|Wait-List Control Condition (WLC)|Wait-List Control Condition (WLC) group will not receive therapy sessions and will continue usual care with their providers. This group will be offered the same cognitive behavior therapy as the group receiving the CBT-TTF intervention, after the 18 week study period.
2995630|NCT02592434|Placebo Comparator|Placebo|Control arm: matching placebo tablets or solution for tofacitinib
2995631|NCT02592421|Active Comparator|Dapagliflozin|20 subjects will receive dapagliflozin 10mg
2995632|NCT02592421|Placebo Comparator|Placebo|10 subjects will receive placebo
2995633|NCT02592408|Active Comparator|Pf: ASP|In falciparum patients (Pf): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP)
2995634|NCT02592408|Active Comparator|Pv: ASP + 14DPQ on day 2|In vivax patients (Pv): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and 14 days of primaquine (14DPQ) starting on day 2
2995635|NCT02592408|Active Comparator|Pf: ASP + SDPQ|In falciparum patients (Pf): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and a single dose of primaquine (SDPQ) on day 2
2995636|NCT02592408|Active Comparator|Pv: ASP + 14DPQ on day 42|In vivax patients (Pv): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and 14 days of primaquine (14DPQ) starting on day 42
2995637|NCT02592395|Experimental|Electrochemotherapy with FOLFIRINOX|During the first cycle of chemotherapy, patients will receive electroporation of the primary pancreatic tumor prior to administration of chemotherapy with FOLFIRINOX . The schedule of administration of FOLFIRINOX will be administered as per standard of care.
2995638|NCT02592382|Placebo Comparator|Isotonic saline spray|Isotonic saline (0.9% of NACL) given as nasal spray 3 times a day ( one puff for each nostril) for a two months period
2995639|NCT02592382|Experimental|Xylitol spray|Solid Xylitol diluted in normal saline(0.9% NACL) to a concentration of 5%. given as a nasal spray 3 times a day(one puff for each nostril) for two months period
2995640|NCT02592356|Experimental|Cabozantinib or Lenvatinib|"At baseline, and at months 3, 6, 12 basic tests of strength and balance performed. Full body dual-energy x-ray absorptimetry scan (DXA) performed at baseline, and at months 3, 6, and 12. Participant's weight, height, hip and waist circumference measurements done at baseline and repeated at every study visit. Questionnaires completed at baseline, and months 1,2, 3, twice during months 4 and 5, and at months 6 and 12.~After baseline visit, participants start receiving either cabozantinib or lenvatinib according to the treatment plan from their doctor."
2995641|NCT02592343|Experimental|Experimental: Lyophilized Fecal Microbiota Transplantation|All eligible patients with a history of recurrent or refractory CDI will receive 2 lyophilized FMTs
2995642|NCT02592330|Experimental|CALEC|The first three subjects enrolled into the study will automatically receive CALEC. Subjects 4-27 will be randomized to either the study treatment, CALEC, or to the standard treatment for LSCD, which is conjunctival limbal autograft (CLAU) in a 2:1 ratio. Participants receiving CALEC will have a corneal biopsy in their non-diseased eye, which will provide cells for the creation of the CALEC graft. The CALEC will be made at the Good Manufacturing Practice (GMP) Laboratory, Dana Farber Cancer Institute and transported to Mass. Eye and Ear Infirmary for application to the participant's diseased eye during their standard corneal reconstruction procedure.
2995643|NCT02592330|Active Comparator|CLAU|Subjects 4-27 will be randomized to either the study treatment, CALEC, or to the standard treatment for LSCD, which is conjunctival limbal autograft (CLAU) in a 2:1 ratio. Subjects randomized to the standard treatment arm will undergo CLAU surgery, with the biopsy performed at the time of surgery.
2995644|NCT02592317|Experimental|JNJ 56021927|Participants will receive drug cocktail (comprising of midazolam [2 milligram {mg}], warfarin [10 mg], vitamin K (10 mg), omeprazole (40 mg), and fexofenadine [30 mg]) orally on Study Day 1 and 43 (Cycle 2 Day 1). On Study Day 8 and 50, pioglitazone 15 mg will be administered orally and on Study Day 9 and 51, rosuvastatin 10 mg will be administered orally. JNJ 56021927, 240 mg once daily will be administered on Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
2995645|NCT02592304|Other|dual energy ct|
2995646|NCT02592291|Experimental|MHealth Group|Participants randomized into this group will use the mHealth system throughout the study in conjunction with their standard of care
2995647|NCT02592291|No Intervention|Control|Participants randomized into this group will not use the mHealth system throughout the study, but will continue with their standard of care.
2995648|NCT02592278|Experimental|Fluoride Varnish each 6 months|Fluoride Varnish application every 6 months.
2995649|NCT02592278|Experimental|Fluoride Varnish each 3 months|Fluoride Varnish application every 3 months.
2995650|NCT02592278|Active Comparator|Fluoride tooth paste|Control group. Twice a day brush with fluoride toothpaste.
2995651|NCT02592252|Experimental|Microfinance + gender training|Microfinance + 10 sessions of participatory gender training
2995652|NCT02592252|Experimental|Microfinance only|Receive microfinance only
2995653|NCT02592252|Experimental|Gender training only|10 sessions of participatory gender training for women and their male partners
2995654|NCT02592252|No Intervention|No intervention|No microfinance or participatory gender training
2995655|NCT02592239|Experimental|Patients|Functional dyspepsia patients will be studied using functional brain MRI before and after receiving a test meal. Cognitive and hedonic response will be evaluated using 10 score scales.
2995656|NCT02592239|Experimental|Controls|Healthy subjects recruited by public advertisement will be studied using functional brain MRI before and after receiving a test meal. Cognitive and hedonic response will be evaluated using 10 score scales.
2995657|NCT02592226|Active Comparator|Control group|
2995658|NCT02592226|Experimental|Protocol Group|
2995659|NCT02592213|Experimental|Treatment|Treatment of lymphedema with cell-assisted lipotransfer using autologous stromal vascular fraction
2995660|NCT02592200|Experimental|Lactobacillus gasseri|Lactobacillus gasseri DSM 27123 capsules, 1×109 CFU (divided in two doses)
2995661|NCT02592200|Placebo Comparator|Placebo|Placebo capsules (two doses)
2995662|NCT02592187|Experimental|Experimental intervention|ReMemory-MCI training
2995663|NCT02592187|Active Comparator|Control intervention|Active control training
2995664|NCT02592174|Other|HIV subjects|"Evaluation of health-related quality of life and collection of social and demographic informations at the inclusion visit.~Neurocognitive assessment with neuropsychologist and walking speed, grasp force and one leg stand assessments at the neurocognitive visit.~Two substudies will be proposed:~cerebral images sub-study (80 patients in the centers of Montpellier and the centers of Nîmes)~sub-study on immune activating markers with sample's collection (plasma), 85 patients in the centers of Montpellier and the centers of Nîmes."
2995665|NCT02592161|Experimental|Experimental|Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks
2995666|NCT02592161|Placebo Comparator|Placebo comparator|Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment) Three times a day, oral administration for 24weeks
2995667|NCT02592148||Health subjects|Male and female
2995668|NCT02592122|Active Comparator|Atomization inhalation|First of all, investigators need to give patients to do the test, the result is more than 12% is positive group, less than 12% is negative group.Second, randomly selected into the atomization group
2995669|NCT02592122|Active Comparator|Without atomization inhalation|First of all, investigators need to give patients to do the test, the result is more than 12% is positive group, less than 12% is negative group.Secondly, the random selection is not the atomization group
2995670|NCT02592109|Experimental|Enhanced Counseling using CFR based on LP|"The counseling will be done by individual face-to-face communications. The intervention's arm will get a counseling with an additional of 7-day cycle with adequate n-3 and optimal n-3/6 ratio for complementary feeding menu obtained from linear programming formulation.~The counseling consisted of nutritional status in children aged 12-23 months and how to determine the nutritional status; the principle of balanced diet; definition, function, and source of omega-3; example of menu that contains adequate omega-3. The duration of counseling is approximately 30 minutes, once a week for ten weeks. The mother or caregiver will also receive daily menu for seven days that should be followed during the intervention. The daily menu comprised of 3 main meals and 2 snacks."
2995671|NCT02592109|Active Comparator|General CFR Counseling|"The control's arm will get general counseling combining balance diet and IYCF principal, which already been used by Ministry of Health, with additional of 7-day cycle menu guidance modified from existing or available menu which can be downloaded for public on Ministry of Health official website.~The counseling consisted of nutritional status in children aged 12-23 months and how to determine the nutritional status; the principle of balanced diet based on Ministry of Health's Recommendation, and example of balanced diet menu. The duration of counseling is approximately 30 minutes, once a week for ten weeks. The mother or caregiver will also receive daily menu for seven days that should be followed during the intervention. The daily menu comprised of 3 main meals and 2 snacks."
2995672|NCT02592096|Experimental|0.1% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
2995673|NCT02592096|Experimental|0.3% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
2995674|NCT02592096|Experimental|0.5% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
2995675|NCT02592096|Active Comparator|Pazufloxacin mesilate injection|0.3g, 30 minutes for ventricular injection
2995676|NCT02592083|Active Comparator|A: Endocrine treatment|Pre- or perimenopausal women are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women); postmenopausal women receive an aromatase inhibitor. The preoperative treatment is continued for further 12 weeks, provided that re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
2995677|NCT02592083|Experimental|B: Endocrine treatment + palbociclib|Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period. The combined treatment is continued for further 12 weeks, provided that re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
2995678|NCT02592083|Experimental|C: Endocrine treatment + palbociclib|Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period. The combined treatment is continued for further 12 weeks, if re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
2995679|NCT02592070|Experimental|30 minute treadmill walking|All participants will walk on the treadmill for 30 minutes and perform a battery of cognitive tasks immediately prior, immediately after, and one hour after completion of the 30 minute walking period.
2995680|NCT02592057||SOF-based regimens|Adults with chronic HCV infection in India who are being treated with a SOF-based treatment regimen as per the approved prescribing information.
2995681|NCT02592044|Experimental|Aromatherapy with lavender essential oil|The 2 drops of lavender essential oil will put on 5x5 cm gauze and the patient will inhale it for 5 minutes and during peripheral venous cannulation.
2995682|NCT02592044|Placebo Comparator|Placebo|The 2 drops water will put on 5x5 cm gauze ant the patient will inhale it for 5 minutes and during peripheral venous cannulation.
2995683|NCT02592031|Experimental|XM17|XM17 will be administered by 1 mL syringes in graduated steps of 0.01 mL.
2995684|NCT02592031|Experimental|Gonal-f®|Gonal-f® will be provided in pens with integrated vials of 0.5 mL
2995685|NCT02592031|Active Comparator|Zoladex®|Zoladex® 3.6 mg will be administered by subcutaneous injection
2995686|NCT02592018|Experimental|Secukinumab|All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.
2995687|NCT02591992|Active Comparator|Cardiac CT|60 patients with high pre-test probability o coronary artery disease will be randomly chosen and undergo computed tomography angiography (cardiac CT) as the first-choice imaging diagnostics
2995688|NCT02591992|Active Comparator|Invasive coronary angiography|60 patients with high pre-test probability o coronary artery disease will be randomly chosen and undergo invasive coronary angiography
2995689|NCT02591966||Biomarker group|"The patients who receive neoadjuvant systemic treatments:~The patients who have distant metastatic sites at first and recur from surgery:~The patients who are going to receive first-line chemotherapy:"
2995690|NCT02591953|Experimental|Ultrasound-guided Injection|Injection performed with ultrasound-guidance
2995691|NCT02591953|Active Comparator|Landmark-guided Injection|Injection performed at point of maximal tenderness along biceps tendon
2995692|NCT02591940||Aortic Coarctation|interventional treatment in heart catheter (stenting/angioplasty) surgical repair of coarctation
2995693|NCT02591940||Aortic Valve Disease|surgical repair in aortic valve disease (reconstruction/valve replacement)
2995786|NCT02591368|Active Comparator|Mini Tight rope with two-suture|
2995694|NCT02591927|Active Comparator|Glucose-Insulin-Potassium|Rackley's Glucose-Insulin-Potassium formula consisting of 30% glucose (300 mg/L), 50 units of regular insulin per liter and 80 mEqu of KCL per liter.
2995695|NCT02591927|Placebo Comparator|Glucose 5%|Glucose 5%
2995696|NCT02591914|Experimental|Altering regimens of Fovista™and Anti-VEGF Therapy|"All subjects will be treated with Fovista™ 1.5 mg/eye in combination with anti-VEGF therapy.~The following doses of Anti-VEGF therapy will be delivered based on the Investigator's discretion:~Lucentis® 0.5 mg/eye~Avastin® 1.25 mg/eye~Eylea® 2 mg/eye~Subjects will be treated with Fovista™ and Anti-VEGF therapy every month for the first three months.~The regimen for administration of each intravitreal agent will be as follows:~Injection Day #1-Administration of Fovista™ 1.5mg/eye~Injection Day #2-Administration of Fovista™ 1.5mg/eye followed by anti-VEGF therapy after Fovista™ injection~The same regimen will be delivered monthly until the subject reaches maximum visual acuity benefit. Maximum visual acuity is defined as no increase in ETDRS visual acuity at two consecutive visits.~Subsequent re-treatment with the Anti-VEGF therapy will use a PRN (as-needed) regimen based on protocol specified retreatment criteria."
2995697|NCT02591901|Experimental|Uro Vaxom|Uro Vaxom, Once daily for 3 months
2995698|NCT02591901|Placebo Comparator|Placebo|Placebo identical to main drug in shape and form
2995699|NCT02591888|Active Comparator|Liposomal bupivacaine|Subjects in this arm will received the drug - liposomal bupivacaine 30 ml.
2995700|NCT02591888|Placebo Comparator|Placebo|Subjects in this arm will received the placebo - normal saline 30 mL.
2995701|NCT02591862|Other|Coversin|"This is an open label, non-comparator study.~Patient will be given a single ablating dose of 0.57mg/kg per subject followed by daily repeat maintenance doses. The initial repeat dose will be 25% of the ablating dose. If this is insufficient to maintain complement inhibition at ≤10% of baseline (pre-treatment) level after 5 days of treatment the daily dose will be increased by doubling until that level of inhibition is achieved. In the event of 100% inhibition being achieved the dose may be titrated downwards at the PI's discretion until a satisfactory clinical result is obtained. If at any point in treatment complement inhibition falls to less than 50% of baseline a further ablating dose of 0.57mg/kg should be given."
2995702|NCT02591849|Active Comparator|Glucagon-like peptide-1 (GLP-1)|Twelve eligible renal transplant recipients with PTDM and twelve age, gender, BMI and renal function-matched non-diabetic renal transplant recipients will be randomized to continuous unblinded intravenous infusion of GLP-1 with an infusion rate of 0.8 pmol/kg/min or isotonic saline (placebo) on two experimental days performed 2-4 weeks apart. The GLP-1 infusion will consist of 42.5 nmol/mL GLP-1 (7-36) amide, 12.5 mL 5% human albumin and isotonic saline added to a total volume of 50 mL. After 60 min, a 2 hour hyperglycemic clamp will be initiated, where plasma glucose will be elevated by 5 mmol/L from each individual fasting plasma glucose in both groups. This will be done to measure concentrations of glucagon and insulin in hyperglycemic conditions.
2995703|NCT02591849|Placebo Comparator|Isotonic saline|The included patients will receive concomitant intravenous infusion of isotonic saline on one of the two experimental days
2995704|NCT02591836|Experimental|Gemcabene 300 mg|Gemcabene 300 mg QD
2995705|NCT02591836|Experimental|Gemcabene 600 mg|Gemcabene 600 mg QD
2995706|NCT02591836|Experimental|Gemcabene 900 mg|Gemcabene 900 mg QD
2995707|NCT02591836|Placebo Comparator|Placebo|
2995708|NCT02591836|Active Comparator|Atorvastatin 10 mg|
2995709|NCT02591836|Active Comparator|Atorvastatin 40 mg|
2995710|NCT02591836|Active Comparator|Atorvastatin 80 mg|
2995711|NCT02591836|Experimental|Gemcabene 300 mg & Atorvastatin 10 mg|
2995712|NCT02591836|Experimental|Gemcabene 300 mg & Atorvastatin 40 mg|
2995713|NCT02591836|Experimental|Gemcabene 300 mg & Atorvastatin 80 mg|
2995714|NCT02591836|Experimental|Gemcabene 600 mg & Atorvastatin 10 mg|
2995715|NCT02591836|Experimental|Gemcabene 600 mg & Atorvastatin 40 mg|
2995716|NCT02591836|Experimental|Gemcabene 600 mg & Atorvastatin 80 mg|
2995717|NCT02591836|Experimental|Gemcabene 900 mg & Atorvastatin 10 mg|
2995718|NCT02591836|Experimental|Gemcabene 900 mg & Atorvastatin 40 mg|
2995719|NCT02591836|Experimental|Gemcabene 900 mg & Atorvastatin 80 mg|
2995720|NCT02591823||Healthy Controls|Healthy subject who accompanying patients to rheumatology OPD or healthy subjects who are staff at Columbia Asia Hospital,Bangalore.
2995721|NCT02591823||Cases (patients on methotrexate)|Subjects attending the rheumatology OPD of Columbia Asia hospitals bengaluru, who are diagnosed as having Rheumatoid arthritis and fulfill the ACR/ EULAR 2010 classification criteria for rheumatoid arthritis and are started on low dose methotrexate will included as cases
2995722|NCT02591810|Active Comparator|Serial Casting|Participants will receive the intervention of the placement of serial casting/splinting for the injured wrist. This is not a surgical intervention.
2995723|NCT02591810|Active Comparator|Kirschner wires|Participants will receive the intervention of percutaneous fixation with Kirschner wires for the injured wrist. This will be performed surgically.
2995724|NCT02591810|Active Comparator|Foveal repair|Participants will receive the intervention of open anatomic foveal repair of the ligaments of the injured wrist. This is a surgical intervention.
2995725|NCT02591797|Experimental|"hand-eye-mouth technique"|"hand-eye-mouth (MOB) seeks to focus the patient in performing a sequence of movements in a fun way so that your attention is diverted from the puncture dental needle, also it seeks to the patient does not see the needle. The operator prior to infiltrate local anesthetic teaches the child a game to put the sleepy little water.After explain a first time, the sequence once or twice is repeated until the patient has mastered. We call this test. When we apply the anesthetic, the entire sequence must be repeated as in trials with the same tranquility and in the same tone of the game. The operator will use this technique during the inferior alveolar and lingual nerve block procedure"
2995726|NCT02591797|Active Comparator|Conventional technique|the operator will explain how he/she will do the inferior alveolar and lingual nerve block procedure in phrases appropriates to the child. Then quietly cover the child´s field of view by hand during the inferior alveolar and lingual nerve block
2995727|NCT02591784|Experimental|Nimotuzumab group|Nimotuzumab+radiotherapy
2995728|NCT02591771|Experimental|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
2995729|NCT02591758||Stable Angina with coronary angiogram|This study aims to correlate the biometric data collected and derived from the Hexoskin with the standard physiological assessment, in patients referred for coronary angiography for limiting angina. Afterwards, the clinician will decide of the best treatment strategy for the patient: coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) or no revascularization.
2995730|NCT02591732||Patient treated with Apixaban|
2995731|NCT02591732||Patient treated with Rivaroxaban|
2995732|NCT02591732||Patient treated with Dabigatran|
2995733|NCT02591732||Patient treated with vitamin K antagonists|
2995734|NCT02591719|Experimental|MagPro magnetic stimulator (HF rTMS)|Most activated area from fNIRS with language task: Perilesional Broca's area
2995735|NCT02591719|Sham Comparator|MagPro magnetic stimulator (sham)|Most activated area from fNIRS with language task: Perilesional Broca's area
2995736|NCT02591719|Active Comparator|MagPro magnetic stimulator (LF rTMS)|Most activated area from fNIRS with language task: Contralesional homologs of Broca's area
2995737|NCT02591706|Active Comparator|Dental implant (C1)|"Internal Conical Connection: The C1 has a six-position cone index, except for the C1 narrow platform that has a four-position cone index. The conical connection is 2.00mm in depth, with a 12° cone. As a result of our meticulous manufacturing process a perfect fit between the implant and the abutment is achieved, eliminating micro-movements and minimizing bone resorption.~Patient will be randomly assigned to one of the two groups after flap opening."
2995738|NCT02591706|Experimental|Dental implant (V3)|"The unique triangular shape of the coronal portion of the V3 implant results in less titanium and more bone and soft tissue visible in the esthetic zone, for a restorative-driven approach and easier soft tissue management. The V3 provides doctors with a more advantageous starting point; where greater volume of bone and soft tissue is achieved at the onset of implant placement.~Patient will be randomly assigned to one of the two groups after flap opening."
2995739|NCT02591693|Experimental|Caregiver Training|"Three home visits by a specialist occupational therapist, each lasting 1-2 hours. Assessment and training to confidently achieve up to three goals relating to practical activities of daily living identified by patient and caregiver.~On-going usual care from multi-professional team at hospice."
2995740|NCT02591693|No Intervention|Usual Care|On-going usual care from multi-professional team at hospice.
2995741|NCT02591680|Experimental|Neuromuscular training|Neuromuscular, this arm will receive neuromuscular training and muscle strengthening.
2995742|NCT02591680|Active Comparator|Strength|Strength, this arm will receive only muscle strengthening.
2995743|NCT02591667|Experimental|Active treatment|"Patients will first undergo upfront staging laparoscopy with retrieval of tumor tissue for standard pathology.~Two to 4 weeks after initial surgical exploration, patients will receive 4 cycles of FOLFOXIRI + bevacizumab, q2w. The last chemotherapy cycle will be given without bevacizumab.~Five to 7 weeks after the last administration of bevacizumab (i.e., 3 to 5 weeks after completion of chemotherapy), patients will undergo surgery with the intent to perform complete surgical cytoreduction of all peritoneal tumor deposits. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, will be given at the discretion of the investigator."
2995744|NCT02591654|Experimental|Pembrolizumab and FLT|Subjects will receive WB-DW MRI and FLT PET to assess disease burden after receiving pembrolizumab.
2995745|NCT02591641|Experimental|Standard of Care First, then Liquicell|Subjects were secured on a standard ambulance stretcher, with a shear and pressure sensors attached to the body. Starting at 0 degrees head-of-bed (HOB) elevation, the ambulance traveled on a closed driver training course accelerating up to 30 mph and decelerating to a stop 5 times. Shear and pressure measurements were taken during the runs. The HOB was then elevated to 15 and 30 degrees respectively, and the procedure repeated. Subjects were asked to rate their comfort at each of the HOB elevations using a 0-10 scale. Following the first set of 15 runs, the course was repeated with the LiquiCell® ASMO.
2995746|NCT02591641|Experimental|Liquicell First, then Standard of Care|Subjects were secured on a standard ambulance stretcher with an anti-shear mattress overlay placed on top of the stretcher, with a shear and pressure sensor attached to the body. Starting at 0 degrees head-of-bed (HOB) elevation, the ambulance traveled on a closed driver training course accelerating up to 30 mph and decelerating to a stop 5 times. Shear and pressure measurements were taken throughout the runs. The HOB was then elevated to 15 and 30 degrees respectively, and the procedure repeated. Subjects were asked to rate their comfort at each of the HOB elevations using a 0-10 scale. Following the first set of 15 runs, the course was repeated without the LiquiCell ASMO.
2995747|NCT02591628|Active Comparator|Intervention|"Intervention is HCTZ prescription conversion to chlorthalidone. Intervention patients are defined as patients of physicians randomized to intervention. All these patients will have their current prescription of hydrochlorothiazide (HCTZ) switched to an equipotent dose of Chlorthalidone. These patients can choose to decline this intervention, and will be followed for 9 months with no other intervention to observe primary and secondary outcomes."
2995748|NCT02591628|No Intervention|Usual Care|"Usual care patients are defined as patients of physicians randomized to usual care. All these patients will keep their current prescription for HCTZ and work with their physician like normal. These patients will be followed for 9 months with no intervention to compare primary and secondary outcomes to the intervention group."
2995749|NCT02591615|Active Comparator|Arm A|"For Squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles~OR~For Non-squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles"
2995750|NCT02591615|Active Comparator|Arm B|"MK-3475 200 mg/m2 IV every 21-days for up to 4 cycles~Patients with CR, PR, or SD by irRC will then be treated with:~For Squamous Carcinoma:~Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles~OR~For Non-squamous Carcinoma~Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles"
2995751|NCT02591602|Experimental|CASI|Teleradiology service for patients residing at home or in nursing homes
2995752|NCT02591602|No Intervention|CONTROLLI|X-ray hospital department
2995787|NCT02591355|Experimental|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma injection
2995788|NCT02591355|Placebo Comparator|Saline|Saline solution injection
2995753|NCT02591589|Experimental|Normoxic group|To standardize key aspects of ventilator support, tidal volume will be set to 6-8ml/kg and PEEP levels will be set to 0-5cm H2O, allowing flexibility for provider preference. For normoxic oxygenation FiO2 will be set at 0.35 (35%) ideally to maintain PaO2 above 70mmHg (or saturations greater than or equal to 92%), and titrated up if need be to prevent potentially injurious hypoxemia (saturations below 92%). During cardiopulmonary bypass, blended air/ oxygen mixture will be titrated to arterial blood gas analysis with maintenance of PaO2 between 100mmHg and 150mmHg.
2995754|NCT02591589|Active Comparator|Hyperoxic group|To standardize key aspects of ventilator support, tidal volume will be set to 6-8ml/kg and PEEP levels will be set to 0-5cm H2O, allowing flexibility for provider preference. For hyperoxic oxygenation FiO2 will be set at 1.0 (100%) throughout the intraoperative period, including cardiopulmonary bypass.
2995755|NCT02591576||ST-elevation myocardial infarction (STEMI)|
2995756|NCT02591576||non-ST-elevation myocardial infarction (NSTEMI)|
2995757|NCT02591563||Healthy children|6-36 months of age who will have the following study procedures: Throat culture, Nasopharyngeal swab, tympanocentesis
2995758|NCT02591550||patients with normal cough sensitivity|
2995759|NCT02591550||patients with high cough sensitivity|
2995760|NCT02591550||healty controls|
2995761|NCT02591537|Experimental|OxyGenesys Dissolved Oxygen Dressing|OxyGenesys Dissolved Oxygen Dressing will be applied.
2995762|NCT02591537|No Intervention|Standard Tegaderm Dressing|Tegaderm will be applied.
2995763|NCT02591524|Experimental|Cystic fibrosis airway colonization|Flexible bronchoscopy via the nasal route on the date of baseline visit, nasal lavage at baseline and after 6 month
2995764|NCT02591511|Experimental|PAtient-Centered Computerized Educating System for Stroke|In this study, The PAtient-Centered Computerized Educating System for Stroke (PACCESS) System is base on mobile application(APP). Patient can install on mobile platform and reading the health education.
2995765|NCT02591511|Active Comparator|Traditional health education|In this study, the traditional health education mean stroke education handbook.
2995766|NCT02591498|Active Comparator|Auditory|Administration of 40 hours of auditory training exercises
2995767|NCT02591498|Active Comparator|Visual|Administration of 40 hours of visual training exercises
2995768|NCT02591498|Placebo Comparator|Video Games|Administration of 40 hours of commercial video games
2995769|NCT02591485|Experimental|Attention Control Training|Computerized attention modification training, comprised of six sessions that delivered by internet, in purpose of modulate biases in attention for threat stimuli.
2995770|NCT02591485|No Intervention|Follow-up only|In this condition, a follow up interviews will be conducted 3 and 6 months since the traumatic event had occurred.
2995771|NCT02591472|Active Comparator|Usual Care (UsCare)|This group will receive UsCare for orthopedic trauma involves surgical intervention, acute care therapies, post-acute rehabilitation and follow-up clinic visits after discharge. Additionally, the following test will be performed: Lower Extremity Gain Scale (LEGS), dynamometer isometric handgrip strength, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11), and Patient-Reported Outcomes Measurement Information System (PROMIS).
2995772|NCT02591472|Experimental|Integrated Care (ICare)|This group will receive ICare for orthopedic trauma involves surgical intervention, acute care therapies, post-acute rehabilitation and follow-up clinic visits after discharge, plus simultaneous psychosocial support via the Transform-10 Program.. Additionally, the following test will be performed: Lower Extremity Gain Scale (LEGS), dynamometer isometric handgrip strength, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11), and Patient-Reported Outcomes Measurement Information System (PROMIS).
2995773|NCT02591459|Other|Autism|Using the app to assist routine anticipation for autistic children in Android mobile devices
2995774|NCT02591433|Experimental|Supportive care (JeffQuit group therapy)|Patients undergo three, 1-hour group therapy sessions held by a JeffQuit practitioner over a 1-month period. Patients receive strategies for managing the psychological, habitual, and physiological components of smoking and help with developing a planned quit date. Patients are also provided with advice on how to switch to cigarette brands with less nicotine and then how to substitute the nicotine patch and gum for cigarettes. The JeffQuit counselor is available for additional individual support as needed.
2995775|NCT02591420|Experimental|Group 1: immediate ART and placebo infusion|Participants will start ART and will receive a single infusion of placebo at Day 0.
2995776|NCT02591420|Experimental|Group 2: immediate ART and VRC01 infusion|Participants will start ART and receive a single infusion of VRC01 at Day 0.
2995777|NCT02591420|Experimental|Group 3: immediate VRC01 infusion and subsequent ART|Participants will receive a single infusion of VRC01 on Day 0 followed by ART initiation on Day 7.
2995778|NCT02591407|Active Comparator|TAP Block- Exparel|Transversus abdominis plane block utilizing the medication Exparel®
2995779|NCT02591407|Active Comparator|Continuous Epidural Analgesia|Continuous Epidural Analgesia
2995780|NCT02591394|Experimental|STEP Clinic|
2995781|NCT02591394|Active Comparator|Usual Care|
2995782|NCT02591381|Experimental|STANDARD AUS Placement|Standard placement of an artificial urinary sphincter involves a small incision made in the patient's perineum or scrotum and a fluid-filled cuff is placed around the bulbar urethra (the portion of the urethra between the bladder neck and penis). Connected to the cuff with tubing, is a balloon filled with fluid that is placed behind the pubic bone or in the space between the peritoneum and abdominal muscles. A control pump is placed in the scrotum and allows the device to cycle, thus either exerting pressure to close off the urethra or releasing pressure to allow the urethra to open and the patient to void.
2995783|NCT02591381|Experimental|TRANSCORPORAL AUS Placement|Transcorporal placement has been introduced as a way to reduce risk of erosion and involves tunneling the cuff through the erectile bodies. The same incision is made as for the standard approach, and then an incision is made in each corpus cavernosum (cylinders of tissue that allow for erection). This allows the cuff to be placed around both the urethra and through the lining of the corporal bodies, increasing the bulk of tissue behind the urethra to protect it from erosion.
2995784|NCT02591368|Active Comparator|Ligament reconstr. tendon interposition|
2995785|NCT02591368|Active Comparator|Mini Tight rope with one-suture|
2995789|NCT02591342||CPT stem|Patients treated with a polished, tapered femoral stem as a hip arthroplasty for a displaced femoral neck fracture
2995790|NCT02591342||SP2 stem|Patients treated with a anatomic femoral stem as a hip arthroplasty for a displaced femoral neck fracture
2995791|NCT02591329|Experimental|Experimental|The experimental condition (EXP) will receive the targeted intervention material developed and designed by the researchers using focus group discussions with parents. This information will include salient benefits of the consumption of calcium-rich products. In addition, self-regulatory strategies will be provided to encourage purchasing and consumption of calcium-rich products and address any potential barriers to purchase and consumption. Material will sent on four different occasions via mail. At time one (week 0) participants will be sent a 13-month calendar, at time 2 (week 8) participants will be sent a grocery pad and a recipe book. At time 3 and 4 (week 16 and 22 respectively) participants will be sent a newsletter.
2995792|NCT02591329|Active Comparator|Standard Care|Individuals in the Control condition (CON) will receive general healthy eating materials including Canada's Food Guide, Healthier Grocery Shopping Guide and Cooking with Kids. Material will sent on four different occasions via mail. At time one (week 0) participants will be sent a 13-month calendar, at time 2 (week 8) participants will be sent a note pad and an activity book. At time 3 and 4 (week 16 and 22 respectively) participants will be sent a newsletter.
2995793|NCT02591316||Breast cancer survivor|Inclusion criteria: Female breast cancer survivors (30-70yrs of age) that have completed primary treatment (chemotherapy, radiation therapy or both) within past 60 months
2995794|NCT02591316||Control|Females (30-70yrs of age) with no previous cancer diagnosis.
2995795|NCT02591303|Experimental|Insomnia group|Patients with insomnia: sleep complaints, of more than 3 nights a week, more than 3 months, affected daytime functioning, objectified low sleep quality (Sleep Efficiency <85%) with 10 days actigraphy
2995796|NCT02591303|Experimental|Control group|No sleep problems either self reported or objectified through actigraphy (Sleep Efficiency >85%)
2995797|NCT02591290|Experimental|Menactra® Vaccine|Participants received 2-dose series of the study vaccine with 8-week interval.
2995798|NCT02591277||Harvoni|Adult patients with chronic genotype 1 HCV infection with or without compensated cirrhosis who take Harvoni as part of routine clinical care at a participating clinic/hospital.
2995799|NCT02591251|Active Comparator|The povidone-iodine group|The patients will be subjected to povidone-iodine (Betadine7.5%, Phama Care) for vaginal cleaning before the laparoscopic surgery
2995800|NCT02591251|Active Comparator|Normal saline group|The patients will be subjected to normal saline solution (Sod. Chloride 0.9%, Nile) for vaginal cleaning before the laparoscopic surgery.
2995801|NCT02591238|Placebo Comparator|non-smoker + placebo|non-smoker oral placebo
2995802|NCT02591238|Active Comparator|non-smoker + melatonin|non-smoker oral melatonin
2995803|NCT02591238|Placebo Comparator|smoker + placebo|smoker oral placebo
2995804|NCT02591238|Active Comparator|smoker + melatonin|smoker oral melatonin
2995805|NCT02591225|Experimental|Dabigatranetexilate|Dabigatran capsula 150 mg; oral; bid; treatment period 12 months
2995806|NCT02591225|Active Comparator|Phenprocoumon|Phenprocoumon INR adjusted; oral; once daily; treatment period 12 months
2995807|NCT02591212|Active Comparator|#ConnectDots|"Green Dot Intensive Bystander Training (INT Condition) (Randomized):~Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.~Administered by: UK VIP Delivery Mode: Class or large groups of 100-150 students; training lasts 3 hours Required: Elective. All students randomized to this condition will be scheduled for training."
2995808|NCT02591212|Placebo Comparator|#ConnectWell|"Wellness Initiatives for Student Empowerment delivered by UK's Student Wellness Office Programming: Addresses elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.~Administered by: UK VIP/Student Wellness Ambassadors Delivery Mode: Class or large groups of 100-150 students; training lasts 3 hours Required: Elective. All students randomized to this condition will be scheduled for training"
2995809|NCT02591199|Experimental|URG101|A single 15 mL dose of URG101,a mix of buffered Lidocaine (200 mg) and Heparin (50,000 IU), delivered to the bladder via catheter.
2995810|NCT02591199|Placebo Comparator|Placebo|A single 15 mL dose of placebo delivered to the bladder via catheter.
2995811|NCT02591199|Experimental|Lidocaine|A single 15 mL dose of buffered Lidocaine (200 mg) delivered to the bladder via catheter.
2995812|NCT02591199|Experimental|Heparin|A single 15 mL dose of buffered Heparin (50,000 IU) delivered to the bladder.
2995813|NCT02591186|Experimental|Acupuncture arm|Participants receiving acupuncture during IVF process
2995814|NCT02591186|No Intervention|Control|Control arm not receiving acupuncture during IVF process
2995815|NCT02591173|Experimental|Angiotensin-(1-7)|Patients will receive an intravenous infusion of five ascending doses of Angiotensin-(1-7). The doses are: 1, 2, 4, 8 and 16 ng/kg/min. Each dose will be maintained for 10 minutes, for a total of 50 minutes.
2995816|NCT02591173|Placebo Comparator|Saline|Patients will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will be maintained for 50 minutes.
2995817|NCT02591160|Other|HCTZ cessation|Patients will stop taking HCTZ for 3 months while submitting serial blood and 24 hour urine samples
2995818|NCT02591147|Active Comparator|Silver Diamine Fluoride 38%|Group 1 (SDF 38%) will receive the application of silver diammine fluoride (38% SDF solution) in addition to 5% sodium fluoride varnish to each approximal carious lesion (scores RA1,RA2,RA3) in a posterior tooth (premolar or molar) that is in contact with an adjacent tooth, using super floss, for a duration of 3 minutes under rubber dam isolation.
2995895|NCT02590614|Experimental|800 IU Vitamin D|Participants will be taking 800 IU/d of vitamin D3 for two months
2995896|NCT02590614|Placebo Comparator|Placebo|Placebo made by Vital Nutrients, Inc. to look exactly like the 800 IU/d caplets by the same company.
2995819|NCT02591147|Placebo Comparator|Placebo (Sterile water)|Group 2 Placebo (control) will receive the application of sterile water (placebo) in addition to 5% sodium fluoride varnish to each approximal carious lesion (scores RA1,RA2,RA3) in a posterior tooth (premolar or molar) that is in contact with an adjacent tooth, using super floss, for a duration of 3 minutes under rubber dam isolation.
2995820|NCT02591134|Experimental|Non Nutritive Sweetened Beverages|Non-nutritive sweeteners (NNS) beverages will be provided to participants using a home delivery system and they are expected to consume at least two portions (330ml) per day.
2995821|NCT02591134|Placebo Comparator|Control Water Beverages|Water beverages will be used as a comparator to NNS beverages during the trial. These beverages will encompass a range of water-based drinks that contain no NNS. Including water as a comparator is vital to understand whether NNS beverages are equally as effective as water during phases of weight loss and weight maintenance.
2995822|NCT02591108|Experimental|Safety and Efficacy|Parallel treatment; use of standard TOF peripheral Stimulator to Novel Train of Four Device
2995823|NCT02591108|Active Comparator|Microstim|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
2995824|NCT02591095|Experimental|ABT-263|oral Navitoclax (ABT-263) daily
2995825|NCT02591069|Experimental|All patients will undergo the same procedure|
2995826|NCT02591056|Experimental|Erchonia Verju Laser + Green PRESS 8|All subjects receive 12 combination treatments over 6 weeks (two per week) with the Erchonia® Verju™ Laser and the Green PRESS 8 devices simultaneously.
2995827|NCT02591043|Other|Follow-up|Patients have not received a structured follow up examination or evaluation of outcome after surgery. Therefore this study aims at conducting a follow up examination regarding functional outcome, pain and radiologic healing in these patients.
2995828|NCT02591030|Placebo Comparator|GEMCIS|
2995829|NCT02591030|Experimental|mFOLFIRINOX|
2995830|NCT02591017|Other|morphine drops solo and placebo spray|"morphine 2% drops~daily fixed dose of morphine equivalents < 100 mg, 0.2 mg/kg Body weight morphine drops every hour in reserve due to international Standards~daily fixed dose of morphine equivalents =/> 100 mg, 15% of the fixed daily dose in morphine drops every hour in reserve due to international standards"
2995831|NCT02591017|Other|ketamine/chitosan spray nasal and placebo drops|5 mg ketamine all 5 minutes, maximal 4 times an hour
2995832|NCT02591017|Other|morphine drops and ketamine/chitosan spray nasal|see above
2995833|NCT02591004|Experimental|Magesium sulphate|"Patients in group A will receive Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins & 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first).~Doppler on fetal middle cerebral artery"
2995834|NCT02591004|Active Comparator|Nifedipine|"Patients in group B will receive Nifedipine ( Epilat 10mg ® EIPICO Egypt ), as there is no recommended dose for the use of nifedipine as neuroprotectant, the dose given in this study will be same as that used for tocolysis. Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses.~Doppler on fetal middle cerebral artery"
2995835|NCT02590991||Prebiotics group|No intervention since is a follow-up study
2995836|NCT02590991||Prebiotics & Probiotics group|No intervention since is a follow-up study
2995837|NCT02590991||Control group|No intervention since is a follow-up study
2995838|NCT02590978|Experimental|Early cholecystectomy|Cholecystectomy within the first 72 hours of admission.
2995839|NCT02590978|Other|Control (Delayed cholecystectomy)|Standard care arm. Cholecystectomy is delayed until normalization of laboratory values, abdominal pain resolves and oral intake is restored.
2995840|NCT02590965|Placebo Comparator|Control Group|Placebo is a capsule in the form of 1mg and 5 mg, orally, once daily, 3 weeks on/1week off with best supportive care.
2995841|NCT02590965|Experimental|Treatment Group|The subjects will receive oral Fruquintinib at fasting state 5mg+best supportive care, once daily for the first 3 consecutive weeks and dose holiday for 1 week according to their dose regimens until the occurrence of disease progression, unacceptable toxicity, or withdrawal of consent
2995842|NCT02590952|Experimental|Epitinib|Epitinib is a capsule in the form of 5mg and 20mg Route: oral (daily)
2995843|NCT02590939|Experimental|Active device|60 minutes of active external trigeminal nerve stimulation with a CEFALY Active device
2995844|NCT02590939|Sham Comparator|Sham device|60 minutes of placebo external trigeminal nerve stimulation with a CEFALY Placebo device
2995845|NCT02590926||Patients|"patients with stable angina and/or documented ischemia presenting with:~An angiographic stenosis of more than 50% and less than 90% of the left main~Any proximal descending anterior with a stenosis of more than 50% and less than 90%~Two or three vessel disease with a stenosis of more than 50% and less than 90% and a left ventricle ejection fraction less than 40%~Single remaining patent coronary artery with stenosis >50% and less than 90%"
2995846|NCT02590913|Experimental|group fructose|Volunteer was randomized into either group fructose or glucose
2995847|NCT02590913|Experimental|group glucose|After one-week washout period, volunteer was crossed over for either group glucose or fructose.
2995848|NCT02590900||at delivery|women who underwent cesarean at delivery, and needed iv paracetamol as part of multimodal analgesia. In these cases, paracetamol was administered q6h (2g loading dose, 1g q6h for 24 h), and blood and urine samples were collected to describe paracetamol disposition at delivery.
2995849|NCT02590900||postpartum|a subgroup of 8 women initially included in at delivery, underwent a second PK study 2-3 months postpartum and another PK study about 1 year after delivery. This PK study was based on a single iv paracetamol administration (2 g), and blood and urine samples were collected to describe paracetamol disposition in postpartum
2995850|NCT02590900||healthy female volunteers|"a group of 8 young healthy women not on oral contraceptives underwent a single PK study (2 g intravenous paracetamol) and blood and urine samples were collected to described paracetamol disposition in healthy female volunteers, not on oral contraceptives.~Raw data as published by Gregoire et al (Clin Pharm Ther 2007) were available in 14 young women, all on contraceptives."
2995950|NCT02590211|Other|pathological poker players|(comparator)
2995851|NCT02590887|Experimental|drink manufactured from lupine peptides|"Beverage drink containing 0.5mg/ml of protein hydrolysate extracted from food grade lupine flour. The drink will be formulated as 200 mL tetra brik subjected to a test of microbiological safety according to the Spanish law (RD 135/2010 of 12 February 2010). The final beverage shall consist of:~Oily phase: refined sunflower oil 5% w/w of the emulsion~Aqueous phase (water) 95% w/w of the emulsion, containing:~Hydrolyzed Lupine 0.5% w/w of the aqueous phase~Xanthan Gum 0.125% w/w of the aqueous phase~Sugar 6% w/w of the aqueous phase~The samples will guard and kept by the investigator until the day of delivery to the volunteers.~The duration of treatment is 4 weeks, during which the volunteers consume the contents of a tetra brik daily."
2995852|NCT02590874|Experimental|Duloxetine group|Active drug group
2995853|NCT02590874|Placebo Comparator|Placebo group|Inactive drug group
2995854|NCT02590861|Experimental|Dental implant|All participants will receive the same intervention, this is a single group study.
2995855|NCT02590848|No Intervention|Group with no intervention|This group will receive healthy recommendations of eating fresh fruits
2995856|NCT02590848|Experimental|Group with walnut intake|This group will receive healthy recommendation of eating fresh fruits + 30 g of walnut kernels per day during 6 months.
2995857|NCT02590835|Active Comparator|Control group|Treated with conventional orthodontics
2995858|NCT02590835|Experimental|Test group|subjected to piezo-assisted orthodontics
2995859|NCT02590822|No Intervention|Standard Care|The Standard Care group will be contacted weekly (where possible) to reinforce cognitive behavioural adaptations and encourage compliance to diet and exercise. They will be provided with standard lifestyle advice according to NICE guidance.
2995860|NCT02590822|Experimental|Total Dietary Replacement|"Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.~The TDR will be undertaken alongside health behaviour coaching and relapse prevention contact & current medications will need to be adjusted initially and throughout the study."
2995861|NCT02590822|Experimental|Supervised Exercise|"The exercise group will attend thrice weekly 60minute supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. An initial assessment of cardiorespiratory fitness will be performed (VO2 max) to allow design of a tailored exercise programme.~Current medication will need to be adjusted initially and throughout the study."
2995862|NCT02590809|Experimental|Treatment group|20 patients
2995863|NCT02590809|Placebo Comparator|Placebo group|20 patients
2995864|NCT02590796||Hospitalised patients with delirium|hospitalised patients with delirium in general wards.
2995865|NCT02590796||Hospitalised patients with dementia/ no delirium|Hospitalised patients with a diagnosis of dementia who do not have delirium in general wards.
2995866|NCT02590796||Hospitalised patients with no delirium or dementia|Hospitalised patients with no delirium or dementia in general wards.
2995867|NCT02590796||Outpatients with dementia|People with a diagnosis of dementia who are living in the community.
2995868|NCT02590796||Healthy volunteers|Healthy volunteers who are living in the community who do not have a cognitive impairment.
2995869|NCT02590796||ICU delirium|Patients with delirium who are hospitalised in the intensive care units.
2995870|NCT02590796||ICU no delirium|Patients who do not have delirium who are hospitalised in intensive care units.
2995871|NCT02590783|Experimental|experimental intervention surgery|screw osteosynthesis of the sacrum and in certain cases additional plate osteosynthesis of dislocated pubic rami fractures, postoperative analgesia, physiotherapy, work-up for osteoporosis, geriatric rehabilitation if necessary
2995872|NCT02590783|Active Comparator|control intervention conservative|analgesia, physiotherapy, work-up for osteoporosis, geriatric rehabilitation if necessary
2995873|NCT02590770|Active Comparator|gaze-contingent|attention modification: participants will receive gaze-contingent feedback according to their viewing patterns
2995874|NCT02590770|Placebo Comparator|non-gaze contingent|Placebo: participants will receive non-gaze-contingent feedback according to their viewing patterns
2995875|NCT02590757|Active Comparator|NIV-NAVA|Noninvasive ventilation in this group is practiced with NIV-NAVA
2995876|NCT02590757|Active Comparator|N-CPAP|Patients in this group will receive nasal continuous positive airway pressure as routinely in neonatal intensive care unit.
2995877|NCT02590744|Experimental|eye patch|cover the sick eye with eye patch for 3 hours preoperatively.
2995878|NCT02590744|Placebo Comparator|non-eye patch|do not cover the sick eye before surgery.
2995879|NCT02590731||Control group|Pfeiffer test 6 or above. No or mild cognitive impairment
2995880|NCT02590731||Cognitivt impaired|Pfeiffer test less than 6. Moderate to severe cognitive impairment.
2995881|NCT02590718|Experimental|Group 1|optimized postoperative management(lying without the pillow for half an hour after lumbar puncture)
2995882|NCT02590718|No Intervention|Group 2|traditional postoperative management(lying without the pillow and fasting water and food for four hours after lumbar puncture)
2995883|NCT02590705|Experimental|Group 1|surface anesthesia with lidocaine
2995884|NCT02590705|No Intervention|Group 2|no anesthesia
2995885|NCT02590692|Experimental|CPCB-RPE1 treatment|Subretinal implantation of CPCB-RPE1 in dry AMD patients
2995886|NCT02590679|Experimental|PRAS|pulmonary regurgitation after surgical repair of congenital right ventricular outflow tract
2995887|NCT02590666|Experimental|Bipolar electrode|Polyps resection with bipolar electrode
2995888|NCT02590666|Active Comparator|Microscissors or graspers|Polyps resection with microscissors or graspers
2995889|NCT02590653|Experimental|Group A|Group A patients will start atorvastatin at a dose of 80 mg/day between 24 and 96 hours after the onset of STEMI
2995890|NCT02590653|Active Comparator|Group K|Group K patients will start atorvastatin at a dose of 20 mg/day between 24 and 96 hours after the onset of STEMI
2995891|NCT02590640|Active Comparator|Inhibitory insular rTMS|Inhibitory (1 Hz) repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
2995892|NCT02590640|Sham Comparator|Sham insular rTMS|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
2995893|NCT02590627|Active Comparator|A|Artemether-lumefantrine
2995894|NCT02590627|Experimental|B|Dihydroartemisinin-piperaquine
2995897|NCT02590601|Active Comparator|Bromocriptine + Guideline-driven medical therapy|"In addition to heart failure treatment described above, patients will be administered bromocriptine 2.5 mg orally twice daily for 14 days, followed by 2.5 mg orally daily for 42 days.~Although not a study procedure, we recommend anticoagulation with prophylactic doses of subcutaneous low-molecular weight heparin during the whole duration of bromocriptine therapy."
2995898|NCT02590601|Other|Guideline-driven medical therapy|New onset PPCM will be managed according to the principles of guideline-driven medical therapy for new-onset heart failure as per the position statement for treatment of PPCM published by the European Society of Cardiology (ESC) and the Canadian Cardiovascular Society (CCS) update on heart failure and pregnancy . The choices and administration of GDMT will be left at the discretion of the treating physician
2995899|NCT02590588|Experimental|Idelalisib|Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.
2995900|NCT02590575|Other|CO2 removal|
2995901|NCT02590562||RA patients treated with routine clinical practice|Describe in routine clinical practice the treatment patterns of usage of biological DMARDs in patients suffering from RA including frequency of monotherapy, biological DMARDs usage status (types, dosage), concomitant DMARDs usage information (type and dosage)
2995902|NCT02590549|Experimental|MyoRing Implantation combined with corneal cross linking|Surgical technique: Implantation of a MyoRing in a corneal pocket was performed by using a PocketMaker microkeratome a guided, vibrating diamond blade to create a stromal pocket 9 mm in diameter at a 300-μm depth via a 4- to 5-mm-wide corneal tunnel followed by Corneal Collagen Crosslinking (standard surface UVA irradiation (370 nm, 3 mW/cm2) using Ufalink device)
2995903|NCT02590536|Experimental|sildenafil citrate|Group A (45 patients): pregnancies affected by Fetal Growth Restriction (FGR) being treated with sildenafil citrate 25 mg of sildenafil citrate every 8 hours starting at diagnosis of FGR until delivery
2995904|NCT02590536|Placebo Comparator|placebo|Group B (45 patients): pregnancies affected by Fetal Growth Restriction (FGR) being treated with placebo every 8 hours starting at diagnosis of FGR until delivery.
2995905|NCT02590523|Experimental|A: Vancomycin|Intracameral vancomycin injection given at conclusion of cataract case
2995906|NCT02590523|Experimental|B: Moxifloxacin|Intracameral moxifloxacin injection given at conclusion of cataract case
2995907|NCT02590523|Placebo Comparator|C: Placebo|Intracameral placebo injection with BSS given at conclusion of cataract case
2995908|NCT02590510|Experimental|The small dose of group|The dose of methotrexate is 10 mg
2995909|NCT02590510|Active Comparator|The high dose of group|The dose of methotrexate is 15 mg
2995910|NCT02590497|Experimental|Diagnostic (MRI, tumor tissue analysis)|Patients undergo MRI before and after gadolinium contrast administration, including 3D volumetric T1-weighted sequence, FLAIR sequence, diffusion weighted imaging, and perfusion MRI. Tissue samples are also analyzed for the tumor genetic profile.
2995911|NCT02590471|Active Comparator|Stenting of the femoral artery.|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent of all the extension is mounted.
2995912|NCT02590471|Experimental|Stenting of the femoral artery and fasciotomy.|Under local anesthesia standard endovascular exposure is made and lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent of all the extension is mounted. The exposure is carried out to the distal part of superficial femoral artery when it lives Hunter's canal and the first portion of popliteal artery. Intermuscular vastoadductoria sept is dissected and the following arteries are ligated and dissected: а. superior medialis genus, а. superior lateralis genus.
2995913|NCT02590458|Experimental|Short Breast MRI (SBMRI)|Routine scheduled MRI with contrast performed on women at high risk of developing breast cancer. One day after routine MRI, short breast MRI (SBMRI) with contrast performed. After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan.
2995914|NCT02590445|Active Comparator|Active stimulation|Stimulator on followed by off
2995915|NCT02590445|Sham Comparator|Sham stimulation|Stimulator off followed by on
2995916|NCT02590432|Experimental|Linaclotide 145 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
2995917|NCT02590432|Experimental|Linaclotide 290 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
2995918|NCT02590419|No Intervention|Control Group|Control Group (involvement of BrightMatter™ Plan (BMP)): Patients with temporal lobe epilepsy, who have been identified as candidates for anterior temporal lobe resection (ATLR) will be recruited. All epilepsy patients will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol. Surgery will be carried out according to usual standard of care, without the use of processing for DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative (6-month) visual field assessments (Estermann Perimetry and Humphrey Perimetry) will also be carried out . Primary outcomes will be assessed to identify the baseline incidence of visual of postoperative visual field deficits.
2995951|NCT02590198||ANAES algorithm|Each center will start the study by applying the usual ANAES algorithm. The date of implementation of the new algorithm based on PCT will be determined randomly. Therefore, within each center, there will be an initial period in which the standard algorithm is applied and a second one during which the PCT-based algorithm is applied
2995952|NCT02590198||PCT algorithm|Each center will start the study by applying the usual ANAES algorithm. The date of implementation of the new algorithm based on PCT will be determined randomly. Therefore, within each center, there will be an initial period in which the standard algorithm is applied and a second one during which the PCT-based algorithm is applied
2996020|NCT02589743|Experimental|Excite and H (Adhesive and Sealant)|Pit and fissure sealing using adhesive and sealant
2995919|NCT02590419|Experimental|Treatment Arm|Treatment group (involvement of all three products BrightMatter™ Plan (BMP), BrightMatter™ Bridge (BMB), and BrightMatter™ Guide(BMG): A treatment group (prospective enrollment) that uses the interventional technology will be recruited based on the same eligibility criteria as control cohort. All epilepsy patients will have clinical MRI scans that include a DTI protocol. For this treatment group of patients, the BrightMatter system (BMB,BMP, and BMG) will be employed pre-operatively and intra-operatively for planning before and guidance during anterior temporal lobe resection (ATLR). Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative (6-month) visual field assessments (Estermann Perimetry and Humphrey Perimetry) will also be carried out. Primary outcomes will be assessed to evaluate the effect of surgical planning and guidance with DTI tractography on outcomes, by comparison against the control cohort.
2995920|NCT02590406|Active Comparator|Beach chair (BC) and ZEEP|Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
2995921|NCT02590406|Experimental|Reverse Trendelenburg and NIPPV|"Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface"
2995922|NCT02590393|Active Comparator|Nicotine + NNTAs|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks. E-cigarette cartridges will contain tobacco extract with nicotine + NNTAs in a vehicle of propylene glycol. The yields of nicotine and NNTAs will be in the range of typical commercial cigarettes (e.g., 0.6 mg nicotine delivered in 10 puffs of 35 mL), with a ratio of NNTA:nicotine yield that is also typical of commercial cigarettes.
2995923|NCT02590393|Active Comparator|Nicotine control|"Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks. E-cigarette cartridges will contain the same concentration of nicotine, but very low amounts (1/10th) of NNTAs as in Group 1. This specialized product will be developed from low nicotine, low NNTA content tobacco extract currently used in the Spectrum cigarettes offered as part of the National Institute on Drug Abuse (NIDA) drug supply program. This extract will then be fortified with additional nicotine to match nicotine levels in Group 1. A propylene glycol vehicle will remain the same as in Group 1."
2995924|NCT02590393|Active Comparator|Vehicle control|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks. E-cigarette cartridges will contain only propylene glycol vehicle and extract from low nicotine/NNTA content tobacco. The nicotine yield will be less than 0.05 mg per 10 puffs of 35 mL, i.e., less than 1/10 of the yield in the other two groups, and NNTA yield will be correspondingly low.
2995925|NCT02590380|Active Comparator|treatment group (MESA)|Patients randomized to the treatment group will receive surgery with the MESA Rail Deformity System.
2995926|NCT02590380|Active Comparator|control group (USS II)|Patients randomized to the control group will receive surgery with the DePuy Synthes USS II System.
2995927|NCT02590367|Experimental|FOLFOX regimen&HD6610 Granule|Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the HD6610 Granule will be given 2 times a day.
2995928|NCT02590367|Placebo Comparator|FOLFOX regimen&HD6610 Granule placebo|Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the placebo HD6610 Granule
2995929|NCT02590354|Experimental|Treatment interruption|The ART treatment in patients with a very low viral reservoir will be interrupted.
2995930|NCT02590328||Screened patients|SCID screening: some drops of blood are placed on a second Guthrie card when current screening is performed after parents' information and consent. The card drawn for the protocol will follow the usual network except that the test for quantifying TRECs will be realized to determine the presence of SCID.
2995931|NCT02590315|Experimental|Digital Breast Tomosynthesis - DBT|Invitation for breast screening and random allocation. Participants randomised to DBT will be screened with bilateral, two-view combo mode (DBT images are obtained with DM images). DBT participants will have an additional radiation exposure for the combined DM and DBT examinations.
2995932|NCT02590315|Active Comparator|Conventional digital mammography - DM|Invitation for breast screening and random allocation. Participants randomised to DM will be screened with bilateral, two-view DM.
2995933|NCT02590302|Other|Dyads receiving the Implementation Phase|Dyad 1 (CHEO-YSB) Dyad 2 (CGH-CCH) Dyad 3 (WDMH-CCH) Dyad 4 (QCH-YSB)
2995934|NCT02590289|Experimental|BBI-5000 Dose 1|Low dose of BBI-5000
2995935|NCT02590289|Experimental|BBI-5000 Dose 2|Middle dose of BBI-5000
2995936|NCT02590289|Experimental|BBI-5000 Dose 3|High dose of BBI-5000
2995937|NCT02590289|Experimental|BBI-5000 Dose 4|High dose of BBI-5000
2995938|NCT02590276|Experimental|Evaluation|Characterization
2995939|NCT02590263|Experimental|Arm A of Phase 1 portion|ABT-414 administered every other weeks monotherapy
2995940|NCT02590263|Experimental|Phase 2 portion|ABT-414 administered every other weeks in combination with temozolomide
2995941|NCT02590263|Experimental|Arm C of Phase 1 portion|ABT-414 administered every other weeks in combination with radiation and temozolomide
2995942|NCT02590263|Experimental|Arm B of Phase 1 portion|ABT-414 administered every other weeks in combination with radiation and temozolomide
2995943|NCT02590250||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
2995944|NCT02590237|Active Comparator|Direct Laryngoscopy|The trachea will be intubated via direct laryngoscopy using a traditional straight blade (Miller) laryngoscope.
2995945|NCT02590237|Experimental|KingVision Video Laryngoscope|The trachea will be intubated using the Ambu KingVision Video Laryngoscope size 1 pediatric blade.
2995946|NCT02590224|Active Comparator|Ferrous bis-glycinate group|The patients will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets (Pharaferro 27 tablets) once daily for eight consecutive weeks.
2995947|NCT02590224|Active Comparator|Ferrous glycine sulphate group|The patients will receive 567.6 mg of ferrous glycine sulphate capsules (Ferrosanol duodenale capsules, Schwarz) once daily for eight consecutive weeks.
2995948|NCT02590211|Other|non-poker players|(control group)
2995949|NCT02590211|Other|expert unproblematic poker players|(comparator)
2995953|NCT02590185|Experimental|cocktail probe drugs|"A capsule of omeprazole ABBOTT® 10mg~10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)~1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)~A tablet of fexofenadine Zentiva® 120mg"
2995954|NCT02590146|Experimental|Intervention Group|Patients in this group will participate in pain management counseling and choose non-pharmacologic pain control supports to use during their procedure in addition to the standard of care pain management offered in the office
2995955|NCT02590146|No Intervention|Control group|Patients in this group will receive standard of care pain management offered in the office.
2995956|NCT02590133|Experimental|Nedaplatin+5-Fu+Endostar|Drug: Recombinant Human Endostatin Injection (Endostar) Endostar, 15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Fluorouracil (5-Fu) 5-Fu, 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Nedaplatin Nedaplatin, 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
2995957|NCT02590133|Active Comparator|Nedaplatin+5-Fu|Drug: Fluorouracil (5-Fu) 5-Fu, 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Nedaplatin Nedaplatin, 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
2995958|NCT02590120|Active Comparator|Enteral nutrition product : product A|Administration during 16 hours.
2995959|NCT02590120|Active Comparator|Enteral nutrition product : product B|Administration during 16 hours.
2995960|NCT02590107|Experimental|Supportive care (Boost Plus, Pro-Stat 101)|Participants receive Boost Plus PO BID or Pro-Stat 101 PO BID beginning one week before scheduled HSCT and continuing until hospital discharge. If participants do not tolerate the Boost Plus or Pro-Stat, they receive a milkshake PO QD as an alternative.
2995961|NCT02590094|Active Comparator|A|Study Group A: Subjects receive 2.5 mg intravitreal bevacizumab 1-3 days prior to vitrectomy.
2995962|NCT02590094|Active Comparator|B|Study Group B: Subjects receive 2.5 mg intravitreal bevacizumab 5-10 days prior to vitrectomy.
2995963|NCT02590094|Active Comparator|C|Study Group C: Subjects receive 1.25 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
2995964|NCT02590094|Active Comparator|D|Study Group D: Subjects receive 0.625 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
2995965|NCT02590094|Active Comparator|E|Study Group E: Subjects receive 2.5 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
2995966|NCT02590094|Active Comparator|F|Study Group F: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-10 days prior to vitrectomy.
2995967|NCT02590094|Active Comparator|G|Study Group G: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-3 days prior to vitrectomy.
2995968|NCT02590094|Active Comparator|H|Study Group H: Subjects receive 1.25 mg intravitreal ziv-aflibercept 5-10 days prior to vitrectomy.
2995969|NCT02590094|Active Comparator|I|Study Group I: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-10 days prior to vitrectomy, and then receive 1.25 mg intravitreal ziv-aflibercept at the completion of the vitrectomy.
2995970|NCT02590081|Active Comparator|Normal saline|Normal saline will be used for wash back procedure at the end of hemodiaysis.
2995971|NCT02590081|Experimental|dextrose 5%|Dextrose 5% will be used for wash back procedure at the end of hemodiaysis.
2995972|NCT02590068|Experimental|Hepatitis C infected volunteers|Zoster vaccine live (Zostavax), 0.65 ml dose, administered subcutaneously to Hepatitis C infected volunteers
2995973|NCT02590068|Active Comparator|Healthy volunteers|Zoster vaccine live (Zostavax), 0.65 ml dose, administered subcutaneously to healthy volunteers
2995974|NCT02590055|Experimental|Intervention arm|D1, 8 Gemcitabine 1000mg/m2 IV over 30 minutes D1, 8 Docetaxel 35mg/m2 IV over 1hr
2995975|NCT02590042|Experimental|ADSC-SVF-002|Cells will be administered at 1x10^6 cells/mL of defect. If administered with fat, the cells will be administered at 1.2x10^6 cells/mL of defect.
2995976|NCT02590029|Experimental|Mindfulness|15 minute mindfulness session
2995977|NCT02590029|Experimental|Suggestion|15 minute therapeutic suggestion session
2995978|NCT02590029|Active Comparator|Psychoeducation|15 minute psychoeducation session
2995979|NCT02590016|Experimental|Insulin-glucose-infusion|Insulin-glucose-infusion is administered once active labour begins and will be continued until birth.
2995980|NCT02590016|Active Comparator|Observation|Plasma glucose level is measured every 1-2 hours during active labour and insulin-glucose-infusion is started if plasma glucose level exceeds 7,5 mmol/l in two subsequent measurements.
2995981|NCT02590003|Experimental|Platinum-based doublet chemotherapy|"Carboplatin AUC 5 30 minute infusion IV on day 1~Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle"
2995982|NCT02590003|Active Comparator|Single agent chemotherapy|-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle
2995983|NCT02589990|Experimental|Strength training|Strength training, 4 rep of 4RM x 4 sets in leg press.
2995984|NCT02589977|Other|normal participants|"No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) >60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
2995985|NCT02589977|Other|hypertensive participants|"No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) >60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
2995986|NCT02589977|Other|HFpEF patients|"No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) >60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
2996018|NCT02589743|Experimental|Single Bond and F (Adhesive and Sealant)|Pit and fissure sealing using adhesive and sealant
2996019|NCT02589743|Active Comparator|Helioseal Clear Chroma - H (Sealant)|Pit and fissure sealing using only sealant
2995987|NCT02589964|Active Comparator|Probiotic|"Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days. The treatment is Florajen-3. The ingredients in Florajen-3 are:~Lactobacillus acidophilus—over 7.5 billion Bifidobacterium lactis—over 6.0 billion Bifidobacterium longum—over 1.5 billion"
2995988|NCT02589964|Placebo Comparator|Placebo|"Placebo will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days. The ingredients in the placebo are:~Rice maltodextrin"
2995989|NCT02589938|Active Comparator|Standard Oral Hygiene|All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.
2995990|NCT02589938|Experimental|Standard Oral Hygiene + True Acupuncture|"All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.~The True acupuncture points will be at 3 sites on each ear, a site on the chin, on each forearm, a site on each hand, a site on each leg, and one placebo needle for a total of 14 sites. All sites will be applied for 20 minutes."
2995991|NCT02589938|Other|Standard Oral Hygiene + Sham Acupuncture|"All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.~The Sham acupuncture points will be given according to the same schedule as the active acupuncture points, except the Sham needles will be placed below, above or between true active points."
2995992|NCT02589925|Sham Comparator|sham stimulation|ineffective neurostimulation of the Nucleus basalis Meynert combined with subthalamic nucleus (STN) stimulation using Vercise deep brain stimulation
2995993|NCT02589925|Active Comparator|NBM stimulation|effective neurostimulation of the Nucleus basalis Meynert combined with subthalamic nucleus (STN) stimulation using Vercise deep brain stimulation
2995994|NCT02589899||Needle placement in different tissue types|Needle placement and impedance measurements in different tissue types
2995995|NCT02589886|Active Comparator|intervention|This arm will receive the education and self-help internet intervention added to usual care
2995996|NCT02589886|No Intervention|control|This arm will receive usual care only
2995997|NCT02589873|Active Comparator|In-Person Diabetes Prevention Program|An in-person group delivery modality of a CDC recognized Diabetes Prevention Program (DPP), delivered by the Young Men's Christian Association (YMCA). This group receives lifestyle coaching in a group setting, meeting weekly for 16 weeks followed by 3 biweekly sessions, and 5 monthly maintenance sessions.
2995998|NCT02589873|Active Comparator|Online Diabetes Prevention Program|An online delivery modality of a CDC recognized Diabetes Prevention Program (DPP), delivered by Canary Health's Virtual Lifestyle Management program. This group completes online learning sessions weekly for 16 weeks followed by 8 monthly maintenance sessions.
2995999|NCT02589847|Experimental|open label|RBX2660 (microbiota suspention)
2996000|NCT02589834|Active Comparator|Quran group|The patients listened to Quran recitation by a compact disc player through an occlusive headphone, started after induction of spinal anesthesia and continued throughout the entire cesarean section duration.
2996001|NCT02589834|No Intervention|Non-Quran group|Those patients did not listen to Quran and subjected to operative room noise throughout the surgery.
2996002|NCT02589821|Experimental|Sulfatinib|Sulfatinib 300 mg, orally, once daily (QD)
2996003|NCT02589821|Placebo Comparator|Placebo|Placebo 300 mg, orally, once daily (QD)
2996004|NCT02589808|Other|Echocardiography|Cardiac ultrasound scan.
2996005|NCT02589795|Experimental|Group 1: ID/EP + IM|"0.6 mg DNA-C CN54ENV, intradermally with electroporation, at Weeks 0, 4 and 8. 2 mg DNA-C CN54ENV, intramuscularly without electroporation, at Weeks 0, 4 and 8.~50 µg CN54gp140, intradermally without electroporation, at Week 20."
2996006|NCT02589795|Experimental|Group 2: ID + IM/EP|"0.6 mg DNA-C CN54ENV, intradermally without electroporation, at Weeks 0, 4 and 8.~2 mg DNA-C CN54ENV, intramuscularly with electroporation, at Weeks 0, 4 and 8. 50 µg CN54gp140, intradermally without electroporation, at Week 20."
2996007|NCT02589795|Experimental|Group 3: ID/EP + IM/EP|0.6 mg DNA-C CN54ENV, intradermally with electroporation, at Weeks 0, 4 and 8. 2 mg DNA-C CN54ENV, intramuscularly with electroporation, at Weeks 0, 4 and 8. 50 µg CN54gp140, intradermally without electroporation, at Week 20.
2996008|NCT02589782|Experimental|Regimen 1|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated
2996009|NCT02589782|Experimental|Regimen 2|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
2996010|NCT02589782|Experimental|Regimen 3|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
2996011|NCT02589782|Active Comparator|Control Regimen|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
2996012|NCT02589769|Experimental|unsaturated fat|an intervention diet substituting unsaturated fats from oil and nuts for saturated fats from meat and dairy foods
2996013|NCT02589769|Active Comparator|saturated fat|a control diet with whole fat dairy and meat with saturated fats that are not fat reduced.
2996014|NCT02589756|Experimental|The fatty fish group|Participants will eat fatty fish and avoiding nuts)
2996015|NCT02589756|Experimental|The nut group|Participants who will avoid fatty fish
2996016|NCT02589756|Placebo Comparator|The control group|Participants who will avoid both fatty fish and nuts
2996017|NCT02589743|Active Comparator|Fluroshield - F (Sealant)|Pit and fissure sealing using only sealant
2996021|NCT02589730|Experimental|online mutual management|The patients received the online coaching of a doctor and diabetes educator via smart phone based welltang app.
2996022|NCT02589730|Experimental|online self-management|The patients received the online coaching of a doctor alone via smart phone based welltang app.
2996023|NCT02589730|No Intervention|hospital regular management|The patients received usual care and did not use smart phone.
2996024|NCT02589691|Experimental|Rocuronium|Intra-venous injection during induction anesthesia of 0.3 mg/kg (1 mL/kg) of rocuronium
2996025|NCT02589691|Placebo Comparator|Placebo|Intra-venous injection during induction anesthesia of 1 mL/kg of sodium chloride 0.9%
2996026|NCT02589678|Other|MMR/Tdap-IPV|Participants receiving MMR vaccine (Measles, mumps, and rubella) at 0 months/at enrollment, followed by Tdap-IPV vaccine (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) at 3 months.
2996027|NCT02589678|Other|Tdap-IPV/MMR|Participants receiving Tdap-IPV vaccine (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) at 0 months/at enrollment, followed by MMR vaccine (Measles, mumps, and rubella) at 3 months.
2996028|NCT02589665|Experimental|Low Dose Mirikizumab Induction|"Low dose mirikizumab~Participants who do not have a clinical response may choose to participate in the unblinded study extension period"
2996029|NCT02589665|Experimental|Mid Dose Mirikizumab Induction|"Mid dose mirikizumab~Participants who do not have a clinical response may choose to participate in the unblinded study extension period"
2996030|NCT02589665|Experimental|High Dose Mirikizumab Induction|"High dose mirikizumab~Participants who do not have a clinical response may choose to participate in the unblinded study extension period"
2996031|NCT02589665|Placebo Comparator|Placebo Induction|"Placebo~Participants who do not have a clinical response may choose to participate in the unblinded study extension period"
2996032|NCT02589665|Experimental|Mirikizumab Maintenance Dose Schedule 1|Dose schedule 1 mirikizumab
2996033|NCT02589665|Experimental|Mirikizumab Maintenance Dose Schedule 2|Dose schedule 2 mirikizumab
2996034|NCT02589665|Placebo Comparator|Placebo Maintenance|Placebo
2996035|NCT02589652||Switch group|Patients who have been assigned to pegylated interferon alfa-2a.
2996036|NCT02589652||Sequential combination group (S-C group)|Patients who have been assigned to pegylated interferon alfa-2a plus entecavir.
2996037|NCT02589652||ETV group|Patients who have been assigned to entecavir monotherapy.
2996038|NCT02589639|Experimental|empagliflozin 10 mg|
2996039|NCT02589639|Experimental|empagliflozin 25 mg|
2996040|NCT02589639|Placebo Comparator|placebo|
2996041|NCT02589626|Experimental|empaglifrozin 10 mg|empagliflozin 10 mg tablet and placebo matching empagliflozin 25 mg tablet
2996042|NCT02589626|Experimental|empagliflozin 25 mg|empagliflozin 25 mg tablet and placebo matching empagliflozin 10 mg tablet
2996043|NCT02589613|Placebo Comparator|PLACEBO|Single intragastric instillation of 300ml tap water via nasogastric tube
2996044|NCT02589613|Active Comparator|GLUCOSE|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
2996045|NCT02589613|Active Comparator|FRUCTOSE|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
2996046|NCT02589600|Experimental|Active Medication Group|Annual dose: intravenous zoledronic acid (Reclast) 5.0 mg; vitamin D (800 IU/daily) and calcium (approximately 1200 mg/daily, dietary + supplements)
2996047|NCT02589600|Placebo Comparator|Placebo Group|Annual dose: intravenous saline; vitamin D (800 IU/daily and calcium (approximately 1200 mg/daily, dietary + supplements)
2996048|NCT02589587|Active Comparator|sleeve gastrectomy|Morbidly obese patients scheduled for sleeve gastrectomy will be examined by endoscopy before and 3 months after surgery. Biopsies will be taken from stomach and duodenum.
2996049|NCT02589587|Other|no intervention|Lean, healthy controls will undergo endoscopy and biopsies will be taken from stomach and duodenum.
2996050|NCT02589574|No Intervention|Control|Subjects of the control group will receive the usual announcement on the dates and times of offering free influenza vaccination, and reminder from hospital, and access to informational flyers posted at the hospital
2996051|NCT02589574|Experimental|Intervention|Subjects of the intervention group besides the usual information same as those stated in the control group, will receive four reminders on dates and details for free influenza vaccine. Together with the reminder, electronic text messages of educational information will be received
2996052|NCT02589561|Active Comparator|face to face fitting|face to face fitting of hearing aids
2996053|NCT02589561|Experimental|remote fitting|remote fitting of hearing aids
2996054|NCT02589535||septic|Group Gb: postoperative septic patients in intensive care unit (ICU)] Gb1: the group of septic patients treated with extracorporeal hemoperfusion therapy and conventional therapy according to the Surviving Sepsis Campaign guidelines Gb2 group treated with conventional therapy according to the Surviving Sepsis Campaign guidelines
2996055|NCT02589535||no septic|Ga: postoperative patients in emergency surgical ward (ES)
2996056|NCT02589535||healthy|Healthy people
2996057|NCT02589522|Experimental|Group I (VX-970, whole-brain radiation therapy)|Patients undergo whole-brain radiation therapy QD 5 days a week for 15 fractions. Patients also receive ATR kinase inhibitor M6620 IV over 60-90 minutes twice a week, 18-30 hours after first radiation therapy. Treatment continues for 3 weeks in the absence of disease progression or unacceptable toxicity.
2996058|NCT02589522|Experimental|Group II (VX-970, surgery, whole-brain radiation therapy)|Patients receive ATR kinase inhibitor M6620 IV over 60-90 minutes 2-4 hours prior to surgery. After surgery, patients undergo whole-brain radiation therapy and receive ATR kinase inhibitor M6620 as in Group I.
2996059|NCT02589509|Experimental|Direct-Metacognitive|Direct attention training followed by metacognitive strategy training
2996060|NCT02589509|Experimental|Metacognitive-Direct|Metacognitive strategy training followed by direct-attention training
2996061|NCT02589496|Experimental|pembrolizumab|Pembrolizumab 200 mg every 3 weeks
2996062|NCT02589483|Experimental|Prospective pilot|Patient included prospectivly will be all treated according to study protocol.The rectal anastomosis will be reinforced with HemoPatch.
2996063|NCT02589470|Experimental|COMETE|patients will attend a specific rehabilitation programme of memory
2996064|NCT02589470|No Intervention|CONTROL|the control group where patients will benefit from a standard treatment
2996067|NCT02589444|Experimental|Participants with vitamin D deficiency - treatment group|Participants with 25-hydroxyvitamin D (25(OH)D) ≤30 ng/mL taking oral high-dose vitamin D3 (50,000 IU) once a week and providing stool and sputum sample at screening and 3 months after screening.
2996068|NCT02589444|Sham Comparator|Participants with vitamin D deficiency - placebo group|Participants with 25-hydroxyvitamin D (25(OH)D) concentrations ≤30 ng/mL taking a sham comparator (placebo) once a week and providing stool sample and sputum sample at screening and 3 months after screening.
2996069|NCT02589444|Other|Participants without vitamin D deficiency|Participants with 25-hydroxyvitamin D (25(OH)D) concentrations > 30 ng/mL with no intervention and providing stool sample and sputum sample at screening and 3 months after screening.
2996070|NCT02589431||Patients with severe sepsis|
2996071|NCT02589431||Controls|Healthy subjects
2996072|NCT02589418|Experimental|Healthy subjects|All subjects participate at 3 experimental conditions (Acupuncture, Sham-Acupuncture and No Acupuncture) at 3 different days in a randomized order.
2996073|NCT02589405|Experimental|Benzaknen treatment regimen|Benzac® 5% Gel (once daily) + Dermotivin® Soft Liquid soap (twice daily) + Cetaphil® Dermacontrol Moisturizer SPF30 (once daily)
2996074|NCT02589392|Experimental|Moisturizer + Body wash|Cetaphil® Restoraderm® moisturizer (2/day) + Cetaphil® Restoraderm® Skin body wash (1/day)
2996075|NCT02589392|Active Comparator|Body wash|Cetaphil® Restoraderm® body wash (1/day)
2996076|NCT02589379||Pancreatic Resection|All consecutive patients undergoing pancreatic resection for benign or malignant disease and meet inclusion criteria.
2996077|NCT02589366|Experimental|Lymphoseek plus Vital Blue Dye|Lymphoseek plus Vital Blue Dye: Single dose of 50 µg Lymphoseek radiolabeled with 75 MBq Tc 99m injected pre-operatively followed by next day intra-operative administration of vital blue dye.
2996078|NCT02589353|Experimental|Acarbose|Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain ~484 microgram acarbose; total maximum exposure of each subject to acarbose will be ~14-30 mg each session (1-20 sessions)
2996079|NCT02589340|Experimental|Buspirone|Two week titration up to 10 mg tablet/3 times a day for 7 days
2996080|NCT02589340|Placebo Comparator|Placebo|Two week titration up to 3 tablets/3 times a day for 7 days
2996081|NCT02589327|Experimental|Exercise Intervention|Hight intensity resistance training group
2996082|NCT02589327|No Intervention|Control|No-exercise control group
2996083|NCT02589314|Other|root planning|
2996084|NCT02589301|Experimental|Pegfilgrastim|Pegfilgrastim (Hematopoietic Growth Factor) injectable solution 6 mg / 0,6mL in a single subcutaneous application.
2996085|NCT02589301|Active Comparator|Neulastim (pegfilgrastim)|Neulastim injectable solution 6 mg / 0,6mL in a single subcutaneous application.
2996086|NCT02589288|Active Comparator|Continuous Infusion|Patients receive a postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
2996087|NCT02589288|Experimental|Automatic Intermittent Bolus|Patients receive a postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% and 4 ml PCA bolus, lockout 20 minutes every hour via electronic infusion pump (Micrel device, Greece).
2996088|NCT02589275|Experimental|TNX-102 SL Tablet 2.8 mg|1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 3 months
2996089|NCT02589249|Placebo Comparator|Placebo|placebo
2996090|NCT02589249|Active Comparator|AyuFlex1|AyuFlex1 (500 mg/d)
2996091|NCT02589249|Active Comparator|AyuFlex2|AyuFlex2 (1000 mg/d)
2996092|NCT02589236|Placebo Comparator|Placebo|Placebo Capsule
2996093|NCT02589236|Experimental|Cavosonstat (N91115) 200 mg|Cavosonstat (N91115) 200 mg twice daily (BID)
2996094|NCT02589236|Experimental|Cavosonstat (N91115) 400 mg|Cavosonstat (N91115) 400 mg BID
2996095|NCT02589223|Active Comparator|Multisensory Stimulation Group|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. Subjects assigned to the multisensory stimulation group will receive the multisensory stimulation protocol designed for the study, which will include a variety of techniques designed to awaken the individual. Stimulus provided may include: visual activities (i.e. presenting the individual with objects/pictures to look at), auditory information (i.e. playing music or speaking), tactile stimuli (i.e. touching the individual with materials of different textures), taste and smell stimuli (i.e. offering items for the individual to taste or smell).
2996096|NCT02589223|Placebo Comparator|Control Group|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. During each session, subjects will be played a pre-recorded reading of complex material for 30 minutes, in order to assist with control/blinding.
2996097|NCT02589210|Experimental|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
2996098|NCT02589197||Group 1 (Medial-Pivot)|Group 1 will be implanted with the EVOLUTION® MP System with Cruciate Sacrificing (CS) tibial inserts.
2996099|NCT02589197||Group 2 (Posterior-Stabilized)|Group 2 will be implanted with the Zimmer® NexGen® PS TKA system.
2996100|NCT02589197||Group 3 (Control Group)|Non-implanted control subjects
2996101|NCT02589184|Experimental|hypergravity WITH isometric load|Patient performing rehabilitation exercises under hypergravity as well as loaded isometric squats
2996102|NCT02589184|Experimental|hypergravity WITHOUT isometric load|Patient performing rehabilitation exercises under hypergravity
2996103|NCT02589184|Experimental|normal gravity WITH isometric load|Patient performing rehabilitation exercises under normal gravity as well as loaded isometric squats
2996104|NCT02589184|Active Comparator|normal gravity WITHOUT isometric load|Patient performing rehabilitation exercises under normal gravity
2996105|NCT02589171|Experimental|Neo Close Abdominal Closure|
2996106|NCT02589171|Active Comparator|Carter Thomason Device|
2996107|NCT02589158|Experimental|Evotaz®, washout, then Rezolsta®|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days, undergo a ten-day wash out period and then take Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
2996142|NCT02588872|Active Comparator|Hyaluronic Acid (HA)|Hyaluronic acid administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of ultra high molecular weight hyaluronan (16mg) in a 2mL injection.
2996108|NCT02589145|Experimental|Lenalidomide + Vorinostat/Gem/Bu/Mel + AutoSCT|"Vorinostat and lenalidomide administered orally at the same time within 1 hour before the daily dose of chemotherapy.~Gemcitabine administered as a loading dose of 75 mg/m2 followed by infusion on days -8 and -3.~Busulfan test dose administered as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1.~Melphalan administered at 60 mg/m2 on days -3 and -2.~Patients with CD20+ tumors receive rituximab 375 mg/m2 on day -9 in the AM as an inpatient.~Dexamethasone 8 mg by vein twice a day from day -8 to day -2. Caphosol oral rinses 30 mL four times a day used from day -8. Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on day -8.~Pyridoxine 100 mg by vein or mouth three times a day from day -1. Enoxaparin 40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3."
2996109|NCT02589132|No Intervention|Standard of Care|Families receiving Standard of Care
2996110|NCT02589132|Experimental|Mobile-Thrive application|Standard care plus Mobile-Thrive app
2996111|NCT02589119|Other|MSC-AFP|Single Treatment Group
2996112|NCT02589106|Experimental|Anisotropic Textile Braces|The design of the anisotropic textile braces will provide different mechanisms with rigid, semi-rigid and flexible materials: a) axial elongation through a close fit of the brace supported with textile composites on the lateral sides of the trunk, b) 3-point pressure with push and counter-pushes through semi-rigid pads inserted inside the pocket lining, c) pulling or compression to correct kyphosis or lordosis in the sagittal plane with elastic bands, d) derotation between the pelvis and shoulders with uneven straps, and e) an active mechanism with sensors added to the brace to maintain correct posture.
2996113|NCT02589093|Experimental|Stimulation|Subjects will receive progressive electrical stimulations with an external nerve stimulator over the ulnar nerve, from 0 mA to 30 mA in increments of 5 (2 Hz single twitch mode), for 3 minutes at each intensity. They will be asked to score their pain level (NRS 0-10) every minute. ANI will be recorded constantly.
2996114|NCT02589080|Experimental|Non-invasive sensory feedback|
2996115|NCT02589067|Experimental|Experimental|Randomized to 15mL 0.12% Chlorhexidine Gluconate oral rinse, to be used twice daily for 60 seconds for 7 days.
2996116|NCT02589067|Placebo Comparator|Placebo|Randomized to 15mL saline placebo oral rinse, to be used twice daily for 60 seconds for 7 days.
2996117|NCT02589054||Patients|
2996118|NCT02589041|Experimental|Intraneural|Using an Up-and-down methodology, the first patient receives 15 ml ropivacaine 1% intraneural injection. If unsuccessful, following patient will receive an increased dose of LA (2 ml). If successful, following patient will be randomized to have either the same LA dose (9 out of 10 probability) or 2 ml reduction of LA dose (1 out of 10 probability)
2996119|NCT02589028|Experimental|premeal protein bar first|"intervention: premeal protein-enriched bar intake~protein enriched bar(total serving: 30g, 43.28% carbohydrate; 1.29% fat; 40.39% protein; 42.63% fiber) will be given 30 minutes before breakfast~protein enriched bar is provided with 150 ml of water~amount of protein bar : 30g~breakfast : plain bagel, cream cheese, strawberry jam, orange juice 210ml"
2996120|NCT02589028|Other|breakfast first|"intervention: breakfast follows by protein bar~protein enriched bar is provided with 150 ml of water shortly after breakfast~amount of protein bar : 30g~breakfast : plain bagel, cream cheese, strawberry jam, orange juice 210ml"
2996121|NCT02589002|Experimental|Sucralose|Ingestion of 15% of the ADI of sucralose daily during two weeks
2996122|NCT02589002|No Intervention|Control|Absence of sucralose ingestion
2996123|NCT02588989||transposition of the great arteries|Patients with a TGA
2996124|NCT02588976|Other|ACT measurements|ACT measurements by SONOCLOT Analyzer during cardiac surgery
2996125|NCT02588963|Experimental|Experimental Group 1|Children whose caregivers were subjected to a health education session
2996126|NCT02588963|Experimental|Experimental Group 2|Children who were subjected to nasal clearance protocol
2996127|NCT02588963|Experimental|Experimental Group 3|Children whose caregivers were subjected to health education session and who were subjected to respiratory physiotherapy protocol
2996128|NCT02588963|Placebo Comparator|Control Group|Children who were not subjected to respiratory physiotherapy protocol for nasal clearance and whose parents were not subjected to health education session
2996129|NCT02588950|Experimental|Part A: U-500R Single Injection|Bolus of U-500R administered via single subcutaneous (SC) injection in one of the two periods
2996130|NCT02588950|Experimental|Part A: U-500R CSII|Bolus of U-500R administered via continuous subcutaneous insulin infusion (CSII) in one of the two periods
2996131|NCT02588950|Experimental|Part B: U-500R TID|U-500R administered thrice-daily (TID) via SC injection under steady state conditions for 5 to 10 days
2996132|NCT02588950|Experimental|Part B: U-500R BID|U-500R administered twice-daily (BID) via SC injection under steady state conditions for 5 to 10 days
2996133|NCT02588937|Experimental|EntecaBell ODT.|
2996134|NCT02588937|Active Comparator|Baraclude Tab.|
2996135|NCT02588924||Second University of Naples|the present research project is aimed at measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
2996136|NCT02588924||Neuromed IRCCS|the present research project is aimed at measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
2996137|NCT02588911|Active Comparator|Conventional Surgery|Limb with GSV insufficiency in the same patient, randomised to conventional surgery
2996138|NCT02588911|Active Comparator|Radiofrequency Ablation|Limb with GSV insufficiency in the same patient, randomised to radiofrequency ablation
2996139|NCT02588898||Patients with type 2 diabetes|Patients (both men and women) with diagnosed type 2 Diabetes for at least 5 years. Blood collection and electrophysiological tests were performed.
2996140|NCT02588898||Controls free of diabetes|Controls (both men and women) are people of the same age who are free of Diabetes. Blood collection and electrophysiological tests were performed.
2996141|NCT02588885|Experimental|Trauma-sensitive Care|Participants will attend 7, one-hour psychotherapy sessions, which will be concurrent with trauma-sensitive care at physical therapy appointments.
2996143|NCT02588872|Experimental|Platelet-rich Plasma (PRP)|Platelet-rich plasma administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of leukocyte poor, buffer/additive free, singe spin, platelet-rich plasma averaging 4mL in volume.
2996144|NCT02588846|Experimental|Stage 1: Optimise nodal treatment margin|During Stage 1: Optimise nodal treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. The nodal target position stability will be evaluated by the cone beam computed tomography (CBCT) imaging before and after each treatment session for the first 10 patients.
2996145|NCT02588846|Experimental|Stage 2: Use treatment margin|During Stage 2: Use treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. At the same time, multi-leaf collimator (MLC) tracking will be used to reshape the radiation beam in real-time using the margin size determined in Stage 1.
2996146|NCT02588833|Experimental|Cohort 1|180 mg APL-2/day
2996147|NCT02588833|Experimental|Cohort 2|270 mg APL-2/day
2996148|NCT02588820|Experimental|Antiretroviral treatment|
2996149|NCT02588807|Experimental|Spirit1|Patients will take a daily nutritional supplement for 8 months
2996150|NCT02588794|Active Comparator|intervention|Standart CVVHD plus CytoSorb 300 ml device (3804606CE01)
2996151|NCT02588794|No Intervention|control|Standart CVVHD
2996152|NCT02588781|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 IV Q 3 weeks
2996153|NCT02588768|Active Comparator|Active PBMT|Active PBMT was applied employing MR4 Laser Therapy Systems outfitted with LaserShower 50 4D emitters (both manufactured by Multi Radiance Medical, Solon - OH, USA). The cluster style emitter contains 12 diodes comprising of four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode).
2996154|NCT02588768|Placebo Comparator|Placebo PBMT|Placebo PBMT was applied using the same device that emitted the same sounds and light, but with no effective irradiation.
2996155|NCT02588755|Active Comparator|TACE+ Tegafur|Patients will be treated with Tegafur after resection soon, and TACE in 4 or 8 weeks after resection.
2996156|NCT02588755|Experimental|TACE|Patients will be treated with TACE alone in 4 or 8 weeks after resection.
2996157|NCT02588742|Experimental|melatonin group|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
2996158|NCT02588742|Placebo Comparator|control group|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
2996159|NCT02588729|Experimental|Pregnant+ app for smartphone (Gravid+)|The intervention consists of the Pregnant+app downloaded on women`s smartphone. The app contains culturally adapted information about physical activity, diet and management of GDM. The Gravid+app will be available in Norwegain, Urdu and Somali. Women will have the opportunity to automatically transfer their blood glucose levels to their smartphones via Bluetooth.
2996160|NCT02588729|No Intervention|No admission to Pregnant+ app (Gravid+)|The control group will receive standard care at the outpatient departments. Participants to not receive the Pregnancy
2996161|NCT02588716|Active Comparator|Terlipressin|Terlipressin will be given at the beginning of surgery as an initial bolus dose of (1 mg over 30 mins) followed by a continuous infusion of 2μg/kg/h to be continued throughout the surgery then gradually withdrawn over 4 hours
2996162|NCT02588716|Placebo Comparator|Control|same volumes of normal saline with the same rate of infusion, throughout the operation then gradually withdrawn over 4 hours.
2996163|NCT02588703|Experimental|Cognitive Behavioral Therapy|9-session 2-hour group cognitive behavioral therapy
2996164|NCT02588703|Active Comparator|Usual Care|9-session 2-hour group counseling
2996165|NCT02588690||Women participating in screening|Community screening project targets women of color and/or low income women over 21 years of age in economically and ethnically diverse greater Los Angeles community. Women will be risk stratified based on ASCVD risk calculation and if labeled high risk will be referred to physician services. In 1 year, women will have their ASCVD re-risk stratify to see if seeing a physician/ health care provider reduced overall ASCVD risk scores.
2996166|NCT02588677|Experimental|masitinib 3 mg/kg/day (1) + riluzole|
2996167|NCT02588677|Experimental|masitinib 4.5 mg/kg/day (2) + riluzole|
2996168|NCT02588677|Placebo Comparator|placebo + riluzole|
2996169|NCT02588664|No Intervention|Usual Care|Participating hospitals randomized to the usual care group will provide their usual, post-acute stroke care to their patients.
2996170|NCT02588664|Active Comparator|COMPASS Intervention|Participating hospitals randomized to the intervention will change the structure and process for delivery of post-acute stroke care.
2996171|NCT02588651|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg intravenously (IV) once every 3 weeks
2996172|NCT02588638||Adult patients|Unclear movement disorder, unclear cognitive decline
2996173|NCT02588638||Patients < 18 years|Patients with (penetrating) suspected cerebral neurogenetic diseases
2996174|NCT02588625|Experimental|Part A - BMS-986020|BMS-986020 or Placebo tablets specified dose on specified days
2996175|NCT02588625|Experimental|Part B - BMS-986020|BMS-986020 or Placebo tablets specified dose on specified days
2996176|NCT02588612|Experimental|Autologous Genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T|
2996177|NCT02588599|Experimental|Erchonia LUNULA|The Erchonia LUNULA emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
2996178|NCT02588586|Experimental|3BNC117 + ART Interruption|Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.
2996179|NCT02588573|Active Comparator|1-Day Acuvue® Moist contact lens|Participants will be fitted with the Clariti 1-day lens to one eye, and the 1-Day Acuvue® Moist® lens to the other eye, according to the randomization scheme.
2996180|NCT02588573|Active Comparator|Clariti 1-day contact lens|Participants will be fitted with the Clariti 1-day lens to one eye, and the 1-Day Acuvue® Moist® lens to the other eye, according to the randomization scheme.
2996222|NCT02588313|Active Comparator|Mango fruit powder 300mg|Mango fruit powder 300mg
2996181|NCT02588560||HCV lymphoma patients with chemotherapy|Lymphoma patients who are positive for anti-HCV and are planning to receive chemotherapy for lymphoma
2996182|NCT02588547|Active Comparator|Granisetron 1|Intravenous granisetron 1 mg
2996183|NCT02588547|Active Comparator|Granisetron 0.7|Intravenous granisetron 0.7 mg
2996184|NCT02588547|Placebo Comparator|Placebo|intravenous 0.9% Sodium chloride (2 ml)
2996185|NCT02588534|Active Comparator|Treatment A-etanercept (ENBREL®) via auto-injector device|Single dose of etanercept (ENBREL®) in a pre-filled syringe administered with an auto-injector device manufactured by Scandinavian Health Limited (SHL)
2996186|NCT02588534|Other|Treatment B-etanercept (ENBREL®) via Manual injection|single dose of etanercept (ENBREL®) in a syringe given by manual injection (reference treatment)
2996187|NCT02588521|Experimental|AL-794|AL-794 administered orally in a suspension
2996188|NCT02588521|Placebo Comparator|Vehicle|Suspension vehicle alone
2996189|NCT02588508|Experimental|Warm packs|The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.
2996190|NCT02588508|Experimental|Perineal massage|"The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like count coins."
2996191|NCT02588508|No Intervention|Hands off|Hands off group does not receive any perineal manipulation and they are only observed.
2996192|NCT02588495|No Intervention|Fasting|Participant will remain fasted following initial gastric ultrasound
2996193|NCT02588495|Experimental|Food intake|Participant will ingest either 250mL of clear fluid (apple juice) or 250mL of coffee and a muffin following initial gastric ultrasound
2996194|NCT02588482|Experimental|electroencephalography recording|Cerebral measurements from high-density and conventional electroencephalography are recorded simultaneously
2996195|NCT02588469|Experimental|Interventional group|Physical activity program coupled with compression socks wearing during 3 months.
2996196|NCT02588469|Active Comparator|control group|Physical activity program without compression socks during 3 months.
2996197|NCT02588456|Experimental|Single Arm|
2996198|NCT02588443|Experimental|Arm1|Arm I provides one dose of RO70097890 as a single agent in the neoadjuvant setting. Patients will recover from any toxicities and will then have their disease surgically resected. After recovery from surgery patients will proceed to adjuvant therapy which will include nab-paclitaxel 125mg/m2 and gemcitabine 1000mg/m2 on days 1,8 and 15 of a 28 day cycle along with RO7009789 0.2mg/kg on day 3 of each cycle. Four cycles of adjuvant therapy will be given. All medications are administered intravenously.
2996199|NCT02588443|Experimental|Arm2|Arm II provides one dose of RO7009789 two days after one dose of nab-paclitaxel and one dose of gemcitabine prior to surgery. Nab-paclitaxel and gemcitabine are given on day 1. RO7009789 will be given on day 3. Patients will recover from any toxicities and will then have their disease surgically resected. Patients will receive four cycles of these same medications in an adjuvant fashion after recovering from surgical resection. A cycle will consist of nab-paclitaxel (125mg/m²), gemcitabine (1000mg/m²) given on days 1,8 and 15 of a 28 day cycle along with RO7009789 0.2mg/kg on day 3 of each cycle.
2996200|NCT02588417|Active Comparator|dexamethasone|dexamethasone 4 mg administered intrathecally during active stage of labor once only in combination with levobupivacaine
2996201|NCT02588417|Active Comparator|levobupivacaine|levobupivacaine 2.5 mg in 2 ml administered intrathecally during active stage of labor once and alone and then epidural levobupivacaine 7ml of 2.5 mg concentrationis administered till the end of labor
2996202|NCT02588391|Experimental|Active Brain Training|"The children in this arm receive one type of Brain Training with online computer games that actively matches their skill level."
2996203|NCT02588391|Experimental|Passive Brain Training|"The children in this arm receive one type of Brain Training with online computer games that are at a consistent skill level."
2996204|NCT02588391|Other|Cross-over|"Following completion of the 6-month follow-up sessions after completion of Brain Training, each group is allowed to cross-over to the other arm of Brain Training (open-label extension)."
2996205|NCT02588378||Early dry AMD (no GA)|multi-modal cSLO imaging
2996206|NCT02588378||Late dry AMD (with GA)|multi-modal cSLO imaging
2996207|NCT02588378||Reticular Pseudodrusen (RPD)|multi-modal cSLO imaging
2996208|NCT02588378||Polypoidal Choroidal Vasculopathy (PCV)|multi-modal cSLO imaging
2996209|NCT02588378||Retinal Angiomatous Proliferaion (RAP)|multi-modal cSLO imaging
2996210|NCT02588378||Central Serous Retinopathy (CSR)|multi-modal cSLO imaging
2996211|NCT02588378||RPE Detachment (RPED)|multi-modal cSLO imaging
2996212|NCT02588378||New onset CNVM (wet AMD)|multi-modal cSLO imaging
2996213|NCT02588378||Healthy (non-AMD) controls|multi-modal cSLO imaging
2996214|NCT02588365|Experimental|Brain Training (Active)|"The children in this arm receive one type of Brain Training with online computer games that actively matches their skill level."
2996215|NCT02588365|Experimental|Brain Training (Passive)|"The children in this arm receive one type of Brain Training with online computer games that are at a consistent level."
2996216|NCT02588365|Experimental|Cross-over|"Following completion of the 6-month follow-up sessions after completion of Brain Training, each group is allowed to cross-over to the other arm of Brain Training (open-label extension)."
2996217|NCT02588352|Experimental|Healthy volunteers|Open label administration of salt tablets for one week
2996218|NCT02588339|Experimental|Panobinostat (PANO) Therapy|Participants will be treated with standard of care chemotherapy agents prior to their allogeneic hematopoietic cell transplant. For Graft Versus Host Disease (GVHD) prevention, participants will receive PANO, Sirolimus and Tacrolimus.
2996219|NCT02588326|Active Comparator|MFF 1, then MFF 2|Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray. After a wash out period then Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray. All formulations will be a 200 mcg single dose.
2996220|NCT02588326|Active Comparator|MFF 2, then MFF 1|Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray. After a wash out period then Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray. All formulations will be a 200 mcg single dose.
2996221|NCT02588313|Active Comparator|Mango fruit powder 100mg|Mango fruit powder 100mg
2996257|NCT02588014||Control|Neurotypical individuals
2996223|NCT02588313|Placebo Comparator|Placebo formulation|Placebo formulation
2996224|NCT02588300|Experimental|Drug induced sleep endoscopy|Patients upper airway is assessed by drug induced sleep endoscopy
2996225|NCT02588287|Experimental|Tenofovir PK before and after SOF/LDV|
2996226|NCT02588274|Experimental|Acupuncture|Zhongliao (BL 33), Shenshu (BL 23), Huiyang (BL 35), and Sanyinjiao (SP 6) acupuncture points (Table 1). After patients are in prone position with relax, the investigators will use 75% alcohol pads to sterile the skin around the acupuncture points, and then insert steel needles (Huatuo, Suzhou, China 0.3mm*40mm/0.3mm*75mm) into the acupuncture points. For bilateral Zhongliao (BL 33), the needle will be inserted into about 50-60mm with 45 degree, for Huiyang (BL 35), the needle will be inserted into 50-60mm. for Shenshu (BL 23) and Sanyinjiao (SP 6), the needles will be inserted vertically to a depth of 25-30 mm. The treatment sessions are 24 after baseline, 3 times a week, and the each time the patients will accept a 30 minutes treatment.
2996227|NCT02588274|Placebo Comparator|placebo needle|The participants in placebo needle group will receive placebo needle at the same acupuncture points to treatment group. Investigators will use a sort of blunt needle that cannot penetrate skin and stimulate deep tissues while the thrusting and twisting manipulation will be used by acupuncturists to mock the treatment procedure and blind the patients. The duration and frequency of sessions are same to the treatment group.
2996228|NCT02588261|Experimental|ASP8273|Patients randomized to this arm will receive a daily dose of ASP8273
2996229|NCT02588261|Active Comparator|erlotinib/gefitinib|Patients randomized to this arm will receive a daily dose of either erlotinib or gefitinib
2996230|NCT02588248|Experimental|Peppermint Oil|1.6% Peppermint oil solution
2996231|NCT02588248|Placebo Comparator|Placebo|standard water solution
2996232|NCT02588235|Experimental|Ezetimibe and Atorvastatin Therapy|Atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
2996233|NCT02588235|Active Comparator|Atorvastatin Therapy|Atorvastatin (20 mg/day）
2996234|NCT02588222||Healthy children|Healthy children, aged 6-18 years old.
2996235|NCT02588209|Experimental|SMART Training|This group will receive the Strategic Memory Advanced Reasoning Training (SMART) program, twice a week for four weeks.
2996236|NCT02588209|Active Comparator|Health|This group will receive the Brain Health Workshop educational program, twice a week for four weeks.
2996237|NCT02588196|Experimental|treatment of dexamethasone group|
2996238|NCT02588183|Experimental|ArticFont Advance ST|Patients undergoing PV isolation with the ArticFont Advance ST Cryoenergy Balloon Catheter
2996239|NCT02588170|Experimental|Sulfatinib|Sulfatinib 300 mg, orally, once daily (QD)
2996240|NCT02588170|Placebo Comparator|Placebo|Placebo 300 mg, orally, once daily (QD)
2996241|NCT02588157|Active Comparator|İnsertion time|handling the device till the glottic visualisation of Macintosh, McGrath MAC X-Blade and Glidescope
2996242|NCT02588157|Active Comparator|intubation time|handling the device till seeing the endotracheal tube entering from the vocal cords Macintosh, McGrath MAC X-Blade and Glidescope
2996243|NCT02588144|Active Comparator|[standard STN]|Device: standard stimulation on subthalamic (STN) contacts
2996244|NCT02588144|Experimental|[STN+SNr]|Device: Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr)
2996245|NCT02588131|Experimental|tremelimumab plus MEDI4736|Tremelimumab in combination with MEDI4736
2996246|NCT02588118||male group|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
2996247|NCT02588118||female group|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
2996248|NCT02588105|Experimental|Safety and Tolerability|All patients will receive AZD0156 as a monotherapy or in combination with either olaparib, cytotoxic chemotherapies, or novel anti-cancer agents to assess safety and tolerability
2996249|NCT02588092|Experimental|ADCT-301|"In Part 1 (dose-escalation), Weekly administration - Patients will receive an IV infusion of ADCT-301, on Days 1, 8, and 15 of each 3-week (21-day) cycle.~3-week administration - Patients will receive an IV infusion of ADCT-301, on Day 1 of each 3-week (21-day) cycle.~The dose escalation will be conducted according to a 3+3 design. In Part 2 (expansion), patients will be assigned to receive the recommended dose and/or schedule of ADCT-301 as determined by the Dose Escalation Steering Committee (DESC)."
2996250|NCT02588079|Experimental|Internet-based cognitive behavioral therapy|The treatment program consists of 12 modules that are offered during 12 weeks on Internet. Modules consist of parental education, psycho-education for the children, exposure, cognitive restructuring and home exercises. A psychologist guides parents and children through the treatment with continuous contact using the message function on the Internet platform that is used.
2996251|NCT02588079|No Intervention|Wait list|Participants are not offered any active controlled psychological interventions but have free access to dental health services, which could involve exposure and other behavioral strategies applied by dental staff.
2996252|NCT02588066|Experimental|Index test|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
2996253|NCT02588066|No Intervention|Reference test|No Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
2996254|NCT02588027|Active Comparator|Control|Ibuprofen 400mg by mouth three times daily. Patients will also receive the standard opiate medication (hydrocodone/acetaminophen 10mg/325mg) for the UCSF orthopaedic clinic for postoperative pain control.
2996255|NCT02588027|Placebo Comparator|Placebo|Placebo tablet by mouth three times daily. Patients will also received the standard opiate medication (hydrocodone/acetaminophen 10mg/325mg) for the UCSF orthopaedic clinic for postoperative pain control.
2996256|NCT02588014||Schizophrenia|Individuals with schizophrenia
2996259|NCT02587988|Experimental|HCP1302+HGP0904Placebo|HCP1302+HGP0904Placebo for 12weeks
2996260|NCT02587988|Active Comparator|HCP1302Placebo+HGP0904|HCP1302Placebo+HGP0904 for 12weeks
2996261|NCT02587975|Experimental|Evogliptin 10 mg|Single oral administration of 2 tablets of evogliptin 5 mg with water 250 mL
2996262|NCT02587962|Experimental|Birinapant in combination with pembrolizumab|Birinapant in combination with pembrolizumab
2996263|NCT02587936|Experimental|Collaborative model|Group to receive Collaborative model of primary care and subspecialty care enhanced by Pieces and Practice Facilitator
2996264|NCT02587936|No Intervention|Standard Care|Group to receive regular care
2996265|NCT02587910|Placebo Comparator|Non-invasive arm|Participants in this arm, who fit the inclusion criteria and have a GERD Q score of 3 or more, will be randomized to receive either Melanole, a herbal derived melanin, 300 mg, 2 capsules three times a day or placebo for 10 days.To assess the symptomatic improvement, GERD Q score will be calculated on day 0 (before administration of the product) and then on days 11 and 30 having taken the product for 10 days.
2996266|NCT02587910|Placebo Comparator|Invasive arm|Participants in this arm will undergo a 24-hour pH monitoring before administration of Melanole, the herbal melanin or placebo. They will then be randomized to receive either Melanole or placebo for 10 days. pH metry will be repeated between days 7 and 10 from the study product or placebo.
2996267|NCT02587897||Dental Hygiene Students|Students enrolled in the 2-year dental hygiene academic coursework programs at the University of Southern California and Loma Linda University who are exposed to high-intensity work-related hand activities as part of their training program.
2996268|NCT02587897||Occupational Therapy Students|Students enrolled in the 2-year occupational therapy academic coursework program at the University of Southern California.
2996269|NCT02587884|Active Comparator|Group TACE|Patients will treated with TACE after resection.
2996270|NCT02587884|No Intervention|Group Control|Patients will treated without TACE after resection.
2996271|NCT02587871|Experimental|Treatment (cytarabine, G-CSF mobilized peripheral blood cells)|Approximately 4-6 weeks after completion of induction chemotherapy, patients receive cytarabine IV over 1-3 hours BID on days -7 to -2 and G-CSF mobilized peripheral blood cells (microtransplant) IV over 15-20 minutes on day 0. Treatment repeats every 8-10 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
2996272|NCT02587858||PKAN|This group consists of individuals diagnosed with PKAN using a combination of MRI and PANK2 gene sequencing.
2996273|NCT02587858||PLAN|This group consists of individuals diagnosed with PLAN from PLA2G6 gene sequencing.
2996274|NCT02587858||BPAN|This group consists of individuals diagnosed with BPAN from WDR45 gene sequencing.
2996275|NCT02587845|Active Comparator|IV group|Intravenous tranexamic acid injection Group IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
2996276|NCT02587845|Experimental|Topical group|Intra-articular tranexamic acid injection Group Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
2996277|NCT02587832|Active Comparator|HHHFNC|Randomized to HHHFNC
2996278|NCT02587832|Active Comparator|NCPAP|Randomized to NCPAP
2996279|NCT02587819|Experimental|Treatment with BSCT|21 patients with BCC were treated with BSCT (anti-nf-P2X7) 10% Ointment topically applied twice daily for 28 consecutive days.
2996280|NCT02587806|Experimental|Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC)|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
2996281|NCT02587793||Barcelona Clinic Liver Cancer (BCLC) staging|The tumor stages of the patient are classified as BCLC stage 0, A, B, C, or D.
2996282|NCT02587780||Inactive|people who perform < 30mins.day physical activity at a 'moderate' level of intensity.
2996283|NCT02587780||Active|people who perform 30mins-60 mins.day of physical activity at a 'moderate' level of intensity.
2996284|NCT02587780||Very active|People who perform > 60 mins.day of physical activity at a >moderate level of intensity.
2996285|NCT02587767|Experimental|577-MPL|"577nm micropulse laser(577-MPL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Multiple laser spots will be applied, covering the leakage area."
2996286|NCT02587767|Active Comparator|HD-PDT|Half-dose photodynamic therapy (HD-PDT) is administered to the patients. At 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689nm, and a treatment duration of 83 seconds.
2996287|NCT02587754|Active Comparator|Verum acupuncture|10 sessions of verum acupuncture
2996288|NCT02587754|Placebo Comparator|Placebo acupuncture|10 sessions of placebo acupuncture via use of placebo acupuncture needles
2996289|NCT02587741|Experimental|oral drugs|oral anti-diabetic drugs only.metformin,start from 500mg bid,if blood glucose dose not reach the standard，added to 500mg tid→1000mg bid.if metformin reach the biggest dosage，added gliclazide modified release tablets，from 30mg qd,if blood glucose dose not reach the standard,add dosage 30mg qd→60 mg qd→90mg qd→120mg qd(max).if still not reach the target，add acarbose 50mg tid
2996290|NCT02587741|Experimental|lantus|basal insulin combine with oral drugs,started with insulin glargine 0.2 u/kg subcutaneous injection at 10pm（at 8am if patients are night workers）,add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs.
2996291|NCT02587741|Experimental|Novomix30|premixed insulin combine with oral drugs,started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs .
2996292|NCT02587728||Carpal Tunnel Blood Draw|Participants with confirmed diagnosis of Carpal Tunnel Syndrome who will undergo blood draw for laboratory analysis for amyloidosis.
2996293|NCT02587715|Experimental|AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
2996294|NCT02587702|Experimental|Improved Infant Formula Group|Containing β-Palmitate Content
2996295|NCT02587702|Placebo Comparator|General Infant Formula Group|Excluding β-Palmitate Content
2996296|NCT02587702|Active Comparator|Human Milk Group|Containing β-Palmitate Content Naturely in Human Milk
2996297|NCT02587689|Experimental|anti-MUC1 CAR T Cells|The subject's T cells will be modified in one or two different ways that will allow the cells to identify and kill the MUC1+ tumor cells.
2996298|NCT02587676||denture liners|Evatouch Super (EVA; Neo Dental Chemical products, Washington, USA), GC RELINE (GCR; GC Dental Products Corp, Tokyo, Japan), Mucopren soft (MCP; Kettenbach GmbH & Co KG, California, USA) Soften (SFT; KAMEMIZU CHEM, Osaka, Japan), FD Soft (FDS; KAMEMIZU CHEM, Osaka, Japan), and Bio Liner (BIO; Nissin Dental Products, Kyoto, Japan).
2996299|NCT02587663|Active Comparator|Group 1 (standard of care)|Patients undergo standard of care diagnostic imaging comprising bilateral mammography and targeted breast ultrasound.
2996300|NCT02587663|Experimental|Group 2 (bilateral whole-breast ultrasound)|Patients undergo standard of care diagnostic imaging as in Group 1. Patients also undergo bilateral whole-breast ultrasound.
2996301|NCT02587663|Experimental|Group 3 (bilateral breast contrast-enhanced MRI)|Patients undergo standard of care diagnostic imaging as in Group 1. Patients also undergo bilateral breast contrast-enhanced MRI.
2996302|NCT02587650|Experimental|Arm A (capmatinib)|Patients with MET fusion receive capmatinib PO BID on day 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
2996303|NCT02587650|Experimental|Arm B (ceritinib)|Patients with ALK fusion receive ceritinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
2996304|NCT02587650|Experimental|Arm C (regorafenib)|Patients with RET or BRAF fusion receive regorafenib PO QD on day 1-21. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
2996305|NCT02587650|Experimental|Arm D (entrectinib)|Patients with NTRK1, NTRK2, NTRK3, OR ROS1 fusion receive entrectinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
2996306|NCT02587624||RMN AF ablation|Consecutive patients with class I or class IIa indication for catheter ablation for symptomatic atrial fibrillation according to the current guidelines.
2996307|NCT02587611|Experimental|Elemental liquid diet|"Elemental liquid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and healthy subjects drink it within 5 min.~Elemental liquid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and is administered within 15 min using the gastrostomy tube."
2996308|NCT02587611|Active Comparator|Standard semi-solid diet|"Standard semi-solid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and healthy subjects drink it within 5 min.~Standard semi-solid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and is administered within 15 min using the gastrostomy tube."
2996309|NCT02587598|Experimental|INCB053914|Monotherapy
2996310|NCT02587598|Experimental|INCB053914 + Azacitidine|
2996311|NCT02587598|Experimental|INCB053914 + I-DAC|
2996312|NCT02587598|Experimental|INCB053914 + Ruxolitinib|
2996313|NCT02587585|Experimental|Feedback against tailored target|For each two hour epoch, the watch calculate the level of activity for the same epoch the day before, and adds 5% as the new target to be achieved.
2996314|NCT02587585|Sham Comparator|No Feedback|For participants assigned to the control group, the smart watch will not provide any activity feedback against a target; it simply shows which two hour epoch a person is in.
2996315|NCT02587572|Experimental|LMSCs 10 million IV|A total of 10 subjects will receive: A single peripheral intravenous (IV) infusion of 10 x10^6 (10 million) of LMSCs to be administered on day 1.
2996316|NCT02587572|Placebo Comparator|Placebo (Plasmalyte A,HSA) IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of Plasmalyte A containing human serum albumin (HSA) to be administered on day 1.
2996317|NCT02587572|Experimental|LMSCs 20 million IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of 20x10^6 (20 million) LMSCs to be administered on day 1.
2996318|NCT02587572|Experimental|LMSCs100 million IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of 100x10^6 (100 million) LMSCs to be administered on day 1.
2996319|NCT02587559|No Intervention|Control|usual medical advice regarding symptomatic control and activity modification
2996320|NCT02587559|Experimental|Experimental|Six visits of physical therapy to provide manual therapy and therapeutic exercise
2996321|NCT02587546|Experimental|laryngeal carcinoma|patients with T1-T2 (some T3) laryngeal carcinoma will undergo treatment using thulium contact laser surgery - tumour resection
2996322|NCT02587546|Experimental|bilateral vocal cord paralysis|patients with bilateral vocal cord paralysis treated with partial arytenoidectomy will be treated using thulium laser surgery and laterofixation
2996323|NCT02587546|Experimental|subglottic stenosis|patients with subglottic stenosis treated endoscopically (incisions and dilatation) will be treated with thulium laser surgery
2996324|NCT02587533|Active Comparator|Hypoxia without dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. No pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
2996325|NCT02587533|Active Comparator|Hypoxia with dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. Counteracting pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
2996326|NCT02587533|Active Comparator|Hyperoxia without dopamine|Nearly complete hemoglobin oxygen saturation. No additional pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
2996327|NCT02587533|Active Comparator|Hyperoxia with dopamine|Nearly complete hemoglobin oxygen saturation. Additional pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
2996328|NCT02587520|Experimental|SP0173 Vaccine Formulation 1|Participants assigned to receive SP0173 vaccine formulation 1
2996329|NCT02587520|Experimental|SP0173 Vaccine Formulation 2|Participants assigned to receive SP0173 vaccine formulation 2
2996330|NCT02587520|Experimental|SP0173 Vaccine Formulation 3|Participants assigned to receive SP0173 vaccine formulation 3
2996331|NCT02587520|Experimental|SP0173 Vaccine Formulation 4|Participants assigned to receive SP0173 vaccine formulation 4
2996332|NCT02587520|Active Comparator|Control Vaccine Group 1|Participants assigned to receive a licensed Tdap vaccine 1
2996333|NCT02587520|Active Comparator|Control Vaccine Group 2|Participants assigned to receive a licensed Tdap vaccine 2
2996334|NCT02587507|Placebo Comparator|Water|The subjects will ingest the HFHC meal with 500mL of water.
2996335|NCT02587507|Experimental|Orange juice|The subjects will ingest the HFHC meal with 500mL of orange juice.
2996336|NCT02587507|Active Comparator|Water with glucose|The subjects will ingest the HFHC meal with 500mL of water with glucose (isocaloric control of the orange juice).
2996337|NCT02587494|Active Comparator|Early cardiac catheterization|Cardiac catheterization performed as early as possible, within 12h post ROSC following OHCA, with possible PCI during mild therapeutic hypothermia or apyrexia
2996338|NCT02587494|No Intervention|Medical arm|Initial therapy does not include cardiac catheterization. Cardiac catheterization with possible PCI is allowed after completion of mild therapeutic hypothermia or apyrexia for >24h post ROSC.
2996339|NCT02587468|Experimental|Juice Plus+(R)|Check of phenolic absorption between baseline and after 8wks of intake before-after comparison
2996340|NCT02587455|Experimental|Low Dose Radiotherapy Arm|Pembrolizumab and radiotherapy
2996341|NCT02587455|Experimental|High Dose Radiotherapy Arm|Pembrolizumab and radiotherapy
2996342|NCT02587442|Experimental|RadProtect®|RadProtect® is not a full-closed micelle, and uses ferrous iron to provide linkage between PEG-b-PGA and amifostine. Transferrin and other related proteins can chelate with ferrous iron and break the micelle releasing amifostine into the blood stream.
2996343|NCT02587429|Experimental|Patienteducation|(Patients with PCS>22). An education in pain coping delivered by physiotherapists. The education consist of seven sessions over a four months period. Each session is individual and will last 30 minutes. Focus will be on pain behaviour and pain coping based on Cognitive Behavioral Therapy.
2996344|NCT02587429|No Intervention|Control group 1|(Patients with PCS>22). Patients randomly assigned to this arm will undergo usual treatment for total knee arthroplasty.
2996345|NCT02587429|No Intervention|Control group 2|(Patients with PCS<12). Patients in this arm will undergo usual treatment for total knee arthroplasty. Patients in this arm are not randomized but matched by age, gender and BMI with patients in control group 1.
2996346|NCT02587416|Experimental|Gemcabene 300 mg|Gemcabene 300 mg
2996347|NCT02587416|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
2996348|NCT02587416|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg
2996349|NCT02587403|Active Comparator|Fortiva™ Porcine Dermis|Fortiva Porcine Dermis implantation during repair of complex ventral hernia
2996350|NCT02587403|Active Comparator|Strattice™ Reconstructive Tissue Matrix|Strattice tissue matrix implanted during repair of complex ventral hernia
2996351|NCT02587390|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
2996352|NCT02587390|Active Comparator|Simvastatin 80 mg|Simvastatin 80 mg
2996353|NCT02587377|Other|Cohort 1|single cohort of patient
2996354|NCT02587364|Experimental|Gemcabene 50 mg|Gemcabene 50 mg
2996355|NCT02587364|Experimental|Gemcabene 150 mg|Gemcabene 150 mg
2996356|NCT02587364|Experimental|Gemcabene 450 mg|Gemcabene 450 mg
2996357|NCT02587364|Experimental|Gemcabene 750/600 mg|Gemcabene 750/600 mg
2996358|NCT02587364|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
2996359|NCT02587364|Placebo Comparator|Placebo|Placebo
2996360|NCT02587351|Active Comparator|Metoprolol succinate|Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).
2996361|NCT02587351|Placebo Comparator|Placebo|Matched placebo
2996362|NCT02587338|Experimental|Verum tDCS|Left frontal anodal stimulation, supraorbital right cathodal stimulation
2996363|NCT02587338|Experimental|Sham tDCS|sham stimulation, same electrode positions
2996364|NCT02587325|Experimental|ABI-009|
2996365|NCT02587312|Active Comparator|Normal Nicotine Content Cigarettes|SPECTRUM cigarette: 0.8 mg nicotine with 10.5 mg tar (standard nicotine and tar yields of commercially available cigarettes; control condition)
2996366|NCT02587312|Experimental|Very Low Nicotine Content Cigarettes|SPECTRUM cigarette: 0.03 mg nicotine with 9 mg tar
2996367|NCT02587286|Experimental|Gather app|Use of the Gather mHealth diabetes management system
2996368|NCT02587286|No Intervention|Control|Control group participants will be recruited from the same clinics and will also fit all study inclusion and exclusion criteria. Participants will be recommended to test their BG as per usual care in India. Providers will not contact control group participants between regular visits, though they will respond to queries directed at them in typical fashion.
2996369|NCT02587273|Other|Fentanyl|This is a pharmacokinetics study with a single arm. All participants will will undergo the intervention described under the intervention section
2996370|NCT02587260|Active Comparator|Sequence I|Ticagrelor in the period I Prasugrel in the period II Clopidogrel in the period III
2996371|NCT02587260|Active Comparator|Sequence II|Ticagrelor in the period I Clopidogrel in the period II Prasugrel in the period III
2996372|NCT02587260|Active Comparator|Sequence III|Prasugrel in the period I Ticagrelor in the period II Clopidogrel in the period III
2996373|NCT02587260|Active Comparator|Sequence IV|Prasugrel in the period I Clopidogrel in the period II Ticagrelor in the period III
2996374|NCT02587260|Active Comparator|Sequence V|Clopidogrel in the period I Ticagrelor in the period II Prasugrel in the period III
2996375|NCT02587260|Active Comparator|Sequence VI|Clopidogrel in the period I Prasugrel in the period II Ticagrelor in the period III
2996376|NCT02587234|Experimental|Active|2 hours of active peripheral nerve stimulation paired with 4 hours of intensive task-oriented upper extremity training
2996377|NCT02587234|Sham Comparator|Sham PNS|2 hours of sham peripheral nerve stimulation paired with 4 hours of intensive task-oriented upper extremity training
2996378|NCT02587221|Experimental|aQIV|MF59-adjuvanted Quadrivalent Influenza Vaccine (aQIV)
2996379|NCT02587221|Active Comparator|Non-influenza Comparator Vaccine|Non-influenza comparator vaccine
2996380|NCT02587208|Active Comparator|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
2996414|NCT02586948|Experimental|extracorporeal CO2 removal|extracorporeal CO2 removal initiated shortly after intubation, using the veno-venous Hemolung device
2996415|NCT02586935|Active Comparator|Tideglusib|
2996416|NCT02586935|Placebo Comparator|Placebo|
2996381|NCT02587208|Active Comparator|plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
2996382|NCT02587195|Experimental|Teriflunomide|Teriflunomide 14 mg Once Daily
2996383|NCT02587182|Experimental|Dry needling|Dry needling in the masseter and temporalis muscles
2996384|NCT02587169|Experimental|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
2996385|NCT02587156|Experimental|Meal serving at high dietary protein|Test the handling of meal-served protein when habituated to high dietary protein at an amount above 1.5 g protein/kg/day
2996386|NCT02587156|Active Comparator|Meal serving at low dietary protein|Test the handling of meal-served protein when habituated to high dietary protein at an amount below 0.8 g protein/kg/day
2996387|NCT02587143|Active Comparator|Control|Alcohol -based spray as placebo will be administrated before arterial puncture.
2996388|NCT02587143|Experimental|Ethyl chloride|Ethyl choride will be administrated before arterial puncture.
2996389|NCT02587130|Experimental|communicating and none-communicating patients|20 communicating patients (evaluated with the visual analogue pain scale (VAS)) and 20 none-communicating patients or patients presenting cognitive disturbance or vigilance (evaluated with the Algoplus scale)
2996390|NCT02587117|Experimental|lycopene group|Lycopene- 4 mg capsule by mouth single dose per day for 2 months
2996391|NCT02587117|Active Comparator|Prednisolone group|Prednisolone- 40 mg capsule by mouth single dose per day for 2 months
2996392|NCT02587104|Experimental|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
2996393|NCT02587091|No Intervention|Control Arm|In this arm communities were told by word of mouth advertisement that a comprehensive antenatal care clinic would be held. There was no advertisement of portable ultrasound.
2996394|NCT02587091|Experimental|Intervention Arm|In this arm communities were told by word of mouth advertisement that a comprehensive antenatal care clinic would be held. In addition, it was advertised that portable ultrasound would be provided free of charge in addition to standard comprehensive antenatal care.
2996395|NCT02587078|Active Comparator|Volulyte|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
2996396|NCT02587078|Active Comparator|Jonosteril|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
2996397|NCT02587065|Experimental|peginterferon beta-1a|125 μg administered subcutaneously (SC) every 2 weeks
2996398|NCT02587052||Tacrolimus|100 patients treated with generic tacrolimus
2996399|NCT02587052||Prograf|100 patients treated with Prograf
2996400|NCT02587039|Placebo Comparator|Control: Usual care|This group will receive usual care and delirium assessments.
2996401|NCT02587039|Experimental|Treatment: Ischemic Pre-conditioning|Remote Ischemic pre-conditioning before cardiac surgery and delirium assessments.
2996402|NCT02587013|Experimental|In situ uterine repair|The uterus is repaired in situ within the abdominal cavity, without exteriorization; intra-abdominal repair
2996403|NCT02587013|Active Comparator|Exteriorization of the uterus|The uterine incision is repaired with the exteriorization of the uterus; extra-abdominal repair
2996404|NCT02587000|Active Comparator|Ulipristal acetate|ESMYA® : 2 tablets of 5mg per day during 3 months, per os
2996405|NCT02587000|Placebo Comparator|Placebo|2 tablets of 5mg per day during 3 months, per os
2996406|NCT02586987|Experimental|Dose escalation: Selumetinib+MEDI4736|"An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736. 4 cohorts of double combination (Selumetinib+MEDI4736).~The decision to escalate to the next dose level/cohort will be made by the Safety Review Committee (SRC) following the completion of the dose limiting toxicity (DLT) assessment period for at least 3 evaluable patients in each cohort."
2996407|NCT02586987|Experimental|Mandatory paired biopsy expansion cohort: Selumetinib+MEDI4736|One or more independent mandatory paired biopsy expansion cohorts for double combination treatment will start after safety and tolerability have been established for the relevant dose. It will be tumour-type specific for double combination, the tumor type will be determined from emerging data.
2996408|NCT02586987|Experimental|Dose escalation: Selumetinib+MEDI4736+tremelimumab|"An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736 and an IV dose of tremelimumab.~For triple combination treatment, the starting dose of selumetinib (DL1) will be determined by the SRC based on emerging data from dose escalation cohorts of double combination treatment."
2996409|NCT02586987|Experimental|Mandatory paired biopsy expansion cohort: triple combination|One or more independent mandatory paired biopsy expansion cohorts for triple combination treatment will start after safety and tolerability have been established for the relevant dose. It will be tumour-type specific for triple combination, the tumor type will be determined from emerging data.
2996410|NCT02586974|Experimental|Group H+WB|32 patients will receive warmed, humidified CO2 insufflation with the Humigard® device, along with the hot air warming blanket used as a routine in our institution (forced air warming blanket at 38°C : Bear Hugger®)
2996411|NCT02586974|No Intervention|Group WB|32 patients will receive standard CO2 insufflation, along with the hot air warming blanket used as a routine in our institution (forced air warming blanket at 38°C : Bear Hugger® and a standard insufflation with non-humidified, non-heated CO2)
2996412|NCT02586961|Placebo Comparator|0.9% saline solution - oral betamethasone placebo|Control arm: 0.9% saline solution - oral betamethasone placebo
2996413|NCT02586961|Experimental|adrenaline - oral betamethasone|Experimental arm : adrenaline and betamethasone
3024651|NCT02398188|Experimental|LIPO-202|Experimental arm
2996417|NCT02586909|Experimental|RVT-101 35 mg tablets|once daily, oral tablets
2996418|NCT02586896|Experimental|Strengths-based Case Management (SBCM)|The structure of SBCM follows the widely accepted functions of case management—assessment, planning, linking, monitoring and advocacy—and the theory-driven gestalt of the strengths perspective. Strengths-based principles include an emphasis on client strengths, teaching clients a method for setting and completing goals, and development of a strong working alliance.
2996419|NCT02586896|Active Comparator|Screening, Assessment and Referral (SAR)|Following randomization, participants in the SAR condition will be provided with minimal scripted feedback to let them know that their assessment indicates substance dependence, and given a recommendation to seek treatment.
2996420|NCT02586883|Experimental|Patients with multiple bronchi dilations|
2996421|NCT02586883|Active Comparator|Control patients without transport abnormality|
2996422|NCT02586883|Active Comparator|Patients with typical cystic fibrosis|
2996423|NCT02586857|Experimental|Cohort 1|ACP-196 200mg administered PO BID
2996424|NCT02586844||Neuroendocrine tumors (NETs)|Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.
2996425|NCT02586844||panNETs|Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.
2996426|NCT02586831|Active Comparator|Arm A|"The treatment arm A includes commercially available drugs approved for other indications:~Anti-Thymocyte Globulin (ATG or Thymoglobulin®) will be administered at a dose of 2.5mg/kg as two divided IV infusions of 0.5mg/kg and 2mg/kg (day 0 and 1).~Pegylated GCSF (Neulasta®) will be administered at a dose of 6mg SC every two weeks for a total of 6 doses (Day 2, 14, 28, 42, 56, and 70).~Low-dose Interleukin 2 (Aldesleukin; IL-2 or Proleukin®), 1 million IU/dose will be given SC for 5 consecutive days (days 10-14), and then every two weeks.~Etanercept (Enbrel®) will be administered at a dose of 25 mg SC weekly up to 52 weeks.~Exenatide (Bydureon®): 2 mg SC weekly up to 52 weeks; Adjust according to symptoms."
2996427|NCT02586831|Placebo Comparator|Arm B|The subjects randomized in Arm B (control group) will receive respective placebos in a blinded fashion.
2996428|NCT02586818||Normal|SOC fingerstick and venous blood draw for subject not on anticoagulation medications.
2996429|NCT02586818||Therapeutic|SOC fingerstick and venous blood draw for subjects who are indicated for and have been on anticoagulation medications for greater than or equal to 3 months. Results from this study will be used solely for research purposes and will not be used for anticoagulation management of study subjects. No patient follow up is required.
2996430|NCT02586805|Experimental|DX-2930 300 mg every 2 weeks|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
2996431|NCT02586805|Experimental|DX-2930 300 mg every 4 weeks|300 mg DX-2930 administered every 4 weeks by subcutaneous injection
2996432|NCT02586805|Experimental|DX-2930 150 mg every 4 weeks|150 mg DX-2930 administered every 4 weeks by subcutaneous injection
2996433|NCT02586805|Placebo Comparator|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
2996434|NCT02586792|Experimental|Group 2|N up to 10 in prior receipt of a placebo in DMID Protocol 07-0023 will receive 45 mcg of HA/0.75 ml of Monovalent inactivated influenza A/H7N9 virus vaccine
2996435|NCT02586792|Experimental|Group 1|N up to 40 in prior receipt of a monovalent inactivated influenza A/H7N7 virus vaccine in DMID Protocol 07-0023 will receive 45 mcg of HA/0.75 ml of Monovalent inactivated influenza A/H7N9 virus vaccine
2996436|NCT02586779|Experimental|whatsApp messages|consultations in the experimental group will be generated with whatsApp. Patients' all radiographies, laboratory results, electrocardiographs, tomography images, wound images and/or extremity pictures will be sent to consultant physician via whatsApp.
2996437|NCT02586779|Other|control group|consultations in the control group will be generated without whatsApp.
2996438|NCT02586766|Experimental|Behavioral: Project Sync|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care
2996439|NCT02586766|No Intervention|Comparison Group|This group did not receive an intervention, but did receive an informational pamphlet of resources in the area (enhanced usual care).
2996440|NCT02586753|Experimental|Paclitaxel plus Cisplatin with radiotherapy|patients will receive concurrent chemoradiotherapy with drug Paclitaxel plus Cisplatin
2996441|NCT02586753|Experimental|S1 plus Cisplatin with radiotherapy|patients will receive concurrent chemoradiotherapy with drug S1 plus Cisplatin
2996442|NCT02586740||Pulmonary artery rehabilitation|Patients with pulmonary artery stenosis or small pulmonary arteries following surgical repair for tetralogy of Fallot with pulmonary atresia and major aortopulmonary collaterals undergoing cardiac catheterization.
2996443|NCT02586727|Active Comparator|six week dosing regimen arm|Patients will receive an intravitreal aflibercept injection the first visit, and then again every six weeks. Treatment will be given at each visit.
2996444|NCT02586727|Active Comparator|treat and extend dosing regimen arm|Patients will receive an intravitreal aflibercept injection the first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward. Patients with decreased radiation maculopathy by one grade or more will extend re-evaluation by two weeks. Patients with increased radiation maculopathy by one grade or more will have re-evaluation decreased by one week. Patients that show no maculopathy grade change will remain at the same re-evaluation interval.
2996445|NCT02586714||Normal weight|
2996446|NCT02586714||Overweight|
2996447|NCT02586714||Obese|
2996448|NCT02586701|Active Comparator|Prehabilitation Plus|Patients in this group will be enrolled in a multimodal program before surgery involving supervised exercise, nutrition counseling and relaxation strategies. Supervised exercise is provided once a week for four weeks before surgery as well as during the hospital stay post surgery. Patients are to continue with a home-based exercise program for 8 weeks after discharge.
2996449|NCT02586701|No Intervention|Rehabilitation|Patients in this group are provided with in-hospital supervised exercises with a kinesiologist post surgery until discharge. Patients, upon discharge are provided with a home-based exercise program, nutritional counseling and relaxation strategies for 8 weeks.
2996613|NCT02585622|Experimental|Bone marrow-derived Mesenchymal Stromal Cells|
2996450|NCT02586688|Active Comparator|Phase I TMS Active|Blinded Active TMS coil (Phase I). Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
2996451|NCT02586688|Sham Comparator|Phase I TMS Sham|Blinded Sham TMS coil (Phase I) Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)
2996452|NCT02586688|Other|Phase II Open Label Active TMS|Open label active TMS coil. Open label active NeuroStar® TMS.
2996453|NCT02586688|Other|Phase III Long-Term Follow up TMS Active|Long term follow up with open label active TMS for retreatment as needed. Open label active NeuroStar® TMS.
2996454|NCT02586675|Experimental|Tamoxifen and Ribociclib with Goserelin|Phase I dose escalation followed by Phase Ib dose expansion. Tamoxifen and Ribociclib, with Goserelin added for premenopausal or peri-menopausal participants. Ribociclib: Capsules/Tablets for oral use 400 mg OR 600 mg Days 1-21 of each 28 day cycle or daily. Tamoxifen: Tablets for oral use 20 mg daily (all days of every cycle without interruption). Goserelin: Subcutaneous injection 3.6 mg Day 1 of each 28 day cycle.
2996455|NCT02586649|Experimental|Tiotropium Bromide group|The study participants will be randomly assigned to receive Tiotropium bromide,single dose (inhalation capsule - 18 mcg) over the course of 24 hours on day one of visit 1 or during visit 3.On the day of the first scheduled visit ( visit 1 ),study participants will be asked to arrive between 12-1 pm at the pulmonary laboratory at the JJPVAMC (7A-13). Baseline blood pressure (BP) and heart rate (HR) measurements will be obtained prior to drug administration. Tiotropium bromide capsule containing active ingredients will be orally inhaled through a SPIRIVA HandiHaler. Measurements of exhaled nitric oxide, pulmonary function ( spirometry , static lung volumes and specific airway conductance) will be performed at 20 and 24 hours. The same schedule will be followed for visits 3 and 4;vists 3 and 4 will be scheduled between 14 and 21 days after visit 2.
2996456|NCT02586649|Placebo Comparator|Placebo|The study participants will be randomly assigned to receive placebo , single dose (inhalation capsule - 18 mcg) over the course of 24 hours on day one of visit 1 or during visit 3.On the day of the first scheduled visit ( visit 1 ),study participants will be asked to arrive between 12-1 pm at the pulmonary laboratory at the JJPVAMC (7A-13). Baseline blood pressure (BP) and heart rate (HR) measurements will be obtained prior to drug administration. Placebo capsule containing active ingredients will be orally inhaled through a SPIRIVA HandiHaler. Measurements of exhaled nitric oxide, pulmonary function ( spirometry , static lung volumes and specific airway conductance) will be performed at 20 and 24 hours. The same schedule will be followed for visits 3 and 4;vists 3 and 4 will be scheduled between 14 and 21 days after visit 2.
2996457|NCT02586636|Other|OCT1 -/-|Cohort of patients with two loss of function alleles for OCT1. The participants within this group will receive metformin at increasing dose to a maximum tolerated dose over two distinct four week treatment periods. The concurrent treatment order of omeprazole and placebo will be randomised within the cohort.
2996458|NCT02586636|Other|OCT wt/wt|"Cohort of patients with two normal or wild type alleles for OCT1. The participants within this group will receive metformin at increasing dose to a maximum tolerated dose over two distinct four week treatment periods. The concurrent treatment order of omeprazole and placebo will be randomised within the cohort."
2996459|NCT02586623|Experimental|Droxidopa capsules|100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally (equal to patients individual dose at the end of the Open-Label Period). During the Titration Period and Open-Label Period, patients will receive 100, 200, 300, 400, 500, or 600 mg TID of droxidopa, orally.
2996460|NCT02586623|Experimental|Placebo capsules|Matching placebo three times daily orally
2996461|NCT02586610|Experimental|Neoadjuvant Treatment|"All subjects will receive concurrent chemoradiation and pembrolizumab neoadjuvant treatment for 6 weeks:~Pembrolizumab 200 mg IV Days 1, 22 and 43~Capecitabine 825 mg/m2 PO in twice daily doses (total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days~Radiation therapy 50.4 GY. Daily fractions of 1.8 Gy over a 6 week interval, excludes weekends"
2996462|NCT02586597|Experimental|PAS 10: TMS and median nerve stimulation|Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation. The interval between median nerve stimulation and TMS was chosen to be 10 ms, which is called PAS10. PAS 10: TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
2996463|NCT02586597|Experimental|PAS 25:TMS and median nerve stimulation|PAS 25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. PAS 25:TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
2996464|NCT02586597|Sham Comparator|PAS100:TMS and median nerve stimulation|PAS Control Paradigm: The interval between median nerve stimulation and TMS was chosen to be 100 ms, which is called PAS100. PAS100:TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
2996465|NCT02586571||Exclusive Breastfeeding A|Mother/infant pairs with exclusive breastfeeding up to 6 months of age. Secondary outcome measure 2 (Metabolisable energy content of breast milk) measured in this group only.
2996466|NCT02586571||Exclusive Breastfeeding B|Mother/infant pairs with exclusive breastfeeding up to 6 months of age.
2996467|NCT02586571||Partial Breastfeeding|Mother/infant pairs with partial breastfeeding along with complementary foods at 6 months of age.
2996468|NCT02586558|Active Comparator|Experimental Infant Formula|Milk-based infant formula with prebiotics
2996469|NCT02586558|Placebo Comparator|Reference group|Milk-based infant formula without prebiotics
2996470|NCT02586545|Experimental|Shared care model|Four visits a year: one annual comprehensive check-up at the outpatient diabetes clinic and three quarterly visits at the general practitioner.
2996471|NCT02586545|No Intervention|Mono sectorial care|Treament as usual including four visits a year with the diabetes team at the outpatient clinic: an annual comprehensive check-up, identical to the one received by the intervention group, and three quarterly visits.
2996472|NCT02586519|Experimental|Active SurroSense Rx System + RCW|Patients randomized to the experimental group will be fitted with an active (alerting) version of the SurroSense R® smart insole System. This device will be placed in the RCW, underneath the liner. The device tab will be fed up the instep, through a hole in the liner, and affixed to the dorsum of the RCW by way of a tie.
2996473|NCT02586519|Sham Comparator|Inactive SurroSense Rx System + RCW|Patients randomized to this group will be fitted with an inactive (non-alerting) version of the device in an identical fashion.
2996614|NCT02585622|Placebo Comparator|Cryostor CS10|
2996474|NCT02586519|Sham Comparator|Inactive SurroSense Rx System + iTCC|Patients in this group will be fitted with an inactive (non-alerting) version of the device in an identical fashion. The RCW will be further secured using a device specific tie such that it acts as an iTCC.
2996475|NCT02586506|Experimental|Placebo ELLIPTA inhaler|Subjects will be provided the ELLIPTA inhaler, which is a molded plastic two-sided inhaler that holds two individual blister strips containing either lactose or a blend of lactose and magnesium stearate. Subjects will continue to use regular COPD medications throughout the study as per protocol.
2996476|NCT02586493|Experimental|Placebo ELLIPTA inhaler|Subjects will be provided the ELLIPTA inhaler, which is a molded plastic two-sided inhaler that holds two individual blister strips containing either lactose or a blend of lactose and magnesium stearate. Subjects will continue to use regular COPD medications throughout the study as per protocol.
2996477|NCT02586467|Experimental|Gain-Framed|Participants receive messages that highlight the potential benefits of engaging in a specific behaviour (i.e., what positive outcomes they could experience from consuming milk and milk products).
2996478|NCT02586467|Experimental|Loss-Framed|Participants receive messages that highlight the potentially loses of not engaging in a specific behaviour (i.e., what they could lose from not consuming milk and milk products).
2996479|NCT02586467|Experimental|Self-Regulatory Efficacy|Participants receive messages that provide them with tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.)
2996480|NCT02586467|Experimental|Gain-Framed + Self-Regulatory Efficacy|Participants receive messages that highlight the potential benefits of engaging in a specific behaviour (i.e., what positive outcomes they could experience from consuming milk and milk products) and these messages also provide tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.).
2996481|NCT02586467|Experimental|Loss-Framed + Self-Regulatory Efficacy|Participants receive messages that highlight the potentially loses of not engaging in a specific behaviour (i.e., what they could lose from not consuming milk and milk products) and these messages also provide tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.).
2996482|NCT02586454|Experimental|Transmuscular quadratus lumborum (QL) block|Bilateral QL block using 20 ml 0.375% ropivacaine in each side (to a maximum dose 3 mg/kg) plus patient controlled analgesia morphine (1mg/bolus morphine, lockout time 5 minutes) post operative
2996483|NCT02586454|Active Comparator|Control|Patient controlled analgesia morphine (1mg/bolus morphine, lockout time 5 minutes) post operative
2996484|NCT02586441|Experimental|Electroencephalography|"Standard monitoring included electrocardiogram, noninvasive arterial blood pressure, pulse oximetry, and BIS-VISTATM sensor at OR.~Raw EEG in a steady state was collected for 5 minutes.~Anesthesia was induced with intravenous 1% propofol (1.5-2.5 mg/kg) and rocuronium bromide (0.6 mg/kg)~Mechanical ventilation was initiated~Anesthesia was maintained with desflurane at an end-tidal concentration of 6-7 %, with a fraction of inspired oxygen of 0.5 (fresh gas flow; O2 1.5 L/min and air 2.5 L/min).~On completion of the surgery, all anesthetic gases were discontinued and the FiO2 was increased to 1.0.~After extubation, BIS-VISTA TM monitoring was stopped."
2996485|NCT02586415|Active Comparator|endovascular thrombectomy therapy|"Treatment with one or more thrombectomy devices (only the devices listed in this protocol are approved for use in DEFUSE 3) plus standard medical therapy for patients who have evidence of an ICA or MCA M1 occlusion and a Target Mismatch Profile.~Devices approved for use in DEFUSE 3:~Trevo Retriever~Solitaire™ FR Revascularization Device~Penumbra thrombectomy system~Covidien MindFrame Capture Revascularization Device"
2996486|NCT02586415|No Intervention|Medical Management|standard medical therapy alone
2996487|NCT02586402|Experimental|Pegolsihematide|Participants received Pegolsihematide by intravenous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
2996488|NCT02586402|Active Comparator|Epoetin Alfa|Epoetin Alfa administration 1 to 3 times per week. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
2996489|NCT02586389||Non-hematological Cancer Cohort|Eligible subjects will have been previously diagnosed with a non-hematological cancer with tumor present at baseline blood draw.
2996490|NCT02586376|Sham Comparator|0J LLLT|The intervention will be made with the machine off.
2996491|NCT02586376|Experimental|4J LLLT|The Laser radiation will be made with 4J by spot.
2996492|NCT02586376|Experimental|6J LLLT|The Laser radiation will be made with 6J by spot.
2996493|NCT02586376|Experimental|8J LLLT|The Laser radiation will be made with 8J by spot.
2996494|NCT02586363|Active Comparator|Baraclude Tab. 0.5mg, fasting|Single dose Baraclude Tab. 0.5mg, fasting state
2996495|NCT02586363|Experimental|Cavir Tab. 0.5mg, fasting|Single dose Cavir Tab. 0.5mg, fasting state
2996496|NCT02586363|Experimental|Cavir Tab. 0.5mg, high fatty meal|Single dose Cavir Tab. 0.5mg, high fatty meal
2996497|NCT02586350|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration. Subjects who received Anlotinib will not be eligible for the open-label phase.
2996498|NCT02586350|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration.
2996538|NCT02586077|Experimental|Exparel|Patients will receive a single shot popliteal block (standard of care) and then undergo their standardized procedure. Patients will then receive 20cc Exparel and 10cc of normal saline at the conclusion of the case.
2996539|NCT02586064|Experimental|IPT-PTSD|Relationally-focused intervention addressing PTSD symptoms and relationship dysfunctions, 12 weekly sessions
2996499|NCT02586337|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration. Subjects who received Anlotinib will not be eligible for the open-label phase.
2996500|NCT02586337|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration.
2996501|NCT02586324|Other|global medium|
2996502|NCT02586324|Experimental|SSM|
2996503|NCT02586311|Experimental|CKD-330 16/5mg + Amlodipine 5mg placebo|CKD-330 16/5mg + Amlodipine 5mg placebo, po, q.d.
2996504|NCT02586311|Active Comparator|CKD-330 16/5mg placebo + Amlodipine 5mg|CKD-330 16/5mg placebo + Amlodipine 5mg, po, q.d.
2996505|NCT02586298|Experimental|ICSI with mitochondria|Half of the Metaphase II oocytes retrieved after the controlled ovarian stimulation will be randomized to this group and autologous mitochondria from the patient's ovarian cortex will be introduced into the oocyte during the intracytoplasmic sperm injection in the vitro fertilization treatment.
2996506|NCT02586298|Active Comparator|Control ICSI without mitochondria|The other half of the metaphase II oocytes retrieved after the controlled ovarian stimulation will be randomized to this group and will not receive autologous mitochondria during the intracytoplasmic sperm injection (ICSI) in the vitro fertilization treatment. Control Group
2996507|NCT02586285|Active Comparator|S-Adenosyl Methionine Treatment|Patients will be treated with S-Adenosyl Methionine treatment after curative resection.
2996508|NCT02586285|No Intervention|Control group|Patients will be treated without S-Adenosyl Methionine treatment after curative resection.
2996509|NCT02586272|Experimental|Daifert|• Interventional Group: The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
2996510|NCT02586272|Other|Control Group|Control Group: The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
2996511|NCT02586259||Cortiment®|Treatment according to routine clinical practice.
2996512|NCT02586246|Experimental|CDP870 group from Study 275-08-002|Subjects with active rheumatoid arthritis who are participating in Study 275-08-002 of CDP870
2996513|NCT02586246|Experimental|CDP870 group from Study 275-08-004|Subjects with active rheumatoid arthritis who are participating in Study275-08-004 of CDP870
2996514|NCT02586233|Experimental|DS-1040b|Intravenous (IV) infusion of DS-1040b ranging from 0.6 mg to 9.6 mg of DS-1040b
2996515|NCT02586233|Placebo Comparator|Placebo|IV infusion of placebo
2996516|NCT02586220||normal pregnant women|150 normal pregnant women (28-32 weeks' gestation)
2996517|NCT02586220||pregnant women with gestational|100 pregnant women with gestational diabetes (28-32 weeks' gestation)
2996518|NCT02586207|Experimental|Single Arm|Pembrolizumab + Cisplatin + Radiation
2996519|NCT02586194|Experimental|Control (Subjects with normal hepatic function)|Oral
2996520|NCT02586194|Experimental|Mild hepatic impairment|Oral
2996521|NCT02586194|Experimental|Moderate hepatic impairment|Oral
2996522|NCT02586181|Placebo Comparator|Vitamin D and Calcium|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate"
2996523|NCT02586181|Experimental|Vitamin D, Calcium, Vitamins B9, B6, B12|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
2996524|NCT02586168|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
2996525|NCT02586168|Placebo Comparator|Placebo|Placebo
2996526|NCT02586155|Experimental|High-Intensity statin therapy+RVX000222|Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)
2996527|NCT02586155|Active Comparator|High-Intensity statin therapy+Placebo|Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)
2996528|NCT02586142|Experimental|Botulinum toxin type A(BTX-A) injection|To inject Botulinum toxin type A on the spasticity lower extremities for participants by ultrasounds guidance.
2996529|NCT02586142|Active Comparator|BTX-A injection plus stretching exercise|Inject Botulinum toxin type A on the spasticity lower extremity for participants by ultrasounds guidance. After injection, arrange them to receive stretching exercise in Kaoshiung Chang Gung Memorial Hospital 3 time per week for 3 months.
2996530|NCT02586129|Experimental|YH14755|PO, Once Daily, 16 weeks
2996531|NCT02586129|Active Comparator|Metformin|PO, Once Daily, 16 weeks
2996532|NCT02586129|Active Comparator|Rosuvastatin|PO, Once Daily, 16 weeks
2996533|NCT02586116|Active Comparator|nanOss|nanOss Cervical IBF System with nanOss BA Bone Void Filler
2996534|NCT02586116|Active Comparator|C-Plus|C-Plus PEEK IBF Device with autograft
2996535|NCT02586103||MRI|Patients who undergo simulated practice MRI on the day of or prior to their scheduled MRI.
2996536|NCT02586090|Active Comparator|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
2996537|NCT02586090|Experimental|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
2996540|NCT02586064|Active Comparator|PE|Exposure based intervention including exposure to memories and avoided places and activities
2996541|NCT02586051|Experimental|Cohort 1: Single Dose Obinutuzumab|"Desensitization period: Participants will receive obinutuzumab on Day 1 followed by high dose intravenous immunoglobulin (IVIG) on Days 22 and 43 of treatment period.~Transplantation period: Participants who are found to qualify for transplantation and receive a compatible kidney offer after inclusion will receive two additional infusions of obinutuzumab (one at the time of transplantation [within the first 48 hours of the transplantation] and second at Week 24 post-transplantation)."
2996542|NCT02586051|Experimental|Cohort 2: Repeated Dose Obinutuzumab|"Desensitization period: Participants will receive obinutuzumab on Days 1 and 15 followed by high dose IVIG on Days 22 and 43. An additional dose of obinutuzumab may be administered on Day 169 at investigator's discretion.~Transplantation period: Participants who are found to qualify for transplantation and receive a compatible kidney offer after inclusion will receive two additional infusions of obinutuzumab (one at the time of transplantation [within the first 48 hours of the transplantation] and second at Week 24 post-transplantation)."
2996543|NCT02586038|Experimental|MLN-DEX arm|"Patients will receive nine 28-days induction cycles.~MLN9708: 4,0 mg orally on days 1, 8, 15 Dexamethasone: 40 mg orally on days 1, 8, 15, 22."
2996544|NCT02586038|Experimental|MLN-DEX-CYCLO arm|"Patients will receive nine 28-days induction cycles.~MLN9708: 4,0 mg orally on days 1, 8, 15 Dexamethasone: 40 mg orally on days 1, 8, 15, 22. Cyclophosphamide: 300 mg/sqm orally on days 1, 8, 15"
2996545|NCT02586038|Experimental|MLN-DEX-THAL arm|"Patients will receive nine 28-days induction cycles.~MLN9708: 4,0 mg orally on days 1, 8, 15 Dexamethasone: 40 mg orally on days 1, 8, 15, 22. Thalidomide: 100 mg/day orally"
2996546|NCT02586025|Experimental|Trastuzumab, Pertuzumab, Docetaxel|Prior to surgery: trastuzumab, pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC): trastuzumab and pertuzumab up to 1 year total.
2996547|NCT02586025|Experimental|Trastuzumab, Placebo, Docetaxel|Prior to surgery: trastuzumab, placebo, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/FEC chemotherapy: trastuzumab and placebo up to 1 year total.
2996548|NCT02586012|Experimental|TBW, LBM, IBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on TBW (Total Body Weight); Week 2, the dose will be based on LBM (Lean Body Mass); and Week 3, the dose will be based on IBW (Ideal Body Weight).
2996549|NCT02586012|Experimental|LBM, IBW, TBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on LBM (Lean Body Mass); Week 2, the dose will be based on IBW (Ideal Body Weight); and Week 3, the dose will be based on TBW (Total Body Weight).
2996550|NCT02586012|Experimental|IBW, TBW, LBM|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on IBW (Ideal Body Weight); Week 2, the dose will be based on TBW (Total Body Weight); and Week 3, the dose will be based on LBM (Lean Body Mass).
2996551|NCT02586012|Experimental|TBW, IBW, LBM|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on TBW (Total Body Weight); Week 2, the dose will be based on IBW (Ideal Body Weight); and Week 3, the dose will be based on LBM (Lean Body Mass).
2996552|NCT02586012|Experimental|LBM, TBW, IBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on LBM (Lean Body Mass); Week 2, the dose will be based on TBW (Total Body Weight); and Week 3, the dose will be based on IBW (Ideal Body Weight).
2996553|NCT02586012|Experimental|IBW, LBM, TBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on, IBW (Ideal Body Weight); Week 2, the dose will be based on LBM (Lean Body Mass); and Week 3, the dose will be based on TBW (Total Body Weight).
2996554|NCT02585999|Other|Xulane|All participants using the Xulane contraceptive patch for 12 continuous weeks
2996555|NCT02585986|Active Comparator|Probiotic|daily intake of 1 capsule containing probiotic.
2996556|NCT02585986|Placebo Comparator|Placebo|daily intake of 1 capsule containing placebo
2996557|NCT02585973|Other|open label, single-arm, Phase 1b|AZD1775 when added to standard of care concomitant chemotherapy (cisplatin) and radiation
2996558|NCT02585960|Experimental|Pharmacokinetic (PK) evaluation of BAX 855|Participants will first undergo an initial pharmacokinetic (PK) assessment. Following the PK assessment participants will be randomized to one of 2 dosing regimens.
2996559|NCT02585960|Experimental|Twice Weekly Dosing|Standard treatment arm
2996560|NCT02585960|Experimental|Every Other Day Dosing|Intensified treatment arm
2996561|NCT02585947|Experimental|tenofovir for 24 weeks|"prophylactic (preemptive) treatment~300mg for 24 weeks~once daily"
2996562|NCT02585947|Experimental|tenofovir for 48 weeks|"prophylactic (preemptive) treatment~300mg for 48 weeks~once daily"
2996563|NCT02585934|Experimental|RVT-101|RVT-101 adjunct to 5 mg or 10 mg donepezil
2996564|NCT02585934|Placebo Comparator|Placebo|Placebo adjunct to 5 mg or 10 mg donepezil
2996565|NCT02585921|No Intervention|Health & Wellness|Following enrollment, participants will learn about health and wellness.
2996566|NCT02585921|Experimental|Organ Donation Video Education|Following recruitment, participants will watch and discuss videos about organ donation.
2996567|NCT02585921|Experimental|Organ Donation Discussion Education|Following recruitment, participants will learn techniques to introduce and discuss the topic of organ donation with parents or guardians.
2996568|NCT02585921|Experimental|Both Video and Discussion Education|Following recruitment, participants will watch and discuss videos about organ donation and then learn techniques to introduce and discuss the topic of organ donation with parents and guardians.
2996569|NCT02585908|No Intervention|Experimental Group A(control group)|regular treatment and follow up
2996570|NCT02585908|Experimental|Experimental Group B|CIK will be used against tumor cells.
2996571|NCT02585908|Experimental|Experimental Group C|γδ T will be used against tumor cells.
2996572|NCT02585908|Experimental|Experimental Group D|CIK and γδ T will be used against tumor cells.
2996610|NCT02585648|Experimental|Patients with dry eye syndrome 2|20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1
2996611|NCT02585635||Families|Families of children with haemophilia
2996573|NCT02585895|Experimental|Evolocumab|Participants received 140 mg evolocumab every 2 weeks (Q2W) administered by subcutaneous injection for 6 weeks during the primary period of the study. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
2996574|NCT02585895|Active Comparator|Low Density Lipoprotein Cholesterol (LDL-C) Apheresis|Participants continued apheresis at the same schedule, every week (QW) or every two weeks (Q2W), as prior to study entry, for the first 6 weeks. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
2996575|NCT02585882|Experimental|Communal preschool feeding with fluoridated salt|"According to the allocation concealment, subjects of the test group were preschool children at the Kindergarten Wattenscheid in Gambia, Brikama-Kabafita, West Coast Region, The Gambia."
2996576|NCT02585882|No Intervention|Communal preschool feeding with no fluoridated salt|"Subjects of the control group were preschool children at the Kindergarten Bottrop in Gambia, Brikama, West Coast Region, The Gambia."
2996577|NCT02585869|Experimental|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
2996578|NCT02585869|Experimental|Gemcabene 300 mg|Gemcabene 300 mg once daily (QD)
2996579|NCT02585869|Experimental|Gemcabene 600 mg|Gemcabene 600 mg once daily (QD)
2996580|NCT02585869|Experimental|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
2996581|NCT02585869|Placebo Comparator|Placebo|Placebo once daily (QD)
2996582|NCT02585856|Experimental|PDT+stent|Patients with unresectable CCA are performed PDT and biliary stent with ERCP
2996583|NCT02585856|Placebo Comparator|stent|Patients with unresectable CCA are performed biliary stent with ERCP alone
2996584|NCT02585843|Experimental|High-dose|Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
2996585|NCT02585843|Active Comparator|Standard of Care|Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)
2996586|NCT02585817|Experimental|Remote CIED Management|Patients with a CIED will undergo remote monitoring with information technology.
2996587|NCT02585804|Experimental|Dapagliflozin (trade name Farxiga®)|Oral tablet, 10mg, PO, 8 weeks
2996588|NCT02585791|Experimental|vape NFEC containing 100% PG|Subjects will then be instructed how to use the NFEC (eGo-T® with light emitting diode (LED) display) for 1 week of regularly vaping NFEC containing 100% Propylene Glycol . Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 mAh battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to ~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
2996589|NCT02585791|Experimental|vape 100% vegetable glycerin -VG|Subjects will then be instructed how to use the NFEC (eGo-T® with LED display) for 1 week of regularly vaping NFEC containing 100% VG. Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 mAh battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to ~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
2996590|NCT02585791|Experimental|vape PG+VG|Subjects will then be instructed how to use the NFEC (eGo-T® with LED display) for 1 week of regularly vaping NFEC containing 50% PG and 50% VG. Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 milliamp hours (mAh) battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to ~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
2996591|NCT02585778|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to stable, maximally tolerated dose of statin therapy with or without other lipid-modifying therapy (LMT), insulin alone or with other antihyperglycemic drugs for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
2996592|NCT02585778|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) SC injection Q2W added to stable, maximally tolerated dose of statin therapy with or without other LMT, insulin alone or with other antihyperglycemic drugs for 24 weeks.
2996593|NCT02585765|Experimental|Pioglitazone|Subjects will receive 8 weeks of daily pioglitazone (30mg/day).
2996594|NCT02585765|Placebo Comparator|Placebo|Subjects will receive 8 weeks of daily placebo capsules.
2996595|NCT02585752|Experimental|Single centre, single arm|Noninvasive ventilation with expiratory modulation. Assessment of comfort and blood gases.
2996596|NCT02585739|Experimental|patient|patient with Cluster headache
2996597|NCT02585739|Other|healthy subject|patient without Cluster headache
2996598|NCT02585726|Active Comparator|Historical Control with Propensity Analysis|
2996599|NCT02585726|Experimental|VenaSeal Treatment Arm|
2996600|NCT02585713|Experimental|Arm I (apixaban)|Patients receive apixaban 10 mg PO BID on days 1-7 and lower-dose apixaban 5 mg PO BID on days 8-180.
2996601|NCT02585713|Experimental|Arm II (dalteparin)|Patients receive dalteparin 200 IU/kg/day SC QD on days 1-30 and lower-dose dalteparin 150 IU/kg/day SC QD on days 31-180.
2996602|NCT02585700|Experimental|Influenza Vaccine Split, Inactivated|"0.5 mL of influenza vaccine, split, inactivated with 15 mcg of HA of each of 3 strains:~NYMC BX-51B reassortant of B/Massachusetts/2/2012~X-181 reassortant of H1/A/California/7/2009~X-223A reassortant of H3/A/Texas/50/2012."
2996603|NCT02585700|Placebo Comparator|Phosphate buffered saline|0.5 mL of phosphate buffered saline
2996604|NCT02585687|Experimental|liver Perfusion MRI|liver perfusion MRI will be performed in patients to assess the early response (7 days) to antiangiogenic treatments
2996605|NCT02585674|Experimental|MyStar DoseCoach|MyStar DoseCoach - Device-supported treat-to-target regimen. Insulin glargine is administered subcutaneously on top of potential background therapy using oral anti-diabetic drug(s) or GLP1 RA injectable antihyperglycemic drug(s).
2996606|NCT02585674|Active Comparator|Routine Titration|Routine Titration - Routine titration defined by the Investigator. Insulin glargine is administered subcutaneously on top of potential background therapy using oral anti-diabetic drug(s) or GLP1 RA injectable antihyperglycemic drug(s).
2996607|NCT02585661|Active Comparator|Dairy product + Salt 1|Dairy product fortified with enriched Fe-54 salt (1)
2996608|NCT02585661|Experimental|Dairy product + Salt 2|Dairy product fortified with enriched Fe-57 salt (2)
2996609|NCT02585648|Experimental|Patients with dry eye syndrome 1|20 patients with dry eye syndrome, they will receive intervention 1 for one week and then cross over to intervention 2
2996615|NCT02585596|Experimental|YH23537 1000mg/day|YH23537 500mg 1 tab, placebo 500mg 2tab twice a day (before morning,evening meal) during 12 weeks
2996616|NCT02585596|Experimental|YH23537 2000mg/day|YH23537 500mg 2tab, placebo 500mg 1tab twice day (before morning,evening meal) during 12 weeks
2996617|NCT02585596|Experimental|YH23537 3000mg/day|YH23537 500mg 3tab a day twice day (before morning,evening meal) during 12 weeks
2996618|NCT02585596|Experimental|YH23537 3000mg/day loading 1000mg/day|YH23537 500mg 3tab twice a day (before morning,evening meal) during 4weeks and YH23537 500mg tab twice a day (before morning,evening meal) during 8weeks
2996619|NCT02585596|Placebo Comparator|Placebo|YH23537 500mg placebo 3tab twice a day
2996620|NCT02585583|Other|Radiosurgical thalamotomy|Patients will undergo to radiosurgical thalamotomy by Cyberknife system.
2996621|NCT02585570|Experimental|Low dose phenylephrine|phenylephrine 0.5 mcg/kg/min
2996622|NCT02585570|Experimental|High dose phenylephrine|phenylephrine 1.0 mcg/kg/min .
2996623|NCT02585570|No Intervention|Normal saline|normal saline for 5minutes
2996624|NCT02585557|Experimental|Cluster A|50 practices randomly assigned to start intervention at month 9. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
2996625|NCT02585557|Experimental|Cluster B|50 practices randomly assigned to start intervention at month 11. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
2996626|NCT02585557|Experimental|Cluster C|50 practices randomly assigned to start intervention at month 12. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
2996627|NCT02585557|Experimental|Cluster D|50 practices randomly assigned to start intervention at month 14. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
2996628|NCT02585557|Experimental|Cluster E|50 practices randomly assigned to start intervention at month 16. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
2996629|NCT02585544|Other|Genital prolapse|Single arm: i.e., all patients
2996630|NCT02585531|Experimental|HS3% group|Administration of nebulized hypertonic saline for 4 days. Hypertonic Saline 3% 3 ml.
2996631|NCT02585531|Active Comparator|ED group|Administration of nebulized epinephrine and dexamethasone for 4 days. Epinephrine 1:1000 solution. Dexamethasone solution 8mg/2ml.
2996632|NCT02585518||Obese|Children and adolescents with a BMI at or above the 85th percentile for age and sex
2996633|NCT02585518||Healthy control|Children and adolescents with a BMI below the 85th percentile for age and sex
2996634|NCT02585505|Active Comparator|Intravenous|stem cells will be injected through intravenously in the subjects
2996635|NCT02585505|Active Comparator|superior pancreaticoduodenal|stem cells
2996636|NCT02585505|Active Comparator|splenic artery|stem cells will be injected through splenic in the subjects
2996637|NCT02585492|Active Comparator|head-of-bed elevated 15°|Mother's head-of-bead elevated 15°. Intervention: Head-of-bed elevated 15° during 2 hours after the delivery.
2996638|NCT02585492|Experimental|head-of-bed elevated 45°|Mother's head-of-bead elevated 45°. Intervention: Head-of-bed elevated 45°during 2 hours after delivery.
2996639|NCT02585479|Experimental|systemic chemotherapy|Pirarubicin 30mg/m2 intravenously on Day 1 and Oxaliplatin 100 mg/m2 intravenously on Day 2 every 3 weeks until disease progression or limiting toxicity.
2996640|NCT02585479|Active Comparator|Transcatheter Arterial Chemoembolization|Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using Gelfoam every 4 weeks until disease progression or limiting toxicity.
2996641|NCT02585466||BIS25|BIS 25 levels were subsequently maintained via propofol TCI 0.2 microg mL-1 TCI adjustments. Stable BIS values that showed no further decline and remained within BIS ±5 ofBIS 25 of the previous BIS value were considered an indicator of pseudo-steady state plasma effect-site equilibration
2996642|NCT02585466||BIS50|BIS 50 levels were subsequently maintained via propofol TCI 0.2 microg mL-1 TCI adjustments. Stable BIS values that showed no further decline and remained within BIS ±5 of either BIS 50 levels of the previous BIS value were considered an indicator of pseudo-steady state plasma effect-site equilibration
2996643|NCT02585453|Experimental|Patients with dry eye syndrome 1|20 Patients with dry eye syndrome
2996644|NCT02585453|Active Comparator|Patients with dry eye syndrome 2|20 Patients with dry eye syndrome
2996645|NCT02585453|Active Comparator|Patients with dry eye syndrome 3|20 Patients with dry eye syndrome
2996646|NCT02585440|Experimental|Group A|CMX157, tablet, 5 mg, QD, 14 days versus CMX157 placebo, 5 mg, tablet, QD, 14 days
2996647|NCT02585440|Experimental|Group B|CMX157, tablet, 10 mg, QD, 14 days versus CMX157, placebo tablet, 10 mg, QD, 14 days
2996648|NCT02585440|Experimental|Group C|CMX157, tablet, 25 mg, QD, 14 days versus placebo CMX157, placebo tablet, 25 mg, QD, 14 days
2996649|NCT02585440|Experimental|Group D|CMX157, tablet, 50 mg, QD, 14 days versus CMX157, placebo tablet, 50 mg, QD, 14 days
2996650|NCT02585440|Experimental|Group E|CMX157, tablet, 100 mg, QD, 14 days versus CMX157, placebo tablet, 100 mg, QD, 14 days
2996651|NCT02585427|Experimental|low glycemic index rice with butter|50 g available low glycemic index rice cooked with 48 g butter ( equal 40 g saturated fatty acid)
2996652|NCT02585427|Experimental|low glycemic index rice with olive oil|50 g available low glycemic index rice cooked with 44 g olive oil ( equal 40 g monounsaturated fatty acid)
2996653|NCT02585427|Experimental|low glycemic index rice with grapeseed oil|50 g available low glycemic index rice cooked with 40 g grapeseed oil ( equal 40 g polyunsaturated fatty acid)
2996654|NCT02585427|Experimental|high glycemic index rice with butter|50 g available high glycemic index rice cooked with 48 g butter ( equal 40 g saturated fatty acid)
2996655|NCT02585427|Experimental|high glycemic index rice with olive oil|50 g available high glycemic index rice cooked with 44 g olive oil ( equal 40 g monounsaturated fatty acid)
2996656|NCT02585427|Experimental|high glycemic index rice with grapeseed oil|50 g available high glycemic index rice cooked with 40 g grapeseed oil ( equal 40 g polyunsaturated fatty acid)
2996659|NCT02585401||Eylea product and application information / Cohort 1|Physicians prescribing aflibercept in Canada will be selected to reflect the distribution of retinal specialists and ophthalmologists who prescribe aflibercept.
2996660|NCT02585388|Active Comparator|Vinorelbine|Vinorelbine (metronomic) alone 3 times per week ( mondays, wednesdays, Fridays or Thursdays, Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.
2996661|NCT02585388|Experimental|Vinorelbine+Anastrozole or Letrozole|"Vinorelbine metronomic 3 times per week (mondays, wednesdays, Fridays or Thursdays,Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.~And:~Letrozole 2,5 mg every day or Anastrozole 1 mg every day. Until progression of disease or toxicity"
2996662|NCT02585375|Experimental|Patients with glaucoma or ocular hypertension 1|35 patients with glaucoma or ocular hypertension
2996663|NCT02585375|Active Comparator|Patients with glaucoma or ocular hypertension 2|35 patients with glaucoma or ocular hypertension
2996664|NCT02585362|Active Comparator|Intervention group|Participants will receive physical exercise, nutrition counseling and a whey protein Supplement over 12 weeks
2996665|NCT02585362|No Intervention|Control group|Participants will receive standard care
2996666|NCT02585349||First-ever and recurrent ischemic and hemorrhagic stroke|First-ever and recurrent ischemic and hemorrhagic stroke patients are enrolled in the study. Recurrent strokes are only included if the patient is fully recovered from the previous event, which occurred at least 3 years ago, without obvious residual symptoms.
2996667|NCT02585336|No Intervention|Observation|
2996668|NCT02585336|Experimental|Brief intervention|
2996669|NCT02585323|Active Comparator|Immediate Intervention Group|Education session, Fitbit/FitViz, PT counselling: Participants receive this intervention in Months 1-3. The session will include a presentation on physical activity, an individual goal-setting session with a registered physiotherapist, and an orientation to the Fitbit Flex and the FitViz app. In Months 1 and 2, participants will use the Fitbit/FitViz. The PT will review the progress with participants via 20-minute bi-weekly phone calls, and progressively modify their activities. In Month 3, participants will continue using the Fitbit/FitViz and have access to a PT via email as needed, but no bi-weekly phone calls. In Months 4-9, participants may continue using the Fitbit/FitViz without access to a PT.
2996670|NCT02585323|Placebo Comparator|Delayed Intervention Group|Same intervention with a 3 month delay: The full intervention will be initiated in Month 4 and with a brief education session, use of a Fitbit Flex paired with the FitViz app, and counseling by a physiotherapist. In Months 6-9, participants will continue using Fitbit/FitViz without the PT phone calls.
2996671|NCT02585297||Control- semen|Semen of fertile men
2996672|NCT02585297||Control- vaginal discharge|Vaginal discharge of partners of fertile men
2996673|NCT02585297||Case-semen|Semen of infertile men
2996674|NCT02585297||Case- vaginal discharge|Vaginal discharge of partners of infertile men
2996675|NCT02585284||vicenarian|20 to 29 years. Five males and five females
2996676|NCT02585284||tricenarian|30 to 39 years. Five males and five females
2996677|NCT02585284||quadragenarian|40 to 49 years. Five males and five females
2996678|NCT02585284||quinquagenarian|50 to 59 years. Five males and five females
2996679|NCT02585284||sexagenarian|60 to 69 years. Five males and five females
2996680|NCT02585284||septuagenarian|70 to 79 years. Five males and five females
2996681|NCT02585284||octogenarian|80 to 89 years. Five males and five females
2996682|NCT02585284||nonagenarian|90-99 years. Five males and five females
2996683|NCT02585271|Other|Transanal decompression tube|Patients undergo placement of the transanal decompression tube as a bridge to surgery
2996684|NCT02585271|Other|Stent|Patients undergo placement of the stent as a bridge to surgery
2996685|NCT02585258|Experimental|arm A|prednisolone 5 mg per day
2996686|NCT02585258|Placebo Comparator|arm B|placebo capsules once per day
2996687|NCT02585245||NRS2002 Nutrition Risk Screen|Patients identified at HIgh, medium or Low Risk in Hospitalized patients. Determining accuracy of identifiying patients affected by malnutrition.
2996688|NCT02585245||ThedaCare RD/RN Nutrition Risk Screen|Patients identified at HIgh, medium or Low Risk in Hospitalized patients. Determining accuracy of identifiying patients affected by malnutrition.
2996689|NCT02585232|Active Comparator|Care Consultation (CC)|"Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment - much like an interview guide - which then immediately shapes development of concrete action plans."
2996690|NCT02585232|Experimental|Care Consultation + Counseling (CC+C)|Care Consultation + Counseling (CC+C): is consistent with the original CC protocol in that the therapist partners with each dyad in a patient-centered way to prioritize unmet needs as identified during the CC initial assessment. Once this phase has been completed, typically within the first 2 sessions, the CC+C therapist will determine when to initiate counseling sessions targeting 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.). The counseling component of the CC+C intervention incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework.
2996691|NCT02585219||High-grade Glioma Patients|"Patients with suspicion of newly diagnosed high-grade glioma eligible for standard therapy (surgical resection followed by chemoradiotherapy).~Patients with a second brain tumor, brain surgery earlier or prior radiotherapy to the brain are excluded. Patients with only a biopsy be excluded.~The group will consist of 10 patients. This number may be adjusted for patients who are found to have a different diagnosis after histological examination or fall out. For a pilot feasibility study our experience that a number of 10 patients is sufficient for PET examination."
2996692|NCT02585206|No Intervention|Arm 1|"All 4 factors off - standard text message program~Personalization OFF Integration OFF Dynamic Tailoring OFF Message Intensity OFF"
2996693|NCT02585206|Active Comparator|Arm 2|Personalization OFF Integration OFF Dynamic Tailoring OFF Message Intensity ON
2996694|NCT02585206|Active Comparator|Arm 3|Personalization OFF Integration OFF Dynamic Tailoring ON Message Intensity OFF
2996695|NCT02585206|Active Comparator|Arm 4|Personalization OFF Integration OFF Dynamic Tailoring ON Message Intensity ON
2996696|NCT02585206|Active Comparator|Arm 5|Personalization OFF Integration ON Dynamic Tailoring OFF Message Intensity OFF
2996697|NCT02585206|Active Comparator|Arm 6|Personalization OFF Integration ON Dynamic Tailoring OFF Message Intensity ON
2996698|NCT02585206|Active Comparator|Arm 7|Personalization OFF Integration ON Dynamic Tailoring ON Message Intensity OFF
2996699|NCT02585206|Active Comparator|Arm 8|Personalization OFF Integration ON Dynamic Tailoring ON Message Intensity ON
2996700|NCT02585206|Active Comparator|Arm 9|Personalization ON Integration OFF Dynamic Tailoring OFF Message Intensity OFF
2996701|NCT02585206|Active Comparator|Arm 10|Personalization ON Integration OFF Dynamic Tailoring OFF Message Intensity ON
2996702|NCT02585206|Active Comparator|Arm 11|Personalization ON Integration OFF Dynamic Tailoring ON Message Intensity OFF
2996703|NCT02585206|Active Comparator|Arm 12|Personalization ON Integration OFF Dynamic Tailoring ON Message Intensity ON
2996704|NCT02585206|Active Comparator|Arm 13|Personalization ON Integration ON Dynamic Tailoring OFF Message Intensity OFF
2996705|NCT02585206|Active Comparator|Arm 14|Personalization ON Integration ON Dynamic Tailoring OFF Message Intensity ON
2996706|NCT02585206|Active Comparator|Arm 15|Personalization ON Integration ON Dynamic Tailoring ON Message Intensity OFF
2996707|NCT02585206|Active Comparator|Arm 16|Personalization ON Integration ON Dynamic Tailoring ON Message Intensity ON
2996708|NCT02585206|No Intervention|WEB|"Phase II arm.~Full access to standard BecomeAnEX.org web-based smoking cessation program."
2996709|NCT02585206|Active Comparator|WEB+OA_TXT|"Phase II arm.~Full access to standard BecomeAnEX.org web-based smoking cessation program PLUS optimal-adherence text message program from Phase I."
2996710|NCT02585193|Other|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
2996711|NCT02585180|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions Drainage
2996712|NCT02585180|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
2996713|NCT02585167|Active Comparator|Operation|the fistula will be excised after dividing the sphincter and primary reconstruction
2996714|NCT02585167|Experimental|VAAFT|the fistula tract will be visualized by scope, closing the internal opening with absorbable sutures.
2996715|NCT02585141|Experimental|aspiration|Aspiration of perianal abscess(MEDIPLAST® 13 G, 2,5 x 110 mm) under general anesthesia followed by antibiotic treatment with Clindamycin tablet 300 mg 3 times daily for 7 days
2996716|NCT02585141|Active Comparator|incision|Surgical incision of perianal abscess under general anesthesia.
2996717|NCT02585128|Other|Patients following TAVI|
2996718|NCT02585115||Non-pregnant women with symptoms|Non-pregnant women with one or more symptoms of UTI. All women will make a paired urine sample (first void and midstream void) of the same urine sample.
2996719|NCT02585102|Other|Recommended Vegetables|Diet provided consisting of recommended vegetable intake per Dietary Guidelines for Americans amounts for 8 weeks.
2996720|NCT02585102|Other|Usual Vegetables|Diet consisting of usual vegetable intake amounts for 8 weeks.
2996721|NCT02585089|Active Comparator|Spanish cured-pork ham|"One group will receive dry-cured pork ham of >10 months proteolysis (intervention product).~Intervention: Dietary intake Dry-cured pork ham contains high doses of bioactive peptides produced during more than 10 months of proteolysis."
2996722|NCT02585089|Placebo Comparator|Cooked pork ham|The other group will receive cooked, uncured ham (placebo product). Intervention: Dietary intake. Cooked ham does not display bioactive peptides as they are produced during proteolysis of pork ham.
2996723|NCT02585076||Cohort 1|Patients aged 60 years or older regardless of gender and race with a documented diagnosis of hypertension will be enrolled into this study after the decision for electrocardiographic screening for AF has been made by the investigator
2996724|NCT02585063||Dual assessment|Where there is time and space, participants will be allocated to have a clinical assessment by the IP optometrist during their wait for the clinical assessment with the ophthalmologist. Both clinical assessments are needed to obtain measurement of agreement. There is no intervention. but participants have two clinical assessments rather than just one.
2996725|NCT02585050||patients alive discharged from hospital|patients alive discharged from hospital following CPR
2996726|NCT02585037|Experimental|Kinesio Taping for facilitation|To provide the facilitation of muscle activity (G1 group) a Kinesio Taping® bandage will be applied to the muscle starting at its origin up to the location of muscle insertion. Bandage in group G1 will be applied following the protocol proposed by method of technical, which defined the direction of the bandage and an applied tension of 10% to 15% (paper off). With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
2996727|NCT02585037|Experimental|Kinesio Taping for inhibition|For inhibition of muscle activity (G2 group), the Kinesio Taping® bandage will be placed over the muscle starting at the insertion location and ending at the muscle origin. Bandage in group G2 will be applied following the protocol proposed by method of technical, which defined the direction of the bandage and an applied tension of 10% to 15% (paper off). With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
2996728|NCT02585037|Placebo Comparator|Kinesio Taping and Placebo|For the control group (G3 group) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis. Bandages in the G3 group will be applied laterally to produce a similar visual effect, which control for the placebo effect, but without tension so that a muscle stimulus will be not generated. With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
2996729|NCT02585024|Experimental|1.5 mg cytisine|1.5 mg cytisine given as a single dose
2996730|NCT02585024|Experimental|3 mg cytisine|3 mg cytisine given as a single dose
2996731|NCT02585024|Experimental|4.5 mg cytisine|4.5 mg cytisine given as a single dose
2996732|NCT02585024|Experimental|1.5 mg cytisine six times a day|1.5 mg (1 capsule) is given six times a day (0, 2, 4, 6, 8 and 10 hours) for 5 days
2996733|NCT02585024|Experimental|3 mg cytisine three times a day|3 mg (2 capsules) are given three times a day (0, 4 and 8 hours) for 5 days
2996734|NCT02585024|Experimental|4.5 mg cytisine two times a day|4.5 mg (3 capsules) are given two times a day (0 and 6 hours) for 5 days
2996735|NCT02585011|Experimental|Ropivacaine|Local infiltration anesthesia, single shot during surgery. 150 ml Ropivacaine (2mg/ml), added 0.5 ml Epinephrine (1mg/ml)
2996736|NCT02585011|Placebo Comparator|Placebo|Single shot during surgery.150 ml saline
2996737|NCT02584998|No Intervention|Usual care|These patients will continue to receive the current practice at the Philadelphia VA Medical Center (VAMC) of offering screening during an office visit. Other interventions will be embedded within this existing program for a pragmatic approach. However, all participants in the trial, including those in usual care (UC), will receive follow-up of test results and navigation to diagnostic colonoscopy for positive FIT results.
2996738|NCT02584998|Active Comparator|Screening invitation-reminder|Participants will receive UC and also receive an invitation letter with information about CRC testing. The information will include lay-audience description of screening tests and symptoms that should prompt diagnostic work-up. The packet will have instructions to contact the study team if participants believe they are not eligible and to update the contact information on record. The letter will inform participants that a telephone reminder will follow in 4 weeks from invitation letter if screening is not completed. They will also receive notification of test results and navigation to colonoscopy, if needed. For the purposes of this intervention, Week 1 will be the week the invitation letter was sent (time zero).
2996739|NCT02584998|Active Comparator|Mailed-FIT|Participants randomized to Mailed-FIT will receive a mailed FIT pre-notification letter (plus a screening invitation) followed by the kit 1 week later. Participants will receive instructions to contact the study team if they believe they are not eligible and to update their contact information. They will be informed that a telephone reminder will follow 4 weeks from notification letter if screening is not completed. Participants who do not return their kit within 4 weeks after their pre-notification letter was mailed will receive a live telephone reminder, followed by 2 additional calls at the end of weeks 5 and 6, if needed. For the purposes of this intervention, Week 1 will be the week the pre-notification letter was sent (time zero).
2996740|NCT02584985|Other|ETAP : Endoscopic Transanal Proctectomy|"Primary transanal approach :~Careful positioning in Lithtomy, dilatation and anal exposure with standard retractor. Mucosa incision and internal sphincter dissection according to tumor extension. Primary conventional dissection up to circumferential exposure of fascia recti. Secondary implantation of transanal endoscopic device Begin mesorectal endoscopic dissection postero-anteriorly, then laterally with nerve-sparing dissection. Level assessment of posterior dissection (vertical segment). End with peritoneal opening anteriorly (Douglas).~Secondary transabdominal approach :~Type of laparoscopic approach multiport or singleport. Level of arterial section, extension of colonic mobilization, site for specimen extraction (transanal / transabdominal), type of colonic reconstruction."
2996741|NCT02584985|Other|Standard Transabdominal Laparoscopic proctectomy|Primary transanal conventional dissection (sphincter preservation assessment) or not, type of laparoscopic approach multiport or singleport, level of arterial section, extension of colonic mobilization, conditions of mesorectal excision and nerve preservation, site for specimen extraction (transanal / transabdominal) and type of colonic reconstruction.
2996742|NCT02584972||children with Autism Spectrum Disorder|no intervention required
2996743|NCT02584972||heathy children|no intervention required
2996744|NCT02584959|Experimental|Experimental/Placebo|Subjects will be randomized to receive C1 Esterase Inhibitor in the 1st Treatment period and then switch to Placebo in the 2nd treatment period.
2996745|NCT02584959|Experimental|Placebo/Experimental|Subjects will be randomized to receive a placebo treatment in the 1st Treatment period and then switch to receive C1 Esterase Inhibitor in the 2nd treatment period.
2996746|NCT02584959|Experimental|Experimental/ Experimental|Subjects will be randomized and receive C1 Esterase Inhibitor in both 1st as well as the 2nd treatment period
2996747|NCT02584946|Placebo Comparator|Low-AVA oat flour cookies|
2996748|NCT02584946|Experimental|High-AVA oat flour cookies|
2996749|NCT02584933|Experimental|ceritinib|The starting dose of study treatment for patients in this protocol should be the same as the dose provided in the parent ceritinib study at the time of the rollover.
2996750|NCT02584920|Experimental|HLX01|375mg/m2 iv single dose
2996751|NCT02584920|Active Comparator|Rituximab|375mg/m2 iv single dose
2996752|NCT02584907|Experimental|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
2996753|NCT02584907|No Intervention|Standered Enteral Nutrition|Diet in standard group will be 20% from protein, 30% from fat and 50% from carbohydrate
2996754|NCT02584894|Placebo Comparator|rTMS 1Hz|Subjects have 8 session of trauma exposure with repeated transcranial magnetic stimulation (rTMS) at 1Hz on dorsolateral prefrontal cortex (1Hz rTMS is describe in the literature to have no effect on the dorsolateral prefrontal cortex). psychoneurological assessment. Electrodermal conductance measure With conductivity meter . Heart rate measure With electrocardiogram
2996755|NCT02584894|Experimental|rTMS 10Hz|Subjects have 8 session of trauma exposure with repeated transcranial magnetic stimulation (rTMS) at 10Hz on dorsolateral prefrontal cortex (10Hz rTMS is describe in the literature to have effect on the dorsolateral prefrontal cortex). psychoneurological assessment. Electrodermal conductance measure With conductivity meter. Heart rate measure with electrocardiogram
2996756|NCT02584881|Experimental|Intervention|A safe opioid prescription protocol will be implemented with these trauma patients
2996757|NCT02584881|No Intervention|Control|Standard care at discharge will be implemented with these trauma patients
2996758|NCT02584868|Experimental|Volulyte|Investigational drug: HES 130/0.4 (6%) in an isotonic electrolyte solution (brand name=Volulyte®)
2996759|NCT02584868|Active Comparator|Voluven|Control drug: HES 130/0.4 (6%) in sodium chloride 0.9% (brand name=Voluven®)
2997300|NCT02581059|Active Comparator|Regorafenib Only|Regorafenib will be administered 160 mg once daily for the first 21 days of each 28-day cycle for 2 cycles.
2996760|NCT02584855|Experimental|Ixekizumab|"Open Label Period: Starting dose of 160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline followed by 80 mg given as one SC injection every two weeks (Q2W) from week 2 to randomization (week 36).~Double Blind Period: 80 mg ixekizumab given as one SC injection Q2W from randomization to week 104."
2996761|NCT02584855|Placebo Comparator|Placebo|"Open Label Period: Starting dose of 160 mg ixekizumab given as two SC injections at baseline followed by 80 mg given as one SC injection Q2W from week 2 to randomization (week 36).~Double Blind Period: Placebo given as one SC injection Q2W any time from randomization to week 104."
2996762|NCT02584855|Experimental|Ixekizumab Open Label|Open Label Period: Starting dose of 160 mg ixekizumab given as two SC injections at baseline followed by 80 mg given as one SC injection Q2W from week 2 to week 104.
2996763|NCT02584829|Experimental|Group 1 (avelumab and MHC class I up-regulation)|Patients who do not have a HLA type for which T cells can be generated or for whom T cells cannot be generated for technical issues receive avelumab intravenously (IV) over 1 hour every 2 weeks for 12 months. Within 7-10 days after completion of 1-3 doses of avelumab, patients receive MHC class I up-regulation intervention comprising either localized radiation therapy or recombinant interferon beta via intra-tumor injection.
2996764|NCT02584829|Experimental|Group 2 (avelumab, MHC class I up-regulation, T cells)|Patients who have an HLA type for which T cells can be generated receive avelumab IV over 1 hour every 2 weeks for 12 months. Patients also receive MHC class I up-regulation intervention as in Group 1 between 7-10 days after the first infusion of avelumab and 2-5 days before the first infusion of MCPyV TAg-specific polyclonal autologous CD8+ T cells. Patients receive two infusions of MCPyV TAg-specific polyclonal autologous CD8+ T cells IV over 60-120 minutes.
2996765|NCT02584816|Experimental|Group 1 - BRV-PV Lot A|BRV-PV Lot A + DPT- HepB-Hib + OPV
2996766|NCT02584816|Experimental|Group 2 - BRV-PV Lot B|BRV-PV Lot B+ DPT- HepB-Hib + OPV
2996767|NCT02584816|Experimental|Group 3 - BRV-PV Lot C|BRV-PV Lot C + DPT- HepB-Hib + OPV
2996768|NCT02584816|Active Comparator|Group 4 - ROTARIX|ROTARIX + DPT-HepB-Hib + OPV
2996769|NCT02584790|Other|Post radiotherapy 8 weeks NPC patient|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
2996770|NCT02584777|Experimental|Pacritinib|Oral administration
2996771|NCT02584764|Experimental|CBT with Internet support|16 sessions of Cognitive behavior therapy in group with Internet support between group sessions
2996772|NCT02584751|Active Comparator|Able-Bodied non-GERD|Able-bodied patients who are not diagnosed with GERD during screening will act as controls.
2996773|NCT02584751|Active Comparator|SCI non-GERD|SCI patients who are not diagnosed with GERD during screening will act as controls
2996774|NCT02584751|Experimental|SCI GERD|For those SCI subjects who are identified with GERD, they will undergo a 8week treatment of Omeprazole to reduce GERD
2996775|NCT02584751|Active Comparator|Able-bodied GERD|For those AB subjects who are identified with GERD will act as controls. Note they will not receive treatment for GERD in this study. We will notify their primary care physician during the study so that they may receive treatment.
2996776|NCT02584738|Experimental|Nebulized Magnesium Sulfate|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4.~Intravenous methylprednisolone or oral prednisolone"
2996777|NCT02584738|Placebo Comparator|Nebulized isotonic saline|Nebulized salbutamol and ipratropium bromide with 2.5 ml of isotonic saline. Intravenous methylprednisolone or oral prednisolone
2996778|NCT02584725|Active Comparator|5 mg/kg/dose tranexamic acid|5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
2996779|NCT02584725|Active Comparator|10 mg/kg/dose tranexamic acid|10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
2996780|NCT02584725|Active Comparator|15 mg/kg/dose tranexamic acid|15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
2996781|NCT02584712|No Intervention|Control|This group do not participated in the intervention protocol (exercise training), and was followed throughout the entire process. Autonomic activity was assessed before and after 4 weeks.
2996782|NCT02584712|Active Comparator|Exercise Training|This group undergone exercise training intervention during 4 weeks.
2996783|NCT02584699|Experimental|SABR|SABR group includes patients receiving pre-identified fractionated Stereotactic Ablative Radiotherapy (SABR)
2996784|NCT02584686|Experimental|(BTX) A Group|The treatment group will be injected intracavernously with a trimix solution for colour Doppler assessment, followed, on a separate day by 50 units of Botulinum toxin (BTX) A.
2996785|NCT02584686|Placebo Comparator|Saline Group|The control group, 12 patients, will be injected with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) during penile colour Doppler assessment followed on a separate day with a normal saline injection.
2996786|NCT02584673|Experimental|CAIG|The participants in this group (test group) will utilize the same procedure utilizing existing ultrasound equipment with the supplemental CAIG system.
2996787|NCT02584673|No Intervention|Control|The participants in the control group will receive the procedure with traditional ultrasound methods and equipment.
2996788|NCT02584660|Experimental|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food, for approximately 69 days for a total treatment duration of 90 days.
2996789|NCT02584660|Experimental|local Standard-of-care|Participants will receive local Standard-of-care as per local protocol and defined by the medical team caring for the participant.
2996790|NCT02584647|Experimental|Phase 1: PLX3397 and Sirolimus|Cohort 1 (Phase 1): Subjects with unresectable or metastatic sarcoma will take orally PLX3397 (600 - 1000mg) in combination with Sirolimus (2-6mg) daily .
2996791|NCT02584647|Experimental|Phase 2: PLX3397 and Sirolimus|Cohort 2 (Phase 2): Subjects with unresectable or metastatic Malignant Peripheral Nerve Sheath Tumors (MPNSTs) will take PLX3397 and Sirolimus at the recommended Phase 2 dose (RP2D).
2996792|NCT02584634|Experimental|Group A|ALK negative Non-Small Cell Lung Cancer
2996793|NCT02584634|Experimental|Group B|ALK positive Non-Small Cell Lung Cancer
2996794|NCT02584621|Experimental|Check Yourself App With Feedback|Participants complete Check Yourself, an electronic health screening app and receive personalized, motivational feedback on their health behaviors prior to their visit with their health provider. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Health providers receive a summary report of health risk behaviors from Check Yourself prior to the visit.
2996795|NCT02584621|No Intervention|Usual Care|Participants are asked to complete health risk screening questions on a tablet computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors.
2996796|NCT02584608|Experimental|Treatment|ACTIMMUNE 50 µg/m2 subcutaneously three times per week (TIW) for 8 weeks
2996797|NCT02584582|Experimental|Liraglutide + Liquid meal test|Liraglutide 1.2 mg once daily for 14 days (0.6 mg/day for one week, escalated to 1.2 mg/day after one week)
2996798|NCT02584582|Experimental|Exenatide + Liquid meal test|Exenatide 10 mcg twice daily for 14 days (5 mcg twice daily for one week, escalated to 10 mcg twice daily after one week)
2996799|NCT02584582|Other|Baseline + Liquid meal test|Baseline day with no additional medication
2996800|NCT02584569|Experimental|TAK-915|TAK-915 100 mg suspension, orally, once on Day 1. Additional TAK-915 dose levels may be incorporated based on dose level review meetings (DLRMs) following approximately every 2 participants and based on prior occupancy, duration of occupancy, safety, tolerability, and available pharmacokinetic (PK) data.
2996801|NCT02584556|Experimental|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks within 4-6 weeks after hepatic resection(a total of 4 cycles).
2996802|NCT02584556|Active Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization (Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou)) within 4-6 weeks after hepatic resection(a total of 1 cycle).
2996803|NCT02584543|Experimental|HEV vaccine and HBV vaccine Co-administration group|
2996804|NCT02584543|Active Comparator|HEV vaccine control group|
2996805|NCT02584543|Active Comparator|HBV vaccine control group|
2996806|NCT02584530|No Intervention|Standard procedure group|PICC line insertion using anatomical landmarks guidance and tip placement confirmation by X-ray
2996807|NCT02584530|Experimental|Interventional group|Ultrasound guidance for PICC line placement and X-ray
2996808|NCT02584517||GCA|Patients referred with suspected GCA, whose final diagnosis is GCA
2996809|NCT02584517||Not GCA|Patients referred with suspected GCA, whose final diagnosis is another disorder
2996810|NCT02584504|Experimental|Alirocumab 150 mg Q4W|Double-blind treatment period (DBTP): participants received Alirocumab 150 mg subcutaneous (SC) injection every 4 weeks (Q4W) alternating with placebo (for alirocumab) Q4W added to lowest-strength statin therapy (atorvastatin 5 mg daily), stable non-statin Lipid-Modifying Therapy (LMT) or diet therapy alone for 12 weeks. Participants completed DBTP, entered in open-label treatment period (OLTP), received alirocumab 150 mg Q4W. Alirocumab dose up-titrated to 150 mg every 2 weeks (Q2W) at Week 24(OLTP:Week 12), when targeted LDL-C level at Week 20 not achieved as Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012: (1) ≥100 mg/dL (2.59 mmol/L) in heFH participants/non-familial hypercholesterolemia (non-FH) participants with history of documented coronary heart disease;2) ≥120 mg/dL (3.10 mmol/L) in non-FH participants who had a history of documented diseases or other risk factors as categorized in primary prevention category III)
2996811|NCT02584504|Experimental|Alirocumab 150 mg Q2W|In DBTP, participants received Alirocumab 150 mg SC injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg daily), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
2996812|NCT02584504|Placebo Comparator|Placebo Q2W|In DBTP, participants received Placebo (for alirocumab) SC injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
2996813|NCT02584491|Experimental|Functional gait-related training|16 session, 6-week intensive functional gait-related training intervention based on motor learning principles that includes a motor imagery practice component.
2996814|NCT02584478|Experimental|AL3818 plus carboplatin and paclitaxel|"Phase 1b: Sequential deescalating dosing evaluation to determine the recommended Phase II dose (RP2D). For 21-day treatment cycles, cohort 1 (3 subjects) will be administered carboplatin (AUC 5/6 over 30 minutes) and paclitaxel (175mg/m2 over 3 hours) intravenously on Day 1. AL3818 is orally administered daily starting on Day 8 until Day 21 (14 days) at an initial dose of 12 mg/day.~Phase 2a: subjects will receive chemotherapy and oral AL3818 for 6 cycles (18 weeks, 21-day cycles of treatment) followed by continuous maintenance treatment of oral AL3818 for up to 12 months. Subjects will be administered carboplatin (AUC 5/6 over 30 minutes) and paclitaxel (175mg/m2 over 3 hours) intravenously on Day 1. AL3818 is orally administered daily starting on Day 8 until Day 21 (14 days) at the RP2D found in Phase 1b."
2996815|NCT02584465|Active Comparator|A-Tamoxifen|Tamoxifen 40mg/day 2 film-coated tablet containing 20 mg of Tamoxifen/day until progression
2996816|NCT02584465|Experimental|B-Regorafenib|Regorafenib 120mg/day 3 film-coated tablet containing 40 mg of Regorafenib/day, 3 weeks/4 until progression
2996836|NCT02584309|Active Comparator|Arm 2: control (standard of care doxorubicin + olaratumab)|"Doxorubicin is given as standard of care. Doxorubicin is typically given at 75 mg/m2 on Day 1 of a 21-day cycle.~--Olaratumab is typically given on Days 1 and 8 of 21-day cycle at a dose of 15 mg/kg. Both doxorubicin and olaratumab are being given as routine care; their administration is not dictated per protocol.~The last 10 patients enrolled after completion of enrollment to Arm 1 (dexrazoxane & standard of care doxorubicin) will be enrolled to Arm 2 (control arm - standard of care doxorubicin only)"
2996817|NCT02584452|Active Comparator|Continuous Adductor Canal Nerve Catheter|Ultrasound guided femoral nerve block with 20cc of 2% mepivacaine <20 minutes prior to in room time. Intraoperative patients will undergo initiation of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert this group will receive ultrasound guided adductor canal continuous nerve catheter using normal saline bolus followed by 1/8% bupivacaine infusion through catheter at 8cc/h.
2996818|NCT02584452|Active Comparator|Long Acting Single Bolus Adductor Canal Nerve Block|Ultrasound guided femoral nerve block with 20cc of 2% mepivacaine <20 minutes prior to in room time. Intraoperative patients will undergo initiation of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert this group will receive ultrasound guided adductor canal nerve block with 10cc of 0.5% ropivacaine and 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve.
2996819|NCT02584439|Other|ivabradine-placebo|Volunteers will receive, at meal, ivabradine 5 mg morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8). A wash out period (12 to 16 days) will follow this first period of treatment. of wash-out . Then, volunteers will receive, at meal, lactose capsule (placebo) morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8).
2996820|NCT02584439|Other|placebo-ivabradine|Volunteers will receive, at meal, lactose capsule (placebo) morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8). A wash out period (12 to 16 days) will follow this first period of treatment. of wash-out . Then, volunteers will receive, at meal, ivabradine 5 mg morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8).
2996821|NCT02584426|Experimental|Cefazolin Treatment|Subjects will receive antibiotic treatment with phonophoresis (i.e., hypodermoclysis) during test 1, and will be given standard of care for 8 weeks.
2996822|NCT02584426|No Intervention|Standard of Care Control|Subjects will not receive intervention and will receive standard of care for 8 weeks.
2996823|NCT02584413|Experimental|Arm 1: MRI of brain with gadolinium contrast|-Eligible children whose guardians have consented to their participation will undergo routine clinical brain MRI with gadolinium contrast. The MRI scan will last no more than 45 minutes
2996824|NCT02584400|Experimental|[18F]HX4 PET imaging|Injection with the hypoxia tracer [18F]HX4 and PET imaging at baseline for esophageal, rectal, prostate cancer, primary brain tumor (grade IV glioma) and brain metastases and after 2 weeks of radiotherapy for esophageal, rectal and brain metastases
2996825|NCT02584387|Experimental|3D VVRET|"Behavioral: 3D Video Virtual Reality Exposure Therapy (VVRET)~1 30 minute 3D VRET treatment session for arachnophobia."
2996826|NCT02584387|No Intervention|Waitlist|Participants randomized to the waitlist group will complete all study procedures except the 3D VVRET. After the conclusion of their sessions, these participants will be offered the full 3D-VVRET treatment.
2996827|NCT02584374||Patients|with suspected iliac vein compression, but with no signs of compression on venography and if venography with balloon occlusion test is performed.
2996828|NCT02584374||Healthy controls|"Healthy subjects between 18-45 years of age~Venography with balloon occlusion test will be performed."
2996829|NCT02584361|Active Comparator|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
2996830|NCT02584361|Active Comparator|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA)
2996831|NCT02584348|Experimental|Gastric Ultrasound|Preoperative qualitative ultrasound assessment of gastric contents will be performed
2996832|NCT02584335|Active Comparator|"Lidocaine solution (A)"|"Two sterile gauzes will be dampen with the content of the second syringe (the content of the first syringe is always 20 ml of saline solution and it is the first sterile gauzes administrated always) that will contain 20ml of 0.5% lidocaine dilution when the wound treatment process is assigned to the letter A. The nurse has a third syringe exactly like this second syringe to apply if necessary (process still painful to the patient)."
2996833|NCT02584335|Placebo Comparator|"Saline solution (B)"|"Two sterile gauzes will be dampen with the content of the second syringe (the content of the first syringe is always 20 ml of saline solution and it is the first sterile gauzes administrated always) that will contain 20ml of saline solution when the wound treatment process is assigned to the letter B. The nurse has a third syringe exactly like this second syringe to apply if necessary (process still painful to the patient). In this case, the three syringes supplied to the nurse, have saline solution."
2996834|NCT02584322|Experimental|ERAS patients|Enhanced recovery pathway
2996835|NCT02584309|Experimental|Arm 1: dexrazoxane & standard of care doxorubicin + olaratumab|"Dexrazoxane will be given intravenously on an outpatie2. -nt basis over 15 minutes on each day that doxorubicin is given.~Dexrazoxane should be given no more than 30 minutes prior to administration of doxorubicin, which is typically given on Day 1 of a 21-day cycle.~Dosing is a 10:1 ratio of dexrazoxane to doxorubicin; doxorubicin is typically given at 75 mg/m2, so dexrazoxane dosing would be 750 mg/m2.~Olaratumab is typically given on Days 1 and 8 of 21-day cycle at a dose of 15 mg/kg. Both doxorubicin and olaratumab are being given as routine care; their administration is not dictated per protocol.~In the event of a national shortage of dexrazoxane, 72-hour infusional doxorubicin can be used instead of dexrazoxane and bolus doxorubicin.."
2996837|NCT02584296|No Intervention|Usual care control|Phase 1 will be observation only, and will be considered a usual care control group, activity at home.
2996838|NCT02584296|Experimental|Biobehavioral self management approach|Phase 2 participants will receive the Biobehavioral self management approach (BSMA) intervention aligned with the IMB model; introduced over three days of each five-day consolidation chemotherapy hospital admission.
2996839|NCT02584283|Experimental|Dual hypothermic oxygenated perfusion|The liver is procured with a segment of supratruncal aorta. The intervention is restricted to the liver graft after arrival in the transplant center and before implantation. The donor liver is subjected to 2 hours of hypothermic oxygenated perfusion via the portal vein and the supratruncal aorta applied by the Liver Assist®. Before perfusion, the liver is flushed via the portal vein with 1 L Belzer machine perfusion solution. The perfusion is pressure controlled and set to a mean of 25 mmHg (arterial) and 5 mm Hg (portal). The perfusion fluid is 4 L Belzer machine perfusion solution with additional 3 mmol/L glutathione. The perfusion fluid is 12°C, when the temperature is set at 10°C. The oxygen flow is set at 0.5 mL/min of 100% oxygen on each of the two membrane oxygenators.
2996840|NCT02584283|No Intervention|Care as usual|The donor liver is procured with a segment of 5 cm circular supratruncal aorta left attached to the coeliac trunc. The patients randomized to the control group will receive a liver graft preserved by conventional SCS without any further intervention.
2996841|NCT02584270|Experimental|Prosthesis + Articulation Therapy|This arm will receive a palatal augmentation prosthesis with standard articulation therapy, and is the study arm.
2996842|NCT02584270|Other|No Prosthesis; Articulation Therapy Only|This arm will not receive a palatal augmentation prosthesis, but will receive standard articulation therapy, and is the control arm.
2996843|NCT02584257|Placebo Comparator|Placebo dose|Placebo dose: 1 actuation each from 2 different placebo Reference inhalation aerosols and one actuation each from 2 different placebo Test inhalation aerosols
2996844|NCT02584257|Active Comparator|90 mcg Reference Product|90 mcg of Reference product: 1 actuation each from the Reference product inhalation aerosol and the placebo Reference inhalation aerosol and 1 actuation each from 2 different placebo Test product inhalation aerosols
2996845|NCT02584257|Active Comparator|180 mcg of Reference product|180 mcg of Reference: 1 actuation each from 2 different Reference inhalation aerosols and 1 actuation each from 2 different placebo Test product inhalation aerosols
2996846|NCT02584257|Experimental|90 mcg of Test product|90 mcg of Test product: 1 actuation each from the Test product inhalation aerosol and the placebo Test inhalation aerosol and 1 actuation each from 2 different placebo Reference inhalation aerosols
2996847|NCT02584257|Experimental|180 mcg of Test product|180 mcg of Test product: 1 actuation each from 2 different Test product inhalation aerosols and 1 actuation each from 2 different placebo Reference product inhalation aerosols
2996848|NCT02584244|Experimental|LUM Imaging System|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 12 patients will be recruited at the dose level that produces optimal LUM015 activity. Patients will undergo their planned surgical resection 2-6 hours after LUM015 injection. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
2996849|NCT02584231|Experimental|Patients needing an urinary concentration test|Patients who need a urinary concentration test because of uro- or nephropathy (age: 6 months - 8 year)
2996850|NCT02584231|Experimental|Patients suffering from treatment resistant nocturnal enuresis|Patients suffering from treatment resistant nocturnal enuresis (age: 5 - 8 year)
2996851|NCT02584218|Experimental|Non-invasive resin based caries sealing|Application of resin based sealant after acid etching of carious occlusal surface
2996852|NCT02584218|Active Comparator|Invasive resin based restoration|Application of resin based resin restoration after operative intervention of caries lesion, excavation and preparation on occlusal surface
2996853|NCT02584205|Experimental|Powerbreathe|We will use the powerbreathe Classic light resistance in this intervention (inspiratory muscle training). Both groups will receive the equipment, but the intervention group will do the training with a load 40% of the maximum inspiratory pressure.
2996854|NCT02584205|Placebo Comparator|Control|"This group will also receive the equipment (powerbreathe classic light) but will do the training with a load less than 10% of the maximum inspiratory pressure (insufficient charge to train the muscles)."
2996855|NCT02584192|Experimental|the rehabilitation group|entailing an early home-based CR program
2996856|NCT02584192|Other|the control group|enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care.
2996857|NCT02584179|Experimental|Biparametric MRI before biopsy|"Biparametric MRI is a reduced Multiparametric MRI using less scan sequences and no intravenous contrast.~All men will have standard transrectal ultrasound guided biopsies"
2996858|NCT02584166||Intervention group|38 maternity units with allocated to the intervention group: coordinating team disseminated protocols related to the management of cases, and organized mortality morbidity conferences (MMC) in each unit with staff concerned. These MMC were realized by the same outside medical binomial composed of a midwife and an obstetrician (outreach visit with a leader ship). Among the 38 maternity units, MMC were performed with the medical binomial and professionals of human science in 20 units to identify the defense mechanisms manifested by medical staff which could disturb the decision making. In the others 18 units, MMC were performed with only the outside medical binomial. Coordinating team defined with teams the area of improvement before each MMC. 3 or 4 MMC were performed according to their activity.
2996859|NCT02584166||Control group|No intervention in 57 maternity units
2996860|NCT02584153|Experimental|Myoseal|The fibrin sealant and silver microparticles are sprayed onto the surface of the sutured myofascial incision following abdominal surgery.
2996861|NCT02584140|Other|AEGIS|All participants will be assigned to this arm of the study.
2996862|NCT02584127|Experimental|High reinforcement cessation program|The High Reinforcement (HR) condition included five monthly, online interim surveys with financial incentives for these assessments and also for program completion. All participants completed an eligibility survey and a baseline survey. All participants were offered a financial incentive to complete the six-monh followup survey. All participants were provided access to a six step, cognitive-behavioral smoking cessation program self-administered online.
2996893|NCT02583906|Other|cpap treatment|patients randomized to the 'no cpap' arm will not be treated by CPAP
2996894|NCT02583906|No Intervention|no cpap|patients randomized to the 'cpap' arm will be treated by CPAP
3024652|NCT02398188|Placebo Comparator|Placebo|Placebo comparator
2996863|NCT02584127|Experimental|Low reinforcement cessation program|Participants in the Low Reinforcement (LR) condition participants completed an eligibility survey and a baseline survey. All participants were offered a financial incentive to complete the six-monh followup survey. All participants were provided access to a six step, cognitive-behavioral smoking cessation program self-administered online.
2996864|NCT02584114|Experimental|Memory training group|The intervention is self-administration of 4 hours of memory training over 4 days per week, for 3 weeks (12 hours total). Memory training will be done with the Peak app for memory training http://www.peak.net.
2996865|NCT02584114|Active Comparator|Non-memory training group|The intervention is self-administration of 4 hours of training of games that do not involve memory such as language and card games over 4 days per week, for 3 weeks (12 hours total).
2996866|NCT02584101|Experimental|ACT|ACT therapy
2996867|NCT02584101|Active Comparator|Enhanced Treatment as Usual|Group support
2996868|NCT02584075|Experimental|Lifestyle intervention|
2996869|NCT02584062|Experimental|no-touch fluid-air exchange group|All patients in no-touch fluid-air exchange group will have a surgery of vitrectomy metrectomy and internal membrane peeling and gas tamponed.In this surgery ,investigator will not touch the macular area,especially the area of the macular hole and investigator will not have the fluid-air exchange of the macular area.
2996870|NCT02584062|Experimental|the tradional group|All patients in no-touch fluid-air exchange group will have a surgery of vitrectomy metrectomy and internal membrane peeling and gas tamponed.In this surgery ,investigator will touch the macular area and investigator will have the fluid-air exchange.
2996871|NCT02584049|Active Comparator|Osteopathy|3 sessions of Osteopathic treatment in addition to the usual follow
2996872|NCT02584049|Sham Comparator|Sham osteopathy|3 sessions of Sham osteopathy treatment in addition to the usual follow
2996873|NCT02584036||Receiving Influenza Vaccine|Patients who receive an influenza vaccine at a participating pharmacy site will be eligible to: a) receive a vaccination forecast review, b) be evaluated for unmet vaccination needs, c) receive patient education, and d) have vaccination needs met.
2996874|NCT02584023|Placebo Comparator|Control|No intervention during the perioperative period. Perform lung ultrasound twice only for the diagnostic purpose after the endotracheal intubation and and at the end of surgery.
2996875|NCT02584023|Active Comparator|Alveolar recruitment|Perform lung ultrasound twice during the perioperative period after the endotracheal intubation and and at the end of surgery. Conduct alveolar recruitment maneuver after first lung ultrasound assessment.
2996876|NCT02584010|Experimental|Kelofin Aerosol|Silicon-based Aerosol that will be applied over the postoperative scar two times a day
2996877|NCT02584010|Experimental|Kelofin Gel|Silicon-based Gel that will be applied over the postoperative scar two times a day
2996878|NCT02584010|No Intervention|Control|This group will not receive any intervention as a control group.
2996879|NCT02583997|Active Comparator|Routine third molar extraction|"Patients randomized to this arm will have all four wisdom teeth removed according to usual, standard care (i.e. with suturing of the lower alveoli).~Intervention: Suturing of lower alveoli"
2996880|NCT02583997|Experimental|Third molar extraction without suturing|"Patients randomized to this arm will have all four wisdom teeth removed according to usual, standard care, except that the resulting alveoli will not be sutured.~Intervention: Non suturing of lower alveoli"
2996881|NCT02583984||Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic Surgery with Lung Resection, such as lobectomy, segmentectomy
2996882|NCT02583984||Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic Surgery without Lung Resection, such as esophageal surgery, mediastinal surgery
2996883|NCT02583971||Patients with AF|"Split into 3:~Those patients on treatment for AF involving blood thinning medicines (anticoagulants) +/- heart rate limiting drugs such as B blockers or digoxin. 100 patients in this group.~Patients undergoing direct current cardioversion (DCCV) to temporarily restore normal (sinus) rhythm. 100 patients in this group.~Patients undergoing an AF ablation to permanently restore sinus rhythm. 300 patients in this group."
2996884|NCT02583958|Experimental|Device Urgo 3103166|Soft-adherent hydro-desloughing dressing
2996885|NCT02583958|Active Comparator|Device Aquacel Extra|Hydrofibre dressing
2996886|NCT02583945|Experimental|kidney treatment bundle (KDIGO)|Consequent postoperative application of a kidney treatment bundle: Protocol based hemodynamic optimization and monitoring, regular screening of creatinine in serum and of urine output, no use of potential nephrotoxic medication and normoglycemia.
2996887|NCT02583932|Experimental|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis. The MMi consists of 3-4 weekly sessions of 30-90 min each with an intervener (psychologist, social worker, or nurse) who provides the necessary ingredients to foster a good therapeutic alliance (i.e., trust, warmth, empathy, neutrality, and authenticity), encourages self-exploration and systematically addresses different levels of meaning (i.e., situational, global, existential, historical).
2996888|NCT02583932|Placebo Comparator|Empathic Visitor (EV)|Empathic visitors will meet with patients over 3-4 weekly sessions of 30-90 minutes as in the experimental group. They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic listener will be specifically instructed to avoid initiating discussions about meaning (e.g., perspective-taking, how the patient interprets his/her feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present). If the patient initiates discussions about these topics, the visitor will simply listen without further intervening.
2996889|NCT02583932|No Intervention|Usual Care Control Group|Treatment as usual in tertiary care hospital, typically medically-focused. All participants will be free to use hospital- or community-based supports, which will be tracked in all groups throughout the study by questionnaire and through a chart review. Both recruiting centres include well established psychosocial oncology services including psychiatrists, psychologists and social workers.
2996890|NCT02583919|Experimental|ISIS-GCGRRx - Dose Level 1|ISIS-GCGRRx - Dose Level 1
2996891|NCT02583919|Experimental|ISIS-GCGRRx - Dose Level 2|ISIS-GCGRRx - Dose Level 2
2996892|NCT02583919|Placebo Comparator|Placebo|Placebo
2996895|NCT02583893|Experimental|Sirolimus, MEC chemotherapy|Patients undergo collection of bone marrow samples prior to sirolimus dosing on day 4 and within 1 week and no later than day 45 of hematologic recovery. Patients receive sirolimus PO on days 2-9 (loading dose on day 1 only), and standard MEC chemotherapy comprising mitoxantrone hydrochloride IV over 15 minutes, etoposide IV over 1 hour, and cytarabine IV over 1 hour every 24 hours on day 4-8.
2996896|NCT02583867|Experimental|Exercise|Participants will complete an exercise dose of 15 kilocalories per kilogram of bodyweight per week (KKW). This is equivalent to approximately 150 minutes/week of aerobic exercise. This dose will be completed in at least 3 sessions per week for 12 weeks.
2996897|NCT02583854|Active Comparator|Hemostasis achieved by TR Band|After the transradial procedure and randomization TR Band will be applied to achieve hemostasis. Patient experience and complications after the application will be measured.
2996898|NCT02583854|Experimental|Hemostasis achieved by RY Stop|After the transradial procedure and randomization, RY Stop will be applied to achieve hemostasis. Patient experience and complications after the application will be measured.
2996899|NCT02583841|Active Comparator|Scaling and Root Planing( SRP)|This was an interventional study in which scaling and root planing was done in systemically healthy patients with chronic periodontitis
2996900|NCT02583841|No Intervention|Control Group|Scaling and root planing was not done , that is no intervention is carried out in the patients of this group.
2996901|NCT02583828|Active Comparator|Cyclophosphamide alone|Patients who were resistant to letrozole will be randomized to receive cyclophosphamide alone or letrozole plus cyclophosphamide. Patients in this arm will receive cyclophosphamide 50 mg daily.
2996902|NCT02583828|Experimental|Cyclophosphamide plus letrozole for resistant patients|Patients who were resistant to letrozole will be randomized to receive cyclophosphamide alone or letrozole plus cyclophosphamide. Patients in the this will receive cyclophosphamide 50 mg daily plus letrozole 2.5 mg daily.
2996903|NCT02583828|Experimental|Cyclophosphamide plus letrozole for treat-naive patients|Patients who haven't received letrozole hormonotherapy will be randomized to receive letrozole plus cyclophosphamide or letrozole alone. Patients in this arm will receive cyclophosphamide 50 mg daily plus letrozole 2.5 mg daily.
2996904|NCT02583828|Active Comparator|letrozole alone|Patients who haven't received letrozole hormonotherapy will be randomized to receive letrozole plus cyclophosphamide or letrozole alone. Patients in this arm will receive letrozole 2.5 mg daily.
2996905|NCT02583815||Cancer Patients|This is an open label feasibility pilot study of commercially available physical activity monitoring devices in patients receiving systemic therapy at the Harold Simmons Cancer Center, UT Southwestern Medical Center.
2996906|NCT02583802|No Intervention|Control group|Control group received regular hemodialysis treatment, no given Ear pills and Shengmai capsule completed in the treatment of the first stage. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
2996907|NCT02583802|Experimental|Ear pills and Shengmai capsule|On regular hemodialysis based on given auricular Ear pills and Shengmai capsule
2996908|NCT02583789|Active Comparator|oral treprostinil|Dosing of oral treprostinil will be initiated at 0.125 mg three times daily. Dose escalations of oral treprostinil can occur every 72 hours (three consecutive doses) in 0.125 mg increments. Subjects will be titrated as tolerated to a goal dose of 2mg TID over a 6-week period.
2996909|NCT02583789|Placebo Comparator|Placebo|Placebo mimics oral treprostinil and will be taken three times a day
2996910|NCT02583776|Experimental|Unblinded CGM|"CGM data will be unblinded, with Hypo/hyperglycemia alarms on. Data will be recorded from CGM every three hours and intervention to adequate glucose intake will be performed to keep glycemia in normal range (72-144mg/dl) if necessary."
2996911|NCT02583776|Other|Blinded CGM|Hypo/hyper alarms are off. CGM data will be blinded. Glucose intake will be adequate according to 2-3 capillary glycemic tests per day.
2996912|NCT02583763||Fetuses/Children with IUGR|"The moving sequences of the heart movement are collected at the regular ultrasound examinations during pregnancy. Following delivery the investigators plan to examine the baby with cardiac ultrasound, echocardiography, between 12 and 72 hours after delivery and again when the child is 3-4 months old and at 7 years of age.~Blood sample will be taken from the umbilical cord at birth and again at 7 years of age. The investigators will analyse the blood for growth factors and cardiac markers. An additional ethical approval was accepted 2015 for analysing epigenetic factors in the children's DNA."
2996913|NCT02583763||Healthy Controls|"The moving sequences of the heart movement are collected at two occasions approximately 4 weeks apart. This takes place during gestational weeks 28-36. Following delivery the investigators plan to examine the baby with cardiac ultrasound, echocardiography, between 12 and 72 hours after delivery and again when the child is 3-4 months old and at 7 years of age.~Blood sample will be taken from the umbilical cord at birth and again at 7 years of age. The investigators will analyze the blood for growth factors and cardiac markers. An additional ethical approval was accepted 2015 for analysing epigenetic factors in the children's DNA."
2996914|NCT02583750|Experimental|OGTT after deprived sleep first|Participants came to the lab to perform the oral glucose tolerance test after three nights of sleep deprivation, then another test after three nights of sufficient sleep
2996915|NCT02583750|Experimental|OGTT after sufficient sleep first|Participants came to the lab to perform the oral glucose tolerance test after three nights of sufficient sleep, then another test after three nights of deprived sleep
2996916|NCT02583737|Active Comparator|group lyophilized bone allograft|sinus lifting with tissue bank lyophilized bone filling
2996917|NCT02583737|Active Comparator|group freeze bone allograft|sinus lifting with freeze bone bank filling
2996918|NCT02583698|Experimental|Carvedilol|Tab Carvedilol 3.125 mg twice daily followed by 6.25 mg BD and finally 12.5 mg BD if SBP > 90 mmHg and HR >55/min
2996919|NCT02583698|Placebo Comparator|placebo|
2996920|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 4 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 2 will receive LDV/SOF + ASV for 4 weeks.
2996921|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 4 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 2 will receive LDV/SOF + SMV for 4 weeks.
2996922|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 6 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 4 will receive LDV/SOF + ASV for 6 weeks.
2996981|NCT02583295|Active Comparator|Maternal sound group|Maternal sound
2996923|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 6 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 4 will receive LDV/SOF + SMV for 6 weeks.
2996924|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 8 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA > 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + ASV for 8 weeks.
2996925|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 8 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA > 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + SMV for 8 weeks.
2996926|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 12 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <2 log drop by week 4 will receive LDV/SOF + ASV for 12 weeks.
2996927|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 12 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <2 log drop by week 4 will receive LDV/SOF + SMV for 12 weeks.
2996928|NCT02583672|Experimental|N-acetylcysteine|The first 10 GD1 subjects will take 1800mg NAC twice daily (3600mg/day) orally for approximately 90 days. An interim analysis will be performed to determine if this dose produces changes in systemic redox status and brain glutathione (GSH) levels. If no signal of a significant change is observed, the remaining 20 subjects will receive up to 3600 mg NAC orally twice a day (7200 mg/day).
2996929|NCT02583659||Combined chemotherapy|AGC patients treated with first-line combined chemotherapy
2996930|NCT02583633|Active Comparator|Group one have received Transdermal nitroglycerin|transdermal GTN (Schwarz Pharma AG, Monheim, FRG) were prescribed and placed on the patient forearm. Each patch contained 37.4 mg of glyceryl trinitrate which was released in blood stream (10mg/24hour). After one hour of the first patch application, the uterine contractions were evaluated.
2996931|NCT02583633|Active Comparator|Group two have received nifedipine|"For the nifedipine group, nifedipine 5mg softgel (Daana Pharma Co., Tabriz, Iran) was prescribed. In this group, the order of medicine prescription was as below;~One softgel every 20 min (4 doses)~Two softgel every 6 hr (4 doses)~One softgel every 6 hr (4 doses)~One softgel every 8 hr (3 doses) Likewise, the uterine contractions were checked every one hour and if the contraction didn't subside or there was any change in dilation and effacement, the treatment were stopped and another tocolytic were applied."
2996932|NCT02583620|Other|Emmetropic volunteers|Blood sample
2996933|NCT02583620|Other|High myopic volunteers|Blood sample
2996934|NCT02583607|Experimental|Brava and fat transfer|"The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.~Woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it."
2996935|NCT02583594|Experimental|alemtuzumab (subcutaneous injection)|Dose 1 (initial course) of alemtuzumab will be administered subcutaneously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine [loratadine, cetirizine, dexchlorpheniramine], paracetamol, acyclovir) will be administered prior alemtuzumab administration.
2996936|NCT02583594|Experimental|alemtuzumab (intravenous infusion)|Dose 1 (initial course) of alemtuzumab will be administered intravenously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine [loratadine, cetirizine, dexchlorpheniramine], paracetamol, acyclovir) will be administered prior alemtuzumab administration.
2996937|NCT02583581|Experimental|Participants diagnosed with migraine|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv)
2996938|NCT02583568|Experimental|Part 1|In part 1 a dose escalation will be performed for the tracer bevacizumab-800CW in four different dose groups (4,5mg 10mg 25mg 50mg)
2996939|NCT02583568|Experimental|Part 2|In part 2, the two best performing dose groups of bevacizumab-800CW of part 1 will be expanded to a total of 10 patients per group.
2996940|NCT02583555|Active Comparator|Active patient support|Interview followed by frequent telephone support Questionnaire every 3 months
2996941|NCT02583555|No Intervention|Controls|Questionnaire every 3 months
2996942|NCT02583542|Experimental|Dose Escalation Phase (Phase Ib)|This phase will investigate two different dosing schedules of AZD2014: a continuous daily schedule (CC-Schedule) and an intermittent schedule of 2 days on and 5 days off treatment (IC-Schedule). The dose of Selumetinib (AZD6244) will remain unchanged in both schedules. The outcome of this investigation will determine whether an additional schedule of combined intermittent Selumetinib (AZD6244) (3 days on and 4 days off treatment) with intermittent AZD2014 will be considered (II-Schedule). The II-Schedule will be initiated following the completion of the corresponding continuous regimens and will only be investigated if escalation of the AZD2014 dose in the IC-Schedule is not feasible with the corresponding continuous Selumetinib (AZD6244) regimen. Up to three individual dose levels of Selumetinib (AZD6244) might subsequently be explored within the intermittent schedule of Selumetinib (AZD6244).
2996943|NCT02583542|Experimental|Dose Expansion Phase (Phase IIa)|"Following the definition of the recommended Phase 2 Dose (RP2D), three NSCLC and one TNBC dose expansion cohorts are planned to perform a preliminary assessment of the anti-tumour efficacy in different molecular settings and to further establish the safety profile of the selected RP2D. These cohorts are:~Triple-negative breast cancer (TNBC)~Squamous cell lung cancers~Non-squamous cell lung cancers with KRAS mutations~Non-squamous cell lung cancers with wild-type KRAS"
2996944|NCT02583529|Experimental|Back Tibial Nerve Electrostimulation|They will be assessed before and after 12 weeks of treatment with home PTNE through specific form of questionnaires assessing incontinence, quality of life and voiding diary. After the end of treatment will be made up of patients to verify the effectiveness of treatment in 30 to 90 days.
2996945|NCT02583529|Placebo Comparator|Placebo Electrostimulation|They will be assessed before and after 12 weeks of treatment with home PTNE through specific form of questionnaires assessing incontinence, quality of life and voiding diary. After the end of treatment will be made up of patients to verify the effectiveness of treatment in 30 to 90 days.
2996946|NCT02583516|Experimental|A - Continuous Administration|960 mg of vemurafenib po, bid, days 1 to 28 and 60 mg of cobimetinib po, od, days 1 to 21, for each 28-days' cycle.
2996982|NCT02583282|Experimental|Doxycycline|Intrapleural doxycycline
2996983|NCT02583282|Active Comparator|Iodopovidine|Intrapleural iodopovidine
2997491|NCT02579733|Active Comparator|Azathioprine|Azathioprine (1.5mg/kg) po for 1 year
2996947|NCT02583516|Experimental|B - Intermittent Administration|960 mg of vemurafenib po, bid, days 1 to 28 and 60 mg of cobimetinib po, od, days 1 to 21, for each 28-days' cycle, during 12 weeks. After that period, patients will be treated with both drugs at the same doses indicated previously, but with an intermittent pattern: vemurafenib days 1 to 28 followed by 14 days off (4 weeks on and 2 weeks off) and cobimetinib days 1 to 21 followed by 21 days off (3 weeks on and 3 weeks off)
2996948|NCT02583503||Hindfoot alignment view x ray|Patients undergoing TKR for osteoarthritis will have an additional x ray (hindfoot alignment view) as well as the standard hip knee ankle x ray extended to include the heel.
2996949|NCT02583490|Experimental|Low Pulse Amplitude ECT (LAP)|Right Unilateral LAP ECT
2996950|NCT02583490|Active Comparator|standard Right Unilateral ECT|standard Right Unilateral ECT
2996951|NCT02583477|Experimental|MEDI4736 +nab-paclitaxel + gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
2996952|NCT02583477|Experimental|MEDI4736+AZD5069|MEDI4736 via IV infusion and oral AZD5069
2996953|NCT02583464|Experimental|Test-Reference|A new formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).
2996954|NCT02583464|Experimental|Reference-Test|A branded formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (R) followed by a new formulation (T).
2996955|NCT02583451|Experimental|Treatment A|Treatment A is a placebo tablet matching lemborexant and placebo tablet matching zopiclone on nights in the clinic; placebo tablet matching lemborexant on nights at home.
2996956|NCT02583451|Experimental|Treatment B|Treatment B is zopiclone 7.5 mg tablet and placebo tablet matching lemborexant on nights in the clinic; placebo tablet matching lemborexant on nights at home.
2996957|NCT02583451|Experimental|Treatment C|Treatment C is lemborexant 2.5 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 2.5 mg tablet on nights at home.
2996958|NCT02583451|Experimental|Treatment D|Treatment D is lemborexant 5 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 5 mg tablet on nights at home.
2996959|NCT02583451|Experimental|Treatment E|Treatment E is lemborexant 10 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 10 mg tablet on nights at home.
2996960|NCT02583438|Experimental|Lifestyle intervention|
2996961|NCT02583425|Experimental|DFN-11|DFN-11 Injection upon occurrence of migraine
2996962|NCT02583412|Active Comparator|Group 1: Accelerated Schedule|
2996963|NCT02583412|Active Comparator|Group 2: Standard Schedule|
2996964|NCT02583399|Experimental|Ibuprofen|Ibuprofen, 10 mg/kg
2996965|NCT02583386|Active Comparator|Free From Falls training group|Subjects randomized to this group will receive an 8 week exercise and educational program on fall prevention (Free From Falls fall prevention program). They will have mobility and quality of life assessments taken at baseline, after the training program has been completed, and 3 and 6 months later. During this time, their falls will be recorded monthly using prospective falls calendars.
2996966|NCT02583386|No Intervention|Wait-list control group|Subjects in this group will participate in the same mobility and quality of life assessments and completion of the falls calendars, but will receive no training classes during this time. These subjects will have the opportunity to receive the class sessions when all assessment visits have been completed.
2996967|NCT02583386|Active Comparator|FFF training group w/ Fall Detector|"Subjects randomized to this group will receive an 8 week exercise and educational program on fall prevention (Free From Falls fall prevention program). They will have mobility and quality of life assessments taken at baseline, after the training program has been completed, and 3 and 6 months later. During this time, their falls will be recorded monthly using prospective falls calendars.~In addition, this group will be asked to wear electronic fall detectors on their bodies for the first 10 weeks of their participation in the study."
2996968|NCT02583386|Other|Wait-list control w/ Fall Detector|"Subjects in this group will participate in the same mobility and quality of life assessments and completion of the falls calendars, but will receive no training classes during this time. These subjects will have the opportunity to receive the class sessions when all assessment visits have been completed.~In addition, this group will be asked to wear electronic fall detectors on their bodies for the first 10 weeks of their participation in the study."
2996969|NCT02583373|Active Comparator|CAL02 Low-dose|Liposomal formulation
2996970|NCT02583373|Active Comparator|CAL02 High-dose|Liposomal formulation
2996971|NCT02583373|Placebo Comparator|Placebo|Saline
2996972|NCT02583360|Active Comparator|Modified Flow Rate|This group of subjects will be prescribed the use of a bottle nipple that has a slower flow rate than what the subject was initially using.
2996973|NCT02583360|Active Comparator|Modified Thickening|This group of subjects will receive modified thickening. The subjects will be prescribed thickened formula using a standard thickening agent.
2996974|NCT02583334|Experimental|Verum Acupuncture|After diagnosis by rheumatologist, participants will be randomized to receive verum acupuncture or sham acupuncture treatment. In the verum acupuncture group, participants will receive verum acupuncture (Device: 30# acupuncture needle) three times a week, for 4 weeks (12 treatment in total).
2996975|NCT02583334|Sham Comparator|Sham Acupuncture|After diagnosis by rheumatologist, participants will be randomized to receive verum acupuncture or sham acupuncture treatment. In the sham acupuncture group, participants will receive sham acupuncture (Device: Streitberger device) three times a week, for 4 weeks (12 treatment in total).
2996976|NCT02583321|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions
2996977|NCT02583321|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
2996978|NCT02583308|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions
2996979|NCT02583308|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
2996980|NCT02583295|Active Comparator|Music group|Music sound
2996984|NCT02583269|Experimental|Treatment (muscadine grape skin extract)|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
2996985|NCT02583256|Experimental|aQIV-aQIV|Subjects previously vaccinated with aQIV followed one year later by aQiV
2996986|NCT02583256|Experimental|aQIV-QIV|Subjects previously vaccinated with aQIV followed one year later by QIV
2996987|NCT02583256|Experimental|QIV-aQIV|Subjects previously vaccinated with QIV followed one year later by aQIV
2996988|NCT02583256|Experimental|QIV-QIV|Subjects previously vaccinated with QIV followed one year later by QIV
2996989|NCT02583230|Experimental|MedLink|For 8 weeks, the patient who is newly prescribed antidepressant medication will receive a mobile phone app (and a phone if they do not have a compatible Android phone) and a GSM enable pill bottle in order to provide and receive feedback regarding medication adherence.
2996990|NCT02583217||Ketamine|Ketamine+propofol
2996991|NCT02583217||Remifentanyl|Remifentanyl+propofol
2996992|NCT02583204|No Intervention|Control - standard care|Participants will receive standard care regarding nail toxicity. This entails advice to keep nails trim and the provision of a nail oil to massage into the nail daily. Participants will also receive advice in relation to general healthy living.
2996993|NCT02583204|Experimental|Intervention - Oncolife drops|Participants will receive the same standard care as the control arm, except for the nail drops. The participants will also receive Onicolife nail drops to be applied twice daily.
2996994|NCT02583204|Experimental|Intervention - Nail polish|Participants will receive the same standard care as the control arm, except for the nail drops. The participants will also receive a dark coloured nail polish to be applied as instructed.
2996995|NCT02583191|Experimental|Rivaroxaban|Arm A: Rivaroxaban
2996996|NCT02583191|Active Comparator|low-molecular heparine|Arm B: standard treatment with low-molecular heparine
2996997|NCT02583178|Experimental|Aegis Sierra Ligation System|The Aegis Sierra Ligation System is a series of devices designed for epicardial ligation of the Left Atrial Appendage through a minimally invasive transcatheter approach.
2996998|NCT02583165|Experimental|Monotherapy arm|MEDI1873
2996999|NCT02583152||MPS patient cohort|Participants with Mucopolysaccharidosis. types I-IV, VI and VII will be recruited from the paediatric and adult ophthalmology. Participants over the age of three who are able to comply and be investigated.
2997000|NCT02583139|Experimental|Music Narrative Group|Prescribed medical/chemotherapy treatment plus standard care + Designed Music Narratives
2997001|NCT02583139|No Intervention|Control Group|Prescribed medical/chemotherapy treatment plus standard care
2997002|NCT02583126|Experimental|Music Group|Prescribed medical/chemotherapy treatment plus standard care + Guided Imagery and Music
2997003|NCT02583126|No Intervention|Control Group|Prescribed medical/chemotherapy treatment plus standard care
2997004|NCT02583113||Total and Unicompartment Knee Replacement|
2997005|NCT02583100|Experimental|Intensive Feedback|Participants in this arm will receive intensive feedback on their complication rates, surgical technique, and peri-operative surgical management from peer surgeons participating in the study.
2997006|NCT02583100|Active Comparator|Routine Feedback|Participants in this arm will receive routine feedback on their complication rates.
2997007|NCT02583074|Experimental|Stimulation Group|Patients in 'Neurostimulation Group' will receive subthalamic nucleus deep brain stimulation for 3 months.
2997008|NCT02583074|Sham Comparator|Sham-stimulation Group|Patients in 'Sham-stimulation Group' will receive sham stimulation of subthalamic nucleus for 3 months.
2997009|NCT02583048|Experimental|Arm 1: Bedaquiline|Participants will receive 400 mg of bedaquiline once a day for 2 weeks followed by 200 mg of bedaquiline three times a week for 22 weeks.
2997010|NCT02583048|Experimental|Arm 2: Delamanid|Participants will receive 100 mg of delamanid twice a day for 24 weeks.
2997011|NCT02583048|Experimental|Arm 3: Bedaquiline and Delamanid|Participants will receive 400 mg of bedaquiline once a day and 100 mg of delamanid twice a day for 2 weeks. They will then receive 200 mg of bedaquiline three times a week and 100 mg of delamanid twice a day for 22 weeks.
2997012|NCT02583035|Other|Nurse telephone contact|3 days of consultation, telephone follow-up of the patient by the nurse coordinator of the Geriatric Oncology Unit to validate
2997013|NCT02583022|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
2997014|NCT02583022|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
2997015|NCT02583022|Active Comparator|Elidel cream 1%|Elidel cream 1%, Twice daily for 4 weeks
2997016|NCT02583009|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 4 weeks
2997017|NCT02583009|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 4 weeks
2997018|NCT02583009|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
2997019|NCT02583009|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
2997020|NCT02582996|Experimental|Cefalium®|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.
2997021|NCT02582996|Active Comparator|Tylenol®|Acetaminophen
2997022|NCT02582983|Experimental|Enfuvirtide|Participants received Enfuvirtide 90 mg subcutaneously (SC) twice daily (BID).
2997023|NCT02582970|Experimental|Bevacizumab + Chemotherapy|Participants will receive IV bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 2 weeks in combination with standard of care chemotherapy regimen (5-Fluorouracil/Irinotecan/Oxaliplatin) until disease progression or until termination of the study.
2997024|NCT02582957|Experimental|Sigh breaths|Sigh breaths consisting of a Tidal volume (VT) that produces a plateau pressure (Pplat) of 35 cmH2O (or 40 cmH2O in patients with BMIs > 35 or in patients with moderate or severe abdominal distension from ascites, blood and/or ileum, or prone patients). The sigh breaths will be delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
2997025|NCT02582957|No Intervention|Usual Care|Usual care, meaning that the treating physician will be free to treat the patient in any way he or she sees fit, including utilizing invasive mechanical ventilation as they wish.
2997166|NCT02582008|Experimental|Arm A (bupropion hydrochloride)|Patients receive bupropion hydrochloride PO for 3 days and then BID for up to 1 year post RT/CRT.
2997026|NCT02582944|Experimental|Arm 1: Electromagnetic navigation|"The bronchoscope will be inserted transorally into the tracheobronchial tree and a standard airway inspection will be performed.~Following airway inspection, the bronchoscope will be removed and the tip tracked steerable catheter with optical system will be advanced transorally through the vocal cords and into the tracheobronchial tree.~Once the tip tracked catheter has been advanced to the peripheral pulmonary target lesion, the optical SpinView system will be removed from the tip tracked catheter and the 1.4mm radial endobronchial ultrasound mini-probe will be inserted through the tip-tracked catheter into the lung periphery to confirm the presence of a peripheral pulmonary lesion and accurate navigation.~Once target confirmation has been performed using radial probe endobronchial ultrasound, biopsy of the peripheral lesion will be performed using biopsy forceps, brushes and aspiration needles."
2997027|NCT02582931|Experimental|Arm 1: MRI-guided SBRT|"Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.~Patients will be planned for an initial dose of 35Gy to the planning target volume (PTV), with dose adaptation and reduction allowed based on safety constraints that are generally accepted, up to a maximum allowed total dose of 50Gy in five fractions to the PTV.~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site"
2997028|NCT02582918|No Intervention|Group 1: Usual Care|Usual care with opportunistic visit-based HCC surveillance.
2997029|NCT02582918|Experimental|Group 2: Patient Education and Patient Navigation Services|Mailed HCC surveillance outreach with patient education and patient navigation services.
2997030|NCT02582905|Placebo Comparator|Placebo|Matching placebo given beginning at 1 capsule BID increasing to 2 capsules BID at week 1, 3 capsules BID at week 2, and 4 capsules BID at weeks 3-12.
2997031|NCT02582905|Experimental|Citicoline|Citicoline will be given beginning at 250 mg BID with an increase to 500 mg BID at week 1, 750 mg BID at week 2, and 1000 mg BID at weeks 3-12.
2997032|NCT02582905|Experimental|Pregnenolone|Pregnenolone will be given beginning at 50 mg BID with an increase to 100 mg BID at week 1, 150 mg BID at week 2, and 250 mg BID at weeks 3-12.
2997033|NCT02582892|Other|Vit D|Vit D 20 mg/day
2997034|NCT02582879||Patient with CLL/SLL|Patients with CLL/SLL in a real-world setting initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL therapies/regimens.
2997035|NCT02582866|Experimental|Lacosamide|"Lacosamide (LCM) will be administered orally twice daily from 200 mg/day to 600 mg/day (at approximately 12 hour intervals in the morning and in the evening) in 2 divided doses. Medication must not be chewed and must be swallowed with a sufficient amount of fluid. The investigator may maintain the subject's LCM dose, decrease the dose in decrements of 100 mg/day per week to a minimum dose of LCM 200 mg/day, or increase the dose in increments of 100 mg/day per week up to a maximum dose of LCM 600 mg/day.~Subjects stopping LCM should be tapered off LCM at recommended decreasing steps of 200 mg/day/week. A slower taper (eg, 100 mg/day/week) or faster taper is permitted, if medically necessary; however, the maximum duration of tapering should not exceed 6 weeks."
2997036|NCT02582853||Patients diagnosed with GBS|"Patients will undergo a lumbar puncture as a part of the diagnostic procedure as soon as they are suspected to be suffering from GBS on clinical grounds with blood test. The procedure and a blood test will be repeated after 6 months.~Lumbar puncture Blood sample"
2997037|NCT02582853||Symptomatic controls|Controls include patients with unspecified neurological symptoms or diseases who will undergo a lumbar puncture at the Department of Neurology at Aarhus University Hospital as part of their diagnostic work up irrespective of this study. We expect to include 40 symptomatic controls.
2997038|NCT02582840|Experimental|dapagliflozin 5mg|dapagliflozin tablet 5mg
2997039|NCT02582840|Experimental|dapagliflozin 10mg|dapagliflozin tablet 10mg
2997040|NCT02582840|Placebo Comparator|Placebo|dapagliflozin tablet 5mg placebo or 10 mg placebo
2997041|NCT02582827|Experimental|ABI-011|IDN 5404 protein-bound particles for injectable suspension
2997042|NCT02582814|Experimental|dapagliflozin 5mg|dapagliflozin tablet 5mg
2997043|NCT02582814|Experimental|dapagliflozin 10mg|dapagliflozin tablet 10mg
2997044|NCT02582801|Experimental|breast cancer|Perform 18F-Alfatide Ⅱ PET/CT in breast cancer patients
2997045|NCT02582801|Active Comparator|benign breast lesions|Perform 18F-Alfatide Ⅱ PET/CT in patients with benign breast lesions
2997046|NCT02582788|Active Comparator|Bleach|Patients will use bleach added to their baths twice a week.
2997047|NCT02582788|Active Comparator|Vinegar|Patients will use vinegar (dilute acetic acid) added to their baths twice a week.
2997048|NCT02582775|Experimental|Arm A: HCT with 300 cGY of TBI|Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant without mesenchymal stem cell infusions.
2997049|NCT02582775|Experimental|Arm B: HCT plus MSC, 300 cGY of TBI|Epidermolysis bullosa patients treated per study regimen with chemotherapy and hematopoietic stem cell transplant with mesenchymal stem cell infusions using 300 cGY of TBI.
2997050|NCT02582775|Experimental|Arm C: Re-Transplant with 300 cGY of TBI|Epidermolysis bullosa patients treated regardless of original transplant arm with re-transplant using 300 cGy of TBI.
2997051|NCT02582775|Experimental|Arm D: HCT with 200 cGY BID of TBI|Epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGY BID of TBI (400 cGy total).
2997052|NCT02582775|Experimental|Arm E: HCT plus MSC, 200 cGY BID of TBI|Epidermolysis bullosa patients treated with hematopoietic cell transplant plus serial MSC infusions using 200 cGY BID of TBI (400 cGy total)
2997053|NCT02582762|Experimental|Nail gel|apply nail gel twice daily
2997054|NCT02582749|Active Comparator|Control Arm A|All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days.
2997055|NCT02582749|Experimental|Experimental Arm B|All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days. Radium-223 dichloride, 50 kBq/kg body weight, will be administered as a bolus intravenous (IV) injection at intervals of every 28 days for up to 6 cycles.
2997056|NCT02582736||Olanzapine|Exposure to olanzapine will be defined as a prescription for olanzapine on the date of cohort entry.
2997199|NCT02581774||prolonged pregnancies|Labor Monitoring and normal delivery tracking
2997057|NCT02582736||Other atypical antipsychotics|Exposure to atypical antipsychotics will be defined as a prescription for an atypical antipsychotic other than olanzapine (clozapine, quetiapine, ziprasidone, paliperidone, or aripiprazole) on the date of cohort entry.
2997058|NCT02582736||Typical antipsychotics|Exposure to typical antipsychotics will be defined as a prescription for a typical antipsychotic (chlormezanone, chlorpromazine, chlorprothixene, flupenthixol, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, mesoridazine, methotrimeprazine, perphenazine, pimozide, pipotiazine, tetrabenazine, thiopropazate, thioproperazine, thioridazine, thiothixene, trifluoperazine or zuclopenthixol) on the date of cohort entry.
2997059|NCT02582736||Risperidone (reference)|Exposure to risperidone will be defined as a prescription for risperidone on the date of cohort entry.
2997060|NCT02582723|Active Comparator|High protein/high fat hard cheese|Served for breakfast together with bread, juice and coffee, tea or water
2997061|NCT02582723|Active Comparator|High protein/low fat hard cheese|Served for breakfast together with bread, juice and coffee, tea or water
2997062|NCT02582723|Experimental|Low protein/high fat creme cheese|Served for breakfast together with bread, juice and coffee, tea or water
2997063|NCT02582710|Experimental|VASCAZEN|Patients treated with Vascazen
2997064|NCT02582710|Placebo Comparator|Placebo|Patients treated with a placebo
2997065|NCT02582697|Active Comparator|Standard Arm - Standard BEP|"Participants 16 years or older will receive 4 cycles of Standard BEP as follows:~Bleomycin 30,000 IU IV weekly for 3 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1 - 5~Pegylated G-CSF 6 mg SCI on day 6~Patients < 16 years old and weighs ≥ 45 kg will receive:~Bleomycin *15,000 - 30,000 IU IV weekly for 3 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1 - 5~Pegylated G-CSF 6 mg SCI on day 6~Patients <16 years old and weighs < 45 kg will receive:~Bleomycin *15,000 - 30,000 IU IV weekly for 3 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1 - 5~Filgrastim 10mcg/kg/day on day 6, until post-nadir Absolute Neutrophil Count ≥1 x10^9/ L~The dose of bleomycin is decided by the treating physician and based on the patient's Body Surface Area.~Each cycle is 3 weeks (21 days).~The planned total duration of treatment is 12 weeks."
2997066|NCT02582697|Experimental|Experimental Arm - Accelerated BEP|"Participants 16years or older will receive 4 cycles of Accelerated BEP as follows:~Bleomycin 30,000 IU IV wkly for 2 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1- 5~Pegylated G-CSF 6 mg SCI on day 6~Patients <16years and weighs ≥45 kg will receive:~Bleomycin *15,000 - 30,000 IU IV wkly for 2 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1 - 5~Pegylated G-CSF 6 mg SCI on day 6~Patients <16years and weighs <45 kg will receive:~Bleomycin *15,000 - 30,000 IU IV wkly for 2 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1 - 5~Filgrastim 10mcg/kg/day on day 6, until ANC ≥1 x10^9/ L~Each cycle is 2 weeks (14days)~Following 4xBEP cycles, patients will receive additional bleomycin as follows:~- Bleomycin *15,000 - 30,000 IU IV wkly for 4 doses~* The dose of bleomycin is decided by the treating physician and based on the patient's BSA.~The planned total duration is 12 weeks."
2997067|NCT02582684|Experimental|Arm 1: DTG 50 mg + 3TC 300 mg|Dolutegravir 50mg and Lamivudine 300mg, orally daily
2997068|NCT02582671||Chronic Hepatitis C|Participants with chronic hepatitis C who are being treated with the AbbVie Regimen +/- Ribavarin.
2997069|NCT02582658||Chronic infection of HCV GT1 or GT4|Participants with confirmed chronic hepatitis C genotype 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN ± Ribavirin (RBV) according to standard of care and in line with the current local label
2997070|NCT02582645|Experimental|OWT - open window technique|In this arm, a palatally impacted canine will be exposed surgically and left for max 9 months. No traction will be applied during this time.
2997071|NCT02582645|Active Comparator|CWT - closed window technique|In this arm, a palatally impacted canine will be exposed surgically, an attachment will be bonded to the tooth and traction will be applied after healing period is complete (1-2 weeks).
2997072|NCT02582632|Experimental|Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir|Ombitasvir/Paritaprevir/Ritonavir(25 mg/150 mg/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 8 weeks
2997073|NCT02582619||Rehabilitation Professionals|Focus group consisting of rehabilitation professionals that will inform the study on vocational rehabilitation interventions rendered during acute to in-patient rehabilitation in KwaZulu-Natal.
2997074|NCT02582619||People living with Spinal Cord Injuries (PLWSCI)|"Focus group consisting of PLWSCI that will inform the study on the perspective of the patient on vocational rehabilitation needs or desires during acute care and in-patient rehabilitation.~This group will inform the study on the employment rate amongst people living with spinal cord injuries as well as factors that influence employment.~This group will also inform the study on the perceived barriers and facilitators of employment"
2997075|NCT02582619||Stakeholders|"Representatives from the following departments or organisations will be invited to participate in the interviews and focus groups:~Government Departments:~Education Social Development Health Labour Transport~Private Companies:~Insurance Companies and Health Risk Management companies Non-profit Organisations QASA DPSA"
2997076|NCT02582619||Experts|A delphi technique will be used to get an expert opinion and consensus on the aspects of the model to be developed.
2997077|NCT02582606|Experimental|Regular|Regular meal pattern
2997078|NCT02582606|Experimental|Irregular|Irregular meal pattern
2997079|NCT02582593|Active Comparator|Cognitively Normal Group NIR|Transcranial Near Infrared Stimulation for cognitively normal participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
2997080|NCT02582593|Sham Comparator|Cognitively Normal Group - Sham|Cognitively Normal Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
2997200|NCT02581761|Experimental|Cytotec treatment group|patient with pregnancy of unkown location will receive cytotec 800 mcg per vaginal
2997081|NCT02582593|Active Comparator|Amnestic MCI Groups - Amnestic and Nonamnestic NIR|Transcranial Near Infrared Stimulation for amnestic and nonamnestic participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
2997082|NCT02582593|Sham Comparator|Amnestic MCI Groups - Amnestic and Nonamnestic - Sham|Amnestic and Nonamnestic Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
2997083|NCT02582593|Active Comparator|Parkinson Disease Group NIR|Transcranial Near Infrared Stimulation for Parkinson Disease participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
2997084|NCT02582593|Sham Comparator|Parkinson Disease Group Sham|Parkinson Disease Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
2997085|NCT02582580|Active Comparator|Perineal Massage|Massage is made in the perineum and vagina using your fingers to promote stretching of pelvic floor structures, making them more flexible and distensíveis, avoiding trauma during vaginal birth.
2997086|NCT02582580|Active Comparator|Vaginal Dilator|This device consists of a silicone balloon in an eight shape that, after inserted into the vagina, is inflated by manual pumping, promoting a stretching of the structures around it (hymenal edge, connective tissues and muscles perivaginal). This equipment assists the stretching of tissues around the vagina and the pelvic floor muscles, minimizing the risk of injury from the birth canal during the passage of the baby.
2997087|NCT02582580|Active Comparator|Pelvic floor muscles training|Exercises emphasizing conscious muscle relaxation, i.e., considering a resting time based on the contraction time. The resting time was double of the sustaining time of each contraction up to the 38th week of pregnancy, after remaining fixed this relaxation time up to the moment of delivery. This time was chosen because during the expulsive labor phase, there is a need for the pelvic floor muscles to consciously relax during a long period, in order to facilitate the descendants and rotational movements of the baby's head and consequently, its passage. This exercises does not aim only muscle strength but also contraction promotion, which aims body and perineal awareness, muscle tone, coordination and appropriate motor control to allow an active muscle relaxation in the second labor stage.
2997088|NCT02582567|Experimental|Exercise intervention|3 times per week from the 17th week of gestation until delivery
2997089|NCT02582567|No Intervention|Control group|Usual care (control) group
2997090|NCT02582554|Experimental|Intervention|Intervention: NutriSTEP The intervention will be the administration of NutriSTEP, a nutrition risk screening questionnaire for preschoolers along with a nutrition education brochure called How to Build a Healthy Preschooler
2997091|NCT02582554|No Intervention|Control|Control: Wait-list control The wait-list control group will complete the NutriSTEP and receive the nutrition education information at the end of the 3 month study period
2997092|NCT02582541|Active Comparator|SEMS alone|Endoscopic retrograde cholangiopancreatography (ERCP) was performed under standard operating conditions with a duodenoscope (TJF 260V, Olympus, Tokyo, Japan) to confirm the length of the biliary stricture, diameter, and position. An uncovered self expanding metallic stent (SEMS) (Wallstent, Boston Scientific, USA) would be placed across the biliary stricture.
2997093|NCT02582541|Experimental|SEMS plus radiofrequency ablation|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. The Habib EndoHBP catheter (Emcision, London, United Kingdom) was placed through the biliary stricture under fluoroscopic guidance. The RFA energy can be delivered repetitively at different tumor sites within one procedure, according to the stricture size. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
2997094|NCT02582528|Experimental|cognitive remediation treatment and MI|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS) and motivational interviewing, a client-centered, directive method for enhancing intrinsic motivation to change.
2997095|NCT02582528|Active Comparator|cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
2997096|NCT02582515|Experimental|D-cycloserine + Habit Reversal Training|Participants randomly assigned to the D-cycloserine (DCS) condition will receive a single dose of DCS immediately prior to a single session of habit reversal training. Participants will be evaluated 1 week later for improvement in tics targeted in the treatment session.
2997097|NCT02582515|Placebo Comparator|Placebo + Habit Reversal Training|Participants randomly assigned to the placebo condition will receive a single dose of placebo immediately prior to a single session of habit reversal training. Participants will be evaluated 1 week later for improvement in tics targeted in the treatment session.
2997098|NCT02582502|Experimental|Treatment|This arm will receive Hyperbaric Oxygen Therapy immediately after consent into study.
2997099|NCT02582502|Other|Wait list Treatment|This arm will receive Hyperbaric Oxygen Therapy two months after consenting into study.
2997201|NCT02581761|Placebo Comparator|Placebo treatment group|patient with pregnancy of unkown location will receive suppository which contain Whitepsol H-15 with no active material (Cytotec).
2997202|NCT02581748|Experimental|safety|Assessment of safety of HLX02 at different doses
2997100|NCT02582489|Experimental|Meniscectomy with Bone Marrow Aspirate Concentrate (BMAC)|Subjects will undergo the scheduled meniscectomy procedure. Following the procedure the investigator will make a small incision and create the marrow access channel in the proximal tibia. The experimental group will then have bone marrow harvested and BMAC will be prepared using a BMAC harvesting system. The automated centrifuge system rapidly concentrates cellular contents and growth factors in bone marrow aspirate using flow cytometry. The BMAC will be injected intra-articularly.
2997101|NCT02582489|Placebo Comparator|Meniscectomy with Placebo|Subjects will undergo the same meniscectomy procedure and will also have an incision and marrow access channel made in the proximal tibia, however no bone marrow will be harvested. The control group will have a placebo injection of saline into the affected knee.
2997102|NCT02582450||Patients with haemophilia|Sample of patients with haemophilia over 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
2997103|NCT02582437|Experimental|Chronic Opioid User|"The patients (ASA class I-III) who receive elective surgery s aging between 41 and 69 and signed in informed consent to participate in this trial voluntarily.~The Patients who use opioid medication daily and regularly immediately before the day of surgery for more than four weeks. The minimum criteria for opioid dose in the intervention goup is oral morphine 20mg per day: Morphine Equivalent Daily Dose(MEDD)"
2997104|NCT02582437|No Intervention|Opioid Naive patient|"The patients (ASA class I-III) who receive elective surgery aging between 41 and 69 and signed in informed consent to participate in this trial voluntarily.~The patients who do not use opioid medications immediately before the day of surgery for four weeks."
2997105|NCT02582424|Experimental|PDL-0101|EPA +astaxanthin
2997106|NCT02582424|Placebo Comparator|placebo|olive oil
2997107|NCT02582411||Group 1: 18-34 years|Patients in age group 18-34 years
2997108|NCT02582411||Group 2: 35-49 years|Patients in age group 35-49 years
2997109|NCT02582411||Group 3: 50-64 years|Patients in age group 50-64 years
2997110|NCT02582411||Group 4: 65-80 years|Patients in age group 65-80 years
2997111|NCT02582398|Experimental|Light Therapy|One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.
2997112|NCT02582398|Placebo Comparator|Placebo Light|The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (<400nm or >500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
2997113|NCT02582385||Amyotrophic lateral sclerosis (ALS)|Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from patients who died with an amyotrophic lateral sclerosis.
2997114|NCT02582385||Control|Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from one non-ALS case.
2997115|NCT02582372|Experimental|dexmedetomidine|25 patients recieve subarachnoidal anesthesia with 12,5 mgrs of bupivacaine 0,5% plus 10 micrograms of dexmedetomidine, with needle 25 gauge
2997116|NCT02582372|Active Comparator|fentanyl|25 patients recieve subarachnoidal anesthesia with 12,5 mgrs of bupivacaine 0,5% plus 25 micrograms of fentanyl, with needle 25 gauge
2997117|NCT02582359|Experimental|MLN9708|"Phase I dose escalation study of MLN9708 with induction chemotherapy~MLN9708 -oral on predetermined days per cycle~Cytarabine, continuous infusion for predetermined duration and dosage~Daunorubicin short IV infusion or rapid injection for predetermined~Phase I dose escalation study of MLN9708 with consolidation chemotherapy after establishment of MTD with induction"
2997118|NCT02582346|Experimental|MRI acquisition - no contrast agent|Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
2997119|NCT02582333||Tenofovir|Chronic hepatitis B patients who receive tenofovir as their first anti-HBV therapy and are indicated for stopping tenofovir therapy
2997120|NCT02582333||Entecavir|Chronic hepatitis B patients who receive entecavir as their first anti-HBV therapy and are indicated for stopping entecavir therapy
2997121|NCT02582320||Study patients|Patients with Relapsed or refractory CLL or 17p deleted CLL fulfilling the eligibility criteria required by the Named Patient Program (NPP) who received at least 1 dose of Ibrutinib 420 mg daily before November, 30th 2014.
2997122|NCT02582307|Experimental|Hyoscine butylbromide|Hyoscine butylbromide 10mg oral single dose
2997123|NCT02582307|Active Comparator|Acetaminophen|Acetaminophen 15mg/kg oral single dose (maximum 1000mg)
2997124|NCT02582281|Experimental|Non touch technique|"the intrauterine device TCu 380A will be inserted in the conventional method as follows: First, insert the speculum and view the cervix. The position of the cervix will very often confirm if the uterus is anteverted or retroverted. Second, using the Allis forceps hold the back of a cotton-ball swab and dip it into a povidine-iodine disinfectant solution, or equivalent. Swab the cervix. Then cut the threads to the appropriate length and remove the speculum.~This technique omits the sounding of the uterus which is considered a quintessential procedure before IUD insertion for which there is no one established piece of evidence.The IUD is checked afterwards by transvaginal ultrasound."
2997125|NCT02582281|Experimental|Traditional IUD insertion|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound.
2997126|NCT02582268|Experimental|TAS guided IUD insertion|the female will be asked to be full bladder. the trans-abdominal probe will be placed by an assistant on the suprapubic region. under speculum examination, the intrauterine device IUD (TCu 380A) will be placed till it reaches the fundus of the uterus and then released.
2997127|NCT02582268|Experimental|Traditional IUD insertion|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound. the trans-abdominal probe will also be placed by an assistant on the suprapubic region ( the image would be on freeze mode) as it is not actually used , it is just to make the same settings for the participant females.
2997269|NCT02581293|Experimental|Both of them will be closed|Group 3: Both of them will be closed
3027606|NCT02377999|Experimental|Treatment of genetial warts with Picato|
2997128|NCT02582255|Experimental|SABIN mOPV2|"Polio Sabin™ Mono Two (oral) is a WHO prequalified, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P712,Ch,2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2. Magnesium chloride is used as a stabilizer. Polio Sabin™ Mono Two (Oral) contains trace amounts of neomycin sulphate and polymyxin B sulphate.~One dose of vaccine (0.1 mL) is contained in two drops which are delivered from the polyethylene dropper supplied with vaccine."
2997129|NCT02582242|Experimental|BIAsp 30 TID|
2997130|NCT02582242|Active Comparator|BIAsp 30 BID|
2997131|NCT02582229|Experimental|Interventionnal|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
2997132|NCT02582216|Experimental|Open label|
2997133|NCT02582203|Active Comparator|Ceftaroline|600 mg IV (over 1 hour) every 12 hours for renal function > 50 mL/min, adjusted for renal function based on package insert for no more than 14 days.
2997134|NCT02582203|Active Comparator|Vancomycin|Dosed by institutional pharmacy protocol to reach goal trough level of 10 - 20 mg/L steady state concentration for no more than 14 days.
2997135|NCT02582190|Other|Colchicine group|Colchicine add on therapy in atrial fibrillation
2997136|NCT02582177|Experimental|Candicort®|Ketoconazole + betamethasone dipropionate
2997137|NCT02582177|Active Comparator|Baycuten N®|Clotrimazole + Dexamethasone acetate
2997138|NCT02582164|Experimental|Adult|Duke Biomedical Engineering's long-working distance OCT system imaging of adult participants ages ≥18 year of age
2997139|NCT02582164|Experimental|Teenage minors|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥13-≤17 years of age
2997140|NCT02582164|Experimental|Children-pre teen|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥7-≤12 years of age
2997141|NCT02582164|Experimental|Target age group ≥6 months to ≤6 years|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥6 months to ≤6 years of age
2997142|NCT02582151|Sham Comparator|Sham tibial nerve stimulation|Use of peripheral nerve stimulator in a location that will not actively stimulate the tibial nerve.
2997143|NCT02582151|Active Comparator|Tibial nerve stimulation|Transcutaneous peripheral nerve stimulator in a location that will actively stimulate the tibial nerve.
2997144|NCT02582138|Experimental|Multicomponent intervention (MCI)|The multicomponent intervention will include a physical activity programme, a nutritional intervention and an information and communications intervention.
2997145|NCT02582138|Active Comparator|Healthy Aging Lifestyle Education (HALE)|The health aging lifestyle education programme will be based on workshops. Participants will receive information on a variety of topics of relevance to older persons (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
2997146|NCT02582125|Experimental|ONO-4538|ONO-4538 water-soluble injection, 100 mg/vial, 3 times once every 2 weeks in each 6-week cycle
2997147|NCT02582112|Active Comparator|Warming group|Active Comparator: Warming group
2997148|NCT02582112|Placebo Comparator|Control group|Control group
2997149|NCT02582099|Active Comparator|Gentamicin|Gentamicin nasal irrigation in chronic rhinosinusitis amount 20 ml each pernostril
2997150|NCT02582099|Placebo Comparator|Normal saline|Normal saline nasal irrigation in chronic rhinosinusitis amount 20 ml each pernostril
2997151|NCT02582086|Experimental|BOR15001L7 Cream|BOR15001L7 Cream with 5% 15019L0
2997152|NCT02582086|Placebo Comparator|Placebo Cream|Placebo Cream
2997153|NCT02582073|Placebo Comparator|Placebo (0.5ml)|Six 0.5ml injections of placebo consisting of L-Tyrosine, Ph. Eur 2%
2997154|NCT02582073|Placebo Comparator|Placebo (1.0ml)|Six 1.0ml injections of placebo consisting of L-Tyrosine, Ph. Eur 2%
2997155|NCT02582073|Experimental|Grass MATA MPL (0.5ml) 5100SU|Six 0.5 mL injections sequentially of placebo, placebo, 300, 800, 2000 and 2000 SU of Grass MATA with 50 µg/0.5 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 5100SU).
2997156|NCT02582073|Experimental|Grass MATA MPL (1.0ml) 10200SU|Six 1.0 mL injections sequentially of placebo, placebo, 600, 1600, 4000 and 4000 SU of Grass MATA per 1.0 mL and 50 µg/1.0 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 10200 SU).
2997157|NCT02582073|Experimental|Grass MATA MPL (1.0ml) 18200SU|Six 1.0 mL injections sequentially of placebo, 600, 1600, 4000, 4000, 4000 and 4000 SU of Grass MATA per 1.0 mL and 50 µg/1.0 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 18200 SU).
2997158|NCT02582073|Active Comparator|Grass MATA (0.5ml) 5100SU|Six 0.5ml injections sequentially of placebo, placebo, 300, 800, 2000 and 2000 SU of Grass MATA adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 5100SU).
2997159|NCT02582060|Other|Severe Hemophilia A Subjects|The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
2997160|NCT02582047|Active Comparator|Influenza vaccination with PPV23|concomitant vaccination with trivalent inactivated influenza vaccine and 23-valent polysaccharide pneumococcal vaccine
2997161|NCT02582047|Active Comparator|Influenza vaccination with PCV13|concomitant vaccination with trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine
2997162|NCT02582034|Active Comparator|Standard dosimetry|Standard Internal Radiation Therapy : Dose of radiation delivered to the tumoral volume is fixed : 120 Gray (GY)
2997163|NCT02582034|Experimental|Optimized dosimetry|Optimized Internal Radiation Therapy : Dose of radiation absorbed by the tumor is > 205 GY, if possible 250 or 300 Gy.
2997164|NCT02582021||Women|Women undergoing clinically-ordered coronary angiography for signs and symptoms of ischemia who have no obstructive coronary artery disease (CAD)
2997165|NCT02582021||Women or men|Women and men hospitalized for signs and symptoms of ischemia and evidence of Heart Failure with preserved ejection fraction (HFpEF) who have not undergone a clinically-ordered coronary angiography
2997270|NCT02581293|Experimental|None of them will be closed|Group 4: None of them will be closed
2997167|NCT02582008|Active Comparator|Arm B (varenicline, NRT)|Patients receive smoking cessation treatment tailored to individual smokers based on preference, smoking history and contra-indications. Patients are given the choice of one of the NCCN-recommended first-line pharmacotherapy options for smoking cessation comprised of varenicline PO daily for 1 week and then BID for 12 weeks or combination of nicotine patch and acute NRT for 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Treatment with varenicline or NRT can be extended up to 6 months to 1 year as needed.
2997168|NCT02581995|Experimental|Arm 1 / Quality of Life|Aflibercept treatment in subjects with diabetic macular edema (DME)
2997169|NCT02581982|Experimental|Treatment (pembrolizumab, paclitaxel)|Patients receive pembrolizumab IV over 30 minutes on day 1 and paclitaxel IV over 60 minutes on day 1 and 8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
2997170|NCT02581969||Prophylaxis|Prophylaxis group: treatment is based on regularly repeated infusions of clotting factor, 20-30 IU/kg -3 times a week
2997171|NCT02581969||On-demand|On-demand group: treatment administered when bleeding episode occur
2997172|NCT02581956|Experimental|Walking Exercise|For the exercise group, subjects were asked to follow a simple walking regimen. Walk normally with stable and comfortable stride rates during their exercise. The duration and frequency was initiated at a 30-minute or more daily exercise at least five days per week and gradually increased to a maximum of 60 minutes within subject's comfort zone.
2997173|NCT02581956|Placebo Comparator|No Intervention|No exercise required
2997174|NCT02581943|Experimental|Arm I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
2997175|NCT02581943|Experimental|Arm II (pembrolizumab, paclitaxel, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1, paclitaxel IV over 1 hour and carboplatin IV over 1 hour on days 1, 7 and 14. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
2997176|NCT02581930|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2997177|NCT02581917||Ancillary-Correlative (metabolic changes)|Patients undergo collection of PBMC samples for analysis via cell isolation, glycolytic flux and oxygen consumption assays, viability assays, and western blot at baseline, 24, 48, and 72 hours after starting chemotherapy.
2997178|NCT02581904|Experimental|High Risk - Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
2997179|NCT02581904|Active Comparator|High Risk - Dry Gauze Dressing Care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
2997180|NCT02581904|Active Comparator|Low Risk - Dry Gauze Dressing Care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
2997181|NCT02581891|Experimental|Early-start T&E / Arm 1|Early-start T&E arm: test group, early treatment individualization
2997182|NCT02581891|Active Comparator|Late-start T&E / Arm 2|Late-start T&E arm; per label, control group, treatment individualization after Year 1
2997183|NCT02581878|Experimental|Period 1|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma
2997184|NCT02581878|Experimental|Period 2|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma or patients with Relapsed or refractory Diffuse large B-cell lymphoma (R/R-DLBCL)
2997185|NCT02581865|Placebo Comparator|Placebo|Placebo administered once daily for 8 weeks
2997186|NCT02581865|Experimental|Dose Group 1|Fixed dose administered once daily for 8 weeks
2997187|NCT02581865|Experimental|Dose Group 2|Fixed dose administered once daily for 8 weeks
2997188|NCT02581852|Other|Single arm assessment|Cross sectional assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning of rheumatoid arthritis patients with different disease activity levels.
2997189|NCT02581839|Experimental|Eribulin Mesylate|The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
2997190|NCT02581826|Active Comparator|Silodosin|"Silodosin capsules of 4 mg, oral: 4 mg once daily with a meal, total dosage 12 mg for 14-21 days.~This arm received Silodosin in the first intervention period and Placebo in the second period (after washout period of 14-21 days).~The patients received 4 mg of Silodosin 1 times a day, total dosage 12 mg for 14-21 days."
2997191|NCT02581826|Placebo Comparator|Placebo|"Placebo capsules of 4 mg, oral: 4 mg once daily with a meal, total dosage 12 mg for 14-21 days.~This arm received Placebo in the first period and Silodosin in the second period (after washout period of 14-21 days).~The patients received 4 mg of Placebo 1 times a day, total dosage 12 mg for 14-21 days."
2997192|NCT02581813|Experimental|RDa (Recommended dairy group)|4 servings of dairy per day + exercise (3 times per week with combination of aerobic and resistance exercise).
2997193|NCT02581813|Experimental|LDa (Low dairy group)|0-1 serving of dairy per day + exercise (the same as the RDa group)
2997194|NCT02581813|No Intervention|GCon (growth controls)|This no-intervention group will serve as the control to account for growth during the study.
2997195|NCT02581800|No Intervention|Control group|The control group includes hospital consultations (usual care) on the hospital 2-3 times a week (1-2 hours) and the possibility to call the neonatal ward 24 hours a day all week until the infant gets full nutrition from the breast or bottle and gains weight. The parents register nutrition on a paper between the visits to the hospital.
2997196|NCT02581800|Experimental|App group/intervention group|The intervention group will receive the Smartphone application at inclusion time and learn to use it in the hos-pital. When the families go home they will use the application and receive planned video consultations 2-3 times a week and the possibility to call the neonatal ward 24 hours a day all week whenever needed, until the infant gets full nutrition from the breast or bottle and gains weight. Parents will borrow a baby weight to weigh the baby at home.
2997197|NCT02581787|Experimental|Treatment (fresolimumab, SABR)|Patients receive fresolimumab IV on days 1, 15, and 36 and undergo SABR in 4 fractions between days 8 and 12.
2997198|NCT02581774||term isolated oligohydramnios|Labor Monitoring and normal delivery tracking
2997203|NCT02581748|Active Comparator|PK comparative|Randomised, double-blind, parallel group Phase I study to compare PK profiles and to assess the safety and immunogenicity between HLX02 and Herceptin®(U.S. and German)
2997204|NCT02581735||Patients with haemophilia|"Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.~At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale ."
2997205|NCT02581722|Experimental|Adolescent male population|Male circumcision using the PrePex device among healthy adolescent males and contraindicated subjects due to Preputial adhesions and /or narrow foreskin/Phimosis
2997206|NCT02581709|Experimental|Countering cognitive impairment|Each participant will complete neuropsychological assessments at baseline (prior to chemotherapy) and after chemotherapy. Patients identified as experiencing cognitive decline measured using Reliable Change Index on at least one cognitive function measure from before until after chemotherapy will be offered the intervention. Participants in the interventions will complete a neuropsychological assessment after completion of the intervention. Questionnaires to assess other non-cognitive factors e.g. quality-of-life will be administered at the end of chemotherapy to all participants and after the intervention to participants in the intervention.
2997207|NCT02581696|Other|Single arm|This is a follow-up study of BR-LAF-CT-101, a phase 1 study to evaluate the drug-drug interaction and safety of Lafutidine and Irsogladine maleate in healthy adult volunteers. Subjects judged to be appropriate to this study by screening.
2997208|NCT02581683|Experimental|Magnesium|Participants in this arm will receive magnesium sulfate + ropivacaine via adductor canal block
2997209|NCT02581683|Active Comparator|Non-magnesium|Participants in this arm will receive ropivacaine via adductor canal block
2997210|NCT02581683|Sham Comparator|Sham|Participants in this arm will receive a sham adductor canal block
2997211|NCT02581670|Experimental|Oligometastatic breast cancer patients|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients medically inoperable, using VMAT RapidArc approach.
2997212|NCT02581657|Experimental|PE0139 Injection|PE0139 Subcutaneous Injection - 6 weekly doses
2997213|NCT02581657|Placebo Comparator|Placebo Injection|Placebo Subcutaneous Injection - 6 weekly doses
2997214|NCT02581644||Patients survey|Adult patients treated with belatacept for renal transplantation
2997215|NCT02581644||HCP survey|HCP with at least 1 patient taking belatacept
2997216|NCT02581644||Retrospective chart review study|Adult patients treated with belatacept for renal transplantation
2997217|NCT02581631|Experimental|Nivolumab+Brentuximab Vedotin|Nivolumab+Brentuximab Vedotin dose as specified
2997218|NCT02581618|Experimental|Study group|"Remote ischemic preconditioning arm~Blood pressure cuff will be inflated up to 200 mmHg in the non-dominant arm for 5 minutes before guiding catheter engagement."
2997219|NCT02581618|No Intervention|Control group|No intervention will be performed. Percutaneous coronary intervention will be performed without ischemic preconditioning.
2997220|NCT02581605||Osteotomy Arm|Patients due to undergo an osteotomy around the knee. To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
2997221|NCT02581605||Partial Knee Replacement Arm|Patients due to undergo a partial knee replacement. To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
2997222|NCT02581592|Experimental|Hepatic Impairment|Eight subjects with Moderate Hepatic Impairment (Child-Pugh B). Drug: TD-4208 175mcg, inhaled, single dose.
2997223|NCT02581592|Experimental|Normal Hepatic Function|Eight healthy participants matched to participants with moderate hepatic impairment. Drug: TD-4208 175mcg, inhaled, single dose.
2997224|NCT02581579|Active Comparator|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis
2997225|NCT02581579|Placebo Comparator|Placebo|MANITOL CAPSULES
2997226|NCT02581566|Active Comparator|Intrathecal Dexmedetomidine Group|30 patients will be given Intrathecal Dexmedetomidine plus Intrathecal Bupivacaine
2997227|NCT02581566|Active Comparator|Intraarticular Dexmedetomidine Group|30 patients will be given Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
2997228|NCT02581566|Other|control Group|30 patients will be given Intrathecal Bupivacaine
2997229|NCT02581553|Experimental|Sequence AB|Day 1: lesinurad/allopurinol FDC tablets (Treatment A); Day 8: lesinurad + allopurinol (Treatment B)
2997230|NCT02581553|Experimental|Sequence BA|Day 1: lesinurad + allopurinol (Treatment B); Day 8: lesinurad/allopurinol FDC tablets (Treatment A).
2997231|NCT02581553|Experimental|Sequence CD|Day 1: lesinurad/allopurinol FDC tablets (Treatment C [fasted]); Day 8: lesinurad/allopurinol FDC tablets (Treatment D [fed]).
2997232|NCT02581553|Experimental|Sequence DC|Day 1: lesinurad/allopurinol FDC tablets (Treatment D [fed]); Day 8: lesinurad/allopurinol FDC tablets (Treatment C [fasted]).
2997233|NCT02581553|Experimental|Sequence EF|Day 1: lesinurad/allopurinol 200/200 FDC tablets (Treatment E); Day 8: coadministered lesinurad 200 mg + allopurinol 200 mg (100 mg × 2)
2997234|NCT02581553|Experimental|Sequence FE|Day 1: coadministered lesinurad 200 mg + allopurinol 200 mg (100 mg × 2) (Treatment F); Day 8: lesinurad/allopurinol 200/200 FDC tablets (Treatment E).
2997235|NCT02581540||Suspected Cardiac Chest Pain|This cohort is observed for the incidence of MACE (death, non-fatal myocardial infarction and emergency revascularisation)
2997236|NCT02581527|Active Comparator|Control|Ethambutol, isoniazid, rifampicin, and pyrazinamide followed by 4 months daily isoniazid and rifampicin.
2997237|NCT02581527|Experimental|Regimen 1|Ethambutol, isoniazid, high dose rifampicin, and pyrazinamide followed by 2 months of daily isoniazid and rifampicin 1200mg.
2997238|NCT02581527|Experimental|Regimen 2|Ethambutol, isoniazid, high dose rifampicin, and pyrazinamide followed by 2 months of daily isoniazid and rifampicin 1800mg.
2997239|NCT02581514|Experimental|Algorithm|Eosinophilia is assessed following the diagnosis algorithm
2997271|NCT02581280||On ECMO|patients who are concomitantly receiving teicoplanin or levofloxacin or piperacillin/tazobactam or remifentanil or sufentanil or clopidogrel or ticagrelor during ECMO
2997787|NCT02577770|Experimental|400mg caffeine plus acupuncture|In healthy subjects
2997240|NCT02581501|Experimental|Gemcitabine, ABRAXANE®, and Xeloda|"Level-1~ABRAXANE® 75 mg/m2 over 30 min Days 5 and 12~GEMCITABINE 600 mg/m2 over 60 min Days 5 and 12.~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day~Level 1~ABRAXANE® 100 mg/m2 over 30 min Days 5 and 12~GEMCITABINE 600 mg/m2 over 60 min Days 5 and 12~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day~Level 2~ABRAXANE® 125 mg/m2 over 30 min Days 5 and 12~GEMCITABINE 600 mg/m2 over 75 min Days 5 and 12~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day~Level 3~ABRAXANE® 125 mg/m2 over 30 min Days 5 and 12~GEMCITABINE 750 mg/m2 over 75 min Days 5 and 12~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day"
2997241|NCT02581488|Experimental|Santyl|Collagenase ointment applied topically once per day for up to six weeks.
2997242|NCT02581488|Active Comparator|Product containing silver|Products containing silver will be applied per Investigator instructions and instructions for use/package insert for up to six weeks.
2997243|NCT02581475|Active Comparator|Group A|"Extending withdrawal time in the proximal colon: After cecal intubation, the colonoscopy is withdrawn to the hepatic flexure and then to the splenic flexure with an extended withdrawal time during colonoscopy.~From cecum to hepatic flexure, 1.5-2 min is required and 2.5-3 min is required from heptic flexure to splenic flexure."
2997244|NCT02581475|Experimental|Group B|Segmental examination twice of the proximal colon: After cecal intubation, the colonoscopy is withdrawn to the hepatic flexure and then the colonoscopy is intubated to the cecum again. The same procedure is performed in the colonic segment from hepatic flexure to splenic flexure. The withdrawal time in each colonic segment is similar to the group A.
2997245|NCT02581462|Experimental|FLOT alone|Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT
2997246|NCT02581462|Experimental|FLOT + Herceptin/Pertuzumab|Pre-operative therapy with FLOT + Herceptin/Pertuzumab followed by surgical resection followed by post-operative therapy with FLOT + Herceptin/Pertuzumab
2997247|NCT02581449|Experimental|omega-3 group|omega-3 soft gelatin capsules 1000 mg (500mg EPA+250mg DHA)once daily for four months
2997248|NCT02581449|Placebo Comparator|placebo group|empty soft gelatin capsules with matched size, color and shape once daily for four months
2997249|NCT02581436|Experimental|kSORT assay based follow-up|Post Transplant surveillance based on the result of the kSORT assay.
2997250|NCT02581436|Active Comparator|Standard follow-up|Post Transplant surveillance based on standard of care.
2997251|NCT02581423|Experimental|Capecitabine|Participants will receive capecitabine for up to approximately 6 months.
2997252|NCT02581410|Experimental|GSK1437173A Group|Subjects ≥ 65 years of age who received Zostavax vaccine ≥ 5 years earlier and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
2997253|NCT02581410|Active Comparator|Control Group|Subjects ≥ 65 years of age who never received Zostavax vaccine and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
2997254|NCT02581397|Experimental|Transpulmin suppository|"It is a rectal suppository that is manufactured by Aché S.A. and which is composed of camphor, eucalyptol, guaiacol and menthol.~The rectal suppositories will be dispensed to 90 participants of this group within a cartridge. Each cartridge contains one strip with five suppositories.~The participant must manage 1 suppository in the morning and 1 at night via rectal suppository (12/12h).~The duration of treatment may be up to 03 or 07 days, depending on the visit discharge."
2997255|NCT02581397|Experimental|Guaiacol suppository|"It is a rectal suppository that is manufactured by Aché S.A. and consists of guaiacol.~The rectal suppositories will be dispensed to 90 participants of this group within a cartridge. Each cartridge contains one strip with five suppositories.~The participant must manage 1 suppository in the morning and 1 at night via rectal suppository (12/12h).~The duration of treatment may be up to 03 or 07 days, depending on the visit discharge."
2997256|NCT02581397|Active Comparator|Transpulmin syrup|"It is a syrup which is manufactured by Aché S.A. and which is composed of guaifenesin.~Transpulmin syrup will be dispensed to 90 participants of this group in a bottle of 150ml plus a dosing cup.~The participant shall administer 7,5ml orally every 4 hours, The duration of treatment may be up to 07 days."
2997257|NCT02581384|Experimental|Stereotactic Body Radiotherapy|"Stereotactic Body Radiotherapy (SBRT)~Different dose levels will be used in the two cohorts.~Ewing sarcoma, rhabdomyosarcoma, and others with non-renal tumor patients begin at a pre-determined dose per protocol.~Wilms tumors or other primary renal tumors renal tumor patients begin at pre-determined dose per protocol.~The two cohorts will be enrolling patients independently and simultaneously."
2997258|NCT02581371|Experimental|Cerebrolysin infusion|Cerebrolysin, solution for injection, 10 ml vials. Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
2997259|NCT02581371|Placebo Comparator|Placebo infusion|Sodium chloride 0.9%, solution for infusion, 100 ml. Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval.
2997260|NCT02581358|Experimental|Scolioscan (Ultrasound imaging system)|This diagnostic study is a single arm study with all participants receiving investigation with the Scolioscan (a diagnostic ultrasound machine) for quantitative assessment of spinal deformity
2997261|NCT02581345|Experimental|M923|Participants assigned to receive M923
2997262|NCT02581345|Active Comparator|Humira|Participants assigned to receive Humira
2997263|NCT02581345|Other|M923 and Humira|Participants assigned to receive M923 and Humira
2997264|NCT02581332|Other|Behavioral: Mindfulness Meditation|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
2997265|NCT02581319|Other|Periodontal treatment|Both groups of patients (smokers and non-smokers) will receive periodontal treatment consisting of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects will be made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
2997266|NCT02581306|Other|Exercise session|All subjects will exercise for 1 hour at a moderate intensity. There are no different arms in this study
2997267|NCT02581293|Experimental|Only visceral peritoneum will be closed|Group1: Only visceral peritoneum will be closed
2997268|NCT02581293|Experimental|Only parietal peritoneum will be closed|Group 2: Only parietal peritoneum will be closed
2997272|NCT02581280||Off ECMO|patients who are concomitantly receiving teicoplanin or levofloxacin or piperacillin/tazobactam or remifentanil or sufentanil or clopidogrel or ticagrelor after removing ECMO
2997273|NCT02581254|Experimental|Thin Wire Snare Arm|Use of Thin Wire Snare to resect polyp <10mm
2997274|NCT02581254|Experimental|Thick Wire Snare Arm|Use of Thick Wire Snare to resect polyp <10mm
2997275|NCT02581241|Experimental|drug-induced long QT syndrome|"20 adults aged above 18 years which were hospitalized in Tel Aviv medical center between January 2013 and June 2015 due to drug-induced long QT syndrome and the associated torsades de pointes, have no exclusion criteria and provide informed consent to participate in the study.~Interventions. Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
2997276|NCT02581241|Active Comparator|control|"20 adults aged above 18 years which were hospitalized in Tel Aviv medical center between January 2013 and June 2015 and were treated with specific drugs (antibiotics) that potentially prolong the QT interval but they do not have drug-induced long QT syndrome, have no exclusion criteria and provide informed consent to participate in the study.~Interventions. Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
2997277|NCT02581228||Training Set|The objective of the Training stage is to assess the predictive potential of ML-PrediCare for melanoma patients' response to Ipilimumab, Pembrolizumab and Nivolumab.
2997278|NCT02581228||Validation Set|The objective of the Validation stage is to test the predictive power of ML -PrediCare in an independent set of patients diagnosed with melanoma.
2997279|NCT02581215|Experimental|Arm A: Experimental Arm|"mFOLFIRINOX will be administered every 2 weeks, and consist of:~Oxaliplatin 85 mg/m2 over 2-4 hours~Irinotecan 165 mg/m2 over 90 minutes~5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.~Arm A will receive ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks."
2997280|NCT02581215|Placebo Comparator|Arm B: Placebo Arm|"mFOLFIRINOX will be administered every 2 weeks, and consist of:~Oxaliplatin 85 mg/m2 over 2-4 hours~Irinotecan 165 mg/m2 over 90 minutes~5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.~Arm B will receive a placebo infusion every 2 weeks. Due to the double-blinded nature of this study, the volume of placebo will be calculated as if it were ramucirumab"
2997281|NCT02581202||HIV-1 infected participants|Treatment-experienced HIV-1 infected participants with an undetectable plasma HIV-1 RNA level
2997282|NCT02581189||Hepatitis C positive participants|Hepatitis C positive participants
2997283|NCT02581176|Experimental|Apixaban|Apixaban 10 mg two times daily for 1 week, then apixaban 5mg two times daily for 6 months, then apixaban 2.5 mg two times daily for as long as the treating physician finds it necessary.
2997284|NCT02581163||GT 1 or 4 treatment-naïve or -experienced CHC participants|Treatment-naïve or -experienced participants with confirmed CHC, genotype (GT) 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN ± RBV according to standard of care and in line with the current local label
2997285|NCT02581150|Other|Outpatient hospitalisation|"The intervention is the Treatment of Occlusive Arterial Disease, during an ambulatory hospitalisation, with the use of an arterial closure device (ACD).~The patients treated for PAD (Peripheral Arterial Disease) are informed and prepared in the morning of D0. The surgical endovascular procedure is performed at D0 before 1:00 p.m. The patients leave the hospital in the evening at D0 after a systematic visit."
2997286|NCT02581150|Other|Conventional inpatient hospitalisation|"The intervention is the Treatment of Occlusive Arterial Disease, during a conventional hospitalisation, with or without ACD (ACD will be used at the discretion of the interventionalist).~The patients treated for PAD arrive at the hospital the day before surgery (D-1). The surgical endovascular procedure takes place the next day (D0). The day after (D1), the patients leave the hospital after a systematic visit."
2997287|NCT02581137|Experimental|Prevention (extended-release metformin hydrochloride)|Patients receive extended-release metformin hydrochloride PO QD for 2 weeks and then BID for 10-12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
2997288|NCT02581124|Experimental|Experimental: JTZ-951 and Lapatinib|Tablets; JTZ-951, single dose on non-dialysis Days 1 and 5; Lapatinib, single dose on non-dialysis Day 5
2997289|NCT02581111|Experimental|Naloxone|Naloxone 8-mg IV given once after baseline ABG
2997290|NCT02581111|Sham Comparator|Placebo|Equivalent volume of saline given once
2997291|NCT02581098||Diabetic Wound patients|Diabetic wound patients, non-infected wounds will receive a total of 4 visits over a 14 week period. At study visit 1 -3, two tissue biopsies, wound fluid collection, wound imaging, wound measurements, and Adverse Event review will be collected. At study visit 4 their medical chart, wound data, wound image and adverse event review will be completed.
2997292|NCT02581098||Diabetic Wound patients with a Negative Pressure Therapy|Diabetic wound patients, non-infected wounds will receive a total of 4 visits over a 14 week period. At study visit 1 -3, two tissue biopsies, negative pressure wound therapy sponge, wound imaging, wound measurements, and Adverse Event review will be collected. At study visit 4 their medical chart, wound data, wound image and adverse event review will be completed.
2997293|NCT02581085|Placebo Comparator|Placebo Vehicle|Subjects will take 2 placebo capsules following AM meal, 2 placebo capsules following PM capsules
2997294|NCT02581085|Active Comparator|Tocotrienol supplement|Subjects will take (2) 200 mg TCT capsules following AM meal, (2) 200 mg TCT following PM meal
2997295|NCT02581072|Experimental|SB204 4%|SB204 4% once
2997296|NCT02581072|Experimental|SB204 8% or 12 %|SB204 8 or 12 % (supratherapeutic) once
2997297|NCT02581072|Active Comparator|Moxifloxacillin|Moxifloxacillin 400 mg orally
2997298|NCT02581072|Placebo Comparator|placebo gel|Placebo (Vehicle) gel
2997299|NCT02581059|Experimental|Regorafenib + Ginseng|Regorafenib will be administered 160 mg once daily for the first 21 days of each 28-day cycle. Subjects will receive 1,000 mg ginseng orally twice daily every day for 4 weeks (2 cycles).
2997492|NCT02579733|Placebo Comparator|Sugar pill|Placebo drug identical to azathioprine (1.5mg/kg) po for 1 year
2997301|NCT02581046|Experimental|3 month surgical group|Phacoemulsification pediatric cataract surgery is performed at the age of 3 month of patients without IOL implantation.
2997302|NCT02581046|Experimental|6 month surgical group|Phacoemulsification pediatric cataract surgery is performed at the age of 3 month of patients without IOL implantation..
2997303|NCT02581033|Experimental|Nucleoside analogue therapy cessation|To determine if a sustained virological response can be achieved after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
2997304|NCT02581020||1|Participants who were treated with 2D regimen (ombitasvir/ paritaprevir/ ritonavir) and completed 48 weeks of follow up from the prior Phase 2 or 3 studies conducted in Japan.
2997305|NCT02581007|Experimental|Reduced-Intensity Mismatched Transplant|Fludarabine, Melphalan & Post-transplant cyclophosphamide
2997306|NCT02580994|Experimental|Pembrolizumab + chemotherapy|Pembrolizumab, in combination with cis/carboplatin and etoposide for 4 cycles intravenous 200mg on day 1 (every 3 weeks), pembrolizumab continued alone as continuation maintenance until progressive disease
2997307|NCT02580994|Active Comparator|Chemotherapy|4 cycles of cis/carboplatin and etoposide
2997308|NCT02580981|Experimental|Genomic Testing|"Newly diagnosed ALL patients will undergo genomic studies listed in Primary Objective 1. Analyses will be performed on a bone marrow (BM) aspirate at initial diagnosis (patients with an absolute blast count of at least 1,000/μL, may submit 2 mL of peripheral blood at diagnosis for each 1 mL of required BM. In patients in whom the aspirate cannot be obtained, a core biopsy will be used).~In addition, flow cytometric analysis and deep sequencing will be used to characterize and monitor the molecular heterogeneity and clonal evolution of disease during front-line therapy. BM, blood, and buccal specimens will be collected on day 29 of induction treatment and possibly at a later time point if relapse occurs."
2997309|NCT02580968|Experimental|electro-acupuncture|100hz, 2min. electro-acupoint: LI4(Large Intestine4) with LV3(Liver3).5times a week. lasting for 4 weeks.
2997310|NCT02580968|Active Comparator|routin medicine|one tablet of flunarizine hydrochloride tablet per day. lasting for 20days
2997311|NCT02580955|Experimental|LEGFLOW DCB|patients treated with the LEGFLOW Paclitaxel-Eluting Peripheral Balloon Dilatation Catheter
2997312|NCT02580942|Experimental|Acupoint sticking therapy group|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
2997313|NCT02580942|Sham Comparator|Sham sticking therapy group|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
2997314|NCT02580929|Experimental|radiation|
2997315|NCT02580929|No Intervention|no radiation|
2997316|NCT02580916|Experimental|Group 1 (Postal)|These are patients who will be identified from the histological diagnosis of their skin cancer by members of the direct care team and deemed 'low risk'; SCQOLIT questionnaires will be administered by post.
2997317|NCT02580916|Experimental|Group 2 (Clinic-based)|These are patients who will be identified from the histological diagnosis of their skin cancer by members of the direct care team, for whom all aspects of the study will be conducted in the Dermatology clinic. SCQOLIT questionnaires will be administered according to the protocol.
2997318|NCT02580916|No Intervention|Group 3 (Interviews)|A Qualitative Researcher (Co-Investigator) will undertake structured interviews with approximately 20 patients from both Group 1 and 2. Potential participants will be invited to volunteer their contact details at the time of consent to the Questionnaire study. This is optional; they may refuse to do so and still take part in the main questionnaire study. The patient will then be contacted by the Qualitative Researcher (Co-Investigator) at a later date and subsequently consented for the interview.
2997319|NCT02580916|No Intervention|Group 4 (Clinician focus group)|We aim to discuss the project at the end of the study period in the same setting, to establish staff perspectives on the study, to establish usefulness of the SCQOLIT tool and to identify any barriers to implementation.
2997320|NCT02580890|Experimental|tDCS active|"Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline. The stimulator to be used will be the Chattanooga Ionto ISO 13485. Stimulation will be performed for 5 days, one time per day."
2997321|NCT02580890|Sham Comparator|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
2997322|NCT02580877|Experimental|67.5 mg oral insulin crystals daily|67.5 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given daily for six months
2997323|NCT02580877|Experimental|500mg oral insulin crystals every other week|500 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given every other week for six months
2997324|NCT02580864||IBD patients|120 adult patients (Caucasian, male/female,18-65 years old) with moderate-severe active Crohns disease (220≤ CDAI ≤450; blood CRP ≥5 mg/L and/or fecal calprotectin ≥250mg/L) and with indication for anti-TNF therapy according to the normal clinical practice
2997325|NCT02580864||No-IBD patients|30 no-IBD controls with no GI disorders, as defined by medical history and standard clinical chemistry values, afferent to the out-patient clinic
2997326|NCT02580851|Other|Coronary angiography|Patients directly undergo diagnostic coronary angiography. A PCI is performed according to current guidelines in case of ≥70% stenosis in a coronary vessel with ≥2 mm diameter.
2997327|NCT02580851|Other|Cardiac magnetic resonance imaging|Patients receive adenosine perfusion CMR for functional testing, first. The examination is conducted on a 3.0 Tesla whole-body scanner with a 32-channel phased-array cardiac receiver coil according to a well-established standard protocol [21-23]. In case reversible ischemia can be detected, subjects are sent to coronary angiography and PCI afterwards.
2997328|NCT02580838|Experimental|early OnabotulinumtoxinA group|OnabotulinumtoxinA will be injected immediately when spasticity develop in early OnabotulinumtoxinA group.
2997493|NCT02579720||Group 1: Pollinex® Quattro Patients|Patients treated with Pollinex® Quattro
2997329|NCT02580838|Active Comparator|late OnabotulinumtoxinA group|OnabotulinumtoxinA will be injected at 6 months after emergence of spasticity in late OnabotulinumtoxinA group.
2997330|NCT02580838|No Intervention|no OnabotulinumtoxinA group|OnabotulinumtoxinA will not be injected for this group.
2997331|NCT02580825|Active Comparator|Biofeedback gait retraining|The intervention program will take four weeks while in each week their will be two exercise sessions and a total of 8 sessions. Each session length is about 9 minutes. Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). During the meeting, participant will receive biofeedback that will displayed on a computer screen that shows the forces that develop in the knee joint so that the patient can see graphically the forces that develop around the knee joint and will be guided / try to reduce the values of the graph by changing the intensity of his landing on the tracks. In all training the time that the biofeedback is shown will be reduced.
2997332|NCT02580825|Active Comparator|Exercise|The control group will receive the same training program: four weeks while in each week their will be two exercise sessions and a total of 8 sessions. Each session length is about 9 minutes. Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). This group will not provide the biofeedback.
2997333|NCT02580812|Experimental|MONALISA 5-years old children|Clinical and neuropsychological evaluation procedure 90 children
2997334|NCT02580812|Active Comparator|EPIPAGE 5 -years old children|Cohort of prematurely borne children and their controls Clinical and neuropsychological evaluation procedure 270 children
2997335|NCT02580799||Breast Cancer Pathology Samples|Breast cancer pathology samples were evaluated for a period of 70 days.
2997336|NCT02580786|Experimental|Breastfeeding peer support|Internet-based breastfeeding peer-support group in social media (Facebook). The mothers are allowed to use the group based on their individual needs from the recruitment to the first birthday of their child. Peer support is provided by three voluntary mothers. The mothers can discuss breastfeeding-related issues and ask questions. A midwife will moderate the group.
2997337|NCT02580786|No Intervention|Routine breastfeeding support|Routine breastfeeding support provided in the hospital and in the maternal and child health clinics
2997338|NCT02580773|Other|Prophylactic anticoagulation|
2997339|NCT02580773|Experimental|Curative anticoagulation|
2997340|NCT02580760||Cosmetic silicone injection|People responding to inclusion criteria with a history of cosmetic silicone injection
2997341|NCT02580747|Experimental|anti-meso CAR T cells|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Patients receive anti-meso-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity."
2997342|NCT02580734|Placebo Comparator|placebo|tablet without melatonin
2997343|NCT02580734|Experimental|melatonin|tablet with melatonin
2997344|NCT02580721|Active Comparator|Thick mucosal tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted.
2997345|NCT02580721|Experimental|Thin mucosal tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted.
2997346|NCT02580721|Experimental|Thickened mucosa with connective tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted. Soft tissue augmentation will be performed with sub epithelial connective tissue graft.
2997347|NCT02580721|Experimental|Thickened mucosa with ADM|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted. Acellular dermal matrix, thick 1 x 4 cm will be used for vertical soft tissue augmentation.
2997348|NCT02580708|Experimental|Rociletinib and Trametinib|
2997349|NCT02580695|Experimental|Umbilical-cord mesenchymal stromal cells|"Umbilical-cord mesenchymal stromal cells (UC-MSCs)~Allogeneic UC-MSCs 20 x 10e6 diluted on 3 mL of saline solution + 5% of Plasma AB~Arm 2a: single infusion group. UC-MSCs at 0 month~Arm 2b: double infusion group. UC-MSCs at 0 and 6 months"
2997350|NCT02580695|Active Comparator|Hyaluronic Acid (HA)|Drug: Hyaluronic Acid 3 mL of HA intra-articular injection at baseline and 6 months
2997351|NCT02580682|Experimental|Sanfu herbal patch|one kind of acupoint application which used in hot dog days of summer,The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba asarum), Bai Jie Zi (Semen Sinapis Albae), and Rou Gui (Cortex Cinnamomi) at a ratio of 2:2:1:1:2:1.The bilateral Feishu (BL13), Pishu (BL20), Shenshu (BL23), Neiguan (PC6), and Guanyuan (CV4) acupoints were selected for treatment
2997352|NCT02580682|Experimental|Sanfu moxibustion|use moxibustion in hot dog days of summer,and adopting the indirect moxibustion box method at the bilateral BL13, BL20, and BL23 acupoints
2997353|NCT02580682|Experimental|Sanfu herbal patch and Sanfu moxibustion|use herbal patch and moxibustion together in hot dog days
2997354|NCT02580682|No Intervention|controlled|patients in this group will not accept herbal patch or moxibustion therapy in these 3 years. After the 3-year experimental period they will be offered corresponding treatments for free as well, so they are in our wait list.
2997355|NCT02580669|Experimental|Progressive Multiple Sclerosis|22 patients with Progressive Multiple Sclerosis will be included and they get an Neuropsychological assessment, a Neurologic consultation and MRIs (with vasoreactivity testing)
2997356|NCT02580669|Experimental|Multiple Sclerosis, Relapsing-Remitting|22 patients with Multiple Sclerosis, Relapsing-Remitting will be included and they get an Neuropsychological assessment, a Neurologic consultation and MRIs (with vasoreactivity testing)
2997357|NCT02580669|Experimental|Healthy volunteers (22 patients)|22 healthy volunteers will be included and they get an Neuropsychological assessment and MRIs (with vasoreactivity testing)
2997358|NCT02580656|Experimental|Metacognitive Therapy|Metacognitive Therapy (MCT) is a brief psychological intervention which will be delivered over a course of six, one hour weekly sessions. Treatment will follow a manualised protocol.
2997359|NCT02580643||APS Injection|Autologous Protein Solution
2997422|NCT02580175|Active Comparator|Blinded evacuation|Ring evacuation was performed in the conventional way without use of ultrasound followed by sharp gentle curettage until complete evacuation
2997426|NCT02580162|Experimental|Peer Treatment, Not a Peer|Families receive FBT for Pediatric Weight Management by Peers and parents are NOT Peer Interventionists
2997360|NCT02580630|Active Comparator|Training and glucocorticosteroid|"Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then every month.~All patients are informed to a reduction in running and jumping sports for the first 3 months, thereafter slowly progressing to normal sports activity.~Ultrasound guided injection with glucocorticosteroid: 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml in Kagers triangle underneath the thickest part of the achilles tendon. Injection is given every months until the tendon pain is markedly diminished (max 3 injections)."
2997361|NCT02580630|Active Comparator|Training and local anesthetic|"Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then every month.~All patients are informed to a reduction in running and jumping sports for the first 3 months, thereafter slowly progressing to normal sports activity.~Ultrasound guided injection with local anaestethic: 1ml Lidocain 5 mg/ml and 1 ml intralipid (for blinding) in Kagers triangle underneath the thickest part of the achilles tendon. Injection is given every months until the tendon pain is markedly diminished (max 3 injections)."
2997362|NCT02580617|Experimental|ALLO-ASC|Group 1: 5.0 x 10^7 cells Group 2: 7.5 x 10^7 cells Group 3: 10.0 x 10^7 cells
2997363|NCT02580604|Experimental|Calcium Infusion|Continuous calcium infusion during exercise
2997364|NCT02580604|Placebo Comparator|Saline Infusion|Continuous saline infusion during exercise
2997365|NCT02580591|Experimental|Empagliflozin low dose|
2997366|NCT02580591|Experimental|Empagliflozin high dose|
2997367|NCT02580591|Experimental|Empagliflozin medium dose|
2997368|NCT02580591|Placebo Comparator|Placebo|
2997369|NCT02580578||All Participants|Female patients who are diagnosed and treated for symptoms associated with their uterine fibroids per routine clinical practice. No intervention is administered in this study.
2997370|NCT02580552|Experimental|Part A, MF|Intratumoral Injection of MRG-106
2997371|NCT02580552|Experimental|Part B, MF|Subcutaneous, intravenous or a combination of systemic and intratumoral administration of MRG-106 with stable background therapy
2997372|NCT02580552|Experimental|Part C, MF|Subcutaneous or intravenous administration of MRG-106 as monotherapy
2997373|NCT02580552|Experimental|Part D, CLL|Subcutaneous or intravenous administration of MRG-106 as monotherapy
2997374|NCT02580552|Experimental|Part E, DLBCL|Subcutaneous or intravenous administration of MRG-106 as monotherapy
2997375|NCT02580552|Experimental|Part F, ATLL|Subcutaneous or intravenous administration of MRG-106 as monotherapy
2997376|NCT02580539|Experimental|Autologous or allogenic (stem cell donor) T cells|Subjects receive an autologous anti-EBV T-cell line or a T-cell line derived from the patient's allogeneic (stem cell transplant) donor.
2997377|NCT02580539|Experimental|"Allogeneic third party T cells"|Subjects receive a T-cell line from a matched or partially matched related donor.
2997378|NCT02580526|Active Comparator|V-E mask ventilation technique crossover C-E mask ventilation|
2997379|NCT02580526|Active Comparator|C-E mask ventilation technique crossover V-E mask ventilation|
2997380|NCT02580513|No Intervention|Control|3 days with normal circadian alignment.
2997381|NCT02580513|Experimental|Circadian Misalignment|3.5 days in which the subjects will undergo a maximal circadian misalignment of 12 hours by means of a midday nap during the second day, and a subsequent start of a new normal wake period, shifted 12 hours.
2997382|NCT02580500|Active Comparator|group 1|Pilonidal dermoid cyst surgery in Spinal anaesthesia
2997383|NCT02580500|Active Comparator|group 2|Pilonidal dermoid cyst surgery in Epidural anaesthesia
2997384|NCT02580487||retrospective group|Patients whose pain evaluation, analgesics used and details of surgery were collected from patient files
2997385|NCT02580487||Prospective group|Patients who were interviewed before and after surgery when they were at the hospital
2997386|NCT02580474|Experimental|Daclatasvir plus Asunaprevir|
2997387|NCT02580461|Experimental|Immediate Exercise Group|One half of the participants enrolled in the 24 week center-based structured exercise and education program will be randomized to the immediate exercise group. The immediate exercise group will receive a 12 week center based structured exercise program followed by a 12 week maintenance of exercise program.
2997388|NCT02580461|No Intervention|Delayed Exercise Group|One half of the participants enrolled in the 24 week center-based structured exercise and education program will be randomized to the delayed exercise group. This will be a wait list control group and the participants will receive no active intervention for 12 weeks. The wait list control group will then be enrolled in the 12 week structured exercise intervention.
2997389|NCT02580448|Experimental|Female Triple Negative Breast Cancer Patients|TNBC Patients - Enrollment is complete in this cohort
2997390|NCT02580448|Experimental|Female Estrogen Receptor (+) Breast Cancer Patients|Female ER(+) BC Patients - Enrollment is complete in this cohort
2997391|NCT02580448|Experimental|Male Breast Cancer Patients|Locally advanced or metastatic males with BC
2997392|NCT02580409|Other|Single-arm studies|Behavioral Intervention
2997393|NCT02580396|Other|Patients eligible for CanADVICE+® (smart phone app)|
2997394|NCT02580383||Group none|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.~When both needles were positioned inadequately for a facet joint."
2997395|NCT02580383||Group partial|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.~when one of the needles for a facet joint medial branch was placed inadequately."
2997396|NCT02580383||Group complete|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.~When all needles were placed adequately.'"
2997397|NCT02580370|Experimental|Dose A|Botulinum toxin type A
2997398|NCT02580370|Placebo Comparator|Dose B|Placebo comparator
2997423|NCT02580175|Active Comparator|Evacuation under ultrasound guidance|Ring evacuation was performed under ultrasound guidance followed by sharp gentle curettage until complete evacuation. The surgery was considered complete when the endometrial cavity appeared as a regular echogenic line.
2997424|NCT02580162|Active Comparator|Pro.Treatment, Not a Peer|Families receive FBT for Pediatric Weight Management by Professionals interventionists and parents are NOT Peer Interventionists
2997399|NCT02580357|Sham Comparator|Low Level Laser therapy (LLLT) Sham|The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue. The applications were performed by a different operator (CAS) from the one who measured the study parameters. During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications.
2997400|NCT02580357|Experimental|GaAlAs Laser therapy (LLLT) 60 J/cm²|The irradiation was performed with a GaAlAs diode laser that continuously emitted a wavelength of 660 nm with a power of 30 mW. The patients allocated for the group 60 received the following protocol for laser application: Two (2) points of irradiation were performed using a total energy density (fluence) of 60 J/cm2 and a time of 60 seconds (30 J/cm2 per point and an application time of 30 seconds per point). During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications. The power of the equipment was calibrated prior to each application.
2997401|NCT02580357|Experimental|GaAlAs Laser therapy (LLLT) 30 J/cm²|The irradiation was performed with a GaAlAs diode laser that continuously emitted a wavelength of 660 nm with a power of 30 mW. The patients allocated for the group 30 received the following protocol for laser application: Two (2) points of irradiation were performed using a total energy density (fluence) of 30 J/cm2 and a time of 30 seconds (15 J/cm2 per point and an application time of 15 seconds per point). During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications. The power of the equipment was calibrated prior to each application.
2997402|NCT02580344|Other|Ibuprofen|
2997403|NCT02580331|Placebo Comparator|SRP and placebo|Oral prophylaxis followed by placement of placebo gel
2997404|NCT02580331|Active Comparator|SRP and 1% metformin|Oral prophylaxis followed by placement of 1% metformin gel
2997405|NCT02580318|Experimental|all study participants|subjects consumed alcohol to a BrAC of 0.1 and then performed the following manipulations while using the breathalyzer: poor effort, hyperventilation (immediate), hyperventilation (after 5 minutes), hyperventilation (after 10 minutes), drinking water (immediate), drinking water (after 5 minutes)
2997406|NCT02580305|Active Comparator|Experimental: SUVN-502 Low dose|SUVN-502 Low dose adjunct to base treatment with Donepezil and Memantine
2997407|NCT02580305|Active Comparator|Experimental: SUVN-502 High dose|SUVN-502 High dose adjunct to base treatment with Donepezil and Memantine
2997408|NCT02580305|Placebo Comparator|Placebo|Placebo adjunct to base treatment with Donepezil and Memantine
2997409|NCT02580279|Experimental|EGCG group|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution;The solution is sprayed three times a day at 0.05 ml/cm2 to the whole radiation field until two weeks after radiation completion; Patients who developed grade Ⅱ radiation-induced dermatitis have the option to either withdraw from the study or to continue with EGCG. Patients are follow general good skin care practices during radiation therapy, such as not applying water soaks to relieve itching or pain, not vigorously rubbing the irradiated area, or not erasing ink marks; patting the skin dry with a soft towel; avoiding exposure to the sun; and wearing loose and cotton clothes. They are advised not to use deodorant, lotion, cream, make up, perfume or any other product on the area during the course of radiation therapy.
2997410|NCT02580279|Placebo Comparator|placebo|The placebo is 0.9% saline solution.Patients are also to follow general good skin care practices which is same as the EGCG group.
2997411|NCT02580253|Experimental|Individualized Chemotherapy|Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)
2997412|NCT02580253|Active Comparator|mFOLFOX6|Oxaliplatin (85 mg/m2 )+Fluorouracil (2800 mg/m2 ) q2w
2997413|NCT02580240|Placebo Comparator|Placebo|Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
2997414|NCT02580240|Experimental|hydrocortisone|Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
2997415|NCT02580227|Active Comparator|Tranexamic Acid|Patients will be randomized 1:1 onto active TXA arm, or placebo arm.
2997416|NCT02580227|Placebo Comparator|Placebo|Patients will be randomized 1:1 onto active TXA arm, or placebo arm.
2997417|NCT02580214|Experimental|Acerto|Preoperative immune nutrition for 5 days (Impact, Nestle) Preoperative fasting of 2h with a drink containing 12% maltodextrine No intravenous fluids postoperatively
2997418|NCT02580214|No Intervention|Control|No immune nutrition Preoperative fasting of 6-8 h Crystalloid intravenous fluids until PO day 1
2997419|NCT02580201|Experimental|Oral Polio Vaccine|"Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.~The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container."
2997420|NCT02580188|No Intervention|Moderate block|Maintenance dose of 0.15-0.3 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
2997421|NCT02580188|Experimental|Deep block|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
2997425|NCT02580162|Experimental|Pro.Treatment, Peer|Families receive FBT for Pediatric Weight Management by Professionals and parents ARE Peer Interventionists
2997427|NCT02580162|Experimental|Peer Treatment, Peer|Families receive FBT for Pediatric Weight Management by Peers and parents ARE Peer Interventionists
2997428|NCT02580149|Active Comparator|Ticagrelor|Loading dose of 180 mg on day one, followed by a regular intake (90 mg twice daily) for 14 days
2997429|NCT02580149|Active Comparator|Clopidogrel|Loading dose of 600 mg on day one, followed by a regular intake (75 mg once daily) for 14 days
2997430|NCT02580123|Experimental|Experimental group|Received the intervention program.
2997431|NCT02580123|No Intervention|Control group|received the standard care
2997432|NCT02580110|Experimental|sucrose|14 days intervention with daily intake of a beverage (1000 ml) including 66g sucrose.
2997433|NCT02580110|Experimental|stevia glycosides|14 days intervention with daily intake of a beverage (1000ml) including 0.220 g stevia glycosides.
2997434|NCT02580110|Experimental|saccharin|14 days intervention with daily intake of a beverage (1000ml) including 0.216g saccharin.
2997435|NCT02580097||Stroke|Ischemic stroke patients with sympton onset in 48 hours and no contradiction to MRI scan
2997436|NCT02580084|Active Comparator|aorta femoral bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
2997437|NCT02580084|Experimental|hybrid intervention|Iliac Arteries With Stenting and Plasty of the Common Femoral Artery
2997438|NCT02580071|Experimental|Sheng-Yu-Tang|"Treatment group will receive standard of care, as well as:~2-3 months post-HSCT, patients will be administered the herbal formula Sheng-Yu-Tang (聖愈湯), which they will receive for 6 months. The herbal formula will be provided from a GMP herbal company and will be given in granulated form."
2997439|NCT02580071|No Intervention|Control|Control group will receive standard of care
2997440|NCT02580058|Experimental|avelumab|Arm A: avelumab alone
2997441|NCT02580058|Experimental|avelumab plus pegylated liposomal doxorubicin (PLD)|Arm B: avelumab plus PLD
2997442|NCT02580058|Active Comparator|PLD|Arm C: PLD alone
2997443|NCT02580032||Child Treatment Naïve group (Group A)|Pre-pubertal boy or girl, ages of 9 to 13 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of equal or below 7.0 ng/ml.
2997444|NCT02580032||Child Maintenance group (Group B)|Pre-pubertal boy or girl, ages of 9 to 13 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of equal or below 10.0 ng/ml who have been taking prescription treatment for GHD for 6 months or more.
2997445|NCT02580032||Parent Treatment Naïve group (Group C)|Parents/guardians, who live with a pre-pubertal boy or girl, age 4 to 9 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of below or equal to 7.0 ng/ml.
2997446|NCT02580032||Parent Maintenance group (Group D)|Parents/guardians, who live with a pre-pubertal boy or girl, age 4 to 9 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of below or equal to 10.0 ng/ml who have been taking prescription treatment for GHD for 6 months or more.
2997447|NCT02580019|No Intervention|conventional stroke treatment|Control group without intervention, whereas they receive conventional stroke treatment that including rehabilitation
2997448|NCT02580019|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation accompanied with conventional treatment including rehabilitation
2997449|NCT02580006|Experimental|EPORON→EPREX|"EPORON PFS(PreFilled Syringe) 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.~And wash out for 4 weeks. EPREX INJ.(Injection) 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29."
2997450|NCT02580006|Experimental|EPREX→EPORON|"EPREX INJ. 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.~And wash out for 4 weeks. EPORON PFS 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29."
2997451|NCT02579993|Experimental|Stem Cell Transplantation|Cultivated Limbal Stem Cell Transplantation
2997452|NCT02579980|Experimental|DCE and DWI MRI group|Patients will undergo a baseline MR exam at enrollment within 4 weeks prior to scheduled surgery, which will include DW-MRI and DCE-MRI prior to surgery and tumor tissue collection.
2997453|NCT02579967|Experimental|1/IOC Arm|Immunosuppression Only Conditioning Arm
2997454|NCT02579967|Experimental|2/RIC Arm|Reduced Intensity Conditioning Arm (after 20 patients enroll on the RIC arm. At that time, the RIC arm will close to further enrollment.)
2997455|NCT02579967|Experimental|3/MAC Arm|Myeloablative Conditioning Arm
2997456|NCT02579967|Experimental|4/RIC-MMF Arm|Reduced Intensity Conditioning with MMF duration de-escalation design (Enrollment will start on the RIC-MMF arm after 20 patients enroll on the RIC arm)
2997457|NCT02579954|No Intervention|control group|
2997458|NCT02579954|Experimental|intervention|Rehabilitation
2997459|NCT02579941|Experimental|Pregnant women at term, vaginal childbirth|
2997460|NCT02579941|Experimental|Pregnant women at term, cesarean delivery|
2997461|NCT02579941|Experimental|Female volunteers, age 18 to 40|
2997462|NCT02579928|Experimental|Ketamine|A dose of 0.5 mg/kg of Ketamine will be administered intravenously over 40 minutes. The maximum total dose allowed in this study will be 50mg.
2997463|NCT02579928|Active Comparator|Midazolam|A dose of 0.045mg/kg of Midazolam will be administered Intravenously over 40 minutes. The maximum total dose allowed in this study will be 4.5mg.
2997487|NCT02579759|Active Comparator|PXT3003 dose 2|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
2997488|NCT02579759|Placebo Comparator|placebo|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
2997489|NCT02579746|Experimental|intervention|The intervention group received usual care plus the DASHNa-CC intervention.
2997464|NCT02579915|Experimental|FaceAnxiety - Mental Habits|Treatment will consist of 8, 30-minute, twice-weekly sessions designed to: a) decrease attention bias to threat and b) extinguish threat interpretations/reinforce benign interpretations of ambiguity. Attention bias will be modified via a dot probe task that increases attentional control by directing attention away from threat faces via probe location. Patients will complete 256 trials per session. Interpretation bias will be modified via a word-sentence association task which provides positive feedback when participants endorse benign interpretations of ambiguous sentences and negative feedback for threat interpretations. Participants will complete 150 training trials per session. A FaceAnxiety Specialist facilitates program completion.
2997465|NCT02579915|Active Comparator|FaceAnxiety - Symptom Tracking|Treatment will consist of weekly self-assessment of anxiety and depression symptoms via on-line surveys. A FaceAnxiety Specialist will facilitate program completion.
2997466|NCT02579902|Active Comparator|Vitamin D3|50000 IU vitamin D3 capsule, one capsule every 2 weeks for 6 months.
2997467|NCT02579902|Placebo Comparator|placebo|Placebo capsule, one capsule every 2 weeks for 6 months.
2997468|NCT02579889|Experimental|Active group - CLS ON|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON; Intervention: DDD+CLS
2997469|NCT02579889|Active Comparator|Control group - CLS OFF|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
2997470|NCT02579876|Active Comparator|Viaskin Milk 500 mcg|Viaskin patch containing milk protein. The patch is applied to the skin
2997471|NCT02579876|Placebo Comparator|Viaskin Placebo|Viaksin patch without any milk protein.
2997472|NCT02579863|Active Comparator|Lenolidomide + dexamethasone|Participants receive lenalidomide 25 mg orally (PO) on Days 1 to 21 of each treatment cycle, and dexamethasone 40 mg PO weekly
2997473|NCT02579863|Experimental|Pembrolizumab + lenalidomide + dexamethasone|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W), lenalidomide 25 mg PO on Days 1 to 21 of each treatment cycle, and dexamethasone 40 mg PO weekly
2997474|NCT02579850|Experimental|CHF 5993 + Ultibro matched placebo|"Fixed triple therapy with BDP/FF/GB 100/6/12.5 mcg (CHF 5993) administered 2 puffs twice daily via pMDI + Fixed combination of indacaterol and of glycopyrronium (Ultibro® Breezhaler®) matched placebo administered once daily via DPI for 52-week treatment.~Patient used to take pMDI medication using a spacer will be provided with a new spacer for the study.~7 study visits including : central spirometry tests, Local laboratory, COPD assessment test (visit 1 only), Local laboratory Assessments Saint George's Respiratory Questionnaire EXACT-pro questionnaire"
2997475|NCT02579850|Active Comparator|Ultibro + CHF 5993 matched placebo|"Fixed combination of indacaterol 85 mcg and of glycopyrronium 43 mcg (Ultibro® Breezhaler®) administered once daily via DPI + Fixed triple therapy with BDP/FF/GB (CHF 5993) matched placebo administered 2 puffs twice daily via pMDI for 52-week treatment.~Patient used to take pMDI medication using a spacer will be provided with a new spacer for the study.~7 study visits including : central spirometry tests, Local laboratory, COPD assessment test (visit 1 only), Local laboratory Assessments, Saint George's Respiratory Questionnaire, EXACT-pro questionnaire"
2997476|NCT02579837|No Intervention|Usual Screening|Participants randomized to the Usual Screening group will be advised by their Endocrinologist during their Diabetes Clinic visit to arrange an eye examination with their usual eye care professional (as per current standard of care).
2997477|NCT02579837|Experimental|On-Site Screening|"Participants randomized to the On-Site Screening group will be advised by their Endocrinologist during their Diabetes Clinic visit to arrange an eye examination with their usual eye care professional (as per current standard of care). However, they will also undergo non-mydriatic ultra-widefield (UWF) retinal imaging (both 100 and 200 degrees) using the Optos 200Tx UWF retinal imaging device in the Ophthalmology Department on the same day as their Diabetes Clinic visit.~Half of this group will by random allocation undergo optical coherence tomography (OCT) using the Zeiss Cirrus OCT, which may or may not be done on the same day (for practical reasons regarding availability of OCT at the hospital)."
2997478|NCT02579824|Experimental|DS-3032b|"Dose Escalation Phase: DS-3032b administered once daily by mouth on Days 1 - 21 of a 28 day cycle. Starting dose level 90 mg/day.~Dose Expansion Phase: Starting dose level maximum tolerated dose from Dose Escalation Phase."
2997479|NCT02579811|Experimental|Axitinib|All subjects will be given axitinib on an individualized dosing schedule. Axitinib will be administered orally beginning with 5mg twice a day and can be escalated or reduced if specific grade 2 or greater toxicity develops. Axitinib will continue until progression. At progressive disease, dose escalation above current dose is allowed based on investigator discretion of clinical benefit. However, axitinib should be discontinued if a subject experiences a second RECIST progressive disease following dose escalation, patient intolerability, or at provider discretion.
2997480|NCT02579798|Experimental|PEEP 10 cmH20|In this group, a PEEP of 10 cmH20 is applied for the duration of the intervention and a recruitment maneuver is applied each time the SpO2 (oxygen pulsated saturation) drops below 95%.
2997481|NCT02579798|Active Comparator|optimal PEEP|"In this group, 10 cmH20 PEEP is applied immediately. Then the optimal PEEP is sought at three key moments. It is determined by the best value of lung compliance found in the patient. It is sought by increasing or decreasing the value of the PEEP by increments or decrements of 2 cmH20. If after 6 respiratory cycles, the value of the compliance is increased, the investigator continues to increase the value of the PEEP. On the other hand, if the value of compliance is reduced, the investigator reduces the value of PEEP. The value of the PEEP selected shall in no event exceed the set pressure range (maximum pressure plate of 30 cmH20 and maximum inspiratory peak pressure 40cmH20). A recruitment maneuver is applied each time the SpO2 drops below 95%, as in the PEEP 10cmH2O group."
2997482|NCT02579785|Experimental|mhealth intervention|Receives standard care which includes face to face post-MR family counselling and provision of existing hotline phone number. Also receives Mobile phone based intervention for post-abortion contraceptive uptake.
2997483|NCT02579785|No Intervention|Standard Care|Receives standard care which includes face to face post-MR family counselling and provision of existing hotline phone number.
2997484|NCT02579772|Active Comparator|N-acetylcysteine|Pharmacological treatment with N-acetylcysteine (NAC) pills
2997485|NCT02579772|Placebo Comparator|Placebo|Treatment with placebo pills
2997486|NCT02579759|Active Comparator|PXT3003 dose 1|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
2997490|NCT02579746|Active Comparator|control|The control group received usual care.
2997494|NCT02579720||Group 2: Control Patients|Patients who decided to use only anti-allergic drugs during the grass pollen season
2997495|NCT02579707|Active Comparator|Treatment A: Unfed|Treatment A: Single oral dose of AG-120 at Hour 0 on Day 1, following a 10-hour overnight fast.
2997496|NCT02579707|Active Comparator|Treatment B: Fed|Treatment B: Single oral dose of AG-120 at Hour 0 on Day 1, 30 minutes after the start of a high-fat breakfast.
2997497|NCT02579707|Experimental|Part 2 Single Dose|PART 2 is an open-label study to determine the safety and PK parameters of a single 1000-mg oral dose of AG-120.
2997498|NCT02579681|Experimental|BG00012|BG00012 administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter.
2997499|NCT02579668|Experimental|Language therapy in BSL|Working with Deaf practitioners to provide language activities in British Sign Language aimed at developing children's language skills.
2997500|NCT02579655|Active Comparator|Copayment Elimination and Personalized Education|In this arm, participants would have copayment elimination (no cost for preventative medications for hypertension, diabetes, and cardiovascular disease) and free enrollment in a new personalized education program to help participants manage their chronic conditions
2997501|NCT02579655|Active Comparator|Copayment Elimination Only|In this arm, participant's would be randomized to Copayment Elimination (no cost for preventative medications for hypertension, diabetes, and cardiovascular disease) and receive some basic educational information about their chronic disease
2997502|NCT02579655|Active Comparator|Personalized Education Only|In this arm, participants would be randomized to free enrollment in a new personalized education program to help patients manage their chronic conditions
2997503|NCT02579655|No Intervention|No intervention|In this arm, participants will have access to some basic online educational information about their chronic disease. There is no intervention in this arm. The comparative group.
2997504|NCT02579642|Placebo Comparator|Placebo|Propofol at usual induction doses for ECT (0.75 - 1 mg/kg IV bolus) with placebo (normal saline)
2997505|NCT02579642|Experimental|Ketamine|Propofol at usual induction doses for ECT (0.75 - 1 mg/kg IV bolus) with the addition of low-dose ketamine 0.2 mg/kg (or 0.5 mg/kg - see interim analysis)
2997506|NCT02579629|Active Comparator|Ropivacaine 0.1%|Subjects undergoing their first,second or third cesarean sections will receive a bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump for 3 days after the cesarean section.
2997507|NCT02579629|Experimental|Ropivacaine 0.2%|Subjects undergoing their first,second or third cesarean sections will receive a bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump for 3 days after the cesarean section.
2997508|NCT02579629|Active Comparator|Normal Saline|Subjects undergoing their first, second or third cesarean sections will receive a bolus dose of 8ml normal saline followed by an infusion of 8ml/hr of normal saline using the On-Q® elastomeric pump for 3 days after the cesarean section.
2997509|NCT02579616|Experimental|24 mg Lenvatinib|Participants with unresectable BTC and disease progression or failure following one prior gemcitabine-based doublet chemotherapy regimen (combination of gemcitabine and cisplatin, or gemcitabine and other platinum agent/fluoropyrimidine agent).
2997510|NCT02579603|Experimental|Nintedanib|Nintedanib 150 mg bid
2997511|NCT02579603|Experimental|Nintedanib and Pirfenidone|Nintedanib 150 mg bid combined with pirfenidone up to 801 mg tid
2997512|NCT02579590||DEMPA group|This group are using DMPA (Depot Medroxyprogesterone Acetate 150 mg) injection every 3 month for 6-12 month
2997513|NCT02579590||Implanon group|"This group are using Implanon  (etonogestrel implant) 68 mg implant for 6-12 month"
2997514|NCT02579590||Cerazette group|This group are using Cerazette pills (75 micrograms desogestrel) one pill every day for 28 days without pill-free interval for 6-12 month.
2997515|NCT02579590||Normal healthy group|Those women not using any method of contraception
2997516|NCT02579577||Decision making cohort|Any people identified as being important within the network of care for children with life-limiting illnesses.
2997517|NCT02579564|Experimental|chemotherapy with Oncorine and Endostar|Systemic chemotherapy with standard schemes, such as GP (Gemcitabine/Cisplatin), NP (Vinorelbine/Cisplatin), TP (Paclitaxel/Cisplatin) or PP (Pemetrexed/Cisplatin). Thoracic cavity perfusion of recombinant human adenovirus type 5 injection 1.5ml and Endostar 30mg each time, twice a week for four times.
2997518|NCT02579564|Active Comparator|chemotherapy with cisplatin|Systemic chemotherapy with standard schemes without cisplatin, such as Gemcitabine, Vinorelbine, Paclitaxel or Pemetrexed. Thoracic cavity perfusion of cisplatin 30mg/m2 each time, twice a week for four times.
2997519|NCT02579551|Experimental|Treatment (surgical excision)|Patients undergo surgical excision of the skin lesion consisting of 1 and 2 mm circumferential margins during visit 1.
2997520|NCT02579538||Total Knee Arthroplasty|Patients undergoing unilateral total knee arthroplasty
2997521|NCT02579538||Thoracic/Breast Surgery|Patients undergoing mastectomy, thoracotomy, or video-assisted thoracoscopic surgery (VATS)
2997522|NCT02579525|Experimental|Targeted tissue perfusion guidance (TTP)|TTP-guidance based on clinical signs of peripheral perfusion.
2997523|NCT02579525|Active Comparator|Macrocirculatory - guidance (MCG)|MCG-guidance based on recommended macrocirculatory parameters.
2997524|NCT02579512||Extra-corporeal ECG Signal Analysis|
2997525|NCT02579499|Active Comparator|Fixed high-potent statin group|According to 2013 ACC/AHA guideline, patients will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels.
2997526|NCT02579499|Experimental|Targeted LDL-C goal statin group|Patients will be tiltrated statin intensity guided by follow-up LDL-C level
2997527|NCT02579473|Experimental|Cohort 0|"Subjects in Cohort 0 will receive a single subcutaneous injection of 20 mg SER-214, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
2997528|NCT02579473|Experimental|Cohort 1|"Subjects in Cohort 1 will receive a single SC injection of 50 mg SER-214 at the beginning of each week for two consecutive weeks, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
2997566|NCT02579239|Experimental|ATYR1940|Intrapatient dose escalation of intravenous ATYR1940 administered twice weekly at doses of 0.3, 1.0, or 3.0 mg/kg for up to 12 weeks.
2997529|NCT02579473|Experimental|Cohort 2|"Subjects in Cohort 2 will receive a single SC injection of 50 mg SER-214 at the beginning of week one, followed by a weekly SC injection of 100 mg SER-214 for two consecutive weeks, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
2997530|NCT02579473|Experimental|Cohort 3|"Subjects in Cohort 3 will receive a single SC injection of 50 mg SER-214 at the beginning of week one, followed by a single SC injection of 100 mg SER-214 at the beginning of week two, followed by a single SC injection of 200 mg SER-214 for two consecutive weeks, followed by a two week wash-out period, to determine PK and terminal wash-out PK of rotigotine and pro-drug SER-214."
2997531|NCT02579460|Experimental|Barrett's esophagus patients|Patients with Barrett's Esophagus will be enrolled. The intervention is cessation of acid-suppressing medications. Biopsies will be taken during endoscopy at Day 0, 7, and 14.
2997532|NCT02579434|Experimental|Male young adults|Arm 1: Male healthy volunteers aged from 20 to 45 years Midazolam (IV) on day 1
2997533|NCT02579434|Experimental|Male elderly adults|Arm 2: Male healthy volunteers aged over 45 years Midazolam (IV) on day 1
2997534|NCT02579434|Experimental|Female elderly adults|Arm 3: Female healthy volunteers aged over 45 years Midazolam (IV) on day 1
2997535|NCT02579434|Experimental|Female young adults|Arm 4: Female healthy volunteers aged 20 to 45 years Midazolam (IV) on day 1, Day 15
2997536|NCT02579421|Active Comparator|Progesterone|200 mg progesterone BID
2997537|NCT02579421|Placebo Comparator|placebo|placebo BID
2997538|NCT02579408||LDLT donor|Donors of living donor-related liver transplantation
2997539|NCT02579395|Experimental|With spouse/romantic partner|
2997540|NCT02579395|Experimental|Without spouse/romantic partner|
2997541|NCT02579395|Other|Control|No Intervention
2997542|NCT02579382|Placebo Comparator|TDF + placebo|TDF + placebo
2997543|NCT02579382|Experimental|TDF + vesatolimod 1 mg|TDF + vesatolimod 1 mg
2997544|NCT02579382|Experimental|TDF + vesatolimod 2 mg|TDF + vesatolimod 2 mg
2997545|NCT02579382|Experimental|TDF + vesatolimod 4 mg|TDF + vesatolimod 4 mg
2997546|NCT02579369|Experimental|ALLO-ASC-DFU|
2997547|NCT02579369|Active Comparator|Conventional Therapy|
2997548|NCT02579356|Experimental|Part1-A|The Part1-A of groups take Telmisartan once a day for 6 days in period 1. After wash-out period, they take Telmisartan and Atorvastatin once a day for 6 days in period 2.
2997549|NCT02579356|Experimental|Part1-B|The Part1-B of groups take Telmisartan and Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Telmisartan once a day for 6 days in period 2.
2997550|NCT02579356|Experimental|Part2-A|The Part2-A of groups take Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Telmisartan and Atorvastatin once a day for 6 days in period 2.
2997551|NCT02579356|Experimental|Part2-B|The Part2-B of groups take Telmisartan and Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Atorvastatin once a day for 6 days in period 2.
2997552|NCT02579343|Experimental|Auricular Acupuncture + Lexipro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants in this group will be treated twice weekly during their follow-up visits with micro-currents of electricity through auricular acupuncture.
2997553|NCT02579343|Sham Comparator|Sham Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
2997554|NCT02579330|Experimental|Coloshield Group|In the Intervention group the Coloshield Device (double balloon system) will be introduced at the beginning of surgery followed by a washout of the rectum with 500ml of saline solution. The grade of macroscopic contamination will be assessed.
2997555|NCT02579330|Sham Comparator|Control Group|In the control Group the grade of macroscopic contamination will be assessed after rectal washout with 500ml of saline solution.
2997556|NCT02579317|Experimental|Resonance Breathing|Breathing is paced to the cardiovascular resonance frequency where heart, respiratory, and brain signals become aligned. This can potentially positively impact cognitive-emotional functioning.
2997557|NCT02579317|Placebo Comparator|Non-Resonance Breathing|Breathing is paced at a non-resonance frequency. It does not align heart, respiratory, and brain signals, and thus does not impact cognitive-emotional functioning.
2997558|NCT02579291|Experimental|Dry needling|The experimental group will receive a single session of Bobath therapy including techniques targeting modulation of central nervous system. In addition, this group will receive a single session of dry needling into the tibialis posterior muscle with a disposable stainless steel needle (0.3mm x 50mm)
2997559|NCT02579291|Active Comparator|Bobath|This group will receive a single session of Bobath therapy including techniques targeting modulation of central nervous system.
2997560|NCT02579278||mrEMVI positive rectal tumours|20 patients will be registered whose rectal tumours are mrEMVI positive (i.e. EMVI is present in baseline and post-chemoradiotherapy MRI scans).
2997561|NCT02579278||mrEMVI negative rectal tumours|20 patients registered who were mrEMVI positive at baseline MRI but have become mrEMVI negative post-chemoradiotherapy.
2997562|NCT02579265|Experimental|Smoflipid 20%|"Smoflipid is a lipid emulsion containing soybean oil, MCTs (medium-chain triglycerides), olive oil, and fish oil. Smoflipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions."
2997563|NCT02579265|Active Comparator|Intralipid® 20%|"Intralipid is a long-chain triglyceride emulsion derived from purified soybean oil and egg yolk phospholipids. Intralipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions."
2997564|NCT02579252|Experimental|AADvac1|"AADvac1 is a suspension for subcutaneous injection. AADvac1 is provided in single-use vials. Dosage: 40 µg Axon peptide 108 (coupled to keyhole limpet haemocyanin (KLH)) using aluminium hydroxide (containing 0.5 mg Al3+) as adjuvant, in a phosphate buffer.~Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses."
2997565|NCT02579252|Placebo Comparator|Placebo|Placebo is a suspension for subcutaneous injection. Placebo is provided in single-use vials. Dosage: aluminium hydroxide (containing 0.5 mg Al3+), in a phosphate buffer. Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses.
2997567|NCT02579239|Placebo Comparator|Placebo|Patients will receive an initial infusion of placebo at Week 1, supplied as normal saline and administered via IV infusion over a 30-minute period.
2997568|NCT02579226|Experimental|Part A|Part A dose-escalation will evaluate the safety and tolerability of AZD2811 monotherapy at increasing doses in patients with advanced solid tumours. Patients will receive AZD2811 on Days 1 and 4 of a 28-day cycle or Day 1 only in cycles of either 21 or 28 days.
2997569|NCT02579226|Experimental|Part B|Part B will include patients with relapsed or refractory small-cell lung cancer (SCLC). Patients will receive AZD2811 monotherapy at the recommended Phase 2 dose (RP2D).
2997570|NCT02579213||women candidates for amniocentesis|pregnant women candidates for amniocentesis between 17-33 gestational weeks
2997571|NCT02579200|Active Comparator|Inspiratory Muscle Training (IMT)|POWERbreathe®KHA (IMT group)
2997572|NCT02579200|Sham Comparator|Sham Training|POWERbreathe®KH2 (sham group)
2997573|NCT02579187|Placebo Comparator|control group|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). A biodegradable sponge (type I bovine collagen) to stabilize the blood clot will be placed.The site will be stabilized with a simple external, cross mattress suture. Blood , wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
2997574|NCT02579187|Active Comparator|Experimental group 1|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 10µg of pSil-miR200c plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
2997575|NCT02579187|Active Comparator|Experimental group 2|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 10µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
2997576|NCT02579187|Active Comparator|Experimental group 3|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
2997577|NCT02579174|Other|Manual (tibia) and manual (femur)|Knee replacement with Medacta GMK Sphere implants using manual instrumentation for both the tibia component and the femur component
2997578|NCT02579174|Other|Manual (tibia) and custom (femur)|Knee replacement with Medacta GMK Sphere implants using manual instrumentation for the tibia component and custom instrumentation for the femur component
2997579|NCT02579174|Other|Custom (tibia) and custom (femur)|Knee replacement with Medacta GMK Sphere implants using custom instrumentation for both the tibia component and the femur component
2997580|NCT02579174|Other|Custom (tibia) and manual (femur)|Knee replacement with Medacta GMK Sphere implants using custom instrumentation for the tibia component and manual instrumentation for the femur component
2997581|NCT02579161|Active Comparator|Antibiotics for a 24 hour period|"Antibiotics for a 24 hour period~Intervention drug to be determined based on patient history etc."
2997582|NCT02579161|Active Comparator|Continued antibiotics|"Continued antibiotics until the removal of any external catheters~Intervention drug to be determined based on patient history etc."
2997583|NCT02579148|Experimental|HUCMSC injection|once intracavernous injection of 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells
2997584|NCT02579148|Experimental|collagen scaffolds/HUCMSC injection|once intracavernous injection of collagen scaffolds loaded with 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells
2997585|NCT02579135|Experimental|Project HEART|Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
2997586|NCT02579135|Other|Control: Project Growing Minds|Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.
2997587|NCT02579109|Other|autistic patient|patient with autistic trouble
2997588|NCT02579109|Other|healthy volunteers|healthy volunteers
2997589|NCT02579096|Active Comparator|Allopurinol|Patients will be titrated up to the dose that will lower to target uric acid levels.
2997590|NCT02579096|Sham Comparator|Placebo (Febuxostat)|Placebo in the shape of Febuxostat will be given with allopurinol
2997591|NCT02579096|Active Comparator|Febuxostat|Febuxostat will be titrated up to the dose that will lower to target uric acid levels.
2997592|NCT02579096|Sham Comparator|Placebo (Allopurinol)|Placebo in the shape of Allopurinol will be given with Febuxostat
2997593|NCT02579083|Experimental|Segment A: Single MB66 Administration|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
2997594|NCT02579083|Placebo Comparator|Segment B: Repeated Administrations Placebo Film|The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
2997595|NCT02579083|Experimental|Segment B: Repeated Administrations MB66|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
2997596|NCT02579070|Experimental|DFUPS (visual and thermal images)|Visual and thermal imaging with DFUPS and standard foot care. The study investigator will have access to the thermal and visual images captured with DFUPS.
2997597|NCT02579070|Placebo Comparator|DFUPS ( visual images)|Visual and blinded thermal imaging with DFUPS and standard foot care. The study investigator will have access only to the visual images and will be blinded to the thermal images which will be captured at each visit but accessed only at the end of the study.
2997598|NCT02579057|Active Comparator|Furosemide Injection Solution, USP|Single dose determined by Investigator (maximum dose 160mg) administered intravenously by IV bolus over approximately 2 minutes (reference treatment)
2997599|NCT02579057|Experimental|Furosemide Injection Solution (SCP-101)|80 mg dose administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours (test treatment)
2997600|NCT02579044|Other|Everolimus and Lonafarnib|Single arm. Phase I: Lonafarnib with escalating doses of everolimus to determine MTD Phase II: Lonafarnib plus everolimus at MTD (efficacy assessment)
2997601|NCT02579031|Active Comparator|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent Orsiro
2997602|NCT02579031|Active Comparator|Xience|Durable-polymer everolimus-eluting stent Xience
2997603|NCT02579018|Experimental|Anorexia Nervosa (AN)|Diagnosis of anorexia spectrum disorder and stable use of all medications ≥ three months.
2997604|NCT02579018|Experimental|Matched Controls|No diagnosis of anorexia spectrum disorder. Stable use of all medications ≥ three months. Also age (+/- 2 years) and gender matched to AN study participant and exercise regularly.
2997605|NCT02579018|Experimental|Healthy Controls|No diagnosis of anorexia spectrum disorder. Stable use of all medications ≥ three months. Do not exercise regularly.
2997606|NCT02579005|Experimental|Patients with a living donor|Radiation + PBMC
2997607|NCT02579005|Experimental|Patients with a UCB donor|Radiation + UCB
2997608|NCT02578992|Experimental|Head-lift Position|The patients' head was placed in the head-lift position(A 7 cm high pillow was set beneath the patients' head with head in neutral position) and then the patient was intubated with Trachway by single-handed chin lift technique
2997609|NCT02578992|No Intervention|Neutral Position|The patients' head was placed in the neutral position and then the patient was intubated with Trachway by single-handed chin lift technique
2997610|NCT02578979|Experimental|ECG for 5 days|Patients will receive 12-lead electrocardiogram for 5 days during their hospitalization.
2997611|NCT02578979|Active Comparator|24-h Holter|Patients will receive a 24-h Holter during their hospitalization.
2997612|NCT02578966|Experimental|Motivational Interview|INTERVENTION GROUP: in this group, composed of 6 UBS, the children and their respective mothers/fathers/responsible adults will be attended by the dentists at least once a year with an approach based on the Motivational Interview.
2997613|NCT02578966|Active Comparator|Traditional health education|CONTROL GROUP: in this group, composed of 6 UBS, the children and their respective mother/fathers/responsible adults will be attended by the dentists at least once a year based on the recommendations by the Brazilian Ministry of Health (BRASIL,2008-a) and on SSC-GHC's protocol (BRASIL, 2008-b). Additionally, the professional guidance script and the parents' booklet of SSC-GHC's oral health Program may be used.
2997614|NCT02578953|Experimental|Sequence 1-Dutasteride test product and then Reference product|Participants will receive treatment A in period 1 and treatment B in period 2. Where treatment A= dutasteride 0.5 mg capsule test product, treatment B= dutasteride 0.5 mg capsule reference product.
2997615|NCT02578953|Experimental|Sequence 2-Dutasteride reference product and then test product|Participants will receive treatment B in period 1 and treatment A in period 2. Where treatment A= dutasteride 0.5 mg capsule test product, treatment B= dutasteride 0.5 mg capsule reference product.
2997616|NCT02578940|Experimental|Single arm|Fluciclovine 18F injection (tracer) for PET Scan
2997617|NCT02578927|Experimental|GT+Ex|Ingestion of one dose of 2 g of green tea (GT) ingested at 10 minutes after the period of rest. After the Ingestion, the volunteers practice aerobic exercise (EX) in treadmill.
2997618|NCT02578927|Placebo Comparator|PL+Ex|Ingestion of one dose 2 g of placebo (PL) ingested at 10 minutes after the period of rest. After the Ingestion, the volunteers practice aerobic exercise (EX) in treadmill.
2997619|NCT02578927|Active Comparator|Green Tea|Ingestion of one dose 2g of green tea (GT) at 10 minutes after the period of rest. In this section the volunteers does not practice aerobic exercise.
2997620|NCT02578914|Experimental|NS2 Ophthalmic Drops (0.5%)|NS2 Ophthalmic Drops (0.5%)
2997621|NCT02578914|Sham Comparator|NS2 Ophthalmic Drops Vehicle (0.0%)|NS2 Ophthalmic Drops Vehicle (0.0%) control
2997622|NCT02578901|Active Comparator|Tranexamic Acid (TXA)|IV or PO administered after meeting inclusion/exclusion criteria
2997623|NCT02578901|Placebo Comparator|Placebo|IV Normal Saline or PO placebo pills administered after meeting inclusion/exclusion criteria
2997624|NCT02578888|Active Comparator|Palliative Therapy|EORTCQLQ-30 and FAMCARE questionnaire every 6 weeks for 3 visits.
2997625|NCT02578888|Experimental|Palliative Therapy+ idiographic|EORTC QLQ-30, and FAMCARE questionnaire every 6 weeks for 3 visits plus patients undergo idiographic assessment.
2997626|NCT02578862|Experimental|Total Intravenous|Intravenous propofol for maintenance of anesthesia
2997627|NCT02578862|Active Comparator|Inhaled Anesthetic|Inhaled volatile anesthetic for maintenance of anesthesia
2997628|NCT02578849||PD_no_LID|Patients with Parkinson´s disease without dyskinesia
2997629|NCT02578849||PD_LID|Patients with Parkinson´s disease with L-DOPA induced dyskinesia
2997630|NCT02578849||HC|Health controls, age-mathced.
2997631|NCT02578836|Experimental|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
3028342|NCT02373150|Experimental|Group A2|Dose 2 or placebo
2997632|NCT02578823|Experimental|TTM-36|"Participants assigned to TTM-36 Arm will be managed by Arcticgel™ and Arctic Sun® to maintain core temperatureTemperature at 36.0℃ for 72 hours.~After targeted temperature management(TTM), Fever will be controlled for remaining 7 days by conventional antipyretic treatment. (Treat core temperature ≥ 38.3℃).~A total of 40 participants will be enrolled."
2997633|NCT02578823|Active Comparator|Conventional treatment|"Participants who are assigned to this Arm will be treated with conventional antipyretic treatment regarding the occurrence fever for 7 days.(Treat core temperature ≥ 38.3℃).~A total of 20 participants will be enrolled."
2997634|NCT02578810||Eclampsia|In 24 patients with Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts.
2997635|NCT02578810||Control|In 24 control patients without Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts
2997636|NCT02578797|Experimental|Apalutamide|Prostate Cancer participants will receive the study drug on an outpatient basis except for Cycle 1 (Day 1 and Day 2) and Cycle 3 (Day 1), when intake must occur at study site under overnight fasted conditions.
2997637|NCT02578784|Placebo Comparator|POBA-after-Cutting Balloon|After cutting balloon angioplasty, subsequent angioplasty is performed using a standard, non-coated balloon (plain old balloon, POBA).
2997638|NCT02578784|Active Comparator|DCB-after-Cutting Balloon|After cutting balloon angioplasty, subsequent angioplasty is performed using a drug-coated balloon (DCB)
2997639|NCT02578771|Experimental|ZuraPrep with 70% Isopropyl alcohol|Test Article ZuraPrep with 70% isopropyl alcohol (IPA) will be compared with reference positive control Chloraprep
2997640|NCT02578771|Experimental|ZuraPrep without 70% IPA|Vehicle test article ZuraPrep without isopropyl alcohol will be compared with normal saline
2997641|NCT02578771|Active Comparator|ChloraPrep Teal Tint|Test Article ZuraPrep with 70% isopropyl alcohol will be compared with reference positive control ChloraPrep [Chlorhexidine gluconate(CHG)/IPA] Teal Tint
2997642|NCT02578771|Placebo Comparator|Normal Saline 0.85%|Vehicle test article ZuraPrep without isopropyl alcohol will be compared with normal saline 0.85%
2997643|NCT02578758|Experimental|Transdiagnostic Internet-Based Protocol|Intervention group that carries out the Transdiagnostic Internet-Based Protocol and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages).
2997644|NCT02578758|Experimental|Transdiagnostic Internet-Based Protocol+Positive Affect|Intervention group that carries out the Transdiagnostic Internet-Based Protocol+Positive Affect component and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages).
2997645|NCT02578758|Other|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
2997646|NCT02578745|Experimental|Prophylactic NPWT|Women assigned to prophylactic NPWT will have the PICO device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4.
2997647|NCT02578745|Active Comparator|Standard Dressing|Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
2997648|NCT02578732|Experimental|FOLFOXA|
2997649|NCT02578719|Placebo Comparator|drug: bupivacaine|Placebo comparator: bupivacaine first 3 months 0.5% 1 cc bupivacaine diluated with 1.5 cc saline enjection will be used in GON block once a month. If effectiveness is proved then blindness will be opened and all patients will be blocked by 0.5% 1 cc bupivacaine diluated with 1.5 cc saline once a month for 3 months.
2997650|NCT02578719|Placebo Comparator|placebo|first 3 months 2.5 cc saline enjection will be used in GON block once a month. If effectiveness is proved then blindness will be opened and all patients will be blocked by 0.5% 1 cc bupivacaine diluated with 1.5 cc saline once a month for 3 months.
2997651|NCT02578706|Active Comparator|Aspirin and placebo|At week 0, participants will be administered aspirin 81mg (one tablet) and placebo for clopidogrel 75 mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
2997652|NCT02578706|Active Comparator|Clopidogrel and placebo|At week 0, participants will be administered clopidogrel 75 mg (one tablet) and placebo for aspirin 81 mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
2997653|NCT02578706|Placebo Comparator|Placebos only|At week 0, participants will be administered placebo for aspirin 81 mg (one tablet) and placebo for clopidogrel 75mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
2997654|NCT02578680|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 (with vitamin supplementation) IV PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 every 3 weeks (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.
2997655|NCT02578680|Active Comparator|Control|Participants receive saline placebo IV PLUS pemetrexed 500 mg/m^2 (with vitamin supplementation) IV PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 Q3W for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. If progression occurs, participants may be able to receive pembrolizumab Q3W for the remainder of the study or until documented progression.
2997656|NCT02578667|No Intervention|Gorbly Compression not needed|
2997657|NCT02578667|Experimental|Gorbly Compression may benefit|the use of the Gorbly device with the consent of the patient
2997690|NCT02578446|Experimental|Uncemented Triathlon Tritanium CR|Primary total knee replacement with Uncemented Triathlon Tritanium CR Total Knee System
2997691|NCT02578446|Active Comparator|Cemented Triathlon CR|Primary total knee replacement with Cemented Triathlon CR Total Knee System
2997658|NCT02578654|Experimental|Interventions|"Additional HIV care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment. These interventions are specifically added on routine care during the post-intervention period. The routine care does not include the additional round and the three telephone calls and is assessed during the pre-intervention period."
2997659|NCT02578641|Experimental|Arm A|4 cycles of combination IV Gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days, followed sequentially by T-cell immunotherapy (2 cycles) of autologous EBV specific Cytotoxic T Lymphocytes every 2 weeks, followed by EBV-specific CTL immunotherapy (4 cycles) every 8 weeks after 6 weeks from the second cycle.
2997660|NCT02578641|Active Comparator|Arm B|6 cycles of combination IV gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days.
2997661|NCT02578628|Active Comparator|Active|These subjects will continue to receive Patient Engagement services.
2997662|NCT02578628|No Intervention|Control|These patients will have all Patient Engagement services discontinued.
2997663|NCT02578602|Experimental|Diagnostic (gadoxetate disodium MRI)|Patients receive gadoxetate disodium IV and then undergo enhanced liver MRI.
2997664|NCT02578589|Active Comparator|surgery|
2997665|NCT02578589|Active Comparator|Conservative treatment|
2997666|NCT02578576||patients with flare-up|Disease flare-up is demonstrated by coloscopy at one month after resection.
2997667|NCT02578576||patients without flare-up|No flare-up is found by coloscopy at one month after resection.
2997668|NCT02578550|Experimental|Treatment Sequence (AB)|Participant will receive a single oral tablet of darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) (Treatment A) in period 1, then 1 tablet of DRV 800 mg + 1 tablet of COBI 150 mg + 1 tablet of FTC/TAF 200/10 mg FDC (Treatment B) in period 2
2997669|NCT02578550|Experimental|Treatment Sequence (BA)|Participant will receive 1 tablet of DRV 800 mg + 1 tablet of COBI 150 mg + 1 tablet of FTC/TAF 200/10 mg FDC (Treatment B) in period 1, then a single oral tablet of D/C/F/TAF (800/150/200/10 mg) FDC (Treatment A) in period 2
2997670|NCT02578537|Experimental|Ticagrelor group|ticagrelor 180mg loading, followed by 90mg bid for 30 days
2997671|NCT02578537|Active Comparator|Clopidogrel group|clopidogrel 600mg loading, followed by 75mg/d for 30 days
2997672|NCT02578524||Accommodating Lenses|Patients who underwent surgery with an accommodating lens implant.
2997673|NCT02578524||Multifocal Lenses|Patients who underwent surgery with an multifocal lens implant.
2997674|NCT02578511|Experimental|Ixazomib (MLN9708) in combination with standard POMP/D|"Patients who are receiving maintenance therapy with the POMP/D (Methotrexate, 6-Mercaptopurine, Vincristine, Prednisone/Dexamethasone) will be enrolled. Each cycle will be 28 days. The patients will receive IV vincristine, dexamethasone or prednisone, methotrexate and 6 - Mercaptopurine. Ixazomib will be administered on days 1, 8 and 15.~Both prednisone and dexamethasone are acceptable drugs in maintenance therapy. For example, in the HyperCVAD regimen or the CALGB 8811 prednisone is used. Patients will continue the same maintenance regimen they are receiving and ixazomib will be added to that."
2997675|NCT02578498|Placebo Comparator|High carbohydrate diet|high carbohydrate intake
2997676|NCT02578498|Active Comparator|Low carbohydrate diet|low carbohydrate intake
2997677|NCT02578485|Experimental|AVideogame|Session with active video game lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
2997678|NCT02578485|Active Comparator|SVideogame|Session with active video sedentary lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
2997679|NCT02578485|Placebo Comparator|EMIntensity|Session with walk on a treadmill with moderate intensity lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
2997680|NCT02578485|Placebo Comparator|EISVideogame|Session with walk on a treadmill with intensity similar reached in session with VGA and lasting 60 minutes performing heart rate and perceived exertion measurements every 10 minutes.
2997681|NCT02578485|Sham Comparator|Control|Participants remained for 60 minutes at rest performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
2997682|NCT02578472|Experimental|Group 1 (Sequence ABC)|Participants will receive Treatment A (2 capsules of 20 milligram [mg] JNJ-42847922) in Period 1, Treatment B (10 mg zolpidem and 1 placebo capsule) in Period 2 and Treatment C (2 placebo capsules) in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
2997683|NCT02578472|Experimental|Group 2 (Sequence BCA)|Participants will receive Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
2997684|NCT02578472|Experimental|Group 3 (Sequence CAB)|Participants will receive Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
2997685|NCT02578472|Experimental|Group 4 (Sequence ABC)|Participants will receive Treatment A in Period 1, Treatment B in Period 2 and Treatment C in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
2997686|NCT02578472|Experimental|Group 5 (Sequence BCA)|Participants will receive Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
2997687|NCT02578472|Experimental|Group 6 (Sequence CAB)|Participants will receive Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
2997688|NCT02578459|Experimental|Intrathecal Drug Delivery (ITDD)|These subjects will have a Prometra System implanted and managed with the appropriate drug regimen to treat their pain.
2997689|NCT02578459|Active Comparator|Conventional Medical Management (CMM)|These subjects will be treated with conventional medical management to treat their pain.
2997692|NCT02578433|Experimental|Mindful Self Compassion|Participants will receive a shortened form (6 weeks) of mindful self compassion meditation, once a week for 75 minutes, furthermore they get an audio cd and a handout to practice during the week
2997693|NCT02578433|Other|Progressive Muscle Relaxation|Participants will receive progressive muscle relaxation once a week for 75 minutes, furthermore they get an audio cd and a handout to practice during the week
2997694|NCT02578420|Placebo Comparator|open-label placebo|"Participants (N=40) will have the information that they are receiving an inert cream (i.e. placebo). Placebo will be described as an inert or inactive cream, with no medication in it. Additionally, participants will be told that placebo has been shown in rigorous clinical testing to produce significant mind-body self-healing processes. The placebo administration will be combined with the following scientific rationale/verbal suggestion: (a) placebos are effective analgesics, (b) classical conditioning as a possible mechanism of this effect, (c) compliance is important for outcome and (d) positive expectations increase placebo effects, but are not necessary."
2997695|NCT02578420|Sham Comparator|deceptive placebo|"Participants (N=40) will have the information that they are receiving an analgesic cream (Antidolor, containing Lidocain), while in fact they will receive an inert cream, only. Antidolor will be described as an analgesic cream."
2997696|NCT02578420|Placebo Comparator|control group|Participants (N=40) will have the information that they are receiving an inert control cream.
2997697|NCT02578420|No Intervention|no treatment group|"Participants (N=40) will be told that they are in the no treatment group and that they will not receive an analgesic cream."
2997698|NCT02578407|Experimental|Accommodative/Vergence Therapy|Accommodative/Vergence Therapy. No drug involved.
2997699|NCT02578394|Active Comparator|Group A|Anakinra 100mg and Placebo Depo-Medrone
2997700|NCT02578394|Active Comparator|Group B|Depo-Medrone 120mg and Placebo (Anakinra)
2997701|NCT02578381|Experimental|Boston Scientific PW versus St Jude PW|Performance of Boston Scientific PW vs St Jude PW
2997702|NCT02578381|Experimental|Boston Sci PW vs Boston Sci PW|Boston Sci PW vs Boston Sci PW
2997703|NCT02578381|Active Comparator|St Jude PW versus St Jude PW|Performance of St Jude PW vs St Jude PW
2997704|NCT02578368|Experimental|Arm A: FLOT chemotherapy + surgery (OP)|"4 cycles (8 weeks) FLOT pre-OP - surgery - 4-8 cycles FLOT (8-16 weeks) post-OP~Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).~* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.~For HER-2 positive disease, trastuzumab should be added:~Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1"
2997705|NCT02578368|Active Comparator|Arm B: FLOT chemotherapy alone|"4 cycles (8 weeks) FLOT followed by further 4-8 cycles FLOT (8-16 weeks)~Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).~* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.~For HER-2 positive disease, trastuzumab should be added:~Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1"
2997706|NCT02578355||Coronary CT Angiography (CCTA)|Patients included in the OPeRA Registry are those that have previously undergone clinically-indicated CCTA as part of their standard of care.
2997707|NCT02578342||Healthy volunteers|healthy volunteer between age of 20 to 55 will undergo MRI examination.
2997708|NCT02578342||ADHD subjects without medication|Medication-naive subjects with ADHD (20-55 years) will undergo MRI examination.
2997709|NCT02578342||ADHD subjects with medication|Subjects with ADHD (20-55 years), under medication will undergo MRI examination.
2997710|NCT02578329|Experimental|Med Diet|Intensively advised Mediterranean diet
2997711|NCT02578329|Active Comparator|Low Fat diet|usual low-fat dietary advice
2997712|NCT02578316|Experimental|Lenvatinib 24 mg|Participants with advanced solid tumors or lymphomas, who are unsuitable for, or had failed, existing therapies.
2997713|NCT02578303|Experimental|Dementia group|"Assessed by the insertion of an interaction parameter between cerebral blood flow and the group label(dementia or no-dementia).~ROC method will be used to find a threshold value of IAH that separates the two groups.~Interventions:~Vascular flow measurement by PC-MRI~Neuropsychological assessment~Registration of sleep apnea~Registration of blood pressure~ECG holters~Blood test~Geriatric standard evaluation"
2997714|NCT02578303|Other|control group|"Assessed by the insertion of an interaction parameter between cerebral blood flow and the group label(dementia or no-dementia).~ROC method will be used to find a threshold value of IAH that separates the two groups.~Interventions:~Vascular flow measurement by PC-MRI~Neuropsychological assessment~Registration of sleep apnea~Registration of blood pressure~ECG holters~Blood test~Geriatric standard evaluation"
2997715|NCT02578290|Experimental|Treatment|Clinical Decision Support (CDS)
2997716|NCT02578290|No Intervention|Control|Will not receive Clinical Decision Support (CDS)
2997717|NCT02578277|Experimental|Single sequence, 3-period DDI (drug-drug interaction)|Single sequence
2997718|NCT02578264||All participants|All subjects enrolled in the study will provide tumor and normal tissue and blood samples.
2997719|NCT02578251|Experimental|Paracetamol|Patients will receive paracetamol intravenously (1 g in 100 mL) over 15 minutes (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
2997720|NCT02578251|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
2997721|NCT02578238||Subjects with pediatric CD|Pediatric CD subjects who have been prescribed Humira® by the treating physician
2997722|NCT02578212|Placebo Comparator|Control|"All participants will also be introduced to the control cream: This cream is a control cream."
2997783|NCT02577809|Active Comparator|Fentanyl25|1.8ml 0.5% hyperbaric bupivacaine with 25μg fentanyl (2.3ml volume) administered into the intrathecal space
2997784|NCT02577783|Experimental|PDD arm|patients involved in PDD arm will accept chemotherapy of PDD regimen (doxorubicin hydrochloride liposome plus bortizomib and dexamethasone )
2997723|NCT02578212|Sham Comparator|Placebo|"All participants will then be introduced to an analgesia expectation: This cream is a powerful pain killer, while receiving an inert cream. In this study participants will be told that they will receive a potent painkiller as well as a control cream. Making use of placebo cream is an established method to induce placebo expectations . Moreover, to increase the analgesic effect, heat pain stimuli intensity will be surreptitiously lowered for the placebo trials to a temperature corresponding to 30% of the VAS intensity and to 60% for the control trials. As the occurrence of a placebo response is highly dependent on expectations, the deceptive procedure described above is used in order to maximally enhance expectations and therefore placebo response. Participants will be debriefed after the completion of study participation."
2997724|NCT02578199|Experimental|motivational interviewing and nutrition|Motivational interviewing and nutritional counseling.
2997725|NCT02578186|Experimental|Diphenhydramine Hydrochloride|Diphenhydramine (50 mg) elixir taken when subjects had trouble falling asleep
2997726|NCT02578186|Placebo Comparator|Placebo|Placebo elixir taken when subjects had trouble falling asleep
2997727|NCT02578173||AVERT PLUS|The AVERT PLUS will be used on the first 10 patients enrolled in the study. The AVERT PLUS is a contrast monitoring system which is used to precisely measure the volume of contrast delivered to the patient.
2997728|NCT02578173||Non device group|The second group of 10 patients will undergo the scheduled angiography using the standard method of measuring contrast dye delivery.
2997729|NCT02578160|Experimental|Tell-Show-Do Behavior Technique|This technique will involve verbal explanations related to the inferior alveolar and lingual nerve block procedure in phrases appropriate to the developmental level of the patient (tell);demonstrations for the patient of the visual, auditory, olfactory, and tactile aspects of the procedure in a carefully defined, nonthreatening setting (show); and then, without deviating from the explanation and demonstration, completion of the procedure (do).
2997730|NCT02578160|Active Comparator|"Conventional Technique"|The operator will explain how he/she will do the inferior alveolar and lingual nerve block procedure in phrases appropriates to the child. Then quietly cover the child's field of view by hand during the inferior alveolar and lingual nerve block.
2997731|NCT02578147|Experimental|Mighty Girls|Girls in this group complete 3 different activities after school: 6 classroom sessions, 4 DRAMA-RAMA game play sessions, and 4 short game experience surveys. Classroom sessions are 1 hour long, 3 days a week for 2 weeks. Topics include: goal setting, choices and their effects; defining what makes a behavior risky; learning how to not get talked into doing risky things by friends (e.g., going to a party at a house where parents are not home); and learning to be critical of TV shows and other media that make it seem like lots of teens are having sex. These sessions teach girls skills and strategies that help them score game points in DRAMA-RAMA. These are important skills and strategies that they can use in everyday life to make wise choices. Classroom sessions are designed to be fun.
2997732|NCT02578147|Active Comparator|Game Girls|Girls in this group take part in activities that can be done from home or anywhere they have Wi-Fi access: 4 Science Valley game play sessions and 4 short game experience surveys. Science Valley is a web based game in which girls explore a virtual world and experiment with objects in this world using a computer, tablet or cell phone. Girls will play this game for about 20-30 minutes. There are no classroom sessions required to be able to play Science Valley. Science Valley is designed to be fun and to give girls a chance to build skills important to doing well in school: her problem solving and critical thinking skills. Girls will be given a link to use to access Science Valley on the internet. At the end of the game, they do a short game experience survey that asks questions about how easy, how hard, how fun etc. it was to play Science Valley. This survey will appear on the screen at the end of the Science Valley game play session.
2997733|NCT02578134|Experimental|US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks for 5 weeks of US-guided percutaneous electrolysis. This intervention consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the plantar fascia insertion. In addition, patients will be asked for conducting a best-evidence low-load exercise programs for the intrinsic foot musculature. The exercise program will be asked to be performed on an individual basis twice every day.
2997734|NCT02578134|Sham Comparator|Sham US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks for 5 weeks of sham US-guided percutaneous electrolysis. In this case, the acupuncture needle will be inserted in the soft tissue, in this case the plantar fascia insertion without the application of the galvanic electrical current. In addition, patients will be asked for conducting a best-evidence low-load exercise programs for the intrinsic foot musculature. The exercise program will be asked to be performed on an individual basis twice every day.
2997735|NCT02578121|Experimental|Ixazomib, Pomalidomide, Dexamethasone|Protasome/IMiD combination of Ixazomib 4mg days 1, 8, and 15, Pomalidomide 4mg days 1-21 amd Dexamethasone 20 mg days 1, 8, 15 and 22 of a 28 day cycle
2997736|NCT02578108|Active Comparator|no diagnostic genicular nerve blocks|no diagnostic genicular nerve blocks prior to genicular nerve ablation Intervention: genicular nerve radiofrequency ablation
2997737|NCT02578108|Active Comparator|diagnostic genicular nerve blocks|Set of diagnostic genicular nerve blocks prior to genicular nerve ablation Intervention: genicular nerve radiofrequency ablation
2997738|NCT02578095|Placebo Comparator|Placebo (for VK5211)|Placebo QD
2997739|NCT02578095|Experimental|Active VK5211- 0.5mg|0.5mgQD
2997740|NCT02578095|Experimental|Active VK5211- 1.0mg|1.0mg QD
2997741|NCT02578095|Experimental|Active VK5211- 2.0mg|2.0mg QD
2997742|NCT02578082|Experimental|Renal Impairment|Eight subjects with Severe Renal Impairment (eGFR <30 mL/min/1.73m2). Intervention is TD-4208, 175mcg, inhaled, single dose.
2997743|NCT02578082|Experimental|Normal Renal Function|"Eight healthy participants matched to participants with severe renal impairment.~Intervention is TD-4208, 175mcg, inhaled, single dose."
2997744|NCT02578069|Experimental|Experimental|NOVA Intracranial sirolimus eluting stent system
2997745|NCT02578069|Active Comparator|Control|Apollo Intracranial stent system
2997746|NCT02578056|Experimental|Mid-urethral sling|Patients randomized to anti-incontinence surgery will undergo TVT sling placement as the standard technique at the same time of genital prolapse surgery.
2997785|NCT02577783|Active Comparator|PAD arm|patients involved in PAD arm will accept chemotherapy of PAD regimen (doxorubicinplus bortizomib and dexamethasone )
2997786|NCT02577770|Experimental|200mg caffeine plus acupuncture|In healthy subjects
2997747|NCT02578056|Sham Comparator|POP|Patients randomized to the sham group will be submitted to genital prolapse surgery and sham incisions as if they had undergone the TVT procedure (two small incisions of 0.5 cm in the suprapubic region in a similar way to that used for the insertion of the sling). These incisions intended to keep the raters blind to the achievement or otherwise of the sling during the postoperative evaluation.
2997748|NCT02578043|Experimental|Clindamycin and BPO Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% applied to the face once daily for 84 days.
2997749|NCT02578043|Active Comparator|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) applied to the face once daily for 84 days.
2997750|NCT02578043|Placebo Comparator|Placebo|Placebo (vehicle of the test product) applied to the face once daily for 84 days.
2997751|NCT02578030|Experimental|SHP465 12.5 mg|A single dose of SHP465 12.5 mg for Subjects aged 6-12 years
2997752|NCT02578030|Experimental|SHP465 25 mg|A single dose of SHP465 25 mg for Subjects aged 13-17 years
2997753|NCT02578017|Experimental|Mobile DOT|All Participants will utilize Mobile DOT for 6 months. The Mobile DOT intervention includes: reminder alerts, participant videos, research staff feedback on adherence, and contingency management.
2997754|NCT02578017|No Intervention|Post-intervention observation|All participants will not receive any additional adherenece intervention after completing the Mobile DOT arm. Participants will be observed for 6 months.
2997755|NCT02578004||100 patients suffering from pressure ulcer|100 subjects were having at least one wound of pressure ulcer (74 men and 26 women) middle-aged (55.5±20 years) and were recruited from many services of three University Regional hospitals of Tunisia.
2997756|NCT02578004||213 healthy subjects|213 healthy subjects (125 men and 88 women) middle-aged (51.5±17 years). Although, healthy individuals, were included as controls, followed in the outpatient services of the University Hospital Farhat Hached and they considered clinically free of pressure ulcer and tissue necrosis.
2997757|NCT02577991|No Intervention|Control group|No steroid
2997758|NCT02577991|Experimental|IV steroid|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
2997759|NCT02577991|Experimental|Local steroid|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
2997760|NCT02577978|Other|Medacta Sphere|Ball-and-socket
2997761|NCT02577978|Other|Medacta PS|Cam-and-post
2997762|NCT02577965|Experimental|Female Arm|Female gender diagnosed with ST segment Elevation Myocardial Infarction (STEMI). Interventions: Angiography, thrombus aspiration, optical coherence tomography and percutaneous coronary intervention, implantation of XIENCE PRIME Everolimus Eluting Coronary Stent. Angiography and Optical Coherence Tomography follow up at 9 months.
2997763|NCT02577965|Active Comparator|Male Arm|Male Gender with diagnose of ST segment Elevation Acute Myocardial Infarction (STEMI). Interventions: Angiography, thrombus aspiration, optical coherence tomography and percutaneous coronary intervention, implantation of XIENCE PRIME Everolimus Eluting Coronary Stent. Angiography and Optical Coherence Tomography follow up at 9 months.
2997764|NCT02577952||People with Lipodystrophy & family|People currently living with lipodystrophy and their family members.
2997765|NCT02577939|Experimental|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
2997766|NCT02577926|Experimental|Ruxolitinib|Ruxolitinib will be administered orally at a dose of 10 mg twice daily (both PV and ET) for two consecutive years.
2997767|NCT02577926|Active Comparator|Best available therapy (BAT)|BAT may include all currently used treatment options. BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc). BAT will be administrated for two consecutive years.
2997768|NCT02577913||FC patch low|Women taking FC Patch low, a transdermal patch releasing 60 micrograms gestodene/24 hours + 13 micrograms ethinyl estradiol/24 hours
2997769|NCT02577913||LNG-COC|Women taking levonorgestrel-containing COCs: 1) monophasic preparations containing 20 - 30mcg of ethinylestradiol; 2) multiphasic preparations containing up to 40mcg of ethinylestradiol
2997770|NCT02577900|Experimental|Acticoat absorbent|Apply Acticoat absorbent onto the ulcer
2997771|NCT02577900|Active Comparator|Honey gel sheet|Apply Honey gel sheet onto the ulcer
2997772|NCT02577900|Other|Jelonet|Apply Jelonet onto the ulcer
2997773|NCT02577874||Chinese Subjects|7 blood glucose tests taken over a two hour period
2997774|NCT02577874||European Subjects|7 blood glucose tests taken over a two hour period
2997775|NCT02577861|Experimental|Holoclar|Treatment with Holoclar (medicinal product), including biopsy, graft production and implantation of the graft containing stem cell
2997776|NCT02577848|Experimental|GLP-1 group|liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
2997777|NCT02577848|Placebo Comparator|placebo|placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.
2997778|NCT02577835||Hypertensive patients|No intervention. Patients will be sumbitted to standard tests required for hypertension management, including ambulatory blood pressure monitoring, and pharmacologically treated according to recommendations of international guidelines. The registry will include data from subjects fulfilling the inclusion criteria and whose data are contained in existing databases collected by the participating centers and who are regularly followed-up at the center. New subjects can be enrolled for this project, but they must be submitted to ambualtory blood pressure monitoring because it is required for evaluating their hypertension status, according to current recommendations.
2997779|NCT02577822|Other|Arm 1|Short femoral stem
2997780|NCT02577822|Other|Arm 2|standard-length stem
2997781|NCT02577809|Active Comparator|Morphine100|1.8ml 0.5% hyperbaric bupivacaine with 0.1mg preservative-free morphine (mixed in 0.4ml normal saline to a volume of 2.3ml) administered into the intrathecal space
2997782|NCT02577809|Active Comparator|Morphine50|1.8ml 0.5% hyperbaric bupivacaine with 0.05mg preservative-free morphine (mixed in 0.4ml normal saline to a volume of 2.3ml) administered into the intrathecal space
2997788|NCT02577770|Placebo Comparator|Decaffeinated plus acupuncture|In healthy subjects
2997789|NCT02577757|Other|healthy volunteers|achieving functional MRI
2997790|NCT02577757|Experimental|Eligible patients with awakened surgery|achieving functional MRI
2997791|NCT02577744|Active Comparator|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
2997792|NCT02577744|Active Comparator|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
2997793|NCT02577731|Other|Severe Trauma|Bone marrow collection. Blood collection. Clinical data collection.
2997794|NCT02577731|Other|Elective Hip Repair|Bone marrow collection. Blood collection. Clinical data collection.
2997795|NCT02577731|Other|Healthy Young Bone Marrow Control|Deidentified freshly isolated bone marrow samples from healthy young control subjects will be purchased for a tissue bank.
2997796|NCT02577718|Experimental|Nitroglycerin-Citrate-Ethanol (NiCE)|Antimicrobial Nitroglycerin-Citrate-Ethanol catheter lock solution was administered for 2 hours then flushed
2997797|NCT02577705|Experimental|Self Empowerment Groups|Intervention activities included helping participants to open savings accounts at a local federal credit union with 1:1 matches of up to twenty dollars per month for 12 months. Participants also received financial empowerment and Peer Support curriculum, weekly for about 3 hours per week for 28 weeks.
2997798|NCT02577705|Experimental|Financial Empowerment|Intervention activities included helping participants to open savings accounts at a local federal credit union with 1:1 matches of up to twenty dollars per month for 12 months. Participants also received financial empowerment weekly for about 3 hours per week for 28 weeks.
2997799|NCT02577705|No Intervention|Control Group|The Control group did not receive assistance in opening a matched savings account, and were required by the County Assistance Office to participate in other Temporary Assistance for Needy Families (TANF) mandated work participation activities according to standard procedure.
2997800|NCT02577692|Experimental|Oxygen|Day 1: breathing of 100% oxygen; Day 2: ambient air breathing
2997801|NCT02577692|Experimental|Ambient|Day 1: breathing of 100% oxygen; Day 2: ambient air breathing
2997802|NCT02577666|Experimental|Ecologically-Based Therapy + TAU|receives Ecologically-Based Therapy which includes the Community Reinforcement Approach, Strengths-Based Case Management (6 months) and rental assistance for housing (3 months) + TAU
2997803|NCT02577666|Experimental|Housing Only + TAU|receives 3 months of rental assistance for housing only + TAU
2997804|NCT02577666|Other|treatment as usual (TAU)|receives usual treatments/interventions (TAU) within in the community
2997805|NCT02577653|Other|subjects|participant undergoing posturographic evaluation
2997806|NCT02577640|Experimental|Dose Escalation (DE) Phase|Here a traditional 3+3 design will be used to determine the compliance, tolerability and dose limiting toxicities in this unique patient population. Dose escalation with soy bread will be continued until dose-limiting toxicities are observed in >33% of the participants or the daily target dose of 4 slices of bread [132 mg soy isoflavone] is reached.
2997807|NCT02577640|Experimental|Maximum Tolerated Dose (MTD) Phase|After the Phase I study has been completed, an additional 10 chronic pancreatitis patients will be treated at the best tolerated dose of soy bread for 4 weeks to further verify safety and toxicity.
2997808|NCT02577627||Training Set|The Training Set will be used to calibrate the Predicare models and algorithms and assess its predictive potential in a retrospective manner. Patients data will be collected according to the oncological indications (NSCLC, SCLC, Prostate cancer, Breast cancer and Colon cancer) and the applied treatment protocols, and their data will be integrated and processed by the PrediCare algorithm.
2997809|NCT02577627||Validation Set|The Validation Set will be used to validate the prediction power of the device in a prospective manner. The files of patients assigned to Validation Set of the study will be used for the blind prediction of TTP under each specific treatment, based on the baseline individual information. This will be done by inputting into PrediCare the information of each individual patient, available prior to treatment onset (baseline; clinical data, imaging data, histology/cytology, oncomarkers, genetic screening, hematology, biochemistry) for creating a personalized mathematical models and predicting TTP of this specific patient. These predictions will be then compared to the clinically observed TTP for all the patients.
2997810|NCT02577614|Experimental|FEIBA|Single dose of commercially available FEIBA
2997811|NCT02577614|Placebo Comparator|Normal Saline|Single dose of NaCl 0.9%
2997812|NCT02577601|Active Comparator|UPA Only|During the first treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10). Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.
2997813|NCT02577601|No Intervention|Washout Cycle|The month following this first treatment month (washout-cycle),there will be no study visits during this menstrual cycle but there will be contact with study staff (1 or 2 times) by telephone or email to discuss any health changes that are experiencing.
2997814|NCT02577601|Active Comparator|UPA + COC|During the second treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10) and then 2 days later start birth control pills. Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.
2997815|NCT02577588|Experimental|re-activated T cells|Ten patients with CRC stage UICC IV under routine first line FOLFOX 6/Bevacizumab therapy are planned to receive a singular treatment with an autologous T cell product at a dose of 5x10^7 (first three or six patients) or 5x10^8 (last four or seven patients) cells.
2997816|NCT02577575|Experimental|Oxytocin|40 IU Oxytocin
2997817|NCT02577575|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
2997818|NCT02577549|Experimental|Diet & Exercise|Participants will attend an exercise class 3 days/week for 18 months. The exercise program will consist of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's will also attend individual and group diet sessions. Each participant's minimum weight loss goal will be 10% of baseline body weight.
2997852|NCT02577315|Experimental|Reference - Empagliflozin + Metformin|free combination of 1 tablet of 25 mg Empagliflozin and 1 tablet of 1000 mg of Metformin, oral with 200 mL of water under fed conditions
3028343|NCT02373150|Experimental|Group A3|Dose 3 or placebo
2997819|NCT02577549|Active Comparator|Attention Control|The attention control intervention will cover an 18-month period. There will be four total face to face group meetings over the 18 months, with one meeting each at months 1, 6, 12, and 18; and during the other months (months 2-5, 7-11, 13-17) participants will receive a combination of informational packets, webinars, and/or emails based on continued monitoring of participant needs and delivered via their preferred mode of contact.
2997820|NCT02577536||1 All Subjects|No interventions
2997821|NCT02577523|Experimental|ND0612 (Levodopa/Carbidopa solution) Dosing Regimen 1|Dosing Regimen 1 of ND0612 (Levodopa/Carbidopa solution) continuous SC infusion over 24 hours
2997822|NCT02577523|Experimental|ND0612 (Levodopa/Carbidopa solution) Dosing Regimen 2|Dosing Regimen 2 of ND0612 (Levodopa/Carbidopa solution) continuous SC infusion over 14 hours
2997823|NCT02577510|Experimental|Nerve Stimulation- Xylocaine injection|Anesthesia of the lateral femoral cutaneous nerve using local anesthetic will be randomly assigned on the right or left side to receive nerve stimulation-xylocaine or ultrasound guided -xylocaine injections in all patients. One patient will therefore have both nerve stimulation AND ultrasound guided injections, only the side of the injection will be randomly assigned to one of the two modalities. Once one technique has been used to freeze one side, the other side will be frozen using the other technique.
2997824|NCT02577510|Experimental|Ultrasound guided Xylocaine injection|Anesthesia of the lateral femoral cutaneous nerve using local anesthetic will be randomly assigned on the right or left side to receive nerve stimulation-xylocaine or ultrasound guided -xylocaine injections in all patients. One patient will therefore have both nerve stimulation AND ultrasound guided injections, only the side of the injection will be randomly assigned to one of the two modalities. Once one technique has been used to freeze one side, the other side will be frozen using the other technique.
2997825|NCT02577497|Experimental|Beclomethasone|Subjects are being randomized to 8 weeks of beclomethasone or fluticasone treatment followed by a 4 week study drug washout with resumption of standard asthma medication regimen for 4 weeks, followed by 8 weeks of beclomethasone or fluticasone (whichever drug was not taken the first 8 weeks)
2997826|NCT02577497|Experimental|fluticasone|Subjects are being randomized to 8 weeks of beclomethasone or fluticasone treatment followed by a 4 week study drug washout with resumption of standard asthma medication regimen for 4 weeks, followed by 8 weeks of beclomethasone or fluticasone (whichever drug was not taken the first 8 weeks)
2997827|NCT02577484||Participants|Subjects who satisfy both general and angiographic inclusion/exclusion criteria, and who have the pressure measurement taken with the Navvus catheter.
2997828|NCT02577471||During pregnancy|Pregnant ladies filled bowel function questionnaires
2997829|NCT02577471||After delivery|ladies within three weeks of delivery filled bowel function questionnaires
2997830|NCT02577471||Controls|Non pregnant ladies filled bowel function questionnaires
2997831|NCT02577458|Experimental|CM082 plus everolimus|CM082 plus everolimus
2997832|NCT02577445||CSA patients without remedē system|For all patients diagnosed with CSA who will not move forward with remedē® system therapy, the intention is to obtain information on their alternate therapy, if any, and safety information, including all cause mortality and all cause hospitalizations during phone calls at 6, 12 and 24 months after enrollment.
2997833|NCT02577445||CSA patients with remedē system|"For all patients diagnosed with CSA and referred for implant / or have already been implanted with remedē system, information from the implant procedure will be collected.~Patients will be asked to complete quality of life questionnaires at baseline and during follow-up visits.~Patients will be evaluated at the time of therapy activation which may be followed by one or more titration visits. Patient follow-ups will be programmed at 6 and 12 months, and yearly, up to 5 years post-implant, until the last patients reach their 2-year follow-up.~Echocardiogram for patients with reduced ejection fraction (≤ 45%) and follow-up respiratory polygraphy are considered standard of care, however, to ensure sufficient data, related to the study objectives, are being collected, baseline and 12-months echocardiogram for a subgroup of patients and respiratory polygraphy at 12-month follow-up for all patients must be done when participating in this study:"
2997834|NCT02577432|Active Comparator|(S) separate.|fentanyl and hyperbaric bupivacaine (sequentially)
2997835|NCT02577432|Active Comparator|(M) mixed|fentanyl and hyperbaric bupivacaine.(mixed)
2997836|NCT02577419|Experimental|Target Fortification|
2997837|NCT02577419|Experimental|Higher Initial Concentration|
2997838|NCT02577419|Active Comparator|Portagen Growth Reference|
2997839|NCT02577406|Experimental|AG-221 plus Best supportive care (BSC)|Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days, plus BSC.
2997840|NCT02577406|Active Comparator|Conventional care regimen (CCR)|Continuous 28-day cycles of BSC only, azacitidine subcutaneously (SC) plus BSC, low-dose cytarabine (LDAC) SC plus BSC, or intermediate-dose cytarabine (IDAC) intravenously (IV) plus BSC. Subjects will be assigned by the investigator to one of the CCR treatment options based on the investigator's assessment of subjects' eligibility.
2997841|NCT02577393|Experimental|EGCG group|
2997842|NCT02577393|Placebo Comparator|placebo|
2997843|NCT02577380|Experimental|IPV/GBV HIV testing and counseling|For the randomized controlled trial, first-time antenatal care clients will be randomly assigned to IPV/GBV HTC HIV testing.
2997844|NCT02577380|No Intervention|Standard HIV testing and counseling|For the randomized controlled trial, first-time antenatal care clients will be randomly assigned to Standard HIV testing and counseling.
2997845|NCT02577367|Experimental|Levothyroxine on empty stomach|Levothyroxine will be given on empty stomach, by holding enteral feeding for 2 hours before and 2 hours after Levothyroxine administration
2997846|NCT02577367|Active Comparator|Levothyroxine during feeding|Levothyroxine will be given while the enteral feeding is running
2997847|NCT02577354|Experimental|Treatment|
2997848|NCT02577354|Experimental|Control|
2997849|NCT02577341|Experimental|Nimotuzumab|five cycles of Nimotuzumab and daily RT (65Gy in 25 fractions) to the chest, combined with five cycles of docetaxel and cisplatin.
2997850|NCT02577341|Placebo Comparator|Placebo|five cycles of placebo and daily RT (65Gy in 25 fractions) to the chest, combined with five cycles of docetaxel and cisplatin
2997851|NCT02577315|Experimental|Test - Empagliflozin/Metformin|fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin, oral with 200 mL of water uder fed conditions
3029920|NCT02362620||Cabazitaxel|Cabazitaxel 20-25mg/m2 IV every 3 weeks
2997853|NCT02577302|Experimental|CAN-Stim Group-StimGuard CAN-Stim System|"Intervention: tibial medical device~Subjects randomized to this group will have the Protect CAN-Stim System tibial medical device implanted for the duration of the study."
2997854|NCT02577302|Active Comparator|SNS Group - Interstim® System|"Intervention: SNS Medical device~Subjects randomized to SNS will have their Stage I device implanted and tested during a 2-week period. Stage I will have a tined, quadripolar lead placed in the S3 (preferred) or S4 (alternate) foramen in the standard fashion using fluoroscopic guidance and motor response. Motor responses can include a contraction of the levators (bellows response) with or without plantar flexion of the great toe. Subjects who are not demonstrating an appropriate motor response will not have the device implanted and will be exited from the study."
2997855|NCT02577289|Active Comparator|Control group ( Hydroxyappetite)|Patients will undergo open sinus lift using nano crystalline hydroxyapatite as augmentation material and placing implants simultaneously then evaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)
2997856|NCT02577289|Experimental|Test group (PRF)|Patients will undergo open sinus lift using PRF as sole augmentation material and placing implants simultaneously then Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)
2997857|NCT02577276|Experimental|Tele-motion rehabilitation system|Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
2997858|NCT02577250|Experimental|Six ketamine infusions|Six infusions of 0.5 mg/kg ketamine hydrochloride solution over 2 weeks.
2997859|NCT02577237|Experimental|Intervention Group: Caregiver education|The intervention includes caregivers who will receive an education and support program throughout radiation treatment in addition to usual care by their doctors and nurses.
2997860|NCT02577237|Active Comparator|Control Group: educational booklet|The control group will receive an educational booklet about caregiving in addition to usual care by their doctors and nurses
2997861|NCT02577224|Experimental|Intervention|Participants randomized to the intervention group (patient-initiated treatment) will be asked to initiate their own treatment during the nine months they are taking part in the trial. Intervention group participants will receive information about when and how to initiate an appointment. Contact details for the service will be provided along with information on how quickly an appointment will be made, with whom and the procedure in the case of an emergency. All patients requesting an appointment will be booked in to the next available slot within the twice weekly ring‐fenced nurse-led clinics. Any subsequent scheduled appointments will be cancelled and all future treatment will be initiated by the patient.
2997862|NCT02577224|No Intervention|Control|Participants in the control group will receive treatment as usual. This consists of scheduled appointments in the hospital-based nurse-led botulinum toxin clinic. The frequency with which these appointments takes place are based on clinical judgement, but tend to range between every 6 weeks to every 4 months.
2997863|NCT02577211|Experimental|Hipocaloric enteral nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg.
2997864|NCT02577211|Active Comparator|Normocaloric enteral nutrition|25 kcal per kg of body weight and 1.7 grams of protein per kg.
2997865|NCT02577198|Experimental|Intervention|Electronic Health Records with computerised decision support system activated Medilogy Decision Support System (MediDSS)
2997866|NCT02577198|Other|Control|Electronic Health Records with computerised decision support system silenced Medilogy Decision Support System (MediDSS) silenced
2997867|NCT02577185|Experimental|botulinum toxin type A|Experimental drug
2997868|NCT02577185|Placebo Comparator|sodium chloride 9 mg/ml|Vehicle drug
2997869|NCT02577172|Experimental|Exercise group|Aerobic- and Strength Training program
2997870|NCT02577172|Active Comparator|Control group|One lifestyle counseling session
2997871|NCT02577159|Experimental|Dapagliflozin|Diabetic patients who met the inclusion/exclusion criteria. Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
2997872|NCT02577146|Experimental|Study ultrasound|Study ultrasound with ureteral jet assessment will be obtained after CT diagnosis of ureteral calculus is made. Ureteral jet data will be documented and patients will be followed prospectively for 42 days for spontaneous stone passage or need for surgical intervention.
2997873|NCT02577133|Active Comparator|Lactobacillus reuteri group|Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
2997874|NCT02577133|Placebo Comparator|Placebo group|Placebo (5 drops) for 28 days
2997875|NCT02577120||Low TEWL|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects will be be discontinued from the study.
2997876|NCT02577120||High TEWL - No treatment|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
2997877|NCT02577120||High TEWL - Epiceram skin barrier function|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
2997878|NCT02577120||High TEWL - Ceramiseal|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site
2997879|NCT02577120||High TEWL - Vaseline Petroleum Jelly|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
2997880|NCT02577107|Experimental|Ranibizumab 0.5 mg|Three monthly injections of 0.5mg Ranibizumab
2997881|NCT02577107|Active Comparator|Conbercept 0.5 mg|Three monthly injections of 0.5mg Conbercept
2997882|NCT02577081|Experimental|CAT scan|A CAT scan will be done for all participants. The scan will include the pelvis and 2 femurs.
2997883|NCT02577068|Active Comparator|nefopam group|
2997884|NCT02577068|Active Comparator|propacetamol group|
2997885|NCT02577068|Experimental|nefopam and propacetamol group|
2997886|NCT02577055|Active Comparator|Poly-myomectomy|Women will be treated with surgical removal of all fibroids, either by laparoscopic or abdominal route
2997887|NCT02577055|Experimental|embolisation|Women will be treated with fertility sparing uterine arteries embolization (i..e. with ultra thin catheter, and particles' diameter > 500µm)
2997888|NCT02577042|Experimental|Raltegravir + Atorvastatin|Switching the PI by raltegravir, plus Kivexaâ or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks
2997889|NCT02577042|Active Comparator|PI-based regimen + Atorvastatin|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.
2997890|NCT02577029|Experimental|ARC-520 administered alone|ARC-520 (2 mg/kg or 4 mg/kg every 4 weeks) for 48 weeks (13 doses).
2997891|NCT02577029|Experimental|ARC-520 with nucleoside and Peginterferon|ARC-520 (2 mg/kg every 4 weeks - 48 weeks) + entecavir (0.5 mg daily - about 60 weeks) or tenofovir (300 mg daily - about 60 weeks) + Peginterferon alpha 2a (180 mcg weekly) - 48 weeks
2997892|NCT02577029|Experimental|ARC-520 with Peginterferon|ARC-520 (2 mg/kg every 4 weeks - 48 weeks) + Peginterferon alpha 2a (180 mcg weekly) - 48 weeks
2997893|NCT02577016|Experimental|Sitagliptin + Ipragliflozin|Sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.
2997894|NCT02577016|Active Comparator|Placebo + Ipragliflozin|Placebo to sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.
2997895|NCT02577003|Experimental|Ipragliflozin + Sitagliptin|Ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
2997896|NCT02577003|Active Comparator|Placebo + Sitagliptin|Placebo to ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
2997897|NCT02576990|Experimental|Pembrolizumab: rrPMBCL|Participants with rrPMBCL receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to a maximum of 35 administrations (approximately 2 years).
2997898|NCT02576990|Experimental|Pembrolizumab: rrRS|Participants with rrRS receive pembrolizumab 200 mg IV Q3W for up to a maximum of 35 administrations (approximately 2 years). Effective with Protocol Amendment 04, enrollment into this cohort was closed.
2997899|NCT02576977|Experimental|Pembrolizumab+Pomalidomide+Dexamethasone|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W) PLUS pomalidomide 4 mg orally (PO) on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
2997900|NCT02576977|Active Comparator|Pomalidomide+Dexamethasone|Participants receive pomalidomide 4 mg PO on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
2997901|NCT02576964|Experimental|Capecitabine + Peginterferon alfa-2a|Treatment-naive participants with advanced liver cancer will receive combination treatment with capecitabine (1000 milligrams per meter-squared [mg/m^2] twice daily orally on Days 1 to 14 of each 21-day cycle) and peginterferon alfa-2a (180 micrograms (mcg) subcutaneous [SC] every week during each 21-day cycle) until at least 6 cycles (18 weeks) or disease progression, intolerable toxicity, or consent withdrawal.
2997902|NCT02576951|Experimental|LY2951742 Solution Formulation-Part A|LY2951742 solution formulation in a prefilled syringe given SC once.
2997903|NCT02576951|Placebo Comparator|Placebo-Part A|Placebo in a prefilled syringe given SC once.
2997904|NCT02576951|Experimental|LY2951742 Lyophilized Formulation-Part B|LY2951742 lyophilized (freeze dried) formulation given SC once.
2997905|NCT02576951|Experimental|LY2951742 Solution Formulation-Part B|LY2951742 solution formulation in a prefilled syringe given SC once.
2997906|NCT02576938|Experimental|Baricitinib|"Administered once daily in multiple oral dose cohorts for 16 weeks~(Triamcinolone 0.1% topical also permitted)"
2997907|NCT02576938|Placebo Comparator|Placebo|"Administered orally once daily, for 16 weeks~(Triamcinolone 0.1% topical also permitted)"
2997908|NCT02576925||Eligible patients|Adults having had a transient diplopia during the last 8 days.
2997909|NCT02576912|Experimental|Active Delta-9-THC and Placebo Pregnenolone|
2997910|NCT02576912|Experimental|Active Delta-9-THC and Active Pregnenolone|
2997911|NCT02576912|Experimental|Placebo Delta-9-THC and Active Pregnenolone|
2997912|NCT02576912|Placebo Comparator|Placebo Delta-9-THC and Placebo Pregnenolone|
2997913|NCT02576899|Active Comparator|Stage 1b Study of ACT-PT vs. FFS|This study involves a randomized clinical trial study of 50 Veteran smokers with PTSD and tobacco dependence randomized to one of two different types of psychosocial treatment: 10 individual sessions of ACT-PT (n= 25) versus 10 individual sessions of the American Lung Association's Freedom From Smoking Program [FFS] (n=25). This study has two primary aims: 1) Evaluate the relative feasibility and acceptability of the two interventions (including ease of recruitment, randomization proportion, staff and Veteran acceptance of the treatment, retention rates, treatment adherence, fidelity, ease of the assessment process), and 2) Evaluate the preliminary efficacy of ACT-PT vs. FFS with the primary outcomes of tobacco use, PTSD symptoms, health-related quality of life, and functional impairment.
2997914|NCT02576899|Placebo Comparator|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
2997915|NCT02576886|Experimental|Supine/Prone Imaging|The patient will be imaged in the standard supine position and then an additional image will be acquired of the patient in the prone position.
2997916|NCT02576873||Hemodiafiltration|End-stage renal disease patients who were treated with high-efficiency hemodiafiltration for more than 6 months
2997917|NCT02576860|Experimental|Treatment|CLS001 (Omignan) gel applied once daily
2997918|NCT02576860|Placebo Comparator|Vehicle Gel|Vehicle gel applied once daily
2997919|NCT02576847|Experimental|Treatment|Omiganan gel applied once daily
2997920|NCT02576834|Experimental|CTSP + SAU|10 sessions of Cognitive Therapy for Suicide Prevention (CTSP) provided over 6 months, with optional 9 booster sessions + SAU
2997921|NCT02576834|Other|Services as Usual (SAU)|client receives services they would normally receive within the community
2997922|NCT02576821|Other|Patients with Hippocampal sclerosis non AD|Patients with Hippocampal sclerosis non AD (n=40)
2997923|NCT02576821|Other|Patients with Alhzeimer's Disase|Patients with Alhzeimer's Disase (n=40)
2997924|NCT02576821|Other|Patients with DLFT|Patients with DLFT (n=20)
2997925|NCT02576821|Other|Patients with CBD/PSP|Patients with CBD/PSP (n=20)
2997926|NCT02576821|Other|Normal controls|Normal controls (n=20)
2997927|NCT02576808|Experimental|Ginger extract|Drug
2997928|NCT02576808|Active Comparator|Loratadine|Drug
2997929|NCT02576795|Experimental|BMN 270|BMN 270 is administered as a single IV Infusion.
2997930|NCT02576782|Active Comparator|perineural dexamethasone group|21 patients received perineural dexamethasone plus bupivacaine 0.5%
2997931|NCT02576782|Active Comparator|systemic dexamethasone group|21 patients received systemic (intravenous) dexamethasone plus perineural bupivacaine 0.5%
2997932|NCT02576782|Sham Comparator|control group|21 patients received only perineural bupivacaine 0.5% plus intravenous saline
2997933|NCT02576769||Basal cell carcinoma|Basal cell carcinoma
2997934|NCT02576756||with difficult intubation|Control population
2997935|NCT02576756||without difficult intubation|Control population
2997936|NCT02576743||Healthy subjects|Subjects with no contraindications to magnetic resonance imaging will undergo 4D flow MRI scanning. 7 Tesla MRI
2997937|NCT02576743||Patients|Patients with an unruptured brain aneurysm or an unruptured arteriovenous malformation (AVM) with no contraindications to magnetic resonance imaging will undergo 4D flow MRI scanning 7 Tesla MRI
2997938|NCT02576730||Fratures|patient with foot and ankle fractures and surgery with ORIF
2997939|NCT02576730||healthy subjects|patients without foot and ankle fracture s
2997940|NCT02576717|Experimental|1 mg RPC1063 (Ozanimod) oral capsule|1 mg RPC1063 (Ozanimod) oral capsule daily
2997941|NCT02576691||The PCI group|The PCI group was composed of patients who underwent PCI following the return of spontaneous circulation or after CA.
2997942|NCT02576691||Non-PCI group|Non-PCI group included patients who didn't undergo PCI or were subjected to PCI before CA
2997943|NCT02576678|Experimental|Open label apremilast|"Apremilast doses of 10-mg, 20-mg or 30-mg tablets have been selected to determine the dose range in adolescents and children with moderate to severe plaque psoriasis. These pediatric dosages are expected to achieve exposures similar to those achieved in adult psoriasis and psoriatic arthritis (PsA) subjects treated with apremilast 30 mg orally twice daily (BID).~A staggered, stepwise approach by age range and weight (starting with older and heavier subjects) is considered appropriate for this first-time-in-children study. Doses for younger and lower body weight subjects will be adjusted based on safety and PK data from older and heavier subjects.~Subjects will be divided into 2 age groups with at least 16 subjects in each group. Dosing within and between groups will be staggered, based on PK data collected and on a minimum of 2 weeks of safety data."
2997944|NCT02576665|Experimental|Toca 511/Toca FC|"Toca 511: 14 mL intravenously daily for 3 days followed by up to 4 mL intratumorally or into resection cavity walls following biopsy or resection. Cutaneous melanoma patients may receive intralesional injections (up to 4 mL) daily for 5 days.~Toca FC: 220 mg/kg/day orally starting at Week 5-6. Cycles are 5- to 7- day courses of treatment every 4 to 6 weeks."
2997945|NCT02576652|Other|Tetracycline/Demeclocycline|
2997946|NCT02576639|Placebo Comparator|Placebo|Matching placebo to CNP520 was taken once daily (qd) orally for 13 weeks.
2997947|NCT02576639|Experimental|CNP520 2 mg|CNP520 2 mg was taken qd orally for 13 weeks.
2997948|NCT02576639|Experimental|CNP520 10 mg|CNP520 10 mg was taken qd orally for 13 weeks.
2997949|NCT02576639|Experimental|CNP520 35 mg|CNP520 35 mg was taken qd orally for 13 weeks.
2997950|NCT02576639|Experimental|CNP520 85 mg|CNP520 85 mg was taken qd orally for 13 weeks.
2997951|NCT02576626|Other|A|Participants start with Ultibro (indacaterol/glycopyrronium 110/50) + placebo nebulization , then after a new washout period of 7 days they will receive ipratropium/salbutamol nebulization and placebo Breezhaler Interventions: indacaterol/glycopyrronium 110/50 Breezhaler® ,Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation, Placebo by nebulisation
2997952|NCT02576626|Other|B|"Participants start with ipratropium/salbutamol nebulization and placebo Breezhaler , then after a new washout period of 7 days they will receive Ultibro(indacaterol/glycopyrronium 110/50) + placebo nebulization.~Interventions: indacaterol/glycopyrronium 110/50 Breezhaler® ,Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation, Placebo by nebulisation"
2997953|NCT02576613|Experimental|MPP-S|at least 30 weekly sessions of modified psychodynamic psychotherapy
2997954|NCT02576613|Experimental|standard therapy (TAU)|clinical standard treatment, including supportive therapeutic contacts, pharmacotherapy, creative and occupational therapies, psychoeducation, group therapies, excluding structured individual or group psychotherapy
2997955|NCT02576600|Experimental|PUPILLO|Videopupillometer Algiscan peroperative remifentanil target concentration adapted every five minutes to pupillary diameter in patients under propofol and remifentanil TCI
2997956|NCT02576600|Sham Comparator|STANDARD|peroperative remifentanil target concentration as standard practice in patients under propofol and remifentanil TCI
2997957|NCT02576587|Other|Case (diagnosed with PAF)|"Cases. Patients with Paroxysmal Atrial Fibrillation who present to Electrophysiology Clinic at UHCMC and the Cleveland Clinic Foundation will be approached for recruitment in the study.~Cases found to have an apnea hypopnea index >=15 will be asked to continue in the study for 3 months wearing a Continuous Positive Airway Pressure (CPAP) machine."
2997958|NCT02576587|No Intervention|Controls|Controls. Patients without AF will be recruited from General Cardiology and Internal Medicine clinics (geographically similar to controls). Selection bias will be minimized as there are a broad range of reasons for patients to present to these clinics.
2997959|NCT02576574|Experimental|Arm A: Avelumab|
2997960|NCT02576574|Active Comparator|Arm B: Platinum-containing chemotherapy regimen|"Platinum-containing chemotherapy regimen: Investigator's choice platinum containing chemotherapy regimen to be administered consisting of one of the following:~Non-squamous tumor histology~Pemetrexed (500 milligram per meter square [mg/m^2]) +cisplatin (75 mg/m^2) or Pemetrexed (500 mg/m^2) + carboplatin (AUC 6 mg/mL*min)~Squamous tumor histology~Paclitaxel (200 mg/m^2) +carboplatin (AUC 6 mg/mL*min)~Gemcitabine (1250 mg/m^2)+ cisplatin (75 mg/m^2)~Gemcitabine (1000 mg/m^2 )+carboplatin (AUC 5 mg/mL*min)"
2997961|NCT02576574|Experimental|Arm C: Avelumab|
2997962|NCT02576561|Experimental|TVGV-1 (cohort 1)|Antigen + Adjuvant - 0.6 mg lyophilized PEK fusion protein + 0.6 ml* GPI- 0100 (1:1 ratio)
2997963|NCT02576561|Active Comparator|GPI-0100 (cohort 1)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein. 0.6 mg lyophilized placebo cake + 0.6 ml* GPI- 0100 (1:1 ratio)
2997964|NCT02576561|Placebo Comparator|Placebo (cohort 1)|Placebo- 0 mg lyophilized PEK fusion protein. 0.6 mg lyophilized placebo cake + 0.6 ml placebo-diluent (1:1 ratio)
2997965|NCT02576561|Experimental|TVGV-1 (cohort 2)|Antigen + Adjuvant - 0.9 mg lyophilized PEK fusion protein + 0.9 ml* GPI- 0100 (1:1 ratio)
2997966|NCT02576561|Active Comparator|GPI-0100 (cohort 2)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein. 0.9 mg lyophilized placebo cake + 0.9 ml* GPI- 0100 (1:1 ratio)
2997967|NCT02576561|Placebo Comparator|Placebo (cohort 2)|Placebo - 0 mg lyophilized PEK fusion protein. 0.9 mg lyophilized placebo cake + 0.9 ml placebo diluent (1:1 ratio)
2997968|NCT02576561|Experimental|TVGV-1 (cohort 3)|Antigen + Adjuvant - 1.2 mg lyophilized PEK fusion protein + 1.2 ml* GPI- 0100 (1:1 ratio)
2997969|NCT02576561|Active Comparator|GPI-0100 (cohort 3)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein + 1.2 mg lyophilized placebo cake 1.2 ml* GPI- 0100 (1:1 ratio)
2997970|NCT02576561|Placebo Comparator|Placebo (cohort 3)|Placebo - 0 mg lyophilized PEK fusion protein. 1.2 mg lyophilized placebo cake + 1.2 ml placebo-diluent (1:1 ratio)
2997971|NCT02576548|Experimental|Arm 1|MEDI 4276
2997972|NCT02576535|Experimental|Fractionated stereotactic radiosurgery|The radiation dose will be delivered by the standard, FDA approved Leksell gamma unit (Gamma knife; Elekta Instruments, Atlanta, GA). Treatment dose and volume will be determined using the Gamma Plan software provided with the unit (Elekta Instruments, Atlanta, GA).
2997973|NCT02576522|Experimental|brain metastatic patients|Patients with single, large brain metastases from solid tumors
2997974|NCT02576509|Experimental|Nivolumab|Nivolumab specified dose on specified days
2997975|NCT02576509|Active Comparator|Sorafenib|Sorafenib specified dose on specified days
2997976|NCT02576496|Experimental|EDO-S101|EDO-S101, IV, 20mg/m2 up to 150mg/m2 Day1 of each 21 day cycle
2997977|NCT02576470|Experimental|Videofluoroscopy (VF) and Barium|This group will receive the following types of procedures during visits. Videofluoroscopy (VF) and Barium to provide biofeedback for targeted dysphagia swallowing maneuver.
2997978|NCT02576470|Active Comparator|Surface Electromyography (sEMG)|This group will receive the following types of procedures during visits. sEMG images will be used to provide biofeedback for the targeted dysphagia swallowing maneuver.
2997979|NCT02576470|Active Comparator|Mixed VF and sEMG|This group will receive the following types of procedures during visits. Videofluoroscopy (VF) and Barium, and EMG images will be used to provide biofeedback for the targeted dysphagia swallowing maneuver.
2997980|NCT02576470|Experimental|VF with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium images with anodal transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
2997981|NCT02576470|Experimental|sEMG with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images with anodal transcranial direct current stimulation and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
2997982|NCT02576470|Experimental|Mixed VF, sEMG with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images with anodal transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
2997983|NCT02576470|Sham Comparator|VF with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium images without the transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
2997984|NCT02576470|Sham Comparator|sEMG with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images without the transcranial direct current stimulation and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
2997985|NCT02576470|Sham Comparator|Mixed VF, sEMG with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images without transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
2997986|NCT02576470|Experimental|VF with reward|This group will receive the following the procedure outlined below for biofeedback. The biofeedback is based on the videofluoroscopy (VF) and Barium with financial reward.
2997987|NCT02576470|Experimental|sEMG with financial reward|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images with financial reward. The financial reward will only be done for 3-days.
2997988|NCT02576470|Experimental|Mixed VF, sEMG with financial reward|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images with financial reward. The financial reward will only be done for 3 days.
2997989|NCT02576457|Experimental|BMS-936559|BMS-936559 Intravenous infusion on specified days
2997990|NCT02576457|Other|Placebo|Placebo on specified days
2997991|NCT02576444|Experimental|Group 1|Patients with cholangiocarcinoma harboring IDH 1/2 tumors will be treated with olaparib. Patients with tumors harboring mutation in HDR genes will be treated with olaparib.
2997992|NCT02576444|Experimental|Group 2|Patients with tumors harboring PTEN, PIK3CA, AKT, or ARID1A mutations or other molecular aberrations leading to dysregulation of the PI3K/AKT pathway will be treated with AZD5363 plus olaparib.
2997993|NCT02576444|Experimental|Group 3|Patients with tumors harboring either TP53 or KRAS mutations or mutations in KRAS and TP53 will be treated with AZD1775 plus olaparib. TP53 mutations must be found on the TP53 mutation eligibility list.
2998448|NCT02573545|Experimental|Test group: with IFE|Patients treated with IFE software
2997994|NCT02576444|Experimental|Group 4|Patients with tumors harboring mutations in HDR genes, including ATM, CHK2, APOBEC, MRE11 complex, will be treated with AZD6738 and olaparib.
2997995|NCT02576431|Other|Non Small Cell Lung Cancer|Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101
2997996|NCT02576431|Other|Thyroid|Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101
2997997|NCT02576431|Other|Sarcoma|Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101
2997998|NCT02576431|Other|Colorectal|Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101
2997999|NCT02576431|Other|Salivary|Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101
2998000|NCT02576431|Other|Biliary|Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101
2998001|NCT02576431|Other|Primary CNS|Brain Tumor Measurable by RANO Oral LOXO-101
2998002|NCT02576431|Other|All Other Solid Tumors|Tumor Histology not in Cohorts 1-7 Evaluable but not Measurable Disease Oral LOXO-101
2998003|NCT02576418|Experimental|Partosure TTD Test|PartoSure TTD test will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
2998004|NCT02576392|Experimental|Intervention|Informational letter mailed approximately 2 weeks prior to surgery, informational letter mailed approximately 2 weeks post surgery, pharmacist call if refill opioid medicine more than 28 days after surgery
2998005|NCT02576392|No Intervention|Control|Usual Care
2998006|NCT02576379||HEMS patients|Patients suspected of suffering from a vascular condition within the geographical area covered by both HEMS and GEMS, and were transported by Helicopter Emergency Medical System (HEMS) to the regional stroke unit at Copenhagen University Hospital Roskilde in a 36-month period from May 1st 2010 until April 30th 2013.
2998007|NCT02576379||GEMS patients|Patients suspected of suffering from a vascular condition within the geographical area covered by both HEMS and GEMS, and were transported by Ground Emergency Medical System (GEMS) to the regional stroke unit at Copenhagen University Hospital Roskilde in a 40-month period from January 1st 2010 until April 30th 2013.
2998008|NCT02576366|Experimental|Voriconazole|Four hundred mg of voriconazole (2 tablets of 200 mg Vfend; Pfizer, Karlsruhe, Germany) will be administered twice daily on day 2. Two hundred mg of voriconazole (1 tablet of 200 mg Vfend) will be administered twice daily on days 3, 4, 5 and 6.
2998009|NCT02576366|Experimental|Rifampin|Six hundred mg of rifampicin (2 tablets of 300mg Rifadine; Sanofi, Belgium) will be administered once daily on days 7 through 13.
2998010|NCT02576353|Experimental|Cohort 1|After a 10-hour fast, the 10 participants in this cohort are randomized to receive Fentanyl Sublingual (under the tongue) Spray (FSS) 100 mcg (n=8), or Fentanyl Citrate Intravenously (FCIV) 50 mcg (n=2).
2998011|NCT02576353|Experimental|Cohort 2|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 200 mcg (n=8), or FCIV 50 mcg (n=2).
2998012|NCT02576353|Experimental|Cohort 3|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 400 mcg (n=8), or FCIV 50 mcg (n=2).
2998013|NCT02576353|Experimental|Cohort 4|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 600 mcg (n=8), or FCIV 50 mcg (n=2).
2998014|NCT02576353|Experimental|Cohort 5|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 800 mcg (n=8), or FCIV 50 mcg (n=2).
2998015|NCT02576340|Active Comparator|study|drug was administered
2998016|NCT02576340|No Intervention|control|no drug administered
2998017|NCT02576327|Experimental|Aprepitant Arm|Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）+ Aprepitant125mg（Day1-2）、80mg（Day3-6）
2998018|NCT02576327|Active Comparator|Control Arm|Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）
2998019|NCT02576314|Active Comparator|Sofosbuvir and Daclatasvir|Participants will receive Sofosbuvir (SOF) 400 mg and Daclatasvir (DCV) 60 mg daily for 12 weeks.
2998020|NCT02576314|Active Comparator|Ledipasvir/sofosbuvir|Participants will receive Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet daily for 12 weeks.
2998021|NCT02576301|Experimental|Phase 2 AML|OXi4503 at MTD plus cytarabine 1g/m2/day
2998022|NCT02576301|Experimental|Phase 2 MDS|OXi4503 at MTD plus cytarabine 1g/m2/day
2998023|NCT02576301|Experimental|OXi4503 dose escalation|MTD for OXi4503 will be determined
2998024|NCT02576301|Experimental|OXi4503 + cytarabine dose escalation|MTD of the combination of OXi4503 + cytarbine will be determined
2998025|NCT02576288|Experimental|Sitagliptin|100mg will be administered by mouth daily for 28days
2998026|NCT02576288|Placebo Comparator|Matching Placebo|One placebo will be administered by mouth daily for 28days
2998027|NCT02576275|Experimental|Duvelisib + Rituximab + Bendamustine|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.~Bendamustine is administered as an intravenous (IV) infusion and is supplied for injection in single-use vials at two strengths, 25 mg and 100 mg.~Rituximab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
2998028|NCT02576275|Placebo Comparator|Placebo + Rituximab + Bendamustine|"Placebo is administered orally and supplied as formulated capsules to match the active 5 mg and 25 mg capsules of duvelisib.~Bendamustine is administered as an IV infusion and is supplied for injection in single-use vials at two strengths, 25 mg and 100 mg.~Rituximab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
2998029|NCT02576262||HPV-positive women，30-65 years of age|
2998030|NCT02576249|Active Comparator|Ropivacaine and Methylprednisolone|0.2% ropivacaine and methylprednisolone knee joint injection
2998031|NCT02576249|Experimental|Saline and Methylprednisolone|0.9% normal saline and methylprednisolone knee joint injection
2998032|NCT02576236|Experimental|Triple therapy guided by result of the molecular resistance|"If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.~If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days."
2998033|NCT02576236|Active Comparator|Quadruple concomitant therapy|high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days
2998034|NCT02576223|Active Comparator|Ropivacaine hydrochloride|Ropivacain 7.5mg/ml, 5 ml injected perineural at the suprascapular nerve.
3029962|NCT02362295||census|qualitative interview
2998035|NCT02576223|Placebo Comparator|Isotonic Saline|0.9% Saline solution, 5 ml injected perineural at the suprascapular nerve.
2998036|NCT02576197|Active Comparator|Probiotic|one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)
2998037|NCT02576197|Placebo Comparator|Placebo|one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
2998038|NCT02576184|Experimental|Biologic Mesh|Biologic mesh placed in retromuscular position
2998039|NCT02576184|Experimental|Synthetic Mesh|Synthetic mesh placed in retromuscular position
2998040|NCT02576184|No Intervention|No Mesh|No mesh
2998041|NCT02576171|Experimental|Group-therapy + ICBT|This is an open trial with only one study arm
2998042|NCT02576158||Subjects will be women, 30-65 years of age|Patients who are at average risk of developing cervical intraepithelial neoplasia or cervical cancer who are eligible for cervical cancer screening will be asked to collect Cervical Exfoliated Cells sample for the HPV integration screening test and for the HPV testing and TCT. Subjects with HPV positive will undergo colposcopy within 90 days of enrollment.
2998043|NCT02576145|Experimental|Group A (With Daclizumab Therapy)|Participants who were receiving a full course of 5 doses of daclizumab (1 milligram per kilogram [mg/kg]) with Day 1 vaccine administered immediately prior to the fifth dose.
2998044|NCT02576145|Active Comparator|Group B (Post Daclizumab Therapy)|Participants who completed a full course of daclizumab therapy in the previous 4 to 18 months.
2998045|NCT02576119|Experimental|Part 1: Sentinal Cohorts|Study is in 2 sequential cohorts (BMS-955176 or placebo) each to evaluate the safety, tolerability, and PK following multiple-dose administration of BMS-955176.
2998046|NCT02576119|Experimental|Part 2: Main QTc Study|3 period nested crossover study.
2998047|NCT02576106|Experimental|Cryoablation|Cryoablation of the tumor followed by a lumpectomy as practiced in standard care
2998048|NCT02576093|Experimental|0.1% WOL071-007|Formulation containing 0.1% WOL071-007 for topical application
2998049|NCT02576093|Experimental|0.3% WOL071-007|Formulation containing 0.3% WOL071-007 for topical application
2998050|NCT02576093|Experimental|1.0% WOL071-007|Formulation containing 1.0% WOL071-007 for topical application
2998051|NCT02576093|Placebo Comparator|WOL071-007 Placebo|Formulation containing Placebo of WOL071-007 for topical application
2998052|NCT02576080|Active Comparator|Standard Group|The Standard Group will receive adjuvant imatinib at a dose of 400 mg per day for a period of 3 years. Patients will be assessed for metastases every three months for three years with thoraco-abdominal and pelvic CT scan.
2998053|NCT02576080|Other|Experimental Group|The Experimental Group will receive the same thoraco-abdominal and pelvic CT scan. Surveillance
2998054|NCT02576067|Experimental|Low dose methotrexate|average dose of 15-20 mg po/weekly
2998055|NCT02576067|Placebo Comparator|Placebo|matching placebo
2998056|NCT02576054|Experimental|V501|0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
2998057|NCT02576041|Experimental|Placebo (run-in); Bilastine|At V0, the enrolled patient received the complete drug-kit and started a 7 (+3)-day wash-out period with placebo. At the end of the 7 (+3)-days of placebo-treatment period, patients repeated the F1-high speed simulator test at Visit V1, and afterwards initiated the 7 (+3)-day treatment period with active treatment (bilastine).
2998058|NCT02576028|Other|standard treathment|two sessions of 45 minutes of active exercises for 10 days
2998059|NCT02576028|Experimental|FM associated to standard treathment|the same intervention of CG except on days 2 and 7 where one session treatment was replaced with a FM treatment.
2998060|NCT02576015|Experimental|Group L|Participants in group L will receive a single injection for femoral nerve block combined with continuous femoral nerve block intra-operatively. The femoral nerve block will be performed before the induction of anesthesia on the leg to be operated. Then the patients were given the 2% lidocaine 10 ml and 1% ropivacaine 10 ml as initial dose,then,the patients will receive a continuous infusion of 0.15% ropivacaine at 15 ml/h.Intra-operatively, bispectral index score (BIS) was titrated with the adjusting of desflurane to maintain the index between 50-60.After the surgery,these patients will receive continuous femoral nerve analgesia till 3 days post-operatively( the loading dose was set at 5 ml of 0.15% ropivacaine followed by an infusion of 0.15% ropivacaine at 5 ml/h, with bolus of 5 ml and the lock time of 30 min).
2998061|NCT02576015|Sham Comparator|Group D|Participants in group D will receive the placement of femoral nerve catheter preoperatively. The same dose of 0.9% saline was injected and infused as group L intra-operatively. Bispectral index score (BIS) was titrated with the adjusting of desflurane to maintain the index between 30-40.After the surgery,these patients will receive continuous femoral nerve analgesia till 3 days post-operatively( the loading dose was set at 5 ml of 0.15% ropivacaine followed by an infusion of 0.15% ropivacaine at 5 ml/h, with bolus of 5 ml and the lock time of 30 min).
2998062|NCT02576002||Pediatric PAH patients|US pediatric population with PAH in MarketScan database during the period 2010-2013
2998063|NCT02575989|Active Comparator|1: control group|Classic - current management of trauma patients by French medical teams
2998064|NCT02575989|Experimental|2: interventional group|"Intervention Name : monitoring, treatment, control and prevention of hypothermia~Continuous monitoring of body temperature~Ambulance warming (target : 30°C)~Patient warming with dedicated blanket~Infusion fluid warming (and temperature control)"
2998065|NCT02575976|Experimental|comprehensive CR|education and exercise-based cardiac rehabilitation
2998066|NCT02575976|Active Comparator|exercise-based CR|Exercise-based cardiac rehabilitation
2998067|NCT02575976|Other|wait list control|no cardiac rehabilitation
2998068|NCT02575963|Experimental|Phase 1 (Completed)|"Cytarabine + Lintuzumab-Ac225 Cytarabine days 1 to 10 of each cycle. Doses were divided into 2 equal fractions with the first fraction given approx. 4-7 days after 1 cycle of low dose cytarabine and the second fraction given 4-7 days after the first fraction, followed by up to 11 more cycles. Furosemide (Phase 1 only) and Spironolactone were administered after Lintuzumab-Ac225.~Experimental: Phase 2~Experimental: Lintuzumab-Ac225 The Phase II dose determined during the Phase I dose escalation was 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8. Spironolactone is administered after Lintuzumab-Ac225."
2998069|NCT02575950|Experimental|LEO43204 0,018%|Experimental drug
2998070|NCT02575950|Placebo Comparator|Vehicle|Placebo
2998071|NCT02575937|Experimental|Diabetes group|During the trial period, the participants who are diagnosed of diabetes are instructed to consume low glycemic diet every day
2998072|NCT02575937|Experimental|Fatty group|During the trial period, the participants who are diagnosed of obesity are instructed to consume low glycemic diet every day
2998073|NCT02575937|Experimental|Impaired glucose tolerance group|During the trial period, the participants who are diagnosed of impaired glucose tolerance are instructed to consume low glycemic diet every day
2998074|NCT02575924|Active Comparator|sequential medium female age>=40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
2998075|NCT02575924|Active Comparator|sequential medium female age<40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
2998076|NCT02575924|Active Comparator|sequential medium sperm testis retrieval|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
2998077|NCT02575924|Active Comparator|one step medium female age>=40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
2998078|NCT02575924|Active Comparator|one step medium female age<40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
2998079|NCT02575924|Active Comparator|one step medium sperm testis retrieval|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
2998080|NCT02575911|Experimental|LenSx|LASIK surgery in both eyes using LenSx® Femtosecond Laser System
2998081|NCT02575898|Other|One|"Creative writing and questionnaires interventions:~First Session, Second Session, Third through Sixth Sessions"
2998082|NCT02575885|Experimental|Arm I (different type of ENDS product at each visit)|Participants are asked to smoke ad lib a single cigarette of their own brand and provided with a different type of ENDS product at each visit (e-cigarette, disposable e-cigarette, eGo, personal vaporizer, e-cigar, and e-pipe) over 3.5-4 hours at least 7 days apart for 7 weeks. Participants are provided with cartridges of the same amounts of nicotine with regular (tobacco) or menthol flavor according to smoker's preference, instructed on how to use the product, asked to practice using it for 7 days, and return to the study center for their next visit.
2998083|NCT02575885|Experimental|Arm II (BLU e-cigarette ENDS product with different flavors)|Participants are asked to smoke ad lib a single cigarette of their own brand and provided with the BLU e-cigarette ENDS product with nicotine solution of one of five flavors over 3.5-4 hours at least 7 days apart for 6 weeks. Participants are provided with cartridges of maximum available amounts of nicotine and different flavors at each visit, instructed on how to use the product, asked to practice using it for 7 days, and return to the study center for their next visit.
2998084|NCT02575872|Experimental|Exercise Intervention|Participants partake in 30 minutes of group discussions regarding physical activity behavior followed by 60 minutes of moderate-intensity exercise comprised of 5 minutes warm-up, 25 minutes cardiovascular training, 20 minutes of resistance training exercises using body weight and exercise band, and 10 minutes of cool-down and stretching once weekly for 12 weeks. Participants also complete a brisk walk for 90 minutes per week outside of class for 12 weeks.
2998085|NCT02575872|No Intervention|wait-list for intervention|Participants receive a handout indicating the importance of physical activity and improved nutrition for health outcomes. After 12 weeks, patients are invited to participate in the physical behavior intervention as in Group I.
2998086|NCT02575859|Experimental|Adjuvant HIPEC|Adjuvant HIPEC will be performed simultaneously with primary tumor resection in patients undergoing curative surgery for primary colorectal cancer associated with risk factors for the development of metachronous peritoneal metastases.
2998087|NCT02575859|No Intervention|Matched control|"Comparable controls will be retrospectively selected from patients undergoing curative surgery for colorectal cancer at the National Cancer Institute (Milan, Italy) during the same period.~Every single control patient will be matched with a.patient in HIPEC group according to the following criteria: i) risk-factor for metachronous PM (minimal synchronous PM vs. ovarian metastases vs. pathological tumor [pT] stage (pT4a/b); ii) pathological node (pN) stage (pN0 vs. pN1/2); iii) grading (well/moderately vs. poorly differentiated); iv) histological subtype (adenocarcinoma vs. mucinous/signet ring cell carcinoma); v) sex; vi) age (+/-5 years). The investigators will be blinded to patient outcomes during the process."
2998088|NCT02575846|Active Comparator|Human Milk|Neonates fed human milk
2998089|NCT02575846|Placebo Comparator|Formula|Neonates fed formula
2998090|NCT02575833|Placebo Comparator|Placebo|Participants received a single dose of placebo administered by intravenous infusion on day 1.
2998449|NCT02573545|Active Comparator|Test group: without IFE|Patients treated with Numaris 4 software
2998091|NCT02575833|Experimental|Erenumab|Participants received a single dose of erenumab 140 mg administered by intravenous infusion on day 1.
2998092|NCT02575820||RBC_old|shelf life of red blood cells of 15 or higher days
2998093|NCT02575820||RBC_new|shelf life of red blood cells 14 or lower days
2998094|NCT02575807|Experimental|Phase 1 Arm 1 CRS-207/Epacadostat|CRS-207: 1×10^9 CFU by IV infusion over 1 hour Epacadostat: 100 or 300 mg Oral BID
2998095|NCT02575807|Experimental|Phase 1 Arm 2 CRS-207|CRS-207: 1×10^9 CFU by IV infusion over 1 hour
2998096|NCT02575807|Experimental|Phase 2 Arm 1 CRS-207/Pembrolizumab|Pembrolizumab: 200 mg by IV infusion over 30 minutes CRS-207: 1×10^9 CFU by IV infusion over 1 hour
2998097|NCT02575807|Experimental|Phase 2 Arm 2 CRS-207/Pembro/Epacadostat|Pembrolizumab: 200 mg by IV infusion over 30 minutes CRS-207: 1×10^9 CFU by IV infusion over 1 hour Epacadostat: 300 mg Oral BID
2998098|NCT02575794|Experimental|Treatment (terameprocol)|"Patients receive terameprocol PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pharmacological Study"
2998099|NCT02575781|Experimental|SAR428926-Escalating cohort|SAR428926 will be administered intravenously up to disease progression or dose limiting toxicities
2998100|NCT02575781|Experimental|SAR428926 in triple negative breast cancer-Expansion Cohort 1|SAR428926 will be administered intravenously at maximum tolerated dose (MTD) up to disease progression or unacceptable toxicity
2998101|NCT02575781|Experimental|SAR428926 in solid tumors-Expansion Cohort 2|SAR428926 will be administered intravenously at the MTD up to disease progression or unacceptable toxicity
2998102|NCT02575768||Severe AS: asymptomatic|Asymptomatic
2998103|NCT02575768||Severe AS: pure angina|Presence of exertional chest pain
2998104|NCT02575768||Normal controls|Healthy controls
2998105|NCT02575755|Experimental|Efficacy Study: Azithromycin plus piperaquine|At baseline, participants receive three daily doses (0, 24 and 48 hours) of i) 1 g azithromycin as 2 x film-coated 500 mg tablets ii) 960 mg piperaquine tetraphosphate tablets as 3 x 320 mg tablets
2998106|NCT02575755|Active Comparator|Efficacy Study Control: National Standard Treatment|At baseline, participants receive a single dose of sulfadoxine-pyrimethamine comprising 1,500 mg of sulfadoxine and 75 mg pyrimethamine in tablet form
2998107|NCT02575755|Experimental|Pharmacokinetic Study: Azithromycin plus piperaquine|At baseline, participants receive three daily doses (0, 24 and 48 hours) of i) 1 g azithromycin as 2 x film-coated 500 mg tablets ii) 960 mg piperaquine tetraphosphate tablets as 3 x 320 mg tablets
2998108|NCT02575742||Young women without chronic constipation|Healthy women without chronic constipation who are aged between 18-40 years
2998109|NCT02575742||Older women without chronic constipation|Healthy women without chronic constipation who are aged between 70-90 years
2998110|NCT02575742||Young women with chronic constipation|Women with symptoms of chronic constipation who are aged between 18-40 years
2998111|NCT02575742||Older women with chronic constipation|Women with symptoms of chronic constipation who are aged between 70-90 years
2998112|NCT02575729|Experimental|Inject betamethasone by sonography|Use 5/8 in medical needles inject betamethasone 7mg (1ml) in distal wrist crease by sonography- guided. Entering skin with 30 degrees from the ulnar side of palmaris longus tandon. Changing direction of injection to prevent median nerve injury if patients feel numbness or pain in hand.
2998113|NCT02575729|Active Comparator|Inject betamethasone directly|Use 5/8 in medical needles inject betamethasone 7mg (1ml) in distal wrist crease directly. Entering skin with 30 degrees from the ulnar side of palmaris longus tandon. Changing direction of injection to prevent median nerve injury if patients feel numbness or pain in hand.
2998114|NCT02575716|Experimental|Muscle relaxant|Intubation with McGrath video laryngoscope after fentanyl 1.5 mcg/kg, xylocaine 1.5 mg/kg and propofol 3 mg/kg muscle relaxant use rocuronium 0.6 mg/kg
2998115|NCT02575716|Placebo Comparator|Placebo|Intubation with McGrath video laryngoscope after fentanyl 1.5 mcg/kg, xylocaine 1.5 mg/kg and propofol 3 mg/kg placebo use NSS 0.6 mg/kg
2998116|NCT02575703|Experimental|[¹⁴C]-LY3023414|Single oral dose of [¹⁴C]-LY3023414 administered on Day 1
2998117|NCT02575690|Placebo Comparator|Placebo group|Obese patients with well-treated hypertension that receive placebo (pure microcrystalline cellulose)
2998118|NCT02575690|Experimental|Spirulina group|Obese patients with well-treated hypertension that receive Hawaiian spirulina (Cyanotech Corporation, Hawaii, US)
2998119|NCT02575677||Parturients with oxycodone|Parturients who were given oxycodone
2998120|NCT02575664|Experimental|Buprenorphine|Buprenorphine 5 microg/h/7days patch
2998121|NCT02575664|Placebo Comparator|Placebo|Placebo patch
2998122|NCT02575651|Experimental|Fluzoparib|Each subject will receive a single dose of fluzoparib on day 1, and then subject will receive fluzoparib twice daily for 28 days during cycle 1.
2998123|NCT02575638|Experimental|Treatment population|The study drug, CZ48, is administered orally in capsule form t.i.d. Capsules in 30mg and 50mg of drug are available for dosing. This is a dose escalation study so dosage has not yet been determined. Study drug is take on day 1 - 5 and then no drug on day 6 and 7. This is repeated for 4 weeks, or one course.
2998124|NCT02575625|Experimental|Fibroscan exam|"Step 1: feasibility study of the method on 10 healthy volunteers Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an hepatic biopsy et whom the histological answer is clean steatosis (NAFLD).~Experimental procedures consist in:~Fibroscan measure, preceded by tracking sonography.~liver MRI (for substudy about MRI comparison, in step 2)~a blood test for biological assessment of liver functions"
2998125|NCT02575612|Experimental|vacuum-assisted biopy|All patients enrolled in this study received a vacuum-assisted biopsy before surgery.
2998126|NCT02575599|Active Comparator|Lifestyle counselling|Intervention group: Eighty six adults with type 2 diabetes will be recruited from the general practices where the trained nurses in Guided self-determination programme are working.
2998127|NCT02575599|No Intervention|Regular consultation|Control group: Eighty six adults with type 2 diabetes will be recruited from general practices with employed registered nurses without the Guided self-determination training.
2998128|NCT02575586|Experimental|Dry Needling into MTrPs.|Intervention-Dry Needling: Deep Dry Needing into the medial Myofascial Trigger Point of the soleus muscle.
2998374|NCT02574078|Experimental|Group E Nivolumab + Crizotinib|Opdivo/Crizotinib specified dose on specified days
2998129|NCT02575586|Active Comparator|Dry Needling out of MTrPs.|Control-Dry Needling: Deep Dry Needling distal to Myofascial Trigger Point of the soleus muscle (in the same taut band).
2998130|NCT02575573||Admitted patients at the ED|
2998131|NCT02575560||weekly use erolotinib vs history data|Drug: erolotinib erolotinib 1050mg, oral, once a week, continues to disease progression or death or stop by physician
2998132|NCT02575547||NC+CCRT|Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin)
2998133|NCT02575534|Experimental|observational|"All patients will undergo 12-lead ECG and transthoracic echocardiography on the day of the study. These studies will be performed on patients as their previously implanted device is reprogrammed to pace in different modes. Patients will then receive an infusion of procainamide (12 mg/kg up to a maximum of 1 g) at a rate of 20 mg/min. Repeat ECG and echocardiograms will then be performed.~The patient's device will be programmed to a specific setting before and after the procainamide infusion."
2998134|NCT02575521|Placebo Comparator|Propofol-Dexmedetomidine group|this group is planned to receive intravenous anaesthesia only
2998135|NCT02575521|Active Comparator|Sevoflurane group|this group is planned to receive sevoflurane/fentanyl anaesthesia
2998136|NCT02575508|Experimental|Treatment (oxaliplatin, irinotecan, fluorouracil, BGJ398)|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously over 46 hours on days 1 and 15. Patients also receive pan FGFR kinase inhibitor BGJ398 PO QD on days 8-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2998137|NCT02575495|Experimental|7 days course of antibiotic treatment|To assign the 7 days course of antibiotic treatment, start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture
2998138|NCT02575495|Active Comparator|14 days course of antibiotic treatment|To assign the 14 days course of antibiotic treatment, start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture
2998139|NCT02575482|Experimental|Single and Multiple ascending dose|Single dose of SUVN-D4010 in healthy male subjects
2998140|NCT02575482|Placebo Comparator|Placebo|Placebo in healthy male subjects
2998141|NCT02575456|Experimental|Group A|(4×10^10vp/vial, 4 vials): 1 ml sterilization injection water per dose to dilute 2 vials (4×10^10 vp/vial), one shot in each arm, total dose of 1.6×10^11vp. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
2998142|NCT02575456|Experimental|Group B|(4×10^10vp/vial, 2 vials): 1 ml sterilization injection water per dose to dilute 1 vial (4×10^10vp/vial), total dose of 8×10^10vp, one shot in each arm. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
2998143|NCT02575456|Placebo Comparator|Group C|(0 vp/ vial, 2 vials):1 ml sterilization injection water per dose to dilute 1 vial, total dose of 0 vp. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
2998144|NCT02575443|Experimental|Moderate block (MB) group|
2998145|NCT02575443|Experimental|Deep block (DB) group|
2998146|NCT02575430||Subjects with IRD|IRD phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by RPE65 or LRAT gene mutations.
2998147|NCT02575417|Experimental|Patient Only|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.~Eligibility Criteria for Patient Only Groups:~are 18 years or older~speak and read English~have at least one chronic illness (cancer, chronic pulmonary disease, coronary artery disease, congestive heart failure, peripheral vascular disease, severe chronic liver disease, diabetes with end organ damage, renal failure)~have not completed an advance directive within the past 18 months~are able to sit for about 2.5-3 hours~are able to focus on the game for about 1.5-2 hours~can complete required surveys"
2998148|NCT02575417|Experimental|Caregiver Only|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.~Eligibility Criteria for Caregiver Only Groups:~are 18 years or older~speak and read English~have been an unpaid caregiver for an adult over the age of 18 in the last 12 months. Being an unpaid caregiver may include helping with personal needs or household chores, managing a person's finances, arranging for outside services, or visiting regularly to see how they are doing. This person need not live with participants in order for them to identify as caregivers;~are able to sit for about 2.5-3 hours~are able to focus on the game for about 1.5-2 hours~can complete required survey~care recipient is capable of discussing medical issues~care recipient has not completed an AD in past 18 months"
2998149|NCT02575417|Experimental|Surrogate Decision Maker with Patient|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.~Eligibility Criteria for Surrogate Decision Maker and Patient Group:~considers themselves a surrogate decision maker for an adult with a chronic illness (defined in Patient Only Group)~are 18 years or older~speak and read English~are able to sit for about 2.5-3 hours~are able to focus on the game for about 1.5-2 hours~can complete required surveys~both patient and surrogate decision maker are able to attend study session together~patient must meet eligibility criteria defined in Patient Only group"
2998150|NCT02575404|Experimental|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
2998151|NCT02575404|Experimental|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
2998152|NCT02575404|Experimental|8 mg/kg GR-MD-02|8 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
2998153|NCT02575391|Experimental|Whole Food Intervention Treated|Group of participants given the experimental WFI along with standard cancer treatment.
2998154|NCT02575378|Other|Metronomic chemotherapy|Metronomic Chemotherapy for maintenance treatment with Capecitabine 300mg/m2 twice a day, everyday.
2998155|NCT02575378|Experimental|Metronimic chemotherapy plus Chinese Traditional Medicine|"Metronomic Chemotherapy for maintenance treatment with Capecitabine 300mg/m2 twice a day, everyday.~Chinese Traditional Medicine"
2998156|NCT02575365|Experimental|Fingolimod arm|Treatment will be 0.5 mg p.o fingolimod daily
2998157|NCT02575339|Experimental|Phase I MLN0128 Dose Escalation Study|"Subjects will receive MLN0128 orally on days 1, 8, 15 and 22 in successive cohorts.~Cohort 1 MLN0128 15mg each week (QW); Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW"
2998158|NCT02575339|Experimental|Phase II Arm A: MLN0128|Subjects randomized to experimental arm will receive MLN0128 orally at the recommended phase II dose (RP2D) once weekly.
2999085|NCT02569372|Experimental|GC1102 240,000 IU(Single does)|GC1102 240,000 IU(Single does) I.V.
2998159|NCT02575339|Active Comparator|Phase II Arm B: Sorafenib|Subjects randomized to control arm will receive sorafenib 400mg by mouth (PO) twice a day (BID) daily.
2998160|NCT02575326|Other|Standard Control|Teens in the control group will receive standard or usual care as provided by their physician.
2998161|NCT02575326|Other|Intervention|Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
2998162|NCT02575313|Experimental|Whole Food Intervention Treated|Group of participants given the experimental WFI along with standard cancer treatment.
2998163|NCT02575300|Experimental|Ibrutinib Therapy|Ibrutinib Initial Dose 560 mg by mouth (PO) every day (QD)
2998164|NCT02575287||NERD group|(Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a positive ph-impedanciometry for reflux
2998165|NCT02575287||Control group|(Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a negative ph-impedanciometry for reflux
2998166|NCT02575274|Experimental|JHS COL-HAP91 + JHS HAP-91|Surgical flaps debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Bone defects will be treated with JHS COL-HAP91 (porous hydroxyapatite + collagen) + JHS HAP-91 (porous hydroxyapatite). Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day, and Nimesulide 100 mg 2 times/day will be prescribed.
2998167|NCT02575274|Other|surgical and mechanical debridement|Surgical flaps: All groups will receive the same surgical treatment for implant surface decontamination. Surgical intervention will be performed with full thickness mucoperiosteal flaps. Debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day and Nimesulide 100 mg 2 times/day will be prescribed.
2998168|NCT02575261|Experimental|Experimental:CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen by infusion.
2998169|NCT02575261|No Intervention|No Intervention|
2998170|NCT02575248|Experimental|Group A|patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2
2998171|NCT02575248|Active Comparator|group B|patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2
2998172|NCT02575235|Experimental|1.5mg Cetylpyridinium Chloride|1.5mg CPC will be taken daily for four weeks.
2998173|NCT02575235|Experimental|4.5mg Cetylpyridinium Chloride|4.5mg CPC will be taken daily for four weeks.
2998174|NCT02575235|Placebo Comparator|Control|Placebo will be taken daily for four weeks
2998175|NCT02575222|Experimental|Nivolumab|
2998176|NCT02575209||Women schiz.|Women with recent diagnosis of schizophrenia
2998177|NCT02575209||Men schiz.|Men with recent diagnosis of schizophrenia
2998178|NCT02575209||Women healthy|Women without diagnosis of schizophrenia or other neurological and/or psychiatric diagnosis
2998179|NCT02575209||Men healthy|Men without diagnosis of schizophrenia or other neurological and/or psychiatric diagnosis
2998180|NCT02575196||Cardiac arrest|Consecutive adult cardiac arrest patients with sustained ROSC in an academic medical center
2998181|NCT02575183|Experimental|Varenicline (Chantix)|"76 participants will be assigned to 4 behavioral therapy cessation for smoking cessation and will be randomized to receive Varinecline with instructions for administration for 12 weeks starting 1 week before Smoking Quit Date as suggested by the manufacturer: Days 1 to 3: 0.5 mg orally once a day Days 4 to 7: 0.5 mg orally twice a day Days 8 to end of treatment: 1 mg orally twice a day. Intervention 'Varinecline (Chantix)' and Intervention 'Behavioral Therapy'"
2998182|NCT02575183|Placebo Comparator|Placebo|"76 participants will be assigned to 4 behavioral therapy cessation for smoking cessation and will be randomized to receive a Placebo for Varinecline with instructions for administration for 12 weeks starting 1 week before Smoking Quit Date as suggested by the manufacturer: Days 1 to 3: a placebo (matched to 0.5 mg of Varenicline) orally once a day Days 4 to 7: a placebo (matched to 0.5 mg of Varenicline) orally twice a day Days 8 to end of treatment: a placebo (matched to 1 mg of Varenicline) orally twice a day.~Intervention 'Placebo (for Varenicline)' and Intervention 'Behavioral Therapy'"
2998183|NCT02575170|Experimental|Amino acid|Intravenous infusion of amino acid solution started approximately one hour prior to spinal anaesthesia after recording the baseline vital parameters. Each patient in experimental group received a total of 200 ml at 2 ml/kg/min.
2998184|NCT02575170|Placebo Comparator|Ringer's Lactate solution|Intravenous infusion of Ringer's lactate solution started approximately one hour prior to spinal anaesthesia after recording the baseline vital parameters. Each patient in experimental group received a total of 200 ml at 2 ml/kg/min.
2998185|NCT02575157|No Intervention|Discontinuing usage|Patients will discontinue use of bisphosphonates. Bone markers and BMD will be monitored until a need for reinitiation of treatment within 2-years is identified or needed.
2998186|NCT02575144|Experimental|BiRd|"Subjects on the BiRD arm will receive clarithromycin, Revlimid (lenalidomide), and dexamethasone in 28-day cycles. Dosing is as follows:~Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.~Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of >60 cc/min. Patients with a calculated creatinine clearance of <60 cc/min will receive 15 mgs PO daily on days 1-21 of a 28 cycle.~Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle."
2998187|NCT02575144|Active Comparator|Rd|"Subjects on the Rd arm will receive Revlimid, and dexamethasone in 28-day cycles. Dosing is as follows:~Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of >60 cc/min. Patients with a calculated clearance of <60 cc/min will receive 15 mgs PO daily on days 1-21 of a28 cycle. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up. Vomited doses will not be made up.~Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle. Missed or vomited doses will not be made up. If subject cannot tolerate oral dexamethasone, it will be given intravenously"
2998188|NCT02575131|Experimental|TNO whole wheat bread yeast basis|NBC-1: four slices of whole wheat bread yeast basis (98 grams) spread with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at TNO
2998189|NCT02575131|Active Comparator|TNO whole wheat sourdough bread|NBC-2- four slices of whole wheat sourdough bread (98 grams) with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water. at TNO
2998190|NCT02575131|Experimental|TNO Oatmeal|PepsiCo, Inc.-1 - One portion of Steel Cut oatmeal: 66.8 grams of oats boiled for 25 minutes in 500 grams of water and consumed with 307 grams of skimmed milk at TNO
2998191|NCT02575131|Active Comparator|TNO original Cheerios|PepsiCo, Inc.-2 - One portion of original Cheerios (ready to eat cereal): 70 grams prepared with 307 grams of skimmed milk and consumed with about 275 grams of water at TNO
2998192|NCT02575131|Experimental|TNO standard breakfast|"TNO breakfast: one slice of white bread with a fried egg and 200 mL orange juice. With spray oil a frying pan is prepared to fry an egg (medium size).~The breakfast is consumed at TNO"
2998193|NCT02575131|Experimental|Home whole wheat bread yeast basis|NBC-1: four slices of whole wheat bread yeast basis (98 grams) spread with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at home
2998194|NCT02575131|Active Comparator|Home whole wheat sourdough bread|NBC-2- four slices of whole wheat sourdough bread (98 grams) with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at home
2998195|NCT02575131|Experimental|Home Oatmeal|PepsiCo, Inc.-1 - One portion of Steel Cut oatmeal: 66.8 grams of oats boiled for 25 minutes in 500 grams* of water and consumed with 307 grams of skimmed milk at home
2998196|NCT02575131|Active Comparator|Home original Cheerios|PepsiCo, Inc.-2 - One portion of original Cheerios (ready to eat cereal): 70 grams prepared with 307 grams of skimmed milk and consumed with about 275 grams of water at home
2998197|NCT02575131|Experimental|Home standard breakfast|"one slice of white bread with a fried egg and 200 mL orange juice. With spray oil a frying pan is prepared to fry an egg (medium size).~The breakfast is consumed at home"
2998198|NCT02575105||Pediatric Hydrocephalus|In the first study 15 pediatric patients with hydrocephaly and 15 pediatric control patients at approximately the same age group will be included in the study.
2998199|NCT02575105||Pediatric Control|In the first study 15 pediatric patients with hydrocephaly and 15 pediatric control patients at approximately the same age group will be included in the study.
2998200|NCT02575105||Adult Hydrocephalus|In the second study 15 post cerebral hemorrhage adult patients undergoing ventriculo-peritoneal shunt placements and 15 adult control patients will be included in the study
2998201|NCT02575105||Adult Control|In the second study 15 post cerebral hemorrhage adult patients undergoing ventriculo-peritoneal shunt placements and 15 adult control patients will be included in the study
2998202|NCT02575092|Active Comparator|Group A, without hypertension|The patients who will not be taken the drugs of antihypertension and antihomocysteine.
2998203|NCT02575092|Experimental|Group B, hypertension|The hypertensive patients with their plasma Hcy levels <10 umol/L will be taken the drugs of antihypertension(Enalapril Maleate Tablets,as the program-based antihypertension)
2998204|NCT02575092|Experimental|Group C,hypertension and hyperhomocysteinemia|The hypertensive patients with their plasma Hcy levels ≥10 umol/L will be taken the drugs of antihypertension and antihomocysteine( Enalapril Maleate and Folic Acid Tablets,as the program-based antihypertension)
2998205|NCT02575079|Experimental|Parafilm|Pediatric patients undergoing hematopoietic stem cell transplant (HCT) with central venous catheters (CVCs) will have pre-cut, single-use sections of parafilm applied over the CVC hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC and routine CVC care will be continued, per institutional standard of practice, until the CVC is removed.
2998206|NCT02575066|Other|radiotherapy combined with pazopanib|patients during the first part of the study received concurrent radiotherapy (25x2Gy) and pazopanib (QD 800 mg). The patients of the second part of the study will receive concurrent radiotherapy (18x2Gy) and pazopanib (QD 800 mg).
2998207|NCT02575053||Latex group|patients who report ( a high risk for) latex allergy and will be operated on
2998208|NCT02575040|Other|Fecal microbiota transplantation|Fecal microbiota transplantation only
2998209|NCT02575027|Experimental|Treatment (4pi radiotherapy)|Patients undergo 4pi radiation simulation and planning followed by 5 to 10 daily fractions of 4pi palliative radiotherapy. If an acceptable plan cannot be achieved using 4pi planning, then the patient will be treated with standard radiation therapy planning for palliative re-irradiation.
2998210|NCT02575014|Experimental|Preoperative HBOT|25 out of 50 patients will receive 2 preoperative hyperbaric oxygen therapy treatments, one the day before their operation, the other within 5 hours preceding their operation. The participants will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator. Day 0 will be the first day of their HBOT treatment, Day 1 will be the day of their operation and second/final HBOT treatment.
2998211|NCT02575014|No Intervention|No HBOT|25 out of 50 patients will not receive preoperative hyperbaric oxygen therapy. Day 1 will be the day of the operation.
2998212|NCT02575001||Type 1 diabetes|"Children with Type 1 diabetes, age from 8 to 15 years.~The following interventions/exposures will be administered:~Behavioral: Psychological background determinations, Genetic: Genetic susceptibility determination, Procedure/Surgery: Cortisol release test, Procedure/Surgery: Saliva cortisol measurement."
2998213|NCT02575001||Hashimoto thyroiditis|"Children with known Hashimoto Thyroiditis, age from 8 to 15 years.~The following interventions/exposures will be administered:~Behavioral: Psychological background determinations, Genetic: Genetic susceptibility determination, Procedure/Surgery: Saliva cortisol measurement."
2998214|NCT02575001||Healthy control|"Healthy primary school pupils, age from 8 to 15 years.~The following interventions/exposures will be administered:~Behavioral: Psychological background determinations, Genetic: Genetic susceptibility determination, Procedure/Surgery: Saliva cortisol measurement."
2998215|NCT02574988||SCAR Patients|Patients diagnosed with severe cutaneous adverse reactions with be recruited
2998216|NCT02574975|Active Comparator|Methacholine diagnosing group|Methacholine bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
2998217|NCT02574975|Experimental|Adenosine monophosphate diagnosing group|Adenosine monophosphate bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
2998218|NCT02574975|Experimental|Leukotriene D4 diagnosing group|Leukotriene D4 bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
2998219|NCT02574975|Experimental|Astograh diagnosing group|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
2998220|NCT02574975|Experimental|budesonide /formoterol treatment group|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three month
2998221|NCT02574962|Experimental|Acthar® Gel|For the first two weeks participants will receive 1 mL of study drug subcutaneously every other day. After that, participants will received 1 mL of study drug twice a week for up to 6 months.
2998222|NCT02574949|Active Comparator|Conventional rate fluoroscopy|Radiation: 15 FPS Cine 15 PPS
2998223|NCT02574949|Experimental|Intermediate frame rate 7.5 fps|Radiation: 7.5 low Frame rate
2998224|NCT02574949|Experimental|Low frame rate|Low Cine 10 PPS
2998225|NCT02574936|Other|modified Karydakis,surgical technique|a new surgical technique(modified Karydakis) to be compared with standard Karydakis
2998226|NCT02574923|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
2998227|NCT02574910|Experimental|Abiraterone acetate 1 mg/kg/d|Abiraterone acetate will be administered orally at a daily dose of 1 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
2998228|NCT02574910|Experimental|Abiraterone acetate 2 mg/kg/d|If the 1 mg/kg/d dosing does not result in androstenedione level normalization, abiraterone acetate will be administered orally at a daily dose of 2 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
2998229|NCT02574910|Experimental|Abiraterone acetate 4 mg/kg/d|If the 2 mg/kg/d dosing does not result in androstenedione level normalization, abiraterone acetate will be administered orally at a daily dose of 4 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
2998230|NCT02574897|Experimental|Electronic Symptom Survey|Patients randomized to the intervention arm will fill out the daily PRO-CTCAE electronic symptom survey. The intervention consists of sending the results of the surveys in the intervention arm to the clinical care team. The four symptom-specific PROMIS subsets (Anxiety, Depression, Fatigue, and Sleep Disturbance) will be filled out weekly while patients are admitted to the hospital. Patients will again complete the 6 minute walk distance testing, HRQoL surveys, and PASS assessment at the time of discharge. Patients in the intervention arm will complete a satisfaction survey at discharge. HRQoL (by mail) and PASS (by telephone) will be assessed for a third time 30 days after discharge.
2998231|NCT02574897|Active Comparator|Blinded Electronic Symptom Survey|Patients in the control arm will only fill out the symptom survey at the time of admission and days 7, 10, and 14. The results of symptom surveys from the patients in the control arm will not be sent to providers, but will be used for data analysis purposes only. The four symptom-specific PROMIS subsets (Anxiety, Depression, Fatigue, and Sleep Disturbance) will be filled out weekly while patients are admitted to the hospital. Patients will again complete the 6 minute walk distance testing, HRQoL surveys, and PASS assessment at the time of discharge. HRQoL (by mail) and PASS (by telephone) will be assessed for a third time 30 days after discharge.
2998232|NCT02574884|Other|Recently infected subjects|Actual population of blood donors primo-infected with HCV with specific intervention for the study : one blood sample during the inclusion visit
2998233|NCT02574884|No Intervention|Retrospective cases|Population of infected blood donors in 2007, 2008 and 2009 No blood sample
2998234|NCT02574884|Other|Individuals sources|Specific intervention for the study : one blood sample during the inclusion visit
2998235|NCT02574871||Single Group|Psychological and biological data collection
2998236|NCT02574858|Experimental|QRH-886620|The first three subjects will squirt via syringe into their mouths (po) 4.2 mg (2.1ml) mg of reconstituted (with 5 ml of 0.9% saline) QRH-882260 heptapeptide (~100 µM concentration). They will be asked to wait 5 minutes and then drink at least 4-8oz of tap water. The remaining seven subjects will receive (squirted via syringe into their mouths) 1mg (5ml) of reconstituted (with 5ml of 0.9% saline) QRH-882260 heptapeptide (~100 µM concentration).
2998237|NCT02574845|Experimental|R (Reference) Rosuvastatin|1film-coated tablet as single dose, fasted
2998238|NCT02574845|Experimental|T1 (Test 1) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (10 mg) as single dose, fasted
2998239|NCT02574845|Experimental|T2 (Test 2) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (50 mg) as single dose, fasted
2998240|NCT02574845|Experimental|T3 (Test 3) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (500 mg) as single dose, fasted
2998241|NCT02574845|Experimental|T4 (Test 4) Rosuvastatin + Furosemide|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (1 mg) as single dose, fasted
2998242|NCT02574845|Experimental|T5 (Test 5) Rosuvastatin + Furosemide|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (5 mg) as single dose, fasted
2998243|NCT02574832|Experimental|Spinal Lidocaine Administration|"Spinal anesthesia will be induced with isobaric 2% lidocaine and 15 μg fentanyl.~The study lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). If the lidocaine dose provides an unsatisfactory anesthetic, the case will be categorized as a failure. After a failed case, the next participant will receive a lidocaine dose increased by 4 mg. If the lidocaine dose provides satisfactory anesthesia, the next participant's lidocaine dose will determined by a biased allocation method with a 90% chance of maintaining the dose and a 10% chance of decreasing the dose by 4 mg."
2998244|NCT02574819|Experimental|Drug|Methylnaltrexone (MNTX) nearly 0.15mg/kg administered every other day for 2 weeks.
2998245|NCT02574819|Placebo Comparator|Placebo|Placebo administered every other day for 2 weeks.
2998246|NCT02574806||Healthy newborn|Healthy newborn at term of healthy mother.
2998247|NCT02574806||Preeclamptic newborn|Newborn at term of mother with pre-eclampsia with severity features.
2998823|NCT02571049|Experimental|Sumatriptan 3 mg then 6 mg|DFN-11 (sumatriptan, 3 mg) and placebo first then two DFN-11 injections
2998248|NCT02574780|Experimental|Grupo I TFC|Women with lymphedema , perform complex physical therapy with manual lymphatic drainage, compression bandaging and exercises linfomiocinéticos.
2998249|NCT02574780|Experimental|Grupo II TFC X PFM|Standard treatment for lymphedema perform complex physical therapy associated with a muscular strength protocol.Muscle-building arm with load
2998250|NCT02574767|Experimental|Lifestyle counseling + PUFA supplement|Home-based Diet and Physical activity plus n3LC-PUFAs supplementation
2998251|NCT02574767|Experimental|Routine diet & PA + PUFA Supplementation|Routine Diet & Physical Activity counseling care plus n3LC-PUFAs supplementation.
2998252|NCT02574767|Experimental|Lifestyle counseling + PUFA placebo|Home-based Diet and Physical Activity plus placebo for n3LC-PUFAs supplementation.
2998253|NCT02574767|Placebo Comparator|Routine diet & PA + PUFA placebo|Routine Diet & Physical Activity counseling plus placebo for n3LC-PUFAs supplementation.
2998254|NCT02574754|Experimental|warfarin|Subjects will receive a single dose of warfarin 10 mg PO at each of 3 visits. The study days will be separated by at least 14 days to allow adequate time for the drug to reach washout.
2998255|NCT02574741|Active Comparator|Aripiprazole|Aripiprazole oral solution (1mg/mL) for 12 weeks. dosages range from 2-10mg per day.
2998256|NCT02574741|Active Comparator|Placebo|50% will be randomized to placebo.
2998257|NCT02574741|Active Comparator|Behavioral Intervention|All subjects will receive behavioral therapy, in addition to either active study drug (aripiprazole) or placebo.
2998258|NCT02574728|Experimental|Oral sirolimus, celecoxib, etoposide, and cyclophoshphamide|Participants in this group will receive oral sirolimus and celecoxib in addition to cycles of oral etoposide and cyclophosphamide for up to two years.
2998259|NCT02574715||Levonorgestrel (Jaydess, BAY86-5028)|women aged 18 to 29 years following 6 (±1) months of Jaydess® use as their contraceptive method.
2998260|NCT02574702|No Intervention|Control Group|Patients with primary loop ileostomy closure without drainage of the surgical wound
2998261|NCT02574702|Experimental|Drainage Group|"Patients with the application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure.~Intervention: application of a contralateral drainage in surgical wound closure."
2998262|NCT02574689|Experimental|HIPP Intervention|The physical activity intervention emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals), and includes regular mailings (three mailings in month 1, two mailings in months 2 and 3, one mailing in months 4, 5, 6, 8, and 10) of physical activity manuals that are matched to the participant's current level of motivational readiness and individually-tailored computer expert system feedback reports.
2998263|NCT02574689|Active Comparator|Wellness Contact Control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the ACS website (www.cancer.org) will be mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
2998264|NCT02574663|Experimental|TGR-1202|TGR-1202 daily dose
2998265|NCT02574663|Experimental|TGR-1202 + nab-paclitaxel + gemcitabine|TGR-1202 oral daily dose + nab-paclitaxel + gemcitabine both as an IV infusion
2998266|NCT02574663|Experimental|TGR-1202 + FOLFOX|TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen)
2998267|NCT02574663|Experimental|TGR-1202 + FOLFOX + Bevacizumab|TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen) + bevacizumab IV infusion
2998268|NCT02574650|Experimental|Open Label|Non-randomized, open label clinical study that intends to treat up to 30 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.
2998269|NCT02574637|Experimental|MEDI2070 High dose|MEDI2070 intravenous (IV) infusion and Placebo SC injection weeks 0 and 4 wks. Then subcutaneous (SC) dose of MEDI2070 every 4 wks through week 24. Beginning at wk 28, SC dose of MEDI2070 once every 4 weeks during the Open-label Period.
2998270|NCT02574637|Experimental|MEDI2070 High-Med dose|MEDI2070 intravenous (IV) infusion wk 0 and then subcutaneous (SC) dose of MEDI2070 every 4 wks through week 24. Beginning at wk 28, SC dose of MEDI2070 once every 4 weeks during the Open-label Period.
2998271|NCT02574637|Experimental|MEDI2070 Low-Med dose|Subcutaneous (SC) dose of MEDI2070 every 4 wks through week 24. Beginning at wk 28, SC dose of MEDI2070 once every 4 weeks during the Open-label Period.
2998272|NCT02574637|Experimental|MEDI2070 Low dose|Subcutaneous (SC) dose of MEDI2070 every 4 wks through week 24. Beginning at wk 28, SC dose of MEDI2070 once every 4 weeks during the Open-label Period.
2998273|NCT02574637|Placebo Comparator|Placebo|Placebo SC and IV infusion wks 0 & 4 and then SC dose of placebo every 4 weeks through wk 24. SC dose of MEDI2070 once every 4 weeks during Open Label period.
2998274|NCT02574624|Experimental|Intraocular Assistance|Intraocular assistance in patients undergoing standard of care vitreous surgeries
2998275|NCT02574611|Active Comparator|SCI observational|"Individuals with SCI will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a typical (eating, sleeping, mobility, etc.)"
2998276|NCT02574611|Active Comparator|Able-bodied observational|"Able-bodied individuals (non SCI) will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a typical (eating, sleeping, mobility, etc.)"
2998277|NCT02574611|Experimental|SCI drug group|Individuals with SCI will undergo a second day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of neostigmine and glycopyrrolate
2998278|NCT02574611|Placebo Comparator|SCI placebo group|Individuals with SCI will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of normal saline solution (placebo)
2998279|NCT02574598|Experimental|Docetaxel + MK-3475|"Docetaxel 75 mg/m2 every 3 weeks until progression of disease~MK-3475 (administered on day 8) 200mg every 3 until progression of disease"
2999086|NCT02569372|Experimental|GC1102 80,000 IU(Multiple does)|GC1102 80,000 IU(Multiple does) I.V.
2998280|NCT02574598|Active Comparator|Docetaxel|Docetaxel 75 mg/m2 every 3 weeks until progression of disease followed by MK-3475 200mg every 3 until progression of disease
2998281|NCT02574585|Experimental|Treated group|Twenty subjects will be randomly assigned to receive two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
2998282|NCT02574585|No Intervention|Control group|Twenty subjects will be randomly assigned to be clinically followed, without any specific intervention.
2998283|NCT02574572|Experimental|Single group|Patients with spinal cord injury that will undergo laminectomy and autologous mesenchymal cells intralesional injection
2998284|NCT02574559|Experimental|Caregiver of Child With Autism Spectrum Disorder|Caregivers attending eight weekly sessions of Cognitive Based Compassion Training Sessions and Meditation.
2998285|NCT02574546||Surgery|Women undergoing mastectomy are eligible for enrollment.
2998286|NCT02574533|Experimental|Vigil™ + Pembrolizumab|"Biological: Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens.~Drug: Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter"
2998287|NCT02574520|Experimental|SABER®-Bupivacaine|Extended Release Solution for instillation; SABER®-Bupivacaine /Once
2998288|NCT02574520|Active Comparator|Bupivacaine HCl|Solution for infiltration; Bupivacaine HCl/Once
2998289|NCT02574507|Experimental|Couples-Based Behavioral Weight and Symptom Management|Participants will receive 12 session (6 weekly and 6 biweekly) of a behavioral weight and symptom management intervention.
2998290|NCT02574481|Experimental|ELUVIA Stent Implantation|Percutaneous stent placement in the SFA/PPA
2998291|NCT02574481|Active Comparator|Zilver PTX Stent Implantation|Percutaneous stent placement in the SFA/PPA
2998292|NCT02574468|Active Comparator|DPC+Dexa|forty intact premolars were randomly assigned to 1 of 4 treatment groups (n=10): I) DPC, II) MP, III) DPC+dexamethasone, and IV) MP+dexamethasone. After administration of local anesthesia (3% mepivacaine plain; Septodont, Cedex, France) dental rubber dam was applied and tooth surface disinfected with 2% chlorhexidine gluconate. Occlusal cavity was prepared using high speed diamond fissure bur and buccal pulp horn was mechanically exposed (approximately 1.2 mm in diameter) using a sterile high speed carbide round bur. In MP, depth of penetration to the pulp was 0.5 mm
2998293|NCT02574468|Active Comparator|MP+Dexa|forty intact premolars were randomly assigned to 1 of 4 treatment groups (n=10): I) DPC, II) MP, III) DPC+dexamethasone, and IV) MP+dexamethasone. After administration of local anesthesia (3% mepivacaine plain; Septodont, Cedex, France) dental rubber dam was applied and tooth surface disinfected with 2% chlorhexidine gluconate. Occlusal cavity was prepared using high speed diamond fissure bur and buccal pulp horn was mechanically exposed (approximately 1.2 mm in diameter) using a sterile high speed carbide round bur. In MP, depth of penetration to the pulp was 0.5 mm
2998294|NCT02574455|Experimental|IMMU-132|Sacituzumab govitecan (10 mg/kg on Days 1 and 8 of 21-day cycles)
2998295|NCT02574455|Active Comparator|Control Arm|"Treatment of Physician's Choice determined before randomization from only one of the following treatments (see Appendix 2 for more details on administration and dosing management):~Eribulin (1.4 mg/m2 IV on Days 1 and 8 of a 21-day cycle). See section 6.5.1 Capecitabine (1000-1250 mg/m2 orally twice daily on Days1-14 of a 21-day cycle). See section 6.5.2 Gemcitabine (800-1200 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle). See section 6.5.3 Vinorelbine (25 mg/m2 weekly IV on Day 1 weekly) See section 6.5.4 (Note: eligible patients with Grade 2 neuropathy should not be prescribed vinorelbine as TPC)"
2998296|NCT02574442||Initial Colposcopy Visit|Women with a scheduled colposcopy and biopsy appointment at the Women's Clinic at Vancouver General Hospital
2998297|NCT02574429|Experimental|Cognitive Processing Therapy|Individuals who have either completed Standard Dialectical Behavior Therapy (DBT) for Borderline Personality Disorder (BPD) and/or are currently enrolled in DBT who have co-occuring PTSD.
2998298|NCT02574403|Experimental|without eculizumab|
2998299|NCT02574377|Experimental|A: myDC vaccination|intranodal injection with tumor peptide-loaded myeloid dendritic cells
2998300|NCT02574377|Experimental|B: pDC vaccination|intranodal injection with tumor peptide-loaded plasmacytoid dendritic cells
2998301|NCT02574377|Experimental|C: combined myDC/pDC vaccination|intranodal injection with tumor peptide-loaded myeloid and plasmacytoid dendritic cells
2998302|NCT02574364|Active Comparator|traditional incision|traditional incision : McBurney incision,Rectus incision,Appendix Transverse incision or Tenderness point incision,it was invaginated at the discretion of the surgeon.
2998303|NCT02574364|Experimental|modified incision|modified incision :The application of abdomen CT before surgery provides a new approach to the incision and new perception.
2998304|NCT02574351||obese asthmatic|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
2998305|NCT02574351||normal asthmatic|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group
2998306|NCT02574351||obese control|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
2998307|NCT02574351||normal control|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
2998308|NCT02574338|Active Comparator|group - 1 Foley's Catheter|will have cervical ripening with intracervical extraamniotic Foley's catheter for 24 hours
2998309|NCT02574338|Active Comparator|Group - 2 Prostaglandin E1 Analogue|will have cervical ripening with intravaginal misoprostol inserted into the posterior fornix every six hours to a maximum of four doses (24 hours)
2998310|NCT02574325|Placebo Comparator|Placebo|Placebo
2998311|NCT02574325|Experimental|ARI-3037MO|ARI-3037MO
2998312|NCT02574312|Active Comparator|TKA with RUI|44 Subjects will receive TKA with RUI per their study doctor's standard of care. These 44 subjects will receive the TKA using Reusable instruments (RUI).
2998313|NCT02574312|Experimental|TKA with SUI|44 Subjects will receive TKA with SUI per their study doctor's standard of care. These 44 subjects will receive the TKA using Single Use Instruments (SUI).
2998314|NCT02574299|No Intervention|1: Normal hearing children without SLI, transversal group|Normal hearing children without Specific Language Impairment (SLI),Transversal group for test-retest measures
2998315|NCT02574299|No Intervention|2: Normal hearing children without SLI, longitudinal group|Normal hearing children without Specific Language Impairment (SLI), longitudinal group without training
2998316|NCT02574299|Other|3: Normal hearing children with SLI, longitudinal group|Normal hearing children with Specific Language Impairment (SLI), longitudinal group with training
2998317|NCT02574299|No Intervention|4: Normal hearing adults without SLI, transversal group|Normal hearing adults without Specific Language Impairment (SLI), transversal group for test-retest measures
2998318|NCT02574299|No Intervention|5: Normal hearing adults without SLI, longitudinal group|Normal hearing adults without Specific Language Impairment (SLI), longitudinal group without hearing aids (HA)
2998319|NCT02574299|Other|6: Hearing Impaired candidates for HA, longitudinal group|Hearing Impaired adult candidates for hearing aids (HA), longitudinal group with hearing aids (HA)
2998320|NCT02574286|Experimental|Velaglucerase alfa 60 Unit per kilogram (U/kg)|Participant will be receiving velaglucerase alfa 60 U/kg every other week (EOW) as 60 minute intravenous infusion.
2998321|NCT02574273|Active Comparator|Secret Agent Society (SAS) Program|The Secret Agent Society (SAS) Program is an intervention which involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home. Parents will attend weekly parent support training sessions. 3 and 6 month booster sessions are conducted with both parents and children to help families with maintaining the skills that they have learned and to problem-solve new challenges that arise. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits, for both parent and child participants.
2998322|NCT02574273|Other|Waitlist Group / Treatment As Usual|Participants may be randomly allocated to the wait list control condition, where participants will receive treatment as usual during the 3 month period when the intervention group will participate in the SAS Program. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic. The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits.
2998323|NCT02574260|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec 10⁸ plaque forming units (PFU)/mL (up to 4 mL depending on tumor size) administered intratumorally every 2 weeks, on Day 1 and Day 15 of 28-day cycles until discontinuation criteria were met.
2998324|NCT02574247|Experimental|Training|Participants in the Training arm will undergo 15 hours of computerized auditory training across 10 laboratory visits. Medial olivocochlear reflex function and speech perception abilities will be measured before, during, and after the training visits to examine the changes in the measurements across time.
2998325|NCT02574247|No Intervention|Control|Participants in the Control arm will undergo the same number of visits as the Training arm, but will not participate in computerized auditory training. Medial olivocochlear reflex function and speech perception abilities will be measured at each visit to establish the test-retest reliability of these measurements in the absence of any training.
2998326|NCT02574247|No Intervention|Speech Group|Participants in the Speech Group will undergo 1 visit. Medial olivocochlear reflex function and speech perception abilities will be measured at this visit to establish the correlation between these measures in the absence of any training.
2998327|NCT02574234|Experimental|Patients with orthopedic surgery|"Patients will be included in the consultation of anesthesia. The usual laboratory tests will be carried out and a determination of apelin and inflammatory cytokines. Assessment of cognitive functions using the Informant Questionnaire on Cognitive Decline in the Elderly (ICQODE), Mini Mental State examination (MMS) and the scale of Instrumental activities of daily living (IADL).~Day of surgery: liquid sampling cerebrospinal. Day 1 to day 7 postoperatively: determination of inflammatory cytokines and apelin, postoperative delirium research (Confusion Assessment Method (CAM)), residual cognitive dysfunction research (MMS, IADL, IQCODE).~3 months after operation: evaluation of cognitive performance (IQCODE, IADL)"
2998328|NCT02574221|Experimental|stannous fluoride toothpaste|brush twice a day for 8 weeks
2998329|NCT02574221|Sham Comparator|cavity protection toothpaste|brush twice a day for 8 weeks
2998330|NCT02574208|Active Comparator|"HIV testing by ELISA"|Patients enrolled in this arm will be tested by usual HIV Elisa
2998331|NCT02574208|Experimental|"HIV testing by rapid test"|Patients enrolled in this arm will be tested by the new rapid HIV test
2998332|NCT02574182||Control subjects under 40 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
2998333|NCT02574182||Control subjects over 60 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
2998334|NCT02574182||MCI subjects over 60 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
2998335|NCT02574169|Experimental|Alveolar recruitment maneuvers Group 1|alveolar recruitment maneuvers by CPAP then alveolar recruitment maneuvers by eSigh
2998336|NCT02574169|Experimental|Alveolar recruitment maneuvers Group 2|alveolar recruitment maneuvers by eSigh then alveolar recruitment maneuvers by CPAP
2998337|NCT02574156|Experimental|Conventional Group|Patients randomized for Conventional Group will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 140 mg/dl and 180 mg/dl.
2998338|NCT02574156|Experimental|Moderate Group|Patients randomized for ModerateGroup will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 100 mg/dl and 130 mg/dl.
2998339|NCT02574130|Experimental|Nebulized amikacin|Amikacin 400 mg nebulized every 12 hours plus intravenous antibiotic(s) for 10 days
2998340|NCT02574130|Placebo Comparator|placebo|nebulized placebo every 12 hours plus intravenous antibiotic(s)for 10 days.
2998410|NCT02573805||erectile dysfunction group|International Index of Erectile Function (IIEF-5) questionnaire≥22 Rigiscan test are performed for two nights
3030931|NCT02355808|Other|Non Superfast GP + Tailored Leaflet|
2998341|NCT02574117|Experimental|flap with corticotomy and bone allograft|Maxillary expansion with quad helix appliance was applied to posterior teeth with cross bite. Then corticotomy surgical procedure associated with addition of commercially available bone allograft; demineralized freeze-dried bone allograft on the buccal surface of maxillary 1st premolar, 2nd premolar and 1st molar areas.
2998342|NCT02574104||Institution 1|"McGill University Health Center NICU staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Complete"
2998343|NCT02574104||Institution 2|"Rochester University Medical Center NICU staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Complete"
2998344|NCT02574104||Institution 3|"Parkland Memorial Hospital NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Complete"
2998345|NCT02574104||Institution 4|"Eastern Maine Medical Center NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Active"
2998346|NCT02574104||Institution 5|"Brigham and Women's Hospital NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Active"
2998347|NCT02574104||Institution 6|"Centre hospitalier universitaire Sainte-Justine NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Active"
2998348|NCT02574104||Institution 7|"Golisano Children's Hospital of Southwest Florida NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Preparing"
2998349|NCT02574104||Institution 8|"Florida Hospital for Children NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Preparing"
2998350|NCT02574104||Institution 9|"Memorial Hospital of South Bend NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Pending"
2998351|NCT02574104||Institution 10|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
2998352|NCT02574104||Institution 11|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
2998353|NCT02574104||Institution 12|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
2998354|NCT02574104||Institution 13|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
2998355|NCT02574104||Institution 14|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
2998356|NCT02574104||Institution 15|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
2998357|NCT02574091|Experimental|Cohort 1-Experimental|"4 healthy adult participants will be randomized to receive 1% icotinib hydrochloride cream, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
2998358|NCT02574091|Placebo Comparator|Cohort 1-Placebo|"2 healthy adult participants will be randomized to receive placebo (blank cream), applied twice daily for 7 consecutive days (final dose on the morning of Day 8).~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
2998359|NCT02574091|Experimental|Cohort 2-Experimental|"4 healthy adult participants will be randomized to receive 2% icotinib hydrochloride cream, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
2998360|NCT02574091|Placebo Comparator|Cohort 2-Placebo|"2 healthy adult participants will be randomized to receive matching placebo, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
2998361|NCT02574091|Experimental|Cohort 3-Experimental|"6 patients with mild to moderate psoriasis will be randomized to receive 1% icotinib hydrochloride cream, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
2998362|NCT02574091|Placebo Comparator|Cohort 3-Placebo|"2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
2998363|NCT02574091|Experimental|Cohort 4-Experimental|"6 patients with mild to moderate psoriasis will be randomized to receive 2% icotinib hydrochloride cream, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
2998364|NCT02574091|Placebo Comparator|Cohort 4-Placebo|"2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
2998365|NCT02574078|Experimental|Group A Nivolumab|Opdivo specified dose on specified days
2998366|NCT02574078|Experimental|Group A Nivolumab + SOC maintenance therapy|"Opdivo/Bevacizumab specified dose on specified days~Opdivo/Pemetrexed specified dose on specified days"
2998367|NCT02574078|Active Comparator|Group A SOC maintenance therapy|"Bevacizumab specified dose on specified days~Pemetrexed specified dose on specified days"
2998368|NCT02574078|Experimental|Group B Nivolumab|Opdivo specified dose on specified days
2998369|NCT02574078|Other|Group B Best supportive care|Therapy directed against specific symptoms of disease, i.e., palliative radiation or palliative surgery
2998370|NCT02574078|Active Comparator|Group C Investigator's choice chemotherapy|"Carboplatin/nab-paclitaxel specified dose on specified days~Carboplatin/paclitaxel specified dose on specified days~Carboplatin/pemetrexed specified dose on specified days~Carboplatin/docetaxel specified dose on specified days~Carboplatin/gemcitabine specified dose on specified days~Paclitaxel specified dose on specified days~Docetaxel specified dose on specified days~Gemcitabine specified dose on specified days~Pemetrexed specified dose on specified days"
2998371|NCT02574078|Experimental|Group C Nivolumb|Opdivo specified dose on specified days
2998372|NCT02574078|Active Comparator|Group D Erlotinib|Erlotinib specified dose on specified days
2998373|NCT02574078|Experimental|Group D Nivolumab + Erlotinib|Opdivo/Erlotnib specified dose on specified days
2998375|NCT02574065|Experimental|L. reuteri DSM 17938 group|"L. reuteri DSM 17938 will be given at a dose of 100000000 colony forming units (CFU) per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.~Each day, at about the same time, the infants will be given 5 drops (1x100000000 CFU) of the study product in connection with feeding."
2998376|NCT02574065|Placebo Comparator|Placebo group|The placebo consists of an identical formulation without L. reuteri. Each day, at about the same time, the infants will be given 5 drops placebo in connection with feeding.
2998377|NCT02574052|Other|Behavioral|"The whole experiment was divided into three phases with each phase lasting two weeks.~First Stage-Behavioral: just record participants' food choices Second Stage-Behavioral: menu labelling without nutrition education Third Stage- Behavioral; menu labelling with nutrition education"
2998378|NCT02574039|Experimental|Oat bran|66g oat bran made up in 350ml skimmed milk
2998379|NCT02574039|Placebo Comparator|Control|Refined grain product and 350ml skimmed milk
2998380|NCT02574026|Experimental|Psychomotor tasks|20 healthy subjects and 10 tetraplegic patients will participate to acquisition of MEG, EEG, MRI data during a motor tasks
2998381|NCT02574013|Experimental|sponge-assisted surgery group|Patients offered surgery with use of the retractor sponge
2998382|NCT02574013|No Intervention|Control group|Patients receiving standard care, i.e. surgery in Trendelenburg position
2998383|NCT02574000||Single group baseline and follow-up|"Single group of adult stroke patients assessed using ShoulderQ shoulder pain questionnaire and Clinical shoulder examination at two time-points:~Baseline: within 72 hours post-stroke Follow-up: at 8-10 weeks post-stroke"
2998384|NCT02573987|Active Comparator|Oxygen/nitrous oxide equimolar mix|96 participants undergoing chorionic villi sampling. self administered inhalation of equimolar mixture of oxygen and nitrous oxide (MEOPA)
2998385|NCT02573987|Active Comparator|Lidocaine|96 participants undergoing chorionic villi sampling infiltrative local anaesthesia of 1% lidocaine
2998386|NCT02573974|Other|Case group|the intervention, specific to the study, is to take samples on patients with advanced gastrointestinal cancer
2998387|NCT02573974|Other|Control group|the intervention, specific to the study, is to take samples on non-undernourished patients supported for adjuvant chemotherapy as part of colorectal cancer
2998388|NCT02573961|Active Comparator|laser|Subjects will receive 24 activated laser acupuncture group treatments. The laser will be applied for 10 seconds to each of the selected acupuncture points. In addition they will be instructed to take a tailored low caloric diet
2998389|NCT02573961|Active Comparator|high protein low carbohydrate diet|Subjects will be instructed to take a tailored high protein/low carbohydrate/low caloric diet.
2998390|NCT02573961|Sham Comparator|control|Subjects in the control group will undergo sham laser acupuncture treatment with no laser power output. In addition they will be instructed to take a tailored low caloric diet .
2998391|NCT02573935|Experimental|Clarithromycin|Clarithromycin combined with VCD induction therapy
2998392|NCT02573935|Placebo Comparator|Placebo|Placebo combined with VCD induction therapy
2998393|NCT02573922|Experimental|Oxycodone-naloxone|Oxycodone-naloxone prolonged release tablet twice a day
2998394|NCT02573922|Active Comparator|Oxycodone|Oxycodone prolonged release tablet twice a day
2998395|NCT02573909|Experimental|Oxycodone intravenously|Oxycodone 0,1 mg/kg IV
2998396|NCT02573909|Experimental|Oxycodone epidurally|Oxycodone 0,1 mg/kg epidurally
2998397|NCT02573896|Experimental|NK cells with Ch14.18 & Lenalidomide|Patients in this arm will receive a designated dose of NK cells on Day 5 and 17.5 mg/m2/dose of Ch14.18 on Day 1-4. Patients on Dose Level 4 will also receive 25mg/m2/dose of Lenalidomide during Day -6 through 14 of treatment.
2998398|NCT02573883|Experimental|Prior Clobetasol Exposure|Patients with biopsy proven lichen sclerusos previously treated with clobetasol propionate
2998399|NCT02573883|Active Comparator|No Prior Clobetasol Exposure|Patients with biopsy proven lichen sclerusos never previously treated with clobetasol propionate.
2998400|NCT02573870|Experimental|Batefenterol + Fluticasone Furoate|Subjects will self-administer batefenterol/fluticasone furoate 300/100 micrograms inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.
2998401|NCT02573870|Placebo Comparator|Placebo|Subjects will self-administer matching placebo inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.
2998402|NCT02573857|Experimental|DSM265 P. falciparum|Cohort 1: the efficacy of a single administration of 400 mg DSM265 for the clearance of asexual blood stages of P. falciparum will be determined. Activity of a second single dose of 400 mg DSM265 against gametocytes will be assessed in this cohort only if sexual stages are identified by PCR following the initial drug treatment.
2998403|NCT02573857|Experimental|OZ439 P. vivax|Cohort 2: subjects will be infected with P. vivax by IBSM, then treated with a single 200 mg dose OZ439. If recrudescence occurs following initial drug treatment with 200 mg OZ439, then affected participants who reach the treatment threshold will receive a single 400 mg dose of OZ439.
2998404|NCT02573857|Experimental|DSM265 P. vivax|Cohort 3: subjects will be infected with P. vivax by IBSM, then treated with a single 400 mg dose of DSM265
2998405|NCT02573844|Active Comparator|A: Proklama ( 1 sachet/ day)|"15 patients belonging to group A will receive drug A (Proklama: 1 sachet/ day). The treatment will be administred starting from visit 3 for a 2 weeks- treatment's period.~After a 2 weeks wash out's period, patients belonging to group A, starting from visit 5, will receive drug B ( Placebo: 1 sachet/day)."
2998406|NCT02573844|Placebo Comparator|B: Placebo ( 1 sachet/ day)|"15 patients belonging to group B will receive drug B (Placebo: 1 sachet/ day). The treatment will be administred starting from visit 3 for a 2 weeks- treatment's period.~After a 2 weeks wash out's period, patients belonging to group B, starting from visit 5, will receive drug A ( Proklama: 1 sachet/day)."
2998407|NCT02573831|Placebo Comparator|Placebo|The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if needed
2998408|NCT02573831|Experimental|Oxycodone|The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
2998409|NCT02573818||SEDASYS System|
2998411|NCT02573805||control group|International Index of Erectile Function (IIEF-5) questionnaire＜22 Rigiscan test are performed for two nights
2998412|NCT02573779||Infants fed mother's own milk|Infants fed >50% mother's own milk with enteral feeding.
2998413|NCT02573779||Donor milk fed infants|Infants fed <50% mother's own milk (and thus >50% donor human milk) with enteral feeding.
2998414|NCT02573766|Experimental|Neurofeedback Training|Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
2998415|NCT02573766|Sham Comparator|Sham Neurofeedback Training|Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
2998416|NCT02573766|Other|Standard of Care|Seven questionnaires regarding symptoms and quality of life completed at baseline, at follow up, and again in one month. Participants receive EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.
2998417|NCT02573753|Experimental|sleep restriction|Sleep restriction
2998418|NCT02573753|No Intervention|normal sleep|Normal sleep
2998419|NCT02573753|Experimental|weight gain|Weight gain
2998420|NCT02573740|Experimental|ABT-957|ABT-957 given twice a day for 84 days
2998421|NCT02573740|Placebo Comparator|Placebo|Placebo given twice a day for 84 days
2998422|NCT02573727|Experimental|Nor Adrenaline + Albumin|"Intravenous continous infusion of terlipressin at the dose of 2 mg every 24 hours with the maximum daily cumulative dose of 12 mg/day.~In case of no response the dose of the terlipressin will be progressively increased to the maximum infusion dose of 12 mg/24 hour.~Patients will be given 1g/Kg of albumin per day, which will be discontinued if CVP is more than 18 cm H2O."
2998423|NCT02573727|Active Comparator|Terlipressin + Albumin|"Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours designed to achieve an increase in MAP of at least 10 mmHg or an increase in 4-h urine output of more than 200 ml. When one of these goals was not achieved, the noradrenaline dose was increased every 4 h in steps of 0.5 mg/h, up to the maximum dose of 3 mg/h.~Patients will be given 1g/Kg of albumin per day, which will be discontinued if CVP is more than 18 cm H2O."
2998424|NCT02573714|Experimental|Intranasal Ketamine|Patients allocated to receive intranasal ketamine (intervention) in addition to standard pain therapy. Patients enrolled in this arm will utilize the FPS-R and follow-up PedsQL-SCD.
2998425|NCT02573714|Placebo Comparator|Normal Saline|Patients allocated to receive intranasal normal saline (placebo) in addition to standard pain therapy. Patients enrolled in this arm will utilize the FPS-R and follow-up PedsQL-SCD.
2998426|NCT02573701|Experimental|1 Guideline treatment|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
2998427|NCT02573701|Active Comparator|2 Treatment as Usual|Participants will receive the Treatment as Usual (atypical antipsychotic) plus psychosocial treatment decided by clinician
2998428|NCT02573688|Experimental|Interdisciplinary Therapy|The Therapy includes: Physical Exercise (three times week - 180 minutes); Nutrition, Psychology, Physiotherapy (once a week - 60 minutes each one)
2998429|NCT02573662||Case subjects|Physical active non-diabetic individuals of age 18 to 50 years, who are undergoing knee surgical procedures at the Arthroscopic Center at Amager/Hvidovre Hospitals are recruited as cases for this case-control study. OGTT, blood- and urine sampling and DXA scans will be performed 3 times throughout the study period.
2998430|NCT02573662||Control group|Non-diabetic individuals matched for age, gender and physical activity are recruited as control subjects to establish a reference level likely to image the cases before they experienced their knee injury. Blood- and urine sampling, OGTT and DXA scans will be carried out 1-3 times for each control subject. No lifestyle intervention is implemented.
2998431|NCT02573649|Active Comparator|CLS-ON first|Closed-loop Stimulation on first
2998432|NCT02573649|Active Comparator|CLS-OFF first|Closed-loop Stimulation off first
2998433|NCT02573623||HIV-infected children with confirmed TB|Hospitalized children with TB confirmed by culture or GeneXpert
2998434|NCT02573623||HIV-uninfected children aged<5 years with confirmed TB|Hospitalized children aged<5 years with TB confirmed by culture or GeneXpert
2998435|NCT02573623||HIV-uninfected children aged>4 years with confirmed TB|Hospitalized children aged>4 years with TB confirmed by culture or GeneXpert
2998436|NCT02573623||HIV-infected control children|Children hospitalized in the surgery ward without any evidence of tuberculosis infection
2998437|NCT02573623||HIV-uninfected controls aged <5 years|Children <5 years hospitalized in the surgery ward without any evidence of tuberculosis infection
2998438|NCT02573623||HIV-uninfected controls aged >4 years|Children >4 years hospitalized in the surgery ward without any evidence of tuberculosis infection
2998439|NCT02573610|Experimental|DE-108|High concentration / Antibacterial Ophthalmic Solution
2998440|NCT02573610|Active Comparator|Levofloxacin 0.5%|Low concentration / Antibacterial Ophthalmic Solution
2998441|NCT02573597|Active Comparator|Part A Group 1|CEI bupivacaine and CEI sufentanil
2998442|NCT02573597|Active Comparator|Part A Group 2|PIEB bupivacaine and PIEB sufentanil
2998443|NCT02573597|Active Comparator|Part B Group 3|CEI bupivacaine and PIEB sufentanil
2998444|NCT02573597|Active Comparator|Part B Group 4|PIEB bupivacaine and CEI sufentanil
2998445|NCT02573571||Clostridium difficile infection|Patients with Clostridium difficile-associated diarrhea for development of biomarkers
2998446|NCT02573558||DEX|patients who received dexmedetomidine during the operation
2998450|NCT02573519|Active Comparator|Diabetic patient|"The study consists of four different parts:~11C Donepezil PET/CT scan~3D-Transit~3D-Transit during treatment with pyridostigmine~3D-Transit after Malone appendicostomy (only diabetic patients who had a Malone-surgery for severe obstipation ordered during standard clinical practice)"
2998451|NCT02573519|Active Comparator|Healthy subjects|"The study consists of two different parts:~11C Donepezil PET/CT scan~3D-Transit"
2998452|NCT02573506|Experimental|Consolidation|consolidation chemotherapy of pemetrexed or docetaxel after CCRT: pemetrexed(500mg/㎡) in non-squamous lung cancer or docetaxel(60mg/㎡)in squamous lung cancer after split-course concurrent chemoradiotherapy
2998453|NCT02573506|Active Comparator|Observation|split-course concurrent chemoradiotherapy
2998454|NCT02573493|Experimental|Arm 1: nab-Paclitaxel and cisplatin (AP)|"Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment~If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)~If <PR, move directly to CRT if not surgical candidates.~CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.~It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk."
2998455|NCT02573493|Experimental|Arm 2: nab-Paclitaxel (A)|"Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment~If CR/PR, three more weeks of nab-paclitaxel followed by CRT~If <PR, move directly to CRT if not surgical candidates.~CRT includes cetuximab will will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.~It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk."
2998456|NCT02573480|Experimental|Wraparound Care|Wraparound care initiated in the ED at the time of injury and continuing for approximately 1 year in the community.
2998457|NCT02573467|Experimental|BYM338/bimagrumab 10 mg/kg|Participants received BYM338 10 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
2998458|NCT02573467|Experimental|BYM338/bimagrumab 3 mg/kg|Participants received BYM338 3 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
2998459|NCT02573467|Experimental|BYM338/bimagrumab 1 mg/kg|Participants received BYM338 1 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
2998460|NCT02573467|Placebo Comparator|Placebo|Participants received placebo administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
2998461|NCT02573454|Experimental|Prosocial Exercise|Participants are provided with the intervention (App Assignment). In this arm, the participants are randomly assigned to the Prosocial Exercise group use a GPS exercise app named Charity Miles, in which users can earn donations for charities based on the miles they walk or run (approximately 25 cents for every mile).
2998462|NCT02573454|Active Comparator|Personal Exercise|Participants are provided with the intervention (App Assignment). In this arm, the participants are randomly assigned to the Personal Exercise group use a traditional GPS exercise app named Nike + Running, in which users can track the mileage that they walk or run (i.e., there is no opportunity to earn donations for charity through exercise behaviour).
2998463|NCT02573441|Experimental|Math + Liaison Service|To help with mathematics, participants will be assigned to a workbook based version of the JUMP Math program which will be completed at home with a parent. This intervention focuses on mental math skills. In addition all participants will receive the liaison service program.
2998464|NCT02573441|Experimental|Working Memory + Liaison Service|To help with working memory, participants will be assigned to Cogmed, a game-like computer exercise focusing on improving working memory. In addition all participants will receive the liaison service program.
2998465|NCT02573441|Other|Liaison Services|Participants in this group will only receive the liaison service program for 12 weeks before being assigned to one of the intervention groups.
2998466|NCT02573428||Autism Spectrum Disorder|Individuals who receive a clinical diagnosis of Autism Spectrum Disorder
2998467|NCT02573428||Developmental/Psychiatric Controls|Individuals who receive a clinical diagnosis of another developmental or psychiatric disorder
2998468|NCT02573428||Healthy Controls|Individuals who have no specific developmental or psychiatric diagnosis
2998469|NCT02573415|Experimental|Uterus Transplantation|Women will undergo deceased donor uterine transplantation after IVF.
2998470|NCT02573402|Experimental|Transcutaneous Tibial Nerve Stimulation|Transcutaneous Tibial Nerve Stimulation (TTNS) applied to subjects for 2-week protocol.
2998471|NCT02573402|Sham Comparator|Control|Sham stimulation.
2998472|NCT02573389|No Intervention|"Retrospective and prospective non-stented"|Non-stented patients undergoing distal pancreatectomy retrospectively (2008-2015) and prospectively from 2015 to 2017.
2998473|NCT02573389|Experimental|"Prospective stented"|Patients who undergo prophylactic pancreatic duct stenting prior to a distal pancreatectomy starting approximately September 2015.
2998474|NCT02573376|Other|Sofosbuvir/Ledipasvir with Directly Observed Therapy (DOT)|Participants randomized to vDOT will be provided a smart phone with cellular service and will be pre-programmed with the mobile phone-based video application and contact information for study personnel.
2998475|NCT02573376|Other|Sofosbuvir/Ledipasvir with Wirelessly Observed Therapy (WOT)|Participants on WOT will be provided the Wisepill portable medication dispenser.
2998824|NCT02571049|Experimental|Sumatriptan 6 mg then 3 mg|Two DFN-11 (sumatriptan, 3 mg) injections first then DFN-11 injection and placebo
2998476|NCT02573363|Experimental|selinexor, cytarabine, and mitoxantrone|"INDUCTION CHEMOTHERAPY: Patients receive high-dose cytarabine and mitoxantrone hydrochloride per standard of care on days 1 and 5, and selinexor PO on days 2, 4, 9, and 11.~CONSOLIDATION CHEMOTHERAPY: Patients receive high-dose cytarabine per standard of care on days 1, 3, and 5, and selinexor PO on days 2, 4, 9, and 11. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CHEMOTHERAPY: Patients achieving at least stable disease after consolidation chemotherapy may receive selinexor PO on days 1, 8, 15, and 22 at the discretion of principal investigator."
2998477|NCT02573350|Experimental|Delamanid|All patients received an initial dose of 100 mg BID (200 mg total daily dose), with an option to titrate to 200 mg BID (400 mg total daily dose) after an initial 2-week hospitalization at the investigator's discretion.
2998478|NCT02573337|Experimental|Intradermal injection|Emervel Classic Lidocaine and/or Emervel Deep Lidocaine
2998479|NCT02573324|Placebo Comparator|Placebo, radiation and TMZ|Placebo is given on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. Placebo is given on Day 1 & 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
2998480|NCT02573324|Experimental|ABT-414, radiation and TMZ|ABT-414 is given on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. ABT-414 is given on Day 1 & 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
2998481|NCT02573311|Experimental|men|
2998482|NCT02573298|Active Comparator|Ice|patients randomized to receive local ice on inflamed joint
2998483|NCT02573298|Active Comparator|Cold gas|patients randomized to receive cold gas on inflamed joint
2998484|NCT02573285|Active Comparator|Simple Aspiration|Subjects in this arm will undergo initial management of their pneumothorax with a simple aspiration procedure. The procedure will involve placement of a small catheter into the chest cavity and applying negative pressure to manually aspirate the air out of the chest cavity, which will allow the lung to re-expand.
2998485|NCT02573285|Active Comparator|Surgeon Preference|Subjects that choose the surgeon preference arm of the study are enrolling for prospective data collection only. These subjects will not have any portion their care directed by the study protocol. The decision to proceed with any treatment or intervention will be made jointly by the surgeon and the patient and his or her legal guardian. Any standard treatment option may be utilized, including simple aspiration, chest tube placement, or an operation (VATS).
2998486|NCT02573272||Epileptic patients with AEDs and eslicarbacepine|
2998487|NCT02573259|Experimental|Arm 1 PF-06801591|0.5 mg/kg IV every 21 days (Part 1)
2998488|NCT02573259|Experimental|Arm 2 PF-06801591|1.0 mg/kg IV every 21 days (Part 1)
2998489|NCT02573259|Experimental|Arm 3 PF-06801591|3.0 mg/kg IV every 21 days (Part 1)
2998490|NCT02573259|Experimental|Arm 4 PF-06801591|10 mg/kg IV every 21 days (Part 1)
2998491|NCT02573259|Experimental|Arm 5 PF-06801591|300 mg SC every 28 days (Part 1 and 2)
2998492|NCT02573246|Experimental|Cognitive Restructuring+rTMS (left)|Participants in this arm will be administered the neuromodulation enhanced cognitive restructuring intervention over the left side of the brain and will partake in short term and long term follow up testing.
2998493|NCT02573246|Sham Comparator|Cognitive Restructuring + sham rTMS|Participants in this arm will receive cognitive restructuring alone as an active intervention and will partake in short term and long term follow up testing.
2998494|NCT02573246|Experimental|Cognitive Restructuring+rTMS (right)|Participants in this arm will be administered the neuromodulation enhanced cognitive restructuring intervention over the right side of the brain and will partake in short term and long term follow up testing.
2998495|NCT02573233|Experimental|Dupilumab|Dupilumab every 2 weeks (loading dose with a double dose) added to current controller medications (eg, fluticasone propionate/salmeterol, budesonide/formoterol, mometasone furoate/formoterol)
2998496|NCT02573233|Placebo Comparator|Placebo|Placebo (for dupilumab) every 2 weeks (loading dose with a double dose) added to current controller medications
2998497|NCT02573220|Experimental|Treatment (FOLFIRI and cetuximab)|Patients receive irinotecan hydrochloride IV over 1-2 hours, fluorouracil IV continuously over 46 hours, and leucovorin calcium IV on days 1 and 15. Patients also receive cetuximab IV over 2 hours on days 3 and 15 of course 1 and days 1 and 15 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2998498|NCT02573194|Experimental|Animal source of proteins|Breakfast based on animal proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
2998499|NCT02573194|Experimental|Plant source of proteins|Breakfast based on plant proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
2998500|NCT02573194|Experimental|Animal and plant source of proteins|Breakfast based on both animal and plant proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
2998501|NCT02573194|Experimental|Low protein|Breakfast very low in protein: 1700 kJ, 5 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
2998502|NCT02573181|Experimental|V114|Participants previously (>=1 year ago) vaccinated with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of V114 on Day 1
2998503|NCT02573181|Active Comparator|Prevnar 13™|Participants previously (>=1 year ago) vaccinated with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1
2998504|NCT02573168|Experimental|GeneSight Psychotropic (GEN)|The GeneSight Psychotropic (GEN) product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection. More specifically, patients are tested for clinically important genetic variants of multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to metabolize, tolerate or respond to medications.
2998539|NCT02573012|Experimental|Tocilizumab+prednisone (tapering dose)|Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) with 1 mg decrements every 4 weeks or matching placebo orally for 24 weeks.
2998866|NCT02570737||Prevalent patients|Patients who have been diagnosed with more than three months from diagnosis to start of the Registry.
2998505|NCT02573168|Experimental|Enhanced-GeneSight Psychotropic (E-GEN)|The current GEN test lacks predictive genes for antipsychotic-induced weight gain (AIWG), a major complication of antipsychotic drug use. Therefore, the Enhanced-GeneSight Psychotropic (E-GEN), which is an enhanced version of the GEN test, was developed by incorporating 6 new genes (represented by 7 SNPs) that are predictive for AIWG, to those used in the GEN algorithm. An increasing risk level associated with AIWG is estimated by an increasing number of risk genotypes that a given patient possesses among the 7 SNPs.
2998506|NCT02573168|Active Comparator|Treatment as Usual (TAU)|"The comparator chosen for this study provides a real world comparison of standard of care for patients who receive no pharmacogenomics guidance.~Patients randomized to the TAU arm will also have their DNA collected and a pharmacogenomic-based interpretive report will be generated using GEN testing. However, this report will not be shared with the treating clinicians until completion at 12 months of the study. Therefore, patients in this arm will receive clinical treatment as usual, without the use or knowledge of genotyping results by their treating clinicians."
2998507|NCT02573155|Experimental|Sequence 1, Part 1|Period 1: Dose 1 Period 2: Dose 3 Period 3: Dose 5
2998508|NCT02573155|Experimental|Sequence 2, Part 1|Period 1: Placebo Period 2: Dose 3 Period 3: Dose 5
2998509|NCT02573155|Experimental|Sequence 3, Part 1|Period 1: Dose 1 Period 2: Placebo Period 3: Dose 5
2998510|NCT02573155|Experimental|Sequence 4, Part 1|Period 1: Dose 1 Period 2: Dose 3 Period 3: Placebo
2998511|NCT02573155|Experimental|Sequence 5, Part 1|Period 1: Dose 2 Period 2: Dose 4 Period 3: Dose 6
2998512|NCT02573155|Experimental|Sequence 6, Part 1|Period 1: Placebo Period 2: Dose 4 Period 3: Dose 6
2998513|NCT02573155|Experimental|Sequence 7, Part 1|Period 1: Dose 2 Period 2: Placebo Period 3: Dose 6
2998514|NCT02573155|Experimental|Sequence 8, Part 1|Period 1: Dose 2 Period 2: Dose 4 Period 3: Placebo
2998515|NCT02573155|Experimental|Sequence 1, Part 2|Period 1: Treatment A Period 2: Treatment B Period 3: Treatment E Period 4: Treatment C Period 5: Treatment D
2998516|NCT02573155|Experimental|Sequence 2, Part 2|Period 1: Treatment B Period 2: Treatment C Period 3: Treatment A Period 4: Treatment D Period 5: Treatment E
2998517|NCT02573155|Experimental|Sequence 3, Part 2|Period 1: Treatment C Period 2: Treatment D Period 3: Treatment B Period 4: Treatment E Period 5: Treatment A
2998518|NCT02573155|Experimental|Sequence 4, Part 2|Period 1: Treatment D Period 2: Treatment E Period 3: Treatment C Period 4: Treatment A Period 5: Treatment B
2998519|NCT02573155|Experimental|Sequence 5, Part 2|Period 1: Treatment E Period 2: Treatment A Period 3: Treatment D Period 4: Treatment B Period 5: Treatment C
2998520|NCT02573155|Experimental|Sequence 6, Part 2|Period 1: Treatment D Period 2: Treatment C Period 3: Treatment E Period 4: Treatment B Period 5: Treatment A
2998521|NCT02573155|Experimental|Sequence 7, Part 2|Period 1: Treatment E Period 2: Treatment D Period 3: Treatment A Period 4: Treatment C Period 5: Treatment B
2998522|NCT02573155|Experimental|Sequence 8, Part 2|Period 1: Treatment A Period 2: Treatment E Period 3: Treatment B Period 4: Treatment D Period 5: Treatment C
2998523|NCT02573155|Experimental|Sequence 9, Part 2|Period 1: Treatment B Period 2: Treatment A Period 3: Treatment C Period 4: Treatment E Period 5: Treatment D
2998524|NCT02573155|Experimental|Sequence 10, Part 2|Period 1: Treatment C Period 2: Treatment B Period 3: Treatment D Period 4: Treatment A Period 5: Treatment E
2998525|NCT02573142|Active Comparator|Education-only|Subjects in the education-only control will receive standard of care clinical treatment in the Duke Healthy Lifestyles clinic and educational materials describing community-based resources for physical activity and how to access them.
2998526|NCT02573142|Experimental|Bull City Fit Intervention|Subjects in the Bull City Fit intervention will receive standard of care clinical treatment in the Duke Healthy Lifestyles clinic and unlimited access to a community-based wellness program that includes physical fitness activities and cooking classes.
2998527|NCT02573129|Experimental|Red Meat Restricted|Following a 2-wk baseline testing period to assess cardiometabolic and emotional well-being and habitual diet, subjects will consume a Mediterranean-style, weight-maintenance diet that is restricted in lean, minimally processed red meat for 5 weeks.
2998528|NCT02573129|Experimental|Red Meat Rich|Following a 4-wk wash out period and a 2-wk baseline testing period to assess cardiometabolic and emotional well-being and habitual diet, subjects will consume a Mediterranean-style, weight-maintenance diet that is rich in lean, minimally processed red meat for 5 weeks.
2998529|NCT02573116|Experimental|Obstructive sleep apnea with chronic parodontis|patients with severe obstructive sleep apnea (OSA) and chronic parodontis treated for OSA by continuous positive airway pressure (CPAP) and intensive periodontal treatment
2998530|NCT02573116|No Intervention|Obstructive sleep apnea without chronic parodontis|patients with severe OSA treated by CPAP
2998531|NCT02573090|Experimental|Non-invasive resin based fissure sealing|Application of resin based fissure sealing after acid etching of carious occlusal surface
2998532|NCT02573090|Active Comparator|Invasive resin based restoration|Application of resin based resin restoration after operative intervention of caries lesion, excavation and preparation on occlusal surface
2998533|NCT02573051|Active Comparator|Misoprostol plus isosorbide mononitrate|this group will receive 800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries) plus 40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company) will be inserted into the posterior vaginal fornix
2998534|NCT02573051|Active Comparator|Misoprostol plus placebo|This group will receive misoprostol 800 µg plus placebo in the same site.
2998535|NCT02573038|Experimental|Aflibercept|Intravitreal injection of aflibercept (EYLEA) / 2mg
2998536|NCT02573025|Experimental|Test Followed by Reference|Participants will receive PEG-IFN alfa-2a BA-free formulation (Test) in Period 1, followed by PEG-IFN alfa-2a market formulation (Reference) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
2998537|NCT02573025|Experimental|Reference Followed by Test|Participants will receive PEG-IFN alfa-2a market formulation (Reference) in Period 1, followed by PEG-IFN alfa-2a BA-free formulation (Test) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
2998538|NCT02573012|Experimental|Tocilizumab+prednisone (constant dose)|Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) or matching placebo orally for 24 weeks.
2998616|NCT02572518||2 doses of yellow fever vaccine|30 days,1-5 years and 6 years or more after last dose
2998540|NCT02572999||Valvular heart disease|All patients aged 70 years or older, consecutively admitted for elective heart valve surgery or if admitted for elective transcatheter aortic valve implantation, or if a patient presents with symptomatic moderate to severe valvular heart disease on hospital admission as evidenced by moderate to severe valve regurgitation or stenosis will be included in this cohort. Participants will be observed up to 30 days post-hospital discharge
2998541|NCT02572986|Experimental|Permethrin cream 5%|Manufactured by Dr. Reddy's Laboratories, Ltd
2998542|NCT02572986|Active Comparator|Elimite™ Cream (permethrin) 5%|Manufactured by Prestium Pharma, Inc
2998543|NCT02572973|Active Comparator|Active Treatment|The Acoustic Neuromodulation (ANM) active treatment intervention is a non-invasive form of therapy in which certain sounds at certain intervals are delivered to a subject through headphones five times over the course of two weeks. The sounds are delivered for 12 minutes at each session. The level of sound during Sound Stimuli (SS) presentation is relatively low (20-40 decibels), and the volume level can be adjusted downward if the subject requests it. The active intervention sounds used in the trial couple sequential frequencies to the base frequency in a nonlinear (exponential) manner following a special algorithm developed by Dr. Izvarina. This algorithm varies both the rate of change and duration of the overlaying modulation that is presented to the brain.
2998544|NCT02572973|Placebo Comparator|Non-Active Placebo|The Acoustic Neuromodulation (ANM) treatment intervention is a non-invasive form of therapy in which certain sounds at certain intervals are delivered to a subject through headphones five times over the course of two weeks. The sounds are delivered for 12 minutes at each session. The placebo sounds used in this trial mimic the active sounds, but instead of using nonlinear modulation, they are coupled to the base frequency in a linear manner. Both the sequence used as well as the rate of change and duration of this overlaying modulation are the same as that used for the active sounds. The only difference is use of a linear algorithm for the placebo sounds and a nonlinear (exponential) algorithm for the active sounds.
2998545|NCT02572960|Placebo Comparator|Cholecalciferol|Cholecalciferol 70 mcg/day for 12 weeks Placebo Valsartan daily for 2 weeks
2998546|NCT02572960|Active Comparator|Valsartan|Placebo cholecalciferol/day for 12 weeks Valsartan 80 mg/day for 2 weeks
2998547|NCT02572960|Placebo Comparator|Placebo|Placebo cholecalciferol/day for 12 weeks Placebo Valsartan daily for 2 weeks
2998548|NCT02572960|Active Comparator|Cholecalciferol and Valsartan|Cholecalciferol 70 mcg/day for 12 weeks Valsartan 80 mg/day for 2 weeks
2998549|NCT02572947|Experimental|Dolutegravir monotherapy|10 patients will be simplified to monotherapy of dolutegravir tablet 50mg once daily for 24 weeks
2998550|NCT02572934||Chemotherapy group (CT-group)|Patients treated with chemotherapy >20 years ago
2998551|NCT02572934||Radiotherapy group (RT-group)|Patients treated with radiotherapy >20 years ago
2998552|NCT02572934||Surgery-only group (SU-group)|Patients treated with only orchidectomy >20 years ago
2998553|NCT02572934||Control-group|Healthy controls
2998554|NCT02572921|Experimental|Positive Psychotherapy|Experimental Group (Positive Psychotherapy)
2998555|NCT02572921|Active Comparator|Cognitive Behavioral Therapy|Active Control Group (Cognitive Behavioral Therapy)
2998556|NCT02572908|Active Comparator|Fermented wheat bread for 7 days|Long sourdough fermentation
2998557|NCT02572908|Placebo Comparator|Yeast baked wheat bread for 7 days|Regular toast bread
2998558|NCT02572908|Other|Run-in|Gluten-free diet for 7 days before entering either bread period
2998559|NCT02572895|Active Comparator|Optimal dose|One capsule with a proanthocyanidins standardized cranberry extract of 18,5 mg twice a day, i.e. in the morning and at night.
2998560|NCT02572895|Placebo Comparator|Control dose|One capsule with a proanthocyanidins standardized cranberry extract of 1 mg twice a day, i.e. in the morning and at night.
2998561|NCT02572882|No Intervention|Pre-treatment|This arm is the 8-week observation period before the p-inulin treatment phase.
2998562|NCT02572882|Experimental|p-inulin|This arm is the 12 week p-inulin treatment phase (8 grams twice daily, oral).
2998563|NCT02572882|No Intervention|Post-treatment|This arm is the 8-week observation period after the p-inulin treatment phase.
2998564|NCT02572869||segmental mandibulectomy and free fibular flap reconstruction|Patients who underwent segmental mandibulectomy and free fibular flap reconstruction at MSK between 1987 and 2014
2998565|NCT02572856|Experimental|CGM patients|Apply continuous glucose monitor, calibrate and make glucose measurements. Measurements are blinded to the care provider
2998566|NCT02572843|Experimental|MEDI4736|Patients whose tumor is deemed resectable at diagnosis will receive 3 cycles (21 days each) of standard chemotherapy with cisplatin/docetaxel followed by 2 cycles (14 days each) of neoadjuvant immunotherapy with MEDI4736 750 mg. Following surgery, patients with complete resection (R0) of their tumor will be administered adjuvant treatment with MEDI4736 750 mg for up to one year or until recurrence, death, unacceptable toxicity or consent withdrawal (whichever occurs first). Patients with incomplete R1/R2 resection, including patients with extracapsular spread of mediastinal lymph node metastases, may undergo standard radiotherapy prior to adjuvant treatment with MEDI4736.
2998567|NCT02572830|Experimental|Delayed Bilateral Eye Movements|Delayed Bilateral Eye Movements after reactivation of fear-memory.
2998568|NCT02572830|Active Comparator|Undelayed Bilateral Eye Movements|Undelayed Bilateral Eye Movements after reactivation of fear-memory.
2998569|NCT02572817|Experimental|High-titer anti-influenza plasma|Participants will receive two intravenous infusions of high-titer anti-influenza plasma on Study Day 0.
2998570|NCT02572817|Active Comparator|Low-titer (control) anti-influenza plasma|Participants will receive two intravenous infusions of low-titer anti-influenza plasma on Study Day 0.
2998571|NCT02572804|Active Comparator|Rectus Sheath Catheter Group|Patients will have rectus sheath catheters surgically inserted with infusion of 0.125% Bupivicaine at 5mls an hour.
2998572|NCT02572804|Active Comparator|Epidural Group|Patients will have a standard epidural placement with infusion of 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response
2998573|NCT02572791|Experimental|Periodic personal decolonization|All household participants will perform chlorhexidine body washes twice weekly for 3 months and apply mupirocin ointment to the anterior nares twice daily for five consecutive days each month for 3 months.
2998574|NCT02572791|Experimental|Household environmental hygiene|In addition to their usual cleaning, households will be asked to perform targeted household hygiene focusing on sources known to harbor S. aureus and serve as reservoirs for transmission.
2998575|NCT02572791|Experimental|Integrated personal/household hygiene|Participants in households randomized to this arm will perform the Periodic Personal Decolonization plus the Household Environmental Hygiene, described above in arms 1 and 2.
2998576|NCT02572765||Normotensive|Normotensive subjects
2998577|NCT02572765||Hypertensive|Hypertensive subjects
2998578|NCT02572752|Experimental|Treatment T (Test)|Nintedanib, 1 capsule, oral with 240 mL of water
2998579|NCT02572752|Experimental|Treatment R - 1 (Reference)|Nintedanib, 2 capsules, oral with 240 mL of water
2998580|NCT02572752|Experimental|Treatment R - 2 (Reference)|Nintedanib, 2 capsules, oral with 240 mL of water
2998581|NCT02572739||haemodynamics measuring|those with already implemented PICCO device get impedance device (NICCOMO) attached
2998582|NCT02572726|Active Comparator|active rTMS|active repeated transcranial magnetic stimulation over primary motor cortex along 5-10 daily sessions
2998583|NCT02572726|Sham Comparator|'sham' rTMS|'sham' repeated transcranial magnetic stimulation over primary motor cortex along 5-10 daily sessions
2998584|NCT02572713||Early PD|20 early PD not requiring dopamine replacement therapy have been enrolled.
2998585|NCT02572713||Moderate PD|20 moderate PD on dopamine replacement therapy without motor fluctuations have been enrolled.
2998586|NCT02572713||Advanced PD|21 advanced PD with motor fluctuations have been enrolled.
2998587|NCT02572713||Healthy Controls|21 healthy controls have been enrolled.
2998588|NCT02572700||Patients with psoriatic arthritis|PsA patients initiating anti-rheumatic treatment in routine care will be included as one group in the observational study. Analyses will be carried out for the overall study population as well as for subgroups (e.g., stratified according to treatment intervention) in an exploratory manner.
2998589|NCT02572687|Experimental|Ramucirumab + MEDI4736 (NSCLC)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given intravenously (IV) every 3 weeks (q3w) of a 21 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q3w. Participants may continue to receive study treatment until discontinuation criteria are met."
2998590|NCT02572687|Experimental|Ramucirumab + MEDI4736 (Gastric/GEJ)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given IV every 2 weeks (q2w) of a 28 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q2w. Participants may continue to receive study treatment until discontinuation criteria are met."
2998591|NCT02572687|Experimental|Ramucirumab + MEDI4736 (HCC)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given IV q2w of a 28 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q2w. Participants may continue to receive study treatment until discontinuation criteria are met."
2998592|NCT02572674|Other|experimental arm|Experimental follow up : Neuropsychological assessment at 6 month and genetic samples
2998593|NCT02572661|Other|Squamous Head and Neck Cancer|radiation
2998594|NCT02572648||Participants with Heart Failure|Participants with heart failure will complete neurocognitive tests and undergo magnetic resonance imaging (MRI).
2998595|NCT02572648||Healthy Controls|Healthy controls will complete neurocognitive tests and undergo magnetic resonance imaging (MRI).
2998596|NCT02572635|Experimental|Cohort 1|50 µg of PnuBioVax
2998597|NCT02572635|Experimental|Cohort 2|200 µg of PnuBioVax
2998598|NCT02572635|Experimental|Cohort 3|500 µg of PnuBioVax
2998599|NCT02572635|Placebo Comparator|Placebo|Placebo
2998600|NCT02572622|Experimental|spinal decompression group|only 15 sessions of spinal decompression therapy were applied.
2998601|NCT02572622|Experimental|combine group|10 patients participated in this group. for two weeks electrotherapy, deep friction massage and traction and last two weeks electrotherapy and exercise totally 15 session of treatment were applied.
2998602|NCT02572622|Experimental|exercise group|10 patients participated in this group. for two weeks electrotherapy, deep friction massage and last two weeks electrotherapy and exercise totally 15 session of treatment were applied whi
2998603|NCT02572609|Experimental|Mucosolvan ® adult syrup|
2998604|NCT02572609|Experimental|Ambroxol hydrochloride soft pastille|
2998605|NCT02572596|Experimental|rhTPO treatment group|Subject will receive chemotherapy with intermediate-dose CTX 2.5/m2 for 2 days. 10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed. rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
2998606|NCT02572596|Active Comparator|non- rhTPO treatment group|Subject will receive chemotherapy with intermediate-dose CTX 2.5/m2 for 2 days. 10 ug/kg/d of G-CSF was administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
2998607|NCT02572583|Experimental|Liugan Shuangjie Heji Group|Liugan Shuangjie Heji, take orally, 4 times a day, 100 ml each time (i.e. two doses per day), for a course of five days.
2998608|NCT02572583|Active Comparator|Shufeng Jiedu Capsule Group|Shufeng Jiedu Capsule, take orally, 3 times a day, 4 capsules each time, for a course of five days.
2998609|NCT02572583|Active Comparator|Oseltamivir Phosphate Capsule Group|Oseltamivir Phosphate Capsule, take orally, 2 times a day, 75 mg each time, for a course of five days.
2998610|NCT02572570|Experimental|Filtek Bulk Fill Posterior|Commercially available tooth-colored filling that will be used for direct restoration as per manufacturer's instructions.
2998611|NCT02572570|Active Comparator|Filtek Supreme Ultra|Commercially available tooth-colored filling that will be used for direct restoration as per manufacturer's instructions.
2998612|NCT02572557|Experimental|Spray cryotherapy using liquid nitrogen|Device: TruFreeze Spray CryoTherapy Drug: Liquid nitrogen
2998613|NCT02572544|Experimental|Participants|All participants perform all exams under 3 conditions, that is baseline, single pinhole glasses, and multiple pinhole glasses
2998614|NCT02572531|Active Comparator|L. reuteri|L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA lozenges three times daily for 2 weeks
2998615|NCT02572531|Placebo Comparator|Placebo|Placebo lozenges three times daily for 2 weeks
2998617|NCT02572505|Experimental|HIV-Discordant Couple|A couple in which the man is HIV-seropositive and the woman is HIV-seronegative who wish to have a biologically related child. Couple will use condoms for all sexual acts except one act of unprotected intercourse during the fertile period when the woman will be taking the drug Truvada.
2998618|NCT02572492|Experimental|Carfilzomib/dexamethasone maintenance|Carfilzomib/dexamethasone maintenance after salvage HDT
2998619|NCT02572492|Sham Comparator|Observation without maintenance|Observation without maintenance after salvage HDT
2998620|NCT02572466||ESRD group|"Aged 18 years or older.~was diagnosed as End-stage renal disease for more than one year.~Attend hemodialysis 3 times a week consistently for more than 6 months.~Hemodialysis with Kt/V > 1.2~No urine output or is less than 500 ml per day.~No symptoms of myocardial infarction Or were hospitalized with the similar diagnosis during the two weeks."
2998621|NCT02572466||Control group|"Aged 18 years or older.~without kidney disease (eGFR > 60 ml/min/1.73m2)"
2998622|NCT02572453|Experimental|Treatment (onalespib)|Patients receive onalespib IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2998623|NCT02572427|Experimental|Education for intubation skills|Interventions: Training for Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP); 7 minute excerpt from the NRP training video regarding intubation; cognitive instruction which consisted of equipment needed for intubation; hands on instruction using the Storz video laryngoscope with manikins in simulation lab.
2998624|NCT02572427|Active Comparator|No added education for intubation skills|Interventions: Training for Routine Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP) training; no additional training for intubating newborns.
2998625|NCT02572414|Experimental|Health Promotion Intervention|Men Together Making a Difference Health Promotion Intervention consisted of three, 3-hour weekly small-group intervention sessions led by a trained facilitator using a detailed, scripted manual designed to increase adherence to guidelines for physical activity, 5-a-Day diet, and colon cancer screening.
2998626|NCT02572414|Active Comparator|Health Awareness Control|Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
2998627|NCT02572401|Experimental|HIV Risk Reduction Only|STAND HIV Risk Reduction Intervention. Participants will not receive the Text Messaging Intervention.
2998628|NCT02572401|No Intervention|No-Intervention No-Text Message Control|Participants do not receive the STAND HIV Risk Reduction Intervention or the Text Messaging Intervention.
2998629|NCT02572401|Experimental|HIV Risk Reduction and Text Messaging|STAND HIV Risk Reduction Intervention and Text Messaging Intervention. Participants will receive the intervention and text messages.
2998630|NCT02572401|Experimental|Text Messaging Only|Text Messaging Intervention. Participants will receive the text messages but not the STAND HIV Risk Reduction Intervention.
2998631|NCT02572388|Active Comparator|Group 1|10µg of R21 mixed with 50µg of Matrix-M on days 0, 28, and 56.
2998632|NCT02572388|Active Comparator|Group 2|50µg of R21 on days 0, 28, and 56.
2998633|NCT02572388|Active Comparator|Group 3|50µg of R21 mixed with 50µg of Matrix-M on days 0, 28, and 56.
2998634|NCT02572388|Active Comparator|Group 4|2µg of R21 mixed with 50µg of Matrix-M
2998635|NCT02572375|Experimental|Codeine Phosphate/Guaifenesin ER Tablet|Patients receiving an extended release tablet dosage form of a combination drug of Codeine Phosphate and Guaifenesin twice a day for 6 and a half days total. Total dosage [2 tablets] is 60 mg Codeine Phosphate and 1200 mg Guaifenesin twice a day for a daily total of 120 mg Codeine Phosphate and 2400 mg Guaifenesin.
2998636|NCT02572375|Active Comparator|Codeine Phosphate/Guaifenesin IR Tablet|Patients receiving an immediate release tablet dosage form of a combination drug of Codeine Phosphate and Guaifenesin six times a day for 6 and a half days total. Dosage is 20 mg Codeine Phosphate and 400 mg Guaifenesin six times a day for a daily total of 120 mg Codeine Phosphate and 2400 mg Guaifenesin.
2998637|NCT02572349|Experimental|IW-1701|Single Dose
2998638|NCT02572349|Placebo Comparator|Matching Placebo for IW-1701|Single Dose
2998639|NCT02572336|Active Comparator|THR-18|Single administration of intravenous THR-18 solution
2998640|NCT02572336|Placebo Comparator|Placebo|Single administration of intravenous THR-18 lookalike solution
2998641|NCT02572323|Active Comparator|Immediate group|2mg of tesamorelin is injected once a day for 6 months, then no treatment is given for 6 months
2998642|NCT02572323|Placebo Comparator|Deferred group|No treatment is given for 6 months, then 2mg of tesamorelin is injected once a day for 6 months
2998643|NCT02572310|Experimental|HV Cement|Simplex High Viscosity Bone Cement
2998644|NCT02572297||video-EEG|Patients suffering from drug-resistant partial epilepsy for whom a video-EEG monitoring of their seizures was scheduled as part of pre-surgical assessment
2998645|NCT02572284|Experimental|Dose Escalation of SBRT|Stereotactic Body Radiation Therapy (SBRT) followed by prostatectomy and Quality of Life questionnaires. The radiation will be given for only 5 days. Conventional radiation to the prostate is given over 7-8 weeks.
2998646|NCT02572271|Active Comparator|Rubins Mastopexy|Patients are allocated to a mastopexy using Rubins technique
2998647|NCT02572271|Active Comparator|LOPOSAM|Patients are allocated to a mastopexy using the LOPOSAM technique
2998648|NCT02572258|Experimental|Nutritional oats cookie and educational session|Nutritional cookie with oats and nuts
2998649|NCT02572258|No Intervention|Educational session only|
2998650|NCT02572245|Active Comparator|PF-06410293 PFS (Prefilled Syringe)|PF-06410293 40 mg administered by Prefilled Syringe (PFS)
2998651|NCT02572245|Active Comparator|PF-06410293 PFP (Prefilled Pen)|PF-06410293 40 mg administered by Prefilled pen
2998652|NCT02572232|Experimental|Combitube, Easytube, Laryngeal masks|Combitube, Easytube, Laryngeal mask airway are intubated in pediatric airway manikins by probands in randomized order.
2998653|NCT02572219|Active Comparator|Nutraceutical|Treated with nutraceutical compound
2998654|NCT02572219|Placebo Comparator|Placebo|Treated with placebo
2998655|NCT02572206|Other|PET/SPECT and MRI scans|"PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation.~30 minute structural MRI will be obtained to permit co-registration of PET images."
2998657|NCT02572180|Active Comparator|NIRS-based NF in 3D|A near-infrared spectroscopy (NIRS)-based neurofeedback training in which participants learn to increase the BOLD signal in prefrontal cortical regions will take place in a 3D virtual reality classroom environment.
2998658|NCT02572180|Active Comparator|NIRS-based NF in 2D|A near-infrared spectroscopy (NIRS)-based neurofeedback training in which participants learn to increase the BOLD signal in prefrontal cortical regions will take place in a 2D (normal computer screen) classroom environment.
2998659|NCT02572180|Active Comparator|EMG-based BF in 3D|An electromyogram (EMG)-based biofeedback training in which participants learn to self-regulate activity of the musculi supraspinatus will take place in a 3D virtual reality classroom environment.
2998660|NCT02572167|Experimental|Brentuximab Vedotin + Nivolumab|Brentuximab vedotin plus nivolumab
2998661|NCT02572154|Other|Cases|men from couples with RPL after natural pregnancies, had blood and sperm samples for sperm DNA fragmentation exploration
2998662|NCT02572154|Other|Controls|men from couples who have a child consequently to a natural pregnancy, had blood and sperm samples for sperm DNA fragmentation exploration
2998663|NCT02572141|Experimental|Perioperative chemotherapy|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens
2998664|NCT02572141|Active Comparator|Postoperative chemotherapy|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens
2998665|NCT02572128|Experimental|Study 1|Iron fortified rice hot or cold extruded.
2998666|NCT02572128|Experimental|Study 2|Iron and zinc fortified rice hot extruded or coated.
2998667|NCT02572115|Active Comparator|Intervention arm - jumped the line|"This arm is presented with the possibility to use the emergency access button that enables the patient to bypass the telephone waiting line. This arm represents the patients who choose to use the intervention."
2998668|NCT02572115|Active Comparator|Intervention arm - did not jump the line|"This arm is presented with the possibility to use the emergency access button that enables the patient to bypass the telephone waiting line. This arm represents the patients who got the option to use the intervention but DID NOT."
2998669|NCT02572115|No Intervention|Control|This arm does not get the intervention.
2998670|NCT02572102|Experimental|Energy Drink|Two 16 ounce containers of an Energy Drink
2998671|NCT02572102|Active Comparator|Panax Ginseng|800 mg of Panax Ginseng in 70 mL of cherry syrup, 20 mL of lime juice, 410 mL of carbonated water
2998672|NCT02572102|Placebo Comparator|Placebo|70 mL of cherry syrup, 20 mL of lime juice, 410 mL of carbonated water
2998673|NCT02572089|Experimental|2mg Intranasal Naloxone|Administer 0.1mL spray of the 20 mg/mL formulation in one nostril
2998674|NCT02572089|Experimental|4mg(a) Intranasal Naloxone|Administer 0.1mL spray of the 20 mg/mL formulation in both nostrils
2998675|NCT02572089|Experimental|4mg(b) Intranasal Naloxone|Administer 0.1mL spray of the 40mg/mL formulation in one nostril
2998676|NCT02572089|Experimental|8mg Intranasal Naloxone|Administer 0.1mL spray of the 40mg/mL formulation in both nostrils
2998677|NCT02572089|Experimental|Intramuscular Naloxone|Administer 1mL of 0.4mg/mL formulation intramuscularly
2998678|NCT02572076|Experimental|Motus Cleansing System (MCS)|The MCS enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter & fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
2998679|NCT02572050|Experimental|Robotic Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy (RDG) with D2 LND for patient with stage II or III gastric cancer The primary efficacy endpoint of number of dissected lymph nodes in the N2 area (which is #7, #8a, #9, #11p and #12a according to the JRSSGC) after oncologic resection for clinical stage II or III gastric adenocarcinoma.assessment.
2998680|NCT02572037||Group I|Penile sensory hyperexcitability: Latencies of GPSEP and/or DNSEP of them are abnormal. They will receive treatment of Compound Lidocaine Cream-a kind of local anaesthetics that is widely used to treat PE.
2998681|NCT02572037||Group II|Sympathetic hyperexcitability: Latency of PSSR are abnormal.They will be treated with Dapoxetine(Priligy)-a kind of selective serotonin reuptake inhibitor(SSRI) which has been shown effective to PE.
2998682|NCT02572037||Group III|Mixed type: Both Latencies of GPSEP and/or DNSEP and Latency of PSSR are abnormal.They will receive both Compound Lidocaine Cream and Dapoxetine.
2998683|NCT02572037||Group IV|Others: Both Latencies of GPSEP, DNSEP and Latency of PSSR are normal.They will receive further tests. (This group is not the main objects to be observed in this study.)
2998684|NCT02572024|Active Comparator|Baroreflex activation therapy|BAT ON
2998685|NCT02572024|Placebo Comparator|Placebo|BAT OFF
2998686|NCT02572011|No Intervention|Control|Participants in the control (CON) group will not complete any formalised balance training as part of the current study.
2998687|NCT02572011|Experimental|Experimental|Participants in the experimental group will complete the Home-based Games Console Balance Training intervention.
2998688|NCT02571998|Experimental|Treatment|Omiganan (CLS001) Topical Gel applied once daily
2998689|NCT02571998|Placebo Comparator|Vehicle Gel|Vehicle Topical Gel applied once daily
2998690|NCT02571972|Experimental|Dorzolamide-timolol|"On enrollment, eligible patients will have visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan and will then receive the same intravitreal pharmacologic agent administered at prior visit.~Subsequent follow-up visits will be at an identical interval to pre-enrollment visit intervals (4, 5, or 6 week intervals) for the study duration.~Each subsequent visit will consist of visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan, and intravitreal injection of same pharmacologic agent as prior visits~At study conclusion, mean central macular thickness, maximum subretinal fluid height, and maximum pigment epithelial detachment height will be measured over the study period for all patients"
2998691|NCT02571959|Experimental|amoxicillin and clavulanic acid|All volunteers receive a dose of amoxicillin and clavulanic acid
2998692|NCT02571946|Experimental|Proton beam therapy|
2998693|NCT02571933||Grammar English|Patients who primarily speak Grammar English. Patients will answer the FPS-R in Grammar English both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
2998694|NCT02571933||Pidgin English|Patients who primarily speak Pidgin English. Patients will answer the FPS-R in Pidgin English both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
2998695|NCT02571933||French|Patients who primarily speak French. Patients will answer the FPS-R in French both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
2998696|NCT02571907|Experimental|Zenith® Branch Endovascular Graft-Iliac Bifurcation|Zenith® Branch Endovascular Graft-Iliac Bifurcation in combination with the Atrium iCAST™ and the Zenith® Flex AAA Endovascular Graft
2998697|NCT02571894|No Intervention|Observational arm|Participants randomized to observational arm will receive standard oncological followup and care.
2998698|NCT02571894|Experimental|Intervention arm|Intervention arm receives standard oncological followup and care + subclinical cardiotoxicity surveillance and treatment.
2998699|NCT02571881|Active Comparator|Oxycodone|Oxycodone 10 mg prolonged release tablet twice a day after caesarean section
2998700|NCT02571881|Experimental|Oxycodone-naloxone|Oxycodone-naloxone 10/5 mg prolonged release tablet twice a day after caesarean section
2998701|NCT02571855|Experimental|Part A: ACT-541468 multiple ascending doses|Six young adults will receive ACT-541468 in the morning from Day 1 to Day 5 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 10, 25 and 75 mg per day
2998702|NCT02571855|Placebo Comparator|Part A: Placebo|For each ACT-541468 dose level tested in Part A, 2 young adults will receive matching placebo in the same conditions (total number of subjects = 6)
2998703|NCT02571855|Experimental|Part B: ACT-541468 single ascending doses|Six elderly will receive ACT-541468 in the morning of Day 1 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 5, 15 and 25 mg
2998704|NCT02571855|Placebo Comparator|Part B: Placebo|For each ACT-541468 dose level tested in Part B, 2 elderly will receive matching placebo in the same conditions (total number of subjects = 6)
2998705|NCT02571855|Experimental|Part C: repeated dose of ACT-541468|Sixteen young adults and eight elderly will receive ACT-541468 (planned dose: 25 mg) in the evening for 7 days (8 days for 6 of the 16 young adults).
2998706|NCT02571855|Placebo Comparator|Part C: Placebo|Four young adults and 2 elderly will receive matching placebo in the same conditions as subjects receiving the active compound in Part C
2998707|NCT02571842|Experimental|Rituximab|"Drug: Rituximab~•Rituximab 375 mg/m2 on treatment month 1, 2, 3, 4~Other Name: Mabthera"
2998708|NCT02571842|Active Comparator|ACEI/ARB plus corticosteroids|"Drug: ACEI/ARB~An ACEI and /or ARBs will be used to achieve proteinuria reduction and a blood pressure goal of <130/80 mmHg. Patients not attaining the target blood pressure with an ACEI or ARB alone should be treated with the combination of ACEI + ARB~Corticosteroids will be used as prednisolone 0.5 mg/kg/day with gradually taper off in 6-8 weeks to 5mg/day daily~Other Name: Enalapril, Lorsartan, Prednisolone"
2998709|NCT02571829|Experimental|ribociclib|single arm ribociclib Oral 600 mg x 1 a day duration according to response.
2998710|NCT02571816|Experimental|ASP2215: Subjects with mild hepatic impairment|Subjects with Child Pugh classification score of 5-6 (mild)
2998711|NCT02571816|Experimental|ASP2215: Subjects with moderate hepatic impairment|Subjects with Child Pugh classification score of 7-9 (moderate)
2998712|NCT02571816|Experimental|ASP2215: Subjects with normal hepatic function|Healthy subjects that match with respect to age, sex and body mass index (BMI)
2998713|NCT02571803|Experimental|Dietary And Lifestyle Counseling|Patients receiving strict dietary counseling (implementation of the DASH diet) and lifestyle changes support atop of optimal medical treatment as per 2013 ESC guidelines on the management of stable coronary artery disease.
2998714|NCT02571803|Active Comparator|Optimal Medical Treatment|Patients receiving optimal medical treatment as per 2013 ESC guidelines on the management of stable coronary artery disease.
2998715|NCT02571790|Experimental|Relaxation optimized virtual reality|six relaxation sessions with virtual reality
2998716|NCT02571790|Experimental|Classical relaxation (without Virtual Reality).|six relaxation sessions without virtual reality
2998717|NCT02571777|Experimental|QVM149 150/50/160 µg o.d.|QVM149 150/50/160 µg o.d. delivered via Concept1
2998718|NCT02571777|Experimental|QVM149 150/50/80 µg o.d.|QVM149 150/50/80 µg o.d. delivered via Concept1
2998719|NCT02571777|Active Comparator|QMF149 150/160 µg o.d.|QMF149 150/160 µg o.d. delivered via Concept1
2998720|NCT02571777|Active Comparator|QMF149 150/320 µg o.d.|QMF149 150/320 µg o.d. delivered via Concept1
2998721|NCT02571777|Active Comparator|Salmeterol/fluticasone|Salmeterol xinafoate /fluticasone propionate 50/500 µg b.i.d. delivered via Accuhaler®.
2998722|NCT02571764|Experimental|Nutritional Oats Cookie|
2998723|NCT02571751|Experimental|Breast Augmentation|
2998724|NCT02571738|Active Comparator|CHAM|Cryopreserved Human Amniotic Membrane
2998725|NCT02571738|Placebo Comparator|Control|Standard of Care
2998726|NCT02571725|Experimental|Olaparib and Tremelimumab|"Each cycle is 28 days:~Olaparib at 300 mg, orally, twice daily + Tremelimumab at 10 mg/kg, intravenously, every 4 weeks for the first 6 doses, then every 12 weeks until disease progression or unacceptable toxicity.~If 1 of the first 3 patients experiences a regimen-limiting toxicity (RLT), 3 more patients will be treated with 10 mg/kg Tremelimumab in Phase 1. If 2 or more of 6 patients experience RLT, then 6 mg/kg Tremelimumab will be tested~If at 6 mg/kg, 1 or more of 3 patients experience RLT, 3 patients will be treated at 3 mg/kg Tremelimumab~If at 3 mg/kg, 1 or more patients experience RLT, the study will be discontinued for safety purposes~In Phase 2, patients will receive doses of Olaparib and Tremelimumab determined in the Phase 1 portion as described above, based on tolerability."
2998727|NCT02571712|Other|GANFORT®|One drop of GANFORT® (bimatoprost 0.03% plus timolol 0.5%) instilled in each affected eye once daily in the evening for 24 weeks.
2998728|NCT02571699|Active Comparator|Subgluteal sciatic block|Subgluteal block with similar volume
2998729|NCT02571699|Experimental|Subgluteal block|Subgluteal block with decreasing volume
2998939|NCT02570334|Experimental|HIV-unexposed uninfected children|Children born to HIV-uninfected mothers
2998730|NCT02571673||Survivors of head and neck cancer|Data collection will take place in two parts. Aim 1: Part 1 will enroll 10 patients at MSK to participate in component pilot testing and usability testing of HN-STAR and the associated surveys. We will also elicit feedback from the NP. After incorporating any changes to HN-STAR or the surveys based on findings from Aim 1: Part 1, Aim 1: Part 2 will enroll 30 additional patients from MSK and 15 from HH to provide feedback on usability. We will also survey each patient's PCP in Aim 1: Part 2.
2998731|NCT02571660|Active Comparator|conventional treatment|GINA treatment fot asthma +vit.D low supplementation dose
2998732|NCT02571660|Experimental|conventional treatment + vitamin D3|GINA treatment fot asthma +vit.D high supplementation dose
2998733|NCT02571634|Other|Open label|Open label, no blinding, everyone receives Lazanda.
2998734|NCT02571621||Patients intubated with Combitube|Patients with Combitube intubation undergoing general anesthesia with ASA class I and II
2998735|NCT02571608|Active Comparator|Metformin|Metformin, dosage same as the patient's regular dosage
2998736|NCT02571608|Placebo Comparator|Placebo|Placebo
2998737|NCT02571595|Experimental|Immediate dCBT-I group|Digital cognitive behavioural therapy for insomnia (dCBT-I) is a 6 session training program (spanning 6 to 12 weeks) designed to improve sleep. Participants in the immediate dCBT-I group will receive the Sleepio intervention shortly after enrollment.
2998738|NCT02571595|Experimental|Waitlist control group|Participants in the waitlist control group will receive sleep hygiene recommendations from validated online resources for HIV patients (http://www.catie.ca/en/positiveside/winter-2013/sleep-tight) around the time of enrollment. They will start the digital cognitive behavioural therapy for insomnia (dCBT-I) intervention 12-14 weeks after the initial enrollment.
2998739|NCT02571582||Patients died|"All patients underwent extensive evaluation:~- Body composition, Diabetes; dyslipidemia, hemoconcentration, hypertension, exercise capacity: 6-Minute Walk test procedure, renal function, inflammatory markers, cause and place of death, time tracking concentrator, quality of life and pulmonary Function."
2998740|NCT02571582||living patients|"All patients underwent extensive evaluation:~- Body composition, Diabetes; dyslipidemia, hemoconcentration, hypertension, exercise capacity: 6-Minute Walk test procedure, renal function, inflammatory markers, cause and place of death, time tracking concentrator, quality of life and pulmonary Function."
2998741|NCT02571569|Experimental|Without inhibitors|Dose escalation steps for participants without inhibitors - intravenous infusion and subcutaneous injection
2998742|NCT02571569|Experimental|With inhibitors|Dose escalation steps for participants with inhibitors - intravenous infusion and subcutaneous injection
2998743|NCT02571569|Experimental|Without inhibitors_multiple dose|Multiple dose cohort for participants without inhibitors - a single subcutaneous injection once a week for 6 weeks
2998744|NCT02571556|Experimental|Dexamethasone Phosphate Ophthalmic Solution|
2998745|NCT02571543|Experimental|Intervention|"2 Stage study design. Stage 1: 8 patients will be treated with the lower dose of 400mg of Ibuprofen. Should the efficacy be insufficient (3 or less patients) then the study will stop and stage 1 will recommence with 800mg.~Stage 2: 17 patients will be treated either with the lower dose of 400mg or the higher dose of 800mg of Ibuprofen should the respective stage 1 have been successful (4 or more patients showing an effect)."
2998746|NCT02571543|No Intervention|Control|The control group will consist of a no-treatment group of patients undergoing Intrauterine Insemination (IUI) or Timed Sexual intercourse (TSI), to verify the delay between LH-Peak onset and ovulation. 42h after Beta-HCG injection inducing LH-Peak, ovulation will be determined by ultrasound examination.
2998747|NCT02571530|Experimental|Intra-arterial Cerebral Infusion of Trastuzumab|Super-selective Intra-arterial Cerebral Infusion of Trastuzumab After Blood-Brain Barrier Disruption
2998748|NCT02571517|Experimental|Glucocorticoids|"methylprednisolone intravenous administration of 2mg/kg/day (divided in two doses) and/or oral prednisolone 2,5 mg/kg/day (in two divided doses) during 7 days.~Patients younger than 2 year, who required hospitalization, affected by moderate or severe bronchiolitis"
2998749|NCT02571517|Placebo Comparator|Placebo|"will receive iv/oral glucose 5% solution as placebo of 2mg/kg/day and/or 2,5 mg/kg/day (divided in two doses) during 7 days.~Patients younger than 2 year, who required hospitalization, affected by moderate or severe bronchiolitis."
2998750|NCT02571504|Experimental|Immediate cognitive training group|Plasticity-based Adaptive Cognitive Remediation (PACR) is an 8 week training to improve executive functions (e.g., working memory, flexibility, cognitive control) as well as attention. Participants in the immediate cognitive training group will receive the PACR intervention shortly after enrollment.
2998751|NCT02571504|Experimental|Waitlist control group|Participants in the waitlist control group will receive a brochure with 8 simple tips for better brain health around the time of enrollment. They will begin the Plasticity-based Adaptive Cognitive Remediation (PACR) intervention within 8 weeks of the initial enrollment.
2998752|NCT02571491|Experimental|Ketamine Hydrochloride|"Received a combination of ketamine, remifentanil and morphine hydrochloride established by the following dosage regimen:~KETAMINE HYDROCHLORIDE 0,5mg/Kg Intravenous bolus administered during the anesthetic induction, followed by 2 mcg / Kg / min of intravenous infusion during and after surgery until 72 hours postoperation~during surgery remifentanil 0,3 mcg / kg / min.~at the end of the operation morphine hydrochloride150 mcg / kg, PCA infusion postoperatively."
2998753|NCT02571491|Placebo Comparator|Placebo|"Received a combination of physiological serum, remifentanil and morphine hydrochloride established by the following dosage regimen:~0,9 % physiological serum 0,5mg/Kg administered by an intravenous (IV) line during the anesthetic induction, followed by 2 mcg / Kg / min of intravenous infusion during and after surgery until 72 hours postoperation~during surgery remifentanil 0.3 mcg / kg / min.~at the end of the operation morphine hydrochloride150 mcg / kg, PCA infusion postoperatively."
2998754|NCT02571478|Experimental|7-Month Wait List Group|Couples will be randomly assigned to a wait list group. This group will wait seven months before starting The Marriage Checkup.
2998755|NCT02571478|Experimental|MC Right Away|Couples will be randomly assigned to receive The Marriage Checkup right away.
2998784|NCT02571296|Placebo Comparator|Group B|"subjects will receive placebo twice daily from (14-18 weeks) until 36 weeks or delivery.~Subjects: 106 cases Name: placebo Form: oral tablets Dosage: one tablet Frequency: every 12 hours Duration: 14-36 weeks gestational age."
2998865|NCT02570737||Incident patients|Patients with less than three months from diagnosis to start of the Registry or those who have been diagnosed during the recruitment period.
2998756|NCT02571452|Experimental|Brief Behavioral Treatment for Insomnia|Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
2998757|NCT02571452|Active Comparator|Progressive Muscle Relaxation|Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
2998758|NCT02571439|Experimental|Surgical TAP block|surgeon administered intraoperative TAP block using 0.5% ropivacaine
2998759|NCT02571439|Active Comparator|Conventional TAP block|Conventional, Anesthesiologist administered post-operative TAP block using 0.5% ropivacaine
2998760|NCT02571426|Active Comparator|Propofol|Continuous infusion during surgery. Individual dosage.
2998761|NCT02571426|Active Comparator|sevoflurane|Inhalational anesthetic during surgery. Individual dosage
2998762|NCT02571413|Other|oral presentation|"Scoring the correct use of INC before, immediate after and 3 months after oral presentation without demonstration how to use INCS"
2998763|NCT02571413|Other|animated cartoon-aided VDO|"Scoring the correct use of INC before, immediate after and 3 months after animated cartoon-aided teaching how to use INCS"
2998764|NCT02571400||Patients scheduled to undergo surgery|Patients scheduled to undergo surgery at St Vincent's Private Hospital Sydney
2998765|NCT02571387|Experimental|Mindfulness|Computerized mindfulness-based intervention. 10 minutes per day, every day for 12 months of MP3 listening. Guidelines are in line with main mindfulness-based interventions (MBSR, MBCT, ACT). Participants can choose between 4 audio recordings (sessions): awareness of the breathing, awareness of postures and bodily sensations, acceptance of thoughts and emotions, and awareness of bodily sensations and related thoughts and emotions while executing 5 squats.
2998766|NCT02571387|Sham Comparator|Sham meditation|"Computerized sham meditation intervention. 10 minutes per day, every day for 12 months of MP3 listening. The unique guideline is to meditate at the beginning of each session. Participants can choose between 4 audio backgrounds: forest, night, beach, and river."
2998767|NCT02571387|No Intervention|Treatment as usual|Usual care in a nutrition pole in France: nutrition, diet, exercise.
2998768|NCT02571374|Experimental|symbiotic group|Symbiotic group
2998769|NCT02571374|Placebo Comparator|placebo group|placebo group
2998770|NCT02571361|Active Comparator|Treatment A:|Paracetamol 1g + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
2998771|NCT02571361|Active Comparator|Treatment B:|Paracetamol 1g + placebo orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
2998772|NCT02571361|Active Comparator|Treatment C:|Placebo + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
2998773|NCT02571361|Active Comparator|Treatment D:|Paracetamol 0,5 g + ibuprofen 200 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
2998774|NCT02571348|Active Comparator|4 weeks and 8 weeks|Micro-osteoperforation will be done on either side of the maxilla at 4 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 8 weeks and the contralateral site will serve as the control
2998775|NCT02571348|Active Comparator|8 weeks and 12 weeks|Micro-osteoperforation will be done on either side of the maxilla at 8 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 12 weeks and the contralateral site will serve as the control
2998776|NCT02571348|Active Comparator|12 weeks and 4 weeks|Micro-osteoperforation will be done on either side of the maxilla at 12 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 4 weeks and the contralateral site will serve as the control
2998777|NCT02571335|Experimental|Intensive Training|Treatment consists of endurance training in both groups of physiologically defined heart rate controlled cycling at 50-60 rounds per minutes (rpm) and progressive resistance training. Training groups differ in the applied intensities and frequencies.The IT will train less frequent but training sessions will be more intensive in its effects. Training will be performed daily in six sessions (three morning and three afternoon sessions), synchronized and individually matched to a ratio of active versus passive sessions of 2:1.
2998778|NCT02571335|Active Comparator|Normal Training|The NT is the normal training performed out of the daily routine and outlines the usual care of the Valens clinic. Training will be performed in up to eight training sessions that will not be synchronized and not individually matched to a ratio of active versus passive sessions.
2998779|NCT02571322|Experimental|Whole Body Vibration training|Use of the HyperVibe Whole Body Vibration training device for 12 weeks 3 times per week crossover to aerobic exercise
2998780|NCT02571322|Placebo Comparator|Aerobic Exercise|Aerobic exercise training for 12 weeks 3 times per week crossover to use of the HyperVibe Whole Body Vibration training device
2998781|NCT02571309|Other|Smartphone app - Asthmatuner|"The app Asthmatuner contains four different modes;~Lung function testing with Bluetooth connection of external spirometry~Symptom evaluation~Actual treatment plan, based om lung function and symptoms~Trend views of lung function, symptoms and asthma control"
2998782|NCT02571309|Other|Conventional|Conventional treatment and Asthmatuner will be stratified and harmonized into categories of asthma management and current state-of-art at each health care centre. Each group harmonized group will include 43 subjects.
2998783|NCT02571296|Active Comparator|group A|"subjects will recieve twice daily tablets of 100 mg of oral Micronized Progesterone from (14-18 weeks) until 36 weeks or delivery.~Subjects: 106 cases Name: Oral micron ized progesterone Form: oral tablets Dosage: one tablet Frequency: every 12 hours Duration: 14-36 weeks gestational age."
2998820|NCT02571075|No Intervention|Group 2 don't receive anything|They do not receive any any acupuncture only standard of care.
2998821|NCT02571062|Experimental|experimental formulation|crossover design
2998785|NCT02571283|Experimental|Randomized Group A [Cocktail Injection]|"COCKTAIL INJECTION:~Cocktail Injection Consists of:~Ropivacaine (Brand Name: Naropin) 5 mg/ml (49.25 ml) Ketorolac (Brand Names: Toradol, Sprix, Acuvail, Acular) 30 mg/ml (1 ml) Epinephrine (Brand Names: EpiPen, Adrenaclick, Medihaler-Epi, Twinject) 1 mg/ml (0.5 ml) Clonidine (Brand Names: Kapvay, Catapres, Duraclon, Nexiclon) 0.1 mg/ml (0.08 mg = 0.8 ml) Normal Saline added to total of 100 cc Dosage Form: Injection Dosage: See above Frequency: Single dose"
2998786|NCT02571283|Experimental|Randomized Group B [Cocktail Injection Plus Exparel]|"COCKTAIL INJECTION PLUS EXPAREL:~Cocktail Injection Consists of:~Ropivacaine (Brand Name: Naropin) 5 mg/ml (49.25 ml) Ketorolac (Brand Names: Toradol, Sprix, Acuvail, Acular) 30 mg/ml (1 ml) Epinephrine (Brand Names: EpiPen, Adrenaclick, Medihaler-Epi, Twinject) 1 mg/ml (0.5 ml) Clonidine (Brand Names: Kapvay, Catapres, Duraclon, Nexiclon) 0.1mg/ml (0.08 mg = 0.8 ml) Normal Saline added to total of 100 cc Dosage Form: Injection Dosage: See above Frequency: Single dose~Bupivacaine Liposome (Brand Name: Exparel) Dosage Form: Injection Dosage: 20 ml Single use vial, 1.3% (13.3 mg/ml) Frequency: Single dose"
2998787|NCT02571283|Experimental|Randomized Group C [Marcaine Plus Exparel]|"MARCAINE PLUS EXPAREL:~Bupivacaine Hydrochloride (Brand Name: Marcaine, Sensorcaine) Dosage Form: Injection Dosage: 3 ml vial, 0.5% solution Frequency: Single dose~Bupivacaine Liposome (Brand Name: Exparel) Dosage Form: Injection Dosage: 20 ml Single use vial, 1.3% (13.3 mg/ml) Frequency: Single dose"
2998788|NCT02571270|Active Comparator|Active lifestyle|Active lifestyle involves nutritional education, physical activity and active recreation.
2998789|NCT02571270|Active Comparator|Lifestyle counseling|Lifestyle counseling helps patients to have better self-care.
2998790|NCT02571270|Active Comparator|secondary prevention|Secondary prevention it is essential to prevent a new unfavorable event.
2998791|NCT02571270|Active Comparator|survival|The survival of patients with heart failure may increase with exercise training.
2998792|NCT02571257|Placebo Comparator|Placebo|Placebo treatment on stable background statin therapy
2998793|NCT02571257|Experimental|Gemcabene 300 mg QD|Gemcabene (also known as CI-1027) treatment on stable background statin therapy
2998794|NCT02571257|Experimental|Gemcabene 900 mg QD|Gemcabene (also known as CI-1027) treatment on stable background statin therapy
2998795|NCT02571244|Experimental|Motivational Interview plus text message|Inside the hospital: All participants have received the written materials. Patients with high tobacco dependence (Fagerstrom screening test score 5 or higher) have received also Nicotine Replacement Therapy (NRT). The written materials provided information on benefits of quitting and strategies for a successful quit plan, including information on relapse prevention. Post discharge extended treatment: Participants in this arm have received a telephone counseling session using a motivational interviewing approach and fifteen or eight days of text messages. The timing, duration, and content of the counseling session were consistent with guideline-based recommendations.
2998796|NCT02571244|No Intervention|Control Arm|Inside the hospital: All participants have receive the written materials. Patients with high tobacco dependence (Fagerstrom screening test score 5 or higher) have received also Nicotine Replacement Therapy (NRT). The written materials provided information on benefits of quitting and strategies for a successful quit plan, including information on relapse prevention. Post discharge extended care: None
2998797|NCT02571231|Experimental|HFV+vg|volume guarantee given
2998798|NCT02571231|Experimental|HFV-VG|Volume guarantee not given
2998799|NCT02571218|Active Comparator|mCPVA|"Subjects in the mCPVA arm will undergo intervention called modified circumferential pulmonary vein ablation, which is considered to be the standard ablation treatment for AF."
2998800|NCT02571218|Experimental|Substrate+mCPVA|Subjects in the Substrate+mCPVA arm will undergo intervention of substrate mapping and substrate-targeted ablation guided by the investigational device, followed by completion of modified circumferential pulmonary vein ablation.
2998801|NCT02571192|Experimental|Experimental Drug|single oral dose radiolabelled 50mg of SHP626
2998802|NCT02571179|Experimental|Intranasal fentanyl 50 microg/dose|patient was given intranasal fentanyl 50 microg/dose up to 250 microg
2998803|NCT02571166|Experimental|HSV529|
2998804|NCT02571153|Placebo Comparator|Saline group|Normal saline 0.9% (5 mL)
2998805|NCT02571153|Experimental|Ketamine 0.2|ketamine 0.2 mg/kg (5 mL)
2998806|NCT02571153|Experimental|Ketamine 0.4|ketamine 0.4 mg/kg (5 mL)
2998807|NCT02571140|Active Comparator|Active Comparator|Subcutaneous injection of Teriparatide
2998808|NCT02571140|Experimental|Oral PTH (1-34)|Oral administration of pill with API with different optimizations
2998809|NCT02571127|Experimental|Only treatment|two weekly applications (monday and thursday or tuesday and friday) for 12 weeks
2998810|NCT02571114|Active Comparator|Control 1|white bread - 25 g available carbohydrate
2998811|NCT02571114|Active Comparator|Control 2|white bread - 25 g available carbohydrate
2998812|NCT02571114|Sham Comparator|Frozen Yogurt|unflavoured frozen yogurt - 25 g available carbohydrate
2998813|NCT02571114|Experimental|Saskatoon Berry Frozen Yogurt|frozen yogurt containing powder prepared from Saskatoon berries - 25 g available carbohydrate
2998814|NCT02571101|Experimental|Test 1|Test 1 subjects will take one tablet of CDFR0812-15/25mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks.
2998815|NCT02571101|Experimental|Test 2|Test 2 subjects will take one tablet of CDFR0812-15/50mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks.
2998816|NCT02571101|Placebo Comparator|Comparator|Comparator subjects will take one tablet of Condencia and another tablet of CDFR0812-Placebo before sexual intercourse in on-demand for 8 weeks.
2998817|NCT02571088|Experimental|Training Program|The treatment will consist in an endurance training program. Only patients of the trained group will be subjected to this training program which will typically consist in 3 training sessions per week during 8 weeks i.e., 24 training sessions. Each training session will last 45 min. All training sessions will take place at the hospital and will be under medical supervision.
2998818|NCT02571088|No Intervention|No Training Program|It will be asked to the control patients to not change their habitual physical activity during the entire period of observation
2998819|NCT02571075|Experimental|Group 1 - Receives auricular acupuncture|"Receives Battlefield Acupuncture (BFA) as soon a anesthesia is initiated and needles removed right before they are extubated and awakened."
2998822|NCT02571062|Experimental|final formulation|crossover design
2998825|NCT02571036|Experimental|Escalation|Escalation Phase: DCC-2618 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours or once daily (QD) for repeated 28-day cycles. Participants may continue to receive study drug until discontinuation criteria are met.
2998826|NCT02571036|Experimental|Expansion Cohort 1|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 3 prior therapies.
2998827|NCT02571036|Experimental|Expansion Cohort 2|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 4 prior therapies.
2998828|NCT02571036|Experimental|Expansion Cohort 3|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received at least one prior therapies not no more that 2 prior therapies.
2998829|NCT02571036|Experimental|Expansion Cohort 4|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with Systemic Mastocytosis and other hematologic malignancies.
2998830|NCT02571036|Experimental|Expansion Cohort 5|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with malignant gliomas.
2998831|NCT02571036|Experimental|Expansion Cohort 6|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with other solid tumors.
2998832|NCT02571010|Experimental|Vibrotactile stimulation|"Patients in this arm will have~treatment by medications and rehabilitation~treatment by vibrotactile at medical center~stimulation at home by soft tissue~non stimulation on allodynia area"
2998833|NCT02571010|Sham Comparator|Sham Stimulation with Vibradol device switched off|"Patients in this arm will have~treatment by medications and rehabilitation~Sham vibrotactile treatment at medical center but with Vibradol device switched off~abdominal breath exercises at home~non stimulation on allodynia area"
2998834|NCT02571010|Other|Standard Medical treatment|Observational group, treated as usually by medications and rehabilitation.
2998835|NCT02570997|Active Comparator|CT1812|"In cohorts 1-6, 8 subjects will be enrolled. 6 subjects will receive CT1812. Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.~Should an MTD not be identified, additional cohorts at higher doses may be enrolled. The maximum dose administered will not exceed 1350mg."
2998836|NCT02570997|Placebo Comparator|Matching Placebo|In cohorts 1-6, 8 subjects will be enrolled. 6 subjects will receive matching placebo.
2998837|NCT02570984|Active Comparator|Active|omalizumab 0.016 mg/kg/IU total IgE
2998838|NCT02570984|Placebo Comparator|Placebo|looks like active drug
2998839|NCT02570971|No Intervention|Control|Patients will receive supportive care measures.
2998840|NCT02570971|Experimental|Investigational|Patients will receive 500mL of 20% mannitol
2998841|NCT02570958|Experimental|Indocyanine green|
2998842|NCT02570945|Experimental|Intervention|Pharmacist-physician medication review
2998843|NCT02570945|No Intervention|Control|
2998844|NCT02570932|Experimental|Autologous Mesenchymal Bone Marrow Cell|"All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow expanded Stem Cell (CME)~Pharmaceutical form: Suspension in autologous plasma cell Route of administration: Intrathecal in subarachnoid space by lumbar puncture. Dose: Total dose of 300 x 106 CME, given in 3 injections of 100 x 106 CME, at intervals of 3 months between each administration."
2998845|NCT02570919|Active Comparator|IGRT 45 Gy in 5 fractions of 9 Gy|Arm A: Hypofractionated IGRT at a prescription dose of 45 Gy in 5 fractions of 9 Gy delivered in five consecutive days
2998846|NCT02570919|Experimental|IGRT 24 Gy single dose|Arm B: single fraction IGRT at a prescription dose of 24 Gy
2998847|NCT02570893|Experimental|adjuvant chemoradiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.
2998848|NCT02570893|Experimental|adjuvant radiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.
2998849|NCT02570880|Experimental|Bread sample vs. glucose solution|glycemic index
2998850|NCT02570867||normal control group|Normal control group: healthy volunteers will be received Functional magnetic resonance imaging（fMRI) and eye examination including visual acuity, visual field, intraocular pressure, anterior chamber angle, corneal thickness and optic nerve fiber thickness one time.
2998851|NCT02570867||POAG group|POAG: The primary open angle glaucoma cases were will be received Functional magnetic resonance imaging（fMRI) and eye examination including visual acuity, visual field, intraocular pressure, anterior chamber angle, corneal thickness and optic nerve fiber thickness one time.
2998852|NCT02570854|Experimental|CSJ137|In Part 1 up to 48 subjects will receive a single dose of CSJ137. In Part 2, up to 40 patients will be randomized to one of 2 arms with equal allocation: one CSJ137 dose arm from Part 1 and a placebo arm. Each patient in Part 2 will receive up to 2 doses (repeat dose).
2998853|NCT02570854|Placebo Comparator|Placebo|In Part 2, up to 40 patients will be randomized to one of 2 arms with equal allocation: one CSJ137 dose arm from Part 1 and a placebo arm. Each patient in Part 2 will receive up to 2 doses (repeat dose).
2998854|NCT02570841|Active Comparator|Capsaicin|Treatment with Topical High dose Capsaicin
2998855|NCT02570841|Placebo Comparator|Placebo|Treatment with Topical Placebo
2998856|NCT02570828|Experimental|Thermal imaging|All subjects in the study will have thermal images of the chest taken using the FLIR ONE attachment to an iPhone.
2998857|NCT02570815|Experimental|indocyanine green|Non-toxic, fluorescent dye
2998858|NCT02570802|Other|ultrasound of peripheral nerves|Ultrasonographic examination
2998859|NCT02570789|Experimental|patients with sunitinib or pazopanib|This will be a non-randomized, proof-of-concept, prospective, longitudinal, multi-center study in patients with metastatic clear cell renal cell carcinoma with good or intermediate risk (based on MSKCC criteria) treated with sunitinib or pazopanib in first line.
2998860|NCT02570776||observation|Cohort of patients for Endoscopy & they are assessed for Helicobacter pylori through the histopathology & also throgh C14 C UBT.
2998861|NCT02570763|Experimental|Active Stimulation|Active tDCS administration during the first 20 minutes of each of the six therapy sessions.
2998862|NCT02570763|Sham Comparator|Sham Stimulation|Sham tDCS administration during the first 20 minutes of each of six therapy sessions.
2998863|NCT02570750||Group 1: smokers patients group|smokers (more than 10 cigarettes per day)
2998864|NCT02570750||Group 2 : non-smokers patients group|Smoking status will be classified as current and never/former. Former smokers will be defined as those who had stopped smoking at least 1 year before being interviewed for this study
2998867|NCT02570724|Active Comparator|Blood Patch arm|Standard of care arm: injection of autologous blood approximately 40 mL of blood sample into the epidural space at a rate of 1 ml / about 5 seconds.
2998868|NCT02570724|Active Comparator|"Drug: injection of HES  Voluven®  patch arm"|"Drug: injection of HES  Voluven®  into the epidural space of 15 to 30 ml at a rate of 1 ml / about 5 seconds"
2998869|NCT02570711|Experimental|Regimen 1|ACP-196 and nab-paclitaxel and gemcitabine
2998870|NCT02570711|Experimental|Regimen 2|Nab-paclitaxel and gemcitabine
2998871|NCT02570685|Experimental|Reflective Interpersonal Gratitude|An interpersonal gratitude journal, designed to foster gratitude for one's existing social relationships, by writing and reflecting on people and positive daily encounters for which one is grateful.
2998872|NCT02570685|Experimental|Reflective-Behavioral Gratitude|An interpersonal gratitude journal, designed to foster gratitude for one's existing social relationships, by writing and reflecting on people and positive daily encounters for which one is grateful. In addition participants are asked to choose a friend express this gratitude to them at the end of each week.
2998873|NCT02570685|Active Comparator|Neutral Control Journal|Write about and reflect on things that occurred over the course of the day.
2998874|NCT02570672|Experimental|Metformin|Subjects will be randomized to metformin (titrated up to 1000 mg twice daily, as tolerated)
2998875|NCT02570672|Placebo Comparator|Placebo|Subjects will be randomized to metformin (titrated up to 1000 mg twice daily, as tolerated) vs. placebo.
2998876|NCT02570659|No Intervention|Information Folder|A folder with advise and exercises used by physiotherapeutic clinic of Södersjukhuset Hospital (Treatment as usual)
2998877|NCT02570659|Experimental|Information Video|A multiprofessional information video
2998878|NCT02570646|Experimental|QA-DDS|Patients will receive exposure to the QA-DDS tool from their dental care practitioner.
2998879|NCT02570633|Experimental|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
2998880|NCT02570633|Placebo Comparator|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
2998881|NCT02570620|Experimental|Observational cohort of patients|Patients will benefit from an ultrasonography of the cervix through endovaginal before induction of prostaglandins
2998882|NCT02570594|Other|healthy volunteers|
2998883|NCT02570581|Placebo Comparator|Plain jelly control|Plain jelly control
2998884|NCT02570581|Active Comparator|Jelly with: Paracetamol|"Jelly with:~Paracetamol"
2998885|NCT02570581|Active Comparator|Jelly with Furosemide|Jelly with Furosemide
2998886|NCT02570581|Active Comparator|Jelly with Levothyroxine sodium salt|Jelly with Levothyroxine sodium salt
2998887|NCT02570581|Active Comparator|Jelly with memantine|Jelly with memantine
2998888|NCT02570581|Active Comparator|jelly with zopiclone|Jelly with zopiclone
2998889|NCT02570581|Active Comparator|jelly with alprazolam|elly with alprazolam
2998890|NCT02570581|Active Comparator|jelly with Oxazepam|Jelly with Oxazepam
2998891|NCT02570581|Active Comparator|jelly with donepezil|jelly with donepezil
2998892|NCT02570581|Active Comparator|Jelly with clopidogrel|jelly with clopidogrel
2998893|NCT02570581|Active Comparator|jelly with ramipril|jelly with ramipril
2998894|NCT02570581|Active Comparator|jelly with Paracetamol + Furosemide + Levothyroxine sodium sa|Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
2998895|NCT02570581|Placebo Comparator|Plain apple compote control|Plain apple compote control
2998896|NCT02570581|Active Comparator|Apple compote Paracetamol|Apple compote Paracetamol
2998897|NCT02570581|Active Comparator|Apple compote Furosemide|Apple compote Furosemide
2998898|NCT02570581|Active Comparator|Apple compote Levothyroxine sodium salt|Apple compote Levothyroxine sodium salt
2998899|NCT02570581|Active Comparator|Apple compote Memantine|Apple compote Memantine
2998900|NCT02570581|Active Comparator|Apple compote Zopiclone|Apple compote Zopiclone
2998901|NCT02570581|Active Comparator|Apple compote Alprazolam|Apple compote Alprazolam
2998902|NCT02570581|Active Comparator|Apple compote Oxazepam|Apple compote Oxazepam
2998903|NCT02570581|Active Comparator|Apple compote Donepezil|Apple compote Donepezil
2998904|NCT02570581|Active Comparator|Apple compote Clopidogrel|Apple compote Clopidogrel
2998905|NCT02570581|Active Comparator|Apple compote Ramipril|Apple compote Ramipril
2998906|NCT02570581|Active Comparator|Apple Paracetamol Furosemide Levothyroxine NACL Memantine Zopi|Apple Paracetamol Furosemide Levothyroxine NACL Memantine Zopiclone Alprazolam
2998907|NCT02570568|Active Comparator|Conventional Venepuncture|Veins will be identified by a combination of visualization and palpation. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
2998908|NCT02570568|Experimental|Veinlite|Placing Veinlite onto the skin will cause the outlines of the veins to show up. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
2998940|NCT02570321|Experimental|Bacterial ulcer cross-linking|Standard of care topical treatment for bacterial ulcer plus cross-linking
2998941|NCT02570321|Active Comparator|Bacterial ulcer control|Standard of care topical treatment for bacterial ulcer
2998909|NCT02570568|Experimental|Pen-torch Transillumination|The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
2998910|NCT02570542|Active Comparator|3-4 x 10^6 CD34+ stem cells/kg|Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.
2998911|NCT02570542|Experimental|6-8 x10^6 CD34+ stem cells/kg|Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.
2998912|NCT02570529|Experimental|Albis®|The intervention group
2998913|NCT02570529|Placebo Comparator|Placebo|The placebo comparator group
2998914|NCT02570516|Active Comparator|Indigo carmine colonoscopy|Colonoscopy using indigo carmine is performed in second place
2998915|NCT02570516|Experimental|NBI colonoscopy|Colonoscopy using NBI is performed in first place
2998916|NCT02570503|Experimental|ROP/KET/CLON/EPI/SAL|Ropivacaine (ROP) (5mg/ml)- 50ml Ketorolac (KET) (30mg/ml)- 1ml Clonidine (CLON) (0.1mg/ml)- 0.8ml Epinephrine (EPI) (1mg/ml)- 0.5ml 0.9% sodium chloride SAL)--47.7 ml
2998917|NCT02570503|Placebo Comparator|Placebo|0.9% Sodium Chloride- 100ml
2998918|NCT02570490|Experimental|CEM-102 (Sodium fusidate)|1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy (10 days total)
2998919|NCT02570490|Active Comparator|Linezolid|600 mg by mouth every 12 hours for 10 days
2998920|NCT02570477|Active Comparator|Fecal Microbiota Transplantatio|Fecal Microbiota Transplantation of stool from healthy donor to recipient.
2998921|NCT02570477|Active Comparator|Standard Therapy|125mg Vancomycin four times per day
2998922|NCT02570464|Experimental|Patients undergoing aortic aneurysm surgery with RIPC|Blood drawn is done for patient undergoing elective open infrarenal abdominal aortic aneurysm repair surgery with Remote ischemic preconditioning (RIPC)
2998923|NCT02570464|Sham Comparator|Patients undergoing aortic aneurysm surgery without RIPC|Blood drawn is done for patient undergoing elective open infrarenal abdominal aortic aneurysm repair surgery without Remote ischemic preconditioning (RIPC)
2998924|NCT02570451||undergoing any elective SDA surgical procedure|500 patients Patient Survey Independent Activities of Daily Living Score Sheet Geriatric Depression Scale Short Form Activities of Daily Living Score Sheet Grip Strength Mini Cog RAND 36-Item Short Form Health Survey Confusion Assessment Method (CAM)
2998925|NCT02570451||scheduled for elective joint replacement surgery|Patient Survey Independent Activities of Daily Living Score Sheet Geriatric Depression Scale Short Form 211 patients Activities of Daily Living Score Sheet Grip Strength Mini Cog RAND 36-Item Short Form Health Survey Confusion Assessment Method (CAM)
2998926|NCT02570438||Older surgical patients|older patients (≥ 65 years of age) presenting to Massachusetts General Hospital (MGH) or Newton-Wellesley Hospital (NWH) for elective noncardiac, non-neurological surgery requiring hospital admission
2998927|NCT02570425|Placebo Comparator|Spiromax followed by Turbohaler|Training on BF Spiromax followed by SYMBICORT Turbohaler
2998928|NCT02570425|Placebo Comparator|Turbohaler followed by Spiromax|Training on SYMBICORT Turbohaler followed by BF Spiromax
2998929|NCT02570399|Experimental|Lymph nodal metastatic lesions|Oligometastatic patients with abdominal-pelvic lymph nodes
2998930|NCT02570386|Active Comparator|Control arm|Women allocated to the control arm will either undergo fresh embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.
2998931|NCT02570386|Active Comparator|Intervention arm|Fresh embryo transfer will not be undertaken in this group. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.
2998932|NCT02570373|Experimental|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
2998933|NCT02570360|Active Comparator|exercise|Participants will engage in their outpatient treatment program as-usual, but additionally complete 30mins of moderately intense aerobic exercise 3 times per week for 6 weeks. They will complete 6 weeks of treatment, totaling 18 sessions with exercise.
2998934|NCT02570360|Placebo Comparator|treatment-as-usual|Participants will engage in their outpatient treatment program as-usual,but additionally complete 6 weekly, hour-long visits to complete questionnaires. They will complete 6 weeks of treatment (6 sessions total).
2998935|NCT02570347|Active Comparator|Routine use arm|"All participants allocated to this arm will be given~Injection Tetanus toxoid 0.5 ml intramuscularly Stat~Antibiotic (Co-amoxiclav) will be given to all patients for a minimum duration of 5 days.~Daily clinical assessment would be done. Change of antibiotics is allowed if clinical failure occurs.~Use of antibiotics for emergent indications unrelated to the bitten limb such as nosocomial infections would be allowed at the treating physician's discretion."
2998936|NCT02570347|Experimental|Clinically-directed use arm|"Participants allocated to this arm will be given~Injection Tetanus toxoid 0.5 ml intramuscularly Stat~Daily clinical assessment would be done. Antibiotic (Co-amoxiclav) will be started only if clinical failure occurs.~Use of antibiotics for emergent indications unrelated to the bitten limb such as nosocomial infections would be allowed at the treating physician's discretion."
2998937|NCT02570334|Experimental|HIV-infected children diagnosed before 7 months of life|HIV-infected children diagnosed before 7 months of life
2998938|NCT02570334|Experimental|HIV-exposed uninfected children|HIV-uninfected children born to HIV-infected mothers
3030932|NCT02355808|No Intervention|Superfast|
2998942|NCT02570321|Experimental|Fungal ulcer cross-linking plus natamycin|Standard of care topical treatment for fungal ulcer with natamycin plus cross-linking
2998943|NCT02570321|Active Comparator|Fungal ulcer control with natamycin|Standard of care topical treatment for fungal ulcer with natamycin
2998944|NCT02570321|Experimental|Fungal ulcer cross-linking plus amphotericin|Standard of care topical treatment for fungal ulcer with amphotericin plus cross-linking
2998945|NCT02570321|Active Comparator|Fungal ulcer control with amphotericin|Standard of care topical treatment for fungal ulcer with amphotericin
2998946|NCT02570308|Experimental|Dose escalation|Dose escalation cohorts of the intra-patient escalation regimen
2998947|NCT02570308|Experimental|Dose expansion|Dose expansion cohort with the recommended phase 2 dose of the intra-patient dose escalation regimen
2998948|NCT02570295|Experimental|Swiss Army Physical Fitness Training|"Sport according to the new sport concept (Swiss Army Physical Fitness Training) of the Swiss Armed Forces"
2998949|NCT02570295|No Intervention|Traditional Sport Concept|Sport according to the traditional sport concept of the Swiss Armed Forces
2998950|NCT02570282|Experimental|Sildenafil|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
2998951|NCT02570282|Placebo Comparator|Placebo|Placebo IP will be the same as SST-6007 without the active ingredient, sildenafil citrate. It will be matched in appearance, smell, consistency, and color to SST-6007
2998952|NCT02570269|Active Comparator|AuraGain|The patient will get a fiberoptic Intubation via the AuraGain larynxmask
2998953|NCT02570269|Placebo Comparator|Slotted Guedeltubus|The patient will get a fiberoptic intubation via the slotted Guedeltubus
2998954|NCT02570256|Experimental|Deficit-fields to reduce error|We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
2998955|NCT02570256|Experimental|Deficit-fields to expand range of motion|Amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
2998956|NCT02570256|Experimental|Deficit-fields to improve function|Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
2998957|NCT02570243|Active Comparator|Standard dose of Heparin|50IU/Kg heparin intravenously
2998958|NCT02570243|Experimental|High dose of Heparin|100IU/Kg heparin intravenously
2998959|NCT02570230|Placebo Comparator|Control|NSS infusion
2998960|NCT02570230|Experimental|Ketamine|Ketamine 0.2 mg/kg/hr intravenous infusion
2998961|NCT02570217|Experimental|HHHFNC|The patients receive respiratory support by mean of Heated Humidified High Flow Nasal cannula
2998962|NCT02570217|Active Comparator|NCPAP|Patients receive respiratory support by Nasal Continuous Positive Airways Pressure(NCPAP)
2998963|NCT02570204|Experimental|Self-assessment of abortion outcome|Patients enrolled in the study will self-assess the outcomes of their medical abortion with the aid of a multi-level pregnancy test (MLPT) which they will perform at home.
2998964|NCT02570191|Experimental|Peginterferon alfa-2a|Participants received 180 micrograms (uG) of Pegasys (0.5 milliliter [mL] solution) once a week subcutaneously for 48 weeks.
2998965|NCT02570178|No Intervention|standard practice advice|standard practice advice
2998966|NCT02570178|Other|balance training|balance training using the Nintendo™ Wii console and its balance board.
2998967|NCT02570165|Experimental|Batefenterol 37.5 mcg|Each subject will receive batefenterol 37.5 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
2998968|NCT02570165|Experimental|Batefenterol 75 mcg|Each subject will receive batefenterol 75 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
2998969|NCT02570165|Experimental|Batefenterol 150 mcg|Each subject will receive batefenterol 150 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
2998970|NCT02570165|Experimental|Batefenterol 300 mcg|Each subject will receive batefenterol 300 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
2998971|NCT02570165|Experimental|Batefenterol 600 mcg|Each subject will receive batefenterol 600 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
2998972|NCT02570165|Experimental|UMEC/VI 62.5/25 mcg|Each subject will receive UMEC/VI 62.5/25 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
2998973|NCT02570165|Experimental|Placebo|Each subject will receive placebo (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
2998974|NCT02570152|Experimental|AFI Group|Population living in randomly selected households in geographically-defined communities. Households including at least one member aged less than 18 years will be considered eligible if at least one adult (aged no more than 50 years) and one child (aged less than 18 years) consent (and assent if applicable) to participate in the study.
2998975|NCT02570139|Experimental|Cavilon Advanced Skin Protectant|Product applicator contains liquid barrier applied on buttocks/thighs with it drying rapidly to durable barrier film. It's applied 3x/per week.
2998976|NCT02570139|Active Comparator|ConvaTec Sensi-Care Protective Barrier|Marketed product applied following manufacturer's recommendation. The product is 15% zinc oxide with petrolatum.
2998977|NCT02570126|Experimental|VAR_HSA_F Group|2 doses of Varilrix HSA-free vaccine, one at Visit 1 (Day 0) and the other at Visit 2 (Day 42), will be given to the subjects in this group. The vaccine will be administered subcutaneously in the triceps region of the left arm
2998978|NCT02570126|Active Comparator|VAR Group|2 doses of Varilrix™ vaccine, one at Visit 1 (Day 0) and the other at Visit 2 (Day 42), will be given to the subjects in this group. The vaccine will be administered subcutaneously in the triceps region of the left arm
2999015|NCT02569840|Other|Amino Acid Feed|An amino acid based multi-nutrient powdered feed
2999087|NCT02569372|Experimental|GC1102 120,000 IU(Multiple does)|GC1102 120,000 IU(Multiple does) I.V.
2998979|NCT02570113|Experimental|Renal Denervation by Neurolysis|Infusion of 0.6 ml of dehydrated alcohol (not less than 95% by volume) into the peri-adventitial space of the renal artery, to achieve renal denervation by neurolysis, via three simultaneous deployed needles, situated at the distal end of the Peregrine System Infusion Catheter.
2998980|NCT02570100|Experimental|Biological collection|Before, during and after their treatment by chemotherapy, patients will undergo laboratory examinations.
2998981|NCT02570087|Active Comparator|Successful CTO PCI|Successful chronic total coronary occlusion percutaneous intervention (CTO-PCI)
2998982|NCT02570087|No Intervention|Unsuccessful CTO PCI|Unsuccessful chronic total coronary occlusion percutaneous intervention (CTO-PCI)
2998983|NCT02570074|Experimental|Fosfomycin - 3 doses QoD|Fosfomycin given as a 3 gm dose, every other day for 3 doses
2998984|NCT02570074|Experimental|Fosfomycin - 7 doses QD|Fosfomycin given as a 3 gm dose, once a day for 7 doses
2998985|NCT02570061|Experimental|telephone|Information about the Calmette study was given by telephone
2998986|NCT02570061|Active Comparator|face-to-face|Information about the Calmette study was given face-to-face at a consultation at the hospital
2998987|NCT02570048||Experimental: Mutebutton intervention|This one armed trail will recruit participants who have been diagnosed with Tinnitus for a minimum of 6 months. Participants will use the Mutebutton device in their own home for 30 minutes every day for 12 weeks. The intervention requires sitting in a quiet space with the earphones on and the tongue tip placed on their tongue.
2998988|NCT02570035||Mirabegron group|Subjects with overactive bladder and cardiovascular disease prescribed mirabegron
2998989|NCT02570022|Experimental|Liposomal bupivacaine|Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
2998990|NCT02570022|Active Comparator|Inter-scalene nerve block|Patients in this group received preoperative ultrasound guided inter-scalene nerve blocks by senior anesthesiologist using ropivicaine.
2998991|NCT02570009|Active Comparator|TEAMS|
2998992|NCT02570009|Active Comparator|TEAMS+|
2998993|NCT02569996|Experimental|Rituximab|Participants will receive rituximab 375 milligrams per meter square (mg/m^2) every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
2998994|NCT02569983||Observational cohort|Observational study - all suspected or confirmed ovarian cancer patients
2998995|NCT02569970|Active Comparator|FLUOXETINE|4 weeks of treatment before video-EEG monitoring
2998996|NCT02569970|Placebo Comparator|PLACEBO|1 month of treatment before EEG video.
2998997|NCT02569957|Active Comparator|Arm I (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 (+/- 1 day window for each treatment day). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2998998|NCT02569957|Experimental|Arm II (topotecan hydrochloride, acetylcysteine)|Patients receive topotecan hydrochloride as in Arm I. Patients also receive acetylcysteine IV over 60 minutes on days 1, 8, 15, and 22 (+/- 1 day window for each treatment day) and acetylcysteine PO BID on days 2-7, 9-14, 16-21, and 23-28, unless administration window was utilized. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2998999|NCT02569944|Active Comparator|perineal bag|Perineal bag was placed in infants to collect an urine sample.
2999000|NCT02569944|Experimental|Bladder stimulation|Bladder stimulation technique was used in infants of this arm to obtain an urine sample
2999001|NCT02569931|Experimental|study group|"36 participants recruited aged between 18 to 50 years of age~Participants will be considered eligible for the study group if they have had two or more episodes of patellar dislocation or multiple episodes of subluxation with at least one of the following:~i. Positive patellar apprehension test ii. Tenderness along the medial retinaculum iii. Abnormal patellar tracking or position.~The study group will undergo gait analysis and electromyography before surgery and 6 months after surgery.~During surgery the study group will undergo intra-operative tracking and pressure measurements."
2999002|NCT02569931|Other|control group|"36 participants recruited aged between 18 to 50 years of age, matched for age and gender with the study group. Control participants should be healthy subjects with no history of knee injury or surgery.~The control group will undergo gait analysis and electromyography."
2999003|NCT02569918|Experimental|Surface electrical stimulation|Operation of hand prosthesis with surface electrical sensory feedback
2999004|NCT02569905|Active Comparator|Groups Parecoxib sodium|Fifty-one, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
2999005|NCT02569905|Active Comparator|Groups Flurbiprofen|Fifty-two, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
2999006|NCT02569905|Placebo Comparator|Group Saline|Fifty-one, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
2999007|NCT02569892|Experimental|Laser Arm|Sub-threshold laser utilizing Pascal laser with endpoint-management software
2999008|NCT02569892|Sham Comparator|Sham Laser Arm|Sham laser treatment
2999009|NCT02569879||Infants Group|"All infants ≤12 months of age in Bogota, reported with pertussis disease in the national databases of Bogota, between January 2005 and December 2014.~All infants ≤12 months of age in Bogota, deceased between January 2005 and December 2014 due to pertussis disease (primary diagnosis), based on death certificate information.~All infants ≤12 months of age in Bogota, with ALRTI, between January 2005 and December 2014.~All infants ≤12 months who have received primary pertussis vaccination in Bogota, between January 2005 and December 2014."
2999010|NCT02569879||Pregnant women Group|• Pregnant women will be included in the study to assess the vaccination coverage of Boostrix from March 2013 to December 2014
2999011|NCT02569866|Active Comparator|Antibiotics Group|Capsules containing cephalexin/500mg will be administrated to the subjects, 4 times daily, for seven days during the postoperative period of reduction mammaplasty.
2999012|NCT02569866|Placebo Comparator|Placebo Group|Capsules containing placebo/500mg will be administrated to the subjects, 4 times daily, for seven days during the postoperative period of reduction mammaplasty.
2999013|NCT02569853|Experimental|DFN-11|DFN-11 active injection upon occurrence of migraine
2999014|NCT02569853|Placebo Comparator|Placebo|Placebo injection upon occurrence of migraine
3030933|NCT02355808|Other|Non Superfast GP|
2999016|NCT02569827|Placebo Comparator|Cohort 1|"Placebo Q6H for 5 days~A total of 72 participants (18 participants per group assuming up to two drop-outs per group) will be assigned in a randomised double-blind fashion."
2999017|NCT02569827|Active Comparator|Cohort 2|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg)
2999018|NCT02569827|Active Comparator|Cohort 3|Modipafant 100 mg Q12H alternating with placebo Q12H 5 days (total of 10 modipafant doses = 1000 mg)
2999019|NCT02569827|Active Comparator|Cohort 4|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg total).
2999020|NCT02569814|Other|Group 1|Subjects of Group 1 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 1 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 15th day.
2999021|NCT02569814|Other|Group 2|Subjects of Group 2 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 2 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 15th day.
2999022|NCT02569801|Active Comparator|Fulvestrant|Participants will receive 500 milligrams (mg) of fulvestrant as two intramuscular injections (250 mg each) on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.
2999023|NCT02569801|Experimental|GDC-0810|Participants will receive three 200 mg tablets (total dose = 600 mg) of GDC-0810 orally once daily until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.
2999024|NCT02569788|Experimental|CIRT arm|treated with carcon ion radiotherapy.
2999025|NCT02569775|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
2999026|NCT02569762|Experimental|Sucralose-Aspartame|Generic name: sucralose or aspartame, Dosage form: powder, Duration:seven days.
2999027|NCT02569762|Experimental|Aspartame-Sucralose|Generic name: aspartame or sucralose, Dosage form: powder, Duration:seven days.
2999028|NCT02569749||Group 1|Patients with pacemaker indication (pacemaker already implanted or to be implanted)
2999029|NCT02569749||Group 2|Patients with ICD or CRTD therapy indication (device already implanted or to be implanted)
2999030|NCT02569749||Group 3|Patients with heart failure an preserved LVEF (40-50%)
2999031|NCT02569749||Group 4|Patients with heart failure and reduced LVEF (<40%)
2999032|NCT02569736||Tocilizumab|Patients with active moderate to severe RA fulfilling ACR criteria and requiring TCZ treatment, according to the EU label and French authority recommendations, who accept to enter the study and to sign the informed consent.
2999033|NCT02569736||Methotrexate|Patients with active moderate to severe RA fulfilling ACR criteria and requiring MTX treatment, according to the EU label and French authority recommendations, who accept to enter the study and to sign the informed consent.
2999034|NCT02569736||Healthy Controls|Healthy controls will be defined as people non-affected by an inflammatory disease (such as RA, ankylosing spondylitis, lupus…). This group will be constituted with patients affected by sciatica, osteoarthritis, osteoporosis…
2999035|NCT02569723|Experimental|carbon C 14 oxaliplatin and oxaliplatin|Patients receive carbon C 14 oxaliplatin microdose IV over 120 minutes. Beginning not more than 4 weeks after the initial carbon C 14 oxaliplatin microdose administration, patients receive FOLFOX6 comprised of leucovorin calcium IV, fluorouracil IV over 2 hours (over 46-48 hours via ambulatory infusion pump on days 1 and 2), and oxaliplatin (contain carbon C 14 microdose course I only) IV over 2 hours on day 1.
2999036|NCT02569710|Experimental|Cohorts 1 and 2 (Without Cirrhosis) : AL-335+ODV+SMV|Treatment-naïve non-cirrhotic Hepatitis C virus (HCV)-infected participants will receive AL-335 and Odalasvir (ODV) with Simeprevir (SMV) for 8 weeks.
2999037|NCT02569710|Experimental|Cohort 1b (Without Cirrhosis) : AL-335+ODV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV for 8 weeks.
2999038|NCT02569710|Experimental|Cohort 3 (Without Cirrhosis) : AL-335+ODV+SMV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV with SMV for 6 weeks.
2999039|NCT02569710|Experimental|Cohort 4 (Without Cirrhosis) : AL-335+ODV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV up to 8 or 12 weeks.
2999040|NCT02569710|Experimental|Cohort 5 (Without Cirrhosis) : AL-335+ODV + SMV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV with SMV up to 8 or 12 weeks.
2999041|NCT02569710|Experimental|Cohorts 6, 7, 8 and 12 (With Cirrhosis) : AL-335+ODV+SMV|Treatment naïve or treatment experienced HCV-infected participants with compensated cirrhosis will receive AL-335 and ODV with SMV for 8 weeks.
2999042|NCT02569710|Experimental|Cohorts 9, 10 and 11 (With Cirrhosis) : AL-335+ODV+SMV|Treatment naïve or treatment experienced HCV-infected participants with compensated cirrhosis will receive AL-335 and ODV with SMV for 12 weeks.
2999043|NCT02569710|Experimental|Cohorts 12 to 15: AL-335+ODV With/without SMV|Based on safety, pharmacokinetic (PK), and viral load data, the treatment duration (4 to 12 weeks) and dose levels (AL-335: 400-1,200 milligram [mg], ODV: 25-50 mg with/without SMV: 75-150 mg) may be changed for ongoing and future cohorts (up to 15) after obtaining agreement from the Sponsor and the Principal Investigator.
2999044|NCT02569697|Other|HEC Placebo Gel|The placebo gel will come in pre-filled individual applicators (4mL). Placebo gel is clear in color and contains HEC as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide.
2999045|NCT02569697|Other|Placebo Vaginal Insert|The placebo vaginal inserts will be supplied in white plastic bottles. The placebo inserts are white to off-white in color, uncoated and bullet-shaped. The inserts are composed of ingredients generally recognized as safe including isomalt, xylitol, polyvinylpyrrolidone K 30, hydroxypropyl methylcellulose, poloxamer, and sodium stearyl fumarate. The inserts are approximately ½ to 1 inch long and approximately ¼ to ½ inch thick, similar in size to vaginal tablets that are currently available.
2999046|NCT02569697|Other|Placebo Vaginal Film|The placebo vaginal films will be individually wrapped. The placebo vaginal film is a thin, clear to translucent sheet with dimensions of 2 in x 2 in. The ingredients include hydroxyethyl cellulose (HEC), hydroxypropyl methyl cellulose (HPMC, E5), sodium carboxymethyl cellulose (NaCMC), and glycerin.
2999084|NCT02569372|Experimental|GC1102 180,000 IU(Single does)|GC1102 180,000 IU(Single does) I.V.
2999047|NCT02569697|Other|Placebo Intravaginal ring (IVR)|The placebo IVRs will be supplied in individual foil pouches. Each ring has a longer white to off-white segment and a shorter transparent/translucent segment, and ingredients include polyurethane, glycerin, water and modified starch.
2999048|NCT02569684|Active Comparator|Arm A|Prebiotic fibers: Oligofructose and inulin
2999049|NCT02569684|Placebo Comparator|Arm B|Maltodextrin
2999050|NCT02569671|Other|Immediate Placement - Test|Straumann Bone Level Tapered Implant - Immediate Placement - Implant is placed at the time of tooth extraction to replace a single tooth.
2999051|NCT02569671|Other|Delayed Placement - Control|Straumann Bone Level Tapered Implant - Delayed Placement - Implant is placed after 16-18 weeks of healing to replace a single tooth.
2999052|NCT02569658|Experimental|Tranexamic Acid Group|Group will be administered 1 gram tranexamic acid IV bolus (10 ml solution) 10 minutes prior to incision.
2999053|NCT02569658|Placebo Comparator|Placebo Group|Group will be administered 10 ml normal saline placebo IV bolus 10 minutes prior to incision
2999054|NCT02569645|Experimental|Single Arm - Rosuvastatin|This is a single arm, of Rosuvastatin (Crestor®) 40 mg orally daily starting 2 weeks prior to the initiation of radiation at week 1 and stopped 4 weeks after the completion of radiation at the start of week 12 or 13, depending on whether 25 or 30 fractions of radiotherapy are given.
2999055|NCT02569632|Experimental|Open Label: MenB-FHbp|Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)
2999056|NCT02569619|Experimental|Activity Intervention|The activity intervention is MoVo-LISA (Göhner & Fuchs, 2007). A psychological program with two group sessions of 90 minutes and one one-on-one session of about 15 minutes. The patients develop aims for their health, ideas, how to reach these aims through physical activity and make detailed plans, how to implement activity in their everyday routine. Difficulties and barriers are discussed.
2999057|NCT02569619|Active Comparator|Healthy Diet Intervention|The healthy diet intervention is a modification of MoVo-LISA. A psychological program with two group sessions of 90 minutes and one one-on-one session of about 15 minutes. The patients develop aims for their health, ideas, how to reach these aims through a healthy diet and make detailed plans, how to implement a healthy diet in their everyday routine. Difficulties and barriers are discussed.
2999058|NCT02569606||Timeframe 2005 - 2007|Data of timeframe 2005 up to 2007 will be included
2999059|NCT02569606||Timeframe 2012 - 2014|Data of timeframe 2012 up to 2014 will be included
2999060|NCT02569593|Other|RYGB-patient|Patients with a planned RYGB at UZ Leuven will be recruited. Iron supplements, more specific Ferrodyn and Vista Ferrum will be administrated in these patients before and 1, 3, 6 and 12 months post-RYGB with at least 7 days between the administration of the different supplements.
2999061|NCT02569567||US elastography|"Participants who have the plan of liver transplantation or liver biopsy within 4 weeks will be screened from the outpatient clinic.~Two types of ultrasonographic elastography(US elastography) techniques including Smart-Shear Wave(SSW) imaging and transient elastography(TE) will be performed as a diagnostic method for hepatic fibrosis."
2999062|NCT02569554|Experimental|PF-06463922|each subject will receive four single doses of PF-06463922 without food, with food, with rabeprazole (without food), and one of the two new formulations without food.
2999063|NCT02569541|Experimental|CEM-102 (Sodium fusidate)|"1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy:~6 months of treatment; or~24 months of treatment (if continued on chronic suppressive therapy)"
2999064|NCT02569528||Patients|Patients of consenting providers will complete a short survey and interview.
2999065|NCT02569528||Providers|Physicians treating patients with atrial fibrillation will complete a short survey and interview.
2999066|NCT02569515|Experimental|Epoetin Beta|Patients will be administered 3 times (X) 30 International unis per kilogram(IU/Kg body weight per week of eopetin beta subcurtaneously using the device RecoPen. The dosage could be increased every 4 weeks by 3 X20 IU/Kg.
2999067|NCT02569502|Experimental|Enfuvirtide|Participants will receive 180 milligrams (mg) of enfuvirtide adminstered twice daily as subcutaneous injections
2999068|NCT02569489|Experimental|HBI-8000, Paclitaxel, Trastuzumab|HBI-8000 at the assigned dose twice weekly while receiving weekly paclitaxel and trastuzumab for a minimum of 8 weeks (2 treatment cycles)
2999069|NCT02569476|Experimental|BGB-3111 and obinutuzumab|In the dose-escalation part, the dose levels and regimens will be evaluated. In the indication-specific expansion cohorts, patients will be assigned to different cohorts based on histology type.
2999070|NCT02569463|Experimental|Low-does rhIL-2 therapy|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks
2999071|NCT02569450||Intervention arm|Hospitals randomly assigned to the intervention arm with surgical outcomes monitoring
2999072|NCT02569450||Hospitals in control arm|Hospitals randomly assigned to the control arm without surgical outcome monitoring
2999073|NCT02569437|Experimental|Doxycycline|Doxycycline plus oral methylprednisolone and nasal saline sprays
2999074|NCT02569437|Placebo Comparator|Sugar pill|placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.
2999075|NCT02569424|Experimental|ventilated patients|Patient's position (Supine or Trendelenburg strict -20°)
2999076|NCT02569411|No Intervention|No Incentive|Those allocated to the control group will be contacted by email, mail, and phone, but will not receive a financial incentive
2999077|NCT02569411|Experimental|Incentive|Those allocated to the intervention group will be contacted by email, mail, and phone, and will be asked to provide the IPD from their RCT and they will be given a financial incentive.
2999078|NCT02569398|Experimental|Group 1|Participants will receive one atabecestat, 5 milligram (mg) tablet orally once daily up to 54 months.
2999079|NCT02569398|Experimental|Group 2|Participants will receive one atabecestat, 25 mg tablet orally once daily up to 54 months.
2999080|NCT02569398|Experimental|Group 3|Participants will receive one matching placebo tablet orally once daily up to 54 months.
2999081|NCT02569385||spontaneous breathing trials|spontaneous breathing trials in patients with prolonged weaning
2999082|NCT02569372|Experimental|GC1102 80,000 IU(Single does)|GC1102 80,000 IU(Single does) I.V.
2999083|NCT02569372|Experimental|GC1102 120,000 IU(Single does)|GC1102 120,000 IU(Single does) I.V.
3030934|NCT02355808|Other|Superfast Tailored Leaflet|
2999088|NCT02569372|Experimental|GC1102 180,000 IU(Multiple does)|GC1102 180,000 IU(Multiple does) I.V.
2999089|NCT02569372|Experimental|GC1102 240,000 IU(Multiple does)|GC1102 240,000 IU(Multiple does) I.V.
2999090|NCT02569359|Experimental|Shea nut oil|100% shea nut oil extract with 75% triterpene esters. Daily dosage is three 750 mg soft gel capsules (2250 mg/per day) taken in the morning for 3 months
2999091|NCT02569359|Placebo Comparator|Placebo|placebo which comprised 100% canola oil or starch mixed soybean oil
2999092|NCT02569346|Active Comparator|Triumeq whole|Single-dose Triumeq as a whole tablet in a fasted state
2999093|NCT02569346|Experimental|Triumeq crushed + breakfast|Single-dose crushed and suspended Triumeq in a fasted state
2999094|NCT02569346|Experimental|Triumeq crushed + drip feed|250 ml drip feed (Nutrison) followed by a single-dose crushed and suspended Triumeq
2999095|NCT02569333|Experimental|Educational Video|Subjects to have access to educational video during hospital stay
2999096|NCT02569333|No Intervention|Usual Care|Patients to receive usual care and will not have access to educational video.
2999097|NCT02569320|Experimental|Treatment (pomalidomide, dexamethasone, HDAC inhibitor AR-42)|Patients receive pomalidomide PO daily on days 1-21, dexamethasone PO BIW or TIW weeks 1-3, and HDAC inhibitor AR-42 PO BIW or TIW for weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2999098|NCT02569307|Active Comparator|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
2999099|NCT02569307|Active Comparator|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2mg once daily dose
2999100|NCT02569307|Active Comparator|Placebo|Placebo added to TAU
2999101|NCT02569307|Active Comparator|Minocycline Plus Omega-3 fatty acids|Minocycline+Omega-3 fatty acids added to TAU ,Minocyline will be administered in 200mg once daily dose and Omega-3 fatty acids 1.2 g taken as once daily dose
2999102|NCT02569294|Experimental|Choice 1: Yoga intervention|See intervention description
2999103|NCT02569294|Experimental|Choice 2: Hypnosis intervention|See intervention description
2999104|NCT02569294|Experimental|Choice 3: CBT intervention|See intervention description
2999105|NCT02569294|No Intervention|Control group|Participants who agreed not to participate in any of the interventions proposed.
2999106|NCT02569281|Experimental|US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks including best-evidence manual therapy and an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles. The exercise program will be asked to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks. In addition, they will receive one session of US-guided percutaneous electrolysis. This intervention consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
2999107|NCT02569281|Active Comparator|Eccentric exercise|Patients will receive one weekly session for 5 weeks including best-evidence manual therapy and an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles. The exercise program will be asked to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
2999108|NCT02569268||exposure population|No special intervention(s) .
2999109|NCT02569242|Experimental|Nivolumab Arm|Nivolumab 240 mg/body solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
2999110|NCT02569242|Active Comparator|Active Comparator Arm （Docetaxel/Paclitaxel）|"Docetaxel: Intravenously administered at a dose of 75 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~OR~Paclitaxel: Intravenously administered at a dose of 100 mg/m2 weekly for 6 weeks followed by 2-week drug holiday until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends"
2999111|NCT02569229||Patients with Cystic Fibrosis|Patients between 10-20 years of age with genetically determined cystic fibrosis followed at the university children`s hospital Basel and university children`s hospital Kinderklinik Bern, Switzerland. All patients will get the diagnostics for glucose tolerance with 3 different methods (CGMS, OGTT and optionally IVGTT).
2999112|NCT02569216|Experimental|Electrical Inhibition (EI) intervention|Electrical Inhibition (EI) uterine pacemaker is activated only when there is a preterm uterine contraction. The EI uterine pacemaker delivers a 1-15mA (20mA maximum) constant direct current for only 2 seconds only while there is a preterm uterine contraction.
2999113|NCT02569203|Placebo Comparator|control group|standard enteral nutrition
2999114|NCT02569203|Experimental|test group I|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
2999115|NCT02569203|Experimental|test group II|high-protein enteral nutrition of immune modulating nutrients without β-glucan
2999116|NCT02569190|Experimental|Walkbot|Receive conventional physical therapy (session I for 30 min/day) with Walkbot training 3 days a week for 8 weeks, 20 session in all.
2999117|NCT02569138|Experimental|Insole (Experimental)|specially designed insole, featuring hard and thin design, modified insole
2999118|NCT02569138|Experimental|Insole (Control)|usual insole found in footwear, non-modified insole
2999119|NCT02569125|Experimental|Everolimus (RAD001) 4.5 mg/m² daily over|Everolimus (RAD001) 4.5 mg/m² daily over 12 months. Patients will be on Everolimus (RAD001) therapy for 12 months; discontinuation can be necessary due to intolerable toxicity, withdrawal of consent, death or termination of the trial. After 12 months treatment is stopped. If there is progress of disease (see below) after end of therapy, re-start with Everolimus (RAD001) on a compassionate use is possible.
2999120|NCT02569112|Active Comparator|cryolipolysis|Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
2999121|NCT02569112|Experimental|cryolipolysis, multipolar RF, varipulse|Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
2999158|NCT02568800|Active Comparator|Usual Cefepime Infusion|Cefepime infusion should last no more than 30 minutes
2999159|NCT02568787|Experimental|Rice bran arabinoxylan compound (RBAC)|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
2999122|NCT02569099|Experimental|Intervention using standardised care|"Caregiver training /standardised care: where the participants (caregivers)s are trained on caring for relative who has survived a stroke once only for one hour using a developed curriculum.~Plus Conventional care: where the participants continue to receive the usual care as offered in protocols for treatment of stroke in Zimbabwe."
2999123|NCT02569099|No Intervention|Control|No training offered to caregivers but conventional care only where the people who have survived a stroke receive the usual care as offered in protocols for treatment of stroke in Zimbabwe.
2999124|NCT02569073|Experimental|Dronabinol|Patients who receive Dronabinol 5 mg, every other night, orally.
2999125|NCT02569073|Placebo Comparator|Placebo|Patients who receive Placebo every other night, orally
2999126|NCT02569060|Experimental|Immediate Intervention|"Participants randomized to the Intervention Arm will immediately begin a four-component intervention.~Testing and monitoring of blood glucose levels~Referral to and/or coordination with primary care provider~Diabetes-appropriate food packages~Diabetes self-management education and support"
2999127|NCT02569060|Active Comparator|Waitlist Control|"Participants randomized to the Waitlist Control arm will receive no intervention for six months, after which time they will begin a modified, four-component intervention.~Testing and monitoring of blood glucose levels~Referral to and/or coordination with primary care provider~Diabetes-appropriate food packages~Limited diabetes self-management education and support"
2999128|NCT02569047|Active Comparator|Atraumatic Restorative Treatment|The cavity will be prepared according to the ART (Atraumatic Restorative Treatments) steps and filled with the dental material Glass Ionomer Cement without local anesthesia.
2999129|NCT02569047|Experimental|Hall Technique|The cavity will not receive any preparation. A stainless crown will be placed and cemented with the dental material Glass Ionomer Cement without local anesthesia.
2999130|NCT02569034|Active Comparator|Young Adults|These participants will perform the Effort-Expenditure for Rewards Task (EEfRT) while an functional magnetic resonance imaging (fMRI) is performed. They will also complete a battery of both cognitive and anhedonia questionnaires.
2999131|NCT02569034|Experimental|Older Adults|These participants will perform the Effort-Expenditure for Rewards Task (EEfRT) while an functional magnetic resonance imaging (fMRI) is performed. They will also complete a battery of both cognitive and anhedonia questionnaires.
2999132|NCT02569021||Biphasic DBS stimulations|Subjects in this group will have Biphasic DBS stimulation setting performed, Unified Parkinson's Disease Rating Scale (UPDRS), Tremor Rating Scale (TRS), kinesia accelerometer assessment, Trigno wireless system (EMG) assessment and GaitRite walking assessment performed.
2999133|NCT02569008|Experimental|1 ml / Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 1 ml/Kg IV over 5 minutes
2999134|NCT02569008|Experimental|2 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 2 ml/Kg IV over 5 minutes
2999135|NCT02569008|Experimental|3 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 3 ml/Kg IV over 5 minutes
2999136|NCT02569008|Experimental|4 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 4 ml/Kg IV over 5 minutes
2999137|NCT02568995|Experimental|LIA|Local infiltration analgesia using a combination of ropivacaine 300 mg + ketorolac 30 mg + adrenaline 0.5 mg
2999138|NCT02568995|Active Comparator|Femoral nerve block|Ultrasound guided 3-in-1 block using 30 ml of 0.75% ropivacaine
2999139|NCT02568982||"De Novo patient with Cushing's disease"|
2999140|NCT02568969|Experimental|Lactate monitoring|The patients in the group will be subjected to the continuous perioperative monitoring of the venous blood lactate
2999141|NCT02568930||Heart Transplantation (HT)|The cohort includes advanced heart failure patients (60-80 years of age) listed for HT and their caregivers.
2999142|NCT02568930||Mechanical Circulatory Support (MCS)|The cohort includes advanced heart failure patients (60-80 years of age) scheduled for DT MCS and their caregivers.
2999143|NCT02568917|Active Comparator|Conventional Restoration|Conventional Restoration - Composite Resin (Bulk Fill)
2999144|NCT02568917|Experimental|Atraumatic Restorative Treatment|Atraumatic Restorative Treatment - Ketac Molar Easy Mix
2999145|NCT02568904||Alcohol binge|Healthy volunteers receive 2ml vodka 40% per kg bodyweight as a binge
2999146|NCT02568891|Active Comparator|Probiotic|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
2999147|NCT02568891|Placebo Comparator|Placebo|similar looking and tasting placebo without bacteria
2999148|NCT02568878|Experimental|Creatine monohydrate|5 grams of daily creatine monohydrate by mouth for 8 weeks
2999149|NCT02568865||Major Depressive Disorder|
2999150|NCT02568865||Healthy Volunteers|
2999151|NCT02568852|Active Comparator|group 1|Laparoscopic cholecystectomy in general anaesthesia
2999152|NCT02568852|Active Comparator|group 2|Laparoscopic cholecystectomy in combined anaesthesia (Spino epidural).
2999153|NCT02568839|Active Comparator|A|"docetaxel + trastuzumab sc + pertuzumab. Treatment with all three drugs is given on day 1, repeated every three weeks. Six courses of preoperative treatment. Response evaluations after every 2nd course. In case of no change (NC), treatment is switched to arm B.~Postoperatively, patients receive 2 courses of treatment with the combination epirubicin + cyclophosphamide (EC), followed by adjuvant trastuzumab, radiotherapy, eventually endocrine treatment."
2999154|NCT02568839|Experimental|B|"trastuzumab emtansine. Treatment is given on day 1, repeated every three weeks. Six courses of preoperative treatment. Response evaluations after every 2nd course. In case of no change (NC), treatment is switched to arm A.~Postoperatively, patients receive 4 courses of treatment with the combination epirubicin + cyclophosphamide (EC), followed by adjuvant trastuzumab, radiotherapy, eventually endocrine treatment."
2999155|NCT02568826|Experimental|IDN 5243|IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities for intramuscular administration in 4 mg/mL vials. It will be administered twice daily for 5 consecutive days with the first administration in the morning (8.00-10.00 AM) and the second in the evening (6.00-8.00 PM).
2999156|NCT02568813|Experimental|Scales passation|
2999157|NCT02568800|Experimental|Prolonged Cefepime Infusion|Cefepime infusions should last 4 hours at least
3030935|NCT02355808|Other|Superfast GP + Tailored Leaflet|
2999160|NCT02568787|Placebo Comparator|Placebo|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
2999161|NCT02568774|Experimental|Traditional Acupuncture|Acupoints which are empirical for treating OAB in terms of Traditional Chinese medicine theory are used (in the sequence of scalp reproduction area and motor area of the unaffected side, RN3, bilateral BL32, BL33, BL28, BL39). And Ear point urinary bladder, and Ear point uterus will be treated after removal of needles. Needles will be left for 30 minutes and then removed. Subjects will be treated with acupuncture 2 times per week for the first 2 weeks and 1 per week for the 3rd and 4th week.
2999162|NCT02568774|Other|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
2999163|NCT02568761|Active Comparator|Injection snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate. 0.5 ml of the solution will be implemented in three different regions of the submucosal layer of the soft palate, one median and two paramedians.
2999164|NCT02568761|Active Comparator|Oropharyngeal Exercises|Weekly sessions of myofunctional exercises under the supervision of a qualified professional, lasting about 30 minutes each, combined with daily exercises without supervision for a period of three months.
2999165|NCT02568748|Experimental|CIK with TACE for HCC stage B|HCC patients stage B treated with TACE and CIK as adjuvant therapy.
2999166|NCT02568748|Experimental|TACE only for HCC stage B|HCC patients stage B treated with TACE without receiving CIK cells infusion
2999167|NCT02568748|Experimental|CIK in HCC stage C or D|HCC stage C or D will receive supportive treatment in addition to CIK cells infusion
2999168|NCT02568748|No Intervention|Supportive treatment in HCC stage C or D|HCC stage C or D will receive supportive treatment only .
2999169|NCT02568735|Experimental|Etoricoxib|Etoricoxib 60mg if body weight≤ 60kg, 90mg if body weight 61-90kg and 120mg if body weight> 90kg by mouth
2999170|NCT02568735|Active Comparator|Dexketoprofen|Dexketoprofen 0,5 mg/kg up to 50 mg intravenously
2999171|NCT02568722|Active Comparator|Standard RRT initiation|RRT initiation will be guided by the presence of one or more clinical indications. Even in the absence of one of these indications, RRT may be commenced at the discretion of the treating physician.
2999172|NCT02568722|Experimental|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of the patient meeting the eligibility criteria.
2999173|NCT02568709|Active Comparator|Interventional|40 IU Oxytocin
2999174|NCT02568709|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
2999175|NCT02568683|Experimental|Dose Escalation: ENTO|Participants will be enrolled sequentially in a 3 + 3 dose escalation design to receive escalating dose of ENTO + VCR at dose levels 1 to 4 with the objective of defining the maximum tolerated dose (MTD) or recommended dose for the dose expansion stage. Following the determination of the MTD of the dose levels 1 to 4 (or concurrently with the opening of dose level 4), the safety of administering ENTO with VCR when administered as a 4-day prolonged continuous infusion may be evaluated in the continuous infusion dose escalation level (dose level C1) with the objective of investigating the schedule of dosing ENTO when administered with VCR as a continuous infusion
2999176|NCT02568683|Experimental|Dose Expansion: VCR + ENTO (Cohort A)|Based on the tolerability, safety, and efficacy data from the dose escalation phase, participants with relapsed or refractory DLBCL may receive VCR + ENTO.
2999177|NCT02568683|Experimental|Dose Expansion: VCR + ENTO (Cohort B)|Based on the tolerability, safety, and efficacy data from the dose escalation phase, participants with relapsed or refractory B-cell NHL (non-DBLCL) may receive VCR + ENTO.
2999178|NCT02568670|Experimental|according to clinical signs|removal the peripheral catheter according to clinical signs
2999179|NCT02568670|No Intervention|sistematically every 96 hours|removal the peripheral catheter every 96 hours
2999180|NCT02568657|Active Comparator|Celox group|Celox placement is very simpe . During cesarean section celox is loaded in the lower uterine segment and part of it is passed through the cervix to the vagina. If PPH occurs after vaginal delivery the celox is inserted through the cervix to pack the lower uterine segment. Removal of Celox after 24 hours.
2999181|NCT02568657|Active Comparator|Bakri balloon group|Before insertion the balloon, ensure that the bladder is empty by placing a Foley catheter. Grasp the cervix with ring forceps. Insert the balloon into the cavity of the uterus under ultrasound guidance; making sure that the entire portion of the balloon passes the cervical canal above the internal cervical os. Once the correct placement is confirmed, inflate the balloon with sterile saline using the enclosed syringe.
2999182|NCT02568644|Experimental|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerois) and intravenous ketoprofen (100mg).
2999183|NCT02568644|Placebo Comparator|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose) and intravenous ketoprofen (100mg).
2999184|NCT02568631|Experimental|serious game JeStiMulE|"Evaluation of the social cognition for adults with autism.~The objective of the players of JeStiMulE (Educational Game for Multisensory Stimulation of Children with developmental disorders) will be to end the game after a period of learning and two periods of game (with emotional words and with idiomatic expressions understanding each three modules). The session ends when the module is carried out, what corresponds approximately at 1 am by module, that is 6 sessions of game.~Evaluation of the social cognition for adults with autism."
2999185|NCT02568631|Placebo Comparator|control video game|"Evaluation of the social cognition for adults with autism.~The objective of the players of the control video game will be to play 6 sessions of one hour.~Evaluation of the social cognition for adults with autism."
2999186|NCT02568618|Other|Immediate|Subjects will receive the results of the Pain Medication DNA Insight (TM) test at Visit 1.
2999187|NCT02568618|Other|Delayed|Subjects will receive the results of the Pain Medication DNA Insight (TM) test at Visit 4. After 3 months of standard treatment.
2999188|NCT02568605|Experimental|Prebiotic Fibre|The intervention group will receive two 8g packets/day of prebiotic fibre to add to 250 ml of water and consume 30 minutes prior to breakfast and dinner.
2999189|NCT02568605|Placebo Comparator|Placebo|The control group will receive two 3g packets/day of maltodextrin to add to 250 ml of water and consume 30 minutes prior to breakfast and dinner.
2999190|NCT02568605|Other|Weight Loss|All participants will be supported through Registered Dietitian visits to achieve approximately 10% weight loss.
2999191|NCT02568592|Experimental|High Fat|High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
2999192|NCT02568592|Experimental|Normal|Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
2999193|NCT02568592|Experimental|Normal + Extra Fat|Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORM (Normal), with an additional 30% extra energy coming from fat.
2999194|NCT02568579||Breastfed|collection of blood/stool/breast milk samples and information about feeding changes and introduction of solid foods. - Cord Blood sample, stool samples monthly and blood sample at 6 month and 12 months of age
2999195|NCT02568579||Bottlefed|collection of blood/stool samples and information about feeding changes and introduction of solid foods. Coord blood sample, stool samples monthly and blood sample at 6 month and 12 month of age.
2999196|NCT02568566|Experimental|Prevention (Gardasil 9)|Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline (priming injection) and at 24 and 30 months (booster injections).
2999197|NCT02568553|Experimental|Treatment (blinatumomab, lenalidomide)|"INDUCTION: Patients receive blinatumomab IV continuously on days 1-56 and lenalidomide PO on days 29-49 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients achieving response receive including stable disease blinatumomab IV continuously on days 1-7 and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receiving response including stable disease after completion of Consolidation receive lenalidomide PO on days 1-21. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
2999198|NCT02568527|Experimental|PLGA Scaffold|Poly Lactide-co-Glycolic Acid (PLGA) 50:50
2999199|NCT02568514|No Intervention|Usual care|Patients admitted to hospital floors without any other intervention.
2999200|NCT02568514|Experimental|Secure text messaging|Patients admitted to hospital floors on which physicians and other staff are able to communicate with each other (not to the patient) using mobile secure text messaging.
2999201|NCT02568501|Experimental|Daily feedback|Participants receive daily feedback from wireless glucometers that transmit data on glucose monitoring adherence.
2999202|NCT02568501|Experimental|Daily Feedback, incentives|Participants receive daily feedback from wireless glucometers that transmit data on glucose monitoring adherence. Participants are eligible for a financial incentive if adherent.
2999203|NCT02568488|Experimental|metformin|PCOS women receiving metformin 850 mg orally twice daily over a period of 6 months
2999204|NCT02568475|Experimental|Decision aid|"Provision of Go to the Hospital or Stay Here?"
2999205|NCT02568475|No Intervention|No decision aid|Does not receive the decision aid.
2999206|NCT02568462|Experimental|Coronary Scaffold Implantation|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
2999207|NCT02568449|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2999208|NCT02568436|No Intervention|Conventional Decrowding|Crowded upper incisors will be treated in the conventional manner with a fake irradiation without using low level laser therapy.
2999209|NCT02568436|Experimental|Low Level Laser Therapy|Each maxillary incisor will be subjected to low level laser therapy at specific times in order to accelerate tooth movement
2999210|NCT02568423|Experimental|Mirikizumab IV|Mirikizumab given by intravenous (IV) infusion once.
2999211|NCT02568423|Experimental|Mirikizumab SC|Mirikizumab given by subcutaneous (SC) injection once.
2999212|NCT02568423|Placebo Comparator|Placebo IV|Placebo given by IV infusion once.
2999213|NCT02568423|Placebo Comparator|Placebo SC|Placebo given by SC injection once.
2999214|NCT02568410||CABG on CPB|Patients undergoing elective coronary artery bypass grafting using cardiopulmonary bypass. No study interventions beyond the standard clinical practice for these surgeries at Duke University Medical Center. No study drug administration.
2999215|NCT02568397|Experimental|Dabigatran Etexilate|Single dose of dabigatran etexilate administered orally.
2999216|NCT02568397|Experimental|Lanabecestat and Dabigatran Etexilate|Single dose of lanabecestat administered orally once daily on Days 3 to 21. Single doses of dabigatran etexilate administered orally on Days 16 and 20 during the lanabecestat dosing.
2999217|NCT02568384|Experimental|Users of Onyx BG Meter / App System|"Subjects with diabetes used the Onyx Blood Glucose (BG) Meter / App System at home. The enrollment goal for the intended use population:~40 to 70% of subjects will have type 1 diabetes~Not more than 30% of subjects will use an insulin pump"
2999218|NCT02568345|Experimental|sugammadex ED90|"Sequential design method up-and-down of the biased coin aimed to determine the minimum effective dose in 90% of patients (ED90).~The following doses were chosen: 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8 mg/kg."
2999219|NCT02568332|Experimental|Group 1|"Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.~Subjects: 20 HIV seropositive individuals"
2999220|NCT02568319|Experimental|LIPO-202|Experimental arm
2999221|NCT02568319|Placebo Comparator|Placebo|Placebo comparator
2999222|NCT02568306|Experimental|NNC0165-1562|
2999223|NCT02568306|Placebo Comparator|Placebo|
2999224|NCT02568293|Experimental|SBCV|SBCV is administered to the site immediately post balloon dilation.
2999225|NCT02568293|Placebo Comparator|Control|Saline is used as a control and is delivered immediately post balloon dilation.
2999226|NCT02568280|Experimental|Faster aspart|
2999227|NCT02568280|Active Comparator|Insulin aspart|
2999228|NCT02568267|Experimental|NTRK1/2/3-rearranged NSCLC|Oral entrectinib (RXDX-101)
2999229|NCT02568267|Experimental|ROS1-rearranged NSCLC|Oral entrectinib (RXDX-101)
2999230|NCT02568267|Experimental|ALK- or ROS1-rearranged NSCLC|"with CNS-only progression previously treated with crizotinib~Oral entrectinib (RXDX-101)"
2999231|NCT02568267|Experimental|NTRK/1/2/3-rearranged mCRC|Oral entrectinib (RXDX-101)
2999232|NCT02568267|Experimental|ROS1-rearranged mCRC|Oral entrectinib (RXDX-101)
2999233|NCT02568267|Experimental|ALK-rearranged mCRC|Oral entrectinib (RXDX-101)
2999234|NCT02568267|Experimental|NTRK1/2/3-rearranged other solid tumor|Oral entrectinib (RXDX-101)
2999235|NCT02568267|Experimental|ROS1-rearranged other solid tumor|Oral entrectinib (RXDX-101)
2999236|NCT02568267|Experimental|ALK-rearranged other solid tumor|Oral entrectinib (RXDX-101)
2999237|NCT02568254|Active Comparator|Lens 1/ Lens 2/ Lens 3|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (nesofilcon A) third.
2999238|NCT02568254|Active Comparator|Lens 1 / Lens 3 / Lens 2|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 2 (nelfilcon A) third.
2999239|NCT02568254|Active Comparator|Lens 2/ Lens 3/ Lens 1|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 1 (etafilcon A) third .
2999240|NCT02568254|Active Comparator|Lens 2 / Lens 1/ Lens 3|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nesofilcon A) third. Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
2999241|NCT02568254|Active Comparator|Lens 3 / Lens 1 / Lens 2|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nelfilcon A) third.
2999242|NCT02568254|Active Comparator|Lens 3 / Lens 2 / Lens 1|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (etafilcon A) third.
2999243|NCT02568241|Experimental|interferon Alfa-2b|High-risk acute leukemia patients after hematopoietic stem cell transplantation receive interferon Alfa-2b after prophylactic DLI
2999244|NCT02568228|Experimental|Krill group|Krill oil capsules. 4 g/day encapsulated krill oil (Rimfrost Sublime) corresponding to ~900 mg/day EPA + DHA + DPA for 8 weeks. The participants will be instructed to take the capsules with the breakfast and dinner meals.
2999245|NCT02568228|Experimental|Fish group|Lean and fatty fish. Three weekly test-meals, containing two meals of fatty fish and one meal of lean fish for 8 weeks corresponding to ~900 mg/day EPA + DHA + DPA.
2999246|NCT02568228|Placebo Comparator|Control group|Placebo capsules. 4 g/day encapsulated high oleic sunflower oil (HOSO) for 8 weeks. The participants will be instructed to take the capsules with the breakfast and dinner meals.
2999247|NCT02568215|Experimental|Group 1: Low-Dose VRC01|Participants will receive an IV infusion of 10 mg/kg of VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
2999248|NCT02568215|Experimental|Group 2: High-Dose VRC01|Participants will receive an IV infusion of 30 mg/kg of VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
2999249|NCT02568215|Placebo Comparator|Group 3: Placebo for VRC01|Participants will receive an IV infusion of placebo for VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
2999250|NCT02568202||Survey|
2999251|NCT02568189|Experimental|Sepsis 1|Sepsis patients receiving SonoSite Maxx Series Ultrasound System ultrasound prior to clinical orders including medication and fluid orders being placed by the treating physician
2999252|NCT02568189|Active Comparator|Sepsis 2|Sepsis patients having SonoSite Maxx Series Ultrasound System ultrasound performed after clinical orders have been placed by the treating physician
2999253|NCT02568189|Experimental|Gastroenteritis 1|Patients with gastroenteritis receiving SonoSite Maxx Series Ultrasound System ultrasound prior to having orders placed by treating physician
2999254|NCT02568189|Active Comparator|Gastroenteritis 2|Patients with gastroenteritis having SonoSite Maxx Series Ultrasound System ultrasound after initial clinical orders are placed by treating physician
2999255|NCT02568176|Experimental|Cohort 1|Participants will receive single oral dose of midazolam 6 milligram (mg) on Day 1 and 17. Participants will self-administer esketamine intranasally thrice per day on morning of Day 2, 5, 9, 12 and 16 (84 mg).
2999256|NCT02568176|Experimental|Cohort 2|Participants will receive single oral dose of bupropion 150 mg on Day 1 and 19. Participants will self-administer esketamine intranasally thrice per day on morning of Day 4, 7, 11, 14 and 18 (84 mg).
2999257|NCT02568163|Other|questionary|
2999258|NCT02568150|Other|Intervention|Onset time of improvement effect of glabellar lines at maximum frown of botulinum toxin treatment
2999259|NCT02568137|Experimental|Behavioral|Nurse-directed mobile health technology using smart phones to promote adherence to antihypertensive medication.
2999260|NCT02568137|No Intervention|Usual background care|Standard care
2999261|NCT02568124|Experimental|Tranexamic acid|Tranexamic acid 750 mg daily until complete radiological resolution of the chronic subdural hematoma or a maximum of 20 weeks.
2999262|NCT02568124|Placebo Comparator|Placebo|Placebo tablet daily until complete radiological resolution of the chronic subdural hematoma or a maximum of 20 weeks.
2999263|NCT02568111|Experimental|brimonidine tartrate|Participants will apply gel to injection site erythema area after IRE development post peginterferon beta-1a injection
2999264|NCT02568111|Placebo Comparator|Vehicle Gel|Participants will apply vehicle gel placebo to injection site erythema area after IRE development post peginterferon beta-1a injection
2999265|NCT02568098|Experimental|TMEC-14-022 (OxTREC 39-14)|Subjects had previously taken drug CQ and PQ
2999266|NCT02568098|Experimental|TMEC 12-004 (OxTREC 58-11)|Subjects had previously taken drug PQ and DHA-PQP
2999267|NCT02568098|Experimental|New subject|"Subjects who not previously participated in study TMEC 12-004 (OxTREC ref. 58-11) and study TMEC 14-022 (OxTREC ref. 39-14)."
2999268|NCT02568085|Experimental|1|thyroidectomy + Arista
2999269|NCT02568085|No Intervention|2|Thyroidectomy
2999270|NCT02568085|Experimental|3|Thyroidectomy with neck + Arista
2999271|NCT02568085|No Intervention|4|Thyroidectomy with neck
2999272|NCT02568059|Experimental|100 mg SHT extract|The Sahastara remedy alcoholic extract capsule dose 100 mg.
2999273|NCT02568059|Experimental|200 mg SHT extract|The Sahastara remedy alcoholic extract capsule dose 200 mg.
2999274|NCT02568046|Experimental|Sym004 + FOLFIRI|"Phase 1b, dose-escalation:~Dose Level 1: Sym004 12 mg/kg + FOLFIRI (Q2W)~Dose Level 2: Sym004 15 mg/kg + FOLFIRI (Q2W)~Dose Level 3: Sym004 18 mg/kg + FOLFIRI (Q2W)~If the toxicity profile of Dose Level 1 indicates that this dose is not tolerated, successive lower dose levels will be explored:~Dose Level -1: Sym004 9 mg/kg + FOLFIRI~Dose Level -2: Sym004 9 mg/kg (loading dose) + FOLFIRI, followed by 6 mg/kg + FOLFIRI~Dose Level -3: Sym004 6 mg/kg + FOLFIRI~FOLFIRI regimen consists of Irinotecan, Folinic Acid, and Fluorouracil (5-FU)"
2999275|NCT02568046|Experimental|Sym004 (RP2D) + FOLFIRI|"Phase 2a, dose-expansion:~Receiving Sym004 in the RP2D in combination with FOLFIRI~FOLFIRI regimen consists of Irinotecan, Folinic Acid, and Fluorouracil (5-FU)"
2999276|NCT02568033|Experimental|A|"Chemotherapy:~for Non-Squamous Cell: Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of 21 day cycle or Carboplatin AUC6 and Paclitaxel 75 mg/m2 on day 1 of 21 day cycle~for Squamous Cell: Cisplatin 75 mg/m2 and docetaxel 75mg m2 day 1 of 21 day cycle or Carboplatin AUC6 and paclitaxel 200 mg/m2 day 1 of 21 day cycle~Radiation- Stereotactic radiosurgery Peripheral Lung lesion: 60 Gy over 3 fractions Central Lung lesion: 50 Gy over 5 fractions Hilar and Mediastinal LNs 40-50Gy over 5 fractions~Schedule is:~2 cycles of chemotherapy, followed by SRS, followed by 2 additional cycles of chemotherapy."
2999277|NCT02568020|No Intervention|low-protein diet(LPD)|All patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
2999278|NCT02568020|Experimental|LPD+KA|LPD+KA group will be supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
2999279|NCT02568007|No Intervention|No Cyproheptadine treatment|Patients will receive standard of care behavior and nutritional interventions. They will not receive cyproheptadine.
2999280|NCT02568007|Experimental|Continuous Cyproheptadine|Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for a total of two months. Standard dose of 0.25 mg/kg divided BID will be used.
2999281|NCT02568007|Experimental|Cycled Cyproheptadine|Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for two weeks cycled with no cyproheptadine given for two weeks for a total of two months. Patients on cycled dosing will be given cyproheptadine for two weeks, then no medication for two weeks; repeating this cycle for the two month duration of study
2999282|NCT02567994|Experimental|Teneligliptin|20mg qd
2999283|NCT02567994|Active Comparator|Sitagliptin|100mg qd
2999284|NCT02567981|Experimental|21 micronutrient fortified supplement|21 micronutrient-fortified supplement
2999285|NCT02567981|Active Comparator|Current Standard of Nutritional Care|Cereal Fortificado (Fortified Cereal) Ferrous sulphate Vitamin A
2999286|NCT02567968|Placebo Comparator|Placebo|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
2999287|NCT02567968|Active Comparator|Caffeine|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
2999288|NCT02567955|Active Comparator|Gardasil-9 and Gardasil-9|Subjects in this arm will receive two doses of Gardasil-9 according to 0-6 month schedule
2999289|NCT02567955|Active Comparator|Cervarix and Gardasil-9|Subjects in this arm will receive one dose of Cervarix and one dose of Gardasil-9 according to 0-6 month schedule
2999290|NCT02567942|Other|propofol group|The patient who anesthetized by using propofol.
2999291|NCT02567942|Other|sevoflurane group|The patient who anesthetized by using propofol.
2999292|NCT02567929|Active Comparator|propofol group|The patient who anesthetized by using propofol.
2999293|NCT02567929|Active Comparator|sevoflurane group|The patient who anesthetized by using propofol
2999294|NCT02567916|Experimental|FRESOFOL MCT|To compare the incidence and intensity of pain on injection that is caused by propofol (LCT propofol) versus fresofol (MCT/LCT propofol) .
2999295|NCT02567916|Active Comparator|Propofol|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol (LCT propofol) versus fresofol (MCT/LCT propofol).
2999296|NCT02567903|Active Comparator|No Tourniquet|Knee arthroscopy without the use of a thigh tourniquet.
2999297|NCT02567903|Experimental|Tourniquet|Knee arthroscopy with the use of a thigh tourniquet.
2999298|NCT02567890|Experimental|Internet-based DBI|Internet-based DBI, which consists of four interactive occasions, some homework assignments, and monitoring
2999299|NCT02567890|Placebo Comparator|Expressive writing|Expressive Writing (placebo/attention control) where participants write texts. This is the active control condition.
2999300|NCT02567890|No Intervention|Waiting list|A wait-list control condition.Those in the wait-list condition will not receive any treatment until they have done the 6-month follow-up assessment.
2999301|NCT02567877||levothyroxine in thyroidectomy patients|patients undergoing thyroidectomy for nodular thyroid disease
2999302|NCT02567864|Experimental|Healthy Beat Accupunch|The HBA exercise program includes: 1) warm-up: 5 slow and gentle exercises to regulate qi, loosen up the body, and elevate the energy for a safe transition to the next phase, 2) accupunch: 14 low-to-medium speed exercises to punch the 14 meridians to enhance the cardiovascular-respiratory workout, and 3) relaxation: 5 low-speed, muscle relaxing exercises with deep breaths to sooth the body and mind. It is conducted 3 times per week and 40 minutes per practice.
2999303|NCT02567864|Active Comparator|control|The control group maintains daily activities.
2999304|NCT02567851|Experimental|Brentuximab Vedotin|brentuximab vedotin will be administered at an initial dose of 1.8 mg/kg every 3 weeks as a 30-minute outpatient i.v. infusion. A maximum of 16 cycles
2999305|NCT02567838|Experimental|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
2999306|NCT02567838|Placebo Comparator|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
2999307|NCT02567825|Active Comparator|Treatment A- surgical management|Tympanostomy tube placement
2999308|NCT02567825|Other|Treatment B - nonsurgical management|Nonsurgical management
2999309|NCT02567812||In-patient with PID|In-patient with PID who diagnosed at Kangbuk Samsung Hospital
2999310|NCT02567799|Experimental|Single-arm|Ascending dose evaluation of BIO 300 Oral Suspension (3 dose levels) given in combination with paclitaxel/carboplatin and radiotherapy.
2999311|NCT02567786|Active Comparator|Fresh Frozen Plasma|The priming of the CPB oxygenator will be done with 15 ml/kg of FFP in addition to packed red blood cells.
2999312|NCT02567786|Active Comparator|Plasmalyte|The priming of the CPB oxygenator will be done with 15 ml/kg of Plasmalyte in addition to packed red blood cells.
2999313|NCT02567773|Experimental|Part A: GSK2881078|The first cohort subjects will receive GSK2881078 1.5 mg (for males) or 0.75 mg (for females) twice daily for 3 days followed by once daily for 25 days. The subsequent cohort subjects will receive GSK2881078 doses selected after reviewing the unblinded data from at least 2 weeks of dosing of at least 6 subjects in the first cohort. Each cohort subjects will receive GSK2881078 dose twice daily for the first 3 days followed by 25 days of once daily.
2999314|NCT02567773|Placebo Comparator|Part A: Placebo|Subjects will receive placebo twice daily for 3 days followed by once daily for 25 days.
2999315|NCT02567773|Experimental|Part B: GSK2881078-Itraconazole|Subjects will receive GSK2881078 (dose level will be determined based on the results from Part A) on Day 1 of Period-1 and Day 6 of Period-2. Subjects will also receive itraconazole 200 mg twice daily on Day1 of Period-2 and 200 mg once daily on Days 2-34 of Period-2.
2999316|NCT02567760|Active Comparator|MP1 group|Subjects receive the MP1 product at the dose of 400 mg/day for 8 weeks.
2999317|NCT02567760|Placebo Comparator|Placebo group|Subject receive the Placebo product for 8 weeks.
2999318|NCT02567747||Study cohort|The Total population will include all subjects included in the study. Only aggregated information will be collected for these subjects.
2999319|NCT02567734|Experimental|Irreversible electroporation|In this group，eligible patients were selected to receive the CT-guided percutaneous irreversible electroporation ablation.
2999320|NCT02567721||Study Cohort|Subjects who will receive influenza vaccination between 1 September 2015 and 30 November 2015 in the 9 GP practices from who clinical data routinely collected as part of clinical consultations in primary care will be extracted.
2999321|NCT02567708|Experimental|GSK2269557 and Placebo|Each subject will complete two treatment periods: GSK2269557 1000 mcg in one treatment period, and matching placebo in the other treatment period. Each treatment will be administered once daily for 28 days (+/- 2 days) via the DISKUS DPI. The treatment periods will be separated by a washout of at least 4 weeks.
2999322|NCT02567695|Experimental|Treatment Sequence 1|Treatment A with one 300 mg capsule (high-strength) of GBT440 administered in a fasted state (test) in dosing Period 1 followed by Treatment B with 300 mg (3 × 100 mg) capsules (low-strength) of GBT440 administered in a fasted state (reference) in dosing Period 2.
2999323|NCT02567695|Experimental|Treatment Sequence 2|Treatment B with 300 mg (3 × 100 mg) capsules (low-strength) of GBT440 administered in a fasted state (reference) in dosing Period 1 followed by Treatment A with one 300 mg capsule (high-strength) of GBT440 administered in a fasted state (test) in dosing Period 2.
2999324|NCT02567682|Experimental|Fixed sequence, 2-periods|An open-label, fixed sequence, 2-period drug interaction study Period 1 Treatment A: Single dose of drug cocktail on Day 1 Period 2 Treatment B: GBT440 on Days 1 through 3 and Treatment C: Single dose of drug cocktail on Day 4 and GBT440 on Days 4 through 7
2999325|NCT02567656|Experimental|Single arm|RP6530 administered orally twice a day.
2999326|NCT02567643|Experimental|Stereotactic Radiosurgery|
2999327|NCT02567630|No Intervention|Typical Developing|This will include assessments of Typically Developing (TD) children matched by age and gender to the intervention group participants. No intervention will be provided for this group of participants.
2999328|NCT02567630|Experimental|Intervention at enrollment|Cerebral palsy children: Inclusion criteria will be diagnosis of hemiparetic or asymmetric CP as determined by published algorithms and neurologic exam, corrected age (CA) between 12 and 24 months.
2999329|NCT02567630|Experimental|Intervention waiting period|Cerebral palsy children: Inclusion criteria will be diagnosis of hemiparetic or asymmetric CP as determined by published algorithms and neurologic exam, corrected age (CA) between 12 and 24 months. Intervention period will begin after a 7 month waiting period upon enrollment.
2999330|NCT02567617|Active Comparator|Intervention group|Group receiving capsules with polyphenols.
2999331|NCT02567617|Placebo Comparator|Placebo controlled group|Group receiving capsules with starch.
2999332|NCT02567604||Focus groups|AMD patients' caregivers defined as people actively taking part in providing support for AMD patients (e.g. family members, unpaid friends, volunteers)
2999333|NCT02567591|Experimental|A: physical activity program|at home physical activity program (during 12 weeks)
2999334|NCT02567591|No Intervention|B: conventional management|conventional management
2999335|NCT02567578|Experimental|YH12852 0.1 mg|twice daily for 4 weeks
2999336|NCT02567578|Experimental|YH12852 0.25 mg|twice daily for 4 weeks
2999337|NCT02567578|Experimental|YH12852 0.5 mg|twice daily for 4 weeks
2999338|NCT02567578|Placebo Comparator|Placebo|twice daily for 4 weeks
2999339|NCT02567565||cataract patients|cataract patients undergoing phacoemulsification
2999340|NCT02567552|Experimental|Prolutex|Subcutaneous progesterone
2999341|NCT02567552|Active Comparator|Prontogest|Intramuscular progesterone
2999342|NCT02567539|Experimental|Recurrent high grade glioma|IMRT with or without radiosensitive therapy
2999343|NCT02567526|No Intervention|Usual Care Control Group|Eligible, consented residents continued to receive usual care from nursing home staff and were monitored by trained research staff.
2999344|NCT02567526|Experimental|Between-meal Intervention Group|Non-nursing staff trained as Feeding Assistants were utilized to deliver supplements and snacks twice per day, between meals for 24 study weeks.
2999345|NCT02567513|No Intervention|Usual Care control group|Eligible, consented residents continue to receive usual care from nursing home staff and are independently monitored by trained research staff.
2999346|NCT02567513|Experimental|Supplement Intervention|Residents are offered a variety of supplement types and flavors consistent with prescribed orders twice per day (morning and afternoon), five days per week, for 24 consecutive weeks by trained research personnel. Research staff also provide the appropriate level and amount of assistance to encourage consumption.
2999480|NCT02566629||IBS patients in episodes phase|collect faeces from IBS patients in episodes remission phase
2999347|NCT02567513|Experimental|Snack Intervention|Residents are offered a variety of snack options (foods and fluids, including supplement) consistent with prescribed orders twice per day (morning and afternoon), five days per week, for 24 consecutive weeks by trained research personnel. Research staff also provide the appropriate level and amount of assistance to encourage consumption.
2999348|NCT02567500|Experimental|Patients with auditory hallucination|"Patients with auditory hallucination:~Evaluation at time 0 and 6 month after of:~The social cognitive marker (NeuroPsychologic assessment (NEPSY) II) : theory of mind and affect recognition~The emotional marker:~Differential Emotion Scale IV (DES IV): emotional individual stability~Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~Evaluation of diagnosis with Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV criteria:~Mini International Neuropsychiatric Interview (MINI) -Kids~Psychosis section of Kiddie-SADS"
2999349|NCT02567500|Placebo Comparator|Patients without auditory hallucination|"Patients without auditory hallucination:~Evaluation at time 0 and 6 month after of:~The social cognitive marker (NEPSY II) : theory of mind and affect recognition~The emotional marker:~Differential emotion scale IV (DES IV): emotional individual stability~Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~Evaluation of diagnosis with Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV criteria:~Mini International Neuropsychiatric Interview (MINI) -Kids~Psychosis section of Kiddie-SADS (Schedule for Affective Disorders and Schizophrenia )"
2999350|NCT02567487|Active Comparator|Group Levobupivacaine high volume|TAP block with levobupivacaine 0.25% of 0.5 ml/kg under general anesthesia
2999351|NCT02567487|Active Comparator|Group Levobupivacaine low volume|TAP block with levobupivacaine 0.25% of 0.25 ml/kg under general anesthesia
2999352|NCT02567474|No Intervention|control|no intervention
2999353|NCT02567474|Experimental|intervention|self management intervention based on 5A model
2999354|NCT02567461|Experimental|DAPT plus high-dose edoxaban|High-dose edoxaban will be represented by edoxaban 60mg od, which will be reduced to 30mg od in patients with ClCr ≤50mL/min.
2999355|NCT02567461|Experimental|DAPT plus low-dose edoxaban|Low-dose edoxaban will be defined as edoxaban 30mg od, which will be reduced to 15mg od in patients with ClCr ≤50mL/min.
2999356|NCT02567461|Active Comparator|DAPT|Aspirin 81 mg od plus clopidogrel 75 mg od
2999357|NCT02567448|Active Comparator|COPD Group|Patients who were previously diagnosed of moderate to severe COPD as determined by spirometry. All patients will have sleep and pulmonary physiologic measurements.
2999358|NCT02567448|Active Comparator|Normal Control Group|Patients who are healthy, without major medical or sleep problems, and have normal spirometry. All patients will have sleep and pulmonary physiologic measurements.
2999359|NCT02567435|Experimental|Regimen A (VAC/VI)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37. Patients also undergo RT beginning at week 13 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
2999360|NCT02567435|Experimental|Regimen B (VAC/VI/temsirolimus)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37 and temsirolimus IV over 30-60 minutes on day 1 of weeks 1-12 and 21-42. Patients also undergo RT as in Regimen A. Treatment continues in the absence of disease progression or unacceptable toxicity.
2999361|NCT02567435|Experimental|Regimen C (FOXO1 fusion negative, VAC/VA)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-10 and 13-22, dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, and 22, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 4, 7, and 10. Patients undergo RT beginning at week 13 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
2999362|NCT02567422|Experimental|Treatment (M6620, cisplatin, radiation therapy)|Patients receive ATR kinase inhibitor M6620 IV over 60 minutes on day -7 and then weekly on day 2 and cisplatin IV over 30-60 minutes weekly on day 1. Patients also undergo radiation therapy once daily, 5 days a week. Treatment continues for up to 7 weeks in the absence of disease progression or unacceptable toxicity.
2999363|NCT02567409|Experimental|Arm A (M6620, gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV over 60 minutes on day 1. Patients also receive ATR kinase inhibitor M6620 IV over 60 minutes on days 2 and 9. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
2999364|NCT02567409|Experimental|Arm B (gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride and cisplatin as in Arm A.
2999365|NCT02567396|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2999366|NCT02567383|Experimental|Hyperthermia|Hyperthermia; Thermotron RF-8, radiation, Cisplatin and Taxotere
2999367|NCT02567370|Placebo Comparator|Placebo|
2999368|NCT02567370|Active Comparator|AMG 581|
2999369|NCT02567357|Active Comparator|Visual Scheduling|A caregiver training package on the use of a pictorial (visual) schedule to illustrate each day's expected activities to a child. Caregivers will be trained to ensure that activities occur as described in the schedule as far as possible, thus the expected mechanism of action is the reduction of (unexpected change) antecedents of children's temper outbursts.
2999402|NCT02567110||Participants with Major Depression|Participants with major depression will complete neurocognitive and psychiatric assessments, complete self-report forms and undergo Magnetic Resonance Imaging scans. Blood and spinal fluid specimens will also be collected for estimation of inflammatory markers.
2999481|NCT02566629||IBS patients in remission phase|collect faeces from IBS patients in remission phase
2999482|NCT02566629||healthy controls|collect faeces from healthy controls
2999370|NCT02567357|Experimental|Signalling change|A caregiver training package where parents are taught to present a distinctive visual-verbal cue to a child whenever they become aware that a change will take place in the child's usual/expected activities. Caregivers will be trained to only ever present to cue if they can be sure that a change to the child's routine or plan will occur, thus the expected mechanism of action is the child's learned association between the presentation of the cue and the subsequent occurrence of a change to their expectations. Signalled changes will therefore be more predictable for the child, and should therefore be easier for them to deal with.
2999371|NCT02567344|Experimental|Active rTMS|Active rTMS will be delivered to the Left DLPFC at 10Hz. A total of 4000 pulses will be delivered.
2999372|NCT02567344|Sham Comparator|Sham rTMS|Sham rTMS will be delivered to the Left DLPFC at 10 Hz using an electronic sham system used in multiple other investigations. A total of 4000 pulses of sham rTMS will be delivered.
2999373|NCT02567331|Experimental|Capecitabine|Participants will receive oral capecitabine 1250 milligrams per square meter (mg/m^2) twice daily for 14 days followed by 7 day rest period for 6 cycles.
2999374|NCT02567318|Experimental|MRI-scan|All study participants will complete a MRI-scan of the brain
2999375|NCT02567305||Actual Sepsis|"For infants below 44 weeks inclusive of corrected age clinical sepsis is defined, according to the Expert Meeting on Neonatal and Pediatric Sepsis (Report on the Expert Meeting on Neonatal and Pediatric Sepsis - 8 June 2010, EMA London). Confirmed sepsis is defined as positive culture for pathogens in a sample from a normally sterile site and at least one laboratory sign or clinical sign (not shown)~For children above 44 weeks corrected age clinical sepsis is defined according to the Goldstein criteria (Goldstein et al, 2005). Confirmed sepsis: positive culture for pathogens in a sample from a normally sterile site and at least one laboratory sign or clinical sign (not shown)"
2999376|NCT02567305||Suspected Sepsis|None of the above.
2999377|NCT02567292|No Intervention|Retrospective Control Group|Approximately 150 patients with congenital gastrointestinal disorders who were treated in the neonatal intensive care unit (NICU) at Children's Healthcare of Atlanta-Egleston and other participating institutions from 2012 to 2015, who had non-human milk (HM) diets will be identified as retrospective controls using the electronic medical records system.
2999378|NCT02567292|Experimental|Exclusive Human Milk Diet Group|A minimum of 150 patients with CGD admitted to participating NICUs who meet inclusion criteria and provide informed consent will be enrolled in the prospective arm of the study. These patients will be fed an EHMD comprised of mother's own milk (MOM) or pasteurized donor human milk (DM). Fortification will be provided with human milk derived human milk fortifier, either a human milk-based fortifier (Prolact+ H2MF®) for infants born at less than 37 weeks GA or <2,200g birth weight or the term-equivalent version (PBCLN-002) formulated for infants >37 weeks and/or >2,200g at birth. Infants will receive this EHMD until they have achieved full enteral feedings for 7 days with bowel in continuity
2999379|NCT02567279|Active Comparator|Denosumab subcutaneous injections|The treated group (n = 42) will receive Denosumab (60 mg, two subcutaneous injections at M0 and M6) associated with a daily treatment of vitamin D (800 IU) + calcium (1000 mg).
2999380|NCT02567279|Placebo Comparator|Placebo subcutaneous injections|The control group (n = 42) will received a placebo injection (two subcutaneous injections at M0 and M6) with daily treatment of vitamin D (800 IU) +calcium (1000 mg).
2999381|NCT02567266|Experimental|Unified Protocol for Adolescents (UP-A)|Participants will be treated with the Unified Protocol for the Treatment of Emotional Disorders in Adolescence. Their clinicians will also receive feedback using the Youth Outcomes Questionnaire feedback system.
2999382|NCT02567266|Experimental|Treatment as Usual Plus (TAU+)|Participants will be treated by clinicians who receive feedback using the Youth Outcomes Questionnaire, but who otherwise use Treatment as Usual
2999383|NCT02567266|Active Comparator|Treatment as Usual (TAU)|Participants will receive Treatment as Usual provided at the study clinics.
2999384|NCT02567253|Experimental|low dose, normothermic|CRS + normothermic (37°C) intraoperative intraperitoneal chemoperfusion, with 75mg/m² Cisplatin during 90min + adjuvant chemotherapy
2999385|NCT02567253|Experimental|high dose, normothermic|CRS + normothermic (37°C) intraoperative intraperitoneal chemoperfusion, with 100mg/m² Cisplatin during 90min + adjuvant chemotherapy
2999386|NCT02567253|Experimental|low dose, hyperthermic|CRS + hyperthermic (41°C) intraoperative intraperitoneal chemoperfusion, with 75mg/m² Cisplatin during 90min + adjuvant chemotherapy
2999387|NCT02567253|Experimental|high dose, hyperthermic|CRS + hyperthermic (41°C) intraoperative intraperitoneal chemoperfusion, with 100mg/m² Cisplatin during 90min + adjuvant chemotherapy
2999388|NCT02567240|Experimental|Carbon monoxide-bubbled mediums|Islets will be harvested with Carbon monoxide-saturated mediums
2999389|NCT02567240|No Intervention|Normal mediums|Islets will be harvested with regular mediums
2999390|NCT02567227|Experimental|Cognitive Remediation|An individualized computerized cognitive remediation program.
2999391|NCT02567227|Active Comparator|Active control|Individualized computer based exposure and interactive health education classes.
2999392|NCT02567214|Experimental|Ultibro® versus sham Spiriva®|"Indacaterol 110 µg/Glycopyrronium 50 µg Inhaled~1 time per day 21 days"
2999393|NCT02567214|Experimental|Sham Ultibro® versus Spiriva®|"Tiotropium 18 µg Inhaled~1 time per day 21 days"
2999394|NCT02567201|Experimental|Electrophysiological assessment of Healthy subjects|Experiences 1, 2 and 3 with healthy subjects
2999395|NCT02567201|Experimental|Electrophysiological assessment of patients|Experiences 1, 2 and 3 with patients
2999396|NCT02567188||Cohort of CKD Participants|Pre-dialysis participants with CKD treated with MIRCERA according to the current standard of care and in line with the current local summary of product characteristics were observed for maximum of 12 months.
2999397|NCT02567149|Experimental|Cidofovir|Cidofovir clinical resolution of treated warts as evaluated by the investigators
2999398|NCT02567136||Amyotrophic Lateral Sclerosis|Patients with ALS
2999399|NCT02567136||Healthy Controls|Healthy control volunteers
2999400|NCT02567123|Experimental|Experimental|Runners are switched from a rearfoot strike running pattern to a forefoot strike running pattern.
2999401|NCT02567123|No Intervention|Control|Runners continue to use their normal rearfoot strike running pattern with no intervention in place.
2999483|NCT02566616|Experimental|Intervention|"Cubital Tunnel Release with stimulator for nerve location~1 hour of Ulnar nerve stimulation"
3031021|NCT02355106|Experimental|Treatment|Atrial flutter Ablation
2999403|NCT02567110||Participants without Depression|Participants without depression will complete neurocognitive and psychiatric assessments, complete self-report forms and undergo Magnetic Resonance Imaging scans. Blood and spinal fluid specimens will also be collected for estimation of inflammatory markers.
2999404|NCT02567097|Active Comparator|Control|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to form their plan to quit smoking.
2999405|NCT02567097|Active Comparator|Implementation Intention|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to form a specific 'if-then' plan using an implementation intention basis.
2999406|NCT02567097|Experimental|Weekly Self-Incentivising|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to specify a self-incentive on which they could implement at the end of each week which they have been successful in not smoking.
2999407|NCT02567097|Experimental|Monthly Self-Incentivising|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to specify a self-incentive on which they could implement at the end of each month which they have been successful in not smoking.
2999408|NCT02567084|Other|"CERAMENT™ |BONE VOID FILLER"|"Intraoperativ application of medical device: CERAMENT™ |BONE VOID FILLER 5cc/10cc/18cc"
2999409|NCT02567071|Experimental|Intervention Group|75 children born by planned C-section will be exposed to the perineal microbiota of their mothers through perineal impregnated swab.
2999410|NCT02567071|Placebo Comparator|Placebo Group|75 children born by planned C-section will be exposed to clean swab.
2999411|NCT02567071|No Intervention|Control Group|75 children born vaginally.
2999412|NCT02567058|Experimental|3 groups of subjects|"3 groups:~group I : healthy volunters~group II : patient with an immobilisation (between 1 and 2 months)~group III : patient with an antecedent of Achilles tendon breakage during the 10 past years~Each group have the same interventions : ultrasound exam, IPAQ questionnaire"
2999413|NCT02567045|Experimental|Fecal occult blood testing|"Annual FIT and colonoscopy in case of a positive test. Fecal occult blood testing: annual FIT (two rounds) without diet restriction, one stool sample. Positive cut-off = 10 μg Hemoglobin/g feces.~Colonoscopy will be performed in case of a positive FIT."
2999414|NCT02567045|Active Comparator|one-time Colonoscopy|One-time Colonoscopy with sedation
2999415|NCT02567032|Experimental|Oxytocin|40 IU Oxytocin
2999416|NCT02567032|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
2999417|NCT02567019|Experimental|periodontal diseases|blood samples will be done for patients suffering of periodontal diseases
2999418|NCT02567019|Active Comparator|healthy volunteers|blood samples will be done for healthy volunteers
2999419|NCT02567006|Active Comparator|Short Message Service (SMS) group|Receiving SMS message reminders 1 week before scheduled vaccination
2999420|NCT02567006|Placebo Comparator|Usual care|Not receiving SMS messages
2999421|NCT02566993|Experimental|Test|Lurbinectedin (PM01183) / Doxorubicin
2999422|NCT02566993|Active Comparator|Control 1|CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR))
2999423|NCT02566993|Active Comparator|Control 2|Topotecan
2999424|NCT02566980||Pre-partum|130 pregnant women will be enrolled in first trimester. Healthy women or those with any degree of depressive symptoms are eligible. Blood samples and psychiatric assessments will take place once every trimester and once in the post-partum. At delivery placenta will be collected. Enrollment takes place at Spectrum Health Ob/gyn out-patient clinics in Grand Rapids, Michigan.
2999425|NCT02566980||Post-partum|50-100 women experiencing perinatal depression with and without suicidality will be enrolled from a partial hospitalization program, the Mother and Baby unit as well as outpatient clinics at Pine Rest Christian Mental Health Services, Grand Rapids, Michigan.
2999426|NCT02566967|Other|open label|open label use of tofacitinib at either 5 mg bid or 10 mg bid delending on treat to target goal
2999427|NCT02566954|Experimental|3D measurement of the lower limb by EOS|"The intervention is to performed an additional radiologic exam by the EOS® system of imaging. This imaging is not usually realized for the patient.~3 dimensional study of lower limbs and feet of children in standing position will be performed using the EOS® system (EOS® Imaging, France)"
2999428|NCT02566941|Experimental|Stimulated|Patients included in the 'stimulated' group will be stimulated at the level of the quadriceps twice a day, bilaterally and simultaneously, five days per week from Monday to Friday (Stimulator: Gymna Belgium, DUO 400). The stimulation protocol (rectified alternating current; frequency, 75 Hz; intensity, 0-80 mA; pulse duration, 350 microseconds) is the one proposed by the manufacturer for atrophy prevention. The intensity of the electrical current will be gradually increased, without exceeding 80mA or the pain threshold of the patient.
2999429|NCT02566941|No Intervention|Control|
2999430|NCT02566928|Experimental|Decolonization and Decontamination|Index Patients will receive: 1) guidelines-directed care, which may consist of incision, drainage, oral antibiotics, and antibiogram-based antibiotic prescribing, and 2) a home-based intervention implemented by Community Health Workers/Promotoras that includes index patient and household member education and instructions to complete a decolonization and decontamination regimen, along with printed materials describing a standard hygiene protocol for reducing household contamination. Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of 2% mupirocin ointment to the anterior nares with a clean cotton applicator for five days, as well as daily bathing with chlorhexidine wash for five days. The household decontamination hygiene protocol includes the use of hand-washing, surface disinfection, and laundering.
2999431|NCT02566928|No Intervention|Usual Care|Index Patients will receive: 1) guidelines-directed care, which may consist of incision, drainage, and oral antibiotics, as well as antibiogram-based antibiotic prescribing, and 2) printed materials describing a standard hygiene protocol for reducing household contamination.
2999476|NCT02566681|Experimental|MSC construct for Osteonecrosis|Patients with definite diagnosis of osteonecrosis of the jaw by clinical and radiological examination of any etiology will receive a construct made of Bone Marrow Stem Cell + Tricalcium Phosphate + Demineralized Bone Matrix (MSC+TP+DBM).
2999477|NCT02566668||Asthmatic|1 year observational follow-up
2999478|NCT02566668||Non-Asthmatic|1 year observational follow-up
2999432|NCT02566915|No Intervention|CPET submaximal without EPAP|Will be collected clinical and anthropometric data of the participants and they are packaged in self-evaluation form. Evaluation of pulmonary function at rest will be rescued from patient charts. When carried out for over six months, will be repeated by the researchers. Patients will conduct incremental CPET of 5-10W/min limited by symptoms (FEV1 <1L-5W or FEV1> 1L-10W) (Visit 1). After a period of 2-7 days the CPET will be performed submaximal with 75% of the peak load reached in the incremental CPET (visits 2-3). During the visit without EPAP will be maintained using the facial mask applied without resistance.
2999433|NCT02566915|Experimental|CPET submaximal with EPAP|Will be collected clinical and anthropometric data of the participants and they are packaged in self-evaluation form. Evaluation of pulmonary function at rest will be rescued from patient charts. When carried out for over six months, will be repeated by the researchers. Patients will conduct incremental CPET of 5-10W/min limited by symptoms (FEV1 <1L-5W or FEV1> 1L-10W) (Visit 1). After a period of 2-7 days the CPET will be performed submaximal with 75% of the peak load reached in the incremental CPET (visits 2-3). The application of EPAP (10cmH2O) via face mask (Vital RHDSON Signs®, New Jersey, USA) will be randomized with the help of opaque envelopes to be given in one visit. IC serial measurements will be carried out before, during and immediately after the exercise.
2999434|NCT02566902|Active Comparator|T-piece Nebulizer|"Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental T-piece Nebulizer (Hudson RCI® Micro Mist® nebulizer Teleflex Medical®, Research Triangle Park, NJ). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed."
2999435|NCT02566902|Experimental|Breath-Enhanced Nebulizer|"Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental Breath-Enhanced Nebulizer (NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer Salter Labs®, Arvin, CA). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed."
2999436|NCT02566889|Experimental|Dose Escalation Group|Participants must have completed: a) recommended infliximab induction dosing regimen of 5 milligram (mg)/kilogram (kg) at Weeks 0, 2, and 6, followed by at least 1 maintenance doses of 5 mg/kg every 8 weeks (q8wk); or b) induction regimen with doses >6 mg/kg and have received at least 2 maintenance doses of 5 mg/kg q8wk with clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose; or c) maintenance doses >6 mg/kg within past 6 months and at least 2 maintenance doses of 5 mg/kg q8wk with clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose; d) must have lost clinical response, after first or subsequent q8wk maintenance dose of infliximab 5 mg/kg for participants who have completed the recommended infliximab induction dosing regimen or, after most recent (second or later) q8wk maintenance dose of infliximab 5 mg/kg for participants with an induction regimen with doses >6 mg/kg or with previous maintenance doses >6 mg/kg.
2999437|NCT02566889|Experimental|Reference Group|Participants must have completed: a) the recommended infliximab induction dosing regimen of 5 mg/kg at Weeks 0, 2, and 6, and have maintained a stable clinical response to infliximab after at least 1 maintenance doses of 5 mg/kg q8wk; or b) an induction regimen with doses >6 mg/kg and have received at least 2 maintenance doses of 5 mg/kg q8wk and have maintained clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose 5 mg/kg maintenance dose; or c) maintenance doses >6 mg/kg within the past 6 months and at least 2 maintenance doses of 5 mg/kg q8wk and have maintained a clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose 5 mg/kg maintenance dose.
2999438|NCT02566876|Active Comparator|Mixture of three Bifidobacteria|Patients were administered 1 sachet per day of a mixture of three Bifidobacteria (namely, 3 billions of Bifidobacterium longum BB536®, 1 billion of Bifidobacterium infantis M-63®, and 1 billion of Bifidobacterium breve M-16V®) for six weeks. Subsequently, no preparation was administered for a 2-week-''washout'' period. At each follow-up visit subjects underwent a complete physical examination, data recorded on the daily diaries were collected and compliance to treatment was verified.
2999439|NCT02566876|Placebo Comparator|Placebo|Patients were administered 1 sachet per day of placebo for six weeks. Subsequently, no preparation was administered for a 2-week-''washout'' period. At each follow-up visit subjects underwent a complete physical examination, data recorded on the daily diaries were collected and compliance to treatment was verified.
2999440|NCT02566863|Experimental|Dexmedetomidine|Dexmedetomidine, 1 mcg/kg over 10 minutes, followed by a maintenance infusion, given to achieve sedation for eye surgery procedure
2999441|NCT02566850|Experimental|Ekso Users|SCI subjects using Ekso
2999442|NCT02566837|Active Comparator|ELEC|electrical stimulation guidance
2999443|NCT02566837|Experimental|ECHO|ultrasound guidance
2999444|NCT02566824|Experimental|Cognitive Behavioural & Skills Training|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they undergo the 12 weeks of group cognitive behavioral and skills training therapy.
2999445|NCT02566824|Active Comparator|Supportive Group Therapy|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they undergo the 12 weeks of supportive group therapy.
2999446|NCT02566824|Active Comparator|Treatment as Usual - community resources|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they are referred to their treating physicians and are free to use any resources that are available to them in their communities.
2999447|NCT02566811|Experimental|Abdominal surgery with lymphadenectomy|"Patients will receive a hysterectomy and bilateral salpingo-oophorectomy (BSO)* with lymph node dissection to determine whether lymph nodes are positive or negative:~Positive: patients will receive systemic adjuvant treatment to include chemotherapy Negative: patients will receive vaginal brachytherapy only~Patients will then be followed up, to include assessment of adverse events and quality of life.~*There is an option for patients to be randomised following a pre-trial hysterectomy and BSO. If randomised to this arm, the lymph node dissection will be performed as a separate procedure."
2999479|NCT02566655|Experimental|Fucosylated MSC for Osteoporosis|Autologous Bone Marrow fucosylated mesenchymal stem cells will be infused intravenously on Day 0. The first four patients enrolled will receive a single dose of 2 million cells/Kg and the last six patients enrolled, will receive a single dose of 5 million cells/kg.
2999518|NCT02566291||Supreme Group|Measuring Success rate and Insertion Time
2999448|NCT02566811|Active Comparator|Abdominal surgery, no lymphadenectomy|"Patients will receive a hysterectomy and bilateral salpingo-oophorectomy (BSO)*. Patients will receive systemic adjuvant treatment to include chemotherapy.~Patients will then be followed up, to include assessment of adverse events and quality of life.~*There is an option for patients to be randomised following a pre-trial hysterectomy and BSO. If randomised to this arm, no further surgery will be given and the patient will proceed to receive systemic adjuvant treatment to include chemotherapy."
2999449|NCT02566798|Experimental|Oleogrape|Patients are taking capsules of OleograpeSEED (Extract of grape and olive) 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days
2999450|NCT02566798|Placebo Comparator|Placebo|Patients are taking capsules of placebo (lactose) 3 times a day in the morning, at noon and in the evening during 7 days
2999451|NCT02566785|Experimental|Intervention Group|Those allocated to the intervention group will participate in a supervised group session exercise one time per week and be asked to exercise two more times per week at home.
2999452|NCT02566785|Other|Wait List Control Group|The wait list control group will not participate in the intervention and will be asked to continue their usual activity level during the first 12 weeks and will receive the multi-component balance intervention during weeks 12-24.
2999453|NCT02566772|Experimental|TAS3681|TAS3681 will be provided as 25 mg and 100 mg tablets to be administered QD orally for 28 days, at least 1 hour before or 2 hours after a meal. Number of cycles: approximately 6 or until discontinuation criteria is met, followed by an expansion phase..
2999454|NCT02566759|Experimental|Part 1, Cohort 1: TAK-831 100 mg|TAK-831 100 milligram (mg), suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
2999455|NCT02566759|Experimental|Part 1, Cohort 2: TAK-831 250 mg|TAK-831 250 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
2999456|NCT02566759|Experimental|Part 1, Cohort 3: TAK-831 500 mg|TAK-831 500 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
2999457|NCT02566759|Experimental|Part 1, Cohort 4: TAK-831 30 mg|TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
2999458|NCT02566759|Experimental|Part 1, Cohort 5: TAK-831 750 mg|TAK-831 750 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
2999459|NCT02566759|Experimental|Part 1, Cohort 6: TAK-831 10 mg|TAK-831 10 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
2999460|NCT02566759|Experimental|Part 2, Cohort 1: TAK-831 30 mg|TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
2999461|NCT02566759|Experimental|Part 2, Cohort 2: TAK-831 100 mg|TAK-831 100 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
2999462|NCT02566759|Experimental|Part 2, Cohort 3: TAK-831 200 mg|TAK-831 200 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
2999463|NCT02566759|Experimental|Part 2, Cohort 4: TAK-831 400 mg|TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
2999464|NCT02566759|Experimental|Part 3, Cohort 1: TAK-831 400 mg|TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once daily from Days 1 to 14.
2999465|NCT02566759|Experimental|Part 4:TAK-831(Tablet Fasted+ Tablet Fed + Suspension Fasted)|TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
2999466|NCT02566759|Experimental|Part 4:TAK-831(Tablet Fed + Tablet Fasted + Suspension Fasted)|TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
2999467|NCT02566759|Experimental|Part 4:TAK-831(Suspension Fasted+ Tablet Fed + Tablet Fasted)|TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
2999468|NCT02566746|Experimental|Chait Trapdoor caecostomie catheter|Patients randomized in this arm will undergo percutaneous endoscopic caecostomy with Chait Trapdoor caecostomie catheter
2999469|NCT02566746|Active Comparator|Continuation of optimal medical therapy|Patients randomized in this arm will continue this medical treatment of constipation with laxative and / or suppositories and / or enemas retrograde
2999470|NCT02566733|Experimental|Remiva|This experimental group will use a generic drug of remifentanil, Remiva™ from Hana Pharmaceutical company.
2999471|NCT02566733|Active Comparator|Ultiva|This arm group will use a brand-named drug of remifentanil, Ultiva™ from GlaxoSmithKline company.
2999472|NCT02566720|Other|Treatment and MRI scanning|After informed consent has been obtained, the subjects will be examined by a physician and assigned a Disability Ratings Scale (DRS) score. Subjects will undergo MRI tractography study, which does not require the administration of contrast. All participants will receive oral amantadine at escalating doses to ensure tolerance (50mg twice daily for 7 days, then 100mg twice daily for 1 week, then 150mg twice daily, then 200mg twice daily). The usual length of stay on the inpatient brain injury program is ninety days. The MRI tractography study and DRS score will be repeated near the time of discharge or ninety days from enrollment.
2999473|NCT02566707|Experimental|PRADAII regimen|Use of PRADAII regimen during 12 weeks. This regimen consists of atazanavir 400 mg QD, dolutegravir 50 mg QD, lamivudine 300 mg QD.
2999474|NCT02566694||Failed implants|All patients undergoing revision of an orthopaedic implant (previously this was limited to metal hips but this has now expanded to other orthopaedic implants)
2999475|NCT02566694||Controls with different failure modes|We will compare findings with different types of orthopaedic implants and categories of failure mode.
2999519|NCT02566291||Gain Group|Measuring Success rate and Insertion Time
2999484|NCT02566616|Active Comparator|Non-Intervention|Cubital Tunnel Release with stimulator for nerve location NO prolonged ulnar nerve stimulation
2999485|NCT02566603|Experimental|PRTX-100|Patients will be assigned to consecutive PRTX-100 interventions as they are enrolled into the study. Between three and six patients will be enrolled per intervention level. Intervention levels range from 3 to 24 micrograms of PRTX-100 per kilogram of patient weight. Patients may receive up to four weekly infusions of PRTX-100 over the study treatment period. PRTX-100 doses ≤ 500 μg will be infused intravenously over 30 minutes. PRTX-100 doses > 500 μg will be infused over 60 minutes. Patients will remain under observation for 4 hours after initiation of PRTX-100 dosing for safety management.
2999486|NCT02566590|Experimental|Control|Participants will complete bed rest but will receive a non-protein placebo supplement
2999487|NCT02566590|Experimental|NMES + PRO|Participants will receive daily treatment with neuromuscular electrical stimulation (NMES) and daily supplements of a protein drink.
2999488|NCT02566577|Active Comparator|Fresh RBC transfusion/Storage-aged RBC transfusion|Subjects will receive a transfusion of packed red blood cell (RBC) units of fresh blood (<10 days old) followed by a transfusion of packed RBC units of storage-aged (>21 days old) blood.
2999489|NCT02566577|Active Comparator|Storage-aged RBC transfusion/Fresh RBC transfusion|Subjects will receive a transfusion of packed red blood cell (RBC) units of storage-aged (>21 days old) blood followed by a transfusion of packed RBC units of fresh blood (<10 days old).
2999490|NCT02566564|Experimental|open label, single arm|Open label, single arm, dose escalating
2999491|NCT02566551|Experimental|Prostate artery embolization|Prostatic artery embolization (PAE) To perform embolization, gelatin microspheres (300-500 microns) will be used in this arm
2999492|NCT02566551|Active Comparator|Transurethral resection of the prostate|Transurethral resection of the prostate (TURP) A bipolar electrosurgery generator will be used to perform TURP
2999493|NCT02566525|Experimental|CytoSorb Device|Standard of care plus treatment with CytSorb device installed on the CPB machine
2999494|NCT02566525|No Intervention|Control|Standard of care
2999495|NCT02566512|Other|Tracheostomy cuff inflated|The tracheostomy cuff will be inflated.
2999496|NCT02566512|Other|Tracheostomy cuff deflated|The tracheostomy cuff will be deflated.
2999497|NCT02566499|Experimental|Abnormal x-ray Mammography group|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
2999498|NCT02566486|Other|Reciprocating system|Waveone root canal instrumentation file
2999499|NCT02566486|Other|Rotational system|ProTaper Next root canal instrumentation file
2999500|NCT02566460|Experimental|lactate clearance group|Refer to lactate clearance rate to perform resuscitation therapy
2999501|NCT02566460|Sham Comparator|SCVO2 group|Refer to SCVO2 to perform resuscitation therapy
2999502|NCT02566447||Symptomatic|Subjects will be categorized by the clinician as symptomatic for Trichomonas vaginalis infection.
2999503|NCT02566434|Experimental|Methionine|All participants will consume free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day for the duration of a 4-week intervention period. Participants will cease intake when signs of toxicity are measured in blood work.
2999504|NCT02566421|Experimental|Treatment (precision medicine)|Patients receive treatment based on the results of their genomic sequencing analyses.
2999505|NCT02566408|Experimental|Supportive Care (interview about KAPs towards PA)|"Participants undergo a 2-hour one-on-one interview and answer survey questions about their beliefs, attitudes, and preferences (KAPs) towards physical activity (PA). Ten topics will be used to explore older women's attitudes toward PA. Six topics will also be used to explore ethnic-specific and culture-specific contexts that surround older women's participation in PA.~REFINEMENT OF THE PA INTERVENTION: Approximately 1-2 months after the conclusion of interviews, participants are invited to a joint session and presented with results of analyzed data. Participants are asked to review results and themes identified from interviews, and to concur whether conclusions capture their KAPs. Through this process a set of preferences that is agreed upon by all as most critical for enhancing PA participation, adherence, and retention will be identified."
2999506|NCT02566395|Experimental|Haploidentical Stem Cell Transplantation|Subjects will receive pretransplantation conditioning of total-body irradiation (1,200 cGy delivered in 8 fractions over 4 days [Days -9 through -6] and cyclophosphamide (60 mg/kg IV daily x 2 on Days -3 and -2). Donor lymphocyte infusion will occur on day -6; donor CD34+ cells will be infused on Day 0.
2999507|NCT02566382|Experimental|shoulder arthroscopy arthrodesis|The shoulder surgery will be realized under arthroscopy only.
2999508|NCT02566369|Experimental|CD5789 (trifarotene) 50μg/g Cream|CD5789 (trifarotene) 50μg/g Cream
2999509|NCT02566369|Placebo Comparator|Placebo Cream|Placebo cream
2999510|NCT02566356|Experimental|Oxytocin|40 IU Oxytocin
2999511|NCT02566356|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
2999512|NCT02566343||COPD cohort|confirmed COPD: 240 patients with COPD confirmed by spirometry undergoing high-risk noncardiac major surgery in the University Medical Center Hamburg-Eppendorf will be included in this group.
2999513|NCT02566343||Control cohort|disproved COPD: 80 patients without COPD (clinical risk factors but negative spirometry) undergoing high-risk noncardiac major surgery will be included as a control group.
2999514|NCT02566330||EndoBarrier|Participants who were previously enrolled in the randomized clinical EndoBarrier procedure trial at the MUMC and the Atrium Medical Centre Heerlen.
2999515|NCT02566317|Active Comparator|Move|A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace.
2999516|NCT02566317|Experimental|Stand & Move|Move intervention (A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace) plus the installation of a sit-stand workstation.
2999517|NCT02566304|Experimental|RIC HSCT, GVHD prophylaxis|"RIC: Patients receive fludarabine phosphate IV over 60 minutes on days -10 to -8 and cyclophosphamide IV over 2 hours on days -3 and -2. Patients also undergo TBI followed by a DLI on day -6.~TRANSPLANT: Patients undergo CD34+ peripheral blood stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus PO beginning day -1 with a taper initiated on day 42 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD."
2999520|NCT02566278|Experimental|Obstructive Sleep Apnea|Upper airway collapsibility (passive Pcrit) will be measured using both clinically available equipment and research equipment in patients with obstructive sleep apnea (OSA) and stable on treatment of continuous positive airway pressure (CPAP) > 3 months to verify the Pcrit measurement obtained by the clinical equipment.
2999521|NCT02566265|Experimental|Fluzone High Dose Vaccine then Fluzone High Dose Booster|Fluzone High dose vaccine administered at Day 0. Fluzone High dose vaccine administered as a booster after 30 days from the initial vaccine.
2999522|NCT02566265|Active Comparator|Standard of Care|Fluzone High-Dose if age greater than or equal to 65 or Standard dose influenza vaccine if age less than 65 at day 0. Placebo administered 30 days after the initial vaccine.
2999523|NCT02566252|Experimental|PUL-042|PUL-042 Inhalation Solution
2999524|NCT02566252|Experimental|Cromolyn sodium|Pre-Treatment with cromolyn sodium followed by PUL-042 Inhalation Solution Administration
2999525|NCT02566252|Experimental|Albuterol sulfate|Pre-Treatment with albuterol sulfate followed by PUL-042 Inhalation Solution Administration
2999526|NCT02566239|Experimental|Shared Data|"Share activity data with care team.~Participants will have sensor technology installed in their home and caregivers will be provided with the data via our caregiver tool.~This group will be newly enrolled as part of this study and randomized to either the shared data or non-shared data groups. Randomization will be stratified by continuing care retirement community site and include statistical balancing on demographic factors."
2999527|NCT02566239|No Intervention|Non-shared Data|"Participants will have sensor technology installed in their home and caregivers will NOT have data provided via our caregiver tool.~This group will be newly enrolled as part of this study and randomized to either the shared data or non-shared data groups. Randomization will be stratified by continuing care retirement community site and include statistical balancing on demographic factors."
2999528|NCT02566226|Placebo Comparator|Bupivacaine with normal saline|
2999529|NCT02566226|Active Comparator|Bupivacaine with intrathecal morphine|
2999530|NCT02566213|Other|Motor skills measurements|
2999531|NCT02566200||IM group|Patients admitted in intensive care for a myocardial infarction
2999532|NCT02566187|Other|Group 1|Subjects of Group 1 take Fimasartan and Atorvastatin Individual Tablets at 1st day as period I. And then, after wash out for 7 days, as period II, subjects of Group 1 take a Fimasartan/Atorvastatin Combination Tablet at 8th day.
2999533|NCT02566187|Other|Group 2|Subjects of Group 2 take a Fimasartan/Atorvastatin Combination Tablet at 1st day as period I. And then, after wash out for 7 days, as period II, subjects of Group 2 take Fimasartan and Atorvastatin Individual Tablets at 8th day.
2999534|NCT02566148||HIV group|group living with HIV
2999535|NCT02566148||Hepatitis B group|group living with chronic hepatitis B
2999536|NCT02566148||Reference group|group who has neither HIV nor hepatitis B
2999537|NCT02566135|Active Comparator|Group-I|Tracheal intubation using I-gel and ventilating bougie insertion. In Group-I, following general anaesthesia I-gel is to be inserted, through it ventilating bougie is to be inserted then I-gel is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
2999538|NCT02566135|Active Comparator|Group-C|Tracheal intubation using C-LMA and ventilating bougie insertion. In Group-C, following general anaesthesia C-LMA is to be inserted, through it ventilating bougie is to be inserted then C-LMA is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
2999539|NCT02566122||muscle strength ,muscle mass|
2999540|NCT02566109|Other|Fast MRI|All patients who agree to participate in this study will have a 10 minute fast MRI scan and Baseline and 6 month time periods. The fast MRI will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
2999541|NCT02566096|Placebo Comparator|TAP with bupivicaine|30 patients receive ultrasound guided transversus abdominis-plane block (TAP) with local anesthetic 20 ml of bupivacaine 0.5 % diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of the abdominal wall.
2999542|NCT02566096|Active Comparator|TAP with bupivicaine with morphine|30 patients receive ultrasound guided transversus abdominis-plane block (TAP) with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of the abdominal wall.
2999543|NCT02566083|Active Comparator|non-toric intraocular lens|non-toric approved intraocular lens
2999544|NCT02566083|Active Comparator|toric intraocular lens|approved toric intraocular lens
2999545|NCT02566070|Active Comparator|Continuous Gastric Feeding (CGF)|CGF group will have total daily enteral nutrition requirement delivered at a constant rate via infusion over the entire 24 hour period.
2999546|NCT02566070|Experimental|Bolus Gastric Feeding (BGF)|BGF group will have total daily enteral nutrition requirement delivered in interval, finite volumes over the course of the 24 hour period.
2999547|NCT02566057|Experimental|PGx testing guided treatment (PGT)|Results of the GeneceptTM Assay will be provided to their prescribers who may use the knowledge to guide medication management.
2999548|NCT02566057|No Intervention|Treatment as usual condition (TAU)|Patients will also utilize the GeneceptTM Assay but the results will not be provided back to their prescribers, who will treat the patients without the knowledge of pharmacogenetic testing results.
2999549|NCT02566044|Experimental|CQBW276|"Cohorts 1 and 2 will enroll 8 patients each (6:2 QBW276 and placebo, respectively).~Cohort 1: dose is 3 mg bid (6 mg daily) QBW276 or placebo for 7 days. Cohort 2: dose and frequency will be confirmed after cohort 1 is complete. The duration is 14 days.~Cohort 3: dose and frequency will be confirmed after cohort 2 is complete. The duration is approximately 4 months. Patients will be randomized to one of two treatment sequences: QBW276 in Period 1 and Placebo in Period 2 or Placebo in Period 1 and QBW276 in Period 2. Twenty four patients are required to complete cohort 3."
2999550|NCT02566044|Placebo Comparator|Placebo|"Cohorts 1 and 2 will enroll 8 patients each (6:2 QBW276 and placebo, respectively).~Cohort 1: dose is 3 mg bid (6 mg daily) QBW276 or placebo for 7 days. Cohort 2: dose and frequency will be confirmed after cohort 1 is complete. The duration is 14 days.~Cohort 3: dose and frequency will be confirmed after cohort 2 is complete. The duration is approximately 4 months. Patients will be randomized to one of two treatment sequences: QBW276 in Period 1 and Placebo in Period 2 or Placebo in Period 1 and QBW276 in Period 2. Twenty four patients are required to complete cohort 3."
2999551|NCT02566031|Experimental|Indacaterol and glycopyrronium (QVA149)|QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 12 weeks
2999552|NCT02566031|Active Comparator|Tiotropium|Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 12 weeks
2999553|NCT02566018||experimental intervention|A greater degree of initial displacement is tolerated to allow for conservative, non-operative treatment in more simple fracture patterns. Two-part fractures with marked displacement including two part patterns with a non-displaced greater or minor tuberosity fracture (formally three part fractures) are treated with a proximal humerus nail; and displaced three and four part fractures are primarily managed with a reverse total shoulder arthroplasty. Proximal Humeral Internal Locking System (PHILOS)-plates are only used exceptionally in this group of patients.
2999554|NCT02566018||control intervention|"Since May 2013 we have changed our treatment algorithm for the treatment of fractures of the humeral head in the elderly. Before this change in algorithm we used PHILOS plates extensively and rarely Inverse Shoulder prostheses.~In general all proximal humerus fractures were operated except minimally or undisplaced."
2999555|NCT02566005|Active Comparator|misoprostol group|The women in the misoprostol only group will receive 25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist
2999556|NCT02566005|Active Comparator|misoprostol and foley bulb group|Women in the combination group will receive vaginal misoprostol per standard protocol. In addition, a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours. Oxytocin will be initiated in those patients who were not in labor after expulsion or removal of the catheter.
2999557|NCT02565992|Experimental|CAVATAK and pembrolizumab|Intratumoral CAVATAK administration on trial days 1, 3, 5 and 8 and at 3-weekly intervals up to a maximum of 19 total with intravenous pembrolizumab (2 mg/kg solution) starting on day 8 and continuing every 3 weeks, up to 2 years.
2999558|NCT02565979|Active Comparator|Resveratrol|resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
2999559|NCT02565979|Placebo Comparator|Placebo|placebo will be given for 6 months, twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
2999560|NCT02565966|Experimental|Modified Atkins Diet (MAD)|
2999561|NCT02565966|No Intervention|Normal Diet|Those patients in the normal diet (no intervention) group will also meet with the epilepsy center nutritionist to review the food diary and completion of this document, similar to those in the intervention (MAD) group. No dietary restrictions will be made in this group.
2999562|NCT02565953|Experimental|Paclitaxel-releasing PTA balloon catheter|Treatment of renal dialysis arteriovenous fistula stenosis with paclitaxel-releasing percutaneous transluminal angioplastic (PTA) balloon catheter.
2999563|NCT02565953|Active Comparator|PTA Balloon catheter|Treatment of renal dialysis arteriovenous fistula stenosis with percutaneous transluminal angioplastic (PTA) balloon catheter.
2999564|NCT02565940||diabetic patient with foot infection|
2999565|NCT02565927|Experimental|Radioactive stent|Patients diagnosed as MAO treated with radioactive airway stent loaded with Iodine-125 seeds
2999566|NCT02565927|Active Comparator|Traditional airway stent|Patients diagnosed as MAO treated with traditional airway stent
2999567|NCT02565914|Experimental|Part A Treatment Cohort: VX-661/ivacaftor|VX-661 100 mg/ ivacaftor 150 mg fixed dose combination (FDC) tablet daily (qd) in the morning and ivacaftor 150 mg tablet qd in the evening
2999568|NCT02565914|No Intervention|Part A Observational Cohort|Long-term Follow-up
2999569|NCT02565914|Experimental|Part B Treatment: VX-661/ivacaftor|VX-661 100 mg/ ivacaftor 150 mg fixed dose combination (FDC) tablet daily (qd) in the morning and ivacaftor 150 mg tablet qd in the evening
2999570|NCT02565901|Experimental|Arm I (sirolimus, docetaxel, carboplatin)|Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30 minutes on day 1. Beginning in course 2 and continuing in subsequent courses, patients also receive sirolimus PO on day -2. Treatment repeats every 21 days for 10 courses in the absence of disease progression or unacceptable toxicity.
2999571|NCT02565901|Experimental|Arm II (sirolimus, docetaxel, carboplatin)|Patients receive sirolimus PO on day -2. Patients also receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 courses in the absence of disease progression or unacceptable toxicity.
2999572|NCT02565888|Active Comparator|Treatment A|Daclatasvir 30 mg QD film-coated tablet + atazanavir 300mg QD hard capsule + ritonavir 100mg QD from film-coated tablet for 10 days.
2999573|NCT02565888|Experimental|Treatment B|Daclatasvir 30 mg QD film-coated tablet + atazanavir 300mg QD hard capsule + cobicistat 150mg QD from film-coated tablet for 10 days.
2999574|NCT02565875|Experimental|SLL Presentation|"Intervention: Standardized Language of Laparoscopy (SLL) Presentation and simulated laparoscopic task performed on a low-fidelity pelvis simulator~Will witness a presentation on the use of a SLL for communication between the primary and assistant surgeons during laparoscopy as previously determined by a national survey of Canadian experts and a modified delphi technique."
2999575|NCT02565875|Placebo Comparator|Control Presentation|"Intervention: Surgical Anatomy (SA) Presentation and simulated laparoscopic task performed on a low-fidelity pelvis simulator~Will witness a presentation of similar duration as the intervention group on laparoscopy but not related to communication (laparoscopic anatomy). The simulated laparoscopic task will be identical to the SLL group."
2999576|NCT02565862|Active Comparator|Treatment A|"Day 1-2: 500mg twice daily (BID) metformin film-coated tablets~Day 3-8: 1000mg BID metformin film-coated tablets"
2999577|NCT02565862|Experimental|Treatment B|"Day 15-16: 500mg BID metformin film-coated tablets + 60mg once daily (QD) daclatasvir film-coated tablets~Day 17-22: 1000mg BID metformin film-coated tablets~+ 60mg QD daclatasvir film-coated tablets"
2999578|NCT02565849||Control group|Recruited volunteers aged above 18 years with no history of smoking or hospitalization in the last three months without cardiac dysfunction, orthopedic or lung.
2999579|NCT02565849||Sickle Cell Anemia normal spirometry|Recruited patients aged above 18 years with no history of smoking or hospitalization in the last three months, ability to independent ambulation and spirometry tests and plethysmography with normal medical report.
2999580|NCT02565849||Sickle Cell Anemia spirometry abnormal|Recruited patients aged above 18 years with no history of smoking or hospitalization in the last three months, ability to independent ambulation and spirometry tests and plethysmography with altered medical report.
2999581|NCT02565836||fixed-dose aPCC|Patients receiving fixed-dose activated prothrombin complex concentrate (FEIBA VH) for reversal of warfarin-associated major hemorrhage.
2999582|NCT02565836||variable-dose PCC|Patients receiving vairable-dose inactivated prothrombin complex concentrate (Kcentra) for reversal of warfarin-associated major hemorrhage.
2999583|NCT02565823|Experimental|Exercise intervention|Subjects will undergo an acute bout of exercise for 45 mins at 75% of peak aerobic capacity
2999584|NCT02565810|Experimental|SB5 40mg|
2999585|NCT02565797|Experimental|DabirAIR overlay-ORICU|Patients scheduled for neurosurgical procedures will be placed over DabirAIR alternating pressure overlay (placed on top of standard of care support surface) in the operating room and in the post-op ICU.
2999586|NCT02565797|Experimental|DabirAIR overlay-OR|Patients scheduled for neurosurgical procedures will be placed over DabirAIR alternating pressure overlay (placed on top of standard of care support surface) in the operating room alone and on standard of care support surface in the post-op ICU.
2999587|NCT02565797|No Intervention|Control-SOC|Patients scheduled for neurosurgical procedures will be placed on standard of care support surface in the operating room and post-op ICU. Data will be abstracted through retrospective chart review.
2999588|NCT02565784|Experimental|Intradermal injection|Restylane and/or Perlane
2999589|NCT02565771||Young adult survivors of childhood cancer|Adults treated for childhood cancer in Rhône-Alpes region in France between 1987 and 1992 with deregulation ANS or autonomic imbalance.
2999590|NCT02565758|Experimental|Arm A4 (ABBV-085)|ABBV-085 administered on at 28 day cycle and enrolling at MD Anderson
2999591|NCT02565758|Experimental|Arm A3 (ABBV-085)|ABBV-085 will be administered at every cycle (28-day cycles).
2999592|NCT02565745|Experimental|Skin Dressing|Hydrocolloid dressings applied during hospitalization
2999593|NCT02565745|Active Comparator|Moisturizing cream|Use of moisturizing cream, as part of conventional skin care
2999594|NCT02565732|Experimental|Dose A|Botulinum toxin type A
2999595|NCT02565732|Experimental|Dose B|Botulinum toxin type A
2999596|NCT02565732|Placebo Comparator|Dose C|Placebo comparator
2999597|NCT02565719|Experimental|REP 2139-Mg with Viread and Pegasys|REP 2139-Mg in combination with tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys).
2999598|NCT02565719|Experimental|REP 2165-Mg with Viread and Pegasys|REP 2165-Mg in combination with tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys).
2999599|NCT02565719|Active Comparator|Viread and Pegasys with crossover to REP 2139-Mg and Pegasys|Tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys) - crossover into add-on REP 2139-Mg therapy (triple combination) in patients with < 3 log reduction in serum HBsAg from baseline after 24 weeks of Pegasys exposure.
2999600|NCT02565719|Active Comparator|Viread and Pegasys with crossover to REP 2165-Mg and Pegasys|Tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys) - crossover into add-on REP 2165-Mg therapy (triple combination) in patients with < 3 log reduction in serum HBsAg from baseline after 24 weeks of Pegasys exposure.
2999601|NCT02565706|Experimental|WIC Fresh Start Program|Participants in this arm receive the Fresh Start program.
2999602|NCT02565706|Active Comparator|Existing Online Health Education|Participants in this arm receive existing online WIC health education.
2999603|NCT02565706|Experimental|WIC Fresh Start Program (FMNP)|Participants in this arm receive the Fresh Start program and WIC Farmers' Market Nutrition Program (FMNP) vouchers redeemable at farmers' markets.
2999604|NCT02565706|Active Comparator|Existing Online Health Education (FMNP)|Participants in this arm receive existing online WIC health education and WIC Farmers' Market Nutrition Program (FMNP) vouchers redeemable at farmers' markets.
2999605|NCT02565693|Experimental|Apixaban|"Apixaban: oral, 5 mg twice daily. If two of the three following criteria are met, the dose will be reduced to 2.5 mg twice daily:~Age ≥ 80 years~Body weight ≤ 60 kg~Serum creatinine ≥ 133 μmol. Additionally, if the creatinin clearance is below 30 ml per minute, the dose will be reduced to 2.5 mg twice daily."
2999606|NCT02565693|Other|Avoiding oral anticoagulants|"The following treatment regimens are allowed in the comparator arm:~- No antithrombotic treatment~or:~Acetylsalicylic acid 80 mg once daily~Carbasalate calcium 100 mg once daily~Clopidogrel 75 mg once daily~Acetylsalicylic acid 80 mg once daily and dipyridamole 200 mg twice daily~Carbasalate calcium 100 mg once daily and dipyridamole 200 mg twice daily"
2999607|NCT02565680|Placebo Comparator|placebo|tablets of Xyzall 5mg/ day during 5 days + placebo 40mg/ day during 4 days
2999608|NCT02565680|Experimental|prednisone|tablets of Xyzall 5 mg/j during 5 days + prednisone 40 mg/ day during 4 days
2999609|NCT02565667|Experimental|KOL group|KOL stapler was used for rectal anastomosis
2999610|NCT02565667|Active Comparator|traditional stapler group|traditional stapler was used for rectal anastomosis
2999611|NCT02565654||Rifaximin group|Patients are treated with rifaximin (Alfa Wassermann Pharmaceutical Co., Ltd. Italy) for 14 days at a daily dosage of 1200 mg (400 mg, three times daily)
2999612|NCT02565641|Experimental|Capecitabine + Gemcitabine|Participants will receive oral capecitabine (830 milligrams per meter-squared [mg/m^2]) twice daily (BID) as intermittent treatment (Days 1 to 21 every 4 weeks [q4w]) along with IV infusion of gemcitabine (1000 mg/m^2) once weekly as intermittent treatment (4-week cycles of 3-week treatment period and 1-week rest period).
2999613|NCT02565628|Experimental|PF-06669571|Once daily (QD) for 7 days
2999614|NCT02565628|Placebo Comparator|Placebo|QD for 7 days
2999615|NCT02565615||Atorvastatin dose titration (single-arm)|Judged by investigators, patients in cardiology department who are using atorvastatin can be included into this study, if they are eligible. During the study, the dose can be titrated based on the judgement of investigator
2999616|NCT02565602|Other|Ca-41 & Sr-84 (isotope tracers) & vit D|Dosages: 3.7 kBq (100 nCi) Ca-41, 5 mg of Sr-84 and 400IU of vitamin D (daily)
2999617|NCT02565589||ICU patient|Critically ill patients who were enrolled less than 24 hours after ICU admission.
2999618|NCT02565589||Control|Age-, sex-, and BMI-matched healthy subjects.
2999619|NCT02565576|Active Comparator|CFZ533|CFZ533
2999620|NCT02565576|Placebo Comparator|Placebo|Placebo
2999621|NCT02565563|Active Comparator|Eye Movements|Eye Movement Desensitisation Reprocessing with eye movements (measuring Heart Rate Variability using HeartMath)
2999622|NCT02565563|Active Comparator|No Eye Movements|Eye Movement Desensitisation Reprocessing without eye movements (measuring Heart Rate Variability using HeartMath)
2999623|NCT02565550|Experimental|IBS patients|eat the low FODMAPs diet for one week
2999624|NCT02565550|Active Comparator|healthy controls|eat the low FODMAPs diet for one week
2999625|NCT02565537|Active Comparator|iDesign WFG LASIK|Wavefront-guided LASIK
2999626|NCT02565537|Active Comparator|Wavelight WFO LASIK|Wavefront-optimized LASIK
2999627|NCT02565524|Experimental|genetic and phenotypic profile|blood sample, clinical and neurocognitive assessment
2999628|NCT02565511|Experimental|Arm#1|CAD106 (450 µg) + Alum (450 µg) given i.m. at week 1, 7, 13 and quarterly thereafter
2999629|NCT02565511|Placebo Comparator|Arm#2|Placebo to CAD106 + Alum (450 µg) given i.m. at week 1, 7, 13 and quarterly thereafter
2999630|NCT02565511|Experimental|Arm#3|CNP520 (50 mg) capsules oral intake (p.o.)
2999631|NCT02565511|Placebo Comparator|Arm#4|Placebo to CNP520 capsules oral intake (p.o.)
2999632|NCT02565498|Other|Preoperative Radiation Therapy (Arm A)|Preoperative intensity modulated radiation therapy followed by surgery
2999633|NCT02565498|Experimental|Postoperative Radiation Therapy (Arm B)|Surgery followed by postoperative intensity modulated radiation therapy
2999634|NCT02565485|No Intervention|Standard IV Preload|Patients in this arm will receive 500mL of Lactated Ringer's solution, which is the standard IV fluid preload used on Labor and Delivery at MetroHealth Medical Center
2999635|NCT02565485|Experimental|Volume Replacement IV Preload|Patients in this arm will receive 1500mL of Lactated Ringer's solution
2999636|NCT02565472|Experimental|Apple Juice|12 oz apple juice
2999637|NCT02565472|Experimental|Grape Juice|12 oz grape juice
2999638|NCT02565459|Experimental|Mesenchymal Stromal Cells (MSC)|A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party (from healthy donors) MSCs will be performed in patients randomized to the MSC procedure in addition to the kidney transplantation.
2999639|NCT02565459|No Intervention|No intervention|
2999640|NCT02565446|Other|MRE|"To evaluate new MRE sequence that is capable of distinguishing liver fibrosis and inflammation. MRE has emerged as the potential alternative to invasive liver biopsy and possibly the reference standard for non-invasive diagnosis of liver fibrosis. All 80 participants undergoing bariatric surgery will complete a non-invasive determination of liver inflammation and fibrosis by MRE. The proposed sample size for this experiment will be calculated based on sensitivity and specificity of MRE for differentiating various stages of fibrosis. We are looking for differentiation of simple steatosis from steatohepatitis and steatohepatitis with fibrosis."
2999641|NCT02565433|Experimental|questionnaire administration|Quality of life questionnaires administration (EORTC QLQ C30 and BN20 / IADL / HADS / MoCa Edmonton Symptom Assessment Scale)
2999642|NCT02565420|Active Comparator|Lactated Ringer's solution|During the perioperative period of the colorectal, orthopedic or similar surgery the patient will receive an intervention of Lactated Ringer's solution fluids.
2999643|NCT02565420|Placebo Comparator|normal saline|During the perioperative period of the colorectal, orthopedic or similar surgery the patient will receive an intervention of normal saline solution.
2999644|NCT02565407|Experimental|Proprioceptive training|This arm will receive specialized robot-aided proprioceptive training of the wrist next to usual care.
2999645|NCT02565407|Active Comparator|Usual care|This arm will receive what participants have been receiving from their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy at home, day rehabilitation, or outpatient visits.
2999646|NCT02565394|Experimental|Micro-Break with Dynamic Activity|Micro Break with web based application of a video to lead surgeons through dynamic exercise activities
2999647|NCT02565394|No Intervention|Comparator|A baseline survey will be completed following a surgical day with no dynamic activities
2999648|NCT02565381|Active Comparator|Control (N=25)|"Transdermal nicotine patch~In-person smoking cessation counseling"
2999649|NCT02565381|Experimental|Financial rewards (N=25)|"Transdermal nicotine patch~In-person smoking cessation counseling~Contingent financial rewards for smoking abstinence"
2999650|NCT02565381|Experimental|Text messaging (N=25)|"Transdermal nicotine patch~In-person smoking cessation counseling~Text messages to support smoking abstinence"
2999651|NCT02565368|Experimental|RT group|R: Reference drug(Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg) 1T T: Test drug(CKD-395 0.5/1000mg) 1T
2999652|NCT02565368|Experimental|TR group|T: Test drug(CKD-395 0.5/1000mg) 1T R: Reference drug(Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg) 1T
2999653|NCT02565355|Other|Lifestyle Modification/Dietary Exclusion|In the lifestyle modification group, where specific IgG antibodies to foods are identified, the intervention is appropriate dietary elimination. The IgG antibody results will be disclosed and specific dietary elimination advice will be provided by an experienced dietician; provide diet alternatives to prevent nutritional deficiencies and improve adherence to diet. To improve compliance, a maximum of 2 high IgG positive foods will be eliminated at any one time in each 4 week period. Children will be followed-up in PG clinic at 4-weekly intervals for 16 weeks. Response is defined as more than 50% improvement in frequency and severity of abdominal pain. They will be assessed at visits 2, 3, 4 and 5 for follow-up, and non-responders, will cross over to the other arm of the study.
2999728|NCT02564874|Experimental|Sugary beverage|1-2 soda-based drinks/juice to be taken in determined portions equivalent to 15% of dietary energy intake, chosen from 9-point hedonic preferences questionnaire completed by participant (coke, sprite, etc.)
2999729|NCT02564861|Experimental|DS-1971a (Low Dose)|Participants in Cohort 1 who receive a low dose of DS 1971a in an oral suspension
2999730|NCT02564861|Experimental|DS-1971a (Mid dose)|Participants in Cohort 2 who receive a mid dose of DS 1971a in an oral suspension
2999654|NCT02565355|Other|The Standard Treatment Group|The standard therapy group will not receive results of IgG antibody testing. The patients will receive conventional treatment for Abdominal Pain as per usual practice at the Pediatric GI (PG) Clinic - counseling, reassurance, improving coping strategies and pain relief as appropriate. Children will be followed-up in PG clinic at 4-weekly intervals for 16 weeks. Response is defined as more than 50% improvement in frequency and severity of abdominal pain. They will be assessed at visits 2, 3, 4 and 5 for follow-up, and non-responders, will cross over to the other arm of the study.
2999655|NCT02565342|Experimental|Interscalene brachial plexus block|
2999656|NCT02565316|Active Comparator|Nepeta menthoides Boiss & Bohse freeze dried extract capsule|
2999657|NCT02565316|Active Comparator|Sertraline capsule|
2999658|NCT02565303|Experimental|L2-3 intervertebral group|The initial dose of ropivacaine for subarachnoid is chosen as 12 mg in L2-3 intervertebral space group.
2999659|NCT02565303|Experimental|L3-4 intervertebral group|The initial dose of ropivacaine for subarachnoid is chosen as 15 mg in L3-4 group.
2999660|NCT02565290|Active Comparator|Omega-3|2 capsules of omega 3 - 2 times a day
2999661|NCT02565290|Placebo Comparator|Soy oil|2 capsules of soy oil - 2 times a day
2999662|NCT02565277|Active Comparator|Influenza Vaccine|Fluzone injection once IM
2999663|NCT02565277|Placebo Comparator|Placebo|Saline Injection once IM
2999664|NCT02565264|Experimental|plasma-derived exosomes|plasma-derived exosomes
2999665|NCT02565251|Experimental|Sepsis grup 1|Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
2999666|NCT02565251|Experimental|Sepsis grup 2|Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
2999667|NCT02565251|Experimental|Soc septic grup 1|Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
2999668|NCT02565251|Experimental|Soc septic grup 2|Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours andVolumeView/Ev1000 monitoring during the next 4 hours
2999669|NCT02565225||RheumaLive App use|RheumaLive App use and evaluation of feasibility
2999670|NCT02565225||RheumaLive App use & threshold values|RheumaLive App use and evaluation of feasibility
2999671|NCT02565212|Experimental|GROUP 1|montelukast sodium and mometasone
2999672|NCT02565212|Active Comparator|Group 2|montelukast
2999673|NCT02565212|Active Comparator|Group 3|mometasone furoate
2999674|NCT02565199|Experimental|Single motor training only|For a pilot experiment, healthy, right-handed subjects will complete one testing session. During the testing session, subjects will complete motor training. The results of this experiment will determine the motor training protocol used in the main experiment.
2999675|NCT02565199|Experimental|Repetitive TMS during motor training|Healthy, right-handed subjects will complete five testing sessions. During each testing session, subjects will complete motor training while receiving one of five repetitive transcranial magnetic stimulation (rTMS) protocols. Subjects will receive a different rTMS protocol at each testing session. By the end of the study, each subject will have received all rTMS protocols.
2999676|NCT02565186|Experimental|lasmiditan 100 mg|single tablet with second dose for rescue/recurrence
2999677|NCT02565186|Experimental|lasmiditan 200 mg|single tablet with second dose for rescue/recurrence
2999678|NCT02565173|Experimental|trabodenoson 4.5% BID|trabodenoson 4.5% Ophthalmic Formulation
2999679|NCT02565173|Experimental|trabodenoson 6.0% QD|trabodenoson 6.0% Ophthalmic Formulation
2999680|NCT02565173|Experimental|trabodenoson 3.0% QD|trabodenoson 3.0% Ophthalmic Formulation
2999681|NCT02565173|Active Comparator|timolol 0.5% BID|timolol 0.5% Ophthalmic Formulation
2999682|NCT02565173|Placebo Comparator|placebo BID|placebo Ophthalmic Formulation
2999683|NCT02565160||Septic Arthritis|Patients suspected of having septic arthritis
2999684|NCT02565160||Osteoarthritis|Patients suffering with osteoarthritis undergoing an intervention
2999685|NCT02565160||Joint Revision|Patients who has a prosthetic joint in situ
2999686|NCT02565147|Active Comparator|primary PCI with Heparin|Heparin to be dosed according to standard of care for completion of PCI per site. An ACT>250 at the end of the procedure is recommended.
2999687|NCT02565147|Experimental|primary PCI with Bivalirudin|Bivalirudin given as a bolus (0.75mg/kg) followed by 4 hr infusion after the completion of primary PCI using the PCI dose (1.75mg/kg/h)
2999688|NCT02565134|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 4 weeks
2999689|NCT02565134|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 4 weeks
2999690|NCT02565134|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
2999691|NCT02565134|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
2999692|NCT02565121|Experimental|Olfactory disorder after brain trauma|Recruited from 250 patients with moderate to severe traumatic brain injury in the Hodeskadeprosjektet (TBI) cohort. Treatment with (first) corticosteroids and (second) olfactory stimulation.
2999693|NCT02565108|Experimental|GWP42003-P 20 mg/kg/Day Dose|"Participants received GWP42003-P 20 milligrams [mg]/kilogram [kg]/day orally, twice daily immediately after their clobazam (CLB) dose. Participants titrated GWP42003-P to 20 mg/kg/day over 10 days and remained at this dose for the 21-day treatment period. Participants who then did not enter the open-label extension (OLE) or withdrew early had a 10-day taper (10% per day) period. Participants who transferred to the OLE (still blinded at that stage) tapered off their GWP42003-P treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P for the OLE.~All participants (in the GWP42003-P and Placebo treatment groups) were on a stable dose of CLB at Baseline, administered either once or twice daily as per the physician's preferred CLB dosing regimen for each participant, and continued taking CLB, as an Investigational Medicinal Product (IMP), for the duration of this study."
2999731|NCT02564861|Experimental|DS-1971a (High dose)|Participants in Cohort 3 who receive a high dose of DS 1971a in an oral suspension
2999732|NCT02564861|Experimental|Pooled placebo|Participants in Cohort 1, 2 or 3 who receive matching DS-1971a Placebo
2999733|NCT02564848|Experimental|Lumpectomy without sentinel node biopsy|Subjects will undergo standard of care lumpectomy. A biopsy of the sentinel node will not be performed. After surgery, subjects will receive standard of care radiation on the affected breast and hormonal therapy.
2999694|NCT02565108|Placebo Comparator|Placebo|"Participants received placebo (0 mg/milliliter [mL] GWP42003-P) orally, twice daily immediately after the participant's CLB dose. Participants titrated the placebo dose over 10 days, followed by a 21-day treatment period. Participants who then did not enter the OLE or withdrew early had a 10-day taper (10% per day) period. Participants who transferred to the OLE (still blinded at that stage) tapered off their placebo treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P for the OLE.~All participants (in the GWP42003-P and Placebo treatment groups) were on a stable dose of CLB at Baseline, administered either once or twice daily as per the physician's preferred CLB dosing regimen for each participant, and continued taking CLB, as an IMP, for the duration of this study."
2999695|NCT02565095|Other|Carotid Baroreflex measurements|
2999696|NCT02565082|Experimental|Sickle cell disease|This arm will include an approximate number of 50 sickle cell disease patients, homozygous and heterozygous.
2999697|NCT02565082|Other|Control|This arm will include an approximate number of 30 healthy volunteers.
2999698|NCT02565069|Experimental|Treatment group|Use of CartoFinder™ device with CARTO® 3 System V5 Navigation to treat complex arrhythmias
2999699|NCT02565056|Active Comparator|Self-help|Self-help book completed over 6 weeks with up to 30 minutes of telephone support per week.
2999700|NCT02565056|No Intervention|Treatment as usual|Treatment as usual.
2999701|NCT02565043|Experimental|RENASYS TOUCH Negative Pressure Wound Therapy Device|"Active Device: RENASYS TOUCH NPWT device administered to all patients using the intermittent/variable therapy mode, for up to 28 days of therapy."
2999702|NCT02565043|Active Comparator|RENASYS TOUCH Negative Pressure Wound Therapy System|"Active Device: RENASYS TOUCH NPWT device administered to all patients using the continuous therapy mode for up to 28 days of therapy."
2999703|NCT02565030||CTEPH surgical disease, operated|Patients with proximal CTEPH who have undergone Pulmonary Endarterectomy (PEA) surgery
2999704|NCT02565030||CTEPH surgical disease, not operated|"Patients with proximal CTEPH with operable distribution of disease& have not undergone PEA surgery due to the following reasons:~Multiple co-morbidities~Patients choice~Mild disease /symptoms~Awaiting Surgery"
2999705|NCT02565030||CTEPH non surgical|Patients with distal CTEPH with inoperable distribution of disease inaccessable to surgery.
2999706|NCT02565030||IPAH|Patients with IPAH as per European Society of Cardiology(ESC) criteria
2999707|NCT02565017||Breast Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
2999708|NCT02565017||Lung Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
2999709|NCT02565017||Colorectal Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
2999710|NCT02565004||1|Patients who were enrolled on protocol 09-C-0079, or family members of patients who were enrolled on protocol 09-C-0079
2999711|NCT02565004||2|Individuals found to harbor a germline APC promoter lB variant not previously enrolled in Cohort l.
2999712|NCT02564978|Experimental|Minocycline|Oral administration of minocycline or placebo.
2999713|NCT02564965|Other|Greater than 50% Necrosis|Subjects who have greater than 50% necrosis as determined by MRI, Endoscopic Ultrasound (EUS), or direct transluminal endoscopic imaging of the collection. This stratification group will be randomized to either the double pigtail plastic stent or the AXIOS metal stent.
2999714|NCT02564965|Other|Less than 50% Necrosis|Subjects who have less than 50% necrosis as determined by MRI, Endoscopic Ultrasound (EUS), or direct transluminal endoscopic imaging of the collection. This stratification group will be randomized to either the double pigtail plastic stent or the AXIOS metal stent.
2999715|NCT02564952|Experimental|GWP42003-P|"Administered orally, twice daily (morning and evening; immediately after the participant's clobazam dose), commencing with titration of 100 mg/mL GWP42003-P to 20 mg/kg/day over 10 days in a blinded manner.~Participants remain on the maintenance dose for the remainder of the 12-month treatment period. However, investigators may subsequently decrease or increase the participant's dose (to a maximum of 30 mg/kg/day) until the optimum dose is found.~Dosing is tapered (10% each day) for participants who do not immediately continue to use GWP42003-P once market authorization is granted, or for those who withdraw early."
2999716|NCT02564939|Active Comparator|ramelteon|receive ramelteon
2999717|NCT02564939|Placebo Comparator|placebo|receive placebo
2999718|NCT02564926|Experimental|Dapagliflozin|Dapagliflozin 10mg + Metformin 1000mg
2999719|NCT02564926|Active Comparator|Glimepiride|Glimepiriide 1-2mg + Metformin 1000mg
2999720|NCT02564913||control group|
2999721|NCT02564913||pre-DM group|
2999722|NCT02564913||DM group|
2999723|NCT02564900|Experimental|Part 1 Dose escalation|Part 1 is a dose escalation to identify the Maximum Tolerated dose (MTD) or the recommended phase 2 dose of DS-8201a guided by the modified continuous reassessment method using a Baysian logistic regression model following escalation with overdose control principal.
2999724|NCT02564900|Experimental|Part 2 Dose expansion|Part 2 is a dose expansion to examine the safety and efficacy of DS-8201a and it is consist of multiple cohorts: in subjects with trastuzumab emtansine (T-DM1)-treated HER2 overexpressing breast cancer (Part 2a); trastuzumab-treated HER2 overexpressing gastric or gastroesophageal junction adenocarcinoma (Part 2b); HER2 low expressing breast cancer (Part 2c), and HER2 expressing other solid malignant tumor (Part 2d)
2999725|NCT02564887|Other|Traditional Therapy Only|"Standard of care therapy for qualifying population (with opportunity to crossover and be assigned to the IOPI device if so desired after initial 8 week standard of care therapy completion."
2999726|NCT02564887|Experimental|Traditional Therapy with IOPI|Standard of care therapy plus the addition of the IOPI instrument
2999727|NCT02564874|Experimental|Savory snack|1-2 assigned snacks to be taken in determined portions equivalent to 15% of dietary energy intake, chosen from 9-point hedonic preferences questionnaire completed by participant (chips, pretzels, etc.)
2999734|NCT02564835|Experimental|Yoga|The Yoga Program includes two 90-minute classes every week tor a total of 12 weeks.
2999735|NCT02564835|Active Comparator|Physical Activity|The Physical Activity Program includes two 90-minutes classes every week for a total of 12 weeks.The intervention is based on the Exercise for People Living with Cancer program and will include nine resistance exercises (e.g. standing push up, squats, standing leg curl) and 8 flexibility exercises (e.g. shoulder stretch, quadriceps stretch, hamstrings and lower back stretch) targeted for the whole body as well as a brief warm up and cool down (walking).
2999736|NCT02564835|No Intervention|Usual Care|Participants randomized to this arm will receive standard care only.
2999737|NCT02564822||Migraneurs - Visual stimulation|Patients will be recruited via advertisements on the university. Patients should have migraine diagnosis according to the International Classification of Headache Disorders (ICHD-III) criteria and clinical diagnosis by a neurologist.
2999738|NCT02564822||Control - Visual stimulation|Healthy volunteers will be recruited via advertisements on the university. For control subjects the individuals should not have migraine diagnosis assessed according to IHCD-III criteria.
2999739|NCT02564809|Experimental|Fit Brains training|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will be performing a cognitive training program (Fit Brains training) 6 hours a week for 8 weeks.
2999740|NCT02564809|Experimental|Exercise + Fit Brains training|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will be performing a combination of aerobic exercise and a cognitive training program (Fit Brains training) for 6 hours a week over 8 weeks.
2999741|NCT02564809|Sham Comparator|Balanced And Tone|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will complete 3 weekly training sessions of 1 hour for 8 weeks.
2999742|NCT02564796|Placebo Comparator|Control|Group II (non-treatment group): Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
2999743|NCT02564796|Experimental|Epoetin alfa and iron supplements|Group I (treatment group): Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
2999744|NCT02564770||Rheumatoid arthritis (RA) participants|Participants who had been treated with rituximab for RA are reviewed retrospectively using chart review from Baseline until and their most recent visit to the rheumatologist prior to the conduct of the chart review.
2999745|NCT02564744|Experimental|Debio 1562|Participants with a diagnosis of relapsed and/or refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma (FL), Marginal Zone/Mucosa-associated Lymphoid Tissue (MZ/MALT), Mantle Cell Lymphoma (MCL) or other Non-Hodgkin's Lymphoma (NHL) with the Sponsor's approval, will receive Debio 1562 and Rituximab in 3 different parts of study i.e., Safety run in, Part 2 and Expansion (Part 3). Participants in Part 2 will be enrolled in two parallel cohorts (Cohort A and Cohort B).
2999746|NCT02564718|Experimental|Arm 1|Rivaroxaban oral suspension from granules will be dosed according to body weight as oral 0.1% suspension (1 mg/mL)
2999747|NCT02564705||anterior cohort|Anterior Lumbar Interbody Fusion (ALIF)
2999748|NCT02564705||posterior cohort|"Posterolateral Fusion (PLF)~Posterior Lumbar Interbody Fusion (PLIF)~Transforaminal Lumbar Interbody Fusion (TLIF)"
2999749|NCT02564679|Experimental|Sleeve gastrectomy|These patients are surgically treated with laparoscopic sleeve gastrectomy in association to lifestyle intervention (hypocaloric diet and physical activity)
2999750|NCT02564679|Experimental|Lifestyle Intervention|These patients are treated with lifestyle intervention (hypocaloric diet and physical activity)
2999751|NCT02564666|Active Comparator|Telephone counseling|regular telephone counseling per week
2999752|NCT02564666|No Intervention|No telephone counseling|no regular telephone counseling
2999753|NCT02564653|Other|Technical Assistance, training,clinical reminders|provider adherence to tobacco use treatment guidelines
2999754|NCT02564653|Other|TTC + help of community health workers|We will assess this secondary aim by comparing smoking cessation outcomes among smokers who receive brief provider counseling alone only vs. smokers who receive provider counseling + community health worker counseling. The purpose of this assessment is to specifically analyze the impact of the community health worker counseling component of the intervention using a quasiexperimental design that leverages the larger RCT.
2999755|NCT02564640|Active Comparator|videolaryngoscope|patients intubated by using the videolaryngoscopy
2999756|NCT02564640|Active Comparator|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
2999757|NCT02564627|Experimental|Self-applied patch|The patients will use a self-applied patch weekly for PENS of dermatome T6. A 1200 Kcal/day diet will be also prescribed.
2999758|NCT02564627|Active Comparator|Conventional procedure|The patient will attend weekly the Outpatient Clinic for receiving the PENS of dermatome T6. The procedure will be performed by the Medicine Doctor. A 1200 Kcal/day diet will be also prescribed.
2999759|NCT02564627|Other|1200 Kcal/day diet|A 1200 Kcal/day diet will be also prescribed.
2999760|NCT02564614|Experimental|RO7070179|Participants will receive RO7070179, 13 mg/kg/week, 2-hour IV infusion every week in a 6-week cycle, after two loading doses in Week 1 of Cycle 1 on Day 1 and Day 4. If a dose-limiting toxicity (DLT) occurs in more than 33% of participants at any time, the dose will be reduced to 10 mg/kg/week. The dose will be further reduced to 6 mg/kg/week if more than 33% of treated participants have a DLT.
2999761|NCT02564601|Experimental|A1 Piano Training|16 weekly classes will be provided to the piano training group. Each piano class session will focus upon review of materials (15-20 min), and the remaining portion of the class will focus upon learning new skills and concepts. This course includes finger dexterity exercises, basic piano technique, and basic piano repertoire.
2999811|NCT02564302|No Intervention|Control|These patients will not receive a device, but have to fill out a quality of life questionnaire at the time of enrollment and 3 months after their procedure.
2999812|NCT02564302|Experimental|Treatment Group|These patients will receive the device. they are expected to use it for at least 5 minutes per day. Patients in this arm will fill out a quality of life questionnaire at the time of enrollment and 3 months after their procedure.
2999813|NCT02564289||Healthy Chronic snus users|Healthy subjects that used snus for more than 15 years.
2999762|NCT02564601|Experimental|A2 Computer Cognitive Training|16 weekly classes will be provided to the computerized cognitive training group. Computerized cognitive training involves process-based computerized practice of adaptive perceptual exercises. Each computer cognitive training class session will focus upon practice of cognitive exercises that vary in difficulty ranging from basic auditory processing speed to application through memory and working memory exercises. Within each exercise, the stimuli (i.e., tones, speech sounds, words, sentences) become less discriminable and speed of presentation increases (making the exercises more difficult) as performance improves.
2999763|NCT02564601|No Intervention|A 3 No Treatment Controls|No classes will be provided to our control group. This is a no-treatment control group.
2999764|NCT02564588|Experimental|Dasotraline|Dasotraline 4, 6, 8 mg
2999765|NCT02564588|Placebo Comparator|Placebo|Placebo Comparator
2999766|NCT02564575|Experimental|Cohort 1|Participants will receive two doses, separated by 4-8 weeks, of approximately 10^6 PFU/mL of the HPIV3-EbovZ GP vaccine.
2999767|NCT02564575|Experimental|Cohort 2|Participants will receive two doses, separated by 4-8 weeks, of approximately 10^7 PFU/mL of the HPIV3-EbovZ GP vaccine.
2999768|NCT02564562|Experimental|Treatment|Radiolabeled PF-06463922 in healthy volunteers
2999769|NCT02564549|Active Comparator|Group 1 (TRUS-guided biopsy)|"Baseline and annual systematic TRUS-guided biopsy performed as per standard of care by urologists for a total of one baseline diagnostic biopsy and two active surveillance systematic biopsies.~mpMRI at the end of the 2nd year with targeted biopsy of any Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesion. Patients needing image- guided targeted biopsies will undergo this procedure by interventional radiology, which is a common standard of care at HHM VAMC.~Optional transperineal template biopsy of the prostate performed at end of 2nd year (month 25-30).~Patients will be followed, as per standard of care, for any potential infections from biopsies.~Annual PSA tests performed as per routine standard of care."
2999770|NCT02564549|Experimental|Group 2 (mpMRI with targeted biopsy)|"Baseline systematic transrectal ultrasound-guided biopsy performed as per standard of care by urologists.~Baseline and annual mpMRI with targeted biopsy of any Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesion. Patients needing image- guided targeted biopsies will undergo this procedure by interventional radiology, which is a common standard of care at HHM VAMC.~Optional transperineal template biopsy of the prostate performed at end of 2nd year (month 25-30).~Patients will be followed, as per standard of care, for any potential infections from biopsies.~Annual PSA tests performed as per routine standard of care."
2999771|NCT02564536|Experimental|Arm 1: Pacritinib and Decitabine|"Patients will receive one cycle of single agent pacritinib.~Patients who tolerate single agent pacritinib will then receive up to 11 cycles of pacritinib and decitabine combination therapy.~Patients who do not tolerate single agent pacritinib (require dose interruption for more than 7 days before Cycle 2 Day 1) will be considered non-evaluable and replaced.~Pacritinib will be administered orally at a dose of 200 mg twice daily continuously for Days 1 through 28 of a 28-day cycle.~Decitabine will be administered as a subcutaneous injection in clinic on Days 1, 5, 8, 12, 15, 19, 22, and 26 of a 28-day cycle.~Patients may continue treatment for up to 12 cycles."
2999772|NCT02564523|Experimental|Group 1|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
2999773|NCT02564523|Experimental|Group 2|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 57) or placebo (Day 1/Day 57) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
2999774|NCT02564523|Experimental|Group 3|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 85) or placebo (Day 1/Day 85)
2999775|NCT02564497|Other|Process E Belatacept|Active Pharmaceutical Ingredient (API) of Belatacept manufactured by Process E
2999776|NCT02564497|Other|Process C Belatacept|Active Pharmaceutical Ingredient (API) of Belatacept manufactured by Process C
2999777|NCT02564484||Neuropathy|Adult survivors who developed persistent treatment-related neuropathy.
2999778|NCT02564484||Control|Adult survivors who did not develop persistent treatment-related neuropathy.
2999779|NCT02564471|Experimental|Chloroquine|Chloroquine Phosphate tablet for oral administration 500 mg chloroquine phosphate (equivalent to 300 mg base)
2999780|NCT02564471|Experimental|Atovaquone and Proguanil (Malarone)|"Malarone tablet for oral administration 250 mg atovaquone and 100 mg proguanil hydrochloride.~RabAvert rabies vaccine, at least 2.5 IU of rabies antigen."
2999781|NCT02564471|Experimental|Doxyclycline|"Doxycycline hyclate tablet for oral administration, contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.~RabAvert rabies vaccine, at least 2.5 IU of rabies antigen."
2999782|NCT02564471|Active Comparator|Rabies|RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.
2999783|NCT02564458|Experimental|Interval Exercise Training/Motivational Accelerometry (IET/MA)|All patients on the experimental arm receive the intervention of 5-12 weeks of pre-transplant IET, motivational accelerometry via the FitBit Surge, pre- and post-fitness assessments, and periodic quality of life and symptom surveys.
2999784|NCT02564458|No Intervention|Normal Standard of Care (control)|All patients on the control arm participate in the pre- and post-fitness assessment, are given the FitBit Surge without the motivational component, and are also given periodic quality of life and symptom surveys.
2999785|NCT02564445|Experimental|Control|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.~They will be given information on the federal and CDC guidelines for physical activity and will also be told that they should strive to achieve 10,000 steps per day to help promote weight loss."
2999786|NCT02564445|Experimental|Gamification|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.~All participants play a game with their teammate that includes points, levels and the opportunity to win a trophy, plaque or medal. They will advance or not advance based on their progress with weight loss and physical activity through 24 weeks. During the 12-week follow-up they'll be asked to maintain or make progress toward their weight loss goal."
2999787|NCT02564445|Experimental|Gamification + Share Data with PCP|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.~Participants will be asked to allow the study team to share their weight and step data with their primary care physician (PCP).~All participants play a game with their teammate that includes points, levels and the opportunity to win a trophy, plaque or medal. They will advance or not advance based on their progress with weight loss and physical activity through 24 weeks. During the 12-week follow-up they'll be asked to maintain or make progress toward their weight loss goal."
2999788|NCT02564432||POP 10 patient cohort|this is an observational study
2999789|NCT02564419|Experimental|Medtronic Activa PC+S|"Objective of this pilot phase early feasibility study is to assess the safety and feasibility of Medtronic Activa PC+S implant (device) by;~Evaluating the ability of the Activa PC+S system to sense ECoG signals in subjects living with quadriplegia (C5 or C6 level).~Assessing the feasibility of activating fundamental upper extremity muscles to reproduce hand grasp.~These are important first steps towards creating and designing a device that can enhance or assist in performing activities of daily living (ADL) in the life of these subjects. Attachment 15.3"
2999790|NCT02564406|Experimental|hypercapnic patients|patients with acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease, refused endotracheal intubation after failing NIV and were treated withLow flow etracorporeal CO2 removal
2999791|NCT02564393||T|Control
2999792|NCT02564393||A|Adult with cystic fibrosis
2999793|NCT02564380|Experimental|Arm A: Pembrolizumab|Pembrolizumab 200 mg every three weeks until disease progression (maximum 2 years)
2999794|NCT02564380|Placebo Comparator|Arm B: Placebo|Placebo i.v. every three weeks until disease progression (maximum 2 years)
2999795|NCT02564367|Experimental|Treatment|"First Cohort 1:~(n = 30 patients) 18 cycles S-1~consecutively Cohort 2: (n = 30 patients) 9 cycles S-1"
2999796|NCT02564354|Experimental|ΔF508 Homozygous|QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
2999797|NCT02564354|Experimental|ΔF508 Compound Heterozygous|QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
2999798|NCT02564341|Experimental|TEACH Collaborative Care Intervention|Physicians randomized to the intervention will receive: 1) collaboration with an IT enabled nurse care manager; 2) physician education and academic detailing; and 3) facilitated access to a specialist in addictions to help manage the most challenging HIV-infected patients on COT.
2999799|NCT02564341|No Intervention|Standard of Care Control|Physicians in the control group will receive information summarizing guidelines for COT but will not have access to the support of the TEACH intervention.
2999800|NCT02564328|Active Comparator|Intravenous stem cell transplantation|Intravenous transplantation of autologous bone marrow mesenchymal stem cell plus conventional treatment include rehabilitation
2999801|NCT02564328|No Intervention|Conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
2999802|NCT02564315|Active Comparator|Reduction/Supportive+Skill Counseling|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Supportive Counseling and Skill Training Counseling. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Skill Training Counseling; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
2999803|NCT02564315|Active Comparator|Reduction/Supportive Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Supportive Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
2999804|NCT02564315|Active Comparator|Reduction/Skill Counseling+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Skill Training Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Skill Training Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
2999805|NCT02564315|Active Comparator|Reduction/Brief Info+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Brief Information. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
2999806|NCT02564315|Active Comparator|Recycling/Supportive+Skill Counseling|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Supportive Counseling and Skill Training Counseling. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Skill Training Counseling; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
2999807|NCT02564315|Active Comparator|Recycling/Supportive Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Supportive Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
2999808|NCT02564315|Active Comparator|Recycling/Skill Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Skill Training Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Skill Training Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
2999809|NCT02564315|Active Comparator|Recycling/Brief Info+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Brief Information. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
2999810|NCT02564315|Placebo Comparator|Preparation Phase Control/No Phase 3|"This arm includes Phase 2 (Preparation) Control Treatment and No Phase 3 (Cessation) Treatment. More specifically, treatments include the following:~Phase 2: Preparation Phase Control Treatment~Phase 3: No Treatment"
2999814|NCT02564289||Healthy Controls|Healthy subjects that are never-users of snus.
2999815|NCT02564276|Experimental|Indocyanine Green on the right side|Indocyanine Green will be injected on the right side of the cervix and Methylene blue on the left side of the cervix.
2999816|NCT02564276|Experimental|Methylene Blue on the right side|Methylene blue will be injected on the right side of the cervix and Indocyanine Green on the left side of the cervix.
2999817|NCT02564263|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg, intravenously (IV) on Day 1 of every 21-day (3-week) cycle (Q3W) for up to 35 administrations (approximately 2 years)
2999818|NCT02564263|Active Comparator|Standard Therapy|Participants receive Investigator's choice of paclitaxel 80-100 mg/m^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m^2 IV on Day 1 of every 14-day (2-week) cycle
2999819|NCT02564237|Experimental|Group 1: StreptAnova™|Three (3) 0.6 mL doses (600 µg protein) of StreptAnova™ (Group A streptococcal (GAS) vaccine) will be will be administered on days 0, 30 and 180.
2999820|NCT02564237|Active Comparator|Group 2: Comparator|Three (3) 0.5 mL doses of comparator (Hepatitis B vaccine, Hepatitis A vaccine, OR Human Papillomavirus vaccine) will be administered on days 0, 30 and 180.
2999821|NCT02564211|Experimental|Ipragliflozin|Ipragliflozin one 50 mg tablet co-administered with one 50 mg sitagliptin once daily (QD) for 52 weeks in addition to diet and exercise therapy.
2999822|NCT02564198|Experimental|Ramucirumab|"(Part A-Non-CNS Solid Tumors) Escalating doses of ramucirumab given intravenously (IV) every other week over a 6-week cycle. Participants may continue treatment until discontinuation criteria are met.~(Part B-CNS Tumors) Maximum tolerated dose and/or recommended Phase 2 Dose (RP2D) determined from Part A of ramucirumab given IV every other week over a 6-week cycle. Participants may continue treatment until discontinuation criteria are met."
2999823|NCT02564185|Active Comparator|Control|"The control group will follow usual practice."
2999824|NCT02564185|Experimental|Education program|"The Education program group benefit in addition of a therapeutic education program including nursing follow-up at 1, 3 and 6 months."
2999825|NCT02564172|Experimental|CMS group|Conus medullaris stimulation with pentapolar surgical lead plus optimal medical management.
2999826|NCT02564172|Active Comparator|OMM group|Optimal medical management alone.
2999827|NCT02564159|Experimental|Muscle ultrasound|measurement of quadriceps diameter and biochemical markers
2999828|NCT02564146|Active Comparator|nab-paclitaxel and gemcitabine (A)|"Induction treatment: 3 cycles nab-paclitaxel and gemcitabine~Continuous treatment after randomization: Continuing application of nab-paclitaxel and gemcitabine treatment cycles"
2999829|NCT02564146|Experimental|gemcitabine monotherapy and nab-paclitaxel and gemcitabine (B)|"Induction treatment: 3 cycles nab-paclitaxel and gemcitabine~Continuous treatment after randomization: alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles"
2999830|NCT02564133|Experimental|detection of a patent foramen ovale|
2999831|NCT02564107|Experimental|Ibandronate|Female participants with metastatic bone disease secondary to breast cancer will receive ibandronate for a period of 25 weeks.
2999832|NCT02564094|Experimental|Epoetin beta|Participants with hematologic or solid malignancies will receive epoetin beta for a treatment period of approximately 20 weeks.
2999833|NCT02564081|Experimental|Static Stretching lower limb|Three 30 s bouts of static stretching for the gastrocnemius and the hamstrings respectively
2999834|NCT02564081|Active Comparator|Static stretching Cervical|Six 30 s bouts of static stretching of the cervical spine in the sagittal plane (flexion only)
2999835|NCT02564081|No Intervention|Ctrl|No intervention
2999836|NCT02564068|Experimental|Oxytocin Only|Subjects will come in for one visit, and will receive only oxytocin
2999837|NCT02564068|Experimental|Oxytocin & Placebo Crossover|Subjects will come in for two visit: They will receive either placebo or oxytocin on visit 1 and the other intervention of visit 2. Subjects will be blinded as to which drug they are receiving on which visit.
2999838|NCT02564055|Experimental|GSK2894512 1% cream twice daily|Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram [mg/g]) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
2999839|NCT02564055|Experimental|GSK2894512 1% cream once daily|Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
2999840|NCT02564055|Experimental|GSK2894512 0.5% cream twice daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
2999841|NCT02564055|Experimental|GSK2894512 0.5% cream once daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
2999842|NCT02564055|Placebo Comparator|Vehicle cream twice daily|Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
2999843|NCT02564055|Placebo Comparator|Vehicle cream once daily|Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
2999844|NCT02564042|Experimental|GSK2894512 1% cream twice daily|Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram [mg/g]) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
2999845|NCT02564042|Experimental|GSK2894512 1% cream once daily|Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
2999846|NCT02564042|Experimental|GSK2894512 0.5% cream twice daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
2999847|NCT02564042|Experimental|GSK2894512 0.5% cream once daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
2999848|NCT02564042|Placebo Comparator|Vehicle cream twice daily|Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
3000044|NCT02562846||ECT patients|Depressive patients receiving electroconvulsive therapy.
2999849|NCT02564042|Placebo Comparator|Vehicle cream once daily|Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
2999850|NCT02564029|Experimental|PF-06372865 dose level 1|17.5 milligram (mg) single dose
2999851|NCT02564029|Experimental|PF-06372865 dose level 2|52.5 mg single dose
2999852|NCT02564029|Placebo Comparator|Placebo|Single dose
2999853|NCT02564029|Active Comparator|Lorazepam|2mg single dose
2999854|NCT02564016|Active Comparator|Capped Epidural|Group 1 (control) will have the epidural catheter capped and left in place.
2999855|NCT02564016|Experimental|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
2999856|NCT02564003||Oxycodone|Oxycodone 0,1 mg/kg iv
2999857|NCT02563990|Experimental|High Pressure|High pressure injection of Ropivacaine local anesthetic at greater than 20 psi
2999858|NCT02563990|Active Comparator|Low Pressure|Low pressure injection of Ropivacaine local anesthetic at less than 15 psi
2999859|NCT02563977||DIEP flap breast reconstruction|15 patients who have had DIEP flap breast reconstruction and preoperative CT scan of the abdomen
2999860|NCT02563951|Experimental|GNS Spray 0.5mg|One spray of GNS 0.5mg/spray into right nostril.
2999861|NCT02563951|Experimental|GNS Spray 1.0mg|One spray of GNS 0.5mg/spray into both left and right nostril.
2999862|NCT02563951|Experimental|GNS Spray 2.0mg|One spray of GNS 1.0mg/spray into both left and right nostril.
2999863|NCT02563951|Active Comparator|Kytril 1mg (IV injection)|A dose of 1mg of Granisetron IV injection (kytril 1mL, 3mg/mL/vial) will be administered as a slow IV injection (over 30 seconds)
2999864|NCT02563951|Active Comparator|Kytril 1mg (Tablet)|a single dose (kytril 1mg, one tablet) orally administered with 240mL of water
2999865|NCT02563938|Experimental|AK001|Up to six single ascending doses of AK001.
2999866|NCT02563938|Placebo Comparator|Saline Solution|Saline solution will be administered as a single infusion.
2999867|NCT02563925|Experimental|Radiation and Tremelimumab|Subjects will get either whole brain radiation treatment (WBRT) or stereotactic radiosurgery (SRS), as per standard of care, with tremelimumab administered every 28 days. Patients, for whom concurrent HER2 directed therapy trastuzumab is indicated, as determined by the treating investigator, will be enrolled in a parallel HER2 directed therapy trastuzumab safety cohort. Protocol Expansion: Dose 1 of tremelimumab & durvalumab (75 mg & 1500 mg, respectively) will ideally be administered 2 days prior to initiation of brain radiotherapy (or between 5 days prior & 3 days after initiation of radiotherapy). Subjects will get either WBRT or SRS, depending on the number & size of their brain metastases. Following the 1st dose, tremelimumab & duvralumab will be administered q28 days from the date of 1st tremelimumab & durvalumab administration, plus or minus 1 week, for 4 cycles. After the 4th cycle, durvalumab will be administered alone until progression of disease or unacceptable toxicity.
2999868|NCT02563912|Experimental|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
2999869|NCT02563912|Active Comparator|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
2999870|NCT02563899|Experimental|Umeclidinium|Subjects will receive umeclidinium once daily before bedtime for 14 days.
2999871|NCT02563899|Placebo Comparator|Vehicle|Subjects will receive vehicle once daily before bedtime for 14 days.
2999872|NCT02563886|Experimental|EAMT, then standard care|Electrically Assisted Movement Therapy precedes usual and customary care.
2999873|NCT02563886|Active Comparator|Standard care, then EAMT|Usual and customary care precedes Electrically Assisted Movement Therapy.
2999874|NCT02563873|No Intervention|Standard pacemaker settings|Standard pacemaker settings will be programmed and the patient will complete a symptom limited exercise tolerance test with metabolic gas exchange
2999875|NCT02563873|Experimental|Tailored pacemaker settings|The pacemaker settings will be altered to match optimal heart rate range with respect to cardiac contractility, as determined by echocardiography. This will be programmed and the patient will complete a symptom limited exercise tolerance test with metabolic gas exchange.
2999876|NCT02563860|Experimental|Open label|"Treatment with Lovastatin, dose escalating trial according to the following schedule:~10 mg daily for 8 week 20 mg daily for 8 weeks 40 mg daily for 16 weeks."
2999877|NCT02563847|Active Comparator|0.52 g L-Tryptophan|0.52 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
2999878|NCT02563847|Active Comparator|1.56 g L-Tryptophan|1.56 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
2999879|NCT02563847|Active Comparator|1.56 g L-Leucine|1.56 g L-Leucine in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
2999880|NCT02563847|Active Comparator|50 g Xylitol|50 g Xylitol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
2999881|NCT02563847|Active Comparator|75 g Erythritol|75 g Erythritol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
2999882|NCT02563847|Placebo Comparator|75 g Glucose|75 g Glucose in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
2999883|NCT02563847|Placebo Comparator|Tap water|300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
2999884|NCT02563834|Experimental|Saline|Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
2999885|NCT02563834|Experimental|Insulin Clamp|Studies will be performed on a separate day under fasting conditions, using an insulin infusion to achieve steady state insulin/glucose clamp conditions. Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
2999909|NCT02563704|Active Comparator|QNLD2|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.~Patients received 12.5 mg/kg bw of QB over 4 hours by IV infusion every 12 hours diluted in 10 ml/kg bw of 10% dextrose solution.~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
3000045|NCT02562833|Experimental|Self-Management and exercise|
2999886|NCT02563821|Active Comparator|PCEA-DC|"Injection of a 2 mL initial epidural loading dose consisting of a blend (10 mL) of levobupivacaine 20 mg, sufentanil 10 µg to assure the absence of motor block and so exclude intrathecal placement of the epidural catheter.~Injection of the rest of the loading dose (8mL).~In this group the pump is programmed to deliver a continuous infusion at 10 mL /h consisting of levobupivacaine 0,573 mg/mL, sufentanil 0,37 µg/mL, clonidine 1,38 µg/ mL. Additional 5 mL patient-activated boluses will be allowed with a lockout interval of 10 minutes.~If the parturient feels she has inadequate analgesia after having activated the PCEA bolus twice in a thirty minutes period, an additional manual bolus of 6 mL of levobupivacaine 2,5 mg/mL will be administered until the Pain Visual Analog Scale (PVAS) is < 3/10."
2999887|NCT02563821|Active Comparator|PCEA-BIP|"Injection of a 2 mL initial epidural loading dose consisting of a blend (10 mL) of levobupivacaine 20 mg, sufentanil 10 µg to assure the absence of motor block and so exclude intrathecal placement of the epidural catheter.~Injection of the rest of the loadind dose (8 mL)~In this group the pump is programmed to deliver automated mandatory boluses of 5 mL consisting of levobupivacaine 0,573 mg/mL, sufentanil 0,37 µg/mL, clonidine 1,38 µg/mL every 30 minutes. Additional 5 mL patient-activated boluses will be allowed with a lockout interval of 10 minutes.~If the parturient feels she has inadequate analgesia after having activated the PCEA bolus twice in a thirty minutes period, an additional manual bolus of 6 mL of levobupivacaine 2,5 mg/mL will be administered until the Pain Visual Analog Scale (PVAS) is < 3/10 (0 = no pain and 10 = insufferable pain)."
2999888|NCT02563808|Active Comparator|Survey: Standard Version|Males will receive standard decision aid version for prostate cancer. Females will receive standard decisions aid for early stage breast cancer.
2999889|NCT02563808|Experimental|Survey: Anticipated Regret Version|Males will receive anticipated regret-augmented version for prostate cancer. Females will receive anticipated regret-augmented version for early breast cancer.
2999890|NCT02563795||Group I|Pregnant with BMI<30 and having spinal anesthesia with 10 mg hyperbaric bupivacaine
2999891|NCT02563795||Group II|Pregnant with BMI<30 and having spinal anesthesia with 7,5 mg hyperbaric bupivacaine+25 mcg fentanyl
2999892|NCT02563795||Group III|Pregnant with BMI>30 and having spinal anesthesia with 10 mg hyperbaric bupivacaine
2999893|NCT02563795||Group IV|Pregnant with BMI>30 and having spinal anesthesia with 7,5 mg hyperbaric bupivacaine+25 mcg fentanyl
2999894|NCT02563782|Sham Comparator|Control group|Sham surgery and placebo immunosuppressive therapy (IMT)
2999895|NCT02563782|Active Comparator|Active Group|Sub-retinal transplantation of MA09-hRPE cells and IMT
2999896|NCT02563769|Experimental|Treatment Arm 1|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Clavulanic Acid 250 mg (low dose); Day #3: Clavulanic Acid 500 mg; Day #4: Placebo
2999897|NCT02563769|Experimental|Treatment Arm 2|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Clavulanic Acid 250 mg (low dose); Day #3: Placebo; Day #4: Clavulanic Acid 500 mg
2999898|NCT02563769|Experimental|Treatment Arm 3|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Placebo; Day #3: Clavulanic Acid 250 mg (low dose); Day #4: Clavulanic Acid 500 mg
2999899|NCT02563756|Experimental|UKA, unicompartmental knee replacement|Procedure: Participants are operated with a mobile bearing medial unicompartmental knee arthroplasty (Oxford). They are followed with CT, functional tests and PROM, compared with those operated with TKA.
2999900|NCT02563756|Experimental|TKA, total knee replacement|Procedure: Participants are operated with a cruciate retaining conventional tricompartmental prosthesis (PFC). They are followed with CT, functional tests and PROM, compared with those operated with UKA.
2999901|NCT02563743|Experimental|Problem-solving based intervention|Problem-solving based intervention with a participative approach. During the intervention a systematic assessment of the match between the employee and the work environment is considered. The intervention applies a participatory approach where the supervisor and the employee are guided by the OHS consultant and encouraged to actively take part in problem solving concerning the work situation. The intervention consists of three meetings, one between the OHS consultant and a representative for the employer (usually the nearest supervisor), one between the consultant and the employee and then a third meeting where all three parties participate.
2999902|NCT02563743|Active Comparator|Treatment as usual|The control intervention consists of the usual interventions given at the participating OHS. These interventions are also work-directed and usually also include participation of both the employee and the supervisor. However, structured problem solving methods and the systematic consideration of the match between the employee and the job situation are not applied. The content of the control condition will vary between different occupational health service units.
2999903|NCT02563730|Experimental|Lung biopsy|assess the additional diagnostic value of cryobiopsy in patients with suspected Idiopathic Interstitial Pneumonia (IIP). Cryoprobe vs VATS
2999904|NCT02563717|Active Comparator|Reference Device: T-piece System|
2999905|NCT02563717|Active Comparator|Investigational Device: The New System|
2999906|NCT02563704|Active Comparator|ARTES|"Injectable Artesunate.Each vial contained 60 mg anhydrous artesunic acid, which was dissolved in 1 ml of 5% sodium bicarbonate (provided with the drug) and then mixed with 5 ml saline solution (provided with the drug) before injecting into an indwelling intravenous catheter.~Patients received 2.4 mg/kg bw of parenteral artesunate at H0, H12, H24 and thereafter once daily, for a minimum of 24 hours.~Patients exited from the protocol if they had clinically recovered and parasitaemia was negative."
2999907|NCT02563704|Active Comparator|QLD|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.~Patients received a loading dose of 16.6 mg/kg bw of QB by intravenous (IV) infusion over 4 hours followed 8 hours after the start of the loading dose, with a maintenance dose of QB at 8.3 mg/kg bw over 4 hours every 8 hours diluted in 10 ml/kg bw of 10% dextrose solution.~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
2999908|NCT02563704|Active Comparator|QNLD3|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.~Patients received 8.3 mg/kg bw of QB over 4 hours by IV infusion every 8 hours diluted in 10 ml/kg bw of 10% dextrose solution.~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
2999910|NCT02563691|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy will be delivered to the prostate (if not previously treated) and to all metastatic tumours.
3000046|NCT02562833|Active Comparator|Educational|
2999911|NCT02563678|Active Comparator|Diabetics with active, chronic infection|Adult patients with diabetes mellitus and current antibiotic use for active infection will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
2999912|NCT02563678|Active Comparator|No diabetes or infection|Adult patients without diabetes and not using antibiotics will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
2999913|NCT02563678|Active Comparator|Critically ill patients with infection|Adult patients with acute, life-threatening infection for which hyperbaric oxygen is clinically indicated will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
2999914|NCT02563678|Active Comparator|Carbon monoxide patients|Adult patients with acute carbon monoxide poisoning will have blood drawn before and after their first clinical hyperbaric oxygen treatment.
2999915|NCT02563678|Active Comparator|Glucose tolerance test|Diabetic patients co-enrolled in a hyperbaric oxygen and glucose control study will have blood drawn before and after their glucose tolerance test and their first clinical hyperbaric oxygen treatment.
2999916|NCT02563678|Experimental|Brain injury research subjects|Research subjects co-enrolled in a study examining hyperbaric oxygen for post-concussive symptoms will have blood drawn before and after their first and fourth hyperbaric chamber sessions.
2999917|NCT02563678|Experimental|Hyperbaric chamber inside attendants|Hyperbaric chamber inside attendants will have their blood drawn before, mid-session, and after their chamber exposure during their regular duty day. The hyperbaric chamber exposure will include hyperbaric air and hyperbaric oxygen components (hyperbaric air/oxygen).
2999918|NCT02563678|Active Comparator|Volunteers, hyperbaric oxygen|Healthy adult volunteers will have blood drawn before and after a single hyperbaric chamber session.
2999919|NCT02563678|Experimental|Volunteers, normobaric pressure|Healthy volunteers will have their blood drawn before and after breathing 100% oxygen at atmospheric pressure (normobaric oxygen) for 120 minutes.
2999920|NCT02563665||advanced chronic kidney disease|Subjects on dialysis with GFR (Glomerular Filtration Rate) > 30
2999921|NCT02563665||Renal replacement therapy.|Subjects who are not on dialysis with GFR (Glomerular Filtration Rate) < 15
2999922|NCT02563652||Major abdominal surgery|Patients undergoing major abdominal surgery (laparotomy). Surgical procedures considered for inclusion include, but are not restricted to, procedures such as gastrectomy, pancreatic surgery, liver resection, open prostatectomy, colonic surgery, radical cystectomy with ileal conduit, open nephrectomy and vascular abdominal aortic surgery.
2999923|NCT02563613|Experimental|Physical Exercise (PE)|Physical exercise will be promoted through the use of one of three positive psychology themes: joy, gratitude and savoring. It will comprise of a core intervention session on physical exercise, a booster session at 1 month to consolidate the knowledge and skills that they have gained, followed by a follow-up session at 3 months on healthy diet. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
2999924|NCT02563613|Experimental|Healthy Diet (HD)|Healthy diet will be promoted through the use of one of three positive psychology themes: joy, gratitude and savoring. It will include a core intervention session on healthy diet, a booster session at 1 month to consolidate the knowledge and skills that they have gained, followed by a follow-up session at 3 months on physical exercise. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
2999925|NCT02563613|Placebo Comparator|Wait-list Control (C)|The control group will consist of a tea gathering session at the beginning and 1 month later, followed by a follow-up session at 3 months on physical exercise or healthy diet. The tea gathering sessions will cover topics unrelated to the intervention, such as arts and crafts workshops. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
2999926|NCT02563600|Experimental|Pre-letter telephone call|A brief 10 min telephone call to patients on waiting list prior to receipt of appointment invitation letter.
2999927|NCT02563600|Experimental|Post-letter telephone call|A brief 10 min telephone call to patients on waiting list prior to receipt of appointment invitation letter.
2999928|NCT02563600|No Intervention|No telephone call|No telephone call made to patient.
2999929|NCT02563587|Experimental|Group LT-CT|Laughter therapy with conventional treatment
2999930|NCT02563587|Placebo Comparator|Group AW-CT|Accompaniment without causing the laughter of children more conventional treatment
2999931|NCT02563587|Sham Comparator|Group CT|Conventional treatment only
2999932|NCT02563574|Experimental|Motivational Interviewing Group|This group of participants will receive the motivational interviewing. In addition to blood specimen collection, a questionnaire assessment and neurocognitive assessments will also be performed.
2999933|NCT02563574|Active Comparator|Control Group|This group of participants will not receive motivational interviewing. They will have blood specimen collection, questionnaire assessment, and neurocognitive assessments performed.
2999934|NCT02563561|Experimental|Apaziquone and Placebo|One Dose of Apaziquone and One Dose of Placebo
2999935|NCT02563561|Experimental|Apaziquone and Apaziquone|Two Doses of Apaziquone
2999936|NCT02563561|Placebo Comparator|Placebo and Placebo|Two Doses of Placebo
2999937|NCT02563548|Experimental|PEGPEM|PEGPH20 + pembrolizumab
2999938|NCT02563535|Experimental|Drug-eluting balloon|angioplasty with Litos drug-eluting balloon
2999939|NCT02563535|Active Comparator|conventional PTA|angioplasty with conventional balloon
2999940|NCT02563522|Active Comparator|Active|VM202 + standard of care
2999941|NCT02563522|Placebo Comparator|Control|Placebo (VM202 Vehicle) + standard of care
2999942|NCT02563509|Experimental|HIV-specific CD8 cells|Transfusing HIV-specific CD8 cells 50-100mlonce a week for four times.
2999943|NCT02563509|No Intervention|Regualar therapy|Only receiving Highly active anti-retroviral therapy(HAART).
2999944|NCT02563496|Experimental|Tafenoquine + Chloroquine|Two formulations of TQ will be made available; a 150 milligram (mg) film-coated tablet (TQ adult tablet), and a 50mg fast-dispersing film coated tablet (TQ pediatric tablet). Subjects will receive single oral dose of TQ based on their weight on Day 1, co-administered with CQ. There will be four weight bands of >=5 to <=10 kg, >10 to <=20 kg, >20 to =<35 kg and >35 kg with proposed starting doses for pediatrics from 100 to 300 mg TQ. Subjects with >35 kg weight will receive the TQ adult tablet. Subject will receive CQ per local/national guidelines.
3000338|NCT02560948|Experimental|gpASIT+TM|
2999945|NCT02563483|Experimental|Yoga and compassion meditation program|"The duration of this group was 8 weeks. The program included sessions 3 times per week, with each session lasting 1 hour and 15 minutes. The volunteers performed yoga classes composed of asana (poses), pranayama (breathing exercise) and meditation."
2999946|NCT02563483|No Intervention|control|this group was a non treatment group.
2999947|NCT02563457|Experimental|case|diabetic patients who will receive periodontal treatment blood sampling
2999948|NCT02563457|Experimental|control|diabetic patients without periodontal treatment (no periodontal treatment) blood sampling
2999949|NCT02563444|Experimental|Ultrasound fusion guiding system|
2999950|NCT02563431|Active Comparator|SP-ED|Classic use
2999951|NCT02563431|Experimental|4P-ED|Literature update
2999952|NCT02563418|Experimental|Patient with Huntington's disease|
2999953|NCT02563405|Active Comparator|doxazosin|To observe the effects of doxazosin (4 mg) on uric acid in plasma and blood pressure variability after 12 weeks of treatment
2999954|NCT02563405|Active Comparator|nifedipine|To observe the effects of nifedipine (30 mg) on uric acid in plasma and blood pressure variability after 12 weeks of treatment
2999955|NCT02563392|Experimental|Uterine arteries occlusion|Laparoscopic myomectomy with preventive uterine arteries occlusion
2999956|NCT02563392|Active Comparator|No uterine arteries occlusion|Laparoscopic myomectomy without preventive uterine arteries occlusion
2999957|NCT02563379||Dippers|"Dipping pattern is defined as daytime-nighttime BP/daytime BP reduction - based on either ABP monitoring- greater than 10% for systolic and/or diastolic BP.~Extreme dipping is marked nocturnal systolic and/or diastolic BP fall>20% of daytime systolic and/or diastolic values or night/day systolic and/or diastolic BP ratio <0.8.~Patients in this group will be dippers or extreme dippers. We aim to examine the association of this BP pattern with the development of asymptomatic episodes of paroxysmal atrial fibrillation, in hypertensive subjects."
2999958|NCT02563379||Non-dippers|"Non-dipping and rising: no reduction or increase in nocturnal systolic and/or diastolic BP or night/day systolic and/or diastolic BP ratio ≥1.~In this group we aim to examine whether an association exists between the non-dipping pattern and the development of asymptomatic episodes of paroxysmal atrial fibrillation in hypertensive subjects."
2999959|NCT02563379||Morning Hypertensives|"It is known that morning surge is the excessive systolic and/or diastolic BP elevation rising in the morning.~Patients in this group will have morning hypertension that is classified into two types:~the morning-surge type, characterized by a marked increase in blood pressure in the early morning, and the nocturnal-hypertension type, characterized by high blood pressure that persists from nighttime until early morning.~In our study we will examine whether an association between morning hypertension and asymptomatic episodes of paroxysmal atrial fibrillation exists in hypertensive subjects."
2999960|NCT02563366|Experimental|MSCs group|Patients with early poor graft function receive allogeneic BM-MSCs at the dose of 1*10^6/kg every week for four consecutive doses.
2999961|NCT02563366|Placebo Comparator|Control group|Patients with early poor graft function receive placebo of MSCs, i.e. saline every week for four consecutive doses.
2999962|NCT02563353|Active Comparator|controlgroup|Teriparatide, 20 microgram/day. 24 months of treatment
2999963|NCT02563353|Experimental|studygroup 1|"Teriparatide, 20 microgram/day. 24 months of treatment.~12 months of Whole-body vibration on vibration platforms."
2999964|NCT02563353|Experimental|studygroup 2|"Teriparatide, 20 microgram/day. 24 months of treatment.~24 months of Whole-body vibration on vibration platforms"
2999965|NCT02563340|Experimental|MSCs group|cAMR patients in this group receive additional intravenous allogeneic BM-MSCs (1*10^6/kg) every two weeks for four consecutive doses, besides current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.
2999966|NCT02563340|Active Comparator|Control group|cAMR patients in this group receive current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.
2999967|NCT02563327|Active Comparator|Standard Therapy|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~Study drug doses: rifampin, 600 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg."
2999968|NCT02563327|Experimental|Rifapentine-containing Regimen|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and ethambutol, followed by Nine weeks of daily treatment with rifapentine and isoniazid. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~Study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg."
2999969|NCT02563327|Experimental|Rifapentine- and Moxifloxacin-containing Regimen|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~Study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; moxifloxacin, 400 mg."
2999970|NCT02563314|Experimental|intervention|
2999971|NCT02563314|Other|control|
2999972|NCT02563301|Active Comparator|McGrath Series 5|Videolaryngoscope used to perform indirect (video) laryngoscopy and tracheal intubation
2999973|NCT02563301|Active Comparator|Macintosh|Laryngoscope used to perform direct laryngoscopy and tracheal intubation
2999974|NCT02563288|Active Comparator|Esmolol|Esmolol 500mcg/kg before induction in anesthesia following by 300mcg/Kg/min until extubation.
2999975|NCT02563288|Active Comparator|Dexmedetomidine|Dexmedetomidine 1mcg/Kg following by 0.7mcg/Kg/h until end of surgery.
2999976|NCT02563275|Other|Human fine motor skills measurements during weightlessness|
2999977|NCT02563262|Other|body angles measurements during weightlessness|body angles : ankle, knee, hip, shoulder, elbow, wrist, and neck.
2999978|NCT02563249|Other|Dexterity, Coordination,Perception measurements|Dexterity, Hand-eye Coordination and Perception of Orientation and Distances
2999979|NCT02563236|Experimental|Parabolic flight and Augmented Reality interface alignments|
2999980|NCT02563223|Other|electromyographic (EMG) measurements|Interaction between gravity (weightlessness, hypergravity, and normal gravity) and pull-down force ont EMG amplitude and EMG timing.
2999981|NCT02563210|Experimental|airway resistance measurement|interruption and plethysmography techniques airway resistance measurement at each routine visit
2999982|NCT02563197|Experimental|T-326|Non Cystic fibrosis bronchiectasis patients will be enrolled for determination of peak inspiratory flow.
2999983|NCT02563184|Active Comparator|COPD|Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.
2999984|NCT02563184|Active Comparator|Control|Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.
2999985|NCT02563171|Placebo Comparator|Healthy periodontium without obesity|GCF samples were taken at baseline Intervention: Gingival crevicular fluid collection
2999986|NCT02563171|Active Comparator|Chronic periodontitis without obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
2999987|NCT02563171|Placebo Comparator|Healthy periodontium with obesity|GCF samples were taken at baseline Intervention: Gingival crevicular fluid collection
2999988|NCT02563171|Active Comparator|Chronic periodontitis with obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
2999989|NCT02563158|No Intervention|Hx with hepatic inflow occlusion|Hepatectomy is carried out using Pringle maneuver in cycles of 15 minutes clamping + 5 minutes unclamping of the hepatoduodenal ligament.
2999990|NCT02563158|Experimental|Hx with non-occlusion technique|Hepatectomy without hepatic inflow occlusion (non-occlusion technique)
2999991|NCT02563145|Experimental|Real-time fMRI feedback|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the experimental condition will receive 10 sessions of real-time fMRI feedback of insula- or amygdala activation (dependent on activation patterns during pre-testing), 1 session/week. Each session will last about 1 1/2 hours.~After training completion (10 weeks after the beginning of the treatment phase), subjects will undergo post-treatment assessment and follow up (6 months after the end of the training phase)."
2999992|NCT02563145|Active Comparator|Treatment as usual|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the comparator TAU arm will receive several sessions of psychoeducation and counseling with their parents/caregivers or group training over 10 weeks.~Within the sessions, investigators will focus on psychoeducational issues and provide general counseling for the families. After 10 weeks, subjects will undergo post-treatment assessment and follow up (6 months after the end of the treatment phase)."
2999993|NCT02563145|No Intervention|Typically developing (TD) control group|Healthy typically developing subjects will only participate in pre-training assessment to allow for comparison.
2999994|NCT02563132|Experimental|Carbon dioxide insufflation colonoscopy (CO2)|Carbon dioxide during both insertion and withdrawal phase of the colonoscopy.
2999995|NCT02563132|No Intervention|Air insufflation colonoscopy (AI)|Air insufflation during both insertion and withdrawal phase of the colonoscopy.
2999996|NCT02563119|Active Comparator|Gastric Bypass Group|Twenty morbidly obese patients undergoing gastric bypass surgery
2999997|NCT02563119|Active Comparator|Sleeve Group|Twenty morbidly obese patients undergoing sleeve gastrectomy
2999998|NCT02563119|No Intervention|Healthy controls|Thirty healthy, lean controls
2999999|NCT02563106|Experimental|SYN-004|SYN-004 150 mg
3000000|NCT02563106|Placebo Comparator|Placebo|Matching placebo
3000001|NCT02563093|Experimental|Study Group 1|Adults 18 to < 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine
3000002|NCT02563093|Experimental|Study Group 2|Adults 18 to < 65 years of age randomly assigned to receive an intradermal injection of one dose of Fluzone Intradermal Quadrivalent vaccine
3000003|NCT02563093|Experimental|Study Group 3|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine
3000004|NCT02563093|Experimental|Study Group 4|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone High-Dose vaccine
3000005|NCT02563080||First attack of acute pancreatitis|50 patients with first attack of moderately severe or severe acute pancreatitis treated in Helsinki University Hospital.
3000006|NCT02563067|Experimental|QAW039 Dose 1|QAW039 Dose 1 once daily
3000007|NCT02563067|Experimental|QAW039 Dose 2|QAW039 Dose 2 once daily
3000008|NCT02563067|Placebo Comparator|Placebo|Placebo once daily
3000009|NCT02563054|Active Comparator|5-Fluorouracil + Cisplatin|Participants will receive 5-FU in combination with cisplatin upto disease progression.
3000010|NCT02563054|Experimental|Capecitabine + Cisplatin|Participants will receive capecitabine in combination with cisplatin upto disease progression.
3000011|NCT02563041|Experimental|30%TSC|After each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of 30%TSC solution exactly equivalent to the catheter internal lumen.
3000012|NCT02563041|Active Comparator|Heparin 5000 U/mL|After each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of unfractionated sodium heparin 5000 U/mL solution exactly equivalent to the catheter internal lumen.
3000013|NCT02563028|Experimental|SightSaver Visual Stimulator|A SightSaver Visual Stimulator mask will be applied during surgery. Baseline VEPs will be recorded prior to prone positioning. At the end of surgery, after supine positioning, the SightSaver Visual Stimulator mask will be removed and discarded.
3000014|NCT02563015|Experimental|Cholecalciferol 400|400 IU orally per day
3000015|NCT02563015|Experimental|Cholecalciferol 1000|1000 IU orally per day
3000016|NCT02563015|Active Comparator|Reference 400|400 IU orally per day
3000042|NCT02562859|Experimental|GLPG1837 as oral tablet fasted|Single dose of 500 mg GLPG1837 as oral tablet after an overnight fast
3000043|NCT02562859|Experimental|GLPG1837 as oral tablet fed|Single dose of 500 mg GLPG1837 as oral tablet after a high-fat high-calorie breakfast
3000017|NCT02563002|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years). Participants that have stopped the initial course of pembrolizumab and have stable disease but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 year additional).
3000018|NCT02563002|Active Comparator|Standard of Care|Participants receive 1 of 6 possible standard chemotherapy regimens: mFOLFOX6, or mFOLFOX6+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or mFOLFOX6+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle, or FOLFIRI, or FOLFIRI+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or FOLFIRI+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle. Participants with documented disease progression following chemotherapy can crossover to receive pembrolizumab for up to 35 cycles (approximately 2 years). Participants that have stopped pembrolizumab and have stable disease but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 year additional).
3000019|NCT02562989|Experimental|Part 1, Healthy Young Participants|Healthy young participants received a single intravenous (IV) dose of ~185 megabecquerel (MBq) [18F]MK-6240 in Part 1 of the study
3000020|NCT02562989|Experimental|Part 2, Healthy Elderly Participants|Healthy elderly participants received a single IV dose of ~160 MBq [18F]MK-6240, in Part 2 of the study
3000021|NCT02562989|Experimental|Part 2, AD and Amnestic MCI Elderly Participants|AD and amnestic MCI participants received up to two IV doses of ~160 MBq [18F]MK-6240 in Part 2 of the study
3000022|NCT02562976||early gastric cancer group|use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia in patients with early gastric cancer or high-grade neoplasia(HGN)
3000023|NCT02562976||non-early gastric cancer group|patients diagnosed as non- gastritis, gastritis or low-grade neoplasia (LGN) by pathology were defined as non-EGC group
3000024|NCT02562963|Experimental|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10^9 NKT cells in one course of treatment. Intervention: Biological: NKT cell
3000025|NCT02562950|Experimental|Midazolam and 500 mg GLPG1837|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12) and multiple oral doses of GLPG1837 (250 mg b.i.d daily for 10 days) from Days 2 to 11.
3000026|NCT02562950|Experimental|Midazolam and 1000 mg GLPG1837|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12) and multiple oral doses of GLPG1837 (500 mg b.i.d daily for 11 days) from Days 2 to 12.
3000027|NCT02562937|Experimental|Intervention|text messages related to sedentary behaviour
3000028|NCT02562937|No Intervention|Control|text messages unrelated to sedentary behaviour.
3000029|NCT02562924|Active Comparator|Budesonide rinse group|"1a. Days 0-7: 40 mg prednisone daily, saline sinus rinse 4 times daily, nasal saline spray q 1 hour while awake b. Days 7-91: 8oz saline/budesonide sinus rinse BID c. After day 91: i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse once daily.~Reevaluate at day 119:~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.~In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182."
3000030|NCT02562924|Experimental|MEDIHONEY® rinse alone group|"Days 0-7: Same as 1a;~Days 7-91: 8oz saline sinus rinse followed with 0.5oz of MEDIHONEY® in 50 cc of normal saline.~After day 91:~i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse once daily. Reevaluate at day 119:~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.~In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182."
3000031|NCT02562924|Experimental|MEDIHONEY® and budesonide rinse group|"Days 0-7: Same as 1a.;~Days 7-91: 8oz saline/budesonide sinus rinse followed by 0.5oz of MEDIHONEY® in 50 cc of normal saline BID.~After day 91:~i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse BID. Continue with this regimen till day 182.~ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse once a day.~Reevaluate at day 119:~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 3.c.i till day 182.~In case endoscopy shows no polyps, edema and discharge: Continue as per 3.c.ii till day 182."
3000032|NCT02562898|Experimental|Dose escalation for safety and toxicity|All patients in phase Ib dosing escalation with extended safety and toxicity cohorts will start treatment with daily dosing of ibrutinib concurrently with standard doses of gemcitabine and nab-paclitaxel. Ibrutinib (560 mg/day, 840 mg/day, or 420 and 280 mg/day if de-escalation is necessary) will be started on day 1. Approximately patients 15-30 will be enrolled in escalation and extended safety cohort.
3000033|NCT02562898|Experimental|Immune Response cohort|Subjects who are assigned to the Immune Response Cohort will have a biopsy before starting ibrutinib-only therapy. They will then receive ibrutinib for 7 days and have a second biopsy after completing the ibrutinib-only therapy, before starting the combination of chemotherapy with ibrutinib. Approximately 20 patients will be enrolled in this arm.
3000034|NCT02562885|Experimental|Acoustic pulses|"During NREM sleep:~15 minutes without acoustic pulses~15 minutes with acoustic pulses~15 minutes without acoustic pulses~Two different protocols are applied:~(A) tone application at the Down-phase of sleep slow wave (SSW) (B) tone application at the Up-phase of SSW.~Participants with Rolandic epilepsy/BECTS or generalized spike waves: Protocol A and B alternatingly.~Participants with ESES/CSWS: only Protocol A."
3000035|NCT02562872|Experimental|Cohort 1 Active DSM265|
3000036|NCT02562872|Placebo Comparator|Cohort 1 Placebo|
3000037|NCT02562872|Experimental|Cohort 2a Active DSM265|
3000038|NCT02562872|Placebo Comparator|Cohort 2a Placebo|
3000039|NCT02562872|Experimental|Cohort 2b Active DSM265|
3000040|NCT02562872|Placebo Comparator|Cohort 2b Placebo|
3000041|NCT02562859|Experimental|GLPG1837 as oral suspension fasted|Single dose of 500 mg GLPG1837 as oral suspension after an overnight fast
3000047|NCT02562820|Experimental|Ketamine|Subjects will receive intravenous infusion of a 0.1, 0.5, 1.0, 2.0 or 4.5 mg/kg dose over the course of 40 minutes
3000048|NCT02562820|Placebo Comparator|Placebo|Subjects will receive an intravenous infusion of normal saline over the course of 40 minutes
3000049|NCT02562807|Active Comparator|Treatment A|TAS-303 18mg single-dose and then Placebo single-dose.
3000050|NCT02562807|Placebo Comparator|Treatment B|Placebo single-dose and then TAS-303 18mg single-dose.
3000051|NCT02562807|Active Comparator|Treatment C|TAS-303 9mg single-dose and then Placebo single-dose.
3000052|NCT02562807|Placebo Comparator|Treatment D|TAS-303 Placebo single-dose and then TAS-303 9mg single-dose.
3000053|NCT02562794|Experimental|Intervention|Family Strengthening Intervention-Refugees. A total of 20 Somali Bantu and 20 Bhutanese refugee families will participate in a Family Strengthening Intervention adapted for use with refugees.
3000054|NCT02562794|No Intervention|Control|A total of 20 Somali Bantu and 20 Bhutanese refugee families will receive services as usual.
3000055|NCT02562781|Active Comparator|Supplemental Oxygen|Inspired oxygen fraction > 0.5 and SpO2 = 98-100%
3000056|NCT02562781|Experimental|Air or supplemental oxygen|Air or lowest possible inspired concentration of oxygen to maintain SpO2 > 90%
3000057|NCT02562768|Experimental|LY3154207|LY3154207 administered orally once daily in multiple-ascending dose cohorts for 14 days.
3000058|NCT02562768|Placebo Comparator|Placebo|Placebo matching LY3154207 administered once daily for 14 days.
3000059|NCT02562755|Experimental|Pexa-Vec followed by Sorafenib|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 1e9 pfu at day 1 and weeks 2 and 4, followed by sorafenib at Week 6.
3000060|NCT02562755|Active Comparator|Sorafenib|Sorafenib (400 mg twice daily) begins on Day 1.
3000061|NCT02562742||SOF+REB|Adult patients with genotype 2 chronic HCV infection with or without compensated cirrhosis who take SOF+REB as part of routine clinical care at a participating clinical site.
3000062|NCT02562729|Experimental|Nerve-Sparing Radical Hysterectomy (NSRH)|Type C1 Hysterectomy
3000063|NCT02562716|Experimental|Arm I (mFOLFIRINOX, surgery)|Patients receive oxaliplatin IV over 2 hours and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive 5-fluorouracil IV over 46 hours on days 1-3 and 15-17. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or better undergo pancreatectomy 4-8 weeks after completion of first 3 courses of treatment. Within 4-8 weeks following pancreatectomy, patients receive an additional 3 courses of oxaliplatin, irinotecan hydrochloride, and fluorouracil treatment in the absence of disease progression or unacceptable toxicity.
3000064|NCT02562716|Experimental|Arm II (gemcitabine, nab-paclitaxel, and surgery)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or better undergo pancreatectomy 4-8 weeks after completion of first 3 courses of treatment. Within 4-8 weeks following pancreatectomy, patients receive an additional 3 courses of paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride treatment in the absence of disease progression or unacceptable toxicity.
3000065|NCT02562703|Active Comparator|ACTIVE tVNS|tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
3000066|NCT02562703|Sham Comparator|SHAM tVNS|tVNS will be applied by the external simulator (Monarch). The stimulation will be turned off after 60 seconds following previous trials.
3000067|NCT02562690||Acute Coronary Syndrome|"Patients with acute chest pain and persistent ST-segment elevation or new left bundle branch block on the 12 lead ECG. This is termed ST-segment Elevation Myocardial Infarction (STEMI).~Patients with acute chest pain but without persistent ST-segment elevation. These patients, based on the measurement of cardiac biomarker values (troponin), will be further classified as Non-ST-segment Elevation Myocardial Infarction (NSTEMI) or unstable angina.~Where possible, all patients will have tests of thrombotic status including thrombin generation assays, TEG and GTT."
3000068|NCT02562677|Experimental|ACTIVE tNS|TNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed on the forehead just above the supraorbital foramen bilaterally. The study protocol will follow the rational of our previous trials with TNS.
3000069|NCT02562664|Active Comparator|CC with placebo|100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle with placebo tablets taken twice daily continuously for three cycles.
3000070|NCT02562664|Active Comparator|CC plus Metformin|received t100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle with plus Metformin 500 mg twice daily continuously for three cycles.
3000071|NCT02562651|Experimental|Doxycycline|100 mg of Doxycycline bid for seven days in pts with STEMI underwent PCI (percutaneous coronary intervention) and with current medical therapy
3000072|NCT02562651|Active Comparator|Active comparator|Standard care for STEMI
3000073|NCT02562638|No Intervention|Group 1 Fasting|Group 1(control group) Fasting for both solids and fluids for up to 4 hours pre-procedure
3000074|NCT02562638|Experimental|Group 2 Non-fasting|Group 2 (intervention arm) Clear fluids up to 1 hour before the procedure and fasting for solids up to 4 hours pre-procedure
3000075|NCT02562625|Experimental|Pembrolizumab Alone|If the patient is randomised to the Pembrolizumab Arm Only then they will receive 200mg of pembrolizumab every 3 weeks.
3000076|NCT02562625|Experimental|Pembrolizumab plus Radiotherapy|If The patient is randomised to this arm they will receive 200mg of pembrolizumab every 3 weeks in combination with a radiotherapy dosage of 24Gy in 3 fractions to be given over 3 consecutive days (only).
3000077|NCT02562612|Experimental|SM-88|SM-88 multiple ascending doses
3031706|NCT02350322|Experimental|Schoolmeal with fatty fish|Fatty fish diet
3000078|NCT02562599|Experimental|drug:raltitrexed safety and efficacy|"To receive the safety and efficacy of raltitrexed-cisplatin neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with raltitrexed-cisplatin~Interventions:~Neochemotherapy (Induction Chemotherapy) Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles).~Concurrent Chemotherapy Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles) .~Radiation: Intensity-modulated radiotherapy (IMRT)"
3000079|NCT02562586|Active Comparator|Closed Suction Drainage System|Group 1: patients undergoing total hip replacement received a Closed Suction Drainage System for 24 hours after the surgical procedure
3000080|NCT02562586|No Intervention|No Closed Suction Drainage System|Group 2: patients undergoing total hip replacement have not received a Closed Suction Drainage System after the surgical procedure
3000081|NCT02562573|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once a day.
3000082|NCT02562560|Experimental|TGA|
3000083|NCT02562560|Experimental|Controls|
3000084|NCT02562547||All Vaginal Births|The application of the Hem-Avert Perianal Stabilizer
3000085|NCT02562534|Other|Patients with conductives troubles|Patients with conductives troubles
3000086|NCT02562534|Other|Patients with rythm troubles|Patients with rythm troubles
3000087|NCT02562534|Other|Volonteers|Volonteers with normal ECG
3000088|NCT02562521|Experimental|Smoking Cessation Treatment|The intervention will consist of Contingency management (CM) in conjunction with effective first line pharmacotherapy (dual nicotine replacement therapy [NRT] or varenicline) and brief counseling to rapidly induce cessation and to maintain abstinence long term. Pharmacotherapy will be flexible. Participants will also be given the option of receiving additional behavioral support by being referred to the CT Quitline and using text or mobile phone apps for quitting.
3000089|NCT02562521|No Intervention|Delayed Treatment Control|Participants in this arm will be offered the Smoking Cessation Treatment 6 weeks later
3000090|NCT02562508|Experimental|9-17y (0,1,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
3000091|NCT02562508|Experimental|9-14y (0,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
3000092|NCT02562508|Experimental|18-26y (0,1,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
3000093|NCT02562495|Experimental|CT scan and Ultrasonography|Up to three measurements (CT scan and Ultrasonography), will be made concurrently between the day of admission (D1) in intensive care unit and the tenth day ( D10 ) .
3000094|NCT02562482|Experimental|Group 1|CHIKV vaccine (VRC-CHKVLP059-00-VP) at Day 0 and Day 28 (+14 days)
3000095|NCT02562482|Placebo Comparator|Group 2|Phosphate Buffered Saline (VRC-PBSPLA043-00-VP) at Day 0 and Day 28 (+14 days)
3000096|NCT02562469|Experimental|ACTIVATE|ACTIVATE is a computerized neurocognitive training program (ACTIVATE; see: www.c8sciences.com) that simultaneously targets eight core neurocognitive factors (i.e., sustained attention, working memory (WM), response inhibition, speed of information processing, cognitive flexibility and control, multiple simultaneous attention, category formation, and pattern recognition and inductive thinking). ACTIVATE Is completed at home via computer with parent support. ACTIVATE intervention is conducted 3-5 times per week for between 20-30 minutes over the course or 3-4 months.
3000097|NCT02562456|Active Comparator|Conventional restorations using Filtek Z-350 composite resin|Occlusal and occlusal-proximal composite resin restorations in primary molars using the Scotchbond Multi-purpose adhesive system and the Filtek Z-350 composite resin.
3000098|NCT02562456|Experimental|Atraumatic Restorative Treatment using Fuji IX|Occlusal and occlusal-proximal ART restorations in primary molars using the high viscosity GIC Fuji IX.
3000099|NCT02562443|Experimental|rigosertib + best supportive care (BSC)|
3000100|NCT02562443|Active Comparator|Physician's Choice (PC) + best supportive care (BSC)|
3000101|NCT02562430|Experimental|Active Treatment|12.5 % will be randomized to Welbutrin XL in phase 1 of the study.
3000102|NCT02562430|Active Comparator|Placebo Group|87.5% will be randomized to receive placebo in phase 1 of the study.
3000103|NCT02562417|Placebo Comparator|No IV dexamethasone|Patients will receive an equivalent volume of normal saline.
3000104|NCT02562417|Experimental|IV dexamethasone|Patients will receive 0.1 mg/kg of dexamethasone.
3000105|NCT02562391|Active Comparator|PVI+Box lesions|Patients were treated with video-assisted thoracoscopy under general anesthesia, according to a previously described protocol. In brief, PVI was performed from the epicardial side with a bipolar radiofrequency ablation clamp. At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. In addition to PVI, the bilateral epicardial ganglia were found by high-frequency stimulation and ablated, as confirmed by the absence of a vagal response after ablation. Finally additional lines were made to create a posterior box lesion. Sensing and pacing maneuvers verified isolation of the posterior box.
3000106|NCT02562391|Experimental|PVI+Box lesions+LAA cutting|Patients were treated with video-assisted thoracoscopy under general anesthesia, according to a previously described protocol. In brief, PVI was performed from the epicardial side with a bipolar radiofrequency ablation clamp. At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. In addition to PVI, the bilateral epicardial ganglia were found by high-frequency stimulation and ablated, as confirmed by the absence of a vagal response after ablation. Finally additional lines were made to create a posterior box lesion. Sensing and pacing maneuvers verified isolation of the posterior box.The left atrial appendage was removed by stapling and then cutting.
3000107|NCT02562378|Experimental|Trastuzumab + doxorubicin|Trastuzumab and non-pegylated liposomal doxorubicin: Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2, 50 mg/m2 and 60 mg/m2) IV
3000108|NCT02562365|Experimental|A: three steps chemotherapy|Cyclophosphamide 400mg（250mg/m2）+Etoposide 100mg (70mg/m2)d1-d3 iv 4w/6cycles , followed by Carboplatin (AUC=5)+Cyclophosphamide 600mg(400mg/m2)d1-d2 iv 8w/6cycles.
3000109|NCT02562365|No Intervention|B: Follow-up|No interevention
3000409|NCT02560389|Placebo Comparator|Placebo|Placebo administered in pill form once by mouth
3000110|NCT02562352|Experimental|TAPER program|"The intervention arm is comprised of:~Identification of medications that are appropriate for discontinuation/dose reduction.~Linked pharmacist/family physician consultations with patient to discuss medication discontinuation/dose reduction."
3000111|NCT02562352|No Intervention|Control|Standard of Care as wait list control
3000112|NCT02562339|Experimental|SMART-3RP for Parents or Caregivers|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
3000113|NCT02562339|Experimental|SMART-3RP for Adolescent Patients|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
3000114|NCT02562326|Experimental|BioChaperone insulin lispro|
3000115|NCT02562326|Active Comparator|Humalog®|
3000116|NCT02562313|Experimental|BioChaperone insulin lispro|
3000117|NCT02562313|Active Comparator|Humalog®|Insulin lispro
3000118|NCT02562300|Active Comparator|Sublingual misoprostol|The patients in this arm received 400 micrograms of sublingual misoprostol, immediately after delivery of the neonate.
3000119|NCT02562300|Active Comparator|oxytocin|The patients in this arm received 20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h , immediately after delivery of the neonate.
3000120|NCT02562287|Experimental|Clozapine|Clozapine, P.O., flexible dose, for up to 6 months
3000121|NCT02562287|Active Comparator|Risperidone, olanzapine or quetiapine|Risperidone, olanzapine or quetiapine, according to clinical indication, flexible dose, for up to 6 months
3000122|NCT02562274|Placebo Comparator|Placebo group|Subjects are received the placebo product which has same color and smell look like the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) treatments once daily for 8 weeks
3000123|NCT02562274|Active Comparator|MP 50 mg/day|Subjects are received the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) 50 mg/day treatments once daily for 8 weeks
3000124|NCT02562274|Active Comparator|MP 1500 mg/day|Subjects are received the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) 1500 mg/day treatments once daily for 8 weeks
3000125|NCT02562261||Healthy|
3000126|NCT02562261||Uncomplicated Infection|Showing signs of infection as defined by International Sepsis Definitions Conference 2003
3000127|NCT02562261||Sepsis|"Sepsis is defined as systemic inflammatory response syndrome (i.e. presence of two or more of the following~Temperature of <36 °C (96.8 °F) or >38 °C (100.4 °F)~Heart rate >90bpm~Respiratory rate >20/min or PaCO2<32 mmHg (4.3 kPa)~WBC <4x109/L (<4000/mm³), >12x109/L (>12,000/mm³), or 10% bands in response to an infectious process.."
3000128|NCT02562261||Severe Sepsis/Septic Shock|Severe sepsis is defined as sepsis with sepsis-induced organ dysfunction or tissue hypoperfusion [manifesting as hypotension, elevated lactate (serum lactate 2 times the upper limit of normal), or decreased urine output (urine output < 0.5 ml/kg/hr)] Septic shock is defined as severe sepsis plus persistently low blood pressure (< 5th percentile for age or systolic blood pressure < 2 standard deviations below normal for age) following the administration of intravenous fluids.
3000129|NCT02562248|Active Comparator|Intervention|Randomization is at the clinic level. Two clinics will be randomized to receive the revised module to screen for anxiety and ADHD among children who present with parental concern of disruptive behaviors. Parents who have concerns of disruptive behaviors will trigger the module and be administered both the Vanderbilt for ADHD and Screen for Childhood Anxiety Related Emotional Disorders (SCARED) screening tools.
3000130|NCT02562248|Active Comparator|Control|Randomization is at the clinic level. Two clinics will be randomized as the control clinics meaning that they will continue to provide care as usual for families who present to the clinic with concerns of disruptive behaviors. Currently, CHICA administers the Vanderbilt for ADHD screening tool.
3000131|NCT02562235|Experimental|Riociguat|Body-weight adjusted dose equivalent to the exposure of (0.5mg) 1.0 - 2.5 mg three times a day (TID), individual dose titration (IDT) in adults treated for PAH.
3000132|NCT02562222|Experimental|anodal tDCS on M1|anodal tDCS on left primary motor cortex
3000133|NCT02562222|Experimental|cathodal tDCS on M1|cathodal tDCS on left primary motor cortex
3000134|NCT02562222|Experimental|anodal tDCS on V1|anodal tDCS on visual cortex
3000135|NCT02562222|Experimental|cathodal tDCS on V1|cathodal tDCS on visual cortex
3000136|NCT02562222|Experimental|anodal tDCS on M1 and cathodal on V1|dual tDCS - anodal tDCS on left primary motor cortex and cathodal on visual cortex
3000137|NCT02562222|Experimental|cathodal tDCS on M1 and anodal on V1|dual tDCS - cathodal tDCS on left primary motor cortex and anodal on visual cortex
3000138|NCT02562222|Sham Comparator|sham tDCS|sham tDCS
3000139|NCT02562209|Experimental|PACER diet|High Protein Atkin's Complete (Lacto) VEgetaRian Diet (PACER Diet) to be followed for 8 weeks.
3000140|NCT02562209|Active Comparator|Standard weight reducing diet|This group was prescribed Standard weight reducing diet to be followed for 8 weeks.
3000141|NCT02562196|Experimental|optimized protocol chosen|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with optimal protocol (defined in phase 1) and sham tDCS will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. An interval of 48hs between sessions will be taken.
3000142|NCT02562196|Sham Comparator|sham tDCS|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with optimal protocol (defined in phase 1) and sham tDCS will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. An interval of 48hs between sessions will be taken.
3000143|NCT02562183|Experimental|kallikrein group|Subjects receive kallikrein treatment according to real clinical practice (suggest above 14days treatment),0.15 peptide nucleic acids(PNA), once a day.
3000144|NCT02562170|Active Comparator|TiLoop Bra|immediate breast reconstruction with an implant and TiLoop Bra
3000145|NCT02562170|Active Comparator|Protexa|immediate breast reconstruction with an implant and Protexa
3000146|NCT02562157|Experimental|Patients with antro duodenal obstructions|NOTES gastroenteric anastomosis
3000147|NCT02562144|Experimental|Xylocaine spray|
3000148|NCT02562144|Placebo Comparator|Placebo|
3000410|NCT02560389|Active Comparator|100mg L-DOPA|100mg levodopa administered in pill form once by mouth
3000149|NCT02562118|Experimental|Lenvatinib + Letrozole|Single agent lenvatinib daily continuously x 2 weeks, followed by Letrozole 2.5mg daily + lenvatinib x 12 weeks
3000150|NCT02562105||Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
3000151|NCT02562092|No Intervention|Focus Group|Participants will complete a questionnaire and will be involved in a group discussion regarding good sites within the community to perform HIV testing.
3000152|NCT02562092|Other|Venue Testing Group- Negative Test|Participants will perform a rapid HIV test and will be asked to answer questions about their sexual life and living situation. No followup is needed for a negative HIV test.
3000153|NCT02562092|Other|Venue Testing Group- Positive Test|Participants will perform a rapid HIV test and will be asked to answer questions about their sexual life and living situation. Participants with a positive HIV test will receive care from a psychologist and case manager for one year.
3000154|NCT02562079|Experimental|subjects SSc diagnosed|
3000155|NCT02562079|Experimental|subjects Localised sclerosis diagnosed|
3000156|NCT02562079|Experimental|subjects Sc|
3000157|NCT02562066|Experimental|amifampridine phosphate -placebo|Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive amifampridine in Period I and then crossed over to receive placebo in Period II. Each randomized treatment period is 7 days in duration and is separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
3000158|NCT02562066|Experimental|placebo - amifampridine phosphate|Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive placebo in Period I and then crossed over to receive amifampridine in Period II. Each randomized treatment period is 7 days in duration and separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
3000159|NCT02562053|Active Comparator|Fluoxetine|Women will receive daily oral fluoxetine 20 mg in addition to an oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation.
3000160|NCT02562053|Active Comparator|Combined oral contraceptives and fluoxetine|Women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation in addition to oral fluoxetine 20 mg daily.
3000161|NCT02562053|Placebo Comparator|Placebo|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine
3000162|NCT02562040|Active Comparator|Watchful Waiting with Supportive Care|All Watchful Waiting with Supportive Care (WWSC) participants will receive information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
3000163|NCT02562040|Experimental|Early Adenotonsillectomy|All Early Adenotonsillectomy (eAT) participants will receive information about healthy sleep habits for children, undergo adenotonsillectomy within 4 weeks of randomization and receive appropriate clinical referrals for management of co-morbidities
3000164|NCT02562027|Experimental|High-risk NSCLC participants|"Baseline assessment of demographics and comorbidities~Comorbidity scoring by interview and chart review: the Adult Comorbidity Evaluation 27, Charlson Comorbidity Index, Global Initiative for Chronic Obstructive Lung Disease, Cumulative Illness Rating Scale, and COMorbidities in Chronic Obstructive Lung Disease.~Katz Activities of Daily Living: assessment of grip strength, walk speed, and activities of daily living~HRQOL questionnaires will also be administered prior to treatment and then repeated throughout follow-up: the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30, EORTC QLQ-LC13, Modified Medical Research Council, EQ-5D, CES-D, and Medical Outcomes Study Social Support Survey.~All questionnaire responses will be obtained with the use of a computer assisted interview system which can be used to collect data in person or through telephone interviews"
3000165|NCT02562014|Other|Lean|Participants with body mass index <=25
3000166|NCT02562014|Other|Overweight|Participants with body mass index >25
3000167|NCT02562001|Experimental|Outpatient active group|This group will receive active tDCS, combined with Lokomat gait training
3000168|NCT02562001|Experimental|Inpatient active group|This group will receive active tDCS, combined with Lokomat gait training
3000169|NCT02562001|Experimental|Outpatient placebo group|This group will receive placebo tDCS, combined with Lokomat gait training
3000170|NCT02562001|Experimental|Inpatient placebo group|This group will receive placebo tDCS, combined with Lokomat gait training
3000171|NCT02561988|Experimental|Avapritinib (also known as BLU-285)|Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.
3000172|NCT02561975|Experimental|Patient suffering from complex congenital heart disease|
3000173|NCT02561962|Experimental|Dose Exploration|
3000174|NCT02561949|Experimental|YRI + Employment Program|Immediately following enrollment participants will complete the YRI intervention, followed by an income generating activity program.
3000175|NCT02561949|Experimental|Employment Program|Immediately following enrollment participants will complete an income generating activity program.
3000176|NCT02561936|Experimental|Panel 1: Group 1|Participants will receive Treatment A (25 milligram [mg] rilpivirine [RPV] formulated as the oral tablet under fed condition [standardized breakfast]) followed by Treatment D (25 mg RPV formulated as granules formulation G002 [10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast]) followed by Treatment B (25 mg RPV formulated as dispersible tablet formulation G007 [10*2.5 mg tablets, dispersed in water] under fed condition) followed by Treatment C (25 mg RPV formulated as dispersible tablet formulation G009-01 [10*2.5 mg tablets, dispersed in water] under fed condition).
3000177|NCT02561936|Experimental|Panel 1: Group 2|Participants will receive treatment B followed by treatment A then treatment C followed by treatment D.
3000178|NCT02561936|Experimental|Panel 1: Group 3|Participants will receive treatment C followed by treatment B then treatment D followed by treatment A.
3000179|NCT02561936|Experimental|Panel 1: Group 4|Participants will receive treatment D followed by treatment C then treatment A followed by treatment B.
3000180|NCT02561936|Experimental|Panel 2: Group 1|Participants will receive Treatment E (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast] condition) followed by Treatment H (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [yoghurt] condition) followed by Treatment F (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fasted condition) followed by Treatment G (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast] condition).
3000181|NCT02561936|Experimental|Panel 2: Group 2|Participants will receive Treatment F followed by Treatment E then Treatment G followed by Treatment H.
3000182|NCT02561936|Experimental|Panel 2: Group 3|Participants will receive Treatment G followed by Treatment F then Treatment H followed by Treatment E.
3000183|NCT02561936|Experimental|Panel 2: Group 4|Participants will receive Treatment H followed by Treatment G then Treatment E followed by Treatment F.
3000184|NCT02561923|Experimental|Rivaroxaban|Participants will be administered a single 20 milligram (mg) dose of rivaroxaban orally on Day 1 in Part 1.
3000185|NCT02561923|Experimental|Rivaroxaban plus tranexamic acid (TXA)|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, tranexamic acid (TXA) 1.0 gram (g) - (over 10 mins) intravenously administered on Day 4 in Part 2.
3000186|NCT02561923|Experimental|Rivaroxaban plus Kcentra|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, participants will be randomized to receive a single dose of Kcentra (a 4-factor PCC), 50 international units per kilogram (IU/kg), intravenously administered (maximum rate of 210 [international units per minute] IU/min) on Day 4 in Part 2.
3000187|NCT02561923|Experimental|Rivaroxaban plus Saline|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, saline [Kcentra saline control or TXA saline control] on Day 4 in Part 2.
3000188|NCT02561897|Experimental|Edoxaban|Edoxaban 30 or 60 mg
3000189|NCT02561897|Active Comparator|Warfarin|Warfarin 1 -1 0 mg
3000190|NCT02561884|Experimental|AB|Olostar Tab. followed by Olmetec and Crestor
3000191|NCT02561884|Experimental|BA|Olmetec and Crestor followed by Olostar Tab.
3000192|NCT02561871|Experimental|Group 1|Two subsequent Intramuscular injections of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 1 and Day 85, and one intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on Day 169.
3000193|NCT02561871|Experimental|Group 2|Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 1, an intramuscular injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 85 and and an intramuscular injection of placebo control consisting of the vaccine formulation buffer on Day 169.
3000194|NCT02561871|Experimental|Group 3|Three intramuscular injections of placebo control on Day 1, Day 85 and Day 169.
3000195|NCT02561858|Experimental|acid load test|
3000196|NCT02561845||rosuvastatin group|patients who received rosuvastatin
3000197|NCT02561832|Experimental|Arm 1|Part A: ascending doses of olaparib in combination with carboplatin will be administered to investigate safety and tolerability and to define the MTD and/or RD for part B. Patients will be treated with this combination up to cycle 4, after cycle 4 they can continue with combination or monotherapy (carboplatin or olaparib). Cohorts will be started sequentially, based on SRC recommendation. Part B will start after MTD/RD identification in part A. Patients will receive olaparib and carboplatin combination for first 4 cycles (21 days per cycle), at the dose, frequency and schedule recommended from Part A. This will be followed by another 4 cycles of standard cancer therapy consisting of anthracycline and cyclophosphamide regimen. Total of 8 treatment cycles will be given before final surgery
3000198|NCT02561806|Active Comparator|Ustekinumab|45 mg ustekinumab given as SC injection for participants ≤100 kilograms (kg) and 90 mg SC injection for participants >100 kg at Week 0, 4, 16, 28, and 40. Placebo for ixekizumab injections will be used for blinding.
3000199|NCT02561806|Experimental|Ixekizumab|160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline followed by 80 mg ixekizumab given as a single SC injection once every 2 weeks from week 2 through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 52.Placebo for ustekinumab injections will be used for blinding.
3000200|NCT02561793|Active Comparator|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
3000201|NCT02561793|Placebo Comparator|Placebo|Women will receive a placebo 12 weeks before starting IVF/ICSI
3000202|NCT02561780|Active Comparator|Curriculum|"The curriculum is a mental health literacy resource designed to inform high school curricula and contains six distinct modules: 1) stigma of mental illness; 2) understanding mental health and mental illness; 3) information on specific mental illnesses; 4) experiences of mental illness; 5) seeking help and finding support; and 6) the importance of positive mental health.~A research assistant trained teachers on The Curriculum Guide content in a half-day session. Teachers implemented The Curriculum Guide, which requires approximately 6 hours of classroom time, during regular instruction of the Healthy Living course."
3000203|NCT02561780|Active Comparator|Curriculum +eLearning Follow-up|"The curriculum is a mental health literacy resource designed to inform high school curricula and contains six distinct modules: 1) stigma of mental illness; 2) understanding mental health and mental illness; 3) information on specific mental illnesses; 4) experiences of mental illness; 5) seeking help and finding support; and 6) the importance of positive mental health.~A research assistant trained teachers on The Curriculum Guide content in a half-day session. Teachers implemented The Curriculum Guide, which requires approximately 6 hours of classroom time, during regular instruction of the Healthy Living course. Students are asked to complete follow-up modules online. These modules are only accessible after completion of the Healthy Living course."
3031814|NCT02349607|Experimental|PF-05089771 300 mg + pregabalin 300 mg|
3000204|NCT02561780|No Intervention|Teaching As Usual (Control)|Schools randomized to this arm of the study received the unadulterated Healthy Living course, taught as usual.
3000205|NCT02561767|Experimental|MSCs group|"Allogeneic bone marrow-derived mesenchymal stem cells (10^6/kg) from third party donors is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21.Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.~The third-party MSCs have no similar HLA alleles of kidney donors, and have no HLA alleles specific to preformed anti-HLA antibodies in recipients prior to KTx."
3000206|NCT02561767|Placebo Comparator|Control group|Placebo (saline) is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21. Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.
3000207|NCT02561754|Active Comparator|Face-To-Face/CD|Delivery: Face-to-face Diet: Conventional diet
3000208|NCT02561754|Experimental|Technology delivery/CD|Delivery: Technology Diet: Conventional diet
3000209|NCT02561754|Experimental|Technology delivery/eSLD|Delivery: Technology Diet: enhanced Stop Light Diet
3000210|NCT02561741|Experimental|COV155|
3000211|NCT02561728|Experimental|Plagiocephaly|Children with a misshaped head due to positioning. This is also known as flat head. Children with plagiocephaly will be treated with either the Hangar Helmet or the P-Pod helmet.
3000212|NCT02561728|Experimental|Craniosynostosis|Craniosynostosis occurs when one or multiple sutures fuse too early. Several sutures may be fused alone or in combination. An open or endoscopic surgical procedure to open the suture(s) is necessary to allow for normal brain growth and development. After surgery a cranial remolding helmet is used to direct skull growth. Children with craniosynostosis will be treated with either the Hangar Helmet or the P-Pod helmet
3000213|NCT02561702|Experimental|Mexiletine first/placebo second|Participants will receive 150 mg of mexiletine by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of placebo (240 mg of lactose powder) taken by mouth 3 times daily
3000214|NCT02561702|Experimental|placebo first/mexiletine second|Participants will receive placebo (240 mg of lactose powder) taken by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of 150 mg of mexiletine by mouth 3 times daily
3000215|NCT02561689|Experimental|Fissure sealant material 1|Fissure sealing with Delton FS+ Fissure sealing withClinpro Sealant Fissure sealing withGrandio Seal Fissure sealing withControl Seal Fissure sealing withUltraSeal XT+ UltraSeal XT hydro
3000216|NCT02561689|Experimental|Fissure sealant material 2|Fissure sealing with Delton FS+ Fissure sealing withClinpro Sealant Fissure sealing withGrandio Seal Fissure sealing withControl Seal Fissure sealing withUltraSeal XT+ UltraSeal XT hydro
3000217|NCT02561676|Experimental|Web-Based Education Program Type 1|The education program involves ten weeks of web-based classes (1.5 hours per class) given once per week with daily homework assignments of approximately 30 minutes per day.
3000218|NCT02561676|Experimental|Web-Based Education Program Type 2|The education program involves ten weeks of web-based classes (1.5 hours per class) given once per week with daily homework assignments of approximately 30 minutes per day.
3000219|NCT02561663|Experimental|NWT-03, followed by placebo|Dietary Supplement: NWT-03, an egg-white protein hydrolysate For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given Dietary Supplement: Placebo A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
3000220|NCT02561663|Experimental|Placebo, followed by NWT-03|Dietary Supplement: NWT-03, an egg-white protein hydrolysate For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given Dietary Supplement: Placebo A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
3000221|NCT02561650|Experimental|COV155|
3000222|NCT02561637|Experimental|Case management|Before admission the spouse-patient dyads will take part in an interview with the case manager assessing the spouses' needs during admission through an individual care plan. During admission the case manager will follow-up and assess the goals and actions of the individual care plan and coordinate with other health professionals. During the discharge meeting the case manager will provide additional information to the spouse according to needs assessed in the care plan. After discharge the case manager will conduct a follow-up telephone call for the spouse 3-4 days and 10 days after the patient's discharge consisting of information similar to that provided at the discharge meeting.
3000223|NCT02561637|Other|Control group|Spouses and patients in the control group will receive usual care and written and oral information about the fast-track program and principles in general from the nursing staff. The usual care and information is provided before admission in the out-patient facilities and during admission
3000224|NCT02561624|Experimental|Intervention|Use of behaviour change communication via text messages to pregnant women receiving an electronic voucher for long lasting insecticide treated nets redemption through antenatal clinics.
3000225|NCT02561624|No Intervention|Control|Control group receives no behaviour change communication via text message, but receives an electronic voucher for long lasting insecticide treated nets redemption through antenatal clinics.
3000226|NCT02561611|No Intervention|Control Group|"Usual Working Condition Group (UWC)~The no-intervention control condition will be asked to maintain their usual work and lifestyle throughout the study. Participants may be contacted by Pennington Biomedical staff during the intervention."
3000227|NCT02561611|Experimental|Intervention Group|"Combined Intervention (Walk More and Pedal Desk; WMPD)~Participants in the WMPD condition will engage in both step-counting (Walk More, WM) and pedal desk (PD) intervention components."
3000228|NCT02561598||Malignant Hyperthermia|Samples from persons who have a malignant hyperthermia diagnosis.
3000229|NCT02561598||Controls|Children who participated in pharmacogenetic research and had exposure to malignant hyperthermia triggering agents.
3000230|NCT02561585|Experimental|LEO 124249|LEO 124249 ointment 30 mg/g twice daily
3000231|NCT02561585|Placebo Comparator|Vehicle|LEO 124249 ointment vehicle twice daily
3000232|NCT02561572|Experimental|Intervention|Acupuncture at the Yintang point for 30 minutes.
3000233|NCT02561572|No Intervention|Control|No intervention for 30 minutes.
3000234|NCT02561559||Lung metastasis from soft-tissue sarcoma|Lung metastases from soft-tissue sarcoma
3000411|NCT02560389|Active Comparator|200mg L-DOPA|200mg levodopa administered in pill form once by mouth
3000235|NCT02561546|Experimental|TAE plus p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
3000236|NCT02561546|Active Comparator|Trans-catheter embolization|Trans-catheter embolization (TAE) will be given once per month
3000237|NCT02561533|Experimental|BRAF immunohistochemistry (IHC)|
3000238|NCT02561520|Experimental|PRP and PPP|PRP eye drops and PPP eye drops will be prepared from patient's own blood by Magellan technology. Patients will receive eye drops in sterile amber glass droppers. Patients will be instructed to keep refrigerated each bottle after opening for 7 days and keep frozen the unopened bottles up to 30 days.
3000239|NCT02561507||American College of Surgeons members|Survey participants
3000240|NCT02561494|Placebo Comparator|Control|Intravenous normal saline 2 ml is given slowly as a placebo before the anesthesia induction and after finishing anesthesia.
3000241|NCT02561494|Experimental|Nefopam|Intravenous nefopam 20 mg is given slowly before the anesthesia induction and after finishing anesthesia.
3000242|NCT02561481|Active Comparator|Sulforaphane|"Sulforaphane (SF) will be administered once a day orally in an approximate dose of 1 µmol/lb (2.2 kg µmol/kg) body weight. Each SF tablet will contain 125 mg broccoli seed powder (equivalent to ~ 15 µmol SF). The total dose per day will depend on participants' body weight:~30-50 lb: 3 tablets (45 µmol/day) 50-70 lb: 4 tablets (60 µmol/day) 70-90 lb: 6 tablets (90 µmol/day) 90-110 lb: 7 tablets (105 µmol/day) 110-130 lb: 8 tablets (120 µmol/day)~For pilot study, all participants (n=10) will receive SF for 14 days. For main clinical trial, 25 participants will randomly receive SF for 15 weeks (phase 1). During phase 2, a single-arm crossover from placebo to sulforaphane arm will take place, and all participants will receive SF from 15-30 weeks."
3000243|NCT02561481|Placebo Comparator|Placebo|"Placebo tablets identical in size and similar in appearance to the active tablets will be used. Number of placebo tablets will be equivalent to the active tablets depending on participants' body weight.~For the main clinical trial, 25 participants will be randomly allocated to receive placebo for 15 weeks (phase 1). During phase 2, a single-arm crossover from placebo arm to sulforaphane arm will take place, and all participants will receive sulforaphane from 15-30 weeks."
3000244|NCT02561468|Experimental|Nefopam|20 mg nefopam in 100 ml normal saline is infused before starting operation.
3000245|NCT02561468|Placebo Comparator|Control|100 ml normal saline is infused before starting operation.
3000246|NCT02561455|Experimental|ASP2215|Subject will continue dosing at the dose received in original study.
3000247|NCT02561442|Active Comparator|IV ceftriaxone (0.5hr) 1 gm|ceftriaxone for injection, (total dose = 1.0 g) administered IV over 30 minutes via infusion pump (Open Label)
3000248|NCT02561442|Experimental|subcutaneous ceftriaxone, (2hr), 1 gm|ceftriaxone for injection, (total dose = 1.0 g) administered subcutaneous over 2 hours (Blinded).
3000249|NCT02561442|Experimental|subcutaneous ceftriaxone, (2 hr), 2 gm|ceftriaxone for injection, (total dose = 2.0 g) administered subcutaneous over 2 hours (Blinded).
3000250|NCT02561429|Experimental|SPT of histamine|SPT of histamine concentration 1, 5 and 10 mg/ml
3000251|NCT02561416|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) The MBSR consists in eight 2-h group sessions and an all-day mindfulness retreat, and offers intensive and structured training in mindfulness meditation to help patients to relate to their physical and psychological conditions in more accepting and nonjudgmental ways. Participants will be encouraged to engage in home mindfulness practices. Sessions will be lead by 4 MBSR accredited instructors.
3000252|NCT02561416|Active Comparator|Psycho-educational Program|Psycho-educational Program (FibroQol) It consists of eight 2-h group sessions including information about FMS (4 sessions) based on a consensus document of the Health Department of Catalonia + autogenic relaxation (4 sessions).
3000253|NCT02561416|Other|Treatment As Usual|Treatment As Usual.
3000254|NCT02561403|Experimental|EVO multitask video game|
3000255|NCT02561403|Experimental|EVO words video game|
3000256|NCT02561403|No Intervention|Assessment Only|
3000257|NCT02561390|Experimental|Skin prick test with aeroallergens|Mean wheal diameters of SPT with commercial and local American coakroach, house dust mite, cat, dog and mold
3000258|NCT02561390|Experimental|specific IgE measurement|specific IgE levels of commercial and local American coakroach, house dust mite, cat, dog and mold
3000259|NCT02561377|Experimental|resistance training|Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.
3000260|NCT02561377|Experimental|aerobic training|Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
3000261|NCT02561377|No Intervention|standard care|standard care complied with the daily lifestyle.
3000262|NCT02561338|Experimental|HMS5552 dose 1|BID oral administration
3000263|NCT02561338|Experimental|HMS5552 dose 2|BID oral administration
3000264|NCT02561338|Experimental|HMS5552 dose 3|QD oral administration
3000265|NCT02561338|Experimental|HMS5552 dose 4|QD oral administration
3000266|NCT02561338|Placebo Comparator|Placebo|Placebo, BID/QD oral administration
3000267|NCT02561325|Experimental|NaCI group|a clinical trial protocol intended to highlight a possible differential effect in the biological effects of the same sodium intake (2.56 g / day) orally, depending on the nature salt.
3000268|NCT02561325|Placebo Comparator|placebo NaCI|a clinical trial protocol intended to highlight a possible differential effect in the biological effects of the same sodium intake (2.56 g / day) orally, depending on the nature salt.
3000269|NCT02561312||RMPET|For rapid manual partial exchange transfusion, participants with a weight >50kg, 500 ml of whole blood is removed from the participant via a single lumen central venous line, followed by infusion of 500 ml of saline. A 30 second wait time is utilized for equilibration to occur. A second 500 ml aliquot is removed, and then two units of packed red blood cells (PRBC) are infused. (This is customized for a patient with large red blood cell mass). For participants <50 kg, the individual exchange aliquots are adjusted to 10 ml/kg or normal saline and PRBC.
3000270|NCT02561312||Simple Transfusion|For simple transfusion, the volume of packed red blood cells (PRBC) to be transfused in the participant is 10-15 cc/kg. No normal saline exchange is required. All blood is transfused through a single lumen central venous line.
3000870|NCT02557295||Remsima™|Patients who are taking Remsima™ for the treatment
3000271|NCT02561299|Experimental|OA with adjunctive DCB angioplasty|Lesion preparation with Peripheral Orbital Atherectomy System followed by drug-coated balloon angioplasty
3000272|NCT02561299|Active Comparator|DCB angioplasty|014 Drug Coated Balloon angioplasty
3000273|NCT02561286|Experimental|HIV risk reduction|BRO HIV Risk Reduction Intervention
3000274|NCT02561286|Active Comparator|Health promotion control|Health Promotion Intervention
3000275|NCT02561273|Experimental|Treatment (combination chemotherapy, lenalidomide)|"Patients receive cyclophosphamide IV, doxorubicin hydrochloride IV and vincristine sulfate IV on day 1, etoposide IV over 30-60 minutes on days 1-3, prednisone PO on days 1-5, and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients responding after 6 courses of treatment may then undergo an autologous stem cell transplant or receive maintenance lenalidomide at the discretion of the physician or patient choice as follows:~TRANSPLANT: Patients undergo autologous stem cell transplant per standard of care.~MAINTENANCE LENALIDOMIDE: Patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
3000276|NCT02561260||autoimmune encephalitis|
3000277|NCT02561260||unknowm encephalitis|
3000278|NCT02561260||other encephalopathy|
3000279|NCT02561247|Experimental|Prismaflex HF20 CRRT|Patients included in this arm will be treated for a minimum period of 24 hours and up to 72 hours with each Prismaflex® HF 20 Set with BUN, creatinine and bicarbonate being measured for statistical analysis at 12 hour intervals during CRRT treatment.
3000280|NCT02561234|Experimental|AEB1102|AEB1102 (Co-ArgI-PEG) will be administered IV weekly.
3000281|NCT02561221|Experimental|Lifestyle Counseling|Patients in the Lifestyle Counseling Arm will attend weekly (15 in-person) sessions in the first six months, followed by monthly sessions for the remaining 18 months. The behavioral intervention will be delivered by a trained health coach embedded in the primary care clinic. Primary Care Practitioners in the experimental arm will receive a series of webinars on obesity science to help them manage and treat obese patients.
3000282|NCT02561221|No Intervention|Usual Care|Patients assigned to the usual care arm will continue to interact with their Primary Care Practitioners according to their usual schedule, and will receive a series of newsletters on topics of interest, including importance of sleep for health, household money management, family coping skills, smoking cessation, etc. Primary Care Practitioners in the usual care arm will receive a webinar describing the current Centers for Medicare and Medicaid (CMS) approach to reimbursing for obesity treatment, and a reminder informational brochure will be sent to the Primary Care Practitioners each year.
3000283|NCT02561208|Active Comparator|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps and SMS text messages.
3000284|NCT02561208|No Intervention|Usual Care Group|Women with HPV self-collected tests receive usual care.
3000285|NCT02561195|Experimental|Low-dose C. difficile Vaccine (accelerated schedule)|
3000286|NCT02561195|Experimental|High-dose C. difficile Vaccine (accelerated schedule)|
3000287|NCT02561195|Placebo Comparator|Placebo (accelerated schedule)|
3000288|NCT02561195|Experimental|Low-dose C. difficile Vaccine (non-accelerated schedule)|
3000289|NCT02561195|Experimental|High-Dose C. difficile Vaccine (non-accelerated schedule)|
3000290|NCT02561195|Placebo Comparator|Placebo (non-accelerated schedule)|
3000291|NCT02561182||Patients aged 5 years old and with a known diagnosis of a OGS|
3000292|NCT02561169|Experimental|Oseltamivir|75 mg oseltamivir orally twice daily for 5 days within 72 hours of symptom onset
3000293|NCT02561169|Placebo Comparator|Placebo|75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir
3000294|NCT02561156|Experimental|Part 1 Cohort 1: TAK-653 0.3 mg|TAK-653 0.3 milligram (mg), tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
3000295|NCT02561156|Experimental|Part 1 Cohort 2: TAK-653 1.0 mg|TAK-653 1.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
3000296|NCT02561156|Experimental|Part 1 Cohort 3: TAK-653 3.0 mg|TAK-653 3.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
3000297|NCT02561156|Experimental|Part 1 Cohort 4: TAK-653 5.0 mg|TAK-653 5.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
3000298|NCT02561156|Experimental|Part 1 Cohort 5: TAK-653 9.0 mg|TAK-653 9.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
3000299|NCT02561156|Experimental|Part 1 Cohort 6: TAK- 653 TBD|TAK-653, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation to be decided (TBD) based on safety, tolerability, and available PK and pharmacodynamics (PD) data from previous cohorts.
3000300|NCT02561156|Experimental|Part 1 Additional Cohorts: TAK- 653 TBD|TAK-653, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
3000301|NCT02561156|Experimental|Part 2 Cohort 1: TAK-653 0.3 mg|TAK-653 0.3 mg, tablet, orally, once on Day 1, and once daily (QD) from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
3000302|NCT02561156|Experimental|Part 2 Cohort 2: TAK-653 1.0 mg|TAK-653 1.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
3000303|NCT02561156|Experimental|Part 2 Cohort 3: TAK-653 3.0 mg|TAK-653 3.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
3000339|NCT02560935|Active Comparator|Moderate Dose Hydroxyurea|Hydroxyurea at 20 mg/kg/day (range 17.5 to 26 mg/kg/day) for primary stroke prevention.
3000304|NCT02561156|Experimental|Part 2 Cohort 4: TAK-653 TBD|TAK-653, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
3000305|NCT02561156|Experimental|Part 2 Cohort 5: TAK-653 TBD|TAK-653, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
3000306|NCT02561156|Experimental|Part 2 Additional Cohorts: TAK-653 TBD|TAK-653, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
3000307|NCT02561143|Experimental|Intervention group|Patients in the intervention group will be given dietary supplement (Improved Atta: 100 g) daily along with nutritional counseling and physical activity counseling for six months.
3000308|NCT02561143|Placebo Comparator|Control group|Patients in the control group will be given whole wheat flour (100 g) daily along with nutritional counseling and physical activity counseling for six months.
3000309|NCT02561130|Experimental|Intervention|Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise
3000310|NCT02561130|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
3000311|NCT02561117|Active Comparator|q8h|Metronidazole given every 8 hours
3000312|NCT02561117|Experimental|q24h|Metronidazole given once daily
3000313|NCT02561104|Experimental|LenSx|Laser-assisted cataract surgery performed using the LenSx femtosecond laser.
3000314|NCT02561104|Experimental|Phaco|Traditional manual phacoemulsification cataract surgery
3000315|NCT02561091|Placebo Comparator|Placebo|Placebo gel for intratympanic use
3000316|NCT02561091|Experimental|AM-111 0.4 mg/ml|AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
3000317|NCT02561091|Experimental|AM-111 0.8 mg/ml|AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
3000318|NCT02561078|Experimental|Human regular U-500 insulin administered by CSII|Human regular U-500 insulin administered by CSII and titrated based on blood glucose readings for 26 weeks with a 2-week MDI lead-in.
3000319|NCT02561078|Active Comparator|Human regular U-500 insulin administered by MDI|Human regular U-500 insulin administered subcutaneously (SC) by MDI three times a day and titrated based on blood glucose readings for 26 weeks.
3000320|NCT02561065|Experimental|Lifestyle intervention high risk group.|Participants in the intervention group will receive the intervention on top of standard care.
3000321|NCT02561065|No Intervention|Standard care high risk group.|Each participant in the standard care group will receive care as usual, provided by his own occupational physician (OP) and other possible care providers.
3000322|NCT02561065|Experimental|Lifestyle intervention low risk group.|Participants in the intervention group will receive the intervention on top of standard care.
3000323|NCT02561065|No Intervention|Standard care low risk group.|Each participant in the standard care group will receive care as usual, provided by his own occupational physician (OP) and other possible care providers.
3000324|NCT02561039|Experimental|Ibandronate IV Infusion|Participants will receive ibandronate, 6 mg via IV infusion, every 3 to 4 weeks for 4 months.
3000325|NCT02561039|Experimental|Ibandronate PO Tablet|Participants will receive ibandronate, 50 mg PO daily, for 4 months.
3000326|NCT02561026|Experimental|FP Transfusion|patients randomized to receive frozen plasma transfusions
3000327|NCT02561026|No Intervention|no FP Transfusion|patients not receiving frozen plasma transfusions
3000328|NCT02561013|Experimental|3M™ Coban™ Custom Fit Compression System|3M™ Coban™ Custom Fit Compression System will be custom-fitted at first subject visit and will thereafter be applied and removed daily by the study subject. It will be worn throughout the day by the study subject and removed before bedtime. It will provide therapeutic compression for edema control to help in the healing of venous leg ulcers.
3000329|NCT02561013|Active Comparator|Profore|Profore multi-layer compression bandaging system will be applied at the first subject visit and will be worn by the study subject continuously for 7 days, at which time it will be replaced with a new system, or, in the case of a product or non-product reason, replaced before 7 days. It will provide therapeutic compression for edema control to help in the healing of venous leg ulcers
3000330|NCT02561000|Experimental|PZ-128 0.3 mg/kg|PZ-128, 0.3 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
3000331|NCT02561000|Experimental|PZ-128 0.5 mg/kg|PZ-128, 0.5 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
3000332|NCT02561000|Placebo Comparator|Placebo|Placebo, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
3000333|NCT02560974|Experimental|Capecitabine + Oxaliplatin|Patients will receive oral capecitabine (1000 mg/m^2 BID on Days 1 to 15 ) plus IV oxaliplatin (130 mg/m^2 on Day 1) during each 3-week cycle for up to 8 cycles (6 months).
3000334|NCT02560974|No Intervention|Observation|Participants will not receive any treatment but will be seen regularly by a physician.
3000335|NCT02560961|Experimental|Kinesio Taping protocol - Group A|Kinesio Taping (Kinesio Tex Gold®; color: black) will be applied by an experienced, duly trained researcher. The technique described by Kase [1] for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
3000336|NCT02560961|Placebo Comparator|Placebo Taping - Group B|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The technique described by Kase [1] for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) and ending near the posterior surface of the heel.
3000337|NCT02560948|Placebo Comparator|Placebo|
3000340|NCT02560935|Active Comparator|Low Dose Hydroxyurea|Hydroxyurea at 10 mg/kg/day (range 7 to 15 mg/kg/day) for primary stroke prevention.
3000341|NCT02560922|Experimental|Pain Coping Skills Training|This group will take part in an 11-week pain coping skills training (CST) intervention.
3000342|NCT02560922|No Intervention|Wait list Control|The other group will be the wait list group and will receive the pain CST program after completing all follow-up study measures.
3000343|NCT02560909|Experimental|Experimental|The experimental group will receive one dose MF59 adjuvanted intramuscular vaccine.
3000344|NCT02560909|Active Comparator|Control|The control group will receive one dose of the standard 2015-2016 nonadjuvanted vaccine.
3000345|NCT02560870|Active Comparator|Aloe Vera mouthwash|mouthwash (Aleo Vera)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
3000346|NCT02560870|Active Comparator|Chlorhexidine mouthwash|mouthwash (Chlorhexidine )10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
3000347|NCT02560831|Experimental|Therapeutic exercise and Pompage|strengthening exercises, balance training and knee's pompage
3000348|NCT02560831|Active Comparator|Control|Educational lectures.
3000349|NCT02560818|Active Comparator|Control population : Healthy Volunteers|10 Healthy Volunteers will be recruited
3000350|NCT02560818|Experimental|Patients|blood samples of 50 patients will be used (use of blood collection in study EXSAL N°ID-RCB 2009-A00833-54)
3000351|NCT02560805|Experimental|Veterans|Subjects with post-traumatic stress disorder (PTSD) will be evaluated using microneurography, static handgrip exercise, cold pressor test, combat virtual reality video clip, and baroreflex sensitivity using sodium nitroprusside and phenylephrine. For the second phase, they will be randomized to either losartan or atenolol.
3000352|NCT02560805|Experimental|Control|Healthy controls will be evaluated using microneurography, static handgrip exercise, cold pressor test, combat virtual reality video clip, and baroreflex sensitivity using sodium nitroprusside and phenylephrine.
3000353|NCT02560792|Experimental|Positive Affect Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise, and then read that most people indicated this level of intensity leads to positive affect. To further encourage participants to think about how the supposed typical affective response might apply to them personally, they were also asked to describe how they thought the exercise might lead to positive feelings.
3000354|NCT02560792|Experimental|Negative Affect Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise, and then read that most people indicated this level of intensity leads to negative affect. To further encourage participants to think about how the supposed typical affective response might apply to them personally, they were also asked to describe how they thought the exercise might lead to negative feelings.
3000355|NCT02560792|Experimental|Control Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise - affect was not mentioned.
3000356|NCT02560779|Experimental|TRC105 and Sorafenib|Bi-weekly TRC105 in combination with standard dose Sorafenib.
3000357|NCT02560766|Experimental|HORIZANT 300 mg|HORIZANT 300 mg once daily
3000358|NCT02560766|Experimental|HORIZANT 600 mg|HORIZANT 600 mg once daily
3000359|NCT02560766|Placebo Comparator|Placebo|Placebo once daily
3000360|NCT02560753|Experimental|T3D-959 3mg|Nine subjects will take 3mg by mouth once daily for two weeks, with or without food.
3000361|NCT02560753|Experimental|T3D-959 10mg|Nine subjects will take 10mg by mouth once daily for two weeks, with or without food.
3000362|NCT02560753|Experimental|T3D-959 30mg|Nine subjects will take 30mg by mouth once daily for two weeks, with or without food.
3000363|NCT02560753|Experimental|T3D-959 90mg|Nine subjects will take 90mg by mouth once daily for two weeks, with or without food.
3000364|NCT02560740|Experimental|PerOx Arm|PerOx Quench arm 4g/sachet each time by water, q6h
3000365|NCT02560740|Placebo Comparator|Comparative Arm|PerOx Quench placebo 4g/sachet each time by water, q6h
3000366|NCT02560727||colonoscope via of FMT|FMT pathway is colonoscope
3000367|NCT02560727||Transendoscopic enteral tubing|FMT was performed via TET tube
3000368|NCT02560688|Experimental|Period 1 - DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg)
3000369|NCT02560688|Other|Period 2 - Clopidogrel|Clopidogrel (Plavix) administered orally over 5 days (300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5)
3000370|NCT02560688|Experimental|Period 2 - DS-1040b and Clopidogrel|Concomitant administration of DS-1040b (20 mg single 12-hour intravenous infusion) and clopidogrel (single 75 mg oral dose)
3000371|NCT02560675||120 healthy subjects|"One hundred and twenty healthy subjects (range 20-79; 20 subjects per age decade, 10 M and 10 F) will participate in the first phase of the study aimed to collect normative data from healthy population.~Study design Phase I - Normative data collection for the inhibitory and excitatory pain modulation responses, a study on healthy subjects (no blood tests)"
3000372|NCT02560675||750 subjects wuith acute whiplash-injury|"Seven hundred and fifty acute whiplash-injury based mild TBI will participate in this study.~Phase II - Multi-modal assessment of acute mild TBI whiplash patients and follow-up"
3000373|NCT02560662|Experimental|Physical activity|Individual consultation with a physiotherapist in order to increase the participants existing level of physical activity by adding 30minutes of physical activity daily, preoperatively and 4 weeks postoperatively.
3000374|NCT02560662|No Intervention|Control|Participants randomized to the control group will not be advised to change their current level of physical activity.
3000375|NCT02560649|Experimental|A:PEG+NUC (HBsAg<200IU/ml at week 24)|"Peginterferon alfa-2a 180μg /wk plus nucleoside analogue(NUC):~HBsAg<200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
3000376|NCT02560649|Active Comparator|B:PEG+NUC(HBsAg>200IU/ml at week 24)|"Peginterferon alfa-2a 180μg /wk plus+nucleoside analogue(NUC):~HBsAg>200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
3000377|NCT02560649|Active Comparator|C:NUC(HBsAg>200IU/ml at week 24)|"nucleoside analogue(NUC):~HBsAg>200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
3000378|NCT02560636|Experimental|Group A Pembrolizumab and radiotherapy|Those with locally advanced bladder cancer
3000379|NCT02560636|Experimental|Group B Pembrolizumab and radiotherapy|Patients whose cancer has spread from the bladder (metastatic bladder cancer)
3000380|NCT02560623|Active Comparator|Cases - Barrett's Esophagus|Subjects will have sponge capsule procedure, blood draw, and clinically indicated endoscopy with endoscopic brushings of the esophagus.
3000381|NCT02560623|Active Comparator|Controls - No Barrett's Esophagus|Subjects will have sponge capsule procedure, blood draw, and clinically indicated endoscopy with endoscopic biopsies of the esophagus.
3000382|NCT02560610|Active Comparator|OC000459|Once daily dose of 50mg OC000459 tablets orally for 12/24 weeks
3000383|NCT02560610|Placebo Comparator|Placebo|Once daily dose of placebo tablets orally for 12/24 weeks
3000384|NCT02560597|Experimental|repetitive transcranial magnetic stimulation|rTMS delivered over the epileptogenic focus
3000385|NCT02560584|Experimental|Cysview arm|"In this single-arm trial, Cystoscopy in white light followed by blue light (BL) is performed in all applicable patients during 2 study visits; Visit 2 (Surveillance) and Visit 3 (Operating room procedure)~All patients receive instillation of 100 mg hexaminolevulinate hydrochloride as intravesical solution (50 mL) in the bladder prior to cystoscopy. Retention time: 1-3 hours.~Surveillance cystoscopy is performed with the investigational device KARL STORZ D-Light C PDD Flexible Videoscope System"
3000386|NCT02560571|Experimental|all patients|all study patients will undergo ultrasound and blood test
3000387|NCT02560558|Experimental|Belatacept 8-weekly|Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.
3000388|NCT02560558|Active Comparator|Belatacept 4-weekly|Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.
3000389|NCT02560545|Active Comparator|Cannabis oil|Cannabis oil, 20% THC 0.2 mg/kg
3000390|NCT02560545|Placebo Comparator|Placebo|Oil
3000391|NCT02560532|Experimental|Clazosentan|Diluted solution administered as a continuous intravenous infusion at a rate of 15 mg/h for up to a cumulative maximum of 10 days
3000392|NCT02560519|Active Comparator|Ringers acetate solution|Ringer-Acetat Baxter Viaflo® (Baxter Finland, Finland): Ringer-Acetat is iso-oncotic solution.Pharmacodynamic and pharmacokinetic properties: The osmotic effect is approximately the same as that of blood plasma. Electrolytes are given to receive or to keep normal osmotic conditions in the extracellular as well as the intracellular compartment. Acetate is oxidized into bicarbonate, mainly in the muscles and peripheral tissues and gives a weak alkalizing effect. Qualitative and quantitative list of composition: 1000 ml of Ringer-Acetat Baxter Viaflo contains 5.86 g sodium chloride, 0.30 g potassium chloride dihydrate, 0.29 g, 0.20 g magnesium chloride hexahydrate, 4.08 g sodium acetate trihydrate. List of excipients: Water for injections, Hydrochloric acid.
3000393|NCT02560519|Experimental|Albumin solution|Albuman® 200g/L (Sanquin, the Netherlands) is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.The solution contains 100 mmol/l of sodium (2.3 g/L). Pharmacodynamic properties: Albumin stabilises circulating blood volume and is a carrier of hormones, enzymes, medicinal products and toxins. Pharmacokinetic properties. Under normal conditions, the average half-life of albumin is about 19 days. Albuman® 40g/L is a solution containing 40 g/l (4%) of total protein of which at least 95% is human albumin. The solution contains 140 mmol/l of sodium (3.2 g/L).
3000394|NCT02560506|Experimental|Elastic assisted treadmill walking|Participants will participate in treadmill training with a low cost pulley system device made of rubber bands (Theraband(R)), which will assist therapists in advancing limbs while gait training.
3000395|NCT02560493|No Intervention|Control Condition|Participants randomly assigned to the control condition will be asked to continue their usual physical activity habits and will not interact with the intervention staff.
3000396|NCT02560493|Experimental|Exergaming Condition|Participants randomly assigned to the exergaming condition will participate in a 6 month exergaming intervention.
3000397|NCT02560480||groin injury (group A)|magnetic resonance imaging performed in all athletes with acute or subacute groin injury
3000398|NCT02560480||control (group B)|magnetic resonance imaging performed in selected asymptomatic control athletes
3000399|NCT02560467|Experimental|Patients with HCM|This is a prospective, non-blinded single center study. Subjects with known HCM with variant will be recruited. MCE at rest and during vasodilator stress will be performed. Full echocardiography including for diastolic function and regional strain imaging will also be performed. Patient history and questionnaires will be used for evaluation of symptoms and arrhythmias.
3000400|NCT02560454|Experimental|Cogmed®|"Cogmed® : working memory training (unifactorial) Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling."
3000401|NCT02560454|Experimental|Presco®|"Presco® : different cognitive function are trained (multifactorial) Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling."
3000402|NCT02560454|No Intervention|Control|Control ( waiting list)
3000403|NCT02560441|Other|chemotherapy followed by radiotherapy|Patients receive 3 cycles of IPGDP (ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6) chemotherapy followed by radiotherapy.
3000404|NCT02560441|Other|radiotherapy followed by chemotherapy|Patients receive radiotherapy followed by 3 cycles of IPGDP (ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6) chemotherapy.
3000405|NCT02560441|Other|IPGDP regimen chemotherapy|Patients receive 6 cycles of ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6. 6 cycles, every 3 weeks one cycle.
3000406|NCT02560415|Experimental|1: Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
3000407|NCT02560415|Active Comparator|2: Comparator|Treatment as usual
3000408|NCT02560402||Patients with sepsis or trauma|Adult patients, admitted to the intensive or medium care unit with sepsis or trauma
3001003|NCT02556268|Experimental|Riociguat and ATRIPLA|
3000412|NCT02560376|Experimental|68Ga-NOTA-exendin-4 PET/CT|The patients were injected with 55.5-111 MBq of 68Ga-NOTA-exendin-4 PET/CT in one dose intravenously and underwent PET/CT scan 30-60 min later.
3000413|NCT02560363|Experimental|Treatment sequence 1|Period 1:Fast ER formulation of AZD9977 Period 2:Intermediate ER formulation of AZD9977 Period 3:Slow ER formulation of AZD9977 Period 4:IR formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
3000414|NCT02560363|Experimental|Treatment sequence 2|Period 1:Intermediate ER formulation of AZD9977 Period 2:IR formulation of AZD9977 Period 3:Fast ER formulation of AZD9977 Period 4:Slow ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
3000415|NCT02560363|Experimental|Treatment sequence 3|Period 1:Slow ER formulation of AZD9977 Period 2:Fast ER formulation of AZD9977 Period 3:IR formulation of AZD9977 Period 4:Intermediate ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
3000416|NCT02560363|Experimental|Treatment sequence 4|Period 1:IR formulation of AZD9977 Period 2:Slow ER formulation of AZD9977 Period 3:Intermediate ER formulation of AZD9977 Period 4:Fast ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
3000417|NCT02560337|Experimental|Cabazitaxel|"25 mg/m2 administered as a one hour intravenous infusion on day 1 of a 3-week cycle.~Treatment continues until progression or unacceptable toxicity.~On progression there is an option of crossing over to tocotrienol."
3000418|NCT02560337|Experimental|Tocotrienol|"900 mg (300 mg x 3 every day) until progression or unacceptable toxicity.~On progression there is an option of crossing over to cabazitaxel."
3000419|NCT02560324|Experimental|Ramelteon|"The study will be performed using 8mg of ramelteon, which is currently marketed for the treatment of sleep problems. The proposed study follows the typical dosing regimen for ramelteon (8mg once a day) for 5 days during each quit assessment period.~Ramelteon will be purchased and packaged into blister packs by the Investigational Drug Service (IDS) at the University of Pennsylvania. In accordance with FDA recommendations, subjects will be instructed to take study medication within 30 min prior to going to bed and avoid taking study medication with or immediately after a high fat meal."
3000420|NCT02560324|Placebo Comparator|Placebo|"5-day placebo-controlled medication period.~Placebo ingredients will be purchased, encapsulated, and packaged into blister packs by the IDS at UPenn. Both active medication and placebo will look identical.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take ramelteon during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by ramelteon during the second medication period."
3000421|NCT02560311||HER2+ metastatic breast cancer|
3000422|NCT02560298|Experimental|Arm A (cisplatin, fluorouracil or capecitabine)|Patients receive cisplatin IV over 1-4 hours on day 1 and fluorouracil IV continuously over 24 hours on days 1-4. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients with complications associated with the central venous access which prevent further infusion of fluorouracil and only after discussion with the Chief Investigator receive capecitabine BID on days 1-4.
3000423|NCT02560298|Experimental|Arm B (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3000424|NCT02560285||Development / 2000 participants|"Age >18 years;~Patients undergoing cardiac surgery procedures (elective, urgent or emergency) for CABG; heart valve surgery; CABG + heart valve surgery; ascending aorta surgery + heart valve surgery or CABG, who have mortality risk with STS score>5 or EuroSCORE II>5."
3000425|NCT02560285||Validation / 1000 participants|"Age >18 years;~Patients undergoing cardiac surgery procedures (elective, urgent or emergency) for CABG; heart valve surgery; CABG + heart valve surgery; ascending aorta surgery + heart valve surgery or CABG, who have mortality risk with STS score>5 or EuroSCORE II>5."
3000426|NCT02560272|Experimental|Minhai-HIB|Participants at age 1 to 5 years of enrollment will receive one dose on Hib vaccine. Participants at age 6 to 11 months of enrollment will receive 2 doses on Hib vaccine at one months apart. Participants at age 2 to 5 months of enrollment will receive 3 doses on Hib vaccine at one months apart.
3000427|NCT02560272|Active Comparator|Act-HIB®|Participants at age 1 to 5 years of enrollment will receive one dose on Hib vaccine. Participants at age 6 to 11 months of enrollment will receive 2 doses on Hib vaccine at one months apart. Participants at age 2 to 5 months of enrollment will receive 3 doses on Hib vaccine at one months apart.
3000428|NCT02560259|Active Comparator|Physiotherapy Group|Physiotherapy
3000429|NCT02560259|Placebo Comparator|Conservative group|Conservative treatment
3000430|NCT02560246||Preterm Labor|Singleton pregnancy between 20 0/7 36 6/7 weeks gestational age who is admitted with PTL or cervical insufficiency (Equal or greater than 2 cm dilated) or PPROM
3000431|NCT02560246||Term Labor|Admitted to the hospital with spontaneous labor (regular contractions, cervical dilation) or spontaneous rupture of membranes
3000432|NCT02560233|Experimental|Contingent|Contingent RT-fMRI-NF
3000433|NCT02560233|Sham Comparator|Non-contingent|Sham RT-fMRI-NF
3000434|NCT02560220|Experimental|Intervention arm|Patients receive MIC cell therapy together with standard immunosuppressive therapy
3000435|NCT02560207|Active Comparator|Intermittent cefotaxime|Cefotaxime 1 gram (1000 mg) is to be administered 4 times daily for 4 days
3000436|NCT02560207|Experimental|Continuous cefotaxime|After a 1 gram (1000 mg) Cefotaxime loading dose, Cefotaxime 4 gram (4000 mg) is to be administered as a continuous infusion in 24h for 4 days .
3000437|NCT02560194|Active Comparator|Flexible Sigmoidoscopy|People randomized to this arm are offered flexible sigmoidoscopy in addition to FOBT at the age of 60.
3000438|NCT02560194|Placebo Comparator|FOBT only|People in this are offered fecal occult blood testing only.
3000439|NCT02560181|Other|HDR whole gland salvage treatment|Locally recurrent prostate cancer Whole gland HDR brachytherapy administered Whole gland dose=10.5Gy x 2 fractions delivered one week apart GTV dose=13.5Gy x 2 fractions delivered one week apart
3000440|NCT02560168|Experimental|Coronary artery disease|Patients scheduled for computed tomographic coronary angiography (CTA)
3000441|NCT02560155|No Intervention|Nose-SA-carriers control|Control Group, no intervention
3000506|NCT02559661||Medical students|Students with limited knowledge of the anatomy and pathology of the eye.
3000442|NCT02560155|Active Comparator|Nose-SA-carriers decolonized|"Chlorhexidine sol 4%; Mupirocin 2% nasal ointement~1 shower/day for 5 days and Nasal ointement 2x/d in each nostril for 5 days preoperatively"
3000443|NCT02560155|No Intervention|Non-nose-SA-carriers control|Control Group, no intervention
3000444|NCT02560155|Active Comparator|Non-nose-carriers decolonized|Chlorhexidine sol 4% shower, daily for 5 days preoperatively
3000445|NCT02560142||All Participants|Healthy participants will undergo behavioral assessment and fMRI.
3000446|NCT02560129||ICU Survivors|ICU survivors will be seen in a MICU Recovery Clinic where Questionnaires, Physical and Cognitive Function assessments will be measured
3000447|NCT02560103||Single group|No treatment
3000448|NCT02560090|Placebo Comparator|Control Group|Survey assessments as well as collection of medical records and billing information.
3000449|NCT02560090|Active Comparator|Telephonic Nurse Intervention|Survey assessments as well as collection of medical records and billing information. A nurse will communicate with participants via telephone to support diabetes self-management practices.
3000450|NCT02560090|Active Comparator|In-person Community Health Worker Intervention|Survey assessments as well as collection of medical records and billing information. A community health worker will work with participants in person to support diabetes self-management practices.
3000451|NCT02560077|Placebo Comparator|placebo|The placebo and cashew apple fruit juice had the same color and smell
3000452|NCT02560077|Active Comparator|cashew apple juice 120 mg/day|The subjects who were assigned as the low dose treatment group received cashew apple fruit juice extract at dose of 120 mg/day
3000453|NCT02560077|Active Comparator|cashew apple juice 240 mg/day|The subjects who were assigned as the high dose treatment group received cashew apple fruit juice extract at dose of 240 mg/day
3000454|NCT02560064||laparotomy and small bowel length|measurement of small bowel length in laparotomies
3000455|NCT02560051|Active Comparator|Definitive local therapy|3 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 12 months ADT (degarelix)
3000456|NCT02560051|Active Comparator|Nodal only/Low-volume bone|4 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 18 months ADT (degarelix)
3000457|NCT02560051|Active Comparator|High volume/no prior tx|5 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 24 months ADT (degarelix)
3000458|NCT02560038|Experimental|Combination chemotherapy|Combination chemotherapy consisting of gemcitabine and cisplatin plus paclitaxel on a 21-day cycle.
3000459|NCT02560025|Experimental|Alisertib / MLN8237|"This phase II clinical trial will study the efficacy of the aurora A kinase inhibitor alisertib combined with chemotherapy in higher-risk newly diagnosed AML. Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with 5+2 chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles."
3000460|NCT02560012|Other|Personalized therapy|"Subjects will receive one of the four first-line therapy agents based on their tumor's profile. The first-line agents are sunitinib, temsirolimus, sorafenib, or pazopanib. These are all routine drugs for RCC treatment and will be given at their approved doses and dosing schedules.~Upon disease progression, subject's tumor(s) will be biopsied again to create another tumor profile. The second-line agents are everolimus or axitinib. Both of these are routine drugs for RCC treatment and will be given at their approved doses and dosing schedules."
3000461|NCT02559999|Other|EEG responses|The study compares electroencephalographical responses (EEG) to painful stimuli tonic to those evoked by non-painful stimuli and with or without virtual reality
3000462|NCT02559973|Experimental|RBP-6000 - Light MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with a light molecular weight (MW) polymer.
3000463|NCT02559973|Experimental|RBP-6000 - Heavy MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with a heavy molecular weight (MW) polymer.
3000464|NCT02559973|Active Comparator|RBP-6000 - Intermediate MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with an intermediate molecular weight (MW) polymer (reference).
3000465|NCT02559960||Breviscapine Powder-Injection|Breviscapine Powder-Injection will be given to the patients, and the investigators will record all the information including ADR, application of Breviscapine Powder-Injection and the combined medications, etc.
3000466|NCT02559934|Experimental|SR-T100 gel|A single dose of 0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract) in 25 cm2 skin area covered by an occlusive dressing at least 20 hours a day and will be given once daily for sixteen consecutive weeks.
3000467|NCT02559921|Experimental|rhRIG（20 IU/kg）only|Subjects received rhRIG（20 IU/kg） on day 0
3000468|NCT02559921|Experimental|rhRIG（40 IU/kg）only|Subjects received rhRIG（40 IU/kg） on day 0
3000469|NCT02559921|Active Comparator|HRIG（20 IU/kg）only|Subjects received HRIG（20 IU/kg）on day 0
3000470|NCT02559921|Experimental|rhRIG（20 IU/kg）+ vaccine|Subjects received rhRIG（20 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
3000471|NCT02559921|Experimental|rhRIG（40 IU/kg）+ vaccine|Subjects received rhRIG（40 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
3000472|NCT02559921|Experimental|HRIG（20 IU/kg）+ vaccine|Subjects received HRIG（20 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
3000473|NCT02559921|Placebo Comparator|placebo + vaccine|Subjects received placebo in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
3000474|NCT02559908|Experimental|Treatment Group_VYC-25L|VYC-25L injection into the chin and/or jaw areas on Day 1, volume determined by the investigator (up to 4.0 mLs) and repeat treatment if applicable
3000507|NCT02559661||Ophthalmological trainees|The trainees have never done eye surgery but have a better understanding of the eyes pathology and anatomy than the medical students.
3000475|NCT02559908|Other|Control Group_No treatment then VYC-25L|No treatment for 3 months followed by VYC-25L injection into the chin and/or jaw areas, volume determined by the investigator (up to 4.0 mLs) and repeat treatment if applicable.
3000476|NCT02559895|Experimental|ALD403 Dose Level 1|ALD403 Dose Level 1 (IV)
3000477|NCT02559895|Experimental|ALD403 Dose Level 2|ALD403 Dose Level 2 (IV)
3000478|NCT02559895|Experimental|ALD403 Dose Level 3|ALD403 Dose Level 3 (IV)
3000479|NCT02559895|Placebo Comparator|Placebo|Placebo (IV)
3000480|NCT02559869||Amyotrophic Lateral Sclerosis (ALS)|Subjects will be diagnosed with possible, probable, probable-lab supported, or definite ALS.
3000481|NCT02559869||Healthy Controls|Subjects with no known neurological disorder.
3000482|NCT02559856|Active Comparator|Apixaban|10 mg PO twice-a-day for 1 week, then 5 mg PO, twice daily for 3 or 6 months of treatment.
3000483|NCT02559856|Active Comparator|Rivaroxaban|15 mg PO twice-a-day for 3 weeks, then 20 mg PO once daily for 3 or 6 months of treatment.
3000484|NCT02559843|Experimental|pomegranate juice|200 ml pomegranate juice + lifestyle modification
3000485|NCT02559843|Active Comparator|control|lifestyle modification including dietary recommendations
3000486|NCT02559830|Experimental|transduced CD34+ hematopoietic stem cell|Transplantation of autologous CD34+ hematopoietic stem cells transduced with ARSA/ABCD1 encoding lentiviral vector. Dosage: 2x10^6/Kg （Minimum）to 20x10^6/Kg （Maximum） transduced CD34+ cells at bedside for infusion
3000487|NCT02559817|Experimental|Linaclotide Dose A|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose A: 18 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg~Dose A: 36 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose A: 36 micrograms solid oral capsule in children 12-17 years of age"
3000488|NCT02559817|Experimental|Linaclotide Dose B|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose B: 36 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg~Dose B: 72 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose B: 72 micrograms solid oral capsule in children 12-17 years of age"
3000489|NCT02559817|Experimental|Linaclotide Dose C|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose C: 72 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg~Dose C: 145 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose C: 145 micrograms solid oral capsule in children 12-17 years of age"
3000490|NCT02559817|Experimental|Linaclotide Approved Adult Dose|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Approved Adult Dose: 290 micrograms solid oral capsule in children 12-17 years of age"
3000491|NCT02559817|Placebo Comparator|Matching Placebo|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast~Placebo liquid oral solution or placebo solid oral capsule in children 7-11 years of age~Placebo solid oral capsule in children 12-17 years of age"
3000492|NCT02559804||patients NB with SCI|Survival and late effects. Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse/progression).
3000493|NCT02559791|Experimental|Study participants|All study participants will receive 2 monthly doses of placebo followed by 4 monthly doses of IV reslizumab 3mg/kg
3000494|NCT02559778|Active Comparator|Standard Immunotherapy without DFMO|One of the following drugs will be chosen for each subject based on molecular guided results: bortezomib, crizotinib, dasatinib, lapatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin. At the end of immunotherapy, DFMO will be given BID for 730 days.
3000495|NCT02559778|Active Comparator|Standard Immunotherapy with DFMO|One of the following drugs will be chosen for each subject based on molecular guided results: bortezomib, crizotinib, dasatinib, lapatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin PLUS 1000mg/m2 BID of DFMO. At the end of immunotherapy, DFMO will continue to be given BID for 730 days.
3000496|NCT02559752||Arm 1: NIH Toolbox Cognitive Battery testing|"This study will use the NIH Toolbox Cognitive Battery computer testing software to investigate the cognitive outcomes in children with CNS tumors receiving PBRT.~Participants recruited for the study will complete one 45-minute testing session prior to the completion of the first week of radiation therapy.~They will then complete serial tests 6-12 months after the completion of PBRT and then yearly thereafter."
3000497|NCT02559739||Sleep deficiency/fragmentation|Patients with sleep deficiency/fragmentation
3000498|NCT02559739||No sleep deficiency/fragmentation|Patients without sleep deficiency/fragmentation
3000499|NCT02559726|Experimental|O-HCM|20 patients with Hypertrophic Cardiomyopathy with outflow-tract obstruction
3000500|NCT02559726|Experimental|NO-HCM|20 patients with Hypertrophic Cardiomyopathy without outflow-tract obstruction
3000501|NCT02559726|Other|healthy volunteers|20 healthy volunteers
3000502|NCT02559713|Experimental|Vedolizumab|Vedolizumab 300 milligram (mg), IV infusion over 30-minutes, single dose on Day 1.
3000503|NCT02559700|Experimental|Brain training programme|Participants will complete a package of online brain training games focusing on reasoning and problem solving. The intervention will be accessed via a computer. There is no minimum or maximum dosage but participants will be recommended to complete the intervention five times a week. The package takes approximately 10 minutes to complete, depending on individual performance.
3000504|NCT02559687|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks (Q3W) for up to 35 treatments (approximately 2 years)
3000505|NCT02559674|Experimental|Phase Ib/II ALT-803 w/ gemcitabine and nab-paclitaxel|
3001004|NCT02556268|Experimental|Riociguat and COMPLERA|
3000508|NCT02559661||Vitreoretinal surgeons|The vitreoretinal surgeons knows the eyes anatomy and pathology well and have training and skills in vitreoretinal surgery.
3000509|NCT02559648|Active Comparator|Denosumab|In Group A, 60 mg Denosumab will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180)
3000510|NCT02559648|Placebo Comparator|Placebo|In Group B placebo will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180)
3000511|NCT02559635|No Intervention|No bowel stimulation|Patients undergoing loop ileostomy closures without having had bowel stimulation beforehand
3000512|NCT02559635|Experimental|Bowel stimulation|Patients undergoing loop ileostomy closures having undergone bowel stimulation beforehand
3000513|NCT02559622|Experimental|300 mg secukinumab|300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)
3000514|NCT02559622|Experimental|150 mg secukinumab|150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)
3000515|NCT02559622|Other|Placebo followed by 300 mg secukinumab|Placebo until week 12 followed by 300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)
3000516|NCT02559622|Other|Placebo followed by 150 mg secukinumab|Placebo until week 12 followed by 150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)
3000517|NCT02559609|Active Comparator|job activity contracting|Standard services plus job activity contracting and alcohol monitoring
3000518|NCT02559609|Experimental|reinforcement for negative alcohol samples|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for negative breath alcohol recordings
3000519|NCT02559609|Experimental|reinforcement for completing activities|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for completing job-related activities
3000520|NCT02559609|Experimental|reinforcement for negative alcohol samples & activities|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for negative breath alcohol recordings and for completing job-related activities
3000521|NCT02559596||Cases|Adults (aged 16+) with stored serum samples collected for the Health Survey for England (HSE) between 2009 and 2013, who have a record of hospitalisation for stroke, transient ischaemic attack or myocardial infarction occurring after their participation in the HSE.
3000522|NCT02559596||Controls|Adults (aged 16+) with stored serum samples collected for the Health Survey for England (HSE) between 2009 and 2013, who do not have a record of hospitalisation for stroke, transient ischaemic attack or myocardial infarction and are matched to cases on age, gender and year of participation in the HSE.
3000523|NCT02559583||Participants with Chronic Lymphocytic Leukemia (CLL)|This is an observational study. Data will be captured for Participant's with diagnosis of Chronic Lymphocytic Leukemia according to hospital records in the questionnaire provided by the Sponsor.
3000524|NCT02559583||Participants with Multiple Myeloma (MM)|This is an observational study. Data will be captured for Participant's with diagnosis of Multiple Myeloma (MM) according to hospital records in the questionnaire provided by the Sponsor.
3000525|NCT02559583||Participants with Non-Hodgkin's lymphoma (NHL)|This is an observational study. Data will be captured for Participant's with diagnosis of non-Hodgkin's lymphoma (NHL) data according to hospital records in the questionnaire provided by the Sponsor.
3000526|NCT02559570|Experimental|Linaclotide Dose A|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose, which will be taken at the study center after at least a 2-hour fast.~Dose A: 9 micrograms liquid oral solution in children 6-11 years of age with weight 18 to <35 kg~Dose A: 18 micrograms liquid oral solution in children 6-11 years of age with weight ≥ 35 kg~Dose A: 18 micrograms liquid oral solution or solid oral capsule in children 12-17 years of age"
3000527|NCT02559570|Experimental|Linaclotide Dose B|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose, which will be taken at the study center after at least a 2-hour fast.~Dose B: 18 micrograms liquid oral solution in children 6-11 years of age with weight 18 to <35 kg~Dose B: 36 micrograms liquid oral solution in children 6-11 years of age with weight ≥ 35 kg~Dose B: 36 micrograms liquid oral solution or solid oral capsule in children 12-17 years of age"
3000528|NCT02559570|Experimental|Linaclotide Dose C|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose, which will be taken at the study center after at least a 2-hour fast.~Dose C: 36 micrograms liquid oral solution in children 6-11 years of age with weight 18 to <35 kg~Dose C: 72 micrograms liquid oral solution in children 6-11 years of age with weight ≥ 35 kg~Dose C: 72 micrograms liquid oral solution or solid oral capsule in children 12-17 years of age"
3000529|NCT02559570|Experimental|Linaclotide Approved Adult Dose|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Approved Adult Dose: 145 micrograms oral solution or solid oral capsule in children 12-17 years of age"
3000530|NCT02559570|Placebo Comparator|Matching Placebo|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast~Placebo liquid oral solution in children 6-11 years of age~Placebo solid oral capsule or placebo liquid oral solution in children 12-17 years of age"
3000531|NCT02559557|Experimental|Supportive care (Spanish-adapted skills training)|"PHASE I (FOCUS GROUPS): Parents undergo a semi-structured interview with bilingual research assistants over 120 minutes. The content and purpose of the intervention is explained, and the focus group discussions elicit feedback on the intervention components and content of the sessions, and whether the material is culturally and linguistically appropriate. Following the focus group discussion, parents receive a copy of the educational handouts that they may choose to use with their child if they like.~PHASE II (PILOT TESTING): Parents of children age 5 to 17 years, 11 months old undergo adapted skills training in Spanish over 60 minutes (8 training sessions total) or 80 minutes (6 training sessions total). The adapted skills training sessions focus on parenting strategies and learning techniques. Sessions include homework assignments and techniques for parents to apply with their child for at least 30 minutes, 3 times a week at home."
3000532|NCT02559544|Experimental|Arm 1|
3000533|NCT02559531|Experimental|Intervention group|EMS providers will evaluate computerized clinical scenarios using a mobile triage device
3000534|NCT02559518|Experimental|anodal ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
3000535|NCT02559518|Experimental|cathodal ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
3000536|NCT02559518|Sham Comparator|sham ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
3000537|NCT02559518|Experimental|high frequency c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
3000538|NCT02559518|Experimental|low frequency c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
3000539|NCT02559518|Sham Comparator|sham c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
3000540|NCT02559505|Experimental|6-12 months Seasonal IIV|Children 6 - 12 months of age vaccinated with seasonal IIV
3000541|NCT02559505|Experimental|3-12 months natural infection|Children 3-12 months of age presenting with natural influenza infection
3000542|NCT02559505|Experimental|13-35 months Seasonal IIV|Children 13-35 months of age vaccinated with seasonal IIV
3000543|NCT02559505|Experimental|13-35 months natural infection|Children 13-35 months of age presenting with natural influenza infection
3000544|NCT02559505|Experimental|3-5 years Seasonal IIV|Children 3-5 years of age vaccinated with seasonal IIV
3000545|NCT02559505|Experimental|3-5 years natural infection|Children 3-5 years of age presenting with natural influenza infection
3000546|NCT02559505|Experimental|6-8 years Seasonal IIV|Children 6-8 years of age vaccinated with seasonal IIV
3000547|NCT02559505|Experimental|6-8 years natural infection|Children 6-8 years of age presenting with natural influenza infection
3000548|NCT02559492|Experimental|Group A: Itacitinib + epacadostat|Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
3000549|NCT02559492|Experimental|Group B: Itacitinib + INCB050465|Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
3000550|NCT02559479|Active Comparator|18%-Protein diet|Energy-restricted diet wit the following composition: 18% protein, 30% fat and 52% carbohydrates
3000551|NCT02559479|Active Comparator|35%-Protein diet|Energy-restricted diet wit the following composition: 35% protein, 30% fat and 35% carbohydrates
3000552|NCT02559466|Experimental|Patients stimulated with a H-TMS (deep)|20 sessions navigated with Deep Transcranial Magnetic Stimulation
3000553|NCT02559466|Other|Patients stimulated with a conventional TMS|20 sessions navigated with Conventional Transcranial Magnetic Stimulation
3000554|NCT02559453|Active Comparator|2 operations|Subjects in this arm will receive a maximum of two surgical debridements of their wound.
3000555|NCT02559453|Active Comparator|3 or more operations|Subjects in this arm will receive three or more surgical debridements of their wound.
3000556|NCT02559440|Active Comparator|mometasone furoate|In the first treatment stage, 120 children were assigned to mometasone furoate (50μg, 1 puff in each nostril every evening) after two week's run-in period.
3000557|NCT02559440|Placebo Comparator|Placebo|In the first treatment stage, 120 children were assigned to control group (normal saline) after two week's run-in period.
3000558|NCT02559440|Active Comparator|Oxymetazoline + Placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving Oxymetazoline and placebo.
3000559|NCT02559440|Placebo Comparator|Placebo + placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving placebo and placebo.
3000560|NCT02559440|Active Comparator|mometasone furoate + Placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving mometasone furoate and placebo.
3000561|NCT02559440|Active Comparator|mometasone furoate + Oxymetazoline|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving mometasone furoate and Oxymetazoline.
3000562|NCT02559427|Active Comparator|Immediate SPA treatment|3-week immediate SPA treatment (soon after randomization)
3000563|NCT02559427|Sham Comparator|Late SPA treatment|3-week late SPA treatment (soon after primary endpoint at 4 1/2 months visit)
3000564|NCT02559414|No Intervention|Control|This arm of 10 subjects will be assigned randomly via a computer generated treatment sequence, and then be given no antiplatelet medication.
3000565|NCT02559414|Active Comparator|Aspirin|This arm of 20 subjects will be assigned randomly via a computer generated treatment sequence, and then be given aspirin.
3000566|NCT02559414|Active Comparator|Clopidogrel|This arm of 20 subjects will be assigned randomly via a computer generated treatment sequence, and then be given clopidogrel.
3000567|NCT02559388|Active Comparator|montelukast|montelukast 10 milligram, daily for 30 days
3000568|NCT02559388|Placebo Comparator|placebo|Placebo one tablet for 30 days
3000569|NCT02559336|No Intervention|Control|Usual care: Oncology team refers patients to palliative care team if deemed appropriate
3000570|NCT02559336|Experimental|Intervention|Integrated oncology care and palliative care
3000571|NCT02559310|Experimental|Lefamulin|Intravenous lefamulin with potential step-down to oral lefamulin
3000572|NCT02559310|Active Comparator|Moxifloxacin +/- Linezolid|Intravenous moxifloxacin with potential step-down to oral moxifloxacin +/- linezolid
3000573|NCT02559297|Active Comparator|Sevoflurane|In sevoflurane arm (n=20) at the beginning after successful intubation, 2 L/min nitric oxide (N2O), 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O.
3000574|NCT02559297|Experimental|Desflurane|In desflurane arm (n=20) at the beginning after successful intubation, 2 L/min N2O, 2 L/min O2, and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 MAC of desflurane in 50% O2 and 50% N2O.
3000670|NCT02558634|Sham Comparator|DBS-off (sham-stimulation)|"Ventral intermediate Nucleus (VIM) Thalamic DBS off~DBS system includes:~Implantable Pulse Generator (IPG)~DBS Lead~DBS Lead Extension Kit"
3000575|NCT02559284|Experimental|A - Experimental|Treatment Arm: 100 patients using Respimer® NetiFlow® solution as standard treatment for healing of nasal surgery wounds following an endoscopic ethmoidectomy as a postoperative care after ethmoid sinus surgery
3000576|NCT02559284|Active Comparator|B - Comparator|Control Arm: 100 patients using saline solution (0.9% NaCl) as standard treatment for healing of nasal surgery wounds following an endoscopic ethmoidectomy as a postoperative care after ethmoid sinus surgery
3000577|NCT02559258|Experimental|Cohort 1|
3000578|NCT02559258|Experimental|Cohort 2|
3000579|NCT02559258|Experimental|Cohort 3|
3000580|NCT02559258|Experimental|Cohort 4|
3000581|NCT02559258|Experimental|Cohort 5|
3000582|NCT02559245|Experimental|Ficus carica|45 grams Ficus carica before breakfast and lunch with 1 glass of water every day respectively (total consumption: Ficus carica 90g/d)
3000583|NCT02559245|Experimental|Descurainia Sophia|30 grams Descurainia Sophia before breakfast and lunch with 1 glass of water every day respectively (total consumption: Descurainia Sophia 60g/d)
3000584|NCT02559245|No Intervention|controled|participants will follow their usual diet
3000585|NCT02559232||DOAC treated patients|Patients diagnosed with Non-Valvular Atrial Fibrillation at risk of stroke or systemic embolism treated in primary care centres with DOAC.
3000586|NCT02559206|Experimental|30 μg linaclotide DR1 and placebo|
3000587|NCT02559206|Experimental|100 μg linaclotide DR1 and placebo|
3000588|NCT02559206|Experimental|300 μg linaclotide DR1 and placebo|
3000589|NCT02559206|Experimental|30 μg linaclotide DR2 and placebo|
3000590|NCT02559206|Experimental|100 μg linaclotide DR2 and placebo|
3000591|NCT02559206|Experimental|300 μg linaclotide DR2 and placebo|
3000592|NCT02559206|Experimental|290 μg linaclotide IR and placebo|
3000593|NCT02559206|Placebo Comparator|Placebo|
3000594|NCT02559193||No treatment.|Data collection only trial design.
3000595|NCT02559180|Experimental|Single Arm|aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
3000596|NCT02559167|Active Comparator|Cannabidiol|Participants will receive CBD 800 mg for 92 consecutive days starting on Day 2 of a 10-day inpatient detoxification period followed by 12 weeks of outpatient follow-up
3000597|NCT02559167|Placebo Comparator|Placebo|Participants will receive placebo for 92 consecutive days starting on Day 2 of a 10-day inpatient detoxification period followed by 12 weeks of outpatient follow-up
3000598|NCT02559154|Experimental|modified BZ group|Patients with newly diagnosed or pre-treated MM(prior therapy not including bortezomib) received regimen with bortezomib (1.6mg/㎡) as an intravenous bolus once weekly on day 1, 8 in a 3 weeks cycle, in combination with dexamethasone,with or without doxorubicin/ cyclophosphamide/mitoxsnteone/thalidomide
3000599|NCT02559154|Active Comparator|conventional BZ group|Patients with newly diagnosed or pre-treated MM(prior therapy not including bortezomib) received bortezomib (1.3mg/㎡) administration twice weekly on day 1,4, 8,11 in a 3 weeks cycle, in combination with dexamethasone,with or without doxorubicin/ cyclophosphamide/mitoxsnteone/thalidomide
3000600|NCT02559141|Other|Study group (SG)|"Before induction of anaesthesia:~Arterial line~Nexfin Monitoring System~Measurement of cardiac index (CI), pulse pressure variation (PPV) and mean arterial pressure (MAP)~Baseline blood samples. Induction of anaesthesia~Study Group:~PPV ≤10%, 500 ml of crystalloids/colloids as long as CI was ≥2.5 l/min/m²~Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min)."
3000601|NCT02559141|No Intervention|Control group (CG)|"MAP ≥65 mmHg~CVP ≤12 mmHg~Haemoglobin level ≥8 g/dl.~Maintenance of MAP ≥65 mmHg by using crystalloids/colloids, bolus injection of theodrenaline/cafedrine or continuous infusion of norepinephrine (0.03 µg/kg/min) according to clinical evaluation."
3000602|NCT02559128||HF+T2D+|40 patients with chronic HF and type 2 diabetes or prediabetes without previous pharmacological treatment
3000603|NCT02559128||HF+T2D-|20 subjects with HF without T2D or prediabetes
3000604|NCT02559128||HF-T2D+|20 subjects with T2D or prediabetes alone
3000605|NCT02559128||HF-T2D-|20 healthy control volunteers
3000606|NCT02559115|Experimental|PET/CT imaging with 68Ga-RM2|The intervention is the administration of a single dose of 150-200 MBq 68Ga-RM2 (mass <= 30 μg) for imaging purposes. This will be followed by a 30-40 min PET/CT study after a waiting period of 60 min (+/- 10 min). Prior clinical experience suggests that imaging can be performed within 1 hour post injection (27, 28). MR imaging and prostatectomy will be performed as standard of care at MSKCC.
3000607|NCT02559102|Experimental|Dex Group|Intravenous dexmedetomidine sedation prior to single shot caudal anaesthesia and maintenance infusion of dexmedetomidine during bilateral inguinal hernia surgery.
3000608|NCT02559102|Active Comparator|GA Group|General sevoflurane anaesthesia with endotracheal intubation and single shot caudal anaesthesia for inguinal hernia surgery. This is currently the standard anaesthetic technique for bilateral inguinal hernia surgery in neonates and infants in KKH.
3000609|NCT02559089||anti-NMDA receptor encephalitis|
3000610|NCT02559089||other autoimmune encephlitis|
3000611|NCT02559089||other encephalopathy|
3000612|NCT02559076|Experimental|Ten Steps Leaflet|Ten steps leaflet advice for healthy lifestyle
3000613|NCT02559076|No Intervention|Usual care|Usual care given
3000614|NCT02559063|Experimental|Vision-based speed of processing|Vision-based speed of processing training will use the INSIGHT online program (Posit Science), which includes five games (i.e., Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All games share visual components, and the tasks become increasingly more difficult and require faster reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
3000671|NCT02558621|Experimental|Device: AQrate Robotic Assistance System|Precise positioning of surgical instruments and spinal implants during general spinal surgery.
3000672|NCT02558608|Experimental|WR AND DIPL|patients undergo wedge resection and dissection the inferior pulmonary ligament by thoracoscopic surgery or video assisted thoracoscopic surgery
3000615|NCT02559063|Active Comparator|Mental leisure activities|Mental leisure activities control activities were chosen to: 1) control for computer, online experience [and amount of time]; 2) not induce acute stress (i.e., without time management, speed component, or novel cognitive stimuli); 3) simulate participants' everyday mental activities; and 4) entertain participants to keep them from dropping out. Cross-word, Sudoku, and solitaire games will be used, which were also used in previous VSOP training study as control exercises. Participants can choose to practice any combination of games. At the end of their participation, the MLA control group will be provided with free 6-week access to the VSOP training program.
3000616|NCT02559037|Experimental|Acupuncture-moxibustion group|"Acupuncture acupoints: ST36, ST37, SP6, SP9, SP4, LR3, LI3，all are bilateral.Sterile disposable stainless steel needles (with a diameter of 0.30 mm and length of 40 mm or 25 mm) were used. The needles were directly inserted 20-30mm into the skin and elicited a de-qisensation. The needle was kept in position for 30 min.~Moxibustion acupoints: ST25，ST36，both are bilateral. Using mild-warm moxibustion，keep transcutaneous temperature maintained at 43 ℃ ± 1 ℃, 30min for each acupoint. Moxibustion and acupuncture were performed at the same time once every other day, three times a week, a total of 24 weeks of moxibustion treatment. After the treatment, subjects were followed up in the 36 weeks and 48 weeks."
3000617|NCT02559037|Placebo Comparator|Placebo acupuncture-moxibustion group|"Sham acupuncture points: same to the experimental group. Needles with the same diameter and length as those used in the experimental group were used for needling; however, the needles were directly inserted only 1-2 mm into the skin, without eliciting a de-qisensation.~Sham moxibustion acupoints: same to the experimental group;using mild-warm moxibustion，keep transcutaneous temperature maintained at 37 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of 24 weeks of moxibustion treatment. After the treatment, subjects were followed up in the 36 weeks and 48 weeks."
3000618|NCT02559024|Experimental|21 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 21 days prior to surgery
3000619|NCT02559024|Experimental|14 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 14 days prior to surgery
3000620|NCT02559024|Experimental|7 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 7 days prior to surgery
3000621|NCT02559011||All study participants|Patients who need a TAVI with symptomatic severe aortic valve stenosis
3000622|NCT02558972|Placebo Comparator|Northera-single dose|Study #1 -Does single large dose (600mg) of Northera improve upright hemodynamics and orthostatic intolerance in POTS and VVS
3000623|NCT02558972|Placebo Comparator|Northera- chronic administration|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day.
3000624|NCT02558959|Experimental|Irinotecan and Capecitabine|irinotecan 180mg/m2 d1, capecitabine 1000mg/m2 bid d1-10, q2w
3000625|NCT02558959|Active Comparator|Irinotecan|irinotecan 180mg/m2 d1, q2w
3000626|NCT02558946|Active Comparator|Physical Therapy Treatment Group|Written and verbal information on performing Kegel exercises (exercises that aim to strengthen pelvic floor muscles) will be provided at the pre-op clinic visit. The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 1-6 weeks preoperative, 7-10 days postoperative, and 4-8 weeks postoperative .
3000627|NCT02558946|Active Comparator|Control Group|Written and verbal information on performing Kegel exercises (exercises that aim to strengthen pelvic floor muscles) will be provided at the pre-op clinic visit.
3000628|NCT02558933|Experimental|Epigallocatechin gallate (EGCG) treated|Intervention: Epigallocatechin gallate (EGCG) administered FAS children: An oral dose of 9 mg/Kg/day of EGCG will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment
3000629|NCT02558894|Experimental|MEDI4736 monotherapy|MEDI4736 via IV infusion.
3000630|NCT02558894|Experimental|tremelimumab+MEDI4736|MEDI4736+tremelimumab via IV infusion.
3000631|NCT02558881||Virtual colonoscopy|"With virtual colonoscopy, the patient does not need to be hospitalized for examination, which is usually done without hospitalization. A bowel preparation is necessary. It may vary from site to site, but it generally comprises polyethylene glycol or sodium phosphate. The residual stools are marked by ingestion of a radiopaque product to differentiate colic lesions. But no contrast agent is injected intravenously. The patient should be supine and a rectal probe is set up to inject either air or CO2. The vesting period does not exceed thirty seconds apnea, and overall completion time of the examination (patient table) is about 10 minutes."
3000632|NCT02558881||Colon capsule|The colon capsule comprises two cameras located at both ends. Image acquisition is set between four to thirty-five images per second. It begins immediately after ingestion of the capsule which allows recording of esophageal and gastric images. She paused for 2 hours (to save batteries) while crossing the small intestine. It is reactivated in the terminal ileum. The films analysis time is approximately 1 hour, and the capsule remains on average 3 hours in the colon.
3000633|NCT02558868|Experimental|Oxaliplatin + Irinotecan|Irinotecan：160 mg/m2，iv 120 min，d1 q2w oxaliplatin: 85 mg/m2，iv 120 min，d1 q2w
3000634|NCT02558868|Active Comparator|Irinotecan|Irinotecan：180 mg/m2，iv 120 min，d1 q2w
3000635|NCT02558855|Active Comparator|Thrust Joint Manipulation|Patients will receive thrust joint manipulation to their lumbar spine in side lying.
3000636|NCT02558855|Sham Comparator|Non-thrust Joint Manipulation|Patients will receive non-thrust joint manipulation, oscillations into slight rotation, without cavitation, to their lumbar spine in side lying.
3000637|NCT02558842|Experimental|Education Strategy|Educational Strategy and Oversight Distance
3000638|NCT02558842|No Intervention|Routine|Routine hospital assistance
3000639|NCT02558829|Experimental|GHST Sequence A|1st Macimorelin-GHST, 2nd Insulin Tolerance Test
3000640|NCT02558829|Experimental|GHST Sequence B|1st Insulin Tolerance Test, 2nd Macimorelin-GHST
3000673|NCT02558608|Active Comparator|WR|patients undergo wedge resection by thoracoscopic surgery or video assisted thoracoscopic surgery without dissection the inferior pulmonary ligament
3000674|NCT02558595|Experimental|Niacinamide|Participants will be asked to take niacinamide at a dose of 30 mg/kg/d orally.
3000675|NCT02558595|Placebo Comparator|Placebo|Participants will be asked to take a placebo pill at a dose of 30 mg/kg/d orally.
3000641|NCT02558816|Experimental|Ibrutinib - GA101 - GDC_0199|"Step A : C1:Ibrutinib 560mg D2 28 / GA101 1000mg D1/2,8,15 ; C2-6:Ibrutinib 560mg day 1-28 / GA101 1000mg day 1 ; C7-C24 (maintenance):Ibrutinib 560mg D1-28 (until progression) / GA101 1000mg D1 every 2cycles (from C8)~Step B : C1:Ibrutinib 560mg D2 - 28 / GA101 1000mg D/2,8,15 ; C1bis:Ibrutinib 560mg D1-28 / GA101 1000mg D1 / GDC-0199:20mg/d at W1, 50mg/d at W2, 100mg at W3 and 200 mg/d at W4 ; C2-6:Ibrutinib 560mg D1-28 / GA101 1000mg D1 / GDC199:400mg/d at W1 and 400, 600 or 800 mg/d at W2-3-4 and 400, 600 or 800 mg/d C3 to C6 ; C7-C23 (maintenance):Ibrutinib 560mg D1-28 (until progression) / GA101 1000mg D1 every 2 cycles (from C8) / GDC-0199 : 400, 600 or 800 mg D1-28~Step C : C1 to C2W1 : identical as step B. Then, dose of GDC-199 as recommended in step B at C2W2-3-4 and in C3 to C6.~C7-C23:Ibrutinib 560mg D1-28 (until progression) / GA101 1000mg D1 every 2 cycles (from C8) / GDC-0199 as recommended in step B from D1 to D28"
3000642|NCT02558803|No Intervention|Usual Care|The clinical team will be left to identify the need for a follow-up HPV vaccine through existing mechanisms
3000643|NCT02558803|Experimental|Simple Reminder|A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.
3000644|NCT02558790|Experimental|L-Threonic Acid Magnesium Salt (L-TAMS)|Subjects received open label L-Threonic acid Magnesium salt for 12 weeks. Subjects took MMFS202 (6-hour release) and MMFS302 (12-hour release) by mouth each day, up to three times a day.
3000645|NCT02558777|Experimental|Intervention Group|Multicomponent nurse-led intervention (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain)
3000646|NCT02558777|No Intervention|Control Group|Usual care
3000647|NCT02558764|No Intervention|Control|No intervention; basic wound contact absorbent dressings will be used as per current standard of care.
3000648|NCT02558764|Other|PICO|PICO device will be used for prevention of wound complications. This is a portable negative pressure wound treatment device. Patients will have the device for 7 days after undergoing kidney transplant surgery.
3000649|NCT02558751|Active Comparator|HIV positive PPV23|HIV-positive individuals 50-65 years of age immunized with one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23
3000650|NCT02558751|Active Comparator|HIV positive PCV13/PPV23|HIV-positive individual 50-65 years of age, Intervention: one dose of 13-valent pneumococcal conjugate vaccine,PCV13, followed 8 weeks later with one dose of 23-valent pneumococcal polysaccharide vaccine, PPV23
3000651|NCT02558751|Active Comparator|HIV negative PCV13/PPV23|HIV-negative individual 50-65 years of age, Intervention: one dose of 13-valent pneumococcal conjugate vaccine,PCV13, followed 8 weeks later with one dose of 23-valent pneumococcal polysaccharide vaccine, PPV23
3000652|NCT02558738||Ectoin Ear Spray|treatment according to instruction for use
3000653|NCT02558738||Normison ear spray|treatment according to instruction for use
3000654|NCT02558725|No Intervention|one capsule of iron supplement|instructed to take one capsule at least 2 hours after consumption of dairy products
3000655|NCT02558725|Active Comparator|two capsules of iron supplement|instructed to take two capsules of Aktiferrin F at least 2 hours after consumption of dairy products
3000656|NCT02558712|Other|Face to face exam|Standard of clinical care, 8 point eye exam
3000657|NCT02558699|Active Comparator|conventional group|Group operating the atrial fibrillation by physician's personal experience, not by virtual simulation.
3000658|NCT02558699|Experimental|3D atrial computer model|Group choosing choose the best effective rotor mapping by simulating 3D atrial computer model which consider patinet's heart size and shape.
3000659|NCT02558686|Experimental|Eccentric Exercise|Individuals will perform 3 sets of 10 repetitions of eccentric exercise of the infraspinatus muscle after the application of trigger point dry needling
3000660|NCT02558686|Sham Comparator|Detuned Ultrasound|Individuals will received 10 minutes of detuned ultrasound on the infraspinatus muscle after the application of trigger point dry needling
3000661|NCT02558686|Placebo Comparator|Placebo|Individuals will not perform any action after the application of trigger point dry needling
3000662|NCT02558673|Experimental|Egg|Study meals were administered in commonly consumed serving sizes (3 hard-boiled eggs) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
3000663|NCT02558673|Experimental|Beef|Study meals were administered in commonly consumed serving sizes (6 oz beef [Philly-Gourmet Beef Patties]) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
3000664|NCT02558673|Experimental|Fish|Study meals were administered in commonly consumed serving sizes (6 oz fish [cod fillet]) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
3000665|NCT02558673|Active Comparator|Fruit|Study meals were administered in commonly consumed serving sizes (2 single-serve packages of Mott's natural applesauce) and provided comparable amounts of control (or active comparator). Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period. For the fruit control, 50 mg deuterium-labeled methyl-d9-TMAO (d9-TMAO; Cambridge Isotopes) was added to one cup of water for oral consumption to enable the tracing of the metabolic fate of TMAO, and to assess its bioavailability and clearance.
3000666|NCT02558660|Experimental|Double Up Food Bucks|Clinic-based educational intervention about an existing SNAP healthy food incentive program, as well as a $10 voucher to spend on produce at farmers markets
3000667|NCT02558647|Experimental|CBT for insomnia (CBT-I)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) comprises a fully automated, interactive, and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention
3000668|NCT02558647|Active Comparator|Psychoeducation about Sleep (PE)|The PE intervention gives participants access to a website with information about insomnia symptoms; the impact, prevalence, and causes of insomnia; when to seek input from a doctor; and basic lifestyle, environmental, and behavioral strategies that may help to improve sleep.
3000669|NCT02558634|Experimental|DBS-on|"Ventral intermediate Nucleus (VIM) Thalamic DBS on~DBS system includes:~Implantable Pulse Generator (IPG)~DBS Lead~DBS Lead Extension Kit"
3000863|NCT02557334|Experimental|High Dose Strawberry Powder|40 g freeze dried strawberry powder
3000676|NCT02558582|Experimental|Immediate Rehabilitation|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
3000677|NCT02558582|Experimental|Immediate Rehabilitation with oxygen|"The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
3000678|NCT02558582|Experimental|Delayed Rehabilitation|Waiting group that participates in the rehabilitation program after 3 months. The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
3000679|NCT02558582|Experimental|Delayed Rehabilitation with oxygen|"Waiting group that participates in the rehabilitation program after 3 months. The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
3000680|NCT02558569|Experimental|Levobupivacaine|Scalp nerve block with 0.5% Levobupivacaine adds up to intravenous fentanyl for intraoperative pain control during supratentorial craniotomy with brain tumor removal. The scalp block includes 4-6 nerves which give sensory supply to related location with the use of total 10-15 ml of 0.5% Levobupivacaine. Intravenous fentanyl is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given. is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given.
3000681|NCT02558569|Sham Comparator|NSS|Scalp nerve block with 10-15 ml of 0.9% sodium chloride(NaCl), or normal saline (NSS) includes 4-6 nerves which give sensory supply to related location (sham block). Intravenous fentanyl is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given.
3000682|NCT02558556|Experimental|NIRF-LC|"This group of patients will undergo near-infrared fluorescence cholangiography assisted laparoscopic cholecystectomy by use of a Laparoscopic Fluorescence Imaging System (Karl Storz), in combination with one intravenous injection of contrast agent ICG. The ICG is given directly after induction of anesthesia in a dose of 1 ml of 2,5 mg/ml solution.~Intraoperatively every 2-5 minutes (more often if desired by surgeon) camera is switched to ICG mode for fluorescence cholangiography, until CVS is established.~Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done.~The complete procedure will be recorded on video."
3000683|NCT02558556|No Intervention|CLC|"This group will undergo conventional laparoscopic cholecystectomy as in standard practice with no other intervention.~Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done.~The complete procedure will be recorded on video.~Postoperatively, as in the NIRF-LC arm, the videos will be analysed to determine whether CVS is actually established, is the transition of the cystic duct into the gallbladder visualized? Is transition of the cystic artery into the gallbladder visualized? Furthermore, cost-minimalisation will be calculated."
3000684|NCT02558543|Active Comparator|Stromal Vascular Fraction|The injection is made for the patients of the both groups in the sub-dermic plan on the side faces of fingers distal and proximal or 4 times 0,25ml by finger, all in all every finger will be injected of 1ml of diluted Stromal Vascular Fraction ( experimental group) , or placebo (ringer lactate) ( placebo group)
3000685|NCT02558543|Placebo Comparator|Placebo|The injection is made for the patients of the both groups in the sub-dermic plan on the side faces of fingers distal and proximal or 4 times 0,25ml by finger, all in all every finger will be injected of 1ml of diluted Stromal Vascular Fraction ( experimental group) , or placebo ( placebo group)
3000686|NCT02558530|Other|Low carbohydrate diet|Isocaloric diet, <20 g carbohydrates per day
3000687|NCT02558517|No Intervention|Prednisone maintenance|Patients will be kept under Prednisone 5 milligrams/day. Other treatments will be maintained (in particular HYDROXYCHLOROQUINE, METHOTEXATE etc..)
3000688|NCT02558517|Experimental|Prednisone discontinuation|Prednisone will be stopped and remplaced by HYDROCORTISONE for one month (20 mg/day). Other treatments will be maintained (in particular HYDROXYCHLOROQUINE, METHOTEXATE etc..)
3000689|NCT02558504|Active Comparator|Oesophagectomy|While surgical reference technique for invasive cancer of the lower esophagus is the technique according to Lewis Santy, there is no consensus on the technique and surgical approaches lack of specific work in the particular case of superficial lesions . The centers will have the choice of using the technique according to Lewis Santy with gastric plasty or technique of esophagectomy without thoracotomy with lower mediastinal dissection. In the absence of consensus to date available, abdominal surgery time will be by laparotomy or laparoscopy (laparoscopic assisted technique called). In both cases, an exploratory laparoscopy for diagnostic purposes is realized to remove an extension of the disease that would indicate against-resection with curative intent. For surgery, patients will be put under antisecretory therapy proton-pump inhibitor; this at least throughout the duration of the study.
3000690|NCT02558504|Experimental|Radiofrequency ablation|"The equipment processing is:~The radiofrequency generator,~The radiofrequency balloon 360,~the radiofrequency probe 90.~The radiofrequency treatment should be carried out according to the following protocol:~The radiofrequency treatment is done within 2 months following the last endoscopic assessment.~The maximum number of sessions is 4, including 2 maximum with 360 Halo probe.~Endoscopy is performed under general anesthesia.~The removal must begin at the top 1cm above the upper pole of the lesion and must end 1cm below the lower pole of the lesion.~The patient is left fasting until morning. In case of chest pain, the patient may receive analgesics.~During the time of treatment, the patient must follow an antisecretory therapy pump inhibitor with dual proton dose orally. The patient should avoid taking aspirin or nonsteroidal anti-inflammatory drugs during the 10 days following each session."
3000691|NCT02558491|Experimental|Decision Support System|Blinded CGM data will be collected prior to the Experimental Admission and analyzed by the study team to determine the optimal insulin therapy parameters that will be used during the Experimental Admission.
3000864|NCT02557334|Placebo Comparator|Placebo Powder|40 g color and taste matched placebo powder
3000692|NCT02558491|No Intervention|Usual Care|Subjects will use their own insulin parameters, including basal rate, correction factor and carbohydrate-insulin ratio, and determine their own insulin usage during the Control Admission.
3000693|NCT02558465||Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxavban administration group
3000694|NCT02558439|Placebo Comparator|Placebo|Subjects will receive a single injection of placebo into the index knee following local anesthesia and adjunct joint cooling.
3000695|NCT02558439|Experimental|0.5 mg CNTX-4975|Subjects will receive a single injection of 0.5 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.
3000696|NCT02558439|Experimental|1.0 mg CNTX-4975|Subjects will receive a single injection of 1.0 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.
3000697|NCT02558426||CVD patients|Patients with CVD at various stages (C2-C6 of CEAP classification of CVD) with varicose veins and eligible to receive Open Venous Surgery.
3000698|NCT02558413|Active Comparator|BTA-C585 oral capsules|25 or 100 mg oral capsules; Single ascending doses (SAD) from 50 mg to 800 mg
3000699|NCT02558413|Placebo Comparator|BTA-C585 matching placebo|BTA-C585 Matching placebo capsules; single doses
3000700|NCT02558400|Experimental|PG324 Ophthalmic Solution|1 drop daily (evening) both eyes
3000701|NCT02558400|Active Comparator|Netarsudil (AR-13324) Ophthalmic Solution|1 drop daily (evening) both eyes
3000702|NCT02558400|Active Comparator|Latanoprost Ophthalmic Solution|1 drop daily (evening) both eyes
3000703|NCT02558387|Experimental|Nintedanib arm|Nintedanib has never been applied to salivary gland cancer. Nintedanib was given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
3000704|NCT02558374|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
3000705|NCT02558374|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5% BID|1 drop twice daily (BID) in the morning (AM) & evening (PM) in both eyes (OU)
3000706|NCT02558361|Other|Open label, single arm|"Baseline visit:assess disease activity,synovial tissue biopsy of the knee with active synovitis [target joint] and punch skin biopsy of a target psoriatic plaque. Perform a similar punch skin biopsy on adjacent normal skin. Start apremilast (standard dosing). Perform venipuncture: blood samples will be obtained for routine studies, quantitative RT-PCR & ex vivo cytokine production assays. UA/pregnancy test.~Month 1: assess disease active , monitor for AE's; repeat punch skin biopsy of target psoriatic plaque. Blood samples will be obtained for RT-PCR and ex vivo cytokine production assays.~Month 3: same as month 1; repeat synovial tissue biopsy from target knee joint and punch skin biopsy on target psoriatic plaque. Blood samples for RT-PCR ex vivo cytokine production assays and routine studies."
3000707|NCT02558348|Experimental|AL3818|"Part 1 (Phase 1b): Cohort 1 will initiate at a dose of 12 mg/day of AL3818, for 21-Day cycles (14 days of AL3818 treatment followed by 7 days of rest). After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, two additional cohorts will be sequentially enrolled at 16 mg/day and 20 mg/day doses of AL3818 for the same 21-day cycles.~Part 2 (Phase 2a): Each subject will receive a dose of up to 20 mg AL3818 or a maximum of the MTD from Part 1 (Phase 1b) of this study for continuous 21-Day cycles of therapy (14 days of AL3818 treatment followed by 7 days of rest)."
3000708|NCT02558322||Primary medical care in rural areas|People living in districts, where less than 50% of the population live in cities with more than 20,000 residents and the population density outside of the cities is below 100 people per km². Excluding people living in cities with a population of at least 100,000 residents.
3000709|NCT02558322||Primary medical care in region environs|People living in districts, where 50% or more of the population live in cities with more than 20,000 residents and/or population density outside of the cities is above 100 people per km². Excluding people living in cities with a population of at least 100,000 residents.
3000710|NCT02558322||Primary medical care in in urban areas|People living in cities with a population of at least 100,000 residents.
3000711|NCT02558309||Intracranial Pressure Reduction|"Subjects scheduled to undergo gradual, step-wise reduction of Intracranial Pressure (ICP) will be screened.~The Glasgow Coma Scale will be administered to ascertain the cognitive ability of the participant.~A slit lamp examination and indirect ophthalmoscopy will be performed.~Experimental:~The subject's eye will be held open with an eye speculum during the exam.~Another eye exam, which includes a slit lamp examination and indirect ophthalmoscopy, will be performed.~Intraocular Pressure will be measured.~An Optic Coherence Tomography (OCT) will be performed.~At each step along the process of ICP reduction, the eye exam, IOP & OCT will be performed.~Optional:~The Ophthalmology study team will raise the IOP using an Ophthlmodynanometer. It will be raised to 20 mmHg and 40 mmHg while OCT scans are obtained.~OCT scans will be taken at pre-manipulation, 20mmHg, 40mmHg, and post-manipulation at each step of the ICP lowering procedure."
3000712|NCT02558296|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.
3000713|NCT02558296|Placebo Comparator|Placebo tablets|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
3000714|NCT02558283|Experimental|JUVÉDERM® VOLIFT® with Lidocaine - Right Side|JUVÉDERM® VOLIFT® with lidocaine injected into the right nasolabial fold on Day 1, with optional touch-up injections into the right nasolabial fold on Month 1.
3000715|NCT02558283|Active Comparator|Restylane® - Right Side|Restylane® injected into the right nasolabial fold on Day 1, with optional touch-up injections into the right nasolabial fold on Month 1.
3000716|NCT02558283|Experimental|JUVÉDERM® VOLIFT® with Lidocaine - Left Side|JUVÉDERM® VOLIFT® with lidocaine injected into the left nasolabial fold on Day 1, with optional touch-up injections into the left nasolabial fold on Month 1.
3000717|NCT02558283|Active Comparator|Restylane® - Left Side|Restylane® injected into the left nasolabial fold on Day 1, with optional touch-up injections into the left nasolabial fold on Month 1.
3000718|NCT02558270|Active Comparator|patients dapa|Patients will be administered Dapagliflozin 10mg
3000719|NCT02558270|Placebo Comparator|patients placebo|Patients will be administered a placebo
3000720|NCT02558270|Active Comparator|controls dapa|controls will be administered Dapagliflozin 10mg
3000721|NCT02558270|Placebo Comparator|controls placebo|controls will be administered a placebo
3000865|NCT02557321|Experimental|Phase 1b|PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
3000722|NCT02558257||Palliative Care Survey|Initial consultation visit followed by phone survey within 1 week +/- 4 days of initial consultation.
3000723|NCT02558231|Experimental|Triple oral combination treatment|Macitentan, tadalafil, and selexipag
3000724|NCT02558231|Placebo Comparator|Dual oral combination treatment|Macitentan, tadalafil, and placebo
3000725|NCT02558218|Active Comparator|Systane ultra group|Participants in this group were administered systane ultra quid (Alcon, Fort Worth) for two months postoperatively), additionally to tobradex quid (Alcon, Fort Worth) for 20 days postoperatively.
3000726|NCT02558218|Active Comparator|Control group|Participants in this group were administered the standard postoperative medication [tobradex quid (Alcon, Fort Worth) for 20 days postoperatively.]
3000727|NCT02558205||CT Perfusion and PET/CT|Patients undergo both a CT liver perfusion study pre Y-90 treatment and a PET/CT of liver following Y-90 treatment. For the PET/CT no additional radioactivity is required.
3000728|NCT02558192|Experimental|Probiotics|Vials containing 3 x 10^9 Colony Forming Units of LGG, vitamins ( B and C) and zinc
3000729|NCT02558192|Placebo Comparator|Placebo|Vials containing water, maltodextrin, magnesium stearate, potassium sorbate, sodium benzoate, citric acid, fructose, flavor.
3000730|NCT02558179||Nugent Score >/= 7|Signs and symptoms of vaginitis/vaginosis, including vaginal discharge, pruritis, irritation, and/or dyspareunia. Diagnosis of bacterial vaginosis (study group) according to Nugent score and/or diagnosis of vulvovaginal candidiasis; and/or diagnosis of Trichomonas vaginalis.
3000731|NCT02558179||Nugent Score< 7|Signs and symptoms of vaginitis/vaginosis, including vaginal discharge, pruritis, irritation, and/or dyspareunia. Bacterial vaginosis not diagnosed according to Nugent score (<7).
3000732|NCT02558166||Patients with shock|"Critically ill patients admitted to the intensive care unit (ICU)~with shock due sepsis/SIRS, cardiac failure or hemorrhage~age > 18 years,~noradrenalin support~< 24 hours of ICU admission~Signed informed consent"
3000733|NCT02558166||Patients without shock|"Critically ill patients admitted to the intensive care unit (ICU)~without shock, without vasopressor support and without fluid dependent circulation~age > 18 years~< 24 hours of ICU admission~Signed informed consent"
3000734|NCT02558153|Experimental|DEB - drug eluting balloon (APERTO)|Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting APERTO balloon
3000735|NCT02558153|Active Comparator|standard PTA|Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug-eluting balloon (POBA, plain old balloon angioplasty).
3000736|NCT02558140|Experimental|Part 1: Dose Escalation|All participants will be given RO6874813 as a single low dose of 0.5 milligrams per kilogram (mg/kg) via intravenous (IV) infusion in a 7-day pharmacokinetic (PK) run-in period (Cycle 0). This is followed by dose escalation (Cycle 1) for which participants will receive escalating doses of RO6874813 (starting dose = 1 mg/kg) via IV infusion every week (qw) or every 2 weeks (Q2W) for 28 to 42 days to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).
3000737|NCT02558140|Experimental|Part 2: Tumor Biopsy and Imaging|The first 15 participants with fibroblast activation protein-alpha positive (FAP+) tumors will be treated at the RP2D and dosing schedule as determined in Part 1, and will undergo paired tumor biopsies for biomarker assessments. Up to 5 participants with FAP+ tumors will undergo baseline and on-treatment tumor biopsies for biomarker assessments at a dose below the RP2D. The dose for these participants can be escalated to RP2D after 4 weeks of treatment and upon completion of biomarker assessment.
3000738|NCT02558140|Experimental|Part 3: Preliminary Efficacy Assessment|Participants with locally advanced or metastatic non-resectable FAP+ sarcoma will be treated with RO6874813 at the RP2D and as per schedule determined upon completion of Part 1. Participants continuing treatment with RO6874813 beyond 36 weeks will enter the extension phase of Part 3 and will be monitored for disease status and clinical safety per routine standard of care.
3000739|NCT02558127||50 asthma patients|50 asthma patients with bronchial mucus hypersecretion
3000740|NCT02558127||asthma patients|50 asthma patients without bronchial mucus hypersecretion
3000741|NCT02558114|Other|Group A|Patients will receive ribavirin during 12 weeks
3000742|NCT02558114|Other|Group B|"Patients will receive:~ribavirin during 12 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is undetectable at week 4 after treatment start (adjust to renal function)~- ribavirin during 24 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is detectable at week 4 after treatment start (adjust to renal function)"
3000743|NCT02558101|Active Comparator|Control invitation materials|Invitation materials and strategy mimicking those of existing UK screening programmes for other cancer types
3000744|NCT02558101|Experimental|Intervention invitation materials|A targeted, stepped and low information burden invitation strategy and materials, specifically designed to improve uptake by reducing barriers to participation among smokers from socioeconomically deprived backgrounds.
3000745|NCT02558088|Experimental|salmeterol|
3000746|NCT02558075|Experimental|MoodLifters Program|A program to provide evidence-based education and skills to reduce psychological distress and enrich people's lives.
3000747|NCT02558062|Experimental|BAC ONE administration|All participants in this clinical study will be dosed on one occasion with BAC ONE. The final dosage will be 80 µg (± 25%).
3000748|NCT02558049|Experimental|Decision aid|Patients will receive the patient decision aid during a 15 minute consultation with a clinical pharmacist.
3000749|NCT02558036|Active Comparator|C-Mac D-Blade Neutral Position|C-Mac D-Blade videolaryngoscope with patients head and neck in neutral position.
3000750|NCT02558036|Active Comparator|C-Mac D-Blade Sniffing Position|C-Mac D-Blade videolaryngoscope with patients head and neck in sniffing position.
3000751|NCT02558036|Active Comparator|King Vision Neutral Position|King Vision videolaryngoscope with patients head and neck in neutral position.
3000752|NCT02558036|Active Comparator|King Vision Sniffing Position|King Vision videolaryngoscope with patients head and neck in sniffing position.
3000753|NCT02558023|Experimental|Urapidil|"Urapidil (Eupressyl*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.~The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.~Maximum dose of 30 mg.h-1."
3000866|NCT02557321|Experimental|Phase 2 (Arm 1)|PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
3000867|NCT02557321|Active Comparator|Phase 2 (Arm 2)|Pembrolizumab (2 mg/kg every 3 weeks)
3000754|NCT02558023|Active Comparator|Nicardipine|"Nicardipine : IV~1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.~Maximum dose of 6 mg.h-1"
3000755|NCT02558010|Experimental|Methadone Group|Patients will receive a total of 0.2mg/kg IV methadone intraoperative (0.1mg / kg preincision and 0.1mg/kg prior to emergence) with a maximum dosing of 20 mg.
3000756|NCT02558010|Active Comparator|Control Group|Patient will receive normal saline placebo initially, then morphine prior to emergence.
3000757|NCT02557997||ART-naive (primary infection)|ART-naive (primary infection) HIV infected adults
3000758|NCT02557997||ART-naïve (chronic infection)|ART-naïve (chronic infection) HIV infected adults
3000759|NCT02557997||ART-controlled|ART-controlled HIV infected adults
3000760|NCT02557997||ART-failing|ART-failing HIV infected adults
3000761|NCT02557984|Placebo Comparator|Placebo|Placebo Pill
3000762|NCT02557984|Experimental|Amisulpride|400 mg Amisulpride (Solian®)
3000763|NCT02557984|Experimental|Naltrexone|50 mg Naltrexone (Naltrexin®)
3000764|NCT02557971||BOTOX®|Patients with idiopathic overactive bladder (OAB) treated with onabotulinumtoxinA (BOTOX®) injections into the bladder as standard of care in clinical practice. No intervention was administered in this study.
3000765|NCT02557958|Experimental|Azithromycin|Azithromycin 250mg daily, single daily use for 8 weeks
3000766|NCT02557958|Placebo Comparator|Placebo|Placebo daily for 8 weeks
3000767|NCT02557945|Experimental|Gabapentin|Gabapentin 3600mg PO daily
3000768|NCT02557945|Placebo Comparator|Placebo|Matching placebo PO daily
3000769|NCT02557932|Active Comparator|Standard triple therapy|7 day-PPI based standard triple therapy
3000770|NCT02557932|Active Comparator|Bismuth quadruple therapy|10 day-bismuth quadruple therapy
3000771|NCT02557919|Experimental|Motivational Interviewing Training|Staff at the intervention sites were trained in basic tobacco control and motivational interviewing. Two booster trainings were held over 6 months.
3000772|NCT02557919|Other|Usual Best Practice|Staff at the usual best practice sites received basic tobacco control training.
3000773|NCT02557906|Experimental|Implant and Surgimend|Breast reconstruction surgery with an implant and an ADM (Surgimend)
3000774|NCT02557906|Active Comparator|Autologous tissue|Breast reconstruction surgery with autologous tissue
3000775|NCT02557906|Active Comparator|Implant + dermal sling/LD flap|Breast reconstruction surgery using a dermal sling or a latissimus dorsi (LD)flap
3000776|NCT02557893|Experimental|Resistance exercise|Resistance exercise involved 12 weeks of weight lifting exercise
3000777|NCT02557893|Sham Comparator|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
3000778|NCT02557893|Placebo Comparator|Pregnancy education|Maternity nurses taught six bimonthly pregnancy education classes (~20 per class) which covered several topics including information about what to expect during normal labor and delivery, common interventions during delivery (medications, induction, Cesarean delivery), parenting skills needed for baby care, breastfeeding, baby and child cardiopulmonary resuscitation, typical child development and communicating with infants. No physical activity education was included in the curriculum. The pregnancy education participants formed an attention control group.
3000779|NCT02557880|Experimental|Sleep Application Diary|A sleep application diary which will automatically report results back to sleep doctor is used in addition to standard sleep hygiene counseling.
3000780|NCT02557880|Active Comparator|Treatment as Usual|Sleep hygiene counseling
3000781|NCT02557867|Experimental|Obese|Body composition measurement before surgery using Dual energy X-ray absorptiometry. Dexmedetomidine infusion during surgery. Venous blood sampling for dexmedetomidine plasmatic levels during and after surgery. Liver blood flow indirect non-invasive assessment after surgery using indocyanine. Liver biopsy during surgery.
3000782|NCT02557867|Experimental|Non-obese|Body composition measurement before surgery using Dual energy X-ray absorptiometry. Dexmedetomidine infusion during surgery. Venous blood sampling for dexmedetomidine plasmatic levels during and after surgery. Liver blood flow indirect non-invasive assessment after surgery using indocyanine. Liver biopsy during surgery.
3000783|NCT02557854|Experimental|Doxil + MR-HIFU Hyperthermia|Liposomal doxorubicin (Doxil) 50mg IV every 4 weeks followed by Magnetic Resonance High Intensity Focused Ultrasound hyperthermia (MR-HIFU) with Philips Sonalleve System to 42C for 30 minutes every 4 weeks
3000784|NCT02557841|Experimental|anodal ctDCS|Volunteers will be submitted to anodal ctDCS + motor learning assessments (SRTT and Handwriting test).
3000785|NCT02557841|Experimental|cathodal ctDCS|Volunteers will be submitted to cathodal ctDCS + motor learning assessments (SRTT and Handwriting test).
3000786|NCT02557841|Sham Comparator|sham ctDCS|Volunteers will be submitted to sham ctDCS + motor learning assessments (SRTT and Handwriting test)
3000787|NCT02557828|Active Comparator|palpation|participants who are randomized to have radial arterial cannulation via palpation technique
3000788|NCT02557828|Active Comparator|ultrasound|participants who are randomized to have radial arterial cannulation via a new ultrasound technique
3000789|NCT02557815|Experimental|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial Magnetic Stimulation: Active 10hz stimulation over the right dorsolateral Prefrontal Cortex (dlPFC)
3000790|NCT02557815|Sham Comparator|Sham stimulation|Repetitive Transcranial Magnetic Stimulation: sham stimulation over the right dlPFC
3000791|NCT02557802|Experimental|Group A|Nasal spray at day 0, intramuscular injection at day 28
3000792|NCT02557802|Experimental|Group B|Intramuscular injection at day 0, nasal spray at day 28
3000793|NCT02557789|Experimental|Treatment A|Lefamulin as a 600 mg IR tablet in the fasted state
3000794|NCT02557789|Experimental|Treatment B|Lefamulin as 600 mg API in capsule (three 200 mg capsules) in the fasted state
3000795|NCT02557789|Experimental|Treatment C|Lefamulin as 150 mg i.v. in 250 mL citrate buffered saline infused over 1 h
3000796|NCT02557789|Experimental|Treatment D|Lefamulin as a 600 mg IR tablet one hour after breakfast
3000868|NCT02557308||Remsima™|Patients who are taking Remsima™ for the treatment
3001005|NCT02556268|Experimental|Riociguat and STRIBILD|
3000797|NCT02557776|Experimental|Genetic testing of BRCA1 and BRCA2|"For detailes, please see Study procedure. Women with newely diagnosed breast cancer are offered written genetic counseling and screening of mutations in BRCA1 and BRCA2."
3000798|NCT02557763|Experimental|Oxford UKA|Oxford unicompartmental knee arthroplasty is partial knee replacement. Oxford unicompartmental knee arthroplasty is applied for medial compartmental of knee.
3000799|NCT02557737|Experimental|Ultrasonography direct-guidance|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
3000800|NCT02557737|Experimental|Electric stimulation|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Electric stimulation
3000801|NCT02557737|Active Comparator|Surface anatomy landmark|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.
3000802|NCT02557724||liver transplant patients|5 blood samples at time points as described in protocol
3000803|NCT02557724||Liver resection patients|3 blood samples at time points described in protocol
3000804|NCT02557698|Experimental|Balneum oil bath|Balneum oil bath, bathing every other day for four weeks
3000805|NCT02557698|No Intervention|standard skin cleanser|Usual skin cleanser (non-oil containing), bathing or showering every other day for four weeks
3000806|NCT02557685|No Intervention|Fecal Microbiota Translantation|After completing at least 10 days course of antibiotic treatment for C. difficile infection, subjects will receive Fecal Microbiota transplantation with a 300 mL fecal suspension delivered via sigmoidoscopy.
3000807|NCT02557672|Active Comparator|Fresh frozen plasma|After cardiopulmonary bypass, patients will receive protamine at dose 0.01 mg/unit of heparin given with target activated clotting time (ACT) within 10% of baseline value. After protamine administration the ACT, complete blood count (CBC), prothrombin time (PT)/ international normalized ratio (INR), activated partial thromboplastin time (APTT), and fibrinogen, will be collected via preexisting arterial access. If ACT >10% baseline additional protamine will be given at the anesthesiologists discretion. Evaluation and determination of excessive microvascular bleeding in the surgical field will occur 10 minutes after return of ACT to within 10% of baseline. Patients with clinical evidence of excessive microvascular bleeding in the surgical field as determined by the surgical team, along with a PT >16.6 sec/ INR >1.6 sec will receive fresh frozen plasma as this is standard therapy per our institutional algorithm at a dose of 10-15 mL/kg rounded up to the nearest unit.
3000808|NCT02557672|Experimental|Prothrombin complex concentrate|After cardiopulmonary bypass, patients will receive protamine at dose 0.01 mg/unit of heparin given with target ACT within 10% of baseline value. After protamine administration the ACT, CBC, PT/ INR, APTT, and fibrinogen, will be collected via preexisting arterial access. If ACT >10% baseline additional protamine will be given at the anesthesiologists discretion. Evaluation and determination of excessive microvascular bleeding in the surgical field will occur 10 minutes after return of ACT to within 10% of baseline. Patients with clinical evidence of excessive microvascular bleeding in the surgical field as determined by the surgical team, along with a PT >16.6 sec/ INR >1.6 sec will receive Prothrombin complex concentrate (Human) 15 units/kg.
3000809|NCT02557646||Pegasys + Copegus|Treatment naive participants with confirmed chronic hepatitis C who are started on combined Pegasys-Copegus treatment in accordance with current guidelines and SPCs, and whose treatment has been approved by the Interferon Committee.
3000810|NCT02557633|Placebo Comparator|Placebo|2% w/v L-Tyrosine
3000811|NCT02557633|Experimental|Grass MATA MPL 10200 SU|Grass MATA MPL cumulative dose 10200 SU given as six injections of placebo, placebo, 600SU, 1600SU, 4000SU and 4000SU.
3000812|NCT02557633|Experimental|Grass MATA MPL 18200 SU|Grass MATA MPL cumulative dose 18200 SU given as six injections of 600SU, 1600SU, 4000SU, 4000SU, 4000SU and 4000SU.
3000813|NCT02557620|Experimental|semaglutide OD + placebo semaglutide OW|
3000814|NCT02557620|Placebo Comparator|placebo semaglutide OW + placebo semaglutide OD|
3000815|NCT02557620|Experimental|semaglutide OW + placebo semaglutide OD|
3000816|NCT02557607|Other|Monitoring a subarachnoid hemorrhage|Any patient hospitalized at the University Hospital of Angers in neurosurgical intensive care unit for supervision by ASL and DTC a subarachnoid hemorrhage from all etiologies (excluding traumatic). An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
3000817|NCT02557594|Experimental|Viread → DA-2802|"Viread 300mg(Tenofovir disoproxil fumarate)~DA-2802 319mg(Tenofovir disoproxil orotate)"
3000818|NCT02557594|Experimental|DA-2802 → Viread|"Viread 300mg(Tenofovir disoproxil fumarate)~DA-2802 319mg(Tenofovir disoproxil orotate)"
3000819|NCT02557581|Experimental|Terbutaline|Beta2-adrenergic stimulation with terbutaline
3000820|NCT02557581|Placebo Comparator|Placebo|Placebo
3000821|NCT02557581|Experimental|Clenbuterol|Beta2-adrenergic stimulation with clenbuterol
3000822|NCT02557568|Experimental|Hemodialysis patients (HPs)|staphylococcus aureus carriage is measured in nose
3000823|NCT02557568|Experimental|Healthcare Workers (HCWs)|staphylococcus aureus carriage is measured in nose
3000824|NCT02557542|Experimental|One Stop Vein Clinic|Patients randomised to this group will be invited to the One Stop Vein Clinic, offering same day diagnosis and treatment
3000825|NCT02557542|Active Comparator|Normal Care Pathway|Patients randomised to this group will be invited to the Normal Care Pathway
3000826|NCT02557529|Experimental|Progressive Resistance Training|12 weeks progressive resistance training (PRT) during and after concomitant chemoradiotherapy. Also optional/voluntary physical activity performed on their own is registered, as well as diet diary.
3000827|NCT02557529|Active Comparator|Control|Control arm. Optional/voluntary physical activity performed on their own is registered, as well as diet diary.
3000828|NCT02557516|Experimental|Single arm|IPH2201 combined with ibrutinib
3000829|NCT02557503|Experimental|Oxaliplatin by HAIC after TACE|To investigate the therapy effect and security of oxaliplatin on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
3000830|NCT02557503|No Intervention|Fluorouracil by HAIC after TACE|To investigate the therapy effect and security of fluorouracil on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
3000869|NCT02557308||Other anti-TNF drugs|Patients who are taking other anti-TNF drugs such as infliximab (Remicade®), etanercept, adalimumab, etc.
3000831|NCT02557490|Experimental|Oxaliplatin by TACE|Oxaliplatin for the therapy of Colorectal Cancer With Liver Metastases by TACE.No interventions was raltitrexed for the therapy of Colorectal Cancer With Liver Metastases by TACE.
3000832|NCT02557490|No Intervention|Raltitrexed by TACE|Raltitrexed for the therapy of Colorectal Cancer With Liver Metastases by TACE.
3000833|NCT02557477|Active Comparator|Active|Participants received 3 capsules of Omega 3/6 fatty acids twice daily
3000834|NCT02557477|Placebo Comparator|Placebo|Participants received 3 capsules of identical placebo (palm oil) twice daily
3000835|NCT02557464|Experimental|Alzheimer's disease group|24 patients with an Alzheimer's disease or related disorders
3000836|NCT02557464|Active Comparator|control group|24 age matched controls participants
3000837|NCT02557451|Experimental|surgery + antiangiogenic|surgery (vitrectomy - air - TPA) with injections of an antiangiogenic
3000838|NCT02557451|Experimental|intravitreal injection of gas/TPA + antiangiogenic|intravitreal injection of gas - TPA with injections of an antiangiogenic
3000839|NCT02557438||Roux-en-Y Gastric Bypass|Males and females aged 13-21 undergoing Roux-en-Y gastric bypass (RYGB) surgery
3000840|NCT02557438||Vertical Sleeve Gastrectomy|Males and females aged 13-21 undergoing vertical sleeve gastrectomy (VSG) surgery
3000841|NCT02557438||Non-surgical Obese Controls|Males and females aged 13-21 who are obese and not undergoing weight loss surgery
3000842|NCT02557425||Maternal SP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive 3 doses of sulfadoxine-pyrimethamine (SP), and children receive every 3 month dihydroartemisinin-piperaquine (DP). No intervention is given in the observational PROTECT study.
3000843|NCT02557425||Maternal 3 dose DP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive 3 doses of DP, and children receive every 3 month DP.No intervention is given in the observational PROTECT study.
3000844|NCT02557425||Maternal 3 dose DP/Child monthly DP|In this group in the PROMOTE-II study, mothers receive 3 doses of DP, and children receive monthly DP. No intervention is given in the observational PROTECT study.
3000845|NCT02557425||Maternal monthly DP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive monthly DP, and children receive every 3 month DP. No intervention is given in the observational PROTECT study.
3000846|NCT02557425||Maternal monthly DP/child monthly DP|In this group in the PROMOTE-II study, mothers receive monthly DP, and children receive every monthly DP. No intervention is given in the observational PROTECT study.
3000847|NCT02557412|Placebo Comparator|Conventional treatment|Hygiene and diet recommendations on sleep.
3000848|NCT02557412|Active Comparator|Intensive lifestyle intervention|Lifestyle intervention will consist of a structured intervention in a specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% [saturated fats <7% monounsaturated fats up to 20% and polyunsaturated fats <10% ] and proteins: 15-20%), which will be repeated in each review. Also, be recommended to increase daily physical activity, setting a target walking 10,000 steps a day. To do this, to patients assigned to this treatment arm, will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
3000849|NCT02557412|Active Comparator|Continuous positive airway pressure|Treatment with nasal continuous positive airway pressure (CPAP). Treatment begins with an empirical pressure of 8 centimetres of water (cmH2O) and in a period of three weeks, the pressure is adjusted by titration with an automatic positive airway pressure device (AutoSet II, ResMed).
3000850|NCT02557399|Experimental|Duac® fixed dose combination gel|Subjects will use Duac® fixed dose combination gel (clindamycin phosphate 1.2% and benzoyl peroxide 3%) with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) for 12 weeks.
3000851|NCT02557399|Active Comparator|Combination therapy: ADA 0.1% gel + CLDM 1% gel|Subjects will use combination therapy of ADA 0.1% gel with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) and subjects will also apply CLDM 1% gel twice daily, once in the morning and once in the evening (at bedtime) for 12 weeks. The CLDM 1% gel should apply subsequent to the application of ADA 0.1% gel in the evening. The CLDM 1% gel should be applied to ILs only.
3000852|NCT02557386|Experimental|A Levobupivacaine 5 mL|Adductor canal nerve block with levobupivacaine 0.25% 5 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
3000853|NCT02557386|Experimental|B Levobupivacaine 10 mL|Adductor canal nerve block with levobupivacaine 0.25% 10 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
3000854|NCT02557386|Experimental|C Levobupivacaine 15 mL|Adductor canal nerve block with levobupivacaine 0.25% 15 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
3000855|NCT02557386|Experimental|D Levobupivacaine 20 mL|Adductor canal nerve block with levobupivacaine 0.25% 20 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
3000856|NCT02557386|Experimental|E Levobupivacaine 25 mL|Adductor canal nerve block with levobupivacaine 0.25% 25 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
3000857|NCT02557386|Experimental|F Levobupivacaine 30 mL|Adductor canal nerve block with levobupivacaine 0.25% 30 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
3000858|NCT02557373|Placebo Comparator|Vitamin A|Randomized participants will receive a one-dose of vitamin A supplementation (100,000 IU) at the beginning of the trial.
3000859|NCT02557373|Experimental|Rice Bran + Vitamin A|Randomized participants will receive a one-dose of vitamin A supplementation (100,000 IU) at the beginning of the trial plus consume a measured dose of rice bran daily.
3000860|NCT02557360|Experimental|S-adenosyl-L-methionine|Patients with primary biliary cirrhosis will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
3000861|NCT02557347|Experimental|Intervention|Aggressive fluid management
3000862|NCT02557334|Experimental|Low Dose Strawberry Powder|40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
3000871|NCT02557295||Other anti-TNF drugs|Patients who are taking other anti-TNF drugs such as infliximab (Remicade®), etanercept, adalimumab, etc.
3000872|NCT02557295||Biologic naive patients|Biologic naive patients (in Korea only)
3000873|NCT02557269|Active Comparator|Group HPMC|Hydroxyl-propyl-methyl-cellulose (HPMC) powder added immediately after other intranasal treatment options
3000874|NCT02557269|Placebo Comparator|Group Placebo|Lactose powder (placebo) added immediately after other intranasal treatment options
3000875|NCT02557269|Other|Group Immunotherapy|Immunotherapy group with grass allergens sublingually (Staloral #688) and rescue medication
3000876|NCT02557217|Experimental|NP202|1000mg oral NP202 daily for 90 days
3000877|NCT02557217|Placebo Comparator|Placebo|Oral placebo daily for 90 days
3000878|NCT02557204|Active Comparator|conventional technique|the nasogastric tube will be inserted gently through a selected nostril with the head being maintained in the neutral position.
3000879|NCT02557204|Experimental|head in the lateral position technique|the patient's head will be turned to the right lateral position. Nasogastric tube will be inserted through the right nostril without any maneuvers of the neck.
3000880|NCT02557204|Experimental|endotracheal tube assisted technique|Nasogastric tube will be inserted the trimmed 7.5 mm internal diameter endotracheal tube what cut proximal end with sterile scissors and endotracheal tube will be advanced blindly into the oral cavity to a depth of approximately 18 cm without laryngoscope together the nasogastric tube.
3000881|NCT02557204|Experimental|videolaryngoscope technique|Nasogastric tube was inserted transnasally and advanced into esophagus under direct vision.
3000882|NCT02557191||Group 1|Preterm infants <32 weeks gestational age
3000883|NCT02557178|Experimental|Activity Monitor plus Health Coaching|Device: Actigraph Participants will wear the device daily during weeks 1, 9, and 17. Daily steps and activity will be measured. It will identify if they complete a prescribed exercise regimen.Participants in the intervention condition (wearing the Actigraph) will also receive supportive health coaching to encourage them to exercise.
3000884|NCT02557178|No Intervention|Control|
3000885|NCT02557165||COPD patients|Patients with mild to moderate COPD having a scheduled lung surgery. Vastus lateralis and diaphragm muscle biopsies performed during surgery
3000886|NCT02557165||Patients with normal lung function|Patients with normal lung function having a scheduled lung surgery. Vastus lateralis and diaphragm muscle biopsies performed during surgery.
3000887|NCT02557152||Patients that were treated with the GentleWave System|
3000888|NCT02557139|Experimental|Regimen A|200 mg KD025 tablet in the fasted state
3000889|NCT02557139|Experimental|Regimen B|200 mg KD025 tablet in the fed state
3000890|NCT02557139|Experimental|Regimen C|200 mg KD025 as drug in capsule in the fed state
3000891|NCT02557126|Experimental|URC102|URC102
3000892|NCT02557126|Placebo Comparator|Placebo|Placebo
3000893|NCT02557113|Active Comparator|Vertebroplasty|This Group Underwent the Vertebroplasty Procedure (Injection of Bone Cement into the Fractured Osteoporotic Vertebral Body)
3000894|NCT02557113|Experimental|Cavuplasty|This Group Underwent the Cavuplasty Procedure (Small Cavity was Created in the Vertebral Body Prior to Injection of Bone Cement)
3000895|NCT02557100|Experimental|Abatacept in combination with methotrexate|Abatacept subcutaneous (SC) injection, 125 mg, weekly for 24 weeks. Methotrexate (MTX) for at least 12 weeks prior to randomization with a stable oral dose for at least 4 weeks, Subjects must randomize on the maximum tolerated dose of oral methotrexate (minimum of 15 mg and maximum of 25 mg per week), dose of MTX < 15 mg/week but ≥ 7.5 mg/week is permitted if subjects are intolerant to higher doses. Open-label Abatacept subcutaneous (SC) injection, 125 mg, weekly and maintain the enrollment dose of MTX unless toxicity or intolerability occurs during the study.
3000896|NCT02557100|Active Comparator|Adalimumab in combination with methotrexate|Adalimumab SC injection, 40 mg, once every two weeks for 24 weeks, Methotrexate (MTX) for at least 12 weeks prior to randomization with a stable oral dose for at least 4 weeks, Subjects must randomize on the maximum tolerated dose of oral methotrexate (minimum of 15 mg and maximum of 25 mg per week), dose of MTX < 15 mg/week but ≥ 7.5 mg/week is permitted if subjects are intolerant to higher doses. Open-label Abatacept subcutaneous (SC) injection, 125 mg, weekly and maintain the enrollment dose of MTX unless toxicity or intolerability occurs during the study.
3000897|NCT02557087|Experimental|Hyoscine|Intravenous administration of Hyoscine N-butylbromide diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
3000898|NCT02557087|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
3000899|NCT02557074|Experimental|IL2 - Group A|"Patient will received IL2 low doses (1.5 to 3MUI/d) -~IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment~IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses"
3000900|NCT02557074|Placebo Comparator|Placebo - Group B|NaCl 9% serum (placebo) NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
3000901|NCT02557061|Experimental|Patient with colorectal cancer|Colorectal surgery (resection) and blood sampling are done for patient with colorectal cancer
3000902|NCT02557035|Experimental|I.V. palonosetron infusion plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
3000903|NCT02557035|Active Comparator|I.V. palonosetron bolus plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
3000904|NCT02556996|Experimental|Killed ETEC/rCTB vaccine|Three doses administered orally at 2-week intervals
3000905|NCT02556996|Placebo Comparator|Placebo|Three doses administered orally at 2-week intervals
3000906|NCT02556983||Suspected appendicitis|Patients who are suspected as having acute appendicitis
3000907|NCT02556970|Experimental|Single-port surgery|"After induction of anaesthesia and lung isolation, a single intercostal incision will be placed laterally. This will usually be anterior to the border of the latissimus dorsi muscle, and in the 4th-7th space as appropriate to the planned surgery.~A soft tissue wound protector can be used to protect the wound edges, but rigid intercostal retraction is not permitted. All instruments will be placed via this incision."
3000908|NCT02556970|Active Comparator|Multiple port surgery|Patients in this arm will have 3 separate incisions placed to site the camera and other instruments. This will involve three separate incisions.
3000909|NCT02556957|Experimental|HealthScouts Intervention|HealthScouts (CHWs) regularly visit residents and counsel them using a motivational interviewing approach, supported by a smartphone application.
3000910|NCT02556957|Active Comparator|Standard of Care|Referral by RCCS to HIV services. Free HIV clinic available in the community.
3000911|NCT02556944|Experimental|Mix and matched patients|Mix and matched patients will get phacoemulsification with multifocal intraocular lens implantation with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally.
3000912|NCT02556931|Experimental|PBSCT D90|Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 90 or Day 180 depending on GVHD status.
3000913|NCT02556931|Experimental|PBSCT D60|Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 60 or Day 180 depending on GVHD status.
3000914|NCT02556918|Experimental|Sitagliptin|"Subjects undergoing cardiac surgery with type 2 diabetes (T2D) will be randomized to receive one tablet of sitagliptin once a day.Subjects with stress hyperglycemia (defined as a blood glucose (BG) greater than 180 mg/dL) in the intensive care unit (ICU) will continue to receive sitagliptin and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.~Interventions:~Drug: Sitagliptin Drug: Regular Human Insulin Drug: Insulin glargine Drug: Supplemental insulin (Insulin lispro) Drug: Supplemental insulin (Insulin aspart)"
3000915|NCT02556918|Placebo Comparator|Placebo|"Subjects undergoing cardiac surgery with type 2 diabetes will be randomized to receive one tablet of placebo once a day.Subjects with stress hyperglycemia (defined as a blood glucose (BG) greater than 180 mg/dL) in the intensive care unit (ICU) will continue to receive a placebo and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.~Interventions:~Drug: Placebo Drug: Regular Human Insulin Drug: Insulin glargine Drug: Supplemental insulin (Insulin lispro) Drug: Supplemental insulin (Insulin aspart)"
3000916|NCT02556905||Korean patients|All Korean patients intended to be treated with REVLIMID® according to the approved package insert
3000917|NCT02556892|Experimental|Ibrutinib|Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
3000918|NCT02556879|Other|Liver retransplantation|"Donor specific antibodies :Additional samples for Donor specific at each visit~Serum bank : Additional samples for serum bank at each visit if possible~DNA banq : Additional sample for DNA banq at inclusion visit if possible~Liver biopsy :Liver biopsy at 12 and 24 months after retransplantation (dependind the centers : procedure performed in routine or interventional procedure)~Liver ultrasounds and Fibroscan : Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (dependind the centers : procedure performed in routine or interventional procedure)"
3000919|NCT02556866|Experimental|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
3000920|NCT02556866|Placebo Comparator|placebo|Prednisone treatment plus placebo administered by slow intravenous infusion at day 1 (D1), D8, D15 and D22.
3000921|NCT02556853|Experimental|Ultrasound|Determination of correct placement of the double lumen tube by lung ultrasound.
3000922|NCT02556853|Active Comparator|Clinical|Determination of correct placement of the double lumen tube by clinical examination.
3000923|NCT02556840|Active Comparator|Insulin therapy from the beginning of pregnancy|"Insulin therapy (Glargine/Lantus®, Détémir/Levemir® , Insulatard® , Umuline NPH® , Lispro/Humalog® , Asparte/Novorapid® or Actrapid ®) administered from the beginning of pregnancy according to maternal blood glucose (if fasting blood glucose > 0.95g/l or post-prandial blood glucose > 1.20g/l) as recommended by the national guidelines for gestational diabetes mellitus.~Insulin administered to patients either by subcutaneous injections or by pump."
3000924|NCT02556840|Experimental|Insulin therapy initiated according to fetal growth|"Insulin therapy (Glargine/Lantus®, Détémir/Levemir® , Insulatard® , Umuline NPH® , Lispro/Humalog® , Asparte/Novorapid® or Actrapid ®) initiated according to fetal growth evaluated by ultrasonography measurements. MODY2 women will not be treated with insulin until delivery, except when the fetal abdominal circumference exceeds ≥ the 75 percentile on one US or maternal fasting capillary blood glucose is ≥ 1,20 g/L or maternal post-prandial capillary blood glucose is ≥ 2,00 g/L.~Insulin administered to patients either by subcutaneous injections or by pump."
3000925|NCT02556827||H, Rosacea patients|"Rosacea patients who were between the ages of 18-70, having no systemic illness and who were not smoking.~Obtaining a blood sample; TOC, TAC, OSI, PON-1, ARES, MPO, TNF-α, IL-1β, MMP-1 and MMP-9 levels in venous blood were measured Reflectance confocal microscopy; 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM. Sebum rate at forehead and right cheek were evaluated with sebumeter. Dermoscopic photoaging scale were assessed by using video dermoscopy."
3000926|NCT02556827||K, Healthy volunteers|"Healthy volunteers who were compatible in terms of age, sex and skin phenotype, having no systemic illness and who were not smoking.~Obtaining a blood sample; TOC, TAC, OSI, PON-1, ARES, MPO, TNF-α, IL-1β, MMP-1 and MMP-9 levels in venous blood were measured Reflectance confocal microscopy; 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM. Sebum rate at forehead and right cheek were evaluated with sebumeter. Dermoscopic photoaging scale were assessed by using video dermoscopy."
3000927|NCT02556814|Experimental|caffeic acid tablet and dexamethasone|Oral administration of caffeic acid tablets 0.3g three times per day for 3 months. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
3000928|NCT02556814|Active Comparator|Placebo and dexamethasone|Oral administration of placebo tablets 0.3g three times per day for 3 months. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
3000929|NCT02556801|Placebo Comparator|SUBLIVAC FIX Phleum Prat. 0 AUN/ml|40 patients will receive placebo (SUBLIVAC FIX Phleum Pratense 0 AUN/ml) sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
3000930|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 10,000 AUN/ml|40 patients will receive SUBLIVAC FIX Phleum Pratense 10,000 AUN/ml) sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
3000931|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 40,000 AUN/ml|40 patients will receive SUBLIVAC FIX Phleum Pratense 40,000 AUN/ml sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
3000932|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 80,000 AUN/ml|40 patients will receive SUBLIVAC FIX Phleum Pratense 80,000 AUN/ml sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
3000933|NCT02556788|Experimental|CD5789 (Trifarotene) 50µg/g Cream|
3000934|NCT02556788|Placebo Comparator|Placebo cream|
3000935|NCT02556775||Alternative Product Arm|Participant stops HYQVIA treatment (if the participant is still treated) and a licensed human normal immunoglobulin other than HYQVIA for intravenous (IV) or subcutaneous (SC) infusion or an alternative treatment will be administered, as determined by the physician.
3000936|NCT02556775||HYQVIA Arm|Participant continues to receive HYQVIA (Immune Globulin (Human) 10% with recombinant human hyaluronidase (rHuPH20)), according to her treatment regimen.
3000937|NCT02556762|Experimental|SMART boost|Radiotherapy with simultaneous modulated accelerated boost
3000938|NCT02556762|Active Comparator|Standard dose RT|Standard dose radiotherapy
3000939|NCT02556749|Experimental|Cranberry Juice Beverage|16 ounces of 54% cranberry juice cocktail
3000940|NCT02556749|Placebo Comparator|Placebo Beverage|Color, calorie, and taste matched beverage without cranberry bioactives
3000941|NCT02556736|Experimental|Group 1|Single intravitreal injection of RST-001
3000942|NCT02556723|Experimental|Ziv-aflibercept IV|All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks.
3000943|NCT02556710|Experimental|4 mL AMPION™|AMPION™, 4 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
3000944|NCT02556710|Placebo Comparator|4 mL Saline Placebo|Saline placebo, 4 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride.
3000945|NCT02556697|Experimental|patients with a suspicion of emphysema|A bronchoscopy with in vivo confocal endomicroscopy is assessed for patient with a suspicion of emphysema
3000946|NCT02556697|Experimental|patients with a suspicion of scleroderma|A bronchoscopy with in vivo confocal endomicroscopy is assessed for patient with a suspicion of sclerodermia
3000947|NCT02556671||Moderate CKD Patients Undergoing PCI|
3000948|NCT02556671||Normal renal function Patients Undergoing PCI|
3000949|NCT02556658|Experimental|Smartpilot View group|General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
3000950|NCT02556658|Active Comparator|Control group|General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
3000951|NCT02556645|Experimental|Web-PE|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
3000952|NCT02556645|Active Comparator|PCT|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies.
3000953|NCT02556632|Experimental|Arm I (curcumin-based gel)|Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
3000954|NCT02556632|Experimental|Arm II (HPR Plus)|Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
3000955|NCT02556632|Placebo Comparator|Arm III (placebo gel)|Patients apply placebo gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
3000956|NCT02556619|No Intervention|Standard Therapy|Patients will undergo standard medical care for Hepatocellular Carcinoma diagnosis.Patients however will not be denied early palliative care if requested.
3000957|NCT02556619|Experimental|Early Palliative Care/Symptom Control|"Patients will undergo palliative care services at time of Hepatocellular Carcinoma diagnosis.~Palliative care and symptom control services are adapted from the National Consensus Project for Quality Palliative Care.~Early referral, patients meeting inclusion criteria will be enrolled and referred to palliative care within 3 weeks of the index consultation with Medical-Oncology, Surgical-Oncology or Gastroenterology.~Intervention will be:~Establish palliative care goals~Symptom Assessment and Control~End-of-Life Care"
3000958|NCT02556606|Experimental|Ketamine 0.10 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
3000959|NCT02556606|Experimental|Ketamine 0.25 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
3000960|NCT02556606|Experimental|Ketamine 0.50 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
3000961|NCT02556606|Active Comparator|Midazolam 0.03 mg/kg|randomly assigned to a single 40 min infusion of either MID 0.03mg/Kg
3000962|NCT02556593|Experimental|IMRT & erlotinib|Patients in experimental group receive IMRT and erlotinib: Daily IMRT(45Gy in 15 fractions) to the brain metastases with daily erlotinib(150mg.po) for three weeks
3000963|NCT02556593|Active Comparator|whole-brain radiotherapy|Patients in this group receive WBRT at 30Gy in 10 fractions
3000964|NCT02556580|Active Comparator|Conscious healthy volunteers|Intervention: intravenious infusion Drug: albumin 20%
3000965|NCT02556580|Experimental|Surgery under general anesthesia|Intervention: intravenious infusion Drug: albumin 20%
3000966|NCT02556580|Experimental|Post-surgical inflammation|Intervention: intravenious infusion Drug: albumin 20%
3000967|NCT02556567|Other|Intervention|Participants will wear the Fitbit® Charge Heart Rate (HR) wristband for eight weeks.
3000968|NCT02556554|No Intervention|Routine Care|Standard of Care in the Pregnancy and Women's Health clinic.
3000969|NCT02556554|Active Comparator|Dexcom G4 Platinum CGM system|An intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy.
3000970|NCT02556554|Active Comparator|Dexcom G4 Platinum CGM system with Share™|A treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™ remote monitoring capabilities during pregnancy.
3000971|NCT02556528|Experimental|Health Coaching|
3000972|NCT02556515|Active Comparator|Trapeziektomi and ligament interposition|Interpositional arthroplasty Interpositional arthroplasty (Burton-Pellegrini procedure)
3000973|NCT02556515|Experimental|Total joint replacement|Elektra CMC1 uncemented prosthesis Elektra prosthesis
3000974|NCT02556502|Experimental|FDG PET positive or negative|
3000975|NCT02556476||ICU patients|The actual cohort of 148 critically ill medical patients that received the treatment in the intensive care unit (ICU). The interventions include interventions that are usually performed within the ICU such as mechanical ventilation, non-invasive ventilation, neuromuscular blockade, renal replacement therapy.
3000976|NCT02556463|Experimental|Escalation MEDI9197|MEDI9197
3000977|NCT02556463|Experimental|Escalation MEDI9197 with durvalumab|MEDI9197 in combination with durvalumab
3000978|NCT02556463|Experimental|Escalation MEDI9197 durvalumab radiation|MEDI9197 in combination with durvalumab and palliative radiation
3000979|NCT02556463|Experimental|MEDI9197 with palliative radiation|MEDI9197 in combination with palliative radiation
3000980|NCT02556450|Experimental|Spironolacton Group|Spironolacton Sandoz given 25mg daily oral use
3000981|NCT02556450|No Intervention|Control group|Only background treatment
3000982|NCT02556437|Experimental|Group A|24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia) followed by 24 weeks of treatment with HyQvia
3000983|NCT02556437|Experimental|Group B|24 weeks of treatment with HyQvia followed by 24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia)
3000984|NCT02556424|Active Comparator|Reference Drug|Intravitreal implant of 700μg of dexamethasone (Ozurdex®)
3000985|NCT02556424|Experimental|Tested Drug|Subconjunctival injection of 16 mg triamcinolone (Kénacort Retard®)
3000986|NCT02556411|Active Comparator|LNG-IUS|LNG-IUS 13,5 mg di Levonorgestrel
3000987|NCT02556411|Experimental|combined oral contraceptive plus LNG-IUS|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg+ LNG-IUS 13,5 mg di Levonorgestrel
3000988|NCT02556398|Experimental|Intervention - Educ Module and App|"Participants in this arm to be given smartphone app (Sugar Sleuth) and educational module."
3000989|NCT02556385|Experimental|High frequency rTMS|Most activated area from fNIRS with language task: Perileisional Broca's area
3000990|NCT02556385|Active Comparator|Low Frequency rTMS|Most activated area from fNIRS with language task: Contralesional homologs of Broca's area
3000991|NCT02556372|Experimental|JKB-122|AIH-positive subjects (n=20) who are intolerant, refractory, ineligible or unwilling to take current therapies, and have liver enzymes that are 2 to 10 times the upper limit of normal
3000992|NCT02556346|Experimental|MT-3724 Phase 1 5 mcg/kg/dose|MT-3724 5 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
3000993|NCT02556346|Experimental|MT-3724 Phase 1 10 mcg/kg/dose|MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
3000994|NCT02556346|Experimental|MT-3724 Phase 1 20 mcg/kg/dose|MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
3000995|NCT02556346|Experimental|MT-3724 Phase 1 50 mcg/kg/dose|MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
3000996|NCT02556346|Experimental|MT-3724 Phase 1b|MT-3724 IV for 6 doses over 12 days for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Phase 1 portion of the study)
3000997|NCT02556333|Experimental|FTC/TAF|Emtricitabine 200mg/tenofovir alafenamide 25mg (FTC/TAF) tablet to be given orally once daily to be added to a failing regimen for 10 days. If HIV RNA decline by >= 0.5 log copies/mL, patient will continue on FTC/TAF with a new antiretroviral regimen for 48 weeks. If < 0.5 log copies/mL decline, patient will be taken off FTC/TAF.
3000998|NCT02556320|Experimental|Epileptic patient|Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
3000999|NCT02556307||Peginterferon alfa-2a + Ribavirin|
3001000|NCT02556294|Experimental|Self-acceptance behavioral intervention|The intervention will consist of individual and 4 group counseling sessions and 6 individual counseling sessions. The individual sessions are focused on specific individualized risk reduction plans, whereas the group sessions are focused on increasing self-acceptance and reducing HIV risk. Additionally, participants in this arm will receive HIV and STI counseling and testing.
3001001|NCT02556294|Other|Comparison/Control|The comparison group will receive HIV and STI counseling and testing.
3001002|NCT02556281|Experimental|Patient with colorectal cancer|Blood sampling is done for patient with colorectal cancer
3001007|NCT02556268|Experimental|Riociguat and antiretroviral protease inhibitor with TRIUMEQ|
3001008|NCT02556255|Experimental|CathiTM Atherectomy Hybrid Catheter|Percutaneous Transluminal Atherectomy (PTA) catheter for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD)
3001009|NCT02556242|Experimental|Targeted indoor residual spraying|The intervention arm of the trial will receive Indoor Residual Spraying delivery through targeted spraying in the neighbourhood of recent local cases only.
3001010|NCT02556242|Active Comparator|Generalised Indoor residual spraying|The reference (control) arm of the trial will receive Indoor Residual Spraying through generalised annual spraying of all structures, as is the current standard practice.
3001011|NCT02556229|Experimental|Aflibercept|Intravitreal injection of aflibercept (EYLEA) / 2mg
3001012|NCT02556203|Experimental|Rivaroxaban + ASA|Rivaroxaban + ASA (Acetylsalicylic acid) followed by rivaroxaban alone
3001013|NCT02556203|Active Comparator|ASA + Clopidogrel|ASA + Clopidogrel followed by ASA alone
3001014|NCT02556177|Active Comparator|mTBI patient group (Segment 1)|"1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit~Patients in the acute period following recent diagnosis of mild traumatic brain injury (mTBI)"
3001015|NCT02556177|Active Comparator|non-TBI patients (Segment 2)|Control subjects with no recent mild traumatic brain injury. 1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit
3001016|NCT02556164|Experimental|Real EA|"Real EA as intervention is performed at the selected standard acupuncture points and De-qi is achieved with needle manipulation before electric stimulation is delivered."
3001017|NCT02556164|Sham Comparator|Sham EA|Sham EA as intervention is performed for the control group at non-acupuncture points without needle manipulation. The electric stimulation in sham acupuncture was performed in a similar fashion to the real EA.
3001018|NCT02556151|Active Comparator|1 Hz|Six sessions of weekly therapy with 1 Hz magnetic stimulations of the lumbar and sacral regions.
3001019|NCT02556151|Active Comparator|5 Hz|Six sessions of weekly therapy with 5 Hz magnetic stimulations of the lumbar and sacral regions.
3001020|NCT02556151|Active Comparator|15 Hz|Six sessions of weekly therapy with 15 Hz magnetic stimulations of the lumbar and sacral regions.
3001021|NCT02556138|Experimental|Orbera Intragastric Balloon|All subjects will be receiving the ORBERA Intragastric Balloon
3001022|NCT02556125||Cervical SCI|Participants with acute, traumatic cervical spinal cord injuries (C-SCIs), classified according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) as A-C (complete SCI (A); motor complete SCI (B); motor incomplete with minimal motor function (C)), affecting C1-C6 spinal cord segments, and who have been scheduled to undergo implantation of a diaphragm pacer, or who have recently received (in past 5-days) implantation of intramuscular diaphragm pacing electrodes due to severe respiratory impairments and dependence on mechanical ventilation.
3001023|NCT02556112|Active Comparator|Group Lifestyle Balance|Participants receive the Group Lifestyle Balance intervention as per the standard curriculum
3001024|NCT02556112|Active Comparator|Better Body Better Life|Participants receive the Better Body Better Life intervention as per the standard curriculum
3001025|NCT02556112|Active Comparator|Fitness Improvement Program|Participants take the Fitness Improvement Program on-line
3001026|NCT02556099|Experimental|Hydroxyurea Treatment|Hydroxyurea will be administered once daily by mouth. Participants will be monitored monthly to maximum tolerated dose and quarterly thereafter with periodic clinical evaluations, laboratory tests, and transcranial doppler examinations every 6 months.
3001027|NCT02556086|Experimental|Daclatasvir + Sofosbuvir|Daclatasvir 30, 60, 90 mg tablet (dose is dependent on cART regimen) + Sofosbuvir 400 mg tablet oral dosing once daily for 8 weeks
3001028|NCT02556073|Active Comparator|Usual care|"Usual care means that intervention by fluticasone/salmeterol 125/25 2 puffs bid plus salbutamol as needed acts as asthma controller and patients will be scheduled to revisit clinics."
3001029|NCT02556073|Experimental|Usual care+Smartphone action|Intervention by fluticasone/salmeterol 125/25 2 puffs bid plus salbutamol as needed and Smartphone action, which provides the real-time health information of surroudings and actively remind the patients to use controller.
3001030|NCT02556060|Experimental|lamotrigine|lamotrigine extended release up to 200 mg/day,
3001031|NCT02556060|Placebo Comparator|Placebo|Identical Placebo
3001032|NCT02556047|Other|Injections|"Two injections of 0.1 ml sterile saline per injection using Star intradermal safety device 1.2mm needle length~Two injections of 0.1 ml sterile saline per injection using Star intradermal safety device 1.5mm needle length~Two injections of 0.1 ml saline per subject using Mantoux technique by N&S"
3001033|NCT02556034||Disease evaluation|Rheumatoid arthritis evaluations.
3001034|NCT02556021|Experimental|CJ-12420 50mg|CJ-12420 50 mg, tablet, once daily, oral administration for up to 4 weeks
3001035|NCT02556021|Experimental|CJ-12420 100mg|CJ-12420 100 mg, tablet, once daily, oral administration for up to 4 weeks
3001036|NCT02556021|Placebo Comparator|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
3001037|NCT02555995|Experimental|All study participants|Patient's eyes are OCT-scanned with standard device and investigational device.
3001038|NCT02555982|Experimental|EXPERIMENTAL GROUP|"Patients eligible for inclusion will be randomized to one of the two groups:~Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
3001039|NCT02555982|Other|CONTROL GROUP|"Patients eligible for inclusion will be randomized to one of the two groups:~Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
3001040|NCT02555943|Active Comparator|Prophylactic/Early anti-HBV treatment|HCV/HBV co-infection patients in this arm will receive nucleos(t)ides analog (Entecavir or Tenofovir disoproxil fumarate) for the treatment of hepatitis B infection before or at the commencement of direct anti-HCV treatment using DAAs (Ledipasvir/Sofosbuvir; or Sofosbuvir and Daclatasvir, or Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir; or Sofosbuvir+Ribavirin).
3001078|NCT02555696||nab-paclitaxel|nab-paclitaxel 260mg/m^2 in intravenous (IV) infusion every 3 weeks until progression or toxicity
3001041|NCT02555943|Experimental|Deferred anti-HBV treatment|HCV/HBV co-infection patients in this arm will receive nucleos(t)ides analog (Entecavir or Tenofovir disoproxil fumarate) for the treatment of hepatitis B infection when HBV viral breakthrough occurred during anti-HCV treatment using DAAs (Ledipasvir/Sofosbuvir; or Sofosbuvir and Daclatasvir, or Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir; or Sofosbuvir+Ribavirin).
3001042|NCT02555917|Experimental|Remnant preserving|"Anterior cruciate ligament reconstruction:~anterior cruciate ligament remnant will be preserved in the operation"
3001043|NCT02555917|Active Comparator|Remnant resecting|"Anterior cruciate ligament reconstruction:~anterior cruciate ligament remnant will be removed in the operation"
3001044|NCT02555904||Heart failure syndrome & pulmonary congestion|Patients who are admitted for inpatient management with acute heart failure syndrome with pulmonary congestion who require intravenous diuretics are potential candidates for the study and shall be screened for suitability based on the inclusion and exclusion criteria.
3001045|NCT02555878|Experimental|Rivaroxaban|Participants will be administered rivaroxaban 10 milligram (mg) tablet orally once daily for 180 days.
3001046|NCT02555878|Experimental|Placebo|Participants will be administered matching placebo tablet orally once daily for 180 days.
3001047|NCT02555852||Users of PPIs|Exposure to proton pump inhibitors (PPIs) will be defined as a prescription for a PPI (esomeprazole, omeprazole, pantoprazole, lansoprazole, rabeprazole, and combinations) on the same day as the cohort entry defining prescription for an NSAID.
3001048|NCT02555852||Users of H2RAs|Exposure to histamine-2 receptor antagonists (H2RAs) will be defined as a prescription for a H2RA (cimetidine, ranitidine, famotidine, nizatidine, niperotidine, roxatidine, ranitidine bismuth citrate, lafutidine, cimetidine combinations, and famotidine combinations) on the same day as the cohort entry defining prescription for an NSAID.
3001049|NCT02555852||Unexposed group (Reference)|Patients that are considered to be unexposed will be defined as patients not prescribed a PPI or H2RA on the same day as the cohort entry defining prescription for an NSAID.
3001050|NCT02555839||Pomalidomide and Dexamethasone|Pomalidomide 4mg capsules by mouth (PO) on days 1 though 21 of a 28 day cycle and Dexamethasone 40mg PO on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicty
3001051|NCT02555813||Abraxane + Gemcitabine|Abraxane 125mg by intravenous( IV) infusion + Gemcitabine 1000mg by intravenous on Days 1, 8, 15 of every 21 day cycle until progression
3001052|NCT02555800|Experimental|Bevacizumab|Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
3001053|NCT02555800|Experimental|Cidofovir|Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
3001054|NCT02555800|Placebo Comparator|Saline|Patients will receive 3 intralesional injections of 3.5 mL of saline solution every 3 to 6 weeks in a submucosal plane after surgical debulking.
3001055|NCT02555787||Patients converted from tacrolimus BD to Advagraf|Oral
3001056|NCT02555774|Experimental|cognitive training|Cognitive training programs 2 times a week for 3 months (totally 24 sessions) for 90 minutes per session. Lifestyle modification is educated first, then weekly phone call for lifestyle modification is done by investigators.
3001057|NCT02555774|Active Comparator|lifestyle modification|This group receives only lifestyle modification for 3 months. Lifestyle modification is educated at the first, then weekly phone call for lifestyle modification is done by investigators. The method of lifestyle modification is same with the first arm.
3001058|NCT02555774|No Intervention|No intervention|This group receives no intervention.
3001059|NCT02555761||Lastacaft®|One drop of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) in each eye daily as prescribed as standard of care in clinical practice.
3001060|NCT02555748|Active Comparator|Pazopanib|"The daily dose of pazopanib will be the standard dose i.e. 800 mg once a day (2 tablets of 400 mg in one oral administration per day) administered each day, continuously, during the treatment phase (complete cycle will be defined as a 6-week period).~During the first stage of the study (Part I), adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage of the study (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part."
3001061|NCT02555748|Active Comparator|Sunitinib|"Sunitinib will be administered at the standard dose of 50 mg, once daily during 4 consecutive weeks, followed by a wash-out period of 2 weeks (corresponding to a complete cycle of 6 weeks).~During the first stage of the study (Part I), dose adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part."
3001062|NCT02555735||Metastatic Pancreatic Cancer|Treatment naive study participants with metastatic pancreatic cancer treated with physician-choice standard of care chemotherapy, either FOLFIRINOX or Gemcitabine+nab-paclitaxel.
3001063|NCT02555722|Experimental|fanfilcon A (test)|Subjects will be randomized to wear fanfilcon A lens (test) for one month of daily wear during the study.
3001064|NCT02555722|Active Comparator|enfilcon A (control)|Subjects will be randomized to wear enfilcon A lens (control) for one month of daily wear during the study.
3001065|NCT02555709|Placebo Comparator|Placebo 1|healthy volunteers
3001066|NCT02555709|Experimental|VTP-43742 Dose 1|healthy volunteers
3001067|NCT02555709|Experimental|VTP-43742 Dose 2|healthy volunteers
3001068|NCT02555709|Experimental|VTP-43742 Dose 3|healthy volunteers
3001069|NCT02555709|Experimental|VTP-43742 Dose 4|healthy volunteers
3001070|NCT02555709|Experimental|VTP-43742 Dose 5|healthy volunteers
3001071|NCT02555709|Experimental|VTP-43742 Dose 6|healthy volunteers
3001072|NCT02555709|Experimental|VTP-43742 Dose 7|healthy volunteers
3001073|NCT02555709|Placebo Comparator|Placebo 2|psoriatic patients
3001082|NCT02555670||BIA and CT|Patients who had a CT-scan made for diagnostic reasons.
3001083|NCT02555657|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations.
3001084|NCT02555657|Active Comparator|Chemotherapy|Participants receive capecitabine, eribulin, gemcitabine, or vinorelbine as TPC in accordance with local regulations and guidelines.
3001085|NCT02555644|Experimental|Prexasertib + Cisplatin + Radiation Therapy (Part A)|"Prexasertib administered intravenously (IV) every 14 days over an approximately 49-day treatment period.~Cisplatin administered IV every 7 days over an approximately 49-day treatment period.~Intensity modulated radiation therapy administered 5 days per week over an approximately 49-day treatment period.~Participants may remain on treatment until completion of the treatment period."
3001086|NCT02555644|Experimental|Prexasertib + Cetuximab + Radiation Therapy (Part B)|"Prexasertib administered IV every 14 days over an approximately 56-day treatment period.~Cetuximab administered IV every 7 days over an approximately 56-day treatment period.~Intensity modulated radiation therapy administered 5 days per week over an approximately 56-day treatment period (starting at Week 2).~Participants may remain on treatment until completion of the treatment period."
3001087|NCT02555631|Experimental|lifestyle intervention|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
3001088|NCT02555618|Experimental|TAK-850|A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.
3001089|NCT02555618|Active Comparator|Influenza HA Vaccine|A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.
3001090|NCT02555566|Experimental|Kidney transplant recipients|"blood sampling is done for determination of EPHX Lys55Arg and other polymorphisms status in Kidney transplant recipients.~flow-mediated distal stimulation of the forearm radial artery by cutaneous heating is assessed for evaluation of EEts level in Kidney transplant recipients."
3001091|NCT02555553|No Intervention|Treatment as Usual|"The control group for the RCT will be a usual care condition in which participants are free to seek any assistance for their ED during the study period."
3001092|NCT02555553|Experimental|CBT-GSH with Noom Monitor|Participation will include 12 weeks of guided cognitive-behavioral therapy- guided self help (CBT-GSH) with an MA-level health coach or nutritionist from the KPNW health plan. Patients will use a self-help book, Overcoming Binge Eating (2013) by Christopher Fairburn. The first session will last 60 minutes, and each subsequent session lasts 20-25 minutes. The first four sessions are weekly, with the subsequent four twice monthly. Self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session.
3001093|NCT02555540|Active Comparator|Boostrix, Male, >/= 5 years, D2 visit|"25 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
3001094|NCT02555540|Active Comparator|Boostrix, Male, >/= 5 years, D3 visit|"25 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
3001095|NCT02555540|Active Comparator|Boostrix, Female, >/= 5 years, D2 visit|"25 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
3001096|NCT02555540|Active Comparator|Boostrix, Female, >/= 5 years, D3 visit|"25 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
3001097|NCT02555540|Placebo Comparator|Placebo, Male, >/= 5 years, D2 visit|"5 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
3001098|NCT02555540|Placebo Comparator|Placebo, Male, >/= 5 years, D3 visit|"5 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
3001099|NCT02555540|Placebo Comparator|Placebo, Female, >/= 5 years, D2 visit|"5 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
3001100|NCT02555540|Placebo Comparator|Placebo, Female, >/= 5 years, D3 visit|"5 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
3001101|NCT02555540|Active Comparator|Boostrix, Male, <5 years, D2 visit|"25 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
3001102|NCT02555540|Active Comparator|Boostrix, Male, <5 years, D3 visit|"25 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
3001103|NCT02555540|Active Comparator|Boostrix, Female, <5 years, D2 visit|"25 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
3001159|NCT02555124|Experimental|Cohort A|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 or Placebo on Day 1, fasted condition.
3031815|NCT02349607|Placebo Comparator|Placebo|
3001104|NCT02555540|Active Comparator|Boostrix, Female, <5 years, D3 visit|"25 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
3001105|NCT02555540|Placebo Comparator|Placebo, Male, <5 years, D2 visit|"5 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
3001106|NCT02555540|Placebo Comparator|Placebo, Male, <5 years, D3 visit|"5 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
3001107|NCT02555540|Placebo Comparator|Placebo, Female, <5 years, D2 visit|"5 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
3001108|NCT02555540|Placebo Comparator|Placebo, Female, <5 years, D3 visit|"5 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
3001109|NCT02555514||Knee Osteoarthritis|The study population consists of 100 enrolled patients with different stages of knee OA and varus malalignment >4° with respect to the mechanical loading axis of the lower extremity. A minimum of 40 patients are to be included per year, so that the study period will be planned from January 1st, 2015 to June 30th, 2017. Preliminary results will be reviewed by the end of every year and intermediate reports will be generated by the sub-study-groups
3001110|NCT02555501|Experimental|PDT + Low level laser|"PDT (photosensitizer and low level laser) and low level laser~Photosensitizer: aqueous solution of 0.005% methylene blue; Low level laser: infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium) and red emitter with active medium InGaAlP (phosphide and Indium, Gallium and Potassium)"
3001111|NCT02555501|Active Comparator|Low level laser|Low level laser: infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium) and red emitter with active medium InGaAlP (phosphide and Indium, Gallium and Potassium)
3001112|NCT02555488|Experimental|2|in the second group diode laser (810 nm, 1.2 W, 30 s) was irradiated. Then second samples were taken from all canals.
3001113|NCT02555488|Experimental|1|In the first group Photodynamic therapy (PDT) with Methylene blue and diode laser (810 nm, 0.2 W, 40 second) was done
3001114|NCT02555475|No Intervention|Group 1, tertiary hospital based care|Group 1: (n=190) Following their initial screen, these participants will be referred to a tertiary hospital for hepatitis C care, transient elastography and DAA treatment (traditional / standard model of care).
3001115|NCT02555475|Experimental|Group 2, community based care|Group 2: (n=190) Following their initial screen, these participants will be offered community based hepatitis C care and treatment. Hepatitis C care, transient elastography and DAA treatment will be delivered at the primary healthcare centre only.
3001116|NCT02555462|Experimental|Real-Ear Measurement|The study arm goes through a comparative test run followed by a comparative hearing aid fitting.
3001117|NCT02555449|Experimental|[¹⁴C]-LY3202626|Single oral dose of LY3202626 containing 100 micro curies of radioactivity
3001118|NCT02555410||Brain Sentinel Seizure Detection and Warning System|To test the usability of the Brain Sentinel Seizure Detection and Warning System(also known as the SPEAC system) in a patient home setting.
3001119|NCT02555397|Experimental|Single|Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at a dose of 1 x 10e10 to 1 x 10e12 viral particles.
3001120|NCT02555384|Active Comparator|crowded drawing task|children will be asked to draw on a pattern presented under crowded viewing conditions.
3001121|NCT02555384|Placebo Comparator|uncrowded drawing task|children will be asked to draw on a pattern presented under uncrowded viewing conditions
3001122|NCT02555371|Experimental|Arm Mepolizumab 100 mg|There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). Subjects will receive mepolizumab (100 mg SC) every 4 weeks throughout study
3001123|NCT02555371|Placebo Comparator|Arm Placebo|There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). During Part A, B and D, subjects will receive open label mepolizumab (100 mg SC) every 4 weeks and during Part C, subjects will receive placebo SC every 4 weeks.
3001124|NCT02555358|Experimental|A（DOX）|Interventions：This arm wil receive four cycles of DOX (docetaxel 60mg/m2 on day 1,oxaliplatin 130mg/m2 on day 1 and capecitabine 1,000 mg/m2 per day on days 1 to 14, repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as adjuvant therapy
3001125|NCT02555358|Active Comparator|B（Xelox）|Interventions：This arm wil receive four cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox as adjuvant therapy
3001126|NCT02555358|Active Comparator|C（Xelox）|Interventions：This arm wil receive eight cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as adjuvant therapy.
3001127|NCT02555345||classic asthma/No intervention|Patients with classic asthma were stable.Chest X-ray or CT scan was normal.Fenofibrate(FeNO) was performed.Spirometry was needed. The leicester cough questionnaire (LCQ) was offered to physicians.Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
3001160|NCT02555124|Experimental|Cohort B|Participants will receive single oral dose of 20 mg of JNJ-42847922 or Placebo on Day 1, fasted condition.
3001128|NCT02555345||CVA/No intervention|Chest X-ray or CT scan was normal.FeNO was performed. Spirometry was needed. The LCQ was offered to physicians. Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
3001129|NCT02555345||EB/No intervention|Chest X-ray or CT scan was normal.FeNO was performed. Spirometry was needed. The LCQ was offered.Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
3001130|NCT02555345||Healthy/No intervention|Chest X-ray or CT scan was normal.FeNO was performed.Spirometry was needed. Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
3001131|NCT02555332||Women underwent screening for thyroid function|All these women underwent screening for thyroid function (TSH,FT4,TPOAb) at the first antenatal visit and the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation. The correlation between the combination of TSH level and TPOAb status and the risk of Gestational Diabetes Mellitus was analyzed.
3001132|NCT02555319|Experimental|Transcatheter Pulmonary Valve|Transcatheter Pulmonary Valve (TaeWoong Medical Co., Ltd. Korea)
3001133|NCT02555306|Experimental|Low Dose DE-122|Single intravitreal injection of Low Dose DE-122 Injectable Solution
3001134|NCT02555306|Experimental|Medium-Low Dose DE-122|Single intravitreal injection of Medium-Low Dose DE-122 Injectable Solution
3001135|NCT02555306|Experimental|Medium-High Dose DE-122|Single intravitreal injection of Medium-High Dose DE-122 Injectable Solution
3001136|NCT02555306|Experimental|High Dose DE-122|Single intravitreal injection of High Dose DE-122 Injectable Solution
3001137|NCT02555293|Experimental|film-coated Rifaximin (550 mg)|(550 mg) tablet twice daily for at least 14 days but up to 28 days dependent on the need for a PVE and the period between PVE (portal vein embolization) or randomization and surgery. Preoperative Rifaximin treatment in case of a PVE will start the day after PVE and will last for 14-21 days. In case patients are not pre-treated with a PVE they will receive Rifaximin for 7-10 days prior to surgery. Regardless of PVE, patients will receive additional Rifaximin treatment the first 7 days postoperatively.
3001138|NCT02555293|No Intervention|standard therapy|Patients directed to the control group will not receive Rifaximin.
3001139|NCT02555280|Experimental|The coflex® Interlaminar Technology|The coflex device was designed to address the clinical needs of spinal stenosis patients by providing stabilization of the affected level without fusion. The coflex is an interspinous process functional dynamic implant designed to impart a stabilizing effect at the treated level(s). The coflex device was approved by FDA in 2012.
3001140|NCT02555280|Active Comparator|Decompression|Lumbar decompression back surgery is when a small portion of the bone over the nerve root and/or disc material from under the nerve root is removed to give the nerve root more space and provide a better healing environment.
3001141|NCT02555267||Elderly patients with DLBCL|Elderly patients (age>=65 years) with DLBCL treated with R-CHOP chemotherapy
3001142|NCT02555254|Experimental|Low speed of rewarming|Patients will be placed in targeted temperature controlled at 33°C for 24 hours. Then, intervention will be proceeded after randomization: slowly rewarmed (0.25°C/h) to targeted temperature controlled at 37°C for 24 hours.
3001143|NCT02555254|Experimental|Fast speed of rewarming|Patients will be placed in targeted temperature controlled at 33°C for 24 hours. hen, intervention will be proceeded after randomization: fastly rewarmed (0.50°C/h) for targeted temperature controlled at 37°C for 24 hours.
3001144|NCT02555241|Experimental|One Baseline Session|Designated for participants #1 and #2. Participants complete 1 Baseline Session followed immediately by 12 weeks of standard treatment. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
3001145|NCT02555241|Experimental|Two Baseline Sessions|Designated for participants #3 and #4. Participants complete a Baseline Session followed by a 12 week wait period before repeating a Baseline Session followed immediately by 12 weeks of standard treatment. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
3001146|NCT02555241|Experimental|Three Baseline Sessions|Designated for participants #5 and #6. Participants complete a Baseline Session followed by two repetitions of the Baseline Session (each 12 weeks apart) and 12 weeks of standard treatment immediately following the third session. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
3001147|NCT02555228|Experimental|Simethicone premedication|Liquid simethicone (1ml volume) in 5mls of water
3001148|NCT02555228|Placebo Comparator|Placebo|Just 5 mls of water
3001149|NCT02555215|Experimental|dimethyl fumarate|Participants will receive 120 mg capsule(s) taken orally.
3001150|NCT02555189|Experimental|Enzalutamide|Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3001151|NCT02555189|Experimental|Enzalutamide + Ribociclib|Patients receive enzalutamide PO QD on days 1-28 and ribociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3001152|NCT02555176|Experimental|Low Carbohydrate Diet|Patients follow a normocaloric, low-carbohydrate diet for 10-28 days (from the time of cancer diagnosis to definitive surgical treatment).
3001153|NCT02555163|Experimental|HoLERBT|Holmium (Ho: YAG) Laser En Bloc Resection Of Bladder Tumor
3001154|NCT02555163|Active Comparator|cTURBT|Conventional Transurethral Resection Of Bladder Tumors
3001155|NCT02555150|Active Comparator|PRC-063|Titration during which subjects will be titrated from a starting dose of 45 mg/day (dosed once daily) of PRC-063 oral capsules up to his/her final dose (45, 70 or 100 mg/day of PRC-063). This phase will be 10 to 21 days long.
3001156|NCT02555150|Active Comparator|lisdexamfetamine dimesylate|Titration during which subjects will be titrated from a starting dose of 30 mg/day of lisdexamfetamine up to his/her final dose (30, 50 or 70 mg/day of LDX). This phase will be 10 to 21 days long.
3001157|NCT02555150|Placebo Comparator|Placebo|Subjects will be dosed once daily with a placebo oral capsule for 10 to 21 days.
3001158|NCT02555137||outcome cohort study|'prediction score' and 'rule-out criteria'
3001161|NCT02555124|Experimental|Cohort C|Participants will receive single oral dose of 40 mg of JNJ-42847922 or Placebo on Day 1, fasted condition.
3001162|NCT02555111|Experimental|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
3001163|NCT02555111|No Intervention|untreated|the patient won't receive any treatment during his study participation.
3001164|NCT02555085|Experimental|IV Dose 1|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
3001165|NCT02555085|Experimental|IV Dose 2|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
3001166|NCT02555085|Experimental|IV Dose 3|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
3001167|NCT02555085|Experimental|IV Dose 4|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
3001168|NCT02555085|Experimental|IV Dose 5|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
3001169|NCT02555085|Experimental|IV Dose 6|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
3001170|NCT02555085|Experimental|IV Dose 7|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
3001171|NCT02555085|Experimental|SC Dose|Single SC dose or matching placebo
3001172|NCT02555072|Other|naive children and adults for yellow fever vaccine|both sexes; ages between 9 months and 4 years, 11 months and 29 days old; 18 years to 50 years old
3001173|NCT02555059||BAYQ3939|Pediatrics patients treated with Ciproxan injection in daily clinical practice.
3001174|NCT02555046|No Intervention|General Anaesthesia|EVAR-treatment is preformed with the patient in General Anaesthesia
3001175|NCT02555046|Experimental|Local Anaesthesia|EVAR-treatment is preformed with the patient in Local Anesthesia
3001176|NCT02555033|Experimental|M-RT|Machine-based resistance training. Exercising 'traditional' machine-based resistance training.
3001177|NCT02555033|Experimental|M-IRT|Machine-based instability resistance training; a similar training program with exercise-machines, but with additional unstable devices placed between participant and exercise-machine or floor respectively.
3001178|NCT02555033|Experimental|F-IRT|Free weight instability resistance training; conducted free-weight resistance training on unstable devices using dumbbells instead of exercise-machines.
3001179|NCT02555020|Experimental|Allocated to MN NPO group,|"Patients was administered in hospital~Randomization~Patient was allocated to MN group~Patients were NPO from mid night (MN) to Surgery"
3001180|NCT02555020|Placebo Comparator|Allocated to Placebo group|"Patients was administered in hospital~Randomization~Patient was allocated to Placebo group~Patients received 400 mL of water 12 hours before anesthesia and 400 mL 2 hours before anesthesia."
3001181|NCT02555020|Active Comparator|Allocated to Carbohydrated group|"Patients was administered in hospital~Randomization~Patient was allocated to Carbohydrated group~Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal."
3001182|NCT02555007|Experimental|Oral Vinorelbine|
3001183|NCT02554994|Active Comparator|Intervention|"ASPRA (Aging Study of PyeongChang Rural Area) cohort is a population-based, prospective cohort study of older adults living in PyeongChang County of South Korea. This cohort study is supported by public health center, named PyeongChang Health Center and Country Hospital managed by government, to improve the quality of aged public health services.~All participants will be recruited from ASPRA cohort. After 6 months of usual care period, eligible participants are screened by characteristics of ASPRA database, and are assigned to a multifactorial intervention arm."
3001184|NCT02554994|Active Comparator|usual care|The other participants enrolled to ASPRA cohort are acted as a control arm. The usual care according to ASPRA protocol will be maintained.
3001185|NCT02554981|Experimental|RESTASIS®|1 drop of RESTASIS® ophthalmic emulsion instilled in each eye twice a day for 6 months.
3001186|NCT02554968||Study participants|Study participants will complete study related documents including a demographics questionnaire and the shoulder-related patient reported outcome measures.
3001187|NCT02554955|Experimental|Daclizumab + Mycophenolate mofetil|Participants will receive intravenous (IV) daclizumab (2 milligrams per kilogram [mg/kg] within 6 hours after transplantation and 1 mg/kg every 2 weeks for a total of five doses), along with mycophenolate mofetil (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg twice daily [BID] within first week and 1 grams per day [g/day] BID from second week onwards) and sirolimus (3 mg/day) for 6 months.
3001188|NCT02554942|Experimental|Epoetin beta|Participants will receive weekly SC injection of epoetin beta (450 international units per kilogram [IU/kg]) for 16 weeks.
3001189|NCT02554929|Experimental|Taming Sneaky Fears Group|An 11 week (introduction plus 10 week) manualized treatment protocol utilizing cognitive behavioral strategies specifically developed for children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
3001190|NCT02554929|Active Comparator|Parent Psychoeducation and Child Socialization Group|An 11 week (introduction plus 10 week) manualized treatment protocol focusing on parent psychoeducation and child socialization in children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
3001191|NCT02554916||Dual-belt Exercise|The participants assigned to this group will use the dual-belt treadmill 3 times a week for 16 weeks.
3001192|NCT02554916||Treadmill Exercise|The participants assigned to this group will use the treadmill 3 times a week for 16 weeks.
3001193|NCT02554916||Usual Care|The participants assigned to this group will not use the treadmills.
3001194|NCT02554903|Experimental|Macitentan 10 mg po|Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.
3001195|NCT02554903|Placebo Comparator|Placebo sugar pill|Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.
3001243|NCT02554721|Experimental|Group 2 (CYP2C19 Wild Type)|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
3001196|NCT02554890|Experimental|sacubitril/valsartan (LCZ696)|"Initial dose for patients randomized to sacubitril/valsartan (LCZ696) will be determined by the blood pressure at the time of randomization. Study treatment will be titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration will be based on blood pressure at the time of the visit. Dose adjustments will only be allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.~Patients will be required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."
3001197|NCT02554890|Active Comparator|Enalapril|"Initial dose for patients randomized to enalapril will be determined by the blood pressure at the time of randomization. Study treatment will be titrated to the target dose of enalapril 10 mg bid. Titration will be based on blood pressure at the time of the visit. Dose adjustments will only be allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.~Patients will be required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"
3001198|NCT02554877|Placebo Comparator|Placebo|
3001199|NCT02554877|Experimental|PF-06291874, 30 mg|
3001200|NCT02554877|Experimental|PF-06291874, 60 mg|
3001201|NCT02554877|Experimental|PF-06291874, 100 mg|
3001202|NCT02554864|Active Comparator|Adductor Canal Block- Injection -Site A|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site A - after the sartorius muscle crosses over the femoral artery
3001203|NCT02554864|Active Comparator|Adductor Canal Block - Injection -Site B|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site B - before the sartorius muscle crosses over the femoral artery
3001204|NCT02554864|Active Comparator|Adductor Canal Block -Injection -Site C|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site C - as the sartorius muscle crosses over the femoral artery
3001205|NCT02554851|Placebo Comparator|placebo|This group will receive the standard medication and the placebo drug
3001206|NCT02554851|Experimental|recombinant human Epidermal Growth Fact|This group will receive the standard medication and the recombinant human Epidermal Growth Factor (HEBERPROT)
3001207|NCT02554838|Active Comparator|Rehabilitation|"Rehabilitation :~Physical activity~Home assessment and modification"
3001208|NCT02554838|Experimental|Rehabilitation and CBT|"Rehabilitation associated with cognitive behavioral therapy (CBT) :~Physical activity~Home assessment and modification~Cognitive behavioral therapy"
3001209|NCT02554825|Experimental|Healthy Futures|
3001210|NCT02554825|Other|Control|
3001211|NCT02554812|Experimental|Cohort A1|NSCLC patients treated with avelumab + utomilumab (Dose level 1)
3001212|NCT02554812|Experimental|Cohort A2|NSCLC patients treated with avelumab + utomilumab (Dose level 2)
3001213|NCT02554812|Experimental|Cohort A3|NSCLC patients treated with avelumab + utomilumab (Dose level 3)
3001214|NCT02554812|Experimental|Cohort A4|Melanoma patients treated with avelumab +utomilumab
3001215|NCT02554812|Experimental|Cohort A5|SCCHN patients treated with avelumab + utomilumab
3001216|NCT02554812|Experimental|Cohort A6|TNBC patients treated with avelumab + utomilumab
3001217|NCT02554812|Experimental|Cohort A7|SCLC that has progressed after at least 1 line of platinum-containing therapy treated with avelumab +utomilumab
3001218|NCT02554812|Experimental|Cohort A8|NSCLC first-line Stage IV treated with avelumab +PF-05082566
3001219|NCT02554812|Experimental|Combination B Dose Escalation|PF-04518600 + avelumab in selected tumor types
3001220|NCT02554812|Experimental|Combination B Expansion Cohorts|PF-04518600 + avelumab in selected tumor types
3001221|NCT02554812|Experimental|Combination C Dose escalation cohorts|PD 0360324 + avelumab in selected tumor types
3001222|NCT02554812|Experimental|Combination C Dose expansion cohorts|PD 0360324 + aveluamb in selected tumor types
3001223|NCT02554812|Experimental|Combination D Dose escalation cohorts|PF-05082566 + PF-04518600 + avelumab in selected tumor types
3001224|NCT02554812|Experimental|Combination D Dose expansion cohorts|PF-05082566 + PF-04518600 + avelumab in selected tumor types
3001225|NCT02554812|Experimental|Cohort A9|NSCLC first-line Stage IV treated with avelumab +utomilumab (sequential starting with utomilumab monotherapy followed by combination)
3001226|NCT02554812|Experimental|Cohort A10|NSCLC first-line Stage IV treated with avelumab + utomilumab (sequential starting with avelumab monotherapy followed by combination)
3001227|NCT02554799|Experimental|40 mg MMV390048 tablet formulation A fasted|40 mg MMV390048 tablet formulation A, in fasted state
3001228|NCT02554799|Experimental|40 mg MMV390048 tablet formulation B fasted|40 mg MMV390048 tablet formulation B fasted
3001229|NCT02554799|Experimental|40 mg MMV390048 formulation A or B, with milk or fasted|Optional cohort: 40 mg of MMV390048 in the formulation that has been shown to have the most favourable PK profile, taken with milk or in the fed state.
3001230|NCT02554786|Experimental|QMF149 150/160 µg|QMF149 150/160 µg o.d. via Concept1
3001231|NCT02554786|Experimental|QMF149 150/320 µg|QMF149 150/320 µg o.d. via Concept1
3001232|NCT02554786|Active Comparator|MF 400 µg o.d.|MF 400 µg o.d via Twisthaler®
3001233|NCT02554786|Active Comparator|MF 400 µg b.i.d.|MF 400 µg b.i.d. via Twisthaler®
3001234|NCT02554786|Active Comparator|salmeterol /fluticasone|salmeterol xinafoate /fluticasone propionate 50/500 µg b.i.d. via Diskus®
3001235|NCT02554773|Experimental|ALN-AT3SC|
3001236|NCT02554760|Experimental|Fat Reduction|The treatments are designed to see if the fat, on the flanks, can be reduced.
3001237|NCT02554747|Experimental|Navigated laser|Aflibercept, Navilas®
3001238|NCT02554747|Active Comparator|Conventional laser|Aflibercept, Pascal
3001239|NCT02554734|Experimental|Levodopa standard carbidopa|Levodopa, carbidopa, ODM-104
3001240|NCT02554734|Experimental|Levodopa modified carbidopa|Levodopa, carbidopa, ODM-104
3001241|NCT02554734|Active Comparator|Stalevo|Levodopa, carbidopa, entacapone
3001242|NCT02554721|Experimental|Group 1 (CYP2C19 Wild Type)|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Acetylsalicylic acid 100 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Acetylsalicylic acid 100mg once daily for 1 week (Days 22-28)
3001315|NCT02554240|Experimental|DA-5202 Low dose|- DA-5202 10mg
3001316|NCT02554240|Active Comparator|Na Hyaluronate 20mg|Na Hyaluronate 20mg
3001244|NCT02554721|Experimental|Group 3 (CYP2C19 heterozygous (*1/*2) )|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
3001245|NCT02554721|Experimental|Group 4 (CYP2C19 homozygous (*2/*2))|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
3001246|NCT02554695|Placebo Comparator|placebo|single subcutaneous injection of placebo (normal saline)
3001247|NCT02554695|Active Comparator|Denosumab|single subcutaneous injection of denosumab 60 mg
3001248|NCT02554695|No Intervention|young normal premenopausal women|no intervention
3001249|NCT02554682|Other|Sexual Health|Parents of teens between the ages of 14 and 15 will review psychoeducational workbooks related to sexual health at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 4 to 5 months post baseline we will collect data to assess the efficacy of the study materials.
3001250|NCT02554682|Other|Alcohol Prevention|Parents of teens between the ages of 14 and 15 will review psychoeducational workbooks related to alcohol prevention at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 4 to 5 months post baseline we will collect data to assess the efficacy of the study materials.
3001251|NCT02554682|No Intervention|Sexual Health & Alcohol Control Group|Parents of teens between the ages of 14 and 15 will receive their usual care at their well-child visit appointment with their primary care giver (baseline) and then at 4 to 5 months post baseline we will collect data. At the end of the post data collection, the control group will get all of the study materials from both the sexual health and alcohol prevention groups.
3001252|NCT02554682|Other|Teen Driving|Parents of teens between the ages of 16 and 17 who are planning on having the medical certification for the permit application completed and plan on taking their driving permit test in the next 8 weeks will review psychoeducational workbooks related to teen driving at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 6 months post baseline we will collect data to assess the effectiveness of the study materials.
3001253|NCT02554682|No Intervention|Teen Driving Control|Parents of teens between the ages of 16 and 17 who are planning on having the medical certification for the permit application completed and plan on taking their driving permit test in the next 8 weeks will receive their usual care at their well-child visit appointment with their primary care giver (baseline) and then at 6 months post baseline we will collect data. At the end of the post data collection, the control group will get all of the study materials from the teen driving group.
3001254|NCT02554669|No Intervention|Control|No physical activity
3001255|NCT02554669|Experimental|Postabsorptive physical activity|Physical activity performed before breakfast
3001256|NCT02554669|Experimental|Postprandial physical activity|Physical activity performed in the postprandial period after breakfast
3001257|NCT02554643|Experimental|Diet & Soccer|"Nutritional Intervention (Diet) once a week, during 12 weeks~+ Soccer training, 3 times a week, during 12 weeks"
3001258|NCT02554643|Experimental|Diet & Running|"Nutritional Intervention (Diet) once a week, during 12 weeks~+ Running training, 3 times a week, during 12 weeks"
3001259|NCT02554643|Active Comparator|Diet|Nutritional Intervention (Diet) once a week, during 12 weeks
3001260|NCT02554630||Preterm Neonate|Neonates of gestational age 24-37 weeks. Blood collection will be performed at the time of a clinically required heelstick or blood draw. Microfluidic techniques, utilizing whole blood, will be employed to characterize the baseline genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function. Meconium will be collected for microbiome analysis. Clinical outcomes will be recorded from the electronic medical record.
3001261|NCT02554630||Term Neonates|Neonates of gestational age 37-42 weeks. Blood collection will be performed at the time of a clinically required heelstick or blood draw. Microfluidic techniques, utilizing whole blood, will be employed to characterize the baseline genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function. Meconium will be collected for microbiome analysis. Clinical outcomes will be recorded from the electronic medical record.
3001262|NCT02554630||Healthy Adult Control|Healthy Adult aged 18-55 years will undergo a single blood collection by the way of vein puncture. Microfluidic techniques, utilizing whole blood, will be employed to evaluate the genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function.
3001263|NCT02554604||Pregnant woman|Pregnant woman with identified risk factors for the development of preeclampsia
3001264|NCT02554578|Experimental|Pharmaceutical care programme supported by mHealth|
3001265|NCT02554578|No Intervention|Routine healthcare by the transplant team|
3001266|NCT02554565|Other|Tumor biopsies and blood sampling|
3001267|NCT02554552|Experimental|YY1201 2ml|YY1201 2ml
3001268|NCT02554552|Experimental|YY1201 3ml|YY1201 3ml
3001269|NCT02554552|Placebo Comparator|Placebo 2ml|Phosphate buffered saline 2ml
3001270|NCT02554552|Placebo Comparator|Placebo 3ml|Phosphate buffered saline 3ml
3001271|NCT02554539|Experimental|Obese|Women, aged 21-45 with BMI >30
3001272|NCT02554539|Experimental|Normal weight|Women, aged 21-45 with BMI < 25
3001273|NCT02554526||Combination therapy|Effects of aPCC reaction in the presence of FVIII
3001274|NCT02554513|Active Comparator|EPG Tx|An articulatory-kinematic treatment in conjunction with visual biofeedback specifically tongue to palate contact to improve speech production
3001275|NCT02554513|Active Comparator|Sound Production Treatment (SPT)|An articulatory-kinematic treatment that uses integral stimulation to improve speech production.
3001317|NCT02554227||Spondylodiscitis|
3001318|NCT02554214|Experimental|Glafkos device|
3001276|NCT02554500|Experimental|Intact scaphoid bone|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
3001277|NCT02554500|Experimental|Intact metacarpal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
3001278|NCT02554500|Experimental|Fractured scaphoid bone|"Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
3001279|NCT02554500|Experimental|Fractured metacarpal bone|"Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
3001280|NCT02554500|Experimental|Intact metatarsal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metatarsal bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
3001281|NCT02554487|Experimental|sSDB ASV+|sSDB ASV+: Patients with an AHI > 20/h assessed during the first night of stroke that are randomized to ASV treatment (AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)).
3001282|NCT02554487|No Intervention|sSDB ASV-|sSDB ASV-: Patients with an AHI > 20 no ASV treatment.
3001283|NCT02554487|No Intervention|no SDB|no SDB: Stroke patients without SDB (AHI < 5 / h) serve as a control group to observe the evolution of the lesion volume and stroke outcome without the additional burden of SDB.
3001284|NCT02554474|Active Comparator|Immediate Intervention Group|Education, Fitbit/FitViz, physiotherapist counselling. These 3 components will be delivered to the participants in Months 1 and 2. The session will include a short presentation about physical activity in everyday life, an individual goal-setting session with a registered PT, and an orientation to the Fitbit and FitViz app. Participants will use the Fitbit/FitViz. The PT will review the progress with participants via bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will continue using the Fitbit/FitViz and have access to a PT via email as needed, but no bi-weekly phone calls.
3001285|NCT02554474|Placebo Comparator|Delayed Intervention Group|Same intervention with a 2 month delay: The full intervention will be initiated in Month 3 and 4 with a brief education session, use of a Fitbit paired with the FitViz app, and counseling by a PT. In Month 5-6, participants will continue the intervention without the PT phone calls, but will have email access to PT, if needed.
3001286|NCT02554461||female players|national team players
3001287|NCT02554461||male players|national team players
3001288|NCT02554448|Experimental|Circulating Tumor Cells|Use ISET system to test the number of CTCs from patients before and during treatment.
3001289|NCT02554435|Active Comparator|Pedometer|All participants will be given 5 A's counseling and a digital pedometer (Digi-walker CW-700/701, YAMAX, San Antonio, TX). Participants will be asked to log their daily steps measured by the pedometer in an activity diary.
3001290|NCT02554435|Experimental|Electronic Activity Monitor (EAM)|"All participants will be given an EAM (UP24 by Jawbone, San Francisco, CA) and the corresponding UP24 application (app) on their smart device. In addition to monitoring activity, the app allows for social comparison and social interaction. Participants will friend other participants to utilize these features."
3001291|NCT02554422|Experimental|PalpEar|Intraoperative palpation of the ossicles using the PalpEar device, to measure mobility of the ossicle chain.
3001292|NCT02554409||Pregnancy Cases|No Intervention as part of this protocol
3001293|NCT02554396|Experimental|PRX-100|PRX-100 ophthalmic solution
3001294|NCT02554396|Placebo Comparator|Placebo|saline solution
3001295|NCT02554383|Active Comparator|Treatment A|Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
3001296|NCT02554383|Placebo Comparator|Treatment B|Placebo made to match the study antibiotic will be taken bid orally for 10 days
3001297|NCT02554370|Experimental|Psychoeducational programme|Psychoeducational programme
3001298|NCT02554370|No Intervention|Usual care|No psychoeducational programme
3001299|NCT02554357|Experimental|Exparel block in arthroscopic surgery|Evaluation of Exparel block in arthroscopic shoulder surgery.
3001300|NCT02554357|Experimental|Bupivacaine block in shoulder surgery|Evaluation of Bupivacaine block in shoulder surgery.
3001301|NCT02554344|Experimental|All Patients|Fourteen subjects with histologically confirmed squamous CIN3 will be enrolled in a single arm study. All patients will receive 500 mg of curcumin administered orally, twice a day for 12 weeks upon enrollment on trial.
3001302|NCT02554331|Experimental|Patients RBD|Patients RBD subject to FP-CIT single-photon emission computed tomography and Neuropsychological evaluation and Gait recording with sensors
3001303|NCT02554331|Other|controls healthy volunteers|controls healthy volunteers subject to Neuropsychological evaluation and Gait recording with sensors
3001304|NCT02554318|Experimental|Intervention|"TB standard therapy with fixed dose combination :~once per day by mouth for 2 months Fixed dose combination = RHZE (150mg/75mg/400mg/275mg) R=rifampicin, H=isoniazid, Z=pyrazinamide, E=ethambutol,~Patients with body weight: 30 - 37 kg = 2 tablets, 38 - 54 kg = 3 tablets, 55 - 70 kg = 4 tablets, and ≥71 kg = 5 tablets~and 166.5 grams cooked fermented soybean (tempeh) daily for two months"
3001305|NCT02554318|Active Comparator|Control|"TB standard therapy with fixed dose combination :~once per day by mouth for 2 months Fixed dose combination = RHZE (150mg/75mg/400mg/275mg) R=rifampicin, H=isoniazid, Z=pyrazinamide, E=ethambutol,~Patients with body weight: 30 - 37 kg = 2 tablets, 38 - 54 kg = 3 tablets, 55 - 70 kg = 4 tablets, and ≥71 kg = 5 tablets"
3001306|NCT02554305|Active Comparator|Fusion oxygenation system|Fusion oxygenation machine will be used during the operation.
3001307|NCT02554305|Active Comparator|Affinity oxygenation system|Affinity oxygenation machine will be used during the operation.
3001308|NCT02554305|No Intervention|Peripheral vascular procedure|No oxygenation machine will be used in this group
3001309|NCT02554305|No Intervention|percutaneous coronary intervention|No oxygenation machine will be used in this group
3001310|NCT02554279|Experimental|menotropin|menotropins for injection
3001311|NCT02554279|Active Comparator|recombinant FSH|
3001312|NCT02554253|Active Comparator|ketamine|Ketamine induction
3001313|NCT02554253|Active Comparator|Propofol|Propofol induction
3001314|NCT02554240|Experimental|DA-5202 High dose|- DA-5202 20mg
3001319|NCT02554201|Experimental|Electrical pudendal nerve stimulation|Electrical pudendal nerve stimulation At a frequency of 2.0 Hz and a moderate intensity (25~35 mA); 60 minutes three times a week for a total of four weeks
3001320|NCT02554201|Active Comparator|Transvaginal electrical stimulation|At a current intensity of < 60 mA (as high as possible to get a contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-min periods of stimulation); 30 min three times a week for a total of four weeks.
3001321|NCT02554188|Placebo Comparator|Control|Participants will receive Seasonal influenza (flu) vaccine.
3001322|NCT02554188|Experimental|Diet|Participants will consume 2 cycles of a 5-day low calorie fasting-mimicking diet with approximately 3 weeks of gap period prior to receiving standard Seasonal influenza (flu) vaccine.
3001323|NCT02554175|Experimental|the target propofol concentration|patients were allocated to 1 of 6 groups of predefined propofol target Ce for induction, namely, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5 µg.mL-1.Propofol was administered to achieve target propofol Ce.
3001324|NCT02554162|Active Comparator|Extruded wholegrain rye flakes|Rye products with varying structures
3001325|NCT02554162|Active Comparator|Extruded wholegrain rye puffs|Rye products with varying structures
3001326|NCT02554162|Active Comparator|Fresh wholegrain rye bread|Rye products with varying structures
3001327|NCT02554162|Active Comparator|Wholegrain rye beverage|Rye products with varying structures
3001328|NCT02554162|Active Comparator|Fresh wheat bread|Rye products with varying structures
3001329|NCT02554149||stem anteversion|a hip lateral radiograph and CT scan were taken to measure stem anteversion
3001330|NCT02554136|Experimental|Sequence 1|HGP0918 -> HGP0816 -> HGP0918 + HGP0816
3001331|NCT02554136|Experimental|Sequence 2|HGP0816 -> HGP0918 + HGP0816 -> HGP0918
3001332|NCT02554136|Experimental|Sequence 3|HGP0918 + HGP0816 -> HGP0918 -> HGP0816
3001333|NCT02554136|Experimental|Sequence 4|HGP0918 -> HGP0918 + HGP0816 -> HGP0816
3001334|NCT02554136|Experimental|Sequence 5|HGP0816 -> HGP0918 -> HGP0918 + HGP0816
3001335|NCT02554136|Experimental|Sequence 6|HGP0918 + HGP0816 -> HGP0816 -> HGP0918
3001336|NCT02554123|Experimental|Vitamin E ointment|Vitamin E ointment application. Every 12 hours during 7 days.
3001337|NCT02554123|Placebo Comparator|Vaseline ointment|Vaseline ointment application. Every 12 hours during 7 days.
3001338|NCT02554110|Experimental|Stimulator Active Device|Intervention: This intervention arm will use a Stimulator Active Device peripheral nerve stimulation. Participants will receive a cutaneous stimuli in response to oxygen desaturations in postoperative surgical patients.
3001339|NCT02554110|Sham Comparator|Stimulator Sham Device|No intervention: This arm will use a Stimulator Sham Device peripheral nerve stimulation.Participants will not receive a cutaneous stimuli in response to oxygen desaturations in postoperative surgical patients.
3001340|NCT02554097||EST+LC group|Patients accept the management of endoscopic sphincterotomy and laparoscopic cholecystectomy.
3001341|NCT02554097||LCBDE+LC group|Patients accept the management of laparoscopic common bile duct exploration and laparoscopic cholecystectomy.
3001342|NCT02554097||LTCBDE+LC group|Patients accept the management of laparoscopic transcystic common bile duct exploration and laparoscopic cholecystectomy.
3001343|NCT02554084|Experimental|Dry Eye Disease|Optical Coherence Tomography
3001344|NCT02554084|Active Comparator|Normals|Optical Coherence Tomography
3001345|NCT02554071|Experimental|Pharmacist - Smoking Cessation Support'|Active Comparator Arm Receive smoking assessment Initial Smoking Cessation Counselling Smoking Cessation Prescription/Non-Prescription Product as required Follow-up Counselling
3001346|NCT02554058|Experimental|Cycling and Mechanical stimulation|Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
3001347|NCT02554045|Active Comparator|Tadalafil|Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks
3001348|NCT02554045|Placebo Comparator|Placebo|Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
3001349|NCT02554032|Active Comparator|Axillary artery cannulation|Axillary artery cannulation for antegrade cerebral perfusion
3001350|NCT02554032|Active Comparator|Innominate artery cannulation|Innominate artery cannulation for antegrade cerebral perfusion
3001351|NCT02554019|Experimental|BT063|50 mg BT063 administered by intravenous (IV) infusion 8 times
3001352|NCT02554019|Placebo Comparator|Placebo|Placebo administered by IV infusion 8 times
3001353|NCT02554006|Other|good clinical practice|all patients will receive education from physician regarding management of dual antiplatelet therapy as part of the routine discharge process
3001354|NCT02554006|Experimental|bundle group|patients assigned to the bundle group will receive visits and materials as described by the protocol (counseling)
3001355|NCT02553993|Experimental|Wii Fit|The Wii Fit training was conducted using the Wii Fit bundle from Nintendo, which consists of the Wii console, a Wii Balance Board, and the Wii Fit Plus balance game disc. The Wii balance board has 4 transducers, which could assess the player's force distribution and resultant movements in the center of pressure (COP). The participants stood on the board and used the change of COP to play the games. Five games (Tilt, Soccer Heading, Balance Bubble, Penguin Slide, and Perfect 10) were selected from the Wii Fit Plus package based on the motor demand of these games. The major movement patterns to play the games included right-left weight shifting and front-back weight shifting.
3001356|NCT02553993|Experimental|Tetrax biofeedback|"The Tetrax biofeedback games aimed at postural rehabilitation to help patients or athletes improve their balance abilities. There were 11 games in Tetrax system; 8 games (Speedtrack, Catch, Skyball, Gotcha, Speedball, Tag, Freeze, Immobilizer) were chosen based on the same principle as those used for choosing Wii Fit games. The parameters of games' difficulties included target size and/or speed of target movement, which could be adjusted according to the patients' ability.~For the Wii Fit or Tetrax group, at each session, the supervising therapist chose 3 to 5 games for participants according to their ability, needs, and favorites."
3001357|NCT02553993|Placebo Comparator|Conventional weight-shifting|The conventional weight-shifting exercise group performed balance exercises with the similar movements and time required by the 2 exergame systems but without video games. By using occupational activities, participants did weight shifting in the sagittal and frontal planes. The investigators also used a balance board (Reebok Core board) for multi-directional weight shifting training
3001358|NCT02553980|Experimental|Physical activity promotion|"Participants in this group will attend the Follow Your Virtual Trainer (FYVT) program"
3001359|NCT02553980|Placebo Comparator|Placebo|Control group
3001360|NCT02553967|Experimental|Immediate breast reconstruction|"Total mastectomy + immediate reconstructive surgery~6 months after surgery : Functional MRI and questionnaires"
3001361|NCT02553967|Experimental|Secondary breast reconstruction|"Within 2 months before surgery : Functional MRI~Reconstructive surgery~6 months after surgery : Functional MRI and questionnaires"
3001362|NCT02553954|Experimental|Collection of healthy skin tissue|Collection of healthy skin tissue
3001363|NCT02553941|Experimental|azacitidine, ibrutinib|Patients receive azacitidine intravenous infusion over 10-40 minutes or subcutaneous on days 1-7 or 1-5 and 8-9, and ibrutinib by mouth one daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3001364|NCT02553928|Experimental|Memantine (once daily)|Memantine 20 mg once daily, tablets, orally AND Placebo tablets once daily, orally
3001365|NCT02553928|Experimental|Memantine (twice daily)|10 mg given twice daily, tablets, orally
3001366|NCT02553915|Placebo Comparator|Placebo|Soybean oil placebo capsules, 4 capsules daily for 12 weeks
3001367|NCT02553915|Experimental|EPA 1 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
3001368|NCT02553915|Experimental|EPA 2 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
3001369|NCT02553915|Experimental|EPA 4 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
3001370|NCT02553902|Active Comparator|Combination therapy|"Sleep Position Trainer + Mandibular Advancement device combination The SPT is a sensor that measures the sleeping position, and gives the user feedback about wrong positions with a soft vibration. A user is then able to react to the signal and turn into a non-supine position. To stimulate compliance, information is provided about nightly behaviour, implicating a learning pattern by viewing the data on a home computer.~MRA or oral appliances (OA) works by advancing the mandible and its attached soft tissue structures forward they aim to increase upper airway size."
3001371|NCT02553902|Active Comparator|CPAPContinuous positive airway pressure|Continuous positive airway pressure (CPAP) functions as a pneumatic splint to maintain upper airway patency. Possible side effect can be related to the interface, pressure and negative social factors.
3001372|NCT02553889|Experimental|PK Cohort|A 4-week screening period followed by a 4-week treatment period followed by a 6-week post-treatment evaluation period. Treatment period includes 1 dose of 300 mg ISIS 416858 on Day 1 and again on Day 29. Both doses of Study Drug will be administered subcutaneously (SC).
3001373|NCT02553889|Placebo Comparator|Cohort A|"Patients in Cohort A will be randomized to receive either 200 mg ISIS 416858 or placebo. A 2:1 ratio will be used.~For Cohort A, the study will include a 4-week screening period and a 12-week treatment period followed by a 12-week post-treatment evaluation period.~Cohort A will receive Study Drug (ISIS 416858 or placebo) twice a week during the first 2 weeks, followed by once weekly for the remaining 10 weeks of the treatment period. All doses of Study Drug will be administered subcutaneously (SC) 10 minutes after completion of the hemodialysis treatment."
3001374|NCT02553889|Placebo Comparator|Cohort B|"Patients in Cohort B will be randomized to receive either 300 mg ISIS 416858 or placebo. A 2:1 ratio will be used.~For Cohort B, the study will include a 4-week screening period and a 12-week treatment period followed by a 12-week post-treatment evaluation period.~Cohort B will receive Study Drug (ISIS 416858 or placebo) twice a week during the first 2 weeks, followed by once weekly for the remaining 10 weeks of the treatment period. All doses of Study Drug will be administered subcutaneously (SC) 10 minutes after completion of the hemodialysis treatment."
3001375|NCT02553876||Observational|All patients referred with pain in the hand and/or upper limb will be evaluated. Patients will first be assessed for suitability for neurostimulation implantation and then included in the study. Patients wiil fill in questionnaires (pain scores, Quality of Life and satisfaction) at baseline and post-operatively at regular intervals (as per standard of care in the Netherlands.)
3001376|NCT02553863|Experimental|Intervention group|Acupuncture for 30min [twice weekly for 8 weeks]
3001377|NCT02553863|Other|Control group|Standard care
3001378|NCT02553850||Ibandronate|Patients receiving ibandronate will be evaluated for bone turnover markers for 12 months. Ibandronate is not an investigational medicinal product (IMP) in this study.
3001379|NCT02553837|Experimental|Treatment only|Drug: Hantavax injectionSchedule: The basic vaccination(0, 1, 2months) and The boost vaccination(13months)
3001380|NCT02553824|Experimental|Phentermine/Topiramate-First + Placebo|Patients randomly assigned to this condition will receive the study medication first, have a 2 week washout, and then crossover to receive the control medication/placebo
3001381|NCT02553824|Placebo Comparator|Placebo-First + Phentermine/Topiramate|Patients randomly assigned to this condition will receive the control medication (placebo) first followed by a 2 week washout, and then receive the study medication.
3001382|NCT02553811|Experimental|intervention|accuracy diagnostic in carpal tunnel syndrome = evaluation and comparison ultrasonography X electromyography
3001383|NCT02553798|Experimental|DRM04|DRM04 Topical Wipes
3001384|NCT02553785|Experimental|Revivent TC|Surgical treatment of left ventricle using the Revivent TC System
3001385|NCT02553772|Experimental|OM3 Tear|Carboxymethylcellulose based eye drop [Omega-3 (OM3) Tear] administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
3001386|NCT02553772|Active Comparator|REFRESH OPTIVE® ADVANCED|Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
3001387|NCT02553759|Experimental|Effective movement|This group will see a 1-minute video showing an individual performing a cervical rotation movement to each side, first 10 times towards the right and then 10 times towards the left. The movement will be performed effectively over the entire course of the cervical path, approximately 80º
3001388|NCT02553759|Active Comparator|Ineffective movement|This group will see a 1-minute video showing an individual performing a cervical rotation movement ineffectively, without achieving the maximum cervical travel, performing approximately 40º. First, 10 movements towards the right will be performed and then 10 towards the left
3001389|NCT02553746|Experimental|Ultrasound|
3001390|NCT02553746|Active Comparator|Landmarks|
3001497|NCT02553148||South Africa|One of the 23 countries studied
3001391|NCT02553733|Active Comparator|Beetroot juice (Beet-It Organic Shot)|Subjects will consume 70 ml of beetroot juice (Beet-It Organic Shot) twice per day (morning, afternoon) for 5 to 7 days to assess the short term effects of this nitrate supplement on graded treadmill walking responses (day 4) and vasodilator/vasoconstrictor responses in the coronary and lower leg circulations (day 5 or 6 or 7). On both study visits, subjects will consume their morning dose 1 hour 45 min before experiments begin.
3001392|NCT02553733|Placebo Comparator|Beetroot juice placebo (Beet-It Organic Placebo)|Subjects will consume 70 ml of beetroot juice placebo (Beet-It Organic Placebo) twice per day (morning, afternoon) for 5 to 7 days to assess the short term effects of this nitrate supplement on graded treadmill walking responses (day 4) and vasodilator/vasoconstrictor responses in the coronary and lower leg circulations (day 5 or 6 or 7). On both study visits, subjects will consume their morning dose 1 hour 45 min before experiments begin.
3001393|NCT02553720|Experimental|Aqua Group|Conventional management plus aquatic exercise At least 15 minutes of walking 3 times/week for 3 months
3001394|NCT02553720|Other|Control Group|Conventional management without aquatic exercise
3001395|NCT02553707|Experimental|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
3001396|NCT02553694|Experimental|Enhanced education and Enhanced follow up|Subjects will watch a short video and will be contacted by an MD by phone
3001397|NCT02553694|Active Comparator|Usual education and Usual follow up|Standard education by American Academy of Sleep Medicine (AASM)- created educational pamphlets and will be contacted by a sleep center staff member by phone
3001398|NCT02553694|Experimental|Enhanced education and Usual follow up|Subjects will watch a short video immediately prior to the initiation of the in-laboratory polysomnogram and will be contacted by sleep center non-MD staff member by phone
3001399|NCT02553694|Experimental|Usual education with Enhanced follow up|Standard education by American Academy of Sleep Medicine (AASM)- created educational pamphlets and contacted by an MD by phone
3001400|NCT02553681|Experimental|HPT treated|Hydra-PEG Treatment (HPT) treated RGP contact lenses made from roflufocon D
3001401|NCT02553681|Active Comparator|untreated|untreated RGP contact lenses made from roflufocon D
3001402|NCT02553668|Experimental|Hyperoxia|Participants receive 100% oxygen
3001403|NCT02553655|Active Comparator|4x 5min Limb Preconditioning|Either the right or left leg of the participant(s) will be made transiently ischemic for 5 minutes following by 5 minutes of rest. This will be repeated for 4 times.
3001404|NCT02553655|Active Comparator|3x 10min Limb Preconditioning|Either the right or left leg of the participant(s) will be made transiently ischemic for 10 minutes following by 5 minutes of rest. This will be repeated for 3 times.
3001405|NCT02553655|Sham Comparator|3x 10min Sham Preconditioning|Either the right or left leg of the participant(s) will be squeezed without causing ischemia for 10 minutes following by 5 minutes of rest. This will be repeated for 3 times.
3001406|NCT02553642|Experimental|melanoma and bladder cancer patients|All eligible patients with melanoma will receive ipilimumab at a dose of 3 mg/kg combined with nivolumab at a dose of 1 mg/kg. The ipilimumab and nivolumab will be dosed every 3 weeks for 4 doses. Thereafter, patients may be eligible to continue to receive nivolumab monotherapy at a dose of 240 mg administered every 2 weeks for up to 2 years All eligible patients with bladder cancer will receive nivolumab at a dose of 240 mg administered every 2 weeks for up to 2 years, if the patient is clinically benefitting, the PI and treating investigator may elect to continue treatment beyond 2 years. All eligible patients with bladder cancer will receive nivolumab at a dose of 240 mg administered every 2 weeks for up to 2 years, if the patient is clinically benefitting, the PI and treating investigator may elect to continue treatment beyond 2 years.
3001407|NCT02553629|Active Comparator|moderate neuromuscular block|rocuronium 0.1-0.6 mg/kg aimed at a train of four of 1 - 2 twitches
3001408|NCT02553629|Experimental|deep neuromuscular block|rocuronium 0.1-0.6 mg/kg aimed at a post tetanic count of 1 - 2 twitches
3001409|NCT02553616|Experimental|Behavioral intervention|Intervention to promote healthy behaviors.
3001410|NCT02553603|Placebo Comparator|Mild Cognitive Impairment, Placebo|Subjects aged 55 - 85 years, scored between 23- 26 on screening Mini Mental Status Exam, receiving placebo Growth Hormone Releasing Hormone (GHRH).
3001411|NCT02553603|Placebo Comparator|Non-cognitively impaired, Placebo|Subjects aged 55- 85 years, scored between 27-30 on screening Mini Mental Status Exam, receiving placebo Growth Hormone Releasing Hormone (GHRH).
3001412|NCT02553603|Experimental|Mild Cognitive Impairment, GHRH|Subjects aged 55 - 85 years, scored between 23- 26 on screening Mini Mental Status Exam, receiving active Growth Hormone Releasing Hormone (GHRH).
3001413|NCT02553603|Experimental|Non-cognitively impaired, GHRH|Subjects aged 55 - 85 years, scored between 27-30 on screening Mini Mental Status Exam, receiving active Growth Hormone Releasing Hormone (GHRH).
3001414|NCT02553577||Conventional cigarettes -only|Women who are pregnant and use conventional tobacco products -only
3001415|NCT02553577||Electronic Cigarette (ecig) (ENDS) -ONLY|Women who are pregnant and use electronic cigarettes (ecigs) -only
3001416|NCT02553577||Conventional + ecig use (DUAL)|Women who are pregnant and use conventional + ecigs (dual)
3001417|NCT02553564|Experimental|Intervention group|"Checklist driven clinical encounter after hospital discharge~- Participant will receive standard medical care with the addition of a checklist driven clinical encounter upon return to the dialysis unit after hospital discharge.~* participants in both group will be receiving standard post discharge care which includes nursing assessment, social work intervention as needed and new dialysis orders."
3001418|NCT02553564|No Intervention|Usual care group|"Participant will receive standard medical care upon return to the dialysis unit after hospital discharge.~* participants in both group will be receiving standard post discharge care which includes nursing assessment, social work intervention as needed and new dialysis orders."
3001419|NCT02553551|Experimental|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given."
3001420|NCT02553551|Placebo Comparator|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given."
3001498|NCT02553148||Tajikistan|One of the 23 countries studied
3001499|NCT02553148||United Kingdom|One of the 23 countries studied
3001500|NCT02553148||United States|One of the 23 countries studied
3001421|NCT02553538|Experimental|Patient Navigation Intervention|Participants randomized to the intervention arm were transferred to a navigator roster within the TopCare application for the 8-month study period. Navigators utilized TopCare to track these participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
3001422|NCT02553538|No Intervention|Standard of Care - No Intervention|Participants randomized to the control arm received usual care within TopCare, which meant that clinicians and staff could elect to send the participant a reminder letter about their overdue cancer screening exams, reach out to schedule overdue exams, or document appropriate reasons for deferral or exclusion.
3001423|NCT02553525|Experimental|Therapeutic Stimulation Patterns|This group will receive temporal patterns of stimulation that are designed to suppress oscillatory neural activity at theta- or beta-frequencies. These patterns are hypothesized to alleviate motor symptoms.
3001424|NCT02553525|Experimental|Symptogenic Stimulation Patterns|This group will receive symptogenic patterns of stimulation that are designed to exacerbate oscillatory neural activity at theta- or beta-frequencies. These patterns are hypothesized to exacerbate motor symptoms.
3001425|NCT02553499|Experimental|MK-1248 Monotherapy|Participants will receive MK-1248 at assigned dose (starting Dose A), intravenously (IV) on Day 1 of each 21-day cycle (Q3W); maximum of 4 doses.
3001426|NCT02553499|Experimental|MK-1248 + Pembrolizumab|Participants will receive MK-1248 at determined dose, IV Q3W, maximum of 4 doses + pembrolizumab, 200 mg IV Q3W for up to 2 years.
3001427|NCT02553486||Internationally adopted children|All internationally adopted children, who arrived in France between 2008 and 2013, living in four French districts
3001428|NCT02553473|Active Comparator|Doxycycline for 6 weeks|Doxycycline 200 mg once daily for six weeks
3001429|NCT02553473|Placebo Comparator|Doxycycline for 2 weeks + placebo|Doxycycline 200 mg once daily for two weeks + placebo for four weeks.
3001430|NCT02553460|Experimental|Treatment|"Participants who meet eligibility requirements will receive remission induction, consolidation treatment, reinduction, reintensification and maintenance therapy.~Interventions: ITMHA, dexamethasone, mitoxantrone, pegaspargase or asparaginase Erwinia chrysanthemi, bortezomib, vorinostat, cyclophosphamide, mercaptopurine, methotrexate, leucovorin calcium, cytarabine, etoposide, and vincristine."
3001431|NCT02553447|Experimental|Arm I (high-dose cholecalciferol)|Patients receive high-dose cholecalciferol PO daily for 3 years in the absence of disease progression or unacceptable toxicity.
3001432|NCT02553447|Experimental|Arm II (low-dose cholecalciferol)|Patients receive low-dose cholecalciferol PO daily for 3 years in the absence of disease progression or unacceptable toxicity.
3001433|NCT02553447|No Intervention|Arm III (control)|Patients receive no intervention.
3001434|NCT02553434|Experimental|Pigtail catheter (case)|Inserting 14 French pigtail catheter
3001435|NCT02553434|No Intervention|Chest tube|inserting 32-36 French chest tube
3001436|NCT02553421|Experimental|Pilot|A non-alarming ivWatch device will monitor the IV sites of these subjects. The goal of this small pilot study is to give clinicians an opportunity to perform the protocol and operate the ivWatch device and to give researchers the ability to make adjustments prior to starting the subsequent non-alarming group.
3001437|NCT02553421|Experimental|Non-alarming|150 patients will be enrolled in the non-alarming group. The ivWatch device will monitor the IV sites but will not issue infiltration notifications.
3001438|NCT02553421|Experimental|Alarming|150 patients will be enrolled in the alarming group. The IV sites will be monitored with the ivWatch Model 400 infiltration notifications enabled.
3001439|NCT02553408|Other|Neo meter|This is a single arm purely qualitative (interview only) study with no comparator. All participants will use the FreeStyle Precision Neo-Meter for at least 3 months for self-monitoring of their blood glucose.
3001440|NCT02553382|Experimental|Dietary, Herbal|
3001441|NCT02553382|Placebo Comparator|Positive Control|
3001442|NCT02553369||Enrolled patients|Patient randomly enrolled in the study within a cohort of patient followed for HIV infection.
3001443|NCT02553356|Experimental|Fasted|PT2385 taken after fasting.
3001444|NCT02553356|Experimental|Non-Fasting|PT2385 taken after eating a high calorie meal.
3001445|NCT02553343|Experimental|QIV HD1 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 1)
3001446|NCT02553343|Experimental|QIV HD2 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 2)
3001447|NCT02553343|Active Comparator|TIV HD1 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of licensed High Dose trivalent influenza vaccine
3001448|NCT02553343|Active Comparator|TIV HD2 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of investigational High-Dose trivalent influenza vaccine
3001449|NCT02553330|Experimental|INCB018424 Phosphate Cream|"Part A: Open-label treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks;~Part B: Double-blind treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks."
3001450|NCT02553330|Placebo Comparator|Placebo Cream|Part B: Double-blind treatment is 24 weeks (and/or treatment with INCB018424 Phosphate Cream if eligible) and follow-up is an additional 12 weeks.
3001451|NCT02553317|Experimental|caplacizumab|Initial i.v. dose followed by daily s.c. injections for a maximum period of 6 months
3001452|NCT02553317|Placebo Comparator|placebo|Initial i.v. dose followed by daily s.c. injections for a maximum period of 6 months
3001453|NCT02553291|Experimental|SystemCHANGE|Subjects will participate in SystemCHANGE behavioral intervention focusing on diet and exercise. This six-session intervention focuses on system redesign of an individual's interpersonal environment and daily routines using small self-designed experiments to increase healthy behavior.
3001454|NCT02553291|Active Comparator|Control|Subjects randomized to the control group will receive an usual care condition and pamphlets on diet and exercise from the U.S. Department of Agriculture and the American Heart Association (AHA)
3001501|NCT02553148||Zimbabwe|One of the 23 countries studied
3001502|NCT02553135|Experimental|Injection of AAV2-REP1|Injection of AAV-REP1, 1.00x10e11 vg, subretinal injection of total volume of 100 μL.
3001455|NCT02553278|Experimental|Treatment with VelaShape device|"One treatment will be performed by the VelaShape device on one randomized abdominal subarea, while the other abdominal subarea will not be treated and will serve as a control. Biopsies will be harvested during abdominoplasty and cultured. Two histology samples, for each subject, will be obtained during the abdominoplasty surgery, The arm is divided to 6 sub-groups, where each Sub-group contains up to 2 subjects as follows:~Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 5 days after treatment Sub-group 3: Surgery 10 days after treatment Sub-group 4: Surgery 20 days after treatment Sub-group 5: Surgery 30 days after treatment Sub-group 6: Surgery 60 days after treatment Sub-group 7: Surgery 90 days after treatment"
3001456|NCT02553278|Experimental|Treatment with Contour I V3 device|"One treatment will be performed by Contour I V3 device on one randomized abdominal subarea, while the other abdominal subarea will not be treated and will serve as a control. Biopsies from treated and untreated subareas will be harvested during abdominoplasty and cultured. Two histology samples, for each subject, will be obtained during the abdominoplasty surgery. The arm is divided to 6 sub-groups, where each Sub-group contains up to 2 subjects as follows:~Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 10 days after treatment Sub-group 3: Surgery 20 days after treatment Sub-group 4: Surgery 30 days after treatment Sub-group 5: Surgery 60 days after treatment Sub-group 6: Surgery 90 days after treatment"
3001457|NCT02553265|Active Comparator|Placebo, Low Dose Carbidopa, High Dose Carbidopa|This is a 14-week study. Patients will receive, in random order, high dose carbidopa (600mg/day), low dose carbidopa (300 mg/day) or placebo. Between each crossover, there will be a titration down over 2-days followed by a 2-day washout.
3001458|NCT02553265|Active Comparator|High Dose Carbidopa, Placebo, High Dose Carbidopa|This is a 14-week study. Patients will receive, in random order, high dose carbidopa (600mg/day), low dose carbidopa (300 mg/day) or placebo. Between each crossover, there will be a titration down over 2-days followed by a 2-day washout.
3001459|NCT02553265|Active Comparator|Low Dose Carbidopa, High Dose Carbidopa, Placebo|This is a 14-week study. Patients will receive, in random order, high dose carbidopa (600mg/day), low dose carbidopa (300 mg/day) or placebo. Between each crossover, there will be a titration down over 2-days followed by a 2-day washout.
3001460|NCT02553252|Experimental|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants will receive training in SKY soon after completing baseline assessments.
3001461|NCT02553252|No Intervention|wait list control (WLC)|Participants will receive training in SKY after 12 weeks have passed since the baseline assessment.
3001462|NCT02553239|Experimental|Cryoablation|Cryoablation with the CoolLoop® catheter
3001463|NCT02553226|Active Comparator|Continued group|Recieve routine treatment with oxytocin according to the danish national guidelines.
3001464|NCT02553226|Placebo Comparator|discontinued group (placebo)|The routine treatment with oxytocin will be discontinued and replaced with isotonic saline, when the active phase of labour is established.
3001465|NCT02553213|Experimental|LSG group|Laparoscopic sleeve gastrectomy
3001466|NCT02553213|Experimental|LRYGB group|Laparoscopic Roux-en-Y gastric bypass
3001467|NCT02553213|Other|Control group|Caloric restriction
3001468|NCT02553200|Active Comparator|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
3001469|NCT02553200|Experimental|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
3001470|NCT02553200|Sham Comparator|BreatheMAX (unload and non-oscillated)|inspiratory and expiratory breathing exercise for 10 breathes/set, 10 sets/day and rest 1 minute between set
3001471|NCT02553187|Experimental|Treatment group|Kanglaite Injection plus standard therapy.
3001472|NCT02553187|No Intervention|Control group|Blank control and standard therapy.
3001473|NCT02553174||Ketorolac|Patients who receive ketorolac perioperatively
3001474|NCT02553174||Caldolor|Patients who receive Caldolor perioperatively
3001475|NCT02553174||No NSAIDS|Patients who do not receive NSAIDS perioperatively
3001476|NCT02553161|Experimental|MED - Escitalopram with psychotherapy|Youth will also be assigned a board certified child psychiatrist (Drs. Singh or Chang at Stanford; Drs. DelBello or Patino at UC), who will be blind to treatment condition and see youth weekly for the first 4 weeks, then biweekly until 16 weeks. Youth in the MED condition will be given the USFDA (US Food & Drug Administration) approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks.
3001477|NCT02553161|Placebo Comparator|No MED -Psychotherapy|All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
3001478|NCT02553161|No Intervention|Healthy Control|60 (30 at Stanford, 30 at University of Cincinnati) 12- to 17-year old male and female typically developing healthy controls. Healthy controls will receive behavioral, neural, and physiological assessments at baseline only. healthy controls will be scanned at baseline only and serve as a reference group to determine whether MRI changes observed in the high-risk group from baseline to week 4 are toward or away from normal.
3001479|NCT02553148||Argentina|One of the 23 countries studied
3001480|NCT02553148||Armenia|One of the 23 countries studied
3001481|NCT02553148||Australia|One of the 23 countries studied
3001482|NCT02553148||Brazil|One of the 23 countries studied
3001483|NCT02553148||China|One of the 23 countries studied
3001484|NCT02553148||Egypt|One of the 23 countries studied
3001485|NCT02553148||Ethiopia|One of the 23 countries studied
3001486|NCT02553148||Germany|One of the 23 countries studied
3001487|NCT02553148||India|One of the 23 countries studied
3001488|NCT02553148||Indonesia|One of the 23 countries studied
3001489|NCT02553148||Jordan|One of the 23 countries studied
3001490|NCT02553148||Kenya|One of the 23 countries studied
3001491|NCT02553148||Kyrgyzstan|One of the 23 countries studied
3001492|NCT02553148||Malaysia|One of the 23 countries studied
3001493|NCT02553148||Malawi|One of the 23 countries studied
3001494|NCT02553148||Mexico|One of the 23 countries studied
3001495|NCT02553148||Russia|One of the 23 countries studied
3001496|NCT02553148||Serbia|One of the 23 countries studied
3001503|NCT02553122|Other|Control Group|This group of patients will receive standard protocol to control intra-operative blood loss.
3001504|NCT02553122|Active Comparator|Treatment Group|This group of patients will receive TXA, Evicel and standard protocol to control intra-operative blood loss.
3001505|NCT02553109||small unruptured paraclinoid aneurysm|Patients with newly diagnosed, small (less than 5mm) unruptured paraclinoid aneurysms who will visit one of the study centers during the period from January 2015 to February 2017. Patients would be eligible for enrollment if they were 20 years of age or older and had an unruptured paraclinoid aneurysm that is less than 5 mm in the largest dimension. All patients who would visit a study center during the enrollment period and meet these criteria will be asked to join the study. The cohort will consists of patients who agree to participate. Target population of this study is 645 aneurysms.
3001506|NCT02553096|Experimental|ACCESS|ACCESS is used when participants experience more COPD symptoms.
3001507|NCT02553096|No Intervention|paper plan|Paper exacerbation action plan is used when participants experience more COPD symptoms.
3001508|NCT02553083|Active Comparator|Group 1|Nexium 40 mg and amoxicillin 1.5 gr twice daily for 14 days
3001509|NCT02553083|Active Comparator|Group 2|Nexium 40 mg and doxycycline 200 mg twice daily for 14 days
3001510|NCT02553083|Active Comparator|Group 3|Nexium 20 mg, clarythromicin 500 mg, and amoxicillin 1 gr twice daily for 14 days
3001511|NCT02553070||Pharmacy Students|Participants will be asked to indicate their perception of poisoning severity by answering a short survey.
3001512|NCT02553057|Active Comparator|Group 1|mechanical ventilation with Tidal volume 4 ml/kg and PEEP 8-10 cm H2o
3001513|NCT02553057|Active Comparator|Group2|mechanical ventilation with Tidal volume 6 ml/kg and PEEP 8-10 cm H2o
3001514|NCT02553057|Active Comparator|Group 3|mechanical ventilation with Tidal volume 8 ml/kg and PEEP 8-10 cm H2o
3001515|NCT02553044|Experimental|50 000IU Vitamin D3|50 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
3001516|NCT02553044|Experimental|150 000IU Vitamin D3|150 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
3001517|NCT02553044|Experimental|500 000IU Vitamin D3|500 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
3001518|NCT02553044|No Intervention|Concurrent Control|Control group to receive no intervention.
3001519|NCT02553018|Experimental|Auto-injector of methotrexate|"The Auto-injector is a disposable, fixed, single dose, auto-injector to be used for Methotrexate (25mg/ml) therapy.~Dosage form: solution for injection Dosage: 0.3ml contains 7.5mg of Methotrexate, 0.4ml contains the 10.0mg of Methotrexate, 0.6ml contains 15.0 mg of Methotrexate, 0.8ml contains 20.0 mg of Methotrexate, 1.0ml contains 25.0 mg of Methotrexate.~Frequency: one injection per week Duration: until the end of the study"
3001520|NCT02553018|Active Comparator|Pre-filled syringe of methotrexate|"Pre-filled syringes contains a volume of 1 ml with attached injection needle. Dosage form: solution for injection. Dosage: 0.15 ml contains 7.5 mg of methotrexate, 20 ml contains 10 mg of methotrexate, 0.30 ml contains 15 mg of methotrexate, 0.40 ml contains 20 mg of methotrexate, 0.50 ml contains 25 mg of methotrexate disodium.~Frequency: one injection per week Duration: until the end of the study"
3001521|NCT02553005|Sham Comparator|sham acupuncture|False acupuncture treatment using not acupuncture points
3001522|NCT02553005|Experimental|verum acupuncture|Real acupuncture treatment
3001523|NCT02553005|No Intervention|Control|
3001524|NCT02552992|Experimental|Yoga Classes|Study Participants will receive: 12 weekly yoga classes, a book and a home practice audio recording.
3001525|NCT02552992|Active Comparator|Self-Directed Mind-Body Program|Study Participants will receive: The Back Pain Helpbook, a mind-body self-care program for better living.
3001526|NCT02552966|Experimental|UESAD|Upper Esophageal Sphincter Assist Device
3001527|NCT02552953|Experimental|CYC065|CYC065 will be administered every 3 weeks.
3001528|NCT02552940||Rheumatoid Arthritis participants treated with Tocilizumab SC|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
3001529|NCT02552927|Experimental|CALF|Chest shield with aluminum foil
3001530|NCT02552927|Sham Comparator|SHIELD|Chest shield without aluminum foil
3001531|NCT02552901|Experimental|LFT Dye Detection Monitor|
3001532|NCT02552901|Active Comparator|Serial Blood Draws|
3001533|NCT02552888|Experimental|treatment|Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg by mouth once per day.
3001534|NCT02552888|Placebo Comparator|Placebos|identical placebos.
3001535|NCT02552875|Active Comparator|Tetanic Stimulation|50 Hz tetanic stimulation for 5 seconds before TOF-twitch stabilization at the one arm
3001536|NCT02552875|Active Comparator|Staircase Stimulation|TOF-twitch stabilisation without 50 Hz tetanic stimulation at the contralateral arm
3001537|NCT02552862|Active Comparator|Vivomixx®|"Vivomixx® is a probiotic mixture of 8 proprietary strains. Thirty consecutive patients with cirrhosis and SBP will be randomized to receive Vivomixx® , sachets containing 450 x 109 bacteria, 2 every 12 hours during all the hospitalization until a maximum of 30 days (n=15), or placebo (n=15).~All patients will receive endovenous antibiotics and also intravenous albumin 1.5 g/kg weight the first day and 1 g/kg weight the third day of treatment. The management of patients will follow current guidelines."
3001538|NCT02552862|Placebo Comparator|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
3001539|NCT02552849||Overall study|Specific treatment, dose, and treatment duration will be decided by the investigator independently of the participation of a patient in the study.
3001540|NCT02552836|Experimental|Interpersonal Psychotherapy (IPT)|Patients assigned to IPT will receive 12 sessions of individual therapy of approximately 50 minutes duration. Therapy will be manualized and slightly adapted to meet the needs of patients with Parkinson`s Disease. Therapy focuses on one of four interpersonal events that are linked with onset or maintenance of depression (role transition, role disputes, unresolved grief, and interpersonal deficits).
3001541|NCT02552836|Active Comparator|Supportive Psychotherapy (SP)|Patients assigned to SP will receive 12 sessions of individual therapy of approximately 50 minutes duration. SP strives to create a supportive therapeutic relationship by emphasizing non-specific therapeutic interactions and techniques. Therapy will be manualized,
3001633|NCT02552264|Placebo Comparator|Waitlist control|Acceptance and Commitment Therapy
3001542|NCT02552823|Placebo Comparator|White bread 1|Groups 1 and 2, Visit 1 White bread (equal to 50g available carbohydrate) given to fasting participant
3001543|NCT02552823|Experimental|Pea variety 1 with rice|Group 1,Visit 2-5 Pea variety 1 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
3001544|NCT02552823|Experimental|Pea variety 2 with rice|Group 1, Visit 2-5 Pea variety 2 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
3001545|NCT02552823|Experimental|Pea variety 3 with rice|Group 1, Visit 2-5 Pea variety 3 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
3001546|NCT02552823|Experimental|Rice|Group 1, Visit 2-5 Rice (equal to 50g available carbohydrate) given as breakfast to fasting participants
3001547|NCT02552823|Placebo Comparator|White bread 2|Groups 1 and 2, Visit 6 White bread (equal to 50g available carbohydrate) given to fasting participant
3001548|NCT02552823|Experimental|Pea variety 1 with potato|Group 2, Visit 2-5 Pea variety 1 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
3001549|NCT02552823|Experimental|Pea variety 2 with potato|Group 2, Visit 2-5 Pea variety 2 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
3001550|NCT02552823|Experimental|Pea variety 3 with potato|Group 2, Visit 2-5 Pea variety 3 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
3001551|NCT02552823|Experimental|Potato|Group2, Visit 2-5 Potato (equal to 50g available carbohydrate) given as breakfast to fasting participants
3001552|NCT02552810|Active Comparator|Plasma of Argon|Abutment cleaning by plasma of Argon protocol .
3001553|NCT02552810|Active Comparator|Steam clean|Abutment cleaning by steam clean device.
3001554|NCT02552797|Experimental|Using Power Up|Participants will use 'Power Up' to help them make shared decisions about their treatment or care
3001555|NCT02552797|No Intervention|Not using Power Up|Participants will continue treatment as usual
3001556|NCT02552784|Experimental|patients and their parents with inherited metabolic diseases|The population is a dynamic/open cohort consists of all patients MHMRS diagnosed and supported in one of the six Centers of Reference for Metabolical disease or one of the three Centers of Competence for Hereditary Metabolic Diseases or in the Center of Réference for Hereditary liver Metabolism Diseases since 2000. For each patient, the date of entry into the cohort is the diagnostic date of MHMRS. The study includes all prevalent and incident cases .
3001557|NCT02552771|Active Comparator|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
3001558|NCT02552771|Active Comparator|Mitral repair with leaflet resection|Removal of one or both of the mitral leaflets that flop or bulge back.
3001559|NCT02552758|Experimental|Omega-3 fatty acid|omega-3 fatty acid
3001560|NCT02552758|Placebo Comparator|placebo|placebo
3001561|NCT02552745||study group|parecoxib sodium was administered postoperatively
3001562|NCT02552745||control group|parecoxib sodium was not administered postoperatively
3001563|NCT02552732|Experimental|NHF without Oxygen|Patients without an existing Oxygen prescription will receive NHF without Oxygen using myAIRVO™ 2.
3001564|NCT02552732|Experimental|NHF with Oxygen|Patients with an existing Oxygen prescription will receive NHF with Oxygen using myAIRVO™ 2.
3001565|NCT02552706|Experimental|probiotics group|Administration of probiotics 500mg begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is continuous until preterm infants grow up to 36 weeks post menstrual age.
3001566|NCT02552706|Placebo Comparator|control group|control group received 1 mL of a 5% glucose solution. Administration of control group begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is also continuous until preterm infants grow up to 36 weeks post menstrual age.
3001567|NCT02552693|Experimental|Experimental Facility|"Enhanced training, supervision and support for MOHCC Standard Operating Procedure (SOP) implementation of identifying, tracing and returning to care (tracking and tracing) defaulting mother/infant pairs.~Facilities in the experimental group will receive additional training, supervision and support in identifying, tracing and returning to care defaulting mother/infant pairs."
3001568|NCT02552693|No Intervention|Control Facility|Facilities in the control group will be operating as described in the MOHCC SOP. (Standard practice in tracking and tracing of defaulting mother/infant pairs)
3001569|NCT02552680|Experimental|Exercise + guideline|Participants will participate in eight meetings consisting of exercise and guidelines on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.
3001570|NCT02552680|Active Comparator|brochure|Participants will receive a manual-brochure - containing information about general health.
3001571|NCT02552667|Experimental|HCP1102+HGP0711Placebo|HCP1102Placebo+HGP0711Placebo(1week) -> HCP1102+HGP0711Placebo(4weeks) Each 1 capsule, once daily
3001572|NCT02552667|Active Comparator|HCP1102Placebo+HGP0711|HCP1102Placebo+HGP0711Placebo(1week) -> HCP1102Placebo+HGP0711(4weeks) Each 1 capsule, once daily
3001573|NCT02552654|Experimental|Hydrocortisone and Stress Film|Administration of 10mg hydrocortisone before the trauma film.
3001574|NCT02552654|Experimental|Placebo and Stress Film|Administration of placebo before the trauma film.
3001575|NCT02552641|Experimental|Test 1|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, in fasting conditions, twice daily
3001576|NCT02552641|Experimental|Test 2|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, after meals, twice daily
3001577|NCT02552641|Experimental|Test 3|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, twice daily in schedules variables with an interval of at least 8 hours between the doses
3001578|NCT02552628|Experimental|"Stimulation on"|"The deep brain stimulation is on"
3001579|NCT02552628|Sham Comparator|"Stimulation off"|"The deep brain stimulation is off"
3001628|NCT02552290|Other|Control group|Subjects assigned to the control group will receive no intervention. They will stay behind the curtained research area for approximately 3 minutes in a seated position.
3001670|NCT02551991|Experimental|nal-IRI + 5-FU/LV + oxaliplatin|
3001580|NCT02552615|Experimental|body awareness therapy (BAT)|Each session started with short warm-up, continued with specific exercises. Following each session, verbal reflexions was taken for 10 minutes. Exercises fulfilled in lying, sitting, standing and walking positions. Additionally program included vocal-breathing exercises and massage. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
3001581|NCT02552615|Active Comparator|Traditional exercises|Program included traditional exercises intended for strengthening back, abdominal, pelvis and shoulder girdle muscles and muscles in convex side of the curve, stretching exercises especially for the concave side of the curve, flexibility exercises for spine, postural training and breathing exercises. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
3001582|NCT02552615|Experimental|core stabilization exercises|Exercises started to progress from static to dynamic positions in which muscle activation incorporate into functional tasks including trunk and extremity movements. Local, global muscle stability training, global muscle mobility training and strengthening training of these core structure was carried out progressively advancing more difficult. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
3001583|NCT02552602|Active Comparator|Group A|Study participants in this arm will be given Multivitamin A
3001584|NCT02552602|Active Comparator|Group B|Study participants in this arm will be given Multivitamin B
3001585|NCT02552602|Active Comparator|Group C|Study participants in this arm will be given Multivitamin C
3001586|NCT02552589|Experimental|Test group|Amine fluoride toothpaste
3001587|NCT02552589|Placebo Comparator|Control group|Placebo Sodium monofluorophosphate toothpaste
3001588|NCT02552576|Experimental|Voncento|The frequency and dose of Voncento administration will be determined by the investigator using the information included in the Voncento Summary of product characteristics (SmPC)
3001589|NCT02552563|No Intervention|Usual Care|Standard care received by veterans in the Corporal Michael J. Crescenz VA Medical Center
3001590|NCT02552563|Active Comparator|Dementia Care Management|CG education, continuous support, communication and coping skills training, and veteran monitoring, via CG report, of medication, symptoms, and service needs.
3001591|NCT02552550||Ability to swallow, speak and quality of life|This will just be an evaluation, before any treatment, his ability to swallow, speak and quality of life then, as in normal practice, after 3, 6 and 12 months after treatment.
3001592|NCT02552537|Active Comparator|Omeprazole|patients will take Omeprazole 40mg, in capsules, once a day, during five days before walnut challenge
3001593|NCT02552537|Sham Comparator|Placebo|patients will take Mannitol, in capsules, once a day, during five days before walnut challenge
3001594|NCT02552524|Experimental|rTMS active then rTMS placebo|"A 20 minute session of rTMS active at the frequency of 10 Hz then, 7 days later, a 20 minute session of rTMS placebo (rTMS active then rTMS placebo).~Patient will also have cognitive tests before and after rTMS session and HRV recording during visit."
3001595|NCT02552524|Experimental|rTMS placebo then rTMS active|"A 20 minute session of rTMS placebo then, 7 days later, a 20 minute session of rTMS active at the frequency of 10 Hz (rTMS placebo then rTMS active).~Patient will also have cognitive tests before and after rTMS session and HRV recording during visit"
3001596|NCT02552511||Exposure|Perinatal factors exposure
3001597|NCT02552498|Experimental|vertical|Strangulation is applied on the the buccal side of the attached gingiva, parallel to the long axis of tooth 12, at the distal third of the tooth.
3001598|NCT02552498|Experimental|horizontal|Strangulation is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the tooth 12, 2 mm far from the gingival margin.
3001599|NCT02552498|Experimental|papilla base|Strangulation is applied on the the buccal side of the attached gingiva, on the base of the mesial papilla of tooth 12, in straight line going from one side of papilla to the other.
3001600|NCT02552459|Active Comparator|sufentanil|sufentanil 150μg，intravenous administration during the following 72 hours after operation.
3001601|NCT02552459|Experimental|sufentanil&dexmedetomidine 1|sufentanil 150μg，dexmedetomidine 0.05μg/kg/h，intravenous administration during the following 72 hours after operation.
3001602|NCT02552459|Experimental|sufentani&dexmedetomidine 2|sufentanil 150μg，dexmedetomidine 0.1μg/kg/h，intravenous administration during the following 72 hours after operation.
3001603|NCT02552459|Experimental|sufentanil&dexmedetomidine 3|sufentanil 150μg，dexmedetomidine 0.15μg/kg/h ，intravenous administration during the following 72 hours after operation.
3001604|NCT02552446||All patients|All ICU patients mechanically ventilated staying more than 72 hours were included and indirect calorimetry was performed and compared to predictive energy expenditure formulas using different body weights.
3001605|NCT02552433||Body Contouring Surgery|All patients who undergo BCS after bariatric surgery.
3001606|NCT02552407||Manual Aspiration Thrombectomy with PCI|Subjects from the randomized controlled trials to be included in this meta-analysis will have been randomly allocated to Manual Aspiration Thrombectomy followed by percutaneous coronary intervention (PCI).
3001607|NCT02552407||PCI Alone|Subjects from the randomized controlled trials to be included in this meta-analysis will have been randomly allocated to percutaneous coronary intervention (PCI) alone without manual aspiration thrombectomy.
3001608|NCT02552394|Experimental|HuJ591 Administration|6 subjects will be treated at 300 mg dose. The decision about treating subjects at the lower dose will depend upon their response. If ≥4 of 6 subjects respond at the 300 mg level, then 6 more subjects will be recruited at the 200 mg level. If ≥4 of 6 subjects respond at the 200 mg level than 6 more subjects will be recruited at the next dose level of 100 mg. If ≥ 4/6 subjects respond at this level, then 6 subjects will be recruited at the last dose level of 50 mg. At any level, if the first four consecutive subjects respond, the next two subjects will be enrolled in the same dose-level cohort and further subjects will be recruited at the next dose level. Response at every dose level is defined by conversion from an unfavorable CTC count at baseline to a favorable CTC count.
3001629|NCT02552277|Experimental|PDA-002 Dose Level 1: 3 x 10^6 cells|3 x 10^6 PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
3001630|NCT02552277|Experimental|PDA-002 Dose Level 2: 30 x 10^6 cells|30 x 10^6 PDA-002 cells administered IM on study Days 1, 29, and 57.
3001631|NCT02552277|Placebo Comparator|Placebo|Subjects will receive placebo administered IM on study days 1, 29, and 57.
3001632|NCT02552264|Active Comparator|Immediate intervention|Acceptance and Commitment Therapy
3001609|NCT02552381||Group I|"Patients without LMWH treatment.~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.~The following assays will be performed for these patients :~Fibrin Structure dosed at baseline and every month using prototype assays~Other markers activity : sP selectin for platelet activation, heparanase and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance, all measured at baseline and every 3 months."
3001610|NCT02552381||Group II|"Patients with LMWH treatment at prophylactic dose at enrollment only.~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.~The following assays will be performed for these patients :~Fibrin Structure dosed at baseline and every month using prototype assays,~Anti-FXa activity measured at baseline and every month,~Other markers activity : sP selectin for platelet activation, heparanase and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance, all measured at baseline and every 3 months."
3001611|NCT02552381||Group III|"Patients with LMWH treatment at therapeutic dose.~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.~The following assays will be performed for these patients :~Fibrin Structure dosed at baseline and every month using prototype assays,~Anti-FXa activity measured at baseline and every month,~Other markers activity : sP selectin for platelet activation, heparanase and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance, all measured at baseline and every 3 months."
3001612|NCT02552368|Experimental|Experimental|IpsiHand is a device which includes a robotic glove that you wear on your hand and a headset that you wear on your head. The headset picks up your thoughts and sends them to the robotic glove, to control opening and closing of your hand.
3001613|NCT02552355|Experimental|Metformin: Carbohydrate|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training with post-exercise consumption of a isocaloric carbohydrate beverage. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4.
3001614|NCT02552355|Experimental|Metformin: Protein|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training with post-exercise consumption of a protein beverage. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4.
3001615|NCT02552355|Placebo Comparator|Placebo: Carbohydrate|Daily oral administration of matching placebo with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training with post-exercise consumption of a isocaloric carbohydrate beverage. The dose of matching placebo will begin as one tablet for the first week and will increase by one tablet/day/week until reaching 4 tablets by week 4.
3001616|NCT02552355|Placebo Comparator|Placebo: Protein|Daily oral administration of matching placebo with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training with post-exercise consumption of a protein beverage. The dose of matching placebo will begin as one tablet for the first week and will increase by one tablet/day/week until reaching 4 tablets by week 4.
3001617|NCT02552342|Active Comparator|methylprednisolone|This group was entitled to receive methylprednisolone 80mg/day for 3 days，then 40mg/day for 3 days
3001618|NCT02552342|Placebo Comparator|Placebo|This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug
3001619|NCT02552329|No Intervention|Control group|Since no medication or other treatments are currently approved by Food and Drug Administration (FDA) for treatment of MCI, participants in the usual care group will not receive any form of treatment. They will receive an educational material about cognitive impairment. They will also be asked to maintain their daily routine.
3001620|NCT02552329|Experimental|Tai Chi exercise group|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down.
3001621|NCT02552316|Other|NB-UVB Phototherapy|NB-UVB phototherapy is a therapy which uses ultraviolet B (UVB) light directed at the skin. This type of light therapy is given through the use of phototherapy booths which contain fluorescent tubes that emit UVB light. Booths used for phototherapy look similar to commercial tanning booths. NB-UVB phototherapy affects psoriasis by causing changes to the cells of the skin and producing a local effect by reducing the number of certain types of skin cells which have an impact on psoriasis formation.
3001622|NCT02552303|Active Comparator|CBT for Insomnia (CBTI) + Armodafinil|CBT-I with Armodafinil (active medication)
3001623|NCT02552303|Placebo Comparator|CBTI + Placebo|Cognitive Behavioral Therapy for Insomnia with Placebo medication
3001624|NCT02552303|Active Comparator|Armodafinil|Medication (armodafinil) only, without CBTI.
3001625|NCT02552303|Placebo Comparator|Placebo|Placebo only, without CBTI.
3001626|NCT02552290|Active Comparator|Cervicothoracic manipulation|Description of a Right C7/T1 manipulation. The subject will lie prone. The therapist will stand on the L side of the subject facing in a cephalic direction (towards the patient's head). The therapist's right hand makes contact with the thumb on the right side of the spinous process of the first thoracic vertebra. The therapist left hand supports the head making contact on the temporal bone. The hand/neck is gently laterally flexed to the right, until slight tension is palpated in the tissues. A high-velocity low-amplitude thrust will be applied towards the subjects left side. If cavitation does not occur (an audible pop) the subject will be repositioned and the manipulation attempted a second time. A maximum of 2 attempts will be performed for each side of the neck.
3001627|NCT02552290|Active Comparator|Upper trapezius stretch|"The subjects will be in a supine position. A researcher will passively place the subject's head into flexion, side-bending away and rotation towards the side to be stretched until the muscle barrier is met. The researcher will depress the subject's shoulder with 100 Newtons of force measured with a Micro FET pressure dynamometer (Hoggan Health Industries, Salt Lake City, UT).) Once this pressure amount is achieved the stretch will be held for 30 seconds. This will be repeated two times on each side.~The subject will be asked to provide continuous feedback about the stretch felt and the degree of discomfort (if any) felt during the 30 second stretches."
3001634|NCT02552251|Experimental|A: hydrocortisone|hydrocortisone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
3001635|NCT02552251|Experimental|B :dexamethasone (DECTANCYL)|dexamethasone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
3001636|NCT02552251|Experimental|C : prednisone (CORTANCYL)|prednisone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
3001637|NCT02552238|Experimental|Lumason|Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection
3001638|NCT02552225|Experimental|amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
3001639|NCT02552225|Placebo Comparator|placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
3001640|NCT02552212|Experimental|Certolizumab Pegol 200 mg Q2W|Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.
3001641|NCT02552212|Placebo Comparator|Placebo|Matching placebo to Certolizumab Pegol (CZP) injections are administered every 2 weeks from Week 0 onwards.
3001642|NCT02552199||with hyperhidrosis|Patients with primary hyperhidrosis
3001643|NCT02552199||healthy|Healthy adult patients
3001644|NCT02552186|Active Comparator|Pectus Excavatum Group|The first group (PE Group) will consist of patients presenting to the All Children's Hospital Johns Hopkins Medicine (ACH JHM) Pediatric Surgery or Cardiac Surgery Clinics and the outpatient clinic system at Johns Hopkins Hospital for evaluation of pectus excavatum. Clinical measurements will be obtained using calipers.
3001645|NCT02552186|No Intervention|Control Group|The second group (Control Group) will be age and gender matched patients presenting to the Radiology department of ACH JHM undergoing CT chest for indications other than chest wall deformity.
3001646|NCT02552173||stem anteversion|intraoperative surgeon's estimation and postopertive CT sacn were taken to measure stem anteversion
3001647|NCT02552160||Patients on Duaklir® Genuair®|Patients on fixed-dose combination Duaklir® Genuair® (Aclidinium/Formoterol)
3001648|NCT02552160||Patients on Ultibro® Breezhaler®|Patients on fixed-dose combination Ultibro® Breezhaler® (Glycopyrronium/Indacaterol)
3001649|NCT02552160||Patients on Anoro®|Patients on fixed-dose combination Anoro® (Umeclidinium/Vilanterol)
3001650|NCT02552147|Experimental|Transdermal nicotine first, placebo last|Subject will receive transdermal nicotine 7 mg daily for 7 days, placebo patch for 7 days, then placebo patch for a final 7 days.
3001651|NCT02552147|Experimental|Transdermal placebo first, nicotine last|Subject will receive transdermal placebo daily for 7 days, placebo patch for another 7 days, then transdermal nicotine 7 mg daily for a final 7 days.
3001652|NCT02552134|Experimental|frequent participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence.
3001653|NCT02552134|Experimental|medium participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence
3001654|NCT02552134|Experimental|low participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence
3001655|NCT02552134|Active Comparator|recommendation to be active|"During the stay in the health care resort participants are introduced to be active in the future. They will receive a brochure Physical Activity: Health for all."
3001656|NCT02552121|Experimental|Tisotumab vedotin (HuMax-TF-ADC)|
3001657|NCT02552108|Experimental|Behavioural experiments (CBT)|"Behavioural experiments involve selecting a specific thought to be tested (e.g., uncertainty makes me unable to act) and designing a detailed experiment to test out the thought."
3001658|NCT02552108|No Intervention|Waiting list|12 week wait (with assessments) before being transferred to the experimental condition.
3001659|NCT02552095|Other|Triathlon PKR|Patient who receives the Triathlon.
3001660|NCT02552082|Other|Scorpio NRG|
3001661|NCT02552069|Other|Tritanium® cup|
3001662|NCT02552056|Experimental|CAMH training|"Intervention clinics will receive a CAMH integration package comprising of:~Training PHC workers (midwives, nurses and/or clinical officers) on how to screen and refer for CAMH, based on WHO mhGAP implementation guide.~Support supervision in the clinics to reinforce training and provide on-job support to PHC staff.~Provision of job aids and training materials"
3001663|NCT02552056|No Intervention|No CAMH training|Clinics will continue to provide the standard of care.
3001664|NCT02552043|Experimental|Nintendo Wii exercise program group|The EG will perform a domiciliary Pulmonary Rehabilitation program of 30-60 min exercise, 5 days/week during 6 weeks using a Nintendo Wii platform with the game EA SPORTS ACTIVE 2. The exercise activities were loaded into each participant´s console during the clinical interview and adjusting the exercises according to their age in 2 groups (>12 years and <13 years). The program consisted of 6 different workouts (1st and 2nd weeks: legs exercises; 3rd week: upper limb exercises; 4th week: thorax exercises; 5th and 6th weeks: cardio exercises), so the patients had a gradual increase reaching the maximum load at the end of training.
3001665|NCT02552043|No Intervention|Control group|The CG carried out their routine patient management
3001666|NCT02552030|Experimental|Blood pressure-measurement|Seven repetitive blood pressure measurements will be performed the left or right arm of all participants with an iPhone 4s and a conventional oscillometric device 'cuff device (Omron HBP-1300-E Pro)'
3001667|NCT02552017|Active Comparator|Endocuff Vision-assisted Colonoscopy|Participants in this arm undergo Endocuff Vision-assisted colonoscopy
3001668|NCT02552017|No Intervention|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy
3001669|NCT02552004|Experimental|pCLE|Patients subject to endocrine or digestive surgery will have intraoperative pCLE examination. The installation and surgical opening will be performed according to standard protocols. The contrast agent, fluorescein, will be injected intravenously to allow tissue visualization with pCLE. During the surgery, the surgeon will perform the pCLE examination, to obtain and record video sequences of in situ structures. Frozen sections will be obtained on the same samples and will further guide the surgical decision-making.
3001671|NCT02551978|Experimental|Intervention|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). The game equips the children with knowledge about the core areas nutrition, physical activity, and psychosocial factors.
3001672|NCT02551978|No Intervention|Control|Children in the same primary school, aged between 9 and 12 years do receive basic information during the study phase.
3001673|NCT02551965|Experimental|Caregiver of cancer patient followed in geriatric oncology|caregiver of cancer patient with 70 years old or more, for which a treatment is planned, along with their long term evolution
3001674|NCT02551952|Experimental|MentalPlus® PILOT-I|This preliminary group will be submitted to the digital game MentalPlus®, also be the submitted to fMRI before and after surgery. The results of standardized tests and the data of the MentalPlus® of patients undergoing surgery will be compared with the results of the same tests and the data of the MentalPlus® of healthy volunteers with similar characteristics regarding the variables age and education.
3001675|NCT02551952|Experimental|MentalPlus® PILOT-II|This preliminary group will be of healthy volunteers submitted to the digital game MentalPlus®. The results of standardized tests and the data of the MentalPlus® of volunteers will be compared with the results of tests of patients undergoing surgery and the data of the MentalPlus®.
3001676|NCT02551952|Active Comparator|Group I: MentalPlus®|Evaluated with neuropsychological tests and MentalPlus® before surgery. After surgery, from the 3rd postoperative day a tablet will be use with MentalPlus® in 7 versions for cognitive training during 7 days (7 versions with interfaces adapted for ages up to 20 years and 7 versions for ages over it).
3001677|NCT02551952|Sham Comparator|Group II: MentalPlus®|Ratings with neuropsychological testing and evaluation with MentalPlus® before surgery will be realized. After surgery, from the 3rd postoperative day a tablet will be use for entertainment with short films (20 minutes) for use in the placebo effect of digital game MentalPlus® this group also will be submitted to fMRI before and after surgery. (With the intention to respond to the specificity of findings in relation to the control for active placebo effect)
3001678|NCT02551939|Experimental|fat graft|Autologous Fat Grafting
3001679|NCT02551926|Experimental|mobile text messaging|Patients will receive some SMS in a regular interval.
3001680|NCT02551926|Experimental|virtual communities|Patients will receive some messages by a virtual community in a regular interval.
3001681|NCT02551926|Experimental|brochures|Patients will receive some messages by as a printed media
3001682|NCT02551926|Active Comparator|Control|control group will be included without any intervention
3001683|NCT02551913|Active Comparator|control|The adolescents will not receive any specific information
3001684|NCT02551913|Experimental|Intervention|The adolescents will receive relevant information on the importance of adequate sleep, the consequences of sleep deprivation, Provide information about others' approval,Provide normative information about others' behaviour,Goal setting ,action planning, coping planning, Set graded tasks,Prompt self-monitoring of sleep behaviour
3001685|NCT02551900|Experimental|Warm water exercise & Cold water exercise|
3001686|NCT02551900|Active Comparator|Warm water exercise & Land cycling exercise|
3001687|NCT02551887|No Intervention|Usual Care|Usual Care Only
3001688|NCT02551887|Active Comparator|Automated Reminder|Reminder
3001689|NCT02551887|Experimental|Automated Reminder Plus Script|Provider sees both reminder and script.
3001690|NCT02551874|Experimental|Saxagliptin/Dapagliflozin/Metformin|Oral route. Saxagliptin/Dapa adminsitered once daily for 24 weeks at a dose of 5 mg Saxagliptin and 10 mg Dapagliflozin
3001691|NCT02551874|Active Comparator|Insulin Glargine, Lantos/Metformin|Insulin glargine administered once a day with starting dose of 0.2 Unit per kg or 10 units.
3001692|NCT02551861|Active Comparator|Daclatasvir + Sofosbuvir|Daclatasvir 60mg tablet and Sofosbuvir 400mg tablet oral dosing once daily for 8 weeks
3001693|NCT02551861|Active Comparator|Daclatasvir + Sofosbuvir + Ribavirin|Daclatasvir 60mg tablet + Sofosbuvir 400mg tablet+ Ribavirin 1000-1200mg tablet(weight based dosing) oral dosing split into am and pm once daily for 8 weeks
3001694|NCT02551848|Experimental|Essential tremor treatment|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined by biomechanical analysis of tremulous movements for tremor therapy in both upper extremity every 12 weeks over 72 weeks. BoNT-A dose will range from 50-300 U per arm
3001695|NCT02551835||Tromso Impaired Glucose Tolerance (IGT) study|RCT on 20000 IU vitamin D3/week versus placebo for 1 year among persons with impaired glucose tolerance and/or impaired fasting glucose.
3001696|NCT02551835||Tromso OBESITY study|RCT on 20000 or 40000 IU vitamin D3/week plus 500 mg calcium/day versus placebo plus 500 mg calcium/day for 1 year among persons with a high body mass index.
3001697|NCT02551835||Tromso Bone Mineral Density (BMD) study|RCT on 40000 IU vitamin D3/week plus 800 IU/day and 1000 mg calcium/day versus placebo plus 800 IU/day and 1000 mg calcium/day for 1 year among women with a low bone mineral density.
3001698|NCT02551835||Tromso CLAMP study|RCT on 40000 IU vitamin D3/week versus placebo for 6 months among persons with 25(OH)D values <42 nmol/L.
3001699|NCT02551835||Tromso DEPRESSION study|RCT on 40000 IU vitamin D3/week versus placebo for 6 months among persons with 25(OH)D values <55 nmol/L.
3001700|NCT02551835||Styrian Vitamin D Hypertension Trial|RCT on 2800 IU vitamin D3/day versus placebo for 8 weeks among persons a history of arterial hypertension and 25(OH)D values <75 nmol/L.
3001701|NCT02551835||Paravit study|RCT on 7000 IU vitamin D3/day versus placebo for 6 months among persons with a high body mass index and 25(OH)D values <50 nmol/L.
3001702|NCT02551835||Oosterwerff study|RCT on 1200 IU vitamin D3/day plus 500 mg calcium/day versus placebo plus 500 mg calcium/day for 16 weeks among non-western immigrants with pre-diabetes and 25(OH)D values <50 nmol/L.
3001703|NCT02551835||Chel study|RCT on 600 IU vitamin D3/day (or daily equivalent) versus placebo for 4 months among nursing home residents >70 years of age.
3001704|NCT02551835||Wicherts study|RCT on 800 IU vitamin D3/day versus 100,000 IU/3 months versus sunlight advice for 6 months among non-western immigrants with 25(OH)D values <25 nmol/L.
3001705|NCT02551835||University College Cork (UCC) 1 study|RCT on 200, 400, or 600 IU vitamin D3/day versus placebo for 22 weeks among persons > 63 years of age.
3001706|NCT02551835||UCC 2 study|RCT on 200, 400, or 600 IU vitamin D3/day versus placebo for 22 weeks among persons 20-40 years of age.
3001707|NCT02551822|Active Comparator|Cycling|"Sacral neuromodulator devices (implanted pulse generator) will be programmed to on-off cycles (on 16 seconds, off 8 seconds). This means the devices are not continuously on. Rather they are on a cycling program."
3001708|NCT02551822|Active Comparator|Continuous|"Sacral neuromodulator devices (implanted pulse generator) will be programmed to be on continuously. This means the devices are continuously on. They are on a continuous program."
3001709|NCT02551809|Experimental|3 priming doses followed by 4 boosters|Subjects will receive 7 doses of UB-311.
3001710|NCT02551809|Experimental|3 priming doses followed by 2 boosters|Subjects will receive 5 doses of UB-311 and 2 doses of placebo.
3001711|NCT02551809|Placebo Comparator|Placebo|Subjects will receive 7 doses of placebo.
3001712|NCT02551796|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery.
3001713|NCT02551796|Experimental|laser in situ keratomileusis|The patients in this group chose to receive the laser in situ keratomileusis surgery.
3001714|NCT02551796|Experimental|FS assisted laser in situ keratomileusis|The patients in this group chose to receive the FS assisted laser in situ keratomileusis surgery.
3001715|NCT02551783|Experimental|Urethroplasty with buccal mucosa graft|Intervention: Procedure/Surgery: Urethroplasty with buccal graft. In this arm the graft is placed on the dorsal wall of the urethra.
3001716|NCT02551783|Active Comparator|Ventral Buccal|Intervention: Procedure/Surgery: Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
3001717|NCT02551770|Active Comparator|Test (with Emdogain)|Scaling and root planing with Emdogain
3001718|NCT02551770|Other|Control (without Emdogain)|Scaling and root planing without Emdogain
3001719|NCT02551757|Experimental|Active-CPAP|Patients assigned to active-CPAP were treated with auto-titrating CPAP, where an auto-titrator adjusted the delivered pressure between 4 to 20 cm of water to eliminate obstructive events for a goal apnea-hypopnea index less than or equal to 5.
3001720|NCT02551757|Sham Comparator|Sham-CPAP|The sham-CPAP device in our study was designed to entail no risks beyond those with standard CPAP and provide a high level of blinding. The sham-CPAP device is an auto-titrating CPAP with an internal flow restrictor and a modified elbow attached to the nasal mask. The elbow modification creates a larger than standard air leak that serves to prevent any chances of carbon dioxide rebreathing and delivers a pressure at the mask in¬terface of roughly 0.75 to 1 cm water. The elbow modification is not noticeable when the device is fully assembled to avoid the possibility of unblinding patients, providers, or study personnel. The elbow modification could only be used on standard nasal masks; consequently full facemasks and nasal pillows were excluded for patients in both active and sham-CPAP.
3001721|NCT02551744|Experimental|histamine-2 receptor antagonist group|famotidine 40 mg qd for 6 months.
3001722|NCT02551744|Active Comparator|proton pump inhibitor group|pantoprazole 40 mg qd for 6 months.
3001723|NCT02551731|Experimental|Full Analysis Set - All Participants|The dose of Cannabidiol Oral Solution will begin at 20 mg/kg/day [10 mg/kg twice per day (BID)], will be adjusted at any time if the investigator feels the safety or well-being of the participant is at risk, and will be titrated up or down according to protocol-stipulated parameters and at the investigator's discretion after Day 14 to enhance efficacy. Dose will not exceed 40 mg/kg/day.
3001724|NCT02551718|Experimental|Treatment (chemosensitivity testing, chemotherapy)|Leukemia cells purified from blood or bone marrow samples are analyzed for sensitivity to individual drugs and drug combination and by next generation sequencing.
3001725|NCT02551705|Experimental|functional Imaging mutation carrier|Premanifest mutation carrier, behavioral and neural emotional memory processing
3001726|NCT02551705|Active Comparator|functional Imaging non-carrier|non-carrier family member, behavioral and neural emotional memory processing
3001727|NCT02551692|Placebo Comparator|NRT|
3001728|NCT02551692|Placebo Comparator|VAR|
3001729|NCT02551692|Placebo Comparator|PLAC|
3001730|NCT02551679|Active Comparator|Angiogenic Cell Precursors|Intra-muscular injections of Angiogenic Cell Precursors (ACPs) in the ischemic leg
3001731|NCT02551679|Placebo Comparator|Cell culture medium|Intra-muscular injections of cell culture medium in the ischemic leg
3001732|NCT02551666|Active Comparator|Tai Chi exercise intervention|Participants will perform 30-minute Tai Chi sessions (Yang Short form) 3 times a week for 4 weeks.
3001733|NCT02551666|Experimental|Balance recovery training|Participants will practice balance recovery on a modified treadmill for approximately 30-minutes per session, 3 sessions a week for 4 weeks.
3001734|NCT02551653|Experimental|[11C]-GSK2256098|Subjects will receive single IV bolus injection of [11C]-GSK2256098 over about 30 seconds. Each unit dose will contain up to 500 millibecquerel (MBq) of [11C]-GSK2256098 with maximum [11C]-GSK2256098 mass <=10 microgram (mcg).
3001735|NCT02551640|Experimental|Group A|"Receive a Samsung smartphone~Receive the FeatForward app~Receive a Samsung smartwatch~Continue to receive medical care as usual"
3001736|NCT02551640|No Intervention|Group B|"Receive a Samsung smartphone~Receive a Samsung smartwatch~Continue to receive medical care as usual"
3001737|NCT02551627|Experimental|Test Product|MMN fortified beverage powder [27 gram (g)] made up in 150 milliliter (mL) of water, will be administered orally as a single serve, twice daily for 18 weeks.
3001738|NCT02551627|Active Comparator|Control|Isocaloric beverage powder without micronutrient fortification (27 g), made up in 150 mL of water will be administered orally as a single serve, twice daily for 18 weeks.
3001739|NCT02551614|Experimental|Group 1: healthy subjects|Subjects will undergo inhaled challenge, either with lipopolysaccharide or saline in a 2:1 ratio, prior to imaging assessments. Assessments will be performed during one study day on an outpatient basis.
3001740|NCT02551614|Experimental|Group 2: COPD patients|Subjects will undergo imaging assessments during one study day on an outpatient basis. Approximately 10 of these COPD patients will repeat this study day 7-10 days after completion of the first study day to assess the reproducibility of the technique.
3001741|NCT02551601||Healthy volunteers|to measure the subfoveal choroidal thickness in healthy volunteers
3001742|NCT02551588||Valvular aortic stenosis surgery|"Patients with symptomatic AVS had indication for surgery. They were proposed to have per procedure cardiac biopsy.~They were followed when possible one year after surgery."
3001743|NCT02551588||Valvular aortic stenosis without surgery|These patients with asymptomatic AVS had no indication for surgery. They were followed when possible one year after inclusion.
3001744|NCT02551588||Control subject|Patients without history of cardiac infarction, primary or secondary myocardiopathy or of radiotherapy or chemotherapy.
3001745|NCT02551575|Active Comparator|Treatment of MTX and HCQ|Patients were treated with methotrexate (MTX), hydroxychloroquine (HCQ), oral Qingre Huoxue granule placebo and Qingre Huoxue external preparation placebo.
3001746|NCT02551575|Experimental|Treatment of TCM|Patients were treated with oral Qingre Huoxue granule, Qingre Huoxue external preparation, methotrexate placebo and hydroxychloroquine placebo.
3001747|NCT02551575|Experimental|Integrative Medicine|The patients were treated with methotrexate, hydroxychloroquine, oral Qingre Huoxue granule and Qingre Huoxue external preparation.
3001748|NCT02551562|Placebo Comparator|Group A: Basic Skin Care|Subjects will use a basic skin care regime following a full facial rejuvenation with hyaluronic acid soft-tissue filler and botulinum neurotoxin.
3001749|NCT02551562|Experimental|Group B: NuDerm® System|Subjects will use the Nu-Derm® system following a full facial rejuvenation with hyaluronic acid soft-tissue filler and botulinum neurotoxin.
3001750|NCT02551549|Experimental|CD101 IV|multiple ascending dose intravenous infusion
3001751|NCT02551549|Placebo Comparator|Placebo|normal saline
3001752|NCT02551536|Active Comparator|Group A|FDC tablet of montelukast 10 mg and levocetrizine 5 mg was given once daily for 4 weeks
3001753|NCT02551536|Experimental|Group B|FDC tablet of montelukast 10 mg and fexofenadine 120 mg was given once daily for 4 weeks
3001754|NCT02551523|Experimental|Dolutegravir monotherapy|92 patients will be simplified to once daily dolutegravir monotherapy.
3001755|NCT02551523|Active Comparator|Standard of care combination antiretroviral therapy|46 patients will go on with standard of care combination antiretroviral therapy consisting of either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor or a integrase inhibitor in combination with two nucleoside reverse transcriptase inhibitors.
3001756|NCT02551510|Active Comparator|Suture|Skin incision closure with standard subcuticular technique
3001757|NCT02551510|Active Comparator|Experimental: Histoacryl®|Skin incision closure with topic skin adhesive Histoacryl®
3001758|NCT02551497|Experimental|Other drug|Other drug BID
3001759|NCT02551497|Experimental|placebo|Placebo to match BID
3001760|NCT02551484|Experimental|Procedure 1|Measures with 60 minutes interval during the consultation of equipment, functional testing, receuil pain.
3001761|NCT02551484|Experimental|Procedure 2|Measuring J15, J30 J 45 and after the different settings functional amputation, pain and tissue oxygenation.
3001762|NCT02551471||French patients|
3001763|NCT02551471||Australians patients|
3001764|NCT02551458|Experimental|Arm A: Systematic surgery|
3001765|NCT02551458|Experimental|Arm B: Surveillance and rescue surgery in cases of resectable|
3001766|NCT02551445|Experimental|Gradual exposure to food stimuli|The intervention entails 2 sessions of psychoeducation and a clinical assessment including a discussion on learned food-related fears, role of food-related fears in the maintenance of anorexia nervosa, anxiety and its time course, avoidance, exposure and habituation, irrational fears and safety behaviors; and 8 sessions of in vivo exposure to foods, starting from the least scary food of a hierarchy of threatening foods created by each patient. Each session will involve exposure to a new food item and patients will be encouraged to confront their fear by looking at and touching the chosen food item. They will also be encouraged to eat the food and reflect on the consequences of eating and assessing those relative to their fears (e.g. checking whether they have lost control or changed shape after eating).
3001767|NCT02551432|Experimental|Paclitaxel pembrolizumab|"PD-L1 Induction phase : Paclitaxel 175 mg/m2, Day 1 q 3weeks, intravenous,~Post Induction treatment phase: Paclitaxel 175 mg/m2, Day 1 q 3weeks (maximum up to total 6 cycles) + pembrolizumab 200 mg D1 q 3 weeks, intravenous,~Maintenance phase: pembrolizumab 200 mg D1 q 3 weeks, intravenous till PD or unacceptable toxicity"
3001768|NCT02551419|Experimental|ketogenic drink|MCT ketogenic drink: ketogenic drink providing 30 g/d of MCT oil in 250 ml of lactose-free skim milk for 6 months supplementation
3001769|NCT02551419|Placebo Comparator|Placebo|Lactose-free skim milk-based placebo drink containing high-oleic sunflower oil of equivalent energy value to the active arm for a 6 months supplementation
3001770|NCT02551393|Experimental|Intervention Group|Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home Blood pressure monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
3001771|NCT02551393|No Intervention|Control Group|Usual Care of hypertension in primary care clinic
3001772|NCT02551380|Experimental|Treated|treatment with Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
3001773|NCT02551380|Placebo Comparator|control|treatment with one capsule of placebo twice a day during 12 weeks
3001774|NCT02551367|Experimental|letrozole|patients receive letrozole 2.5 mg twice daily from day 2 to day 6 of the cycle , for 3 consecutive cycles, hcg hormone10.000 iu im injection is given when mature follicle diameter reach 18 mm by trans vaginal ultrasound.
3001775|NCT02551367|Active Comparator|clomiphene citrate|patients will receive clomiphene citrate 50 mg twice daily from day 2 to day 6 of the cycle for 3 consecutive cycles , hcg 10.000 hormone iu im injection is given when mature follicle diameter reach 18 mm by trans vaginal ultrasound .
3001776|NCT02551354|Experimental|Patients|"Pain assess by :~Visual Analogic Scale (VAS).~Portable video pupillometer"
3001777|NCT02551341|No Intervention|control|normal ventilation
3001778|NCT02551341|Experimental|intervention|higher PEEP ventilation
3001779|NCT02551328||Sevofluorane|Patients preconditioned with Sevo
3001780|NCT02551328||Propofol|Patients with no preconditioning
3001781|NCT02551315||Type 2 diabetics, no fractures|Postmenopausal women and men with T2DM, without prevalent fragility fractures (longitudinal follow-up)
3001782|NCT02551315||Type 2 diabetics, prevalent fractures|Postmenopausal women and men with T2DM, with prevalent fragility fractures
3001783|NCT02551315||Controls, no fractures|Age and sex-matched non-diabetic controls, without fragility fractures (longitudinal follow-up)
3001784|NCT02551315||Controls, prevalent fractures|Age and sex-matched non-diabetic controls
3001785|NCT02551302|Other|PLIF|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF).
3001786|NCT02551302|Other|Hybrid system (PLIF + flexible pedicle screw system above the|The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion.
3001787|NCT02551289||Patients|Patients newly diagnosed with Coeliac disease before starting treatment with a gluten free diet
3001788|NCT02551289||Healthy volunteers|Participants who do not meet criteria for a clinical diagnosis of Coeliac disease as determined by screening blood sample.
3001789|NCT02551276|Experimental|Experimental|Beta2-adrenergic stimulation with salbutamol and resistance training for 10 weeks
3001790|NCT02551276|Placebo Comparator|Control|Placebo and resistance training for 10 weeks
3001791|NCT02551263||Observational group|All patients will receive adequate treatment for breast cancer which selected by the primary physician after enrollment using the Japanese Breast Cancer Society Clinical Practice Guideline of Breast Cancer and the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Investigators at the investigational sites will enter patient data into an electronic data capture (EDC) system up to the third chemotherapy in the study.
3001792|NCT02551250||Study|Surveillance of HCC by biannual ultrasonography AND annual noncontrast MRI
3001793|NCT02551237|Active Comparator|Radiochemotherapy|"Patients who will be treated with~radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks associated with~oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.~The surgery will be planned 7 weeks (±1 week) after the end of preoperative treatment"
3001794|NCT02551237|Experimental|Radiotherapy|"Patients who will be treated with radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm) without chemotherapy.~The surgery will be planned 7 weeks (±1 week) after the end of preoperative treatment"
3001795|NCT02551224|Experimental|Breezhaler, then Ellipta|Half of the patients will be assigned to first receive a single dose of placebo via the Breezhaler® followed by a single dose of placebo via the Ellipta® inhalation device. The evaluation questionnaires after using each device.
3001796|NCT02551224|Experimental|Ellipta, then Breezhaler|Half of the patients will be assigned to first receive a single dose of placebo via the Ellipta® followed by a single dose of placebo via the Breezhaler® inhalation device. The evaluation questionnaires after using each device.
3001797|NCT02551211|Experimental|Patients with resectable non-small cell lung cancer|
3001798|NCT02551198|Active Comparator|HAPREP® (PEG-Asc)|"subjects randomized to 2L polyethylene glycol with ascorbic acid (PEG-Asc) were instructed to use PEG-Asc for bowel preparation~: PEG-Asc(500mLx2 times q30min)[PM 7-9, the day before colonoscopy] + PEG-Asc(500mLx2 times q30min)[AM 5-7, the day of colonoscopy]"
3001799|NCT02551198|Experimental|SUCLEAR® (OSS)|"subjects randomized to oral sulfate solution were instructed to use oral sulfate solution (OSS) for bowel preparation~: OSS(1b/177mL)[PM 7-9, the day before colonoscopy] + OSS(1b/177mL)[AM 5-7, the day of colonoscopy]"
3001800|NCT02551185|Experimental|ACY-241 in combination with Paclitaxel|
3001801|NCT02551172|Experimental|experimental sequence|Run-in period → Treatment period HGP0816 20mg 1tab HCP1105 4capsues +Placebo of HGP0816
3001802|NCT02551172|Placebo Comparator|comparative sequence|Run-in period → Treatment period HGP0816 20mg 1tab Placebo of HCP1105 4capsues +HGP0816 20mg
3001803|NCT02551159|Experimental|Monotherapy|MEDI4736 monotherapy.
3001804|NCT02551159|Experimental|Combination Therapy|MEDI4736+Tremelimumab combination therapy
3001805|NCT02551159|Active Comparator|Standard of Care|Standard of Care treatment
3001806|NCT02551146|Experimental|A Locator with retention elements|"GC Pilier Locator abutment with retention elements:~For patients in the experimental group (arm A) the connection of the full dentures to the implants will be achieved by fitting the dentures with GC Pilier Locator abutments with retention elements."
3001807|NCT02551146|Active Comparator|B Locator without retention elements|"GC Pilier Locator abutment without retention elements:~For patients with the active comparator (arm B) the full dentures will get Pilier Locator abutments without retention elements and thus no connection to the implants."
3001808|NCT02551133|Active Comparator|0.1 mg/kg dexamethasone|0.1 mg/kg dexamethasone intravenous will be given 1 h before surgery.
3001809|NCT02551133|Active Comparator|0.2 mg/kg dexamethasone|0.2 mg/kg dexamethasone intravenous will be given 1 h before surgery.
3001810|NCT02551120||Patients|Patients with idiopathic hypoparathyroidism, autosomal dominant hypocalcaemia and pseudohypoparathyroidism.
3001811|NCT02551107|Experimental|Congenital heart disease|"Inclusion criteria: All participants, less than one year of age, with CHD will be eligible for this study with the exception of those patients with only patent foramen ovale (PFO) and patent ductus arteriosus (PDA). The diagnosis of CHD will be confirmed by echocardiography.~Exclusion criteria: Participants with only PDA or PFO, without written informed consent, patients older than one year of age or any subject on oxygen at the time of nNO assessment."
3001812|NCT02551107|Active Comparator|Controls|The control group will consist of age matched infants, less than one year of age, without CHD or acute respiratory illness. The participants will also require written informed consent and will have to be breathing room air at the time of the nNO test.
3001813|NCT02551094|Active Comparator|colchicine|0.5 mg tablet of colchicine taken once a day
3001814|NCT02551094|Placebo Comparator|colchicine placebo|0.5 mg tablet of placebo taken once a day
3001815|NCT02551081||Birth Defects|Neonates were diagnosed as birth defects who were recieving genomic sequencing and personalized treatment in NICU.
3001816|NCT02551068|Experimental|60% Oxgyen|While participants are exercising, they will be breathing 60% oxygen through a mask.
3001817|NCT02551068|Placebo Comparator|Standard of Care|While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
3001888|NCT02550665|Experimental|donepezil 15mg titration|donepezil 15mg during the first 4 weeks before escalation to 23mg
3001818|NCT02551055|Experimental|MLN1117 + TAK-659 (Cohort A)|MLN1117 300, 600 or 900 milligram (mg), tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and TAK-659 100 mg (as determined in study C34001 [NCT02000934]), tablets, orally, once daily, in 28-day treatment cycles until progressive disease or unacceptable toxicity.
3001819|NCT02551055|Experimental|MLN1117 + Alisertib (Cohort B)|MLN1117 300, 600 or 900 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib, 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until progressive disease or unacceptable toxicity.
3001820|NCT02551055|Experimental|MLN1117 + Paclitaxel (Cohort C)|MLN1117 300, 600, or 900 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 milligram per square meter (mg/m^2), infusion, intravenously, once weekly on Days 1, 8, and 15, and 1 week off, in 28-day treatment cycles until progressive disease or unacceptable toxicity.
3001821|NCT02551055|Experimental|MLN1117 + Docetaxel (Cohort D)|MLN1117 300, 600, or 900 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m^2, infusion, intravenously, on Day 1 once every 3 week in 21-day treatment cycles until progressive disease or unacceptable toxicity.
3001822|NCT02551042|Experimental|Active treatment arm|Fibrogammin®P, coagulation factor XIII concentrate (Human) IV infusion
3001823|NCT02551042|Placebo Comparator|Placebo arm|Placebo will be 0.9 % Sodium chloride solution IV infusion
3001824|NCT02551029|Experimental|Duodenal capsaicin infusion|Through a naso-duodenal tube, a capsaicin solution will be infused into the duodenum. After infusion with capsaicin for several minutes, placebo (saline) infusion into the duodenum follows. Thereafter, capsaicin infusion will recommence, followed again by placebo infusion
3001825|NCT02551016||Primary care only|Patients with heart failure recorded in primary care and never hospitalized for heart failure
3001826|NCT02551016||Primary care and secondary care|Patients with heart failure recorded in primary care with at least one record of a heart failure related hospitalization.
3001827|NCT02551016||Secondary care only|Patients with heart failure recorded in at least one heart failure related hospitalization without a concurrent primary care record.
3001828|NCT02551003|Experimental|Cord blood with hypothermia|Autologous cord blood will be collected after birth and stored in Cord Blood Bank of hospital. All cord blood samples are routinely performed by dedicated, trained UCB collection staff and is restricted to deliveries of mothers who have given prior written informed consent for collection. If the mother delivered a baby with signs of HIE or cerebral infarction, Bank staff collected UCB utilizing standard procedures. Collected UCB was transported at roomtemperature in validated shippers to the NICU. Infusions were started when cells and study staff were available for administration and monitoring. Infants received up to 3 infusions, with the first dose as soon as possible after birth, and at, 48, and 72 postnatal hours. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
3001829|NCT02551003|Active Comparator|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
3001830|NCT02550990|Active Comparator|Cognitive training group|One 60-min session of cognitive training. Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment.
3001831|NCT02550990|Active Comparator|Aerobic exercise training group|One 60-min session of aerobic exercise training. Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment.
3001832|NCT02550990|Experimental|Sequential training group|"One 30-min session of aerobic exercise training + one 30-min session of cognitive training.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
3001833|NCT02550977|Experimental|Gestodene/EE Patch|
3001834|NCT02550964||HCQ/CQ|Patients who treated with HCQ(Hydroxychloroquine) or CQ(Chloroquine) for autoimmune diseases such as Rheumatoid arthritis(RA), systemic lupus erythematosus(SLE) will be recruited, and get the composite examination for toxic maculopathy.
3001835|NCT02550951|Experimental|pre-operation Lymphedema|before magnetic resonance imaging(MRI), GADOVIST PFS [Bayer Korea] 7.5mL and local anesthetics 0.5m L mixed. and then 24 gauge needle using about 1 mL by the first , and second , the third the space between the toes intradermal injection , and then about 1-2 minutes , and massage the injection site, and Acquiring an image(coronal T1-weighted three-dimensional gradient-echo sequence) of the foot from a range including up to the pelvis from the comparison with lymphoscintigraphy
3001836|NCT02550951|Experimental|post-operation Lymphedema|before magnetic resonance imaging(MRI), GADOVIST PFS [Bayer Korea] 7.5mL and local anesthetics 0.5m L mixed. and then 24 gauge needle using about 1 mL by the first , and second , the third the space between the toes intradermal injection , and then about 1-2 minutes , and massage the injection site, and Acquiring an image(coronal T1-weighted three-dimensional gradient-echo sequence) of the foot from a range including up to the pelvis from the comparison with lymphoscintigraphy
3001837|NCT02550938|Experimental|7 Aligner Cohort weartime 1|Seven Aligner cohort will change aligners at a designated interval Invisalign is the intervention.
3001838|NCT02550938|Experimental|7 Aligner Cohort weartime 2|Seven Aligner cohort will change aligners at a modified interval Invisalign is the intervention.
3001839|NCT02550938|Experimental|12 aligner cohort weartime 1|Twelve Aligner cohort will change aligners at a designated interval Invisalign is the intervention.
3001840|NCT02550938|Experimental|12 aligner cohort weartime 2|Twelve Aligner cohort will change aligners at a modified interval Invisalign is the intervention.
3001841|NCT02550925|Experimental|Acceptance and Commitment Therapy Group|
3001842|NCT02550925|Active Comparator|Usual Care|
3002002|NCT02549885|Experimental|Static stretching|Static stretching of neck muscles.
3001843|NCT02550912|Active Comparator|Vitamin D group|Patients will receive vitamin D drug with generic name: V drops manufactured by Medical Union Pharmaceuticals, Egypt Dosage form: liquid drops Dosage, frequency, and Duration:1000 international units per day for 3 months then 1000 international units per 25 pounds per day for another 3 months.
3001844|NCT02550912|Placebo Comparator|Placebo group|Patients will receive glucose syrup same taste and color as vitamin D3 drops with same dosage regimen to vitamin D group.
3001845|NCT02550899|Active Comparator|Bulkamid injection treatment group 1|Injection at four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
3001846|NCT02550899|Active Comparator|Bulkamid injection treatment group 2|injection at three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
3001847|NCT02550899|Active Comparator|Bulkamid injection treatment group 3|injection at three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
3001848|NCT02550886||Patient/Caregiver Dyad|
3001849|NCT02550873|Experimental|PRM-151 10mg / kg|Dosing Every 4 Weeks
3001850|NCT02550873|Placebo Comparator|Placebo|Dosing Every 4 weeks
3001851|NCT02550860|Active Comparator|soybean oil (SO)-based IVFE (Medialipide)|
3001852|NCT02550860|Active Comparator|fish oil (FO)-containing IVFE (Lipidem)|fish oil (FO)-containing IVFE (Lipidem)
3001853|NCT02550834|Experimental|Experimental : Curling group|
3001854|NCT02550834|No Intervention|Control : Usual care group|
3001855|NCT02550821|Experimental|1|Patients with Bronchiectasis
3001856|NCT02550821|Active Comparator|2- Control|Healthy subjects
3001857|NCT02550808||Heart failure|
3001858|NCT02550808||Chronic obstructive pulmonary disease|
3001859|NCT02550808||Chronic kidney disease|
3001860|NCT02550808||Malignancy|
3001861|NCT02550808||Controls|
3001862|NCT02550795|Placebo Comparator|Control|administration of 0.9% normal saline 10ml
3001863|NCT02550795|Active Comparator|Dexmedetomidine|administration of 0.5ug/kg of dexmedetomidine (5ml)
3001864|NCT02550795|Active Comparator|Dexmedetomidine and dexamethasone|administration of 0.5 ug/kg of dexmedetomidine and dexamethasone 5mg (total 5ml)
3001865|NCT02550782|Active Comparator|perineural bupivacaine|"patient-controlled infraclavicular perineural bupivacaine~(1% bupivacaine (marcaine), 5 ml bolus dose, infusion rate of 5 ml / h, lockout time 1 hour)"
3001866|NCT02550782|Experimental|perineural dexmedetomidine|"patient-controlled infraclavicular perineural dexmedetomidine~(1% bupivacaine + 200 mic / 100cc dexmedetomidine, 5 ml bolus dose, infusion rate of 5 ml / h, lockout time 1 hour)"
3001867|NCT02550769|Experimental|TRANSANAL TOTAL MESORECTAL EXCISION|Transanal approach of total mesorectal excision.
3001868|NCT02550769|Active Comparator|Laparoscopic-LAR|Type of surgical intervention as control group: Laparoscopic low anterior resection with total mesorectal excision for rectal cancer
3001869|NCT02550756|Experimental|0.2 mg of CNTX-4975|CNTX-4975 will be provided at a capsaicin concentration of 2.0 mg/ml and will be diluted to final concentration using sterile water and 30% PEG 300. Dose volume 1.0 mL-2.0 mL will be used at the discretion of the investigator. Capsaicin concentration will be 0.1 to 0.2 mg/ml
3001870|NCT02550756|Experimental|0.6 mg of CNTX-4975|CNTX-4975 will be provided at a capsaicin concentration of 2.0 mg/ml and will be diluted to final concentration using sterile water and 30% PEG 300. Dose volume 1.0 mL-2.0 mL will be used at the discretion of the investigator. Capsaicin concentration will be 0.3 to 0.6 mg/ml
3001871|NCT02550743|Experimental|Dose 1|BYL719, capectabine and radiation Dose: 200mg/day
3001872|NCT02550743|Experimental|Dose 2|BYL719, capectabine and radiation Dose: 250mg/day
3001873|NCT02550743|Experimental|Dose 3|BYL719, capectabine and radiation Dose: 300mg/day
3001874|NCT02550743|Experimental|Dose -1|BYL719, capectabine and radiation Dose: 150mg/day
3001875|NCT02550730|Experimental|Birth Sisters|Half of the women who agree to participate in the evaluation will be randomized to the Birth Sisters Best beginnings for Babies Program, which includes community doula support and consultation with Medical Legal Partnership when indicated.
3001876|NCT02550730|Active Comparator|Routine care|Half of the women who agree to participate in the evaluation will be randomized to the usual maternity care group
3001877|NCT02550717||Acetylsalicylic Acid|New users of low-dose Acetylsalicylic Acid (ASA)
3001878|NCT02550717||Other medications|Users of other medications such as clopidogrel, oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs)
3001879|NCT02550704|Experimental|Irritable Bowel Syndrome with diarrhea|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability. Intestinal permeability is not routinely performed and is assessed in colonic biopsies (occludin, claudin and ZO-1 by western blot, qPCR and immunofluorescence)
3001880|NCT02550691|Experimental|Subject carrying 3 copies of the SMN1 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
3001881|NCT02550691|Other|Subject carrying 2 copies of the SMN1 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
3001882|NCT02550691|Other|Subject carrying 3 copies of the SMN2 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
3001883|NCT02550678|Experimental|Cohort 1|Study Participants will receive ASN-002 at a dose 5X 10(10) vp, weekly injection in tumor nodules for 3 weeks.
3001884|NCT02550678|Experimental|Cohort 2|Study Participants will receive ASN-002 at a dose of 1.5X 10(11) vp weekly injection in tumor nodules for 3 weeks
3001885|NCT02550678|Experimental|Cohort 4|Study Participants will receive ASN- 002 at a dose of 3.0X 10(11) vp weekly injections in tumor nodules for 3 weeks.
3001886|NCT02550678|Experimental|Cohort 5|Study Participants will receive ASN- 002 at a dose of 2.25X 10(11) vp weekly injections in tumor nodules for 3 weeks.
3001887|NCT02550678|Experimental|Combination Cohorts|Study Participants will receive ASN- 002 at either dose of Cohorts II, IV or V in combination with a low dose 5-FU (1mg/2.5 mg/5mg/10mg or 25mg) weekly injections in tumor nodules for 3 weeks.
3031816|NCT02349607|Active Comparator|pregabalin 300 mg|
3001889|NCT02550665|Experimental|donepezil 10mg & 23 mg alternating|alternating donepezil 10mg and 23mg during the first 4 weeks before escalation to 23mg
3001890|NCT02550665|Active Comparator|no titration of donepezil|no titration and direct escalation to 23mg donepezil
3001891|NCT02550652|Experimental|Obinutuzumab|Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated based on tolerability to a target dose of 2.0 - 2.5 grams per day (g/day) (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.
3001892|NCT02550652|Placebo Comparator|Placebo|Participants will receive placebo matching to obinutuzumab IV infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated based on tolerability to a target dose of 2.0 - 2.5 g/day (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.
3001893|NCT02550639|Active Comparator|A1-prophylaxis group,positive elispot test|POSITIVE ELISPOT TEST, PROPHYLAXIS GROUP (CMV PROPHYLAXIS)
3001894|NCT02550639|Experimental|A2- preemptive group,positive elispot test|POSITIVE ELISPOT TEST, PREEMPTIVE GROUP (NO CMV PROPHYLAXIS)
3001895|NCT02550639|Active Comparator|B1- prophylaxis group,negative elispot test|NEGATIVE ELISPOT TEST, PROPHYLAXIS GROUP (CMV PROPHYLAXIS)
3001896|NCT02550639|Experimental|B2- preemptive group,negative elispot test|NEGATIVE ELISPOT TEST, PREEMPTIVE GROUP (NO CMV PROPHYLAXIS)
3001897|NCT02550626||Delirium|occurrence of post-operative delirium
3001898|NCT02550626||No delirium|no presence of post-operative delirium
3001899|NCT02550600|Experimental|Intervention group|Intervention: iLA activve treatment. iLA activve treatment also requires anticoagulation with un-fractionized heparin and pre-defined PTT-goals (45s-60s depending on blood flow).
3001900|NCT02550600|Active Comparator|Control group|"Controls: standard care according to good clinical practice and recent guidelines; no extracorporeal lung assist.~For ethical reasons patients of the control group can be treated with iLA activve after fulfilling the primary endpoint criterium of an increase in SOFA ≥3 points. These cross-over patients will be analyzed as controls (intention to treat)."
3001901|NCT02550574|Experimental|Wound closure with 2-octylcyanoacrylate|One side of the patient's wound defect will be assigned to wound closure with 2-octylcyanoacrylate liquid bonding agent).
3001902|NCT02550574|Active Comparator|Wound closure with 5-0 vicryl sutures|One side of the patient's wound defect will be assigned to wound closure with 5-0 vicryl sutures.
3001903|NCT02550561|Experimental|Posterior Tibial Nerve Stimulation|PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots. If benefits are obtained, 12 weeks of treatment is followed by spaced maintenance sessions at timing of provider and patient discretion.
3001904|NCT02550548|Experimental|GIP infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP infused at 4 incremental dosages, (initial dose will be 2.0 ng/kg/min, followed by 4.0, 8.0, and 16.0 ng/kg/min). Each dose will be infused continuously for 30 minutes, followed immediately by the next higher dose. The total time of this procedure is 240 minutes.
3001905|NCT02550548|Experimental|GLP-1 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GLP-1 infused at 4 incremental dosages, (initial dose will be 1.0 ng/kg/min, followed by 2.0, 3.0, and 4.0 ng/kg/min). Each dose will be infused continuously for 30 minutes, followed immediately by the next higher dose. The total time of this procedure is 240 minutes.
3001906|NCT02550548|Experimental|GIP + GLP-1 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP + GLP-1 infused simultaneously at 4 incremental dosages (doses will be half the amounts described above). These doses will be infused continuously for 30 minutes, followed immediately by the next higher doses. The total time of this procedure is 240 minutes.
3001907|NCT02550548|Experimental|GIP + Ex-9 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP infused at 4 incremental dosages (as described above) with Ex-9 infused at a steady dose of 2.5 mcg/kg/min starting 90 minutes before the GIP infusion and maintained throughout the clamp experiment. The total time of this procedure is 240 minutes.
3001908|NCT02550535|Experimental|Gene-modified WT1 TCR-transduced T cells|A single dose of bulk WT1 TCR-transduced T cells (≤ 2 x 107/kg) will be intravenously (i.v.) administered following protocol-specified lymphodepletive conditioning regimen. Additionally, daily IL-2 subcutaneous injections (1x106 units/m2 subcutaneously (s.c.)) will be administered for 5 days concomitantly to each subject, following infusion of the ATIMP.
3001909|NCT02550522|Experimental|BCI|Brain-computer interface (BCI) platform including two implanted remotely powered ElectroCorticoGraph (ECoG) recording devices and an exoskeleton
3001910|NCT02550509|Experimental|patients with hemiplegia after stroke|ultrasound echogenicity paraclinical assessment and elastography to patients with hemiplegia following stroke with an indication of injection of botulinum toxin into the triceps sural
3001911|NCT02550496|Experimental|tinea capitis|
3001912|NCT02550483|Active Comparator|Beta-Carotene Tomato Juice|Participants will receive high beta-carotene tomato juice daily as part of controlled diet (base diet + high beta-carotene tomato juice).
3001913|NCT02550483|Active Comparator|Lycopene Tomato Juice|Participants will receive high lycopene tomato juice daily as part of controlled diet (base diet + high lycopene tomato juice).
3001914|NCT02550483|Placebo Comparator|Placebo Beverage|Participants will receive placebo beverage daily as part of controlled diet (base diet + placebo beverage).
3001915|NCT02550470|Active Comparator|Randomized to Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.7,8
3001916|NCT02550470|Active Comparator|Randomized to Drager 800 Absorbent|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
3001917|NCT02550470|Active Comparator|Randomized to Drager Free|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
3001918|NCT02550457|No Intervention|Control group|It will not apply any tape.
3001919|NCT02550457|Experimental|Experimental group 1|Apply the KT with tension in the erector spine muscles.
3001920|NCT02550457|Experimental|Experimental group 2|Apply the KT without tension in the erector spine muscles.
3001921|NCT02550457|Placebo Comparator|Placebo group|Apply Micropore tape in the erector spine muscles.
3001922|NCT02550444|Placebo Comparator|Control|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
3001923|NCT02550444|Experimental|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
3001924|NCT02550444|Experimental|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
3001925|NCT02550418|Experimental|Budesonide|
3001926|NCT02550405|Experimental|Craving behavioral intervention|The craving behavioral intervention (CBI) was developed based on the framework of craving, combining with behavior intervention (Dong and Potenza, 2014), and conducted among individuals with IGD.
3001927|NCT02550405|No Intervention|Control|The control group were individuals with Internet gaming disorder who did not receive any intervention but were scanned twice with the similar interval period as experimental group.
3001928|NCT02550392|Experimental|Group psychoeducation|The intervention group will receive a group psychoeducational intervention (designed in Phase 1: Qualitative study) in addition to self-help leaflets and usual care.
3001929|NCT02550392|No Intervention|Control group|Participants in the usual care control group will continue to receive all other services routinely available to them as is usual practice and will also be provided with self-help leaflets on relevant topics. This group is included to inform the design of a future definitive trial and to document the impact of information provision as part of usual care.
3001930|NCT02550379|Placebo Comparator|Placebo|The placebo protocol consists of 3 phases, baseline, training, and test. The baseline phase consists of 45 trials which calculates the balance point at which the participant rates a face as 'happy' rather than 'disgusted' over a continuum of 15 faces ranging from happy through ambiguous to disgust. 3 training blocks are then administered with 30 trials per block. Behavioural feedback is given during training (correct/incorrect) based on the participant's balance point at baseline. A test phase is then administered which is identical to the baseline phase to reassess the participant's balance point. The task takes approximately 15 minutes to complete all 3 phases.
3001931|NCT02550379|Experimental|Intervention|The ER training protocol consists of 3 phases, baseline, training, and test. The baseline phase consists of 45 trials which calculates the balance point at which the participant rates a face as 'happy' rather than 'disgusted' over a continuum of 15 faces ranging from happy through ambiguous to disgust. 3 training blocks are then administered with 30 trials per block. Behavioural feedback is given during training (correct/incorrect) based on the participant's balance point however this balance point is adjusted by 2 points on the 15 face continuum to train the participant to rate more faces as 'happy'. A test phase, identical to the baseline phase, is then administered to reassess the participant's balance point. The task takes approximately 15 minutes to complete all 3 phases.
3001932|NCT02550366|Other|CMR|Subjects with no contraindication to magnetic resonance imaging, who will undergo cardiac MRI scanning.
3001933|NCT02550353|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery
3001934|NCT02550353|Experimental|FS assisted laser in situ keratomileusis|The patients in this group chose to receive the femtosecond laser-assisted laser in situ keratomileusis surgery.
3001935|NCT02550340||Acute alcohol intake|Visitors of the Munich Octoberfest or similar events who fulfil in- and exclusion criteria
3001936|NCT02550327|Experimental|All Patients|"All patients will receive Nab-paclitaxel, Gemcitabine, Cisplatin, and Anakinra given on Day 1 and 8 of a 21 day cycle (two weeks on with one week rest). Anakinra will be self-administered subcutaneously corresponding with chemotherapy.~The patient will complete a total of 6 cycles of chemotherapy."
3001937|NCT02550314|Experimental|NPC-18,FBG-18|"Intervention drug:~NPC-18;trafermin(recombination) and gelatin spnge, combination drug FBG-18;fibrin glue~Usage:NPC-18 and FBG-18 is administered at the same time for regenerative treatment of tympanic membrane"
3001938|NCT02550301||Mean Platelet Volume|4 blood samples (1 pre procedure before clopidogrel loading) and 3 after Percutaneous Coronary Intervention will be drawn to assess the MPV
3001939|NCT02550288|Active Comparator|Ezetimibe 10 mg|1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.
3001940|NCT02550288|Active Comparator|Atorvastatin 10 mg|1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.
3001941|NCT02550288|Active Comparator|Atorvastatin 20 mg|2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.
3001942|NCT02550288|Experimental|Ezetimibe 10 mg + Atorvastatin 10 mg|1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks
3001943|NCT02550288|Experimental|Ezetimibe 10 mg + Atorvastatin 20 mg|1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks
3001944|NCT02550275|Other|presymptomatic patient|patient with Unified Huntington's Disease Rating Scale (UHDRS) < 5
3001945|NCT02550275|Other|symptomatic patient|patient with Unified Huntington's Disease Rating Scale (UHDRS) > 5
3001946|NCT02550275|Other|controls|unaffected patient with Huntington's disease
3001947|NCT02550262|Experimental|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
3001948|NCT02550262|Experimental|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
3001949|NCT02550262|Experimental|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
3001950|NCT02550262|Experimental|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
3001951|NCT02550249|Experimental|Nivolumab|Nivolumab 3 mg every 2 weeks
3001952|NCT02550236||LIFE Child Health|The LIFE Child HEALTH cohort is a sample of 10.000 children and adolescents. A basic program that will be carried out annually at each study centre visit. This program includes clinical history (perinatal and past medical history, medications, allergies, immunizations, developmental history and family history) clinical examination, collection of blood, hair and urine samples, anthropometry and different age-dependent questionnaires. Questionnaires are completed by the parents and starting at the age of eight years also by the child itself.
3001953|NCT02550236||LIFE Child Obesity|The LIFE Child OBESITY cohort is a sample of 1,500 obese children and adolescents that will be assessed and compared to a lean control group (N=1,500) with equally detailed phenotyping including metabolic and cardiovascular evaluation. The LIFE Child OBESITY cohort (including the control group) performs the basic program of the LIFE Child HEALTH cohort plus additional parameters such as electrical bioimpedance, assessment of basal metabolic rate, oral glucose tolerance test, spiroergometry and measurement of endothelial function using EndoPAT.
3001954|NCT02550236||LIFE Child Health: Pregnancy/Birth|The LIFE child Pregnancy/Birth cohort is a sample of 2,000 pregnant women and their offspring. Prenatal examinations are conducted during the 24th to 26th and 34th to 36th week of gestation. During the first year of life, data is collected from children at 3, 6 and 12 month of age.
3001955|NCT02550223|Experimental|Oblique|Ultrasound guided radial artery catheterization using oblique view obtained by tilting the US probe 30-45 degrees over the course of the artery
3001956|NCT02550223|Active Comparator|Transverse group|Ultrasound guided radial artery catheterization using transverse view
3001957|NCT02550223|Active Comparator|Longitudinal group|Ultrasound guided radial artery catheterization using longitudinal view
3001958|NCT02550210|Experimental|Breast Cancer Locator (BCL)|The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
3001959|NCT02550197|Experimental|QIV Group|Subjects will receive one dose of the Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation
3001960|NCT02550197|Active Comparator|TIV Group|Subjects will receive one dose of the Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation
3001961|NCT02550184|Experimental|Ultrasonography findings unblinded|"Intervention group: Patients in this group will receive a focused ultrasonography examination of the heart and the lungs which will be performed by the investigator.~Intervention: The treating physician receives the results from the ultrasonographic examination (=unblinding of ultrasonography examination results)."
3001962|NCT02550184|Active Comparator|Ultrasonography findings blinded|"Control group: Patients in this group will receive a focused ultrasonography examination of the heart and the lungs which will be performed by the investigator.~Active Comparator: The ultrasonographic examination results will remain blinded for the treating physician."
3001963|NCT02550158|Experimental|Educated Group|"Training of patients by the educational program EDU-MICI"
3001964|NCT02550158|Other|Control group|"During the first 6 months : no training of patients by the educational program EDU-MICI. Then, a crossover allowed uneducated patients to benefit from the educational program the next 6 months."
3001965|NCT02550145|Experimental|Exendin(9-39)|IV infusion of Exendin (9-39).
3001966|NCT02550145|Placebo Comparator|Placebo|IV infusion of normal saline
3001967|NCT02550132|Experimental|Participants|All volunteers will participate in an experimental session. Participants will be delivered four different spinal manipulations (SMT) at T7 with a rate of force application of about 2200 Newtons/seconds and a preload force of 25 Newtons (N). SMTs will differed in their time to peak force (ms) and peak force (N), respectively fixed as follow for each applied SMT: (1)57 ms / 150 N, (2)80 ms / 200 N, (3)102 ms / 250 N and (4)125 ms / 300 N.
3001968|NCT02550119|Experimental|Arm I (aprepitant, dolasetron mesylate, dexamethasone)|Patients receive dolasetron mesylate PO or IV, dexamethasone PO or IV, and aprepitant PO 1 day before chemotherapy and dexamethasone PO and aprepitant PO on days 2 and 3 after chemotherapy begins during course 2-3.
3001969|NCT02550119|Placebo Comparator|Arm II (placebo, dolasetron mesylate, dexamethasone)|Patients receive dolasetron mesylate and dexamethasone as in Arm I and placebo PO 1 day before chemotherapy and dexamethasone PO and placebo PO on days 2 and 3 after chemotherapy begins during courses 2-3.
3001970|NCT02550106|Experimental|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
3001971|NCT02550093|Active Comparator|Oxytocin|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Oxytocin prior to Thermal Evaluation System Testing.
3001972|NCT02550093|Placebo Comparator|Normal Saline|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Normal Saline prior to Thermal Evaluation System Testing.
3001973|NCT02550080|Experimental|The prospective genetic screening arm|Prospective HLA-B*1301 screen before administrated treatment included dapsone
3001974|NCT02550080|Active Comparator|The control arm|No HLA-B*1301 screen before administrated treatment included dapsone
3001975|NCT02550067|Active Comparator|Depot medroxyprogesterone acetate (DMPA)|Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
3001976|NCT02550067|Active Comparator|Levonorgestrel implant (LNG)|Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
3001977|NCT02550067|Active Comparator|Copper T380a IUD|Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
3001978|NCT02550054|Experimental|Erythropoietin|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
3001979|NCT02550054|Placebo Comparator|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
3001980|NCT02550041|Other|Cystic fibrosis|
3001981|NCT02550028|Experimental|Oral levetiracetam|Oral levetiracetam 50 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
3001982|NCT02550028|Active Comparator|Intravenous phenobarbital|Intravenous phenobarbital 20 loading dose (add to 40 mg/kg if seizure discontrol). 5 mg/kg 24 hourly maintenance
3001983|NCT02550015|Experimental|Training|Supervised high intensity interval training (uphill treadmill walking 4 x 4 min at 90-95% of peak heart rate) 3 times weekly for 8 weeks
3001984|NCT02550015|Other|standard care|Standard clinical follow-up care, including general information about importance of physical activity as part of a healthy lifestyle
3001985|NCT02550002||Strict treatment regimen with aflibercept|Treatment intervals with aflibercept in the strict retinal fluid treatment regimen will be extended by two weeks only if no SRF in the central subfoveal field and no IRF can be detected SD-OCT examination.
3001986|NCT02550002||Relaxed treatment regimen with aflibercept|Treatment intervals with aflibercept in the relaxed retinal fluid treatment regimen will be extended by two weeks only if SRF in the central subfoveal field is ≤100 μm in a vertical extent and no IRF is detected on SD-OCT examination.
3001987|NCT02549989|Experimental|LY3023414|This is an MSKCC investigator-initiated, single-center, non-randomized, open-label, phase II study to evaluate the activity of LY3023414 dosed at the RP2D of 200 mg orally twice daily in patients with recurrent or persistent endometrial cancer.
3001988|NCT02549976|Experimental|Evaluation group|"Digestive damage will be assessed on patients by using the methods described in the Lemann index protocol, dependant of Crohn's disease locations.~All patients will have clinical examination and abdominal magnetic resonance imaging analyses. Upper endoscopy, colonoscopy, and pelvic magnetic resonance imaging analyses will be performed according to disease locations :~Upper tract location : upper endoscopy~Colorectal location : colonoscopy~Perianal location : pelvic MRI~All patients : abdominal MRI"
3001989|NCT02549963|Experimental|WATCHMAN LAA Occlusion Device|Subjects assigned to receive the WATCHMAN Left Atrial Appendage Occlusion Device.
3001990|NCT02549963|Active Comparator|Rivaroxaban|Subjects assigned to receive the Rivaroxaban therapy.
3001991|NCT02549950|Active Comparator|Conventional OrthodonticTreatment|Conventional orthodontic mechanics: canine and incisor retraction
3001992|NCT02549950|Experimental|Accelerated Tooth Movement|Accelerated orthodontics: Peizo-Corticision Accelerated canine and Incisor retraction
3001993|NCT02549937|Experimental|Sulfatinib|Dose escalation phase:five sulfatinib dose levels at 50,100, 200, 300 and 400 mg/day will be dosed; Expansion phase: Subjects will receive RP2D sulfatinib daily treatment continuously with every 28-day treatment cycle.
3001994|NCT02549924|Experimental|Resveratrol|Individuals with T2DM inadequately controlled with metformin 2000 mg/day and A1C ≥7%.
3001995|NCT02549924|Placebo Comparator|Placebo|Individuals with T2DM inadequately controlled with metformin 2000 mg/day and A1C ≥7%.
3001996|NCT02549911|Experimental|HIPEC,Chemotherapy AND surgery|"surgical exploration,if PCI<20,then we perform this study~HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~chemotherapy(3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )~after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles"
3001997|NCT02549898|Experimental|Vascular inflammation|Subjects with habitual unilateral migraine without aura, undergo a baseline MRI scan, undergo pharmacological induction of a migraine attack, and subsequently are MRI scanned prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI ).
3001998|NCT02549898|Experimental|Effect of sumatriptan|Subjects with habitual unilateral migraine without aura, undergo a baseline MRI scan and then undergo pharmacological induction of a migraine attack. Sumatriptan is given and subjects subsequently undergo MRI scans prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI).
3001999|NCT02549898|Experimental|Pilot w/o cilostazol|Subjects without habitual unilateral migraine without aura undergo a baseline MRI scan. Subjects are then MRI scanned prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI).
3002000|NCT02549898|Experimental|Pilot w/ cilostazol|Subjects without habitual unilateral migraine without aura undergo a baseline MRI scan and then receive cilostazol. Subjects are then MRI scanned prior (BBI-MRI) to and after Feraheme infusion (USPIO-MRI).
3002001|NCT02549885|Experimental|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
3031817|NCT02349607|Active Comparator|ibuprofen 600 mg|
3002003|NCT02549872||Dementia|Patients with a recorded diagnosis of dementia in primary or secondary care
3002004|NCT02549872||Non-dementia|Patients without a recorded diagnosis of dementia in primary or secondary care
3002005|NCT02549859|Experimental|DBS 60Hz|"Patients will have a randomized double-blind prospective crossover study with usual medication on state under 3 different DBS stimulation frequency condition (60Hz vs 130Hz vs DBS off). Aspiration frequency on modified barium swallowing test and swallowing difficulty on questionnaire, FOG in stand-walk-sit test and questionnaire, and other axial and motor function will be assessed under each DBS condition. Changes in measurements between 60Hz and 130Hz at each visit and under 60Hz between two visits of 8 months apart on average will be analyzed, with swallowing function and FOG as primary, and the rest as secondary outcomes, correcting for potential carryover effect. Changes between other DBS conditions might also be explored in this 2-year study."
3002006|NCT02549859|Experimental|DBS 130Hz|As above
3002007|NCT02549859|Experimental|DBS off|As above
3002008|NCT02549846|Active Comparator|Acute Group|Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment initiated within 24 hours after admission
3002009|NCT02549846|Other|Stable Group|Not start or withdraw Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment for a weak after admission.
3002010|NCT02549833|Experimental|Vaccines before and after surgery|GBM6-AD lysate protein 1 mg and poly-ICLC 1.4 mg administered as one formulation every week leading up to standard-of-care surgery to remove the WHO grade II glioma (Days -23±2, -16±2, -9±2 and 24-48 hours prior to scheduled surgery), every 3 weeks after surgery (Weeks A1, A4, A7, A10, A13, A16; defining Week A1 as the first post-surgery vaccine), and two booster vaccines (Weeks A32 and A48).
3002011|NCT02549833|Active Comparator|Vaccines after surgery only|GBM6-AD lysate protein 1 mg and poly-ICLC 1.4 mg administered as one formulation every 3 weeks after standard-of-care surgery to remove the WHO grade II glioma only (Weeks A1, A4, A7, A10, A13, A16; defining Week A1 as the first post-surgery vaccine) and two booster vaccines (Weeks A32 and A48). Patients will not receive vaccines before surgery.
3002012|NCT02549820|Experimental|FETO|Fetoscopic Endoluminal Tracheal Occlusion (FETO) will be performed by placing a detachable balloon inside the fetal airway and removing the balloon after several weeks.
3002013|NCT02549807||Children muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured (muscle elasticity measure)
3002014|NCT02549807||Adolescent muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured ((muscle elasticity measure)
3002015|NCT02549807||Adult muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured (muscle elasticity measure)
3002016|NCT02549794|Active Comparator|High concentration (370)|CT angiography with hign concentration iodine contrast agent of 370 mg iodine/ml
3002017|NCT02549794|Experimental|Low concentration (320)|CT angiography with low concentration iodine contrast agent of 320 mg iodine/ml
3002018|NCT02549794|Experimental|Low concentration (270)|CT angiography with low concentration iodine contrast agent of 270 mg iodine/ml
3002019|NCT02549781|Experimental|Gambler performing Go-Nogo|"In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
3002020|NCT02549781|Active Comparator|Social layer performing Go-Nogo|"In this study, social player performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
3002021|NCT02549781|Placebo Comparator|non-gamer witnesses performing Go-Nogo|"In this study, non-gamer witnesses performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
3002022|NCT02549768|Active Comparator|Dexmedetomidine|Use of dexmedetomidine during surgery (1 mcg/kg in 10 minutes, then infusion at 0.7 mcg/kg/h)
3002023|NCT02549768|Placebo Comparator|Placebo|"Use of crystalloid solution (sodium chloride 0.9%), injection pump programmed with drug Dexmedetomidine with 1 mcg/kg in 10 minutes, infusion 0.7 mcg/kg/h."
3002024|NCT02549755|Other|Radiotherapy treatment monitoring of hepatocellular carcinoma|All patients enrolled in the trial will undergo 3 PET/CT studies using 11C-acetate at the injected radiotracer. The patients will be imaged prior to their radiation therapy and at 1 and 3 months following the completion of their radiation therapy. They will also undergo an MRI scan of the liver at each of those time points.
3002025|NCT02549742|Experimental|Electrochemotherapy|25 patients treated with electrochemotherapy
3002026|NCT02549729|No Intervention|Control|Control group not using hormonal replacement therapy will not receive supervised pelvic floor muscle training. This group will be assessed at baseline and up to 12 weeks. For ethics reason at the end of the study women of the control group will be invited to receive the pelvic floor muscle training program. However, this will not be part of the study.
3002059|NCT02549521|Active Comparator|Oral magnesium substitution|Daily 240 mg Magnesium Nycomed Pharma. Intervention day 0 - day 28.
3002027|NCT02549729|Experimental|Exercise|Experimental group not using hormonal replacement therapy will receive supervised pelvic floor muscle training.
3002028|NCT02549729|No Intervention|Hormone Therapy|Experimental group using hormonal replacement therapy will not receive supervised pelvic floor muscle training.
3002029|NCT02549729|Experimental|Exercise and Hormone Therapy|Experimental group using hormonal replacement therapy will receive supervised pelvic floor muscle training.
3002030|NCT02549716|Experimental|IV acetaminophen + oral placebo|Patients in this group will receive IV acetaminophen and an oral placebo. The IV formulation will be given using the FDA approved OFIRMEV which comes in a single glass bottle at a concentration of 1000mg/100ml (10mg/ml) containing a total of 1 gram of acetaminophen.
3002031|NCT02549716|Experimental|Oral acetaminophen + IV placebo|Patients in this group will receive oral acetaminophen and a saline solution placebo through their IV. The enteral formulation will be in the standard tablet form of 500mg per pill. Patients will receive two pills, or 1 gram of acetaminophen.
3002032|NCT02549703||Relapsing Remitting Multiple Sclerosis|Patients with Relapsing Remitting Multiple Sclerosis/Clinically Isolated Syndrome
3002033|NCT02549703||Secondary Progressive Multiple Sclerosis|
3002034|NCT02549703||Primary Progressive Multiple Sclerosis|
3002035|NCT02549690|Active Comparator|Testosterone gel|Testosterone gel 10mg, used transdermally, once a day. Treatment duration: 6-8 weeks
3002036|NCT02549690|Active Comparator|DHEA|DHEA 25mg tablet, orally, three times per day. Treatment duration: 6-8 weeks
3002037|NCT02549677|Experimental|EC regimen|Epirubicin, cyclophosphamide
3002038|NCT02549677|Active Comparator|TC regimen|docetaxel, cyclophosphamide
3002039|NCT02549664||LQT/HCM sedentary patients|LQT/HCM sedentary lifestyle
3002040|NCT02549664||LQT/HCM moderate/vigorous exercise|LQT/HCM participate in moderate or vigorous exercise
3002041|NCT02549651|Experimental|MEDI4736|
3002042|NCT02549651|Experimental|MEDI4736 and tremelimumab|
3002043|NCT02549651|Experimental|MEDI4736 and AZD9150|
3002044|NCT02549638||Tissue Collection|We plan to prospectively collect 5 bronchoscopic biopsies, 3ml blood and one tumor and adjacent normal samples from 200 qualified patients who meet the study criteria. If a patient has already had a bronchoscopy and has samples available that were previously collected and stored for research at the Mayo Clinic we will use those samples.
3002045|NCT02549625|Experimental|Single-arm|Intracoronary delivery of autologous bone marrow-derived mononuclear cells using catheterization procedure
3002046|NCT02549612|Experimental|Moniri Otovent|A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to ambu bag balloon. A safety valve is used to prevent too high air pressure. The ambu bag balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. On the first day, a low pressure balloon is used, then it is changed with a higher pressure balloon. If no effect is noticed, (the child should experience clicking sound in one or both ears) after day 3, the balloon is replaced with a new balloon with additionally higher pressure. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one week.
3002047|NCT02549612|No Intervention|Control|No intervention is used in this group.
3002048|NCT02549599|Other|Delayed Treatment|Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered.
3002049|NCT02549599|Experimental|Chat/Text Program|Participants will receive real-time answers to questions they have about sexual and reproductive health topics from trained chat agents via the digital intervention program.
3002050|NCT02549599|Other|Website Content|Participants will be routed to the Planned Parenthood website to information and content about issues regarding sexual and reproductive health.
3002051|NCT02549586|Experimental|Autologous HSCT|Eligible participants will undergo an Autologous Hematopoietic Stem Cell Transplant (HSCT) as a two-step intervention.
3002052|NCT02549573|Active Comparator|Apokyn treatment before physical therapy|"APOKYN treatment before the PT Intervention Visit. Subjects in the APO+ group will administer their usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit."
3002053|NCT02549573|Other|Apokyn treatment withheld before physical therapy|"APOKYN treatment withheld before the PT Intervention Visit. Subjects in the APO- group will not take carbidopa/levodopa and APOKYN for at least 3 hours before or during the PT Intervention Visit. No rescue therapy will be allowed during the PT. Intervention Visit. If the PT Intervention Visit needs to be stopped early, the Physical Therapist will record this along with a reason for the discontinuation."
3002054|NCT02549560|Active Comparator|tDCS GROUP|These patients will be submitted to 2 daily sessions of cerebral stimulation, starting from the first day after the surgery, for 4 consecutive days, with each session having 20 minutes, and a minimum break of 8 hours between them. Will be applied a direct current stimulus of 2 milliampere (mA) in the right anode and in the left cathode on the prefrontal right region.
3002055|NCT02549560|Sham Comparator|CONTROL GROUP|In these patients will be applied, with the same equipment used in tDCS, a simulated stimulus similar to the active one. They will also be submitted to some psychological test to evaluate theirs mnemonics, attentional, executive and global functions.
3002056|NCT02549547|Experimental|Lifestyle Intervention|Physical Activity focused, interdisciplinary, Group Medical Visits (GMVs)
3002057|NCT02549534||Women with Breast Cancer (WBC)|"Defined as women who:~Are 18 to 85 years old at the time of enrollment;~Have histologically-confirmed, first-time, non-metastatic breast cancer (Stage I-IIIB);~Have no history of neurotoxic chemotherapy or radiation treatment at the time of enrollment;~Will be receiving weekly paclitaxel (Taxol® or generic paclitaxel), 80-100mg/m2, or bi-weekly (i.e., dose-dense) Taxol, 175 mg/m2, as a part of their treatment regimen OR~Will be receiving an anthracycline and cyclophosphamide (AC) therapy followed by weekly or bi-weekly (i.e., dose-dense; 175 mg/m2) paclitaxel (Taxol® or generic paclitaxel, 80-100mg/m2);~Are willing to participate in up to four study sessions."
3002058|NCT02549534||Healthy Female Controls (HCs)|"Defined as women who:~Are 18 to 85 years old at the time of study enrollment;~Can read, write, and understand English,~Are willing to participate in three planned study sessions."
3002060|NCT02549521|Placebo Comparator|Magnesium + or Magnesium -|Placebo tablets without magnesium.
3002061|NCT02549508|Experimental|AutoCPAP with SensAwake On|The comfort feature 'SensAwake' will be turned on whilst participants continue to receive PAP therapy
3002062|NCT02549508|Active Comparator|AutoCPAP with SensAwake Off|The comfort feature 'SensAwake' will be turned off whilst participants continue to receive PAP therapy
3002063|NCT02549495||Patients with Diabetes or Hypertension|All patients in the four study communities will receive the community health worker intervention provided by CES, as it is incorporated into the standard of care. However, they will receive the intervention at different points in time depending on which community they lived in, as community health worker programs can only be started at every-three-month intervals
3002064|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 20% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve (Naproxen sodium) 220 mg tablet
3002065|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 30% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet
3002066|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 40% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet
3002067|NCT02549469|Active Comparator|Naproxen sodium 220 mg|Bioequivalence in healthy adult subjects in a fasted state
3002068|NCT02549456|Experimental|Natural orifice specimen extraction|Conventional laparoscopic resection of colorectal cancer with natural orifice specimen extraction
3002069|NCT02549456|Experimental|Laparoendoscopic resection|Laparoscopic assisted transanal endoscopic resection of rectal cancer
3002070|NCT02549443|Active Comparator|Insulin|hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.
3002071|NCT02549443|Active Comparator|Insulin and amino acids|"hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.~Amino Acids (AA) in amounts to preserve normal AA"
3002072|NCT02549443|Active Comparator|Insulin and hyperaminoacidemia|"hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.~AA in amounts to increase AA plasma concentrations to supra-normal levels (hyperaminoacidemia)"
3002073|NCT02549430|Experimental|Arm A|Palbociclib monoterapy
3002074|NCT02549430|Experimental|Arm B|Palbociclib + HT (Anastrozole, Letrozole, Exemestane, Fulvestrant)
3002075|NCT02549417|Experimental|KHK7580|
3002076|NCT02549404|Experimental|KHK7580|
3002077|NCT02549391|Experimental|KHK7580|
3002078|NCT02549391|Active Comparator|KRN1493|
3002079|NCT02549378|Experimental|patients with a hypercapnia test|confocal microscopy patients with a hypercapnia test
3002080|NCT02549365|Experimental|Intervention|Administration of Live attenuated influenza vaccine (LAIV) as per national guidance. Surveillance thereafter through nasal swabbing in the event of influenza-like illness.
3002081|NCT02549365|Other|Controls|Surveillance in siblings of participants in the Intervention arm, through nasal swabbing in the event of influenza-like illness, irrespective of their vaccination status.
3002082|NCT02549352|Experimental|LEO 43204 gel|Treatment once daily for 3 days
3002083|NCT02549352|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
3002084|NCT02549339|Experimental|LEO 43204 gel|Treatment once daily for 3 days
3002085|NCT02549339|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
3002086|NCT02549326|Placebo Comparator|Obese, placebo|Placebo daily for 12 weeks
3002087|NCT02549326|Active Comparator|Obese, vitamin D|Vitamin D3 50 µg / daily for 12 weeks
3002088|NCT02549326|Placebo Comparator|Control, placebo|Placebo daily for 12 weeks
3002089|NCT02549326|Active Comparator|Control, vitamin D|Vitamin D3 50 µg / daily for 12 weeks
3002090|NCT02549313||position changes of head with brain lesion|patient with position changes of the head: registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 °.
3002091|NCT02549300|No Intervention|Control Group|15 patients will be included in control group. Control group will just receive advices about life style modifications, such as teaching good postural habits, using right glasses, not smoking, regular and quality sleep habits.
3002092|NCT02549300|Experimental|Study Group|15 patients will be included in study group. Study group will be treated with connective tissue massage in addition to life style modifications (such as teaching good postural habits, using right glasses, not smoking, regular and quality sleep habits.). Connective tissue massage will be applied 5 times a week, totally 20 sessions in a month. Each session lasts approximately 20-30 minutes. Connective tissue massage will be applied on basic part, lower thoracic, scapular, inter scapular and neck regions.
3002093|NCT02549287|Experimental|SafeCare|SafeCare, an evidence-based home visiting program
3002094|NCT02549287|Active Comparator|Supportive Case Management|Child welfare services as usual
3002095|NCT02549274|Experimental|self-rehabilitation + physiotherapy|Patients will have, in addition to conventional physiotherapy, to visit two training sessions in self-rehabilitation at the hospital. They will then perform a self-rehabilitation / day session.
3002096|NCT02549274|Active Comparator|physiotherapy|Patients will have only conventional physiotherapy
3002097|NCT02549261|Experimental|the tolerance trial of treatment|nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
3002098|NCT02549261|Experimental|A|nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
3002099|NCT02549261|Placebo Comparator|B|chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
3002100|NCT02549248||Idiopathic interstitial diseases|" Test group : patients suffering from idiopathic interstitial lung diseases including sarcoidosis and idiopathic pulmonary fibrosis.~Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen."
3002164|NCT02548832|Active Comparator|Berberine more Placebo|Men and women aged 30 to 60 years with an established diagnosis of mixed dyslipidemia: total cholesterol> 200 mg / dL, triglycerides> 150 mg / dL
3002232|NCT02548338|Other|electric scalpel (ES)|Breast surgery is performed using regular electric scalpel
3002101|NCT02549248||Non idiopathic intertitial diseases|" Control group : patients suffering from interstitial lung diseases of known aetiologies, such as hypersensibility pneumonitis, infectious or cancerous interstitial diseases and interstitial diseases caused by drug reactions.~Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen."
3002102|NCT02549222||Control Cohort|During the Control cohort period patients will have study data collected following transfusion with only conventional PCs for up to 21 days of transfusion support, as clinically indicated in a manner that is consistent with the local standard of care.
3002103|NCT02549222||INTERCEPT Cohort|During the INTERCEPT phase, patients will receive only INTERCEPT PCs and will have study data collected following transfusion for up to 21 days of transfusion support, as clinically indicated in a manner that is consistent with the local standard of care.
3002104|NCT02549209|Experimental|Investigational Treatment|"Subjects with no prior therapy:~Pembrolizumab administered at 200 mg~Paclitaxel administered at 175mg/m2~Carboplatin administered at an AUC of 6~Subjects with prior external beam radiation therapy (XRT) and/or platinum-based chemotherapy must initiate paclitaxel and carboplatin at a reduced dose:~Pembrolizumab administered at 200 mg~Paclitaxel administered at 135mg/m2~Carboplatin administered at an AUC of 5"
3002105|NCT02549196|Active Comparator|Group 1|patients treated with with donepezil 5 or 10 mg/day
3002106|NCT02549196|Active Comparator|Group 2|patients who have never been treated with donepezil before (donepezil naïve) or who have not received any other AChEI for the past 6 months.
3002107|NCT02549183|Active Comparator|Arm 1|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to A KHz
3002108|NCT02549183|Active Comparator|Arm 2|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to B KHz
3002109|NCT02549183|Active Comparator|Arm 3|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to C KHz
3002110|NCT02549183|Active Comparator|Arm 4|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to D KHz
3002111|NCT02549170|Experimental|Epoch 1: HYQVIA/HyQvia|HYQVIA/HyQvia contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20)
3002112|NCT02549170|Placebo Comparator|Epoch 1: Placebo with rHuPH20|Placebo treatment consists of a placebo solution (0.25% human albumin in Lactated Ringer's solution) and rHuPH20
3002113|NCT02549170|Experimental|Epoch 2: IGIV|Intravenous immunoglobulin G treatment
3002114|NCT02549144|Experimental|Low versus high fat/cholesterol diet|The first day of the study protocol a low-fat/low-cholesterol (LFLC) normocaloric diet for 14 days was prescribed to the participants followed by a high-fat/high-cholesterol (HFHC) normocaloric diet for further 14 days.
3002115|NCT02549131|Active Comparator|Suture|Randomizing to Suture closure of Cesarean Section wound. In woman meeting inclusion criteria and not meeting exclusion criteria.
3002116|NCT02549131|Active Comparator|Staples|"Women in this Arm will be assigned to Standard Surgical Staples closure of Cesarean section.~Women will have met inclusion criteria and not meet exclusion criteria and willing to consent to study. Intervention is the randomization to either Arm. Both are standard of care at this facility."
3002117|NCT02549118|Experimental|Tenoxicam|Intravenous administration of tenoxicam, a lyophilisate with 20 mg to be dissolved and diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
3002118|NCT02549118|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
3002119|NCT02549105|Active Comparator|EMLA CREAM|EMLA CREAM 5 mg TOPICAL APPLICATION FOR CS WOUND AND ASSESSMENT FOR POST OPERATIVE PAIN IN FIRST 6 HOURS
3002120|NCT02549105|Active Comparator|LIDOCAINE INFILTERATION|LIDOCAINE 1 % 20 ml INFILTERATION FOR WOUND AND ASSESSMENT OF POST OPERATIVE PAIN IN FIRST 6 HOURS
3002121|NCT02549092|Active Comparator|Optimized Medical Treatment|26 Week Period
3002122|NCT02549092|Experimental|ABT-SLV187|26 Week Period
3002123|NCT02549053|Experimental|Barrett esophagus patients|esophagus biopsies (pathologic and healthy zones)
3002124|NCT02549053|Sham Comparator|control patients|esophagus biopsies (healthy zones)
3002125|NCT02549040|Experimental|MK-1439 fixed sequence treatment|After a minimum 10 hour overnight fast, participants are treated with a single oral dose of MK-1439 over a 5 Period fixed sequence. Each period is separated by a 14 day washout.
3002126|NCT02549027|Experimental|Sequence (MK-1064): 50 mg→250 mg→Placebo→120 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 50 mg MK-1064, Period 2 - single dose of 250 mg MK-1064, Period 3 - single dose of placebo, Period 4 - single dose of 120 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
3002127|NCT02549027|Experimental|Sequence (MK-1064): Placebo→50 mg→120 mg→250 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of placebo, Period 2 - single dose of 50 mg MK-1064, Period 3 - single dose of 120 mg MK-1064, Period 4 - single dose of 250 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
3002128|NCT02549027|Experimental|Sequence (MK-1064): 120 mg→Placebo→250 mg→50 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 120 mg MK-1064, Period 2 - single dose of placebo, Period 3 - single dose of 250 mg MK-1064, Period 4 - single dose of 50 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
3002165|NCT02548832|Active Comparator|Bezafibrate more placebo|Men and women aged 30 to 60 years with an established diagnosis of mixed dyslipidemia: total cholesterol> 200 mg / dL, triglycerides> 150 mg / dL
3034027|NCT02334592|No Intervention|Control group|
3002129|NCT02549027|Experimental|Sequence (MK-1064): 250 mg→120 mg→50 mg→Placebo|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 250 mg MK-1064, Period 2 - single dose of 120 mg MK-1064, Period 3 - single dose of 50 mg MK-1064, Period 4 - single dose of placebo. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
3002130|NCT02549014|Experimental|Panel A: MK-1064 5 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 5 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
3002131|NCT02549014|Experimental|Panel B: MK-1064 10 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 10 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
3002132|NCT02549014|Experimental|Panel A: MK-1064 25 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 25 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
3002133|NCT02549014|Experimental|Panel B: MK-1064 50 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 50 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
3002134|NCT02549014|Experimental|Panel A: MK-1064 100 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 100 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
3002135|NCT02549014|Experimental|Panel B: MK-1064 150 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 150 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
3002136|NCT02549014|Experimental|Panel A: MK-1064 200 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 200 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
3002137|NCT02549014|Experimental|Panel B: MK-1064 250 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 250 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
3002138|NCT02549014|Experimental|Panel A: MK-1064 25 mg (Fed)|In Period 5, participants received a single MK-1064 dose of 25 mg administered in the evening following a standard high-fat breakfast.
3002139|NCT02549014|Experimental|Panel B: MK-1064 50 mg (Night)|In Period 5, participants received a single MK-1064 dose of 50 mg administered in the evening after a 4-hour fast.
3002140|NCT02549014|Placebo Comparator|Panels A & B: Placebo|Within each of up to 5 treatment periods, 2 participants were randomly assigned to receive single oral doses of matching placebo in a fasted stated. There was to be a minimum 7-day washout between treatment periods for any given participant.
3002141|NCT02549001|Experimental|P-3058 10%|P-3058 10%
3002142|NCT02549001|Placebo Comparator|vehicle of P-3058 10%|vehicle of P-3058 10%
3002143|NCT02549001|Active Comparator|amorolfine 5%|Loceryl®
3002144|NCT02548988|Experimental|Healthy|Healthy women are submitted to selective neuromuscular electrical stimulation on VMO.
3002145|NCT02548988|Experimental|Patellofemoral pain syndrome|Women with patellofemoral pain syndrome are submitted to selective neuromuscular electrical stimulation on VMO.
3002146|NCT02548975||Delirium|Patients diagnosed with delirium at any time postoperatively with the CAM-ICU.
3002147|NCT02548975||No delirium|Patients not diagnosed with delirium postoperatively.
3002148|NCT02548962|Experimental|Phase 1: Dose Finding|Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO
3002149|NCT02548962|Experimental|Phase 2: Treatment Arm A|Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO
3002150|NCT02548962|Experimental|Phase 2: Treatment Arm B|Placebo PO+ Pomalidomide PO+ Dexamethasone PO
3002151|NCT02548936|Experimental|Lipid-lowering treatment|The Lipid-lowering treatment is Ezetimibe+Simvastatin Drug Combination by oral administration. The patients in intervention group received simvastatin (10mg/day) + ezetimibe (20 mg/day) combined therapy for 12 month.
3002152|NCT02548936|No Intervention|No lipid-lowering treatment|Without any Lipid-lowering treatment for 12 month.
3002153|NCT02548923|Active Comparator|dexmedetomidine group|Patients who received dexmedetomidine for sedation
3002154|NCT02548923|No Intervention|propofol group|Patients who received propofol for sedation
3002155|NCT02548910|Experimental|Phlebotomy|For patients randomized to phlebotomy, the intervention will consist of the standard of care (low CVP surgery), plus whole blood phlebotomy. Blood will be collected in citrated whole blood collection bag.
3002156|NCT02548910|No Intervention|Control|Standard of care (low CVP surgery). In this arm, standard anesthesia will be maintained.
3002157|NCT02548897|Experimental|Freezing of gait in PD|All participants will undergo an deep brain stimulation (DBS) for the FOG, and an electroencephalography (EEG) to better understand the neurophysiological underpinnings of the symptom. In addition, review changes in scalp recorded EEG and gait parameters during natural FoG episodes while participants are ambulatory in an advanced gait laboratory setting using a wireless EEG amplifier with active electrodes.
3002158|NCT02548884|Active Comparator|Pancreatic sphincterotomy|Pancreatic sphincterotomy technique used in difficult biliary cannulation
3002159|NCT02548884|Active Comparator|Double guide wire|Double guide wire technique used in difficult biliary cannulation
3002160|NCT02548871|Experimental|Teen Outreach Program|Teen Outreach Program
3002161|NCT02548871|No Intervention|Comparison|Business as usual
3002162|NCT02548858|Active Comparator|Perineorrhaphy|Patients who are randomized to receive a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure
3002163|NCT02548858|Active Comparator|No Perineorrhaphy|Patients who are randomized not to receive a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure
3002230|NCT02548351|Experimental|25 mg Obeticholic Acid|25 mg Obeticholic Acid daily for the remainder of the study
3002166|NCT02548832|Experimental|Berberine more Bezafibrate|Men and women aged 30 to 60 years with an established diagnosis of mixed dyslipidemia: total cholesterol> 200 mg / dL, triglycerides> 150 mg / dL
3002167|NCT02548806|Experimental|Clonidine MBT 50µg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50µg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
3002168|NCT02548806|Experimental|Clonidine MBT 100µg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100µg single dose ,a single-dose of reference catapres 100μg tablets..
3002169|NCT02548806|Active Comparator|Catapres 100μg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
3002170|NCT02548793|Active Comparator|VSI Kit|Education: CPR Training using the CPR Anytime VSI Kit Individuals will learn chest-compression only CPR (no rescue breaths) using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
3002171|NCT02548793|Experimental|Mobile Application|Education: CPR Training via Mobile App Individuals will learn chest-compression only CPR (no rescue breaths) using a newly developed mobile training application.
3002172|NCT02548780|Experimental|Chemoembolization + Pharmacokinetics|"First cohort: Chemoembolization with Doxorubicin-loaded LifePearl™ microspheres (TACE): Escalation of dose loaded in microspheres from 75 mg to 150 mg. Pharmacokinetic testing in all patients.~Second cohort: Chemoembolization with doxorubicin-loaded LifePearl™microspheres: microspheres loaded with maximum tolerated dose as established with dose escalation arm. Pharmacokinetic testing in all patients."
3002173|NCT02548767|Experimental|HFCS-EB|Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided energy-balanced diet. The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain 75% of energy requirement. All and only the provided beverage and diet will be consumed for eight weeks.
3002174|NCT02548767|Placebo Comparator|Asp-EB|Consume 3 servings/day of aspartame-sweetened beverage along with the provided energy-balanced diet. The 3 aspartame-sweetened beverages will contain 0% of energy requirement and the remainder of the provided diet will contain 100% of energy requirement. All and only the provided beverage and diet will be consumed for eight weeks.
3002175|NCT02548767|Experimental|HFCS-AL|Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided ad libitum diet. The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain approximately 125% of energy requirement. All the provided beverage will be consumed for eight weeks. Only the provided beverage and diet will be consumed for eight weeks. The provided diet will be consumed ad libitum and the uneaten portions will be returned to study staff.
3002176|NCT02548767|Placebo Comparator|Asp-AL|Consume 3 servings/day of aspartame-sweetened beverage along with the provided ad libitum diet. The 3 aspartame-sweetened beverages will contain 0% of energy requirement and the remainder of the provided diet will contain approximately 125% of energy requirement. All the provided beverage will be consumed for eight weeks. Only the provided beverage and diet will be consumed for eight weeks. The provided diet will be consumed ad libitum and the uneaten portions will be returned to study staff.
3002177|NCT02548754|Experimental|Active|Patients will receive 1 hour of active low level tragus stimulation daily for 6 months
3002178|NCT02548754|Sham Comparator|Sham|Patients will receive 1 hour of sham low level tragus stimulation daily for 6 months
3002179|NCT02548741|Active Comparator|Treatment (Metformin)|Forty patients with elevated glycosylated hemoglobin A1c (HbA1c) > 6.0% (patients with type 2 diabetes mellitus or prediabetes) but HbA1C < 9.0%. They will receive the active comparator (metformin).
3002180|NCT02548741|Placebo Comparator|Placebo|Forty patients with elevated glycosylated hemoglobin A1c (HbA1c) > 6.0% (patients with type 2 diabetes mellitus or prediabetes) but HbA1C < 9.0%. They will receive the placebo comparator.
3002181|NCT02548741|Other|Non-diabetic|Forty matched non-diabetic patients with HbA1C ≤ 5.6%. They will not receive either treatment (metformin) or placebo.
3002182|NCT02548728|Experimental|Oxytocin|Self administration three times on the first day, then twice daily treatment with intranasal oxytocin spray for 4 days.
3002183|NCT02548728|Placebo Comparator|Placebo|Self administration three times on the first day, then twice daily treatment with intranasal spray that does not contain oxytocin for 4 days.
3002184|NCT02548715|Placebo Comparator|Control|Daily placebo
3002185|NCT02548715|Experimental|Treatment|Participants administered daily levothyroxine at 1.6mcg/kg to a target normal TSH, measured at 6 weeks after the initiation of therapy
3002186|NCT02548702|Experimental|Community-based sport|Patients with type 2 diabetes will receive motivational counselling and will be allocated to a low intensity community-based sporting activity (Fit4Life programme) depending on their interests and perceived barriers to taking part.
3002187|NCT02548702|No Intervention|Control|One in 10 participants will be allocated to a control group who do not receive the intervention
3002188|NCT02548689||Non-scarring hair loss|Patients seen at Northwestern Memorial Hospital or Northwestern Medical Faculty Foundation physician offices that have undergone evaluation for hair loss and have a diagnosis of androgenetic alopecia, telogen effluvium or alopecia areata.
3002189|NCT02548689||Control|Age-matched controls who do not have a history of hair loss and have normal scalp skin without evidence of hair loss.
3002190|NCT02548676||Glaucoma Patients|Patients with primary open angle glaucoma
3002191|NCT02548676||Healthy controls|age- and sex matched controls
3002192|NCT02548663|Experimental|active; sport therapy|active exercise carefully calibrated on residual capacities.
3002193|NCT02548663|Experimental|passive; osteopathic treatment|manipulative treatment according to osteopathic principles.
3002194|NCT02548650|Experimental|Patients with diabetes|Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.
3002231|NCT02548351|Placebo Comparator|Placebo|One tablet daily for the remainder of the study
3035153|NCT02327221|Active Comparator|Ovasave - Dose 10e4|
3002195|NCT02548650|Active Comparator|Patients without diabetes|Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.
3002196|NCT02548637|Experimental|Acupuncture Therapy|Based on the Traditional Chinese Medicine theory, investigators will use the systemic treatment methods (full body treatment with the joint specifications). Every patient will receive the standard protocols of these points uniformly regardless of their symptoms. The only variable will be the location of placement of the four electrodes (two positive charges and two negative charges) to the needle points at the most painful joints bilaterally. Needles will be in place a total of 45 minutes per session. The Thermal Design Power (TDP) infrared heat lamp will be applied concurrently to the most painful joint(s) for the entire 45 minutes. Acupuncture will be administered twice a week for 6 weeks, then once a week for an additional 4 weeks.
3002197|NCT02548611|Experimental|Prasugrel|single-dose loading with 60 mg of prasugrel pre PCI
3002198|NCT02548611|Active Comparator|Clopidogrel|loading with 600 mg of clopidogrel pre PCI
3002199|NCT02548598||AIMS-Full Characterization|Participants in this group undergo characterization at the UCSF Airway Clinical Research Center 6 weeks following their scheduled sinus surgery.
3002200|NCT02548598||AIMS-OR|Participants in this group complete limited questionnaires and provide biological samples that are collected during their scheduled sinus surgery. No further characterization in done in this group.
3002201|NCT02548598||AIMS-M|Participants returning to UCSF Sinus Center clinic following sinus surgery who have nasal secretions that are removed by a study clinician will provide samples at these clinic visits.
3002202|NCT02548585|Experimental|MEDI0382|MEDI0382 administered subcutaneously
3002203|NCT02548585|Placebo Comparator|Placebo|Placebo administered subcutaneously
3002204|NCT02548572|Experimental|Treatment group|Subjects in the treatment group will undergo bilateral transcorneal electrical stimulation using OkuStim device once a week for fifty-two weeks
3002205|NCT02548572|Placebo Comparator|Sham group|Subjects in the Sham group will wear the OkuSpex and OkuEl (applied to cornea upon the lower lid) and be attached to the OkuStim device in the same manner as the treatment group, but will receive no electrical stimulation for the 30 minutes that the TES fiber is applied to the cornea (even though the device has been turned on) once a week for fifty-two weeks
3002206|NCT02548559|Experimental|Cannabidiol|1 ml of sublingual cannabidiol tincture (10 mg/ml CBD) administered three times per day (TID) for four weeks.
3002207|NCT02548546|Active Comparator|Surveillance|No Surgery with ECHO and ECG-gated MRA imaging.
3002208|NCT02548546|Active Comparator|Surgery-Open|Open Surgery with ECHO and ECG-gated MRA imaging.
3002209|NCT02548546|Active Comparator|Surgery-EVAR|EVAR with ECHO and ECG-gated MRA imaging.
3002210|NCT02548533|Active Comparator|Region 1|Standard topical anesthesia using eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) applied two hours before treatment.
3002211|NCT02548533|Experimental|Region 2|Anesthesia using articaine hydrochloride 40 mg/ml and epinephrine 10 µg/ml solution (AHES) applied on ablative fractional laser (AFXL) pretreated skin 15 minutes prior to the treatment.
3002212|NCT02548494|Placebo Comparator|Control Group|The control group will receive all traditional methods of treatment for DKA including iv insulin, correction of fluid loss, and electrolyte correction, including a placebo subcutaneous injection.
3002213|NCT02548494|Experimental|Treatment Group|The study group will receive the same treatment including iv insulin, correction of fluid loss, and electrolyte correction, but will be supplemented with a subcutaneous glargine injection.
3002214|NCT02548481||BESTA scale|BESTA scale is administered at T0, T1 (3 months) and T2 (1 year)
3002215|NCT02548468|Experimental|Reduced Intensity Conditioning, DLI, PBSCT|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -11 to -8 and undergo total body irradiation BID on day -7. Patients also receive donor CD3+ enriched T lymphocyte infusion on day -6 and high-dose cyclophosphamide IV over 2 hours on days -3 to -2.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV with taper (drug wean) by day 60 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD."
3002216|NCT02548455|Experimental|Treatment|Subjects implanted with the Quartet 1457Q LV lead
3002217|NCT02548442||Autism Spectrum Disorder|Subjects identified as having Autism Spectrum Disorder using behavioral based methods.
3002218|NCT02548442||Developmental Delay|Subjects identified as having a developmental delay that is not Autism Spectrum Disorder using behavioral methods.
3002219|NCT02548442||Typically Developing Children|Subjects identified as not having a developmental delay or autism spectrum disorder using behavioral methods as well as not having another serious medical or psychological condition.
3002220|NCT02548416|Active Comparator|PEEP group|Induction and maintenance of anaesthesia in a conventional manner. Peroperative ventilatory settings using positive end-expiratory pressure.
3002221|NCT02548416|Active Comparator|Control group zero PEEP|Induction and maintenance of anaesthesia in a conventional manner. Peroperative ventilatory settings using zero end-expiratory pressure.
3002222|NCT02548403|Active Comparator|PEG-Asc|group 1 (PEG-Asc, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
3002223|NCT02548403|Active Comparator|PEG-Asc with simethicone|group 2 (PEG-Asc with simethicone, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure.Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
3002224|NCT02548390|Experimental|RXDX-107|
3002225|NCT02548377|Experimental|Remote ischemic preconditioning|Four 5-minute cycles of upper extremity ischemia, each separated by five minutes of reperfusion. The treatment will be carried out with a tourniquet inflated to 200 mmHg during general anaesthesia prior to flap ischemia and transfer.
3002226|NCT02548377|Sham Comparator|Sham|The tourniquet will be attached to the patient's upper extremity but never inflated.
3002227|NCT02548364|Experimental|Calcifediol|One capsule with 15,690 IU p.o. every two weeks
3002228|NCT02548364|Placebo Comparator|Placebo|One capsule with placebo p.o. every two weeks
3002229|NCT02548351|Experimental|10 mg Obeticholic Acid|10 mg Obeticholic Acid daily for the remainder of the study
3002233|NCT02548338|Other|argon plasma coagulation (APC)|Breast surgery is performed using argon plasma coagulation scalpel
3002234|NCT02548312|Experimental|Review 1- competing interest statement 1|Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.
3002235|NCT02548312|Experimental|Review 1- competing interest statement 2|Variations of financial competing interest statements.
3002236|NCT02548312|Experimental|Review 1- competing interest statement 3|Variations of financial competing interest statements.
3002237|NCT02548312|Experimental|Review 1- competing interest statement 4|Variations of financial competing interest statements.
3002238|NCT02548312|Experimental|Review 2- competing interest statement 1|Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.
3002239|NCT02548312|Experimental|Review 2- competing interest statement 2|Variations of financial competing interest statements.
3002240|NCT02548312|Experimental|Review 2- competing interest statement 3|Variations of financial competing interest statements.
3002241|NCT02548312|Experimental|Review 2- competing interest statement 4|Variations of financial competing interest statements.
3002242|NCT02548299|Experimental|Cooking Lecture|Participants in this arm will receive cooking education through lecture/PowerPoint presentation led by our executive chef. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
3002243|NCT02548299|Experimental|Cooking Demo|Participants in this arm will receive cooking education through observation of our executive chef who will explain cooking techniques and healthy food preparation practices as he cooks a healthy recipe(s) for participants to sample. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
3002244|NCT02548299|Experimental|Hands-on Cooking|Participants in this arm will receive cooking education through hands on practical experience with our executive chef in a teaching kitchen. Participants will be able to sample what they prepare. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
3002245|NCT02548286|Active Comparator|Candesartan and Amlodipine|Candesartan 8mg and Amlodipine 5mg, PO, 1day or 22day
3002246|NCT02548286|Experimental|CKD-330|CKD-330 8/5mg, PO, 1day or 22day
3002247|NCT02548273||Diabetics|diabetics with cataract who opted for phacoemulsification surgery
3002248|NCT02548273||controls|non-diabetics with cataract who opted for phacoemulsification surgery (subjects without corneal opacity, PXF ,high myopia, uveitis)
3002249|NCT02548260|Experimental|Syndactyly without compression|Relative immobilization with a syndactyly (CE conformity), no compression is worn.
3002250|NCT02548260|Experimental|Syndactyly with compression|Relative immobilization with a syndactyly (CE conformity), compression (CE conformity) is worn over the finger
3002251|NCT02548260|Experimental|Rigid splint without compression|Rigid immobilization with a custom made thermoplastic splint (CE conformity), no compression is worn
3002252|NCT02548260|Experimental|Rigid splint with compression|Rigid immobilization with a custom made thermoplastic splint (CE conformity), compression (CE conformity) is worn over the finger
3002253|NCT02548247|Experimental|Orafti® Inulin|Daily consumption of 12g Orafti® Inulin (3x 4g/d) over a period of 4 weeks
3002254|NCT02548247|Placebo Comparator|Placebo|Daily consumption of 12g/ Maltodextrin (3x 4g/d) over a period of 4 weeks
3002255|NCT02548234|Experimental|Mirror therapy|Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
3002256|NCT02548234|Experimental|Bilateral arm training|Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
3002257|NCT02548208|Active Comparator|Verum focused extracorporeal shockwave therapy|Verum focused extracorporeal shockwave therapy is applied at 7 equidistant points, perpendicular to the belly of the biceps brachii muscle on a thought line between the radial tuberosity and the coracoid process (Dermagold120, Tissue Regeneration Technologies, Woodstock, Georgia, U.S.). Shock waves are generated by electrohydraulic mechanisms.
3002258|NCT02548208|Sham Comparator|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy. The study personal is blinded to the applicators. All handling, adjustments and noises are thus same in this group.
3002259|NCT02548208|No Intervention|Control|Control procedure stipulates participants to lay down on the same therapy table for 5 minutes receiving no intervention.
3002260|NCT02548195|Experimental|GEMOX|oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2; every three weeks for 6-8 cycles in total.
3002261|NCT02548195|Active Comparator|Capecitabine|capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
3002262|NCT02548182|No Intervention|control|A standardized education material on diet, exercise, and behavior modification were provided to all participants, and each participant received a one-to-one education on diet and exercise from a trained nurse for 5 minutes each session.
3002263|NCT02548182|Active Comparator|smartcare|Participants allocated to a smartcare arms received the Fit.life™ wireless physical activity tracker (Fit.life™, Suwon, Korea) that measures daily and weekly physical activity. It is convenient for data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer, and has been validated for measurement of free-living physical activity in adults [REF]. Participants allocated to a smartcare arms were also provided a standardized education material on diet, exercise, and behavior modification.
3002264|NCT02548182|Active Comparator|smartcare plus financial incentives|Participants in the 'smartcare plus financial incentive' arms were told that they are entitled to receive financial incentives depending on their achievement of the physical activity and weight target, and the amount they ca expect .The investigators provide financial incentives classified as process-based incentive and outcome-based incentive in addition to smartcare group intervention. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group.
3002265|NCT02548169|Active Comparator|Group 1|Group 1 will consist of patients with resectable, borderline resectable or locally advanced pancreatic cancer. Group 1 will receive DC Vaccine + Standard of Care Chemotherapy.
3002266|NCT02548169|Active Comparator|Group 2|Group 2 will consist of patients with metastatic pancreatic cancer, newly diagnosed/untreated metastatic pancreatic cancer, or metastatic pancreatic cancer who have undergone prior neo-adjuvant therapy. Group 2 will receive DC Vaccine + Standard of Care Chemotherapy.
3002267|NCT02548156|Other|Test dentifrice|1.5g (± 0.05g) of Test dentifrice followed by 10mL of de-ionised water rinse, then 10 mL orange juice rinse
3002268|NCT02548156|Other|Reference dentifrice|1.5g (± 0.05g) of Reference dentifrice followed by 10mL of de-ionised water rinse, then 10 mL water rinse
3002269|NCT02548156|Other|Comparator dentifrice|1.5g (± 0.05g) of Comparator dentifrice followed by 10mL of de-ionised water rinse, then 10 mL orange juice rinse
3002270|NCT02548143|Experimental|Coagulation Factor VIIa (Recombinant)|A dose of 75 μg/kg (minor surgery or invasive procedure) or 200 μg/kg (major surgery or major invasive procedure) of LR769 will be administered as an initial intravenous (IV) bolus dose of LR769 within ≤2 minutes before the surgical incision or start of the invasive procedure. For both minor and major procedures, the initial dose will be followed by repeated administration of 75 µg/kg of LR769 every 2 hours (±5 minutes) for the first 48 hours after completion of the procedure and then as per the dosing schedules in the protocol for major or minor surgeries or invasive procedures. The minimum duration of LR769 treatment for major procedures will be 5 days, and for minor procedures 2 days except for certain procedures that may not require this duration of treatment.
3002271|NCT02548130||Patients before MELD score|Recipients before the MELD score
3002272|NCT02548130||Patients after the MELD score|Recipients after the MELD score
3002273|NCT02548117|Active Comparator|Finasteride|ARM 1 subjects will receive finasteride 5 mg orally daily.
3002274|NCT02548117|No Intervention|No Treatment|The ARM 2 (control group) will not receive any study treatment.
3002275|NCT02548104|Experimental|Adductor canal block (ACB)|Group I Adductor canal block (ACB): 0.25% bupivacaine with 1:200,000 epinephrine 30 ml Anterior Femoral Block (AFB): Saline 15 ml Interspace between the popliteal artery and the capsule of the knee (iPACK) block: Saline 15 ml
3002276|NCT02548104|Active Comparator|ACB + AFB|Group I I Adductor canal block (ACB): 0.25% bupivacaine with 1:200,000 epinephrine 30 ml Anterior Femoral Block (AFB): 0.25% bupivacaine with 1:200,000 epinephrine 15 ml Interspace between the popliteal artery and the capsule of the knee (iPACK) block: Saline 15 ml
3002277|NCT02548104|Active Comparator|ACB + iPACK|Group III Adductor canal block (ACB): 0.25% bupivacaine with 1:200,000 epinephrine 30 ml Anterior Femoral Block (AFB): Saline 15 ml Interspace between the popliteal artery and the capsule of the knee (iPACK) block: 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
3002278|NCT02548104|Active Comparator|ACB + AFB + iPACK|Group IV Adductor canal block (ACB): 0.25% bupivacaine with 1:200,000 epinephrine 30 ml Anterior Femoral Block (AFB): 0.25% bupivacaine with 1:200,000 epinephrine 15 ml Interspace between the popliteal artery and the capsule of the knee (iPACK) block: 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
3002279|NCT02548091|Active Comparator|Preventive non invasive ventilation|Patients will receive the non invasive ventilation (NIV) systematically during the whole procedure of pulmonary angioplasty, and then systematically in post procedure period, 1 hour every 4 hours, during the whole hospitalization in post anesthesia care unit (PACU).
3002280|NCT02548091|Other|Non invasive ventilation on demand|Patients will not receive the NIV during the procedure of pulmonary angioplasty; in case of respiratory decompensation in post procedure period they will receive NIV during the whole hospitalization in PACU according to the following criteria: paradoxical breathing, respiratory rate above 25/minutes, a ratio of arterial oxygen pressure to fraction of inspired oxygen values (PaO2/FiO2) below 200.
3002281|NCT02548078|Experimental|GSK3390107A+Nimenrix Group|Subjects in the GSK3390107A+Nimenrix Group received the investigational GSK3390107A vaccine at the Day 0 visit and Nimenrix at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
3002282|NCT02548078|Experimental|Nimenrix+GSK3390107A Group|Subjects in the Nimenrix +GSK3390107A Group received Nimenrix at the Day 0 visit and the investigational GSK3390107A vaccine at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
3002283|NCT02548065|Active Comparator|Balneotherapy|"Daily thermal-mineral bath with mineral water named Debole of Vetriolo for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)"
3002284|NCT02548065|Placebo Comparator|Placebo|daily thermal bath with tap water bath for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)
3002285|NCT02548052|Experimental|GSK2981278, Vehicle, Betamethasone valerate|All subjects will receive all six treatments (GSK2981278 ointment 0.03%, 0.1%, 0.8%, 4%, vehicle to match GSK2981278 ointment and betamethasone valerate 0.1% cream); with random assignment of the treatments to 6 test fields on identified stable plaque(s) on the upper extremities, thighs and/or trunk. Subjects will be treated once-daily (except Days 7 and 14) over 19 days (a total of 16 applications) under semi-occlusive conditions (covered by an adhesive non-woven fabric).
3002286|NCT02548039||Asian Normogonadotrophic Anovulatory Women|Asian women with normal gonadotropin levels but do not ovulate.
3002287|NCT02548026|Experimental|High Eating Frequency (High EF)|8 Eating Occasions
3002288|NCT02548026|Experimental|Low Eating Frequency (High EF)|3 Eating Occasions
3002289|NCT02548013|Experimental|Home management|outpatient management patients if stable will be discharged to continue treatment at home
3002290|NCT02548013|Active Comparator|hospital management|Inpatient management patients will continue there treatment in hospital till delivery
3002291|NCT02548000|Experimental|Resistance training|Resistance training will be performed three times a week, for 12 weeks, composed by 12 resistance exercises for all body muscles with 2-3 series and 12-8 repetitions in each exercise.
3002292|NCT02548000|Active Comparator|Stretching control|The control group will perform one stretching session a week.
3002293|NCT02547987|Experimental|Docetaxel/Carboplatin|Docetaxel 75 mg/m2 plus Carboplatin AUC 6 IV on Day 1 of each 21 day cycle for 6 cycles
3002329|NCT02547779|Active Comparator|Physiologically-balanced|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
3002294|NCT02547974|Experimental|GSK3277513A F1 Group|Subjects, 18 - 40 years, receiving two doses of the non adjuvanted GSK Biologicals' NTHi Mcat investigational vaccine (GSK3277513A ) containing formulation 1 (F1) of PD, PE-PilA and UspA2 during Step 1 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
3002295|NCT02547974|Experimental|GSK3277513A F2 Group|Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 2 (F2) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
3002296|NCT02547974|Experimental|GSK3277513A F3 Group|Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 3 (F3) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
3002297|NCT02547974|Placebo Comparator|Placebo Group|Subjects, 18 - 40 years, receiving two doses of placebo (saline solution) during Step 1 of the study and subjects, 50 - 70 years, receiving two doses of placebo (saline solution) during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
3002298|NCT02547961|Experimental|HER2-CAR-T|In interventional studies, participants are assigned to accept HER-2-targeting CAR T Cells infusion so that researchers can evaluate the effects and safety of the CAR-T cell.
3002299|NCT02547961|No Intervention|No Intervention|
3002300|NCT02547948|Experimental|CAR T cells|In interventional studies, participants are assigned to accept CD19-targeting CAR T Cells infusion so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. Arm refers to each group or subgroup of participants in a clinical trial that receives specfic interventions (or no intervention) according to the study protocol. This is decided before the trial begins.
3002301|NCT02547948|No Intervention|No Intervention|
3002302|NCT02547935|Experimental|Dapagliflozin 10mg|Tablets administered orally once daily for 24 weeks
3002303|NCT02547935|Experimental|Dapagliflozin 10mg + Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks
3002304|NCT02547935|Placebo Comparator|Placebo|Tablets administered orally once daily for 24 weeks
3002305|NCT02547922|Experimental|Anifrolumab - Lower Dose|Anifrolumab - Lower Dose
3002306|NCT02547922|Experimental|Anifrolumab - Higher Dose|Anifrolumab - Higher Dose
3002307|NCT02547922|Placebo Comparator|Placebo|Placebo IV Q4W plus SOC
3002308|NCT02547909|Experimental|Study group|a probe-based Confocal Laser Endomicroscopy examination will be done using a standard recto-sigmoidoscopy, in women suffering from endometriosis who are referred for a TRUS examination as part of a suspected deep endometriosis diagnostic workup. pCLE images will be compared to normal bowel mucosa.
3002309|NCT02547896|Experimental|Pain control using codeine + diclofenac|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, receiving for pain relief after the procedure 50mg of codeine + 50mg of diclofenac
3002310|NCT02547896|Experimental|Pain control using diclofenac|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, receiving for pain relief after the procedure 50mg of diclofenac
3002311|NCT02547883|Experimental|Patients stopping statin|
3002312|NCT02547883|No Intervention|Patients continuing statin|
3002313|NCT02547870|Experimental|Rilpivirine Long-Acting Parenteral Formulation (RPV‐LA)|Participants will receive oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1 and intramuscular (IM) injection of rilpivirine long‐acting parenteral formulation 600 mg once on day 1 of session 2.
3002314|NCT02547870|Experimental|Aged RPV‐LA|Participants will receive oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1 and IM injection of aged rilpivirine long‐acting parenteral formulation 600 mg once on day 1 of session 2.
3002315|NCT02547857||Cohort 1|All women who undergo pelvic US in the ED, assuming they meet inclusion/exclusion criteria
3002316|NCT02547844|Active Comparator|efavirenz + emtricitabina + tenofovir|Patients assigned to the control group will continue receiving the same medication than before to be included in the study: Atripla (efavirenz + emtricitabina + tenofovir)
3002317|NCT02547844|Experimental|rilpivirina + emtricitabina + tenofovir|Patients assigned to the experimental group will change the medication that are taking before to enter in the study ( atripla) for eviplera (rilpivirina + emtricitabina + tenofovir)
3002318|NCT02547831||Observational approach|Patients will be placed on wait and see approach and then shifted to specific treatment in case of progression
3002319|NCT02547818|Active Comparator|Group I|ALZT-OP1a active capsules for inhalation and ALZT-OP1b placebo capsules for oral administration.
3002320|NCT02547818|Active Comparator|Group II|ALZT-OP1a active capsules for inhalation and ALZT-OP1b active tablets for oral administration.
3002321|NCT02547818|Active Comparator|Group III|ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b active tablets for oral administration.
3002322|NCT02547818|Placebo Comparator|Group IV|ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b placebo tablets for oral administration.
3002323|NCT02547805|Placebo Comparator|Placebo|Five (5) capsules of placebo by mouth (PO) three times per day (TID) with meals
3002324|NCT02547805|Experimental|ALLN-177|Five (5) capsules of ALLN-177 (1,500 units per capsule) PO TID with meals
3002325|NCT02547792|Experimental|VXA-BYW.10 (Low Dose) Oral Vaccine|Single administration of Influenza B (Low Dose) oral vaccine tablets
3002326|NCT02547792|Experimental|VXA-BYW.10 (High Dose) Oral Vaccine|Single administration of Influenza B (High Dose) oral vaccine tablets
3002327|NCT02547792|Placebo Comparator|Placebo Tablets|Matching placebo dose (size and number of tablets) to low dose vaccine (part 1) and high dose (part 2)
3002328|NCT02547779|Active Comparator|0.9% Saline|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
3002549|NCT02546310|Placebo Comparator|HTL0009936 matching placebo|matching infusion
3002330|NCT02547766|Experimental|Anakinra Arm|All patients in this arm receive Anakinra in a pre-post design. That is, outcome markers are measured, the intervention (Anakinra) is applied, and the outcome markers are measured again at various intervals to determine effect.
3002331|NCT02547753||Transplanted group|patients who are kidney receptors for at least 6 months and need tooth extraction
3002332|NCT02547753||Control group|healthy patients who need tooth extraction
3002333|NCT02547740||Early Glaucomatous Damage|Patients with early functional glaucomatous damage.
3002334|NCT02547740||Ophthalmologically Healthy|Healthy subjects that are ophthalmologically normal
3002335|NCT02547727|Experimental|Four-site intradermal vaccination|0.1 ml of rabies vaccine is distributed to 4 sites over both arms and thigh intradermally on day 0. Blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
3002336|NCT02547727|Active Comparator|Intramuscular vaccination|0.5 ml of rabies vaccine is injected to one arm on day 0 and 3.Blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
3002337|NCT02547714|Experimental|Secukinumab (AIN457) 300 mg|Participants received secukinumab 300 mg subcutaneously (s.c.) (two 150 mg injections) on Day 1 and at Weeks 1, 2, 3, 4, 8 and 12.
3002338|NCT02547701|Experimental|P-3058|
3002339|NCT02547688|Other|Nasal High Flow|All subjects are in this group
3002340|NCT02547662|Experimental|Treatment (ixazomib citrate, pomalidomide, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3002341|NCT02547649|Experimental|V114 Formulation A|Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1
3002342|NCT02547649|Experimental|V114 Formulation B|Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1
3002343|NCT02547649|Active Comparator|Prevnar 13™|Participants receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1
3002344|NCT02547636||Subjects/specimens that meet the inclusion criteria|Subjects/specimens that meet the inclusion criteria
3002345|NCT02547623|Active Comparator|dexamethasone depot|dexamethasone depot 517 mcg
3002346|NCT02547623|Active Comparator|standard of care|prednisolone drops 1%
3002347|NCT02547597|Experimental|Carvedilol|Carvedilol 25 mg twice a day
3002348|NCT02547597|Active Comparator|Atenolol|Atenolol 50 mg twice a day
3002349|NCT02547584|Active Comparator|Group 1: with baseline anxiety+catheter ablation|Baseline anxiety will be defined as; Cardiac Anxiety Questionnaire (CAQ) score >2.14 Hospital Anxiety and Depression Questionnaire (HAD) >7 State-Trait Anxiety Inventory (STAI): State-anxiety score >40
3002350|NCT02547584|Active Comparator|Group 2: Without baseline anxiety + catheter ablation|Cardiac Anxiety Questionnaire (CAQ) score <2.14 Hospital Anxiety and Depression Questionnaire (HAD) <7 State-Trait Anxiety Inventory (STAI): State-anxiety score <40
3002351|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, split-dose; 3)Clear liquid|
3002352|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, split-dose; 3)Low residue|
3002353|NCT02547571|Active Comparator|1) Early colonoscopy; 2) Low volume split-dose; 3)Clear liquid|
3002354|NCT02547571|Active Comparator|1) Early colonoscopy; 2) Low volume split-dose; 3)Low residue|
3002355|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, day before; 3)Clear liquid|
3002356|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, day before; 3)Low residue|
3002357|NCT02547571|Active Comparator|1) Later colonoscopy; 2) High-dose, split-dose; 3)Clear liquid|
3002358|NCT02547571|Active Comparator|1) Later colonoscopy; 2) High-dose, split-dose; 3)Low residue|
3002359|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume split-dose; 3)Clear liquid|
3002360|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume split-dose; 3)Low residue|
3002361|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume day before; 3)Clear liquid|
3002362|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume day before; 3)Low residue|
3002363|NCT02547558|Experimental|Indacaterol|"Drug:~-Indacaterol, inhaled, single dose, 300 mcg~Diagnostic Interventions:~Arterial blood gases~Cardiac output~Vital signs~Exhaled breath~Spirometry"
3002364|NCT02547545||All|The side effects after chemotherapy were observed for all patients. Potential risk factors would be explored for the side effects such as chemotherapy realted vomit.
3002365|NCT02547532||usual COPD|Patients meeting the diagnostic criteria for COPD and without AATD
3002366|NCT02547532||normal smokers|subjects with a history of smoking, without symptoms, without AATD and with normal lung function
3002367|NCT02547532||normal non smokers|subjects without a history of smoking, without symptoms, without AATD and with normal lung function
3002368|NCT02547532||AATD not treated|patients with COPD, with AATD and not on augmentation therapy for AATD
3002369|NCT02547532||AATD treated|patients with COPD, with AATD on augmentation therapy for AATD
3002370|NCT02547519|Experimental|oral insulin capsule (dose escalation using 3 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 22.5 mg rH-insulin crystals; dose 3 is 67.5 mg rH-insulin crystals. The insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) and contained in hard gelatine capsules. The study treatment will be given orally.
3002371|NCT02547519|Placebo Comparator|Placebo capsule|Daily treatment with placebo capsules containing filling substance (microcrystalline cellulose).
3002372|NCT02547506||Parkinson Disease (Boxing)|Individuals with Parkinson Disease who participate in boxing on a regular basis
3002373|NCT02547506||Parkinson Disease (Group Exercise)|Individuals with Parkinson Disease who participate in group exercise other than boxing on a regular basis
3002374|NCT02547506||Healthy Controls|Individuals without disability who participate in group exercise other than boxing on a regular basis
3002375|NCT02547493|Active Comparator|pneumococcal polysaccharide vaccine|Patients are vaccinated vith Peumo23/Pneumovax on the first day. Abatacept started on frst day.
3002376|NCT02547493|Active Comparator|pneumococcal conjugate vaccine|"Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.~Abatacept started on frst day."
3002377|NCT02547480|Experimental|TACE with irinotecan loaded LifePearl|10 patients receiving unilobar treatment: day 1=chemoembolization of first lobe of liver, day 14=chemoembolization of second lobe of liver, day 30=chemoembolization of first lobe of liver, day 44= chemoembolization of second lobe of liver; AND 10 patient receiving bilobar treatment: day 1=chemoembolization of both lobes of the liver, day 30=chemoembolization of both lobes of the liver
3002378|NCT02547454||CKD participants treated with Mircera|Participants with CKD received Mircera, as per routine clinical practice and was followed for approximately 36 months.
3002379|NCT02547441|Experimental|Treatment|CLS001 (Omiganan) gel applied once daily
3002380|NCT02547441|Placebo Comparator|Vehicle Gel|Vehicle gel applied once daily
3002381|NCT02547428|Experimental|CTN SR first, then Placebo|Participants will receive CTN SR at a TDD of 400 mg followed by placebo (after washout period). CTN SR will be titrated up from 100 to 400 mg daily, at specified increments, for 3 weeks. Placebo will be titrated in the same manner to protect the blind.
3002382|NCT02547428|Experimental|Placebo first, then CTN SR|Participants will receive placebo followed by CTN SR at a TDD of 400 mg (after washout period). CTN SR will be titrated up from 100 to 400 mg daily, at specified increments, for 3 weeks. Placebo will be titrated in the same manner to protect the blind.
3002383|NCT02547415||patients with questionnaires and psychological testing|children and adolescents with chronic pain without proven medical cause, type painful somatic complaints
3002384|NCT02547402|Experimental|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
3002385|NCT02547389|Active Comparator|Intervention Group (IG)|IG additionally received community health programs with health workers(intensive education, consultation services, maintenance of anepilepsy tracking card, and repeated reminders).
3002386|NCT02547389|Other|Control Group (CG)|Patients in the CG were supplied with only printed epilepsy educational module
3002387|NCT02547376||Eligible patients with Soft Tissue Sarcoma|Primary Soft Tissue Sarcoma group
3002388|NCT02547363|Experimental|LEO 43204|Treatment once daily for 3 days
3002389|NCT02547363|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
3002390|NCT02547350|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy
3002391|NCT02547350|Experimental|single intravesical instillation|intravesical instillation within 24 hours postoperatively
3002392|NCT02547350|Experimental|multiple intravesical instillation|intravesical instillation every 1 week for the first 2 months, then once a month for the rest 10 months
3002393|NCT02547337||Type 1 diabetes|
3002394|NCT02547337||Healthy subjects|
3002395|NCT02547324|Experimental|Slump sitting|Slump sitting flexion of lumbar spine
3002396|NCT02547324|Active Comparator|Forward bending|Forward erect bending of lumbar spine
3002397|NCT02547311|Experimental|Team Clinic Intervention|Middle School and High School Team Clinic Intervention
3002398|NCT02547311|No Intervention|Standard Clinical Care - Control|Standard Clinical Care - Control
3002399|NCT02547298|Experimental|All patients|All patients in this study receive hydrodistension
3002400|NCT02547285||Shoes characteristics in elderly people|The subjects will test different characteristics on the same shoe. A single parameter vary for each test (Different insole, heel height, stem length ...)
3002401|NCT02547272||Nasal and rectal samples|ICU patients with nasal and rectal bacterial samples for the presence of S Aureus
3002402|NCT02547259|Experimental|schizophrenic pain words test|schizophrenic will have memory test with pain words on computer
3002403|NCT02547259|Experimental|schizophrenic negative words test|schizophrenic will have memory test with negative words on computer
3002404|NCT02547259|Other|Healthy volunteer pain words test|Healthy volunteer will have memory test with pain words on computer
3002405|NCT02547259|Other|Healthy volunteer negative words test|Healthy volunteer will have memory test with negative words on computer
3002406|NCT02547246|Experimental|rTMS session|Patients will have a 20 minute session of rTMS at a frequency of 10 Hz.
3002407|NCT02547246|Placebo Comparator|rTMS placebo (SHAM) session|Patients will have a 20 minute session of placebo rTMS
3002408|NCT02547233|Experimental|LEO 43204 gel|Treatment once daily for 3 days
3002409|NCT02547233|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
3002410|NCT02547220|Experimental|Cinryze®|Participants will receive 5000 Units of CINRYZE (50 millilitre [mL] of CINRYZE/ 50 mL of normal saline) on Day 1 and 2500 Units of CINRYZE (25 mL of CINRYZE/ 75 mL of normal saline) on Day 3, 5, 7, 9, 11, and 13 respectively.
3002411|NCT02547220|Placebo Comparator|Placebo|Participants will receive 7 doses of matched placebo over 13 days of treatment.
3002412|NCT02547194||No touch vein grafts|The grafts were harvested with there surrounding tissues.
3002413|NCT02547194||Conventional vein grafts.|The grafts were stripped from surrounding tissue.
3002414|NCT02547181|Experimental|Splint|Patients will be provided instructed to use a tensor bandage as well as specific behaviours to prevent movement of the injured part of the hand.
3002415|NCT02547181|Experimental|Behavioral Modification|Patients are given a removable plaster/fiberglass splint with a tensor bandage underneath
3002416|NCT02547168|Experimental|iRhythm ZIO XT patch group|This is the only arm in the study and patients within it will have a small, pebble shaped device adhered to their chests. This is an ECG (electrocardiogram) monitor and will measure the incidence of atrial fibrillation. It will have to be worn for 14 days before and after the lung resection procedure
3002417|NCT02547155|Experimental|Spinal anesthesia|Subjects randomized to spinal anesthesia will receive Bupivacaine 0.75%, 8-12.5 mg dose depending on estimated duration of surgery and anesthesiologist decision. In addition to spinal anesthesia, these subjects will possibly have concurrent administration of fentanyl, midazolam, and propofol so that they are mildy sedated or sleeping.
3002418|NCT02547155|Active Comparator|General anesthesia|Subjects randomized to general anesthesia will receive propofol induction, in combination with a muscle relaxant and inhalational gas per anesthesia standard of care at our institution
3002419|NCT02547142|Experimental|Early Palliative Care Group|This is the intervention group and will consist of patients that have been randomized into the early palliative group, with a consultation expected to take place within one week of randomization. Patients in this group will still receive appropriate guideline based oncologic care including any surgical, brachytherapy, chemotherapy or radiotherapy services, along with palliative services.
3002420|NCT02547129|Active Comparator|Static Antibiotic Spacer|Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the static antibiotic spacer being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
3002421|NCT02547129|Active Comparator|Articulating Antibiotic Spacer|Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the static antibiotic spacer being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
3002422|NCT02547116|No Intervention|Standard anti-staphylococcal antibiotic|
3002423|NCT02547116|Experimental|Standard anti-staphylococcal antibiotic + Rifampin|Individuals with known, persistent small-colony variant MRSA, who are treated with standard anti-staphylococcal antibiotics, will be treated with their standard therapy in addition to Rifampin.
3002424|NCT02547103|Experimental|Chlorhexidine gluconate|Chlorhexidine gluconate-soaked cloths, clean topical area around catheter exit site with CHG 2% soaked cloths
3002425|NCT02547103|Active Comparator|Normal saline (usual care)|Normal saline, clean topical area around catheter exit site
3002426|NCT02547103|Active Comparator|Mupirocin ointment|Mupirocin ointment 2%, clean topical area around catheter exit site with Mupirocin ointment
3002427|NCT02547090||CP who underwent PSF by two attendings in 2012|
3002428|NCT02547090||CP who underwent PSF by a single surgeon from 2008-2010|
3002429|NCT02547077|Experimental|Wound Closure with 2-octylcyanoacrylate|One side of the patient's wound defect will be assigned to wound closure with 2-octylcyanoacrylate liquid bonding agent).
3002430|NCT02547077|Active Comparator|Wound Closure with 5-0 Fast Absorbing Gut|One side of the patient's wound defect will be assigned to wound closure with 5-0 fast absorbing gut sutures.
3002431|NCT02547064|Active Comparator|90 degree|The ETT with the 90° angle stylet was bent at a point 8 cm from its distal end.
3002432|NCT02547064|Experimental|70 degree|The ETT was bent by 70° at a point 6 cm from its distal end and the proximal portion of the ETT was formed as the shape of the GL blade until the point of the handle.
3002433|NCT02547051|Experimental|Food allergy and vocal cord tension|To determine if dietary allergen responses and frequency and severity of vocal cord tension.
3002434|NCT02547038|Experimental|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
3002435|NCT02547038|Active Comparator|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
3002436|NCT02547025|Experimental|rabeprazole+3 antibiotics|patients who have positive result of culture with equal to or more than three susceptible antibiotics are treated by non-bismuth quadruple therapy (rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days
3002437|NCT02547025|Experimental|rabeprazole+bismuth+2 antibiotics|patients who have positive result of culture with one or two susceptible antibiotics are treated by bismuth-containing therapy (rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days
3002438|NCT02547025|Active Comparator|rabeprazole+amox+tetr+levo|patients who have negative result of culture or whose culture data are unavailable will be treated by (rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days
3002439|NCT02547012|Experimental|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
3002440|NCT02547012|Active Comparator|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.
3002441|NCT02546999|Experimental|botox|Botox® (onabotulinumtoxin A),injections in the calf muscles. The total maximum body dose of Botox® in this study will be 420 Units. Maximum dose per injection site will be 50 Units. The gastrocnemius muscle will receive 5-6 Units Botox® per kg, but maximum 180 Units in each leg. The soleus muscle will receive 2 Units Botox® per kg with maximum dose 60 Units in each leg. Dilution: 100 Units Botox® in 1 ml 0.9% sodium chloride, and the maximum volume per injection site will be 0,5 ml in both study groups. The route of administration is intramuscular injection.
3002442|NCT02546999|Placebo Comparator|placebo|Sterile 0,9% Sodium Chloride injection The placebo dose will be the same dose in ml as the reconstituted Botox
3002443|NCT02546986|Experimental|CC-486 plus Pembrolizumab|In the experimental arm, participants will receive a combination of two investigational drugs, CC-486 and pembrolizumab every 21-days.
3002444|NCT02546986|Experimental|Pembrolizumab plus Placebo|In this control arm, participants will receive pembrolizumab as a 30 minute IV infusion on day 1 of each 21-day cycle and placebo will be administered by mouth daily on days 1 to 14 of each 21 day cycle. Placebo will also be administered in order to allow blinding of the study.
3002445|NCT02546973||Patients with anal cancer|All patients with anal cancer during 2011-2013 will be asked to participate
3002446|NCT02546960|Experimental|ExPEC4V (4 : 4 : 4 : 4)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in microgram [mcg]) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V (4:4:4:4) or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the DRC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the DRC.
3002540|NCT02546349|Experimental|high eNO: ICS/LABA|patients with eNO >=23.5 ppb, receive inhaled corticosteroid (ICS)/long-acting beta2 agonist (ICS/LABA) of fluticasone/salmeterol 250/25 mcg/puff, 2 puffs bid.
3002541|NCT02546349|Active Comparator|high eNO: LAMA|patients with eNO >=23.5 ppb, receive long acting muscarinic antagonist (LAMA) of tiotropium 2 inhalations 2.5 mcg/inhalation, once daily
3002542|NCT02546349|Experimental|Low eNO: ICS/LABA|patients with eNO < 23.5 ppb, receive fluticasone/salmeterol 250/25 mcg/puff, 2 puffs bid
3002447|NCT02546960|Experimental|ExPEC4V (4 : 4 : 4 : 8)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses (4 : 4 : 4 : 8/8 : 8 : 8 : 8) of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the DRC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the DRC.
3002448|NCT02546960|Experimental|ExPEC4V (8 : 8 : 8 : 8)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses (4 : 4 : 4 : 8/8 : 8 : 8 : 8) of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the DRC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the DRC.
3002449|NCT02546960|Experimental|ExPEC4V (8 : 8 : 8 : 16)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses (8 : 8 : 8 : 16/16 : 16 : 16 : 16) of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the DRC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the DRC.
3002450|NCT02546960|Experimental|ExPEC4V (16 : 16 : 16 : 16)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses (8 : 8 : 8 : 16/16 : 16 : 16 : 16) of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the DRC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the DRC.
3002451|NCT02546960|Placebo Comparator|Placebo|Participants will be stratified according to their age in 2 groups >= 18 to <50 years and >=50 years. Part 1: Participants will receive matching placebo to ExPEC4V as an intramuscular injection into the deltoid muscle. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe and well tolerated based on the review of safety data through Day 8 by the DRC.
3002452|NCT02546947|No Intervention|Appropriate clinical group|group of patients with clinical dose adjustment
3002453|NCT02546947|Active Comparator|TOF adapted group|group with an objective of less than 2 responses to TOF stimulation monitored
3002454|NCT02546934|Experimental|ABX, cisplatin|AP (ABX and cisplatin combination)
3002455|NCT02546934|Active Comparator|Gemcitabine, Cisplatin|GP (Gemcitabine and Cisplatin combination)
3002456|NCT02546908||High-risk localized Prostate Cancer (PC)|No intervention will be administered in this study. Participants with High-risk localized PC will be enrolled. High-risk localized PC involves clinical T stage greater than or equal to (>=) cT3a and one of the following high risk features: Gleason score 8-10 or prostate specific antigen (PSA) level above 20 nanogram per milliliter (ng/mL).
3002457|NCT02546908||Non-metastatic Biochemically Recurrent PC|No intervention will be administered in this study. Participants with Non-metastatic biochemically recurrent PC will be enrolled. A non-metastatic biochemically recurrent PC involves a confirmed PSA value of >0.2 ng/mL following prostatectomy (European Association of Urology (EAU) guidelines), a PSA value of 2 ng/mL or more above the nadir following radiation therapy (American Society for Radiation Oncology (ASTRO) guidelines).
3002458|NCT02546908||Metastatic PC|No intervention will be administered in this study. Participants with Metastatic PC will be enrolled.
3002459|NCT02546882|Experimental|stromal vascular fraction|The adipose tissue in abdomen or thigh will be harvested and digested at 37 °C for 60 min with 0.2% collagenase I/Ⅲ. After filtration and centrifugation, mature adipocytes are separated from the cell pellet. The pellet then is treated with erythrocyte lysis buffer twice to remove red cell fragment. The harvested pellet is stromal vascular fraction (SVF).
3002460|NCT02546882|Placebo Comparator|saline|1 ml saline without cells will be used as placebo.
3002461|NCT02546869|Experimental|Lebrikizumab|Participants will receive lebrikizumab SC using prefilled syringes (PFS), q4w up to Week 12.
3002462|NCT02546856|Active Comparator|Heart Failure (HF) cardiologist up-titration|Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.
3002463|NCT02546856|Experimental|HF nurse up-titration|Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.
3002543|NCT02546349|Active Comparator|Low eNO: LAMA|patients with eNO < 23.5 ppb, receive tiotropium 2 inhalations 2.5 mcg/inhalation, once daily
3002544|NCT02546336|Experimental|Ultrasound-Guided Hip Denervation|This is a pilot study. 15 Hip Osteoarthritis patients with chronic pain will be recruited in this pilot arm. These will undergo Ultrasound-Guided Cooled Radiofrequency Hip Denervation as intervention.
3002545|NCT02546323|Experimental|Rosuvastatin|20 mg tablets, Daily oral dose
3002464|NCT02546843|Experimental|Group A|"After anesthesia induction: intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol 2.0mg/kg the neuromuscular blockade will be induced with rocuronium 0.6 mg/kg (1 mg/kg only in a case of a rapid sequence induction).~maintaining the depth of neuromuscular blockade - rocuronium: the appropriate depth of the block will be maintained with repeated boluses of rocuronium 0.3 mg/kg according to TOF 0, PTC 0-1.~Specific Neuromuscular Blockade reversal will be performed with Sugammadex intravenously. The proper dosage of sugammadex will depend on the depth of the blockade:at TOF -1-2 (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered"
3002465|NCT02546843|Active Comparator|Group B|"After anesthesia induction: intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol 2.0mg/kg the neuromuscular blockade will be induced with cisatracurium 0.15mg/kg intravenously.~Maintaining the depth of neuromuscular blockade - cisatracurium:the appropriate depth of the block will be maintained with repeated boluses of cisatracurium 0.03 mg/kg - according to TOF maintaining of muscular relaxation TOF 1.~Nonspecific Neuromuscular Blockade reversal will be performed with neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously, the reversal will be applicated in case of TOF 1 or higher."
3002466|NCT02546830|Experimental|FreeO2 v2.2 active|Automatic Oxygen Administration
3002467|NCT02546830|Active Comparator|FreeO2 v2.2 with manual oxygenation|Manual Oxygen Administration
3002468|NCT02546804|Experimental|HOT SALT WATER|3% HOT SALT WATER , 25ml used for rinsing for 60 sec, twice daily for 60 days.
3002469|NCT02546804|Experimental|POTASSIUM PERMANGANATE|0.01% POTASSIUM PERMANGANATE, 10ml used for rinsing for 60 sec, twice daily for 60 days.
3002470|NCT02546804|Active Comparator|CHLORHEXIDINE|0.2% CHLORHEXIDINE, 10ml used for rinsing for 60 sec, twice daily for 60 days.
3002471|NCT02546791||Chronic myeloid leukemia patients treated with Dasatinib|patients with a diagnosis of chronic myeloid leukemia treated with Dasatinib for at least 45 days
3002472|NCT02546778|Experimental|Dermosux RF|The group received the radio frequency for 20 minutes with the frequency of 1 MHz with 40 W.
3002473|NCT02546765|Experimental|IV acetaminophen & IV propofol|"20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU~1g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively"
3002474|NCT02546765|Experimental|IV acetaminophen & IV dexmedetomidine|"A loading infusion of 0.5 - 1 µg/kg given over 10 minutes will be administered. After the loading infusion, a maintenance infusion of 0.1-1.4 µg/kg/hr will be initiated.~1 g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively"
3002475|NCT02546765|Active Comparator|IV propofol & placebo|20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl.
3002476|NCT02546765|Active Comparator|IV dexmedetomidine & placebo|0.1-1.0 µg/kg/hour IV dexmedetomidine given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of i.v. acetaminophen at 100ml 0.9% NaCl.
3002477|NCT02546752|Experimental|THEO Video Arm|"THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). Two programs have been developed. Parents/guardians of children who have not received the first HPV vaccine, will first assess whether the family has already decided in favor of the HPV vaccine or if they would like more information. The parent/guardian will be shown a video specific to where they are in the decision-making process. After completion, the THEO system will then ask the parent/guardian a series of Post Video questions. Parents/guardians of children who have received the first or second vaccine in the series, will emphasize the need to make the first vaccine count. Pre and post video questions have been developed."
3002478|NCT02546752|No Intervention|Usual Care Arm|This arm will receive usual care.
3002479|NCT02546739|Experimental|Experimental: 1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
3002480|NCT02546739|Experimental|Experimental: 2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
3002481|NCT02546739|Experimental|Experimental: 3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
3002482|NCT02546726|Experimental|Heat & Aerobic Training (HEAT) Condition|Participants will receive supervised, moderate intensity (50-75% maximum heart rate) aerobic exercise sessions, 3 times per week for 50 minutes in duration. After the exercise portion of each session, participants assigned to the HEAT condition will be asked to sit quietly on the bench in the steam-room within their same-sex locker room for no more than 20 minutes. They will start at 11 minutes to get acclimated to the mild heat stress, and gradually work up to 20 minutes. A trained research staff member will be stationed outside the room.
3002483|NCT02546726|Active Comparator|Exercise Only|Participants will receive supervised, moderate intensity (50-75% maximum heart rate) aerobic exercise sessions, 3 times per week for 50 minutes in duration. After the exercise portion of each session, participants assigned to the Exercise Only condition will be asked to sit quietly on the bench in the lobby of the fitness facility, initially for 11 minutes and then gradually working up to 20 minutes.
3002484|NCT02546713|Other|Group 1|Abutments with a concave configuration of the subcritical contour (emergence shape).
3002485|NCT02546713|Other|Group 2|Abutments with convex configuration of the subcritical contour (emergence shape)
3002486|NCT02546700|Experimental|Lebrikizumab: Biomarker-high|Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
3002487|NCT02546700|Experimental|Lebrikizumab: Biomarker-low|Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
3002488|NCT02546700|Placebo Comparator|Placebo: Biomarker-high|Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
3002489|NCT02546700|Placebo Comparator|Placebo: Biomarker-low|Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
3002490|NCT02546687||Canidate for elective esophagectomy|Venous blood sampling from gastric tube during elective esophagectomy
3002491|NCT02546674|Experimental|Nilotinib|Patients with newly diagnosed CML in chronic phase will be enrolled.
3002546|NCT02546323|Placebo Comparator|Placebo|Matching placebo tablets
3002547|NCT02546310|Experimental|HTL0009936 high dose|high dose infusion
3002492|NCT02546661|Experimental|Module A: AZD4547 Monotherapy|"AZD4547 will be given orally twice daily until disease progression.~Patients who receive AZD4547 as monotherapy will have the option to cross over to durvalumab as monotherapy at the point of objective progression, as long as the following criteria are met:~The investigator believes it is in the patient's interest to receive durvalumab;~The patient consents to the continued treatment;~It is clinically appropriate for the patient to continue on durvalumab treatment;~The patient satisfies the key eligibility criteria for receiving durvalumab treatment."
3002493|NCT02546661|Experimental|Module A: Durvalumab + AZD4547|AZD4547 will be given orally twice daily until disease progression. Patients will also receive durvalumab by IV infusion once every 4 weeks.
3002494|NCT02546661|Experimental|Module B: Durvalumab + Olaparib|Durvalumab will be given by IV infusion once every 4 weeks. Olaparib will be given orally twice daily.
3002495|NCT02546661|Experimental|Module C: Durvaluamb + AZD1775|Durvalumab will be given by IV infusion once every 4 weeks. AZD1775 will be given orally in approximate 12 hour intervals over 3 days (6 doses) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
3002496|NCT02546661|Experimental|Module D: Durvalumab monotherapy|Durvalumab will be given by IV infusion once every 4 weeks.
3002497|NCT02546661|Experimental|Module E: Durvalumab + Vistusertib|Durvalumab will be given by IV infusion once every 4 weeks. Vistusertib will be given orally twice per day on an intermittent schedule (2 days on, 5 days off).
3002498|NCT02546661|Experimental|Module F: Durvaluamb + AZD9150|AZD9150 will be given as monotherapy on Days -7, -5, and -3 of a one week lead-in period. Combination dosing with IV AZD9150 followed by IV Durvalumab begins on Day 1 of each 28 day cycle. Thereafter AZD9150 is given weekly and Durvalumab is given once every 4 weeks.
3002499|NCT02546648|Experimental|Tranexamic Acid vs. matching placebo|Tranexamic Acid 1g bolus with anesthesia induction followed by 1g bolus at the start of surgical closure.
3002500|NCT02546648|Experimental|Rosuvastatin vs. matching placebo|Rosuvastatin 20 mg orally or matching placebo once per day until 30 days after surgery
3002501|NCT02546635|Experimental|Potential food effect|
3002502|NCT02546635|Experimental|Multi-dosing|
3002503|NCT02546622||Arm A Prospective|"Patients who are switching to a new Factor VIII and Factor IX Replacement Product for Hemophilia A and B which was FDA approved after January 1, 2013.~These patients will be followed prospectively for up to 1 year."
3002504|NCT02546622||Arm B Retrospective|"Patients who have recently switched to a new Factor VIII and Factor IX Replacement Product for Hemophilia A and B which was FDA approved after January 1, 2013.~Patients must have switched products within the past 50 weeks at the time of enrollment.~These patients will be assessed retrospectively and/or followed prospectively for up to 1 year."
3002505|NCT02546609|Experimental|Leu Met Sil 0.5mg|Leu-Met-Sil 0.5: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
3002506|NCT02546609|Experimental|Leu Met Sil 1.0mg|Leu-Met-Sil 1.0: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
3002507|NCT02546609|Placebo Comparator|Placebo|Placebo: 3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
3002508|NCT02546596|Experimental|Electro-hyperthermia plus radiation|External beam radiation 40 Gy with 20 fractions (4 weeks) Electro-hyperthermia twice a week, one hour for each session
3002509|NCT02546583|Experimental|Increased Intravenous Loop Diuretic (Bumetanide or Furosemide)|2.5x Visit 1 dose
3002510|NCT02546583|Experimental|Loop Diuretic (Bumetanide or Furosemide) + IV Chlorothiazide|Loop diuretic (Bumetanide or Furosemide) dose remains the same as visit 1 dose but now with the addition of 500-1000 mg IV chlorothiazide
3002511|NCT02546583|No Intervention|Observational Arm|Subjects taking an IV loop diuretic (Bumetanide or Furosemide) that have sodium output greater than 100 mmol. These subjects will continue to be followed and have data collected on them.
3002512|NCT02546570|Experimental|Healthy adult controls (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
3002513|NCT02546570|Experimental|Adults with PTSD (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
3002514|NCT02546570|Experimental|Trauma-exposed/no-PTSD adults (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
3002515|NCT02546557||OPTICABG|Patients undergoing a coronary artery bypass graft surgery for the repair of a multi-vessel disease or left main-coronary disease.
3002516|NCT02546544|Other|Linsitinib|
3002517|NCT02546531|Experimental|Dose escalation (defactinib, pembrolizumab, gemcitabine)|"Defactinib is an oral drug which will be administered on an outpatient basis at the prescribed dose twice a day daily during each 21-day cycle.~Pembrolizumab is an intravenous (IV) drug which will be administered on an outpatient basis over 30 minutes (-5/+10) at a dose of 200 mg on Day 1 of each 21-day cycle.~Gemcitabine is an IV drug which will be administered on an outpatient basis over 30 minutes at the prescribed dose on Days 1 and 8 of each 21-day cycle.~Participants enrolled in Dose Level 1 and 2 will not receive gemcitabine."
3002518|NCT02546531|Experimental|Dose expansion (defactinib, pembrolizumab, gemcitabine)|"Defactinib is an oral drug which will be administered on an outpatient basis at the prescribed dose twice a day daily during each 21-day cycle.~Pembrolizumab is an intravenous (IV) drug which will be administered on an outpatient basis over 30 minutes (-5/+10) at a dose of 200 mg on Day 1 of each 21-day cycle.~Gemcitabine is an IV drug which will be administered on an outpatient basis over 30 minutes at the prescribed dose on Days 1 and 8 of each 21-day cycle.~Participants enrolled in Dose Level 1 and 2 will not receive gemcitabine."
3002548|NCT02546310|Experimental|HTL0009936 low dose|low dose infusion
3002519|NCT02546518|Experimental|Moniri Otovent|A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to ambu bag balloon. A safety valve is used to prevent too high air pressure. The ambu bag balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. During the first week day, a low pressure balloon is used, then it is changed with a higher pressure balloon. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one month.
3002520|NCT02546518|Active Comparator|Tympanostomy tube in the ear drum|Operation for insertion of tympanostomy tube under general anesthesia.
3002521|NCT02546505|No Intervention|Control|The current situation with current way brands show or not nutritional information on Front of Pack (FoP) - without consumer information
3002522|NCT02546505|Experimental|Intervention n°1|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods. No additional consumer information
3002523|NCT02546505|Experimental|Intervention n°2|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods. Additional consumer information specifically targeting nutritional information and explaining the 5-CNL will be performed (this information will consist in a concept shown to respondents before the shopping session).
3002524|NCT02546492|Experimental|Acthar|The study cohort. In this cohort Acthar gel will be administered to the enrolled patient with chrnic AMR.
3002525|NCT02546479||Patientis|patients diagnosed with scoliosis and other spinal deformities
3002526|NCT02546466|Experimental|Functional Star-shape taping (FST)|For the Functional Star-shape taping (FST) procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
3002527|NCT02546466|Sham Comparator|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
3002528|NCT02546466|Active Comparator|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
3002529|NCT02546453|Other|Tumoral specific genetic alterations|NGS techniques (next generation sequencing) will be used to identify specific genetic alterations of tumoral cells of a patient. If specific genetic alterations is detected, they will be used to detect circulating tumor DNA and/or circulating/disseminated tumoral cells (CTC/DTC) in peripheral samples (blood, bone marrow, cerebral spinal fluid) collected before, during and after treatment.
3002530|NCT02546440|Experimental|treatment arm|patients are treated with dimethylfumarate over 24 weeks. Dosage will be escalated weekly from 30 mg/d to 720 mg/d over 9 weeks. The dose escalation scheme is the same as approved for psoriasis treatment in Germany
3002531|NCT02546427|Experimental|Treatment|"Step 1: Pelvic Lymph Node Irradiation~Helical TomoTherapy (HT): 41.25 Gy in 15 fractions of 2.75 Gy each~Step 2: Treat boost volume to prostate and seminal vesicles~Acceptable treatment modalities:~CyberKnife SBRT: 19 Gy in 2 fractions of 9.5 Gy each with SBRT~Permanent prostate implant (PPI):~108 Gy for low dose rate PPI with I-125 90 Gy for low dose rate PPI with Pd-103 HDR brachytherapy: 15 Gy in one fraction for HDR"
3002532|NCT02546414||Esophageal varices haemorrhage group|HBV hepatic cirrhosis with first esophageal varices haemorrhage were included and stratified using their Child-Pugh score. The platelet count were evaluated, and ultrasound was used to measure the longest diameter of the spleen. The platelet count(PC)/spleen diameter (SD)ratio was calculated and analyzed to determine whether it can predict the variceal haemorrhage. Upper gastrointestinal endoscopy was used as the gold standard.
3002533|NCT02546414||no haemorrhage but esophageal varice presence|HBV hepatic cirrhosis with no esophageal varices haemorrhage were included and upper gastrointestinal endoscopy were validate.They also stratified using their Child-Pugh score. The platelet count and longest diameter of the spleen were evaluated, The PC/SD ratio was calculated and analyzed to determine whether it can predict the variceal presence.
3002534|NCT02546414||no esophageal varice but cirrhotic|HBV hepatic cirrhosis with no esophageal varices were included and also validated by upper gastrointestinal endoscopy.They stratified using their Child-Pugh score. The platelet count and longest diameter of the spleen were evaluated,The PC/SD was calculated and analyzed to determine whether it can predict the variceal absence .
3002535|NCT02546401|Experimental|Group 1|"Patients will perform their bolus for 2 weeks before meals (BE) and for 2 weeks after meals (AF).~Intervention: drug (insulin Aspart)"
3002536|NCT02546401|Experimental|Group 2|"Patients will perform their bolus for 2 weeks after meals (AF) and for 2 weeks before meals (BE).~Intervention: drug (insulin Aspart)"
3002537|NCT02546388|Experimental|Patients with clinical suspicion of cardiac sarcoidosis|Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Indium-111 Pentreotide (OctreoScan) or Gallium-68 DOTATATE. The imaging protocol will consist of imaging at 4 and 24 hours after OctreoScan injection or 1 hour after injection for DOTATATE.
3002538|NCT02546375||Chronic Myeloid Leukaemia|Patients diagnosed with chronic myeloid leukaemia treated with Bosutinib
3002539|NCT02546362|Experimental|Active|12 weeks of treatment using Cefaly twice a day (treatment session of 20 minutes)
3002550|NCT02546297|Active Comparator|ICS/LABA Group|Symbicort，Inhalation，Individualized medication，six months，The treatment will be exchanged in the 7th month.
3002551|NCT02546297|Active Comparator|LAMA Group|Tiotropium Bromide，Inhalation,Individualized medication，six months，The treatment will be exchanged in the 7th month.
3002552|NCT02546284|Experimental|Single Agent lenzilumab|Dose levels: lenzilumab IV infusion once monthly for a 28 day dosing cycle (with extra dose on Day 15 during cycle). Three (3) to Six (6) subjects will be enrolled into planned escalating cohorts of 200 mg, 400 mg or 600 mg lenzilumab.
3002553|NCT02546271|Experimental|Treatment Group|GPS program - an 8-week, peer-led group counselling program using motivational interviewing techniques.
3002554|NCT02546258|Other|A Funagl Nail Treatment|Marketed treatment of Fungal Nail Follow instructions on pack
3002555|NCT02546245|Experimental|Heroes of Knowledge Game|
3002556|NCT02546245|Active Comparator|Attention/Time Control Games|
3002557|NCT02546232|Active Comparator|Control|Paclitaxel 80 mg/m2 weekly for 12 weeks, thereafter current standard chemotherapy for 12 weeks
3002558|NCT02546232|Experimental|Additional therapy|"Carboplatin AUC 6 (area under curve; mg/ml/min) once every 3 weeks, for 12 weeks.~Paclitaxel 80 mg/m2 weekly for 12 weeks, thereafter current standard chemotherapy for 12 weeks"
3002559|NCT02546219||Adults with EoE|Adult patients with active eosinophilic esophagitis will under blood collection and esophagus biopsies in order to perform eosinophil isolation and characterization.
3002560|NCT02546206|Experimental|Probiotic Yoghurt|Probiotic yoghurt consumption
3002561|NCT02546206|Placebo Comparator|Natural Yoghurt|Natural yoghurt consumption
3002562|NCT02546193|Experimental|Outpatient Foley catheter|Women randomized to the outpatient Foley catheter group will present to the Family Birth Center in the evening. They will undergo a basic history, fetal nonstress test, ultrasound for presentation and amniotic fluid index, and cervical exam, and then a Foley catheter will be placed for cervical ripening. After fetal monitoring, they will return to their own homes. They will return to the Family Birth Center in the morning for continuation of their labor inductions in the inpatient setting, unless other concerns prompt them to seek care sooner.
3002563|NCT02546193|Active Comparator|Inpatient usual care|Women randomized to the inpatient usual care group will present to the Family Birth Center in the evening for their scheduled induction of labor. They will undergo a basic history, fetal nonstress test, ultrasound for presentation and amniotic fluid index, and cervical exam. Cervical ripening will commence with either a Foley catheter or vaginal misoprostol per the discretion of the managing obstetric team. They will remain in the inpatient setting throughout their entire labor induction course.
3002564|NCT02546180|Experimental|YouTube Video Viewers|Subjects in this arm were randomized to viewing YouTube videos.
3002565|NCT02546180|Active Comparator|Standard Education|Subjects in this arm were randomized to standard preoperative education.
3002566|NCT02546167|Experimental|Cohort 1|will receive 1-5x10^7 CART-BCMA cells given as a split dose infusion over 3 days.
3002567|NCT02546167|Experimental|Cohort 2|Cyclophosphamide infusion prior to 1-5x10^7 CART BCMA cells given as a split dose infusion over 3 days.
3002568|NCT02546167|Experimental|Cohort 3|Cyclophosphamide infusion prior to 1-5x10^8 CART BCMA cells given as a split dose infusion over 3 days.
3002569|NCT02546154||CKD, iron deficiency anaemia|10% Iron Isomaltoside 1000 administered intravenously to Chronic Kidney Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
3002570|NCT02546154||IBD, iron deficiency anaemia|10% Iron Isomaltoside 1000 administered intravenously to Inflammatory Bowel Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
3002571|NCT02546141|Active Comparator|skimmed milk (UHT)|portion size that contains 25 g of protein, oral, single administration
3002572|NCT02546141|Active Comparator|skimmed milk (pasteurized)|portion size that contains 25 g of protein, oral, single administration
3002573|NCT02546141|Active Comparator|skimmed yoghurt|portion size that contains 25 g of protein, oral, single administration
3002574|NCT02546141|Active Comparator|full-fat milk (UHT)|portion size that contains 25 g of protein, oral, single administration
3002575|NCT02546141|Active Comparator|non-homogenized full-fat milk (pasteurized)|portion size that contains 25 g of protein, oral, single administration
3002576|NCT02546141|Active Comparator|full-fat cheese (semi-matured)|portion size that contains 25 g of protein, oral, single administration
3002577|NCT02546141|Active Comparator|whey protein|portion size that contains 25 g of protein, oral, single administration
3002578|NCT02546141|Active Comparator|micellar casein|portion size that contains 25 g of protein, oral, single administration
3002579|NCT02546128|Experimental|intervention|"rehabilitation + active-dose ESWT (extra-corporeal shockwave therapy)"
3002580|NCT02546128|Placebo Comparator|control|"rehabilitation + placebo-dose ESWT (extra-corporeal shockwave therapy)"
3002581|NCT02546115|Active Comparator|Intervention|standard practice (structured rehabilitation programme) + TNS
3002582|NCT02546115|Active Comparator|control|standard practice (structured rehabilitation programme)
3002583|NCT02546102|Experimental|1|Arm 1 will receive ICT-107 in combination with the standard of care, temozolomide (TMZ). ICT-107 will be given once a week for 4 weeks in the induction phase. During the maintenance phase, ICT-107 will be given monthly for the 11 months after induction and once every 6 months thereafter until depletion of supply or confirmation of progressive disease (PD). Administration is intradermal in axilla.
3002584|NCT02546102|Placebo Comparator|2|Arm 2 will receive TMZ with a blinded control. Control will be given once a week for 4 weeks in the induction phase. During the maintenance phase, Control will be given monthly for the 11 months after induction and once every 6 months thereafter until depletion of supply or confirmation of progressive disease (PD). Administration is intradermal in axilla.
3002585|NCT02546089|Active Comparator|intervention group|"local anaesthetic - lidocaine 1%, dry needling, autologous blood injection,~+ structured rehab programme"
3002586|NCT02546089|Placebo Comparator|control group|"local anaesthetic - lidocaine 1%, dry needling,~+ structured rehab programme"
3002587|NCT02546076|Active Comparator|Laser coagulation|Er:YAG laser treatment with coagulation modality
3002588|NCT02546076|Active Comparator|Laser w/o coagulation|Er:YAG laser treatment without coagulation modality
3002589|NCT02546063|Other|GoCARB app|Smartphone app
3002590|NCT02546063|No Intervention|Conventional carbohydrate estimating methods|Individual usual carbohydrate estimation methods (weighing, experience, carbohydrate exchange tables etc.).
3002591|NCT02546050|Experimental|Metformin|18 weeks study with intervention during week 6 to 12: the intervention consist of 500 mg of metformin once daily for week 7, then 500 mg twice daily week 8, 1000 mg + 500 mg daily week 9 and 1000 mg + 1000 mg daily for weeks 10-12.
3002592|NCT02546037||SOLACEA 21H|single haemodiafiltration treatment using a SOLACEA 21H dialyzer (Nipro Corp, Osaka, Japan)
3002593|NCT02546037||FX100|single haemodiafiltration treatment using a FX100 dialyzer (Fresenius MC, Bad Homburg, Germany)
3002594|NCT02546024||Treatment responder|Participants who receive standard care and achieve HAM-D score reduction of 50% or more, or score below 8 at Week 12.
3002595|NCT02546024||Treatment non-responder|Participants who receive standard care but have HAM-D score reduction less than 50% at Week 12.
3002596|NCT02545998|No Intervention|Standard care|Patients will receive a face-to-face asthma review
3002597|NCT02545998|Active Comparator|Telehealthcare|Patients will receive a telephone consultation and e-mail with attached PAAP and video link
3002598|NCT02545985|Experimental|Prolim stent implantation|In patients with symptomatic coronary artery disease Prolim stent was implanted in coronary arteries
3002599|NCT02545972|Experimental|Once a day tacrolimus|Tacrolimus extended release will be given at an initial once daily dose equivalent to the total daily dose of the twice a day Tacrolimus formulation.
3002600|NCT02545959|Active Comparator|Control group|receive a single pulse of methylprednisolone IV (120mg)
3002601|NCT02545959|Experimental|Rituximab IT group|receive a single intrathecal infusion of rituximab (with IV methylprednisolone 120mg to avoid side effect)
3002602|NCT02545959|Experimental|Rituximab IT + IV group|receive Rituximab IT as previous and Rituximab IV (375mg/m2) the same day
3002603|NCT02545946|Active Comparator|Traditional|cutaneous abscess with be opened in the traditional incision and drainage technique with large incision, breaking up of pockets of pus, washing out the pocket and with or without packing gauze placed into residual cavity
3002604|NCT02545946|Active Comparator|Minimally Invasive|Cutaneous abscess will be opened with two small incisions just large enough to pass a vessel loop through both to keep them open. Pockets of pus will be broken up and the cavity washed out before placing the loop through both incisions and loosely tieing it over the skin
3002605|NCT02545933|Experimental|DAPT plus vorapaxar|Aspirin plus prasugrel or ticagrelor plus vorapaxar 2.5mg od
3002606|NCT02545933|Experimental|Prasugrel/ticagrelor plus vorapaxar|Prasugrel or ticagrelor plus vorapaxar 2.5mg od
3002607|NCT02545933|Active Comparator|DAPT|Aspirin in addition to prasugrel or ticagrelor
3002608|NCT02545907|Experimental|KTD treatment|"Participants in the escalation phase will receive carfilzomib (K), thalidomide (T), and dexamethasone (D) in combination. The dose of thalidomide will be 50mg/day. The dose of dexamethasone will be 20mg on Day 1, 8, and 15. Carfilzomib will be administered on Day 1, 8, and 15, but the level of carfilzomib delivered with depend on the cohort allocation. The dose of carfilzomib may be:~Level -1 - 27mg/m2~Level 0 - 36mg/m2~Level 1 - 45mg/m2~Level 2 - 56mg/m2~Participants will receive up to six cycles of treatment. Following determination of the maximum tolerated dose and recommended dose, the trial will be opened to an expansion phase where participants will receive the RD of carfilzomib, along with thalidomide and dexamethasone, using the schedule outlined above."
3002609|NCT02545894|No Intervention|BASELINE TESTING|Language and cognitive assessments conducted
3002610|NCT02545894|Experimental|Treatment|"Intervention given:~visual tracking pressing a button every time a picture is seen on the screen~playing dominoes and snap~pressing a button every time a specific picture is seen on the screen~Pressing a button every time a specific sound is heard~Matching objects to a picture~Matching gestures to objects~Matching two connected objects~Sorting objects by categories~Matching sounds to objects~Complete the category and odd on out with objects~Choosing target objects by pointing~Choosing objects to complete the category by pointing"
3002611|NCT02545894|No Intervention|Post intervention|Repeated testing
3002612|NCT02545868|Experimental|Group A: OCR + Vaccines|Participants will receive dual infusion of OCR 300 milligrams (mg) on Day 1 and then on Day 15, and then participants will further receive immunization course (TT-containing adsorbed vaccine, 23-PPV either unboosted or boosted with 13-PCV, influenza vaccine, and repeated administration with KLH) at 12 weeks post-OCR treatment until Week 24. Participants who complete the 24-week immunization study period will have the option for retreatment with a single infusion of 600 mg OCR on Day 169 and subsequent single infusions (600 mg OCR) at intervals of 24 weeks. Participants who have received one or more infusions of OCR will enter the 48-week safety follow-up period.
3002613|NCT02545868|Other|Group B: Vaccines (Optional OCR in Extension)|Participants will receive immunizations (TT-containing adsorbed vaccine, 23-PPV, influenza vaccine, and repeated administration with KLH) on Day 1 until Week 12 of the immunization period. Participants who complete the 12-week immunization study period will have the option to receive two single infusions of OCR 300 mg, on Day 84 and Day 98, and subsequent single infusions (600 mg OCR) at intervals of 24 weeks. Participants who have received one or more infusions of OCR will enter the 48-week safety follow-up period.
3002614|NCT02545855|Experimental|Arm A (myAIRVO2® + HOT, HOT)|Subjects will receive the myAIRVO2® therapy plus HOT for week 1-6 and HOT only for week 7-12. After treatment period (week 1-12), willing subjects can continue the myAIRVO2® therapy plus HOT for week 13-52 regardless of treatment arm assignment.
3002615|NCT02545855|Experimental|Arm B (HOT, myAIRVO2® + HOT)|Subjects will receive HOT only for week 1-6 and the myAIRVO2® therapy plus HOT for week 7-12. After treatment period (week 1-12), willing subjects can continue the myAIRVO2® therapy plus HOT for week 13-52 regardless of treatment arm assignment.
3002616|NCT02545842|Experimental|Group 1|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=5.6 mmol/L
3002617|NCT02545842|Experimental|Group 2|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=6.1 mmol/L
3002618|NCT02545842|Experimental|Group 3|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=7.0 mmol/L
3002619|NCT02545829|Experimental|Sequence 1|HGP1406 → HIP1302
3002621|NCT02545816|Other|study group|Patients (age ≥ 18 years) admitted to the ICU with an acute neurological insult which will be sedated/ventilated (Glasgow Coma Scale (GCS) ≤ 8).
3002622|NCT02545803|Other|study group|Adult patients (age ≥ 18 years) at the Intensive Care Unit (ICU) who become refractory to conventional mechanical ventilation and are switched to HFPV.
3002623|NCT02545790||Persistent hypertrophy|Elevated cardiac mass at follow-up time point as measured by Echocardiographic and Serologic evaluations.
3002624|NCT02545790||Normal geometry|Normal cardiac mass at follow-up time point as measured by Echocardiographic and Serologic evaluations.
3002625|NCT02545777|Active Comparator|treatment group|Take oral medicine of tonifying spleen and descending turbid, one bag each time, two times a day, continuous treatment for 10 days.The onset of the joints afford steeping washing and wet wrapping medicine of descending turbid and clearing heat, once per day, continuous treatment for 10 days.
3002626|NCT02545777|Active Comparator|Control group|Take diclofenac sodium enteric-coated, 50 mg, three times a day, continuous treatment for 10 days.
3002627|NCT02545764|Experimental|Intervention|Strength and neuromuscular exercise programme
3002628|NCT02545764|No Intervention|Control|Control group will receive opportunity for the training programme after data capturing is finished
3002629|NCT02545751|Experimental|SBRT and Thymalfasin arm|SBRT is given during combined therapy to one of the lesions, 25Gy in 5 fractions over one week, conformally to maximally spare normal tissue or organ. Thymalfasin treatment is given twice a week with an interval of 3-4 days until tumor progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
3002630|NCT02545738|Experimental|Liraglutide|Liraglutide s.c. up-escalated to 1.8 mg/day for 12 weeks.
3002631|NCT02545738|Placebo Comparator|Placebo|Placebo s.c. for 12 weeks.
3002632|NCT02545712||Neonatal patients|Receiving 2 or more drugs at one day during their hospitalisation. For each drug, it is listed whether it is an extemporaneous, registered, the preparation, dosis, amount, interval, formulation and route of administration. It is noted if the drug contains ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propanyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerin and/or sorbitol.
3002633|NCT02545712||Pediatric patients (28 days ≤ 5 years)|Receiving 3 or more drugs at one day during their hospitalisation. For each drug, it is listed whether it is an extemporaneous, registered, the preparation, dosis, amount, interval, formulation and route of administration. It is noted if the drug contains ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propanyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerin and/or sorbitol.
3002634|NCT02545699|Experimental|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
3002635|NCT02545699|Active Comparator|Standard Colonoscopy|Standard Colonoscopy
3002636|NCT02545686|Experimental|one|"this is a single arm study. All subjects treated the same way, and undergo four interventions:~Chest wall movement assessment without CPAP~Breath hold assessment without CPAP~Chest wall movement assessment with CPAP~Breath hold assessment with CPAP"
3002637|NCT02545673|Experimental|Enhanced Linkage|Participants will receive the enhanced linkage to care Intervention. Behavioral: Enhanced linkage to care Intervention Multiple sessions will focus on providing orientation to the HIV care system, counseling to help clients identify and reduce barriers to engagement in care, assistance disclosing and identifying a treatment supporter, and stigma reduction through increasing social support. The approach is guided by the HIV Stigma Framework.
3002638|NCT02545673|Active Comparator|Standard-of-care plus|Behavioral: Participants will receive the standard-of-care (paper-based referrals) plus return of CD4 test results to their home.
3002639|NCT02545660|Experimental|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the QLF group will be shown the QLFD images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
3002640|NCT02545660|Experimental|White light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown the White light images.Standardized oral hygiene reinforcement shall be given based on the White light images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
3002641|NCT02545647|No Intervention|Standard RYGB|65 patients undergo a standard Roux-en-Y gastric bypass
3002642|NCT02545647|Active Comparator|Banded RYGB|65 patients undergo a banded RYGB (BRYGB)
3002643|NCT02545634|Placebo Comparator|Placebo powder|Placebo powder contains the same ingredients as the probiotic powder except the L. helveticus R0052 and B. longum R0175. All participants will consume the placebo for 28 days during one of two dosing phases.
3002644|NCT02545634|Experimental|Probiotic powder|The Investigational Product is formulated with a combination of two active ingredients: L. helveticus R0052 and B. longum R0175 and the percentage of each strain is 90% and 10% respectively. The minimum total count of L. helveticus R0052 and B. longum R0175 is 3 x 109 colony forming units (CFU) per stick during the shelf-life. The IP also contains the following excipients: xylitol (sweetener), maltodextrin (coating agent), fruit flavor and malic acid (acidity regulator). The total weight is 1.5 g per stick. All participants will consume the placebo for 28 days during one of two dosing phases.
3002645|NCT02545621||ARDS Group (acute respiratory distress syndrome)|The purpose of this monocentric observational prospective pathophysiology study is to compare alveolar monocyte/macrophage activation profiles between patients with or without ARDS
3002646|NCT02545621||control group|The purpose of this monocentric observational prospective pathophysiology study is to compare alveolar monocyte/macrophage activation profiles between patients with or without ARDS
3002647|NCT02545608|Experimental|Restylane Vital|Restylane Vital in one of the hands
3002648|NCT02545608|No Intervention|No treatment|No treatment in the other hand.
3002649|NCT02545595|Experimental|Sugammadex 1mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
3002650|NCT02545595|Experimental|Sugammadex 2mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
3002651|NCT02545595|Experimental|Sugammadex 4mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
3002652|NCT02545582||Therapy|Heart failure patients implanted with the VITARIA system
3002653|NCT02545569|Active Comparator|Hearing Device Type A|In the ear (ITE) hearing aid, 1-3 weeks wearing
3002654|NCT02545569|Experimental|Hearing Device Type B|In the ear (ITE) hearing aid, 1-3 weeks wearing
3002655|NCT02545556|Experimental|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
3002656|NCT02545556|Placebo Comparator|control|liver cancer patients received traditional therapy
3002657|NCT02545543|Experimental|Seqirus Quadrivalent Inactivated Influenza Vaccine|The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
3002658|NCT02545543|Active Comparator|Comparator Quadrivalent Influenza Vaccine|The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
3002659|NCT02545530|Active Comparator|transdermal clonidine+|apply one transdermal clonidine(2.5mg) each week for 4 weeks besides regular antihypertensive agents, reduce oral antihypertensive agents' dosage or type if blood pressure decreased.
3002660|NCT02545530|No Intervention|transdermal clonidine-|regular antihypertensive treatment
3002661|NCT02545517|Experimental|Booster dose single group|Subjects who received a primary series of accelerated or conventional rabies PrEP IM regimen in the parent study, will receive a booster dose based on their individual antibody concentrations measured over time.
3002662|NCT02545504|Experimental|Andecaliximab|Andecaliximab plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by andecaliximab plus LV+5-FU during subsequent cycles
3002663|NCT02545504|Placebo Comparator|Placebo|Placebo plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by placebo plus LV+5-FU during subsequent cycles
3002664|NCT02545491|Experimental|Care for Child Development group|Training of caregivers on the Care for Child Development (CCD) program, in addition to the training on Infant and Young Child feeding program by World Vision.
3002665|NCT02545491|Active Comparator|World Vision Lebanon training group|caregivers will receive training in Infant and Young Child Feeding (WV-IYCF) offered by World Vision.
3002666|NCT02545478||Infected Group|subjects with suspected infection
3002667|NCT02545478||Non-infected group|subjects without any infection
3002668|NCT02545465||BAY63-2521|Patients who have been switched from a Pulmonary Hypertension treatment to Adempas
3002669|NCT02545452|Experimental|BAY98-7196|Investigate the pharmacokinetics effect of a vaginally administered antimycotic (miconazole) during the use of an intra-vaginal ring (IVR) releasing anastrozole (ATZ) and levonorgestrel (LNG)
3002670|NCT02545452|Experimental|Administered Antibiotic|Investigate the pharmacokinetics effect of a vaginally administered antibiotic (clindamycin) during the use of an IVR releasing ATZ and LNG
3002671|NCT02545452|Experimental|Administered Spermicide|Investigate the pharmacokinetics effect of a vaginally administered spermicide (nonoxynol-9) during the use of an IVR releasing ATZ and LNG
3002672|NCT02545452|Experimental|Tampons|Investigate the pharmacokinetics effect of the concomitant use of tampons during the use of an IVR releasing ATZ and LNG; investigate the pharmacokinetics over an extended IVR wearing period of 35 days
3002673|NCT02545439|Experimental|ALKS 5461|Sublingual tablet
3002674|NCT02545426|Active Comparator|Calcium dialysate 2.5mEq/L|Dialysis with low calcium concentration
3002675|NCT02545426|Active Comparator|Calcium dialysate 3.5mEq/L|Dialysis with high calcium concentration
3002676|NCT02545413|Experimental|Probiotic|Probiotic VSL#3 will be given at a dose of one capsule thrice daily for 8 weeks, amounting to a total of 337.5 billion CFU/day. Each capsule contains 112.5 billion viable lyophilized bacteria of four strains of Lactobacillus (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734), three strains of Bifidobacterium (B. longum DSM 24736, B. breve DSM 24732, B. infantis DSM 24737) and one strain of Streptococcus (S. thermophilus DSM 24731) and excipients.
3002677|NCT02545413|Placebo Comparator|Placebo|Placebo capsules will be given at a dose of one capsule thrice daily for 8 weeks; Placebo capsules contain all excipients as present in capsules (without the 8 strains of bacteria as mentioned above).
3002678|NCT02545374|Experimental|Telemedicine|"In the telemedicine arm, all patients will be supported by Telemedicine protocol according to the development of telemedicine in the region.~The use of teleconsultation allows the couple expert doctor / nurse expert to perform a complex of wound assessment consultation and / or chronic. The use of telemedicine allows for acts of telecare, when the nurse applicant sought a remote support of an expert nurse (under the responsibility of a doctor) for the realization of an act. The use of tele-expertise enables physicians to remotely bring special expertise to improve patient care."
3002679|NCT02545374|Active Comparator|Control|"In the control arm, patient care depend on his home, as is currently the case:~If it is in the action zone of Cicat-LR network, then it will be supported by an expert nurse of the network that are physically visit the patient's home-lon is the protocols established by the network.~If not, then it will be supported by the customs of the attending physician and nursing teams who follow him."
3002680|NCT02545361|Experimental|KAHR002|premedication (20mg Dexamethasone (IV), 10mg Loratadine (P.O), and 1gr Paracetamol (P.O), 1 hour before treatment) with 2µg/kg KAHR-102 subcutaneous (SC) injection
3002681|NCT02545322|Experimental|Adaptive Radiotherapy|"Follow-up CT scans during week 3 and week 5 of Treatment~Image-guided adaptive Radiotherapy arm:~Follow-up CT scans are performed on a conventional CT-simulator. Deformable Image Registration between the planning-CT and the follow-up CT (fCT) is done using a dedicated Software package. Delineations for target volumes and organs at risk are transferred to the fCT based on the Deformation vector fields calculated during deformable Image registration. Volumetric changes in target volumes and organs-at-risk are assessed. The initial treatment plan is transferred to the fCT scan. Dosimetric consequences of morphologic changes are analysed with the Focus on target dose coverage for the planning target volume. Adaption and plan re-optimisation are performed."
3002682|NCT02545309||SSC-CIP|Patients with secondary sclerosing cholangitis in critically ill patients
3002683|NCT02545309||control|Patients with similar degree of critical illness who do not develop secondary sclerosing cholangitis in critically ill patients
3002684|NCT02545296|Other|In-vitro Diagnostics|All infants are recruited into the same arm.
3002685|NCT02545283|Experimental|Idasanutlin plus Cytarabine|Participants will receive induction therapy idasanutlin and cytarabine for 5 days followed by 23 days of rest in Cycle 1 (treatment cycle length=28 days). Responding participants may continue with consolidation therapy for a maximum of 2 additional cycles including idasanutlin and cytarabine for 5 days followed by 23 days of rest in each cycle (treatment cycle length=28 days). After each cycle, for participants achieving CRp or complete remission with incomplete blood count recovery (CRi), up to 28 additional days are allowed for blood count recovery, if needed.
3002686|NCT02545283|Placebo Comparator|Placebo plus Cytarabine|Participants will receive induction therapy idasanutlin matching placebo and cytarabine for 5 days followed by 23 days of rest in Cycle 1 (treatment cycle length=28 days). Responding participants may continue with consolidation therapy for a maximum of 2 additional cycles including idasanutlin matching placebo and cytarabine for 5 days followed by 23 days of rest in each cycle (treatment cycle length=28 days). After each cycle, for participants achieving CRp or CRi, up to 28 additional days are allowed for blood count recovery, if needed.
3002687|NCT02545270|Experimental|Group 1: 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation after surgery is completed.
3002688|NCT02545270|Experimental|Group 2: 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation after surgery is completed.
3002689|NCT02545270|Experimental|Group 3: 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation after surgery is completed.
3002690|NCT02545257|Active Comparator|Active comparator|In addition to normal, standard care, participants allocated to intervention group will receive a coordinated medication management model containing prescription review, drug-related problems (DRP) risk assessment and required action based on the DRP risk assessment.
3002691|NCT02545257|No Intervention|Control group (standard care)|Normal, standard care (control group)
3002692|NCT02545244|Experimental|Black Tea|0.5% Black Tea as Mouthwash, 5mL to be used twice daily for 30 seconds undiluted.
3002693|NCT02545244|Active Comparator|Green Tea|0.5% Green Tea as Mouthwash, 5mL to be used twice daily for 30 seconds undiluted.
3002694|NCT02545244|Active Comparator|Chlorhexidine|0.12% Chlorhexidine Mouthwash 5mL to be used twice daily.
3002695|NCT02545231|Active Comparator|Low dose 1mg pitavastatin|pitavastatin 1mg which is considered low dose statin will be administered for 36 months
3002696|NCT02545231|Active Comparator|High dose 4mg pitavastatin|pitavastatin 4mg which is considered high dose statin will be administered for 36 months
3002697|NCT02545218|Active Comparator|Perineorraphy.|Secondary surgical repair of the perineal body. Operation is performed by a urogynecologist in an operation theater in local anesthesia. The operation aims to re-create the anatomy in the injured perineum using 2-4 sutures.
3002698|NCT02545218|Active Comparator|Pelvic floor exercise.|Tutored pelvic floor exercise. A trained physio therapist evaluate the pelvic floor musculature and helps the patient to perform proper pelvic floor exercises using biofeedback. The patient receives a training scheme and meets the therapist regularly every second week during 4 months.
3002699|NCT02545205|Experimental|Hybrid Assistive Limb (HAL)|
3002700|NCT02545205|Active Comparator|Conventional gait training|
3002701|NCT02545192|Experimental|Active LFMS treatment|20 minutes of active Low Field Magnetic Stimulation using the LFMS device.
3002702|NCT02545192|Sham Comparator|Sham LFMS treatment|20 minutes of sham Low Field Magnetic Stimulation using the LFMS device.
3002703|NCT02545179|Experimental|intervention|web-based daily care training 12 week interactive web based caring training education
3002704|NCT02545179|No Intervention|control|Previous therapy
3002705|NCT02545166||Carotid endarterectomy patients|40 male and female patients, aged 18 years and over, scheduled for carotid endarterectomy. Fasted pre-operative (arterial and capillary), peri-operative (arterial) and 1-hour and 24-hour post-operative (arterial) blood samples will be collected and analysed for serum purine concentration.
3002706|NCT02545166||Control patients|80 age and sex-matched control patients scheduled for non-vascular, non-oncological day surgery. A single pre-operative fasted capillary (finger-prick) blood sample will be collected and analysed for serum purine concentration.
3002707|NCT02545153|Active Comparator|Fibrin sealant|Tisseel, Baxter (Aprotinin and Fibrinogen)
3002708|NCT02545153|Placebo Comparator|Control|Suturing the incision without fibrin glue
3002709|NCT02545140||UK (Lead Site)|"Data will be collected from 100 adolescents from each participating site providing clinical data for 500 adolescents providing a cross-sectional cohort from each of the following countries:~UK (Lead Site) Germany Portugal Greece Spain (Basque Country)"
3002710|NCT02545127|Experimental|Merotocin (a selective oxytocin-receptor agonist)|
3002711|NCT02545127|Placebo Comparator|Placebo|
3002712|NCT02545114|Other|Tolvaptan|Intervention arm. Open label, no control group
3002713|NCT02545088|Experimental|Study group Hybrid Assistive Limb (HAL)|
3002714|NCT02545088|Active Comparator|1st control group|
3002715|NCT02545088|Active Comparator|2nd control group|
3002716|NCT02545075|Experimental|Ipilimumab|Intravenously (IV) 3 mg/kg every 3 weeks (at week 1,4,7,10) and thereafter (q3w/4 doses) at the time of progression
3002717|NCT02545075|Experimental|Dacarbazine|IV solution 250 mg/m2 (Day 1-5, every 3weeks/at week 1, 4, 7, 10,13,16,19,22)
3002718|NCT02545062|Experimental|group of type 1 and 2 diabetics|"A group of type 1 and 2 diabetes patients who meets the inclusion criteria will be done the MoCa test. A fingertip blood glucose will be made previous to the begin with the test in order to avoid doing it on a hypoglycemia event. The participants are instructed to do or respond the items in a organized manner. For each items there's a score. If the participant has 12 years of education or fewer, a point is added to his total score. At the end of the test the investigator will sum all sub items scores listed on the right side of the test paper. The maximum score is 30.~The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria."
3002719|NCT02545062|Experimental|control group|The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria.
3002720|NCT02545049|Experimental|BAY94-8862|Finerenone tablet
3002722|NCT02545036|Experimental|TCM daycare model|30 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The intervention is Traditional Chinese Medicine (TCM) daycare model, which provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage on meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total). And the model will be provided by a team work clinical care system organized by doctors, nurses, pharmacists and case managers, also provide a comprehensive TCM care system for every visit.
3002723|NCT02545036|No Intervention|Control group|30 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The control group will only receive assessment and follow-up without intervention.
3002724|NCT02545023||Observational (Supportive care, health-related QOL)|Participants complete the demographic questionnaire, SCNS-34, SF-36, and the Lifestyle Needs Survey. Within 1 year of completing questionnaires, some participants may complete a one-hour in-person one-on-one interview comprising questions about the challenges and experiences of cancer survivorship, their health and well-being, and supportive care needs.
3002725|NCT02545010|Experimental|LDWART + paclitaxel|All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices. Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.
3002726|NCT02544997|Experimental|Poziotinib|12mg P.O. for 2wks q21days
3002727|NCT02544984|Placebo Comparator|placebo|The control group will be provided with a placebo medication of similar taste, color, texture, and consistency as the study medication, and will be dispensed once a day on Monday, Wednesday, and Friday.
3002728|NCT02544984|Experimental|azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will be not be adjusted if a new weight is obtained during the trial period.
3002729|NCT02544971|Experimental|NF-N group|Neurofeedback in a neutral context
3002730|NCT02544971|Active Comparator|NF-T group|Neurofeedback in a trauma-related context
3002731|NCT02544971|Active Comparator|Control group|Treatment as usual
3002732|NCT02544958|Experimental|Er:YAG laser|4 treatments of 1 month interval
3002733|NCT02544945|Active Comparator|Standard Bolus|The radiotherapy treatment days when the standard bolus is used
3002734|NCT02544945|Experimental|3D printed bolus|the radiotherapy treatment days when the 3D bolus is used
3002735|NCT02544932|Experimental|dabigatran 110mg or 150mg|After once enrolled, subjects will be randomized to dabigatran group. (110mg or 150mg twice a day)
3002736|NCT02544932|Experimental|ribaroxaban 20mg|After once enrolled, subjects will be randomized to ribaroxaban group. (20mg once daily)
3002737|NCT02544932|Active Comparator|warfarin|After once enrolled, subjects will be randomized to warfarin group. (controlled by INR 2-3)
3002738|NCT02544919|No Intervention|Control group|No Intervention group: Patients do not receive any lipid emulsion of any type during the study period
3002739|NCT02544919|Active Comparator|SMOF Group|Intervention Group: Patients receive 1 gm.kg.day-1 SMOFlipid for 48 hours before the operation and 5 days post-operatively.
3002740|NCT02544906|No Intervention|Control|No drugs will be given. the emergence agitation will be monitored and recorded
3002741|NCT02544906|Experimental|Propofol group|Propofol at dose of 1 mg/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded
3002742|NCT02544906|Experimental|dexmedetomedine group|dexmedetomedine at dose of .5 mic/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded
3002743|NCT02544893|Active Comparator|bupivacaine|0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on paravertebral block
3002744|NCT02544893|Active Comparator|dexmedetomidine|100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on paravertebral block
3002745|NCT02544893|Active Comparator|serum phsyologic|0,9% 21 ml serum physiologic
3002746|NCT02544880|Experimental|Phase 1 - Tadalafil + Vaccine|Tadalafil, Anti-MUC1 Vaccine, and Anti-Influenza Vaccine -
3002747|NCT02544880|Experimental|Phase 2 - Arm TV|Tadalafil, Anti-MUC1 Vaccine, and Anti-Influenza Vaccine
3002748|NCT02544880|Placebo Comparator|Phase 2 - Arm TVp|Tadalafil and Vaccine Placebo
3002749|NCT02544880|Placebo Comparator|Phase 2 - Arm TpV|Tadalafil Placebo; Anti-MUC1 Vaccine and Anti-Influenza Vaccine.
3002750|NCT02544880|Other|Phase 1/2 - Non-Randomized Control Group|For eligible participants who are unwilling to receive study treatment but consent to correlative peripheral blood collection and/or tumor specimen collection, DTH Skin Testing and follow-up for recurrence.
3002751|NCT02544867|Experimental|Reduction in sitting time|Those randomized to this condition focused on reducing their overall sitting time by two hours per day (a goal achieved in similar studies [17,18] that represented approximately a 25% reduction in daily sitting time). Participants were encouraged to reach this goal by standing in bouts of roughly 10 minutes per hour. The purpose of this arm was to investigate whether we could replicate improvements in sitting time achieved in other worksite studies in our cohort of older adults, which included both workers and non-workers.
3002752|NCT02544867|Experimental|Increase in sit-to-stand transitions|Those randomized to the sit-to-stand condition focused on increasing the number of sit-to-stand transitions they performed throughout the day with a goal of adding 30 additional transitions per day. Previous studies have not succeeded in increasing the number of sit-to-stand transitions in older adults, possibly because they focused on reducing overall sitting time, encouraged longer standing breaks and did not provide a specific goal for sit-to-stand transitions [26-28]. An increase in sit-to-stand transitions would not be expected with an increase standing intervention alone, as prolonged standing reduces the opportunity for sit-to-stand transitions.
3002753|NCT02544854|Experimental|Ages 1 year - 3 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
3002754|NCT02544854|Experimental|Ages 4 years - 8 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
3002755|NCT02544854|Experimental|Ages 9 years - 11 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
3002756|NCT02544841|Experimental|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is the treatment condition. SSI is an in-person, individual-level, clinic-based intervention that aims to reduce risky sexual behaviors among sexually active adolescent females.
3002757|NCT02544841|Active Comparator|Female Sexual Health|Female Sexual Health is the control counterfactual condition. It is an individual-level, information-only sex education program that aims to increase participants' knowledge on various topics related to STIs.
3002758|NCT02544828|Experimental|Experimental group|Iron Sucrose 200mg
3002759|NCT02544828|Placebo Comparator|Control Group|placebo
3002760|NCT02544815|Active Comparator|Digoxin|Oral digoxin 0.25 mg: one pill per day for three consecutive days.
3002761|NCT02544815|Placebo Comparator|Placebo|Oral placebo for three days.
3002762|NCT02544802|Experimental|ADMSCs|Three intra-articular injections of ADMSCs at the dose of 8~10x10^6 cells/injection
3002763|NCT02544789|Experimental|clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
3002764|NCT02544776|Experimental|Clomifene citrate and Amlodipine|Amlodipine 5mg tablet and Clomifene citrate 50 mg tablet once by mouth daily at morning starting from day number 5 of menstrual cycle till day number 9.
3002765|NCT02544776|Active Comparator|Clomifene citrate|Clomifene citrate 50mg and once daily at morning starting from day number 5 of menstrual cycle till day number 9
3002766|NCT02544763|Experimental|25 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
3002767|NCT02544763|Experimental|50 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
3002768|NCT02544763|Placebo Comparator|Placebo|Placebo oral solution matching 100 mg/mL GWP42003-P.
3002769|NCT02544750|Experimental|GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening). Participants will be dosed up to a maximum of 50 mg/kg/day. Dose may be lower if Investigator judges benefit and/or tolerability issues.
3002770|NCT02544737|Experimental|Apatinib arm|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
3002771|NCT02544724|Experimental|NM-IL-12|NM-IL-12 will be administered subcutaneously
3002772|NCT02544711|Experimental|Prospective group :Innovation|Surgical treatment using a patient specific instrument (PSI)
3002773|NCT02544711|Other|Retrospective group: Reference|Conventional surgical treatment without PSI, using 2D imaging planification
3002774|NCT02544698|Experimental|One dose of PCV13a vaccine in aged 18 years and older|One dose of PCV13a vaccine will be given in aged 18 years and older
3002775|NCT02544698|Experimental|One dose of PCV13a vaccine in aged 2-5 years old|One dose of PCV13a vaccine will be given in aged 2-5 years old
3002776|NCT02544698|Experimental|One dose of PCV13 vaccine will be given at 2, 4, 6 months|One dose of PCV13 vaccine will be given at 2, 4, 6 months respectively in aged 2 months old
3002777|NCT02544698|Experimental|One dose of PCV13 vaccine will be given at 3、4、5 months|One dose of PCV13 vaccine will be given at 3、4、5 months respectively in aged 3 months old
3002778|NCT02544685|Active Comparator|Synbiotics group|"Interventions: administration of Probio-Fix Inum + Beneo Synergy 1~Start of prophylaxis: 5 days before or 2 days after starting chemotherapy~Prophylaxis duration: 3 months"
3002779|NCT02544685|Placebo Comparator|Placebo group|"Interventions: administration of placebo~Start: 5 days before or 2 days after starting chemotherapy~Duration: 3 months"
3002780|NCT02544672|Experimental|Myoelectric Elbow-Wrist-Hand Orthosis|
3002781|NCT02544659|Experimental|pamidronate disodium|the patients will be administered intravenous pamidronate disodium
3002782|NCT02544646|Other|trabeculectomy|
3002783|NCT02544633|Experimental|Arm 1|MGCD265 in patients with MET activating mutations in tumor tissue
3002784|NCT02544633|Experimental|Arm 2|MGCD265 in patients with MET gene amplifications in tumor tissue
3002785|NCT02544633|Experimental|Arm 3|MGCD265 in patients with MET activating mutations in blood (circulating tumor DNA)
3002786|NCT02544633|Experimental|Arm 4|MGCD265 in patients with MET gene amplifications in blood (circulating tumor DNA)
3002787|NCT02544620||Total Hip arthroplasty|"Unselected primary THA~American Society of Anesthesiologists (ASA) score I/II~Can be operated as #1 or #2~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
3002788|NCT02544620||Total Knee arthroplasty|"Unselected primary TKA~American Society of Anesthesiologists (ASA) score I/II~Can be operated as #1 or #2~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
3002789|NCT02544620||unicompartmental knee arthroplasty|"Unselected primary UKA~American Society of Anesthesiologists (ASA) score I/II~Can be operated as #1 or #2~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
3002790|NCT02544607|Experimental|Ketamine|All eligible participants will receive open label ketamine
3002791|NCT02544594|Active Comparator|Extra-Corporal Life Support (ECLS)|Standard treatment plus Extra-Corporal Life Support (ECLS) (from Sorin) in patients with cardiogenic shock due to myocardial infarction.
3002792|NCT02544594|No Intervention|Standard treatment|Standard treatment alone without Extra-Corporal Life Support (ECLS) in patients with cardiogenic shock due to myocardial infarction.
3002793|NCT02544581||Mandated impaired professionals|Physicians and other licensed healthcare professionals in mandated monitoring programs by State licensing boards due to Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment.
3002794|NCT02544581||Non-mandated adults|A general population of adults in aftercare following residential treatment for Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment.
3002795|NCT02544568|Experimental|High-Carb Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
3002913|NCT02543931|Experimental|Meriva, high dose|Participants will take 4 Meriva-500mg capsules twice a day for one month
3002796|NCT02544568|Experimental|High-Protein Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
3002797|NCT02544568|Experimental|High-Fat Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
3002798|NCT02544568|Experimental|High-Fibre Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr).
3002799|NCT02544555|Experimental|Intentional intraluminal approach|Intentional intraluminal approach is the way that the passage of guidewire in chronic total occlusive femoro-popliteal arterial lesion is performed via intraluminal route using various intraluminal devices. in an intraluminal approach, the response to the balloon is more favorable, but the outcome depends on the experience of the surgeon, and the approach requires more time and is more costly.
3002800|NCT02544555|Active Comparator|Intentional subintimal approach|Intentional subintimal approach is the method that recanalization is performed via subintimal route with a 0.035-inch looped guidewire and a supporting catheter at the occlusion site. Due to its simplicity and low cost, this approach has been used for many patients with femoropopliteal occlusion.
3002801|NCT02544542|Experimental|Rectum cooling system|Insert the self-made device into the patient's rectum, pump ice-cold saline in to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by controlling the pumping speed of saline.
3002802|NCT02544542|Active Comparator|Hyper-hypothermia blanket|Let the patient sleep on the hyper-hypothermia blanket, set the target temperature to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by adjusting the target temperature of the device accordingly.
3002803|NCT02544529|Experimental|Echothiophate Iodide|Echothiophate Iodide 0.03% one drop to each eye three times per week for 18 weeks
3002804|NCT02544529|Placebo Comparator|Carboxymethylcellulose Sodium (0.5%)|Carboxymethylcellulose Sodium (0.5%) one drop to each eye three times per week for 18 weeks
3002805|NCT02544516|Experimental|Patients|patients suffering schizophrenic disorders and who will perform cognitive tasks + PANSS+ IQ
3002806|NCT02544516|Active Comparator|control group|healthy patients who will perform cognitive tasks
3002807|NCT02544503|Experimental|Stroke Patients|Subjects will undergo single pulse transcranial magnetic stimulation (TMS), paired pulse transcranial stimulation (ppTMS), and low frequency repetitive transcranial magnetic stimulation (rTMS) at one month and six months post stroke.
3002808|NCT02544503|Active Comparator|Healthy Controls|Subjects will undergo single pulse transcranial magnetic stimulation (TMS), paired pulse transcranial stimulation (ppTMS), and low frequency repetitive transcranial magnetic stimulation (rTMS) at one month and six months.
3002809|NCT02544477|Experimental|High-flow nasal cannula oxygen (HFNCO)|Patients will receive HFNCO treatment with a gas flow level = 50 L/min and a FiO2 set to maintain peripheral oxygen saturation (SpO2) of 92% - 98%.
3002810|NCT02544477|Active Comparator|standard oxygen therapy|Patients will receive oxygen treatment by means of a conventional face mask, with a level of fraction of inspired oxygen (FiO2) set to maintain peripheral oxygen saturation (SpO2) of 92% - 98%.
3002811|NCT02544464|Experimental|Experimental group|ferric carboxymaltose 1000 mg
3002812|NCT02544464|Placebo Comparator|Control group|placebo
3002813|NCT02544451|Experimental|Treatment Cohort: lumacaftor/ivacaftor (6 through 11)|Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (subjects aged 6 through 11 years)
3002814|NCT02544451|Experimental|Treatment Cohort: lumacaftor/ivacaftor (12 and older)|LUM 400 mg q12h/IVA 250 mg q12h (subjects aged 12 years and older)
3002815|NCT02544451|No Intervention|Observational Cohort|Long-term Follow-up
3002816|NCT02544438|Experimental|Astarabine|Astarabine
3002817|NCT02544425|Experimental|VIDL+ASCT|"VIDL Induction (repeated 28 days) : VP-16, Ifosfamide, Dexamethasone, L-asparaginase~Peripheral blood stem cell mobilization:Etoposide~Conditioning regimen for autologous stem cell transplantation:Busulfan,Melphalan,Etoposide"
3002818|NCT02544412|Experimental|Intervention Group|"A novel mindfulness-based well-being training for preservice teachers will be employed. The intervention will be held once a week for 8-10 weeks. Two 4-hour days of mindfulness will also be implemented during the intervention period. The intervention will involve training in a range of attentional and constructive (Dahl, Lutz, & Davidson) contemplative practices. During the follow-up period participants will receive weekly 15 minute booster trainings."
3002819|NCT02544412|No Intervention|Control Group|Teacher education as usual. These participants will continue with the prescribed teacher training regime established by the Early Education Certification Program at the university.
3002820|NCT02544399||Subject practicing golf and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
3002821|NCT02544399||Subject practicing foot walk and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
3002822|NCT02544399||Subject sedentary and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
3002823|NCT02544386||Patients|Patients who have experienced a vascular hemiplegia and accept bone measure by MRI and 3D CT scan
3002824|NCT02544373|Active Comparator|Immediate PAP therapy (Group 1)|Subjects will receive PAP treatment for OSA as soon as possible after baseline PSG and repeat baseline cognitive testing 3 months after initiation of PAP therapy. PAP therapy is considered standard clinical care for OSA. It involves wearing an apparatus that includes a hose and a mask (that covers the nose, or nose and mouth), connected to a small machine that blows air into the airway during sleep. The degree of air pressure given depends on your apnea severity, and the supplied air pressure can be continuous or change with your breathing pattern (bilevel).
3002825|NCT02544373|Other|Standard Care PAP therapy (Group 2)|Subjects will delay PAP treatment for 3 months following their baseline sleep study, and repeat their baseline cognitive testing prior to PAP treatment for sleep apnea. PAP therapy is considered standard clinical care for OSA. It involves wearing an apparatus that includes a hose and a mask (that covers the nose, or nose and mouth), connected to a small machine that blows air into the airway during sleep. The degree of air pressure given depends on your apnea severity, and the supplied air pressure can be continuous or change with your breathing pattern (bilevel).
3035154|NCT02327221|Active Comparator|Ovasave - Dose 10e6|
3002826|NCT02544360|Experimental|Intervention|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
3002827|NCT02544360|No Intervention|Control|The control group consists of schools participating in the survey but not receiving the intervention.
3002828|NCT02544347|Other|diabetes mellitus group|gingival crevicular fluid was collected
3002829|NCT02544347|Other|Control group|gingival crevicular fluid was collected
3002830|NCT02544347|Other|diabetics with chronic periodontitis group|non-surgical periodontal treatment was completed and gingival crevicular fluid was collected
3002831|NCT02544347|Other|chronic periodontitis group|non-surgical periodontal treatment was completed and gingival crevicular fluid was collected
3002832|NCT02544334||RA - naïve to biologics|This group will consist of 25 Rheumatoid Arthritis (RA) adult subjects who have not been treated with biologics (naïve to biologics). During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
3002833|NCT02544334||Healthy Controls|This group will consist of 25 adult subjects which will be healthy controls from members of the same household as the 25 naive to biologics, and be of the same age. During the exam the following will take place: dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
3002834|NCT02544334||RA responsive to anti-TNF|This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who have been responsive to first line anti-TNF-alpha therapy. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
3002835|NCT02544334||RA non responsive to anti-TNF|This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who are resistant to two or more anti-TNF-alpha therapies, and be of the same age as the RA responsive to anti-TNF group. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
3002836|NCT02544321|Active Comparator|Bromocriptine QR|4 weeks of investigational drug Bromocriptine QR
3002837|NCT02544321|Placebo Comparator|Placebo|4 weeks of placebo
3002838|NCT02544308|Active Comparator|No further treatment|No further treatment
3002839|NCT02544308|Experimental|Lenalidomide + Dexamethasone|Lenalidomide 25mg orally daily on days 1-21 Dexamethasone 20mg orally on days 1, 8, 15 & 22 Up to 9 cycles
3002840|NCT02544295|Experimental|Clinical interview-Virtual reality task:1|Healthy controls will be assessed by a clinical interview by a psychiatrist, once, 1 day-duration and Virtual reality task, once, 1 day-duration
3002841|NCT02544295|Experimental|Clinical interview-Virtual reality task:2|Patients will be assessed by a clinical interview by a psychiatrist, once, 1 day-duration and Virtual reality task, once, 1 day-duration
3002842|NCT02544282|Active Comparator|Pecs II|General anesthesia followed by a Pecs II block and opioids if required
3002843|NCT02544282|Placebo Comparator|Placebo|General anesthesia followed by a placebo Pecs II block and opioids if required
3002844|NCT02544269|Experimental|Lumbosacral plexus blockade|Peripheral nerve blockade of lumbar and sacral plexus with ropivacaine max 225 mg perineural
3002845|NCT02544269|Active Comparator|Continuous spinal anesthesia|Continuous spinal anesthesia with plain bupivacaine max 15 mg intrathecal
3002846|NCT02544256|Experimental|Mild hypothermia|After induction to general anaesthesia the patients will be cooled to 33° C. Targeted body temperature 33,8° C - 34,8° will be maintained up to the end of microcirculation measurement after aneurysm clipping.
3002847|NCT02544256|No Intervention|Normothermia|The body temperature will be maintained in the range 35,8° C - 36,8° C.
3002848|NCT02544243|Experimental|A|Vinorelbine 25 mg/m2 d1, 8; Gemcitabine 1000 mg/m2 d1, 8 q 3 weeks
3002849|NCT02544243|Experimental|B|Vinorelbine 25 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1,2,3 q 3 weeks
3002850|NCT02544217|Experimental|Single Escalating|2 alternating groups receiving escalating single doses of active/placebo
3002851|NCT02544217|Experimental|Multiple Escalating|3 multiple escalating groups, receiving active/placebo
3002852|NCT02544204|Active Comparator|8 mg JVS-100|Biological/Vaccine: JVS-100 Injection Intramuscular Injection
3002853|NCT02544204|Placebo Comparator|8 mg placebo|Biological/Vaccine: Placebo Injection Intramuscular Injection
3002854|NCT02544204|Active Comparator|16 mg JVS-100|Biological/Vaccine: JVS-100 Injection Intramuscular Injection
3002855|NCT02544204|Placebo Comparator|16 mg placebo|Biological/Vaccine: Placebo Injection Intramuscular Injection
3002856|NCT02544191|Experimental|GnRHa/ hCG/ hMG|3.6mg GnRHa (Goserelin, AstraZeneca UK Limited) every 28days for 5 months. After 2 months from the first Goserelin injection, all subjects were treated with hCG (Pregnyl, N.V. Organon Oss,Holland ) at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG (Urofollitropin for Injection, Livzon Pharm Group Inc., China) at a dose of 150 IU every 3 days for 2 months.
3002857|NCT02544178||diagnostic procedure|neurocognitive tests before and after radiotherapy
3002858|NCT02544165|Experimental|Caffeine intake|100mg of Caffeine intake
3002859|NCT02544165|Experimental|Cigarette smoking|smoking of one cigarette
3002860|NCT02544165|Experimental|Caffeine intake and Cigarette smoking|100mg of Caffeine intake and smoking of one cigarette
3002861|NCT02544165|No Intervention|Control group|no intervention group
3002862|NCT02544152|Experimental|Lubiprostone|8 mcg capsules twice daily (BID)
3002863|NCT02544152|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
3002864|NCT02544126|Experimental|eSMART-MH|HIV+ young adults will be randomized to receive Electronic Self-Management Resource Training for Mental Health (eSMART-MH)
3002865|NCT02544126|Active Comparator|Attention Control|HIV+ young adults will be randomized to receive screen-based health education
3002914|NCT02543918|Experimental|Ixekizumab + Boostrix® + Pneumovax®23|"Ixekizumab administered once by subcutaneous injection (SQ) at week 0 and once at week 2.~Boostrix® and Pneumovax®23 administered once by intramuscular (IM) injection into opposing arms at week 2."
3002915|NCT02543918|Other|Boostrix® + Pneumovax®23|Boostrix® and Pneumovax®23 administered once by IM injection into opposing arms at week 2.
3002866|NCT02544113|Experimental|Thymo|Subjects randomized to the (Delay CNI) group will be treated with Thymoglobulin® (total dose of 4.5 mg/kg) administered in three doses; (each dose being 1.5 mg/kg - administered Day 0 [after transplant], Day 2, and Day 4 post transplant), along with CNI delay for 10 days. CNI will be initiated on postoperative (post-transplant) Day 10. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
3002867|NCT02544113|Placebo Comparator|Control|Subjects randomized to the (Early CNI) group (Control group) will receive no antibody therapy for induction and will start CNI therapy on postoperative (post-transplant) Day 2. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
3002868|NCT02544100||Database Entry / Biospecimen Collection|Systematic Medical information of infants born with severe encephalopathy entered into database. In addition, Blood, urine, CFS samples will be collected.
3002869|NCT02544087|No Intervention|The basic treatment|Comply to the Chinese guidlines of acute ischemic stroke in 2014
3002870|NCT02544087|Other|Clearing heat|Treat with KDZ injection on the basis of basic treatment
3002871|NCT02544087|Other|Promoting blood circulaton|Treat with Xueshuantong injection on the basis of basic treatment
3002872|NCT02544087|Experimental|Clearing heat&Promoting blood circulaton|Treat with both KDZ injection and Xueshuantong injection on the basis of basic treatment
3002873|NCT02544074||eSAGE score of 10|Participants who score a 10 on the eSAGE. Interventions include neuropsychological testing.
3002874|NCT02544074||eSAGE score of 11|Participants who score an 11 on the eSAGE. Interventions include neuropsychological testing.
3002875|NCT02544074||eSAGE score of 12|Participants who score a 12 on the eSAGE. Interventions include neuropsychological testing.
3002876|NCT02544074||eSAGE score of 13|Participants who score a 13 on the eSAGE. Interventions include neuropsychological testing.
3002877|NCT02544074||eSAGE score of 14|Participants who score a 14 on the eSAGE. Interventions include neuropsychological testing.
3002878|NCT02544074||eSAGE score of 15|Participants who score a 15 on the eSAGE. Interventions include neuropsychological testing.
3002879|NCT02544074||eSAGE score of 16|Participants who score a 16 on the eSAGE. Interventions include neuropsychological testing.
3002880|NCT02544074||eSAGE score of 17|Participants who score a 17 on the eSAGE. Interventions include neuropsychological testing.
3002881|NCT02544074||eSAGE score of 18|Participants who score a 18 on the eSAGE. Interventions include neuropsychological testing.
3002882|NCT02544074||eSAGE score of 19|Participants who score a 19 on the eSAGE. Interventions include neuropsychological testing.
3002883|NCT02544074||eSAGE score of 20|Participants who score a 20 on the eSAGE. Interventions include neuropsychological testing.
3002884|NCT02544074||eSAGE score of 21|Participants who score a 21 on the eSAGE. Interventions include neuropsychological testing.
3002885|NCT02544074||eSAGE score of 22|Participants who score a 22 on the eSAGE. Interventions include neuropsychological testing.
3002886|NCT02544074||eSAGE score of 9|Participants who score a 9 on the eSAGE. Interventions include neuropsychological testing.
3002887|NCT02544074||eSAGE score of 8|Participants who score an 8 on the eSAGE. Interventions include neuropsychological testing.
3002888|NCT02544074||eSAGE score of 6|Participants who score a 6 on the eSAGE. Interventions include neuropsychological testing.
3002889|NCT02544074||eSAGE score of 7|Participants who score a 7 on the eSAGE. Interventions include neuropsychological testing.
3002890|NCT02544074||eSAGE score of 5|Participants who score a 5 on the eSAGE. Interventions include neuropsychological testing.
3002891|NCT02544074||eSAGE score of 4|Participants who score a 4 on the eSAGE. Interventions include neuropsychological testing.
3002892|NCT02544074||eSAGE score of 3|Participants who score a 3 on the eSAGE. Interventions include neuropsychological testing.
3002893|NCT02544074||eSAGE score of 2|Participants who score a 2 on the eSAGE. Interventions include neuropsychological testing.
3002894|NCT02544061|Experimental|NM-IL-12|Single 12 µg unit subcutaneous dose of NM-IL-12 plus Standard of Care (SOC)
3002895|NCT02544061|No Intervention|Standard of Care|Standard wound management: wet to dry dressing care and perioperative antimicrobial therapy
3002896|NCT02544035|Experimental|1|6-11 month-olds
3002897|NCT02544035|Experimental|2|12-18 month-olds (1-1.5 year olds)
3002898|NCT02544035|Experimental|3|19-35 month-olds (1.5-2 year-olds)
3002899|NCT02544035|Experimental|4|36-71 month-olds (3-5 year-olds)
3002900|NCT02544035|Experimental|5|72-107 month-olds (6-8 year-olds)
3002901|NCT02544035|Experimental|6|108-144 month-olds (9-12 year-olds)
3002902|NCT02544035|Experimental|8|12-18 month-olds (1-1.5 year olds)
3002903|NCT02544035|Experimental|9|19-35 month-olds (1.5-2 year olds)
3002904|NCT02544035|Experimental|10|36-71 month-olds (1.5-2 year olds)
3002905|NCT02544035|Experimental|11|72-107 month-olds (6-8 year-olds)
3002906|NCT02544035|Experimental|12|108-144 month-olds (9-12 year-olds)
3002907|NCT02544035|Experimental|7|6-11 month-olds
3002908|NCT02543983|Experimental|1|Participants will be administered open-label intravenous ketamine.
3002909|NCT02543944|Active Comparator|Gabapentin|"Gabapentin started on day 3 of week 1, increased up to a maximum dose of 800 mg BID by day 3 of week 2 and maintained for 2 weeks followed by 5-day taper.~Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.~During week 4, detoxed subjects get 0.1 mg of clonidine followed by oral naltrexone (NTX) at 6.25 mg and another 6.25 mg (day 1), 25 mg (day 2) and 50 mg (day 3) then depot NTX injection (later on day 3 or day 4)."
3002910|NCT02543944|Placebo Comparator|Placebo|"Participants in this arm begin receiving placebo (microcrystalline cellulose) in twice daily capsules on day 3 of week 1 and continue to do so through the beginning of week 5.~Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.~During week 4, detoxed subjects get 0.1 mg of clonidine followed by oral naltrexone (NTX) at 6.25 mg and another 6.25 mg (day 1), 25 mg (day 2) and 50 mg (day 3) then depot NTX injection (later on day 3 or day 4)."
3002911|NCT02543931|Placebo Comparator|Placebo|Participants will take 4 placebo capsules twice a day for one month
3002912|NCT02543931|Experimental|Meriva, low dose|Participants will take 4 Meriva-250mg capsules twice a day for one month
3002916|NCT02543905||Family History Cohort|"Men with a family history of prostate cancer defined as:~Men with a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at <70 years~Men with two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at <70 years~Men with three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age"
3002917|NCT02543905||Black African / Black Caribbean Cohort|Both parents and all 4 grandparents from that origin
3002918|NCT02543892|Experimental|Adult 0.6mg PATH-wSP|Two 0.6 mg doses of PATH-wSP with a 28 day interval between doses
3002919|NCT02543892|Placebo Comparator|Adult Placebo Low Dose|Two injections of normal saline with a 28 day interval between injections
3002920|NCT02543892|Experimental|Adult 1.0 mg PATH-wSP|Two 1 mg doses of PATH-wSP with a 28 day interval between doses
3002921|NCT02543892|Placebo Comparator|Adult Placebo High Dose|Two injections of normal saline with a 28 day interval between injections
3002922|NCT02543892|Experimental|Toddler 0.6mg PATH-wSP|Two 0.6 mg doses of PATH-wSP with a 28 day interval between doses
3002923|NCT02543892|Placebo Comparator|Toddler Placebo Low Dose|Two injections of normal saline with a 28 day interval between injections
3002924|NCT02543892|Experimental|Toddler 1.0 mg PATH-wSP|Two 1 mg doses of PATH-wSP with a 28 day interval between doses
3002925|NCT02543892|Placebo Comparator|Toddler Placebo High Dose|Two injections of normal saline with a 28 day interval between injections
3002926|NCT02543879|Experimental|Dose Escalation FT-1101|Following a 3+3 dose escalation strategy, the first cohort of patients will be administered FT-1101 at 10 mg, oral capsules, once weekly on a continuous basis. Subsequent cohorts dose and frequency will be determined by investigators and sponsor following observations of previous cohorts. Dose escalation will continue until the MTD is determined.
3002927|NCT02543879|Experimental|Dose Expansion FT-1101|Once the MTD is determined, the Recommended Phase 2 Dose (RP2D) will be identified. 3 Expansion cohorts of up to 20 patients each will be treated with the RP2D of FT-1101
3002928|NCT02543879|Experimental|Dose Escalation FT-1101 + azacitidine|Following a 3+3 dose escalation strategy, the first cohort of AML/MDS patients will be administered FT-1101 at approximately 50% or lower than the MTD identified for the single agent FT-1101. Subsequent cohorts dose will be determined by investigators and sponsor following observations of previous cohorts. Dose escalation will not exceed the dose determined to be the single agent MTD for that schedule.
3002929|NCT02543879|Experimental|Dose Expansion FT-1101 + azacitidine|Once the MTD is determined, the Recommended Phase 2 Dose (RP2D) will be identified. 1 Expansion cohorts of up to 20 AML/MDS patients each will be treated with the RP2D of FT-1101 in combination with azacitidine.
3002930|NCT02543866|Experimental|Fecal Microbiota Transplantation|Subjects will receive 50mL of prepared stool fecal via nasogastric tube
3002931|NCT02543853|Active Comparator|veres needle entry arm|Vere needle will be used to provide penumoperiteum than postoperative gastrointestinal functions will be compared
3002932|NCT02543853|Active Comparator|direct trocar entry arm|Direct trocar entry will be used to provide penumoperiteum than postoperative gastrointestinal functions will be compared
3002933|NCT02543840|Experimental|Implementation Facilitation|Implementation Facilitation consists of the Center for Disease Control's Replicating Effective Programs, plus External Facilitation. The intervention lasts 6 months followed by a 6-month step-down period.
3002934|NCT02543840|Placebo Comparator|Educational Materials|Dissemination of available materials explaining the Collaborative Chronic Care Model and implementation tools. Sites randomized to delay initiation of facilitation will have these materials plus technical assistance for 4 or 8 months prior to full implementation facilitation.
3002935|NCT02543827|Experimental|MV140 I|The subjects will receive daily dose of MV140 during 6 months
3002936|NCT02543827|Experimental|MV140 II|The subjects will receive daily dose of MV140 during 3 months and placebo during 3 months
3002937|NCT02543827|Placebo Comparator|Placebo|The subjects will receive daily dose of placebo during 6 month
3002938|NCT02543801|Active Comparator|Liposomal Bupivacaine|Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac
3002939|NCT02543801|Active Comparator|Ropivacaine|Ropivacaine Clonidine Epinephrine Ketorolac
3002940|NCT02543788|Other|patients|patients with chronic optic neuropathy in multiple sclerosis
3002941|NCT02543788|Other|Controls|healthy volunteers
3002942|NCT02543775|Experimental|Sentinel lymph node mapping|Patients who consent to the study will have preoperative and intraoperative SLN mapping performed. This will include injection of a radioisotope (Technetium 99) into the cervix and imaging (SPECT/CT) at Nuclear Medicine in the morning prior to surgery in an effort to identify the lymph node basin containing the sentinel nodes. Intraoperatively, blue dye will also be injected into the cervix to aid in location of the sentinel nodes.
3002943|NCT02543762||Inflammatory Bowel Disease|"Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis and Crohn disease.~Ulcerative colitis is a chronic inflammatory condition characterized by relapsing and remitting episodes of inflammation limited to the mucosal layer of the colon. It almost invariably involves the rectum and typically extends in a proximal and continuous fashion to involve other portions of the colon.~Crohn disease is characterized by transmural inflammation and by skip lesions. The transmural inflammatory nature of Crohn disease may lead to fibrosis and strictures, and to obstructive clinical presentations that are not typically seen in ulcerative colitis. More commonly, the transmural inflammation results in sinus tracts, giving rise to microperforations and fistulae.~Crohn disease may involve the entire gastrointestinal tract from mouth to perianal área patients with long-standing inflammatory bowel disease are prone to the development of colorectal cancer"
3002944|NCT02543749|Experimental|DC vaccine|"Autologous DC pulsed with leukemia-associated peptides+adjuvant.~Ten vaccinations over 26 weeks with 10 x 106 freshly thawed DC Intradermal injections (1-2 ml volume)"
3002945|NCT02543736|Other|Instrumented Treadmill System|The Instrumented Treadmill System records vertical ground reaction force and pressures.
3002980|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 3|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
3035155|NCT02327221|Active Comparator|Ovasave - Dose 10e7|
3002946|NCT02543723|Active Comparator|MEMS Intervention|Participants randomized to the lite group will receive a Medication Event Monitoring System (MEMS) device with feedback. Participants will be advised to only open their pill bottles when they take their medications. Participants will also be given a MEMS diary to record unscheduled cap openings, such as those to refill the bottle, so that those unscheduled events unrelated to adherence can be removed from analysis. The nurse coach will explain to the participant how to interpret the feedback report.
3002947|NCT02543723|Active Comparator|Nurse Coach Intervention|Before beginning their OCA regimen, participants in Arm 2 will be administered a barriers/facilitators screening tool that will help the nurse coach identify specific adherence strategies (i.e. cognitive education, knowledge skills, and affective support) tailored to the participant's needs. Once a tailored intervention plan is developed, participants will receive a 60-minute session conducted by the nurse coach. Participants will receive weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period (whichever occurs first).
3002948|NCT02543710|Experimental|phase 4 implementation study|The historical MoMaTEC1 outcome data, collected from 2001-2015 serve as control arm. These data have been rigorously collected and quality controlled with extensive clinical annotation and follow-up data, and reflect the outcome in (for a larger part) the same population as expected for MoMaTEC2 as there have not been major changes in surgical or medical treatment for endometrial cancer in this time period that could cause confounding. Internal validity, and to a degree also external validity, covering practice in multiple countries, should in this way be assured.
3002949|NCT02543710|Experimental|phase 2b biomarker study|For the current study, stathmin is used as an integrated marker and does not dictate treatment modality, therefore there is no requirement for a control arm.
3002950|NCT02543697|Experimental|Adrenal venous sampling|Patients going trough an adrenal venous sampling to find out if hypercortisolism is uni or bilaterally produced.
3002951|NCT02543684|Experimental|ready to eat mixed meal 1|
3002952|NCT02543684|Experimental|ready to eat mixed meal 2|
3002953|NCT02543684|Experimental|ready to eat mixed meal 3|
3002954|NCT02543684|Experimental|oral glucose load|
3002955|NCT02543671|Active Comparator|vitamin D3 enriched cheese|vitamin D3 enriched, reduced-fat yellow cheese
3002956|NCT02543671|Placebo Comparator|plain cheese|plain (non-fortified) reduced-fat yellow cheese
3002957|NCT02543658|Experimental|Neostigmine|Intramuscular injection of neostigmine combined the traditional treatment of Acute Pancreatitis combined with Intra-abdominal Hypertension according to the associated guidelines
3002958|NCT02543658|Other|The traditional treatment|The traditional treatment of Acute Pancreatitis combined with Intra-abdominal Hypertension according to the associated guidelines
3002959|NCT02543645|Experimental|Varlilumab and Atezolizumab|
3002960|NCT02543632||Treated group|Subjects who meet the inclusion/exclusion criteria listed and also are approved via anatomical inclusion criteria for treatment with the Parachute Implant System.
3002961|NCT02543632||Control group|Subjects who meet the inclusion/exclusion criteria listed and also are are excluded for treatment with the Parachute Implant System due to anatomical characteristics such as obstructing pseudochordae, calcification, or wall thickness.
3002962|NCT02543619|Active Comparator|Gow-Gates injection|An injection technique for infra alveolar nerve anesthesia
3002963|NCT02543619|Active Comparator|Infra alveolar nerve block injection|An injection technique for infra alveolar nerve anesthesia
3002964|NCT02543606|Experimental|Esomelone|powder for injection/ infusion Esomeprazole 40mg
3002965|NCT02543606|Active Comparator|Nexium|powder for injection/ infusion Esomeprazole 40mg
3002966|NCT02543593|Experimental|Intervention|Participants will receive active transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
3002967|NCT02543593|Sham Comparator|Placebo|Participants will receive sham transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
3002968|NCT02543580|Experimental|single acupoint|transcutaneous electric acupoint stimulation is given at bilateral neiguan or 30min before anesthesia induction
3002969|NCT02543580|Experimental|double acupoints|transcutaneous electric acupoint stimulation is given at Danzhong and bilateral neiguan or 30min before anesthesia induction
3002970|NCT02543580|Experimental|sham electroacupuncture|electrode attached but no stimulation
3002971|NCT02543567|Experimental|Group 1|Ad26.ZEBOV 5*10^10 viral particles (vp) single dose intramuscular (IM) injection on Day 1; MVA‐BN‐Filo 1*10^8 Infectious Unit [Inf. U.] single dose IM injection on Day 57
3002972|NCT02543567|Experimental|Group 2|Ad26.ZEBOV 2*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN‐Filo 5*10^7 Inf. U single dose IM injection on Day 57
3002973|NCT02543567|Experimental|Group 3|Ad26.ZEBOV 0.8*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA‐BN‐Filo 5*10^7 Inf. U. single dose IM injection on Day 57
3002974|NCT02543567|Experimental|Group 4|Participants will receive intramuscular (IM) injection of Placebo (0.9% saline) once on Day 1 and Day 57
3002975|NCT02543541|Active Comparator|Standard Supportive Care|
3002976|NCT02543541|Experimental|Structured Supportive Care|
3002977|NCT02543528|Experimental|etafilcon A (1-Day) and etafilcon A (Reusable)|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
3002978|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 1|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
3002979|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 2|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
3002981|NCT02543502|Experimental|periodontal treatment|Group will receive treatment: periodontal treatment
3002982|NCT02543502|No Intervention|Control Group.|Group will not receive treatment: periodontal treatment
3002984|NCT02543476||patients' group with tumor sample|SCCHN patients having available archived tumor sample(s).
3002985|NCT02543463|Other|With Navigation system|Large diameter head with Trident X3 insert with Navigation system
3002986|NCT02543463|Other|Without Navigation system|Large diameter head with Trident X3 insert with conventional instrumentation
3002987|NCT02543450|Experimental|Cardiovascular/task-oriented training|8 cardiovascular exercises at moderate intensity, interrupted by 1-minute active breaks of task-oriented exercises.
3002988|NCT02543450|Active Comparator|Upper limb strength training program|Nine 5-minute station circuit session. Patients work 2+2 minutes in each exercise, with a 30-second rest between the 2-minute periods and between stations.
3002989|NCT02543437|Other|Trident Acetabular X3 Insert|28mm, 32mm and 36mm liner
3002990|NCT02543424|Experimental|Patient group|Brain damaged adults with either hemiparesis and/or hemineglect. Brain damaged children with developmental and/or acquired disease inducing hemiparesis and/or hemineglect.
3002991|NCT02543424|Sham Comparator|Control group|Healthy adults and children.
3002992|NCT02543411|Experimental|Lidocaine group|Administration of lidocaine 1%
3002993|NCT02543411|Placebo Comparator|Control group|Administration of normal saline
3002994|NCT02543398|Other|Ridge preservation|"The molar extraction socket is grafted with FDA approved materials, which includes a bone graft material derived from human donors (enCore®, Osteogenics biomedical, Lubbock, TX) and a membrane (like a thin sheet of paper) covering the grafted extraction socket. The membrane used will need to be removed at a later point since it is non-resorbable (it will not dissolve by itself). This membrane is made of dense polytetrafluoroethylene (dPTFE) (Cytoplast™, Osteogenics biomedical, Lubbock, TX). The procedure is called Ridge preservation"
3002995|NCT02543398|Other|No ridge preservation|"The molar extraction socket is left to heal by itself without any grafting material or membrane, i.e. Spontaneous Healing (No ridge preservation is performed)"
3002996|NCT02543385|Active Comparator|SKET|Intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol infusion according to Schnider model through target control infusion pump.
3002997|NCT02543385|Placebo Comparator|PLACEBO|Intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model through target control infusion pump.
3002998|NCT02543372|Experimental|Behavioral Couples Therapy|The participants receive 10 modules each containing treatment focusing on gambling and relationship functioning. The modules consist of text, videos, images and assignments. The participants receive support from an assigned therapist via email and telephone. Both the gamblers and the CSOs receive 10 modules each.
3002999|NCT02543372|Active Comparator|Cognitive Behavioral Therapy|The participants receive 10 modules each containing treatment focusing on gambling and relationship functioning. The modules consist of text, videos, images and assignments. The participants receive support from an assigned therapist via email and telephone. The gamblers receive 10 modules, but the CSOs do not receive any modules.
3003000|NCT02543359|Experimental|Clinicians and Supervisors|After randomization clinicians and supervisors from community behavioral health agencies receive training in one of three PCIT training models: Train the Trainer (TTT), Learning Collaborative (LC) or Web-Supported Self Study (SS).
3003001|NCT02543359|Experimental|Administrators|After randomization administrators from participating community behavioral health agencies receive one of three treatments for PCIT (1/3 Learning Collaborative, 1/3 other treatment - none, and 1/3 other treatment - none).
3003002|NCT02543359|Experimental|Parent-Child Dyads|Parent-child dyads receive Parent-Child Interaction Therapy (PCIT) treatment from trained clinicians/supervisors.
3003003|NCT02543346|Other|cetirizine hydrochloride|
3003004|NCT02543346|Placebo Comparator|placebo|
3003005|NCT02543333||Asthma|Patients attending outpatient clinic as part of their clinical care who have FEV1 less than 80% of predicted and are referred by their clinician for a bronchodilator test
3003006|NCT02543333||Acute Asthma|Inpatients admitted for an acute asthma exacerbation
3003007|NCT02543333||Normal|Participants with no current or previous diagnosis of a respiratory condition
3003008|NCT02543320|Experimental|LORETA Neurofeedback|Participants undergo a baseline EEG prior to starting radiotherapy and during each neurotherapy session as required by LORETA. Participants undergo neurotherapy once a day, three days a week, for a total of 6 treatments. Pain and symptom questionnaires completed at baseline, before each LORETA neurofeedback session, 1 week after completion of neurofeedback sessions, and at the end of radiotherapy.
3003009|NCT02543307|Experimental|Nurse-led Patient Pathways|Patients were cared for under the three NPP developed for the orthopedic populations: NPP-1) patients with total hip arthroplasty; NPP-2) exploration and decompression of the spinal cord; and NPP-3) rotator cuff reconstruction. NPP are characterized by four principles: evidence-based nursing, patient and family centred care, comprehensive discharge planning beyond hospital discharge and nurses' responsibility for patients` processes. The principles support and strengthen patient and family preferences as well as formalize nursing activities, and therefore contribute to process transparency in relation to other health care professionals. Aims: to improve patients` and health care professionals` as well as institutional outcomes.
3003010|NCT02543307|No Intervention|Standard usual nursing care|Patients in the control group will receive usual nursing care, which is based on the institutional principles and standards of care for surgical patients. Based on the type of surgery and assessment of the nurse the nursing process is used to care for the patients. The nurses will be ending their activities with discharge of the patients.
3003011|NCT02543294|Experimental|Anthracycline Treatment Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
3003012|NCT02543294|Experimental|Herceptin Treatment Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
3003107|NCT02542644|Other|Patients with Fuchs endothelial dystrophy scheduled for DMEK|
3003422|NCT02540408||presence of COPD|COPD patients are defined according to the results of a spirometry
3003013|NCT02543294|Experimental|Combination of Treatments Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
3003014|NCT02543281|Active Comparator|aCRT Off|The adaptive CRT algorithm will be turned off for the CRT device implanted in the patients in this arm.
3003015|NCT02543281|Experimental|aCRT On|The adaptive CRT algorithm will be turned on for the CRT device implanted in the patients in this arm.
3003016|NCT02543268|Experimental|Group 1|Ad26.ZEBOV -Batch #1, single dose intramuscular (IM) injection on Day 1; MVA-BN‐Filo, single dose IM injection on Day 57
3003017|NCT02543268|Experimental|Group 2|Ad26.ZEBOV -Batch #2, single dose intramuscular (IM) injection on Day 1; MVA-BN‐Filo, single dose IM injection on Day 57
3003018|NCT02543268|Experimental|Group 3|Ad26.ZEBOV -Batch #3, single dose intramuscular (IM) injection on Day 1; MVA-BN‐Filo, single dose IM injection on Day 57
3003019|NCT02543268|Experimental|Group 4|Placebo (0.9% saline)‐ single dose IM injection on Day 1 and Day 57
3003020|NCT02543255|Experimental|Abiraterone acetate + prednisone + leuprolide + cabazitaxel|Participants randomized to this arm will receive abiraterone acetate (1000 mg/day), prednisone (5 mg twice daily), leuprolide (22.5 mg every 3 months), and cabazitaxel (25 mg/m2, with 6 mg pegfilgrastim administered 24 h following cabazitaxel) prior to radical prostatectomy.
3003021|NCT02543255|Active Comparator|Abiraterone acetate + prednisone + leuprolide|Participants randomized to this arm will receive abiraterone acetate (1000 mg/day) , prednisone (5 mg twice daily), and leuprolide (22.5 mg every 3 months) prior to radical prostatectomy.
3003022|NCT02543242|Experimental|Intervention|Participants will undergo the InTone TM (InControl Medical, LLC) medical device treatment for Urinary Incontinence. The frequency of treatment is once/day (12 minutes), 5-6 days/week. The route of administration is vaginal.
3003023|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 1|Dose Level 1 of OPT-302 in combination with Lucentis™
3003024|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 2|Dose Level 2 of OPT-302 in combination with Lucentis™
3003025|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 3|Dose Level 3 of OPT-302 in combination with Lucentis™
3003026|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 4|Dose Level 3 of OPT-302 monotherapy
3003027|NCT02543229|Experimental|Part 2 Dose expansion - Cohort 5|OPT-302 (at Maximum Tolerated Dose [MTD] or highest dose tested in Part 1) in combination with Lucentis™
3003028|NCT02543229|Experimental|Part 2 Dose expansion - Cohort 6|OPT-302 (at MTD or highest dose tested in Part 1) monotherapy
3003029|NCT02543216|Experimental|CC genotype|4-week study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. The same diets were instructed for both genotypes.
3003030|NCT02543216|Experimental|TT genotype|4-week study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. The same diets were instructed for both genotypes.
3003031|NCT02543203|Active Comparator|Essential Oil Mixture A|"Topical: Apply 1 drop to the back of the neck and 1 drop to the feet. Rub in the oil for 30 seconds to 1 minute. Each bottle has an orifice that allows the oil to be expelled drop by drop. Dilution is not required, except for the most sensitive skin. Apply in the morning.~Aromatic Method: Diffuse one diffuser-full (8-12 drops of oil in water) at night."
3003032|NCT02543203|Active Comparator|Essential Oil Mixture B|"Topical: Apply 1 drop to the back of the neck and 1 drop to the feet. Rub in the oil for 30 seconds to 1 minute. Each bottle has an orifice that allows the oil to be expelled drop by drop. Dilution is not required, except for the most sensitive skin. Apply in the morning.~Aromatic Method: Diffuse one diffuser-full (8-12 drops of oil in water) at night."
3003033|NCT02543190|Experimental|compliance surveillance|"Prospective audits by study personnel~Call from the clinic nurse practitioner or physician's assistant within 7 days of discharge to administer a screening questionnaire to identify patients at risk of dehydration. Study personnel will ensure this phone call is made."
3003034|NCT02543190|No Intervention|Usual Care|educational session at the start of the study
3003035|NCT02543177|Experimental|group A|direct coronary angiography
3003036|NCT02543177|Experimental|group B|direct coronary angiography plus ischemic precondition
3003037|NCT02543177|Experimental|group C|delayed coronary angiography; the kidneys will be irrigated prior to coronary angiography
3003038|NCT02543177|Experimental|group D|delayed coronary angiography plus ischemic precondition; the kidneys will be irrigated prior to coronary angiography
3003039|NCT02543164|Other|REFERENCE: white bread|Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
3003040|NCT02543164|Other|TEST: b-glucan enriched bread|Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
3003041|NCT02543151|Experimental|SpyGlass Choledochoscopy procedure|Any patient referred to endoscopic management for biliary post liver transplant complication without previous treatment will be submitted to SpyGlass (direct visualization system) choledochoscopy procedure.
3003042|NCT02543138|Experimental|Closed thoracostomy|Closed thoracostomy using the new trocar by novice
3003043|NCT02543125|Active Comparator|NIPPV|NIPPV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,peak inspiratory pressure( PIP)：12-22cm H2O,positive and expiratory pressure(PEEP):5-7cm H2O,Rate:30-60 per minute to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP)<6cm H2O,R:30 per minute .
3003044|NCT02543125|Active Comparator|NHFOV|NHFOV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,MAP：6-14 cm H2O,Hertz(HZ):5-10 to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP)<6cm H2O.
3003045|NCT02543099|Experimental|policosanol|Patients will receive policosanol 20mg daily until the end of the trial.
3003046|NCT02543099|Placebo Comparator|placebo|Patients will receive placebo 20mg daily until the end of the trial;
3003108|NCT02542631|Experimental|Bolus Insulin Patch (Calibra Finesse)|Use of the wearable patch to deliver meal-related bolus insulin dose
3003047|NCT02543086|Experimental|Multiple Sequential Cohort|"This study is divided in 2 parts (Part A and part B). Each participant in each of the cohorts will be inoculated with viable parasites of Plasmodium falciparum-infected human erythrocytes administered intravenously. For Part A & Part B, commencement of treatment will be determined by Quantitative-Polymerase Chain Reaction results.~The First cohort of Part A (A1) will be dosed with a single dose of KAE609. During Part A, an additional second single-dose of KAE609 may be tested (~15 days after first dose of KAE609 but may vary) if sexual parasitemia is identified. Subsequent cohorts of part A (An) will be dosed based on the results of first cohort (A1).~Subjects enrolled in Cohort B will receive a pre-treatment with Piperaquine followed by KAE609 (~15 days)."
3003048|NCT02543073|Experimental|MSCs|MSCs will be given the patients in MSCs group. Besides, azithromycin (AZM) and glucocorticoid will also be administered.
3003049|NCT02543073|Active Comparator|Non-MSCs|AZM and glucocorticoid will be given for the patients in Non-MSCs group.
3003050|NCT02543060|Experimental|stannous fluoride toothpaste|brush twice a day for 8 weeks
3003051|NCT02543060|Sham Comparator|cavity protection toothpaste|brush twice a day for 8 weeks
3003052|NCT02543047|Active Comparator|Right Region|Angioshield will be applied to provide Mechanical Support for Vein Grafts Used in CABG in the right region of the heart
3003053|NCT02543047|Active Comparator|Left Region|Angioshield will be applied to provide Mechanical Support for Vein Grafts Used in CABG in the left region of the heart
3003054|NCT02543034|Experimental|Betafoam Wound Dressing|This contains 3% povidone iodine. Dressing will be routinely changed on day 3 and day 7, and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
3003055|NCT02543034|Active Comparator|Petrolatum Gauze|Dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
3003056|NCT02543034|Active Comparator|Allevyn Wound Dressing|Allevyn adhesive wound dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
3003057|NCT02543021|Active Comparator|Conventional chromoendoscopy|Patients will undergo colitis surveillance colonoscopy with indigo carmine chromoendoscopy (dye spray)
3003058|NCT02543021|Experimental|Virtual chromoendoscopy|Patients will undergo colitis surveillance colonoscopy with FICE(TM) virtual chromoendoscopy
3003059|NCT02543008|Experimental|Physical activity plus thoracic mobilization|Subjects randomly allocated to this arm will be submitted to a 10 minutes anaerobic exercise (2 minutes warming up, 5 minutes of 75% to 85% maximal heat rate, 3 minutes slowdown), followed by 5 minutes of passive intervertebral thoracic mobilization (3 sets of 1 minute, grade III, and 1 minute rest between each set).
3003060|NCT02543008|Active Comparator|Physical activity|Subjects allocated to this arm will be submitted to the same anaerobic exercise protocol, without the thoracic mobilization.
3003061|NCT02543008|Placebo Comparator|Placebo|Subjects in this group will be conducted to a placebo thoracic mobilization, without anaerobic exercise protocol. The investigator will apply only a manual contact, to mimic the genuine thoracic mobilization. The same 5 minutes period will be respected, and the same position of therapist and subject.
3003062|NCT02542995|No Intervention|Non-intervention|Usual clinical conditions
3003063|NCT02542995|Other|Intevention|"QI interventions and got to see their own survey data - examples include:~Workflow redesign:~Medical Assistant (MA) data entry Improved clinic efficiency projects Assessed workflow with staff Provided time for MAs and RNs to perform tasks Paired MAs and providers Non-physician staff assist with forms~Communication improvement:~Improved teamwork Improved communication between provider groups Routine clinician meetings discussing meaningful topics Survey of providers for wish list of issues Routine emails from leaders Clinicians meeting with leaders~Chronic disease QI projects:~Establishing quality metrics with clinician input Automated Rx refill line Med reconciliation project Screening project for diabetics Screening for depression Improved patient portals"
3003064|NCT02542982|Experimental|Active treatment|Group of patients on active treatment will receive intensive motor training for 45 min/day, 5 days/week, for 2 weeks, which would be preceded by 20 minutes of 2 mA anodal tDCS over the ipsilesional motor cortex.
3003065|NCT02542982|Sham Comparator|Sham comparator|Group of patients on sham treatment will receive intensive motor training for 45 min/day, 5 days/week, for 2 weeks, which would be preceded by sham tDCS over the ipsilesional motor cortex.
3003066|NCT02542969|Other|Treatment|Simvastatin followed by Rosuvastatin then MGL-3196 daily followed by separate co-administration of Simvastatin and Rosuvastatin
3003067|NCT02542956|Active Comparator|Exparel|Injection of Exparel
3003068|NCT02542956|Active Comparator|Marcaine|Receive Marcaine in a pain pump or by injection
3003069|NCT02542943|Experimental|Experimental Oral Rinse1|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 1 for 1 minute. This regimen will be performed twice daily for 8 weeks.
3003070|NCT02542943|Experimental|Experimental Oral Rinse 2|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
3003071|NCT02542943|Placebo Comparator|Placebo Oral Rinse|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Placebo Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
3003072|NCT02542930|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin;
3003073|NCT02542917||All patients|IBDoc home test for faecal calprotectin
3003074|NCT02542904|Active Comparator|LME|the anastomosis was performed as stapled side-to-side with local excision of the mesenteric tissue adjacent to the diseased bowel
3003075|NCT02542904|Active Comparator|EME|the anastomosis was performed as a stapled side-to-side anastomosis with extensive excision of mesenteric tissue.
3003109|NCT02542631|Active Comparator|Insulin Pen (Novo-Nordisk FlexPen®)|Use of the pen device to deliver meal-related bolus insulin dose
3003110|NCT02542618|Experimental|Inquiry Based stress Reduction (IBSR)|"IBSR intervention is the clinical implementation of a mindful-process, named The Work developed by Byron Katie. It teaches the individual to identify and question the thoughts that causes stress and suffering through four questions and turnarounds."
3003076|NCT02542891|Experimental|Blended CBT|"Internet based blended depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with smart phone components. The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, and (4) relapse prevention. These will be delivered over 16 sessions (8 online and 8 face-to-face), once a week. The online platform is called Moodbuster.~The trial will not interfere with regular medication treatment, and patient's care will be monitored throughout the study."
3003077|NCT02542891|Active Comparator|Treament as Usual (TAU)|"In order to increase the comparability between the two arms, we defined TAU as a traditional face to face CBT of 16 sessions. These sessions will be administered over a course of 16 weeks.~The trial will not interfere with regular medication treatment, and patient's care will be monitored throughout the study."
3003078|NCT02542878|Experimental|FOAM ROLLER|"Treatment with foam roller will be applied for 60 seconds to this group. Subjetc lye in supine position over the foam roller placed on back muscle extensors. Then, they must slide the body on the device, from postero-superior iliac spine to the dorsal zone.~A brief explanation of this self-application will be showed prior the intervention."
3003079|NCT02542878|Placebo Comparator|PLACEBO|An intervention similar (position and time) to the experimental group will be done, but the used device will be a very soft roller not compressing the contact zone.
3003080|NCT02542865|Experimental|Test Group|Fortified malt based food (27 grams) made up in 150 mL lukewarm water administered twice daily
3003081|NCT02542865|No Intervention|Control Group|No treatment was administered
3003082|NCT02542852|Experimental|Open label single arm|Introduction of treatment regimen with atazanavir 300mg qd + ritonavir 100mg qd + dolutegravir 50mg qd
3003083|NCT02542839|Experimental|Real rTMS Stimulation|Repetitive TMS will be delivered over each cerebellar hemisphere, using a NeuroStar TMS therapy system. The coil will be positioned 3 cm lateral to the inion on the line joining the inion and the external auditory meatus. The coil position will be marked on the skin. 900 pulses will be delivered consecutively to each side with a frequency of 1 Hz and at an intensity of 90% of the resting motor threshold (RMT) for a total duration of 15 min for each cerebellar hemisphere. The RMT will be defined as the lowest stimulation intensity required to evoke a 50 μV potential in a target muscle. Constant coil position will be continuously monitored during the experiment. A similar protocol will be observed for the contralateral cerebellum. In addition, this group will have the following performed: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) test, Cerebellar-brain Inhibition (CBI) measurement, and Craniocervical Dystonia Questionnaire (CDQ-24) questionnaire to fill out.
3003084|NCT02542839|Sham Comparator|Sham rTMS Stimulation|Patients will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using sham NeuroStar TMS therapy system coil which produces discharge noise and vibration without stimulating the cerebral cortex. This technique has been suggested to provide more effective blinding compared to other methods use in previous controlled studies. In addition, this group will have the following performed: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) test, Cerebellar-brain Inhibition (CBI) measurement, and Craniocervical Dystonia Questionnaire (CDQ-24) questionnaire to fill out.
3003085|NCT02542826|Experimental|Pulmonary Rehabilitation|
3003086|NCT02542813|Experimental|IM oxytocin - IH placebo/IH oxytocin (50, 200, 400, 600)|Subjects will receive IM oxytocin, IH placebo/IH oxytocin at doses of 50, 200, 400, 600 mcg.
3003087|NCT02542813|Experimental|IM oxytocin - IH placebo/IH oxytocin (50)|Subjects will receive IM oxytocin and IH placebo and/or IH oxytocin at 50 mcg.
3003088|NCT02542800|Experimental|Healthy participants|
3003089|NCT02542787|Experimental|Active|VSN16R (Canbex name for molecule) oral capsules, 50mg-400mg daily or twice daily, total exposure 26 days
3003090|NCT02542787|Placebo Comparator|Placebo|Placebo capsules, 50mg-400mg daily or twice daily, total exposure 26 days
3003091|NCT02542761|Experimental|CFPF first, then FPF|After a 4 week acclimation period, subjects were studied on their current carbon fiber composite foot (CFPF), followed by another 4 week acclimation period, then studied on the study provided fiberglass composite foot (FPF).
3003092|NCT02542761|Experimental|FPF first, then CFPF|After a 4 week acclimation period, subjects were studied on the study provided fiberglass composite foot (FPF), followed by another 4 week acclimation period, then studied on their current carbon fiber composite foot (CFPF).
3003093|NCT02542748|Experimental|norepinephrine|norepinephrine is injected after spinal anesthesia
3003094|NCT02542748|Other|ephedrine|ephedrine is injected after spinal anesthesia
3003095|NCT02542735||Andalusian di@bet.es cohort|Representative of Andalusian population
3003096|NCT02542722|Active Comparator|Control|General dietary and physical exercise recommendations
3003097|NCT02542722|Experimental|Intervention|Intensive intervention on dietary and physical exercise habits.
3003098|NCT02542709|Active Comparator|Active transcranial magnetic stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
3003099|NCT02542709|Sham Comparator|Sham transcranial magnetic stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
3003100|NCT02542696|Experimental|APL-130277|APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
3003101|NCT02542683||physical activity program|enrollment for 12 months in a structured physical activity program
3003102|NCT02542683||delayed physical activity program|No intervention for 12 months, then enrollment in structured physical activity program
3003103|NCT02542670||Cancer colon with no distant metastasis|Genetic: Whole genome Sequencing
3003104|NCT02542670||Cancer colon with distant metastases|Genetic: Whole genome Sequencing
3003105|NCT02542670||control group|Genetic: Whole genome Sequencing
3003106|NCT02542657|Experimental|Treatment (PiC-D therapy)|"Patients receive pomalidomide PO QD on days 1-21; ixazomib citrate PO on days 1, 8, and 15; clarithromycin PO BID on days 15-21 of course 1 and days 1-21 of courses 2-6; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY:~Patients receive pomalidomide, ixazomib citrate, and dexamethasone as above and receive clarithromycin PO BID or QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3003111|NCT02542618|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a psychological treatment method, focusing on a structured way to identify and modify unhelpful thinking patterns, underlying assumptions and idiosyncratic cognitive schemes about the self, the world (including other people) and the future.
3003112|NCT02542605|Experimental|AMG 334|
3003113|NCT02542605|Placebo Comparator|Placebo|
3003114|NCT02542605|Other|PACAP-38 Challenge Agent|
3003115|NCT02542592|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
3003116|NCT02542592|Placebo Comparator|Placebo|Preoperative single dose of isotonic Sodium Chloride
3003117|NCT02542579||Subjects for pyrosequencing analysis|Dyspeptic subjects who visited for evaluation and agreed on 16S rRNA pyrosequencing analysis
3003118|NCT02542566|Active Comparator|early weight bearing|early weight bearing and accelerated physiotherapy rehabilitation
3003119|NCT02542566|Active Comparator|protected weight bearing|protected weight bearing and conservative physiotherapy rehabilitation.
3003120|NCT02542553|Experimental|Bilateral BAL|Bronchoscopies are performed in strict accordance with consensus guidelines. The left or right lung is examined with a flexible fiberoptic bronchoscope. If localized infiltrates are present on the chest radiograph, the tip of the scope is wedged into a subsegment of the area displaying the most marked opacity. In the presence of diffuse opacity or when no clear roentgenographic abnormalities are observed, the tip is positioned in the lingula or right middle lobe. Five 20-ml aliquots of sterile normal saline are then injected and reaspirated with a syringe. Bronchoscopy is then repeated in the same manner in the contralateral lung with a second, sterile bronchoscope of the same brand and model.
3003121|NCT02542540|Experimental|OI Children training with Nintendo Wii console|Training for 3 months using the Nintendo Wii console on physical capacity in a group of children with Osteogenesis Imperfecta
3003122|NCT02542540|No Intervention|Children with OI without training|No training
3003123|NCT02542527|Experimental|Pumping with a fluid filled breast pump|Participants pump (each breast 25 min) with the new fluid filled breast pump
3003124|NCT02542514|Experimental|Ibrutinib|ibrutinib in monotherapy 28 days/cycles
3003125|NCT02542488||Pregnant women with BMI >39 at booking|All women will receive routine care and in addition will complete the 8 question STOPBANG screening tool and have overnight oximetry recorded.
3003126|NCT02542475|Experimental|Mood Improvement|Mood change with daily Low Field Magnetic Stimulation in participants suffering from affective disorders and/or anxiety
3003127|NCT02542462|Active Comparator|Rotarix® alone|monovalent rotavirus vaccine (Rotarix®, RV1)
3003128|NCT02542462|Active Comparator|Rotarix®,with other routine vaccines|monovalent rotavirus vaccine (Rotarix®, RV1), plus additional immunizations
3003129|NCT02542462|Active Comparator|RotaTeq®, alone|pentavalent rotavirus vaccine (RotaTeq®, RV5)
3003130|NCT02542462|Active Comparator|RotaTeq®,with other routine vaccines|pentavalent rotavirus vaccine (RotaTeq®,RV5) plus additional immunizations
3003131|NCT02542449|Active Comparator|Globes®|Partecipants received twice a day for 3 months Globes® (Pharmextracta, Pontenure, Piacenza, Italy) formulated to be enteric-coated and containing 150 mg/dose of Greenselect Phytosome® and pure piperine (15 mg/dose) from Piper nigrum L.
3003132|NCT02542449|Placebo Comparator|Placebo|Partecipants received twice a day for 3 months placebo (undistinguishable from Globes in terms of size, shape, taste, odor, primary and secondary packaging).
3003133|NCT02542436||Cohort 1: bevacizumab|Participants with metastatic colorectal cancer between 2010-2013, who received bevacizumab (25 mg/ml concentrate for solution for infusion) with first-line chemotherapy.
3003134|NCT02542436||Cohort 2: no bevacizumab|Participants with metastatic colorectal cancer between 2005-2008, who did not receive bevacizumab with first-line chemotherapy.
3003135|NCT02542423|Other|patients undergoing cardiac surgery|
3003136|NCT02542410|Active Comparator|Control|Norethindrone acetate 5 mg po daily x 6 months
3003137|NCT02542410|Experimental|Experimental|cabergoline 0.5 mg PO twice weekly x 6 months
3003138|NCT02542397|Experimental|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
3003139|NCT02542384|Active Comparator|CR845 IV 1 mcg/kg|CR845 IV solution will be supplied in 2 mL glass vials.Study drug will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
3003140|NCT02542384|Active Comparator|CR845 IV 0.5 mcg/kg|CR845 solution will be supplied in 2 mL glass vials. Study drug will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
3003141|NCT02542384|Placebo Comparator|Placebo IV|Placebo will be supplied in matched vials containing the same volume of buffer but with no active drug. It will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
3003142|NCT02542371||HIV infected with known subclinical atherosclerosis|
3003143|NCT02542371||HIV infected without known subclinical atherosclerosis|
3003144|NCT02542371||Non-HIV infected with known subclinical atherosclerosis|
3003145|NCT02542371||Non-HIV infected without known subclinical atherosclerosis|
3003146|NCT02542345|Experimental|magnetic resonance imaging|
3003147|NCT02542332|Active Comparator|With Data|Participants received statistical data about lung cancer screening
3003148|NCT02542332|No Intervention|Without Data|Participants had no statistical data on lung cancer screening
3003149|NCT02542319|Experimental|Magnesium|Oral Magnesium Hydroxide (Mablet 360 mg) twice daily for 12 months.
3003150|NCT02542319|Placebo Comparator|Placebo|Matching placebo tablets twice daily for 12 months.
3003151|NCT02542306|Experimental|fibrinogen concentrate-treated group|The initial fibrinogen concentrate dose was 25 - 50 mg/kg, but additional fibrinogen concentrate was administered repeatedly if the first infusion of fibrinogen concentrate did not increase the fibrinogen level over 2.0 g/L.
3003152|NCT02542306|No Intervention|non-fibrinogen concentrate-treated group|The participants who did not received fibrinogen concentrate treatment were enrolled as the non-fibrinogen concentrate-treated group
3003153|NCT02542293|Experimental|Combination Therapy|Durvalumab (PD-L1 monoclonal antibody) + Tremelimumab (monoclonal antibody directed against CTLA-4)
3003154|NCT02542293|Active Comparator|Standard of Care|Standard of Care chemotherapy treatment
3003342|NCT02540993|Placebo Comparator|Placebo|Matching placebo
3003155|NCT02542280|Experimental|endometrial injury|Endometrial injury during ovarian stimulation combined with intrauterine insemination.
3003156|NCT02542280|Active Comparator|no endometrial injury|Ovarian stimulation combined with intrauterine insemination.
3003157|NCT02542267|Other|Gore VIABAHN Endoprosthesis|Gore VIABAHN Endoprosthesis deployed to treat failed non-covered stent(s) in the Superficial Femoral Artery
3003158|NCT02542254|Active Comparator|Salbutamol alone|200 micrograms salbutamol, ipratropium matched placebo and RPL554 matched placebo
3003159|NCT02542254|Experimental|Salbutamol and RPL554|200 micrograms salbutamol, ipratropium matched placebo and 6 mg RPL554
3003160|NCT02542254|Active Comparator|Ipratropium|Salbutamol matched placebo, 40 micrograms ipratropium and RPL554 matched placebo
3003161|NCT02542254|Experimental|Ipratropium and RPL554|Salbutamol matched placebo, 40 micrograms ipratropium and 6 mg RPL554
3003162|NCT02542254|Experimental|RPL554|Salbutamol matched placebo, ipratropium matched placebo and 6 mg RPL554
3003163|NCT02542254|Placebo Comparator|Placebo|Salbutamol matched placebo, ipratropium matched placebo and RPL554 matched placebo
3003164|NCT02542241|Experimental|Sodium Chloride [3%]|
3003165|NCT02542241|Active Comparator|Sodium Chloride [0.9%]|
3003166|NCT02542215|Experimental|Cobiprostone 30 mcg four times daily|Cobiprostone 30 mcg
3003167|NCT02542215|Placebo Comparator|Placebo 0 mcg four times daily|Placebo
3003168|NCT02542202|Experimental|Stereotactic body radiation therapy|Patients undergo stereotactic body radiation therapy on day 1 over 3 times a week for 28 days in the absence of disease progression or unacceptable toxicity.
3003169|NCT02542176|Experimental|Freeze-dried Whole Grape Powder|
3003170|NCT02542176|Placebo Comparator|Grape Powder Placebo|
3003171|NCT02542150|Experimental|acetate arm|IV acetate given during magnetic resonance scan
3003172|NCT02542150|Experimental|alcohol arm|jello shots given before magnetic resonance scan
3003173|NCT02542137|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
3003174|NCT02542124|Experimental|NM-IL-12|NM-IL-12
3003175|NCT02542111|Experimental|V-GDP|Bortezomib 1.6 mg/m2/d iv d1 and d8 Gemcitabine 1000mg/m2/d iv d1 and d8 Dexamethasone 40mg/d iv d1-4 cisplatin 25 mg/m2 iv d2-4 Frequency every 28 days Total cycles 4
3003176|NCT02542098|Experimental|HYD 20 - 120 mg|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets administered orally every 24 hours
3003177|NCT02542085|Active Comparator|laparoscopic repair|patients who are randomized to have a laparoscopic mesh repair
3003178|NCT02542085|Active Comparator|hybrid repair|patients who are randomized to have a laparoscopic mesh repair and fascial closure
3003179|NCT02542072|Active Comparator|comfilcon A|Participants were randomized to wear the comfilcon A lens pair for one month during the cross over study.
3003180|NCT02542072|Active Comparator|samfilcon A|Participants were randomized to wear the samfilcon A lens pair for one month during the cross over study.
3003181|NCT02542059||Responders|Patients with resolved type 2 diabetes after bariatric surgery, will undergo 68Ga-exendin PET/CT
3003182|NCT02542059||Non-responders|Patients with unresolved type 2 diabetes after bariatric surgery, will undergo 68Ga-exendin PET/CT
3003183|NCT02542046|Active Comparator|Barium|Patients who received barium sulfate oral contrast for abdominopelvic CT
3003184|NCT02542046|Active Comparator|diatrizoate|Patients who received diatrizoate oral contrast for abdominopelvic CT
3003185|NCT02542046|Active Comparator|iohexol|Patients who received iohexol oral contrast for abdominopelvic CT
3003186|NCT02542033|Active Comparator|verum|500mL treated apple juice with low sugar content given on one experimental day
3003187|NCT02542033|Placebo Comparator|control|500mL un-treated apple juice with normal sugar content given on one experimental day
3003188|NCT02542007|Experimental|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
3003189|NCT02542007|Active Comparator|Nano Polymer-free sirolimus-eluting stent system|The Nano polymer-free sirolimus-eluting stent produced by LePu medical.
3003190|NCT02541994|Other|Ultrasound Testing|Single arm with all patients getting measurements of axial length and central corneal thickness.
3003191|NCT02541968|Active Comparator|Face-to-face CBT|16 sessions of individual CBT delivered in 14 weeks.
3003192|NCT02541968|Experimental|Internet-based CBT|Internet-based CBT (ICBT) with therapist support (14 weeks).
3003193|NCT02541968|Experimental|ICBT without therapist support|Internet-based CBT without therapist support (14 weeks).
3003194|NCT02541955|Active Comparator|40 Units|40 units of Acthar per week
3003195|NCT02541955|Active Comparator|80 Units|80 units of Acthar twice per week
3003196|NCT02541942|Other|Collection of specimen|
3003197|NCT02541929|Experimental|DHA|DHA (2grams/day) for 26 weeks
3003198|NCT02541929|Placebo Comparator|placebo|placebo (4 capsules per day) for 26 weeks
3003199|NCT02541916|Experimental|Controlled weaning of immunosuppression|Participants who are found to have the tolerance gene expression profile during phase 1 of the study will undergo closely monitored immunosuppression weaning during phase 2.
3003200|NCT02541903|Experimental|Gilotrif|Gilotrif will be administered orally at 40 mg dosage once daily. Continuous administration of 4 weeks is considered one cycle. Therapy will continue until progression of the disease or severe toxicities. Labs will be monitored with routine blood collections every cycle and a CT scan will be done every two cycles (8 weeks).
3003201|NCT02541890|Experimental|Work place intervention|Work place intervention in addition to rehabilitation program.
3003202|NCT02541890|No Intervention|Rehabilitation program only|Rehabilitation program without intervention at the work place.
3003203|NCT02541877|Experimental|Down sizing valve in type-0 BAS|Down Sizing Transcatheter Self-expandable Valve in Type-0 BAS
3003204|NCT02541877|Active Comparator|Standard sizing valve in type-0 BAS|Standard Sizing Transcatheter Self-expandable Valve in Type-0 BAS
3003205|NCT02541877|Active Comparator|Standard sizing valve in TAS|Standard Sizing Transcatheter Self-expandable Valve in TAS
3003343|NCT02540967||BAY86-4875|Gadovist administration goup
3003206|NCT02541864|Experimental|Bismuth quadruple therapy|pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
3003207|NCT02541864|Active Comparator|Hybrid therapy|(pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
3003208|NCT02541838|Experimental|Muscle, Balance, and aerobic exercise|This trial will have a single experimental arm that will include the following interventions: Leg muscle strengthening, balance training using balance perturbations, and aerobic exercise. All individuals in this trial will receive all interventions listed.
3003209|NCT02541825|Experimental|the stent of diameter of 7mm|Procedure/Surgery:Jugular vein puncture and catheterization. Device:RUPS-100(COOK Company)sheath ,7mm balloon,Pigtail catheter,the stent of diameter of 7mm (Bard,Fluency) Drug(including placebo):No Biological/Vaccine:No
3003210|NCT02541825|Other|the stent of diameter of 8mm|Procedure/Surgery:Jugular vein puncture and catheterization. Device:RUPS-100(COOK Company)sheath ,8mm balloon,Pigtail catheter,the stent of diameter of 8mm (Bard,Fluency) Drug(including placebo):No Biological/Vaccine:No
3003211|NCT02541812|Experimental|Patients|Ten sessions of 1Hz repetitive Transcranial Magnetic Stimulation of the dorsal anterior cingulate cortex in patients with obsessive compulsive disorder
3003212|NCT02541812|Active Comparator|Healthy Control Subjects|One session of 1Hz repetitive Transcranial Magnetic Stimulation of the dorsal anterior cingulate cortex in healthy control individuals
3003213|NCT02541799|Experimental|Telemedicine|Participants allocated to this arm will be approached the using a telemedicine medium to discuss study participation. The consent form will be administered while the investigator is on a telemedicine link.
3003214|NCT02541799|Active Comparator|Standard Care|Participants allocated to this arm will be approached in standard fashion where the investigator approaches the patient face to face. The consent form will be administered while the investigator is in the participant's room.
3003215|NCT02541786|Active Comparator|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
3003216|NCT02541786|Experimental|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
3003217|NCT02541773||Chronic Heart Failure Patients|Undergoing CRT implantation, all will be observed for 6 months and will be defined at the end of the observation period as responder or non-responder
3003218|NCT02541760|Experimental|Montelukast|4 ml monteleukast daily for one month
3003219|NCT02541760|Active Comparator|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
3003220|NCT02541760|No Intervention|Control|No intervention
3003221|NCT02541747|Active Comparator|massage|massage for 30 min, once a week for 4 weeks
3003222|NCT02541747|No Intervention|control|Rest as control
3003223|NCT02541734|Experimental|gelofusine and 111In-exendin 4 SPECT/CT|subjects will receive a gelofusine injection before the injection of the radiopharmaceutical (111In-exendin 4)
3003224|NCT02541734|Placebo Comparator|saline and 111In-exendin 4 SPECT/CT|As a control, subjects will receive an injection of saline before the injection of the radiopharmaceutical (111In-exendin 4)
3003225|NCT02541721|Experimental|LabiaStick#01|Each participant will have an at least 2-week baseline period followed by a 4-week treatment period with LabiaStick#01.
3003226|NCT02541708|Experimental|IV ferric carboxymaltose|IV Ferric carboxymaltose is given at a dose calculated according to the severity of anemia and patients weight. The maximal weekly dose is 1000mg. If total dose exceeds 1000mg the dose is split in 1-3 infusions with one infusion per week.
3003227|NCT02541708|Active Comparator|Ferrous sulphate 60mg+Folic acid 0.25mg|Three dried ferrous sulphate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia.
3003228|NCT02541695|Active Comparator|1E10 CFU Escherichia coli (E. coli)|"1E10 Colony Forming Units (CFU) Diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food research). Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain.~At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
3003229|NCT02541695|Experimental|5E10 CFU Escherichia coli (E. coli)|"5E10 Colony Forming Units (CFU) Diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food research). Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain.~At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 5E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
3003230|NCT02541682|Other|Control|Participants who have PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 3 and showing no symptom of nausea and/or vomiting during the three control visits. Control visits are performed a month apart.
3003231|NCT02541682|Other|Mild nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 4-6 during the three control visits. Control visits are performed a month apart.
3003232|NCT02541682|Other|Moderate nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 7-12 during the three control visits. Control visits are performed a month apart.
3003233|NCT02541682|Other|Severe nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 13-15 during the three control visits. Control visits are performed a month apart.
3035156|NCT02327221|Placebo Comparator|Placebo|
3003234|NCT02541669|Experimental|TAK-491 40 mg (Open Label)|TAK-491 40 milligram (mg), tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
3003235|NCT02541669|Experimental|TAK-491 80 mg (Open-label)|TAK-491 80 mg, tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
3003236|NCT02541669|Experimental|TAK-491 40 mg (Double-blind)|TAK-491 40 mg, tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
3003237|NCT02541669|Experimental|TAK-491 80 mg (Double-blind)|TAK-491 80 mg, tablet, orally, once daily and TAK-491 40 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
3003238|NCT02541669|Placebo Comparator|Placebo|TAK-491 40 mg placebo-matching tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10.
3003239|NCT02541656|Experimental|preloaddependence indice after volume expansion in laparoscopy|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
3003240|NCT02541617|Active Comparator|Movement Disorder Center|Device programming, Deep Brain stimulator will be programmed at the implanting center, standard of care
3003241|NCT02541617|Experimental|Programming by community Neurologist|Device programming, Deep Brain Stimulator will be programmed by community Neurologist
3003242|NCT02541604|Experimental|Atezolizumab|Participants will receive intravenous (IV) infusion of atezolizumab (maximum 1200 milligrams [mg]) on Day 1 of each 21-day cycle.
3003243|NCT02541591|Experimental|Neuroprotect|MAP between 85-100mmHg SVO2 between 65-75%
3003244|NCT02541591|Active Comparator|Control|MAP>65mmHg
3003245|NCT02541565|Experimental|Treatment (pembrolizumab, combination chemotherapy)|Patients receive pembrolizumab IV over 30 minutes on day 1 and prednisone PO on days 1-5. Patients also receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 2 of course 1 and on day 1 of subsequent courses. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3003246|NCT02541552|Experimental|Knee arthroscopic patient|"1) Male and females 2) Age 16-60 years 3) Scheduled surgery 4) Knee arthroscopy 5) ASA Class I - III~Volume finding study to follow up-and-down design using a single cohort of patients. Intervention of patient will be dependent on effect of previous patients dose of and response to Ropivacaine 0.5% injectate."
3003247|NCT02541539|Active Comparator|Lactobacillus casei Zhang|Intervention consists of daily administration of 2g probiotic Lactobacillus casei Zhang, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 months.
3003248|NCT02541539|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 months.
3003249|NCT02541526|Experimental|mirtazapine|30 mg mirtazepine will be given to patients on day 6 of their treatment for a period pf 3 days to observe for tolerability followed by 60 mg from day 9 of treatment until the end of the study (16 weeks).
3003250|NCT02541526|Placebo Comparator|Placebo|matched placebo mirtazapine capsules will be given to patients in this group
3003251|NCT02541513|Experimental|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for 3 days followed by an injection of Paliperidone 150 mg injection on Day 8
3003252|NCT02541500|Experimental|Minocycline|Patients in this arm will receive oral minocycline
3003253|NCT02541487||Nutritional/Physical Activity (NuPA) Intervention|Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
3003254|NCT02541487||Physical Activity only (PAo) Intervention|Obese participants in the FIT-PLESE clinical trial randomized to the exercise only arm that achieve pregnancy.
3003255|NCT02541487||Infertile, non-lifestyle intervention controls|Obese women (60) with unexplained infertility who meet the inclusion/exclusion criteria for FIT-PLESE but decline participation in the trial and who elect to undergo CC-IUI treatment and achieve pregnancy without prior diet and exercise interventions.
3003256|NCT02541474|Other|Integrated care|All patients fitting inclusion criteria will receive care from The Patient -centered health care team ( PACT ) which is a service model for frail elderly patients with multiple long term conditions.
3003257|NCT02541474|No Intervention|Usual care|All patients in the Control hospitals (Bodø and Narvik) that match the index patient from the intervention group, and who consents to participate in the study. Eligible patients receive an invitation to participate from the local study nurse. Included controls receive usual care in control hospital and municipalities. Data collection in intervention and control groups are the same.
3003258|NCT02541461|Other|Non-Obese|Patients who underwent laparoscopic gastrectomy and with BMI < 25 kg/m2
3003259|NCT02541461|Other|Obese|Patients who underwent laparoscopic gastrectomy and with BMI ≥ 25 kg/m2
3003260|NCT02541448|Active Comparator|AIS at 9±1mmHg|Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 9±1mmHg
3003261|NCT02541448|Active Comparator|AIS at 15±1mmHg|Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 15±1mmHg.
3003262|NCT02541435||conventional radiotherapy|450 breast cancer patients treated with conventional radiotherapy with or without anthracyclines and/or trastuzumab during 2007-2012
3003263|NCT02541435||breath controlled radiotherapy|350 breast cancer patients treated with laser assisted breath controlled radiotherapy with or without anthracyclines and/or trastuzumab during 2015-2017
3003264|NCT02541435||controls|per participating patient 2 age-matched female controls from the HUNT-3 population (total 800)
3003265|NCT02541422|Active Comparator|NAC group|Patients receiving NAC after drinking to breathalyzer value 0.1
3003266|NCT02541422|Placebo Comparator|Placebo group|Patients receiving placebo after drinking to breathalyzer value 0.1
3003267|NCT02541409|Active Comparator|SOF+PEG+RBV|Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks
3003268|NCT02541409|Active Comparator|SOF+RBV|Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks
3003269|NCT02541396|Placebo Comparator|Group A|"Placebo wafers given every 2 hours Placebo capsule given every 4 hours Placebo wafers top-up dose given at hour 1"
3003270|NCT02541396|Active Comparator|Group B|"Placebo wafers given every 2 hours Oxycodone given every 4 hours Placebo wafers top-up dose given at hour 1"
3003271|NCT02541396|Experimental|Group C|"Wafermine™ 35 mg wafer + placebo wafer given every 2 hours Placebo capsule given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
3003272|NCT02541396|Experimental|Group D|"Wafermine™ 35 mg wafer + placebo wafer given every 2 hours Oxycodone 5 mg capsule every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
3003273|NCT02541396|Experimental|Group E|"Wafermine™ 35 mg + placebo wafer given every 4 hours Placebo wafers given every 2 hours Placebo capsule given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
3003274|NCT02541396|Experimental|Group F|"Wafermine™ 35 mg + placebo wafer given every 4 hours Placebo wafers given every 2 hours Oxycodone 5 mg given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
3003275|NCT02541396|Experimental|Group G|"Wafermine™ 70 mg given every 4 hours Placebo wafer given every 2 hours Placebo capsule given every 4 hours 2 Placebo wafers top-up dose at hour 1"
3003276|NCT02541383|Other|Arm A Part 1|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)
3003277|NCT02541383|Experimental|Arm B Part 1|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) plus daratumumab
3003278|NCT02541383|No Intervention|Arm A Part 2|Observation
3003279|NCT02541383|Experimental|Arm B Part 2|daratumumab
3003280|NCT02541370|Experimental|anti-CD133 CAR T cells|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Patients receive anti-CD133-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity."
3003281|NCT02541357|No Intervention|Usual care|Does not receive a specific study intervention
3003282|NCT02541357|Experimental|preoperative relaxation program|preoperative relaxation program
3003283|NCT02541357|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
3003284|NCT02541357|Experimental|preop relaxation and surgery education|preoperative relaxation program AND single education unit
3003285|NCT02541344|Active Comparator|Dose 1 of IQP-VV-102|Total 4 tablets (2 tablets with active ingredients and 2 placebo tablets) to be taken, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
3003286|NCT02541344|Active Comparator|Dose 2 of IQP-VV-102|Total 4 tablets (4 tablets with active ingredients) to be taken, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
3003287|NCT02541344|Placebo Comparator|Placebo|Total 4 placebo tablets, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
3003288|NCT02541331|Experimental|ISMIGEN|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest
3003289|NCT02541331|Placebo Comparator|PLACEBO|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest
3003290|NCT02541318|Experimental|Practice-from Beginning Group|"The Practice-from Beginning Group will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the Practice-2 month Later Group. Then, after 2 weeks, the participants of Practice-from Beginning Group and Practice-2 month Later Group will crossover. The Practice-from Beginning Group has no intervention, but the Practice-2 month Later Group will practice Duo-in exercise for 2 months."
3003291|NCT02541318|Other|Practice-2 month Later Group|"The Practice-from Beginning Group will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the Practice-2 month Later Group. Then, after 2 weeks, the participants of Practice-from Beginning Group and Practice-2 month Later Group will crossover. The Practice-from Beginning Group has no intervention, but the Practice-2 month Later Group will practice Duo-in exercise for 2 months."
3003292|NCT02541305|Active Comparator|Cotrol|No propioceptive program.
3003293|NCT02541305|Experimental|Experimental|Propioceptive program
3003294|NCT02541292||Patient group|Patients over 18 years old with confirmed FSHD (facioscapulohumeral muscular dystrophy).
3003295|NCT02541279|Experimental|Intervention|The intervention group received 6 sessions of shoulder exercises controlled by a physiotherapist.
3003296|NCT02541279|Active Comparator|Control|The control group received a paper explaining the same exercises which were performed by the intervention group. This group made the exercises at home.
3003297|NCT02541266||Group 1|Patients currently recruited to studies with imaging at The Marsden
3003298|NCT02541266||Group 2|Patients who have previously participated in studies with imaging at The Marsden
3003299|NCT02541266||Group 3|Patients attending for scans as part of their clinical pathway
3003300|NCT02541253|Experimental|GC3110A|One injection : 0.5ml or 0.25ml, IM on day 0 Two injection : 0.5ml or 0.25ml, IM on day 0
3003301|NCT02541253|Active Comparator|GCFLU Pre-filled Syringe inj.|One injection : 0.5ml or 0.25ml, IM on day 0 Two injection : 0.5ml or 0.25ml, IM on day 0
3003302|NCT02541240|Experimental|Resilience Curriculum|The intervention is exposure to an 8-hour Resilience Curriculum. It will provide education for participants about methods to increase protective factors against stress, the use of effective coping strategies, and the importance of accessing social support, with the goal of better managing stress and enhancing resilience. The curriculum will include a didactic component, skills-building training, and homework exercises to encourage the application of the skills.
3003303|NCT02541240|No Intervention|No Resilience Curriculum|The Waitlist Control group will receive no exposure to the Resilience Curriculum. After the final data is collected, this group will be offered the opportunity to attend a condensed 2-hour version of the curriculum.
3003304|NCT02541227||Cerebrolysin group|Patients who are treated with Cerebrolysin; dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
3003305|NCT02541227||Control group|Patients who are not treated with Cerebrolysin; treatment follows local clinical practice
3003306|NCT02541201|Experimental|Plant sterols-enriched low-fat milk|Daily consumption of 1.5g of plant sterols as provided by two servings of 273 ml of plant sterols-enriched low-fat milk for consecutive 3 weeks, each serving taken right before breakfast and lunch.
3003548|NCT02539563|No Intervention|no peanut ball|the peanut shaped birthing ball will not be utilized during labor
3003307|NCT02541201|Placebo Comparator|Low-fat milk|Daily consumption of two servings of 273 ml of low-fat milk (without plant sterols) for consecutive 3 weeks, each serving taken right before breakfast and lunch.
3003308|NCT02541188||breast cancer in young women is in the Maghreb|breast cancer in young women (< 40years old) is in the Maghreb
3003309|NCT02541188||Breast cancer in young women in the western countries|Breast cancer in young women (< 40years old) in the western countries
3003310|NCT02541175||All study participants|In order to cover a wide variety of common arrhythmias but keeping the number of subjects needed low (pilot study), the subjects are pre-selected according to following 4 categories: 1) 4 patients with intermitting or persisting atrial fibrillation. 2) 4 patients with atrial flutter 3) 6 patients with frequent atrial or ventricular extra-systoles. 4) 6 cardiac healthy subjects.
3003311|NCT02541162|Experimental|INFORMED|"Interventional Group (I): Couples enrolled during the diagnosis will receive written information as usual about the disease and in addition they benefit special oral interviews and written information about experiences of their sexuality during the illness.The document used for the interventional group is Sexuality and Cancer and will be given to couples. (intervention: Oral information and interviews about sexuality and self experience during the disease). Qualitative analysis will be provided by a psychologist"
3003312|NCT02541162|No Intervention|ORDINARY USE|"Non-interventional Group (NI): Couples enrolled during the diagnosis will only receive written information about their experience of disease . The document used fot the non interventional group is Live during and after cancerand will be given to couples. Qualitative analysis will be provided by a psychologist"
3003313|NCT02541149||Group 1:|Fifty patients with early stage hepatocellular carcinoma(BCLC stage A)
3003314|NCT02541149||Group 2|Twenty five patients with chronic liver disease diagnosed based on clinical, laboratory, and ultrasonographic investigations;
3003315|NCT02541149||Group 3|Control Group: Fifteen healthy, age and sex-matched subjects with seronegative hepatitis viral markers
3003316|NCT02541136|Experimental|Exercise|Participants in this arm took part in the aerobic exercise component of the study and attended St. James's Hospital in Dublin twice a week for 16 weeks. Furthermore, exercising participants were asked to engage in recorded aerobic activity outside of the class, which followed a standardised progression from 1-3 additional sessions, at the same intensity as the week's class.
3003317|NCT02541136|No Intervention|Control|Participants in the control group didn't change their sedentary habits.
3003318|NCT02541123||Cohort A|CT negative for acute intracranial lesion with initial blood draw within 4 hours of head injury
3003319|NCT02541123||Cohort B|CT negative for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
3003320|NCT02541123||Cohort C|CT positive for acute intracranial lesion with initial blood draw within 4 hours of head injury
3003321|NCT02541123||Cohort D|CT positive for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
3003322|NCT02541123||Cohort E|Uninjured control group
3003323|NCT02541097|Active Comparator|Language therapy-Individual treatment|Participants will receive intervention for naming impairment based on either phonological or semantic cues.
3003324|NCT02541097|Active Comparator|Language therapy-Group treatment|Following the individual therapy, participants will be randomly assigned to either verbal or non-verbal group
3003325|NCT02541084||PRN group|wAMD-patients treated with anti-VEGF therapy ´pro re nata´ (PRN)
3003326|NCT02541084||TAE group|wAMD-patients treated with anti-VEGF therapy ´treat-and-extend´ (TAE)
3003327|NCT02541084||PRN-to-TAE switcher group|wAMD patients treated with anti-VEGF therapy and switching from PRN to TAE regimens
3003328|NCT02541071|Experimental|Yohimbine and Stress Film|Administration of 10mg yohimbine before the trauma film.
3003329|NCT02541071|Experimental|Placebo and Stress Film|Administration of placebo before the trauma film.
3003330|NCT02541071|Experimental|Clonidine and Stress Film|Administration of 0.15mg clonidine before the trauma film.
3003331|NCT02541058||Patients without confirmed 22q.11.2 deletion/duplication|
3003332|NCT02541058||Patients with confirmed 22q.11.2 deletion/duplication|
3003333|NCT02541045|Placebo Comparator|Group 1: Placebo|Placebo
3003334|NCT02541045|Experimental|Group 2: Metadoxine|therapy with metadoxine
3003335|NCT02541032|Active Comparator|Intensive Dental Treatment|Patients will undergo up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm. All patients will be reexamined at 3, 6 and 9 months for safety checks. Patients will be given instructions in basic oral hygiene and treated for stroke risk factors in accordance to the current guidelines for secondary stroke prevention.
3003336|NCT02541032|Active Comparator|Standard Dental Treatment|Patients will undergo supragingival mechanical scaling and polishing. They will be informed of the presence and severity of their periodontal disease and will be advised to be seen by their dentist if their condition requires immediate attention. If they have no dental provider they will be referred for care. All patients will be reexamined at 3, 6 and 9 months for safety checks. Among the group the periodontal condition will be monitored to assure there is no progression of disease. If any site demonstrates an increase in periodontal pockets >3mm, they will receive site-directed scaling and root planing. Patients will be given instructions in basic oral hygiene and treated for stroke risk factors in accordance to the current guidelines for secondary stroke prevention. At the completion of the study, the control treatment patients will be offered to receive the same dental care as provided to the intensive treatment group as needed.
3003337|NCT02541019|Experimental|Palonosetron|Palonosetron (iv) one minute before anesthesic induction.
3003338|NCT02541019|Experimental|Ondansetron|ondansetron (iv) one minute before anesthesic induction and ondansetron regular three times a day for two days after the surgery.
3003339|NCT02541006|Experimental|Tiotropium 18 mcg dry powder for inhalation|Tiotropium 18 mcg dry powder for inhalation, one inhalation, once daily with the DISCAIR
3003340|NCT02541006|Active Comparator|SPIRIVA 18 mcg HANDIHALER|Tiotropium 18 mcg dry powder capsul for inhalation one capsule once daily with the HandiHaler
3003341|NCT02540993|Experimental|BAY94-8862|Finerenone tablet
3003344|NCT02540954|Experimental|Flexible dosing intervals|Flexible dosing intervals: 2 mg aflibercept (Eylea) injected intravitreally with flexible injection intervals (more than 8 weeks)
3003345|NCT02540954|Experimental|Fixed injection intervals|2 mg aflibercept (Eylea) injected intravitreally with fixed injection intervals (8 weeks ±7 days)
3003346|NCT02540928|Experimental|AMG 319 Hydrate|Up to 36 patients will be randomised into the Active Treatment arm to receive AMG 319 400 mg once daily administered orally for a minimum of 20 days and a maximum of 29 days prior to resection surgery
3003347|NCT02540928|Placebo Comparator|Placebo|Up to 18 patients will be randomised into the Placebo arm to receive Placebo once daily administered orally for a minimum of 20 days and a maximum of 29 days prior to resection surgery
3003348|NCT02540915||All patients 17 years or younger|Standard of Care - Registry. Must have been 11 yrs or under at initial treatment/evaluation.
3003349|NCT02540902|Experimental|All-poly|Knee arthroplasty with all-polyethylene tibia
3003350|NCT02540889|Experimental|trial arm|100 hours of therapy.
3003351|NCT02540889|No Intervention|Normal therapy arm|12 weeks of normal therapy.
3003352|NCT02540876|Experimental|Treatment (ilorasertib)|Patients receive ilorasertib PO BID on days 1, 8, 15, 29, and 36. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
3003353|NCT02540863|Experimental|myofascial release protocol and Rocabado exercise therapy|"Myofascial Release Protocol:~Suboccipital release.~Compression - decompression of temporomandibular joint.~Horizontal release of temporomandibular joint.~Deep fascia release in temporal region.~Masseter deep fascia release.~Pterygoiddeep fascia release.~Intraoral pterygoid deep fascia release."
3003354|NCT02540863|Active Comparator|exercise therapy|Rocabado´s 6 x 6 exercises program utilizes six exercises six times by day. The patient is in supine position with a loop of 6 cm in the cervical area, and the therapist sits at the head of the bed.
3003355|NCT02540850||CRC group|stage 0-IV CRC subjects
3003356|NCT02540850||precancerous disease group|subjects with adenoma or polyps
3003357|NCT02540850||other disease group|subjects with other bowel diseases, other cancers, and subjects with no evidence of disease
3003358|NCT02540837|Experimental|Bupivacaine|Obturator nerve block
3003359|NCT02540837|Placebo Comparator|Saline|Saline is injected as a placebo
3003360|NCT02540824|Experimental|Apatinib single agent arm|Apatinib, single agent, 750mg once daily p.o until disease progression
3003361|NCT02540811|Experimental|dCELL® ACL Scaffold|
3003362|NCT02540785|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery.
3003363|NCT02540785|Experimental|small-incision lenticule extraction|The patients in this group chose to receive the small-incision lenticule extraction surgery.
3003364|NCT02540772|Experimental|Neuropsychological treatment|The tested treatment is a combination of neuropsychological rehabilitation procedures: learning, episodic memory recall after a delay, selective attention, inhibition of predominant responses and awareness of deficits.
3003365|NCT02540772|No Intervention|No treatment|Patients in the control group only performed the baselines.
3003366|NCT02540759|Placebo Comparator|High oleic sunflower oil (HOSO)|10 ml HOSO/day in a single dose, 28 days
3003367|NCT02540759|Experimental|High dose Buglossoides oil|10 ml Buglossoides oil/day in a single dose, 28 days
3003368|NCT02540759|Experimental|Medium dose Buglossoides oil|6 ml Buglossoides oil + 4 ml HOSO/day in a single dose, 28 days
3003369|NCT02540759|Experimental|Low dose Buglossoides oil|3 ml Buglossoides oil + 7 ml HOSO/day in a single dose, 28 days
3003370|NCT02540746|Experimental|ERG Skills Training|ERG Skills Training for 12 weeks
3003371|NCT02540746|Experimental|ERG Skills Training + ME|ERG Skills Training for 12 weeks preceded by Motivational Enhancement for 4 weeks
3003372|NCT02540746|Experimental|ERG Skills Training + FAM|ERG Skills Training with concurrent 12-week Family Skills Training
3003373|NCT02540746|Experimental|ERG Skills Training + ME + FAM|ERG Skills Training with concurrent 12-week Family Skills Training preceded by Motivational Enhancement for 4 weeks
3003374|NCT02540733||Diabetic stroke|
3003375|NCT02540733||Non-diabetic storke|
3003376|NCT02540720|Experimental|group 1|Dexamethasone 0.5mg/kg.d i.v.
3003377|NCT02540720|Experimental|group 2|Dexamethasone & gamma globulin Dexamethasone 0.5mg/kg.d i.v. & gamma globulin i.v. qd*3d, and the total dose is 2g/kg
3003378|NCT02540720|Experimental|group 3|Dexamethasone & hemoperfusion Dexamethasone 0.5mg/kg.d i.v & hemoperfusion should be given at least three times in five days
3003379|NCT02540707|Placebo Comparator|Solifenacin|Women with overactive bladder syndrome will be treated by solifenacin 5 mg qd * 12 weeks
3003380|NCT02540707|Experimental|Mirabegron|Women with overactive bladder syndrome will be treated by mirabegron 25 mg qd * 12 weeks
3003381|NCT02540694|Active Comparator|EBUS-TBNA using 22G needle|EBUS-TBNA using 22G needle (transbronchial route)
3003382|NCT02540694|Active Comparator|EBUS-TBNA using 25G ProCore needle|EBUS-TBNA using 25G ProCore needle (transbronchial route)
3003383|NCT02540694|Active Comparator|EUS-B-FNA using 22G needle|EUS-B-FNA using 22G needle (transoesophageal route)
3003384|NCT02540694|Active Comparator|EUS-B-FNA using 25G ProCOre needle|EUS-B-FNA using 25G ProCOre needle (transoesophageal route)
3003385|NCT02540668|Experimental|Warfarin|Single oral dose of 15 mg warfarin on Day 1.
3003386|NCT02540668|Experimental|Lanabecestat + Warfarin|Lanabecestat administered orally once daily on Days 8 to 27, with a single oral dose of 15 mg warfarin co-administered on Day 22.
3003387|NCT02540655|Experimental|Stemchymal®|Infusion of Stemchymal®
3003388|NCT02540655|Placebo Comparator|Vehicle|Infusion of excipients
3003389|NCT02540642|Active Comparator|Vitamin B12 and Antidiabetics|Tablet Methylcobalamin 500 ug once daily with other usual antidiabetic drugs
3003390|NCT02540642|No Intervention|antidiabetics|Only regular antidiabetic drugs will be given
3003391|NCT02540629|No Intervention|Before intervention|The before intervention group will include patients from January, 2013 through December, 2014, as to refer to the historic control population who did not receive any of study interventions.
3003419|NCT02540434|Active Comparator|Cryopreciptiate Arm|Subjects will be infused with cryoprecipitate if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
3003392|NCT02540629|Experimental|After intervention|The main study phase will begin in January, 2016 through December, 2017, for a total of two years. Patients during the main study phase will have received one or more study interventions as applicable.
3003393|NCT02540616|Experimental|Transcranial Electrical Stimulation-Real|The participant will perform real TES. The forms of TES used in this study will include transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or transcranial random noise stimulation (tRNS). Each stimulation session will last for 20-minutes.
3003394|NCT02540616|Sham Comparator|Transcranial Electrical Stimulation-Sham|The participant will perform sham TES for 20-minutes. The form of sham TES will depend on the active arm, e.g. if tACS is on the active arm, then the sham tACS will be a different frequency of stimulation. If tDCS is the active arm, then a short ramp up of tDCS followed by a ramp down (about 60-seconds) will be used as the sham arm.
3003395|NCT02540603|Experimental|Full Face Mask|F&P Jupiter Full Face Mask with Headgear
3003396|NCT02540590||Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement before and after root coverage surgery. In this group the roots are covered by a combination of modified coronally advanced flap and xenograft collagen matrix (Mucograft).
3003397|NCT02540590||CTG|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement before and after root coverage surgery. In this group the roots are covered by a combination of modified coronally advanced flap and subepithelial connective tissue graft (CTG), which was harvested from the patient's palate.
3003398|NCT02540551|Experimental|Sentinel node procedure.|Intervention: injection of blue dye and radioactive tracer (99mTc-nanocolloid or Nanocoll) in remains of the ovarian ligaments.
3003399|NCT02540538|Active Comparator|HB vaccine naive - HBVaxPro|Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBVaxPro-10ug at day 0, 30, and 180.
3003400|NCT02540538|Experimental|HB vaccine naive - HBAI20|Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.
3003401|NCT02540538|Experimental|Non-responders - HBAI20|"Subjects have been vaccinated 6 times with a Hepatitis B vaccine without developing a protective immune response, measured as anti Hepatitis B surface antigen antibodies, superior to 10mIU/ml.~Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180."
3003402|NCT02540525|Experimental|Single incision mini-sling|Experimental group: surgery to treat stress urinary incontinence with the Ophira mini sling systemt®
3003403|NCT02540525|Active Comparator|Transobturator sling|Control group: surgery to treat stress urinary incontinence with the Unitape T Plus®.
3003404|NCT02540512|Placebo Comparator|Standard Drug Group|"Participants randomized into this group will be receiving the standard medical care and placebo acupuncture. For the placebo acupuncture procedure, the ASP® needles will be double taped onto the ear in the same anatomical position as the acupuncture groups. The needles will be taped so that the needles will never puncture the skin. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed."
3003405|NCT02540512|Experimental|Standard Drug Plus Acupuncture Group|"The participants in this group will receive auricular acupuncture following the Battlefield Acupuncture Protocol. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed (in the acupuncture groups, the physician administering the treatment will not know if the patient is receiving the standard drug or the placebo pill). The physician can administer up to 10 needles (5 in each ear) until the patient has a significant drop in pain (pain level 0 or 1)."
3003406|NCT02540512|Experimental|Acupuncture Group|"The participants in this group will receive auricular acupuncture following the Battlefield Acupuncture Protocol. The physician can administer up to 10 needles (5 in each ear) until the patient has a significant drop in pain (pain level 0 or 1). The patient will then be given a placebo pill."
3003407|NCT02540499|Experimental|DIBH VMAT|"Volumetric modulated arc radiotherapy in visually guided voluntary -deep inspiration breath-hold for patients with locally advanced NSCLC referred for concomitant radiotherapy 2 Gy x 33, 5 F/W and 3 courses of platinum based combination chemotherapy.~Will be compared to a historic cohort of patients treated with VMAT in free breathing"
3003408|NCT02540486|Experimental|LTHome web tool|The long-acting insulin glargine titration web tool (LTHome) will provide insulin glargine titration suggestions based on user inputted blood glucose readings.
3003409|NCT02540486|Active Comparator|Enhanced Usual Therapy (EUT)|The Enhanced Usual Therapy arm will receive insulin glargine titration instructions that are the usual therapy provided by the physician/HCP, in addition to diabetes education.
3003410|NCT02540473|Experimental|Group therapy|12 week manualized group therapy (one hour per week)
3003411|NCT02540473|Other|Control Group|Participants get one hour of time away from patient care/duties to do as they wish.
3003412|NCT02540460|Experimental|LCB01-0371 800mg|LCB01-0371 800mg
3003413|NCT02540460|Experimental|LCB01-0371 800mg BID|LCB01-0371 800mg BID
3003414|NCT02540460|Experimental|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
3003415|NCT02540460|Placebo Comparator|Placebo|LCB01-0371 800mg, LCB01-0371 800mg BID, LCB01-0371 1200mg BID
3003416|NCT02540447|Experimental|Purge|"The donor surgical team excised the right liver lobe (without inclusion of the middle hepatic vein) and preserved it on the back table with cold custodiol (4°C solution, Portal vein (PV) was completely anastomosed and the right hepatic vein (RHV) was anastomosed with the recipient hepatic vein apart from last suture that was left for drainage of the liver graft contents of the preservative solution into the peritoneal cavity using portal blood after portal declamping based on the graft volume and suctioned through an external sucker, then completed the RHV anastomosis."
3003417|NCT02540447|No Intervention|No Purge|The donor surgical team excised the right liver lobe (without inclusion of the middle hepatic vein) and preserved it on the back table with cold Custodiol (4°C solution, Both portal vein and RHV were completely anastomosed prior to portal declamping and the graft preservative contents were washed into the systemic circulation by the portal blood at portal declamping.
3003418|NCT02540434|Active Comparator|RiaSTAP Arm|Subjects will be infused with RiaSTAP if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
3003420|NCT02540421||Case|Recurrent lesions
3003421|NCT02540421||Control|Absence of lesions
3003423|NCT02540395|Active Comparator|Group A: Standard of care|"Standard of care immunosuppressive regimen based on TAC (Prograf) (achieving 4-8ng/ml trough levels), MMF (Cellcept, Myfortic, Myfenax)(1gr bid) and steroids (6-methyl prednisolone, Urbason, Methypred) (according to KDIGO guidelines).~All patients in group A recieve the tripple-drug IS as suggested by guidelines. In case of rejection the patients are treated with high dosage of Methypred and/or Thymoglobuline"
3003424|NCT02540395|Experimental|"Group B: Low Immunosuppression regimen"|"(based on TAC monotherapy (Prograf) to achieve 8-10 ng/ml trough levels during the first 4 weeks after transplantation and 6-8 ng/ml thereafter, MMF (Cellcept, Myfortic, Myfenax) (1g bid) during the first 7 days post-transplant and stopped thereafter) and steroids (6-methyl prednisolone; Urbason, Methypred) (tapering until discontinuation on month 2 post-transplant).~In contrast to Group A the patients are treated with a two drug IS combination consisting of Prograf and Methypred. In case of rejection the patients are treated with hifg dosage of Methypred and/or Thymoglobuline."
3003425|NCT02540382|Experimental|covered stent|"Procedure/Surgery: Jugular vein puncture and catheterization. Device: RUPS-100 (COOK Company) sheath, 8 mm balloon, Pigtail catheter, 8 mm covered stents (Bard, Fluency).~Drug (including placebo): No Biological/Vaccine: No Radiation: No Behavioral (e.g., Psychotherapy, Lifestyle Counseling): No Genetic (including gene transfer, stem cell and recombinant DNA): No Dietary Supplement (e.g., vitamins, minerals): No."
3003426|NCT02540382|Other|bare stent|"Surgery: Jugular vein puncture and catheterization. Device: RUPS-100 (COOK Company) sheath, 8 mm balloon, Pigtail catheter, 8 mm bare stents (EV3, protégé; Cordis, Smart).~Drug (including placebo): No Biological/Vaccine: No Radiation: No Behavioral (e.g., Psychotherapy, Lifestyle Counseling): No Genetic (including gene transfer, stem cell and recombinant DNA): No Dietary Supplement (e.g., vitamins, minerals): No."
3003427|NCT02540369||BAY86-5321- with wAMD|Patients with wet Age Related Macular Degeneration (wAMD) both naïve and previously treated patients
3003428|NCT02540369||BAY86-5321 - with DME|Patients with Diabetic Macular Edema (DME) both naïve and previously treated patients
3003429|NCT02540356|Experimental|Single-Route Arm|BAX69 administered weekly by intraperitoneal (IP) infusion only
3003430|NCT02540356|Experimental|Double-Route Arm|BAX69 administered weekly by intravenous (IV) infusion + intraperitoneal (IP) infusion
3003431|NCT02540343||acute neck pain patients|Participant recently received the diagnosis of neck pain (< 30 days) >18 years old able to speak, read and write German, questionnaires
3003432|NCT02540343||chronic neck apin patients|Participant has neck pain for a longer period of time (> 90 days) > 18 years old able to speak, read and write German, questionnaires
3003433|NCT02540343||test persons|no neck pain > 18 years old able to speak, read and write German, questionnaires
3003434|NCT02540330|Active Comparator|Intramuscular Fulvestrant|500mg fulvestrant administered intramuscularly
3003435|NCT02540330|Experimental|Intraductal Fulvestrant|up to 500mg fulvestrant administered intraductally
3003436|NCT02540317|Experimental|Active treatment, Internet-based CBT|Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy. Participants will be stratified based on diagnosis, i.e. adjustment disorder and burnout.
3003437|NCT02540317|No Intervention|Waiting list control|The control condition is a waiting list. Participants in this arm receive no active treatment. After 12 weeks on waiting list, participants are crossed over to treatment.
3003438|NCT02540304|Experimental|TPP program|Reducing the Risk, Safer Sex Intervention, Cuidate!
3003439|NCT02540304|No Intervention|Business as Usual|Business as usual
3003440|NCT02540291|Experimental|E7046|Participants with tumor types that harbor high levels of myeloid infiltrate based on the Cancer Genome Atlas (TCGA).
3003441|NCT02540278|Experimental|Treatment|Received the 11 lesson Positive Prevention Curriculum
3003442|NCT02540278|No Intervention|Control|Did not receive any sex-related instruction
3003443|NCT02540265|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
3003444|NCT02540265|Experimental|N1539 60mg|N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.
3003445|NCT02540265|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
3003446|NCT02540239|Placebo Comparator|2L PEG|only used 2L PEG
3003447|NCT02540239|Experimental|Simethione+2L PEG|used 2L PEG+Simethione
3003448|NCT02540226|Active Comparator|Intravenous tranexamic acid|Patients will receive 1g tranexamic acid in 100mL solution intravenously in the operating room before inflation of the tourniquet. They will again receive the same IV solution in the post-anesthesia care unit, approximately 3 hours after the first solution was given. They will also receive a 75cc topical saline solution approximately 5 minutes before the tourniquet is released.
3003449|NCT02540226|Experimental|Topical tranexamic acid|Patients will receive 3g tranexamic acid in 75mL solution topically in the operating room, approximately 5 minutes before the tourniquet is released. It will sit for 5 minutes before the solution is suctioned off by the surgeon. They will also receive 2 intravenous saline solutions: one in the operating room before inflation of the tourniquet, and one in the post-anesthesia care unit 3 hours after the first solution was given.
3003450|NCT02540213||MIRCERA Ready-To-Use-Syringe|Participants will use MIRCERA ready-to-use-syringes (methoxy polyethylene glycol epoetin beta 0.6 micrograms per kilogram [mcg/kg]) every 2 weeks (q2w) up to 9 months
3003451|NCT02540200|Active Comparator|Standard treatment|The patients undergo standard bone marrow stimulation technique (i.e. microfracture) for the treatment of their chondral lesions of the hip. This is currently the standard treatment for this condition.
3003452|NCT02540200|Experimental|BST-CarGel|In addition to undergoing the standard intervention with microfracture, BST-CarGel (the device of interest for the study) is applied during the intervention.
3003453|NCT02540187||haemophilia A|"Blood specimen for measuring :~Free TFPI and TFPI activity levels~Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)~Thrombin generation assay (TGA) in fresh PRP and frozen PPP~Hemorrhage score for each patient"
3003454|NCT02540187||Haemophilia B|"Blood specimen for measuring :~Free TFPI and TFPI activity levels~Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)~Thrombin generation assay (TGA) in fresh PRP and frozen PPP~Hemorrhage score for each patient"
3003455|NCT02540174|Experimental|Arm A|integrated addiction treatment program
3003456|NCT02540174|Other|Arm B|standard of care
3003457|NCT02540161|Experimental|non-bevacizumab failures|Non-bevacizumab failure (either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen) will receive Sym004 intravenously every two weeks.
3003458|NCT02540161|Experimental|bevacizumab failures|Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment) will receive Sym004 intravenously every two weeks.
3003459|NCT02540148|Experimental|Active Treatment|Subjects will undergo three treatment sessions to the enrolled eyes within 5 days of the 1st treatment, followed by a treatment session on one day during week 2 with the Nova Oculus™ transpalpebral micro-current electrical stimulation device.
3003460|NCT02540148|Sham Comparator|Non-active treatment|Subjects will undergo three non-active treatment sessions (no micro-current will be administered by the Nova Oculus™ transpalpebral micro-current electrical stimulation device) to the enrolled eyes within 5 days of the 1st treatment, followed by another non-active treatment session on one day during week 2.
3003461|NCT02540135|Experimental|Arm A|Flourescein plus intraoperative MRI
3003462|NCT02540135|Active Comparator|Arm B|intraoperative MRI alone
3003463|NCT02540122|Active Comparator|Subject A (Neophytes)|Subjects will wear the Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, and Marketed Contact Lens 4 for a 6-hour period in a bilateral and random fashion, with a washout period of one week between lenses. Each subject will randomly be assigned to one of four unique sequences of a 4 x 4 crossover design. A block size of two sequences will be used.
3003464|NCT02540122|Active Comparator|Subject B (Habitual Lens Wearers)|Subjects will wear the Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, and Marketed Contact Lens 4 for a 6-hour period in a bilateral and random fashion, with a washout period of one week between lenses. Each subject will randomly be assigned to one of four unique sequences of a 4 x 4 crossover design. A block size of two sequences will be used.
3003465|NCT02540109|Experimental|High-Definition tDCS (Active)|
3003466|NCT02540109|Experimental|High-Definition tDCS (Sham)|
3003467|NCT02540096|Experimental|Intervention (Mental Practice)|Participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups). They will also participate in a structured mental practice session (lasting 30 minutes and three times a week), totaling 12 sessions at the end of this intervention.
3003468|NCT02540096|Placebo Comparator|Control group|Participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes. They will also participate in a cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions.
3003469|NCT02540083|Active Comparator|FFDM|Subjects will undergo 2D breast imaging with full-field digital mammography (FFDM) device
3003470|NCT02540083|Experimental|DBT|Subjects will undergo 3D breast imaging with digital breast tomosynthesis (DBT) device
3003471|NCT02540070|Active Comparator|Periarticular|Patients in group 1 will receive periarticular infiltration of LA mixture (100 ml) consisting of 0.3% ropivacaine, 2.5 µg/mL of epinephrine, 10 mg of morphine and 30 mg of ketorolac at the end of surgery and sham injections of saline into the motor sparing knee blocks preoperatively.
3003472|NCT02540070|Experimental|Motor free|Patients in group 2 will receive motor sparing knee blocks with 0.5% ropivacaine with 2.5 µg/mL of epinephrine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Sham injections of saline (100 ml) will be injected periarticularly at the end of surgery.
3003473|NCT02540070|Experimental|Motor free with Dex|Patients in group 3 will receive motor sparing knee blocks with 0.5% ropivacaine with 1 µg/Kg of dexmedetomidine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Patients in group 3 will receive sham injections of saline (100 ml) periarticularly at the end of surgery.
3003474|NCT02540057|Active Comparator|Flexor carpi radialis|These patients will have their trapeziectomy with ligament reconstruction and tendon interposition using the flexor carpi radialis tendon.
3003475|NCT02540057|Active Comparator|Abductor pollicis longus|These patients will have their trapeziectomy with ligament reconstruction and tendon interposition using the abductor pollicis longus tendon.
3003476|NCT02540044|Experimental|ANSWER-2 decision aid|The Intervention Group will receive simple instructions to access ANSWER-2 and complete the program on their own computers within two days. At the end of the session, ANSWER-2 will produce a one-page summary summarizing the participant's questions, concerns, and preferred medication option.
3003477|NCT02540044|Active Comparator|Control Group (TAS Consumer Guide)|The Control Group will receive the online Arthritis Medications: A Consumer's Guide, published by The Arthritis Society. It contains standard information about biologics, including an introduction of the different biologic options, dosages and side effects.
3003478|NCT02540031|Experimental|Additional oral preparation|"The investigational or experimental arm will receive standard oral preparation plus additional oral preparation (1l of polyethylene glycol (PEG)+ascorbic acid (Asc)) for colonoscopy.~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
3003479|NCT02540031|Active Comparator|Standard oral preparation|"The control arm will receive currently used oral preparation (2L of polyethylene glycol+ascorbic acid) for colonoscopy.~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
3003480|NCT02540018|Active Comparator|Paclitaxel-coated Luminor® Balloon Catheter|The balloon dilatation procedure, including deployment to the target lesion and balloon inflation, deflation and retrieval, is performed under fluoroscopic observation. An endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion is mandatory. After pre-dilatation of the target lesion an angiographic assessment will be performed (DSA or XA). Randomization will be performed by envelope pull. The treatment group represents the Luminor® DEB PTA. After dilation of the target lesion, the PTA catheter is withdrawn through the introducer sheath, and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.
3003549|NCT02539550|Placebo Comparator|Placebo|Placebo
3003550|NCT02539550|Experimental|PF-06266047|PF-06266047
3004848|NCT02530996||200|Telehealth outreach for Veterans and routine clinic visits
3003481|NCT02540018|Active Comparator|Uncoated Balloon Catheter|Identical procedure also for control arm with PTA balloon (see below): After pre-dilatation, randomization will be performed by envelope pull. The control group requires an uncoated balloon catheter. After dilation of the target lesion, the PTA catheter is withdrawn and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.
3003482|NCT02540005||Aneurysmatic subarachnoid haemorrhage|Acute subarachnoid haemorrhage (confirmed by computed tomography, CT, or cerebrospinal fluid erythrocyte count over 1000 x 106/l) AND confirmed origin either with computed angiography (CTA) or digital subtraction angiography (DSA)
3003483|NCT02540005||Control patients|Elective craniotomy due to non-ruptured intracranial aneurysm
3003484|NCT02539992|Active Comparator|Triathlon® CR/Kinematic Alignment|Receive the Triathlon® Cruciate Retaining Total Knee System (Triathlon® CR) in a procedure using patient-specific cutting guides to reproduce the natural kinematic alignment of the knee.
3003485|NCT02539992|Active Comparator|Triathlon® CR/Neutral Overall Limb Alignment|Receive the Triathlon® CR device in a procedure using patient-specific cutting guides modified to provide neutral overall limb alignment of the knee.
3003486|NCT02539992|Active Comparator|Triathlon® CR/Conventional Limb Alignment|Receive the Triathlon® CR device in a procedure using traditional instrumentation intended to achieve a neutral overall limb alignment of the knee.
3003487|NCT02539979|Active Comparator|IV Paracetamol|Patients will receive 1gram of IV paracetamol mixed in 100ml infused over 15 minutes. The patients will undergo radiofrequency lesioning of two consecutive levels of lumbar facets under fluoroscopic guidance
3003488|NCT02539979|Placebo Comparator|IV Placebo (Normal Saline)|Patients will receive 100ml of normal saline infused over 15 minutes. The patients will undergo radiofrequency lesioning of two consecutive levels of lumbar facets under fluoroscopic guidance
3003489|NCT02539966|Experimental|Cohort A|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group A (6-month angiographic follow-up)
3003490|NCT02539966|Experimental|Cohort B|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group B (9-month angiographic follow-up)
3003491|NCT02539966|Experimental|Cohort C|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group C (6-month angiographic follow-up), Long Lesion/Multi-Vessel
3003492|NCT02539940||Patients with critical limb ischemia|Patients undergoing endovascular intervention of below-the-knee arteries with ELUTAX SV DEB (drug-eluting balloon).
3003493|NCT02539927||Controlled|
3003494|NCT02539927||Not controlled|
3003495|NCT02539927||Control status yet to be clarified|
3003496|NCT02539914|Experimental|VR motor-cognitive task|The VR motor-cognitive task group will perform a virtual reality motor and cognitive attention/memory task customized to each user in terms of the positive content.
3003497|NCT02539914|Active Comparator|Standard rehabilitation|The standard rehabilitation group will perform conventional motor and cognitive rehabilitation tasks.
3003498|NCT02539901||12-30 months-old deaf children|Children with deafness of bilateral deep perception had : Evaluation of the detection of non-linguistic sounds, Early Social Communication Scale (ECSP) and psychomotor infancy development scale or Lézine Brunet-Revised scale
3003499|NCT02539901||6-9 years-old deaf children|"Free hearing test categorization and NEPSY (two domains: memory and learning and attention and executive functions) in 6-9 years-old deaf child cohort with deafness of bilateral deep perception and carrying a cochlear implant"
3003500|NCT02539901||12-30 months-old normal hearing children|Evaluation of the detection of non-linguistic sounds in 12-30 months-old normal hearing child cohort
3003501|NCT02539901||6-9 years-old normal hearing children|'Free hearing test categorization' in 6-9 years-old normal hearing child cohort
3003502|NCT02539875|Experimental|AWARD, Brief leaflet, Referral leaflet, active referral|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit as soon as possible and not later than a quit date (which will qualify them for the QTW prizes), Refer smokers to smoking cessation services, and Do it again: to repeat the intervention. Brief innovative leaflet on health warning and smoking cessation. A 2-side color printed A4 leaflet will be designed to systematically cover the most important messages to motivate smoking cessation. A 2-side color printed A4 referral leaflet will be used for motivate and assist the smokers to use the smoking cessation services. the smokers will be active refer to various smoking cessation services in Hong Kong (using the referral leaflet) and motivate the smokers to use the smoking cessation services.
3003503|NCT02539875|Experimental|AWARD, Brief leaflet|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit as soon as possible and not later than a quit date (which will qualify them for the QTW prizes), Refer smokers to smoking cessation services, and Do it again: to repeat the intervention. Brief innovative leaflet on health warning and smoking cessation. A 2-side color printed A4 leaflet will be designed to systematically cover the most important messages to motivate smoking cessation.
3003504|NCT02539875|Active Comparator|Smoking cessation booklet, general advices|"Participants will receive minimal intervention, including: (1) the 12-page smoking cessation booklet (provided by COSH); (2) very brief, minimal and general smoking cessation advice include: Please quit smoking for improving health and save money, Please refer to the booklet for the details about smoking cessation and Please call us if you have any enquiry."
3003505|NCT02539862|Experimental|cognitive behavioral therapy online|patients receive cognitive behavioral therapy via an online program
3003506|NCT02539862|Other|no cognitive behavioral therapy online|patients receive psychoeducation by a doctor
3003507|NCT02539849|Other|adalimumab + FOS|Adalimumab will be administered during 12 weeks in combination with daily FOS 6g. (FOS administration will start 2 weeks before Adalimumab)
3003508|NCT02539836|Experimental|Obese children|Obese children will be intervented by dietary nutrition based on plant fermentation extract for 2 months.
3003509|NCT02539823|Placebo Comparator|Control|Subjects will receive a solution that resemble the Cannabidiol solution but do not have have its properties
3003510|NCT02539823|Experimental|CBD 400mg|Subjects will receive 400mg of cannabidiol
3003511|NCT02539823|Experimental|CBD 800mg|Subjects will receive 800 mg of cannabidiol
3003580|NCT02539316|Active Comparator|Médialipides|parenteral nutrition by Médialipides (dosage form depending child's weight as recommended by the SPC)
3003512|NCT02539810|Experimental|Renal artery stenting|"Renal artery angioplasty plus stenting and standardized and optimized medication regimen.~Patients are treated with renal artery stenting plus a standardized optimal medical treatment, including the antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits."
3003513|NCT02539810|Active Comparator|standardized and optimized medication regimen|Patients are treated with a standardized optimal medical treatment including the antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
3003514|NCT02539797|Experimental|tDCS anodal stimulation|anodal stimulation
3003515|NCT02539797|Active Comparator|tDCS cathodal stimulation|cathodal stimulation
3003516|NCT02539797|Sham Comparator|Sham stimulation|Sham stimulation. Termination of electrical stimulation following 30 seconds
3003517|NCT02539784|Experimental|Spinal Cord Stimulation|
3003518|NCT02539771|Other|Nocturnal VOC|
3003519|NCT02539771|Other|Diurnal VOC|
3003520|NCT02539771|Other|Slightly symptomatic|
3003521|NCT02539758|Experimental|ocular massage|over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.We observed changes of anterior chamber depth before and after ocular massage by LenstarLS900,and changes of intraocular pressure before and after ocular massage by Goldmann tonometer
3003522|NCT02539745||primary open-angle glaucoma patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in primary open-angle glaucoma patients.
3003523|NCT02539745||randomly age-matched people|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in randomly age-matched people.
3003524|NCT02539719|Experimental|SC-003|Phase 1a (Escalation) - IV infusion Phase 1b (Expansion) - IV infusion
3003525|NCT02539719|Experimental|SC-003 in combination with ABBV-181|Phase 1a (Escalation) - IV infusion of SC-003 followed by IV infusion of ABBV-181 Phase 1b (Expansion) - IV Infusion of SC-003 followed by IV infusion of ABBV-181
3003526|NCT02539706|Experimental|Follıcular group|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.
3003527|NCT02539706|Active Comparator|Luteal group|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.
3003528|NCT02539693|Experimental|Clonidine 75|Patients will receive sacrococcygeal local anesthesia with 75µg/mL of clonidine. The anesthetic mixture will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 0.5 mL with 0.5 mL of saline (thus 75 µg/mL).
3003529|NCT02539693|Experimental|Clonidine 150|Patients will receive sacrococcygeal local anesthesia with 150µg/mL of clonidine. The anesthetic mixture will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 1 mL (thus 150 µg/mL).
3003530|NCT02539680|Experimental|normal renal function|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
3003531|NCT02539680|Experimental|CKD stage 3-5 (not on dialysis)|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
3003532|NCT02539680|Experimental|on dialysis|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
3003533|NCT02539654|Experimental|EXE844|EXE844 Sterile Otic Suspension, 0.3%, single ototopical dose (4 drops) in each ear following tympanostomy tube insertion
3003534|NCT02539641|Other|Good responder RYGB|Good responders after Roux-en-Y gastric bypass (RYGB). EWL > 50%. Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
3003535|NCT02539641|Other|Bad responder RYGB|Bad responders after Roux-en-Y gastric bypass (RYGB). EWL < 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
3003536|NCT02539641|Other|Good responder SG|Good responders after sleeve gastrectomy (SG). EWL > 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
3003537|NCT02539641|Other|Bad responder SG|Bad responders after sleeve gastrectomy (SG). EWL < 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
3003538|NCT02539641|Other|Duodenal-jejunal bypass liner|Patients who will have a duodenal-jejunal bypass liner (DJBL) Intervention: Gastric emptying scintigraphy before and after implantation of DJBL
3003539|NCT02539628|Experimental|Intermittent bolus|ropivacaine 0.2%, 21 ml every 3 hours
3003540|NCT02539628|Active Comparator|Continuous infusion|ropivacaine 0.2%, 7ml/h
3003541|NCT02539615|Experimental|ForeCYTE Breast Aspirator - Nipple Aspirate Fluid Collection|Nipple Aspirate is collected using the ForeCYTE Breast Aspirator
3003542|NCT02539602|Experimental|Need to Know (N2K)|The intended dosage for treatment participants is 16 lessons (25 minutes each) each year of the program (8 in the fall and 8 in the spring). The program consists of 3 years (48 lessons) of curriculum intended for 9th, 10th and 11th grade students to be delivered in a group or classroom setting of up to 32 students. There are 16 lessons in each year of the curriculum. Eight lessons are intended to be taught in the fall semester and eight in the spring. Each lesson is 25 minutes long, and can be taught in any class period that allows for 25 minutes of content instruction.
3003543|NCT02539602|No Intervention|Counterfactual|The counterfactual condition received no intervention.
3003544|NCT02539589|Experimental|Becoming a Responsible Teen (BART)|Becoming a Responsible Teen (BART) is the treatment condition. BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk.
3003545|NCT02539589|Active Comparator|Healthy Living|Healthy Living is the control counterfactual condition. It is a knowledge-based intervention that aims to impact nutrition, healthy eating, body image, and exercise.
3003546|NCT02539576|Experimental|ABC/DTG/3TC FDC|Each subject will receive treatment with a single oral dose of ABC 600 mg/DTG 50 mg/3TC 300 mg FDC tablet administered under the fasted state
3003547|NCT02539563|Active Comparator|peanut ball|the peanut shaped birthing ball after labor analgesia will be utilized
3003551|NCT02539537|Active Comparator|Arm A: Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 30 minutes on D1 of each week for the 4 weeks of the first cycle (1 cycle = 4 weeks). For the following five cycles, gemcitabine infusion on D1, D8 and D15 of each cycle, followed by 1 week without injection (i.e. in total 4 cycles over 24 weeks; with 19 administrations of Gemcitabine).
3003552|NCT02539537|Experimental|Arm B: Folfirinox|"Administered once every 14 days for 24 weeks (12 cycles). A cycle equals 14 days with injection on D1 of each cycle. Treatment starts with oxaliplatin (85 mg/m²) administration; IV infusion over 2 hours, followed by the simultaneous administration (using a Y-tubing) of folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours and irinotecan 180 mg/m² IV infusion over 90 min. The irinotecan will begin 30 min. after the start of the folinic acid infusion.~5-FU IV 2,400 mg/m²/h will be administered over 46 hours after the end of the folinic acid infusion, i.e. 1200 mg/m²/day for the duration of 2 days.~Treatment will be continued for 24 weeks (12 cycles)."
3003553|NCT02539524|Active Comparator|Pulmonary Rehabilitation Group|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
3003554|NCT02539524|Experimental|Yoga Group|Yoga Bhastrika Pranayama breathing exercises consisted of: 12-week pulmonary rehabilitation (two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs). After each pulmonary rehabilitation session, participants of this group performed 10 bhastrika pranayama breathing exercises (1 bhastrika is formed by 20 kapalabhati followed by 1 surya bedhana - described earlier).
3003555|NCT02539511|Experimental|CI-581a+MET|Administration of CI-581a during wk 2 at 0.71 mg/kg in the context of a 5 wk course of MET
3003556|NCT02539511|Active Comparator|CI-581b+MET|Administration of CI-581b during wk 2 at 0.025 mg/kg in the context of a 5 wk course of MET
3003557|NCT02539498|Active Comparator|Control|Control post menopausal women without PHPT
3003558|NCT02539498|Experimental|Experimental|Post menopausal women with PHPT followed for one year
3003559|NCT02539485|Other|heating precondition|The mean maximum sealing pressure, gas leakage, gastric distension, postoperative sore throat and other complication were compared between heating precondition group and control group.
3003560|NCT02539472|Experimental|investigation|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
3003561|NCT02539459|Experimental|Treatment (everolimus)|Patients will take 10 mg (1 tablet) of everolimus each day for 4 months
3003562|NCT02539446|Other|stable condition & attentional focus|for measure the relationships between task difficulty and attentional focus on supraposture
3003563|NCT02539446|Other|unstable condition & attentional focus|for measure the relationships between task difficulty and attentional focus on supraposture
3003564|NCT02539433|Experimental|F-18-F-DOPA i.v.|F-18-F-DOPA i.v. one injection of a dose of up to 8.5 mCi (millicurie). Standard PET scanning started 60-90 minutes post injection.
3003565|NCT02539420|No Intervention|Control|"Patients assigned to the control group will receive any treatment for status asthmaticus that does not entail use of positive pressure ventilation."
3003566|NCT02539420|Experimental|Late BiPAP treatment|"Patients assigned to the late treatment group will be started on BiPAP greater than 6 hours after randomization."
3003567|NCT02539420|Experimental|Early BiPAP treatment|"Patients assigned to the early treatment group will be started on BiPAP as soon as possible after randomization."
3003568|NCT02539407||Anti-infectives|"Anti-infectives of the following : β-lactam antibiotics, Aminoglycosides, Glycopeptides, Fluoroquinolone, Daptomycin, Rifampin, Trimethoprim, Sulfamethoxazole, Clarithromycin, Fungal, Antiviral~Pharmacokinetics"
3003569|NCT02539394|Experimental|Treatment|Procedure: Anterior Cervical Discectomy and Fusion. The treatment arm will receive 40 mg of Methylprednisolone Acetate delivered with a Hemostatic Matrix Kit prior to closure.
3003570|NCT02539394|Placebo Comparator|Control|Procedure: Anterior Cervical Discectomy and Fusion. The control group will receive only a Hemostatic Matrix Kit prior to closure.
3003571|NCT02539381|Other|Gold Standard Assessments|"Formal perimetry (Goldman or Octopus visual field)~Albert's visual inattention test~Star cancellation visual inattention test~line bisection test~These are performed as part of the routine assessment in the visual stroke orthoptic clinic and neuro-ophthalmology clinics.~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.~Researcher will record a score (0-10) to quantify the participant's compliance"
3003572|NCT02539381|Other|Usual Clinical Screening Practice|"Visual field assessment to confrontation~Visual inattention assessment to bilateral stimuli~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.~Researcher will record a score (0-10) to quantify the participant's compliance"
3003573|NCT02539381|Other|Stroke Vision App|"Digital tumbling E visual accuity assessment~Digital visual field assessment~Digital line crossing assessment~Digital shape cancellation assessment~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.~Researcher will record a score (0-10) to quantify the participant's compliance"
3003574|NCT02539355|Active Comparator|Diet A|Standard Healthy Diet (Diet A)
3003575|NCT02539355|Experimental|Diet B|Alternative Test Diet (Diet B)
3003576|NCT02539342|Experimental|Caphosol Arm|Caphosol Arm: Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day from the start of chemotherapy until 7 days after the completion of chemotherapy AND until the ANC is >500 after count recovery OR until the the symptoms or oral mucositis resolve, whichever occurs last. Patients will also complete a study diary to record symptoms of oral mucositis.
3003577|NCT02539342|Active Comparator|Control Arm|Control Arm: Subjects randomized to the Control Arm will use Biotene 4 times per day. They will also complete a study diary to record doses and any symptoms of oral mucositis. This will begin at the start of chemotherapy until for 7 days AND until ANC >500 after nadir or oral mucositis resolves (whichever occurs later)
3003578|NCT02539329||patient|Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and positive for anti-FGFR3 antibodies. These patients will have Neurological assessment and Blood sample.
3003579|NCT02539329||control|Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and negative for anti-FGFR3 antibodies
3004849|NCT02530996||32|SSc receive BH4 intervention (blinded)
3003581|NCT02539316|Experimental|SmofLIPID|parenteral nutrition by Smoflipid (dosage form depending child's weight as recommended by the SPC)
3003582|NCT02539303|Experimental|Intervention|Infusion of Yamani-15/5 chemical solution.
3003583|NCT02539290|Experimental|Uterine flushing|Detection of ovulation, injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge, and sexual intercourse within 12 hours after intervention
3003584|NCT02539290|Sham Comparator|Vaginal flushing|Detection of ovulation, injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge, and sexual intercourse within 12 hours after intervention
3003585|NCT02539277|Experimental|Treatment group|Jinyebaidu granule, blunt, 10g / time, three times a day; Fufangshuanghua granule placebo, blunt, 6g / time, 4 times a day.
3003586|NCT02539277|Active Comparator|Control group|Fufangshuanghua granule, blunt, 6g / time, 4 times a day; Jinyebaidu granule placebo, blunt, 10g / times, three times a day.
3003587|NCT02539251||Validation of Arabic ASQ-3|This group of patients will serve as a reference for validation of the Arabic ASQ-3
3003588|NCT02539238|Active Comparator|control|Annual BLS training
3003589|NCT02539238|Experimental|intervention|Brief CPR training dispersed over a year period of time with real-time feedback during working hour
3003590|NCT02539225|Experimental|S-1/Oxaliplatin + Ramucirumab|"(Part A) Ramucirumab intravenously (IV) on day 1 and day 8 along with S-1 by mouth (PO) on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B.~(Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
3003591|NCT02539225|Active Comparator|S-1/Oxaliplatin + Placebo|"(Part A) Placebo IV on day 1 and day 8 along with S-1 PO on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B.~(Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
3003592|NCT02539212|Active Comparator|microwave ablation|microwave ablation
3003593|NCT02539212|Active Comparator|radiofrequency ablation|radiofrequency ablation
3003594|NCT02539199|Active Comparator|Misoprostol modified-release pessary|
3003595|NCT02539199|Active Comparator|Misoprostol, per-oral tablets|
3003596|NCT02539186|Experimental|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve in intervention group.
3003597|NCT02539186|Active Comparator|splinting|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study in control group.
3003598|NCT02539173|Experimental|Experimental|Ultrasound scan of diaphragm is made preoperatively during the pre-anesthetic visit, patients are informed of the purpose of the study. Written consent is collected after oral and written information.
3003599|NCT02539160|Active Comparator|CKD - Ticagrelor 90|Patients with chronic kidney disease will receive ticagrelor 90mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 60mg twice/daily for 7-10 days.
3003600|NCT02539160|Experimental|CKD - Ticagrelor 60|Patients with chronic kidney disease will receive ticagrelor 60mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 90mg twice/daily for 7-10 days.
3003601|NCT02539160|Active Comparator|Non-CKD - Ticagrelor 90|Patients without chronic kidney disease will receive ticagrelor 90mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 60mg twice/daily for 7-10 days.
3003602|NCT02539160|Experimental|Non-CKD - Ticagrelor 60|Patients without chronic kidney disease will receive ticagrelor 60mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 90mg twice/daily for 7-10 days.
3003603|NCT02539147||patients with severe sepsis|blood samples from patients with severe sepsis
3003604|NCT02539134|Experimental|Part 1, Cohort 1: TAK-935 100 mg QD|TAK-935 100 milligram (mg), solution, orally, once daily (QD) or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
3003605|NCT02539134|Experimental|Part 1, Cohort 2: TAK-935 300 mg QD|TAK-935 300 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
3003606|NCT02539134|Experimental|Part 1, Cohort 3: TAK-935 300 mg BID|TAK-935 300 mg, solution, orally, twice daily (BID) or TAK-935 placebo-matching solution, orally, BID for up to 10 days.
3003607|NCT02539134|Experimental|Part 1, Cohort 4: TAK-935 600 mg QD|TAK-935 600 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 10 days.
3003608|NCT02539134|Experimental|Part 1, Cohort 5: TAK-935 400 mg QD|TAK-935 400 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
3003609|NCT02539134|Experimental|Part 2, Cohort 6: TAK-935 Dose 1|TAK-935 first decided dose as determined from other TAK-935 trials and Cohorts 1 to 4 of Part 1, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
3003610|NCT02539134|Experimental|Part 2, Cohort 7: TAK-935 Dose 2|TAK-935 second decided dose as determined from other TAK-935 trials and Cohorts 1 to 4 of Part 1, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
3003611|NCT02539121|Experimental|Acupuncture|In the intervention group with real acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the point Ren Mai 6. This point is located on the anterior midline, between the umbilicus and the upper part of the pubic symphysis, at a distance of 0.3d from the umbilicus, being d the distance from the umbilicus to the upper part of the pubic symphysis. A sterilized steel needle of 0.25x40 mm is inserted in this point at 15-30 mm, depending on the adipose tissue of the woman. After that, the needle is covered with a opaque plastic cup and the cup is fixed with the adhesive tape.
3003639|NCT02538900|Experimental|Group 1|Low-intensity, self-paced walking exercise
3003640|NCT02538900|Experimental|Group 2|Standard high intensity, ischemic pain-inducing walking exercise
3003641|NCT02538900|Active Comparator|Group 3|Non-exercising attention control group
3003642|NCT02538887||Radio Frequency Surgical Detection|
3003612|NCT02539121|Placebo Comparator|Control|In the control group the puncture of the Ren Mai 6 is not performed, the acupuncturist disinfects the abdominal area with antiseptic and put the needle in the area of Ren Mai 6 without puncturing, after that, the needle is fixed but not punctured, and it is covered with a opaque plastic cup fixed with adhesive tape, guaranteeing that neither the mother nor the midwife responsible of measuring the variables can identify the assigned group.
3003613|NCT02539108|Experimental|Study Group 1|Participants at 6 months to < 36 months age at enrollment
3003614|NCT02539108|Experimental|Study Group 2|Participants at 3 years to < 9 years age at enrollment
3003615|NCT02539095|Experimental|Cartizol, collagen injection|Their eligibility to participate in the study is checked, and they are randomized either into the intra-articular collagen injection group based on a randomization table.
3003616|NCT02539095|Placebo Comparator|Normal Saline injection|Their eligibility to participate in the study is checked, and they are randomized either into the (placebo) injection group based on a randomization table.
3003617|NCT02539082|Placebo Comparator|placebo injection|placebo, normal saline, injection in the plantar facia through randomization
3003618|NCT02539082|Experimental|Regenseal injection|Regenseal, collagen, injection in the plantar facia through randomization
3003619|NCT02539069|Experimental|Chondron Implantation|Chondron Implantation for the suject with cartilage defect through arthroscopy
3003620|NCT02539056|Experimental|Chondron Implantation|Chondron Implantation for the suject with cartilage defect
3003621|NCT02539043|Active Comparator|Focused ultrasound cavitation: Lipofocus|The first group will receive only the application of focused ultrasound cavitation.
3003622|NCT02539043|Active Comparator|Focused ultrasound and drainage: Lipofocus|The second group will receive focused ultrasound cavitation followed by stereodynamic drainage.
3003623|NCT02539030|Active Comparator|microfracture|simple microfracture for cartilage defect of knee
3003624|NCT02539030|Experimental|modified microfracture using collagen|modified microfracture using collagen (CartiFill) for cartilage defect of knee
3003625|NCT02539017|Experimental|Combined|Combined Chemo Therapy and immunotherapy with double dendritic cell (DC) and cytokine-induced killer (CIK) cell
3003626|NCT02539017|Active Comparator|Chemo|Control group: Chemo Therapy group
3003627|NCT02538991|Experimental|Bulkamid|
3003628|NCT02538991|Active Comparator|Tension-free Vaginal Tape|
3003629|NCT02538978|Experimental|Device Arm|Device arm subjects will receive an intra-operative point of care aspiration, preparation and intramuscular injection of autologous bone marrow concentrate (aBMC) into the afflicted lower index limb.
3003630|NCT02538978|Placebo Comparator|Placebo Arm|Placebo arm subjects will undergo an intra-operative point of care aspiration and preparation of bone marrow via the investigational device exactly as the Treatment Arm. However, instead of receiving the dosing with the aBMC device output, they will receive an intramuscular injection of diluted autologous peripheral blood into the afflicted lower index limb.
3003631|NCT02538965|Experimental|Lenalidomide|Lenalidomide API will administered at a starting dose of 2 mg/kg/day. Lenalidomide will be provided as either a capsule (2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg or 25 mg) or as an oral suspension (10mg/mL).
3003632|NCT02538952|Experimental|Xpert package|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the experimental phase therefore include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; (c) training health facility personnel in TB diagnostic algorithms; and (d) Xpert device activation. The combination of the ICF interventions and rollout of the Xpert device is referred to as the Xpert package in this protocol."
3003633|NCT02538952|Active Comparator|Active comparator|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the active comparator phase therefore include only: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only standard of care microscopy-based TB diagnostic algorithms are available during this phase."
3003634|NCT02538952|No Intervention|Standard of Care|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. There are no interventions in the standard of care arm (retrospective cohort). There are no ICF interventions and no Xpert device activations in this phase. Only the standard of care TB case finding procedures and microscopy-based TB diagnostic algorithm are available during this phase."
3003635|NCT02538939|Experimental|Injection of sodium thiosulfate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sodium thiosulfate
3003636|NCT02538926|Experimental|Treatment (DA-EPOCH-A)|Patients receive etoposide, doxorubicin hydrochloride, and vincristine sulfate IV continuously over days 1-4, cyclophosphamide IV over 1 hour on day 5, and prednisone PO BID on days 1-5. Patients also receive asparaginase IM or IV over 1-2 hours every 2-3 days, beginning day 7 of each course. Patients who are CD20 positive and Philadelphia chromosome negative also receive rituximab IV on day 1 or 5. Patients who are Philadelphia chromosome positive also receive imatinib mesylate PO on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3003637|NCT02538913|Experimental|Exercise training|Patients randomized to the exercise training group will be individually instructed in correct pelvic floor muscle contractions and intensive pelvic floor muscle training to perform daily. In addition they will be encouraged to exercise regularly ≥3 days/week. The exercise program will be individualized and consisting of both aerobic and strength exercise training.
3003638|NCT02538913|Active Comparator|Usual care|Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
3003643|NCT02538874|Experimental|Part A: Single Ascending Dose (SAD)|BMS-986171 or Placebo on specified days
3003644|NCT02538874|Experimental|Part B: Multiple Ascending Dose (MAD)|BMS-986171 or Placebo on specified days
3003645|NCT02538874|Experimental|Part C: Multiple Ascending Dose in Japanese subjects (J-MAD)|BMS-986171 or Placebo on specified days
3003646|NCT02538861|Active Comparator|ARM-A|Arm-A patients will receive the standard of care diagnostic test at Baptist Hospital, which includes SPECT imaging
3003647|NCT02538861|Active Comparator|ARM-B (Group-1)|Group-1 will receive CT Angiography and CT myocardial perfusion with new Revolution CT scanner.
3003648|NCT02538861|Active Comparator|ARM-B (Group-2)|The Group-2 of arm B will receive SPECT imaging test.
3003649|NCT02538848|Experimental|50mg in SAD|single dose of 50mg HTD4010 or placebo injectable in healthy volunteers
3003650|NCT02538848|Experimental|100mg in SAD|single dose of 100mg HTD4010 or placebo injectable in healthy volunteers
3003651|NCT02538848|Experimental|200mg in SAD|single dose of 200mg HTD4010 or placebo injectable in healthy volunteers
3003652|NCT02538848|Experimental|300mg in SAD|single dose of 300mg HTD4010 or placebo injectable in healthy volunteers
3003653|NCT02538835|Experimental|Metacognitive Therapy|
3003654|NCT02538835|Active Comparator|Mindfulness based cognitive therapy|
3003655|NCT02538835|Placebo Comparator|Support groups|
3003656|NCT02538822|Experimental|thoracic ascending aorta (ATA)|the risk of rupture of thoracic ascending aorta (ATA) is assessed fom the dynamic imaging and mechanical testing
3003657|NCT02538796|Experimental|Patients group 1|TEA + Grober Test + Task 1 + Grober Test
3003658|NCT02538796|Experimental|Patients group 2|TEA + Grober Test + Task 2 + Grober Test
3003659|NCT02538796|Experimental|Patients group 3|TEA + Grober Test + Implicit Task 3 + Grober Test
3003660|NCT02538796|Experimental|Patients group 4|TEA + Grober Test + Explicit Task 3 + Grober Test
3003661|NCT02538796|Active Comparator|Healthy volonteers group 1|TEA + Grober Test + Task 1 + Grober Test
3003662|NCT02538796|Active Comparator|Healthy volonteers group 2|TEA + Grober Test + Task 2 + Grober Test
3003663|NCT02538796|Active Comparator|Healthy volonteers group 3|TEA + Grober Test + Implicit Task 3 + Grober Test
3003664|NCT02538796|Active Comparator|Healthy volonteers group 4|TEA + Grober Test + Explicit Task 3 + Grober Test
3003665|NCT02538783|No Intervention|Control|Participants will receive weekly tips and weekly feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weekly feedback will pertain to whether or not the participant met his/her goal of weighing at least 6/7 days. The weekly tips will give information and suggestions on how to make it easier to weigh-in most days of the week. No financial incentive other than for the midpoint and end of study surveys will be given.
3003666|NCT02538783|Experimental|Escalating lottery|Participants will receive weekly tips and weekly feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weekly feedback will pertain to whether or not the participant met his/her goal of weighing at least 6/7 days. The weekly tips will give information and suggestions on how to make it easier to weigh-in most days of the week. In addition to the incentives for midpoint and end of study surveys, participants who meet their weekly goal (weighing in 6 of 7 days) will be eligible for the weekly lottery during the first 6 months of the study. The expected weekly winning for the lottery is $3.55 in week 1 and this expected value will increase by $0.43 per week for each week the participant achieves their goal of weighing 6/7 days. All incentive earnings will be paid out on a monthly basis.
3003667|NCT02538770|Experimental|Rapid Anyplex TMII RV16 Detection|Intervention is the rapid performance of Anyplex TMII RV16 detection
3003668|NCT02538770|Active Comparator|Delayed Anyplex TMII RV16 Detection|Comprative intervention is the delayed performance of Anyplex TMII RV16 detection
3003669|NCT02538744|Placebo Comparator|placebo|placebo po 1x/day from day -12 through 4
3003670|NCT02538744|Active Comparator|doxazosin 8 mg|day -12 through -9: Doxazosin 1 mg po 1x/day day -8 through -5: Doxazosin 2 mg po 1x/day day -4 through -1: Doxazosin 4 mg po 1x/day day 1 through 4: Doxazosin 8 mg po 1x/day
3003671|NCT02538731|Other|Dilation-assisted group|Dilation-assisted group:Dilation-assisted stone extraction
3003672|NCT02538731|Other|laser lithotripsy group|laser lithotripsy group:laser lithotripsy
3003673|NCT02538718|Active Comparator|YTP(ritodrine) arm|who randomly assigned to have Yutopar(ritodrine) as tocolytics
3003674|NCT02538718|Experimental|MgSO4 arm|who were randomised to have MgSO4 as tocolytics
3003675|NCT02538705|Experimental|Neovasculgen|
3003676|NCT02538692|Experimental|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a classic formula of traditional Chinese medicine for IBS-D. It is composed of 4 herbs: Radix Paeoniae Alba, Ledebouriella seseloides Wolff, pericarpium citri reticulatae and Rhizoma Atractylodis Macrocephalae. The granules will be administrated for thrice daily at a dose of 15g per time. The total duration of treatment is 4 weeks.
3003677|NCT02538692|Placebo Comparator|Placebo|It is a placebo that made with similar appearance and taste as the Tong-Xie-Yao-Fang granules.
3003678|NCT02538679|Placebo Comparator|PLACEBO|No TAP block performed
3003679|NCT02538679|Experimental|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
3003680|NCT02538679|Experimental|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
3003681|NCT02538666|Experimental|Nivolumab monotherapy|Nivolumab intravenous fusion
3003682|NCT02538666|Experimental|Nivolumab and ipilimumab combination therapy|Nivolumab and ipilimumab intravenous fusion
3003683|NCT02538666|Placebo Comparator|Placebo|Placebo
3003684|NCT02538653|Experimental|Sandwich biscuits high in SDS|50 g of sandwich product with high level of SDS together with a glass of 250 mL of Evian water.
3003685|NCT02538653|Active Comparator|Co-extruded cereals low in SDS|48.3 g of co-extruded cereals low in SDS together with a glass of 250 mL of Evian water.
3003686|NCT02538640|Experimental|High-SDS biscuit|50 g of moist biscuit with high-SDS content and low GI with a glass of water
3003687|NCT02538640|Active Comparator|Low-SDS breakfast cereals|42 g of extruded cereals with no SDS and medium to high GI with a glass of water
3003688|NCT02538627|Experimental|MM-151+MM-121 Dose Escalation|MM-151 and MM-121 dose escalation in lung, head and neck, and colorectal cancers
3003689|NCT02538627|Experimental|MM-151+ trametinib Dose Escalation|MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.
3003690|NCT02538627|Experimental|MM-151+MM-141 Dose Escalation|MM-151 and MM-141 dose escalation in lung, head and neck, and colorectal cancers
3003691|NCT02538627|Experimental|MM-151+trametinib Dose Escalation|MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.
3003692|NCT02538627|Experimental|Colorectal cancer Expansion|Doses established in part 1 of the study
3003693|NCT02538627|Experimental|Head and neck Expansion|Doses established in part 1 of the study
3003694|NCT02538614|Experimental|Phase 1b Idelalisib + BI 836826|Participants will receive escalating doses of idelalisib + BI 836826. 2 dose combinations (highRP2D and lowRP2D) will be determined for further evaluations in Phase 2.
3003695|NCT02538614|Experimental|Phase 2 Idelalisib + BI 836826|Participants will be randomly assigned to receive 1 of the 2 dose combinations selected from Phase 1b.
3003696|NCT02538601|Experimental|CBT-A|An 8-session, CBT-based group smoking cessation program (CBT-A) enhanced with transdiagnostic skills for the management of anxiety and fear-based avoidance behaviors.
3003697|NCT02538601|Active Comparator|CBT-S|An 8-session, CBT-based, traditional group CBT based smoking cessation program.
3003698|NCT02538588|Experimental|Nebulizer 1|Nebulization with akita nebulizer
3003699|NCT02538588|Active Comparator|Nebulizer 2|Nebulization with eFlow nebulizer
3003700|NCT02538575|Experimental|6-minute walk test|
3003701|NCT02538562||Study Population|Available tumor samples from patients with gastric or gastroesophageal junction cancer will be analyzed. No study visits or interventions are planned.
3003702|NCT02538549|Active Comparator|ACE4 and TAU|This group will receive ACE4 as an intervention and treatment as usual.
3003703|NCT02538549|No Intervention|TAU Only|This group will receive only the treatment as usual.
3003704|NCT02538536|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
3003705|NCT02538510|Experimental|Treatment (vorinostat, pembrolizumab)|Patients receive vorinostat PO QD or via PEG on days 1-5 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3003706|NCT02538497|Experimental|NBO plus routine care|The Newborn Behavioral Observation
3003707|NCT02538497|Other|Routine care|
3003708|NCT02538484|Active Comparator|Letrozole|Letrozole 2.5 mg by mouth daily for 30 days.
3003709|NCT02538484|Active Comparator|Fish Oil|Fish oil 2700 mg by mouth daily for 30 days.
3003710|NCT02538484|Active Comparator|Letrozole and Fish Oil|Letrozole 2.5 mg and Fish oil 2700 mg by mouth daily for 30 days.
3003711|NCT02538471|Experimental|Arm 1 - Study Drug & Radiation therapy|"Study Drug: Enrolled patients will receive 300 mg/day of LY2157299. LY2157299 will be administered as an oral drug tablet.~The study drug will be administered orally on a 28-day cycle (1 cycle=28 days), every 2 weeks, or 14 days on / 14 days off. Blood samples will be obtained at baseline, and weeks 2, 6 and 15 for immune monitoring.~Radiation therapy : Patients will receive Radiation therapy to a metastatic site at a dose of 7.5 Gy, given consecutively on days 1, 3 and 5, during Week 1 of their treatment."
3003712|NCT02538458|Active Comparator|Test group|3 % hypertonic saline up to 72H.
3003713|NCT02538458|Placebo Comparator|Placebo control group|"3 % hypertonic saline up to 24H.~Followed by 48 hours of placebo (nebulized 0.9% normal saline)."
3003714|NCT02538445|Experimental|Patients group 1|Memorization of the verbs by miming the action
3003715|NCT02538445|Experimental|Patients group 2|Memorization of the verbs by imagining the action
3003716|NCT02538445|Experimental|Patients group 3|Memorization of the action verbs by means of another word
3003717|NCT02538445|Experimental|Patients group 4|Simple memorization of the verbs
3003718|NCT02538445|Active Comparator|Healthy volonteers group 1|Memorization of the verbs by miming the action
3003719|NCT02538445|Active Comparator|Healthy volonteers group 2|Memorization of the verbs by imagining the action
3003720|NCT02538445|Active Comparator|Healthy volonteers group 3|Memorization of the action verbs by means of another word
3003721|NCT02538445|Active Comparator|Healthy volonteers group 4|Simple memorization of the verbs
3003722|NCT02538432|Experimental|RQ-00000007 Alone|RQ-0000007 250 mg will be self-administered orally, with or without food, each morning and evening, approximately 12 hours apart.
3003723|NCT02538432|Active Comparator|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be given as an IV.
3003724|NCT02538419|Active Comparator|Peer Support|Participants randomized to this arm will receive support from a 'CPAP Peer Leader', delivered as part of a group of other participants as well as targeted one-on-one support throughout the study.
3003725|NCT02538419|Active Comparator|Individual Education|Participants randomized to this arm will receive individual support and education from a trained investigator.
3003726|NCT02538406||non segmental withdrawal|A standard of care colonoscopy will be done on the patient without extra time on the right side of the colon.
3003727|NCT02538406||Segmental withdrawal|A standard of care colonoscopy will be done on the patient , however the time spent in the right side of the colon will be more than half of the normal colonoscopy procedure (i.e. more than 3 minutes)
3003728|NCT02538393|Experimental|Treatment A-C-B-D|Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the first intervention period; followed by a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the second intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the third intervention period; and then a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
3003765|NCT02538224|Active Comparator|experimental(case): group A|Group A: 2.5%ketoprofen gel + 3 % doxycycline gel which(0.05cc,mixed gel) be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months .
3003766|NCT02538224|Sham Comparator|control: group B|Group B: 2.5%ketoprofen gel which (0.05cc,gel)be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months .
3003729|NCT02538393|Experimental|Treatment B-A-D-C|Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the first intervention period; followed by a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the second intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the third intervention period; and then a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
3003730|NCT02538393|Experimental|Treatment C-D-A-B|Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the first intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the second intervention period; followed by a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the third intervention period; and then a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
3003731|NCT02538393|Experimental|Treatment D-B-C-A|Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the first intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the second intervention period; followed by a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the third intervention period; and then a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
3003732|NCT02538380|Experimental|EUS-B-FNA for LAG analysis|All patients will undergo a mediastinal nodal staging procedure with the EBUS scope (EBUS + EUS-B) (routine clinical care) followed by an evaluation of the LAG including LAG sampling (experimental). Subsequently, all patients undergo a conventional EUS procedure with sampling of the LAG (current standard of care)
3003733|NCT02538367|Experimental|YH12852 IR 0.05mg|Once daily
3003734|NCT02538367|Experimental|YH12852 IR 0.1mg|Once daily
3003735|NCT02538367|Experimental|YH12852 IR 0.3mg|Once daily
3003736|NCT02538367|Experimental|YH12852 IR 0.5mg|Once daily
3003737|NCT02538367|Experimental|YH12852 IR 1mg|Once daily
3003738|NCT02538367|Experimental|YH12852 IR 2mg|Once daily
3003739|NCT02538367|Experimental|YH12852 IR 3mg|Once daily
3003740|NCT02538367|Experimental|YH12852 DR1 0.5mg|Once daily
3003741|NCT02538367|Experimental|YH12852 DR1 1mg|Once daily
3003742|NCT02538367|Experimental|YH12852 DR1 2mg|Once daily
3003743|NCT02538367|Experimental|YH12852 DR1 4mg|Once daily
3003744|NCT02538367|Experimental|YH12852 DR2 8mg|Once daily
3003745|NCT02538367|Active Comparator|Prucalopride 2mg|Once daily
3003746|NCT02538367|Placebo Comparator|Placebo|Once daily
3003747|NCT02538354|Experimental|Riboflavin supplementation in quiescent disease|Group 1 (n=42) will consist of patients with disease in remission (quiescent disease).
3003748|NCT02538354|Experimental|Riboflavin supplementation in active disease|Group 2 (n=42) will consist of patients with active disease.
3003749|NCT02538341|Active Comparator|Zoster Vaccine Live (Zostavax)|Zostavax (zoster vaccine live) is used to prevent herpes zoster virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active Herpes Zoster Vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.
3003750|NCT02538341|Placebo Comparator|Placebo Normal Saline|Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.
3003751|NCT02538328|Active Comparator|harmonic scapel|Obesity surgery cases where hamonic scalpel is used for the comparison of different surgical devices
3003752|NCT02538328|Placebo Comparator|Ligasure sealing device|Ligasure used in obesity surgery for the comparison of different surgical devices Randomly chosen cases where ligasure is used instead of hamonic scalpel in surgical procedures comparison of multiple dissectors
3003753|NCT02538315||Surgery plus PET/CT imaging|Dopaminergic stem cell transplant and [18F]FDOPA PET/CT
3003754|NCT02538302|Experimental|Minirin|120 microgram per day for 2 months, then 60 microgram per day for 2 months, then 60 microgram every two days for two months
3003755|NCT02538302|Active Comparator|Oxybutynin|5 mg Oxybutynin twice a daily for 6 months
3003756|NCT02538289|Other|Patients admitted before talks|Patients admitted to Cardiology or Respiratory Medicine Departments before the interventional teaching talks.
3003757|NCT02538289|Other|Patients admitted after talks|Patients admitted to Cardiology or Respiratory Medicine Departments after the interventional teaching talks.
3003758|NCT02538276||Group carotid endarterectomy (CEA)|Patients submitted to carotid endarterectomy
3003759|NCT02538276||Group carotid stenting (CAS)|Patients submitted to carotid artery stenting
3003760|NCT02538263|Experimental|Volume-targeted noninvasive ventilation|For Volume-targeted noninvasive ventilation, the target VT was set at 10 ml/kg of ideal body weight, with inspiratory positive airway pressure (IPAP) ranging from 10 cmH2O up to 25 cmH2O.
3003761|NCT02538263|No Intervention|Pressure-limited noninvasive ventilation|For Pressure-limited noninvasive ventilation, IPAP was initially set at 10 cmH2O, and was adjusted by increments of 1-2 cmH2O according to patients' tolerance (up to 25 cmH2O) to obtain a VT of 8-10 ml/kg of ideal body weight and a respiratory rate (RR) less than 25 breaths/min.
3003762|NCT02538250|Experimental|1 Nutricomp Drink Plus|Nutricomp Drink Plus
3003763|NCT02538237|Experimental|ibuprofen mouthwash|Subgingival Irrigation of ibuprofen 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed
3003764|NCT02538237|Sham Comparator|placebo mouthwash|Subgingival Irrigation of placebo 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed
3003800|NCT02537964|No Intervention|Standard bathing|Standard bathing with water +/- mild soap according to age and gestational week
3003767|NCT02538211|Placebo Comparator|Control|"Control group - subjects will receive no antibiotics~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
3003768|NCT02538211|Active Comparator|Broad-spectrum antibiotics|"Subjects will receive 7 days of pre-treatment (days -9 to -3) with:~Ciprofloxacin 500mg 2dd1~Vancomycin 250mg 3dd2~Metronidazole 500mg 3dd1~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
3003769|NCT02538211|Active Comparator|Narrow-spectrum antibiotics|"Subjects will receive 7 days of pre-treatment (days -9 to -3) with:~• Vancomycine 250mg 3dd2~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
3003770|NCT02538198|Experimental|Lenalidomide|Subjects will receive lenalidomide 10 mg by mouth daily on days 1-21 of a 28-day cycle. Subjects may continue lenalidomide until disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or the end of the study (5 years); whatever comes first. Patients who complete at least four cycles of treatment will be considered evaluable.
3003771|NCT02538185|Placebo Comparator|Vaccine injected ID with classical syringe|"Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);~Left forearm, ID with classical syringe filled with vaccine (0.1mL);~Non-dominant deltoid, Intramuscular (IM) with classical syringe filled with placebo (0.5mL)."
3003772|NCT02538185|Active Comparator|Vaccine injected ID with NanoJect device (DebioJect™)|"Right forearm, ID with NanoJect device (DebioJect™) filled with vaccine (0.1mL);~Left forearm, ID with classical syringe filled with placebo (0.1mL);~Non-dominant deltoid, IM with classical syringe filled with placebo (0.5mL)."
3003773|NCT02538185|Placebo Comparator|Vaccine injected IM with classical syringe|"Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);~Left forearm, ID with classical syringe filled with placebo (0.1mL);~Non-dominant deltoid, IM with classical syringe filled with vaccine (0.5mL)."
3003774|NCT02538172|Experimental|Intervention|T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
3003775|NCT02538172|Other|Control|T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
3003776|NCT02538159|Experimental|Experimental CVC|CVC insertion Non-tunneled Central venous catheter insertion
3003777|NCT02538159|Experimental|Experimental PICC|PICC insertion Peripherally inserted catheter
3003778|NCT02538146|Experimental|Treatment|Acetyl-L-carnitine 1000mg 2X per day for 3 months
3003779|NCT02538133|Experimental|99mTc-Exametazime (HMPAO)-labeled leucocytes|
3003780|NCT02538120|Active Comparator|Diabetes type 1 patients|The intervention will be : Microvascular assessment with laser speckle contrast imaging
3003781|NCT02538120|Active Comparator|Matched control-subjects|The intervention will be : Microvascular assessment with laser speckle contrast imaging
3003782|NCT02538107||Kidney Transplant Participants|Participants with kidney transplant and a chronic kidney disease who were receiving methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care.
3003783|NCT02538094|Sham Comparator|Sham Stimulation|Transcranial direct current stimulation (tDCS) that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS.
3003784|NCT02538094|Experimental|Anodal Stimulation|Transcranial direct current stimulation using Anodal stimulation over the area of interest.
3003785|NCT02538081|Active Comparator|Risperidone plus placebo|Risperidone titrated to a dose equivalency of the patients' prior dose of olanzapine plus placebo
3003786|NCT02538081|Active Comparator|Risperidone plus DMXB-A|Risperidone titrated to a dose equivalency of the patients' prior dose of olanzapine plus DMXB-A
3003787|NCT02538068|Experimental|Daily Surveys|Participants complete a daily survey regarding their daily life meaning, mood, physical activity, and other activities for 4 weeks.
3003788|NCT02538068|Active Comparator|Random Surveys (8)|Participants complete 8 random surveys over the first 4 weeks.
3003789|NCT02538055|Placebo Comparator|General Health Program|Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
3003790|NCT02538055|Experimental|Living Healthy Program|Participants in this arm worked with a Community Health Worker (CHW) who provided the Living Healthy Program. The Living Healthy Program was a cognitive-behavioral therapy based lifestyle modification program. Participants and CHW interacted by telephone 8 times over 3 months.
3003791|NCT02538042|Experimental|MCE+|Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
3003792|NCT02538042|Other|MCE- (Control)|Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
3003793|NCT02538029|Experimental|Dual Task Group|This group will complete an exercise intervention that involves performing dual tasking activities (simultaneously performing 2 things at once). This group will exercise 3x/wk for 8 weeks.
3003794|NCT02538029|Active Comparator|Single Task Group|This group will complete an exercise intervention that involves performing single task activities. The participant will perform motor tasks and cognitive tasks individually. This group will exercise 3x/wk for 8 weeks.
3003795|NCT02538016|Other|Tolvaptan|
3003796|NCT02538003|Experimental|Group 1(RT):LCB01-0371 Tablet 800mg|"Period:LCB01-0371 Tablet 800mg(Reference: Taken drug before meal)~Period: LCB01-0371 Tablet 800 mg(Test: Taken drug after meal)"
3003797|NCT02538003|Experimental|Group 2(TR):LCB01-0371 Tablet 800mg|"Period:LCB01-0371 Tablet 800mg(Test:taken drug after meal)~Period: LCB01-0371 Tablet 800 mg(Reference:taken drug before meal)"
3003798|NCT02537977|Experimental|CAR-T cells|Autologous 2nd generation CD19-directed CAR-T cells
3003799|NCT02537964|Experimental|Chlorhexidine bath|Intervention: All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
3035181|NCT02327078|Experimental|(Phase 2): Nivolumab + Epacadostat|
3003801|NCT02537951|Experimental|AFI intensity in healthy volunteers|10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope
3003802|NCT02537951|Active Comparator|negative control 1: lidocaine/prilocaine|10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1hour after application of lidocaine/prilocaine creme (negative control 1)
3003803|NCT02537951|Active Comparator|negative control 2: 8% capsaicin|-10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1week after application of an 8% capsaicin patch (negative control 2)
3003804|NCT02537938|Experimental|NGP 555|NGP 555 given once a day for 14 days as a capsule; 100 mg, 200 mg, or 400 mg
3003805|NCT02537938|No Intervention|Placebo|Placebo comparator given once a day for 14 days as a capsule.
3003806|NCT02537925|Active Comparator|concurrent_radiochemotherapy|Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
3003807|NCT02537925|Experimental|celecoxib_radiochemotherapy|Celecoxib 200mg bid po; Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
3003808|NCT02537912|Active Comparator|Sugarlock®|Subjects ingested 2 capsules Sugarlock® (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks.
3003809|NCT02537912|Placebo Comparator|Placebo|Subjects ingested 2 capsules placebo (Control group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks.
3003810|NCT02537899|Other|Treatment|NeuroAiD
3003811|NCT02537886||Evaluation Group|Researchers will conduct a focus group to evaluate VIC after it has been developed and used by patients. Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC. We will use this information to enhance the generalizability of the VIC approach.
3003812|NCT02537873|Experimental|Arm 1: Lorcaserin and Cocaine IV|"Lorcaserin 10 mg administered orally once daily for 6 days then increasing to twice daily for 3 days.~Cocaine IV (intravenous) administered in ascending doses of 0, 10, 20, 40 mg on study days 1, 2, 6 and 12."
3003813|NCT02537873|Placebo Comparator|Arm 2: Placebo Comparator and Cocaine IV|Dextrose placebo in gelatin capsule identical to experimental drug. Cocaine IV (intravenous) administered in ascending doses of 0, 10, 20, 40 mg on study days 1, 2, 6 and 12.
3003814|NCT02537860|Experimental|Three PVB injections|Patients will receive three PVB injections from T12 to L2 and placebo at T11 and L3
3003815|NCT02537860|Experimental|Five PVB injections|Patients will receive five PVB injections between T11 and L3.
3003816|NCT02537847|Experimental|Sitafloxacin group|The first third days of treatment was open label and all patients were given intravenous carbapenems. After day 3, the patients were randomized to either sitafloxacin group or ertapenem group by the use of a computer-generated random number allocation schedule and block size of four. The patients were allocated to the sitafloxacin group or ertapenem group using the sealed envelope method.
3003817|NCT02537847|Active Comparator|control group|Intervention was prescribed ertapenem for patients.
3003818|NCT02537834|Experimental|Tofogliflozin ＋GLP-1 analogue|Tofogliflozin administered once daily for 52 weeks. GLP-1 analogue administered as base treatment.
3003819|NCT02537795||Deep Brain Stimulation Patients|Patients who have previously been treated with a deep brain stimulation procedure for obsessive compulsive disorder will be included in this group
3003820|NCT02537795||Deep Brain Stimulation Family Members|Family members of patients who have previously been treated with a deep brain stimulation procedure for obsessive compulsive disorder will be included in this group
3003821|NCT02537795||Anterior Capsulotomy Patients|Patients who have previously been treated with an anterior capsulotomy procedure for obsessive compulsive disorder will be included in this group
3003822|NCT02537795||Anterior Capsulotomy Family Members|Family members of patients who have previously been treated with an anterior capsulotomy procedure for obsessive compulsive disorder will be included in this group
3003823|NCT02537782|Other|Cardiac resynchronisation therapy implantation|Patients with current guideline-based indication for CRT implantation.
3003824|NCT02537769|Experimental|LVAD+TVR|In addition to left ventricular assist device (LVAD) placement with the inflow cannula in the left ventricular apex and outflow cannula placed in the ascending aorta, a repair of the regurgitating tricuspid valve will be performed. A Patent Foramen Ovale, if present, will be closed primarily. Echocardiographic parameters relevant to study will be collected throughout the procedure.
3003825|NCT02537769|Active Comparator|LVAD only|LVAD placement will be performed without additional tricuspid valve repair (TVR). The inflow cannula will be sutured to the left ventricular apex followed by the outflow cannula placed in the ascending aorta. This will be performed under cardiopulmonary bypass. Echocardiographic parameters relevant to study will be collected throughout the procedure.
3003826|NCT02537756|Experimental|1- High Choice, Deep Processing|Parents will use a tablet-based application (Project Voice) that directs them to verbalize their own arguments based on topics they choose
3003827|NCT02537756|Experimental|2- Low Choice, Deep Processing|Parents will use a tablet-based application (Project Voice) that directs them to verbalize their own arguments based on topics assigned to them
3003828|NCT02537756|Experimental|3- High Choice, Shallow Processing|Parents will use a tablet-based application (Project Voice) that directs them to listen to arguments based on topics they choose
3003829|NCT02537756|Experimental|4- Low Choice, Shallow Processing|Parents will use a tablet-based application (Project Voice) that directs them to listen to arguments based on topics assigned to them
3003830|NCT02537730|Active Comparator|Bioclean MPS VII / comfilcon A combination|Participants were randomized to the Bioclean MPS VII / comfilcon A combination for one week during the cross over study.
3003831|NCT02537730|Active Comparator|Aosept Clearcare / comfilcon A combination|Participants were randomized to the Aosept Clearcare / comfilcon A combination for one week during the cross over study.
3003861|NCT02537522|Experimental|Test/Control - Phase 1|Over visits 1 and 2, subject will wear Contact Lenses with 8.5 BC in right eye and Contact Lenses with 9.0 BC in left eye in a contralateral manner.
3003862|NCT02537522|Experimental|Control/Test - Phase 1|Over visits 1 and 2, subject will wear Contact Lenses with 9.0 BC in right eye and Contact Lenses with 8.5 BC in left eye in a contralateral manner.
3003863|NCT02537522|Experimental|Test/Control - Phase 2|During Phase 2, subjects will wear a pair of Contact Lenses with 9.0 BC at Period 1 and Contact Lenses with 8.5 BC at Period 2 in a bilateral manner.
3003832|NCT02537704|Experimental|Group Lifestyle Balance Program|"Participants will be assigned to an adaptation of the Group Lifestyle Balance Program, a behavioral curriculum implemented in the Diabetes Prevention Program Study. The Group Lifestyle Balance Program will be provided weekly for the first 3.5 months, bi-weekly from 3.5 to 6 months and then monthly until 12 months. Health care providers will be trained for the implementation of the intervention.~Additionally, participants will attend at least one monthly visit with a nutritionist (individually).~The lifestyle objectives for participants will be as follows:~To lose 5-10% of initial weight through healthy eating.~To do 150 minutes of physical activity each week."
3003833|NCT02537691|Other|Inhaled Corticosteroids (ICS) + Controller Medications|Participants with severe asthma Global Initiative for Asthma (GINA) step 4/5 as indicated by current treatment with daily ICS consisting of >/=500 mcg FP administered by DPI (or equivalent), and at least one of the following controller medications: LABAs, LTRAs, LAMAs, theophylline or oral corticosteroids.
3003834|NCT02537678|Experimental|Stepped Care TF-CBT|Stepped Care TF-CBT consist of two steps. Step One is a parent-led therapist-assisted treatment and Step Two is standard TF-CBT.
3003835|NCT02537678|Active Comparator|Standard TF-CBT|Standard TF-CBT consist of therapist-directly weekly in-office therapy based on the trauma-focused components of TF-CBT.
3003836|NCT02537665|Other|incidence of bleeding|the effect of the epidural catheter filled with heated or normal saline before inserting into epidural on the incidence of bleeding.
3003837|NCT02537665|Placebo Comparator|inserting time of catheter|record the time from beginning of catheter inserting to completing the placement of the catheter.
3003838|NCT02537652||Major Stroke|Patients diagnosed with major stroke who will undergo blood pressure assessment
3003839|NCT02537652||Minor stroke|Patients diagnosed with minor stroke who will undergo blood pressure assessment
3003840|NCT02537639||Control group|Control group. Standard teaching in transesophageal echocardiography.
3003841|NCT02537639||Intervention group|Intervention group. Additional teaching with a transesophageal echocardiography simulator.
3003842|NCT02537626|Active Comparator|Erchonia ALS Laser|The Erchonia ALS Laser is a mains powered variable hertz laser device made up of five independent red laser diodes mounted in scanner devices and positioned equidistant from each other. Each scanner emits 7.5 milliwatts (mW) ± 1.0 mW 640 nanometers (nm) with a tolerance of ±10 nm of red laser light.
3003843|NCT02537626|Placebo Comparator|Placebo Laser|The Placebo Laser is identical in appearance and operation to the Erchonia ALS Laser but does not emit any therapeutic light.
3003844|NCT02537613|Experimental|Arm A- obinutuzumab -> ibrutinib|Participants enrolled in Arm A will receive obinutuzumab weekly starting cycle 1, and will receive obinutuzumab monthly during cycles 2-6. Participants will begin to take ibrutinib daily starting cycle 2 and will continue with daily ibrutinib until the end of treatment.
3003845|NCT02537613|Experimental|Arm B- ibrutinib -> obinutuzumab|Participants enrolled in Arm B will begin to take ibrutinib daily starting cycle 1 and will continue with daily ibrutinib until the end of treatment. Participants will begin to receive obinutuzumab weekly starting cycle 2, and will receive obinutuzumab monthly during cycles 3-7
3003846|NCT02537613|Experimental|Arm C- obinutuzumab/ibrutinib|Participants enrolled in Arm C will begin to take ibrutinib daily starting cycle 1 and will continue with daily ibrutinib until the end of treatment. At the same time, participants will begin to receive obinutuzumab weekly starting cycle 1, and will receive obinutuzumab monthly during cycles 2-6.
3003847|NCT02537600|Experimental|Cobimetinib + Vemurafenib combination|"Every patients will be treated with :~Vemurafenib 1920 mg / day from day 1 to day 28 continuously Cobimetinib 60 mg / day from day 1 to day 21 One cycle = 28 days Intervention = Cobimetinib + Vemurafenib combination treatment. Only one arm."
3003848|NCT02537587|Active Comparator|Control 1|67g of Control energy bar containing 4g protein, 15g fat, 42g carbohydrate, 2g fiber, and 24g sugar.
3003849|NCT02537587|Active Comparator|Control 2|86g of Control energy bar containing 5g protein, 20g fat, 55g carbohydrate, 3g fiber and 30g sugar
3003850|NCT02537587|Experimental|15/0|Experimental bar with 15% added resistant starch and 0% added protein; 66g portion containing 3g protein, 7g fat, 50g carbohydrate, 10g fiber and 16g sugar
3003851|NCT02537587|Experimental|15/0-LS|Experimental bar with 15% added resistant starch and 0% added protein with reduced sugar; 84g portion containing 4g protein, 8g fat, 55g carbohydrate, 15g fiber and 15g sugar
3003852|NCT02537587|Experimental|15/5|Experimental bar with 15% added resistant starch and 5% added protein; 75g portion containing 9g protein, 7g fat, 52g carbohydrate, 12g fiber and 17g sugar
3003853|NCT02537587|Experimental|10/5|Experimental bar with 10% added resistant starch and 5% added protein; 72g portion containing 10g protein, 8g fat, 49g carbohydrate, 9g fiber and 19g sugar
3003854|NCT02537587|Experimental|10/10|Experimental bar with 10% added resistant starch and 10% added protein; 80g portion containing 17g protein, 7g fat, 49g carbohydrate, 9g fiber and 18g sugar
3003855|NCT02537574|Experimental|NTX/BUP|Oral naltrexone + sublingual buprenorphine
3003856|NCT02537574|Active Comparator|NTX/PBO-B|Oral naltrexone + sublingual placebo
3003857|NCT02537574|Placebo Comparator|PBO-N/PBO-B|Oral placebo naltrexone + sublingual placebo buprenorphine
3003858|NCT02537561|Experimental|Arm 1: Cisplatin, Gemcitabine, Talazoparib Solid Tumors|"Dose levels of the drugs will be dependent on which dose level the participants is enrolled.~Cisplatin will be infused as a 30 minute intravenous piggyback (IVPB) on Day 1 of each 21 day cycle.~Gemcitabine will be infused as a 30 minute IVPB on Days 1 and 8 of each 21 day cycle. On day 1, gemcitabine will be given before cisplatin.~Talazoparib will be started with cycle 2. It is an oral drug which will be administered on an outpatient basis daily.~Cisplatin and gemcitabine will be given for a total of 6 cycles.~Talazoparib may be continued as a single agent maintenance therapy."
3003859|NCT02537561|Experimental|Arm 2: Cisplatin, Gemcitabine, Talazoparib NSCLC|"Dose levels of the drugs will depend on what the MTD is in the dose escalation portion of the study~Cisplatin will be infused as a 30 minute intravenous piggyback (IVPB) on Day 1 of each 21 day cycle.~Gemcitabine will be infused as a 30 minute IVPB on Days 1 and 8 of each 21 day cycle. On day 1, gemcitabine will be given before cisplatin.~Talazoparib will be started with cycle 2. It is an oral drug which will be administered on an outpatient basis daily.~Cisplatin and gemcitabine will be given for a total of 6 cycles.~Talazoparib may be continued as a single agent maintenance therapy."
3003860|NCT02537548|Experimental|Treatment (RPLND)|Patients undergo RPLND.
3003905|NCT02537249|Sham Comparator|Saline 0.9%|
3003864|NCT02537522|Experimental|Control/Test - Phase 2|During Phase 2, subjects will wear a pair of Contact Lenses with 8.5 BC at Period 1 and Contact Lenses with 9.0 BC at Period 2 in a bilateral manner.
3003865|NCT02537509|Active Comparator|Cholecalciferol|Administration of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)
3003866|NCT02537509|Placebo Comparator|Placebo of cholecalciferol|Administration of placebo of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)
3003867|NCT02537496|Experimental|Alzheimer's disease rTMS|The intervention procedure done in this group is repetitive Transcranial Magnetic Stimulation.
3003868|NCT02537496|Sham Comparator|Alzheimer's disease rTMS Sham|The intervention procedure done in this group is Repetitive Transcranial Magnetic Stimulation - Sham
3003869|NCT02537496|No Intervention|Healthy Control|Healthy control group will only participate in baseline assessments which include baseline neuropsychological testing and baseline measurement of neuroplasticity. This will be used to standardize neuropsychological test scores and to compare the baseline neuroplasticity between healthy participants and Alzheimer's disease (AD) participants. Healthy control group will not get rTMS intervention.
3003870|NCT02537483|Experimental|IDP-120 Gel|IDP-120 Gel, applied topically to the face once daily for 12 weeks.
3003871|NCT02537483|Active Comparator|IDP-120 Component A|IDP-120 Component A, applied topically to the face once daily for 12 weeks
3003872|NCT02537483|Active Comparator|IDP-120 Component B|IDP-120 Component B, applied topically to the face once daily for 12 weeks
3003873|NCT02537483|Placebo Comparator|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel, applied topically to the face once daily for 12 weeks
3003874|NCT02537470|Other|Arm 1|Placebo
3003875|NCT02537470|Experimental|Arm 2|Biphasic remogliflozin etabonate
3003876|NCT02537457|Experimental|BAY59-7939 Rivaroxaban granule|
3003877|NCT02537457|Active Comparator|BAY59-7939 Rivaroxaban tablet|
3003878|NCT02537444|Experimental|Regimen 1|Drug: acalabrutinib monotherapy
3003879|NCT02537444|Experimental|Regimen 2|Drug: Combination of acalabrutinib and pembrolizumab
3003880|NCT02537431|Experimental|Open-Label Burosumab Q4W|1.0 mg/kg burosumab monthly (Q4W), calculated based on baseline weight and up to a maximum dose of 90 mg.
3003881|NCT02537418|Experimental|durvalumab ± tremelimumab|"durvalumab; Day 1 every 3 weeks or 4 weeks~tremelimumab; every 3-6 weeks for a total of 1-6 doses"
3003882|NCT02537405|Experimental|BAY59-7939 granule|
3003883|NCT02537405|Active Comparator|BAY59-7939 tablet|
3003884|NCT02537392|Experimental|Vitamin B Complex and Folic Acid|Daily supplements containing vitamin B1 (2 mg), vitamin B2 (2 mg), vitamin B6 (2 mg), vitamin B12 (2 μg), calcium pantothenate (2 mg), nicotinamide (15 mg) and folic acid (0.4 mg).
3003885|NCT02537392|Experimental|Iron and Folic Acid|Daily supplements of iron (60 mg) and folic acid (0.4 mg).
3003886|NCT02537392|Active Comparator|Folic Acid|Daily supplement of 0.4 mg folic acid.
3003887|NCT02537379||SOF+COPE|Adult patients with genotype 2 chronic HCV infection with or without compensated cirrhosis who take SOF+COPE as part of routine clinical care at a participating clinical site.
3003888|NCT02537366|Placebo Comparator|Placebo|Sodium Chloride 0,9 % Continuous IV infusion begun one hour before NIV session at 0.07 ml/kg/h Adaptation to sedation status by changing infusion speed of 0.02 ml/kg/h every 30 minutes up to 0.14 ml/kg/h Sedation objective Richmond Agitation Sedation Scale -3 (moderate sedation) to 0 (alert and calm)
3003889|NCT02537366|Experimental|DEX|Dexmedetomidine diluted to 10 µg/ml in Sodium Chloride 0,9 % Continuous IV infusion begun one hour before NIV session at 0.7 µg/kg/h (= 0.07 ml/kg/h) Adaptation to sedation status by changing infusion speed of 0.2 µg/kg/h (= 0.02 ml/kg/h) every 30 minutes up to 1.4 µg/kg/h (= 0.14 ml/kg/h) Sedation objective Richmond Agitation Sedation Scale -3 (moderate sedation) to 0 (alert and calm)
3003890|NCT02537353|Placebo Comparator|Group 1|Patients with a clinical diagnosis of upper gastrointestinal bleeding and that during endoscopy revealed to non-varicose bleeding lesions in the endoscopic treatment being necessary. The group will be submitted to injection of adrenaline at a proportion of 1: 10,000 in the four quadrants of the lesion associated with application of metal clips. The patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
3003891|NCT02537353|Active Comparator|Group 2|Patients with a clinical diagnosis of upper gastrointestinal bleeding and that during endoscopy revealed to non-varicose bleeding lesions in the endoscopic treatment being necessary. The group will be submitted to injection of adrenaline at a proportion of 1: 10,000 in the four quadrants of the lesion associated with application adsorption powder, marketed under the name Hemospray. The patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
3003892|NCT02537340||EMVI-MR positive|Patients with primary rectal cancer and extramural vascular invasion detected by staging MR
3003893|NCT02537340||EMVI-MR negative|Patients with primary rectal cancer and without extramural vascular invasion detected by staging MR
3003894|NCT02537314|Active Comparator|benzocaine|0.5% benzocaine solution in saline/HCl administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
3003895|NCT02537314|Placebo Comparator|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
3003896|NCT02537301||ERCP-chat group|All the doctors who finished their ERCP training in Xijing Hospital of Digestive Diseases and were invited to join in a chatting group in a mobile social app (Wechat).
3003897|NCT02537288|Experimental|Placebo matched to fedovapagon|One dose of placebo (matched to fedovapagon)
3003898|NCT02537288|Experimental|Fedovapagon 2 mg|One dose of 2 mg fedovapagon
3003899|NCT02537288|Experimental|Fedovapagon 20 mg|One dose of 20 mg fedovapagon
3003900|NCT02537288|Experimental|Moxifloxacin 400 mg (open label)|One dose of moxifloxacin 400 mg (open label)
3003901|NCT02537275|Experimental|wearing contact lense group|normal subjects after wearing tinted/normal contact lenses
3003902|NCT02537262|Experimental|carbohydrate group|
3003903|NCT02537262|Placebo Comparator|NPO(None Per Oral) group|
3003904|NCT02537249|Experimental|Dexmedetomidine|
3003906|NCT02537236|Experimental|Group one|20 subjects received Therapeutic Lifestyle Changes diet more 1.05 grams of fish oil omega 3 fatty acids
3003907|NCT02537236|Active Comparator|Group two|20 subjects received conventional diet more 1.05 grams of fish oil omega 3 fatty acids
3003908|NCT02537236|Experimental|Group three|20 subjects received Therapeutic Lifestyle Changes diet more 2.10 grams of fish oil omega 3 fatty acids.
3003909|NCT02537236|Active Comparator|Group four|20 subjects received conventional diet more 2.10 grams of fish oil omega 3 fatty acids
3003910|NCT02537236|Placebo Comparator|Group five|20 subjects, control group received conventional diet.
3003911|NCT02537223|Experimental|BYL719, Cisplatin, and Radiation Therapy|BYL719, orally, at a starting dose of 200-350 mg, once daily, for 7 weeks. Cisplatin, intravenously, at 100 mg/m2 over 1 hour, every 3 weeks for 3 doses. Radiation therapy, Monday to Friday, for 7 weeks.
3003912|NCT02537210|Active Comparator|Mesalazine|mesalazine 2g od po for 12 months
3003913|NCT02537210|Placebo Comparator|Placebo oral capsule|placebo 5 capsules od po for 12 months
3003914|NCT02537197|Experimental|Treatment Group|Regular Naltrexone dosing (approximately 12 weeks): Initially, participants will be given seven 25mg oral naltrexone (ReVia, Generic Health, or similar) half tablets at intake (days 1-7). The Full dosing regimen will begin if no toxicity issues are present and consists of fourteen 50mg tablets (two per day; 100mg). If required, dosages can be stepped up or down. If adverse symptoms persist (or if gambling symptoms escalates), the participant will be removed from the study and given alternative treatments. Participants will receive the following week's medication at each Calgary Opioid Dependence Program visit. Pill counts will be made at each visit. Physicians will monitor the progress of participants from intake and adjust dosages up or down to control gambling behaviour.
3003915|NCT02537184|Other|Group 1 - Recall Interval of 4 months|"Oral clinical conditions:~Only at baseline all childrens will receive 5% sodium FV (Duraphat, Colgate Oral Pharmaceuticals). Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment Procedure/Surgery: Oral clinical conditions Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
3003916|NCT02537184|Other|Group 2 - Recall Interval of 8 months|"Oral clinical conditions:~Only at baseline all childrens will receive 5% sodium FV (Duraphat, Colgate Oral Pharmaceuticals). Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment Procedure/Surgery: Oral clinical conditions Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
3003917|NCT02537171|Active Comparator|Apatinib 750mg group|Apatinib mesylate tablets(ATAN) is taken 750mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death.The dose of the study drug may be modified following the occurence of a clinically significant adverse event(AE).
3003918|NCT02537171|Active Comparator|Apatinib 500mg group|Apatinib Mesylate Tablets(ATAN) is taken 500mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death.Treatment will be discontinued if the subject is unable to tolerate a daily dose of 500mg.
3003919|NCT02537158|Experimental|sorafenib group|sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
3003920|NCT02537158|Experimental|TACE group|TACE group patients will accept TACE therapy once at a month after resection.
3003921|NCT02537158|No Intervention|control group|Control group patients will not accept any intervention,except necessary supportive treatment.
3003922|NCT02537145||Obese pregnant women|20 obese pregnant women (BMI ≥ 30)
3003923|NCT02537145||Lean pregnant women|20 lean pregnant women (BMI 18,5 - 25)
3003924|NCT02537132|Experimental|Home Group|Adaptation and training to Non Invasive Ventilation (NIV) (not less than five sessions), at home
3003925|NCT02537132|Active Comparator|Outpatient Group|Adaptation and training to Non Invasive Ventilation (NIV) (not less than five sessions), at the outpatient clinic
3003926|NCT02537119|Experimental|Dynamic massage therapy|Rubbing on hamstrings combined with articular movement
3003927|NCT02537119|Active Comparator|Massage therapy|Rubbing on hamstrings
3003928|NCT02537106|Experimental|1.5% NaCl|After standardized induction to general anesthesia group A patients will be given the infusion of hyperosmotic 1.5% NaCl 5 ml/kg/BW during 15 min.
3003929|NCT02537106|Experimental|3% NaCl|After standardized induction to general anesthesia group B patients will be given the infusion of hyperosmotic 3% NaCl 5 ml/kg/BW during 15 min.
3003930|NCT02537093|Active Comparator|Synchronous telepsychiatry (STP)|Control Arm/Synchronous telepsychiatry (STP): After baseline assessment, subjects will be assessed by a psychiatrist using live interactive videoconferencing every 6 months for a 1 year follow up (3 STP assessments: baseline plus 2 assessments). A report with treatment recommendations following American Psychiatric Association guidelines will be sent to the PCP who will be able to have adlib telephone or email consultations with the telepsychiatrist. The telepsychiatrist will have access to all previous clinical information about the patients.
3003931|NCT02537093|Experimental|Asynchronous telepsychiatry (ATP)|Intervention Arm (ATP): All ATP assessments at 6 monthly intervals post baseline will be conducted by an ATP trained clinician. This interview will be video recorded.The ATP clinicians will then fill out a standardized medical template that will be reviewed by a psychiatrist who will provide a written assessment and psychiatric treatment plan. He will have access to any previous assessments and the PCP will also have continuing access to this psychiatrist by phone or email between the 3 consultations.
3003932|NCT02537080|Experimental|Nimodipine group|1 tbl of 30 mg nimodipine will be administered orally with premedication
3003933|NCT02537080|Experimental|Control group|1 tbl of placebo will be administered orally with premedication
3003934|NCT02537067|Experimental|Autologous cultured Chondrocyte|Subjects who give consent will be screened and those who meet trial criteria will receive CHONDRON (Autologous cultured Chondrocyte) by transplant.
3003935|NCT02537054|Experimental|Aflibercept|2 mg/ dose (pro re nata, maximum 1 dose/ month), intravitreal use
3003936|NCT02537041|Other|healthy volunteers|to obtain normal values diastolic myocardial stiffness references. The objective will be to confirm the increase with age in myocardial stiffness assessed by elastography in healthy subjects.
3004236|NCT02534922|Experimental|Daily dosing|Daily subcutaneous dosing of Prolanta, a human prolactin receptor antagonist
3003937|NCT02537041|Other|diastolic Heart Failure|older patients with isolated diastolic HF (EF> 45%, 60-80 years, n = 20) and infiltrative cardiomyopathy restrictive-type amyloidosis (n = 20) . The objective will be to study the results of elastography on two separate clinical types of IC diastolic well identified.
3003938|NCT02537041|Other|systolic Heart Failure|"elderly patients with heart failure with impaired ejection (<45%) fraction, but no segmental dysfunction.~The evaluation of myocardial stiffness by elastography in all these patients will be compared to conventionally ultrasound and biological parameters currently used for diagnosis of elderly's diastolic HF"
3003939|NCT02537028|Experimental|MSC2364447C 25 mg|
3003940|NCT02537028|Experimental|MSC2364447C 75 mg|
3003941|NCT02537028|Placebo Comparator|Placebo|
3003942|NCT02537015|Experimental|Bimatoprost Ocular Insert|Treatment with the ForSight VISION5 Product in both eyes (OU).
3003943|NCT02537002|Experimental|Cohort 1- PF-05230907 or Placebo|
3003944|NCT02537002|Experimental|Cohort 2- PF-05230907 or Placebo|
3003945|NCT02536989|Experimental|1|receive high dose PPI treament with intravenous omeprazole 80 mg stat and then 8mg/hr infusion for 3 days
3003946|NCT02536989|Active Comparator|2|receive usual dose PPI treatment with ntravenous omeprazole 40 mg stat and then 40 mg q12h for 3 days
3003947|NCT02536976|Experimental|Active treatment|mirabegron
3003948|NCT02536976|Placebo Comparator|Placebo|Matching placebo
3003949|NCT02536963|Other|PVS Screening|All enrolled participants will be screened with the Pediatric Vision Scanner (PVS screening) during a well-child visit to compare whether the results of the PVS match the results of the regular eye examination performed during the well-visit.
3003950|NCT02536963|Other|Reference examination|All enrolled participants will receive a reference examination performed by a fellowship-trained pediatric ophthalmologist. Results will be compared with PVS screening results.
3003951|NCT02536950|No Intervention|Blinded Sensor|Subjects will wear a blinded Dexcom G4P (Generation 4 Platinum) AP (Artificial Pancreas) glucose sensor for a week
3003952|NCT02536950|Experimental|Fixed set point|Subjects will be in a hotel and use a fixed set point for glucose control for two days initialized at 130 mg/dl. The setpoint will be adjusted, if necessary, over the two days in the hotel before they are sent home for 5 days
3003953|NCT02536950|Experimental|Variable Set Point|"Subjects will begin using a variable setpoint which will make adjustments based on their past glucose control over the previous day"
3003954|NCT02536937|Experimental|GZ385660 (healthy subjects)|Single dose of eliglustat tartrate will be given under fed conditions
3003955|NCT02536937|Experimental|GZ385660 (subjects with mild renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
3003956|NCT02536937|Experimental|GZ385660 (subjects with moderate renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
3003957|NCT02536937|Experimental|GZ385660 (subjects with severe renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
3003958|NCT02536924|Experimental|Waiting room intervention plus TAU|The treatment group will receive waiting room intervention plus treatment as usual.
3003959|NCT02536924|Experimental|Only TAU.|The control group will receive only treatment as usual.
3003960|NCT02536911|Experimental|GZ385660 (healthy subjects)|Single dose of eliglustat tartrate will be given under fed conditions
3003961|NCT02536911|Experimental|GZ385660 (subjects with mild hepatic impairment)|Single dose of eliglustat tartrate will be given under fed conditions
3003962|NCT02536911|Experimental|GZ385660 (subjects with moderate hepatic impairment)|Single dose of eliglustat tartrate will be given under fed conditions
3003963|NCT02536898|Experimental|Fracture liaison service|"Information, assessment & lifestyle advice~refer to DXA scan, except patients with dementia, difficulties laying on the back or short life exp.~Blood samples~Sufficient intake of Vitamin D & calcium, combined with physical activity will be recommended with lifestyle advice (smoking & alcohol intake)~Patients With Hip, Vertebral or two or more low-trauma fractures are recommended treated with anti-osteoporosis drug~Other fractures, treatment recommended if FRAX score≥20% for major fracture & T-score≤-1.5~Fracture patients with reduced kidney function will be treated with anti-RANKL~Anti-osteoporosis drug prescribed by hospital physician~Follow-up phone call after 3 months and visit to talk with coordinating nurse after 1 year~Patients with spine or femoral neck T-scores≤-3.5, >2 severe vertebral fractures & those who suffer a second fracture while using anti-osteoporosis drug, will be referred for further examination and teriparatide treatment will be considered"
3003964|NCT02536898|Other|Current treatment|Treatment as offered before intervention.
3003965|NCT02536885|Experimental|Liberal group|During the surgery, blood pressure of the patients will be maintained within ± 25% of the patient's normal blood pressure.
3003966|NCT02536885|Experimental|Restrictive group|During the surgery, blood pressure of the patients will be maintained within ± 10% of the patient's normal blood pressure.
3003967|NCT02536859|Experimental|IDeg|
3003968|NCT02536859|Active Comparator|IGlar U300|
3003969|NCT02536846|Experimental|Second Generation Antipsychotic Drug|Olanzapine; a single 2.5 mg dose PO daily followed by 5 mg dose PO daily for 14 days
3003970|NCT02536833|Experimental|SM04690, 0.03mg/2mL|Single intra-articular injection of SM04690
3003971|NCT02536833|Experimental|SM04690, 0.07mg/2mL|Single intra-articular injection of SM04690
3003972|NCT02536833|Experimental|SM04690, 0.23mg/2mL|Single intra-articular injection of SM04690
3003973|NCT02536833|Placebo Comparator|Placebo|Single intra-articular injection of placebo
3003974|NCT02536820|Other|Conventional treatment + PNIT|PNIT: Psychoneuroimmuno therapy Conventional treatment: Usual treatment that each diabetic patient recieved
3003975|NCT02536820|Active Comparator|Conventional treatment|Conventional treatment: Usual treatment that each diabetic patient recieved
3003976|NCT02536807|Experimental|Hyaluronan|Hyaluronan gel injection
3003977|NCT02536807|Placebo Comparator|Control|Control placebo gel injection
3004011|NCT02536508|Experimental|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate (GFF) metered dose inhaler (MDI) (PT003, GFF MDI)
3004012|NCT02536508|Experimental|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate (BFF) metered dose inhaler (MDI) (PT009, BFF MDI)
3004134|NCT02535663|Placebo Comparator|placebo|Dietary Supplement: placebo consumed one pack (150ml) of dairy yogurt without RG per day for 8 weeks
3003978|NCT02536794|Experimental|Treatment (MEDI4736, tremelimumab)|Patients receive anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour and tremelimumab IV over 1 hour on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Four weeks after the last combination dose, patients continue to receive anti-B7H1 monoclonal antibody MEDI4736 every 2 weeks for up to 18 additional doses in the absence of disease progression or unacceptable toxicity. Patients achieving PD or clinical benefit (CR, PR, or SD) may be retreated with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks.
3003979|NCT02536781|Placebo Comparator|Placebol|Placebo
3003980|NCT02536781|Active Comparator|Anthocynin|Anthocyanin
3003981|NCT02536768|Experimental|Intervention|Minimum package of interventions to improve ART adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
3003982|NCT02536768|No Intervention|Comparison|Standard of care HIV treatment
3003983|NCT02536755|Experimental|eliglustat|Cytochrome P450 (CYP) 2D6 Intermediate (IM), Extensive (EM) and Ultra-Rapid (URM) Metaboliser patients will be treated at 84 mg twice daily. CYP2D6 Poor Metabolisers (PM) will be treated at 84 mg once daily.
3003984|NCT02536742|Experimental|Experimental|Palbociclib plus Fulvestrant
3003985|NCT02536729||Oral Sodium Phosphate - Normal preparation|Oral sodium phospate exposure with special diet (Liquid)
3003986|NCT02536729||Oral Sodium Phosphate - Modified preparation|Oral sodium phospate exposure with special diet (Liquid), but the participant can normally lunch the day before the test
3003987|NCT02536729||polyethylene glycol + Electrolytes|polyethylene glycol + Electrolytes exosure with special diet (Liquid)
3003988|NCT02536716|Active Comparator|Platform-matched dental implant|Platform-matched dental implant placement to measure marginal bone loss, gingival margin position, and papilla fill.
3003989|NCT02536716|Experimental|Platform-switched dental implant|Platform-switched dental implant placement to measure marginal bone loss, gingival margin position, and papilla fill.
3003990|NCT02536703|Experimental|Lotus Valve System|Transcatheter Aortic Valve Implantation (TAVI) with Lotus Valve System
3003991|NCT02536690|Active Comparator|Group P|Induction with propofol bolus. Dose will be started at 1 mg/kg and will be adjusted as described in summary.
3003992|NCT02536690|Active Comparator|Group PR|Induction with propofol and remifentanil. Remifentanil infusion 0.25 mcg/kg/min for 5 min followed by propofol bolus Propofol dose will be started at 1 mg/kg and will be adjusted as described in summary.
3003993|NCT02536690|Active Comparator|Group PMR|"Induction with propofol, midazolam and remifentanil. Remifentanil infusion 0.25 mcg/kg/min for 5 min followed by midazolam 0.03 mg/kg bolus 1 min after remifentanil infusion start and propofol bolus administration.~Propofol dose will be started at 1 mg/kg and will be adjusted as described in summary."
3003994|NCT02536664||First-line Stratum|Participants who were untreated and decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
3003995|NCT02536664||Relapsed/Refractory Stratum|Participants who relapsed after treatment with chemotherapeutic regimens with or without Rituximab and were decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
3003996|NCT02536638||Pyelonephritis Group|patients with pyelonephritis
3003997|NCT02536638||Without pyelonephritis Group|patients without pyelonephritis
3003998|NCT02536625||Everolimus|Immunomonitoring
3003999|NCT02536612|Experimental|Lottery|"Conditional economic incentive (CEI) lotto arm participants will get a chance to win a type of lottery or lotto ticket with a 50% chance of winning each time: (a) if they come back to the clinic and are still using a modern contraception method after 3 months (including IUD, injectable contraceptive, or implant); (b) if they come back to the clinic and are still using modern contraception after 6 months; and (c) if they come back to the clinic at 6 months and they don't have a new curable STD (such as syphilis).~They will also will receive reimbursement to cover their transport and time at baseline, at 3 months and at 6 months."
3004000|NCT02536612|Active Comparator|No Lottery|Participants in the Control (No CEI Lotto) group will receive reimbursement to cover their transport and time at baseline, at 3 months and at 6 months; they will NOT have a chance to win a lottery even if they are still using a modern contraception and are free of new curable STDs.
3004001|NCT02536586|Experimental|LY3023414|LY3023414 administered orally, twice daily in 21-day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
3004002|NCT02536573|No Intervention|Control|Intraoperative fluoroscopy of the hip is used to visually estimate the acetabular cup angle and make any necessary adjustments.
3004003|NCT02536573|Experimental|Radlink Surgical Positioning System|Fluoroscopic image of the hip joint is imported into the Radlink Surgical Positioning software. The software calculates a target cup position using bony landmarks, and the surgeon matches the cup to the target.
3004004|NCT02536560||Antibiotics|150 infants, (because of hospital protocol) treated with antibiotics because of a perinatal infection during the first week of life
3004005|NCT02536560||Controls|The control group comprises 300 healthy newborns, born in the hospital and needing clinical observation for 24-48 hours for several reasons like maternal comorbidity, low probability of neonatal infection, blood sugar monitoring, meconium containing amniotic fluid, or delivery by caesarean section
3004006|NCT02536547||patients with suspected VAP|"All patients with suspected VAP will be included in the study (new or extension of a radiological image in a patient in mechanical ventilation for at least 48 hours associated with at least two of the following:criteria :~fever ≥38.5 ° C or <36, 5 ° C leukocytosis> 10 * 103 / ml or leukopenia <4 * 103 / ml secretions purulent tracheal reduction in PaO2 / FiO2 <300 or PaO 2 <60 mmHg"
3004007|NCT02536534||Patients with PAH and CTEPH|Patients diagnosed with symptomatic Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and stable on optimal medical therapy who meet the study's eligibility criteria
3004008|NCT02536521||Hemodynamically stable|
3004009|NCT02536521||Hemodynamically unstable|Hemodynamically unstable patients are defined as those with a 20% decrease in systolic blood pressure according to the change of intraabdominal pressure.
3004010|NCT02536508|Experimental|BGF MDI (PT010) 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) (PT010, BGF MDI)
3037236|NCT02313168||2|intraoperative FRONT score
3004013|NCT02536495|Experimental|Treatment (docetaxel, selinexor)|Patients receive docetaxel IV on day 1 and selinexor PO BID on days 1, 3, 7, 9, 13, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3004014|NCT02536482|Experimental|Amix|Dietary supplement. The formula is based in free amino-acid to treat children with cow`s milk allergy. The children should have a minimum consumption of 400 mL, daily.
3004015|NCT02536469|Experimental|HuMax-IL8|HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
3004016|NCT02536430|Active Comparator|Buccal infiltration of Ketorolac|A buccal infiltration of 30 mg/mL of Ketorolac Tromethamine was applied for the patients in case group.
3004017|NCT02536430|Placebo Comparator|buccal infiltration of Normal Saline|A buccal infiltration of Normal Saline was applied for the patients in control group.
3004018|NCT02536417|Active Comparator|Treatment arm: melatonin|melatonin 0.5 mg as treatment, to be given daily at bedtime
3004019|NCT02536417|Placebo Comparator|Placebo arm|Sugar pill identical in appearance to the melatonin 0.5 mg tablets used in treatment arm
3004020|NCT02536404|Experimental|Etrasimod (APD334) High Dose|
3004021|NCT02536404|Active Comparator|Placebo|
3004022|NCT02536391|Experimental|Sequence 1: Tablet/Capsule/Tablet with food|Day 1: ipatasertib tablet administered after fast, Day 8: ipatasertib capsule administered after fast, Day 15: ipatasertib tablet administered after high-fat meal.
3004023|NCT02536391|Experimental|Sequence 2: Tablet/Tablet with food/Capsule|Day 1: ipatasertib tablet administered after fast, Day 8: ipatasertib tablet administered after high-fat meal, Day 15: ipatasertib capsule administered after fast.
3004024|NCT02536391|Experimental|Sequence 3: Capsule/Tablet/Tablet with food|Day 1: ipatasertib capsule administered after fast, Day 8: ipatasertib tablet administered after fast, Day 15: ipatasertib tablet administered after high-fat meal.
3004025|NCT02536391|Experimental|Sequence 4: Capsule/Tablet with food/Tablet|Day 1: ipatasertib capsule administered after fast, Day 8: ipatasertib tablet administered after high-fat meal, Day 15: ipatasertib tablet administered after fast.
3004026|NCT02536391|Experimental|Sequence 5: Tablet with food/Tablet/Capsule|Day 1: ipatasertib tablet administered after high-fat meal, Day 8: ipatasertib tablet administered after fast, Day 15: ipatasertib capsule administered after fast.
3004027|NCT02536391|Experimental|Sequence 6: Tablet with food/Capsule/Tablet|Day 1: ipatasertib tablet administered after high-fat meal, Day 8: ipatasertib capsule administered after fast, Day 15: ipatasertib tablet administered after fast.
3004028|NCT02536365|Experimental|Sensory Integration Therapy|Children receive manualized SIT intervention that follows principles of sensory integration. SIT directly addresses the specific sensory factors hypothesized to underlie the child's functional skills difficulties and follows the Data Driven Decision Making Process, to tailor the intervention to the child's specific sensory issues.
3004029|NCT02536365|Active Comparator|Applied Behavioral Analysis|This involves examination of environmental variables that influence behavior and altering those variables to improve the child's skills. Intervention is individualized based on identified needs of the child, assessment of environmental variables impacting their performance of specific functional skills, and their abilities.
3004030|NCT02536365|No Intervention|No Treatment|Treatment as usual will occur through the treatment period. As with the other treatment conditions, the participant agrees to refrain from beginning new treatments during participation in this study.
3004031|NCT02536352|Experimental|Fluoride prenatal vitamin|Prenatal vitamin-mineral containing 3 mg fluoride
3004032|NCT02536352|Active Comparator|Standard prenatal vitamin|Prenatal vitamin-mineral containing 0 mg fluoride
3004033|NCT02536339|Experimental|Pertuzumab + Trastuzumab|Participants with CNS metastases secondary to HER2-positive MBC will receive pertuzumab in combination with high-dose trastuzumab until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
3004034|NCT02536326|Experimental|renal denervation|
3004035|NCT02536313|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
3004036|NCT02536313|Experimental|SOF/VEL/VOX + RBV|SOF/VEL/VOX + RBV for 12 weeks
3004037|NCT02536300|Experimental|Idelalisib 150 mg|Participants will receive idelalisib 150 mg twice daily. Based on the 8-week blinded independent review committee (IRC) response assessment, participants may be discontinued from the study or may receive blinded or open-label idelalisib 150 mg twice daily.
3004038|NCT02536300|Experimental|Idelalisib 100 mg|Participants will receive idelalisib 100 mg twice daily. Based on the 8-week blinded IRC response assessment, participants may either be dose escalated to open-label 150 mg twice daily or maintain blind and continue on idelalisib 100 mg twice daily.
3004039|NCT02536287|Experimental|total PTX without autotransplantation|all parathyroid glands were found and removed
3004040|NCT02536287|Active Comparator|total PTX with autotransplantation|all parathyroid glands were found and removed,and then a portion of it is sliced into 1*1*1 mm pieces for autotransplantation
3004041|NCT02536274|Experimental|Schwertbad Aachen|20 Patients with specific back pain will get Lumbo Sensa® bandage. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
3004042|NCT02536274|Experimental|Schön Klinik Fürth|20 Patients with specific back pain will get Dynaflex® flexion orthosis. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
3004100|NCT02535897|Active Comparator|CHO-PRO|500 ml of flavoured water containing 40 g carbohydrate and 40 g whey protein
3004177|NCT02535377||Low cryoresistance|Low resistance to sperm cryopreservation (decreased sperm motility >20%)
3004043|NCT02536274|No Intervention|Schön Klinik Fürth & Schwertbad Aachen|20 Patients with specific back pain will get no intervention. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
3004044|NCT02536274|No Intervention|RPE|20 healthy Subjects of the same age without back pain participate in the course for one time to prove the significance of the procedures. (control group) Study related procedures include a course with 6 exercises: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
3004045|NCT02536261||Withdrawal group|Withdrawal observation after reaching the withdrawal standard
3004046|NCT02536261||Continue treatment group|Continue treatment obsevation after reaching the withdrawal standard
3004047|NCT02536248|Experimental|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
3004048|NCT02536248|Placebo Comparator|Placebo|Placebo for 6 weeks
3004049|NCT02536235|Experimental|Intervention: intraoperative topical heat|
3004050|NCT02536235|No Intervention|Control: no intraoperative heat|
3004051|NCT02536222|Experimental|Reactive case investigation : FT/FDA with DHA-PQ|All consenting household members eligible to receive DHA-PQ and living in a household where anyone in the household tests positive with a malaria rapid diagnostic test (RDT) will receive the age-appropriate treatment dose of DHA-PQ. If no one in the household tests RDT positive then no one in the household will receive DHA-PQ.
3004052|NCT02536222|No Intervention|No Intervention: Standard of Care (Control)|The standard of care arm will have the standard of care offered by the Ministry of Health which applies to all arms. This includes available mosquito net coverage and passive case detection of individuals seeking treatment from a health provider at a health post or community.
3004053|NCT02536209|Experimental|Regimen 1|Period 1: MT-8554 low dose, Period 2: MT-8554 high dose, Period 3: Placebo and Period 4: Oxycodone hydrochloride, respectively single dosing
3004054|NCT02536209|Experimental|Regimen 2|Period 1: MT-8554 high dose, Period 2: Oxycodone hydrochloride, Period 3: MT-8554 low dose and Period 4: Placebo, respectively single dosing
3004055|NCT02536209|Experimental|Regimen 3|Period 1: Placebo, Period 2: MT-8554 low dose, Period 3: Oxycodone hydrochloride and Period 4: MT-8554 high dose, respectively single dosing
3004056|NCT02536209|Experimental|Regimen 4|Period 1: Oxycodone hydrochloride, Period 2: Placebo, Period 3: MT-8554 high dose and Period 4: MT-8554 low dose, respectively single dosing
3004057|NCT02536196|Experimental|Intervention|Embolic Protection with transcatheter aortic valve implantation (TAVI)
3004058|NCT02536196|Active Comparator|Control Arm|Transcatheter aortic valve implantation (TAVI) without embolic protection
3004059|NCT02536183|Experimental|Part A|LTLD will be administered intravenously in combination with MR-HIFU ablation on day 1 of every 21 day cycle. There will be two potential dose escalation of LTLD with highest dose not to exceed the adult recommended MTD. Patients may receive up to a total of 6 cycles.
3004060|NCT02536183|Experimental|Part B|LTLD at dose determined from Part A will be administered intravenously on day 1 of every 21 day cycle. MR-HIFU induced MHT will follow immediately post LTLD infusion for one hour to target area with target temperatures of 40-45°C. Patients may receive up to a total of 6 cycles
3004061|NCT02536170|Experimental|L-Arginine|Participants will be randomized to receive an intravenous (IV) infusion of L-arginine (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
3004062|NCT02536170|Experimental|Loading Dose and L-Arginine|Participants will be randomized to receive an intravenous (IV) infusion of one-time loading dose of L-arginine (200 mg/kg) followed by standard dose (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
3004063|NCT02536170|Placebo Comparator|Placebo|Participants will be randomized to receive an intravenous (IV) infusion of placebo (normal saline 1-2 ml/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
3004064|NCT02536157|Active Comparator|Dorsal block splint|Thermoplastic splint in 20 degrees flexion applied to the dorsum of the PIPJ.
3004065|NCT02536157|Experimental|Volar gutter splint|Thermoplastic splint in 0 degrees flexion applied to the volar surface of the finger.
3004066|NCT02536144|Experimental|MCCES|Magnetic -controlled capsule endoscopy system (MCCES) is a robot system that the capsule would be swallowed to observe the mucosa of the human alimentary canal especially the colon under the control of the magnetic-manipulator.
3004067|NCT02536144|Active Comparator|Colonoscopy|Colonoscopy has now been in use for many years to visualize and diagnose abnormalities of the colon and it is the gold standard for detecting colorectal lesions.In this study,the additional utility of the colonoscopy is to monitor the movement of the Magnetic -controlled capsule endoscopy.
3004068|NCT02536131|Other|Study group|7-10 sessions gut-directed hypnotherapy within 12 weeks
3004069|NCT02536118||Patients implanted with Micra System|Patients implanted with a Micra Transcatheter Pacing System are eligible for enrollment into the Micra PA Registry.
3004070|NCT02536105|Active Comparator|Methylphenidate HCl ER tablets 1|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
3004071|NCT02536105|Placebo Comparator|Placebo|During the double-blind period, in one of the 4 study weeks, the study participant will take a blinded placebo instead of one of the the 3 active comparators.
3004101|NCT02535884|Experimental|Stimulation group|Patients in the stimulation group will be stimulated immediately after implantation of the Stimulator (ACTIVA® PC neurostimulator (Model 37601))
3004072|NCT02536105|Active Comparator|Methylphenidate HCl ER tablets 2|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
3004073|NCT02536105|Active Comparator|Methylphenidate HCl ER for suspension|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
3004074|NCT02536092|Experimental|755nm and 1064nm Nd:YAG laser|755nm and 1064nm Nd:YAG laser
3004075|NCT02536066|No Intervention|Control|maintain usual physical activity patterns
3004076|NCT02536066|Experimental|Intervention|Addition of daily postprandial physical activity in addition to usual activity patterns
3004077|NCT02536040|Experimental|38% diamine silver fluoride|Topical application of 38% diammine silver fluoride to active cavity
3004078|NCT02536040|Placebo Comparator|Water|Topical application of fluoride free water to active cavity
3004079|NCT02536027|Experimental|septic AKI patients|septic AKI patients requiring CVVH
3004080|NCT02536014|Experimental|Dexmedetomidine|
3004081|NCT02536014|Active Comparator|Saline|
3004082|NCT02536001|Other|One mesh Endofast reliant system|Patients with anterior compartment stage III and uterus prolapse grade II will be treated with one mesh - Anterior Endofast reliant system (fixation of posterior arms to the sacrospinous ligament)
3004083|NCT02536001|Other|two meshes Endofast reliant system|intervention: Patients with anterior compartment stage III and uterus prolapse grade II will be treated with 2 meshes: anterior Endofast reliant system mesh to correct the anterior compartment and posterior Endofast reliant system mesh to correct the apical prolapse (fixation to the sacrospinous ligament)
3004084|NCT02535988|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of colorectal cancer receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy; Systemic agents are either capecitabine (Xeloda), paclitaxel or S-1;
3004085|NCT02535975|Experimental|Metformin|Metformin 500mg PO three times a day for 24 weeks
3004086|NCT02535975|Placebo Comparator|Placebo|Placebo tab. PO three times a day for 24 weeks
3004087|NCT02535962|Experimental|Corticosteriod + Probiotic Treatment|"Corticosteroid dosing of 1 mg/kg of body weight given once at the onset of the febrile period, repeated once within 24 hours if necessary, but no more than two doses per cycle. The second dose of corticosteroid treatment is only to be given within one day following the initial dosage if the fever persists.~Investigational drug (Intervention is Lactobacillus acidophilus and Bifidobacterium lactis): Patients will be instructed to take one sachet of the study product mixed into a 60 ml of water that is not hot. Each sachet will contain Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 at a dose of 5*109 CFU of each strain. The investigational product will be taken daily for the duration of the study, which is a year."
3004088|NCT02535962|Placebo Comparator|Corticosteriod + PlaceboTreatment|"Corticosteroid dosing of 1 mg/kg of body weight given once at the onset of the febrile period, repeated once within 24 hours if necessary, but no more than two doses per cycle. The second dose of corticosteroid treatment is only to be given within one day following the initial dosage if the fever persists.~Placebo: will be taken daily and patients will be instructed to take one sachet of placebo mix into 60ml of water that is not to hot. The placebo will be taken daily for the duration of the study, which is one year. Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product."
3004089|NCT02535949|Experimental|Tranexamic Acid 2 Gram|One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury
3004090|NCT02535949|Experimental|Tranexamic Acid 4 Gram|One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury
3004091|NCT02535949|Placebo Comparator|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
3004092|NCT02535936|Other|3Tesla MRI with DTI-MRI and rsfcMRI|Patients will receive 2 post-operative MRI's with DTI and rsfcMRI at 2 months and 12 months.
3004093|NCT02535923|Experimental|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
3004094|NCT02535923|Active Comparator|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
3004095|NCT02535910|Experimental|breakfast rich in vitamin D3|subjects are asked to consume a breakfast with (20µg) vitamin D3 fortified milk and butter
3004096|NCT02535910|Experimental|breakfast rich in 25(OH) D3|subjects are asked to consume a breakfast with (20µg) 25(OH) D3 fortified milk and butter
3004097|NCT02535910|Placebo Comparator|Control|subjects are asked to consume a normal milk and butter (no vitamin D is added) in the breakfast
3004098|NCT02535897|Placebo Comparator|CON|500 ml of flavoured water
3004099|NCT02535897|Active Comparator|CHO|500 ml of flavoured water containing 80 g carbohydrate
3004102|NCT02535884|Sham Comparator|Non-stimulation group|Patients in the non-stimulation group will not be stimulated for the first three months after implantation of the Stimulator (ACTIVA® PC neurostimulator (Model 37601))
3004103|NCT02535871|Experimental|IDP-121 Lotion|IDP-121 Lotion, applied topically to the face, once daily for 12 weeks.
3004104|NCT02535871|Placebo Comparator|IDP-121 Lotion Vehicle|IDP-121 Vehicle Lotion, applied topically to the face, once daily for 12 weeks
3004105|NCT02535858|Experimental|Heart and respiratory rate and video|To determine the limits between normal and emotional anxious, thirty volunteers male's adults (GL) with age range between 20 and 50 years were recruited. None of them had any pathology associated with anxiety or psychiatric disorders, and none was drugs user or taking medication.
3004106|NCT02535858|Experimental|Heart and respiratory rate and VE|A second group has fifty adult volunteers (DG) ongoing outpatient chemical dependency clinic [treatment average's population: 5 months and 14 days]. The patients were abstained from drugs use for at least two months, and they were selected to test the VE. None of the DG's participants had any pathology associated with anxiety or psychiatric disorders, and none was taking medications. The DG volunteers were narcotic users of two or more illicit drugs, such as alcohol, marijuana, tobacco, cocaine and crack cocaine. Addiction for alcohol and tobacco were 72% and 56% respectively. The group's percentage for using psychoactive drugs were, 70% for cocaine and crack cocaine and 32% for marijuana.
3004107|NCT02535845|Experimental|Self-persuasion group|HPV information plus self-persuasion intervention in a tablet-based application (Project Voice)
3004108|NCT02535845|Active Comparator|Information only group|HPV information only in a tablet-based application (HPV Informational Video)
3004109|NCT02535832|Placebo Comparator|Placebo|From the total participants enrolled into the cross-sectional study, the investigator will identify up to 18 participants who have insulin resistance and recruit them to participate in the placebo arm. Participants will take matching placebo throughout the 15 weeks of treatment.
3004110|NCT02535832|Active Comparator|Pioglitazone|From the total participants enrolled into the cross-sectional study, the investigator will identify up to 18 participants who have insulin resistance and recruit them to participate in the pioglitazone arm. Participants will start by taking increasing doses for three weeks as follows: 1 capsule (15 mg) per day for 7 days, 1 capsule per day (30 mg) for 7 days, and 1 capsule (45mg), if tolerated. Participants will continue this dose (45 mg) throughout the 12 weeks of treatment.
3004111|NCT02535819|Experimental|Subluxation|Nucleus is hydrodissected until it lilts above the capsular bag, rotated to face the incision then tumbled and emulsification continues from the opposite equator outside in until complete
3004112|NCT02535819|Other|Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
3004113|NCT02535806|Experimental|Treatment Arm|"Velcade will be given IV push on days 1,4,8 and 11 at a dose of 1.3 mg/m2/dose. At least 72 hours must have relapsed between doses.~IT Methotrexate (CNS Negative patients only) on days 1 and 8; age based dosing IT Methotrexate/Hydrocortisone/AraC (CNS positive patients only) on days 1, 8, 15 and 22; age based dosing.~Dexamethasone: Days 1-5 and 15-19; 10mg/m2/dose PO BID. Mitoxantrone: Days 1 and 2; 10mg/m2/dose Vincristine: days 1, 8, 15, and 22 at 1.5 mg/m2 (Maximum dose 2 mg) PEG-asparaginase: Days 3 and 17, 2500 IU/m2/dose"
3004114|NCT02535793|Other|laboratory workers with symptoms in presence of drosophila|
3004115|NCT02535780|Experimental|TMS Treatment Group|15 sessions active Transcranial magnetic stimulation (TMS) treatment
3004116|NCT02535780|Sham Comparator|TMS Sham Group|15 sessions sham Transcranial magnetic stimulation (TMS) treatment
3004117|NCT02535780|Experimental|tDCS Treatment Group|15 sessions active Transcranial direct current stimulation (tDCS) treatment
3004118|NCT02535780|Sham Comparator|tDCS Sham Group|15 sessions sham Transcranial direct current stimulation (tDCS) treatment
3004119|NCT02535767|Experimental|A: 0.40 mg/kg PQ G6PDd|0.40 mg/kg of primaquine (as a single dose) in G6PD-deficient individuals
3004120|NCT02535767|Experimental|B: PQ in G6PDd|A single dose of primaquine in G6PD-deficient men, exact dose to be decided by DSMB based on findings in previous dose group. The minimum change in dose from the last study dose is 0.05 mg/kg, and the maximum change is 0.20 mg/kg of primaquine). Dose is not to exceed 0.75 mg/kg primaquine.
3004121|NCT02535767|Experimental|C: PQ in G6PDd|A single dose of primaquine in G6PD-deficient men, exact dose to be decided by DSMB based on findings in previous dose group. The minimum change in dose from the last study dose is 0.05 mg/kg, and the maximum change is 0.20 mg/kg of primaquine). Dose is not to exceed 0.75 mg/kg primaquine.
3004122|NCT02535767|Experimental|D: PQ G6PDn|A single dose of primaquine in G6PD-normal men, at the highest tolerable dose determined by the DSMB, from previous dose groups.
3004123|NCT02535754|Experimental|ALIVE|Email program N=170
3004124|NCT02535754|Experimental|CCS BCY|Comprehensive program N=285
3004125|NCT02535754|Experimental|ALIVE + CCS BCY|Email + comprehensive program N=225
3004126|NCT02535741|Other|Triathlon CR Total Knee System|Primary total knee replacement
3004127|NCT02535715|Experimental|ORAMED ORMD-0801 capsules|Two 8 mg ORAMED capsules containing insulin then Three 8mg ORAMED capsules containing insulin then One 16mg ORAMED capsules containing insulin
3004128|NCT02535689|Active Comparator|1|ARM 1: 10 of SLE patients will be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily.
3004129|NCT02535689|Active Comparator|2|ARM 2: 10 of SLE patients will NOT be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily.
3004130|NCT02535689|Placebo Comparator|3|ARM 3: 10 of SLE patients will be with variable genotypes will receive placebo twice daily.
3004131|NCT02535676|Active Comparator|Active tDCS|Sham Comparator: Sham Stimulation In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the temporo-parietal cortex with the Transcranial Direct Current Stimulation. The device will deliver a charge of 2mA for 20 minutes.
3004132|NCT02535676|Sham Comparator|Sham tDCS|Sham Comparator: Sham Stimulation In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the temporo-parietal cortex with the Transcranial Direct Current Stimulation. The device will deliver a charge of 2mA for 1 minute, after that the device will be automatically turned off for 19 minutes.
3004133|NCT02535663|Experimental|test group|Dietary Supplement: RG consumed one pack (150ml) of dairy yogurt containing RG (100mg Korean citrus Hallabong peel polysaccharide) per day for 8 weeks
3004135|NCT02535650|Experimental|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles.
3004136|NCT02535637||Mothers-Infant|Mothers who were planning to exclusively breastfeed for six months were enrolled into the study along with their infant.
3004137|NCT02535624|Active Comparator|ANGIO|Patients with persistent hemodynamic instability (systolic blood pressure (SBP) <90 mmHg after the transfusion of 4 packed red blood cell (PRBC) units in the emergency department) were taken urgently to the angiography suite for pelvic angiography. These patients had to tolerate transfer to the suite. Patients receiving primarily angioembolization therapy were defined as the ANGIO group.
3004138|NCT02535624|Active Comparator|PACKING|Indication for pelvic packing was persistent SBP<90 mmHg during the initial resuscitation period with 3000 ml of intravenous (IV) crystalloids and transfusion of 4 PRBC units. These patients were treated primarly with retroperitoneal packing, while angioembolization OR staff was unavailable (5pm-7am), and were defined as the PACK group.
3004139|NCT02535611|Active Comparator|Memantine|Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.
3004140|NCT02535611|Placebo Comparator|Placebo|Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.
3004141|NCT02535598|Active Comparator|Normal presentation|Standard internet based CBT presentation.
3004142|NCT02535598|Experimental|Enhanced presentation|Enhanced internet CBT presentation.
3004143|NCT02535598|Active Comparator|Normal support|Standard internet based CBT support.
3004144|NCT02535598|Experimental|Enhanced support|Enhanced internet CBT support.
3004145|NCT02535585|Active Comparator|knotted anchors|Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).
3004146|NCT02535585|Active Comparator|knotless anchors|Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
3004147|NCT02535572|Experimental|FEAST|Patients will receive the FEAST form of ECT
3004148|NCT02535572|Active Comparator|RUL UB|Patients will receive the standard of care, right unilateral ultrabrief ECT (RUL UB)
3004149|NCT02535559|Experimental|Intervention|Classes receive anti-tobacco presentations from Teens Against Tobacco Use members
3004150|NCT02535559|No Intervention|Wait list control|Classes continue as usual without receiving anti-tobacco presentations from Teens Against Tobacco Use members until the end of the year, when data collection is complete.
3004151|NCT02535533|Experimental|Study Treatment|"During the Dose-Escalation Part 1, patients will receive SLM twice daily for 14 days followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert. Treatment will continue until disease progression or unacceptable toxicity.~During the Expansion Part 2, patients will be treated at the maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1. SLM will be given orally twice daily for 14 days followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert. Treatment will continue until disease progression or unacceptable toxicity."
3004152|NCT02535507|Experimental|Pyrotinib treatment arm|pyrotinib treatment arm
3004153|NCT02535494|No Intervention|Standard Training|Participants receive our standard overdose training.
3004154|NCT02535494|Experimental|Extensive Training|Participant receives an more in-depth, extensive training concerning opioid overdose.
3004155|NCT02535494|Experimental|Extensive Training w/ Significant Other|Participant and their significant other both receive a more in-depth, extensive training concerning opioid overdose.
3004156|NCT02535481|Experimental|Epidermal Graft|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts as per existing normal clinical practice.
3004157|NCT02535481|Experimental|Split Thickness Skin Graft|Split thickness skin graft will be harvested using air dermatome as per normal clinical practise.
3004158|NCT02535468||Prospective Arm|
3004159|NCT02535468||Contrived Arm|
3004160|NCT02535455|Experimental|ACES Pilot|This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
3004161|NCT02535429|Experimental|massage|massage
3004162|NCT02535429|No Intervention|Control|
3004163|NCT02535416|Experimental|ARC-520 Cohort 1|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.6 mL/min + cetirizine
3004164|NCT02535416|Experimental|ARC-520 Cohort 2A|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.9 mL/min + cetirizine
3004165|NCT02535416|Experimental|ARC-520 Cohort 2|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.75 mL/min + diphenhydramine
3004166|NCT02535416|Experimental|ARC-520 Cohort 3|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.9 mL/min + diphenhydramine
3004167|NCT02535416|Experimental|ARC-520 Cohort 4|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 1.2 mL/min + diphenhydramine
3004168|NCT02535416|Experimental|ARC-520 Cohort 5|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 1.5 mL/min + diphenhydramine
3004169|NCT02535416|Experimental|ARC-520 Cohort 6|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 5 minute slow bolus push + diphenhydramine
3004170|NCT02535416|Experimental|ARC-520 Cohort 7|Single dose, intravenous administration of ARC-520 at 5.0 mg/kg 0.9 mL/min + diphenhydramine
3004171|NCT02535416|Experimental|ARC-520 Cohort 8|Single dose, intravenous administration of ARC-520 at 6.0 mg/kg 0.9 mL/min + diphenhydramine
3004172|NCT02535403|Experimental|ICBT|14 weeks of internet-based cognitive behavioral therapy with therapist support
3004173|NCT02535403|No Intervention|Wait-list|14 weeks wait-list control
3004174|NCT02535390|Experimental|Action based cognitive remediation|Participants in this condition will engage in simulated real world tasks in addition to standard cognitive remediation and group therapy sessions.
3004175|NCT02535390|Active Comparator|Standard cognitive remediation|Participants in this condition will engage in computerized cognitive training exercises in addition to standard cognitive remediation and group therapy sessions.
3004176|NCT02535377||High cryoresistance|High resistance to sperm cryopreservation (decreased sperm motility <20%)
3004178|NCT02535364|Experimental|JCAR015 (CD19-targeted CAR T cells)|JCAR015 was administered as two intravenous (IV) infusions separated by 14 to 28 days.
3004179|NCT02535351|Active Comparator|A: TKIs|sunitinib 50 mg orally 4 weeks on/ 2 weeks off or pazopanib 800 mg orally continuously
3004180|NCT02535351|Experimental|B: TKIs + Cytoreductive Nephrectomy|Cytoreductive nephrectomy + sunitinib 50 mg orally 4 weeks on/ 2 weeks off or pazopanib 800 mg orally continuously
3004181|NCT02535338|Experimental|Treatment (erlotinib hydrochloride, onalespib lactate)|Patients receive erlotinib hydrochloride PO daily and onalespib lactate IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
3004182|NCT02535325|Experimental|Treatment (pemetrexed, methoxyamine, cisplatin, RT)|"COURSES 1-2: Patients receive pemetrexed disodium IV over 10 minutes and methoxyamine PO day 1; and cisplatin IV over 0.5-24 hours on day 3. Patients also undergo 3-D conformal RT or IMRT QD 5 days a week (3 days of week 1 and 4 days of week 4) for 30 fractions total.~COURSES 3-4: Beginning at least 10 days after RT completion, patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 0.5-24 hours on day 1.~Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
3004183|NCT02535312|Experimental|Arm A (methoxyamine, pemetrexed disodium, cisplatin)|Patients receive methoxyamine PO on days 1-4, pemetrexed disodium IV over 10 minutes on day 1, and cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond course 6 if the patient continues to benefit from treatment at the discretion of the treating physician.
3004184|NCT02535312|Experimental|Arm B (methoxyamine, pemetrexed disodium)|Patients receive methoxyamine PO on days 1-4 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond course 6 if the patient continues to benefit from treatment at the discretion of the treating physician.
3004185|NCT02535299|Experimental|insulin|basic insulin treatment：glargine 10-30 units once a day based on the glucose control for 6 months.
3004186|NCT02535286|Experimental|Pembrolizumab + Ublituximab + TGR-1202|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Pembrolizumab IV infusion at scheduled intervals
3004187|NCT02535273|Experimental|Low-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery"
3004188|NCT02535273|Experimental|Moderate-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery"
3004189|NCT02535273|Experimental|High-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery"
3004190|NCT02535273|Placebo Comparator|normal saline Control group|Intravenous injection normal saline equal quantity，completed within 10 minutes. Local anesthesia: lidocaine Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
3004191|NCT02535260||Fertility Monitor|Clearblue Fertility Monitor
3004192|NCT02535247|Experimental|Treatment|MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles
3004193|NCT02535221|Experimental|Endocrine therapy;|Interventions：Goserelin+TAM+AI：Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.
3004194|NCT02535221|Active Comparator|Chemotherapy|Interventions：Epirubicin+CTX+5-Fu：Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
3004195|NCT02535208|Experimental|Restrictive transfusion group|
3004196|NCT02535208|Active Comparator|Liberal transfusion group|
3004197|NCT02535195|Active Comparator|Ginger|Participants were randomly divided based on age, sex and severity of steatosis in two groups. Randomization lists were computer-generated by a statistician and participants, project managers and employees at the clinic were completely unaware (blind) about intervention and control groups. At the first visit, baseline data were gathered and patients advised to consume 2 capsules content 500 mg of ginger (made in Green Plants of Life Pharmaceutics Co., Iran) or placebo (starch) one hour after breakfast and two capsules after dinner for 3 weeks. Capsules was administrated for all patients in the first week for 3 weeks and in each visit new series of supplement was prescribed.
3004198|NCT02535195|Placebo Comparator|Placebo|2 capsules content 500 mg of placebo(starch) (made in Green Plants of Life Pharmaceutics Co., Iran) one hour after breakfast and two capsules after dinner for 3 weeks. Capsules was administrated for all patients in the first week for 3 weeks and in each visit new series of supplement was prescribed.
3004199|NCT02535182||Control Arm|Patients who participate as controls on the main study will be controls on this ancillary study. The control arm will have blood drawn at baseline, day -2 and day -28 for the Rap1 testing.
3004200|NCT02535182||Propranolol Arm|Patients who participate on the propranolol arm on the main study will be on the propranolol arm on this ancillary study. The propranolol arm will have blood drawn at baseline, day -2 and day -28 for the Rap1 testing.
3004201|NCT02535169|Experimental|Health Education and Coaching|1. To evaluate whether a health education and coaching strategy in overweight and obese adolescents (≥85th percentile) with high risk for type 2 diabetes is superior to usual care (single nutrition consultation) for weight management, clinical health outcomes (measures of glucose tolerance), lifestyle behavior outcomes (diet and physical activity) and outcomes of importance to patients such as satisfaction with the health care team, treatment goals, and psychosocial functioning.
3004202|NCT02535169|Placebo Comparator|Usual Care|1. Dietary consult only
3004203|NCT02535156|Experimental|Schizotypal Personality Disorder|Schizotypal Personality Disorder (SPD) patients. They received two interventions: risperidone 1 mg and placebo (lactose).
3004204|NCT02535156|Experimental|Healthy controls|Control group consisting of healthy volunteers.They received two interventions: risperidone 1 mg and placebo (lactose).
3004205|NCT02535143|Experimental|Test Group|Group will prepare a test cavity in an acrylic block. They will receive 250 ml of a commercially available energy drink containing caffeine and taurine (Red Bull, Red Bull GmBh Austria) three hours after the last meal. The participants will then be required to perform a post intervention test cavity preparation 30 minutes after consuming the drink.
3004206|NCT02535143|Placebo Comparator|Control Group|Group will prepare a test cavity in an acrylic block. They will receive 250ml of a commercially available carbonated apple juice (Appy Fizz, Parle Agro, Mumbai, India) three hours after the last meal. The participants will then be required to perform a post intervention test cavity preparation 30 minutes after consuming the drink.
3004207|NCT02535130|Experimental|Nebulization combined to positive expiratory pressure|Experimental arm
3004208|NCT02535130|Active Comparator|Nebulization|Control arm
3004209|NCT02535117|Experimental|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
3004210|NCT02535117|Active Comparator|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
3004211|NCT02535104|Experimental|Treatment group|1 mg/ml solution of ranpirnase applied twice daily
3004212|NCT02535104|Placebo Comparator|Control|Vehicle - innert gel
3004213|NCT02535091|Experimental|YKP3089 Adjunctive Therapy|
3004214|NCT02535078|Experimental|Arm 1|IMCgp100 with durvalumab (MEDI4736)
3004215|NCT02535078|Experimental|Arm 2|IMCgp100 with tremelimumab
3004216|NCT02535078|Experimental|Arm 3|IMCgp100 with durvalumab (MEDI4736) and tremelimumab
3004217|NCT02535078|Experimental|Arm 4|IMCgp100 (single agent)
3004218|NCT02535065|Experimental|Endovascular Graft|The Zenith Low Profile AAA Endovascular Graft and ancillary components
3004219|NCT02535052||Chronic Kidney Disease (CKD) patients|Any gender, aged 65 years and over. Chronic kidney disease with eGFR between 15 and 60 ml/min. No immunological cause of kidney disease. Not immunosuppressed. To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
3004220|NCT02535052||Healthy Control subjects|Any gender, aged 65 years and over. No known renal disease and eGFR 60ml/min or greater. Not immunosuppressed. To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
3004221|NCT02535039|Placebo Comparator|Placebo|Before anesthesia induction, with electroacupuncture can cave, inside the closed cavity, foot three mile point, cupping model for continuous wave type, current pulse frequency of 2 hz, adjust the intensity of the electric acupuncture, with patients complained of needle feeling, can accept no pain and discomfort.Intraoperative sustained electroacupuncture.The same volume of physiological saline will be given.
3004222|NCT02535039|Experimental|Methylprednisolne|in the anaesthesia to 1 mg/kg intravenous methylprednisolone, methylprednisolone continuous use 1 mg/kg * d until the third day after surgery.Before anesthesia induction, with electroacupuncture can cave, inside the closed cavity, foot three mile point, cupping model for continuous wave type, current pulse frequency of 2 hz, adjust the intensity of the electric acupuncture, with patients complained of needle feeling, can accept no pain and discomfort.Intraoperative sustained electroacupuncture.
3004223|NCT02535026||Breast Cancer Participants|Breast tissue samples from female participants with a breast cancer diagnosis that undergo an anatomopathological examination of surgical specimens and/or core needle biopsies will be considered for analysis in this study.
3004224|NCT02535013|Placebo Comparator|Control|No intervention during the perioperative period. Perform lung ultrasound twice only for the diagnostic purpose at the end of surgery and 6 to 12 hours after surgery in the intensive care unit.
3004225|NCT02535013|Active Comparator|Ultrasound|Perform lung ultrasound three times during the perioperative period; after the induction of general anesthesia, at the end of surgery, and 6 to 12 hours after surgery in the intensive care unit. According to the lung ultrasound finding, conduct appropriate interventions such as, alveolar recruitment maneuver for atelectasis, or chest tube insertion for pneumothorax.
3004226|NCT02535000|Experimental|Group C (control)|subjects who will receive one capsule of placebo before the surgery and being repeated the next day
3004227|NCT02535000|Active Comparator|Group D (duloxetine)|subjects who will receive one capsule of duloxetine 60 mg before the surgery and being repeated the next day
3004228|NCT02534987|Experimental|iCPR2 intervention|EMR integrated clinical prediction rule system guiding antibiotic prescription choices for strep and pneumonia
3004229|NCT02534987|No Intervention|iCPR2 control|Standard education/academic detailing on appropriate treatment of strep and pneumonia
3004230|NCT02534961|Active Comparator|prophylactic antibiotics group|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy.
3004231|NCT02534961|No Intervention|on-demand antibiotics group|Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established.
3004232|NCT02534948|Experimental|Mindfulness and acceptance group therapy|The intervention group will consist of female participants who will be provided MABT in a group.The intervention will consist of 10 group therapy sessions. Each session will be conducted for 120 minutes.
3004233|NCT02534948|No Intervention|wait list control group|The control group will be the waiting list control group will receive no interventions in the first stage.
3004234|NCT02534935|Experimental|rLP2086 vaccine|"Arm stratified by age:~≥12 to <18 months and ≥18 to <24 months"
3004235|NCT02534935|Active Comparator|Control|"Arm stratified by age:~≥12 to <18 months and ≥18 to <24 months"
3004237|NCT02534909|Experimental|LFG316|During the treatment period, all patients will receive LFG316
3004241|NCT02534883|Active Comparator|Group 1|Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol).
3004242|NCT02534883|Placebo Comparator|Group 2|Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery.
3004243|NCT02534870|Experimental|ABT-450/r/ABT-267 + ABT-333|ABT-450/r/ABT-267 will be administered once daily in the morning and ABT-333 will be administered in the morning and evening for 14 days.
3004244|NCT02534857|Experimental|Intervention arm|Those allocated to the intervention arm, all the oocytes will be exposed to spermatozoa for 2 hours and gently wash through two organ dishes containing 1.5 ml of equilibrated medium, and then transferred to the corresponding microdroplet of equilibrated fresh medium. Surrounding cumulus cell will be retained, not removed from the ooctyes.
3004245|NCT02534857|Placebo Comparator|Control arm|Women who allocated to the control arm, all the oocytes will be exposed to spermatozoa for 20 hours, and checked for fertilization on day 1 (20 hours) after denuding
3004246|NCT02534844|Experimental|VTS-270|"Part A: Three (3) different VTS-270 lumbar intrathecal doses (900 mg, 1200 mg, and 1800 mg) administered IT every 2 weeks for 8 weeks in 9 subjects; 3 subjects will receive sham treatment. Dose for Part B to be selected for the remainder of the study.~Part B: Approximately 51 subjects, including 12 from Part A, will receive lumbar intrathecal infusions of VTS-270 or sham (randomized 2:1) every 2 weeks for a total of 52 weeks.~Part C: Open-label extension with IT treatment every 2 weeks.~All subjects (sham and drug-treated) with clinically defined worsening following > 6 months of treatment in Part B will be eligible to enter Part C.~All subjects who complete Part B will be eligible to enter Part C."
3004247|NCT02534844|Sham Comparator|Sham Procedure Control|Sixteen (16) subjects, including 3 from Part A.
3004248|NCT02534831|Experimental|Soft Tissue Manual Therapy Protocol|Soft tissue manual therapy protocol. Seven techniques of manual therapy in 30 minutes.
3004249|NCT02534818|Experimental|Group 1|lower fluorescein sodium dosage 0.02ml/kg for gastric intestinal metapalsia
3004250|NCT02534818|Active Comparator|Group 2|conventional fluorescein sodium dosage 0.1ml/kg for gastric intestinal metapalsia
3004251|NCT02534805||Patient Buddy|Subjects and caregivers will be given iphones loaded with the App that will be used to enter medications, issues and orientation questions. They will be seen at day 15 and day 30 and will receive a phone call day 7 and day 21 inquiring about issues that would need medical attention
3004252|NCT02534792||Revalvulation time early|Early revalvulation by homograft or percutaneous valve
3004253|NCT02534792||Revalvulation time late|Late revalvulation by homograft or percutaneous valve
3004254|NCT02534779|Experimental|Placebo Vaginal Insert|Placebo insert
3004255|NCT02534766||Patients who attended the MISSION COPD clinics|COPD patients who attended the MISSION COPD clinics, identified as having uncontrolled or potentially severe COPD or unrecognised COPD from GP records by the MISSION clinical team
3004256|NCT02534766||Health Care Professionals|Health Care Professionals who attended the MISSION COPD clinics in a professional/ clinical capacity.
3004257|NCT02534753|Experimental|Single Group|
3004258|NCT02534740|Experimental|4 soft gel capsules of 20 mg tafamidis meglumine|
3004259|NCT02534740|Experimental|48.8 mg tafamidis soft gel capsule formulation 1|
3004260|NCT02534740|Experimental|48.8 mg tafamidis soft get capsule formulation 2|
3004261|NCT02534740|Experimental|61 mg tafamidis soft gel capsule formulation 1|
3004262|NCT02534740|Experimental|61 mg tafamidis soft gel capsule formulation 2|
3004263|NCT02534714||Retrospective (Part 1) Group|This is a retrospective pilot study in patients diagnosed with any form of spinal disease who underwent spinal fusion at OSF/INI by Dr. Daniel Fassett, MD, MBA, Neurosurgeon from November 1, 2012 to October 31, 2014. Only spinal fusion patients with a serum Vitamin D level prior to or at time of surgery and after surgery are included in this review. The following variables will be utilized to characterize the sample: age, sex, ethnicity, BMI, smoking history, pre-op Vitamin D level and supplement given. The charts reviewed will belong to subjects who were closely followed at the OSF/INI clinic.
3004264|NCT02534714||Prospective (Part 2) Group|"This is a prospective pilot study in subjects diagnosed with any form of spinal disease that underwent cervical, thoracic, and/or lumbar spinal fusion at OSF/INI by Dr. Daniel Fassett, MD, MBA, Neurosurgeon from July 1, 2015 to June 30, 2016.~(Screening period July 1, 2015-June 30, 2016)~Only spinal fusion patients with a serum Vitamin D level, and Bone Marrow Density prior to or at time of surgery are included in this study. The following variables will be utilized to characterize the sample: age, sex, ethnicity, BMI, smoking history, pre-op Vitamin D level and supplement given. The subjects were closely followed at the OSF/INI clinic post-operatively at 3, 6, and 12 months. Pre-op Vitamin D level and Bone Marrow Density will be measured at the baseline, and again at 3, 6, and 12 months."
3004265|NCT02534701||ERIC® and SOFIA™|ERIC® device in combination with SOFIA™ Distal Access Catheter
3004266|NCT02534688|Experimental|LNG-IUS group|Single intervention LNG IUS
3004267|NCT02534688|Experimental|DMPA group|Three intervention DmPA 12 wk apart
3004268|NCT02534662|Experimental|Treatment Arm|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
3004269|NCT02534649|Other|Experimental|Newly obtained biopsy and Blood samples collection
3004270|NCT02534636|Experimental|Part A: Single ascending dose|BMS-986165 or Placebo specified dose on specified days
3004271|NCT02534636|Experimental|Part B: Multiple ascending dose|BMS-986165 or Placebo + Interferon alpha-2a recombinant specified dose on specified days
3004272|NCT02534636|Experimental|Part C: Multiple ascending dose|BMS-986165 or Placebo specified dose on specified days
3004273|NCT02534636|Experimental|Part D: Relative Bioavailability|BMS-986165 (Liquid) + BMS-986165 (Capsule) + Famotidine specified dose on specified days
3004274|NCT02534623|Active Comparator|Spinal anesthesia|Transurethral resection of the bladder performed under spinal anesthesia.
3004275|NCT02534623|Active Comparator|General anesthesia|Transurethral resection of the bladder performed under general anesthesia.
3004276|NCT02534610|Experimental|Group ETORICOXIB PREOP|Preoperative (1 h) per os (PO) 120 mg Etoricoxib (Arcoxia) and 1 placebo pill PO at the end of surgery.
3004277|NCT02534610|Experimental|Group ETORICOXIB POSTOP|Preoperative (1 h) 1 placebo pill PO and 120 mg Etoricoxib PO at the end of surgery (Arcoxia).
3004278|NCT02534610|Placebo Comparator|Group PLACEBO|1 placebo pill PO 1 h preoperative and 1 placebo pill PO postoperative at the end of surgery.
3004279|NCT02534597|Experimental|pctm|Receives the earliest Promotores training, followed by direct caregiver training, materials support, and technical assistance.
3004280|NCT02534597|Experimental|p_ctm|Receives the earliest Promotores training, followed by delayed caregiver training, delayed materials support, and delayed technical assistance.
3004281|NCT02534597|Experimental|_pmt|Receives the delayed Promotores training, followed by receipt of materials support and technical assistance.
3004282|NCT02534597|Experimental|_p_mt|Receives the delayed Promotores training, followed by delayed receipt of materials support and technical assistance.
3004283|NCT02534597|Experimental|_pct|Receives the delayed Promotores training, followed by caregiver training and technical assistance.
3004284|NCT02534597|Experimental|_p_ct|Receives the delayed Promotores training, followed by delayed caregiver training and technical assistance.
3004285|NCT02534597|Experimental|_pt|Receives the delayed Promotores training, followed by technical assistance.
3004286|NCT02534597|Experimental|_p_t|Receives the delayed Promotores training, followed by delayed technical assistance.
3004287|NCT02534597|Experimental|_pc|Receives the delayed Promotores training, followed by a full caregiver training only.
3004288|NCT02534597|Experimental|_p_c|Receives the delayed Promotores training, followed by delayed caregiver training.
3004289|NCT02534571|Experimental|TC-325|Endoscopic Application of a Hemostatic Powder TC-325, <=150gm , once
3004290|NCT02534571|Active Comparator|standard treatment|standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine <=20 clip or4 pulse , once only
3004291|NCT02534558|Experimental|miR-29a precursor oligonucleotide|Effects of IL-1β, miR-29a precursor oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
3004292|NCT02534558|Experimental|miR-29a antisense oligonucleotide|Effects of IL-1β, miR-29a antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
3004293|NCT02534545|Experimental|Doctormate® (200mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) once daily for 12 months
3004294|NCT02534545|Sham Comparator|Doctormate® (60mmHg)|Patients will be treated with the Renqiao Remote Ischemic Conditioning Device (Doctormate®) (60mmHg) once daily for 12 months
3004295|NCT02534532||Cohort 1|Females and males ≥65 years old, attending to the primary care centers, located in three different major cities in Colombia, that are willing to participate in the study, and do not present any exclusion criteria
3004296|NCT02534519||people negative in bg MNSs antigen U|"Blood group (bg) system MNSs. Individuals with phenotype U-. Homo- and heterozygous individuals may be considered."
3004297|NCT02534519||people positive in bg MNSs antigen St(a)|"Blood group (bg) system MNSs. Individuals with phenotype St(a)+. Homo- and heterozygous individuals may be considered."
3004298|NCT02534506|Experimental|Urelumab (+ Nivolumab) intravenous (IV) infusion|
3004299|NCT02534493|Experimental|Carpal Tunnel Medical Device (CTMD)|Carpal Tunnel Tissue Manipulation Device (CTMD)
3004300|NCT02534480|Active Comparator|NGP 555 25 mg|NGP 555 25 mg capsule and placebo by mouth once per day
3004301|NCT02534480|Active Comparator|NGP 555 50 mg|NGP 555 50 mg capsule and placebo by mouth once per day
3004302|NCT02534480|Active Comparator|NGP 555 100 mg|NGP 555 100 mg capsule and placebo by mouth once per day
3004303|NCT02534480|Active Comparator|NGP 555 200 mg|NGP 555 200 mg capsule and placebo by mouth once per day
3004304|NCT02534480|Active Comparator|NGP 555 300 mg|NGP 555 300 mg capsule and placebo by mouth once per day
3004305|NCT02534467|Experimental|Montelukast-Standard|8 weeks of montelukast and standard therapy crossing over to 8 weeks of only standard therapy
3004306|NCT02534467|Active Comparator|Standard-Montelukast|8 weeks of standard therapy only crossing over to 8 weeks of montelukast and standard therapy
3004307|NCT02534454|Experimental|Active TDCS + Active Retraining|2.0 milliamperes (mA) of transcranial direct current stimulation (TDCS) applied during active nicotine avoidance retraining
3004308|NCT02534454|Experimental|Sham TDCS + Active Retraining|0.1 mA of transcranial direct current stimulation (TDCS) applied during active nicotine avoidance retraining
3004309|NCT02534454|Experimental|Active TDCS + Sham retraining|2.0 mA of transcranial direct current stimulation (TDCS) applied during sham nicotine avoidance retraining
3004310|NCT02534454|Experimental|Sham TDCS + Sham Retraining|0.1 mA of transcranial direct current stimulation (TDCS) applied during sham nicotine avoidance retraining
3004311|NCT02534441|Experimental|Skin patch testing to 6 known and 3 novel surfactants|
3004312|NCT02534428|Experimental|wool-first (wool-standard)|superfine merino wool clothing to be worn for 6 weeks followed by 6 weeks of standard clothing (cotton)
3004313|NCT02534428|Active Comparator|cotton-first (standard-wool)|standard (cotton) clothing to be work for 6 weeks followed by 6 weeks of superfine merino wool clothing
3004314|NCT02534415|Active Comparator|Periodontal dressing material|Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
3004315|NCT02534415|Experimental|0.2% Hyaluronic acid gel|0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
3004316|NCT02534415|Experimental|0.8% Hyaluronic acid gel|0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
3004317|NCT02534402|Experimental|Prednisone Group|30mg of prednisone PO (orally) everyday for 5 days.
3004318|NCT02534402|No Intervention|Control Group|no treatment
3004319|NCT02534389|Experimental|fish oil group|4 soft gel with omega-3 fish oil
3004320|NCT02534389|No Intervention|control group|without intervention
3004321|NCT02534376|Experimental|Treatment|Vytorin (ezetimibe 10mg-simvastatin 40mg)
3004322|NCT02534363|Active Comparator|Aripiprazole & cognitive battery|Aripiprazole 5-30 mg/day. Cognitive battery at baseline and at 1 year.
3004850|NCT02530983||Esophagectomy/Esophageal Reconstruction|Patients who have undergone esophagectomy or esophageal reconstruction
3004323|NCT02534363|Active Comparator|Quetiapine & cognitive battery|Quetiapine 100-600 mg/day. Cognitive battery at baseline and at 1 year.
3004324|NCT02534363|Active Comparator|Ziprasidone & cognitive battery|Ziprasidone 40-160 mg/day. Cognitive battery at baseline and at 1 year.
3004325|NCT02534350|Experimental|Presatovir|Presatovir for a total of 14 days
3004326|NCT02534350|Placebo Comparator|Placebo|Presatovir placebo for a total of 14 days
3004327|NCT02534337|Experimental|GEMOX|gemcitabine 1000 mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2.
3004328|NCT02534337|Active Comparator|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2.
3004329|NCT02534324||High SBP+antihypertensive meds|Patients with pre-discharge systolic blood pressure at discharge < 180 mmHg
3004330|NCT02534324||Severely high SBP+antihypertensive meds|Patients with pre-discharge systolic blood pressure at discharge >= 180 mmHg
3004331|NCT02534311||Tocilizumab|Participants will receive tocilizumab (162 milligrams [mg]) SC injection for 48 weeks.
3004332|NCT02534298|Experimental|single sided deafness|single sided deafness and asymmetrical hearing loss patients functional magnetic resonance imaging
3004333|NCT02534298|Other|control group|Normal hearing subject functional magnetic resonance imaging
3004334|NCT02534285|Sham Comparator|Control|Patients of the control group receive a Sham hearing protection with no effect on noise attenuation.
3004335|NCT02534285|Active Comparator|Intervention|Patients of the Intervention group receive a Hearing protection with a noise attenuation of 20-45 decibel.
3004336|NCT02534272||Symptomatic subjects|Subjects with intestinal symptoms
3004337|NCT02534272||Asymptomatic subjects|Subjects without intestinal symptoms
3004338|NCT02534246|Experimental|Pro Core EUS guided Fine Needle Biopsy|Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) with reverse bevel design for diagnosis of pancreatic lesions.
3004339|NCT02534246|Experimental|Shark Core EUS guided Fine Needle Biopsy|SharkCore ultrasound biopsy needle (Medtronic [Beacon] 25 gauge) with six cutting edge surfaces and an opposing bevel design for diagnosis of pancreatic lesions.
3004340|NCT02534233|Experimental|CryoBalloon ablation|Patients having ablation of dysplastic tissue in esophagus.
3004341|NCT02534220|Active Comparator|Manual Toothbrush|Patients were instructed in the Roll Brushing Technique, twice daily for 2 min.
3004342|NCT02534220|Experimental|Oscillating-rotating toothbrush|Patients received manufacturer's instructions for use, including brushing twice daily for 2 min.
3004343|NCT02534207|Experimental|Basmisanil in Japanese Healthy Volunteers|Japanese healthy volunteers will receive a single oral dose of RO5186582 within 15 minutes after completing a standard meal.
3004344|NCT02534194||Newborn Infant|Newborn babies (within 7 days of birth) born between 23-42 weeks.
3004345|NCT02534181|Active Comparator|Intervention group|"Patients will undergo a caloric management protocol:~Days 1 and 2:~Reduction of caloric intake to 5kcal/kg/day;~Replacement of serum phosforus, potassium and magnesium;~Administration of 100mg intravenous thiamine, vitamins and microelements.~From day 3:~If serum phosphorus < 2.5mg/dL, protocol will be followed according to day 2;~If serum phosphorus > 2.5mg/dL, a gradual increase to target caloric intake will ensue."
3004346|NCT02534181|No Intervention|Control group|"Nutritional management will be followed according to institutional protocol.~Electrolyte replacement will be provided at the clinician's discretion."
3004347|NCT02534168|Experimental|skin conductance|The skin conductance monitor will be applied to all study patient. There is no second arm to the study
3004348|NCT02534155|Active Comparator|MitraClip® Therapy|MitraClip® system is a CE marked medical device, which consists of two parts (Clip Delivery System and Steerable Guide Catheter). It is a single sized, percutaneously implanted mechanical Clip. The MitraClip® device grasps and coapts the mitral valve leaflets resulting in fixed approximation of the mitral leaflets throughout the cardiac cycle. The procedure is performed in the cardiac catheterisation laboratory with echocardiographic and fluoroscopic guidance while the patient is under general anaesthesia.
3004349|NCT02534155|Active Comparator|Surgery|Surgical therapy of degenerative mitral regurgitation: repair or replacement of mitral valve, clinical standard
3004350|NCT02534142||Completed followup|All members aged 50-74 who completed a fecal occult blood test between 1/1/2014 and 1/1/2015, who had a positive result and had a colonoscopy following the result.
3004351|NCT02534142||Did not complete followup|All members aged 50-74 who completed a fecal occult blood test between 1/1/2014 and 1/1/2015, who had a positive result and did not have a colonoscopy following the result.
3004352|NCT02534129|Experimental|Single Arm|Radiation field is divided into two sections, one treated with Difinsa53 and the other with Aquaphor
3004353|NCT02534116|Experimental|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will have incisional vacuum-assisted closure (VAC) therapy performed.
3004354|NCT02534116|Active Comparator|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision.
3004355|NCT02534090||Feeding Intolerant Preterm Infants|32 weeks to 36 weeks 6 days old of post menstrual age infants, feeding intolerants monitored with INVOS device for rSO2
3004356|NCT02534090||Feeding Tolerant Preterm Infants (Controls)|32 weeks to 36 weeks 6 days old of post menstrual age infants without problems through the enteral feedings.
3004357|NCT02534077|Experimental|1|Drug: Omegaven
3004358|NCT02534064|Experimental|Group A: 2 yogurts|consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
3004359|NCT02534064|Experimental|Group B: 1 yogurt|consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product during 8 weeks.
3004360|NCT02534064|No Intervention|Group C: No yogurt|no changes in dietary habits during 24 weeks.
3004361|NCT02534051|Active Comparator|Clinical care pathway|The intervention is the clinical care pathway designed by investigators, informed by the national guideline co-authored by one of the team, and supplemented by the review of the literature
3004362|NCT02534051|No Intervention|Usual Care|The control group will receive the usual prenatal care.
3004363|NCT02534038|Placebo Comparator|Placebo|Placebo drug to be taken twice a day for 6 weeks
3004745|NCT02531685|Experimental|Cohort 5|Up to 31 subjects receive TBD mcg dmLT intradermally on days 1, 22 and 43. 4 subjects receive placebo.
3004364|NCT02534038|Active Comparator|AVP-786|Participants randomized to AVP-786 will take one dose of AVP-786 once a day and one dose of placebo once a day for the first 7 days; from day 8, participants will receive AVP-786 twice a day for 5 weeks.
3004365|NCT02534025|Experimental|P group|Elevation of Cuff pressure to 200 mm Hg for 5 minutes four times 5 minutes apart
3004366|NCT02534025|No Intervention|C group|no intervention will be added to routine anesthetic mangement
3004367|NCT02534012|Experimental|PVB group|Patients will receive nerve stimulator guided paravertebral block
3004368|NCT02534012|Experimental|GA group|Patients will receive general anesthesia
3004369|NCT02533999|Experimental|Surgical Instrument|"PEAK® Plasma Surgery System [PEAK PlasmaBlade® TnA Tonsil and Adenoid Tissue Dissection Device] (Medtronic, Inc) is a marketed device. The PEAK® system generates plasma, an electrically conductive cloud produced when radiofrequency energy contacting tissue and the tissue breaks down. The system was designed to have the precision of a scalpel, minimal bleeding as with electrosurgery, but reduced collateral thermal tissue damage. The PEAK® Plasma System setting will be standardized for tonsils, to 2 for coagulation and 1 for cutting; and for adenoids, to 7 for coagulation, and 7 for cutting."
3004370|NCT02533999|Active Comparator|Electrosurgery|Electrosurgery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to achieve hemostasis or varying degrees of tissue destruction. It is commonly used for tonsillectomy and adenoidectomy in pediatric patients. The electrocautery setting will be standardized to 12 for tonsils and 30 for adenoids.
3004371|NCT02533986|Placebo Comparator|Control drink|Dietary supplement: Control drink As control, subjects are asked to consume 150 ml control drink containing equal amount of insoluble fiber (cellulose) and sugar for 28 days. In addition, on days-1 and 28, subjects will receive an acute challenge of placebo drink at our clinical facility. After 30 min. control drink intake, subjects will be given standardized breakfast corresponding to 50 g available carbohydrates.
3004372|NCT02533986|Experimental|Berry peel drink|Dietary supplement: Berry peel drink Subjects are asked to consume 150 ml experimental drink containing a berry peel fruit powder. In addition, on days-1 and 28, subjects will receive an acute challenge of test drink at our clinical facility. After 30 min. berry drink intake, subjects will be given standardized breakfast corresponding to 50 g available carbohydrates.
3004373|NCT02533973|Active Comparator|Xamiol® gel|calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as diproprionate) once daily as required, for up to 28 weeks
3004374|NCT02533973|Active Comparator|. Daivonex® scalp solution|calcipotriol 50mcg/g twice daily as required, for up to 28 weeks
3004375|NCT02533960||NOAC|"Ischemic stroke substudy: inclusion of 1000 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs).~Hemorrhagic stroke substudy: inclusion of 334 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs)."
3004376|NCT02533960||VKA|"Ischemic stroke substudy: inclusion of 1000 patients under treatment with vitamin K antagonists (VKA).~Hemorrhagic stroke substudy: inclusion of 333 patients under treatment with vitamin K antagonists (VKA)"
3004377|NCT02533960||Without OAC|"Ischemic stroke substudy: inclusion of 1000 patients without oral anticoagulation.~Hemorrhagic stroke substudy: inclusion of 333 patients without oral anticoagulation."
3004378|NCT02533947|Experimental|Exercise group|The exercise program will be developed through a pilot phase with 10 patients prior to the start of the main study.
3004379|NCT02533947|Other|Control group|A waitlist control group will get the intervention after 7 month of treatment as usual.
3004380|NCT02533934|Experimental|Study Drug|Treatment with Harvoni
3004381|NCT02533921|Other|Standard of Care|Usual care as in including both a Primary Care Physician (PCP) and neurologist.
3004382|NCT02533921|Active Comparator|Interdisciplinary outpatient palliative care|Usual care augmented by an outpatient interdisciplinary palliative care team.
3004383|NCT02533908|Active Comparator|Fentanyl intranasal|Fentanyl Sintetica 0.1mg/2ml: 1.5ug/kilogram intranasal= 0.03ml/kg once
3004384|NCT02533908|Placebo Comparator|NaCl 0.9% intranasal|NaCl 0.9% Sintetica 18mg/2ml: same dosage as fentanyl= 0.03ml/kg
3004385|NCT02533895|Experimental|Treatment with AV0113|"14 sarcoma and 7 non-sarcoma are treated with AV0113, an anti-tumour immune therapy with autologous DCs loaded with tumour cell lysates in order to establish the feasibility and safety of tumour vaccination.~Peripheral blood mononuclear cells (MNCs) are obtained from patients by leukocyte apheresis. Monocytes enriched by density gradient centrifugation from MNCs will be used to generate immature DCs. These immature DCs will be loaded with autologous tumour cell lysates obtained by needle biopsy or surgery prior to tumour vaccination. The antigen loaded immature DCs will then receive a final maturation stimulus transmitted by exposure to lipopolysaccharide and interferon-gamma. Maturation enables DCs to present antigen with high efficiency to T-lymphocytes."
3004386|NCT02533895|Other|Historic control|In order to be able to compare the survival data of 14 sarcoma patients treated with AV0113, 42 historic control sarcoma patients from the data base of the Department of Orthopaedics, Medical University Vienna, that will be matched for disease, recurrences, relapses etc. will be included into this study.
3004387|NCT02533882|Experimental|Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors.
3004388|NCT02533882|Active Comparator|Adapted Yoga|Yoga classes will consist of postures adapted by qualified yoga instructors who have extensive experience in disability.
3004389|NCT02533882|No Intervention|Waitlist Control|This group will receive biweekly newsletters on a variety of topics. At the end of this trial, they will receive a home based intervention.
3004390|NCT02533869|Experimental|Low-dose CT for acute appendicitis|Low-dose computed tomography for diagnosing acute uncomplicated appendicitis Laparoscopic appendectomy
3004391|NCT02533856|No Intervention|Usual Care|Discharge from emergency department by usual care
3004392|NCT02533856|Experimental|ETOC|Discharge from emergency department with increased support services provided by BoardRounds after ED discharge
3004393|NCT02533843|Active Comparator|Arm I|ablation at sources guided by FIRMap (using RhythmView™ Workstation from TOPERA) Intervention: AF ablation
3005098|NCT02529332|Experimental|Omega-3 Supplementation Group|Omega-3 supplementation
3005099|NCT02529332|No Intervention|Control Group|
3004394|NCT02533843|Active Comparator|Arm II|ablation at sources guided by FIRMap (using RhythmView™ Workstation from TOPERA) + conventional pulmonary vein antrum isolation (PVAI) Intervention: AF ablation
3004395|NCT02533843|Active Comparator|Arm III|Extended PVAI plus ablation of non-PV triggers and complex fractionated atrial electrograms (CFAE) Intervention: AF ablation
3004396|NCT02533830|Active Comparator|gum chewing group.|"Group A (81 Women) Who Received One Stick of Sugarless Gum (Samara for food & Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation"
3004397|NCT02533830|Placebo Comparator|Placebo group|Group B (81 Women) had Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
3004398|NCT02533817|Experimental|Dietary Sugar - Fructose|Each participant consumed 20% daily caloric requirement as fructose.
3004399|NCT02533817|Active Comparator|Dietary Sugar - Glucose|Each participant consumed 20% daily caloric requirement as glucose.
3004400|NCT02533791|Experimental|low dose group|4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)
3004401|NCT02533791|Experimental|high dose group|1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)
3004402|NCT02533791|Placebo Comparator|placebo group|placebo
3004403|NCT02533778|Experimental|Interventional mechanical thrombectomy|Mechanical thrombectomy with either Penumbra system, TREVO, or Solitaire device for acute stroke symptom onset between 8 - 24 hours
3004404|NCT02533765|Experimental|Olaparib|Olaparib 300mg twice daily continuously
3004405|NCT02533752||Main Group|This an observational registry - there is only one group
3004406|NCT02533739|Experimental|Patient group|This group will consist of vestibular patients and/or participants with vertigo.
3004407|NCT02533739|Sham Comparator|Control group|This group will consist of participants without vestibular/vertigo impairments.
3004408|NCT02533726|Experimental|Treatment - Optimal Turning|All patients will have a sensor applied. Patients within this arm will receive care from nurses who have access to a User Dashboard that provides visual advisories for patient turning, based on data obtained from a wearable patient sensor (Leaf Healthcare, Inc.).
3004409|NCT02533726|Active Comparator|Control - Standard Care|All patients will have a sensor applied. Patients within this arm will receive care from nurses who DO NOT have access to a User Dashboard that provides visual advisories for patient turning. Instead, these patients will receive standard care practices, patient turning initiated by nurses as necessary.
3004410|NCT02533713|Experimental|Immediate gait training|Participants assigned to this arm will begin Exoskeleton assisted gait training right away and will continue training for the first 6 months of the study.
3004411|NCT02533713|Other|Delayed gait training|Participants assigned to this arm will not gait train for 6 months. They will engage in Exoskeleton assisted gait training for the last 6 months of the study.
3004412|NCT02533700|Experimental|CEOP/IVE/GDP chemotherapy regimen|2 cycles of CEOP(cyclophosphamide,vincristine, pharmorubicin and prednisone),2 cycles of IVE(ifosfamide, pharmorubicin, etoposide phosphate)and 2 cycles of GDP(gemcitabine, cis-platinum, and dexamethasone)
3004413|NCT02533700|Active Comparator|CEOP chemotherapy regimen for 6 cycles|6 cycles of CEOP regimen(cyclophosphamide,vincristin,pharmorubicin and prednisone)
3004414|NCT02533687|Active Comparator|Bipolar TURP-1|Transurethral resection of prostate (TURP) with bipolar resectoscope (Gyrus brand)
3004415|NCT02533687|Active Comparator|Bipolar TURP-2|TURP with bipolar resectoscope (Olympus brand)
3004416|NCT02533687|Active Comparator|Monopolar TURP|TURP with monopolar resectoscope (Karl Storz brand)
3004417|NCT02533674|Experimental|gemcitabine plus PM060184|
3004418|NCT02533661|Experimental|Family-centered intervention program|"The FCIP group received:~In-hospital intervention: modulation of the NICU, teaching of child development skills, feeding support,massage,parent support and education,transition home preparation.~After-discharge: clinic (1, 2, 4, 9 months) and home visits (0, 6, 12 months) for teaching of child development skills, feeding support, dyadic interaction activities, modulations of home environment, parent support and education."
3004419|NCT02533661|No Intervention|Usual care program|"The UCP group received:~In-hospital intervention: environmental modulation and teaching of child development skills.~After-discharge:telephone calls (0, 1, 2, 4, 6, 9 and 12 months): consultation on general care concerns"
3004420|NCT02533648|Experimental|Allopurinol|Allopurinol, experimental arms, type 2 diabetes subjects receive 2 capsules of allopurinol 150 mg daily for 3 month
3004421|NCT02533648|Placebo Comparator|Placebo|Placebo, type 2 diabetes subjects receive 2 capsules of lactose (placebo) daily for 3 month
3004422|NCT02533635|Experimental|A-first intervention|Subjects in Arm A receive Ganoderma tea (30g) daily for 8 weeks initially, followed by 8 weeks no intervention.
3004423|NCT02533635|Experimental|B-second intervention|Subjects in Arm B receive no intervention for 8 weeks initially, followed by receiving Ganoderma tea (30g) daily for 8 weeks .
3004424|NCT02533622||Standard of care|Patients admitted to the ICU will receive current standard of care related to mobility
3004425|NCT02533622||Progressive mobility|patients admitted to the ICU will receive mobility per Progressive Mobility protocol using TotalCare beds and lifts
3004426|NCT02533609||Piperacillin/Tazobactam|Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics
3004427|NCT02533609||Imipenem/Cilastatin|Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics
3004428|NCT02533583||symptomatic newborn|the symptomatic newborn cohort( symptomatic definition see detail),all of babies will referred for chest X-ray,and within 2 hours performing echocardiography to exclude critical and serious heart disease.All clinical assessment will do by attending doctor.
3004429|NCT02533583||Asymptomatic newborn|the asymptomatic newborn cohort will gave pulse oximetry and clinical assessment every 8 hours within 3 days.everybody have positive results will been preformed chest X-ray and echocardiography.All clinical assessment will do by attending doctor.
3004430|NCT02533570|Experimental|Brentuximab vedotin|4 dose groups
3004431|NCT02533570|Placebo Comparator|Placebo|Matching placebo
3004461|NCT02533310|Experimental|VR-OST treatment with virtual spiders|VR-OST consists of simulated OST treatment without the use of live spiders and with the support of a virtual therapist.
3004803|NCT02531295|Experimental|Kansui 1g per day x 2 days|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 2 consecutive daily doses.
3004432|NCT02533557|Experimental|2P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced at the behind site of the initial puncture site. And the needle is penetrated the nerve sheath with a direction of upward, and then the same process is performed and LA 15 mL is injected.
3004433|NCT02533557|Active Comparator|1P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced with a direction of upward at the same puncture site and penetrated the nerve sheath. If hand muscle twitching is observed at 0.3 mA, LA 15 mL is injected.
3004434|NCT02533544||tenofovir disoproxil fumarate monotherapy|a group which treated with tenofovir disoproxil fumarate
3004435|NCT02533531|Experimental|1-Lead Outpatient Telemetry|1-Lead Outpatient Patch study participants. Patients assigned to outpatient telemetry monitoring will receive the 1-Lead patch upon discharge from hospital inpatient status. ECG data will be submitted by the 1-lead patch to a central database.
3004436|NCT02533518|Experimental|patients with lung cancer|
3004437|NCT02533505|Active Comparator|Symbicort pressurized Metered Dose Inhaler (pMDI)|Symbicort pressurized Metered Dose Inhaler (pMDI)
3004438|NCT02533505|Placebo Comparator|Placebo of reference drug|Placebo of reference drug
3004439|NCT02533492|Active Comparator|Vicryl|Vicryl suture for wound closure after total knee replacement
3004440|NCT02533492|Experimental|vicryl plus|Vicryl plus suture for wound closure after total knee replacement
3004441|NCT02533479|Experimental|Caloric restriction|three alternate days weekly along 4 weeks.
3004442|NCT02533466|Experimental|Test Product|Subjects will apply a full ribbon of dentifrice and brush their teeth for 1 timed minute using a wetted toothbrush, swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
3004443|NCT02533466|Placebo Comparator|Reference Product|Subjects will apply a full ribbon of dentifrice and brush their teeth for 1 timed minute using a wetted toothbrush, swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
3004444|NCT02533453|Experimental|Bydureon|exenatide once weekly
3004445|NCT02533440|Experimental|EXPAREL and Local Anesthetics|In the experimental group, patients will receive EXPAREL and local anesthetics, and will be prescribed opioid and non-opioid analgesics (for use only if in pain).
3004446|NCT02533440|Active Comparator|Oral Opioid and Local Anesthetics|In the control group, patients will receive local anesthetics at the time of surgery and oral opioid or non-opioid analgesics (for use only if in pain).
3004447|NCT02533427|Experimental|SOF/VEL/GS-9857+GS-9857|"Part A: Participants without a documented history of taking norgestimate/ethinyl estradiol for at least one menstrual cycle will receive norgestimate/ethinyl estradiol. Participants with a documented history of taking norgestimate/ethinyl estradiol may enroll directly into Part B of the study.~Part B: Participants will continue taking norgestimate/ethinyl estradiol for the remainder of the study and will receive SOF/VEL/GS-9857 FDC plus GS-9857."
3004448|NCT02533414|Experimental|UAS (+)|RIRS with UAS: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
3004449|NCT02533414|Active Comparator|UAS (-)|RIRS without UAS: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
3004450|NCT02533401|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants will receive rituximab (375 milligrams per meter-squared [mg/m^2] intravenously [IV]) on Cycle 1 Day 1, followed by fludarabine (25 mg/m^2 once daily IV) and cyclophosphamide (250 mg/m^2 once daily IV) for Days 2 to 4 of Cycle 1. Then rituximab (500 mg/m^2 IV) will be administered on Day 1 of Cycles 2 to 6, followed by IV fludarabine (25 mg/m^2 once daily IV) and cyclophosphamide (250 mg/m^2 once daily IV) on Days 1 to 3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length, and the overall duration of treatment will be approximately 6 months.
3004451|NCT02533388|Experimental|Electrical acupoint stimulation|Electrical acupoint stimulation at the Hegu (LI4), Neiguan (PC6), Lieque (LU7), Chize (LU5), Futu (LI18) and Renying (ST9) acupoints, Stimulus frequency was an alternate dense-disperse frequency of 2/10 Hz ( 2 Hz for 10 s and 10 Hz for 5 s). The optimal intensity ranged from 6-15 mA, which was adjusted to maintain a slight twitching of the regional muscles according to individual maximum tolerance.
3004452|NCT02533388|Sham Comparator|Sham stimulation|Sham stimulation only connected to the apparatus, but electronic stimulation was not applied.
3004453|NCT02533375|Experimental|Patients receiving adalimumab|Subcutaneous injection at Week 0 and then every other week on and after Week 2. Dose escalation is allowed for subjects who do not have appropriate response on or after Week 8.
3004454|NCT02533362|Experimental|ANF-Rho|pegfilgrastim Anti-Neutropenic Factor (ANF)
3004455|NCT02533349|Active Comparator|Proton pump inhibitor + prokinetics|Patient will be prescribed proton pump inhibitor (pantoprazole, 40mg, 1T QD) with prokinetics (Motilitone, 30mg, 1T, TID) for 3months.
3004456|NCT02533349|Placebo Comparator|Proton pump inhibitor + placebo|Patient will be prescribed proton pump inhibitor (pantoprazole, 40mg, 1T QD) with placebo (Motilitone, 30mg, 1T, TID) for 3months.
3004457|NCT02533336|Experimental|DL+LLINs|DL treated with abamectin and fenpyroximate
3004458|NCT02533336|No Intervention|LLINs|LLINs only
3004459|NCT02533323|Experimental|P-Gemox|P-Gemox:gemcitabine :1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days.
3004460|NCT02533310|Experimental|OST treatment with in-vivo spiders|OST consists of increasingly intense interactions with an in-vivo phobic stimuli and human therapist non-phobic behavior modelling.
3004462|NCT02533297|Experimental|clinical education|the researcher used the checklist to assess the student's mastery level skill l while changing a skill and recorded his score on the learning curve based on a 1 (no mastery) to 100 (complete mastery) scoring scale. This procedure continued until the learning curve reached to a plateau state, i.e. either reaching to the full mastery score (100) or revealing no significant change in three subsequent sessions. All the students achieved mastery (the plateau state) after performing the task for at most ten times.
3004463|NCT02533284|Experimental|Magnesium sulfate group|US guided TAP with magnesium sulfate
3004464|NCT02533284|Experimental|B group|TAP bupevecaine
3004465|NCT02533284|Placebo Comparator|C group|control TAP saline
3004466|NCT02533271|Experimental|Experimental group|The intervention of Experimental group is Short-course radiotherapy with neoadjuvant chemotherapy, which consists of a short-course radiotherapy (SCRT, 5 Gy x 5 alone), then after 7-10 days of radiotherapy completed, patients will receive neoadjuvant chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are prescribed preoperatively, then followed by a total mesorectal excision(TME) and postoperative adjuvant chemotherapy. If patients are eligible for postoperative chemotherapy this should consist of at least 2 cycles, which are the same as neoadjuvant chemotherapy.
3004467|NCT02533271|Other|Control group|The intervention of Control group is long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively, followed by a total mesorectal excision(TME) and then postoperative adjuvant chemotherapy. The radiotherapy is given in combination with capecitabine in a dose of 825 mg/m2 twice daily on days when radiotherapy, excluding weekends. If patients are eligible for postoperative chemotherapy this should consist of at least 6 cycles of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once every 3 weeks.
3004468|NCT02533245|Experimental|Tx exercise group|"Convenience sample of solid organ transplant recipients (heart, kidney, lung, liver, pancreas, small bowel) participating in the Transplantoux exercise training intervention.~Intervention:~Home-based individualized exercise training program~Supervised group training sessions~Climb of the Mont Ventoux"
3004469|NCT02533245|No Intervention|Tx matched control group|Controls are retrieved from the Leuven University Hospital heart, kidney, lung, liver, pancreas, small bowel transplant database and matched (1:4 matching) based on type of transplant, gender, age and time since transplant.
3004470|NCT02533245|Experimental|Healthy exercise group|"Convenience sample of health care providers (e.g. doctor, paramedic or medical companion involved in care programs for organ Tx) and patient's family members and friends participating in the Transplantoux exercise training intervention.~Intervention:~Supervised group training sessions~Climb of the mont ventoux"
3004471|NCT02533232|Placebo Comparator|placebo|Matching placebo for Minocycline
3004472|NCT02533232|Experimental|Minocycline|Minocycline 200mg once a day orally
3004473|NCT02533206|Experimental|EPIC|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic. The participant will be discharged home from the clinic following their procedure.
3004474|NCT02533206|Active Comparator|FESS|The control intervention is functional endoscopic sinus surgery (FESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia
3004475|NCT02533193|Active Comparator|enhanced recovery after surgery protocal|ERAS perioperative cares patients planned to undergoing laparoscopic gastrectomy, following the ERAS protocols.
3004476|NCT02533193|Active Comparator|Conventional perioperative cares|Conventional perioperative cares patents will be managed by our hospital's critical pathways.
3004477|NCT02533180|Other|Immunosuppression withdrawal (ISW)|Gradual immunosuppression withdrawal according to the protocol defined algorithm
3004478|NCT02533167|Experimental|skin to skin|skin to skin initiated on all consented CS while in the operating room
3004479|NCT02533154|Experimental|BAC treatment group|20 patients with mild or moderate dry eye syndrome receiving BAC containing Prosicca eyedrops for 1 month
3004480|NCT02533154|Active Comparator|non-BAC treatment group|20 patients with mild or moderate dry eye syndrome receiving preservative-free Prosicca sine eyedrops for 1 month
3004481|NCT02533141|Experimental|Intervention group|10 healthy subjects receiving at first simvastatin for 4 weeks, then crossover. Measurements will be done with the Dynamic Vessel Analyzer (DVA) and Laser Doppler Velocimetry (LDV).
3004482|NCT02533141|Placebo Comparator|Placebo group|10 healthy subjects receiving at first placebo for 4 weeks, then crossover. Measurements will be done with the Dynamic Vessel Analyzer (DVA) and Laser Doppler Velocimetry (LDV).
3004483|NCT02533128|Placebo Comparator|Liberal blood pressure management|
3004484|NCT02533128|Active Comparator|Tight blood pressure management|
3004485|NCT02533102|Experimental|Part A: E7050 100 mg tablet under fasted conditions|Participants will receive a single tablet containing 100 mg E7050 following an overnight fast.
3004486|NCT02533102|Experimental|Part A: E7050 100 mg tablet with low-fat breakfast|Participants will receive a single tablet containing 100 mg E7050 with a standard low-fat meal.
3004487|NCT02533102|Experimental|Part A: E7050 100 mg tablet with high-fat breakfast|Participants will receive a single tablet containing 100 mg E7050 with a standard high-fat meal.
3004488|NCT02533102|Experimental|Part B: E7050 200 mg tablet under fasted conditions|Participants will receive a single dose of 200 mg (two 100 mg tablets) of E7050 under fasted conditions.
3004489|NCT02533102|Experimental|Part B: E7050 400 mg tablet under fasted conditions|Participants will receive a single dose of 400 mg (four 100 mg tablets) of E7050 under fasted conditions.
3004490|NCT02533089|Experimental|KT intervention|Multifaceted KT strategy employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
3004491|NCT02533089|No Intervention|Control|Control sites will receive no intervention, with LHW training left to the discretion of the health centers TB focus LHW. Control sites will not have access to the point of care tool.
3004492|NCT02533076|Other|Cystinosis Patients|Cystinosis patients
3004493|NCT02533076|Other|Healthy volunteers|Healthy volunteers
3004591|NCT02532608|Experimental|Acute sleep deprivation|Registration of habitual sleep and sleep after sleep deprivation
3004494|NCT02533063|Active Comparator|Combination Treatment|"In the loading + vibration group (intervention group), subjects will be seated in the VibeTech One system and vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
3004495|NCT02533063|Sham Comparator|Sham Treatment|"In the loading only group (control group) participants will be seated in the vibration device (VibeTech One) and will experience loading of their leg muscles through the device."
3004496|NCT02533050|Experimental|Patients treated|Patients with CAD and SAS. This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an Epworth sleepiness score (ESS) <10. After randomization, they will be treated with CPAP treatment.
3004497|NCT02533050|No Intervention|Patients non-treated|Patients with CAD and SAS. This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an ESS <10. After randomization, they will be not treated.
3004498|NCT02533050|No Intervention|Control group|Patients with CAD but without SAS (AHI<15).
3004499|NCT02533037|Active Comparator|Traditional Instability Tools|Participants will use traditional instability tools during the impairment-based rehabilitation intervention.
3004500|NCT02533037|Experimental|Ankle destabilization shoes|Participants will use ankle destabilization shoes during the impairment-based rehabilitation intervention.
3004501|NCT02533024|Experimental|Group Cohort|All subjects will have nerve conduction studies (Electromyography/EMG) pre-operatively, monitored intra-operatively and immediately post-operative.
3004502|NCT02533011||24 Hours|HBP lab test performed 24 hours after meeting sepsis inclusion criteria.
3004503|NCT02533011||48 Hours|HBP lab test performed 48 hours after meeting sepsis inclusion criteria.
3004504|NCT02533011||72 Hours|HBP lab test performed 72 hours after meeting sepsis inclusion criteria.
3004505|NCT02532998|Experimental|Treatment Sequence 1|Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
3004506|NCT02532998|Experimental|Treatment Sequence 2|Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
3004507|NCT02532998|Experimental|Treatment Sequence 3|Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
3004508|NCT02532998|Experimental|Treatment Sequence 4|Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
3004509|NCT02532998|Experimental|Treatment Sequence 5|Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
3004510|NCT02532998|Experimental|Treatment Sequence 6|Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
3004511|NCT02532998|Experimental|Treatment Sequence 7|Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
3004512|NCT02532998|Experimental|Treatment Sequence 8|Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + AZD9977 Period 3: fludrocortisone + eplerenone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
3004513|NCT02532985|Placebo Comparator|Negative control|No added fiber
3004514|NCT02532985|Active Comparator|Positive fiber control|90g positive control fiber
3004515|NCT02532985|Experimental|Novel fiber 30g|30g novel fiber
3004516|NCT02532985|Experimental|Novel fiber 60g|60g novel fiber
3004517|NCT02532985|Experimental|Novel fiber 90g|90g novel fiber
3004518|NCT02532972|Experimental|Cochlear Implant surgery|All subjects will be part of a single arm involving placement of the Med-El MAESTRO Cochlear Implant with Flex 28 electrode array
3004519|NCT02532959||Diagnostic Breath Analysis|Patients at risk of SIRS
3004520|NCT02532946|Experimental|Bedsider counseling group|Women exposed to: Bedsider.org counseling will be offered a computer or tablet at check-in to clinic. The outcome measure is measured at the patient's surgical abortion procedure appointment, or at medical abortion follow-up, which can range up to 10 days after enrollment
3004521|NCT02532946|No Intervention|Routine counseling group|Women were given counseling in the providers' usual practice style. They were given a card with Bedsider.org's web address along with the counseling.
3004522|NCT02532933|Active Comparator|Medialized Dome Patella|Subjects with total knee arthroplasty using the DePuy Synthes Attune Posterior Stabilized Rotating Platform including patella resurfacing with a medialized dome component geometry
3004523|NCT02532933|Active Comparator|Anatomic Patella|Subjects with total knee arthroplasty using the DePuy Synthes Attune Posterior Stabilized Rotating Platform including patella resurfacing with an anatomic component geometry
3004524|NCT02532920||Atopic dermatitis|Atopic dermatitis is diagnosis as Hanifin and Rajka from physician.
3004846|NCT02531009||Healthy|Approximately 10 healthy adults will be enrolled into this study
3004525|NCT02532907||Patients who will have their second Liver biopsy at week 4|The 4 week time point is performed in lieu of the 12 week and the purpose of this time point is to evaluate earlier responses and transcriptional changes that might predict viral clearance or treatment failure in a subset of patients.
3004526|NCT02532907||Patients who will have their second Liver biopsy at week 12|Liver biopsies will be obtained at week 12 when most DAA treatments end in order to compare the hepatic responses induced or reduced by clearance of HCV
3004527|NCT02532894|Experimental|Esmoke|Inhaling e-cigarette vapor
3004528|NCT02532894|No Intervention|Control|
3004529|NCT02532881|Experimental|Treatment as ususal (TAU) + Video Access|Patients in this arm receive access to various videos on the study website as well as treatment as usual (written information provided by the clinic).
3004530|NCT02532881|Placebo Comparator|Treatment as usual (TAU)|Patients in this arm receive treatment as usual (written information provided by the clinic).
3004531|NCT02532868|Experimental|MK-0457|Participants received MK-0457 at assigned dose as a continuous intravenous infusion (CIV) over 24 hours; one group of participants also received MK-0457 100 mg capsules, orally, prior to the CIV.
3004532|NCT02532855|Experimental|Sitagliptin|Participants receive sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 5 mg once daily for 4 weeks followed by sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 10 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with an sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.
3004533|NCT02532855|Active Comparator|Dapagliflozin|Participants receive dapagliflozin 5 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 4 weeks followed by dapagliflozin 10 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with an sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.
3004534|NCT02532842||Participants with Schizophrenia|This is a retrospective, non-interventional, multicenter study to retrospectively evaluate hospitalization and medical resource use, patterns of paliperidone palmitate use, and clinical outcomes documented within the medical records of young, adult, newly diagnosed schizophrenia participants for the first 12 months of continuous treatment with paliperidone palmitate. Only retrospective data available from clinical routine practice and documented in a participant's medical record will be collected.
3004535|NCT02532829||GROUP NS-A|Healthy Participants: No known disease, no previous surgery, HbA1c<5.7%, BMI<25 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
3004536|NCT02532829||GROUP NS-B|Obese, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI>30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
3004537|NCT02532829||GROUP NS-C|Non-obese, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI<30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
3004538|NCT02532829||GROUP NS-D|Obese non-diabetic: HbA1c<5.7%, No signs and history of T2D, and BMI>30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
3004539|NCT02532829||Group SG|Type 2 Diabetic participants who underwent a sleeve gastrectomy, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
3004540|NCT02532829||Group MGB|Type 2 Diabetic participants who underwent a mini-gastric bypass, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
3004541|NCT02532829||Group IT|Type 2 Diabetic participants who underwent a sleeve gastrectomy with ileal transposition, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
3004542|NCT02532829||Group TB|Type 2 Diabetic participants who underwent a sleeve gastrectomy with transit bipartition, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
3004543|NCT02532816|Experimental|HND-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + fortified biscuit (ferrous fumarate 83.5 mg, zinc oxide 50.95 mg, Calcium carbonate 3104.05 mg, Thiamine Mononitrate1.85 mg, Nicotinic Acid 30.45 mg, Pyridoxine Hydrocloride 2.90 mg, Pteroyl monoglutamic acid 764.90 mcg, Cyanocobalamin 0.95 mcg, Retinol Palmitate (dry) 742.50 mcgRE)
3004544|NCT02532816|Active Comparator|SND-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + fortified biscuit (ferrous fumarate 32.6 mg, zinc oxide 3.78 mg, Calcium carbonate 874.12 mg, Thiamine Mononitrate1.25 mg, Nicotinic Acid 17.95 mg, Pyridoxine Hydrocloride 1.10 mg, Pteroyl monoglutamic acid 329.90 mcg, Cyanocobalamin 0.55 mcg)
3004545|NCT02532816|Placebo Comparator|NDN-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + non fortified biscuit
3004546|NCT02532803|Experimental|Novel pelvic MRI scan assessment|All patients with rectal tumours of 20-50mm in size who consent to enter the trial will receive novel staging report for their pelvic MRI scan.
3004547|NCT02532790|Experimental|group 1|Prednisone Drug : prednisone 1.5mg/kg/d for 4-6 weeks, then 1.5mg/kg/d qod for 4 weeks, reduce 5mg every 2-4 weeks If the proteinuria decreases by less than 50% after treating for two months, this candidate reaches the ending point.
3004548|NCT02532790|Experimental|group 2|Angiotension converting enzyme inhibitors(ACEI) Drug: lotensin 0.2-0.3mg/kg/d (the maximum dose is 20mg)
3004629|NCT02532387||BWH ED/EDOU patients|"Subjects who present to the Brigham and Women's Hospital (BWH) ED or EDOU who meet all inclusion and no exclusion criteria.~Intervention: Telephone follow-up at 7 and 30 days."
3004549|NCT02532777|Experimental|Prednisone & Cyclophosphamide|"Drug: prednisone & cyclophosphamide & Angiotensin-converting enzyme inhibitor(ACEI).~Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.~cyclophosphamide: 0.1mg/kg. Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
3004550|NCT02532777|Experimental|Prednisone & Mycophenolate mofetil|"Drug: prednisone & mycophenolate mofetil & Angiotensin-converting enzyme inhibitor(ACEI).~Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.~mycophenolate mofetil: 25mg/kg/d bid (the maximum dose is 1.5g/d). Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
3004551|NCT02532777|Experimental|Prednisone & Leflunomide|"Drug: prednisone & leflunomide & Angiotensin-converting enzyme inhibitor(ACEI). Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.~Leflunomide: give patients the induction dose 1mg/kg/d for three days (the total dose is under 40mg/kg)，then give the maintaining dose 0.5mg/kg/d.~Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
3004552|NCT02532764|Experimental|QR-010|QR-010 administered via inhalation either as a single dose or three times weekly for four weeks.
3004553|NCT02532764|Placebo Comparator|Placebo|Placebo (normal saline) administered via inhalation either as a single dose or three times weekly for four weeks.
3004554|NCT02532738|Experimental|MSC-1|Patients in this arms receive routine treatment with 3×10E6/kg of MSC
3004555|NCT02532738|Experimental|MSC-2|Patients in this arms receive routine treatment with 6×10E6/kg of MSC
3004556|NCT02532738|Placebo Comparator|Ctrl|Patients in this arms receive routine treatment with NS injection
3004557|NCT02532725||Lean|Men aged 35-55 years, having <20% body fat
3004558|NCT02532725||Obese|Men aged 35-55 years, having >29% body fat
3004559|NCT02532712|Experimental|Single dose group-Group 1-Experimental|Single dose, 500mg of Study drug(EC-18)
3004560|NCT02532712|Placebo Comparator|Single dose group-Group 1-Placebo|Single dose, 500mg of Placebo
3004561|NCT02532712|Experimental|Single dose group-Group 2-Experimental|Single dose, 1000mg of Study drug(EC-18)
3004562|NCT02532712|Placebo Comparator|Single dose group-Group 2-Placebo|Single dose, 1000mg of Placebo
3004563|NCT02532712|Experimental|Single dose group-Group 3-Experimental|Single dose, 2000mg of Study drug (EC-18)
3004564|NCT02532712|Placebo Comparator|Single dose group-Group 3-Placebo|Single dose, 2000mg of Placebo
3004565|NCT02532712|Experimental|Single dose group-Group 4-Experimental|Single dose, 4000mg of Study drug (EC-18)
3004566|NCT02532712|Placebo Comparator|Single dose group-Group 4-Placebo|Single dose, 4000mg of Placebo
3004567|NCT02532712|Experimental|Multiple dose group-Group 1-Experimental|Multiple dose, Study drug(EC-18) 500mg, Once daily, for 14 days
3004568|NCT02532712|Placebo Comparator|Multiple dose group-Group 1-Placebo|Multiple dose, Placebo 500mg, Once daily, for 14 days
3004569|NCT02532712|Experimental|Multiple dose group-Group 2-Experimental|Multiple dose, Study drug(EC-18) 1000mg, Once daily, for 14 days
3004570|NCT02532712|Placebo Comparator|Multiple dose group-Group 2-Placebo|Multiple dose, Placebo 1000mg, Once daily, for 14 days
3004571|NCT02532712|Experimental|Multiple dose group-Group 3-Experimental|Multiple dose, Study drug(EC-18) 2000mg, Once daily, for 14 days
3004572|NCT02532712|Placebo Comparator|Multiple dose group-Group 3-Placebo|Multiple dose, Placebo 2000mg, Once daily, for 14 days
3004573|NCT02532712|Experimental|Multiple dose group-Group 4-Experimental|Multiple dose, Study drug(EC-18) 4000mg, Once daily, for 14 days
3004574|NCT02532712|Placebo Comparator|Multiple dose group-Group 4-Placebo|Multiple dose, Placebo 4000mg, Once daily, for 14 days
3004575|NCT02532699|Active Comparator|AC mycelia|Subjects receive three capsules per day containing either 420 mg of AC mycelia.
3004576|NCT02532699|Placebo Comparator|Placebo|Subjects receive three capsules per day containing starch placebo of similar appearance.
3004577|NCT02532686|Experimental|DAAOI-2|DAAOI-2: 500-2000mg/d
3004578|NCT02532686|Placebo Comparator|placebo|
3004579|NCT02532673||Hyperbilirubinemia Cohort|Patients will be included who have evidence of hyperbilirubinemia (laboratory test of grade 2 or greater or > 2 medical claims with an International Classification of Diseases, Ninth Revision, Clinical Modification code of 782.4 or 277.4 in any position) in the first 90 days after initiating Atazanavir therapy.
3004580|NCT02532673||Non-hyperbilirubinemia cohort|Patients will be included who have no evidence of hyperbilirubinemia (no laboratory test of grade 2 or greater or any medical claims with an International Classification of Diseases, Ninth Revision, Clinical Modification of 782.4 or 277.4 in any position) in the 12-month follow-up period.
3004581|NCT02532660|Experimental|Escitalopram + LABCAT TCJUSS|Escitalopram 10mg + LABCAT TCJUSS 1000 mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night);
3004582|NCT02532660|Placebo Comparator|Escitalopram + LABCAT TCJUSS placebo|Escitalopram 10mg + LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
3004583|NCT02532660|Experimental|Escitalopram Placebo + LABCAT TCJUSS|Escitalopram Placebo + LABCAT TCJUSS 1000 mg daily (2 capsules in the morning + 2 capsules at night).
3004584|NCT02532647|Experimental|Remimazolam|Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation.
3004585|NCT02532647|Active Comparator|Midazolam|Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation.
3004586|NCT02532647|Placebo Comparator|Placebo|Placebo administered in double-blind manner.
3004587|NCT02532634|Experimental|ramosetron, aprepitant, dexamethasone|"Ramosetron 0.3mg IV day1~Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3~Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4"
3004588|NCT02532634|Active Comparator|palonosetron, aprepitant, dexamethasone|"Palonosetron 0.25mg IV day1~Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3~Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4"
3004589|NCT02532621|Experimental|Arterial & Venous InterGraft Connectors|Arterial & Venous InterGraft Connectors will be implanted to create an AV shunt for dialysis access.
3004590|NCT02532621|Experimental|Venous InterGraft Connector|Venous InterGraft Connector will be implanted and used with a sutured arterial anastomosis to create a AV shunt for dialysis access.
3004592|NCT02532595|Active Comparator|Group 1 manual therapy and exercise|manual therapy with soft tissue mobilization to trigger points in the gastrocnemius, soleus, and tibialis posterior; exercise including stretching, concentric and eccentric exercises to the hip, triceps surae, tibialis posterior and foot intrinsics.
3004593|NCT02532595|Experimental|Group 2 TDN, manual therapy and exercise|trigger point dry needling (TDN) to trigger points in the gastrocnemius, soleus and tibialis posterior; manual therapy with soft tissue mobilization to trigger points in the gastrocnemius, soleus, and tibialis posterior; exercise including stretching, concentric and eccentric exercises to the hip, triceps surae, tibialis posterior and foot intrinsics.
3004594|NCT02532582||Living Liver Donor Transplant Donors|All adult living liver donors and liver surgery patients at Northwestern Memorial Hospital (same surgical setup is used for living liver donor surgery and liver surgery (e.g. retractors, arterial line for monitoring, surgeons). Living liver donors and liver surgery patients for enrollment to receive neuromuscular monitoring)
3004595|NCT02532569|Other|Japanese encephalitis vaccine|After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose,SC
3004596|NCT02532556|Experimental|1|Stimulation of muscle in this order: vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius
3004597|NCT02532556|Experimental|2|Stimulation of muscle in this order: rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials
3004598|NCT02532556|Experimental|3|Stimulation of muscle in this order: vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris
3004599|NCT02532556|Experimental|4|Stimulation of muscle in this order: tibialis anterior, peroneus longus, and the medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis
3004600|NCT02532556|Experimental|5|Stimulation of muscle in this order: peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior
3004601|NCT02532556|Experimental|6|Stimulation of muscle in this order: medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus
3004602|NCT02532556|Experimental|7|Stimulation of muscle in this order: lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius,
3004603|NCT02532543|Active Comparator|Group A- Allograft, Membrane|Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
3004604|NCT02532543|Active Comparator|Group B- Alloplast, Membrane|Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
3004605|NCT02532543|Active Comparator|Group C- Xenograft, Membrane|OsteoGraf/N-300 , Symbios OsteoShield Collagen Resorbable Membrane
3004606|NCT02532543|Active Comparator|Group D- Membrane|Symbios OsteoShield Collagen Resorbable Membrane
3004607|NCT02532530|Other|Study group|Adult patients (age ≥ 70 years) undergoing elective on-pump cardiac surgery (i.e. valve replacement with or without 'Coronary Artery Bypass Graft' (CABG) surgery)
3004608|NCT02532517|Experimental|Enterprise|
3004609|NCT02532504|Experimental|CBT seven sheets|"8 sessions of CBT based intervention called change your life with seven sheets of paper"
3004610|NCT02532504|No Intervention|Treatment As Usual|Treatment As Usual
3004611|NCT02532491|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
3004612|NCT02532491|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
3004613|NCT02532478||Stoma reversed|Patients whose ileostomy have been closed after laparoscopic low anterior resection
3004614|NCT02532478||Stoma not-reversed|Patients whose ileostomy have not been closed due to some problems
3004615|NCT02532465|Active Comparator|Air-Q|The Air-Q is composed of an airway tube that connects to an elliptical mask with a cuff which is inserted through the patient's mouth, down the windpipe, and once deployed forms an airtight seal on top the glottis (unlike tracheal tubes which pass through the glottis) allowing a secure airway to be managed by a health care provider.
3004616|NCT02532465|Experimental|i-gel|The i-gel is designed to create a non-inflatable anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures whilst avoiding the compression trauma that can occur with inflatable supraglottic airway devices.
3004617|NCT02532452|Experimental|Viral Specific CTL Infusion|3rd party donor derived CTL infusion
3004618|NCT02532439|Experimental|Patient group|Measure bone quality and quantity with HR-pQCT and DEXA of patient group Patient group is patient with one of the following pathology : Osteoporosis, Bone Fragility, articular inflammatory disease or Endocrine diseases
3004619|NCT02532439|Experimental|control group|Measure bone quality and quantity with HR-pQCT and DEXA of control group. Patient group is patient with episode of acute back pain or radicular pain
3004620|NCT02532426||COPD patients with chronic hypoxemia|COPD patients with chronic and severe arterial hypoxemia at rest (paO2<55mmHg).
3004621|NCT02532426||COPD patients with normoxia|COPD patients with normoxia at rest (paO2>67mmHg), matched for age, sex, bronchial obstruction and lean mass.
3004622|NCT02532413|Experimental|HBeAg(+):Poly IC+Entecavir|"45 subjects(HBeAg-positive chronic hepatitis B). Combination therapy will last 24 weeks from 0 week.~Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks. Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week"
3004623|NCT02532413|Active Comparator|HBeAg(+):Entecavir|45 subjects(HBeAg-positive chronic hepatitis B). Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks.
3004624|NCT02532413|Experimental|HBeAg(-):Poly IC+Entecavir|"45 subjects(HBeAg-negative chronic hepatitis B). Combination treatment will last 24 weeks from 0 week.~Drug: Enticavir 0.5mg, P.O.,qd, duration:48 weeks. Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week"
3004625|NCT02532413|Active Comparator|HBeAg(-):Entecavir|45 subjects(HBeAg-negative chronic hepatitis B). Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks.
3004626|NCT02532400|Experimental|Neoadjuvant endocrine therapy|Six months of exemestane or anastrozole plus goserelin.
3004627|NCT02532400|Active Comparator|Neoadjuvant chemotherapy|Six cycles of docetaxel plus epirubicin and cyclophosphamide(TEC).
3004628|NCT02532387||MGH ED/EDOU patients|"Subjects who present to the Massachusetts General Hospital (MGH) ED or EDOU who meet all inclusion and no exclusion criteria.~Intervention: Telephone follow-up at 7 and 30 days."
3004630|NCT02532387||Control subjects|"Contemporary controls: subjects diagnosed with Venous Thromboembolism (VTE) in the ED and who are not eligible for outpatient treatment~Historical controls:~Subjects enrolled in the prospective and retrospective SPEED-D study (PI: Kabrhel) and diagnosed with PE between 2006-2012.~Subjects diagnosed with VTE in the MGH and BWH ED in the 18 months prior to the use of the clinical outpatient treatment of PE protocol."
3004631|NCT02532374|Experimental|Nicorette® inhalator then P3L|Each subject will use the Nicorette® inhalator (15 mg) on Visit 3, and then use the P3L aerosol at nicotine dose levels of approximately 50 µg/puff, 80 µg/puff and 150 µg/puff on Visits 4, 5 and 6, respectively.
3004632|NCT02532361||Cohort 1 / Hysteroscopic device placement|Patients that had undergone sterilization through hysteroscopic device placement
3004633|NCT02532361||Cohort 2 / Tubal ligation|Patients that had undergone sterilization through tubal ligation
3004634|NCT02532348||HIV Patients with antiretroviral therapy|Blood samples in HIV patients under 2 NRTIs (Nucleosidic analogs of Transcriptase Reverse Inhibitors) and 1 PI or 2 NRTIs and 1 NNRTI, for at least one year with a plasmatic viral load under 40 cp/ml.
3004635|NCT02532348||HIV patients without antiretroviral therapy|Blood samples in HIV patients never treated by antiretroviral therapy
3004636|NCT02532335|Active Comparator|Morbid Obesity OCA|Obeticholic acid 25 mg/day in three weeks
3004637|NCT02532335|Placebo Comparator|Morbid Obesity Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
3004638|NCT02532335|Active Comparator|Healthy Volunteers OCA|Obeticholic acid Obeticholic acid 25 mg/day in three weeks
3004639|NCT02532335|Placebo Comparator|Healthy volunteers Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
3004640|NCT02532322|Experimental|IV acetaminophen|IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
3004641|NCT02532322|Placebo Comparator|normal saline|normal saline (placebo control) 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
3004642|NCT02532309|Experimental|Rosuvastatin dose adjustment|
3004643|NCT02532309|Experimental|Rosuvastatin fixed dose|
3004644|NCT02532296|Active Comparator|Control|Receive usual hospital discharge, care transition and post-discharge care.
3004645|NCT02532296|Experimental|Transition Coach Intervention|In addition to usual care, the intervention group receives care from a trained Transition Coach to support patients for 30 days after discharge.
3004646|NCT02532283|Experimental|JNJ-63623872 plus Oseltamivir|Participants will be administered JNJ-63623872 600 milligram (mg) tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
3004647|NCT02532283|Experimental|Placebo plus Oseltamivir|Participants will be administered placebo tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
3004648|NCT02532270|Experimental|Group C|Arterial pressure of the patients in Group C is measured by continuous non-invasive arterial pressure (CNAP).When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug .If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
3004649|NCT02532270|Experimental|Group N|Arterial pressure of the patients in Group N is measured by intermittent oscillometric non-invasive arterial pressure (NIAP).When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug .If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
3004650|NCT02532257|Experimental|Lenalidomide + Rituximab + Ibrutinib|Participants receive 12 cycles of Lenalidomide, 15 mg daily on Days 1 - 21 of Cycle 1, and 20 mg daily on Days 1 - 21 of Cycles 2 through 12. Cycles are 28 days in length. Participants receive Rituximab, 375 mg/m2 on Days 1, 8, 15, and 22 of Cycle 1, and Day 1 of Cycles 2 through 12. Participants receive Ibrutinib 560 mg daily, starting on Day 1 of Cycle 1 and continued through 12 cycles.
3004651|NCT02532244||sample collection|Each participant will have blood drawn for genetic analysis and for establishment of a lymphoblastoid cell line. The investigator will also collect saliva and buccal swabs for genetic analysis
3004652|NCT02532231|Experimental|Nivolumab|Participants receive Nivolumab 3 mg/kg by vein every 2 weeks for 6 cycles. One cycle defined as 4 weeks. Continuation beyond 6 cycles allowed for participants deriving benefit without unacceptable toxicity. The dose after 6 cycles may be modified to an every 4 weeks schedule until 12 months from start of therapy, then every 3 months until disease progression.
3004653|NCT02532218|Active Comparator|Active|ARI-3037MO (niacin analog) 3g bid for 24 wks
3004654|NCT02532218|Placebo Comparator|Placebo|Matching Placebo 3g bid for 24 wks
3004655|NCT02532192|Experimental|Belinostat + RDHAP Chemotherapy|Belinostat administered by vein on Days 1 - 2 of a 21-day cycle. Rituximab administered by vein on Day 2. Cisplatinum administered by vein on Day 2. Cytarabine administered by vein on Day 3 during the initial cohorts, and on Day 2 in the cohort of modified DHAP scheduling. Ciprofloxacin 500 mg twice daily for 10 days and Fluconazole 100 mg daily for 10 days may be utilized at the discretion of the treating physician.
3004656|NCT02532179|Experimental|Mouse Allergenic Extract|Participants will receive escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol.
3004657|NCT02532166|Other|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and chromoendoscopy with Lugol for detection of esophageal lichen.
3004658|NCT02532153|Other|Open-Label Ketamine|
3004659|NCT02532140|Experimental|WCK 5107|A single administration of the investigational product will be administered intravenously in 7 SAD cohorts at different dose level . The SAD cohorts will enroll 10 subjects ( 8 on active drug and 2 on placebo)
3004660|NCT02532140|Experimental|WCK 5107 1000 mg and Cefepime 2000 mg|In the crossover cohorts (WCK 5107 and cefepime, both alone and in combination), 9 subjects will receive all 3 treatments.
3004661|NCT02532140|Experimental|WCK 5107 2000 mg and Cefepime 2000 mg|In the crossover cohorts (WCK 5107 and cefepime, both alone and in combination), 9 subjects will receive all 3 treatments.
3004744|NCT02531685|Experimental|Cohort 4|13 subjects receive 2.0 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
3004662|NCT02532127|Experimental|Saliva sampling|Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
3004663|NCT02532114|Experimental|Treatment (niclosamide, enzalutamide)|Patients receive niclosamide PO TID and enzalutamide PO daily. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
3004664|NCT02532101|Experimental|Oil Palm Phenolics|500 mg gallic acid equivalent (GAE), twice daily, 3 months
3004665|NCT02532088|Experimental|Oil Palm Phenolics|500 mg gallic acid equivalent (GAE), twice daily, 12 months
3004666|NCT02532088|Placebo Comparator|Placebo|Placebo
3004667|NCT02532075|Experimental|Inspiratory Warm Up|(IWU). Two sets of 15 breaths
3004668|NCT02532075|Experimental|Expiratory Warm Up|(EWU). Two sets of 15 breaths
3004669|NCT02532075|Experimental|Combination Warm Up|(RWU). One set of 15 breaths inspiratory and one set of 15 breaths expiratory
3004670|NCT02532075|Other|Control Trial|No warm up
3004671|NCT02532062|Experimental|Supplementation|Participants who are assigned to the Supplementation arm will receive a vitamin D supplement containing 4,000 units of vitamin D3 (cholecalciferol; capsule form) plus an oral multivitamin containing 400 units of vitamin D3 daily for a period of one year.
3004672|NCT02532062|Active Comparator|Placebo|Participants who are assigned to the Placebo arm will receive a placebo supplement plus an oral multivitamin containing 400 units of vitamin D3 daily for a period of one year.
3004673|NCT02532049|Active Comparator|Group 1|ChAd63 Pfs25-IMX313 (5x10^9 vp)
3004674|NCT02532049|Active Comparator|Group 2A|ChAd63 Pfs25-IMX313 (5x10^10 vp)
3004675|NCT02532049|Active Comparator|Group 2B|ChAd63 Pfs25-IMX313 (5x10^10) and MVA Pfs25-IMX313 (1x10^8 pfu) 8 weeks later
3004676|NCT02532049|Active Comparator|Group 2C|ChAd63 Pfs25-IMX313 (5x10^10) and MVA Pfs25-IMX313 (2x10^8 pfu) 8 weeks later
3004677|NCT02532036|Experimental|Starter Group|Receive 1x10^7 pfu aerosol inhaled MVA85A at day 0.
3004678|NCT02532036|Experimental|Group A|Receive 5x10^7 pfu aerosol inhaled MVA85A, and intramuscular saline placebo both at day 0.
3004679|NCT02532036|Experimental|Group B|Receive 5x10^7 pfu intramuscular MVA85A, and aerosol inhaled saline placebo both at day 0.
3004680|NCT02532023|Active Comparator|omega 3 fatty acid supplementation|patients with migraine receive 2 capsules 1000 mg omega3, 2 times a day, for 2 months.
3004681|NCT02532023|Active Comparator|curcumin supplementation|patients with migraine receive 2 capsules 1000 mg curcumin, 2 times a day, for 2 months.
3004682|NCT02532023|Placebo Comparator|omega 3 fatty acid Placebo|patients with migraine receive 2 capsules of omega 3 fatty acid placebo for 2 months.
3004683|NCT02532023|Placebo Comparator|curcumin placebo|patients with migraine receive 2 capsules of curcumin placebo for 2 months.
3004684|NCT02532010|Active Comparator|Arm A: Pacritinib and Decitabine|Arm A: Each cycle: Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
3004685|NCT02532010|Active Comparator|Arm B: Pacritinib and Cytarabine|Arm B: Each cycle: Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
3004686|NCT02531997|Active Comparator|Hypnotic Relaxation Therapy|Hypnotic relaxation will be performed in three sessions, two weeks apart, over 6 weeks. The hypnosis sessions will build on each other in terms of content.
3004687|NCT02531997|Other|Progressive Muscle Relaxation (PMR)|The PMR will consist of progressive tensing and relaxing of the muscles from head to toe to a soothing sound of the participant's choosing.
3004688|NCT02531984|Experimental|Withdrawal of Azithromycin treatment|
3004689|NCT02531984|Other|ongoing Azithromycin treatment|
3004690|NCT02531971|Active Comparator|Duragesic®|Each of the 24 Subjects will start the study with a Run-In Session (Study Session I) of intravenous fentanyl citrate infusion by giving a single-dose of 100 µg fentanyl citrate infusion. After that, 12 Subjects be randomized to the Duragesic® fentanyl TDDS (25 µg/h) for 3 days (Study Session II), and then will cross over to the Mylan fentanyl TDDS (25 µg/h) for 3 days (Study Session III)
3004691|NCT02531971|Active Comparator|Mylan Generic Fentanyl|Each of the 24 Subjects will start the study with a Run-In Session (Study Session I) of intravenous fentanyl citrate infusion by giving a single-dose of 100 µg fentanyl citrate infusion. After that, 12 Subjects be randomized to the Mylan fentanyl TDDS (25 µg/h) for 3 days (Study Session II), and then will cross over to the Duragesic® fentanyl TDDS (25 µg/h) for 3 days (Study Session III)
3004692|NCT02531958|Experimental|1 Egg|Consumption of 1 egg per day for 4 weeks
3004693|NCT02531958|Experimental|2 Eggs|Consumption of 2 eggs per day for 4 weeks
3004694|NCT02531958|Experimental|3 Eggs|Consumption of 3 eggs per day for 4 weeks
3004695|NCT02531945|Experimental|Intervention|"The device used in this research to the topography examination is three-dimensional morphometry device of AXS Medical society : the BIOMOD L.~'Use of Biomod device' for all the patient in addition to the conventional X-ray examination."
3004696|NCT02531932|Active Comparator|Carboplatin alone|AUC 4 every 3 weeks as an IV infusion
3004697|NCT02531932|Experimental|Carboplatin + Everolimus|Carboplatin AUC 4 every 3 weeks IV infusion plus daily oral everolimus 5mg pill
3004698|NCT02531919|Experimental|Sodium Bicarbonate|Dose concentration of 0.5 g/kg/day
3004699|NCT02531906|Experimental|Arm I (gabapentin)|"Patients receive gabapentin PO TID for up to 7 weeks during radiotherapy.~All patients may continue to receive treatment for pain throughout their course of chemoradiation therapy (and up to 24 months following CRT if continuing on a pain regimen)."
3004700|NCT02531906|Experimental|Arm II (gabapentin, methadone, oxycodone)|"Patients receive gabapentin PO TID, methadone hydrochloride PO BID, and oxycodone hydrochloride PO Q8H PRN for up to 7 weeks during radiotherapy.~All patients may continue to receive treatment for pain throughout their course of chemoradiation therapy (and up to 24 months following CRT if continuing on a pain regimen)."
3004701|NCT02531867|Experimental|Asfotase Alfa|Patients will receive asfotase alfa by subcutaneous injection. Asfotase alfa will be administered at either 2 mg/kg 3 times per week or 1 mg/kg 6 times per week depending on investigator's discretion.
3004702|NCT02531854|Experimental|ADXS11-001 + Pemetrexed|
3004703|NCT02531854|Active Comparator|Pemetrexed Only|
3004847|NCT02531009||SSc|Participants with dcSSc and lcSSc
3004704|NCT02531841|Active Comparator|Arm A|"Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~Rituximab 375 mg/m²/d i.v. (d0,5)~Methotrexate 3.5 g/m² i.v. (d1)~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~Thiotepa 30 mg/m² i.v. (d4)~Consolidation Treatment 2 cycles of R-DeVIC (every 3 weeks):~Rituximab 375 mg/m²/d i.v. (d0)~Dexamethasone 40 mg/d i.v. (d1-3)~Etoposide 100 mg/m²/d i.v. (d1-3)~Ifosfamide 1500 mg/m²/d i.v. (d1-3)~Carboplatin 300 mg/m² i.v. (d1)"
3004705|NCT02531841|Active Comparator|Arm B|"Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~Rituximab 375 mg/m²/d i.v. (d0,5)~Methotrexate 3.5 g/m² i.v. (d1)~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~Thiotepa 30 mg/m² i.v. (d4)~Consolidation Treatment High-dose chemotherapy~Carmustine* 400 mg/m² i.v. (d-6)~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~Autologous Stem Cell Transplantation (d0)~*if not available at study site, Busulfan can be administered instead:~Busulfan 3,2 mg/kg/d i.v. (d-8-(-7))~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~Autologous Stem Cell Transplantation (d0)"
3004706|NCT02531828|Experimental|Biopolymer Film|Application of dressings for surgical correction.
3004707|NCT02531828|Active Comparator|Polyurethane Film, or the like|Application of dressings for surgical correction
3004708|NCT02531815|Experimental|Cohort 1 (subcutaneous [SC]) PF-06741086, Placebo|
3004709|NCT02531815|Experimental|Cohort 2 (SC) PF-06741086, Placebo|
3004710|NCT02531815|Experimental|Cohort 3 (SC) PF-06741086, Placebo|
3004711|NCT02531815|Experimental|Cohort 4 (Intravenous [IV]) PF-06741086, Placebo|
3004712|NCT02531815|Experimental|Cohort 5 (IV) PF-06741086, Placebo|
3004713|NCT02531815|Experimental|Cohort 6 (IV) PF-06741086, Placebo|
3004714|NCT02531815|Experimental|Cohort 7 (IV) PF-06741086, Placebo|
3004715|NCT02531815|Experimental|Cohort 8 (subcutaneous [SC]) PF-06741086|
3004716|NCT02531802|Experimental|ETVAX (Full dose)|Full dose of ETVAX vaccine added to bicarbonate buffer solution administered orally on Day 0 and 14
3004717|NCT02531802|Experimental|ETVAX (Full dose) + 10 ug dmLT|Full dose of ETVAX vaccine with 10 ug dmLT added to bicarbonate buffer solution administered orally on Day 0 and 14
3004718|NCT02531802|Experimental|ETVAX (1/2 dose)|Half an adult dose of ETVAX vaccine to bicarbonate buffer solution administered orally on Day 0 and 14
3004719|NCT02531802|Experimental|ETVAX (1/2 dose) + 10 ug dmLT|Half an adult dose of ETVAX vaccine with 10 ug dmLT added to bicarbonate buffer solution administered orally on Day 0 and 14
3004720|NCT02531802|Experimental|ETVAX (1/2 dose) + 5 ug dmLT|Half an adult dose of ETVAX vaccine with 5 ug dmLT added to bicarbonate buffer solution administered orally on Day 0 and 14
3004721|NCT02531802|Experimental|ETVAX (1/2 dose) + 2.5 ug dmLT|Half an adult dose of ETVAX vaccine with 2.5 ug dmLT added to bicarbonate buffer solution administered orally on Day 0 and 14
3004722|NCT02531802|Experimental|ETVAX (1/4 dose)|Quarter adult dose of ETVAX vaccine added to bicarbonate buffer solution administered orally on Day 0 and 14
3004723|NCT02531802|Experimental|ETVAX (1/4 dose) + 5 ug dmLT|Quarter adult dose of ETVAX vaccine with 5 ug dmLT added to bicarbonate buffer solution administered orally on Day 0 and 14
3004724|NCT02531802|Experimental|ETVAX (1/4 dose) + 2.5 ug dmLT|Quarter adult dose of ETVAX vaccine with 2.5 ug dmLT added to bicarbonate buffer solution administered orally on Day 0 and 14
3004725|NCT02531802|Experimental|ETVAX (1/8 dose)|One eighth an adult dose of ETVAX vaccine added to bicarbonate buffer solution administered orally on Day 0 and 14
3004726|NCT02531802|Experimental|ETVAX (1/8 dose) + 5 ug dmLT|One eighth an adult dose of ETVAX vaccine with 5 ug dmLT added to bicarbonate buffer solution administered orally on Day 0 and 14
3004727|NCT02531802|Experimental|ETVAX (1/8 dose) + 2.5 ug dmLT|One eighth an adult dose of ETVAX vaccine with 2.5 ug dmLT added to bicarbonate buffer solution administered orally on Day 0 and 14
3004728|NCT02531802|Placebo Comparator|Placebo|Sodium bicarbonate buffer
3004729|NCT02531789||Observation|45 patients receiving elective colorectal surgery
3004730|NCT02531776|Experimental|Subcutaneous insertions of needles|36 subcutaneous needle insertions per participant with 18 differently designed needles. 30test participants in total. No fluid will be injected. Pain perception will be rated by the subjects, penetration force and skin blood perfusion will be measured, and any skin reactions will be assessed.
3004731|NCT02531763|No Intervention|Control|FHS participants who enrolled with family member will not receive the social incentive intervention and will participate individually but will set a daily step goal and receive daily feedback on whether he or she achieved the goal or not.
3004732|NCT02531763|Active Comparator|Intervention|FHS participants who enrolled with a family member will be placed on a team as connected individuals (both in the same family) who will set a daily step goal, receive daily feedback on whether they achieved their goal, and receive the social incentive intervention.
3004733|NCT02531750||Achilles tendon rupture|Patients with acute Achilles tendon rupture.
3004734|NCT02531737|Experimental|traitment|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle including docetaxel 75 mg/m2 by intravenous infusion on day 1
3004735|NCT02531724|Active Comparator|Levosimendan|Levosimendan will be given as a loading dose of 12 ug/kg during 30 minutes, and then a continuous infusion of 0,1 ug/kg/min for 180 minutes.
3004736|NCT02531724|Placebo Comparator|Placebo|Sodium chloride will be given as a loading dose during 30 minutes and then a continuous infusion for 180 minutes at a rate mimicking the levosimendan group above.
3004737|NCT02531711|Experimental|Diet A|Dietary intervention: Dietary fats are adjusted. Key study foods and oils are provided for 12 weeks. Participants learn which foods to eat and which to avoid.
3004738|NCT02531711|Active Comparator|Diet B|Dietary intervention: This diet also adjusts dietary fats, and provides key study foods and oils for 12 weeks.
3004739|NCT02531698|Experimental|Bivalent rLP2086|Bivalent rLP2086 (containing 60 μg each of a purified subfamily A and subfamily B rLP2086 protein, adsorbed to aluminum in a sterile buffered isotonic suspension) in a 0.5-mL dose for injection.
3004740|NCT02531698|Other|Licensed pediatric hepatitis A vaccine|
3004741|NCT02531685|Experimental|Cohort 1|13 subjects receive 0.1 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
3004742|NCT02531685|Experimental|Cohort 2|13 subjects receive 0.3 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
3004743|NCT02531685|Experimental|Cohort 3|13 subjects receive 1.0 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
3037954|NCT02308163|Experimental|ASP015K low dose group|oral
3004746|NCT02531646|Experimental|Predicate & Invest. DE - Human Subjects|Radiation -Thirty to forty (30-40) patients will receive a DR standard of care chest exam using the DRX Plus detector and a DE exam. Each DE patient exam includes high energy and low energy image exposures using the investigational device. These images are used by the DE console software to generate additional DE images (e.g. bone and soft tissue).
3004747|NCT02531646|Experimental|Predicate & Invest. DT - Human Subjects|Radiation - Fifteen to twenty (15-20) patients will receive a DR standard of care chest exam using the DRX Plus detector, and a DT exam. Each DT patient exam includes a scout image (chest PA) and a DT scan using the investigational DT SW. The DT scan is used by the DT console software to generate tomographic images.
3004748|NCT02531646|Experimental|Predicate & Invest. DT - Phantom Images|Radiation - Eleven (11) phantoms of various anatomy will be imaged with linear tomography (LT) as predicate and DT for investigational.
3004749|NCT02531633|Experimental|Part A: Sirukumab, Dose 1+prednisone (6-month taper)|Subjects will receive blinded sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
3004750|NCT02531633|Experimental|Part A: Sirukumab, Dose 1+prednisone (3-month taper)|Subjects will receive blinded sirukumab 100 mg SC q2w for 52 weeks plus a pre-specified maximum of 3-month oral prednisone taper regimen.
3004751|NCT02531633|Experimental|Part A: Sirukumab, Dose 2+prednisone (6-month taper)|Subjects will receive blinded sirukumab 50 mg SC every 4 weeks (q4w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
3004752|NCT02531633|Placebo Comparator|Part A:Placebo to match sirutkumab+prednisone (6-month taper)|Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
3004753|NCT02531633|Placebo Comparator|Part A:Placebo to match sirukumab+prednisone (12-month taper)|Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 12-month oral prednisone taper regimen.
3004754|NCT02531633|Experimental|Part B:Open-label sirukumab 100 mg SC (if applicable)|Subjects completing Part A will receive open label 100 mg SC q2w for a maximum of 52 weeks based on remission status and disease activity at the primary 52-week endpoint or prednisone tapering status of subject during Part A. Methotrexate will be provided to subjects, alone or in addition to sirukumab treatment during Part B, based on the discretion of the investigator.
3004755|NCT02531620|Experimental|Physiatry|Pre-operative Physiatry assessment and intervention
3004756|NCT02531620|Other|Routine Care|Patients will receive routine pre-operative care, this study arm does not have an intervention.
3004757|NCT02531594|Experimental|SBIRT|"An assessment form, motivational interviewing, personalized educational materials, immediate access to cessation resources, a 12-week supply of nicotine replacement therapy and weekly booster materials for 12 weeks.~nicotine"
3004758|NCT02531594|Placebo Comparator|HHC|The Healthy Habits Control program has been previously developed and used in the out-patient setting, and will be used as an attention control in which caregivers will receive instruction on healthy lifestyle choices to improve their child's health. Cessation assistance will be offered at the study's conclusion.
3004759|NCT02531581|Experimental|Furosémide|"Furosemide: a dose of 40 mg IV bolus initially and live according to the diuretic response: possibility of 2nd Live IV bolus 40 mg if urine output <500 cc / 24 at the 4th hour.~Establishment of an infusion G5 500cc% in vein custody."
3004760|NCT02531581|Active Comparator|NaCl 9% isotonic|"Infusion of 500 cc of isotonic NaCl 9% in 4 hours and 1000 cc 24-hour peripheral vein. The filling is being used in an empirical in severe EP and this group is therefore the control group."
3004761|NCT02531568|Experimental|Warfarin and MT-3995|Subjects will be administered a single dose of warfarin on day1. Subjects will be administered MT-3995 Days 8 to 20. Subjects will be administered MT-3995 and warfarin on Day21. Subjects will be administered MT-3995 from Day 22 to 27.
3004762|NCT02531555|Active Comparator|Group M|Mechanical periodontal treatment (Group M): Scaling and root planing were performed with Gracey curettes until the operator feels that root surface is clean, hard and smooth.
3004763|NCT02531555|Experimental|Group L|Pocket disinfection with diode laser (Group L): Subgingival irradiation with a GaAlAs diode laser (CHEESE®, Gigaa Laser, China) was applied to residual pockets each for 20 sec in continious mode. The diode laser had a wavelenght of 810 nm and power output of 1 W for subgingival irradiation (Maximum output power of device was 7 W). Diode laser application was performed parallel to root surface by a 200 µm fiber tip inserted at the bottom of periodontal pocket and slowly moved from apical to coronal direction in a sweeping motion without local anesthesia.
3004764|NCT02531555|Experimental|Group M+L|Combined treatment (Group M+L): Following mechanical periodontal treatment, pocket irradiation with diode laser was performed as mentioned above.
3004765|NCT02531542|Other|READ echography|
3004766|NCT02531529|Experimental|D group|intraoperative dexmedetomedine infusion
3004767|NCT02531529|Sham Comparator|F group|Intraoperative fentanyl infusion
3004768|NCT02531516|Experimental|Apalutamide|Participants will receive apalutamide (240 mg), by mouth, once daily for overall 30 months, plus bicalutamide placebo, by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
3004769|NCT02531516|Active Comparator|Control group|Participants will receive apalutamide placebo, by mouth, once daily for overall 30 months, plus bicalutamide (50 mg), by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
3004770|NCT02531503||Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of asthma medication during the past 12 months.
3004771|NCT02531490|Active Comparator|randomized, interventiongroup|Women with a hyperdynamic vasodilated profile, characterized by a mean arterial pressure (MAP)/ Heart rate (Hr) ratio ≤ 1.1 are prescribed a beta-blocker. Women with a hypodynamic vasoconstrictive profile (MAP/Hr ratio ≥ 1.4) are prescribed nifedipine. Women with normodynamic profile (MAP/Hr ratio in between 1.1 and 1.4) are prescribed Methyldopa.
3004772|NCT02531490|No Intervention|randomized, control-group|Women who give informed consent for randomization, and are randomized to the control group will not be medicinally treated for mild to moderate gestational hypertension.
3004773|NCT02531490|No Intervention|not-randomized, control-group|Women who do not want to be randomized, but who give informed consent for follow-up on their data until discharge after delivery. They will receive standard care, i.e. no medication is prescribed for mild to moderate gestational hypertension.
3004774|NCT02531477|Experimental|experimental group|Intracarotid injection of propofol to detect efficacy and safety as a novel route for drug delivery
3004775|NCT02531464|Experimental|Experimental: supportive care|Family caregivers (FC) in the experimental arm (supportive care) will be exposed to a multi-faceted intervention to help them cope with their caregiving role, support them and respond to their needs; the intervention includes 3 components: 1) systematic distress screening and problems assessment of FCs at 2-month interval during the study period; 2) privileged contact with an oncology nurse away from the patient to further identify and address FCs' problems; 3) liaison by the oncology nurse with the family physician of FCs fwho will have reported high distress or needing help
3004776|NCT02531464|No Intervention|Control: usual care|In the control arm (usual care), FCs will assist to their relative initial visit to the pivot nurse in oncology (PNO) . The PNO screens patients for distress and assesses their needs. She does a bio-psycho-social comprehensive evaluation and may provide help and information. She responds to questions and refers to appropriate resources, staying available for patients and their FCs throughout the cancer care trajectory. However, most PNO interventions target the patient, with no systematic distress screening and problems assessment for FCs, nor any service and resource specifically dedicated to them. If FCs clearly express distress or particular needs, the PNO will address them or refer to appropriate resources, but, in usual care, only few FCs receive support services
3004777|NCT02531451|Experimental|Ibuprofen|Resistance exercise 20 sessions during 8 weeks Daily consumption of 1200 mg ibuprofen (400 mg x 3) during 8 weeks
3004778|NCT02531451|Active Comparator|Acetylsalicylic acid|Resistance exercise 20 sessions during 8 weeks Daily consumption of 75 mg acetylsalicylic acid (75 mg x 1) during 8 weeks
3004779|NCT02531438|Experimental|Omadacycline|Omadacycline IV; Omadacycline tablets
3004780|NCT02531438|Active Comparator|Moxifloxacin|Moxifloxacin IV; Moxifloxacin tablets
3004781|NCT02531425|Experimental|IT-pIL12-EP|intratumoral injection of plasmid-IL12 following immediately by electroporation
3004782|NCT02531412|Experimental|Spironolactone|Spironolactone 25 mg PO daily for three days. During five days investigators will collect values of plasma creatinine, sodium, potassium, blood ureic nitrogen, vital signs and urinary output.
3004783|NCT02531412|Placebo Comparator|Placebo|Placebo 25mg PO daily for three days During five days investigators will collect values of plasma creatinine, sodium, potassium, blood ureic nitrogen, vital signs and urinary output.
3004784|NCT02531399|Experimental|Healthy Subjects|20 healthy female and male volunteers, age 18-45 years, non-smokers. Measurements with FDOCT, DVA, LDV and LSFG will be done in all healthy subjects.
3004785|NCT02531373|Experimental|Adult: V114 Medium Dose|Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 on Day 1.
3004786|NCT02531373|Experimental|Adult: V114 High Dose|Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 on Day 1.
3004787|NCT02531373|Experimental|Adult: V114 Medium Dose with Alternative Carrier Protein|Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein on Day 1.
3004788|NCT02531373|Experimental|Adult: V114 High Dose with Alternative Carrier Protein|Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein on Day 1.
3004789|NCT02531373|Experimental|Infant: V114 Medium Dose|Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 at 2, 4, 6, and 12 to 15 months of age.
3004790|NCT02531373|Experimental|Infant: V114 High Dose|Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 at 2, 4, 6, and 12 to 15 months of age.
3004791|NCT02531373|Experimental|Infant: V114 Medium Dose with Alternative Carrier Protein|Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
3004792|NCT02531373|Experimental|Infant: V114 High Dose with Alternative Carrier Protein|Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
3004793|NCT02531373|Active Comparator|Infant: Prevnar 13™|Infant participants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12 to 15 months of age.
3004794|NCT02531360|Experimental|[18F]MNI-815 (MNI-815)|At the [18F]MNI-815 PET imaging visit, subjects will be injected with no more than 10mCi of [18F]MNI-815
3004795|NCT02531347|Experimental|Telemedical blood pressure monitoring|Telemedical home blood pressure measurements for three days every second week. The average of all measures excluding day one is electronically transmitted to the General Practitioners. Following communication primarily by email or telephone.
3004796|NCT02531347|Active Comparator|Conventional blood pressure monitoring|Conventional blood pressure monitoring
3004797|NCT02531334|Experimental|TA-65|TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
3004798|NCT02531334|Placebo Comparator|Placebo|Placebo will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
3004799|NCT02531321|Experimental|Ritonavir|Participants taking antiretroviral regimens including ritonavir-boosted protease inhibitors will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
3004800|NCT02531321|Active Comparator|Control|Participants taking antiretroviral regimens known not to interact with oral contraceptives will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
3004801|NCT02531308|Experimental|R-CHOP with Metformin|"Rituximab 375 mg/m2 IV infusion Day 1 Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 (2 mg cap) IV Day 1 Prednisone 100 mg PO Days 1-5 Pegfilgrastim 6 mg subcutaneous within 72 hours of cyclophosphomide Metformin 500 mg PO daily D 1-7, 500 mg twice daily D8-21, 850 mg twice daily D22 - 30days post study.~Cycles are 21 days. Above treatment given for 4 cycles, then restaging done. If complete response (CR) or partial response (PR), 2 more cycle given; stable disease (SD) or progressive disease (PD)- salvage therapy off study."
3004802|NCT02531295|Experimental|Kansui 1g per day x 1 day|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 1 daily dose.
3004804|NCT02531295|Experimental|Kansui 1g per day x 3 days|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 3 consecutive daily doses.
3004805|NCT02531282|Experimental|Health promotion in patient education|The self-management patient education has been developed at the Healthy Life Centre in Trondheim municipality based on cognitive behavioural theory and psychomotor physiotherapy. The intervention is developed in a health promotion framework focusing on salutogenesis aiming to improve the participants ability to activate their own resources for health behaviour changes .
3004806|NCT02531282|Active Comparator|Physical activity in groups|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. .
3004807|NCT02531269||Patients treated with DCV (NPP)+Sofosbuvir +/- Ribavirin (RBV)|
3004808|NCT02531269||Patients treated with DCV (NPP) + Simeprevir +/- RBV|
3004809|NCT02531269||Patients treated with DCV(post-marketing) + Sofosbuvir +/- RBV|
3004810|NCT02531269||Patients treated with DCV(post-marketing) + Simeprevir +/- RBV|
3004811|NCT02531256|Experimental|LMA Protector|Single Use Supraglottic Airway Device with 2 ports for gastric access (male and female port)
3004812|NCT02531243|Experimental|CALMS|12 session family therapy using multi-user biofeedback games
3004813|NCT02531217|Experimental|ATYR1940|ATYR1940 will be given intravenously at a dose of 3.0 mg/kg, weekly
3004814|NCT02531204|Experimental|ASP1585 granules preceding group|
3004815|NCT02531204|Active Comparator|ASP1585 capsules preceding group|
3004816|NCT02531191|Experimental|New Tablet Preceding Group|
3004817|NCT02531191|Experimental|Current Tablet Preceding Group|
3004818|NCT02531178|Experimental|low dose ABBV-257|Low dose every other week (eow), Weeks 0-8
3004819|NCT02531178|Experimental|Medium dose of ABBV-257|Medium dose every other week (eow), Weeks 0-8
3004820|NCT02531178|Experimental|high dose of ABBV-257|high dose every other week (eow), Weeks 0-8
3004821|NCT02531165|Experimental|Morphine|"Pre-hospital Ticagrelor 180 mg loading dose orally.~Morphine, initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required.~Aspirin 500 mg loading dose orally (or intravenously).~Unfractioned heparin 5'000 IU loading dose intravenously, additional doses to achieve an ACT >250 sec during PCI are allowed.~Primary PCI."
3004822|NCT02531165|Experimental|Fentanyl|"Pre-hospital Ticagrelor 180 mg loading dose orally.~Fentanyl, initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required.~Aspirin 500 mg loading dose orally (or intravenously).~Unfractioned heparin 5'000 IU loading dose intravenously, additional doses to achieve an ACT >250 sec during PCI are allowed.~Primary PCI."
3004823|NCT02531152|Experimental|SAR366234 (Dose 1)|A low dose of SAR366234 will be administered 2 drops per eye per day for 28 days
3004824|NCT02531152|Experimental|SAR366234 (Dose 2)|A medium dose of SAR366234 will be administered 1 drop per eye per day for 28 days
3004825|NCT02531152|Experimental|SAR366234 (Dose 3)|A medium dose of SAR366234 will be administered 2 drops per eye per day for 28 days
3004826|NCT02531152|Experimental|SAR366234 (Dose 4)|A high dose of SAR366234 will be administered 1 drop per eye per day for 28 days
3004827|NCT02531152|Experimental|SAR366234 (Dose 5)|A high dose of SAR366234 will be administered 2 drops per eye per day for 28 days
3004828|NCT02531152|Active Comparator|Latanoprost|A dose of Latanoprost will be administered 1 drop per eye per day for 28 days
3004829|NCT02531139|Experimental|MAP maintained at 80 mmHg|During anesthesia MAP is maintained at 80 - 90 mmHg MAP using continuous infusion of phenylephrine.
3004830|NCT02531139|Active Comparator|MAP maintained at 60 mmHg|During anesthesia MAP is maintained at minimum of 60 mmHg using continuous infusion of phenylephrine.
3004831|NCT02531126|Experimental|RPC0163 (Ozanimod)|
3004832|NCT02531113|Experimental|RPC1063 (Ozanimod)|
3004833|NCT02531100|Experimental|BonyPid-500TM implantation|Standard of care (SOC) treatment (Manual and ultrasonic debridement and surface decontamination) followed by BonyPid-500TM implantation.
3004834|NCT02531100|Other|SOC treatment|Standard of care treatment (Manual and ultrasonic debridement and surface decontamination) only
3004835|NCT02531087||Individuals with OI|Individuals with OI with confirmed specific genetic mutations
3004836|NCT02531087||Controls/Unaffected|Individuals who do not have OI and who are not related to an individual with OI
3004837|NCT02531074|Experimental|Mobile Application plus Usual Care|
3004838|NCT02531074|Active Comparator|Food Journal plus Usual Care|
3004839|NCT02531061|Experimental|active erosion|"HR-pQCT for measure bone parameters in active erosion group. The active erosion group will be defined by grades 2 and 3, ie by the presence of Doppler signals confluence in less than 50% of the synovial surface (grade 2) and in over 50% of the surface synovial for grade 3"
3004840|NCT02531061|Experimental|inactive erosion|"HR-pQCT for measure bone parameters in active erosion group. The inactive erosion group will be defined by grades 0 and 1, ie the absence of Doppler signal for grade 0 and the presence of some non confluence Doppler signals for the grade 1"
3004841|NCT02531048|Experimental|healthy volunteers|"Healthy volunteers are able to participate to this study. They must not have neurological troubles. They will have different stimulations :~laser stimulations on lower limbs~laser stimulations cervical~20 laser stimulations for each site on the upper limbs~laser stimulations on face and neck"
3004842|NCT02531035|Experimental|Treatment A|Sotagliflozin (fasted conditions)
3004843|NCT02531035|Placebo Comparator|Treatment B|Placebo (fasted conditions)
3004844|NCT02531022|Active Comparator|Control|Participants will be given standard exercise recommendations that are given to all patients based on the federal guidelines. They will monitor their step counts using a wearable device and receive daily feedback.
3004845|NCT02531022|Experimental|Intervention|Participants will be given a wearable device to monitor daily step counts with automated daily feedback on goal attainment via text message or email. A baseline step count will be calculated for each participant (weeks 1-2) and then they will be given a daily step goal with an increase of 15 percentage point each week during the 8-week ramp-up period (weeks 3-10) with a maximum goal of 10,000 steps. Then they'll be asked to maintain that step count (maintenance period). During the ramp-up and maintenance period they'll have a financial incentive of $14 allocated each week and $2 taken away each day the goal is not achieved. They'll be followed up for 8 weeks without incentives
3004851|NCT02530957|Experimental|Interventional|In the interventional group, a preoxygenation by NIV (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) combined to HNFC (Flow of 60L/min, FiO2 = 100%) is applied.
3004852|NCT02530957|Other|Reference|In the reference group, a preoxygenation by NIV only (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) is applied.
3004853|NCT02530944||Lupus patients|People diagnosed with Systemic Lupus Erythematosus by a physician
3004854|NCT02530931|Experimental|patients with Meniere's disease|
3004855|NCT02530918|Experimental|Part 1 DS-7080a dose escalation|3 sequential ascending dose levels (1.0, 2.0, 4.0 mg), every 4 weeks for 12 weeks
3004856|NCT02530918|Experimental|Part 2 DS-7080a|Specific dose (either the maximum tolerated dose or 4.0 mg) of DS-7080a determined in Part 1, every 4 weeks for 12 weeks
3004857|NCT02530918|Active Comparator|Part 2 ranibizumab|Ranibizumab 0.5 mg, every 4 weeks for 12 weeks
3004858|NCT02530918|Experimental|Part 2 DS-7080a and ranibizumab|Specific dose of DS-7080a determined in Part 1 and ranibizumab 0.5 mg, every 4 weeks for 12 weeks
3004859|NCT02530918|Experimental|Part 3 DS-7080a|Specific dose of DS-7080a determined in Part 1, every 4 weeks for 12 weeks
3004860|NCT02530918|Experimental|Part 3 ranibizumab|Ranibizumab 0.3 mg, every 4 weeks for 12 weeks
3004861|NCT02530905|Experimental|SRP-4045 (double-blind dose titration)|Approximately 8 genotypically confirmed DMD patients amenable to exon 45 skipping
3004862|NCT02530905|Placebo Comparator|Placebo (double-blind dose titration)|Approximately 4 genotypically confirmed DMD patients amenable to exon 45 skipping.
3004863|NCT02530905|Experimental|SRP-4045 (open label)|Approximately 12 DMD patients who completed the double-blind dose titration part of the study.
3004864|NCT02530892||Measurement Group|"This group contains oocytes and embryos which have their mechanical properties (elasticity and viscosity) measured prior to fertilization (oocytes) or within 24 hours after fertilization (embryos). The investigators are calling this mechanical measurement the EmbryoHug. All participants in the study will have half their embryos measured in this group. Outcomes will be evaluated after 6 days of embryo culture, at the time of pregnancy test, at 5-6 weeks, and at 8-10 weeks, and correlated with EmbryoHug parameters."
3004865|NCT02530879|Experimental|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
3004866|NCT02530879|Active Comparator|Antireflux medication|"Intervention includes treatment with one of the following:~Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day~Lansoprazole-Dose range 15mg per day- 30mg twice a day~Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day~Rantidine-Dose range: 150 mg twice a day or 300 mg once a day.~Rantidine may be used in combination with any of the above"
3004867|NCT02530879|Experimental|Voice therapy and Anti-reflux therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
3004868|NCT02530866|Active Comparator|Standard care|Women in this arm will target fasting blood glucose values <95 mg/dL and 1 hour post-prandial values <140 mg/dL
3004869|NCT02530866|Experimental|Intensive therapy|Women in the arm will target fasting blood glucose values <90 mg/dL and 1 hour post-prandial values <120 mg/dL.
3004870|NCT02530853|Experimental|Group A|Laser acupuncture
3004871|NCT02530853|Sham Comparator|Group B|Simulation Laser acupuncture
3004872|NCT02530840|Experimental|medical team|personal meetings and follow-up of un-balanced diabetic patients by trained medical team (nurse and doctor), which designed to promote adherence to healthy life style and medical therapy.
3004873|NCT02530840|Experimental|peers group|group meetings and follow-up of un-balanced diabetic patients by trained peers (peers: balanced diabetic patients),which designed to promote adherence to healthy life style and medical therapy.
3004874|NCT02530840|Experimental|SMS notifications|un-balanced diabetic patients receiving daily SMS with content,which designed to promote adherence to healthy life style and medical therapy.
3004875|NCT02530840|No Intervention|control|un-balanced diabetic patients will get the basic and regular treatment for diabetic patients according to Clalit Health Services. In addition, the patients will have the same check-ups like all the patients in the experimental arms.
3004876|NCT02530827||LIPO-HIPO-|HIV-seropositive without lipodystrophy and no use of lipid-lowering drugs.
3004877|NCT02530827||LIPO+HIPO-|HIV-seropositive with lipodystrophy and no use of lipid-lowering drugs.
3004878|NCT02530827||LIPO+HIPO+|HIV-seropositive with lipodystrophy and use of lipid-lowering drugs.
3004879|NCT02530814||Lake Apopka Farmworkers|This group will have a onetime blood collection and questionnaires regarding health status and health concerns.
3004880|NCT02530814||Existing Data Group|The investigators will collect existing data from the National Health and Nutrition Examination Survey (NHANES) for the range of concentrations of these chemicals in the blood of Americans.
3004881|NCT02530801|Other|Avastin and 5 fluorouracil|Subconjunctival injection of bevacizumab combined with 5 fluorouracil
3004882|NCT02530788|Active Comparator|Selenium Supplement (sodium selenite)|Active arm receiving Selenium in form of sodium selenite
3004883|NCT02530788|Placebo Comparator|Placebo|Placebo arm receiving Sodium Chloride solution
3004884|NCT02530775|Active Comparator|instrumented arthrodesis|"Degenerative Spondylolisthesis and Spinal Stenosis patients having a surgical procedure. The surgical procedure is the intervention and is a spinal fusion with use of instrumentation and lumbar laminectomy. No additional drug or device intervention."
3004885|NCT02530775|Active Comparator|non-instrumented arthrodesis|"Degenerative Spondylolisthesis and Spinal Stenosis patients having a surgical procedure. The surgical procedure is the intervention and is a spinal fusion without the use of instrumentation and lumbar laminectomy. No additional drug or device intervention."
3004886|NCT02530762|Placebo Comparator|Negative control|No added fiber
3004887|NCT02530762|Active Comparator|Positive Fiber control|50g positive control fiber
3004888|NCT02530762|Experimental|Novel Fiber 10g|10g novel fiber
3004889|NCT02530762|Experimental|Novel Fiber 30g|30g novel fiber
3004890|NCT02530762|Experimental|Novel Fiber 50g|50g novel fiber
3004891|NCT02530736||IPF_RESP|Pulmonary Rehabilitation: a 6 - 8 week exercise and education programme (this is part of usual care)
3004892|NCT02530723|Experimental|Once a week|Group 1 will be invited to perform resistance training exercise 1 day/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
3004893|NCT02530723|Experimental|Twice a week|Group 2 will be invited to perform resistance training exercise 2 days/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
3004894|NCT02530723|Experimental|Thrice a week|Group 3 will be invited to perform resistance training exercise 3 days/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
3004895|NCT02530723|No Intervention|wait-control|Participants in this group will serve as controls prior to participating in power training in 1 of the above treatment groups. The control period will last as long as the exercise period, or 3 months. Controls will participate in the same testing time points as the exercisers (baseline, midpoint, and post-intervention).
3004896|NCT02530710|Experimental|Q203|Q203 drug products (10mg and 100mg tablets)
3004897|NCT02530710|Placebo Comparator|Placebo|Placebo tablets (same excipients used in Q203 drug products)
3004898|NCT02530697|Active Comparator|Group 1 - Antimoniate|20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days. Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.
3004899|NCT02530697|Experimental|Group 2 - Miltefosine and Pentoxifylline|Miltefosine 2,5mg/kg/day up to 50mg 2x/daily. Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.
3004900|NCT02530684||Knee osteoarthritis|Patients with knee osteoarthritis
3004901|NCT02530684||Control participants|Individuals without signs of knee osteoarthritis
3004902|NCT02530671|Active Comparator|Manual toothbrush|ADA reference manual toothbrush
3004903|NCT02530671|Experimental|Power toothbrush|Multi-directional power toothbrush
3004904|NCT02530658||Participants|"Patients with newly diagnosed, relapsed, or refractory tumors who are prospectively or currently accepted to undergo treatment at SJCRH and their biological parents or legally authorized representative.~Interventions: Study Introduction Visit, Informed Consent Visit, Informed Consent Follow-Up Visit, Return of Results Conversation, two Return of Results Follow-Up Visits, Tissue Sample (when available), Blood Sample or Skin Biopsy."
3004905|NCT02530645|Experimental|OnTrack + BMI|Brief motivational interview plus the use of a smartphone application to monitor alcohol and marijuana use and sexual risk behaviors.
3004906|NCT02530645|Active Comparator|Treatment as Usual|Treatment as usual involves substance use/HIV referral and treatment as regularly offered to all participants who report substance use and sexual risk behaviors at Covenant House New York.
3004907|NCT02530632|Active Comparator|Sevoflurane anesthesia|Anesthesia maintained with inhalational sevoflurane
3004908|NCT02530632|Experimental|Propofol anesthesia|Anesthesia maintained with intravenous propofol continuous infusion
3004909|NCT02530619|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3004910|NCT02530606|Experimental|Diagnostic (PAI)|Patients undergo PAI over 15-30 minutes prior to the ovarian excision.
3004911|NCT02530593||Patients with colon cancer|All patients presenting with a newly diagnosed colon cancer regardless of tumour stage
3004912|NCT02530580|Experimental|20 mg AZD7325|10 mg AZD7325 in orange capsule, Size 0, 2 capsules as a single oral dose
3004913|NCT02530580|Placebo Comparator|Placebo|10 mg Microcrystalline cellulose in orange capsule, Size 0, 2 capsules as a single oral dose
3004914|NCT02530567|Experimental|Intervention|"The measurement of portosystemic pressure gradient will be performed before liver biopsy.~Then liver biopsy is performed. The MRI was performed on the day of biopsy or within one week around the completion of the biopsy.~The MRI machine used is the Siemens 3T."
3004915|NCT02530554|Experimental|CHG 3 min|3 min application time
3004916|NCT02530554|Active Comparator|Comparator CHG|Marketed CHG
3004917|NCT02530541|Experimental|CHG 1 min|1 min application time
3004918|NCT02530541|Experimental|CHG 2 min|2 min application time
3004919|NCT02530541|Active Comparator|Comparator CHG|Marketed CHG
3004920|NCT02530528|Experimental|CHG 1 min|1 min application time
3004921|NCT02530528|Experimental|CHG 2 min|2 min application time
3004922|NCT02530528|Experimental|CHG 3 min|3 min application time
3004923|NCT02530528|Active Comparator|Comparator CHG|Marketed CHG
3004924|NCT02530515|Experimental|Chemotherapy + Activated T-Cell Infusion|"Participants receive Rituximab by vein on Day -5.~Participants receive Fludarabine and Cyclophosphamide by vein on Day -5, -4 and -3.~Participant receives activated T-cells by vein on Day 0.~Study staff calls participant starting about a year and a half after the activated T-cell infusion every 6 months for up to 5 years."
3004925|NCT02530515|Experimental|Chemotherapy + Activated T-Cell Infusion + Lenalidomide|"Participants receive Rituximab by vein on Day -5.~Participants receive Fludarabine and Bendamustine by vein on Day -5, -4 and -3,~Participant receives activated T-cells by vein on Day 0.~Participants receive Lenalidomide by mouth 1 time each day for about 6 months after blood counts are high enough after activated T-cell infusion.~Study staff calls participant starting about a year and a half after the activated T-cell infusion every 6 months for up to 5 years."
3004926|NCT02530515|Experimental|Activated T-Cell Infusion 17p Deletion Group|"Participants receive expanded T cells without lymphodepleting chemotherapy.~Study staff calls participant starting about a year and a half after the activated T-cell infusion every 6 months for up to 5 years."
3037955|NCT02308163|Experimental|ASP015K high dose group|oral
3004927|NCT02530502|Experimental|Treatment (RT, temozolomide, pembrolizumab)|"RT PORTION: Patients undergo focal RT over 42 days, and receive concurrent temozolomide PO QD on days 1-42 and pembrolizumab IV over 30 minutes on days 1, 22, and 43.~POST-RT: After completion of RT, patients receive temozolomide PO QD on days 1-5 and 29-34 of course 1 and days 1-5 and 29-33 of subsequent courses, and pembrolizumab IV over 30 minutes on days 1, 22, and 43. Treatment repeats every 9 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, patients deriving benefit may continue to receive pembrolizumab for an additional 12 months."
3004928|NCT02530489|Experimental|MPDL3280A + Nab-paclitaxel|"MPDL3280A administered at 1200 mg by vein every 3 weeks for 12 weeks in the neoadjuvant setting in combination with Nab-paclitaxel 100 mg/m2 by vein weekly for 12 weeks.~Within 4 weeks after surgery, participants start another 4 cycles of MPDL3280A in the adjuvant setting to complete a total of 8 cycles of treatment with MPDL3280A."
3004929|NCT02530476|Experimental|Selinexor + Sorafenib|"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.~Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle."
3004930|NCT02530476|Experimental|Cohort 1 (FLT3-ITD inhibitor failure cohort)|"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
3004931|NCT02530476|Experimental|Cohort 2 (FLT3-ITD inhibitor naive cohort)|"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
3004932|NCT02530463|Experimental|Cohort 1 - Nivolumab|"Hypomethylating failure MDS cohort: Nivolumab 3 mg/kg by vein every 2 weeks for 6 cycles. One cycle defined as 4 weeks.~After 6 cycles (or earlier if evidence of progression), the use of azacitidine (AZA) allowed to test the concept of re-sensitization."
3004933|NCT02530463|Experimental|Cohort 2 - Ipilimumab|"Hypomethylating failure MDS cohort: Ipilimumab 3 mg/kg by vein every 3 weeks. One cycle defined as 4 weeks.~After 6 cycles (or earlier if evidence of progression), the use of AZA allowed to test the concept of re-sensitization."
3004934|NCT02530463|Experimental|Cohort 3 - Nivolumab + Ipilimumab|"Hypomethylating failure MDS cohort: Nivolumab and Ipilimumab~Nivolumab 3 mg/kg by vein on days 1 and 15 (i.e. 2 planned doses of Nivolumab) and Ipilimumab 3 mg/kg by vein on day 1. One cycle defined as 4 weeks.~After 6 cycles (or earlier if evidence of progression), the use of AZA allowed to test the concept of re-sensitization."
3004935|NCT02530463|Experimental|Cohort 4 - 5-azacitidine + Nivolumab|"Previously untreated MDS cohort: Azacitidine and Nivolumab~Azacitidine 75 mg/m2 by vein daily for 5 days every 4 weeks followed on day 6 by Nivolumab 3 mg/kg by vein every 2 weeks. A cycle considered 4 weeks."
3004936|NCT02530463|Experimental|Cohort 5 - 5-azacitidine + Ipilimumab|"Previously untreated MDS cohort: 5-azacitidine and Ipilimumab~Azacitidine 75 mg/m2 by vein daily for 5 days every 4 weeks followed on day 6 by Ipilimumab 3 mg/kg by vein every 4 weeks. A cycle considered 4 weeks."
3004937|NCT02530463|Experimental|Cohort 6 - 5-azacitidine + Nivolumab + Ipilimumab|"Previously untreated MDS cohort: Azacitidine with Nivolumab and Ipilimumab~Azacitidine 75 mg/m2 by vein daily for 5 days every 4 weeks followed on day 6 and day 20 by Nivolumab 3 mg/kg by vein and Ipilimumab 3 mg/kg by vein on day 6. A cycle considered 4 weeks."
3004938|NCT02530450||Group 1|Initially blinded to continuous glucose monitoring (CGM) data after 1st use Not blinded to continuous glucose monitoring data after 2nd and 3rd use
3004939|NCT02530450||Group 2|Never blinded to continuous glucose monitoring (CGM) data
3004940|NCT02530437|Experimental|Phase IB: Taladegib + Chemoradiation|Phase 1B: Participants take Taladegib 1 time a day by mouth. Radiation therapy delivered every weekday for 5 ½ weeks. Once a week during this time, participants also receive Paclitaxel and Carboplatin by vein.
3004941|NCT02530437|Experimental|Taladegib Before Chemoradiation|"Phase II: If participant is one of the first 27 enrolled in Phase 2, they will take Taladegib for 7 days before beginning chemoradiation. Participant continues to take Taladegib every day until they complete chemoradiation. Radiation therapy delivered every weekday for 5 ½ weeks. Once a week during this time, participants also receive Paclitaxel and Carboplatin by vein.~Research upper endoscopy on day 8 from the start of treatment."
3004942|NCT02530437|Experimental|Taladegib + Chemoradiation|"Phase II: If participant joins the study after 27 participants have been enrolled, they will start Taladegib on the same day they begin chemoradiation. Participant will continue to take Taladegib every day until they complete chemoradiation. Radiation therapy delivered every weekday for 5 ½ weeks. Once a week during this time, participants also receive Paclitaxel and Carboplatin by vein.~Research upper endoscopy on day 8 from the start of treatment."
3004943|NCT02530424|Experimental|Trast-pert-palbo-fulve|Patients will receive an association of drugs (trastuzumab, pertuzumab, palbociclib plus or minus fulvestrant) as neoadjuvant chemotherapy. Definitive surgery will be performed not earlier than 14 days and not later than 28 days after the last dose of any of the drugs in the combination. After completion of surgical treatment patients will receive irradiation as locally acceptable.
3004944|NCT02530411|Experimental|Experimental|Fulvestrant 500mg Intra Muscular (IM) Day 1 (D1), D15, then D1 of every 28 day cycle Vandetanib 300 mg Per os (po) daily Clinician review D1, D15, weeks 4, 8, 12, 16, 20, 24 then 12 weekly. Computerised Axial Tomography (CT) at week 8, 16, 24 then 12 weekly.
3004945|NCT02530411|Placebo Comparator|Control|Fulvestrant 500mg IM D1, D15, then D1 of every 28 day cycle Placebo po daily Clinician review D1, D15, weeks 4, 8, 12, 16, 20, 24 then 12 weekly. CT at week 8, 16, 24 then 12 weekly.
3004946|NCT02530398|Experimental|cinobufacini group|48 patients(half males and half females) will be in the group.Central venous catheters will be preserved for drainage of ascites, after the drainage of most of ascites, we will slowly inject a dilute concentration of cinobufacini injection with escalated dosage through the catheters. Then we will evaluate the observation indexes, including adverse events, vital signs, electrocardiogram, blood routine, urine routine, hepatic and renal function, etc.
3004947|NCT02530385|Experimental|FMT|Active FMT capsules
3004948|NCT02530385|Placebo Comparator|Placebo|Placebo capsules
3005108|NCT02529267||Did not experience abuse|Did not experience IPV in the past 12 months.
3004949|NCT02530372|Experimental|UriCap-F|"The UriCap-F is an FDA cleared Class I device intended for urinary management in women.~The device is comprised of a multiple use unit and a single use unit. The multiple use unit is intended to be reused by the same patient for up to 30 days. It is removed every 24 hours, rinsed under running water, dried and re-applied.~The UriCap is held in position by means of a single-use medically approved adhesive tape."
3004950|NCT02530359|Active Comparator|Group 1|Pirfenidone extended release 600mg per mouth every 12 hours for 7 days.
3004951|NCT02530359|Active Comparator|Group 2|Pirfenidone extended release 600mg per mouth in the morning and placebo by night (each treatment every 12 hrs) for 7 days.
3004952|NCT02530359|Placebo Comparator|Group 3|Placebo equivalent per mouth every 12 hrs for 7 days.
3004953|NCT02530346|Active Comparator|Mechanical Bowel Preparation|"Patients will receive enteric polyethylene glycol at 100 ml/kg/dose during 4 hours, and up to 3 times, prior to surgery.~Enemas with normal saline 20 ml/kg/do will be administered through the stomas 3 times a day"
3004954|NCT02530346|Experimental|No Mechanical Bowel Preparation|Patients will not receive any preparation prior to surgery
3004955|NCT02530333|No Intervention|Basketball Control|Control group of basketball players
3004956|NCT02530333|Experimental|Basketball intervention|Intervention group of basketball players
3004957|NCT02530333|No Intervention|Soccer Control|Control group of soccer players
3004958|NCT02530333|Experimental|Soccer Intervention|intervention group of soccer players
3004959|NCT02530320|Experimental|Palbociclib (PD0332991)|Palbociclib will be administrated orally at a dose of 125 mg/day during 21 days followed by a break of 7 days. All patients included will be treated in the same arm. Treatment will be administrated until disease progression, unacceptable adverse side effects or study end.
3004960|NCT02530307|Experimental|HT-3951 (15mg)|HT-3951 capsules administered once daily
3004961|NCT02530307|Placebo Comparator|Placebo|Placebo capsules administered once daily
3004962|NCT02530294|Experimental|glycopyrronium|glycopyrronium Topical Wipes
3004963|NCT02530294|Placebo Comparator|Vehicle|glycopyrronium Topical Wipes, Vehicle
3004964|NCT02530281|Experimental|glycopyrronium|glycopyrronium Topical Wipes
3004965|NCT02530281|Placebo Comparator|Vehicle|glycopyrronium Topical Wipes, Vehicle
3004966|NCT02530268||Ankylosing Spondylitis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
3004967|NCT02530268||Psoriatic Arthritis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
3004968|NCT02530255|Placebo Comparator|Placebo|Study subjects receiving placebo: Intervention - two capsules, one morning and one night for one year; placebo for cycloastragenol
3004969|NCT02530255|Active Comparator|cycloastragenol|Study subjects receiving cycloastragenol: Intervention - cycloastragenol; oral capsules 8mg. per day (two capsules) one in the morning and one at night for one year.
3004970|NCT02530242|Other|End-tidal Carbon Monoxide Subjects|Children between 1-18 years old with Sickle Cell Anemia
3004971|NCT02530242|Other|End-tidal Carbon Monoxide Controls|Healthy children age matched with subjects.
3004972|NCT02530229||Periprosthetic joint infection|Patients with suspected periprosthetic joint infection of the hip, knee and shoulder
3004973|NCT02530229||Septic arthritis|Patients with suspected septic arthritis of a native joint of the hip, knee and shoulder
3004974|NCT02530216|No Intervention|Usual care|Individuals in this arm will undergo usual care with their physician.
3004975|NCT02530216|Experimental|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Individuals in the AEGIS arm will be invited to use AEGIS/My GI Health prior to their clinic visit. For those who complete AEGIS/My GI Health, their physician will have access to their AEGIS symptom report (includes a GI symptom heat map and GI history) and tailored education prescription.
3004976|NCT02530203|Other|Conventional treatment|Non interventional group, patients that belong to this arm will receive the conventional treatment for CABG and they will wear the Holter for 5 days.
3004977|NCT02530203|Experimental|Spinal Cord Stimulation System|This group will receive the Spinal Cord Stimulation System and they will wear the Holter for 5 days.
3004978|NCT02530190|No Intervention|Control|20 minutes of supine rest
3004979|NCT02530190|Active Comparator|Intermittent pneumatic compression|20 minutes of intermittent pneumatic compression
3004980|NCT02530190|Active Comparator|Massage|20 minutes of massage therapy
3004981|NCT02530177||Patients having CYTOTOXIC CHEMOTHERAPY|Participants will undergo study related assessments and the appropriate HRQoL questionnaires will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for (clinically indicated) standard-of-care visits. Initially, these visits will be coinciding with the appropriate chemotherapy dosing cycles (as applicable to select study cohorts), and subsequently they will be performed during the standard-of-care follow-up visits.
3004982|NCT02530177||Patients having ENDOCRINE THERAPY|Participants will undergo study related assessments and Medical and Personal History Questionnaire data collection forms and the appropriate HRQoL questionnaires, will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for standard-of-care visits. Initially, these visits will be coinciding with the appropriate therapy and subsequently they will be performed during the standard-of-care follow-up visits.
3004983|NCT02530177||COMPARATOR (menopausal women)|Menopausal women will include unrelated visitors accompanying breast cancer patients (e.g. friends) attending the breast medicine or dermatology clinics, or female employees of MSKCC. There will be no follow-up visits (after baseline) for participants in the comparator cohort.
3004984|NCT02530164|Active Comparator|real tDCS|
3004985|NCT02530164|Placebo Comparator|sham tDCS|
3004986|NCT02530151|Experimental|Morphine with Clonidine|11 mL intra-articular injection of 10 mg morphine and 100 mcg clonidine in .9% NaCl solution at conclusion of hip arthroscopy procedure
3004987|NCT02530151|Placebo Comparator|Normal Saline|11 mL intra-articular injection of .9% NaCl solution at conclusion of hip arthroscopy procedure
3004988|NCT02530138|Active Comparator|Synbiotic|2 synbiotic capsules for 28 weeks
3004989|NCT02530138|Placebo Comparator|maltodexterin|two capsules per day for 28 weeks
3005100|NCT02529319|Experimental|MRI-Guided Ablation|"Surgery~Patients will undergo catheter ablation using DE-MRI as a guide for fibrosis imaging."
3004990|NCT02530125|Experimental|Treatment (pidilizumab)|Patients receive pidilizumab IV over approximately 5 hours on day 1. Treatment repeats every 42 days for 3 courses in the absence of disease progression or unacceptable toxicity.
3004991|NCT02530112||Phase 1|
3004992|NCT02530112||Phase 2|
3004993|NCT02530112||Phase 3|
3004994|NCT02530099|No Intervention|Control group|Receive no training.
3004995|NCT02530099|Experimental|CN-group|Receive basic camera navigation training.
3004996|NCT02530099|Experimental|Procedure-group|Receive training on a laparoscopic procedure.
3004997|NCT02530086|Active Comparator|Placement of a Nasogastric tube|Placement of a Nasogastric tube
3004998|NCT02530086|Experimental|No placement of a Nasogastric tube|No placement of a Nasogastric tube
3004999|NCT02530073|Experimental|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|An un-blinded non-randomized single arm pilot study of FETO in fetuses with congenital diaphragmatic hernia (CDH)
3005000|NCT02530060|Experimental|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine|Participants will receive single oral dose of fixed dose combination (FDC) tablet comprising of Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine on Day 1.
3005001|NCT02530047|Experimental|Mesenchymal Stem Cells + Interferon Beta (MSC-INFβ)|MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion. Starting dose: 10^5 MSC/kg once a week for 4 treatments. Up to 4 dose levels of MSC-INFβ tested. Symptom questionnaire completed once a week for 4 weeks.
3005002|NCT02530034|Experimental|Hu8F4|Phase I Starting dose of Hu8F4 is 1 mg by vein over about 30 minutes on Days 0, 7, 14, and 21 of each 28-day cycle.
3005003|NCT02530034|Experimental|Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia|Phase II Starting dose of Hu8F4 is the maximum tolerated dose from Phase I.
3005004|NCT02530034|Experimental|Acute Myeloid Leukemia|Phase II Starting dose of Hu8F4 is the maximum tolerated dose from Phase I.
3005005|NCT02530034|Experimental|Chronic Myeloid Leukemia in Blast Phase|Phase II Starting dose of Hu8F4 is the maximum tolerated dose from Phase I.
3005006|NCT02530021||Heart rate monitor|"Hospitalized patients with chest pain and suspected ischemic heart disease who are candidates for non invasive exercise stress test by their treating physician.~The patients will perform a one hour heart rate variability monitoring prior to the stress test."
3005007|NCT02529995|Experimental|AZD9291 40 mg|Cohort 1: 40 mg once daily
3005008|NCT02529995|Experimental|AZD9291 80 mg|Cohort 2: 80 mg once daily
3005009|NCT02529982|Active Comparator|intervention|500 mg curcumin capsule
3005010|NCT02529982|Placebo Comparator|control|placebo
3005011|NCT02529969|Active Comparator|intervention|500 mg curcumin capsule
3005012|NCT02529969|Placebo Comparator|placebo|500 mg placebo
3005013|NCT02529956|Experimental|UCB4940 8 mg|Single intravenous (iv) infusion of UCB4940 8 mg over at least 60 minutes.
3005014|NCT02529956|Experimental|UCB4940 40 mg|Single intravenous (iv) infusion of UCB4940 40 mg over at least 60 minutes.
3005015|NCT02529956|Experimental|UCB4940 160 mg|Single intravenous (iv) infusion of UCB4940 160 mg over at least 60 minutes.
3005016|NCT02529956|Experimental|UCB4940 480 mg|Single intravenous (iv) infusion of UCB4940 480 mg over at least 60 minutes.
3005017|NCT02529956|Experimental|UCB4940 640 mg|Single intravenous (iv) infusion of UCB4940 640 mg over at least 60 minutes.
3005018|NCT02529956|Placebo Comparator|Placebo|Single intravenous (iv) infusion of Placebo over at least 60 minutes.
3005019|NCT02529943||Surgery Group|Consecutive patients from a two surgeon practice
3005020|NCT02529930|Experimental|Cohort 1: 3mg VB10.16 Vaccine|VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 3, Week 6, 3mgs per vaccination
3005021|NCT02529930|Experimental|Cohort 2: 3mg VB10.16 Vaccine|VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 4, Week 8, 3mgs per vaccination
3005022|NCT02529917|Experimental|Hemp powder|Hemp powder supplement
3005023|NCT02529917|Active Comparator|Soy powder|Soy powder supplement
3005024|NCT02529904|Experimental|MF59 - ATIV|"All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.~Adult participants will receive one dose of MF59-ATIV."
3005025|NCT02529891||COPD Patients|Patients with COPD, within 48h after hospital admission for exacerbation.
3005026|NCT02529891||non-COPD patients|Healthy person of the entourage of COPD patients.
3005027|NCT02529878|Experimental|conversion treatment|after 3 cycles S1/Paclitaxel chemotherapy plus Apatinib,subsequent surgery will be conducted with curative intent
3005028|NCT02529865|Experimental|ADRCs and Adipose tissue|Periurethral injection of autologous adipose derived regenerative cells and adipose tissue
3005029|NCT02529852|Experimental|Lenalidomide + Obinutuzumab + CHOP|"Phase I: Participants take Lenalidomide by mouth on Days 1 - 14 of each cycle. Participants receive Obinutuzumab by vein over 3 - 4 hours on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6. Participants receive Cyclophosphamide by vein over about 1 hour on Day 1 of all cycles. Participants receive Doxorubicin and Vincristine by vein over about 15 minutes each on Day 1 of all cycles.~Phase II: Participants treated at the recommended phase II dosing (RP2D) of Lenalidomide determined in the Phase Ib portion for 6 cycles of therapy. Dose of Obinutuzumab, Cyclophosphamide, Doxorubicin and Vincristine remain the same as in Phase I.~Each study cycle is 21 days."
3005030|NCT02529839|Experimental|Experimental|"Fludarabine 30mg/m2 for 4 days, Cyclophosphamide 50mg/kg for 2 days, Alemtuzumab administered subcutaneously 24mg total dose.~Autologous bone marrow transplantation"
3005031|NCT02529826|Experimental|Testicular biopsy|Cancer affected prepubertal boys will undergo testicular biopsy for testicular fragments cryopreservation. The biopsy will be performed by an attending urologist, before any gonadotoxic therapy is initiated. Testicular biopsy specimens will be divided immediately on the operating table. Two thirds of the specimen will be cryopreserved for potential use by the patient at a later date and will have the patient's details and will stay at the sperm bank of Hadassah Medical Center. The other third of specimen will be used for research purposes in an effort to advance the science of isolating and culturing human SSC's for fertility research.
3005101|NCT02529319|Active Comparator|Conventional Ablation|"Surgery~Patients will undergo conventional catheter ablation as described by the HRS guidelines."
3005102|NCT02529306||two parallel group|group with inflammatory markers high levels and control group with inflammatory normal levels markers.
3005032|NCT02529813|Experimental|Participant (Autologous)-Derived CAR T Cells|"Participant (Autologous)-derived CAR T cells infused for active disease following lymphodepleting chemotherapy at discretion of treating physician. Three lymphodepletion regimens considered at discretion of treating physician.~T-cell infusion given by vein either all on one day or split into two days. It can be given up to 1 month after last chemotherapy treatment."
3005033|NCT02529800|Experimental|Sequence 1|High fat diet+HGP0412 → High fat diet+HIP1402 → fasted state+HIP1402
3005034|NCT02529800|Experimental|Sequence 2|High fat diet+HIP1402 → fasted state+HIP1402 → High fat diet+HGP0412
3005035|NCT02529800|Experimental|Sequence 3|fasted state+HIP1402 → High fat diet+HGP0412 → High fat diet+HIP1402
3005036|NCT02529787|Experimental|A Test|Test drug (Doxirazole) 1 capsule contains 60 mg of Dexlansoprazole
3005037|NCT02529787|Active Comparator|B Reference|Reference drug (Dexilant) 1 capsule contains 60 mg of Dexlansoprazole
3005038|NCT02529774|Experimental|Systemic Chemotherapy plus Hepatic Artery Infusion (HAI)|
3005039|NCT02529774|Active Comparator|Systemic Chemotherapy|
3005040|NCT02529761|Experimental|Sorafenib combined with TACE|220 subjects in this study group will receive the treatment of sorafenib combined with conventional TACE.
3005041|NCT02529761|Active Comparator|TACE monotherapy|110 subjects in this study group will receive the treatment of conventional TACE monotherapy.
3005042|NCT02529748|Experimental|Participants for Surface Skin Sampling|Adult volunteers with healthy, intact skin will have surface skin wipe samples collected following contact with the approved test substances to measure the quantitative transfer of the test substances to and from the skin surface.
3005043|NCT02529709|Experimental|High-protein meal condition|
3005044|NCT02529709|Active Comparator|High-monounsaturated fat meal condition|
3005045|NCT02529696||Medical device, accelerometer|A wrist and chest accelerometer will be worn for the duration of stay in the ICU. Data will be generated from patient movement and recorded. Neither the generated data or the worn devices will influence care team's decisions during the patients' stay.
3005046|NCT02529683|Experimental|Nuvaring (only arm)|Nuvaring use for six months, with monthly pickup of rings and returning of used rings, and other behavioral/clinical assessments conducted during the visit on day 21 of the menstrual cycle.
3005047|NCT02529670|Experimental|Laser|15 patients will be positioned in a prone horizontal position under anesthetic monitoring. The intervertebral foramen between the second and third lumbar vertebrae will be accessed by percutaneous puncture guided by fluoroscopy. Laser Photon III® (DCM) will be applied through fiber optics crossing G18 cannulas, during 84 seconds.
3005048|NCT02529670|Active Comparator|Radiofrequency|15 patients will receive radiofrequency in the second dorsal root ganglion through tubes G20, 150 mm long and 5 mm active tip in contact with the target, neuromodulation will be held for 300 seconds at 42oC.
3005049|NCT02529670|Active Comparator|Drug: Lidocaine|In the local anesthetic group, 15 patients will receive the injection of 1 ml lidocaine without vasoconstrictor will be applied in the tubes G18, 150 mm long to block the second dorsal root ganglion.
3005050|NCT02529657|Placebo Comparator|Placebo|23 patients were induced to think they will be getting the same treatment, although the LLLT is not operating.
3005051|NCT02529657|Experimental|Low level Laser Therapy|25 patients were submitted to spine surgery and have received low level laser therapy during surgery, 24 hours after surgery and 48 hours after surgery.
3005052|NCT02529644|Active Comparator|Comparison (Standard Information Arm)|The comparison/standard information churches will receive standard multilevel HIV education information that is similar in type to those provided to the intervention churches. These churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. These churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.
3005053|NCT02529644|Experimental|Intervention|Taking It to the Pews (TIPS) will be delivered through church-based multilevel (community, church-wide, ministry group, interpersonal/individual) activities by trained church leaders using religiously/ culturally-tailored study materials packaged in a TIPS HIV Tool Kit and following a scripted, study implementation manual.
3005054|NCT02529631|Active Comparator|Drug: orlistat 60mg capsules|"A tailored blister-strip for one day contains~three capsules with orlistat 60mg Administration: 3 times daily 1 capsule with each meal containing fat concomitant with~six placebo tablets Administration: 3 times daily 2 tablets with each main meal"
3005055|NCT02529631|Active Comparator|Medical device: polyglucosamine|"A tailored blister-strip for one day contains~three placebo capsules Administration: 3 times daily 1 capsule with each meal containing fat concomitant with~six tablets Administration: 3 times daily 2 tablets (whereas the 2 tablets in the mold breakfast are placebo tablets and the remaining 4 tablets for lunch and dinner contains poliglucosamine"
3005056|NCT02529618||Football Athlete Group|"All football athlete participants in this arm will take the integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT) test. Participants who sustain a concussion during the football season will complete the iDETECT test and a standing balance test (BESS assessment) four times after injury. Participants in this arm are eligible to receive the Riddell High Impact Technology (HIT) System or the i1 Biometrics Vector Mouth Guard.~NOTE: Football athletes who sustain a concussion during the football season will be evaluated and managed according to standard concussion screening and return-to-play (RTP) protocols. Performance on iDETECT or other study related tasks will NOT be used to make diagnosis, management, or return to play decisions. Study staff will not assist with or influence diagnosis, management, or return-to-play decision making by teams' medical personnel."
3005103|NCT02529293|Active Comparator|BioChaperone Lispro U-100|injection of 2 doses of 0.2 U/kg on separate visits
3005104|NCT02529293|Experimental|BioChaperone Lispro U-200|injection of 2 doses of 0.2 U/kg on separate visits
3005105|NCT02529280|Experimental|Intervention|The intervention group will receive three components: 1) a culturally sensitive, individually tailored, 30-minute computer-based BCCT video; 2) a bilingual, low-literacy booklet aimed at encouraging patients to communicate with family and friends and 3) assistance from a patient navigator.
3005106|NCT02529280|No Intervention|Usual Care|The usual care control group will receive the usual care breast cancer clinical trial information materials offered by the CTRC to their eligible patients.
3005107|NCT02529267||Experienced abuse|Experienced IPV in the past 12 months
3005057|NCT02529618||Non-Collision Sport Athlete Group|"Non-collision sport athletes who are active in a school's Fall athletic program will be take the integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT) test, standing balance test (BESS assessment), and complete a questionnaire at the beginning of the sport season. Participants will be asked to take the iDETCT test up to 5 more times during the season. Participants who sustain a concussion during the athletic season will be asked to take additional iDETECT tests four times after the injury.~NOTE: Non-collision sport athletes who sustain a concussion during the season will be evaluated and managed according to standard concussion screening and return-to-play (RTP) protocols. Performance on iDETECT or other study related tasks will NOT be used to make diagnosis, management, or return to play decisions. Study staff will not assist with or influence diagnosis, management, or return-to-play decision making by teams' medical personnel."
3005058|NCT02529605|Active Comparator|Product B® IsaGenesis®, Then IsaGenesis®|Participants will come into the clinic in a fasting state to receive the Product B® IsaGenesis®, which will be a one time dose of the liquid-gel formulation contained in 2 capsules, 1280 mg per capsule. After a washout period of 7 days, they will then come back to the clinic in a fasting state to receive the IsaGenesis®. This will be given for a comparison in a one time dose of the dried powder extract contained in 2 capsules; 1070 mg per capsule.
3005059|NCT02529605|Active Comparator|IsaGenesis®, Then Product B® IsaGenesis®|Participants will come into the clinic in a fasting state to receive the IsaGenesis®, which will be a one time dose of the dried powder extract contained in 2 capsules; 1070 mg per capsule. After a washout period of 7 days, they will then come back to the clinic in a fasting state to receive the Product B® IsaGenesis®. This will be given for a comparison in a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.
3005060|NCT02529592|Experimental|Endotoxin|Endotoxin at 2ng/kg of body weight administered intravenously
3005061|NCT02529592|Placebo Comparator|Placebo|Placebo administered intravenously
3005062|NCT02529579|Active Comparator|Gemcitabine|Standard Gemcitabine Therapy
3005063|NCT02529579|Experimental|cellular immunotherapy & Gemcitabine|iAPA-DC/CTL adoptive cellular immunotherapy combined Standard Gemcitabine Therapy
3005064|NCT02529553|Experimental|LY3076226|"Part A (dose escalation in advanced cancer): LY3076226 administered intravenously (IV) on day 1 of each 21 day cycle.~Part B (dose expansion in advanced urothelial carcinoma): LY3076226 administered IV on day 1 of each 21 day cycle."
3005065|NCT02529540|Other|Group 1|Self-refraction with adjustable glasses
3005066|NCT02529540|Other|Group 2|Subjective refraction by an expert refractionist after auto refraction and receiving custom standard glasses
3005067|NCT02529540|Other|Group 3|Subjective refraction by an expert refractionist after auto refraction and receiving ready-made glasses
3005068|NCT02529527|Experimental|MyFamilyPlan|Web-based health education tool (interactive self-assessment) provided for participant completion 7-10 days prior to a scheduled primary care visit.
3005069|NCT02529527|No Intervention|Control|Standard preconception health education document provided for participant review 7-10 days prior to a scheduled primary care visit.
3005070|NCT02529514|Active Comparator|Baclofen|Baclofen 25 mg per os for 7 days at 10 pm every day
3005071|NCT02529514|Placebo Comparator|Placebo|Placebo per os for 7 days at 10 pm every day
3005072|NCT02529501||SA|Patients undergoing spinal anesthesia
3005073|NCT02529501||GA|Patients undergoing short general anesthesia
3005074|NCT02529488|Experimental|TFNT00|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation
3005075|NCT02529475|Experimental|Gadoteric acid|Gadoteric acid 0.2 mmol/kg
3005076|NCT02529462|Experimental|NEUROPHARMAGEN-Guided Treatment|In the study patient group, the psychiatrist will have the results of the NEUROPHARMAGEN genetic test as supporting information to help him/her select the best treatment for the patient.
3005077|NCT02529462|Active Comparator|Treatment As Usual|"In the control patient group, treatment as usual will be selected and prescribed in accordance with routine clinical practice ."
3005078|NCT02529449|Placebo Comparator|Placebo|once daily
3005079|NCT02529449|Experimental|ASP1941 Low dose group|once daily
3005080|NCT02529449|Experimental|ASP1941 Middle dose group|once daily
3005081|NCT02529449|Experimental|ASP1941 High dose group|once daily
3005082|NCT02529423|Placebo Comparator|Placebo|Placebo
3005083|NCT02529423|Experimental|Multi‐nutrient supplement|Multi‐nutrient supplement
3005084|NCT02529423|Experimental|Placebo + Behavioral Activation|Placebo + Behavioral Activation
3005085|NCT02529423|Experimental|Multi‐nutrient + Behavioral Activation|Multi‐nutrient + Behavioral Activation
3005086|NCT02529410|Experimental|Triventricular pacing|2 Left ventricular leads and one right ventricular lead
3005087|NCT02529410|Active Comparator|Biventricular leads|1 left ventricular lead and one right ventricular lead
3005088|NCT02529397|Experimental|Adaptive Working Memory Training|The experimental group will receive working memory training through a commercial computerized program: five weeks of adaptive working memory training concurrently with a behavioral weight loss program. Adaptive working memory training becomes progressively more challenging depending on an individual's performance on a given task. They will attend weekly classes of a behavioral weight loss program.
3005089|NCT02529397|Placebo Comparator|Non-adaptive Working Memory Training|The control group will receive five weeks of non-adaptive (placebo) cognitive training concurrent with the identical behavioral weight loss program as in the experimental group. Non-adaptive cognitive training remains at a constant level.
3005090|NCT02529384||malignant group|The lesion which is malignant tumors in breast
3005091|NCT02529384||begin group|The lesion which is begin lesion in breast
3005092|NCT02529384||The control group|Patient's ipsilateral or contralateral normal breast parenchyma were collected as a control group
3005093|NCT02529371|Experimental|UriCap-RM|The device is comprised of a reusable part and a single use adhesive tape. The device is removed once daily and the reusable part is rinsed, dried and reapplied with a new adhesive tape.
3005094|NCT02529358|Experimental|EG stand|Standardized text messages
3005095|NCT02529358|Experimental|EG ind|Personalized text messages
3005096|NCT02529358|Other|Control|Standardized text messages after 10 weeks
3005097|NCT02529345|Experimental|RoadSaver stent|patient treated with the RoadSaver stent of Terumo
3005109|NCT02529254|Experimental|Video coaching|14 residents in general surgery from PGY-1(post graduate year-1) to PGY-4 Block randomized to the intervention group who will receive a 30 minute video coaching session as the intervention
3005110|NCT02529254|No Intervention|Control|14 residents in general surgery from PGY-1 to PGY-4 block randomized to the control group
3005111|NCT02529241|Experimental|Group 1: LCB01-0371|Period 1: LCB01-0371 Tablet 400 mg Period 2: LCB01-0371 Tablet 400 mg
3005112|NCT02529241|Experimental|Group 2: LCB01-0371|Period 1: LCB01-0371 Tablet 800 mg Period 2: LCB01-0371 Tablet 1200 mg
3005113|NCT02529228|Experimental|CON-2|Consuming 2 Low Protein, High Carbohydrate Meals i.e. changing Meal Frequency and Protein Composition.
3005114|NCT02529228|Experimental|CON-6|Dividing meal intake into 6 smaller Low Protein, High Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
3005115|NCT02529228|Experimental|PRO-2|Consuming 2 High Protein, Low Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
3005116|NCT02529228|Experimental|PRO-6|Dividing meal intake into 6 smaller High Protein, Low Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
3005117|NCT02529215|Experimental|Just-in-time training (JITT) group|Receive a 20min just-in-time simulation-based teaching session targeting: (1) CPR quality and (2) medication administration within 3 hours of the scheduled in situ simulation.
3005118|NCT02529215|No Intervention|No additional training (control) group|Control group who receives no additional training.
3005119|NCT02529202|Experimental|Dexmedetomidine group|Neonates with hypoxic-ischemic encephalopathy will receive a dexmedetomidine maintenance infusion of 0.4 mcg/kg/hr during treatment with therapeutic hypothermia and during re-warming (78 hours total).
3005120|NCT02529189|Active Comparator|Nitrate-rich beetroot juice|70 ml of a beetroot juice concentrate containing ~5 mmol nitrate
3005121|NCT02529189|Placebo Comparator|Nitrate-deplete beetroot juice|70 ml of a beetroot juice concentrate that is nitrate-depleted
3005122|NCT02529176|Experimental|Best-practice alert|Receive the best-practice alert (BPA) during the course of their clinical work in the electronic medical record.
3005123|NCT02529176|No Intervention|No alert|Physicians will receive no best-practice alert from the electronic medical record.
3005124|NCT02529163|Active Comparator|Late-life Schizophrenia ICP|"The Late-Life Schizophrenia ICP arm will follow a medication algorithm composed of 3 trials and titration schedule with prompts.~First trial is Risperidone (2- 4mg daily).~Second trial: Quetiapine (100 - 400mg daily) OR Aripiprazole (100 - 200mg daily) OR OR Ziprasidone (80mg daily) OR Loxapine (100mg daily)~Third trial: Clozapine (450mg daily) or Olanzapine (20mg daily)~If non compliant depot preparation of: Paliperidone (50 - 150mg monthly), Risperidone (12.5 - 50mg q 2 weeks), Flupentixol (10 - 20mg q 2-3 weeks) or Aripiprazole ( up to 400mg monthly)~Prompts will be given to for non-pharmacological interventions such as:~metabolic monitoring~skin hygiene~pain management~nutritional counseling~counseling"
3005125|NCT02529163|Active Comparator|Treatment as Usual (TAU)|The TAU will not receive any prompts to follow a specific treatment. The TAU group will be treated according to the current standard of care by the treating physician. They will have an opportunity to be offered the same non-pharmacological interventions seen with the ICP group but at the discretion of the treating physician. Pharmacological interventions will include an anti-psychotic medication that is selected at the discretion of treating physician with no set titration schedule or timeline to meet a maximum dosage. Max dosage will be decided by the treating physician.
3005126|NCT02529137||Surgical pathology cases|Cases will be selected from the sites Laboratory Information Systems using the in- and exclusion criteria.
3005127|NCT02529124|Placebo Comparator|CONTROL|a group of subjects receiving a placebo nutrient supplement (per kg of body mass: 0.25g maltodextrin; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks
3005128|NCT02529124|Active Comparator|PROTEIN|a group of subjects receiving a nutrient supplement (per kg of body mass: 0.33g milk protein + 0.25ug vitamin D + 10mg calcium; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks
3005129|NCT02529124|Active Comparator|PROTEIN+PHYSICAL ACTIVITY|a group of subjects receiving a nutrient supplement (per kg of body mass: 0.33g milk protein + 0.25ug vitamin D + 10mg calcium; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks plus a prescribed regimen of physical activity
3005130|NCT02529111|Experimental|intervention|"The Echonavigator software will be used on all patients. It will be used after the introduction of the percutaneous closure of ASD prosthesis. The image fusion on fluoroscopy will then be applied."
3005131|NCT02529098|Sham Comparator|asymptomatic patients|fMRI Asymptomatic patients
3005132|NCT02529098|Experimental|symptomatic patients|fMRI patients with visual difficulties
3005133|NCT02529085|Experimental|Infants with PWS|Blood samples for the bank in link with a multicenter database including clinical data on birth, auxology, endocrine functions and feeding behaviour
3005134|NCT02529085|Other|control group|Blood samples for the bank in children hospitalized for a planned surgery for malformation, orthopaedic or visceral surgery
3005135|NCT02529072|Experimental|Group I|Patients will receive nivolumab 3 mg/kg IV every 2 weeks for 8 weeks followed by surgery. Following resection, nivolumab and DC vaccine will be administered every 2 weeks (± 1) for a total of 3 vaccines, followed by biweekly treatment with nivolumab and monthly DC vaccinations for a total of 5 more vaccines. Patients will continue to receive nivolumab every 2 weeks until progression.
3005136|NCT02529072|Experimental|Group II|Patients will initially receive the fourth cycle of nivolumab then receive nivolumab 3 mg/kg IV and DC vaccine every 2 weeks for a total of 3 vaccines, and then surgery. Subsequent to surgery, the patient will resume biweekly treatment with nivolumab and monthly DC vaccinations for a total of 5 more vaccines. Patients will continue to receive nivolumab every 2 weeks until progression.
3005137|NCT02529059|Experimental|Switch from Atripla to Eviplera|
3005138|NCT02529046|Active Comparator|Aerobic exercise associated with CLA|CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%).
3005139|NCT02529046|Placebo Comparator|Aerobic exercise|Placebo group received 4 g/day of olive oil.
3005140|NCT02529020|Experimental|Mouthguard|All subjects perform all tests wearing mouthguard.
3005141|NCT02529020|Experimental|No mouthguard|All subjects perform all tests without mouthguard
3005142|NCT02529007|Active Comparator|Standard|These patients have standard colonoscopy performed
3005143|NCT02529007|Experimental|Endocuff|These patients have colonoscopy performed with the endo-cuff attached to the end of the colonoscope
3005144|NCT02528994|Experimental|Serine 6g daily|Randomized participants will take 6g daily of dietary serine supplement
3005145|NCT02528994|Experimental|Serine 12g daily|Randomized participants will take 12g daily of dietary serine supplement
3005146|NCT02528994|Experimental|Serine 24g daily|Randomized participants will take 24g daily of dietary serine supplement
3005147|NCT02528994|Experimental|Serine 48g daily|Randomized participants will take 48g daily of dietary serine supplement
3005148|NCT02528981|Experimental|Probiotic|L. rhamnosus GR-1 and L. reuteri RC-14 will be supplied to 100 randomized pregnant people in gelatin capsules containing 2.5 billion viable cells of each strain (CFU). These organisms have been previously shown to colonize the vagina after being taken orally (11) and displace the pathogens causing bacterial vaginosis (12) and vaginal yeast infections (13), and have been shown to be an effective treatment, or accessory to treatment of these conditions. (7- 9, 13)
3005149|NCT02528981|Placebo Comparator|Placebo|Placebo capsules will be supplied to 100 randomized pregnant people in gelatin capsules that are identical to the probiotics that the experimental group will receive.
3005150|NCT02528968|Other|Educational Package|Patients will receive a standardised PK focused educational package in the form of a short video film.
3005151|NCT02528955|Active Comparator|A:De-Intensification Radiotherapy (RT) primary tumor region|"A:De-Intensification Radiotherapy (RT) primary tumor region~≤ pT2, R ≥ 5 mm, L0, Pn0~> 3 lymph node metastasis or patients with < 3 ipsilateral lymph node metastasis and a bilateral primary tumor without adequate contralateral neck dissection"
3005152|NCT02528955|Active Comparator|B:De-Intensification Radiotherapy contralateral lymph nodes|"> pT2 and/or R < 5mm and/or L1 and/or Pn1~≤ 3 ipsilateral lymph node metastasis (and contralateral pN0 (>= 6 resected lymph nodes) or contralateral cN0 in patients wih strictly ipsilateral localised ( >= 5 mm distance from midline) cancer of the oral cavity or oropharynx"
3005153|NCT02528955|Active Comparator|C:De-Intensification RT primary tumor region /contralateral LN|"≤ pT2, R ≥ 5 mm, L0, Pn0~≤ 3 ipsilateral lymph node metastasis (and contralateral pN0 (>= 6 resected lymph nodes) or contralateral cN0 in patients wih strictly ipsilateral localised ( >= 5 mm distance from midline) cancer of the oral cavity or oropharynx"
3005154|NCT02528942|Experimental|Radiation therapy|The functional avoidance radiation therapy plan will be delivered using a standard course of radiation treatment on a linear accelerator. Patients will receive daily radiation treatment for 15-35 days.
3005155|NCT02528929|Active Comparator|At-risk serology|Gluten-free diet
3005156|NCT02528929|Active Comparator|Not at-risk serology|Gluten-free diet
3005157|NCT02528916||Primary Knee Arthroplasty Patients|Patients who consented, met inclusion and exclusion criteria, had plasma and synovial fluid samples drawn as described in the included protocol. No interventions were completed. No changes to standard of care treatment completed.
3005158|NCT02528903|Experimental|Cohort A|
3005159|NCT02528903|Experimental|Cohort B|
3005160|NCT02528903|Experimental|Cohort C|
3005161|NCT02528903|Experimental|Cohort D|
3005162|NCT02528903|Experimental|Cohort E|
3005163|NCT02528890||preganat women between 34 - 40 weeks|Eligible pregnant women, who meet the inclusion criteria, will have a vaginal/anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
3005164|NCT02528877|Experimental|Supportive care (ruxolitinib phosphate, tacrolimus, sirolimus)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV on days -9 to -5 and melphalan IV over 20 minutes on day -4. Beginning greater than 48 hours after completion of melphalan, patients undergo peripheral blood stem cell or bone marrow transplant according to standard guidelines on day 0.~GVHD PROPHYLAXIS: Patients receive ruxolitinib phosphate PO BID on days -3 to 30 tapered to day 60, tacrolimus IV continuously or PO BID on days -3 to 100 , and sirolimus PO QD on day -3 to 100. Treatment continues in the absence of disease progression or unacceptable toxicity."
3005165|NCT02528864||Normal endometrium|Control group (n=30) comprising surgical candidates with normal endometrial tissue will be collected for comparison.
3005166|NCT02528864||Endometrial/uterine cancer|"1st year: 50 eligible patients surgical candidates of endometrial cancer with pre-operative imaging and biological samples collected during operation.~2nd year: Enroll another 50 surgical candidates and complete the data regarding clinical MRS/diffusion-weighted imaging and tissue high resolution MRS. Together with the 50 cancer subjects in the first year there will be in total 100 cancer subjects for analysis.~3rd year: Collect enough positive events with any myometrial involvement (n=30), cervical stromal invasion (n=10) and nodal metastasis (n=10). Together with the 100 cancer subjects in the first and second years there will be in total 150 cancer subjects for analysis."
3005167|NCT02528851|Experimental|Higher CPAP|Infants extubated to CPAP level 2cm H2O higher than extubation EAP
3005168|NCT02528851|Active Comparator|Equivalent CPAP|Infants extubated to CPAP equivalent to extubation EAP
3005169|NCT02528838||Patients receiving Revlimid according to clinical practice|
3005170|NCT02528825|Experimental|smooth emergence|ASA I-II, aged 19-65 years undergoing general anesthesia with DLT for lung wedge resection were enrolled in this study.After completing the surgery, the propofol infusion was stopped, and effect-site concentration of remifentanil was titrated to predetermined concentration ( initial concentration being 1.5ng/ml for the first patient).The predetermined concentration was maintained at least 10 min throughout emergence for the effect site concentration and plasma concentration can be expected stable. The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
3005171|NCT02528812|Experimental|Ipsi-R|Intervention group 1 included participants receiving heavy roller massage via the TheraBand Roller Massager on the calf that exhibited the higher tenderness (Ipsilateral Rolling: Ipsi-R)
3005172|NCT02528812|Experimental|Contra-R|Intervention group 2 included participants receiving heavy roller massage via the TheraBand Roller Massager on the calf of the contralateral limb (Contralateral Rolling: Contra-R)
3005173|NCT02528812|Sham Comparator|Sham group|The sham group received light stroking of the skin with TheraBand roller massager on the calf that exhibited the higher tenderness
3005174|NCT02528812|Experimental|Ipsi-M|Intervention group 3 included participants receiving manual massage on the calf that exhibited the higher tenderness (Ipsilateral Manual: Ipsi-M)
3005175|NCT02528812|No Intervention|control group|received no intervention
3005176|NCT02528799|Experimental|Nexvax2 DQ2.5 Homozygotes (Cohort 1)|Nexvax2 by ID injections for a total of 14 doses over 46 days.
3005177|NCT02528799|Placebo Comparator|Nexvax2 Placebo DQ2.5 Homozygotes (Cohort 1)|Nexvax2 Placebo by ID injections for a total of 14 doses over 46 days.
3005178|NCT02528799|Experimental|Nexvax2 DQ2.5 Non-homozygotes (Cohort 2)|Nexvax2 by ID injections for a total of 14 doses over 46 days.
3005179|NCT02528799|Placebo Comparator|Nexvax2 Placebo DQ2.5 Non-homozygotes (Cohort 2)|Nexvax2 Placebo by ID injections for a total of 14 doses over 46 days.
3005180|NCT02528799|Experimental|Nexvax2 DQ2.5 Non-homozygotes (Cohort 3)|Nexvax2 by ID injections for 18 doses (up to 27 doses) over 60 days (maximum of 91 days).
3005181|NCT02528799|Placebo Comparator|Nexvax2 Placebo DQ2.5 Non-homozygotes (Cohort 3)|Nexvax2 Placebo by ID injections for 18 doses (up to 27 doses) over 60 days (maximum of 91 days).
3005182|NCT02528786|Other|All Participants|Participants who received namilumab previously in M1-1188-002-EM (PRIORA, [NCT01317797]) will have blood samples collected on Day 1.
3005183|NCT02528773||HIV positive|Persons newly diagnosed with HIV.
3005184|NCT02528760|Experimental|Metaclopromide group|
3005185|NCT02528760|Experimental|Erythromycin group|
3005186|NCT02528760|Placebo Comparator|Placebo group|
3005187|NCT02528747||Study population|Breast cancer patients with metastatic bone disease
3005188|NCT02528721|Experimental|Initial Diagnosis Subjects|Patients with clinical indication for H.pylori infection
3005189|NCT02528721|Experimental|Post Therapy Subjects|Patients wishing to confirm eradication of initially diagnosed H.pylori infection that are after treatment within the last 6 months
3005190|NCT02528708|Placebo Comparator|Placebo|At the same time of randomization code generation, blood samples for a baseline ROTEM® analysis will be drawn, and blood products will be ordered. Patients will be eligible to receive study drug (fibrinogen concentrate or 0.9% saline solution), according to the randomization code previously generated, only if FIBTEM® - A10 value is <18 mm (corresponding to a MCF value of <20 mm, that is a plasma fibrinogen level <3 g/L).
3005191|NCT02528708|Experimental|Fibrinogen concentrate|At the same time of randomization code generation, blood samples for a baseline ROTEM® analysis will be drawn, and blood products will be ordered. Patients will be eligible to receive study drug (fibrinogen concentrate or 0.9% saline solution), according to the randomization code previously generated, only if FIBTEM® - A10 value is <18 mm (corresponding to a MCF value of <20 mm, that is a plasma fibrinogen level <3 g/L).
3005192|NCT02528695|Active Comparator|Healthy euglycemic clamp|In 5 healthy volunteers an 18F-FDG PET/CT will be performed during an euglycemic clamp
3005193|NCT02528695|Active Comparator|healthy hypoglycemic clamp|In 5 healthy volunteers an 18F-FDG PET/CT will be performed during a hypoglycemic clamp
3005194|NCT02528695|Experimental|Type 2 diabetes hypoglycemic clamp|In 5 type 2 diabetes patients, an 18F-FDG PET/CT will be performed during a hypoglycemic clamp
3005195|NCT02528682|Experimental|Single arm|MiHA-loaded PD-L-silenced DC Vaccination
3005196|NCT02528669|Experimental|RX Navigait|Individuals in this group will be given an activity tracking device that receives and displays walking reminders and daily walking goals. In addition, they will be given additional education about the benefits of walking. The device will track daily steps taken, minutes of walking, and frequency of walking bouts throughout the day.
3005197|NCT02528669|No Intervention|Control Group|Participants in this group will be given an activity tracking device that receives and displays walking reminders and daily walking goals but will not receive additional education regarding the benefits of walking. The device will track daily steps taken, minutes of walking, and frequency of walking bouts throughout the day.
3005198|NCT02528656|Experimental|Pectus Excavatum|Patients with pectus excavatum who do not require surgery, will be treated with the Vacuum bell device.
3005199|NCT02528656|Experimental|Pectus Carinatum|Patients with pectus carinatum who do not require surgery, will be treated with the Dynamic Compression System.
3005200|NCT02528643|Experimental|enzalutamide|once daily
3005201|NCT02528643|Placebo Comparator|placebo|once daily
3005202|NCT02528630|Experimental|Exercise group|Performed a session regarding joint protection and energy conservation and a progressive resistance strength training program for intrinsic muscles of the hand for 12 weeks.
3005203|NCT02528630|Active Comparator|Control group|Performed a session regarding joint protection and energy conservation
3005204|NCT02528617|Other|Gaucher Type 1 or 3|Velaglucerase alfa IV 60 units/kg every other week for duration of the study.
3005205|NCT02528604|Active Comparator|Catheter Ablation|Left atrial catheter ablation for persistent atrial fibrillation and implantable loop recorder.
3005206|NCT02528604|Active Comparator|Pacemaker and AV node ablation|Participants will have a permanent pacemaker implant followed by AV node ablation
3005207|NCT02528604|Active Comparator|DC cardioversion|Participants will have electrical cardioversion with concomitant anti-arrhythmic therapy and implantable loop recorder.
3005208|NCT02528591|Experimental|renal transplant patient|
3005209|NCT02528578|Experimental|healthy volunteers|
3005210|NCT02528565||Patients with failed RYGB (EWL <50%)|
3005211|NCT02528552|Active Comparator|LH80 PRO|Low level laser therapy
3005212|NCT02528552|Sham Comparator|Sham device|No low level laser therapy
3005213|NCT02528539|Experimental|ITP (Integrative Thearpy Program)|"This ITP intervention consists of two distinct phases, Phase I, the active treatment phase and Phase II, the follow-up phase.~Phase I (Intervention phase) begins post-operatively in 4-6 weeks with a baseline visit that includes 30-minute acupuncture treatment, followed by the 30-minute self-management educational session, and the participants will return weekly for 10 weeks.~Phase II (Follow up phase) begins at month 6 and ends at month 18 from the surgery. The phase II consists of 1-hour quarterly ITP therapy at months 6, 9, 12, 15, and 18 and monthly telephone visits between ITP therapies at months 7, 8, 10, 11, 13, 14, 16, and 17. Self-management reinforcement and support will be implemented during telephone follow up visits"
3005214|NCT02528526|Experimental|Treatment|Add-on application of Myo-inositol trispyrophosphate, total of 9 times, 3 applications per week, over 3 weeks.
3005215|NCT02528513|Experimental|midazolam|"Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.~After the spontaneous breathing trial safety screen is passed, midazolam will continue to be used for sedation, with the dosage adjusted to achieve the desired level of sedation."
3005216|NCT02528513|Experimental|midazolam/propofol|"Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.~After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to achieve the desired level of sedation."
3005217|NCT02528513|Experimental|midazolam/dexmedetomidine|"Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.~After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5 μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to achieve the desired level of sedation."
3005218|NCT02528500|Experimental|TAMBE Device|Study designed to assess the feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in the treatment of patients with aortic aneurysms involving the visceral branch vessels. Patients with thoracoabdominal or pararenal abdominal aortic aneurysms are eligible for screening for participation in the study. The particular characteristics of the patient's aneurysm and anatomy will determine ultimate eligibility for enrollment. Only patients who meet all of the eligibility criteria will be enrolled.
3005219|NCT02528474|Experimental|Pantera Lux|
3005220|NCT02528474|Active Comparator|SeQuent Please|
3005221|NCT02528461||Sofosbuvir|"All patients receiving Sofosbuvir based treatment regimes during the study period will be included in the study.~All patients will receive all interventions (galactose elimination capacity test, gastroscopy, fibroscan), except liver biopsy which the patients may decline to participate in without affecting the participation in the rest of the study. If varices are found during the gastroscopy a liver vein catheterization will be performed."
3005222|NCT02528448|Active Comparator|plasma-lyte|Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
3005223|NCT02528448|Active Comparator|0,9% saline|Continuous 1 hour infusion of 0,9% saline15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
3005224|NCT02528435||JIA patients|observationational study including children diagnosed with JIA. Patients aged 9 years and above, whom are treated with low-dose MTX may be included.
3005225|NCT02528435||ALL patients|observationational study including children diagnosed with ALL. Patients aged 9 years and above, whom are in maintenance treatment with low-dose MTX may be included.
3005226|NCT02528422|Active Comparator|50 µg Acyl-Ghrelin|Intravenous injection on examination day.
3005227|NCT02528422|Active Comparator|100 µg Acyl-Ghrelin|Intravenous injection on examination day.
3005228|NCT02528422|Placebo Comparator|Isotonic Sodium Chloride|Intravenous injection on examination day.
3005229|NCT02528409|Placebo Comparator|Placebo|10 milligrams per day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.
3005230|NCT02528409|Experimental|Vortioxetine|10 milligrams per day day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.
3005231|NCT02528396|Experimental|BioChaperone insulin lispro|
3005232|NCT02528396|Active Comparator|Humalog®|
3005233|NCT02528383|Experimental|Vagifem|Postmenopausal women diagnosed with breast cancer, are currently on an anti-estrogen called an aromatase inhibitor and you have agreed to undergo treatment with Vagifem based on your physician's recommendation.
3005234|NCT02528370|Experimental|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
3005235|NCT02528370|No Intervention|No telEPOC / Usual Care|"The control group follows the usual care protocol in our health system. That includes periodic control by their primary and respiratory specialist. They receive non-structured information/education about COPD and follow a programmed control agenda depending on the severity of the disease every 4-6 months.~Generally speaking the differences between the two cohorts were the educational structured program and the telemonitoring control."
3005236|NCT02528357|Experimental|Part 1A: GSK3174998 Monotherapy- Dose escalation|Subjects will receive GSK3174998 intravenously (IV) (dose range 0.003 to 10.0 milligram per kilogram [mg/kg]) every 3 weeks (Q3W) for up to 2 years or 35 cycles, whichever comes first.
3005237|NCT02528357|Experimental|Part 1B: GSK3174998 Monotherapy- Cohort expansion|Subjects will receive GSK3174998 IV (at one dose level shown to be tolerable in dose escalation part 1A) Q3W for up to 2 years or 35 cycles, whichever comes first.
3005238|NCT02528357|Experimental|Part 2A: GSK3174998+ pembrolizumab - Dose escalation|Subjects will receive GSK3174998 IV (dose range 0.003 to 10.0 mg/kg) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for up to 2 years or 35 cycles, whichever comes first.
3005239|NCT02528357|Experimental|Part 2B: GSK3174998+ pembrolizumab - Cohort expansion|Subjects will receive GSK3174998 IV (at one dose level shown to be tolerable in dose escalation of part 2A) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for 2 years or 35 cycles, whichever comes first.
3005240|NCT02528344|Experimental|HIIT - RA|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
3005241|NCT02528331|Experimental|rTMS and Cognitive Behavior Therapy|
3005242|NCT02528318|Experimental|Aerosolized lucinactant (Medium Dose)|Medium Dose: Lucinactant for inhalation with nCPAP; 1 repeat dose will be allowed if repeat dosing criteria are met.
3005243|NCT02528318|Experimental|Aerosolized lucinactant (High Dose)|High Dose: Lucinactant for inhalation with nCPAP; 1 repeat dose will be allowed if repeat dosing criteria are met.
3005244|NCT02528318|Experimental|Aerosolized lucinactant (High Extension 1)|High Extension 1: Lucinactant for inhalation with nCPAP; 1 repeat dose will be allowed if repeat dosing criteria are met.
3005245|NCT02528318|Experimental|Aerosolized lucinactant (High Extension 2)|High Extension 2: Lucinactant for inhalation with nCPAP; 1 repeat dose will be allowed if repeat dosing criteria are met.
3005246|NCT02528318|Active Comparator|nCPAP alone|nCPAP therapy alone
3005247|NCT02528305|Experimental|High-intensity Interval Training (HIT)|6 week control period with no intervention then 6 weeks of twice weekly HIT
3005248|NCT02528292||Active Rheumatoid Arthritis|Patients with active Rheumatoid Arthritis with a DAS 28 score of greater than 5.1 and eligible for anti-TNF alpha therapy according to National Institute for Clinical Excellence guidelines will be recruited in this study
3005249|NCT02528279|Other|Coartem|"Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight > 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food."
3005250|NCT02528266|Experimental|Nerve Capping Device|Implant with the experimental device
3005251|NCT02528253|Placebo Comparator|Placebo to Week 16; tanezumab 5 mg SC|
3005252|NCT02528253|Placebo Comparator|Placebo to Week 16, tanezumab 10 mg SC|
3005253|NCT02528253|Experimental|Tanezumab 5 mg SC|
3005254|NCT02528253|Experimental|Tanezumab 10 mg SC|
3005255|NCT02528253|Active Comparator|Tramadol PR oral|
3005256|NCT02528240|Experimental|+ L-PRF|With leukocyte and platelet rich fibrin
3005257|NCT02528240|Active Comparator|- L-PRF|Without leukocyte and platelet rich fibrin
3005258|NCT02528227|Experimental|Language Curriculum|The Language Intervention group will receive some of the known methods for early language development. Six lessons will include: Knowing your Baby, Reading Aloud, Sing-A-Long, Mimicking First Sounds, Language Game and Narrating Your Day. Parents will receive feedback every 2 weeks from a Language Environment Analysis digital language processor (LENA).
3005259|NCT02528227|Placebo Comparator|Health and Safety Curriculum|Parents will receive six lessons on important infant safety topics including, feeding safety, care seat safety, bath safety, back to sleep/SIDS prevention, taking a temperature and signs of infection, infection control methods and vaccine information. Parents will receive LENA feedback at discharge from NICU.
3005260|NCT02528214|Experimental|Dupilumab|Dupilumab every 2 weeks (loading dose with a double dose) added to current controller medications
3005261|NCT02528214|Placebo Comparator|Placebo|Placebo (for dupilumab) every 2 weeks (loading dose with a double dose) added to current controller medications
3005262|NCT02528201|Active Comparator|Celecoxib 200 milligrams mg QD|celecoxib 200 milligrams (mg) once a day (QD)
3005263|NCT02528201|Active Comparator|Celexocib 400 mg QD|celecoxib 400 milligrams (mg) once a day (QD)
3005264|NCT02528201|Active Comparator|Diclofenac 50 mg TID|diclofenac 50 milligrams (mg) three times a day (TID)
3005265|NCT02528188|Active Comparator|NSAID|Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
3005266|NCT02528188|Experimental|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks plus oral placebo for NSAID (naproxen, celecoxib or diclofenac ER) twice daily for 56 weeks
3005267|NCT02528188|Experimental|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for NSAID (naproxen, celecoxib or diclofenac) twice daily for 56 weeks
3005268|NCT02528175|Experimental|MRg-FU|Hyperthermia via magnetic resonance-guided focused ultrasound will be administered once per week for three weeks concurrent with standard radiation and chemotherapy.
3005269|NCT02528149||patients with renal aneurysm|Patient with one or more renal artery aneurysm (RAA) operated and with tissue; adjacent part and aneurysm; cryopreserved. Blood sample performed at day 1.
3005270|NCT02528136|Experimental|Carbetocin|One minute injection of carbetocin 100 µg after the delivery of the baby
3005271|NCT02528136|Active Comparator|Oxytocin|One minute injection of oxytocin 2.5 U after the delivery of the baby
3005272|NCT02528123|Experimental|Small incision lenticule extraction|Patients with high myopia will undergo a SMILE procedure to correct their refraction. Proxymetacaine 0.5% and Oxybuprocaine 0.4% will be used as anaesthetic during the procedure. Tobramycin and dexamethasone, and ofloxacin will be used four times a day for one week after the procedure.
3005273|NCT02528110|Sham Comparator|Radical gastrectomy without HIPEC|Patients will be treated with a D2 radical gastrectomy for locally advanced gastric cancer and postoperative chemotherapy (SOX or XELOX)
3005274|NCT02528110|Experimental|Radical gastrectomy with HIPEC|Patients will be treated with a D2 radical gastrectomy for locally advanced gastric cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (SOX or XELOX)
3005275|NCT02528097|Placebo Comparator|Active Comparator Standard Care|albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
3005276|NCT02528097|Experimental|Experimental|Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure (Cr > 1.0 or BUN or Cr > baseline). If albumin not administered at 48 hours, BUN and Cr will be monitored daily for 72 hours and will be administered if Cr > 1.0 or BUN or Cr are above baseline.
3005277|NCT02528084|Experimental|yoga intervention|patients in the group are asked to follow an online video instructing them various yoga poses. Patients in this group are asked to do the yoga exercises 2-3 times a week, for a total of 6 weeks.
3005278|NCT02528084|Experimental|standard exercises intervention|patients in this group are asked to follow an online standard exercises video. Patients in this group are asked to follow specific exercises 2-3 times a day, for a total of 6 weeks.
3005279|NCT02528084|No Intervention|control|patients in this group carry forth with their daily activities. They are not asked to follow the online yoga video or the online standard exercise video.
3005389|NCT02527330||Stable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, LVEF>=55%
3005280|NCT02528071||Patients|ALS patients performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity at the onset of the disease and repeated every 3 months up to respiratory failure or death
3005281|NCT02528071||Control|Healthy controls performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity. This arm will enable to establish reference values of IHT
3005282|NCT02528058||Myopic traction maculopathy|
3005283|NCT02528032|Other|Echocardiographic evaluation|Echocardiographic evaluation of heart function with new processing tools
3005284|NCT02528019|Active Comparator|DPP-4 inhibitors|sitagliptin (25-100mg daily), vildagliptin (50-100mg daily), alogliptin (12.5-25mg daily), linagliptin (2.5-5mg daily), teneligliptin (20-40mg), anagliptin (100-200mg daily), saxagliptin (2.5-5mg daily) or trelagliptin (50-100mg weekly)
3005285|NCT02528019|Active Comparator|SGLT2 inhibitors|ipragliflozin (50-100mg daily), dapagliflozin (5-10mg daily), luseogliflozin (2.5-5mg), tofogliflozin (20mg daily), canagliflozin (100mg daily) or empagliflozin (10-25mg daily)
3005286|NCT02528019|Active Comparator|Glimepiride|glimepiride (0.5-8mg daily)
3005287|NCT02528006|Other|Titanium Bridges|Surgery
3005288|NCT02527993|Experimental|Glucobay|Tablet Glucobay (acarbose) 50 mg x 6 daily for 7 days.
3005289|NCT02527993|Experimental|Januvia|Tablet Januvia (sitagliptin) 100 mg orally O.D for 7 days.
3005290|NCT02527993|Experimental|Verapamil|Tablet Verapamil 120 mg orally O.D for 7 days.
3005291|NCT02527993|Experimental|Victoza|Subcutaneous injection of Victoza (liraglutide) 0,6-1,2 mg O.D for three weeks.
3005292|NCT02527993|Experimental|Signifor|Subcutaneous injection of Signifor (pasireotide) 300 µg as a single dose prior to a meal tolerance test.
3005293|NCT02527980||dual users|Individuals who at the point of study enrollment are using both electronic cigarettes (ecig) and commercial cigarettes (CCs)
3005294|NCT02527980||commercial cigarette (CC) only users|Individuals who at the point of study enrollment are using exclusively commercial cigarettes
3005295|NCT02527967||Group 1 (≤4 days)|Group 1 consisted of patients whose hospital stay was shorter or equal to the target LOS (≤ 4 days).
3005296|NCT02527967||Group 1 (>4 days)|In group 2 were patients whose hospital stay was longer than 4 days.
3005297|NCT02527954||Infertile with Y-chromosome deletions|"No intervention will be performed.~Couples whose infertile men has a Y-chromosome microdeletion (detected in blood cells by Polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 1)"
3005298|NCT02527954||Infertile without Y-chromosome deletions|"No intervention will be performed.~Couples whose infertile men has not any Y-chromosome microdeletion (detected in blood cells by polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 2)"
3005299|NCT02527941|Experimental|metronidazole|50 women who test negative for HIV and classical sexually transmitted infections but test positive for Bacterial Vaginosis will be treated with metronidazole at a dosage of 400mg/dose, 3 doses per day, for 7 days (as per Kenyan National Guidelines).
3005300|NCT02527928||desoxycholate|Amphotericin B desoxicholate
3005301|NCT02527928||Anfolipidcomplex|Amphotericin B complex lipid
3005302|NCT02527928||ABLiposomal|Amphotericin B liposomal
3005303|NCT02527915|Experimental|Mental Health eConsults|Primary care clinics that will receive the eConsults intervention at the start of the study.
3005304|NCT02527915|Active Comparator|Usual care|"Primary care clinics that will deliver care as usual for nine months, and will receive the eConsults intervention nine months subsequent to the eConsults intervention clinics."
3005305|NCT02527902|Experimental|IgAN with glomerular filtration rate (GFR) >90 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with glomerular filtration rate (GFR) >90 ml/min/1.73 m2
3005306|NCT02527902|Experimental|IgAN with GFR 60-89 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 60-89 ml/min/1.73 m2
3005307|NCT02527902|Experimental|IgAN with GFR 30-59 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 30-59 ml/min/1.73 m2
3005308|NCT02527902|Experimental|IgAN with GFR 15-29 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 15-29 ml/min/1.73 m2
3005309|NCT02527902|Experimental|IgAN with GFR < 15ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR < 15ml/min/1.73 m2.
3005310|NCT02527889|Experimental|Exercise Group|The exercise group will receive a supervised resistive exercise training. Subjects in the exercise group will attend small group-based exercise sessions twice a week for 8 weeks supervised by physiotherapists.
3005311|NCT02527889|No Intervention|Control Group|The control group will receive no exercise training and continue to receive standard medical care.
3005312|NCT02527876|Experimental|High Intensity Interval Training/FitBit Flex|Meet with personal trainer once per week for 20-minute exercise session
3005313|NCT02527876|Experimental|Moderate Intensity/FitBit Flex|Meet with personal trainer once per week for 30-minute exercise session and exercise two times a week outside of personal trainer
3005314|NCT02527876|Placebo Comparator|Delayed Control/FtBit Flex|No exercise offered
3005315|NCT02527863|Active Comparator|60 mg Tolvaptan|Oral administration of 60 mg tolvaptan on each examination day.
3005316|NCT02527863|Placebo Comparator|Placebo|Oral administration of a Unikalk tablet.
3005317|NCT02527850|Experimental|treatment with real laser|10 min irradiation with B-cure soft laser on 3 points of quadriceps muscle.
3005318|NCT02527850|Sham Comparator|sham laser|10 min irradiation with sham B-cure soft laser on 3 points of quadriceps muscle.
3005319|NCT02527837|Active Comparator|Sodium nitrite|Sodium nitrite, 240 micrograms/kg/hour for 2 hours
3005320|NCT02527837|Placebo Comparator|Placebo|Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
3005321|NCT02527824|Experimental|Oxaliplatin, Irinotecan, S-1(OIS)|"intervention with triple combination chemotherapy with oxaliplatin, irinotecan, and S-1 Treatment will be delivered as a 2-week cycle.~Oxaliplatin 65 mg/m2 iv on day 1~Irinotecan 135 mg/m2 iv on day 1~S-1 80 mg/m2/day on day 1-7"
3005322|NCT02527811|Experimental|ulinastatin group|the ulinastatin group will be administered as follows:Ulinastatin 30,000 unit/kg will be diluted into saline solution and administered intravenously in the surgery; Postoperative administration will be 30,000unit/kg divided into 3 regimens until leave ICU.
3005417|NCT02527109|Experimental|Nifedipine 12 mg/day|Intra-anal Nifedipine 12 mg administered OD.
3005323|NCT02527811|No Intervention|control group|patients of control group received conventional therapy,eg,General anesthetic drug and monitoring during the whole process of surgery;Mechanical ventilation and close monitoring to prevent and manage respiratory acidosis and alkalosis and so on.
3005324|NCT02527798|Experimental|Furosemide Cohort 1|Within cohort 1, infants will be randomized using a 3:1 scheme to receive furosemide or placebo. Those randomized to receive furosemide will receive (1mg/kg daily intravenously or 2 mg/kg daily enterally for 28 days.
3005325|NCT02527798|Placebo Comparator|Placebo Cohort 1|Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
3005326|NCT02527798|Experimental|Furosemide Cohort 2|Cohort 2 Infants will receive furosemide (1mg/kg every 6 hours intravenously or 2 mg/kg every 6 hours daily enterally) for 28 days.
3005327|NCT02527798|Experimental|Furosemide Cohort 3|Cohort 3 Infants will receive furosemide (2mg/kg every 6 hours intravenously or 4 mg/kg every 6 hours daily enterally) for 28 days.
3005328|NCT02527798|Placebo Comparator|Placebo Cohort 2|Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
3005329|NCT02527798|Placebo Comparator|Placebo Cohort 3|Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
3005330|NCT02527785|Experimental|Oxaliplatin, Irinotecan, S-1(OIS)|"triple combination with oxaliplatin, irinotecan, and S-1.~Treatment will be delivered as a 2-week cycle.~Oxaliplatin 65 mg/m2 iv on day 1~Irinotecan 135 mg/m2 iv on day 1~S-1 80 mg/m2/day on day 1-7"
3005331|NCT02527772|Experimental|Liposomal Doxorubicin+Gemcitabine|Gemcitabine 1000mg/m2,d1,8;Liposomal Doxorubicin 30mg/m2,d1.q4w
3005332|NCT02527772|Active Comparator|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks
3005333|NCT02527746|Experimental|F-627 80 µg/kg|F-627 at the dose of 80 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
3005334|NCT02527746|Experimental|F-627 240 µg/kg|F-627 at the dose of 240 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
3005335|NCT02527746|Experimental|F-627 320 µg/kg|F-627 at the dose of 320 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
3005336|NCT02527733|Active Comparator|Ranibizumab|After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
3005337|NCT02527733|Active Comparator|Ranibizumab and laser|After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers. Macular laser photocoagulation will be performed when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
3005338|NCT02527720|Experimental|Mindfulness Therapy|For the current study the investigators have developed a breathing-based, adapted for feasible application among SUD populations, and easy to carry out in clinical or non-clinical settings referred to as breathing-based mindfulness training (BBMT). BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention (more details below).
3005339|NCT02527707|Experimental|lonafarnib/ritonavir|Lonafarnib starting at 50 mg bid in combination with ritonavir 100 mg bid and escalating to lonafarnib 75 mg bid and then 100 mg bid as tolerated. The duration of the study for each patient is 6 months of treatment and 6 months follow-up.
3005340|NCT02527694|Experimental|Flexible Stretcher Cart Group|Patients in this group will be transported on the new flexible stretcher cart and receive mechanical CPR during transport to the hospital. The intervention will be given during elevator transport (if applicable) as well as in the moving ambulance.
3005341|NCT02527694|No Intervention|Standard Stretcher Cart Group|Patients in this group will be transported on the standard stretcher cart and receive manual CPR during transport to the hospital. The resuscitation protocol will follow the current standard protocol used by the EMS providers.
3005342|NCT02527681|Experimental|Ceftobiprole|single dose of ceftobiprole at 7.5 mg/kg body weight, given as a 4-hour constant-rate infusion of ceftobiprole medocaril
3005343|NCT02527668|Experimental|Calcifediol Hy.D (25-hydroxyvitamin D)|20 μg Calcifediol Hy.D (25-hydroxyvitamin D) (one capsule) per day for 6 months
3005344|NCT02527668|Active Comparator|Vitamin D3 (cholecalciferol)|3200 IU Vitamin D3 (cholecalciferol) (one capsule) per day for 6 months
3005345|NCT02527668|Placebo Comparator|Placebo|1 Placebo capsule per day for 6 months
3005346|NCT02527655|Experimental|Choice-Based Physical Activity and Active Transportation|Participants will meet one-on-one with an activity coach to develop a choice-based physical activity and active transportation plan based on their interest, abilities, and resources; attend group-based motivational meetings; and receive ongoing support and encouragement for physical activity and active transportation (e.g., telephone-assisted support, community centre and transit passes).
3005347|NCT02527655|No Intervention|Wait-List Control|Participants will be offered the Choice-Based Physical Activity and Active Transportation intervention after the experimental arm has completed the study.
3005348|NCT02527642|Active Comparator|CRM sequential media (C1/C2)|CRM sequential media, formulated according to the stages of embryo development, is used to culture the embryos from oocyte fertilization to blastocyst stage.
3005349|NCT02527642|Active Comparator|CRM single step media (C3)|CRM single step media is used to culture the embryos from oocyte fertilization to blastocyst stage.
3005350|NCT02527642|Experimental|Vitrolife media G1/2 Sequential|Vitrolife sequential media, formulated according to the stages of embryo development, is used to culture the embryos from oocyte fertilization to blastocyst stage.
3005351|NCT02527642|Experimental|Vitrolife G-TL Time Lapse media Single Step|G-TL Time Lapse Single step (time lapse) media is formulated for continuous culture from oocyte fertilization to blastocyst stage.
3005352|NCT02527629||Decellularized human valves|Aortic heart valve replacement
3005353|NCT02527616|Experimental|IV followed by IC (investigation)|The patient undergoes the FFR measurement with the standard measurement first followed by FFR measurement using the FFR Infusion Microcatheter
3005354|NCT02527616|Experimental|IC (investigation) followed by IV|The patient undergoes the FFR measurement using the FFR Infusion Microcatheter measurement first followed by measurement via the standard measurement
3005355|NCT02527603|Experimental|Spaso Method|Randomized for Sp method + 1 initial dose of 50mg dexketoprofen IM or 25mg Oral
3005356|NCT02527603|Experimental|Boss-Holzach-Matter Method|Randomized for BHM method +1 initial dose of 50mg dexketoprofen IM or 25mg Oral
3005357|NCT02527590|Experimental|patient with neuropathic pain with allodynia|
3005358|NCT02527590|Experimental|healthy volunteers|
3005359|NCT02527577|Experimental|ropivacaïne chlorhydrate monohydrate|
3005360|NCT02527577|Placebo Comparator|placebo|
3005361|NCT02527564|Experimental|Suvorexant|"50% of enrolled participants will be randomly assigned to receive double-blind suvorexant for one week, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the last 4 nights.~Following the one-week double-blind, placebo-controlled phase, 100% of participants will receive open-label suvorexant for 3 months, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the remainder of 3 months."
3005362|NCT02527564|Placebo Comparator|Placebo|50% of enrolled participants will be randomly assigned to receive double-blind placebo pill for one week, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the last 4 nights.
3005363|NCT02527551|Other|Haptic massage|6 weeks of deep haptic massage at 2 sessions of 30 minutes per week.
3005364|NCT02527538||Pleth|The masimo probe is attached on the index fingertip and cover with black cover in all patients. Record the pleth variability index and blood pressure
3005365|NCT02527525|Experimental|Stepped Care|150 subjects will be randomized to the stepped care intervention. All 150 participants will be assigned a parent coach after randomization to stepped care condition. At the child's next follow up clinic visit participants who have elevated depression scores OR who's child has not met A1c target will move on to Step 2 of the intervention- 5 sessions with a study interventionist. At the following child's clinic visit, participants can either remain in Step 1, move to Step 2, or if needed, move on to Step 3- using a continuous glucose monitor for 1 week followed by a meeting with a certified diabetes educator and a diabetes team clinical psychologist.
3005366|NCT02527525|No Intervention|Usual Care|Participants randomized to usual care will participate in regular diabetes clinic visits and diabetes education, as they would have done without participation in this study.
3005367|NCT02527512|Active Comparator|Povidone-Iodine|"0.35% povidone-iodine (Betadine)"
3005368|NCT02527512|Active Comparator|Normal Saline|Sterile sodium chloride (NaCl) solution
3005369|NCT02527499|Experimental|ROCBT group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Ride-On Cars with Bimanual Training Program (ROCBT) group.
3005370|NCT02527499|Active Comparator|Early Mobility Training group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Early Mobility Training Program group.
3005371|NCT02527499|Active Comparator|Regular Therapy group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Regular Therapy Program group.
3005372|NCT02527486||No predefined subgroups|
3005373|NCT02527473|No Intervention|Standard Education Group|Control group will receive standard basic life support training for one hour.
3005374|NCT02527473|Experimental|HEROS Group|HEROS group will receive the dispatcher-assisted basic life support training that includes standardized video-based CPR education, interactive role-playing with the dispatcher as well as group discussion for one hour.
3005375|NCT02527434|Experimental|treme mono to be sequenced to MEDI4736 mono or combination|tremelimumab monotherapy, with the option for eligible patients to be sequenced to MEDI4736 monotherapy or MEDI4736 + tremelimumab combination therapy after progressive disease (PD)
3005376|NCT02527421|Experimental|DFD01 Spray Group 1|DFD01 spray, twice daily, 15 days
3005377|NCT02527421|Experimental|DFD01 Spray Group 2|DFD01 spray, twice daily, 29 days
3005378|NCT02527395|Other|Clinical pain models|Brief thermal sensitization. Heat pain detection threshold. Pain during 1 min. thermal stimulation
3005379|NCT02527382|Experimental|Closed stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a distal clamp is placed on the rectal stump.
3005380|NCT02527382|No Intervention|Open stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while no distal clamp is placed on the rectal stump.
3005381|NCT02527369|Experimental|XP1100RF group|Subjects in the XP1100RF group will be treated with the XP1100RF device.
3005382|NCT02527356|Experimental|ROC-Stand group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training (ROC-stand).
3005383|NCT02527356|Active Comparator|ROC-Sit group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training (ROC-sit)
3005384|NCT02527356|Active Comparator|Regular Therapy group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for regular therapy.
3005385|NCT02527343|Active Comparator|volanesorsen 300mg|volanesorsen administered subcutaneously once weekly for 52 weeks
3005386|NCT02527343|Placebo Comparator|Placebo|Placebo administered subcutaneously once weekly for 52 weeks.
3005387|NCT02527343|Active Comparator|Open Label Extension (OLE)|Volanesorsen administered subcutaneously once weekly for 104 weeks
3005388|NCT02527330||Control group|Age- and gender-matched healthy volunteers recruited as normal control group.
3005390|NCT02527330||Unstable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, currently LVEF<55%.
3005391|NCT02527304|Experimental|Treatment (adaptive staged SBRT)|Patients undergo adaptive staged SBRT. Within 14-21 days, patients may undergo a second treatment of adaptive staged SBRT at the discretion of the treating physician based on clinical parameters, diagnostic interval imaging, and achievement of spinal cord dose constraints.
3005392|NCT02527291||Study Group|"The Study group will comprise of seropositive CMV patients undergoing cardiothorathic surgery and having a complicated postoperative course.~In addition to the routine blood work which includes: CBC, chemistry and INR, blood work for CMV PCR will be done three times: at enrollment, follow up 1 (7 days post operation) and follow up 2 (14 days post operation).~Blood work for Interleukin28 (IL28) will be done at enrollment. All visits include data collection from computerized medical records."
3005393|NCT02527291||Control Group 1|"The first control group will be comprised of patients who are seropositive CMV undergoing cardiothorathic surgery and having a normal postoperative course.~In addition to the routine blood work which includes: CBC, chemistry and INR, blood work for CMV PCR will be done two times: at enrollment and follow up 1 (7 days after discharge).~Blood work for Interleukin28 (IL28) will be done at enrollment. All visits include data collection from computerized medical records."
3005394|NCT02527291||Control Group 2|"The second control group will include seronegative patients for CMV undergoing cardiothorathic surgery with complicated and uncomplicated post-operative course.~Blood work for CMV PCR and IL28 will be done at enrollment. All other visits include data collection from computerized medical records only."
3005395|NCT02527278||Laparoscopic tubal ligation (no pain)|Women who have laparoscopic tubal ligation, with no previous diagnosis of pain at baseline
3005396|NCT02527278||Laparoscopic tubal ligation (pain)|Women who have laparoscopic tubal ligation, with a previous diagnosis of pain at baseline
3005397|NCT02527278||Hysteroscopic sterilization (no pain)|Women who have hysteroscopic sterilization, with no previous diagnosis of pain at baseline
3005398|NCT02527278||Hysteroscopic sterilization (pain)|Women who have hysteroscopic sterilization, with a previous diagnosis of pain at baseline
3005399|NCT02527265|Experimental|Afrezza (Technosphere Insulin)|"Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.~During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day."
3005400|NCT02527252|Experimental|Craniosacral therapy|"All treatments were applied by two experienced therapists with a 10-year certification in manipulative therapy after completion of their physical therapy degree and more than 20 years of clinical experience with patients. All patients received the intervention on the day of their initial examination. The techniques took 50 minutes and were conducted as follows:~Pelvic Diaphragm Release.~Respiratory Diaphragm Release.~Thoracic Inlet Release.~Hyoid release.~Sacral technique for stabilize L5/sacrum.~CV-4 Still Point Induction."
3005401|NCT02527252|Active Comparator|Classic Massage|Classics massage protocol was compounded by the following techniques of soft tissues massage: effleurage, petrissage, friction, and kneading. The techniques took thirty minutes.
3005402|NCT02527226|No Intervention|No facial exercises|This group will not receive any training in facial exercises.
3005403|NCT02527226|Experimental|Facial exercises|This group will receive instruction to perform a series of self-administered exercises of facial expression and movements.
3005404|NCT02527213|Experimental|Sodium Thiosulfate|Sodium Thiosulfate at 25g in 100 ml normal sterile saline (NSS)
3005405|NCT02527213|Placebo Comparator|Placebo|similarly-formulated placebo in 100 ml NSS
3005406|NCT02527200|Experimental|Liraglutide|
3005407|NCT02527200|Placebo Comparator|Placebo|
3005408|NCT02527187|Experimental|Betula verrucosa allergen extract|"The investigational product contained the allergen extract of the pollen of Betula verrucosa and will be tested by administration onto skin. The test will be carried out on the forearm following prick test technique.~The allergen extract of the pollen of Betula verrucosa will be tested in four concentrations (100, 50, 25 and 10 HEP/mL)."
3005409|NCT02527174|Experimental|Study treatment arm|"Will receive volasertib combined with idarubicin plus cytarabine in a 3+7 schedule as induction chemotherapy. Volasertib dose will be given on day 4 in a dose escalation schedule over 3 dose levels (140 mg/m2, 170 mg/m2, 200 mg/m2) in successive cohorts.~Non-hematologic toxicity will be determined using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteria for adverse events. Hematologic toxicity will be determined by days to absolute neutrophil count (ANC) and platelet recovery."
3005410|NCT02527161|Other|ShapeMatch Cutting Guides with Triathlon|"The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.~They are intended for single use only."
3005411|NCT02527148|Active Comparator|OtisMed® ShapeMatch® with Triathlon|Participants randomised to the Intervention Group will undergo Total Knee Replacement (TKR) with the Stryker Triathlon® Total Knee System and OtisMed® ShapeMatch® Technology with the goal of kinematic alignment (re-aligning the limb to its pre-disease kinematic alignment).
3005412|NCT02527148|Active Comparator|Stryker Precision Knee Navigation|Participants randomised to the Control Group will undergo Total Knee Replacement (TKR) with the Stryker Triathlon® Total Knee System guided by Stryker Precision Knee Navigation with the goal of neutral alignment to the mechanical axis. This is the standard method for TKR with Triathlon® Knee System and this group will serve as a control reference for the intervention group.
3005413|NCT02527135|Experimental|Behavioural|Intervention arm receiving weekly HIV sensitization text messages
3005414|NCT02527135|No Intervention|Control|No weekly messages were sent to this group
3005415|NCT02527122|Experimental|Allergen extracts|"Skin prick test of 4 concentrations of D. pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of one forearm. Assessment of the wheal size after 15 minutes.~Skin prick test of 4 concentrations of D. farinae allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the other forearm. Assessment of the wheal size after 15 minutes."
3005416|NCT02527109|Placebo Comparator|Placebo|Intra-anal placebo administered BID.
3005418|NCT02527109|Experimental|Nifedipine 24 mg/day|Intra-anal Nifedipine 12 mg administered BID.
3005419|NCT02527096|Experimental|dolutegravir(Tivicay®) and lamivudine(Epivir®)|
3005420|NCT02527083|Active Comparator|BIA|Balanced Inhalational Anesthesia (consisting of a sevoflurane inhaled anesthestic only)
3005421|NCT02527083|Active Comparator|TIVA-K|Total intravenous anesthetic with ketamine
3005422|NCT02527083|Active Comparator|TIVA-R|Total intravenous anesthetic with remifentanil
3005423|NCT02527070|Experimental|Red LED|Light emitting diodes, 670 nm, 50 mW/cm2, Quantum Warp10 (Quantum Devices Inc, Barneveld, WI, USA); RESPeRATE; Heat/cold provocation
3005424|NCT02527070|Active Comparator|Near Infrared LED|Light emitting diodes, 830 nm, 55 mW/cm2, Omnilux new-U (Photomedex, Horsham, PA, USA); RESPeRATE; Heat/cold provocation
3005425|NCT02527044|Experimental|Treatment: FFR prior to CABG|Patients will undergo a fractional flow reserve prior to their coronary bypass surgery. The results will be blinded from both physician and patients. 6 months after surgery, the investigators will evaluate the impact of preoperative FFR on arterial bypass graft functionality
3005426|NCT02527031|Active Comparator|Pre hospital ECMO|ECMO Insertion on pre hospital setting for a refractory cardiac arrest
3005427|NCT02527031|Active Comparator|In Hospital ECMO|ECMO Insertion on in hospital setting for a refractory cardiac arrest
3005428|NCT02527018||Healthy Subjects|Measurement of hemodynamic levels (BNP) of healthly term subjects using the Nexfin sphygmomanometer device.
3005429|NCT02527018||Preeclamptic Subjects|Measurement of hemodynamic levels (BNP) of preeclamptic subjects using Nexfin sphygmomanometer device.
3005430|NCT02527005|Active Comparator|Azithromycin|Tabs Azithromycin 500mg daily for 3 days
3005431|NCT02527005|Active Comparator|Sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets every 4 weeks for 3 doses
3005432|NCT02526992|Other|patients with anti-TNF therapy|patients with rheumatoid polyarthritis inadequately controlled by a conventional treatment, occurring during the first 12 months of initiation of an anti-TNF therapy
3005433|NCT02526979|Experimental|mirabegron|single dose
3005434|NCT02526966|Other|patient with primitive form of IgA nephropathy|
3005435|NCT02526953|Experimental|Paclitaxel|Patients will receive intensity-modulated radiotherapy with dose based on T stage. The planned doses to the primary tumor and pelvis are 52-58 Gy and 44 Gy, respectively.The concurrent chemotherapy regimen will consist of paclitaxel 45 mg/m2 on days 3,10,17,24,31, capecitabine 625 mg/m2 bid on treatment days and mitomycin C 10 g/m2 on day 1.
3005436|NCT02526953|Active Comparator|Standard|Patients will receive intensity-modulated radiotherapy with dose based on T stage. The planned doses to the primary tumor and pelvis are 52-58 Gy and 44 Gy, respectively.The concurrent chemotherapy regimen will consist of capecitabine 825 mg/m2 bid on treatment days and mitomycin C 12 g/m2 on day 1.
3005437|NCT02526940||blood CD4 cells count < 200/mm3|"patients with blood CD4 cells count at the time of initiation of HAART< 200/mm3.~Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years"
3005438|NCT02526940||blood CD4 cells count : 200 - 300/mm3|patients with blood CD4 cells count at the time of initiation of HAART between 200 and 300/mm3 Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years
3005439|NCT02526940||blood CD4 cells count >350/mm3|"patients with blood CD4 cells count at the time of initiation of HAART> 350/mm3.~Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years"
3005440|NCT02526927|Experimental|Patients 20 - 30 years-old|HR-pQCT and DEXA for measure bone quality and quantity
3005441|NCT02526927|Experimental|Patients 10 - 20 years-old|Blood samples, HR-pQCT and DEXA for measure bone quality and quantity
3005442|NCT02526914|Experimental|Intranasal Oxytocin|Participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).
3005443|NCT02526914|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).
3005444|NCT02526914|Placebo Comparator|Intranasal placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient. Participants will self-administer 5 puffs per nostril.
3005445|NCT02526901||No treatment|
3005446|NCT02526888|Experimental|Sequence AB|During Period 1, subjects receive a single dose of ACT-541468 on Day 1. During Period 2, they receive Diltiazem from Day 1 to Day 7 and a single dose of ACT-541468 on Day 4
3005447|NCT02526888|Experimental|Sequence BA|During Period 1, subjects receive Diltiazem from Day 1 to Day 7 and a single dose of ACT-541468 on Day 4. During Period 2, they receive a single dose of ACT-541468 on Day 1
3005448|NCT02526875|Experimental|night|Telminuvo®Tab. 40/2.5mg ,Once daily, from 6 pm to 10 pm, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
3005449|NCT02526875|Active Comparator|morning|Telminuvo®Tab. 40/2.5mg ,Once daily, from 6 am to 10 am, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
3005450|NCT02526862|No Intervention|A-Mask or direct interface|Mask or direct interface
3005451|NCT02526862|Active Comparator|B-Autoadhesive polyurethane dressing|Protection of the dermis with autoadhesive polyurethane dressing (Allevyn Thin®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
3005452|NCT02526862|Active Comparator|C-Semi-permeable hydrogel-foam|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing (Askina Transorbent Border®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
3005453|NCT02526862|Active Comparator|D-Hyper hydrogenated fatty acids|Protection of the dermis with hyper hydrogenated fatty acids (Linovera®) in the contact areas with the NIVM interface or mask. It will apply with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
3005526|NCT02526394|Active Comparator|1|Repevax + Meningitec
3005527|NCT02526394|Active Comparator|2|Repevax + Neis-VacC
3005528|NCT02526394|Active Comparator|3|Repevax + Menitorix
3005454|NCT02526849|Experimental|Fecal microbiota transplantation (FMT)|On day 1-6, patients received 100ml fresh FMT by nasointestinal tube, once per day. The nasointestinal tube was placed in the patient's proximal jejunum through endoscopy. Then, donor fecal microbiota was infused within 5 minutes through nasointestinal tube.
3005455|NCT02526849|Experimental|Conventional treatment|Conventional treatment was taken by both of two groups. If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax®, Ipsen, Paris, France). If ineffective, an enema could be used.
3005456|NCT02526836|Other|Comparison group|"including the number of cases with complete data who underwent surgery using the conventional method.~Conventional surgery"
3005457|NCT02526836|Active Comparator|Intervention group|"including a convenient sample of about 20 patients which is expected to be recruited, for whom Complete Mesocolic Excision (CME) and Central Vascular Ligation (CVL) will be done.~Complete mesocolic excision with central vascular ligation"
3005458|NCT02526823|Active Comparator|R-CHOP/CHOPE or ABVD chemotherapy regimen|R-CHOP/CHOPE every 21 days or ABVD every 28 days for total 6 courses
3005459|NCT02526823|Experimental|R-CDOP/CDOPE or DBVD chemotherapy regimen|R-CDOP/CDOPE every 21 days or DBVD every 28 days for total 6 courses
3005460|NCT02526810|Active Comparator|GROUP A|using continuous subcutaneous insulin injection with insulin lispro, Humalog, initiating with 0.5-0.8 IU/kg.
3005461|NCT02526810|Experimental|GROUP B|using glargine combined with oral drugs: insulin glargine, Lantus( initiating with 0.2 IU/kg) with metformin hydrochloride, Glucophage 500mg bid and gliclazide modified release tablets, Diamicron modified release(MR) tablets 60mg qd.
3005462|NCT02526784|Active Comparator|Injection A|Degarelix s.c. standard injections
3005463|NCT02526784|Experimental|Injection B|Degarelix s.c. optimised injections
3005464|NCT02526784|Experimental|Injection C|Degarelix i.m. injections
3005465|NCT02526771|Experimental|conventional lymph node dissection|conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
3005466|NCT02526771|Active Comparator|unconventional lymph node dissection|unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
3005467|NCT02526758|Experimental|beclomethasone / formoterol|beclomethasone 100ug and formoterol 6ug , 2 inhalations, twice daily ,for three months
3005468|NCT02526758|Active Comparator|budesonide / formoterol|budesonide 160ug and formoterol 4.5ug, 2 inhalations ,twice daily ,for three month
3005469|NCT02526745|Experimental|high doses of virus content between 4.7～5.0 lgPFU|live attenuated vaccine against herpes zoster with high doses of virus content between 4.7～5.0 lgPFU in 20 adults aged 50-80 years old on day 0
3005470|NCT02526745|Experimental|low doses of virus content between 4.7～5.0 lgPFU|live attenuated vaccine against herpes zoster with low doses of virus content between 4.7～5.0 lgPFU in 20 adults aged 50-80 years old on day 0
3005471|NCT02526745|Experimental|high doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with high doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
3005472|NCT02526745|Experimental|middle doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with middle doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
3005473|NCT02526745|Experimental|low doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with low doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
3005474|NCT02526745|Placebo Comparator|placebo|placebo in 100 adults aged 50-80 years old on day 0
3005475|NCT02526732|Experimental|individual training program|Patients will be offered an individual training program. Physical performance and surrogate parameters of liver inflammation will assessed in physical examinations before and after the training phase.
3005476|NCT02526719|No Intervention|Standard Nipple-Sparing Mastectomy|Patients in the control group will receive usual care. The surgical oncologist will perform the NSM and sentinel lymph node biopsy if indicated (active breast cancer or DCIS). We will submit a nipple core biopsy and a 1cm thick biopsy of immediately retro-areolar ductal tissue for permanent section pathology for control patients, and all patients will have the mastectomy specimen submitted for permanent section pathology. Under the same general anaesthesia, the plastic surgeon will perform the IBR (2-stage tissue expander to implant or 1-stage direct to implant). Patients who later have a positive nipple core and retro-areolar biopsy will have a discussion with the surgical oncologist regarding the need for revision breast surgery to excise the NAC, as is current practice.
3005477|NCT02526719|Experimental|Nipple Delay Intervention|Patients in the experimental group will have a nipple-delay intervention in addition to usual care. The nipple delay procedure will be performed by the plastic surgeon in the minor clinic procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
3005478|NCT02526706|Experimental|Glaucoma Study Group|Glaucoma patients scheduled for trabeculectomy were recruited for this study and VisionBlue dye is injected prior to the surgery.
3005479|NCT02526693|Experimental|Glaucoma|Glaucoma patients are recruited from WIllsEye glaucoma care, who will be tested with the RAPDx Pupillography machine
3005480|NCT02526693|Experimental|Healthy Control|Healthy subjects are recruited from the WillsEye clinic, who will be tested with the RAPDx Pupillography machine
3005481|NCT02526680|Experimental|Glaucoma Subjects|All 13 glaucoma subjects will be given the OrCam low vision aid device
3005482|NCT02526667|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
3005483|NCT02526667|Placebo Comparator|Vehicle Cloth|Excipients on cloth
3005484|NCT02526667|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
3005485|NCT02526654|Experimental|Glaucoma Subjects|Subjects with glaucoma are recruited for testing Heidelberg Edge Perimeter visual Field machine to observe its efficiency to detect glaucoma in comparison to Octopus visual field machine. Optical Coherence Tomography imaging of the optic nerve head is also performed.
3005529|NCT02526394|Active Comparator|4|Boostrix + Meningitec
3005486|NCT02526654|Experimental|Normal Control|Subjects that do not have glaucoma and are recruited for testing Heidelberg Edge Perimeter visual Field machine to observe its efficiency in detecting glaucoma in comparison to Octopus visual field machine. Optical Coherence Tomography imaging of the optic nerve head is also performed.
3005487|NCT02526641||AbbVie|
3005488|NCT02526628||Testosterone naïve KS|Men with Klinefelter syndrome without testosterone treatment. After initial examination standard treatment with testosterone will be effectuated according to current guidelines.
3005489|NCT02526628||Testosterone treated KS|Men with Klinefelter syndrome receiving testosterone treatment
3005490|NCT02526628||Controls 1|Matched healthy male controls for testosterone naive KS
3005491|NCT02526628||Controls 2|Matched healthy male controls for testosterone treated KS
3005492|NCT02526615|Placebo Comparator|Placebo|placebo, 2 tablets per day
3005493|NCT02526615|Active Comparator|Metformin|500mg 1 tablet 2 times per day for the first 2 weeks, then after that 2 tables 2 times per day
3005494|NCT02526615|Active Comparator|Rosiglitazone|2 mg 1 tablets 2 times per day for the first 2 weeks, then after that 2 tablets 2 times per day
3005495|NCT02526602|Experimental|Preservation (endopelvic fascia)|During robotic assisted laparoscopic radical prostatectomy endopelvic fascia are preserved.
3005496|NCT02526602|Active Comparator|Opening (endopelvic fascia)|During robotic assisted laparoscopic radical prostatectomy endopelvic fascia are opened.
3005497|NCT02526576|Experimental|Stromal Vascular Fraction|Subjects will receive SVF assisted fat transfer
3005498|NCT02526576|Active Comparator|Control -regular fat transfer|Subjects will receive regular fat transfer
3005499|NCT02526563||Iliac crest wound catheter group|These patients will receive an iliac crest wound catheter after an iliac crest bone harvest to repair a palatal defect. This catheter is part of standard of care. This study will collect blood to measure unbound ropivicaine levels.
3005500|NCT02526550|Experimental|Imojev|Live attenuated chimeric Japanese Encephalitis vaccine, 0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh and Simultaneous administration of Inactivated Hepatitis A vaccine, 0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
3005501|NCT02526537||Gefitinib|Stage IB NSCLC Patients with high risk factors and EGFR gene sensitive mutation who can not tolerate or decline chemotherapy and choose Gefitinib for postoperative therapy (Gefitinib 250 mg daily for 2 years).
3005502|NCT02526537||Non-specific treatment|Stage IB NSCLC Patients with high risk factors and EGFR gene sensitive mutation who can not tolerate or decline chemotherapy and choose Non-specific treatment.(Chinese herbal medicine and nonspecific immunomodulators as adjuvant anti-cancer treatment for 2 years).
3005503|NCT02526524|Experimental|600 mg Met DR qAM|600 mg metformin delayed-release once daily in the morning
3005504|NCT02526524|Experimental|900 mg Met DR qAM|900 mg metformin delayed-release once daily in the morning
3005505|NCT02526524|Experimental|1200 mg Met DR qAM|1200 mg metformin delayed-release once daily in the morning
3005506|NCT02526524|Experimental|1500 mg Met DR qAM|1500 mg metformin delayed-release once daily in the morning
3005507|NCT02526524|Placebo Comparator|Placebo-1|placebo match for 600 and 1200 mg Met DR qAM treatment groups
3005508|NCT02526524|Placebo Comparator|Placebo-2|placebo match for 900 and 1500 mg Met DR qAM treatment groups
3005509|NCT02526524|Active Comparator|2000 mg Met IR|1000 mg metformin immediate-release twice daily
3005510|NCT02526511|Experimental|Diagnostic (pMRI)|Patients undergo DCE, DSC, or ASL pMRI within 30 days of biopsy or surgery. Patients with organ confined tumors selected for active surveillance or surgery and patients with metastatic renal cell carcinoma undergo follow up pMRI at 1-6 months.
3005511|NCT02526498|Experimental|Treatment (APBI using HDR brachytherapy)|Within 1-5 days after balloon placement, patients undergo APBI using HDR brachytherapy over 15-60 minutes for 2-3 days.
3005512|NCT02526485||Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture. Participants will be enrolled in equal numbers from three categories determined by their observed clinical course: (1) participants without HIT testing negative for heparin/PF4 antibodies (controls); (2) participants without HIT testing positive for heparin/PF4 antibodies (seroconversion cases); (3) participants with HIT testing positive for both heparin/PF4 antibodies (HIT cases).
3005513|NCT02526472|Experimental|transabdominal US guidance (UGET)|ET under transabdominal US guidance (UGET)
3005514|NCT02526472|Experimental|TV-US ET guidance (mTVET)|ET after transvaginal US uterine measurement (mTVET)
3005515|NCT02526459|Experimental|birth plan|Use of birth plan
3005516|NCT02526459|No Intervention|no birth plan|No use of birth plan
3005517|NCT02526446|Experimental|Self-administered acupressure|The intervention consists of a total of 28 hours over a period of 8 weeks. It comprises of individual learning and practice, self-practice at home, and home follow-up.
3005518|NCT02526446|Other|Wait-list control|The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
3005519|NCT02526433||Pregnancy women and new mothers|The study tracks what interventions women are already registered in and compares these with their mental wellbeing.
3005520|NCT02526420|Experimental|Cohort A: Somavaratan in Older Adults|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects >= 35 years of age
3005521|NCT02526420|Experimental|Cohort B: Somavaratan in Younger Adults|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects < 35 years of age
3005522|NCT02526420|Experimental|Cohort C: Somavaratan in Women on Estrogen|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in female subjects on oral estrogen (regardless of age)
3005523|NCT02526407|No Intervention|Control|Participants continue with usual care. No planned intervention.
3005524|NCT02526407|Active Comparator|Group play|Participants take part in 10 weeks of group play activities for one hour per week with their baby in a community setting alongside any usual care they may be receiving.
3005525|NCT02526407|Experimental|Singing|Participants take part in 10 weeks of group singing activities for one hour per week with their baby in a community setting alongside any usual care they may be receiving.
3005532|NCT02526394|Active Comparator|7|Repevax + quadrivalent meningococcal conjugate )Nimenrix / Menveo)
3005533|NCT02526394|Active Comparator|8|Boostrix + quadrivalent meningococcal conjugate )Nimenrix / Menveo)
3005534|NCT02526381|Experimental|Danlou Tablets|Danlou prescription is a tablet, each piece weighs 0.3 g, taken orally, three times a day, five at a time, from jilin Cornell's pharmaceutical corporation, Limited Liability Company .
3005535|NCT02526381|Experimental|Tongmai Yangxin Pills|Tongmai Yangxin prescription is a pill,each pill weighs 0.1 g,taken orally, 2 times a day,40 pills at a time,produced by tianjin new pharmaceutical group corporation, Limited Liability Company . LeRenTang pharmaceutical.
3005536|NCT02526381|No Intervention|no drugs|
3005537|NCT02526368|Experimental|Pre-surgical Prostate Cancer patients|"A minimum of 20 patients will be required to have high-risk localized disease as defined by primary Gleason score of 4 or 5 on prior prostate biopsy.~Magnetic Resonance (MR) scan using pyruvate (13C) injection prior to prostate surgery.Participants will remain monitored on the study until the time of your radical prostatectomy or 30 days after the pyruvate (13C) injection, whichever is longer."
3005538|NCT02526355|Experimental|Mobile based Intervention|Mobile based Intervention (Learning Through Play Plus) comprised of both LTP and CBT
3005539|NCT02526355|No Intervention|Waiting List Control|Waiting List Control group will receive no intervention, but intervention will be offered to interested participants at the end of the study
3005540|NCT02526342|Active Comparator|Negative Pressure Wound Therapy|Patients receive a Negative Pressure Wound Therapy-Dressing (V.A.C. Ultra (KCI®,San Antonio, Texas, USA) with a subatmospheric pressure of 125mmHg to cover the muscle flap for five days following surgery.
3005541|NCT02526342|No Intervention|Conventional Dressing|Patients receive a conventional dressing for the muscle flap including fatty gauze and cotton gauze.
3005542|NCT02526329|Experimental|Treatment (donor regulatory T lymphocytes)|Patients receive donor regulatory T lymphocytes intravenously (IV) over 5 minutes or less on day 0. Some patients receive a second infusion of frozen donor regulatory T lymphocytes 5-7 days after the initial infusion or 2 additional infusions separated by 5-7 days.
3005543|NCT02526316|Other|P16_37-63 Vaccination|Patients will receive P16_37-63 peptide (100 μg) combined with Montanide® ISA-51 VG subcutaneously once a week for four weeks, followed by a 4 week rest period (1 cycle). The vaccination is to be started one week before the initiation or continuation of the cisplatin-based chemotherapy.
3005544|NCT02526303|Experimental|Anticoagulation|Drug: Nadroparin Calcium and Warfarin Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,along with Nadroparin Calcium 85IU／kg，subcutaneous, q12h,for the first 5 days at least.
3005545|NCT02526303|No Intervention|Non-anticoaglated|No anticoagulatoin or other treatment for PVT will be used in this group of patients.
3005546|NCT02526290|Experimental|Active - Device|The Oculeve Intranasal Lacrimal Neurostimulator will be administered two to ten times per day for up to three minutes per administration.
3005547|NCT02526277|Active Comparator|MMF07 Foot Massager device|Participants randomized to the MMF07 Foot Massager device arm will be provided the MMF07 Foot Massager device and instructed to set this device at setting 3, then increase or decrease the setting to their desired level of comfort, to be used for 30 minutes at bedtime.
3005548|NCT02526277|Active Comparator|Heat therapy|Participants randomized to heat therapy will be provided an electric heating pad and will be instructed to use this pad at a medium setting for 30 minutes at bedtime.
3005549|NCT02526277|Active Comparator|MMF07 Foot Massager device and heat therapy|Participants randomized to both the MMF07 Foot Massager device and heat therapy will be provided both the MMF07 Foot Massager device and electric heating pad. Participants will be instructed to set the MMF07 Foot Massager device at setting 3, then increase or decrease the setting to their desired level of comfort. They will also be instructed to use the electric heating pad at a medium setting at the same time for 30 minutes at bedtime.
3005550|NCT02526277|No Intervention|No treatment|Participants receiving no intervention will be asked to not alter their nighttime routine.
3005551|NCT02526264|Experimental|Krankenhaus Nordwest Concept|specific preoperative education program realised by a specialized stoma-therapist containing individualized information on material maintenance, hygiene, nutrition, complications, activities of daily life and occupation
3005552|NCT02526264|Experimental|Standard concept|standard preoperative education program administered by a surgeon containing information on surgery, outcome, risks and alternatives
3005553|NCT02526238|Experimental|TMS and trunk rotation|TMS and trunk rotation
3005554|NCT02526238|Sham Comparator|Sham TMS and trunk rotation|Sham TMS and trunk rotation
3005555|NCT02526225|Active Comparator|ginkgo diterpene lactone meglumine injection|ginkgo diterpene lactone meglumine injection
3005556|NCT02526225|Placebo Comparator|Ginkgo diterpene lactone meglumine injection simulation|Ginkgo diterpene lactone meglumine injection simulation
3005557|NCT02526212|Experimental|G-BMT, Buprenorphine|This arm will receive the G-BMT intervention, which will include group visits where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. The G-BMT intervention will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
3005558|NCT02526212|Active Comparator|Treatment as usual, Buprenorphine|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
3005559|NCT02526199|Active Comparator|Group BA|Bupivacaine + Adrenaline Sciatic nerve block with Bupivacaine 0.5% + Epinephrine 5 microg/ml
3005560|NCT02526199|Experimental|Group BAD|Bupivacine + Adrenaline + Dexamethasone Sciatic nerve block with Bupivacaine 0.5% + Epinephrine 5 microg/ml PLUS Dexamethsone 8 mg
3005561|NCT02526186|No Intervention|Standard of Care|Standard of Care only
3005562|NCT02526186|Experimental|Battlefield Auricular Acupuncture|Standard of Care plus Battlefield Auricular Acupuncture
3005563|NCT02526173|Experimental|dHACM|This group will receive RALP using full nerve sparing technique plus dHACM application.
3005564|NCT02526173|Other|Control|This group will receive RALP using full nerve sparing technique only.
3005565|NCT02526160|Experimental|KRN23 1 mg/kg|KRN23 1 mg/kg administered subcutaneously (SC) every 4 weeks, for the duration of the study.
3037956|NCT02308163|Placebo Comparator|Placebo group|oral
3005566|NCT02526160|Placebo Comparator|Placebo|Placebo administered SC every 4 weeks through Week 24, followed by KRN23 1 mg/kg, for the duration of the study.
3005567|NCT02526147|No Intervention|Control|Receives no intervention
3005568|NCT02526147|Experimental|Cash|Household receives cash transfer monthly for 6 months
3005569|NCT02526147|Experimental|Voucher|Household receives food voucher to use at local supermarket monthly for 6 months
3005570|NCT02526147|Experimental|Food|Household receives food transfer composed of rice, lentils, canned sardines, and vegetable oil, monthly for 6 months
3005571|NCT02526134|Experimental|Laying of medical devices|radio opaque markers
3005572|NCT02526121|Experimental|Phlebotomy associated with dietary and lifestyle counseling|
3005573|NCT02526121|Active Comparator|Dietary and lifestyle counseling.|
3005574|NCT02526108|Experimental|HIFT|High Intensity Functional Training group exercise session. Each session is 45 minutes. Participants will be asked to complete 3 sessions.
3005575|NCT02526082||Total, observational|Various cardiovascular risk groups described below
3005576|NCT02526082||High-risk intervention|Healthy but at high risk in 1974
3005577|NCT02526082||High-risk control|Healthy but at high risk in 1974
3005578|NCT02526082||Low-risk conrtol|Healthy and at low risk in 1974
3005579|NCT02526082||Sick control|Medications or clinical disease in 1974
3005580|NCT02526082||Refused|Refused or no response in 1974
3005581|NCT02526069|Other|SweetSpot users|Participants will interact with the smartphone application for as long or as little as they wish. They will be asked to complete questionnaires at baseline (pre), 4 weeks (post), and to attend an interview.
3005582|NCT02526056|Experimental|Physiotherapists|The physiotherapist have to play the exergame once.
3005583|NCT02526056|Experimental|elderly people|The elderly people have play the exergame twice.
3005584|NCT02526043|Experimental|laparoscopic hepatectomy|The HCC patients who meet the Louisville consensus will be underwent the liver resection by laparoscopic surgery
3005585|NCT02526043|Experimental|Open hepatectomy|The HCC patients who meet the Louisville consensus will be underwent the liver resection by open surgery
3005586|NCT02526030|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day, during study duration
3005587|NCT02526030|Active Comparator|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
3005588|NCT02526030|Active Comparator|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
3005589|NCT02526017|Experimental|Phase 1 a monotherapy dose escalation|FPA008: specified dose on specified days
3005590|NCT02526017|Experimental|Phase 1a combination therapy dose escalation|FPA008 + BMS-936558: specified dose on specified days
3005591|NCT02526017|Experimental|Phase 1b combination therapy dose expansion|FPA008 + BMS-936558: specified dose on specified days
3005592|NCT02526004|Active Comparator|Standard Empiric Treatment|Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin
3005593|NCT02526004|Experimental|Microbiome Guided Treatment|Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin and 3rd Antibiotic based on the Microbiome analysis
3005594|NCT02525991|Experimental|Staccato® Delivery System Loxapine|Staccato® Delivery System Loxapine, 9.1 mg one dose
3005595|NCT02525978|Experimental|Healthy Controls|Healthy controls will complete the video task and imaginal task in one session
3005596|NCT02525978|Experimental|Depressed + Ketamine|Subjects with major depressive disorder (MDD) who are scheduled to receive ketamine infusions will complete the video task and imaginal task twice. The first visit will be before any ketamine treatment. The second visit will be within 1 week after first ketamine infusion. This is NOT at treatment study. Study inclusion is open to participants with MDD who are already planning to receive ketamine treatment at Emory. No treatment is offered through this study.
3005597|NCT02525965|Experimental|Wide resection margin >1cm|Surgical removal of lesions choosing the method of wide resection margin >1cm
3005598|NCT02525965|Active Comparator|Narrow resection margin <1cm|Surgical removal of lesions choosing the method of narrow resection margin <1cm
3005599|NCT02525952|Experimental|Hepatectomy with NDR 0-2|Surgical removal of all lesions for patients with a NDR score 0-2 according to the NDR scoring system
3005600|NCT02525952|Active Comparator|TACE with NDR 0-2|Transarterial chemoembolization for patients with a NDR score 0-2 according to the NDR scoring system
3005601|NCT02525952|Experimental|Hepatectomy with NDR >2|Surgical removal of all lesions for patients with a NDR score more than 2 according to the NDR scoring system
3005602|NCT02525952|Active Comparator|TACE with NDR >2|Transarterial chemoembolization for patients with a NDR score more than 2 according to the NDR scoring system
3005603|NCT02525939|Active Comparator|dalcetrapib|dalcetrapib 600 mg po QD
3005604|NCT02525939|Placebo Comparator|placebo|matching placebo tablet po QD
3005605|NCT02525926|Experimental|denervation|
3005606|NCT02525926|Sham Comparator|control group|
3005607|NCT02525913|Other|Bi-lateral mastectomy|
3005608|NCT02525900|Placebo Comparator|Wound Infiltration|0.5mg/kg of 0.25% bupivacaine will be injected around the incision for wound infiltration
3005609|NCT02525900|Experimental|TAP Blocks|20mL of 0.25% bupivacaine will be injected on each side of the abdomen for ssTAP procedures
3005610|NCT02525900|Experimental|TAP Catheters|20mL of 0.25% bupivacaine will be injection on each side of the abdomen and catheters placed for repeat bolus every 12 hours with 20mL of 0.25% Bupivacine until 48 hours post procedure or hospital discharge.
3005611|NCT02525874|Experimental|dimethyl fumarate|120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter
3005612|NCT02525861|Active Comparator|GLASSIA with lower particulate level|GLASSIA lot(s) produced within acceptable range, with lower particulate level
3005613|NCT02525861|Active Comparator|GLASSIA with higher particulate level|GLASSIA lot(s) produced within acceptable range, with higher particulate level
3005614|NCT02525848|Active Comparator|dexamethasone|intravenous dexamethasone 8 mg 2 minutes before induction of anesthesia;
3005615|NCT02525848|Active Comparator|gapabentin|oral gabapentin 600 mg 1 hour before induction of anesthesia
3005616|NCT02525848|Active Comparator|Aprepitant|aprepitan 80mg 1 hour before induction of anesthesia.
3005772|NCT02524938|Sham Comparator|Control group|Conventional coffee (habitual diet)
3005617|NCT02525835|Experimental|Low Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) or a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
3005618|NCT02525835|Experimental|High Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) or a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
3005619|NCT02525822|Experimental|IDP-123 Lotion|IDP-123 Lotion, applied topically to the face, once daily for 12 weeks.
3005620|NCT02525822|Active Comparator|Tazorac Cream, 0.1%|Tazorac Cream (tazarotene 0.1%), applied topically to the face, once daily for 12 weeks.
3005621|NCT02525822|Placebo Comparator|Vehicle Cream|Vehicle Cream, applied topically to the face, once daily for 12 weeks.
3005622|NCT02525822|Placebo Comparator|Vehicle Lotion|Vehicle Lotion, applied topically to the face, once daily for 12 weeks.
3005623|NCT02525809|Other|mobility insert with tripod attachment (Novae E®)|mobility insert with tripod attachment (Novae E®)
3005624|NCT02525809|Other|mobility insert with press fit pure (Sunfit®)|mobility insert with press fit pure (Sunfit®)
3005625|NCT02525809|Other|fixed insert (Quartz®).|fixed insert (Quartz®).
3005626|NCT02525796|Placebo Comparator|Placebo + Cinacalcet|Patients with primary hyperparathyroidism will receive placebo for 4 weeks followed by the addition of cinacalcet for 2 weeks
3005627|NCT02525796|Active Comparator|Amiloride + Cinacalcet|Patients with primary hyperparathyroidism will receive amiloride for 4 weeks followed by the addition of cinacalcet for 2 weeks
3005628|NCT02525796|Experimental|Eplerenone + Cinacalcet|Patients with primary hyperparathyroidism will receive eplerenone for 4 weeks followed by the addition of cinacalcet for 2 weeks
3005629|NCT02525770|Active Comparator|acetabular liner in X3 polyethylene|acetabular in X3 polyethylene
3005630|NCT02525770|Active Comparator|acetabular liner in N2VAC® conventional polyethylene|hip replacement with acetabular liner in N2VAC® conventional polyethylene
3005631|NCT02525757|Experimental|Group 1: Chemotherapy + Radiation|"Participants receive standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period when they receive no chemotherapy or radiation.~Consolidation Phase: After the rest period, participants receive MPDL3280A in addition to chemotherapy for 2 cycles.~Maintenance Phase: After completing the consolidation period, participants continue to receive MPDL3280A alone for up to 1 year."
3005632|NCT02525757|Experimental|Group 2: MPDL3280A + Chemotherapy + Radiation|"Participants receive MPDL3280A, standard chemotherapy, and radiation therapy for 6-7 weeks. This will be followed by a rest period of 3-4 weeks, during which time participant receives 1 dose of MPDL3280A but no chemotherapy or radiation.~Consolidation Phase: After the rest period, participants receive MPDL3280A in addition to chemotherapy for 2 cycles.~Maintenance Phase: After completing the consolidation period, participants continue to receive MPDL3280A alone for up to 1 year."
3005633|NCT02525744|Experimental|LY900014|Test formulation. Single dose of LY900014 administered subcutaneously (SC) in three to four of five periods.
3005634|NCT02525744|Active Comparator|Insulin Lispro|Reference formulation. Single dose of Insulin Lispro administered SC in one to two of five periods.
3005635|NCT02525731||Patient Cohort|The TEACH patient cohort component will establish an observational cohort of HIV-infected patients on chronic opioid therapy.
3005636|NCT02525718|Placebo Comparator|Placebo|Subjects will be randomly selected to receive saline (placebo), administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.
3005637|NCT02525718|Active Comparator|0.25 % bupivacaine w/ epinephrine & 4mg dexamethasone|"Subjects will be randomly selected to receive selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone. The injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue.~Subjects will be randomly selected to receive the local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery."
3005638|NCT02525705|Experimental|Every EA patients|This is a one group interventional study. Every patient is included in the same arm.
3005639|NCT02525692|Experimental|ONC201 (Q3W GBM)|
3005640|NCT02525692|Experimental|ONC201 (Q1W GBM)|
3005641|NCT02525692|Experimental|ONC201 (Q1W GBM Surgical)|
3005642|NCT02525692|Experimental|ONC201 (Q1W H3 K27M Glioma)|
3005643|NCT02525692|Experimental|ONC201 (Q1W H3 K27M Glioma Surgical)|
3005644|NCT02525679|Experimental|BI 655130|
3005645|NCT02525679|Placebo Comparator|Placebo|
3005646|NCT02525653|Experimental|Albumin-Bound Paclitaxel and Gemcitabine|During each 21-day cycle, albumin-bound paclitaxel at 100mg/mg2 over 120 minutes and gemcitabine at 1000mg/m2 over 30 minutes will be given intravenously on days 1 and 8 of each 21 day cycle. Treatment will continue until disease progression or intolerable side effects. After the 4th cycle of treatment, patients will have the option of discontinuing gemcitabine and proceeding with weekly albumin-bound paclitaxel as maintenance therapy.
3005647|NCT02525640|Experimental|Hearing Aid|CROS hearing aid
3005648|NCT02525627|Active Comparator|Trident cup, X3 inserts, 28 mm head|Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
3005649|NCT02525627|Active Comparator|Trident cup, X3 inserts, 40 mm head|Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
3005650|NCT02525614|Active Comparator|Triathlon Standard Keel|Triathlon Cruciate Retaining knee (CR) with a tibial keel of standard length randomised against Triathlon Cruciate Retaining knee (CR) with a tibial part with a short keel, both system will be used with cemented fixation. The short tibial keel is thought to facilitate the surgery due to easier access and better positioning possibilities. This study is aimed to evaluate if the short tibial keel will have equal fixation and migration properties as the standard keel.
3005770|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 96 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 96 mg/m2 . Drug infusions will last approximately 2 hours.
3038057|NCT02307487|Experimental|Cohort C|160 mg MMC in 60ml gel
3005651|NCT02525614|Active Comparator|Triathlon Short Keel|Triathlon Cruciate Retaining knee (CR) with a tibial keel of standard length randomised against Triathlon Cruciate Retaining knee (CR) with a tibial part with a short keel, both system will be used with cemented fixation. The short tibial keel is thought to facilitate the surgery due to easier access and better positioning possibilities. This study is aimed to evaluate if the short tibial keel will have equal fixation and migration properties as the standard keel.
3005652|NCT02525601|Active Comparator|Triathlon CR cemented|Triathlon Cruciate Retaining knee with cemented fixation randomised versus Triathlon Cruciated Retaining knee with uncemented fixation. The aim with this study is to evaluate the uncemented Peri-Apatite (PA) knee fixation and migration properties versus the cemented version.
3005653|NCT02525601|Active Comparator|Triathlon CR uncemented|Triathlon Cruciate Retaining knee with cemented fixation randomised versus Triathlon Cruciated Retaining knee with uncemented fixation. The aim with this study is to evaluate the uncemented PA knee fixation and migration properties versus the cemented version.
3005654|NCT02525588|Active Comparator|N2Vac polyethylene inlay|Conventional UHMWPE inlay in a Triathlon CS fixed bearing total knee prosthesis
3005655|NCT02525588|Active Comparator|X3 highly cross-linked polyethylene|X3 highly cross-linked polyethylene inlay in a Triathlon CS fixed bearing total knee prosthesis
3005656|NCT02525575|Experimental|Project Life Force Group Treatment|"Project Life Force Clinical Intervention: is a manualized, weekly 90-minute group treatment lasting 3 months coinciding with the time frame for enhanced monitoring of Veterans identified as high-risk. The use of Dialectical Behavior Therapy skills in PLF differs from other DBT interventions in that it focuses primarily on emotion regulation (ER), distress tolerance and interpersonal effectiveness in the specific context of implementing a safety plan. Mindfulness is not covered. PLF is augmented with additional skill modules on strengthening friendships and education pertaining to suicide risk, suicide means restriction and suicide prevention mobile Apps."
3005657|NCT02525562|Other|Scorpio NRG Total Knee System|Patients eligible for Scorpio NRG Total Knee System with X3 insert
3005658|NCT02525562|Other|Triathlon Total Knee System|Patients eligible for Triathlon Total Knee System with X3 insert
3005659|NCT02525562|Other|Triathlon Partial Knee Resurfacing|Patients eligible for Triathlon PKR System with X3 insert
3005660|NCT02525549|Experimental|Test product|Adapalene and Benzoyl Peroxide Gel
3005661|NCT02525549|Active Comparator|Reference product|Adapalene and Benzoyl Peroxide Gel (Reference)
3005662|NCT02525549|Placebo Comparator|Placebo product|Placebo gel
3005663|NCT02525536|Experimental|Trebananib 3 mg/kg|Trebananib (AMG 386) 3 milligram/kilogram (mg/kg), 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
3005664|NCT02525536|Experimental|Trebananib 10 mg/kg|Trebananib (AMG 386) 10 mg/kg, 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
3005665|NCT02525536|Experimental|Trebananib 30 mg/kg|Trebananib (AMG 386) 30 mg/kg, 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
3005666|NCT02525523|Experimental|Alicaforsen|Alicaforsen enema, 240mg once daily for 6 weeks
3005667|NCT02525523|Placebo Comparator|Placebo|Placebo enema, once daily for 6 weeks
3005668|NCT02525510|Active Comparator|Pump Eligible - Normothermia - Pump Both Kidneys|Normothermia and Machine Perfusion Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Recovered kidneys will receive machine perfusion prior to implantation.
3005669|NCT02525510|Active Comparator|Pump Eligible - Hyporthermia and Pump Right Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage.
3005670|NCT02525510|Active Comparator|Pump Eligible - Hyporthermia and Pump Left Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Left Kidney will receive machine perfusion prior to implantation and the Right Kidney will receive cold storage.
3005671|NCT02525510|Active Comparator|Not Pump Eligible - Normothermia|Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery.
3005672|NCT02525510|Active Comparator|Not Pump Eligible - Hypothermia|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery.
3005673|NCT02525497|Experimental|FM peritoneal dialysis machine|FM peritoneal dialysis machine APD 10L/10h;
3005674|NCT02525497|Active Comparator|HOMECHOICE peritoneal dialysis machine|HOMECHOICE peritoneal dialysis machine APD 10L/10h;
3005675|NCT02525484|Experimental|Pirfenidone ACBD treatment sequence|Participants will be given 801 milligrams (mg) single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 1 and in fasted state (treatment C) on Day 4, 801-mg tablet in fed state (treatment B) on Day 7 and in fasted state (treatment D) on Day 10.
3005676|NCT02525484|Experimental|Pirfenidone BADC treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, 801-mg tablet in fed state (treatment B) on Day 1, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 4, 801-mg tablet in fasted state (treatment D) on Day 7 and capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 10.
3005677|NCT02525484|Experimental|Pirfenidone CDAB treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 1, 801-mg tablet in fasted state (treatment D) on Day 4, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 7 and 801-mg tablet in fed state (treatment B) on Day 10.
3005678|NCT02525484|Experimental|Pirfenidone DBCA treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, 801-mg tablet in fasted state (treatment D) on Day 1 and in fed state (treatment C) on Day 4, capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 7 and in fed state (treatment A) on Day 10.
3005679|NCT02525471|Experimental|RNS60|"Following screening visit to determine eligibility, enrolled subjects will undergo the baseline visit within 6 weeks where the first intravenous (IV) infusion of study medication, RNS60, will be administered. Study medication for inhalation use will be dispensed at this time, and again at weeks 7 and 15. Subjects will continue once a week follow ups to receive RNS60 by IV infusion, continuing inhalation use the remaining 6 days per week, for 24 weeks total. Additionally, eligible subjects will undergo PET imaging at baseline and again between weeks 18 and 23.~In addition, upon nearing completion of the core study, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug, following the optional extension phase schedule of activities."
3005680|NCT02525458|Experimental|QAMS-containing PMMA|PMMA containing 5% QAMS
3005681|NCT02525458|Placebo Comparator|QAMS-free PMMA|PMMA containing 0% QAMS
3005682|NCT02525445|Active Comparator|acupuncture positive communication|Genuine acupuncture needles combined with positive communication regarding the expected treatment effects
3005683|NCT02525445|Sham Comparator|sham acupuncture positive communication|Sham acupuncture needles combined with positive communication regarding the expected treatment effects
3005684|NCT02525445|Active Comparator|acupuncture neutral communication|Genuine acupuncture needles combined with neutral communication regarding the expected treatment effects
3005685|NCT02525445|Sham Comparator|sham acupuncture neutral communication|Sham acupuncture needles combined with neutral communication regarding the expected treatment effects
3005686|NCT02525432|Experimental|Autologous BMMNC Infusion|Subjects randomized to the treatment group will undergo a bone marrow harvest and then receive an autologous infusion of BMMNC's starting with the lowest dose (6 x 10^6 cells/kg body weight) and progressing to the high dose of 9 x 10^6 cells/kg body weight using a Bayesian adaptive dose escalation design.
3005687|NCT02525432|Placebo Comparator|Placebo Infusion|"Subjects randomized to the placebo control group will undergo a sham bone marrow harvest."
3005688|NCT02525419|Experimental|Weight Loss Phase|12 week weight loss phase consisting of High Protein - Intermittent Fast-Low Calorie diet in 43 Obese Men and Women
3005689|NCT02525419|Experimental|Weight Loss Maintenance Phase|52 week weight loss maintenance phase consisting of either High Protein - Intermittent Fast (HP-IF) or Heart Healthy (HH) diet
3005690|NCT02525393|Experimental|tDCS+rTMS|Stroke patients were treated with an initial two weeks of transcranial direct current stimulation and after six months with two weeks of repetitive transcranial magnetic stimulation.
3005691|NCT02525393|Experimental|rTMS+tDCS|Stroke patients were treated with an initial two weeks of repetitive transcranial magnetic stimulation and after six months with two weeks of transcranial direct current stimulation.
3005692|NCT02525393|Sham Comparator|Sham stimulation|Stroke patients were treated with two weeks of sham transcranial direct current stimulation.
3005693|NCT02525380|Experimental|Doxorubicin loadeing-DC Bead(Device)|"DC Bead comprises hydrogel microspheres that are biocompatible, hydrophilic, non resorbable, precisely calibrated and capable of loading doxorubicin.~DC Bead is produced from polyvinyl alcohol."
3005694|NCT02525367|Experimental|PD-Experimental|PD patients using the online cognitive training for 8 weeks, 3 times a week
3005695|NCT02525367|Active Comparator|PD-Control|PD patients using the active control condition for 8 weeks, 3 times a week
3005696|NCT02525367|Experimental|MS-Experimental|MS patients using the online cognitive training for 8 weeks, 3 times a week
3005697|NCT02525367|Active Comparator|MS-Control|MS patients using the active control condition for 8 weeks, 3 times a week
3005698|NCT02525367|Experimental|postECT-Experimental|Depressed elderly treated with ECT patients using the online cognitive training for 8 weeks, 3 times a week
3005699|NCT02525367|Active Comparator|postECT-Control|Depressed elderly treated with ECT patients using the active control condition for 8 weeks, 3 times a week
3005700|NCT02525341|Experimental|Yoga Group|Participants in the yoga group received a total of eight weekly 45 minute yoga classes. Handouts were provided for participants to practice the yoga program for additional 30 minutes a day, 4 days a week at home.
3005701|NCT02525341|Active Comparator|Aerobic and Strengthening Exercise Group|Participants in the exercise group received a total of eight weekly 45 minute exercise classes. Handouts were provided for participants to practice the program at home for 30 minutes a day, 3 days a week (on non-consecutive days).
3005702|NCT02525341|Active Comparator|General education|Participants in this group received a one-time OA educational brochures from the Arthritis Foundation including topics focusing on the disease process, diet and exercise and OA management education. Participants were instructed not to begin any new exercise programs during the study period.
3005703|NCT02525328||CT subjects|blood or saliva specimen
3005704|NCT02525328||subjects without CT|blood or saliva specimen
3005705|NCT02525315|Experimental|Transcranial magnetic stimulation: rTMS|rTMS : 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
3005706|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 1|HT-100 multiple dose administration (dose 1).
3005707|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 2|HT-100 multiple dose administration (dose 1).
3005708|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 3|HT-100 multiple dose administration (dose 1).
3005709|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 4|HT-100 multiple dose administration (dose 1).
3005710|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 5|HT-100 multiple dose administration (dose 1).
3005711|NCT02525289|No Intervention|Control Group|six hours after extubation receiving breathing exercises. After 48 hour postoperative time, sitting on armchair and keeping the erect position and walking in the same place.
3005712|NCT02525289|Active Comparator|Bed Rotation Group|six hours after extubation receiving breathing exercises and submitted the continuous rotational bed therapy in the first postoperative day until 48 hours.
3005713|NCT02525289|Active Comparator|Orthostatic Group|six hours after extubation receiving breathing exercises and changing the body position following the sequence: sitting on the bed, sitting on the bed with the feet on the floor , standing and walking in the same place, in the first postoperative day until 48 hours.
3005714|NCT02525276|Experimental|training + HT|training + HT
3005715|NCT02525276|Experimental|training - HT|training - HT
3005718|NCT02525263|Experimental|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
3005719|NCT02525250|Experimental|Acute myeloïd leukemia|Realization of 3 blood samples at day 0, day 15 and day 28.
3005720|NCT02525237|Experimental|Apatinib plus S-1|Apatinib (500 mg qd p.o.) concomitantly with S-1 (40 mg/m2 qd days 1-14 q3w p.o.)
3005721|NCT02525224|Other|Nutritional Supplement|Proprietary nutritional supplement, Minimal Erythema Dose (MED)
3005722|NCT02525211|Experimental|Ropivacaine|Ropivacaine
3005723|NCT02525211|Placebo Comparator|placebo|physiological saline
3005724|NCT02525198|Placebo Comparator|Placebo|Placebo group: 12 month daily ingestion of placebo oil and flavonoid-poor matched extract
3005725|NCT02525198|Experimental|fatty acid/flavonoid blend|Experimental group: 12 month daily ingestion of 1.5 g EPA+DHA and 500 mg flavonoids
3005726|NCT02525172|Experimental|ITT|immune modulation therapy
3005727|NCT02525159|Active Comparator|DIM pills|75 mg of 3,3´-diindolylmethane (DIM) once a day for 30 days
3005728|NCT02525159|Placebo Comparator|Placebo pills|2 pills once a day for 30 days
3005729|NCT02525146|Experimental|Intervention|Patients randomized to the intervention arm receive intensive social work case management based on the ARTAS (Antiretroviral Treatment and Access to Services) model. Patients may participate in 6-12 visits over a six-month period aimed at addressing barriers to re-engagement in HIV care. Participants complete a battery of research questions at Baseline, 6-months, and 12-months and HIV-1 viral load and CD4 count labwork at Baseline and at 12-months post enrollment.
3005730|NCT02525146|No Intervention|Usual Care|Patients randomized to the usual care arm are provide contact information for an HIV primary care clinic and for local AIDS service organizations. Patients are then encouraged to contact these organizations to re-establish care. Participants complete a battery of research questions at Baseline, 6-months, and 12-months and HIV-1 viral load and CD4 count labwork at Baseline and at 12-months post enrollment. Patients in the usual care arm are offered the intensive casework intervention after their 12-month followup is complete.
3005731|NCT02525133|Experimental|XaraColl|3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose
3005732|NCT02525133|Placebo Comparator|Placebo|3 placebo implants
3005733|NCT02525120|Experimental|Triojection System for ozone injection|Triojection is a system including a single-use sterile syringe cartridge and an accessory console. The console is interfaced to a supply of medical oxygen and uses this supply to fill the syringe with oxygen. Ozone is produced by applying a high voltage to electrodes physically located within the syringe. When a concentration of 35µg/ml is reached, the cartridge is removed from the console. The sterile syringe, containing the gas, is extracted from the protective housing and the gas is administered directly to the center of the herniated disc through a spinal needle.
3005734|NCT02525120|Active Comparator|Surgical discectomy|The surgical group will be receive a standard surgical discectomy to remove the herniated disc material.
3005735|NCT02525107|Experimental|SCD patients on Hydroxyurea|Omega-3 capsules [750 mg], 4 capsules a day for 52 weeks. [Each capsule will contain 417.9mg Docosahexaenoic acid [DHA], 50.8 mg Eicosapentaenoic acid [EPA] and 11.9mg Arachidonic acid [AA] and 1000 IU Vitamin E]
3005736|NCT02525107|Experimental|SCD patients not on Hydroxyurea|Dietary Supplement: Placebo [730 mg], 4 capsules a day for 52 weeks.[Each capsule will contain 538.2mg Oleic Acid [OA] and 1000 IU Vitamin E]
3005737|NCT02525094|Experimental|MEDI9929 280 mg|Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
3005738|NCT02525094|Placebo Comparator|Placebo|Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
3005739|NCT02525081|Experimental|ACE-inhibitor|"In both the placebo and Ramipril group medication will start with either 2,5 mg (Blood Pressure<130) or 5 mg (Blood Pressure>130) daily. After 2-3 weeks the dose is doubled to 5 mg or 10 mg unless blood pressure is below 115 mmHg. If blood pressure continues to be higher than 115 mmHg for patients up titrated to 5 mg treatment dose will be doubled to 10 mg at the third visit.~Patients taking a dose of~2,5 mg will take a half tablet a day~5 mg will take one whole tablet a day~10 mg will take two tablets a day"
3005740|NCT02525081|Placebo Comparator|Placebo|"In both the placebo and Ramipril group medication will start with either 2,5 mg (Blood Pressure<130) or 5 mg (Blood Pressure>130) daily. After 2-3 weeks the dose is doubled to 5 mg or 10 mg unless blood pressure is below 115 mmHg. If blood pressure continues to be higher than 115 mmHg for patients up titrated to 5 mg treatment dose will be doubled to 10 mg at the third visit.~Patients taking a dose of~2,5 mg will take a half tablet a day~5 mg will take one whole tablet a day~10 mg will take two tablets a day"
3005741|NCT02525068|Experimental|Phase ISafety Run-In|18 patients will receive the combination of enzalutamide and AZD5363 (on an intermittent schedule 4 days on 3 days off) to determine the AZD5363 dose to be used for the randomised phase II and single stage phase II expansion cohort. Approximately three dose‐levels of AZD5363 in combination with enzalutamide are planned although other dose levels may be required.
3005742|NCT02525068|Placebo Comparator|Randomised phase II|100 patients will be randomised in a 1:1 ratio to receive 160mg enzalutamide od + AZD5363 bid 4 days on 3 days off (recommended dose from Phase I) vs 160mg enzalutamide od + matching placebo bid 4 days on 3 days off.
3005743|NCT02525068|Experimental|Single stage phase II expansion cohort|Following progression on enzalutamide alone, 18 patients will receive enzalutamide 160mg od and AZD5363 bid (recommended dose from phase I) 4 days on 3 days off
3005744|NCT02525055|Experimental|Infectious titre 1|Infectious titre 1
3005745|NCT02525055|Experimental|Infectious titre 2|Infectious titre 2
3005746|NCT02525055|Experimental|Infectious titre 3|Infectious titre 3
3005747|NCT02525055|Experimental|Infectious titre 4|Infectious titre 2
3005748|NCT02525042||Patients with ankylosing spondylitis|Patients with ankylosing spondylitis
3005749|NCT02525042||Comparator 1|family controls
3005750|NCT02525042||Comparator 2|population controls
3005771|NCT02524938|Experimental|Treatment group|Chlorogenic Acid (CGA) 400mg/day (CGA-enriched coffee)
3005751|NCT02525029|Experimental|1: High-Risk aGVHD|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses.~Individual patient dose reductions: If a patient has toxicity that meets the definition of dose limiting, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.~Continue protocol treatment through day 7. Assess response at day 7:~If a complete or partial response, continue protocol treatment followed by hCG maintenance twice weekly for 10 doses beginning day 9 to 12.~If no response, the patient will be taken off study treatment."
3005752|NCT02525029|Experimental|2a: Steroid-Dependent aGVHD|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses.~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.~Continue protocol treatment through day 14. Assess response at day 14:~If a complete or partial response, continue protocol treatment followed by hCG at the assigned dose maintenance twice weekly for 10 doses beginning day 15 to 17.~If no response, the patient will be taken off study treatment"
3005753|NCT02525029|Experimental|2b: Steroid-Refractory aGVHD|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses.~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.~Continue protocol treatment through day 14. Assess response at day 14:~If a complete or partial response, continue protocol treatment followed by hCG at the assigned dose maintenance twice weekly for 10 doses beginning day 15 to 17.~If no response, the patient will be taken off study treatment"
3005754|NCT02525016|Experimental|assessment of plasmatic lidocaine rate|Patients will receive intravenous administration of lidocaine based on a modified body weight ; blood sampling will be performed to assess plasmatic concentration of lidocaine
3005755|NCT02525003|Placebo Comparator|Group 1: placebo|Group 1: daily dose of regular bread (87 g/d) and placebo pill (0 µg of vitamin D/d) for 8 weeks
3005756|NCT02525003|Experimental|Group 2: Vitamin D2 supplement|Group 2: daily dose of regular bread (87 g/d) and D2 supplement (25 µg of vitamin D2/d.) for 8 weeks
3005757|NCT02525003|Experimental|Group 3: Vitamin D3 supplement|Group 3: daily dose of regular bread (87 g/d) and D3 supplement (25 µg of vitamin D3/d.) for 8 weeks
3005758|NCT02525003|Experimental|Group 4: Vitamin D2-fortified bread|Group 4: D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
3005759|NCT02524990|Experimental|Home-based follow-up with SQPT|For the intervention, a semiquantitative pregnancy test (SQPT) will be performed at the health center before the participants take mifepristone, and again two weeks later by the participants, at home. Study staff will call the participants at two weeks to follow-up with the participants.
3005760|NCT02524977|Active Comparator|Educational Intervention Only|"Educational Intervention Only - Educational package was delivered as 2 didactic noon-conferences on atrial fibrillation with a review of up-to-date anticoagulation guidelines for stroke prevention, and distribution of educational materials. Physicians delivering the noon conference series at all of the general internal medicine and primary care practice sites included 3 stroke neurologists, 2 cardiologists, and a general internist (PI) who were co-investigators in this study. Internists who were faculty at the University of Cincinnati and Internal Medicine residents also had an opportunity to participate in the first of the noon conferences in a special Department of Medicine Grand Rounds delivered by the PI.~All practices (intervention and control groups) received the educational package focused on physicians, and clinical and non-clinical staff who would be involved in this QI process."
3005761|NCT02524977|Experimental|Educational Intervention plus Decision Support|Educational Intervention plus Decision Support - Physicians in the intervention arm received a practice-level and physician-level summary report via a secure web site designed for patients with treatment recommendations that were discordant with current therapy, along with an explanation for the recommendation, the gain or loss in QALYs predicted by the decision model and the current 2014 ACC/AHA/HRS guidelines. Providers were also reminded of upcoming visits for patients being seen within the next week so they could review their reports and use them in discussions with their patients.
3005762|NCT02524964|Experimental|sodium tanshinone IIA sulfonate|sodium tanshinone IIA sulfonate (80 mg q.d. for 7 days)
3005763|NCT02524964|Sham Comparator|control|same volume/day of normal saline.
3005764|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 20 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 20 mg/m2. Drug infusions will last approximately 2 hours.
3005765|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 26 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 26 mg/m2. Drug infusions will last approximately 2 hours.
3005766|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 34 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 34 mg/m2 . Drug infusions will last approximately 2 hours.
3005767|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 44 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 44 mg/m2 . Drug infusions will last approximately 2 hours.
3005768|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 57 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 57 mg/m2. Drug infusions will last approximately 2 hours.
3005769|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 74 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 74 mg/m2 . Drug infusions will last approximately 2 hours.
3005773|NCT02524925|Active Comparator|fast track protocol|Oral fluids intake (0.5 lt) 6 hours after operation Mobilization 4 hours after operation Check discharge criteria the 4th-6th postoperative day
3005774|NCT02524925|No Intervention|conventional protocol|Oral intake after bowel mobilization Mobilization after the 1st postoperative day Check discharge criteria the 7th-15th postoperative day
3005775|NCT02524899|Active Comparator|Cognitive Remediation Therapy and placebo|7.5 weeks of twice weekly cognitive remediation sessions
3005776|NCT02524899|Experimental|Guanfacine and CRT|7.5 weeks of twice weekly cognitive remediation sessions with 8 weeks of guanfacine
3005777|NCT02524886|Active Comparator|Immediate stimulation|Patients will be implanted with a Medtronic electorde and Active PC pulse generator for deep brain stimulation at baseline and GPi electric stimulation will start immediately after surgery
3005778|NCT02524886|Sham Comparator|Delayed stimulation|Patients will be implanted with a Medtronic electorde and Active PC pulse generator for deep brain stimulation at baseline and GPi electric stimulation will start 3 months after surgery
3005779|NCT02524860|Experimental|MRI-ultrasound fusion device|Using the Focal-Fusion Bx device, the urologist will fuse ('coregister') the MRI to the TRUS imaging
3005780|NCT02524847|Experimental|UVADEX® and ECP|All patients will receive UVADEX® (methoxsalen) Sterile Solution in Conjunction with the THERAKOS® CELLEX® Photopheresis System, as part of the same interventional treatment for 12 weeks. Treatments will be given 3 times a week for Weeks 1-4 and 2 times a week for Weeks 5-12.
3005781|NCT02524834|Experimental|Endovascular Device Implantation|Endoluminal exclusion of thoracoabdominal lesion
3005782|NCT02524821|Active Comparator|drugs only, fasted|1 x 850 mg metformin tablet, under fasting conditions.
3005783|NCT02524821|Experimental|Gelesis100 plus drugs, fasted|3 x 0.75 g Gelesis100 capsules, followed 30 minutes later by the administration of 1 x 850 mg metformin tablet, under fasting conditions.
3005784|NCT02524821|Active Comparator|drugs only, fed|1 x 850 mg metformin tablet, followed by the ingestion of a high-fat, high-caloric meal.
3005785|NCT02524821|Active Comparator|Gelesis100 plus drugs, fed|3 x 0.75 g Gelesis100 capsules, followed by the ingestion of a high-fat, high-caloric meal, followed by the administration of 1 x 850 mg metformin tablet (fed conditions).
3005786|NCT02524795|Experimental|Hiomega-3 supplement|"Patients in the study group received, throughout 12 weeks, two tablets per day of omega-3 fatty acids (540mg of EPA and DHA of 100mg; Hiomega-3 supplement of Naturalis® company). Participants were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment.~Variables measured at each visit included: disease activity index, using the Systemic Lupus Disease Activity Index (SLEDAI-2k)16; damage index (Systemic Lupus International Collaboration Clinics/American College of Rheumatology damage index - SLICC/ACR)17; fasting lipid and glucose proﬁle; standard laboratory tests to assess SLE ; cytokines (IL-6, IL-10), adipokines (leptin, adiponectin) C-reactive protein (CRP), nutritional assessment, and in use medications."
3005787|NCT02524795|No Intervention|Control group|"Patients in the control group did not receive the nutrient nor any kind of placebo. They were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment.~Variables measured at each visit included: disease activity index, using the Systemic Lupus Disease Activity Index (SLEDAI-2k)16; damage index (Systemic Lupus International Collaboration Clinics/American College of Rheumatology damage index - SLICC/ACR)17; fasting lipid and glucose proﬁle; standard laboratory tests to assess SLE ; cytokines (IL-6, IL-10), adipokines (leptin, adiponectin) C-reactive protein (CRP), nutritional assessment, and in use medications."
3005788|NCT02524782|Experimental|MEDI-4166|MEDI-4166 administered subcutaneously
3005789|NCT02524782|Placebo Comparator|Placebo|Placebo administered subcutaneously
3005790|NCT02524769|Other|conjugated estrogen|All patients in the study will receive 0.625 mg conjugated estrogen/gram to use 0.5 grams twice weekly with the applicator for 12 weeks.
3005791|NCT02524756|Active Comparator|Group (A)|laparoscopic nerve sparing radical hysterectomy type III/C1
3005792|NCT02524756|Active Comparator|Group (B)|laparoscopic radical hysterectomy type III/C2
3005793|NCT02524743|Placebo Comparator|Placebo (Group I)|"For pretreatment the patients were administered IV 5ml normal saline.~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
3005794|NCT02524743|Active Comparator|Group II|"For pretreatment the patients were administered IV acetaminophen 50 mg~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
3005795|NCT02524743|Active Comparator|Group III|"For pretreatment the patients were administered IV acetaminophen 25 mg.~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
3005796|NCT02524743|Active Comparator|Group IV|"For pretreatment the patients were administered IV lidocaine 20 mg~The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
3005828|NCT02524470|Experimental|VSP Study Participants|Vital Signs Patch system study participants. Each study participant will receive the VSP System - NEHB Configuration and then the VSP System - PAL Configuration. Vital signs will be taken and adhesive will be assessed for each participant for each configuration.
3005829|NCT02524457||Premenopausal|Premenopausal women going through gynecological surgery
3005797|NCT02524743|Active Comparator|Group V|"For pretreatment the patients were administered IV lidocaine 40 mg.~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
3005798|NCT02524730|Other|Scorpio NRG CR Total Knee System|Primary total knee replacement
3005799|NCT02524717|Experimental|JNJ-56021927|Participants with mild and moderate hepatic impairment and with normal hepatic function will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
3005800|NCT02524704||Healthy controls|Subjects between the ages of 2 and 21 with healthy lungs. Electrical impedance tomography data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, and during FEV1 and FEF 25-75 spirometry maneuvers for subjects over age 8.
3005801|NCT02524704||CF patients scheduled for a CT scan|Subjects with CF between the ages of 2 and 21 who are either clinically indicated for a CT scan of the lungs or are scheduled for a pulmonary CT scan as part of their routine care. Electrical impedance tomography data data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, during forced expiratory volume in 1 second (FEV1) and forced expiratory flow (FEF) 25-75 spirometry maneuvers for subjects over age 8, and immediately before or after pulmonary CT scanning.
3005802|NCT02524704||CF patients with pulmonary exacerbation|"Subjects with CF between the ages of 8 and 21 who are being started on intravenous (IV) antibiotics for a clinically diagnosed pulmonary exacerbation.~Electrical impedance tomography data data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, during FEV1 and FEF 25-75 spirometry maneuvers upon admission for a pulmonary exacerbation and following 7 to 14 days hospitalized treatment including IV antibiotics. Further data will be collected at the same time with CT scanning if the scan is part of the patient's standard of care."
3005803|NCT02524678|Placebo Comparator|Placebo|Placebo
3005804|NCT02524678|Active Comparator|URC102|URC102
3005805|NCT02524665|Experimental|MAXCLARITY II|MAXCLARITY II Foam Cleanser (2.5% BPO) plus Foam Treatment (2.5% BPO) and (0.5% Salicylic Acid) Toner Foam. Available over the counter. Each subject applies both arms (MAXCLARITY II and MURAD) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
3005806|NCT02524665|Active Comparator|MURAD|MURADClarifying Cleanser (1.5% SA) plus Exfoliating Acne Treatment Gel (1% SA) and Skin Perfecting Lotion. Available over the counter. Each subject applies both arms (MAXCLARITY II and MURAD) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
3005807|NCT02524652|Experimental|Local infiltration analgesia|Infiltration of the knee by the surgeon with local anaesthetics under general anaesthesia.
3005808|NCT02524652|Active Comparator|Adductor canal block|Injection of local anaesthetics under ultrasound guidance in the adductor canal by the anaesthesiologist after the surgery, before awaking the patient.
3005809|NCT02524639|Experimental|Sirolimus|All enrolled subjects will receive Sirolimus 1 mg/m2/day twice a day for 6 weeks.
3005810|NCT02524626|Sham Comparator|Sham stimulation|no stimulation of vagus nerve
3005811|NCT02524626|Active Comparator|Vagus stimulation|Stimulation of the vagus nerve at the beginning and the end of the surgery
3005812|NCT02524600|Experimental|"New Technology IQ-SPECT applied to myocardial imaging"|
3005813|NCT02524587|Active Comparator|acetabular polyethylene vitamys®|acetabular polyethylene vitamys®
3005814|NCT02524587|Active Comparator|standard polyethylene acetabular irradiated at 3 Mrad|standard polyethylene acetabular irradiated at 3 Mrad
3005815|NCT02524574|Experimental|cardiac Rehabilitation|
3005816|NCT02524561|Active Comparator|CEE pill, active progesterone|Conjugated equine estrogens 0.45 mg/day, placebo patch, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
3005817|NCT02524561|Active Comparator|estradiol patch, active progesterone|Transdermal estradiol, 50 mcg/day, placebo tablet, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
3005818|NCT02524561|Placebo Comparator|placebo|Placebo tablet, placebo patch, placebo progesterone
3005819|NCT02524548|Experimental|SMS reminder|Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor
3005820|NCT02524548|No Intervention|Standard care|Routine care
3005821|NCT02524535|Other|Therapetic alliance|
3005822|NCT02524522|Active Comparator|INTELLiVENT-ASV mode|Active comparator: Discontinuation of mechanical ventilation in postoperative period will be provided using automatically driven mode - INTELLiVENT-ASV. In the INTELLiVENT-ASV mode target EtCO2 will be 30-35 mm Hg, target SpO2 - 94-98%, quick wean option - activated.
3005823|NCT02524522|Active Comparator|SIMV mode|Active comparator: Discontinuation from mechanical ventilation in postoperative period will be provided using physician driven protocol. The synchronized intermittent mandatory ventilation (SIMV) mode settings will be as follows: PEEP 5 cm of water, FiO2 to achieve SpO2 > 94 %. Inspiratory pressure will be adjusted to deliver a tidal volume (VT) of 8 mL/kg predicted body weight; pressure support will be 2 cm of water higher. Respiratory rate (RR) will be adjusted to provide EtCO2 of 30-35 mm Hg. Respiratory rate and inspiratory pressure will be decreased gradually every 30 minutes. After decrease of inspiratory pressure to 6 cm of water (8 cm of water in case of BMI > 30 kg/m2) and respiratory rate to 6/min, the spontaneous breathing trial (SBT) will be started.
3005824|NCT02524509||CHONDRON|Patients who already received autologous chondrocyte implantation using CHONDRON (Autologous Cultured Chondrocyte) for knee cartilage defects
3005825|NCT02524509||Microfracture|patients already underwent microfracture
3005826|NCT02524483|Experimental|Therapeutic Challenge Group|The Therapeutic Challenge Group will complete the Therapeutic Challenge Program twice a day, five days each week for 6 weeks.
3005827|NCT02524483|Active Comparator|Therapeutic Exercise Group|The Therapeutic Exercise Group will complete the Therapeutic Exercise Program twice a day, five days each week for 6 weeks.
3005830|NCT02524457||Postmenopausal|Postemnopausal women going through gynecological surgery
3005831|NCT02524457||Postmenopausal + HT|Postmenopausal women going through gynecological surgery who has been taking hormone treatment through the past year (as a minimum)
3005832|NCT02524444|Active Comparator|Mefloquine|Tabs Mefloquine 250mg 3 doses 4 weeks apart
3005833|NCT02524444|Active Comparator|Sulphadoxine-Pyrimethamine|500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets 4 weeks apart for 3 doses
3005834|NCT02524431|Active Comparator|Glaucoma subjects|During glaucoma surgery, collection of trabecular meshwork tissue during surgery that is not needed is cut away from the surgical site. The physician will keep this tissue for analysis by the researchers at Wills Eye Hospital and Thomas Jefferson University Center for Translational Medicine.
3005835|NCT02524431|Active Comparator|Control cadaver eyes|control cadaver eye are ordered and the collection of trabecular meshwork tissue during surgery and is processed at Thomas Jefferson University
3005836|NCT02524418|Other|Cholangiopancreatoscopy|A standard of care Endoscopic Retrograde Cholangiopancreatoscopy (ERCP) will be performed using the Spyglass DS. The clinical outcomes will be collected and analyzed.
3005837|NCT02524405||Normal Controls|Sixty normal elders, 50-90 years old who are within normal limits on the study neuropsychological battery will be enrolled. All patients involved in the study will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET.
3005838|NCT02524405||Alzheimer's Disease (AD)|Sixty-five subjects meeting the National Institute on Aging-Alzheimer's Association (NIA-AA) core clinical criteria for probable AD dementia will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
3005839|NCT02524405||Mild Cognitive Impairment (VCI)|Sixty-five subjects meeting the National Institute on Aging-Alzheimer's Association criteria for amnestic or multi-domain MCI with MoCA score ≥18 will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
3005840|NCT02524405||Subcortical Vascular Impairment (VCI)|Sixty-five subjects meeting the American Heart Association-American Stroke Association (AHA-ASA) criteria for probable vascular dementia (VaD) or probable vascular mild cognitive impairment (VaMCI) due to subcortical ischemic vascular disease , and probable or possible Cerebral Amyloid Angiopathy using the Modified Boston Criteria116 will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
3005841|NCT02524405||LBD Spectrum|Sixty- five subjects with: Dementia with Lewy Bodies (DLB) meeting the criteria for probable Dementia with Lewy Bodies with MMSE score ≥20; or PD-MCI meeting the proposed Level I criteria for Mild Cognitive Impairment in Parkinson's Disease with MoCA score 18-24; or; PDD meeting the criteria for probable Parkinson's Disease - Dementia and MMSE score ≥20 will be enrolled. All patients involved will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
3005842|NCT02524392|Experimental|Independent medical evaluation|Independent medical evaluation (IME) of another doctor than the treating general practitioner.
3005843|NCT02524392|No Intervention|Treatment as usual|Treatment as usual by the treating general practitioner. There will be one randomized control group in one county. Sick-listed in other counties serve as an extra control group.
3005844|NCT02524379|Experimental|DiaBeta Treatment Arm|Enrolled patients will receive 12 doses of DiaBeta starting within 8 hours of SCI. The dosing regimen involves an initial dose of 1.25 mg followed by eleven consecutive doses of 0.625 mg every 6 hours. The total daily dose of DiaBeta on Day 1, Day 2 and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.
3005845|NCT02524366|Experimental|Transcorporal AUS|The artificial urinary sphincter is placed through the tunica albuginea of the corpora cavernosa in order to theoretically provide a protective backing on the urethra.
3005846|NCT02524366|Active Comparator|Standard AUS|The artificial urinary sphincter is placed in the standard fashion.
3005847|NCT02524353|Experimental|cardiac surgery|cardiac surgery
3005848|NCT02524340||Juvenile Idiopathic Arthritis|Children diagnosed with Juvenile Idiopathic Arthritis
3005849|NCT02524327|Experimental|Toolbox: Automated group|"Toolbox: Automated administration of intravenous anesthetic (propofol 1%) and analgesic (remifentanil, Ultiva(r)) guided by the Bispectral index through a controller with a previously described algorithm.~Objective of depth anesthesia: 40-60"
3005850|NCT02524327|Active Comparator|Manual group|"Manual administration of intravenous anesthetic (propofol 1%) and analgesic (remifentanil, Ultiva(r)) guided by the Bispectral index as usually performed in the operative theater.~Objective of depth anesthesia: 40-60"
3005851|NCT02524301|Experimental|anorexia nervosa patients|Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
3005852|NCT02524301|Experimental|Recovered anorexia nervosa patients|Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
3005853|NCT02524301|Experimental|Healthy Volonteers|Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
3005854|NCT02524288|Experimental|ENG-E2 125 μg/300 μg|Participants will receive up to 13 cycles of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3005855|NCT02524275|Experimental|Treatment (docetaxel, capecitabine)|Patients receive docetaxel IV over 1 hour on day 1 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3005856|NCT02524262|Experimental|Slow-release L-cysteine|Oral intake of slow-release L-cysteine 200 mg before challenge with ethanol.
3005857|NCT02524262|Placebo Comparator|Placebo|Oral intake of identically-looking placebo capsules
3005858|NCT02524249|Active Comparator|Early caffeine group|90 newborns will be randomized to receive caffeine within 24 hours of life. They will receive 20mg/kg IV bolus followed by IV or PO 5mg/kg daily for the next 14 days. The clinical team may decide to give PO caffeine if the newborn tolerates >75% of fluid goals by feeds.
3005952|NCT02523599|Placebo Comparator|Placebo|3 placebo implants
3005953|NCT02523586||Oxygen administration|Via Simple Mask, Via Non-rebreather, Via OxyMask, Via Anesthesia Mask (head strap and J-R circuit), Via Room Air
3005859|NCT02524249|Placebo Comparator|Late caffeine group|90 newborns will be randomized to receive a placebo (dextrose) in the first 24 hours of life. They will receive a 20mg/kg IV bolus followed by IV or PO 5mg/kg daily for the next 14 days. The clinical team may decide to give the placebo orally is the newborn tolerates >75% of fluid goals by feeds.
3005860|NCT02524236|Active Comparator|Botox 50 IU|"Intervention: Botox 50 IU vial will be reconstituted with saline 0.9% to a total volume of 5 ml. All patients will receive five injections of 1 mL of the BoNT-A solution, including two injections in each lateral lobe (one proximal and one distal) and one injection in the median lobe. The injection depth will be 7-10 mm.~Botox injection in the prostate"
3005861|NCT02524236|Active Comparator|Botox 100 IU|"Intervention: Botox 100 IU vial will be reconstituted with saline 0.9% to a total volume of 5 ml. All patients will receive five injections of 1 mL of the BoNT-A solution, including two injections in each lateral lobe (one proximal and one distal) and one injection in the median lobe. The injection depth will be 7-10 mm.~Botox injection in the prostate"
3005862|NCT02524223|Other|Population of couples candidate for MAP program|MAP = medically assisted procreation
3005863|NCT02524210|Experimental|Arm A|"Period  Dabigatran~Washout period (at least 6 days)~Period  Rabeprazole + Dabigatran~Washout period (at least 6 days)~Period  Omeprazole + Dabigatran"
3005864|NCT02524210|Experimental|Arm B|"Period Rabeprazole + Dabigatran ~Washout period (at least 6 days)~Period  Dabigatran~Washout period (at least 6 days)~Period  Omeprazole + Dabigatran"
3005865|NCT02524210|Experimental|Arm C|"Period  Rabeprazole + Dabigatran~Period  Omeprazole + Dabigatran~Period  Dabigatran"
3005866|NCT02524197|Active Comparator|CR845 0.25 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
3005867|NCT02524197|Active Comparator|CR845 0.50 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
3005868|NCT02524197|Active Comparator|CR845 1 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
3005869|NCT02524197|Active Comparator|CR845 5 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
3005870|NCT02524184|Experimental|Sildenafil|Eleven patients receive sildenafil 100mg/day (25 mg at 8 AM plus 25 mg at 4 PM plus 50 mg at 10 PM)for 7 days.
3005871|NCT02524184|Placebo Comparator|Placebo group|An identical placebo for 7 days in placebo group.
3005872|NCT02524171|Experimental|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
3005873|NCT02524171|No Intervention|Usual Care (UC)|Usual care provided by the mental health residential rehabilitation treatment programs, which patients in both groups are in.
3005874|NCT02524158|Experimental|Yoga|The yoga intervention will consist of 2x weekly, 60-minute Hatha Yoga classes for 12 weeks, geared toward a CLBP population. Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
3005875|NCT02524158|No Intervention|Delayed Treatment Control - Usual Care|Participants randomly assigned to this arm are allowed to continue all existing treatments. Participants and their primary care physician are asked to not change treatments unless medically necessary. participants are asked to not do yoga for 6 months. They are given free yoga and a yoga mat after 6 months.
3005876|NCT02524145|Active Comparator|Healthy Seniors|"Fifteen healthy senior volunteers > 60 years of age. Subjects will be healthy with no chronic medical problems and on no cardiac medications except for statins. All control subjects will have a Body Mass Index (BMI) <30, with exercise histories of less than 3 days per week of aerobic exercise.~Intervention: Static handgrip and Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
3005877|NCT02524145|Experimental|HFpEF|"Patients with HFpEF will provide data from their cardiologist or primary care physician that confirm the following: a) signs and symptoms of heart failure; b) an ejection fraction > 0.50; and c) objective evidence of diastolic dysfunction.~Intervention: Static handgrip and Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
3005878|NCT02524145|Active Comparator|Healthy Young|"Fifteen volunteers <45 yrs will be enrolled. Subjects will be healthy with no chronic medical problems and on no cardiac medications except for statins and have BMI <30.~Intervention: Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
3005879|NCT02524132|Experimental|Physical Activity|5 minute movement breaks
3005880|NCT02524119|Experimental|LEE001 with Chemoembolization|A total of 40 patients will be enrolled and undergo chemoembolization. Patients will receive LEE011 (600 mg PO once daily, 3 weeks on/1 week off) on Day 1 with chemoembolization. Patients can receive a total of 4 chemoembolization treatments within 6 month following first treatment as needed to treat initial HCC lesion.
3005881|NCT02524106|Experimental|Bococizumab|150 mg bococizumab injected subcutaneously every 2 weeks for a duration of 52 weeks
3005882|NCT02524106|Placebo Comparator|Placebo|150 mg placebo injected subcutaneously every 2 weeks for a duration of 52 weeks
3005883|NCT02524093|Experimental|Intervention|Participants in this arm will be given the Positive Mental Training programme. This consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly the participant needs to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
3005884|NCT02524093|Placebo Comparator|Control|Will receive treatment as usual for 12 weeks, when will be asked to complete rating scales again. They will then be given the Positive Mental Training programme.
3005885|NCT02524080|Other|Emergency Department|Triage to optimal healthcare level
3005886|NCT02524080|Other|Healthcare Center|Triage to optimal healthcare level
3005887|NCT02524067|Experimental|Intervention|Intervention: Circadian lighting, systematic information, music, foreclosure of the individual patient
3005888|NCT02524054|Experimental|Aerosol furosemide Study 2a|Subjects will inhale 40mg of furosemide aerosol over the course of 10-15 min. This will be a single, unblinded administration.
3005889|NCT02524054|Experimental|Aerosol furosemide Study 2b Arm F|Inhalation of furosemide aerosol one one day then placebo saline aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
3005890|NCT02524054|Experimental|Aerosol furosemide Study 2b Arm S|Inhalation of saline aerosol one one day then furosemide aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
3005891|NCT02524041|Experimental|secondary hyperparathyroidism|Blood specimen and HR-pQCT for measure bone quality and quantity
3005892|NCT02524028||Case Participant Cohort|Participants with atrial fibrillation
3005893|NCT02524028||Control Participant Cohort|Participants without atrial fibrillation or any other heart disease
3005894|NCT02524015|Other|Control|Standard Physical Therapy
3005895|NCT02524015|Experimental|Intervention|Novel Physical Therapy
3005896|NCT02524002|Placebo Comparator|Usual Clear Diet|This intervention consists of soup broth, variety of juices (apple, cranberry, grape), ginger ale, water, and ice.
3005897|NCT02524002|Experimental|Accel Gel|"This intervention is an enhanced clear liquid gel is Accel Gel, produced by PacificHealth Labs of Matawan, NJ. This gel has 4:1 carb to protein ratio formula, and ingredients that are not contraindicated in pregnancy (only the flavors with minimal caffeine are used).~http://www.pacifichealthlabs.com/accel-gel-all-natural-rapid-energy-gel-product.html"
3005898|NCT02523989||study group|children confirmed to have developmental delays
3005899|NCT02523989||control group|children with typical development
3005900|NCT02523976|Experimental|Arm A|Dasatinib 100 mg per day will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Dasatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy.Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients who keep BCR/ABL negative can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation chemotherapy.
3005901|NCT02523963|Experimental|study group|"children with developmental delays participated 6 sessions of family work shop~The family work shop has 5 courses, with 6 families in one course.~Intervention of one course: 2-3 hours per session, one time per week, for a total of 6 weeks."
3005902|NCT02523963|No Intervention|control|children with normal development not participate the work shop followed up at before, and 6 weeks later
3005903|NCT02523950|Active Comparator|Staged group|Procedure/Surgery: Phacoemulsification + IOL implantation is performed in the first stage and DMEK is performed secondarily.
3005904|NCT02523950|Active Comparator|Combined group|Procedure/Surgery: Phacoemulsification + IOL implantation and DMEK are performed simultaneously.
3005905|NCT02523937||Group without PE or DVT|"PE or DVT have to be confirmed or discarded by combining Wells score clinical probability, D-Dimer, and imaging tests.~The criteria for exclusion of PE or DVT are:~low or intermediate clinical probability and D-dimer <0,50 µg/mL~low and moderate clinical probability and negative spiral computed tomography CT and/or proximal lower limb venous compression ultrasonography (US)~high clinical probability and negative CT and US.~Soluble Fibrin assay will be performed in comparison with D-dimer assays."
3005906|NCT02523937||Group with PE or DVT|"PE or DVT have to be confirmed or discarded by combining Wells score clinical probability, D-Dimer, and imaging tests.~The criteria for confirmation of PE or DVT are:~PE on spiral computed tomography (CT)~proximal deep vein thrombosis on ultrasonography (US).~Soluble Fibrin assay will be performed in comparison with D-dimer assays."
3005907|NCT02523924|Experimental|18F-DCFPyL PET/CT|Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT
3005908|NCT02523911|Active Comparator|Simethicone Group|Early in the evening prior to colonoscopy, patients will be instructed to consume one 6 ounce bottle of oral sodium sulfate/potassium sulfate/magnesium sulfate (Suprep) solution (containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, and magnesium sulfate 1.6 grams) diluted with 16 ounces of water over one hour. Over the next hour, the patient will be instructed to drink an additional 32 ounces of water. On the day of colonoscopy, the same procedure will be repeated. Patients will take 2.4 mL simethicone in a half glass of water immediately after consuming each dose of the Suprep. All of the bowel preparation solution and required water should be consumed at least 2 hours prior to colonoscopy.
3005909|NCT02523911|Placebo Comparator|Placebo Group|Early in the evening prior to colonoscopy, patients will be instructed to consume one 6 ounce bottle of oral sodium sulfate/potassium sulfate/magnesium sulfate (Suprep) solution (containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, and magnesium sulfate 1.6 grams) diluted with 16 ounces of water over one hour. Over the next hour, the patient will be instructed to drink an additional 32 ounces of water. On the day of colonoscopy, the same procedure will be repeated. Patients will take 2.4 mL of placebo (identical in appearance to simethicone) in a half glass of water immediately after consuming each dose of the Suprep. All of the bowel preparation solution and required water should be consumed at least 2 hours prior to colonoscopy.
3005954|NCT02523573||Study population|Adult ARF ICU patients needing BAL with HFNC
3006051|NCT02522936|Experimental|Biotene|Participants will be given Biotene oral spray to use as needed when taking oxybutynin.
3005910|NCT02523898|Experimental|metformine and clomiphene citrate|. metformin will be given at a dose of 500 mg three times a day for 8weeks. .In case of failure of ovulation after the end of this period, metformin was continued and patients were given 100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration In cases of ovulation with CC without pregnancy, the patients were advised to participate in other two similar cycles of therapy with 100 mg clomiphene. When ovulation did not occur with 100 mg CC, its dose will be increased to 150 mg and the same treatment protocol will be used for this dose.
3005911|NCT02523898|Active Comparator|placebo and clomiphene citrate|"The patients in group two will be receiving placebo. In case of failure of ovulation after the end of this period, placebo was continued and patients were given 100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration .In cases of ovulation with CC without pregnancy, the patients were advised to participate in other two similar cycles of therapy with 100 mg clomiphene.When ovulation did not occur with 100 mg CC, its dose will be increased to 150 mg and the same treatment protocol will be used for this dose. .~10 days). ."
3005912|NCT02523872||Acute respiratory failure|Patients with acute respiratory failure who might benefit from a strategy designed to limit fluid administration
3005913|NCT02523859|Active Comparator|Propofol|Propofol for induction will be given as a bolus administered manually at 2.0-2.5 mg/kg slowly over approximately 1 minute. Immediately after the propofol bolus for induction has been given, propofol maintenance will be started at a dose of 3.0-9.0 mg/kg/hr and adjusted as needed.
3005914|NCT02523859|Experimental|Remimazolam|Remimazolam for induction will be given at 6.0 mg/kg/hr, which can be increased to 12.0 mg/kg/hr for one minute if loss of consciousness is not reached after 3 minutes. Immediately after the remimazolam dose for induction has been given, remimazolam maintenance will be given at 1.0 mg/kg/hr and adjusted by down-titration or up-titration to a maximum of 3.0 mg/kg/hr.
3005915|NCT02523846|Active Comparator|Background morphine infusion to IV-PCA Morphine|Calculate based on patient's age, in mg/hour
3005916|NCT02523846|Experimental|Patient re-education to IV-PCA Morphine|Using patient information leaflet
3005917|NCT02523833|Other|Chronic HP patients|Chronic hypersensitivity pneumonitis patients - use of salbutamol
3005918|NCT02523820|Experimental|fluticasone propionate|Fluticasone 1 mg + Normal saline (NSS) upto 4 ml nebulized after extubation
3005919|NCT02523820|Placebo Comparator|placebo|Normal saline (NSS) 4 ml nebulized after extubation
3005920|NCT02523807||Patients with Parkinson's Disease|Patients with tremor due to Parkinson Disease
3005921|NCT02523807||Patients with Essential tremor|Patients with tremor due to Essential tremor
3005922|NCT02523794|Experimental|Electro-kinetically Modified Water|Subjects will drink 2 to 3 500 mL bottles of EMW daily for 3 months
3005923|NCT02523794|Placebo Comparator|Placebo|Subjects will drink 2 to 3 500 mL bottles of purified drinking water daily for 3 months
3005924|NCT02523781|No Intervention|Control group|The control group does not receive the information pamphlet
3005925|NCT02523781|Experimental|Intervention group|The intervention group receives the information pamphlet
3005926|NCT02523768|Experimental|ATG-F|The ATG-Fresenius® is administered by slow infusion over four hours after antihistamine (2 bulbs Polaramine® IV) and intravenous methylprednisolone (minimum 30mg); it is started on day 0 prior to surgery at doses of 4 mg / kg, and then continued to day 1, day 2 to 4mg / kg, then day 3, day 4 at the dose of 3 mg / kg
3005927|NCT02523768|Active Comparator|Simulect|The anti CD25 (basiliximab, Simulect®) is administered intravenously before surgery of renal transplantation (Day 0 and Day + 4 (1 ampoule of 20 mg x 2 times).
3005928|NCT02523755|Active Comparator|Epidural analgesia Ropivacaine|Placement of an epidural catheter to achieve pain relief
3005929|NCT02523755|Sham Comparator|Absence of epidural analgesia|No placement of an epidural catheter either because of patient refusal or contraindication
3005930|NCT02523742|Other|Neuropsychiatric Disorders|Neuropsychiatric Disorders patients
3005931|NCT02523742|Other|Healthy volunteers|control subjects matched to patients by age, sex, socio-cultural level and laterality
3005932|NCT02523729|No Intervention|control|subjects drunk no Anke Malz product.
3005933|NCT02523729|Experimental|intervention one|subjects drunk one can Anke Malz product.
3005934|NCT02523729|Experimental|intervention two|subjects drunk two cans Anke Malz product.
3005935|NCT02523716|Experimental|Hypoxia|Mild hypoxia of 15% oxygen, equivalent altitude of 2440m over a period of 7 days
3005936|NCT02523716|Sham Comparator|Normoxia|Exposure to normal, sea-level air
3005937|NCT02523703|Other|Healthy Volunteers|Healthy Volunteers
3005938|NCT02523703|Other|Multiple Sclerosis patient|Multiple Sclerosis patient
3005939|NCT02523690|Experimental|Intervention|Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
3005940|NCT02523690|Placebo Comparator|Control|Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
3005941|NCT02523664|Active Comparator|Hydrocortisone|10 mg hydrocortisone orally
3005942|NCT02523664|Placebo Comparator|Placebo|placebo orally
3005943|NCT02523651|Experimental|DPSC injection|20 patients will receive DPSC injection（1000000 cells/ 0.5ml） at the local periodontal defects immediately after periodontal scaling and root planing.
3005944|NCT02523651|Placebo Comparator|Placebo control|20 patients will receive saline injection at the local periodontal defects immediately after periodontal scaling and root planing.
3005945|NCT02523638|Other|Pegylated- Proline-Interferon alpha-2b|Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen single arm
3005946|NCT02523625||Healthy volunteers|Age and gender matched to patient groups to undergo ultrasound of temporal and axillary arteries
3005947|NCT02523625||Patients with headache|Patients with new headache not due to GCA to undergo ultrasound of temporal and axillary arteries
3005948|NCT02523625||Patients with GCA (new)|Patients with new diagnosis of GCA to undergo ultrasound of temporal and axillary arteries
3005949|NCT02523625||Patients with GCA (flare)|Patients with apparent flare of GCA to undergo ultrasound of temporal and axillary arteries
3005950|NCT02523612|Experimental|Patients with atypical lesions|
3005951|NCT02523599|Experimental|XaraColl|3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose
3005955|NCT02523560|Experimental|telerehabilitation group|1 week hospital rehabilitation and 8 weeks home-based telerehabilitation and telemanagement (including HomeMonitoring)
3005956|NCT02523560|No Intervention|control group|Patients qualified to the control group will undergo a 9-week procedure appropriate to their clinical condition/status standardized for a particular center (usual care).
3005957|NCT02523547|Experimental|Cavir|entecavir/0.5mg/day
3005958|NCT02523547|Active Comparator|Baraclude|entecavir/0.5mg/day
3005959|NCT02523534|Experimental|Recurrence Mapping|Participant undergoing their first ablation that fit our inclusion/exclusion criteria will undergo new atrial fibrillation mapping techniques to help identify the sources of atrial fibrillation. The participant will have an MRI and ECG prior to a clinically indicated ablation.
3005960|NCT02523521|No Intervention|Bronchopylmonary Dysplasia Control|Nothing
3005961|NCT02523521|Experimental|Bronchopylmonary Dysplasia Intervention|physical activity program.
3005962|NCT02523521|No Intervention|Healthy children|Nothing.
3005963|NCT02523508|Experimental|Experimental group|Passive manual lumbar mobilization on L2-3 level
3005964|NCT02523508|Placebo Comparator|Control group|Passive limb mobilization which did not involve the spine
3005965|NCT02523469|Experimental|ALT-803 + Nivolumab dose escalation|"Up to 21 patients will receive ALT-803 + Nivolumab in the dose escalation phase to determine the maximum tolerated dose.~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. The starting dose level for ALT-803 is 6 microgram (mcg)/kilogram (kg); the second dose level is 10 mcg/kg; the third dose level is 15 mcg/kg; and the fourth dose level is 20 mcg/kg.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
3005966|NCT02523469|Experimental|Arm A: ALT-803 + Nivo naive|"Patients who have not received PD-1 blockade (nivolumab, pembrolizumab, or atezolizumab) will be enrolled to Arm A in the Phase II part of the study.~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. ALT-803 will be administered at the recommended phase II dose of 20mcg/kg.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
3005967|NCT02523469|Experimental|Arm B: ALT-803 + Nivolumab progressor|"Patients who have had PD-1 blockade (nivolumab, pembrolizumab, or atzolizumab) and progressed will be enrolled to Arm B in the Phase II part of the study.~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. ALT-803 will be administered at the recommended phase II dose of 20mcg/kg.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
3005968|NCT02523469|Experimental|ALT-803 + Nivolumab Exploratory Arm 1|"All eligible patients will be enrolled into one of two exploratory dosing arms.~For exploratory Arm 1:~The dose level for ALT-803 is 20 mcg/kg. ALT-803 will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5) for up to 4 cycles.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
3005969|NCT02523469|Experimental|ALT-803 + Nivolumab Exploratory Arm 2|"All eligible patients will be enrolled into one of two exploratory dosing arms.~For exploratory Arm 1:~The dose level for ALT-803 is 10 mcg/kg. ALT-803 will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5) for up to 4 cycles.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
3005970|NCT02523456|Experimental|Introduce EWS and Training on EWS|The group of patients who admitted to a ward where the staff has trained on EWS and EWS has been introduced.
3005971|NCT02523456|No Intervention|EWS not introduced|The group of patients who admitted to a ward where the staff has no special training on EWS and EWS has not been introduced.
3005972|NCT02523443|Active Comparator|IV PCA after surgery|general anesthesia with post-operative IV PCA with a standard demand pump
3005973|NCT02523443|Experimental|PCEA during and after surgery|general anesthesia with post-operative thoracic epidural analgesia with a standard demand pump
3005974|NCT02523430|Experimental|HepaSphere|nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
3005975|NCT02523430|Placebo Comparator|control|nasopharyngeal carcinoma patients received traditional therapy
3005976|NCT02523417|Experimental|HepaSphere|breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
3005977|NCT02523417|Placebo Comparator|control|breast cancer patients received traditional therapy
3005978|NCT02523404|Experimental|HepaSphere|lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
3005979|NCT02523404|Placebo Comparator|control|lung cancer patients received traditional therapy
3005980|NCT02523391|Experimental|Treatment Period 1|Either 5mg TA-8995 Capsule or Tablet
3005981|NCT02523391|Experimental|Treatment Period 2|Either 5mg TA-8995 Capsule or Tablet
3005982|NCT02523378|Experimental|ESAS Self-Administration - Group A|Participants complete the symptom questionnaire alone. It is then counterchecked by health care professional (HCP).
3005983|NCT02523378|Experimental|ESAS Assisted-Completion - Group B|Participants complete the symptom questionnaire with the help of the research nurse or assistant.
3005984|NCT02523365|Experimental|HepaSphere|cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
3005985|NCT02523365|Placebo Comparator|control|cervical carcinoma patients received traditional therapy
3005986|NCT02523352|Experimental|Treatment|Volunteers with a BMI > 35 Kg/m2 and central fat distribution, without any past medical history
3005987|NCT02523326||Group A|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group A at 10 days
3005988|NCT02523326||Group B|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group B at 20 days
3005989|NCT02523326||Group C|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group C at 30 days
3005990|NCT02523313|Active Comparator|Nivolumab + Placebo|Nivolumab (3 mg/kg) i.v. every 2 weeks + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10
3005991|NCT02523313|Experimental|Nivolumab + Ipilimumab|Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) i.v. every 3 weeks for 4 doses. Both study drugs are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12: Nivolumab as maintenance and at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
3005992|NCT02523313|Placebo Comparator|Double Placebo Control|Placebo instead of Nivolumab and Placebo instead of Ipilimumab i.v. every 3 weeks for 4 doses. Both placebos are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab as maintenance and applied as IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
3005993|NCT02523300|Experimental|TEVAR+GC|The patients underwent TEVAR. Then glucocorticoids will be intravenously given after TEVAR
3005994|NCT02523300|Placebo Comparator|TEVAR+Vehicle|The patients underwent TEVAR. Then saline will be given after TEVAR
3005995|NCT02523287|Active Comparator|Fluad - 5 study visits (114 subjects)|"0,5 ml adjuvanted, subunit seasonal trivalent influenza vaccine (2014-2015). Administration: Intramuscular, deltoid.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 21 (blood sampling)."
3005996|NCT02523287|Active Comparator|Fluad - 3 study visits (114 subjects)|"0,5 ml adjuvanted, subunit seasonal trivalent influenza vaccine (2014-2015). Administration: Intramuscular, deltoid.~3 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 7 (blood sampling). On day 21 there's a phone call for safety follow-up."
3005997|NCT02523287|Placebo Comparator|Saline - 5 study visits (6 subjects)|"0,5 ml saline. Administration: Intramuscular, deltoid.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 21 (blood sampling)."
3005998|NCT02523287|Placebo Comparator|Saline - 3 study visits (6 subjects)|"0,5 ml saline. Administration: Intramuscular, deltoid.~3 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 7 (blood sampling). On day 21 there's a phone call for safety follow-up."
3005999|NCT02523274|Placebo Comparator|Placebo + exercise|Placebo capsules will be taken orally daily in combination with exercise
3006000|NCT02523274|Experimental|Resveratrol 250 mg/day + exercise|250 mg/day resveratrol taken orally in combination with exercise
3006001|NCT02523274|Experimental|Resveratrol 1000 mg/day + exercise|1000 mg/day resveratrol taken orally in combination with exercise
3006002|NCT02523261|Experimental|ADAPT|
3006003|NCT02523261|Active Comparator|Stent Retriever|
3006004|NCT02523248|Active Comparator|Tonsillectomy|Tonsillectomy with cold steel
3006005|NCT02523248|Active Comparator|Uvulopalatopharyngoplasty|Tonsillectomy and uvulopalatoplasty; using cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
3006006|NCT02523235|Active Comparator|proximal catheter insertion|"Adductor canal catheters: Inserted as described by Jæger et al., 2013: …we performed an ultrasound survey at the medial part of the thigh, halfway between the superior anterior iliac spine and the [superior border of the] patella. In a short axis view, we identified the femoral artery underneath the sartorius muscle, with the vein just inferior and the saphenous nerve just lateral to the artery.~Popliteal catheters: Using an ultrasound, the bifurcation of the sciatic nerve will be identified in short axis and marked at a point immediately distal at which point the two main branches of the sciatic nerve are separate and a hypoechoic area can be viewed between the two. This level will be marked on the skin. The needle will be inserted to intersect the sciatic nerve 6-7 cm proximal to the mark on the skin (therefore, proximal to the sciatic bifurcation) and injection with saline used to ensure subepimyseal spread."
3006007|NCT02523235|Experimental|distal catheter insertion|"Adductor canal catheters: Inserted as described by Manickam et al. 2009~Popliteal catheters: Using an ultrasound, the bifurcation of the sciatic nerve will be identified in short axis and marked at a point immediately distal at which point the two main branches of the sciatic nerve are separate and a hypoechoic area can be viewed between the two. This level will be marked on the skin. The needle tip will be inserted into the hypoechoic area between the two branches of the sciatic nerve immediately distal to the sciatic nerve bifurcation between the paraneurium and epineurium (the subparaneural space/compartment). As described by Tran et al, An adequate position was defined as the presence of circular expansion of the paraneural sheath... Once circular expansion was obtained, we injected."
3006008|NCT02523222|No Intervention|CONTROL|Infants at risk for transient neonatal hypoglycemia following standard-of-care.
3006009|NCT02523222|Active Comparator|Dextrose Gel|Infants given 40% Dextrose gel (0.5ml/kg) in the buccal mucosa after their first feed, within the first hour of life.
3006010|NCT02523209||Bone quality and quantity|measure of bone quality and quantity parameters by HRpQCT and by DEXA
3006011|NCT02523196|Active Comparator|Hepatic Venous Pressure Gradient (HVPG)|Successful Hepatic Venous Pressure Gradiant (HVPG) testing is required prior to administration of the HepQuant-SHUNT test.
3006012|NCT02523196|Experimental|HepQuant-SHUNT (HQ-Shunt)|Comparison of Disease Severity Index (DSI) from HQ-SHUNT with HVPG in identifying patients with cirrhosis and patients with varices.
3006013|NCT02523183||Subjects with medically refractory epilepsy|Pediatric epilepsy patients who are followed at Children's Hospital Colorado with medically refractory epilepsy, and whom the family has decided to treat with medical cannabis.
3006014|NCT02523170|Experimental|EUS guided nCLE|For patients with indeterminate cystic lesions of the pancreas, in addition to routine diagnostic investigations, patients participating in the study will undergo needle based confocal laser endomicroscopy (using the AQ-flex 19 probe - Mauna Kea Technologies, Paris France) at the time of their endoscopic ultrasound.
3006015|NCT02523157|Experimental|Intervention|Wellbeing Plan
3006016|NCT02523157|Active Comparator|Control|Control task. Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
3006017|NCT02523144|Active Comparator|Chloral Hydrate + placebo|Oral chloral hydrate sedation in flavored syrup plus nasal saline placebo
3006018|NCT02523144|Active Comparator|Dexmedetomidine 2mcg/kg + placebo|Nasal dexmedetomidine sedation 2 mcg/kg plus oral flavored syrup placebo
3006019|NCT02523144|Active Comparator|Dexmedetomidine 3mcg/kg + placebo|Nasal dexmedetomidine sedation 3 mcg/kg plus oral flavored syrup placebo
3006020|NCT02523131|Experimental|24/7 closed loop insulin delivery|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature over a 12-week period using 24/7 Medtronic insulin pump 640G and Android smartphone.
3006021|NCT02523131|Active Comparator|Sensor augmented pump therapy|Insulin pump therapy combined with unmasked real-time continuous glucose monitoring system for 12 weeks using Medtronic insulin pump 640G. Pump suspend features will be turned off.
3006022|NCT02523105|Other|Participants diagnosed with depression.|EEG monitoring and evaluation
3006023|NCT02523105|Other|Healthy participants.|EEG monitoring and evaluation
3006024|NCT02523092|Experimental|Acthar gel|After a 4-week period of baseline monitoring, Acthar gel will be administered by intramuscular or subcutaneous injection. Initial dosing will be 40 U every 72 hours (or twice per week) for 4 weeks. Dosage will then be increased to 80 U with similar frequency for 8 weeks and up to 16 weeks.
3006025|NCT02523079|Experimental|Cognitive Behavioral Group Therapy for Insomnia|Includes 6 group sessions (90 minutes each). The groups are led by trained psychologist or nurse of occupational health services. The manualized treatment is based on the general CBT-I model and includes components such as sleep hygiene, relaxation, stimulus control, sleep restriction and cognitive restructuring. In addition, participants receive information on how to schedule sleep, wake and light based on circadian principles while working differently timed shifts.
3006026|NCT02523079|Experimental|Cognitive Behavioral Self-help Therapy for Insomnia|Mainly computerized self-help intervention. Includes an individual session before and after the intervention (30 minutes each) led by trained psychologist or nurse of occupational health services. The self-help treatment is based on the general CBT-I model and includes components such as sleep hygiene, relaxation, stimulus control, sleep restriction and cognitive restructuring. In addition, participants receive information on how to schedule sleep, wake and light based on circadian principles while working differently timed shifts.
3006027|NCT02523079|Experimental|Sleep Hygiene Guidance|Includes one individual session (60 minutes) led by trained psychologist or nurse of occupational health services. The intervention is based on sleep hygiene guidance.
3006028|NCT02523066||Mitral Valve or Aortic Valve Replancement|One-arm group
3006029|NCT02523053|Active Comparator|Hepatectomy|Surgical removal of all lesions
3006030|NCT02523053|Experimental|Hepatectomy plus 5-Fluorouracil|Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
3006031|NCT02523040|Experimental|Lenalidomide|"After the screening procedures confirm participation in the research study.~- Lenalidomide Oral, Daily for 21 days of each cycle"
3006032|NCT02523027|Experimental|Experimental Group 1:|Oral nutritional supplement (List No S691/Z0) and dietary counseling
3006033|NCT02523027|Experimental|Experimental Group 2|Oral nutritional supplement (List No- P968/Z0) and dietary counseling.
3006034|NCT02523027|No Intervention|Control Group|Dietary Counselling only.
3006035|NCT02523014|Experimental|Arm A - vismodegib|Patients receive vismodegib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3006036|NCT02523014|Experimental|Arm B - GSK2256098|Patients receive FAK inhibitor GSK2256098 PO BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3006037|NCT02523001||Naïve-S|Patients with hypercholesterolemia starting statin treatment for primary or secondary prevention of cardiovascular diseases.
3006038|NCT02523001||ONC-S|Patients with hypercholesterolemia who had been treated with statin for at least one year and continued their previous therapy during the study period
3006039|NCT02523001||Naïve-MC|Patients with mild hypercholesterolemia either refusing initial statin treatment or intolerant to standard statin treatment and starting with monacolin K
3006040|NCT02523001||Naïve-Diet|Patients refusing an initial pharmacologic treatments and choosing the hypolipidic diet
3006041|NCT02522988|Experimental|Group 1a|During the first 3-week period of the study, Group 1 will serve as the experimental arm and will receive the open-label placebo intervention. Group 1 participants will take 2 placebos in the morning and 2 placebos in the evening for 21 days.
3006042|NCT02522988|No Intervention|Group 2a|During the first 3-week period of the study, Group 2 will serve as the comparator arm.
3006043|NCT02522988|No Intervention|Group 1b|During the last 3-week period of the study, Group 1 will serve as the comparator arm.
3006044|NCT02522988|Experimental|Group 2b|During the last 3-week period of the study, Group 2 will serve as the experimental arm and will receive the open-label placebo intervention.Group 2 participants will take 2 placebos in the morning and 2 placebos in the evening for 21 days.
3006045|NCT02522975|Active Comparator|Reference group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form:Injection Strength:2000IU,3000IU,4000IU Frequency and Dosage:subcutaneously injection once a week for a period of 52 weeks. The initial dose of EPREX® will be 60 IU/kg body weight."
3006046|NCT02522975|Experimental|Experimental group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form:Injection Strength:2000IU,3000IU,4000IU Frequency and Dosage:subcutaneously injection once a week for a period of 52 weeks. The initial dose of EPIAO® will be 60 IU/kg body weight."
3006047|NCT02522962|Experimental|GroupCoreSIT|Before the group training starts, the physiotherapist in charge of the group does a clinical assessment of each participant in order to individualise the training. Each training group will consist of three participants. The training sessions will last for 60 minutes, performed three days per week, for six weeks, between 10 am and 5 pm.
3006048|NCT02522962|Active Comparator|Standard care|The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
3006049|NCT02522949|Active Comparator|ColdZyme|ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
3006050|NCT02522949|Placebo Comparator|Placebo|Sugar based mouth spray manufactured to mimic ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
3006052|NCT02522936|No Intervention|Routine care|Participants will be given routine care.
3006053|NCT02522923|Experimental|Physical Therapist|Participants randomized to this arm will receive care from a physical therapist first.
3006054|NCT02522923|Active Comparator|Primary Care Provider|Participants randomized to this arm will receive care from a primary care provider first.
3006055|NCT02522910|Experimental|Roniciclib with Docetaxel|
3006056|NCT02522897|Active Comparator|Ranibizumab|"Patients receive intravitreal injections of 0,5 mg Ranibizumab (Lucentis®) / injection following the treat-and-extend scheme for 12 months."
3006057|NCT02522897|Experimental|Ranibizumab + Laser|"Apart from receiving intravitreal injections of 0,5 mg Ranibizumab (Lucentis®) / injection following the treat-and-extend scheme for 12 months, patients receive a panretinal photocoagulation on visit 3 and / or 4."
3006058|NCT02522884|Experimental|Tack Implant|Implantation of a Tack using the Intact Vascular Tack Endovascular System for the repair of post angioplasty dissections.
3006059|NCT02522871|Experimental|OCS Liver System|OCS Liver System
3006060|NCT02522871|Other|Control|Standard of care (ice)
3006061|NCT02522858|Placebo Comparator|Placebo|After fixation of the block level of spinal anesthesia, and just before starting dexmedetomidine, normal saline 0.5mL would be injected intravenously.
3006062|NCT02522858|Experimental|Atropine|After fixation of the block level of spinal anesthesia, and just before starting dexmedetomidine, ,atropine 0.03mg/kg would be injected intravenously.
3006063|NCT02522845|Active Comparator|Compression|Patients randomised to this group will be asked to wear Class II compression stockings for 1 week
3006064|NCT02522845|No Intervention|No Compression|Patients randomised to this group will not be provided with any compression
3006065|NCT02522832|Experimental|Titre 1|Low infectious titre of innoculum
3006066|NCT02522832|Experimental|Titre 2|Medium infectious titre of innoculum
3006067|NCT02522832|Experimental|Titre 3|High infectious titre of innoculum
3006068|NCT02522819|Experimental|obstructive sleep apnea in the acute phase of stroke|Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke
3006069|NCT02522806|Experimental|Group A|Endometrial biopsy (EB) between J17 and J22 of previous ovarian hyperstimulation cycle.
3006070|NCT02522806|No Intervention|Group B|none endometrial biopsy
3006071|NCT02522780|Experimental|Mesalamine|2 g extended release granules (sachet)
3006072|NCT02522780|Placebo Comparator|Placebo.|Matching placebo
3006073|NCT02522767|Experimental|Mesalamine|4 g extended release granules (sachet)
3006074|NCT02522767|Placebo Comparator|Placebo|Matching placebo
3006075|NCT02522754|Placebo Comparator|Placebo|Placebo
3006076|NCT02522754|Experimental|Protesomal Vaccine 1 x 30 µg|Protesomal Vaccine 1 x 30 µg
3006077|NCT02522754|Experimental|Protesomal Vaccine 2 x 30 µg|Protesomal Vaccine 2 x 30 µg
3006078|NCT02522754|Experimental|Protesomal Vaccine 2 x 15 µg|Protesomal Vaccine 2 x 15 µg
3006079|NCT02522741|Experimental|Parenting STAIR|
3006080|NCT02522728|Active Comparator|Triathlon CR|Triathlon Cruciate Retaining (CR) versus Triathlon Posterior Stabilized (PS): During knee prosthesis surgery the surgeon many times need to make a judgement on if to keep a defect anatomical structure or if to replace it with knee prosthesis with a design that allows for adjustment of this defect. This study is aimed to evaluate which prosthetic choice to be made in respect of stability, long-term results and patient outcome.
3006081|NCT02522728|Active Comparator|Triathlon PS|Triathlon Cruciate Retaining (CR) versus Triathlon Posterior Stabilized (PS): During knee prosthesis surgery the surgeon many times need to make a judgement on if to keep a defect anatomical structure or if to replace it with knee prosthesis with a design that allows for adjustment of this defect. This study is aimed to evaluate which prosthetic choice to be made in respect of stability, long-term results and patient outcome.
3006082|NCT02522715|Experimental|Treatment (cabazitaxel, enzalutamide)|Patients receive cabazitaxel IV over 1 hour on day 1 and enzalutamide PO QD on days 1-21 (days 2-21 of course 1). Patients also receive prednisone PO BID as standard of care with cabazitaxel. Courses repeat every 21 days for 6-10 courses in the absence of disease progression or unacceptable toxicity. Patients may continue enzalutamide PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.
3006083|NCT02522702||Routine colonoscopy Cohort|
3006084|NCT02522689|Active Comparator|Ultra-mini PCNL|Endoscopic kidney stone surgery: Patients will undergo ultra-mini percutaneous nephrolithotripsy.
3006085|NCT02522689|Active Comparator|Micro PCNL|Endoscopic kidney stone surgery: Patients will undergo micro percutaneous nephrolithotripsy.
3006086|NCT02522676|Active Comparator|Conventional PCNL|Endoscopic kidney stone surgery: Patients will undergo conventional percutaneous nephrolithotripsy.
3006087|NCT02522676|Active Comparator|Mini PCNL|Endoscopic kidney stone surgery: Patients will undergo mini percutaneous nephrolithotripsy.
3006088|NCT02522676|Active Comparator|Ultra-mini PCNL|Endoscopic kidney stone surgery: Patients will undergo ultra-mini percutaneous nephrolithotripsy.
3006089|NCT02522676|Active Comparator|Micro PCNL|Endoscopic kidney stone surgery: Patients will undergo micro percutaneous nephrolithotripsy.
3006090|NCT02522676|Active Comparator|Retrograde intrarenal surgery|Endoscopic kidney stone surgery: Patients will undergo retrograde intrarenal surgery.
3006091|NCT02522676|Active Comparator|Extracorporeal shock wave lithotripsy|Non-invasive kidney stone treatment: Patients will undergo extracorporeal shock wave lithotripsy.
3006092|NCT02522663|No Intervention|Usual Care|Today, no post-discharge telephone support is offered as standard care from the hospital.
3006093|NCT02522663|Experimental|Intervention group|Experimental group is offered 24/7-telephone support during the first 1 month post-discharge, and patients are actively called at day 2 and day 9 day after discharge.
3006094|NCT02522650|Experimental|Amiloride Phase|Subject receives 5mg of Amiloride twice daily for 8 weeks.
3006095|NCT02522650|Active Comparator|Triamterene Phase|Subject receives 50mg of Triamterene twice daily for 8 weeks.
3006096|NCT02522650|No Intervention|Washout Phase|Subject does not take any study medication for 4 weeks
3006097|NCT02522637|Active Comparator|Exercise training F1|Patients will be treated with a specific rehabilitation in-hospital program consisting of one daily sessions of 30 minutes of exercise (Frequency 1 : Program F1 )
3006098|NCT02522637|Experimental|Exercise training F2|Patients will be treated with a specific rehabilitation in-hospital program consisting of two daily sessions of 30 minutes of exercise (Frequency 2 : Program F2 )
3006099|NCT02522624|Experimental|Decision Aid (DA)|The decision aid (DA) will be provided to participants randomized to the experimental/intervention group.
3006100|NCT02522624|No Intervention|Control|Participants randomized to the control group will receive usual care. They will be directed to the healthcare.gov website and asked to follow the prompts to view and select (if applicable) a health insurance plan.
3006101|NCT02522611|Experimental|Resiniferatoxin|Patient receives one dose of Resiniferatoxin intrathecally
3006102|NCT02522598|Experimental|VVZ-149 injection|VVZ-149 Injections will be mixed with saline,then intravenous infusion for 8hr. The drug product will be administered with a loading dose of 1.8 mg/kg for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h for 7.5 hours.
3006103|NCT02522598|Placebo Comparator|Placebo|placebo group will receive an water for injection the same volume and period of experimental group.
3006104|NCT02522585||Conservative management|Patients diagnosed of CIN-II by directed biopsy
3006105|NCT02522572|Experimental|Group A|4 doses of plerixafor and plasmapheresis
3006106|NCT02522572|Experimental|Group B|4 doses of plerixafor, 1 dose of bortezomib, and plasmapheresis
3006107|NCT02522572|Experimental|Group C|6 doses of plerixafor, 2 doses of bortezomib, and plasmapheresis
3006108|NCT02522559|Experimental|Spice Intervention|Spice intervention: Student-approved vegetable recipes will be served in the school cafeteria.
3006109|NCT02522546||nasopharyngeal swab|Children ages 1-5 years and their household contacts
3006110|NCT02522533|Experimental|Physical Therapy|Patients will be receiving 6 weeks of an exercise program.
3006111|NCT02522520|Active Comparator|Pedometer intervention|"Individual progressive pedometer intervention of low to moderate intensity.~Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity."
3006112|NCT02522520|Active Comparator|Pedometer + hospital based intervention|"Individual progressive pedometer intervention and 5 sessions supervised interval walking + followed by supervised hospital-based intervention of moderate to high-intensity~Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity."
3006113|NCT02522507|Experimental|Empowering youth towards employment|This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
3006114|NCT02522507|No Intervention|Control group|The control group will have access to the employment activities during the 12-week employment readiness learning but will not have access to a mentor.
3006115|NCT02522494|Active Comparator|Intervention|Patients randomized to the intervention will view the video
3006116|NCT02522494|Other|Pamphlet alone|Patients randomized to the pamphlet alone will only receive the pamphlet
3006117|NCT02522481|Experimental|Lumason|Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection
3006118|NCT02522468|Experimental|Radioactive Seed Localization|Radioactive Seeds
3006119|NCT02522468|Active Comparator|Wire Localization|Wire
3006120|NCT02522455|Other|Preterm infants with RDS|
3006121|NCT02522442|Experimental|1|Auto Bilevel; auto-titrating bilevel positive airway pressure device with pressure flexing used as experimental treatment for obstructive sleep apnea
3006122|NCT02522442|Active Comparator|2|CPAP; continuous positive airway pressure used as comparator treatment for obstructive sleep apnea
3006123|NCT02522429|Experimental|Focused Ultrasound Device|
3006124|NCT02522403|Active Comparator|Rehabilitation|The investigators will be apply laser acupuncture for the rehabilitation of the wrist and hand of the patients, with the laser device in an off position, plus exercise of wrist flexion, extension, cubital and radial deviation, pronation and supination of the forearm. The investigators will be use ten different acupuncture points for treat this patients.
3006125|NCT02522403|Experimental|Low Lever Laser acupuncture|The investigators will utilize an low level laser therapy device apply into each acupuncture point. Ten acupuncture points will be used. Each acupuncture point will be irradiated for 30 seconds at 8,000 Hz.
3006126|NCT02522390||Nutrition Researcher Cohort|This cohort study is an observational, one-group study. The intervention consists of research activities that participants are asked to perform throughout the cohort, including the use of do-it-yourself devices, filling out online-questionnaires and sample collection with supplied kits for the analysis of various health parameters. The frequency with which participants are asked to measure these health parameters varies, ranging from once to weekly.
3006127|NCT02522377|Experimental|Ketamine Infusions|Subjects who are randomized to be on this group will receive a standard dose of ketamine interleaved with Electroconvulsive Treatments.
3006128|NCT02522377|Active Comparator|Midazolam|Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
3006129|NCT02522364|Active Comparator|BioMonitor|Participants randomized for this arm will be implanted with a BioMonitor device an implantable loop recorder inserted under the skin in the region of the thorax. It continuously records heart rhythm for a period of up to 7 years. The device will be interrogated at 1 month intervals. All arrhythmic events and conductive disturbances will be noted. In addition will be followed as specified in the standard arm
3006130|NCT02522364|Active Comparator|Standard|Participants randomized for this arm will be followed by biannual office visits initialing clinical evaluation, review of clinical events, review and update of medical therapy. Participants will undergo ECG holter examination at 3 and 6 months after discharge
3006131|NCT02522351|Active Comparator|Thicken Up Clear concentration 1|Thicken Up Clear at concentration 1
3006132|NCT02522351|Active Comparator|Thicken Up Clear concentration 2|Thicken Up Clear at concentration 2
3006133|NCT02522351|Active Comparator|Thicken Up Clear concentration 3|Thicken Up Clear at concentration 3
3006134|NCT02522351|Experimental|Cereal extract concentration 1|Cereal extract at concentration 1
3006135|NCT02522351|Experimental|Cereal extract concentration 2|Cereal extract at concentration 2
3006136|NCT02522351|Experimental|Cereal extract concentration 3|Cereal extract at concentration 3
3006137|NCT02522338|Other|iohexol plasma clearance|patients had received iohexol for measuring GFR
3006138|NCT02522325|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo, administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
3006139|NCT02522325|Experimental|Phendimetrazine|Subjects will be maintained on oral phendimetrazine (up to 210 mg/day) administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
3006140|NCT02522299|Experimental|GSK2269557 1000 microgram (mcg)|Each subject will receive 2 inhalations of GSK2269557 (30 seconds apart, 2 x 500 mcg, total dose of 1000 mcg) once daily for 84 consecutive days via DISKUS™ device. DISKUS is registered product of GSK groups of companies.
3006141|NCT02522299|Placebo Comparator|Placebo|Each subject will receive 2 inhalations of placebo once daily for 84 days via DISKUS device
3006142|NCT02522286|No Intervention|Usual Care|Standard clinical care in primary care offices
3006143|NCT02522286|Experimental|Ask 3 Questions|Patients using 3 questions to their physicians when making medical decisions during the office visit.
3006144|NCT02522286|Experimental|Open Communication|This arm has three components: (1) Patients, physicians, and medical assistants watching a video aimed at encouraging open communication; (2) Patients fill out a Visit Companion Booklet about what are the most important issues they want to discuss with their physicians, record their next steps, and teach back on their next steps; (3) physicians receiving communication coaching from a Standardized Patient Instructor on patient-centered communication.
3006145|NCT02522286|Experimental|Ask 3 Questions + Open Communication|A combination of both the Ask 3 and Open Communication arms.
3006146|NCT02522260|Active Comparator|Group 1|Intervention Strength/aerobic exercise, weights, bike or treadmill
3006147|NCT02522260|Active Comparator|Group 2|Intervention Aerobic exercise, bike or treadmill
3006148|NCT02522260|Active Comparator|Group 3|Standard supportive care
3006149|NCT02522247|Active Comparator|Uvulopalatoplasty|Surgery with cold steel, single sutures of palate and tonsillar pillars including palatopharyngeal muscle
3006150|NCT02522247|No Intervention|Controls|Only waiting 6 months
3006151|NCT02522234|Experimental|F-627 240 µg/kg|"F-627 at the dose of 240 mcg/kg administered by s.c. injection on Day 2 of each cycle for up to 6 cycles.~Chemotherapy (docetaxol, doxorubicin and cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for up to 6 cycles."
3006152|NCT02522234|Experimental|F-627 320 µg/kg|"F-627 at the dose of 320 mcg/kg administered by s.c. injection on Day 2 of each cycle for 6 cycles.~Chemotherapy (docetaxol, doxorubicin and cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for up to 6 cycles."
3006153|NCT02522221|Experimental|Tecarfarin|Tecarfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator.
3006154|NCT02522221|Active Comparator|Warfarin|Warfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator.
3006155|NCT02522208|Experimental|BiDil Extended Release (XR)|BiDil XR isosorbide dinitrate 40 mg and hydralazine hydrochloride 75 mg 2 capsules 9 hours apart for one day
3006156|NCT02522208|Active Comparator|BiDil Immediate Release (IR)|BiDil isosorbide dinitrate 20 mg and hydralazine hydrochloride 37.5 mg 3 tablets 6 hours apart for one day
3006157|NCT02522182|Experimental|Intensive Secondary Prevention Programme|The Nurse-led Intensive Secondary Prevention Programme consists of programmed 9 sessions involving the trained nurses and the patients randomised to the experimental programme: before discharge, and one, three, six, 12, 18, 24, 36 and 48 months follow up. During the sessions the nurse will record the main clinical parameters (risk factors, lifestyle habits, adherence to therapy, psychological characteristics), any discrepancies between patient reports and the recommended goals and then activate the interventions in order to correct the discrepancies. The activation of the pre-established multidisciplinary network (anti-smoking, anti-diabetes and anti-hypertension centres, and psychological support) is completely under the nurses' control.
3006158|NCT02522182|Active Comparator|Usual Treatment|The patients randomised to the control group will follow the Usual Treatment for secondary prevention of the hospital to which they were admitted
3006159|NCT02522169|Active Comparator|Conventional treatment|"The patients of the control group undergo Infliximab-maintenance according to the approved dosing scheme, initially with 5 mg/kg body weight Infliximab. Before each administration laboratory parameters will be controlled (Albumin, CrP, Calprotectin) and disease activity scores will be obtained (PCDAI / PUCAI). Infliximab trough levels will be assessed but not have any implication. In the presence of clinical signs of a disease exacerbation and after exclusion of other causes an adjustment of the dosage will follow for the next Infliximab-infusion:~A) interval shortening, or B) Dose increase to 10 mg / kg body weight. With a clinical stable course of the disease without signs of deterioration, the dosage and the eight-week interval will be maintained."
3006160|NCT02522169|Experimental|Intervention Group|Aiming to maintain the therapeutic window of Infliximab a de- or increase of the dose or infusion interval will be carried out for the following administration, provided the patient shows no signs of a clinical worsening. With good trough levels and clinically stable conditions the therapy will be continued without modification until next check-up. In the case of an eminent disease exacerbation Infliximab trough levels and the search for anti - Infliximab antibodies should guide further treatment decisions. With trough levels below the target range antibody testing should be performed.
3006161|NCT02522156|Experimental|Looming Vulnerability Induction|"Four audiotape-guided imagery exercises, each lasting about 3 minutes:~Conveyor Belt: Places the participants in a dimly-lit factory, in which they are being carried along faster and faster on a conveyor belt as they smoke. This conveyor belt is described as ultimately leading to the diagnosis of lung cancer.~Office Building: Places participants in an office all alone, watching calendar pages fly off the wall. As participants smoke and time progresses, participants are meant to feel their lungs withering away and their heart beat becoming weaker and weaker.~Train Tracks: Set in the open plains on top of a set of railroad tracks. As participants smoke, a train heading directly towards them gains speed.~Clock Ticking: In this timing exercise, participants are instructed to imagine terrible health consequences related to smoking coming closer and closer to them as they smoke. Participants are asked to keep track of time for a period of three minutes."
3006162|NCT02522156|Placebo Comparator|Control|"Four audiotape-guided imagery exercises, as follows:~Escalator (parallel to conveyor belt above): Takes place in an empty mall in the morning. The participants imagine they are slowly and steadily being carried by the escalator until they reach the top.~Metro (parallel to office building): Involves riding public transportation while reading a magazine, steadily flipping the pages.~Driving (parallel to Train Tracks): Involves driving a car. The car in this case moves steadily with no traffic hindrances that would cause a reduction of speed.~Human Clock (parallel to Clock Ticking): Another timing exercise. In this case, the participants receive instruction to pretend they are a human clock."
3006163|NCT02522143|Sham Comparator|Informational Sessions|Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
3006164|NCT02522143|Experimental|Condensed-DBT treatment intervention|Condensed-DBT treatment intervention includes all DBT components, tailored to students.
3006165|NCT02522130|Active Comparator|lidocaine group|Group A will receive 10 ml 1% lidocaine (Xylocaine 1%, Astra Zeneca, Egypt) Para cervical block prior to insertion of IUD (injection sites at cervix-vaginal junction typically at 4 ,8 O'clock), Then 3 minutes waiting period between the administration of the Para cervical block and IUD insertion,
3006166|NCT02522130|Active Comparator|misoprostol group|Group B will receive 400 mcg oral misoprostol (Sigma, Egypt) prior to IUD insertion
3006167|NCT02522130|Active Comparator|non steroid group|Group C will receive oral naproxen (Naprosyn, Syntax, Egypt) prior to IUD insertion
3006168|NCT02522130|Placebo Comparator|placebo group|group D will receive placebo tablets.
3006169|NCT02522117|Active Comparator|Atorvastatin|24 patients received oral atorvastatin 40 mg once a day, for 4 weeks.
3006170|NCT02522117|Placebo Comparator|Placebo|24 patients received oral placebo 40 mg once a day, for 4 weeks.
3006171|NCT02522104|Experimental|Normal-renal function|Normal-renal function: 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men
3006172|NCT02522104|Experimental|Glomerular hyperfiltration|Glomerular renal hyperfiltration: GFR > 130 mL/min/1.73m2 in women and GFR > 140 mL/min/1.73m2 in men.
3006173|NCT02522104|Experimental|Moderate renal failure|Moderate renal failure: 30 ≤ GFR ≤ 60 mL/min/1.73m2
3006174|NCT02522091|Other|young healthy volunteers (18-44 years old)|young healthy volunteers (18-44 years old)
3006175|NCT02522091|Other|healthy volunteers (45-69 years old)|healthy volunteers (45-69 years old)
3006176|NCT02522091|Other|Mild Cognitive Impairment Patients|Mild Cognitive Impairment Patients
3006177|NCT02522091|Other|Alzheimer's Disease patient|Alzheimer's Disease patient
3006178|NCT02522091|Other|old healthy volunteers (70+ years old)|old healthy volunteers (70+ years old)
3006179|NCT02522078|Active Comparator|Dry Misoprostol|400 µg of dry misoprostol
3006180|NCT02522078|Experimental|Wet misoprostol|400 µg of wet misoprostol
3006181|NCT02522065||Healthy controls|A sample of 30 healthy volunteers will be recruited to compare the typing signal with that of the cases.
3006182|NCT02522065||Early Parkinson's disease cases|A sample of 30 early PD cases (i.e. less than five years of disease and no axial signs or fluctuations) that are going to be prescribed de novo dopaminergic therapy will be recruited.
3006183|NCT02522052|Experimental|Blue mussel diet|5 meals a week including blue mussels
3006184|NCT02522052|Active Comparator|Meat/control diet|5 meals a week including meat
3006185|NCT02522039|Experimental|Latanoprost|solution, 1 drop of 50ug/ml latanoprost, was given to study eye after washout period of 1 week between drugs
3006186|NCT02522039|Experimental|Timolol|solution, 1 drop of 5mg/ml timolol , was given to study eye after washout period of 1 week between drugs
3006187|NCT02522039|Experimental|dorzolamide|solution, 1 drop of 20 mg/ml dorzolamide, was given to study eye after washout period of 1 week between drugs
3006188|NCT02522039|No Intervention|Other|no drug given and pupil measurements were performed before and at 30 and 180 min at equivalent hours as drugs measurements
3006189|NCT02522026||Healthy volunteers|
3006190|NCT02522026||Healthy smokers|
3006191|NCT02522026||COPD GOLD1|
3006192|NCT02522026||COPD GOLD2|
3006193|NCT02522026||COPD GOLD3/4|
3006194|NCT02522013|Experimental|Aminophylline group|IV injection of aminophylline
3006195|NCT02522013|Placebo Comparator|isotonic saline group|IV injection of isotonic saline group
3006196|NCT02522000||Patients with functional dyspepsia|
3006197|NCT02522000||Healthy controls|
3006198|NCT02521987|Active Comparator|8mm Port|Participates will be randomized to have an 8 mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
3006199|NCT02521987|Experimental|12mm Port|Participates will be randomized to have an 12mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
3006200|NCT02521974|Experimental|SABIN monovalent OPV2 vaccine|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid
3006201|NCT02521961|Experimental|Arm I (support group sessions)|Participants attend support group sessions over 1-1.5 hours once weekly for 10 weeks. The sessions include facilitated discussions among participants about the following topics: stress management and emotional coping strategies, nutrition and physical activity, sexuality and body image, medical advocacy, self-care and social support. Participants receive a binder in which the rationale for each topic, techniques learned, and activities completed during each session will be summarized and are shown a Chair-robics DVD.
3006202|NCT02521961|Active Comparator|Arm II (control)|Participants receive one phone call to arrange a follow-up with the promotora, a note acknowledging their participation in the study, and a community resource booklet. Participants are then yoked into one of the 3 intervention groups and asked to attend a 30 minute session similar to Arm I.
3006203|NCT02521948|Experimental|MANTA Vascular Closure Device|The MANTA device, developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10‐18F) interventional devices.
3006204|NCT02521935|Active Comparator|Complete traditional dentures|Complete maxillary/mandible dentures made in the traditional manner.
3006205|NCT02521935|Active Comparator|Complete CADCAM dentures|Complete maxillary/mandible dentures made with CADCAM (computer-aided design/computer-aided manufacturing) technology
3006206|NCT02521922|Experimental|VSP Study Participants|Vital Signs Patch system study participants. Each study participant will receive the VSP System - NEHB Configuration and then the VSP System - PAL Configuration. Vital signs will be taken and adhesive will be assessed for each participant for each configuration.
3006207|NCT02521909||Tooth Extraction|Intervention is Tooth Extraction for Assessment of Different Apex Locators. All people in the study will contribute one or more teeth, which will be extracted for other clinical purposes, for device comparative testing
3006208|NCT02521896|Experimental|Steerable sheath for intracardiac access|Vado Steerable sheath system consisting of a dilator and steerable sheath for left atrial access, positioning of ablation catheters and placement of mapping and ablation catheters for circumferential ablation
3006209|NCT02521883|Active Comparator|Device: Sooma tDCS|The active group will receive active Sooma tDCS treatment for the first three weeks followed by maintenance treatments at weeks 5 and 6.
3006210|NCT02521883|Placebo Comparator|Device: Sham tDCS|The placebo group will receive sham tDCS treatment for the first three weeks followed by sham maintenance treatments at weeks 5 and 6.
3006211|NCT02521870|Experimental|Dose Escalation Phase 1b|Determine the MTD of escalating doses of SD-101(1) administered in combination with pembrolizumab.
3006212|NCT02521870|Experimental|Dose Expansion Phase 2 (1)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.
3006213|NCT02521870|Experimental|Dose Expansion Phase 2 (2)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent or metastatic melanoma.
3006214|NCT02521870|Experimental|Dose Expansion Phase 2 (3)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.
3006215|NCT02521870|Experimental|Dose Expansion Phase 2 (4)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent head and neck squamous cell carcinoma.
3006216|NCT02521857|Experimental|ALKS 5461|Sublingual tablet
3006217|NCT02521844|Experimental|ETC-1922159|Single-arm open label
3006218|NCT02521831|Active Comparator|General Anesthesia|"Inhalational anesthesia with Isoflurane 1-2% in 50%/50% oxygen/air mixture.~This arm will receive the General Anesthesia (isoflurane) intervention exclusively."
3006219|NCT02521831|Active Comparator|Spinal Anesthesia|"These infants will not receive any anesthetic gas prior to the spinal. These infants will be conscious for this procedure.~Spinal will be administered, containing 0.25% isobaric bupivacaine, 1 mg/kg (maximum 5mg), Clonidine, 1 µg/kg, and Epinephrine, 1:200,000.~This arm will receive the Spinal Anesthesia (bupivacaine) intervention exclusively."
3006220|NCT02521818|Experimental|Modified Atkins Diet|modified Atkins diet; fewer than 20 mg. carbohydrates per day, supplemented by extra dietary fats
3006221|NCT02521818|Active Comparator|NIA Diet for Seniors|Diet recommended by NIA for seniors
3006222|NCT02521805|Sham Comparator|PA|Animal protein and no fiber (control)
3006223|NCT02521805|Experimental|PAF|Animal protein added fiber
3006224|NCT02521805|Experimental|PVF|Vegetable protein naturally containing dietary fiber
3006225|NCT02521805|Experimental|PAVM|Animal protein and dietary fiber in meal
3006226|NCT02521792|Experimental|Palovarotene|The protocol is open only to the subjects who completed Clementia Study PVO-1A-202. Eligible subjects will receive a weight-based equivalent dose of palovarotene 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days. Should treatment be extended beyond 6 weeks, a weight-based equivalent dose of 5 mg will be administered in 2-week increments.
3006227|NCT02521779|Experimental|Test Meal Saturated Fat|Saturated-fat Treatment Meal
3006228|NCT02521779|Experimental|Test Meal N-6 Fat|N-6 fat Treatment Meal.
3006229|NCT02521779|Experimental|Test Meal N-3 Fat|N-3 fat Treatment Meal.
3006230|NCT02521779|Experimental|Test Meal Low-fat|Low-fat Treatment Meal.
3006231|NCT02521753|Active Comparator|Metformin|Metformin 850mg twice a day for six months
3006232|NCT02521753|Experimental|Magnesium|Magnesium chloride 250mg daily for six months
3006233|NCT02521753|Experimental|PUFA omega 3|Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) 1.1mg daily for six months
3006234|NCT02521740||caregivers|someone who takes care and lives with a disabled elderly
3006235|NCT02521740||controls|someone who lives with an healthy elderly
3006236|NCT02521727||exposed siblings/children|"Consecutive subjects with non-advanced adenomas will be identified from the colonoscopy database at Prince of Wales Hospital, Alice Ho Miu Ling Nethersole Hospital, Queen Elizabeth Hospital and the bowel cancer screening center at Siu Lek Yuen. Figure 1 illustrates subject recruitment flow chart. They will be consented to provide details on their number of FDR, their FDR contact details, and cause of death in FDR who are deceased. FDR aged 40 to 70 years of consecutive patients with newly diagnosed non-advanced adenomas confirmed from endoscopy and pathology reports will be contacted via phone and invited for an interview and a colonoscopy.~COLONOSCOPY With informed consents, experienced colonoscopists (GI physicians, colorectal surgeons) will perform colonoscopy under intravenous sedation, midazolam and pethidine after adequate bowel preparation."
3006265|NCT02521571|Placebo Comparator|Control Group|
3006291|NCT02521376|Experimental|Cohort 1 (Moderate Hepatic Impairment)|Entospletinib administered on Days 1-5.
3006292|NCT02521376|Experimental|Cohort 2 (Severe Hepatic Impairment)|Entospletinib administered on Days 1-5.
3006293|NCT02521376|Experimental|Cohort 3 (Mild Hepatic Impairment)|Entospletinib administered on Days 1-5.
3006294|NCT02521363|Experimental|Upfront Breast Surgery|Patients will have the microdevice implanted prior to breast surgery, in the absence of neoadjuvant chemotherapy
3006676|NCT02518633||control subjects|subjects with no obstructive sleep apnoea
3006237|NCT02521727||unexposed siblings/children|"Subjects (Control) FDR aged 40 to 70 years of asymptomatic average risk subjects who had undergone a colonoscopy in our bowel cancer screening programme between 2010 and 2014 and found to have a normal colonoscopy will be invited to participate by phone and invitation letters, to attend a health talk and to undergo a colonoscopy.~Confounding factors including use of drugs (aspirin and non-steroidal anti-inflammatory drugs), lifestyle factors (smoking, and diet questionnaire) and history of medical conditions (obesity with calculation of body mass index, diabetes, history of cardiovascular disease) between cases and controls will be recorded.~COLONOSCOPY With informed consents, experienced colonoscopists (GI physicians, colorectal surgeons) will perform colonoscopy under intravenous sedation, midazolam and pethidine after adequate bowel preparation."
3006238|NCT02521714|Experimental|Treatment A: 25mg capsule -under fasted condition|Single oral dose of 25mg lenalidomide (reference formulation, 1 x 25mg capsule) under fasted condition.
3006239|NCT02521714|Experimental|Treatment B: 25mg oral suspension - under fasted condition|Single oral dose of 25mg lenalidomide (test formulation, 2.5mL oral suspension) under fasted condition.
3006240|NCT02521714|Experimental|Treatment C: 25mg oral suspension -under fed condition|Single oral dose of 25mg lenalidomide (test formulation, 2.5mL oral suspension) under fed condition.
3006241|NCT02521701|Experimental|NFL101|"Level 1: 100 µg~50 µg per injection (in each arm), two injections at day 1 and two injections at day 29~The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.~Level 2: 200 µg~100 µg per injection (in each arm), two injections at day 1 and two injections at day 29~The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL."
3006242|NCT02521688||Group I (PTD + CP)|include ten mothers exhibiting spontaneous preterm delivery with moderate to severe chronic periodontitis +incisional biopsy from placenta and GCF sample
3006243|NCT02521688||Group II (TD + CP)|include ten mothers exhibiting spontaneous term delivery with moderate to severe chronic periodontitis+incisional biopsy from placenta and GCF sample
3006244|NCT02521688||Group III (PTD + HP)|include tenmothersexhibiting spontaneous preterm delivery with healthy periodontium +incisional biopsy from placenta and GCF sample
3006245|NCT02521688||Group IV (TD + HP)|ten mothersexhibiting spontaneous term delivery with healthy periodontium(Armitage GC. 1999)+ incisional biopsy from placenta and GCF sample
3006246|NCT02521675|Other|Diabrasport then Rest|Between each period, the patient should respect a wash-out period of at least one week, during which they will be asked not to practice physical activity.
3006247|NCT02521675|Other|Rest then Diabrasport|Between each period, the patient should respect a wash-out period of at least one week, during which they will be asked not to practice physical activity.
3006248|NCT02521662|Active Comparator|Patch|21mg nicotine patch daily for 14 weeks (including a 2 week prequit period) plus behavioural support for six weeks post-quit
3006249|NCT02521662|Active Comparator|Patch and nicotine-free e-cigarette|21mg nicotine patch (daily) and nicotine-free e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit
3006250|NCT02521662|Active Comparator|Patch and nicotine e-cigarette|21mg nicotine patch (daily) and nicotine e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit
3006251|NCT02521649|Experimental|10µg, Stage I-III|10µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
3006252|NCT02521649|Experimental|100µg, Stage I-III|100µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
3006253|NCT02521649|Experimental|250µg, Stage I-III|250µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
3006254|NCT02521649|Experimental|100µg, Stage IV|100µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
3006255|NCT02521649|Experimental|250µg, Stage IV|250µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
3006256|NCT02521636|Placebo Comparator|Anibiotic therapy guided with actual french recommandations|Guided by the antibiotic 2006 recommendations of the French consensus conference on anti-infective therapy of respiratory tract infections in low immuno-competent adult.
3006257|NCT02521636|Experimental|Anibiotic therapy guided with serum PCT value|"Guided antibiotic therapy serum PCT at admission, revalued at day 1, day 3 and day 6 as long as PCT is not less than 0.1 ng / mL:~PCT <0.1 ng / mL: no antibiotics~0.1 <PCT <0.25 ng / mL: antibiotic advised~PCT> 0.25 ng / mL: highly recommended antibiotics"
3006258|NCT02521623|Experimental|Surgimend|Patients randomized to this arm will receive SurgiMend® Acellular Dermal Matrix in their direct to implant primary breast reconstruction.
3006259|NCT02521623|Active Comparator|Strattice|Patients randomized to this arm will receive Strattice™ Acellular Dermal Matrix in their direct to implant primary breast reconstruction.
3006260|NCT02521610|Placebo Comparator|Placebo|Healthy volunteers will receive the placebo equivalent to RG7625 as oral capsules once or twice daily for 8 days. Each cohort will receive intradermal administration of 4 antigens (tetanus toxoid, tuberculin purified protein derivative [PPD], Candida albicans, and Trichophyton species) and a negative control at Screening and on Day 7 of treatment to assess for DTH.
3006261|NCT02521610|Experimental|RG7625|Participants will undergo a series of Screening visits prior to treatment and 7- to 14-day follow-up. Healthy volunteers will be enrolled in up to 4 cohorts and will receive RG7625 as oral capsules once or twice daily for 8 days. The first cohort is planned to receive 100 milligrams (mg) on Day 1, followed by 100 mg twice daily on Days 3 to 9. Subsequent dose and frequency decisions will be based upon observations in previous cohort(s). Each cohort will receive intradermal administration of 4 antigens (tetanus toxoid, tuberculin PPD, Candida albicans, and Trichophyton species) and a negative control at Screening and on Day 7 of treatment to assess for DTH.
3006262|NCT02521597|Experimental|Cellscope|The intervention for this study will be the use of a smartphone otoscope attachment called CellScope Oto.
3006263|NCT02521597|Active Comparator|Traditional otoscope|The control group will be using a classic otoscope
3006264|NCT02521571|Experimental|Intervention Group|
3006266|NCT02521558|Experimental|Intervention Group|In the Intervention Group, patients will receive an iPad with the Constant Therapy cognitive rehabilitation application. Patients in the Intervention Group will practice the memory tasks developed for the Constant Therapy application for a total of six months. On a weekly basis, a clinician and/or research assistant will check in with the patient to answer any questions or address any concerns the patient has with using the Constant Therapy application, or how to perform any of the memory tasks. At the end of six months, each individual in the Intervention Group is assessed with standard cognitive testing to determine if there was any change on overall cognition.
3006267|NCT02521558|Active Comparator|Control Group|The Control Group will not receive any intervention. The Control Group will be given simple sets of puzzle booklets to practice over the 6 month period (e.g., word search puzzles, number and/or math puzzles). The Control Group will also receive standardized cognitive testing at the end of 6 months. Weekly check-ins by a clinician and/or research assistant will also occur in the Control Group. Every 4th patient recruited for the study will be assigned to the Control Group.
3006268|NCT02521545|Experimental|BIIB061|Single oral dose of 30 mg BIIB061 of the new formulation
3006269|NCT02521532|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
3006270|NCT02521532|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
3006271|NCT02521519|Other|One side of the patient's back|medial branch block (MBB): Using sterile conditions, 25 gauge needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
3006272|NCT02521519|Other|Other side of the patient's back|These injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
3006273|NCT02521506|Experimental|Verio Pattern Alert® activated|In this cohort, the patients will monitoring the glucose levels with capillar glucometer and they have activated the software Verio Pattern Alert® that could predict the glucose trends.
3006274|NCT02521506|Active Comparator|Verio Pattern Alert® deactivated|In this cohort, the patients will monitoring the glucose levels with capillar glucometer.
3006275|NCT02521493|Experimental|Arm A (standard risk)|"INDUCTION II: Patients receive cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV over 1-15 minutes, and thioguanine PO BID on days 1-4. Induction II continues for a minimum of 28 days.~INDUCTION III: Patients receive cytarabine, daunorubicin hydrochloride, and thioguanine as in Induction II. Induction III continues for a minimum of 28 days.~INTENSIFICATION I: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 60-120 minutes on days 1-3. Intensification I continues for a minimum of 28 days.~INTENSIFICATION II: Patients receive cytarabine and etoposide as in Intensification I. Intensification II continues for a minimum of 28 days."
3006276|NCT02521493|Experimental|Arm B (high risk)|"INDUCTION II: Patients receive high dose cytarabine IV over 1-3 hours Q12 hours on days 1-4 and mitoxantrone hydrochloride IV over 15-30 minutes on days 3-6. Induction II continues for a minimum of 28 days.~INTENSIFICATION I: Patients receive high dose cytarabine IV over 1-3 hours Q12 hours and etoposide IV over 90-120 minutes on days 1-5. Intensification I continues for a minimum of 28 days.~INTENSIFICATION II: Patients receive high dose cytarabine IV over 3 hours Q12 hours on days 1, 2, 8, and 9. Patients also receive asparaginase or asparaginase Erwinia chrysanthemi IM or IV over 30 minutes on days 2 and 9. Intensification II continues for a minimum of 28 days."
3006277|NCT02521480|Active Comparator|Active Transcranial Magnetic Stimulation|During TMS treatment, a coil, which creates a magnetic field, will be placed on the left prefrontal area of the head. Active TMS will stimulate for 4 seconds, pause for 26 seconds, and repeat this for approximately 40 minutes. There will be a total of 3000 pulses during treatment. We expect TMS to decrease pain and depression.
3006278|NCT02521480|Sham Comparator|Sham Transcranial Magnetic Stimulation|During sham TMS, a coil will be placed on the left prefrontal area of the head. Sham TMS will simulate active treatment as described in active arm.
3006279|NCT02521467|Active Comparator|PRF|Platelets Rich Fibrin
3006280|NCT02521467|Placebo Comparator|palatal stent|Palatal stent
3006281|NCT02521454|Experimental|MBRT|Mindfulness-Based Resilience Training
3006282|NCT02521454|No Intervention|WL Control|waitlist control group
3006283|NCT02521441|Experimental|F-627, 10 mg/dose|F-627 at dose of 10 mg/dose administered by subcutaneous injection on Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
3006284|NCT02521441|Experimental|F-627, 20 mg/dose|F-627 at dose of 20 mg/dose administered by subcutaneous injection on Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
3006285|NCT02521441|Experimental|Filgrastim, 5 mcg/kg/dose|Filgrastim of 5 mcg/dose administered by subcutaneous injection for up to two weeks, start from Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
3006286|NCT02521415|Experimental|ketamine|ketamine (1mg/kg)
3006287|NCT02521415|Active Comparator|fentanyl|fentanyl (1.5 micrograms/kg)
3006288|NCT02521402|Other|Keloid Revision Surgery with Biovance|All enrolled patients will have Biovance applied during Keloid Revision Surgery
3006289|NCT02521389|Experimental|Part 1|3 sequential groups (Groups A, B and C), comprising 3, 6 and 6 subjects, respectively, with 2 optional additional groups (Groups D and E), each comprising 6 subjects, to assess alternative dose levels or formulations (described below), if required.
3006290|NCT02521389|Experimental|Part 2|Single dose, 2-way crossover design to assess a selected formulation of PWT-143 in the fed and fasted states in 8 subjects.
3006677|NCT02518620|Experimental|ALX-0061|
3006295|NCT02521363|Experimental|Neoadjuvant Therapy|Patients will have the device placed and retrieved on a core biopsy the following day, then receive neoadjuvant chemotherapy prior to definitive breast surgery.
3006296|NCT02521350||Control|- older than 40 years patients with no specific gender, who will stay at least one night in hospital will be included into our study. And cardiovascular, urological surgery patients and patients with known renal insufficiency will be excluded.
3006297|NCT02521337||pregnant women not in active labor|
3006298|NCT02521337||pregnant women in preterm labor|
3006299|NCT02521337||pregnant women in term labor|
3006300|NCT02521324|Experimental|Immediate treatment (IT)|Subjects from this group will perform 2 weeks of DGB with the DGB2 system immediately after 1 week of baseline monitoring. All subjects will answer questionnaires pertaining to their sleep quality.
3006301|NCT02521324|Active Comparator|Wait list control (WLC)|The subjects from the WLC group will do the same (answer questionnaires and perform 2 weeks of DGB with the DGB2 system) at a 1 week delay.
3006302|NCT02521311|Experimental|Clemastine|Participants will receive clemastine until 3 months and then will be off treatment until 9 month time point.
3006303|NCT02521311|Placebo Comparator|Placebo|Participants will receive placebo until 3 months and then will be off treatment until 9 month time point.
3006304|NCT02521298|Active Comparator|Strength Training + Placebo|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.~Placebo: Ultrasound-guided subcutaneous injection of 2 ml isotonic saline over the proximal part of the common extensor tendon origin using a 0,8 mm needle. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
3006305|NCT02521298|Experimental|Strength Training + Cortico-Steroid Inj.|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.~Cortico-Steroid Injection: Ultrasound-guided injection of 1 ml depomedrol 40 mg/ml + 1 ml lidocaine 10 mg/ml deep to the proximal part of the common extensor tendon origin using a 0,8 mm needle. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
3006306|NCT02521298|Experimental|Strength Training + Dry Needling|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.~Dry Needling: Ultrasound-guided penetration of the proximal part of the common extensor tendon origin is repeated 10 times using a 0,8 mm needle, followed by subcutaneous injection of 2 ml isotonic saline superficial to the tendon. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
3006307|NCT02521285|Experimental|Arm A (aspirin)|Patients receive aspirin PO QD for 12 months.
3006308|NCT02521285|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD for 12 months.
3006309|NCT02521272|Experimental|air pocket|Breathing in the simulated avalanche snow.
3006310|NCT02521259||low Bispectral index (BIS) group|BIS range under 40
3006311|NCT02521259||high BIS group|BIS range from 40 to 60
3006312|NCT02521246|Experimental|Test 1: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan Cilexetil 16 mg + Chlorthalidone 12,5 mg) a day, in the morning.
3006313|NCT02521246|Experimental|Test 2: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan Cilexetil 16 mg + Chlorthalidone 25 mg) a day, in the morning.
3006314|NCT02521246|Active Comparator|Comparator: Losartan+hydrochlorothiazide (Hyzaar®)|The patients will take 1 tablet (Losartan 100 mg + Hydrochlorothiazide 25 mg) a day, in the morning.
3006315|NCT02521233|Experimental|Test 1: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 12,5 mg) a day, in the morning.
3006316|NCT02521233|Experimental|Test 2: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 25 mg) a day, in the morning.
3006317|NCT02521233|Active Comparator|Comparator: losartan+hydrochlorothiazide (Hyzaar®)|he patients will take 1 tablet (Losartan 50 mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
3006318|NCT02521220|Experimental|L-citrulline|Oral food-supplemental amino-acid L-citrulline. 2 times 3g per day.
3006319|NCT02521220|Placebo Comparator|Maltodextrin|Maltodextrin as placebo. 2 times 3g per day
3006320|NCT02521207|Experimental|Part 1 OXP001|OXP001 formulation containing 800mg ibuprofen single dose
3006321|NCT02521207|Active Comparator|Part 1 Ibuprofen control|Ibuprofen control 800mg single dose
3006322|NCT02521207|Experimental|Part 2 OXP001|OXP001 formulation containing 800mg ibuprofen three times per day
3006323|NCT02521207|Experimental|Part 2 Ibuprofen control|Ibuprofen control 800mg three times per day
3006324|NCT02521194|Experimental|Caregiver Questionnaire|Questionnaire completion regarding opinion on the inpatient occupational therapy session person being cared for received.
3006325|NCT02521194|Experimental|Patient Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
3006326|NCT02521181|Experimental|Lower Dose Sodium Bicarbonate|Participants will receive oral 0.5 milliequivalents (mEq)/kg-lean body weight (LBW)/day of sodium bicarbonate. Half of the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
3006327|NCT02521181|Experimental|Higher Dose Sodium Bicarbonate|Participants will receive 0.8 mEq/kg-LBW/day of sodium bicarbonate. Half the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
3006503|NCT02519933|Active Comparator|mNT-BBAVF|Patients in Chronic Kidney Disease (CKD) stage 4-5 without previous dysfunctional fistula access
3006328|NCT02521181|Placebo Comparator|Placebo|Participants will take the same number of placebo capsules as if they were assigned to receive either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of sodium bicarbonate. Half the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
3006329|NCT02521168|Experimental|Oral triiodothyronine|Oral T3 (triiodothyronine) is given 1 mcg/kg every 6 hourly through naso-gastric tube since induction of anaesthesia for 60 hours
3006330|NCT02521168|Placebo Comparator|Placebo|Placebo (saccharin lactic) is given every 6 hourly through naso-gastric tube since induction of anaesthesia for 60 hours
3006331|NCT02521155|Experimental|Intervention group|Safeguard Your Smile an oral health literacy intervention.
3006332|NCT02521155|No Intervention|Control group|No intervention, only a conventional pamphlet will be given.
3006333|NCT02521142||AMD: treatment-naive|
3006334|NCT02521142||AMD: active neovascular AMD|
3006335|NCT02521129|Experimental|Ablation|Intervention: ablation of biopsy needle track with a new device
3006336|NCT02521116|Other|Healthy subjects|healthy study subjects, age 18-80 years
3006337|NCT02521103|Other|Triathlon Tritanium Cone Augments|Cases who receive the Triathlon TS Total Knee System with at least one Triathlon Tritanium Cone Augment
3006338|NCT02521090|Experimental|Treatment (EGFRBi-armed autologous T cells)|"PHASE I: Patients receive EGFRBi-armed autologous T cells IT twice weekly for 4 weeks.~PHASE II: Patients receive EGFRBi-armed autologous T cells* IT twice weekly for 4 weeks and then IV over 15-30 minutes twice weekly for 2 weeks.~*NOTE: Six selected patients receive EGFRBi-armed autologous T cells IV on day -3, -2, or -1 prior to first IT infusion."
3006339|NCT02521077|Experimental|Odd Cycle Intravenous Ascorbic Acid|Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their odd-numbered chemotherapy cycles. During the even-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).
3006340|NCT02521077|Experimental|Even Cycle Intravenous Ascorbic Acid|Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their even-numbered chemotherapy cycles. During the odd-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).
3006341|NCT02521064||Exclusive Enteral Nutrition (EEN)|The patient will be admitted to hospital for placement of the nasogastric tube and commencement of exclusive enteral nutrition (EEN). Nutritional feeds will consist of a semi-elemental (whey-peptide based) formula that will make up all of the patient's daily caloric needs (120% of BMR). Feeds will slowly be titrated up to full volume and strength during the hospital stay. The patient will receive instructions how to decrease the number of hours of feeds once at home. The patient will be seen in clinic at two weeks and will receive a phone call from the dietician at 4 weeks to assess progress and symptom improvement. At 8 weeks, food will start to be reintroduced slowly, as per the dietician's instructions.
3006342|NCT02521064||Prednisone|Patients who receive the prednisone intervention will follow the Division of Pediatric Gastroenterology and Nutrition protocol for corticosteroid induction therapy, with 2 weeks of high dose IV/PO prednisone (maximum 40mg/day) followed by a 6 week wean (approximately decreasing 5mg/day per week). The patient will receive a phone call from the nurse practitioner at two weeks and will be seen in clinic at 4 weeks to assess progress and symptom improvement.
3006343|NCT02521051|Experimental|Alectinib and Bevacizumab.|"Phase 1~Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Alectinib, orally, twice a day, per cycle~Bevacizumab, iv, once per cycle~Phase II In the phase II portion of this study, the investigators will evaluate the combination of alectinib plus bevacizumab in ALK-positive patients with untreated or progressive, asymptomatic brain metastases. Eligible participants will receive alectinib plus bevacizumab at the recommended phase II doses determined in the phase I portion of the study."
3006344|NCT02521025|Experimental|Intermittent feeding|Intermittent feeding pattern throughout the bedrest period, with 4 boluses per day
3006345|NCT02521025|Experimental|Continuous feeding|Continuous feeding pattern throughout the bedrest period, with 4 boluses per day, without breaks in food supply.
3006346|NCT02521012|Active Comparator|Vitamin D 10 micrograms|"Vitamin D supplementation 10 micrograms/day given to depressed individuals, defined as reference"
3006347|NCT02521012|Experimental|Vitamin D 100 micrograms|Vitamin D supplementation 100 micrograms/day given to depressed individuals
3006348|NCT02520999|Active Comparator|5days|5 days after blood sampling, various external pressure test will be done. Blood wil be stored in refrigerator(Celsius 4 degree) until study day. External pressure 0, 100, 150, 200, 250, 300mmHg will be applied to each blood sample.
3006349|NCT02520999|Active Comparator|35days|35 days after blood sampling, various external pressure test will be done. Blood wil be stored in refrigerator(Celsius 4 degree) until study day. External pressure 0, 100, 150, 200, 250, 300mmHg will be applied to each blood sample.
3006350|NCT02520986|Experimental|Carbon dioxide Laser ablation|Excision of genital warts using a carbon dioxide laser, ie CO2 Laser
3006351|NCT02520986|Active Comparator|Electrocoagulation|Excision of genital warts using a superficial electrical coagulation mode, ie spray coagulation
3006352|NCT02520973|Experimental|Universal screening|All HIV + pregnant women will be asked to give a sputum sample for TB prior to TB symptom screen
3006353|NCT02520973|Active Comparator|Symptom- directed screening|Only symptomatic HIV+ pregnant women will be asked to give a sputum sample for TB
3006354|NCT02520947|Experimental|Bispectral index|The group that desflurane titrated according to bispectral index monitoring
3006355|NCT02520947|Other|Minimum alveolar concentration|The group that desflurane consumption titrated according to minimum alveolar concentration monitoring
3006356|NCT02520934|Experimental|Case_Miglustat|Besides regular ERT, patients in this group also need to take Miglustat for 24 months.
3006357|NCT02520934|No Intervention|Control|Patients will be tested for their pupil cycle time.
3006358|NCT02520921|Active Comparator|Arm 1 : Novel strategy|enteric coated aspirin 100 mg in the morning and 100 mg in the evening
3006359|NCT02520921|Active Comparator|Arm 2 : Conventional strategy|enteric coated aspirin 100 mg in the morning
3006449|NCT02520284|Placebo Comparator|Placebo (Cohort 1)|Participants will receive GS-5745 placebo weekly for 8 weeks. Based on Week 8 assessment results, participants will either continue on blinded treatment or will be offered open-label GS-5745 weekly.
3006360|NCT02520908||HSCT|Patients with an available sibling or 10/10 HLA-matched unrelated donor who undergo reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation (HSCT), will be included in the study. The reduced-intensity conditioning usually includes Fludarabine 90 mg/m2 IV and Melphalan 140 mg/m2 IV. As usual care, patients will receive peripheral blood stem cells from their sibling donor if available, otherwise from their 10/10 HLA-matched unrelated donor
3006361|NCT02520908||Standard care|Patients with no available sibling or 10/10 HLA-matched unrelated donor who therefore do not receive allogeneic HSCT but receive best standard of care treatment, will be included in the study, as the control group
3006362|NCT02520895||large B lymphoma cells (group 1)|30 patients with large B lymphoma cells at diagnosis and who will receive an immunochemotherapy treatment patients will have blood samplings
3006363|NCT02520895||indolent B-cell lymphomas (group 2)|30 patients with indolent B-cell lymphomas without invasion excess blood lymphoma 1 giga / L at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings
3006364|NCT02520895||indolent B-cell lymphomas (group 3)|20 Patients with indolent B-cell lymphomas with lymphocytosis (> 1 Giga / L) at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings
3006365|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 4)|20 patients with LLC never treated before and will receive an immunochemotherapy treatment (fludarabine +/- endoxan +/- rituximab or alemtuzumab)- patients will have blood samplings
3006366|NCT02520895||T-cell lymphoma (group 5)|10 Patients with T-cell lymphoma in 1st line therapy and will receive a combination of chemotherapy- patients will have blood samplings
3006367|NCT02520895||follicular lymphoma (group 6)|6 patients with follicular lymphoma in first line or relapsed and will receive a single immunotherapy treatment (rituximab)- patients will have blood samplings
3006368|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 7)|6 patients with LLC never treated and will receive a combination of rituximab, fludarabine, endoxan- patients will have blood samplings
3006369|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 8)|6 patients with LLC stage A followed for a period of 18 months without treatment- patients will have blood samplings
3006370|NCT02520882|Experimental|68Ga-NOTA-Aca-BBN(7-14) PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-Aca-BBN(7-14) in one dose intravenously and underwent PET/CT scan 30 min later.
3006371|NCT02520869|Active Comparator|swim-up|swim-up technique for semen processing
3006372|NCT02520869|Active Comparator|zeta test|zeta test technique for semen processing
3006373|NCT02520856||Hypertrophic cardiomyopathy|"All patients with newly diagnosed unexplained HCM will be prospectively included.~All patients will undergo both classical genetic analysis and WES technology."
3006374|NCT02520843|Experimental|Crohn's disease treated by SVF|Patients with Crohn's disease and fistula-in-ano refractory to conventional medical and surgical treatment, treated by Stromal Vascular Fraction ( SVF) reinjection
3006375|NCT02520830|Active Comparator|Blueberry Group|Dietary Supplement: 22 gram freeze-dried blueberry powder per day
3006376|NCT02520830|Placebo Comparator|Placebo Group|blueberry polyphenol deprived powder 22 gram per day
3006377|NCT02520817||Antioxidant supplementation and zinc plus Lactulose(Group A)|Patients With MHE were assigned to receive zinc and antioxidant plus lactulose (group A)
3006378|NCT02520817||Lactulose only (Group B)|Patients with MHE were assigned to receive lactulose oly (group B)
3006379|NCT02520804|Active Comparator|normal saline|normal saline for fluid resuscitation and maintenance for 72 hours
3006380|NCT02520804|Experimental|sterofundin|sterofundin for fluid resuscitation and maintenance for 72 hours
3006381|NCT02520791|Experimental|Treatment (MEDI-570)|Patients receive anti-ICOS monoclonal antibody MEDI-570 IV over 1-4 hours on day 1. Treatment repeats every 3 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3006382|NCT02520778|Experimental|Treatment (navitoclax, osimertinib)|Patients receive navitoclax PO QD on days 1-28 and osimertinib PO QD on days 4-28 (days 1-28 during dose-expansion). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
3006383|NCT02520752|Experimental|INC280|
3006384|NCT02520739|Placebo Comparator|Virgin Olive Oil|Virgin olive oil obtained by traditional procedures (VOO);
3006385|NCT02520739|Experimental|Optimized High Phenolic Content Oil|Optimized virgin olive oil with a high phenolic content (OHPCO);
3006386|NCT02520739|Experimental|Functional Olive Oil|Functional olive oil (FOO) with both high phenolic compounds and triterpene content.
3006387|NCT02520726|Experimental|Sertraline|Patients age 18-65: sertraline 50mg PO qday for one week, then 100mg PO qday for one week, then 150mg PO qday for one week, then 200mg PO qday for one week, with flexible titration. Patient age >65: sertraline 25mg PO qday for one week, then 50mg PO qday for one week, then 75mg PO qday for one week, then 100mg PO qday for one week, with flexible titration
3006388|NCT02520726|Placebo Comparator|Placebo|Placebo 1 capsule PO qday for one week, then 2 capsules PO qday for one week, then 3 capsules PO qday for one week, then 4 capsules PO qday for one week.
3006389|NCT02520713|Other|Genetic testing and GAIN report|All enrolled patients will submit specimens for sequencing and analysis.
3006390|NCT02520700|Experimental|Study participants|This was split scalp design - so each patient had one half of scalp treated with daylight PDT and one side treated with the artificial white light PDT - a surgical light (Maquet Power 500 LED surgery light)
3006391|NCT02520687|Experimental|Dietary nitrate, beetroot juice|Once daily 70mL dose of beetroot juice, containing 400mg inorganic nitrate, for 7 consecutive days.
3006392|NCT02520687|Placebo Comparator|Nitrate-depleted beetroot juice|Once daily 70mL dose of beetroot juice, depleted of nitrate, for 7 consecutive days.
3006393|NCT02520674|Other|Glaucoma and Ocular Hypertension|Patients to be examined with both smartphone ophthalmoscopy and slit-lamp biomicroscopy.
3006394|NCT02520661|No Intervention|Usual Care|Older adults discharged from an ED to home who receive the usual processes and services.
3006395|NCT02520661|Active Comparator|Care Transitions Intervention|Older adults discharged from an ED to home who receive the Care Transitions Intervention.
3006450|NCT02520284|Experimental|GS-5745 (Cohort 2)|Participants will receive open-label GS-5745 at the optimal regimen (based on Cohort 1 data analysis) for the first 8 weeks, followed by blinded GS-5745 weekly or every 2 weeks (whichever is determined to be the optimal regimen) for a total of 43 doses.
3006396|NCT02520648|Active Comparator|Neuro-lymphatic treatment|Participants were positioned in prone, with the head in neutral position and the arms beside the body. They were asked to perform conscious breathing. The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement. Neuro-lymphatic reflexes as referred to applied kinesiology, are locations on the body that are believed to affect a specific muscle and organ. Duration of the treatment is 15 minutes.
3006397|NCT02520648|Experimental|Articulatory spinal manual therapy.|Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached. Three repetitions are performed at each vertebral level. It is done bilaterally, then longitudinal pressures are applied on dorsal vertebrae during expiratory time, 3 repetitions. It ends like treatment 1. This technique aims to normalize possible slight dysfunctions of the spine, enhance the feeling of comfort and pain, and relax the spine. Duration of the treatment is 15 minutes.
3006398|NCT02520648|Experimental|Articulatory costal Manual therapy.|The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier. Three repetitions are performed at each costal level. It is done bilaterally, then longitudinal pressures are applied on dorsal vertebrae during expiratory time, 3 repetitions. It ends like treatment 1. This technique aims to normalize the mobility of the ribs, enhance the feeling of comfort and pain, and relax the spine. Duration of the treatment is 15 minutes.
3006399|NCT02520635|Active Comparator|TEMODAL® standard therapy regimen|4 weeks after surgery, patients are administered with radiotherapy that consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily 5 dyas a week over a period of 6 weeks. Concomitant TEMODAL® are administered orally at a daily dose of 75mg/m2 from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days. After a 4-week break, patients were then to receive up to 6 cycles of adjuvant TEMODAL® chemotherapy according to the standard 5-day schedule every 28 days.The dose is 150mg/m2 once daily for cycle 1 and is increase to 200mg/m2 at the beginning of cycle 2, so long as there were no hematologic toxic effects.
3006400|NCT02520635|Experimental|post-surgery supra-early TEMODAL® chemotherapy|Within 24 hours after surgery, Supra-early TEMODAL® Chemotherapy is administered orally at 75mg/m2/day for 28 days for patients pathologically confirmed as GBM. 4 weeks after surgery, patients are administered with radiotherapy that consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily 5 dyas a week over a period of 6 weeks. Concomitant TEMODAL® are administered orally at a daily dose of 75mg/m2 from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days. After a 4-week break, patients were then to receive up to 6 cycles of adjuvant TEMODAL® chemotherapy according to the standard 5-day schedule every 28 days.The dose is 150mg/m2 once daily for cycle 1 and is increase to 200mg/m2 at the beginning of cycle 2, so long as there were no hematologic toxic effects.
3006401|NCT02520622|Experimental|Control|Patients use digital photographs loaded onto a mobile device
3006402|NCT02520622|Experimental|Reminders|Patients use digital photographs loaded onto a mobile device and receive skin exam reminders
3006403|NCT02520622|Experimental|Social Support|Patients use digital photographs loaded onto a mobile device and a social support network
3006404|NCT02520622|Experimental|Combined|Patients use digital photographs loaded onto a mobile device and a social support network and receive skin exam reminders
3006405|NCT02520583|Experimental|MICROBAC|Bacterial cultures
3006406|NCT02520583|Placebo Comparator|Placebo|Maltodextrin
3006407|NCT02520570||general department|Patients using ulinastatin in department beyond ICU would be labelled as general department group.
3006408|NCT02520570||ICU|Patients using ulinastatin in ICU would be labelled as ICU group.
3006409|NCT02520557||Case|Cases will be individuals with documented definite or probable Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), or drug reaction with eosinophilia and systemic symptoms (DRESS) or symptom onset consistent with one of these conditions within the first 4 months of using ESL (including up to 14 days after discontinuing ESL) will be considered a potential case. Blood draw or Saliva.
3006410|NCT02520557||Control|Controls will be individuals who have used ESL for at least 6 weeks and who have not developed SCAR. Blood draw or saliva.
3006411|NCT02520544|Active Comparator|Accolade stem|All patients in a participating centre matching all of the inclusion criteria and none of the exclusion criteria and who receive the Accolade or Accolade II stem and Trident/Tritanium cup with X3 liner.
3006412|NCT02520544|Active Comparator|Accolade II stem|All patients in a participating centre matching all of the inclusion criteria and none of the exclusion criteria and who receive the Accolade or Accolade II stem and Trident/Tritanium cup with X3 liner.
3006413|NCT02520531|Active Comparator|Scorpio PS|Patients on the waiting list for a total knee prosthesis who fulfil the inclusion and exclusion criteria will be asked to participate in this study and are randomized to receive the Scorpio PS Total Knee Replacement.
3006414|NCT02520531|Active Comparator|Scorpio NRG PS|Patients on the waiting list for a total knee prosthesis who fulfil the inclusion and exclusion criteria will be asked to participate in this study and are randomized to receive the Scorpio NRG PS Total Knee Replacement.
3006415|NCT02520518|Experimental|Dapagliflozin: ad libitum dietary intake|Daily oral administration of dapagliflozin with ad libitum dietary intake. The dose of dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
3006416|NCT02520518|Experimental|Dapagliflozin: weight maintenance|Daily oral administration of dapagliflozin with supplemented dietary intake to achieve weight maintenance. The dose of dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
3006479|NCT02520102|Experimental|sargramostim|Sargramostim is administered daily until the absolute neutrophil count (ANC) equals or exceeds 1500/mm^3 for 3 consecutive measurements or up to 42 days post-induction chemotherapy.
3006417|NCT02520518|Placebo Comparator|Placebo: ad libitum dietary intake|Daily oral administration of a placebo with ad-libitum dietary intake. Matching placebo for dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
3006418|NCT02520518|Placebo Comparator|Placebo: dietary restriction|Daily oral administration of a placebo plus dietary restriction such that weight loss is matched to participants in Arm 1. Matching placebo for dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
3006419|NCT02520505|Other|Expectant Management: Timed Intercourse|Patients randomized to expectant management will be counseled on timed intercourse and the window in which intercourse should be performed during the randomization phone call. Patients will be encouraged to contact their fertility doctor and the primary investigator if they become pregnant and an estimated date of confinement will be calculated based upon the patient's last menstrual period. Patients will also be notified that they will be contacted at the end of the six month timeframe to inquire as to whether or not they became pregnant.
3006420|NCT02520505|Active Comparator|Supraovulation + IUI|Women randomized to super ovulation (SO) will be treated according to a standard protocol under the care of their staff physician and fertility nurses. The patient will be treated with 100mg/day of clomiphene citrate starting on day 3 of the menstrual cycle and ending on day 7. Intrauterine insemination will be performed 36 hours after the hCG surge (follicle rupture) by inserting a catheter through the cervix of the patient in dorsal lithotomy position.
3006421|NCT02520492|Experimental|noninvasive method of ICP measurements|"Patients will receive a noninvasive measurement of ICP variations during each of their follow up consultation. These measurements will last until 30 minutes for the first consultation (parameters to determine) and 10 minutes for the others. A postural test will be performed during the ICP measurements when the patient condition will make it possible to do.~Measurements will be performed by a device with noninvasive acoustic probes placed in the ear, and in case of electrophysiological test, regular electrodes on the brow."
3006422|NCT02520479|Experimental|sandwich protocols|"sandwich protocols: Patients with newly diagnosed ENKTL is given 2 cycles of P-CHOP[cyclophosphamide(CTX), 750 mg/m2 day 1; vincristine(VCR), 1.4 mg/m2 day 1 (maximal dose 2 mg),adriamycin(ADM) 50 mg/m2 day 1; dexamethasone(DXM) 10 mg days 1-8; Pegaspargase 2500 international unit day 1] before radiotherapy(RT) and then two consolidation cycles after RT."
3006423|NCT02520466|Active Comparator|flavanol-containing drink|flavanol-containing drink
3006424|NCT02520466|Placebo Comparator|flavanol-free drink|flavanol-free drink
3006425|NCT02520453|Experimental|Durvalumab|Durvalumab 20 mg/Kg IV Q 4 weeks for 1 year, or until disease relapse or unacceptable toxicity
3006426|NCT02520453|Placebo Comparator|Placebo|Placebo Q 4 weeks for 1 year, or until disease relapse or unacceptable toxicity
3006427|NCT02520440||GIF and/or MOF patients|Development during the ICU stay of gastro-intestinal failure and/or multiple organ failure. Investigators performed in each patient monitoring of plasmatic levels of Citrulline, monitoring of plasmatic levels of Arginine and Glutamine, and intra-abdominal pressure monitoring.
3006428|NCT02520440||Controls|patients admitted to ICU without gastrointestinal failure and/or multiple organ failure during the intensive care unit stay. Investigators performed in each patient monitoring of plasmatic levels of Citrulline, monitoring of plasmatic levels of Arginine and Glutamine, and intra-abdominal pressure monitoring.
3006429|NCT02520427|Experimental|AMG 330|Comparison of different dosages of drug
3006430|NCT02520414|Experimental|Symphion®|Patients treated in-office with Symphion® Bipolar Hysteroscopic Tissue Resection System.
3006431|NCT02520401|Experimental|Test|Probiotic tablet
3006432|NCT02520401|Placebo Comparator|Control|Control tablet
3006433|NCT02520388|Experimental|HLD200 (methylphenidate)|"Experimental: HLD200 (methylphenidate)~The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core. Following a minimum 72-hour washout, subjects will be randomized (1:1) to double-blind HLD200 to be taken once daily during the evening for a period of 3-weeks prior to testing."
3006434|NCT02520388|Placebo Comparator|Placebo|Placebo capsules will be composed of microcrystalline cellulose beads in place of MPH containing beads found in the HLD200 capsules. Following a minimum 72-hour washout, subjects will be randomized (1:1) to double-blind placebo to be taken once daily during the evening for a period of 3-weeks prior to testing.
3006435|NCT02520375|Experimental|Prebiotic|This group will be administered a prebiotic mouthrinse and toothpaste
3006436|NCT02520375|Placebo Comparator|Control|This group will be administered a control mouthrinse and toothpaste
3006437|NCT02520362||Postmenopausal Women|Postmenopausal Women
3006438|NCT02520362||Women with post menopausal osteoporosis|Women with post menopausal osteoporosis
3006439|NCT02520362||Prolia for unapproved indications|Patients who receive Prolia for unapproved indications
3006440|NCT02520362||Men with osteoporosis|Men with osteoporosis treated with denosumab
3006441|NCT02520336|Experimental|active management|Laboratoy test request given postpartum with phone reminder prior to test
3006442|NCT02520336|No Intervention|Routine care|
3006443|NCT02520323||Blood only|20 sarcoidosis subjects and 20 healthy controls will complete lifestyle questionnaires and have blood drawn for microbiome analyses.
3006444|NCT02520323||Blood and BAL|10 sarcoidosis subjects, 10 healthy controls, and 10 subjects with non-sarcoid interstitial lung disease will complete lifestyle questionnaires and undergo blood sampling for microbiome analyses as well as bronchoscopy for bronchoalveolar lavage microbiome analyses.
3006445|NCT02520310|Experimental|AVJ-514|The AVJ-514 system
3006446|NCT02520297|Experimental|TRV130|Drug: TRV130
3006447|NCT02520284|Experimental|GS-5745 weekly (Cohort 1)|Participants will receive GS-5745 weekly doses for 8 weeks. Based on Week 8 assessment results, participants will either continue on blinded treatment or will be offered open-label GS-5745 weekly.
3006448|NCT02520284|Experimental|GS-5745 every 2 weeks (Cohort 1)|Participants will receive weekly GS-5745 doses alternating with placebo for 8 weeks. Based on Week 8 assessment results, participants will either continue on blinded treatment or will be offered open-label GS-5745 weekly.
3008455|NCT02506465|Sham Comparator|Sham arm|Foley catheter is used during the study
3006451|NCT02520284|Experimental|GS-5745 every 2 weeks (Cohort 2)|Participants will receive open-label GS-5745 at the optimal regimen (based on Cohort 1 data analysis) for the first 8 weeks, followed by weekly GS-5745 doses alternating with placebo for a total dose of 21 active GS-5745 doses. Note this treatment group will only be initiated if the optimal dosing regimen is determined to be weekly.
3006452|NCT02520284|Placebo Comparator|Placebo (Cohort 2)|Participants will receive open-label GS-5745 at the optimal regimen (based on Cohort 1 data analysis) for the first 8 weeks, followed by GS-5745 placebo weekly or every 2 weeks (whichever is determined to be the optimal regimen).
3006453|NCT02520284|Experimental|Extended Treatment Phase|All participants that complete 52 weeks of treatment (in either Cohorts 1 or 2) will have the option to enter the Extended Treatment Phase to receive open-label GS-5745 weekly.
3006454|NCT02520271|Active Comparator|Depression|Behavioral activation only
3006455|NCT02520271|Active Comparator|Depression and SUD|Motivational interview and Behavioral activation
3006456|NCT02520258|Experimental|Aspartame Consumers - Cohort 1|"Experimental Group/Arm~Phase I - Questionnaires and fasting oral glucose tolerance test (OGTT).~Phase II - (If OGTT results are abnormal, participants will be invited to participate in Phase II) Five (5) week study phase with Prudent Metabolic Diet and Intervention of diet soda containing aspartame only; Week 1: Prudent Metabolic Diet and 36oz diet soda po daily, Week 2-4: Prudent Metabolic Diet and no diet soda, Week 5: Prudent Metabolic Diet and 36 oz diet soda po daily."
3006457|NCT02520258|Active Comparator|Aspartame Naive Participants - Cohort 2|"Control Group/Arm~Phase I - Questionnaires and fasting oral glucose tolerance test (OGTT).~Phase II - Not applicable for this cohort."
3006458|NCT02520245|Experimental|Open-Label|
3006459|NCT02520232|Experimental|Physical activity program (A)|Physical exercises
3006460|NCT02520232|Experimental|Physical activity program (B)|Physical exercises
3006461|NCT02520232|No Intervention|Control|No physical exercices assigned by the protocol
3006462|NCT02520219|Experimental|GDP+Endostar|"Patients in this group will be given conventional chemotherapy medicine:~GDP (gemcitabine+dexamethasone+cis-platinum)chemotherapy by treatment guidelines for Peripheral T-cell Lymphoma and Endostar."
3006463|NCT02520219|Active Comparator|GDP|"Patients in this group will be given conventional chemotherapy medicine:~GDP (gemcitabine+dexamethasone+cis-platinum) chemotherapy by treatment guidelines for Peripheral T-cell Lymphoma."
3006464|NCT02520206||Arthritis|subjects with arthritis
3006465|NCT02520206||Health control subjects|Health control
3006466|NCT02520193|No Intervention|Standard mobilization strategy|
3006467|NCT02520193|Experimental|protocolized early mobilization strategy|
3006468|NCT02520180|Experimental|Firehawk™ stent system|MicroPort Firehawk™ stent system
3006469|NCT02520180|Active Comparator|Xience family Everolimus-Eluting Stent|Abbott Xience family Everolimus-Eluting Stent
3006470|NCT02520167|Experimental|Dietary and Lifestyle Counseling|Women randomized to the intervention group will meet with a dietary counselor for 15 minutes at every prenatal appointment. They will receive a dietary and lifestyle curriculum based on the Diabetes Prevention Program curriculum (11 lessons) with one additional lesson providing prenatal breastfeeding education. They will also have access to a private online Facebook page for additional education and peer group support.
3006471|NCT02520167|No Intervention|Standard of Care|Usual prenatal care consists of regular clinical appointments, pregnancy ultrasounds, and recommendations to use prenatal multivitamins, eat a balanced diet, and remain physically active. Women with a pre-pregnant body mass index > 30 complete early glucose screening (as early as possible after presentation at the clinic) to detect pre-existing diabetes, and all women undergo routine gestational diabetes screening at 24-28 weeks. Women who test positive for pre-existing diabetes or gestational diabetes are referred to a registered dietitian.
3006472|NCT02520154|Experimental|Pembrolizumab + Paclitaxel + Carboplatin|Participants receive Carboplatin area under curve (AUC) 6 by vein on Day 1 and Paclitaxel 80 mg/m2 by vein on Days 1,8,15 every 21 days for a total of 3 cycles of therapy. Participants without evidence of progression undergo interval cytoreductive surgery. After surgery, participants restart chemotherapy at previously prescribed doses, with addition of Pembrolizumab 200 mg by vein on Day 1 every 21 days for a total of 3 cycles. Then Pembrolizumab maintenance therapy 200 mg by vein every 21 days for a total of 20 cycles or until progression.
3006473|NCT02520141|Experimental|Ramucirumab|Ramucirumab administered at 8 mg/kg intravenously on Day 1 of each 14 day cycle. Treatment continues until progression unless other reasons for study discontinuation occur.
3006474|NCT02520128|Other|Cohort 1 (closed to recruitment)|"Cohort 1: Patients with Limb/limb girdle soft tissue sarcoma (STS) receiving (neo)-adjuvant radiotherapy (Intensity Modulated Radiotherapy)~Dose schedules for Cohort 1:~Pre-operative RT - 50 Gy in 25 daily fractions over 5 weeks~Post-operative RT - 60 Gy in 30 daily fractions to the high dose planning target volume (PTV) and 52.2 Gy in 30 daily fractions to the low dose PTV treated concurrently over 6 weeks~Post-operative RT (positive resection margins) - 66 Gy in 33 daily fractions to the high dose PTV, and 53.46Gy in 33 fractions to the low dose PTV treated concurrently over 6 ½ weeks."
3006475|NCT02520128|Other|Cohort 2|"Cohort 2: Patients with Ewing sarcoma of the spine/pelvis receiving definitive radical or (neo)-adjuvant radiotherapy (Intensity Modulated Radiotherapy)~Dose schedules for Cohort 2:~Pre-operative RT - 50.4 Gy in 28 daily fractions over 5½ weeks~Post-operative RT - 54 Gy in 30 daily fractions over 6 weeks~Primary RT - 54 Gy in 30 daily fractions over 6 weeks."
3006476|NCT02520128|Other|Cohort 3|"Cohort 3: Patients with non-Ewing primary bone sarcomas of the spine/pelvis receiving definitive radical or adjuvant Radiotherapy (Intensity Modulated Radiotherapy)~Dose schedule for Cohort 3:~Primary RT - 70 Gy in 35 daily fractions over 7 week~Post-operative RT (non-chordoma) - primary bone sarcoma 60 Gy in 30 daily fractions over 6 weeks~Post-operative RT (chordoma) - 70 Gy in 35 daily fractions over 7 weeks."
3006477|NCT02520115|Experimental|Arm I (induction)|Patients receive valproic acid PO BID on days -7 to -3 and QD on day -2 and dexamethasone PO QD on days -5 and -2 and BID on days -4 and -3. Patients undergo collection of serum and tissue samples for analysis via PCR and IHC at baseline, time of surgery, and 7-14 days after surgery.
3006478|NCT02520115|Experimental|Arm II (surveillance and recurrence)|Patients receive valproic acid PO BID on days -7 to -3 and QD on day -2 and dexamethasone PO QD on days -5 and -2 and BID on days -4 and -3. Patients undergo collection of serum samples for analysis via PCR and IHC at the time of clinically suspected recurrence, 2 days after completion of induction, and 7-14 days after induction.
3006480|NCT02520089|Active Comparator|Bone autograft|The investigator it will obtain bone autograft of iliac crest ipsilateral of each patient. And apply into the pseudoarthrosis focus at the moment of the fixation with a locking compression plates.
3006481|NCT02520089|Experimental|platelet rich plasma plus Bone autograft|Other group of patients it will be extracted 40 mL of peripheric blood sample, and processed with a double-centrifugation technique to obtain 5 mL of platelet rich plasma, and collocated into the focus of pseudoarthrosis after standard fixation with locking compression plates and Bone Autograft of Iliac Crest.
3006482|NCT02520076|Experimental|AAT treated group|Study subjects will receive Alpha-1 Antitrypsin (AAT) study drug intravenously in 4 doses over 15 days around the time of their transplant. The islets will also be prepared in a solution of AAT.
3006483|NCT02520063|Experimental|Phase I Cohort 1|Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks
3006484|NCT02520063|Experimental|Phase I Cohort 2|Letrozole 2.5 mg PO daily until surgery, everolimus 10 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks
3006485|NCT02520063|Experimental|Phase I Cohort -1|Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 10 mg/kg IV q 2 weeks for 24 weeks
3006486|NCT02520063|Experimental|Phase II|Letrozole 2.5 mg PO daily until surgery, everolimus 5 or 10 mg PO daily for 24 weeks, and TRC105 15 or 10 mg/kg IV q 2 weeks for 24 weeks. Dose and regimen to be determined based on data from the phase I component.
3006487|NCT02520050|Active Comparator|Traditional MNT|Will be instructed to follow a MNT plan as recommended by the ADA through consultation with a RD.
3006488|NCT02520050|Active Comparator|Structured MNT|Will be instructed to follow a MNT plan as applied in the Why WAIT™ program, which includes structured dietary plan, dietary modification and use of diabetes-specific meal replacement (Ultra Glucose Control®; Metagenics Inc.) three times per day.
3006489|NCT02520050|Active Comparator|Structured MNT plus Weekly Support|Will be instructed to follow a MNT plan as applied in the Why WAIT™ program, which includes structured dietary plan, dietary modification and use of diabetes-specific meal-replacement (Ultra Glucose Control®; Metagenics Inc.) three times per day plus weekly coaching.
3006490|NCT02520024|Experimental|Self-directed Care|"Individuals in the experimental condition will work with a specially trained certified peer specialists (CPS) who will serve as recovery coaches to develop an individualized recovery plan that describes their goals and desires. They will then work with the team to select both the behavioral health treatment and rehabilitation services, and the non-behavioral health materials and resources they believe are necessary to achieve their goals."
3006491|NCT02520024|No Intervention|Treatment as usual|Participants in the control condition will receive services as usual.
3006492|NCT02520011|Experimental|ACM (Stage 1 / Stage 2)|A: alvocidib, 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
3006493|NCT02520011|Active Comparator|CM (Stage 2)|C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 1-3; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
3006494|NCT02520011|Experimental|Exploratory Arm - NDHR|A: alvocidib, 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
3006495|NCT02520011|Experimental|Exploratory Arm A - MCL-1 Dependence 30-<40%|A: alvocidib, 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
3006496|NCT02520011|Experimental|Exploratory Arm B - MCL-1 Dependence 15-<30%|A: alvocidib, 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
3006497|NCT02520011|Experimental|Exploratory Arm C - MCL-1 Dependence 0-<15%|A: alvocidib, 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
3006498|NCT02519998||Concussed patients|The clinical focus of this study will be on concussed athletes, both children and adults, and we will also include non-sports patients who have mild traumatic brain injury due to other situations including slip and fall, occupational, motor vehicle accidents, assault, and blast exposure.
3006499|NCT02519998||Non-concussed patients|Cohort control. Primarily athletes who undergo routine pre-season baseline assessment
3006500|NCT02519985|Experimental|Repeatability and Reproducibility of ArcScan Insight 100|"For repeatability and reproducibility in normal eyes (n=20):~Firstly, 5 consecutive repeated ArcScan Insight 100 scans of the cornea and anterior segment will be performed by the first operator.~After a break of about 30 minutes, 5 consecutive repeated ArcScan Insight 100 scans of the cornea and anterior segment will be performed by the second operator.~For repeatability and reproducibility in eyes after laser refractive surgery (n=20):~Firstly, 5 consecutive repeated ArcScan Insight 100 scans of the cornea will be performed by the first operator.~After a break of about 30 minutes, 5 consecutive repeated ArcScan Insight 100 scans of the cornea will be performed by the second operator."
3006501|NCT02519972|Experimental|Low dose computed tomography|All the Low dose computed tomography of lung was performed with 64 slices multidetectors CT in single hold breath covering entire lung. The protocol of scanning parameters (120KVp, 40-80 mA, 1.25 mm or less in thickness) was standardized. The raw data would be reconstructed to axial images (3 mm thickness and interval) and coronal images (3 mm thickness and interval). The scan should be finished in a single breath (15-20 second) from the thoracic inlet to adrenal glands.
3006502|NCT02519946|Experimental|On-Line Diet and Exercise Intervention|
3038692|NCT02303002|Placebo Comparator|Dose E|Dose E: Placebo
3006504|NCT02519933|Active Comparator|BCAVF|Patients in CKD stage 4-5 without previous dysfunctional fistula access
3006505|NCT02519920|Experimental|group 1|This group patients were given dosages of fluorescein sodium 0.01ml/kg intravenous administration.
3006506|NCT02519920|Experimental|group 2|This group patients were given dosages of fluorescein sodium 0.02ml/kg intravenous administration.
3006507|NCT02519920|Experimental|group 3|This group patients were given dosages of fluorescein sodium 0.05ml/kg intravenous administration.
3006508|NCT02519920|Active Comparator|group 4|This group patients were given dosages of fluorescein sodium 0.1ml/kg intravenous administration.
3006509|NCT02519907|Experimental|Surface Electrical Stimulation|Please see information under 'Detailed description'
3006510|NCT02519894|Experimental|Intervention group|Intensive low sodium education and immediate sodium intake feedback by dietary scanning calculator
3006511|NCT02519894|Placebo Comparator|Controlled group|Standard education
3006512|NCT02519881|Experimental|modified microfracture using collagen|modified microfracture using collagen (CartiFill) for cartilage defect of ankle
3006513|NCT02519881|Active Comparator|microfracture|simple microfracture for cartilage defect of ankle
3006514|NCT02519868|Experimental|Experimental arm|Patients will have both interventions: electrical stimulation followed by chemical stimulation
3006515|NCT02519855|Experimental|Concomitant Vaccination|ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4
3006516|NCT02519855|Experimental|Nonconcomitant Vaccination|Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4
3006517|NCT02519842|Experimental|Fosaprepitant Regimen Cycle 1|Participants received a single dose of fosaprepitant 150 mg (or age-based adjustment) administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron IV on Day 1 prior to chemotherapy and at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy. Participants may have also received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
3006518|NCT02519842|Placebo Comparator|Control Regimen Cycle 1|Participants received a single dose of matched placebo for fosaprepitant IV on Day 1 prior to chemotherapy plus ondansetron IV on Day 1 prior to chemotherapy and at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy. Participants may have also received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
3006519|NCT02519842|Experimental|Fosaprepitant Regimen Cycles 2-6|Participants received a single dose of fosaprepitant 150 mg (or age-based adjustment) IV on Day 1 prior to chemotherapy plus a 5-hydroxytryptamine 3 (5-HT3) antagonist on Day 1 prior to chemotherapy and per product label or standard of care. Participants may also have received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
3006520|NCT02519829|Active Comparator|Monocryl closure|"The skin incision is closed with monocryl dissolvable sutures and a topical adhesive (glue) called Dermabond and covered with a Tegaderm dressing.~Intervention: Monocryl closure, Tegaderm dressing"
3006521|NCT02519829|Active Comparator|Vicryl and staple closure|"The skin incision is closed with vicryl and staples and covered with a gauze dressing.~Intervention: Vicryl and Staple closure, Gauze dressing"
3006522|NCT02519816|Experimental|Intervention|Open-label phase II study. After signing informed consent, patients will undergo 6 times an apheresis during the 6-month treatment period. These cells will be manufactured into the Rhitol and frozen in aliquots. Then re-infused.
3006523|NCT02519777|Placebo Comparator|Arm A: Placebo MVC and placebo DTG|In addition to their existing ART regimens, participants in Arm A will receive placebo for MVC and placebo for DTG.
3006524|NCT02519777|Experimental|Arm B: DTG and placebo MVC|In addition to their existing ART regimens, participants in Arm B will receive DTG and placebo for MVC.
3006525|NCT02519777|Experimental|Arm C: MVC and DTG|In addition to their existing ART regimens, participants in Arm C will receive MVC and DTG
3006526|NCT02519764|Experimental|Hydration when thirsty|Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.
3006527|NCT02519764|Experimental|Not hydration when thirsty|"Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a hydration when thirsty protocol."
3006528|NCT02519751|Experimental|D3 Creatine followed by creatine supplementation|Every participant will be orally administered with 60mg of D3 Creatine in a fasted state in a non-gelatin capsule. Creatine supplemented throughout the study will be administered in the following doses-0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.
3006529|NCT02519738|Active Comparator|Silver Nitrate|Silver Nitrate is supplied in the form of pre-packaged applicator sticks to parents and patients. The concentration is 75% Silver Nitrate and 25% Potassium Nitrate. Application will be done 3 times a week for a period of 3 weeks.
3006530|NCT02519738|Active Comparator|Kenalog (Triamcinolone)|Kenalog is a topical corticosteroid that shares anti-inflammatory, anti-pruritic, and vasoconstrictive actions.The dosage of Kenalog used in the study is 0.5%. Application is topical, and the frequency is 3 times a day for the 3 week trial period. FDA approved use of Kenalog in the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It has not been studied whether Kenalog has any proven advantage over Silver nitrate in the treatment of granulation tissue, but it has been used for the treatment of granulation tissue at the gastrostomy site with good effect.
3006531|NCT02519738|Active Comparator|Washcloth Abrasion|Washcloth abrasion will be done with regular soap and water applied to a washcloth. The granulation tissue will be gently washed and abraded once daily for three weeks.
3006532|NCT02519725|Active Comparator|With diary|a ICU diary is open by staff for the patient and his relatives during the ICU stay
3006533|NCT02519725|No Intervention|Without diary|No diary is open during the ICU stay
3006534|NCT02519712|Experimental|Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells|This is a single center trial to assess the feasibility of standard induction chemotherapy followed by a single dose of unmanipulated G-PBSC for the treatment of elderly patients with newly diagnosed AML.
3006535|NCT02519699|Experimental|Norepinephrine|Noradrenaline continuous infusion IV
3006602|NCT02519283|Active Comparator|GUIDED-HF|GWTG:HF has been successfully implemented across multiple inpatient populations and health systems over the last decade and has been shown to improve HF disparities.
3006536|NCT02519686||Trendelenburg position maneuver|Trendelenburg (TD) positioning (supine with head tilt-down) is used in abdominal and gynecological surgery as well as during colonoscopy to allow better access to the pelvic organs, as gravity pulls the bowel out of the pelvic cavity and the rectosigmoid angle straightens.
3006537|NCT02519686||Left lateral position maneuver|Left Lateral (LL) position (patient laying on their side, traditionally used for colonoscopies)
3006538|NCT02519660|Experimental|Lidocaine/Tetracaine patch (Ralydan)|Ralydan patch is a drug delivery system designed to release local anaesthetics (lidocaine and tetracaine) through the skin. It is applied in the site of venipuncture 30 minutes before needle procedure
3006539|NCT02519660|Active Comparator|Lidocaine/Prilocaine cream (EMLA)|EMLA cream is an eutectic mixture of local anaesthetic (lidocaine, prilocaine). It is applied in the site of venipuncture 60 minutes before needle procedure
3006540|NCT02519647|Active Comparator|tracheal intubation with Gliderite|Gliderite will be used for intubation
3006541|NCT02519647|Experimental|Tracheal intubation with S-Guide|S-Guide will be used for intubation
3006542|NCT02519634|Other|Group 1|Patients in Group 1 undergo Super-Mini Percutaneous Nephrolithotomy
3006543|NCT02519634|Other|Group 2|Patients in Group 2 undergo Retrograde Intrarenal Surgery
3006544|NCT02519621|Active Comparator|NPWT PRO|Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage
3006545|NCT02519621|Active Comparator|NPWT PRO with Irrigation|Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage with simultaneous delivery of topical wound treatment solutions and suspensions over the wound bed (saline irrigant).
3006546|NCT02519621|Active Comparator|KCI Ulta NPWT|KCI Ulta NPWT without irrigation.
3006547|NCT02519608|Active Comparator|Aspirin 100 mg + Clopidogrel 75 mg|dual antiplatelet therapy as suggested by guidelines with aspirin 100 mg and clopidogrel 75 mg daily
3006548|NCT02519608|Experimental|Aspirin 100 mg + Ticagrelor 90 mg x2|dual antiplatelet therapy with aspirin 100 mg and ticagrelor 90 mg x 2 daily
3006549|NCT02519595|Experimental|ketamine IV 1 mg/kg|Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
3006550|NCT02519595|Experimental|Ketamine IV 1.5 mg/kg|Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
3006551|NCT02519595|Experimental|Ketamine IV 2 mg/kg|Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
3006552|NCT02519582|Experimental|Niclosamid|Patients receive 2 g niclosamide orally per day until progression or toxicity
3006553|NCT02519569|Experimental|Intervention group|Internet-based cognitive-behavioral therapy for complicated grief
3006554|NCT02519556|Experimental|Probiatop|Probiotic comprising the mixture of strains: Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus paracasei and Bifidobacterium lactis, at a dose of 1 gram sachet, once a day for 6 months
3006555|NCT02519556|Placebo Comparator|Placebo|Placebo of Maltodextrin in sachet
3006556|NCT02519543|Placebo Comparator|placebo|placebo comparator to be given twice daily
3006557|NCT02519543|Experimental|metformin|metformin 1500 mg daily to be given as follows: 500mg am and 1000 mg pm
3006558|NCT02519530|Experimental|Intervention|Behavioral: Teen Outreach Program
3006559|NCT02519530|No Intervention|Comparison|This group did not receive TOP, they received business as usual health curriculum offered through the public school system
3006560|NCT02519517|Experimental|permissive hypercapnia|during one lung ventilation, right ventricular function was assessed by TEE and the effect of rising PCO2 appreciated
3006561|NCT02519504||Duarte galactosemia|Pediatric subjects with Duarte galactosemia will undergo direct assessments of cognitive skills (memory, executive function, and auditory processing), communication processes (speech and language), physical development (including motor skills, coordination, and occurrence of tremors), and social-emotional development.
3006562|NCT02519504||Control|Pediatric subjects without Duarte galactosemia will undergo direct assessments of cognitive skills (memory, executive function, and auditory processing), communication processes (speech and language), physical development (including motor skills, coordination, and occurrence of tremors), and social-emotional development.
3006563|NCT02519504||Parent/Caregiver|Parents/caregivers of children with Duarte galactosemia or parents/caregivers of healthy children will participate in focus groups or complete ratings of child emotional and behavioral outcomes, child social skills, child special education or other intervention experiences, if any (a possible covariate), and their own (caregiver) stress levels.
3006564|NCT02519491|Active Comparator|Modified Allen's Test|The Modified Allen's Test to assess radial and ulnar patency.
3006565|NCT02519491|Active Comparator|Iphone assessment|iPhone assessment of radial and ulnar patency.
3006566|NCT02519478|Experimental|Helmetless Tackling Training (HuTT)|The HuTT program is modeled after a tackling drill progression common to the sports of rugby and American football, but participants do not wear helmets or should pads as they normally would in football. Drills will be executed at 50%-75% effort. The goal of the contact is to execute proper technique. Drills will be supervised at all times and feedback will be provided to confirm proper technique and correct improper technique. The HuTT drill will be completed in two phases and takes approximately 6-10 minutes per session. A research assistant will ensure adherence and standardization of the treatment throughout the season. Subjects in the intervention group will participate in HuTT 4 times per week throughout the 2 weeks of pre-season and 2 times a week during in-season.
3006567|NCT02519478|No Intervention|Control|Control group subjects participate in normal football activities as they would normally have during a football season
3006568|NCT02519465|Active Comparator|HEATED FLOW|The volunteers were randomly allocated into three groups - group 1 - 10l/min cold or heated, group 2 - 30l/min cold or heated, group 3 - 50 l /min - cold or heatedPhase 1 - 10l/min or 30l/min or 50l/min of the oxygen heated .
3006569|NCT02519465|Active Comparator|COLD FLOW|The volunteers were randomly allocated into three groups - group 1 - 10l/min cold or heated, group 2 - 30l/min cold or heated, group 3 - 50 l /min - cold or heatedPhase 1 - 10l/min or 30l/min or 50l/min of the oxygen cold
3006570|NCT02519452|Experimental|Part 1: Cohort 1|Participants will receive 1200 mg (daratumumab 1200 milligram (mg) with Recombinant Human Hyaluronidase [rHuPH20] 30,000 U) via mixing immediately before Subcutaneous (SC) infusion once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
3039367|NCT02298231|Experimental|Group 2|Mystic Isle (MI) Balance Training
3006571|NCT02519452|Experimental|Part 1: Cohort 2|Participants will receive 1800 mg (daratumumab 1800 milligram (mg) with Recombinant Human Hyaluronidase [rHuPH20] 45,000 U) via mixing immediately before SC infusion once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
3006572|NCT02519452|Experimental|Part 1: Cohort 3|Participants will receive mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery at a dose which will be decided by Study Evaluation Team (SET) once weekly by SC infusion in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression. Also up to three additional optional cohorts (Cohorts 3b, 3c, and 3d) may be enrolled to repeat a dose level of daratumumab.
3006573|NCT02519452|Experimental|Part 2: Cohort 4|Participants will receive 1800 mg co-formulated daratumumab and rHuPH20 preparation initially administered by SC infusion once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles. The dose level and schedule for any additional cohorts would be selected based on the daratumumab pharmacokinetic profile and safety profile (reviewed by the SET) that will be observed in Cohort 4.
3006574|NCT02519452|Experimental|Part 2: Cohort 5|Participants will receive co-formulated daratumumab and rHuPH20 preparation at a dose which will be decided by Study Evaluation Team based on the Pharmacokinetic and safety results. The dose level and schedule for this cohort would be selected based on the daratumumab pharmacokinetic profile (Ctrough prior to Cycle 3 Day 1 dose) and safety profile that is observed in the initial cohort (Cohort 4).
3006575|NCT02519439|Experimental|ganaxolone|Up to a maximum of 1800 mg/day
3006576|NCT02519426||Cumulative complexity score <9|Mandibular third molar surgery patients with Juodzbalys and Daugela impacted mandibular third molars surgical extraction complexity index cumulative score lower than 9.
3006577|NCT02519426||Cumulative complexity score y≥9|Mandibular third molar surgery patients with Juodzbalys and Daugela impacted mandibular third molars surgical extraction complexity index cumulative score higher than 9.
3006578|NCT02519426||Pell Gregory index <Class 2B|Mandibular third molar surgery patients with Pell Gregory index Class 1A, Class 1B, Class 1C, or Class 2A
3006579|NCT02519426||Pell Gregory index ≥Class 2B|Mandibular third molar surgery patients with Pell Gregory index Class 2B, Class 2C, Class 3A, Class 3B, or Class 3C
3006580|NCT02519426||Winter index <Horizontal impaction|Mandibular third molar surgery patients with Winter predicted index of Mesio-Angular, Disto-Angular or Vertical impaction
3006581|NCT02519426||Winter index ≥Horizontal impaction|Mandibular third molar surgery patients with Winter predicted index of Horizontal, Buccal / Lingual Obliquity, Transverse, Inverse impaction
3006582|NCT02519400|Experimental|Amitriptyline|Single oral dose of amitriptyline, 25 mg
3006583|NCT02519387|Experimental|Buprenorphine Transdermal Patch|Buprenorphrine transdermal patch 5mg/10mg, every 7 days, for 3 months
3006584|NCT02519374|Placebo Comparator|Placebo|Placebo
3006585|NCT02519374|Active Comparator|PROMITOR® dose 1|Investigational product dose 1
3006586|NCT02519374|Active Comparator|PROMITOR® dose 2|Investigational product dose 2
3006587|NCT02519374|Active Comparator|PROMITOR® dose 3|Investigational product dose 3
3006588|NCT02519348|Experimental|MEDI4736 & Tremelimumab|MEDI4736 (Durvalumab) in combination with Tremelimumab (Regimen 1)
3006589|NCT02519348|Experimental|MEDI4736|MEDI4736 (Durvalumab) given as monotherapy
3006590|NCT02519348|Experimental|Tremelimumab|Tremelimumab given as monotherapy
3006591|NCT02519348|Experimental|MEDI4736 & Tremelimumab.|MEDI4736 (Durvalumab) in combination with Tremelimumab (Regimen 2)
3006592|NCT02519335|Other|Dexrazoxane|"Trial subjects will be assigned preoperatively to receive Dexrazoxane at one of three doses: low (200mg/m2/dose), medium (300mg/m2/dose), or high (400mg/m2/dose). Four patients will be assigned to each dosing regimen for a total of 12 patients.~The medication will be administered in the operating room 15-30 minutes prior to starting cardiopulmonary bypass (dose #1), after finishing cardiopulmonary bypass (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3)."
3006593|NCT02519322|Experimental|Group A - Nivolumab|"Neoadjuvant phase: Nivolumab 3 mg/kg by vein every 2 weeks on weeks 1, 3, 5 and 7 prior to surgical excision.~Adjuvant Phase: Nivolumab 3 mg/kg by vein every 2 weeks postoperatively for 6 months.~CNPE: July 11, 2017"
3006594|NCT02519322|Experimental|Group B - Nivolumab + Ipilimumab|"Neoadjuvant Phase: Nivolumab 1 mg/kg by vein combined with Ipilimumab 3 mg/kg by vein every 3 weeks on weeks 1, 4 and 7 prior to surgical excision.~Adjuvant Phase: Nivolumab 3 mg/kg by vein every 2 weeks postoperatively for 6 months.~CNPE: July 11, 2017"
3006595|NCT02519322|Experimental|Group C - Nivolumab + Relatlimab|Nivolumab 480 mg combined with Relatlimab 160 mg every 28 days for 2 doses prior to surgical excision, then 10 doses of Nivolumab 480 mg with Relatlimab 160 mg, post-operatively.
3006596|NCT02519309|Experimental|onsite|Education (the virta program) for the onsite group will be delivered in person, with 26 classes over 12 months including group and individual sessions. Sessions will be scheduled weekly for the first 3 months, biweekly during months 4-6, and monthly thereafter. Each session will last approximately 90 minutes.
3006597|NCT02519309|Experimental|web-based|Education (the virta program) for the web-based educational group will be the same content as the onsite group, but delivered via the web and completed at the participant's own pace.
3006598|NCT02519309|No Intervention|Control (usual care)|The study will make no intervention to this group. Participants in this group will be recent referrals to a local diabetes education program and care for their condition will continue to be managed by their own medical providers.
3006599|NCT02519296|Active Comparator|Prolonged Exposure Therapy|"In total 30 Danish veterans will be recruited, who meet the ICD-10 diagnostic criteria for PTSD, and treated with PE.~Intervention with eight sessions of PE, psychometrics, blood analyses and fMRI."
3006600|NCT02519296|Active Comparator|30 Danish veterans without PTSD|"A group of controls will be recruited consisting of age-appropriate same sex veterans who have participated in international missions similar to the patient group.~Observation with psychometrics, blood analyses and fMRI."
3006601|NCT02519283|Active Comparator|Standard of Care|In keeping with the strategy-based pragmatic nature of the trial, the discharge procedures will largely be kept as they are in common practice. Investigators will standardize usual care for ED discharge to include HF medication reconciliation as well as encourage 7-day follow-up.
3006675|NCT02518633||men with obstructive sleep apnoea|Continuous positive airway pressure devices
3006603|NCT02519270|Experimental|Dose Escalation Stage|The Dose-Escalation Stage will employ a modified 3 + 3 cohort design, subjects will receive up to 26 doses of IGN002.
3006604|NCT02519270|Experimental|Expansion Stage|In the Expansion Stage, subjects will receive up to 24 doses of IGN002 at the maximum tolerated dose administered weekly in three 8-week cycles
3006605|NCT02519257|Experimental|CAD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
3006606|NCT02519257|Experimental|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
3006607|NCT02519244|Experimental|Robot-assisted rehabilitation|Subjects will participate in individualized locomotion training sessions using wearable lower limb exoskeleton, Ekso®. Each training session will last up to 60 minutes, 5 days per week for 3 weeks, for a total of 15 sessions. During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit.
3006608|NCT02519231|Active Comparator|Treatment|This study arm includes naproxen as potential treatment for heavy or prolonged bleeding or dysmenorrhea may provide useful preliminary data for a larger, adequately powered placebo-controlled comparative trial testing additional promising treatments, such as tranexamic acid.
3006609|NCT02519231|Placebo Comparator|placebo|This study arm includes capsules that are exactly like the active treatment medication (naproxen), but there is no active treatment medication in these tablets.
3006610|NCT02519205||ED Nurses|ED triage nurses from Duke University Hospital (DUH) and Duke Regional Hospitals (DRH).
3006611|NCT02519192|Experimental|VAC Arm, Vac sponge irrigations|For patients who fall under the VAC arm, a physician will do the initial placement of the wound VAC (V.A.C.Ulta™ Negative Pressure Wound Therapy System) at the patient's bedside. An information sheet will be provided to the patient, and the patient will be taught how to irrigate the sponge system independently. While inpatient, nursing will perform VAC sponge irrigation.
3006612|NCT02519192|Active Comparator|NonVac, ostomy bag, wet to dry dressings|For patients who fall under the non-VAC arm, a physician or wound care nurse will perform the initial application of the ostomy bag or wet to dry dressing change. An information sheet will be provided to the patient. While inpatient, members from the nursing or physician team will perform ostomy bag application and ostomy dressing changes.
3006613|NCT02519179|Experimental|Conventional vs. Opaque, Weighted Bottle|This is a within-subject experiment; mothers will be asked to feed their infants from a clear, conventional bottle during one visit and an opaque, weighted bottle during the other visit. Order of conditions will be counterbalanced.
3006614|NCT02519166|Other|Patients with chronic wounds|
3006615|NCT02519153|Placebo Comparator|control|patient receive placebo for 4 weeks and followed for passage of stone distal ureter
3006616|NCT02519153|Active Comparator|sildenafil|patient receive sildenafil 50 mg for 4 weeks once per day and followed for passage of stone distal ureter
3006617|NCT02519140|Experimental|Cook medical EMR Gel|"Prospective study involving excised human stomachs and colon harvested from sleeve gastrectomies and colectomies performed for benign or malignant disease.~Different Cook submucosal injections of varying viscosities will be injected into different areas of the excised stomachs or colons.~Data collected will involve lifting characteristics and dissection adequacy of the varying viscosities of gel."
3006618|NCT02519127|Experimental|Low glycaemic load diet|Subjects will be following a low glycaemic load diet, typically high in polyphenols, proteins, vegetables, pulses, fibres and nuts, and low in glycemic carbohydrates, for six continuous weeks.
3006619|NCT02519127|Experimental|Western diet|Subjects will be following a western diet, typically high in saturated fat, refined sugars and salt, and low in fruit and vegetables and fibers, for six continuous weeks.
3006620|NCT02519114|Experimental|Bone MarrowTransplantation|KIR-mismatched haploidentical bone marrow transplantation
3006621|NCT02519101|Experimental|Continunous blood pressure monitoring|Patients receive continuous noninvasive blood pressure monitoring in addition to intermittent monitoring
3006622|NCT02519101|No Intervention|Intermittent blood pressure monitoring|Control group with intermittent blood pressure monitoring
3006623|NCT02519036|Experimental|IONIS HTTRx|IONIS HTTRx is administered intrathecally at 4 week intervals over the course of a 13 week treatment period for dose levels A, B, C, D and E.
3006624|NCT02519036|Placebo Comparator|Placebo|A placebo is administered intrathecally at 4 week intervals over the course of 13 weeks.
3006625|NCT02519023|Experimental|TAP-Block with liposomal bupivacaine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side. In the same arm the surgeon infiltration into the incision will consist of 10 ml of normal saline per port site, 5 ml prior to incision and 5 ml prior to closure at each port site.
3006626|NCT02519023|Active Comparator|Surgical infiltration with bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
3006627|NCT02519010|Experimental|A Test|Test drug (Amlodipine/Valsartan) 1 tablet contains Amlodipine 10 mg & valsartan 160 mg
3006628|NCT02519010|Active Comparator|B Reference|Reference drug (Exforge) 1 tablet contains Amlodipine 10 mg & valsartan 160 mg
3006629|NCT02518997|Experimental|All enrolled infants|All participants will have Parental Reading Aloud at the prescribed intervals while being monitored for cardio-respiratory stability.
3006630|NCT02518971|Experimental|tamsulosin|0.4 mg daily for five days pre-op through post-op day one (seven total)
3006631|NCT02518971|Placebo Comparator|placebo|One capsule daily for five days pre-op through post-op day one (seven total)
3006632|NCT02518958|Experimental|RRx-001 + Nivolumab|Patients enrolled in this trial will receive study drug (RRx-001) on Day 1 as a single agent. Nivolumab (3 mg/kg) will be administered on Day 2 or Day 3 as a single agent.
3006633|NCT02518945|Placebo Comparator|Placebo|"12 weeks of treatment with Insulin, Liraglutide and Dapagliflozin Placebo"
3006634|NCT02518945|Active Comparator|Active drugs|"12 weeks of treatment with Insulin, Liraglutide and Active Dapagliflozin Drug"
3006635|NCT02518932|Experimental|Drug GLP-1 (32-36) Amide|To examine insulinomemtic of the last 5 amino acids of GLP-1 from 60-180 min during a 4 hour hyperglycemic clamp
3006636|NCT02518932|Placebo Comparator|Placebo|To examine the effect of saline on glucose uptake
3006637|NCT02518919|No Intervention|Standard|Patients will receive intravenous ketamine (1-2mg/kg)
3006638|NCT02518919|Experimental|Child Life Intervention|Child life therapist will comfort the child during all painful procedures(including IV insertion) and during sedation
3006639|NCT02518919|Experimental|Music Listening|Patients will listen to music of their choice using headphones during sedation
3006640|NCT02518906|Experimental|Adolescent Identity Treatment|Psychotherapeutic treatment performed routinely at the centres in Basel and Santiago de Chile
3006641|NCT02518906|Experimental|DBT-A|Psychotherapeutic treatment performed routinely at the centre in Heidelberg
3006642|NCT02518880|Other|Plasma volume measurements|
3006643|NCT02518867|Experimental|high intensity iTBS|high intensity iTBS: 100% of active motor threshold for 3 days.
3006644|NCT02518867|Experimental|low intensity iTBS|low intensity iTBS: 80% of active motor threshold for 3 days.
3006645|NCT02518867|Sham Comparator|sham iTBS|sham iTBS for 3 days.
3006646|NCT02518854||study|children aged 6-18 years with pre-metabolic syndrome
3006647|NCT02518854||control|children aged 6-18 years without pre-metabolic syndrome
3006648|NCT02518841|Active Comparator|Achilles Tendon Stretching|This is the arm of participants who will first be assigned to perform 6 weeks of achilles tendon stretching as demonstrated in the protocol. As this is a crossover design study, this arm will then switch to 6 weeks of ThermaWedge TM stretching.
3006649|NCT02518841|Experimental|ThermaWedge TM|This is the arm of participants who will first be assigned to perform 6 weeks of ThermaWedge TM stretching as demonstrated in the protocol. As this is a crossover design study this arm will then switch to 6 weeks of Achilles Tendon Stretching
3006650|NCT02518828|Active Comparator|High SpO2|In the high SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range ≥96%
3006651|NCT02518828|Active Comparator|Low SpO2|In the low SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range 90-92%
3006652|NCT02518815|Experimental|Prewarming group|Prewarmed for 20 minutes prior to OR using 3M Bair Paws System, a forced air warming blanket. This warming blanket was then used intraoperatively throughout the case.
3006653|NCT02518815|No Intervention|Control group|Patients received standard care, which is no active prewarming prior to OR. A full body, forced air warming blanket (same as treatment group) was used intraoperatively throughout the case.
3006654|NCT02518802|Experimental|Synchronous therapy|'Gefitinib and Pemetrexed' Synchronous use of Gefitinib for 2 years during or after chemotherapy with Pemetrexed plus Cisplatin regimen. Gefitinb, 250mg per day,take orally for 2 years. Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
3006655|NCT02518802|Active Comparator|Chemotherapy|Pemetrexed: Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
3006656|NCT02518789|Experimental|Low-dose Dexmedetomidine|-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 0.5 µg/kg，completed within 15 minutes.
3006657|NCT02518789|Experimental|High-dose Dexmedetomidine|-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 1 µg/kg，completed within 15 minutes.
3006658|NCT02518789|Placebo Comparator|normal saline Control group|-Pretreatment before anesthesia induction：Intravenous injection normal saline equal quantity，completed within 15 minutes.
3006659|NCT02518776|Other|Neuropsychological tests|
3006660|NCT02518763|Experimental|Vitamin D3, 100 000 IU weekly, 4 times|
3006661|NCT02518750|Experimental|Study Participants|"Participants with ALL will receive the following interventions in three treatment blocks:~Block A: Dexamethasone, panobinostat, liposomal vincristine, mitoxantrone, peg-asparaginase, bortezomib, intrathecal triples.~Block B: High-dose methotrexate, 6-mercaptopurine, intrathecal triples, high-dose cytarabine.~Block C: Nelarabine or clofarabine, cyclophosphamide, etoposide."
3006662|NCT02518737||GIP-receptor deficient|Persons with a mutation (Glu354Gln) causing their GIP-receptor to loose function.
3006663|NCT02518737||Controls|Matched controls, with a normal functioning GIP-receptor.
3006664|NCT02518724|Active Comparator|RIPC intervention group|"The experiment protocol consist 2 series (with a month between them), both series include the described 3 days:~Day 1 - anthropometry measurements and VO2max test (BRUCE protocol). Day 2 - steps test (heled protocol). Day 3 - anaerobic test (wingate protocol), 1 hour rest and time to exhaustion test (heled protocol).~the second series will be performed after RIPC intervention exposure at the beginning of every meeting."
3006665|NCT02518724|Placebo Comparator|false exopsure group|"The experiment protocol consist 2 series (with a month between them), both series include the described 3 days:~Day 1 - anthropometry measurements and VO2max test (BRUCE protocol). Day 2 - steps test (heled protocol). Day 3 - anaerobic test (wingate protocol), 1 hour rest and time to exhaustion test (heled protocol).~the second series will be performed after placebo intervention exposure at the beginning of every meeting."
3006666|NCT02518711|Experimental|Behavioral teacher program|The behavioral teacher program was used by the participant's teacher in the classroom during 18 weeks.
3006667|NCT02518711|No Intervention|Control group|Children within the control group did not receive the behavioral teacher program but were allowed to receive regular care
3006668|NCT02518698||Cohort 1 / Treatment patterns|Patients with castrated resistant prostate cancer and bone metastases
3006669|NCT02518685|Experimental|TransPyloric Shuttle (TPS)|TransPyloric Shuttle plus lifestyle counseling
3006670|NCT02518685|Sham Comparator|Control|Sham procedure plus lifestyle counseling.
3006671|NCT02518672|Active Comparator|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
3006672|NCT02518672|Placebo Comparator|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
3006673|NCT02518659|Other|Inulin|Intervention by inulin, max 20gr per day
3006674|NCT02518659|No Intervention|No Inulin|Same Patients of arm inulin. Here the phase without inulin supplementation (own controls)
3040810|NCT02288481|Placebo Comparator|Cohort 2 placebo|Placebo Suspension
3006678|NCT02518607|Experimental|Group 1, Session 1, Active|"Lowest dose of SAD:~MGB-BP-3, 250 mg liquid filled enterically coated capsule, single dose"
3006679|NCT02518607|Experimental|Group 1, Session 2, Active|"Dose Escalation SAD:~MGB-BP-3, 2X250 mg liquid filled enterically coated capsule, single dose"
3006680|NCT02518607|Experimental|Group 1, Session 3, Active|Dose Escalation SAD MGB-BP-3, 3X250 mg liquid filled enterically coated capsules, single dose
3006681|NCT02518607|Experimental|Group 2, Session 1, Active|Dose Escalation SAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules, single dose
3006682|NCT02518607|Experimental|Group 2, Session 2, Active|Dose Escalation SAD MGB-BP-3, 5X250 mg liquid filled enterically coated capsules, single dose
3006683|NCT02518607|Experimental|Group 2, Session 3, Active|Dose Escalation SAD MGB-BP-3, 6X250 mg liquid filled enterically coated capsules, single dose
3006684|NCT02518607|Experimental|Group 3, Active|Lowest dose of MAD MGB-BP-3, 2X250 mg liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10
3006685|NCT02518607|Experimental|Group 4, Active|Dose Escalation MAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10
3006686|NCT02518607|Experimental|Group 5, Active|Dose Escalation MAD MGB-BP-3, 8X250 mg liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10
3006687|NCT02518607|Placebo Comparator|Group 1, Session 1, Placebo|"Lowest dose of SAD:~Placebo, 1 liquid filled enterically coated capsule, single dose"
3006688|NCT02518607|Placebo Comparator|Group 1, Session 2, Placebo|Placebo, 2 liquid filled enterically coated capsules, single dose
3006689|NCT02518607|Placebo Comparator|Group 1, Session 3, Placebo|Placebo, 3 liquid filled enterically coated capsules, single dose
3006690|NCT02518607|Placebo Comparator|Group 2, Session 1, Placebo|Placebo, 4 liquid filled enterically coated capsules, single dose
3006691|NCT02518607|Placebo Comparator|Group 2, Session 2, Placebo|Placebo, 5 liquid filled enterically coated capsules, single dose
3006692|NCT02518607|Placebo Comparator|Group 2, Session 3, Placebo|Placebo, 6 liquid filled enterically coated capsules, single dose
3006693|NCT02518607|Placebo Comparator|Group 3, Placebo|Placebo 2 liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10
3006694|NCT02518607|Placebo Comparator|Group 4, Placebo|Placebo 4 liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10
3006695|NCT02518607|Placebo Comparator|Group 5, Placebo|Placebo 8 liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10
3006696|NCT02518594|Active Comparator|Progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to < 35 wks
3006697|NCT02518594|Placebo Comparator|Placebo|placebo softgel capsule, daily from randomization to < 35 wks
3006698|NCT02518594|Active Comparator|Arabin Pessary|placement management from randomization to < 35 wks
3006699|NCT02518581|Other|Doubly labelled water|
3006700|NCT02518568|Experimental|Drug|
3006701|NCT02518555|Experimental|Arm A (concurrent vaccines and ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Patients also receive pneumococcal 13-valent conjugate vaccine IM on day 1 of courses 3 and 5 and trivalent influenza vaccine IM and DTaP vaccine IM on day 1 of course 4. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3006702|NCT02518555|Experimental|Arm B (sequential vaccines and ibrutinib)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 1 of courses 1 and 3 and trivalent influenza IM and DTaP vaccine IM on day 1 of course 2. Beginning in course 4, patients receive ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity.
3006703|NCT02518542|Active Comparator|Per oral endoscopic therapy A|Per oral endoscopic myotomy
3006704|NCT02518542|Active Comparator|Per oral endoscopic therapy B|Prolonged dilatation by implantation of large diameter stents.
3006705|NCT02518542|Active Comparator|Per oral endoscopic therapy C|Dilatation
3006706|NCT02518542|Active Comparator|Laparoscopic surgery|Laparoscopic Heller myotomy
3006707|NCT02518529|Experimental|250µg dose treatment|Subjects were treated with a 250mcg/0.2ml G17DT injection at weeks 0, 2 and 6.
3006708|NCT02518516||High potency statin users|Exposure will be defined as a new prescription for a high dose statin (rosuvastatin, high doses of atorvastatin, and high doses of simvastatin between 1 January 1997 and 30 of April 2008, or 1 year after the beginning of data availability.
3006709|NCT02518516||Low potency statin users|Exposure will be defined as a new prescription for a low dose statin (all doses of fluvastatin, all doses of pravastatin, all doses of lovastatin; low doses of atorvastatin and simvastatin) between 1 January 1997 and 30 of April 2008, or 1 year after the beginning of data availability.
3006710|NCT02518503||High potency statin users|Exposure will be defined as a new prescription for a high dose statin (high doses of rosuvastatin, high doses of atorvastatin, and high doses of simvastatin) between 1 January 1997 and 31 March 2011, or 1 year after the beginning of data availability.
3006711|NCT02518503||Low potency statin users|Exposure will be defined as a new prescription for a low dose statin (all doses of fluvastatin, all doses of pravastatin, all doses of lovastatin; low doses of atorvastatin and simvastatin) between 1 January 1997 and 31 of March 2011, or 1 year after the beginning of data availability.
3006712|NCT02518477|Experimental|exercise group|"The first 20 weeks, twice-weekly 60 minute session of physical exercise supervised by the research assistant and once weekly home exercise programme is offered. The exercise intervention will consist of stretching, scar tissue mobilization and resistance exercises.~For the following 32 weeks a home-training manual specifying three times weekly training is provided. At week 26 an individual booster session will be offered. In the case of lymphedema, referral to trained lymphedema physiotherapist for evaluation of appropriate intervention is made."
3006713|NCT02518477|No Intervention|usual care control group|Receives all standard care offered from the operating hospital and rehabilitation in the municipality.
3006748|NCT02518204|Experimental|NP, BPT|Conventional in-person neuropsychological assessments, followed by a 10 minute break, followed by a computerized assessment battery
3006749|NCT02518191|Experimental|GnRHa group|Eligible patients with breast cancer treated with GnRHa while receiving chemotherapy.
3006714|NCT02518464|Experimental|Ticagrelor 90 mg twice per day|Interventions include the following: All participants will have a loading dose of Ticagrelor (Brilinta) 180 mg administered in the office at the time of enrollment. Thereafter, for 28 days, Ticagrelor 90 mg tablet will be taken once in the morning and once in the evening, as close to 12 hours apart as possible. Each day, the subject will receive a text message reminder to login to the website, to record her/his headache activity.
3006715|NCT02518451|Experimental|(Test) Group I|Valsartan 160 mg film-coated caplets of PT Dexa Medica
3006716|NCT02518451|Active Comparator|(Reference) Group II|Valsartan 160 mg film-coated caplets (Diovan® 160)
3006717|NCT02518438|Active Comparator|the tramadol group|A preprepared 20 ml solution (tramadol 2 mgkg-1 within a 0.9% saline solution) was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
3006718|NCT02518438|Placebo Comparator|the placebo group|A preprepared 20 ml solution (0,9% saline solution) was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
3006719|NCT02518412|Experimental|Active tDCS|Participants receive active tDCS stimulation. Half of the participants receive active tDCS stimulation, i.e 30 minutes active stimulation of the temporal cortex.
3006720|NCT02518412|Placebo Comparator|Placebo tDCS|Participants receive placebo tDCS stimulation. Half of the participants receive placebo tDCS stimulation, i.e 30 minutes inactive stimulation of the temporal cortex.
3006721|NCT02518399|Experimental|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
3006722|NCT02518399|Sham Comparator|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
3006723|NCT02518373|Experimental|G17DT & Omeprazole|"A 14-day washout period~An Omeprazole Treatment Period 1 (Day -15 to Day -1)~A G17DT treatment period (Day 0 to Day 85)~An Omeprazole Treatment Period 2 (Day 86 to Day 100)"
3006724|NCT02518360|Experimental|OSTEOPATHIC PROTOCOL|"Physiotherapist applies an osteopathic treatment in non-specific low back pain patients.~The experimental group is treated with osteopathy, three sessions (20 minutes/session) and a frequency one session/week. Osteopathic treatment osteopathic is a body adjustment protocol. This protocol adjusts the musculoskeletal disorders since neck to lower limbs in the experimental group. Before treatment, immediately after the last session and a month later, are measured stabilometric parameters, height and Oswestry."
3006725|NCT02518360|Active Comparator|Auto Stretching|The patients realizes stretching protocol: two stretching global postures once a week (10 minutes for each posture) for three weeks: the first is for the anterior muscular chain and the second posture to stretch the posterior muscle chain. Before three stretching, immediately after the last session and a month later, are measured stabilometric parameters, height and Oswestry.
3006726|NCT02518347|Experimental|FDS-Strawberry|Freeze-dried strawberry powder (50g/d)
3006727|NCT02518347|Placebo Comparator|Placebo|Powder matched for carbohydrates and fiber in the strawberries
3006728|NCT02518334|Experimental|Alcohol consumption|Alcohol consumption and wine consumption
3006729|NCT02518321|Experimental|Standard Toileting First|This group will complete the standard toileting trial before the TAT toileting trial.
3006730|NCT02518321|Experimental|TAT Toileting First|This group will complete the TAT toileting trial before the standard toileting trial.
3006731|NCT02518308|Experimental|Arm I (MBSR intervention)|Patients undergo an 8-week MBSR course, comprising weekly 2.5 hour classes and one 6-hour Saturday class at week 6 or 7. The MBSR program involves instruction in mindfulness meditation and yoga, and gives homework assignments involving practicing the well-being techniques taught in class. Patients are required to record and report time spent on home practice in a journal daily, and receive a weekly reminder to report their home practice.
3006732|NCT02518308|No Intervention|Arm II (control)|Patients do not participate in the intervention, but are given the option to be placed on a waitlist for the MBSR course and may complete it within 6 months after the final study visit.
3006733|NCT02518295|Active Comparator|Positive control|Ultra high temperature (UHT) milk containing 18 g total lactose
3006734|NCT02518295|Active Comparator|Positive control with S. thermophilus|UHT milk containing 18 g total lactose+ S. thermophilus
3006735|NCT02518295|Active Comparator|Positive control with B. longum|UHT milk containing 18 g total lactose+ B. longum
3006736|NCT02518295|Placebo Comparator|Negative control|Lactose free milk
3006737|NCT02518269|Active Comparator|G7 MoP (Arcom XL) + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an Arcom Xl liner and a metal head
3006738|NCT02518269|Active Comparator|G7 MoP (E1) + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and will be operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an E1 liner and a metal head.
3006739|NCT02518269|Active Comparator|G7 CoC + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive a ceramic liner and a ceramic head
3006740|NCT02518256|Other|(Suspected) Ovarian Epithelial Cancer|Lavage of the Cavum uteri and proximal fallopian tubes
3006741|NCT02518243|Experimental|Alzheimer's Disease|
3006742|NCT02518230|Other|Neurally Adjusted Ventilatory Assist|Subject will be randomized to NAVA ventilation. Intervention is mechanical ventilation with Neurally Adjusted Ventilatory Assist for 12 hours.
3006743|NCT02518230|Other|Synchronized Interm. Mandatory Assist|Subject will be randomized to SIMV(PC)PS ventilation. Intervention is mechanical ventilation with Synchronized Intermittent Mandatory Assist with Pressure Support for 12 hours.
3006744|NCT02518217|Active Comparator|Apps Only|
3006745|NCT02518217|Experimental|ShapeUp Empower|
3006746|NCT02518217|Experimental|ShapeUp Empower + Incentives|
3006747|NCT02518204|Experimental|BPT, NP|Computerized assessment battery, followed by a 10 minute break, followed by conventional in-person neuropsychological assessments
3006750|NCT02518191|No Intervention|None GnRHa group|Eligible patients with breast cancer treated with GnRHa while receiving chemotherapy.
3006751|NCT02518178|Active Comparator|NFC Sticker|Participants will receive an NFC (Near Field Communication) sticker, placed on their existing immunization (MAMTA) card. This will serve as a comparator to the NFC necklace while still allowing for patient data to be digitized and utilized by the health service provider, Seva Mandir.
3006752|NCT02518178|Experimental|NFC Necklace|Participants will receive a necklace with an NFC pendant, which interfaces with the Khushi Baby mobile application to digitize the data. This arm will allow for the assessment of peer influence effects of the necklace as a social symbol.
3006753|NCT02518178|Experimental|NFC Necklace + Voice Reminder|In addition to the NFC necklace, mothers of the participants in this arm will receive dialect-specific voice call reminders, informing them about the next camp and the importance of vaccinations.
3006754|NCT02518165|Active Comparator|Proprietary spearmint extract|Subjects randomized into the active treatment group will be asked to consume 900 mg/day of the proprietary spearmint extract.
3006755|NCT02518165|Placebo Comparator|Microcrystalline cellulose|Subjects randomized into the placebo group will be asked to consume 900 mg/day of the excipient, microcrystalline cellulose.
3006756|NCT02518152|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating periodontal defect
3006757|NCT02518152|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating periodontal defect
3006758|NCT02518152|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate for treating periodontal defect
3006759|NCT02518139|Active Comparator|TD-4208-1|88 mcg
3006760|NCT02518139|Active Comparator|TD-4208-2|175 mcg
3006761|NCT02518139|Active Comparator|Tiotropium|18 mcg
3006762|NCT02518126||control|Women with IUGR embryos so that their fetal weight estimate puts them in a percentile bellow 10th percentile
3006763|NCT02518126||IUGR|Women with AGA embryos so that their fetal weight estimate puts them in a percentile between 20th and 80th percentiles
3006764|NCT02518113|Experimental|LY3039478 + Dexamethasone (Adult)|Part A: LY3039478 administered orally three times per week (TIW) at escalating doses and dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.
3006765|NCT02518113|Experimental|LY3039478 + Dexamethasone (Pediatric)|Part B: LY3039478 administered orally TIW at escalating doses and dexamethasone administered orally twice a day (BID) on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.
3006766|NCT02518113|Experimental|Phase 2: LY3039478 + Dexamethasone|LY3039478 administered orally TIW and dexamethasone administered orally BID on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.
3006767|NCT02518113|Placebo Comparator|Phase 2: Placebo + Dexamethasone|Placebo administered orally TIW and dexamethasone administered orally BID on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.
3006768|NCT02518100|Experimental|VSP 3-Lead Study Participants|"Intervention: Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration The participants of this arm will have the following vital signs taken and recorded by the VSP System in the 3-lead (NEHB) configuration:~Arterial blood oxygen Saturation (SpO2) ECG Heart Rate Surface Temperature Respiration"
3006769|NCT02518100|Experimental|VSP 1-Lead Study Participants|"Intervention: Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration. The participants of this arm will have the following vital signs taken and recorded by the VSP System in the 1-lead (PAL) configuration:~Arterial blood oxygen Saturation (SpO2) ECG Heart Rate Surface Temperature Respiration"
3006770|NCT02518087|Experimental|CPB-oXiris®|Non emergent cardiac surgery patients requiring expected CPB time > 60 minutes: double valve replacement or valve replacement plus coronary arterial bypass graft (CABG).
3006771|NCT02518087|No Intervention|CPB-Standard|Non emergent cardiac surgery patients requiring expected CPB time > 60 minutes: double valve replacement or valve replacement plus coronary arterial bypass graft (CABG).
3006772|NCT02518074|Other|HEARING AND VESTIBULAR INTERACTIONS|Hearing and Vestibular Interactions during two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
3006773|NCT02518048|Active Comparator|LEO 90100 Aerosol foam|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g (LEO 90100 Aerosol foam)
3006774|NCT02518048|Active Comparator|Betesil® 2.25 mg|Betamethasone (as valerate). Each 7.5 cm x 10 cm medicated plaster contains: 2.250 mg of betamethasone valerate (corresponding to 1.845 mg of betamethasone).(Betesil® )
3006775|NCT02518035|Placebo Comparator|Control|No silicone gel treatment after remove of stitches
3006776|NCT02518035|Experimental|Experimental|Silicone gel applied for twice per day
3006777|NCT02518022|Experimental|Intervention|For carbohydrates in beer, subjects will get covering by Insulin (1/2 of calculated amount). As well Insulin basal rate will set to half for 12 hours
3006778|NCT02518022|No Intervention|Standard|No Insulin Treatment of carbohydrates in beer.
3006779|NCT02518009||Men with gender dysphoria|Genetic men treated with estrogen
3006780|NCT02518009||Women with gender dysphoria|Genetic women treated with androgen
3006781|NCT02517996|Experimental|1% Lidocaine|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters 1% lidocaine after anesthesia induction.
3006782|NCT02517996|Placebo Comparator|Normal Saline|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
3006783|NCT02517983||Chronic respiratory disease|
3006784|NCT02517970|Experimental|Classical Music versus Television show|This is within-subject study; all infants will be exposed to both conditions. Order of presentation will counterbalanced across infants.
3006785|NCT02517957|Experimental|Qinzhuliangxue Keli|Qinzhuliangxue Keli(common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets placebo (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.)
3006786|NCT02517957|Active Comparator|loratadine tablets|Qinzhuliangxue Keli placebo (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.),Loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.).
3008721|NCT02504580|Experimental|Part B Cohort G|400 mg HTX-011B by instillation
3006787|NCT02517957|Active Comparator|Qinzhuliangxue and loratadine|Qinzhuliangxue Keli (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.).
3006788|NCT02517944||Familial hypercholesterolemia patients|"clinical data~biological data~cardiac and aortic RMI with gadolinium"
3006789|NCT02517944||Control group|"clinical data~biological data~cardiac and aortic RMI with gadolinium"
3006790|NCT02517931|Active Comparator|Sphenopalatine Ganglion Block|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. Sphenopalatine ganglion block will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
3006791|NCT02517931|Placebo Comparator|Placebo|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
3006792|NCT02517918|Experimental|Sirolimus combined with CP, MT and ZA|Drug : Metronomic Cyclophosphamide, Methotrexate, Sirolimus, Zoledronic acid Assessment of the maximum tolerated dose of sirolimus Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally. Zoledronic Acid will be administrated by infusion (IV).
3006793|NCT02517905|Experimental|Bupivacaine liposome|Subjects will receive a single dose of 133 mg (10 mL)
3006794|NCT02517905|Placebo Comparator|Placebo|Subjects will receive a single dose of placebo (normal saline, 10 mL)
3006795|NCT02517892|Experimental|Patients with metastatic oncogen-driven cancer|
3006796|NCT02517879|Experimental|Group 1 - 1-3 days|Community health worker hang-up visit 1-3 days after the community point distribution
3006797|NCT02517879|Experimental|Group 2 - 5-7 days|Community health worker hang-up visit 5-7 days after the community point distribution
3006798|NCT02517879|Experimental|Group 3 - 10-12 days|Community health worker hang-up visit 10-12 days after the community point distribution
3006799|NCT02517879|Experimental|Group 4 - 15-17 days|Community health worker hang-up visit 15-17 days after the community point distribution
3006800|NCT02517879|Placebo Comparator|Group 5 - No hang-up visit|Did not receive any hang-up visit after the community point distribution
3006801|NCT02517866|Experimental|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of <140/85 mmHg at Week 6.
3006802|NCT02517853|Experimental|Tibial nerve stimulation|Tibial nerve stimulation during 16 sessions
3006803|NCT02517853|Sham Comparator|Sham comparator|Sham tibial nerve stimulation during 16 sessions
3006804|NCT02517840||Nonagenarian CLI|Patients suffering from Critical Limb Ischemia aged 90 year-old or above who undergo limb revascularization by means of open surgery or endovascular revascularization
3006805|NCT02517827|Active Comparator|Endovascular procedure|Common femoral artery (target lesion) to be treated with directional atherectomy and paclitaxel-coated balloon angioplasty. Optional: stentimplantation.
3006806|NCT02517827|Active Comparator|Surgery|Common femoral artery (target lesion) to be treated with open, surgical endarterectomy
3006807|NCT02517814|Experimental|Patients with cardiomyopathy|Patients with vitamin D deficiency and cardiomyopathy will receive supplementation with vitamin D 400 units per day for 6 months.
3006808|NCT02517801|Experimental|Anthocyanin capsules|Chronic intake of 2 capsules for 30 days (2x daily)
3006809|NCT02517801|Placebo Comparator|placebo capsules|Chronic intake of 2 capsules for 30 days (2x daily)
3006810|NCT02517788|Experimental|Part A: Interferon beta-1a in HSA-free solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU biosimilar interferon beta-1a without albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
3006811|NCT02517788|Experimental|Part A: Interferon beta-1a combined with HSA+ solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU biosimilar interferon beta-1a with albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
3006812|NCT02517788|Active Comparator|Part A: Interferon beta-1a in marketed HSA+ solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU original interferon beta-1a with albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
3006813|NCT02517788|Experimental|Part B: Interferon beta-1a in HSA-free solution|Twelve additional volunteers will participate in part B, receiving 4 x 18 MIU biosimilar interferon beta-1a with albumin as s.c. doses at 48 hours intervals as 3 pre-filled syringes (3 sites 1 cm apart in abdominal wall on each dosing day, alternating right side for odd dose [i.e. dose 1 and 3] and left side for even dose [i.e. dose 2 and 4]).
3006814|NCT02517788|Active Comparator|Part B: Interferon beta-1a in marketed HSA+ solution|Part B: Twelve additional volunteers will participate in part B, receiving 4 x 18 MIU original interferon beta-1a with albumin as s.c. doses at 48 hours intervals as 3 pre-filled syringes (3 sites 1 cm apart in abdominal wall on each dosing day, alternating right side for odd dose [i.e. dose 1 and 3] and left side for even dose [i.e. dose 2 and 4]).
3006815|NCT02517775|Active Comparator|Cranberry 320|Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
3006816|NCT02517775|Active Comparator|Cranberry 640|Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
3006817|NCT02517775|Active Comparator|Cranberry 960|Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
3006818|NCT02517775|Active Comparator|Cranberry 1280|Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
3008722|NCT02504580|Placebo Comparator|Part C Cohort C|Saline Solution by instillation
3006819|NCT02517775|Active Comparator|Cranberry 1600|Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
3006820|NCT02517775|Placebo Comparator|Cranberry deprived supplement|Placebo comparator: Cranberry deprived supplement Acute intake of 500 mL (1x daily)
3006821|NCT02517762|Experimental|Stay active|Receive the advice by the physician to stay as active as possible in spite of the pain experienced
3006822|NCT02517762|Experimental|Adjust activity|Receive the advice by the physician to adjust the activity according to the pain, i.e. to avoid activities, movements or positions that cause or worsen the pain
3006823|NCT02517749|Active Comparator|Usual Care Group|Patients in this group will be managed as per the British Thoracic Society guideline for management of malignant pleural effusions. They will undergo chest tube insertion and undergo Talc pleurodesis with 4g of SteriTalc
3006824|NCT02517749|Active Comparator|Indwelling Pleural Catheter Group|Patients in this group will undergo Indwelling Pleural Catheter (IPC) insertion. This will be inserted as per standard practice. They will undergo Talc pleurodesis via the IPC with 4g SteriTalc
3006825|NCT02517736|Experimental|sorafenib at a dose of 800 mg / day|
3006826|NCT02517723|Experimental|SIC + NET|Waiting List + Standard Inpatient Care + Narrative Exposure Therapy
3006827|NCT02517723|Active Comparator|SIC + DBT|Waiting List + Standard Inpatient Care + Dialectical Behavior Therapy
3006828|NCT02517710|Placebo Comparator|Control|Group of patients receiving standard hysterotomy closure with synthetic braided suture
3006829|NCT02517710|Experimental|Stratfix|group of patients having the hysterotomy incision closed with barbed synthetic suture. Time to closure, blood loss, and postoperative pain
3006830|NCT02517697|Experimental|Active drug|14 Nitrogen (N) Sodium Nitrite 40mg three times daily (TID)
3006831|NCT02517697|Placebo Comparator|Placebo|placebo capsules three time daily (TID)
3006832|NCT02517684|Experimental|Top-down|Infliximab and azathioprine; patients will receive 5 infliximab infusions of 5 mg/kg (IFX induction at week 0, 2 and 6, followed by 2 maintenance infusions every 8 weeks). IFX will be discontinued after 5 IFX infusions. Patients will also receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
3006833|NCT02517684|Active Comparator|Step-up|Step-up treatment will consist of standard induction treatment by either oral prednisolone 1 mg/kg (maximum 40 mg) once daily for 4 weeks, followed by tapering in 6 weeks until stop, or EEN with polymeric feeding for 6-8 weeks after which normal foods are gradually reintroduced within 2-3 weeks. Either of these induction treatments will be combined with oral AZA 2-3 mg, once daily, as maintenance treatment.
3006834|NCT02517671|Other|EECP Treatment|35 one hour (1hr) sessions of Enhanced External Counterpulsation (EECP).
3006835|NCT02517658|Active Comparator|Standard Discharge Teaching|Parents will receive standard discharge teaching from the nurse prior to discharge.
3006836|NCT02517658|Experimental|Video w/ post exam immediately after video|Parents will watch the video and then take the post test immediately after watching the video.
3006837|NCT02517658|Experimental|Video w/ post exam after discharge teaching|Parents will watch the video but wait to take the post exam until after the discharge instructions are given by the nurse prior to discharge.
3006838|NCT02517632|Experimental|Exercise group|This arm will be submitted to a exercise session and counseling from pharmaceutical and nutritional professionals.
3006839|NCT02517632|Other|Control group|This arm will have only the counseling from pharmaceutical and nutritional professionals.
3006840|NCT02517619|Experimental|Dexamethasone Phosphate Ophthalmic Solution|Dexamethasone phosphate ophthalmic solution (40 mg/mL)
3006841|NCT02517619|Active Comparator|Prednisolone Acetate Ophthalmic (1%)|Prednisolone Acetate Ophthalmic (1%)
3006842|NCT02517606|Experimental|Conventional physical therapy plus HPCS|Conventional physical therapy (Combination of manual therapy techniques and exercises for spinal segmental stabilization) plus the addition of hip posterolateral complex strengthening (HPCS)
3006843|NCT02517606|Active Comparator|Conventional physical therapy|Conventional physical therapy (Combination of manual therapy techniques and exercises for spinal segmental stabilization)
3006844|NCT02517593|Other|PRS|Providing polygenic risk score (PRS)
3006845|NCT02517580|Experimental|Vitamin K2 (MK7)|Vitamin K2 (MK7) 360 mcg/day PO once daily for 8 weeks
3006846|NCT02517567|Other|Sequence 1|Delefilcon A, then narafilcon A, then somofilcon A, then no lens wear. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
3006847|NCT02517567|Other|Sequence 2|Narafilcon A, then no lens wear, then delefilcon A, then somofilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
3006848|NCT02517567|Other|Sequence 3|Somofilcon A, then delefilcon A, then no lens wear, then narafilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
3006849|NCT02517567|Other|Sequence 4|No lens wear, then somofilcon A, then narafilcon A, then delefilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
3006850|NCT02517554||Remote cancer genetic services by videoconference|
3006851|NCT02517554||Remote cancer genetic services by telephone|
3006852|NCT02517554||Usual Care|
3006853|NCT02517541|Experimental|Test period|The arm consists of a two-week baseline period where subjects apply their own product and a 12 weeks test period where the subjects apply the intervention (SenSura Mio Convex Soft)
3006854|NCT02517528|Experimental|ABT-450/r/ABT-267 + ABT-333 + Ribavirin|ABT-450/r/ABT-267 once daily + ABT-333 twice daily + weight-based RBV divided twice daily for 12 weeks
3006855|NCT02517515|Experimental|Double-blind 3-DAA|Double-blind 3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
3006856|NCT02517515|Experimental|Double-blind Placebo Followed by Open-label 3-DAA|Double-blind placebo for 12 weeks, followed by open-label 3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
3006857|NCT02517502|Experimental|DHA|Participants will be asked to take four 400 mg (1600 mg; 1.6 grams) capsules of DHA daily. Participants will start taking capsules before the start of and for the duration of their neoadjuvant chemotherapy.
3007094|NCT02515942|Experimental|CLG561+LFG316|CLG561+LFG316, one IVT injection every 28 days for a total of 12 injections
3006858|NCT02517502|Placebo Comparator|Placebo|Participants will be asked to take four 400 mg (1600 mg; 1.6 grams) capsules of a matched placebo daily. Participants will start taking capsules before the start of and for the duration of their neoadjuvant chemotherapy.
3006859|NCT02517489|Experimental|Hydrocortisone|Patients in the treatment group will receive intra-venous hydrocortisone (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)
3006860|NCT02517489|Placebo Comparator|Placebo|Patients of the control group will receive an intravenous placebo by intravenous route (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)
3006861|NCT02517476|Experimental|Nutritional support|For the purpose of this study, we have developed nutritional guidelines by consensus and adapted to current guidelines (e.g., ESPEN, ASPEN). These guidelines specify a reinforced nutritional therapy strategy to cover nutritional requirements, focusing on nutritional targets based on the specific nutritional diagnoses defined by the IDNT. The nutritional guidelines may vary according to important medical diagnoses (i.e. renal failure). They specify not only nutritional targets, but also escalation of the route (i.e. food fortification, oral, enteral, parenteral) if targets cannot be achieved (≤75%) every 5 hours. Nutritional goals are being assessed daily in patients in the intervention group.
3006862|NCT02517476|No Intervention|"Usual care (appetite-guided) controls"|"In control patients, we will use conventional nutrition according to the ability and desire of the patient to eat, using standard care food provided by the hospital kitchen (appetite-guided)."
3006863|NCT02517463||Pre-ovulatory|Ulipristal acetate 30 mg single oral dose
3006864|NCT02517463||Post-ovulatory|Ulipristal acetate 30 mg single oral dose
3006865|NCT02517450|Experimental|experimental group|The subjects had to participate an adventure-based training programme.
3006866|NCT02517450|Placebo Comparator|placebo control group|The subjects had to participate a placebo control programme
3006867|NCT02517437|Active Comparator|Suprascapular & axillary blocks|Suprascapular and axillary blocks.
3006868|NCT02517437|Active Comparator|Interscalene block|Interscalene block.
3006869|NCT02517424|Experimental|High THC/Low CBD Cannabis|Investigational product will be administered via vaporization up to 2 grams per day as needed.
3006870|NCT02517424|Experimental|High THC/High CBD cannabis|Investigational product will be administered via vaporization up to 2 grams per day as needed.
3006871|NCT02517424|Placebo Comparator|Low THC/Low CBD cannabis|Product will be administered via vaporization up to 2 grams per day as needed.
3006872|NCT02517411|Experimental|Experimental group|COPD patients with stable disease will be recruited and they will receive physiotherapy added to standard care.
3006873|NCT02517411|Other|Control group|COPD patients with stable disease will be recruited and they will receive standard care.
3006874|NCT02517398|Experimental|MSB0011359C (M7824)|
3006875|NCT02517385|Experimental|Phosphatidylcholine paste|One dose of phosphatidylcholine paste 600 mg given orally 3 times a day at Days 0, 28, 56, and 84
3006876|NCT02517372|Active Comparator|Cohorte 1|"Low dose pemirolast sodium (CRD007) given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
3006877|NCT02517372|Active Comparator|Cohorte 2|"Medium dose CRD007 given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
3006878|NCT02517372|Active Comparator|Cohorte 3|"High dose CRD007 given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
3006879|NCT02517359|Experimental|Single dose, healthy volunteers|
3006880|NCT02517359|Experimental|14 day repeat dose, healthy volunteers|
3006881|NCT02517359|Experimental|28 day repeat dose, healthy volunteers|
3006882|NCT02517359|Experimental|14 day repeat dose, asthma patients|
3006883|NCT02517359|Experimental|14 day repeat dose, smokers|
3006884|NCT02517346|Active Comparator|Standard follow up-Sleep Unit|Patients diagnosed as OSA, treated with CPAP and followed up in sleep unit
3006885|NCT02517346|Experimental|Telemonitoring|Patients diagnosed as OSA and treated with CPAP in sleep unit, followed up by telemonitoring system
3006886|NCT02517333|Other|Proof-of-principle (PoP)|"Proof-of-principle phase of the study. All participants undergo the exercise intervention as part of the feasibility.~Screen within Year 9 Class~Targeted recruitment for those scoring in bottom 5th percentile~Invite students to take part in 6-week intervention~Enroll students participating~Pre-intervention assessment~Start 6-week Epic Club gym intervention (1-2 times weekly for 45-60 mins) consisting of 30 min cardiovascular exercise and 25-30 min strength/resistance and weight training~Post-intervention assessment~Exit to longer-term sport/physical activity"
3006887|NCT02517320|Experimental|MT-3995 Low|
3006888|NCT02517320|Experimental|MT-3995 Middle|
3006889|NCT02517320|Experimental|MT-3995 High|
3006890|NCT02517320|Placebo Comparator|Placebo|
3006891|NCT02517307|Experimental|glycerol/saline|Glycerol/Saline infusion
3006892|NCT02517307|Experimental|intralipid|Intralipid/Heparin infusion
3006893|NCT02517294|Active Comparator|standard nasotracheal tube|Nasotracheal intubation using 'standard' side-beveled nasotracheal tubes
3006894|NCT02517294|Active Comparator|Parker flex-tip nasotracheal tube|Nasotracheal intubation using 'experimental' flex-tip midline-beveled nasotracheal tubes
3006895|NCT02517281|Experimental|Patients having received targeted therapies|Patients treated using targeted therapies
3006896|NCT02517268|Active Comparator|Standard 7-Day Pathway|Patients follow the standard 7-day pathway following pancreaticoduodenectomy
3006897|NCT02517268|Experimental|Accelerated 5-Day Pathway|Patients follow the Whipple accelerated 5-day pathway following pancreaticoduodenectomy. The accelerated pathway includes more rapidly leaving the ICU setting, early mobilization and enhanced physical therapy, multimodal pain control, dietary modifications, and increased and standardized phone contact by a nurse practitioner during the first week following hospital discharge.
3006898|NCT02517255|Experimental|Cardiac Magnetic Resonance Imaging|Cardiac MRI will be performed within 7 days of rescue percutaneous coronary intervention (PCI) and after 3 and 6 months.
3006899|NCT02517242|Experimental|Pens Device|All patients will receive pens device, insulin, blood glucose monitor, lancet tapes, capillary blood glucose tests (3 tests/day). All will be evaluated monthly for six months
3008723|NCT02504580|Active Comparator|Part C Cohort D|0.25% bupivacaine hydrochloride injection
3006900|NCT02517242|Active Comparator|Syringe|All patients will receive syringe to insulin, insulin, blood glucose monitor, lancet tapes, capillary blood glucose tests (3 tests/day). All will be evaluated monthly for six months
3006901|NCT02517229|Other|in balance control in response to microgravity|to evaluate changes in balance control in response to microgravity during reactive balance tasks compared to normal gravity.
3006902|NCT02517216|Other|parabolic flight and MRI scans|
3006903|NCT02517190|Other|Stress response measurements|
3006904|NCT02517177|Other|Cardiovascular parameters measurements|
3006905|NCT02517164||Fallers|patients aged 50 years and over who already fell
3006906|NCT02517164||At risk of falls|patients aged 50 years and over at risk of falls
3006907|NCT02517151|Experimental|Ferric carboxymaltose|200 mg in normal saline (NS) 100 ml administered i.v. at day 0 and then every 4 weeks up to week 24.
3006908|NCT02517151|Placebo Comparator|Placebo|normal saline (NS) 100 ml administered i.v. at day 0 and then every 4 weeks up to week 24.
3006909|NCT02517138|Other|Measurements of eye movements and perception|
3006910|NCT02517125|Experimental|Patients with head and neck cancer|
3006911|NCT02517112|Other|Cardiovascular parameters measurements|
3006912|NCT02517099|Active Comparator|Pathological phenotype|Regular inhaled steroids- Beclometasone dipropionate 200mcg bd for 4 months OR antibiotic therapy- Co- amoxiclav (0.3ml/kg bd) or Azithromycin (10mg/kg od) for 4 weeks
3006913|NCT02517099|Active Comparator|Clinical guidelines|The children will be treated as directed by their Consultant Paediatrician. The treatment may include- regular inhaled steroids- beclometasone dipropionate 200mcg bd for 4 months OR antibiotic therapy- Co-amoxiclav (0.3ml/kg bd) or Azithromycin (10mg/kg od) for 4 weeks
3006914|NCT02517086|Active Comparator|therapeutic exercises|The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
3006915|NCT02517086|Active Comparator|elastic compression|exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
3006916|NCT02517086|Active Comparator|functional compressive bandaging|exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
3006917|NCT02517060||Healthy participants|Male or female healthy participants
3006918|NCT02517047|Experimental|CareTRx Device|Subject will receive CareTRx device for rescue inhaler as well as the application downloaded to their Android phone. The device will track when the rescue inhaler is administered. The information will then be loaded to phone app.
3006919|NCT02517034|Experimental|Arm I (geriatric assessment-driven treatment)|Patients follow an intervention plan created by the NP using the results of the geriatric assessment. The NP discusses the results of the assessment and treatment recommendations with the patient. They also share the treatment plan, proposed referrals, and specific vulnerabilities with the Primary Care Physician and community oncologist. Some patients complete the intervention plan via Telehealth, which uses telecommunication technology to provide health services over a distance.
3006920|NCT02517034|Active Comparator|Arm II (standard of care)|Patients follow a standard of care treatment plan at the discretion of the primary oncologist. Beginning 6 months from the start of chemotherapy, patients undergo the geriatric assessment as in Arm I. Some patients complete the standard of care treatment plan via Telehealth.
3006921|NCT02517021|Experimental|Pro-netupitant/Palonosetron plus Dexamethasone|Intravenous Pro-netupitant/Palonosetron (260 mg/0.25 mg) powder for solution for infusion (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
3006922|NCT02517021|Active Comparator|Netupitant/Palonosetron plus Dexamethasone|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
3006923|NCT02517008|Experimental|Mama kits intervention|"Health facilities randomized to this arm provided mama kits - packages of childcare materials including a cloth (chitenge), baby blanket, and diaper - to all mothers who delivered at these facilities between June 1, 2013 - Aug 31, 2013."
3006924|NCT02517008|No Intervention|No intervention|Health facilities randomized to this arm provided obstetric services as normal.
3006925|NCT02516995|Experimental|Patients with prostate cancer|
3006926|NCT02516982||Screening - Scrolling layout|"Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:~Section 1: Demographic information survey~Section 2: Whooley questions~Section 3: Edinburgh Postnatal Depression Scale~All questions will be presented on a single screen. This means that participants will have to scroll vertically in order to answer all the questions."
3006927|NCT02516982||Screening - Paging layout|"Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:~Section 1: Demographic information survey~Section 2: Whooley questions~Section 3: Edinburgh Postnatal Depression Scale~Only one question will be presented at any given time. This means that participants will have to navigate through multiple pages in order to answer all the questions."
3006928|NCT02516982||Retrospective plus momentary assessment|Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of 6 consecutive days, once a month for 6 months. During the 6 assessment days, participants will be required to complete the Edinburgh Postnatal Depression Scale, 5 momentary questions on a 5-point pictorial scale, and 2 contextual questions.
3006929|NCT02516982||Retrospective assessment|Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of one day a month for 6 months. The assessment days will consist of a single administration of the Edinburgh Postnatal Depression Scale.
3006958|NCT02516813|Experimental|Phase Ia Arm A: MSC2490484A +Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 10 times, for two consecutive weeks in concomitance with fractionated radiotherapy (RT) (5 fractions /week).
3006930|NCT02516969|Experimental|Stereotactic Body Radiotherapy|Subjects will receive Stereotactic Body Radiotherapy at the following levels: Treatment Volumes <25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.
3006931|NCT02516956|Experimental|Breakfast meal 1|"Breakfast meal 1 is isocaloric (330 kcal) and similar for protein and fiber contents in relation to the other two experimental breakfasts. It has the same sugar and lipid profiles as Breakfast meal 2 and health-related cognitive perception as Breakfast meal 3.~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
3006932|NCT02516956|Experimental|Breakfast meal 2|"Breakfast meal 2 is isocaloric (330 kcal) and balanced for protein and fiber contents with regard to the other two experimental breakfasts. It has the same sugar and lipid profiles as Breakfast meal 1 but a higher health-related cognitive perception than the other two experimental breakfasts.~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
3006933|NCT02516956|Experimental|Breakfast meal 3|"Breakfast meal 3 is isocaloric (330 kcal) and similar for protein and fiber contents in relation to the other two experimental breakfasts. It has the same health-related cognitive perception as Breakfast meal 1 but lower lipid and higher sugar amounts than the other two experimental breakfasts.~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
3006934|NCT02516956|Placebo Comparator|Breakfast meal 4|"Breakfast meal 4 is a non-caloric meal representing fasting condition (control arm).~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
3006935|NCT02516943|Active Comparator|Control|The patient were retrospectively included according to the last digit of their admission number (odd number). The had arterial blood gas analysis every 4 hour during the ICU stay.
3006936|NCT02516943|Active Comparator|Guideline|The patient were prospectively included and they had arterial blood gas analysis following the pathological- based guidelines for arterial blood gas analysis in patients aftercardiac surgery
3006937|NCT02516930|Other|Crowdsourced video|One-minute crowd-sourced video promoting condom use among men who have sex with men and transgender individuals.
3006938|NCT02516930|Other|Social marketing video|One-minute social marketing video promoting condom use among men who have sex with men and transgender individuals
3006939|NCT02516917|Experimental|Attention Training Technique (ATT)|Participants will receive 3-5 sessions of the ATT over a period of 3-5 weeks. A set of standardised instructions will be read to each participant and then they will engage in the procedure for a period of 12 minutes. Participants will listen to a set of auditory stimuli and follow the directions of the recording. This will ask them to focus their attention on selected sounds or spatial locations, switch attention between different sounds and locations, before allocating their attention to all sounds simultaneously. Participants will be given a recording of the ATT on a C.D and asked to practice this at least once before the second session.
3006940|NCT02516904|Experimental|CD101 IV|single intravenous infusion ascending dose
3006941|NCT02516904|Placebo Comparator|Placebo|normal saline
3006942|NCT02516891|Experimental|hydrophilic wire/Drug-Eluting Stents|Will include 100 patients with coronary bifurcation lesions in that they will be treated with stents and in which the technique is used jailed guide.
3006943|NCT02516891|No Intervention|Non hydrophilic wire/Drug-Eluting Stents|Will include 100 patients with coronary bifurcation lesions in that they will be treated with stents and in which the technique is used jailed guide.non hydrophilic guide.
3006944|NCT02516878|Experimental|Acupuncture group|"Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated."
3006945|NCT02516878|Sham Comparator|Control group|"For subjects assigned to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to serve as sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin instead of insertion.~The Semen Vaccariae embedded tape used in treatment group will be applied on 4 non-acupoints at the helix unilaterally, retained until the next visit and then the alternate ear will be used."
3006946|NCT02516865|Experimental|Group 1|
3006947|NCT02516865|Experimental|Group 2|
3006948|NCT02516865|No Intervention|Group 3|
3006949|NCT02516852|Experimental|Intervention|
3006950|NCT02516852|No Intervention|Control|
3006951|NCT02516839|Experimental|Regulation of Cues (ROC)|The ROC program provides psychoeducation, coping skills, self-monitoring and experiential learning.
3006952|NCT02516839|Experimental|Behavioral Weight Loss (BWL)|The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
3006953|NCT02516839|Experimental|BWL+ ROC|BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments.
3006954|NCT02516839|Active Comparator|Nutrition Education, Stress Management Social Support|Nutrition Education, Stress Management and Social Support will be covered. Mindfulness will be practiced in every session.
3006955|NCT02516826|Experimental|Rosuvastatin Arm|Rosuvastatin 10mg in combination with placebo of Olmesartan 20mg plus placebo of Olmesartan/Rosuvastatin(Combination) 20/10mg orally once daily
3006956|NCT02516826|Experimental|Olmesartan Arm|Olmesartan 20mg in combination with placebo of Rosuvastatin 10mg plus placebo of Olmesartan/Rosuvastatin(Combination) 20/10mg orally once daily
3006957|NCT02516826|Experimental|Combination Arm|Olmesartan/Rosuvastatin(Combination) 20/10mg in combination with placebo of Rosuvastatin 10mg plus placebo of Olmesartan 20mg
3007095|NCT02515942|Sham Comparator|Sham Injection|One sham injection every 28 days for total of 12 sham injections
3040811|NCT02288481|Experimental|Cohort 3 60 mg TBA-354|
3006959|NCT02516813|Experimental|Phase Ia Arm B: MSC2490484A+Fractionated RT|Subjects will receive MSC2490484A capsule once daily up to 35 times, for 7 consecutive weeks in concomitance with fractionated RT and Cisplatin (5 fractions/week).
3006960|NCT02516813|Experimental|Phase Ib Arm A Expansion: MSC2490484A+Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 35 times in concomitance with fractionated RT (5 fractions /week).
3006961|NCT02516813|Experimental|Phase Ib Arm B Expansion: MSC2490484A+Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 35 times in concomitance with fractionated RT (5 fractions /week) and cisplatin.
3006962|NCT02516813|Experimental|cPOP: MSC2490484A+Fractionated RT|Clinical proof-of-principle (cPOP) study, subjects will receive MSC2490484A capsule (this dose will be administrated 1 day after the first dose of RT on Day 1 and within 1.5 hour before the second single high dose of RT on Day 2.
3006963|NCT02516800||Aortic valve calcification|Patients with calcific aortic valve disease, age = 65 years or below
3006964|NCT02516800||Control group|Matched control group
3006965|NCT02516787|Other|EEG and NIRS measurements|
3006966|NCT02516774|Experimental|Dose escalation|Adalimumab will be administrated subcutaneously 1h prior to chemotherapy at D1W1, D1W3, D1W5, D1W7, and D1W9, starting with the chemotherapy for a total duration of 9 weeks (5 injections in total)
3006967|NCT02516761|Experimental|Low-impact aerobic exercise combined with music therapy|Intervention consists in working the muscles which are mostly affected by fibromyalgia through group exercises, which are dynamic, smooth and aim functionality. This exercise is done to the rhythm of melodic music, adapted to the tastes of the participants and also adapted on the way to perform the exercise.
3006968|NCT02516761|Experimental|Low-impact aerobic exercise|Then intervention is like the previous group but with the difference that physical activity is not performed to the rhythm of chosen melodic music. Therefore, exercises are done with general chill-out music throughout the session, without adaptation of the exercise to the music.
3006969|NCT02516761|Active Comparator|Control group|With this group no intervention is done, but they are assessed like the other groups.
3006970|NCT02516735|Experimental|Group 1|I-scan with magnification targeted biopsies for gastric intestinal metapalsia.
3006971|NCT02516735|Active Comparator|Group 2|Standard endoscopy with a standard biopsy protocol from the five standard biopsy sites following the updated Sydney System including two from the distal antrum (within 2-3cm from the pylorus, greater/lesser curvature), one from the incisura and two from the mid corpus (greater/lesser curvature).
3006972|NCT02516722|Experimental|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
3006973|NCT02516696|Experimental|BiRD treatment regimen|Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles.
3006974|NCT02516696|Active Comparator|Rd treatment regimen|Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles.
3006975|NCT02516683||Shigella sonnei-exposed cohort|Shigella sonnei infection - A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
3006976|NCT02516683||control cohort|A control cohort of age and sex-matched, non-infected 105 contemporary hospital employees.
3006977|NCT02516670|Experimental|Arm A (docetaxel, ascorbic acid)|Patients receive docetaxel IV on day 1 and ascorbic acid IV twice weekly. The first ascorbic acid treatment will be given on day 1 (same day as docetaxel). Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
3006978|NCT02516670|Placebo Comparator|Arm B (docetaxel, placebo)|Patients receive docetaxel IV on day 1 and placebo IV twice weekly.The first placebo treatment will be given on day 1 (same day as docetaxel). Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
3006979|NCT02516657||Liraglutide 0.6 mg|Liraglutide 0.6 mg daily injection x 7 days
3006980|NCT02516644|Experimental|Virtual reality|Xbox Kinect + treadmill training
3006981|NCT02516644|Active Comparator|Conventional Therapy|Specific conventional training for Parkinson's Disease
3006982|NCT02516631|Active Comparator|Oral (A)|One tablet of Angusta™ (25 µg) or 1/8 of a tablet of Cytotec® (25 µg).
3006983|NCT02516631|Active Comparator|Oral (B)|Two tablets of Angusta™ 25 µg or ¼ of a tablet of Cytotec®.
3006984|NCT02516631|Active Comparator|Sublingual (C)|Two tablets of Angusta™ (total dose of 50 µg) or ¼ of a tablet of Cytotec® (50 µg.
3006985|NCT02516618|Experimental|Cohort 1|Participants in this cohort will receive dose 1 of Fasinumab or placebo
3006986|NCT02516618|Experimental|Cohort 2|Participants in this cohort will receive dose 2 of Fasinumab or placebo
3006987|NCT02516618|Experimental|Cohort 3|Participants in this cohort will receive dose 3 of Fasinumab or placebo
3006988|NCT02516618|Experimental|Cohort 4|Participants in this cohort will receive dose 4 of Fasinumab or placebo
3006989|NCT02516618|Experimental|Cohort 5|Participants in this cohort will receive dose 5 of Fasinumab or placebo
3006990|NCT02516605|Experimental|LJN452|
3006991|NCT02516605|Placebo Comparator|Placebo|
3006992|NCT02516592|Experimental|QVA149 110/50 micrograms|QVA149 110/50 micrograms o.d. Capsules for inhalation
3006993|NCT02516592|Active Comparator|salmeterol/fluticasone 50/500 micrograms|salmeterol/fluticasone 50/500 micrograms b.i.d. Dry inhalation powder
3006994|NCT02516566|Experimental|PEEP group|Mechanical ventilation with PEEP 8 cmH2O
3006995|NCT02516566|No Intervention|No PEEP group|Mechanical ventilation with no PEEP
3006996|NCT02516553|Experimental|arm A|once daily continuous oral intake in 3-week cycles
3006997|NCT02516553|Experimental|arm B|once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles
3006998|NCT02516540|No Intervention|Control|Study participants are instructed regarding a healthy diet according to the recommendations of the German Nutrition Society (DGE) and are informed about positive effects of physical activity on incidence and prognosis of breast cancer
3007096|NCT02515929|Experimental|Oligomeric Proanthocyanidins|90 mg exocian cran 408 plus 120mg Vitamin C, 1 tablet by mouth, every 24 hours for 21 days
3006999|NCT02516540|Experimental|Intervention|Structured exercise training plus mediterranean diet: Study participants receive a lifestyle intervention of 12 months duration (3 months intensive intervention plus 9 months maintenance using monthly contacts and meetings). The intervention comprises a structured intensified training based on the results of physical performance diagnostics and a nutrition program based on a mediterranean diet.
3007000|NCT02516527|Experimental|Induction Phase:Ipilimumab|Ipilimumab dose as specified
3007001|NCT02516527|Experimental|Maintenance Phase:Ipilimumab|Ipilimumab dose as specified
3007002|NCT02516514|Experimental|Multi-sampling strategy|2 or 3 blood cultures in 24 hours worked at ½ hour intervals with seeding at least a pair of flasks, aerobic and anaerobic, by blood culture.
3007003|NCT02516514|Active Comparator|Single-sampling strategy|1 single dose of venous blood 30ml ± 10ml with seeding 4 blood culture bottles (aerobic and anaerobic 2 2).
3007004|NCT02516501|Active Comparator|Control|Control group that will not receive advice to follow a ketogenic diet or reduce carbohydrates.
3007005|NCT02516501|Experimental|Intervention group 1|Patients who will receive each radiotherapy (RT) fraction after an overnight fast and subsequently ingest a ketogenic breakfast consisting of (i) up to 250 ml of a medium chain triglyceride drink (betaquik, vitaflo) plus (ii) 10g amino acids (MyAmino, dr. reinwald gmbh + co kg).
3007006|NCT02516501|Experimental|Intervention group 2|Patients who will follow a ketogenic diet throughout the whole period of RT, Patients don't have to fast prior to each RT fraction, but will receive MyAmino analogous to Intervention group 1.
3007007|NCT02516475|Active Comparator|zinc sulfate|1 zinc sulfate capsule for 15 weeks
3007008|NCT02516475|Placebo Comparator|starch|1 corn starch capsule for 15 weeks
3007009|NCT02516462|Experimental|IVM|Immature oocytes recovered from each subject will be placed into IVM media for maturation.
3007010|NCT02516449|Experimental|Patient decision aids|Participants read and fill a patient decision aid before being provided education on asthma.
3007011|NCT02516449|No Intervention|Usual care|Participants do not read and fill a patient decision aid before being provided education on asthma.
3007012|NCT02516436|Experimental|BEMA Buprenorphine NX|Buprenorphine with naloxone in a buccal film
3007013|NCT02516436|Active Comparator|Buprenorphine|Buprenorphine in a buccal film
3007014|NCT02516423|Experimental|ixazomib + lenalidomide + dexamethasone + zoledronic acid|Patients receive 4 mg ixazomib by mouth on days 1, 8 and 15. Patients also receive 15 mg lenalidomide by mouth on days 1-21, 12 mg dexamethasone by mouth on days 1, 8, 15, and 22 and zoledronic acid (dose based on creatinine clearance on day 1) IV infusion on day 1. Patients receive treatment every 28 days for a maximum of 6 cycles.
3007015|NCT02516423|Active Comparator|zoledronic acid|Patients receive zoledronic acid (dose based on creatinine clearance on day 1) IV on day 1. Patients receive treatment every 28 days for a maximum of 6 cycles.
3007016|NCT02516410|Experimental|VX-661/IVA|VX-661 100 milligram (mg) plus IVA 150 mg fixed dose combination (FDC) tablet administered orally in the morning and IVA 150 mg film-coated tablet administered orally in the evening up to Week 12.
3007017|NCT02516410|Placebo Comparator|Placebo|Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA film-coated tablet administered orally in the evening up to Week 12.
3007018|NCT02516397|Experimental|Omnia group|After 2 weeks of run-in period, subjects take 2 Omnia pills per meal (3 meals a day) for 12 weeks.
3007019|NCT02516397|Placebo Comparator|Placebo group|After 2 weeks of run-in period, subjects take 2 Placebo pills per meal (3 meals a day) for 12 weeks.
3007020|NCT02516384|Experimental|Fecal Microbiota Transplantation|Individuals with Ulcerative Colitis will undergo a fecal microbiota transplantation.
3007021|NCT02516371|Other|lymphocytes|To evaluate the subpopulation of lymphocytes in cancer patients
3007022|NCT02516345|Active Comparator|Child-based Incentive (CBI)|"Children earn rewards each week (with the week beginning on Monday and ending on Sunday) that they log 10,000 daily steps on the Fitbit according to the schedule below and their matched parent logs at least 2,000 steps on ≥4 of 7 days each week (regardless of which 4 of the 7 days they wear it). Incentives are tied, in addition to child's activity, to parent's Fitbit wear so that the investigators are better able to capture parent's activity in this arm.~Step Targets for Children in CBI arm:~Months 1 - 3: ≥10,000 daily steps on ≥4 out of 7 days each week~Months 4 - 6: ≥10,000 daily steps on ≥5 out of 7 days each week~Months 7 - 12: ≥10,000 daily steps on ≥6 out of 7 days each week"
3007023|NCT02516345|Experimental|Family-based Incentive (FBI)|"Children earn rewards each week that they log daily steps on the Fitbit according to the schedule below but only if their matched parent also logs 10,000 steps according to the schedule below. Otherwise, children earn no incentive for that week.~Step targets for children and parents in FBI arm:~Months 1 - 3: ≥10,000 daily steps on ≥4 out of 7 days each week~Months 4 - 6: ≥10,000 daily steps on ≥5 out of 7 days each week~Months 7 - 12: ≥10,000 daily steps on ≥6 out of 7 days each week"
3007024|NCT02516332|Experimental|Supervised Aerobic Exercise|Patients will exercise three times per week, under medical supervision, at a level of 70-85% of their VO2peak as determined at the time of their baseline exercise stress test. Patients' exercise will consist of 10 minutes of gradual warm-up exercises followed by 35 minutes of continuous walking, biking, or jogging, and 5 minutes of cool down exercises for a total a 50 minutes per session. Patients will be instructed to monitor their radial pulses and will be checked at least three times per session to ensure that they are within their prescribed exercise training ranges.
3007025|NCT02516332|Experimental|Lexapro|Treatment in the medication will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service. The investigators will use the SSRI escitalopram (Lexapro), which has received FDA approval for the treatment of anxiety, in 5 mg capsules. Medication will be dispensed as capsules of escitalopram in individually coded bottles. Medication adherence will be assessed using pill count at each study visit. Patients will visit face-to-face with a study psychiatrist at week 0 (baseline), week 1, week 2, week 4, week 8, and week 12 with phone encounters at weeks 3 and 6. The psychiatrist will make all medication adjustments based primarily upon Spielberger Anxiety Scores. Depending on symptoms, daily escitalopram doses will be titrated to 10 mg after week 2 and to 15 mg or placebo equivalent at week 3 if patients show no change or only minimal improvement.
3007059|NCT02516150|Active Comparator|Glucagon without Ethanol|Volunteers will not receive an infusion of IV ethanol at this visit. 50 micrograms of glucagon will be administered via subcutaneous injection.
3007026|NCT02516332|Placebo Comparator|Placebo|Treatment in the medication and placebo pill arms will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service, who have extensive experience in clinical trials. Medication will be taken once daily in the morning but can be switched to once daily in the evening if deemed necessary. Placebo medication administration will follow the same protocol as outlined for Lexapro.
3007027|NCT02516319|Active Comparator|Serial Blood Draws|Cohorts 3 and 4 - weight based doses of ICG dye followed by serial blood draws at 5, 10, 15 and 20 minutes post ICG injection.
3007028|NCT02516319|Experimental|Liver Funtion Test Dye Detection Monitor|All cohorts receive continuous LFT monitoring post ICG injection.
3007029|NCT02516306|Experimental|EV06 Ophthalmic Solution|EV06 Ophthalmic Solution: Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.
3007030|NCT02516306|Placebo Comparator|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution (EV06 vehicle): Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.
3007031|NCT02516293|Experimental|Intervention group|"Physical exercise intervention~Nutritional counseling~Pharmaceutical counseling"
3007032|NCT02516280|Experimental|Hyperbaric gaseous cryotherapy group|Conventional rehabilitation with Cryoton ™ hyperbaric cryotherapy
3007033|NCT02516280|Active Comparator|Control ice bag group|Conventional rehabilitation with ice bag cryotherapy. Application of a bag of crushed ice directly on the anterior aspect of the knee.
3007034|NCT02516267|Placebo Comparator|Control Group|Patients who will discontinue inhibitor-ADP for 5 days before surgery, and must be operated on the first working day after completing the 5 days without the drug. This group will have its aggregability evaluated by platelet function testing (Multiplate ADP®) immediately before the transport to the operating room.
3007035|NCT02516267|Active Comparator|Intervention Group|Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained> 46 AU, when they will be immediately released to CABG, to be held on the first working day after release.
3007036|NCT02516254|Experimental|fortified bread|daily intake of fortified bread (1000IU vitamin D per 50 g) plus placebo
3007037|NCT02516254|Experimental|supplement|daily intake of plain bread (50 g) plus supplement (1000 IU per tablet)
3007038|NCT02516254|Placebo Comparator|placebo|daily intake of plain bread plus placebo
3007039|NCT02516241|Experimental|Combination Therapy|MEDI4736 (Durvalumab) + Tremelimumab
3007040|NCT02516241|Experimental|Monotherapy|MEDI4736 (Durvalumab)
3007041|NCT02516241|Active Comparator|Standard of Care|Standard of Care Chemotherapy Treatment
3007042|NCT02516228|Experimental|GTEN 100|All patients will receive treatment according to the protocol with the GTEN 100 device, pulsed only.
3007043|NCT02516215||1_Hypertension|Patients with diagnosed hypertension, without other systemic diseases
3007044|NCT02516215||2_Diabetes mellitus|Patients with diagnosed diabetes mellitus, without other systemic diseases
3007045|NCT02516215||3_Hypertension and diabetes mellitus|Patients with both diagnosed hypertension and diabetes mellitus
3007046|NCT02516215||4_end stage renal disease with hemodialysis|Patients with end stage renal disease with hemodialysis
3007047|NCT02516215||5_Peripheral arterial occlusive disease|Patients with disgnosed peripheral arterial occlusive disease
3007048|NCT02516215||6_Coronary artery disease|Patients with diagnosed coronary artery disease
3007049|NCT02516215||7_liver cirrhosis|Patients with diagnosed liver cirrhosis
3007050|NCT02516215||8_Anemia|Patients with diagnosed anemia
3007051|NCT02516202|Active Comparator|Vagifem|"One hundred participants will be randomized into the Vagifem® 'active' arm. These women will receive a bottle of Vagifem® tablets (estradiol 10 mcg). One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.~Vagifem® tablets contain 10.3 mcg of estradiol hemihydrate equivalent to 10 mcg of estradiol. The excipient (inactive) ingredients are hypromellose, lactose monohydrate, maize starch, and magnesium stearate. Vagifem® comes as a small white film-coated tablet. The coating is made of hypromellose and polyethylene glycol.~A placebo gel visually similar to Replens composed of inert hydroxyethylcellulose gel (pH adjusted) applied every 3 days over entire 12 weeks."
3007052|NCT02516202|Active Comparator|Replens|"One hundred participants will be randomized into the Replens® 'active' arm. These women will receive a tube containing Replens® vaginal gel, with 2.5 gm applied vaginally every 3 days over 12 weeks.~Replens® is a bioadhesive polycarbophil-based moisturizing vaginal gel containing; purified water (vehicle humectant), glycerin (moisturizer), mineral oil (as a moisturizer), polycarbophil and carbomer homopolymer type B (allow the product to stick to the vaginal wall), hydrogenated palm oil glyceride (moisturizer), sorbic acid (preservative, antimicrobial), methylparaben, sodium hydroxide (adjusts pH of product so it is suitable for vaginal use).~A placebo tablet visually identical to Vagifem® is inserted daily for 2 weeks, then 2 days/week for remaining 10 weeks."
3007053|NCT02516202|Placebo Comparator|Placebo|"One hundred participants will be randomized into the 'placebo' arm of the study. This arm is comprised of two placebo preparations; placebo tablet and placebo gel applied on the same schedule as 'active' arms.~The placebo tablet coating and excipient ingredients will be the same as are used for Vagifem®; the coating is made of hypromellose and polyethylene glycol and the excipient (inactive) ingredients are hypromellose, lactose monohydrate, maize starch, and magnesium stearate.~Placebo gel. The product is an inert hydroxyethylcellulose gel (pH adjusted)."
3007054|NCT02516189|Experimental|Group A|group of elderly participants of strength training program
3007055|NCT02516189|No Intervention|Group B|group of seniors who did not practice strength training program
3007056|NCT02516176|Experimental|Treadmill Training|Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
3007057|NCT02516163|Other|Shapematch Cutting Guides|"The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.~They are intended for single use only."
3007058|NCT02516150|Experimental|Glucagon with Ethanol|Volunteers will receive an infusion of IV ethanol that will increase their BAC (blood alcohol content) to 0.1. Once their BAC has stabilized at 0.1%, 50 micrograms of glucagon will be administered via subcutaneous injection.
3007093|NCT02515942|Experimental|CLG561|CLG561, one IVT injection every 28 days for a total of 12 injections
3007060|NCT02516137|Experimental|Dry needling group|Subjects with tight hamstrings will receive dry needling to the hamstrings with the needle inserted into the muscle tissue in addition to a standard hamstring stretching exercise program.
3007061|NCT02516137|Sham Comparator|Sham dry needling group|Subjects with tight hamstrings will receive sham dry needling to the hamstrings with the needle inserted into the subcutaneous tissue in addition to a standard hamstring stretching exercise program.
3007062|NCT02516137|Placebo Comparator|No needling group|Subjects with tight hamstrings will receive no needling but have the tip of a blunt needle handle placed on the skin over the hamstrings in addition to a standard hamstring stretching exercise program.
3007063|NCT02516124||NISSC|Autologous HSCT
3007064|NCT02516111|Active Comparator|Open flap debridement group|SRP with Open flap debridement (OFD) alone for treating intrabony defect
3007065|NCT02516111|Active Comparator|PRF group|SRP with Open flap debridement (OFD) with autologous Platelet rich fibrin (PRF) placement into intrabony defect
3007066|NCT02516111|Active Comparator|Alendronate group|SRP with Open flap debridement (OFD) with 1% Alendronate (ALN) placement into intrabony defect
3007067|NCT02516111|Active Comparator|Atorvastatin group|SRP with Open flap debridement (OFD) with 1.2% Atorvastatin (ATV) placement into intrabony defect
3007068|NCT02516098|Active Comparator|Hyoscine butylbromide SCT|
3007069|NCT02516098|Experimental|Hyoscine butylbromide|
3007070|NCT02516085|Experimental|L-arginine and metformin|7.5 g L-arginine p.o. and 500 mg metformin p.o. per day (3x 2.5 g, respectively 3x 250 mg) for 16 weeks
3007071|NCT02516072|No Intervention|Control|Patients will receive iv hydration prior to procedure dependent on classification of risk as per eGFR.
3007072|NCT02516072|Experimental|Remote Ischaemic preconditioning (RIPC)|Patients will receive iv hydration prior to procedure dependent on classification of risk as per eGFR. Additionally, patients will receive RIPC; a blood pressure cuff will be placed around one arm of the patient, it will then be inflated to a pressure of 250mmHg for 5 minutes. The cuff will then be deflated and the arm allowed to reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles immediately prior to the procedure.
3007073|NCT02516059|Active Comparator|Oxycodone and naloxone (Targin®)|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
3007074|NCT02516059|Active Comparator|Oxycodone (Oxycontin®)|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
3007075|NCT02516059|Placebo Comparator|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
3007076|NCT02516046|Experimental|Autopsy Cohort|End-of-life subjects (life expectancy ≤ 6 months) consenting to brain donation at autopsy.
3007077|NCT02516020|Active Comparator|Global|EmbryoSingle step culture medium Embryos are cultured in single step culture from day 1 to day 5 Other Name: Global medium (LifeGlobal)
3007078|NCT02516020|Active Comparator|Origio|Sequential media Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast) Other Name: Sequential Blast (Origio)
3007079|NCT02515994|Experimental|senofilcon C|JJVCI investigational contact lens daily wear replacement.
3007080|NCT02515994|Active Comparator|comfilcon A|Marketed contact lens daily wear replacement.
3007081|NCT02515981|Experimental|Incentives|Participants randomly assigned to the incentive arm, will receive cash incentives for engaging in healthy lifestyle behaviors.
3007082|NCT02515981|Experimental|No Incentives|Participants randomly assigned to the no incentives arm, will not receive cash incentives for engaging in healthy lifestyle behaviors.
3007083|NCT02515968|Active Comparator|Desflurane|Anesthesia is maintained with desflurane during surgery.
3007084|NCT02515968|Experimental|Propofol|Anesthesia is maintained with propofol during surgery.
3007085|NCT02515955|Experimental|Cohort 1|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
3007086|NCT02515955|Experimental|Cohort 2|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
3007087|NCT02515955|Experimental|Cohort 3|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
3007088|NCT02515955|Experimental|Cohort 4|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
3007089|NCT02515955|Experimental|Cohort 5|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
3007090|NCT02515955|Experimental|Cohort 6|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
3007091|NCT02515955|Experimental|Cohort 7|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
3007092|NCT02515955|Experimental|Cohort 8|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
3040812|NCT02288481|Placebo Comparator|Cohort 3 placebo|Placebo Suspension
3007097|NCT02515929|Placebo Comparator|Placebo|Similar organoleptic experimental arm,1 tablet by mouth, every 24 hours for 21 days
3007098|NCT02515903|Experimental|Intra-endoscopy|This intervention arm will receive intra-endoscopic evacuation surgery for ICH.
3007099|NCT02515903|Placebo Comparator|Stereotactic Aspiration|This arm will receive stereotactic aspiration surgery for ICH evacuation.
3007100|NCT02515890|Experimental|Drug protocol A (single drug)|All subjects will receive either midazolam, dexmedetomidine, or ketamine, on separate visits. in randomized fashion. They will also experience intermittent experimental pain delivered by peripheral nerve stimulation.
3007101|NCT02515890|Experimental|Drug protocol B (two drugs)|All subjects will receive one drug followed by another, on separate visits, in randomized fashion. They will also experience intermittent experimental pain delivered by peripheral nerve stimulation.
3007102|NCT02515890|Experimental|Drug protocol C (all 3 drugs)|Subjects will receive all 3 drugs, in randomized fashion, across separate study visits. They will also experience intermittent experimental pain delivered by peripheral nerve stimulation.
3007103|NCT02515877|Experimental|Radiotherapy + Vistide + Chemoterapy|
3007104|NCT02515864|Experimental|FYU-981 anticipated therapeutic dose|Drug: FYU-981, FYU-981 Placebo, Moxifloxacin Placebo (Oral)
3007105|NCT02515864|Experimental|FYU-981 supratherapeutic dose|Drug: FYU-981, Moxifloxacin Placebo (Oral)
3007106|NCT02515864|Placebo Comparator|Placebo|Drug: FYU-981 Placebo, Moxifloxacin Placebo (Oral)
3007107|NCT02515864|Active Comparator|Moxifloxacin|Drug: Moxifloxacin, FYU-981 Placebo (Oral)
3007108|NCT02515851|Active Comparator|Active Group|Group that receives actual liposomal bupivacaine injections
3007109|NCT02515851|Placebo Comparator|Placebo Group|Group that receives placebo injections
3007110|NCT02515838|Placebo Comparator|Placebo|Placebo infusion
3007111|NCT02515838|Experimental|Sevuparin|Sevuparin infusion
3007112|NCT02515812|Experimental|Adrenergic Function Explorations with CZT camera|I-123-MIBG and CZT Camera (D-SPECT)
3007113|NCT02515812|Active Comparator|Adrenergic Function Explorations with Anger camera|I-123-MIBG and Anger Camera
3007114|NCT02515799|Active Comparator|Tacholiquine|Inhalation
3007115|NCT02515799|Placebo Comparator|Saline Solution 0,9%|Inhalation
3007116|NCT02515786|Experimental|oxygen humidification|Oxygen by nasal catheter delivery will be humidified by bubles.
3007117|NCT02515786|No Intervention|Dry oxygen|oxygen by nasal catheter delivery will be dry
3007118|NCT02515773|Experimental|MET and LIFE|Participants randomized to this group will receive both Metformin and lifestyle intervention.Participants randomized to treatment with MET will start at a dose of 500 mg orally at night and slowly titrated in 2-week intervals to ensure that each patient achieves maximum insulin-sensitizing effects of the drug while minimizing the chance of side effects. Investigators will also recommend that MET be taken with food to minimize side effects. If a participant's BMI percentile <5% (=underweight) his/her treatment with MET will be discontinued. Although the risk of low vitamin B12 while taking MET is associated with age > 50 years and having type II diabetes, Investigator will monitor B12 levels and a CBC throughout study participation.
3007119|NCT02515773|Experimental|Healthy lifestyle intervention (LIFE)|Participants randomized to this group will receive just lifestyle intervention alone.This healthy lifestyle intervention (LIFE) consists of counseling participants and families regarding a healthy eating plan, physical activity and sedentary activities. Prior to study initiation, clinical site staff will participate in a live (or taped) training session from a dietician to lean to administer LIFE. A trained site staff member (e.g. medical assistant or case manager) will meet with participants and their families for a 15-20 minute session at baseline that will focus on nutritional issues using the Traffic Light Plan (TLP).
3007120|NCT02515760|Experimental|Lung cancer group|Bone marrow puncture in patients with non-small cell lung cancer
3007121|NCT02515760|Experimental|Control group (healthy donors)|Bone marrow puncture in healthy donors
3007122|NCT02515747|No Intervention|conservative treatment|Men and women with stable CHD verified by angiography from one center and allocated to three treatment arms in real-world practice: 1. conservative treatment with statins, antiaggregants, antianginal drugs in standard dosage
3007123|NCT02515747|Active Comparator|percutaneous coronary intervention|2. elective balloon angioplasty alone or stent implanation on the basement of drugs treatment
3007124|NCT02515747|Active Comparator|coronary artery bypass grafting|elective surgery myocardial revascularisation on the basement of drugs treatment
3007125|NCT02515734|Active Comparator|FOLFOXIRI+Bmab|Patients in the FOLFOXIRI + Bmab group receive until 12 cycles of FOLFOXIRI plus bevacizumab, consisting of a 30-minute infusion of bevacizumab at a dose of 5 mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and bevacizumab every 14 days until disease progression.
3007126|NCT02515734|Experimental|FOLFOXIRI+Cmab|Patients in the experimental group received until 12 cycles of FOLFOXIRI plus cetuximab, consisting of a 30-minute infusion of cetuximab first time at a dose of 400 mg per kilogram, after the second time at a dose of 250mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and cetuximab every 14 days until disease progression.
3007127|NCT02515721|Experimental|pCLE-TB|Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.
3007128|NCT02515721|Experimental|Virtual Chromoendoscopy -SB|Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
3007129|NCT02515708|Experimental|Normothermic Liver perfusion|This group has the liver grafts preserved using the Normothermic Liver perfusion Device.
3040813|NCT02288481|Experimental|Cohort 4 150 mg TBA-354|
3007130|NCT02515708|Other|Normothermic Machine Perfusion (single pump)|This group has the liver grafts preserved using a single-pump variant of the Normothermic Liver perfusion Device.
3007131|NCT02515695|Experimental|0.5 MIU i.v. and 1.5 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
3007132|NCT02515695|Experimental|1 MIU i.v. and 3 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
3007133|NCT02515695|Experimental|2 MIU i.v. and 6 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
3007134|NCT02515695|Experimental|4 MIU i.v. and 12 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
3007135|NCT02515682|Active Comparator|High equol|High equol group will be given natural S-equol supplementation 20mg per day for 24 week.
3007136|NCT02515682|Active Comparator|Low equol|Low equol group will be given natural S-equol supplementation 10mg/d (+10mg starch) for 24 weeks
3007137|NCT02515682|Placebo Comparator|Placebo|Placebo group will be given placebo control (made from starch) 20 mg per day for 24 weeks.
3007138|NCT02515669|Active Comparator|RO7239361|RO7239361 subcutaneous injections on specified days
3007139|NCT02515669|Placebo Comparator|Placebo|Placebo subcutaneous injections on specified days
3007140|NCT02515656|Experimental|POLYGYNAX®|Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
3007141|NCT02515656|Active Comparator|miconazole + placebo|Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
3007142|NCT02515643||Endothelial dysfunction in Cohort 1|Assessment of endothelial dysfunction in healthy subjects who will undergo a nephrectomy as part of the living donor program at each participating center.
3007143|NCT02515643||Endothelial dysfunction in Cohort 2|Assessment of endothelial dysfunction in renal transplant recipients from cohort 1
3007144|NCT02515630|Experimental|Momelotinib|MMB for 24 weeks (± 7 days)
3007145|NCT02515617|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period, patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions Drainage
3007146|NCT02515617|Experimental|Period with endotracheal tubes allowing SSD|During this period, patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
3007147|NCT02515604|Active Comparator|Single dose group|
3007148|NCT02515604|Active Comparator|Repeated dose group|
3007149|NCT02515578|Active Comparator|Standard practice transformation support|Primary care practices will receive a cardiovascular care toolkit, practice facilitation, practice assessment with feedback, health information technology assistance, academic detailing, and periodic collaborative learning sessions
3007150|NCT02515578|Experimental|Enhanced practice transformation support|Primary care practices will receive practice facilitation, practice assessment with feedback, health information technology assistance, academic detailing, and periodic collaborative learning sessions PLUS patient advisory council support and a modified cardiovascular care toolkit based on combined practice and patient input regarding the local context.
3007151|NCT02515565|Experimental|Experimental group|Patients with a clinical diagnosis of pneumonia will be included in this group. They will be included in a physiotherapy program added to the standard medical treatment.
3007152|NCT02515565|Other|Control group|Patients with a clinical diagnosis of pneumonia will be included in this group. They will receive only the standard medical treatment based on cephalosporin with or without erythromycin.
3007153|NCT02515552|Other|All applicants|Study applicants who consented and completed the application to participate in the Fibromyalgia Wellness Project. From that point forward all subjects used the intervention program to at whatever frequency they chose voluntarily. It was recommended subjects complete a SMARTLog at least three times per week for at least three months.
3007154|NCT02515539|Experimental|CardiAQ TMVI System (Transapical & Transfemoral DS)|CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
3007155|NCT02515526|Active Comparator|Reference|A cocktail of six different test substances to be administered orally followed by an I.V. dose of midzolam
3007156|NCT02515526|Experimental|Test|A cocktail of six different test substances to be administered orally followed by an I.V. dose of midzolam. In addition, ethanol will be administered at six different time points with of reaching a blood alcohol concentration of 1 per mille to see its effect on the activity of major cytochrome P450 enzymes, NAT-2 and P-glycoprotein.
3007157|NCT02515513|Active Comparator|Pancreatic Cancer Patients|During the surgical resection for the pancreatic cancer a muscle tissue biopsy sample will be performed.
3007158|NCT02515513|Active Comparator|Surgical Patients with benign pathology|During surgical resection for patients with benign right upper quadrant pathology, a muscle tissue biopsy sample will be performed.
3007159|NCT02515500|Active Comparator|Gradual Cessation|
3007160|NCT02515500|Experimental|Gradual Cessation w/ Quitbit|
3007161|NCT02515487|Experimental|Breast cancer patients receiving chemotherapy treatment|
3007938|NCT02509975|Experimental|Prostate Artery Embolization|Transarterial administration of OCL 503 to the arteries feeding the prostate.
3007162|NCT02515474|Active Comparator|LCBDE group (single step)|Choledocholithiasis patient, after Laparoscopic Cholecystectomy (LC) to remove the gallbladder, Laparoscopic Common Bile Duct Exploration (LCBDE) was performed for removing the bile duct stone(s) in laparoscopy. Choledochoscope detection or cholangiograms should be chosen as a method of obtain stone clearance. T-tube was acceptable if needed.
3007163|NCT02515474|Active Comparator|ERCP group (sequential step)|Choledocholithiasis patient, Endoscopic Retrograde cholangiopancreatography (ERCP) was performed for removing the bile duct stone(s) in endoscopy prior to Laparoscopic Cholecystectomy (LC). Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be chosen accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
3007164|NCT02515461|Experimental|Intervention: Low energy shockwave therapy|Low energy shockwave therapy performed on both kidneys applying 3000 shocks on each kidney.
3007165|NCT02515448|Experimental|Gentamicine injectable(day 1+2)and then gentamicine inhalation|
3007166|NCT02515435|Experimental|apatinib single agent|apatinib, single agent, 500mg or 750mg Qd po, continue until disease progression
3007167|NCT02515422|Active Comparator|Group 1, Ketamine|Ketamine, 1 mg/kg (Ketalar®, 10 mL inj., 50 mg ketamine hydrochloride/ml, Pfizer Drug Company, USA) was administered subcutaneously before the closure of pfannenstiel incision.
3007168|NCT02515422|Active Comparator|Group 2, Bupivacaine|Bupivacaine 0.5% 20 mL (100 mg) (Marcaine®, 20 mL inj. 5 mg bupivacaine hydrochloride/ml, AstraZeneca Drug Company, Turkey) was administered subcutaneously before the closure of pfannenstiel incision.
3007169|NCT02515422|Active Comparator|Group 3, Ketamine+Bupivacaine|Ketamine 1 mg/kg (Ketalar®) and bupivacaine 0.5% (100 mg) (Marcaine®) were administered subcutaneously before the closure of pfannenstiel incision.
3007170|NCT02515422|Placebo Comparator|Group 4, Placebo|Placebo (0.9% saline solution) was administered subcutaneously before the closure of pfannenstiel incision.
3007171|NCT02515409||CPAP|CPAP, as a first line treatment to OSAS.
3007172|NCT02515409||HHHFNC|Treatment with HHHFNC after CPAP treatment fails.
3007173|NCT02515396|Experimental|Treatment Group A|MMI-0100 Inhaled, once daily x 5, followed by 3 week washout period, followed by Placebo Inhaled, once daily x 5
3007174|NCT02515396|Experimental|Treatment Group B|Placebo Inhaled, once daily x 5, followed by 3 week washout period, followed by MMI-0100 Inhaled, once daily x 5
3007175|NCT02515383||Adolescent Cancer Group|"Part 1: Adolescent participants complete the MDASI (adolescent version). Study staff then conduct interview regarding the symptom questionnaire. After the interview participants complete the EQ-5D and a single-item quality of life (QOL) questionnaire.~Part 2: MDASI (adolescent version) administered twice, one day apart, to assess test-retest reliability. MDASI (adolescent version) then administered at 5 additional time points, each a week apart. Participants also complete the EQ-5D and a single item quality of life question only after first MDASI (adolescent version) completion. First 20 participants are interviewed by study staff regarding the symptom questionnaire."
3007176|NCT02515370|Other|Friends for Life Circles|The intervention will include formation of peer support groups of eight to ten women in the community with incorporation of income generating activities to improve maternal adherence to clinic appointments and life long antiretroviral therapy
3007177|NCT02515370|No Intervention|Standard|Normal standard of care and follow up. The standard care provided in the clinic will be provided for the control arem
3007178|NCT02515357|Placebo Comparator|Control group|This arm will receive standard care.
3007179|NCT02515357|Experimental|Mediterranean lifestyle group|This arm will receive a hypocaloric diet and attend a comprehensive 6-month lifestyle intervention based on the Mediterranean lifestyle.
3007180|NCT02515357|Experimental|Mediterranean diet group|This arm will receive a hypocaloric diet and attend a comprehensive 6-month dietary intervention based on the Mediterranean dietary pattern.
3007181|NCT02515344|Experimental|A: nominative list|"Providing a list of patients not compliant with CRC sreening~General Practitioners allocated to the intervention group (A) will receive:~a nominative list of their patients who were not compliant to colorectal cancer screening.~a document providing general information about colorectal cancer screening"
3007182|NCT02515344|Active Comparator|B: general information|"Providing general information about CRC screening~General Practitioners allocated to group (B) will receive:~- a document providing general information about colorectal cancer screening (but will not receive the nominative list of patients non compliant to colorectal cancer screening)"
3007183|NCT02515344|No Intervention|C: usual practice|General Practitioners allocated to group (C) will not receive any information (as in usual practice)
3007184|NCT02515331|Experimental|LHW090 100 mg|LHW090 100 mg once daily for 28 days
3007185|NCT02515331|Experimental|LHW090 200 mg|LHW090 200 mg once daily for 28 days
3007186|NCT02515331|Placebo Comparator|Placebo|Matching placebo to LHW090 oral dose for 28 days
3007187|NCT02515318|Experimental|Physiotherapy program|Patients with COPD are included in this group. They will receive a physiotherapy program during the hospitalization due to acute exacerbation of COPD, additionally to the standard medical treatment
3007188|NCT02515318|Active Comparator|Control group|Patients with COPD are included in this group. They will receive the medical standard treatment during the hospitalization due to acute exacerbation of COPD.
3007189|NCT02515305|Experimental|Test product|
3007190|NCT02515305|Active Comparator|Reference product|
3007191|NCT02515305|Placebo Comparator|Placebo product|
3007192|NCT02515292||IUGR: newborn with intrauterine growth restriction|"Inclusion criteria:~newborn infants with symmetrical (both weight and height lower than 10th percentile) or asymmetrical (birth weight is lower than 10th percentile but height and age-appropriated height) intrauterine growth restriction~agreement of the parents that their child to be included in the study"
3007193|NCT02515292||control: newborn without intrauterine growth restriction|"Inclusion criteria:~- matches newborn without intrauterine growth restriction in terms of gender and gestational age as IUGR group"
3007194|NCT02515279||Participants With Hepatitis C|All participants were treated with Peginterferon alfa-2a+Ribavirin (Pegasys/Copegus) according to the summary of product characteristics and to the investigator's discretion. The daily recommended dose for Pegasys, for the treatment of chronic Hepatitis C, was 180 micrograms once weekly by subcutaneous administration. Copegus was administered orally in doses according to the physician's decision (depending on the participant's weight and genotype). All participants were observed for 12 months.
3007195|NCT02515253|Experimental|Prescription group|Participants in this group will receive the standard care for benign breast pain sufferers (administered by the Queen Alexandra Hospital in Portsmouth) and will also attend the Department of Sport and Exercise Science at the University of Portsmouth for an individual bra prescription. Participants will be prescribed an appropriate bra to wear over an eight week intervention period.
3007196|NCT02515253|Other|Standard care group|Participants in this group will receive the standard care for benign breast pain sufferers administered by the Queen Alexandra Hospital in Portsmouth.
3007197|NCT02515240|Active Comparator|healthy controls|healthy individuals, HIV negative, 19-50 yrs if age, immunized with one shot of PPV23 vaccine.
3007198|NCT02515240|Active Comparator|newly diagnosed HIV >200|Newly diagnosed HIV positive patients with CD4 count >200, immunized with one shot of PPV23 vaccine.
3007199|NCT02515240|Active Comparator|newly diagnosed HIV <200|Newly diagnosed HIVpositive patients with CD4 count <200, immediately immunized with one shot of PPV23 vaccine.
3007200|NCT02515240|Active Comparator|newly diagnosed HIV <200 delayed|Newly diagnosed HIV positive patients with CD4 count <200 delayed immunization with one shot of PPV23 vaccine, treated for 6-12 months with Highly Active Anti-Retroviral Therapy (HAART) first.
3007201|NCT02515240|Active Comparator|HAART experienced HIV>200|HIV positive, on HAART treatment for 5 years, nadir CD4 count <200, but at present CD4 count is >200, immunized with one shot of PPV23 vaccine.
3007202|NCT02515240|Active Comparator|HAART experienced HIV<200|HIVpositive, on HAART treatment for 5 years, nadir CD4 count <200, and at present CD4 count is <200, immunized with one shot of PPV23 vaccine.
3007203|NCT02515227|Experimental|6MHP + Pembrolizumab|6 MHP (200 mcg each peptide) will be administered intradermally and subcutaneously on days 1, 8, 15, 43, 64, and 85. Pembrolizumab (200 mg) will be administered intravenously every 3 weeks for up to 2 years, beginning on day 1.
3007204|NCT02515201|Active Comparator|Taurolidine|Taurolidine be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Taurolidine infusion will be used TaurolockTM with ampoule presentation containing 3 ml.
3007205|NCT02515201|Active Comparator|Heparin|Heparin be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Heparin infusion will be used with heparin solution contain 50 International Unit (UI)/ml.
3007206|NCT02515188|Experimental|propacetamol group|
3007207|NCT02515188|Placebo Comparator|placebo group|
3007208|NCT02515175|Experimental|GEN-003 60ug / Matrix-M2 50ug|GEN-003/M2 (60 ug of each antigen) with Matrix-M2 adjuvant (50ug), administered as a 0.5mL intramuscular (IM) injection
3007209|NCT02515175|Experimental|GEN-003 60ug / Matrix-M2 75ug|GEN-003/M2 (60 ug of each antigen) with Matrix-M2 adjuvant (75ug), administered as a 0.5mL intramuscular (IM) injection
3007210|NCT02515175|Placebo Comparator|Placebo|0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection
3007211|NCT02515162|Experimental|Fischer Cone Biopsy Excisor|Conization Methode using a triangular electrode , i.e. Fischer Cone Biopsy Excisor
3007212|NCT02515162|Active Comparator|Loop Excision Procedure|Conization Methode using a circular electrode , i.e. Loop excision Procedure
3007213|NCT02515149|No Intervention|Standard of care|Referral laboratory based CD4 measurement after home-based HIV testing
3007214|NCT02515149|Experimental|Point of care|POC CD4 testing after home-based HIV testing
3007215|NCT02515136|Experimental|Parkinson's disease|Parkinson's disease patients
3007216|NCT02515136|Other|Controls|Healthy volunteers paired with Parkinson's disease patients on sex and age group, whose data will be extracted from a CNRS existing database
3007217|NCT02515123|Experimental|E-Motion System|E-motion tube + E-motion EPG 1000
3007218|NCT02515123|Sham Comparator|E-Motion Sham Decive|E-motion tube + SHAM E-motion EPG 1000
3007219|NCT02515110|Experimental|Treatment (EBRT)|"External Beam Radiation Therapy (EBRT). Within 10 weeks after the last breast cancer surgery or the last dose of adjuvant chemotherapy, patients undergo hypofractionated RNI five days a week over 3-4 weeks.~The two subgroups are Cohort (A) sentinel lymph node (SLN) and Cohort (B) axillary lymph node (ALN) dissection. They are categorized depending on type of axillary surgery and treatment group. The type of axillary surgery is Sentinel lymph node (SLN) biopsy only vs axillary dissection with or without previous SLN biopsy. The treatment groups are lumpectomy vs mastectomy vs mastectomy/reconstruction."
3007220|NCT02515097|Experimental|IDP-122 Lotion|halobetasol propionate [HP] 0.01%
3007221|NCT02515097|Active Comparator|IDP-122 Vehicle Lotion|Vehicle
3007222|NCT02515084|Experimental|18F-FDG-PET and dw-MRI|At the inclusion, both all patients, a 18F-FDG-PET/CT and a dw-MRI will be performed
3007223|NCT02515071|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
3007224|NCT02515071|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
3007225|NCT02515058|Experimental|PUROS (Non-Freeze-Dried bone allograft)|Ridge preservation bone grafting surgery with Non-Freeze-Dried cancellous bone allograft (PUROS)
3007226|NCT02515058|Active Comparator|FDBA (Freeze-Dried bone allograft)|Ridge preservation bone grafting surgery with Freeze-Dried cancellous bone allograft (FDBA)
3007227|NCT02515045|Active Comparator|TriMoxiVanc|The formulation containing triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin used as an injection at the end of the uneventful phacoemulsification procedure. The compounded Tri-Moxy-Vanco will be delivered into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
3007228|NCT02515045|Active Comparator|TriMoxiVanc + Ilevro|Nepafenac ophthalmic suspension 0.3% will be started 3 days prior to surgery QD and continue QD for 4 weeks after surgery. The compounded Tri-Moxy-Vanco will be injected into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
3007318|NCT02514330|Experimental|Interval Training at 1% incline|Procedure: Initial Drop Jump (20;30;40 cm), Six Stimulus of High Intensity Interval Training at 1% incline, Final Drop Jump (20;30;40 cm)
3007229|NCT02515045|Active Comparator|Control|"Moxifloxacin HCl 0.1%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.~Nepafenac ophthalmic suspension 0.3% : 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.~Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued."
3007230|NCT02515032|Experimental|NF Cachexia|Nutrifriend Cachexia, an Omega-3 enriched fruit juice (non complete dietary formula).
3007231|NCT02515032|Placebo Comparator|Placebo|An isocaloric placebo comparator
3007232|NCT02515019|No Intervention|Group Sevo1.8%|Anaesthesia was maintained with a constant inspired concentration of sevoflurane 1.8% (Sevorane; Abbvie, Wiesbaden, Germany) administered via the ventilator. From the beginning of CPB, a constant flow of sevoflurane 1.8% was administered with the oxygenator fresh-gas supply, using a common anaesthetic vaporiser (Draeger Vapor Version 2000; Draeger, Luebeck, Germany). Following successful weaning from CPB, sevoflurane was again administered at an inspired concentration of 1.8% using the ventilator.
3007233|NCT02515019|Experimental|Bispectral index Monitoring|The sevoflurane concentration via the ventilator and the oxygenator fresh gas supply was titrated to maintain a target BIS value between 40 and 60 (BIS-Monitor, Covidien, Boulder, Colorado, USA). However, the concentration of sevoflurane in the oxygenator fresh gas supply was not reduced below 0.3%.
3007234|NCT02515006|Experimental|Homeopathy|Individualized homeopathy treatment as a supportive care
3007235|NCT02515006|No Intervention|Control|Usual Care
3007236|NCT02514993||Study group|Inclusion criteria for the study were (a) sternal fracture and concomitant thoracic spine fracture, (b) Injury Severity scale (ISS) ≥ 16, (c) age under 50 years, (d) presence of a whole body computed-tomography (CT-scan) performed at admission of the patient to the hospital.
3007237|NCT02514993||Control group|The inclusion criteria for the control group included: (a) Thoracic spine fracture without concomitant sternal fracture, (b) ISS ≥ 16, (c) age under 50 years, (d) presence of a whole body computed-tomography (CT-scan) performed at admission of the patient to the hospital.
3007238|NCT02514980|Active Comparator|Bupivacaine group|Infraorbital nerve block using bupivacaine 0.25% on each side.
3007239|NCT02514980|Active Comparator|Bupivacaine-Ketamine group.|Infraorbital nerve block using bupivacaine 0.25% combined with 0.5mg/kg ketamine on each side.
3007240|NCT02514967|Experimental|Blisibimod|
3007241|NCT02514967|Placebo Comparator|Placebo|
3007242|NCT02514954|Experimental|BioChaperone® Combo|1 single dose 400 U/mL
3007243|NCT02514954|Active Comparator|Humalog® Mix25|1 single dose 100 U/mL
3007244|NCT02514941|Experimental|pre OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period will be performed within three days before the scheduled proximal Roux-en-Y gastric bypass surgery. A gastroduodenoscopy with biopsy of the lower duodenum will be performed before the first pharmacokinetic study period.
3007245|NCT02514941|Experimental|post OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period will be performed 5-7 days after the scheduled proximal Roux-en-Y gastric bypass surgery. A sampling of a tissue specimen from the jejunum will be collected during the operation.
3007246|NCT02514941|Experimental|one year post OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period and a gastrojejunoscopy with biopsy of the jejunum will be performed about one year after the scheduled proximal stomach bypass surgery.
3007247|NCT02514928|Experimental|pancreatoduodenectomy & nerve resection|Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
3007248|NCT02514928|Active Comparator|pancreatoduodenectomy|Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
3007249|NCT02514915|Other|Stereotactic Radiosurgery|Subjects will receive stereotactic radiosurgery prior to resection
3007250|NCT02514902|Experimental|Lateral Flow Device|Determine the feasibility of testing whole blood samples from patients with acute stroke (both ischemic and hemorrhagic) and traumatic brain injury being evaluated in the Emergency Department and Inpatient Services at University of Kentucky. No diagnostic or treatment decisions will be based on the results for any patient and the patient will not be told of the results.
3007251|NCT02514889|Active Comparator|Calorie-counting|Intervention protocol adapted from Diabetes Prevention Program lifestyle change intervention.
3007252|NCT02514889|Experimental|MyPlate|Intervention protocol adapted from Dietary Approaches to Stop Hypertension dietary pattern.
3007253|NCT02514876|Experimental|Single arm- Foresight ICE System|This open label feasibility study will evaluate the Foresight ICE system for imaging chambers of the heart and guiding transseptal puncture during an atrial fibrillation (AF) ablation procedure.
3007254|NCT02514863||Patients undergoing CMR|"Assessment of hemodynamic function using:~CMR~EV with an inter-electrode gap (lower pair) of 5 cm~EV with an inter-electrode gap (lower pair) of 15 cm"
3007255|NCT02514850|Experimental|Biochaperone Combo|single subcutaneous injection of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy
3007256|NCT02514850|Active Comparator|Humalog Mix25|single subcutaneous dose of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy
3007257|NCT02514850|Active Comparator|Humalog and Lantus|simultaneous subcutaneous injections of 0.2 U/kg Humalog and 0.6 U/kg Lantus
3007258|NCT02514837|Experimental|Temperature measured by RTM device|Both the internal temperature and skin temperature will be measured non-invasively through the skin.
3007259|NCT02514824|Experimental|MLN0128|"Dose escalation will occur using a standard 3+3 dose escalation approach. Each cohort should be evaluated for tolerability after completing 2 cycles of treatment before proceeding to escalation or de-escalation. The phase II part of the study will use the phase II dose or RP2D determined during the phase I part of the study.~MLN0128, orally, on predetermined days per treatment cycle"
3040814|NCT02288481|Placebo Comparator|Cohort 4 placebo|Placebo Suspension
3007260|NCT02514811|Experimental|The Teen Outreach Program|TOP is a youth development and service learning program for youth designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP program model consists of three components implemented in school, after school, or in community settings over nine months: (1) weekly curriculum sessions, (2) community service learning, and (3) positive adult guidance and support. The TOP Changing Scenes Curriculum is separated into four age-/stage-appropriate levels, Level 1 is typically for youth ages 12 or 13 and Level 4 is typically for youth age 17. The intended program dosage for each participant is a minimum of 25 weekly sessions and at least 20 hours of community service learning over nine months. One or two facilitators, who plan the order of sessions based on the needs and interest of youth, implemented TOP in a group of 10 to 25 youth.
3007261|NCT02514811|No Intervention|Control Group|Students in the control condition receive a benign intervention called the Community Voices (CV) program, which like TOP, meets in a group setting. The CV students are convened four times during the program year. Sessions are the same length as the TOP sessions. The first and last CV sessions are primarily focused on survey data gathering. At the two other sessions, CV students are convened to discuss current issues among young people in their community. The CV program specifically does not include any sexuality education or community service learning opportunities.
3007262|NCT02514798|Experimental|High-flow humidified nasal oxygen delivery system|We will describe effects of varying settings of high-flow nasal oxygen (10-30-45-60 L/min) on respiratory rate, tidal volume, and diaphragmatic work of breathing in patients with severe COPD. We will also describe changes in gas exchange and effects on the subjects' comfort and dyspnea. This will be measured using, esophageal and gastric balloons, respiratory inductance plethysmography (RIP) system, and Sentec transcutaneous monitoring system.
3007263|NCT02514798|Active Comparator|CPAP (Positive Control)|"We want to describe the breathing responses to varying setting of CPAP in the subject population. We plan to use the CPAP response as a positive control, to determine if our population responds as described by CPAP studies in the literature. This will be measured using, esophageal and gastric balloons, respiratory inductance plethysmography (RIP) system, and Sentec transcutaneous monitoring system."
3007264|NCT02514772|Experimental|GP2013 - proposed biosimilar rituximab|10 mg/mL in 500 mg (50 mL) single-use vials. For i.v. administration, two 500 mg vials (1000 mg of active molecule) of concentrate are diluted in 0.9% NaCl solution and infused i.v. The treatment course consists of 2 i.v. infusions 2 weeks apart (at Day 1 and Day 14).
3007265|NCT02514772|Active Comparator|Originator rituximab - Rituxan ® or MabThera ®|10 mg/mL in 500 mg (50 mL) single-use vials. For i.v. administration two 500 mg vials (1000 mg of active molecule) of concentrate are diluted in 0.9% NaCl solution and infused i.v. The treatment course consists of 2 i.v. infusions 2 weeks apart (at Day 1 and Day 14).
3007266|NCT02514759|Experimental|The Teen Outreach Program|TOP is a youth development and service learning program for youth designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP program model consists of three components implemented in school, after school, or in community settings over nine months: (1) weekly curriculum sessions, (2) community service learning, and (3) positive adult guidance and support. The TOP Changing Scenes Curriculum is separated into four age-/stage-appropriate levels, Level 1 is typically for youth ages 12 or 13 and Level 4 is typically for youth age 17. The intended program dosage for each participant is a minimum of 25 weekly sessions (one per week at 40-50 minutes each) and at least 20 hours of community service learning over nine months. One or two facilitators, who plan the order of sessions based on the needs and interest of youth, implemented TOP in a group of 10 to 25 youth.
3007267|NCT02514759|No Intervention|Control group|The control group received business as usual.
3007268|NCT02514746|Experimental|SA-14-14-2 live, attenuated JE vaccine (CD-JEV)|Participants previously vaccinated with CD-JEV, will receive a booster dose of CD-JEV four years after initial vaccination
3007269|NCT02514733||Young donor|Kidney transplant recipient > 60 years of age who received organ from donor <=40 years of age
3007270|NCT02514733||Old donor|Kidney transplant recipient >= 60 years of age who received organ from donor >=50 years of age
3007271|NCT02514720|Other|Fast Nicotine Metabolizers|Those in the upper tertile of NMR for cigarette/nicotine metabolism.
3007272|NCT02514720|Other|Slow Nicotine Metabolizers|Those in the lower tertile of NMR for cigarette/nicotine metabolism
3007273|NCT02514694|Active Comparator|LEO 32731|Active
3007274|NCT02514694|Placebo Comparator|Placebo|Placebo
3007275|NCT02514681|Active Comparator|Trastuzumab + chemotherapy|Trastuzumab + chemotherapy Chemotherapy regimen is chosen from the following; Docetaxel, Paclitaxel, nab-paclitaxel ,Vinorelbine, Eribulin, Capecitabine or Gemcitabine
3007276|NCT02514681|Experimental|Trastuzumab+ pertuzumab + chemotherapy|Trastuzumab+ pertuzumab + chemotherapy Chemotherapy regimen is chosen from the following; Docetaxel, Paclitaxel, nab-paclitaxel, Vinorelbine, Eribulin, Capecitabine or Gemcitabine
3007277|NCT02514668|Experimental|Isatuximab|Isatuximab (escalating dose) on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression
3007278|NCT02514655|Experimental|1: Nosten® monitoring|One experimental group with the control of the cuff pressure by Nosten® device
3007279|NCT02514655|Active Comparator|2: Manual monitoring|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
3007280|NCT02514642|Experimental|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients withStable Coronary Artery Disease
3007281|NCT02514642|Active Comparator|clopidogrel|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose clopidogrel.
3007282|NCT02514629|Placebo Comparator|Placebo|Placebo for 52 weeks
3007283|NCT02514629|Experimental|Metformin|Metformin 850 mg tablets twice daily for 52 weeks
3007284|NCT02514629|Experimental|Testosterone|Testosterone Undecanoate 1000 mg/4ml im injection each 12 weeks for 52 weeks
3007285|NCT02514629|Experimental|Metformin + Testosterone|Metformin 850 mg tablets twice daily + Testosterone Undecanoate 1000 mg/4ml im injection each 12 weeks for 52 weeks
3007319|NCT02514330|Experimental|Interval Training at 10% incline|Procedure: Initial Drop Jump (20;30;40 cm), Six Stimulus of High Intensity Interval Training at 10% incline, Final Drop Jump (20;30;40 cm)
3007320|NCT02514330|No Intervention|Control|Procedure: Initial Drop Jump (20;30;40 cm), 20 min Rest, Final Drop Jump (20;30;40 cm)
3007286|NCT02514616|Active Comparator|Active Electric Stimulation Therapy|The subject receives Active Electric Stimulation Therapy for 12 weeks, 2 weeks after laparoscopic IPG and lead implant procedure. The subject and physician will be blinded to the randomization group assignment. The subject continues on stimulation treatment after 14 weeks and an extended open-label follow-up phase includes annual visits through 5 years.
3007287|NCT02514616|Sham Comparator|Delayed Electric Stimulation Therapy|The subject receives no active Electric Stimulation Therapy for 12 weeks, 2 weeks after laparoscopic IPG and lead implant procedure. The subject and physician will be blinded to the randomization group assignment. The subject will receive Active Electric Stimulation Therapy at week 14 visit, and an extended open-label follow-up phase includes annual visits through 5 years.
3007288|NCT02514603|Experimental|Prexasertib|Prexasertib intravenously (IV) on day 1 of a 14 day cycle. Treatment with prexasertib may continue until disease progression, unacceptable toxicity, or other discontinuation criteria are met.
3007289|NCT02514590|Experimental|Freedom SCS System - High Frequency|High Frequency (HF) Group: Epidural Space midline covering vertebrae levels T8 through T11 (one stimulator placed at the top of T8 and the second stimulator placed at the middle of T9).
3007290|NCT02514590|Active Comparator|Freedom SCS System - Low Frequency|Low Frequency (LF) Group: Epidural Space covering vertebrae level determined by paresthesia mapping for painful area.
3007291|NCT02514577|Experimental|IDP-122 Lotion|halobetasol propionate [HP] 0.01%
3007292|NCT02514577|Active Comparator|IDP-122 Vehicle Lotion|Vehicle
3007293|NCT02514564||2x/wk|This group will be consisted of patients that will perform exercise two times a week.
3007294|NCT02514564||3x/wk|This group will be consisted of patients that will perform exercise three times a week.
3007295|NCT02514564||Control|This group will not perform exercise.
3007296|NCT02514551|Experimental|12mg/kg Ramucirumab + 80 mg/m² Paclitaxel|12mg/kg ramucirumab administered intravenously (IV) on day 1 and day 15 (28 day cycles) in combination with 80 mg/m² paclitaxel administered IV on day 1, day 8 and day 15.
3007297|NCT02514551|Active Comparator|8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel|8 mg/kg ramucirumab administered IV on day 1 and day 15 (28 day cycles) in combination with 80 mg/m² paclitaxel administered IV on day 1, day 8 and day 15.
3007298|NCT02514538|Experimental|Non-effervescent tablets|Comparing the effect of two different formulations of paracetamol (effervescent or non-effervescent tablets) in the blood pressure of hypertensive patients after 3 weeks treatment . The washing time between the two periods is approximately 1 week (minimum 3 days).
3007299|NCT02514538|Active Comparator|Effervescent Paracetamol|Comparing the effect of two different formulations of paracetamol (effervescent or non-effervescent tablets) in the blood pressure of hypertensive patients after 3 weeks treatment . The washing time between the two periods is approximately 1 week (minimum 3 days).
3007300|NCT02514525|Other|CryoBalloon Ablation System|Cryoablation treatment of patients with previously untreated (treatment naïve) Barrett's epithelium.
3007301|NCT02514512|No Intervention|Standard SABR|Patients receive standard treatment
3007302|NCT02514512|Experimental|MLC Tracking SABR|Patients are treated with MLC tracking
3007303|NCT02514473|Experimental|LUM/IVA|Fixed-dose combination with lumacaftor (LUM) 200 mg every 12 hours (q12h)/ ivacaftor (IVA) 250 mg q12h
3007304|NCT02514473|Placebo Comparator|Placebo|Matching placebo q12h
3007305|NCT02514460|Active Comparator|Intervention: Stents|Stents group
3007306|NCT02514460|Active Comparator|Intervention: Atherectomy|Direct Atherectomy group
3007307|NCT02514447|Experimental|Trilaciclib (G1T28) + Topotecan|All patients in Part 1 will receive trilaciclib (G1T28) prior to standard chemotherapy, topotecan. Patients will have PK assessment completed on days 1 and 4 in cycle 1 only. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
3007308|NCT02514447|Experimental|Trilaciclib (G1T28)/Placebo + Topotecan|All patients in Part 2 will be randomized 2:1 to receive either trilaciclib (G1T28) or placebo administered prior to standard chemotherapy, topotecan. Patients will have limited PK assessments completed on day 4 in cycle 1 only. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
3007309|NCT02514434|Experimental|Ultrasonography|Subjects will be regularly screened for HCC by ultrasonography with serum AFP(alpha fetoprotein).
3007310|NCT02514434|Experimental|Non-contrast MRI|Subjects will be regularly screened for HCC by non-contrast magnetic resonance imaging(MRI) with serum AFP(alpha fetoprotein).
3007311|NCT02514421|Experimental|Electrochemotherapy with gemcitabine/nab-paclitaxel|During the first cycle of chemotherapy, patients will receive electroporation of the primary pancreatic tumor prior to administration of chemotherapy with gemcitabine and abraxane. The schedule of administration of gemcitabine and nab-paclitaxel will be administered as per standard of care. The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.
3007312|NCT02514408||Ancillary-Correlative (collection of blood samples)|Patients undergo placement of a central line via the right femoral vein and undergo ORC. Blood samples are collected and analyzed for CTCs pre-surgery, at 30 minutes and 1 hour once ORC begins, post-surgery, and 7 days after surgery.
3007313|NCT02514382|Experimental|Treatment (dexamethasone, bortezomib, wild-type reovirus)|Patients receive dexamethasone PO, IV, or IM and bortezomib SC (preferably) or IV over 3-5 seconds on days 1, 8, and 15. Patients also receive wild-type reovirus IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3007314|NCT02514356|Active Comparator|Own adherence|Participants in this group receive a weekly message by SMS. They receive the intervention 'Behavioral: Own Adherence'.
3007315|NCT02514356|Active Comparator|Own and group level adherence|Participants in this group receive a weekly message by SMS. They receive the intervention 'Behavioral: Own and Group Adherence'.
3007316|NCT02514343|Experimental|Magnesium sulfate|Will administrate 1 ml of magnesium sulfate 10% and 1.5 mL of sterile water
3007317|NCT02514343|Experimental|Bupivacaine|Will administrate 1 ml of magnesium sulfate 10% and 1.5 ml of bupivacaine (5mg/ml)
3007321|NCT02514317|Experimental|percutaneous treatment|percutaneous treatment of carpal tunnel syndrome under ultrasound guidance in interventional radiology room.
3007322|NCT02514291|Experimental|Sleep intervention|Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
3007323|NCT02514291|No Intervention|Standard care|Standard pediatric neurology care
3007324|NCT02514278|Experimental|Chemotherapy and Radiochemotherapy|"Neoadjuvant chemotherapy Folfirinox, 4 cycles:~oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2~5FU: 2400 mg/m2~Radiochemotherapy : 2 to 4 weeks after chemotherapy, 5 weeks (50 Gy, 2 Gy/session; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7)"
3007325|NCT02514278|Active Comparator|Radiochemotherapy|Radiochemotherapy: 5 weeks (50 Gy, 2 Gy/session ; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7, excluding weekends)
3007326|NCT02514265||UCPPS patients|"All participants in this study are men or women who have been diagnosed with Urologic Chronic Pelvic Pain Syndrome (UCPPS). Approximately one-half of the participants will be male, and one-half will be enriched to meet the body map pain location criteria of pelvic pain (PP) only. In addition, enrichment recruitment of 240 UCPPS patients (120 males; 120 females) will also be targeted for those who answer no to questionaire question about specific Bladder pain symptoms."
3007327|NCT02514252|Experimental|Fentanyl Sublingual Spray (FSS)|Hospitalized participants asked to complete a number of surveys at baseline. Participants then receive one single dose of intravenous opioid rescue for their first episode of breakthrough pain, and then receive up to 4 doses of FSS for subsequent episodes of breakthrough pain. Initial FSS starting dose is proportional to the patient's morphine equivalent daily dose (MEDD). Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose. At the time of discharge, if FSS was helpful in controlling participant's pain, they are then able to continue with FSS use for 1 month. Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
3007328|NCT02514239|Experimental|BI 836909|given as continuous intravenous infusion
3007329|NCT02514226|Placebo Comparator|G1-control group|"Arm description: G1 - control group - (n = 30) dental hygiene orientation (DHO) + supragingival treatment + simulation of using photodynamic therapy (PDT).~In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes and ultrasound. Supragingival treatment will be performed above the gingival margin. The simulation of using photodynamic therapy (PDT) will be performed with laser turned off. No antibiotics and oral antiseptics will be prescribed."
3007330|NCT02514226|Active Comparator|G2- positive control group|"Arm description: G2 - positive control group (gold standard) - (n = 30) - DHO + periodontal treatment + simulation of using PDT.~All participants will receive periodontal treatment - scaling and root planning (SRP) by an experienced specialist with universal curetes and ultrasound in a full mouth manner. The simulation of using photodynamic therapy (PDT) will be performed with laser turned off. No antibiotics and oral antiseptics will be prescribed"
3007331|NCT02514226|Active Comparator|G3 -experimental active comparator group|"Arm description: G3 - experimental group - (n = 30) DHO +SRP + PDT with methylene blue~In G3, periodontal treatment and photodynamic therapy (PDT) will be performed. The scaling and root planing will be performed identical as G2. The PDT will be administered in periodontal pockets > 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the photosensitizer"
3007332|NCT02514213|Experimental|Arm A|2mg INO-5150 and electroporation device CELLECTRA®-5P
3007333|NCT02514213|Experimental|Arm B|8.5mg INO-5150 and electroporation device CELLECTRA®-5P
3007334|NCT02514213|Experimental|Arm C|2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
3007335|NCT02514213|Experimental|Arm D|8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
3007336|NCT02514200|Experimental|Topography-based CXL (KXL2)|Individualized pulsed topography-based corneal crosslinking; 1 second on, 1 second off; 7.2J/cm2 - 15.0J/cm2; arcuate treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.
3007337|NCT02514200|Active Comparator|Conventional pulsed CXL (pCXL)|Conventional pulsed corneal crosslinking; 1 second on, 1 second off; 5.4 J/cm2; 8 mm central treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.
3007338|NCT02514187|Other|Evaluation of hyperthyroidism|For the evaluation of hyperthyroidism each research subject will undergo imaging using both cyclotron-produced 99mTc and the current standard method used at the site for thyroid imaging (either 123I or generator-produced 99mTc). Each study will be performed on a separate day, with flexibility to schedule either study first.
3007339|NCT02514187|Other|Evaluation of altered osteogenesis by bone scintigraphy|For the evaluation of altered osteogenesis by bone scintigraphy each research subject will serve as his/her own control, and undergo imaging using both generator- and cyclotron-produced 99mTc. Each study will be performed on a separate day, with flexibility to schedule either study first.
3007340|NCT02514174|Experimental|Afatinib|afatinib starting at 30 mg daily dose
3007341|NCT02514161|Active Comparator|Inspiratory Muscle Training Group (IMT)|"The IMT program consisted of supervised and domiciliary exercises.~- The supervised exercises was performed in the presence of physiotherapist. This consisted of 30 min 2 days for 4 weeks using the threshold device (Powerbreathe classic level 1, Gaiam Ltd; Southam, Warwickshire, UK). This program involve 5 sets of 5 repetitions with 30 seconds rest between each one. The load of the training was distributed as follow:~First week: 30% Maximum Inspiratory Pressure (MIP)~Second week: 40% MIP~Third week: 50% MIP~Fourth week: 60% MIP~- The domiciliary exercises consisted of Yoga Breathing Exercises (Pranayama) that combines the inspiration and expiration through one or both nostrils, and requires the activation of chest and abdomen"
3007378|NCT02513927|Active Comparator|A|To observe the effects of metoprolol (95 mg) on blood pressure variation after 12 weeks of treatment.Then to observe the effects of Nifedipine (30 mg) on blood pressure variation after 12 weeks of treatment.
3007342|NCT02514161|Experimental|IMT + Manual Therapy and Motor Control Exercises|"The protocol for this group is identical to the previous group with the sole difference that is added a manual therapy (MT) and a motor control exercises (MCE). The MT protocol was performed for 15min, whereas the MCE was 10min. Below it described both protocols:~- MT:~Upper cervical region mobilization in flexion~Lower cervical postero-anterior mobilization + maintained traction~Costovertebral joint postero-anterior mobilization~Thoracic vertebral posteroanterior mobilization~Thrust dorsal~- MCE:~Isometric contraction of the deep neck flexors.~Isometric contraction of the neck extensors.~Neural self-mobilization.~Cervical retraction with theraband.~Sphinx.~Scapular adduction exercises in prone.~Scapular adduction exercises in sitting position with theraband."
3007343|NCT02514148|Other|NO Intervention Control group|No therapeutic intervention are being giving to the group of patients, they only will have their Neurologist previously prescribed pharmacological treatment.
3007344|NCT02514148|Experimental|Therapeutic exercise( TE)|The intervention giving to the patients consist on a therapeutic exercise protocol based on neck and low intensity general exercises.
3007345|NCT02514148|Experimental|Therapeutic patient education ( TPE)|The intervention giving to the patients consist on a therapeutic patient education based on pain neurophysiology protocol.
3007346|NCT02514148|Experimental|TE + TPE|The intervention giving to the patients consist on the combination of the therapeutic exercise protocol and the therapeutic patient education protocol.
3007347|NCT02514148|Experimental|TE + TPE + Manual therapy|The intervention giving to the patients consist on the combination of the therapeutic exercise protocol and the therapeutic patient education protocol plus a manual therapy techniques protocol.
3007348|NCT02514135||Elevated Intra-abdominal Pressure|Patients with intra-abdominal pressure > 12 mmHg at any time throughout admission
3007349|NCT02514135||Normal Intra-abdominal Pressure|Patients with intra-abdominal pressure < 12 mmHg throughout admission
3007350|NCT02514122|Experimental|Ketamine|Participants will receive subcutaneous ketamine (1mg/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections at a dose of 1mg/kg.
3007351|NCT02514122|Placebo Comparator|Saline|Participants will receive subcutaneous saline (0.02cc/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
3007352|NCT02514109||patient|Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuronopathy.
3007353|NCT02514109||control|Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuropathy excluding a neuronopathy.
3007354|NCT02514083|Experimental|1|
3007355|NCT02514070|Experimental|Group 1|Subjects randomized to the EPA-rich fish oil arm will take the equivalent to 3g of EPA /day (12 gel capsules/day) for 6 more or less 1 weeks and cross-over to the DHA-rich capsule arm
3007356|NCT02514070|Experimental|Group 2|Subjects randomized to the DHA-rich fish oil arm will take the equivalent to 3g of DHA /day (12 gel capsules/day) for 6 more or less 1 weeks and cross-over to the EPA-rich capsule arm
3007357|NCT02514057||Healthy|Volunteers over 18 years
3007358|NCT02514057||Gastrointestinal disorders|Over 18 and with any gastrointestinal or liver disorder
3007359|NCT02514057||Non-gastrointestinal disorders|Over 18 and with any medical condition requiring hospital attention in which there is no primary gastrointestinal or liver disease
3007360|NCT02514044|Experimental|Dexedrine+sham tDCS+speech therapy|10 mg Dexedrine and speech therapy for 10 days
3007361|NCT02514044|Experimental|active tDCS+placebo+speech therapy|1.5 mA anodal tDCS and speech therapy for 10 days
3007362|NCT02514044|Experimental|Dexedrine+tDCS+speech therapy|10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 10 days
3007363|NCT02514044|Experimental|sham stimulation+placebo+speech therapy|Sham stimulation, placebo and speech therapy for 10 days
3007364|NCT02514044|Experimental|Dexedrine+tDCS+Speech Therapy|10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day
3007365|NCT02514044|Experimental|placebo+tDCS+Speech Therapy|1.5 mA anodal tDCS, and speech therapy for 1 day
3007366|NCT02514031|Experimental|ARQ-761|"A 2 week lead-in monotherapy of ARQ-761 (The amount of ARQ-761 that will be given to the participant will depend on the time at which the participant was enrolled in the study~Afterwards the 28-day cycle of combination treatment of ARQ-761 along with gemcitabine (1000 mg/m2) + nab-paclitaxel (125 mg/m2) will begin."
3007367|NCT02514018|Other|Immediate Group|Live-attenuated varicella-zoster virus vaccine (≥ 19,400 Plaque-forming unit - PFU) administered as a single-dose at day 0
3007368|NCT02514018|Other|Delayed Group|Live-attenuated varicella-zoster virus vaccine (≥ 19,400 PFU) administered as a single-dose at day 84 (+/- 3 days)
3007369|NCT02514005|Active Comparator|Manual therapy|Overall bilateral manipulation (L5-S1-SI), Hip joint gapping, Stretching the hip rotators with hip and knee flexion, Femorotibial Gapping, Decompression of connective tissue of the patellofemoral region, Internal and external joint line opening in laterality, Mobilization of the base of the fibula, Tibiofibular-talus gapping, and Muscle strengthening.
3007370|NCT02514005|Experimental|Manual therapy and Dry needling|Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps.
3007371|NCT02513992|Experimental|intra-arterial injection of tracer|The perfusion tracer 99m-Technetium Ethyl Cysteinate Dimer will be injected via an intra-arterial catheter by a pressure injector to obtain a subtracted ictal SPECT co-registered with MRI (SISCOM)
3007372|NCT02513979|Active Comparator|angiotensin type II receptor antagonists|Hypertensive patients treated with angiotensin type II receptor antagonists
3007373|NCT02513979|No Intervention|No treatment|Normotensive patients
3007374|NCT02513953|Experimental|Endometriosis|Four port laparoscopy by way of intervention was needed for convenience in aspirating the cystic fluid and reversal of the cyst wall taking care not to destroy the normal ovarian tissue to minimize loss of ovarian reserve
3007375|NCT02513940|Experimental|Testosterone|Testosterone gel 1% 100 mg daily x 7 days
3007376|NCT02513940|Experimental|Progesterone|Progesterone 400 mg orally daily x 7 days
3007377|NCT02513940|Placebo Comparator|Placebo|Dual matching placebo capsules and placebo topical gel every day x 7 days
3007379|NCT02513927|Active Comparator|B|To observe the effects of Nifedipine (30 mg) on blood pressure variation after 12 weeks of treatment. Then to observe the effects of metoprolol (95 mg) on blood pressure variation after 12 weeks of treatment.
3007380|NCT02513914|Experimental|Dural Venous Sinus Stenting|Pt. will undergo pre-treatment with aspirin and clopidogrel. Transfemoral venous access will be obtained (pt. heparinized).Guide catheter will be placed in jugular bulb ipsilateral to dural venous sinus stenosis. Stent will be deployed across stenotic segment. Balloon angioplasty will not be performed unless initial stenosis is not easily traversed with stent. No pressure measurements will be taken during stent placement. Patients will undergo serial physical/neuro exams for 24 hours post-procedure. Daily dual anti-platelet treatment will continue for 6 months after initial procedure, after which clopidogrel will be discontinued and aspirin 81mg daily will be prescribed indefinitely. If significant bilateral venous sinus stenosis is present, stenosis with more severe pressure gradient will be stented. In pt. with bilateral venous sinus stenosis with equivalent pressure gradients, side will be at surgeon's discretion.
3007381|NCT02513914|Active Comparator|Cerebrospinal Fluid Shunting|Choice of shunt procedure (ventriculoperitoneal, ventriculoatrial, or lumboperitoneal), catheter laterality, brand and shunt equipment (including shunt catheters and valves), valve settings of programmable shunt valves (when applicable), intrathecal antibiotic administration and the use of stereotactic navigation will be at the discretion of neurosurgeon. Shunt procedures will be performed per the standard of care, under general anesthesia. An optional surgical procedure guidance document will be provided for other sites. Patients will undergo serial physical and neurological examinations for 24 hours post-procedure prior to discharge.
3007382|NCT02513901|Experimental|Chidamide|"Step 1 - Six participants will receive Chidamide 10 mg twice a week(BIW) for 4 consecutive weeks.~Step 2 - Another six participants will receive Chidamide 30 mg twice a week(BIW) for 4 consecutive weeks.~Participants will be enrolled into Step 1 first; if the dose given to Step 1 is well tolerated and no safety concerns are noted, Step 2 will be enrolled."
3007383|NCT02513888|Experimental|Vitamin D + diet and lifestyle|subjects will be given vitamin D supplement will be given along with diet nd lifestyle modification
3007384|NCT02513888|Placebo Comparator|placebo + diet and lifestyle|Subjects will be given placebo with diet and lifestyle
3007385|NCT02513875|Experimental|vitamin D with diet and lifestyle|vitamin D supplementation along with diet and lifestyle modification was given
3007386|NCT02513875|Placebo Comparator|placebo with diet and lifestyle modification|placebo with diet and lifestyle modification was given
3007387|NCT02513862|Experimental|APRP group|APRP group is performed autologous platelet-rich plasma harvest technique before administration of heparin to the patient,the red blood cell(RBC) component is retransfused to the patient when the RBC transfusion protocol is reached,and the autologous platelet-rich plasma is transfused to the patient immediately after heparin is neutralized with protamine.
3007388|NCT02513862|No Intervention|control group|APRP group receive no autologous platelet-rich plasma harvest technique.
3007389|NCT02513849|Experimental|Tamoxifen treatment|Patients will be administered tamoxifen, 80mg/ day orally for 4 days as a loading dose, followed by 20mg/ day thereafter until gastroscopy and biopsy 4 weeks later.
3007390|NCT02513836|Experimental|Pre-education intervention|All study participants will be tested with a questionnaire (POEM; Patient Opioids Education Measurement) on their opioid knowledge during 1st visit at the pain clinic.
3007391|NCT02513836|Other|Post-education intervention|All study participants will be educated on opioids via an education sheet, pamphlet and video from the Institute for Safe Medication Practices (ISMP) Canada. They will repeat the questionnaire (POEM) after this education on opioid knowledge on the same day.
3007392|NCT02513823|Experimental|Intervention|2,000 IU of vitamin D given to African American women for 10 weeks
3007393|NCT02513810|Experimental|Short-term DAPT after Biofreedom|
3007394|NCT02513810|Active Comparator|Long-term DAPT after Biofreedom|
3007395|NCT02513797|Experimental|LARIAT + PVI Treatment Group|Percutaneously isolate and ligate the Left Atrial Appendage (LAA) from the left atrium (LA) with the LARIAT System prior to planned pulmonary vein isolation (PVI) catheter ablation
3007396|NCT02513797|Active Comparator|PVI Catheter Ablation Group|Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
3007397|NCT02513784|Experimental|Antibacterial mouthwash|Subjects will be randomized to twice daily chlorhexidine gluconate mouthwash for 21 days.
3007398|NCT02513784|No Intervention|No intervention|Subjects will be randomized to no intervention for 21 days.
3007399|NCT02513771|Active Comparator|Sitagliptin Arm|Sitagliptin (Januvia) 100 mg one tablet daily p.o. for 16 weeks, followed by a 4-week post-treatment follow-up.
3007400|NCT02513771|Placebo Comparator|Placebo Arm|Placebo for sitagliptin one tablet daily p.o.for 16 weeks, followed by a 4-week post-treatment follow-up.
3007401|NCT02513758||HIV patients|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
3007402|NCT02513745|Active Comparator|Conventional|Surgeon's standard of care prior to getting VERION. Spherical power will be selected using the surgeon's preferred formula (Haigis, Holladay 2, Holladay, or other) and biometry method (IOL Master, Lenstar). Astigmatism correction will be planned using the surgeon's preferred keratometry method and calculator/nomogram to determine toric power and corneal incisions (i.e. Alcon toric calculator, Holladay toric calculator, Abbott Medical Optics (AMO) LRI calculator, etc). At time of surgery, axis of placement will be marked using blue ink marks. Corneal incisions will be made manually.
3007403|NCT02513745|Active Comparator|Verion|Digital Surgical Planning and Positioning Tools + ORA System with VerifEye or VerifEye +. Spherical power of the IOL will be selected using the Verion Planner with the surgeon's preferred formula with an optimized A-constant (Haigis, Holladay 2, Holladay, or other). Both toric lenses and corneal incisions will be calculated with the Verion Planner using the Verion Reference Unit keratometry and white to white measurements, and Lenstar biometry. The VERION Digital Markers L and M will be used for axis of placement and confirmed using ORA System with VerifEye or VerifEye +.
3007404|NCT02513732||XIENCE Xpedition 2.25 mm stent arm|Patients receiving XIENCE Xpedition 2.25 mm stent
3007405|NCT02513719||XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
3007406|NCT02513693|Experimental|Standard Neuromuscular Blockade|"Drug: rocuronium + neostigmine~Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Train-of-Four (TOF) count = 1-2, TOF-count measurement every 1 min. Neuromuscular blockade reversal at the end of anesthesia: neostigmine 0.03 mg/kg iv + atropine 0.5-1.0 mg iv Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1.5-2.5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv Extubation when patient is conscious and attained the recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
3007407|NCT02513693|Experimental|Deep Neuromuscular Blockade|"Drug: rocuronium + sugammadex~Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Post-tetanic Count (PTC) = 1-2; PTC measurement every 4 min. Neuromuscular blockade reversal at the end of anesthesia: sugammadex 2 mg/kg iv (when PTC is 18-20 and TOF-count 0) or sugammadex 4 mg/kg iv (when PTC under 18).~Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1,5-2,5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv.~Extubation when patient is conscious and attained recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
3007408|NCT02513680|Active Comparator|LASER and LED therapy application|The first group will use the two techniques under study combined: Infrared Laser + Amber LED (830 nm - 150mW + 590 nm - 1.500 mW)
3007409|NCT02513680|Active Comparator|LED Therapy application|The second group will use only Amber LED (590 nm - 1.500 mW)
3007410|NCT02513667|Experimental|ALK-inhibitor naive patients|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months.
3007411|NCT02513667|Experimental|Patients recieved prior ALK inhibitor|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months.
3007412|NCT02513654|Experimental|Lamotrigine dispersible tablets 25mg, 50mg, 100mg|Each subjects will start dosing with lamotrigine 25mg dispersible tablet once daily at Day 1 and remain at this dose level for 2 weeks (Days1-14), then will be titrated to 50 mg once daily at Day 15 and last for weeks 3-4 (Days 15-28), and then titrated to 100 mg once daily at Day 29 during weeks 5-6 (Days 29-42).
3007413|NCT02513641|Experimental|Moderate Hypoxia|2-weeks of nightly exposure (7-12 hrs) to moderate hypoxia (~2,400 meters) using the Hypoxico Altitude Training Systems device.
3007414|NCT02513602||TEST group (kidney transplanted)|"Kidney transplanted patients, passed through dialysis phase presenting a mandibular edentulism. It will be scheduled one or two dental implants to be inserted in mandible.~This group will be subjected to a dental implant insertion procedure."
3007415|NCT02513602||CONTROL group (healthy patients)|Healthy patients, with an inserted mandibular implant, retrospectively enrolled with a preoperative cbct scan.
3007416|NCT02513589|Experimental|Experimental arm|
3007417|NCT02513576|Experimental|Physiotherapy exercises|Two strategies of abdominal exercises with and without movement of the upper limbs applied in patients with sternal instability as randomization.
3007418|NCT02513563|Experimental|Carboplatin/Paclitaxel/AZD1775|Treatment: Combination of AZD1775 plus carboplatin and paclitaxel. Participants will be treated with this combination of drugs twice daily on days 1 and 2 and once on day 3 for a total of 5 doses during each 21 day cycle of treatment.
3007419|NCT02513550|Experimental|80 mg Ixekizumab Q2W|160 milligrams (mg) ixekizumab given as 2 subcutaneous (SQ) injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 2 weeks (Q2W) to week 52.
3007420|NCT02513550|Experimental|80 mg Ixekizumab Q4W|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 4 weeks (Q4W) to week 52. Placebo administered SQ, Q2W to maintain blind.
3007421|NCT02513550|Experimental|80 mg Ixekizumab Q4W/Q2W|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2 as needed to week 52. Placebo administered SQ, Q2W to maintain blind.
3007422|NCT02513550|Experimental|80 mg Ixekizumab Q2W Maximum Extended Enrollment (ME2) Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q2W to week 52.
3007423|NCT02513550|Experimental|80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q4W to week 52. Placebo administered SQ, Q2W to maintain blind.
3007424|NCT02513550|Experimental|80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2 as needed to week 52. Placebo administered SQ, Q2W to maintain blind.
3007425|NCT02513524||Direct Observed Therapy test|Patients with resistant hypertension (as defined in the eligibility criteria) will be enrolled. They will all have undergone 24 hour ambulatory blood pressure monitoring (ABPM) before enrollment. As part of the study, the subjects will undergo direct observed therapy testing, followed by another 24 hour ABPM, which will be repeated at 1 month.
3007426|NCT02513511|Experimental|Hypnosis|the investigators will put the patient into a hypnotic state and analyze laryngoscopy under hypnosis, followed by intubation.
3007427|NCT02513498|Experimental|Treatment (ixazomib citrate)|Patients receive ixazomib citrate PO once weekly on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response, partial response, or stable disease may receive an additional 6 courses of ixazomib citrate.
3007428|NCT02513485|Active Comparator|Sinemet/Placebo|Subjects with major depression will be given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet will be given first followed by placebo at the subsequent visit.
3007429|NCT02513485|Active Comparator|Placebo/Sinemet|Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit.
3007430|NCT02513472|Experimental|Eribulin Mesylate + Pembrolizumab|Participants with mTNBC previously treated with 0 (stratum 1) or 1 to 2 (stratum 2) lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting.
3007431|NCT02513459|Experimental|ABBV-066|
3007432|NCT02513446|Experimental|BI 1026706|Single dose
3007433|NCT02513446|Experimental|BI 1026706 + Itraconazole|7 days of itraconazole treatment combined with a single dose of 1026706 on day 4
3007434|NCT02513433|Active Comparator|Bupivacaine & Levobupivacaine|Bupivacaine 15 ml 0.5% and Levobupivacaine 15 ml 0.5% in epidural route before surgery
3007435|NCT02513433|Active Comparator|Bupivacaine & Ropivacaine|Bupivacaine 15 ml 0.5% and Ropivacaine 15 ml 0.75% in epidural route before surgery
3007436|NCT02513433|Active Comparator|Ropivacaine & Levobupivacaine|Ropivacaine 15 ml 0.75% and Levobupivacaine 15 ml 0.5% in epidural route before surgery
3007437|NCT02513420|Experimental|Perineal muscle training|This group will recibe a training of a combination of perineal massage and pelvic floor muscle excersice that will start after 33 weeks of gestation. Every week until the childbith, They will be evaluated with a diary.
3007438|NCT02513420|No Intervention|Usual prental care|Usually pregnant women have not a training focused in pelvic floor muscle, so this group won't receive any indication of pelvic floor training except if They complains of urinary incontinence.
3007439|NCT02513407|Experimental|Group I (EML)|Participants complete an assessment on knowledge, attitudes, and behaviors at baseline and attend 2 weekday sessions comprised of interactive education segment that is culturally responsive, and based on the community EML program, and topics including: nutrition guideline, nutrition label reading, comparison shopping/grocery store tour, recipe modification and healthy food preparation, eating healthy on a budget, and making healthy choices outside the home (e.g., restaurants) and physical activity over 1 hour led by CHE, a physical activity conducted by Duarte Fitness Centers instructors over 30 minutes, and cooking/taste test demonstration co-led by the CHE and local chef over 30 minutes over 12 weeks. Participants are also prescribed and encouraged to participate in 3 days a week exercise classes (for > 30 minutes) including salsa, Zumba and other aerobic exercises that are provided at Duarte Fitness Center.
3007440|NCT02513407|Active Comparator|Group II (control)|Participants receive a fitness tracker to track their physical activity and be wait listed to receive the intervention during month 10-12.
3007441|NCT02513394|Experimental|Arm A|Palbociclib at a dose of 125 mg orally once daily, Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle for a total duration of 2 years, in addition to standard adjuvant endocrine therapy for a duration of at least 5 years.
3007442|NCT02513394|Other|Arm B|Standard adjuvant endocrine therapy for a duration of at least 5 years.
3007443|NCT02513381|Active Comparator|Vitamin D3, 3200IU|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
3007444|NCT02513381|Placebo Comparator|Placebo|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
3007445|NCT02513368|Experimental|Bio-Oss®, Bio-Gide®|augmentation procedure with Bio-Oss® and Bio-Gide®
3007446|NCT02513368|Active Comparator|connective tissue graft|augmentation procedure with connective tissue graft
3007447|NCT02513355|Experimental|NP(Changchun marina+cisplatin)+Endostar|Patients in this group will be given conventional chemotherapy medicine,NP plan (Changchun marina+cisplatin)recommended by treatment guidelines for Advanced non small cell lung cancer. Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles;Changchun marina;25mg/m2,d1 and d8,cisplatin 80mg/m2,d1, q21d×4
3007448|NCT02513355|Experimental|TP(Taxol+cisplatin or parapl) +Endostar|"Patients in this group will be given conventional chemotherapy medicine,TP(Taxol+cisplatin)recommended by treatment guidelines for Advanced non small cell lung cancer.~Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles; Taxol;135-175mg/m2,d1,cisplatin or parapl 75mg/m2,d1,q21d×4."
3007449|NCT02513342|Experimental|Endostar+Docetaxel+Cisplatin|Patients in this group will be given conventional chemotherapy medicine: Docetaxel+Cisplatin chemotherapy recommended by treatment guidelines for Advanced Non-small Cell Lung Squamous Carcinoma , and the Endostar-Recombinant human endostatin injection is injected by 30mg continuous intravenous injection pump,d1-d7.
3007450|NCT02513342|Active Comparator|Docetaxel+Cisplatin|Patients in this group will be given conventional chemotherapy medicine: Docetaxel+Cisplatin chemotherapy recommended by treatment guidelines for Advanced Non-small Cell Lung Squamous Carcinoma.
3007451|NCT02513329|Active Comparator|Bupivicaine|Stellate Ganglion Block injection with bupivacaine
3007452|NCT02513329|Sham Comparator|Saline|Saline injection
3007453|NCT02513316||Study I (AF)|Prospective cohort study of patients anticoagulated after cardioembolic stroke started on best practice oral anticoagulant (without prior use) for presumed cardioembolic ischaemic stroke due to non-valvular AF with follow up for the occurrence of ICH, ischaemic stroke and cognitive function for an average of two years. Our main baseline exposures (risk factors of interest) are the presence of CMBs on MRI, and genetic polymorphisms in candidate genes with potential functional relevance to ICH risk.
3007454|NCT02513316||Study II (ICH)|Observational and genetics study of intracerebral haemorrhage Patients with ICH (non anticoagulant-related ICH cases and anticoagulant-related ICH cases).
3007455|NCT02513303|Experimental|Treatment Group|AV fistula surgery with investigational product (Sirolimus-eluting Collagen Implant)
3007456|NCT02513303|No Intervention|Control Group|AV fistula surgery without investigational product
3007457|NCT02513290|Experimental|Bilastine group|Bilastine 20 mg administered once a day for ten days.
3007458|NCT02513290|Experimental|Loratadine group|Loratadine 10 mg administered once a day for ten days.
3007459|NCT02513251||Case group|Chronic pain patient
3007509|NCT02512887|Active Comparator|Dorsal Penile Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine without epinephrine into the dorsal portion of the penis.
3007510|NCT02512874|Other|Pulmonary Rehabilitation|One arm study - all participants will go to pulmonary rehabilitation, received questionnaires, DEXA scans, Dynamometer and gait speed tests and activity measured through an activity monitor.
3007939|NCT02509962|Experimental|Slow sodium tablets|Increased dietary salt intake
3007460|NCT02513238|Active Comparator|Stemcells injected into submandibularis|The surgical procedure is done under local anaesthesia using ultrasonic guidance and sterile technique. After receiving the MSC-suspension , the surgeon will identify the submandibular glands and inject the suspension MSCs into the submandibular gland. Calculation of injected number of MSCs pr. participant rests on the following calculation: 2.8 x 10^6 MSC / Cm^3 X volume , where volume is the volume of the submandibular gland, and a gland-volume of app. 7-8cm3 is the norm. Therefore the amount of cells given to each participant will be app. 4.6 x 10^7 MSC in total. Afterwards the participant will be given a band-aid and over the counter analgesics.
3007461|NCT02513238|Placebo Comparator|Saltwater injected into submandibularis|The surgical procedure is done under local anaesthesia using ultrasonic guidance and sterile technique. After receiving the placebo-suspension , the surgeon will identify the submandibular glands and inject the suspension. Placebo will be 2ml of Isotonic NaCl (0,9mg/ml) and HA 1%.
3007462|NCT02513225|Experimental|Intervention|The adapted Project EMPWR will be comprised of 2 sessions delivered approximately 7-10 days apart by a trained Apache paraprofessional interventionist. In the first session, interventionists will use curriculum to help participants understand their personal risk factors for STDs including HIV/AIDS (i.e., substance use, mental and emotional health, sexual health, etc.) and develop an achievable personalized risk-reduction plan that emphasizes individual and community-based strengths and resources.The second counseling session will consist of the disclosure of results (if tested) and the provision of social support to help participants develop a longer-term risk-reduction plan. At visit two, participants in both groups will be offered a STD screening protocol test.
3007463|NCT02513225|Other|Control|The comparison condition will consist of Optimized Standard Care (OSC) alone. All participants will receive OSC at the first visit. OSC includes the distribution of educational pamphlets and provision of information on substance use, signs and symptoms of mental health problems, and information about STD screening resources. At visit two, participants in both groups will be offered a STD screening protocol test.
3007464|NCT02513212|Other|oxalate liquid, SnF2 paste, manual toothbrush|Potassium oxalate liquid, professionally applied Stannous fluoride paste, self applied Manual toothbrush
3007465|NCT02513212|Other|oxalate liquid, SnF2 paste, power toothbrush|Potassium oxalate liquid, professionally applied Stannous fluoride paste, self applied Power toothbrush
3007466|NCT02513199|Experimental|TACE/SBRT combination|
3007467|NCT02513199|Active Comparator|TACE alone|
3007468|NCT02513186|Experimental|Isatuximab|"Isatuximab (escalating dose) + bortezomib + cyclophosphamide + dexamethasone (VCDI): Induction phase will be 50 weeks (12 cycles). The duration of a cycle will be 42 days (6 weeks) for Cycle 1 (C1) and 28 days (4 weeks) for subsequent cycles. The duration of a cycle of the maintenance phase will be 28 days (4 weeks). After C12, isatuximab will be administered at its initial assigned dose and dexamethasone once every 28 days.~Isatuximab + bortezomib + dexamethasone + lenalidomide (VRDI): Induction phase will be 24 weeks (4 cycles at 6 weeks/cycle). The duration of a cycle of the maintenance phase will be 28 days (4 weeks). Maintenance therapy may continue until disease progression, unacceptable AE or patient willingness to discontinue.~Enrollment to begin after the VCDI cohort is completed."
3007469|NCT02513173||Low back pain group|No intervention
3007470|NCT02513173||Control|No intervention
3007471|NCT02513160|Experimental|Beclomethasone dipropionate BAI 320|"Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) at 320 mcg/day (40 mcg/inhalation, 4 inhalations twice daily)~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
3007472|NCT02513160|Experimental|Beclomethasone dipropionate BAI 640|"Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) at 640 mcg/day (80 mcg/inhalation, 4 inhalations twice daily)~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
3007473|NCT02513160|Active Comparator|Beclomethasone dipropionate MDI 320|"Beclomethasone dipropionate Metered Dose Inhaler (MDI) 320 mcg/day (40 mcg/inhalation, 4 inhalations twice daily)~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
3007474|NCT02513160|Placebo Comparator|Placebo|"Pooled breath-actuated inhaler (BAI) or metered-dose inhaler (MDI) placebo groups. Participants were instructed to take 4 inhalations twice daily for 6 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
3007475|NCT02513147|Experimental|2 NRTI+ Dolutegravir|22 patients will be treated with 2 NRTI+Dolutegravir 50 mg during 24 weeks
3007476|NCT02513147|Active Comparator|2 NRTI + PI|22 patients will be treated with 2 NRTI + PI during 24 weeks
3007477|NCT02513121|Active Comparator|Dietary modification|Low free sugar diet
3007478|NCT02513121|No Intervention|Observational Arm|Standard of care
3007479|NCT02513108|Active Comparator|same day discharge|patients discharged same day after uncomplicated PCI
3007480|NCT02513108|No Intervention|standard care|standard care where patients are discharged the day after procedure after adequate observation
3007481|NCT02513095|Experimental|Ryanodex|Ryanodex (dantrolene sodium) for injectable suspension administered as an IV bolus, in addition to standard of care (SOC) treatment.
3007482|NCT02513095|No Intervention|Standard of Care only (SOC)|Standard of Care (SOC) treatment only, consisting of body cooling and supportive measures implemented immediately.
3007483|NCT02513082|Experimental|Femoral nerve block|Femoral nerve block will be performed just one time after total knee arthroplasty in general anesthesia state
3007484|NCT02513082|Active Comparator|Adductor canal block|Adductor canal block will be performed just one time after total knee arthroplasty in general anesthesia state
3007511|NCT02512861|Active Comparator|Bupivacaine|Bupivacaine as a parasternal nerve block following pediatric cardiothoracic surgery
3007512|NCT02512861|Placebo Comparator|Placebo|Normal Saline
3007513|NCT02512848||endometrial neoplasms|patients with risk of endometrial cancer in the postmenopausal period
3007514|NCT02512835||Clinic patients|Aims 1a and 1b: The participants include all unique patients seen at the 12 study practices (approximately 170,000 patients over the past two years).
3007485|NCT02513069|Experimental|Mobile Contingency Management (mCM)|"The mCM arm represents a proactive tele-health intervention that combines guideline based cognitive-behavioral smoking cessation telephone counseling, a tele-medicine clinic for access to nicotine replacement therapy (NRT), and intensive behavioral therapy administered via a smart phone (with carbon monoxide monitor) based application. NRT may include nicotine patches (21 mg, 14 mg, and or 7 mg) used daily for six weeks from the smoking quit date. Dosage will depend on participants' reported smoking patterns and carbon monoxide readings. NRT may also include a rescue method, i.e., either nicotine gum or nicotine lozenge. The participants' preferred NRT rescue method will be prescribed and used as needed to reduce smoking craving for six weeks from the smoking quit date."
3007486|NCT02513069|Active Comparator|Tele-Health for Smoking Ccessation|"TELE-HEALTH FOR SMOKING CESSATION is a proactive tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same guideline based cognitive-behavioral smoking cessation telephone counseling, and tele-medicine clinic for access to NRT as in the mCM intervention. NRT may include nicotine patches (21 mg, 14 mg, and or 7 mg) used daily for six weeks from the smoking quit date. Dosage will depend on participants' reported smoking patterns and carbon monoxide readings. NRT may also include a rescue method, i.e., either nicotine gum or nicotine lozenge. The participants' preferred NRT rescue method will be prescribed and used as needed to reduce smoking craving for six weeks from the smoking quit date."
3007487|NCT02513030||Replacement of defibrillator|
3007488|NCT02513017|Experimental|Stimulus Control Instructions (SCI)|"SCI is a behavioral treatment that aims to assist persons with insomnia to re-associate the bed and the bedroom with falling asleep or back to sleep, and to acquire a consistent sleep pattern. SCI entails specific instructions that focus on developing new sleep habits, such as avoiding activities other than sleep (e.g., reading, watching TV) in bed, and getting out of bed if unable to fall asleep and engaging in quiet activities until sleepy.~A trained therapist will deliver the session in which the following topics will be covered: education about sleep, factors that influence sleep, behaviors that promote or interfere with sleep, and SCI. The session will be offered in a small group (4-6) format, based on availability of participants and to avoid any delay in treatment receipt."
3007489|NCT02513017|Experimental|Sleep Restriction Therapy (SRT)|SRT aims at consolidating sleep by limiting sleep to a specified time and restricting the amount of time spent in bed. Sleep time is individualized based on the persons' sleep needs, and the sleep-wake schedule is planned to fit the persons' lifestyle. The sleep-wake schedule is changed to accommodate improvements in the persons' sleep, over time.. A trained therapist will deliver the session in which the following topics will be covered: education about sleep, factors that influence sleep, behaviors that promote or interfere with sleep, and SRT. The session will be offered in a small group (4-6) format, based on availability of participants and to avoid any delay in treatment receipt.
3007490|NCT02513017|No Intervention|No therapy|No behavioral therapy for the management of insomnia is provided. However, a list of general recommendations and suggestions are provided to participants.
3007491|NCT02513004|Experimental|Ticagrelor|Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose.Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
3007492|NCT02513004|Active Comparator|Clopidogrel|Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
3007493|NCT02512991||HEMS patients|Patients bound for Percutaneous Coronary Intervention (PCI) at the PCI centre at Copenhagen University Hospital, Rigshospitalet, and who were transported by Helicopter Emergency Medical Service (HEMS) in a 36-month period (May 1st 2010 - April 30th 2013).
3007494|NCT02512991||GEMS patients|Patients bound for Percutaneous Coronary Intervention (PCI) at the PCI centre at Copenhagen University Hospital, Rigshospitalet, and who were transported by Ground Emergency Medical Service in a 40-month period (January 1st 2010 - April 30th 2013).
3007495|NCT02512978|Experimental|Levothyroxine group|The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.
3007496|NCT02512978|No Intervention|Standard therapy group|The patients in this group receive standard therapy in consistent with the local clinical practice.
3007497|NCT02512965|Active Comparator|Standard Conventional Radiotherapy|Standard Conventional Radiotherapy (CRT) 20 Gy in 5 fractions
3007498|NCT02512965|Experimental|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy (SBRT) 24 Gy in 2 fractions
3007499|NCT02512952|Active Comparator|Group 1|SRP with Open flap debridement (OFD) alone for treating periodontal pocket
3007500|NCT02512952|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into bone defect
3007501|NCT02512952|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Titanium Platelet rich fibrin (TPRF) placement into bone defect
3007502|NCT02512939|Experimental|Contacts of TB cases|Blood test, not yet marketed, development phase
3007503|NCT02512926|Experimental|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide
3007504|NCT02512913|Experimental|Adapted/enhanced MAPS|Counseling sessions delivered by phone to the pregnant/postpartum women and to the husbands/partners
3007505|NCT02512913|No Intervention|Usual Care|Couples in the control condition will receive usual care
3007506|NCT02512900|Experimental|MEDI9929, 140 mg, Cohort 1 (12 to 14 years)|On Day 1, one MEDI9929 subcutaneous injection of 70 mg was given into the anterior aspect of one thigh immediately followed by the second injection of 70 mg into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants with 12 to 14 years of age.
3007507|NCT02512900|Experimental|MEDI9929, 140 mg, Cohort 2 (15 to 17 years)|On Day 1, one MEDI9929 subcutaneous injection of 70 mg was given into the anterior aspect of one thigh immediately followed by the second injection of 70 mg into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants with 15 to 17 years of age.
3007508|NCT02512887|Experimental|Caudal Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine 1mL/kg without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
3007515|NCT02512835||Clinicians|Aims 2 and 3: The clinicians in this analysis will include 15 participants recruited from the approximately 100 clinicians at the 12 practices
3007516|NCT02512822|Experimental|Participants|Noninvasive Radiofrequency
3007517|NCT02512809|Experimental|Isoflurane Arm|Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with isoflurane.
3007518|NCT02512809|Experimental|Dexmedetomidine/remifentanil Arm|Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with dexmedetomidine and remifentanil infusions..
3007519|NCT02512809|No Intervention|MRI Control Arm|Otherwise healthy pediatric patients, aged 0-5 years, undergoing MRI with general anesthesia for evaluation of non-neurologic disease. Patients will receive a standardized general anesthetic with isoflurane.
3007520|NCT02512796||Transplant patients, MRI with Gadolinium contrast dye|Patients with kidney, pancreas or liver transplant and exposed to gadolinium contrast agents.
3007521|NCT02512796||Non-transplant patients, MRI with Gadolinium contrast dye|Non-transplant patients exposed to gadolinium contrast.
3007522|NCT02512796||Healthy controls, no transplant no Gadolinium contrast dye|Age- and sex-matched healthy controls not exposed to gadolinium contrast.
3007523|NCT02512783|Active Comparator|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine immediately prior to propofol induction.
3007524|NCT02512783|Placebo Comparator|Normal Saline|Administration of 1ml of pre-treatment normal saline immediately prior to propofol induction.
3007525|NCT02512770|Experimental|dilatation|esaphageal dilatation group
3007526|NCT02512770|No Intervention|control|control group ( only endoscopy for control)
3007527|NCT02512757||Group 1|Patients with lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and diagnosed with primary lung cancer who have not yet initiated treatment of any kind for their lung cancer will contribute a fasting blood sample.
3007528|NCT02512757||Group 2|Patients whose most recent screening imaging is within 60 days who have lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and determined to not be cancerous OR that have demonstrated no nodule growth for >2 years by repeat CT imaging will contribute a fasting blood sample.
3007529|NCT02512757||Group 3|Patients who have undergone low-dose computed tomography (LDCT) or standard computed tomography (CT) or X-ray testing to screen for lung cancer with no nodules suspicious for lung cancer within 1 year prior to signing informed consent will contribute a fasting blood sample.
3007530|NCT02512744|No Intervention|Capping trial protocol|"Decannulation protocol based on tolerance to 24 hours capping trial to decide when to decannulate.~Decapping during the capping trial for aspiration of respiratory secretions is considered a failure criteria of the trial.~High flow conditioned oxygen therapy through tracheal cannula will be applied during periods out of capping trials."
3007531|NCT02512744|Experimental|Suctioning frequency protocol|"Decannulation protocol based on suctioning frequency to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).~Intervention: suctioning frequency of respiratory secretions will be recorded untill fulfill decannulation criteria. Capping trials will not be allowed in this group.~High flow conditioned oxygen therapy will be applied through tracheal cannula during all the study period."
3007532|NCT02512731|Active Comparator|Goal directed fluid therapy using esophageal doppler monitor|The esophageal doppler monitor directs the fluid therapy.
3007533|NCT02512731|No Intervention|Fluid therapy using standard management|The esophageal doppler monitor is in place however blinded to the healthcare providers, fluid management is as per standard clinical practice.
3007534|NCT02512718|Experimental|Fish Oil Lipid Emulsion|1 g/kg intravenous fish oil lipid emulsion (Omegaven) daily, provided starting day of transplant through day 30 or hospital discharge, whichever comes first.
3007535|NCT02512718|Active Comparator|Soybean Oil Lipid Emulsion|1 g/kg intravenous soybean oil lipid emulsion (SOLE) daily, provided starting day of transplant through day 30 or hospital discharge, whichever comes first.
3007536|NCT02512705|Other|Seclusion Room|The current practice is followed as a control group A.
3007537|NCT02512705|Experimental|Physical Restraint|Patient is placed in physical restraints to enable delivery of chemical restraints and medical monitoring and is monitored 1:1.
3007538|NCT02512692|Experimental|90Y TARE with Gemcitabine and Cisplatin|"90Y TARE will be given on day 3 or 4 of cycle 1 and start at 75% of the dose calculated by the body surface area formula and escalated by 25% per cohort in combination with cisplatin 25 mg/m2 and gemcitabine 300 mg/m2 in cycles 1 and 2.~Once the 90Y TARE has reached the 100% dose level, the gemcitabine dose will increase to 600mg/m2 in dose level 3 and 1000mg/m2 in dose level 4. The cisplatin dose will remain at 25/mg/m2.~For all dose levels, from cycle 3 to cycle 8, the cisplatin dose will be 25mg/m2 and the gemcitabine dose will be 1000mg/m2."
3007539|NCT02512679|Other|Cyclophosphamide Dose Level 1|"Cyclophosphamide given by Intravenous (IV) at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level.~Drug to be given in combination of Busulfan, Campath and Fludarabine"
3007540|NCT02512679|Other|Cyclophosphamide Dose Level 2|Cyclophosphamide given by intravenous (IV) at a total dose of 70 mg/kg (divided in two doses) given once a day for two days in combination with Busulfan, Campath and Fludarabine.
3007541|NCT02512679|Other|Cyclophosphamide Dose Level 3|Cyclophosphamide given by intravenous (IV) at total does of 35 mg/kg as a one time dose in combination with Busulfan, Fludarabine and Campath
3007542|NCT02512679|Other|Cyclophosphamide Dose Level 4|No cyclophosphamide given with Busulfan, Fludarabine and Campath
3007543|NCT02512666|Experimental|Non-Invasive Imaging|"Commercial portable optical microscope (AM4113-N5UT Dino-Lite ) which will be employed during the study for a pre determined time of non-invasive imaging of the nailfold capillaries in ASCT patients.~For Autologous Stem Cell Transplant (ASCT) participants, the imaging will be performed once prior to ASCT upon admission to the hospital, and then daily after ASCT (starting on day +7) until count recovery"
3007544|NCT02512653|Experimental|1|Cupressus arizonica allergen extract at 4 different concentrations. Positive control. Negative control
3007545|NCT02512640|Active Comparator|Volume-controlled ventilation|Volume-controlled ventilation throughout the surgery
3007546|NCT02512640|Active Comparator|Pressure-controlled ventilation|Pressure-controlled ventilation throughout the surgery
3007547|NCT02512627|Active Comparator|Cognitive training group (Cog)|The BrainHQ program will be used to train different cognitive functions of the participants. The participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions. The tasks will become more difficult as the participants progress in their abilities.
3007548|NCT02512627|Active Comparator|Physical exercise group (PE)|The participants in this group participate in multimodal exercise programs including aerobic exercise, balance, and strength training. The entire exercise program for the PE group will contain 10 minutes of warm-up, 70 minutes of physical exercise, and 10 minutes of cool-down. The 70 minutes of exercise session will be break up into 2 to 3 parts, and the participants can rest as needed during the exercise period.
3007549|NCT02512627|Experimental|Sequential training group (Seq)|The participants in this group will first perform 45 minutes of physical exercise followed by 45 minutes of cognitive training. The physical exercise training will be similar to the programs used in the PE group. The entire exercise program for the PE group will contain 5 minutes of warm-up, 35 minutes of physical exercise, and 5 minutes of cool-down. The cognitive training will be implemented with BrainHQ similar to what has been described in the COG group.
3007550|NCT02512627|Experimental|Dual-task training group (Dual)|In this group, the participants will be instructed to perform physical exercise and cognitive tasks simultaneously (e.g., math calculation while stepping). The difficulty of the cognitive tasks will increase as the participants improve in their performance.
3007551|NCT02512614|No Intervention|Comparison|Hand hygiene education.
3007552|NCT02512614|Experimental|Intervention|Hand hygiene education and 4 antimicrobial hand towels
3007553|NCT02512601|Experimental|Sulodexide|Compression therapy + Sulodexide (two capsules of Sulodexide 15 mg twice daily).
3007554|NCT02512588|Experimental|BTD-001|
3007555|NCT02512588|Experimental|Placebo|
3007556|NCT02512575|Experimental|AZD9567 oral suspension|"In Part A: up to 8 cohorts with single ascending doses (starting at 2 mg up to 200 mg).~In Part B: one cohort with a single dose"
3007557|NCT02512575|Placebo Comparator|Placebo|Subjects randomized to placebo in the first 8 cohorts will receive the same dose volume of oral suspension as subjects on AZD9567 and subjects randomized to placebo in cohort 9(prednisolone cohort) will receive the same number of capsules as subjects on prednisolone.
3007558|NCT02512575|Experimental|Prednisolone capsules|"Within each cohort 6 subjects will be randomized to receive prednisolone 60mg oral capsules and 2 subjects randomized to receive matching placebo in a fasted state.~Sentinel dosing will not be employed for the prednisolone cohort. The SRC will not be required to evaluate the prednisolone cohort. This cohort can be performed at any time during clinical execution of the study provided the protocol amendment was approved."
3007559|NCT02512562|Active Comparator|Group 1: AL-335, Simeprevir and ACH-3102|AL-335, ACH-3102, and Simeprevir dosed in healthy human volunteers once daily for 24 days.
3007560|NCT02512562|Active Comparator|Group 2: AL-335, Simeprevir and ACH-3102|AL-335, ACH-3102, and Simeprevir dosed in healthy human volunteers once daily for 24 days.
3007561|NCT02512549|Active Comparator|Rehabilitation|Patients with diagnosed Chronic Obstructive Pulmonary Disease with severe airflow obstruction (spirometric forced expiratory volume in one second (FEV1) below 50% of the normal) and modified medical research council (mMRC) dyspnea grading 1 to 3 will undergo pulmonary rehabilitation program thrice a week for 2 months.
3007562|NCT02512549|No Intervention|Usual Care|Patients with COPD as described in rehabilitation arm, will be provided usual care from the hospital outpatient clinic.
3007563|NCT02512536|Experimental|Experimental|"Intervention:~Subjects receiving a single ultrasound scan guided injection of Botulinum Toxin type A into the supraspinatus muscle belly.~Drug: Dysport 300 units im. One single injection over course of study."
3007564|NCT02512523|Experimental|Teneligliptin|Film-coated tablet for oral administration Dosage: 20mg/tablet Frequency and duration: 1 tablet/day for 4 weeks
3007565|NCT02512523|Active Comparator|Sitagliptin|Film-coated tablet for oral administration Dosage: 100mg/tablet Frequency and duration: 1 tablet/day for 4 weeks
3007566|NCT02512510|Active Comparator|TD-4208-1|88 mcg
3007567|NCT02512510|Active Comparator|TD-4208-2|175 mcg
3007568|NCT02512510|Placebo Comparator|Placebo|Placebo
3007569|NCT02512497|Experimental|Romidepsin + Busulfan + Fludarabine + Stem Cell Transplant|"Part 1:~Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies. Fludarabine 40 mg/m2 by vein on Days -6 to -3. Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the optimal dose. Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1. Stem cell infusion on Day 0.~Romidepsin Maintenance Therapy - Part 2:~Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
3007570|NCT02512484||high risk TB individuals attending A&E Departments|Assessment against inclusion/exclusion criteria in terms of risk of TB. If eligible, assessment and testing as appropriate for active or latent TB
3007571|NCT02512471|Experimental|middle aged group|brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB
3007572|NCT02512471|Active Comparator|young group|brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB
3007573|NCT02512458|Experimental|Cabazitaxel|Patient will be treated with iv cabazitaxel 25mg/m2 q 21days per standard clinical practice for up to 10 cycles or until disease progression or unacceptable toxicity or physician's decision or patient's consent withdrawal (whichever occurs first).
3007574|NCT02512445|Experimental|Trauma Informed Guilt Reduction Therapy|6-session psychotherapy intervention
3007575|NCT02512445|Active Comparator|Supportive Care Therapy|6-session psychotherapy intervention
3007576|NCT02512419|Experimental|Text-Enhanced Physical Activity Intervention Arm|The Spanish-language PA intervention is based on SCT and Transtheoretical Model (TTM), and emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting PA goals).
3007648|NCT02511964|Experimental|Interval Training at 1% incline|Six Sessions of High Intensity Interval Running (100% VO2Max) at 1% incline; Group metabolically balanced.
3007577|NCT02512419|Active Comparator|Health Education Control Arm|The health education control arm will receive the publicly available NHBLI Spanish-language booklets on heart-healthy behaviors for Latinos, which include information on PA, diet, and stress management.
3007578|NCT02512406||Patients with Tourette Syndrome|Questionnaires including the Sensory Profile or the Adult/Adolescent Sensory profile and Children's Yale-Brown Obsessive Compulsive Scale or Yale Global Tic Severity Scale will be administered. When time permits, the Children's Yale-Brown Obsessive Compulsive Scale or Yale-Brown Obsessive Compulsive Scale will also be administered. Demographic data will also be collected for each study patient.
3007579|NCT02512393|Experimental|Active tDCS|This group will receive five daily sessions of 2mA, 20 minutes of Transcranial Direct Current Stimulation (tDCS). The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, and gait speed, Assessment of conditioned pain modulation, and Blood test.
3007580|NCT02512393|Sham Comparator|Sham tDCS|This group will receive five daily sessions of 2mA, current for 30 seconds tDCS. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, Assessment of conditioned pain modulation, and gait speed and Blood test.
3007581|NCT02512380|Experimental|SLOT group|4 cycles preoperative chemotherapy with Docetaxel+oxaliplatin+s1 . Gastric resection. 6 cycles adjuvant chemotherapy with sequential oxaliplatin+s1 or oxaliplatin+s1,then s1 for 6 months。
3007582|NCT02512380|Active Comparator|SOX group|3 cycles preoperative chemotherapy with oxaliplatin+s1. Gastric resection. 4 cycles adjuvant chemotherapy with sequential oxaliplatin+s1
3007583|NCT02512367|Experimental|Intervention|
3007584|NCT02512367|Placebo Comparator|Surveillance|
3007585|NCT02512354|Other|Fetus|
3007586|NCT02512354|Other|Parents of the fetus|
3007587|NCT02512328|No Intervention|Regular colonoscopy preparation|Comparison group. Regular colonoscopy preparation
3007588|NCT02512328|Experimental|APP supported colonoscopy preparation|APP as additional device for colonoscopy preparation
3007589|NCT02512315|Active Comparator|CRT group (Group A)|Patients who are allocated into in this group will be treated with concurrent chemoradiation (CRT).
3007590|NCT02512315|Experimental|NACT-CRT group (Group B)|Patients who are allocated into in this group will be treated with 4 cycles of neoadjuvant chemotherapy (NACT, docetaxel plus cisplatin) followed by CRT.
3007591|NCT02512302|Experimental|SUN-101 via eFlow nebulizer|50 mcg glycopyrrolate via Electronic Nebulizer
3007592|NCT02512302|Experimental|SUN-101 via eFlow nebulizer with activated charcoal|50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
3007593|NCT02512302|Active Comparator|Seebri® Breezhaler®|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
3007594|NCT02512302|Active Comparator|Seebri® Breezhaler® with activated charcoal|: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
3007595|NCT02512302|Active Comparator|: Glycopyrrolate Injection|50 mcg glycopyrrolate via IV infusion
3007596|NCT02512289|Active Comparator|Real stimulation|real tDCS associated with robot-assisted therapy (RAT)
3007597|NCT02512289|Sham Comparator|Sham stimulation|Sham tDCS associated with RAT
3007598|NCT02512276|Experimental|Telepharmacist intervention|Patients diagnosed with diabetes, hypertension, or hyperlipidemia exhibiting sub-optimal adherence to their medications [defined as combined (average of averages) proportion of days covered (PDC) < 80%] who also have poor or worsening disease control.
3007599|NCT02512276|No Intervention|Usual care|Patients randomized to this arm will receive usual care.
3007600|NCT02512263|Experimental|Intervention group|They will have to do all the tests and to follow the home-based training program during 9 weeks.
3007601|NCT02512263|No Intervention|control group|They will have to do all the tests but not to follow the home-based training program.
3007602|NCT02512237|Experimental|Phase 1a: Dose-Escalation|Six cohorts with escalated dose levels of ARX788 at 0.33 mg/kg, 0.66 mg/kg, 1.3 mg/kg, 2.2 mg/kg, 2.9 mg/kg and 3.8 mg/kg will be administered every 3 weeks via intravenous infusion to determine the MTD.
3007603|NCT02512237|Experimental|Phase 1b: Dose-evaluation 1|Breast cancer subjects with high HER2 expression, categorized as ISH positive or IHC3+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
3007604|NCT02512237|Experimental|Phase 1b: Dose-evaluation 2|Breast cancer subjects with mid/low HER2 expression, categorized as ISH negative AND IHC2+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
3007605|NCT02512237|Experimental|Phase 1b: Dose-evaluation 3|Gastric cancer subjects with high HER2 expression, categorized as ISH positive or IHC3+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
3007606|NCT02512224||Parenteral nutrition|investigators selected participants aged 20 years or older who had undergoneparenteral nutrition by central venous port insertion between April 1, 2012, and March 31, 2013.
3007607|NCT02512224||Enteral nutrition|investigators selected participants aged 20 years or older who had undergone enteral nutrition by percutaneous endoscopic gastrostomy, percutaneous transesophageal gastrotubing, or ileostomy between April 1, 2012, and March 31, 2013.
3007608|NCT02512211||Patients adults|Sample of patients with haemophilia over 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
3007609|NCT02512211||Children with haemophilia|Sign hemophilia patients under 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
3007610|NCT02512211||Parents of children with haemophilia|Sample of parents of children with hemophilia under 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
3007611|NCT02512198|Experimental|Bronchodilators|"Prescription Data Feedback to GP Practices - practices will be fed back data for people with presumed asthma who have either been dispensed more than 12 short-acting beta-agonist bronchodilators in the last 12 months who are not concurrently prescribed inhaled corticosteroids (poor asthma control with inadequate prevention) or been dispensed a long-acting beta-agonist bronchodilator as a single agent in the last 12 months who are not or are only infrequently concurrently prescribed inhaled corticosteroids (potentially harmful prescribing). To minimise inclusion of people with COPD, patient aged 35 years and older prescribed long-acting antimuscarinic bronchodilators will be excluded.~Practices in the bronchodilator arm are controls for the antibiotic experimental arm (below)."
3007612|NCT02512198|Experimental|Antibiotics|"Prescription Data Feedback to GP Practices - number of women in the GP practice aged 12 years and older dispensed more than 6 courses of urinary tract infection (UTI) antibiotics in the last year. UTI antibiotics are defined as trimethoprim, nitrofurantoin, co-trimoxazole, quinolones and cefalexin.~Practices in the antibiotic arm are controls for the bronchodilator experimental arm (above)."
3007613|NCT02512185||Chemotherapy|Men starting first-line chemotherapy for mCRPC (typically Docetaxel and Prednisone)
3007614|NCT02512185||Abiraterone|Men with mCRPC starting Abiraterone
3007615|NCT02512185||Enzalutamide|Men with mCRPC starting Enzalutamide
3007616|NCT02512172|Experimental|Oral CC - 486 & MK-3475|Oral CC - 486 300 mg days 1-14 or 21 every 28 days + IV MK-3475 200 mg days 1 and 15 every 28 days
3007617|NCT02512172|Experimental|Romidepsin & MK-3475|Romidepsin 14 mg/m2 days 1, 8 and 15 + IV MK-3475 200 mg days 1 and 15 every 28 days
3007618|NCT02512172|Experimental|Oral CC - 486 & Romidepsin & MK-3475|Oral CC - 486 300 mg days 1-14 or 21 + romidepsin 7 mg/m2 (days 1, 8 and 15) + IV MK-3475 200 mg days 1 and 15 every 28 days.
3007619|NCT02512159|Experimental|drenovac handcrafted|Patients treatment with the handicraft topical device negative pressure therapy Economic craft
3007620|NCT02512159|Active Comparator|Healing|"Patients who were managed with traditional conservative treatment."
3007621|NCT02512146||Irritable bowel syndrome|Patients meeting Rome III criteria of irritable bowel syndrome. Intervention: colonoscopy.
3007622|NCT02512146||Normal controls|"Asymptomatic individuals for health surveillance or patients for follow up after polypectomy.~Intervention: colonoscopy."
3007623|NCT02512133|Experimental|MIGS Hydrus Ivantis|opening the anterior chamber (2mm.) injecting visco-material, injecting the Hydrus stent in the Schlemm's canal under gonioscopic control
3007624|NCT02512133|Experimental|SLT|Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
3007625|NCT02512120|Experimental|volume controlled ventilation|Randomized 23 patients will be applied VCV during RALP.
3007626|NCT02512120|Active Comparator|autoflow-volume controlled ventilation|Randomized 23 patients will be applied autoflow-VCV during RALP.
3007627|NCT02512107|Active Comparator|Juice Plus+|Subject will be taking supplement.
3007628|NCT02512107|Placebo Comparator|Placebo|Subjects will be taking the placebo.
3007629|NCT02512068|Experimental|SYR-472 25 mg|One tablet of SYR-472 25 mg orally once weekly before breakfast (in both Treatment Period I and II)
3007630|NCT02512068|Experimental|Placebo and SYR-472 25 mg|Treatment Period I: One placebo tablet orally once weekly before breakfast Treatment Period II: One tablet of SYR-472 25 mg orally once weekly before breakfast
3007631|NCT02512055|Experimental|Group 1|Pediatric patients undergoing repeat radiotherapy session under ketamine sedation
3007632|NCT02512042|Experimental|Brinzolamide 1% Ophthalmic suspension|Brinzolamide Pharmaceutical dosage form: Ophthalmic suspension Strength: 1% Manufactured by: Indoco Remedies, Ltd for Watson Pharma Pvt. Ltd
3007633|NCT02512042|Active Comparator|Azopt® 1% Ophthalmic suspension|Azopt® (Contains Brinzolamide) Pharmaceutical dosage form: Ophthalmic suspension Strength: 1% Manufactured by: Alcon Laboratories, Inc
3007634|NCT02512029|Experimental|TBI Subjects|Subjects with history of recent subacute Traumatic Brain Injury (TBI) will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of 18F-AV-1451 2 to 6 weeks following injury. They will return for a follow-up injection approximately 6 months following injury.
3007635|NCT02512029|Experimental|Control|Cognitively healthy volunteer subjects will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of 18F-AV-1451.
3007636|NCT02512016|Other|Nulliparous Women in Third Trimester|Study Procedures
3007637|NCT02512003|Experimental|Fantom Treatment group|
3007638|NCT02511990|Experimental|Group 1A|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml~3 mg/kg, single dose IV administration of 10-1074"
3007639|NCT02511990|Experimental|Group 1B|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml~10 mg/kg, single dose IV administration of 10-1074"
3007640|NCT02511990|Experimental|Group 1C|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml~30 mg/kg, single dose IV administration of 10-1074"
3007641|NCT02511990|Experimental|Group 1D|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml~30 mg/kg, single dose IV administration of 10-1074"
3007642|NCT02511990|Experimental|Group 2A|"HIV-uninfected individuals~3 mg/kg, single dose IV administration of 10-1074"
3007643|NCT02511990|Experimental|Group 2B|"HIV-uninfected individuals~10 mg/kg, single dose IV administration of 10-1074"
3007644|NCT02511990|Experimental|Group 2C|"HIV-uninfected individuals~30 mg/kg, single dose IV administration of 10-1074"
3007645|NCT02511990|Experimental|Group 2D|"HIV-uninfected individuals~30 mg/kg, single dose IV administration of 10-1074"
3007646|NCT02511977||overdenture with annual maintenance|Rehabilitation should be: overdenture with at least 2 implants placed in the mandible and 3 implants in the maxilla per person. They were divided into two groups: Group I: Annual maintenance for the past seven years
3007647|NCT02511977||overdenture whitout annual maintenance|Group II: individuals who have not returned for the last seven years. Individuals who said they went to the dentist at least once a year, for whatever treatment, were included in the maintenance group. Individuals who denied any visit to the dentist in the last seven years were included in the no maintenance group.
3040815|NCT02288481|Experimental|Cohort 5 400 mg TBA-354|
3007649|NCT02511964|Experimental|Interval Training at 10% incline|Six Sessions of High Intensity Interval Running (100% VO2Max) at 10% incline; Group metabolically balanced.
3007650|NCT02511964|No Intervention|Control|Only Dependent Variables Measures
3007651|NCT02511951|Experimental|one-layer duct-to-mucosa anastomosis|one-layer duct-to-mucosa anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
3007652|NCT02511951|Active Comparator|two-layer duct-to-mucosa anastomosis|two-layer duct-to-mucosa anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
3007653|NCT02511938|Experimental|Menu Only intervention|Restaurants will receive a new healthy kids' menu
3007654|NCT02511938|Experimental|Menu Plus Intervention|Restaurants will receive a new healthy kids' menu, supporting marketing materials, and brief trainings for customer service staff and kitchen staff to support and promote the new menu items.
3007655|NCT02511925||ICU Cluster 1|Adult Intensive Care Unit - Royal Brompton Hospital
3007656|NCT02511925||ICU Cluster 2|Paediatric ICU - Royal Brompton Hospital
3007657|NCT02511925||ICU Cluster 3|Adult Intensive Care Unit - Harefield Hospital
3007658|NCT02511912|Experimental|V-Wave|"This is a single arm study, all eligible patients will receive the V-Wave implantable shunt.~The V-Wave device is implanted via standard femoral venous access and inter-atrial septal puncture intervention and is placed through the Fossa Ovalis."
3007659|NCT02511899|Active Comparator|Mango fruit powder 100mg|Mango fruit powder 100mg
3007660|NCT02511899|Active Comparator|Mango fruit powder 300mg|Mango fruit powder 300mg
3007661|NCT02511886|Experimental|Arbaclofen Placarbil (AP)|Orally administered Arbaclofen Placarbil (AP) sustained release (SR) tablets
3007662|NCT02511886|Placebo Comparator|Placebo|Subjects remain on placebo for entire study
3007663|NCT02511873|Experimental|Fycompa|Fycompa dose is chosen based on tolerability and efficacy. 2mg to 8mg daily for 6 weeks then washed out.
3007664|NCT02511873|Placebo Comparator|Placebo|Inactive ingredient equal to 2mg tablets
3007665|NCT02511860|Placebo Comparator|Placebo|Patients will consume a placebo pill containing methylcellulose.
3007666|NCT02511860|Active Comparator|Active|Patients will consume 850 mg of burdock twice per day.
3007667|NCT02511847|Other|single-arm|"Drug: Afatinib (single group assignment)~First phase: Afatinib montherapy~The following phases: combination with oral afatinib and weekly paclitaxel in a 3-weekly course for total of four courses."
3007668|NCT02511834|Experimental|VEST supported|Vein graft supported by VEST
3007669|NCT02511834|Active Comparator|Control|Vein grafts unsupported by VEST
3007670|NCT02511821|Experimental|Supportive Care (Vivofit watch, online surveys)|Patients complete online surveys comprising questions about quality of life, symptoms, and activity level, and wear a wristband device (Vivofit watch) 3-7 days prior to and after surgery. After going home, patients complete the symptom survey three times a week and quality of life survey once a week for 2 weeks post-surgery.
3007671|NCT02511808|Active Comparator|Step-up Treatment: MI|After receiving one session of Brief Advice (BA), participants will be assessed at week 4 for response to this treatment. Those who are deemed non-responders to the BA will be randomly assigned to receive either Motivational Interviewing (MI) or more BA. In this arm, participants will receive two sessions of MI.
3007672|NCT02511808|Other|Control: BA|After receiving one session of Brief Advice (BA), participants will be assessed at week 4 for response to this treatment. Those who are deemed non-responders to the BA will be randomly assigned to receive either Motivational Interviewing (MI) or more BA. In this arm, participants will receive one additional session of BA.
3007673|NCT02511808|Active Comparator|Step-up Treatment: Specialist Care|After receiving one session of Brief Advice (BA) and two sessions of Motivational Interviewing (MI) or one session of BA over the first 8 weeks of the study, participants will be assessed at week 8 for response to this treatment. Those who are deemed non-responders will be randomly assigned to receive Behavioral Self-Control Training (BSCT) or more MI if they were randomized to MI at week 4 or five sessions of combined MI and BSCT or one more session of MI if they were randomized to BA at week 4. In this arm, participants will receive four sessions of BSCT if they received MI at the previous randomization or five sessions of combined MI and BSCT if they received BA at the previous randomization.
3007674|NCT02511808|Other|Control: MI|After receiving one session of Brief Advice (BA) and two sessions of Motivational Interviewing (MI) or one session of BA over the first 8 weeks of the study, participants will be assessed at week 8 for response to this treatment. Those who are deemed non-responders will be randomly assigned to receive Behavioral Self-Control Training (BSCT) or more MI if they were randomized to MI at week 4 or five sessions of combined MI and BSCT or one more session of MI if they were randomized to BA at week 4. In this arm, participants will receive one session of MI if they received MI at the previous randomization or two sessions of MI if they received BA at the previous randomization.
3007675|NCT02511795|Experimental|AZD1775 (6 doses/week) + Olaparib|"In this Arm, AZD1775 will be given twice daily over 3 days (6 doses) on Days 1-3 of Week 1 and Days 8-10 of Week 2. Olaparib will be given orally BID on Days 1-14.~All patients will enter an olaparib sub-study in order to assess multiple dose pharmacokinetics of olaparib prior to entering the main study. In the olaparib PK sub-study patients will take olaparib for 3 consecutive days and venous blood samples will be collected on Day 3. The PK sub-study must be initiated 10 days prior to the Cycle 1 Day 1 administration of the AZD1775 and olaparib combination. The patient will experience a short gap in treatment (approximately 4-5 days) between Day 3 of the olaparib PK sub-study and Cycle 1 Day 1 AZD1775 and olaparib combined dosing."
3007676|NCT02511795|Experimental|AZD1775 (10 doses/week) + Olaparib|"In this Arm, AZD1775 will be given twice daily over 5 days (10 doses) on Days 1-5 of Week 1 and Days 8-12 of Week 2. Olaparib will be given orally BID on Days 1-14.~All patients will enter an olaparib sub-study in order to assess multiple dose pharmacokinetics of olaparib prior to entering the main study. In the olaparib PK sub-study patients will take olaparib for 3 consecutive days and venous blood samples will be collected on Day 3. The PK sub-study must be initiated 10 days prior to the Cycle 1 Day 1 administration of the AZD1775 and olaparib combination. The patient will experience a short gap in treatment (approximately 4-5 days) between Day 3 of the olaparib PK sub-study and Cycle 1 Day 1 AZD1775 and olaparib combined dosing."
3007708|NCT02511574|Experimental|cervical pessary|Patients with uterine cervical length ≤ 25 mm are randomized to use the cervical pessary or natural progesterone to compare their effectiveness in the reduction of preterm birth rates.
3007677|NCT02511782|Experimental|Acute Graft versus Host Disease|This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop acute graft versus host disease. Skin cell samples will be collected using the D-SQUAME Skin Sampling Discs. The first baseline skin sample will be obtained prior to the preparative regimen for stem cell transplant. Samples will be collected weekly after stem cell infusion until 8 weeks, if acute GVHD does not develop. If acute GVHD does develop, weekly samples will continue to be collected until resolution of acute GVHD or development of chronic GVHD, whichever occurs first. Blood samples will be collected at these same time points.
3007678|NCT02511782|Experimental|Chronic Graft versus Host Disease|This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop chronic graft versus host disease. Skin cell samples will be collected weekly for 4 weeks using the D-SQUAME Skin Sampling Discs. Blood samples will be collected at these same time points.
3007679|NCT02511782|Active Comparator|Healthy Controls|This study arm includes healthy age matched controls as comparisons to study participants who develop graft versus host disease. These controls may be either healthy age matched siblings of patients who develop acute graft versus host disease or healthy age matched siblings of patients that are seen in the bone marrow transplant, oncology, or hematology clinics. A one-time single skin cell sample will be collected using a D-SQUAME Skin Sampling Disc. Blood samples will not be collected from the healthy controls.
3007680|NCT02511769|Experimental|WEB-MAP CBT|Web-MAP Group. Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
3007681|NCT02511769|Active Comparator|WEB-MAP Educational Control Group|OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
3007682|NCT02511756|Other|Perfusion-computed tomography (CTP)|Patients undergo a total of four perfusion-computed tomographies from baseline to progression of disease.
3007683|NCT02511743||physicians|physicians taking care of patients with chronic Hepatitis B Virus infection
3007684|NCT02511730|Experimental|FFDM Plus DBT|Breast Images with FFDM and DBT
3007685|NCT02511730|Active Comparator|FFDM|Breast Images with FFDM alone
3007686|NCT02511717|Sham Comparator|Sham|Transcutaneous stimulation in a location and with settings not relation to the bladder nerves, 3x/week for 30 minutes for 12 weeks
3007687|NCT02511717|Active Comparator|Transcutaneous nerve stimulation|Transcutaneous stimulation of the bladder nerves, 3x/week for 30 minutes for 12 weeks
3007688|NCT02511704|Experimental|Electronic cigarette|"Multiple dose~Nicotine 0.8 mg, administrated by electronic cigarette (10 puffs) + Nicotine 0.8 mg, administrated by electronic cigarette (10 puffs) separated by 60 minutes"
3007689|NCT02511704|Active Comparator|Cigarette|"Multiple dose~Nicotine 0.8 mg, administrated by cigarette (10 puffs) + Nicotine 0.8 mg, administrated by cigarette (10 puffs) separated by 60 minutes"
3007690|NCT02511691|Other|18F-PSS232|Subjects receive baseline PET with 18F-PSS232 and stimulation PET with 18F-PSS232 after medical challenge with N-acetylcystein
3007691|NCT02511678|Experimental|Cryoablation|All subjects will have one cryoablation procedure on one painful metastatic lesion involving bone using a Galil Medical cryoablation system and needles.
3007692|NCT02511665|Experimental|Metformin|Metformin given , 1g twice a day for 4 weeks until prostatectomy +/- one week
3007693|NCT02511665|Placebo Comparator|Placebo|placebo given , 1g twice a day for 4 weeks until prostatectomy +/- one week
3007694|NCT02511665|Experimental|PET-MRI|5 patients in this arm will all receive metformin and undergo two additional PET- MRI scans, one before and one after treatment
3007695|NCT02511652|Active Comparator|Ambu AuraGain|Insertion of the supraglottic device and evaluation of its clinical performance
3007696|NCT02511652|Active Comparator|LMA Supreme|Insertion of the supraglottic device and evaluation of its clinical performance
3007697|NCT02511639|Experimental|Arm A: Everolimus & Aromatase inhibitors|Everolimus 10 mg po daily + Aromatase inhibitors (Exemestane 25 mg po daily or Letrozole 2.5 mg po daily or Anastrozole 1 mg po daily)
3007698|NCT02511639|Active Comparator|Arm B: Aromatase inhibitors|Aromatase inhibitors (Exemestane 25 mg po daily or Letrozole 2.5 mg po daily or Anastrozole 1 mg po daily)
3007699|NCT02511626||Case group|Women with a surgically confirmed diagnosis of endometriosis
3007700|NCT02511626||Control group 1|Women without any evidence of endometriosis (= no clinical symptom and/or no surgical evidence of endometriosis)
3007701|NCT02511626||Control group 2|Women without endometriosis (surgically confirmed) but chronic abdominal/pelvic pain due to other reasons (e.g. Crohn's disease, colitis etc)
3007702|NCT02511613|Placebo Comparator|Placebo|Monthly intravitreal ranibizumab plus Placebo Ophthalmic solution
3007703|NCT02511613|Active Comparator|Active|Monthly intravitreal ranibizumab plus Squalamine Lactate Ophthalmic solution 0.2%
3007704|NCT02511600|Experimental|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest. Participants complete pain scale 3 times each day while in the hospital.
3007705|NCT02511600|Active Comparator|Standard of Care|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest. Participants complete pain scale 3 times each day while in the hospital.
3007706|NCT02511587|Active Comparator|intra muscular application|intra muscular application of FSME-Immune vaccination
3007707|NCT02511587|Experimental|subcutaneous application|subcutaneous application of FSME-Immune vaccination
3007709|NCT02511574|Active Comparator|natural progesterone|Patients with uterine cervical length ≤ 25 mm are randomized to use the cervical pessary or natural progesterone to compare their effectiveness in the reduction of preterm birth rates.
3007710|NCT02511561|Experimental|0.1 mL OTO-201|Ciprofloxacin
3007711|NCT02511561|Experimental|0.2 mL OTO-201|Ciprofloxacin
3007712|NCT02511561|Experimental|0.4 mL OTO-201|Ciprofloxacin
3007713|NCT02511548|Experimental|Intervention|Financial incentive
3007714|NCT02511548|No Intervention|Control|No financial incentive
3007715|NCT02511535|Experimental|Allergic patients|Allergic patients receive TBE booster vaccination
3007716|NCT02511535|Experimental|Allergic patients with de-sensitization treatment|Allergic patients with de-sensitization treatment receive TBE booster vaccination
3007717|NCT02511535|Active Comparator|Healthy controls|Healthy controls receive TBE booster vaccination
3007718|NCT02511522|Active Comparator|Best Supportive Care|Patients will be randomized 1:1 to receive best supportive care alone
3007719|NCT02511522|Experimental|Best Supportive Care + RT 8 Gy/1|Patients will be randomized 1:1 to receive best supportive care plus radiation therapy (8 Gy in 1 fraction),
3007720|NCT02511509|Experimental|Bifrontal electroconvulsive therapy|The ECT courses will be held twice or three times a week. There is no stated minimal nor maximal number of ECT courses. If there is no improvement after 12 courses, the ECT will be regarded as ineffective.
3007721|NCT02511509|Active Comparator|Bitemporal electroconvulsive therapy|The ECT courses will be held twice or three times a week. There is no stated minimal nor maximal number of ECT courses. If there is no improvement after 12 courses, the ECT will be regarded as ineffective.
3007722|NCT02511483|Placebo Comparator|IV-PCA morphine + Placebo PO|"Pain control after surgery will be performed through IV-PCA morphine. Placebo will be administered with the same schedule of Propranolol in the experimental arm.~Parallel evaluation of Quantitative Sensory Testing (QST), Psychometric assessment and COMT-haplotypes will be included along the trial."
3007723|NCT02511483|Experimental|IV-PCA morphine + Propranolol PO|"The morning of the surgery a dose of Propranolol 20 mg PO will be administered. After surgery pain control will be performed with IV-PCA morphine; in addition a second dose of Propranolol 20 mg PO will be administered .~During the first and second postoperative day Propranolol 30 mg PO (BID) will be administered. Parallel assessment of Quantitative Sensory Testing (QST), Psychometric assessment and COMT-haplotypes will be included along the trial."
3007724|NCT02511470|Other|CPR with metronome on|Participants will perform two minutes of uninterrupted chest compressions on a pediatric manikin with the metronome on. Data for compression rate and depth will be collected during this time interval.
3007725|NCT02511470|Other|CPR with metronome off|Participants will perform two minutes of uninterrupted chest compressions on a pediatric manikin with the metronome off. Data for compression rate and depth will be collected during this time interval.
3007726|NCT02511444|Other|single arm|All patients will have GBS culture and real time PCR performed.
3007727|NCT02511431|Experimental|Group 1|Lonafarnib/Ritonavir at 50 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
3007728|NCT02511431|Experimental|Group 2|Lonafarnib/Ritonavir at 75 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
3007729|NCT02511431|Experimental|Group 3|Lonafarnib/Ritonavir at 100 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
3007730|NCT02511431|Experimental|Group 4|Placebo for 12 weeks then Lonafarnib/Ritonavir at 50 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
3007731|NCT02511431|Experimental|Group 5|Placebo for 12 weeks then Lonafarnib/Ritonavir at 75 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
3007732|NCT02511431|Experimental|Group 6|Placebo for 12 weeks then Lonafarnib/Ritonavir at 100 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
3007733|NCT02511405|Experimental|Arm 1|VB-111 + Bevacizumab
3007734|NCT02511405|Active Comparator|Arm 2|Bevacizumab
3007735|NCT02511392|Active Comparator|Group 1: Real rTMS-1 Hz|Included 15 patients, they received 1 Hz rTMS with intensity of 100% of the RMT continuous with total 2000 applied in 200 trains, each of 10 pulses, with 5 seconds intertrain interval
3007736|NCT02511392|Active Comparator|Group 2: Real rTMS-10 Hz|Included 15 patients, they received 10 Hz rTMS with intensity of 100% of the RMT applied in 10 trains, each of them 200 pulses, with 20 seconds intertrain interval
3007737|NCT02511392|Sham Comparator|Group 3: Sham rTMS|Included 15 patients; they received the same number of pulses 2000 pulse applied in 200 trains, each of 10 pulses, with 5 seconds intertrain interval, but coil was placed over the same area but perpendicular to the scalp.
3007738|NCT02511379|Experimental|Systane Balance|Propylene Glycol 0.6% eye drops, 1 drop QID (with the last dose of each day at bedtime) in each eye for 90 days
3007739|NCT02511366|Experimental|ileal infusion of casein|Ileal infusion of casein
3007740|NCT02511366|Placebo Comparator|ileal infusion of tap water|ileal infusion of tap water
3007741|NCT02511353|Placebo Comparator|placebo|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: placebo 600 mcg/kg/day.
3007742|NCT02511353|Experimental|ivermectin 300 mcg/kg|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 300 mcg/kg/day and placebo 300 mcg/kg/day.
3007743|NCT02511353|Experimental|ivermectin 600 mcg/kg|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 600 mcg/kg/day.
3007744|NCT02511340|Experimental|Flumatinib mesylate tablet 600 mg qd|Flumatinib, 600mg, qd
3007745|NCT02511327||Preterm born infants of vaccinated women|Preterm born infants (< 37 weeks of gestation) whose mothers have received an acellular pertussis vaccine during pregnancy, within the national recommended vaccination programme. Infant vaccination against pertussis is performed according to the national recommended schedule.
3007746|NCT02511327||Term born infants vaccinated women|Term born infants (>= 37 weeks of gestation) whose mothers have received an acellular pertussis vaccine during pregnancy, within the national recommended vaccination programme. Infant vaccination against pertussis is performed according to the national recommended schedule.
3007747|NCT02511327||Term born infants unvaccinated women|Term born infants (>= 37 weeks of gestation) whose mothers have not received an acellular pertussis vaccine during pregnancy. Infant vaccination against pertussis is performed according to the national recommended schedule.
3007748|NCT02511327||Preterm born infants unvaccinated women|Preterm born infants (< 37 weeks of gestation) whose mothers have not received an acellular pertussis vaccine during pregnancy.Infant vaccination against pertussis is performed according to the national recommended schedule.
3007749|NCT02511314|Experimental|Intervention|"Tena Identifi is an integrated electronic monitoring system based upon a wearable continence pad which allows registration of resident's micturition patterns over a 72 hour period, allowing caregivers to construct an individualised continence care plan, including use of appropriate products.~To create a voiding report, a resident wears the Identifi Sensor Wear with an attached Identifi Logger for three consecutive days (72 hours). The logger continuously logs the moisture status of the brief. The resulting data is sent to a server via 3 G signal where it is mapped onto a graph indicating voiding times and volumes."
3007750|NCT02511314|No Intervention|Control Intervention|"The control portion of the study is usual care, defined as the routine practices and procedures, including continence assessment approach, prescribed in the nursing home unit or facility."
3007751|NCT02511301|Experimental|Cyrcadia CBR™ Device|Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis.
3007752|NCT02511288||Cohort 1|Patients with advanced NSCLC and no druggable molecular alteration at time of diagnostic
3007753|NCT02511288||Cohort 2|Patients with advanced NSCLC harboring targetable molecular alterations
3007754|NCT02511288||Cohort 3|Patients with advanced NSCLC treated by immunotherapy
3007755|NCT02511275|Other|renal microdialysis|patient with renal microdialysis
3007756|NCT02511262||Specimen Collection|Prospective patients with symptoms of upper respiratory infections which may be attributable to Mycoplasma pneumoniae, or from patients suspected of having Mycoplasma pneumoniae.
3007757|NCT02511249||cohort|"1 evaluation day : The evaluation team included a neuropsychologist, a speech therapist and either a pediatric neurologist or a pediatric physical and rehabilitation medicine practitioner.~tests carried out : Global intellectual functioning (WISC-IV), Oral language (N-EEL), Gross and fine motor abilities (clinical examination, Box & Block test, 9 Hole Peg test)"
3007758|NCT02511236|Experimental|Group Cognitive Behavioral Therapy|Participants may receive 8 group cognitive behavioral therapy (CBT) sessions and eight weeks of transdermal nicotine patches (TNP) [21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)].
3007759|NCT02511236|Active Comparator|General Health Education|Participants may receive group general health education (GHE) sessions and eight weeks of transdermal nicotine patches (TNP) [21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)].
3007760|NCT02511223|Experimental|Single Arm|Only one Arm,All patients will receive Olaparib 300 mg (MILIGRAM)bid p.o till disease progression
3007761|NCT02511210|Active Comparator|regional anesthesia|spinal anesthesia or peripheral nerve block
3007762|NCT02511210|Active Comparator|general anesthesia|intubated patients
3007763|NCT02511197|Experimental|68Ga-NOTA-PRGD2 injection & PET/CT scan|The patients were intravenously injected with 68Ga-NOTA-PRGD2 in one dose in nearly 111 MBq and then underwent PET/CT scan 0.5 h later.
3007764|NCT02511184|Experimental|Dose finding and dose expansion phases|Find and expand the maximum tolerated dose of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks.
3007765|NCT02511171|No Intervention|No intervention|Subjects do not receive osteopathic care
3007766|NCT02511171|Experimental|Cranial osteopathic manipulative treatment|Subjects receive individualised osteopathic treatment
3007767|NCT02511145|Active Comparator|Microneedles pretreatment and Metvixia|minizone with Microneedles pretreatment and Metvixia cream application
3007768|NCT02511145|Active Comparator|Microneedles pretreatment and Metvixia under occlusion|minizone with Microneedles pretreatment and Metvixia cream application with occlusion
3007769|NCT02511145|Active Comparator|Laser pretreatment and Metvixia|minizone with laser pretreatment and Metvixia cream application
3007770|NCT02511145|Active Comparator|Laser pretreatment and Metvixia under occlusion|minizone with Laser pretreatment and Metvixia cream application with occlusion
3007771|NCT02511145|Active Comparator|Metvixia|minizone with Metvixia cream application, without pretreatment
3007772|NCT02511145|Active Comparator|Metvixia under occlusion|minizone with Metvixia cream application under occlusion, without pretreatment
3007773|NCT02511145|Experimental|Microneedles pretreatment only|minizone with Microneedles pretreatment only
3007774|NCT02511145|Experimental|Laser pretreatment only|minizone with Laser pretreatment only
3007775|NCT02511145|No Intervention|Normal skin|Normal skin control mini-zone
3007776|NCT02511132|Experimental|Vigil + temozolomide + irinotecan|(i) oral temozolimidetemozolomide 100 mg/m2 daily (Days 1 - 5, total dose 500 mg/m2/cycle), (ii) irinotecan 50 mg/m2 daily (Days 1 - 5, total dose 250mg/m2/cycle), orally or irinotecan 20mg/m2 daily (Days 1 - 5, total dose 100mg/m2/cycle), intravenously (iii) peg-filgrastim 100μg/kg (Day 6) subcutaneously (optional and may be administered at home), and (iv) Vigil 1.0 x 10e7 cells/injection, intradermally on Day 15 and every 43 weeks thereafter. One cycle = 21 days.
3007777|NCT02511106|Experimental|AZD9291|AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
3007778|NCT02511106|Placebo Comparator|Placebo AZD9291|Matching placebo for AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
3007779|NCT02511093|Experimental|TBC intervention|"A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:~BP measurements;~an educational and counselling intervention on patient adherence;~an educational and counselling intervention on lifestyle (physical activity and diet).~Physicians adjust antihypertensive medications based on nurse and pharmacist feedback."
3007780|NCT02511093|No Intervention|Usual care|
3007781|NCT02511080|Active Comparator|Spot-on group|Use active measures against intraoperative hypothermia
3007782|NCT02511080|No Intervention|control|standard measures against intraoperative hipothermia
3007783|NCT02511067|Active Comparator|Ranibizumab 0.3 mg|Mandatory monthly treatments with Intravitreal (IVT) ranibizumab (0.3 mg) starting at Baseline (BL) until Month 6. Starting at Month 6, treatments will be administered on as-needed basis, based on retreatment criteria.
3040816|NCT02288481|Placebo Comparator|Cohort 5 placebo|Placebo Suspension
3007784|NCT02511067|Experimental|Tocilizumab (8.0 mg/kg)|Mandatory monthly Intravenous (IV) infusions with tocilizumab (8.0 mg/kg) starting at Baseline (BL) until Month 6. Starting at Month 6, treatments will be administered on as-needed basis with IVT ranibizumab (0.3 mg), based on the retreatment criteria.
3007785|NCT02511067|Experimental|Tocilizumab (8.0 mg /kg) plus Ranibizumab 0.3 mg|Mandatory Intravitreal (IVT) ranibizumab 0.3 mg at Baseline (BL) followed with an IV infusion of tocilizumab (8.0 mg/kg) on same day starting at Baseline (BL) until Month 6. Combination treatments (IVT ranibizumab 0.3 mg followed by IV tocilizumab 8.0 mg/kg infusion administered at same visit) will be given every month until Month 6. Starting at Month 6, treatments will continue to be administered on as-needed basis with IVT ranibizumab (0.3 mg), based on retreatment criteria.
3007786|NCT02511054|Experimental|1a|Arm 1a (n=2), the pilot phase, is designed to examinethat the dosing of PYR on 2, 3 days post DVI with Sanaria PfSPZ Challenge while under CQ prophylaxis does not result in subpatent parasitemia (positive qRT-PCR result defined as two consecutive samples > 20 parasites/uL or a single positive qRTPCR (Bullet) 100) or a single episode of patent parasitemia (positive blood smear defined as two unambiguous parasites in a thicksmear) in (Bullet)1/2 subjects. Subjects will considered enrolled into the study upon receipt of the loading dose of CQ (2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
3007787|NCT02511054|Experimental|2|Arm 2 (n=12) will receive the selected regimen of pyrimethamine, on 2, 3 days (unless another Arm other than Arm 1a is determined from the pilot phase) post Sanaria PfSPZ Challenge via DVI while under CQprophylaxis. These subjects will be considered enrolledinto the study upon receipt of the loading dose of CQ(2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
3007788|NCT02511054|Experimental|3|Arm 3 (n=6) will receive Sanaria PfSPZ Challenge DVI while under CQ prophylaxis without PYR treatment. These subjects will be considered enrolled into the study upon receipt of the loading dose of CQ (2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
3007789|NCT02511054|Experimental|4|Arm 4 (n=5) will only receive one dose of Sanaria PfSPZ Challenge at CHMI as a positive control for thestudy. Subjects in Arm 4 will be considered enrolledon the day of Sanaria PfSPZ Challenge via DVI.
3007790|NCT02511041|Experimental|1|This is a prospective exploratory study of nucleoside and monosaccharide supplement-ation and its effect on immunologic parameters in patients with evidence of altered glycosylation and immunologic abnormalities. Up to 50 subjects will receive escalating doses of oralmonosaccharide until a maximum tolerated dose is found and maintained for 6 weeks. Then nucleosidesupplementation will be added and the maximum tolerated dose will continue for 12 weeks. Parameters of interest will be assessed at NIH every 8 weeks. Themaximum participation time for each subject is 252 days. We will begin with PGM3 deficient patients, who will self-administer oral GlcNAc followed by dual supplementation with GlcNAc and Uridine. The remaining subjects will then receive these supplements following the same step-wise approach.
3007791|NCT02510976|Active Comparator|Prucalopride|Prucalopride tablet 2 mg
3007792|NCT02510976|Placebo Comparator|Placebo|matching placebo tablet
3007793|NCT02510963|Experimental|Tenofovir 24 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 24 weeks of gestation to 1 month postpartum
3007794|NCT02510963|Experimental|Tenofovir 28 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 28 weeks of gestation to 1 month postpartum
3007795|NCT02510963|Active Comparator|Tenofovir 32 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 32 weeks of gestation to 1 month postpartum
3007796|NCT02510950|Experimental|Arm 1: Peptide/poly-ICLC|"For all patients, concurrent chemoradiation with temozolomide will be given per standard of care and is outside the scope of this study as per standard of care.~The long peptide + poly-ICLC will be given on Cycle 1 Day 1 of maintenance temozolomide.~If the vaccine is not ready by this time, the first vaccination will begin on Day 1 of the next cycle of maintenance temozolomide.~The peptide + poly-ICLC vaccine will be given again on Days 8, 15, and 22 of the first cycle, as a priming strategy.~On all subsequent cycles, the peptide vaccine + poly-ICLC will be given on Day 22 (+/-3 days)."
3007797|NCT02510937|Experimental|Low dose CC-90001|Low dose (100 mg) CC-90001 administered orally once daily (QD) for 12 continuous weeks
3007798|NCT02510937|Experimental|High dose CC-90001|High-dose (200 mg) CC-90001 administered orally Once Daily (QD) for 12 continuous weeks
3007799|NCT02510924|Active Comparator|Tracheal intubation with Airtraq sp|Tracheal intubation with Airtraq sp.
3007800|NCT02510924|Experimental|Tracheal intubation with Airtraq Mobile|Tracheal intubation with Airtraq Mobile
3007801|NCT02510911|Experimental|Caffeine (100 mg)|Verum 1 with 100 mg caffeine
3007802|NCT02510911|Experimental|Caffeine (200 mg)|Verum 2 with 200 mg caffeine
3007803|NCT02510911|Placebo Comparator|Starch|approx. 250 mg corn starch as placebo
3007804|NCT02510898|Experimental|Intervention Arm|All subjects enrolled in the study will receive the intervention. This is a one-arm study.
3007805|NCT02510885|Experimental|SD-OCT Angiography|Study participants will undergo imaging of both eyes with the AngioVue unit (approximately 60 seconds/eye), per standard operating protocol. Imaging is noncontact, and pharmacologic dilation will not be used for the purposes of this study. In most instances, study participants will undergo only a single imaging session on a single day. However, potential participants will be asked to consent for additional imaging sessions (up to 12) that may occur over the course of subsequent future visits to the clinic. Additionally, study participants will be asked to consent to prospective collection of clinical and demographic data, to correlate findings of OCT-A imaging to subsequent clinical course.
3007806|NCT02510872|Experimental|18F-FDG PET combined with CT with iodinated contrast injection|18F-FDG PET combined with CT with iodinated contrast injection
3007807|NCT02510872|Sham Comparator|18F-FDG PET combined with CT without injection|18F-FDG PET combined with CT without injection
3007808|NCT02510859|Experimental|Systematic nutritional consultation at home|"Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled Dietary own program will be given to the patient."
3007906|NCT02510144|Active Comparator|Chlorhexidine|A preoperative Chlorhexidine gluconate solution 4.0% (i.e Hibiclens)
3007809|NCT02510859|No Intervention|Traditional nutritional follow up|Traditional nutritional follow up that is to say with a nutritional consultation before starting treatment and then when necessary on medical advice
3007810|NCT02510846|Experimental|Intensive educative program|5 hours a week
3007811|NCT02510846|Active Comparator|Usual practice of educative program|1 hour a week
3007812|NCT02510833|Experimental|Continuing Intervention Group|
3007813|NCT02510833|Active Comparator|Control Group|
3007814|NCT02510820|Active Comparator|Synergi / comfilcon A|Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study.
3007815|NCT02510820|Active Comparator|Biotrue / comfilcon A|Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study.
3007816|NCT02510807|Experimental|Pedometer group|Patients will be instructed to walk a minimum of three times per week up to one half hour total walking time. If they started to get pain in their legs, they will be instructed to stop and rest, and then to start again when the pain has subsided. The pedometer group will be instructed to carry the pedometer in their pocket during these exercise periods.
3007817|NCT02510807|No Intervention|Control group|Patients will be instructed to walk a minimum of three times per week up to one half hour total walking time. If they started to get pain in their legs, they will be instructed to stop and rest, and then to start again when the pain has subsided.
3007818|NCT02510794|Experimental|Ranibizumab Dose 1|Participants will receive ranibizumab delivered through the implant with Dose 1 formulation in the study eye on Day 1 and if required, implant refill will be done starting from Month 1 according to protocol-defined refill criteria.
3007819|NCT02510794|Experimental|Ranibizumab Dose 2|Participants will receive ranibizumab delivered through the implant with Dose 2 formulation in the study eye on Day 1 and if required, implant refill will be done starting from Month 1 according to protocol-defined refill criteria.
3007820|NCT02510794|Experimental|Ranibizumab Dose 3|Participants will receive ranibizumab delivered through the implant with Dose 3 formulation in the study eye on Day 1 and if required, implant refill will be done starting from Month 1 according to protocol-defined refill criteria.
3007821|NCT02510794|Active Comparator|Ranibizumab 0.5 mg ITV injection|Participants will receive ranibizumab 0.5 mg monthly ITV injections of 10 mg/mL formulation at Day 1 and every month thereafter.
3007822|NCT02510781|Experimental|A group|docetaxel+carboplatin+trastuzumab
3007823|NCT02510781|Active Comparator|B group|Epirubicin+docetaxel+trastuzumab-docetaxel+trastuzumab
3007824|NCT02510768|Experimental|ELAPR002f|ELAPR002f A tropoelastin polymer cross-linked with hyaluronic acid.
3007825|NCT02510768|Experimental|ELAPR002g|ELAPR002g A tropoelastin polymer cross-linked with hyaluronic acid.
3007826|NCT02510768|Placebo Comparator|Saline|Saline
3007827|NCT02510755|Other|PTSD group|PTSD group
3007828|NCT02510755|Other|Healthy Volunteers|Healthy Volunteers, age-matched controls.
3007829|NCT02510742|Active Comparator|SPG neurostimulation|SPG neurostimulation of frequency 20 Hz
3007830|NCT02510742|Sham Comparator|Control|Sham neurostimulation of amplitude=0
3007831|NCT02510729|Active Comparator|SPG neurostimulation|Sphenopalatine ganglion (SPG) neurostimulation of 20 Hz
3007832|NCT02510729|Placebo Comparator|Sham Stimulation|Sham stimulation with amplitude=0
3007833|NCT02510716|Experimental|Scheduled Gradual Reduction (SGR)|Four week SGR program plus support text messages.
3007834|NCT02510716|Active Comparator|Support Message Only|Support text messages only.
3007835|NCT02510703|Other|Type 2 diabetes group|Type 2 diabetes group
3007836|NCT02510703|Other|no diabetes|no diabetes
3007837|NCT02510677|Other|myocardial perfusion scintigraphy|Low-dose dobutamine gated SPECT and CZT camera for the assessment of parameters of left ventricular dyssynchrony in heart failure patients eligible for the implantation of a cardiac resynchronization device.
3007838|NCT02510664|Experimental|Intervention|There is no control/comparator group for this pilot study - all participants receive the intervention
3007839|NCT02510651|Experimental|ORSHFS|Melanocyte-keratinocyte suspension.
3007840|NCT02510625|Active Comparator|Bankart repair|Arthroscopic bankart repair
3007841|NCT02510625|Experimental|Anatomic Glenoid Reconstruction|Arthroscopic distal tibia bone graft
3007842|NCT02510612|Experimental|Dexmedetomidine|Patients in group D will be given dexmedetomidine during anesthesia induction and maintenance phase respectively.In induction phase infuse 1μg/Kg of dexmedetomidine in 10 minutes， the speed in maintenance phase is 0.4μg/Kg.h
3007843|NCT02510612|Placebo Comparator|placebo|Patients in group P will be given normal saline during anesthesia induction and maintenance phase
3007844|NCT02510599|Experimental|Solithromycin|Solithromycin 200 mg PO QD for 1 week, followed by 200 mg PO TIW for 12 weeks
3007845|NCT02510586|Experimental|Sevo_postconditioning|Patients receiving sevoflurane 1.0 minimum alveolar concentration (MAC) for 30 minutes after revascularization competed.
3007846|NCT02510586|No Intervention|Non_postconditioning|Patients not receiving sevoflurane postconditioning after revascularization completed
3007847|NCT02510573||sTBI group|The patients with isolated head trauma and postresuscitation GCS score of 8 or less.
3007848|NCT02510560|Experimental|NTRA-2112 A|NTRA-2112 A - Dose 1 To be administered orally with daily feed for 28 days or until discharge from hospital.
3007849|NCT02510560|Experimental|NTRA-2112 B|NTRA-2112 B - Dose 2 To be administered orally with daily feed for 28 days or until discharge from hospital.
3007850|NCT02510560|Placebo Comparator|Placebo|Placebo To be administered orally with daily feed for 28 days or until discharge from hospital.
3007851|NCT02510547|Active Comparator|CrossBoss Catheter|Crossing the CTO with upfront use of the CrossBoss catheter
3007852|NCT02510547|Active Comparator|Antegrade Wire Escalation Strategy|Crossing the CTO with upfront antegrade wire escalation strategy
3007853|NCT02510534|Active Comparator|Control|This arm receives Menopur 150 international units x 1 dose
3007854|NCT02510534|Active Comparator|Treatment|This arm receives Menopur 150 international units x 1 dose and Endometrin 100mg twice a day x 14 days
3007855|NCT02510521|Placebo Comparator|in rest situation|No intervention during one week. Daily usual activities are allowed.
3007907|NCT02510144|Experimental|Benzoyl Peroxide|A preoperative 5% benzoyl peroxide wash prep (i.e. Brevoxyl-4 and Brevoxyl-8)
3007856|NCT02510521|Experimental|after acute muscle exercise by NMES|"A working session of 20 minutes with three sequences electrostimulation:~warming-up sequence~work sequence (starting at 50% of the intensity achieved during warm-up)~relaxation sequence~Electrostimulation relates both quadriceps are stimulated simultaneously and jointly. During the sessions, the patient sits on a chair or on a chair, legs bent at 90 °. So that there is no extension of the legs when electrostimulation (which could be painful), a strap is placed behind the legs of the chair or armchair and holds the pegs."
3007857|NCT02510521|Experimental|after a daily workout sequence with NMES in one week|"Working sessions of 20 minutes 7 days in a row, including :~warming-up sequence~work sequence (starting at 50% of the intensity achieved during warm-up)~relaxation sequence~Electrostimulation relates both quadriceps are stimulated simultaneously and jointly. During the sessions, the patient sits on a chair or on a chair, legs bent at 90 °. So that there is no extension of the legs when electrostimulation (which could be painful), a strap is placed behind the legs of the chair or armchair and holds the pegs."
3007858|NCT02510508|Experimental|Group CRAFT|"All CSO's who are allocated to CRAFT group condition will be offered seven sessions of a CRAFT Group format. Each group will meet for 90 minutes weekly and will be completed within 2 months. The group content is based on the CRAFT techniques described by a training manual written by Roozen, Smith and Meyers (2015). Furthermore the CSOs in this condition will also receive a Dutch version of the CRAFT self-help book (Self Directed CRAFT Delivery), Get your loved one sober: Alternatives to nagging, pleading and threatening (Meyers & Wolfe, 2012). Groups will engage in a combination of didactic teaching, role-play of new communication styles and discuss their experiences utilizing CRAFT skills."
3007859|NCT02510508|Active Comparator|Self-Directed CRAFT Delivery|"CSO's allocated to the Self- Directed CRAFT Delivery will receive the Dutch version of the CRAFT self-help book, Get your loved one sober: Alternatives to nagging, pleading and threatening (Meyers & Wolfe, 2012). The book helps CSO's how to utilize the CRAFT model in their daily lives. It includes guidelines for responding to IP behavior, improving positive communication skills, improving the CSO's own well-being and explains how to engage the IP into treatment."
3007860|NCT02510508|No Intervention|Non-intervention|Participants assigned to the non-intervention condition will be placed on a Group CRAFT waiting list.
3007861|NCT02510495|No Intervention|"0 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was deflated immediately. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
3007862|NCT02510495|Experimental|"30 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
3007863|NCT02510495|Experimental|"60 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
3007864|NCT02510495|Experimental|"180 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
3007865|NCT02510495|Experimental|"300 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
3007866|NCT02510482||Aortic valve stenosis|Individuals with clinically stable moderate aortic valve stenosis
3007867|NCT02510469|Experimental|Apatinib Maintenance Therapy After Adjuvant Chemotherapy|Apatinib Mesylate Tablets 500 mg qd p.o. after XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)
3007868|NCT02510469|No Intervention|Only Adjuvant Chemotherapy|No Intervention After XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)
3007869|NCT02510456|Experimental|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging (DOSI)
3007870|NCT02510443||BAY1454032|All subjects who give their consent and meet the eligibility criteria will be scheduled for an insert placement procedure
3007871|NCT02510430|Experimental|Reducing Sitting Time Group|This group will be asked to reduce overall accumulated sitting time by 2 hours per day.
3007872|NCT02510430|Experimental|Re-Patterning Sitting Time Group|This group will be asked to use standing breaks to interrupt long bouts of sitting time.
3007873|NCT02510430|Placebo Comparator|Usual Care|This is an attention control group and is not asked to make changes to sitting time.
3007874|NCT02510417|Experimental|VSTs against three viruses|Patients will receive 2 x 107 partially HLA-matched VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused after discussion with the principal investigator, patient and/or guardian and the treatment team. If participants have a partial response (as defined by a 50% fall in viral load) they are eligible to receive up to 4 additional doses from day 28 after the initial infusion and at 2 weekly intervals thereafter.
3007937|NCT02509988|Active Comparator|Control (standard nutritional drink)|"Standard nutritional drink comes in the form of a sachet to mix with water & take twice a day (once in the morning and once in the evening).~The drink will be taken before the participant becomes pregnant (for up to 1 year) and throughout pregnancy."
3009331|NCT02500810|Experimental|monosialoganglioside|patients receive monosialoganglioside.
3007875|NCT02510404|Experimental|mCTLs against three viruss|The investigator will use 3 different dose levels starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. They will give the option of administering 2 additional doses (at the same level) of the same or different cell lines, 28 days after the first dose, in subjects that have limited or no improvement in viral count after one dose in the absence of any toxicities attributable to the infusion,or who receive other therapy that may affect the persistence or function of the infused mCTLs.
3007876|NCT02510391|Experimental|PIPA|Modularized treatment for anxiety in children ages 3-7 years old
3007877|NCT02510378|Experimental|Short course radiotherapy|"Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.~After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy."
3007878|NCT02510365|Experimental|Functional collagen scaffold|Functional neural regeneration collagen scaffold transplantation.
3007879|NCT02510352||Rotator cuff tear|patients with a symptomatic rotator cuff tear treated without surgical repair
3007880|NCT02510339||Observational|The Lysholm Knee score and the SF-36 questionnairs will be given to patients presenting to Orlando Regional Medical Center with open or closed fractures of the tibial shaft during their follow up visits post operativily.
3007881|NCT02510313|No Intervention|Classic VUP (Control)|Families receive benefits (cash) in exchange for state-sanctioned labour intensive work.
3007882|NCT02510313|No Intervention|Expanded VUP|Families receive benefits (cash) in exchange for state-sanctioned flexible labour within close proximity (2 km) to household. Eligible for variation of minimum graduation package benefits, such as asset transfer, financial literacy, skills training, sensitizations.
3007883|NCT02510313|Experimental|Sugira Muryango & Classic VUP|Families receive combination of Sugira Muryango and benefits (cash) in exchange for state-sanctioned labour intensive work.
3007884|NCT02510313|Experimental|Sugira Muryango & Expanded VUP|Families receive combination of Sugira Muryango and benefits (cash) in exchange for state-sanctioned flexible labour within close proximity (2 km) to household. Eligible for variation of minimum graduation package benefits, such as asset transfer, financial literacy, skills training, sensitizations.
3007885|NCT02510287|Active Comparator|Continuous Epidural Infusion|"An initial dose of 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution) will be given.~A continuous infusion of 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour) will then be administered.~Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.~If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered."
3007886|NCT02510287|Experimental|Programmed Intermittent Epidural Bolus|"An initial dose of 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution) will be given.~A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour.~Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.~If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered ."
3007887|NCT02510274|Experimental|Part1, ASP3325 Tablet A|ASP3325 tablets A will be orally administered with 150 mL of water in fasting condition on non-dialysis day in Day 1
3007888|NCT02510274|Experimental|Part2, ASP3325 Tablet B group 1|ASP3325 tablets B will be orally administered t.i.d. 30 minutes before each meal for 2 weeks
3007889|NCT02510274|Experimental|Part2, ASP3325 Tablet B group 2|ASP3325 tablets B will be orally administered t.i.d. 30 minutes just after each meal for 2 weeks
3007890|NCT02510261|Experimental|Patisiran (ALN-TTR02)|
3007891|NCT02510248|Experimental|Study Drug|Study drug will be AL-704 once or twice daily for up to 7 days in dosages ranging from 100 mg to 1500 mg.
3007892|NCT02510248|Placebo Comparator|Placebo|Placebo to match study drug dosing.
3007893|NCT02510235|Experimental|Lubricin|Lubricin 150 µg/ml eye drops solution
3007894|NCT02510235|Active Comparator|Sodium Hyaluronate|Sodium hyaluronate 0.13% eye drops
3007895|NCT02510222|Experimental|Oral Magnesium sulfate|Magnesium sulphate 4% concentration orally ( 65 mg per day for children one to three years of age; 110 mg per day for children four to eight years of age; 350 mg per day for children older than eight years) for 1 month
3007896|NCT02510222|Placebo Comparator|Control|Fifty children with cerebral palsy will be treated with conventional therapy as physiotherapy. They will receive placebo.
3007897|NCT02510209|Experimental|Teen Outreach Program|
3007898|NCT02510209|No Intervention|Control|Business as usual.
3007899|NCT02510196|Active Comparator|reminder|participants in this group will be reminded to use ultrasound for neuraxial anesthesia on a regular basis
3007900|NCT02510196|No Intervention|control|participants in this group will not be reminded to use ultrasound for neuraxial anesthesia
3007901|NCT02510183|Active Comparator|Acupressure Wrist Band|Patient receive preoperative education a day before surgery, education for acupressure application on the day of surgery, an acupressure wrist band is applied on P6 acupoint in both wrist an hour before surgery
3007902|NCT02510183|Placebo Comparator|Placebo Wrist Band|Patient receive preoperative education a day before surgery, an placebo acupressure wrist band is applied in both wrist an hour before surgery
3007903|NCT02510183|No Intervention|Control Grup Without Band|Patient receive preoperative education a day before surgery, and patient are only visited an hour before surgery
3007904|NCT02510157|Active Comparator|dexamethasone|Dexamethasone is administered intravenously before induction of anaesthesia. Deep neuromuscular blockade is induced with rocuronium and is assessed by acceleromyography (post-tetanic count stimulation) on the ulnar nerve of the patient's hand. At the end of surgery, sugammadex 4 mg/kg is administered to reverse neuromuscular blockade.
3007905|NCT02510157|Placebo Comparator|normal saline|Normal saline is administered intravenously before induction of anaesthesia. Deep neuromuscular blockade is induced with rocuronium and is assessed by acceleromyography (post-tetanic count stimulation) on the ulnar nerve of the patient's hand. At the end of surgery, sugammadex 4 mg/kg is administered to reverse neuromuscular blockade.
3009332|NCT02500810|No Intervention|control|blank control
3007908|NCT02510131|Active Comparator|Pelvic floor exercise|"Participants randomized to Kegel's exercises will be asked to contract their pelvic floor muscle for 1-10 seconds, followed by 10 seconds' relaxation.~Length of duration of exercise is tailored to individual's ability in contracting her pelvic floor muscle.~Each cycle is equivalent to 1 contraction and 1 relaxation phase. Participants will be asked to perform 3 sessions per day, and to perform their Kegel exercises at home daily.~1 session of Kegel's exercise is consists of 20 cycles of slow twitch fibre contraction and 30 repetitions of fast twitch fibre for 1 minute."
3007909|NCT02510131|Experimental|Hyacinth exercise|"In this arm participants are also taught Kegel's exercises but will be additionally taught extra steps which mirrored Muslim's praying steps.~As well as their Kegel's exercises, participants will be asked to perform the extra steps at least 63 minutes per week.~Participants may choose to perform these at the same time or at a different time from their Kegel's exercises. Participants will be asked to perform 1 cycle (3 minutes and 1 second) for 3 sessions a day for daily.~Each cycle is consists of repetition of 4 positions: standing upright- 90 degree bow- prostration-sitting."
3007910|NCT02510118|Experimental|conventional chemotherapy + placebo ChangTai Keli|Patients in this group will be given conventional chemotherapy medicine: modified FOLFOX6 (mFOLFOX6) chemotherapy or XELOX recommended by treatment guidelines for colon cancer, and the placebo ChangTai Keli corresponding to the traditional Chinese syndrome of dampness stasis type of spleen deficiency.
3007911|NCT02510118|Experimental|conventional chemotherapy + ChangTai Keli|Patients in this group will be given conventional chemotherapy medicine: modified FOLFOX6 (mFOLFOX6) chemotherapy or XELOX recommended by treatment guidelines for colon cancer, and the ChangTai Keli corresponding to the traditional Chinese syndrome of dampness stasis type of spleen deficiency, a herbal extract twice daily for 26 weeks for lower dosage.
3007912|NCT02510105|Experimental|ARDS patients|
3007913|NCT02510092|Active Comparator|Coronary artery diseae with revascularization indicated|Subjects with coronary artery disease, that require and are eligible for percutaneous revascularization.
3007914|NCT02510092|No Intervention|Coronary artery disease not requiring revascularization|Subjects with coronary artery disease that do not require revascularization.
3007915|NCT02510066|Experimental|Acupuncture|Acupuncture participants would receive electroacupuncture on Jiaji (Ex-B2) points for 3 times in a week.
3007916|NCT02510066|Placebo Comparator|Placebo acupuncture|Placebo acupuncture participants would receive placebo acupuncture on non-point points for the same period.
3007917|NCT02510053|Other|Patients With IFI in ICU|40 patients receive Caspofungin for an Invasive Fungal Infection(IFI) in the Intensive Car will be recruited
3007918|NCT02510040||Convergence insufficiency|Eligible adults with convergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
3007919|NCT02510040||Divergence insufficiency|Eligible adults with divergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
3007920|NCT02510040||Small-angle hypertropia|Eligible adults with small-angle hypertropia can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
3007921|NCT02510027||Women aged 30-64 years old|Women aged 30 to 64 years who attend the Cervical Cancer Screening Program in 100 health centers in the state of Tlaxcala, Mexico
3007922|NCT02510014|Experimental|Roll-over Subjects|Subjects who completed RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 6 months in the Treatment period.
3007923|NCT02510014|Experimental|De Novo Subjects|Subjects who did not participate in RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 12 months in the Treatment period.
3007924|NCT02510001|Experimental|Dose Escalation Phase Dose 1.|Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
3007925|NCT02510001|Experimental|Dose Escalation Phase 2.|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
3007926|NCT02510001|Experimental|Dose Escalation Phase 3.|Crizotinib 250mg OD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
3007927|NCT02510001|Experimental|Diose Escalation Phase 4.|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
3007928|NCT02510001|Experimental|Dose Escalation Phase 5.|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
3007929|NCT02510001|Experimental|Dose Escalation Phase 6.|Crizotinib 200mg OD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
3007930|NCT02510001|Experimental|Dose Escalation Phase 7|Binimetinib 30mg BD continuous administration or days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
3007931|NCT02510001|Experimental|Dose Escalation Phase 8|Binimetinib 45mg BD continuous administration or days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
3007932|NCT02510001|Experimental|Dose Escalation Phase 9|Binimetinib 45mg BD continuous administration or days 1-21 every 28 days. PF-02341066 250mg BD continuous administration
3007933|NCT02510001|Experimental|Dose Escalation Phase 10|Binimetinib 30mg BD continuous administration or days 1-21 every 28 days. PF-02341066 250mg OD continuous administration
3007934|NCT02510001|Experimental|Dose Escalation Phase 11|Binimetinib 45mg BD continuous administration or days 1-21 every 28 days. PF-02341066 250mg OD continuous administration
3007935|NCT02510001|Experimental|Dose Expansion Phase|PF-02341066 (Crizotinib) 200mg OD/ 200mg BD Days 1-28 continuously Binimetinib 30mg/45mg Dosage to be determined once the recommended Phase II dose has been identified in the dose escalation phase.
3007936|NCT02509988|Experimental|Intervention (study nutritional drink)|"Study nutritional drink comes in the form of a sachet to mix with water & take twice a day (once in the morning and once in the evening).~The drink will be taken before the participant becomes pregnant (for up to 1 year) and throughout pregnancy."
3009367|NCT02500615|Experimental|0 PG: 100 VG|
3009368|NCT02500615|Experimental|30 PG: 70 VG|
3007940|NCT02509949|Experimental|Dexmedetomidine|Dexmedetomidine ivpump 0.2ug/kg/h during living donor renal transplantation.
3007941|NCT02509949|Placebo Comparator|Saline|Saline ivpump 0.2ug/kg/h during living donor renal transplantation.
3007942|NCT02509936|Active Comparator|Standard of Care Arm|In this arm enrolled children will receive the national standard of care for growth support, which includes growth monitoring, a food ration, and a multiple micronutrient powder supplement.
3007943|NCT02509936|Experimental|Home-based Education|In the intervention arm, children will receive the national standard of care for growth support, which includes growth monitoring, a food ration, and a multiple micronutrient powder supplement. In addition, they will receive monthly home visits from a community health promoter who will provide detailed dietary assessments and individualized dietary coaching and education to parents.
3007944|NCT02509923|Experimental|1|3-way cross-over, Z-215 10 mg/day / Z-215 20 mg/day / Rabeprazole Sodium 10 mg/day
3007945|NCT02509923|Experimental|2|3-way cross-over, Z-215 20 mg/day / Z-215 40 mg/day / Rabeprazole Sodium 20 mg/day
3007946|NCT02509923|Experimental|3|3-way cross-over, Z-215 20 mg/day (before breakfast) / Z-215 20 mg/day (after breakfast) / Rabeprazole Sodium 10 mg/day (after breakfast)
3007947|NCT02509910||Standard therapy|intraoperative standard fluid therapy for major abdominal surgery
3007948|NCT02509910||Goal directed therapy|intraoperative goal directed fluid therapy based on an angorithm lead by SVV/CI for major abdominal surgery patients
3007949|NCT02509897|Active Comparator|Hypoxic training|Endurance training
3007950|NCT02509897|Placebo Comparator|Normoxic training|Endurance training
3007951|NCT02509871|Other|Body composition measurement|DXA, impedance
3007952|NCT02509858|Active Comparator|thyroxine in eythyroid diabetics|50 μg of thyroxine once daily, for 2 months.
3007953|NCT02509858|Active Comparator|thyroxine in euthyroid healthy humans|50 μg of thyroxine once daily, for 2 months.
3007954|NCT02509858|Placebo Comparator|placebo in euthyroid diabetics|50 μg of placebo once daily, for 2 months.
3007955|NCT02509845|Experimental|Adolescent Safety Only Cohort|Prior to commencing enrollment of subjects 12-17 years of age in Study Arms 1 & 2, a safety only cohort of 4 to 8 adolescent subjects will receive 4 administrations of C16G2 on Day 0.
3007956|NCT02509845|Experimental|Study Arm 1|Subjects will receive 2 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 1 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
3007957|NCT02509845|Experimental|Study Arm 2|Subjects will receive 4 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 2 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
3007958|NCT02509832|Other|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after PCI.
3007959|NCT02509832|Other|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
3007960|NCT02509819|Experimental|Military Performance Lab testing|Subjects who use IDEOs will come to the Military Performance Lab for one test session during which they will walk in standardized shoes with six different foam heel wedges (Heel Cushion Material Bulk (foam) from Kingsley Manufacturing Company) in random order. Control data will also be collected on able-bodied individuals. Control subjects will also come to the MPL for one test session in which they will walk using the same standardized shoes. For all subjects, biomechanical gait data will be collected as the subjects walk along a walkway in the MPL. This data will be used to calculate roll-over shape, instantaneous radius of curvature, COP velocity, and ankle moment.
3007961|NCT02509806|Experimental|Apatinib Maintenance Therapy After First-line Chemotherapy|Apatinib Mesylate Tablets 500 mg qd p.o. after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）
3007962|NCT02509806|No Intervention|No Intervention After First-line Chemotherapy|No Intervention after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）
3007963|NCT02509793|Experimental|Tetrabenazine|Xenazine (tetrabenazine), pill, dosage titrated to effect, three times a day, 12 weeks
3007964|NCT02509780|Experimental|Vichy|
3007965|NCT02509767|Experimental|Self-Administration|Subjects who are randomized to self-administration will be taught self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA sc) by a clinic nurse or other qualified personnel using instructions based on the packaging insert. If willing, subjects will then self-administer DMPA sc under supervision. Subjects who are able to correctly self-administer DMPA sc as assessed by the supervising nurse and who are interested in continued home self-administration will then be provided medication (3 doses of DMPA sc), a self-administration kit (includes alcohol swabs, cotton pads, bandages, mini sharps disposal container), and instructions to do so for the subsequent 3 injections indicating the appropriate dates for injection. All subjects will receive reminders when their next injection is due.
3007966|NCT02509767|Other|Clinic Administration (Standard Care)|Subjects who are randomized to clinic administration will receive subcutaneous depot medroxyprogesterone acetate (DMPA sc) injection administered by a clinic nurse or other qualified personnel and receive standard care. They will be instructed to make an appointment to return to the clinic as usual to receive subsequent injections every 12-14 weeks. All subjects will receive reminders when their next injection is due.
3007991|NCT02509624|Experimental|Severe hepatic impairment (Class C)|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of GS-4997 on Day 1.
3007992|NCT02509611|Experimental|Immediate treatment|Participants who are randomly assigned to the immediate treatment group will receive 60-minute biweekly Hatha yoga for 12 weeks.
3008027|NCT02509351|Experimental|misoprostol|women receiving pre-operative rectally administered 400 microgram misoprostol
3008028|NCT02509351|Active Comparator|placeboo|women receiving placebo
3007967|NCT02509754|Experimental|Atrial fibrillation catheter ablation|Atrial fibrillation (AF) catheter ablation is performed following each Center's common practice. Activated clotting time (ACT) is maintained above 350 seconds. The left atrium (LA) is accessed by transseptal puncture or through a patent foramen ovale. A multipolar catheter and an irrigated-tip ablation catheter are inserted into the LA and a 3-dimensional reconstruction of the LA and pulmonary veins (PVs) ostia is performed. The mainstay is to obtain a complete antral PVs isolation, defined by complete elimination of PVs potentials. PVs isolation may be accompanied by the creation of linear lesions (roof line, left isthmus) or ablation of complex fractioned atrial electrograms. Patients are discharged on oral anticoagulation and optimal medical therapy. Each center will evaluate patients for ICD implantation; a loop recorder may be implanted if within routine clinical practice.
3007968|NCT02509754|Experimental|Rate control arm|Patients randomized to rate control only arm will undergo ICD implantation and optimization of the rate control therapy. In case of uncontrolled ventricular rate at 24-h ECG Holter, defined as a mean resting heart rate higher than 90 bpm, patients will receive atrioventricular (AV) node ablation and resyncronization therapy (CRT-D) implantation, performed following common practice at each Center. In case of failure or technical difficulties of the transvenous approach, epicardial screw-in or steroid-eluting passive lead is implanted via a limited thoracotomy. Transcatheter AV node ablation is performed as follows: a non-irrigated tip ablation catheter is introduced on the right side of the interatrial septum and ablation performed on the fast pathway region or the smallest His bundle signal. The goal of the procedure is AV modulation below 30 bpm or complete AV block.
3007969|NCT02509741|Experimental|Educational intervention|High-protein and low-GI diet education
3007970|NCT02509741|Experimental|Dietary intervention|High-protein and low-GI diet plus education
3007971|NCT02509741|Experimental|Internet-of-things (IOT) monitoring intervention|Dietary intervention plus IOT monitoring
3007972|NCT02509741|No Intervention|control|Routine diet recommendation
3007973|NCT02509728|Active Comparator|standard nutrition|standard nutrition
3007974|NCT02509728|Experimental|choline supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
3007975|NCT02509728|Experimental|DHA supplementation|in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
3007976|NCT02509728|Experimental|choline and DHA supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride and 60mg/kg of DHA for 10 days
3007977|NCT02509715|No Intervention|Standard Conventional group|Standard conventional thyroid surgery
3007978|NCT02509715|Active Comparator|IONM group|Intraoperative nerve monitoring used thyroid surgery
3007979|NCT02509702|Experimental|Connected to Care|The SMS intervention will consist of 15 text messages that will be sent to the intervention group over a period of 10 months. There will be two types of text messages: (1) educational text messages; and (2) SMS reminders for the follow-up appointment.
3007980|NCT02509702|No Intervention|Control|The control group will receive standard care, which is a follow-up appointment at 14 months written on an appointment card.
3007981|NCT02509689|Experimental|Single Arm|"The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions."
3007982|NCT02509676|Experimental|dynamic stretching exercise|This group will perform dynamic stretching exercise to their left side gastrocnemius muscles for 5 weeks (5 days a week, 3 sets of exercise a day, each set including 5 repetitions of dynamic stretching lasting 45 seconds)
3007983|NCT02509676|No Intervention|control|this group will not perform any stretching exercises for 5 weeks
3007984|NCT02509663|Active Comparator|Sinuplasty balloon|Patients will receive the innovative health technology to treat frontal sinusitis : a balloon sinuplasty
3007985|NCT02509663|Active Comparator|Conventional surgical procedure|Patients will be treated with the conventional procedure : a sinus surgery with rigide instrumentation
3007986|NCT02509637|Active Comparator|Flutter Intervention|After initial evaluation, the subjects will perform breathing exercises with quiet inspiration and prolonged expiration on the device for thirty minutes, with breaks of one minute every four minutes. Immediately after the exercise will be performed new assessment against Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied the acceptability and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for weight, adhesiveness and purulence.
3007987|NCT02509637|Active Comparator|Chest Compression Intervention|After initial evaluation, the subjects will be instructed to perform deep breaths between three quiet inspiration brought, and expiration will be accompanied by bilateral compression with the therapist's hands on the lower ribs during thirty minutes with one minute intervals of rest every four minutes. Immediately after the exercise will be performed new assessment against Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied the acceptability and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for weight, adhesiveness and purulence.
3007988|NCT02509637|Active Comparator|Crontrol Intervention|After initial evaluation, patients will be remain seated quiet breathing without any guidance for thirty minutes. Immediately after this time will be held reassessment with Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied to acceptance and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for wight, adhesiveness and purulence.
3007989|NCT02509624|Experimental|Mild hepatic impairment (Class A)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of GS-4997 on Day 1.
3007990|NCT02509624|Experimental|Moderate hepatic impairment (Class B)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of GS-4997 on Day 1.
3007993|NCT02509611|Active Comparator|Waitlist control|Participants who are randomly assigned to the wait-list group will receive no intervention during the first 12 weeks. Not only will they serve as the comparative group, they will also serve as their own control and receive the same yoga intervention at the end of 12 weeks when the immediate treatment group completed their program.
3007994|NCT02509598|Experimental|Tc99m tilmanocept and Vital Blue Dye (optional)|0.5 mCi, 50 ug of Tc99m tilmanocept single administration. Optionally, 1-3 mL of vital blue dye, single administration (per institution's standard of care).
3007995|NCT02509585|Experimental|Tc99m tilmanocept|2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
3007996|NCT02509572|Experimental|Decision Support Arm|Patients randomized to the intervention will complete a sexual health screen (SHS). The results of the SHS will provide decision support for STI testing by risk stratifying patients with screening recommendations to the clinician based on risk.
3007997|NCT02509572|No Intervention|Usual Care Arm|Patients randomized to the usual care arm will complete the sexual health screen (SHS). However these results and the STI testing decision support will not be shared with the clinician.
3007998|NCT02509559|Active Comparator|Propanolol|Memory performance for pictures, electrocortical activity, pharmacokinetics, skin-conductance, pulse waves, burdening heart frequency, pulmonary function, α-amylase in saliva, heart rate and blood pressure after administration of one Propranolol-CT 80 mg film-coated tablet.
3007999|NCT02509559|Placebo Comparator|Placebo|Memory performance for pictures, electrocortical activity, pharmacokinetics, skin-conductance, pulse waves, burdening heart frequency, pulmonary function, α-amylase in saliva, heart rate and blood pressure after administration of one placebo capsule.
3008000|NCT02509546|Experimental|Treatment (8-chloro-adenosine)|Patients receive 8-chloro-adenosine IV over 4 hours on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3008001|NCT02509533|Experimental|V.A.C.® Therapy|In this arm, investigators will use the V.A.C.® Therapy after a transplants of leg ulcers.
3008002|NCT02509533|Active Comparator|usual dressing method (compresses)|In this arm, investigators will use the usual dressing method after a transplants of leg ulcers.
3008003|NCT02509520|No Intervention|Mobility-based Physical Rehab (MPR)|ICU control group receiving only mobility based rehabilitation (MPR).
3008004|NCT02509520|Active Comparator|MPR and Neuromuscular Stimulation and HPRO|ICU group receiving mobility based rehabilitation and NMES and High protein supplementation.
3008005|NCT02509507|Experimental|Phase 1b Talimogene Laherparepvec|Talimogene Laherparepvec
3008006|NCT02509507|Experimental|Phase 1b Talimogene Laherparepvec + Pembrolizumab|Combination treatment of Talimogene Laherparepvec and Pembrolizumab
3008007|NCT02509494|Experimental|Stage 1: Active vaccination|Ad26.ZEBOV will be administered as a 0.5 milliliter (mL) intramuscular (IM) injection (prime); MVA-BN-Filo will be administered as a 0.5 mL IM injection (boost). The third vaccination using Ad26.ZEBOV will be administered as a 0.5 mL IM injection (2 years post prime).
3008008|NCT02509494|Experimental|Stage 2: Active vaccination|Ad26.ZEBOV will be administered as a 0.5 mL IM injection (prime); MVA-BN-Filo will be administered as a 0.5 mL IM injection (boost).
3008009|NCT02509494|Experimental|Stage 2: Active vaccination for children|Ad26.ZEBOV will be administered as a 0.5 mL IM injection (prime); MVA-BN-Filo will be administered as a 0.5 mL IM injection (boost). Children aged less than 2 years at randomization will receive a third vaccination at 3 months post boost with Placebo.
3008010|NCT02509494|Active Comparator|Stage 2: Control vaccination|MenACWY will be administered as a 0.5 mL IM injection on Day 1 (prime) and placebo on Day 57 (boost).
3008011|NCT02509494|Active Comparator|Stage 2: Control vaccination for children|MenACWY will be administered as a 0.5 mL IM injection on Day 1 (prime) and placebo on Day 57 (boost). Children aged less than 2 years at randomization will receive a third vaccination at 3 months post boost with MenACWY.
3008012|NCT02509481|Active Comparator|Single MDA|Single mass drug administration of ivermectin (150 µg/kg) + albendazole (400 mg) performed after the start of the rainy season as part of public health efforts to eliminate lymphatic filariasis.
3008013|NCT02509481|Experimental|Repeated MDA|Same at Active Comparator, but then followed by five more mass drug administrations of ivermectin only (150 µg/kg) every three weeks thereafter.
3008014|NCT02509468|No Intervention|Observational|"Patients will first be included in an observational period, then, at a randomized time different from one to another, will all receive the experimental treatment (i.e. sirolimus).~This design has been defined a the randomized placebo-phase design (Feldman et al. J Clin Epidemiol. 2001 Jun;54(6):550-7)"
3008015|NCT02509468|Experimental|Experimental|At a randomized date, patients will start treatment with sirolimus (beginning dose: 0.08mg/kg/day)
3008016|NCT02509455||Normal 1|SwayStar device used 1st, Sensoro used 2nd
3008017|NCT02509455||Normal 2|Sensoro device used 1st, SwayStar used 2nd
3008018|NCT02509442|Other|Diffusion of direct electric stimulation|Neurosurgery awakened
3008019|NCT02509429|Experimental|Control-to-Range algorithm and Threshold Low Glucose Suspend|"On this arm, patients will realize two investigational sessions:~the first with Control-to-Range algorithm (CTR),~the second with Threshold Low Glucose Suspend (TLGS)."
3008020|NCT02509429|Experimental|Threshold Low Glucose Suspend and Control-to-Range algorithm|"On this arm, patients will realize two investigational sessions:~the first with Threshold Low Glucose Suspend (TLGS),~the second with Control-to-Range algorithm (CTR)."
3008021|NCT02509403|Experimental|Intervention|Essential oils infused Perineal Hygiene wipe
3008022|NCT02509390|Experimental|Severe trauma patients|All severe trauma patients (ISS>15) admitted in our trauma center Blood samples (additional blood tubing)
3008023|NCT02509377|Experimental|BMI 35.0 to 40.0|"Mothers who meet all inclusion exclusion criteria for open fetal repair of myelomeningocele except BMI.~These mothers have a BMI between 35.0 and 40.0"
3008024|NCT02509364||AE-IPF|"Diagnosis criteria for AE-IPF:~Diagnosed IPF patient experiences unexplained dyspnea within 1 month~With objective evidence of hypoxia and new onset of pulmonary infiltration based on imaging examination~With other diagnosis like pulmonary embolism, pneumothorax or heart failure excluded."
3008025|NCT02509364||Stable-IPF|"Diagnosis criteria for Stable-IPF:~Exclusion of other known causes of ILDs~Presence of a usual interstitial pneumonitis (UIP) pattern on high-resolution computed tomography (HRCT)~Specific combinations of HRCT and surgical lung biopsy pattern in patients subjected to surgical lung biopsy."
3008029|NCT02509338|Experimental|Electrode deep brain stimulation|Monocontact electrode deep brain stimulation
3008030|NCT02509312|Experimental|Experimental|Patients in this arm will be given ketorolac at cord clamp with standard dose of 30 mg, then 3 additional 30 mg doses every 6 hours
3008031|NCT02509312|Placebo Comparator|Control|Patients in this arm will be given a placebo medication at cord clamp, and then 3 additional doses of placebo every 6 hours.
3008032|NCT02509299|Experimental|Experimental group 1|30 patients will be involved in the Physiotherapy program 1, a physiotherapy intervention based on resistance exercises added to standard treatment.
3008033|NCT02509299|Experimental|Experimental group 2|30 patients will be involved in a the physiotherapy program 2, an intervention based on respiratory exercises added to standard treatment
3008034|NCT02509299|Other|Control group|30 patients will receive standard medical treatment without physiotherapy intervention
3008035|NCT02509286|Experimental|Perioperative Chemotherapy (FLOT):|"The FLOT Arm consists of the FLOT protocol, which consists of 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel. Repetition every 2 weeks (d15, q2w). Four neoadjuvant cycles (8 weeks) prior to surgery and four adjuvant cycles (8 weeks) postoperatively are given.~Surgery is carried out by transthoracic subtotal esophagectomy or by transabdominal distal esophageal resection plus gastrectomy depending on tumor localization."
3008036|NCT02509286|Active Comparator|Neoadjuvant Chemoradiation (CROSS):|"The CROSS Arm consists of the CROSS protocol, which consists of neoadjuvant radiation therapy (41.4Gy / 23fractions) and concurrent chemotherapy with Carboplatin and Paclitaxel (5 weeks) prior to surgery.~Surgery is carried out by transthoracic subtotal esophagectomy or by transabdominal distal esophageal resection plus gastrectomy depending on tumor localization."
3008037|NCT02509273|Experimental|CLONIDINE HYDROCHLORIDE|solution for i.v. infusion (maximum 55 μg/kg per day; maximum 7 day treatment)
3008038|NCT02509273|Active Comparator|MIDAZOLAM|solution for i.v. infusion (maximum 5.5 mg/kg per day; maximum 7 day treatment)
3008039|NCT02509260|Experimental|Prevena™ incisional NPWT|Prevena wound management system: Post op application of the Prevena™ wound management system will be applied.
3008040|NCT02509260|Active Comparator|Standard Wound Dressings|Standard Wound Dressings: Control patients with standard wound dressings will have gauze and tape dressings applied.
3008041|NCT02509247|Experimental|Telemonitoring group|Patients allocated to the telemonitoring group started with wireless telemonitoring after the titration period, i.e. in the beginning of habituation phase of CPAP treatment.
3008042|NCT02509247|No Intervention|Usual care group|Patients were followed-up during the habituation phase according to hospital's standard procedure.
3008043|NCT02509221||Less than 30 minutes|
3008044|NCT02509221||30-60 minutes|
3008045|NCT02509221||More than 60 minutes|
3008046|NCT02509208|Experimental|SurgiClot|All qualified subjects will be treated with the SurgiClot haemostatic dressing
3008047|NCT02509195|Experimental|Switch to Triumeq|HIV-1 infected subjects currently receiving stable antiretroviral therapy switch their treatment to abacavir/lamivudine/dolutegravir (Triumeq).
3008048|NCT02509182|Active Comparator|100% FiO2|100% oxygen administered during pulmonary lobectomy surgery.
3008049|NCT02509182|Experimental|60% FiO2|60% oxygen administered during pulmonary lobectomy surgery.
3008050|NCT02509169|Experimental|TAE plus p53 gene|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
3008051|NCT02509169|Active Comparator|TAE|Trans-catheter embolization (TAE) will be given once per month
3008052|NCT02509156|Experimental|Allo-MSCs|Target dose of 100 million allo-MSCs
3008053|NCT02509156|Placebo Comparator|Placebo|Buminate solution
3008054|NCT02509143|Experimental|High-dose acupuncture with intravenous infusion of ramosetron|Three sessions of acupuncture on the points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4), Pericardium 6 (PC6), Heart 8 (HT8), and Gall Bladder 41 (GB41) within 48 hours after surgery
3008055|NCT02509143|Active Comparator|P6 stimulation with intravenous infusion of ramosetron|P6 stimulation by wearing a study wristband within 48 hours after surgery
3008056|NCT02509143|Active Comparator|Intravenous infusion of ramosetron|A mixture of standard antiemetic medication (5-Hydroxytryptophan receptor antagonist; ramosetron hydrochloride 0.3 mg) and analgesics, including anon-steroidal anti-inflammatory drug (NSAID) (ketorolac tromethamine 120 mg), and a semi-synthesized opioid (oxycodone 20 mg), will be infused by intravenous patient-controlled analgesia (1ml bolus/20 min lockout, 1ml/hr continuous infusion).
3008057|NCT02509130||Patients who attended RAAC/SAAC.|Patients who have previously attended the Rapid Access Asthma Clinic (RAAC) will be approached for the quantitative study. Patients who went onto the attend the Severe Asthma Assessment Clinics (SAAC) will also be approached for the quantitative and qualitive parts of the study.
3008058|NCT02509130||Patients eligible for RAAC, but DNA'd|Patients identified by the GP search, who did not attend the previous MISSION clinics will be approached to participate in the quantitative part of the study.
3008059|NCT02509130||Asthma Outpatients|Patients who are attending outpatient clinics as new referrals will be approached to participate in the quantitative part of the study.
3008060|NCT02509130||Healthcare Professionals|Healthcare professionals who performed the MISSION RAAC or SAAC will be approached for qualitative interview part of the study only.
3008061|NCT02509117|Experimental|Single Ascending Dose Cross-over|Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
3008062|NCT02509117|Experimental|Multiple Ascending Dose PF-06751979|Multiple dose administration to Healthy Subjects in parallel cohorts(PF-06751979)
3008063|NCT02509117|Placebo Comparator|Multiple Ascending Dose Placebo|Multiple dose administration to Healthy Subjects in parallel cohorts(Placebo)
3008064|NCT02509117|Experimental|Multiple Dose Elderly PF-06751979|Multiple dose administration to Healthy Elderly Subjects (PF-06751979)
3008065|NCT02509117|Placebo Comparator|Multiple Dose Elderly Placebo|Multiple dose administration to Healthy Elderly Subjects (Placebo)
3008066|NCT02509104|Experimental|Cohort 1 Fasted condition|Each subject will receive both treatments A and B in either of period 1 or 2 with a washout period of 28 days between treatment periods. Subjects will receive the study treatments under fasting conditions.
3008154|NCT02508571|Experimental|Preterm infant single intervention|Direct swallowing training (DST) for preterm infant
3008067|NCT02509104|Experimental|Cohort 2 Fed condition|Each subject will receive both treatment A and B in either of period 1 or 2 with a washout period of 28 days between treatment periods. Subjects will receive the study treatments under fed (high fat breakfast) conditions.
3008068|NCT02509091|Experimental|The experimental group|fundamental treatment combining with the therapy of bronchoalveolar lavage and local Amikacin injection.(fundamental treatment including anti-infection,eliminating phlegm,oxygen therapy etc.)
3008069|NCT02509091|No Intervention|The controlled group|fundamental treatment(including anti-infection,eliminating phlegm,oxygen therapy etc.)
3008070|NCT02509078|Active Comparator|Early Neuromuscular Blockade (NMB)|Patients will receive cisastracurium besylate for the first 48 hours of the trial.
3008071|NCT02509078|No Intervention|Control: No Routine Early NMB|Use of non-study NMB will be discouraged.
3008072|NCT02509065|Active Comparator|Usual Care|Comparator week to all closed-loop control, utilizing usual diabetes care and the subject's own insulin pump.
3008073|NCT02509065|Experimental|145 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 145 mg/dl and using only an insulin pump.
3008074|NCT02509065|Experimental|130 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is for subjects with type 1 diabetes only. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
3008075|NCT02509065|Experimental|130 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
3008076|NCT02509065|Experimental|115 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 115 mg/dl using both an insulin and a glucagon pump.
3008077|NCT02509065|Experimental|100 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 100 mg/dl using both an insulin and a glucagon pump.
3008078|NCT02509065|Experimental|110 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
3008079|NCT02509065|Experimental|110 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
3008080|NCT02509065|Experimental|120 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 120 mg/dl and using only an insulin pump.
3008081|NCT02509052|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3008082|NCT02509039|Experimental|CC-122|CC-122 is administered orally, on a 5 continuous days out of 7 days per week intermittent dosing schedule.
3008083|NCT02509026|Experimental|Etanercept|etanercept 50 mg QW
3008084|NCT02509000|Active Comparator|Active-mode|Air purifier in active-mode
3008085|NCT02509000|Sham Comparator|Sham-mode|Air purifier in sham-mode
3008086|NCT02508987||Group 1|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as periodontally healthy.Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index. 18.50-24.99 kg/m2: Normal-weight"
3008087|NCT02508987||Group 2|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as gingivitis. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index.~18.50-24.99 kg/m2: Normal-weight"
3008088|NCT02508987||Group 3|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'generalized chronic periodontitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index.18.50-24.99 kg/m2: Normal-weight"
3008089|NCT02508987||Group 4|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as either 'periodontally healthy'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
3008090|NCT02508987||Group 5|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'gingivitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
3008111|NCT02508844|Experimental|Vivomixx®|Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus and Streptococcus thermophilus
3008112|NCT02508844|Placebo Comparator|Placebo|microcrytalline cellulose, magnesium stearate and silicon dioxide.
3009369|NCT02500615|Experimental|50 PG: 50 VG|
3008091|NCT02508987||Group 6|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'generalized chronic periodontitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
3008092|NCT02508961|Experimental|Web-based physio|Participants receive an online individualised exercise programme to complete over the internet twice per week. Exercises can be a combination of aerobic, strengthening and balance exercises. Participants receive a weekly phone call from a physiotherapist for the first two weeks to check on progress. After this, every 2 weeks online exercise diaries are remotely monitored by a physiotherapist and exercise programmes progressed as appropriate.
3008093|NCT02508961|Active Comparator|Print-out exercise programme|Participants receive printed exercise programme to complete twice per week. Exercises can be a combination of aerobic, strengthening and balance exercises. Participants receive a weekly phone call from a physiotherapist for the first two weeks to check on progress. Participants complete a paper exercise diary and after the first 2 weeks if they require a progression to their exercise programme they contact their physiotherapist.
3008094|NCT02508935|Other|XARTEMIS XR|
3008095|NCT02508922|Experimental|Vitamin D3|2000iu vitamin D will be taken daily for 20 weeks.
3008096|NCT02508922|Placebo Comparator|Placebo|Matching placebo drops will be taken daily for 20 weeks
3008097|NCT02508909|Experimental|Videoscopic ilioinguinal lymphadenectomy for melanoma|Melanoma groin lymph node metastasis.
3008098|NCT02508896|Experimental|AFFITOPE® AT04A+adjuvant|3 injections of 15µg AFFITOPE® AT04A+adjuvant once every 4 weeks and 1 boost immunization at a dose of 75μg, which will be applied one year after the 3rd immunization
3008099|NCT02508896|Experimental|AFFITOPE® AT06A+adjuvant|3 injections of 15µg AFFITOPE® AT06A+adjuvant once every 4 weeks and 1 boost immunization at a dose of 75μg, which will be applied one year after the 3rd immunization
3008100|NCT02508896|Placebo Comparator|Adjuvant without active component|3 injections of Placebo once every 4 weeks and 1 boost immunization which will be applied one year after the 3rd immunization
3008101|NCT02508883||Upper gastrointestinal bleeding|patients with cancer who presented or were admitted in the emergency room, wards or intensive care units of the Cancer Institute of São Paulo (ICESP), with a recent episode of upper gastrointestinal bleeding.
3008102|NCT02508870|Experimental|Cohort A: Atezolizumab - HMA R/R MDS|Participants with MDS who are HMA R/R will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (Q3W) (21-day cycle). Treatment will continue for up to 17 cycles or until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first. Participants who achieve/maintain a partial response (PR) or hematological improvement (HI) after receiving 17 cycles of therapy may continue on study treatment beyond Cycle 17 until loss of clinical benefit.
3008103|NCT02508870|Experimental|Cohort B: Atezolizumab+Azacitidine - HMA R/R MDS|Induction: Participants with MDS who are HMA R/R will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 milligrams per square meter (mg/m^2) subcutaneously (SC) on Days 1 to 7 of 28-day cycle, for 6 cycles. Maintenance: Participants who complete induction treatment will receive atezolizumab 1200 mg IV infusion Q3W (21-day cycle) for up to 8 additional cycles. Participants who achieve/maintain a PR or HI after completing the 8 cycles of atezolizumab maintenance therapy, may continue on study treatment until loss of clinical benefit.
3008104|NCT02508870|Experimental|Cohort C1: Atezolizumab+Azacitidine - HMA-Naive MDS|Participants with MDS who are HMA-naive will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first.
3008105|NCT02508870|Experimental|Cohort C2: Atezolizumab+Azacitidine - HMA-Naive MDS|If the participants enrolled in Cohort C1 fulfil the dose limiting toxicity (DLT) criteria, then additional participants with MDS who are HMA-naïve will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first.
3008106|NCT02508870|Experimental|Cohort A2: Atezolizumab - HMA R/R MDS|If atezolizumab alone or in combination with azacitidine is found to be initially safe and tolerable in participants with HMA R/R MDS in both Cohorts A and B, then additional randomly assigned participants will receive atezolizumab 1200 mg IV infusion Q3W (21-day cycle). Treatment will continue for up to 17 cycles or until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first. Participants who achieve/maintain a PR or HI after receiving 17 cycles of therapy may continue on study treatment beyond Cycle 17 until loss of clinical benefit.
3008107|NCT02508870|Experimental|Cohort B2: Atezolizumab+Azacitidine - HMA R/R MDS|If atezolizumab alone or in combination with azacitidine is found to be initially safe and tolerable in participants with HMA R/R MDS in both Cohorts A and B, then additional randomly assigned participants will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, for 6 cycles during induction. Participants who complete induction treatment will receive maintenance atezolizumab 1200 mg IV infusion Q3W (21-day cycle) for up to 8 additional cycles. Participants who achieve/maintain a PR or HI after completing the 8 cycles of atezolizumab maintenance therapy, may continue on study treatment until loss of clinical benefit.
3008108|NCT02508857|Active Comparator|ketorolac|intravenous ketorolac (30 mg) is injected in bolus, followed by continuous infusion of saline solution (Group K) during the surgical procedure
3008109|NCT02508857|Experimental|magnesium|intravenous magnesium sulfate (20 mg/kg) is injected in bolus, followed by continuous infusion of magnesium sulfate (2 mg/kg/h) (Group M) during the surgical procedure
3008110|NCT02508857|Placebo Comparator|saline|intravenous saline solution (20 ml) is injected in bolus, followed by continuous infusion of saline infusion during the entire procedure (Group S).
3009370|NCT02500615|Experimental|70 PG: 30 VG|
3009371|NCT02500615|Experimental|100 PG: 0 VG|
3008113|NCT02508831|Experimental|Bilateral amputation of upper limb|Patients with bilateral amputation of upper limb will receive a double upper limb allograft
3008114|NCT02508818|Other|Cardiovascular measurements|
3008115|NCT02508805|Experimental|Neuromultivit +Voltaren+Sirdalud|"Neuromultivit 2ml i.m. once a day for 7 days, then 2 ml i.m. one time every other day for 10 days.~Voltaren 100mg per os once a day for 20 days. Sirdalud 2 mg per os three times a day for 20 days."
3008116|NCT02508805|Active Comparator|Voltaren+Sirdalud alone|Voltaren 100mg per os once a day for 20 days Sirdalud 2 mg per os three times a day for 20 days
3008117|NCT02508792|Active Comparator|LASER|"Subject will receive application of LASER before muscle fatigue protocol.~Note: this is a crossover study."
3008118|NCT02508792|Placebo Comparator|LASER PLACEBO|"Subject will receive application of LASER (now deactivated) before muscle fatigue protocol.~Note: this is a crossover study."
3008119|NCT02508779|Experimental|Bump2Be|Blood Glucose Awareness Training for pregnancy or preconception
3008120|NCT02508779|Active Comparator|Routine Care|Routine care provided by subject's medical team
3008121|NCT02508766|Experimental|Plantar stimulation|The manipulation was performed with the subject in the supine position. The intervention lasted ten minutes and consisted of four stages: 5 glide pressures focused on each interdigital space, that lasted 10 seconds in duration, 5 compression-decompression of each metatarsophalangeal joint, 5 glide pressures applied for 5 seconds each, on the region of metatarsal heads, 5 static pressures applied for 10 seconds each, focused on four points of the sole.
3008122|NCT02508766|No Intervention|Control group|Volunteers received no intervention. They just sat there for 20 minutes before being evaluated.
3008123|NCT02508753|Experimental|CXA-101/tazobactam therapeutic dose|
3008124|NCT02508753|Experimental|CXA-101/tazobactam supra-therapeutic dose|
3008125|NCT02508753|Active Comparator|Moxifloxacin|
3008126|NCT02508753|Placebo Comparator|Placebo|
3008127|NCT02508740|Experimental|normal renal function|Healthy subjects with normal renal function (Stage 1, >90 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
3008128|NCT02508740|Experimental|mild renal impairment|Patients with mild renal impairment (Stage 2, 60-89 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
3008129|NCT02508740|Experimental|moderate renal impairment|Patients with moderate renal impairment (Stage 3, 30-59 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
3008130|NCT02508740|Experimental|severe renal impairment|Patients with severe renal impairment (Stage 4, <30 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
3008131|NCT02508740|Experimental|End Stage Renal Disease (ESRD)|Patients with End Stage Renal Disease (ESRD) receiving dialysis for at least 3 months preceding the initial dose in this study (Stage 5) will participate in 2 treatment periods and will receive a single oral dose of 0.25 mg bevenopran at 3 hours after completion of the last hemodialysis session of the week in Period 1 and a single oral dose of 0.25 mg bevenopran at 3 hours before initiation of the last hemodialysis session of the week in Period 2
3008132|NCT02508727|Other|Healthy volunteers|Healthy volunteers
3008133|NCT02508727|Other|Subjects with an anterior myocardial infarction sequela|Subjects with an anterior myocardial infarction sequela
3008134|NCT02508727|Other|Subjects with lower myocardial infarction sequelae|Subjects with lower myocardial infarction sequelae
3008135|NCT02508714|Active Comparator|Orsiro DES (Biotronik)|The ORSIRO hybrid coating DES (Biotronik, Switzerland) is a device which includes a modern, highly flexible, thin-strut stent platform, eluting sirolimus from a thin biodegradable BIO-lute coating grom PLLA (poly(L-lactic acid)) which is located mainly on the abluminal side.
3008136|NCT02508714|Active Comparator|RESOLUTE ONYX DES (Medtronic)|The RESOLUTE ONYX is a permanent polymer DES that uses a novel highly flexible metallic stent backbone with increased radiographic visibility eluting the drug zotarolimus from the BioLinx durable polymer coating. The stent platform uses corewire technology that allows the stent to have a denser core metal surrounded by outer layer of cobalt-chromium.
3008137|NCT02508701|Other|Altruistic inside-dorm|Altruistic & personal message with direct recommendation and access to the vaccine on-site
3008138|NCT02508701|Other|Generic inside-dorm|Generic message and access to the vaccine on-site
3008139|NCT02508701|Other|Generic outside-dorm|Generic message and off-site access to the vaccine
3008140|NCT02508701|Other|Altruistic outside-dorm|Altruistic & personal message with direct recommendation and off-site access to the vaccine
3008141|NCT02508688|Experimental|thoracoscopic mesh repair group|63 patients with refractory HH (> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair were included in this study.
3008142|NCT02508662||Advanced Cancer (Refractory) with Genomic Mutation|Participants with advanced cancer who have exhausted standard treatment option and have no potential clinical trial available, and who have potentially actionable alterations on genomic profiling.
3008143|NCT02508649|Placebo Comparator|Placebo|
3008144|NCT02508649|Experimental|Selepressin 1|Starting dose 1.7 ng/kg/min
3008145|NCT02508649|Experimental|Selepressin 2|Starting dose 2.5 ng/kg/min
3008146|NCT02508649|Experimental|Selepressin 3|Starting dose 3.5 ng/kg/min
3008147|NCT02508649|Experimental|Selepressin 4|Starting dose 5.0 ng/kg/min
3008148|NCT02508636|Experimental|Single Arm|"Enzalutamide: 160 mg (for 40 mg capsules) per day; Oral - swallow capsules hole, with or without food; Enzalutamide therapy to begin within 0-7 days of the date of the first Luteinizing Hormone-Releasing Hormone (LHRH) agonist administration for total duration of 24 months.~Leuprolide: any duration formulation: single 7.5mg injection every month; single 22.5 mg injection every 3 months; single 30mg injection every 4 months; single 45 mg injection every 6-months based on the manufacturer for a total of 24 months; Intramuscular injection"
3008149|NCT02508623|Experimental|Rifaximin|Rifaximin 550 mg 1 tablet BID for 60 days
3008150|NCT02508623|Placebo Comparator|Placebo|Placebo 1 tablet BID for +60 days
3008151|NCT02508597|Other|Physicians receiving smoking cessation training|On the training day, the investigators will explain at the beginning of the workshop the purpose of the training, and the details of the brief smoking cessation intervention to all physicians who attend the training workshop.
3008152|NCT02508584|Experimental|Intervention|This is a single patient treatment IND
3008153|NCT02508571|Placebo Comparator|Preterm infant control|Preterm infant without intervention
3008155|NCT02508571|Experimental|Preterm infant combined interventions|Combined DST and oral sensorimotor stimulation (OSMS) for preterm infant
3008156|NCT02508558|Other|Measurements under different gravity states|motion perception and locomotor operation performance under different gravity states
3008157|NCT02508545|Other|perceived egocentric distance measurements - parabolic flight|perceived egocentric distance (PED) measurements during parabolic flight
3008158|NCT02508532|Experimental|Avapritinib (formerly BLU-285)|Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.
3008159|NCT02508519|Experimental|Zonal|The zonal acupuncture group will receive a treatment according to a zonal method and a pain level will be estimated by the investigator according to a visual analog pain scale (VAS) before and 10 minutes and 15 minutes after the beginning of the treatment and the change of the pain level will be recorded. If possible the pain level will be measured again approximately 24 hours after the treatment and the change of the pain level will be again recorded.
3008160|NCT02508519|Experimental|Balance|The balance acupuncture group will receive a treatment according to a balance method, and a pain level will be estimated according to a visual analog pain scale (VAS) before and 10 minutes and 15 minutes after the beginning of the treatment and the change of the pain level will be recorded. If possible the pain level will be measured again approximately 24 hours after the treatment and the change of the pain level will be again recorded.
3008161|NCT02508519|No Intervention|Control|The control group will provide only the estimation of the the pain level according to a visual analog pain scale (VAS) but receive no acupuncture treatment. Then if possible the pain level will be measured again approximately 24 hours after the first measurement and the change of the pain level will be recorded.
3008162|NCT02508506|Experimental|ALKS 5461|Sublingual tablet
3008163|NCT02508493||Major Depressive Disorder Population|100 Individuals with DSM-5-defined MDD, aged 18-65
3008164|NCT02508493||Healthy Control Population|100 healthy controls matched on age, sex and years of education
3008165|NCT02508480|Experimental|Photovoice|Participants in this arm will attend a 10-week peer-led Photovoice program conducted in group format.
3008166|NCT02508480|Active Comparator|Enhanced Control|Participants in this arm will attend a 60-minute peer-led group discussion on stigma and discrimination, and be eligible to participate in the 10-week Photovoice program after completing all study assessments.
3008167|NCT02508467|Experimental|BLU-554|BLU-554 capsules for oral administration.
3008168|NCT02508454||Greater Miami Area Community|Members of the Miami area who qualify for the study, are not an employee of BHSF, and enroll.
3008169|NCT02508454||Baptist Health South Florida Employees|Employees of BHSF who qualify for the study and enroll.
3008170|NCT02508441|Experimental|Andes-1537 for Injection|Part 1 is an open-label, dose-escalation study. Part 2 is an open-label, dose-expansion study.
3008171|NCT02508428|Active Comparator|Crosslinked Marathon polyethylene|
3008172|NCT02508428|Active Comparator|Standard Enduron polyethylene|
3008173|NCT02508415|Experimental|Non Surgical Periodontal Therapy|Will receive oral hygiene education, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine mouth rinse twice a day
3008174|NCT02508415|No Intervention|No Non Surgical Periodontal Therapy|No treatment received
3008175|NCT02508402|Active Comparator|dexamethasone group|The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular After six hours of the initial dose, the labour induction will start via Oxytocin .III. The interval between the initiation of induction and the beginning of the active phase of labour is recorded (a cervical dilatation of 4 cm plus 3 forceful contractions over a 10-minute span each last from 40-60 Sec).
3008176|NCT02508402|Placebo Comparator|Placebo group|and the participants of placebo Group will not receive Dexamethasone or any other cervical ripening agent.II.two milliliters of normal saline given.
3008177|NCT02508389|Experimental|Low Dose GC4419: 30mg/day|30 mg GC4419/day prior to IMRT
3008178|NCT02508389|Experimental|High Dose GC4419: 90mg/day|90 mg GC4419/day prior to IMRT
3008179|NCT02508389|Placebo Comparator|Placebo|Placebo daily, prior to IMRT
3008180|NCT02508376|Experimental|ID93 (10 mcg) + AP10-602 (10 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
3008181|NCT02508376|Experimental|ID93 (10 mcg) + AP10-602 (5 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
3008182|NCT02508376|Experimental|ID93 (10 mcg) + GLA-SE (5 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
3008183|NCT02508376|Experimental|ID93 (10 mcg) alone|N=10 subjects will receive intervention on Days 1, 29, 57
3008184|NCT02508363|Active Comparator|Health Fair Alone (Control)|"No Follow Up Participant does not require referrals or assistance and was not advised to see a provider in the next three months.~Regular follow-up call within two weeks of health fair by IHCD intern or staff. Participant has abnormal values, requires referrals or assistance or was advised to see a provider in the next three months.~Up to 3 call attempts to get participant into needed care. Further contact only by participant request.~Urgent follow-up call or in-person assistance within 1 day of health fair by IHCD intern or staff Participant advised to seek urgent care within one week.~Three total call or in-person attempts to get participant into needed care. Further contact only by participant request The follow up call attempts may extend up to 3 months past the date of health fair to complete any needs the driver may have."
3008185|NCT02508363|Experimental|Health Fair + Navigator Case Management|"• Follow-up call or further in-person assistance within one day for urgent follow-up, or call within two weeks for regular needs. Three call attempts.~Navigator Case Management by trained staff~Tailored assistance for any health needs a minimum of once a month 12 months. Assistance includes pre-appointment reminder calls, post-appointment follow up calls, and health promotion reminders.~NCM case management will continue follow-up at a minimum of once per month or as requested by the participant for the study duration and will consistently offer appointment reminders and follow-ups."
3008216|NCT02508142|Active Comparator|Hyoscine-N-Butylbromide|20 mg Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL)
3008217|NCT02508142|Placebo Comparator|Placebo|100 mL normal saline
3008218|NCT02508129|Experimental|Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia (BBTI) employs behavioral strategies for managing insomnia and is administered in 4 brief weekly contacts with a therapist via online web conferencing.
3009593|NCT02499198|Experimental|Arm 5|Nornicotine level equal to 10% of commercial smokeless tobaccos
3008186|NCT02508363|Experimental|Health Fair + Taxi Health Improvement Promoters|"Health Fair standard services Follow-up call or further in-person assistance within one day for urgent follow-up, or call within two weeks for regular needs. Three call attempts.~Taxi health Improvement Promoters (TIPs)~Weekly check-ins with each participant, in person or by phone, about scheduling of, and attendance at, primary care appointments along with other health or study questions Mosio Text Messaging Program~Send primary care provider recommendations to participant up to three times~Two pre-appointment reminders & one post-appointment check-in~Twice weekly health promotion reminders after primary care appointment"
3008187|NCT02508350|Experimental|daptomycin|Daptomycin for injection 10-12mg/kg/day,determination of plasma concentration
3008188|NCT02508337|Experimental|XG-102|sterile ophthalmic solution for sub-conjunctival injection
3008189|NCT02508337|Placebo Comparator|placebo|sterile ophthalmic solution for sub-conjunctival injection
3008190|NCT02508324|Other|Intervention|"All potential recipients will have complete (HLA) typing and determination of HLA antibodies. An appropriate umbilical cord blood unit (CBU) will be identified or in the absence of an appropriate CBU, a haplo-identical cells (donor) will be identified.~Within 72 hours after completion of the chemotherapy regimen, and no sooner than 24 hours after administration of the last dose of chemotherapy, umbilical cord graft or haplo-graft will be administered."
3008191|NCT02508311|Active Comparator|Active Oral Beta-2|Subjects will receive 16 weeks of active medication.
3008192|NCT02508311|Placebo Comparator|Placebo|Subjects will receive 16 weeks of placebo medication.
3008193|NCT02508298|Active Comparator|Indocyanine green retention test|A baseline venous sample of 5 ml of venous will be drawn for pre-infusion measurement. Under sterile conditions 0.5 mg/kg body weight of ICG will be injected into vein. Further blood samples (5 ml each) will be collected at 5, 10, 15 and 20 minute intervals after the injection from a peripheral vein in the opposite arm using another intravenous catheter. After serum is separated by centrifugation, optical densities will be measured at 804 nm using a calibrated method for measurement of ICG level s. ICG retention at 15 minutes and elimination rate constant will be calculated by fitting the serum disappearance curve to a single exponential decay equation.This will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
3008194|NCT02508298|Active Comparator|Liver stiffness measurement|ARFI measurements of the liver will be obtained using a standard ultrasound probe. The patient will be lying on his back and will be asked to hold his/her breath for 2-5 seconds during measurements.These will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
3008195|NCT02508298|Active Comparator|Spleen stiffness measurement|ARFI measurements of the spleen will be obtained using a standard ultrasound probe. The patient will be lying on his back and will be asked to hold his/her breath for 2-5 seconds during measurements.These will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
3008196|NCT02508272||Trauma patients|age ≥18 y ISS ≥ 17 points admission < 6 h.
3008197|NCT02508259|Active Comparator|Suramin|20 mg/kg suramin in 50 ml of saline by intravenous infusion over 30 minutes
3008198|NCT02508259|Placebo Comparator|Saline|50 ml of saline by intravenous infusion over 30 minutes
3008199|NCT02508246|Experimental|Treatment (WEE1 inhibitor MK-1, cisplatin, docetaxel, surgery)|Patients receive WEE1 inhibitor MK-1775 PO BID on days 2-4, 9-11, and 16-18, and day -7 prior to course 1, day 1 for PD assessment. Patients also receive cisplatin IV on days 1 (or up to two days after last dose of WEE1 inhibitor MK-1775 lead-in is completed), 8 (or 7 days after first chemotherapy dose), and 15, and docetaxel IV on days 1, 8, and 15. Patients experiencing progressive disease undergo surgical resection. Patients not deemed surgically resectable proceed to chemoradiation as clinically indicated. Patients experiencing stable disease or partial response may receive 2 additional courses of treatment every 28 days in the absence of disease progression or unacceptable toxicity.
3008200|NCT02508233||Control|Healthy subjects (without ankle osteoarthritis) for validation of translation
3008201|NCT02508233||ankle OA|Ankle osteoarthritis patients to ensure validity of translated scale
3008202|NCT02508220|Other|Oxy-Placebo|Syntocinon first, Placebo second 2 puffs in each nostril
3008203|NCT02508220|Other|Placebo-Oxy|Placebo first, Syntocinon second 2 puffs in each nostril
3008204|NCT02508207|Placebo Comparator|Placebo|Participants received placebo matched to tezacaftor (TEZ)/ivacaftor (IVA) fixed dose combination (FDC) tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 29 days.
3008205|NCT02508207|Experimental|TEZ/IVA|Participants received 100 milligram (mg) TEZ/150 mg IVA FDC tablet orally once daily in the morning followed by 150 mg IVA tablet orally once daily in the evening for 29 days.
3008206|NCT02508194|Active Comparator|Placebo + Inactivated Influenza Vaccine (IIV)|Participants received a single intramuscular (IM) injection of placebo (matched with MEDI7510) in one arm and single IM injection of (IIV) in the contralateral arm.
3008207|NCT02508194|Experimental|MEDI7510 + IIV|Participants received a single IM injection of MEDI7510 in one arm and single IM injection of IIV in the contralateral arm.
3008208|NCT02508181|Active Comparator|I-gel intra ocular pressure|supraglottic airway device
3008209|NCT02508181|Active Comparator|LMA Supreme intra ocular pressure|supraglottic airway device
3008210|NCT02508168|Experimental|Sequence I: AB|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets, orally, once, on Day 1 of Period 1, followed by a 7-day washout period, followed by alogliptin 12.5 mg tablets and metformin 1000 mg tablets, orally, once, on Day 1 of Period 2.
3008211|NCT02508168|Experimental|Sequence II: BA|Alogliptin 12.5 mg tablets, orally and metformin 1000 mg tablets, orally, once, on Day 1 of Period 1, followed by a 7-day washout period, followed by SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets, orally, once, on Day 1 of Period 2.
3008212|NCT02508155|Experimental|MEDI7352 IV|Up to 10 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses.
3008213|NCT02508155|Placebo Comparator|IV Placebo|Up to 10 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses.
3008214|NCT02508155|Experimental|MEDI7352 Subcutaneous Injection|2 cohorts of subjects are planned to be dosed by subcutaneous injection, one single ascending dose cohort and one multiple ascending dose cohort
3008215|NCT02508155|Placebo Comparator|Subcutaneous Placebo|2 cohorts of subjects are planned to be dosed by subcutaneous injection, one single ascending dose cohort and one multiple ascending dose cohort.
3008219|NCT02508129|Experimental|Sleep Healthy Using the Internet (SHUTi)|SHUTi is an automated, interactive, personalized web-based program for improving insomnia through the use of Cognitive-Behavioral Therapy strategies for insomnia.
3008220|NCT02508129|Placebo Comparator|Enhanced Usual Care (EUC)|EUC involves the primary care physician's current treatment; feedback to patients and providers on assessment and treatment recommendations; an educational video from Emmi Solutions, Inc.
3008221|NCT02508116|Experimental|CYP2C19 Genotype guided|Prospective CYP2C19 genotyping to decide antiplatelet therapy.
3008222|NCT02508116|No Intervention|Control group|Antiplatelet therapy will be decided based on usual care
3008223|NCT02508103|Experimental|Oxytocin, then Placebo|"Participants were randomized to receive Intransal Oxytocin for late luteal phase administration during one menstrual cycle, then received Intranasal Placebo for late luteal phase administration of a subsequent menstrual cycle.~Intranasal Oxytocin spray (40 IU, 3x/day) for 4-5 days; Intranasal Placebo spray (3x/day) for 4-5 days"
3008224|NCT02508103|Experimental|Placebo, then Oxytocin|"Participants were randomized to receive Intranasal Placebo for late luteal phase administration during one menstrual cycle, then received Intransal Oxytocin for late luteal phase administration of a subsequent menstrual cycle.~Intranasal Oxytocin spray (40 IU, 3x/day) for 4-5 days; Intranasal Placebo spray (3x/day) for 4-5 days"
3008225|NCT02508090||Study Population|Participants who previously received 12 weeks of miravirsen monotherapy in Study SPC3649-207 will complete up to 36 months of safety and efficacy follow-up without investigational treatment.
3008226|NCT02508077|Experimental|Treatment (panitumumab and FOLFIRI)|Patients receive panitumumab IV over 30-90 minutes, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium PO, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
3008227|NCT02508064|Experimental|Part 1|BMS-663068 1 × 600 mg extended-release (ER) tablet formulation
3008228|NCT02508064|Experimental|Part 1: Prototype 1|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 1)
3008229|NCT02508064|Experimental|Part 1: Prototype 2|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 2)
3008230|NCT02508064|Experimental|Part 1: Prototype 3|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 3)
3008231|NCT02508064|Experimental|Part 1: Prototype 4|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 4)
3008232|NCT02508064|Experimental|Part 1: Prototype 5|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 5)
3008233|NCT02508064|Experimental|Part 2|BMS-663068 1 × 600 mg ER tablet formulation
3008234|NCT02508064|Experimental|Part 2: Prototype 1|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 1)
3008235|NCT02508064|Experimental|Part 2: Prototype 2|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 2)
3008236|NCT02508064|Experimental|Part 2: Prototype 3|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 3)
3008237|NCT02508064|Experimental|Part 2: Prototype 4|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 4)
3008238|NCT02508051|No Intervention|No daily emails|The usual care group will receive no intervention except for a reminder every six months to take a test of journal-based CME questions from 2 anesthesiology journals
3008239|NCT02508051|Placebo Comparator|Article email links|The email link group will get e-mailed web links to different specific articles, including articles on which the CME questions are based, published in 2 anesthesiology journals Monday through Friday with a reminder to take the same test every six months
3008240|NCT02508051|Experimental|Blog email links|The experimental group will get e-mailed web links to blogs Monday through Friday based on the same specific articles as in group 2; each daily blog will focus on a specific article, including articles on which CME questions are based, the blogs will have web links to the articles on which they are based and every six months group 3 will get a reminder to take the same test.
3008241|NCT02508038|Experimental|TCRαβ+/CD19+ depleted Haploidentical HSCT+ Zoledronate|Patients will undergo a reduced-intensity conditioning regimen consisting of ATG, Fludarabine, Thiotepa, and Melphalan prior to transplant with a KIR/KIR ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCR-αβ+ and CD19+ cells. Patients (except those in Cohort A) will receive two doses of Zoledronate (at a 28 day interval) following transplant. Dose and post-transplant timing of Zoledronate administration is dependent upon patient Cohort.
3008242|NCT02508012|Experimental|Immuno monitoring|in case of loss of response, the clinician uses immunomonitoring data to adapt the treatment following a treatment algorithm.
3008243|NCT02508012|No Intervention|No immuno monitoring|in case of loss of response, immunomonitoring data are not transmit to the clinician who adapts the treatment with classical biological informations.
3008244|NCT02507999|Experimental|Goal Directed Therapy - Flotrac Use Arm|This arm will employ the use of the Flotrac device to monitor cardiac output, cardiac index, stroke volume, stroke volume variation, and blood pressure management.
3008245|NCT02507999|No Intervention|Non-Goal Directed Therapy|In this arm, patients will have the Flotrac machine attached to their arterial catheter but the screen that displays the monitor readings will be covered and machine alarms will be turned off. The anesthesiologist will not be aware of the Flotrac monitor readings.
3008246|NCT02507986|Active Comparator|7-Day Holter monitor|This arm will receive a 7-Day Holter monitor directly after randomization.
3008247|NCT02507986|Experimental|Single lead ECG device|This arm will be asked to take a single lead ECG two times per day and in case of complaints with a single lead ECG device.
3008248|NCT02507973||Airway Pressure Release Ventilation:APRV|Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and Low Tidal Volume Ventilation on patient intracranial pressure and hemodynamic values.
3008249|NCT02507973||Low Tidal Volume Ventilation:LOTV|Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and LOTV on patient intracranial pressure and hemodynamic values.
3008281|NCT02507687|Active Comparator|Selective Laser Trabeculoplasty (SLT)|SLT administered on Day 1 followed by Sham Bimatoprost SR administered on Day 4, Weeks 16 and 32 in the other eye.
3008282|NCT02507661|Experimental|alveolar ridge preservation - 2 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months
3008283|NCT02507661|Active Comparator|no-preservation of alveolar ridge - 2 months|no-preservation of alveolar ridge - 2 months
3008250|NCT02507960|Other|Pilot Study|The patient will undergo a conventional CT simulation in supine position without the breast immobilization cup. The purpose of the CT simulation is-two-fold: 1) the investigators will see if the TB volume can be accurately delineated and if the TB volume is too large for Gamma Pod boost; and 2) the CT images are used for planning the patient's whole breast irradiation. If, after viewing the CT images and the patient is deemed a study candidate and consents, the participants will receive a second CT-sim and the Gamma Pod TB boost treatment on the same day as described below.
3008251|NCT02507934|Experimental|Lubricin|Lubricin 150 μg/ml eye drops solution
3008252|NCT02507934|Active Comparator|Sodium Hyaluronate|Sodium hyaluronate 0.18% eye drops
3008253|NCT02507895|Experimental|MI-BCI training|subjects will undergo 12 sessions over 4 weeks of MI-BCI training
3008254|NCT02507882|Experimental|HCC|This group will include patients with chronic hepatitis C (no. =135)
3008255|NCT02507882|Experimental|HCC with Cirrhosis|This group will include patients with chronic hepatitis C (no. =135) with cirrhosis (F4).
3008256|NCT02507882|Experimental|HCV related HCC patients|This group will include patients with HCV related HCC (no. =135) This is confirmed by presence of focal lesion detected by Imaging (computed tomography (CT) and ultrasound), and elevated serum AFP.
3008257|NCT02507869|Experimental|Affect-Guided Prescription|Intervention: Participants in the affect-guided condition are instructed to exercise while monitoring how they feel, and to adjust the intensity of their exercise to maintain a pleasant affective response.
3008258|NCT02507869|Active Comparator|Heart Rate-Guided Prescription|Intervention: Participants in the heart rate-guided condition are instructed to exercise while monitoring their heart rate, and to adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
3008259|NCT02507856||investigational group|early/late dabigatran
3008260|NCT02507856||control group|vitamin k antagonist (vka)
3008261|NCT02507843|Active Comparator|Vitamin D group|Cholecalciferol will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
3008262|NCT02507843|Placebo Comparator|Placebo group|Placebo will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
3008263|NCT02507830||Glubran 2 fixation|Mesh fixation with Glubran 2 glue in primary inguinal hernia repair
3008264|NCT02507817||31-32 with Mg for neuroprotection|"Women in 31-32 weeks gestation that where treated with Magnesium Sulphate for neuroprotection.~blood sample and tissue sample (placenta)."
3008265|NCT02507817||33-34 without Mg for neuroprotection|"Women in 33-34 weeks gestation that per protocol are not entitled for treatment with Magnesium Sulphate for neuroprotection.~blood sample and tissue sample (placenta)."
3008266|NCT02507817||PET with Mg after 34 weeks|"Women that had severe preeclamsia and where treated with Magnesium Sulphate for seizure prophylaxis and delivere after 34 weeks of gestation.~blood sample and tissue sample (placenta)."
3008267|NCT02507817||control|"Low risk pregnanacies in similar weeks to group 3 that did not require any special teatment and delivered after 34 weeks of gestation.~blood sample and tissue sample (placenta)."
3008268|NCT02507804|Experimental|Arm A diary arm|Patients in Arm A are required to complete a patient diary. This will be reviewed by an Investigator at every visit in order to gain Adverse Event and Concomitant Medication information.
3008269|NCT02507804|Active Comparator|Arm B standard of care|Patients will be asked to recall Adverse Events and Concomitant Medication information as standard of care practice would dictate.
3008270|NCT02507791|Experimental|Early Fitbit|"Patients will receive Fitbit in the first phase of the study. In addition to attending weekly weight management classes, patients will wear Fitbit Charge HR devices to track heart rate, active minutes, steps taken, calories burned, and sleep patterns. Patients will receive weekly phone calls to review this data, and further recommendations will be given to encourage additional physical activity as clinically indicated based on time spent being physically active. The goal will be for individuals to reach 10,000 steps per day, though if subjects are significantly under that goal, realistic goal-setting (recommended increases of physical activity of 10% at a time). Patients will continue this intervention for 12 weeks. After 12 weeks, they will return for reassessment. This coincides with the completion of the weight loss program. Subjects will then be followed remotely for another 12 weeks and phone call interventions will continue before returning for a final study visit."
3008271|NCT02507791|Active Comparator|Late/Delayed Fitbit|These subjects will follow a similar pattern except they will not receive Fitbit Charge HR devices until the second phase of the study (specifically after completion of the 12 week weight loss program). In the first phase, these subjects will receive weekly phone calls to offer them the same attention as the experimental group, but instead of reviewing Fitbit data, these subjects will subjectively report their physical activity in minutes and by qualifying their physical activity as light, moderate, or vigorous. These individuals, after 12 weeks, will return for reassessment. At that time, these individuals will receive Fitbits and receive weekly telephone calls for an additional 12 weeks before returning for a final study visit.
3008272|NCT02507778|Other|biopsy|needle will be inserted before and after biopsy and will measure circulating tumor cells.
3008273|NCT02507765|Experimental|Treatment (SBRT, TACE)|Patients undergo SBRT on day 1 and TACE on day 2.
3008274|NCT02507752||Rituximab|Participants who are receiving 1000 milligrams (mg) intravenous (IV) infusion of rituximab on Day 1 and Day 15 as part of standard of care of the treating site will be included in this observational study.
3008275|NCT02507739|Other|possibility to walk during labor|possibility to walk during labor
3008276|NCT02507739|Other|no possibility to walk during labor|no possibility to walk during labor
3008277|NCT02507726|Experimental|Flexima Active Soft convexe|Flexima Active soft convexe (1 to 3 appliances per day)
3008278|NCT02507700|Active Comparator|popliteal block|Popliteal block will be performed with a single dose of 0.3 ml·kg(-1) of 0.25% bupivacaine.
3008279|NCT02507700|Sham Comparator|Plaster cover|Only plaster cover will be applied without nerve block for sham procedure.
3008280|NCT02507687|Experimental|Bimatoprost SR|Sham selective laser trabeculoplasty (SLT) administered on Day 1 followed by Bimatoprost sustained release (SR) Dose A administered on Day 4, Weeks 16 and 32 in the primary eye.
3009594|NCT02499198|Experimental|Arm 6|Nornicotine level equal to 5% of commercial smokeless tobaccos
3008284|NCT02507661|Experimental|preservation of alveolar ridge - 4 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months
3008285|NCT02507661|Active Comparator|no-preservation of alveolar ridge - 4 months|no-preservation of alveolar ridge - 4 months
3008286|NCT02507661|Experimental|preservation of alveolar ridge - 9 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months
3008287|NCT02507661|Active Comparator|no-preservation of alveolar ridge - 9 months|no-preservation of alveolar ridge - 9 months
3008288|NCT02507648|Experimental|A Test|Test drug (Oseltamivir) 1 tablet contains 75 mg Oseltamivir
3008289|NCT02507648|Active Comparator|B Reference|Reference drug (Tamiflu®) 1 tablet contains 75 mg Oseltamivir
3008290|NCT02507635|No Intervention|healthy volunteers|healthy volunteers
3008291|NCT02507635|Active Comparator|Desloratadine|patients with allergic rhinitis under treatment with Desloratadine 5 mg/day, 4 weeks
3008292|NCT02507635|Active Comparator|Levocetirizine|patients with allergic rhinitis under treatment with Levocetirizine 5 mg/day, 4 weeks
3008293|NCT02507622|Other|gas concentration|Gaz concentration of C02, CO and NH4, 3 exhaled in weightlessness and normal gravity.
3008294|NCT02507609|Active Comparator|M group|moderate neuromuscular blockade group by intermittent injection of rocuronium bromide
3008295|NCT02507609|Active Comparator|D group|deep neuromuscular blockade group by continuous infusion of rocuronium bromide
3008296|NCT02507596|Experimental|Nano-crystalline hydroxyapatite silica gel|hydroxyapaptite bone graft with nano particle size in silica gel will be used to fill in the defect after opening a periodontal flap
3008297|NCT02507596|Sham Comparator|Open flap debridement|an open periodontal flap without adding bone graft.
3008298|NCT02507583|Experimental|Cohort 1|After protocol amendment dated 11 May 2017, all subjects enrolled into the trial will receive 20 chambers for 48 hours.
3008299|NCT02507570|Experimental|Open label|Single arm study to evaluate safety and tolerability of Enzalutamide with concurrent administration of Radium ra 223 dichloride in subjects with symptomatic metastatic prostate cancer.
3008300|NCT02507557||Before GDFM Training|About 200 patients' medical record information will be extracted from the 1st Affiliated Hospital of Chongqing Medical University electronic medical record prior to the start of the training curriculum.
3008301|NCT02507557||After GDFM Training|About 200 patients' medical record information will be extracted from the 1st Affiliated Hospital of Chongqing Medical University electronic medical record after the training program took place
3008302|NCT02507544|Experimental|TRX-818|
3008303|NCT02507518|Experimental|Experimental|Two Pet scan Imaging will be done : 14 days before and 16 days after the beginning of maintenance therapy
3008304|NCT02507505|Active Comparator|Regional Anesthesia|Approximately half of the subjects will be randomized to the arm which receives Regional Anesthesia.
3008305|NCT02507505|Active Comparator|General Anesthesia|Approximately half of the subjects will be randomized to the arm which receives General Anesthesia.
3008306|NCT02507492|Experimental|RM-493 Once Daily|Dose once daily in the morning
3008307|NCT02507479|Experimental|thiotepa|Thiotepa 5-10 mg/kg/d x 2 days
3008308|NCT02507466|Experimental|Variable high-intensity Training|high intensity variable stepping exercise on a treadmill and overground
3008309|NCT02507466|Active Comparator|Variable low-intensity training|low intensity variable stepping exercise on a treadmill and overground
3008310|NCT02507466|Active Comparator|Constant High Intensity Training|high intensity constant (forward) stepping exercise on a treadmill and overground
3008311|NCT02507453|Other|Influence of Gravity on the Size-mass Illusion|to investigate the interaction between perceived size and perceived mass of objects in 0G and 1.8G compared to 1G using the size-mass illusion (SMI)
3008312|NCT02507440|Active Comparator|Viscous Lidocaine|Five minutes prior to intravenous sedation the patients will be asked to gargle with 7.5 ml of 2% lidocaine viscous solution and swallow.
3008313|NCT02507440|Placebo Comparator|Placebo|Five minutes prior to intravenous sedation the patients will be asked to gargle with 7.5 ml of placebo and then swallow. Placebo will be 3% methylcellulose which will be flavored and colored to match the characteristics of 2 % lidocaine.
3008314|NCT02507427|Experimental|Nerve monitoring arm|They will receive pelvic autonomic nerve monitoring and mapping using NIM-Eclipse (Medtronic) during robot-assisted laparoscopic prostatectomy.
3008315|NCT02507414|Experimental|Group 1|"Patients under going Whipple's procedure, gastric resection and liver resection (n=75).~Interventions:~Blood samples obtained pre-, intra-, and one day postoperatively (n=15).~Measurements of microcirculation using LSCI from procedure start and up to 60 min during surgery.~Head down tilt of 20 degrees at three time points."
3008316|NCT02507401||Total laryngectomy patients|Users of voice prostheses
3008317|NCT02507388|Experimental|Brolucizumab 3 mg|Brolucizumab 3 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
3008318|NCT02507388|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
3008319|NCT02507375|Experimental|Cohort 1|Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 100 mg orally (PO).
3008320|NCT02507375|Experimental|Cohort 2|Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 150 mg orally (PO).
3008321|NCT02507362|Experimental|experimental|Radiation: adjusted corneal collagen cross-linking (9mW/cm2 UV-A irradiation for 7 minutes after 30 mitunes of riboflavin instillation) riboflavin 0.1%: after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation epithelial debridement: corneal epithelium will be removed by a cottons swab
3008322|NCT02507362|Active Comparator|control|radiation: accelerated corneal collagen cross-linking (9mW/cm2 UV-A irradiation for 10 minutes after 30 minutes of riboflavin instillation) riboflavin 0.1%: after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation epithelial debridement: corneal epithelium will be removed by a cottons swab
3040817|NCT02288481|Experimental|Cohort 6 1000 mg TBA-354|
3008323|NCT02507349|Active Comparator|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
3008324|NCT02507349|Active Comparator|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
3008325|NCT02507336|Other|Group A - CR+Thalidomide|Patients who achieved complete response (CR) in 20030165 and continue to receive maintenance Thalidomide. Patients in Group A will receive daily oral thalidomide (THALOMID®) as per standard of care and THALOMID® REMS™ guidelines. Patients will continue with thalidomide (THALOMID®) as per standard of care guidelines, until progression of disease, discontinuation due to toxicity, death or study withdrawal. Patients will receive annual clinical/laboratory evaluations.
3008326|NCT02507336|Other|Group B - CR+No Thalidomide|Patients who achieved complete response (CR) in 20030165, but are not receiving maintenance Thalidomide. Patients will receive annual clinical/laboratory evaluations.
3008327|NCT02507336|Other|Group C - PD or Expired|All other patients enrolled in 20030165 who expired or experienced disease progression (PD). Patients will be followed annually for survival.
3008328|NCT02507323|Active Comparator|ticagrelor or matching placebo|ticagrelor (180 mg loading followed by 90 mg twice daily) or matching placebo
3008329|NCT02507323|Active Comparator|prasugrel or matching placebo|prasugrel (60 mg loading followed by 5-10 mg/d) or matching placebo
3008330|NCT02507310|Active Comparator|Control|The room will be kept at 18-20 degrees Celsius. This is within the human thermoneutral zone. It will serve as the control condition.
3008331|NCT02507310|Experimental|Warm Environment|The room will be kept at 25-27 degrees Celsius. This is above the human thermoneutral zone. This will serve as the experimental condition.
3008332|NCT02507297|Experimental|PAP Group|Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly
3008333|NCT02507297|No Intervention|TAU Group|Treatment as usual through obstetrics
3008334|NCT02507284|Experimental|SRX246 120mg BID|SRX246 capsules, administered orally, in divided doses twice daily
3008335|NCT02507284|Experimental|SRX246 160mg BID|SRX246 capsules, administered orally, in divided doses twice daily
3008336|NCT02507284|Placebo Comparator|Placebo|Placebo capsules, administered orally, in divided doses twice daily
3008337|NCT02507271|Experimental|Experimental Group|
3008338|NCT02507271|Placebo Comparator|Control Group|
3008339|NCT02507258||PROFEMUR® Am Femoral Stem|Single study group previously implanted with a primary PROFEMUR® Am Femoral Stem and PROCOTYL® O HA Coated Acetabular Component
3008340|NCT02507245||GHD Children|Treatment with Growth Hormone-Releasing Hormone in children affected by idiopathic growth hormone deficiency (GHD)
3008341|NCT02507232|Active Comparator|Arm A|NovoTTF-200A
3008342|NCT02507232|Active Comparator|Arm B|NovoTTF-200A + Temozolomide 50 mg/m2 daily (oral)
3008343|NCT02507219|Placebo Comparator|Placebo|Subjects will receive one dose of placebo (sugar pill) at one of the three testing sessions . Placebo capsules will be produced in the same manner as the ibuprofen by a local compounding pharmacy in Tulsa, OK.
3008344|NCT02507219|Active Comparator|Ibuprofen, 200mg|Subjects will receive one oral dose of 200mg at one of the three testing sessions. Ibuprofen capsules will be produced by a local compounding pharmacy in Tulsa, OK.
3008345|NCT02507219|Active Comparator|Ibuprofen, 600mg|Subjects will receive one oral dose of 600mg at one of the three testing sessions. Ibuprofen capsules will be produced by a local compounding pharmacy in Tulsa, OK.
3008346|NCT02507206|Experimental|DAR 0-100A then Placebo|15 mg is dissolved in 150 cc NS administered over 30 minutes x 3 consecutive days. Subjects will return a minimum of two weeks later for Visit 5 to receive drug (if randomized initially to placebo) or placebo (if randomized to drug).
3008347|NCT02507206|Placebo Comparator|Placebo then DAR 0-100A|15 mg dissolved in 150 cc NS saline is administered over 30 minutes x 3 consecutive days. Subjects will return a minimum of two weeks later for Visit 5 to receive drug (if randomized initially to placebo) or placebo (if randomized to drug).
3008348|NCT02507206|No Intervention|Healthy Control|patients without diagnosis of SPD
3008349|NCT02507193|Active Comparator|Open reduction internal fixation(ORIF)|This surgical intervention is performed using a plate and screws.Under general anesthesia, an incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.
3008350|NCT02507193|Active Comparator|Intermedullary (IM) Nail|This surgical intervention is performed using an intermedullary nail. Under general anesthesia, an incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
3008351|NCT02507180||Pregnant women with suspected DVT|Pregnant women presenting with suspected DVT will have the LEFt clinical decision rule applied by the attending physician and will have a clinical D-dimer test done.
3008352|NCT02507167|Placebo Comparator|mixed meal|
3008353|NCT02507167|Active Comparator|mixed meal 2 h after single dose rifampin (600 mg)|
3008354|NCT02507154|Experimental|Cetuximab + NK cells|During cycle 1, patient will receive intravenous cetuximab and subcutaneous IL-2 on day 1, followed by NK cell infusion on day 2, with subcutaneous IL-2 for an additional 5 doses three times a week to support NK cell viability and expansion in vivo. Following NK cell infusion, cetuximab will be administered weekly for another 2 weeks. During cycle 2 and 3, one cycle of cetuximab monotherapy will be administered 3 weeks apart. Patients who demonstrate objective tumor response or stable disease after cycle 3 will receive a second infusion of NK cells along with cetuximab during cycle 4 therapy at the same dose and schedule as in cycle 1. This will be followed by 2 additional cycles of cetuximab monotherapy (3 weeks apart).
3008453|NCT02506478||ED patients|All ED patients who are able to drink water/juice, and be able to communicate juice preference.
3008355|NCT02507141||SCC of the oral cavity scheduled for surgery|The patients will be imaged for testing the feasibility of intra-oral imaging. Images will be compared to and evaluated against the corresponding pathology that is routinely prepared during surgery.
3008356|NCT02507128|Experimental|GLP-1 group|The treatment started 30 min before PCI with a dose of 1.8 mg liraglutide (the treatment was administered in the ambulance).
3008357|NCT02507128|Placebo Comparator|Control group|the treatment started 30 min before PCI with a dose of 1.8 mg placebo (the treatment was administered in the ambulance).
3008358|NCT02507115|Experimental|TMAP|Alcohol-related Text messages 4 days/week for 6 weeks
3008359|NCT02507115|Sham Comparator|Control|Motivational Text messages 4 days/week for 6 weeks
3008360|NCT02507102|Experimental|Investigational Voyager Therapy|Investigational treatment with Voyager Therapy
3008361|NCT02507089|Experimental|Intervention|In this arm, the participants will receive access to a password protected website that features tailored information and educational materials on sleep health and the signs of sleep disorders such as obstructive sleep apnea (OSA). There will be both text-based information on sleep health and OSA, and also videos depicting narrative stories about patients who have been diagnosed with OSA and sought treatment.
3008362|NCT02507089|Active Comparator|Control|In this arm, participants will receive access to generic sleep educational materials that do not feature linguistic or cultural tailoring to the target population. This arm will include access to the same general information (materials on sleep health, sleep disorder signs and symptoms) but be intended for a general audience.
3008363|NCT02507076|Experimental|Treatment (ILP with melphalan)|Patients undergo ILP with melphalan IV over 60 minutes.
3008364|NCT02507063||study subjects|Patients age 0-18 with intracranial monitoring devices in place or requiring a VP shunt revision who receive a ocular ultrasound evaluating ONSD
3008365|NCT02507050|Experimental|Intervention|Patients randomised to stop beta blockers and start Ivabradine. Initial dose of 5mg BD, titrated to 7.5mg BD if possible.
3008366|NCT02507050|No Intervention|Standard therapy|Bisoprolol given as standard beta blocker treatment i.e. Bisoprolol (maximum dose 10mg OD).
3008367|NCT02507037|Experimental|gum+PEG|used 2L PEG+sugarless gum
3008368|NCT02507037|Placebo Comparator|PEG|only used 2L PEG
3008369|NCT02507024||Intervention|The online questionnaire includes questions about how ANCA-associated vasculitis effects patients quality of life.
3008370|NCT02507011|Active Comparator|carvedilol|Beta Blocker
3008371|NCT02507011|Placebo Comparator|Placebo|General Placebo
3008372|NCT02506998|Experimental|DLE plus standard medications|"DLE + Second generation anti histamines + Nasal corticosteroids DLE 2mg/5 milliliters (mL) P.O. every 24h per 5 days, followed by 2 mg/mL P.O. twice weekly for 5 weeks, follow by 2 mg/5mL per week for 5 weeks.~Second generation anti histamines at standard dosis every 24h, and Nasal corticosteroids two spray released per nostril every 24 h per 11 weeks"
3008373|NCT02506985|Experimental|rivaroxaban|For the first 3 weeks, patients will receive rivaroxaban 15mg twice-daily; thereafter they will take rivaroxaban 20mg once-daily as per the drug label. Rivaroxaban will be initiated immediately following completion of alterplase infusion, and heparin will be discontinued at the time of rivaroxaban administration.
3008374|NCT02506985|Experimental|heparin-warfarin|Unfractioned heparin (UFH), following hospital protocol to achieve a target PTT or enoxaparin, 1.0mg/kg twice-daily, for a minimal duration of treatment of 5 days. Warfarin may be started on the night after CDT. UFH or enoxaparin should continue until the INR is >= 2.0 on two consecutive measurements at least 24 hours apart with an advised overlap with VKA for 4 to 5 days. VKA dosages will be adjusted to maintain the INR within the therapeutic range (target 2.5, range 2.0 - 3.0).
3008375|NCT02506972|Other|30g oats|Classic Quick Quaker Oats
3008376|NCT02506972|Other|30g oats plus 9g sugar|Classic Quick Quaker Oats
3008377|NCT02506972|Other|40g oats|Classic Quick Quaker Oats
3008378|NCT02506972|Other|60g oats|Classic Quick Quaker Oats
3008379|NCT02506972|Other|22g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
3008380|NCT02506972|Other|29g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
3008381|NCT02506972|Other|33g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
3008382|NCT02506972|Other|44g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
3008383|NCT02506959|Experimental|Refractory Disease - First Stem Cell Transplant Group|Low test dose Busulfan by vein as an outpatient or inpatient. If outpatient test dose Busulfan by vein before hospital admission, then on Days -8 through -5. If inpatient, test dose Busulfan by vein on Day -10, then on Days -8 through -5. Palifermin by vein on Days -12, through -10 if outpatient, and on Days -14 through -12 if inpatient, and on Day 0, +1 and +2 for both groups. Participants swish liquids Caphosol and Glutamine in their mouth 4 times a day beginning on Day -9. Dexamethasone by vein 2 times a day on Days -9 through Day -2. Panobinostat by mouth 1 time a day on Days -8 through Day -2. Gemcitabine by vein on Day -8 and - 3. Melphalan given by vein on Day-3 and -2. Pyridoxine by vein or mouth three times a day from Day -1. Stem cell transplant procedure on Day 0.
3008384|NCT02506959|Experimental|Relapsed Disease - Second Salvage Stem Cell Transplant Group|Low test dose Busulfan by vein as an outpatient or inpatient. If outpatient test dose Busulfan by vein before hospital admission, then on Days -8 through -5. If inpatient, test dose Busulfan by vein on Day -10, then on Days -8 through -5. Palifermin by vein on Days -12, through -10 if outpatient, and on Days -14 through -12 if inpatient, and on Day 0, +1 and +2 for both groups. Participants swish liquids Caphosol and Glutamine in their mouth 4 times a day beginning on Day -9. Dexamethasone by vein 2 times a day on Days -9 through Day -2. Panobinostat by mouth 1 time a day on Days -8 through Day -2. Gemcitabine by vein on Day -8 and - 3. Melphalan given by vein on Day-3 and -2. Pyridoxine by vein or mouth three times a day from Day -1. Stem cell transplant procedure on Day 0.
3008385|NCT02506946||PCOS subjects|Forty adolescents and young adults between the ages of 14 and 25 years with Polycystic Ovary Syndrome (PCOS) at least two years past menarche.
3008386|NCT02506946||Control subjects|Forty unaffected adolescents and young adults between the ages of 14 and 25 years at least two years past menarche.
3008387|NCT02506933|Experimental|Arm I (multi-peptide CMV-MVA vaccine)|Patients receive multi-peptide CMV-MVA vaccine IM on days 28 and 56 post-HCT.
3008388|NCT02506933|Placebo Comparator|Arm II (placebo)|Patients receive placebo IM on days 28 and 56 post-HCT.
3008454|NCT02506465|Experimental|iTIND arm|iTIND implant is implant during the study for 5-7 days.
3008389|NCT02506920|Active Comparator|Pack butter|Oral fat tolerance test contains: Cream, lactic acid culture, salt. Fat contents in grams: Saturated fat (SFA) 52, monounsaturated fat (MUFA) 19.1, polyunsaturated fat (PUFA) 1.6
3008390|NCT02506920|Active Comparator|Kjaergaarden blend butter|Oral fat tolerance test contains:Butter rapeseed oil, lactic acid culture, salt. Fat contents in grams: SFA 37.4, MUFA 27.3, PUFA 1.8
3008391|NCT02506920|Active Comparator|Blend butter|Oral fat tolerance test contains: Butter rapeseed oil, lactic acid culture, salt. Fat contents in grams: SFA 23.7, MUFA 23.2, PUFA 7.8
3008392|NCT02506920|Active Comparator|Fish oil enriched butter|Oral fat tolerance test contains: Butter rapeseed oil, lactic acid culture, fish oil, salt. Fat contents in grams: SFA 22.6, MUFA 26.9, PUFA 0.7
3008393|NCT02506920|Active Comparator|Olive oil enriched butter|Oral fat tolerance test contains: Butter rapeseed oil, olive oil, lactic acid culture, salt. Fat contents in grams: SFA 22.6, MUFA 26.9, PUFA 5.7
3008394|NCT02506920|Active Comparator|Low saturated fat butter|Oral fat tolerance test contains: Butter, lactic acid culture, salt. Fat contents in grams: SFA14.9, MUFA16, PUFA 5.6
3008395|NCT02506907||Atherosclerotic|Patients with atherosclerotic intracranial stenosis
3008396|NCT02506894|Active Comparator|magnesium sulfate|this group will receive magnesium sulfate loading dose 6 g in 500 cc of ringer solution over 20 minutes then maintenance dose of 1 g/ hour for 24 hours.
3008397|NCT02506894|Placebo Comparator|placebo group|this group will receive sodium chloride 0.9% solution for 24 hours.
3008398|NCT02506881|Experimental|BCD-066 → Aranesp - subcutaneous|Volunteers in this group initially will receive a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
3008399|NCT02506881|Experimental|Aranesp → BCD-066 - subcutaneous|Volunteers in this group initially will receive a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
3008400|NCT02506881|Experimental|BCD-066 → Aranesp - intravenous|Volunteers in this group initially will receive a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
3008401|NCT02506881|Experimental|Aranesp → BCD-066 - intravenous|Volunteers in this group initially will receive a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
3008402|NCT02506868|Experimental|BCD-066|Patients in this arm will receive weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
3008403|NCT02506868|Active Comparator|Aranesp|Patients in this arm will receive weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
3008404|NCT02506855|Experimental|Group A|"Study participants will undergo intraoperative transversus abdominis plane (TAP) block with the syringe of medication supplied by the pharmacy using a syringe with attached spinal needle between the transversus abdominis and internal oblique. The spinal needle will be threaded horizontally and as far laterally at the superior aspect of the vertical axis of the incision as possible within this space and anesthetic will be injected after an initial pull back on the syringe to ensure there is no arterial exposure as per the following schedule:~Weight <70kg: Ropivacaine 75mg - 150 mg on each side (20mL ropivacaine 3.75mg/ml each side)~Weight greater than or equal to 70kg: Ropivacaine 100mg - 200mg on each side (20mL ropivacaine 5mg/ml each side"
3008405|NCT02506855|Placebo Comparator|Group B|"Study participants will undergo intraoperative transversus abdominis plane (TAP) block with the syringe of medication supplied by the pharmacy using a syringe with attached spinal needle between the transversus abdominis and internal oblique. The spinal needle will be threaded horizontally and as far laterally at the superior aspect of the vertical axis of the incision as possible within this space and the placebo solution will be injected after an initial pull back on the syringe to ensure there is no arterial exposure as per the following schedule:~Weight <70kg: 20mL each side~Weight greater than or equal to 70kg: 20mL each side"
3008406|NCT02506842|Experimental|nab-paclitaxel + gemcitabine (AG)|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
3008407|NCT02506842|Experimental|oxaliplatin + folinic acid + fluorouracil (OFF)|oxaliplatin at 85mg/m^2 on days 8 and 22, folinic acid at 200mg/m^2 on days 1,8,15 and 22, fluorouracil at 2000mg/m^2 on days 1,8,15 and 22.
3008408|NCT02506829|Active Comparator|Usual care|Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital.
3008409|NCT02506829|Experimental|Financial Incentives|Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital. Financial incentives for: a) speaking with a coach from the Smoker's Quitline ($50), b) completion of another community-based smoking-cessation program ($50), and/or c) use of pharmacotherapies for smoking cessation at 2 weeks ($50); and d) for smoking cessation, confirmed with the use of a cotinine test at 2 months ($150); and e) for smoking cessation, confirmed with the use of a cotinine test at 6 months after study enrollment ($250).
3008410|NCT02506816||Olaparib|Drug exposure has a limited duration 28 (+/- 5) days.
3008411|NCT02506803|Experimental|NAC-GEMABR|Neoadjuvant chemotherapy 2 courses of NAC-GEMABR for subsequent 10 patients.
3008412|NCT02506790|Experimental|Toremifene and metformin|Toremifene 60 mg daily with metformin 850 mg BID
3008413|NCT02506790|Experimental|Toremifene and melatonin|Toremifene 60 mg daily with melatonin 3 mg before sleep daily
3008414|NCT02506790|Active Comparator|Toremifene|Toremifene 60 mg daily
3008415|NCT02506777|Experimental|FDC x 6 cycles with metformin|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days with metformin 850 mg BID
3008416|NCT02506777|Experimental|FDC x 6 cycles with melatonin|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days with melatonin 3 mg before sleep daily
3008417|NCT02506777|Active Comparator|FDC x 6 cycles|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days
3008418|NCT02506751|Experimental|Liothyronine|"Subjects will take oral liothyronine for a total of 24 weeks following the below titration schedule:~0-6 weeks: liothyronine 10mcg po daily (5mcg po BID)~6-12 weeks: liothyronine 20mcg po daily (10mcg po BID)~12-18 weeks: liothyronine 50mcg po daily (25mcg po BID)~18-24 weeks: liothyronine 1mcg/kg/day (0.5mcg/kg po BID), not to exceed 75mcg po daily"
3008419|NCT02506738|Active Comparator|Intervention using mHealth|Patients in the intervention used at home a mobile system to monitor their clinical and health status.
3008420|NCT02506738|No Intervention|Control|Patients in the control group received the usual care.
3008421|NCT02506725|Experimental|Prenatal Care in groups|We will do prenatal care using centering care pregnancy methodology in 10 sessions
3008422|NCT02506725|No Intervention|Control Group|We will do in this arm conventional Prenatal care available in the family clinics
3008423|NCT02506712|Experimental|spinal cord injury|use a wheelchair with and without a assisting device to power manuel wheelchair
3008424|NCT02506712|Other|volunteer|push a wheelchair with and without a assisting device to power manuel wheelchair
3008425|NCT02506699||analgesic effect of rTMS|Observe the analgesic effect of rTMS, reference method of noninvasive stimulation of the motor cortex validated by data from the literature and current practice, after 5 separate sessions a week apart, patients with neuropathic pain chronic, refractory to first and second-line treatments proposed in a multidisciplinary center specializing in chronic pain Lower Normandy.
3008426|NCT02506686|Experimental|Meropenem|Meropenem i.v.
3008427|NCT02506673|Active Comparator|Sedation only with skin conductance monitor|Patients will receive traditional sedation with 2 mg of midazolam on arrival in the OR. Patients in this group will wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
3008428|NCT02506673|Experimental|Sedation & audiovisual aids with skin conductance monitor|Prior to surgery, patients will be asked to wear audiovisual equipment (Zeiss, Cinema ProMED) in the holding area. Patients in this group will also receive 2 mg of midazolam on arrival in OR. Patients in this group will also wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
3008429|NCT02506660|Active Comparator|Intravenous dexamethasone|Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
3008430|NCT02506660|Experimental|Perineural dexamethasone|Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
3008431|NCT02506647|Experimental|Sequence 1|Gan & Lee insulin glargine followed by Lantus
3008432|NCT02506647|Active Comparator|Sequence 2|Lantus followed by Gan & Lee insulin glargine
3008433|NCT02506634||normal endoscopy|endoscopy negative patients, who would be given Esomeprazole MUPS（ Multiple Unit Pellet System）, 20 mg bid for 4 weeks.
3008434|NCT02506634||Esophagitis/BE|patients has esophagitis or Barrett's esophagus, who would be given Esomeprazole MUPS, 20 mg bid for 8 weeks.
3008435|NCT02506621|Experimental|ELR monitoring|"Single arm study. All participants with existing permanent dual chamber pacemakers will be monitored with 5 different Loop recorder devices for a 2 week period to assess there sensitivity and specificity in detecting AF burden. The devices used will be~R test~Nuubo~TECHNOMED pocket ECG~ZIO xt patch~MoMe"
3008436|NCT02506608|Experimental|Operation of sensorized hand prosthesis|"A system composed by the integration of the following non-CE marked medical devices specifically designed for the study will be used in amputees:~STIMEP (multichannel electrical stimulator for the peripheral nervous system; AXONIC)~TIME 4H Intraneural Electrodes (ALBERT-LUDWIGS-UNIVERSITAET FREIBURG)~Sensorized hand Prosthetics for amputees IH2 Prosthetic Azurra Prensilia (Prensilia Ltd.)~Prosthetics sensorized hand for amputees DLR / HIT Hand II (Wessling Robotics)~ODROID software integration within the afferent and efferent bi-directional control of the robotic hand"
3008437|NCT02506595|Experimental|ERRT-M for Nightmares|Exposure, Relaxation, and Rescripting Therapy Military version (ERRT-M) -
3008438|NCT02506595|No Intervention|Waitlist control|Participants randomized to the Waitlist control condition will be contacted once weekly for 5 weeks to monitored status and then invited to participant in treatment.
3008439|NCT02506582|Experimental|Test group|jerusalem artichoke and fermented soybeans powder mixture supplementation
3008440|NCT02506582|Placebo Comparator|Placebo group|placebo supplementation
3008441|NCT02506556|Experimental|experimental|BYL719 350 mg orally daily until progression, undue adverse events or withdrawal of consent.
3008442|NCT02506543|Experimental|COMPASS intervention|Subjects in this group will be pre-tested at the same time with the subjects in the Wait-list control group. Subjects in this group will receive the intervention immediately after the initial pre-test/baseline assessment, which includes life skills education, access to mentors in safe spaces, and a structured parenting intervention for girls' caregivers. Then, the subjects in this group have completed the intervention (at 12-months post-intervention initiation), the subjects in this group will take the post-test at the same time with the subjects in the Wait-list control group.
3008443|NCT02506543|Active Comparator|Wait-list control|No intervention
3008444|NCT02506530|Active Comparator|intensive decongestive treatment (IDT)|Patients will receive an intensive decongestive treatment for 5 days
3008445|NCT02506530|Experimental|IDT + Cellu M6|Patients will receive an intensive decongestive treatment + Cellu M6 for 5 days
3008446|NCT02506530|Active Comparator|Cellu M6 + bandages|Patients will receive an bandages + Cellu M6 for 5 days
3008447|NCT02506517|Experimental|Afatinib|Afatinib, orally, at a dose of 40 mg once a day, every day of each 28 day cycle.
3008448|NCT02506504|Experimental|Inspiratory help then sham ventilation|The initial evaluation is performed using an Inspiratory Pressure Support. After the training, the final evaluation is performed using an Inspiratory help (sham ventilation).
3008449|NCT02506504|Experimental|Sham ventilation then Inspiratory help|"The initial evaluation is performed using an inspiratory help (sham ventilation).~After the training, the final evaluation is performed using an Inspiratory Pressure Support."
3008450|NCT02506491|Experimental|Pilates exercise program|Incorporate Pilates principles to stimulate core muscles in a dynamic and static way, and exercising arms and legs complementarity with balance as an essential part of standing exercises.
3008451|NCT02506491|Experimental|Muscular exercise program|To train core muscles in a dynamic and static way, and exercising arms and legs complementarity with balance as an essential part of standing exercises.
3008452|NCT02506491|Active Comparator|Control group|Healthy active but nonexercising old women
3008456|NCT02506452|Active Comparator|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading device
3008457|NCT02506452|Active Comparator|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading device
3008458|NCT02506439|Experimental|10 mcg Vitamin D3|White-skinned women will receive Cholecalciferol (Vitamin D3) 10 mcg [400 IU] daily
3008459|NCT02506439|Experimental|20 mcg Vitamin D3|White-skinned women will receive Cholecalciferol (Vitamin D3) 20 mcg [800 IU] daily
3008460|NCT02506439|Placebo Comparator|Placebo|White-skinned women will receive a Placebo supplement, identical in appearance and taste to the active product
3008461|NCT02506426|Active Comparator|Endoscopic Sinus Surgery + Septoplasty|A surgery that uses special telescopes through the nostrils to make the nasal septum straight and open the facial sinuses without any incisions. The sinuses are opened using special microscopic instruments and the procedure takes approximately 90 - 120 minutes.
3008462|NCT02506426|Experimental|Septoplasty alone|A surgery that is performed to straighten a bent nasal septum. It is shorter (take approximately 25 - 30 minutes) and less invasive (do not open the facial sinuses) that might provide the same benefits compared to the larger and longer endoscopic sinus surgery.
3008463|NCT02506413|Other|MNCH Intervention Package|"The division assigned to this arm will receive a comprehensive Maternal and Newborn Health (MNH) intervention package using the 'MamaToto Process'. Key intervention activities include:~engaging district leaders in district health system strengthening;~strengthening health facility-based MNH services; and~establishing a Maternal, Newborn, and Child Health focused lay Community Health Worker program."
3008464|NCT02506387||Mitraclip patients|Patients with severe mitral regurgitation in whom decision for mitraclip implantation was made by the heart team.
3008465|NCT02506348|Experimental|Diclofenac+Nepafenac|one drop Diclofenac in one eye one drop Nepafenac in other eye
3008466|NCT02506335|Other|Hep quant cholate testing|diagnostic measure of liver function
3008467|NCT02506322|Experimental|SEKT Cognitive-Behavioral-Emotional|Specific psychotherapy (SEKT - 4 modules) for typical problems of Bipolar patients to maintain remission and to prevent relapse. Including classical elements of self observation, psychoeducation, cognitive and behavioral interventions, social rhythm but also emotion regulation and meta-cognitive techniques. Delivered in a group setting in 4 one day treatment workshops, each one month apart. Homework assignment and electronical monitoring during time between sessions.
3008468|NCT02506322|Active Comparator|FEST Clinical Supportive Educational|This supportive, active control psychotherapy (FEST) is using general principals and non-specific interventions such as positive attitude, optimism, support, empathy, focus on emotion, self-help, strengthening and eliciting own resources, time and room for discussion of personal experiences. Psychoeducation about illness and drug treatment (mood stabilizer) to facilitate compliance.
3008469|NCT02506309|Experimental|SIS single incision sling|SIS - Innovative fixation single incision sling A third generation of the Mid-urethral slings inserted through a SIS single incision sling (SIS) to treat female stress urinary incontinence (SUI).
3008470|NCT02506309|Active Comparator|TOT trans obturato tape/sling|TOT - inside-out trans-obturator tape/sling Trans-obturator slings (TOT) now represent a gold standard in the treatment of female stress urinary incontinence (SUI).
3008471|NCT02506296|Other|Insulin treated T2D diagnosed >=35yrs|"split by presence or absence of severe endogenous insulin deficiency:~Severe deficiency = fasting blood C-peptide ≤0.08nmol/L or stimulated C-peptide ≤0.2nmol/L or post meal urine C-peptide creatinine ratio ≤0.2nmol/mmol~Retained endogenous insulin secretion = fasting blood C-peptide ≥0.25nmol/L or stimulated C-peptide ≥0.6nmol/L or post meal urine C-peptide creatinine ratio ≥0.6nmol/mmol~Groups will be compared for:~glucose variability (via Continuous Glucose Monitoring System (CGM)) and hypoglycaemia risk (via hypoglycaemia questionnaire)~glycaemic response to standard DPPIV inhibitor therapy"
3008472|NCT02506283|Experimental|cooling intervention|subjects in this study receive a single pre-exercise (3x MVC) or post-exercise intervention (3x 30 counter movement jumps), consisting of an external cooling application (Zamar Therapy CT clinic) applied to both thighs. Both interventions have a duration of 20 minutes and a temperature of 8°C
3008473|NCT02506283|Sham Comparator|thermoneutral intervention|subjects in the control group receive a single pre-exercise (3x MVC) or post-exercise (3x 30 counter movement jumps) sham intervention, consisting of a 20 minute external thermoneutral application (Zamar Therapy CT clinic) applied to both thighs. Both sham interventions have a duration of 20 minutes and a temperature of 32°C.
3008474|NCT02506270|Active Comparator|AirSeal Trocar valveless|patients are treated with the AirSeal-CO2-insufflator and trocar-system
3008475|NCT02506270|Sham Comparator|Conventional trocar|patients are treated with a conventional insufflation and trocar system
3008476|NCT02506257|Experimental|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
3008477|NCT02506257|Experimental|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
3008478|NCT02506257|Experimental|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
3008479|NCT02506257|Placebo Comparator|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
3008480|NCT02506244|Experimental|Immediate Monitoring|"Individuals randomized to immediate monitoring will receive the ZIO XT patch sensor and wear it for the first and last 2 week period of the 4 month monitoring period of time 0 to 4 months.~Note: Approximately 250 consenting participants will also be invited to participate in a sub-study to wear an additional monitoring device (Amiigo wristband) continuously over the 4 month monitoring period."
3008481|NCT02506244|Active Comparator|Delayed Monitoring|"Individuals randomized to delayed monitoring will receive usual care for 4 months after which they will receive the ZIO XT patch sensor and wear it for the first and last 2 week period of study months 4 through 8.~Note: Approximately 250 consenting participants will also be invited to participate in a sub-study to wear an additional monitoring device (Amiigo wristband) daily for months 4 through 8."
3008482|NCT02506231|Experimental|Folinic acid|Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.
3008483|NCT02506231|Placebo Comparator|Placebo|Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.
3008484|NCT02506218|Experimental|10 + 20 g protein consumption|10 g breakfast followed by the consumption of a 20g whey protein shake
3008485|NCT02506218|Active Comparator|30 g protein breakfast|
3008486|NCT02506218|Active Comparator|10 g protein breakfast|
3008487|NCT02506205|Experimental|LSVT LOUD|LSVT LOUD was developed based on concepts of neuroplasticity, motor learning, skill acquisition and motor speech. LSVT LOUD trains laryngeal and respiratory functions through loud and effortful phonatory tasks (Ramig, Sapir, Countryman, Pawlas, O'Brien, Hoehn, & Thomson, 2001). It targets vocal intensity via stimulation of effortful speech productions with multiple repetitions and through encouraging self-calibrations of loud voice by patients. LSVT LOUD cues patients to speak loud (e.g., Fox et al., 2002; Ramig et al., 2001; Sapir et al., 2007). Having a single cue may increase treatment effects, as it reduces cognitive load in adults with PD because some of them develop cognitive deficits when PD progresses (Fox et al., 2002). Treatment is intensive, consisting of 4 individual sessions a week for 4 weeks, with 16 sessions in one month.
3008488|NCT02506192|Experimental|Delayed-Release Prednisone|Take oral tablets as directed (2x5mg) with food each evening at bedtime- approximately 10:00 pm
3008489|NCT02506192|Placebo Comparator|Placebo|Take oral tablets as directed (2x5mg) with food each evening at bedtime-approximately 10:00 pm
3008490|NCT02506179||Open-label cohort|Patients will be followed for 52 weeks post initiation of adalimumab (Week 0).
3008491|NCT02506166|No Intervention|No or Mild Sleep Apnea Group (Group 1)|"ICM patients with no or mild sleep apnea enrolled in this arm will continue with standard therapy (ICD/CRT-D implant + maximal medical therapy), but will receive no active Positive Airway Pressure (PAP) therapy for sleep apnea treatment. See Part: Study Population for more details.~In all ICM patients enrolled into ESCAPE-SCD Study, the ICD/CRT-D devices will be implanted based on current ESC Guidelines for primary prevention of sudden cardiac death (see Section: References)"
3008492|NCT02506166|No Intervention|Obstructive Sleep Apnea - Control Group (Group 2)|"ICM patients with predominant obstructive sleep apnea randomised to this arm will receive standard therapy (ICD/CRT-D implant + maximal medical therapy), but no PAP therapy for sleep apnea treatment. See Part: Study Population for more details."
3008493|NCT02506166|Active Comparator|Obstructive Sleep Apnea - Active Group (Group 3)|"ICM patients with predominant obstructive sleep apnea randomised to this arm will receive standard therapy (ICD/CRT-D implant + maximal medical therapy), plus as intervention, all patinets in this group will receive sleep apnea treatment by using PAP device. See Part: Study Population for more details."
3008494|NCT02506166|No Intervention|Central Sleep Apnea Group (Group 4)|"ICM patients with predominant central sleep apnea enrolled in this group will receive standard therapy (ICD/CRT-D implant + maximal medical therapy). Because the SERVE-HF Trial demonstrated a negative effect of predominantly central sleep apnea treatment on cardiovascular mortality in patients with HFrEF by using adaptive servo-ventilation therapy, patients in Group 4 will not receive any PAP therapy for treatment of sleep disordered breathing. See Part: Study Population for more details."
3008495|NCT02506153|Active Comparator|Arm I (high-dose recombinant interferon alfa-2B, ipilimumab)|"INDUCTION THERAPY: Patients receive high-dose recombinant interferon alfa-2B intravenously (IV) over 20 minutes on days 1-5. Treatment repeats weekly for 4 weeks in the absence of disease progression or unacceptable toxicity. Or patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 3 weeks for a total of 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive high-dose recombinant interferon alfa-2B subcutaneously (SC) on days 1, 3, and 5. Treatment repeats every 6 weeks for up to 48 weeks in the absence of disease progression or unacceptable toxicity. Or patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for 3 years in the absence of disease progression or unacceptable toxicity."
3008496|NCT02506153|Experimental|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
3008497|NCT02506140|Experimental|Ticagrelor/ASA|Drugs: Ticagrelor and Acetylsalicylic acid.
3008498|NCT02506140|Active Comparator|Clopidogrel/ASA|Drugs: Clopidogrel and Acetylsalicylic acid.
3008499|NCT02506127|Experimental|Open-label|"Theta burst stimulation (TBS) is a form of repetitive transcranial magnetic stimulation (TMS). Standard TBS parameters consisting of 3-pulse, 50Hz bursts every 200 ms (5 Hz) at an intensity of 80% motor threshold (MT) will be utilized. Intermittent TBS will be delivered in 2-second trains of bursts repeated every 10 seconds for a total of 570 seconds (1800 pulses) in each session.~Each treatment session thus involves < 10 minutes of stimulation. The subject and researchers know what treatment is being administered."
3008500|NCT02506127|Active Comparator|Blinded Active|"Standard TBS parameters consisting of 3-pulse, 50Hz bursts every 200 ms (5 Hz) at an intensity of 80% motor threshold (MT) will be utilized. Intermittent TBS will be delivered in 2-second trains of bursts repeated every 10 seconds for a total of 570 seconds (1800 pulses) in each session.~Each treatment session thus involves < 10 minutes of stimulation. The subject and researcher will not know what type of treatment will be administered."
3008501|NCT02506127|Sham Comparator|Blinded Sham|"This is a sham treatment which will mimic the open-label and blinded active to enable the effects of the supposedly active treatment to be assessed objectively. The subject and researcher will not know what type of treatment will be administered.~Each treatment session will be < 10 minutes in duration."
3008502|NCT02506114|Experimental|Arm A|PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36.
3008503|NCT02506114|Experimental|Arm B|Ipilimumab: 3 mg/kg; intravenously; Days 1 and 21.
3008504|NCT02506114|Experimental|Arm C|PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36. Ipilimumab: 3 mg/kg; intravenously; Days 15 and 36.
3008505|NCT02506101|Experimental|narrow-band ultraviolet B phototherapy|We will use the 3 Series PC & SP Phototherapy Cabinet for treatment of vitiligo.
3008506|NCT02506101|No Intervention|no intervention|untreated
3008540|NCT02505854|Placebo Comparator|Placebo|Hypocaloric diet associated with capsule containing 50g of gelatin and sache of maltodextrin
3008541|NCT02505841|Active Comparator|Group 1|Curare: Atracurium injection at 0.5 mg/kg
3008507|NCT02506088|Experimental|Your Voice Your View|Participants in schools assigned to the treatment group will engage in a four session intervention aimed at prevention of sexual violence. Your Voice Your View is grounded in social norms theory and bystander intervention training. The intervention also includes a social norms marketing campaign.
3008508|NCT02506088|No Intervention|Wait List Control Group|Participants in schools assigned to the wait list control group will complete survey assessments at the same schedule as schools assigned to the treatment group. Schools will have the option to implement Your Voice Your View following completion of the 6-month survey.
3008509|NCT02506075|Experimental|Pre-tDCS group|"In Pre-tDCS group, total sessions of the transcranical direct current stimulator stimulation(tDCS) was done for each three subgroups and visual inattention training was followed after that.~Patient had 2 times of tDCS for 13 minutes with 20minutes of resting interval. After that, additional 2 times of Visual inattention training was done with same protocol."
3008510|NCT02506075|Experimental|Simultaneous tDCS group|In Simultaneous transcranical direct current stimulator(tDCS) group, tDCS and visual inattention training was done simultaneously.
3008511|NCT02506075|No Intervention|Sham control group|without transcranical direct current stimulator(tDCS) or without visual training
3008512|NCT02506062|Experimental|Active Arm - 200 mmHg|Patients who start in the active arm of the study will receive ischemic preconditioning (IPC) treatment consisting of applying the blood pressure cuff to a pressure of 200 mmHg for 2 minutes and thirty seconds with a resting period of two minutes and thirty seconds between treatments. This procedure is performed four times, for a total of twenty minutes per treatment. This treatment will be done three times a week. Patients may choose to treat at home with a portable manual blood pressure machine or may be treated in clinic by research staff. Patients will receive treatment for two weeks followed by a wash-out period (no treatment) of two weeks. Patients will then receive the placebo treatment. This completes their participation in the study.
3008513|NCT02506062|Placebo Comparator|Placebo Arm - 60 mmHg|Patients who start in the placebo arm will receive placebo treatment, consisting of applying the blood pressure cuff to a pressure of 60 mmHg for 2 minutes and thirty seconds with a resting period of two minutes and thirty seconds between treatments. This procedure is performed four times, for a total of twenty minutes per treatment. This treatment will be done three times a week for two weeks followed by a two week wash-out and then two weeks in the active treatment phase, thus completing their participation in the study.
3008514|NCT02506049|Other|S-LPC:Selective Laser Photocoagulation|S-LPC seals connecting vessels, normalizes flow between twins
3008515|NCT02506036|Active Comparator|Control then Social Cognitive Training|Patients assigned to this arm will first receive a control therapy on a laptop followed by the Brain HQ social-cognitive training.
3008516|NCT02506036|Experimental|Social Cognitive Training then Control|Patients assigned to this arm will first receive the Brain HQ social-cognitive training and then undergo a control therapy.
3008517|NCT02506023|Active Comparator|Hemophilia A carriers with mild mutation|Hemophilia A carriers with a mild type mutation will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
3008518|NCT02506023|Active Comparator|Hemophilia A Carriers with severe mutation|Hemophilia A carriers with a severe type mutation will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
3008519|NCT02506023|Active Comparator|Control|Subjects with a mild qualitative platelet dysfunction will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
3008520|NCT02505997|Experimental|Midazolam/Delafloxacin|Each subject will receive a single 5 mg oral dose of midazolam syrup on Day 1, oral 450 mg delafloxacin tablets twice daily (Q12h) for Days 3 to 8, and co-administered a single 5 mg oral dose of midazolam syrup in the AM on Day 8.
3008521|NCT02505984|Active Comparator|Oxytocin|Sub-group of participants receiving oxytocin nasal spray (Syntocinon)
3008522|NCT02505984|Placebo Comparator|Placebo|Sub-group of participants receiving placebo nasal spray
3008523|NCT02505971|Active Comparator|Nadolol group|40 study participants will take Nadolol (oral liquid suspension)
3008524|NCT02505971|Active Comparator|Propranolol group|40 study paticipants will take Propranolol (oral liquid suspension)
3008525|NCT02505958|Other|high caloric intake|Volunteers will receive 3 meals and 3 snacks over a 24 hour period which will contain ~ 6,000 calories. Main meals will consist of ~ 1,500 calories and snacks will contain ~ 500 calories.
3008526|NCT02505958|Other|reduced caloric intake|On days 5 and 6 subjects will receive 3 meals only and each meal will contain ~ 333 calories for a total of 1,000/ 24 hours.
3008527|NCT02505945|Active Comparator|Control Arm|Double-dose PPI [Omeprazole 20 mg BID (twice a day)]
3008528|NCT02505945|Active Comparator|Treatment Arm|LINX Reflux Management System
3008529|NCT02505932||Arthroscopic Latarjet procedure|arthroscopic approach (set Depuy-Mitek, Raynham, MA)
3008530|NCT02505932||Mini-open Latarjet procedure|mini-open approach (set Arthrex, Naples, FL)
3008531|NCT02505919|Experimental|Treatment|AQUABEAM System
3008532|NCT02505919|Active Comparator|Control|Transurethral Resection of the Prostate (TURP)
3008533|NCT02505893|Experimental|Treated|The investigational treatment will be islet transplant in the presence of induction with ATG/G-CSF and rapamycin treatment for one month. One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver. ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant. Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion. Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
3008534|NCT02505880|Active Comparator|1: General anesthesia|General anesthesia
3008535|NCT02505880|Experimental|2: Hypnosis|Hypnosis with local anesthesia
3008536|NCT02505867|Experimental|Device - ASV Therapy|Participants are provided with Adaptive Servo Ventilation (ASV) device during inpatient hospitalization or shortly after discharge.
3008537|NCT02505867|No Intervention|Control|No device provided
3008538|NCT02505854|Placebo Comparator|Probiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of maltodextrin
3008539|NCT02505854|Placebo Comparator|Symbiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of fructooligosaccharide
3008542|NCT02505841|Experimental|Group 2|TAP block and curare: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg then atracurium injection at 0.5 mg/kg
3008543|NCT02505841|Experimental|Group 3|TAP block: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
3008544|NCT02505828|Other|Septic arthritis|with bacteriological identification
3008545|NCT02505828|Other|Juvenile idiopathic arthritis|beyond the ILAR (International League of Associations for Rheumatology) definition
3008546|NCT02505815||Regional Anesthesia|Patients with surgery in regional anesthesia.
3008547|NCT02505815||General Anesthesia|Patients with surgery in general anesthesia.
3008548|NCT02505802|Experimental|BoNT-A treatment group|In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu). Both groups received comprehensive rehabilitation for 8 weeks.
3008549|NCT02505802|No Intervention|Control group|No special treatment was performed in the control group. Both groups received comprehensive rehabilitation for 8 weeks.
3008550|NCT02505776||GLASH VISTA™|Patients with eyelash hypotrichosis prescribed bimatoprost cutaneous solution 0.03% (GLASH VISTA™) as per local standard of care in clinical practice.
3008551|NCT02505763|Experimental|Strategy with thoracic ultrasound|"Use of thoracic ultrasound for the treatment of pleural effusion, treatment and monitoring.~Use of other examinations like chest CT if necessary"
3008552|NCT02505763|No Intervention|Strategy without thoracic ultrasound|"Usual care : without thoracic ultrasound~Use of chest radiography or chest CT scan if necessary, as for treatment and monitoring.~Usual care: without the use of ultrasound Using either chest radiography or TDM if necessary, as for treatment and monitoring."
3008553|NCT02505750|Active Comparator|EBRT 45 Gy/capecitabine + EBRT boost|"3D conformal EBRT 45 Gy (1.8Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days).~A cone down EBRT targeting the GTV will deliver a boost dose of 9 Gy in 5 fractions. On week 14 after the start of treatment, the tumour response evaluation will guide the final strategy: surgery (radical TME or local excision) or watch-and-wait (W-W)."
3008554|NCT02505750|Experimental|EBRT 45 Gy/capecitabine + CXB boost|"Arm B divided in 2 subgroups depending on the tumour diameter:~B1: If the tumour is < 3 cm, a CXB boost dose (90Gy/3 fractions/4 weeks) will be initially delivered to the tumour. After 2 weeks rest, patients will receive 3D conformal EBRT 45 Gy (1.8 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days). Clinical evaluation will be performed 3 weeks after the end of irradiation (week 14) and will guide the final strategy (surgery or W-W) as in arm A.~B2: If the tumour is ≥ 3 cm, patients will receive EBRT first 45 Gy (1.8 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days).~A CXB boost dose (90 Gy/3 fractions/4 weeks) will be delivered to residual tumour, after a rest of 2 weeks. On week 14 after the start of treatment, the tumour response evaluation will guide the final strategy (surgery or W-W) as in arm A. Adjuvant chemotherapy will be left to institution choice."
3008555|NCT02505737|Experimental|TH-CBT|The treatment works by teaching people with PD (PWP) the coping skills needed to manage their emotional reactions to the numerous challenges posed by the disease. Specifically, the treatment targets maladaptive thought patterns (e.g., I have no control; I am helpless) and behaviors (e.g., social isolation, lack of exercise, poor sleep habits, excessive worry), and critically, provides caregivers with the tools needed to encourage the PWPs' practice of their newly acquired coping skills. Treatment is administered over the phone and no travel is required.
3008556|NCT02505737|Other|Enhanced Usual Care|All participants will continue to receive their routine medical treatment under the supervision of their personal doctors (e.g., neurologists, psychiatrists, primary care physicians, therapists) while participating in the study. This routine treatment (e.g., usual care) will be further enhanced with the provision of written educational materials for effective coping with PD, the close clinical monitoring of depressive symptoms by study staff, and the provision of counseling resources in the local community.
3008557|NCT02505724|Active Comparator|Conventional training|Participants received access to a web-based tutorial for laparoscopic suturing and a box trainer for independent practice
3008558|NCT02505724|Experimental|Intervention|Participants received access to a web-based tutorial for laparoscopic suturing and a box trainer for independent practice. In addition, they received two 1/2 hour peer-coaching sessions
3008559|NCT02505711|Experimental|Homestead Food Production|Enrolled in Homestead Food Production program from 2015 to 2019, 48 clusters, approx. 1350 women and 750 children
3008560|NCT02505711|No Intervention|Control|(Health system strengthening in the study area), 48 clusters, approx. 1350 women and 750 children
3008561|NCT02505685||Lung cancer|People that were diagnosed with advanced lung cancer.
3008562|NCT02505672||Study group|Patients older than 18 who are planned to undergo chemoradiotherapy for nasopharyngeal carcinoma.
3008563|NCT02505659|Experimental|EXPERIMENTAL GROUP|Sessions are aiming to neuromuscular and functional training. Each session starts with trunk muscle activation. Patients will then have to realize a neuromuscular training on Huber Motion Lab® followed by multiple exercises targeting functional stability and neuromuscular control. From the 4th session, a jump sequence will be added to the previous exercices. Exercises used in this protocol are based upon successful exercises of protocols already performed on patients with anterior cruciate ligament rupture.
3008564|NCT02505659|No Intervention|CONTRL GROUP|a control group (without preoperative reeducation)
3008565|NCT02505633|Experimental|2P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced at the behind site of the initial puncture site. And the needle is penetrated the nerve sheath with a direction of upward, and then the same process is performed and LA 15 mL is injected.
3008597|NCT02505451|Experimental|controls|Regional myocardial function will be assessed during dobutamine stress echocardiography in healthy subjects.
3008598|NCT02505438|Experimental|Young Unilateral Exercise|Young Individuals (18-30y) studied before and after 6 weeks unilateral resistance exercise training
3009595|NCT02499198|Placebo Comparator|Control|Control group - Herbal snuff only, no Nornicotine
3008566|NCT02505633|Active Comparator|1P1I group|After subcutaneous injection of 1 mL of 2% lidocaine, a nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach from lateral to medial direction. After the needle is penetrated the nerve sheath, the nerve stimulator is then turned on, and the stimulation current starts at 0.5mA. If hand muscle twitching is observed even at 0.3 mA, local anesthetics 30 mL (lidocaine mixed with epinephrine) is injected.
3008567|NCT02505620||Surgical|Surgical correction of OSAS disease
3008568|NCT02505620||Conservative|Conservative treatment of OSAS disease
3008569|NCT02505607|No Intervention|Standard Care Group|In this group, subjects will receive standard counseling regarding Overactive Bladder.
3008570|NCT02505607|Experimental|Care Plan Group|"In this group, subjects will receive counseling regarding Overactive Bladder using a printed Overactive Bladder Plan of Care information sheet."
3008571|NCT02505594||OSA Group|Apnea-hypopnea index (AHI) ≥ 15 events/h
3008572|NCT02505594||Control Group|Apnea-hypopnea index (AHI) < 5 events/h
3008573|NCT02505581|Experimental|Oral + Parenteral prophylaxis|
3008574|NCT02505581|Active Comparator|Only Parenteral prophylaxis|
3008575|NCT02505568|Experimental|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 and will be evaluated for the induction phase at Week 8. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion at Week 14, Week 22, and Week 30 in the maintenance phase and will be evaluated at Week 32.
3008576|NCT02505542|Other|Open-label Certolizumab Pegol|Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 to Week 48 (Part A). Subjects in sustained remission at Week 48 are eligible for randomization into Part B.
3008577|NCT02505542|Experimental|Double-blind Certolizumab Pegol 200 mg Q2W|Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 2 weeks (Q2W) from Week 48 onwards.
3008578|NCT02505542|Experimental|Double-blind Certolizumab Pegol 200 mg Q4W|"Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 4 weeks (Q4W) from Week 48 onwards.~At visits where CZP is not received, subjects receive one injection of Placebo to maintain the study blind."
3008579|NCT02505542|Placebo Comparator|Placebo|One placebo injection is administered every 2 weeks from Week 48 onwards.
3008580|NCT02505542|Other|Placebo to CZP 200 mg Q2W escape|Subjects randomized to Placebo who meet flare criteria receive CZP 400 mg subcutaneous (sc) every 2 weeks (Q2W) for the first 3 visits after flare has been confirmed. After that, CZP 200 mg is given every 2 weeks in open-label fashion.
3008581|NCT02505542|Other|CZP 200 mg Q4W to CZP 200 mg Q2W escape|Subjects randomized to CZP 200 mg Q4W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
3008582|NCT02505542|Other|CZP 200 mg Q2W to CZP 200 mg Q2W escape|Subjects randomized to CZP 200 mg Q2W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
3008583|NCT02505529|Experimental|Resistance Exercise Training|12-weeks of high-intensity, progressive resistance exercise training (3x/wk).
3008584|NCT02505529|Experimental|Mental Imagery|6-weeks of mental imagery of strong muscle contractions and mobility tasks (5x/wk).
3008585|NCT02505529|No Intervention|Control Group|6-weeks of no change in lifestyle.
3008586|NCT02505516|Placebo Comparator|metformin|metformin 500mg
3008587|NCT02505516|No Intervention|not on metformin|
3008588|NCT02505503|Active Comparator|Unloading shoes|The unloading shoe will be a trainer-type shoe with a cosmetically-shaped rocker sole. The sole will have three circular curves whose arc centres are positioned at the anatomical ankle, hip and knee respectively; assuming a vertical lower limb. This is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
3008589|NCT02505503|Placebo Comparator|Unadapted control shoes|The control shoes will be similar in appearance to the unloading shoes, but they will not contain the altered sole.
3008590|NCT02505490|Experimental|No Television|The purpose is to determine whether a change in liking of food will occur with a lack of television.
3008591|NCT02505490|Experimental|Television|The purpose is to determine whether a change in liking of food will occur while watching television.
3008592|NCT02505477|Experimental|N-acetylcysteine|Patients in this group will receive N-acetylcysteine (NAC) 1200mg orally twice daily (total daily dose 2400mg), for eight weeks. Each individual tablet contains 300mg NAC, therefore patients will take two tablets by mouth each morning and two tablets by mouth each evening. Manufacturer: Jarrow Industries, Inc.; Brand name: N-A-C Sustain
3008593|NCT02505477|Placebo Comparator|Placebo|Patients in this group will receive placebo tablets indistinguishable from NAC tablets, with the same protocol as NAC: two placebo tablets by mouth each morning, and two placebo tablets by mouth each evening. Manufacturer: Jarrow Industries, Inc.; Brand name: N-A-C Sustain
3008594|NCT02505464||Pregnant Women & their fetuses/infants|Information about pregnant women and their fetuses/infants, including the medical history, prenatal, perinatal, and postpartum periods (6 weeks after delivery) and throughout the treatment (e.g.surgery) for the child's medical condition (up to approx. child is @ 6 months of age), will be collected in this repository. The analysis of this information may help in understanding of the causes of fetal anomalies.
3008595|NCT02505451|Experimental|Type 2 diabetic patients|Regional myocardial function will be assessed during dobutamine stress echocardiography in asymptomatic patients with type II diabetes (according to the American Diabetes Association, 2012) free of coronary diseases.
3008596|NCT02505451|Experimental|Metabolic syndrom|Regional myocardial function will be assessed during dobutamine stress echocardiography in asymptomatic patients with the Metabolic syndrome (according to Alberti et al 2009) free of diabetes and coronary diseases.
3010979|NCT02489786|Active Comparator|Regimen 3|patient takes 0.125mg of digoxin daily
3008599|NCT02505438|Experimental|Old Unilateral Exercise|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training
3008600|NCT02505438|Experimental|Old Unilateral Exercise and HMB|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training with HMB (beta-hydroxy-beta-methylbutyrate) supplementation
3008601|NCT02505438|Experimental|Old Unilateral Exercise and Omega 3|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training with Omega 3 supplementation
3008602|NCT02505425|Experimental|Active Intervention|"Behavioral: behavioral support~Usual HF Care + ENABLE CHF-PC"
3008603|NCT02505425|Active Comparator|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
3008604|NCT02505399|Experimental|ticagrelor|"In the intervention group, Ticagrelor will be administered orally, according to the following scheme:~180 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~90 mg the following morning (D Day before rotational atherectomy and angioplasty),~90 mg the following evening (D Day after rotational atherectomy and angioplasty),~90 mg twice daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
3008605|NCT02505399|Active Comparator|clopidogrel|"In the control group, Clopidogrel will be administered orally, according to the following scheme:~300 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~75 mg the following morning (D Day before rotational atherectomy and angioplasty),~0 mg the following evening (D Day after rotational atherectomy and angioplasty),~75 mg once daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
3008606|NCT02505386|Active Comparator|Ertapenem IV|IV administration of ertapenem
3008607|NCT02505386|Experimental|Ertapenem SC|SC administration of ertapenem
3008608|NCT02505373|Experimental|Intervention Group ASSIP|Intervention Group ASSIP (Brief Therapy)
3008609|NCT02505373|Active Comparator|Control Group CG|Control Group CG (structured interview)
3008610|NCT02505360|Other|nasal and ear cartilage taken from the newborn|to compare biochemical and histological characteristics of both nasal and ear cartilage taken from the newborn at the time of surgical time cheilorhinoplasty
3008611|NCT02505347|Experimental|No splint|will be able to move the arm as tolerated following surgery.
3008612|NCT02505347|Active Comparator|Splint|will receive a splint following surgery for 6 weeks.
3008613|NCT02505334|Experimental|Liraglutide 1.8 mg|The total trial duration for the 1.8 mg/day treatment arm will be approximately 67 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week main treatment period, a safety extension period of 26 weeks and a follow-up visit.
3008614|NCT02505334|Active Comparator|Liraglutide 0.9 mg|The total trial duration for the 0.9 mg/day treatment arm will be approximately 41 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week treatment period, and a follow-up visit.
3008615|NCT02505321|Experimental|fATDIVA - OTTT (Cases)|"Individuals identified with the polygenic lipodystrophy genetic variants of interest will undergo the Oral Triglyceride Tolerance Test (OTTT) plus an abdominal fat biopsy (optional). Case/control status will be unblinded at analysis."
3008616|NCT02505321|Experimental|fATDIVA - OTTT (Controls)|"Control individuals carrying the average number of risk alleles and matched to individuals identified with the polygenic lipodystrophy genetic variants of interest for gender, age and BMI, will undergo the Oral Triglyceride Tolerance Test (OTTT) plus an abdominal fat biopsy (optional). Case/control status will be unblinded at analysis."
3008617|NCT02505308|Experimental|DIVA-1 CCND2|Individuals carrying a genetic change in the CCND2 gene and controls matched for gender, age and BMI. Participants will undergo the Glucose-Potentiated Arginine-Induced Insulin Secretion (GPAIS) test plus optional faecal elastase measurement. Case/control status will be unblinded at analysis.
3008618|NCT02505308|Experimental|DIVA-2 Low Risk of Diabetes|Individuals carrying the fewest genetic risk alleles for diabetes and controls carrying the average number of genetic risk alleles, matched for gender, age and BMI. Participants will undergo the Glucose-Potentiated Arginine-Induced Insulin Secretion (GPAIS) test plus optional faecal elastase measurement. Case/control status will be unblinded at analysis.
3008619|NCT02505295|Active Comparator|selenium|vial selenium (selenase 500 microgr ) 2000 microgram stat and 1000 microgram daily for 5 days
3008620|NCT02505295|Placebo Comparator|normal saline|40 cc normal saline stat and 20 cc daily for 5 days( in vials like selenase vial)
3008621|NCT02505282||Orthostatic Hypotension|>20mmHg systolic BP drop or >10mmHg diastolic BP drop on standing, and syncopal symptoms on standing
3008622|NCT02505282||Control|No fall in BP or <20mmHg systolic BP drop and <10mmHg diastolic BP drop on standing, and no syncopal symptoms on standing
3008623|NCT02505269|Experimental|Brentuximab Vedotin|"The following procedures will take place during study visits beginning after the screening procedures:~- Participants will receive combination therapy:~Brentuximab Vedotin intravenously on predetermined days per cycle~Adriamycin intravenously on predetermined days per cycle~Dacarbazine intravenously on predetermined days per cycle"
3008624|NCT02505256||case group|cases who presented as breast pain or breast lumps, and no intervention will be administered.
3008625|NCT02505243||HCV patients|HCV patients treated with direct acting antivirals and ribavirin
3008626|NCT02505230|Experimental|Meal Order 1|"[P,P+S,HVP,LVP]~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor)."
3008656|NCT02505009|Experimental|entecavir pretreated vaccine arm|Arm A,case group: 75 cases will be enrolled to receive Engerix-B injection and compared with histological non-vaccine treated controls
3008657|NCT02505009|Experimental|tenofovir pretreated vaccine arm|Arm B case group: A total of 50 patients will be randomized into case (vaccine) and control group according to age, gender, pretreatment HBV DNA level.
3011052|NCT02489188||ankle osteoarthritis|patients with ankle osteoarthritis scheduled for arthroplasty
3008627|NCT02505230|Experimental|Meal Order 2|"[P+S,HVP,LVP,P]~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables."
3008628|NCT02505230|Experimental|Meal Order 3|"[HVP,LVP,P,P+S]~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices)."
3008629|NCT02505230|Experimental|Meal Order 4|"[LVP,P,P+S,HVP]~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices)."
3008630|NCT02505204|Experimental|Clonidine|Will receive bilateral PVB with clonidine.
3008631|NCT02505204|Placebo Comparator|Placebo|Will receive bilateral PVB with placebo.
3008632|NCT02505191|Experimental|Test|St. John's wort prolonged-release tablet 500 mg
3008633|NCT02505191|Active Comparator|Reference|St. John's wort film coated tablets 250 mg (Remotiv N)
3008634|NCT02505178|Experimental|Problem Solving Therapy|Study participation will involve 9 study visits over a total of 12 weeks. This includes 5 sessions of Case Manager implemented PST over a period of 8 weeks (week 1, 3, 5, 7, and 9) and 4 assessment visits (baseline, week 4, week 8, and week 12).
3008635|NCT02505165|Experimental|Parent Uncertainty Intervention|A pediatric cancer-specific, clinic based, six-module interdisciplinary uncertainty intervention. Modules one through three target uncertainty prevention. Modules four through six target uncertainty responses for situations in which uncertainty cannot be prevented or avoided.
3008636|NCT02505165|Other|Education/Support Only|"Sessions in this condition aim to provide education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Information presented will be based upon, Young People with Cancer: A Handbook for Parents, a parent resource developed by the National Cancer Institute. Parents will also be provided with relevant educational brochures from COG. Each session will also include a structured set of questions that will facilitate discussion. All ESO interventionists will be trained in non-directive approaches including reflective listening. Content provided in the ESO sessions will offer valuable information to parents without providing the specific skills of the IMPACT."
3008637|NCT02505152|Experimental|Shunt|Perform percutaneous transhepatic intrahepatic portosystemic shunt
3008638|NCT02505139||Study Group|
3008639|NCT02505126|Experimental|Active tDCS group|Active tDCS
3008640|NCT02505126|Placebo Comparator|Placebo tDCS group|Placebo tDCS : Inactive tDCS
3008641|NCT02505113||CTPV without Montelukast|Patients with CTPV do not receive the treatment of Montelukast.
3008642|NCT02505113||CTPV treated with Montelukast|Patients with CTPV treated with Montelukast (10mg, q.d., p.o.).
3008643|NCT02505100|Experimental|Touching relaxant|session of massage
3008644|NCT02505100|Experimental|Hypnoses|session of hypnoses
3008645|NCT02505100|No Intervention|Standared care|standard care
3008646|NCT02505087|Active Comparator|Placebo followed by N-Acetylcysteine|Arm receiving placebo for 6 months, then N-Acetylcysteine (NAC) for 6 months.
3008647|NCT02505087|Experimental|N-Acetylcysteine followed by Placebo|Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.
3008648|NCT02505087|No Intervention|Healthy volunteers|The purpose of this group is to collect reference values for biochemical markers.
3008649|NCT02505074||Mitral Valve Replacement|Review of retrospective data of those patients who have had surgical replacement of the mitral valve with the Melody valve.
3008650|NCT02505074||Tricuspid Valve Replacement|Review of retrospective data of those patients who have had surgical replacement of the tricuspid valve with the Melody valve.
3008651|NCT02505061|Experimental|Program|The participant‟s performance is indicative of the extent to which early power mobility training is feasible for both young infants and up to 3-year-old child with mobility Disabilities.Parents/caregivers and occupational therapists will be responsible for theHospital-based Program and Regular Therapy Program service respectively
3008652|NCT02505048|Experimental|rucaparib|"Tablets 200 mg and 300 mg per os : 600 mg / bid every day in continuous.~Patients will be treated with rucaparib Cycles are defined in 28-day periods Disease response will be assessed every 8 weeks (RECIST 1.1) Safety will be assessed continuously"
3008653|NCT02505035|Active Comparator|Default ordering of palliative consult|Hospitals randomized to the intervention arm will adopt a system whereby eligible patients are identified by the electronic health record, a consultation is ordered by default, and physicians may cancel the order after being alerted to it, and patients or family members may decline such services.
3008654|NCT02505035|No Intervention|Usual care|There will be no trial-driven approach to care. Inpatient palliative care consultative services will be actively requested by physicians as in usual care.
3008655|NCT02505022||Treatment seeking patients|Patients between 18 and 26 who arrive seeing treatment for new-onset mental health symptoms. They will receive treatment as usual, while being assessed overt he course of one year for changes in role functioning.
3008658|NCT02505009|Active Comparator|Entecavir pretreated control arm|Arm A control group: Age, gender and pretreatment DNA matched histological controls
3008659|NCT02505009|Active Comparator|tenofovir pretreated control arm|Arm B control group: A total of 50 patients will be randomized into case (vaccine) and control group according to age, gender, pretreatment HBV DNA level.
3008660|NCT02504996|Active Comparator|Paracetamol|1 g intravenous paracetamol (Perfalga, Bristol Myers) in 100 ml saline with a rapid infusion.
3008661|NCT02504996|Active Comparator|morphine|0.1 mg/kg morphine in 100 ml saline with a rapid infusion.
3008662|NCT02504996|Placebo Comparator|placebo|100 ml saline
3008663|NCT02504983|Active Comparator|GALNT14 TT|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued.
3008664|NCT02504983|Active Comparator|GALNT14 non-TT TACE alone|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued.
3008665|NCT02504983|Experimental|GALNT14 non-TT TACE plus sorafenib|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation, plus sorafenib adjuvant therapy. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued. patients will receive sorafenib 400 mg/d between each TACE. Patient will start receiving Sorafenib on Day 4 (up to Day 7) after 1st TACE (Day 1) and will interrupt after evening dose 4 days before each next TACE and re-start Sorafenib on Day 4 (up to Day 7) after each TACE cycle.Additional sorafenib treatment is optional and will be judged by investigator in the subject's best medical interest.
3008666|NCT02504970||Anesthesia Group Type|AQI collects data from anesthesia groups. The groups are classified according to practice type
3008667|NCT02504957|Other|Photodynamic therapy|Patients who underwent photodynamic therapy for malignant biliary obstruction.
3008668|NCT02504944|Experimental|Propranolol 0.2% eye drops|Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%). The treatment will be started as soon as the diagnosis of stage 1 ROP is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days. Cardiovascular and respiratory parameters will be continuously monitored. Blood samplings checking metabolic, renal and liver functions will be performed periodically, as well as cardiac function, in order to verify the treatment safety. Propranolol concentrations will be measured on dried blood spots at the steady state (10th day). Serial ophthalmological evaluations will be planned to monitor the efficacy of the treatment, the ROP progression and the possible complications.
3008669|NCT02504931|Experimental|Sertraline|"Subjects will receive a fixed dose of 150 mg sertraline per day. Sertraline dose will be gradually increased by giving sertraline subjects capsules filled with 50 mg for the first three days and then capsules filled with 100 mg for 4 days before beginning the 150 mg per day in the second week. After completing the study Visit 12, subjects will be given an additional two week supply of medicine to gradually taper down so as to minimize any withdrawal discomfort.~Subjects in the Sertraline arm also will receive COPE therapy (Concurrent Treatment with Prolonged Exposure)which involves 12 sessions of manualized cognitive and behavioral therapy including exposure therapy for PTSD."
3008670|NCT02504931|Placebo Comparator|Placebo|"Matching placebo capsules will be filled with corn starch only on the same schedule as the Sertraline.~Subjects in the Placebo arm also will receive COPE therapy (Concurrent Treatment with Prolonged Exposure)which involves 12 sessions of manualized cognitive and behavioral therapy including exposure therapy for PTSD."
3008671|NCT02504892|Experimental|Cohort 1|Birt-Hogg-Dube Syndrome (BHD)-associated renal tumors
3008672|NCT02504892|Experimental|Cohort 2|Sporadic chromophobe renal tumors
3008673|NCT02504827|Experimental|IV Ceftazidime/Avibactam|Ceftazidime/avibactam 2.5gm IV q8h for 3 doses
3008674|NCT02504814|Experimental|ventilatory effects|measuring mean airway pressure, breathing volumes and decrease in hypercapnia
3008675|NCT02504801|Active Comparator|nebulized Budesonide 2mg/4mL|+terbutaline 5mg/2mL,BID+ipratropium 2 puff(40ug)BID
3008676|NCT02504801|Placebo Comparator|nebulized saline 4mL|+terbutaline 5mg/2mL,BID+ipratropium 2 puff(40ug)BID
3008677|NCT02504788|Experimental|Hippocampal-sparing WBRT|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25‐mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of whole brain radiation (WBRT), the technique of volumetric modulated arc therapy (VMAT) via Linac‐based RapidArc®.In terms of dose prescription, a dose of 30 Gy in 12 fractions was prescribed to whole-brain planning target volume (PTV) if the role of RT was considered either adjuvant following craniotomy with tumor removal or therapeutic for treating oligometastatic brain disease.
3008678|NCT02504775|Experimental|Tylenol® Caplets, then Mejoral® 500 Tablets|Participants will first receive one tablet [500 milligram (mg) of paracetamol] of Tylenol® Caplets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting. After a washout period of 72 h, they then will receive one tablet (500 mg of paracetamol) of Mejoral® 500 tablets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting.
3008679|NCT02504775|Experimental|Mejoral® 500 Tablets, then Tylenol® Caplets|Participants will first receive one tablet (500 mg of paracetamol) of Mejoral® 500 tablets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting. After a washout period of 72 h, they then will receive one tablet (500 mg of paracetamol) of Tylenol® Caplets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting.
3008680|NCT02504762|Experimental|Treatment: HCR|Participants will be randomized into the treatment or control group. In the treatment group, participants will be treated with PCI and MICS CABG. In the control group, participants will be treated with conventional CABG for their multivessel CAD.
3008681|NCT02504762|Active Comparator|Control: Conventional CABG|Participants will be randomized into the treatment or control group. In the treatment group, participants will be treated with PCI and MICS CABG. In the control group, participants will be treated with conventional CABG for their multivessel CAD.
3008719|NCT02504580|Experimental|Part B Cohort F|400 mg HTX-002 by infiltration
3008720|NCT02504580|Experimental|Part C Cohort B|200 mg HTX-011B by instillation
3008682|NCT02504749|Active Comparator|Group A: General anaesthesia group|-Standard rapid sequence induction with pre-oxygenation by 100 % OXYGEN FOR 3 MINUTES FOLLOWED BY 4-5 mg/kg thiopental and 100 mg succinylcholine,cricoid pressure was applied once necessary.After correct placement of tracheal tube was confirmed,anaesthesia was maintained with up to 1.5% isoflurane and oxygen,neuromuscular blockade was maintained with 0.4 mg/kg atracurium.
3008683|NCT02504749|Active Comparator|Group B:Spinal anaesthesia group.|"Prehydration with 500 ml lactated ringer solution intravenous within 15 minutes in the sitting position.Low back was prepared and drapped in a sterile fashion with Betadine solution 10%.~Spinal anaesthesia performed at L 2-3 or L 3-4 intervertebral space using a fine needle size 22 G.Injection of local anaesthetics into the subarachnoid space,Bupivacaine(marcaine) 1.5 -3.5 ml used."
3008684|NCT02504723|Experimental|Cyanoacrylate injection plus carvedilol|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.
3008685|NCT02504723|Active Comparator|Cyanoacrylate injection|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
3008686|NCT02504710|Active Comparator|Traditional Learning System|Traditional systems of manual therapy teaching
3008687|NCT02504710|Experimental|Kinematic Real-Time Feedback|Kinematic real time feedback to learn Manual therapy
3008688|NCT02504697||Longitudinal Cohort|For this longitudinal screening cohort, we will enroll 800 participants who currently or historically smoked and who have a 10 year Bach risk model of lung cancer > 2.5% (5). We will include participants 50 to 79 years old, with ≥10 cigarettes/day for current smokers, or ≥20 pack years for former smoker who quit 20 years ago or less. In order to further enrich for lung cancer risk, participants also will have COPD/emphysema or at least one first-degree relative with a diagnosis of lung cancer. We will exclude patients previously diagnosed with lung cancer. These patients will be followed for a total of 4 years with annual follow-up visits. Biosamples from airway and blood will be collected.
3008689|NCT02504684|Active Comparator|1470-nm|Endovenous 1470-nm diode laser
3008690|NCT02504684|Experimental|1920-nm Group|Endovenous 1920-nm diode laser
3008691|NCT02504671|Experimental|GSK3196165, Dose 1 + MTX and Folic acid|Subject will receive GSK3196165 Dose 1 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
3008692|NCT02504671|Experimental|GSK3196165, Dose 2 + MTX and folic acid|Subject will receive GSK3196165 Dose 2 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
3008693|NCT02504671|Experimental|GSK3196165, Dose 3 + MTX and folic acid|Subject will receive GSK3196165 Dose 3 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
3008694|NCT02504671|Experimental|GSK3196165, Dose 4 + MTX and folic acid|Subject will receive GSK3196165 Dose 4 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
3008695|NCT02504671|Experimental|GSK3196165, Dose 5 + MTX and folic acid|Subject will receive GSK3196165 Dose 5 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
3008696|NCT02504671|Placebo Comparator|Placebo + MTX and folic acid|Subjects will receive placebo (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
3008697|NCT02504658|Experimental|Text Message Group|Subjects will set 2 lifestyle goals (exercise and nutrition) and receive health tips and goal status check in messages over 1 month.
3008698|NCT02504658|Active Comparator|Control Group|"The control subjects will set 2 lifestyle goals and receive a educational booklet to review.They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over. The approximate procedure time will be 20-25 minutes."
3008699|NCT02504645|Active Comparator|IPP-201101 200-mcg plus SOC|Patients randomly assigned to IPP-201101 will be administered a dosage of 200 mcg subcutaneously (sc) every 4 weeks for 48 weeks (a total of 13 doses will be administered).
3008700|NCT02504645|Placebo Comparator|PLACEBO plus SOC|Patients randomly assigned to placebo will be administered placebo subcutaneously (sc) every 4 weeks for 48 weeks (a total of 13 doses will be administered).
3008701|NCT02504632|Experimental|test group|Patient with severe, symptomatic AS (Aortic valve area < 0,6 cm2/m2 SC), deemed, after multidisciplinary heart team evaluation, contra-indicated or at high risk for surgery and suitable for TF TAVI with a MCV prosthesis.
3008702|NCT02504632|Other|control group|Patient with stable coronary artery disease, unscathed of AS Patient under aspirin treatment (75-160 mg/d for at least one week)
3008703|NCT02504619|Experimental|CordIn|Transplantation of CordIn
3008704|NCT02504606|Experimental|Besylsartan|amlodipine besylate 6.944mg+losartan K 100mg
3008705|NCT02504606|Active Comparator|Amosartan|amlodipine besylate 7.841mg+losartan K 100mg
3008706|NCT02504593|Other|Community health volunteers|The study subjects are all community health volunteers in community units in Kenya (10 community units in Bungoma East and 6 community units in Kiminini) that have been trained to provide community-based malaria diagnosis through rapid diagnostic testing.
3008707|NCT02504580|Experimental|Part A Cohort A|200 mg of HTX-011 by injection
3008708|NCT02504580|Experimental|Part A Cohort B|400 mg of HTX-011 by injection
3008709|NCT02504580|Experimental|Part A Cohort C|200 mg of HTX-011 by instillation
3008710|NCT02504580|Experimental|Part A Cohort D|400 mg of HTX-011 by instillation
3008711|NCT02504580|Experimental|Part A Cohort E|200 mg HTX-011 injection and 200 mg instillation
3008712|NCT02504580|Placebo Comparator|Part A Cohort F|Saline solution by injection
3008713|NCT02504580|Experimental|Part B Cohort A|200 mg HTX-011A by injection
3008714|NCT02504580|Experimental|Part B Cohort B|400 mg HTX-011A by injection
3008715|NCT02504580|Experimental|Part B Cohort C|200 mg HTX-011B by injection
3008716|NCT02504580|Experimental|Part B Cohort D|400 mg HTX-011B by injection
3008717|NCT02504580|Placebo Comparator|Part B Cohort E|Saline solution by injection
3008718|NCT02504580|Experimental|Part C Cohort A|200 mg HTX-002 by infiltration
3040818|NCT02288481|Placebo Comparator|Cohort 6 placebo|Placebo Suspension
3008724|NCT02504580|Experimental|Part D Cohort A|400 mg HTX-011B via a combination of injection and instillation
3008725|NCT02504580|Experimental|Part E Cohort A|HTX-009 by injection
3008726|NCT02504580|Experimental|Part E Cohort B|HTX-009 by instillation
3008727|NCT02504580|Experimental|Part F Cohort A|300 mg of HTX-011B
3008728|NCT02504580|Experimental|Part F Cohort B|75 mg of 0.25% Marcaine
3008729|NCT02504580|Placebo Comparator|Part F Cohort C|10.26 mL of normal saline
3008730|NCT02504567|Other|Laser ablation|Ablation with laser catheter
3008731|NCT02504567|Other|RF ablation|Ablation with RF catheter
3008732|NCT02504554|Experimental|Oral Group|This group will receive all treatments orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
3008733|NCT02504554|Experimental|Rectal Group|This group will receive some treatments rectally and some orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
3008734|NCT02504541|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
3008735|NCT02504528|Experimental|allergic asthma|asthma patients that sensitive to house dust mites.
3008736|NCT02504528|Experimental|normal controls|normal controls with or without sensitive to house dust mites.
3008737|NCT02504515|Active Comparator|Homeopathy|
3008738|NCT02504515|Active Comparator|Allopathy homeopathy control|
3008739|NCT02504515|Active Comparator|Acupuncture|
3008740|NCT02504515|Active Comparator|Allopathy acupuncture control|
3008741|NCT02504515|Active Comparator|Anthroposophic medicine|
3008742|NCT02504515|Active Comparator|Allopathy anthroposophy control|
3008743|NCT02504502|Experimental|Enhanced genomic report|routine clinical care for return of results per whole genome sequencing study with enhanced genetic test results report developed through phase 1 and 2 of this study
3008744|NCT02504502|Other|Control with delayed access|routine clinical care for return of results per whole genome sequencing study and no intervention through three months. This arm will crossover to receipt of enhanced report upon completion of baseline and 3 month post-baseline followup surveys. Participants in this arm will complete a third survey at 3 months post receipt of enhanced report
3008745|NCT02504489|Active Comparator|Docetaxel (D)|A treatment cycle is 21 days. Treatment will be repeated until disease progression is detected by imaging studies or unacceptable toxicities are encountered. On Day 1, all patients will receive docetaxel 75 mg/m2 by intravenous (IV) infusion over 1 hour. Oral dexamethasone (16 mg, given as 8 mg twice daily) will be given on the day prior to, the day of (Day 1), and the day following docetaxel infusion (Day 2). Routine antiemetic prophylaxis will be administered according to institutional guideline for docetaxel. Institutional guideline/practice should be followed in the event of infusion/hypersensitivity reaction. Diphenhydramine and dexamethasone infusion may be administered in the event of infusion reaction.
3008746|NCT02504489|Experimental|Docetaxel + Plinabulin (DP)|"The treatment regimen for Docetaxel (D) will be followed for this arm. In addition, on Days 1 and 8 of the 21 day cycle, patients will receive Plinabulin (P) administered via IV infusion over 60 minutes. On Day 1, the infusion begins 2 hours from the starting time of docetaxel infusion, i.e, approximately 60 minutes from the end of docetaxel infusion. On day 8, plinabulin infusion will be repeated.~On Day 1, no pre-medication will be routinely administered for plinabulin infusion. Anti-emetics may be prescribed as indicated according to institutional guidelines for chemotherapy. On Day 8, antiemetic prophylaxis may be administered prior to plinabulin infusion. For Cycle 1 Day 8 only, Zofran® (ondansetron) is prohibited due to its interference with QTc study."
3008747|NCT02504476|Active Comparator|AMG 581 - Dose 1|
3008748|NCT02504476|Active Comparator|AMG 581 - Dose 2|
3008749|NCT02504476|Active Comparator|AMG 581 - Dose 3|
3008750|NCT02504476|Active Comparator|AMG 581 - Dose 4|
3008751|NCT02504476|Placebo Comparator|Placebo - Dose 1|
3008752|NCT02504476|Placebo Comparator|Placebo - Dose 2|
3008753|NCT02504476|Placebo Comparator|Placebo - Dose 3|
3008754|NCT02504476|Placebo Comparator|Placebo - Dose 4|
3008755|NCT02504476|Other|AMG 581/Midazolam - Drug Interaction|
3008756|NCT02504463|Experimental|Samidorphan IV|Samidorphan solution for IV administration
3008757|NCT02504463|Experimental|Samidorphan sublingual|[14c]-Samidorphan for sublingual administration
3008758|NCT02504463|Experimental|Samidorphan oral|[14c]-Samidorphan for oral administration
3008759|NCT02504437|Experimental|pre-conditioned BMMSCs|autologous bone marrow mesenchymal stem cells (BMMSCs) with hypoxia pre-condition and endothelial pre-induction.
3008760|NCT02504437|Active Comparator|BMMSCs|autologous bone marrow mesenchymal stem cells (BMMSCs) without pre-condition.
3008761|NCT02504437|Sham Comparator|Controls|standard therapy without autologous bone marrow mesenchymal stem cells (BMMSCs) infusion.
3008762|NCT02504424|Experimental|AeroForm Tissue Expander|AeroForm Tissue Expansion inflation with carbon dioxide by remote control
3008763|NCT02504411|Experimental|Device Assisted Colonoscopy|"Device assisted colonoscopy (DAC) is a technique of attaching disposable devices like Endocuff or Transparent cap at tip of colonoscope to improve mucosal visualization and stability."
3008764|NCT02504411|Active Comparator|Standard Colonoscopy|Standard colonoscopy is the endoscopic examination of the large bowel and the distal part of the small bowel with a camera on a flexible tube passed through the anus.
3008765|NCT02504398|Experimental|Fast injection|Vaccine injections will be given at a rate of approximately 2-4 ml/sec by the immunizer
3008766|NCT02504398|Active Comparator|Slow injection|Vaccine injections will be given at a rate of approximately 10 ml/sec by the immunizer
3008767|NCT02504385|Experimental|Virtual Reality Timocco|The study group will integrate the use of Timocco in occupational therapy sessions. The session will begin with 15 minutes of spatial activity involving sensory-motor practice, 15 minutes of activity in a virtual environment, and 15 minutes of structured activity at a desk.
3008835|NCT02503917||Cervical cancer patients|Patients receiving radiotherapy for cervical cancer at the Royal Marsden who will receive a planning CT scan and daily CBCT scanning as part of their treatment.
3008836|NCT02503904|Active Comparator|TAD+IVAD|
3008768|NCT02504385|Active Comparator|Conventional OT intervention|The control group will be given conventional occupational therapy without using Timocco. In order to ensure that the therapy sessions in this group have a structure similar to that one used in the study group, each session will include 25 to 30 minutes of spatial sensory-motor activity, followed by 15 to 20 minutes of structured practice at a desk.
3008769|NCT02504372|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year (expected maximum 18 doses).
3008770|NCT02504372|Placebo Comparator|Placebo|Participants receive placebo, IV, every 3 weeks, for one year (expected maximum 18 doses).
3008771|NCT02504359|Experimental|Treatment (BEAM allogeneic transplant, ixazomib)|"BEAM CONDITIONING REGIMEN: Patients receive carmustine on day -6, cytarabine and etoposide on days -5 to -2, and melphalan on day -1.~PERIPHERAL BLOOD STEM CELL TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO on days -2 to at least 6 months with a taper as early as 3 months post-transplant and methotrexate IV on days 1, 3, 6, and 11.~MAINTENANCE THERAPY: Beginning between days 100 and 180 post-transplant, patients receive ixazomib PO on days 1 and 14 or days 1, 8, and 15 if the principal investigator deems it medically important. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity."
3008772|NCT02504346|Experimental|Treatment|Non-randomized trial, all patients receive therapy - singel-arm
3008773|NCT02504333|Active Comparator|AG|nab-Paclitaxel followed by Gemcitabine
3008774|NCT02504333|Experimental|AG-mFOLFOX|nab-Paclitaxel followed by Gemcitabine and FOLFOXm at dose levels selected from the phase I trial
3008775|NCT02504320|Experimental|Treatment Sequence ABDC|Febuxostat XR 80 mg capsule Formulation 1 (F1), orally, once on Day 1 of Period 1 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 2 (F2), orally, once on Day 1 of Period 2 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 4 (F4), orally, once on Day 1 of Period 3 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 3 (F3), orally, once on Day 1 of Period 4 (C).
3008776|NCT02504320|Experimental|Treatment Sequence DACB|Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 1 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1 orally, once on Day 1 of Period 2 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 3 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 4 (B).
3008777|NCT02504320|Experimental|Treatment Sequence CDBA|Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 1 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4 orally, once on Day 1 of Period 2 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 3 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 4 (A).
3008778|NCT02504320|Experimental|Treatment Sequence BCAD|Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 1 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3 orally, once on Day 1 of Period 2 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 3 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 4 (D).
3008779|NCT02504307|Experimental|Inspiron|Sirolimus Eluting Stent Inspiron
3008780|NCT02504307|Active Comparator|Cronus|Bare Metal Stent
3008781|NCT02504294|Other|Epoetin Hospira|Epoetin Hospira Arm
3008782|NCT02504294|Other|Standard of Care|Standard of care arm
3008783|NCT02504281||RM|Women 18-43 years of age who are scheduled for IVF or ICSI with a history of recurrent spontaneous abortion (miscarriage occurred earlier than 22 weeks of gestation for equal or greater than 2 times) in our IVF institute.
3008784|NCT02504281||Control|Normal females who are visiting Shanghai JIAI genetics and IVF institute for IVF/ICSI because of only male factor.
3008785|NCT02504268|Experimental|Combination Therapy: Abatacept + Methotrexate|Abatacept 125 mg subcutaneous injection once per week + Methotrexate at least 15mg per week tablet or capsule orally once per week
3008786|NCT02504268|Active Comparator|Methotrexate treatment|Methotrexate at least 15mg per week tablet or capsule orally
3008787|NCT02504268|Placebo Comparator|Abatacept Placebo|Placebo for Abatacept subcutaneous injection once per week
3008788|NCT02504268|Placebo Comparator|Methotrexate Placebo|Placebo to match Methotrexate capsule orally once per week
3008789|NCT02504255||Patients with Crohn's Disease|patients will have biological samplings (blood, urine and faecal sampling) and will fill questionnaires to assess their stress and adaptation
3008790|NCT02504242|Experimental|Inject BMP|ExcelOS Inject / rhBMP-2
3008791|NCT02504242|Active Comparator|Locally Harvested Bone|Locally Harvested Bone
3008792|NCT02504229|Experimental|Chemotherapy+DC-CIK|Combined treatment group:mononuclear cells were obtained aseptically with blood cell separator composition spheresis 1 day before SOX program chemotherapy, cultured DC-CIK cells. SOX program was acted on Day 2. Cells were cultured 14d,2 times back to the patient.A 21d was a cycle, then evaluated the therapeutic effect after two cycles.
3008793|NCT02504229|Active Comparator|Chemotherapy alone|Chemotherapy: two groups were treated with SOX program,specific drugs:Venoclysis of oxaliplatin 130mg/㎡;Day 1; Tegafur,Gimeracil and Oteracil Porassium Capsules 80mg/㎡/d,two oral/d;Day 1 to 12; 21d as one cycle of treatment, evaluated the therapeutic effect after two cycles.
3008794|NCT02504216|Experimental|Rivaroxaban|Rivaroxaban 2.5 mg orally twice daily (5 mg cumulative daily dose)
3008795|NCT02504216|Placebo Comparator|Placebo|Rivaroxaban-placebo orally twice daily
3008796|NCT02504203|Active Comparator|Intervention: BCG and OPV at home visits|Infants randomised to receive vaccines at home visits shortly after birth will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine (BCG-Denmark 1331 (Statens Serum Institute) or BCG Japan (Japan BCG Laboratory) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG vaccination. For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth.
3008837|NCT02503904|Active Comparator|IVAD|
3008797|NCT02504203|No Intervention|Control: No vaccines at home visits|For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth. No vaccines will be administered at these home visits for children in the control arm.
3008798|NCT02504190||lymphoma patients eligible for TEAM conditioning|Lymphoma Patients who are eligible will be included. Patients will undergo TEAM conditioning regimen followed by autologous haematopoietic stem cells transplantation according to standard practice of the centre and drugs label in France.
3008799|NCT02504177|Experimental|The group of keep medication NOAC|The randomization after scheduling of Ablation at clinic The explanation to stop taking medicine of NOAC 24 hours before the ablation
3008800|NCT02504177|Active Comparator|The group of stop medication NOAC 1 day|The randomization after scheduling of ablation at clinic. The explanation to stop taking medicine of NOAC day of ablation
3008801|NCT02504164|Experimental|No premedication|No premedication before sedation
3008802|NCT02504164|Active Comparator|Midazolam|Premedication with midazolam before sedation
3008803|NCT02504151|Experimental|Order 1|The subject will receive treatment with CBD for four weeks, followed by a two week washout period, followed by four weeks of placebo.
3008804|NCT02504151|Experimental|Order 2|The subject will receive placebo for four weeks, followed by a 2 week washout period, followed by four weeks of treatment with CBD.
3008805|NCT02504138|Experimental|Desflurane balanced anesthesia group|
3008806|NCT02504138|Active Comparator|Propofol total intravenous anesthesia group|
3008807|NCT02504125|Experimental|Receving TXA, Study group|Tranexamic acid, Study group tranexamic acid 1g, intravenous injection, pre-operationally
3008808|NCT02504125|Placebo Comparator|Normal saline, Control group|Not receiving tranexamic acid, Control group Normal saline 100mL, intravenous injection, pre-operationally
3008809|NCT02504112||X-Ray PSI Group|Male or female patients, over 18 years old and with indication of total knee arthroplasty
3008810|NCT02504099|Experimental|OBV/PTV/r ± DSV ± RBV for 12 or 24 weeks|OBV/PTV/r (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily]) with or without dasabuvir (250 mg twice daily) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on HCV genotype/subtype and presence of cirrhosis.
3008811|NCT02504086|Experimental|Online Support|3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
3008812|NCT02504073||PT's working in stroke in NW-Switzerland|"54 Physiotherapists (PT's) working in north-west Switzerland (at Bruderholzspital, RehaB Basel, Klinik Tschugg, Reha Rheinfelden, RehaClinic Zurzach) are asked to analyse videos of 6 hemiplegic patients when walking. They are asked to write down their main observations, the major problem and hypotheses about how this major problem is produced.~There is no intervention."
3008813|NCT02504060|Placebo Comparator|Starch capsule|During the 12- weeks treatment phase of the study, the daily dose of 3 tablets will be taken 30 minutes after breakfast, lunch and supper.
3008814|NCT02504060|Experimental|N-acetyl-D-glucosamine|During the 12- weeks treatment phase of the study, the daily dose of 100mg*3 (3 tablets) will be taken 30 minutes after breakfast, lunch and supper.
3008815|NCT02504047|Experimental|T-Cell replete haplo-transplant|Infusion of peripheral blood stem cells from a haploidentical related donor following myeloablative conditioning. Cyclophosphamide, mycophenolate mofetil and tacrolimus will be given for GVHD prophylaxis.
3008816|NCT02504034|Experimental|Transhepatic portosystemic shunt|Patients with cavernous transformation of portal vein undergo transhepatic portalsystemic shunt and other interventional radiology treatment
3008817|NCT02504021|Experimental|Family Consultation Condition|The family consultation will be one, 1-hour session conducted by trained, master's level therapists. The goals of the meetings are: a) Review patient and family understanding of events that caused the hospital admission; b) increase family awareness of the level of cognitive impairment that the patient is experiencing; c) discuss ways the family can get involved and help the patient with their medication and dialysis adherence; d) use motivational interviewing techniques as needed. This will be provided in addition to the usual care that inpatients receive in this unit.
3008818|NCT02504021|No Intervention|Treatment as Usual Control Condition|Standard of care for the nephrology unit.
3008819|NCT02504008|Experimental|AXS-02 (oral zoledronate)|Administered orally in the morning on Days 1, 8, 15, 22, 29, and 36
3008820|NCT02504008|Placebo Comparator|Placebo|Administered orally in the morning on Day 1, 8, 15, 22, 29, and 36
3008821|NCT02503995|Active Comparator|No intervention|Participants not undertaking any additional exercise
3008822|NCT02503995|Experimental|Water-based exercise group|Participants assigned to a water-based exercise group
3008823|NCT02503995|Experimental|Land-based exercise group|Participants assigned to a land-based exercise group
3008824|NCT02503982|Experimental|Solid Organ Transplanted children|Intervention: treatment with prophylactic oral valganciclovir with a fixed dose of 17 mg/kg once daily for prophylaxis, and stratified dose reductions for impaired renal function. Max dose was 900 mg.
3008825|NCT02503969||Screened|Those who received an adequate screen for colorectal cancer.
3008826|NCT02503969||Not Screened|Those who received an adequate screen for colorectal cancer.
3008827|NCT02503956|Experimental|Treated group|Patients treated with perforated punctal plugs
3008828|NCT02503956|Active Comparator|Comparison group|Comparison group treated with standard of care - Lacrimal intubation with Crawford lacrimal tube
3008829|NCT02503943|Experimental|"Liraglutide and Mitiglinide"|"Liraglutide(1.2mg/d) and Mitiglinide(50mg, 3/d)"
3008830|NCT02503943|Active Comparator|"Metformin and Mitiglinide"|"Metformin(500mg, 3/d) and Mitiglinide(50mg, 3/d)"
3008831|NCT02503943|Active Comparator|"Mitiglinide"|"Mitiglinide(50mg, 3/d)"
3008832|NCT02503930|Experimental|Active tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
3008833|NCT02503930|Sham Comparator|Sham tDCS|The Sham tDCS - an inactive stimulation.
3008834|NCT02503917||Healthy volunteers|Healthy female adult volunteers
3008838|NCT02503891|Experimental|Polymer on Ceramic|MP-1 Polymer on Ceramic articulation system
3008839|NCT02503865|Active Comparator|Conventional Patient group|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin
3008840|NCT02503865|Experimental|"Analimentary detoxication Weight loss"|Vegetables and salt diet
3008841|NCT02503865|No Intervention|Healthy people|64 healthy people
3008842|NCT02503852|Experimental|Fat + High Dose ADRC|Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 1,000,000 ADRC prepared with the Celution System per square centimeter of scalp.
3008843|NCT02503852|Experimental|Fat + Low Dose ADRC|Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 500,000 ADRC prepared with the Celution System per square centimeter of scalp.
3008844|NCT02503852|Experimental|Fat Alone|Micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System per square centimeter of scalp.
3008845|NCT02503852|Sham Comparator|No Fat Control|Micro-liposuction followed by subcutaneous scalp injection of normal saline per square centimeter of scalp.
3008846|NCT02503839|Experimental|Arm#1|"arm#1 (n=10) receiving etoricoxib from inclusion day 0 and in 140 days.~Step-wise inclusion starting with arm#1,arm#2 and arm#3 (first group) randomized (2:2:1) and if safety data are satisfactory proceeding with arm #4 and the rest of arm#3 randomized (2:2:1)."
3008847|NCT02503839|Experimental|Arm#2|arm#2 (n=10) receiving H56:IC31 vaccine at day 84 and 140 and no etoricoxib.
3008848|NCT02503839|No Intervention|Arm#3|arm#3 (n=10), the first group (n=5) serving as control to arm#1 and arm#2, the next group (n=5) serving as control to arm#4.
3008849|NCT02503839|Experimental|Arm#4|arm#4 (n=10) receiving etoricoxib from inclusion day 0 and in 140 days and H56:IC31 vaccine at day 84 and 140.
3008850|NCT02503826|Experimental|1.5 SF|Sufentanil,1.5mcg/kg
3008851|NCT02503826|Experimental|2.0 SF|Sufentanil, 2.0mcg/kg
3008852|NCT02503826|Experimental|2.5 SF|Sufentanil, 2.5mcg/kg
3008853|NCT02503813|Experimental|Experimental|Venous blood gas will be obtained at the same time points as arterial blood gas in the apnea challenge test.
3008854|NCT02503800||subjects undergoing venom immunotherapy|The study group will include all the subjects receiving routine venom immunotherapy at the Meir Medical Center Allergy Clinic.
3008855|NCT02503787|Other|Open label treatment|Spinal Cord Stimulation (SCS)
3008856|NCT02503774|Experimental|Monotherapy|MEDI9447 (oleclumab) only
3008857|NCT02503774|Experimental|Combination|MEDI9447 (oleclumab) and MEDI4736 (durvalumab)
3008858|NCT02503761|Active Comparator|Infusion arm|Infants will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection. Each dose will be infused over four hours.
3008859|NCT02503761|Active Comparator|Bolus group|Infants will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection. Each dose will be infused over thirty minutes.
3008860|NCT02503748|Experimental|Intervention|Online Tutorial
3008861|NCT02503735|Other|12 weeks treatment with Sofosbuvir/Ledipasvir (400mg/90mg)|
3008862|NCT02503722|Experimental|Treatment (sapanisertib, osimertinib)|Patients receive sapanisertib PO QD on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 (day 1 is omitted in course 1). Patients also receive osimertinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3008863|NCT02503709|Experimental|Treatment (onalespib, CDKI AT7519)|Patients receive onalespib IV over 1 hour on days 1 and 4 (course 0 only). Patients then receive onalespib IV over 1 hour and CDKI AT7519 IV over 1 hour on days 1, 4, 8, and 11 (course 1 and subsequent courses thereafter). Courses repeat every 21 days (7 days for course 0 only) in the absence of disease progression or unacceptable toxicity.
3008864|NCT02503696||IBD|Subjects will be men and women, 18-84 years of age, inclusive, who have been diagnosed with IBD. Each with a screening colonoscopy resulting in normal findings.
3008865|NCT02503683|Active Comparator|ALN-AAT|
3008866|NCT02503683|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3008867|NCT02503670|Other|HealthyDads.ca web-based program|An on-line self-help psychoeducational website tailored to new dads. Psychoeducational learning modules and tools, including a 6 week physical activity challenge..
3008868|NCT02503670|Other|Control group|No access to the intervention. Will complete the same questionnaires as the Healthydads.ca group over the study period.
3008869|NCT02503657|Placebo Comparator|Double-Blind Treatment|"Subjects who complete all of the screening assessments and meet all inclusion/exclusion criteria will be started on MN-001 (tipelukast) 750 mg or matching placebo bid. Subjects will return to the clinic on Treatment Day 1 to receive their first dose of study medication. Subsequently, subjects will return to the clinic on a regular basis for 26 weeks.~During the Treatment Phase, safety and efficacy parameters will be assessed and concomitant medications will be documented. The safety and tolerability of MN-001 will be evaluated by an Independent Safety Monitor during this phase."
3008870|NCT02503657|Other|Open-Label Extension|Upon completion of the Double-blind Treatment Phase, subjects who were taking placebo, will participate in the open-label extension (OLE) phase for an additional 6 months. Subjects randomized to the MN-001 (tipelukast) group will continue the study drug for additional 6 months.
3008871|NCT02503644|Active Comparator|IVA337 800mg|Patients receive twice daily 400mg IVA337.
3008872|NCT02503644|Active Comparator|IVA337 1200mg|Patients receive twice daily 600mg IVA337.
3008873|NCT02503644|Placebo Comparator|Placebo|Patients receive twice daily placebo.
3008874|NCT02503631||Colorectal cancer patients|Subjects will be men and women, 40-90 years of age, inclusive, each with a colonoscopic biopsy-based diagnosis of colorectal cancer (CRC) and/or a pre-malignant colorectal lesion with large enough residual lesion to require subsequent surgical excision or complex colonoscopic polypectomy.
3008875|NCT02503618||HIV-negative YBMSM|Subjects are young black men who have sex with men in Atlanta, Georgia and are HIV-negative
3008876|NCT02503618||HIV-positive YBMSM|Subjects are young black men who have sex with men in Atlanta, Georgia and are HIV-positive
3008902|NCT02503423|Experimental|Phase 2 - Cohort 3|Treatment with ASTX660 for progressive or relapsed peripheral T-cell lymphoma (PTCL).
3008903|NCT02503423|Experimental|Phase 2 - Cohort 4|Treatment with ASTX660 for relapsed or refractory cutaneous T-cell lymphoma (CTCL).
3042952|NCT02273856||Relapsed/refractory patients with iNHL|
3008877|NCT02503605|Active Comparator|Biosimilar recombinant FSH|Under current practice, 65 participants will be stimulated with 150 international units (IU)/day biosimilar recombinant FSH, .Daily doses of 0.25 miligrams gonadotropin-releasing hormone (GnRH) antagonist will start on day 6 of stimulation. From this day may also vary the dose of recombinant FSH biosimilar according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.1 miligram GnRH agonist will be administered for triggering final oocyte maturation
3008878|NCT02503605|Active Comparator|Urinary FSH|Under current practice, 65 participants will be stimulated with 150 IU/day of urinary FSH. Daily doses of 0.25 miligrams gonadotropin-releasing hormone (GnRH) antagonist will start on day 6 of stimulation From this day may also vary the dose of urinary FSH according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.1 miligram GnRH agonist will be administered for triggering final oocyte maturation
3008879|NCT02503592|Active Comparator|Cochlear Implant group - Vestibular testing|Adult patients who have been implanted with a Med-El Cochlear implant device within the last 3 months who completed pre-op vestibular testing as standard of care. These subjects will undergo a series of post-op vestibular testing, at the 3 month and 12 month follow up visits
3008880|NCT02503592|No Intervention|Control Group - existing historical vestibular data|This group will consist of existing historical vestibular testing data only. No subjects will be enrolled on this arm.
3008881|NCT02503579|Experimental|physical training|Participant receive a submaximal (60% -75% maximal oxygen uptake) physical activity training of 30 minutes during 8 weeks, 2 times a week. Individual heart rates will be monitored during the training.
3008882|NCT02503579|No Intervention|control|"1 training at the beginning of the study~1 training at the end of the study"
3008883|NCT02503566|Experimental|All patients|Optical coherence tomography will be performed in all patients
3008884|NCT02503553|Experimental|Decision aid|"Option grid for cerebral aneurysm treatment~Patients will receive an option grid during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded."
3008885|NCT02503553|Placebo Comparator|Control|Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
3008886|NCT02503540|Other|Aflibercept|Monthly aflibercept for 6 months and then every other month for 6 months.
3008887|NCT02503527|Other|Diben 1.5 kcal HP|Diben 1.5 kcal HP, Food for Special Medical Purposes (diabetes-specific tube feed)
3008888|NCT02503527|Other|Fresubin HP Energy Fibre (1.5 kcal)|Fresubin HP Energy Fibre (1.5 kcal), Food for Special Medical Purposes (standard tube feed)
3008889|NCT02503501|Experimental|Insulin Glulisine|Insulin Glulisine 20 IU (0.1ml/10 units in each nostril) per intranasal dose, 2 times per day for 6 months
3008890|NCT02503501|Placebo Comparator|Placebo|Saline 20 IU (0.1 ml in each nostril) per intranasal dose, 2 times per day for 6 months
3008891|NCT02503488|Experimental|Program Group|The treatment arm will consist of 20 randomly selected participants who will receive Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET) for their traumatic symptomology, aggression, and depression. FORNET consists of a guided exposure of the participant's traumatic experiences in chronological order and integrating them into a coherent biographical memory.The intervention addresses the participant's positive, negative, and violent memories of events that have taken place during their lifetime, and also provides participants an opportunity to asses their current situation and future plans. FORNET can be completed in six sessions and each session lasts 90 minutes on average.
3008892|NCT02503488|Active Comparator|Treatment As Usual (TAU)|Participants in the TAU group will receive group and individual psycho-social support from trained peer-support workers, with 10 sessions occurring throughout the course of the intervention for each participant. In addition, there will be sensitisation trainings as well as mentoring for establishing greater financial independence. Last, TAU will include one-day events promoting social cohesion and peace.
3008893|NCT02503475|Other|Project 1- Real-Time fMRI|"This arm investigates Real-Time fMRI within 4 groups:~Attention Regulation (AR) Group- Experimental Cognitive Regulation (CR) Group- Experimental Sham Group- Sham Comparator Free Strategy Group- Active Comparator"
3008894|NCT02503475|Experimental|Project 2 - CBT/MBSR|"This arm investigates 2 experimental groups:~Cognitive Behavioral Therapy (CBT) Mindfulness Based Stress Reduction (MBSR)"
3008895|NCT02503475|Other|Project 3- Acupuncture|"This arm investigates Acupuncture within 2 groups:~Verum- Experimental Sham- Sham comparator"
3008896|NCT02503462|Experimental|darunavir/ritonavir vs cobicistat|All HIV infected patients will be treated with a darunavir/ritonavir (800/100 mg) once daily containing regimen. Darunavir/ritonavir concentrations will be measured simultaneously in CSF and plasma after 1 month of treatment. The treatment will be switched to darunavir/cobicistat (800/150 mg) once daily and darunavir/cobicistat levels will be measured in CSF and plasma after 1 month of treatment.
3008897|NCT02503423|Experimental|Phase 1 - Part 1|Dose-escalation stage to identify the MTD and the RP2D, defined as either the MTD or a dose below the MTD that the Data and Safety Review Committee (DSRC) agree shows adequate pharmacological evidence of target engagement and/or clinical activity. Subjects will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, [7 days on/ 7 days off] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RP2D is determined.
3008898|NCT02503423|Experimental|Phase 1 - Part 2|Dose-expansion stage to confirm tolerability of ASTX660 at the RP2D using the every-other-week daily dosing regimen. Up to a total of 12 subjects (including the 3 or 6 subjects treated at the RP2D in Part 1) will be treated at the RP2D.
3008899|NCT02503423|Experimental|Phase 1 - Part 3 (optional)|The purpose of the optional Part 3 is to allow for exploration of an alternative dosing regimen of ASTX660 based on emerging safety, PK, and PD data from Parts 1 and 2 (using the original every-other-week dosing regimen), with agreement of the DSRC. If Part 3 is conducted, the plan is to enroll up to 18 evaluable subjects in 1 or more cohorts using a standard 3+3 study design.
3008900|NCT02503423|Experimental|Phase 2 - Cohort 1|Treatment with ASTX660 for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) not responsive or relapsed after standard therapy.
3008901|NCT02503423|Experimental|Phase 2 - Cohort 2|Treatment with ASTX660 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
3011053|NCT02489188||knee osteoarthritis|patients with knee osteoarthritis scheduled for arthroplasty
3008904|NCT02503423|Experimental|Phase 2 - Cohort 5|Treatment with ASTX660 for other tumor types that are characterized by a molecular feature that may confer sensitivity to ASTX660 (eg, oncogenic activation of the NF-κB pathway or documented amplification of the gene loci encoding c-IAP1 or c-IAP2), pending confirmation in writing by the Astex medical monitor.
3008905|NCT02503423|Experimental|Phase 2 - Cohort 6|Treatment with ASTX660 for cervical carcinoma not responsive or relapsed after standard therapy.
3008906|NCT02503410|Active Comparator|Usual Care group|physical therapy (as prescribed during 8 to 12 weeks) and home exercises (at least 2x/week)
3008907|NCT02503410|Experimental|Interactive Home-Based System group|physical therapy (as prescribed during 8 to 12 weeks) and interactive exercises program at home with the Valedo® System (Hocoma AG) (at least 2x/week)
3008908|NCT02503397||Latent iron deficiency|Infants with cord serum ferritin levels ≤ 75 ng/mL
3008909|NCT02503397||Normal iron status|Infants with cord serum ferritin levels > 75 ng/mL.
3008910|NCT02503371||Women under IVF stimulation at the begining and end|Coagulation parameters will be measured for all parturients at the beginning and conclusion of an IVF simulation cycle with the use of thromboelastogram
3008911|NCT02503358|Experimental|Arm I (continuous selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-21 and paclitaxel IV over 30 minutes on days 1 and 8.
3008912|NCT02503358|Experimental|Arm II (intermittent selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-5, 8-12, and 15-19 and paclitaxel as in Arm I.
3008913|NCT02503358|Experimental|Arm III (pulsatile selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-3, 8-10, and 15-17 and paclitaxel as in Arm I.
3008914|NCT02503345|Placebo Comparator|Placebo|Placebo capsules (1, 2 or 5) PO TID
3008915|NCT02503345|Experimental|ALLN-177 low dose|ALLN-177 1,500 units/meal PO TID
3008916|NCT02503345|Experimental|ALLN-177 mid dose|ALLN-177 3,000 units/meal PO TID
3008917|NCT02503345|Experimental|ALLN-177 high dose|ALLN-177 7,500 units/meal PO TID
3008918|NCT02503332|Experimental|APL-2 15 mg/100 µL Monthly for 12 months|A single dose of 15 mg APL-2/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every month for 12 consecutive months.
3008919|NCT02503332|Experimental|APL-2 15 mg/100 µL EOM for 12 months|A single dose of 15 mg APL-2/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injections every other month (EOM) for 12 consecutive months.
3008920|NCT02503332|Sham Comparator|Sham Monthly for 12 months|Subjects will receive a Sham procedure every month for 12 consecutive months.
3008921|NCT02503332|Sham Comparator|Sham EOM for 12 months|Subjects will receive a Sham procedure every other month (EOM) for 12 consecutive months.
3008922|NCT02503319|Experimental|arm A|2 vials ( =1 gram) of Tranexamic Acid oral administered within 5 minutes from the delivery (third stage after labor)
3008923|NCT02503319|Experimental|arm B|2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery(third stage after labor)
3008924|NCT02503319|Active Comparator|arm C|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
3008925|NCT02503306|Experimental|Avanafil dose 1|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
3008926|NCT02503306|Experimental|Avanafil dose 2|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
3008927|NCT02503306|Placebo Comparator|Placebo|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
3008928|NCT02503293|Other|Chrono Super PID then Generic Syringe - Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Chrono Super PID pump and then Generic syringe"
3008929|NCT02503293|Other|Generic Syringe then Chrono Super PID - Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Generic syringe and then Chrono Super PID pump."
3008930|NCT02503280|Experimental|Group A - Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10^8 (200 million) hMSCs. The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
3008931|NCT02503280|Experimental|Group B - Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10^8 (199 million) hMSCs and 1 million C-Kit hCSCs.The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
3008932|NCT02503280|Placebo Comparator|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline [PBS] and 1% human serum albumin [HSA]).The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
3008933|NCT02503267||patients with congenital heart disease|patients with congenital heart disease
3008934|NCT02503254|Experimental|CHTP 1.0|Ad libitum use of the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) for 5 days in confinement
3008935|NCT02503254|Active Comparator|Conventional cigarette (CC)|Ad libitum use of subject's own preferred brand of CC for 5 days in confinement
3008936|NCT02503241|Experimental|PEEP_Titration_INCREMENTAL|"The investigators will compare 3 levels of PEEP (BASELINE versus PEEP INCREMENTAL versus PEEP DECREMENTAL). Baseline PEEP is based in the standard of care PEEP used in the participant units. PEEP incremental value is based in transpulmonary pressure.~Intervention : PEEP INCREMENTAL"
3008937|NCT02503241|Experimental|PEEP_Titration_DECREMENTAL|"The investigators will compare 3 levels of PEEP (BASELINE versus PEEP INCREMENTAL versus PEEP DECREMENTAL). Baseline PEEP is based in the standard of care PEEP used in the participant units. PEEP decremental value is based in lung recruitment maneuver followed by a best compliance curve during PEEP decrements.~Intervention :PEEP DECREMENTAL"
3009021|NCT02502708|Experimental|Group 3b|"Indoximod, in combination with up-front conformal radiation therapy, for pediatric patients with newly diagnosed treatment-naive diffuse intrinsic pontine glioma (DIPG).~Indoximod will be administered at the RP2D of 19.2 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m^2 x 5 days"
3008938|NCT02503228|Other|Receiving MOPS-Preserved Cartilage|"The group will be receiving a cartilage transplant as standard of care. The only difference between the patients participating in this study and non-study participants will be that the cartilage transplant that study participants receive will be preserved in the MOPS instead of the standard media.~The preservation process will be performed by the Musculoskeletal Transplant Foundation. Once the cartilage is received by the Missouri Orthopaedic Institute, it and the study participant will be treated as though they are preserved in the standard media and a non-study participant, respectively."
3008939|NCT02503215|Experimental|Compression Stockings|Patients will wear graduated lower limb compression stockings for a week. The investigators will evaluate if such procedure will cause better sleep performance
3008940|NCT02503202|Experimental|V920 Consistency Lot A|Single 1.0 mL intramuscular injection on Day 1
3008941|NCT02503202|Experimental|V920 Consistency Lot B|Single 1.0 mL intramuscular injection on Day 1
3008942|NCT02503202|Experimental|V920 Consistency Lot C|Single 1.0 mL intramuscular injection on Day 1
3008943|NCT02503202|Experimental|V920 High Dose Lot|Single 1.0 mL intramuscular injection on Day 1
3008944|NCT02503202|Placebo Comparator|Placebo to V920|Single 1.0 mL intramuscular injection on Day 1
3008945|NCT02503189|Experimental|KCT-0809|
3008946|NCT02503189|Placebo Comparator|Placebo|
3008947|NCT02503176|Experimental|KCT-0809|
3008948|NCT02503163|Experimental|KCT-0809|
3008949|NCT02503150|Experimental|APDC + Chemotherapy|Patients in Arm APDC + Chemotherapy will receive APDC combined with chemotherapy.
3008950|NCT02503150|Active Comparator|Chemotherapy|Patients in Arm Chemotherapy will receive chemotherapy only.
3008951|NCT02503137|Experimental|Experimental Arm 1|Topical SM04554 0.15% solution, once daily for approximately 90 days
3008952|NCT02503137|Experimental|Experimental Arm 2|Topical SM04554 0.25% solution, once daily for approximately 90 days
3008953|NCT02503137|Placebo Comparator|Vehicle|Topical vehicle solution, once daily for approximately 90 days
3008954|NCT02503124|Experimental|Chronobiological intervention|Single night's wake therapy followed by bright light therapy for a week as add-on treatment to treatment as usual.
3008955|NCT02503124|Active Comparator|Control|Treatment as usual including a private educational meeting in sleep hygiene.
3008956|NCT02503111|Experimental|Ablative therapy|Ablative therapy involving electrocautery (EC) will occur for participants with AIN-2 and AIN-3. The Hyfrecator ® 2000 Electrosurgical System will be used for EC therapy.
3008957|NCT02503111|Active Comparator|Active Surveillance|The control arm includes active surveillance with observation alone; no treatment in AIN-2 and -3.
3008958|NCT02503098|Experimental|Recovery Record adaptive smartphone application (RR-A)|Participants will have access to all Recovery Record standard functions and will additionally receive tailored, algorithm-generated content targeting cognitive distortions.
3008959|NCT02503098|Active Comparator|Recovery Record standard smartphone application (RR-S)|Participants will have access to all Recovery Record standard functions, including meal monitoring, motivational enhancement, social support, and coping skill strategies.
3008960|NCT02503085|Experimental|Nurofen for Children® (fasted)|Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition
3008961|NCT02503085|Experimental|Nurofen for Children® (fed)|Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition
3008962|NCT02503085|Active Comparator|Algifor Dolo Junior® (fasted)|Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition
3008963|NCT02503085|Active Comparator|Algifor Dolo Junior® (fed)|Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition
3008964|NCT02503072|Active Comparator|Prizes conditional on adherence|Participants in this group are eligible for a prize drawing if they come on their scheduled clinic day. They receive the intervention 'Behavioral: Small lottery prizes based on adherence'.
3008965|NCT02503072|Active Comparator|Prizes conditional on clinic visits|Participants in this group are eligible for a prize drawing if they show 95% adherence or higher based on their MEMS-cap measured adherence. They receive the intervention 'Behavioral: Small lottery prizes based on timely clinic visits'.
3008966|NCT02503046||Arthritis with Periodontitis|"Patients aged between 30-65 years with 6 positive diagnostic criteria for Rhematoid Arthritis. Patients should have Clinical attachment loss >6mm, and Probing pocket depth>5mm in more than 6 teeth to satisfy criteria for periodontitis.~5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA) Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels."
3008967|NCT02503046||Periodontitis group|"Patients aged between 30-65 years with Periodontal findings being presence of atleast 20 teeth in the mouth .More than 6 teeth with Clinical attachment loss >6mm and Probing pocket depth>5mm to satisfy criteria for periodontitis. 5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA).~Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels.."
3008968|NCT02503046||Healthy Subjects|"Subjects aged between 30-65 years with no systemic diseases and periodontitis. 5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA).~Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels.."
3008969|NCT02503033|Experimental|HMPL-523|"Oral administration, at a dose of 100, 200, 400, 600, 800 and 1000mg once daily or 300mg and 400mg twice daily at Dose-escalation stage.~At the Dose-expansion stage, HMPL-523 will be dosed daily and the dose level will be based on the result from the Dose-escalation stage."
3008970|NCT02503020|Active Comparator|Group A|Preterm infants formula A Pretarm infants were fed on formula with Arachidonic acid (0.6%) and Docosahexaenoic acid (0.3%)
3008971|NCT02503020|Active Comparator|Group B|Preterm infants formula B Pretarm infants were fed on formula with Arachidonic acid (0.3%) and Docosahexaenoic acid (0.3%)
3008972|NCT02503007|Placebo Comparator|Placebo|A placebo similar in composition and appearance to the experimental treatment.
3008973|NCT02503007|Experimental|HMB-FA|Active treatment consisting of 3 g of HMB-FA per day.
3008974|NCT02502994|Other|Intervention|Single arm of the castration resistant prostate cancer
3009059|NCT02502435||Matched Healthy Controls|
3009060|NCT02502422|Other|Classic laryngeal mask airway|single arm
3008975|NCT02502981|Experimental|CKD stage 2 & 3|"Patients with CKD stage 2 & 3 (eGFR 30-89ml/min/1.73m2) will be randomly assigned to receive either spironolactone or chlortalidone in a PROBE design.~Subjects will undergo cardiac MRI, carotid femoral pulse wave velocity, 24 hour ambulatory blood pressure monitoring, blood tests for renal function and spot urine analysis for proteinuria (albumin:creatinine ratio) at baseline and after 40 weeks of allocated treatment. Additional blood tests for renal function and potassium level will be assessed at week 1,2,4,8 and 20."
3008976|NCT02502968|Experimental|Cytarabine & BL8040|"Subjects ≥60 years: cytarabine 1g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 2 cycles and BL-8040 (1.25 mg/kg) subcutaneously on days 1 to 5 of each cycle~Subjects <60 years: cytarabine 3g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 3 cycles and BL-8040 (1.25 mg/kg) subcutaneously on days 1 to 5 of each cycle"
3008977|NCT02502968|Active Comparator|Cytarabine & Placebo|"Subjects ≥60 years: cytarabine 1g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 2 cycles and Placebo (for BL-8040) subcutaneously on days 1 to 5 of each cycle~Subjects <60 years: cytarabine 3g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 3 cycles and Placebo (for BL-8040) subcutaneously on days 1 to 5 of each cycle"
3008978|NCT02502942|Experimental|Untreated OSA Muscle Exercise Group|Patients who were previously diagnosed of obstructive sleep apnea (OSA) with apnea hypopnea index (AHI) > 10 events/hr and have previously failed or refused PAP therapy. In this group, patients will learn and practice upper airway muscle exercise for six weeks.
3008979|NCT02502942|Experimental|PAP Therapy Muscle Exercise Group|OSA patients who are currently treated with PAP for their OSA (with AHI of previous sleep study > 10 events/hr). In this group, patients will learn and practice upper airway muscle exercise for six weeks.
3008980|NCT02502942|Experimental|Oral Appliance Muscle Exercise Group|OSA patients who are currently treated with an oral appliance with residual AHI > 10 events/hr. In this group, patients will learn and practice upper airway muscle exercise for six weeks.
3008981|NCT02502942|Active Comparator|Normal Control Sham Exercise Group|Patients of untreated OSA group, PAP therapy group, and oral appliance group are randomized to upper airway muscle exercise versus sham exercise.
3008982|NCT02502929|Active Comparator|Enhanced standard care|Participants in this arm will receive referrals for medical and social services as indicated.
3008983|NCT02502929|Experimental|Lifestyle|"Participants in this arm will receive lifestyle modification from community health workers using the manualized lifestyle intervention called Eat, Walk, Sleep. They will receive individual home visits, health activity group sessions, and supportive phone calls."
3008984|NCT02502929|Experimental|Lifestyle plus Medication Therapy Management|Participants in this arm will receive everything in the Lifestyle arm, plus Medication Therapy Management (MTM). Participants will receive MTM from a pharmacist via telemedicine with the assistance of a community health worker.
3008985|NCT02502916||Preterm infant|Preterm infants born from October 2009 to June 2010 at a gestational age of less than 32 weeks or with birth weight of less than 1,200 g
3008986|NCT02502903|Placebo Comparator|Part A|SAD in NHVs, 7 cohorts, TNT009 by IV infusion (0.3,1, 3, 10, 30, 60, or 100 mg/kg) or placebo.
3008987|NCT02502903|Placebo Comparator|Part B|MAD in NHVs, 4 weekly IV doses of TNT009 (30 or 60mg/kg) or placebo
3008988|NCT02502903|Experimental|Part C|multiple dose in a single cohort of patients with various complement-mediated disorders. All patients in Part C will receive a single IV test dose of 10 mg/kg followed by 4 weekly doses of 60 mg/kg.
3008989|NCT02502877|Other|Midazolam Group|"In the midazolam group the investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after."
3008990|NCT02502877|Active Comparator|Propofol group|"In the propofol group the investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery."
3008991|NCT02502864|Experimental|Standard of Care + Surveys|Standard of Care Docetaxel and Cyclophosphamide (TC) Chemotherapy + Surveys. TC Regimen with Function Assessment of Cancer Therapy (FACT) Surveys. All participants will receive TC for cycle 1 with subsequent cycles repeated every 3 weeks for a total of 4 cycles. All initial dosing will be based on actual body weight and height. Participants will receive up to 4 doses of chemotherapy. Following their 4th dose of chemotherapy, or the last dose of chemotherapy in which blood level monitoring was performed, participants will be assessed for side effects from the chemotherapy and complete their final written 53 question survey about their quality of life.
3008992|NCT02502851|Active Comparator|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy followed by implantation of the ORSIRO sirolimus-eluting stent
3008993|NCT02502851|Active Comparator|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloon followed by implantation of the ORSIRO sirolimus-eluting stent
3008994|NCT02502838||Prolapse surgery without TVT|Patients who plan to undergo prolapse repair alone
3008995|NCT02502838||Prolapse surgery with TVT|Patients who plan to undergo prolapse repair with an additional TVT procedure
3008996|NCT02502825|Experimental|asthma|methacholine(0.031-16mg/ml) bronchial provocation tests. this is a crossover,normal-control study. nebulized with Wright nebulizer for 2 minutes with an output of 0.13ml/min.
3008997|NCT02502825|Experimental|normal controls|methacholine(0.031-16mg/ml) bronchial provocation tests. this is a crossover,normal-control study. nebulized with Devilbiss646 nebulizer for 2 minutes with an output of 0.13ml/min
3008998|NCT02502812|Experimental|Treatment Sequence A (Innovator) - B (Clop F1) - C (Clop F2)|Subjects will receive a single 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 1, 75 mg tablet Clop F1 (Treatment B) in treatment period 2, and 75 mg tablet Clop F2 (Treatment C) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
3008999|NCT02502812|Experimental|Treatment Sequence A(Innovator) -C(Clop F2)-B (Clop F1)|Subjects will receive a single 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 1, 75 mg tablet Clop F2 (Treatment C) in treatment period 2, and 75 mg tablet Clop F1 (Treatment B) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
3009061|NCT02502396||Chart Review - Patterns of Rivaroxaban Usage|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF).
3009062|NCT02502383|Experimental|ACTION PAC|
3009000|NCT02502812|Experimental|Treatment Sequence B (Clop F1) - A (Innovator) - C (Clop F2)|Subjects will receive a single 75 mg tablet Clop F1 (Treatment B) in treatment period 1, 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 2, and 75 mg tablet Clop F2 (Treatment C) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
3009001|NCT02502812|Experimental|Treatment Sequence B (Clop F1) - C (Clop F2) - A (Innovator)|Subjects will receive a single 75 mg tablet Clop F1 (Treatment B) in treatment period 1, 75 mg tablet Clop F2 (Treatment C) in treatment period 2, and 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
3009002|NCT02502812|Experimental|Treatment Sequence C (Clop F2) - A (Innovator) - B (Clop F1)|Subjects will receive a single 75 mg tablet Clop F2 (Treatment C) in treatment period 1, 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 2, and 75 mg tablet Clop F1 (Treatment B) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
3009003|NCT02502812|Experimental|Treatment Sequence C (Clop F2) - B (Clop F1) - A (Innovator)|Subjects will receive a single 75 mg tablet Clop F2 (Treatment C) in treatment period 1, 75 mg tablet Clop F1 (Treatment B) in treatment period 2, and 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
3009004|NCT02502799|Active Comparator|Continued Monitoring and Assessment|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. Participants randomized to the continued monitoring and assessment arm will receive no additional intervention. Primary and secondary outcomes will be monitored.
3009005|NCT02502799|Active Comparator|PT with ACBT|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. For participants randomized to the PT with ACBT arm, parents will participate in behavioral parent training (PT) and adolescents will participate in cognitive behavioral therapy to reduce substance use (CBT).
3009006|NCT02502799|Active Comparator|PT with ACBT and Methylphenidate|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. For participants randomized to the PT with ACBT and Methylphenidate arm, parents will participate in behavioral parent training (PT) and adolescents will participate in cognitive behavioral therapy to reduce substance use (ACBT). Adolescents will also receive methylphenidate.
3009007|NCT02502786|Experimental|humanized anti-GD2 antibody, hu3F8, when combined with GM-CSF|One cycle consists of treatment with hu3F8 at a dose of 2.4mg/kg/dose for 3 days (day 1, 3, and 5) in the presence of subcutaneous (sc) GM-CSF (day -4 through 5). These 3 doses of hu3F8 and 10 days of GM-CSF constitute a treatment cycle. Cycles are repeated at ~2-4 week intervals between first days of hu3F8, through 5 cycles. A maximum of 5 cycles will be administered on protocol.
3009008|NCT02502773|Experimental|crystalloid group|The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery
3009009|NCT02502773|Experimental|colloid group|The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery
3009010|NCT02502760|Experimental|Prehabilitation|"Immediately after randomization and until surgery, patients in this arm will:~- Receive a personalized physical exercise program~- Receive nutritional counselling with Whey protein isolate powder~- Receive relaxation techniques"
3009011|NCT02502760|Active Comparator|Rehabilitation|Patients in this arm will receive the same personalized physical exercise program, nutritional intervention and relaxation techniques as patients in the other arm but to be started after surgery.
3009012|NCT02502747|Experimental|G-CSF and Myocardial Contrast Echocardiography (MCE)|subcutaneous Granulocyte - Colony Stimulating Factor ( on top of optimal standard of care) and Myocardial Contrast Echocardiography with intravenous infusion of sulphur hexafluoride.
3009013|NCT02502747|Active Comparator|Placebo and Myocardial Contrast Echocardiography (MCE)|Patients will be receive optimal standard of care and Myocardial Contrast Echocardiography with intravenous infusion of sulphur hexafluoride.
3009014|NCT02502734|Experimental|Sequence 1: Fluticasone furoate 50 μg and then placebo|Subjects will receive oral inhalation of FF 50 μg administered via ELLIPTA, once daily (OD) for 14 days +/- 4 days in Period 1 followed by oral inhalation of placebo administered via ELLIPTA, OD for 14 days +/- 4 days in Period 2. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.
3009015|NCT02502734|Experimental|Sequence 2: Placebo and then fluticasone furoate 50 μg|Subjects will receive oral inhalation of placebo administered via ELLIPTA OD for 14 days +/- 4 days in Period 1 followed by receive oral inhalation of FF 50 μg administered via ELLIPTA, OD for 14 days +/- 4 days. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.
3009016|NCT02502721|Experimental|Part A|To study effect of DWC20151 on DWC20152 PK
3009017|NCT02502721|Experimental|Part B|To study effect of DWC20152 on DWC20151 PK
3009018|NCT02502708|Experimental|Group 1|"Core Regimen: Dose-escalation of indoximod, in combination with temozolomide, for pediatric patients with progressive brain tumors.~Indoximod will be administered in escalating doses. Initial dosing will be 12.8 mg/kg/dose BID with escalation planned to 22.4 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m^2 x 5 days"
3009019|NCT02502708|Experimental|Group 2|"Expansion cohorts: Indoximod therapy at the pediatric recommended phase 2 dose (RP2D) determined by Group 1, in combination with temozolomide.~Indoximod will be administered at the RP2D of 19.2 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m^2 x 5 days"
3009020|NCT02502708|Experimental|Group 3|"Dose-escalation of indoximod, in combination with up-front conformal radiation therapy, for pediatric patients with progressive brain tumors.~Indoximod will be administered in escalating doses. Initial dosing will be 12.8 mg/kg/dose BID with escalation planned to 22.4 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m^2 x 5 days"
3009063|NCT02502383|Active Comparator|Comparison|
3009064|NCT02502370|Active Comparator|Group1 Arm A Observation|
3009022|NCT02502708|Experimental|Group 4|"Continued access to indoximod in combination with low-dose oral cyclophosphamide and etoposide for patients with progressive disease after treatment with indoximod plus temozolomide.~Indoximod will be administered at 32 mg/kg/dose divided twice daily.~Cyclophosphamide to be given at 2.5 mg/kg/dose daily~Etoposide to be given at 50 mg/m2/dose daily"
3009023|NCT02502695||Cohort 1-VATS-associated best practices|"Data to be collected will include demographic data and information about the pre-operative workup, surgical procedure, postoperative course and early discharge course for these patients.~After the last patient completes the 30-day post surgery follow-up, the investigators will determine a set of best practices to implement at each of the sites for the quality improvement initiative. During the assessment period, no patients will be enrolled into the study."
3009024|NCT02502695||Cohort 2-VATS-associated best practices|-Once the set of VATS-associated best practices, an additional cohort of approximately 200 patients will be enrolled and followed in a manner identical to the first cohort.
3009025|NCT02502682|No Intervention|Control|Receive the bathing standard of care.
3009026|NCT02502682|Experimental|Interventional|Receive daily bathing with 2% Chlorhexidine gluconate bathing wipes.
3009027|NCT02502669|Active Comparator|Finasteride 23.5 mg tablets group|Finasteride 23.5mg tablets and large placebo tablets once per week
3009028|NCT02502669|Active Comparator|Finasteride 33.5 mg tablets group|Finasteride 33.5 mg tablets and small placebo tablets once per week
3009029|NCT02502669|Placebo Comparator|Placebo group|Large and small placebo tablets once per week
3009030|NCT02502643|Experimental|OK-432 pleurodesis|Picibanil ( OK-432 ) ,OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci; UKIMA PLANT OF CHUGAI PHARMA MANUFACTURING CO, LTD; JAPAN).
3009031|NCT02502643|Active Comparator|normal saline pleurodesis|(Normal Saline),Isotonic Sodium Chloride Solution
3009032|NCT02502630|Experimental|Treated with microwave ablation|Patients undergoing MWA for pulmonary metastases from colorectal cancer.
3009033|NCT02502617||Weight Improvement|Patients (n = 30) with severe AN, refered to the specialized medical nutrition section at Odense University Hospital are tested three times during nutritional rehabilitation: At admission, at discharge (or drop out) and two-four months after discharge. The first study is carried out not before the third day of hospitalization after acclimatization and water electrolyte correction.
3009034|NCT02502617||Weight-stable|To investigate the re-test effects of the the surveys, outpatients with a stable weight (less than 5%/3 months) with eating disorders (n = 15) are tested twice with 4-6 weeks interval.
3009035|NCT02502604|Experimental|Goal Management Training|Participants in this arm of the study will attend GMT sessions, which will be administered weekly over a nine-week period following a script with accompanying slides and participant workbooks.
3009036|NCT02502604|No Intervention|Wait List Control|Participants in this category will be placed on a wait-list to receive goal management training following completion of their study participation.
3009037|NCT02502591|Experimental|intervention|Additional pain relief (a Pudendal Nerve Block (PNB)) will be administered during surgery in addition to routine care.
3009038|NCT02502591|No Intervention|control|routine care only
3009039|NCT02502578|Experimental|CNT-01|Patients will receive CNT-01 500 mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
3009040|NCT02502565||Uric Acid Level|
3009041|NCT02502552||Inflammatory Bowel Disease|Inflammatory Bowel Disease patients followed in Saint-Etienne Hospital since 3 years or more. Blood specimen 3 years after a first blood specimen
3009042|NCT02502539|Experimental|autoimmune disease|to identify the mechanisms through which physical activity is liable to mediate inflammatory balance in autoimmune disease settings, and specifically in JIA patients.
3009043|NCT02502526|Experimental|CVS with 45° Balanced Tip|Centurion® Vision System, 45° Balanced Tip used with INTREPID® Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
3009044|NCT02502526|Active Comparator|CVS with 45° MFK Tip|Centurion® Vision System, 45° MFK Tip used with INTREPID® Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
3009045|NCT02502526|Active Comparator|IVS with 45° MFK Tip|lnfiniti® Vision System, 45° MFK Tip used with Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
3009046|NCT02502513|Experimental|Intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department and completion of intrusive memory diary"
3009047|NCT02502513|No Intervention|Control|Usual care in the maternity department plus completion of intrusive memory diary
3009048|NCT02502500|Active Comparator|Celecoxib|Celecoxib
3009049|NCT02502500|Experimental|AKB-6548 and Celecoxib|AKB-6548; celecoxib
3009050|NCT02502487|Placebo Comparator|Tetracaine gel group|Dorsal penile nerve block with saline and tetracaine gel into urethra before rigid cystoscopy
3009051|NCT02502487|Experimental|Dorsal penile nerve block group|Dorsal penile nerve block with ropivacaine and plain lubricating gel into urethra before rigid cystoscopy
3009052|NCT02502487|Experimental|Combination group|Dorsal penile nerve block with ropivacaine and tetracaine gel into urethra before rigid cystoscopy
3009053|NCT02502474|Experimental|Patients undergoing a colonoscopy|Staphylococcus aureus carriage is measured in nose, throat, colon, rectum and groin
3009054|NCT02502461|Sham Comparator|standard care|Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
3009055|NCT02502461|Active Comparator|cuff palpation|Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; inflated cuff palpated and depth adjusted accordingly; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
3009056|NCT02502448|No Intervention|Control group|patients undergoing cardiac surgery supposed not to get aucte normovolemic hemodilution (ANH) before CPB
3009057|NCT02502448|Active Comparator|Acute normovolemic hemodilution group|patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB
3009058|NCT02502435||Patients with Night-Eating Syndrome|
3009068|NCT02502357|Experimental|Healing Statements|Patients in the healing statements group will be read healing statements during anesthesia induction, prior to undergoing surgery.
3009069|NCT02502357|No Intervention|No Healing Statements|Patients in the no healing statements group will not be read healing statements during anesthesia induction prior to undergoing surgery. They will receive standard of care.
3009070|NCT02502344|Experimental|medical intervention group|subjects in this group will accept healthy lifestyle changes such as food control and intensive exercise for 3 months first. Then their insulin resistance will be evaluated again . If their insulin resistance didn't improve, then they will take metformin 0.5g qd to reduce insulin resistance. If their insulin resistance improved, they will continued healthy lifestyle changes.
3009071|NCT02502344|No Intervention|clinical observeral group|subjects in this group will not accept medical interventions
3009072|NCT02502331|Experimental|study group|Test Oral Cholera Vaccine
3009073|NCT02502331|Active Comparator|comparator group|Euvichol®
3009074|NCT02502318|Experimental|Lobectomy using video-thoracoscopy|
3009075|NCT02502318|Active Comparator|Lobectomy using thoracotomy|
3009076|NCT02502305|Experimental|Intervention group|intervention group receives liveonline course training, 3 questionnaires at an interval of 6 weeks
3009077|NCT02502305|No Intervention|Control group|control group receives 3 questionnaires at an interval of 6 weeks
3009078|NCT02502292|Experimental|Intervention: Fotonovela|The Photo Novel Intervention is presented to users of four different facilities (sports clubs, senior homes) who are older than 50 years. The researchers welcome scheduled eligible participants, introduce the study and ask them for their consent. Afterwards, the participants are asked to fill in the questionnaire. Then, participants are randomized to one of the four groups and are presented with the photo novel or traditional brochure either as a hard copy brochure or as pdf on a tablet computer (2x2 group design). They are instructed to read the material in their own pace and answer the accompanying questions after each story / tip.and the accompanying questionnaire.
3009079|NCT02502279|No Intervention|Control|Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters with 0 PEEP/CPAP.
3009080|NCT02502279|Active Comparator|Lung Recruitment- PEEP group|Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters plus lung recruitment manoeuvre with peak inflation pressure 35 cmH2O for 15 seconds followed by PEEP until extubation delivered by the ventilator.
3009081|NCT02502279|Active Comparator|Lung Recruitment- PEEP and CPAP group|"Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters plus~lung recruitment manoeuvre with peak inflation pressure 35 cmH2O for 15 seconds followed by PEEP until extubation delivered by the ventilator.~Postoperative CPAP mask immediately after extubation"
3009082|NCT02502266|Active Comparator|Phase II Arm I (reference regimen)|Patients undergo physician's choice of standard of care chemotherapy, comprising either paclitaxel IV on days 1, 8, 15, and 22 every 28 days (Regimen I); pegylated liposomal doxorubicin hydrochloride IV on day 1 every 28 days (Regimen II); or topotecan hydrochloride IV on days 1, 8, and 15 every 28 days or days 1-5 every 21 days (Regimen III). Treatment continues in the absence of disease progression or unacceptable toxicity.
3009083|NCT02502266|Experimental|Phase II Arm II (cediranib maleate, olaparib)|Patients receive cediranib maleate PO and olaparib PO as determined from an ongoing Phase I study. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3009084|NCT02502266|Experimental|Phase II Arm III (cediranib maleate)|Patients receive cediranib maleate PO daily continuously. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3009085|NCT02502266|Experimental|Phase II Arm IV (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3009086|NCT02502266|Active Comparator|Phase III Arm I (reference regimen)|Patients undergo physician's choice standard of care chemotherapy as in Phase II Arm I.
3009087|NCT02502266|Experimental|Phase III Arm II (cediranib maleate, olaparib)|Patients receive cediranib maleate PO and olaparib PO as in Phase II Arm II.
3009088|NCT02502266|Experimental|Phase III Arm III (single-agent olaparib or cediranib maleate)|Patients receive either olaparib PO or cediranib maleate PO, as determined by the Phase II study. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3009089|NCT02502253|Experimental|Low dose|
3009090|NCT02502253|Experimental|moderate dose|
3009091|NCT02502253|Experimental|High dose|
3009092|NCT02502227|Active Comparator|Mindfulness Training|Mindfulness training intervention consisting of eight weekly 2.5 hour group sessions, a day-long retreat in the sixth week, and daily home mindfulness meditation
3009093|NCT02502227|Active Comparator|Mindful Attention Only Training|Mindful attention only training intervention consisting of eight weekly 2.5 hour group sessions, a day-long retreat in the sixth week, and daily home mindfulness meditation
3009094|NCT02502227|No Intervention|No Treatment Control Condition|No treatment participants will be informed that their participation is important and that they are requested to not seek out similar treatments during this waiting period.
3009095|NCT02502201|Active Comparator|six-minute walk study indoors first|Participants randomized to indoor six-minute walk test first
3009096|NCT02502201|Experimental|six-minute walk study outdoors first|Participants randomized to outdoor six-minute walk test first
3009097|NCT02502201|Active Comparator|six-minute walk study indoors second|Participants randomized to indoor six-minute walk test second
3009098|NCT02502201|Experimental|six-minute walk study outdoors second|Participants randomized to outdoor six-minute walk test second
3009099|NCT02502188|Experimental|Part 1 - CC-90005 and Placebo|CC-90005 or Placebo will be administered orally from low to high dose
3009100|NCT02502188|Experimental|Part 2 - CC-90005 and Placebo|CC-90005 or Placebo will be administered orally from low to high dose
3009101|NCT02502175|Experimental|Opium|patient-centered flexible dosing in line with the national protocol published by Iranian Ministry of Health for maintenance treatment of opioid dependent population
3009102|NCT02502175|Active Comparator|methadone|patient-centered flexible dosing in line with the national protocol published by Iranian Ministry of Health for maintenance treatment of opioid dependent population
3009105|NCT02502149|Experimental|rFVIIIFc (15K scale) 1000 IU vial|Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc (15K scale) 1000 IU vial at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 1000 IU vial.
3009106|NCT02502149|Experimental|rFVIIIFc (15K scale) 6000 IU vial|Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc high strength vial (15K scale) at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 6000 IU vial.
3009107|NCT02502136|Experimental|CO2 in sedated colonoscopy|Carbon dioxide insufflation during colonoscopy with sedation
3009108|NCT02502136|Placebo Comparator|Air in sedated colonoscopy|Room air insufflation during colonoscopy with sedation
3009109|NCT02502136|Experimental|CO2 in mild sedated colonoscopy|Carbon dioxide insufflation during colonoscopy with mild sedation
3009110|NCT02502136|Placebo Comparator|Air in deep sedated colonoscopy|Room air insufflation during colonoscopy with deep sedation
3009111|NCT02502136|Experimental|CO2 in sedated panendoscopy|Carbon dioxide insufflation during panendoscopy with sedation
3009112|NCT02502136|Placebo Comparator|Air in sedated panendoscopy|Room air insufflation during panendoscopy with sedation
3009113|NCT02502136|Experimental|CO2 in mild sedated panendoscopy|Carbon dioxide insufflation during panendoscopy with mild sedation
3009114|NCT02502136|Placebo Comparator|Air in deep sedated panendoscopy|Room air insufflation during panendoscopy with deep sedation
3009115|NCT02502123||OnabotulinumtoxinA (BOTOX®)|Patients diagnosed with chronic migraine headache treated with BOTOX® as standard of care in clinical practice. No intervention was administered in this study.
3009116|NCT02502110|Experimental|rosuvastatin 20mg/day|To receive oral rosuvastatin 20mg/day and regular therapy from 7 days before ablation and last for 3 months.
3009117|NCT02502110|No Intervention|blank control|Regular therapy from 7 days before ablation and last for 3 months. Regular medicines used for AF includes warfarin, metoprolol sustained release tablet, amiodarone, perindopril and irbesartan.
3009118|NCT02502097|Experimental|Gefapixant|Gefapixant 50 mg tablets administered by mouth twice daily for 14 days, followed by placebo (after washout period)
3009119|NCT02502097|Placebo Comparator|Placebo|Matching placebo tablets administered by mouth twice daily for 14 days, followed by gefapixant (after washout period)
3009120|NCT02502084|Experimental|3NT flexible endoscope|Evaluation of 3NT flexible endoscope in terms of access and evaluation of the nasal anatomy
3009121|NCT02502071|Experimental|Sodium Bicarbonate|All participants will receive 2 doses of 1950mg Sodium Bicarbonate
3009122|NCT02502045|Experimental|Morning Simulated Sunlight|Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days. A flexible window of has been allowed to accommodate participants and care routines.
3009123|NCT02502045|Placebo Comparator|Non-Therapeutic Red Light|Non-therapeutic red light control at 5 lux will be used as the control condition
3009124|NCT02502032|Experimental|Cisatracurium 0.005 mg/kg|The group received pretreatment of cisatracurium 0.005 mg/kg.
3009125|NCT02502032|Experimental|Cisatracurium 0.01 mg/kg|The group received pretreatment of cisatracurium 0.01 mg/kg.
3009126|NCT02502032|Experimental|Cisatracurium 0.02 mg/kg|The group received pretreatment of cisatracurium 0.02 mg/kg.
3009127|NCT02502019|Experimental|HEMOBLAST|All subjects will have the investigational device implanted
3009128|NCT02502006|Experimental|High Dose|During each treatment phase, subjects will receive celecoxib (200 mg by mouth twice daily), naproxen (500 mg by mouth twice daily), or placebo (twice daily) for 7 days. Subjects will be instructed to take the study medications twice a day (at approximately 8 AM and 8 PM) on an empty stomach with a full glass of water.
3009129|NCT02502006|Experimental|Low dose|During each treatment phase, subjects will receive celecoxib (100 mg by mouth twice daily), naproxen (250 mg by mouth twice daily), or placebo (twice daily) for 7 days. Subjects will be instructed to take the study medications twice a day (at approximately 8 AM and 8 PM) on an empty stomach with a full glass of water.
3009130|NCT02501993||Screening cohort|All participants will be tested for anti-EBV antibody by using serum samples. Participants are stratified into those having high, moderate and low antibody levels, those having moderate antibody levels are invited to retest annually in the following 3 years and those found to have high antibody levels on these occasions are referred to centers for diagnostic workup for NPC.
3009131|NCT02501980||Screening|All participants will be tested for HBsAg by using serum samples. Among those who are positive for HBsAg, further clinical work-ups including AFP test and ultrasonography for liver exam will be performed. Repeated check-ups will be performed in 6-months among HBsAg positive group and 3-years among HBsAg negative group.
3009132|NCT02501980||Non-screening|All subjects in this arm will be followed by linkage to Cancer Register and Population Register.
3009133|NCT02501967|Experimental|COMET|The intervention consists of completion of the tool (COMET) by means of a 30 minute telephone interview prior to the primary care visit and provision of the tool's output to the patient and primary care physician. The COMET tool takes information about the patient's medications and chronic conditions from the electronic health record, and then supplements this with information obtained by a telephone interview assessing the patient's cognition, social supports, medication adherence, home medication regimen, medication side effects, and health status. In addition, there is a chart review screen to record renal function, blood pressure, and hemoglobin A1C. All of this information is run through a set of algorithms to identify medication reconciliation errors and potentially inappropriate medications.
3009134|NCT02501967|No Intervention|Usual Care|
3009135|NCT02501954|Experimental|Regimen I|Cisplatin 50 mg/m2 IV Days 1 and 29 plus Volume-directed radiation therapy followed by Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2 q 21 days for 4 cycles
3009136|NCT02501954|Active Comparator|Regimen II|Carboplatin AUC 6 plus Paclitaxel 175 mg/m2 q 21 days for 3 cycles followed by Volume-directed radiation therapy followed by Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2 q 21 days for 3 cycles
3009137|NCT02501941|Experimental|Ketamine first|"Randomization to receive ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to other sedation after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring."
3009138|NCT02501941|Experimental|Other sedation (typically propofol) first|Randomization to receive sedative other than ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to ketamine after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring.
3009139|NCT02501928|Experimental|Fesoterodine PR 4 mg|Fesoterodine PR 4 mg for 28 or 40 weeks in open-label treatment period
3009140|NCT02501928|Experimental|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg for 28 or 40 weeks in open-label treatment period
3009141|NCT02501928|Experimental|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg for 28 weeks in open-label treatment period
3009142|NCT02501928|Experimental|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg for 28 weeks in open-label treatment period
3009143|NCT02501915|Experimental|Kinesio Taping (GROUP A)|Received the application of KT from muscle Origin to Insertion
3009144|NCT02501915|Experimental|Kinesio Taping (GROUP B)|received the application of KT from muscle Insertion to Origen
3009145|NCT02501902|Experimental|Palbociclib + Nab-Paclitaxel|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle. Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
3009146|NCT02501889|Experimental|Walnut-rich weight loss diet arm|Participants will have an individualized reduced-calorie diet prescription and weight loss counseling session with the project coordinator, who is a registered dietitian. Composition of prescribed diets will be based on individual preferences. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. All participants will have contact with the project coordinator a minimum of every 1-2 weeks. Walnuts will be provided to participants in the walnut-rich study arm.
3009147|NCT02501889|Active Comparator|Standard weight loss diet arm|Participants will have an individualized reduced-calorie diet prescription and weight loss counseling session with the project coordinator, who is a registered dietitian. Composition of prescribed diets will be based on individual preferences. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Participants assigned to this arm will be instructed to abstain from the consumption of nuts during the study. All participants will have contact with the project coordinator a minimum of every 1-2 weeks.
3009148|NCT02501876||T2D-MCI|110 MCI subjects with type 2 diabetes. There is a retrospectiv observational study. No intervention will be performed.
3009149|NCT02501876||nonT2D-MCI|110 MCI subjects without diabetes. There is a retrospectiv observational study. No intervention will be performed.
3009150|NCT02501863|Experimental|Ropivacaine+fentanyl|"Femoral nerve block with ropivacaine+fentanyl~Interventions: Femoral nerve catheter insertion, spinal anesthesia, IV-PCA with hydromorphone."
3009151|NCT02501863|Experimental|Ropivacaine|"Femoral nerve block with ropivacaine~Interventions: Femoral nerve catheter insertion, spinal anesthesia, IV-PCA with hydromorphone."
3009152|NCT02501850|Experimental|Group A|Type 2 diabetic patients whom were prescribed GLP-1R agonists by the endocrinologist, according to usual clinical practice (liraglutide, exenatide, lixisenatide). The intervention is the prescription of an GLP-1R agonist (liraglutide, exenatide, lixisenatide)
3009153|NCT02501850|Active Comparator|Group B|Type 2 diabetic patients whom were prescribed metformin and/or sulphonilurea, according to usual clinical practice.
3009154|NCT02501837|Experimental|Oxytocin|24 IU Oxytocin (Syntocinon spray), intranasal application 30 min prior to the experiment
3009155|NCT02501837|Placebo Comparator|Placebo|Intranasal application, containing all ingredients except for the peptide, 3 puffs per nostril
3009156|NCT02501824|Experimental|speech therapy first|11 sessions of speech therapy (anthroposophic therapeutic speech), then waiting phase
3009157|NCT02501824|Experimental|speech therapy second|10 weeks of waiting, then 11 sessions of speech therapy (anthroposophic therapeutic speech)
3009158|NCT02501811|Experimental|Mesenchymal Stem Cells (MSC)|Target dose of 150 million MSCs
3009159|NCT02501811|Experimental|Cardiac Stem Cells (CSC)|Target dose of 5 million CSCs
3009160|NCT02501811|Experimental|MSC+CSC Combination Cells (Combo)|Target dose of 150 million MSCs and 5 million CSCs
3009161|NCT02501811|Placebo Comparator|Placebo (Plasmalyte A)|Plasmalyte A
3009162|NCT02501798|Experimental|Drug: Methylphenidate|Drug: Methylphenidate 7 days dosage as (prior to study) clinically titrated long acting Equasym (brand)
3009163|NCT02501798|Active Comparator|Drug: Placebo|Drug: Placebo 7 days Empty green-yellow capsule
3009164|NCT02501785||patient and caregivers|This is a prospective cohort study. Four questionnaires will be used to collect data from caregivers: demographic and socioeconomic data will be collected from the caregiver before the patient's surgery, and caregiver burden information will be collected 15 (+/- 3) days after surgery.
3009165|NCT02501772|Experimental|Sanyinjiao acupressor group|In addition to maintain current treatment included oral anti-hyperglycemia agent and ACEI(angiotensin-converting enzyme inhibitor ) or ARB, subjects should wear ankle band at Sanyinjiao point ( calf , ankle on the foot tip 3 inch ), with the thumb pressing daily five minutes later and carry more than four hours for 8 weeks
3009166|NCT02501772|Sham Comparator|Control Group|In the control group, ankle band was place as same as the those for the SA(Sanyinjiao acupressor) group, but was wearing at the acupoint of Sanyinjiao with anti- surface without pressure. It was applied four hours per day for 8 weeks
3009167|NCT02501759|Experimental|Diagnostic (MRI, MRI-guided biopsy, TRUS-guided biopsy)|Patients receive gadodiamide IV and undergo a diagnostic multiparametric endorectal MRI. Patients with lesions visible on the diagnostic multiparametric endorectal MRI undergo transrectal MRI-guided biopsy within 2 weeks of diagnostic multiparametric endorectal MRI. Patients then undergo TRUS-guided biopsy per standard clinical care approximately 2 weeks after transrectal MRI-guided biopsy.
3009168|NCT02501746|Active Comparator|Usual Clinical Care (UC)|This will be the current standard of care delivered by the AMPATH CDM Program, in accordance with the management protocol for diabetes and hypertension.
3009169|NCT02501746|Experimental|Usual clinical care plus microfinance groups only (MF)|Usual clinical care as described above. In addition, participants will be encouraged to create microfinance groups organized and supported by AMPATH's Safety Net Program.
3009910|NCT02497092|Active Comparator|Slow straight injection|Slow and straight insertion of the needle through the sclera
3009170|NCT02501746|Experimental|Group medical visits only (GMV)|Participants randomized to this arm will be invited to create a group that will attend monthly group medical visits at the rural health facility. Each group medical visit will be staffed by both the rural clinician and the local CHW (educator). Groups will consist of the same patients at each of 12 monthly visits. Each visit will begin with the measurement of fasting blood glucose and resting electronic BP, as well as the ascertainment of medication regimens for BP and diabetes, and extent of adherence to the prescribed regimen.
3009171|NCT02501746|Experimental|GMV integrated into GMV-MF|Clinical care will be provided in the form of group medical visits, and the participants will be actively recruited to create microfinance groups. Thus, the monthly group medical visit will be integrated into the microfinance groups, wherein the visit will consist of an initial microfinance portion, followed by the group medical visit.
3009172|NCT02501733|Other|Medacta GMK Sphere® Knee Prosthesis|All subjects enrolled will receive the Medacta GMK Sphere® Medial Knee Prosthesis
3009173|NCT02501720|Active Comparator|Tourniquet Group|Post burn flexion contractures will be released under tourniquet control
3009174|NCT02501720|Experimental|Tumescent technique group|Post burn flexion contractures will be released using Tumescent solution
3009175|NCT02501681|Active Comparator|crystalloid|Group A (n=20); crystalloid as priming solution used in patients,
3009176|NCT02501681|Active Comparator|colloid|Group B (n=20); colloids as priming solution used in patients
3009177|NCT02501668||Lung cancer in population|Lung cancer cases in sample population (670,258 cases)
3009178|NCT02501668||COPD in population|COPD cases (670,258 cases)
3009179|NCT02501668||COPD with lung cancer|Lung cancer in COPD
3009180|NCT02501668||ILD without IPF|Interstitial lung disease (ILD) cases without idiopathic pulmonary fibrosis (IPF)
3009181|NCT02501668||ILD with lung cancer|Lung cancer cases in ILD
3009182|NCT02501668||Idiopathic pulmonary fibrosis|Idiopathic pulmonary fibrosis cases
3009183|NCT02501668||IPF with lung cancer|Lung cancer cases in IPF patients
3009184|NCT02501668||Connective tissue disorder with ILD|CTD with ILD cases
3009185|NCT02501668||CTD ILD with lung cancer|Lung cancer cases in CTD with ILD
3009186|NCT02501668||CTD without ILD|CTD with ILD cases in sample population
3009187|NCT02501668||CTD without ILD with lung cancer|Lung cancer in CTD without ILD
3009188|NCT02501655|Active Comparator|Phase 1|Jet Nebulizer - control group
3009189|NCT02501655|Experimental|Phase 2|Mesh nebulizers
3009190|NCT02501642|Experimental|Concussion Coach group|"After informed consent and randomization, participants will complete baseline study measures and will receive an iPod touch® with the Concussion Coach Explorer version"
3009191|NCT02501642|Other|Treatment as usual|Treatment as usual
3009192|NCT02501629|Experimental|Reslizumab|Reslizumab Subcutaneous Dosing
3009193|NCT02501629|Placebo Comparator|Placebo|Matching placebo
3009194|NCT02501616|Active Comparator|Metformin first|"Metformin first 8 wks --> Dapagliflozin 8wks.~Metformin for initial 8 weeks. During that period, metformin can be titrated upto 2000 mg/day. After 1 weeks of washout period, 8 weeks' dapagliflozin is followed. During that period, dose of dapagliflozin is maintained 10mg/day."
3009195|NCT02501616|Active Comparator|Dapagliflozin first|"Dapagliflozin first 8 wks --> Metformin 8wks.~Dapagliflozin for initial 8 weeks. After 1 weeks of washout period, 8 weeks' metformin is followed."
3009196|NCT02501603|Experimental|afatinib plus paclitaxel|afatinib plus paclitaxel
3009197|NCT02501590||study|"After the parents sign an informed consent form, they will fill out a demographic questionnaire. Than if the Beery VMI test was not yet administered, it would be performed, as well as the Developmental Coordination Disorder Questionnaire (DCD-Q). Surface electromyography electrodes will be placed on the Upper Trapezius, Extensor Carpi Radialis, and Biceps brachii of the child's dominant hand.~The subject will perform 4 copying tasks and 2 tracing tasks on a tablet placed once on a horizontal surface (while sitting) and once on a vertical surface (while standing)."
3009198|NCT02501590||control|"After the parents sign an informed consent form, they will fill out a demographic questionnaire. Than if the Beery VMI test was not yet administered, it would be performed, as well as the Developmental Coordination Disorder Questionnaire (DCD-Q). Surface electromyography electrodes will be placed on the Upper Trapezius, Extensor Carpi Radialis, and Biceps brachii of the child's dominant hand.~The subject will perform 4 copying tasks and 2 tracing tasks on a tablet placed once on a horizontal surface (while sitting) and once on a vertical surface (while standing)."
3009199|NCT02501577|Experimental|SAD 1|FOI for placement
3009200|NCT02501577|Experimental|SAD 2|FOI für placement
3009201|NCT02501564|Experimental|Naproxen Sodium Codeine|One tablet twice a day
3009202|NCT02501564|Placebo Comparator|Placebo|One tablet twice a day
3009203|NCT02501551|Experimental|Regorafenib|160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
3009204|NCT02501538|Experimental|Transcutaneous O2 device|Continuous diffusion of oxygen (CDO) (topical oxygen) therapy, which will be administered using a portable device.
3009205|NCT02501525|Active Comparator|UAS (+)|RIRS with ureteral access sheath: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
3009206|NCT02501525|Experimental|UAS (-)|RIRS without ureteral access sheath: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
3009207|NCT02501499||Breastfeeding Buddies participants|Mothers that participated in Me Breastfeed workshops. Half will have been in the education-only group and half will have a buddy/peer support person in addition to the workshop.
3009208|NCT02501499||Volunteer Focus Group|Breastfeeding buddies volunteers that deliver education and support programs.
3009209|NCT02501486|Other|ACTH stimulation test|this is a single arm study. An ACTH-stimulation test will be done
3009210|NCT02501473|Experimental|Part 1: Dose Escalation Cohort 1|Intratumoral injections of G100 at 5μg
3009211|NCT02501473|Experimental|Part 1: Dose Escalation Cohort 2|or Intratumoral injections of G100 at 10μg
3009212|NCT02501473|Experimental|Part 2: Patient Expansion G100 and Pembrolizumab|Intratumoral injections G100 or sequential intratumoral G100 and pembrolizumab
3009213|NCT02501473|Experimental|Part 2: Large Tumor (Optional)|Intratumoral injections G100 at 20 μg
3009214|NCT02501473|Experimental|Part 3: Expansion of Dose Group|Intratumoral G100 at 20 µg/dose in patients without restriction of tumor size
3009215|NCT02501460|Active Comparator|Supplement Group|Participants will receive educational handouts and complete research testing to evaluate their physical condition prior to beginning the resistance training and dietary supplementation. Adherence will be assured as described below.
3009216|NCT02501460|Placebo Comparator|Placebo Group|Participants will receive educational handouts and complete research testing to evaluate their physical condition prior to beginning the resistance training and placebo. Adherence will be assured as described below.
3009217|NCT02501447|Experimental|Guided audio-visual relaxation group|The guided relaxation (GR) intervention included a single 12-min GR video clip we administered to subjects at the baseline visit to determine the immediate effects of GR on stress and pain. The GR intervention also included six video clips, which ranged from 2 to 20 minutes in length to determine the short-term (2-week) effects of GR on stress and pain.
3009218|NCT02501447|No Intervention|Attention Control group|For the attention control group, subjects engaged in a 12-min computer-based discussion about their sickle cell disease (SCD) experience. The audio-taped questions and onscreen directions were programmed for self-administration. Subjects' responses were captured via the microphone so that Data Collectors were not involved in this discussion process, and it was equivalent to the guided relation activity.
3009219|NCT02501434|No Intervention|Control|Standard of Care
3009220|NCT02501434|Experimental|LDIVH (Unfractionated Heparin)|Continuous Low-Dose IV Unfractionated Heparin Infusion
3009221|NCT02501421|Active Comparator|TB/FLU-04L|Live recombinant influenza vectored tuberculosis vaccine
3009222|NCT02501421|Placebo Comparator|Placebo|Buffer
3009223|NCT02501408|Experimental|Propriofoot prosthesis|New propriofoot prosthesis is worn instead of usual prosthesis foer 1 month
3009224|NCT02501408|No Intervention|Control|Usual prosthesis is worn for 1 month
3009225|NCT02501395||Patients with Kennedy disease|Men over 18 years old with confirmed Kennedy disease.
3009226|NCT02501395||Healthy, voluntary controls|Gender and age matched healthy, voluntary controls.
3009227|NCT02501382||Patients with NSTI treated with HBOT|NSTI definition: An infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection causing necrosis in subcutis, muscle and/or fascia.
3009228|NCT02501369|Experimental|Self-directed Teen Triple P|"Self-directed Teen Triple P is a behaviourally based parenting intervention that parents follow at home using a workbook. It is based upon social learning theory principles and is used to help parents build upon their existing skills and information to practice positive parenting. Key skills promoted include: Increasing positive parent-teenager interactions, increase desirable behaviour, teach new behaviours and skills, and manage problem behaviour.~As this is a case series design participants will act as their own controls and so there are no other arms to the study."
3009229|NCT02501356|Active Comparator|ISOThrive supplement 1|Participants assigned to the ISOThrive supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
3009230|NCT02501356|Active Comparator|ISOThrive supplement 2|Participants assigned to the ISOThrive supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
3009231|NCT02501356|Placebo Comparator|Placebo supplement|Participants assigned to the placebo supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
3009232|NCT02501343|Experimental|Sodium bicarbonate|High acid load meal (Western style meal) with Sodium bicarbonate (Sodibic 840mg*2)
3009233|NCT02501343|Placebo Comparator|Placebo|High acid load meal (Western style meal) with sodibic-matching placebo
3009234|NCT02501330||Bosutinib|
3009235|NCT02501317|Experimental|Active Perineal Rehabilitation protocol|"study group that will be treated with Active Perineal Rehabilitation protocol"
3009236|NCT02501317|Active Comparator|Kari Bo protocol|control group will be treated with the protocol already widely used
3009237|NCT02501304|Experimental|ReVENT Sleep Apnea System|All patients will be implanted with the ReVENT Sleep Apnea System
3009238|NCT02501291|Experimental|Thalidomide|Thalidomide was administered at a daily dose of 50 mg to the patients. Dosage adjustment of thalidomide from 25mg daily to 100mg daily was tailored individually according to patients' tolerance to thalidomide. To minimize the sedative effect of thalidomide, the investigators recommended patients take a single dose of the study drug in the evening before bedtime.
3009239|NCT02501278|Experimental|Arm A: Immunotherapy during and after CRT + vaccine boost|INO-3112 dosing during chemoradiotherapy plus immunotherapy dosing after chemoradiotherapy in an adjuvant setting and vaccine boost one year after last vaccine dosing.
3009240|NCT02501278|Experimental|Arm B: Immunotherapy during CRT + vaccine boost|INO-3112 dosing during chemoradiotherapy, and vaccine boost one year after last vaccine dosing.
3009241|NCT02501278|Active Comparator|CRT without immunotherapy|Standard chemoradiotherapy without immunotherapy
3009242|NCT02501265|Active Comparator|Varenicline Standard Protocol|Participant choses Varenicline-based treatment and is then randomized to Standard Treatment arm (N=150). Four weeks prior to target quit date (TQD), participant starts placebo Varenicline. Consistent with Varenicline Standard Treatment, 1 week prior to the TQD the participant will switch to active Varenicline and placebo Bupropion. Participant will continue active Varenicline and placebo Bupropion to 12 weeks post-TQD.
3009243|NCT02501265|Active Comparator|Nicotine Patch Standard Protocol|Participant choses Nicotine patch-based treatment and is then randomized to Standard Treatment arm (N=150). Four weeks prior to target quit date (TQD), participant starts placebo Nicotine Patch. One week prior to TQD, participant will start placebo Bupropion. Consistent with Nicotine Patch Standard Treatment, participant will start active Nicotine Patch on TQD. Participant will continue active Nicotine Patch and placebo Bupropion to 12 weeks post-TQD.
3009273|NCT02501057|Experimental|Enhanced Clinician's Guide|Participants in this group receive the Clinician's Guide intervention paired with daily use of HealthCall-S, which includes two cycles of daily use of HealthCall for 30 days, followed by personalized feedback in the form of a graph with a clinic staff member.
3009274|NCT02501044||Hemodialysis Patients|
3009244|NCT02501265|Experimental|Varenicline Adaptive Protocol|Participant chooses Varenicline treatment and is randomized to Adaptive Treatment arm (N=150). Four weeks prior to target quit date (TQD), participant starts active Varenicline. Two weeks prior to TQD, cigarettes smoked per day is assessed. If the number of cigarettes smoked per day is reduced by >50%, the participant is considered a Varenicline responder, and starts placebo Bupropion 1 week prior to the TQD. If the participant DOES NOT reduce cigarettes smoked per day by >50%, the participant is considered a Varenicline non-responder and starts active Bupropion 1 week prior to TQD. Varenicline responders will continue active Varenicline and placebo Bupropion to 12 weeks post TQD. Varenicline non-responders will continue active Varenicline and active Bupropion to 12 weeks post TQD.
3009245|NCT02501265|Experimental|Nicotine Patch Adaptive Protocol|Participant choses Nicotine treatment and is randomized to Adaptive Treatment arm (N=150). Four weeks prior to target quit date (TQD), participant starts active Nicotine Patches. Two weeks prior to TQD, cigarettes smoked per day is assessed. If cigarettes smoked per day is reduced by >50%, the participant is considered a Nicotine Patch responder and starts placebo Bupropion 1 week prior to the TQD. If the participant DOES NOT reduce cigarettes smoked per day by >50%, the participant is considered a Nicotine Patch non-responder and starts active Bupropion 1 week prior to the TQD. Nicotine Patch responders will continue active Nicotine Patches and placebo Bupropion to 12 weeks post TQD. Nicotine Patch non-responders will continue active Nicotine Patches and Bupropion to 12 weeks post TQD.
3009246|NCT02501252|Experimental|CORN Based at health post|Trained CORN based at health post will provide SBA and other RH services on demand at health post or household levels on an outreach bases.
3009247|NCT02501252|Active Comparator|CORN Based at health center|Trained CORN based at health center, but working in the community in an outreach basis will provide SBA and other RH services
3009248|NCT02501252|No Intervention|Control|will be composed of a randomly selected comparable controls clusters. Control clusters (arm) will be similar with the other two arms (groups) except for the intervention.
3009249|NCT02501239|Experimental|Accept Yourself! Intervention|Combined Health At Every Size and Acceptance and Commitment Therapy Psychotherapy Group
3009250|NCT02501239|Active Comparator|Behavioral Weight Loss|Weight Watchers groups
3009251|NCT02501226|Other|Control group|Treatment as usual
3009252|NCT02501226|Experimental|Interventional group|ENVIE psychoeducational program
3009253|NCT02501213|No Intervention|A : observation|Clinical monitoring and best supportive care.
3009254|NCT02501213|Active Comparator|B : diuretics|Diuretics (spironolactone +/- Furosemide) are administered the day after the paracentesis and until the next episode requiring paracentesis.
3009255|NCT02501200|Experimental|TR group|CKD-391 and combination dose of Atrovastatin and Ezetimibe in order
3009256|NCT02501200|Experimental|RT group|combination dose of Atrovastatin and Ezetimibe and CKD-391 in order
3009257|NCT02501187|Experimental|Patients operated for ptosis by levator advancement|patients undergoing surgical repair for aponeurotic ptosis by the procedure- levator advancement.
3009258|NCT02501187|Experimental|Patients operated for ptosis by white line advancement|patients undergoing surgical repair for aponeurotic ptosis by the procedure- white line advancement
3009259|NCT02501187|Experimental|Patients operated for ptosis by Müller resection|patients undergoing surgical repair for aponeurotic ptosis by the procedure- Müller's muscle-conjunctival resection.
3009260|NCT02501161|Experimental|Insulin degludec/liraglutide QD + OAD(s)|
3009261|NCT02501161|Active Comparator|insulin glargine QD + OAD(s)|
3009262|NCT02501148||Carotid artery stenting|Symptomatic and asymptomatic subjects requiring carotid artery stenting, post-dilation performed using the Paladin System with integrated embolic protection
3009263|NCT02501135||Femoral Nerve Blocks|Patients who receive ropivacaine or bupivacaine during femoral nerve block.
3009264|NCT02501122||Adenotonsillectomy|Measuring quality of care in patients undergoing adenotonsillectomy.
3009265|NCT02501109|Experimental|Group A|Healthy volunteers will receive Aripiprazole Oral Soluble Film(OSF) 10mg orally a single of dose within 28 days with water.
3009266|NCT02501109|Experimental|Group B|Healthy volunteers will receive Aripiprazole Oral Soluble Film(OSF) 10mg orally a single of dose within 28 days without water.
3009267|NCT02501109|Experimental|Gruop C|Healthy volunteers will receive the reference drug Abilify tab. 10mg orally a single of dose within 28 days with water.
3009268|NCT02501096|Experimental|Lenvatinib + pembrolizumab|Participants with one of the tumors: non-small cell lung cancer, renal cell carcinoma, endometrial cancer, urothelial cancer, squamous cell carcinoma of the head and neck, or melanoma.
3009269|NCT02501070||Pre-PROGALIAM|Patients treated for myocardial infarction before the implementation of the network for acute myocardial infarction care (2001 to 2005).
3009270|NCT02501070||PROGALIAM|Patients treated for myocardial infarction after the implementation of the network for acute myocardial infarction care (2005 to 2011).
3009271|NCT02501057|Active Comparator|Clinician's Guide|"The Baseline intervention includes a brief meeting (20 minutes or less) with a clinic staff member to discuss drinking and HIV medication adherence. The clinic staff member provides feedback on the participant's drinking, helps the participant set a drinking goal, and make suggestions to help the participant reduce their drinking. Participant receives a booklet called Rethinking Drinking that includes information about alcohol and tips for cutting down on alcohol use or quitting drinking. 30- and 60-day visits last about 10 minutes each, and include a meeting with the clinic staff member again to discuss drinking and HIV medication adherence, and to get additional feedback."
3009272|NCT02501057|Active Comparator|Enhanced Motivational Interviewing|Participants meet with a counselor to discuss their alcohol use, the impact it has on their health, and the possibility of reducing their drinking. The first counseling session is intended to help participants reduce their alcohol use. They are asked to describe the pros and cons of their alcohol use and whether it might be important to reduce or quit drinking. After, they are given a study smartphone and asked to use HealthCall-S daily to help keep track of their drinking. At 30 days, participants review a graph showing the results of HealthCall-S use and discuss it with the counselor. They also have a brief discussion about drinking patterns and goals for reduction. They are then asked to continue using HealthCall-S for the next 30 days, after which the counselor meets with the participant for another brief interview to go over the updated graph, and to discuss their experience with HealthCall-S. They will also have a brief discussion about drinking patterns and goals for reduction.
3009277|NCT02501018|Experimental|CLI Due to ASO with CLBS12 + SOC|This group of subjects with CLI due to ASO will be administered with CLBS12 + SOC for collecting efficacy and safety data.
3009278|NCT02501018|Active Comparator|CLI Due to ASO with SOC|This grop of subjects with CLI due to ASO will be administered with SOC only.
3009279|NCT02501018|Experimental|CLI Due to BD with CLBS12|CLBS12 will be administered to patients with CLI due to BD for collecting safety and efficacy data.
3009280|NCT02501005|Experimental|Treatment Group 1 (TG1)|Prophylactic VT ablation prior to ICD implantation
3009281|NCT02501005|Other|Treatment Group 2 (TG2)|ICD implantation and best medical care until the third appropriate ICD shock occurs and catheter ablation thereafter
3009282|NCT02500992||Transrectal sigmoidectomy|Patients undergoing transrectal NOTES sigmoidectomy
3009283|NCT02500992||Laparoscopic-assisted sigmoidectomy|Patients undergoing laparoscopic-assisted sigmoidectomy
3009284|NCT02500979|Experimental|Pramlintide acetate & regular insulin|Pramlintide will be adiministered by sc infusion at a concentration of 1000ug/mL
3009285|NCT02500979|Placebo Comparator|Placebo and regular insulin|Placebo is similar sterile solution without pramlintide.
3009286|NCT02500966|Experimental|DUDA device|"The number of patients to be recruited in this arm will be 145. Note: The first twenty-five patients who will be included in the study will be allocated in the intervention arm to safety analysis (phase 1); after that all eligible candidates will be randomized 1:1 (phase 2).~Procedure: Loop Electrosurgical Excision Procedure (LEEP) followed by implantation of the device called DUDA (plastic device developed in barretos cancer hospital that will be placed after conization. It has 2.5 cm in length and 5mm in diameter and remains within the endocervical canal for 30 days and is set at 4 points with nonabsorbable sutures in the ectocervix.)"
3009287|NCT02500966|Active Comparator|Control group|"The number of patients to be recruited in this arm will be 120.~Procedure: Loop Electrosurgical Excision Procedure (LEEP) without DUDA device"
3009288|NCT02500953|Experimental|Japanese male single fasted ASP dose-1|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
3009289|NCT02500953|Experimental|Japanese male single fasted ASP dose-2|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
3009290|NCT02500953|Experimental|Japanese male single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
3009291|NCT02500953|Experimental|Japanese male single fasted ASP dose-4|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
3009292|NCT02500953|Experimental|Japanese male single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
3009293|NCT02500953|Experimental|Japanese male single fasted ASP dose-6|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
3009294|NCT02500953|Experimental|Japanese male single fasted ASP dose-7|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
3009295|NCT02500953|Experimental|Japanese female single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
3009296|NCT02500953|Experimental|Japanese female single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
3009297|NCT02500953|Experimental|Caucasian male single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
3009298|NCT02500953|Experimental|Caucasian male single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
3009299|NCT02500953|Experimental|Japanese male single fed ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects after a meal.
3009300|NCT02500953|Experimental|Japanese male single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
3009301|NCT02500953|Experimental|Japanese female single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
3009302|NCT02500953|Experimental|Caucasian male single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
3009303|NCT02500953|Experimental|Japanese male single fed placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects after a meal.
3009304|NCT02500953|Experimental|Japanese male multiple ASP dose-3|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
3009305|NCT02500953|Experimental|Japanese male multiple ASP dose-4|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
3009306|NCT02500953|Experimental|Japanese male multiple ASP dose-5|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
3009307|NCT02500953|Experimental|Japanese female multiple ASP dose-3|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
3009308|NCT02500953|Experimental|Japanese female multiple ASP dose-4|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
3009309|NCT02500953|Experimental|Japanese female multiple ASP dose-5|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
3009310|NCT02500953|Experimental|Japanese male multiple Placebo|Placebo will be administered with 240 mL of water, three times a day, just after a meal.
3009311|NCT02500953|Experimental|Japanese female multiple Placebo|Placebo will be administered with 240 mL of water, three times a day, just after a meal.
3009911|NCT02497092|Active Comparator|Fast angled injection|fast and angled insertion of the needle through the sclera
3009312|NCT02500953|Experimental|Japanese male ASP dose-5 before a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
3009313|NCT02500953|Experimental|Japanese male ASP dose-5 during a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
3009314|NCT02500953|Experimental|Japanese male ASP dose-5 after a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
3009315|NCT02500940|Experimental|Control group|Neoadjuvant chemotherapy with tri-weekly cisplatin plus fluorouracil × 3 cycles (cisplatin 100 mg/m2, day 1, followed by fluorouracil 1000 mg/m2/d, days 1-4 continuous iv infusion, repeated every 3 weeks) + Intensity-Modulated Radiation Therapy ≧ 70 Gy/35 fractions
3009316|NCT02500940|Active Comparator|Test group|Neoadjuvant chemotherapy with weekly cisplatin, fluorouracil and leucovorin × 10 weeks (cisplatin 60 mg/m2 at days 1, 15, 29, 43, 57; alternatively with fluorouracil 2500 mg/m2 + leucovorin 250 mg/m2 at days 8, 22, 36, 50, 64) + Intensity-Modulated Radiation Therapy ≧ 70 Gy/35 fractions
3009317|NCT02500927|Experimental|ASP8273 group|Single oral administration of ASP8273 Capsule A for bioavailability evaluation, followed once daily multiple administration of ASP8273 Capsule
3009318|NCT02500914|Experimental|SC-002|"Part 1A (Dose Escalation) - IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose (MTD) or lower dose that provides adequate PK exposure, immunogenicity, and preliminary evidence of antitumor activity with tolerability.~Part 1B (Dose Expansion) - IV infusion; once MTD and/or RD has been determined in Part 1A, an expansion cohort of approximately 60 patients with SCLC or LCNEC will be enrolled to further characterize the safety profile and clinical activity of the RD. Patients may continue treatment until disease progression, unacceptable toxicity, or withdrawal of consent."
3009319|NCT02500901|Experimental|Experimental Treatment|Subjects will receive enzalutamide 160 mg/day PO in a 28-day lead-in cycle to assess tolerability. If well-tolerated, cycle 1 of combined enzalutamide and niraparib will commence. Enzalutamide will continue at 160 mg PO daily. Niraparib will be administered in three dose-escalation cohorts of 100mg PO, 200mg PO or 300 mg PO daily. Six subjects will be enrolled at each dose level. Each cycle will be 28 days. Combination treatment will continue until documented progression, unmanageable toxicity, or subject or treating investigator decision to discontinue for any reason.
3009320|NCT02500888|Experimental|Treatment|Radiosurgery by linear accelerator.
3009321|NCT02500875|Experimental|PTNiA|"Topical negative pressure therapy with instillation of saline solution (6 times daily).~During the instillation of saline solution, aspiration is stopped for 10-15 minutes and subsequently the device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
3009322|NCT02500875|Experimental|PTNiB|"Topical negative pressure therapy with instillation of Amukine Med 0,05% (6 times daily).~During the instillation of Amukine Med 0,05%, aspiration is stopped for 10-15 minutes and subsequently the device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
3009323|NCT02500875|Active Comparator|PTN|"Topical negative pressure therapy (without instillation). The device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
3009324|NCT02500849|Experimental|Cohort 1:|target busulfan AUC levels: 8,000 µM*min (+/- 1,000)
3009325|NCT02500849|Experimental|Cohort 2:|busulfan AUC levels: 12,000 µM*min (+/- 1,000)
3009326|NCT02500836|Experimental|Cocaine HCI 4% Topical Solution|Cocaine HCl 4% Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. If a pain score of 0 (zero) is recorded, then the diagnostic procedure or surgery proceeds along with safety monitoring for at least 90 minutes after removal of the pledget(s). The subject will be followed for safety for seven days. The total number of pledgets used, and the amount of Cocaine HCl 4% topical solution used (1 mL per pledget) will be recorded.
3009327|NCT02500836|Experimental|Cocaine HCI 10% Topical Solution|Cocaine HCl 10% Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. If a pain score of 0 (zero) is recorded the application then proceed with the diagnostic procedure or surgery along with safety monitoring for at least 90 minutes post removal of pledgets, and, the subject will be followed for safety for at least seven days post solution application. The total number of pledgets used, and the amount of Cocaine HCl 10% topical solution used (1 mL per pledget) will be recorded.
3009328|NCT02500836|Placebo Comparator|Placebo Topical Solution|Placebo Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. The subject will then exit the treatment portion of the trial and be followed for safety for seven days . The total number of pledgets used, and the amount of placebo solution used (1 mL per pledget) will be recorded. After a minimum of 90 minutes from the time of study drug pledget removal, the subjects may have their surgery or diagnostic procedure, and the treatment reverts to standard anesthetic management (e.g. application of lidocaine, tetracaine, bupivicaine or other suitable products at the discretion of the investigator).
3009329|NCT02500823||CHD group|200 consecutive patients were recruited, who have diagnosed with coronary heart disease(CHD) by coronary angiography.
3009330|NCT02500823||Control group|The 200 healthy controls without previous CHD history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
3042990|NCT02273557|Experimental|Asasantin ER (new formulation I - low)|
3009333|NCT02500797|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes once every 2 weeks. Courses repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress after 10 weeks on single agent nivolumab may elect to cross over to Arm II.
3009334|NCT02500797|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 30 minutes every 2 weeks. Courses repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress by imaging during the first 12 weeks of therapy may continue treatment, at the discretion of the patient and treating investigator.
3009335|NCT02500784|Active Comparator|Formoterol A|12 months, formoterol, 20microgram/2ml, inhaler, BID
3009336|NCT02500784|Placebo Comparator|Formoterol B|12 months, normal sailine, 2ml, inhaler, BID
3009337|NCT02500771|Experimental|children and tutors using V-Motive|"The following intervention will be administered:~ABA therapy enhanced with V-Motive software~Tutors treating children with Applied Behavioral Analysis therapy will use the V-Motive software to enhance therapy sessions. Children will receive therapy as usual, but half of their current behavioral programs (skills/goals) will have been selected for enhanced prompting through video modeling."
3009338|NCT02500758|Experimental|Parachlorometaxylenol|Reducing bacterial load after preoperative surgical scrubbing using 3% PCMX. Both hands have been prepared by preparatory handwash.
3009339|NCT02500758|Active Comparator|Clorhexidine digluconate|Reducing bacterial load after preoperative surgical scrubbing using 4% CHG. Both hands have been prepared by preparatory handwash.
3009340|NCT02500745||Transesophageal echocardiography|Patients referred for transesophageal echocardiography for a clinical indication
3009341|NCT02500732|Placebo Comparator|Placebo|Placebo capsule to be given the night before the study tilt, and the morning of the study tilt test.
3009342|NCT02500732|Active Comparator|Atomoxetine|Atomoxetine 40mg PO to be given the night before the study tilt, and the morning of the study tilt test.
3009343|NCT02500719||Healthy Participants|A group of healthy participants will be enrolled first in the pilot phase of the study. This phase allows for the refinement of the application of our Fitted Q Learning algorithm prior to implementing with our PTSD participant group.
3009344|NCT02500719||PTSD Participants|A group of participants with symptoms of PTSD will be enrolled in the implementation phase of the study. This phase allows for the evaluation brain networks thought to mediate emotional arousal, specifically whether participants can learn volitional control of these networks.
3009345|NCT02500706|Experimental|Mealtime faster-acting insulin aspart and insulin degludec|
3009346|NCT02500706|Active Comparator|Mealtime NovoRapid® and insulin degludec|
3009347|NCT02500706|Experimental|Postmeal faster-acting insulin aspart and insulin degludec|
3009348|NCT02500693|Experimental|Screening|
3009349|NCT02500680|Experimental|Group 1 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 1µg (Standard Dose) Single Dose
3009350|NCT02500680|Experimental|Group 2 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 3µg (Standard Dose) Single Dose
3009351|NCT02500680|Experimental|Group 3 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 5µg (Standard Dose) Single Dose
3009352|NCT02500680|Experimental|Group 4 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 9µg (Standard Dose) Single Dose
3009353|NCT02500680|Active Comparator|Group 5A (Phase 1A)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 15µg (Standard Dose) Single Dose
3009354|NCT02500680|Active Comparator|Group 5B (Phase 1B)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose
3009355|NCT02500680|Experimental|Group 6 (Phase 1B)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) Optimal Vaccine Dose from Phase 1A (9µg) (Standard Dose) Single Dose
3009356|NCT02500680|Experimental|Group 7A (Phase 1B extension)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 9µg/HA in 0.5 mL MAS-1 emulsion (Standard Dose) Single Dose
3009357|NCT02500680|Active Comparator|Group 7B (Phase 1B extension)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose
3009358|NCT02500680|Experimental|Group 8A (Phase 1B extension)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 15µg/HA in 0.5 mL MAS-1 emulsion (Standard Dose) Single Dose
3009359|NCT02500680|Active Comparator|Group 8B (Phase 1B extension)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose
3009360|NCT02500667|Experimental|N91115 + Rifampin|N91115 200 mg twice daily (BID) from Study Day 1- 13, Rifampin 600 mg once daily (QD) from Study Day 8 - 12
3009361|NCT02500654|Experimental|Surgery and Emdogain®|access peri-implant surgery with Emdogain® applied after cleaning of implant surface with saline
3009362|NCT02500654|Placebo Comparator|Surgery alone|access peri-implant surgery and cleaning of implant surface with saline
3009363|NCT02500641|Experimental|Febuxostat 80/120 mg/day|"Febuxostat 80/120 mg film coated tablets.The initial daily dose is 80 mg given orally. In case a patient has serum urate level 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained during the study treatment period.~To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg quaque die (QD ) or in case of colchicine intolerance, Naproxen 550 mg bis in die (BID) with Omeprazole (20-40 mg once daily), if indicated to be used."
3009364|NCT02500641|Active Comparator|Allopurinol 100 up to 600 mg/day|"Allopurinol 100/300 mg tablets.The initial daily allopurinol dose is 100 mg given orally, to be escalated of 100 mg every 2 weeks in patients with serum urate concentration >6 mg/dl.~The maximum dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg daily.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD or in case of colchicine intolerance, Naproxen 550 mg BID with Omeprazole (20-40 mg once daily), if indicated to be used."
3009365|NCT02500628|Experimental|Fibromyalgia|Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg orally in the morning
3009366|NCT02500628|Experimental|Antipsychotic use|Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg orally in the morning
3009372|NCT02500602|Experimental|Doxazosin|Participants will be randomly assigned to receive doxazosin (target dose of 16 mg/day) or placebo. Doxazosin will be initiated at 1 mg/day for the first week, 2mg/day for the second week, 4mg/day for the third week, 8mg/day for the fourth week, and then increase to 16 mg/day for the remaining eight weeks (as tolerated). Research staff will administer the study medication or placebo at the weekly visits, and participants will be given take-home doses of the medication or placebo to self-administer on the days in between study visits.
3009373|NCT02500602|Placebo Comparator|Placebo|Placebo pill
3009374|NCT02500589|Experimental|Mood management enhancement|In the SMK-MM enhanced arm, behavioral mood management will be integrated into the evidence-based smoking cessation counseling.
3009375|NCT02500589|Other|Health education control|"In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with personal health care. Participants also will receive chronic-disease-specific self-management information."
3009376|NCT02500576|Experimental|High Dose IL-2 + Lymphodepleting Chemotherapy + TIL Infusion|"Participants receive high dose IL-2 after standard lymphodepleting chemotherapy and TIL infusion.~Cyclophosphamide administered at 60 mg/kg/day by vein on Days -7 and -6. Mesna 60 mg/kg by vein on Days -7 and -6. Fludarabine 25 mg/m2 by vein on Days -5 to -1. On day 0, TIL infused as an inpatient by vein approximately 15-60 minutes depending on the volume of cells infused. Up to 150 billion cells infused.~Participants receive high dose IL-2 at dose of 720,000 IU/kg by vein every 8-16 hours for up to 15 doses starting 12-16 hours after T cell infusion on Day 1.~If participants develop stable or partially responding disease, up to 31 doses (2 years) of MK-3475, 200 mg by vein every 21 days.~Questionnaires completed about quality of life at baseline, Day 63, then every 12 weeks.~After 2 years of pembrolizumab, phone calls made by study staff to participant every 3 months."
3009377|NCT02500576|Experimental|Low Dose IL-2 + Lymphodepleting Chemotherapy + TIL Infusion|"Participants receive low dose IL-2 after standard lymphodepleting chemotherapy and TIL infusion.~Cyclophosphamide administered at 60 mg/kg/day by vein on Days -7 and -6. Mesna 60 mg/kg by vein on Days -7 and -6. Fludarabine at 25 mg/m2 by vein on Days -5 to -1. On day 0, TIL infused as an inpatient by vein approximately 15-60 minutes depending on the volume of cells to be infused. Up to 150 billion cells infused.~Participants receive low dose IL-2 at 2 million IU/kg subcutaneously for 14 days starting 12-16 hours after T cell infusion on Day 1.~If participants develop stable or partially responding disease, up to 31 doses (2 years) of MK-3475, 200 mg by vein every 21 days.~Questionnaires completed about quality of life at baseline, Day 63, then every 12 weeks.~After 2 years of pembrolizumab, phone calls made by study staff to participant every 3 months."
3009378|NCT02500563|Active Comparator|Amino acid based infant formula|
3009379|NCT02500563|Experimental|Extensively hydrolyzed casein infant formula|
3009380|NCT02500563|Other|Mother's own breast milk|
3009381|NCT02500550|Experimental|ATIR101|
3009382|NCT02500537|Experimental|Abdominal Procedures|"Abdominal procedures may include, but are not limited to, laparoscopic sleeve gastrectomy (LSG), laparoscopic Roux-en-Y gastric bypass (LRYGB), and biliopancreatic diversion, as well as hepatic and pancreatic resection.~Device: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology"
3009383|NCT02500537|Experimental|Thoracic Procedures|"Thoracic procedures may include, but are not limited to wedge resection and lobectomy, and may include video assisted thoracic surgery (VATS) or open procedures.~Device: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology"
3009384|NCT02500524|Experimental|10% Cocamide diethanolamine|10% Cocamide DEA aqueous lotion is applied directly to dry hair on a single occasion and is washed off with shampoo after 60 minutes.
3009385|NCT02500524|Active Comparator|1% permethrin creme rinse|1% permethrin creme rinse is applied to shampooed and towel dried hair on a single occasion and left in situ for 10 minutes, then rinsed off with clean water.
3009386|NCT02500485|Experimental|SHR3824 20mg/SP2086 100mg|One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
3009387|NCT02500472|Experimental|Kava Supplement|See intervention description.
3009388|NCT02500459|Experimental|intraparenchymally-administered topotecan|Patients will have topotecan administered directly into the tumor bed using convection-enhanced delivery (CED)
3009389|NCT02500446|Active Comparator|Intensification|Oral dolutegravir 50 mg once daily for 8 weeks added to their current ART regimen.
3009390|NCT02500446|Placebo Comparator|Placebo|Oral placebo once daily for 8 weeks added to their current ART regimen.
3009391|NCT02500433|Experimental|Device: Kinect-Xbox360TM|"Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.~Participants were initially exposed to the games in an hour introductory session, 2 weeks before the study began. All the sessions were supervised by physiotherapist."
3009392|NCT02500433|Other|Conventional therapy|"Conventional therapy was based on neurodevelopment treatment, psychomotor activities and kinesiotherapy during one month, twice per week, with 30 minutes per session.~The treatment includes: active and passive kinesitherapy, muscle and tendons stretching, training of gait and deambulation, such as coordination and handling."
3009426|NCT02500212|Experimental|ENVARSUS tablets|"Envarsus® (tacrolimus) prolonged-release tablets provided in 0.75 mg, 1.0 mg and 4.0 mg dose strengths.~Envarsus® tablets will be administered orally once daily in the morning"
3009427|NCT02500212|Active Comparator|ADVAGRAF capsules|"Advagraf® (tacrolimus) prolonged-release hard capsules provided in 0.5 mg, 1.0 mg, 3.0 mg and 5.0 mg dose strengths.~Advagraf® capsules will be administered orally once daily in the morning"
3009912|NCT02497092|Active Comparator|Fast straight injection|fast and straight insertion of the needle through the sclera
3009393|NCT02500420|Other|Diagnosis examens|"Cardiac MRI: is usually recommended in the diagnosis or in the follow-up of the disease. The MRI will respect the standard protocol: cineMRI sequences, perfusion sequences, LGE sequences at 10 minutes after gadolinium injection. The investigators will realize some additional sequences: T1 mapping before and after gadolinium injection to study the diffuse fibrosis and stress perfusion sequences after injection of a vasodilatator (Persantine°).~Exercice stress echocardiography: is realized almost systematically in all the diagnosis of HCM and it's very informative. The investigators will research left ventricular dysfunction: in particular segmentary hypokinesia and anomalies of deformation parameters (2D Strain) and the development of a dynamic left ventricular outflow obstruction or a mitral regurgitation at exercice."
3009394|NCT02500407|Experimental|Dose Escalation|Participants will receive BTCT4465A (Mosunetuzumab) via intravenous (IV) infusion or subcutaneous (SC) injection as a single-agent or in combination with atezolizumab. Dose escalation will be guided by the observed incidence of DLTs at each dose level.
3009395|NCT02500407|Experimental|Dose Expansion|Participants will receive BTCT4465A (Mosunetuzumab) at the RP2D as a single-agent or in combination with atezolizumab.
3009396|NCT02500394|Placebo Comparator|standard care|Patients in the standard care population receive - if biomarkers are elevated -treatment of AKI in accordance with KDIGO 2012 guidelines
3009397|NCT02500394|Active Comparator|interventional care|Patients in the interventional population receive - if biomarkers are elevated - individualized treatment/volume substitution (balanced electrolyte solution = Ionosteril; 1,25-5 ml/kg/bw/6 hours) ) on the basis of predefined criteria
3009398|NCT02500381|Experimental|SRP-4045|Patients amenable to exon 45 skipping will receive SRP-4045 intravenous (IV) infusions, weekly, at 30 mg/kg for up to 96 weeks in double-blinded period. This will be followed by an open label extension period in which all patients will receive open-label active treatment of SRP-4045 at 30 mg/kg/week IV infusions for up to 96 weeks.
3009399|NCT02500381|Experimental|SRP-4053|Patients amenable to exon 53 skipping will receive SRP-4053 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in double-blinded period. This will be followed by an open label extension period in which all patients will receive open-label active treatment of SRP-4053 at 30 mg/kg/week IV infusions for up to 96 weeks.
3009400|NCT02500381|Placebo Comparator|Placebo followed by SRP-4045 or SRP-4053|Patients amenable to exon 45 or 53 skipping will receive SRP-4045 or SRP-4053 placebo-matching IV infusions, weekly, at 30 mg/kg for up to 96 weeks in double-blinded period. This will be followed by an open label extension period in which all patients will receive open-label active treatment of SRP-4045 or SRP-4053 at 30 mg/kg/week IV for up to 96 weeks.
3009401|NCT02500368|Experimental|silicone hydrogel lens (test)|Participants were randomized to wear silicone hydrogel lens (test) for 1 week during the cross over study.
3009402|NCT02500368|Active Comparator|enfilcon A lens (control)|Participants were randomized to wear enfilcon A lens (control) for 1 week during the cross over study.
3009403|NCT02500355|Active Comparator|Group A|Carpal Tunnel Release via limited approaches with 2 years follow-up.
3009404|NCT02500355|Active Comparator|Group B|Carpal Tunnel Release via standard approach with 2 years follow-up.
3009405|NCT02500355|Placebo Comparator|Group C|Endoscopic Carpal Tunnel Release with 2 years follow-up.
3009406|NCT02500342|Experimental|Drug: Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
3009407|NCT02500342|Placebo Comparator|Drug: Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
3009408|NCT02500329|Experimental|gemigliptin|gemigliptin for 4 weeks
3009409|NCT02500329|Active Comparator|acarbose|acarbose for 4 weeks
3009410|NCT02500316|Experimental|MOD-4023|Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).
3009411|NCT02500290||Acute coronary syndrome|
3009412|NCT02500277|Active Comparator|Cryobiopsy|Pleural biopsy with a flexible cryoprobe
3009413|NCT02500277|Active Comparator|Forceps biopsy|Pleural biopsy with a flexible forceps
3009414|NCT02500264|Active Comparator|Protocol #1|interventions: 1.6Hz, Rampdown 0.4S, electrodes position - both L.Rectus Abdominis, 5cmX5cm Size, on inspirium
3009415|NCT02500264|Active Comparator|Protocol #2|1Hz, Rampdown 0.6S, electrodes position - both Rectus Abdominis, 5cmX5cm Size, on inspirium
3009416|NCT02500264|Active Comparator|Protocol #3|1.6Hz, Rampdown 0.4S, electrodes position - L.Rectus Abdominis and L.External Oblique, 5cmX5cm Size, on inspirium Oblique
3009417|NCT02500264|Active Comparator|Protocol #4|1Hz, Rampdown 0.6S, electrodes position - L.Rectus Abdominis and L.External Oblique, 5cmX5cm Size, on inspirium
3009418|NCT02500251|Experimental|Group A (5 subjects)|Subjects will receive bortezomib and plasmapheresis.
3009419|NCT02500251|Experimental|Group B (5 subjects)|Subjects will receive belimumab, bortezomib, and plasmapheresis.
3009420|NCT02500251|Experimental|Group C (5 subjects)|Subjects will receive belimumab, bortezomib, rituximab, and plasmapheresis.
3009421|NCT02500238||Control|This group will provide 2 breath carbon monoxide (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings will be taken from this group.
3009422|NCT02500238||Smoking|This group will provide 1 breath carbon monoxide test (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings.
3009423|NCT02500238||Vaping|This group will provide 2 breath carbon monoxide test (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings.
3009424|NCT02500225|Active Comparator|Etomidate|0.2 mg/kg etomidate during anesthesia induction
3009425|NCT02500225|Active Comparator|8% sevoflurane|Sevoflurane 8% concentration during anesthesia induction
3009428|NCT02500199|Experimental|Pyrotinib|A two-part Phase I, open-label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy
3009429|NCT02500186|Experimental|High GI meal containing 55% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in high GI meal containing 55% carbohydrate group take 55% carbohydrate white rice diet.
3009430|NCT02500186|Experimental|Low GI meal containing 55% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in low GI meal containing 55% carbohydrate group take 55% carbohydrate brown rice diet
3009431|NCT02500186|Experimental|High GI meal containing 40% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in high GI meal containing 40% carbohydrate group take 40% carbohydrate white rice diet.
3009432|NCT02500160|Experimental|patient specific instrumentation (MRI)|MRI based patient-specific instrumentation
3009433|NCT02500160|Active Comparator|patient specific instrumentation (CT)|CT based patient-specific instrumentation
3009434|NCT02500147|Experimental|Metformin|Adolescents and young adults with PCOS and liver fat greater than or equal to 4.8% will be randomized to metformin or placebo. Metformin ER (extended release) will be administered as two pills of 500 mg each. For the first week subjects will take one pill orally on a daily basis and thereafter will take two pills orally on a daily basis. The intervention will last six months.
3009435|NCT02500147|Placebo Comparator|Placebo|Adolescents and young adults with PCOS and liver fat greater than or equal to 4.8% will be randomized to metformin or placebo. Subjects randomized to placebo will be instructed to take one pill daily by mouth for one week and then to take one pill daily by mouth for the remainder of six months.
3009436|NCT02500134||Normal|Healthy volunteer control without ocular surface disease or prior ophthalmic surgery history
3009437|NCT02500121|Placebo Comparator|Control Arm A|Commercially available normal saline will be used as the placebo. No active placebo drug will be mixed with the normal saline. Treatment will continue, in the absence of prohibitive toxicities or disease progression, for up to 24 months.
3009438|NCT02500121|Experimental|Experimental Arm B|Pembrolizumab, 200mg IV every 3 weeks. Treatment will continue, in the absence of prohibitive toxicities or disease progression, for up to 24 months.
3009439|NCT02500108||Treated with domperidone|Patients who received a new prescription for domperidone (ATC A03FA03) in the year prior to the index date.
3009440|NCT02500108||Unexposed (reference) group|Patients with no prescription for domperidone in the year prior to the index date.
3009441|NCT02500095|No Intervention|Control|12 hours of fasting
3009442|NCT02500095|Experimental|Fasting and saline|72 hours of fasting and concomitant saline
3009443|NCT02500095|Experimental|Fasting and GHR blockade|72 hours of fasting and concomitant Growth hormone receptor (GHR) blockade with Pegvisomant (Somavert) for inhibition of the fasting-induced GH secretion
3009444|NCT02500069|Placebo Comparator|Placebo|Tap water infusion in all three locations (duodenum, jejunum and ileum)
3009445|NCT02500069|Experimental|Duodenum|Infusion of casein in duodenum
3009446|NCT02500069|Experimental|Jejunum|Infusion of casein in jejunum
3009447|NCT02500069|Experimental|Ileum|Infusion of casein in ileum
3009448|NCT02500056|Active Comparator|OM group|Optilene LP mesh
3009449|NCT02500056|Active Comparator|UM group|Ultrapro mesh
3009450|NCT02500043|Experimental|TAS-102|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
3009451|NCT02500043|Experimental|Placebo|35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
3009452|NCT02500030|Experimental|Air Stacking|Air Stacking was performed with the subject seated in his wheelchair using a manual resuscitation bag (LIFESAVER® model 5345, Hudson, Temecula, USA) connected to a corrugated tube with an internal diameter of 22 mm, a one-way valve and a pipette. The maximum capacity of the bag was 1600 mL. A chest physiotherapist insufflated the patient during the inspiratory phase, requesting that inspire as much air as possible
3009453|NCT02500030|Experimental|Glossopharyngeal Breathing|"Glossopharyngeal Breathing was also performed with the subject seated in his wheelchair and performing successive maneuvers of swallowing air until the maximum volume achieve was maintained. Then, the patient was instructed to breathe through ventilometer to register the MIC. Three measurements for each of the techniques were performed, and the highest reading was recorded. A difference of <10% between the measurements was used as the repeatability criterion"
3009454|NCT02500017|Experimental|Melatonin|A commercially available rapid-release formulation of melatonin (5 mg) capsules to be administered once a day for a total of 8 weeks
3009455|NCT02500017|Placebo Comparator|Placebo|Matching placebo capsules to be administered once a day for a total of 8 weeks
3009456|NCT02500004|Active Comparator|Cachectic pancreatic cancer|"Cachectic patients with pancreatic cancer~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
3009457|NCT02500004|Active Comparator|Cachectic NSCLC|"Cachectic patients with non-small cell lung cancer~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
3009458|NCT02500004|Active Comparator|Cachectic COPD|"Cachectic COPD patients.~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
3009520|NCT02499601|Experimental|CORolla™ TAA Stand Alone|Single arm study design including with patients with isolated HFpEF, in NYHA f. Cl. III-IV. These patients will receive the CORolla™ TAA device. For assessments of results, intra-patient comparisons of pre-procedure and follow-up data will be performed;
3009459|NCT02500004|Active Comparator|Non-cachectic COPD|"Non-cachectic COPD patients.~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
3009460|NCT02500004|Other|Healthy individuals|"BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
3009461|NCT02499991|Experimental|Treatment|"Treatment group will keep diary of social events according to training instructions.~Memory intervention will be used."
3009462|NCT02499991|No Intervention|Control|Control group will use own memory of social events without training instructions.
3009463|NCT02499978|Experimental|DRV/COBI, DTG Immediate switch|DARUNAVIR/COBICISTAT (800mg/150MG), DOLUTEGRAVIR 50MG DAILY at randomization and follow through week 48.
3009464|NCT02499978|Active Comparator|DRV/COBI, DTG Delayed Switch|DARUNAVIR/COBICISTAT (800MG150MG), DOLUTEGRAVIR 50MG DAILY at week 24 and follow through week 48.
3009465|NCT02499965|Active Comparator|Topical Ethyl Chloride (Product B)|Ethyl Chloride Topical Aerosol Anesthetic applied to arm
3009466|NCT02499965|Placebo Comparator|Topical Sterile Water (Product A)|Nature's Tears Sterile water in an aerosol can
3009467|NCT02499952|Experimental|Experimental Arm|Pembrolizumab
3009468|NCT02499939|Active Comparator|Standard Care|Participants in this group will receive standard education about CIPN and therapeutic exercises to carry out at home.
3009469|NCT02499939|Experimental|Experimental: Ultrasound Therapy|Participants in this group will receive standard education about CIPN and therapeutic exercises to carry out at home. Participants in this group will also undergo 10 daily treatments of ultrasound therapy (e.g., Monday to Friday for two weeks) that is administered to their toes and fingers. The ultrasound therapy will be administered over the first two weeks of the intervention period.
3009470|NCT02499926|Experimental|Dietary supplement: Arginine|Graded arginine excess intake
3009471|NCT02499913|Active Comparator|breath alcohol monitoring|Breath alcohol samples and self-reports of drinking will be collected once daily at lunch and will be used as objective indicators of recent alcohol use.
3009472|NCT02499913|Experimental|breath monitoring plus prize contingency management|Breath alcohol samples and self-reports of drinking will be collected once daily at lunch and will be used as objective indicators of recent alcohol use. Participants of this group earn opportunities to draw cards from a prize bowl for negative breath samples.
3009473|NCT02499900|Experimental|Copaxone® 40 mg/mL|Subcutaneous Injections 40 mg/mL Three Times a Week for the core period which last 6 months. In the extension period patient are administered Copaxone® 40 mg/mL for months 7 - 12.
3009474|NCT02499900|Active Comparator|Copaxone® 20 mg/mL|Subcutaneous Injections 20 mg/mL Daily for the core period which last 6 months. In the extension period patient are administered Copaxone® 40 mg/mL for months 7 - 12.
3009475|NCT02499887|Active Comparator|Standard of Care|"Standard of Care: 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 4 days (1st dose will have been given in the ED)~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications."
3009476|NCT02499887|Experimental|Treatment|"Treatment: 30 day QVAR® (beclamethasone dipropionate) inhaler (80 mcg, 1 puff twice daily) plus 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 5 days~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications."
3009477|NCT02499874|Experimental|Single treatment arm|All subjects will be administered oral Efavirenz 400mg together with the rest of the oral antiretroviral combination (tenofovir 245 mg/emtricitabine 200mg or tenofovir 245mg/lamivudine 300mg or lamivudine 300mg/zidovudine 600mg) throughout the study period
3009478|NCT02499861|Experimental|Decitabine and Genistein|continuous 24 hours Intravenous decitabine followed by oral genistein for 20 days.
3009479|NCT02499848|Experimental|Intraprostatic administration|PRX302
3009480|NCT02499835|Experimental|Arm I (pTVG-HP plasmid DNA vaccine, concurrent pembrolizumab)|Patients receive pTVG-HP plasmid DNA vaccine ID every other week on days 1, 15, 29, 43, 57, and 71 and pembrolizumab IV over 30 minutes every 3 weeks on days 1, 22, 43, and 64.
3009481|NCT02499835|Experimental|Arm II (pTVG-HP plasmid DNA vaccine, sequential pembrolizumab)|Patients receive pTVG-HP plasmid DNA vaccine ID as in Arm I and pembrolizumab IV over 30 minutes every 3 weeks on days 85, 106, 127, and 148.
3009482|NCT02499835|Experimental|Extended Treatment Arm III|pTVG-HP (100 μg) with rhGM-CSF (208 μg) administered intradermally (i.d.) every 3 weeks, for a maximum of 16 doses. Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 3 weeks, for a maximum of 16 doses, beginning on day 1 after the first pTVG-HP vaccination.
3009483|NCT02499835|Experimental|Extended Treatment Arm IV|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) every 2 weeks, for a maximum of 24 doses Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 4 weeks, for a maximum of 12 doses, beginning on day 1 after the first pTVG-HP vaccination
3009484|NCT02499822|Experimental|Nifedipine GITS 30 mg slow release|Nifedipine GITS 30 mg slow release in tablets.
3009485|NCT02499822|Experimental|Ramipril 10 mg|Ramipril 10 mg in tablets.
3009486|NCT02499809|Experimental|Passive|Passive recovery
3009487|NCT02499809|Experimental|Vibration|Vibration recovery
3009488|NCT02499796|Experimental|Single Arm|"Every patient receives 20 minutes of invasive mechanical ventilation with each of the three humidification systems in random sequence:~Heated and moisture exchanger (HME)~Heated humidifier (HH)~Hygrovent Gold"
3009489|NCT02499783|Experimental|Subjects receiving maintenance dose starting at Week 8|Subjects will be given placebo until Week 4. At Week 4 the standard loading dose of adalimumab at Weeks 4 and 6 followed by the standard maintenance dose beginning at Week 8.
3009490|NCT02499783|Experimental|Subjects receiving maintenance dose starting at Week 4|Subjects will be given the standard loading dose of adalimumab at Weeks 0 and 2 followed by the standard maintenance dose beginning at Week 4.
3010152|NCT02495558|Experimental|Patients with Tracheostomy|Assessment of reflex cough Assessment of the deccanultation outcome (follow-up)
3009491|NCT02499770|Experimental|trilaciclib + carboplatin/etoposide|All patients in part 1 will receive trilaciclib (G1T28) prior to standard chemotherapy- carboplatin and etoposide. Patients will have PK assessments completed on days 1 and 3 in cycle 1 only. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
3009492|NCT02499770|Experimental|trilaciclib/placebo + carboplatin/etoposide|All patients enrolled in part 2 will be randomized to receive either trilaciclib (G1T28) or placebo administered prior to standard chemotherapy- carboplatin and etoposide. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
3009493|NCT02499757|Experimental|flavor and sweetener|E-cigarette with a novel flavor and sweetener added
3009494|NCT02499757|Experimental|flavor and nicotine|E-cigarette with a novel flavor and 12 mg nicotine added
3009495|NCT02499757|Experimental|flavor, nicotine and sweetener|E-cigarette with a novel flavor, sweetener, and 12 mg nicotine added
3009496|NCT02499757|Experimental|flavor|E-cigarette with a novel flavor: without a sweetener and 12 mg nicotine added
3009497|NCT02499744|Active Comparator|HHFNC|HHFNC is provided nasal cannula. Ventilator settings:fraction of inspired oxygen (FiO2):21-40%,flow:2-8(litre,L)/min,to maintain arterial blood hemoglobin oxygen saturation ( SaO2) at 90-95% The weaning process is left to the discretion of the attending physician.,when FiO2: 25%,flow:2(litre,L)/min.
3009498|NCT02499744|Active Comparator|NIPPV|NIPPV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,peak inspiratory pressure( PIP)：12-22cm H2O,positive and expiratory pressure(PEEP):5-7cm H2O,Rate:30-60 per minute to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP):6cm H2O,R:30 per minute .
3009499|NCT02499731|Experimental|Strong Hearts, Healthy Communities|Full Intervention participants will meet twice per week for one hour each time, for approximately 6 months plus monthly community meetings and events. Participants will learn and practice good nutrition and physical activity for improved individual, family and community health.
3009500|NCT02499731|Experimental|Strong Hearts, Healthy Women|Strong Hearts, Healthy Women minimum intervention participants meet once per month for an hour each time for 6 months. Participants will learn and discuss techniques and strategies to improve personal health.
3009501|NCT02499718|Experimental|Noninvasive ventilator|noninvasive positive pressure ventilation combined with long-term oxygen therapy for severe stable chronic obstructive pulmonary disease
3009502|NCT02499718|No Intervention|LTOT|long-term oxygen therapy for severe stable chronic obstructive pulmonary disease
3009503|NCT02499705|Experimental|Sucralose|Flavored beverage with sucralose.
3009504|NCT02499705|Experimental|Sucrose|Flavored beverage with sucrose.
3009505|NCT02499705|Experimental|Sucralose + maltodextrin|Flavored beverage with Splenda + maltodextrin .
3009506|NCT02499692|Experimental|SYNERGYTM Coronary Stent System|Device:SYNERGY MONORAIL Everolimus-Eluting Platinum Chromium Coronary Stent System
3009507|NCT02499679||Patients diagnosed with CAD by cCTA|All clinically stable, symptomatic patients diagnosed with CAD by coronary computed tomography angiography (cCTA), that meet eligibility criteria, and are able and willing to participate are candidates for the ADVANCE Registry. Those patients that meet all inclusion/exclusion criteria and who sign the ethics committee (EC)/institutional review board (IRB) approved informed consent will be enrolled in the registry. FFRCT shall be used in accordance with the current Instructions for Use (IFU) document.
3009508|NCT02499666||Asymptomatic|Patients with known chronic total occlusion who are undergoing percutaneous coronary intervention wtih balloon angioplasty and coronary stent placement who are currently asymptomatic (without any chest pain or anginal equivalent) but have decreased exercise capacity or are easily fatigued. Patients will also be on dual antiplatelet therapy with aspirin and a second agent such as clopidogrel.
3009509|NCT02499666||Symptomatic|Patients with known chronic total occlusion who are undergoing percutaneous coronary intervention with balloon angioplasty and coronary stent placement who are currently symptomatic with chest pain or anginal equivalent.. Patients will also be on dual antiplatelet therapy with aspirin and a second agent such as clopidogrel.
3009510|NCT02499653|Experimental|Psychological Intervention|In addition to the standard care, subjects are participating in a brief psychological support, which will include elements of psychological well-being's promotion and cognitive restructuring exercises (mindfulness).
3009511|NCT02499653|Active Comparator|Videos|The subjects assigned in the Control Group watch some videos relating to the management of their disease.
3009512|NCT02499640|No Intervention|GC|Control group - CG (n = 20), which suffered no recuperative technique
3009513|NCT02499640|Experimental|G1|G1 (n = 20) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 9±1 degrees Celsius
3009514|NCT02499640|Experimental|G2|G2 (n = 20) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 14±1 degrees Celsius
3009515|NCT02499640|Experimental|G3|G3 (n = 20) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 9±1 degrees Celsius
3009516|NCT02499640|Experimental|G4|G4 (n = 20) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 14±1 degrees Celsius
3009517|NCT02499627|Experimental|Bendamustine + Brentuximab for 6 cycles|Bendamustine 90 mg/m2 d1-2. Brentuximab vedotin 1.8 mg/kg d1.Every 21 days for 6 cycles.
3009518|NCT02499614|Experimental|Patients with MET amplification or MET exon 14 mutation|Pretreated NSCLC patients with MET amplification or MET exon 14 mutation with locally advanced or metastatic NSCLC and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal.
3009519|NCT02499614|Experimental|Patients with ROS1 translocation|Pretreated NSCLC patients with ROS1 translocation with locally advanced or metastatic NSCLC and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal.
3009521|NCT02499575|Active Comparator|Regional Block|Group A patients will receive only a pre-operative adductor canal block with 10 mL 0.5% ropivacaine plus a popliteal block with 30 mL 0.5% ropivacaine (total block 40 mL/200 mg).
3009522|NCT02499575|Experimental|Regional Block Plus Exparel|Group B patients will receive the standard of care pre-operative adductor and popliteal block as described (40 mL/200 mg of 0.5% ropivacaine) in addition to a postoperative pericapsular injection of Exparel using 106 mg (8 mL, equivalent to 120 mg bupivacaine HCl), per the same total dose as provided in manufacturer recommendations.
3009523|NCT02499562|Experimental|Hydronidone(180mg) & Entecavir & Placebo|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 2 capsules each time; with co-administration of placebo capsule, three times a day, 2 capsules each time, namely the daily dose of the investigational product is 180mg.~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
3009524|NCT02499562|Experimental|Hydronidone(270mg) & Entecavir & Placebo|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 3 capsules each time; with co-administration of placebo capsule, three times a day, 1 capsules each time, namely the daily dose of the investigational product is 270mg.~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
3009525|NCT02499562|Experimental|Hydronidone(360mg) & Entecavir|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 4 capsules each time; namely the daily dose of the investigational product is 360mg.~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
3009526|NCT02499562|Experimental|Entecavir & Placebo(360mg)|placebo capsule 30mg/capsule placebo capsule, three times a day, 4 capsules each time. The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach.
3009527|NCT02499549|Experimental|10% Cocamide diethanolamine 8 hours|Cocamide DEA topical lotion applied 8 hours/overnight with drying
3009528|NCT02499549|Experimental|10% Cocamide diethanolamine 2 hours|Cocamide DEA topical lotion applied 2 hours with drying, repeated after 7 days
3009529|NCT02499536|Experimental|Study participants|After general anesthesia development of the atelectasis will be investigated by the lung ultrasound
3009530|NCT02499523|Active Comparator|THR with conventional technique|Use of conventional technique in THR
3009531|NCT02499523|Experimental|THR with ACOG|THR with Acetabular Cup Orientation Guides (ACOG)
3009532|NCT02499510|Experimental|GoldenFlow stent|Titanium nitrite coated woven nitinol stent
3009533|NCT02499497|Placebo Comparator|Placebo|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose I or LY SARM Dose 2 daily, oral per cycle.
3009534|NCT02499497|Active Comparator|LY2452473 Dose I|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY2452473 Dose I or LY2452473 Dose 2 daily, oral per cycle.
3009535|NCT02499497|Active Comparator|LY2452473 Dose 2|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY2452473 Dose I or LY SARM Dose 2 daily, oral per cycle.
3009536|NCT02499484|Active Comparator|GTN and eccentric exercises|Participants will complete a 12 week eccentric exercise program and use 0.5cm of glyceryl trinitrate ointment daily for 24 weeks
3009537|NCT02499484|Placebo Comparator|Placebo and eccentric exercises|Participants will use a placebo ointment with no active ingredient for 24 weeks and complete an eccentric exercise program for 12 weeks
3009538|NCT02499471|Other|Before levothyroxine therapy 137.75 μg|18F-FDG PET CT scan after mild cold exposure 6.8 ± 2.8 weeks after thyroidectomy, when plasma free T4-levels were at the minimum, before daily levothyroxine therapy 137.75 ± 25.75 μg.
3009539|NCT02499471|Other|After levothyroxine therapy 137.75 μg|18F-FDG PET CT scan after mild cold exposure four to six months after the initial measurements, after daily levothyroxine therapy 137.75 μg (fT4 levels 23.1 ± 3.9 pmol/L, TSH 0.5 ± 0.6 mU/L)
3009540|NCT02499445|Active Comparator|Remifentanil and propofol|remifentanil (0.75 mcg/kg/min) propofol (TCI effect-site concentration 0.8-1.5 mcg/ml)
3009541|NCT02499445|Active Comparator|remifentanil and sevoflurane 1|remifentanil (0.75 mcg/kg/min) sevoflurane (end-tidal 0.8 vol%)
3009542|NCT02499445|Active Comparator|sevoflurane 2 and sufentanil|sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (TCI effect site concentration 0.35-0.75 ng/ml)
3009543|NCT02499432|Experimental|Motivational Enhancement|Motivational Interviewing/Enhancement is a form of collaborative discussion for strengthening motivation and commitment to change.
3009544|NCT02499432|No Intervention|Standard training|Training as usual
3009545|NCT02499419||Healthy|Individuals without any known heart/ respiratory/ metabolic problems that might limit their exercise capacity
3009546|NCT02499419||Mild MVP|0 or 1 of the following secondary risk factors: Mild MR Flail leaflet Left atrial diameter > 40 mm Atrial fibrillation Age ≥ 50
3009547|NCT02499419||Moderate MVP|2 or more of the above secondary risk factors.
3009548|NCT02499419||Severe MVP|1 or more of the following primary risk factors: EF < 50% MR ≥ moderate
3009549|NCT02499406|Other|Skills group|Dialectical behavior therapy skills group
3009550|NCT02499393|Experimental|TH+MgSO4|Therapeutic hypothermia plus magnesium sulphate intravenous infusion Neonates who were randomized to the study group (TH+MgSO4) received three 250 mg/kg doses of magnesium sulfate given as one - hour continuous infusion spaced 24 hours apart on three consecutive days. 20% Magnesium Sulfuricum (Polpharma), 2 g /10 ml were used.
3009551|NCT02499393|No Intervention|TH- therapeutic hypothermia|therapeutic hypothermia without magnesium sulphate
3009552|NCT02499380||Treatment|Patients treated with PneumRx Coil System
3009553|NCT02499367|Active Comparator|Radiation therapy|Radiotherapy on metastatic lesion
3009554|NCT02499367|Active Comparator|Low dose doxorubicin|15mg flat dose, once weekly for 2 weeks
3009555|NCT02499367|Active Comparator|Cyclophosphamide|metronomic schedule, 50mg daily orally for 2 weeks
3009556|NCT02499367|Active Comparator|Cisplatin|40mg/m2, weekly for 2 weeks
3009557|NCT02499367|Active Comparator|No induction treatment|
3009558|NCT02499354|Active Comparator|Oral Iron|Ferrous Sulfate 325mg (oral) tabs morning and evening
3009559|NCT02499354|Active Comparator|IV Iron|Ferumoxytol intravenous (IV) 1020 mg - 2 vials of 510 mg (IV push, 2-3 mins) each given 2-7 days apart
3009592|NCT02499198|Experimental|Arm 4|Nornicotine level equal to 50% of commercial smokeless tobaccos
3009560|NCT02499341|Active Comparator|Tramadol|Intraoperative administration of a bolus dose of tramadol and continuous intravenous infusion of tramadol for up to 48 h postoperatively.
3009561|NCT02499341|Active Comparator|Ketamine|Intraoperative administration of a bolus dose of ketamine and continuous intravenous infusion of ketamine for up to 48 h postoperatively.
3009562|NCT02499328|Experimental|Part A1: AZD9150 / MEDI4736|Patients allocated in cohort of arm A1 (AZD9150/MEDI4736 will be evaluated for DLT until an MTD is achieved.
3009563|NCT02499328|Experimental|Part A2: AZD5069 / MEDI4736|Patients allocated in cohort of arm A2 (AZD5069/MEDI4736 will be evaluated for DLT until an MTD is achieved.
3009564|NCT02499328|Experimental|Part B1:AZD9150+MEDI4736:PDL1 pretreated|Patients in arm B1 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
3009565|NCT02499328|Experimental|Part B2:AZD5069+MEDI4736:PDL1 pretreated|Patients in arm B2 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
3009566|NCT02499328|Experimental|Part B3: AZD9150+MED4736:naiive 2L|Patients in arm B3 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
3009567|NCT02499328|Experimental|Part B4:AZD5069+MEDI4736:naiive patients|Patients in arm B4 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
3009568|NCT02499328|Experimental|Part B5: AZD9150 in naiive patients|Patients in arm B5 will be evaluated for efficacy until disease progression and then allowed to receive additional MEDI4736 and followed for safety and survival
3009569|NCT02499328|Experimental|Part B6:AZD5069 in naiive patients|Patients in arm B6 will be evaluated for efficacy until disease progression and then allowed to receive additional MEDI4736 and followed for safety and survival
3009570|NCT02499328|Experimental|Part A3: AZD5069/MEDI4736|Patients allocated in cohort of arm A3 (AZD5069/MEDI4736) will be evaluated for DLT and viability as alternate dosing option for Phase 2 studies
3009571|NCT02499328|Experimental|Part A4: AZD9150/Treme/MEDI4736|Patients allocated in cohort of arm A4 (AZD9150/treme/MEDI4736) will be evaluated for DLT and MTD
3009572|NCT02499328|Experimental|Part A5: AZD5069/Treme/MEDI4736|Patients allocated in cohort of arm A5 (AZD5069/treme/MEDI4736) will be evaluated for DLT and MTD.
3009573|NCT02499328|Experimental|Part A6: AZD9150/MEDI4736|Patients allocated in cohort of arm A6 (AZD9150/MEDI4736) will be evaluated for safety, PK and PD.
3009574|NCT02499328|Experimental|Part A7: AZD5069/MEDI4736|Patients allocated in cohort of arm A7 (AZD5069/MEDI4736) will be evaluated for safety, PK and PD.
3009575|NCT02499328|Experimental|Part B7: AZD9150+MEDI4736: naiive 1L|Patients in Arm B7 will be evaluated for efficacy until disease progression and then followed up for safety and survival
3009576|NCT02499315|Experimental|AMG 357|
3009577|NCT02499315|Placebo Comparator|Placebo|
3009578|NCT02499302|Experimental|Mental training|"The intervention consists of one introductory session (patients and their parents/next-of-kin), followed by 9 individual therapy sessions (one each week) of 1.5 hours duration and related home-work, combining elements from cognitive behavioural therapy and music therapy: Important elements of the mental training program are:~Psychoeducation: Theories of CFS/ME pathophysiology and treatment rationale~Relaxation: Bodily stress reduction, mindfulness~Visualization: Contact with positive emotions, techniques of worrying reduction~Experiences: Behavioral 'experiments' (individually adjusted), 'trick into action'~Cognitive challenges: Challenging thoughts about disease process, stimulus and outcome expectancies, prognosis"
3009579|NCT02499302|No Intervention|Routine follow-up|Routine follow-up by the general practitioner, which is normal approach to chronic fatigue following acute EBV infection.
3009580|NCT02499276|Experimental|PSV, PAV, NAVA, Variable-PSV|This is a crossover study in which each patient will be ventilated in the following modes of mechanical ventilation: Pressure Support Ventilation (PSV), Neurally Adjusted Ventilator Assist (NAVA), Proportional assist ventilation (NAVA) and variable Pressure Support Ventilation (Variable-PSV), in a randomised order.
3009581|NCT02499263||Subjects with Ulcerative Colitis|Subject with active moderate-to-severe ulcerative colitis patients with Mayo score of ≥6 points and endoscopic sub-score of ≥2 points despite treatment with corticosteroids and/or immunosuppressants.
3009582|NCT02499250|Experimental|RIPC arm|The subjects will be interviewed and have their baseline frequency and severity of angina pectoris recorded, then they will receive daily remote ischemic conditioning plus optimal medical treatment over 30 days.
3009583|NCT02499250|Active Comparator|Control arm|The subjects will be interviewed and have their baseline frequency and severity of angina pectoris recorded, then they will receive optimal medical treatment over 30 days.
3009584|NCT02499237|Active Comparator|Denosumab|Patients with low bone mass, being treated only with denosumab in the past, who will receive another year of treatment with denosumab and subsequently discontinue treatment for one year
3009585|NCT02499237|Experimental|Denosumab plus zoledronic acid|Patients with low bone mass, being treated only with denosumab in the past, who will receive a single infusion of zoledronic acid and subsequently discontinue treatment for another year
3009586|NCT02499224|Experimental|YYB101|Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks
3009587|NCT02499211|Experimental|Intervention stores|Supermarkets will be the unit of randomization, intervention, and analysis. During randomization, stores are paired by size and percent sales of Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) and Supplemental Nutrition Assistance Program (SNAP) funding. The intervention will last for 2 years, and will consist of in-store marketing of healthier (lower calorie) products through placement and promotion strategies in 6 food and beverage categories: milk; frozen meals; beverages in checkout coolers; bread; salty snacks; and cheese.
3009588|NCT02499211|No Intervention|Non-intervention stores|No intervention administered. Supermarkets will be the unit of randomization, intervention, and analysis. During randomization, stores are paired by size and percent sales of WIC and SNAP funding. The non-intervention stores will not receive an intervention.
3009589|NCT02499198|Experimental|Arm 1|Nornicotine level equal to highest commercial smokeless tobacco tested
3009590|NCT02499198|Experimental|Arm 2|Nornicotine level equal to mean of commercial smokeless tobaccos
3009591|NCT02499198|Experimental|Arm 3|Nornicotine level equal to lowest commercial smokeless tobacco tested
3009596|NCT02499185|Experimental|Nephro Check Test|We take urine samples and analyse the level of [TIMP-2]●[IGFBP-7] using the NephroCheck Test to diagnose AKI
3009597|NCT02499185|Active Comparator|serum creatinine measurement|"This is the Golden standard to diagnose AKI"
3009598|NCT02499172|Other|Cohort 1|Cohort 1: Women who were pregnant and received at least one dose of ShancholTM during the mass OCV vaccination campaign.
3009599|NCT02499172|Other|Cohort 2|Cohort 2: Vaccinated women (i.e., women who received at least one dose) who become pregnant after the mass vaccination campaign; hence their fetus will not have been exposed to the vaccine.
3009600|NCT02499172|Other|Cohort 3|Cohort 3: Women who were pregnant in Chikwawa District at the time of the vaccination campaign in Nsanje District, but who did not receive the vaccine during the campaign.
3009601|NCT02499172|Other|Cohort 4|Cohort 4: Women who become pregnant in Chikwawa District after the vaccination campaign in Nsanje District, and who did not receive the vaccine during the campaign.
3009602|NCT02499159|Experimental|Exparel|Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon's discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
3009603|NCT02499159|Active Comparator|0.25% standard bupivicaine|Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
3009604|NCT02499146|Experimental|Cohort 1|Combination therapy of palbociclib and letrozole
3009605|NCT02499133|Other|adult who suffered traumatic brain injury|
3009606|NCT02499133|Other|control group|
3009607|NCT02499120|Experimental|Palbociclib plus Cetuximab|Palbociclib, 125 mg, orally once daily (QD) with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
3009608|NCT02499120|Active Comparator|Placebo plus Cetuximab|Placebo orally QD with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
3009609|NCT02499107|Experimental|Rice treatment|Dietary Intervention: Ad libitum intake of white rice
3009610|NCT02499107|Experimental|Pasta treatment|Dietary Intervention: Ad libitum intake of pasta
3009611|NCT02499107|Experimental|boiled and mashed potato treatment|Dietary Intervention: Ad libitum intake of boiled and mashed potato
3009612|NCT02499107|Experimental|Baked french fries treatment|Dietary Intervention: Ad libitum intake of baked french fries
3009613|NCT02499107|Experimental|Fried french fries treatment|Dietary Intervention: Ad libitum intake of fried french fries
3009614|NCT02499094|Experimental|Intervention A- Heuristic based|Behavioral-data driven support, both mobile phone application and phone-based, informed by their self-reported symptom assessment as well as simple heuristic-based behavioral measures
3009615|NCT02499094|Experimental|Intervention B- Machine Learning Based|Behavioral-data driven support, both mobile phone application and phone-based, informed by their self-reported symptom assessment as well as machine learning model-based behavioral measures
3009616|NCT02499094|No Intervention|Control|No intervention
3009617|NCT02499081|Experimental|Ixazomib|Ixazomib 4.0 mg given on days 1, 8 15, 22 of a 28 day cycle maximum of 6 cycles.
3009618|NCT02499068|Experimental|COPD, Telehealth|Patients randomized to this arm would be followed by home telehealth devices and monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.
3009619|NCT02499068|No Intervention|COPD, Normal clinical practice|Patients would do the usual clinical practice.
3009620|NCT02499055|Experimental|FearFighter|The experimental group will use the program FearFighter™.
3009621|NCT02499055|No Intervention|Control group|The control group receive no intervention for nine weeks.
3009622|NCT02499042|Experimental|Oxygen reduction|post-ROSC oxygen reduced to 2L per minute then delivered to maintain oxygen saturation 90-94% to hospital
3009623|NCT02499042|Active Comparator|Standard Care|post-ROSC oxygen maintained ≥10L per minute to hospital
3009624|NCT02499029|Experimental|N-Acetylcysteine|Eligible participants were randomized to either NAC (2400 mg/day) or placebo for 8 weeks. The starting dose of NAC was 1200 mg twice daily (2400 mg/day). All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance.
3009625|NCT02499029|Placebo Comparator|Placebo|Identical appearing placebo capsules were dispensed. All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance. Study medications (USP-grade NAC and matched placebo capsules) dispensed to participants by the medical clinician or study staff. Treatment assignment followed a pre-arranged randomization scheme and was carried out by study personnel at the pharmacy (i.e., personnel not involved in clinical management of participants to preserve the double-blind design).
3009626|NCT02499016|Experimental|suprapubic single-incision laparoscopic appendectomy|single incision laparoscopic surgery will be performed for patients in this group.
3009627|NCT02499016|Active Comparator|conventional multiport appendectomy|Conventional laparoscopic surgery will be performed for patients in this group.
3009628|NCT02499003|Experimental|Obinutuzumab and Pixantrone|Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
3009629|NCT02498990|Experimental|Weight reduction|
3009630|NCT02498977|Active Comparator|Arm A (weaning)|All participants satisfying clinical criteria will be weaned off immunosuppression drugs irrespective of biomarker result.
3009631|NCT02498977|Active Comparator|Arm B+ (weaning- positive biomarker)|Participants with a positive biomarker will be weaned of immunosuppression drugs.
3009632|NCT02498977|Active Comparator|Arm B- (maintenance)|Participant with negative biomarker test result will be informed of the result and will remain on baseline maintenance immunosuppression drugs.
3009633|NCT02498951|Experimental|Arm I (obinutuzumab)|Patients receive obinutuzumab IV on days 1 and 2 for the first course, and on day 1 for the subsequent courses. Courses repeat every 60 days for 2 years in the absence of disease progression or unacceptable toxicity.
3009634|NCT02498951|Active Comparator|Arm II (observation)|Patients undergo observation for a total of 3 years.
3009635|NCT02498938||SERPINA1 gene in COPD and periodontitis|patients aged between 30-70 yrs with COPD (satisfying Gold's criteria) and chronic periodontitis (>4mm pocket probing depth)
3009636|NCT02498925|Experimental|Behavioral Activation|"12 weeks (1 50-min session per week) of Behavioral Activation for the anhedonic adolescents.~Behavioral Activation is a psychosocial treatment for depression focused on gradually re-engaging patients with sources of reinforcement and reward in their environment (e.g., increasing activites and interpersonal interactions). In contrast to Cognitive Behavioral Therapy, and as the name implies, Behavioral Activation focuses on behavioral strategies to improve mood and places little emphasis on cognitive restructuring techniques."
3009637|NCT02498912|Experimental|Cyclophosphamide followed by Autologous T Cells|This is a standard phase I dose escalation trial. Cohorts of 3-6 patients will be infused with escalating doses of modified T cells to establish the maximum tolerated dose (MTD) of modified T cells. There are 4 planned dose levels: 3 x 10^5, 1 x 10^6, 3 x 10^6, and 1 x 10^7 4H11-28z/fIL-12/EGFRt+ T cells/kg (Table 1). Cohort I-IV will be treated escalating dose levels. Once the MTD of T cells is established, the next cohort will receive lymphodepleting cyclophosphamide dose of 750 mg/m^2 or a regimen of cyclophosphamide dose 300 mg/m2 x 3 days concurrent with fludarabine dose 25-30 mg/m2 x 3 days 2-7 days prior to starting the T cell infusion at one dose level below the MTD. If the MTD is not established after Cohort IV, Cohort V will receive conditioning chemotherapy 2-7 days prior to starting the T cell infusion at the same dose as Cohort III.
3009638|NCT02498899|Experimental|Video 1 + Questionnaires|Participants complete 4 questionnaires at baseline. Participants then watch a short video. At end of video, 3 questionnaires completed. Participants then read a small story about the patient in the video. Afterwards, another set of questionnaires completed.
3009639|NCT02498899|Experimental|Video 2 + Questionnaires|Participants complete 4 questionnaires at baseline. Participants then watch a short video. At end of video, 3 questionnaires completed. Participants then read a small story about the patient in the video. Afterwards, another set of questionnaires completed.
3009640|NCT02498886|Experimental|Iron deficient anaemic: IDA|"Iron deficient anaemic women.~Interventions: two iron supplements will be used:~IHAT- iron hydroxide adipate tartrate: an analogue of natural food iron. Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.~Each compound will be labelled with a stable isotope of iron:~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
3009641|NCT02498886|Experimental|Iron sufficient: non-IDA|"Women that are not anaemic or iron deficient.~Interventions: two iron supplements will be used:~IHAT- iron hydroxide adipate tartrate: an analogue of natural food iron. Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.~Each compound will be labelled with a stable isotope of iron:~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
3009642|NCT02498886|Experimental|Iron deficient anaemic (IDA): IHAT new manufacture|"Iron deficient anaemic women.~Interventions: two iron supplements will be used:~IHAT new manufacture- iron hydroxide adipate tartrate: an analogue of natural food iron.~Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.~Each compound will be labelled with a stable isotope of iron:~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
3009643|NCT02498873|Active Comparator|Linear Periodization|Linear Periodization Running (Crossover Design)
3009644|NCT02498873|Active Comparator|Non Linear Periodization|Non Linear Periodization Running (Crossover Design)
3009645|NCT02498860|Experimental|Pemebit plus Cisplatin|Pemetrexed (Pemebit 500 mg/m2) plus cisplatin (75 mg/m2) every 3 weeks up to 4 cycles
3009646|NCT02498847|Experimental|ENGAGE intervention|8 in-person weekly treatment sessions with an occupational therapist of 30 minutes - 1 hour duration intervention content provided on website, homework assigned each week after intervention period, monthly calls conducted to check on health status
3009647|NCT02498847|No Intervention|Usual Care|participated in usual care and received monthly calls to check on health status
3009648|NCT02498834|Experimental|Educational Video and Question Prompt List|Parents and adolescents in this group will watch a short educational video in English or Spanish on an iPad about the importance of encouraging adolescents to ask questions and to be involved during their pediatric asthma visits to improve their self-management skills. Also, the adolescents in this group will be handed a question prompt list to complete, which will be collected after the medical visit.
3009649|NCT02498834|No Intervention|Control group|Standard of care will be used
3009650|NCT02498821|Other|Standard of Care (Chest X-ray)|Correct placement of the Peripherally Inserted Central Catheter (PICC) will be confirmed using standard of care (Chest X-ray).
3009651|NCT02498821|Other|Sherlock 3CG® TCS|Correct placement of the Peripherally Inserted Central Catheter (PICC) will be confirmed using Sherlock 3CG® TCS magnetic tracking PICC placement and ECG-based tip confirmation.
3009652|NCT02498808||Healthy controls|Staff or patients attending hospital or visitors attending with patients. They should not have vasculitis or inflammatory arthritis
3009653|NCT02498808||Early rheumatoid arthritis|Newly diagnosed patients with rheumatoid arthritis attending hospital, prior to use of biologic therapies
3009654|NCT02498808||New or relapsing ANCA vasculitis|Newly diagnosed or flaring patients with anti-neutrophil cytoplasm antibody associated systemic vasculitis attending hospital
3009655|NCT02498808||Newly diagnosed giant cell arteritis|Newly diagnosed patients with giant cell arteritis attending hospital
3009656|NCT02498795|Active Comparator|Group of Dry Needling|"They will receive a treatment of dry needling with ultrasound scan together with a treatment in which they will realize eccentric exercise's program that the patient will have to realize in his domicile.~The needle will get in the relevant zone of treatment. The punction will be realized using the technique of entry - Hong's rapid exit. Three punction will realize in the disabled zone of 3 seconds of duration."
3009657|NCT02498795|Active Comparator|Group of electrolysis|"They will receive a treatment of Intratissue Percutaneous Electrolysis with ultrasound scan together with a treatment in which they will realize eccentric exercise's program that the patient will have to realize in his domicile.~The needle will get in the relevant zone of treatment. An intensity of 3 milliampere will be in use, during 3 seconds and one will repeat 3 times."
3009726|NCT02498392|Placebo Comparator|Non Responders-Placebo|Participants who did not respond in the placebo lead-in period will be administered with Matching Placebo orally.
3009658|NCT02498795|Placebo Comparator|Control Group|They will receive a treatment of punction placebo with ultrasound scan together with a treatment in the one that will realize eccentric exercise's program that the patient will have to realize in his domicile.
3009659|NCT02498782|Active Comparator|Fexinidazole, 1800 mg, 2 weeks|1800mg (High Dose) 2 weeks (HD - 2 weeks) Group: Fexinidazole, 1800 mg QD for 2 weeks, followed by placebo to complete 8 weeks (total dose: 25,2 g)
3009660|NCT02498782|Active Comparator|Fexinidazole, 1800 mg, 4 weeks|1800mg (High Dose) 4 weeks (HD - 4 weeks) Group: Fexinidazole, 1800 mg QD for 4 weeks, followed by placebo to complete 8 weeks (total dose: 50,4 g)
3009661|NCT02498782|Active Comparator|Fexinidazole, 1800 mg, 8 weeks|1800mg (High Dose) 8 weeks (HD - 8 weeks) Group: Fexinidazole, 1800 mg QD, for 8 weeks (total dose: 100,8 g)
3009662|NCT02498782|Active Comparator|Fexinidazole, 1200 mg, 2 weeks|1200mg (Dose 2 weeks) 2 weeks (LD - 2 weeks) Group: Fexinidazole, 1200 mg QD for 2 weeks, followed by placebo to complete 8 weeks (total dose: 16,8 g)
3009663|NCT02498782|Active Comparator|Fexinidazole, 1200 mg, 4 weeks|1200mg (Low Dose) 4 weeks (LD - 4 weeks) Group: Fexinidazole, 1200 mg QD for 4 weeks, followed by placebo to complete 8 weeks (total dose: 33,6 g)
3009664|NCT02498782|Active Comparator|Fexinidazole, 1200 mg, 8 weeks|1200mg (Low Dose) 8 weeks (LD - 8 weeks) Group: Fexinidazole, 1200 mg QD for 8 weeks (total dose: 67,2 g)
3009665|NCT02498782|Placebo Comparator|Placebo|Placebo (8 weeks) Group: Fexinidazole matched placebo tablets QD for 8 weeks.
3009666|NCT02498769|Experimental|Epicardial Botulinum|After instituting cardiopulmonary bypass (CPB), botulinum toxin injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 50U (1mL) of botulinum toxin (OnabotulinumtoxinA, Botox®). After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
3009667|NCT02498769|Placebo Comparator|Epicardial Placebo|After instituting cardiopulmonary bypass (CPB), placebo (normal saline) injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 1mL of normal saline. After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
3009668|NCT02498756|Experimental|IP plus CIK|Patients receive ipilimumab and CIK.
3009669|NCT02498756|Active Comparator|IP alone|Patients receive ipilimumab alone.
3009670|NCT02498743|Experimental|Intervention group with television|Animated cartoons with sound were reproduced during the echocardiography
3009671|NCT02498743|No Intervention|control group with usual care|Echocardiography was performed by using the distractions available at the time of test.
3009672|NCT02498730|Active Comparator|Interval Training|6 stimulous (30 s) at 100% VO2Max/ 1 min 30 s to rest, 19 minutes (total exercise), 3 times/ week, 12 weeks
3009673|NCT02498730|Active Comparator|Continuous Training|Running at 60% VO2Max, 25 minutes (total exercise), 3 times/week, 12 weeks
3009674|NCT02498730|Sham Comparator|Control|Only Dependent Variables Measures
3009675|NCT02498717|Active Comparator|RICE (control)|Standard of Care procedures including ice and elevation.
3009676|NCT02498717|Experimental|Cryocompression (experimental)|treatment using the GameReady cryotherapy system
3009677|NCT02498704|Sham Comparator|Sham Needling intervention, Control|Sham dry needling, group does not receive true dry needling intervention.
3009678|NCT02498704|Experimental|Dry Needling Intervention, experimental|Group receives true dry needling intervention.
3009679|NCT02498691|Experimental|Type exposed|endometriosis
3009680|NCT02498691|Experimental|Type unexposed|Without endometriosis
3009681|NCT02498678|No Intervention|control group|After verifying the absence of sevoflurane through the gas analyzer, TOF monitor mode starts with stimuli every 12 to 15 seconds. After 1 minute (min) stimulation, calibration and supramaximal stimulation will be ensured by the built-in calibration function (CAL 2) of the TOF-Watch®. The stability of the response will be documented by at least 2 to 5 min [< 5% variation in the first response (T1) in the TOF]. Monitoring of neuromuscular junction will be held until recovery of the TOF ratio to 0.9 (90%), an expected average of 60 minutes.
3009682|NCT02498678|Experimental|tetanus group|After verifying the absence of sevoflurane through the gas analyzer, a 50-Hz tetanic stimulation will be applied for 5 s and followed after 1 min by TOF stimulation every 15 s. After 1 minute (min) calibration and supramaximal stimulation will be ensured by the built-in calibration function (CAL 2) of the TOF-Watch®. The stability of the response will be documented by at least 2 to 5 min [< 5% variation in the first response (T1) in the TOF]. Monitoring of neuromuscular junction will be held until recovery of the TOF ratio to 0.9 (90%), an expected average of 60 minutes.
3009683|NCT02498665|Experimental|Dosing Escalation Cohort|Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously. Dose-escalation will proceed according to the Criteria for Dose Escalation and Criteria for Determination of Dose-Limiting Toxicity (DLT) as indicated below. Dose Level I: 3.5 mg, Dose Level II: 10.5 mg, Dose Level III: 17.5 mg
3009684|NCT02498665|Experimental|MDS Cohort 1|Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.
3009685|NCT02498665|Experimental|MDS Cohort 2|Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks.
3009686|NCT02498652|Experimental|RDEA3170 2.5 mg, 7.5 mg and 15 mg|RDEA3170 2.5 mg, 7.5 mg and 15 mg once daily (qd) in combination with allopurinol 300 mg (qd and twice daily (bid))
3009687|NCT02498652|Experimental|RDEA3170 5 mg, 10 mg and 20 mg|RDEA3170 5 mg, 10 mg 20 mg qd in combination with allopurinol 300 mg (qd and bid)
3009688|NCT02498639|Active Comparator|BAV without pacing|Patients undergo percutaneous balloon aortic valvuloplasty (BAV) without previous insertion of a temporary pacemaker lead in the right ventricle. Stabilization of the balloon during inflation is done without rapid pacing.
3010220|NCT02495090|Other|Hypospadias|Familial hypospadias trios (patients + parents)
3009689|NCT02498639|Active Comparator|BAV with pacing|Patients undergo percutaneous balloon aortic valvuloplasty (BAV) after previous insertion of a temporary pacemaker lead in the right ventricle. Stabilization of the balloon during inflation is done under rapid pacing.
3009690|NCT02498626||venous saturations|venous saturations from the central venous line, venous side of the heart lung machine and from the pulmonary artery
3009691|NCT02498613|Experimental|Treatment (cediranib maleate, olaparib)|Patients receive cediranib maleate PO QD on day 1. Patients undergoing FMISO scan also receive olaparib PO BID beginning the day after the second FMISO scan and the rest of the patients receive olaparib PO BID beginning day 4 of course 1. Courses repeat every 28 days (35 days for course 1) in the absence of disease progression or unacceptable toxicity.
3009692|NCT02498600|Active Comparator|Group I (nivolumab)|"INDUCTION: Patients receive nivolumab IV over 60 minutes every 2 weeks. Treatment repeats every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive nivolumab IV over 60 minutes every 2 weeks. Treatment repeats every 4 weeks for up to 21 courses in the absence of disease progression or unacceptable toxicity."
3009693|NCT02498600|Experimental|Group II (nivolumab, ipilimumab)|"INDUCTION: Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive nivolumab IV over 60 minutes every 2 weeks. Treatment repeats every 4 weeks for up to 21 courses in the absence of disease progression or unacceptable toxicity."
3009694|NCT02498574|Experimental|Group 1|Non-invasive brain stimulation protocol expected to improve performance, with cognitively challenging game
3009695|NCT02498574|Placebo Comparator|Group 2|Non-invasive brain stimulation protocol not expected to improve performance, with cognitively challenging game
3009696|NCT02498561|Active Comparator|obese-chronic periodontitis patients|GCF, plasma and GCF samples were taken before and after nonsurgical periodontal therapy
3009697|NCT02498561|Placebo Comparator|obese-periodontally healthy controls|GCF, plasma and GCF samples were taken at baseline after oral hygiene instructions
3009698|NCT02498561|Active Comparator|normal weight-CP patients|GCF, plasma and GCF samples were taken before and after nonsurgical periodontal therapy
3009699|NCT02498561|Placebo Comparator|normal weight-PH controls|GCF, plasma and GCF samples were taken at baseline after oral hygiene instructions
3009700|NCT02498548|No Intervention|Control|Individuals with no spinal cord injury or other neurological deficits.
3009701|NCT02498548|No Intervention|Unexercised SCI Knee|"Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. This group will serve as unexercised control for the Trained SCI Knee group"
3009702|NCT02498548|Experimental|Trained SCI Knee|Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. Training will specifically focus on rehabilitation of the knee joint.
3009703|NCT02498535|Experimental|Nitric oxide gas at 160 ppm|Nitric oxide gas at 160 ppm inhaled four times daily for 30 min delivered with air as the carrier via nasal inhalation for a total of 7.5 days. Total dose of 2400 ppm hours.
3009704|NCT02498535|Placebo Comparator|Breathing 20.3% oxygen|Breathing 20.3% oxygen inhaled four times daily for 30 min delivered with air as the carrier via nasal inhalation for a total of 7.5 days.. 100% nitrogen will be injected into the breathing circuit (instead of 99.5% nitrogen and 0.5% NO).
3009705|NCT02498522|Experimental|metformin arm|83 patients will continue metformin until end of 1st trimester (14 weeks gestation)
3009706|NCT02498522|Placebo Comparator|control arm|83 patients will stop metformin at diagnosis of pregnancy ( 5-6 weeks gestation)
3009707|NCT02498509|Experimental|Treatment|CKD-342
3009708|NCT02498509|Active Comparator|Control 1|Mometasone furoate
3009709|NCT02498509|Active Comparator|Control 2|Levocabastine HCL
3009710|NCT02498496|Experimental|Magnesium Sulfate|Administration of a bolus dose of 2 g of MgSO4 in 100 mL of Normal Saline IV, in 20 min.
3009711|NCT02498496|Placebo Comparator|Placebo|Administration of a bolus dose of 100 mL of Normal Saline, in 20 min.
3009712|NCT02498483|Experimental|Acetaminophen arm|Acetaminophen 15 mg/kg PO solution administered via syringe one time immediately post circumcision.
3009713|NCT02498483|No Intervention|Non treatment arm|Routine circumcision without acetaminophen .
3009714|NCT02498457|Active Comparator|low calcium dialysis|patients in this group will be dialyzed using a dialysate with a calcium concentration 1.25mmol/L.
3009715|NCT02498457|Other|Routine dialysis|Patients in this groups will be dialyzed using routine dialysate with a calcium concentration 1.5mmol/L.
3009716|NCT02498444|Experimental|Treprostinil|The subcutaneous continuous treprostinil infusion will start at a dose of 2 ng/kg/min. The dose will be increased over the first 24 hours to goal 10 ng/kg/min through day five. On postoperative day six, the dose will be decreased by 2 ng/kg/min every 8 hours with plans for discontinuation on postoperative day seven.
3009717|NCT02498444|Placebo Comparator|Saline|Saline administration via subcutaneous infusion
3009718|NCT02498431|Experimental|myocardial infraction|Patients with acute myocardial infraction who are admitted to the emergency department of 424 General Military Hospital before and after percutaneous coronary intervention and stent placement
3009719|NCT02498431|Active Comparator|coronary artery disease|Patients with coronary artery disease but not myocardial infraction who are being subjected to coronary angiography and percutaneous coronary intervention and stent placement
3009720|NCT02498431|Active Comparator|Control|Patients subjected to coronary angiography and found with no presence of coronary artery disease
3009721|NCT02498418|Experimental|Treatment 1|Generic rifaximin 200mg tablets. Three times daily for 3 days
3009722|NCT02498418|Active Comparator|Treatment 2|Xifaxan 200mg tablets. Three times daily for 3 days
3009723|NCT02498418|Placebo Comparator|Treatment 3|Placebo tablets. Three times daily for 3 days.
3009724|NCT02498392|Placebo Comparator|Responders-Placebo|Participants who responded in the placebo lead-in period will be administered with Matching Placebo orally.
3009725|NCT02498392|Experimental|Responders-JNJ-42165279|Participants who responded in the placebo lead-in period will be administered with JNJ-42165279 orally at a dose of 25 milligrams (mg) tablets once daily for 6 weeks.
3009759|NCT02498145|Active Comparator|Non-nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette without nicotine.
3009727|NCT02498392|Experimental|Non Responders-JNJ-42165279|Participants who did not respond in the placebo lead-in period will be administered with JNJ-42165279 orally at a dose of 25 mg tablets once daily for 6 weeks.
3009728|NCT02498379|Experimental|Cu[64]-25%CANF-Comb|Single IV injection of 4-8 mCi Cu[64]-25%CANF-Comb followed by PET-CT scan at 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours post injection.
3009729|NCT02498366|Experimental|experimental protocol|50 healthy, male, trained and aged 18-30 will be recruited and asked to undergo a series of physical tests.
3009730|NCT02498353|Experimental|study group|"Preoperative short-course radiotherapy with local boost ,the dose of radiotherapy is PTV-CTV 25Gy/5F with local boost of PTV-GTV 30Gy/5F.~TME surgery after radiotherapy."
3009731|NCT02498353|Active Comparator|control group|"Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F without local boost.~TME surgery after radiotherapy."
3009732|NCT02498340|Experimental|Diet challenge|The patients will have a single blood test after dietetic challenge, they will be subjected to eat non- fava beans diet at doses of 10 -30 gm of 3 different types of non- fava beans( each one will be given once daily for 3 days).
3009733|NCT02498327|Placebo Comparator|Gelatine Capsules|Gelatine capsules containing only inactive ingredients (starch amyral white, di-calcium phosphate DC and magnesium stearate fine), will be taken once per day, in the morning after breakfast, for 30 days. These capsules will be of identical appearance to the experimental comparator.
3009734|NCT02498327|Experimental|Venavine Intensive®|Gelatine capsules containing the active ingredients of: 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butcher's Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate, will be taken once per day, in the morning after breakfast, for 30 days.
3009735|NCT02498314|Experimental|Grade I-II SZ mobilization|Grade I-IISZ hip traction in resting position
3009736|NCT02498314|Experimental|Grade II TZ mobilization|Grade IITZ hip traction in resting position
3009737|NCT02498314|Experimental|Grade III mobilization|Grade III hip traction in resting position
3009738|NCT02498301|Experimental|Rifaximin 550 mg once/day|rifaximin, 550 mg, once daily, by mouth
3009739|NCT02498301|Experimental|Rifaximin 550 mg twice/day|rifaximin, 550 mg, twice daily, by mouth
3009740|NCT02498301|Placebo Comparator|Placebo|Placebo pills, twice daily, by mouth
3009741|NCT02498288|Experimental|Isotretinoin Arm|All subjects in this study will be randomized to receive all the 3 distinct medications of isotretinoin in a sequential manner. Subjects will receive a single dosage of two capsules x 20 mg (40 mg) orally, for three periods, six sequences, with a wash-out period of two weeks to eliminate the first dosage.
3009742|NCT02498275||Healthy volunteers|Blood samples from healthy volunteers will be collected for ex vivo stimulation and for further sample preparation and analysis.
3009743|NCT02498275||Nucleoside/nucleotide analogue-treated CHB patients|Blood samples from nucleoside/nucleotide analogue-treated CHB patients will be collected for ex vivo stimulation and for further sample preparation and analysis.
3009744|NCT02498275||Treatment-naive CHB patients|Blood samples from treatment-naïve CHB patients will be collected for ex vivo stimulation and for further sample preparation and analysis.
3009745|NCT02498249|Experimental|Experimental: low level laser therapy (LLLT)|"For the LLLT irradiation, a paper template with 9 points (area of 1cm and a distance from center to center of 1 cm) will be used, distributed in three columns and three lines. The central point of the template will be positioned above the medium point of a line traced between the acromion and the spinous process of the seventh cervical vertebra, where the treatment should be close to the fixation point of the EMG electrode. The application point of the LLLT was determined by the location of the innervation point of the upper trapezius muscle.~Individuals will be subject to application of low level laser with a total dose of 18 J"
3009746|NCT02498249|Placebo Comparator|Experimental: Placebo low level laser therapy (PLLLT)|"For the PLLLT irradiation, a paper template with 9 points (area of 1cm and a distance from center to center of 1 cm) will be used, distributed in three columns and three lines. The central point of the template will be positioned above the medium point of a line traced between the acromion and the spinous process of the seventh cervical vertebra, where the treatment should be close to the fixation point of the EMG electrode. The application point of the PLLLT was determined by the location of the innervation point of the upper trapezius muscle.~Individuals will be subject to application of low level laser with a total dose of 0 J"
3009747|NCT02498236|Experimental|Oxytocin 6-84 IU|Subjects will be randomly assigned to one of eight doses of intranasal oxytocin.
3009748|NCT02498236|Placebo Comparator|Placebo|Subjects will be administered intranasal placebo using the same spray volume as experimental condition
3009749|NCT02498223|Experimental|research arm|50 subjects (healthy soldiers, male and female) from combat units will undergo the experiment protocol.
3009750|NCT02498210|Experimental|IVF after IVM|"If the patients will not concive during the IVM cycle . results of this following IVF cycle will be compared to the initial IVF preformance~Intervention : In Vitro Maturation Procedure"
3009751|NCT02498197|Experimental|Participatory Intervention|Participatory intervention with workers and their leaders. Workshops with presentation of work tasks with excessive physical load and subsequently plans to reduce these loads
3009752|NCT02498197|Active Comparator|Control|Receive standard information about correct lifting technics, use of assistive technology, and ergonomics
3009753|NCT02498184|Experimental|real acupuncture|traditional chinese acupuncture
3009754|NCT02498184|Sham Comparator|sham acupuncture|non effective acupuncture
3009755|NCT02498171|Experimental|Intrathecal morphine with fentanyl|Single shot of intrathecal morphine 100mcg mixed with 25mcg of fentanyl and filled up to make a 2ml solution. This would then be injected into the subarachnoid space through L2-3 or L3-4 following standard procedures.
3009756|NCT02498171|Active Comparator|Intrathecal morphine with bupivacaine|Single shot of intrathecal morphine 100mcg mixed with 2.5mg of spinal bupivacaine and filled up to make a 2ml solution.This would then be injected into the subarachnoid space through L2-3 or L3-4 following standard procedures.
3009757|NCT02498158||experimental protocol|Functional neural connectivity at rest of 3 groups (heat tolerant, heat intolerant and healthy subjects) will be assessed using the anatomical and functional MRI scans and compared.
3009758|NCT02498145|Experimental|Nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette with nicotine.
3009760|NCT02498132|Experimental|Behavioral Activation|Behavioral Activation will be administered via Moodivate will mirror the core BA components outlined above. Moodivate will also be modified for a mobile environment in key ways, with the most salient being: 1) Elimination of the need for a therapist: By eliminating the need for a therapist, we will be able to reach a broad patient/consumer base that may not utilize traditional therapy resources and will combat the primary barrier to PCPs recommending psychotherapy to their patients with elevated depressive symptoms and 2) Elimination of paper forms: By eliminating paper forms, we will increase the sensitivity of BA to motivational and organizational deficits frequently observed in patients with elevated depressive symptoms while also increasing treatment fidelity by prompting the patient to complete activities at scheduled times and giving the patient reinforcement for completing activities.
3009761|NCT02498132|Active Comparator|Cognitive Based Therapy|Moodkit will be used to administer cognitive based therapy which is commonly compared to behavioral activation.
3009762|NCT02498132|Active Comparator|Treatment as Usual|TAU will be provided to individuals. These subject will be provided with therapy but will not utilize a mobile application.
3009763|NCT02498119||Normal|Patient sample within the normal range of blood results.
3009764|NCT02498119||Abnormal|Patient sample from freshly diagnosed Type 2 Diabetes Mellitus.
3009765|NCT02498106|Active Comparator|nutritional supplement|2 Orthica Soft Multi Mini capsules and 1 Orthica Fish EPA Mini capsule per day; duration: 6 months
3009766|NCT02498106|Placebo Comparator|placebo|During 6 months one group receives 3 placebo supplements daily with identical look and feel to Orthica Soft Multi Mini and Orthica Fish EPA Mini
3009767|NCT02498093|Experimental|Maximal strength training|Maximal strength training supervised by a physiotherapist
3009768|NCT02498093|Active Comparator|Control|Conventional rehabilitation supervised by a physiotherapist
3009769|NCT02498080|Experimental|DEB PTA|Devices: paclitaxel drug eluting balloon PTA
3009770|NCT02498080|Active Comparator|standard PTA|devices: standard balloon PTA
3009771|NCT02498067|Experimental|Intervention|Participants will complete a 10-15 minute questionnaire . After completing the questionnaire, a research assistant (RA) will provide a brief orientation to the rPlan app and use the rPlan app for up to 15 minutes. After viewing rPlan, participants will be asked a series of questions regarding the app's usability, helpfulness, and content appropriateness (10 min). The participant will also be given an STI test.
3009772|NCT02498054|Experimental|Education with new meter feature.|Subjects experience a computer stimulation of a new meter feature ( colour range indicator) to help subjects interpret whether blood glucose results are low, in-range or high based on accepted guidance.
3009773|NCT02498041|Experimental|Transnasal Endoscopy|Unsedated transnasal endoscopy with biopsies
3009774|NCT02498041|Active Comparator|Standard Gastroscopy|Standard endoscopy with biopsies. Patients will decide whether they prefer to have endoscopy with intrevenous sedation or with local anaesthetic only
3009775|NCT02498028||Cervical Fusion|patients with anterior cerivical decompression and fusion
3009776|NCT02498028||Cervical Disc Prostheses|patients with cervical total disc replacement
3009777|NCT02498015|Experimental|"3D regimen"|"The 3D regimen contain two tablets of co-formulated paritepravir/ritonavir/ombitasvir (75/50/12.5 mg) once daily, and one dasabuvir tablet (250 mg) twice daily for genotype 1b without cirrhosis. Treatment will be 12 weeks."
3009778|NCT02498015|Experimental|"3D regimen with ribavirin"|"The 3D regimen with ribavirin contain two tablets of co-formulated paritepravir/ritonavir/ombitasvir (75/50/12.5 mg) once daily, one dasabuvir tablet (250 mg) twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a (with/without) and genotype 1b with cirrhosis. Treatment will be for 12 weeks."
3009779|NCT02498002|Active Comparator|Daily Calorie Restriction (DCR)|During the intervention phase, participants randomised to this treatment condition will be asked to reduce their normal energy intake by 25% on a daily basis.
3009780|NCT02498002|Experimental|Fasting with Weight Loss (IMF-WL)|During the intervention phase, participants randomised to this treatment condition will be asked to alternate between 24 hour cycles of feeding (consume 150% of normal energy intake) and fasting (no energy intake).
3009781|NCT02498002|Experimental|Fasting without Weight Loss (IMF-WS)|During the intervention phase, participants randomised to this treatment condition will be asked to alternate between 24 hour cycles of feeding (consume 200% of normal energy intake) and fasting (no energy intake).
3009782|NCT02497989|Experimental|Inter-personal Communication (IPC)|Interpersonal communication will entail delivery of intervention massages that are custom-made to address individual participants' specific barriers and facilitators of VMMC. RAs will discuss with uncircumcised men why they have not gone for VMMC using the 'VMMC Demand Creation Toolkit'. The aim will be to fully address their barriers and re-enforce their facilitators. RAS will be trained behavioral counselors, circumcised men, female partners, CHWs, or any other cadre of individuals identified during the formative phase.
3009783|NCT02497989|Experimental|Dedicated Service Outlets (DSO)|RAs shall visit all households with eligible men to inform them about the availability of, and give information on location of DSO sites in the Location. DSOs are sites: where services are offered exclusively to men aged ≥25 years by male service providers in the same age bracket; providing services in the evenings/weekends/designated days of the week, and through special mobile services for older men. DSO sites we will strive to shorten the waiting time to ≤ three hours. They will be informed that all other VMMC sites continue to serve all men regardless of age (i.e., including older men) while DSO sites will only serve men aged ≥25 years. RAs will respond to questions using 'All You Need to Know About VMMC' booklet, the same way current recruiters do.
3009784|NCT02497989|Experimental|Combined IPC & DSO|Both Inter-personal Communication (IPC) and Dedicated Service Outlets (DSO) interventions (as described above) will be implemented concurrently. This will be done to determine the effect of both interventions delivered jointly compared to each delivered singly, and compared to no intervention.
3009785|NCT02497989|No Intervention|Control|In these Locations, participants will only be given the 'All You Need to Know About VMMC' booklet at the time of enrollment, which is the standard of care.
3009786|NCT02497976|Active Comparator|Group 1: Experimental|Biological: Certolizumab pegol (Cimzia) 400 mg loading dose given subcutaneously at week 0, 2, and 4 followed by a maintenance dose at week 8
3009787|NCT02497976|Placebo Comparator|Group 2: Placebo Comparator|Placebo: given subcutaneously at week 0, 2, 4, and week 8
3009788|NCT02497963|Experimental|Foreskin Graft-Tubularized Incised Plate|Group of patients with primary hypospadias undergoing Foreskin Graft Tubularized Incised Plate Urethroplasty. The surgery involves making an incision on the midline of the urethral plate, graft inner foreskin, and create a new urethra on a urethral catheter.
3009789|NCT02497963|Active Comparator|Tubularized Incised Plate|Group of patients with primary hypospadias undergoing Tubularized Incised Plate Urethroplasty. The surgery involves making an incision on the midline of the urethral plate, and create a new urethra on a urethral catheter.
3009790|NCT02497950||HeartMate 3|This registry will include all patients that receive the HM3 LVAS in the post-market setting
3009791|NCT02497937|Experimental|GSK2798745 and Placebo|Each subject will be randomized to receive GSK2798745 2.4 milligrams (mg) and Placebo once daily for 7 days, each in one of the two treatment periods. Two treatment periods will be separated by a 14-day washout period.
3009792|NCT02497924|Experimental|GBT440|GBT440 / [C14] GBT440
3009793|NCT02497911|Experimental|Adductor Canal Catheter|Postoperatively, patients will be brought to the PACU. The needle insertion site, approximately 10cm proximal to their operative knee, will be exposed. A sterile field will be utilized and the femoral artery is identified with a high frequency linear transducer proximal to the operative knee. 18g insulated Tuohy needle will be inserted in an out-of-plane approach through the sartorius muscle to a final location in close proximity to the saphenous nerve. Once satisfied with needle placement and following negative aspiration, 15 cc's of 0.5% ropivicaine will be injected through the needle under visualization. A 20-g multi-orifice catheter will be inserted approximately 4 cm beyond the needle tip and secured.
3009794|NCT02497911|Experimental|Intraarticular Catheter|Intra-articular catheters will be placed by the surgeon at the end of the procedure, before wound closure. A bupivacaine 0.5% infusion will be admin through the On-Q system and continued for 48 hours postoperatively.
3009795|NCT02497898|No Intervention|regular chemotherapy|Patients after chemotherapy are just followed up.
3009796|NCT02497898|Experimental|CIK regimen|Patients after chemotherapy will receive at least 3 cycles of Cytokine-induced killer cells (CIK) treatment every 3 months.
3009797|NCT02497885||healthcare personnel group|healthcare worker who was exposed to confirmed MERS patients, irrespective of adequate personal protective equipment.
3009798|NCT02497872|Experimental|Early Precut Sphincterectomy|Biliary stone removal using early precut: Patients enrolled in this arm received biliary drainage through a small incision on the papilla with an endoscopic needle-knife - a technique called precut sphincterotomy.
3009799|NCT02497872|Active Comparator|Pancreatic Duct Stent|Biliary stone removal using persistence of cannulation and a later pancreatic duct stent placement: Patients enrolled in this arm received conventional biliary drainage through persistent biliary cannulation. After completion of biliary drainage, a prophylactic pancreatic duct stent was placed.
3009800|NCT02497859|Experimental|Egg Breakfast (EB)|"The EB will receive the following breakfast:~2 scrambled eggs, 120 mL skim milk, 2 slices of Mrs. Bairds® Extra Thin White Bread, 5 g of butter, and 18 g of Smuckers® Strawberry Jam."
3009801|NCT02497859|Active Comparator|Cereal Breakfast (CB)|"The CB will receive the following breakfast:~1.5 cups of Special K® Ready-to-Eat Original Cereal, 200 ml Silk® Original Soymilk, 1 slice of Nature's Own® Double Fiber Wheat Bread, 13 g of butter, and 10 g of Smuckers® Sugar-Free Strawberry Jam."
3009802|NCT02497846|Experimental|TEOSYAL® PureSense Redensity [I]/MicronJet®|"injection of the acid hyaluronic gel with lidocaine as an anesthetic and a dermo-restructuring complex (including 8 amino acids , 3 antioxidants Acid, vitamin B6 and 2 minerals).~Product will be injected in a unique device group:~in crow's feet in order to cover the zone to be treated. Quantity of product injected will be determined by the injector and noted (up to 1 ml by side). A subject can be injected in the left or/and right side.~using a MicronJet microneedle for the superficial wrinkles."
3009803|NCT02497833|Placebo Comparator|control|the participants in this arm are instruted to consume placebo capsules
3009804|NCT02497833|Experimental|treatment|the participants in this arm are instruted to consume retinoic acid capsules
3009805|NCT02497820|Active Comparator|100 mg daily aspirin|They will receive one small tablets each day for two years in a blinded fashion
3009806|NCT02497820|Active Comparator|300 mg daily aspirin|They will receive two large enteric coated tablets each day for two years in a blinded fashion
3009807|NCT02497820|Active Comparator|600 mg daily aspirin|They will receive two large enteric coated tablets each day for two years in a blinded fashion
3009808|NCT02497794|Active Comparator|postoperative chew gum|The patients in the study group will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours.
3009809|NCT02497794|Placebo Comparator|without postoperative chew gum|The control group will be followed without chew gum.
3009810|NCT02497781|Experimental|ceftazidime-avibactam (CAZ-AVI)|CAZ-AVI to be administered every 8 hours as a 2-hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function)
3009811|NCT02497781|Active Comparator|Cefepime|Patients randomised to receive cefepime should receive the dose, schedule and infusion duration as recommended in the local prescribing information or as prescribed by the investigator. The maximum dose of cefepime in any single infusion should not exceed 2000 mg
3009812|NCT02497768|Experimental|Chewing of nuts|8 samples (4-5 g) of nuts (pistachios or Brazils) on two separate visit days.
3009813|NCT02497755|Experimental|Mobile app|Participants will install an app on their smartphone to add to their treatment for depression and/or anxiety.
3009814|NCT02497742|Active Comparator|Once daily BMP|Patient in this arm will receive once daily basic metabolic panel to monitor electrolytes
3009815|NCT02497742|Active Comparator|Twice daily BMP|Patient in this arm will receive twice daily basic metabolic panel to monitor electrolytes
3009816|NCT02497729|No Intervention|Sniffing Position, No Checklist|Patient in the sniffing position without the use of a written checklist
3009817|NCT02497729|Active Comparator|Sniffing Position, Checklist|Patient in the sniffing position with the use of a written checklist
3009818|NCT02497729|Active Comparator|Head of Bed Up, No Checklist|Patient with the head of bed up and without the use of a checklist
3009819|NCT02497729|Active Comparator|Head of Bed Up, Checklist|Patient with the head of bed up and with the use of a checklist
3009820|NCT02497716|Experimental|Rivaroxaban|Single arm, open label study
3009909|NCT02497092|Active Comparator|Slow angled injection|Slow and angled insertion of the needle through the sclera
3009821|NCT02497703|Experimental|Knee robot|This robotic system has been developed to facilitate functional motor recovery by practices walking with a one joint motor powered exoskeleton
3009822|NCT02497690|Active Comparator|In-person ART|In-person approach to provide ART.
3009823|NCT02497690|Experimental|Telehealth ART|Telemedicine technology approach (e.g. interactive video) to provide ART.
3009824|NCT02497677|Experimental|Circle of Security-Parenting|Circle of Security-Parenting (COS-P) is a brief educative group program for parents
3009825|NCT02497677|Active Comparator|Care as Usual (CAU)|Care as usual (CAU) i.e. the active control condition will be standard practices for infants and families at risk in Copenhagen.
3009826|NCT02497664|Other|Active Breathing Control|Planning-CT will be made of patients using the Active Breathing Control Technique (in expiration and inspiration phase)
3009827|NCT02497651|Experimental|Healthy, heavy smoking men|Twelve healthy, male subjects. Intervention: Will undergo two separate, identical test days. One absent smoking, and one with concomitant smoking.
3009828|NCT02497651|Experimental|Healthy, non-smoking men|Twelve healthy, male subjects. Intervention: Will undergo a liquid mixed meal test and a skin biopsy.
3009829|NCT02497638|Experimental|Metformin and Atorvastatin|Atorvastatin 20 mg once daily until progression with one month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
3009830|NCT02497638|Placebo Comparator|Placebo|One placebo tablet (corresponding to atorvastatin) once daily until progression, with one month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
3009831|NCT02497625|Experimental|Positive Therapeutic Alliance|Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.
3009832|NCT02497625|Active Comparator|Usual Care|Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.
3009833|NCT02497625|Other|Control group|Patients will not receive intervention in the first mo nth of enrollment. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.
3009834|NCT02497612|Experimental|Ferroquine Dose 1 + Artefenomel|"Ferroquine Dose 1 single dose + artefenomel fixed single dose, oral take, for patients >14 years old & body weight ≥35 kg.~Ferroquine weight-adjusted single dose + artefenomel weight adjusted dose, oral take, for patients <35 kg."
3009835|NCT02497612|Experimental|Ferroquine Dose 2 + Artefenomel|"Ferroquine Dose 2 single dose + artefenomel fixed single dose, oral take, for patients >14 years old & body weight ≥35 kg.~Ferroquine weight-adjusted single dose + artefenomel weight adjusted dose, oral take, for patients <35 kg."
3009836|NCT02497612|Experimental|Ferroquine Dose 3 + Artefenomel|"Ferroquine Dose 3 single dose + artefenomel fixed single dose, oral take, for patients >14 years old & body weight ≥35 kg.~Ferroquine weight-adjusted single dose + artefenomel weight adjusted dose, oral take, for patients <35 kg."
3009837|NCT02497612|Experimental|Ferroquine Dose 4 + Artefenomel|"Ferroquine Dose 4 single dose + artefenomel fixed single dose, oral take, for patients >14 years old & body weight ≥35 kg.~Ferroquine weight-adjusted single dose + artefenomel weight adjusted dose, oral take, for patients <35 kg."
3009838|NCT02497599|Experimental|Intraoperative dual-modality imaging|Patients receive a single intravenous dose of Indium-111-DOTA-Girentuximab-IRDye800CW. At day 4 or 5 after antibody injection a whole body planar scan and SPECT/CT scan will be acquired. At day 7 standard of care (partial) nephrectomy will be performed. This will be extended with the use of dual-modality imaging.
3009839|NCT02497586|Experimental|MRS|Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. This is a prospective feasibility study, aiming to recruit 15 consecutive patients with lung cancer to undergo proton MRS. The feasibility and repeatability of the technique will be assessed by analysis of the MR spectra obtained.
3009840|NCT02497560|Active Comparator|Treatment|all natural dietary supplement
3009841|NCT02497560|Other|Treatment + Omega-3s|all natural dietary supplement + omega-3s
3009842|NCT02497560|Placebo Comparator|Placebo|vegetable oil
3009843|NCT02497547|Experimental|Oxytocin 400 IU|Oxytocin 400 IU vaginal gel (1 x 1mL/400 IU oxytocin daily for 12 weeks)
3009844|NCT02497547|Experimental|Oxytocin 200 IU|Oxytocin 200 IU vaginal gel (1 x 1mL/200 IU oxytocin daily for 12 weeks)
3009845|NCT02497547|Placebo Comparator|Placebo|Placebo vaginal gel (1 x 1mL daily for 12 weeks)
3009846|NCT02497534||Friedreich's ataxia|Friedreich's ataxia patients aged 8 to 70 (inclusive). Assessments will include collection of genetic mutation reports, cardiac MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), and motor control testing.
3009847|NCT02497534||Healthy controls|Health controls aged 8 to 70 (inclusive). Assessments will include cardiac MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), and motor control testing.
3009848|NCT02497521||ADPKD|Patients with diagnosis of ADPKD, who are either evaluated for tolvaptan treatment indication, planned for tolvaptan treatment, or are already treated with tolvaptan
3009849|NCT02497508|Experimental|Nivolumab|Nivolumab will be administered 2 weekly by intravenous infusion in a dose of 3 mg/kg
3009850|NCT02497495|No Intervention|GC|Control group - CG (n = 21), which suffered no recuperative technique
3009851|NCT02497495|Experimental|G1|G1 (n = 21) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 9±1 degrees Celsius
3009852|NCT02497495|Experimental|G2|G2 (n = 21) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 14±1 degrees Celsius
3009853|NCT02497495|Experimental|G3|G3 (n = 21) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 9±1 degrees Celsius
3009854|NCT02497495|Experimental|G4|G4 (n = 21) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 14±1 degrees Celsius
3044061|NCT02266537|Placebo Comparator|Placebo|
3009855|NCT02497469|Experimental|Vedolizumab IV|Vedolizumab 300 milligram (mg), infusion, intravenously over 30 minutes on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46. Adalimumab placebo-matching injection, subcutaneously on Day 1, Week 2, and every 2 weeks thereafter up to Week 50.
3009856|NCT02497469|Active Comparator|Adalimumab SC|Adalimumab 160 mg, injection, subcutaneously on Day 1, adalimumab 80 mg, injection, subcutaneously at Week 2, then adalimumab 40 mg, injection, subcutaneously every 2 weeks thereafter up to Week 50. Vedolizumab placebo-matching infusion, intravenously on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46.
3009857|NCT02497456|Experimental|Follow-up counselling|Participants in the experimental arm will receive home-based HIV counselling and testing and referral for HIV care if found to have HIV infection. Additionally, participants will receive home-based follow-up counselling at 1 and 2 months after HIV diagnosis.
3009858|NCT02497456|No Intervention|Standard of care|Participants in this arm will receive only home-based HIV counselling and testing and referral for HIV care if found to have HIV infection.
3009859|NCT02497443|Experimental|study group|Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.anti-epileptic drugs [AEDs]) and receiving autologous mesenchymal stem cells
3009860|NCT02497443|No Intervention|control group|Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.AEDs)
3009861|NCT02497404|Experimental|5 Azacytidine|Patients will be given a five day course of subcutaneous 5-azacytidine, followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irradiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor.
3009862|NCT02497391|Experimental|Evacetrapib Reference (R)|Single oral dose of evacetrapib tablet given one time during one study period.
3009863|NCT02497391|Experimental|Evacetrapib Test 1 (T1)|Single oral dose of evacetrapib tablet given one time during one study period.
3009864|NCT02497391|Experimental|Evacetrapib Test 2 (T2)|Single oral dose of evacetrapib tablet given one time during one study period.
3009865|NCT02497378|Experimental|JNJ-54767414 (Daratumumab) +Bortezomib+Dexamethasone|Participants will be administered JNJ-54767414 (daratumumab) intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, then on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks), First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles. Bortezomib at a dose of 1.3 milligram per meter square (mg/m^2) subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle for 8 treatment cycles and Dexamethasone orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles.
3009866|NCT02497365|Experimental|Group A: Besifloxacin|Patients presenting with bacterial keratitis. These patients will be treated with besifloxacin ophthalmic suspesnion 0.6%, initially 6x a day and tapered down as the patient's condition improves based on the clinical judgement of the treating physician.
3009867|NCT02497365|Active Comparator|Group B: Fortified Antibiotics|Patients presenting with bacterial keratitis. These patients will be treated initially with fortified cefazolin and vancomycin drops every 1 hour around the clock (24hours) for a minimum of 48 hours, and will subsequently have their dosages tapered gradually by the treating physician as is the standard of care for bacterial keratitis.
3009868|NCT02497352|Experimental|Flaxseed|30 g milled brown flaxseed + lifestyle modification
3009869|NCT02497352|Active Comparator|control|lifestyle modification including dietary and physical activity recommendation
3009870|NCT02497339|Experimental|Intervention group|Intervention group (Mindfulness Smoking cessation program): Women in intervention group will be provided 2 sessions mindfulness training within 2 weeks. Each session will last for 2 hours with 8-20 participants. For mindfulness training, it aims to understand women smokers' own life planning, stressors and their correlation with smoking; to help women smokers sit with negative affect and alleviate stress through mindfulness; to educate women smokers gain the self-control and replace the smoking habit; to teach women smokers how to prevent craving and relapse.
3009871|NCT02497339|Experimental|Control group|Control group (Self-help smoking cessation booklet): Only the self-help booklet related to quitting will be provided to the participants.
3009872|NCT02497326|Active Comparator|Polyfax & Lignocain gel or silvazine cream|Polyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash
3009873|NCT02497326|Experimental|Topical heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval."
3009874|NCT02497313|Placebo Comparator|Placebo+Placebo|Oral ingestion of metformin placebo combined with intravenous infusion of isotonic saline.
3009875|NCT02497313|Active Comparator|Placebo+Cholecystokinin|Oral ingestion of metformin placebo combined with intravenous infusion of cholecystokinin.
3009876|NCT02497313|Active Comparator|Metformin+Placebo|Oral ingestion of metformin combined with intravenous infusion of isotonic saline.
3009877|NCT02497313|Active Comparator|Metformin+Cholecystokinin|Oral ingestion of metformin combined with intravenous infusion of cholecystokinin.
3009878|NCT02497300|Experimental|Spironolactone|Participants will be randomized to spironolactone 25mg daily for the 1st or 2nd 6 week treatment period.
3009879|NCT02497300|Active Comparator|Amiloride|Participants will be randomized to amiloride 5mg daily for the 1st or 2nd 6 week treatment period.
3009880|NCT02497287|Experimental|Intranasal Esketamine plus oral antidepressant|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg). Participants greater than or equal to (>=) 65 will start at a dose of 28 mg on Day 1. Direct-entry participants will initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1; transferred-entry participants will continue the same oral antidepressant from ESKETINTRD3005. Optimization/Maintenance Phase: Participants will self-administer esketamine (56mg or 84mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years) intranasally once per week for 4 weeks; transferred entry responder subjects from ESKETINTRD3005 will start at a dose of 28 mg in the first week. All participants will continue their same oral antidepressant during this phase.
3009881|NCT02497274|Experimental|Roux Y gastric bypass|candidates for bariatric surgery by Roux Y gastric bypass with taste assessment and epithelium gustatory smear and biopsy
3009882|NCT02497274|Experimental|Sleeve gastrectomy|candidates for bariatric surgery by sleeve gastrectomy with taste assessment and epithelium gustatory smear and biopsy
3009883|NCT02497261||Avoiding and possibly allergic to peanut|Challenge Group: Children with positive skin prick testing to peanut who are avoiding peanut will undergo a double-blind placebo-controlled peanut challenge (gold standard for peanut allergy diagnosis) if their allergy evaluation suggests that they have a good chance of not being allergic to peanut. Children who pass the challenge are not allergic to peanut. Children who react during the challenge are allergic to peanut and will continue to avoid peanut.
3009884|NCT02497261||Not allergic to peanut|Comparison Group: Children with positive skin prick testing to peanut who are eating and tolerating peanut are not clinically allergic to peanut and may continue eating peanut.
3009885|NCT02497248||- Patients with paroxysmal AF.|Patients with AF episodes that terminates spontaneously or with intervention in less than seven days with clinical indication of pulmonary vein ablation.
3009886|NCT02497248||- Patients with persistent AF.|Patients with AF episodes that fails to self-terminate within seven days or require pharmacologic or electrical cardioversion to restore sinus rhythm with clinical indication of pulmonary vein ablation..
3009887|NCT02497248||- Patients with mitral stenosis.|- Patients with mitral stenosis and clinical indication for AF ablation undergoing percutaneous balloon mitral valvuloplasty (PBMV) with clinical indication of pulmonary vein ablation..
3009888|NCT02497235|Experimental|TAK-935|A single dose of TAK-935 600 milligram (mg), oral solution on Day 1 as a starting dose and up to 370 megabecquerel (MBq) (10 millicurie [mCi]) of [18F]MNI-792 with a mass of up to 5 microgram (mcg), injection intravenously (IV), prior to each PET imaging at Baseline, 45 minutes and 10 hours post-TAK-935 dose. Subsequent dose of TAK-935 oral solution and timing of PET imaging will be based on safety, tolerability and occupancy data from previous level participants.
3009889|NCT02497222|Experimental|RNS60|RNS60 4 ml, inhaled twice daily by nebulization for 21 days.
3009890|NCT02497222|Placebo Comparator|Normal Saline|Normal Saline 4 ml, inhaled twice daily by nebulization for 21 days.
3009891|NCT02497196|Experimental|Part 1:Active tPCS, Active tDCS|12 out of the 48 total health subjects will receive active tPCS and active tDCS. This will be done for 20 minutes simultaneously.
3009892|NCT02497196|Experimental|Part 1: Active tPCS, Sham tDCS|12 out of the 48 total health subjects will receive active tPCS and sham tDCS. This will be done for 20 minutes simultaneously.
3009893|NCT02497196|Experimental|Part 1:Sham tPCS, Active tDCS|12 out of the 48 total health subjects will receive sham tPCS and active tDCS. This will be done for 20 minutes simultaneously.
3009894|NCT02497196|Sham Comparator|Part 1: Sham tDCS, Sham tDCS|12 out of the 48 total health subjects will receive sham tPCS and sham tDCS. This will be done for 20 minutes simultaneously.
3009895|NCT02497196|Experimental|Part 2: Active tPCS/Active tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving active tPCS and active tDCS (1/4 combinations all subjects will receive).
3009896|NCT02497196|Experimental|Part 2: Active tPCS/Sham tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving active tPCS and sham tDCS (1/4 combinations all subjects will receive).
3009897|NCT02497196|Experimental|Part 2: Sham tPCS/Active tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving sham tPCS and active tDCS (1/4 combinations all subjects will receive).
3009898|NCT02497196|Sham Comparator|2: Sham tPCS/Sham tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving sham tPCS and sham tDCS (1/4 combinations all subjects will receive).
3009899|NCT02497183|Experimental|first|a repeat abdominal ultrasound exam to patients following the filling of bowel with contrast material per os.
3009900|NCT02497170|Other|Life style changes|Pre and post after education intervention Education program
3009901|NCT02497157|Experimental|Treatment Arm|Patients receive FOLFOXIRI plus bevacizumab [oxaliplatin (L-OHP): 85 mg/sq.m., irinotecan hydrochloride hydrate (CPT-11): 165 mg/sq.m., continuous intravenous infusion of fluorouracil (CIV 5-FU): 3,200 mg/sq.m., Levofolinate calcium (l-LV): 200 mg/sq.m., bevacizumab: 5 mg/kg]. The treatment will be repeated every 2 weeks, for up to 12 cycles, unless the disease progression, unacceptable toxicity, tumor resection or consent withdrawal.
3009902|NCT02497144|Active Comparator|NMES Group|"Intervention: NMES group will receive neuromuscular electrical stimulation using high frequency galvanic stimulation and breathing exercises.~Neuromuscular electrical stimulation will be applied bilaterally to quadriceps femoris muscle for 3days/6 weeks by a physiotherapist.~NMES group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks."
3009903|NCT02497144|Sham Comparator|Control Group|"Sham: Control group will receive breathing exercises. Control group will perform breathing exercises 120 times/day, 7 days/week, for 6 weeks.~Control group will be followed-up by telephone once a week."
3009904|NCT02497131|Experimental|Brentuximab Vedotin 16 cycles|Subjects will receive 1.8 mg/kg of brentuximab vedotin as an iv infusion administered on Day 1 of each 21-day cycle for a maximum of 16 cycles.
3009905|NCT02497118|Experimental|Endostatin plus NP|drug:Endostatins Intravenous drip， 7.5mg/m^2, d1-14 drug:vinorelbine Intravenous drip 25mg/m^2,IV, d1, d8; drug:Cisplatin，75mg/m^2 Intravenous drip,divide into d1-3 for 2 cycles
3009906|NCT02497118|Active Comparator|NP neoadjuvant chemotherapy|drug:vinorelbine Intravenous drip 25mg/m^2,IV, d1, d8; drug:Cisplatin，75mg/m^2 Intravenous drip,divide into d1-3 for 2 cycles
3009907|NCT02497105|Experimental|Epilepsy/Ketogenic Diet|Children (0-18 years of age) diagnosed with epilepsy will receive the ketogenic diet intervention.
3009908|NCT02497105|No Intervention|Epilepsy/Non-Ketogenic Diet|Children (0-18 years of age) diagnosed with epilepsy will not receive the ketogenic diet intervention.
3011054|NCT02489188||hip osteoarthritis|patients with hip osteoarthritis scheduled for arthroplasty
3009913|NCT02497079|Experimental|Nested PCR for formalin-fixed tissues|In all patients, nested polymerase chain reaction for Mycobacterium tuberculosis is performed with formalin-fixed paraffin-embedded specimens obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
3009914|NCT02497079|Experimental|Nested PCR for fresh tissues|In all patients, nested polymerase chain reaction for Mycobacterium tuberculosis is performed with specimens in sterile saline obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
3009915|NCT02497079|Experimental|Real-time PCR for fresh tissues|In all patients, real-time polymerase chain reaction for Mycobacterium tuberculosis is performed with specimens in sterile saline obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
3009916|NCT02497066|Placebo Comparator|Neuropathic Pain|Subjects with neuropathic pain will receive a neuropathic pain cream combined of Ketamine 10%/Gabapentin 6%/Clonidine 0.2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
3009917|NCT02497066|Placebo Comparator|Nociceptive pain|Subjects with nociceptive pain will receive a nociceptive pain cream combined of Ketoprofen 10%/Baclofen 2%/Cyclobenzaprine 2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
3009918|NCT02497066|Placebo Comparator|Mixed pain|Subjects who have a mixed (nociceptive and neuropathic) pain conditions will receive a mixed pain cream combined of Ketamine 10%/Gabapentin 6%/Diclofenac 3%/baclofen 2%/Cyclobenzaprine 2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
3009919|NCT02497053|Experimental|Arm A|Four cycles of pemetrexed/platinum
3009920|NCT02497053|Active Comparator|Arm B|Six cycles of pemetrexed/platinum
3009921|NCT02497040|Experimental|bupivacaine,levobupivacaine|20 ml of 0.5% bupivacaine 20 ml of 0.5% levobupivacaine
3009922|NCT02497040|Active Comparator|levobupivacaine|20 ml of 0.5% levobupivacaine saline as a placebo
3009923|NCT02497040|Active Comparator|bupivacaine|20 ml of 0.5% bupivacaine saline as a placebo
3009924|NCT02497027|Other|4-Week Group|Pharmacogenetic testing released to physician at 4 weeks following enrollment into study
3009925|NCT02497027|Other|12-Week Group|Pharmacogenetic testing released to physician at 12 weeks following enrollment into study
3009926|NCT02497014|Experimental|1 Stent|Patients who are going to receive 1 stent in the main vessel and the side vessel will be treated with kissing ballon inflation
3009927|NCT02497014|Experimental|2 Stents|Patients who are going to receive 2 stents in both vessels
3009928|NCT02497001|Experimental|BGF MDI (PT010) 320/14.4/9.6 μg ex-actuator|BGF MDI 320/14.4/9.6 μg,Budesonide, Glycopyrronium, Formoterol Fumarate Inhalation Aerosol
3009929|NCT02497001|Experimental|GFF MDI (PT003) 14.4/9.6 μg ex-actuator|GFF MDI 14.4/9.6 μg ex-actuator Glycopyrronium, Formoterol Fumarate Inhalation Aerosol
3009930|NCT02497001|Experimental|BFF MDI (PT009) 320/9.6 μg ex-actuator|BFF MDI 320/9.6 μg, Budesonide, Formoterol Fumarate Inhalation Aerosol
3009931|NCT02497001|Active Comparator|Symbicort|Symbicort® Turbuhaler® (TBH) Inhalation Powder 200/6 μg
3009932|NCT02496988|Other|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
3009933|NCT02496988|Other|Temozolomide+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat
3009934|NCT02496975|Experimental|Cyclosporine A|Participants assigned to this group will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
3009935|NCT02496975|Active Comparator|Placebo|Participants assigned to this group will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
3009936|NCT02496962|Experimental|Statin group|drug: atorvastatin (Pfizer, U.S.); the frequency: 20mg atorvastatin was taken daily; duration: Study treatment was commenced 3 days before sleep deprivation and continued for 2 days during sleep deprivation.
3009937|NCT02496962|Placebo Comparator|Control group|drug: placebo (Pfizer, U.S.); the frequency: Placebo was taken daily; duration: Study treatment was commenced 3 days before sleep deprivation and continued for 2 days during sleep deprivation.
3009938|NCT02496949|Experimental|Icaritin|600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
3009939|NCT02496936|Experimental|Saturated Fat/SFA|30 grams saturated fat in the form of heavy whipping cream will be provided to subject in a smoothie drink
3009940|NCT02496936|Experimental|Monounsaturated Fat/MUFA|30 grams monounsaturated fat in the form of high oleic canola oil will be provided to subject in a smoothie drink
3009941|NCT02496936|Experimental|Polyunsaturated Fat Linoleic/PUFA-LA|30 grams polyunsaturated fat in the form of high linoleic sunflower oil will be provided to subject in a smoothie drink
3009942|NCT02496936|Experimental|Polyunsaturated Fat Alpha-Linolenic/ALA|30 grams polyunsaturated fat in the form of flaxseed oil will be provided to subject in a smoothie drink
3009943|NCT02496936|Experimental|Polyunsaturated Fat Omega-3/LCn3|30 grams polyunsaturated fat in the form of fish oil (Coromega Omega3 Squeeze) will be provided to subject in a smoothie drink
3009944|NCT02496923|Experimental|High flow nasal oxygen therapy (Optiflow™)|In patients randomised to receive high flow nasal oxygen therapy (HFNO) the gas flow through the HFNO will be calculated for each patient, based on their body characteristics, and comfort level. The standard starting flow rate will be 30 L/min, and this will be adjusted up or down between a range of 20-50 L/min with the aim of achieving both patient comfort and a respiratory rate of less than 16 breaths per minute.
3010077|NCT02496026|Sham Comparator|Sham tDCS plus wrist robot therapy|Group B is treated as Group A, but tDCS, even if the cap is applied on the patient head, is not activated and no current is delivered.
3044062|NCT02266524|Experimental|Tamsulosin hydrochloride, very low dose|
3009945|NCT02496923|Active Comparator|Standard oxygen therapy (Hudson face mask or nasal prongs)|Patients randomised to receive standard oxygen therapy will be fitted with a soft face mask or nasal prongs, and the oxygen flow titrated to provide pulse oxygen saturation of at least 95% (93% for those at risk of hypercapnic respiratory failure such as confirmed COPD patients and morbidly obese patients). The standard oxygen therapy group will have their oxygen gas flow reduced to the minimum level which provides saturations of at least 95% (93% for those at risk of hypercapnic respiratory failure such as patients with confirmed COPD and morbidly obese patients).
3009946|NCT02496910|Active Comparator|Group 1 - Period 1|Telmisartan/Amlodipine 80/5 mg (FDC) and Chlorthalidone 25mg
3009947|NCT02496910|Experimental|Group 2 - Period 1|YH22162 FDC tablet of Yuhan Corporation
3009948|NCT02496910|Experimental|Group 1 - Period 2|YH22162 FDC tablet of Yuhan Corporation
3009949|NCT02496910|Active Comparator|Group 2 - Period 2|Telmisartan/Amlodipine 80/5 mg (FDC) and Chlorthalidone 25mg
3009950|NCT02496897|Experimental|FP-02.2 Low Dose|A low dose of the FP-02.2 vaccine.
3009951|NCT02496897|Experimental|FP-02.2 High Dose|A high dose of the FP-02.2 vaccine.
3009952|NCT02496897|Experimental|FP-02.2 Low Dose with IC31® Adjuvant|A low dose of the FP-02.2 vaccine with IC31® Adjuvant.
3009953|NCT02496897|Experimental|FP-02.2 High Dose with IC31® Adjuvant|A high dose of the FP-02.2 vaccine with IC31® Adjuvant.
3009954|NCT02496897|Placebo Comparator|Placebo|Placebo component.
3009955|NCT02496897|Experimental|IC31® Adjuvant|IC31® Adjuvant alone.
3009956|NCT02496884|Experimental|M-CKD DS-5565 7.5 mg BID|Patients with moderate chronic kidney disease (M-CKD) randomized to receive DS-5565 BID during the treatment period.
3009957|NCT02496884|Experimental|S-CKD DS-5565 7.5 mg QD|Fibromyalgia patients with severe chronic kidney disease (S-CKD) randomized to receive a DS-5565 7.5 mg tablet once per day (QD), and a placebo tablet (no drug) QD, for a total of 7.5 mg DS-5565
3009958|NCT02496884|Placebo Comparator|M-CKD Placebo|Patients with M-CKD randomized to receive placebo twice daily (BID) during the treatment period.
3009959|NCT02496884|Placebo Comparator|S-CKD Placebo|Patients with S-CKD randomized to receive placebo once daily (QD) during the treatment period.
3009960|NCT02496871|Active Comparator|KWMP-GP|Weekly group phone calls for 6 months. Group phone calls will last about 45 minutes each. Phone calls will include groups of 12-18 participants.
3009961|NCT02496871|Experimental|KWMP-SM|Participants interact through a private Facebook group. New activities for participants to complete each week for 6 months.
3009962|NCT02496858||Retrospective study|The 200 young adults (ages 18-45) diagnosed with CAD by coronary angiography will be collected from multiple institutions. (since August, 2005 until now). Medical history and risk-factor information were obtained by abstracting information from medical records.
3009963|NCT02496858||Prospective study|The anticipated 300 young CAD patients undergoing coronary angiography will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
3009964|NCT02496845|Experimental|Group A|Topical treatment and PK. Administration of VL#FIA3-30 (dual administration of MH30-01 & IS045-01)
3009965|NCT02496845|Experimental|Groups B, C, D|Dual topical biweekly administration and intraurethral. Triple topical weekly administration. Multiple topical administration. Administration of VL#FIA3-30 (dual administration of MH30-01 & IS045-01)
3009966|NCT02496832|Experimental|FAZA PET-CT scan|"FAZA PET-CT imaging within 14 days of treatment from the EMR200592-001 study.~FAZA PET-CT imaging about 5 weeks after start of treatment from the EMR200592-001 study."
3009967|NCT02496819|Experimental|Metacognitive self-regulated learning intervention|It involves training of daily tasks using a self-correct strategy. Participants' performance will be video-taped and they will then watch the video playback for reflection and self-correction under the guidance of the occupational therapist.
3009968|NCT02496819|Experimental|Sensory Integration intervention|It involves active, fun physical activity completing 8 stations of activities involving tactile, proprioceptive and vestibular tasks. Frequent breaks will be given to avoid exhaustion and fatigue throughout the activities.
3009969|NCT02496819|Active Comparator|Activity-Based Intervention|It provides constructional, drawing and crafts activity. Participants are guided to complete these tasks
3009970|NCT02496806|Experimental|Treatment|400mg capsule containing seaweed extract (treatment) Intervention: Dietary Supplement: Treatment capsule containing seaweed extract (treatment)
3009971|NCT02496793|Experimental|Peer Facilitator and Support Group|Peer-facilitated community support group is the experimental intervention. The intervention tested in this study involved using trained peer facilitators to create demand for and retention within the ANC/PMTCT program.The peer facilitators were volunteer women from the community, who had recently been through the ANC process themselves and could speak about their experience(s). the support group meetings was to develop skills and generate self-efficacy for the women to be able to take actions such as routine antenatal and postnatal clinic attendance using participatory learning techniques. The peer facilitators were provided with job aids which outlined key points for the various educational sessions.
3009972|NCT02496793|No Intervention|Standard Care|ANC/PMTCT activities as per standard of care in Zimbabwe
3009973|NCT02496780|Placebo Comparator|placebo|once or 3x daily injectable placebo (insulin diluent)
3009974|NCT02496780|Experimental|basal insulin levemir|once daily basal insulin therapy with insulin levemir
3009975|NCT02496780|Experimental|rapid-acting insulin Novolog|pre-meal rapid-acting insulin 3x/day with insulin novolog
3009976|NCT02496767|Placebo Comparator|Group 1 - Placebo|Day 1 through Week 48 - 2 placebo tablets twice daily
3009977|NCT02496767|Experimental|Group 2 - 250 mg tirasemtiv|Day 1 through Week 48 - 1 tablet (125 mg) of tirasemtiv and 1 tablet of matching placebo in AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in PM
3009978|NCT02496767|Experimental|Group 3 - 375 mg tirasemtiv|Day 1 through Week 2 - 1 tablet (125 mg) of tirasemtiv and 1 tablet of matching placebo in AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in PM; Weeks 3 through 48 - 1 tablet (125 mg) of tirasemtiv and 1 tablet of matching placebo in AM and 2 tablets of tirasemtiv (250 mg) in PM
3010110|NCT02495818|Sham Comparator|Saline solution|Intervention with suprascapular nerve block with 5ml saline solution guided by Ultrasound combined with homemade exercises (Codman and Hughston exercises).
3044063|NCT02266524|Experimental|Tamsulosin hydrochloride, low dose|
3009979|NCT02496767|Experimental|Group 4 - 500 mg tirasemtiv|Day 1 through Week 2 - 1 tablet (125 mg) of tirasemtiv and 1 tablet of matching placebo in AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in PM; Weeks 3 and 4 - 1 tablet (125 mg) of tirasemtiv and 1 tablet of matching placebo in AM and 2 tablets of tirasemtiv (250 mg) in PM; Weeks 5 through 48 - 2 tablets (250 mg) of tirasemtiv in AM and 2 tablets of tirasemtiv (250 mg) in PM
3009980|NCT02496754|Experimental|New protocol group|Use long term GnRH-a 3.75mg at day 2 of menstrual cycle. Around 30 days later, controlled ovarian hyperstimulation using gonadotropins is initiated.
3009981|NCT02496754|Active Comparator|Standard GnRH-a long protocol|Use short GnRH-a 0.1mg at luteal phase of last menstrual cycle for 10 days and 0.05mg for another 4 days. Once pituitary down regulation is achieved,controlled ovarian hyperstimulation using gonadotropins is initiated. During ovarian stimulation, short GnRH-a is used daily at the dose of 0.05mg until human chorionic gonadotrophin (HCG) trigger.
3009982|NCT02496741|Experimental|Metformin and chloroquine combination|"Metformin will be administered in a 3+3 dose-escalation schedule.~Chloroquine will be administered in a fixed dose."
3009983|NCT02496728|Experimental|Cardiovascular Health|Participants will be given the results of their health assessment and feedback regarding their health behaviors and overall health. Recommendations for change will be given if warranted. Participants will download the study's mobile health application on their smartphone. They will then be asked to report once a week about their health behaviors on the application. Participants will also be asked to self-monitor health behaviors that are not already at ideal levels using the study application (environmental cues). Participants will be asked to join a secret Facebook group where informational materials will be posted, participants can post about study health behaviors and social interaction around health behaviors can occur (social support and environmental cues).
3009984|NCT02496728|Active Comparator|Whole Health|Participants will be given the results of their health assessment. They will then receive educational materials about sunscreen use, safe sex, hydration and vehicular safety. Participants will download the study's mobile health application on their smartphone. They will then be asked to report once a week about their health behaviors on the application. Participants will also be asked to self-monitor how much water they drink using the study application. Participants will be asked to join a secret Facebook group where informational materials will be posted, they can post about study health behaviors and social interaction around health behaviors can occur (social support and environmental cues).
3009985|NCT02496715|Experimental|Treatment 1|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg. Single puff, twice daily (approximately every 12 hr) for 4 weeks
3009986|NCT02496715|Experimental|Treatment 2|Advair 100/50 Diskus pMDI containing fluticasone propionate 100mcg / salmeterol 50 mcg. Single puff, twice daily (approximately every 12 hr) for 4 weeks
3009987|NCT02496715|Placebo Comparator|Treatment 3|Placebo inhalation. Single puff, twice daily (approximately every 12 hr) for 4 weeks
3009988|NCT02496702|Experimental|Training|"The intervention is done in the form of groups of 4-5 participants per set of tiles, with 2-3 set of tiles at a time. As more set can be used it is possible to make groups of more people. The training will consist of 1.5-3 minutes of training (depending on the game) on tiles and the rest while the other 2-3 participants train (4-6 minutes of break). Then the participants will train for 1.5-3 minutes again until each participant have received a total of 13 minutes of training.~The intervention will be done 2 times a week for 12 weeks, each session lasting 1 hour and each participant receiving 13 minutes of training each time (see training plan)."
3009989|NCT02496702|No Intervention|Control|No training.
3009990|NCT02496676|Experimental|Oral Treatment Failures|Patients in whom oral magnesium was not clearly effective will begin a 2-week washout and proceed to Part II. Such patients will be hospitalized to receive 3 days of IV MgSO4 administered 3 times per day for a total daily dose of 30/mg/kg/day. Then they will restart escalating doses of orally selfadministered magnesium Lthreonate and continue for the remaining 24 weeks of the study.
3009991|NCT02496676|Experimental|Arm 2|Arm 2 will receive 12 weeks of placebo followed by 12 weeks of magnesium supplementation
3009992|NCT02496676|Experimental|Arm 1|Arm 1 will receive 12 weeks of magnesium supplementation followed by 12 weeks of placebo
3009993|NCT02496663|Experimental|Treatment (osimertinib, necitumumab)|Patients receive osimertinib PO QD on days 1-21 and necitumumab IV over 50 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3009994|NCT02496650|Experimental|Group D|Dexmedetomidine (DEX) infusion was started in doses 0,2-1,4 μg/kg/hr and titrated to achieve target sedation level; symptom-triggered BZD administration (diazepam 10mg bolus) were used wherever DEX infusion was not enough. Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.
3009995|NCT02496650|No Intervention|Group C|Benzodiasepine (BZD) boluses (diazepam 10mg) were used to achieve target sedation level and to control AWS symptoms (symptom-triggered administration). Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.
3009996|NCT02496637|Experimental|Appetite Awareness|Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues
3009997|NCT02496637|Active Comparator|Nutrition Education|Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
3009998|NCT02496637|No Intervention|No Treatment Control|No intervention, assessment only
3009999|NCT02496624|Other|Lung cancer|
3010000|NCT02496611|Experimental|Meal Replacement Therapy|A short-term (1-3 month) meal replacement induction period design to achieve ≥5% BMI reduction. If participants achieve ≥5% BMI they will be randomized to drug or placebo in phase 2 of the trail.
3010001|NCT02496611|Placebo Comparator|Weight Loss Maintenance with Pharmacotherapy|We hypothesize that adolescents with severe obesity receiving GLP-1RA treatment following a short-term meal replacement induction period will demonstrate superior maintenance of initial BMI reduction 52 weeks following randomization compared to those assigned to placebo (primary endpoint) and that a higher proportion of those assigned to GLP-1RA treatment vs. placebo will maintain ≥5% BMI reduction from baseline to the 52-week time point (secondary endpoint)
3010002|NCT02496598|Experimental|In Vitro Follicle Activation (IVA)|Ovarian tissue will be removed and cultured in vitro with compounds to activate dormant follicles. Following activation, ovarian tissue will be auto-grafted and the patient monitored for follicular growth.
3010003|NCT02496585|Experimental|Nintedanib + Prednisone|The initial dose of nintedanib will be 150mg two times per day orally according to study protocol. Nintedanib will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
3010004|NCT02496585|Experimental|Placebo + Prednisone|Placebo will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
3010005|NCT02496572||Short-course MDR-TB regimen patients|"Short course MDR-TB treatment regimen. New presumptively diagnosed MDR TB patients (adults and children) with Xpert® MTB/RIF or Hain MTBDR, or confirmed with Hain MTBDR plus on positive cultures if initial molecular tests negative or confirmed from MGIT culture/DST if initial molecular tests negative;~Children (<14 years old) suspected of MDR TB without bacteriological confirmation but documented as a close contact of a confirmed MDR TB patient"
3010006|NCT02496559|Active Comparator|Pre-consultation CRP|Every third child included get a CRP-test before the consultation and the doctor have the answer at start of consultation
3010007|NCT02496559|No Intervention|CRP requested|No intervention, the consultation with children as normal, the CRP is used at doctors request.
3010008|NCT02496546|Experimental|LEO 32731 cream|Topical application
3010009|NCT02496546|Placebo Comparator|LEO 32731 cream vehicle|Topical application
3010010|NCT02496533|No Intervention|No Massage|Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before and after imaging. The anxiety VAS will be repeated after the imaging procedure. Subjects in this arm will not receive the hand massage prior to the imaging procedure.
3010011|NCT02496533|Experimental|Hand Massage|Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before massage, after massage but before imaging, and after imaging.The subjects will receive hand massage prior to the imaging procedure. The anxiety VAS will be repeated after the imaging procedure.
3010012|NCT02496520|Experimental|Vaccines with autologous dendritic cells|Vaccines with autologous dendritic cells
3010013|NCT02496507|Experimental|Intervention|Provision of a sit-stand workstation for use at work.
3010014|NCT02496507|No Intervention|Control|Participants were asked to maintain their normal work practices and received no intervention. Participants were offered the opportunity to have a sit-stand workstation installed for 8 weeks after all data collection.
3010015|NCT02496494|Experimental|Tacrolimus conversion group|Cyclosprine was converted to tacrolimus in kidney transplant recipients.
3010016|NCT02496481|Experimental|Group1 Baseline+MI+tailored brochure|"Participants randomized to Group 1 will receive the motivational interviewing intervention in the ED and will be mailed a tailored educational brochure about child passenger safety.~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
3010017|NCT02496481|Experimental|Group2 Baseline+MI+general info|"Participants randomized to Group 2 will receive the motivational interviewing intervention in the ED and will be mailed a generic educational brochure about child passenger safety.~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
3010018|NCT02496481|Experimental|Group3 Baseline+tailored brochure|"Participants randomized to Group 3 will receive no intervention in the ED and will be mailed a tailored educational brochure about child passenger safety~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
3010019|NCT02496481|No Intervention|Group4 Baseline+general info|"Control Group. Participants randomized to this arm will receive no intervention in the ED and will be mailed a generic educational brochure about child passenger safety.~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
3010020|NCT02496468||new-onset wheeze/asthma|children with inhaled or systemic corticosteroid-/leukotriene receptor antagonist-naïve wheeze/asthma, will undergo follow-up after initial recruitment
3010021|NCT02496468||wheeze/asthma under controller therapy|children with wheeze/asthma, already under controller (inhaled or systemic corticosteroids or leukotriene receptor antagonist) therapy, will undergo follow-up after initial recruitment
3010022|NCT02496468||healthy controls|healthy age- and sex-matched controls, will not undergo follow-up after initial recruitment
3010023|NCT02496442|Active Comparator|using Aqueduct|Patients passing procedures with Aqueduct
3010024|NCT02496442|No Intervention|Not using Aqueduct|Patients passing the standard procedures
3010025|NCT02496429|Other|BrownieForSymphony use|Each participant will use the BrownieForSymphony pumpset
3010026|NCT02496416|Experimental|Treatment|The treatment group will participate in an eight week aquatic exercise program during weeks 2-9 of the study. The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Scotch Plains-Fanwood, NJ.. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.
3010027|NCT02496416|Active Comparator|Wait-List Control|The wait-list control group will participate in an eight week aquatic exercise program during weeks 11-19 of the study. The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Scotch Plains-Fanwood, NJ. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.
3010028|NCT02496403|Experimental|Standard Medical Management|Standard Medical Management (SMM) is a relatively brief (1.5 hour per week for 9 weeks), medically-focused behavioral intervention for opioid dependence. The experimental arm does not involve an investigational drug, device, or biologic.
3010111|NCT02495805|Active Comparator|adductor canal block (ACB)|Subjects randomized to this groups receive a continuous proximal adductor canal block (ACB) during surgery.
3010029|NCT02496403|No Intervention|Intensive Outpatient Treatment|The Intensive Outpatient Treatment (IOT) arm is considered usual care and is a predominant model of care in specialty treatment. It incorporates psychosocial support, education, and relapse-prevention approaches and requires attendance at 12-step program. It is a group-based treatment, with individual counseling available as needed. During the initial, 3-week phase, treatment consists of 4-6 hours a day, 7 days a week. In weeks four through 9, treatment consists of 1.5 hours, four days each week. After 9 weeks, patients attend one-hour weekly group meetings for one year. Services include supportive therapy, psycho-education, relapse prevention, and family-oriented therapy. The program emphasis is on abstinence and is similar to many public and private intensive outpatient programs.
3010030|NCT02496390|Placebo Comparator|Autologous|"Patients will be randomized to receive a fecal transplant using their own microbes/Feces (autologous - 9 patients).~Dosage - approx 100ml fecal sample, one time, procedure duration ~1hr"
3010031|NCT02496390|Active Comparator|Allogenic|"Patients will be randomized to receive a fecal transplant of feces/microbiome from the healthy donor (allogeneic - 12 patients).~Dosage - approx 100ml fecal sample, one time, procedure duration ~1hr"
3010032|NCT02496377|Active Comparator|Group 1: Per Os Tardyferon|EPO associated with Iron per os tardyferon before surgery. The oral group received 160 mg ferrous glycine sulfate daily during the month prior surgery, associated with 3 epoetin alpha (EPO) injections (40 000 IU subcutaneous on day - 21, day - 14 and day-7).
3010033|NCT02496377|Experimental|Group 2: IV Ferinject|EPO associated with Iron per IV Ferinject before surgery. The IV group received ferric carboxymaltose 1000 mg IV in 15 minutes one month before surgery, associated with 3 EPO injections.
3010034|NCT02496364|Active Comparator|Group A|"Patients undergoing PLIF will be randomized for Intravenous and topical application of tranexamic acid.~Tranexamic acid diluted in saline solution 0,9% to reach a concentration of 5mg/ml for Intravenous infusion;~Tranexamic acid diluted in saline solution 0,9% to reach a concentration of 30mg/ml topical application."
3010035|NCT02496364|Placebo Comparator|Group B|"Patients undergoing PLIF will be randomized for Intravenous infusion of tranexamic acid and topical application of placebo (i.e. saline solution 0,9%)~Tranexamic acid diluted in saline solution 0,9% to reach a concentration of 5mg/ml for Intravenous infusion;~Placebo for topical application, up to 100ml"
3010036|NCT02496364|Placebo Comparator|Group C|"Patients undergoing PLIF will be randomized for topical application of tranexamic acid and intravenous infusion of placebo (i.e. saline solution 0,9%)~Tranexamic acid diluted in saline solution 0,9 to reach a concentration of 30mg/ml for topical application;~Placebo for intravenous infusion, up to 500ml"
3010037|NCT02496364|Placebo Comparator|Group D|"Patients undergoing PLIF will be randomized for Intravenous and topical application of placebo (i.e. saline solution 0,9%).~Placebo for intravenous infusion, up to 500ml;~Placebo for topical application, up to 100ml."
3010038|NCT02496351|Active Comparator|TENS INTERVENTION|In the immediately postoperative of limb amputation, TENS will be use in this patients during 24 hours. The intensity of the impulse will be determined in a test carried out 3 days before surgery. The other parameters will be continuous, biphasic, compensated and symmetric impulse, frequency of 80 Hz, time impulse between 250 and 290 microseconds, modulation time 5´´
3010039|NCT02496351|Placebo Comparator|TENS NO INTERVENTION|In the immediately postoperative of limb amputation, TENS will be use in this patients during 24 hours, but in this case TENS just will be on. No intensity impulse should be programmed.
3010040|NCT02496338|Experimental|Intervention group|Training program about menopausal health isues
3010041|NCT02496338|No Intervention|Control group|No training program about menopausal health isues
3010042|NCT02496325|Other|perineal technic|
3010043|NCT02496312|Experimental|ECOCAPTURE|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
3010044|NCT02496299|Active Comparator|dexametasone (BD),|BD ,a mixture of 0.2mg/kg dexamethasone in 1ml/kg bupivacaine
3010045|NCT02496299|Active Comparator|Bupivacaine,B|B ,1ml/kg bupivacaine:
3010046|NCT02496286|Experimental|Eligible patients requiring paracentesis for symptom control|
3010047|NCT02496273|Experimental|CEA Specific CTL|Patients receiving CEA-specific CTLs as therapy for Gastric Cancer
3010048|NCT02496247|Experimental|Immediate Herring|Participants in this arm will receive the Canned Herring intervention. Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child), which will be distributed weekly by community health workers. Families will be instructed to feed the study child half a can of herring per day (without reducing usual home food given to the child), and to not share the remaining herring with individuals who are in the Delayed Herring study arm. When families come to collect their weekly distribution they will be asked to bring in at least 7 empty herring cans in order to receive the next ration, and will answer a question about how often the child eats the herring.
3010049|NCT02496247|No Intervention|Delayed Herring (Control)|Families with children in this study arm will not receive any herring during the 8-10 week period when Immediate Herring families receive a weekly ration of herring. After the 8-10 week (end line) measurements, an equal amount of herring will be distributed to the family.
3010050|NCT02496221|Experimental|Albiglutide / Placebo or Placebo / Albiglutide|In treatment period 1, subjects will receive Albiglutide 50 mg or Placebo subcutaneously (SC) after fasting overnight for at least 10 hours according to randomization schedule on Day 1. Subject will also receive CCK (Kinevac) infusion intravenously for a period of 50 minutes after fasting overnight for at least 10 hours on Day 4. After washout period of a minimum of 42 days in treatment period 2, subjects will receive same treatment according to randomization schedule in a cross-over fashion
3010051|NCT02496208|Experimental|Part I (cabozantinib-s-malate, nivolumab)|Patients receive cabozantinib-s-malate PO QD on days 1-28 and nivolumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 21 courses, patients receive nivolumab IV over 60 minutes every 4 weeks in the absence of disease progression or unacceptable toxicity. After progression, patients may receive cabozantinib-s-malate PO QD, nivolumab IV, and ipilimumab IV at the part II RP2D for 4 courses followed by cabozantinib-s-malate PO QD and nivolumab IV every 2 weeks or 4 weeks if post-course 21 in the absence of disease progression or unacceptable toxicity.
3010112|NCT02495805|Active Comparator|femoral nerve block (FNB)|Subjects randomized to this groups receive a continuous femoral nerve block (FNB) during surgery.
3010113|NCT02495792|No Intervention|Control group|Group does not receive the biofeedback sensor
3010052|NCT02496208|Experimental|Part II (cabozantinib-s-malate, nivolumab, ipilimumab)|Patients receive cabozantinib-s-malate PO QD on days 1-21, nivolumab IV over 60 minutes on day 1, and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. After completion of 4 courses with ipilimumab, patients continue receiving cabozantinib-s-malate PO QD on days 1-28 and nivolumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 42 courses in the absence of disease progression or unacceptable toxicity. After 21 courses, patients receive nivolumab IV over 60 minutes every 4 weeks in the absence of disease progression or unacceptable toxicity. After progression, patients may receive cabozantinib-s-malate PO, nivolumab IV, and ipilimumab IV at the part II RP2D for 4 courses followed by cabozantinib-s-malate PO QD and nivolumab IV every 2 weeks or 4 weeks if post-course 21 in the absence of disease progression or unacceptable toxicity.
3010053|NCT02496182|Placebo Comparator|Placebo|Conventional treatment (Prednisone 0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Placebo tablet 2 times at day.
3010054|NCT02496182|Experimental|Pirfenidone 1800 mg|Conventional treatment (0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Pirfenidone long release tablet 900 mg 2 times at day, starting with 600 mg at day
3010055|NCT02496182|Experimental|Pirfenidone 1200 mg|Conventional treatment (0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Pirfenidone long release tablet 600 mg 2 times at day starting with 600 mg at day
3010056|NCT02496169|Experimental|eucaLimus|Percutaneous Coronary Intervention (PCI)
3010057|NCT02496156|Active Comparator|Usual Clinical Practice (UCP)|UCP participants will receive the same clinical and educational management for candidates for insulin pump or continuous glucose monitoring that is received by similar patients who are not enrolled in this study. The respective endocrinology practices at the enrolling sites all strive to meet or exceed the current American Diabetes Association Standards for Clinical Practice in the management of type 1 diabetes in this population. Thorough patient education is the cornerstone of that care, especially regarding the incorporation of insulin pumps and continuous glucose monitors into the treatment regimen for a given patient.
3010058|NCT02496156|Experimental|Shared Medical Decision Making (SMDM)|Participants randomized to SMDM receive all components of UCP supplemented with access to the decision aid website pertinent to the medical decision of interest (pump or CGM). Adolescents and parents will receive password-protected, secure access to the decision for their use until a decision is reached. The platform will then generate a summary report that the adolescent and parent will discuss with a diabetes nurse and then a visit with the treating endocrinologist will be scheduled to conclude the SMDM intervention for that adolescent and parent.
3010059|NCT02496143|Experimental|Cohort 1|500 mg EC-18 dose or placebo
3010060|NCT02496143|Experimental|Cohort 2|1000 mg EC-18 dose orplacebo
3010061|NCT02496143|Experimental|Cohort 3|2000 mg EC-18 dose or placebo
3010062|NCT02496143|Experimental|Cohort 4|4000 mg EC-18 dose or placebo
3010063|NCT02496130||minilaparotomy|Subjects in this group will have tissue (uterus) extracted via mini-laparotomy incision with knife morcellation. Morcellation will be performed within a containment system. Method of extraction/group assignment will be determined clinically by the operating surgeon based on patient characteristics and patient preference.
3010064|NCT02496130||vaginal extraction|Subjects in this group will have tissue (uterus) extracted via vaginal extraction with knife morcellation. Morcellation will be performed within a containment system. Method of extraction/group assignment will be determined clinically by the operating surgeon based on patient characteristics and patient preference.
3010065|NCT02496117|Active Comparator|RNS-checked RDN|20 patients with hypertension will be enrolled undergoing RNS-checked RDN
3010066|NCT02496117|Experimental|RNS-guided RDN|20 patients with hypertension will be enrolled undergoing RNS-guided RDN
3010067|NCT02496104||Preterm infants|Preterm infants born between 25 weeks and 32 weeks + 6 days of gestation
3010068|NCT02496104||Term newborns|Infant born at term
3010069|NCT02496091||ATLANTIS Abutment|The investigational product (ATLANTIS abutment) is already included in a restoration in the subject at enrollment, thus this study does not involve the installation of any investigational products.
3010070|NCT02496078|Active Comparator|Active dual arm|"Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from day 1 to 12 week~Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from 12 to 24 week and follow up to week 48"
3010071|NCT02496078|Placebo Comparator|Placebo arm|"Daclatasvir placebo in tablet form QD and Asunaprevir placebo in soft capsule form BID from day 1 to 12 week~Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from 12 to 36 week and follow up to week 60"
3010072|NCT02496065|Experimental|BLZ-100|
3010073|NCT02496052|Experimental|dried biological amnion graft|patients, who are with IUA, treated by uterine application of amnion membrane + Foley balloon+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
3010074|NCT02496052|Sham Comparator|Foley catheter balloon only|patients, who are with IUA, treated by uterine application of Foley balloon only+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
3010075|NCT02496039|Other|NUEDEXTA®|NUEDEXTA capsules (20 mg dextromethorphan hydrobromide and 10 mg quinidine sulfate) administered orally, once a day from Days 1 to 7 and twice a day from Days 8 to 180
3010076|NCT02496026|Experimental|tDCS plus wrist robot therapy|In addition to standard rehabilitation treatment Group A will perform daily sessions of wrist robot-assisted treatment in combination with tDCS (30 minutes). During first 20 min of each session the patient receives a direct current stimulation through surface sponge electrodes (35 cm2), 2 milliampere intensity: the anodal electrode is placed on presumed lesional area, the cathodal electrode is placed on the controlateral orbital bone.
3010114|NCT02495792|Experimental|Biofeedback group|Group does receive the biofeedback sensor
3010078|NCT02496013|Experimental|68Ga-NEB injection and PET/CT scan|"Patients for blood pool imaging:~The patients were intravenously injected with 68Ga-NEB and underwent PET/CT scan 30~45min after the injection.~Patients for lymph node imaging:~The patients were locally injected 10~20MBq 68Ga-NEB and followed by dynamic regional PET acquisitions."
3010079|NCT02496000|Placebo Comparator|Placebo Comparator|three identical capsules containing placebo
3010080|NCT02496000|Experimental|ORMD-0801 Dose 1|three identical capsules, as follows: capsule #1: one half of Dose 1 capsule #2: one half of Dose 1 capsule #3: placebo
3010081|NCT02496000|Experimental|ORMD-0801 Dose 2 = 1.5 * Dose 1|three identical capsules, as follows: capsule #1, 2, and 3: one half of Dose 1
3010082|NCT02495974||Patients with mCRPC prescribed enzalutamide|Oral
3010083|NCT02495961||Low risk population|Colombian children, between 6 and 12 years old, regular students of a Primary school.
3010084|NCT02495961||High risk population|Mexican children, between 6 and 12 years old, regular students of a Primary school.
3010085|NCT02495948|Other|AOA then ULTRA|Lotrafilcon B contact lenses worn first, followed by samfilcon A contact lenses. Each product worn bilaterally (in both eyes) for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
3010086|NCT02495948|Other|ULTRA then AOA|Samfilcon A contact lenses worn first, followed by lotrafilcon B contact lenses. Each product worn bilaterally for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
3010087|NCT02495935|Experimental|OkuStim®|The OkuStim® group will undergo 30-minute treatments once a week for 12 weeks at 200% threshold level according to their individual phosphene threshold (IPT) readings from the OkuStim® device at the pre-treatment visit (week 1). Rectangular biphasic current pulses (1-ms positive, directly followed by 1-ms negative) will be applied at a frequency of 20 Hz.
3010088|NCT02495935|Sham Comparator|Sham-OkuStim®|Subjects in the Sham-OkuStim® group will wear treatment glasses and corneal electrodes for 30 minutes weekly for 12 weeks, but corneal electrodes will not be activated.
3010089|NCT02495922|Active Comparator|A1|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone), 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone), 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
3010090|NCT02495922|Experimental|A2|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide + elotuzumab (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
3010091|NCT02495922|Experimental|B1|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab , 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
3010092|NCT02495922|Experimental|B2|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide + elotuzumab (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
3010093|NCT02495896|Experimental|Arm A (sEphB4-HSA, nab-paclitaxel, gemcitabine hydrochloride)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, 15, and 22 (beginning course 2), paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3010094|NCT02495896|Experimental|Arm B (sEphB4-HSA, docetaxel)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2) and docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3010095|NCT02495896|Experimental|Arm C (sEphB4-HSA, cisplatin, gemcitabine hydrochloride)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2), cisplatin IV over 120 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3010096|NCT02495883|Other|Essential Tremor Group|"50ml of 40% ethanol will be administered to participants diagnosed with Essential Tremor.~Propranolol SR 60-120mg will be administered daily to participants over an estimated period of two weeks."
3010097|NCT02495883|No Intervention|Health Volunteer Group|Healthy Volunteers
3010098|NCT02495870|Experimental|Pork, 58°C, 72 minutes|Pork muscle (semitendinosus) sous-vide cooked at 58°C for 72 minutes
3010099|NCT02495870|Experimental|Pork, 58°C, 17 hours|Pork muscle (semitendinosus) sous-vide cooked at 58°C for 17 hours
3010100|NCT02495870|Experimental|Meat balls, 58°C, 17 hours|Meat balls made from pork Semitendinosus. Sous-vide cooked at 58°C for 17 hours
3010101|NCT02495870|Active Comparator|Pork, 160°C (until 58°C in core)|Pork muscle (semitendinosus) oven cooked at 160°C until 58° in core.
3010102|NCT02495857|Experimental|Treatment 1|Hyaluronate Injectable Viscosupplement (1% sodium hyaluronate). IA injection to the knee once weekly for 3 weeks
3010103|NCT02495857|Active Comparator|Treatment 2|Euflexxa IA injection to the knee once weekly for 3 weeks
3010104|NCT02495857|Placebo Comparator|Treatment 3|Placebo (normal saline). IA injection to the knee once weekly for 3 weeks
3010105|NCT02495844|Experimental|UCB0942|UCB0942/UCB0942
3010106|NCT02495844|Placebo Comparator|Placebo|Placebo/UCB0942 (after 2-week inpatient period, placebo subjects will receive the experimental medicine, UCB0942).
3010107|NCT02495831|Experimental|Diclofenac sodium|Diclofenac sodium 50 mg oral tablets, single dose
3010108|NCT02495831|Active Comparator|Diclofenac sodium and safinamide|Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose
3010109|NCT02495818|Experimental|Lidocaine|Suprascapular nerve block with infusion of 5ml lidocaine at 2%, guided by Ultrasound combined with homemade exercises (Codman and Hughston exercises).
3044064|NCT02266524|Experimental|Tamsulosin hydrochloride, medium dose|
3010115|NCT02495779|Experimental|Intervention|Given emtricitabine/tenofovir for 2-3 weeks. Brief CBT-based counseling to promote PrEP adherence
3010116|NCT02495766|Experimental|Treatment A: XCEL-MC-ALPHA/Placebo|Single infusion of cryopreserved bone-marrow adult mesenchymal stromal cells followed by placebo infusion at month 6.
3010117|NCT02495766|Experimental|Treatment B: Placebo/XCEL-MC-ALPHA|Single infusion of placebo followed by cryopreserved bone-marrow adult mesenchymal stromal cells infusion at month 6.
3010118|NCT02495753|Experimental|Abdominal and Vaginal Cleansing|In the treatment arm, the vagina will be cleansed prior to usual abdominal cleansing before cesarean section.
3010119|NCT02495753|Active Comparator|Abdominal Cleansing Alone|In the control arm, abdominal cleansing will be performed per routine with no vaginal cleansing.
3010120|NCT02495740|Experimental|E-bike intervention|Intervention is active commuting to work by an electric assisted bike to work for a period of 4 weeks at least 3 times per week with a minimal distance of 6 km per way
3010121|NCT02495740|Active Comparator|Bike intervention|Intervention is active commuting to work by classic bike for a period of 4 weeks at least 3 times per week with a minimal distance of 6 km per way
3010122|NCT02495727|Experimental|Control Group|This group will undertake two-weeks of step-reduction to <1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
3010123|NCT02495727|Experimental|Pre-Training Group|This group will undertake four weeks of strength training exercise (10 sessions) before two-weeks of step-reduction to <1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
3010124|NCT02495727|Experimental|Exercise Snacking Group|This group will undertake home-based 'exercise snacks' of simple lower limb movement (5 minutes, 3 times a day) whilst undertaking two-weeks of step-reduction to <1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
3010125|NCT02495714|Experimental|Intervention schools|Active Learning; One hour each schoolday of physical Activity as part of academic learning Dietary councelling; teaching children and parents about a healty diet
3010126|NCT02495714|No Intervention|Control schools|No intervention
3010127|NCT02495701||Patients|Patients having Hip arthroscopic surgery
3010128|NCT02495688|Experimental|Regional anesthesia|Patients are anesthezised with local aneshtetics administered with ultrasound guidance in the nerval plexus of the arm.
3010129|NCT02495688|Active Comparator|General anesthesia|Patients are anesthezised with general anesthesia and orotrachial airway. Local anesthetics (Chirocaine 5 mg/ml, 10 ml) is administered in the surgical wound during surgery.
3010130|NCT02495675|No Intervention|No flow|Subjects will be spontaneously breathing in room air with no flow.
3010131|NCT02495675|Experimental|Conventional flow via nasal prongs|Subjects will be breathing with nasal prongs delivering 5 L/min of air (inspired fraction of oxygen: 0.21)
3010132|NCT02495675|Experimental|High flow nasal cannulas 20 L/min|Subjects will be breathing with high flow nasal cannulas delivering 20 L/min with an inspired fraction of oxygen of 0.21.
3010133|NCT02495675|Experimental|High flow nasal cannulas 40 L/min|Subjects will be breathing with high flow nasal cannulas delivering 40 L/min with an inspired fraction of oxygen of 0.21.
3010134|NCT02495675|Experimental|High flow nasal cannulas 60 L/min|Subjects will be breathing with high flow nasal cannulas delivering 60 L/min with an inspired fraction of oxygen of 0.21.
3010135|NCT02495662|Experimental|Liposomal prednisolone|Treatment with polyethylene glycol (PEG)-liposomal prednisolone sodium phosphate 150mg in 500ml saline intravenously at 1 and 15 days post surgery.
3010136|NCT02495662|Placebo Comparator|Placebo|Treatment with 500ml normal 0.9% saline intravenously at 1 and 15 days post surgery.
3010137|NCT02495649|Other|[18F]-DOPA|evaluate the added value of PET-CT with [18F]-DOPA tracer for Assessment of the Myocardial Sympathetic Denervation in patients with or suspected with Parkinson's disease.
3010138|NCT02495636|Experimental|Safety Run Up Group|The first 12 patients to be enrolled will initiate therapy with CDX-1401 alone, with the addition of MPDL3280A the day of their 4th CDX-1401 vaccination (week 7). These patients will undergo a tumor biopsy prior to initiation of trial therapy, after their 3rd CDX-1401 vaccination (during week 6) and after their 3rd MPDL3280A infusion (during week 14 or 15, if there are no dose delays). Although we don't expect significant synergistic toxicities of combination therapy based on mechanism of action/ formulation/ administration/ distribution of CDX-1401 and past vaccine/ immune checkpoint trials, these first 12 patients will constitute a safety run in group.
3010139|NCT02495636|Experimental|Expanded Trial Group|If there are no unexpected toxicities (no more than 3 of 12 patients with grade 3+ treatment related events as defined in 4.1.1), an additional 28 patients will be enrolled. Unlike the first 12 patients, these additional 28 patients will initiate both CDX-1401 and MPDL3280A on the same day, and will undergo tumor biopsies before starting trial therapy and after their 3rd CDX-1401 vaccination (during week 6).
3010140|NCT02495623|Active Comparator|Low Dose|21 mg SYN-010
3010141|NCT02495623|Active Comparator|High Dose|42 mg SYN-010
3010142|NCT02495623|Placebo Comparator|Placebo|Placebo
3010143|NCT02495610|Other|Gait analysis and MRI|"Gait analysis: Intervention: Treadmill with pressure sensors (FDM-THM-M-System (Force distribution method-treadmill); 'Zebris' medical GmbH), study-specific, but routine procedures.~MRI: Intervention: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage."
3010144|NCT02495597||Subject-Group|Patients suffering from doctors diagnosed bronchiolitis obliterans
3010145|NCT02495597||Control Group|age- and sex matched to subject-group
3010146|NCT02495584|Experimental|Treatment 1|500ml fortified milk (10µg vitamin D3) +1 supplement capsule (10µg vitamin D3) daily for 24 weeks
3010147|NCT02495584|Experimental|Treatment 2|500ml fortified milk (10µg vitamin D3) +1 supplement capsule (placebo) daily for 24 weeks
3010148|NCT02495584|Experimental|Treatment 3|500ml unfortified milk (placebo) +1 supplement capsule (10µg vitamin D3) daily for 24 weeks
3010149|NCT02495584|Placebo Comparator|Treatment 4|500ml unfortified milk (placebo) +1 supplement capsule (placebo) daily for 24 weeks
3010150|NCT02495571|Experimental|ALS Patients|Study Group: Evaluation of the cough reflex and the voluntary cough by spirometer and nebulizer
3010151|NCT02495571|Other|Healthy Subjects|Control group matched by aged and sex with the study group
3044065|NCT02266524|Experimental|Tamsulosin hydrochloride, high dose|
3010153|NCT02495545|Experimental|CSFD with elevation of MAP|Subjects will receive CSFD and elevation of MAP. Treatments will be 120 hours (5 days) from time treatment is initiated (time 0), and within 24 hours of time of injury. Initiation of CSFD will occur after decompression (during surgery) with a target ITP of 10 mmHg. MAP elevation (norepinephrine drip; goal 100-110 mmHg) will start during surgery, simultaneously with CSFD. 10 mL of CSF will be collected daily for routine lab testing. Post-surgery subjects will be transferred to an intensive care unit (ICU) for duration of treatment or longer if clinically indicated. Target MAP will be sustained within 100-110 mmHg for 5 days. Norepinephrine drip will be used to maintain MAP goal. Subjects will receive other treatment per standard of care at the participating investigational sites.
3010154|NCT02495545|Active Comparator|Maintenance of MAP|Subjects will receive elevation of MAP (norepinephrine drip; goal 85-90 mm Hg). Target MAP will be sustained within 85-90 mmHg in the control group for 5 days. Duration of elevation of MAP treatment will be 120 hours (5 days) from time treatment is (time 0). Subjects will receive the same treatment as the subjects in investigational arm except for the initiation of the CSFD and less aggressive MAP elevation. They will have a drain placed the same way as the experimental subjects. While drain is in place, 10 mL of cerebrospinal fluid will be collected daily for laboratory testing. After that, ITP will be monitored but CSFD will not be initiated. Subjects will receive other treatment per standard of care at participating investigational sites.
3010155|NCT02495532|Active Comparator|Colon Cancer|"The subjects in this group will undergo intervention by having surgery and lymph node clearing technique.~Intervention A: Carnoy solution Intervention B: GEWF solution"
3010156|NCT02495532|Active Comparator|Rectal Cancer|"The subjects in this group will undergo intervention by having surgery and lymph node clearing technique.~Intervention A: Carnoy solution Intervention B: GEWF solution"
3010157|NCT02495519|Experimental|imatinib|Imatinib 400 mg/day until disease progression
3010158|NCT02495506|Experimental|Cold stored platelets|Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery
3010159|NCT02495506|Active Comparator|Room temperature platelets|Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery
3010160|NCT02495493|Experimental|Induction DCS chemotherapy|"Induction chemotherapy -- S-1 35mg/m2 bid day 1-14~Docetaxel 30 mg/m2 day1, 8~Cisplatin 30 mg/m2 day1, 8~Chemoradiotherapy : S-1 20 mg/m2 bid (Day 1-14, 21-28) cisplatin (30 mg/m2/day, Day 1,8, 21,28), Radiotherapy 45 Gy"
3010161|NCT02495480|Experimental|sheathed group|The sterilized disposable sheath covered the outer surface of the colonoscope, then colonoscope will be performed in conventional way;a new sheath will be placed on the endoscope in sheathed group as a intervention
3010162|NCT02495480|No Intervention|conventional group|Colonoscopy will be performed with air insufflation during insertion
3010163|NCT02495467|Experimental|MED2005|MED2005 (0.2% glyceryl trinitrate gel) will be provided in single unit dose aluminium tubes packed in boxes of 5 per subject and per treatment period. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg) of MED2005 (0.2% glyceryl trinitrate gel).
3010164|NCT02495467|Placebo Comparator|MED Placebo|MED2005 Placebo will be provided in single unit dose aluminium tubes packed in boxes of 5 per subject and per treatment period. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg) of MED2005 Placebo.
3010165|NCT02495454|Experimental|Ga101-miniCHOP|"6 courses of GA101-miniCHOP regimen and 2 additional infusions of GA101, every 21 days (for a total of 6 courses of miniCHOP and 10 infusions of GA101).~GA101-miniCHOP regimen:~Cycle 1 GA101: 1000 mg day 1, day 8 and day 15, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os~Cycles 2-6 GA101: 1000 mg day 1, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os~Two additional infusions of GA101: 1000 mg day 1, iv, every 21 days."
3010166|NCT02495441||Dribbling group|Any woman who presents with alleged leakage of amniotic fluid. They will under go rapid Immunoassay Tests for the Detection of PROM
3010167|NCT02495428|Experimental|Kinesio Tape Group|muscle Kinesio Taping in Triceps Surae, Tibialis anterior, and Quadriceps according Kenzo Kase Method
3010168|NCT02495428|No Intervention|Control group|They will do the same measurement of lactate and exercise protocol in treadmill, but always without kinesio tape intervention
3010169|NCT02495415|Experimental|Fenretinide emulsion|Patients enrolled will receive 600 mg fenretinide/m2/day on Day 1, followed by 1200 mg fenretinide/m2/day on Days 2 - 5 as a continuous intravenous infusion via central line over 5 days. Cycles are repeated every 3 weeks.
3010170|NCT02495402|No Intervention|No Intervention: Control|No Intervention
3010171|NCT02495402|Experimental|Motivational Interviewing|A brief interview intervention for substance abuse
3010172|NCT02495389|Other|mirabegron|All study participants will receive 25 mg mirabegron (Myrbetriq) to be taken by mouth once a day for 12 weeks. If after 4 weeks symptoms are not adequately improving, participants will have the option of increasing mirabegron dose to 50 mg per day for the remaining 8 weeks.
3010173|NCT02495376|Active Comparator|Group A|Group A participates in the first available MBSR course.
3010174|NCT02495376|Active Comparator|Group B|Group B waits 16 weeks before participating in the MBSR course.
3010175|NCT02495363||PECS block in additions to general anesthesia|"As standard analgesic protocol participants undergoing mastectomy surgeries under general anesthesia will have an addition of Pectoral Block regional anesthesia.~Following obtaining written informed consent, ultrasound guided PECS Block will be performed by identifying the thoracic muscles, in addition to general anesthesia Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% ."
3010176|NCT02495350||Initially didn't want an epidural and didn't receive one.|
3010177|NCT02495350||Initially didn't want an epidural and did receive one.|
3010178|NCT02495350||Initially wanted an epidural and didn't received one|
3010179|NCT02495350||Initially wanted an epidural and did receive one.|
3010180|NCT02495337||TIssue Collection|Only one arm will be used to collect tissue from Esophageal Adenocarcinoma
3010181|NCT02495324|Experimental|Fimasartan|Placebo daily for 2 weeks and Fimasartan 60mg daily for 2 weeks and 120mg daily for 4 weeks
3010182|NCT02495324|Active Comparator|Valsartan|Placebo daily for 2 weeks and Valsartan 80mg daily for 2 weeks and 160mg daily for 4 weeks
3010183|NCT02495324|Other|Olmesartan medoxomil|Reference group. Placebo daily for 2 weeks and Olmesartan 10mg daily for 2 weeks and 20mg daily for 4 weeks
3010184|NCT02495311||Women with uterine myoma|Women with uterine myoma
3010185|NCT02495311||Women with adenomyosis|Women with adenomyosis
3010186|NCT02495311||Women without uterine myoma or adenomyosis|Control group
3010187|NCT02495298|Experimental|Treatment Fascial Manipulation|Seven patients with diagnosis of CTS, received five sessions of Fascial Manipulation performed by a physiotherapist. The sessions were performed once a week, and each session were 30 to 45 minutes long as to cover different painful spots.
3010188|NCT02495298|Sham Comparator|Placebo Fascial Manipulation|Seven patients with diagnosis of CTS, received five sessions of Sham Fascial Manipulation performed by a physiotherapist. The sessions were performed once a week, and each session were 30 to 45 minutes long as to cover different painful spots.
3010189|NCT02495285||Gelofusine 4%|Children age ≤ 12 years
3010190|NCT02495285||Gelaspan 4%|Children age ≤ 12 years
3010191|NCT02495272|Active Comparator|Control Group|Oxytocin 10IU im was administered after placental delivery
3010192|NCT02495272|Experimental|Study Group|Oxytocin 10IU im was administered after the anterior shoulder could be seen.
3010193|NCT02495259|Experimental|ZU-bend stylet with GlideScope technique|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the ZU-bend with the GlideScope technique of a double lumen endobronchial tube (DLT) placement as part of the anesthesia procedure prior to surgery.
3010194|NCT02495259|Active Comparator|GlideScope with the GlideRite stylet|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the GlideScope with the GlideRite stylet for placement of a double lumen endobronchial tube (DLT) as part of the anesthesia procedure prior to surgery.
3010195|NCT02495259|Active Comparator|Macintosh blade and a regular DLT stylet|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the direct laryngoscopy technique with the Macintosh blade and a regular double lumen endobronchial tube (DLT) stylet as part of the anesthesia procedure prior to surgery.
3010196|NCT02495246|Active Comparator|Group 1|ChAd3-EBO-Z (1x10^11 vp) and Ad26.ZEBOV (5x10^10 vp) 28 days later.
3010197|NCT02495246|Active Comparator|Group 2|Ad26.ZEBOV (5x10^10 vp) and ChAd3-EBO-Z (1x10^11 vp) 28 days later.
3010198|NCT02495246|Active Comparator|Group 3|ChAd3-EBO-Z (1x10^11 vp) and Ad26.ZEBOV (5x10^10 vp) 56 days later.
3010199|NCT02495246|Active Comparator|Group 4|Ad26.ZEBOV (5x10^10 vp) and ChAd3-EBO-Z (1x10^11 vp) 56 days later.
3010200|NCT02495233|Experimental|Phase 1b: ASP2215 in combination with erlotinib|In the Phase 1b, participants will receive escalated doses of ASP2215 in combination with erlotinib once daily to determine the recommended Phase 2 dose (RP2D) of ASP2215.
3010201|NCT02495233|Experimental|Phase 2: ASP2215 in combination with erlotinib|In Phase 2, participants will receive once daily the recommended Phase 2 dose (RP2D) of ASP2215 in combination with erlotinib determined in the Phase 1b part of the study.
3010202|NCT02495220|Experimental|subtenon block Group (SB)|received SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
3010203|NCT02495220|Experimental|intravenous dexmedetomidine Group(IV)|received 1µ/kg IV dexmedetomidine after induction of anesthesia
3010204|NCT02495207|No Intervention|Conventional Surgery|No intervention in this arm. The patients are going to undergo normal surgical intervention. Conventional surgery will be performed to extract the impacted third molars.
3010205|NCT02495207|Experimental|Piezosurgery|Patients here will undergo a piezosurgery to extract their third molars on both sides.
3010206|NCT02495194|Experimental|Active Horticultural Therapy|15 sessions of Horticultural Therapy program teaching the elderly about gardening techniques and for them to benefit from the therapeutic effects of the parks
3010207|NCT02495194|Other|Waitlist Control Group|Participants will receive the same horticultural therapy program at the end of the assessments
3010208|NCT02495181|Sham Comparator|Aflibercept + Verteporfin PDT|- IVT Aflibercept 2 mg on a Treat & Extend Regimen + Verteporfin PDT
3010209|NCT02495181|Sham Comparator|Aflibercept + Sham PDT|IVT Aflibercept 2 mg on a Treat & Extend Regimen + Sham PDT
3010210|NCT02495168|Experimental|Treatment 1|Generic Budesonide/Formoterol fumarate dihydrate (80mcg/4.5mcg) inhalation aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
3010211|NCT02495168|Active Comparator|Treatment 2|Symbicort (Budesonide/Formoterol fumarate dihydrate) inhalation aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
3010212|NCT02495168|Placebo Comparator|Treatment 3|Placebo inhalation aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
3010213|NCT02495155|Active Comparator|Fatigue|Participants who have received treatment for early stage breast cancer and who experience fatigue, rated at least a 4 on a scale of 0-10 during the previous week, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
3010214|NCT02495155|Active Comparator|Treatment-related Pain|Participants who have received treatment for early stage breast cancer and who experience pain, rated at least a 4 on a scale of 0-10 during the previous week, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
3010215|NCT02495155|Active Comparator|Insomnia|Participants who have received treatment for early stage breast cancer and who experience insomnia, assessed as difficulty sleeping over the last week, yes or no, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
3010216|NCT02495129|Experimental|VAY736 lower dose|12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
3010217|NCT02495129|Experimental|VA736 higher dose|12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
3010218|NCT02495103|Experimental|2|Phase II Component
3010219|NCT02495103|Experimental|1|Phase I Component
3010221|NCT02495077|Experimental|Experimental Arm|rATG is co-administered with anti-TNFa (infliximab/Remicade) plus maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.
3010222|NCT02495077|Active Comparator|Control group|rabbit anti-thymocyte globulin (rATG, Thymoglobulin) plus placebo (Sterile normal saline) induction followed by maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.
3010223|NCT02495064|Experimental|Mometasone Furoate Cream(MF)|"participants will be given conventional Chemoradiotherapy and MF.~MF Brief introduction:~Generic name :Mometasone Furoate Cream. Dosage form:Each gram of Mometasone Furoate Cream contains mometasone furoate, USP in a cream base of hexylene glycol, phosphoric acid, propylene glycol stearate, stearyl alcohol and ceteareth-20, titanium dioxide, aluminum starch octenylsuccinate, white wax, white petrolatum, and purified water.~Dosage:Apply a thin film of Mometasone Furoate Cream to the affected skin areas once daily during radiotherapy.~It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."
3010224|NCT02495064|No Intervention|Chemoradiotherapy|conventional Chemoradiotherapy only
3010225|NCT02495051||single group-study|
3010226|NCT02495038|No Intervention|Intubating dose, Group I|"combined ED95 rocuronium and ED95 cisatracurium~ED95, dose causing on average 95% suppression of neuromuscular response."
3010227|NCT02495038|Experimental|10% reduction of combination of Esmeron® and Nimbex®, Group S|This arm reduced 10% of combined ED95 rocuronium and ED95 cisatracurium
3010228|NCT02495038|Experimental|20% reduction of combination of Esmeron® and Nimbex®, Group L|This arm reduced 20% of combined ED95 rocuronium and ED95 cisatracurium
3010229|NCT02495025|Experimental|Telephone-based screening|Families randomized to the intervention arm will be connected with 211 Los Angeles for completion of developmental screening over the phone. Screening will consist of three structured, validated, parent-report tools: the Parental Evaluation of Developmental Status (PEDS), the PEDS Developmental Milestones (PEDS:DM), and the Modified Checklist for Autism in Toddlers (M-CHAT). If any developmental or behavioral concerns are present, the care coordinator at 211 Los Angeles will make appropriate referrals for developmental evaluation and intervention services. A copy of the care plan generated from 211 will be sent to the child's primary care provider and included in the medical record.
3010230|NCT02495025|No Intervention|Usual care|Children randomized to the control group will report for their well-child care visits as scheduled, and will receive clinic-based developmental screening and care coordination. Any developmental or behavioral concerns will be directed to the child's pediatrician, as is the current clinical recommendation.
3010231|NCT02495012|Placebo Comparator|control|5IU/60 kg bolus and 0.002 IU/kg/h continuous infusion for 48 hours
3010232|NCT02495012|Active Comparator|treatment|5IU/60 kg bolus and 0.002 IU/kg/h continuous infusion for 48 hours
3010233|NCT02494999|Experimental|13-valent pneumococcal conjugate vaccine|Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10
3010234|NCT02494999|Active Comparator|Prevnar 13|Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10
3010235|NCT02494986|Experimental|Rilpivirine|Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or oral granules for weight adjusted RPV dose, as applicable, in combination with an investigator selected background regimen consisting of 2 nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs).
3010236|NCT02494973|Active Comparator|Adjuvant systemic chemotherapy with mFOLFOX6|"started within 8 weeks after surgery for a maximal duration of 6 months and at least 3 months, every 14 days:~Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,~Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours."
3010237|NCT02494973|Experimental|Adjuvant HAI oxaliplatin and systemic LV5FU2|"started within 8 weeks after surgery for a maximal duration of 6 months and at least 3 months, and performed every 14 days:~Oxaliplatin 85 mg/m² in 4-6 hours HAI day (D)1,~Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours. In both arms, continuation of targeted therapy (if any) used in the preoperative treatment is allowed."
3010238|NCT02494960|Placebo Comparator|Control Group|The doctor will offer a placebo intervention.
3010239|NCT02494960|Experimental|Intervention Group A|"The doctor will offer the brief smoking cessation AWARD model .~At 1-month follow-up survey, trained study personnel will repeat the brief smoking cessation AWARD model ."
3010240|NCT02494960|Experimental|Intervention Group B|The doctor will offer the brief smoking cessation AWARD model.
3010241|NCT02494947|Experimental|interval training|high intensity interval-based aerobic exercise
3010242|NCT02494947|Other|controls|usual care
3010243|NCT02494934|Experimental|Cognitive-behavioural therapy|Eight sessions of psychotherapy incorporating cognitive-behavioural and sex therapy interventions.
3010244|NCT02494934|Experimental|physical therapy|Eight sessions of physical therapy targeting the pelvic floor muscles.
3010245|NCT02494921|Experimental|Treatment|Docetaxel: 75 mg/m^2; Day 1 of 21-Day Cycle Ribociclib: 200 mg/day; Days 2-14 of 21-Day Cycle Prednisone: 5 mg, oral, twice a day Filgrastim: as clinically indicated
3010246|NCT02494921|Experimental|Alternate Treatment|Docetaxel: 35 mg/m^2; Days 1, 8 , 15 of 21-Day Cycle Ribociclib: 200 mg/day; Days 2-14 of 21-Day Cycle Prednisone: 5 mg, oral, twice a day Filgrastim: as clinically indicated
3010247|NCT02494908|Active Comparator|Healthy controls|Healthy controls with no known neurological disease matched for sex and age with the patients group
3010248|NCT02494908|Active Comparator|IPD patients|Men and women diagnosed with idiopathic parkinson's disease
3010249|NCT02494895|Experimental|Ticagrelor monotherapy|Ticagrelor monotherapy at 3 months after PCI
3010250|NCT02494895|Active Comparator|Ticagrelor with Aspirin|Ticagrelor with Aspirin DAPT(Dual Anti-platelet Treatment)
3010277|NCT02494726||Ischemic Stroke|Ischemic stroke patients who have had blood analyzed using thromboelastography (TEG)
3010278|NCT02494726||Healthy Controls|Healthy controls who have had their blood analyzed using thromboelastography (TEG)
3010279|NCT02494726||Hemorrhagic Stroke|Intracerebral hemorrhage patients who have had their blood analyzed by thromboelastography (TEG)
3010420|NCT02493699|Experimental|Exercise|physical exercise- based intervention (Karate techniques training)
3010251|NCT02494882|Experimental|Adding Ruxolitinib to Combination of Dasatinib + Dexamethasone|"Steroid Pre-Phase (Days -6 to 0) Prednisone 10 mg/m2/day uptitrated to 60/mg/m2/day oral over seven days (capped at 120 mg/day).~Remission Induction (Days 1 to 84) Dasatinib 140 mg oral once daily. Days 1-84. Dexamethasone 10 mg/m2/day oral (capped at 20 mg/day). Days 1-24. Dexamethasone oral taper 10 mg/m2/day (capped at 20 mg/day) to off. Taper days 25-32. Off day 33.~Ruxolitinib phase I cohort dose oral. Days 1-84. Delivered BID. Delivered per the phase I dose cohort. Methotrexate (MTX) 12 mg Intrathecal (IT) for 4 doses on days 22, 43, 64, 85; +/- 3 days.~Post-Remission Induction Therapy (Starting Day 85) Allogeneic HSCT, at the discretion of the treating physician, at any point post-remission induction.~Or, post-remission induction (consolidation) therapy to be determined per the treating physician"
3010252|NCT02494869|Experimental|Nonlinear Aerobic Training (75 minutes/week) closed to accrual|The ultimate goal is for participants to complete 75 minutes/week of structured aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from the (CPETs performed at baseline, midpoint, and Study Follow-Up. The 75 min/wk will be achieved via 3 individual supervised aerobic training sessions at approximately 25 minutes/session. This arm is closed to accrual.
3010253|NCT02494869|Experimental|Nonlinear Aerobic Training (150 minutes/week)|The ultimate goal is for participants to complete 150 minutes/week of structured aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from the CTPETs test performed at baseline, midpoint, and Study Follow-Up. The 150 minutes/week will be achieved by completing 3 aerobic training sessions/week for approximately 50 minutes/session.
3010254|NCT02494869|Experimental|Nonlinear Aerobic Training (300 minutes/week)|The ultimate goal is for participants to complete 300 minutes/week of aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from CPETs performed at baseline, midpoint, and Study Follow-Up. The 300 minutes/week will be achieved by completing 5 aerobic training sessions/week for approximately 60 minutes/session. A minimum of 3 sessions/week are required to be supervised while the remaining 2 sessions can be supervised or unsupervised home-based.
3010255|NCT02494869|Active Comparator|General Physical Activity|Usual care patients will receive a home-based, general physical activity program. Specifically, all patients assigned to general physical activity will receive an initial, in-person consultation with staff exercise physiologist outlining a structured home-based aerobic walking program with a goal up to 150 minutes per week outside of their normal daily activity. Patients will be provided with a fitness tracker (e.g. FitBit) to evaluate exercise duration and intensity. Patients will be asked to records type, duration, and average heart rate during sessions in an exercise log to assess compliance. Staff exercise physiologists will contact patients by telephone or in person on a monthly, or less, basis to check progress, answer questions and record compliance.
3010256|NCT02494856|Experimental|Surgery with Naproxen|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, will be treated to control pain, swelling and trismus with naproxen 500mg.
3010257|NCT02494856|Experimental|Surgery with Naproxen and Esomeprazole|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, will be treated to control pain, swelling and trismus with naproxen 500mg and esomeprazole 20mg.
3010258|NCT02494843|Active Comparator|Online haemodiafiltration|
3010259|NCT02494843|Active Comparator|Haemodialysis|
3010260|NCT02494830|Experimental|ketamine 5 mg intravenous|
3010261|NCT02494830|Experimental|ketamine 10 mg oral|
3010262|NCT02494830|Experimental|ketamine 20 mg oral|
3010263|NCT02494830|Experimental|ketamine 40 mg oral|
3010264|NCT02494830|Experimental|ketamine 80 mg oral|
3010265|NCT02494817|Placebo Comparator|Control group|Couples assigned to the control group will be directed to the website that only has the following: 1) module about learning about effective HIV prevention strategies, 2) sexual health resource center, and 3) a link to download a corresponding smartphone app that will include the sexual health resource center.
3010266|NCT02494817|Active Comparator|Intervention group|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
3010267|NCT02494804|Other|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
3010268|NCT02494804|Other|Temozolomide+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat
3010269|NCT02494791|Other|Endometrial and Ovarian Cancer Participants|All study subjects will be offered the same options for screening and follow-up.
3010270|NCT02494778|Experimental|Pridopidine|The mode of administration is oral. Capsules will be swallowed whole with water. One capsule should be taken in the morning and 1 in the afternoon, 7 to 10 hours after the morning dose. Study drug can be taken irrespective of meals.
3010271|NCT02494765|Active Comparator|I-gelTM|I-gel is a supraglottic device made of gel like material. It is used for administration of anesthesia in selected patients.
3010272|NCT02494765|Active Comparator|Ambu® AuraOnceTM|Ambu AuraOnce (AO) is a supraglottic device having different material and its shaft has greater curvature than I-gel. It is also used for administration of anesthesia in selected patients.
3010273|NCT02494752|Experimental|Stem cell enriched|Fat graft will be enriched with ex vivo expanded stem cells
3010274|NCT02494752|Active Comparator|Non stem cell enriched|Fat graft will not be enriched with ex vivo expanded stem cells
3010275|NCT02494739|Experimental|Yogurt enriched with polyphenols|Two yogurts (400g) enriched with polyphenols (10mg/100g yogurt) per day, for two weeks.
3010276|NCT02494739|Placebo Comparator|Yogurt not enriched with polyphenols|Two yogurts (400g) not enriched with polyphenols per day, for two weeks.
3010415|NCT02493725|Active Comparator|Eculizumab|Eculizumab, 900 mg intravenously once a week
3010280|NCT02494713|Other|ADT + chemotherapy|Patients will be treated with 4 monthly injections of degarelix along with two 8-week cycles of chemotherapy (doxorubicin and ketoconazole, weeks 1, 3, 5 and docetaxel and estramustine, weeks 2, 4, 6). Each cycle of chemotherapy will consist of 6 weeks of chemotherapy and 2 weeks of rest. In the absence of toxicity or disease progression, patients will receive 2 cycles of treatment prior to radical prostatectomy.
3010281|NCT02494700|Experimental|Orbital Radiation|Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy. If there is stable disease or progressive disease, an additional 20 Gy administered to involved site. If there are two consecutive evaluations with no change in disease burden then an additional 20 Gy administered. At one year if there is persistent disease, an additional 20 Gy administered to involved site.
3010282|NCT02494674|Experimental|Bite Counter tracking|Study participants will be asked to track their energy intake via a wearable device called the Bite Counter. Participants will attend weekly meetings to provide feedback on the Bite Counter.
3010283|NCT02494661|Experimental|Healthy Cart and Stress Mangement Videos|Healthy Cart and Stress Management Videos: Participants receive two nutritional intervention videos: active comparator and managing stress while food shopping.
3010284|NCT02494661|Active Comparator|Healthy Cart Video|Healthy Cart Video: Participants receive one nutritional video intervention on how to shop for healthy foods using My Plate Guidelines.
3010285|NCT02494648|Experimental|Inspiratory muscles strengthening|"The device used is : POWERbreathe Fitness Plus, (POWERbreathe International Ltd, UK).~Class I, CE labelled. POWERbreathe fitness Plus uses the technique of training against resistance to increase the strength, the power and the endurance of the respiratory muscles (diaphragm and rib cage)."
3010286|NCT02494648|Placebo Comparator|Control|No intervention
3010287|NCT02494635||Diagnostic (ultrasound, biomarker studies)|Previously collected tumor tissue samples, bladder washings, and urine cells are stained with calcium dye, washed and immersed in external buffer solution, and then transferred to the ultrasound imaging system. Tissue, bladder wash cells and urine cells samples are also analyzed for biomarkers of invasiveness derived from or related to REST gene via qRT-PCR, Western blot, and FISH.
3010288|NCT02494609|Experimental|Treatment A|once daily dosing for 7 days, followed by 7-day washout
3010289|NCT02494609|Experimental|Treatment B|once daily dosing for 28 days
3010290|NCT02494609|Experimental|Treatment C|once daily dosing for 14 days of oral contraceptive, followed by coadministration with sotagliflozin once daily for 7 days
3010291|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 1000 mg/m^2 (Level 2)|Participants will receive a single 1000-mg/m^2 dose of oral (PO) capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1000 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
3010292|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 1250 mg/m^2 (Level 3)|Participants will receive a single 1250-mg/m^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1250 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
3010293|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 825 mg/m^2 (Level 1)|Participants will receive a single 825-mg/m^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 825 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
3010294|NCT02494583|Experimental|Pembrolizumab monotherapy|Participants receive pembrolizumab 200 mg, intravenously (IV) on Day 1 of each 3 week cycle (Q3W)
3010295|NCT02494583|Experimental|Pembrolizumab + cisplatin + 5-FU|Participants receive pembrolizumab 200 mg Q3W + cisplatin 80 mg/m^2 Q3W + 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.
3010296|NCT02494583|Active Comparator|Placebo + cisplatin + 5-FU|Participants receive placebo, IV, Q3W + cisplatin 80 mg/m^2 Q3W + 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.
3010297|NCT02494570|Experimental|ABI-009|
3010298|NCT02494544|Active Comparator|ConforMIS iTotal Knee replacement|iTotal patient-specific knee replacement system
3010299|NCT02494544|Active Comparator|DePuy total knee replacement|Off the shelf knee replacement system
3010300|NCT02494544|Active Comparator|Zimmer total knee replacement|Off the shelf knee replacement system
3010301|NCT02494544|Active Comparator|Biomet total knee replacement|Off the shelf knee replacement system
3010302|NCT02494544|Active Comparator|Smith & Nephew total knee replacement|Off the shelf knee replacement system
3010303|NCT02494544|Active Comparator|Stryker total knee replacement|Off the shelf knee replacement system
3010304|NCT02494531|Other|Positon Emission Tomographic (PET)-scan|2 PET-scan: Fluorodeoxyglucose-PET and florbetapir F 18-PET
3010305|NCT02494518|Active Comparator|Forced Exercise & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~45 minutes of cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed~45 minutes of upper extremity repetitive arm exercises"
3010306|NCT02494518|Active Comparator|Voluntary Exercise & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~45 minutes of cycling on a recumbent stationary bike at your self-selected speed~45 minutes of upper extremity repetitive arm exercises"
3010307|NCT02494518|Active Comparator|Stroke Education & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~45 minutes of stroke education~45 minutes of upper extremity repetitive arm exercises"
3010308|NCT02494505|Experimental|mycophenolate mofetil|
3010309|NCT02494505|Placebo Comparator|placebo|placebo pills
3010310|NCT02494492|Experimental|IVT of regulator T-cells|intravitreous administration of regulator T-cells
3010416|NCT02493725|Placebo Comparator|Placebo|Matched placebo, intravenously once a week
3010311|NCT02494479|Active Comparator|50mg of Purisol daily|One (1) 50 mg tablet of Prurisol and one (1) matching placebo tablet given AM and two (2) matching placebo tablets given PM for 84 (± 3) days
3010312|NCT02494479|Active Comparator|100mg of Purisol daily|One (1) 50 mg tablets of Prurisol and one (1) matching placebo tablet given twice daily (AM and PM) for 84 (± 3) days
3010313|NCT02494479|Active Comparator|200mg of Purisol daily|Two (2) 50 mg tablets of Prurisol given twice daily (AM and PM) for 84 (± 3) days
3010314|NCT02494479|Placebo Comparator|Placebo daily|Two (2) placebo tablets given twice daily (AM and PM) for 84 (± 3) days
3010315|NCT02494466|Active Comparator|Group E (n=10)|Patients with high Ig E levels
3010316|NCT02494466|Active Comparator|Group C (n=10)|Patients with normal Ig E levels
3010317|NCT02494466|Active Comparator|Group M (n=10)|Patients who would be administered with 4mg PO MS 10 days before surgery because of high IgE
3010318|NCT02494453|Experimental|Cardiac MRI|
3010319|NCT02494427|Experimental|1|CAD/CAM manufactured fixed unitary dental prostheses
3010320|NCT02494427|Active Comparator|2|Conventionally manufactured unitary dental prostheses
3010321|NCT02494414||French prospective cohort of cardiac arrest survivors|Outcome of cardiac arrest survivors: prospective cohort of Ile-de-France
3010322|NCT02494401|Active Comparator|Internet-based self-management program|Internet-based self-management program Patients randomized to active treatment intervention will be assigned to the Internet program. The site will be accessed via secured website. The modules will be presented 1-2 per week and will be moderated by a researcher with expertise in moderating Discussion Boards.
3010323|NCT02494401|Other|Education book group|Educational book group. Participants in the control group will receive a copy of The Scleroderma Book: A Guide for Patients and Families, by Dr. Maureen Mayes.
3010324|NCT02494388||Serous cystadenoma|Serous cystadenoma patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
3010325|NCT02494388||Mucinous cystic neoplasms|Mucinous cystic neoplasms patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
3010326|NCT02494388||Intraductal papillary mucinous neoplasms (IPMN)|IPMN patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
3010327|NCT02494388||Mucinous cystdenocarcinoma|Mucinous cystadenocarcinoma patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
3010328|NCT02494388||Other cystic lesions|Other cystic lesions patients (cystic neuroendocrine tumors, solid pseudopapillary neoplasms, cystic lymphangioma, etc.) Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients..
3010329|NCT02494375|Experimental|Sleep and glucose assessement.|
3010330|NCT02494362|Experimental|Experimental Group|Computer gaming hand exercise regimen.
3010331|NCT02494349|Experimental|JLP-1207|JLP-1207 dosing in the fed state(high fat meal)
3010332|NCT02494349|Experimental|Solifenacin 5mg+Tamsulosin 0.2mg|Solifenacin 5mg+Tamsulosin 0.2mg in the fed state(high fat meal)
3010333|NCT02494336|Active Comparator|Trans-incisional rectus sheath block|rectus sheath block under direct visualization through the umbilical incision by the attending surgeon
3010334|NCT02494336|Active Comparator|Laparoscopic guided rectus sheath block|rectus sheath block under direct laparoscopic visualization by the attending surgeon
3010335|NCT02494323|Experimental|Functional Electrical Stimulation|Dual channel stimulation of the peroneal nerve to improve dropfoot
3010336|NCT02494310|Experimental|HRME - Prevention Mobile Unit|Procedures to be done in the mobile unit (van): Visual inspection will be performed with 5% acetic acid (VIA) applied to the cervix followed by standard colposcopy. Proflavine (0.01%) will then be applied topically. Lugol's solution will then be applied and colposcopy performed and abnormal lesions noted. HRME images will be acquired from any areas that are abnormal by VIA and/or colposcopy. VIA, colposcopy and HRME observations will recorded by quadrant. Any abnormal areas by VIA and/or colposcopy will be biopsied. If no abnormal areas are noted, one cervical biopsy will be obtained from a normal appearing area with a HRME image of this area obtained.
3010337|NCT02494310|Experimental|HRME - Barretos Cancer Hospital|Procedures to be done at Barretos Cancer Hospital: Visual inspection will be performed with 5% acetic acid (VIA) applied to the cervix followed by standard colposcopy. Proflavine (0.01%) will then be applied topically. Lugol's solution will then be applied and colposcopy performed and abnormal lesions noted. HRME images will be acquired from any areas that are abnormal by VIA and/or colposcopy. VIA, colposcopy and HRME observations will recorded by quadrant. Any abnormal areas by VIA and/or colposcopy will be biopsied. If no abnormal areas are noted, one cervical biopsy will be obtained from a normal appearing area with a HRME image of this area obtained.
3010338|NCT02494297||Cyproterone Acetate and Ethinyl Estradiol|Users of Diane 35 (EE/CPA, BAY86-5264)
3010339|NCT02494284|Experimental|Short term dual therapy|
3010340|NCT02494284|Active Comparator|Long term dual therapy|
3010341|NCT02494271||Total intravenous anesthesia|Total intravenous anesthesia using propofol and remifentanil
3010342|NCT02494271||Inhalation|Balanced inhalation anesthesia using volatile anesthetics and remifentanil
3010343|NCT02494258|Experimental|Oral Azacitidine (CC-486)|This study is an open-label, single-arm study and is divided into the screening period, treatment period and follow-up period. It is intended to evaluate the long-term safety of CC-486 and is to be taken at the same dose, schedule and frequency used from the last dose of CC-486 given in the parent study.
3010344|NCT02494245|Active Comparator|Intervention|128 participants will take part in the STARFISH intervention
3010345|NCT02494245|No Intervention|Control|Participants allocated to the control group will be given a booklet with general advice on physical activity.
3010346|NCT02494232||minor blunt thoracic trauma patient|demographic data, physical examination findings
3010347|NCT02494219|Experimental|Rapid Immunochromatographic Streptococcal test|Throat swabbing by two port germ Amines agar (copan) swabs,the swabs were randomly labeled as swab A and swab B.Swab A was processed for rapid streptococcal test and swab B was processed for culture in Colombia blood agar.All patients were followed up after 48-72 hours with the final culture results that ultimately determined the need to continue or discontinue treatment.
3010417|NCT02493712|Experimental|High dose|High dose, twice a day for 6 weeks.
3010418|NCT02493712|Placebo Comparator|Placebo: C|Placebo, twice a day
3010348|NCT02494206|Experimental|QBX258 (VAK694 3mg/kg and QAX576 6mg/kg)|This will be a single arm, open label design pilot study, aiming to test the efficacy of QBX258, a combination of two fully human monoclonal antibodies that neutralize the biologic activity of interleukin 4 and interleukin 13 (IL4/IL13), for the treatment of stage I or II breast cancer related upper extremity lymphedema (BCRL).
3010349|NCT02494193|Active Comparator|Regular Treatment|Partial caries removal; Provisional restoration - control; Total caries removal; Definitive restoration.
3010350|NCT02494193|Experimental|Alternative Treatment|Partial caries removal; Provisional restoration - experimental; Total caries removal; Definitive restoration.
3010351|NCT02494180|Placebo Comparator|A: intravenous fentanyl, midazolam|group A will be given intravenous 0.1mg fentanyl and 5mg midazolam prior oocyte retrieval
3010352|NCT02494180|Placebo Comparator|B: intravenous pethidine, diazepam|group B will be given intravenous 25mg pethidine, 5mg diazepam prior oocyte retrieval
3010353|NCT02494167|Experimental|Group A|Treatment with donor-derived multiTAA-specific T cells as adjuvant therapy following HSCT for AML or MDS
3010354|NCT02494167|Experimental|Group B|Treatment with donor-derived multiTAA-specific T cells for relapsed/residual disease following HSCT for AML or MDS
3010355|NCT02494154|Active Comparator|Conventional flow via nasal prongs|Oxygen delivery via conventional nasal interface with flow adjusted to reach a target SpO2 according to the patient's condition.
3010356|NCT02494154|Experimental|High flow nasal cannulas 20L/min|Oxygen delivery via high flow nasal cannulas (20L/min) with fraction of inspired oxygen (FiO2) adjusted to reach a target SpO2 according to the patient's condition.
3010357|NCT02494154|Experimental|High flow nasal cannulas 40L/min|Oxygen delivery via high flow nasal cannulas (40L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.
3010358|NCT02494154|Experimental|High flow nasal cannulas 60L/min|Oxygen delivery via high flow nasal cannulas (60L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.
3010359|NCT02494141|Experimental|Curcumin|25/mg/kg per day for 1 year.
3010360|NCT02494141|Placebo Comparator|Placebo|Equivalent placebo for 1 year.
3010361|NCT02494128|Active Comparator|Intervention group|Education in group leadership
3010362|NCT02494128|No Intervention|Control group|This group fills in the questionnaire. No intervention given.
3010363|NCT02494115|Experimental|subcutaneous drainage|This local treatment consists in inserting in lower limbs several catheters draining into enclosed bags in order to evacuate lymph fluid and to lower local pressure.
3010364|NCT02494102|Placebo Comparator|Placebo|Administered Placebo day of surgery immediately prior to general anesthesia and surgery
3010365|NCT02494102|Active Comparator|Intervention|Administered Modafinil 200mg day of surgery prior to general anesthesia and surgery
3010366|NCT02494076|Experimental|EzPAP|Patients randomized to the EzPAP arm will receive first-line therapies and PEP therapy via EzPAP. All patients will receive 4 cycles with 12 breaths per cycle. 4 cycles is considered one time administration.
3010367|NCT02494076|Sham Comparator|Standard care|Patients randomized to the control arm will receive first-line therapies and standard therapy.
3010368|NCT02494063||SLN|Only sentinel lymph node biopsy, no further pelvic lymph nodes removal, radical hysterectomy.
3010369|NCT02494050|Experimental|Behavioral Activation-Full|Twelve weekly sessions of phone therapy using Behavioral Activation Treatment for Anhedonia.
3010370|NCT02494050|Experimental|Behavioral Activation-Short|Eight weekly sessions of phone therapy using Behavioral Activation Treatment for Anhedonia.
3010371|NCT02494050|Active Comparator|Bipolar Disorder Collaborative Care|Twelve weekly sessions of phone therapy using BDCC manual adapted for anhedonia.
3010372|NCT02494024|Experimental|Single dose C2N-8E12 level 1|Single IV infusion of C2N-8E12
3010373|NCT02494024|Experimental|Single dose C2N-8E12 level 2|Single IV infusion of C2N-8E12
3010374|NCT02494024|Experimental|Single dose C2N-8E12 level 3|Single IV infusion of C2N-8E12
3010375|NCT02494024|Experimental|Single dose C2N-8E12 level 4|Single IV infusion of C2N-8E12
3010376|NCT02494024|Placebo Comparator|Single dose placebo|Single IV infusion of placebo
3010377|NCT02494011|Experimental|traditional exercise (group I)|"Mobilization:2 strokes per one second and repeated 6 times during session~stretching exercise: 15 to 20 minutes~passive range of motion: 5 minutes at beginning and at end~active range of motion: 20 repetition~oedema control: 15s active contraction of fingers of 15s relax for 3 times"
3010378|NCT02494011|Experimental|russian current stimulation (group II)|The frequency was 2.5 kHz for 15 minutes
3010379|NCT02494011|Experimental|CKC (group III)|"wall press exercise - plyometric exercise-Quadruped rhythmic stabilization- press up exercise~closed kinetic chain exercises performed 10 times and each week 2 more repetitions added as a progression"
3010380|NCT02493985|Active Comparator|Atmosphere 1 - Ambient air|First, the subjects will have 1 baseline day in the upright body position. This will be followed by 28 hours of head down tilt body position and ambient air at sea level, followed by 2 hour exposure of 3% carbon dioxide inhalation.
3010381|NCT02493985|Experimental|Atmosphere 2 - 0.5% CO2|First, the subjects will have 1 baseline day in the upright body position. This will be followed by 28 hours of head down tilt body position and air with 0.5% carbon dioxide, followed by 2 hour exposure of 3% carbon dioxide inhalation.
3010382|NCT02493972|Experimental|manual exploration by GelPort|manual exploration in supplement of coelioscopy before laparotomy
3010383|NCT02493959|Experimental|PYY infusion|IV infusion on 4 separate days of PYY or saline in Healthy, normal-weight men, age 18-50 years
3010384|NCT02493946|Experimental|BTX-A-HAC NG|Clostridium Botulinum Toxin Type A (BTX A HAC NG), total treatment volume 0.25mL will be divided into 5 injections (0.05mL per injections) injected in 5 pre-defined sites across the glabellar region. A total of 50 Units of BTX-A-HAC NG will be injected/ cycle.
3010385|NCT02493946|Placebo Comparator|Placebo|The total placebo volume 0.25mL will be divided into 5 injections (0.05mL per injections) injected in 5 pre-defined sites across the glabellar region. Administered in Cycle 1 of the double blind phase only.
3010386|NCT02493933|Active Comparator|Phytoestrogen|Patients received oral PE 120 mg/ day in the form of dry coated tablets (Klimadynon, Bionorica, Germany) 2 tablets three times daily from day 1 to day 12 as adjuvant to CC in the follicular phase of the cycle.
3010419|NCT02493712|Experimental|Low dose|Low dose, twice a day for 6 weeks
3010387|NCT02493933|Active Comparator|Isosorbid mononitrate|Patients received in addition to CC 20 mg Isosorbid mononitrate (ISMN) tablet (EFFOX, Minapharm Co., Egypt under licence of Shwartz pharma,Germany) applied vaginally from day 1 to day 12 of the cycle.
3010388|NCT02493933|Active Comparator|N-Acetyl cysteine|Patients received supplementation to CC with NAC 1200 mg/day orally (N-acetyl cysteine, Sedico, Cairo, ARE) sachets 200 mg each, as two sachets thrice daily from day 1 to day 12 of the cycle.
3010389|NCT02493920|Experimental|SLI group|In this group the preterm infants will receive sustained lung inflation (SLI) with mask in the delivery room; the parameters of respiratory mechanics will be monitored for 5 minutes by means of the forced oscillation technique.
3010390|NCT02493920|No Intervention|Control|Preterm infants will be assisted in the delivery room with a continuous positive airway pressure (CPAP) of 5 cmH2O with mask and the parameters of respiratory mechanics will be monitored for 5 minutes by means of the forced oscillation technique.
3010391|NCT02493907||heart failure|heart failure patients with CRT
3010392|NCT02493894|Experimental|PEG & Cefazolin|patients firstly get liquid diet for 24 hours. After that they get PEG solution (80gr/1Litr) each 8 hours for 24 hours. After 48 hours, cefazolin 1gram, every 6hours for 2 days
3010393|NCT02493894|Sham Comparator|placebo & cefazolin|placebo for PEG and cefazolin 1gram, every 6hours for 2 days
3010394|NCT02493881|Active Comparator|Group 1|The RLNs having motor function on the anterior branch assessed by intraoperative neuromonitoring.
3010395|NCT02493881|Active Comparator|Group 2|RLNs having motor function on anterior and posterior branch assessed by intraoperative neuromonitoring.
3010396|NCT02493868|Experimental|Intranasal Esketamine plus oral antidepressant|Open-Label Induction Phase: Direct-entry participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Open-label Induction Phase. Participants will initiate a new oral antidepressant on Day 1 of this phase. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase. Maintenance Phase: Direct-entry and transferred-entry participants assigned to esketamine will self-administer intranasal esketamine (same dose) once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase.
3010397|NCT02493868|Experimental|Placebo Plus Oral Antidepressant|Optimization Phase: Transferred-entry participants will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase. Maintenance Phase: Direct-entry and transferred-entry participants assigned to intranasal placebo will self-administer intranasal placebo once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase.
3010398|NCT02493855|Experimental|Arm A: Ribavirin Full Dose for Last 10 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) for 12 weeks and weight-based ribavirin (1000 mg or 1200 mg split BID) for the last 10 weeks.
3010399|NCT02493855|Experimental|Arm B: Ribavirin Full Dose for 12 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and weight-based ribavirin (1000 mg or 1200 mg split BID) for 12 weeks.
3010400|NCT02493855|Experimental|Arm C: Ribavirin Low-dose for 12 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and 600 mg ribavirin once daily for 12 weeks.
3010401|NCT02493842|Experimental|Invasive nerve stimulation|"Invasive nerve stimulation using the following experimental devices~Transverse Intrafascicular Multichannel Electrode for human (TIME-4H)~The STIMEP stimulator~The EPIONE Psychophysical Testing Platform software for stimulator control~Nerve stimulation therapy is provided while providing visual guidance to the subject and without the use of hand prosthetic devices"
3010402|NCT02493829|Experimental|AML Cell Vaccine|
3010403|NCT02493816|Experimental|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
3010404|NCT02493803|Experimental|Receive detailed dietary advice|Half of the participants will be randomly allocated to receive detailed dietary advice
3010405|NCT02493803|No Intervention|Receive standard of care dietary advice|These patients will receive dietary advice which is the current standard of care
3010406|NCT02493790||Volunteers|Cognitive and motor performances were measured in a single and dual task situations.
3010407|NCT02493790||COPD patients|Cognitive and motor performances were measured in a single and dual task situations, before rehabilitation, and compared to those of healthy subjects. Then, Chronic Obstructive Pulmonary Disease patients were re-evaluated after rehabilitation.
3010408|NCT02493777|Experimental|HLD200 (methylphenidate)|The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core. Following open-label treatment optimization, subjects will be randomized (1:1) to double-blind HLD200 to be taken once daily during the evening for a period of 1-week prior to testing.
3010409|NCT02493777|Placebo Comparator|Placebo|Placebo capsules will be composed of microcrystalline cellulose beads in place of MPH containing beads found in the HLD200 capsules. Following open-label treatment optimization, subjects will be randomized (1:1) to double-blind placebo to be taken once daily during the evening for a period of 1-week prior to testing.
3010410|NCT02493764|Experimental|IMI/REL|Imipenem 500 mg + relebactam 250 mg + cilastatin 500 mg as a FDC administered intravenously (IV) every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
3010411|NCT02493764|Active Comparator|PIP/TAZ|Piperacillin 4000 mg + tazobactam 500 mg as a FDC administered IV every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
3010412|NCT02493751|Experimental|Dose finding phase and dose expansion phase.|To test the maximum tolerated dose of avelumab (MSB0010718C) in combination with axitinib (AG-013736)
3010413|NCT02493738|Experimental|Lozanoc 50mg|Lozanoc 50mg, oral administration
3010414|NCT02493738|Active Comparator|Sporanox 100mg|Sporanox 100mg, oral administration
3010421|NCT02493699|No Intervention|Control|Not participating in physical exercise- based intervention (Karate techniques training)
3010422|NCT02493673|Active Comparator|CPAP therapy|Continuous positive airway pressure therapy
3010423|NCT02493673|Sham Comparator|Sham CPAP|Sham- Continuous positive airway pressure
3010424|NCT02493660|Experimental|InSpace implantation|Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation
3010425|NCT02493660|Active Comparator|Tendon Repair|Arthroscopic partial repair of rotator cuff
3010426|NCT02493647|Experimental|Love, Sex, & Choices|Love, Sex, and Choices (LSC) is an engaging 12-episode video series to reduce HIV risk in young, adult predominately Black women. A peer video guide was added to the end of LSC episodes to provoke viewers to question their own sex scripts and consider their own need for change. Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods.
3010427|NCT02493647|No Intervention|Attention-Time Control|The Control is a 12-episode popular web miniseries with a storyline that promotes respectful relationships. time and frequency are matched to the active intervention.
3010428|NCT02493634|Other|pressure gradient measurement|Diagnostic procedure to measure pressure gradient in series of patients. Focus is on safety and absence of adverse events
3010429|NCT02493621||Lumbar plexus|Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management.
3010430|NCT02493621||Lumbar Epidural|Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.
3010431|NCT02493608|Active Comparator|scalpel group|Scalpel is the device used to make abdominal wall incision in this group of patient.
3010432|NCT02493608|Active Comparator|Diathermy group|In this study group, abdominal wall incisions are made with diathermy which is a electrosurgical instrument.
3010433|NCT02493595||Cancer|Patients attending One-stop Symptomatic Breast Care clinics with suspicion of a breast lesion in one or both breasts.
3010434|NCT02493582|Other|Apatinib alone|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.
3010435|NCT02493582|Experimental|Apatinib+CIK|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous. plus autologous cytokine-induced killer cells 3 cycles,every 1 year,continuous.
3010436|NCT02493569||Epidemiology breast cancer patients|Observe the features of clinical diagnosis and treatment for female breast cancer patients
3010437|NCT02493556|Experimental|LLLT before muscle damage|Low Level Laser Therapy (LLLT) will be applied before the exercise protocol on one lower limb, while the other will receive placebo treatment. Phototherapy will be applied with an equipment of 810nm and a cluster with five diodes on eight different points of quadriceps muscle, totalizing a dosage of 240J.
3010438|NCT02493556|Placebo Comparator|Placebo LLLT before muscle damage|Placebo LLLT will be applied before the exercise protocol on one lower limb, while the other will receive real treatment. Placebo treatment will also be applied on eight different points of quadriceps muscle, but the equipment will be turned off.
3010439|NCT02493556|Active Comparator|LLLT after muscle damage|Low Level Laser Therapy (LLLT) will be applied after the exercise protocol on one lower limb, while the other will receive placebo treatment. Phototherapy will be applied with an equipment of 810nm and a cluster with five diodes on eight different points of quadriceps muscle, totalizing a dosage of 240J.
3010440|NCT02493556|Placebo Comparator|Placebo LLLT after muscle damage|Placebo LLLT will be applied after the exercise protocol on one lower limb, while the other will receive real treatment. Placebo treatment will also be applied on eight different points of quadriceps muscle, but the equipment will be turned off.
3010441|NCT02493543||Spinal cord injury|Patients (n=90) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed twice: after recruitment and 3 months later.
3010442|NCT02493543||Controls|Control subjects (n=20) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed only once.
3010443|NCT02493530|Experimental|Escalation and expansion|TGR1202 and Ruxolitinib combination
3010444|NCT02493517|Experimental|Lanreotide Autogel® 60mg, 90mg and 120mg|Lanreotide Autogel 90mg from day 1 to week 13, 1 injection every 4 weeks (4 in total), titrated to 60mg, 90mg, or 120mg at week 17, then from week 17 to week 29 each group receives 1 injection every 4 weeks (4 in total/group).
3010445|NCT02493517|Active Comparator|Lanreotide 40mg PR (Lanreotide Acetate for Injection )|Lanreotide PR 40mg from day 1 to week 15, 1 injection every 10 days, then at dose titration (week 16) injection frequency will either remain at 10 days or increase to 14 days or decrease to 7 days up until week 30 or 31.
3010446|NCT02493504|Experimental|Heparin|75 patients were randomly assigned to receive 100units/kg of heparin after dissection prior to anastomosis.
3010447|NCT02493504|No Intervention|Control|75 received no intraoperative heparin injection.
3010448|NCT02493465|Experimental|LVH everolimus|Progression of left ventricular hypertrophy in recipients of kidney transplant after conversion of immunossupression from azathioprine to everolimus.
3010449|NCT02493452|Active Comparator|3.0 mg plecanatide|Plecanatide 3.0 mg dosed daily for 12 weeks
3010450|NCT02493452|Active Comparator|6.0 mg plecanatide|Plecanatide 6.0 mg dosed daily for 12 weeks
3010451|NCT02493452|Active Comparator|Matching placebo|Placebo dosed daily for 12 weeks
3010452|NCT02493439|Experimental|Best Possible Self|Participants are asked to write and imagine about a future in which they have reached all their goals in four different domains: personal, professional, social and health. The participants are instructed to practice the BPS intervention for a month, 5 minutes/day.
3010453|NCT02493439|Placebo Comparator|Daily Activities|Participants are asked to think and write about the activities carried out in the last 24 hours. The participants are instructed to practice the Daily Activities exercise for a month, 5 minutes/day.
3010454|NCT02493426|Placebo Comparator|Placebo|Saline Nasal spray designed to look and feel like the drug intervention
3010455|NCT02493426|Experimental|Intranasal Oxytocin|Oxytocin nasal spray designed to look as seem exactly like Placebo
3010456|NCT02493413||Group A|observational time of three months in the obese group with distressed (type D) personality (high DS 14 score) with moderate aerobic exercise
3044459|NCT02264119|Experimental|Lefradafiban tablet with Pantoprazole|
3010457|NCT02493413||Group B|observational time of three months in obese group without distressed personality (low DS 14 score) with moderate aerobic exercise
3010458|NCT02493387|Experimental|Exercise group|The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the RPE 6-20 scale
3010459|NCT02493387|Active Comparator|PAP group|The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
3010460|NCT02493361|Experimental|Treatment|Pembrolizumab: 200 mg IV, Day 1 of each cycle pIL-12: 1/4 tumor volume at concentration of 0.5 mg/mL intratumoral, Days 1, 5, and 8 of each odd cycle
3010461|NCT02493348|Experimental|Continuous 40 Hz Rhythmic Sensory Stimulation|The intervention consists of Rhythmic Sensory Stimulation of a continuous sine wave single-frequency stimulation (40 Hz). The treatment prescription is 30 minutes daily 40 Hz Rhythmic Sensory Stimulation, 5 days per week, for five weeks of treatment, for a total of 25 sessions.
3010462|NCT02493348|Active Comparator|Intermittent Rhythmic Sensory Stimulation|The stimulation consists of random and intermittent complex wave gamma-range RSS with peaks at 45 Hz and 95 Hz, for 30 minutes daily stimulation, 5 days per week, for a total of five weeks of treatment.
3010463|NCT02493335|Experimental|Budesonide 0.5mg orodispersible tablet twice daily|Budesonide 0.5mg orodispersible tablet twice daily
3010464|NCT02493335|Experimental|Budesonide 1mg orodispersible tablet twice daily|Budesonide 1mg orodispersible tablet twice daily
3010465|NCT02493335|Placebo Comparator|Placebo orodispersible tablet twice daily|Placebo orodispersible tablet twice daily
3010466|NCT02493322|Experimental|Test 1: Olmesartan + Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 20 mg + Chlorthalidone 12,5 mg) a day, in the morning.
3010467|NCT02493322|Experimental|Test 2: Olmesartan + Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 20 mg + Chlorthalidone 25 mg) a day, in the morning.
3010468|NCT02493322|Experimental|Comparator: Benicar HCT®|The patients will take 1 tablet (Olmesartan 20 mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
3010469|NCT02493309|Experimental|Prolonged sitting|
3010470|NCT02493309|Active Comparator|Light activity breaks|
3010471|NCT02493296||Observational|The cohort will have their central aortic pressure, and carotid-femoral and brachio-femoral pulse-wave velocities measured. These measurements will take place pre-operatively, within a week of surgery, 6-weeks and 1-year post-operatively also. The surgery will be abdominal aortic aneurysm repair.
3010472|NCT02493283|Active Comparator|Treatment A|single-dose administration of 100 mg dapsone; sampling of blood, urine and feces; sampling for leucocytes collection and sampling for additional safety analyses (Met-Hb)
3010473|NCT02493283|Active Comparator|Treatment B|multiple-dose administration of 100 mg dapsone s.i.d. for 7 days; sampling of blood, urine and feces; sampling for leucocytes collection and sampling for additional safety analyses (Met-Hb)
3010474|NCT02493270|Experimental|Adjunctive smoking cessation|non-surgical periodontal therapy and concurrent smoking cessation therapy
3010475|NCT02493257|Experimental|intranasal capsaicin|The capsaicin solution will be prepared by using the formula previously reported by Van Rijswijk et al; (0.1mmol/l) diluted in ethanol and 0.9% normal saline (19). Using the MAD, 0.8mL will be delivered to each nasal cavity for a total of 24.4 ug per nasal cavity. 5 consecutive applications of capsaicin or placebo will be administered intranasally, with 1 hour between each application.
3010476|NCT02493257|Placebo Comparator|Vehicle solution|100 μL of 1% ethanol in 0.9% saline solution. 5 consecutive applications of capsaicin or placebo will be administered intranasally, with 1 hour between each application.
3010477|NCT02493244|Experimental|Treatment|Participants clean their eyelids with Cliradex wipes before going to bed at night.
3010478|NCT02493244|No Intervention|Control|No treatment
3010479|NCT02493231|Active Comparator|Nefopam|The generic name is 'ACUPAN'. It is infused during operation. A induction dose is 0.3mg/Kg. A maintenance dose is 65 mcg/kg/hr
3010480|NCT02493231|Active Comparator|Ketamine|It is infused during operation. A induction dose is 0.3 mg/Kg. A maintenance dose is 3 mcg/kg/hr
3010481|NCT02493231|Placebo Comparator|Saline|It is infused during operation. A induction volume is 3mL A maintenance dose is 10mL/hr
3010482|NCT02493218|Experimental|Mindfulness Instruction|Instruction on mindfulness concepts and practices. Classes are 45-90 minutes each and held weekly for 12 weeks.
3010483|NCT02493218|Active Comparator|Health Education Instruction|Instruction on general health and wellness. Classes are 45-90 minutes each and held weekly for 12 weeks.
3010484|NCT02493192|Active Comparator|Meperidine|Use pethidine and haloperidol injection as a pain relief.
3010485|NCT02493192|Experimental|birth ball|Use birth ball as a pain relief.
3010486|NCT02493179|Active Comparator|Serodase 5 mg|Serodase ( Serratiopeptidase) 5 mg
3010487|NCT02493179|Placebo Comparator|Placebo|Placebo
3010488|NCT02493166|Active Comparator|patients with Multiple sclerosis Dual task cost|Dual task cost (cognitive-motor interference), comparing single versus dual task performance (on both motor and cognitive task)
3010489|NCT02493166|Active Comparator|Healthy volontiers Dual task cost|Dual task cost (cognitive-motor interference), comparing single versus dual task performance (on both motor and cognitive task)
3010490|NCT02493140|Active Comparator|Cashew apple extract (Cashewin)|
3010491|NCT02493140|Placebo Comparator|Placebo|
3010492|NCT02493127|Experimental|Standard PCS|Grip strength measurements and completes standard PCS
3010493|NCT02493127|Experimental|Positive PCS|Grip strength measurements and completes positively adjusted PCS
3010494|NCT02493114||Patients with lung cancer|No study intervention
3010495|NCT02493101||Chronic kidney disease|Patients with lupus nephritis and IgA nephropathy
3010496|NCT02493101||Control|Healthy controls
3010497|NCT02493088||Antisocial personality|Individuals Diagnosed with Antisocial Personality Disorder
3010498|NCT02493075|Experimental|CF guided group|Ablation will be performed with smart-touch catheter.The operator will kown the real-time contact force (CF), ablation time, FTI, etc during the procedure.
3013083|NCT02475317|Experimental|LUM001 10mg|5 subjects will receive a low dose of LUM001 (10 mg)
3010499|NCT02493075|Active Comparator|Usual ablation group|Although we use the same catheter,operator will be blinded to CF data during the procedure.
3010500|NCT02493062|Experimental|single-arm study|This single-arm study is described by women who have undergone prenatal fetal open (uterus was opened to perform a fetal intervention/surgery) surgery and cesarean section delivery.
3010501|NCT02493049|Experimental|Domperidone|Add on oral Domperidone 10 mg, three times daily. Target dose:30mg daily. Duration: 16 weeks
3010502|NCT02493049|No Intervention|No add on treatment|No add on treatment. Control group
3010503|NCT02493036|Experimental|High Dose SYN-010|42-mg SYN-010
3010504|NCT02493023|Experimental|navigated bronchoscopy|
3010505|NCT02493010|Experimental|Intervention|Participants will undergo a 4-week intervention (once per week, 1 hour each session). Each intervention session consists of approximately 30 minutes of computerized cognitive behavioral therapy, and 30 minutes of Virtual Reality Exposure Therapy with our novel arousal-based biofeedback system. For Virtual Reality Exposure Therapy, the physiological variables of participants will be continuously monitored and presented to them as feedback. Participants will have to deliver speeches to videotaped audiences while striving to regulate their physiological arousal.
3010506|NCT02493010|No Intervention|Waitlist Control|Participants in Waitlist Control will receive no intervention in the first 4 weeks of the study. After the Intervention group has completed treatment, participants in the Waitlist Control will then undergo the same intervention as the Intervention group.
3010507|NCT02492997|Experimental|Treatment Group|Group treated with the active Venus Versa octipolar applicator and the glycerine gel.
3010508|NCT02492997|Sham Comparator|Control Group|Group treated with the inactive Venus Versa octipolar applicator and the glycerine gel.
3010509|NCT02492984|Experimental|Intravenous infusions of Xyntha|Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
3010510|NCT02492958|Experimental|SA4Ag|Staphylococcus aureus 4-antigen vaccine
3010511|NCT02492958|Placebo Comparator|Placebo|a lyophile match to the vaccine, consisting of excipients of SA4Ag formulation minus the active ingredients
3010512|NCT02492945|Experimental|PDRN group|They take the three times of the ultrasonography-guided injections for four weeks(0,2,4 weeks) under double-blind. PDRN group take ultrasonography-guided 3ml-Rejuvinex injection for the lesion( tear or tendinosis about extensor carpi radialis brevis, extensor digitorum communis, radial collateral ligament ) of lateral epicondylitis for 4 weeks.
3010513|NCT02492945|Active Comparator|Dextrose group|They take the three times of the ultrasonography-guided injections for four weeks(0,2,4 weeks) under double-blind. Dextrose group as active control group takes the 3ml-15%-dextrose solution for same procedure: the lesion( tear or tendinosis about extensor carpi radialis brevis, extensor digitorum communis, radial collateral ligament ) of lateral epicondylitis for 4 weeks. This dextrose solution for common extensor tendons are used as prolotherapy.
3010514|NCT02492932|Experimental|IJV_2nd|Ultrasonography examination of the patients who are assumed to take second attempt of internal jugular venous catheterization
3010515|NCT02492919|Experimental|Medixair®|Cardiac reanimation unit bed with Medixair®
3010516|NCT02492919|No Intervention|NO Medixair®|Cardiac reanimation unit bed with NO Medixair®
3010517|NCT02492906||Osteoarthrosis group|Patients with primary severe knee osteoarthrosis or with chronic knee pain.
3010518|NCT02492906||Healthy patients|Healthy patients
3010519|NCT02492893|Experimental|Hatha Yoga|A 12-session 90-minute weekly hatha yoga intervention, that includes asanas (physical postures), pranayama (breathing exercises) and dhyana (meditation.
3010520|NCT02492893|No Intervention|Treatment as Usual|
3010521|NCT02492867|Experimental|Response-driven Adaptive RT|Patients will receive treatment 5 days per week, in once daily fractions, for 30 treatments with dose per fraction individually adapted over the final 9 treatments. Patients may also receive concurrent chemotherapy with Carboplatin and Paclitaxel.
3010522|NCT02492854|Active Comparator|Standard Sterile Gauze Dressings|In this arm, pts. will be randomized to receive standard sterile gauze dressing post-operatively.
3010523|NCT02492854|Experimental|PICO Negative Pressure Dressings|In this arm, pts. will be randomized to receive PICO single-use negative pressure dressings.
3010524|NCT02492841|Experimental|Mineral trioxide aggregate (MTA)|Mineral trioxide aggregate Root canal repair material
3010525|NCT02492841|Active Comparator|Calcium hydroxide|-material for pulp capping
3010526|NCT02492841|Experimental|Biodentine|Is a calcium-silicate based materia root perforations, apexification, resorptive lesions, and retrograde filling material in endodontic surgery, pulp capping
3010527|NCT02492828||Patients for filled prescriptions for apixaban|
3010528|NCT02492828||Patients for filled prescriptions for warfarin|
3010529|NCT02492815||Population with condition and without condition|Participating in EAP
3010530|NCT02492802||posaconazole-group|patients receiving posaconazole for prophylaxis or treatment of invasive fungal infection
3010531|NCT02492789|Experimental|INCSHR01210|"3 dose levels are designed in this study: 1, 3 and 10 mg/kg.3 to 6 patients (traditional 3+3 design) will be enrolled in each dose cohort. INCSHR01210 injection at a dose of 1, 3 or 10 mg/kg is administered every 2 weeks (q2w, except in the first cycle)."
3010532|NCT02492776|Experimental|Gefapixant + Omeprazole|Gefapixant oral tablets (25mg, 50 mg) administered twice daily for 13 days + Omeprazole oral capsules (20 mg) administered once daily for 8 days
3010533|NCT02492763|Experimental|MK-8521 300 μg|Participants receive double-blind MK-8521 300 μg daily (QD), subcutaneously, over 12 weeks.
3010534|NCT02492763|Experimental|MK-8521 180 μg|Participants receive double-blind MK-8521 180 μg QD, subcutaneously, over 12 weeks.
3010535|NCT02492763|Placebo Comparator|Placebo|Participants receive matching double-blind placebo, QD over 12 weeks.
3010536|NCT02492763|Active Comparator|Liraglutide 1.8 mg|Participants receive open-label 1.8 mg of liraglutide, QD, subcutaneously, over 12 weeks.
3010537|NCT02492750|Experimental|Arm A (lenalidomide, dexamethasone, anakinra)|Patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Patients also receive anakinra SC on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
3010538|NCT02492750|Active Comparator|Arm B (lenalidomide, dexamethasone, placebo)|Patients receive lenalidomide and dexamethasone as in Arm A. Patients also receive placebo SC on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3010539|NCT02492737|Experimental|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression, development of other unacceptable toxicity or Investigator discretion
3010540|NCT02492711|Experimental|Margetuximab plus chemotherapy|Margetuximab 15 mg/kg every 21 days plus Capecitabine 1000 mg/m2 BID for 14 days in a 21-day cycle or Eribulin 1.4 mg/m2 Day 1 and 8 of a 21-day cycle or Gemcitabine 1000 mg/m2 Day 1 and 8 of a 21-day cycle or Vinorelbine 25-30 mg/m2 Day 1 and 8 of a 21-day cycle
3010541|NCT02492711|Active Comparator|Trastuzumab plus chemotherapy|Trastuzumab 8 mg/kg loading dose then 6 mg/kg every 21 days plus Capecitabine 1000 mg/m2 BID for 14 days in a 21-day cycle or Eribulin 1.4 mg/m2 Day 1 and 8 of a 21-day cycle or Gemcitabine 1000 mg/m2 Day 1 and 8 of a 21-day cycle or Vinorelbine 25-30 mg/m2 Day 1 and 8 of a 21-day cycle
3010542|NCT02492698|Experimental|Probiotic group|consumed 2 g of powder of a dual probiotic strains containing Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, twice a day after breakfast and dinner.
3010543|NCT02492698|Placebo Comparator|Placebo group|consumed 2g of powder that did not contain any probiotics, twice a day after breakfast and dinner.
3010544|NCT02492685|Experimental|Contrast enhanced EUS group|Contrast enhanced EUS with quantitative analysis
3010545|NCT02492659|Experimental|trial group|the trial group underwent femtosecond laser-assisted cataract surgery
3010546|NCT02492659|Other|control group|the control group underwent conventional phacoemulsification
3010547|NCT02492646|Experimental|Saline group|In the saline group, disposable endotracheal tube was immersed in the 1 liter of sterile 0.9% sodium chloride irrigation solution before anesthetic induction.
3010548|NCT02492646|Experimental|Dry group|In the dry group, endotracheal tube was peeled off from sterile packing just before orotracheal intubation.
3010549|NCT02492633|Active Comparator|Standard|The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study.
3010550|NCT02492633|Experimental|Enhanced|At a subset of 6 Beacon Communities properties, residents will receive an 'enhanced intervention' in addition to the 'standard intervention' that Beacon Communities is already providing.
3010551|NCT02492620|Active Comparator|Ferric Citrate|Ferric citrate (FC) will be supplied as tablets containing 210mg of ferric iron (as 1g ferric citrate) to those subjects randomized to FC. These participants will be initiated on study drug with a fixed dose of FC beginning with 2 tablet per meal.
3010552|NCT02492620|No Intervention|Standard of Care (SOC)|Participants may receive open-label, non-FC phosphate binders at the discretion of their treating physician. During the Dialysis Period, dose of phosphate binders, use of ESA, intravenous iron and blood transfusions will be at the discretion of the primary treating nephrologist. Participants assigned to the SOC treatment arm may not receive FC at any point during the study.
3010553|NCT02492607|Active Comparator|Standard treatment|Standard treatment according to local policy. This can be either wide local excision only, wide local excision and radiotherapy, or mastectomy. Hormonal therapy is also allowed.
3010554|NCT02492607|Experimental|Active surveillance|Active surveillance : monitoring by annual digital mammography for a period of 10 years
3010555|NCT02492594||Pediatric patients with febrile neutropenia|Peripheral blood sampling - samples from 200 pediatric patients with severe immunosuppression and neutropenic fever will be analyzed
3010556|NCT02492594||Adult patients with febrile neutropenia|Peripheral blood sampling - samples from 200 adult patients with severe immunosuppression and neutropenic fever will be analyzed
3010557|NCT02492568|Experimental|SBRT + Pembrolizumab|Stereotactic Body Radiation Therapy (SBRT) followed by pembrolizumab treatment within 7 days of completion. SBRT: 3 x 8 Gy, given 1-2 weeks prior to start of pembrolizumab. Dose of pembrolizumab is 200 mg, every 3 weeks. Patients can continue the pembrolizumab treatment for maximal 2 years.
3010558|NCT02492568|Active Comparator|Pembrolizumab alone|Dose of pembrolizumab is 200 mg, every 3 weeks.Patients can continue the pembrolizumab treatment for maximal 2 years.
3010559|NCT02492555|Experimental|Scheduled (SI)|"Scheduled means screening every 3rd month ( home FC and DA) plus when needed and upgrade of ususal treatment"
3010560|NCT02492555|Active Comparator|On Demand (OD)|"On Demand means screening of home FC and DA when the patients feel for it and upgrade of usual treatment"
3010561|NCT02492542|Experimental|Electric Stimulation Treatment|Patients in the intervention group were treated with electric stimulation based on the routine clinical nursing.
3010562|NCT02492542|No Intervention|control group|patients in this group only received routine clinical nursing without electric stimulation
3010563|NCT02492529|Other|Healthy volunteers|"60 old healthy volunteers (aged 25-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Neuropsychological tests~Experimental procedure"
3010564|NCT02492529|Experimental|Patients with early Alzheimer disease|"20 patients (aged 60-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Neuropsychological tests~Experimental procedure~A cranial MRI"
3010565|NCT02492529|Experimental|Old healthy volunteers|"20 healthy volunteers (aged 60-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Neuropsychological tests~Experimental procedure~A cranial MRI"
3010566|NCT02492516|Experimental|Stem cell|The patients with diagnosis of ALS who receive adipose derived mesenchymal stem cell.
3010567|NCT02492503|Active Comparator|pacli carb 3|Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
3010568|NCT02492503|Active Comparator|pacli carb 1|Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
3010569|NCT02492490|Experimental|SVF(Stromal Vascular Fraction) derived MSC transprlantation|"transplantation of autologous SVF derived MSC to the recipients of DCD kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF~SVF will be cultured to abstain MSC~The abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD."
3010570|NCT02492490|Active Comparator|Basiliximab|induction with Basiliximab during kidney transplantation from DCD
3010571|NCT02492477|Experimental|6 months|evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase
3010572|NCT02492477|Experimental|12 months|evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase
3010573|NCT02492464|Active Comparator|Red yeast rice|Red yeast rice extract 200 mg, containing 10 mg monacolin K per daily dose, 1 capsule per day, per 6 months
3010574|NCT02492464|Placebo Comparator|Placebo|Placebo 200 mg (neutral fibre), 1 capsule per day, per 6 months
3010575|NCT02492451|Active Comparator|Endometrial Injury|Endometrial injury in luteal phase of preceding IUI cycle
3010576|NCT02492451|Active Comparator|Luteal Phase Support|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
3010577|NCT02492451|No Intervention|Control group|Only IUI
3010578|NCT02492438|Active Comparator|PPV23 naive, PPV23 vaccination|vaccination with PPV-23 in 40 PPV-23 naive patients
3010579|NCT02492438|Experimental|PPV23 naive, PCV13 vaccination|vaccination with PCV-13 in 40 PPV-23 naive patients
3010580|NCT02492438|Experimental|PPV23 > 4 years ago, PCV13 vaccination|vaccination with PCV-13 in 40 patients that received PPV-23 more than 4 years ago
3010581|NCT02492438|Experimental|PPV23 < 4 years, PCV13 vaccination|vaccination with PCV-13 in 40 patients that received PPV-23 less than 4 years ago
3010582|NCT02492412|Experimental|HE10|Drug: HE10 1~2 drops b.i.d at 12 hour interval for 12 weeks
3010583|NCT02492412|Active Comparator|Restasis|Drug: Restasis(Cyclosporine 0.05%) 1~2 drops b.i.d at 12 hour interval for 12 weeks
3010584|NCT02492399|Other|myectomy by Morrow|"Procedure: myectomy by Morrow.~Will be included in a group of 30 patients with obstructive hypertrophic cardiomyopathy and mitral insufficiency. In the case of conservation SAM syndrome and mediated mitral insufficiency, the result will be read as unsatisfactory. Patients will perform advanced myoectomy. All patients who need to be supplemented by the operation extension myoectomy subsequently run out in the second group. When it is impossible to eliminate mediated mitral regurgitation without mitral valve replacement, patients performed myoectomy and mitral valve replacement. The result in this case is read as completely unsatisfactory. Upon reaching 15% replacement mitral valve study terminated.~Evaluation results will be made myoectomy as TEE and direct tensiometer."
3010585|NCT02492399|Other|extended myectomy|"Procedure: extended myectomy.~Will be included in a group of 30 patients with obstructive hypertrophic cardiomyopathy and mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy which supplemented resection and release of the papillary muscles. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. The result in this case will become engrossed in reading as completely unsatisfactory. At achievement of 15% prosthetics of the mitralny valve research stops.~Evaluation results will be made myoectomy as TEE and direct tensiometer ."
3010586|NCT02492386|Experimental|Treatment|Bioabsorbable everolimus-eluting stent deployment
3010587|NCT02492373|Active Comparator|laser+steroid 2 days before and after laser|Before lentigines' treatment with Qs Nd:YAG 532 nm laser, topical 0.05% Clobetasol propionate ointment was applied 2 days on the lesion. Then applied 2 days after the treatment.
3010588|NCT02492373|Other|laser+steroid 2 days after laser|Controlled side. Applied topical 0.05% Clobetasol propionate ointment only 2 days after the laser treatment
3010589|NCT02492360||Severe Toxicity Group|Diagnosis of testicular cancer; History of any grade 3 or higher peripheral neuropathy after receiving standard dose cisplatin completed more than 1 year but within the last 5 years; Long-term persistence (> 6 months) of grade 2 or higher peripheral neuropathy after completion of a cisplatin containing regimen. Interventions: blood sample collection and report of peripheral neuropathy after cisplatin therapy.
3010590|NCT02492360||Control Group|Diagnosis of testicular cancer; No history of neurotoxicity (grade 0-1) after completion of a standard cisplatin-containing chemotherapy regimen completed more than 1 year but within the last 5 years; Matched to a specified subject with neurotoxicity based on age (within 10 years), chemotherapy regimen or total cisplatin dosage. Interventions: blood sample collection and report of peripheral neuropathy after cisplatin therapy.
3010591|NCT02492347|Active Comparator|Neonates exposed to AN SSRI use|A group of newborn babies who have been exposed to SSRIs in pregnancy will receive an Electrocardiogram at 48-72 hours of age.
3010592|NCT02492347|Other|Neonates not exposed to AN SSRI use|A group of newborn babies, who require treatment with intravenous antibiotics for at least 36 hours, having been identified as being at risk of having an infection within 12 hours of being born. They are subsequently confirmed as clinically well and will receive an Electrocardiogram at 48-72 hours of age.
3010593|NCT02492334|Experimental|Doxazosin|Participants will be randomized to receive 12 weeks of doxazosin treatment.
3010594|NCT02492334|Placebo Comparator|Placebo|Participants will be randomized to receive 12 weeks of placebo
3010595|NCT02492321|Active Comparator|EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day
3010596|NCT02492321|Placebo Comparator|Vehicle|Placebo Comparator: One of two study arms: placebo topical administered 3 times per day
3010597|NCT02492308|Experimental|SVF-MSC induction|"collection of autologous SVF~culture of SVF to abstain MSC~infusion of MSC during and after living-relative kidney transplantation"
3010598|NCT02492308|Active Comparator|Basiliximab induction|The control group will be inducted with Basiliximab
3010599|NCT02492295|Experimental|Propofol|"Propofol is administered intravenously as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 (light sedation - awakens to voice <10 seconds) to RASS target of -3 (moderate sedation - movement or eye opening without eye contact) for 15 minutes."
3010655|NCT02491918|Active Comparator|Optic Capture of IOL|intraocular lens implantation in the capsular bag with posterior optic capture
3010656|NCT02491905|Experimental|low dose HL tablet|HL tablet which contains 66.7mg of active compound by oral administration, twice daily in an hour after meal
3044705|NCT02262637||Hypertensive patients - Diabetologists|
3010600|NCT02492282|Experimental|Closed-Loop|This group includes patients with randomization process be assigned to closed loop intravenous anesthesia; the system evaluates, feeds and acts according to the patient's bispectral index, excluding the anesthesiologist. This system use a variable control of specific therapeutic effect; a target value for this variable (set point); an actuator control (infusion pump), a system (patient) and a control algorithm.
3010601|NCT02492282|Active Comparator|Open-Loop|This group includes patients with the randomization process are assigned to open loop in which the application of anesthetics is exclusively with pharmacokinetic parameters using TCI and employs mathematical models drug. For propofol used Schneider model and Minto model for remifentanil based on effective site concentration. Changes will be made by the anesthesiologist according to his criteria, trying to keep the BIS range of 40 and 60.
3010602|NCT02492269|Experimental|Dexmedetomidine|Dexmedetomidine in addition to 15 µg/kg of fentanyl
3010603|NCT02492269|Placebo Comparator|Placebo|Normal saline as a placebo in addition to 15 µg/kg of fentanyl
3010604|NCT02492256|Active Comparator|PVI group|Conventional PVI by circumferential antral ablation according to standard procedures.
3010605|NCT02492256|Experimental|PVI+GP guided by SUMO technology group|Conventional PVI by circumferential antral ablation according to standard procedures and atrial ganglionated plexi ablation guided by the SUMO technology.
3010606|NCT02492243|Experimental|Group 1|Patients with documented myocardial infarction in the 7days prior to enrolment and left ventricular ejection fraction >=40% as assessed by echocardiography within 7 days window after MI,who are not candidate to ICD/CRT/IPG implantation after PCI undergo ILR implantation
3010607|NCT02492230|Active Comparator|Control Group|After successful PCI the control group will take Triple therapy (warfarin + clopidogrel+aspirin) during 45 days and after combination of warfarin+clopidogrel to 6 months after procedure and then only warfarin. Patients will be followed at 45 day, and every 3 months during 12 months of follow up.
3010608|NCT02492230|Experimental|Study Group|Left Atrial Appendage Closure Device will be implanted immediately after successful PCI procedure. It will be implanted via a trans-septal approach by use of a catheter based delivery system to seal the ostium of the LAA. The implantation will be guided by fluoroscopy and TEE to verify proper positioning and stability. The study group will take Triple therapy (warfarin+clopidogrel+aspirin) during 45 days following PCI and after control TEE, warfarin will be discontinued. Then patients from the study group will take DAPT combination (clopidogrel+aspirin) to 6 months after procedure and then only aspirin. Patients will be followed at 45 day, and every 3 months during 12 months of follow up
3010609|NCT02492217|Experimental|Adalimumab|Adalimumab will be provided to trial participants as 0.8 ml single dose pre-filled syringes containing 40mg adalimumab each. A kit will be dispensed to he subject every two weeks, each kit containing one syringe.
3010610|NCT02492204||Survivors|
3010611|NCT02492204||Non survivors|
3010612|NCT02492191|Active Comparator|RAPP, e- assessed follow-up|"A mobile application (app) is installed on each patient's own smartphone. The app includes the Swedish web version of the QoR (SwQoR). After a patient is discharged from the day-surgery department, the patients in the intervention group will answer the RAPP daily for 14 days. His or her smartphone will initiate the postoperative recovery measurements daily through a push function. Each question will appear separately on the mobile phone screen and will disappear from the screen immediately after a response is given. The app also contains a question asking if the patient wants to be contacted by a nurse, which they will answer with a YES or NO. If YES, a nurse at the day surgery department will contact the patient and offer further information and assistance. The number of contacts and the reasons for contact requests will be documented."
3010613|NCT02492191|No Intervention|Control|The control group will receive standard care; i.e., no follow-up
3010614|NCT02492178|Experimental|IR artesunate + IV artesunate|Patients receive 1 dose of intrarectal artesunate (10 mg/ kg b.w.) on admission and 1 dose of intravenous artesunate (2.4 mg/kg body weight) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.
3010615|NCT02492178|Experimental|IV artesunate + IR artesunate|Patients receive 1 dose of intravenous artesunate (2.4 mg/kg b.w) on admission and 1 dose of intrarectal artesunate (10 mg/ kg b.w.) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.
3010616|NCT02492165|Experimental|Age 9 Months through 4 Years Group|Participants age 9 Months through 4 Years old at enrollment
3010617|NCT02492165|Experimental|Age 5 Years through 11 Years Group|Participants age 5 Years through 11 Years old at enrollment
3010618|NCT02492165|Experimental|Age 12 Years through 17 Years Group|Participants age 12 Years through 17 Years old at enrollment
3010619|NCT02492165|Experimental|Age 18 Years through 60 Years Group|Participants age 18 Years through 60 Years old at enrollment
3010620|NCT02492152|No Intervention|Control group|Women who will not be using this medicine that is checked.
3010621|NCT02492152|Experimental|Study group|Women who will use DIANATAL according to manufacturer's protocol from the stage of active labor.
3010622|NCT02492139|Other|Pumping|Each particpant will pump with the current pumpset one week and then two weeks with the pumpset
3010623|NCT02492126||Chronic Cough|Subjects with chronic cough will undergo cough reflex sensitivity testing to citric acid. The dose, starting at 0.03 mol/L citric acid will be administered as single breath inhalations using flow-limited calibrated pots and a dosimeter with 3 placebo inhalations of normal saline randomly interspersed. Following each inhalation, the number of coughs in the subsequent 15 seconds will be counted and recorded. The challenge will be terminated once the citric acid has induced 5 or more coughs.
3010624|NCT02492113|Experimental|Patients with BMI > 35|"ICU patients with a BMI > 35, on pressure support ventilation, scheduled for spontaneous breathing trial for evaluation of extubation~After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs) in randomized order. Either the patient will receive SBT at PEEP = 0-5 cmH2O, with PSV=0 and FiO2 unchanged; or the patient will perform an SBT at Titrated-PEEP, with the PSV=0 and FiO2 unchanged."
3010657|NCT02491905|Experimental|high dose HL tablet|HL tablet which contains 200mg of active compound by oral administration, twice daily in an hour after meal
3010658|NCT02491905|Placebo Comparator|placebo group|Placebo by oral administration, twice daily in an hour after meal
3013084|NCT02475317|Experimental|LUM001 20mg|5 subjects will receive a high dose of LUM001 (20 mg)
3010625|NCT02492100|Experimental|Multi-modality sexual dysfunction intervention|"- Patients in remission > 6 months after allogeneic bone marrow transplant~Patient Enrollment and Baseline Data Collection~First Intervention Visit:~Comprehensive assessment of sexual dysfunction~Normalization & Education~Therapeutic interventions~Referral to Sexual Health Clinic if applicable~Follow-Up Intervention Visit --- Referral to Sexual Health Clinic if applicable"
3010626|NCT02492087|Active Comparator|Tranexamic acid (TXA) Group|Subjects in the TXA group will receive the topical tranexamic acid solution which will be administered intra-operatively, during the caesarean section on the surgical wound and into the intrauterine cavity after the delivery of the baby and the placenta. 60mls of the solution will be applied topically to the placental bed as identified by the surgeon carrying out the surgery by spraying the study solution using a syringe into the uterine cavity. Another 30mls of the solution will be applied to the open incision wound. The surgeon will then proceed to close the first layer of the uterus in the usual manner. The remaining 30mls of the study drug solution is then applied topically on the closed incision wound
3010627|NCT02492087|Sham Comparator|Control Group|Subjects in the Control group will receive topical normal saline solution which will be administered intra-operatively in the same manner as described for the TXA group.
3010628|NCT02492074|Experimental|THC|Subjects receive 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) and corresponding cannabidiol placebo capsules.
3010629|NCT02492074|Experimental|CBD|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and corresponding delta-9-tetrahydrocannabinol placebo capsules.
3010630|NCT02492074|Experimental|CBD+THC|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each)
3010631|NCT02492074|Placebo Comparator|Placebo|Subjects receive corresponding delta-9-tetrahydrocannabinol and cannabidiol placebo capsules
3010632|NCT02492061|Active Comparator|Demand creation|In the intervention arm, demand creation for couples' HCT is done using small group (comprising about 20 people), couple-focused or men-only, interactive sessions. A senior counselor facilitates the sessions in which the advantages and fears associated with couples' HCT are discussed with invited couples or men. The sessions are reinforced by testimonies from couples or men who have ever tested as a couple. Attending couples or men receive couple invitation coupons inviting them to test for HIV together with their partners at a designated health facility in the community.
3010633|NCT02492061|No Intervention|Standard of care|In the standard of care arm, participants receive general adult health talks to educate them about the importance of HIV testing (including couples' HCT) but no invitations are issued to invite couples to test for HIV together with their partners at a designated health facility. However, couples can seek HCT out of their own volition. The sessions are not stratified by marital status, and attendants include all those who are willing and are able to attend.
3010634|NCT02492048|Active Comparator|Split Thickness Skin Graft Harvest|Retrospective review
3010635|NCT02492048|Experimental|Cellutome Epidermal Harvesting System|Prospective patients will receive a skin graft utilizing the Cellutome Epidermal Harvesting System
3010636|NCT02492035|Experimental|Physical activity|Tailoring intervention with kinesiologist
3010637|NCT02492035|Experimental|Diet|Tailoring intervention with nutritionist
3010638|NCT02492035|Experimental|Physical activity and diet|Tailoring intervention with kinesiologist and nutritionist
3010639|NCT02492035|No Intervention|Standard medical care|Follow with family doctor as usual care.
3010640|NCT02492022|Experimental|Probiotic L008-1|Encapsuled combinaison of 2 probiotics
3010641|NCT02492022|Experimental|Probiotic L008-2|Encapsuled combinaison of 2 probiotics
3010642|NCT02492022|Placebo Comparator|Placebo|Encapsuled non active ingredients
3010643|NCT02492009|Placebo Comparator|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
3010644|NCT02492009|Active Comparator|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
3010645|NCT02491996|Experimental|DTIG|Outpatients who treated by DTIG at Outpatient Unit for Gambling Disorder of Kurihama Medical and Addiction Center
3010646|NCT02491983|Active Comparator|Arm A|Combination of Palbociclib and Letrozole
3010647|NCT02491983|Experimental|Arm B|Combination of Palbociclib and Fulvestrant
3010648|NCT02491970|Experimental|Fluticasone/Formoterol|Brand name: Flutiform Dose: 250/10μg (2 puffs/once, BID) Duration of treatment: 12 weeks Mode of administration: oral inhalation
3010649|NCT02491970|Active Comparator|Fluticasone/Salmeterol|Brand name: Seretide Dose: 250/50μg (2 puffs/once, BID) Duration of treatment: 12 weeks Mode of administration: oral inhalation
3010650|NCT02491957|Experimental|LOFT Therapy|LOFT therapy twice weekly for 4 weeks
3010651|NCT02491944|Experimental|Bioavailability of AZD9291|To assess the absolute bioavailability of a single oral dose of AZD9291 with respect to an intravenous microdose of [14C]AZD9291
3010652|NCT02491931|Active Comparator|GLN group|All patients in the GLN group received an oral GLN supplement. The total GLN dose given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of GLN/maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.
3010653|NCT02491931|Placebo Comparator|CONT group|All patients in the GLN group received an oral maltodextrin supplement, similar in shape and texture as GLN supplement. The total placebo given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.
3010654|NCT02491918|Active Comparator|In the bag IOL|Cataract surgery with IOL implantation in the capsular bag
3010812|NCT02490787|Experimental|Concizumab|
3010659|NCT02491892|Experimental|Pertuzumab 1050 mg|Participants will not receive a loading dose, but will receive pertuzumab 1050 milligrams (mg) via intravenous (IV) infusion every 3 weeks until unacceptable toxicity or disease progression.
3010660|NCT02491892|Experimental|Pertuzumab 420 mg|Participants will receive a loading dose of 840 mg via IV infusion at the first infusion of pertuzumab, followed by a maintenance dose of 420 mg every 3 weeks until unacceptable toxicity or disease progression.
3010661|NCT02491879|Experimental|Ketoprofen|Ketoprofen gel
3010662|NCT02491879|Placebo Comparator|Placebo|Placebo form of ketoprofen gel
3010663|NCT02491866|Other|psychiatric patients|patients with schizophrenia, bipolar disorder or depression according DSM V criteria
3010664|NCT02491840|Experimental|Gastric and cardia adenocarcinomas|Biopsy of Gastric and cardia adenocarcinomas
3010665|NCT02491827||Cellvizio mini laser probe|Cellvizio mini laser probe will be administered via the endoscopic device used for the neurosurgical procedure to provide confocal laser endomicroscopy in patients requiring neurosurgery due to glioma multiforme or subcranial tumors
3010666|NCT02491814|Experimental|1% M.F. Milk and Breakfast Cereal|Breakfast meal: 250 ml 1% M.F. Milk, 54 g Cheerios breakfast cereal, 100 mL water
3010667|NCT02491814|Experimental|Yogurt Beverage and Breakfast Cereal|Breakfast meal: 250 ml Yogurt Beverage, 54 g Cheerios breakfast cereal, 100 mL water
3010668|NCT02491814|Experimental|Soy Beverage and Breakfast Cereal|Breakfast meal: 250 ml Soy Beverage, 54 g Cheerios breakfast cereal, 100 mL water
3010669|NCT02491814|Experimental|Almond Beverage and Breakfast Cereal|Breakfast meal: 250 ml Almond Beverage, 54 g Cheerios breakfast cereal, 100 mL water
3010670|NCT02491814|Experimental|Water (control) and Breakfast Cereal|Breakfast meal: 250 ml Water, 54 g Cheerios breakfast cereal, 100 mL water
3010671|NCT02491801|Experimental|3.25% M.F. Milk|3.25% M.F. Milk
3010672|NCT02491801|Experimental|Greek Yogurt|Greek Yogurt (2% M.F.)
3010673|NCT02491801|Experimental|Cheddar Cheese|Regular Fat Cheddar Cheese
3010674|NCT02491801|Experimental|Control 1|Skim milk
3010675|NCT02491801|Experimental|Control 2|Filtered water, calorie-free control
3010676|NCT02491788|Experimental|Drug|10 mg of suvorexant 30 minutes prior to daytime sleep opportunity
3010677|NCT02491788|Placebo Comparator|Placebo|Placebo pill 30 minutes prior to daytime sleep opportunity
3010678|NCT02491762||bilateral|bilateral breast construction candidates will go through respiratory function tests a month prior to surgery, a month after surgery and three months after surgery
3010679|NCT02491762||unilateral|unilateral breast construction candidates will go through respiratory function tests a month prior to surgery, a month after surgery and three months after surgery
3010680|NCT02491749|Experimental|Ultra Fast-Track Anesthesia|Patients who fulfilled the extubation criteria were extubated at the end of surgery and transferred to the ICU for follow up.
3010681|NCT02491749|Experimental|Conventional|patients who did not fulfill extubation criteria were left intubated and sedated and transferred to the ICU for later management
3010682|NCT02491736|Experimental|ketoprofen|2.5% ketoprofen gel
3010683|NCT02491736|Placebo Comparator|Placebo|Placebo gel
3010684|NCT02491723|Experimental|Azithromycin group|Patients with non-cystic bronchiectasis were treated with azithromycin. The intervention was 500mg daily for three to five days.
3010685|NCT02491710|Experimental|Low-cost box trainer|Trainees in this arm will perform their basic laparoscopic skills training on a low-cost tablet-based box trainer.
3010686|NCT02491710|Active Comparator|Standard box trainer|Trainees in this arm will perform their basic laparoscopic skills training on a standard box trainer
3010687|NCT02491697|Active Comparator|Capecitabine Monotherapy|"Patients with advanced breast cancer accept capecitabine monotherapy.~Drug: Capecitabine"
3010688|NCT02491697|Experimental|DC-CIK Immunotherapy+Capecitabine|"Biological/Vaccine: DC-CIK DC-CIK immunotherapy combined with capecitabine are used to treat advanced breast cancer.~Drug: Capecitabine"
3010689|NCT02491684|Placebo Comparator|Placebo (matching)|Placebo, once daily inhalation for 14 days
3010690|NCT02491684|Experimental|Interferon beta-1a|Interferon beta-1a, 24 μg (metered dose) once daily inhalation for 14 days
3010691|NCT02491671|Experimental|Experimental group|Experimental group: At the end of lung resection, lung sutures and 1.5 cm of lung parenchyma on each side will be covered by Hemopatch. No additional measures for preventing air leak will be indicated. In the case of massive air leak in spite of the use of Hemopatch, each surgeon will decide on the indication of additional sutures of tissue plasties. These cases will be accounted for failures on an intention to treat basis.
3010692|NCT02491671|Other|Control group|Control group: The standard preventive measures will be followed in each center, including reinforcement of sutures, pleural tents, suturing pericardial or subcutaneous fat
3010693|NCT02491658|Experimental|Treat Psoriasis Vulgaris with UC-MSCs|Subjects in this arm will receive 6 times UC-MSCs infusions (each time 1×10^6/kg) within 8 weeks.
3010694|NCT02491645|Experimental|Intervention group|"Children would receive both standard therapy and home based sensory interventions as described below,~Standard therapy - children would receive measures like speech and language services, behavioral interventions and educational program regularly as and when decided by the primary care physician. They would be individualized to child specific needs .~Home based sensory interventions - children would receive home based sensory interventions targeting visual and auditory system, tactile abnormalities, proprioceptive and vestibular abnormalities.These interventions would be carried out daily , at least 5 days a week, for a minimum duration of 1hour/day."
3010695|NCT02491645|No Intervention|Control group|This group of children would receive only standard therapy as described below, Standard therapy - children would receive measures like speech and language services, behavioral interventions and educational program regularly as and when decided by the primary care physician. They would be individualized to child specific needs.
3010696|NCT02491632|Experimental|Physical Activity + High Dose Dexamethasone|Participants receive high-dose regimen, 8 mg of dexamethasone orally, twice a day for 7 days. Participants receive a combination of a supervised and home physical activity regimen each week while on study. Participants perform physical activity tests at baseline, Days 8, 15, 29, and 57. Quality of life questionnaires completed at baseline, Days 8, 15, 29, and 57. Study staff calls participants 1 time each week while on study.
3010813|NCT02490787|Placebo Comparator|Placebo|
3044706|NCT02262624|Experimental|Telmisartan/HCTZ fixed combination|
3010697|NCT02491632|Experimental|Physical Activity + Low Dose Dexamethasone|Participants receive low-dose regimen, 4 mg of dexamethasone orally, twice a day for 7 days. Participants receive a combination of a supervised and home physical activity regimen each week while on study. Participants perform physical activity tests at baseline, Days 8, 15, 29, and 57. Quality of life questionnaires completed at baseline, Days 8, 15, 29, and 57. Study staff calls participants 1 time each week while on study.
3010698|NCT02491619|Experimental|Orthodontic decompensation|Orthodontic decompensation in patients with class III dentofacial deformities
3010699|NCT02491606|Experimental|Load only|Loading with tafenoquine 400 mg base for three days followed by placebo weekly.
3010700|NCT02491606|Experimental|Low weekly dose|Loading with tafenoquine 200 mg base for 3 days followed by tafenoquine 200 mg weekly.
3010701|NCT02491606|Experimental|High weekly dose|Loading with tafenoquine to 400 mg base for 3 days followed by tafenoquine 400 mg base weekly.
3010702|NCT02491606|Experimental|Placebo|Loading with placebo for 3 days followed by placebo once weekly.
3010703|NCT02491580||KTx Uppsala|Patients who have received a kidney transplant in Uppsala.
3010704|NCT02491580||KTx Europe|Patients who have received a kidney transplant in Uppsala.
3010705|NCT02491567||Hashimoto Thyroiditis (HT)|Children and adolescents with Hashimoto thyroiditis either hypothyroidic or euthyroidic.
3010706|NCT02491567||Graves Disease (GD)|Children and adolescents with Graves Disease both those on remission and under antihyroid medication.
3010707|NCT02491567||Controls (C)|Healthy individuals matched for gender and age without 1) any autoimmune disease 2) family history of autoimmune disease in the first degree relatives
3010708|NCT02491554|Active Comparator|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based DBS implantation in the thalamic/subthalamic region (Vim-cZI) starting as awake surgery with a brief general anesthesia for stimulator implantation at the end of surgery.
3010709|NCT02491554|Experimental|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided DBS implantation in the dentato-rubro-thalamic bundle (DRT) in general anesthesia.
3010710|NCT02491541|Experimental|Changchun Werersai|A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.
3010711|NCT02491541|Active Comparator|Jilin Maifeng|A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.
3010712|NCT02491528|Experimental|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
3010713|NCT02491528|Active Comparator|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
3010714|NCT02491502|Experimental|Echopulse|Echopulse HIFU
3010715|NCT02491489|Experimental|Painful shoulders|Subjects with shoulder pain undergoing glenohumeral mobilization
3010716|NCT02491489|Active Comparator|Normal shoulders|Subjects without shoulder pain undergoing glenohumeral mobilization
3010717|NCT02491476|Experimental|micro-macroelectrodes|All patients will be implanted with usually 4 intracerebral micro-macroelectrodes(replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
3010718|NCT02491463|Experimental|GSK3389245A_LD GROUP|Subjects in this group will receive 2 doses, one month apart of the GSK3389245A vaccine low dose
3010719|NCT02491463|Experimental|GSK3389245A_HD GROUP|Subjects in this group will receive 2 doses, one month apart, of the GSK3389245A vaccine high dose
3010720|NCT02491463|Active Comparator|Bexsero Group|Subjects in this group will receive 2 doses, one month apart, of Bexsero
3010721|NCT02491463|Placebo Comparator|Placebo Group|Subjects in this group will receive 2 doses, one month apart, of placebo
3010722|NCT02491450|Experimental|A Test|Test drug (Heterosofir)1 tablet contains 400 mg Sofosbuvir
3010723|NCT02491450|Active Comparator|B Reference|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
3010724|NCT02491437|Experimental|Dydrogesterone tablets 3x10 mg|Dydrogesterone tablets 3x10 mg
3010725|NCT02491437|Experimental|Crinone 8% intravaginal progesterone gel 90 mg|Crinone 8% intravaginal progesterone gel 90 mg
3010726|NCT02491424|Experimental|Fixation of ITAP to lower limb amputees.|"Direct skeletal fixation of ITAP to lower limb amputees. 20 patients in the study will be fitted with Intraosseous Transcutaneous Amputation Prosthesis.~The device has been designed to be surgically implanted in a one stage procedure."
3010727|NCT02491411|Experimental|Treatment (dexamethasone and enzalutamide)|Patients receive dexamethasone PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity until there is evidence of PSA progression, clinical disease progression, or radiographic disease progression. At time of progression, dexamethasone will be stopped via a rapid taper over one week if patients were treated for over 30 days. Patients then receive enzalutamide PO once daily on days 1-28. Treatment repeats every 28 days for up to 3 courses in the absence of clinical disease progression or unacceptable toxicity.
3010728|NCT02491398||First-line|Previously untreated CLL requiring therapy according to the NCI criteria and treated with at least one cycle of BR as first-line treatment.
3010729|NCT02491398||Second-line|CLL that received one previous line of treatment using alkylating agents and/or purine analogues with or without monoclonal antibodies, requiring second-line therapy according to the NCI criteria and treated with at least one cycle of BR.
3010730|NCT02491385|Experimental|TEA|thoracic epidural analgesia group
3010731|NCT02491385|Active Comparator|iv-PCA|intravenous patient controlled analgesia group
3010732|NCT02491372|Experimental|Intervention|Acceptance and commitment therapy group
3010733|NCT02491372|No Intervention|Comparison|Treatment as usual
3010734|NCT02491359|Experimental|Treatment (carfilzomib)|Patients receive carfilzomib IV over approximately 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3010735|NCT02491346|Active Comparator|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
3010736|NCT02491346|Experimental|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC.
3010737|NCT02491333|Experimental|true acupuncture + placebo metformin|"True acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.~Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month."
3010738|NCT02491333|Sham Comparator|sham acupuncture + placebo metformin|"Sham acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month. Placement of needles is unlikely to affect ovulation and IR in women with PCOS.~Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month."
3010739|NCT02491333|Active Comparator|sham acupuncture + metformin|"Sham acupuncture and metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.Placement of needles is unlikely to affect ovulation and IR in women with PCOS.~Metformin will be given at 0.5g/times, 3 times one day and for 4 month."
3010740|NCT02491320|Experimental|Pre-treatment acupuncture + letrozole|A 16 week acupuncture pretreatment followed by letrozole(LE). Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. All subjects will be requested to use contraception during the 16 week acupuncture pretreatment. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks. After 16 weeks of acupuncture treatment, LE will start on day 2-3 after a spontaneous period or after a withdrawal bleeding after progestin administration. The subjects will be instructed to have intercourse on a regular basis during the cycles.
3010741|NCT02491320|Active Comparator|Letrozole|LE alone. LE will be started on day 3-5 after a spontaneous period or a withdrawal bleeding following progestin. The subjects will be instructed to have intercourse on a regular basis during the cycles.
3010742|NCT02491307|Experimental|Ginger.io Application Users|This cohort is comprised of individuals that 1) are English-speaking; 2) possess an Android or iOS smartphone; 3) have a diagnosis for anxiety, depression, and/or bipolar disorder; and 4) are active behavioral health patients at any of the four CHCI clinic sites (New London, New Britain, Middletown, or Meriden) where behavioral health providers are using the Ginger.io app with their patients. These patients receive the Ginger.io smartphone application for daily use.
3010743|NCT02491307|No Intervention|Non-application users|This cohort is comprised of individuals that 1) are English-speaking; 2) possess an Android or iOS smartphone; 3) have anxiety, depression, and/or bipolar disorder; and 4) are patient of a behavioral health clinician that is providing paper surveys to patients in clinic. They do not receive the Ginger.io smartphone application.
3010744|NCT02491294|Experimental|School Only|Students whose schools are randomized to this condition only receive the classroom, cafeteria and SPARK active recess components
3010745|NCT02491294|Experimental|School + Family|Students whose schools are randomized to this condition receive the classroom, cafeteria and SPARK active recess components and the family component (family nights, parent blog and action packs)
3010746|NCT02491294|Experimental|School + About Eating|Students whose schools are randomized to this condition only receive the classroom, cafeteria and SPARK active recess components and their parents are invited to participate in the online 6 lesson About Eating program.
3010747|NCT02491294|Experimental|School + Family + About Eating|students whose schools are randomized to this condition receive the classroom, cafeteria and SPARK active recess components and the family component (family nights, parent blog and action packs) and their parents are invited to participate in the online 6 lesson About Eating program.
3010748|NCT02491294|No Intervention|Control|students and their parents in all schools during cohort 1 and 4 (and Ponderosa students in cohort 3) are tested but provided no intervention
3010749|NCT02491281|Experimental|LNA043|LNA043 given intra-articularly
3010750|NCT02491281|Placebo Comparator|Placebo|Placebo given intra-articularly
3010751|NCT02491268|Experimental|Cilostazol 50mg B.I.D.|"After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration.~Protocol treatment defines as follows;~Investigational Treatment:~Cilostazol 50mg B.I.D. p.o. 96 Weeks"
3010752|NCT02491268|Placebo Comparator|Placebo B.I.D.|"After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration.~Protocol treatment defines as follows;~Comparative Treatment:~Placebo B.I.D. p.o. 96 Weeks"
3010753|NCT02491255|Experimental|Lotus Valve System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
3010754|NCT02491229|Other|"Hepafast"|"This group consumes three portions of Hepafast and additionally 200 kcal of vegetables for two weeks. In the following ten weeks, they consume two portions of Hepafast and one meal which follows the instructions of the Low Glycemic and Insulinemic Diet (LOGI)."
3010755|NCT02491229|Other|Control|This group follows the instruction of the LOGI diet for the entire 12 weeks
3010756|NCT02491216|Experimental|Acupressure Group|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
3010757|NCT02491216|No Intervention|Control Group|No acupressure therapy will be provided during the study.
3010758|NCT02491203|No Intervention|Usual care|All study participants in the control group will receive a 4-week written home exercise program (e.g. GRASP) , i.e. the usual care discharge home program.
3010814|NCT02490774|Experimental|Arm 1: BAY1007626, low relase|Intrauterine device with a low in vitro release rate
3010815|NCT02490774|Experimental|Arm 2: BAY1007626, low to medium release|Intrauterine device with a low to medium in vitro release rate
3010816|NCT02490774|Experimental|Arm 3: BAY1007626, medium release|Intrauterine device with a medium in vitro release rate
3010759|NCT02491203|Experimental|Telerehabilitation system|Participants in the experimental group will receive four weeks written home exercise program provided by a clinician, i.e. usual care discharge home program plus virtual reality (VR) and telerehabilitation system. The intensity and choice of game for the home program will be determined by the therapist based on the patient's abilities, interests, motivation and fatigue. The patient's performance for the VR home program will be monitored asynchronously and the program adapted to ensure it remains at an appropriate level for the patient.
3010760|NCT02491190|Experimental|Treatment|Empower educational module: After the patient activation measure/s are collected, for parents or patients assigned to the intervention arm, they will be given an opportunity to launch the EMPOWER video and interactive powerpoint. They will be able to pause on reviewing the educational material and come back to it, as with other assigned education, and they will be able to review it again if they would like. Discharge surveys will be assigned 24 hours prior to the estimated discharge time in Apex. Oneview will display notifications that the surveys have been assigned.
3010761|NCT02491190|No Intervention|Control|Standard care: Those who opt to participate in the study will be randomly assigned to receive standard features of the media center (control group), or standard features plus the educational module intervention. They will complete online (1) a baseline patient activation survey (for patients old enough to complete and for caregivers) at the start of their participation, and (2) an end-of-study survey pre-discharge or at the end of the study period.
3010762|NCT02491177|Other|cMM and Text Messaging|Participants randomized to this arm will receive both the community mentor mother and mobile phone text messaging intervention. The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
3010763|NCT02491177|Other|cMM Only|Participants randomized to this arm will receive the community mentor mother intervention only.The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits.
3010764|NCT02491177|Other|Text Messaging Only|Participants randomized to this arm will receive the mobile phone text messaging intervention only. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
3010765|NCT02491177|No Intervention|Neither cMM nor Text Messaging|Participants randomized to this arm will receive standard of care with no interventions.
3010766|NCT02491164|Experimental|BAC TWO administration|All participants in this clinical study will be dosed on one occasion with BAC TWO. The final dosage will be 80 µg (± 25%).
3010767|NCT02491138|Placebo Comparator|Standard information|In this arm, participants will receive standard information pamphlets about the benefits of good sleeping habits.
3010768|NCT02491138|Experimental|Appearance-based information|In this arm, participants will receive information about how sleep modifies their physical appearance. This will involve a computer transformation that morphs their face according to hours of sleep obtained.
3010769|NCT02491125|Placebo Comparator|Placebo|12 weeks placebo maltodextrin 15g/day ( 5 g in beverage, to be consumed three times a day)
3010770|NCT02491125|Experimental|soluble wheat bran fibre|12 weeks soluble wheat bran fibre 15g/day (5 g in beverage, to be consumed three times a day)
3010771|NCT02491099|Experimental|Afatinib|Afatinib 40 mgs., Q 21 Day times 4 Cycles
3010772|NCT02491086|Experimental|Intervention|The intervention group will receive a free pack of one-week NRT. The nurse will help the subject to decide which NRT product (patch, gum and lozenge) he/she can use and advise how to use the NRT based on his/her smoking habit and amount of cigarette consumption, followed by the delivery of the sampling, instructions of using the NRT sampling, an education card about NRT and a 12-page smoking cessation booklet (Figure 1). Based on the experience in the previous trials, the choice of NRT (either patch, lozenge or gum) will be made according to subject's preference, and the counsellors will provide medication counselling [25-27]. If the subject is willing to continue the counselling at recruitment, the ambassador will further introduce the NRT's side effects, adherence and effectiveness (Table 1). Otherwise, the ambassador will contact the subject for providing these details and enquiring the usage through telephone within 2 days.
3010773|NCT02491086|Active Comparator|Control|The control group subjects will only be advised by the ambassador to purchase the NRT on their own, but will not be given the sampling. The same education card and the 12-page smoking cessation booklet will be provided.
3010774|NCT02491073||Eslicarbazepine acetate treated|
3010775|NCT02491073||Non-Eslicarbazepine acetate treated|
3010776|NCT02491060|Experimental|IDP-121 Lotion|IDP-121 Lotion, applied topically to the face, once daily for 12 weeks.
3010777|NCT02491060|Placebo Comparator|IDP-121 Lotion Vehicle|IDP-121 Vehicle Lotion, applied topically to the face, once daily for 12 weeks
3010778|NCT02491047|Experimental|BonyPid-1000|Implantation of BonyPid-1000 medical device, constructed of bone filler coated with controlled release antibiotic formulation, concomitantly with standard of care treatment (SOC)
3010779|NCT02491047|Other|Study control arm|Standard of care treatment (SOC) only
3010780|NCT02491034|Other|Intervention|Depression Education Intervention
3010781|NCT02491021|Active Comparator|Treatment Group|Treatment Group (TG) The TG underwent a 7-week outpatient rehabilitation programme comprising both exercise and education sessions under the direct supervision of the physiotherapy team. The exercise intervention was 20 minutes, 3x/week (1 supervised, 2 self directed) titrated to a specific intensity based on risk stratification - highvs low risk). The intervention also included 6 x 1 hour education sessions.
3010782|NCT02491021|No Intervention|Control Group|Control Group (CG) The CG received physiotherapy, exercises and education as per current standards of practice in our institution up until hospital discharge. Following discharge no further specific input or education was provided. Participants were contacted at least once during the study period to check on their general well being and to encourage attendance at the second assessment by the physiotherapy team. In line with the ethical requirements for the study, all control subjects were offered the chance to participate in the rehabilitation programme once their trial participation was completed following second assessment.
3010783|NCT02491008|Experimental|Drug: Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
3010784|NCT02491008|Placebo Comparator|Drug: Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
3010785|NCT02490995|No Intervention|Group A|Information given by the anaesthetist during the consultation
3010786|NCT02490995|Experimental|Group B|Movie + Information given by the anaesthetist during the consultation
3010787|NCT02490982||Teriflunomide|Patient-reported outcomes and clinical assessment
3010788|NCT02490956|Experimental|Rabies vaccination|"Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular~Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363"
3010789|NCT02490943|Active Comparator|Warm Compress Pre-Injection|Group A, N = 10, will receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
3010790|NCT02490943|Active Comparator|Cold Compress Post-Injection|Group B, N= 10, will receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
3010791|NCT02490943|No Intervention|No Intervention Pre/Post-Injection|Group C, N= 8, will receive no treatment for six injections following screening.
3010792|NCT02490930|Experimental|Experimental|Five evaluable patients with newly diagnosed high grade gliomas who will undergo standard concomitant radiation and temozolomide followed by adjuvant temozolomide will be accrued to this open-label, single arm, safety study. Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy. Fingolimod will be administered at 0.5 mg every day for the first two weeks. Beginning the third week, they will take fingolimod on Monday, Wednesday and Friday until the end of radiotherapy or until the 28th dose, whichever comes first.
3010793|NCT02490917|Experimental|ACT™ device|Patients randomized to receive the Adjustable Continence Therapy device ACT™
3010794|NCT02490917|Other|AMS 800 ™ device|Patients randomized to receive the artificial urinary sphincter AMS 800 ™
3010795|NCT02490904|Experimental|Eplerenone group|Eplerenone administration within 2 hours prior to patient departure to the operating room and for 4 days after kidney transplantation.
3010796|NCT02490904|Placebo Comparator|Placebo group|Placebo administration within 2 hours prior to patient departure to the operatingroom and for 4 days after kidney transplantation
3010797|NCT02490891|Experimental|PET scan with RGD K5 imaging|PET scan with RGD K5 tracer will be performed before and after two cycles of chemotherapy
3010798|NCT02490878|Experimental|bevacizumab + corticosteroids|"The patient will receive bevacizumab 10 mg/kg IV given on days 1 and 15 of a 28 day cycle for 4 cycles. Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as tolerated, under the management of the treating MD. If patients deteriorate while tapering, dexamethasone will be increased up to a maximum of 16 mg per day, as per treating MD, to manage symptoms.~Patients who meet the criteria for clinical progression will be treated as per treating MD."
3010799|NCT02490878|Experimental|placebo + corticosteroids|"The patient will receive placebo 0.9% NaCl volume equal to bevacizumab volume added to 100 mL bag of 0.9% NaCl delivered IV given on days 1 and 15 of a 28-day cycle for 4 cycles. Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as tolerated, under the management of the treating MD. If patients deteriorate while tapering, dexamethasone will be increased up to a maximum of 16 mg per day, as per treating MD, to manage symptoms.~Patients who meet the criteria for clinical progression will be allowed to receive bevacizumab according to the protocol."
3010800|NCT02490865|Experimental|RNS60|Administration of nebulized RNS60 to test for systemic bioactivity
3010801|NCT02490865|Placebo Comparator|Normal Saline|Administration of normal saline used as control
3010802|NCT02490852|Experimental|Investigational Infant formula|Healthy term infants fed exclusively the investigational Infant Formula
3010803|NCT02490852|Active Comparator|Commercially available Infant formula|Healthy term infants fed exclusively a commercially available Infant Formula
3010804|NCT02490852|Active Comparator|Human milk|Healthy term infants fed exclusively human milk
3010805|NCT02490839|Experimental|High-dose dual therapy|group A-high-dose dual therapy ( rabeprazole 20 mg, tablet, qid + amoxicillin 750 mg, capsule, qid for 14 days)
3010806|NCT02490839|Active Comparator|Bismuth-containing quadruple therapy|group B-bismuth-containing quadruple therapy (rabeprazole 20 mg, tablet, bid + tripotassium dicitrate bismuthate 300 mg, tablet, qid + metronidazole 250 mg, tablet, qid + tetracycline 500 mg qid, capsule, for 10 days)
3010807|NCT02490826|Active Comparator|Table-based T2T intervention|"A combined phonological awareness therapy, listening and discrimination and auditory bombardment activities intervention will be applied. This will be based in a table top material version.~The intervention will consist of 12 weekly sessions (individual) of 45 min in duration, divided into two blocks (6+6) without any breaks."
3010808|NCT02490826|Active Comparator|Tablet-based T2T intervention|"A combined phonological awareness therapy, listening and discrimination and auditory bombardment activities intervention will be applied. This will be based in a tablet (digital) material version.~The intervention will consist of 12 weekly sessions (individual) of 45 min in duration, divided into two blocks (6+6) without any breaks."
3010809|NCT02490813|Placebo Comparator|Control|This arm will receive the placebo.
3010810|NCT02490813|Experimental|Treatment - Chinese Herbal Formula - X|This arm will receive the Chinese Herbal Formula - CHFX as treatment to their existing fish, shrimp or crab allergy.
3010811|NCT02490800|Experimental|Drug: BAL101553|Oral daily administration of BAL101553
3010817|NCT02490774|Experimental|Arm 4: BAY 1007626, high release|Intrauterine device with a high in vitro release rate
3010818|NCT02490774|Active Comparator|Arm 5: Levonorgestrel, Jaydess|Intrauterine device releasing levonorgestrel (Jaydess)
3010819|NCT02490774|Active Comparator|Arm 6: Levonorgestrel, Mirena|Intrauterine device releasing levonorgestrel (Mirena)
3010820|NCT02490761||Study cohort|Patients aged 65 years or over admitted to a geriatric ward in 2 hospitals for more than 3 days
3010821|NCT02490748|No Intervention|RFA alone|Patients undergo radiofrequency ablation alone.
3010822|NCT02490748|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
3010823|NCT02490735|No Intervention|No-CIK|After accepting chemotherapy, patients will regularly follow up.
3010824|NCT02490735|Experimental|CIK|After accepting chemotherapy, patients will receive at least 3 cycles of Cytokine-induced Killer Cells treatment per year
3010825|NCT02490722|Active Comparator|Intervention|Four times two hours interdisciplinary patient education and usual care
3010826|NCT02490722|No Intervention|Control|Usual care
3010827|NCT02490709|Experimental|Local excision|Local excision for rectal cancer with good response
3010828|NCT02490696|Experimental|Miso|In this arm two PET scans wiil be realized. The first one will be made with F-Miso tracer. 24 hours later the FAZA PET scan will be performed. 24 hours after the last PET scan the surgery will be realized. During this surgery a piece of tumor will be collected and analyse by immunohistochemistry for markers of hypoxia
3010829|NCT02490696|Experimental|FAZA|In this arm two PET scans wiil be realized. The first one will be made with FAZA tracer. 24 hours later the F-Miso PET scan will be performed. 24 hours after the last PET scan the surgery will be realized. During this surgery a piece of tumor will be collected and analyse by immunohistochemistry for markers of hypoxia
3010830|NCT02490683|Experimental|Luna Rich X|Luna Rich X©: 500 mg/ day in 4 pills of lunasin-enriched soy protein concentrate Reliv Now: 19 grams of powder/day, that subject will mix and consume daily with water or a beverage they commonly drink
3010831|NCT02490683|Experimental|Reliv Now|19 grams of power/day, that subjects will mix and consume daily with water or a beverage they commonly drink
3010832|NCT02490683|Placebo Comparator|Placebo|Placebo pills containing starch (provided by Reliv International, Inc.)
3010833|NCT02490670|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
3010834|NCT02490670|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods.
3010835|NCT02490657|Experimental|Iloprost group|
3010836|NCT02490657|Placebo Comparator|normal saline|
3010837|NCT02490644||MGB1 in valvular heart surgery|Evaluation of the high mobility group box 1 as a prognostic biomarker in patients undergoing valvular heart surgery
3010838|NCT02490631|No Intervention|Control Arm|Standard of care pre-operative cleansing with soap and water the night before and morning of surgery
3010839|NCT02490631|Experimental|Intervention Arm|2% chlorhexidine gluconate cloths the night before and morning of surgery
3010840|NCT02490618|Experimental|Test|Probiotic tablet
3010841|NCT02490618|Placebo Comparator|Control|Control tablet
3010842|NCT02490605|Experimental|occlusal plate group|"The sample group will receive an occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides). The occlusal plate will be made from Vacuum Form acetate with a thickness of 1.5 mm; the simultaneous, bilateral, occlusal contacts and the canine and anterior guides will be obtained by way of autopolymerizable, acrylic resin with the mandible in a centric relationship."
3010843|NCT02490605|Active Comparator|therapeutic exercises|The control group will only receive orientation to do physiotherapeutic exercises seeking to correctly position the mandible in the resting position (maxillar teeth should be approximately 2 mm away from the mandibular teeth) while the tip of the tongue is positioned and accommodated on the roof of the mouth over the incisive papilla on the hard palate (without touching the teeth). The exercise will consist of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth, 3 times per day, each period consisting of 3 sets with 15 repetitions.
3010844|NCT02490592|Experimental|G1|Thirty children aged seven to twelve years who had seventy one active white spots lesions in permanent anterior teeth randomly assigned to four or eight weekly intervals applications of fluoride foam, Flúor Care (NaF 1.23%), to verified the activity (visual scores) and the dimensional changes of whit spot lesions (with WHO probe and millimeter ruler), caries Management by Risk Assessment (CAMBRA) and OHI-S (Simplified Oral Hygiene Index) of children.
3010845|NCT02490592|Experimental|G2|Twenty-eight children aged seven to twelve years who had seventy five active white spots lesions in permanent anterior teeth randomly assigned to four or eight weekly intervals applications of fluoride gel, Flugel FFA (NaF 1.23%), to verified the activity (visual scores) and the dimensional changes of whit spot lesions (with WHO probe and millimeter ruler), caries Management by Risk Assessment (CAMBRA) and OHI-S (Simplified Oral Hygiene Index) of children.
3010846|NCT02490579||Facebook Survey Group|"During June, 2015, approximately 1200 women will be recruited through Facebook advertisements targeted at English-speaking women age 18-50 years living in the United States. Advertisements will contain 3 key features: an image, a caption, and ad copy followed by a link to the survey website. Individuals who click on the study link in the advertisement will be redirected to the study's Qualtrics web page where they will take a 15 web-page, multiple choice survey developed by the research team. The survey covers these domains: reaction to video, understanding of core message, self-efficacy around lifestyle behaviors, attitudes, beliefs and intentions regarding vaccination during pregnancy, key health information sources during pregnancy, and demographics."
3010847|NCT02490579||Clinical Survey Group|During June-August, 2015, approximately 500 women will be recruited at routine obstetric visits to the University of Michigan's outpatient clinics. Women who check in for an Ob appointment will be offered the opportunity to participate in an anonymous online survey. Individuals who express interest in participating will be provided with a laptop and headphones and directed to the survey Qualtrics site where they will take a 15 web-page, multiple choice survey developed by the research team. The survey covers these domains: reaction to video, understanding of core message, self-efficacy around lifestyle behaviors, attitudes, beliefs and intentions regarding vaccination during pregnancy, key health information sources during pregnancy, and demographics.
3010848|NCT02490579||Social Network Group|Once a pregnant participant completes the survey, she will be asked to provide her email address. If she is willing to do so, Qualtrics will automatically send her an email containing a weblink to the survey for her social network. She can then provide this link to 1 or 2 social network members that she feels influence her health behaviors during pregnancy. These members are asked similar questions about their response to the video, as well as some additional questions about how they advise their pregnant person about different health topics. It is necessary to provide a unique weblink to her, so that the survey responses from the pregnant woman and her unique social network members can be linked.
3010849|NCT02490566|Experimental|Technology Arm|Tablet computer with chronic disease apps will be given to patients. This tablet will also be used for follow-up visits done via video conferencing. Intervention: Telehealth.
3010850|NCT02490553||Dunkirk area|Representative sample of Dunkirk and the surrounding urban area (of ~200 000inhabitants).Dunkirk area is characterize by high emission of industrial air pollutant
3010851|NCT02490553||Lille area|Representative sample of Lille and the surrounding urban area (of ~1 million inhabitants, the fourth urban area in France)
3010852|NCT02490540|Experimental|Anesthesiologist quided analgesia|Sufentanil anesthesiologist analgesia is based on anesthesiologist decision.
3010853|NCT02490540|Experimental|ANI guided analgesia|Sufentanil ANI analgesia based on ANI analgesia monitor figures.
3010854|NCT02490540|Experimental|SPI guided analgesia|Sufentanil SPI analgesia is based on the SPI analgesia monitor figures.
3010855|NCT02490527|Placebo Comparator|Statin only|The subject will consume simvastatin (40mg) and placebo once daily for 3 months.
3010856|NCT02490527|Experimental|Statin and epicatechin|The subject will consume simvastatin (40mg) and pure epicatechin capsules (50mg) once daily for 3 months.
3010857|NCT02490514||Mircera|Patients with stage III-IV CKD received open-label Mircera for 12 months at a dose to be determined by the investigator.
3010858|NCT02490501|Active Comparator|SC0806|Intervention with SC0806 (implantation of device with FGF1 and peripheral nerves) in addition to rehabilitation
3010859|NCT02490501|Other|Controls|Rehabilitation only
3010860|NCT02490488|Experimental|Masitinib (AB1010)|
3010861|NCT02490488|Active Comparator|Gemcitabine|
3010862|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 100 mg/m^2 (Level 3)|Docetaxel will be administered via intravenous (IV) infusion on Day 1 of each 3-week cycle at a dose of 100 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
3010863|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 60 mg/m^2 (Level 1)|Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 60 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
3010864|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 75 mg/m^2 (Level 2)|Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 75 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
3010865|NCT02490462|Experimental|Education + Conventional PhysicalTherapy|Parents of children with cerebral palsy receive instructions for active inclusion of children in everyday activities. The education program for parents will take place once a week for twelve weeks. Children with Cerebral Palsy make conventional physical therapy twice a week for a period of twelve weeks.
3010866|NCT02490462|Active Comparator|Conventional Physical Therapy|Children with Cerebral Palsy make conventional physical therapy twice a week for a period of twelve weeks.
3010867|NCT02490449|Experimental|Exprerimental group|medication after diet
3010868|NCT02490449|Active Comparator|control group|medication before diet
3010869|NCT02490436|Experimental|A: active drug first|Cetuximab in treatment period 1, placebo in treatment period 2, and open-label cetuximab in treatment period 3.
3010870|NCT02490436|Experimental|B: placebo first|Placebo in treatment period 1, cetuximab in treatment period 2, and open-label cetuximab in treatment period 3.
3010871|NCT02490423|Active Comparator|Nudges Intervention|The intervention arm will employ standard cardiovascular clinical care plus the combination of the MoBe Maps Patient Activation Platform with the Intermountain Risk Score to personalize and deliver motivational nudges to each participant.
3010872|NCT02490423|No Intervention|Standard of Care|The standard of care arm will utilize Intermountain cardiovascular clinical program care processes as they are in place today for treatment of the study subjects.
3010873|NCT02490410|Experimental|whey protein|2 x 10g whey protein per day orally for 6 months
3010874|NCT02490410|Other|whey protein+soy protein|10g whey protein + 10g soy protein per day orally for 6 months
3010875|NCT02490410|Other|soy protein|2 x 10g soy protein per day orally for 6 months
3010876|NCT02490397|Experimental|Exposed to Day light|Patients with myocardial infarction (MI): This group will be enrolled on the day of their MI. A blood draw will be performed before any light therapy. The patients will then receive a light box (Square One Wake Up Light NatureBright 10,000 LUX) that they shall use every morning from 8.30-9.00 AM for the next 2 weeks. At the conclusion of the two weeks another blood sample will be drawn.
3010877|NCT02490397|Sham Comparator|Exposed to Room light|Patients with myocardial infarction (MI): This group will be enrolled on the day of their MI and will only be exposed to room light. They will have blood drawn on the day of enrollment and then at 2 weeks after the MI.
3010878|NCT02490384|Active Comparator|Physical exam indicated cerclage|Cerclage
3010879|NCT02490384|No Intervention|Expectant management|No cerclage
3010880|NCT02490371|Experimental|(1) rTMS- PT Ex Group|"1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse (20 minutes) at 90% resting motor threshold (rMT) will conduct for 10 consecutive sessions (5 days per week for 2 weeks) and immediately followed by 30- minutes structured physiotherapy upper limb training.~After the 10 sessions of brain stimulation, the 30-minute structured physiotherapy upper limb training program will continue for another 12 weeks (2 sessions per week)"
3010881|NCT02490371|Placebo Comparator|(2) Placebo- PT Ex Group|"placebo stimulation over contra-lesional M1 region will be conducted for 10 consecutive sessions (5 sessions per week for 2 weeks) of and immediately followed by 30- minutes of structured physiotherapy upper limb training.~Then, the structured physiotherapy upper limb training will continue for another 12 weeks (2 sessions per week)."
3010882|NCT02490358||1|Healthy smoking subjects
3010883|NCT02490358||2|COPD smoking subjects
3010884|NCT02490358||3|COPD ex-smoker subjects
3010885|NCT02490345|Active Comparator|Gabapentin Administration|gabapentin 600mg orally every 8 hours x 48 hours
3010886|NCT02490345|Placebo Comparator|Placebo|Placebo , 1 tablet, orally every 8 hours x 48 hours
3010887|NCT02490332|Experimental|Ventilation tube treatment|Ventilation tube insertion in the tympanic membrane
3010888|NCT02490332|No Intervention|Conservative treatment|Conventional treatment
3010889|NCT02490319||Group 1|Lung cancer patients treated with thoracic radiation therapy
3010890|NCT02490306|Experimental|Hemorrhagic stroke|"Patient group A is defined as patients that are diagnosed with hemorrhagic stroke.~Interventions: Strokefinder MD100 measurement"
3010891|NCT02490306|Experimental|Ischemic stroke|"Patient group B is defined as patients that are diagnosed with ischemic stroke.~Interventions: Strokefinder MD100 measurement"
3010892|NCT02490306|Experimental|Stroke mimics|"Patient group C is defined as patients with stroke mimics, i.e. with initially suspected stroke but not diagnosed with stroke.~Interventions: Strokefinder MD100 measurement"
3010893|NCT02490293|Experimental|Group A (cephalosporin)|"During the period of hospitalization, intake of active drug ('pacetin', 2nd generation cephalosporin). 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days."
3010894|NCT02490293|Placebo Comparator|Group B (placebo)|"During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days."
3010895|NCT02490280|Experimental|Trier Social Stress Test|Participants will be administered the Trier Social Stress Test (TSST). The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
3010896|NCT02490267||1|children with primary or secondary glaucoma
3010897|NCT02490267||2|children w/ cataract or previously treated for cataract
3010898|NCT02490267||3|children w/ microphthalmia, anophthalmia or coloboma
3010899|NCT02490267||control group|age matched children without eye and vision problems.
3010900|NCT02490254||1|Any child (aged 0-16 years) with a new diagnosis of uni or bilateral uveitis.
3010901|NCT02490228|Other|surgical group|transurethral resection of urethral caruncle
3010902|NCT02490215||ARDS, non-ARDS|patients with ARDS and patients without ARDS
3010903|NCT02490202|Experimental|SANGUINATE|Two (2) infusions of SANGUINATE
3010904|NCT02490202|Placebo Comparator|Normal Saline|Two (2) infusions of Normal Saline
3010905|NCT02490189|Experimental|Mindfulness-Based Intervention|Participants in the mindfulness-based intervention arm will receive 12 weekly sessions of 2 to 2.5 hours duration. The intervention will be delivered in a group format. Participants will be assigned weekly homework.
3010906|NCT02490189|Active Comparator|Cognitive Behavior Group Therapy|Participants in the cognitive behavior group therapy arm will receive 12 weekly sessions of 2 to 2.5 hours in duration. Participants will be assigned weekly homework.
3010907|NCT02490176|Experimental|GLP-1 group|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
3010908|NCT02490176|Placebo Comparator|Control group|drug: placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.
3010909|NCT02490163|Experimental|CMNC|the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow.
3010910|NCT02490163|Active Comparator|MNC|The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure.
3010911|NCT02490150|Experimental|Day 5|Administration of corifollitropin alfa on Day 5 after last oral contraceptive pill in a GnRH antagonist protocol in donors.
3010912|NCT02490150|Active Comparator|Day 7|Administration of corifollitropin alfa on Day 7 after last oral contraceptive pill in a GnRH antagonist protocol in donors.
3010913|NCT02490137|Experimental|Game Players|Participants that will play video game
3010914|NCT02490137|No Intervention|Control|No video game experience
3010915|NCT02490124||Type 1 Diabetic|Type 1 Diabetic
3010916|NCT02490124||Control|normal healthy control
3010917|NCT02490111|Experimental|DWJ1319 300 mg BID|DWJ1319 300 mg, orally, twice daily (BID) for up to 12 months
3010918|NCT02490111|Experimental|DWJ1319 300 mg QD|DWJ1319 300 mg, orally, once daily (QD), and DWJ1319 placebo-matching capsules, orally, once daily for up to 12 months
3010919|NCT02490111|Placebo Comparator|Placebo|Placebo, orally, twice daily (BID) for up to 12 months
3010920|NCT02490098|Active Comparator|Single-hormone closed-loop strategy with full boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
3010943|NCT02490020|Experimental|Routine AMR treatment plus MSC to prevent AMR|Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)+MSC( iv 2*10^6cell/kg at d1,d7)
3013085|NCT02475317|Experimental|SHP626 10mg|5 subjects will receive a high dose of SHP626 (10 mg)
3010921|NCT02490098|Active Comparator|Dual-hormone closed-loop strategy with full boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) and Glucagon (Eli Lilly) will be infused using two separate subcutaneous infusion pumps (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
3010922|NCT02490098|Active Comparator|Single-hormone closed-loop strategy with partial boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). For this strategy, meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO. The meal size assessment will be done by the patient.
3010923|NCT02490098|Active Comparator|Dual-hormone closed-loop strategy with partial boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) and Glucagon (Eli Lilly) will be infused using two separate subcutaneous infusion pumps (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). For this strategy, meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO. The meal size assessment will be done by the patient.
3010924|NCT02490098|Active Comparator|Sensor-augmented pump therapy|Subjects will use sensor-augmented pump therapy and freely implement their usual basal rate and CHO-matching full prandial bolus to regulate glucose levels. Patient's usual fast acting insulin analog will be infused using a subcutaneous insulin infusion pump. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
3010925|NCT02490085|Active Comparator|Multiple daily injections|Subjects will use multiple daily injections to regulate glucose levels. Subject's usual insulin analog will be used.
3010926|NCT02490085|Active Comparator|Closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Subject's usual fast-acting insulin analog will be infused using a subcutaneous infusion pumps (Accu-Chek Combo, Roche). The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer every 10 minutes. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
3010927|NCT02490072|Experimental|Dexmedetomidine group|
3010928|NCT02490072|Placebo Comparator|normal saline|
3010929|NCT02490059|Active Comparator|Standard size bronchoscopy|ll procedures were started using SB with an external diameter of 5.0-6.0 mm with a biopsy channel of 2.2-2.8 mm (models Olympus BF-30 and BF-1T160, Olympus, Tokyo, Japan). If during SB the lesion was endoscopically visible the bronchoscopy was continued as standard diagnostic procedure and the patients were excluded from the analysis. Only if no tumour was visible during complete inspection of the bronchial tree using the SB, a participant was randomised by opening a numbered sealed opaque envelope. Randomisation was performed using sequentially numbered (1-40) sealed opaque envelopes (block randomisation: block size 4). For subjects allocated to the SB group, the examination was immediately continued with the same SB bronchoscope.
3010930|NCT02490059|Experimental|Ultrahin bronchoscopy|For subjects randomised to UB, the instrument was changed immediately to an Olympus BF-XP 40 ultrathin bronchoscope with an outer diameter of 2.8 mm and a working channel 1.2 mm during the same bronchoscopy session.
3010931|NCT02490046|Experimental|MS and rec UTIs not using a catheter|people with multiple sclerosis and recurrent urinary tract infections with spontaneous voiding Intervention- will be given D-mannose
3010932|NCT02490046|Experimental|MS and rec UTIs using a catheter|people with multiple sclerosis and recurrent urinary tract infections using either urethral or suprapubic indwelling catheter or intermittent catheterisation Intervention- will be given D-mannose
3010933|NCT02490033|Other|Contact force unblinded|
3010934|NCT02490033|Other|Contact force blinded|
3010935|NCT02490033|Other|ECI unblinded|
3010936|NCT02490033|Other|ECI blinded|
3010937|NCT02490020|Experimental|iv of BMSC to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC iv(2*10^6cell/kg, 48h before op)
3010938|NCT02490020|No Intervention|routine treatment protocol to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)
3010939|NCT02490020|Experimental|ia and iv of MSC to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC (iv 2*10^6cell/kg + ia 5*10^6cell, 48h before op)
3010940|NCT02490020|No Intervention|routine treatment to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)
3010941|NCT02490020|Experimental|Routine CMR treatment plus MSC to prevent CMR|Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)+MSC( iv 2*10^6cell/kg at d1,d7)
3010942|NCT02490020|No Intervention|Routine CMR treatment to prevent CMR|Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)
3044707|NCT02262624|Active Comparator|Telmisartan and HCTZ monocomponents|
3010944|NCT02490020|No Intervention|Routine AMR treatment to prevent AMR|Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)
3010945|NCT02490007||Allergy Cases|All participants appear on the Australian Childhood Immunisation Register (ACIR) and have received their first pertussis vaccination before the age of 16 weeks. They will have been born during the period of change over from whole cell pertussis vaccine to acellular pertussis vaccine (1997-1999). Allergy case participants have all attended allergy clinics associated with tertiary teaching hospitals. They have confirmed IgE-mediated food allergy as defined by the case description and as ascertained by their medical records.
3010946|NCT02490007||Controls|All participants appear on the Australian Childhood Immunisation Register (ACIR) and have received their first pertussis vaccination before the age of 16 weeks. They will have been born during the period of change over from whole cell pertussis vaccine to acellular pertussis vaccine (1997-1999).
3010947|NCT02489994|Experimental|all subjects|Treatment with the ePrime radiofrequency microneedling device in the upper thighs and buttocks
3010948|NCT02489981||Spiriva|Patients with severe persistent asthma
3010949|NCT02489968|Experimental|empagliflozin 10 mg + linagliptin 5 mg|patient to receive a tablet containing low dose empagliflozin and linagliptin once daily
3010950|NCT02489968|Experimental|empagliflozin 10 mg|patient to receive a tablet containing low dose empagliflozin once daily
3010951|NCT02489968|Experimental|empagliflozin 25 mg + linagliptin 5 mg|patient to receive a tablet containing high dose empagliflozin and linagliptin once daily
3010952|NCT02489968|Experimental|empagliflozin 25 mg|patients to receive a tablet containing high dose empagliflozin once daily
3010953|NCT02489955|Experimental|AUC group|
3010954|NCT02489955|Active Comparator|Trough dose monitoring|
3010955|NCT02489942||Jardiance|Patients with T2DM to receive Jardiance tablets 10 mg, 25 mg
3010956|NCT02489929|Experimental|patient suffering of MDS or Myeloid leukemia|The patients suffering of MDS or Acute myeloid leukemia will be the object of 8 sampling of blood (on tube EDTA) distributed as this: the first day of the usual treatment (azacytidine) at T0, T30 MIN, T60 MIN, T90 MIN, T120 MIN, then a second series of taking in the 5th day of treatment at T0, T30 MIN, T90 MIN to determine cytidine deaminase (CDA) activities by following its plasmatic dosage
3010957|NCT02489916|Experimental|CM4307|CM4307 300mg bid，until disease progression,death, unacceptable toxic eff ects, withdrawal of consent by the patient, or decision by the treating physician that discontinuation would be in the patient's best interest
3010958|NCT02489903|Experimental|Small Lung Cancer (Arm 1)|Arm 1): RRx-001 weekly for 3 weeks followed by up to 6 cycles of platinum doublet chemotherapy and then RRx-001 maintenance (for patients with stable disease (SD) or better at discontinuation of platinum).
3010959|NCT02489903|Experimental|Small Lung Cancer (Arm 2)|Arm 2): RRx-001 weekly for 3 weeks followed by the start of platinum based chemotherapy with RRx-001 given on weeks 2 and 3 of every 3 week cycle during platinum doublet chemotherapy for up to 6 cycles and then RRx-001 maintenance (for patients with stable disease (SD) or better at discontinuation of platinum).
3010960|NCT02489903|Experimental|Non Small Cell Lung Cancer|RRx-001 weekly for 3 weeks followed by up to 6 cycles of platinum doublet chemotherapy and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).
3010961|NCT02489903|Experimental|Neuroendocrine tumors|RRx-001 weekly until progression followed by up to 6 cycles of platinum doublet chemotherapy and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).
3010962|NCT02489903|Experimental|Ovarian epithelial cancer|RRx-001 weekly for 3 weeks followed by up to 6 cycles of platinum doublet chemotherapy and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).
3010963|NCT02489890|No Intervention|Non-CIK|After accepting chemotherapy, patients will regularly follow up.
3010964|NCT02489890|Experimental|CIK|After accepting chemotherapy, patients will receive at least 3 cycles of Cytokine-induced Killer Cells treatment per year.
3010965|NCT02489877||Multiple Sclerosis|Patients diagnosed with Multiple Sclerosis
3010966|NCT02489877||without Multiple Sclerosis|Healthy individuals without neurological disease associated
3010967|NCT02489877||with other neurological diseases|Patients diagnosed with the following diseases: Lateral Amniotrofic Sclerosis, Headache , Parkinson's disease, Dementia and Epilepsy.
3010968|NCT02489864|Active Comparator|Terlipressin and albumin|"Patients in this group received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour.~albumin (Albumin 20 percent; Instituto Grífols, Barcelona, Spain) was given at a dose of 10 gram per day."
3010969|NCT02489864|Placebo Comparator|Albumin|Only albumin (Albumin 20 percent; Instituto Grífols, Barcelona, Spain) was given at a dose of 10 gram per day.
3010970|NCT02489851|Active Comparator|Quadratus Lumborum block group|"Quadratus Lumborum block group (QL)~patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%"
3010971|NCT02489851|Active Comparator|Transversus abdominis plane block group|"Transversus abdominis plane block (TAP)~patients will receive a bilateral TAP block using Bupivicaine 0.125%"
3010972|NCT02489825|Other|Augmentation vertebroplasty|Single level fracture fixation with vertebroplasty
3010973|NCT02489825|Other|Augmentation and prophylactic vertebroplasty|Triple level augmentation with VP fixation of the fracture and additional prophylactic vertebroplasty in both the adjacent levels
3010974|NCT02489812|Experimental|music|The Mozart Symphony No 40 in G minor K550 was played in headphones. While the child received restorative treatment in the teeth she heard music in a session and was subjected to other dental treatment session without listening to music. The cardiac and respiratory frequencies were measured with children's finger oximeter while the child listened to music and also in session in which she did not hear music. Changes in the measurements obtained by the oximeter showed levels of anxiety.
3010975|NCT02489799|Active Comparator|Intervention|Advance care planning video
3010976|NCT02489799|Placebo Comparator|Control|Control video - no advance care planning content
3010977|NCT02489786|Active Comparator|Regimen 1|patient takes 0.25mg of digoxin daily except friday
3010978|NCT02489786|Active Comparator|Regimen 2|patient takes 0.25mg of digoxin daily except Thursday and Friday
3010980|NCT02489786|Active Comparator|Regimen 4|digoxin dose is calculated using Jusko-Koup method and given daily
3010981|NCT02489760|Experimental|Adalimumab switch to Etanercept|At week 8, the treatment arm will be switched to etanercept 25 mg subcutaneously biweekly for another 8 weeks.
3010982|NCT02489760|Experimental|Etanercept switch to Adalimumab|At week 8, the control arm will be switched to adalimumab 40 mg subcutaneously biweekly for another 8 weeks.
3010983|NCT02489747|Experimental|WBE group|wheat bran extract
3010984|NCT02489747|Placebo Comparator|Placebo group|placebo
3010985|NCT02489734|Experimental|low concentration (LC)|low concentration group
3010986|NCT02489734|Experimental|high concentration (HC)|high concentration group
3010987|NCT02489708|Experimental|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
3010988|NCT02489695|Experimental|axitinib|axitinib 10mg twice a day
3010989|NCT02489682|Experimental|Informed Consent Format - short written|"Intervention to be administered:~- Short-form written informed consent information, followed immediately by outcomes questionnaire"
3010990|NCT02489682|Experimental|Informed Consent Format - long written|"Intervention to be administered:~- Long-form written informed consent information, followed immediately by outcomes questionnaire"
3010991|NCT02489682|Experimental|Informed Consent Format - video|"Intervention to be administered:~- Video informed consent information, followed immediately by outcomes questionnaire"
3010992|NCT02489669|No Intervention|LVEDP-guided group|Patients allocated to the LVEDP-guided group will continue to receive intravenous 0.9% sodium chloride, according to the protocol suggested in the POSEIDON trial (that is, 5 mL/kg/hr for LVEDP ≤12 mmHg; 3 mL/kg/hr for 13-18 mmHg; and 1.5 mL/kg/h for >18 mmHg). The fluid rate will be eventually modified at the start of the procedure in case of discordance between non-invasive and invasive LVEDP pressure estimate, being the invasive value considered as gold-standard. The fluid rate will continued during the procedure, and for 4 hours post-procedure.
3010993|NCT02489669|Experimental|Renalguard group|Patients enrolled in this group will be treated by hydration with 0.9% saline controlled by the RenalGuard system. On top of the 1.5-5.0 ml/kg/h that patients would have received over the previous hour (according to the non-invasive estimate LVEDP), an initial bolus of 250 ml will be administered. In case of LV ejection fraction ≤30% and/or LVEDP >18 mm Hg the bolus will 150 mL. Therefore, furosemide (0.25 mg/kg) will be administered in order to achieve the optimal urine flow rate (≥300 mL/h). The controlled hydration by the RenalGuard system will be continued during the procedure and for 4 hours following the procedure. Urine flow rate is monitored and maintained at the target value through the procedure and during the following 4 hours. Additional furosemide doses are allowed in case of decrease of the urine flow rate below the target value.
3010994|NCT02489656|Experimental|Coloplast Hydrocoated silicone JJ stent|Double loop ureteral stent endoscopic placement
3010995|NCT02489656|Active Comparator|Boston Percuflex Plus JJ stent|Double loop ureteral stent endoscopic placement
3010996|NCT02489643|Experimental|Receiving training|Patients will be visited and receive information about the prescribed topical treatment according to the normal course and procedure of an outpatient visit at our institution. At the end of the visit, they will also receive practical instructions on dosages and application modalities of the topical therapy.
3010997|NCT02489643|No Intervention|No-receiving training|
3010998|NCT02489630|Experimental|Ketamine|0.1 mg/kg ketamine + opiate analgesic
3010999|NCT02489630|Placebo Comparator|Placebo|0.1 mL/kg normal saline + opiate analgesic
3011000|NCT02489617|Experimental|Pathologic evaluation of excised tissue|"Patient diagnosed with intraductal papilloma without atypia (IPWA) or flat epithelial atypia (FEA).~-- Pathologic evaluation of excised tissue"
3011001|NCT02489604|Experimental|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE 25.9 GBq activity. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
3011002|NCT02489604|Experimental|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE 18.5 GBq activity. Total activity of 18.5 GBq 100 mCi for 5 cycles, every 6 ± 2 weeks (500 mCi)
3011003|NCT02489591|No Intervention|Control|No oral appliance (control) first, oral appliance (BluePro oral appliance or other device) second
3011004|NCT02489591|Experimental|Oral appliance|oral appliance (BluePro oral appliance or other device) first, no oral appliance (control) second
3011005|NCT02489565|No Intervention|Tertiary care|Outpatient from tertiary care with discharge criteria who remains in the tertiary care.
3011006|NCT02489565|Experimental|Primary care|Outpatient discharge from tertiary care to a primary care near the patient's home with the support of telemedicine.
3011007|NCT02489539|Experimental|Short Neck Substudy|Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation ≤ 60˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
3011008|NCT02489539|Experimental|High Neck Angulation Substudy|Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation > 60˚ and ≤ 90˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
3011009|NCT02489526|Active Comparator|VVZ-149 Injections|Following the measurement of each subject's baseline pain intensity, the experimental group will receive a 1.8 mg/kg VVZ-149 intravenous infusion for 0.5 hour. This loading dose will be followed by the maintenance dose of an intravenous VVZ-149 infusion of 1.3 mg/kg/hr for 7.5 hours.
3011010|NCT02489526|Placebo Comparator|Placebo|The placebo group will be administered the corresponding volume of placebo for the proscribed time of the study.
3011011|NCT02489513|Other|Single group assignment|[14C]-AG-120
3011012|NCT02489500|Active Comparator|melphalan|Neupogen 16mcg/kg x 4 days Stem cell collection Drug: high dose melphalan 140 or 200 mg/m2 stem cell infusion
3011013|NCT02489500|Experimental|melphalan + Bortezomib|Neupogen 16mcg/kg x 4 days Stem Cell collection drug: high-dose melphalan 140 or 200 mg/m2 drug: Bortezomib 1.0 mg/m2/dose x 4 doses stem cell infusion
3011014|NCT02489487|Experimental|VM-1500 + Raltegravir|VM-1500 40 mg in combination with 400 mg Raltegravir
3011015|NCT02489487|Experimental|VM-1500 +Darunavir|VM-1500 40 mg in combination with 600 mg Darunavir boosted with 100 mg Ritonavir
3011016|NCT02489487|Experimental|VM-1500|VM-1500 40 mg alone
3044708|NCT02262611||Hypertension patients - Pneumology|
3011017|NCT02489474||Recipients undergoing liver transplantation|Patients undergoing liver transplantation will be included and followed up during the first 72 hours post-liver transplantation in order to confirm the development of acute kidney injury. The patients will be divided into two groups (AKI group vs. non-AKI group) according to the development of acute kidney injury.
3011018|NCT02489461|Experimental|VM-1500 20 mg (Stage I)|VM-1500 20 mg
3011019|NCT02489461|Experimental|VM-1500 40 mg (Stage I)|VM-1500 40 mg
3011020|NCT02489461|Active Comparator|Efavirenz 600 mg (Stage I and Stage II)|Efavirenz 600 mg
3011021|NCT02489461|Experimental|VM-1500 (optima dose) (Stage II)|VM-1500 (optimal dose)
3011022|NCT02489448|Experimental|MEDI4736|"The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments."
3011023|NCT02489435|Experimental|10 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
3011024|NCT02489435|Experimental|20 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
3011025|NCT02489435|Experimental|30 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
3011026|NCT02489422|Experimental|Group I (Yoga Skills Training)|Patients participate in YST consisting of four 30 minute in-person yoga sessions at weeks 2, 4, 6, and 8 that instructs skills to enhance mindfulness and promote relaxation, through instruction of awareness, movement, breathing practices, and meditation.
3011027|NCT02489422|Active Comparator|Group II (Attention Control)|Patients participate in four 30 minute in-person sessions of supportive conversation at weeks 2, 4, 6, 8.
3011028|NCT02489409|Experimental|Experimental group|Gemcitabine (Gem): 1.0 m/m2, iv 0.5h, d1, 8; Navelbine (NVB): 40 mg/d, iv, d1, 8; Platinum (DDP): 30 mg/m2, iv 3h, d1-3; Xeloda Tablets: 2 000 mg/m2, po, d1-14; EndostarTM Injection: 210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h).
3011029|NCT02489409|Active Comparator|Control group|Gemcitabine (Gem): 1.0 m/m2, iv 0.5h, d1, 8; Navelbine (NVB): 40 mg/d, iv, d1, 8; Platinum (DDP): 30 mg/m2, iv 3h, d1-3; Xeloda Tablets: 2 000 mg/m2, po, d1-14.
3011030|NCT02489396||Grocery Customers|All customers who shop on the Rosie site during the intervention period.
3011031|NCT02489383|Active Comparator|Continuous Exercise Training|The interventions of active comparator will be education program and exercise training.
3011032|NCT02489383|Active Comparator|Interval Exercise Training|The interventions of active comparator will be education program and exercise training.
3011033|NCT02489370|Experimental|Telemonitoring (intervention)|"an intervention arm testing the proposed telemonitoring service and a control arm with the current treatment.~Patients assigned to the intervention arm receive a home telemonitoring kit consisting of a tablet, a wireless weight scale and a portable blood pressure meter. The patient is asked to weigh him- or herself every day and the monitoring procedure happens as previously described. In addition a measurement of the blood pressure is also made."
3011034|NCT02489370|No Intervention|Usual care (control)|Patients assigned to the control arm receive treatment as usual, consisting of a recommendation to weigh themselves at home, using their own weight scale, and to report by phone to the polyclinic if there is a significant change in weight.
3011035|NCT02489357|Experimental|Treatment (pembrolizumab, cryosurgery)|Patients receive standard of care degarelix SC once a month for 8 months. Within 1 month of receiving degarelix, patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Within 3 days of receiving pembrolizumab, patients undergo whole gland cryoablation of the prostate.
3011036|NCT02489344|Experimental|GZ/SAR402671|GZ/SAR402671 - Administered once a day, orally for 30 months
3011037|NCT02489318|Experimental|Apalutamide plus ADT|Participants will receive apalutamide 240 milligram (mg) (4X 60 mg tablets) with ADT.
3011038|NCT02489318|Experimental|Placebo plus ADT|Participants will receive matching Placebo with ADT.
3011039|NCT02489305||Participants With Major Depressive Disorder|Participants with major depressive disorder who have responded to oral antidepressant treatment will be observed over time.
3011040|NCT02489292|Experimental|HepaStem|Target total dose 50x10E6 cells/kg
3011041|NCT02489279|Experimental|Active|Behavioral training with the Attentional Intelligence Method mobile software to increase sustained attention skills and self-awareness of attention control.
3011042|NCT02489279|Active Comparator|Control|"Behavioral training with the mobile software game Scrabble to increase concentration."
3011043|NCT02489266|Experimental|Arm 1|Patients will receive cyclophosphamide and fludarabine followed by infusion of the AKTi-treated TIL, followed by high dose aldesleukin.
3011044|NCT02489253||polygenic hypercholesterolemia|patients with high cholesterol level where no mutation was found in their FH-causing genes and had to gene score in their six LDL-C raising gene score undergo a carotid ultrasound, a CT coronary angiogram and a blood test
3011045|NCT02489253||monogenic FH|patients with a mutation in FH-causing gene undergo a carotid ultrasound, a CT coronary angiogram and a blood test
3011046|NCT02489240|Experimental|Vitamin D supplementation group|drug: vitamin D3 tablets (Vigantoletten; Merck Pharma, Germany); the frequency: 2000 IU vitamin D3 tablets were taken daily; duration: study treatment was commenced 3 days before intervention and maintained for 3 days after the procedure.
3011047|NCT02489240|Placebo Comparator|Control group|drug: placebo tablets; the frequency: 2000 IU placebo tablets were taken daily; duration: study treatment was commenced 3 days before intervention and maintained for 3 days after the procedure.
3011048|NCT02489227|Active Comparator|Humira (adalimumab)|Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be reassigned (1:1) to CHS-1420 or continue adalimumab treatment, 1 dose every 2 weeks for weeks 17-23. At week 24 subjects will switch to CHS-1420 open label until study end.
3011049|NCT02489227|Experimental|CHS-1420|CHS-1420 40mg 2 doses at Week 0/Day 0 then 1 dose every 2 weeks starting at Week 1 for 23 weeks. At Week 24 subjects will continue on to CHS-1420 open label until study end.
3011050|NCT02489214|Experimental|donafenib tosilate tablets|200mg bid
3011051|NCT02489201|Experimental|donafenib tosilate tablets|200mg bid
3011055|NCT02489188||lumbar spinal stenosis|patients with lumbar spinal stenosis scheduled for lumbar spinal stenosis decompression
3011056|NCT02489188||muscle contracture|patients with functionally limited range of motion at the knee because of muscle contracture scheduled for manual therapy
3011057|NCT02489188||healthy subjects|healthy subjects
3011058|NCT02489175|Experimental|Stomaplasty KoringTM group|The KoringTM is a stomaplasty ring made of propylene, flexible and non-absorbable. It is fixed to the anterior sheath of the abdominal wall in order to prevent PSH.
3011059|NCT02489175|No Intervention|No preventive measure|In these patients, the stoma creation will be traditional, with no mesh implanted
3011060|NCT02489162|Experimental|MyotonPRO|Experimental: Measurement of biomechanical properties of mimic muscles on the ipsilateral palsy side with the healthy contralateral side ( case - control design)
3011061|NCT02489162|Active Comparator|Non-invasive electromyography (EMG)|Comparing experimental intervention with gold standard
3011062|NCT02489149|Experimental|Multi-sector interventions|"Multi-sector interventions~Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.~For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.~For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.~Helping families to have more knowledge about your citizen rights."
3011063|NCT02489149|Placebo Comparator|Control|Conventional approach of current public food and nutrition policies.
3011064|NCT02489136|Other|Spirit Pass|It is a transfusion of psychic energies. Laying of hands to be in front of the incubator or on bed, at a distance at around 10 to 15 cm, during 10 minutes. Evaluate the effects of spirit passe in newborn and adults before and after ten minutes for 3 days.
3011065|NCT02489136|Placebo Comparator|laying of hands by workes|Laying of hand by workers and volunteers, not belonging to Spiritism.Laying of hands to be in front of the incubator or on bed, at a distance at around 10 to 15 cm, during 10 minutes. Evaluate the effects of spirit passe in newborn and adults before and after ten minutes for 3 days.
3011066|NCT02489136|No Intervention|No intervention|No intervention during, in adults before and after ten minutes for 3 days.
3011067|NCT02489123|Experimental|Treatment (enzalutamide)|Patients receive enzalutamide PO QD. Courses 1-3 repeat every 4 weeks (28 days) and subsequent courses repeat every 12 weeks (84 days) in the absence of disease progression or unacceptable toxicity.
3011068|NCT02489110|Experimental|Webnovela|Caregivers will watch the Webnovela and read related information. The Webnovela is a short online Telenovela in Spanish, specifically designed for Hispanic caregivers on how to cope with dementia caregiving. A DVD will be available to participants without Internet access.
3011069|NCT02489110|Active Comparator|Control|Caregivers will be directed to existing web sites, such as NIA Alzheimer's and Dementia Resources in Spanish. Participants will receive related materials in Spanish language.
3011070|NCT02489097|Active Comparator|Nitrous Oxide|Receives a mixture of 70% Nitrous Oxide in 30% Oxygen
3011071|NCT02489097|Placebo Comparator|Air/Oxygen (placebo)|Receives a mixture of 70% Air in 30% Oxygen
3011072|NCT02489071|Experimental|Brain Training|8-session cognitive training program
3011073|NCT02489071|Experimental|Brain Health|8-session cognitive education program
3011074|NCT02489071|No Intervention|Control|Wait-list control group
3011075|NCT02489045|Experimental|SHAPE measurement|48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
3011076|NCT02489032|Experimental|SBIRT Training & Support Tool|The SBIRT Training & Support Tool has two components, both of which will be evaluated: (1) online SBIRT Training for EAP and behavioral health practitioners conducting alcohol SBIRT with their adult clients and (2) mobile/web interactive alcohol screening tools and brief intervention protocols to facilitate use of SBIRT by practitioners.
3011077|NCT02489032|Other|Waitlist control|Subjects randomized to the control condition will be placed on a wait-list and given access to the SBIRT Training & Support Tool after 3 months and completion of the 3-month follow-up assessment.
3011078|NCT02489019|Placebo Comparator|Control|Individuals assigned to this condition will receive 0.9 mcg/kg sodium chloride (NaCL)
3011079|NCT02489019|Experimental|Low Dose|Individuals assigned to this condition will receive 1 mcg/kg fentanyl
3011080|NCT02489019|Experimental|High Dose|Individuals assigned to this condition will receive 2 mcg/kg fentanyl
3011081|NCT02489006|Experimental|Olaparib Prior to Surgery, Chemotherapy/Olaparib Post Surgery|"Olaparib, orally, at 300 mg twice per day, for 6 weeks (+/- 2 weeks) prior to surgery.~Platinum-based chemotherapy chosen by the study doctor and per standard of care after surgery.~Olaparib, orally, at 300 mg twice per day, continuously, after chemotherapy."
3011082|NCT02489006|Experimental|Olaparib Prior to Surgery and Post Surgery|Olaparib, orally, at 300 mg twice per day, for 6 weeks (+/- 2 weeks) prior to surgery and after surgery.
3011083|NCT02488993||Prospective Phase Rifaximin-α 550mg|Prospective data collection of patients treated with Rifaximin-α 550mg from point of study entry.
3011084|NCT02488993||Prospective Phase No Rifaximin-α 550mg|Prospective data collection of patients NOT treated with Rifaximin-α 550mg from point of study entry.
3011085|NCT02488993||Retrospective Phase|Review of medical records and electronic hospital admissions data for patients with HE who have not received Rifaximin-α 550mg within the previous 12 months.
3011086|NCT02488980|Experimental|Tafenoquine|Tafenoquine 200 mg for three days followed by Tafenoquine 200 once a week for 24 weeks.
3011087|NCT02488980|Active Comparator|Mefloquine|Mefloquine 250 mg for three days followed by Mefloquine 250 once a week for 24 weeks.
3011088|NCT02488980|Placebo Comparator|Placebo|Placebo
3011089|NCT02488967|Active Comparator|Arm I (AC-->WP)|Patients receive doxorubicin hydrochloride IV over 15 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive paclitaxel IV over 60 minutes on day 1. Treatment repeats weekly for 12 courses in the absence of disease progression or unacceptable toxicity.
3044709|NCT02262611||Hypertension patients - Cardiology|
3011090|NCT02488967|Experimental|Arm II (AC-->WP + carboplatin)|Patients receive doxorubicin hydrochloride and cyclophosphamide as in Arm I. Patients then receive paclitaxel IV over 60 minutes on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
3011091|NCT02488954|Experimental|Probiotics|Oral daily take of probiotics in the form of cheese portion (50g) during 8 weeks
3011092|NCT02488915|Experimental|EmboTrap® Revascularization Device|Mechanical Thrombectomy with EmboTrap
3011093|NCT02488902|Placebo Comparator|Placebo|Placebo was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
3011094|NCT02488902|Experimental|Tafenoquine 25mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
3011095|NCT02488902|Experimental|Tafenoquine 50mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
3011096|NCT02488902|Experimental|Tafenoquine 100 mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
3011097|NCT02488902|Experimental|Tafenoquine 200 mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
3011098|NCT02488902|Experimental|Mefloquine 250 mg|Mefloquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
3011099|NCT02488889|Active Comparator|Varenicline vs placebo|Participants will be titrated on varenicline as follows: days 1-3, .5 mg per day; days 4-7, .5 mg twice per day, and days 7-12, 1 mg twice per day. Placebo and varenicline pills will be matched in number of pills and packaging of active medications.
3011100|NCT02488889|Active Comparator|Alcohol beverage vs. placebo beverage|During each experimental session, participants will ingest a beverage containing placebo (0.0 g/kg; 1% volume of ethanol as taste mask) or alcohol (0.8 g/kg). The beverage will be administered in clear plastic-lidded cups in 2 equal portions that will be consumed during a 5-minute interval and separated by a 5-minute interim rest. The beverages will contain 190-proof ethanol prepared with water, flavored drink mix, and a sucralose-based sugar substitute. Doses for women will be 85% of those of men to adjust for sex differences in total body water.
3011101|NCT02488863||Older Adults with Musculoskeletal Pain|Older adults (60+ years old) experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
3011102|NCT02488863||Older Adults without Musculoskeletal Pain|Older adults (60+ years old) not experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
3011103|NCT02488863||Young Controls|Healthy young adults (18-25 years old) not experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
3011104|NCT02488850|Active Comparator|Surgery|An anatomical surgical resection of primary tumor
3011105|NCT02488850|Active Comparator|Radiotherapy|Stereotactic Ablative Radiotherapy (SABR), outpatient treatment that is typically delivered in between 3-8 fractions
3011106|NCT02488837||DBS subjects|deep brain stimulation (DBS) in patients with Parkinson's disease, tremor, dystonia, and Tourette's syndrome
3011107|NCT02488824|Experimental|Warm Temperature Exposure in Tetraplegia|Subjects are persons with higher-level spinal cord injury, levels C3 to T4, and ASIA Impairment Scale (AIS) level A and B, ages 18-68 years. Procedure is exposure to warm temperature (95� F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance
3011108|NCT02488824|Active Comparator|Warm Temperature Exposure in Able-Bodied|Subjects are able-bodied controls matched with participants with tetraplegia for age and gender. Procedure is exposure to warm temperature (95� F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance
3011109|NCT02488798||postmenopausal bleeding group|"100 women with postmenopausal bleeding undergoing 2D greyscale vaginal ultrasound and 3D Endometrial power Doppler and the features were classified using six different vascular patterns described by IETA group including the following patterns; single dominant vessel without branching, with branching, multiple vessels with focal origin, with multifocal origin at the myometrium-endometrium junction, scattered vessels or circular flow (Kucur et al., 2013 ).~All patients then had Office hysteroscopy carried out in the outpatient clinic using vaginoscopic approach (Cooper et al., 2010). With endometrial samples from lesions or from the cavity for histopathological analysis."
3011110|NCT02488785|No Intervention|Control|Patients in this group will attend regular clinical and education appointments as offered by the clinic for their diabetes care.
3011111|NCT02488785|Experimental|Intervention|Patients in this group will be part of a Virtual Diabetes Self-Care and Education Program. They will receive a phone to communicate with a diabetes educator for 6 months. They will connect with the diabetes educator for weekly video conferences of up to 30 minutes for twelve consecutive weeks, followed by 7 phone calls. Additionally, they will receive a weekly text message about diabetes for 6 months.
3011112|NCT02488772|Experimental|Treatment Group|Patients allocated to treatment group will be supplied with sleep interventions (sleep mask and ear plugs), and standardized instructions of use.
3011113|NCT02488772|Active Comparator|Control Group|Patients allocated to control group will be assessed for sleep quality, but not offered sleep mask and ear plugs. They will receive standard of care as decided by treating emergency physician.
3011114|NCT02488759|Experimental|Neoadjuvant Cohort|"Nivolumab intravenous infusion as specified~**Not participating: Japan, Korea, and Taiwan"
3011115|NCT02488759|Experimental|Metastatic Monotherapy Cohort|Nivolumab intravenous infusion as specified
3011116|NCT02488759|Experimental|Nivolumab plus Ipilimumab Cohort|"Nivolumab intravenous infusion as specified with Ipilimumab intravenous infusion as specified~**Not participating: Belgium, France and Germany"
3011117|NCT02488759|Experimental|Nivolumab plus Relatlimab Cohort|"Nivolumab intravenous infusion as specified with Relatlimab intravenous infusion as specified~** Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands~Enrollment is closed for this arm"
3011118|NCT02488759|Experimental|Nivolumab plus Daratumumab Cohort|"Nivolumab intravenous infusion as specified with Daratumumab intravenous infusion as specified~**Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands"
3011119|NCT02488746||EFTR-GERDX|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
3011120|NCT02488733|Experimental|Laparoscopic Sleeve Gastrectomy (LSG)|In addition to conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines.
3011121|NCT02488733|Other|Conventional medical therapy (CMT)|CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss.
3011122|NCT02488720||Clinically normal older inviduals|500 clinically normal older individuals with florbetapir positron emission tomography (PET) scan that does not show evidence of brain amyloid pathology at screening.
3011123|NCT02488707|Active Comparator|LISR group|Cases which undergo rectal resection with laparoscopic intersphincteric resection.
3011124|NCT02488707|Active Comparator|TAMIS Group|Cases with rectal cancer which undergo Transanal minimally invasive Total mesorectal excision.
3011125|NCT02488694|Experimental|Arm A: Afatinib|105 patients to be treated with afatinib
3011126|NCT02488694|Active Comparator|Arm B: Pemetrexed|105 patients to be treated with pemetrexed
3011127|NCT02488681|Experimental|Micra Pacemaker Implant|Micra Pacemaker Implant
3011128|NCT02488668|Experimental|Surface Electrical Stimulation|Please see information under 'Detailed description'
3011129|NCT02488655|Experimental|Echopulse|Echopulse HIFU
3011130|NCT02488642|Experimental|isosorbide dinitrate-oxytocin|"Preinduction with isosorbide dinitrate gel solution (80 mg/1.5 mL) were administered in the posterior fornix every 3 hours. Once a Bishop score of over 7 was reached, oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.~If the cervical conditions (<7 Bishop Score) did not change after the treatment application, a new dose, without exceeding 4 doses, to facilitate cervical ripening."
3011131|NCT02488642|Placebo Comparator|misoprostol-oxytocin|"Preinduction with misoprostol gel solution (100 mcg/1.5 mL) were administered in the posterior fornix every 3 hours. Once a Bishop score of over 7 was reached, oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.~If the cervical conditions (<7 Bishop score) did not change after the treatment application, participants received a new dose, without exceeding 4 doses, to facilitate cervical ripening."
3011132|NCT02488629|Experimental|SCB01A|This study is a single arm, open-label, Phase II trial
3011133|NCT02488616|Active Comparator|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
3011134|NCT02488616|Active Comparator|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
3011135|NCT02488603|Experimental|Decision aids|
3011136|NCT02488603|No Intervention|usual care|
3011137|NCT02488590||CHRONIC OBSTRUCTIVE PULMONARY DISEASE|"Patients with an obstructive spirometry and characteristics of chronic obstructive pulmonary disease~Clinical intervention:~Long acting B agonist (LABA) + Long acting muscarinic receptor antagonist (LAMA) inhaled therapy"
3011138|NCT02488590||ASTHMA|"patients with asthma and a normal spirometry~Clinical intervention: Inhaled corticosteroids (ICS)"
3011139|NCT02488590||ASTHMA COPD OVERLAP SYNDROME|"patients with an obstructive spirometry and characteristics of both COPD and Asthma~Clinical Intervention: LABA + LAMA + ICS"
3011140|NCT02488590||OBSTRUCTIVE ASTHMA|"patients with an obstructive spirometry and characteristics of asthma~Clinical Intervention: LABA + ICS inhaled therapy"
3011141|NCT02488590||OTHER|"patients with another diagnosis or healthy persons~clinical Intervention: undefined - according to diagnosis"
3011142|NCT02488577|Active Comparator|TAMIS TME|T2 N0 Cases which undergo transanal minimally invasive total mesorectal excision.
3011143|NCT02488577|Active Comparator|TAMIS-Local|T2 N0 Cases which will undergo transanal minimally invasive locoregional resection.
3011144|NCT02488564|Experimental|Liposomal doxorubicin +Docetaxel+Trastuzumab+Metformin|"Day 1: Liposome-encapsulated doxorubicin, 50 mg/m2 IV 1 hour infusion; Day 2 and 9: Docetaxel, 30 mg/m2 IV 1 hour infusion; Day 2, 9 and 16: Trastuzumab 4 mg/kg for the first infusion loading dose, then 2 mg/kg/week for subsequent injections.~Day -13 to 0: Metformin is administered as single agent. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10 Metformin 1000 mg will be administered twice a day continuously until end of the study treatment."
3011145|NCT02488551|Experimental|CALM Tools for Living - computer|This intervention includes the delivery of CALM via computer
3011146|NCT02488551|Active Comparator|CALM Tools for Living - manual|This intervention includes the delivery of CALM delivered manual
3011147|NCT02488538|Active Comparator|Combined oral contraceptives and Fuoxetine|Group 1 will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® ScheringAG, Egypt) daily for 21 days starting from the 3rd day of menstruation in addition to oral fluoxetine 20 mg daily. .
3011148|NCT02488538|Active Comparator|Combined oral contraceptives|Group 2 will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine
3011149|NCT02488538|Placebo Comparator|Placebo|Group 3 will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine.
3011150|NCT02488525|Experimental|Wilfactin|Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
3011151|NCT02488525|No Intervention|Control|The control group will receive all treatments according to standard of care which does not include prophylactic administration of Wilfactin®
3011152|NCT02488512|Experimental|90Y-DOTATOC|90Y-DOTATOC
3011153|NCT02488499|Active Comparator|Individualized Treatment|Individualized Treatment: 15 sessions of individualized treatment (i.e., parent-child) that target areas of presenting concern identified during assessment. These may include social problem-solving, emotion regulation, parent-child difficulties.
3011154|NCT02488499|Experimental|Coping Power|Coping Power: 15 sessions of concurrent parent and child group treatment. The child group focuses on developing problem-solving and emotion regulation skills. The parent group focuses on developing parenting skills and problem-solving strategies to manage and reduce their children's disruptive behaviour.
3011155|NCT02488486|Experimental|Automated postoperative sedation|Postoperative sedation is provided automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 40 and 60.
3011156|NCT02488473|Experimental|Ropivacaine + Dexmedetomidine|Adductor Canal Block 20 ml Ropivacaine 5mg/ml + 1 ml Dexmedetomidine 100ug/ml
3011157|NCT02488473|Placebo Comparator|Ropivacaine + Placebo|Adductor Canal Block 20 ml Ropivacaine 5mg/ml + 1 ml Saline
3011158|NCT02488460|No Intervention|Normal math|This arm serves as the control group receiving regular math lessons
3011159|NCT02488460|Experimental|Active math|This arm serves as the intervention group receiving physically active math lessons
3011160|NCT02488434|Active Comparator|fertile chip|sperm selection by using fertile chip and conventional methods
3011161|NCT02488434|No Intervention|classical ICSI procedure|unexplained infertile couples who will be undertaken intracytoplasmic sperm injection (ICSI) for fertilisation
3011162|NCT02488421||Patient treated with Apixaban|
3011163|NCT02488421||Patient treated with Rivaroxaban|
3011164|NCT02488421||Patient treated with Dabigatran|
3011165|NCT02488421||Patient treated with vitamin K antagonists|
3011166|NCT02488408|Experimental|Part A|To identify the maximum tolerated dose (MTD) of BGB324 in patients with relapsed or refractory AML following treatment with cytotoxic chemotherapy or a targeted or biologic agent, or in patients with high risk MDS (Norway only).
3011167|NCT02488408|Experimental|Part B|"To identify the safety and tolerability of BGB324:~as a single agent in patients with AML who are unsuitable for intensive chemotherapy~in a combination with cytarabine in patients with AML who are unsuitable for intensive chemotherapy~in a combination with decitabine in patients with AML who are unsuitable for intensive chemotherapy (US only)~as a single agent in patients with previously treated MDS (US Only) or in patients with high/intermediate (int-2) risk MDS (Norway Only)"
3011168|NCT02488395||de novo Parkinson's patients|"This group includes de novo Parkinson's patients who have just been diagnosed and not started their treatment at the inclusion.~This group will perform three fMRI sessions at different crucial steps of their normal follow up with a neurologist. Their visual abilities will be tested with an ophthalmologic evaluation and their sensitivity to contrast with a visual psycho-physics test."
3011169|NCT02488395||matching controls|"This group includes age-matching control participants to the first Parkinson group.~This group will perform one fMRI session. Their visual abilities will be tested with an ophthalmologic evaluation and their sensitivity to contrast with a visual psycho-physics test."
3011170|NCT02488382|Experimental|Lonquek|treatment with Lonquek for autologous stem cell collection
3011171|NCT02488369|Experimental|Patients with non-Hodgkin's lymphoma|
3011172|NCT02488356|Experimental|Litramine|Patented fibre complex from Opuntia ficus-indica (Litramine)
3011173|NCT02488356|Placebo Comparator|Placebo|Inert fillers that is manufactured to look and taste the same as verum
3011174|NCT02488343|Experimental|Behavioral Intervention|Participants in this group will receive tailored psychological intervention to promote adherence to their drug therapy.
3011175|NCT02488343|No Intervention|Non Intervention group|Participants in this group will be observed but will not receive any intervention.
3011176|NCT02488330|Experimental|Control and/or Onartuzumab treatment|Participants will receive treatment with either the control treatment (erlotinib, bevacizumab) and/or onartuzumab-based study treatment (as during their P-trial) until progression of disease, unacceptable treatment related toxicity, withdrawal of consent, or death (whichever occurs first). All participants will continue on the same dose and schedule of control treatment as specified in their respective P-trial. The dose of onartuzumab will be calculated based on the participant's weight at the screening visit for the E-trial.
3011177|NCT02488317|Other|Intervention arm|These patients will receive the decision aid tool. Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
3011178|NCT02488317|No Intervention|Control arm|These patients will not receive the decision aid tool and will be asked to test their knowledge without it. Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
3011179|NCT02488304|Experimental|HRCT scans|High Resolution Computed Tomography scans will be taken
3011180|NCT02488291|Experimental|0.5 sufentanil|0.5µg/ml sufentanil, 0.1% ropivacaine for 6ml/h
3011181|NCT02488291|Experimental|0.25 sufentanil|0.25µg/ml sufentanil, 0.1% ropivacaine for 6ml/h
3011182|NCT02488278|No Intervention|Self-Monitoring of Glucose Blood Measurements|Self-Monitoring of Glucose Blood Measurements using the GlucoMe Glucose Monitoring Device and App
3011183|NCT02488265|Experimental|Motor training|Balance training, Screening to prevent falls
3011184|NCT02488265|Experimental|Balance RhytmicalTraining|Balance training, Screening to prevent falls
3011185|NCT02488252|Active Comparator|Standard medical care|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker and oral hypoglycemic agents or insulin at stable dose
3011232|NCT02487914|Active Comparator|interferential current|the threshold of pressure, tactile,and pain thresholds were evaluated after the application of interferential current.
3011692|NCT02484846|Experimental|80% TIB|Participants were to spend 80% of their normal time in bed on the night prior to the second visit.
3011186|NCT02488252|Experimental|Chinese Medicine on top of standard medical care|"Semi-individualised Chinese Medicine treatment on top of standard medical care The treatment plan consists of 5 different formulas and will be prescribed to patients categorised to 5 subgroups according to clinical manifestation. Patients having multiple manifestations that fit more than 1 subgroup will not be included.~Minor adjustment of the medication will be allowed and determined by the Chinese Medicine practitioner to reflect actual clinical practice. Dosage will follow strictly the China Pharmacopeia.~A: spleen and kidney Qi deficiency, B: spleen and kidney Yang deficiency, C: spleen and kidney Qi and Ying deficiency, D: liver and kidney Ying deficiency, E: Ying and Yang deficiency~Rehmannia-6 decoction: Wolfiporia cocos, Rehmannia glutinosa, Common macrocarpium Fruit, Dioscorea opposita , Paeonia suffruticosa Andr., Oriental waterplantain rhizome~Rehmannia-8 decoction: Radix Aconiti Lateralis preparata, Cinnamomum cassia Presl, Rehmannia-6 decoction"
3011187|NCT02488239||CRT-P indicated patients|Planned to be implanted with a 3-lead CRT-P system and connected to the remote data collection through the Latitude® system
3011188|NCT02488226|Experimental|Gaze Contingent|Participants will view social videos using Gaze-contingent eye-tracking technology . If the participants looking patterns deviate from a normative pattern, they will be redirected to the normative point of regard using gaze-contingent cues.
3011189|NCT02488226|No Intervention|Control Condition|Participants will view unaltered social videos which do not change based on where the participant is looking.
3011190|NCT02488213|Active Comparator|Usual Diet Guidance|The patients will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed in outpatient patients treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre.
3011191|NCT02488213|Experimental|Nutritional Counseling|The patients will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material.
3011192|NCT02488187|Other|ABUS vs MRI (ultrasound when indicated)|To compare the overall sensitivity and specificity of ABUS versus MRI (and hand-held breast ultrasound when clinically indicated) for the ipsilateral and contralateral breast in newly diagnosed breast cancer patients.
3011193|NCT02488187|Other|ABUS vs mammography (ultrasound when indicated)|To compare the sensitivity and specificity of ABUS versus mammography (and hand-held breast ultrasound when clinically indicated) for the ipsilateral and contralateral breast in newly diagnosed breast cancer patients when MRI is not performed.
3011194|NCT02488174|No Intervention|No Intervention|The pre-intervention control condition will be usual care: that is, clinicians practice as usual without clinician notification of risk and without prompting on care practices as recommended by PROOFcheck.
3011195|NCT02488174|Experimental|PROOFcheck|The intervention for this study will consist of 3 parts: 1) Education of clinicians on prevention of severe ARF and MOF in and out of the ICU, and best practice with regards to patients with severe ARF; 2) Clinicians will be notified that a patient they are taking care of has been identified as being at high risk for developing severe ARF requiring prolong MV; 3) Notified clinicians will be directed to PROOFcheck with a bundle of recommendations for best care for patients with ARF.
3011196|NCT02488161||Patients with colorectal cancer|One cohort of patients with colorectal cancer, studied before the intervention, and one month, one year, two years, three years and five years after.
3011197|NCT02488148|Experimental|Hot yoga|3 hot yoga classes per week to be completed at local studios in Austin, TX.
3011198|NCT02488148|Experimental|Non-heated yoga|3 yoga classes to be completed at local studios in Austin, TX.
3011199|NCT02488148|No Intervention|Control|Maintain usual activities for the 12-week duration of the study.
3011200|NCT02488135|Experimental|Floseal Hemostatic Matrix|Patients will receive Floseal Hemostatic Matrix topically at the location of active bleeding. Floseal is a gel-like fibrin glue that is applied using a syringe and forms a hemostatic clot.
3011201|NCT02488135|Active Comparator|Traditional Nasal Packing|Patients will receive traditional nasal packing to try and abort bleeding. This includes either vaseline gauze or nasal merocels being inserted into the anterior nasal cavity using forceps. These expand upon contact with blood or liquid therefore creating a compression type hemostasis.
3011202|NCT02488122|Experimental|High Impact Exercise|weight bearing exercises, jumps, plyometric exercises
3011203|NCT02488122|Sham Comparator|Low Impact Exercise|Walking, Strength training, Cycling, Yoga.
3011204|NCT02488109|Active Comparator|Higher Calorie Refeeding Protocol|Participants in this arm will receive a higher calorie meal-based refeeding treatment plan in hospital.
3011205|NCT02488109|Active Comparator|Lower Calorie Refeeding Protocol|Participants in this arm will receive a lower calorie meal-based refeeding treatment plan in hospital.
3011206|NCT02488096|Active Comparator|TRUS-Guided Biopsy|Transrectal Ultrasound (TRUS)-guided biopsy systematic 12-core biopsy (standard care)
3011207|NCT02488096|Experimental|MRI + TRUS-Guided biopsy|Prostate MRI later followed by systematic 12-score TRUS-guided biopsy + targeted biopsy of additional MRI-detected scores.
3011208|NCT02488083|Experimental|all subjects treated by UltraShape|all the patients undergo fat reduction treatment by UltraShape
3011209|NCT02488070|Experimental|Diagnostic (68Ga-PSMA PET/CT or PET/MRI)|Patients receive gallium Ga 68-labeled PSMA ligand Glu-urea-Lys(Ahx) IV and then undergo PET/CT or PET/MRI approximately 45-60 minutes later.
3011210|NCT02488057|Active Comparator|Diet-induced weight loss|Investigators will randomize subjects to lifestyle change or lifestyle change plus GLP-1 receptor agonist. Lifestyle change will be developed around a meal replacement strategy. The intervention will be weight loss using Slim-Fast®. Participants will be provided Slim-Fast® meal replacement shakes to utilize for two meals daily plus one to two 100 calorie snacks, similar to the Look AHEAD protocol. The subjects will receive specific menus and training on food composition to prepare one healthy 500 calorie meal daily, for a net hypocaloric diet.
3011211|NCT02488057|Active Comparator|Weight loss plus liraglutide|Patients will be randomized to lifestyle change and the GLP-1 agonist, liraglutide. Subjects in this group will be administered 0.6mg liraglutide, sq injection daily for 1 week, increased to 1.2 mg for 1 week, and then 3.0 mg for the next 10 weeks of the acute phase. This gradual escalation of the dose is designed to minimize gastrointestinal side effects. Empty syringes will be monitored for compliance.
3011212|NCT02488044|Experimental|AEB1102|"AEB1102, modified human Arginase I administered IV Part 1 Each patient may receive up to 7 doses given up to every other week over a maximum of 14 weeks.~Part 2 Each patient will receive up to 8 weeks of repeat-dose therapy."
3011213|NCT02488031|Experimental|Error-reduction|The participants in the error-reduction group will participate in a 4-week home-based training intervention during the month between their pre- and post-test visits. During pre- and post- training visits, Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA), Purdue Pegboard, Brief Test of Attention, 6-minute Walk, Hand Grip Dynamometer, Physical Performance Function, Digit Span, SARA, Montreal Cognitive Assessment, Beck Depression Inventory 2nd Ed, Stroop and biomechanical gait analysis tests will be administered. Also biomechanical assessments of dysmetria and neurophysiological assessment of brain activity will be conducted to evaluate the impact of the training on SCA individuals.
3011214|NCT02488031|Experimental|Best Medical Management|The participants in the best medical management group will undergo identical testing sessions (two visits one month apart) as those in the error-reducing group but will not receive the 4-week error reducing intervention. They will be administered the International Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA) assessments and the following tests: Purdue Pegboard, Brief Test of Attention, 6-minute Walk, Hand Grip Dynamometer, Physical Performance Function, Digit Span, SARA, Montreal Cognitive Assessment, Beck Depression Inventory 2nd Ed, Stroop and biomechanical gait. Biomechanical assessments of dysmetria and neurophysiological assessment of brain activity will be conducted at both visits.
3011215|NCT02488018|Experimental|Provision of experimental honeys|Eight experimental monofloral honeys and reference glucose
3011216|NCT02488005|Experimental|Small Bowel Ultrasound|Subjects will receive a small bowel ultrasound to measure bowel wall thickness at Week 0 and Week 14
3011217|NCT02487992|Experimental|CIK plus S-1 and Bevacizumab|"Cytokine-Induced Killer Cells are used to treat advanced colorectal cancer patients with S-1 and Bevacizumab.~S-1, 60mg,p.o.,Bid,d2-15. Bevacizumab (Avastin),7.5mg/kg,ivgtt,d1. 3 weeks is a cycle. Continue until the disease progress.~Cytokine-induced killer cells 3 cycles,every 1 year. Continue until the disease progress."
3011218|NCT02487992|No Intervention|S-1 and Bevacizumab|"S-1 is an oral anticancer agent, is a derivative of fluorouracil. Bevacizumab (Avastin) is a recombinant human monoclonal IgG1 antibody, which plays a role in the biological activity of human vascular endothelial growth factor. Bevacizumab is mainly used in the treatment of advanced colorectal cancer.~S-1, 60mg,p.o.,Bid,d2-15. Bevacizumab (Avastin),7.5mg/kg,ivgtt,d1. 3 weeks is a cycle. Continue until the disease progress."
3011219|NCT02487979|Experimental|Treatment (glembatumumab vedotin)|Patients receive glembatumumab vedotin IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
3011220|NCT02487966|Experimental|Active tDCS and Active Mirror Therapy|Subjects will receive 20 minutes of active tDCS, while receiving 15 minutes of active Mirror Therapy.
3011221|NCT02487966|Experimental|Active tDCS and sham Mirror Therapy|Subjects will receive 20 minutes of active tDCS, while receiving 15 minutes of sham Mirror Therapy.
3011222|NCT02487966|Experimental|Sham tDCS and active Mirror Therapy|Subjects will receive 20 minutes of sham tDCS, while receiving 15 minutes of active Mirror Therapy.
3011223|NCT02487966|Sham Comparator|Sham tDCS and sham Mirrory Therapy|Subjects will receive 20 minutes of sham tDCS, while receiving 15 minutes of sham Mirror Therapy.
3011224|NCT02487953|Experimental|Nicotine ENDS + Nicotine Patch|Participants will initially receive 1 week of 21 mg nicotine skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive nicotine-containing ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the nicotine patch dose will be gradually reduced according to standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
3011225|NCT02487953|Active Comparator|Nicotine ENDS + Placebo Patch|Participants will initially receive 1 week of placebo skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive nicotine-containing ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the placebo patch size will be gradually reduced to mirror standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
3011226|NCT02487953|Active Comparator|Placebo ENDS + Nicotine Patch|Participants will initially receive 1 week of 21 mg nicotine skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive placebo ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the nicotine patch dose will be gradually reduced according to standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
3011227|NCT02487940|Active Comparator|Intralipid|Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
3011228|NCT02487940|Placebo Comparator|Placebo|Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
3011229|NCT02487927||Weaning success|patients pass SBT and weaning without any ventilation in 48 hours
3011230|NCT02487927||weaning failure|patients do not pass SBT or ventilation with any ventilation in 48 hours
3011231|NCT02487914|Active Comparator|lidocaine iontophoresis using interferential current|the threshold of pressure, tactile,and pain thresholds were evaluated after the iontophoresis of Lidocaine using interferential current.
3011381|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2)|LDV/SOF+RBV for 12 weeks (treatment-experienced)
3011233|NCT02487914|Active Comparator|lidocaine|the threshold of pressure, tactile,and pain thresholds were evaluated after the application of topical Lidocaine.
3011234|NCT02487901|Active Comparator|Ultrasonic osteotome|making gutter on the hinge side of lamina with ultrasonic osteotome
3011235|NCT02487901|Sham Comparator|Drill|making gutter on the hinge side of lamina with conventional drill
3011236|NCT02487888|Experimental|Pain|Patients presenting to a clinic for pain, that will be either blinded to genetic testing results or unblinded to genetic testing results
3011237|NCT02487888|Experimental|Mental Health|Patients presenting to a clinic for mental health disorders, that will be either blinded to genetic testing results or unblinded to genetic testing results
3011238|NCT02487888|Experimental|Cardiovascular|Patients presenting to a clinic for cardiovascular complications, that will be either blinded to genetic testing results or unblinded to genetic testing results
3011239|NCT02487888|Experimental|Arthritis|Patients presenting to a clinic for osteoarthritis or rheumatoid arthritis, that will be either blinded to genetic testing results or unblinded to genetic testing results
3011240|NCT02487888|Experimental|Type 2 Diabetes Mellitus|Patients presenting to a clinic for T2DM, that will be either blinded to genetic testing results or unblinded to genetic testing results
3011241|NCT02487875|Experimental|COPD patients -study group|COPD inpatients GOLD2-4, in stable conditions,hospitalized to follow a pulmonary rehabilitation programme. The study group performs in addition to the standard programme, also a peripheric muscle strength training
3011242|NCT02487875|Active Comparator|COPD patients -control group|COPD inpatients GOLD2-4, in stable conditions,hospitalized to follow a pulmonary rehabilitation programme
3011243|NCT02487862|No Intervention|Screening|Participants were screened for the inclusion and exclusion criteria to select the study group. No intervention has been done.
3011244|NCT02487862|Placebo Comparator|catagerizing the study population|The selected participants where assigned into respective groups
3011245|NCT02487862|No Intervention|Stress Reduction Protocol|Participants were evaluated for the outcome of the intervention.
3011246|NCT02487849|Experimental|HIPEC|If patient is eligible - secondary cytoreductive operation will be followed by HIPEC with 800 mg/m² body surface (KOF) Carboplatin with closed technique.
3011247|NCT02487836|Other|First attempt stenting (T0 = date of the first act)|Efficacy of laying of a biliary stent for chemotherapy realization
3011248|NCT02487823|Experimental|BKM 120 (60 mg)|BKM120 (60 mg) in combination with LH-RH agonists and bicalutamide
3011249|NCT02487823|Experimental|BKM 120 (80 mg)|BKM120 (80 mg) in combination with LH-RH agonists and bicalutamide
3011250|NCT02487823|Experimental|BKM 120 (100 mg)|BKM120 (100 mg) in combination with LH-RH agonists and bicalutamide
3011251|NCT02487810|Experimental|Intuitive|Patients in each arm will be asked all of the same questions. The only difference between the arms will be the instructions regarding how and when to answer the series of hypothetical questions regarding medical interventions. The instructions will be designed to influence patients to think either intuitively or deliberatively about the questions regarding life-sustaining interventions.
3011252|NCT02487810|Experimental|Deliberative|Patients in each arm will be asked all of the same questions. The only difference between the arms will be the instructions regarding how and when to answer the series of hypothetical questions regarding medical interventions. The instructions will be designed to influence patients to think either intuitively or deliberatively about the questions regarding life-sustaining interventions.
3011253|NCT02487797|Experimental|High dose oxytocin regimen|The oxytocin solution will be prepared using 90 units of oxytocin in 500 milliliters of normal saline (sodium chloride 0.9%). The oxytocin infusion will be initiated with a starting oxytocin concentration rate of 6 milliunits/minute (volume rate 2 milliliters/hour) that can be increased at increments of 6 milliunits/minute (volume rate 2 milliliters/hour) every 15-30 minutes until a labor pattern with uterine contractions every 2-3 minutes of moderate to strong intensity is established.
3011254|NCT02487797|Active Comparator|Low dose oxytocin regimen|The oxytocin solution will be prepared using 30 units of oxytocin in 500 milliliters of normal saline (sodium chloride 0.9%). The oxytocin infusion will be initiated with a starting oxytocin concentration rate of 2 milliunits/minute (volume rate 2 milliliters/hour) that can be increased at increments of 2 milliunits/minute (volume rate 2 milliliters/hour) every 15-30 minutes until a labor pattern with uterine contractions every 2-3 minutes of moderate to strong intensity is established.
3011255|NCT02487784|Experimental|Particulate allograft + autogenous bone.|In the test arm of the study the treatment will include a mix of MinerOss CorticoCancellous Particulate allograft + autogenous bone chips.
3011256|NCT02487784|Active Comparator|Block allograft|The positive control treatment will include a block allograft plus Mineross corticocancellous particulate allograft.
3011257|NCT02487771|Placebo Comparator|Placebo Capsule|
3011258|NCT02487771|Experimental|DHA Capsule|
3011259|NCT02487758|Experimental|Ridge preservation Flap|The flap procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal.
3011260|NCT02487758|Experimental|Ridge preservation Flapless|The test will be a flapless technique with tunneling and an intramucosal vertical incision on the buccal.
3011261|NCT02487745|Active Comparator|IPS Only|IPS Only participants will receive the Individual Placement and Support (IPS) supported employment.
3011262|NCT02487745|Experimental|IPS Plus Wage Supplement|IPS Plus Abstinence-Contingent Wage Supplement participants will receive the Individual Placement and Support (IPS) supported employment intervention and abstinence-contingent wage supplements.
3011263|NCT02487732|Active Comparator|Ticagrelor|180mg loading dose, 90mg twice daily for 5 weeks, then crossover to prasugrel
3011264|NCT02487732|Active Comparator|Prasugrel|60mg loading dose, 10mg once daily for 5 weeks, then crossover to ticagrelor
3011265|NCT02487719|Active Comparator|Iron sulfate|"Iron sulfate (or) is given if randomly asigned in this group and Ferritin at inclusion < 50 mcg/L.~intervention: oral iron sulfate 1 tbl daily until birth"
3011266|NCT02487719|Active Comparator|Iron polymaltose|"Iron polymaltose (or) is given if randomly asigned in this group and Ferritin at inclusion < 50 mcg/L.~intervention: oral iron polymaltose 1 tbl daily until birth"
3011382|NCT02487017|Sham Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization treatment according to NCCN guidelines，patients will receive 5-FU Hepatic arterial infusion,3 cycles at least.
3011267|NCT02487719|No Intervention|Multimineral|"Routine supplementation of multivitamin. multimineral only. Ferritin level > 50 mcg/L at inclusion. No additional iron supplementation.~oral multivitamin- multimineral preparation 1 tbl daily until birth as done in daily clinic routine"
3011268|NCT02487706|Experimental|Dolutegravir 50mg/day per 5 days|Dolutegravir 50mg/day per 5 days
3011269|NCT02487693|No Intervention|RFA alone|Patients undergo radiofrequency ablation alone.
3011270|NCT02487693|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
3011271|NCT02487680|Experimental|Breakfast meal|A breakfast like meal will be provided together with a drink to overnight fasted subjects
3011272|NCT02487680|Experimental|Lunch meal|A lunch like meal will be provided together with a drink to overnight fasted subjects
3011273|NCT02487667|Active Comparator|Intervention Group|Therapeutic exercise
3011274|NCT02487667|No Intervention|Control Group|No treatment
3011275|NCT02487654|Active Comparator|Pulmonary vein isolation alone|Current standard of treatment. Catheter ablation within the left atrium that electrically disconnects these veins form the rest of the left atrium (pulmonary vein isolation).
3011276|NCT02487654|Experimental|Ganglionic plexi ablation|Catheter ablation around the nerve supplying the heart and destroying the collection of these nerve endings(ganglionic plexi ablation).
3011277|NCT02487641||Moderat Obesity|60 persons with BMI between 30-34.49 kg/m2
3011278|NCT02487641||Sever Obesity|60 persons with BMI above 34.49 kg/m2
3011279|NCT02487641||Normal weighted|60 persons with BMI between 18.5-24.49 kg/m2
3011280|NCT02487628|Experimental|HQ® Matrix Soft Tissue Mesh|HQ® Matrix Soft Tissue Mesh is a warp-knitted, multifilament, bioengineered scaffold which is comprised of the silk fibroin protein of the Bombyx mori (B. mori) silkworm. The porous network structure makes it soft and pliable and convenient to implant. The mesh is mechanically strong, biocompatible, and long-term bioresorbable. The pore size is suitable for macrophage migration and recruitment, which hinders bacteria growth. The mesh is provided in single sheets of varying widths and lengths and may be cut to the shape or size desired for a specific application. It is sterile and for single-patient use only.
3011281|NCT02487628|Active Comparator|ULTRAPRO® Partially Absorbable Lightweight Mesh|ULTRAPRO® Partially Absorbable Lightweight Mesh (Ethicon, Inc.) is manufactured from approximately equal parts of absorbable poliglecaprone-25 monofilament fiber and non-absorbable polypropylene monofilament fiber. Designed for open and laparoscopic hernia repairs, it allows surgeons the versatility to perform various hernia repairs with a single technology. It offers excellent strength with minimal foreign body mass, to allow patients to heal more naturally with increased comfort and mobility.
3011282|NCT02487602|Active Comparator|A|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a standard radiolabeled lunch.
3011283|NCT02487602|Active Comparator|B|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a standard radiolabeled lunch.
3011284|NCT02487602|Placebo Comparator|C|Placebo capsules 30 minutes before a standard radiolabeled lunch.
3011285|NCT02487602|Experimental|D|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a radiolabeled water.
3011286|NCT02487602|Experimental|E|Up to 5 Gelesis100 and/or placebo capsules 10 minutes before a radiolabeled meal.
3011287|NCT02487589|No Intervention|Control group|"In Italy, medical risks and patients risk behaviour are not systematically registered and addressed by hospital physicians, specialists and general practitioners (GPs).~Patients allocated in control group will receive by the hospital staff tailored recommendations based on their own risk profile. The same information will be sent to their GPs. No restrictions on co-interventions will be placed."
3011288|NCT02487589|Experimental|Treated group|Telephone support, telemonitoring and tele-exercise
3011289|NCT02487576|Other|Carbohydrate-rich_Fat-rich (HC_HF)|Isocaloric carbohydrate-rich meals in the morning (06.00 am - 01.30 pm) and isocaloric fat-rich meals in the evening (04.30 pm - 10.00 pm) for 4 weeks
3011290|NCT02487576|Other|Fat-rich_Carbohydrate-rich (HF_HC)|Isocaloric fat-rich meals in the morning (06.00 am - 01.30 pm) and isocaloric carbohydrate-rich meals in the evening (04.30 pm - 10.00 pm) for 4 weeks
3011291|NCT02487563|Active Comparator|rhTPO|rhTPO, 300U/Kg ，subcutaneous injection，qd x 21d。Within 21 days，if platelet count≥50×109/L，TPO dosage should be stopped.
3011292|NCT02487563|Active Comparator|Decitabine in combination with rhTPO|decitabine, 15mg/m2 daily intravenously for 3 consecutive days (d1-d3); rhTPO, 300U/Kg ，subcutaneous injection，qd x 18d (d7-d25)。Within 18 days，if platelet count≥50×109/L，TPO dosage should be stopped.
3011293|NCT02487550|Experimental|DC-CIK|Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
3011294|NCT02487550|Other|IL-2/IFN-α|Patients receive treatment of IL-2 or IFN-α.
3011295|NCT02487537|Placebo Comparator|Non-sweetened soft drink|4-week-intervention with one liter of custom-made soft drink per day; soft drink does not contain glucose or any kind of sweet tasting substance
3011296|NCT02487537|Active Comparator|Sweetened soft drink|4-week-intervention with one liter of custom-made soft drink per day, soft drinks contains an amount of sweetener, which is isosweet compared to 100 g of sucrose in one liter of beverage
3011297|NCT02487524|Other|Nerve resection with pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
3011298|NCT02487524|Other|Nerve resection without pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
3011299|NCT02487524|Other|No nerve resection but pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
3011300|NCT02487511|Active Comparator|14 days|14 days treatment regimen
3011301|NCT02487511|No Intervention|7 days|7 days treatment regimen
3011302|NCT02487498|Experimental|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
3011303|NCT02487498|Experimental|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
3011304|NCT02487485|Experimental|ketamine + sirolimus (placebo at time 2)|Participants will be treated twice with ketamine 0.5 mg/kg infused over 40 minutes, combined with a single dose of sirolimus 6 mg orally. After two weeks, they will recieve another infusion of ketamine, and a single dose of placebo.
3011649|NCT02485106|Active Comparator|Rifaximin group|Corticosteroid or Pentoxifylline for 28 days Rifaximin 400mg tid for 28 days
3011305|NCT02487485|Placebo Comparator|ketamine + placebo (sirolimus at time 2)|Participants will be treated twice with ketamine 0.5 mg/kg infused over 40 minutes, combined with a single dose of sirolimus 6 mg placebo. After two weeks, they will recieve another infusion of ketamine, and a single dose of sirolimus 6 mg.
3011306|NCT02487472||HZ cohort|All patients ≥ 50 years old with a HZ diagnosis (as the primary diagnoses and no earlier case of HZ) during approximately 6 months inclusion period will be included in the HZ cohort, until total study target is achieved.
3011307|NCT02487472||PHN cohort|All patients of the HZ cohort presenting PHN 3 months after HZ rash onset symptoms will be included secondarily in the PHN cohort.
3011308|NCT02487459|Experimental|BPX-501 and AP1903|"Three cohorts, 3 patients each, will receive two infusions (at the same dose) of BPX-501.~If needed to treat aGVHD, a single dose of 40 mg of AP1903 will be administered IV."
3011309|NCT02487446|Experimental|First QVA149, then Umeclidinium/vilanterol|Participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks. Then after 3 weeks washout, participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks.
3011310|NCT02487446|Experimental|First Umeclidinium/vilanterol, then QVA149|Participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks. Then after 3 weeks washout, participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks.
3011311|NCT02487433|Experimental|Tofacitinib MR 22 mg Fed|Single dose of tofacitinib MR 22 mg administered under fed conditions
3011312|NCT02487433|Experimental|Tofacitinib MR 22 mg Fasted|Single dose of tofacitinib MR 22 mg administered under fasted conditions
3011313|NCT02487420|Other|Arm 18m|arm 18m: 6 months between step 1 and step 2; 6 months between step 2 and step 3, 3 months between all other steps step by step gradual introduction of egg containing food products during 18 months, unless next step can not be taken
3011314|NCT02487420|Other|arm 30 m|arm 30m: 9 months between step 1 and step 2; 9 months between step 2 and step 3, 6 months between all other steps step by step gradual introduction of egg containing food products during 30 months, unless next step can not be taken
3011315|NCT02487407|Experimental|ODM-109|ODM-109 capsules for oral administration
3011316|NCT02487407|Placebo Comparator|Placebo for ODM-109|Placebo ODM-109 capsules for oral administration
3011317|NCT02487394|Active Comparator|Asthma, Smokers and Non-Smokers|In Phase I, One arm will contain subjects who are active smokers and the other arm will contain subjects with no active smoking. Active smoking will be defined as daily use of cigarettes, pipes, cigarillos or cigars at time of entry into the study and through duration of study. No active smoking defined as never smoking or having stopped smoking for 5 years or greater.
3011318|NCT02487394|Active Comparator|COPD, Smokers and Non-Smokers|For Phase II, Phase II will again be divided into two arms based on active smoking status as discussed previously.
3011319|NCT02487381|Experimental|THC|Subjects receive 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) and corresponding cannabidiol placebo capsules.
3011320|NCT02487381|Experimental|CBD|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and corresponding delta-9-tetrahydrocannabinol placebo capsules.
3011321|NCT02487381|Experimental|CBD+THC|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) a
3011322|NCT02487381|Placebo Comparator|Placebo|Subjects receive corresponding delta-9-tetrahydrocannabinol and cannabidiol placebo capsules
3011323|NCT02487368|Experimental|Needle stimulation pad|a self-administered treatment with a mechanical needle stimulation pad, a mechanical device to be used for 30 minutes daily for 14 days.
3011324|NCT02487355|Active Comparator|group (MG)|Magnesium sulfate 50 mg add to 1 ml/kg of 0.25%of bupivacaine
3011325|NCT02487355|Active Comparator|group (D)|Dexmedetomidine 1 μg/ kg to add to 1ml/kg of 0.25%of bupivacaine
3011326|NCT02487355|Active Comparator|group (MD)|50 mg magnesium sulfate and Dexmedetomidine 1 μg/ kg to add to 1ml/kg of 0.25%of bupivacaine
3011327|NCT02487355|Active Comparator|group (C)|1ml/kg of 0.25%of bupivacaine + 1 ml of normal saline
3011328|NCT02487342|Experimental|milk|semi-skimmed milk (< 2% fat, Tesco, UK). All items were isovolumetric (217 mL) and isoenergetic (427 kJ).
3011329|NCT02487342|Active Comparator|orange fruit-juice|orange fruit-juice (Tesco, UK). All items were isovolumetric (217 mL) and isoenergetic (427 kJ).
3011330|NCT02487329|Active Comparator|Calcium hydroxide|Direct pulp capping with a self-hardening calcium hydroxide paste
3011331|NCT02487329|Experimental|Er,Cr:YSGG laser + calcium hydroxide|Direct pulp capping using Er,Cr:YSGG laser combined with calcium hydroxide
3011332|NCT02487329|Experimental|TheraCal LC|Direct pulp capping with resin based tricalcium silicate material
3011333|NCT02487329|Experimental|Er,Cr:YSGG laser + TheraCal LC|Direct pulp capping using Er,Cr:YSGG laser combined with resin based tricalcium silicate material
3011334|NCT02487316|Experimental|crizotinib combined with chemotherapy|crizotinib 250mg, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
3011335|NCT02487303|Active Comparator|Acetaminophen Intravenous|(group 1) 1 gram IV acetaminophen every 8 hours for three doses
3011336|NCT02487303|Active Comparator|Acetaminophen Oral|(group 2) 1 gram oral acetaminophen every 8 hours for three doses
3011337|NCT02487303|No Intervention|No acetaminophen|(group 3) no acetaminophen
3011338|NCT02487290|Experimental|Treatment|Aneufix ACP-T5
3011339|NCT02487277|Experimental|Run-In|PEGPH20: 3ug/kg on Days 1 and 4
3011340|NCT02487277|Experimental|Treatment|PEGPH20: 3ug/kg on Days 1, 8, 15 Gemcitabine: 1000mg/m^2 on Days 1, 8, 15 Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
3011341|NCT02487251|Experimental|Usual Head Start Exposure|Participants receive no additional information about healthy eating, family mealtimes, nutrition education or meal planning beyond any usual coverage of these areas in Head Start.
3011342|NCT02487251|Experimental|Supports for Family Mealtimes|Participants receive one or more interventions intended to promote the frequency of family meals as an obesity prevention strategy. Supports range from the least to the most comprehensive. The interventions include: Meal Delivery, Ingredient Delivery, Community Kitchen, Healthy Eating Classes, Cooking Demonstrations and Provision of Cookware.
3011650|NCT02485106|Active Comparator|Control group|Corticosteroid or Pentoxifylline for 28 days
3011343|NCT02487238|Experimental|Fecal Microbiota Enema|Live, healthy, human donor stool prepared as fecal enemas. Fecal enemas are prepared and collected by Rebiotix(®) (RBX2660), using extensively screened donor stool. Enemas will be administered on site at one of the participating trial sites by trained study investigators. Enemas are given: 2x per week for 6 weeks (total = 12 enemas over 6 weeks). Patients will be masked to enema contents.
3011344|NCT02487238|Placebo Comparator|Normal Saline Enema|Normal saline enemas will be administered on site at one of the participating trial sites by trained study investigators. Enemas are given: 2x per week for 6 weeks (total = 12 enemas over 6 weeks). Patients will be masked to enema contents.
3011345|NCT02487225|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
3011346|NCT02487225|Placebo Comparator|Placebo|Placebo 400 mg , 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
3011347|NCT02487212|Active Comparator|Laser+Topical corticosteroid|Hypertrophic scars were treated with fractional Erbium: Yttrium aluminium garnet (YAG) (2,940-nm) laser, then 0.05% Clobetasol propionate ointment was immediately applied on the perforated scar on one side
3011348|NCT02487212|Placebo Comparator|Laser+Petrolatum gel|Hypertrophic scars were treated with fractional Erbium: YAG (2,940-nm) laser, then topical petrolatum gel was immediately applied on the perforated scar on the other side
3011349|NCT02487199|Experimental|HCV GT1a (3-DAA)|Participants with hepatitis C virus (HCV) genotype 1a (GT1a) infection received 3-direct-acting antiviral agent (3-DAA: ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
3011350|NCT02487199|Experimental|HCV GT4 (2-DAA)|Participants with hepatitis C virus (HCV) genotype 4 (GT4) infection received 2-direct-acting antiviral agent (2-DAA: ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily]) for 12 weeks.
3011351|NCT02487186|Active Comparator|Test group: DB+DOX|Test group: DB (full mouth debridment) +DOX (doxicicline) - 45 minutes of full-mouth debridement + subgingival application of PLGA microspheres loading doxycycline 10%.
3011352|NCT02487186|Active Comparator|Control group: DB alone|"Control group: DB alone (Full-mouth debridment)~Intervention: 45 minutes of full-mouth debridement + subgingival application of void PLGA microspheres."
3011353|NCT02487173|Experimental|Respirio Flu Test|"Upper respiratory tract samples from participants will be tested with:~Respirio Flu Test~Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)~Sofia® Influenza A+B Fluorescent Immunoassay (FIA)"
3011354|NCT02487160|Experimental|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
3011355|NCT02487160|Active Comparator|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
3011356|NCT02487147|Active Comparator|N95 Respirator|Participants in this arm will wear an N95 respirator and safety goggles during Live Attenuated Influenza Vaccine exposure.
3011357|NCT02487147|Experimental|Free Air Portable Air Powered Respirator|Participants in this arm will wear a Free Air PAPR and safety goggles during Live Attenuated Influenza Vaccine exposure.
3011358|NCT02487134|Placebo Comparator|Conventional abdominal wall closure|The aponeurosis is closed with continuous PDS 2/0 sutures, with self-locking anchor knots. The stitches are placed 5-8 mm from the wound edge, 4-5 mm apart.
3011359|NCT02487134|Active Comparator|Reinforcement with resorbable mesh|After closing the aponeurosis with PDS 2/0, a 7 cm wide TIGR Matrix Surgical Mesh is applied on the aponeurosis. The mesh is sutured to the aponeurosis with continuous PDS 2/0, with a wound to suture ratio of 1:4.
3011360|NCT02487121|Experimental|variable interval schedule|12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
3011361|NCT02487121|Active Comparator|self-directed treatment|provision of treatment materials with instruction to work through materials at participant's own pace
3011362|NCT02487108|Experimental|Hydrocodone bitartrate/acetaminophen 5.0 mg/325 mg|every 4 to 6 hours
3011363|NCT02487108|Experimental|Hydrocodone bitartrate/acetaminophen 7.5 mg/325 mg|every 4 to 6 hours
3011364|NCT02487108|Experimental|Hydrocodone bitartrate/acetaminophen 10 mg/325 mg|every 4 to 6 hours
3011365|NCT02487108|Placebo Comparator|Matching placebo|every 4 to 6 hours
3011366|NCT02487095|Experimental|1/Phase I|VX-970 + topotecan at escalating doses
3011367|NCT02487095|Experimental|2/Phase II|VX-970 + topotecan at MTD/RP2D
3011368|NCT02487082|Other|Group A|Melatonin and donepezil (melatonin 3mg and donepezil 1.25-5mg based on age/weight each night) or placebo for 15 weeks
3011369|NCT02487082|Other|Group B|Melatonin and donepezil (melatonin 3mg and donepezil 1.25-5mg based on age/weight each night) or placebo for 15 weeks
3011370|NCT02487069|Experimental|MSD group|The patients will received HSCT from MSD.
3011371|NCT02487069|Experimental|MUD group|The patients will received HSCT from MUD.
3011372|NCT02487069|Experimental|HRD group|The patients will received HSCT from HRD.
3011373|NCT02487043|Experimental|Dental health coaches|Telephone-based case-management intervention. Contact with families every 2 weeks during one year. Including motivational interviewing, support for dental preventive measures at home, answer questions, care coordination) + conventional protocol (Fluoride prevention program)
3011374|NCT02487043|No Intervention|Control group|Conventional protocol (Fluoride prevention program) and follow-up as usual
3011375|NCT02487030|Experimental|LDV/SOF 8 wk TN (Cohort 1, Group 1)|LDV/SOF for 8 weeks (treatment-naive (TN))
3011376|NCT02487030|Experimental|LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2)|LDV/SOF+RBV for 8 weeks (treatment-naive)
3011377|NCT02487030|Experimental|LDV/SOF 12 wk TN (Cohort 1, Group 3)|LDV/SOF for 12 weeks (treatment-naive)
3011378|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4)|LDV/SOF+RBV for 12 weeks (treatment-naive)
3011379|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TE (Cohort 2)|Treatment-experienced (TE) participants who completed treatment in Gilead sponsored study GS-US-334-0138 or in Cohort 1 of this study and did not achieve SVR12 will receive LDV/SOF+RBV for 12 weeks.
3011380|NCT02487030|Experimental|LDV/SOF 12 wk TE (Cohort 3, Group 1)|LDV/SOF for 12 weeks (treatment-experienced)
3011651|NCT02485093|Active Comparator|No pacing|Ventricular intrinsic conduction enhanced
3011383|NCT02487017|Experimental|DC-CIK|After accepting concurrent TACE according to NCCN guidelines,patients will receive 3 cycles of DC-CIK treatment at least.
3011384|NCT02487004||chronic hemodialysis patients|
3011385|NCT02486991|Active Comparator|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
3011386|NCT02486991|Experimental|Tunnel + AlloDerm® + Verticals|The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
3011387|NCT02486978|Placebo Comparator|Control (no supplement)|Reference will be white bread to give 50 g available carbohydrates with placebo capsule
3011388|NCT02486978|Experimental|Dose 1|Test will comprise white bread to give 50 g available carbohydrates and one capsule of pomegranate/olive and one capsule placebo
3011389|NCT02486978|Experimental|Dose 2|Test will comprise white bread to give 50 g available carbohydrates and 2 capsules of pomegranate/olive.
3011390|NCT02486965|Experimental|training group|"The training program consists of three sessions of 45 minutes of physical activity per week for 2 years. During the first 6-9 months, two individual workouts, supervised by a physiotherapist and a session in Living.~Depending on the capacity and exercise tolerance of the patient, patients realize the second phase of training until 2 years of the study: three exercise sessions from 45 to 60 minutes per week of which group session led by a professor of Adapted Physical Activity (APA) and 2 autonomous sessions.~Thermal stimulation with test thermode Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms"
3011391|NCT02486965|Placebo Comparator|control group|A training program supervised by physical therapists and teachers in Adapted Physical Activity, identical to the active program in its follow-up, but the intensity of the sessions is lower than that of the training group
3011392|NCT02486952||Diffuse Large B-Cell Lymphoma (DLBCL)|Participants, who were not treated previously for DLBCL, will receive rituximab (MabThera) in combination with Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) or CHOP-like chemotherapy at the treating physician's discretion and according to package labeling, within approved indication and local approval status of respective drugs. Participants will be followed up for safety and efficacy in accordance with routine practice until progression of disease, unacceptable toxicity, withdrawal of consent or death from any reason.
3011393|NCT02486939|Experimental|CHS-0214|CHS-0214 50 mg weekly
3011394|NCT02486926|Placebo Comparator|Sevoflurane|Anesthesia was maintained with sevoflurane,and the incidence and severity of emergence agitation was investigated.
3011395|NCT02486926|Active Comparator|Remifentanil|Anesthesia was maintained with sevoflurane and remifentanil. The incidence and severity of emergence agitation was compared with sevoflurane group.
3011396|NCT02486926|Active Comparator|Alfentanil|"Anesthesia was maintained with sevoflurane and remifentanil, and alfentanil was administered 10 min before the end of surgery.~The incidence and severity of emergence agitation was compared with sevoflurane group."
3011397|NCT02486926|Other|Thiopental|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
3011398|NCT02486926|Other|Rocuronium|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
3011399|NCT02486913|No Intervention|Conventional Health Check|Patients undergoing conventional National Health Service Health Check
3011400|NCT02486913|Experimental|Enhanced Health Check|Patients undergoing National Health Service Health Check enhanced by risk report
3011401|NCT02486900|Experimental|Neurofeedback training group|The neurofeedback group will perform 6 training sessions over a period of 4 months: 4 fortnightly sessions in the first two months will be followed by 2 monthly 'booster' sessions. Each session will include several behavioural assessments and fMRI-based neurofeedback training in an MRI scanner (1 h). The neurofeedback training phase will be be followed-up by two behavioural assessments 8 and 12 months after the first training.
3011402|NCT02486900|No Intervention|Treatment-as-usual control group|The control group will receive treatment as usual (e.g. medication, counselling) but no neurofeedback training during the study period. Patients in the control group will be invited for four behavioural assessment sessions (baseline assessment, follow-up assessments 4/8/12 months after baseline).
3011403|NCT02486887|Experimental|telemonitoring|telemonitoring of weight, arterial pressure and heart rate at home with connection to a medical platform to monitor the evolution.
3011404|NCT02486887|No Intervention|conventional follow-up|conventional follow-up
3011405|NCT02486874|Experimental|Treatment group|PoreSkin, a human acellular dermal matrix, were used for scar contracture treatment
3011406|NCT02486861||culprit plaque|correlation of OCT characteristics of culprit plaque with incidence of major adverse cardiovascular events (MACEs defined as the composite of death from cardiac causes, non- fatal MI, clinically driven target vessel revascularization (TVR), or re-hospitalization due to unstable or progressive angina according to Braunwald Unstable Angina Classification) and clinical baseline characteristics.
3011407|NCT02486861||non culprit plaque|correlation of OCT characteristics of non culprit plaque of culprit plaque with incidence of major adverse cardiovascular events (MACEs defined as the composite of death from cardiac causes, non- fatal MI, clinically driven target vessel revascularization (TVR), or re-hospitalization due to unstable or progressive angina according to Braunwald Unstable Angina Classification) and clinical baseline characteristics.
3011408|NCT02486848|Placebo Comparator|5% Topical Minoxidil Solution|5% Topical Minoxidil Solution
3011409|NCT02486848|Active Comparator|15% Topical Minoxidil Solution|15% Topical Minoxidil Solution
3011410|NCT02486835|Experimental|"Cough Syrup for adults and children"|Marked (authorized) medical device acting by protecting the oropharynx, in a non pharmacological way, to reduce cough. It contains honey, plantago lanceolata, thymus vulgaris.Dosage form: syrup Dosage: 5 ml three times a day. Frequency: the duration of the study for each patient is 4 nights, 3 days.
3011411|NCT02486835|Placebo Comparator|Placebo|The placebo intervention is a syrup of same taste and colour without the protective components. Dosage form: syrup. Dosage: 5 ml three times a day Frequency: the duration of the study for each patient is 4 nights, 3 days.
3011412|NCT02486822|Experimental|Labor scale|Observation Amniotomy Oxytocin Cesarean Section (CS)
3011413|NCT02486822|Active Comparator|WHO partograph|Observation Amniotomy Oxytocin Cesarean Section (CS)
3044710|NCT02262611||Hypertension patients - Nephrology|
3011414|NCT02486809|Experimental|Treatment 1: Needle and Syringe|Healthy volunteers will receive a single SC injection of lebrikizumab, withdrawn from a vial and administered by a needle and syringe.
3011415|NCT02486809|Experimental|Treatment 2: PFS-NSD|Healthy volunteers will receive a single SC injection of lebrikizumab, administered by PFS-NSD.
3011416|NCT02486796|Active Comparator|Immediate and Continuous Dosing|Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 1 Day 1 of their prescribed neoadjuvant chemotherapy.
3011417|NCT02486796|Active Comparator|Delayed Dosing|Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 3 Day 1 of their prescribed neoadjuvant chemotherapy.
3011418|NCT02486783||Baseline controls (no signs of infection)|Neonates admitted for serial blood draws for uncomplicated hyperbilirubinemia
3011419|NCT02486783||Signs of infection A|No infection: antibiotics stopped after 48 hours; negative cultures
3011420|NCT02486783||Signs of infection B|Clinical infection: 7 day antibiotics; negative cultures
3011421|NCT02486783||Signs of infection C|Sepsis: positive bacterial blood culture
3011422|NCT02486783||Signs of infection D|Meningitis: positive bacterial CSF culture
3011423|NCT02486770|Experimental|Group 1|Aerucin 2.0mg/kg
3011424|NCT02486770|Experimental|Group 2|Aerucin 8.0mg/kg
3011425|NCT02486770|Experimental|Group 3|Aerucin 20.0mg/kg
3011426|NCT02486757|Experimental|Interventional|estradiol 50 mcg transdermal patch x 7 days oral micronized progesterone 0.5 mg/kg/dose TID x 7 days
3011427|NCT02486757|No Intervention|Observational|blood and urine sampling and serial pelvic ultrasounds during cycle 1
3011428|NCT02486744|Active Comparator|80 Units of Acthar|Subjects assigned by random assignment to receive 80 Units of Acthar Gel 2x weekly for 6 months
3011429|NCT02486744|Active Comparator|40 Units of Acthar|Subjects assigned by random assignment to receive 40 Units of Acthar Gel 2x weekly for 6 months
3011430|NCT02486731||Noonan syndrome|Patients with Noonan syndrome
3011431|NCT02486731||LEOPARD syndrome|Patients with LEOPARD syndromes
3011432|NCT02486731||Controls|Healthy subjects
3011433|NCT02486718|Experimental|Atezolizumab|Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed [non-squamous cell NSCLC only]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: Participants will receive atezolizumab 1200 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles and will undergo periodic chest X-ray and CT scan.
3011434|NCT02486718|Active Comparator|Best Supportive Care|Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed [non-squamous cell NSCLC only]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: After enrollment phase participants will receive only the best supportive care and will undergo periodic chest X-ray and CT scan.
3011435|NCT02486705|Active Comparator|PTSD Family Coach Basic|PTSD Coach basic provides an iOS mobile app with extensive information about caregiving for family members of those with PTSD and additional support resources.
3011436|NCT02486705|Experimental|PTSD Family Coach Full|PTSD Family Coach full provides an iOS mobile app with extensive information about caregiving for family members of those with PTSD, additional support resources, tools for coping with caregiving-related stress, and tools for self-monitoring stress symptoms.
3011437|NCT02486692|Experimental|Experimental|Participants using AboutFace
3011438|NCT02486692|No Intervention|Usual Care Condition|Education and Print materials only
3011439|NCT02486679|Active Comparator|PGE2|Patients allocated to vaginal PGE2 (Prostin) for cervical ripening
3011440|NCT02486679|Active Comparator|Foley catheter|Patients allocated to foley catheter placement for cervical ripening
3011441|NCT02486666|Experimental|Experimental Arm|"Experimental Arm:patients will not have any dose titration regardless of anti-Xa level.~Premature neonates will receive enoxaparin 2.0 mg/kg/dose rounded to nearest whole mg twice daily, while term neonates will receive enoxaparin 1.7 mg/kg/dose rounded to nearest whole mg twice daily."
3011442|NCT02486666|Other|Control Arm|"Control Arm: patients who will have dose titration based on anti-Xa levels to maintain a therapeutic range of 0.5-1.0 u/mL (standard of care).~Premature neonates will receive enoxaparin 2.0 mg/kg/dose rounded to nearest whole mg twice daily, while term neonates will receive enoxaparin 1.7 mg/kg/dose rounded to nearest whole mg twice daily."
3011443|NCT02486653|Experimental|Tamsulosin|
3011444|NCT02486653|Placebo Comparator|Placebo|
3011445|NCT02486640||Betaferon|
3011446|NCT02486627|Experimental|Plazomicin|Patients received 15 milligrams per kilogram (mg/kg) plazomicin as an intravenous (IV) infusion once daily followed by matching placebo infusions 8 and 16 hours later. After a minimum of 4 days of IV plazomicin, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
3011447|NCT02486627|Active Comparator|Meropenem|Patients received 1.0 g meropenem as an IV infusion every 8 hours (q8h). After a minimum of 4 days of IV meropenem, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
3011448|NCT02486601|Experimental|nab-paclitaxel + FOLFOX|nab-paclitaxel + FOLFOX nab-paclitaxel: 150 mg/m2 D1 every 2 weeks Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks 5-FU infusion: 2400mg/m2 48h infusion every 2 weeks 6 pre-operative cycles 6 post-operative cycles (optional)
3011449|NCT02486588|No Intervention|Control--no weekly message|10% cash back level, no weekly message, and the standard monthly message
3011450|NCT02486588|Experimental|General Weekly Message|10% cash back, general weekly message, standard monthly message
3011451|NCT02486588|Experimental|Personalized Weekly Message|10 % cash back, personalized weekly message, standard monthly message
3011452|NCT02486588|Experimental|25 percent cash back|25% cash back, personal weekly message, standard monthly message
3011453|NCT02486588|Experimental|Standard monthly message|10%+15% cash back, personal weekly message, standard monthly message
3011454|NCT02486588|Experimental|Unbundled monthly message|10%+15% cash back, personal weekly message, unbundled monthly message
3011652|NCT02485093|Experimental|Pacing|Septal ventricular pacing with optimized AV delay
3011455|NCT02486575|Other|self-learning|Residents training alone with pre-recorded instructions. No tutor intervention, only self-learning training Intervention Type: Behavioral (video-based and instruction based learning)
3011456|NCT02486575|Other|Mentoring|"Residents training with a mentor, giving tailored instruction to each of them and correction to wrong behaviours.~Intervention Type: Behavioral (tutored learning)"
3011457|NCT02486562||People diagnosed with Multiple Sclerosis|
3011458|NCT02486549|Experimental|Supraclavicular Block|Ultrasound guided supraclavicular block with 20 ml of 0.25% bupivacaine will be performed
3011459|NCT02486549|Active Comparator|Interscalene block|Ultrasound guided inter scalene block with 20ml of 0.25% bupivacaine will be performed.
3011460|NCT02486536|Active Comparator|Group A|Fast for 12h before the examination and take 8ml of Simethicone Emulsion (Berlin-Chemie, Germany, containing 40 mg simethicone in 1mL emulsion) with 250ml water 30min before capsule ingestion.CE are performed with the Pillcam SB2 capsule endoscopy system (Given Imaging Co. Ltd., Yoqnem, Israel).
3011461|NCT02486536|Active Comparator|Group B|the same as protocol A plus 1L Polyethylene glycol 11-12h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
3011462|NCT02486536|Active Comparator|Group C|the same as protocol A plus 2L Polyethylene glycol 10-12h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
3011463|NCT02486536|Active Comparator|Group D|Group D: the same as protocol A plus 1L Polyethylene glycol 3-4h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
3011464|NCT02486536|Active Comparator|Group E|Group E: the same as protocol A plus 2L Polyethylene glycol 2-4h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
3011465|NCT02486523|Active Comparator|Control group|"Outpatient management of children diagnosed with severe acute malnutrition.~Interventions allocated:~Behavioral: Group discussions after successful discharge Procedure/Surgery: Outpatient Therapeutic Programme"
3011466|NCT02486523|Experimental|Intervention group|"Outpatient management of children diagnosed with severe acute malnutrition + household WASH package~Interventions allocated:~Behavioral: Hygiene promotion sessions Device: Household WASH package The content of the kit: soap and aquatab for 3 months, 20 liters Jerry can, a cup, a plastic kettle for hand washing and the instructions leaflet.~Behavioral: Household visits during the OTP phase Behavioral: Group discussions after successful discharge Procedure/Surgery: Outpatient Therapeutic Programme"
3011467|NCT02486510|No Intervention|Group 1 (Control)|"Patients receiving intensive chemotherapy with/without stable antiretroviral therapy. Patients not receiving antiretroviral therapy will start it.~Patients randomized to this group will not receive clinical trial treatment (neither Maraviroc or Placebo)"
3011468|NCT02486510|Experimental|Group 2 (Treatment)|"Patients receiving intensive chemotherapy with/without stable antiretroviral therapy and Maraviroc.~Patients not receiving antiretroviral therapy will start this theraphy together with Maraviroc."
3011469|NCT02486497|Active Comparator|5-FU group|Grades of hENT1 immunostaining are 0 or 1.
3011470|NCT02486497|Active Comparator|Gemcitabine group|Grade of hENT1 immunostaining is 2.
3011471|NCT02486484|Experimental|intravitreal ziv-aflibercept|intravitreal ziv-aflibercept
3011472|NCT02486471|Other|Observational approach|Wait and see
3011473|NCT02486471|Active Comparator|Use of Monsel´s Paste|cervical coagulation using a hemostatic agents, ie monsel´s paste
3011474|NCT02486458|No Intervention|Negative control|No treatment will be applied
3011475|NCT02486458|Experimental|Varnish 4 h|Fluoride varnish will be applied on teeth and removed after 4 hours
3011476|NCT02486458|Experimental|Varnish 24 h|Fluoride varnish will be applied on teeth and removed after 24 hours
3011477|NCT02486458|Experimental|Fluoride Gel|Fluoride gell will be applied on teeth and removed after 4 minutes
3011478|NCT02486445|Experimental|Rivaroxaban|Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours.
3011479|NCT02486432|Experimental|Single arm Levodopa/Carbidopa|The intervention is dosing with Sinemet® which is an oral tablet containing Levodopa/Carbidopa. Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
3011480|NCT02486419||Summer|
3011481|NCT02486419||Winter|
3011482|NCT02486406|Experimental|Genotype 4, with or without compensated cirrhosis|12 weeks of treatment
3011483|NCT02486406|Experimental|Genotype 1a, without cirrhosis|12 weeks of treatment
3011484|NCT02486406|Experimental|Genotype 1a, with compensated cirrhosis|24 weeks of treatment
3011485|NCT02486406|Experimental|Genotype 1b, with or without compensated cirrhosis|12 weeks of treatment
3011486|NCT02486393||type of surgery|patients undergoing parotid surgery
3011487|NCT02486380|Experimental|Full face/Nasal masks|Simplus/Eson
3011488|NCT02486367|Active Comparator|Standard care/clopidogrel|600mg load followed by 75mg daily.
3011489|NCT02486367|Experimental|Ticagrelor|180mg load followed by 90mg twice daily for 30 days.
3011490|NCT02486354|Experimental|icotinib|Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
3011491|NCT02486341|Experimental|Human Neutral Protamine Hagedorn (NPH)|The inclusion will be stratified into 2 groups according to the type of basal insulin being at baseline (ratio 1: 1): NPH human insulin / Long-acting basal insulin analogues. The type of insulin will not be changed by this protocol.
3011492|NCT02486341|Experimental|Long-acting basal insulin analogues|
3011493|NCT02486328|Other|Group MM|2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3
3011494|NCT02486328|Other|Group RP|100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3
3011653|NCT02485080|Experimental|Simeprevir + sofosbuvir daily, 24 weeks|Eligible and consenting patients will be treated with sofosbuvir (SOF) 400 mg daily and simeprevir (SMV) 150 mg daily for 24 weeks. Both drugs will be administered orally, per manufacturers' instructions.
3011495|NCT02486315||AXXESS stent|"all consecutive patients with de novo bifurcation lesions treated at the Clinica Mediterranea (Naples) and at the Sapienza University (Rome) were screened for potential inclusion in the present study. Inclusion angiographic criteria were: 1) significant (≥70% diameter stenosis) bifurcation lesion; 2) MV reference diameter between 2.75 and 4.75 mm by visually estimated, 3) SB reference diameter ≥2.25 mm by visual estimate; 4) bifurcation angle (between the distal MV and the SB) <70° by visual estimate. Both protected and unprotected left main bifurcation lesions were allowed to be included, provided that all previous angiographic criteria were satisfied. Patients deemed eligible underwent AXXESS stent implantation"
3011496|NCT02486302||Observation Group|
3011497|NCT02486289|Experimental|NBMI (Emeramide) 100mg|NBMI oral capsules 100mg administered once daily. Double dummy used for blinding i.e. 2 x 50mg NBMI + 1 x 200mg placebo capsule equals in total 3 capsules administered daily.
3011498|NCT02486289|Experimental|NBMI (Emeramide) 300mg|NBMI oral capsules 300mg administered once daily. Double dummy used for blinding i.e. 2 x 50mg NBMI + 1 x 200mg NBMI capsule equals in total 3 capsules administered daily.
3011499|NCT02486289|Placebo Comparator|Placebo|Placebo oral capsules administered once daily. Double dummy used for blinding i.e. 2 x 50mg size + 1 x 200mg size placebo capsules equal in total 3 capsules administered daily.
3011500|NCT02486276|Active Comparator|Sumatriptan|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg
3011501|NCT02486276|Placebo Comparator|Placebo|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placebo
3011502|NCT02486263|Experimental|Study|Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions
3011503|NCT02486263|No Intervention|Conventional|Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.
3011504|NCT02486250||Main Study Recruits|Participants are recruited to come into a clinic and take supervised cognitive tests both online and paper/pencil as well as take unsupervised online cognitive tests at home. Participants will also be given a spit kit in clinic to determine ApOE Status.
3011505|NCT02486250||MRI & PET Substudy|A subset of 34 participants from the Main Study Recruits will be invited to have an MRI and PET scan. The purpose of the sub-study is to obtain feasibility data for collecting longitudinal neuroimaging studies for participants in this sample.
3011506|NCT02486250||ReVeRe 1|A subset of 200 participants from the Main Study Recruits and all MRI & PET Substudy participants will be invited to participate in ReVeRe 1. The purpose of ReVeRe is to validate an additional unsupervised online cognitive measure, administered via an iPad application.
3011507|NCT02486250||ReVeRe 2|A subset of approximately 80 participants from the Main Study Recruits and MRI & PET Substudy participants will be invited to participate in ReVeRe 2. The purpose of ReVeRe 2 is to determine if performance on ReVeRe test battery is sensitive to amyloid positivity in cognitively intact older adults and also sensitive to longitudinal cognitive decline in this patient population.
3011508|NCT02486237||Type 2 diabetes mellitus|Type 2 diabetes mellitus patients, no intervention is performed besides usual clinical practice
3011509|NCT02486224|Experimental|Kona Deep|Subjects will receive Kona Deep post-exercise
3011510|NCT02486224|Placebo Comparator|Spring Water|Subjects will receive commercially available Spring Water post-exercise
3011511|NCT02486224|Active Comparator|Sports Drink|Subjects will receive commercially available Sports Drink post-exercise
3011512|NCT02486211|Placebo Comparator|Placebo|Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
3011513|NCT02486211|Experimental|Amantadine|100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
3011514|NCT02486198|Placebo Comparator|placebo+oxaliplatin-based chemotherapy|equal saline as placebo, one hour before chemotherapy (if with chemotherapy) with oxaliplatin-based chemotherapy (every 2 or 3 weeks), or daily use until neurotoxicity progress.
3011515|NCT02486198|Experimental|GM+oxaliplatin-based chemotherapy|monosialotetrahexosylganglioside Sodium Injection, 40mg or 60mg, one hour before chemotherapy (if with chemotherapy) with oxaliplatin-based chemotherapy (every 2 or 3 weeks), or daily use until neurotoxicity progress.
3011516|NCT02486185|Other|SARC-F|screening test for sarcopenia being studied, the SARC-F
3011517|NCT02486172|Other|Peer supporter|Peer support program
3011518|NCT02486159|Experimental|Herbal plaster and Acupuncture|"In the first year: Acupoint herbal plaster applications every one week over a 4-week period for a total of 4 applications.~In the second year: Acupoint herbal plaster used as the same method as first year, and combined with Acupuncture treatment in the same time."
3011519|NCT02486133|Experimental|A|Prezista & Norvir & Tivicay
3011520|NCT02486133|Active Comparator|B|Prezista & Norvir & Truvada or Prezista & Norvir & Kivexa
3011521|NCT02486107||PECD|percutaneous endoscopic cervical foraminotomy
3011522|NCT02486107||MTPF|microscopic tubular retractor assisted foraminotomy
3011523|NCT02486107||ACDF|anterior cervical discectomy and fusion
3011524|NCT02486081||children with intelligent disabilities|children with ID will be measured via a smart soccer ball. Performance will be measured as acceleration, total time for completion, total distance
3011525|NCT02486081||typical-developed children (TD)|TD children will be measured via a smart soccer ball. Performance will be measured as acceleration, total time for completion, total distance
3011526|NCT02486068|Experimental|ABSORB scaffold|Patient will undergoes elective or emergent percutaneous coronary intervention and will be treated with ABSORB scaffold.
3011527|NCT02486068|Active Comparator|Xience|Patient will undergoes elective or emergent percutaneous coronary intervention and will be treated with Xience Prime.
3011528|NCT02486055|Active Comparator|Cohort 1|In Cohort 1, doses of BPM31510 Oral Nanosuspension 4% will be administered two times per day before the morning and evening meals with no less than 8 and no more than 10 hours between doses. Immediately after administration, subjects will ingest 6 ounces of tap or bottled water. Solid food and drinks, other than water should be restricted to 2 hours before and 1 hour after dosing.
3011691|NCT02484846|Experimental|70% TIB|Participants were to spend 70% of their normal time in bed on the night prior to the second visit.
3044711|NCT02262611||Hypertension patients - Diabetology|
3011529|NCT02486055|Active Comparator|Cohort 2|In Cohort 2 doses BPM31510 Oral Nanosuspension 4% will be administered three times per day before meals, with no less than 4 and no more than 6 hours between doses. Immediately after administration, subjects will ingest 6 ounces of tap or bottled water. Solid food and drinks, other than water should be restricted to 2 hours before and 1 hour after dosing.
3011530|NCT02486042|No Intervention|Standard Nutrition|Infants in this group will receive the standard intravenous nutrition with predominantly Omega-6 fatty acids.
3011531|NCT02486042|Experimental|Omega-3 Group/Added Nutrition|Infants in this group will receive the experimental intravenous nutrition with Omega-3 fatty acids known as Omegaven in addition to standard nutrition.
3011532|NCT02486016|Experimental|Duragesic Reference Fentanyl Patch|Each volunteer participates in two procedure days using the Apotex generic fentanyl patch with heating applied for one hour at hour 11 and hour 18, respectively; then followed by two procedure days using the Duragesic reference fentanyl patch with heating applied for one hour at hour 11 and hour 18, respectively; lastly followed by two procedure days using the Mylan generic fentanyl patch with heating applied for one hour at hour 11 and hour 18, respectively.
3011533|NCT02486016|Active Comparator|Apotex Generic Fentanyl Patch|Each volunteer participates in two procedure days using the Apotex generic fentanyl patch with heating applied for one hour at hour 11 and hour 18, respectively; then followed by two procedure days using the Duragesic reference fentanyl patch with heating applied for one hour at hour 11 and hour 18, respectively; lastly followed by two procedure days using the Mylan generic fentanyl patch with heating applied for one hour at hour 11 and hour 18, respectively.
3011534|NCT02486016|Active Comparator|Mylan Generic Fentanyl Patch|Each volunteer participates in two procedure days using the Apotex generic fentanyl patch with heating applied for one hour at hour 11 and hour 18, respectively; then followed by two procedure days using the Duragesic reference fentanyl patch with heating applied for one hour at hour 11 and hour 18, respectively; lastly followed by two procedure days using the Mylan generic fentanyl patch with heating applied for one hour at hour 11 and hour 18, respectively.
3011535|NCT02486003||mTBI athletes|College athletes who undergo an mTBI during the season
3011536|NCT02486003||Control athletes|College athletes who do not undergo an mTBI during the season
3011537|NCT02486003||Control non-athletes|Control non-athletes with long term follow-up of approximately 4-6 weeks and 3-5 months
3011538|NCT02485990|Experimental|Arm A: Tremelimumab Alone|25 patients will receive tremelimumab alone at 10 mg/kg IV every 4 weeks for 7 doses then every 12 weeks until disease progression.
3011539|NCT02485990|Experimental|Arm B1: DESE Tremelimumab and Olaparib|18 patients will receive tremelimumab (3 or 10 mg/kg IV) every 4 weeks for 7 doses then every 12 weeks and olaparib (150 or 300 mg orally twice a day) until disease progression.
3011540|NCT02485990|Experimental|Arm B2: Tremelimumab and Olaparib|25 patients will receive tremelimumab (every 4 weeks for 7 doses then every 12 weeks) and olaparib (daily) until disease progression. Dose of tremelimumab and olaparib will be determined during the DESE (Arm B1).
3011541|NCT02485977||Pulmonary Hypertension|Adult patients with pulmonary hypertension referred for cardiac catheterization in the PI institution
3011542|NCT02485964|Other|Blood Draw Only|One time blood draw at time of consent; No treatment
3011543|NCT02485951|Active Comparator|Central air injection|The needle was moved radially inside the trephination site and advanced to the central or paracentral cornea.
3011544|NCT02485951|Active Comparator|Peripheral air injection|The needle was inserted into the deep stroma from the trephination site and advanced into the peripheral cornea to approximately 1.5 mm anterior to the limbus.
3011545|NCT02485938|Experimental|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|CAP-1002 is an investigational product consisting of allogeneic cardiosphere-derived cells (CDCs). All subjects assigned to the active treatment arm will receive an intended total dose of 75 million (M) CAP-1002 cells infused as 25M cells into each of the three left ventricle cardiac territories (anterior, lateral, inferior/posterior). If any of the three coronary arteries are deemed by the infusing Investigator to supply less than 30% of the left ventricular myocardium, the infusing Investigator may choose to infuse only 12.5M cells into that coronary artery or arteries. Therefore the full dose of CAP-1002 delivered may range from 50M cells to 75M cells provided that all three arteries are infused.
3011546|NCT02485938|No Intervention|Usual Care|Subjects randomized to receive usual care will continue to be cared for and treated in whatever manner the investigator deems most appropriate for the subject on an ongoing basis, and will receive no infusion.
3011547|NCT02485925|Experimental|Treatment group|THERMOCOOL® SMARTTOUCH™
3011548|NCT02485912|Active Comparator|Group 1|ChAd3-EBO Z (2.5 - 3.7 x 10^10 vp) and MVA-EBO Z (1.0 x 10^8 pfu) 7 days later. Both vaccinations are administered in the same arm.
3011549|NCT02485912|Active Comparator|Group 2|ChAd3-EBO Z (2.5 - 3.7 x 10^10 vp) and MVA-EBO Z (1.0 x 10^8 pfu) 7 days later. The MVA-EBO Z is administered in the opposite arm to the ChAd3-EBO Z.
3011550|NCT02485899|Experimental|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|
3011551|NCT02485886|Experimental|68Ga-BMV101 injection and PET/CT scan|The patients were intravenously injected with 68Ga-BMV101 and underwent PET/CT scan 1 h and 2.5 h after that.
3011552|NCT02485873||Rivaroxaban|Non-valvular Atrial Fibrillation (NVAF) patients who were initiated on rivaroxaban for stroke prevention
3011553|NCT02485873||Vitamin K antagonists (VKA)|NVAF patients who were initiated on VKA (predominately phenprocoumon in Germany) for stroke prevention
3011554|NCT02485860|No Intervention|standard dressings|
3011555|NCT02485860|Experimental|standard dressings with sterile honey|Melectis G
3011556|NCT02485834|Active Comparator|Arm A - surgery, chemotherapy and radiation therapy|Patients undergo surgery within 42 days of completion of pre-registration chemotherapy. Beginning within 49 days of surgery, patients receive 5-FU IV continuously and capecitabine PO BID on days 1-7, and undergo 3D-CRT or IMRT QD on days 1-5. Treatment continues for 5 weeks in the absence of disease progression or unacceptable toxicity.
3011557|NCT02485834|Experimental|Arm B - surgery, chemotherapy and FDG-PET|Beginning within 28 days of day 1 of pre-registration chemotherapy, patients receive docetaxel IV and irinotecan IV on days 1 and 8. Treatment repeats every 3 weeks for 2 courses. Beginning within 42 days of completion of docetaxel and irinotecan, patients undergo surgery. Patients also undergo FDG-PET within 14 days of planned surgery. Beginning within 60 days after surgery, patients receive 3 additional courses of docetaxel and irinotecan hydrochloride courses in the absence of disease progression or unacceptable toxicity.
3011558|NCT02485821|Experimental|Estradiol + Misoprostol|100 patient will receive single dose vaginal estradiol 50mcg tablet (Ethinyl Estradiol manufactured by KAHIRA Pharmaceutical company) and vaginal misoprostol 25mcg tablet (Vagiprost manufactured by ADWIA Pharmaceutical company), misoprostol alone will repeated every 6hours up to five doses.
3011559|NCT02485821|Placebo Comparator|Placebo + Misoprostol|100 patients will receive placebo vaginally and misoprostol 25 mcg which will be repeated every 6 hours up to five doses.
3011560|NCT02485808||Surgical|"Men and women presenting for clinical care for whom surgical treatment of their lower urinary symptoms is planned.~There will be no interventions, as this is an observational cohort."
3011561|NCT02485808||Medical|"Men and women presenting for clinical care for whom medical treatment of their lower urinary symptoms is planned.~There will be no interventions, as this is an observational cohort."
3011562|NCT02485808||Controls|"Men and women who are not experiencing lower urinary tract symptoms.~This group will undergo MRI, pain and auditory sensitivity testing."
3011563|NCT02485808||Neuroimaging & Sensory Testing|"Subjects from the Medical and Surgical Cohorts who agree to additional testing in the form of neuroimaging (via fMRI) and multimodal sensory testing.~This group will undergo MRI, pain and auditory sensitivity testing."
3011564|NCT02485795||Pain patients|Observational; Patients presenting to interventional pain management centers for therapy.
3011565|NCT02485782||Hemodialysis patients|"midweek dialysis session~patients on maintenance hemodialysis at least 3 months~stable dry weight~single-pool Kt/V >1.4~no clinical cardiovascular disease during the 6 months preceding entry"
3011566|NCT02485769|Experimental|PF-06650833|Active arm , PF-06650833 kinase.
3011567|NCT02485769|Placebo Comparator|Placebo|Placebo arm
3011568|NCT02485756|Experimental|Educational handout|Participants in the intervention group will read an educational handout on hormonal contraceptives/antiepileptic interactions.
3011569|NCT02485756|No Intervention|Control (no educational handout)|Those in the standard care group will not receive the educational handout.
3011570|NCT02485743|Active Comparator|Active Diet Products|A range of products that will be provided as part of a weight maintenance diet which contain active ingredients aimed at increasing satiety (such as inulin, β-glucan, protein and mycoprotein). All ingredients are accepted food ingredients approved for human consumption in Europe.
3011571|NCT02485743|Placebo Comparator|Placebo Diet Products|A range of products matching those provided in the Active Diet which will be provided as part of a weight maintenance diet but do not contain additional ingredients aimed at improving satiety (food matrices will be the same - e.g. shakes, cheeses etc but without active ingredients).
3011572|NCT02485730||Adult children of AD patient|Cognitively healthy adult children of AD patient: First-degree descendant of an AD patient (following diagnosis as define in protocol) from 45 to 64 years old.
3011573|NCT02485717|Experimental|Natroba (spinosad)|spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours
3011574|NCT02485717|Placebo Comparator|Placebo|placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad. Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.
3011575|NCT02485704|Experimental|Natroba (spinosad)|spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours
3011576|NCT02485704|Placebo Comparator|Placebo|placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad (vehicle). Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.
3011577|NCT02485691|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m^2 intravenously in 1 hour every 3 weeks + prednisone 10 mg orally given daily + Primary prophylactic G-CSF (the choice of the G-CSF product is left to the Investigator's decision). Treatment will continue until confirmed disease progression or unacceptable toxicity.
3011578|NCT02485691|Experimental|Abiraterone acetate or enzalutamide|Abiraterone acetate oral 1000 mg once daily continuously + prednisone 5 mg orally given twice daily OR enzalutamide oral 160 mg once daily continuously. Treatment will continue until confirmed disease progression or unacceptable toxicity.
3011579|NCT02485678|Experimental|Proactive Telephone Toxicity Management|Proactive Telephone Toxicity Management
3011580|NCT02485678|Active Comparator|Control Arm|Control
3011581|NCT02485665|No Intervention|Kegel exercise education|Prostate cancer patients of control group will received Kegel exercise education for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy.
3011582|NCT02485665|Experimental|Extracorporeal biofeedback device|Prostate cancer patients of intervention group will received extracorporeal biofeedback device (Any Kegel) for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy.
3011583|NCT02485652|Experimental|HM61713|HM61713 800 mg (2 x 400 mg tablets) once daily (QD)
3011584|NCT02485639|Experimental|Arm 1|All study participants will receive licensed inactivated influenza vaccine intramuscularly on Day 1.
3011585|NCT02485626||Anthracycline treated BC patients|AVL or UMCG patients between the age of 40 - 50 at the time of BC diagnosis and treatment, treated with anthracyclines respectively 5-7 years ago and 10-12 years ago.
3011586|NCT02485626||Anthracycline naive BC patients|AVL or UMCG patients between the age of 40 - 50 at the time of BC diagnosis and treatment, treated without anthracyclines respectively 5-7 years ago and 10-12 years ago.
3011587|NCT02485613||bortezominb and dexamethasone group|
3011588|NCT02485600||DUODOPA patients.|Patients starting DUODOPA treatment at time of enrollment.
3011589|NCT02485587|Experimental|Individualized Arousal-Biofeedback|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the experimental condition will receive 20 sessions of arousal (electrodermal activity) feedback, 1 session/week. Each session will last about 1 hour. After the first 10 sessions (10 weeks after the beginning of the training phase), parents/caregivers will be asked to evaluate behavioral measures of aggression.~After training completion (approximately 20 weeks after the beginning of the training phase), subjects will undergo post-treatment assessment (week 20/21) and follow up (6 months after the end of the training phase)."
3011590|NCT02485587|Active Comparator|Treatment as usual|After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the comparator condition will receive several appointments together with their parents/caregivers or group trainings over a timeframe of 20 weeks. Within the sessions, the investigators will focus on psychoeducational issues and provide general counseling for the families. After 10 weeks, parents/caregivers will be asked to evaluate behavioral measures of aggression. After 20 weeks, subjects will undergo post-treatment assessment (week 20/21) and follow up (6 months after the end of the treatment phase).
3011591|NCT02485587|No Intervention|Typically developing (TD) control group|Healthy, typically developing children will only undergo baseline assessment (observational) for comparison
3011592|NCT02485574|Experimental|Bone bridging|To compare bone bridging between anterior bridging cages augmented with auto bone plus β-calcium phosphate + hydroxyapatite in left side of disc space and anterior bridging cages augmented with auto bone in rt side of disc space in transforaminal lumbar interbody arthrodesis
3011593|NCT02485561|Active Comparator|Information only|INTERVENTION: Information about colon cancer and screening tests from sources such as the CDC's Screen for Life campaign.
3011594|NCT02485561|Experimental|Screener Narrative|INTERVENTION: Information + Personal Narrative from someone who was screened for colon cancer
3011595|NCT02485561|Experimental|Survivor Narrative|INTERVENTION: Information + Personal Narrative from someone who was screened for, and diagnosed with, colon cancer
3011596|NCT02485548|Experimental|Raltitrexed plus cisplatin|Raltitrexed plus cisplatin and IMRT
3011597|NCT02485548|Active Comparator|5-fluorouracil plus cisplatin|5-fluorouracil plus cisplatin and IMRT
3011598|NCT02485535|Experimental|Treatment (selinexor)|Beginning on day 60-100 after allo-SCT without evidence of GVHD above grade 1 and disease relapse with stable hematopoietic recovery, patients receive selinexor PO on day 1 of each week or on days 1 and 3 of weeks 1-3. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3011599|NCT02485522||Fecal incontinence|Women age >18 years old with a diagnosis of fecal incontinence
3011600|NCT02485522||Controls|Women age >18 without a diangosis of fecal incontinence
3011601|NCT02485509|Experimental|20 mg VM-1500/Placebo Healthy group|VM-1500 20 mg or placebo single dose.
3011602|NCT02485509|Experimental|40 mg VM-1500/Placebo Healthy group|VM-1500 40 mg or placebo single dose.
3011603|NCT02485509|Experimental|20 mg VM-1500/Placebo Patient group|VM-1500 20 mg or placebo once daily for 7 days.
3011604|NCT02485509|Experimental|40 mg VM-1500/Placebo Patient group|VM-1500 40 mg or placebo once daily for 7 days.
3011605|NCT02485483||VADERA I|RA participants without a concurrent history of depression and who have not received psychotherapy, antidepressants, or inpatient psychiatric treatment in the 3 months before baseline (T0) will be asked to complete the World Health Organization Five Well-Being Index (WHO-5), Patient Health Questionnaire-9 (PHQ-9) and Beck Depression Inventory (2nd edition) (BDI-II) questionnaires and a subsequent structured interview using Montgomery-Åsberg Depression Rating Scale (MADRS) at 2 time-points (T0 and T1 [12 ± 2 weeks]) with a 10-14 week interval between assessments.
3011606|NCT02485483||VADERA II|All RA participants who are able to complete the PHQ-9 and BDI-II questionnaires, and have been scheduled for a RA consultation at one of the participating clinics will be eligible for participation.
3011607|NCT02485470|Experimental|MPACT|A 7-week (7 weeks x 3 sessions per week), on site, functional resistance training (FRT) as well as a walking program concurrent with CCRT will be followed by a 7-week post-CCRT home program. The protocol follows American College of Sports Medicine (ACSM) prescription guidelines for cancer patients.
3011608|NCT02485470|No Intervention|Usual Care|
3011609|NCT02485457|Experimental|Low volume|"The protocol will follow the following steps :~basal measurements (heart rate, arterial pressure, stroke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~followed by passive leg rising and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~second basal measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~followed by low volume loading (250 ml of Ringer solution) and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)"
3011610|NCT02485457|Experimental|High volume|"The protocol will follow the following steps :~basal measurements (heart rate, arterial pressure, stroke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~followed by passive leg rising and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~second basal measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~followed by low volume loading (500 ml of Ringer solution) and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)"
3011611|NCT02485444|Active Comparator|Oxytocin|
3011612|NCT02485444|No Intervention|Observation|
3011613|NCT02485431|Experimental|Deflazacort, fasted|36mg of Deflazacort with 240 ml of room-temperature, non-carbonated water in Fasted state.
3011614|NCT02485431|Experimental|Deflazacort, high-fat meal|36mg of Deflazacort with 240 ml of room-temperature, non-carbonated water with high fat meal served 30 minutes prior to dosing.
3011615|NCT02485431|Experimental|Deflazacort, crushed, fasted|36mg of Deflazacort crushed and mixed with apple sauce.
3011616|NCT02485431|Experimental|Deflazacort alternate strength,fasted|Investigational Formulation Deflazacort tablet (6 X 6mg).
3011617|NCT02485431|Experimental|Deflazacort suspension with apple juice|Deflazacort oral suspension (36mg) mixed with 100ml apple juice in fasted state.
3011618|NCT02485418|Experimental|Propofol infusion|"All subjects will be treated with an intravenous propofol infusion at the following escalating rate schedule:~20 mcg/kg/min for 20 minutes, followed by an increase to 30 mcg/kg/min for 20 minutes and then by an increase to 40 mcg/kg/min for 20 minutes"
3011619|NCT02485405||stressed|stressed volunteers perform Trier social stress test
3011620|NCT02485405||non-stressed|non-stressed volunteers perform Trier social stress test
3011621|NCT02485392|Active Comparator|Single-Site robot-assisted cholecystectomy|Single-Site robot-assisted cholecystectomy
3011622|NCT02485392|Active Comparator|Single-incision laparoscopic cholecystectomy|Single-incision laparoscopic cholecystectomy
3011623|NCT02485379|Other|Prostate biopsy|"Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy."
3011624|NCT02485366|Experimental|Rejuvenated PRBCs|The investigators will restore important energy molecules in stored red blood cells before they are transfused, with a rejuvenating solution (Rejuvesol).
3011625|NCT02485353|Other|Vosaroxin and Cytarabine|
3011626|NCT02485340|Active Comparator|Sumatriptan|headache is induced with 5-ISMN. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg
3011627|NCT02485340|Placebo Comparator|Placebo|headache is induced with 5-ISMN. This headache is treated double-blinded with 1 tablet of placebo (the tablet is similar to the active tablet)
3011628|NCT02485327|Experimental|Afrezza®|"Two-period, replicate single dose, euglycemic clamp study. There will be 2 treatment periods with a replicate administration of 1 dose of Afrezza TI (40U) in both periods.~Each patient will be given a replicate administration of 1 dose level of Afrezza TI with washout duration between treatment periods (5-19 days between periods, ie, 7 to 21 days between dosing occasions)."
3011629|NCT02485314||Participation|Parents will complete the PEM-CY (Participation and Environment Measure for Children and Youth).
3011630|NCT02485301|Experimental|Group EBO-Z|The subjects in the Group EBO-Z will receive the vaccine at Day 0 of the study
3011631|NCT02485301|Placebo Comparator|Group Placebo/ EBO-Z|The subjects in the Group Placebo/ EBO-Z will receive a placebo at Day 0 (as a control) and will receive the investigational ChAd3-EBO-Z vaccine at Month 6
3011632|NCT02485249|Experimental|Dexamethasone Phosphate|Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 14.0 mA-min at 3.5 mA on Day 0, Day 4, and Day 14
3011633|NCT02485236|Active Comparator|Low flow oxygen via nasal cannula|In the low flow oxygen via nasal cannula, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial oxygen saturation of > 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
3011634|NCT02485236|Active Comparator|Humidified Nasal High Flow Therapy|Adjustment of humidified high flow air therapy: To adjust oxygen 1-4 liters per minute to an arterial oxygen saturation of > 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
3011635|NCT02485210|Active Comparator|Covencional treatment|"Convencional endodontic treatment for deciduous teeth, with Surgical chemical preparation with series of Kerr files appropriate for each case, using initial file and an additional two files of larger size, with irrigation and aspiration with 1% sodium hypochlorite (Milton's solution) and endo PTC (Fórmula & Ação) with each change of file.~Filling of root canals with calcium hydroxide (Ultra-cal, Ultradent, Brazil); base of thin gutta-percha and filling with glass ionomer cement; restorative treatment performed in subsequent session."
3011636|NCT02485210|Experimental|Photodynamic therapy|Endodontic Treatment with photodynamic terapy Irrigation of the root canal system Insertion of sterile paper cone immersed in Chimiolux® methylene blue for three minutes; administration of wireless Therapy XT EC laser device (DMC - São Carlos, Brazil) after removal of cone; energy density: 4 J/cm², power: 100 mw; wavelength: 660 nm; exposure time: 40 seconds Filling of root canals with calcium hydroxide (Ultra-cal, Ultradent, Brazil); base of thin gutta-percha and filling with glass ionomer cement; restorative treatment performed in subsequent session
3011637|NCT02485197|Other|Low 25(OH)D|We will recruit individuals with low 25(OH)D (<30ng/mL).
3011638|NCT02485197|Other|High 25(OH)D|"We will recruit individuals with higher 25(OH)D (at least 20ng/mL units higher then that of the low 25(OH)D group)."
3011639|NCT02485184|Active Comparator|TIPS group|Transjugular intrahepatic portosystemic shunt
3011640|NCT02485184|Active Comparator|ET & drugs groups|"Endoscopic therapy.~Non-selective beta blockers.~Anticoagulation therapy."
3011641|NCT02485171|Experimental|Experimental|Introduction of a walking aid device SAFEWALKER for elderly patients during rehabilitation after a post-fall syndrome.
3011642|NCT02485171|No Intervention|No intervention|No introduction of a walking aid device for elderly patients during rehabilitation after a post-fall syndrome.
3011643|NCT02485158|Experimental|AMP, ALC, THC or Placebo 1|All healthy adult volunteers attended 6 sessions in which they received 20mg AMP, 0.8g/kg ALC, and 7.5mg THC, alternating with three placebo sessions.
3011644|NCT02485158|Experimental|AMP, ALC, THC or Placebo 2|All healthy adult volunteers attended 6 sessions in which they received 20mg AMP, 0.8g/kg ALC, and 7.5mg THC, alternating with three placebo sessions.
3011645|NCT02485145|Experimental|A/B|In this crossover trial, the A/B group will receive the test product (A) and then the placebo (B). The topical product contains the following: Diclofenac 3%, Baclofen 2%, Orphenadrine Citrate 5% and Bupivacaine 2% in a VersaPro cream, while the placebo is the VersaPro cream alone. Participants will use the test product for 7 days, applying the topical product to the hands twice a day. There will be a 7 day washout period, and then participants will be given the placebo cream, which will be used for 7 days, applying the topical placebo to the hands twice a day.
3011646|NCT02485145|Experimental|B/A|In this crossover trial, the B/A group will receive the placebo (B) and then the test product (A). The product contains the following: Diclofenac 3%, Baclofen 2%, Orphenadrine Citrate 5% and Bupivacaine 2% in a VersaPro cream, while the placebo is the VersaPro cream alone. Participants will use the placebo product for 7 days, applying the placebo product to the hands twice a day. There will be a 7 day washout period, and then participants will be given the test cream, which will be used for 7 days, applying the topical product to the hands twice a day.
3011647|NCT02485132||T2DM at SU initiation|T2DM newly prescribed a SU
3011648|NCT02485119|Experimental|BAY94-9343|"Cohort 1: Safety, tolerability and PK of 4.5 mg/kg dose given Q3W. Proceeding to Cohort 2 or not will be decided based on both safety variables during Cycle 1 (21 days) of 3 to 6 subjects in Cohort 1 and PK obtained from Cycle 1 (at least Day 1 to Day 5).~Cohort 2: Safety, tolerability and PK of 6.5 mg/kg dose given Q3W. Whether recruitment will be continued up to 9 subjects for Cohort 2 or not will be decided based on safety variables during Cycle 1 (21 days) of the first 3 subjects in Cohort 2. The safety and tolerability of 6.5 mg/kg will be assessed based on the data of 9 subjects during Cycle 1 in Cohort 2, and considering long term toxicity, the safety and tolerability of BAY94-9343 will be assessed all safety data by the end of 3 cycles in Cohort 2."
3011654|NCT02485067|Experimental|THVD-201|"1. Treatment period(12 weeks)~Double dummy(A+B) A. THVD-201: capsule B. Placebo(For Detrusitol 2mg tablet)~One capsule and One tablet bid on an empty stomach~2. Open-label extension period(An additional 12 weeks)~Regardless of the previous type of arm, all patients only take THVD-201 during this period.~One capsule bid on an empty stomach"
3011655|NCT02485067|Active Comparator|Tolterodine (Detrusitol)|"1. Treatment period(12 weeks)~Double dummy(A+B) A. Placebo(For THVD-201): capsule B. Detrusitol 2mg tablet~One capsule and One tablet bid on an empty stomach~2. Open-label extension period(An additional 12 weeks)~Regardless of the previous type of arm , all patients only take THVD-201 during this period.~One capsule bid on an empty stomach"
3011656|NCT02485054||Eligible patients|Adults having had a transient visual disturbance during the last 8 days, except a diplopia
3011657|NCT02485041|Experimental|M→D→D+M|Mirodenafil(M) in period 1, Dapoxetine(D) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
3011658|NCT02485041|Experimental|M→D+M→D|Mirodenafil(M) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Dapoxetine(D) in period 3
3011659|NCT02485041|Experimental|D→M→D+M|Dapoxetine(D) in period 1, Mirodenafil(M) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
3011660|NCT02485041|Experimental|D→D+M→M|Dapoxetine(D) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Mirodenafil(M) in period 3
3011661|NCT02485041|Experimental|D+M→M→D|Dapoxetine+Mirodenafil(D+M) in period 1, Mirodenafil(M) in period 2, Dapoxetine(D) in period 3
3011662|NCT02485041|Experimental|D+M→D→M|Dapoxetine+Mirodenafil(D+M) in period 1, Dapoxetine(D) in period 2, Mirodenafil(M) in period 3
3011663|NCT02485028|Experimental|M→D→D+M|Mirodenafil(M) in period 1, Dapoxetine(D) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
3011664|NCT02485028|Experimental|M→D+M→D|Mirodenafil(M) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Dapoxetine(D) in period 3
3011665|NCT02485028|Experimental|D→M→D+M|Dapoxetine(D) in period 1, Mirodenafil(M) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
3011666|NCT02485028|Experimental|D+M→M→D|Dapoxetine+Mirodenafil(D+M) in period 1, Mirodenafil(M) in period 2, Dapoxetine(D) in period 3
3011667|NCT02485028|Experimental|D+M→D→M|Dapoxetine+Mirodenafil(D+M) in period 1, Dapoxetine(D) in period 2, Mirodenafil(M) in period 3
3011668|NCT02485028|Experimental|D→D+M→M|Dapoxetine(D) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Mirodenafil(M) in period 3
3011669|NCT02485015|Other|Apatinib alone|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.Patients undergo Apatinib.
3011670|NCT02485015|Experimental|Apatinib+CIK|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous. plus autologous cytokine-induced killer cells 3 cycles,every 1 year,continuous.
3011671|NCT02485002|Active Comparator|UAS (+)|RIRS with ureteral access sheath: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
3011672|NCT02485002|Experimental|UAS (-)|RIRS without ureteral access sheath: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
3011673|NCT02484989||Retinopathy of prematurity|Any baby with ROP who is treated or referred to another unit for treatment either in the form of laser therapy, cryotherapy, antiVEGF agent or vitrectomy/scleral buckling (or a combination of above treatments)
3011674|NCT02484976|Experimental|Family Based Behavioral Treatment|Central satiety brain and hormonal responses will be compared pre-and post-Family Based Behavioral Treatment, as well, as to a non-obese sample.
3011675|NCT02484963|Experimental|zolpidem|Tablet zolpidem 5mg once daily will be given for 4 weeks
3011676|NCT02484963|Placebo Comparator|Placebo|One tablet of placebo will be given for 4 weeks
3011677|NCT02484950|Experimental|Rotator cuff repair with stem cells|Using clinically accepted methods, subjects will undergo bone marrow aspiration (from hip, proximal humerus or tibia) through a small incision prior to arthroscopy in the group undergoing MSC augmentation. They will then undergo arthroscopic full thickness rotator cuff repair using a double row, TOE anchor/suture technique with mesenchymal stem cell augmentation.
3011678|NCT02484950|Placebo Comparator|Rotator cuff repair without stem cells|Subjects will undergo arthroscopic full thickness rotator cuff repair using a double row, TOE anchor/suture technique, without augmentation of mesenchymal stem cells. To maintain patient blinding, all patients will receive a small incision around the site of expected bone marrow aspiration (hip, proximal humerus, or tibia), regardless of whether or not they receive bone marrow.
3011679|NCT02484937|Active Comparator|Group 1 (PMS Treatment)|Subjects will be treated monthly for 6 months by Pain Medicine Specialist (PMS) per standard protocol. The PCP will not be involved in the treatment.
3011680|NCT02484937|Experimental|Group 2 (PCP Treatment)|Subjects will be treated monthly for 6 months by the Primary Care Provider (PCP).The PCP will be involved and a multimodal therapeutic strategy will be communicated to the PCP by the PMS. The PCP will make dosage based on an algorithm provided by the PMS on how to adjust drug doses over time. It is not intended that the PCP may have ongoing engagement with the PMS. A direct line of communication will be set up between the PCP and the data integration clinical coordinator to handle serious medical concerns.
3011681|NCT02484924||Clopidogrel Group|Those patients treated with clopidogrel for ACS (before new guideline implementation)
3011682|NCT02484924||Ticagrelor Group|Those patients treated with ticagrelor for ACS (after new guideline implementation)
3011683|NCT02484911|Experimental|Olanzapine regimen|Olanzapine in combination with aprepitant ,palonosetron and dexamethasone.
3011684|NCT02484911|Other|Control regimen|Aprepitant in combination with palonosetron and dexamethasone
3011685|NCT02484898||SEEQ™ MCT/ECM System|SEEQ™ MCT/ECM monitoring for the detection of non-lethal cardiac arrhythmias.
3011686|NCT02484885|Other|Healthy Volunteers|Healthy volunteers will undergo pulmonary function tests, hyperpolarized Xenon MRI at each visit.
3011687|NCT02484872||Lung neoplasms|Lung neoplasms irrespective of stage and histology
3011688|NCT02484859|Active Comparator|remifentanil|i.v. infusion of remifentanil at a rate of 0.25-0.5 µg/kg, followed by an i.v. bolus of 0.5 µg/kg
3011689|NCT02484859|Active Comparator|tramadol + metoprolol|1 mg/kg of tramadol in 100 ml isotonic fluid administered i.v. within the first 30 minutes of the surgery (infusion will be started just before the induction), 5 mg of i.v. metoprolol administered in 2 minutes (after the administration of the neuromuscular blocking agent)
3011690|NCT02484846|Experimental|60% TIB|Participants were to spend 60% of their normal time in bed on the night prior to the second visit.
3011693|NCT02484846|Experimental|90% TIB|Participants were to spend 90% of their normal time in bed on the night prior to the second visit.
3011694|NCT02484846|Active Comparator|100% TIB|Participants were to spend 100% of their normal time in bed (i.e., no change) on the night prior to the second visit.
3011695|NCT02484846|Experimental|115% TIB|Participants were to spend 115% of their normal time in bed on the night prior to the second visit.
3011696|NCT02484846|Experimental|130% TIB|Participants were to spend 130% of their normal time in bed on the night prior to the second visit.
3011697|NCT02484833|Active Comparator|FOLFIRI + Cetuximab until disease progression|FOLFIRI + Cetuximab until disease progression
3011698|NCT02484833|Experimental|FOLFIRI + Cetuximab followed by Cetuximab alone|FOLFIRI + Cetuximab for 8 cycles followed by Cetuximab alone until disease progression
3011699|NCT02484820|Experimental|Pessary|Silicone pessary is associated with standard care Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
3011700|NCT02484820|No Intervention|Control|Standard care only, No silicone pessary will be placed in the vagina.
3011701|NCT02484807||Bosentan + Sildenafil|Combination treatment with Bosentan + Sildenafil at baseline
3011702|NCT02484807||Bosentan + Tadalafil|Combination treatment with Bosentan + Tadalafil at baseline
3011703|NCT02484807||Ambrisentan + Sildenafil|Combination treatment with Ambrisentan + Sildenafil at baseline
3011704|NCT02484807||Ambrisentan + Tadalafil|Combination treatment with Ambrisentan + Tadalafil at baseline
3011705|NCT02484807||Macitentan + Sildenafil|Combination treatment with Macitentan + Sildenafil at baseline
3011706|NCT02484807||Macitentan + Tadalafil|Combination treatment with Macitentan + Tadalafil at baseline
3011707|NCT02484794|Active Comparator|Treatment as Usual|Patients will receive standard outpatient treatment that consists of group psychotherapy, skills training, self-monitoring, nutritional counselling, and meal support.
3011708|NCT02484794|Experimental|Treatment with Smartphone App|Patients will receive the same standard outpatient treatment but will use the smartphone application instead of the paper food record. Patients in this group will receive daily feedback through the app, as opposed to weekly, but will still attend the weekly nutritional counselling group.
3011709|NCT02484781|Active Comparator|Total Hip Arthroplasty|Gait analysis on a trendmill of patients with a well functioning total hip arthroplasty on a trendmill
3011710|NCT02484781|Active Comparator|Resurfacing Hip Arthroplasty|Gait analysis on a trendmill of patients with a well functioning resurfacing hip arthroplasty on a trendmill
3011711|NCT02484768|Experimental|Group A|Infusion of 1000 mg iron isomaltoside 1000 at baseline. The infusion is diluted in 100 mL 0.9 % sodium chloride and given over approximately 15 min
3011712|NCT02484768|Placebo Comparator|Group B|Infusion of 100 mL 0.9 % sodium chloride at baseline given over approximately 15 min
3011713|NCT02484755|Experimental|gefitinib|gifitinib 250 mg oral administration once daily for a total of 4 weeks.
3011714|NCT02484742|No Intervention|Sleep control condition|8 hours of sleep throughout the 18-day stay in the Clinical Research Center
3011715|NCT02484742|Experimental|Insomnia symptom induction condition|4 4-day cycles, each consisting of 3 nights with sleep disruption followed by one night of recovery sleep.
3011716|NCT02484729|Experimental|AZD9977 oral suspension, single doses|In Part A up to 10 cohorts with single ascending doses with AZD9977 as oral suspension. In Part B AZD9977 as oral suspension in IntelliCap® capsule
3011717|NCT02484729|Placebo Comparator|Placebo, oral suspension, single doses|In Part A up to 10 cohorts with single doses with matching placebo to AZD9977
3011718|NCT02484729|Experimental|AZD9977, oral solution, single dose|In Part B, of oral solution of AZD9977 will be used as reference
3011719|NCT02484716|Experimental|Timolol|Timolol 0.5% eye-drops solution packaged in a nasal spray device.
3011720|NCT02484716|Placebo Comparator|Placebo|NaCl solution packaged in a nasal spray device.
3011721|NCT02484703|Placebo Comparator|Placebo|Participants will receive matching placebo by mouth (PO) twice daily (BID) for up to 26 weeks.
3011722|NCT02484703|Experimental|RO5186582 120 mg BID|Participants will receive RO5186582 at a dosage of 120 milligrams (mg) PO BID for up to 26 weeks.
3011723|NCT02484703|Experimental|RO5186582 40 mg BID|Participants will receive RO5186582 at a dosage of 40 mg PO BID for up to 26 weeks.
3011724|NCT02484703|Experimental|RO5186582 60 mg BID|Participants will receive RO5186582 at a dosage of 60 mg PO BID for up to 26 weeks.
3011725|NCT02484690|Active Comparator|Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)|Participants will receive ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) Q4W up to Week 32 (total 9 injections).
3011726|NCT02484690|Experimental|RO6867461, 1.5 mg Q4W|Participants will receive RO6867461 1.5 mg IVT Q4W up to Week 32 (total 9 injections).
3011727|NCT02484690|Experimental|RO6867461, 6 mg Q4W|Participants will receive RO6867461 6 mg IVT Q4W up to Week 32 (9 injections).
3011728|NCT02484690|Experimental|RO6867461, 6 mg Every 4-8 weeks|Participants will receive RO6867461, 6 mg IVT (4 injections) Q4W up to Week 12, followed by 6 mg IVT (2 injections) every 8 weeks up to Week 28.
3011729|NCT02484690|Experimental|Ranibizumab 0.5 mg + RO6867461 6 mg Q4W|Participants will receive ranibizumab, 0.5 mg IVT (3 injections) Q4W up to Week 8, followed by RO6867461, 6 mg IVT (6 injections) Q4W up to Week 32.
3011730|NCT02484677|Experimental|Head and neck cancer patient|Association of Docetaxel, Cisplatin, 5-Fluorouracile for pharmacokinetic evaluation
3011731|NCT02484664|Experimental|celecoxib|Celecoxib 200mg PO QD for 6 months
3011732|NCT02484651|No Intervention|Standard Group|Standard Clinical Practice Group - standard neuromuscular block, with a standard rocuronium dose for intubation (0.6 mg/kg). If required, the reversal of neuromuscular block is performed with neostigmine.
3011733|NCT02484651|Experimental|Deep NMB group|Deep Neuromuscular Block group - with a standard rocuronium dose for intubation (0.6 mg/kg), followed by a constant infusion of rocuronium (10-15 ug/kg/min) to guarantee a PTC less or equal to 2 on the TOF monitor (PTC is evaluated every 5 minutes). The reversal of neuromuscular block is performed with Sugammadex (4 mg/kg).
3011734|NCT02484638|Experimental|CSL689 low-dose|"Part 1: single injection of low-dose CSL689 for PK evaluation~Part 2: up to 2 injections of low-dose CSL689 per bleeding event (bleeding events 1 to 3*)~Part 3: up to 3 injections of low-dose CSL689 per bleeding event * Note: All subjects in the low-dose arm will be treated with high-dose CSL689 for bleeding events 4-6 in Part 2"
3011735|NCT02484638|Experimental|CSL689 high-dose|"Part 1: single injection of high-dose CSL689 for PK evaluation~Part 2: up to 2 injections of high-dose CSL689 per bleeding event (bleeding events 4 to 6*)~Part 3: up to 3 injections of high-dose CSL689 per bleeding event~Note: All subjects in the high-dose arm will be treated with low-dose CSL689 for bleeding events 1-3 in Part 2"
3011736|NCT02484638|Active Comparator|Eptacog alfa low-dose|Single injection of low-dose Eptacog alfa in Part 1 for PK evaluation
3011737|NCT02484638|Active Comparator|Eptacog alfa high-dose|Single injection of high-dose Eptacog alfa in Part 1 for PK evaluation
3011738|NCT02484625|Experimental|Potato Chips|180 kcal
3011739|NCT02484625|Experimental|Greek Yogurt|180 kcal
3011740|NCT02484625|Experimental|Cookies|180 kcal
3011741|NCT02484625|Experimental|Cheese|180 kcal
3011742|NCT02484625|Experimental|2% Milk|180 kcal
3011743|NCT02484612|Experimental|Lean adolescents|15 lean adolescents (BMI Under the national cut-offs for obesity), 12-15 years old, males, will be recruited
3011744|NCT02484612|Experimental|Obese adolescents|15 obese adolescents (BMI above the national cut-offs for obesity), 12-15 years old, males, will be recruited
3011745|NCT02484599|Experimental|CAT active attention bias modification|Active computerized attention training (CAT). Attention training via repeated trials of a modified anti-saccade task with concurrent assessment of eye-movements intended to direct attention towards food stimuli using pictorial food and non-food stimuli (see Werthmann, Field, Roefs, Nederkoorn, & Jansen, 2014).
3011746|NCT02484599|Placebo Comparator|CAT sham bias modification|Sham computerized attention training. Attention training via repeated trials of a modified anti-saccade task with concurrent assessment of eye-movements not intended to change attention processing of food stimuli using pictures of two different non-food stimuli categories (e.g. household and musical instruments).
3011747|NCT02484586|Other|Presbyope group|"40 years and over with a reading add.~Control lens: Etafilcon A, Nelfilcon A, Nesofilcon A, Somofilcon A, 58% Poly-HEMA~Test lens: Etafilcon A~Up to 10 prototype contact lens designs and at least 1 commercially available contact lens designs will be worn by each participant for up to a week on a daily disposable modality. Participants will attend separate fitting and assessment visits for each lens type (Fitting Visit on Day 1, and Assessment Visit as late as Day 7, but may be as early as 6 hours after the Fitting Visit). There will be a minimum 1 night washout period between lens designs, i.e. after an assessment visit but before the next fitting visit."
3011748|NCT02484586|Other|Non-Presbyope group|"18-39 years with no reading add.~Control lens: Etafilcon A, Nelfilcon A, Omafilcon A~Test lens: Etafilcon A~Up to 10 prototype contact lens designs and at least 1 commercially available contact lens designs will be worn by participants for up to a week on a daily disposable modality. Participants will attend separate fitting and assessment visits for each lens type (Fitting Visit on Day 1, and Assessment Visit as late as Day 7, but may be as early as 6 hours after the Fitting Visit). There will be a minimum 1 night washout period between lens designs, i.e. after an assessment visit but before the next fitting visit."
3011749|NCT02484573|Experimental|Propanolol|Patients will take the non-selective beta blocker propranolol for approximately 4 weeks starting immediately after endoscopy for esophageal variceal ligation. Patients will be initiated on a dose of 20mg by mouth every 12 hrs before titration to maximum tolerated dose. Patients will undergo testing before and after treatment for the variables listed in the outcomes section below.
3011750|NCT02484560|Experimental|Ambulatory Patients|Ambulatory patients receiving stem cell therapy
3011751|NCT02484560|Experimental|Non-Ambulatory Patients|non-ambulatory patients receiving stem cell therapy
3011752|NCT02484547|Experimental|Low Dose|Monthly intravenous (IV) infusions
3011753|NCT02484547|Experimental|High Dose|Monthly intravenous (IV) infusions
3011754|NCT02484521|Active Comparator|Schizophrenia patients|Patients diagnosed with Schizophrenia. Will be assigned to PPI monitoring device protocol, according to unified protocol and have questionnaires to assess their status.
3011755|NCT02484521|Other|Healthy subject|This group would be assigned to PPI monitoring device protocol, according to a unified protocol similar to group of patients but not to questionnaires.
3011756|NCT02484508|Experimental|Guli capsule|Guli capsule, the tested drug of this study
3011757|NCT02484508|Active Comparator|Kangguzengsheng capsule|Kangguzengsheng capsule, a CFDA approved drug for articular genu osteoarthritis,is adopted as active comparator in this study
3011758|NCT02484495|Experimental|Program evaluation in intervention areas|"A quasi-experimental matched-control cluster design will be used in which outcomes are compared in intervention and non-intervention areas. The program evaluation will have three points of data collection to assess effect of the program on the nutritional status of children 6-29 months. Sixty intervention clusters have been purposively selected whereas the data will be collected from randomly selected subjects. The following interventions will be provided:~Processed complementary food rations will be distributed to all children 6-23 months of age, from a grain bank based on bartering of raw materials.~Monthly 15 sachets of MNP will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification."
3011759|NCT02484495|No Intervention|Non intervention areas|A quasi-experimental matched-control cluster design will be used in which outcomes will be compared in intervention and non-intervention clusters. The program evaluation will have three points of data collection to assess effect of the program on the nutritional status of children 6-29 months. Matching sixty non-intervention clusters have been purposively selected out of the predetermined non- intervention districts whereas study subjects will be randomly selected from the identified clusters on a population based sampling method both groups. These non-intervention areas do not get processed complementary food rations and do not receive MNPs.
3011760|NCT02484482|Experimental|Group 1|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~Fasting→Standard Meal→High Fat Meal"
3011761|NCT02484482|Experimental|Group 2|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~Standard Meal→High Fat Meal→Fasting"
3011762|NCT02484482|Experimental|Group 3|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~High Fat Meal→Fasting→Standard Meal"
3011763|NCT02484482|Experimental|Group 4|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~Fasting→High Fat Meal→Standard Meal"
3013086|NCT02475317|Experimental|SHP626 20mg|5 subjects will receive a high dose of SHP626 (20 mg)
3011764|NCT02484482|Experimental|Group 5|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~Standard Meal→Fasting→High Fat Meal"
3011765|NCT02484482|Experimental|Group 6|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~High Fat Meal→Standard Meal→Fasting"
3011766|NCT02484469|Experimental|Exposed|The Virtual Human Project videos and Team-Based learning session about leprosy
3011767|NCT02484469|Placebo Comparator|Unexposed|Standard Team-Based learning session about leprosy
3011768|NCT02484456|Placebo Comparator|Test Session 2|2 weeks of single daily dose of placebo pill
3011769|NCT02484456|Experimental|Test Session 1|2 weeks of 1,080 or 1,440 mg/day (single daily dose) of study drug
3011770|NCT02484443|Experimental|Treatment (sargramostim and dinutuximab)|Patients receive sargramostim SC QD on days 1-14 and dinutuximab IV over 10 hours on days 4-7 (dinutuximab infusion may be extended up to a total of 20 hours per day for anticipated toxicities). Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
3011771|NCT02484430|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who are non-responders and in PR at the end of course 4 may receive sapanisertib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3011772|NCT02484417|Experimental|Low Dose RSV Challenge|Half of the volunteers will be randomized to this arm (first 4 participants receiving low dose will not be randomized) and receive a dose of 10^5 PFU of RSV A2. Subsequent clinical, virologic, and immunologic evaluations will be performed during an inpatient stay at the NIH Clinical Center. Subjects will be followed prospectively for a minimum of 2 months. Single intranasal dose of RSV A2 at 10^5 PFU on Day 0.
3011773|NCT02484417|Experimental|Hiigh Dose RSV Challenge|The other half of volunteers will be randomized to this arm and receive 10^6.3 PFU of RSV A2. Subsequent clinical, virologic, and immunologic evaluations will be performed during an inpatient stay at the NIH Clinical Center. Subjects will be followed prospectively for a minimum of 2 months. Single intranasal dose of RSV A2 at 10^6.3 PFU on Day 0.
3011774|NCT02484404|Experimental|P1 MEDI+O|Ph I MEDI4736 + olaparib dose escalation
3011775|NCT02484404|Experimental|P1 MEDI+C|Ph I MEDI4736 + cediranib dose escalation
3011776|NCT02484404|Experimental|P2 MEDI+O|Ph II MEDI4736 + olaparib at RP2D
3011777|NCT02484404|Experimental|P2 MEDI+C|Ph II MEDI4736 + cediranib at RP2D
3011778|NCT02484404|Experimental|P1 MEDI+O+C|Ph I MEDI4736 + olaparib + cediranib dose escalation
3011779|NCT02484404|Experimental|P2 MEDI+O+C|Experimental Ph II MEDI4736 + olaparib + cediranib at RP2D
3011780|NCT02484391|Experimental|Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)|See Detailed Description
3011781|NCT02484378|Experimental|CER-001|CER-001 infusion
3011782|NCT02484378|Placebo Comparator|Placebo|Placebo infusion
3011783|NCT02484365||single arm study|No treatment or intervention will given to the patients
3011784|NCT02484352|Other|0 mg/kg of oxycodone|Intervention: patients receive 10 ml of normal saline without oxycodone through intravenous route before intubation.
3011785|NCT02484352|Other|0.05 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.05 mg/kg of oxycodone in normal saline through intravenous route before intubation.
3011786|NCT02484352|Other|0.1 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.1 mg/kg of oxycodone in normal saline through intravenous route before intubation.
3011787|NCT02484352|Other|0.15 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.15 mg/kg of oxycodone in normal saline through intravenous route before intubation.
3011788|NCT02484352|Other|0.2 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.2 mg/kg of oxycodone in normal saline through intravenous route before intubation.
3011789|NCT02484339|Experimental|Treatment Group A|"Radium-223 dichloride (Xofigo®) 55 kilobecquerel (kBq)/kgbw (6 i.v. injections every 4 weeks)~External beam radiotherapy (EBRT)->conventional or high dose radiotherapy"
3011790|NCT02484339|Other|Treatment Group B|External beam radiotherapy (EBRT) ->conventional or high dose radiotherapy
3011791|NCT02484313|Experimental|Greek yogurt|25 g available carbohydrates
3011792|NCT02484313|Experimental|Cookies|25 g available carbohydrates
3011793|NCT02484300|Experimental|Melatonin 4hrs before bed|Time of dosage comparison on blood serum melatonin phase and subjective sleepiness
3011794|NCT02484300|Experimental|Melatonin 2hrs before bed|Time of dosage comparison on blood serum melatonin phase and subjective sleepiness
3011795|NCT02484300|Experimental|Melatonin|To determine effects of 10mg daily melatonin on chemoreflex control, oxidation status, loop gain and apnea hypopnea index in obstructive sleep apnea
3011796|NCT02484300|Placebo Comparator|Placebo|Placebo outcomes versus melatonin
3011797|NCT02484287|Active Comparator|Integra External Drainage Catheter|The Integra External Drainage Catheter non antibiotic-impregnated EVD catheter
3011798|NCT02484287|Active Comparator|Ventriclear EVD Antibiotic Catheter|The Ventriclear EVD Antibiotic Catheter antibiotic-impregnated EVD catheter
3011799|NCT02484287|Active Comparator|Codman Bactiseal EVD Catheter Set|The Codman Bactiseal EVD Catheter Set antibiotic-impregnated EVD catheter
3011800|NCT02484274|Other|infants followed by pediatrician|
3011801|NCT02484261|No Intervention|Monitoring phase|Patients who have received a Stem cell transplant for Hematologic malignancies will be monitored for signs of relapse with blood tests for CD34+ chimerism. Patients with signs of relapse will have bone marrow aspirate and/or other appropriate tests to confirm presence of relapse. All patients who are confirmed to have relapsed and meet eligibility criteria to receive study drug will be eligible to receive treatment on the treatment arm.
3011802|NCT02484261|Experimental|Treatment phase|Patients with confirmed disease will initiate therapy with bortezomib and pravastatin, a regimen that has efficacy in treatment of leukemia and graft-versus-host disease, while sparing healthy donor hematopoietic stem cells may improve the dismal survival of relapse post allogeneic transplant. Depending on response, patients may receive up to 13 cycles of therapy
3011803|NCT02484248|Active Comparator|cross-over of Ketotifen|Patients will begin the active ketotifen treatment first and cross over to placebo.
3013087|NCT02475317|Placebo Comparator|Placebo|1 to 2 subjects from each arm will receive matched Placebo
3011804|NCT02484248|Placebo Comparator|cross-over of Placebo|Patients will begin the placebo treatment first and cross over to the active ketotifen.
3011805|NCT02484235|Experimental|Group HIIT|Only Aerobic Training with HIIT
3011806|NCT02484235|Experimental|Group Strength|Only Strength Training
3011807|NCT02484235|Experimental|HIIT and Strength|Both intervention HIIT and Strength training
3011808|NCT02484209|Experimental|Glimepiride + metformin|Glimepiride (2-4mg twice daily) + metformin (1500 mg daily) (n = 10 in total) Older subjects with moderate frailty will be assigned for 16 weeks to this arm. A subgroup (n=5) will undergo 3 x 72h periods of CBGM
3011809|NCT02484209|Active Comparator|Metformin|Metformin (1500 mg daily) (n = 10 in total) Older subjects with moderate frailty will be assigned for 16 weeks to this arm. A subgroup (n=5) will undergo 3 x 72h periods of CBGM
3011810|NCT02484196||Couples|Women, with their partners, referred to the Obstetrics and Gynecological Department of the University Hospital for surgical treatment of endometriosis.
3011811|NCT02484196||Women|Women referred to the Obstetrics and Gynecological Department of the University Hospital for surgical treatment of endometriosis.
3011812|NCT02484183|No Intervention|Low-flow oxygen|Low-flow oxygen supplementation if respiratory danger signs are present or if their oxygen saturation is <90%. Respiratory danger signs include any of the following: grunting, severe chest indrawing, very fast breathing (>70 breaths/minute if 1-11 months; >60 breaths/minute if 12-59 months), nasal flaring, stridor in a calm child, or apnea. Low-flow oxygen given by an oxygen concentrator with a nasal cannula. Low-flow is 0.5 liters per minute (LPM) for patients 1-2 months, and 1-2 LPM for patients 2-59 months. For 2-59 month olds oxygen can be increased to a maximum of 2 LPM to maintain a 90% saturation or treat respiratory danger signs.
3011813|NCT02484183|Experimental|bubble CPAP|Bubble continuous positive airway pressure (bCPAP) patients are eligible if respiratory danger signs are present or if oxygen saturation is <90%. bCPAP will be initiated at 7 centimeters (cm) water (H20) if 1-2 months of age or 8cm H20 if 2-59 months of age using the minimum oxygen flow necessary to achieve these pressures. Gradual weaning can be attempted after 24-48 hours of treatment. All changes will be followed by 60 minutes of monitoring.
3011814|NCT02484170|Active Comparator|mannitol in vehicle cream /vehicle cream|one week on the mannitol cream (mannitol 30% in vehicle cream), a 3 day washout period, and one week on the placebo cream (vehicle cream alone). To be applied over the painful area as needed for pain. Usual frequency is 2 to 3 times daily.
3011815|NCT02484170|Active Comparator|vehicle cream /mannitol in vehicle cream|one week on the placebo cream (vehicle cream alone), a 3 day washout period, and one week on the mannitol cream (mannitol 30% in vehicle cream).To be applied over the painful area as needed for pain. Usual frequency is unknown.
3011816|NCT02484157|Experimental|Patient|Patients were checked activated coagulation time by both Hemochron Jr and ACT Plus during cardiac surgery with heparin administration.
3011817|NCT02484144||patients receive usual information|Patients receive usual information before Scheduled Coronarography
3011818|NCT02484144||patients receive modern information|Patients receive usual information and a information by video before Scheduled Coronarography
3011819|NCT02484131|Experimental|Educational materials/mail|Participants in this group will receive educational materials by mail on the first day of the follow-up period.
3011820|NCT02484131|Experimental|Educational materials/participant choice|Participants in this group will receive educational materials by participant choice on the first day of the follow-up period.
3011821|NCT02484131|No Intervention|Control|Participants in this group will not receive any educational materials during hte follow-up period. Educational materials will be sent by mail after the completion of this study.
3011822|NCT02484118|Experimental|Targeted blood flow rate 320 ml/min|Hemodialysis blood flow will be targeted at 320 ml/min during hemodialysis for two weeks
3011823|NCT02484118|Experimental|Targeted blood flow rate 380 ml/min|Hemodialysis blood flow will be targeted at 380 ml/min during hemodialysis for two weeks
3011824|NCT02484105|Experimental|Comforting Conversation|Conversation according to the initital qualitative study.
3011825|NCT02484105|Active Comparator|Standard Communication|Standard information prior to and during endoscopy.
3011826|NCT02484092|Experimental|SPK-9001|Single intravenous (i.v.) infusion of SPK-9001 [an adeno-associated viral (AAV) vector with human factor IX gene] Intervention: Gene Therapy / Gene Transfer
3011827|NCT02484079|Active Comparator|Cold polypectomy|"Patients in this arm will have their polyps removed by cold polypectomy, i.e. a metal sling that is closed around the basis of the polyp, and the polyp is cut off.~After removal there will be taken biopsies from the resection margins, and both the polyp and the biopsies will be examined by a histopathologist to see if the polyp is removed completely."
3011828|NCT02484079|Active Comparator|Hot polypectomy|"Patients in this arm will have their polyps removed by hot polypectomy, i.e. a metal sling taht is closed around the basis of the polyp, electrical currents is applied, and the polyp is cut off.~After removal there will be taken biopsies from the resection margins, and both the polyp and the biopsies will be examined by a histopathologist to see if the polyp is removed completely."
3011829|NCT02484066|Experimental|VBN-EBUS-GS group|Fluoroscopy are not used in this group. EBUS and GS are inserted into bronchi in the assistance of VBN. The EBUS probe and GS are confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
3011830|NCT02484066|Active Comparator|VBN-EBUS-GS-X-ray group|EBUS and GS are inserted into bronchi in the assistance of VBN. The EBUS probe and GS are confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained with fluoroscopic guidance.
3011831|NCT02484053|Experimental|Rheumatologic disease|Rituximab is administered over 120 minutes, 12.5% of the dose will be given over the first 30 minutes and the remaining 87.5% of the dose will be given over 90 minutes.
3011832|NCT02484053|Experimental|Cancer or blood disorder|Rituximab is administered over 90 minutes, 20% of the dose will be given over the first 30 minutes and the remaining 80% of the dose will be given over 60 minutes.
3011833|NCT02484040|Experimental|Two-week course arm|"Experimental arm receive 33 Gy in 10 fractions of radiation for 2 weeks with oral capecitabine.~Two-week course of radiation, 33 Gy/10 fx and oral capecitabine, 825 mg/m2, bid"
3011834|NCT02484040|No Intervention|Conventional arm|conventionally fractionated radiation of 50.4 Gy/28 fx and 5-FU, 500 mg/m2 and leucovorin, 20 mg/m2 for 5 days, monthly or Capecitabine, 825 mg/m2, bid
3011835|NCT02484027|Experimental|statin-therapy|Rosuvastatin orally at a dose of 20mg daily is assigned to patients immediately for the first 3 days of hospitalization. From the fourth day onward, rosuvastatin 10 mg daily will be administered for 1 year.
3011836|NCT02484027|Sham Comparator|non-statin-therapy|No statins is assigned to patients for the first 3 days of hospitalization. From the fourth day onward, rosuvastatin 10 mg daily will be administered for 1 year.
3011837|NCT02484014|Experimental|TSM Arm|Tarang Adolescence Education Programme + SEHER Intervention (delivered by teachers as SEHER Mitra)
3011838|NCT02484014|Experimental|SM Arm|Tarang Adolescence Education Programme + SEHER Intervention (delivered by SEHER Mitra)
3011839|NCT02484014|Other|Comparison Arm|Tarang Adolescence Education Programme
3011840|NCT02484001|Experimental|ESL 800 mg|ESL will be administered orally once daily (QD)
3011841|NCT02484001|Experimental|ESL 1200 mg|ESL will be administered orally once daily (QD)
3011842|NCT02484001|Experimental|ESL 1600 mg|ESL will be administered orally once daily (QD)
3011843|NCT02484001|Experimental|ESL 400 mg|ESL will be administered orally once daily (QD)
3011844|NCT02483975|Experimental|FF 50 mcg|Subjects will receive by oral inhalation FF 50 mcg once daily in the morning via ELLIPTA for 42 days. Subjects will continue to receive oral montelukast once daily in the evening and may use albuterol/salbutamol inhalation aerosol as needed.
3011845|NCT02483975|Placebo Comparator|Placebo|Subjects will receive by oral inhalation placebo once daily in the morning via ELLIPTA for 42 days. Subjects will continue to receive oral montelukast once daily in the evening and may use albuterol/salbutamol inhalation aerosol as needed.
3011846|NCT02483962|Placebo Comparator|Gelatine capsule|Gelatine capsules containing no active ingredients, will be taken once per day, in the morning after breakfast, for 30 days. These capsules will be of identical appearance to the experimental comparator.
3011847|NCT02483962|Experimental|Venavine Intensive®|Gelatine capsules containing the active ingredients of: 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butcher's broom extract and 3,2 mg of vitamin B6, will be taken once per day, in the morning after breakfast, for 30 days.
3011848|NCT02483949|No Intervention|Control|
3011849|NCT02483949|Experimental|Intervention|Lifestyle intervention with peer-counseling follow-up
3011850|NCT02483936|Experimental|Test 1: Olmesartan+Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 40 mg + Chlorthalidone 12,5 mg) a day, in the morning.
3011851|NCT02483936|Experimental|Test 2: Olmesartan+Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 40 mg + Chlorthalidone 25 mg) a day, in the morning.
3011852|NCT02483936|Active Comparator|Comparator 1: Benicar HCT®|The patients will take 1 tablet (Olmesartan 40mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
3011853|NCT02483936|Active Comparator|Comparator 2: Benicar HCT®|The patients will take 1 tablet (Olmesartan 40mg + Hydrochlorothiazide 25 mg) a day, in the morning.
3011854|NCT02483923|Experimental|Group S|
3011855|NCT02483923|Placebo Comparator|Group C|
3011856|NCT02483910|Experimental|Direct Instruction-Language for Learning|Subjects with autism spectrum disorder (ASD) plus moderate language between 4 years and 7 years 11 months will be randomly assigned to receive Direct Instruction-Language for Learning (DI-LL) for 40-48 sessions (roughly twice a week for 24 weeks). Subjects in this arm will be allowed to continue ongoing treatment during the randomized phase of the study
3011857|NCT02483910|Active Comparator|Treatment as Usual|"Subjects with (ASD) plus moderate language between 4 years and 7 years 11 months will be randomly assigned to continue treatment as usual (TAU) for 24 weeks.~NOTE: after the randomized trial, subjects who do not show a positive response at Week 24, will be offered Direct Instruction-Language for Learning (DI-LL) for 24 weeks."
3011858|NCT02483897|Experimental|Tetracaine 0.5% ophthalmic drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
3011859|NCT02483897|Placebo Comparator|placebo (Normal Saline placebo drops)|0.8 mls. drops provided to be used hourly p.r.n. for pain control
3011860|NCT02483884|Experimental|Low risk for recurrence|Diagnostic [68Ga]RM2 is administered to 10 primary prostate cancer patients with low risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
3011861|NCT02483884|Experimental|Intermediate risk for recurrence|Diagnostic [68Ga]RM2 is administered to 10 primary prostate cancer patients with intermediate risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
3011862|NCT02483884|Experimental|High risk for recurrence|Diagnostic [68Ga]RM2 is administered to 10 primary prostate cancer patients with high risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
3011863|NCT02483871|Experimental|Rosuvastatin|Two Cohorts, one at 20 mg and one at 40 mg will enroll in a dose escalation of rosuvastatin
3011864|NCT02483858|Experimental|PQR309|Different dose Evaluation (continous and intermittent) 20-160mg daily
3011865|NCT02483845|Experimental|Natalizumab|Natalizumab therapy will be given at 300mg intravenously every 4 weeks for 24 weeks
3011866|NCT02483832|Active Comparator|Gain-frame|This group will receive messages about the benefits of colorectal cancer screening.
3011867|NCT02483832|Active Comparator|Loss-frame|This group will receive messages about the disadvantages of not getting colorectal cancer screening.
3011868|NCT02483806|Experimental|PEEP 0 cmH2O|PEEP 0 cmH2O (zero end expiratory pressure, ZEEP)
3011869|NCT02483806|Experimental|PEEP 5 cmH2O|
3011870|NCT02483806|Experimental|EEP 10 cmH2O|
3011871|NCT02483793|Active Comparator|Oxybutynin group|This group will be prescribed oxybutynin as well as standard narcotic pain medications. Oxybutynin will be prescribed based off of standard dosing. Patients who are unable to swallow pills will be given oxybutynin elixir (0.5mg/kg/day, divided TID). Patients who are able to swallow pills will be given oxybutynin 5mg either BID or TID.
3011872|NCT02483793|Active Comparator|Tamsulosin group|This group will be prescribed tamsulosin and standard narcotic pain medication. Patients will be given tamsulosin 0.4mg at bedtime. This dosage has been used in other studies for children age ≥ 4.
3011873|NCT02483780|Experimental|Storytelling intervention|"Two communes will be assigned to intervention group. Within each commune, 25 adults with HTN will be enrolled.~Patients will receive 2 DVDs with stories of patients who have successfully controlled their hypertension and Learn More section, which will be coordinated with specific patient stories and will fill in gaps not covered by the storytellers."
3044712|NCT02262598|Experimental|Telmisartan/HCTZ fixed dose|
3011874|NCT02483780|No Intervention|Usual care|"Two communes will be assigned to usual care group. Within each commune, 25 adults with HTN will be enrolled.~Patients will receive 2 DVDs with only didactic material about common non-communicable diseases but without hypertension related stories."
3011875|NCT02483767|Experimental|standard chemotherapy with goserelin|standard chemotherapy with the GnRH agonist goserelin
3011876|NCT02483767|Active Comparator|standard chemotherapy without goserelin|standard chemotherapy without goserelin
3011877|NCT02483754||original MOCA|The Chinese retired military cadres were surveyed with the revised MOCA scale.
3011878|NCT02483754||revised MOCA|The random part of participants were surveyed with the revised MOCA scale.
3011879|NCT02483741|Experimental|Manuka Honey|Manuka Honey will be placed in the sockets of the extracted third molars in this group
3011880|NCT02483741|No Intervention|Traditional Extraction|No any special material will be placed in the sockets of the extracted third molars in this group
3011881|NCT02483728|Other|Metal Allergy Hx +, Metal Patch Test +|These are patients with a history of metal allergy who are patch test positive to metals (metal series, metal disc if available from manufacturer, bone cement components and topical antibiotics) prior to implantation of metal device.
3011882|NCT02483728|Other|Metal Allergy Hx +, Metal Patch Test -|These are patients with a history of metal allergy who are patch test negative to metals (metal series, metal disc if available from manufacturer, bone cement components and topical antibiotics) prior to implantation of metal device.
3011883|NCT02483715|Experimental|High-dose dual therapy|group A-high-dose dual therapy ( rabeprazole 20 mg, tablet, qid + amoxicillin 750 mg, capsule, qid for 14 days)
3011884|NCT02483715|Active Comparator|Bismuth-containing quadruple therapy|group B-bismuth-containing quadruple therapy (rabeprazole 20 mg, tablet, bid + tripotassium dicitrate bismuthate 300 mg, tablet, qid + metronidazole 250 mg, tablet, qid + tetracycline 500 mg qid, capsule, for 10 days)
3011885|NCT02483702|Experimental|Patients under 4 months Receive Irradiated Blood|Patients under 4 months of age will receive irradiated blood products, as per hospital protocol. The patient's extracellular potassium levels will be recorded pre-transfusion, at 30 minute intervals during the transfusion, and post-transfusion. The collected data will be compared to test for correlation between extracellular potassium levels, the type of blood transfused, and the amount of calcium that is administered.
3011886|NCT02483702|Experimental|Patients Over 4 Months Recieve Non-Irradiated Blood|Patients over 4 months of age will receive non-irradiated blood products. The patient's extracellular potassium levels will be recorded pre-transfusion, at 30 minute intervals during the transfusion, and post-transfusion. The collected data will be compared to test for correlation between extracellular potassium levels, the type of blood transfused, and the amount of calcium that is administered.
3011887|NCT02483689|Placebo Comparator|Saline|Patient will be given saline with a maximum of 30 cc either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
3011888|NCT02483689|Experimental|Local|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
3011889|NCT02483676|Experimental|Treadmill+anklebot|This group will receive gait training on a treadmill while wearing the anklebot with the adaptive control system.
3011890|NCT02483676|Active Comparator|Treadmill only|This group will receive gait training on a treadmill, without use of the anklebot.
3011891|NCT02483663||27 Monozygotic Pairs|
3011892|NCT02483663||27 Dizygotic Pairs|
3011893|NCT02483637|Experimental|RejuvenAir|RejuvenAir treatment of the right lower lobe and right main stem bronchus. Each MCS will be tailored to the bronchial area undergoing treatment and the amount of liquid nitrogen delivered will vary depending on the airway diameter.
3011894|NCT02483624|Experimental|Low Dose|10 patients 225 mg of BR-DIM. 2 capsules AM and 1 PM. 52 weeks duration.
3011895|NCT02483624|Experimental|High Dose|10 patients 375 mg of BR-DIM. 3 capsules AM and 2 PM. 52 weeks duration.
3011896|NCT02483624|Placebo Comparator|Placebo|10 patients receiving weight matched placebo. 5 for high dose and 5 for low dose. 52 weeks of weight matched pills.
3011897|NCT02483611|Experimental|Group M|"Magnesium Sulfate. In this group, the patients received magnesium sulfate 40 mg/Kg as a bolus and 20 mg/kg/h by continuous IV infusion during surgery.~After the bolus of magnesium sulfate, 0.15 mg/kg of cisatracurium was infused over 5 seconds."
3011898|NCT02483611|Experimental|Group ML|"Magnesium Sulfate plus Lidocaine. In this group, the patients received 40 mg/kg of Magnesium Sulfate plus 3 mg kg-1 lidocaine as a bolus and 20 mg/kg/h and 3 mg/kg/h, respectively, by infusion continuously during the surgery.~After the bolus of magnesium sulfate and lidocaine, 0.15 mg/kg of cisatracurium was infused over 5 seconds"
3011899|NCT02483611|Placebo Comparator|Group C|"Isotonic Solution. In this group, the patients received the volume of isotonic solution equivalent to the volume of solution infused into experimental groups.~After the bolus of the isotonic solution , 0.15 mg/kg of cisatracurium was infused over 5 seconds"
3011900|NCT02483598|Experimental|Buspirone|Buspirone alone
3011901|NCT02483598|Active Comparator|Buspirone plus grapefruit juice|Buspirone plus grapefruit juice
3011902|NCT02483585|Placebo Comparator|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. At week 12 participants began treatment with erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
3011903|NCT02483585|Experimental|Erenumab|Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. Participants continued to receive erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
3011904|NCT02483572|Experimental|Functional Communication Training|Participants assigned to this condition will receive treatment immediately after assignment. The investigators will implement functional communication training (FCT) to teach the participant an appropriate request response, known as a functional communication response or FCR. FCT training will continue until the participant emits independent FCRs in at least 90% of the 30-s intervals and until destructive behavior decreases by 90% (relative to pre-treatment baseline) for two consecutive sessions.
3012167|NCT02481609|Experimental|NAC arm|Topical intranasal N-acetyl cysteine (NAC 200 mg/2 ml vials) BID for one month
3011905|NCT02483572|No Intervention|Waitlist-Control Condition|Participants assigned to the waitlist-control condition will not immediately receive services. These participants will be paired with an FCT-condition participant such that the no-treatment duration for these participants is yoked to the amount of time their respective FCT-condition participants receive services (e.g., most treatment last approximately 4 months, or 16 weeks); if Participant A finishes treatment in 16 weeks, Participant B will not receive treatment for at least 16 weeks for comparative measures). After the wait period, these participants will then receive the same services as those assigned to the immediate treatment (FCT Condition).
3011906|NCT02483559|Other|Amber Lenses|Participants will be randomized to participate in the amber lens condition first or second. Outcome measures to assess the effects of wearing amber lenses to block the blue light spectrum of light includes mood and sleep rating questionnaires (Positive and Negative Affect Scale, PANAS; Leeds Sleep Evaluation Questionnaire) as well as measuring the levels of melatonin the body is producing while wearing the glasses.
3011907|NCT02483559|Other|Placebo Lenses|Participants will be randomized to participate in the placebo lens condition first or second. Outcome measures to assess the effects of wearing placebo lenses to allow all spectrums of light includes mood and sleep rating questionnaires (Positive and Negative Affect Scale, PANAS; Leeds Sleep Evaluation Questionnaire) as well as measuring the levels of melatonin the body is producing while wearing the glasses.
3011908|NCT02483546|Experimental|huma patient based training|Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
3011909|NCT02483546|Active Comparator|traditionally teaching|students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
3011910|NCT02483533|Experimental|Experimental: LIPO-202|Subjects received either LIPO-202 or Placebo for LIPO-202 in the parent study (LIPO-202-CL-18 or LIPO-202-CL-19). Subjects will not receive any additional treatment in this follow-on study.
3011911|NCT02483533|Placebo Comparator|Placebo Comparator: Placebo|Subjects received either LIPO-202 or Placebo for LIPO-202 in the parent study (LIPO-202-CL-18 or LIPO-202-CL-19). Subjects will not receive any additional treatment in this follow-on study.
3011912|NCT02483520|Experimental|Intervention FamTechCare|This group will submit videos and receive weekly feed back after review by dementia care experts for managing challenging care situations. The intervention is weekly individualized feedback based on video data (FamTechCare).
3011913|NCT02483520|Placebo Comparator|Control and Delayed FamTechCare|This group will submit videos and will receive weekly feedback from a nurse based on their verbal communication until the end of their participation. At the end of the study, they will receive feedback based on submitted videos from dementia care experts (delayed FamTechCare).
3011914|NCT02483507|Active Comparator|Group T: transversal|Implementation of the vascular catheter with transversal approach under ultrasound guidance
3011915|NCT02483507|Active Comparator|Group L: longitudinal|Implementation of the vascular catheter with longitudinal approach under ultrasound guidance
3011916|NCT02483507|Active Comparator|Group O: oblique|Implementation of the vascular catheter with oblique approach under ultrasound guidance
3011917|NCT02483494|Experimental|APN-led Telemedicine|Participants will receive APN-led Telemedicine in addition to usual care.
3011918|NCT02483494|No Intervention|Usual care|Participants will receive the standard of care which includes education by cardiac care nurses and face-to-face consultations.
3011919|NCT02483468|Experimental|tDCS|Active Transcranial Direct Current Stimulation - Stimulation of the left dorsolateral prefrontal cortex with 2mA of electrical current
3011920|NCT02483468|Sham Comparator|tDCS (sham)|Inactive (sham) Transcranial Direct Current Stimulation
3011921|NCT02483455|Experimental|ALC-919 Topical Solution|ALC-919 Topical Solution will be applied twice daily to study area for the treatment of Common Warts
3011922|NCT02483455|Placebo Comparator|Vehicle-Control Topical Solution|Vehicle-Control Topical Solution will be applied twice daily to study area for the treatment of Common Warts
3011923|NCT02483442||No CT Pulmonary Angiography|Low Clinical Pretest Probability with D-dimer < 1000 ug/L and Moderate Clinical Pretest Probability with D-dimer < 500ug/L
3011924|NCT02483442||CT Pulmonary Angiography Required|Low Clinical Pretest Probability with D-dimer > or = 1000ug/L and Moderate Clinical Pretest Probability with D-dimer > or = 500 ug/L and High Clinical Pretest Probability
3011925|NCT02483429|Experimental|VRT Care|Patients randomized to VRT (VOG-guided Rapid Triage) care will have an algorithm-determined patient-specific diagnosis and treatment pathway in the emergency department. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
3011926|NCT02483429|No Intervention|Standard of Care (SOC)|Patients randomized to Standard of Care will undergo usual emergency department care without revealing results of VOG testing. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
3011927|NCT02483429|No Intervention|Observational|Patients who signed an informed consent but did not meet inclusion/exclusion criteria and don't randomize will enter a parallel track observational sub-study with limited 1 and 6 month phone follow-up.
3011928|NCT02483416||group 1|Group without `remote additional personalised nurse-led follow-up: patients will receive the healthcare given routinely by their medical team
3011929|NCT02483416||group 2|Group with `remote additional personalised nurse-led follow-up: patients will receive telephone calls from a nurse in addition to the healthcare given routinely by their medical team
3011930|NCT02483403|Other|Healthy Volunteers|Healthy elderly volunteers will undergo pulmonary function tests, hyperpolarized Helium-3 MRI at each visit.
3011931|NCT02483390|Experimental|Intervention group: All dyads are in the intervention arm.|
3011932|NCT02483377||Observational (treatment summaries and plan report)|"Patients receive treatment summaries and plan report that captures patient data through the use of an intake checklist completed during the initial consultation with the breast oncology team and used to guide referrals to existing services and programmed with generic information related to disease and treatment management plan. Additional elements, such as psycho-social services, exercise, and/or nutrition, identified by the patient self-report, will be incorporated. Patients also complete 3 questionnaires at each clinic visit."
3011933|NCT02483364|Experimental|Experimental|HC-SVT-1001. Intraosseous use. 3x10(6) cells/cm3. (Initial protocol) HC-SVT-1002. Intraosseous use. 3x10(6) cells/cm3. (Protocol amendment)
3011934|NCT02483351|Experimental|Liberal RBC Transfusion Strategy|
3011935|NCT02483351|Active Comparator|Restrictive RBC Transfusion Strategy|
3011936|NCT02483338|Other|Children surgery|
3011937|NCT02483325|Other|Busulfan with adapted doses|Conditioning regimen for allogeneic transplant (Busulfan, Thymoglobuline and Fludarabine)
3011938|NCT02483312|Experimental|IL-12|A single dose of IL-12, given intravenously.
3011939|NCT02483299|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
3011940|NCT02483299|Active Comparator|combined|In the metformin and liraglutide group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
3011941|NCT02483286|Experimental|ICG|Integrated Care Group
3011942|NCT02483286|Experimental|MTG|Muscle Training Group
3011943|NCT02483286|Experimental|XBG|X-box Group
3011944|NCT02483273||Brain dead patients|Brain dead patients certified by cerebral angiography.
3011945|NCT02483273||Healthy volunteers|Any person with no known cerebral pathology.
3011946|NCT02483260|Other|10-day course of treatment|10-day course of treatment with follow-up 14 ± 2 days after first dose
3011947|NCT02483247|Experimental|Combo with Capecitabine|
3011948|NCT02483247|Experimental|Combo with Doxorubicin|
3011949|NCT02483247|Experimental|Combo with Nivolumab (US only)|
3011950|NCT02483247|Experimental|Combo with Pembrolizumab|
3011951|NCT02483247|Experimental|Combo with Paclitaxel|
3011952|NCT02483247|Experimental|Combo with Sunitinib|
3011953|NCT02483234|Experimental|Psoriasis/Psoriatic arthritis|Patients with Psoriasis and inflammatory and/or structural lesions and/or erosions in the MRI/HR-qCT scan will be treated with Secukinumab. Patients with psoriatic arthritis will be treated with Secukinumab. Bone changes will be evaluated influenced by IL-17 blockade
3011954|NCT02483221|Active Comparator|TCI-PCA|
3011955|NCT02483221|Active Comparator|PCA|
3011956|NCT02483208|Experimental|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
3011957|NCT02483208|Other|Advate|Advate infusion to analyze pharmacokinetics.
3011958|NCT02483195|Active Comparator|Combination Group|This group will use a mixed combination of 5% Minoxidil and 200mg Spironolactone for 12 months to be used once daily.
3011959|NCT02483195|Active Comparator|Single Group|This group will use a mixed combination of 5mg Finasteride with placebo topical preparation for 12 months to be used once daily.
3011960|NCT02483182|Experimental|ZEP-3 ointment 1.0%|Topical administration
3011961|NCT02483182|Active Comparator|Acyclovir cream 5%|Topical administration
3011962|NCT02483169|Experimental|Cilostazol+ Probucol|100mg cilostazol bid plus probucol plus placebo of aspirin
3011963|NCT02483169|Active Comparator|Aspirin + Probucol|aspirin plus placebo cilostazol plus probucol
3011964|NCT02483169|Experimental|Cilostazol|cilostazol plus placebo of aspirin
3011965|NCT02483169|Active Comparator|Aspirin|aspirin plus placebo of cilostazol
3011966|NCT02483156|Active Comparator|SOF + RBV|Sofosbuvir 400 mg once daily +RBV (1000 mg/day) for 12-24 weeks
3011967|NCT02483156|Experimental|sof + RBV + AH|Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg for 12-24 weeks
3011968|NCT02483143|Active Comparator|NAC plus normal saline group|1ml/3mgr NAC+NS preCTPA 3 ml/kg for 1 h, 1 ml/kg/h for post CTPA for 6 h
3011969|NCT02483143|Active Comparator|NaHCO3 plus normal saline group|132 mEq NaHCO3+NS preCTPA 3 ml/kg for 1h, post CTPA 1ml/kg/h for 6 h
3011970|NCT02483143|Placebo Comparator|Normal saline alone|preCTPA 3 ml/kg NS for 1h, postCTPA 1ml/kg/h SF for 6 h
3011971|NCT02483130||NAC or Placebo|Participants will receive 2400mg capsules of N-Acetylcysteine or placebo
3011972|NCT02483117||Eating disorder patients by type of compensating behavior.|Data collection started in 2010; one year follow-ups were conducted through 2011-2012. Psychiatrists collaborating in the study informed personally their patients about the objectives of the study, and recorded the sociodemographic information, including age, gender, marital status, level of education, employment status, and people with whom the patient lived. Those who agreed to take part were also sent the questionnaires and informed consent form by mail. They were asked to return these by mail using an enclosed, pre-stamped envelope. Two reminders also were sent at intervals of 15 days to those who did not respond to the first mailing.
3011973|NCT02483104|Experimental|veliparib (ABT-888)|
3011974|NCT02483091|Experimental|Multifaceted KT intervention|Webinars, online vignettes and e-module, copy of guideline recommendations
3011975|NCT02483091|No Intervention|Control|Printed copy of guideline recommendations
3011976|NCT02483078|Active Comparator|PRO 140|PRO140 350mg weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
3011977|NCT02483078|Placebo Comparator|Placebo|Placebo weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
3011978|NCT02483065||inpatients with dementia|
3011979|NCT02483065||inpatients without dementia|
3011980|NCT02483052|Experimental|RejuvenAir|RejuvenAir if the treatment areas are designated as Segmental, males will be dosed for 11 seconds and females for 10 seconds. If dosing is in the Lobar area males will be dosed for 12 seconds and females for 11 seconds.
3011981|NCT02483039|Experimental|AKI Follow-up Clinic|Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. The target appointment date is within 30 days of hospital discharge. Routine laboratory investigations will be performed at minimum every three months. Additional in-person visits with a nephrologist at the AKI Follow-up Clinic will be determined at the local sites based upon the participant's clinical status. If in-person visits at 12, 24, and/or 36 weeks are not necessary given the patient's clinical status, they may be replaced with a telephone visit
3011982|NCT02483039|No Intervention|Usual Care|Participants randomized to this arm will have a letter outlining their AKI diagnosis mailed to their family physician. Participants may still be referred to a nephrologist by their inpatient or outpatient healthcare provider, but these participants will not have access to the AKI Follow-up Clinic. Rather, they will proceed through the standard local nephrology referral pathway. In addition, all usual care participants will be contacted via telephone by study staff every three months to assess their clinical condition and ensure study engagement. All usual care participants will be offered a nephrologist assessment and/or bloodwork one year after randomization to determine if ongoing nephrology care is indicated based upon the same criteria applied to AKI Follow-up Clinic participants.
3011983|NCT02483026|Experimental|Intensive supplements care pre-surgery|Multi vitamins pills vitamin D
3011984|NCT02483026|Other|Standard supplements care pre-surgery|vitamin D (Vitamin D will be given in a reduced doses compared to the intervention group)
3011985|NCT02483013|Active Comparator|Whitening dentifrices|Two groups used whitening dentifrices, three times per day during four weeks
3011986|NCT02483013|Placebo Comparator|Placebo|One group used conventional dentifrice, three times per day during four weeks
3011987|NCT02483000|Experimental|Treatment (PRIT)|"B9E9-FP INFUSION: Patients receive B9E9-fusion protein IV over a minimum of 2 hours on day -17.~CLEARING AGENT INFUSION: Patients receive clearing agent IV over a minimum of 30 minutes on day -15.~RADIOBIOTIN INFUSION: Patients receive indium In 111-DOTA-biotin IV and yttrium Y 90 DOTA-biotin IV over 2-5 minutes on day -14.~BEAM CHEMOTHERAPY: Patients receive BEAM chemotherapy comprising carmustine IV over 3 hours on day -7; etoposide IV over 2 hours BID and cytarabine IV over 4 hours BID on days -6 to -3; and melphalan IV over 30 minutes on day -2.~STEM CELL INFUSION: Patients undergo autologous PBSCT on day 0 per standard of care."
3011988|NCT02482987|Experimental|Cytoplast|Patients will receive ridge preservation procedure with a Cytoplast barrier membrane
3011989|NCT02482987|Experimental|BioXclude|Patients will receive ridge preservation procedure with a BioXclude barrier membrane
3011990|NCT02482948|Active Comparator|Collagenase|This is an enzymatic debridement agent to remove non-viable tissue from wounds to be applied daily
3011991|NCT02482948|Active Comparator|Active leptospermum honey|This is an active medicinal grade honey used to promote autolytic debridement and applied daily
3011992|NCT02482935|Experimental|Abemaciclib High Fat Meal|Abemaciclib capsules administered once orally in the fed state.
3011993|NCT02482935|Experimental|Abemaciclib Fasted|Abemaciclib capsules administered once orally in the fasted state.
3011994|NCT02482922|Experimental|IET and Nutrition|3 times per week of interval exercise training Once daily meal replacement
3011995|NCT02482909|Experimental|Hepatic resection|Hepatic resection is performed as a primary treatment for hepatocellular carcinoma.
3011996|NCT02482909|Experimental|Radiofrequency ablation|Radiofrequency ablation is performed as a primary treatment for hepatocellular carcinoma.
3011997|NCT02482883|Active Comparator|active Transcutaneous Electrical Nerve Stimulation|Arm A, treated by active stimulation of the trigeminovascular system after placement of the TENS device.
3011998|NCT02482883|Sham Comparator|sham Transcutaneous Electrical Nerve Stimulation|Arm B, treated by non-active (sham) stimulation after placement of the TENS device. This absence of stimulation corresponds to the standard of care currently received by patients hospitalized for SAH due to ruptured aneurysm.
3011999|NCT02482870|Active Comparator|Macintosh|Patients scheduled for general anesthesia during the period from January 2014 to June 2014. Each patient has been intubated with a Macintosh laryngoscope.
3012000|NCT02482870|Active Comparator|KingVision|Patients scheduled for general anesthesia during the period from January 2014 to June 2014. Each patient has been intubated with a King Vision video laryngoscope.
3012001|NCT02482857|Experimental|Acetylsalicylic acid 75 mg twice daily|Aspirin 75 mg BID is a new experimental dosing regimen which has shown improved efficiency regarding laboratory parameters in several studies, mainly in diabetic patients.
3012002|NCT02482857|Active Comparator|Acetylsalicylic acid 160 mg once daily|Aspirin 160 mg OD is an accepted and used dosage after CABG.
3012003|NCT02482857|Active Comparator|Acetylsalicylic acid 75 mg once daily|Aspirin 75 mg OD is an accepted and used dosage after CABG.
3012004|NCT02482844|Other|Pacemaker|Every patient included with a de novo LBBB, persistent that is observed beyond 24 hours after the TAVI procedure, will benefit from an endocavitary electrophysiological exploration . According to the meditative delay of conduction, we shall hold the setting-up of a pacemaker in case of delay lengthened HV (> 70 ms) or of infrahissian block, in the opposite case the implantation of an holter with remote monitoring will be made
3012005|NCT02482844|Other|holter implantable|Every patient included with a de novo LBBB, persistent that is observed beyond 24 hours after the TAVI procedure, will benefit from an endocavitary electrophysiological exploration . According to the meditative delay of conduction, we shall hold the setting-up of a pacemaker in case of delay lengthened HV (> 70 ms) or of infrahissian block, in the opposite case the implantation of an holter with remote monitoring will be made
3012006|NCT02482831||Diabetes|Diabatic participants who experienced unilateral lower limb surgery and received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml in Peking Union Medical College Hospital were selected.
3012007|NCT02482831||non-Diabetes|Non-diabatic participants who experienced unilateral lower limb surgery and received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml in Peking Union Medical College Hospital were selected.
3012036|NCT02482636|Other|Group 1|"Group 1 will receive the following interventions:~DTaP/IPV/Hib vaccine IM 0.5ml at 2, 3 and 4 months~13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml at 2, 4 and 12 months~Rotavirus vaccine oral 1.5ml at 2 and 3 months~4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months~Meningococcal C/Hib vaccine IM 0.5ml at 12 months~Measles/Mumps/Rubella (MMR) vaccine IM 0.5ml at 13 months"
3012008|NCT02482818|Placebo Comparator|Control-Placebo|"Administration of Placebo (Lactose instead of Pregabalin) pills in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial.~Initially an increasing dosage of placebo (Lactose) will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days).~Eight days after initial placebo administration, following an assessment by the Doctor of how well subjects are doing on their (drug or placebo), the study placebo will be increased to 100 mg twice a day.~Twenty eight days after initial placebo administration subjects will begin to receive the study placebo in a reducing dose regimen for 7 days then follow up at day 42."
3012009|NCT02482818|Experimental|Pregabalin|"Administration of Pregabalin in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial.~Initially an increasing dosage of Pregabalin will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days).~Eight days after initial medication administration, following an assessment by the Doctor of how well subjects are doing on the medication, the study medication will be increased to 100 mg twice a day.~Twenty eight days after initial drug administration subjects will begin to receive the study medication in a reducing dose regimen for 7 days.~Forty two days after initial drug administration the Doctor will meet with subjects to follow up."
3012010|NCT02482805|Experimental|Power Posing|Individuals hold two, 1-minute postures associated with dominance and high power prior to exposure therapy.
3012011|NCT02482805|Experimental|Submissive Posing|Individuals hold two, 1-minute postures associated with submissiveness and low power prior to exposure therapy.
3012012|NCT02482805|Experimental|Rest|Individuals rest (no postures) for 2 minutes prior to exposure therapy.
3012013|NCT02482792|Experimental|Norwegian Psychomotor Physiotherapy|NPMP is a body-mind awareness approach, often given in a combination of massage, exercises and conversations. The NPMP is individualized, with duration of 45-60 minutes in each session. As the NPMP is a longitudinal and normally slow process to obtain change, treatment can last up till one year, in the beginning once a week, and after some time once a month.
3012014|NCT02482792|Active Comparator|Cognitive Patient Education and PT|The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.They will receive one session weekly with COPE, given by a physiotherapist, maximum 4 times, followed by active individual Physiotherapy (PT).
3012015|NCT02482766|Experimental|INRECSURE|Infants in the INRECSURE arm will undergo the following approach: as soon as possible after the recruitment manoeuver (at CDP-Optimal) a dose of poractant alfa (Curosurf [Chiesi Farmaceutici, Parma, Italy]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. A temporary reduction of frequency may be necessary to increase the VT up to 2.5 ml/kg for improving the surfactant spreading.
3012016|NCT02482766|Active Comparator|INSURE|Infants in the INSURE arm will undergo the following approach: after intubation, a dose of poractant alfa (Curosurf [Chiesi Farmaceutici, Parma, Italy]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. During surfactant administration, infants will be manually ventilated to facilitate surfactant distribution.
3012017|NCT02482753|Experimental|Chidamide + exemestane, open-label|Patients receive 30 mg Chidamide per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3012018|NCT02482753|Experimental|Chidamide + exemestane, double-blinded|Patients receive 30 mg Chidamide twice per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3012019|NCT02482753|Placebo Comparator|placebo + exemestane, double-blinded|Patients receive placebo twice per week and 25 mg exemestane PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3012020|NCT02482740|Experimental|tamoxifen|tamoxifen 20 mg given everyday for 12 months
3012021|NCT02482740|Active Comparator|letrozole|letrozole 2.5 mg given everyday for 12 months
3012022|NCT02482727|No Intervention|non-occlusion training group|The control (non-occlusion training) group will follow the standard post-operative distal radius fracture rehabilitation protocol. Treatment will include passive, active assistive,active range of motion (P/AA/AROM) to wrist, forearm and hand; desensitization as needed; edema control as needed; heat/cold modalities as needed; and strengthening exercises.
3012023|NCT02482727|Experimental|occlusion training with DELFI PTS ii tourniquet|The occlusion training group will follow the same protocol as described above but will utilize occlusion training with the strengthening exercises. Investigators will use an established occlusion training protocol already being. Intervention: occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
3012024|NCT02482714|Experimental|Rehab Institute|This group will do some physical activity in a specialized institute
3012025|NCT02482714|Active Comparator|Club structure|This group will do some physical activity in a club.
3012026|NCT02482688|Experimental|Multisensory Acute|Multisensory intervention delivered within 2 months post-stroke.
3012027|NCT02482688|Experimental|Multisensory Chronic|Multisensory intervention delivered 6 months post-stroke.
3012028|NCT02482688|Active Comparator|Unisensory Acute|Unisensory intervention delivered within 2 months post-stroke.
3012029|NCT02482688|Active Comparator|Unisensory Chronic|Unisensory intervention delivered 6 months post-stroke.
3012030|NCT02482675|Active Comparator|Glucose|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
3012031|NCT02482675|Experimental|Glucose with Non-fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
3012032|NCT02482675|Experimental|Glucose with Whey Protein Isolate|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
3012033|NCT02482675|Experimental|Glucose with Sodium Caseinate|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
3012034|NCT02482649|Experimental|EAA/T|EAA/TEquine-Assisted Activities and Therapy) bi-weekly for 12eeks
3012035|NCT02482649|Active Comparator|Drugs|Methylphenidate or Atomoxetine
3044713|NCT02262598|Active Comparator|Telmisartan and HCTZ monocomponents|
3012037|NCT02482636|Other|Group 2|"Group 2 will receive the following interventions:~DTaP/IPV/Hib vaccine IM 0.5ml at 2, 3 and 4 months~13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml at 3 and 12 months (instead of current routine schedule of 2,4 and 12 months)~Rotavirus vaccine oral 1.5ml at 2 and 3 months~4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months~Meningococcal C/Hib vaccine IM 0.5ml at 12 months~Measles/Mumps/Rubella (MMR) vaccine IM 0.5ml at 13 months"
3012038|NCT02482623|Experimental|Intervention|Dyads in this arm will receive care provided by an interprofessional team trained through the DSM-H to provide patient/caregiver-centered dementia care through home healthcare.
3012039|NCT02482623|No Intervention|Control|Dyads in this arm will receive usual care provided in the home healthcare setting.
3012040|NCT02482610|Active Comparator|Glucose|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
3012041|NCT02482610|Experimental|Glucose with Whole Fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
3012042|NCT02482610|Experimental|Glucose with Non-fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
3012043|NCT02482597|Experimental|WBPA (Whole Body Accleration)|"Whole-body periodic acceleration (WBPA) is a new, non-invasive, and promising therapy for a diverse and growing list of disorders including cardiovascular disease 6. During WBPA, patients lie in the supine position on a bed that is capable of translating back and forth parallel to the ground, along the head-to-foot axis of the patient. Thus, this treatment is best described as a form of passive exercise. The frequency of the translation (up to 180 cycles/minute; cpm) as well as the distance traveled (2-24mm) by the bed can be adjusted by the patient or health care professional."
3012044|NCT02482597|Active Comparator|Active Recovery|Active recovery methods (e.g.walking, biking) have been shown to decrease blood lactate levels more than passive recovery 1,2. This arm requires subjects to walk at a low intensity as recovery.
3012045|NCT02482584|Active Comparator|CPAP treatment|Continuous Positive Airway Pressure (CPAP) treatment during three month.
3012046|NCT02482584|Other|Control group|Control group
3012047|NCT02482571|Experimental|Mild Hypoxia|Subjects are exposed to an intervention that controls the composition of breathed air by using a gas blender (RespirAct). Subjects undergo MRI and MRS while breathing air with both normal oxygen concentration (normoxia) and reduced oxygen concentration (mild hypoxia).
3012048|NCT02482558|Experimental|High GI diet|8 Healthy subjects will be assessed at the start and end of a 7 day high glycaemic in diet following the appropriate High/Low Glycaemic index test breakfast.
3012049|NCT02482558|Experimental|Low GI diet|8 Healthy subjects will be assessed at the start and end of a 7 day low glycaemic in diet following the appropriate High/Low Glycaemic index test breakfast.
3012050|NCT02482545|Experimental|Breakfast Meal Replacement|Once daily of a powdered meal replacement (high fat, high protein) will be consumed, mixed with water, at breakfast.
3012051|NCT02482545|No Intervention|Control|No placebo or intervention
3012052|NCT02482532|Experimental|tvs-CTL Vaccine|Infusion of activated T-cells generated from a patient's own peripheral blood mononuclear cells.
3012053|NCT02482519|Other|10 day overfeeding/fasting|10 day high calorie diet followed by a 10 day fast
3012054|NCT02482506|Other|SG-WLP|Self-guided weight loss program
3012055|NCT02482506|Active Comparator|MF-WLP|Moving Forward Weight Loss Program
3012056|NCT02482493|Active Comparator|All-polyethylene Tibial component|Sigma PFC All polyethylene Tibial component will be implanted
3012057|NCT02482493|Active Comparator|Metal Backed Tibial component|Sigma PFC metal-backed tibial component will be implanted
3012058|NCT02482480|Experimental|Interventional group|"Participants followed a 8‐week intervention program with a total of 24 sessions (12 of those were supervised). The aim of the supervision was to increase the adherence to the treatment and to control the compliance of patients. General physical activity consisted in walking along previously standardized urban parks designed for the urban EPOC training project (Arbillaga-Etxarri et al, 2016). The duration of walking were 30 minutes. The physiotherapist supervised the accomplishment of other activities such as oropharyngeal exercises and diet control.~Oropharyngeal exercises:~Expiratory muscle strength training (EMST):~Masako Manoeuvre~Shaker Head Lift:~Facial exercise"
3012059|NCT02482480|Sham Comparator|Control Group|Control group participants only received general recommendations regarding general physical activity, diet and sleep hygiene. After 8‐weeks of control, they were re‐evaluated with the same evaluation test used in the beginning of the study period. Recommendations for general physical activity were walking during 30 minutes at least 3 times a week maintaining the greatest possible pace. Also, control group patients received the same diet control document as intervention group and verbal advice for sleep hygiene. Approximately 1 month after enrolment, a follow‐up phone call was completed were we also informed about the new re‐evaluation data.
3012060|NCT02482467|Other|Cases|Prenatal diagnosis of ovarian cyst
3012061|NCT02482467|Other|controls|No prenatal diagnosis of cyst
3012062|NCT02482454|Other|RFA alone|Patients undergo radiofrequency ablation alone.
3012063|NCT02482454|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA
3012064|NCT02482441|Experimental|OMP-131R10 intravenous (in the vein) infusions|OMP-131R10 will be administered IV on the first day of each 14-day cycle.
3012065|NCT02482441|Experimental|FOLFIRI (5-FU, irinotecan, leucovorin).|dosing continues up to the 20 mg/kg dose level
3012066|NCT02482428|Experimental|LFX453 0.1% NMC|LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks
3012067|NCT02482428|Experimental|LLFX453 0.15% LCC|LFX453 0.15% liquid crystal cream (LCC) Twice daily applications for a maximum of 12 weeks
3012068|NCT02482428|Placebo Comparator|Vehicle to NMC|Vehicle to nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks
3012069|NCT02482428|Placebo Comparator|Vehicle to LCC|Vehicle to liquid crystal cream (LCC) Twice daily applications for a maximum of 12 weeks
3012070|NCT02482428|Active Comparator|Aldara|Aldara 5% cream 3 applications per week for a maximum of 16 weeks
3012101|NCT02482142|Placebo Comparator|high CHO meal alone|Ingestion of placebo tablets with the high carbohydrate meal
3013575|NCT02471976|No Intervention|Group A|the centres applies their usual practices
3012071|NCT02482415|Experimental|Intervention|Family caregivers were invited to meet in a group for 2 hours once a week for 3 weeks. Each meeting had a specific topic presented by a health care professional of the palliative care team (physician, nurse and social worker). The meetings addressed multi-dimensional issues in dialogue with the participants. A nurse acted as group leader and participated in all meetings. The intervention included both supportive and educational components. Each meeting began with a presentation based on a specific topic (palliative care, practical care and emotional reactions). This was followed by reflection and conversation, and finally a relaxation exercise
3012072|NCT02482415|No Intervention|Control|
3012073|NCT02482402|Experimental|Inhaled Iloprost|2 inhalations per day of 2.5 µg Iloprost [Ventavis®] per inhalation to a maximum of 6 inhalations per day of 5 µg Iloprost per inhalation (total daily dose 5 - 30 µg) will be performed according to each patient's health condition.
3012074|NCT02482402|Placebo Comparator|Placebo inhaled|2 to a maximum of 6 inhalations per day of placebo solution (PLA) will be performed. Study medication will be inhaled using the portable, hand-held I-Neb AAD vibrating mesh technology nebulizer system.
3012075|NCT02482389|Experimental|Single arm 7 Gray (Gy) fraction of radiotherapy|All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
3012076|NCT02482376|Other|Single arm 21Gy stereotactic radiotherapy|Subjects will receive a single fraction of 21Gy of stereotactic radiotherapy before proceeding to surgery.
3012077|NCT02482363|Active Comparator|Active UVA radiation|This arm will receive 20 minutes of UVA to the skin while resting quietly.
3012078|NCT02482363|Sham Comparator|Sham control|This arm will receive 20 minutes of quiet rest and heat but with their skin protected from UVA
3012079|NCT02482350|Experimental|Reading Training|A 3-months study design. There will be three distinct phases: base-line testing, reading training, and follow-up testing. T1-T7 indicate the 7 time-points at which we assess the following: reading speeds (word-per-minute), visual field test, visual search test, and Activities of Daily Living rating scale (T1: Day 1, Initial assessments; T2: Day 30, Pre-training assessments; T3: Day 60, During Reading Training (RT) after 5-hours; T4: During RT after 10-hours; T5: During RT after 15-hours; T6: During RT after 20-hour; T7: Day 90, Post-training assessments). Arabic reading patients with left-sided HA will receive app-delivered reading training in a single subject control based design for 1 month.
3012080|NCT02482337|Experimental|POEM procedure|Patients who underwent POEM
3012081|NCT02482324|Other|Treatment A-B|12 subjects will receive a single oral inhaled dose of ALZT-OP1a, via dry powder inhaler, and a single oral tablet dose of ALZT-OP1b on Day 1, and two doses of ALZT-OP1a and ALZT-OP1b on Day 2, within two minutes of each other. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis. CSF collected on Day 1 only.
3012082|NCT02482324|Other|Treatment B-A|12 subjects will receive two oral inhaled doses of ALZT-OP1a, via dry powder inhaler, and two oral tablet doses of ALZT-OPb, within two minutes of each other, on Day 1, and single doses of ALZT-OP1a and ALZT-OP1b on Day 2. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis. CSF collected on Day 1 only.
3012083|NCT02482311|Experimental|AZD1775|"Single-arm study. AZD1775 will be administered for 3 consecutive days at the start of week 1 and week 2 of each 21-day cycle.~This study will be conducted in two parts, designated Part A and Part B. Part A is a safety lead-in. Part B will commence after the safety lead-in and will investigate the safety and efficacy of AZD1775 monotherapy in expansion cohorts of specific tumour types."
3012084|NCT02482298|Experimental|Dose A|
3012085|NCT02482298|Experimental|Dose B|
3012086|NCT02482298|Placebo Comparator|Placebo|
3012087|NCT02482272|Active Comparator|Lamivudine plus Adefovir or Adefovir|Lamivudine+Adefovir or Adefovir for 48 weeks
3012088|NCT02482272|Experimental|Entecavir plus Adefovir|Entecavir+Adefovir for 48 weeks
3012089|NCT02482233|Experimental|ENDD|"6-week supply of disposable NJOY ENDDs (e-cigarettes)~the number of e-cigarettes will be determined by equating the number of e-cigarettes to the number of cigarettes smoked per day (1 pack per day = 2 e-cigarettes per day = 14 e-cigarettes/week)~veterans will be given detailed instructions for use and also instructed to start with the high nicotine content (4.5%) strength for three weeks, then decrease to the low nicotine content (2.4%) for two weeks, then switch to nicotine-free for the final week~Both groups will receive:~i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery"
3012090|NCT02482233|Active Comparator|NRT (NicoDerm CQ)|"A prescription for 6 weeks of transdermal nicotine replacement (on-formulary at the VA) in the following doses: For smokers of 10 cigarettes per day or more, a 3-week supply of 21 mg/d, 1-week supply of 14 mg/d, 1-week supply of 7 mg/d, and 1-week of 0mg/d. Smokers of <10 cigarettes per day, 3 weeks of 14 mg/d patches 2 weeks of 7 mg/d patches, and 1-week of 0mg/d.~Both groups will receive:~i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery"
3012091|NCT02482220|Experimental|High intensity|in this group, the participants will follow a high intensity physical activity program (High Intensity Interval exercise from 75 to 95% VO2max)
3012092|NCT02482220|Experimental|Moderate intensity|in this group, the participants will follow a moderate intensity physical activity program (Intensity from 50 to 65% VO2max)
3012093|NCT02482207|Experimental|Rosuvastatin|Rosuvastatin 10 mg qd for 1 year and life style modification
3012094|NCT02482207|Placebo Comparator|Placebo|Life style modification alone
3012095|NCT02482194|Experimental|Autologous mesenchymal stem cells|use of mesenchymal stem cells as therapeutic intervention for spinal cord injury patients by autologous transplantation
3012096|NCT02482168|Experimental|APX005M every 3 week|Subjects receive APX005M intravenously every 3 week until disease progression, unacceptable toxicity or death.
3012097|NCT02482168|Experimental|APX005M every 2 week|Subjects receive APX005M intravenously every 2 week until disease progression, unacceptable toxicity or death.
3012098|NCT02482168|Experimental|APX005M every 1 week|Subjects receive APX005M intravenously every 1 week until disease progression, unacceptable toxicity or death.
3012099|NCT02482155|Experimental|ibuprofen|ibuprofen 400 mg granules, oral solution, single administration under fasting conditions
3012100|NCT02482142|Placebo Comparator|phosphorus alone|Effect of phosphorus (500mg) ingestion alone. No meal. Needed to determine the impact of phosphorus alone on DIT
3012102|NCT02482142|Active Comparator|High CHO meal plus phosphorus|Effect of phosphorus (500mg) tablets ingestion of DIT of the high carbohydrate meal
3012103|NCT02482142|Active Comparator|High protein meal plus phosphorus|Effect of phosphorus (500mg) tablets ingestion of DIT of the high protein meal
3012104|NCT02482142|Placebo Comparator|High protein meal alone|Ingestion of placebo tablets with the high protein meal
3012105|NCT02482129|Experimental|LME636|LME636 60 mg/mL ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 1 week (Week 3) and 1 week of masked Vehicle administration (Week 4)
3012106|NCT02482129|Active Comparator|Dexamethasone|Dexamethasone 0.1% ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 2 weeks (Weeks 3 and 4)
3012107|NCT02482103||Patients treated with renal denervation|Patients treated with RD in the Netherlands. The decision to perform RD was made by the treating physician in the participating hospitals.
3012108|NCT02482090|Experimental|Patient group|"All patients receive the same treatment. Alle patients are hospitalized during treatment (approximately 3 weeks) and receive treatment only once.~Stem Cells are harvested a minimum of 3 weeks before treatment for potential later use if the patients are having difficulties recovering from the lymphodepleting chemotherapy.~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine= on day -7 to day -1.~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 5.~Interleukin-2 is administered in an i.v. continous decrescendo regimen starting approximately 6 hours after TIL infusion with a duration of approximately 5 days.~Stem Cells can be administered after treatment if needed."
3012109|NCT02482077|Experimental|SOF+RBV 8 wk|Participants will receive SOF+RBV for 8 weeks.
3012110|NCT02482077|Experimental|SOF+RBV 12 wk|Participants will receive SOF+RBV for 12 weeks.
3012111|NCT02482077|Experimental|SOF+DCV 8 wk|Participants will receive SOF+DCV for 8 weeks.
3012112|NCT02482077|Experimental|SOF+DCV 12 wk|Participants will receive SOF+DCV for 12 weeks.
3012113|NCT02482077|Experimental|LDV/SOF 8 wk|Participants will receive LDV/SOF for 8 weeks.
3012114|NCT02482077|Experimental|LDV/SOF 12 wk|Participants will receive LDV/SOF for 12 weeks.
3012115|NCT02482064|No Intervention|Traditional Obturators|Patients will use traditional obturators which are going to be made from ordinary heat-activated acrylic resin.
3012116|NCT02482064|Experimental|Flexible Obturators|Patients will use the new obturators made from flexible resin.
3012117|NCT02482038|Experimental|geko device|
3012118|NCT02482025|No Intervention|Usual care|Usual care delivered at VA Boston
3012119|NCT02482025|Active Comparator|MHV|Receives Usual Care PLUS My HealtheVet registration and enrollment
3012120|NCT02482025|Active Comparator|MHV + SMMRT|Receives Usual Care PLUS My HealtheVet registration and enrollment PLUS Secure Messaging for Medication Reconciliation Tool
3012121|NCT02482012||Staff|Staff nurses and physicians in the NICU
3012122|NCT02482012||Parents|Parents of infants in the NICU and a smaller group of parents of infants in the well baby nursery.
3012123|NCT02481999||Study group: Patients|"470 children for elective surgery 0,5 to 8 years~Analysis of EEG data will divided in four age-related groups because of the different baseline EEG activity:~0.5 - 12 month: 5-7 Hz activity / blocked by eye opening~12 - 36 month: 7-8 Hz activity / Variability 5 - 10 Hz~3 - 6 years: 8 Hz activity / amplitude 100µV~6 - 8 years 10Hz activity / amplitude 100 µV"
3012124|NCT02481999||Control group: Healthy children for POCD assessment|80 healthy children (siblings of study group children and children from Kindergarten) 0,5 to 8 years with no operation
3012125|NCT02481986|Experimental|Community health worker|Participants in this arm will be offered 10 home visits in a 12-month period from community health workers (CHWs). Visits will cover a core asthma curriculum and provide social support.
3012126|NCT02481986|Active Comparator|Certified asthma educator|Participants in this arm will be offered 2 education sessions with a certified asthma educator in the clinic at start of the study and again at 6-months. These sessions will be followed by a telephone call from the certified asthma educator several weeks after the sessions.
3012127|NCT02481973|Experimental|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy, prescribed according to their characteristic symptoms and confirmed my their miasmatic facial features. Although different individualised remedies may be dispensed, each remedy will be homoeopathic and prepared in accordance with the German Homoeopathic Pharmacopoeia. Each prescription will be in a potency of 30CH which will be taken once daily, according to the GBM. Sucrose pillules will used as the vehicle for each remedy.
3012128|NCT02481960|Experimental|Treatment arm|Intraparenchymal administration of CM-BC2 irinotecan drug-eluting bead in recurrent high grade glioma.
3012129|NCT02481947|Experimental|BLI400 Laxative|BLI400 Laxative
3012130|NCT02481947|Active Comparator|Lubiprostone|Lubiprostone
3012131|NCT02481934|Experimental|NKAE cells infusion + chemotherapy|Expanded and activated autologous NK cells (NKAEs) + chemotherapy (lenalidomide OR bortezomib).
3012132|NCT02481921|Experimental|MEDIC-HF|Multidisciplinary Education & Intervention Class in Heart Failure
3012133|NCT02481921|No Intervention|Usual Care|Usual heart failure care
3012134|NCT02481895|Experimental|Experimental|E-neurocognitive module training.
3012135|NCT02481895|No Intervention|Control|The group will note receive any sort of add-on training, just the recommendations from the therapists.
3012136|NCT02481882|Other|Healthy Volunteers|Healthy Volunteers will undergo an Magnetic Resonance Imaging scan.
3012137|NCT02481882|Other|MS Patients|Patients will undergo and Magnetic Resonance Imaging scan including the use of Prohance (Gadoteridol).
3012138|NCT02481869|Active Comparator|Arthrocentesis/PRP|"At the time of surgery, the participant will have both injured and uninjured ankles cleaned with surgical soap. An needle will be placed into the injured ankle joint and synovial fluid will be drawn out of the ankle and collected into a syringe. Using the same needle, the PRP will be delivered into the same arthrocentesis needle.~Next the uninjured ankle will have the same procedure as the injured ankle, except there will be no injection of PRP. There will only be a aspiration of synovial fluid from the uninjured ankle joint using a different clean needle.~Another aspiration of the synovial fluid will be done at the time of the second surgery in the same manner as before, except there will be no injection of PRP, just an aspiration of both injured and uninjured ankles."
3044714|NCT02262585|Experimental|BIBR 277 tablet|(Mannitol based)
3012139|NCT02481869|Placebo Comparator|Arthrocentesis/Saline|"At the time of surgery, the participant will have both injured and uninjured ankles cleaned with surgical soap. An needle will be placed into the injured ankle joint and synovial fluid will be drawn out of the ankle and collected into a syringe. Using the same needle, the Saline will be delivered into the same arthrocentesis needle.~Next the uninjured ankle will have the same procedure as the injured ankle, except there will be no injection of Saline. There will only be a aspiration of synovial fluid from the uninjured ankle joint using a different clean needle.~Another aspiration of the synovial fluid will be done at the time of the second surgery in the same manner as before, except there will be no injection of Saline, just an aspiration of both injured and uninjured ankles."
3012140|NCT02481856|Experimental|12 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
3012141|NCT02481856|Experimental|7 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
3012142|NCT02481856|Experimental|2 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
3012143|NCT02481856|Placebo Comparator|Placebo|No active ingredient, Oral lyophilisate
3012144|NCT02481843||Hyperoxia|2-hours of hyperoxia (FiO2 = 1.0)
3012145|NCT02481843||Control|2-hours control without hyperoxia
3012146|NCT02481830|Experimental|Arm A Nivolumab|Nivolumab intravenous infusion as specified
3012147|NCT02481830|Active Comparator|Arm B Chemotherapy Topotecan|Topotecan as specified
3012148|NCT02481830|Active Comparator|Arm B Chemotherapy Amrubicin|Amrubicin intravenous infusion as specified (upon investigator's choice, where locally approved for 2nd line SCLC treatment)
3012149|NCT02481817||iSGS patients|Participants will receive standard of care treatment at the respective center and will be followed longitudinally for symptom changes, need for further treatment, complications, and will have Patient-reported outcomes (PROs) administered at a priori determined intervals.
3012150|NCT02481804|Experimental|Dietary intervention|There is one arm. Patients will first have an observation period, whre hey will get standard treatment during four weeks. Thereafter they will have the dietary intervention during 14 weeks.
3012151|NCT02481791|Experimental|Remifentanil|"Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.~Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.~Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min."
3012152|NCT02481765|Experimental|Direct current Stimulation|High definition transcranial direct current stimulation (HD-tDCS)
3012153|NCT02481752|Experimental|AAT Training Group|Individuals in this condition will receive four sessions of AAT training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the training may weaken automatic cigarette-approach and strengthen automatic cigarette-avoidance. Furthermore, they will be told that the opposite effect will be true for the stimuli not related to cigarettes (i.e., the positive stimuli).
3012154|NCT02481752|Sham Comparator|SHAM Training Group|Individuals in this condition will receive four sessions of SHAM training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the purpose of the training is to improve control over these automatic tendencies and that following the training sessions, they will easily be able to push or pull the stimuli regardless of content.
3012155|NCT02481726|Experimental|68Ga|In patients in suspicion of lung cancer or lung tuberculosis; in patients with differential diagnosis difficulties; without treatment or surgery. They underwent a standard routine 18F-FDG PET/CT first, and were injected 10~20MBq 68Ga-Alfatide II in the next day, followed by whole body PET/CT acquisitions.
3012156|NCT02481713|Experimental|MI condition|motivational interview condition
3012157|NCT02481713|Sham Comparator|CI condition|learning style interview condition
3012158|NCT02481687||Ulcerative colitis|"Consecutively admitted patients with active ulcerative colitis, confirmed by histopathology.~I-SCAN and pCLE will be applied in all patients."
3012159|NCT02481687||Crohn's disease|"Consecutively admitted patients with active Crohn's disease, confirmed by histopathology.~I-SCAN and pCLE will be applied in all patients."
3012160|NCT02481674|Experimental|VX15/2503|The study drug VX15/2503 will be administered via monthly intravenous infusions
3012161|NCT02481674|Placebo Comparator|Placebo|A placebo control will be administered via monthly intravenous infusions
3012162|NCT02481661|Experimental|segmentectomy|Patients undergo anatomic segmentectomy by minimal incision thoracotomy or thoracoscopy/VATS.
3012163|NCT02481661|Active Comparator|lobectomy|Patients undergo lobectomy by minimal incision thoracotomy or thoracoscopy/VATS.
3012164|NCT02481648|Experimental|ARM1: Exercise Intervention|"The exercise program is a 4-12 weeks progressive combined resistance and aerobic exercise for participants from time of diagnosis to RP.~Participants will undergo twice weekly group-training (four-six participants/group) combined aerobic-resistance sessions (1hr per session), supervised by trained exercise therapists. In addition, participants will undergo home-based aerobic exercise independently three times a week with the goal to meet the current physical activity guidelines for cancer survivors (150min/week of moderate intensity aerobic activity and two resistance training sessions per week). Participants will also be supplied with the Canadian Physical Activity and Sedentary Behavior Guidelines Handbook and accompanying Log Sheets."
3012165|NCT02481648|No Intervention|ARM2: Control Group|Participants will be asked to exercise as they normally would and will be asked to record their exercise activity on provided activity logs.
3012166|NCT02481635|Experimental|Gemcitabine/Nab-paclitaxel, Radiation and Surgery|"Gemcitabine (neoadjuvant and adjuvant), intravenously, at a dose of 1000 mg/m2 given over 30-40 minutes, on Day 1 of every 28 day cycle for 2 cycles.~Nab-paclitaxel, intravenously, at a dose of 125 mg/m2 given over 30-40 minutes, on Days 1, 8, and 15 of every 28 day cycle for 2 cycles.~Radiation Therapy: 50.4 Gy in 28 fractions (1.8 Gy/fraction)~Surgery: Tumor resection and arterial resection/reconstruction"
3012168|NCT02481596|Experimental|REACH + FAMS|"Participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months.~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
3012169|NCT02481596|Experimental|REACH|"Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence, messages assessing medication adherence with feedback, and targeted to address other self-care behaviors).~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
3012170|NCT02481596|Active Comparator|Helpline & A1c results|"Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
3012171|NCT02481583|Experimental|part 1|12 subjects successively received a single dose of levosulpiride tablets 25, 50, or 100 mg via oral administration and 50-mg of levosulpiride tablets 3 times a day for 7 days.
3012172|NCT02481583|Experimental|part 2|30 subjects were randomly assigned to 1 of 3 treatment groups (25, 50, or 75 mg) via i.m. administration, the 50-mg group subjects also received levosulpiride by i.v. route and repeated administration by i.m. route (twice a day for 3 days).
3012173|NCT02481570|Experimental|Anesthesia optimization|Information from the pharmacokinetic simulation during an anesthetic regimen of a propofol based Total Intravenous Anesthetic (TIVA)
3012174|NCT02481557|Experimental|Oxalate Salt Solution|Professionally applied
3012175|NCT02481557|No Intervention|No Treatment|No Treatment
3012176|NCT02481544|Experimental|Gratitude Journaling Plus Standard of Care|"The most often used gratitude intervention consists of journaling, writing lists of things for which the individual is grateful. This technique was first employed and found to be effectual for enhancing wellbeing by Emmons and McCullough and has been suggested to be as effective as methods frequently used in clinical therapy. We are proposing an 8-week intervention in which the participant records 3-5 things for which they are grateful most days of the week. A longer intervention was chosen because Emmons and McCullough (2003) suggest that healthy behavior changes only occurred in a prolonged multi-week intervention. To ensure some conformity in the intervention, instructions that will be used will be similar to Emmons and McCullough (2003): There are many things in our lives, both large and small, that we might be grateful about. Think back over your day (week) and write down on the lines below up to five things in your life that you are grateful or thankful for."
3012177|NCT02481544|Sham Comparator|Memorable Events Journaling Plus Standard of Care|"In the sham control condition, individuals will record memorable events with methods identical to the gratitude journaling condition: Patients will be asked to record 3-5 memorable events in a given day, on most days of the week. Patients will be contacted once per week to remind them to continue with the memorable events journal. Patients will be given 2 journals during their first testing session (one journal is for the first four weeks and the second is for the second four weeks of journaling). Patients will be contacted once per week to remind them to continue with gratitude journal writing. Patients will be instructed to record the date of each journal entry next to each new day of journaling Patients will be provided with materials to return their first journal by mail and will and return their second journal at the T2 laboratory testing session."
3012178|NCT02481544|No Intervention|Standard of Care|SOC consists of medical care that is included in post-MI treatment, such as physician visits and medication adjustments and cardiac rehabilitation. These patients will not have any active intervention, but will undergo the same testing routine as the gratitude intervention group. These patients will be given the opportunity to participate in the gratitude journaling intervention after they have completed the study. Patient records will be evaluated at each timepoint for changes in medications and medical treatment.
3012179|NCT02481531|Active Comparator|Previously marketed infant formula|Cow's milk-based infant formula
3012180|NCT02481531|Experimental|Previously marketed formula using a similar protein|Cow's milk-based infant formula
3012181|NCT02481518|Experimental|Magnesium|Magnesium preloading group : Magnesium preloading for Cisplatin treatment
3012182|NCT02481518|Active Comparator|Control|Control group : Normal saline preloading for cisplatin treatment
3012183|NCT02481505|Experimental|3 mL Chloroprocaine HCl 1%|Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
3012184|NCT02481505|Experimental|4 mL Chloroprocaine HCl 1%|Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
3012185|NCT02481505|Experimental|5 mL Chloroprocaine HCl 1%|Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
3012186|NCT02481492|Experimental|No flip technique|One group of boys will undergo a circumcision with no flip technique of Shang Ring Circumcision and receive regular follow-up to evaluate pain, operation associated adverse events, wound healing time. The Shang Ring will detach spontaneously without intervention, and the participants are asked to have a visit soon after ring detached. The last scheduled follow-up visit is at 90 days.
3012187|NCT02481492|Experimental|Flip technique|One group of boys will undergo a circumcision with flip technique of Shang Ring Circumcision and receive regular follow-up to evaluate pain, operation associated adverse events, wound healing time. The Shang Ring will be removed at 7 days, and the last scheduled follow-up visit is at 90 days.
3012188|NCT02481479|Other|Single group -Paired comparison|Saxagliptin 2.5mg or 5mg od
3012189|NCT02481466|Experimental|Portfolio diet and structured exercise|Participants will receive advice on a therapeutic diet appropriate for hypercholesterolemia (ie <7% of energy from saturated fat, <200mg/d cholesterol) PLUS the combination of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and be instructed on a standardized physical activity/exercise component supervised by kinesiologists.
3012309|NCT02480673|Active Comparator|Normocaloric diet plus oatmeal|This subjects will consume 1 cookie oatmeal before breakfast and dinner for 90 days along with a normocaloric diet
3012190|NCT02481466|Active Comparator|DASH-like diet and structured exercise|Participants will receive advice to follow a DASH-like diet of whole grains, and low-fat dairy products with fruits and vegetables and a be instructed on the Laval exercise program—a standardized physical activity/exercise component supervised by trained kinesiologists (exercise physiologists).
3012191|NCT02481466|Experimental|Portfolio diet and routine exercise|Participants will receive advice that will conform to the current therapeutic diet appropriate for hypercholesterolemia (ie <7% of energy from saturated fat, <200mg/d cholesterol) PLUS the combination of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and will be provided with a copy of Health Canada Physical Activity Guidelines with advice to increase physical activity.
3012192|NCT02481466|Active Comparator|DASH-like diet and routine exercise|Participants will receive advice to follow a DASH-like diet of whole grains, and low-fat dairy products with fruits and vegetables and will be provided with a copy of Health Canada Physical Activity Guidelines with advice to increase physical activity.
3012193|NCT02481453|Experimental|Rapamycin|rapamycin 1 mg/ml oral solution, 2 mg/day (2 ml/day), once a day, during one year
3012194|NCT02481453|Placebo Comparator|Placebo|Placebo oral solution, 2 ml/day, once a day, during one year
3012195|NCT02481440|Experimental|UC-MSC Transplantation|Intrathecal administration of up to 1x10^6 umbilical cord mesenchymal stem cells per kg to patients with spinal cord injury,every month for 4 months.
3012196|NCT02481440|No Intervention|Control group|No UC-MSC Transplantation
3012197|NCT02481427|Experimental|Total Knee Replacement|TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
3012198|NCT02481427|Experimental|Unicondylar Knee Replacement|UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
3012199|NCT02481414|Experimental|PepCan|PepCan 50 mcg per peptide/injection plus 0.3 mL Candin
3012200|NCT02481414|Active Comparator|Candin|0.3 mL Candin plus sterile saline
3012201|NCT02481401|No Intervention|Control Arm|Will not receive any structured program except for the health promotion education program that the children will receive for up to 5 months. Complementary to the Si! Program. This is essentially healthy habits related information and activities to be performed with their kids through family newsletters. All participants (including controls) have access to the study website for health related information.
3012202|NCT02481401|Experimental|Intensive Individual Intervention Program|A combination of one-on-one personalized lifestyle counseling (8 months with 4 complimentary sessions for a total of 12 months) and a wearable physical activity monitor such as the Garmin Vivofit.
3012203|NCT02481401|Active Comparator|Peer-To-Peer Program Intervention|Monthly meetings for 60-90 minutes in groups of about up to 20 supporting each other in self-control of CV risk factors.
3012204|NCT02481388||Weakness Group (WG)|Patients with heart failure and a maximum inspiratory pressure (MIP) <70% of predicted MIP to age, considered as inspiratory muscle weakness. Following the recruitment process, these volunteers will be evaluated by spirometry and manovacuometry. Afterwards, volunteers will be also assessed in a maximal exercise ramp test. Before and after the ramp test, the optoelectronic pletysmography will be performed to analyse the chest wall tricompartmental distribution and the shortening velocities of rib cages muscles. Also a high-definition ultrasonography will be performed to measure the right diaphragmatic cupule thickness
3012205|NCT02481388||Control group (CG)|Patients with heart failure and do not have a maximum inspiratory pressure (MIP) > 70% of predicted MIP to age, considered as inspiratory muscle weakness. Following the recruitment process, these volunteers will be evaluated by spirometry and manovacuometry. Afterwards, volunteers will be also assessed in a maximal exercise ramp test. Before and after the ramp test, the optoelectronic pletysmography will be performed to analyse the chest wall tricompartmental distribution and the shortening velocities of rib cages muscles. Also a high-definition ultrasonography will be performed to measure the right diaphragmatic cupule thickness
3012206|NCT02481375|Experimental|Multiple micronutrients with iron|"Multiple micronutrient formulations were based on the UNICEF/WHO/UNU standard formulation for pregnant and lactating women (UNIMMAP) with increased iron (from 30 mg to 60 mg elemental iron) for comparability to the iron only group (60 mg). This formulation has 15 micronutrients including iron.~Women will receive the multiple micronutrient with iron for 12 weeks."
3012207|NCT02481375|Active Comparator|Multiple micronutrients without iron|"This formulation has the 14 micronutrients included in the UNIMMAP formulation, but does not include iron.~Women will receive the multiple micronutrient without iron for 12 weeks."
3012208|NCT02481375|Active Comparator|Iron only|"This formulation only has 60 mg elemental iron.~Women will receive iron for 12 weeks."
3012209|NCT02481375|Placebo Comparator|Placebo|"This formulation is a placebo.~Women will receive a placebo for 12 weeks."
3012210|NCT02481362|Active Comparator|Order 1|Order for sessions: Cake, apricots
3012211|NCT02481362|Active Comparator|Order 2|Order for sessions: apricots, Cake
3012212|NCT02481349|Experimental|Phase 1: Couples Based Hatha Yoga Group|Participants and their caregivers take part in up to 15 sessions of Hatha yoga over the course of radiation therapy (up to 5 weekly sessions based on participant's schedule for usually 5-6 weeks). Most of the yoga sessions may be videotaped. At fifth session, participant given a CD and instructions for practicing Hatha yoga at home. During each week of radiation therapy, participant completes a questionnaire about the Hatha yoga sessions. Participant also completes questionnaires before first radiation treatment, and again after completion of radiation treatment schedule (usually 6 weeks later).
3012213|NCT02481349|Active Comparator|Phase 1: Waitlist Group|Participant completes questionnaires before first radiation treatment, and again after completion of radiation treatment schedule (usually 6 weeks later).
3012310|NCT02480673|Active Comparator|Normocaloric diet|This subjects will only go under a normocaloric diet for 90 days
3012214|NCT02481349|Experimental|Phase 2: Dyadic Yoga Group|"Participants and their caregivers take part in up to 15 sessions of Hatha yoga over the course of radiation therapy (up to 5 weekly sessions based on participant's schedule for usually 5-6 weeks). Most of the yoga sessions may be videotaped.~Starting session 5, intervention sessions delivered either in person or via videoconferencing based on the participants' preference."
3012215|NCT02481349|Experimental|Phase 2: Caregiver Yoga Group|Only the caregiver receives yoga sessions up to 5 days per week over the course of patients' RT (up to 15 sessions, 45-60 min. each). The yoga session for caregivers structured just as the dyadic yoga session except that the focus is entirely on the caregiver and promoting practicing self-care.
3012216|NCT02481349|Experimental|Phase 2: Waitlist Control Group|Waitlist control group receives standard of care and completes all assessments on the same timeframe as the intervention group except for the intervention evaluations. Once data collection is completed, caregivers and patients may participate in yoga program if they choose to do so.
3012217|NCT02481336||Cancer patients receiving chemotherapy|"Stage I-IV ovarian cancer receiving chemotherapy Paclitaxel/Carboplatin~Stage II-IV endometrial cancer receiving chemotherapy Paclitaxel/Carboplatin~Stage III & high risk stage II colorectal cancer receiving chemotherapy with mFOLFOX~Questionnaires~Peripheral nervous system examination~Whole Genome Sequence"
3012218|NCT02481323|Active Comparator|Group 1|Isosorbide mononitrate 25mg bd
3012219|NCT02481323|Active Comparator|Group 2|Cilostazol 100mg bd
3012220|NCT02481323|Active Comparator|Group 3|Isosorbide mononitrate 25mg bd and cilostazol 100mg bd start immediately
3012221|NCT02481323|Other|Group 4|Isosorbide mononitrate 25mg bd and cilostazol 100mg bd delayed start
3012222|NCT02481310|Experimental|Treatment (combination chemotherapy, rituximab, ixazomib)|"INDUCTION:~Patients receive ixazomib citrate PO on day 1 and day 8 or 15; etoposide IV, vincristine sulfate IV, and doxorubicin hydrochloride IV continuously over 96 hours on days 1-4; prednisone PO BID on days 1-5; rituximab IV should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr on day 1; and cyclophosphamide IV over 90 minutes on day 5.~CNS PROPHYLAXIS:~Patients with a negative LP receive methotrexate IT once per course. Patients with a positive LP receive methotrexate IT or intraventricularly OR cytarabine IT or intraventricularly OR methotrexate IT or intraventricularly, cytarabine IT or intraventricularly, and therapeutic hydrocortisone IT or intraventricularly.~MAINTENANCE:~Patients not treated with consolidative SCT, receive ixazomib citrate PO BID on days 1, 8, and 15. Treatment repeats every 28 days for up to one year in the absence of disease progression or unacceptable toxicity."
3012223|NCT02481297|Experimental|Cohort 1: Refractory/Relapsed After Prior Therapy|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22), then with start of each course. Lirilumab 3 mg/kg by vein given on Day 1 of each cycle. Rituximab given for the first 12 cycles and Lirilumab continues for up to 24 cycles. Each cycle is 4 weeks.
3012224|NCT02481297|Experimental|Cohort 2: Untreated with High-rRisk mMolecular Features|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22), then with start of each course. Lirilumab 3 mg/kg by vein given on Day 1 of each cycle. Rituximab given for the first 12 cycles and Lirilumab continues for up to 24 cycles. Each cycle is 4 weeks.
3012225|NCT02481284||Laser Doppler Perfusion Imaging|20 consequetive cases undergoing breast reconstruction with Deep inferior epigastric artery perforator flap who had evaluation of the microcirculation of the abdominal skin with laser Doppler perfusion imaging
3012226|NCT02481271|No Intervention|Usual care|Does not receive a specific study intervention
3012227|NCT02481271|Experimental|preoperative relaxation program|preoperative relaxation program
3012228|NCT02481271|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
3012229|NCT02481271|Experimental|preoperative relaxation program+preoperative surgery education|preoperative relaxation program AND single education unit
3012230|NCT02481258|Experimental|Ataciguat (HMR1766)|200mg taken daily for 12 months
3012231|NCT02481258|Placebo Comparator|Matching Placebo|Taken Daily for 12 months
3012232|NCT02481245|Experimental|Bipolar I Disorder|30 currently depressed patients with DSM-IV bipolar I disorder who are currently taking an adequate dose of an FDA-approved anti-manic medication will receive Bezafibrate treatment
3012233|NCT02481232|Experimental|freeze-dried group ACYW135 MCV 4μg|4μg group: vaccines serial number is A0001－A0100（18-55 years-old group A0001－A0020，7-17 years-old group A0021－A0040，1-6 years-old group A0041－A0060，7-10 months-old group A0061－A0080，2 months-old group A0081－A0100）
3012234|NCT02481232|Experimental|freeze-dried group ACYW135 MCV 8μg|8μg group: vaccines serial number is B0001－B0100（18-55 years-old group B0001－B0020，7-17 years-old group B0021－B0040，1-6 years-old group B0041－B0060，7-10 months-old group B0061－B0080，2 months-old group B0081－B0100）
3012235|NCT02481219|Active Comparator|Bowel preparation regimen -Control|"Regimen includes administration of:~Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of polyethylene glycol (PEG) on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository."
3012236|NCT02481219|Experimental|Bowel preparation regimen-Test|"Regimen includes administration of:~Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository."
3012237|NCT02481206|Experimental|Wearable Cardioverter Defibrillator|End Stage Renal Disease (ESRD) patients beginning hemodialysis will use a Wearable Cardioverter Defibrillator for six months
3012238|NCT02481206|No Intervention|Conventional Treatment|Conventional Treatment
3012239|NCT02481193|Experimental|Cisatracurium 0.005 mg/kg|The group received pretreatment of cisatracurium 0.005 mg/kg.
3012240|NCT02481193|Experimental|Cisatracurium 0.01 mg/kg|The group received pretreatment of cisatracurium 0.01 mg/kg
3012241|NCT02481193|Experimental|Cisatracurium 0.02 mg/kg|The group received pretreatment of cisatracurium 0.02 mg/kg
3012242|NCT02481180|Experimental|T0001|
3012243|NCT02481180|Active Comparator|Enbrel|
3012244|NCT02481167||group1|This study was consisted of patients with older than 40 years of age who complained with dry eye.
3014527|NCT02465450|Placebo Comparator|Placebo BID|Placebo twice daily on Days 29-84.
3012245|NCT02481154|Experimental|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression, development of other unacceptable toxicity or Investigator discretion
3012246|NCT02481141|Active Comparator|5-ALA-SFC|"Study product administration will be as follows:~Beginning Week 0: 1 capsule of 50mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 4: 1 capsule of 100mg 5-ALA-SFC twice per day for 8 weeks"
3012247|NCT02481141|Placebo Comparator|Placebo|"Study matching placebo administration will be as follows:~Beginning Week 0: 1 capsule twice per day for 2 weeks Beginning Week 2: 1 capsule twice per day for 2 weeks Beginning Week 4: 1 capsule twice per day for 8 weeks"
3012248|NCT02481128|No Intervention|A (access to lymphoscintigraphy)|Axillary sentinel lymph node biopsy with preoperative access to lymphoscintigraphy findings
3012249|NCT02481128|Experimental|B (no access to lymphoscintigraphy)|Axillary sentinel lymph node biopsy without preoperative access to lymphoscintigraphy findings
3012250|NCT02481115||Critically Ill Children|Children in the Pediatric Critical Care Unit regardless of admitting diagnosis aged at least 6 months of age up to 5 years of age.
3012251|NCT02481089||training group|
3012252|NCT02481076|Experimental|compression therapy|"Intervention arm: administration of~Flowtron Hydroven boot in the Emergency Department~Coban2 Lite after surgery~Flowtron Hydroven boot after surger, before discharge"
3012253|NCT02481076|Other|controle|"The leg is elevated on a Braun frame. This is the old fashioned conservative treatment to prevent swelling."
3012254|NCT02481063|Active Comparator|Eccentric|6 Weeks Training with eccentric Overload (Squat with Yoyo Technology) 3 Consecutive Days Running 1 hour at 80% of Maximus Heart Rate
3012255|NCT02481063|Active Comparator|Control|3 Consecutive Days Running 1 hour at 80% of Maximus Heart Rate
3012256|NCT02481050|Experimental|Eribulin Mesylate|Participants with metastatic HER2-negative breast cancer previously treated with 2 to 5 chemotherapy regimens.
3012257|NCT02481037|Experimental|Intervention group|Embedding a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate practitioners utilizing best-evidence; training these practices' chronic disease management (CDM) professionals to provide asthma education to children with asthma and their parents; and clinicians receiving an EMR embedded dashboard.
3012258|NCT02481037|No Intervention|Control group|Practice will continue with routine care. Control group will be offered the intervention at study completion, if successful.
3012259|NCT02481011||users|patients on antithrombotic drugs admitted to a Norwegian hospital for intracranial hemorrhage (ICH)
3012260|NCT02481011||non-users|patients not on antithrombotic drugs admitted to a Norwegian hospital for intracranial hemorrhage (ICH)
3012261|NCT02480998|Experimental|IL-YANG Flu Vaccine QIV 0.5mL|A single 0.5mL dose administrated as an intramuscular injection.
3012262|NCT02480998|Active Comparator|IL-YANG Flu Vaccine TIV 0.5mL|A single 0.5mL dose administrated as an intramuscular injection.
3012263|NCT02480985|Other|Pituitary function evaluation|Exams performed according to a determined schedule following admission in the intensive care unit in order to determine the risk factors and the outcome associated with pituitary disorders.
3012264|NCT02480972|Other|Magnetic resonance imaging|multiparametric MRI including perfusion, diffusion, MR fat quantification and MR elastography
3012265|NCT02480959|Other|Medial plication|Patient undergoing surgical treatment for recurrent patellar instability that includes medial retinacular plication
3012266|NCT02480959|Other|MPFL reconstruction|Patient undergoing surgical treatment for recurrent patellar instability that includes medial patellofemoral ligament reconstruction using a tendon graft
3012267|NCT02480946|Experimental|Single Ascending Dose and Food Effect|Part A will be a single-dose, sequential-group, double-blind, placebo-controlled study of MBS2320.
3012268|NCT02480946|Experimental|Multiple Ascending Dose|Part B will be a multiple-dose, sequential-group, double-blind, placebo-controlled study to investigate 3 planned dose levels.
3012269|NCT02480946|Experimental|Relative Bioavailability|Part C will be an open-label, randomised, 2-period crossover relative bioavailability study of MBS2320 in capsules or suspension. The intention is to enrol 8 healthy subjects. Each subject will participate in 2 treatment periods.
3012270|NCT02480946|Experimental|Drug-Drug Interaction with Methotrexate|Part D will be a multiple dose study incorporating an open-label, fixed-sequence drug-drug interaction between MBS2320 and methotrexate and biomarker evaluation.
3012271|NCT02480933|Experimental|female cadavers|female cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy
3012272|NCT02480933|Experimental|Male cadavers|male cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy
3012273|NCT02480907|Active Comparator|Workshop Group|Parents of ~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will be involved in the workshop support group for parents for a period of three months, including a written manual, a DVD (Digital Video Disc) with additional information and weekly workshops. Over the course of three months, parents will participate at the 8 workshop sessions and get the manual to read and the DVDs to use at home to illustrate workshop contents with examples and video clips.
3012274|NCT02480907|Active Comparator|Internet-based support group|Parents of ~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will be involved in the Internet-based support group for parents, including material from the manual and the DVD and additional information available online within a structured program. Over the course of three months, parents will get access to the 8 support sessions online with the instruction to work out the program at home. Additionally email support is offered after completing each session.
3012275|NCT02480907|No Intervention|Control group - TAU|Parents of ~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will get treatment as usual and take part in conventional parental intervention groups.
3012276|NCT02480894|Experimental|Sequential Dosing|Treatment A: BMS-663068 orally twice daily (BID) on Days 1 through 4 Treatment B: Maraviroc BID on Days 7 through 11 Treatment C: BMS-663068 BID plus maraviroc BID on Days 12 through 18
3012311|NCT02480660|Experimental|Video Intervention Group|Subjects will be randomized to intervention group where participants will be asked to watch a 7 minute educational video.
3014624|NCT02465021|Experimental|Control 1|Dietary intervention: Water (500 g)
3012277|NCT02480881|Experimental|Single Sequence A, B, C, and D|Treatment A/Cycle 1: OC containing EE and progestin taken by mouth. Treatment B/Cycle 2: OC containing EE and progestin taken by mouth. Treatment C/Cycle 3: Loestrin 1.5/30 taken by mouth. Treatment D/Cycle 4: Loestrin 1.5/30 (alone) and Loestrin 1.5/30 with BMS-663068 taken by mouth.
3012278|NCT02480868|Experimental|ARTEBONE|Bone Void Filler
3012279|NCT02480855|Other|Questionnaire and feedback|Patients that will see a doctor randomized to the intervention group will fill in the Work Stress Questionnaire prior to the visit. The doctor gets the results from the questionnaire and then gives consultation to the patient based on the results.
3012280|NCT02480855|No Intervention|Control group|Patients that will see a doctor randomized to the control group get the usual treatment/consultation and after the visit fill in the Work Stress Questionnaire.
3012281|NCT02480842|Experimental|Alloplastic group A|"After randomization (15 days after surgery):~- Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain."
3012282|NCT02480842|Experimental|Alloplastic group B|"After randomization (15 days after surgery):~- Patients will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction"
3012283|NCT02480842|Experimental|Oncoplastic group A|"After randomization (15 days after surgery):~- Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain."
3012284|NCT02480842|Experimental|Oncoplastic group B|"After randomization (15 days after surgery):~- Patients will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction"
3012285|NCT02480829|Experimental|Amphora OAB Device 3.0 mm|Treatment with the Amphora OAB Device
3012286|NCT02480816|Experimental|Bicarbonated mineral water (BW)|Bicarbonated mineral water
3012287|NCT02480816|Active Comparator|Control mineral water (CW)|Mineral water low in mineral content (control)
3012288|NCT02480803|Active Comparator|continuous levodopa infusion|continuous intrajejunal infusion of levodopa-carbidopa
3012289|NCT02480803|Active Comparator|deep brain stimulation|Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
3012290|NCT02480790||Patients with malignant disease|Patients with ovarian, tubar or primary peritoneal cancer
3012291|NCT02480790||Patients with benign disease|Patients with suspected ovarian cancer where the final pathologic diagnosis is benign
3012292|NCT02480764|Experimental|Azilsartan medoxomil 40 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once, daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 40 mg tablets, orally, once, daily, azilsartan medoxomil 80 mg placebo-matching tablets, orally, once, daily, and valsartan two 80 mg placebo-matching capsules, orally, once, daily, for 8 weeks.
3012293|NCT02480764|Experimental|Azilsartan medoxomil 80 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once, daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 80 mg tablets, orally, once, daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once, daily, and valsartan two 80 mg placebo-matching capsules, orally, once, daily, for 8 weeks.
3012294|NCT02480764|Active Comparator|Valsartan 160 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once, daily, for 2 weeks prior to the start of the treatment period. Treatment Period: valsartan two 80 mg capsules, orally, once, daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once, daily, and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once, daily, for 8 weeks.
3012295|NCT02480751|Experimental|1: Exprimental (TRK-100STP)|high dose
3012296|NCT02480751|Experimental|2: Exprimental (TRK-100STP)|low dose
3012297|NCT02480751|Placebo Comparator|3: Placebo Comparator|Placebo
3012298|NCT02480738|Experimental|Mild cognitive impairment|Intervention: Computerized Cognitive Training Apparatus
3012299|NCT02480738|Experimental|Subjective cognitive impairment|Intervention: Computerized Cognitive Training Apparatus
3012300|NCT02480738|Active Comparator|Normal controls|Intervention: Computerized Cognitive Training Apparatus
3012301|NCT02480725||CJD (Creutzfeldt-Jakob disease) patients|"Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).~Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.~No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.~We plan to collect CSF samples for thrombin activity assay."
3012302|NCT02480725||non-CJD patients with a type of dementia|"Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).~Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.~No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.~We plan to collect CSF samples for thrombin activity assay."
3012303|NCT02480725||CSF samples of non-CJD patient used as control|CSF samples : Thrombin activity will be assayed.
3012304|NCT02480712|Experimental|SOF/VEL|Participants will receive SOF/VEL for 12 weeks
3012305|NCT02480699|Experimental|Hemodialysed patients|
3012306|NCT02480686|Experimental|SOF+PEG+RBV|Participants with HCV genotype 1b infection will receive Sofosbuvir (SOF) 400 mg +PEG+RBV for 12 weeks.
3012307|NCT02480673|Experimental|Free diet plus Chia|This subjects will consume 1 cookie oatmeal with chia before breakfast and dinner for 90 days without changing their diet
3012308|NCT02480673|Experimental|Normocaloric diet plus chia|This subjects will consume 1 cookie oatmeal with chia before breakfast and dinner for 90 days along with a normocaloric diet
3012312|NCT02480660|No Intervention|Control Group|Subjects will be randomized to control group ( no intervention) and receive standard of educational care on adolescent to adult oriented health care transitions.
3012313|NCT02480647|Experimental|levonorgestrel & etonogestrel|"Levonorgestrel releasing intrauterine system~Other names:~Mirena."
3012314|NCT02480647|Active Comparator|etonogestrel|"Etonogestrel implant:~Other name: Implanon Releasing 20μg/day."
3012315|NCT02480634|Active Comparator|High dose group|Zoledronic acid 4 mg + 0.9% sodium chloride injection 100 ml intravenous drip more than 15 min, 28 days for a transfusion cycle , a total of six cycle，Radiotherapy dose: 30Gy/10f
3012316|NCT02480634|Experimental|Low dose group|Zoledronic acid 4 mg + 0.9% sodium chloride injection 100 ml intravenous drip more than 15 min, 28 days for a transfusion cycle, a total of six cycle，Radiotherapy dose: 15Gy/5f
3012317|NCT02480621|No Intervention|Control|Standard of care: Open Reduction Internal Fixation with no injection of pain medications around the affected ankle.
3012318|NCT02480621|Experimental|Liposomal Bupivacaine with Bupivacaine|Intra-operatively, patients receive a local injection of liposomal bupivacaine with bupivacaine around the affected ankle.
3012319|NCT02480608|Experimental|combination Imatinib + Hydroxyurea|Patients who meet the inclusion criteria will be started on 400 mg Imatinib daily. In part 1 of the protocol, the dose of HU will be increased by 500 mg at 3-weekly intervals until the maximal tolerated dose has been reached. In part 2 of the study, patients will be randomized to receive either the combination or Imatinib monotherapy.
3012320|NCT02480608|Active Comparator|monotherapy Imatinib|Imatinib monotherapy
3012321|NCT02480595||EVAR|Patients undergoing endovascular repair with the latest generation Aorfix™ AAA Flexible Stent Graft System for treatment of abdominal aortic and aorto-iliac aneurysms where the aorta in the aneurysm neck is bent through an angle between 0° and 90°
3012322|NCT02480582|Experimental|Almond, then No Food, then Cheese Savouries|Participants first received a mid-morning snack of almonds (0.9g/kg). After a washout period of 5 days, they then received no food. Finally, after another washout period participants received a mid-morning snack of cheese savouries (0.9g/kg).
3012323|NCT02480582|Experimental|Cheese Savouries then Almond, then No Food|Participants first received a mid-morning snack of cheese savouries (0.9g/kg). After a washout period of 5 days, they then received a mid-morning snack of almonds (0.9g/kg). Finally, after another washout period participants received no food.
3012324|NCT02480582|Experimental|No Food, then Cheese Savouries, then Almond|Participants first received no food. After a washout period of 5 days, they then received a mid-morning snack of cheese savouries (0.9g/kg). Finally, after another washout period participants received a mid-morning snack of almonds (0.9g/kg).
3012325|NCT02480582|Experimental|Cheese Savouries, then No Food, then Almond|Participants first received a mid-morning snack of cheese savouries (0.9g\kg). After a washout period of 5 days, they then received no food. Finally, after another washout period participants received a mid-morning snack of almonds (0.9g\kg).
3012326|NCT02480582|Experimental|Almond, then Cheese Savouries, then No Food|Participants first received a mid-morning snack of almonds (0.9g\kg). After a washout period of 5 days, they then received a mid-morning snack of cheese savouries (0.9g\kg). Finally, after another washout period participants received no food.
3012327|NCT02480582|Experimental|No Food, then Almond, then Cheese Savouries|Participants first received no food. After a washout period of 5 days, they then received a mid-morning snack of almonds (0.9g/kg). Finally, after another washout period participants received a mid-morning snack of cheese savouries (0.9g\kg).
3012328|NCT02480569|Experimental|Side-Hole Catheter|2 FFR measurements from an engaged side-hole guide catheter and a disengaged side-hole guide catheter
3012329|NCT02480569|Experimental|Non-Side-Hole Catheter|2 FFR measurements from an engaged non-side-hole guide catheter and a disengaged non-side-hole guide catheter
3012330|NCT02480556|Experimental|Group A|manual seperation of the placenta
3012331|NCT02480556|Active Comparator|Group B|Conservative separation of placenta
3012332|NCT02480543|Active Comparator|PO Misoprostol|Cervical preparation with per-os (PO) Misoprostol 400 mcg 2-4 hours prior to curettage
3012333|NCT02480543|Active Comparator|PV Misoprostol|Cervical preparation with per-vagina (PV) Misoprostol 400 mcg 2-4 hours prior to curettage
3012334|NCT02480543|Active Comparator|Buccal Misoprostol|Cervical preparation with buccal Misoprostol 400 mcg 2-4 hours prior to curettage
3012335|NCT02480530|No Intervention|Control|Patients will be given educational material on the importance of adherence to statin medications. The GlowCaps device will be set to only record adherence.
3012336|NCT02480530|Experimental|Individual Feedback|In addition to educational material on adherence to statin medications, the research coordinator will review set-up of personal reminders for the GlowCaps device which will be set to glow and buzz when the medication is missed. In addition, patients will receive information on the weekly adherence feedback report.
3012337|NCT02480530|Experimental|Feedback Friend|The patient will be given educational material on the importance of adhering to statin medications. The research coordinator will review set-up of alarm features of GlowCaps device. Similar to Arm 2, patients will be given information on interpretation of weekly adherence feedback report. If the patient chooses a family/friend, they will be called and provided information on the interpretation of weekly adherence feedback report. If the patient chooses a reciprocal partner, they will be assigned to another patient who has made a similar choice
3012338|NCT02480517|Experimental|Investigational Therapy (Surround Sound)|Investigational Therapy using external focused ultrasound
3012339|NCT02480517|Sham Comparator|Sham Control|Blinded Sham Control Arm
3012340|NCT02480504|Experimental|intermittent energy restriction|dietary intervention, intermittent energy restriction. Participants in the experimental group will follow av 5:2 diet and consume a very low calorie diet providing 400 (females) to 600 (males) calories of energy to days a week and for an average male participant, this will reduce energy intake approximately 22%.
3012341|NCT02480504|Active Comparator|continuous energy restriction|dietary intervention, continuous energy restrictions.Participants in the active comparator group will be asked to reduce daily energy intake by 22-23%
3012342|NCT02480491||Third day embryos|embryos culture media during third day after fertilization
3012343|NCT02480491||Fifth day embryos|embryos culture media during fifth day after fertilization
3013088|NCT02475317|Experimental|LUM001 50mg twice daily|10 subjects will receive a dose of LUM001 (50 mg) twice daily
3012344|NCT02480478||intrahepatic cholestasis of pregnancy|5 ml whole blood sample is going to collect from intrahepatic cholestasis of pregnancy group for the assessment of serum autotaxin levels
3012345|NCT02480478||healthy control group|5 ml of whole blood is going to taken from healthy control group
3012346|NCT02480465|Experimental|Lobelitazone 0.5mg|Lobelitazone 0.5mg
3012347|NCT02480465|Active Comparator|Sitagliptin 100mg|Sitagliptin 100mg
3012348|NCT02480452||CVI|All children consulting at the CVI clinic (with suspicion of CVI) receiving a diagnosis of CVI
3012349|NCT02480452||no CVI|All children consulting at the CVI clinic (with suspicion of CVI) not receiving a diagnosis of CVI
3012350|NCT02480439|Experimental|TAK-648 Sequence ABC|Regimen A TAK-648 0.3 mg, tablet, orally, 30 minutes after a high fat meal, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 3.
3012351|NCT02480439|Experimental|TAK-648 Sequence BCA|Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen A TAK-648 0.3 mg, tablet, orally, 30 minutes after a high fat meal, once on Day 1 of Period 3.
3012352|NCT02480439|Experimental|TAK-648 Sequence CAB|Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen A TAK-648 0.3 mg, tablet, orally, after a high fat meal, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 3.
3012353|NCT02480426|Experimental|CT-image guidance|Previously acquired portal venous phase of CT datasets and intra-operative CT datasets were registered on a dedicated workstation. The selected volume of interest of the CT-image showing portal vein vasculature was overlaid onto the fluoroscopic display as real-time 3D CT-image guidance during the procedure.
3012354|NCT02480426|Active Comparator|CO2 portography|two two-dimensional (2D) CO2 portograms
3012355|NCT02480400|Experimental|Supported Escitalopram|Escitalopram, with assessment visits at baseline, and weeks 2, 4, 6 and 8
3012356|NCT02480400|Active Comparator|Escitalopram|Escitalopram, with assessment visits at baseline, week 4 and week 8, and a safety visit at week 2
3012357|NCT02480387|Experimental|Treatment Arm|8 weeks treatment with Ledipasvir/Sofosbuvir FDC
3012358|NCT02480374|Experimental|Single Arm|
3012359|NCT02480361|Experimental|Acupuncture|The patients who were received acupuncture after gastric cancer surgery
3012360|NCT02480361|No Intervention|Non-acupuncture|The patients who were not received acupuncture after gastric cancer surgery
3012361|NCT02480348|Experimental|Polymer-free DES (Drug Eluting Stent)|
3012362|NCT02480335|Experimental|Usual care and bosentan|Usual care and also treatment with bosentan.
3012363|NCT02480335|No Intervention|Usual care|Usual care only.
3012364|NCT02480322||Sleeve group|Patients undergoing gastric sleeve resection.
3012365|NCT02480322||Proximal RYGB group|Patients undergoing proximal gastric bypass surgery.
3012366|NCT02480322||Distal RYGB group|Patients undergoing distal gastric bypass surgery.
3012367|NCT02480322||BMI-matched control group|
3012368|NCT02480322||Normal-weight control group|
3012369|NCT02480296|Experimental|MYK-461|Oral Tablet x 28 days
3012370|NCT02480296|Placebo Comparator|Placebo|Oral Tablet x 28 days
3012371|NCT02480283||Control|Subjects aged 18 to 55 who have never used cannabis by self report (validated via urine drug screen), who have never used tobacco/cigarettes and have the capacity to give informed consent.
3012372|NCT02480283||Cannabis Smokers|The exposed cohort will have daily or near daily cannabis smoking histories equivalent to a minimum of 20 joint years (number of joints smoked per day multiplied by years of cannabis smoking), will not have a significant tobacco/cigarette smoking history and will be able to provide informed consent.
3012373|NCT02480257|Experimental|TARA Intervention group|TARA is comprised of 12 weekly classes delivered in a group format by two trained facilitators with approximately 8-15 participants. The 90 minute sessions are designed to promote skills for autonomic regulation, attention modulation, emotion regulation and cognitive control.
3012374|NCT02480244|Experimental|Behavioral intervention|Behavioral intervention consisting of 12 educational sessions promoting healthy diet and increased physical activity
3012375|NCT02480244|Active Comparator|Control|Control arm receives no health-related behavioral intervention
3012376|NCT02480231|Active Comparator|Babcock tensioning technique|Group for whom the retropubic mid-urethral sling was tensioned using a Babcock clamp.
3012377|NCT02480231|Active Comparator|Scissor spacer technique|Group for whom the retropubic mid-urethral sling was tensioned using a surgical scissor as a spacer.
3012378|NCT02480218||Tamoxifen|Chemotherapy-naïve women 65 and older with a first diagnosis of early stage HR+ BC, post surgical resection prescribed tamoxifen.
3012379|NCT02480218||Aromatase Inhibitors|Chemotherapy-naïve women 65 and older with a first diagnosis of early stage HR+ BC, post surgical resection prescribed aromatase inhibitors.
3012380|NCT02480205|Experimental|NeuroBox to deliver the NeuroPAP|
3012381|NCT02480192|Experimental|Experimental Group|After an initial assessment, the experimental group will receive 12 weekly sessions (2 hours long) of Cognitive Behavioural Group Therapy (n=8 per group) for menopausal symptoms including vasomotor symptoms and depressive symptoms. They will then be re-assessed at post-treatment and 3 months post-treatment to determine the effectiveness of the treatment and whether these effects are maintained 3 months after treatment.
3012382|NCT02480192|No Intervention|Wait-List Control|After an initial assessment, the wait-list control group will not receive any treatment for 12 weeks. They will then be re-assessed after 12 weeks and this data will be used to compare this group to the experimental group to determine the effectiveness of the treatment. After this re-assessment they will be offered the same treatment as the experimental group: 12 weekly sessions (2 hours long) of Cognitive Behavioural Group Therapy.
3012383|NCT02480179|Experimental|single arm pilot feasibility study|Hematoencephalography bio/neurofeedback for Brain neural activity modulation. H.E.G. (hematoencephalography) based neurofeedback program. No drug use.
3012384|NCT02480166|Experimental|8 weeks SOF/LED|Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.
3012385|NCT02480166|Experimental|12 weeks SOF/LED|Patients that are either treatment experienced or are cirrhotic will be assigned to 12 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.
3012386|NCT02480153|Experimental|PF-06410293|
3012387|NCT02480153|Active Comparator|Adalimumab|
3012388|NCT02480140|Experimental|Self-regulated constraint-induced movement therapy|Self-regulated constraint-induced movement therapy (SR-CIMT) - participants' non-hemiplegic arm was restrained in a mitt for 4 hours every day, 2 weeks, 5 days a week (therapy days) (CIMT) (the same CIMT protocol as in the CIMT group described under 'comparator/control treatment'); participants were taught using the self-regulation (SR) strategy to relearn the tasks; SR strategy involved participants self reflecting on their abilities and deficits in performing the tasks, identifying problems and solutions in achieving the most independence in the tasks, and then actually carrying out the tasks.
3012389|NCT02480140|Active Comparator|Constraint-induced movement therapy|In the constraint-induced movement therapy group (CIMT), participants' non-hemiplegic arm was restrained in a mitt for 4 hours every day, 2 weeks, 5 days a week (therapy days); therapist provided demonstration on the adapted task performance with one arm (the side of participants' hemiplegic arm), and participants to practice the tasks with the unrestrained hemiplegic arm under supervision.
3012390|NCT02480140|Active Comparator|Conventional occupational therapy|It involved therapist to demonstrate the adapted task performance followed by patient's practice under supervision.
3012391|NCT02480127|Experimental|Endometrial injury|In the intervention group, endometrial sampling is obtained twice by Pipelle [one in the follicular phase (during 8-9 or 11- 13 day in the beginning of buserelin cycle) and the last in the luteal phase (during 19-21 or 20-23 day) preceding the embryo transfer cycle preceding the embryo transfer cycle]. Blood samples (5- 10 cc) are taken in the both groups twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).
3012392|NCT02480127|No Intervention|Control|In the control group endometrial sampling will be done only in the luteal phase of the cycle preceding the embryo transfer cycle. Blood samples (5- 10 cc) are taken twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).
3012393|NCT02480114|Active Comparator|Arm I Standard of Care|Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.
3012394|NCT02480114|Active Comparator|Arm II Standard of Care Plus Gabapentin|Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.
3012395|NCT02480101|Active Comparator|H7N9 LAIV|H7N9 live influenza vaccine
3012396|NCT02480101|Placebo Comparator|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers
3012397|NCT02480088|Experimental|ramosetron|patients receiving ramosetron for prophylaxis of postoperative nausea and vomiting
3012398|NCT02480088|Active Comparator|palonosetron|patients receiving palonosetron for prophylaxis of postoperative nausea and vomiting
3012399|NCT02480075||Chronic pain|Observational ; Adult patients seeking medical treatment that have been diagnosed with chronic pain.
3012400|NCT02480062|Experimental|mWELLCARE software arm|The doctor and nurse care coordinators (NCCs) in the mWELLCARE intervention arm will be trained on the use of mWELLCARE software loaded on a tablet computer. Patients diagnosed with hypertension and/or diabetes will be registered by the nurse using mWellcare application. The nurse will record patient parameters, medical history, medication etc and generate a management plan (including drug recommendation, lifestyle advise) using the mWellcare application based on standard treatment guidelines. The doctor will review the recommendation and agree or disagree giving reasons. Patient will be followed up using SMS.
3012401|NCT02480062|Active Comparator|Usual care arm|"In the control arm or the usual care arm CHCs, the doctor and Nurse will get refresher training in the detection, management and follow up of hypertension and diabetes patients based on standard guidelines. They will be provided with charts for quick reference to standard treatment guidelines. Patients diagnosed with hypertension and/or diabetes will be managed by the doctor at the CHC. The nurse will assist in recording blood pressure, height, weight etc, providing lifestyle advise and follow up advice to patients."
3012402|NCT02480049|Experimental|A Test|test drug (Asmakast)1 tablet contains 10 mg Montelukast
3012403|NCT02480049|Active Comparator|B Reference|reference drug (Singulair) 1 tablet contains 10 mg Montelukast
3012404|NCT02480036|Experimental|Combined IORT and Kyphoplasty|IORT with Kyphoplasty IORT Device: Intrabeam®
3012405|NCT02480023|Experimental|healthcare|QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
3012406|NCT02480010|Experimental|Pertuzumab 1050 mg (Cohort B)|Participants in Cohort B will receive 1050 mg pertuzumab via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
3012407|NCT02480010|Experimental|Pertuzumab 420 mg (Cohort A)|Participants in Cohort A will receive an IV loading dose of 840 milligrams (mg) pertuzumab followed by 420 mg via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
3012408|NCT02479997|Active Comparator|Radioisotope (RI)|"Using RI only as SLNB mapping in breast cancer patients who receive neoadjuvant chemotherapy.~Interventions - patient assigend RI groups are injected only RI~fill the Primay Case Report Form during surgery~PCRF including SLN detection time, duration of SLN approch time to 1st sentinel node dection time, incision length , depth, RI +/- ."
3012446|NCT02479711|Experimental|composite restoration|lower permanent molar with an approximal and /or occlusal carious lesion will be restored with Tetric EvoCeram Bulk Fill composite
3013089|NCT02475317|Experimental|LUM001 100mg|10 subjects will receive a dose of LUM001 (100 mg) once daily
3012409|NCT02479997|Active Comparator|Indocyanine green (ICG) +RI|"Dual sentinel node staining method using mixture of indocyanine green (ICG) and radioisotope (RI) in breast cancer patients who receive neoadjuvant chemotherapy.~Interventions - patient assigend RI groups are injected RI +ICG~prepare fluorescence camera when the surgery begin~surgeon uses the camera to decect fluorescence flow on SLN~fill the Primay Case Report Form during surgery~PCRF including SLN detection time, duration of SLN approch time to 1st sentinel node dection time, incision length , depth, RI +/- , ICG+/-"
3012410|NCT02479984|Experimental|Staging laparoscopy|"Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.~Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port."
3012411|NCT02479971|Active Comparator|Normal saline irrigation|An irrigation of the entire abdominal cavity with 500 ml normal saline will be performed.
3012412|NCT02479971|Experimental|Clindamycin-gentamicin irrigation|An irrigation of the entire abdominal cavity with 500 ml gentamicin and clyndamycin solution will be performed.
3012413|NCT02479958|Experimental|Control|
3012414|NCT02479958|Experimental|APDT 1|
3012415|NCT02479958|Experimental|APDT 2|
3012416|NCT02479932|Active Comparator|Extraperitoneal cesarean|
3012417|NCT02479932|Active Comparator|Transperitoneal cesarean|
3012418|NCT02479919|Experimental|TBS-MPC|Intervention with Magstim® Active TBS aiming Medial Prefrontal Cortex in 18 patients with schizophrenia
3012419|NCT02479919|Active Comparator|TBS-CPDLF|Intervention with Magstim® Active TBS aiming Dorsolateral Prefrontal Cortex in 18 patients with schizophrenia
3012420|NCT02479919|Sham Comparator|TBS-Sham|Intervention with Magstim® Sham TBS in 25 patients with schizophrenia
3012421|NCT02479906|Sham Comparator|Sham Treatment|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
3012422|NCT02479906|Experimental|Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The HAC Coil is designed to stimulate neuronal pathways in the medial prefrontal cortex or motor cortex, including the anterior cingulated cortex.
3012423|NCT02479893||cold snare polypectomy|CSP: In this group polyps will be removed with the cold snare polypectomy technique, as a single piece. Additionally, a 1-2mm of normal tissue around the small polyp will also be ensnared in the CSP.
3012424|NCT02479893||hot snare polypectomy|HSP: In this group polyps will be removed with the hot snare polypectomy technique as a single piece with a electrosurgical snare and monopolar current with a setting of 30-35 W in the endocut function.
3012425|NCT02479893||APC polyp destruction-polypectomy|APC: In APC group polyps will be cauterized by application of high power argon plasma coagulation on small waves at 50-60W and flow at 2lt/min,as result the polyp destruction.
3012426|NCT02479880|Other|Tenofovir DF + increased bone/renal monitoring|Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans every 24 weeks from baseline to Week 96 (5 scans), and monitoring of renal function at 4 and 12 weeks after baseline and every 12 weeks thereafter. With the exception of an enhanced monitoring protocol for bone and renal outcomes, participants will be managed according to local standards of care.
3012427|NCT02479880|Other|Tenofovir DF + prespecified bone monitoring|Participants will receive tenofoir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans at baseline, Week 48, and Week 96. With the exception of pre-specified bone monitoring, participants will be managed according to local standards of care.
3012428|NCT02479867|Experimental|A Test|Test drug (Duricef) 1 tablet contains 1 gm Cefadroxil
3012429|NCT02479867|Experimental|B Reference|Reference drug (Biodroxil) 1 tablet contains 1 gm Cefadroxil
3012430|NCT02479854|Experimental|A Test|test drug (Asmakast)1 chewable tablet contains 5 mg Montelukast
3012431|NCT02479854|Active Comparator|B Reference|reference drug (Singulair) 1 chewable tablet contains 5 mg Montelukast
3012432|NCT02479841|Experimental|self management program|Participation in an 11 week self-management program
3012433|NCT02479841|No Intervention|Control group|
3012434|NCT02479828|Active Comparator|Fascia iliaca compartment block (FICB)|Under ultrasound guidance performing fascia iliaca compartment block, in which 40 ml ropivacaine 0,5% are injected under the fascia iliaca.
3012435|NCT02479828|Placebo Comparator|Placebo (not FICB)|Half of the patients will not receive FICB
3012436|NCT02479815|Other|1gm MNP, 15 sachets per month|Quasi experimental matched control cluster design where for every child 1gm Micronutrient Powder (MNP) for two days, is given which totlas to 15 sachets per month
3012437|NCT02479802|Experimental|Albumin|Plasma exchange with Albumin
3012438|NCT02479789|Experimental|Lidocaine|Subjects in the Lidocaine arm of the randomized trial will receive a bolus of 1 mg /Kg of IV lidocaine followed by 1.5 mg/KG/h of IV lidocaine infusion during the surgery which will be stopped at extubation.
3012439|NCT02479789|Placebo Comparator|Placebo|Subjects in the Placebo arm of the randomized trial will receive a bolus of 1mg/kg Placebo ( 0.9% saline) followed by 1.5 mg/KG/h Placebo ( 0.9% saline) infusion during the surgery which will be stopped at extubation.
3012440|NCT02479776|Active Comparator|Stem cell injection|Stem cells are injected and patients crossed over to placebo at 6 months
3012441|NCT02479776|Placebo Comparator|saline injection|saline is injected and patients crossed over to active arm at 6 months
3012442|NCT02479763|No Intervention|Conventional loss-of-resistance|
3012443|NCT02479763|Experimental|Waveform-confirmed loss-of-resistance|
3012444|NCT02479750|Experimental|ColdZyme|ColdZyme® mouth spray liquid. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
3012445|NCT02479750|Placebo Comparator|Placebo|Sugar based mouth spray liquid manufactured to mimic ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
3012447|NCT02479711|Active Comparator|glass ionomer cement|lower permanent molar with an approximal and /or occlusal carious lesion will be restored with the glass ionomer restoration, Equia
3012448|NCT02479698|Experimental|Cytotoxic T lymphocytes (CTLs)|"CTL product given as single infusion within 5 days of enrollment. CTL dose infused not greater than 2 x 10^5.~If a participant has a partial response, stable disease or progressive disease they will be eligible to receive seven (7) additional doses of CTL at a minimum of 2 weeks interval from the previous CTL infusion"
3012449|NCT02479685|Experimental|SORD-BILL|PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) for subtotal hysterectomy and uterine morcellation, respectivelly, during sacral colpopexy for Pelvic Organ Prolapse.
3012450|NCT02479685|Active Comparator|STANDARD|Conventional monopolar hook and conventional mechanic morcellator for subtotal hysterectomy and uterine morcellation, respectivelly, during sacral colpopexy for Pelvic Organ Prolapse.
3012451|NCT02479672|Active Comparator|VividTrac video laryngoscope|VividTrac® Videolaryngoscope, A device for endotracheal intubation
3012452|NCT02479672|Active Comparator|Direct laryngoscopy|Direct laryngoscopy, A device for endotracheal intubation
3012453|NCT02479659|No Intervention|Control|Facilities in this arm maintained status quo HIV testing and routine childhood immunization services
3012454|NCT02479659|Experimental|Simple Intervention|This included: 1) HIV testing commodity reinforcement and 2) a policy reinforcement meeting
3012455|NCT02479659|Experimental|Comprehensive Intervention|This arm included: 1) HIV testing commodity reinforcement, 2) a policy reinforcement meeting, 3) community sensitization, 4) Opt-out HIV testing for mothers and newborns, and 5) Operational support for service integration
3012456|NCT02479646|Experimental|Treatment A|MYL-1401H: single subcutaneous injection (2mg)
3012457|NCT02479646|Active Comparator|Treatment B|EU-Neulasta: single subcutaneous injection (2mg)
3012458|NCT02479646|Active Comparator|Treatment C|US-Neulasta: single subcutaneous injection (2mg)
3012459|NCT02479633|Other|gingival recession type 1|recession defects without CAL intervention:Coronally advanced flap with connective tissue graft
3012460|NCT02479633|Other|gingival recession type 2|gingival recession with an amount of CAL equal or smaller to the buccal CAL. Intervention: Coronally advanced flap with connective tissue graft
3012461|NCT02479620|Active Comparator|Dexamethasone Delivery|"Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe.~For Subjects randomized into the Dexamethasone Delivery arm, this protocol will utilize a 4 mg/mL preparation of Dexamethasone Sodium Phosphate Injection, USP. Each milliliter of the solution contains 4.37 mg of dexamethasone sodium phosphate equivalent to 4 mg of dexamethasone phosphate or 3.33 mg of dexamethasone. The total dose of Dexamethasone Sodium Phosphate Injection, USP will be diluted by 20% prior to infusion. This will result in a final concentration of 3.2 mg dexamethasone phosphate (3.5 mg dexamethasone sodium phosphate, or 2.67 mg dexamethasone) in each milliliter of solution."
3012462|NCT02479620|No Intervention|Control|"Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe.~Standard endovascular revascularization therapy consisting of atherectomy with or without angioplasty and with or without stent placement. No additional drug will be given to Subjects randomized to Control."
3012463|NCT02479607|Experimental|Intervention group|Use of an application for a smartphone or tablet for daily reporting symptoms and access to self-care advice and health care professionals in real time in combination with standard care according to the clinic´s routines
3012464|NCT02479607|No Intervention|Control group|Standard care according to the clinic's routines.
3012465|NCT02479594|Experimental|competence-feedback|Therapists assigned to this group will receive standardized feedback on their psychotherapeutic competency after every fourth treatment session with a patient for a period of 20 therapy sessions. The feedback will be given by two experienced raters who are licensed as psychological psychotherapists.
3012466|NCT02479594|Placebo Comparator|control|Therapists assigned to this group will receive no competence-feedback.
3012467|NCT02479581|Experimental|ERAS group|Perioperative management follows the Enhanced Recovery after Surgery（ERAS） program
3012468|NCT02479581|Experimental|Conventional control group|Perioperative management follows the conventional program
3012469|NCT02479568|Active Comparator|Control|Control drink (placebo)
3012470|NCT02479568|Experimental|Natural Florida orange juice|100% Florida orange juice (OJ) (natural content of hesperidin)
3012471|NCT02479568|Experimental|Enriched Florida orange juice|100% Florida orange juice (OJ) (enriched hesperidin content)
3012472|NCT02479555|Active Comparator|Treatment Group: Dexamethasone Delivery|"Up to 60 angioplasty procedures at up to 30 sites in Europe and in the United States.~Patients will be randomized 1:1 to receive either the active treatment or control therapy.~Treatment Group: Standard endovascular revascularization therapy consisting of angioplasty followed by Dexamethasondihydrogenphosphat-dinatrium (Ph.Eur.) 4 mg/mL Injektionslösung and with or without stent placement. The drug is diluted to 3.2 mg/mL and administered to the adventitia per Bullfrog Instructions for Use in a dose of 0.8 mg dexamethasone (0.25 mL) per cm of desired vessel treatment length, up to 30 cm."
3012473|NCT02479555|No Intervention|Control Group|"Up to 60 angioplasty procedures at up to 30 sites in Europe and in the United States.~Patients will be randomized 1:1 to receive either the active treatment or control therapy. Control Group: Standard endovascular revascularization therapy consisting of angioplasty with or without stent placement. No specific distribution of gender regarding enrollment or randomization is intended. There will also be a separate randomization of patients with Rutherford 6 score to a maximum of 20 enrolled patients."
3012474|NCT02479542|Active Comparator|Standard Gauze Dressing|Patients with wounds that meet eligibility criteria will be randomized, if randomized to the Standard Gauze Dressing Arm, a saline moistened sterile gauze will be packed into the wound with dry gauze and either tape or other means will be used to secure the dressing. The dressing will be changed daily and measured and photodocumented every 72 hours with the Wound Zoom system.
3012475|NCT02479542|Experimental|WiCare NPWT dressing|Patients with wounds that meet eligibility criteria will be randomized, if randomized to the WiCare NPWT Dressing Arm, a saline moistened sterile gauze will be packed into the wound and then the WiCare dressing and wound pump will be placed on the wound. The dressing will be changed, measured and photodocumented every 72 hours with the Wound Zoom system.
3044715|NCT02262585|Active Comparator|BIBR 277 capsule|
3012476|NCT02479529|Experimental|administration of norepinephrine by dynamic elastance|The norepinephrine weaning strategy is based on an index that reflects the vasomotor tone: dynamic arterial elastance
3012477|NCT02479529|Other|control administration of norepinephrine|The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
3012478|NCT02479516|Experimental|CHAPP intervention communities|"CHAPP intervention: The proposed CHAPP intervention will include:~Diabetes risk assessment (modified FINRISK and assessment of lifestyle risk behaviours) sessions be at least every 2 weeks in accessible community locations, manned by trained volunteers of LLO~Volunteers educate CHAPP participants regarding their diabetes risk factors and ways to practice healthy lifestyle (including referral to local resources/activities) using diabetes education materials adapted for local context~Use of an accepted process have participant data transmitted to a central web database system through a combination of cell-phone and computer-based technology~Have participant assessment result forwarded to the Municipal Health Officer (doctor) for follow-up and screening"
3012479|NCT02479516|No Intervention|Delayed Intervention communities|
3012480|NCT02479503||French Adult Heart Transplantation Center|All center performing adult heart transplantation in France in 2015.
3012481|NCT02479490|Experimental|Prednisone + Everolimus|Prednisone + Everolimus
3012482|NCT02479477|Experimental|Change to sf-36 after intervention|"The intervention is one protocol of labour kinesiotherapy that will be realized tree times per week, eatch intervention with fiveteen minutes, during eitgh weeks.~To change to sf-36 questionary after intervention. the intervention is the use of labour kinesio terapy in the auxiliary nursing The chance is in the score of questionary, we hope that after intervention the score will increase."
3012483|NCT02479464|No Intervention|Part 1|This is the treatment as usual arm to monitor the current standard clinical practice
3012484|NCT02479464|Other|Part 2|This group will be provided with genotyping results after baseline visit to guide clinical medication management
3012485|NCT02479451|Experimental|Nasal theophylline|20 μg intranasal theophylline (theophylline methylpropyl paraben in a 0.4-mL saline solution) once daily (in the morning) into each naris for a total of 6 weeks
3012486|NCT02479438||Diagnosed with GERD|Collect data on GERD patients
3012487|NCT02479425|Active Comparator|3 point turning|patients nursed by the traditional re-positioning (two hours on back, two hours on right and two hours on left).
3012488|NCT02479425|Experimental|2 points turning|patients nursed on the right and left side sonly in 30ْ avoiding the back
3012489|NCT02479412|Experimental|Sequence 1|Placebo once daily for 14 days in Period 1, 58 µg AZD7594 once daily for 14 days in Period 2 and 250 µg AZD7594 once daily for 14 days in Period 3
3012490|NCT02479412|Experimental|Sequence 2|Placebo once daily for 14 days in Period 1, 250 µg AZD7594 once daily for 14 days in Period 2 and 800 µg AZD7594 once daily for 14 days in Period 3
3012491|NCT02479412|Experimental|Sequence 3|Placebo once daily for 14 days in Period 1, 800 µg AZD7594 once daily for 14 days in Period 2 and 58 µg AZD7594 once daily for 14 days in Period 3
3012492|NCT02479412|Experimental|Sequence 4|58 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 800 µg AZD7594 once daily for 14 days in Period 3
3012493|NCT02479412|Experimental|Sequence 6|250 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 58 µg AZD7594 once daily for 14 days in Period 3
3012494|NCT02479412|Experimental|Sequence 8|800 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 250 µg AZD7594 once daily for 14 days in Period 3
3012495|NCT02479412|Experimental|Sequence 5|58 µg AZD7594 once daily for 14 days in Period 1, 800 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
3012496|NCT02479412|Experimental|Sequence 7|250 µg AZD7594 once daily for 14 days in Period 1, 58 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
3012497|NCT02479412|Experimental|Sequence 9|800 µg AZD7594 once daily for 14 days in Period 1, 250 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
3012498|NCT02479399||Suglat group|Tablets
3012499|NCT02479386|Other|Cohort Geographic Atrophy|Cohort of participants with GA secondary to AMD will be evaluated for changes in GA over time.
3012500|NCT02479373|Experimental|Resistance Exercise (RE)|Those assigned to RE will complete baseline and post-testing assessments and participate in 12 weeks of individually-supervised resistance exercise, which will take place in the exercise facility on the Johns Hopkins Bayview Medical Center Campus. Exercises will be performed on Ren-Ex Machines. This equipment is suitable for the proposed study because it provides ultra-low friction movement which creates a personalized resistance profile, which minimizes force on joints and thereby reduces the risk of joint trauma and injury.
3012501|NCT02479373|Other|Control Group (CG)|Those assigned to the CG will complete baseline and post-testing assessments and will also be given JIA educational materials, including physical activity and exercise recommendations from the American Academy of Pediatrics (AAP) Council on Sports Medicine and Fitness (COSMF).
3012502|NCT02479360||Outcome measurement|Each participant will be asked to complete each standardised outcome measure (SOM) three times and each trial will be videotaped by the researcher. The selected SOM's are the 10 metre walk test, the timed up and go test, the functional reach test and the nine-hole peg test. A physiotherapist will watch the video on 2 separate occasions to evaluate intra-rater reliability. Inter-rater reliability will be assessed through asking three other neurofibromatosis specialist professionals (two NF1 consultants and one NF1 specialist nurse) to review the video and to score each measure completed. Once the filmed sessions have been analysed by the relevant clinician's the data will be destroyed in line with Trust policy.
3012503|NCT02479347|Experimental|Chloraprep|Preoperative skin preparation with chlorhexidine 2% in alcohol 70% solution
3012504|NCT02479347|Active Comparator|Povidone-iodine|Preoperative skin preparation with povidone-iodine 10% solution
3012505|NCT02479334|Placebo Comparator|Fat challenge breakfast|200 ml control drink (non-energy flavored water) and high fat breakfast (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
3012506|NCT02479334|Experimental|Fat challenge breakfast+spices|200 ml spices drink (non-energy flavored water + spices extract) and high fat breakfast (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
3012507|NCT02479334|Placebo Comparator|Carbohydrate challenge breakfast|200 ml control drink (non-energy flavored water) and high carbohydrate breakfast (% Energy Carbohydrate:Fat:Prot / 60:20:20), acute study / one time administration
3012508|NCT02479334|Experimental|Carbohydrate challenge breakfast+spices|200 ml spices drink (non-energy flavored water + spices extract) and high carbohydrate breakfast (% Energy Carbohydrate:Fat:Prot / 60:20:20), acute study / one time administration
3012509|NCT02479321|No Intervention|Control group|Hemodynamic optimization according to the standards of perioperative monitoring of our center. In the intraoperative and immediate postoperative period hemodynamic monitoring will be done by controlling blood pressure, heart rate, oxygen saturation and diuresis.
3012510|NCT02479321|Experimental|PGDT noninvasive monitoring group|PGDT based on noninvasive monitoring System ClearSight® and Platform EV Clinic 1000®
3012511|NCT02479308|Active Comparator|Moxifloxacin|Oral tablet
3012512|NCT02479308|Experimental|ALKS 5461|Sublingual tablet
3012513|NCT02479308|Placebo Comparator|Placebo|
3012514|NCT02479295|Active Comparator|Straight Tenckhoff catheter|Tenckhoff catheter with straight intra-abdominal part
3012515|NCT02479295|Active Comparator|Coiled Tenckhoff catheter|Tenckhoff catheter with coiled intra-abdominal part
3012516|NCT02479282|Other|group A|natural cesarean section
3012517|NCT02479282|Other|group B|traditional cesarean section
3012518|NCT02479269|Experimental|intervention|Aerobic exercise+ blood sampling
3012519|NCT02479269|No Intervention|control|Blood sampling
3012520|NCT02479256|Experimental|Clomiphene citrate + placebo|Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily), and one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
3012521|NCT02479256|Experimental|Tamoxifen + placebo|Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily), and one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
3012522|NCT02479243||Collateral Circulation|Symptomatic patients with unilateral MCA severe stenosis confirmed ≥ 90% by magnetic resonance angiography or 70-99% by conventional angiography were performed 3D pseudo-Continuous Arterial Spin Labeling MRI.
3012523|NCT02479230|Experimental|vaccine: gemcitabine hydrochloride|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning 3, 7, or 10 days later, patients receive tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine ID followed by a second vaccination 7 days later. Courses may repeat after at least 4 weeks in the absence of disease progression or unacceptable toxicity.
3012524|NCT02479217||Adjuvant therapy|Patients prescribed Xeloda per registered indicatilons were observed until disease progression or 8 cycles for adjuvant colon cancer
3012525|NCT02479217||Combination Therapy|Patients prescribed Xeloda with docetaxel for metastatic breast cancer after failure to anthacyclines were observed until disease progression
3012526|NCT02479217||Monotherapy|Patients prescribed Xeloda per registered indicatilons were observed until disease progression or 8 cycles for adjuvant colon cancer
3012527|NCT02479204|Experimental|Part A ACT-334441 + atenolol|4 subjects will receive 50 mg of atenolol once daily for 6 days, and a concomitant single administration of ACT-334441 2 mg on Day 6
3012528|NCT02479204|Experimental|Part A ACT-334441 + diltiazem|4 subjects will receive 240 mg of diltiazem once daily for 6 days, and a concomitant single administration of ACT-334441 2 mg on Day 6
3012529|NCT02479204|Experimental|Part B ACT-334441 + atenolol|12 subjects will receive 50 mg of atenolol (once daily) from day 1 to day 15, placebo once on day 6, and ACT-334441 4 mg (once daily) from day 8 to day 15
3012530|NCT02479204|Experimental|Part B ACT-334441 + diltiazem|12 subjects will receive 240 mg of diltiazem (once daily) from day 1 to day 15, placebo once on day 6, and ACT-334441 4 mg (once daily) from day 8 to day 15
3012531|NCT02479191||Female (Treatment Group)|Device: Ovation Abdominal Stent Graft Platform
3012532|NCT02479191||Male (Control Group)|Device: Ovation Abdominal Stent Graft Platform
3012533|NCT02479165|Active Comparator|Opioid group|"If randomized to the opiod group, the patient was given the following regimen for 1 week, upon return from the intensive care unit, after surgery.~Tbl. Oxycodone (slow-release) 10mg, Twice daily for 1 week Tbl. Paracetamol 1000mg, Four times daily for 1 week Tbl.oxycodone 5mg Max 4 times daily, as needed, until discharge. Inj, oxycodone 2.5 mg, Max 4 times daily, as needed, until discharge Tbl. Magnesia 1g, Twice daily, for 1 week Sol. Sodiumpicosulfate 7.5mg/ml 10 drops daily, for 1 week"
3012534|NCT02479165|Active Comparator|Ibuprofene group|"If randomized to the ibuprofen group, the patient was given the following regimen for 1 week, upon return from the intensive care unit, after surgery.~Tbl. Ibuprofen (slow-release) 800mg, Twice daily, for 1 week Tbl. Paracetamol 1000mg, Four times daily, for 1 week Tbl.oxycodone 5mg Max 4 times daily, as needed. Until discharge. Inj, oxycodone 2.5 mg Max 4 times daily, as needed. Until discharge. Tbl. Lanzoprazole 40 mg, Once daily, for 1 week Tbl. Magnesia 1g, Twice daily, for 1 week Sol. Sodiumpicosulfate 7.5mg/ml, 10 drops daily, for 1 week"
3012535|NCT02479152|Active Comparator|LUCAS 2 AD|LUCAS 2 AD will be used for CPR
3012536|NCT02479152|Other|LUCAS2|LUCAS2 will be used for CPR
3012537|NCT02479139|Placebo Comparator|Vehicle|Vehicle for botulinum toxin Type A topical liniment (ANT-1207) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
3012538|NCT02479139|Experimental|ANT-1207 Dose 1|Botulinum toxin Type A topical liniment (ANT-1207) Dose 1 (lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
3012539|NCT02479139|Experimental|ANT-1207 Dose 2|Botulinum toxin Type A topical liniment (ANT-1207) Dose 2 (second lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
3012540|NCT02479139|Experimental|ANT-1207 Dose 3|Botulinum toxin Type A topical liniment (ANT-1207) Dose 3 (mid-level dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
3012541|NCT02479139|Experimental|ANT-1207 Dose 4|Botulinum toxin Type A topical liniment (ANT-1207) Dose 4 (second highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
3012794|NCT02477319||Part A|"Cohort 1: Healthy Controls~Cohort 2: Partial CFTR function CF (class IV/V)~Cohort 3: Absent CFTR function CF (Class I/II)"
3012542|NCT02479139|Experimental|ANT-1207 Dose 5|Botulinum toxin Type A topical liniment (ANT-1207) Dose 5 (highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
3012543|NCT02479126||Interstitial Lung Disease|Patients will be identified from a specified 5 year period based on an International Classification of Diseases-9 (ICD-9) code diagnosis of Interstitial Lung disease (515) or Idiopathic Pulmonary Fibrosis (516.3). The patients will be obtained from the records of the Veterans Integrated Service Network (VISN) 6: VA Mid-Atlantic Health Care Network.
3012544|NCT02479113||Lean with normal glucose tolerance|"Pregnant women who are lean with normal glucose tolerance~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
3012545|NCT02479113||Obese with Normal glucose tolerance|"Pregnant women who are obese with normal glucose tolerance~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
3012546|NCT02479113||Gestational diabetes mellitus|"Pregnant women who have Gestational Diabetes Mellitus~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
3012547|NCT02479100|Other|Undergo a CESM|Patients will undergo an experimental Contrast Enhanced Spectral Mammogram (CESM) in addition to standard diagnostic procedures
3012548|NCT02479100|No Intervention|Follow Standard care|Patient will follow standard care pathway.
3012549|NCT02479087|Experimental|Plasma-derived FVIII/VWF concentrate|"The drug will be delivered through intravenous slow infusion/injection. The starting dosage can vary between the minimum dosage of 50 IU/Kg 3 times a week up to a maximum of 200 IU/kg per day.~This starting dosage will be decided by the Principal Investigator according to patient's condition and other variables.~The initial dosage can be then adjusted on the base of response."
3012550|NCT02479074|Active Comparator|Montelukast (high FeNO)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days Montelukast is a Class B medicine
3012551|NCT02479074|Active Comparator|Prednisolone, Montelukast (high FeNO)|Prednisolone 5 mg and montelukast 10 mg. Patients to take Prednisolone 5 mg, 4 tablets per day for 14 days patients to take Montelukast 10 mg film-coated tablet per day for another 14 days Prednisolone is a Class A medicine Montelukast is a Class B medicine
3012552|NCT02479074|Active Comparator|Montelukast|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days Montelukast is a Class B medicine
3012553|NCT02479048|Active Comparator|Test meal 1 (TM1)|High fat meal (HF) with ½ avocado (~68g)
3012554|NCT02479048|Active Comparator|Test meal 2 (TM2)|High fat meal (HF) with 1 avocado (~136g)
3012555|NCT02479048|Placebo Comparator|Control meal (CM)|High carbohydrate, high saturated fat control meal (CM) without avocado.
3012556|NCT02479035|Active Comparator|Red raspberry meal 1|~125 g fresh weight (1 cup equivalent)
3012557|NCT02479035|Active Comparator|Red raspberry meal 2|~250 g fresh weight (2 cup equivalent)
3012558|NCT02479035|Placebo Comparator|Control meal|0 g red raspberry
3012559|NCT02479022|Experimental|Level 1-7 escalating doses|
3012560|NCT02478996|Experimental|Internet-based exercise program|The intervention group is supervised by a sports scientist eight to twelve weeks before and after surgery. Patients receive an individually designed intensive exercise program based on the functional and Fitness measurements at first diagnosis.
3012561|NCT02478996|No Intervention|Basis therapy|Participants of the Treatment as usual (TAU) group receive written information material enlightening the importance of regular physical activities and general releases on preparation for esophagectomy.
3012562|NCT02478983|Experimental|LMA Supreme|1 arm will receive LMA supreme for airway management
3012563|NCT02478983|Active Comparator|LMA Proseal|1 arm will receive LMA Proseal for airway management
3012564|NCT02478970|Experimental|Corneal endotheliopathy|Patients with primary corneal endotheliopathies, such as posterior polymorphous dystrophy, congenital hereditary endothelial dystrophy, Fuchs' dystrophy, iridocorneal endothelial syndrome will be evaluated with the NIDEK CEM-350 and Konan SP4000
3012565|NCT02478970|Placebo Comparator|Normal|Patients without corneal endotheliopathies will be evaluated with the NIDEK CEM-350 and Konan SP4000
3012566|NCT02478957|Experimental|PA101|PA101, 40 mg administered via inhalation three times daily for 6 weeks
3012567|NCT02478957|Placebo Comparator|Placebo|Placebo, administered via inhalation three times daily for 6 weeks
3012568|NCT02478944|Experimental|Inflammatory bowel disease|Patients with Crohn's disease and ulcerative colitis undergoing manometry
3012569|NCT02478918|Experimental|Receiving reminder phone call|Will receive phone call to remind colonoscopy date and bowel prep
3012570|NCT02478918|No Intervention|Not receiving reminder phone call|Will not receive phone call to remind colonoscopy date and bowel prep
3012571|NCT02478905||surveillance cohort|Flocked mid-turbinate nasal swabs for influenza PCR will be collected from study participants daily
3012572|NCT02478879|Experimental|ZP-PTH Patch|Intradermal microneedle patch coated with 40 mcg of PTH, applied intracutaneously to the abdomen daily for 30 minutes, 14 days of treatment
3012573|NCT02478879|Active Comparator|FORTEO(R) Pen|Marketed FORTEO 20 mcg, administered daily as a subcutaneous injection to the abdomen or thigh for 14 days of treatment.
3012574|NCT02478866|Experimental|BPI-9016M|Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg, 600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
3012575|NCT02478840|Experimental|Lamazym|1 mg Lamazym/kg Body weight
3012576|NCT02478827|Experimental|Working Memory group|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. One experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games are adaptive. Participants randomized to this cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
3012606|NCT02478632|Experimental|DTG 50 mg + RPV 25 mg|Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2)
3012795|NCT02477319||Part B|CF patients who are homozygous for the F508del
3045774|NCT02255916|Experimental|Music|live sound-bed music intervention
3012577|NCT02478827|Experimental|Processing Speed group|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. One experimental group will complete the processing speed training, which involves three games: Line It Up, Sliding Search, and Bubble Math. These games are designed to engage processes involving thinking speed. Participants randomized to this cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks
3012578|NCT02478827|No Intervention|Control group|The control group will wait 10-weeks, during which they will receive treatment-as-usual (TAU), which might involve pharmacotherapy, psychotherapy, or both. After the 10-week waiting period, a post-assessment will be completed.
3012579|NCT02478814|Experimental|Active, Young Adult Males|Subjects will receive different levels of amino acid intakes varying from 0.2 to 2.6 g/kg/day.
3012580|NCT02478801|Experimental|Endurance trained|subjects will receive different levels of amino acids intakes varying from 0.2 to 2.8 g/kg/day.
3012581|NCT02478788|Experimental|LR-MAS - Low-risk ADHD adolescents|ADHD adolescents without any first or second degree-relatives with bipolar disorder. Low-risk ADHD adolescents (n=60) will receive treatment with open-label mixed amphetamine salts-extended release (MAS-XR), which is approved by the United States Food and Drug Administration (USFDA) for the treatment of ADHD and is a commonly prescribed psychostimulant medication for adolescents with ADHD.
3012582|NCT02478788|Experimental|HR-MAS - High-risk ADHD adolescents|"ADHD adolescents with a parent with bipolar disorder (high-risk). High-risk ADHD adolescents will be randomized to double-blind treatment with MAS-XR (n=60) or placebo (n=60). The subjects in this group will receive mixed amphetamine salts-extended release( MAS-XR), which is approved by the United States Food and Drug Administration (USFDA) for the treatment of ADHD and is a commonly prescribed psychostimulant medication for adolescents with ADHD."
3012583|NCT02478788|Placebo Comparator|HR-P - High-risk ADHD on Placebo|"ADHD adolescents with a parent with bipolar disorder (high-risk). High-risk ADHD adolescents will be randomized to double-blind treatment with MAS-XR (n=60) or placebo (n=60). Following initiation of treatment, the ADHD adolescents will have regularly scheduled visits during which symptom and tolerability ratings will be performed."
3012584|NCT02478788|No Intervention|HC (Healthy Controls)|Healthy subjects (n=60) will be recruited from the community and will not receive medication but will undergo MR scans at the same intervals to assess normal variability in imaging parameters between time points as well as to adjust and interpret comparisons within patients (i.e., whether patient values are changing toward or away from those of healthy adolescents). Neuroimaging evaluations will be performed at baseline and Week 12 (or termination).
3012585|NCT02478775|Experimental|Frequent Blood Sampling|Investigators will assess the change in inhibin B levels following repeated bolus dosing of recombinant FSH (rFHS) following Degarelix (GnRH antagonist) blockade over a 2-day period.
3012586|NCT02478762|Active Comparator|Normal glycemic control|GDM women in this group will reach glycemic objectives recommended by the Canadian Diabetes Association: fasting: 5.3 mmol/L and 2-hour after meals: 6.7 mmol/L.
3012587|NCT02478762|Experimental|Low glycemic control|GDM women in this group will reach lower glycemic objectives than those recommended by the Canadian Diabetes Association: fasting: 4.8 mmol/L and 2-hour after meals: 5.9 mmol/L.
3012588|NCT02478749|Experimental|Infant|patients aged younger than 1year
3012589|NCT02478749|Experimental|Child|patients aged 1year to 5years
3012590|NCT02478749|Experimental|Adult|adult patients
3012591|NCT02478736||delirium group|the patients with delirum after on-pump cardiac surgery
3012592|NCT02478736||no delirium group|the patients without delirum after on-pump cardiac surgery
3012593|NCT02478710|Placebo Comparator|Aerosolized Placebo|Placebo tobramycin 0.5 mL 0.9% normal saline q.12h. Placebo vancomycin 0.5 mL 0.9% normal saline q.8h.
3012594|NCT02478710|Experimental|Aerosolized Tobramycin or Vancomycin|Aerosolized tobramycin 300 mg diluted in 5 mL 0.9% normal saline q.12h. Aerosolized vancomycin 125 mg diluted in 5 mL 0.9% normal saline q.8h.
3012595|NCT02478697|Experimental|Tobacco Treatment|The tobacco treatment includes: (a) the ProChange ExpertSystem, a Transtheoretical-model (TTM) tailored, computer-assisted web-delivered program focused on increasing intrinsic motivation, (b) a stage-tailored treatment manual with goal setting for quitting tobacco, and (c) education on proper use of nicotine replacement therapy (NRT, patch plus gum or lozenge) with guidance on obtaining low-cost or free NRT through MediCal, private insurance plans, and community programs.
3012596|NCT02478697|No Intervention|Usual Care|"Usual care includes: completing the study assessments at baseline, 3- and 6-months and receiving referrals to tobacco treatment in the community, including the state quitline, in line with the public health Ask, Advise, Refer model of tobacco cessation intervention."
3012597|NCT02478684|Active Comparator|30 seconds of DCC|30 Seconds of placental blood transfusion
3012598|NCT02478684|Active Comparator|60 seconds DCC|60 Seconds of placental blood transfusion
3012599|NCT02478671|Experimental|TR Band|Each subject will have a Terumo TR Band applied to the wrist with MRI scans done at differing band pressure levels. The diameter of the radial artery will be measured at each level of band compression.
3012600|NCT02478658|Experimental|Intervention|"The acute intervention will consist of 1 session of training following the program:~Resistance Training Exercises. Each participant in the intervention group will perform resistance-training exercises in the form of a circuit. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Initial intensity 6-7 of RPE and ending the set at 9-10. Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round."
3012601|NCT02478658|No Intervention|Control|No intervention
3012602|NCT02478645|Experimental|ramosetron 0.3|
3012603|NCT02478645|Active Comparator|ramosetron 0.45|
3012604|NCT02478645|Active Comparator|ramosetron 0.6|
3012605|NCT02478632|Active Comparator|CAR|Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2).
3013090|NCT02475317|Experimental|LUM001 50mg|10 subjects will receive a dose of LUM001 (50 mg) once daily
3012607|NCT02478619|Active Comparator|IMT group|The volunteers will do the respiratory muscle training through a linear inspiratory pressure resistance device (POWERbreathe®) at 50% of the maximal inspiratory pressure.
3012608|NCT02478619|Placebo Comparator|Control group|Patients will do a placebo respiratory muscle training through a load pressure resistance device (POWERbreathe®) with the minimum load available (10cmH20).
3012609|NCT02478606|No Intervention|Control Group|Without intervention
3012610|NCT02478606|Experimental|Static Group|Will receive passive static stretching in hamstring muscle
3012611|NCT02478606|Experimental|PNF Group|Will receive passive proprioceptive neuromuscular facilitation stretching in hamstring muscle
3012612|NCT02478593|Experimental|Experimental group|Group to receive educational booklet regarding risk/benefits of Benzodiazepine.
3012613|NCT02478593|No Intervention|Control group|Group to receive educational booklet regarding risk/benefits of exercise.
3012614|NCT02478580|Experimental|Nuvigil|A single oral dose of Nuvigil at 150mg dose in preoperative area
3012615|NCT02478580|Placebo Comparator|Placebo|A single oral placebo will be given in preoperative area
3012616|NCT02478567|Experimental|Scapular Training|Initiated scapular training exercise for the first 4 weeks followed by addition of rotator cuff exercises the next four weeks
3012617|NCT02478567|Experimental|Rotator Cuff Training|initiated rotator cuff training exercise for the first 4 weeks followed by addition of scapular training exercises the next four weeks.
3012618|NCT02478554|No Intervention|Population-based|Participants will be randomly assigned to population-based fetal growth curves
3012619|NCT02478554|Active Comparator|Customized-based|Participants will be randomly assigned to customized-based fetal growth curves (intervention)
3012620|NCT02478541|Active Comparator|Sugar Study_low fructose|Consumption of a single test meal that contains fat and a sugary drink made with a low amount of fructose and high amount of glucose
3012621|NCT02478541|Active Comparator|Sugar Study_high fructose|Consumption of a single test meal that contains fat and a sugary drink made with a high amount of fructose and low amount of glucose
3012622|NCT02478528|Experimental|Experimental|
3012623|NCT02478515|Experimental|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
3012624|NCT02478502|Experimental|Cabazitaxel (single arm study)|Cabazitaxel 25 mg/m2 each 3. week (no other drugs will be administered)
3012625|NCT02478489|Experimental|Extended-release injectable naltrexone (XR-NTX)|Monthly XR-NTX (380 mg) Subjects randomized to XR-NTX will receive one intramuscular gluteal injection (in accordance with the FDA approved label/package insert) of 380 mg of NTX for extended-release injectable suspension at study entry (in the hospital) and 1, and 2 months later (outpatient in the primary care clinic), alternating buttocks.
3012626|NCT02478489|Active Comparator|Oral naltrexone (PO-NTX)|Daily PO-NTX (50 mg, up to 100 mg if heavy drinking continues) Subjects randomized to PO-NTX will receive a study prescription (first one in the hospital)(fillable only at the medical center research pharmacy and prepared by the research pharmacist) for a 1-month supply of oral NTX to be taken once daily- 25 mg a day for 3 days, then 50 mg a day. If the subject has a prior history of taking PO-NTX and tolerating it well, the participant may be started at 50 mg. The dose may be increased to 100 mg daily for any participant who continues to have heavy drinking.
3012627|NCT02478463|Experimental|Cabotegravir|Subject will receive CAB 30 mg tablet once daily oral dose for 28 days (4 weeks) followed by a washout period of 14 to 42 days. After the washout, subject will receive a single dose of CAB LA 600 mg IM to gluteal region.
3012628|NCT02478450|Experimental|Cohort 1|Unilateral lumbar surgical transplantation of Q-Cells dose level 1
3012629|NCT02478450|Experimental|Cohort 2|Unilateral cervical surgical transplantation of Q-Cells dose level 1
3012630|NCT02478450|Experimental|Cohort 3|Unilateral cervical surgical transplantation of Q-Cells dose level 2
3012631|NCT02478450|Experimental|Cohort 4|Unilateral cervical surgical transplantation of Q-Cells dose level 3
3012632|NCT02478450|Experimental|Cohort 5|Unilateral cervical surgical transplantation of Q-Cells dose level 4
3012633|NCT02478450|Experimental|Cohort 6|Unilateral cervical surgical transplantation of Q-Cells dose level 5
3012634|NCT02478437|Active Comparator|Group 1|Conventional radiofrequency ablation (RFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.
3012635|NCT02478437|Active Comparator|Group 2|Cooled radiofrequency ablation (CRFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.
3012636|NCT02478424|Experimental|Cannabidiol arm|Patients undergoing an allogeneic hematopoietic cell transplantation will be given standard GVHD prophylaxis comprising cyclosporine and a short course of methotrexate plus CBD 150 mg BID starting 7 days before transplantation until day 100.
3012637|NCT02478411|Experimental|Cycle ergometer physiotherapy|15 minutes of cycle ergometer physiotherapy plus 15 minutes of conventional physiotherapy, once daily, five days a week, as long as patients remain in the intensive care unit
3012638|NCT02478411|Active Comparator|Conventional physiotherapy|30 minutes of conventional physiotherapy, once daily, five days a week, as long as patients remain in the intensive care unit
3012639|NCT02478398|Experimental|MK-3641|Participants receive one MK-3641 sublingual tablet containing 12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U), once daily (QD) for up to 28 weeks. Participants may use study-provided rescue medication(s) as needed to treat rhinoconjunctivitis symptoms.
3012640|NCT02478398|Placebo Comparator|Placebo|Participants receive one placebo sublingual tablet, QD for up to 28 weeks. Participants may use study-provided rescue medication(s) as needed to treat rhinoconjunctivitis symptoms.
3012641|NCT02478385|Active Comparator|Birth environment labour room|Supportive care of labour room designed with special attention on sound and light effects, covering medical devices and insulation from outside noise
3012642|NCT02478385|Placebo Comparator|Labour in a standard labour room|The woman gives labour in a standard labour room
3012675|NCT02478138|Other|Surgical - therapeutic|patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system
3012676|NCT02478125|Active Comparator|burixafor hydrobromide|Four daily doses of burixafor hydrobromide alone
3045960|NCT02254785|Active Comparator|Abiraterone or enzalutamide|
3012643|NCT02478372|Active Comparator|Patient Controlled Epidural (PCEA)|A lumbar epidural was sited using a side-directed technique towards the side of surgery following establishment of the spinal blockade. Following the completion of the operation, patients received 4ml of 0.25% levobupivacaine prior to leaving the operating room. Thereafter they were connected to a PCEA pump (McKinley 545) with no background infusion. Patients could self-medicate with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes to control their pain until the following morning (post-operative day one) when it was stopped. Nurse-administered rescue top-ups of 4ml of 0.25% levobupivacaine were available for insufficient analgesia. The epidural catheter was removed on the morning of post-operative day two (POD2).
3012644|NCT02478372|Experimental|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine. 50ml injected following bone preparation prior to implant cementation perpendicular to the posterior femur through the posterior joint capsule in 10ml aliquots. 30ml proximal to the suprapatellar pouch down to the femur.100ml spread into subcutaneous tissues including; collateral and cruciate ligaments, fatty and connective tissue on the anterior aspect of the incision. A 16 gauge epidural catheter inserted via a medial portal, 20ml was injected via the catheter following closure of wound. Post-operatively, patients received boluses of 40ml ropivacaine 0.2% via the catheter using a mechanical McKinley 595 pump 4 hours after leaving theatre, at 22:00 and 08:00 on post-operative day one.
3012645|NCT02478359|No Intervention|Standard Care|Standard care patients will continue to receive their routine care from Kaiser Permanente Southern California and have access to all health services in accordance with their health plan
3012646|NCT02478359|Experimental|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention includes a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
3012647|NCT02478346|Experimental|All Patients|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 500mg (100mg/ml) will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used).
3012648|NCT02478333|Experimental|ALS-008176 (250 mg) or Placebo|Participants will receive ALS-008176, 250 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
3012649|NCT02478333|Experimental|ALS-008176 (500 mg) or Placebo|Participants will receive ALS-008176, 500 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
3012650|NCT02478333|Experimental|ALS-008176 (750 mg) or Placebo|Participants will receive ALS-008176, 750 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
3012651|NCT02478320|Experimental|Ilorasertib (ABT-348)|"Part 1 Dose of Ilorasertib: 200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.~Part 2 Expansion: Ilorasertib200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle."
3012652|NCT02478307|Active Comparator|Cognitive Therapy|Eight, 2-hours sessions of group delivered cognitive therapy.
3012653|NCT02478307|Active Comparator|Mindfulness Meditation|Eight, 2-hours sessions of group delivered mindfulness meditation.
3012654|NCT02478307|Active Comparator|Mindfulness-Based Cognitive Therapy|Eight, 2-hours sessions of group delivered mindfulness-based cognitive therapy
3012655|NCT02478294||the surgical intervention group|Thoracoscopic LAA Excision plus AF Ablation. Patients receiving thoracoscopic left atrial appendage excision plus atrial fibrillation alation
3012656|NCT02478294||oral anticoagulant treatment group|Warfarin or Novel Oral Anticoagulants. Patients receiving warfarin treatment (INR 2.0-3.0) or novel oral anticoagulants
3012657|NCT02478281|Experimental|Methylene Blue Injection, USP|Single dose of Methylene Blue Injection, USP at a dose of 1 mg/kg solution per kg given intravenously over a period of approximately 5 minutes.
3012658|NCT02478268|Active Comparator|Patients with idiopathic pulmonary fibrosis|
3012659|NCT02478268|Active Comparator|Healthy volunteers|
3012660|NCT02478255|Active Comparator|Patients scheduled to undergo Radiation Therapy (RT)|Patients scheduled to undergo Radiation Therapy (RT) for lung cancer, or other malignancies such as breast cancer or lymphoma that involve significant irradiation of the thoracic cavity.
3012661|NCT02478255|Active Comparator|Healthy volunteers|
3012662|NCT02478242|Active Comparator|Nafamostat mesilate group|Nafamostat mesilate was used for maintenance anticoagulation during continuous renal replacement therapy.
3012663|NCT02478242|Placebo Comparator|No anticoagulation group|Normal saline was used for maintenance anticoagulation during continuous renal replacement therapy.
3012664|NCT02478229|Experimental|SOF and LDV|Single arm: All participants will be started on Sofosbuvir (SOF) 400 mg and Ledipasvir (LDV) 90 mg as a fixed dose combination (FDC) tablet p.o. once daily with or without food starting at the time of liver transplantation (OLT), i.e. first doses given immediately prior to OLT, and continuing for 12 weeks.
3012665|NCT02478216|No Intervention|C group|Remote ischemic preconditioning will not be applied
3012666|NCT02478216|Experimental|R group|Remote ischemic preconditioning will be applied.
3012667|NCT02478203|Placebo Comparator|normal|intubation of a normal airway pediatric manikin with direct laryngoscopy, airtraq , glidescope
3012668|NCT02478203|Active Comparator|tongue edema|intubation of a tongue edema simulated pediatric manikin with diract laryngoscopy, glidescope and airtraq
3012669|NCT02478203|Active Comparator|face-to-face intubation|intubation of an entrapped pediatric manikin with diract laryngoscopy, glidescope and airtraq
3012670|NCT02478190|Experimental|Tight control|Patients in this arm will have a treatment glucose value at ED discharge of 350 mg/dL or lower.
3012671|NCT02478190|Experimental|Loose control|Patients in this arm will have a treatment glucose value at ED discharge of 600 mg/dL or lower.
3012672|NCT02478177||Stroke|Patients who had an acute ischemic stroke while taking one of the novel oral anticoagulants or patients who had an intracerebral hemorrhage while taking warfarin or one of the novel oral anticoagulants
3012673|NCT02478164|Experimental|Ponatinib|Drug will be administered once daily per cycle through oral ingestion.
3012674|NCT02478151|Experimental|OrganOx Metra|OrganOx Metra Device
3046170|NCT02253498|Sham Comparator|Sham Stimulation|placebo
3012677|NCT02478125|Active Comparator|G-CSF|G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
3012678|NCT02478125|Experimental|Docetaxel|"Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV.~The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2"
3012679|NCT02478112|Experimental|Biodegradable Balloon Implant|Biodegradable balloon implanted before radiotherapy
3012680|NCT02478099|Experimental|1 Treatment with MPDL3280A|Treatment with MPDL3280A
3012681|NCT02478086|Experimental|use amine acids parenteral 3.5g|"Amino acids parenteral (Levamin Nomo 10% ®) Group A with an initial doses of amino acids until reaching 3.5 g/kg/day during 28 days.For the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
3012682|NCT02478086|Experimental|use amine acids parenteral 4g|"Group B with an initial doses of 2.5 g/kg/day with daily increments of 0.5 g/kg/day until reaching 4 g/kg/day during 34 days.Weight, urea, creatinine and blood urea nitrogen (BUN) were measured weeklyFor the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
3012683|NCT02478060|Experimental|Cohort 1|Birch-SPIRE or placebo, 2 weeks apart
3012684|NCT02478060|Experimental|Cohort 2|Birch-SPIRE or placebo, 2 weeks apart
3012685|NCT02478060|Experimental|Cohort 3|Birch-SPIRE or placebo, 2 weeks apart
3012686|NCT02478060|Experimental|Cohort 4|Birch-SPIRE or placebo, 2 weeks apart
3012687|NCT02478060|Experimental|Cohort 5|Birch-SPIRE or placebo, 2 weeks apart
3012688|NCT02478047|Active Comparator|only antiemetic|The participants in the control group received standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology cClinical pPractice gGuideline. The 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are administered before the chemotherapy treatment.
3012689|NCT02478047|Experimental|Matching points ST36+CV12|
3012690|NCT02478047|Experimental|Matching points PC6+CV12|
3012691|NCT02478047|Experimental|Matching points CV3+CV12|
3012692|NCT02478034|Experimental|fludrocortisone|effects of fludrocortisone on cognition compared to placebo
3012693|NCT02478034|Placebo Comparator|Placebo|effects of fludrocortisone on cognition compared to placebo
3012694|NCT02478021|Experimental|Hydrocortisone|10 mg hydrocortisone
3012695|NCT02478021|Placebo Comparator|Placebo|1 pill Placebo
3012696|NCT02478008|Experimental|CardiAQ TMVI System (Transapical DS)|
3012697|NCT02477995|Experimental|DTaP Vaccine A|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
3012698|NCT02477995|Active Comparator|DTaP Vaccine B|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B (Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
3012699|NCT02477982||control group|BMI ≤ 25 kgm-2
3012700|NCT02477982||obese group|BMI ≥ 30 kgm-2
3012701|NCT02477969|Experimental|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
3012702|NCT02477969|Experimental|PEX168(200µg)|PEX168,200µg,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
3012703|NCT02477969|Placebo Comparator|Placebo|Placebo,0.5ml,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
3012704|NCT02477956|Experimental|vitamin D3|subjects taking the standard vitamin D protocol with added monthly high dose cholecalciferol of 100,000 IU cholecalciferol
3012705|NCT02477956|Active Comparator|Control|group of subjects taking the standard vitamin D
3012706|NCT02477943||Population Pool|The Population Pool will consist of contact and non-contact athletes recruited at each site participating in the study. The athlete's in this pool will be tested with the study device pre-season and post-season each. The BrainScope Battery consists of 3 components to collect brain electrical activity, a cognitive assessment and a balance/sway measurement.
3012707|NCT02477943||Injured/Control Pool|Injured/Control Pool consisting of athletes who are injured during the season and matched control athletes.The athlete's in this pool will be tested with the study device at time of injury and 3 follow-up time points. The BrainScope Battery consists of 3 components to collect brain electrical activity, a cognitive assessment and a balance/sway measurement. In addition, the injured and matched control athletes will receive advanced MRI neuroimaging.
3012708|NCT02477917|Experimental|Allergovac depot|Allergovac depot with Parietaria judaica pollen extract
3012709|NCT02477904|Experimental|ASD/KD|Children (2-21 years of age) diagnosed with autism spectrum disorder (ASD) will receive the ketogenic diet (KD) intervention.
3012710|NCT02477904|Active Comparator|ASD/non-KD|Children (2-21 years of age) diagnosed with autism spectrum disorder (ASD) will not receive the ketogenic diet (KD) intervention.
3012711|NCT02477904|Active Comparator|non-ASD/non-KD|Typically developing children (2-21 years of age) diagnosed as not having autism spectrum disorder (ASD) will not receive the ketogenic diet (KD) intervention.
3012787|NCT02477358|Experimental|Test|"Teeth are extracted, 2 mm of root removed, Platelet Rich Fibrin placed in socket, tooth replaced and splinted to adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.~Intervention- the PRF is added"
3012712|NCT02477878|Experimental|BPX-501 and AP1903|"All subjects will receive 3 cycles of BPX-501 T cell infusions at escalating dose levels (DL). DL1 on Day 0, DL2 on Days 30 and 60. The first dose of BPX-501 T cells will occur ≥30 days after hematopoietic stem cell transplant (HSCT).~Two doses of AP1903 ( 0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion."
3012713|NCT02477865|Experimental|PEX168(100µg)|PEX168(100µg),100µg,Subcutaneous injection,once a week,for 52 weeks.
3012714|NCT02477865|Experimental|PEX168(200µg)|PEX168(200µg),200µg,Subcutaneous injection,once a week,for 52 weeks.
3012715|NCT02477865|Placebo Comparator|Placebo|Placebo,0.5ml,Subcutaneous injection,once a week for 24 weeks,followed by PEX168(100µg or 200µg) qw sc for 28 weeks.
3012716|NCT02477852|Experimental|anti-tuberculosis treatment two weeks|anti-tuberculosis drugs All the patients in the groups receive anti-tuberculosis treatment with Isoniazid 0.3g po qd, Rifampicin 0.45g po qd, Ethambutol 0.75 g po qd,Pyrazinamide 0.5g po tid. for two weeks.
3012717|NCT02477852|Experimental|anti-tuberculosis treatment four weeks|anti-tuberculosis drugs All the patients in the groups receive anti-tuberculosis treatment with Isoniazid 0.3g po qd, Rifampicin 0.45g po qd, Ethambutol 0.75 g po qd,Pyrazinamide 0.5g po tid. for four weeks.
3012718|NCT02477839|Experimental|Lacosamide|Lacosamide syrup 8 mg/kg/day to 12 mg/kg/day
3012719|NCT02477839|Placebo Comparator|Placebo|Matching placebo syrup
3012720|NCT02477826|Experimental|Arm A: Nivolumab|Nivolumab intravenously (IV) as specified
3012721|NCT02477826|Experimental|Arm B: Nivolumab + Ipilimumab|Nivolumab + Ipilimumab IV as specified
3012722|NCT02477826|Experimental|Arm C: Nivolumab + Platinum doublet chemotherapy|Nivolumab + Platinum doublet chemotherapy (IV) dose as specified
3012723|NCT02477826|Active Comparator|Arm D: Platinum doublet chemotherapy|Chemotherapy administered on specified days of IV chemotherapy.
3012724|NCT02477813|Experimental|Temozolomide|oral Temozolomide 200 mg/m2/die for 5 consecutive days, every 28 days.Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
3012725|NCT02477800|Experimental|Low Dose|Monthly intravenous (IV) infusion
3012726|NCT02477800|Experimental|High Dose|Monthly intravenous (IV) infusion
3012727|NCT02477787|Experimental|treatment|patients will receive donor-derived NK cell infusion after haploidentical HCT
3012728|NCT02477787|No Intervention|control|patients will undergo haploidentical HCT but not receive donor-derived NK cells after HCT
3012729|NCT02477774|Experimental|Arista|Arista to ALT donor site
3012730|NCT02477774|No Intervention|Control|No Arista to ALT donor site
3012731|NCT02477761|No Intervention|Water preload|"During the Water preload study, each subject consume 500 ml of water 30 minutes before a 75 g glucose ingestion"
3012732|NCT02477761|Experimental|Nutrient preload|"During the Nutrient preload study, each subject consume a small mixed meal 30 minutes before a 75 g glucose ingestion. The meal is composed by 50 g of parmesan cheese, one small size boiled egg and 300 ml of water (250 kcal, 23 g protein, 17 g fat and 2 g of carbohydrate)."
3012733|NCT02477748|Active Comparator|MDX|Metadoxine Immediate-release/slow-release, bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.; alternative name: MG01CI.
3012734|NCT02477748|Placebo Comparator|Placebo|Inert tablets
3012735|NCT02477735||Study group|Infants with COME who will be referred for TTI will undergo actigraphy for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
3012736|NCT02477735||Healthy infants|Healthy infants that were recruited from the community well-baby clinics.
3012737|NCT02477722|Experimental|EFP-NF|Subjects are asked to change their brain activity in response to feedback they receive from the brain itself, mediated via various visual or auditory stimuli.
3012738|NCT02477722|Sham Comparator|Sham-NF|Placebo
3012739|NCT02477709|Experimental|Gefapixant|Gefapixant oral tablets (150 mg) administered as a single dose
3012740|NCT02477696|Experimental|acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity.
3012741|NCT02477696|Active Comparator|ibrutinib|Ibrutinib will be orally administered until disease progression or unacceptable toxicity.
3012742|NCT02477670|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
3012743|NCT02477670|Experimental|AVP-786|AVP-786 dose 2 capsules administered twice a day over a 12-week period
3012744|NCT02477644|Experimental|Olaparib|Tablets per os 300 mg
3012745|NCT02477644|Placebo Comparator|Placebo|Tablets per os 300 mg
3012746|NCT02477631|Experimental|Deferiprone|patient treated with study drug
3012747|NCT02477618|Active Comparator|SAGE-547|Intravenous
3012748|NCT02477618|Placebo Comparator|Placebo|Intravenous
3012749|NCT02477605|Experimental|27-gauge pak|CONSTELLATION® 27-gauge combined surgical pak used during vitrectomy surgery
3012750|NCT02477605|Active Comparator|23-gauge pak|CONSTELLATION® 23-gauge combined surgical pak used during vitrectomy surgery
3012751|NCT02477592|Experimental|Individualized substrate modification|Circumferential pulmonary vein isolation(CPVI) ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by Individualized substrate modification.
3012752|NCT02477592|Active Comparator|Stepwise ablation|CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
3012753|NCT02477579|Experimental|NovaCross|NovaCross microcatheter will be used.
3012754|NCT02477566|Experimental|Long-acting Triptorelin|Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal
3012755|NCT02477566|Active Comparator|Short-acting Triptorelin|Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2<40pg/ml in serum, was initiated during the luteal phase
3012756|NCT02477553|Experimental|Quantitative|"Subjects view:~A computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy and stool testing. Includes excerpts from a video from the American Cancer Society.~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting and dying from CRC, (b) the reduction in morbidity and mortality provided by colonoscopy and stool tests, (c) the sensitivity of colonoscopy and stool tests for finding cancer, (d) the false negative values of colonoscopy and stool tests for finding cancer, (e) the risk of heavy bleeding or colon injury from colonoscopy, and (f) the chance of having a positive stool test."
3012757|NCT02477553|Active Comparator|Verbal|"Subjects view:~A computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy and stool testing. Includes excerpts from a video from the American Cancer Society.~Computer-based presentation providing verbal information regarding (a) the lifetime average probability of getting and dying from CRC, (b) the reduction in morbidity and mortality provided by colonoscopy and stool tests, (c) the sensitivity of colonoscopy and stool tests for finding cancer, (d) the false negative values of colonoscopy and stool tests for finding cancer, (e) the risk of heavy bleeding or colon injury from colonoscopy, and (f) the chance of having a positive stool test."
3012758|NCT02477540|Experimental|2-time injection group : Cellgram-CLI|Within 30 days after extracting bone marrow, autologous bone marrow-derived mesenchymal stem cells is directly injected into the lesion. Then the second cell is injected within 30 days after the first cell injection.
3012759|NCT02477527|Experimental|Stribild|Patients to be changed from Atripla to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil and observed for changes in sleep patterns / sleep disturbances.
3012760|NCT02477514|Experimental|Experimental Arm|Day 1: participants will receive midazolam (2 mg); Day 3: participants will receive rosuvastatin (10 mg); Days 5-13: participants will receive tedizolid phosphate (200 mg); Day 14: participants will receive tedizolid phosphate (200 mg) plus midazolam (2 mg); Day 15: participants will receive tedizolid phosphate (200 mg); Day 16: participants will receive tedizolid phosphate (200 mg) plus rosuvastatin (10 mg); Day 17: participants will receive tedizolid phosphate (200 mg)
3012761|NCT02477501|Active Comparator|Ephedrine|A continuous Ephedrine infusion at 10 mcg/kg/min
3012762|NCT02477501|Active Comparator|Norepinephrine|A continuous Norepinephrine infusion at 0.1 mcg/kg/min
3012763|NCT02477488|Experimental|Allopurinol HS|Allopurinol at bedtime compared to AM administration
3012764|NCT02477475||NEXIUM|Oral dose 20mg/day
3012765|NCT02477462||Primary Biliary Cirrhosis|Subjects meeting internationally accepted criteria for the diagnosis of primary biliary cirrhosis
3012766|NCT02477462||Control|Subjects without evidence of primary biliary cirrhosis, liver disease, or inflammatory condition who are of similar age and sex distribution to the Primary Biliary Cirrhosis group
3012767|NCT02477449|Experimental|low dose group|8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS; All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
3012768|NCT02477449|Experimental|mid dose group|12 subjects in 0.5ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
3012769|NCT02477449|Experimental|high dose group|12 subjects in 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
3012770|NCT02477436|Experimental|Avanafil 50mg group|Avanafil 50mg tablet + Placebo 100mg tablet
3012771|NCT02477436|Experimental|Avanafil 100mg group|Avanafil 100mg tablet + Placebo 100mg tablet
3012772|NCT02477436|Experimental|Avanafil 200mg group|Avanafil 100mg 2 tablets
3012773|NCT02477436|Placebo Comparator|Placebo group|Placebo 100mg 2tablets
3012774|NCT02477423|Active Comparator|Randomized & Blinded - Receiving Antibiotics|The infants within this arm of the study meet the inclusion criteria as being low risk. They will be randomized to receive routine ampicillin and gentamicin for the initial 48 hours of their life as a routine rule-out sepsis. Stool samples will be collected throughout hospitalization and at 18 months of life.
3012775|NCT02477423|Placebo Comparator|Randomized & Blinded - Receiving Placebo|The infants within this arm of the study meet the inclusion criteria as being low risk. They will be randomized to receive placebo (saline) in place of ampicillin and gentamicin for the initial 48 hours of their life as a routine rule-out sepsis. Stool samples will be collected throughout hospitalization and at 18 months of life.
3012776|NCT02477423|Other|Routine, non-randomized care|The infants within this arm of the study were consented, but did not meet the inclusion criteria as being low risk after the time of birth. They will receive all care per the primary medical team. Stool samples will be collected throughout hospitalization and at 18 months of life.
3012777|NCT02477410|Experimental|Hydrolysed porcine protein from blood|Dietary intervention with hydrolysed porcine protein from blood
3012778|NCT02477410|Experimental|Hydrolysed porcine protein from muscle|Dietary intervention with hydrolysed porcine protein from muscle
3012779|NCT02477410|Experimental|Hydrolysed whey protein|Dietary intervention with hydrolysed whey protein
3012780|NCT02477397|Experimental|Spiromax Budesonide/formoterol|1. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.
3012781|NCT02477397|Active Comparator|Diskus Fluticasone/salmeterol|2. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
3012782|NCT02477384|Active Comparator|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
3012783|NCT02477384|Active Comparator|EVL plus propranolol|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
3012784|NCT02477371|Experimental|Fractional flow reserve-guided CABG|Patients are randomized to an FFR-guided CABG. FFR-measurements are made on coronary arteries with intermediate stenoses, that are planned for grafting. The FFR-values are blinded for both the operator, the patient and the heart team meeting. The graft plan form the heart team meeting are changed by the study investigator according to the FFR-measurements and randomization, so that coronary arteries with FFR ≤ 0,8 receive grafting and coronary arteries with FFR > 0,8 are deferred.
3012785|NCT02477371|Active Comparator|Angiography-guided CABG|Patients are randomized to an angiography-guided CABG. FFR-measurements are made on coronary arteries with intermediate stenoses, that are planned for grafting. The FFR-values are blinded for both the operator, the patient and the heart team meeting. The graft plan are based on the coronary angiography.
3012786|NCT02477358|No Intervention|Control|Teeth are extracted, 2 mm of root removed and teeth are replaced and splinted to adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
3012796|NCT02477306|Experimental|Study group|60 subjects will receive a single oral dose of idiazole 20mg DR tabs under fasting condition in one period. And the subjects will receive a single dose of PARIET 20 mg DR tabs under fasting condition in the second period. A 7 days washout interval is in between the 2 periods
3012797|NCT02477293|Experimental|Hyeonggaeyeongyo-tang|
3012798|NCT02477280|Experimental|Methylphenidate|Methylphenidate 20 mg Tablet single-dose per os
3012799|NCT02477280|Placebo Comparator|Placebo|Placebo 20 mg Tablet single-dose per os
3012800|NCT02477267|Experimental|Test-Reference Sequence|SL spray, followed by SL film
3012801|NCT02477267|Experimental|Reference-Test Sequence|SL film followed by SL spray
3012802|NCT02477254||SLE patients|SLE patients who received HPV vaccination
3012803|NCT02477254||Control subjects|Healthy subjects who received HPV vaccination
3012804|NCT02477241|Other|Healthy female subjects|Healthy female subjects with or without overactive bladder undergoing functional MRI brain and urodynamic study.
3012805|NCT02477228|Active Comparator|conventional ERCP|ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
3012806|NCT02477228|Active Comparator|Precut ERCP|ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
3012807|NCT02477215|Experimental|MLN9708, Bendamustine and Dexamethasone|"Ixazomib 4 mg, days 1, 8, 15.~Dexamethasone 40 mg oral weekly.~Bendamustine dose levels: 80mg/m2 days 1,2"
3012808|NCT02477202|Experimental|Mirena® IUD|This is a non-randomized study of the effect of Mirena® IUD use of at least 10 days before an RRSO or RRS on cell proliferation within the FTF and when available within ovarian CICs in women aged 35 through 50. The study will compare the results from 14 women using Mirena® with the results from 28 normally cycling women identified under MSK IRB Protocol #14-165 described above; all patients will be aged 35-50 years, and will have undergone the RRSO at MSK. To date we have identified approximately 100 suitable controls and are continuing to identify further suitable controls among women who have recently undergone RRSOs at MSK. The balancing/matching factors will be BRCA status (BRCA1/BRCA2/BRCA-ve), age (35-39/40-44/45-50), parity (nulliparous/parous), and BMI (<30/30+ kg/m^2). As each Mirena® patient completes the study and is deemed evaluable, she will be matched on each of these factors with 2 controls.
3012809|NCT02477189||Study Group|This was the group that received the penis implant, consented for participation and completed the follow-up questionnaire.
3012810|NCT02477176||Small annular defect group|Patients with lumbar defect less than 6mm wide after lumbar discectomy
3012811|NCT02477176||Large annular defect group|Patients with lumbar defect greater than 6mm wide after lumbar discectomy
3012812|NCT02477150|Active Comparator|SLE (vaccine)|Zostavax SC injection (0.65ml)
3012813|NCT02477150|Placebo Comparator|SLE (placebo)|Placebo SC injection (normal saline 0.65ml)
3012814|NCT02477137|Experimental|Intervention group|In combination with usual care according to the routines at the clinic, patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
3012815|NCT02477137|No Intervention|Control group|Usual care according to the routines at the clinic.
3012816|NCT02477124|Active Comparator|transvaginal digital colposcope (TVCD)|Each enrolled patient will undergo the standard of care for cervical cancer screening at her institution, and then the trans-vaginal colposcope will be used to collect digital images of the cervix.
3012817|NCT02477124|Active Comparator|standard of care screening|Each enrolled patient will undergo the standard of care for cervical cancer screening at her institution, and then the trans-vaginal colposcope will be used to collect digital images of the cervix.
3012818|NCT02477098|Experimental|Pre RSB|patients who receive preoperative rectus sheath block of ropivacaine hydrochloride and receive postoperative rectus sheath block of saline
3012819|NCT02477098|Experimental|Post RSB|patients who receive preoperative rectus sheath block of saline and receive postoperative rectus sheath block of Ropivacaine hydrochloride
3012820|NCT02477085||all women with an induced labor|prospective population-based cohort of all women who have an induced labor during one month in seven perinatal networks
3012821|NCT02477072|Active Comparator|Fixed heparin dose (general anesthesia)|Study subjects will be randomized to receive a fixed dose of 5000 units of heparin administered intravenously 2 minutes prior to vascular clamping and blood flow interruption. A subsequent dose of heparin will be administered if requested by the surgeon following a visual assessment of the anticoagulation in the surgical field. Anticoagulation will be monitored at different time points during surgery using ACT and TEG. Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial index and toe-brachial index.
3012822|NCT02477072|Experimental|Weight-adjusted doses of heparin|Study subjects will be randomized to receive 100 units of heparin per kilogram administered intravenously 2 minutes before vascular clamping and blood flow interruption. Subsequent doses of heparin will be administered to maintain the ACT between 300 and 350 seconds at all times during vascular clamping. Anticoagulation will be monitored at different time points during surgery using ACT and TEG. Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial index and toe-brachial index.
3012823|NCT02477072|Active Comparator|Fixed heparin dose (regional anesthesia)|For safety reasons, study subjects under regional anesthesia will automatically be assigned to this group and will receive a fixed dose of 5000 units of heparin administered intravenously 2 minutes prior to vascular clamping and blood flow interruption. A subsequent dose of heparin will be administered if requested by the surgeon following a visual assessment of the anticoagulation in the surgical field. Anticoagulation will be monitored at different time points during surgery using ACT and TEG.
3012824|NCT02477059|Experimental|tocilizumab|2 infusions four weeks apart
3012825|NCT02477059|Placebo Comparator|saline solution|2 infusions four weeks apart
3012826|NCT02477046|Experimental|tOPV + IPV|tOPV (6, 10, and 14 weeks) + IPV (14 weeks) Randomized to receive tOPV plus IPV boost
3012827|NCT02477046|Experimental|bOPV + IPV|bOPV (6, 10, and 14 weeks) + IPV (14 weeks) Randomized to receive bOPV plus 1 IPV boost
3012828|NCT02477046|Experimental|bOPV + 2 IPV|bOPV (6, 10, and 14 weeks) + IPV (14 and 18 weeks) Randomized to receive bOPV plus 2 IPV boost
3012829|NCT02477033|Active Comparator|Butyricicoccus pullicaecorum|Lyophilized Butyricicoccus pullicaecorum 25-3T bacteria, encapsulated with a pH-resistent coating.
3012830|NCT02477033|Placebo Comparator|Placebo (maltodextrin)|Lyophilized maltodextrin, encapsulated with a pH-resistent coating.
3012831|NCT02477020|Experimental|TAK-063 20 mg|TAK-063 20 mg, tablets, orally, once daily for up to 6 weeks. Dose may be titrated down to 10 mg/day, if intolerable.
3012832|NCT02477020|Placebo Comparator|Placebo|TAK-063 matching-placebo tablets, orally, once daily for up to 6 weeks.
3012833|NCT02477007|Experimental|Ibuprofen+placebo of paracetamol|Patients will receive in addition to morphine (usual care) ibuprofen and placebo of paracetamol
3012834|NCT02477007|Experimental|Paracetamol + placebo of ibuprofen|Patients will receive in addition to morphine (usual care) paracetamol and placebo of ibuprofen
3012835|NCT02477007|Experimental|Paracetamol + ibuprofen|Patients will receive in addition to morphine (usual care) paracetamol and ibuprofen
3012836|NCT02477007|Placebo Comparator|Placebo of paracetamol + placebo of ibuprofen|Patients will receive morphine alone(usual care).
3012837|NCT02476994|Experimental|Clinolipid (lipid injectable emulsion, USP) 20%|Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
3012838|NCT02476994|Active Comparator|Intralipid 20% (lipid injectable emulsion, USP)|Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
3012839|NCT02476981|Experimental|Remifentanil|Remifentanil is commonly used in monitored anesthesia care because of its rapid onset and short duration of action.
3012840|NCT02476981|Experimental|Dexmedetomidine|Dexmedetomidine is a highly selective α 2 adrenergic agonist and has both sedative and analgesic properties, and rarely causes respiratory depression.
3012841|NCT02476981|Other|midazolam|Midazolam is commonly used before induction for its anxiolytic effect.
3012842|NCT02476981|Other|propofol|Propofol is the most commonly used in sedative analgesia for its rapid onset and recovery time.
3012843|NCT02476981|Other|ephedrine|Adrenergic agonist to treat hypotension
3012844|NCT02476968|Other|Olaparib|Open Label Drug
3012845|NCT02476955|Experimental|ARQ 092 + carboplatin + paclitaxel|"Subjects will receive ARQ 092 orally at dose levels specified for their respective dose cohorts plus carboplatin (AUC6, intravenously, Day 1) plus paclitaxel (175 mg/m2, intravenously, Day 1) on a 21-day schedule.~The combination treatment will continue for a maximum of 6 x 21-day cycles followed by single agent therapy with ARQ 092 at the cohort dose level and administration schedule to which the subject was enrolled. Subjects will receive treatment with ARQ 092 until progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria is documented."
3012846|NCT02476955|Experimental|ARQ 092 + paclitaxel|ARQ 092 will be administered orally at 200 mg BID weekly of a 28-day cycle in combination with an IV infusion of paclitaxel (80 mg/m2). ARQ 092 will be administered once a week on Day 1, Day 8, Day 15, and Day 22 of each 28-day cycle; paclitaxel will be administered once a week on Day 1, Day 8, and Day 15 for three consecutive weeks followed by one week off of each 28-day cycle. The combination treatment will continue until progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria is documented.
3012847|NCT02476955|Experimental|ARQ 092 + anastrozole|ARQ 092 will be administered orally at 200 mg QD, 5 days on/9 days off of a 28 day cycle in combination with anastrozole which will be administered orally at 1 mg QD continuously. The combination treatment will continue until progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria is documented.
3012848|NCT02476942||Cohort A: Adults and Adolescents with FVIII Inhibitors|Adults and adolescents with hemophilia A of any severity with the presence of FVIII inhibitors will be observed.
3012849|NCT02476942||Cohort B: Children with FVIII Inhibitors|Children with hemophilia A of any severity with the presence of FVIII inhibitors will be observed.
3012850|NCT02476942||Cohort C: Adults and Adolescents without FVIII Inhibitors|Adults and adolescents with severe hemophilia A without the presence of FVIII inhibitors will be observed.
3012851|NCT02476929|Active Comparator|Nasal nitrous oxide|Mesurement of Nasal nitrous oxide in all groups: allergic rhinitis, non-allergic rhinitis, nasosinusal polyps and healthy group
3012852|NCT02476929|Active Comparator|Electronic nose|Measurement with the Electronic nose in all groups: allergic rhinitis, non-allergic rhinitis, nasosinusal polyps and healthy group.
3012853|NCT02476916|Experimental|AG-348 50 mg|Participants with PK deficiency received AG-348, 50 milligrams (mg), twice daily for the Core Period (Week 24). At the Week 24 visit, Core Period participants who had safely tolerated AG-348 and demonstrated clinical activity in response to AG-348 were potentially eligible to immediately roll over to the Extension Period for continued treatment. Participants were assigned to initial doses (50 or 300mg) and were treated across a range of doses due to treatment emergent AEs and Hb levels exceeding mid-point of sex-adjusted ranges.
3012854|NCT02476916|Experimental|AG-348 300 mg|Participants with PK deficiency received AG-348, 300 mg, twice daily for the Core Period (Week 24). At the Week 24 visit, Core Period participants who had safely tolerated AG-348 and demonstrated clinical activity in response to AG-348 were potentially eligible to immediately roll over to the Extension Period for continued treatment. Participants were assigned to initial doses (50 or 300mg) and were treated across a range of doses due to treatment emergent AEs and Hb levels exceeding mid-point of sex-adjusted ranges.
3012855|NCT02476890|Experimental|Placebo then gefapixant 100 mg/Healthy (Sequence A)|Healthy participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
3012856|NCT02476890|Experimental|Gefapixant 100 mg then placebo/Healthy (Sequence B)|Healthy participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
3012857|NCT02476890|Experimental|Placebo then gefapixant 100 mg/Chronic Cough (Sequence A)|Chronic Cough participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
3012858|NCT02476890|Experimental|Gefapixant 100 mg then placebo/Chronic Cough (Sequence B)|Chronic Cough participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
3012859|NCT02476877||Prescribed-drug treatment group|Eight hundred (800) subjects of which 200 subjects in each of the four mental illnesses will continue to receive prescription drug therapy (as prescribed by their physician/psychiatrist) and counseling to treat their mental illness.
3012860|NCT02476877||Naïve drug group|Two hundred (200) subjects of which about 50 subjects in each of the four mental illnesses will be initially drug naïve (i.e. currently not taking psychotropic drugs) at the beginning of the study and continue to be drug naïve until the end of the study (6 months) as they receive counseling for their mental illness.
3012861|NCT02476864|Experimental|Sequence AB|Subjects receive treatment A in Period 1 followed by treatment B in Period 2 with a washout phase of 10 to 14 days between the two treatment periods
3012862|NCT02476864|Experimental|Sequence BA|Subjects receive treatment B in Period 1 followed by treatment A in Period 2 with a washout phase of 10 to 14 days between the two treatment periods
3012863|NCT02476851|Experimental|Supernatant Hemoglobin|"Ensure that whole blood passed through the POLFA needle assembly (the investigational needle assembly or INA) has a supernatant hemoglobin within the acceptable range of < 100mg/dL. In instances where resulting supernatant hemoglobin levels are > 100 mg/dL for the INA, if supernatant hemoglobin levels are > 100 mg/dL for the Kawasumi needle assembly (the control needle assembly or CNA), then there would be justification for removing these data from analyses."
3012864|NCT02476838|Other|traumatic amputation of the hand|may be male or female patients between the ages of 18 and 60 who are missing all or part of one or both hands and forearms
3012865|NCT02476825|Active Comparator|Inhaled fluticasone|Inhaled fluticasone propionate (via dry powder inhaler [Accuhaler]), 500 micrograms b.i.d. for 4 weeks
3012866|NCT02476825|No Intervention|Observational|Observation
3012867|NCT02476812|Experimental|Positive Piggy Bank|"Patients randomized to this group will meet with a research assistant who provides an overview of the intervention, explains the rationale for this treatment, and then gives the patients the instructions, piggy bank, and currency slips. Participants in this group will receive instructions. At the end of the monitoring period, 30 days, they are to close their account by opening the piggy bank and reviewing all of the slips of paper.~Study personnel will contact patients within 72 hours to answer questions. Participants will also be contacted at 30 days to let patients know that they should read all of their currency slips in one sitting. They are also told that the intervention part of the study is over and are asked they complete the follow up questionnaires. Then, study personnel will call again to let the participant know that the second set of questionnaires will be arriving by mail."
3012868|NCT02476812|No Intervention|Waitlist Control|The control group will serve to show the relative benefits of the Positive Piggy Bank intervention. Those in the control group who meet study criteria will also receive regular care after their epidural steroid injection (e.g., physician visits, medication maintenance, standard patient education). These patients will follow the same questionnaire follow up procedures as listed above including phone calls. The phone call at 72 hours will be to simply thank them for their participation in the study. At the end of the study period, approximately three months, Wait List control patients will also be offered the Positive Piggy Bank intervention along with the supportive phone calls. Should they choose to try the Positive Piggy Bank intervention, they will be required to return to the center to pick up supplies and receive instruction. They will also complete study questionnaires by mail at 30 days to assess intra-individual change.
3012869|NCT02476799|Experimental|Rectus sheath block|Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
3012870|NCT02476799|Sham Comparator|Control|Patients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
3012871|NCT02476786|Experimental|Endocrine therapy alone|"Neoadjuvant endocrine therapy will be given at the discretion of the treating physician as directed by the package insert and could include the following: goserelin, anastrozole, letrozole, exemestane, fulvestrant, or tamoxifen~Frequency of office visits will be decided by the treating physician but must occur no less frequently than every 3 to 6 months for tumor assessment~After 6 months and after 12 months, patients will be assessed; patients who progress will have standard care recommended , and at any point a patient can opt to receive standard care even if she has not progressed on neoadjuvant endocrine therapy~Information on quality of life will be collected at baseline, Year 1, and Year 2 by the FACT-B questionnaire~Archival tissue will be collected and sent to Genomic Health for analysis using the Oncotype DX assay. The Recurrence Score predicts chemotherapy benefit and indicates the 10-year risk of recurrence (will not be used to determine treatment)"
3012872|NCT02476773|Experimental|Group 1|"5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
3012873|NCT02476773|Experimental|Group 2|"5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
3012874|NCT02476773|Experimental|Group 3|"5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel, with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
3012875|NCT02476773|Experimental|Group 4|"5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
3012997|NCT02475967|Experimental|Intervention group|The intervention group patients have access to the eLearning platform in addition to conventional cardiac care.
3012876|NCT02476773|Experimental|Group 5|"5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel, with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
3012877|NCT02476773|Experimental|Group 6|"5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
3012878|NCT02476760||Treated with incretins|Current use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) alone or in combination with other anti-diabetic drugs (if the prescription overlaps with the index or event day with a 30-day grace period).
3012879|NCT02476760||Treated with insulin|Any use of insulins between base cohort entry and the index or event day (alone or in combination with other antidiabetic drugs) and no current use of incretin-based drugs.
3012880|NCT02476760||Treated with ≥2 oral hypoglycemic agents|Current use of 2 or more non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alphaglucosidase inhibitors, meglitinides) (if the prescriptions overlap with the index or event day with a 30-day grace period), and no current use of incretin-based drugs or insulins.
3012881|NCT02476760||Treated with a single oral agent|Current use of any single non-insulin anti-diabetic medication (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescription overlaps with the index or event day with a 30-day grace period) and no current use of more than 2 OHAs, incretin-based drugs, or insulins from base cohort entry.
3012882|NCT02476760||Not currently exposed group|All patients not currently exposed to: incretin-based drugs, ≥2 OHAs, a single OHA and no use of insulins since base cohort entry.
3012883|NCT02476747|Experimental|Cold snare polypectomy|CSP will be performed by closing the snare loop after positioning the open snare at the point of lesion.
3012884|NCT02476747|Active Comparator|Endoscopic mucosal resection|EMR will be performed in the way of drawing the lesion into the loop of the snare and resecting followed by saline injection to the its margin.
3012885|NCT02476734|Experimental|subjects with DLBCL|4 subjects with DLBCL
3012886|NCT02476734|Experimental|subjects with FL|4 subjects with FL
3012887|NCT02476708|Experimental|Curcumin 1800mg|curcumin capsule 600mg taken 3 times per day for 8 weeks
3012888|NCT02476708|Placebo Comparator|Placebo|placebo capsule taken 3 times per day for 8 weeks
3012889|NCT02476695||S0/1|S0 = no fibrosis and S1 = portal fibrosis without septa
3012890|NCT02476695||S2|S2 = portal fibrosis with few septa
3012891|NCT02476695||S3|S3 = numerous septa without cirrhosis
3012892|NCT02476695||S4|S4 = liver cirrhosis (compensatory stage)
3012893|NCT02476682||Normal subjects|blood or stool samples will be collected from people referred for screening colonoscopy
3012894|NCT02476682||Colorectal cancer|blood or stool samples will be collected from people with colorectal cancer detected at colonoscopy or resection
3012895|NCT02476682||Polyps <10mm and no high risk features|blood or stool samples will be collected from people with no polyps or low risk polyps (<10mm, no villous component or dysplasia) detected at colonoscopy
3012896|NCT02476682||Advanced Mucosal Neoplasia|blood or stool samples will be collected from people with AMN detected at resection
3012897|NCT02476682||Sessile Serrated Adenoma|blood or stool samples will be collected from people with SSP detected at resection
3012898|NCT02476682||non-colorectal neoplastic disease|Participants with disease that is not colorectal neoplasia. Analysis of this cohort is not a primary endpoint but the investigators will report assay positivity in this group on an opportunistic basis. This cohort will include patients diagnosed with, for example, inflammatory bowel disease or extracolonic cancer.
3012899|NCT02476656||GPNC|CenteringPregnancy group prenatal care
3012900|NCT02476656||IPNC|Individual prenatal care
3012901|NCT02476643||Integrative Therapy|"This group receives and integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.~Patients are admitted to the hospital ward for 14 days."
3012902|NCT02476630||Study subjects|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as blood gases(ScvO2) from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
3012903|NCT02476617|Experimental|Ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV|Ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily [QD]) + dasabuvir (250 mg twice daily [BID]) + weight based Ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided BID)
3012904|NCT02476604|Experimental|Electronic Messaging|Subjects randomized to the intervention arm will receive health coaching and electronic messages at the rate of up to six times per week over an 8 week period.
3012905|NCT02476604|No Intervention|Control|Subjects randomized to the control arm will undergo all of the same measurements for baseline and follow up data but will not receive the intervention of health coaching and electronic messaging.
3012906|NCT02476591||Charge transparency|Providers with access to charge transparency as displayed via a dashboard with patient specific charge data for a given ICU stay
3012907|NCT02476591||Without charge transparency|Providers without access to patient specific charge data
3012908|NCT02476578|Experimental|Intervention Email|An email is sent, alerting the primary care providers about low values of BMI, HbA1c% or cholesterol and advising to consider appropriate dietary and medical revision.
3012909|NCT02476578|No Intervention|Control|No email is sent.
3012910|NCT02476565|Experimental|LMA-Supreme supraglottic device|The LMA-Supreme is a single-use disposable supraglottic airway that utilizes an inflatable cuff
3012911|NCT02476565|Active Comparator|I-gel supraglottic device|The I-gel is an alternative supraglottic device made from thermoplastic elastomer which provides the seal over the airway versus an inflatable cuff.
3012912|NCT02476552|Experimental|Niraparib Oral and IV|Single Oral dose of Niraparib capsules (unlabeled active pharmaceutical ingredient) orally and a 15-minute IV infusion of Niraparib (labeled active pharmaceutical ingredient)
3012913|NCT02476552|Experimental|Niraparib Oral|Single Oral dose of Niraparib capsules (labeled active pharmaceutical ingredient)
3012914|NCT02476539|Experimental|Hemay022|"Part one: Dose Escalation Group Hemay022 tablets will be taken orally once daily in doses of 50mg, 100mg, 200mg, 300mg,400mg or 500mg daily for 28 days.~Part two: Extension Group Hemay022 tablets will be taken in three dose groups that had been assessed by Part one for 28 days."
3012915|NCT02476526|Experimental|Low Volume Contrast|Subjects in this arm will receive a single intravenous injection of low volume iso-osmolar non-ionic radio contrast medium, prior to undergoing 64-MDCT scanning. The use of low volume radio contrast medium constitutes the intervention. Both experimental and control groups receive a) acetylcysteine inhalation (Mucomyst) 1200 mg po BID x 48 hours starting the day prior to the CT scan; and b) isotonic Sodium Bicarbonate Solution 3ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan
3012916|NCT02476526|Sham Comparator|Control|Subjects in this arm will undergo 64-MDCT scanning without Radio Contrast Medium (RCM). Both experimental and control groups receive a) acetylcysteine inhalation (Mucomyst) 1200 mg po BID x 48 hours starting the day prior to the CT scan; and b) isotonic Sodium Bicarbonate Solution 3ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan
3012917|NCT02476500|Active Comparator|Experts|Surgically experienced gynecologists with a personal history of at least 30 LLETZ procedures will undergo a Video Training and subsequently will perform LLETZ on a Training model. Their performance will be scored by using a 23-item OSATS scheme. The exact time Frame for the OSATS-assessment is within 1 hour after the Video Training.
3012918|NCT02476500|Experimental|Novices|Medical students with no previous experience in gynecological surgery will undergo a Video Training and subsequently will perform LLETZ on a Training model. Their performance will be scored by using a 23-item OSATS scheme. The exact time Frame for the OSATS-assessment is within 1 hour after the Video Training.
3012919|NCT02476487|Experimental|FDG PET CT|FDG PET CT
3012920|NCT02476474|Active Comparator|3 cm start of resection|The line of resection for the Laparoscopic Sleeve gastrectomy will start at 3 cm from pylorus (antrum).
3012921|NCT02476474|Active Comparator|6 cm start of resection|The line of resection for the Laparoscopic Sleeve gastrectomy will start at 6 cm from pylorus (antrum).
3012922|NCT02476461|Active Comparator|xiapex|1: xiapex: 0,58 mg clostridium histolyticum administered in the dupuytrens cord as discribed in producers manual
3012923|NCT02476461|Experimental|PNF|percutaneous needle fasciotomi is performed at affected cords
3012924|NCT02476448|Active Comparator|Normal Saline|Infused into the bladder to allow for visualization of bladder walls and urine jets.
3012925|NCT02476448|Experimental|Dextrose 10%|Infused into the bladder to allow for visualization of bladder walls and colored urine jets.
3012926|NCT02476448|Experimental|Phenazopyridine|Will be administered (PO) preoperatively and will be evaluated for its colorization properties during cystoscopy.
3012927|NCT02476448|Experimental|Sodium Fluorescein|Will be administered (IV) prior to the cystoscopy and will be evaluated for its colorization properties during cystoscopy.
3012928|NCT02476435|Active Comparator|Experimental = Active rTMS|Daily rTMS with Active coil 30 minutes of 1Hz rTMS, 5 days per week, for 3 weeks
3012929|NCT02476435|Placebo Comparator|Sham Comparator = Sham rTMS|Daily rTMS with Sham coil 30 minutes of 1Hz rTMS, 5 days per week, for 3 weeks
3012930|NCT02476422|Experimental|Dilcofenac potassium + placebo to Ibuprofen|Single dose of diclofenac potassium 50 mg soft gelatin capsule was given once patient developed moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to ibuprofen 400 mg tablet was also given to patient in order to maintain double dummy method.
3012931|NCT02476422|Active Comparator|Ibuprofen + placebo to diclofenac potassium|Single dose of ibuprofen 400 mg tablet was given once patient develops moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule was also given to patient in order to maintain double dummy method.
3012932|NCT02476409|Experimental|Tolvaptan|Augmentation of current dose of loop diuretic + 30 mg of oral tolvaptan daily
3012933|NCT02476409|Placebo Comparator|Placebo|Augmentation of current dose of loop diuretic
3012934|NCT02476396||patient-subject|Patients will be recruited from the population of patients scheduled to undergo carotid endarterectomy for established clinical indications. These indications include patients scheduled to have a carotid endarterectomy due to the presence of a high-grade atherosclerotic cervical internal carotid artery stenosis with or without clinical symptoms, following the ACAS or NASCET criteria (carotid artery stenosis of 60% or greater without clinical symptoms; stenosis 70% or greater with clinical symptoms).
3012935|NCT02476396||patient-control|The controls will be recruited by the patient-subjects. The investigators will ask their patient-subjects to speak to a spouse or family member to see if they are interested in participating. If they do have an interest they will contact the research team/study coordinator(s). In case, a spouse or a family member is accompanying the patient-subject, they will be recruited at the same time as the patient-subject.
3012936|NCT02476383|Active Comparator|augmented spinal manipulative therapy|Participants in this group will receive spinal manipulative therapy provided by a practitioner interacting in a warm and friendly way who is free to respond to participant conversation. Participants in this group will receive information about the effectiveness of spinal manipulative therapy for some individuals experiencing low back pain.
3012937|NCT02476383|Active Comparator|neutral spinal manipulative therapy|Participants in this group will receive spinal manipulative therapy provided by a practitioner engaging in minimal interaction. Participants in this group will not receive information about the effectiveness of spinal manipulative therapy for some individuals experiencing low back pain.
3012938|NCT02476370|No Intervention|Usual care|Does not receive a specific study intervention
3012939|NCT02476370|Experimental|preoperative relaxation program|preoperative relaxation program
3012940|NCT02476370|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
3012941|NCT02476370|Experimental|preoperative relaxation program+preoperative surgery education|preoperative relaxation program AND single education unit
3012942|NCT02476357|Active Comparator|Harmonic|Harmonic Scalpel (HS; Ethicon Endo-Surgery, Cincinnati, OH)
3012943|NCT02476357|Active Comparator|Control|Monopolar scalpel and ligature
3012944|NCT02476344|Experimental|research arm|40 subjects will undergo the experiment protocol, total 3 days, each consisting different training exercises.
3046532|NCT02251132|Experimental|TPV/RTV High 3|
3012945|NCT02476331|Experimental|Cognitive training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
3012946|NCT02476331|No Intervention|Control|The control group will wait 10-weeks, during which they will receive treatment-as-usual (TAU), which might involve pharmacotherapy, psychotherapy, or both. After the 10-week waiting period, participants will complete post-testing assessments.
3012947|NCT02476318|Experimental|ArterX Vascular Sealant|
3012948|NCT02476305|Experimental|cryoablation|patients undergo cryoablation procedure for desmoid tumor
3012949|NCT02476279|Experimental|Indomethacin alone|Indomethacin 100 mg rectally immediately after ERCP
3012950|NCT02476279|Active Comparator|Indomethacin+pancreatic stent|Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement
3012951|NCT02476266|No Intervention|Control|Participants randomized to this group will come in for testing at pre-intervention, post-intervention, three month wash out and six month wash out. Participants will be asked to continue their activities of daily living. To account for any physical activity changes over the length of the study the Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire will be administered to all individuals. A control group is necessary to compare to show normal disease progression over the length of the study as well as to demonstrate that improvements in outcome measures are due to the interventions and not practice effects.
3012952|NCT02476266|Active Comparator|Strength Training|Individuals randomized to this program will complete three sets of eight to ten repetitions at 70% of their predicted 1-RM for each of the exercises mentioned above. The speed of the movements in this program will be two to three seconds each for the concentric and eccentric components. When participants are able to complete ten repetitions in their third set for two consecutive days, weight will be increased for the following session by 5% of the current weight that they are at in accordance with Canadian Society for Exercise Physiology (CSEP) and American College of Sports Medicine (ACSM) guidelines. Participants will complete a total of 24 sessions over the course of 12 weeks, two times per week for an hour each session.
3012953|NCT02476266|Experimental|Power Training|Participants randomized to this program will complete three sets of 12 to 15 repetitions completed at 40% of predicted 1-RM for each exercises. The concentric part of the movement will be completed as fast as possible, whereas the eccentric component will be accomplished in two to three seconds. The load in this group is lower as it has been shown that by performing power training at lighter loads, the muscles are able to be activated, throughout the entire concentric component, while maintaining a consistent level of force. The progression will be determined through the same means as the conventional strength training group. Participants will complete a total of 24 sessions over 12 weeks, twice per week for an hour each session
3012954|NCT02476253|Experimental|Intervention|Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
3012955|NCT02476253|No Intervention|Control|No intervention
3012956|NCT02476240|Active Comparator|Internally Focused PD-SAFEx|While performing the exercises in PD-SAFEx™, participants will be instructed to focus their attention on sensory feedback. This will include focusing participants' attention on the stretch in their limbs while walking, on the straightness of their backs while sitting, on limb and body orientation in space while coordinating their movements, and on chest movements during breathing exercises. Throughout each exercise session, the instructor and volunteers will constantly provide attention-directing instructions.
3012957|NCT02476240|Experimental|Externally Focused PD-SAFEx|While performing the exercises from the PD-SAFEx™ program, participants will be instructed to focus their attention externally on the movement of coloured labels attached to their feet, knees, elbows and hands. Participants will be reminded and encouraged by the exercise instructor and volunteers to perform all exercises while focusing attention on the labels.
3012958|NCT02476240|No Intervention|Control Group|This group will be asked to refrain from changing activities of their daily lives throughout the 20-week duration of the experiment (from pre-assessment to washout).
3012959|NCT02476227|Experimental|Visitag group|Ablation using CARTO system. Visitag module: automated algorithm to collect RF ablation points using Visitag module. Criteria of ablation point: catheter stability range of motion ≤2.5mm, catheter stability time >15sec, contact force >5g over >50% of time. Optimal contact force suggested: 10-40g.
3012960|NCT02476227|Active Comparator|Control group|Ablation using CARTO system. Manual collection of RF ablation points by operator or by assistant. Optimal contact force suggested: 10-40g.
3012961|NCT02476214|Experimental|Intervention group|Group prenatal care- receiving prenatal care through a group
3012962|NCT02476214|No Intervention|Control group|Individual prenatal care - receiving regular individual prenatal care
3012963|NCT02476201|Experimental|MPP ON|To activate the Multipoint Pacing (MPP) feature to ON in all patients
3012964|NCT02476188|Experimental|Patients|Samples of blood at H0, H+6, H+24 and H+72
3012965|NCT02476188|Experimental|Patients control|Samples of blood at H0
3012966|NCT02476188|Active Comparator|Control (healthy person)|Samples of blood at H0
3012967|NCT02476175|Experimental|Add-on Mirabegron|Experimental: Add-on Mirabegron Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. They will keep the antimuscarinic and Mirabegron will be added (dual therapy).
3012968|NCT02476162||Group 1: Daily for 3 Months|Participants randomly assigned to this group will be instructed to measure their blood pressure (BP) every day during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
3012969|NCT02476162||Group 2: Daily for 1 Week/Month|Participants randomly assigned to this group will be instructed to measure their BP for seven consecutive days once each month during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
3012998|NCT02475967|Active Comparator|Control group|The control group patients receive conventional cardiac care alone.
3012970|NCT02476162||Group 3: 3 Consecutive Days Once/Month|Participants randomly assigned to this group will be instructed to measure their BP for seven consecutive days once each month during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
3012971|NCT02476136||Placebo group|Patients participating in one of the included randomized controlled trials, assigned to the placebo group
3012972|NCT02476136||Intervention group|Patients participating in one of the included randomized controlled trials, assigned to the investigational antidepressant (paroxetine, duloxetine or fluoxetine) or active comparator (venlafaxine) group.
3012973|NCT02476123|Experimental|Mogamulizumab+Nivolumab|"During parts 1 and 2, Mogamulizumab and Nivolumab are administered at appropriate intervals.~Part 1 (Dose Escalation Part) During Cohort 1 to 2, Mogamulizumab and Nivolumab are administered in combination.~Part 2 (Expansion Part) Patients will be treated with maximum tolerated dose established in the dose escalation part for each combination."
3012974|NCT02476097|Placebo Comparator|Sudden discontinuation|placebo for 7 days
3012975|NCT02476097|Active Comparator|Progressive discontinuation|Esomeprazole: Nexium® 20mg, Astra Zeneca , for 7 days
3012976|NCT02476084||Conventional synthetic DMARD naïve|"Naive RA patients commencing Methotrexate and Hydroxychloroquine.~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
3012977|NCT02476084||DMARD-IR: anti-TNF|"Conventional synthetic DMARD inadequate responders commencing Anti-TNF~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
3012978|NCT02476084||DMARD-IR: anti-IL6|"Conventional synthetic DMARD inadequate responders commencing anti-IL6~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
3012979|NCT02476084||DMARD-IR: anti-CTLA-4|"Conventional synthetic DMARD inadequate responders commencing anti-CTLA-4~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
3012980|NCT02476084||DMARD-IR: anti-CD20|"Conventional synthetic DMARD inadequate responders commencing anti-CD20~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
3012981|NCT02476071|Experimental|Mass Media and Stylish Events|Mass Media (radio messages/posters promoting HIV prevention) plus one annual Stylish Man Event (SMEvent), a multimedia/community mobilization event promoting VMC.
3012982|NCT02476071|Active Comparator|Control arm: mass media only|Mass media (radio messages and posters which promote VMC for HIV prevention). .
3012983|NCT02476058|Experimental|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
3012984|NCT02476058|Experimental|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
3012985|NCT02476058|Placebo Comparator|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
3012986|NCT02476045|Active Comparator|ARM A|"Induction phase with panitumumab as 1 hour intravenous infusion at the dosage of 6 mg/kg, given every two weeks, plus FOLFOX-4 chemotherapy as standard guidelines.~Maintenance therapy with 5-FU/LV (De Gramont regimen) plus panitumumab given at 6 mg/Kg every two weeks until progressive disease, unacceptable toxicity or informed consent withdrawal"
3012987|NCT02476045|Experimental|ARM B|"Induction phase with panitumumab as 1 hour intravenous infusion at the dosage of 6 mg/kg, given every two weeks, plus FOLFOX-4 chemotherapy as standard guidelines.~Maintenance therapy with panitumumab alone given at 6 mg/Kg every two weeks until progressive disease, unacceptable toxicity or informed consent withdrawal"
3012988|NCT02476032|Experimental|Prof applied oxalate|Subjects will be randomized to either receive the Prof applied oxalate Crest Sensi-Stop strip (Procter & Gamble™). The oxalate strip contains 3% dipotassium oxalate desensitizing gel. The placebo strip is blank. The strips will be placed by a licensed dental professional and will be in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
3012989|NCT02476032|Active Comparator|Self-applied oxalate|Participants randomized to the Active Comparator Group will have the following intervention: Intervention: self-applied oxalate (Crest Sensi-Stop strip Procter & Gamble™), which contains 3% dipotassium oxalate desensitizing gel. The strip will be placed by the participant, following the manufacturer's directions. The strip will be left in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
3012990|NCT02476032|Sham Comparator|Prof applied placebo|Subjects will be randomized to either receive the Prof applied placebo Crest Sensi-Stop strip (Procter & Gamble™). The oxalate strip contains 3% dipotassium oxalate desensitizing gel. The placebo strip is blank (sham). The strips will be placed by a licensed dental professional and will be in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
3012991|NCT02476019|Experimental|ISIS-FGFR4RX|ISIS-FGFR4RX administered subcutaneously
3012992|NCT02476019|Placebo Comparator|Placebo|Placebo administered subcutaneously
3012993|NCT02476006|Experimental|alirocumab|Periodic alirocumab subcutaneous injections, for up to 30 months
3012994|NCT02475993|Experimental|SMART app|SMART, a mobile phone-based self-monitoring service to enhance outpatient treatment in chronic illness will be tested for its utility to help reduce acute care utilization rates for patients given SMART following acute care visits at the Sickle Cell Day Hospital. SMART will enable symptom monitoring with a particular emphasis on pain measures, co-symptoms, and related interventions aided by provider daily monitoring and support guided by patient report via SMART to provide a Sickle Cell Disease Information interchange (SCDi) service. Instead of using their current routine of triaging phone messages daily, assessing patients' need for intervention, providers will instead monitor patients' entries via SMART daily.
3012995|NCT02475993|No Intervention|Standard of care control group|The control group will get standard of care, including a printed plan for medications to be taken, phone number to call for questions or issues, and the return date for visit
3012996|NCT02475980||Adolescent girls|Adolescent post-menarchal girls ages 13-18 with Medicaid insurance presenting to a pediatric emergency department for a non-emergent complaint who receive comprehensive contraception counseling
3046625|NCT02250508|Active Comparator|Haemate P®|
3012999|NCT02475954|Active Comparator|TH-CBT + Standard Care|Cognitive-behavioral therapy delivered via telehealth with a focus on decreasing depressive symptoms in Parkinson's Disease (PD).
3013000|NCT02475954|Other|Standard Care|VA standard care depression in Parkinson's Disease (PD)
3013001|NCT02475941|Experimental|Early Weight Bearing|Surgeon based prospective cohort supported in the literature to answer research questions in which surgeons have a preferred treatment type. Early weight bearing are those who are permitted in the post operative instructions to be Weight Bear as tolerated after fracture fixation.
3013002|NCT02475941|Active Comparator|Non Weight Bearing|Surgeon based prospective cohort supported in the literature to answer research questions in which surgeons have a preferred treatment type. Non weight bearing are those who are NOT permitted in the post operative instructions to be Weight Bear after fracture fixation.
3013003|NCT02475928|Placebo Comparator|100 mg placebo|100 mg Placebo plus nutritional education
3013004|NCT02475928|Experimental|100 mg zinc supplement|Nutritional education plus 100 mg of zinc gluconate
3013005|NCT02475915|Experimental|ART + VHM|"Group 1: Combination Antiretroviral Therapy prescribed at week 0 for a period of 10 weeks. Likely consisting of two NRTI such as tenofovir and emtricitabine and an NNRTI, such as efavirenz. For subjects on NNRTI therapy, a protease inhibitor, such as darunavir will be substituted for the NNRTI 2 weeks prior to treatment interruption.~Plus: 3 X 14-day cycles of vorinostat administered at weeks 0, 4 and 8; hydroxychloroquine and maraviroc prescribed at week 0 for a period of 10 weeks."
3013006|NCT02475915|Active Comparator|ART alone|Group 2: Combination Antiretroviral Therapy prescribed at week 0 for a period of 10 weeks. Likely consisting of two NRTI such as tenofovir and emtricitabine and either an NNRTI, such as efavirenz. For subjects on NNRTI therapy, a protease inhibitor, such as darunavir will be substituted for the NNRTI 2 weeks prior to treatment interruption.
3013007|NCT02475902|Experimental|Computer guided home exercise program|"A laptop computer & MS Kinect camera will be connected to a 40 TV to deliver guided fall prevention exercises. Research staff will train the participants in the use of the computerized program and be supervised performing the exercises during the instruction period. Then participants will be instructed to exercise 3 times per week for 4 weeks. Half of the participants will begin the study with the computerized version of the home exercise program while the other half begins with the paper booklet version of the home exercise program. After one month the arms will cross over."
3013008|NCT02475902|Active Comparator|Paper guided home exercise program|A paper booklet with pictures and written instructions, and an exercise log for the home exercise program will be given to half of the participants. Participants will be carefully instructed in performing the exercises correctly and then asked to perform the exercises 3 times per week for one month. Participants who began the study with the paper exercise program will switch to the computerized version of the exercise program for the second month.
3013009|NCT02475889||RFA group|patients who received hepatic RFA followed by primary tumor resection were assigned to the RFA group
3013010|NCT02475889||Non-RFA group|patients who received initial primary tumor resection without RFA
3013011|NCT02475876|Other|clindamycin|Each subject will be assigned to study drug (clindamycin or TMP-SMX) at the discretion of the treating clinician. The dose and dosing interval of study drug are dictated by this protocol (see interventions).
3013012|NCT02475876|Other|trimethoprim-sulfamethoxazole|Each subject will be assigned to study drug (clindamycin or TMP-SMX) at the discretion of the treating clinician. The dose and dosing interval of study drug are dictated by this protocol (see interventions).
3013013|NCT02475863|Experimental|Warfarin dosing aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin.
3013014|NCT02475863|Active Comparator|Standard practice|Dosing adjustments according to the normal unit protocol
3013015|NCT02475850|Other|Fall prevention standard of care|"An evidence-based patient-centered intervention that will combine elements of a multifactorial, risk factor-based, standardly-tailored fall prevention strategy developed at Yale, practice guidelines offered by the CDC's STEADI toolbox and the joint American Geriatrics Society/British Geriatrics Society guidelines, and ACOVE practice change approach"
3013016|NCT02475850|Other|Control|Usual fall prevention care
3013017|NCT02475837|Active Comparator|Vorapaxar intervention|"This arm will receive the study drug: Vorapaxar sulfate.~The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm)."
3013018|NCT02475837|Placebo Comparator|Placebo intervention|"This arm will receive the matching placebo.~The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm)."
3013019|NCT02475824|Experimental|MMD arm|Both midazolam® (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea) and meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea) are given intravenously at the initiation of sedation. In addition, a continuous IV infusion of dexmedetomidine (1ug/kg/h, Precedex; Hospira, Seoul, Republic of Korea) is administered 15 min before the ERCP till complete procedure
3013020|NCT02475824|Active Comparator|BPS arm|IV bolus dose of midazolam® (0.06mg/kg, 50% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea) and meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea). Repeated doses of 10-20 mg propofol® are titrated to achieve the target level of sedation. 0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
3013021|NCT02475785|Experimental|FFRD and mini plates group|"Upper will be bonded, levelled and aligned until reaching 0.019 x 0.025 ss archwires.~2 Y shaped mini plates will be inserted in the mandibular symphysis Insertion of the FFRD with Direct application over the mandibular mini plates"
3013022|NCT02475785|Active Comparator|conventional FFRD|"Upper and lower arches will be bonded, levelled and aligned until reaching 0.019 x 0.025 ss archwires.~Insertion of FFRD with application over the lower archwire"
3013023|NCT02475785|No Intervention|untreated control group|Patients will be observed for an average duration of 6-8 months
3013091|NCT02475304|Experimental|Experimental FP187|Treatment with a daily dose of 500mg FP187 (twice daily). Other names: Dimethyl fumarate
3046811|NCT02249286|No Intervention|No intervention|
3013024|NCT02475772|Experimental|Cisplatin and doxorubicin|Cisplatin and doxorubicin will be applied under pressure into the abdomen via laparoscopic trocars. The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
3013025|NCT02475759|Active Comparator|optimal caloric formula|received optimal caloric formula before surgical interference
3013026|NCT02475759|Active Comparator|sub-optimal caloric formula|received suboptimal caloric formula before surgical interference
3013027|NCT02475746|Experimental|PF-06372865 treatment arm|treatment arm includes two treatment periods, a single dose of PF-06372865 (period 1) followed by 8-days itraconazole with a single dose of PF-06372865 co-administered on Day 4
3013028|NCT02475733|Experimental|CAZ-AVI and metronidazole|CAZ-AVI to be administered every 8 hours as a 2 hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function) followed by metronidazole (no later than 30 minutes after CAZ-AVI infusion ) to be administered every 8 hours as 20 to 30 minutes infusion
3013029|NCT02475733|Active Comparator|Meropenem|administered every 8 hours infused over 15 to 30 minutes or up to 1 hour or infusion duration as per local guidelines.
3013030|NCT02475707|Experimental|Group A|Treatment with donor-derived multiTAA-specific T cells as adjuvant therapy following HSCT for ALL.
3013031|NCT02475707|Experimental|Group B|Treatment with donor-derived multiTAA-specific T cells for relapsed/residual disease following HSCT for ALL.
3013032|NCT02475681|Active Comparator|Obinutuzumab in Combination with Chlorambucil|Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles. Chlorambucil will be orally administered on Days 1 and 15 of Cycles 1 through 6.
3013033|NCT02475681|Experimental|Acalabrutinib in Combination with Obinutuzumab|Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles. ACP-196 will be orally administered starting on Cycle 1 Day 1. Daily administration of ACP-196 will continue until disease progression or unacceptable toxicity.
3013034|NCT02475681|Experimental|Acalabrutinib Monotherapy|Acalabrutinib will be orally administered on Cycle 1 Day 1 until disease progression or unacceptable toxicity.
3013035|NCT02475655|Experimental|Arm A: Ruxolitinib|Participants will receive ruxolitinib twice a day for 5 weeks. Participants must remain on ART regimen (not provided by the study) for the duration of the study.
3013036|NCT02475655|No Intervention|Arm B: No Study Treatment|Participants will not receive any study treatment. Participants should be encouraged to remain on ART regimen for the duration of the study.
3013037|NCT02475642|Active Comparator|PVI-ADT|discontinue antiarrhythmic drugs at 3 months post PVI
3013038|NCT02475642|Active Comparator|PVI+ADT|discontinue antiarrhythmic drugs at 12 months post PVI
3013039|NCT02475629|Experimental|Open-Label Ibalizumab plus OBR|2000 mg intravenous ibalizumab (loading dose) on Day 7 followed in 14 days (on Day 21) by 800 mg intravenous ibalizumab administered once every two weeks, plus an Optimized Background Regimen (OBR) beginning on Day 14.
3013040|NCT02475616|Experimental|PCO371|Single oral dose of PCO371
3013041|NCT02475616|Placebo Comparator|Placebo Comparator|Single oral dose of placebo
3013042|NCT02475603|Experimental|tourniquet|Total knee arthroplasty will be performed with tourniquet
3013043|NCT02475603|Experimental|non-tourniquet|Total knee arthroplasty will be performed without tourniquet
3013044|NCT02475590|Experimental|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
3013045|NCT02475590|Experimental|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
3013046|NCT02475577|Experimental|Control|Control: Peripherals with HealthInterlink technology will record and transmit data, without intervention. Subject is able to view graphed data, bring the HealthInterlink tablet/smartphone to the physician's office and share data with family/other caregiver.
3013047|NCT02475577|Experimental|Intervention 1|Intervention 1: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver.
3013048|NCT02475577|Experimental|Intervention 2|Intervention 2: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver, and a call will be placed by the nurse research assistant to study subject (on Blue alerts) or study subject's healthcare professional (on Red alerts). The physicians will have access to the subject's data on a web-based program.
3013049|NCT02475564|Placebo Comparator|placebo|Patients will take once a day a monophasic pill (ethinylestradiol + levonorgestrel) continuously for 42 days with 1 pill of placebo (starch)
3013050|NCT02475564|Experimental|resveratrol|Patients will take once a day a monophasic pill (ethinylestradiol + levonorgestrel) continuously for 42 days with 40mg of resveratrol
3013051|NCT02475551|Experimental|Treatment|IdeS as a single infusion
3013052|NCT02475538|Experimental|Electroacupuncture|"Subjects in this group will be treated with electroacupuncture along with a gradual tapering schedule.~Benzodiazepines will be tapered off over four weeks. The expected reduction rate of benzodiazepines should be 25% in the first two weeks and 12.5% in 3-4 days in week 3 and week 4. If the participants cannot tolerate the effects after tapering according to our suggested plan, the dose can be kept unchanged or they can reduce the dose at a slower pace.~Subjects will receive electroacupuncture 2 times per week for 4 consecutive weeks. Electroacupuncture involves acupuncture needling at traditionally used acupoints according to Chinese medicine theory."
3013081|NCT02475343|Experimental|Keratoconic patients|Patients with keratoconus.Keratoconic patients will receive treatment or measurement including:Schiotz tonometer measurement, UVA/riboflavin corneal crosslinking,Ocular morphology measurement,and routine ophthalmic examination.
3013082|NCT02475343|Experimental|Patients received keratoplasty|Patients received keratoplasty. Patients received keratoplasty will receive treatment or measurement including:Schiotz tonometer measurement,Keratoplasty, Ocular morphology measurement,and routine ophthalmic examination..
3013053|NCT02475538|Placebo Comparator|Placebo acupuncture|"Subjects in this group will be treated with placebo acupuncture along with a gradual tapering schedule.~Benzodiazepines will be tapered off over four weeks. The expected reduction rate of benzodiazepines should be 25% in the first two weeks and 12.5% in 3-4 days in week 3 and week 4. If the participants cannot tolerate the effects after tapering according to our suggested plan, the dose can be kept unchanged or they can reduce the dose at a slower pace.~The subjects will be receive placebo acupuncture 2 times per week for 4 consecutive weeks. Placebo acupuncture is a treatment that simulates the procedure of acupuncture treatment but may not have the effects of acupuncture."
3013054|NCT02475525|Experimental|Arginine enriched oral nutritional supplement group|Patients randomised to the oral nutritional supplement group will continue their normal diet. In addition, this group will commence taking oral nutritional supplement twice daily 5 days prior to surgery and continued for 4 weeks post surgery. Intake of nutritional drink will be suspended during their fasting period prior to surgery and will commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment. Patient adherence to the study protocol with the nutritional supplement regimen will be recorded daily by the patient for four the four weeks the supplement is provided.
3013055|NCT02475525|No Intervention|Control|This group will continue on their normal diet before and after surgery. Normal diet will be suspended during their fasting period prior to surgery and will re commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment.
3013056|NCT02475512|Experimental|Wash wipes|Washing with water and soap (standard care) will be replaced with two wash wipes during 30 days: (1) daily total body wash (using 3M Cavilon Bathing and Cleansing wipes) and (2) Continence Care (using 3M Cavilon Continence Care Wipes). No other preventive barrier or hydration products will be allowed in the genital-anal region.
3013057|NCT02475512|Placebo Comparator|Standard care|Washing will be done using water and pH neutral soap. No other preventive barrier or hydration products will be allowed in the genital-anal region.
3013058|NCT02475499||Treated with incretins|Ever-use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) between (and including) base cohort entry and the index day - 365 days.
3013059|NCT02475499||Treated with sulfonylureas|Ever-use of sulfonylureas between (and including) base cohort entry and the index day - 365 days, and never-use of incretin-based drugs.
3013060|NCT02475499||Treated with other antidiabetic agents|Ever-use of other antidiabetic agents (biguanides, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) between (and including) base cohort entry and the index day - 365 days, with never-use of incretin-based drugs and never use of sulfonylureas.
3013061|NCT02475486|Other|high fatigue|Measure of ANS by VistaO2 device in Rheumatoid arthritis (RA) patients with low disease activity according to DAS28 <3.2 with visual analog scale of fatigue is > 5
3013062|NCT02475486|Other|low fatigue|Measure of ANS by VistaO2 device in Rheumatoid arthritis (RA) patients with low disease activity according to DAS28 <3.2 with visual analog scale of fatigue is < or equal to 5
3013063|NCT02475473|Experimental|Intervention|"The acute intervention will consist of 1 session of training following the program:~Resistance Training Exercises. Each participant in the intervention group will perform resistance-training exercises in the form of a circuit. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Initial intensity 6-7 of RPE and ending the set at 9-10. Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round."
3013064|NCT02475473|No Intervention|Control|Control
3013065|NCT02475460|Experimental|HM 3 LIS|All patients implanted with the HM 3 LVAD via less invasive surgical technique
3013066|NCT02475447|Placebo Comparator|Placebo|Placebo-matched tablets twice daily for 4 weeks.
3013067|NCT02475447|Experimental|Asimadoline|Asimadoline tablets twice daily (5 mg total daily dose) for 8 weeks.
3013068|NCT02475434|Experimental|Cream Supplement group|Infants randomized to the cream supplement group will receive an exclusive HM-based diet with the addition of a HM-derived cream caloric supplement.
3013069|NCT02475434|No Intervention|Control Group|Infants randomized to the Control group will receive the standard regimen of an exclusive HM-based diet (no cream supplement).
3013070|NCT02475421|Experimental|Healthy, lean subjects|Healthy subjects with BMI < 27 kg/m^2
3013071|NCT02475421|Experimental|Healthy, obese subjects|Healthy subjects with BMI > 33 kg/m^2
3013072|NCT02475421|Experimental|Diabetic, lean subjects|Diabetic subjects with BMI < 27 kg/m^2
3013073|NCT02475421|Experimental|Diabetic, obese subjects|Diabetic subjects with BMI > 33 kg/m^2
3013074|NCT02475408|Experimental|Interventional Study Arm|In the presence of a significant right coronary artery stenosis, catheter-based occlusion of the right IMA distal to the take-off of the pericardio-phrenic branch is performed at baseline using a dedicated occlusion device (Amplatzer vascular plug).
3013075|NCT02475395|Experimental|Donor/Tester Subjects|Male subjects use the TRAK device to attain a measurement of sperm concentration from their semen specimen
3013076|NCT02475395|Experimental|Tester Only Subjects|Male or female subjects use the TRAK device to attain a measurement of sperm concentration from another donor's semen specimen.
3013077|NCT02475369|Other|Group 1|"pancrelipase: 3 (three) 20,880 USP units of lipase; 78,300 USP units of protease; 78,300 USP units of amylase tablets with meals and 2 (two) 20,880 USP units of lipase; 78,300 USP units of protease; 78,300 USP units of amylase tablets with snacks.~And Placebo"
3013078|NCT02475369|Other|Group 2|"pancrelipase: 3 (three) 20,880 USP units of lipase; 78,300 USP units of protease; 78,300 USP units of amylase tablets with meals and 2 (two) 20,880 USP units of lipase; 78,300 USP units of protease; 78,300 USP units of amylase tablets with snacks.~And placebo"
3013079|NCT02475356||Mirena|Mirena treatment group
3013080|NCT02475343|Experimental|Control|People without keratoconus, history of ocular surgery, and other diseases mentioned in exclusion criteria. Normal people will receive treatment or measurement including: Schiotz tonometer measurement, UVA/riboflavin corneal crosslinking, Keratoplasty, Ocular morphology measurement,and routine ophthalmic examination.
3013092|NCT02475304|Placebo Comparator|Placebo Comparator|Patients will receive the same number of tablets as patients randomized to FP187 arm in order to maintain the blind. The colour and shape of the FP187 and placebo tablets will be the same so that no visible difference is detectable
3013093|NCT02475291||Significant coronary lesions|Significant lesions with more than 70% diameter stenosis at proximal major coronary arteri(es).
3013094|NCT02475278|Experimental|NoV Vaccine|Norovirus GI.1/GII.4 bivalent Virus-Like Particle (VLP) vaccine (NoV Vaccine) (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminum hydroxide), intramuscular (IM) injection, once on Day 1.
3013095|NCT02475265|Experimental|estradiol 0.045mg/levonorgestrel 0.015mg|6 months of estradiol 0.045mg/levonorgestrel 0.015mg (once weekly patch).
3013096|NCT02475252|Active Comparator|Experts|Surgically experienced gynecologists with a personal history of at least 50 hysteroscopy procedures will perform a hysteroscopy on a training model.
3013097|NCT02475252|Experimental|Novices|Medical students will perform a hysteroscopy on a training model.
3013098|NCT02475239|Experimental|Postural restriction|The patients were instructed to avoid head movements, wear a soft collar during the daytime, wear a supporting pillow and sleep in the semi-upright position at a 45 degree head elevation from the horizontal plane during the nighttime for 48 hours.
3013099|NCT02475239|Active Comparator|Normal daily activity|The patients did not follow any postural restrictions and were asked to live as normally as possible.
3013100|NCT02475226||Patients with body and head trauma|type of the brain injury in patients with brain damage associated both general body and head trauma
3013101|NCT02475226||Patients with pure head trauma|type of the brain injury in patients with brain damage associated pure head trauma
3013102|NCT02475226||Patients with spontaneous hemorrhage|type of the brain injury in Patients with brain damage associated spontaneous hemorrhage
3013103|NCT02475213|Experimental|enoblituzumab plus pembrolizumab|Enoblituzumab: Fc-optimized, humanized monoclonal antibody. Pembrolizumab: Keytruda; human programmed death receptor-1 (PD-1)-blocking antibody approved by the US Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor, or with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.
3013104|NCT02475174|Experimental|Without upper limb elevation|Manual lymphatic drainage will be held with the voluntary supine without upper limb elevation.
3013105|NCT02475174|Experimental|Upper limb elevation to 30º|Manual lymphatic drainage will be held with the voluntary supine with the upper limb elevation to 30º.
3013106|NCT02475161|Experimental|JNJ-42847922 Plus Rabeprazole|Participants will receive JNJ-42847922, 20 milligram (mg) on Day 1 and Day 6. Participants will receive rabeprazole 20 mg once daily from Day 2 to Day 6.
3013107|NCT02475148|Experimental|Part 1: Cohort 1|Participants will receive either JNJ-54175446 0.5 milligram (mg) or placebo on Day 1.
3013108|NCT02475148|Experimental|Part 1: Cohort 2|Participants will receive either JNJ-54175446 2.5 mg or placebo on Day 1.
3013109|NCT02475148|Experimental|Part 1: Cohort 3|Participants will receive either JNJ-54175446 10 mg or placebo on Day 1.
3013110|NCT02475148|Experimental|Part 1: Cohort 4|Participants will receive either JNJ-54175446 30 mg or placebo on Day 1.
3013111|NCT02475148|Experimental|Part 1: Cohort 5|Participants will receive either JNJ-54175446 100 mg or placebo on Day 1.
3013112|NCT02475148|Experimental|Part 1: Cohort 6|Participants will receive either JNJ-54175446 200 mg or placebo on Day 1.
3013113|NCT02475148|Experimental|Part 2: Cohort 7|Participants will receive JNJ-54175446 on Day 1. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.
3013114|NCT02475148|Experimental|Part 3: Cohort 8|Participants will receive JNJ-54175446 on Day 1 along with high fat/high calorie breakfast. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.
3013115|NCT02475135|Experimental|Panel 1: Group 1|Subject will receive a single oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI)/emtricitabine (FTC) /tenofovir alafenamide (TAF) (D/C/F/TAF) under fed conditions (standardized regular breakfast, test Panel 1) on Day 1 of treatment period 1 and by FDC of elvitegravir (EVG)/cobicistat (COBI)/emtricitabine (FTC)/ tenofovir alafenamide (TAF) (E/C/F/TAF) under fed conditions (standardized regular breakfast, reference Panel 1) on Day 1 of treatment period 2.
3013116|NCT02475135|Experimental|Panel 1: Group 2|Subject will receive a single oral tablet of FDC containing E/C/F/TAF under fed conditions (standardized regular breakfast, reference Panel 1) on Day 1 of treatment period 1 and a single oral tablet of FDC containing D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 1) on Day 1 of treatment period 2.
3013117|NCT02475135|Experimental|Panel 2: Group 1|Subject will receive a single oral tablet of D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 2) on Day 1 of treatment period 1 and a single oral tablet of DRV, a tablet of emtricitabine/ tenofovir alafenamide (FTC/TAF) and a tablet of COBI under fed conditions (standardized regular breakfast, reference Panel 2) on Day 1 of treatment period 2.
3013118|NCT02475135|Experimental|Panel 2: Group 2|Subject will receive a single oral tablet of DRV, a tablet of FTC/TAF and a tablet of COBI under fed conditions (standardized regular breakfast, reference Panel 2) on Day 1 of treatment period 2 and a single oral tablet of D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 2) on Day 1 of treatment period 2.
3013119|NCT02475135|Experimental|Panel 3: Group 1|Subject will receive a single oral tablet of D/C/F/TAF under fasted conditions (test Panel 3) on Day 1 of treatment period 1 and a single oral tablet of D/C/F/TAF with a standardized high-fat breakfast (reference Panel 3) on Day 1 of treatment period 2.
3013120|NCT02475135|Experimental|Panel 3: Group 2|Subject will receive a single oral tablet of D/C/F/TAF with a standardized high-fat breakfast (reference Panel 3) on Day 1 of treatment period 1 followed by a single oral tablet of D/C/F/TAF under fasted conditions (test Panel 3) on Day 1 of treatment period 2.
3013121|NCT02475122|Other|open-label study|open-label study
3013122|NCT02475109|Experimental|PAN-90806 Ophthalmic Solution|PAN-90806 Ophthalmic Solution taken daily for 8 weeks.
3013192|NCT02474628|Experimental|Sodium bicarbonate|0.3 g∙kg-1body mass of sodium bicarbonate
3049787|NCT02228824|Active Comparator|Normal nicotine content cigarettes|
3013123|NCT02475096|Experimental|Internet-delivered CBT|Children and parents will receive 10 weekly modules of internet-delivered CBT (Cognitive Behavior Therapy). Parents will also receive 10 weekly specific modules for parents. Main components in the modules directed at children and parents are exposure for symptoms, feared stimuli and situations. The parents modules contain information on how they can support their children in the treatment and is based on social learning theory. Therapist support is provided through written messages within the secure platform. Therapists are trained CBT-psychologists.
3013124|NCT02475083|Experimental|Virtual Reality Group|Rehabilitation with virtual reality using games with balance training goal.
3013125|NCT02475083|Active Comparator|Conventional Group|Conventional physiotherapy with exercises for balance training.
3013126|NCT02475070|Active Comparator|Vildagliptin first|Treatment with vildagliptin 50mg twice daily for two weeks followed by four weeks washout and then treatment with dapagliflozin 10mg once daily for two weeks
3013127|NCT02475070|Active Comparator|Dapagliflozin first|Treatment with dapagliflozin 10 mg once daily for two weeks followed by four weeks washout and then treatment with vildagliptin 50 mg twice daily for two weeks
3013128|NCT02475057|Experimental|Degarelix (LHRH antagonist)|Degarelix (LHRH antagonist) EndoPAT2000
3013129|NCT02475057|Active Comparator|LHRH agonist|LHRH agonist at the discretion of the treating Urologist/Oncologist EndoPAT2000
3013130|NCT02475044|No Intervention|Treatment as usual (TAU)|Participants recive Psycho-education and neuro-psycological diagnosis.
3013131|NCT02475044|Experimental|Cognitive-Behavioral Therapy (CBT)|Participants recive 16 sessions of CBT in addition to arm TAU treatment.
3013132|NCT02475031|Placebo Comparator|Placebo Group (TAP-S)|(TAP-S) - the On-Q reservoir will be filled with saline and set to infuse at rate of 10 ml/hr through the TAP catheter
3013133|NCT02475031|Active Comparator|Active Group (TAP-C)|(TAP-C) - The On-Q reservoir will be filled with 0.2% ropivacaine and set to infuse at rate of 10 ml/hr through the TAP catheter
3013134|NCT02475018|Experimental|Milk fortified with plant sterol esters|250mL of Shuhua Milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
3013135|NCT02475018|Placebo Comparator|Plain milk|250mL of placebo milk(plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
3013136|NCT02475018|No Intervention|No dairy product consumption|Participants have not consumed any dairy product during the 60-days of study period.
3013137|NCT02475005|Experimental|Mobile self management app on smartphone|Mobile self management app on smartphone
3013138|NCT02475005|No Intervention|Treatment as usual|Treatment as usual (control group)
3013139|NCT02474992|Experimental|Intervention|This arm is eligible for participation in the Microclinic intervention, a social network-based educational program.
3013140|NCT02474992|No Intervention|Comparison|This arm is not eligible for participation in the intervention during the first twelve months of the study. Following collection of the primary study endpoints, this arm will also be invited to participate in a Microclinic group. Participants in this arm will still have access to standard HIV care at the facility of their choice. At time of recruitment into the study, prior to randomization, all eligible participants will be counseled on the importance of returning to their clinic for ongoing HIV care.
3013141|NCT02474979|Experimental|CBPM-system|CBPM-system (Continuous Bedside Pressure Mapping System): the bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure. The CBPM-system will be used in addition to standard pressure ulcer prevention (PU reducing mattress, floating heels, repositioning).
3013142|NCT02474979|Experimental|Control|Standard pressure ulcer prevention (PU reducing mattress, floating heels, repositioning).
3013143|NCT02474966|Experimental|Real-Sham dTMS|This arm will be treated before with real deep Transcranial Magnetic Stimulation (dTMS) (the first day) and after with sham dTMS (the second day)
3013144|NCT02474966|Experimental|Sham-Real dTMS|This arm will be treated before with sham deep Transcranial Magnetic Stimulation (dTMS) (the first day) and after with real dTMS (the second day)
3013145|NCT02474953|Experimental|Dosing Sequence 1|Proprietary Curcumin Formulation administered first, Unformulated Comparator Curcumin Product administered second
3013146|NCT02474953|Experimental|Dosing Sequence 2|Unformulated Comparator Curcumin Product administered first, Proprietary Curcumin Formulation administered second
3013147|NCT02474940|Experimental|Intervention #1|NF-HYP
3013148|NCT02474940|Experimental|Intervention #2|MM-HYP
3013149|NCT02474940|Experimental|Intervention #3|HYP-ONLY
3013150|NCT02474927|Experimental|Carfilzomib Treatment Arm|Carfilzomib will be administered at a dose of 20 mg/m2 on two consecutive days, each week for three weeks (Days 1 2, 8, 9, 15, and 16) to constitute one therapeutic cycle. Carfilzomib may be administered for 1-2 complete cycles in the study.
3013151|NCT02474914|Active Comparator|Octreotide|Enrolled patients will be randomized to either the octreotide (sandostatin ) or the placebo group. The randomization process will be done using closed envelop method and will be withdrawn by a nurse after pancreaticoduodenectomy . Patients in the octreotide group will receive sandostatin 100ug SC every 8 hours daily staring from the day of operation to the postoperative day 7. Patients in the placebo group will receive saline administered in a similar manner.
3013152|NCT02474914|Placebo Comparator|Placebo|pancreaticoduodenectomy without octreotide postoperative
3013153|NCT02474901|Active Comparator|QLAIV, HIV-infected|QLAIV administered to HIV-infected individuals 2 to 25 yoa
3013154|NCT02474901|Active Comparator|QLAIV, HIV-uninfected|QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
3013155|NCT02474888||Rituximab|a classical induction regimen with rituximab (decision taken before inclusion), implying an infusion of 375mg/m² per week, for 4 consecutive weeks (from week -3 until week 0) with blood specimen.
3013156|NCT02474875|Active Comparator|Educational program Control Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 4 first sessions: relaxation exercises 2 last sessions: talk about medical issues (drugs, nutrition, importance of sleep...)
3013193|NCT02474615|Experimental|TOOTH ENDODONTIC SURGERY - PBEA|Endodontic surgery 15 teeth - PBEA
3013194|NCT02474615|Experimental|TOOTH ENDODONTIC SURGERY -MTA|Endodontic surgery 15 teeth - MTA
3013157|NCT02474875|Experimental|Educational program High Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 6 sessions: 45 minutes of educational sessions about the neurophysiology of pain + 15 minutes of relaxation exercises
3013158|NCT02474875|Experimental|Educational program Diluted Low Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 6 sessions: 45 minutes of educational sessions about the neurophysiology of pain + 15 minutes of relaxation exercises
3013159|NCT02474875|Experimental|Educational program Concentrated Low Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 4 first sessions: relaxation exercises 2 last sessions: educational sessions about the neurophysiology of pain
3013160|NCT02474862|Experimental|Prenatal Walking Program|The Prenatal Walking Program (PWP) is a gentle walking intervention tailored for pregnant women. The PWP intervention consists of 3 components: 1) biweekly session with a study interventionist; 2) the use of activity monitors to increase motivation and self-monitoring; 3) incentives to promote intervention adherence.
3013161|NCT02474862|Active Comparator|Postpartum Prep Program|In the Postpartum Prep Program control condition (PPP) participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn wellbeing.
3013162|NCT02474849|Active Comparator|Conventional cigarette|
3013163|NCT02474849|Experimental|First-generation e-cigarette|
3013164|NCT02474849|Experimental|Rechargeable cig-like e-cigarette|
3013165|NCT02474849|Experimental|Closed modular system e-cigarette A|
3013166|NCT02474849|Experimental|Closed modular system e-cigarette B|
3013167|NCT02474836|Active Comparator|Atopic subjects|Patients sensitized to other allergenic sources but the allergen extracts under investigation.
3013168|NCT02474836|Active Comparator|Non atopic subjects|Healthy volunteers
3013169|NCT02474836|Other|Allergic Subjects|
3013170|NCT02474823|Other|Sleep Apnea assessment|all participants are in the same arm & undergo the same assessments: PSG, HST, ESAP
3013171|NCT02474810|Experimental|Intensive|In the Intensive Protocol, alteplase intervention is administered to all catheters based on blood flow and/or line reversal
3013172|NCT02474810|Experimental|Standard|In the Standard Protocol, alteplase intervention is administered to all catheters based only on blood flow.
3013173|NCT02474797|Experimental|Diaphragmatic ultrasonography in septic patient|Diaphragmatic Thickening Fraction
3013174|NCT02474745|Experimental|INTERVENTION GROUP|"Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible"
3013175|NCT02474745|Other|CONTROL GROUP|"Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
3013176|NCT02474732|Other|Usability|Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
3013177|NCT02474719|Experimental|conventional scheme followed by alternate schem|"The first day of the study, patients receive an adapted conventional peritoneal dialysis scheme: 2 cycles of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 2 cycles of purification (stasis: 110 mn ; volume 1200cc/m²).~The second day, patients receive an adapted and alternate scheme: 1 cycle of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 1 cycle of purification (stasis: 110 mn ; volume 1200cc/m²), the two cycles being repeated once."
3013178|NCT02474719|Experimental|alternate scheme followed by conventional scheme|"The first day of the study, patients receive an adapted and alternate peritoneal dialysis scheme: 1 cycle of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 1 cycle of purification (stasis: 110 mn ; volume 1200cc/m²), the two cycles being repeated once.~The second day, patients receive an adapted conventional scheme: 2 cycles of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 2 cycles of purification (stasis: 110 mn ; volume 1200cc/m²)."
3013179|NCT02474706|Experimental|cefoxitin|Cefoxitin 2 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis
3013180|NCT02474706|Active Comparator|imipenem|Imimpenem 1 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis
3013181|NCT02474680||Care Coordination Group|Patients participating in the Avera Care Coordination Program for Intervention 'Pharmacogenetic testing'
3013182|NCT02474667|Active Comparator|BB3|Administered IV for 30 min within 24 hours after transplantation and around 24 hours after previous dosing 3 days in a row
3013183|NCT02474667|Placebo Comparator|Normal Saline|Administered IV for 30 min within 24 hours after transplantation and around 24 hours after previous dosing 3 days in a row
3013184|NCT02474654|Experimental|Arm 1: PI+FNB+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, 0.5% Ropivicaine with 1:400,000 Epinephrine 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
3013185|NCT02474654|Experimental|Arm 2:NS+FNB+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, 0.5% Ropivicaine with1:400,000 Epinephrine 30ml, Normal Saline 100ml
3013186|NCT02474654|Experimental|Arm 3: PI+NS+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, Normal Saline 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
3013187|NCT02474654|Experimental|Arm 4: PI+FNB+NS|Bupivicaine 15mg, Fentanyl 15mcg, Normal Saline 0.3ml, 0.5% Ropivicaine with 1:400,000 Epinephrine 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
3013188|NCT02474654|Active Comparator|Arm 5:NS+NS+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, Normal Saline 30ml, Normal Saline 100ml
3013189|NCT02474641|Active Comparator|Standard radiation|"Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or~Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or~Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially"
3013190|NCT02474641|Experimental|Hypofractionation with SIB|Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed
3013191|NCT02474628|Placebo Comparator|Placebo|0.3 g∙kg-1body mass of calcium carbonate
3013195|NCT02474602|Experimental|Group A - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group A, received program 1 before strength training, and the same program 1 after training."
3013196|NCT02474602|Experimental|Group B - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 1 before strength training, and program 2 after training."
3013197|NCT02474602|Experimental|Group C - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group C, received program 2 before strength training, and program 1 after training."
3013198|NCT02474602|Experimental|Group D - Active or Placebo Phototherapy'|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 2 before strength training, and the same program 2 after training."
3013199|NCT02474589|Active Comparator|Active|600 mg tecovirimat capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
3013200|NCT02474589|Placebo Comparator|Placebo|matching placebo capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
3013201|NCT02474576|Experimental|Percutaneous aponeurotomy|Treatment of Dupuytrens-induced finger flessum using percutaneous aponeurotomy
3013202|NCT02474563||Bortezomib, Melphalan, Prednisone (VMP) Group|Participants will not receive any intervention in this study. Participants receiving VMP therapy for MM that was not eligible for autologous stem cell transplantation will be enrolled in the study.
3013203|NCT02474550||CISL 14-03|"Patients who were newly diagnosed with Diffuse Large B cell Lymphoma (DLBCL).~Aged 19 or more~Treated with R-CHOP therapy"
3013204|NCT02474537|Experimental|Normal hepatic function|Subjects with normal hepatic function
3013205|NCT02474537|Experimental|Mild hepatic impairment|Subjects with mild hepatic impairment
3013206|NCT02474537|Experimental|Moderate hepatic impairment|Subjects with moderate hepatic impairment
3013207|NCT02474537|Experimental|Severe hepatic impairment|Subjects with severe hepatic impairment
3013208|NCT02474524|Experimental|Health intervention|+ treatment as usual
3013209|NCT02474524|Active Comparator|Social intervention|+ treatment as usual
3013210|NCT02474511||general anesthesia|In this group，the patient is received radiofrequency ablation under general anesthesia.
3013211|NCT02474511||local anesthesia|In this group，the patient is received radiofrequency ablation under local anesthesia.
3013212|NCT02474498|Active Comparator|EMD alone|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland) and after the flap will be repositioned.
3013213|NCT02474498|Active Comparator|βTCP/HA alone|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
3013214|NCT02474498|Active Comparator|EMD + βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a mixture of enamel matrix derivative proteins (EMD) (Emdogain® Straumann, Basel, Switzerland) and bone substitute consisting of βTCP/HA (Bone Ceramic® Straumann, Basel, Switzerland). Immediately after debridement, EMD will be applied on the root surfaces. The remaining part of the material in the seringe will be then mixed with the bone substitute on a sterile dappen. This mixture will be used to completely fill the defect (EMD + βTCP/HA).
3013215|NCT02474485|Active Comparator|BVS - Absorb|"BVS - Absorb scaffold group will be treated by implantation of drug eluting bioresorbable vascular scaffold (Absorb®). In this arm following interventions will be performed:~BVS Absorb implantation. For in stent restenosis treatment during index procedure.~OCT visualization.During index procedure and at 9 month follow-up.~Control coronary angiography. Control angiography will be performed at 9 month follow-up.~Clinical observation. Clinical observation will be performed at 9, 12 and 60 month follow-up."
3013216|NCT02474485|Active Comparator|DEB - Sequent Please|"In DEB - Sequent Please Group, dilatation of drug eluting balloon Sequent Please ® will be used for treatment of the narrowed part of the artery. In this arm following interventions will be performed:~DEB Sequent Please inflation. For in stent restenosis treatment during index procedure.~OCT visualization.During index procedure and at 9 month follow-up.~Control coronary angiography. Control angiography will be performed at 9 month follow-up.~Clinical observation. Clinical observation will be performed at 9, 12 and 60 month follow-up."
3013217|NCT02474459|Active Comparator|iPad-based Clinical Support Care|Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be performed using an iPad-based decision support system. Outcomes will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-39) and the Multi-Dimensional Caregiver Strain Index (MCSI).
3013218|NCT02474459|Active Comparator|Standard Clinical Care|Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care. Outcomes will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-39) and the Multi-Dimensional Caregiver Strain Index (MCSI).
3013219|NCT02474446|Experimental|1|"Anthropometry measurement, Skin colour grading using Fitzpatrick scale, Dietary intake of calcium and vitamin D using food frequency questionnaire (FFQ), Baseline fasting blood samples for vitamin D, VDBP, VDBP genotype, Calcium, Phosphorus, Albumin, Parathyroid Hormone(PTH), Alkaline Phosphatase, Bone turnover markers(P1NP, CTX).~Fasting urine for Calcium Creatinine ratio. Saliva for bio-available Free Vitamin D measurement.~Vitamin D administration under direct supervision. Spot Urine sample for calcium : creatinine ratio after a week. Repeat all measurements done at baseline except VDBP genotype 4 weeks from baseline."
3013220|NCT02474433|Active Comparator|PO Misoprostol|Patients assigned to PO Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
3013221|NCT02474433|Active Comparator|PV Misoprostol|Patients assigned to PV Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
3013222|NCT02474433|Active Comparator|Buccal Misoprostol|Patients assigned to buccal Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
3013223|NCT02474420|Active Comparator|Deferasirox|deferasirox iron chelation therapy and standard of care by the treating physician
3013224|NCT02474420|Experimental|Deferasirox plus amlodipine|deferasirox iron chelation therapy with amlodipine
3013225|NCT02474407|Experimental|diazepam nasal spray/diazepam rectal gel|"One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.~A single rectal dose of diazepam will be administered to subjects according to the Diastat prescribing information."
3013226|NCT02474394|Active Comparator|Mcgrath|The endotracheal intubation will be provided using Mcgrath series 5 video laryngoscope
3013227|NCT02474394|Active Comparator|Macintosh|The endotracheal incubation will be provided using macintosh laryngoscope
3013228|NCT02474381|Experimental|EPCs plus PTA|Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty
3013229|NCT02474381|Active Comparator|Single PTA|Angioplasty of arteries below tibial plateau level only
3013230|NCT02474368|Experimental|Cohort 1|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Cohort 1 (patients who have received prior radiation in the head and neck with gross unresectable disease)~Intensity Modulated Radiation Therapy (IMRT) : daily for 6 weeks~Cisplatin will be administered intravenously on predetermined days~Stereotactic Body Radiotherapy (SBRT)"
3013231|NCT02474368|Experimental|Cohort 2|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Cohort 2 (patients with metastatic solid tumors of any histology who have targetable lesions within the head and neck) -- Stereotactic Body Radiotherapy (SBRT)"
3013232|NCT02474355|Experimental|AZD9291|Single arm of AZD9291, starting dose of 80mg
3013233|NCT02474342|Experimental|Autologous Adipose Tissue derived MSCs|
3013234|NCT02474329||Cohort 1|"Dutch Parkinson's patients resident in the region of Noord-Holland whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
3013235|NCT02474329||Cohort 2|"Dutch Parkinson's patients resident in the region of Zuid-Holland whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
3013236|NCT02474329||Cohort 3|"Dutch Parkinson's patients resident in the region of Gelderland and Utrecht whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
3013237|NCT02474329||Cohort 4|"Dutch Parkinson's patients resident in the region of Groningen, Friesland, Drenthe and Overijssel whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
3013238|NCT02474329||Cohort 5|"Dutch Parkinson's patients resident in the region of Zeeland, Noord-Brabant and Limburg whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
3013239|NCT02474316|Experimental|PegINF plus nucleos(i)de analgoue|Peginterferon alfa-2a 180μg /wk plus nucleos(t)ide analgoue (NA) 1 piece qd for 48 weeks
3013240|NCT02474316|Active Comparator|nucleos(t)ide analgoue|nucleos(t)ide analgoue (NA) 1 piece qd for 48 weeks
3013241|NCT02474303|Other|HIV Pre-exposure Prophylaxis (PrEP)|Truvada
3013242|NCT02474290|Experimental|Sorafenib group|Sorafenib will be used from day 30 to 180 post-transplantation.
3013243|NCT02474290|No Intervention|non-Sorafenib group|
3013244|NCT02474277|Other|30 sec chair stand test|all patients in this Group receives a diagnostic test for functional impairment
3013245|NCT02474264|Other|male BRCA mutations carriers|Endothelial function assessment and Cardiovascular biomarkers
3013246|NCT02474264|Other|healthy males - control group|Endothelial function assessment and Cardiovascular biomarkers
3013544|NCT02472184|Active Comparator|Endometrial biopsy|Group of patients in which endometrial biopsy will be performed prior to office hysteroscopy
3013247|NCT02474251|Active Comparator|Group A|25 cognitively normal elderly subjects (age 55-75), newly enrolled or currently participating in R01HL118624-01 (IRB S12-03068), a 2-year longitudinal on-going study that is aimed at examining the longitudinal associations between SDB and cognitive decline in the elderly.
3013248|NCT02474251|Active Comparator|Group B|20 cognitively normal adults (age 30-75) with severe SDB (Apnea Hypopnea index [AHI]-all >30/hour) and good CPAP compliance from Mt. Sinai School of Medicnie (MSSM)
3013249|NCT02474238|Experimental|The sequential technique|By using the double frequency YAG laser to make the initial bore and the Nd:YAG laser to complete the perforation on iris.
3013250|NCT02474238|Active Comparator|The pure Nd:YAG laser technique|By using the pure Nd:YAG to make a complete perforation on iris.
3013251|NCT02474212|Active Comparator|Enoxaparin 40 mg s.c.|Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 40 mg thromboprophylaxis every 24 hours for three days (72 hours)
3013252|NCT02474212|Active Comparator|Enoxaparin 40 mg i.v.|Enoxaparin thromboprophylaxis (40 mg) daily as continuous intravenous infusion for three days (72 hours)
3013253|NCT02474212|Active Comparator|Enoxaparin 0.5 mg/kg s.c.|Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 0.5 mg/kg thromboprophylaxis twice a day for three days (72 hours)
3013254|NCT02474212|Active Comparator|Enoxaparin 1 mg/kg i.v.|Enoxaparin thromboprophylaxis 1 mg/kg daily as continuous intravenous infusion for three days (72 hours)
3013255|NCT02474199|Experimental|darTregs|Donor Alloantigen Reactive Tregs (darTregs). Participants will receive a target dose of 400X10^6 darTregs (range 300-500 x10^6) infused intravenously (IV) over an approximate 20-30 minute interval
3013256|NCT02474186|Experimental|Radiation therapy|"Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy~Systemic agents are either capecitabine (Xeloda), paclitaxel, docitaxel or taxol"
3013257|NCT02474173|Experimental|Treatment (onalespib, paclitaxel)|"SAFETY RUN-IN: Patients receive onalespib IV over approximately 1 hour on day -7.~TREATMENT: Patients receive paclitaxel IV over 60 minutes on day 1, 8, and 15. Patients also receive onalespib IV over 1 hour beginning on days 8 and 15 of course 1 and on days 1, 8, and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3013258|NCT02474160||Ancillary-correlative (tissue and blood procurement)|Tumor tissue and blood samples are procured during procedures that are required for the patients? clinical management and stored via xenograft (transplant to another species) models or in vitro cell culture for future analysis.
3013259|NCT02474147|Experimental|Type 2 diabetics|Patients with type 2 diabetes Interventions: processed meat hamburger and vegan sandwich
3013260|NCT02474147|Active Comparator|Obese subjects|Obese subjects without diabetes Interventions: processed meat hamburger and vegan sandwich
3013261|NCT02474147|Active Comparator|Healthy lean controls|Healthy lean controls Interventions: processed meat hamburger and vegan sandwich
3013262|NCT02474134|Other|PF530/Betaferon|Single subcutaneous injection of two interferon beta-1b products (PF530 and Betaferon) 0.25 mg
3013263|NCT02474134|Other|Betaferon/PF530|Single subcutaneous injection of two interferon beta-1b products (Betaferon and PF530) 0.25 mg
3013264|NCT02474108|Placebo Comparator|without prevention|isolated mitral valve replacement or reconstruction, implantation of cardiac monitor
3013265|NCT02474108|Active Comparator|group of prevention|"mitral valve replacement or reconstruction with surgical prevention of AF (concomitant ablation of the left atrium) and implantation of cardiac monitor.~Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe."
3013266|NCT02474095|Experimental|Arm I (ALTENS QIW)|Patients undergo ALTENS delivered via the Codetron machine QIW for 6 weeks in the absence of disease progression or unacceptable toxicity.
3013267|NCT02474095|Active Comparator|Arm II (ALTENS BIW)|Patients undergo ALTENS delivered via the Codetron machine BIW for 12 weeks in the absence of disease progression or unacceptable toxicity.
3013268|NCT02474082|Experimental|Secukinumab|Patients in treatment arm A will receive a dose of 300 mg secukinumab administered as 2 subcutaneous injections of 150 mg in a SensoReady pen (i.e. 2 x 150 mg) at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20.
3013269|NCT02474082|Active Comparator|Fumaric acid (initial and maintenance therapy)|Participants were daily self-administered with fumaric acid derivatives initial and maintenance therapy in dosetitrated scheme as per protocol. Dose was up-titrated weekly (1 tablet/day) until objective was achieved or until tapering was required or until the maximum dose of 2 tablets each at morning, noon and evening was reached, whichever occurred earlier.
3013270|NCT02474069|Active Comparator|Secukinumab Interval Shortening|
3013271|NCT02474069|Active Comparator|Secukinumab 4-weekly|
3013272|NCT02474056||trauma patients|patients with decreased blood volume
3013273|NCT02474056||surgical patients|patients with decreased blood volume
3013274|NCT02474056||non surgical patients|patients with decreased blood voloume
3013275|NCT02474043|Active Comparator|Usual care|Standard health education and prevention counseling by trained staff
3013276|NCT02474043|Experimental|Hep-Net Intervention|Computerized tailored behavioral intervention
3013277|NCT02474017|Experimental|MGR001|MGR001 (FP/Salmeterol) (250/50 µg) twice daily (BID)
3013278|NCT02474004|Experimental|medial meniscus repair|patients receiving medial meniscus repair
3013279|NCT02474004|Active Comparator|medial partial meniscectomy|patients having medial partial meniscectomy
3013280|NCT02473978||Participants undergoing cesarean sections|The participants preoperative data will be compared to intraoperative data and analyzed in order to evaluate the dynamic cerebral oxygen and blood perfusion changes in participants undergoing cesarean sections.
3013281|NCT02473978||Participants throughout cesarean sections|The participants intraoperative data will be compared to preoperative data and analyzed in order to evaluate the dynamic cerebral oxygen and blood perfusion changes in participants undergoing cesarean sections.
3013282|NCT02473965|Experimental|IGIV-C|An IGIV-C loading dose of 2 g/kg and maintenance dose of 1 g/kg will be administered in CS dependent subjects with MG.
3013283|NCT02473965|Placebo Comparator|Placebo|0.9% sodium chloride injection, USP or equivalent
3013569|NCT02472028|Active Comparator|usual strategy|usual strategy based on the usual care of routine care
3013284|NCT02473952|Experimental|IGIV-C|"IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified.~An initial loading dose of 2 g/kg of body weight will be administered at Baseline (Week 0, Visit 1) followed by maintenance doses of 1 g/kg of body weight administered every third week through Week 21 (Visit 8)."
3013285|NCT02473952|Placebo Comparator|Placebo|Placebo: Sterile 0.9% sodium chloride injection or equivalent. Placebo will be infused at the Baseline/Week 0 Visit (Visit 1) using the same volume as would be required for the IGIV-C loading dose. Subsequent placebo maintenance doses will be matched in volume to the IGIV-C maintenance doses and administered every third week until Week 21 (Visit 8).
3013286|NCT02473939|Experimental|VR942 Dose 1|VR942 Dose 1
3013287|NCT02473939|Experimental|VR942 Dose 2|VR942 Dose 2
3013288|NCT02473939|Experimental|VR942 Dose 3|VR942 Dose 3
3013289|NCT02473939|Experimental|VR942 Dose 4|VR942 Dose 4
3013290|NCT02473939|Experimental|VR942 Dose 5|VR942 Dose 5
3013291|NCT02473926|Experimental|Physical Activity Program Intervention|"The intervention seeks to increase physical activity and improve strength by addressing individual , behavioral, and social/environmental factors. Health promotion clinic staff will deliver counseling by phone on a bi-weekly basis - a clinic physician assistant will coordinate with the counselor during in-person clinic visits, teach participants to perform strengthening exercise, and assess for safety concerns associated with type 2 diabetes.~In addition to behavioral counseling targeting social cognitive theory constructs, counselors will assist participants in the intervention group to set specific goals for physical activity in a paper log and on an electronic FitBit activity tracking device.Health promotion clinic staff will encourage participants to advance goals towards meeting U.S. physical activity guidelines of 150 minutes/week of moderate intensity activity and 2-3 days/week of strength activities."
3013292|NCT02473926|Other|Usual Care Group|Participants in the usual care arm will receive three mailings (Intervention Questionnaires) during the intervention phase. Health promotion clinic staff will mail materials from the Center for Disease Control and Prevention website that address general health aging topics.
3013293|NCT02473913|Experimental|Milk Thistle|Each subject will have a 6 week treatment phase with milk thistle.
3013294|NCT02473913|Placebo Comparator|Placebo|6 week placebo phase before or after milk thistle phase depending on randomization.
3013295|NCT02473900|Experimental|Sequence 1|HIP1403→HGP0919
3013296|NCT02473900|Experimental|Sequence 2|HGP0919→HIP1403
3013297|NCT02473887|Experimental|gastroenteritis with persistent vomiting.|patients with gastroenteritis with persistent vomiting received single dose of intravenous ondansetron form orally after being flavored with 1:1 ORA-sweet, the dose of ondansetron was determined based on the patient presenting weight.
3013298|NCT02473874||Skin Spect dermoscope|Skin mole
3013299|NCT02473874||Spatially modulated quantitative|Skin mole
3013300|NCT02473861|Experimental|Immediate exercise arm|The length of the intervention for the immediate exercise group will be determined by treatment protocol and could range from 8 to 13 weeks. The intervention can begin up to one week before the first treatment and will continue until 2 weeks after the final taxane-containing treatment. The intervention will consist of thrice weekly supervised aerobic and resistance exercise training.
3013301|NCT02473861|Experimental|delayed exercise arm|The delayed exercise group will begin an exercise intervention two weeks after completion of their last taxane-containing chemotherapy treatment that will last the length of their taxane chemotherapy plus two weeks. If participants in the delayed exercise group have a surgery planned during the intervention time that will require >1 week off from exercise, the exercise intervention will be delayed until after the surgery. The intervention will consist of thrice weekly supervised aerobic and resistance exercise training.
3013302|NCT02473848|Experimental|Ingenol mebutate 500 ucg|active arm
3013303|NCT02473835|Experimental|Calorie Restriction|Participants reduced calorie intake by 50 % for a period of 3 consecutive days - the target calorie intake for each participant will be determined by a period of energy balance (diet and activity) monitoring.
3013304|NCT02473809|Experimental|Liraglutide|"Liraglutide (Victoza), subcutaneous 1,8 mg once daily for 180 days"
3013305|NCT02473809|Placebo Comparator|Placebo|Saline, subcutaneous once daily for 180 days
3013306|NCT02473796|Experimental|Home based child care|The home based child care included treatment of various various childhood illnessed by locally avialable trained village health workers, improving hygiene and nutrition among children and women throgh health education. This care was in adiition to the local health care provided by the Government's primary health care services.
3013307|NCT02473796|No Intervention|control|The control arm included population where the home based neonatal care was not implimented. The health services were provided by the Government run primary health care services. Vital statistics data was collected by VHWs.
3013308|NCT02473783|Experimental|Treatment Group|The subjects with major depressive disorder who are screened into this study were scheduled for T1-weighted MRI (MRI examination results within 6 months before study are acceptable) prior to the visit of SPECT scans to confirm the absence of organic lesion in the brain and to co-register with SPECT images for the delineation of brain anatomical locations. After the screening visit, eligible subjects received I-123-ADAM SPECT before and after the pharmacological intervention with Sertraline HCl for a treatment period of six weeks. The subjects were observed until no clinically significant adverse events at the drug administration visits before being dismissed.
3013309|NCT02473757||1/Cohort 1|Subjects who have received treatment on an NCI ETIB Branch gene therapy protocol.
3013310|NCT02473744|Experimental|Oedematous lower limb subcutaneous drainage|In case of lymphoedema in palliative situation, a subcutaneous drainage can be performed. It is a simple method, easy to use. After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
3013311|NCT02473731|Experimental|A|Treatment with KTN3379 in HPV positive head and neck cancer patients
3013312|NCT02473731|Experimental|B|Treatment with KTN3379 in HPV negative head and neck cancer patients
3013339|NCT02473471|Experimental|MOP side|Three small holes in cortical bone can be created by Miniscrews.Before application of the MOPs, Patient will be asked to wash their mouth twice by chlorhexidine for 1 minute. Local anesthesia will be given (2% lidocaine with 1:100,000 epinephrine). Microosteoperforation (MOPs) will be performed distal to canine.
3013340|NCT02473471|No Intervention|control side|No intervention in the other side of maxilla (control side)
3051228|NCT02219074|Sham Comparator|Vehicle and laser treatment|
3013313|NCT02473718|Experimental|Fluid minimization group|Patients in the fluid minimization arm will have daily fluid intake and output, baseline central venous pressure, mean arterial pressure, central venous oxygen saturation, pulse pressure variation, and inferior vena cava diameters during inspiration and expiration recorded by a dedicated research fellow. Patients who are intubated will also have corrected flow time, stroke volume, cardiac output, and cardiac index recorded via CardioQ. A fluid challenge in the form of a leg raise or infusion of 250 mL of crystalloid over 5 minutes will then be performed and the parameters repeated. The patient will be judged to be fluid responsive or nonresponsive based on the changes in the parameters. Fluid nonresponsive patients will receive the intervention of the fluid minimization protocol by concentrating continuous infusions, discontinuing maintenance fluids, and minimizing carrier fluids. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance.
3013314|NCT02473718|No Intervention|Usual care group|Patients in the usual care arm will have daily fluid intake and output, baseline central venous pressure, mean arterial pressure, central venous oxygen saturation, pulse pressure variation, and inferior vena cava diameters during inspiration and expiration recorded by a dedicated research fellow. Patients who are intubated will also have corrected flow time, stroke volume, cardiac output, and cardiac index recorded via CardioQ.
3013315|NCT02473705|Active Comparator|Fish Oil and Bicarbonate placebo|1280mg of fish oil per day and bicarbonate placebo
3013316|NCT02473705|Active Comparator|Fish Oil Placebo and Bicarbonate|fish oil placebo and 1mg of bicarbonate per Kg of body weight per day
3013317|NCT02473705|Experimental|Fish Oil and Bicarbonate|1280mg of fish oil per day and 1mg of bicarbonate per Kg of body weight per day
3013318|NCT02473705|Placebo Comparator|Fish Oil placebo and Bicarbonate placebo|Fish oil placebo and Bicarbonate placebo
3013319|NCT02473692||Online MigraineTreatment Optimization|After providing informed consent, participants will complete a series of questionnaires related to their headaches and medication beliefs. After completion, they will have full access to an informational website including access to text-based supplemental materials pertaining to headache and headache treatment, and a series of videos designed specifically for this trial. Participants will be asked to watch seven videos of approximately four-minute length each and to complete a post-assessment question following the completion of each of the first 6 videos. The total time required to complete all study activities will be approximately one hour.
3013320|NCT02473666||All Health Conditions.|All Health Conditions. Area of Focus: Transfusions of blood products.
3013321|NCT02473640|Experimental|150 mg SYN-004|There will be 2 in-house treatment periods: in Treatment Period 1, subjects will receive 2 oral doses of 150 mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone, and in Treatment Period 2, subjects will receive 2 oral doses of 150mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone in the presence of steady-state esomeprazole; Treatment Periods 1 and 2 will be separated by a 5- to 7-day run-in phase, during which subjects will self-administer 40 mg of esomeprazole once daily (QD) in the morning, at home.
3013322|NCT02473627|Experimental|Period 1|Period 1 Day 1: single oral dose of 2.5 mg midazolam hydrochloride Day 2: single oral cocktail dose of 20 mg omeprazole, 15 mg pioglitazone hydrochloride, 500 mg tolbutamide and 150 mg bupropion
3013323|NCT02473627|Experimental|Period 2|"Period 2 Days 1 through 12 repeated doses of 400 mg DS-1971a administered orally bid .~On the days listed below, each probe substrate(s) will be coadministered with the morning dose of DS 1971a:~Day 8: single oral dose of 2.5 mg midazolam hydrochloride Day 9: single oral cocktail dose of 20 mg omeprazole, 15 mg pioglitazone hydrochloride, 500 mg tolbutamide and 150 mg bupropion"
3013324|NCT02473614|Experimental|Music Glove|Music Glove is a glove with sensors attached to the tips of all 5 fingers. The glove is connected to a software musical program like guitar hero. Participants will follow the rhythm or musical notes of the songs and move their fingers accordingly. Participants are reinforced with biofeedback that includes visual and auditory cues when the correct sequences are achieved.
3013325|NCT02473614|Active Comparator|Conventional Hand Exercise Program|Conventional Hand Exercise Program includes range of motion exercises, strengthening exercises, coordinating exercises of the hand and fingers. This exercise program is designed by an occupational therapist and is a general exercise program that a stroke patient will receive when he/she is being discharged from the hospital.
3013326|NCT02473601|Experimental|Mivacurium Chloride by liver dysfunction|Mivacurium Chloride 0.2mg/kg,during anesthesia induction. Mivacurium Chloride 6mg/kg/h,during anesthesia maintenance
3013327|NCT02473601|Other|Mivacurium Chloride by normal liver function|Mivacurium Chloride 0.2mg/kg,during anesthesia induction. Mivacurium Chloride 6mg/kg/h,during anesthesia maintenance
3013328|NCT02473588|Other|LTIA Group|Patients in the LTIA Group (all patients) will have blood pressure recorded continuously. LTIA will be used to measure stroke volume and cardiac output after the completion of data collection
3013329|NCT02473575|Experimental|Caffeine gum|caffeine (300 mg) in gum form x 1 ingestion
3013330|NCT02473575|Placebo Comparator|Placebo gum|placebo gum consumed x 1 ingestion
3013331|NCT02473575|No Intervention|Non-intervention group|A third group of runners will be used to adjust for changes in environmental conditions. They will complete 2 runs without consuming either placebo or experimental treatment
3013332|NCT02473562|Experimental|Varenicline|Varenicline capsule 1 mg BID
3013333|NCT02473562|Placebo Comparator|Placebo|Placebo capsule
3013334|NCT02473549|Experimental|Brain Stimulation|Patients will receive, Sham TDCS, Anodal TDCS, Cathodal TDCS, and Magnetic Resonance Imaging (MRI).
3013335|NCT02473536|Experimental|Stereotactic ablative radiation therapy|SABR
3013336|NCT02473523|Experimental|Participants|"Leukemia, Hodgkin Lymphoma and non-Hodgkin's Lymphoma patients who meet eligibility requirements and consent to participate in the study.~Interventions: Yoga Therapy, PedsQL Multidimensional Fatigue Scale, PedsQL Cancer Module, Verbal Numeric Pain Scale. Biodex System 3 Dynamometer, Jamar Hydraulic Hand Dynamometer, Sit and Reach Test, and Test of Motor Proficiency."
3013337|NCT02473510|Experimental|Trivalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
3013338|NCT02473510|Placebo Comparator|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
3013341|NCT02473458|Placebo Comparator|Control|patients with acute ischemic stroke who received standard care plus placebo filled capsules,
3013570|NCT02472015|No Intervention|normal care|patients who will have normal care
3013342|NCT02473458|Experimental|450 mg licorice|patients with acute ischemic stroke who received standard care plus capsules filled with 450 mg of whole extract of licorice.
3013343|NCT02473458|Experimental|900 mg licorice|patients with acute ischemic stroke who received standard care plus capsules filled with 900 mg of whole extract of licorice.
3013344|NCT02473445|Experimental|Cysteamine Bitartrate Delayed-release|Participants received cysteamine bitartrate delayed-release capsules (RP103) twice daily for up to 2 years. The starting dose was the same as the last dose received in study RP103-MITO-001, the maximum dose was 1.3 g/m²/day.
3013345|NCT02473432|Experimental|RMT + usual care|Device: Orygen-Dual® valve trainer Intensity: 30% of maximal respiratory pressures (increasing intervals: 10 cmH2O per week) Training schedule: 5 sets of 10 repetitions followed by 1-2 minutes of unloaded recovery breathing off the device, two sessions per day, 5 days per week, for 3 weeks.
3013346|NCT02473432|Experimental|NMES + usual care|Device: Vital Stim (Chattanooga Group, Hixson, TN, USA) Administration of 80 Hz transcutaneous electrical biphasic stimulus Schedule: 40 minutes per day, 5 sessions per week during hospitalization in the Neurorehabilitation ward (3 weeks approx).
3013347|NCT02473432|Active Comparator|Usual care|Usual care (standard multidisciplinary inpatient rehabilitation program) consisting of physical, occupational and speech therapy sessions to improve activities of daily life, mobility and communication skills (minimum 3 hours per day, 5 days a week, during 3 weeks), Standard swallow therapy (usual care of dysphagia in stroke patients) consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
3013348|NCT02473419||Vayarin|Vayarin x 16 weeks
3013349|NCT02473419||Placebo|Placebo x 16 weeks
3013350|NCT02473419||Vayarin and Placebo|Placebo x 8 weeks and then Vayarin x 8 weeks
3013351|NCT02473406|Experimental|Thymosin|Thymosin alpha 1 has been shown to have immunomodulatory properties
3013352|NCT02473406|Placebo Comparator|Placebo|physiological saline;
3013353|NCT02473393|Experimental|OPS-2071 50mg/day|OPS-2071 50 mg/day：25 mg tablet administered orally twice daily
3013354|NCT02473393|Experimental|OPS-2071 100 mg/day|OPS-2071 100 mg/day：50 mg tablet administered orally twice daily
3013355|NCT02473393|Experimental|OPS-2071 200 mg/day|OPS-2071 200 mg/day：100 mg tablet administered orally twice daily
3013356|NCT02473393|Experimental|OPS-2071 400 mg/day|OPS-2071 400 mg/day：100 mg two tablets administered orally twice daily
3013357|NCT02473380|Experimental|Intraoperative fluorescence spectroscopy|The experimental device will be assessed during an open surgical approach for surgical removal of the tumors
3013358|NCT02473367|Experimental|Raltegravir Pre- and 4 Period Sequence|Starting five days prior to Period 1 participants will be treated with 1200 mg raltegravir, once daily for five days. In Period 1 participants will be treated with 1200 raltegravir alone; this is followed by Period 2 where participants will be treated with 1200 mg raltegravir and TUMS concomitantly; this is followed by Period 3 where participants will be treated with 1200 mg raltegravir and 12 hours later with Leader Antacid; followed by Period 4 where participants will be treated with 1200 mg raltegravir and 12 hours later with TUMS. The wait between Periods is 2-7 days.
3013359|NCT02473354|Other|Resp Depression Sequence 1 - 3|"Sequence #1: breathe 21% through the facemask and increase ventilation to achieve a target hypocapnic ET CO2 of 25 - 30 mmHg. Subject will then breathe a gas mixture containing 6% CO2 / 30% O2 to achieve a target hypercapnic ET CO2 up to 60 mmHg or HCVR is terminated at the discretion of the PI.~Sequence #2: breathe 21% O2 (normoxia) before remifentanil administration Sequence #3: breathe 50% O2 (hyperoxia) before remifentanil administration"
3013360|NCT02473341|Experimental|Bovine colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.~+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
3013361|NCT02473341|Placebo Comparator|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
3013362|NCT02473328|Experimental|non comparative open study|"In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4), switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.~The administration will be done once a day orally for 48 weeks."
3013363|NCT02473315|Experimental|cryotherapy|
3013364|NCT02473315|Placebo Comparator|light cryotherapy|
3013365|NCT02473302|Placebo Comparator|ham|160g per day during 4 days
3013366|NCT02473302|Experimental|ham + pomegranate extract|160g per day during 4 days
3013367|NCT02473302|Experimental|ham + tocopherol|160g per day during 4 days
3013368|NCT02473302|Placebo Comparator|rare sirloin steak|110g per day during 4 days
3013369|NCT02473302|Experimental|marinated rare sirloin steak|110g per day during 4 days
3013370|NCT02473302|Experimental|marinated cooked sirloin steak|110g per day during 4 days
3013371|NCT02473289|Experimental|Sirukumab 50 milligram (mg)|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
3013372|NCT02473289|Placebo Comparator|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
3013373|NCT02473276|Active Comparator|EPID PFM|"The group EPID PFM will receive 3 mg (6 ml) of preservative-free morphine, followed by 3 ml of sterile normal saline, to be administered through the epidural catheter.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses)."
3013374|NCT02473276|Sham Comparator|EPID SAL|"The placebo group, EPID NS, will receive 6 ml of sterile normal saline via the epidural catheter followed by another 3 ml NS. Sixteen to 24 hours after receiving the first study drug,the patient will then receive the identical study drug (for a total of two doses)."
3013404|NCT02473081|Other|Usual care|Participants in this group received usual care only.
3013405|NCT02473068|Active Comparator|Group 1|Normal
3013406|NCT02473068|Experimental|Group 2|Low
3051229|NCT02219061||GMT|
3013375|NCT02473276|Active Comparator|IT PFM|"The group, IT PFM will receive 200 micrograms (mcg) (0.4 ml) of preservative-free morphine via the intrathecal catheter, followed by a flush of the catheter with 2 ml of sterile saline.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses)."
3013376|NCT02473276|Sham Comparator|IT SAL|The placebo group IT SAL will receive 0.4 ml and then 2 ml of sterile normal saline through the intrathecal catheter.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses).
3013377|NCT02473263|No Intervention|Conventional|No antibiotic administration and no hemodynamic target are required
3013378|NCT02473263|Active Comparator|Aggressive|Antibiotics (Ceftriaxone or piperacillin tazobactam) administration, hemodynamic optimization and opotherapy (norepinephrine, hydrocortisone) when required should be performed in the first 60 minutes after contact with the patient
3013379|NCT02473250|Experimental|Bipolar depressed|Bipolar depressed subjects will have neuroimaging and treatment with fluoxetine in combination with a mood stabilizer (valproate)
3013380|NCT02473237|Experimental|indacaterol|Indacaterol 150 mcgr, one inhaled capsule, dose once time on visit one, with dry powder inhaler device.
3013381|NCT02473237|Active Comparator|Tiotropium|Tiotropium 18 mcgr, 1 inhaled capsule, dose once time a Day, with dry powder inhaler device.
3013382|NCT02473224|Experimental|Cohort 1|9 secretor-positive subjects will receive 1.2x10^4 Genome Equivalent Copies (GEC) oral dose on Day 1; and 2 secretor-positive subjects will receive the placebo, n=11
3013383|NCT02473224|Experimental|Cohort 2|9 secretor-positive subjects will receive either 1.2 x 10^2GEC, or 1.2 x10^6 GEC oral dose on Day 1, depending on the percentage of subjects with illness from Cohort 1; 2 secretor-positive subjects will receive the placebo, n=11
3013384|NCT02473224|Experimental|Cohort 3|9 secretor-positive subjects will receive either 1GEC, 1.2 x 10^1 GEC, 1.2 x 10^2 GEC, 1.2 x 10^3 GEC, 1.2 x 10^5 GEC, 1.2 x 10^6 GEC, or 1.2 x 10^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2; 2 secretor-positive subjects will receive the placebo, n=11
3013385|NCT02473224|Experimental|Cohort 4|8 secretor-negative subjects will receive optimal dose of GEC and 3 secretor-positive subjects will receive optimal dose of GEC as determined by the results of cohorts 1-3, n=11
3013386|NCT02473211|Experimental|SOF+DCV|Participants will receive Sofosbuvir (SOF) 400 mg and Daclatasvir (DCV) 60 mg daily for 12 weeks.
3013387|NCT02473198|Active Comparator|Femoral Nerve Block (Group 1)|"In group1 (standard group) all patients receive the standard current perioperative pain management protocol for TKR.~The patient will then undergo an ultrasound guided femoral nerve block with bupivacaine 0.25% 20 cc. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint. Postoperatively patients will receive narcotic pain medication on a PRN basis."
3013388|NCT02473198|Experimental|Exparel (Group 2)|Group 2 will receive standard perioperative pain management for TKR; will undergo placebo femoral nerve block under ultrasound guidance with normal saline (NS) 20 cc. Following femoral bone cuts they will receive local anesthetic injection mixture of 30cc 0.25% bupivicaine with epinephrine 20 cc of preservative free normal saline, 30mg of toradol and 10 mg of morphine sulfate into the periarticular tissues including periosteum, joint capsule and posterior capsule of the knee joint and collateral ligaments and subcutaneous tissues. Prior to cementing prosthesis, a second injection with mixture of 20mL 1.3% Exparel and 40mL normal saline solution will be injected into the same tissues, joint capsules and collateral ligaments.
3013389|NCT02473185|Experimental|Methylphenidate|Methylfenidate 20 mg Tablet single-dose per os
3013390|NCT02473185|Placebo Comparator|Placebo|Placebo 20 mg Tablet single-dose per os
3013391|NCT02473172|Experimental|Pressure Support Ventilation|Assisted mechanical ventilation
3013392|NCT02473172|Experimental|Neurally Adjusted Ventilatory Assist|Assisted mechanical ventilation
3013393|NCT02473159|Experimental|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
3013394|NCT02473146|Experimental|Mylotarg Arm|"After randomization patients in the experimental arm are assigned to receive chemotherapy with:~Gemtuzumab Ozogamicin 3 mg/m2 (maximum dose: 5 mg) per IV, 60mn on Day 1 and 4 Cytarabine 200 mg/m2 per CIV over 24h on Day 1 to 7"
3013395|NCT02473146|No Intervention|Control Arm|After randomization patients in the control arm are assigned to receive chemotherapy with Idarubicin 12mg/m2 per IV, 30mn on Day 1,2,3 Cytarabine 200 mg/m2 per CIV over 24h on Day 1 to 7
3013396|NCT02473133|Experimental|Personalized dose redistribution|Patients in the will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy (about two thirds of patients are expected as positive). An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week using a twice-a-day fractionated radiotherapy.
3013397|NCT02473133|Sham Comparator|No dose redistribution|Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET result).
3013398|NCT02473120|Experimental|Determination of ESR1 mutations|Blood sample will be collected every 3 months during two years to determine ESR1 mutations
3013399|NCT02473107|Other|Control Caries Detection Strategy|Detection and treatment based on more advanced lesions, despite activity status - Advanced caries lesions detection (no activity assessment)
3013400|NCT02473107|Other|Test Caries Detection Strategy|Detection and treatment based on all detected caries lesions, considering their activity status as a differential in clinical decision-making - All caries lesions detection (+activity assessment)
3013401|NCT02473094|Experimental|Neoadjuvant capecitabine and metformin|"Capecitabine 825 mg/m2 bid D1-5, q7d, for five weeks;~Metformin 2500mg/d for five weeks;~3D radiotherapy 50,4Gy divided in 25 fractions"
3013402|NCT02473094|Placebo Comparator|Neoadjuvant capecitabine and placebo|"Capecitabine 825 mg/m2 bid D1-5, q7d, for five weeks;~Placebo 2500mg/d for five weeks;~3D radiotherapy 50,4Gy divided in 25 fractions"
3013403|NCT02473081|Experimental|Minimal Psychological Intervention|Participants allocated to this group not only received the usual care as given by their family physicians, but also accepted biweekly minimal psychological intervention via telephone during six weeks.
3013407|NCT02473055|Experimental|Kangaroo care|kangaroo Care was skin-to-skin, chest-to-chest placement of preterm infant wearing only a diaper placed up against mother's chest and covered in one receiving blanket folded into fourth
3013408|NCT02473055|No Intervention|control|control infants remained prone in an incubator wearing only diaper
3013409|NCT02473042|Experimental|Electrical Stimulation + Standard of Care Antiemetics|"Participants receive light electrical stimulation to the wrist area during surgery. Participants also receive standard of care drugs to reduce post-operative nausea and vomiting (PONV).~Questionnaire completed about participant's pre-treatment expectations and their nausea about 15 minutes after they wake up after surgery, then every 30 minutes until they leave the clinic."
3013410|NCT02473042|Active Comparator|Standard of Care Antiemetics|"Participants receive standard of care drugs to reduce post-operative nausea and vomiting (PONV).~Questionnaire completed about participant's pre-treatment expectations and their nausea about 15 minutes after they wake up after surgery, then every 30 minutes until they leave the clinic."
3013411|NCT02473029||Cases|Patients admitted to a tertiary hospital, with a clinical suspicion of Horton disease
3013412|NCT02473016|Experimental|Treatment|All subjects will receive both Active (Carbon Dioxide Drug Delivery System) and Placebo. This is a single-blind study so subjects will not know the order. Subjects will receive 3 doses of active and 3 doses of placebo. One dose is a 60 second delivery of CO2 or placebo. At the discretion of the investigator, subjects may receive up to 3 additional doses of CO2.
3013413|NCT02473003|Experimental|High intensity|high intensity exercise 80-90%
3013414|NCT02473003|Experimental|Low/Medium intensity|low/medium intensity exercise 40-50%
3013415|NCT02473003|Experimental|High Intensity with BM|high intensity exercise with Behavioral medicine strategies¨ 80-90%
3013416|NCT02473003|Experimental|Low/Medium intensity with BM|low/medium intensity exercise with Behavioral medicine strategies 40-50%
3013417|NCT02472990|Other|Duchenne muscular dystrophy children|"No drug and no placebo were used in this study. For 2h30 (time)~Measurement of leg strength using a dynamometer~Measurement of Motor Function~Walk test 6 minutes~Walk test 10 meters~Walk analysis: 3D recording of walking~Muscle MRI"
3013418|NCT02472990|Other|Healthy children|"No drug and no placebo were used in this study. For 2h30 (time)~Measurement of leg strength using a dynamometer~Measurement of Motor Function~Walk test 6 minutes~Walk test 10 meters~Walk analysis: 3D recording of walking~Muscle MRI"
3013419|NCT02472977|Active Comparator|BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (SCLC)|Small cell lung cancer (SCLC)
3013420|NCT02472977|Active Comparator|BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (PAC)|Pancreatic cancer (PAC)
3013421|NCT02472964|Active Comparator|Herceptin© + Taxane|"Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.~Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject withdrawal ."
3013422|NCT02472964|Experimental|HerMyl 1401O Trastuzumab + Taxane|"Part 1:Myl 1401OTrastuzumab Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.~Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Myl 1401O( Mylan Trastuzumab) alone once every 3 weeks until DP or subject withdrawal."
3013423|NCT02472951|Active Comparator|Type 2 diabetic subjects|
3013424|NCT02472951|Active Comparator|Prediabetic subjects|
3013425|NCT02472951|Active Comparator|Healthy subjects|
3013426|NCT02472938|Experimental|BG00012|120 mg capsule oral twice daily (BID) during the first week and 240 mg BID thereafter.
3013427|NCT02472938|Placebo Comparator|Placebo|Placebo capsules orally twice a day.
3013428|NCT02472925|Other|Arm 1: Control|"MedSignals pill box will be set into quiet mode to track patient compliance. This mode sends daily adherence data to the Way to Health platform each time the participant opens the pill box, however, does not remind the participant to take the medication."
3013429|NCT02472925|Experimental|Arm 2: Reminders/Feedback|MedSignals pill box will track patient compliance and the Way to Health platform will allow participants to receive tailored text message reminders to take the medication if in case the interval from last cap opening is >30 hours (greater than 6 hours overdue).
3013430|NCT02472925|Experimental|Arm 3: Reminders/Feedback/Incentives|MedSignals pill box will track patient compliance and in addition to reminders with missed doses and weekly adherence feedback, patients in this arm will be eligible to receive a small financial incentive each week they demonstrate perfect >85% adherence. The weekly adherence feedback message will also alert patients whether they earned the incentive for the past week.
3013431|NCT02472912|Experimental|Treatment A|Single Injection of 40mg / 0.8 mL BMO-2
3013432|NCT02472912|Active Comparator|Treatment B|Single Injection of 40mg / 0.8 mL EU-Humira
3013433|NCT02472912|Active Comparator|Treatment C|Single Injection of 40mg / 0.8 mL US-Humira
3013434|NCT02472899||Alzheimer's Disease|Blood sample from subjects older than 60 years with a clinical diagnosis of Alzheimer's Disease
3013435|NCT02472899||Older controls|Blood sample from subjects older than 60 years who are cognitively normal
3013436|NCT02472899||Younger controls|Blood sample from healthy subjects aged 20 to 30 years who are cognitively normal
3013437|NCT02472886|Experimental|LDV/SOF|Treatment-naive participants with genotype 1 HCV infection without cirrhosis will receive LDV/SOF FDC for 8 weeks.
3013438|NCT02472886|Experimental|LDV/SOF Coinfected with HIV-1|Treatment-naive participants with genotype 1 HCV infection without cirrhosis and who are coinfected with HIV-1 will receive LDV/SOF FDC for 8 weeks.
3013439|NCT02472886|Experimental|LDV/SOF+RBV Retreatment|Participants with genotype 1 or 3 HCV infection who failed to achieve SVR12 in Gilead Study GS-US-334-0119 will receive LDV/SOF FDC + RBV for 12 weeks.
3013440|NCT02472873|Experimental|study group - sclerotherapy|Aspiration and Sclerotherapy of endometriomas.
3013441|NCT02472873|Other|control group - cystectomy|cystectomy of endometriomas.
3013442|NCT02472860|Experimental|Cognitive Training|Targeted Cognitive Training (TCT)
3013443|NCT02472860|Placebo Comparator|Control Condition|Youth appropriate online games
3013571|NCT02472015|Experimental|telemedicine|patients who will have telemedicine
3013572|NCT02472002|Experimental|Mesenchymal cell therapy|
3013444|NCT02472847|Placebo Comparator|Placebo|In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning.
3013445|NCT02472847|Active Comparator|Dronabinol|In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning
3013446|NCT02472834|Experimental|Amino acid supplementation NephrAmine®|250 mL of 5.4% amino acid solution (NephrAmine) by intravenous infusion 3 x weekly for 8 weeks plus 4 weeks of follow-up.
3013447|NCT02472834|No Intervention|Standard-of-care|Standard-of-care does not include amino acid supplementation, but this control arm will be evaluated for the same outcomes as the experimental arm for 8 weeks plus 4 weeks of follow-up
3013448|NCT02472821|Active Comparator|Interactive Lesson|Subjects will receive a community-based face-to-face interactive youth educational program on hearing health
3013449|NCT02472821|Active Comparator|Interactive lesson + Web-based booster|Subjects will receive a community-based face-to-face interactive youth educational program on hearing health followed by an Internet-based educational booster
3013450|NCT02472821|No Intervention|No-intervention control|No interventions; pre- and post- measures only.
3013451|NCT02472808|Other|cTBNA without ROSE|Patients who will undergo conventional TBNA without ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
3013452|NCT02472808|Other|cTBNA with ROSE|Patients who will undergo conventional TBNA with ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
3013453|NCT02472808|Other|EBUS-TBNA without ROSE|Patients who will undergo EBUS-TBNA without ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
3013454|NCT02472808|Other|EBUS-TBNA with ROSE|Patients who will undergo EBUS-TBNA with ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
3013455|NCT02472795|Experimental|Investigational treatment - 0.5mg|ACT-334441 0.5 mg
3013456|NCT02472795|Experimental|Investigational treatment - 1mg|ACT-334441 1 mg
3013457|NCT02472795|Experimental|Investigational treatment - 2mg|ACT-334441 2 mg
3013458|NCT02472795|Experimental|Investigational treatment - 4mg|ACT-334441 4 mg
3013459|NCT02472795|Placebo Comparator|placebo|administered orally
3013460|NCT02472769|Active Comparator|IBP-9414|IBP-9414 Oral Daily
3013461|NCT02472769|Placebo Comparator|Placebo|Sterile water
3013462|NCT02472756||Follicular Lymphoma Participants|Previously treated adult participants with relapsed/refractory FL will receive rituximab in combination with chemotherapy regimen. All treatments prescribed during the observation period will be at the treating physician's discretion. Participants will be followed up for safety and efficacy evaluation in accordance with routine practice, up to 30 months.
3013463|NCT02472743|Experimental|Custom-built phototherapy lamp|"Custom-built phototherapy lamp:~All participants will receive light treatment twice weekly for three weeks (or until ulcer/s healing) to one or both hands (both hands if ulcer/s present bilaterally).~The participant will place their hand within the treatment area of the light-based device (total treatment area approximately 15cm2), aiming to centralise the digital ulcer/s to the centre of the treatment region.~At each treatment study visit (visits 1-6 inclusive), the device will undergo a period of (automatic) calibration before use. All three wavelengths (red, infrared and blue) will be delivered simultaneously in combination, with the fluence of the device set at [3J/cm2] (treatment duration approximately 10 to 15 minutes)."
3013464|NCT02472730|Experimental|Cap Assisted Colonoscopy|The distal attachment cap is affixed to the colonoscope before every colonoscopy in this arm.
3013465|NCT02472730|No Intervention|Standard Colonoscopy|Standard colonoscopy without the distal attachment cap is performed in this arm.
3013466|NCT02472717|Experimental|Interventional arm|liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
3013467|NCT02472717|Placebo Comparator|Placebo arm|Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
3013468|NCT02472704|Active Comparator|Gluten challenge|Gluten powder (10 g every 12 hours), 24 weeks
3013469|NCT02472704|Placebo Comparator|Placebo challenge|Placebo (maltodextrin; 10 g every 12 hours), 24 weeks
3013470|NCT02472691|Experimental|Lenalidomide + Aza + DLI|Patients will be included at the time of relapse after first allo-SCT. As standard of care all patients will receive Azacitidine 75 mg/m2/d for 7 days every 28 days for up to 8 cycles and DLIs given after cycle 4, 6 and 8 at a dose of 0.5-1x106CD3/kg (1st DLI), 1-5x106CD3/kg (2nd DLI) and 5-15x106CD3/kg (3rd DLI). As intervention (investigational drug), Lenalidomide will be also started on day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
3013471|NCT02472678|Other|Standard care|The control group will receive standard care.
3013472|NCT02472678|Experimental|Experimental group|In addition to standard care, the experimental group will be given access to the web-based tailored information and support system (with a username/password)
3013473|NCT02472665|Experimental|plasma-derived FVIII/VWF concentrate|Pharmacokinetic single dose study with Fanhdi (high-purity Von Willebrand containing FVIII concentrate)
3013474|NCT02472652|Other|Abilify Maintena|Subjects will be switched to Abilify Maintena (Aripiprazole) LAI monthly doses of 400mg, 300mg, 200mg or 160mg and have their sexual functioning reevaluated over a 3 month period to determine if there is any significant sexual functioning improvement.
3013475|NCT02472639|Experimental|Ostom-i Alert Sensor|Patients will wear Ostom-i sensor
3013476|NCT02472639|Other|No Ostom-i Alert Sensor|Patient will not wear Ostom-i sensor
3013507|NCT02472405|Active Comparator|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
3013573|NCT02471989|Experimental|Low-FODMAP diet|FOS in diet
3013477|NCT02472626|Experimental|Treatment (CPI-613, cytarabine, daunorubicin hydrochloride)|"INDUCTION: Patients receive cytarabine IV continuously on days 1-7, daunorubicin hydrochloride IV on days 1-3, and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 3-7. Patients then undergo biopsy on day 14. Patients experiencing significant residual disease receive cytarabine IV continuously on days 1-5, daunorubicin hydrochloride IV on days 1-2, and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5.~CONSOLIDATION: Beginning 42 days later, patients receive cytarabine IV continuously on days 1-16 and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 2-6. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients not undergoing transplant after consolidation receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
3013478|NCT02472613|Experimental|traditional acupuncture & placebo|Apply traditional acupuncture to treat the ischemic post-stroke depression according to TCM theory.
3013479|NCT02472613|Active Comparator|sham-acupoint acupuncture & fluoxetine|Fluoxetine was given at a dose of 20 mg/day. sham-acupoint will be penetrated for treat the ischemic post-stroke depression.
3013480|NCT02472600|Active Comparator|colistin + neomycin followed by FMT|"CAPSULE APPROACH:~Treatment days 1-5~Colistin sulphate 2 million IU per os 4x/day (for 5 days)~Neomycin sulphate 500 mg (salt) per os 4x/day (for 5 days) Treatment day 6: no treatment~Treatment days 7 and 8:~-15 capsules of capsulized Fecal microbiota transplantation (FMT) per os per day~NASOGASTRIC TUBE APPROACH:~Treatment days 1-5~Colistin sulphate 2 million IU per os 4x/day (for 5 days)~Neomycin sulphate 500 mg (salt) per os 4x/day (for 5 days)~Treatment day 6 and 7:~- Omeprazole 20 mg per os 1 dose on the evening of day 6 and on the morning of day 7~Treatment day 7:~- Infusion of 80 ml of a standardized stool suspension through a nasogastric tube - Fecal microbiota transplantation (FMT)"
3013481|NCT02472600|No Intervention|No intervention|Control arm without any intervention
3013482|NCT02472587||Pap test|Women attending our institute in order to do Pap test
3013483|NCT02472574|Experimental|0.3 mg|Subjects randomized to the 0.3 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle, followed by up to 4 doses of 0.3 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
3013484|NCT02472574|Experimental|0.5 mg|Subjects randomized to the 0.5 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle,followed by up to 4 doses of 0.5 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
3013485|NCT02472574|Experimental|1.0 mg|Subjects randomized to the 1.0 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle,followed by up to 4 doses of 1.0 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
3013486|NCT02472561|Experimental|Mobile Health Application Group 1|"Participants will wear a Fitbit Physical Activity Monitor to objectively quantify physical activity patterns. Once a week (± 3 days) during the 12 week mHealth intervention patients will measure and download their blood pressure and blood glucose (if diabetic) by means of a mHealth blood pressure cuff and mHealth glucometer. Medication adherence will be measured at baseline and 12-weeks by the Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire. Each participant will be provided with a electronic version of the book titled, Your COMPLETE and EASY GUIDE to Understanding Peripheral Artery Disease; patients will be asked to read approximately one chapter per week for educational purposes."
3013487|NCT02472561|No Intervention|Usual Care Group 2|"Participants will follow standard care as ordered by their individual, treating physician. Each participant will be given a paperback copy of the book, Your COMPLETE and EASY GUIDE to Understanding Peripheral Artery Disease. All participants will be contacted by study personnel in order to schedule visits at baseline and 12-weeks for the outcome assessments."
3013488|NCT02472548|Experimental|Group A, DPX-RSV(A) low dose (Step 1)|
3013489|NCT02472548|Experimental|Group B, RSV(A)-Alum low dose (Step 1)|
3013490|NCT02472548|Experimental|Group D, DPX-RSV(A) high dose (Step 2)|
3013491|NCT02472548|Experimental|Group E, RSV(A)-Alum high dose (Step 2)|
3013492|NCT02472548|Placebo Comparator|Group C & F, Placebo control (Step 1 and 2)|
3013493|NCT02472535|Experimental|placebo, MBX-8025 50 mg, 100 mg or 200 mg capsules|
3013494|NCT02472522|Placebo Comparator|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
3013495|NCT02472522|Experimental|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with addition of Dexmedetomidine 1 micrograms/kg to with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
3013496|NCT02472509|Experimental|Open Label|32 patients with hemolytic disorders meeting the inclusion and exclusion criteria will be commenced on Ursodeoxycholic acid (UDCA).
3013497|NCT02472483|Experimental|bipolar disorder|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
3013498|NCT02472483|Experimental|anxious disorders|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
3013499|NCT02472483|Experimental|alcohol disorder|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
3013500|NCT02472470|Experimental|Treatment|intermitten TBS (iTBS) rTMS applied to the left Dorsolateral Prefrontal Cortex (DLPFC) + continuous TBS (cTBS) rTMS applied to the right DLPFC. The order will be counterbalanced. Administration of this treatment takes roughly 10 minutes. This treatment will be applied daily, 5 days/week, for 2 weeks.
3013501|NCT02472457|Placebo Comparator|Free Diet|No dietary restrictions
3013502|NCT02472457|Active Comparator|Crohn Disease Exclusion Diet|The CDED is a palatable diet that excludes foods suspected to have a role in intestinal inflammation.
3013503|NCT02472431|Experimental|ADRC injection|
3013504|NCT02472418|Experimental|DFN-15 120 mg (treatment A)|DFN-15 120 mg (treatment A)
3013505|NCT02472418|Experimental|DFN-15 240 mg (treatment B)|DFN-15 240 mg (treatment B)
3013506|NCT02472418|Placebo Comparator|Placebo (treatment C)|Placebo (treatment C)
3013508|NCT02472405|Active Comparator|595/1064nm Multiplex Laser|One third of the scar will be treated with 595/1064nm Multiplex laser for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
3013509|NCT02472405|No Intervention|Control|One third of the scar will be left untreated for the duration of the study. A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
3013510|NCT02472392|Active Comparator|Treatment Plan A|Rabbit anti-thymocyte globulin (ATG) will be given only to unrelated donor transplant recipients at a dose of 3 mg/kg/day I.V. Equine ATG at a dose of 30mg/kg/day may be substituted in the event of severe allergic reaction to the rabbit ATG. Rabbit ATG is only used with recipients of unrelated donor marrow or peripheral blood transplants. Busulfan (BU) will be given at a dose of 0.8 mg/kg IV q 6 hrs. BU doses will be modified based upon pharmacokinetics data to maintain steady state levels of 600-900 ng/dl. Seizure prophylaxis with levetiracetam should begin prior to the 1st dose of BU and stoped 24 hrs after the last dose of BU. Melphalan will be given at a dose of 60 mg/m2 I.V. over 15-20 min per Pediatric SCT Standards of Practice Manual.
3013511|NCT02472392|Active Comparator|Treatment Plan B|Rabbit anti-thymocyte globulin (ATG) will be given only to unrelated donor transplant recipients at a dose of 3 mg/kg/day I.V. Equine ATG at a dose of 30mg/kg/day may be substituted in the event of severe allergic reaction to the rabbit ATG. Rabbit ATG is only used with recipients of unrelated donor marrow or peripheral blood transplants. Fludarabine will be given at a dose of 30 mg/m2/day IV over 30 mins for 5 doses. Cyclophosphamide will be given at a dose of 50 mg/kg/day IV over 2 hrs for 4 doses.
3013512|NCT02472379|Experimental|Writing: Group 1|Subjects will be asked to write about experiences with familiar individuals in their lives.
3013513|NCT02472379|Placebo Comparator|Writing: Group 2|Subjects will be asked to write about experiences with familiar places in their lives.
3013514|NCT02472366|Other|laser|laser with or without prior history of intraocular corticosteroid therapy
3013515|NCT02472366|Other|laser and anti-VEGF|laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
3013516|NCT02472353|Active Comparator|Standard of Care|Patients will receive standard of care for their breast cancer with no metformin during their treatment with doxorubicin.
3013517|NCT02472353|Experimental|Metformin + Standard of Care|Patients will receive metformin during their treatment with doxorubicin for their breast cancer.
3013518|NCT02472340||Sedentary, Pre-frail|10 sedentary, pre-frail elderly, >61 year of age
3013519|NCT02472340||Active, Healthy|10 Active, healthy elderly, >61 years of age
3013520|NCT02472327|No Intervention|Typical Care|These patients will receive normal peripartum care and support.
3013521|NCT02472327|Experimental|Pre-operative support|These patients will receive additional emotional support prior to undergoing an unplanned cesarean section during labor.
3013522|NCT02472314|Experimental|Liposomal Bupivacaine A|One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty
3013523|NCT02472314|Active Comparator|CISB control for A|Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .
3013524|NCT02472314|Experimental|Liposomal Bupivacaine B|One time injection of 1.3% Liposomal Bupivacaine during Humerus Fracture Fixation
3013525|NCT02472314|Active Comparator|CISB control for B|Peripheral nerve block (CISB) with 0.125% bupivacaine during fracture fixation
3013526|NCT02472301|Experimental|Cowpeas|Cowpea supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
3013527|NCT02472301|Experimental|Common bean|Common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
3013528|NCT02472301|Active Comparator|Corn Soy Flour|Corn flour with 10% soy supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
3013529|NCT02472288|Experimental|Electroacupuncture (EA) group|"Electroacupuncture therapy (10 sessions in total, 5 per a week, 2 weeks)~BL31, BL32, BL33, and BL34 (total 8 acupoints, bilateral)~20 minutes duration, middle frequency (30 Hz) of electrical stimulation~conventional treatments permitted"
3013530|NCT02472288|Sham Comparator|Sham group|"Non-penetrating Park sham electroacupuncture treatment (10 sessions in total, 5 per a week, 2 weeks)~BL31, BL32, BL33, and BL34 (total 8 acupoints on the right and left sides)~20 minutes duration, undelivered electrostimulation of middle frequency (30 Hz)~conventional treatments permitted"
3013531|NCT02472275|Experimental|Treatment (PLX3397, radiation therapy, ADT)|Patients receive multitargeted tyrosine kinase inhibitor PLX3397 PO BID for 6 months, undergo radiation therapy for 2 months daily (Monday-Friday) beginning at month 3, and undergo ADT with leuprolide acetate, goserelin acetate, or degarelix injections in any month.
3013532|NCT02472262|Experimental|Cowpeas|A legume-based complementary food made from cowpeas will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
3013533|NCT02472262|Experimental|Common bean|A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
3013534|NCT02472262|Active Comparator|Corn Soy Flour|Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
3013535|NCT02472249|Experimental|Norepinephrine intra-arteriel/hepatic|This is the only arm of this study. These patients will receive 24 micrograms of norepinephrine in the hepatic artery with subsequent CT perfusion imaging to evaluate liver blood flow.
3013536|NCT02472236|Experimental|Digoxin and PEX168(200µg)|Digoxin: 0.5mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
3013537|NCT02472223|Active Comparator|Betadine 5%|One time in-office use (4-5 drops)
3013538|NCT02472223|Placebo Comparator|Artificial Tears|Standard of Care
3013539|NCT02472210|Placebo Comparator|Placebo|Saline IM Injection
3013540|NCT02472210|Active Comparator|Onabotulinum Toxin A|IM Injection
3013541|NCT02472197|Experimental|morcellation|
3013542|NCT02472197|Active Comparator|standard resection|
3013543|NCT02472184|Active Comparator|Office Hysteroscopy|Group of patients in which office hysteroscopy will be performed prior to endometrial biopsy
3013574|NCT02471989|Active Comparator|Classical GERD diet|avoid fatty meals, head of bed elevation...
3013545|NCT02472171|Experimental|Group 1|"Order of treatments:~A. High saturated fat meal, placebo powder and sunflower oil B. High saturated fat meal, blueberry powder and sunflower oil C. High saturated fat meal, placebo powder and DHA"
3013546|NCT02472171|Experimental|Group 2|"Order of treatments:~A. High saturated fat meal, placebo powder and sunflower oil C. High saturated fat meal, placebo powder and DHA B. High saturated fat meal, blueberry powder and sunflower oil"
3013547|NCT02472171|Experimental|Group 3|"Order of treatments:~B. High saturated fat meal, blueberry powder and sunflower oil A. High saturated fat meal, placebo powder and sunflower oil C. High saturated fat meal, placebo powder and DHA"
3013548|NCT02472171|Experimental|Group 4|"Order of treatments:~B. High saturated fat meal, blueberry powder and sunflower oil C. High saturated fat meal, placebo powder and DHA A. High saturated fat meal, placebo powder and sunflower oil"
3013549|NCT02472171|Experimental|Group 5|"Order of treatments:~C. High saturated fat meal, placebo powder and DHA B. High saturated fat meal, blueberry powder and sunflower oil A. High saturated fat meal, placebo powder and sunflower oil"
3013550|NCT02472171|Experimental|Group 6|"Order of treatments:~C. High saturated fat meal, placebo powder and DHA A. High saturated fat meal, placebo powder and sunflower oil B. High saturated fat meal, blueberry powder and sunflower oil"
3013551|NCT02472158|Experimental|chlorhexidine-gel-impregnated dressing|Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
3013552|NCT02472158|Active Comparator|Polyurethane film dressing|Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
3013553|NCT02472145|Experimental|Decitabine plus Talacotuzumab|"Part A: For Cycle 1 of Part A, participants will receive talacotuzumab on Day 1. Starting from Cycle 2 of Part A, participants may receive decitabine on Day 1, 2, 3, 4, and 5, and talacotuzumab on Day 8 and 22 of a 28-day cycle.~Part B Arm 1: Participants will receive decitabine on Day 1, 2, 3, 4, and 5, and talacotuzumab on Day 8 and 22 of a 28-day cycle."
3013554|NCT02472145|Active Comparator|Decitabine|Participants in Part B Arm 2 will receive decitabine on Day 1,2, 3, 4 and 5 of a 28-day cycle.
3013555|NCT02472132|Experimental|Intervention|Prospective implantation of POC US for CVC tip placement.
3013556|NCT02472132|No Intervention|Control|Retrospective data collection for CVC placement in the medical and surgical ICUs, before the initiation of the study and without the use of POCUS for CVC tip placement.
3013557|NCT02472119|Experimental|rusks made with treated flour|Gluten-free diet adding rusks (100g / day) produced with commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester.
3013558|NCT02472119|Active Comparator|rusks made with not-treated flour|Gluten-free diet adding rusks (100g / day) produced with untreated wheat flour.
3013559|NCT02472093|Active Comparator|Physical exercises treatment|The types of exercises included: low-impact to moderate aerobic training (gradually starting from 50% of the Fc max to 70%-80% of Fc max); walking fast in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes) for a total of 20 consecutive minutes; posture exercises for the back and proprioceptive exercises for the trunk in the supine position to improve axial stability, including diaphragmatic breathing.
3013560|NCT02472093|Experimental|Perceptive Rehabilitation Treatment|Perceptual surfaces is a therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips; usually, over 100 cones are used for each session. Patients were asked to lie down supine on the surface that was formed by the smoothed apex of these cones, creating reaction forces to the patient's weight, generated by the interaction with the cones.
3013561|NCT02472093|Active Comparator|Control group|The control group did brief educational sessions.
3013562|NCT02472080|Experimental|gemcitabine -oxaliplatine combination|
3013563|NCT02472067|No Intervention|Physical Therapy|Usual care of physical therapy and rehabilitation for a musculoskeletal injury. Patients complete self-rated standardized surveys before and following treatment.
3013564|NCT02472067|Experimental|Psychologically-Based Physical Therapy|Psychologically-Based Physical Therapy includes the early identification and management of psychological obstacles to recovery in order to modify maladaptive responses previously found to be associated with chronicity and disability. This is accomplished through patient education, an emphasis on functional goals and encouraging self-care techniques. Patients complete self-rated standardized surveys before and following treatment.
3013565|NCT02472054|Experimental|hemophagocytic lymphohistiocytosis (HLH)|"Alemtuzumab (CAMPATH®)~Initial Treatment (D1 to D3) D1: 0.5 mg / kg / day Alemtuzumab combined with 2 mg /kg/d of IV Methylprednisolone (MP) or PO Prednisolone, and IVC or PO cyclosporine (CSA) (target rate from 150 to 200 ng / ml in the absence of renal failure) D2 and D3: 1 mg / kg / day Alemtuzumab combined with 2 mg / kg / d of IV MP or PO Prednisolone and IVC or PO CSA (target rate 150-200 ng / ml)~The maximum dose of Alemtuzumab is limited to 30 mg per day (1 vial).~Maintenance treatment (D4 to D14)~MP/Prednisolone progressive tapering starting at D4 (2 mg / kg / day) to reach the dose 0.5 mg / kg / day at D14~CSA IVC or PO at a target rate of 150-200 ng / ml"
3013566|NCT02472041|Experimental|Reanimator Group|Reanimator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®), which was connected in a circuit extending along the Muller Resuscitator equipment applied continuously for four series 10 of the patient breaths active and with an interval of two minutes between them in Fowler 45 position
3013567|NCT02472041|Experimental|Control Group|Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment (Table 1). Guidelines to the active, progressive and early mobilization.
3013568|NCT02472028|Experimental|blood pressure lowering algorithm|enhanced strategy aiming to reduce systolic blood pressure to <135 mmHg
3013576|NCT02471976|Other|Group B|strategy promoting early consideration and collegiate vulnerability of patients
3013577|NCT02471963|Active Comparator|Empagliflozin|Empagliflozin, 25 mg/day, oral administration, 6 weeks
3013578|NCT02471963|Placebo Comparator|Placebo|Placebo, oral administration, 6 weeks
3013579|NCT02471950||Elective Cardiac surgery|Those patients scheduled for elective heart surgery requiring cardiopulmonary bypass who will be given 2.5% isoflurane while on bypass.
3013580|NCT02471937|Experimental|Pregnant women negative for GBS colonization|Only women negative for GBS during all the study will be included.
3013581|NCT02471924|Other|Trans thoraciq cardiac ultrasonography|Trans thoraciq cardiac ultrasonography wil be perforfomed for pregnant women having a spinal or spinal-epidural anesthesia for elective caesarean section. All patients are more 18 years old and more 37 weeks pregnancy
3013582|NCT02471911|Experimental|All subjects|"All subjects will receive KPT-330 (selinexor) on days -5 and -3 starting one week before RICE chemotherapy is started. Once chemotherapy starts, selinexor will be given on days 1, 3, and 5 of each chemotherapy cycle.~RICE chemotherapy will consist of Rituximab, ifosfamide, carboplatin, etoposide, and dexamethasone."
3013583|NCT02471898|Experimental|HTX-011|Evaluate the analgesic efficacy of HTX-011
3013584|NCT02471898|Placebo Comparator|Placebo|Saline
3013585|NCT02471885|Experimental|Remote ischaemic conditioning|Remote ischaemic conditioning in the form of a blood pressure cuff on upper arm inflated upto 200 mm Hg (or systolic BP + 20 mm Hg if low platelets e.g. 50-150 x10^9/L, skip remote ischaemic conditioning (RIC) if platelets < 50 x 10^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes, for 4 cycles before beginning of chemotherapy infusion. The entire pre-conditioning phase will last 40 minutes.
3013586|NCT02471885|Placebo Comparator|Control|Blood pressure cuff on upper arm inflated to 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes, for 4 cycles before beginning of chemotherapy infusion. The entire control comparator will last 40 minutes
3013587|NCT02471872|Experimental|Air Pollution Education|Students are presented with a one-hour interactive information session about air pollution and the environment.
3013588|NCT02471872|Placebo Comparator|Non-Air Pollution Education|Students are presented with a one-hour interactive information session about vaccines.
3013589|NCT02471859|Experimental|Part A: GDC-3280|Participants in multiple cohorts and treatment periods will receive single doses of GDC-3280 under fed/fasting conditions.
3013590|NCT02471859|Placebo Comparator|Part A: Placebo|Participants in multiple cohorts and treatment periods will receive single doses of placebo under fed/fasting conditions.
3013591|NCT02471859|Experimental|Part B: GCD-3280|Participants in different cohorts will receive GDC-3280 in multiple ascending doses under fed/fasting conditions.\n
3013592|NCT02471859|Placebo Comparator|Part B: Placebo|Participants in different cohorts will receive placebo in multiple ascending doses under fed/fasting conditions.\n
3013593|NCT02471846|Experimental|Anti-PD-1/PD-L1 Relapsed Cohort I|Approximately 20 participants whose most recent anti-cancer therapy consisted of single-agent programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade and achieved best response of confirmed complete or partial response, or stable disease will receive GDC-0919, at the MTD or maximum administered dose (MAD) determined during the dose-escalation stage, in combination with atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
3013594|NCT02471846|Experimental|Anti-PD-1/PD-L1 Relapsed Cohort II|Approximately 20 participants whose most recent anti-cancer therapy consisted of single-agent PD-1/PD-L1 blockade and achieved unconfirmed partial response or stable disease will receive GDC-0919, at the MTD or MAD determined during the dose-escalation stage, in combination with atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
3013595|NCT02471846|Experimental|Biopsy Cohort A|Approximately 20 participants with melanoma, HNSCC, gastric, ovarian, Merkel cell, cervical, or endometrial cancer will receive GDC-0919 during Cycle 1, followed by combination treatment with GDC-0919 and atezolizumab from Cycle 2 onwards. Serial biopsies of extrahepatic lesions will be performed. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
3013596|NCT02471846|Experimental|Biopsy Cohort B|Approximately 20 participants with melanoma, HNSCC, gastric, ovarian, Merkel cell, cervical, or endometrial cancer will receive atezolizumab during Cycle 1, followed by combination treatment with GDC-0919 and atezolizumab from Cycle 2 onwards. Serial biopsies of extrahepatic lesions will be performed. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
3013597|NCT02471846|Experimental|Dose-Escalation Cohort(s)|Approximately 6 to 65 participants will be enrolled and treated at escalating doses of GDC-0919 in combination with fixed-dose atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio. Successive groups of at least 3 participants will be evaluated during a 21-day window for DLTs, which will determine the enrollment and dosing for subsequent cohorts in the dose-escalation stage. The MTD or MAD, whichever is reached first, will be considered for the expansion stage.
3013598|NCT02471846|Experimental|Expansion Cohorts|Approximately 160 participants (40 per diagnosis) with NSCLC, RCC, TNBC, and UBC will receive GDC-0919, at the MTD or MAD determined during the dose-escalation stage, in combination with Atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
3013599|NCT02471833|Experimental|Telmisartan 20mg|African American subjects with hypertension and at high risk for Alzheimer's disease will be randomly assigned to receive Telmisartan 20mg once a day orally.
3013600|NCT02471833|Experimental|Telmisartan 40mg|African American subjects with hypertension and at high risk for Alzheimer's disease will be randomly assigned to receive Telmisartan 40mg once a day orally.
3013601|NCT02471833|Placebo Comparator|Placebo|African American subjects with hypertension and at high risk for Alzheimer's disease will be randomly assigned to receive placebo once a day orally.
3013602|NCT02471820|Experimental|Lenalidomide, adriamycin & dexamethasone|Lenalidomide 25 mg administered orally for the first 21 days of each 28-day-cycle, plus Adriamycin i.v. on days 1,2,3 & 4 of every cycle, plus Dexamethasone 40 mg orally on days 1, 8, 15 & 22 of every cycle for 4 cycles
3013603|NCT02471807|Experimental|Edwards FORMA Tricuspid Transcatheter Repair System|Edwards FORMA Tricuspid Transcatheter Repair System
3014078|NCT02468440|Experimental|ESPAIR|Patients with an educational therapy's program since registration in transplant list.
3013604|NCT02471794|No Intervention|Standard Shared Medical Appointment|The SMA group will be a standard shared diabetes medical appointment group consisting of up to 10 patients that utilizes the design and curriculum of the SMAs that are currently being held at the Duke Family Medicine Center.
3013605|NCT02471794|Experimental|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum.
3013606|NCT02471794|No Intervention|Retrospective|A retrospective chart review will be conducted once all participants (both SMA group and PHP SMA group) complete the intervention. The retrospective chart review will collect healthcare utilization data six months prior, during, and after each subject's participation in the SMA.
3013607|NCT02471755|Active Comparator|Electro-acupuncture Group|
3013608|NCT02471755|Placebo Comparator|Sham Electro-acupuncture Group|
3013609|NCT02471742||NAC-PC|patients treated with neoadjuvant chemotherapy and NAC-sparing mastectomy
3013610|NCT02471742||NAC|patients treated NAC-sparing mastectomy and adjuvant therapy
3013611|NCT02471742||PC|patients treated with neoadjuvant chemotherapy and conventional mastectomy
3013612|NCT02471729|Experimental|Renal Denervation|patients with chronique heart failure will undergo EnligHTN™ Renal Denervation System as a complementary treatment of their therapy
3013613|NCT02471716|Experimental|Phase 1 FPA008 Dose Escalation|IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose or lower dose that provide adequate PK exposure and biologic activity with tolerability.
3013614|NCT02471716|Experimental|Phase 2 FPA008 Dose Expansion|IV infusion; once MTD and/or RD has been determined in Phase 1, expansion cohorts of approximately 30 patients (each cohort) with PVNS or dt-TGCT will be enrolled to characterize clinical activity and safety profile of the RD. Treatment is planned to continue for up to 24 weeks or 56 weeks.
3013615|NCT02471703||SMF mini-stem hip replacement recipient|Received the device via total hip arthroplasty
3013616|NCT02471690|Active Comparator|Oritavancin|IV -Single Dose - 1200 mg Oritavancin
3013617|NCT02471690|Placebo Comparator|Placebo|250 mL Dextrose 5% in Water
3013618|NCT02471677|Active Comparator|Puregon|Patients will undergo ovarian stimulation using daily injections of recombinant FSH (Puregon), as performed traditionally in IVF cycles
3013619|NCT02471677|Experimental|Elonva|Patients will undergo ovarian stimulation using a single injection of corifollitropin alfa (Elonva)
3013620|NCT02471664|Experimental|Single|Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device
3013621|NCT02471651|Active Comparator|Implant|Subjects randomized to dexamethasone intravitreal implant (0.7mg) will receive the initial treatment at Month 3 (visit 4) and Month 6 (visit 7) and are eligible to receive one additional dose at Month 9 (visit 10), Month 10 (visit 11) or Month 11 (visit 12) for persistent or recurrent macular edema documented on SDOCT. If dexamethasone intravitreal implant (0.7mg) is administered at Month 10 (visit 11) or Month 11 (visit 12) an additional safety study visit will be required at one to two months following Month 12 (visit 13). The investigator can withhold treatment with dexamethasone intravitreal implant (0.7mg) beginning at Month 9 if there is complete resolution of diabetic macular edema document on SDOCT.
3013622|NCT02471651|Active Comparator|Intravitreal anti-VEGF injection|Subjects randomized to continue on anti-vegf therapy will receive intravitreal anti-vegf injections at Month 3 (visit 4) Month 4 (visit 5) and Month 5 (visit 6). Beginning at Month 6 (visit 7), subjects who have received 6 intravitreal anti-vegf injections and continue to present with persistent diabetic macular edema defined as less than 10% reduction or any increase in CST compared to baseline values and CST is greater than 300 microns, will receive dexamethasone intravitreal implant (0.7mg) at Month 6 (visit 7) and Month 9 (visit 10). The follow-up period for all subjects will continue through 12 months from the baseline study visit.
3013623|NCT02471638|Experimental|Single arm study|PQ Bypass System for Femoropopliteal Bypass to complete percutaneous fem-pop bypass
3013624|NCT02471625||Traumatic Brain Injury|Men and women ages 18-65 with suspected acute head trauma within 24-72hrs. of presentation, scoring a 3-15 on initial evaluation on GCS scale.
3013625|NCT02471625||Control|Men and women ages 18-65 with no history of head trauma and a score of 15 on the GCS scale.
3013626|NCT02471599|Experimental|tonsillectomy group|The case group will receive tonsillectomy.
3013627|NCT02471599|Active Comparator|non-tonsillectomy group|The controlled group will not receive tonsillectomy.
3013628|NCT02471586|Active Comparator|Coronary PCI guided by IVUS|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with IVUS guidance according to local standard practice. IVUS imaging is required pre and post stent implantation.~At the end of the procedure, a final IVUS imaging run must be performed.~After the final IVUS run, a blinded OCT imaging run shall be performed to document final stent dimensions and results."
3013629|NCT02471586|Active Comparator|Coronary PCI guided by OCT|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with OCT guidance according to the algorithm described in the protocol. OCT imaging is required pre and post stent implantation.~At the end of the procedure, a final OCT imaging run must be performed."
3013630|NCT02471586|Active Comparator|Coronary PCI guided by Angiography|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with angiography guidance according to local standard practice.~At the end of the procedure, a blinded OCT shall be performed to document final stent dimensions and results."
3013631|NCT02471573|Active Comparator|Freeze-all protocol|Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.
3013632|NCT02471573|Active Comparator|Fresh transfer protocol|Two embryos are selected and transferred fresh in the same cycle.
3013633|NCT02471560|Experimental|dimethyl fumarate|As prescribed by the Investigator according to the local Summary of Product Characteristics.
3051230|NCT02219048|Placebo Comparator|Placebo|Matched blinded placebo
3013634|NCT02471560|Active Comparator|injectable MS DMT|As prescribed by the Investigator according to the local Summary of Product Characteristics.
3013635|NCT02471547|No Intervention|TURBT ONLY|"A total of 150 patients in this arm will be divided into five follow-up sub groups according to pathology reports.~Group 1 - Primary Low risk patients Group 2 - Primary Intermediate risk patients Group 3 - Primary High risk patients Group 4 - Recurrent Intermediate risk patients Group 5 - Recurrent Intermediate risk patients"
3013636|NCT02471547|Experimental|BWT with Mitomycin-C prior TURBT|"A total of 150 patients in this arm will be divided into five follow-up sub groups according to pathology reports.~Group 1 - Primary Low risk patients Group 2 - Primary Intermediate risk patients Group 3 - Primary High risk patients Group 4 - Recurrent Intermediate risk patients Group 5 - Recurrent Intermediate risk patients"
3013637|NCT02471534|Experimental|Pediatric patients with hypovolemia|Right upper abdominal compression is performed in patients with hypovolemic signs including hypotension, decreased urine output and central venous pressure less than 5 mmHg. Changes of blood pressure during abdominal compression is continuously recorded.
3013638|NCT02471521|Experimental|infant 1|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed with or without rocuronium in patients younger than 6 months old while continous gastric auscultation and abdominal sonography are performed.
3013639|NCT02471521|Experimental|infant 2|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed with or without rocuronium in patients aged between 6 and 12 months old while continous gastric auscultation and abdominal sonography are performed.
3013640|NCT02471521|Experimental|child|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed with or without rocuronium in patients aged between 1 and 5 years old while continous gastric auscultation and abdominal sonography are performed.
3013641|NCT02471508|Experimental|Tank top with biofeedback system|"The design of biofeedback tank-top will incorporate sensors to record and monitor the posture of the wearer in real time basis. Alerts will be emitted to the wearer once poor posture is detected. The tank-top will be designed to fit the wearer's body and allow the sensor to be placed securely at the targeted position along the spine to minimize the noise from other factors than the wearers' posture and yet comfortable for long-term wearing."
3013642|NCT02471495|Experimental|Synergo® RITE + MMC|"Induction~Patients will receive 8 weekly treatments of Synergo® RITE + MMC, using the Synergo® System. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. These 8 treatments will be followed by a pause (see Table 1), after which a follow-up cystoscopy (first follow-up control) will be conducted during Weeks 12-13 (from the first treatment).~Maintenance~Patients will receive one Synergo® RITE + MMC treatment every 6 weeks. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. Maintenance treatments will be given until the end of 12 months after the patient's first induction treatment."
3013643|NCT02471482|Experimental|Music First group|"Mozart music lullaby for 30 minutes with recording of cerebral oxygenation (by using Near infrared spectroscopy) and vital signs (respiratory rate, heart rate, oxygen saturations and frequency of apneic episodes continuously) followed by 10 minutes of washout period and then period of no music for next 30 minutes (with same variables recorded as outlined for music session).~This cycle is repeated every 6 hours for 24 hours. In addition, the behavioral response of baby is observed during the study period by video recording which will be in 'Mute' video mode and then reviewed by our developmental staff"
3013644|NCT02471482|Experimental|No Music First group|"No music in first 30 minutes of study followed by 10 minutes of washout period and then 30 minutes of Mozart music lullaby while recording same variables. This cycle was repeated every 6 hours for 24 hours."
3013645|NCT02471456||EVH|Patients that have undergone Endoscopic Vein Harvesting (EVH)
3013646|NCT02471456||OVH|Patients that have undergone open vein harvest (OVH)
3013647|NCT02471443||Surgery for severe endometriosis|Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement
3013648|NCT02471430|Experimental|Arm A|Participants in Arm A will receive panobinostat as an oral tablet on days 0, 2, and 4 of the treatment week. The dose of panobinostat will be a 10 mg tablet.
3013649|NCT02471430|Experimental|Arm B|Participants in Arm B will receive one subcutaneous injection of pegylated Interferon-alpha2a on day 0. The dose of pegylated IFN-alpha2a will be 180 mcg. Simultaneously with interferon-alpha2a, a 10 mg tablet of panobinostat will be administered on day 0. Participants will also receive panobinostat as an oral tablet on days 2 and 4 of the treatment week.
3013650|NCT02471417|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
3013651|NCT02471417|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
3013652|NCT02471404|Active Comparator|Dapagliflozin+metformin|Dapagliflozin + saxagliptin placebo + glimepiride placebo + metformin
3013653|NCT02471404|Active Comparator|Dapagliflozin+saxagliptin+metformin|Dapagliflozin + saxagliptin + glimepiride placebo+ metformin
3013654|NCT02471404|Active Comparator|Glimepiride+metformin|Glimepiride + dapagliflozin placebo + saxagliptin placebo + metformin
3013655|NCT02471391|Experimental|Ibrutinib + ABT-199|
3013656|NCT02471352||2-Healthy Volunteers|Healthy Volunteers
3013657|NCT02471352||1-Skin disease or at risk|Subjects with a skin disease or at risk of developing a skin disease/ Family member of persons with a skin disease
3013658|NCT02471339|Experimental|1/ACT|2 ACT Training Sessions followed by weekly emails and video chats
3013659|NCT02471339|Active Comparator|2/WL|Waitlist group - no intervention for first 8 weeks (then will receive ACT intervention as Arm 1)
3013660|NCT02471326|Experimental|HIV Positive Subjects|VRC-HIVMAB060-00-AB (VRC01) given in HIV-infected Adults (age 18-65 years) on cART with suppressed viremia
3013661|NCT02471313|Experimental|A|Patients with primary hepatic malignancy
3013662|NCT02471274|Experimental|Group 1|healthy control subjects with normal hepatic function
3013663|NCT02471274|Experimental|Group 2|subjects with mild hepatic impairment
3013664|NCT02471274|Experimental|Group 3|subjects with moderate hepatic impairment
3013665|NCT02471274|Experimental|Group 4|subjects with severe hepatic impairment
3014079|NCT02468440|No Intervention|normal care|Patients without educational therapy
3013666|NCT02471248|Experimental|Ankle Robot with Power Assistance|In this experimental group, the Ankle Robot assists the ankle dorsiflexion when the stroke patients voluntarily perform the swing phase gait movement.
3013667|NCT02471248|Placebo Comparator|Sham group|In this sham group, the Ankle Robot provides very low assistance to generate tactile feedback to the stroke patients indicating they are performing the swing phase gait movement, but no assistance will be given to support their ankle dorsiflexion.
3013668|NCT02471235|Experimental|Intervention group|The physiotherapist will provide every patient an individualized physical training programme that fits their cardiopulmonary status. Patients will have the training as out-patient in the physiotherapy department for 4-8 sessions, 2 hours each time, 1-2 times weekly. Home exercise will be taught. Our case manager will give phone calls to the subject every 2 weeks to provide support and reinforcement for having continuous exercise at home for one year. Patients will be invited to attend reinforcement out-patient physiotherapy training once very month or every 2 months if they are willing to attend.
3013669|NCT02471235|No Intervention|Control group|The control group will receive no physiotherapy training by physiotherapist and no phone calls from case manager for reinforcement of home exercise. .
3013670|NCT02471222|Experimental|ADS-5102 (amantadine HCl extended release)|
3013671|NCT02471222|Placebo Comparator|Placebo|
3013672|NCT02471209||Biliary Atresia Infants|Twenty-five infants diagnosed with Biliary Atresia and undergoing surgery were included in the study (age range 1-3 months). Inclusion criteria were persistent yellow skin or sclera, pale stool (in severe cases, clay-like), and hepatomegaly; increased serum bilirubin (progressively or no decline after increase), increased total bilirubin (TBil) dominated by increased direct bilirubin (DBil) (>60%); elevated liver enzymes; ultrasound confirmation of poor gallbladder filling and signs of liver fibrosis; with radionuclide imaging confirmation of obstructed biliary excretion. Infants were excluded if they had concomitant cardiovascular or abdominal organ malformations.
3013673|NCT02471196|Experimental|ORM-12741 low dose|ORM-12741 low dose twice a day for 12 weeks.
3013674|NCT02471196|Experimental|ORM-12741 high dose|ORM-12741 high dose twice a day for 12 weeks.
3013675|NCT02471196|Placebo Comparator|Placebo|Placebo twice a day for 12 weeks.
3013676|NCT02471183|Experimental|Selexipag, Open Label|"Subjects on inhaled treprostinil treatment participate in a 16-week main treatment period including down-titration of treprostinil to end of Week 8 and parallel up-titration of selexipag to the maximum tolerated dose (MTD) up to Week 12, for each individual patient but not above 1600 mcg twice daily.~From Week 12 up to Week 16, patients continue selexipag at their individual MTD. Patients could continue the study drug selexipag during the extended treatment period from Week 16 until commercial availability of selexipag."
3013677|NCT02471157||Eugonadal|Eugonadal men
3013678|NCT02471157||Hypogonadal|Hypogonadal men
3013679|NCT02471144|Experimental|Secukinumab low dose|Secukinumab
3013680|NCT02471144|Experimental|Secukinumab high dose|Secukinumab
3013681|NCT02471144|Placebo Comparator|Placebo|Placebo
3013682|NCT02471144|Active Comparator|Etanercept Comparator|Etanercept
3013683|NCT02471131|Experimental|WATCHMAN Implantation|
3013684|NCT02471118|Experimental|1st 50 subjects to Enter the Study|"At Baseline, subjects will be randomized (1:1) to receive study drug (Adalimumab or placebo). The study drug will be provided as a subcutaneous injection (pre-filled syringe) either Adalimumab (ADA) 40 mg/0.8 mL,every other week (EOW) or matching placebo for Adalimumab every other week for 16 weeks. Efficacy will be assessed at Week 16 while the safety of the study drug will be monitored throughout the study.~At Week 16 all subjects will begin to receive open label ADA 40 mg EOW and will continue to receive open label ADA up to Week 50. An End of Study visit will be done at Week 52. A Telephone Follow-up will be done at Week 62 to review Adverse Events and Concomitant Medications."
3013685|NCT02471118|Experimental|2nd group of 50 subjects|At Baseline, subjects will be randomized (1:1) to receive either adalimumab 40 mg every other week or placebo for 16 weeks. All subjects will begin to receive open label adalimumab 40 mg every other week from week 16-week 30, with An End of Study visit at Week 32. A Telephone Follow-up will be done at Week 42 to review Adverse Events and Concomitant Medications.
3013686|NCT02471105|Experimental|Lumigan 0.01% + Saflutan 15 µg/ml|Bimatoprost 0.01 % Eye drops solution Topical use Once in the evening 3 months
3013687|NCT02471105|Experimental|Saflutan 15 µg/ml + Lumigan 0.01%|Tafluprost Unit Dose Preservative Free 15microgram/ml Eye drops solution Topical use Once in the evening 3 months
3013688|NCT02471092|Placebo Comparator|Water Control|Skim milk products. Water and permeate control; 250mL serving.
3013689|NCT02471092|Active Comparator|Skim Milk|Skim milk products. Skim milk (regular 80:20 protein ratio); 250mL serving.
3013690|NCT02471092|Experimental|High Protein Milk|Skim milk products. High protein milk (regular 80:20 protein ratio); 250mL serving.
3013691|NCT02471092|Experimental|High Protein Milk (Modified Ratio)|Skim milk products. High protein milk with modified protein ratio (40:60 ratio); 250 mL serving.
3013692|NCT02471092|Experimental|Skim Milk (Modified Ratio)|Skim milk products. Skim milk with modified protein ratio (40:60 ratio); 250 mL serving.
3013693|NCT02471066|Experimental|active rTMS|12 patients will be enrolled in this arm.
3013694|NCT02471066|Sham Comparator|sham rTMS|12 patients will be enrolled in this arm.
3013695|NCT02471053|Experimental|Moderate Intensity Exercise|All consenting patients will participate in an aerobic training program, twice-weekly over a 12-week period. Assessments will be performed at baseline (pre-training) and post-program (12-weeks). All participants will continue to receive standard care for their cancer diagnosis.
3013696|NCT02471040|Experimental|Type 1 diabetic subjects|Subjects will undergo a hyperinsulinemic-hypoglycemic clamp with a target glucose level of 55mg/dl. Once a stable glycemic state is reached, subjects will receive a bolus-continuous infusion beta-hydroxybutyrate (BHB) or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study. Throughout the BHB or saline infusion cognitive function will be tested via a standardized testing battery.
3013697|NCT02471040|Active Comparator|Healthy Subjects|Healthy control subjects will undergo a hyperinsulinemic-hypoglycemic clamp with a target glucose level of 55mg/dl. Once a stable glycemic state is reached, subjects will receive a bolus-continuous infusion beta-hydroxybutyrate (BHB) or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study. Throughout the BHB or saline infusion cognitive function will be tested via a standardized testing battery.
3013698|NCT02471027||Experimental group|2009 FIGO staging ⅠB2 or ⅡA2，the treatment is neoadjuvant chemotherapy combined with cervical cancer radical surgery .
3013699|NCT02471027||control group|2009 FIGO staging ⅠB2 or ⅡA2，the treatment is cervical cancer radical surgery.
3013700|NCT02471014||Obese Individuals|Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.
3013701|NCT02471014||Normal Individuals|Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.
3013702|NCT02471001||Heart Surgery Using Heart-lung Machine|All patients who scheduled for an elective heart surgery in Royal Infirmary of Edinburgh using a heart-lung machine and the administration of ether-like anaesthetic, isoflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being two additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
3013703|NCT02470988|Active Comparator|CBASP|Cognitive Behavioural Analysis System of Psychotherapy (CBASP) is a form of therapy specifically designed to treat individuals with chronic depression. CBASP combines a number of elements, with a focus on teaching the client to become aware of their interpersonal behaviour and its consequences.
3013704|NCT02470988|Experimental|CBASP Without DPI|In this arm CBASP will be delivered without Disciplined Personal Involvement (DPI) by the therapist.
3013705|NCT02470962||Patients with muscular dystrophy|Boys aged 8 to 18 years with muscular dystrophy of the Duchenne / Becker type
3013706|NCT02470962||Children without heart disease|Children without heart disease, aged 8-18 years, as CMR comparison group
3013707|NCT02470949|Experimental|Low Social Status|Low Social Status Condition in Monopoly Game.
3013708|NCT02470949|Experimental|High Social Status|High Social Status Condition in Monopoly Game
3013709|NCT02470936|Experimental|Group 1- Lifestyle Intervention|Men will receive a web-based, personalized lifestyle program. They will receive personalized prostate cancer-specific lifestyle recommendations on specific habits based on their eligibility survey responses. They will have access to online lifestyle modules on the website (diet, exercise, not smoking, support, research), receive a Fitbit and access to a Fitbit account and community, and receive text messages and refrigerator magnet to reinforce behaviors. The website will be updated frequently with new tips and material and two weekly blogs will be maintained. Final content is reviewed by study investigators and patient advocates. Men will complete an intervention acceptability survey (acceptability of the website and intervention components) at 3 months.
3013710|NCT02470936|No Intervention|Group 2 - Control|Men randomized to the control group will receive standard of care. They will receive access to the website for a short period (e.g., 1 month) and prostate cancer-specific lifestyle recommendations on the 8 healthy habits targeted after the 3 month trial.
3013711|NCT02470923|Other|Group 1|Usual care including medical advice to quit and confrontation with abnormal spirometry results if relevant.
3013712|NCT02470923|Other|Group 2|Intensive counseling (15 minutes) by a smoking cessation counselor including confrontation with abnormal spirometry results if relevant, and follow up for at least 5 weeks after discharge (will be done weekly by phone for five consecutive weeks).
3013713|NCT02470923|Other|Group 3|Intensive counseling (15 minutes) by a smoking cessation counselor including confrontation with abnormal spirometry results if relevant, offering and providing nicotine replacement therapy (NRT) and follow up (will be done weekly by phone for five consecutive weeks).
3013714|NCT02470910|Experimental|Magnetic resonance imaging|MRI examination after intraprostatic fiducial markers have been placed and prior to beginning radiotherapy
3013715|NCT02470897|Experimental|Arm A (moderate dose SBRT with SIB)|"Patients undergo 5 fractions of moderate dose SBRT with SIB every other day for 10 days following urethral-sparing IMRT planning.~SBRT: 8.0Gy escalated dose"
3013716|NCT02470897|Active Comparator|Arm B (uniform dose SBRT)|"Patients undergo 5 fractions of uniform dose SBRT every other day for 10 days following urethral-sparing IMRT planning.~SBRT: 7.5Gy conventional dose"
3013717|NCT02470884|Experimental|FAST|Subjects treated with the Boston Scientific Fully Absorbable Scaffold
3013718|NCT02470871|Experimental|Low-dose CSL689|Single dose of subject's routine FVII replacement therapy (either eptacog alfa [activated] [ie, comparator drug 1] or pdFVII [ie, comparator drug 2]), followed by a single dose of CSL689 at the low dose
3013719|NCT02470871|Experimental|High-dose CSL689|Single dose of subject's routine FVII replacement therapy (either eptacog alfa [activated] [ie, comparator drug 1] or pdFVII [ie, comparator drug 2]), followed by a single dose of CSL689 at the high dose.
3013720|NCT02470858|Experimental|LDV/SOF+ASV|Participants with genotype 1b HCV infection will receive LDV/SOF FDC + ASV 3 weeks.
3013721|NCT02470858|Experimental|SOF+DCV+SMV|Participants with genotype 1b HCV infection will receive SOF + DCV + SMV for 3 weeks.
3013722|NCT02470858|Experimental|SOF+DCV+ASV|Participants with genotype 1b HCV infection will receive SOF + DCV + ASV for 3 weeks
3013723|NCT02470845|Experimental|Tian Jiu group|The TJ group will undergo a 4-week treatment with herbal patches one session per week and a 4-week post-treatment follow-up, of one assessment session per week. Participants in the TJ group will be treated with herbal patches of Tian Jiu group on five acupoints on the back.
3013724|NCT02470845|Sham Comparator|Placebo-control group|The placebo-control group will undergo a 4-week treatment with placebo patches one session per week and a 4-week post-treatment follow-up, of one assessment session per week. Participants in this group will be treated with placebo patches of placebo-control group on the same acupionts as the TJ group.
3013725|NCT02470845|No Intervention|Waitlist-control group|The waitlist-control group will receive no treatment during the first 4 weeks but, beginning with the 5th week this group will receive TJ treatment for four weeks as compensatory.
3013726|NCT02470832|Experimental|Combination therapy RG1662 + itraconazole|Days 20-29: Oral administration RG1662 twice daily within 30 minutes of a meal + 2 x 100 mg itraconazole once daily with food
3013727|NCT02470832|Experimental|RG1662 Monotherapy|Days 1-10: RG1662 120 mg twice daily (b.i.d.) within 30 minutes of a meal for 10 days (Days 1 to 9, Day 10 only a.m. dose). (Cohort A subjects will receive 1 x 120 mg RG1662 tablets twice daily. In Cohorts B and C the dose of RG1662 will be decided upon following review of the interim safety and pharmacokinetic data of the 4 subjects in Cohort A.)
3013728|NCT02470832|Experimental|itraconazole Monotherapy|Days 15-19: 200 mg of itraconazole twice daily for 5 days (Days 15 to 18, Day 19 only a.m. dose)
3013729|NCT02470819|Experimental|Targeted Therapy|Those who will receive targeted therapy based on their genetic profiling
3013730|NCT02470806|Experimental|PICO|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
3013731|NCT02470806|Active Comparator|tNPWT|NPWT from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
3013732|NCT02470793|Active Comparator|DSAEK group|Subjects operated of Descemet Stripping Automated Endothelial Keratoplasty.
3013733|NCT02470793|Experimental|DMEK group|Subjects operated of Descemet Membrane Endothelial Keratoplasty.
3013734|NCT02470780|Experimental|Three-month follow-up|
3013735|NCT02470780|Experimental|Six-month follow-up|
3013736|NCT02470767||DOAC treated patients|Patients diagnosed with Non-Valvular Atrial Fribilation at risk of stroke or systemic embolism treated in primary care centres with DOAC.
3013737|NCT02470754|Active Comparator|EC Block1/TC Block 2|Participants will be randomized into one of two groups. In this group, participants will be assigned to Electronic Cigarettes only for Study Block #1, then crossover to Tobacco Cigarettes only for Study Block #2.
3013738|NCT02470754|Active Comparator|TC Block 1/EC Block 2|Participants will be randomized into one of two groups. In this group, participants will be assigned to Tobacco Cigarettes only for Study Block #1, then crossover to Electronic Cigarettes only for Study Block #2.
3013739|NCT02470741|Experimental|Letrozole|Oral letrozole 2.5mg/day
3013740|NCT02470741|Placebo Comparator|Placebo and Letrozole|Intermittent oral letrozole 2.5mg/day for 2 months and an identical placebo capsule for 4 months
3013741|NCT02470728|No Intervention|Control Group|Those randomized into the control group will receive the current standard of care for pain management. This standard care pathway involves a pain management specialist consultation only at the request of the primary admitting team. The pain management consultation can occur at any time during the patient's inpatient stay and care by these specialists ends at discharge.
3013742|NCT02470728|Experimental|Treatment Group|Subjects randomized into the treatment (early intervention) group will receive the New Clinical Pathway: pain management care coordinated by pain-management specialists from inpatient admission through 60 days after discharge.
3013743|NCT02470715||Molecular profile|Molecular profiled group receiving treatment based on genetics
3013744|NCT02470702|Experimental|Oritavancin|Subjects randomized to oritavancin will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1200 mg oritavancin, infused intravenously over 3 hours
3013745|NCT02470702|Placebo Comparator|Placebo|Subjects randomized to placebo will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1000 mL D5W, infused intravenously over 3 hours
3013746|NCT02470689|Active Comparator|Diacerin cream 1%|
3013747|NCT02470689|Placebo Comparator|ultraphil cream|
3013748|NCT02470676|Active Comparator|Progesterone|200 mg daily of vaginal progesterone suppositories (Utrogestan)
3013749|NCT02470676|Experimental|Progesterone plus Experimental device|Experimental device + 200 mg daily progesterone vaginal suppositories (Utrogestan)
3013750|NCT02470663|Experimental|Study group|Children recieving DENSITYTM caplets (marketed as Amorphical) 200 mg BID for 12 months
3013751|NCT02470663|Active Comparator|Control group|Children recieving Calcium carbonate 600 mg once daily for 12 months
3013752|NCT02470650|Experimental|elvitegravir/cobicistat/emtricitabine/tenofovir|EVG / COBI / FTC / TDF (Stribild®) 150 elvitegravir, 150 cobicistat, 200 emtricitabine, 245 tenofovir disoproxil. 1 recovered tablet once a day (on a day)
3013753|NCT02470650|Active Comparator|darunavir+ritonavir+lamivudine|Darunavir 800 mg (Prezista®) 1 recovered tablet once a day Ritonavir 100 mg(Norvir® ) 1recovered tablet once a day lamivudine300 mg (Epivir®) 1 recovered tablet once a day
3013754|NCT02470650|Active Comparator|abacavir/lamivudine+rilpivirine|Abacavir 600 mg +lamivudine 300mg (Kivexa®) 1tablet once a day rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
3013755|NCT02470637|Experimental|SAR439065 + insulin lispro|1 of 6 sequences with single administration of 3 dose levels of SAR439065 (Afrezza Technosphere insulin) and 3 dose levels of insulin lispro with a washout duration between dosing days (7 to 28 days)
3013756|NCT02470624||treatment following current guideline|
3013757|NCT02470611|Experimental|Sodium Alendronate|Adjunctive use of 1% sodium alendronate gel as part of periodontitis treatment
3013758|NCT02470611|Placebo Comparator|Placebo|Adjunctive use of placebo gel as part of periodontitis treatment
3013759|NCT02470585|Experimental|Arm 3|Carboplatin/paclitaxel plus veliparib for six 21-day cycles followed by veliparib maintenance therapy for up to 30 additional 21-day cycles
3013760|NCT02470585|Placebo Comparator|Arm 1|Carboplatin/paclitaxel plus placebo for six 21-day cycles followed by placebo maintenance therapy for up to 30 additional 21-day cycles
3013761|NCT02470585|Experimental|Arm 2|Carboplatin/paclitaxel plus veliparib for six 21-day cycles followed by placebo maintenance therapy for up to 30 additional 21-day cycles
3013762|NCT02470572|Active Comparator|Omnyx™ IDP system|Omnyx™ IDP system for Whole Slide Images (WSI)
3013763|NCT02470572|Placebo Comparator|Conventional light microscope|conventional light microscope
3013764|NCT02470559|Experimental|Treatment (aldesleukin, sargramostim, HER2Bi-aACT)|Patients receive HER2Bi-aATC IV over 5-15 minutes and IP within 3-4 days of IV dose weekly for 4 weeks. Patients also receive low-dose aldesleukin SC daily and sargramostim SC twice weekly beginning 3 days before the first HER2Bi-aATC infusions infusion and ending 7 days after the last HER2Bi-aATC infusion. Treatment continues in the absence of disease progression or unacceptable toxicity.
3013765|NCT02470546|Active Comparator|Metformin|Patients receiving metformin
3013766|NCT02470546|Placebo Comparator|Placebo|Patients receiving placebo
3013767|NCT02470533|Active Comparator|Transarterial chemoembolization|Chemoembolization will be performed through a transarterial route delivering drug eluting beads, i.e. hydrogel-based microspheres (Biocompatibles UK, Ltd, HepaSphere Biosphere Medical) loaded with the chemotherapeutic agent doxorubicin.
3013802|NCT02470325|Active Comparator|3 Avidekel|Patients with spasticity and dystonia due to cerebral palsy will consume Avidekel oil (6-to-1 ratio of CBD to THC)
3013768|NCT02470533|Experimental|Stereotactic body radiation therapy|Risk-adapted dose prescription for delivering the highest possible tumor dose not exceeding the maximum dose in 6 fractions of 8-9 Gy, while hepatic normal tissue complication probability (NTCP) < of 5%
3013769|NCT02470520||AKI without CRRT|Patients with AKI who are not treated with continuous renal replacement therapy
3013770|NCT02470520||AKI with CRRT|Patients with AKI who are treated with continuous renal replacement therapy
3013771|NCT02470507||AKI with SIRS|Patients with AKI stage II or III and systemic inflammation without sepsis
3013772|NCT02470507||AKI without SIRS|Patients with AKI stage II or III and no systemic inflammation
3013773|NCT02470507||SIRS without AKI|Patients with systemic inflammation and normal renal function
3013774|NCT02470507||No SIRS and no AKI|Patients after major surgery who do not have an infection, SIRS or AKI
3013775|NCT02470494|Experimental|Sound amplificatoin via EarLens CHD|Sound amplification provided via the EarLens CHD for subjects with hearing impairment.
3013776|NCT02470481||Cohort 1|Participants with psoriatic arthritis among psoriasis particiants attending dermatology clinics.
3013777|NCT02470468|Experimental|DCVAC add on to SOC|Combination therapy with DCVAC and Standard of Care (Carboplatin, Paclitaxel)
3013778|NCT02470468|Experimental|DCVAC and immune enhancers add on to SOC|Combination therapy with DCVAC, immune enhancers (Interferon-α, Hydroxychloroquine) and Standard of Care (Carboplatin, Paclitaxel)
3013779|NCT02470468|Other|Standard of Care Chemotherapy|Standard of Care chemotherapy (Carboplatin, Paclitaxel)
3013780|NCT02470455||Normoglycemic group|25 patients were recruited who were on Atorvastatin and with normal blood glucose and Hb1Ac level.
3013781|NCT02470455||Prediabetic with normal GTT|25 patients were recruited who were on Atorvastatin and with fasting blood sugar level 100-125 mg/dl with normal GTT.
3013782|NCT02470455||Prediabetic with impaired GTT|25 patients were recruited who were on Atorvastatin and with fasting blood sugar level 100-125 mg/dl with impaired GTT.
3013783|NCT02470442|Experimental|Sevoflurane/Desflurane|After induction of general anesthesia with sevoflurane, anesthesia was maintained with desflurane.
3013784|NCT02470442|Experimental|Sevoflurane|the anesthetic induction and maintenance with sevoflurane.
3013785|NCT02470429|Experimental|SYSTANE HYDRATION|SYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
3013786|NCT02470429|Active Comparator|Hyabak 0.15%|Hyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
3013787|NCT02470416|Active Comparator|Case|Patients who have had a previous diagnosis and/or treatment of a duodenal/ampullary polyp at Westmead hospital
3013788|NCT02470416|Active Comparator|Control|Age matched controls having VCE for OGIB/IDA at Westmead hospital.
3013789|NCT02470403|Experimental|Part 1: LIK066 150 mg once daily (qd)|LIK066 150 mg qd within 15 minutes before starting lunch
3013790|NCT02470403|Placebo Comparator|Part 1: Placebo once daily|Matching placebo tablets of LCZ696 150 mg within 15 minutes before starting lunch.
3013791|NCT02470403|Experimental|Part 2: LIK066 75 mg twice daily (bid)|LIK066 75 mg bid before breakfast and dinner
3013792|NCT02470403|Experimental|Part 2: LIK066 50 mg three times daily (tid)|LIK066 50 mg tid before all 3 meals;
3013793|NCT02470403|Placebo Comparator|Part 2: Placebo three times daily|Matching placebo tablets tid before meals.
3013794|NCT02470390|Active Comparator|Nasal fentanyl|"nasal fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute.~Will be administered on either study day 1 or 3 per protocol and randomization."
3013795|NCT02470390|Active Comparator|Sub-Lingual fentanyl|"sublingual fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue.~Will be administered on either study day 1 or 3 per protocol and randomization."
3013796|NCT02470390|Active Comparator|IV fentanyl|"IV fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes.~Will be administered on study day 5 per protocol."
3013797|NCT02470377|Experimental|Transcranial Magnetic Stimulation|After determination of the motor threshold, the TMS coil will be positioned at predetermined locations over the brain using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses (repetitive TMS) at 1Hz up to 10Hz or in theta burst mode will be delivered at one or more locations over the head, depending on the brain location under study (brain locations determined by MRI data). Real or active sham conditions will be used in the study but all participants will receive real treatment at some point during their enrollment. Real rTMS over one area may also be compared to real rTMS over another area.
3013798|NCT02470338|Active Comparator|MBP plus ankle arthroscopy (Group A)|Group A will receive a diagnostic ankle arthroscopy followed by the Modified Brostrӧm Procedure (MBP). In the ankle arthroscopy, multiple pictures are taken inside of the joint to note possible pathologic processes (for example - osteochondral lesions of the talus). Ankle arthroscopy involves one incision in the middle of the ankle anteriomedial (middle) incision and one incision on the outside of the ankle. Each incision (a small cut in the skin) is roughly 5mm in length (which is about 0.2 inches). After the incision is made, the participant will receive a diagnostic ankle arthroscopy.If the surgeon detects an abnormality inside the joint, he will operate on the abnormality with the arthroscope according to the generally accepted principles for treating the abnormality.
3013799|NCT02470338|Sham Comparator|MBP alone (Group B)|Group B will receive sham skin incisions on the ankle a Modified Brostrӧm Procedure (MBP) alone (that is, there will be no diagnostic ankle arthroscopy) followed by the Modified Brostrӧm Procedure (MBP). If a participant is assigned to Group B, the participant will receive two small superficial skin incisions at the sites where the investigators would normally insert instruments for the ankle arthroscopy. As with Group A, there will be one anteriomedial (middle) incision on the middle of the ankle and one anteriolateral (side) incision to on the outside of the ankle. Each incision will be roughly 5mm in length and 5 mm in depth, but will not violate subcutaneous tissue. The width of these incisions will be the width of the blade, at 1mm. However, unlike Group A, the participants in Group B will not have any instruments inserted into their ankle and will not have any operation to repair or remove damaged tissue.
3013800|NCT02470325|Active Comparator|1 Avidekel|Patients with spasticity and dystonia related to genetic neurodegenerative disease will consume Avidekel oil (6-to-1 ratio of CBD to THC)
3013801|NCT02470325|Active Comparator|2 Enriched Avidekel|Patients with spasticity and dystonia related to genetic neurodegenerative disease will consume Enriched Avidekel oil (20-to-1 ratio of CBD to THC)
3013803|NCT02470325|Active Comparator|4 Enriched Avidekel|Patients with spasticity and dystonia due to cerebral palsy will consume Enriched Avidekel oil (20-to-1 ratio of CBD to THC)
3013804|NCT02470312||CRT|Patients who are undergoing CRT implantation utilizing MediGuide system and tools
3013805|NCT02470312||EP|Patients who are undergoing ablation procedures for Atrial Fibrillation, Atrial Flutter, and Ventricular Tachycardia utilizing MediGuide system and tools
3013806|NCT02470299|Experimental|Ketorolac|Once deemed stable in the first 1-3 post-operative days, patients will be receive age-based ketorolac (30 mg <65, 15mg > 65) daily for three days
3013807|NCT02470299|Placebo Comparator|Placebo|Once deemed stable in the first 1-3 post-operative days, patients will be receive placebo daily for three days
3013808|NCT02470286|Experimental|SA001|Dose escalation
3013809|NCT02470286|Placebo Comparator|Placebo|Dose escalation
3013810|NCT02470273||Dermatology patients|Patients with a suspicious skin lesion indicated for biopsy
3013811|NCT02470260||Diabetes|Defined by clinical history or HbA1c criteria (HbA1c greater of equal to 6.5%)
3013812|NCT02470260||Pre-diabetes|Defined by HbA1c criteria (5.7 to 6.4%)
3013813|NCT02470260||Normal glucose tolerance|Defined by HbA1c criteria (< 5.7%)
3013814|NCT02470247|Experimental|Remote ischemic preconditioning|"Remote Ischemic Preconditioning (RIPC) is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.~RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes."
3013815|NCT02470247|Sham Comparator|SHAM remote ischemic preconditioning|"The SHAM Remote Ischemic Preconditioning (SHAM RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol)."
3013816|NCT02470234|Experimental|Methylphenidate HCl ER Capsules|Active drug, administered once
3013817|NCT02470221||Goal-directed fluid therapy|The fluid in group Goal-directed fluid therapy will be administered based upon real-time monitoring stroke volume variation and cardiac output achieved by the Flo-Trac monitoring system.
3013818|NCT02470221||Conventional fluid therapy|The fluid in group Conventional fluid therapy will be administered based on the principle crystalloid solution: colloid solution =2-3:1. The total volume of fluid will be adjusted in accordance with blood pressure, heart rate and urine output of each patient.
3013819|NCT02470195|Experimental|workshop|workshop of procedural simulation
3013820|NCT02470195|No Intervention|control|no specific workshop of procedural simulation
3013821|NCT02470182||At-Home|Overnight sleep at home (30 subjects)
3013822|NCT02470182||Sleep Lab|Overnight sleep at the OHSU sleep lab during routine polysomnography (30 subjects)
3013823|NCT02470182||Sleep Lab + At-Home|Overnight sleep at the OHSU sleep lab during routine polysomnography, followed by overnight sleep at home (30 subjects)
3013824|NCT02470169|Active Comparator|Stimulated IUI|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3rd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
3013825|NCT02470169|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
3013826|NCT02470169|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
3013827|NCT02470156|Experimental|High Intensity Arm (Intervention)|"Women in the High Intensity (intervention) arm are counseled by a wellness coach and have a group meeting each month. They are also interviewed four times (at baseline, 4 months, 8 months, and 12 months). Women in the high intensity group must have monthly contact with coaches during at least 9 of 12 months via participation in a group activity and/or monthly coaching to receive a full dose of the intervention."
3013828|NCT02470156|Active Comparator|Low Intensity Arm (Comparison)|Women in the Low Intensity (comparison) arm are interviewed and coached four times during the study (at baseline, 4 months, 8 months, and 12 months).
3013829|NCT02470143||Bike application arm|The bike application arm contains cardiac patients that will be instructed to use the cycling application during a one month period.
3013830|NCT02470130|Active Comparator|relax actor|actor during simulation and relaxation before debriefing
3013831|NCT02470130|No Intervention|no relax actor|actor during simulation and no relaxation before debriefing
3013832|NCT02470130|Active Comparator|relax observer|observer during simulation and relaxation before debriefing
3013833|NCT02470130|No Intervention|no relax observer|observer during simulation and no relaxation before debriefing
3013834|NCT02470117|Active Comparator|Alginate-based reflux suppressant|Alginate-based reflux suppressant 15 ml oral every 6 hours for 2 weeks
3013835|NCT02470117|Sham Comparator|magnesium-aluminium antacid gel|magnesium-aluminium antacid gel 15 ml oral every 6 hours for 2 weeks
3013836|NCT02470104|Experimental|Enteral Donor Breastmilk|"Donor milk will be pasteurized prior to use.~Given orally or by nasogastric (NG) or nasojejunal (NJ) tube.~Feeding will be supervised and will be advanced as quickly as tolerated with a goal of providing 40-50% of nutritional needs from the donor milk.~It is recognized that the volume of enteral feeds will need to be adjusted per patient tolerance."
3013837|NCT02470104|No Intervention|Control|• Children randomized to the control arm will receive standard enteral or parenteral nutrition per standard clinical practice, supervised by a registered dietician.
3013838|NCT02470091|Experimental|Treatment (denosumab)|Patients receive denosumab SC on day 1 (days 1, 8, and 15 of course 1 only). Treatment repeats every 4 weeks (28 days) for up to 24 months or 26 courses, whichever occurs first, in the absence of disease progression or unacceptable toxicity.
3013839|NCT02470078|Experimental|Pharyngeal electrical stimulation|Pharyngeal electrical stimulation once daily for 10 minutes on three consecutive days.
3013840|NCT02470078|Sham Comparator|Sham stimulation|Sham stimulation once daily for 10 minutes on three consecutive days.
3013841|NCT02470065|Experimental|Neo adjuvant afatinib|once daily afatinib at a dose of 40 mg for 8 weeks followed by surgery with curative intent (anatomical resection and systematic lymph node dissection).
3013842|NCT02470065|Active Comparator|Immediate surgery|immediate surgery with curative intent (anatomical resection and systematic lymph node dissection).
3013843|NCT02470052|Experimental|OL-BF-001|Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
3013844|NCT02470039|Experimental|Oral insulin 338 and subcutaneous placebo|
3013845|NCT02470039|Active Comparator|Subcutaneous insulin glargine and oral placebo|
3013846|NCT02470026|Experimental|Yohimbine-Placebo|single low dose treatment with yohimbine on test day 1, placebo on test day 2
3013847|NCT02470026|Experimental|Placebo-Yohimbin|placebo on test day 1, single low dose treatment with yohimbine on test day 2
3013848|NCT02470013|Experimental|Intervention Group|Nutrition counselling and balanced, energy dense, moderate protein sip feed ('Fortimel Compact, Nutricia GmbH) for 3 months
3013849|NCT02470013|No Intervention|Control Group|Nutrition counselling upon hospital discharge (usual care)
3013850|NCT02470000|Experimental|Experimental Group|Intravascular laser irradiation of blood (ILIB, output power 0.3mW), Transcutaneous electrical nerve stimulation (TENS), stretching exercise.
3013851|NCT02470000|Sham Comparator|Control Group|Intravascular laser irradiation of blood (ILIB, output power 0mW), Transcutaneous electrical nerve stimulation (TENS), stretching exercise.
3013852|NCT02469987|Experimental|MYL-1402O|MYL-1402O (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
3013853|NCT02469987|Active Comparator|US Marketed Avastin (R)|US Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
3013854|NCT02469987|Active Comparator|EU Marketed Avastin(R)|EU Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
3013855|NCT02469974|Experimental|Ruxolitinib / INC 424|Ruxolitinib, Jakafi ®, will be given orally at standard dose daily for 16 weeks pre ASCT and up to 3 months post-ASCT for 10 patients (allowing for 2 additional screen failures). Patients will restart ruxolitinib at 100 days after the ASCT as long as their platelet count is at least 50 x103. For patients whose platelet count is below 50 x103 at day 100, ruxolitinib should be restarted once platelet count reaches 50 x103. The dose of ruxolitinib can be titrated up as per clinical guidelines. PBSC mobilization will include G-CSF 10 mcg/kg/day. HDC for ASCT will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2.
3013856|NCT02469961|Experimental|dexmedetomidine|Participants will receive an interscalene block and be sedated with dexmedetomidine
3013857|NCT02469961|Active Comparator|Propofol|Participants will receive an interscalene block and be sedated with propofol
3013858|NCT02469948|Experimental|Ultrasonography direct-guidance|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
3013859|NCT02469948|Active Comparator|Surface anatomy landmark|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.
3013860|NCT02469922|Experimental|Positron emission tomography|Two additional PET Scan will be performed at 2 and 4 weeks for the first 30 patients. Then for the other patients only one additional PET-Scan will be performed
3013861|NCT02469909|Other|immediate decannulation|In the immediate decannulation group - the tracheostomy tube is removed and the patient would be monitored overnight in an intermediate monitored unit. On the next day a clinical evaluation would be held, and the patient would be discharge or transferred to his department according to the clinical course of the patient
3013862|NCT02469909|Other|Gradual tracheostomy tube decrease|In the gradual decannulation group The tracheostomy tube will be reduced in 2 sizes compared with the initial inner diameter of the tube. The patients will remain with the reduced tube for 48 hours, and the tube will be removed if the patients would meet pre-decannulation evaluation
3013863|NCT02469896|Placebo Comparator|Placebo|8 subjects will receive matching IV placebo every 4 weeks for 3 months.
3013864|NCT02469896|Active Comparator|Active drug|16 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
3013865|NCT02469883|Experimental|Sinotecean|
3013866|NCT02469870|Experimental|Autism Parent Trainer (APT) Vs Control|"Autism Parent Trainer (APT) Experimental Condition. This group will receive Google Hangouts training on autism and lifestyle coaching.~self-paced ABC training online - Parents assigned to the CC will be given access to a self-paced online training program covering the same content as APT."
3013867|NCT02469857|Experimental|AB103 0.5 mg/kg|AB103 0.5 mg/kg, IV, single dose
3013868|NCT02469857|Placebo Comparator|NaCl 0.9%|NaCl 0.9%, IV, single dose
3013869|NCT02469844||Patients with epilepsy having seizures in sleep|
3013870|NCT02469831|Active Comparator|group D|deep neuromuscular block by rocuronium defined :post tetanic (PTC) >1 but no response to a train of four (TOF) stimulation.
3013871|NCT02469831|Active Comparator|group I|intermediate neuromuscular block by rocuronium defined as TOF count of 1-3.
3013872|NCT02469805|Active Comparator|stimulated intrauterine insemination (IUI)|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3rd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
3013873|NCT02469805|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
3013874|NCT02469805|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
3013875|NCT02469792|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected intraarticularly into anterior cruciated ligament.
3013876|NCT02469779|Experimental|ASPIRE Group|Participants complete baseline survey. Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped and audio recorded. 3 to 4 sessions will be completed. After each website session, survey will be completed.
3013877|NCT02469779|Active Comparator|Control Group|Participants complete baseline survey. Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living. This viewing will be videotaped and audio recorded. 3 to 4 sessions will be completed. After each website session, survey will be completed.
3013878|NCT02469766|Active Comparator|Extracorporeal Shockwaves|Patients in this arm will undergo SWL
3013879|NCT02469766|Active Comparator|Semirigid URS|Patients in this arm will undergo Semirigid Ureteroscopy
3013880|NCT02469766|Active Comparator|Flexible URS|Patients in this arm will undergo Flexible Ureteroscopy
3013881|NCT02469753|Experimental|Patients treated with anti-TNF and continuous daily NSAIDs|
3013882|NCT02469753|Active Comparator|Patients treated with anti-TNF and NSAIDs on demand|
3013883|NCT02469740|Experimental|Ticagrelor|Patients in this group will be prescribed ticagrelor 90 mg BD for 4 weeks.
3013884|NCT02469740|Active Comparator|Clopidogrel|Patients in this group will be prescribed clopidogrel 75 mg OD for 4 weeks
3013885|NCT02469727|Experimental|Fitbit + Facebook|Participants will use the Fitbit device and join the Facebook group.
3013886|NCT02469727|No Intervention|Usual care control|No intervention provided.
3013887|NCT02469714|Experimental|Peer Navigator Intervention|Integrated care with a peer navigator to be provided for one year, where data will be collected at baseline, 4, 8 and 12 months.
3013888|NCT02469714|No Intervention|Controlled|Integrated care without a peer navigator, where data will be collected at baseline, 4, 8 and 12 months
3013889|NCT02469701|Experimental|Nivolumab with ablation|"3mg/kg IV over 60 minutes on Day 1 +/- 3 days every 2 weeks until progression for a maximum of 2 years.~Either cryoablation or thermal ablation may be performed as per standard institutional policies.~As of amendment # 7 submitted to sites November 17, 2017, the dosing for Nivolumab per the FDA guidance was amended to a flat dose of 240mg IV Q2 weeks. As of amendment #8 sent to sites February 22, 2017 the dose of Nivolumab was updated to 3 mg/kg with a maximum dose of 240 mg for patients with weights that would correlate to exceed that dose instead of a flat dose secondary to the standard institutional practice and the FDA guidance ."
3013890|NCT02469688|Experimental|Part1 ASP4070 intramuscular vaccination group|ASP4070 high dose x 4 times
3013891|NCT02469688|Experimental|Part1 ASP4070 intradermal vaccination group|ASP4070 high dose x 4 times
3013892|NCT02469688|Experimental|Part2 ASP4070 intramuscular vaccination group 1|ASP4070 high dose x 4 times
3013893|NCT02469688|Experimental|Part2 ASP4070 intramuscular vaccination group 2|ASP4070 high dose x 1 time, Placebo x 3 times
3013894|NCT02469688|Placebo Comparator|Part2 Placebo intramuscular vaccination group|Placebo x 4 times
3013895|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 1|ASP4070 high dose x 4 times
3013896|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 2|ASP4070 low dose x 4 times
3013897|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 3|ASP4070 high dose x 1 time, Placebo x 3 times
3013898|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 4|ASP4070 low dose x 1 time, Placebo x 3 times
3013899|NCT02469688|Placebo Comparator|Part2 Placebo intradermal vaccination group|Placebo x 4 times
3013900|NCT02469675|Experimental|All subjects|"All subjects undergo same full protocol, including different combinations of stimulation on different days:~Transcranial Magnetic Stimulation Cervical Transcutaneous Stimulation Median Nerve Stimulation"
3013901|NCT02469662|Experimental|Retrospective|Patients who have had primary or revision total elbow arthroplasty using the Nexel Total Elbow, and who have surgical details available
3013902|NCT02469662|Experimental|Prospective|Patients who are having primary or revision total elbow arthroplasty who will receive the Nexel Total Elbow
3013903|NCT02469649|Experimental|Dipole Density Mapping|
3013904|NCT02469636|Experimental|Dipole Density Mapping with AcQMap|
3013905|NCT02469623|Experimental|Dipole Density Mapping|
3013906|NCT02469610|Experimental|study|In the study group the surgeon will perform an intercostal Bupivacaine block of 100ml over five intercostal spaces which include the operation cuts. The block will be done in the beginning of the surgery right after the insertion of the video camera to the pleural space.
3013907|NCT02469610|Other|control|In the control group the surgeon will perform the same intercostal block at the end of the surgery just before closing the operation cuts. this approach is used today in our department.
3013908|NCT02469597|Experimental|Single Dose of Furosemide|Furosemide 1 dose
3013909|NCT02469597|Placebo Comparator|Placebo|Normal saline 1 dose
3013910|NCT02469584|Experimental|1|symptomatic cystocele described as Points Aa or Ba >= 0 according to the International Continence Society pelvic organ prolapse quantification system (POP-Q). The changes in POPQ score preoperatively and three months after the anterior colporrhaphy with the new small stitch technic will be analyzed.
3013911|NCT02469571|Active Comparator|Probiotic|5 g of Winclove-607 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71, Lactobacillus salivarius W24 at a concentration of 1.1 x 109 cfu/g twice daily for the 4 weeks
3013912|NCT02469571|Placebo Comparator|Placebo|a similar looking and tasting placebo without bacteria once daily for 4 weeks
3013976|NCT02469220|Experimental|Low FODMAP diet|Diet with a low content of fermentable oligo-, di-, monosaccharides and polyols (low FODMAP diet). The patients will receive dietary instructions from registered clinical dieticians. A food supplement low in FODMAPS are administered in a blinded fashion.
3014622|NCT02465021|Experimental|Snack bar 2|Dietary intervention: 200 Kcal, 15g fat, 12g carbohydrate, 5g fibre, 4g sugar, 8g protein
3013913|NCT02469558|Active Comparator|probiotic|Winclove 851 and 110 consist of 6g of a probiotic mixture containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g and 5g of a prebiotic mixture of galacto-oligosaccharides P11 (GOS), Fructo-oligosaccharides P6 (FOS), Konjac glucomannan P13 (E425), Maltodextrin, Calcium carbonate (E170), Natural Elderflower flavouring, Gum Arabic (E414), Zinc citrate 3-hydrate, Vitamin D3 (Cholecalciferol) and Vitamin B2 (Riboflavin) (E101) daily for 6 months
3013914|NCT02469558|Placebo Comparator|placebo|a similar looking and tasting placebo without bacteria
3013915|NCT02469545|Active Comparator|SSRI and probiotic|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and probiotic (Lactobacillus Plantarum 299v) to a group of patients diagnosed with depression (n=30).
3013916|NCT02469545|Placebo Comparator|SSRI and placebo of probiotic|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and placebo of probiotic (crystalline cellulose powder) to a group of patients diagnosed with depression (n=30).
3013917|NCT02469532||Atherectomy|"Up to 20 atherectomy procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure.~This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-atherectomy revascularization procedures."
3013918|NCT02469532||Angioplasty|"Up to 20 angioplasty procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure.~This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-angioplasty revascularization procedures."
3013919|NCT02469519|Experimental|Betamethasone - ACTIVE|Booster Course of Antenatal Steroids consists of Betamethasone [12 mg intramuscular injection, 24 hours apart X 2 doses] or if unavailable may give Dexamethasone [6 mg intramuscularly 12 hours apart x 4 doses]
3013920|NCT02469519|Placebo Comparator|normal saline - PLACEBO|Normal saline of equivalent volume given intramuscularly at the equivalent dosing regimes listed in experimental arm.
3013921|NCT02469506|Experimental|NMES group|Patients will receive twice daily sessions of neuromuscular electrical stimulation (NMES).
3013922|NCT02469506|No Intervention|Control group|Patients will receive daily visits by the investigator to check progress.
3013923|NCT02469493|Experimental|Acupuncture 1|In this group, patients separately received twice electroacupuncture at bilateral PC6 acupoint before and after Cisplatin administration on the first day of chemotherapy.
3013924|NCT02469493|Experimental|Acupuncture 2|In this group, patients separately received twice electroacupuncture at bilateral PC6 and RN12 acupoints before and after Cisplatin administration on the first day of chemotherapy.
3013925|NCT02469493|Sham Comparator|Sham acupuncture|In this group, patients separately received twice electroacupuncture at bilateral nonacupuncture point (S1 located at lateral of flexor carpi radialis, 2 cun above the wrist. S2 located at 3 cun right side of RN12) before and after Cisplatin administration on the first day of chemotherapy.
3013926|NCT02469493|No Intervention|Waitinglist control|In this group, patients received no electroacupuncture
3013927|NCT02469480|Experimental|FERRIC CARBOXYMALTOSE|max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
3013928|NCT02469480|Active Comparator|ferro sanol(R) duodenal 100 mg|200 mg ferro sanol per day over 12 weeks
3013929|NCT02469467|Experimental|VS-505|750 mg capsule
3013930|NCT02469454|Experimental|early insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum. The ENG implant will be inserted subdermally in the non-dominant arm of volunteers upon local anesthesia with 2% lidocaine with vasoconstrictor, according to the manufacturer's instructions.
3013931|NCT02469454|Active Comparator|conventional insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted after 6 week of the delivery. The ENG implant will be inserted subdermally in the non-dominant arm of volunteers upon local anesthesia with 2% lidocaine with vasoconstrictor, according to the manufacturer's instructions.
3013932|NCT02469441||Arm A|Arm A (treatment arm: coffee): patients after colorectal surgery receive coffee in addition to the regular infusion therapy and/or alimentation
3013933|NCT02469441||Arm B|Arm B (control arm: water / tea): patients after colorectal surgery receive water or tea (excluding black tea) and no coffee until the first bowel movement in addition to the regular infusion therapy and/or alimentation
3013934|NCT02469428|Sham Comparator|Clean air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
3013935|NCT02469428|Experimental|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
3013936|NCT02469415|Experimental|Pacritinib + Azacitidine or Decitabine|"Part 1: Pacritinib 200 mg taken by mouth twice daily. Study cycles administered every 28 days.~Part 2: After 4 cycles of treatment, Pacritinib combined with 5-azacitidine or Decitabine. Pacritinib decreased to 200 mg in morning and 100 mg in evening for first cycle of combined therapy with Pacritinib increased to 200 mg twice a day on subsequent cycles of combined therapy. Those with disease progression prior to 4 cycles of Pacritinib may initiate Pacritinib + HMA study portion prior to completion of 4 cycles. Starting dose of either 5-azacitidine 75 mg/m2 by vein (IV) or Decitabine 20 mg/m2 IVon Days 1 - 5 of Cycles 5 and beyond."
3013937|NCT02469402|Active Comparator|Standard infant formula|Standard infant formula
3013938|NCT02469402|Experimental|Protein reduced formula|Protein reduced alpha-lactalbumin formula
3013939|NCT02469402|No Intervention|Breast-feeding|Exclusive breast-feeding
3013940|NCT02469389|Experimental|ENCoRE|Engaging in Community Roles and Experiences (ENCoRE) includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms. Behavioral strategies include motivational enhancement, psychoeducation, cognitive therapy, and social skills training.
3014623|NCT02465021|Experimental|Snack bar 3|Dietary intervention: 210 Kcal, 16g fat, 12g carbohydrate, 2g fibre, 6g sugar, 6g protein
3013941|NCT02469389|Active Comparator|H&W|Health & Wellness (H&W) will focus on health and wellness issues and education on ways to better manage health-related concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application. Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions), 8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1session).
3013942|NCT02469376|Experimental|Diagnosis with GP1|Injection and scanning of [18F]-GP1
3013943|NCT02469363|Active Comparator|Macintosh laryngoscope|Endotracheal intubation with classic (Macintosh) laryngoscope
3013944|NCT02469363|Active Comparator|Mc-Coy laryngoscope|Endotracheal intubation with Mc-Coy laryngoscope
3013945|NCT02469363|Active Comparator|C-Mac videolaryngoscope|Endotracheal intubation with C-Mac videolaryngoscope
3013946|NCT02469363|Active Comparator|McGrath videolaryngoscope|Endotracheal intubation with McGrath videolaryngoscope
3013947|NCT02469350|Experimental|Rehabilitation with serious game|18 rehabilitation sessions with serious game during a 6-8 weeks period
3013948|NCT02469337|Active Comparator|Preoperative carbohydrate drinks|Patients who were randomised to carbohydrate group ingested 800ml PreOp (Nutricia Clinical Care, 12.5g CHO/100 ml) the night before and 400ml in the morning of surgery, about 2-3 hours before the induction of anaesthesia.
3013949|NCT02469337|Active Comparator|Dichloroacetate infusion|The patients in the dichloroacetate group received the CHO drinks as well as an intravenous infusion of DCA (50mg/kg body weight) over 45 min, one- two hours before the induction of anaesthesia.
3013950|NCT02469337|Active Comparator|Moderate intensity exercise|Patients randomised to exercise group, will perform a 30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate(determined by the formula: (220-Age)*0.7 under close supervision and monitoring of their vital parameters.
3013951|NCT02469337|No Intervention|Control|Patients in this group will have surgery as standard practice with none of the above interventions
3013952|NCT02469324|Active Comparator|Cognitive-Behavioral Therapy|see intervention explanation
3013953|NCT02469324|Experimental|Compassionate Mind Training|
3013954|NCT02469311|Sham Comparator|Primary Control TKA|Patients undergoing a first or primary total knee arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
3013955|NCT02469311|Active Comparator|Primary Treatment TKA|Patients undergoing a first or primary total knee arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
3013956|NCT02469311|Active Comparator|Revision Treatment TKA|Patients undergoing a second or subsequent or a revision total knee arthroplasty will be randomized to the intervention of a chlorhexidine impregnated cloths.
3013957|NCT02469311|Sham Comparator|Revision Control TKA|Patients undergoing a second or revision total knee arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
3013958|NCT02469311|Sham Comparator|Primary Control THA|Patients undergoing a first or primary total hip arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
3013959|NCT02469311|Active Comparator|Primary Treatment THA|Patients undergoing a first or primary total hip arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
3013960|NCT02469311|Sham Comparator|Revision Control THA|Patients undergoing a second or revision total hip arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
3013961|NCT02469311|Active Comparator|Revision Treatment THA|Patients undergoing a second or subsequent or a revision total knee arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
3013962|NCT02469298|Experimental|Danirixin + Oseltamivir matching placebo|Subjects will receive 75 mg oral Danirixin twice daily with Oseltamivir matching placebo twice daily for a total of ten doses over five days
3013963|NCT02469298|Placebo Comparator|Danirixin matching placebo + Oseltamivir matching placebo|Subjects will receive Danirixin matching placebo twice daily with Oseltamivir matching placebo twice daily for a total of ten doses over five days
3013964|NCT02469298|Experimental|Danirixin + Oseltamivir|Subjects will receive 75 mg oral Danirixin twice daily with 75 mg Oseltamivir twice daily for a total of ten doses over five days
3013965|NCT02469298|Active Comparator|Danirixin matching placebo + Oseltamivir|Subjects will receive Danirixin matching placebo twice daily with 75 mg Oseltamivir twice daily for a total of ten doses over five days
3013966|NCT02469285|Experimental|Modified pork|Pork with modified fatty acid composition, more unsaturated fat. 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
3013967|NCT02469285|Active Comparator|Normal pork|Normal pork 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
3013968|NCT02469285|Experimental|Normal pork and berries|Normal pork and berries (strawberry, raspberry, wild blueberry, lingonberry, cloudberry, blackcurrant) 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
3013969|NCT02469272|Experimental|Fecal Microbiota Transplantation|Intervention: standardized preparation of frozen fecal material from lean healthy donors Route: infused into the duodenum through the working channel of the instrument at upper endoscopy Dosing: 1 dose
3013970|NCT02469259|Experimental|Treatment|Subjects will receive either 20IU or 40IU intranasal oxytocin
3013971|NCT02469259|Placebo Comparator|Placebo|Subjects will receive intranasal saline spray
3013972|NCT02469246|Experimental|F/TAF|F/TAF + placebo to match ABC/3TC + allowed third antiretroviral (ARV) agent for 96 weeks
3013973|NCT02469246|Active Comparator|ABC/3TC|ABC/3TC + placebo to match F/TAF + allowed third ARV agent for 96 weeks
3013974|NCT02469233|Experimental|TranS-C|The Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) is comprised of cross-cutting interventions, 'core modules' and 'optional modules'. TranS-C is derived and adapted from our previous disorder-focused research, firmly grounded in basic science and treatment literature.
3013975|NCT02469233|Active Comparator|UC-DT|Usual Care, Delayed Treatment (DT) is comprised of a case manager who co-ordinates care and refers each client for a medication review and to rehabilitation programs. At the end of 6-months in UC-DT, the participants will receive TranS-C.
3013977|NCT02469220|Active Comparator|Standardized FODMAP|Diet with a low content of fermentable oligo-, di-, monosaccharides and polyols (low FODMAP diet). The patients will receive dietary instructions from registered clinical dieticians. A food supplement with FODMAPS are administered in a blinded fashion.
3013978|NCT02469220|No Intervention|Control|Watchful waiting. No diets or food supplements are administered
3013979|NCT02469207||Deceased organ donors|Patients with consent for organ donation towards transplantation and research. Organs not used for transplantation will be used for this study if determined appropriate and necessary.
3013980|NCT02469181||FD(Fabry disease) group|28 patients with newly diagnosed genetically confirmed Anderson-Fabry's disease will undergo diastolic stress echocardiography, LV vortex flow analysis, and cardiac MRI before enzyme replacement therapy(ERT) (baseline study) and after 1 year of treatment with agalsidese beta at the dose of 1mg/kg (follow-up study).
3013981|NCT02469168|Experimental|ReCell|Allocation of treatments (Recell vs Control) to the INTEGRA™ Meshed Bilayer Wound Matrix (MBWM). Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
3013982|NCT02469168|Active Comparator|Control|Allocation of treatments (Recell vs Control) to the INTEGRA™ Meshed Bilayer Wound Matrix (MBWM). Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
3013983|NCT02469155|Experimental|20 mg ITI-007|20 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
3013984|NCT02469155|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
3013985|NCT02469155|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
3013986|NCT02469155|Active Comparator|Risperidone|Risperidone administered orally as visually-matched over-encapsulated tablet once daily for 6 weeks
3013987|NCT02469142|Experimental|ADM tension-free hernia reparation|Use ADM to repair incarcerated inguinal hernia by tension-free
3013988|NCT02469142|Placebo Comparator|traditional tension hernia reparation|Just repair incarcerated inguinal hernia by nothing in tension condition
3013989|NCT02469129|Experimental|Dosimetry Studies Arm|Twelve participants with cancer and eight healthy volunteers will be recruited first to undergo whole-body PET/CT imaging to determine the whole body dosimetry of [18F]FluorThanatrace.
3013990|NCT02469129|Experimental|Kinetic Studies Arm|An additional 30 participants with cancer will undergo a 1-hour dynamic scan upon injection of [18F]FluorThanatrace to determine the kinetics of the tracer in tumors to correlate with tissue-based markers of PARP activity and to obtain metabolite information to help determine the best quantification approach for the PET images.
3013991|NCT02469116|Experimental|Arm 1: (docetaxel, carboplatin, pegylated G-CSF)|"Docetaxel intravenously over 1 hour followed by carboplatin intravenously over 30 minutes-1 hour on day 1 every 21 days for maximum of 6 cycles~Pegylated G-CSF on day 2 every 21 days for maximum of 6 cycles"
3013992|NCT02469103|Experimental|C2 & colonoscopy|C2 and colonoscopy
3013993|NCT02469090|Experimental|APL-130277|APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
3013994|NCT02469090|Placebo Comparator|Placebo|Matching placebo for APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
3013995|NCT02469077|Experimental|exercise plus placebo/morphine/naloxone|Participants randomly assigned to the exercise condition will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks). Immediately before and after participating in this intervention arm, participants will undergo the placebo-controlled morphine and naloxone administration intervention to assess mechanisms of exercise-related changes.
3013996|NCT02469077|Active Comparator|placebo/morphine/naloxone|Participants assigned to the control condition will not undergo any manipulation during this 6 week period, and will be asked to continue their current activity levels and not engage in any additional exercise activity during the study period. Immediately before and after participating in this intervention arm, participants will undergo the placebo-controlled morphine and naloxone administration intervention to assess mechanisms of exercise-related changes.
3013997|NCT02469064|Experimental|Respiratory Muscle Training|Experimental group receives as additional treatment respiratory muscle training.
3013998|NCT02469064|Active Comparator|Conventional physical therapy|Conventional Cardiopulmonary Physical Therapy
3013999|NCT02469051|Other|Breathhold SPECT-MPI vs. standard freebreathing SPECT-MPI|
3014000|NCT02469038|Experimental|AccuCath catheter|We use the AccuCath catheter with ultrasound guidance for IV access for patients in the experimental group.
3014001|NCT02469038|Active Comparator|Control|We will use ultrasound-guided conventional IV for patients in the control group.
3014002|NCT02469025|Experimental|Resting position mobilization group|"This group receive six manual therapy interventions based on manual traction mobilization in a resting position of the hip joint.~In addition the physical therapist teach the patients six exercises to do at home between manual mobilization sessions."
3014003|NCT02469025|Experimental|End range position mobilization group|"This group receive six manual therapy interventions based on manual traction mobilization in an end range position of the hip joint.~In addition the physical therapist teach the patients six exercises to do at home between manual mobilization sessions."
3014004|NCT02469012|Experimental|IFN-free antiviral treatment|Combination #1 or Combination #2 or Combination #3 or Combination #4 or Combination #5
3014005|NCT02468999|Active Comparator|insulin nasal spray|160 Units of human insulin as nasal spray
3014006|NCT02468999|Placebo Comparator|placebo nasal spray|Nasal spray containing placebo solution
3014007|NCT02468986||Uncontrolled Rheumatoid Arthritis|"18-75 years old; Rheumatoid arthritis, defined by 1987 American College Rheumatology criteria; Attending clinic at Aston Center for Rheumatology or Parkland Rheumatology Clinic; Uncontrolled: Patients will be labeled as uncontrolled RA if Disease Activity Score (DAS) score is >3.2 and C-reactive protein (mg/dL) elevated above normal range.~Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP > 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL>160) in the past 6 months; Pregnant or nursing."
3051231|NCT02219048|Experimental|PF-03715455|PF-03715455
3014008|NCT02468986||Controlled Rheumatoid Arthritis|18-75 years old; Rheumatoid arthritis, defined by 1987 American College Rheumatology criteria; Attending clinic at Aston Center for Rheumatology or Parkland Rheumatology Clinic; Controlled: Disease activity score (DAS) <3.2, normal C-reactive protein. Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP > 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL>160) in the past 6 months; Pregnant or nursing.
3014009|NCT02468986||Healthy Controls|18-75 years old. Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP > 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL>160) in the past 6 months; Pregnant or nursing.
3014010|NCT02468973|Other|Life style counseling|Students will meet chronic patients and will counsel for life style
3014011|NCT02468960|Other|OPN strategy (study group)|"Interventions planned in this arm are as follows:~Predilatation with OPN NC balloon catheter.~Absorb BVS implantation.~Treated segment visualization by OCT.~Clinical FU at 12 months."
3014012|NCT02468960|Other|Standard strategy (control group)|"Interventions planned in this arm are as follows:~Predilatation with standard compliant balloon.~Absorb BVS implantation.~Treated segment visualization by OCT.~Clinical FU at 12 months."
3014013|NCT02468934|Experimental|Peripheral Nerve Stimulation|All study subjects will have up to 2 Smartpatch Leads placed in their leg that underwent total knee replacement, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
3014014|NCT02468908|Experimental|Molgramostim nebuliser solution, inhaled|Single dose 150, 300 and 600 ug, multiple dose 300 and 600 ug for 6 days
3014015|NCT02468908|Placebo Comparator|Nebuliser solution, inhaled|Inhaled nebuliser solution
3014016|NCT02468895||Idiopathic Inflammatory Myopathy|PM, DM, sIBM, necrotizing myopathy, anti-synthetase syndrome, suspected myopathy
3014017|NCT02468882|Experimental|Intervention group|"Watercress will be tested in its natural form as a food item that will supplement the usual diet, via the prescription of watercress as whole food added daily to the usual diet. The intervention group will be asked to consume 100 grams of watercress per day, in addition to their usual diet for the total time of RT treatment. These 100 grams of watercress per day will allow the achievement of the daily therapeutic dose."
3014018|NCT02468882|No Intervention|Control group|The control group will receive the standard of care, thus will maintain their ad libitum diet.
3014019|NCT02468869|Experimental|Information structuring skills training|Physicians received a communication skills training focusing on information structuring with the so-called book metaphor for a structured discharge communication with the patient.
3014020|NCT02468869|Active Comparator|Empathy skills training|Physicians received a communication skills training focusing on empathy skills with the acronym NURSE for an empathetic discharge communication with the patient.
3014021|NCT02468856|Active Comparator|Armodafinil|Armodafinil 250 mg tablets, one time administration per study session in the morning of day 2
3014022|NCT02468856|Placebo Comparator|Placebo|one time administration per study session in the morning of day 2
3014023|NCT02468843||Biphasic DBS stimulations|Subjects in this group with have Biphasic DBS stimulation setting performed, Unified Dystonia Rating Scale (UDRS), and Burke-Fahn- Marsden scale (BFMDRS), tremor accelerometer, kinesia accelerometer, and GaitRite walking assessments performed.
3014024|NCT02468830|Experimental|Mirabegron|Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. Patients with significantly bothersome S/E on antimuscarinics will also be included.
3014025|NCT02468817|Active Comparator|Treadmill Exercise|2 (two) 1-hour of vigorous exercise bouts under different thermal conditions, one at 16 degrees C and one at 26 degrees C.
3014026|NCT02468817|Experimental|Magnitude of Ca loss during Exercise at 26 degrees Celcius|Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise.
3014027|NCT02468804|Experimental|Parkinson's Disease Subjects|The PD subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
3014028|NCT02468804|Experimental|Control Subjects|The control subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
3014029|NCT02468791|Experimental|MabionCD20®|A course of MabionCD20® in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.
3014030|NCT02468791|Active Comparator|MabThera®|A course of MabThera® (Rituximab, Roche) in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.
3014031|NCT02468778|Experimental|HeartMate PHP|The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high risk percutaneous coronary interventions (PCI) performed in elective or urgent, hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction.
3014032|NCT02468778|Active Comparator|Any Abiomed Impella® device approved for use in high-risk PCI|Any Abiomed Impella® Device approved for use in high-risk PCI
3014033|NCT02468765||Depressive MS patients|Neuropsychological and emotional evaluation with monitoring
3014034|NCT02468765||Non depressive MS patients|Neuropsychological and emotional evaluation with monitoring
3014035|NCT02468765||Control|Neuropsychological and emotional evaluation with monitoring
3014036|NCT02468752|Sham Comparator|Air|Normobaric air breathing
3014037|NCT02468752|Experimental|Oxygen|Normobaric oxygen breathing
3014076|NCT02468453|Experimental|Cohort 3-general skin rejuvenation|Pulsed dye laser/bipolar radiofrequency (Velos) treatment treatment of general skin rejuvenation including Rosacea, erythematous scars (including acne), and erythematous striae (subjects enrolled in this group must have at least two of the above mentioned treatment indications.
3014077|NCT02468453|Experimental|Cohort 4-improving skin laxity|Velos (Bipolar radiofrequency only) treatment for improving skin laxity or skin tightness/firmness
3051232|NCT02219035||stroke-ischaemic|no interventions
3014038|NCT02468739|Experimental|Ganglioside-monosialic acid arm|"Patients will receive treatment of adjuvant chemotherapy. Ganglioside-monosialic acid(GM1, 80mg per day) will be given at 1 day before the start of chemotherapy for three days (Day -1, 1 and 2).~Chemotherapy regimens:~Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by paclitaxel (175 mg/m2 *4 cycles) after four courses of chemotherapy; Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by docetaxel (75 mg/m2 *4 cycles) after four course of chemotherapy; Docetaxel (75 mg/m2 q21d) combined with cyclophosphamide (600 mg/m2) for four courses.~The first day (D1) of each cycle is treated with taxane-based chemotherapy. 14-21 days are usually as one cycle. The methods of pretreatment and hydration shall be decided by the physicians."
3014039|NCT02468739|Placebo Comparator|placebo arm|"Patients will receive treatment of adjuvant chemotherapy. Placebo will be given at 1 day before the start of chemotherapy for three days (Day -1, 1 and 2).~Chemotherapy regimens:~Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by paclitaxel (175 mg/m2 *4 cycles) after four courses of chemotherapy; Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by docetaxel (75 mg/m2 *4 cycles) after four course of chemotherapy; Docetaxel (75 mg/m2 q21d) combined with cyclophosphamide (600 mg/m2) for four courses.~The first day (D1) of each cycle is treated with taxane-based chemotherapy. 14-21 days are usually as one cycle. The methods of pretreatment and hydration shall be decided by the physicians."
3014040|NCT02468726|Experimental|NER1008|Use of NER1008 enema for bowel cleansing
3014041|NCT02468726|Active Comparator|Fleet|Use of Fleet enema for bowel cleansing
3014042|NCT02468713|Experimental|Group 1|Combiflex® lipid peri as a reference product (Period 1) -> Winuf® peri as a test product (Period 2)
3014043|NCT02468713|Experimental|Group 2|Winuf® peri as a test product (Period 1) -> Combiflex® lipid peri as a reference product (Period 2)
3014044|NCT02468700|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
3014045|NCT02468700|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
3014046|NCT02468687|Other|N-methyl-pyrrolidone|NMP dose escalation in accelerated phase and standard phase
3014047|NCT02468674|No Intervention|Follow-up|All subjects enter an off-drug follow-up until Week 49
3014048|NCT02468661|Experimental|INC280 single agent|
3014049|NCT02468661|Experimental|INC280 in combination with erlotinib|
3014050|NCT02468661|Active Comparator|Platinum in combination with pemetrexed|Platinum (cisplatin or carboplatin) in combination with pemetrexed
3014051|NCT02468635|Other|without training for upper limb|Receive treatment from traditional pulmonary rehabilitation and without resistive training for upper limb (UL)
3014052|NCT02468635|Other|upper limb exercises|Receive the same treatment control with additional upper limb resistance training.
3014053|NCT02468622||MO patients|Patients with migraine without aura. We will take blood samples during spontaneous migraine attacks
3014054|NCT02468622||MA patients|Patients with migraine with aura. We will take blood samples during spontaneous migraine attacks
3014055|NCT02468609|Other|Ultralow-Dose-CT|Additional Ultralow-Dose-CT of the chest
3014056|NCT02468596|Experimental|Patients|Patients suffering from anti-MAG neuropathy
3014057|NCT02468583|Experimental|FX006 32mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
3014058|NCT02468583|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-release formulation
3014059|NCT02468557|Experimental|Idelalisib|Participants will receive a single dose of idelalisib.
3014060|NCT02468557|Experimental|Idelalisib + nab-paclitaxel|Participants will receive escalating doses of idelalisib + nab-paclitaxel.
3014061|NCT02468557|Experimental|Idelalisib + mFOLFOX6|Participants will receive escalating doses of idelalisib + mFOLFOX6.
3014062|NCT02468544|Experimental|Single Arm Intervention Study|All participants will receive individualized text messages based on a schedule determined during the development and refinement of the mHealth text messaging intervention (i.e., once or twice a week). All participants will receive text messages for: 1) medication reminders, 2) appointment reminders, and 3) text messages addressing barriers (educational information to improve HIV knowledge) or promoting facilitators (e.g., routinizing taking of HIV antiretroviral medication) of care engagement. Each participant will complete baseline assessments, and will select their preferences for personalized messages on the day of baseline assessments. Text messages will be deployed for the duration of the 30-day trial. Participants will be followed-up at the completion of the 30-day intervention. Each participant will be asked to complete a follow-up survey, including questions on the acceptability of the mHealth intervention.
3014063|NCT02468531|Other|Oxygen group|50% oxygen inhalation one hour before and after CPB,and Pulmonary Static Inflation with 50% oxygen during CPB.
3014064|NCT02468531|Experimental|Xenon group|50% oxygen inhalation one hour before and after CPB,and Pulmonary Static Inflation with 50%,75% and 100% Xenon during CPB respectively.
3014065|NCT02468518|Experimental|Patients|Vitamin E capsule 200 IU bd x 12 weeks
3014066|NCT02468518|Active Comparator|Arsenic exposed controls|Vitamin E capsule 200 IU bd x 12 weeks
3014067|NCT02468518|Active Comparator|Healthy volunteers|Vitamin E capsule 200 IU bd x 12 weeks
3014068|NCT02468505|Experimental|STEPS|structured psychosocial transition support that includes individual counseling, and education/training for parent and school personnel
3014069|NCT02468505|No Intervention|TAU|typical transition services and supports
3014070|NCT02468492|Experimental|Platelet Rich Plasma|Approximately 5mL of intraarticular PRP once at baseline
3014071|NCT02468492|Other|Normal Saline|Approximately 5mL of intraarticular normal saline once at baseline
3014072|NCT02468466|Experimental|Multi-level suicide prevention programs|The study team, including staff members from the intervention municipalities, provided each municipality with a standardized form of the work plan used in our study. The intervention municipality autonomously conducted the intervention program during the implementation period.
3014073|NCT02468466|Active Comparator|Community intervention as usual|Suicide prevention program as usual
3014074|NCT02468453|Experimental|Cohort 1 -facial skin disorders|Pulsed dye laser/bipolar radiofrequency (Velos) treatment of facial skin disorders including photo-damage, age spots, lentigos, solar telangiectasia and general facial telangiectasia
3014075|NCT02468453|Experimental|Cohort 2 - leg veins|Pulsed dye laser/bipolar radiofrequency (Velos) treatment of leg veins of diameter of at least 1mm, i.e., venulectasia and reticular leg veins.
3014080|NCT02468427|Experimental|hands-on Teaching|Medical students receive a 30 minutes hands-on training session. All study probands perform assisted delivery (operative vaginal delivery) by vacuum extraction on a pelvic model immediately after the training.
3014081|NCT02468427|Active Comparator|Frontal teaching|Medical students receive a 30 minutes frontal teaching session using a training video demonstrating how to perform assisted delivery (operative vaginal delivery) by vacuum extraction on a pelvic model immediately after the training.
3014082|NCT02468414|Experimental|MDGN201 TARGTEPO secreting EPO|MDGN201 TARGTEPO secreting EPO
3014083|NCT02468401|Experimental|Coronary angiography|Patients undergoing coronary angio with or without percutaneous coronary intervention using a new protocol designed to minimize the exposure to contrast medium
3014084|NCT02468388|Experimental|maltitol|
3014085|NCT02468388|Active Comparator|xylitol|
3014086|NCT02468388|Placebo Comparator|gum base|
3014087|NCT02468388|No Intervention|no gum|
3014088|NCT02468375|Experimental|mirabegron 50mg|about 434 OAB patients intake mirabegrone 50mg/day for 12 weeks.
3014089|NCT02468362|Active Comparator|Laparoscopic group|
3014090|NCT02468362|Active Comparator|Open group|
3014091|NCT02468349|Experimental|Telemedicine|The telehealth group will be remotely monitored and managed on medication adherence, dosage titration, and management of drug side effects, through a combination of feed-forward blood pressure monitoring, app-based education and medication reminders, and remote consultations.
3014092|NCT02468349|No Intervention|Standard care|The standard care group will receive face-to-face consultations at one month, 6 months and 12 months.
3014093|NCT02468336|Experimental|AngioDefender|The AngioDefender device uses a novel, proprietary software algorithm to analyze pulse wave amplitude data collected before and after BA occlusion by a standard upper arm sphygmomanometric blood pressure (BP) cuff. The procedure is non-invasive and employs neither ultrasound nor Doppler flow analysis.
3014094|NCT02468336|Active Comparator|Brachial Artery Ultrasound Imaging|A non-invasive procedure for detecting endothelial dysfunction by measuring the flow-mediated dilation of the brachial artery (BA) using high resolution continuous ECG-gated B-mode (2D) ultrasound imaging during reactive hyperemia, a state of transient increase in tissue blood flow that occurs following a brief period of ischemia, e.g., BA occlusion. BA diameter is measured at end-diastole, coincident with the R wave of a simultaneously recorded ECG.
3014095|NCT02468323|Placebo Comparator|Placebo group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of saline 0,9%.
3014096|NCT02468323|Experimental|Ondansetron group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of ondansetron after cord clamping.
3014097|NCT02468323|Experimental|Palonosetron group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of palonosetron after cord clamping.
3014098|NCT02468310|Experimental|Intervention districts|Access to protocols for management of obstetric and neonatal emergencies via text messaging on request in Intervention districts. Maternal and Neonatal emergency protocols
3014099|NCT02468310|No Intervention|Control districts|No access to protocols for management of obstetric and neonatal emergencies via text messaging in control district
3014100|NCT02468297|Experimental|Electronic Acupuncture Shoe|"Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoe three times a week. 6 weeks of treatment was given. Subjects took placebo only in the first week. No placebo or medicine was prescribed to the subjects since the second week."
3014101|NCT02468297|Placebo Comparator|Control group|Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy. Subjects took ibuprofen(400mg, TID) only in the first week. No placebo or medicine was prescribed to the subjects since the second week.
3014102|NCT02468284|Experimental|Degarelix|
3014103|NCT02468258|Active Comparator|endometrial flushing (A)|Oocytes were retrieved 34-36 h after hCG administration and aspirated FF was collected in a sterile container and was centrifuged at 600 rpm for 10 min at room temperature and a 5-ml sample of the supernatant was obtained for laboratory workup, while the remaining amount of supernatant was used to flush the endometrium through an applied uterine catheter in FF group and was discarded in the other group.
3014104|NCT02468258|No Intervention|B|no intervention Control group included 40 women would not have FF endometrial flushing.
3014105|NCT02468245|Active Comparator|Control Arm|"This is a usual care group. Patients in this arm will receive the standard pre-drug initiation training and 4 week clinic follow up visit."
3014106|NCT02468245|Experimental|Intervention arm|Patients in this arm will also receive the standard pre-drug initiation training followed by telephone follow up by an oncology certified chemotherapy nurse (OCN) at week one, two, and three. Patients will then have the standard 4 week follow up clinic visit.
3014107|NCT02468232|Experimental|LCZ696|Before randomization, all patients receive 2 week LCZ696 50 mg twice daily (b.i.d) as single blind run-in active treatment epoch. In double blind epoch, randomized patients in this arm will start with 100 mg twice daily (b.i.d.) for 4 weeks. Patients will then be up-titrated to 200 mg b.i.d. at week 4 if they are tolerant to 100 mg b.i.d. Total duration of treatment will be up to approximately 40 months.
3014108|NCT02468232|Active Comparator|Enalapril|In double blind period, all randomized patients in this arm will receive enalapril 5mg twice daily (b.i.d.) for 4 weeks. Patients will then be up-titrated to 10 mg b.i.d. at week 4 if they are tolerant to 5 mg b.i.d. Total duration of treatment will be up to approximately 40 months.
3014109|NCT02468219|Active Comparator|aortic valve replacement|patients with aortic stenosis submitted to aortic valve replacement procedure
3014110|NCT02468219|Experimental|transcatheter aortic valve implantation|patients with aortic stenosis who underwent to transcatheter aortic valve implantation
3014111|NCT02468206|Active Comparator|BRTO|Balloon-occluded retrograde transvenous obliteration
3014112|NCT02468206|Active Comparator|NBCA|Endoscopic Cyanoacrylate injection in the gastric varix
3014113|NCT02468193|Experimental|Osilodrostat|
3014114|NCT02468180|Active Comparator|BRTO|Balloon-occluded retrograde transvenous obliteration
3014115|NCT02468180|Active Comparator|NBCA|Endoscopic cyanoacrylate injection
3014116|NCT02468167|Active Comparator|BRTO|Balloon-occluded retrograde transvenous obliteration
3014117|NCT02468167|Active Comparator|NBCA|Endoscopic cyanoacrylate injection
3014118|NCT02468154|Experimental|splint|Splint is placed under the cast of children affected by spasticity who have to keep the heel unloaded.
3014119|NCT02468154|Active Comparator|standard care|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
3014120|NCT02468141|Experimental|SJDBT group|Herbal medicine
3014121|NCT02468141|Placebo Comparator|Placebo|Placebo control
3014122|NCT02468128|Experimental|SDE 150mg|Single dose, intramuscular, Sebacoyl Dinalbuphine Ester injection 150 mg (2 ml)
3014123|NCT02468128|Placebo Comparator|placebo|Single dose, intramuscular , Sebacoyl Dinalbuphine Ester placebo injection (2mL)
3014124|NCT02468115|Experimental|VIS410|Single intravenous fixed dose of VIS410
3014125|NCT02468115|Placebo Comparator|Placebo|Single intravenous infusion of placebo
3014126|NCT02468102||Rivaroxaban / Cohort 1|Patients who have filled a prescription for rivaroxaban in any pharmacy in Sweden during the study period.
3014127|NCT02468102||Standard of care drugs / Cohort 2|Patients who have filled a prescription for standard of care drugs (warfarin, aspirin, clopidogrel, ticlopidine, prasugrel or ticagrelor) in any pharmacy in Sweden during the study period.
3014128|NCT02468089|Experimental|Carbepenem+albumin+GMCSF.|
3014129|NCT02468089|Active Comparator|Carbepenem+albumin|
3014130|NCT02468076|Experimental|Radiofrequency ablation (StarMed)|Radiofrequency ablation catheter
3014131|NCT02468063|Experimental|Noradrenaline + low dose terlipressin|
3014132|NCT02468063|Active Comparator|Noradrenaline|
3014133|NCT02468050|Experimental|Self Management|In addition to the weekly supervised exercise session, participants in this arm will view an instructional video. The video will deliver theory driven training of cognitive behavioural strategies for self management of exercise. It is expected that this will improve adherence to the exercise program.
3014134|NCT02468050|Experimental|Exercise|Personalized 6 week moderate intensity (50 - 75% of heart rate reserve) facility and home based exercise program including cardiovascular and muscular conditioning.
3014135|NCT02468050|No Intervention|Prospective Cohort Control|Eligible, consented participants who are unable to attend the weekly exercise sessions will serve as a cohort control group. Participants will be asked to complete patient reported measures of anxiety, depression, and exercise behaviour within 3 days of biopsy, and 6 weeks post biopsy.
3014136|NCT02468037|Experimental|Phlebotomy|All subjects receive counseling to follow a healthy diet and regular exercise. Phlebotomy occurs at the rate of 500 ml (one Unit) of blood per month over the period of 3-6 months. At two-month intervals, serum ferritin and complete blood counts are determined. When serum ferritin reaches the lowest quartile of normal (<50 ng/mL for females and <70 ng/mL for males, but no sooner than 3 months or later than 6 months after beginning phlebotomy, subjects will be retested for glucose tolerance as described
3014137|NCT02468037|No Intervention|Control|Subjects receive counseling to follow a healthy diet and regular exercise.
3014138|NCT02468024|Active Comparator|Arm 1 lung surgery|Sublobar Resection (SR)
3014139|NCT02468024|Experimental|Arm 2 radiation therapy|Stereotactic Ablative Radiotherapy (SAbR)
3014140|NCT02468011|Experimental|Vibration|Whole body vibration with 35 Hz
3014141|NCT02467998||NPWT treated wounds|NPWT from any FDA cleared NPWT device including
3014142|NCT02467985|No Intervention|Control|
3014143|NCT02467985|Experimental|intervention|Flow of insufflation will be set to 2-3L / min. After the intervention, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. Suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who applies 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 sec. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures.
3014144|NCT02467972|Experimental|UBF group|Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
3014145|NCT02467972|Placebo Comparator|Control|Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
3014146|NCT02467972|Experimental|Inulin group|Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
3014147|NCT02467972|Experimental|Nisin group|Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
3014148|NCT02467959||Ultrasound|Ultrasound evaluation
3014149|NCT02467946|Experimental|Adcetris-Levact (BV-Be) Association|Adcetris® (BV) : 1.2 mg/kg intravenously every 3 weeks Levact® (Be): 90 mg/m2/day intravenously for 2 days every 3 weeks. Up to 6 cycles
3014150|NCT02467933|Placebo Comparator|Placebo|The placebo arm receives a placebo letter unrelated to Seroquel
3014151|NCT02467933|Experimental|Informative Letter|The interventional arm prescribers receive an initial informative letter (called a comparative billing report or peer activity report) followed by 2 followup informative letters at approximately 3 month intervals.
3014152|NCT02467920|Experimental|glargine + exenatide|Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily).
3014153|NCT02467920|Active Comparator|aspart 30|Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to aspart 30 ( subcutaneous injection, twice daily).
3014154|NCT02467907|Experimental|Bevacizumab in Combination with Carboplatin and Paclitaxel|Administration of bevacizumab, carboplatin and paclitaxel once every 3 weeks, for at least 6 cycles, until disease progression (as assessed by the investigator), unacceptable toxicity, physician or participant decision or withdrawal of consent. If either chemotherapy or bevacizumab is discontinued, the participant may continue to receive the other ongoing therapy.
3014155|NCT02467894|Experimental|Group-based Care|Participants who are randomized to group-based care will attend monthly outpatient clinic visits as part of a group of 8-10 patients with CKD and hypertension.
3014156|NCT02467894|No Intervention|Usual Care|Participants who are randomized to usual care will see their provider on clinic days when there is no group meeting.
3014157|NCT02467881|Active Comparator|Physical Activity Increase (GLB-MOD)|Participants randomized to this arm will follow the traditional GLB program with an activity goal of 150 minutes per week of moderately intense physical activity similar to a brisk walk. Progression of the activity goal each week is slow and safe with increases of no more than 30 minutes per week. Participants are requested to try and achieve 20-30 minutes per day of moderate activity but, to allow for flexibility, that amount can be split into 10 minute increments. Self-reported monitoring for this group includes keeping track of weight, daily food intake as well the number of minutes each day spent being active as part of their planned activity goal. This is all recorded in the self-monitoring keeping track book.
3014158|NCT02467881|Active Comparator|Sedentary Time Decrease (GLB-SED)|"The GLB curriculum will be adapted to direct participants to decrease the time they spend sitting in a day rather than to increase moderate+ physical activity as is the case in the current GLB program. In order for the participant to become aware of how much time they spend sitting and where most of their sitting time occurs, they will fill out a 7 Day Sedentary Diary that consists of daily entry of time spent sitting over the course of one week. Participants will be asked to eliminate a 45 minute sitting bout in a day with non-sitting activity. They will initially be asked to eliminate 45 minutes of sitting for two days in that week. This will increase one day a week until 7 days in a week are met."
3014159|NCT02467881|Other|6-month delayed (DELAYED)|Those assigned to the DELAYED group at baseline will wait for 6 months to begin intervention. During the delayed time period, these participants will receive periodic health information newsletters. At the end of 6 months, the DELAYED participants will be randomly assigned to GLB-MOD or GLB-SED intervention, and will begin their intervention program at that time.
3014160|NCT02467868|Experimental|MYL-1401H|MYL-1401H
3014161|NCT02467868|Active Comparator|Neulasta|Neulasta
3014162|NCT02467855||Cross-Sectional Cohort|Participants receiving standard of care for hypertension with well-controlled hypertension will participate in 1 visit.
3014163|NCT02467855||Longitudinal Cohort|Participants receiving standard of care for hypertension with history of hypertension who are uncontrolled on the current antihypertensive medications or participants with newly diagnosed hypertension (diagnosed within the past 4 weeks and uncontrolled on antihypertensive therapy) will be observed over the course of 12-16 weeks.
3014164|NCT02467842|Experimental|NBP607-QIV|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine. Contains 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria. Single intramuscular dose, 0.5 ml
3014165|NCT02467842|Active Comparator|NBP607-Y|Trivalent Inactivated Cell Culture-derived Influenza Vaccine. Contains 3 virus strains; A/H1N1, A/H3N2, B/Yamagata. Single intramuscular dose, 0.5 ml
3014166|NCT02467842|Active Comparator|NBP607-V|Trivalent Inactivated Cell Culture-derived Influenza Vaccine. Contains 3 virus strains; A/H1N1, A/H3N2, B/Victoria. Single intramuscular dose, 0.5 ml
3014167|NCT02467829|No Intervention|10° of elbow flexion|This handle height is the nearest position the walker can be set to to achieve 10° of elbow flexion. Elbow flexion is measured with the child standing in their walker using an electronic goniometer.
3014168|NCT02467829|Experimental|30° of elbow flexion|Increase in handle height. This handle height is the nearest position the walker can be set to to achieve 30° of elbow flexion.
3014169|NCT02467829|Experimental|50° of elbow flexion|Increase in handle height. This handle height is the nearest position the walker can be set to to achieve 50° of elbow flexion.
3014170|NCT02467816|Experimental|School lunch intervention|Intervention schools (6 middle and 6 high) will receive the complete school lunch intervention for two school years.
3014171|NCT02467816|No Intervention|School lunch control|Control schools (6 middle and 6 high) will not receive the school lunch intervention for two school years. Lunch delivery will proceed as normal.
3014172|NCT02467803|Active Comparator|Intervention|We applied scapula mobilization with shoulder ROM exercises
3014173|NCT02467803|Other|Control|We applied only shoulder ROM exercises
3014174|NCT02467790|Experimental|Mild renal insufficiency|PEX 168: 200µg,Subcutaneous,one time.
3014175|NCT02467790|Experimental|Moderate renal insufficiency|PEX 168: 200µg,Subcutaneous,one time.
3014176|NCT02467790|Experimental|Normal renal function|PEX 168: 200µg,Subcutaneous,one time.
3014177|NCT02467777|Active Comparator|Forced Air|Bair Hugger
3014178|NCT02467777|Active Comparator|Conductive Warming|VitaHeat
3014179|NCT02467738|Experimental|Cesium-131 Brachytherapy|Patients undergo brachytherapy using Cesium-131 during surgical resection
3014180|NCT02467725|Experimental|Dynamic Culture Platform|Embryos randomized to the dynamic arm will be placed on the NSSB-300 microvibration platform within the designated incubator. The platform will vibrate at a strength setting of 4 for 5 seconds every 60 minutes. The embryos will be placed on the platform at the two pronucleur stage of development and remain on the platform until the blastocyst stage of development at which time the embryos will be biopsied for preimplantation genetic screening and frozen.
3014181|NCT02467725|No Intervention|Static Culture|The embryos randomized to the static or control arm of the study will be placed directly into the incubator and will not have any additional vibration, per routine care. The embryos will be placed in the incubator at the two pronucleur stage of development and remain in the incubator until the blastocyst stage of development at which time the embryos will be biopsied for preimplantation genetic screening and frozen.
3014182|NCT02467686|Active Comparator|Cimicifuga racemosa|"The other group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal and will start with 2 tablets per day of dry extract of Cimicifuga racemosa.~Each tablet contains 20 mg of dry extract of Cimicifuga racemosa standardized between 1 mg and 1.25 mg of triterpene glycosides expressed in 26-deoxyactein. Will be guided 1 tablet 12/12 hours for 6 months.~WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.~FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up."
3014183|NCT02467686|Placebo Comparator|Control|"Control group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal . They will be followed for 6 months and answer Kupperman scale, WHOQOL questionnaire and FSFI questionnaire at the first visit, 3-month and 6-month follow-up.~WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.~FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up."
3014184|NCT02467673|Active Comparator|NANOPARTICULATE estradiol+ progesterone|"The Blood samples are collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal nanostructured estradiol and progesterone is prescribed.~The patients are evaluated 3 months after THRT treatment protocol. All the patients were instructed about how to use the pump for transdermal application, the first application is performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
3014185|NCT02467673|Active Comparator|MICRONIZED estradiol+ progesterone|"The Blood samples are collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal micronized estradiol and progesterone is prescribed.~The patients are evaluated 3 months after THRT treatment protocol. All the patients were instructed about how to use the pump for transdermal application, the first application is performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
3014186|NCT02467660|Experimental|Online Mindfulness Meditation Training|Weekly 1-hr online training and daily meditation for 30-45 min for 6 wks
3014187|NCT02467660|Experimental|Online Health & Wellness Education|6-week training entails completing weekly 1-hour online training and listening to educational podcasts for 30-45 minutes per day
3014188|NCT02467660|No Intervention|Wait List Control|No training
3014189|NCT02467647|Experimental|A|Arm A: HLJDT 150ml three times per day for 6 months and Thalidomide 100mg once per day for 6 months
3014190|NCT02467647|Active Comparator|B|Arm B: Thalidomide 100mg oral once per day for 6 months
3014191|NCT02467634|Experimental|HuCNS-SC|HuCNS-SC sub-retinal transplantation
3014192|NCT02467621|Experimental|Proton pump inhibitor (PPI)|Pantoprazole 40 mg
3014193|NCT02467621|Placebo Comparator|Normal saline|Saline (0.9%)
3014194|NCT02467608|Experimental|Isoniazid with HUEXC030 and RZE|"Subjects who are genotyped as high risk group will be receiving 2 months of intensive treatment comprised of 4 drugs (Isoniazid with HUEXC030 [H], rifampin [R], pyrazinamide [Z] and ethambutol [E]), followed by 4 months of continual chemotherapy consist of Isoniazid, Rifampin (2HRZE/4HR regimen). Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication at least one follow-up visit at 4 weeks after the end of study treatment visit.~Dosage is as below:~Isoniazid with Isoniazid(H):300mg/600mg daily, rifampin [R]: 450~600mg daily, pyrazinamide [Z]; 1000~2000mg daily and ethambutol [E]: 800-1600mg daily)"
3014195|NCT02467608|Other|HRZE|"Subjects who are genotyped as high risk group will be receiving 2 months of intensive treatment comprised of 4 drugs (Isoniazid [H], rifampin [R], pyrazinamide [Z] and ethambutol [E]), followed by 4 months of continual chemotherapy consist of Isoniazid, Rifampin (2HRZE/4HR regimen). Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication at least one follow-up visit at 4 weeks after the end of study treatment visit.~Dosage is as below:~Isoniazid (H):300mg daily, rifampin [R]: 450~600mg daily, pyrazinamide [Z]; 1000~2000mg daily and ethambutol [E]: 800-1600mg daily)"
3014196|NCT02467595|Experimental|R 0.15 group|"Rocuronium bromide 0.15 mg kg-1 group~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and rocuronium bromide 0.15 mg kg-1~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.~When poor intubating condition., added rocuronium bromide 0.3 mg kg-1 .~Drug: Rocuronium bromide Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy."
3014197|NCT02467595|Active Comparator|R 0.3 group|"Rocuronium bromide 0.3 mg kg-1 group~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and rocuronium bromide 0.3 mg kg-1~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.~When poor intubating condition., added rocuronium bromide 0.3 mg kg-1 .~Drug: Rocuronium bromide Rocuronium bromide 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy."
3014198|NCT02467595|Placebo Comparator|S group|"saline~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and saline.~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.~When poor intubating condition., added rocuronium bromide0.3 mg kg-1 ."
3014199|NCT02467582|Experimental|Aspirin 100 mg|Asprin 100 mg daily for 3 years standard chemo if indicated
3014200|NCT02467582|Active Comparator|Placebo|Placebo daily for 3 years standard chemo if indicated
3014201|NCT02467569|Experimental|Hemay020|"Part one: Dose Escalation Group Hemay020 capsules will be taken orally in doses of 25mg, 50mg, 100mg, 200mg or 300mg once daily for 28 days.~Part two: Extension Group Hemay020 capsules will be taken in two dose groups that assessed by Part one for 28 days."
3014202|NCT02467556|Other|intervention|Open label study with psychological intervention and physiotherapy intervention with medication of morphine, memantine for ten weeks (morphine 30mg tbl per day and memantine up to 40mg tbl per day if tolerated).
3014203|NCT02467543|Placebo Comparator|20% Ethanol|20% ethanol containing no active ingredients. Ten drops will be taken three times daily when the pain and cramping of dysmenorrhea start, and should be stopped when the pain and cramping have ceased.
3014204|NCT02467543|Experimental|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol. Ten drops will be taken three times daily when the pain and cramping of dysmenorrhea start, and should be stopped when the pain and cramping have ceased.
3014205|NCT02467530|Experimental|AGE diet|Dietary intervention consistent of consuming low amounts of (AGEs).
3014206|NCT02467530|No Intervention|Original diet|Patients will continue their original diet.
3014207|NCT02467517|Experimental|INTRAVENOUS KETAMINE|
3014208|NCT02467504|Active Comparator|Experimental|hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
3014209|NCT02467504|Placebo Comparator|Placebo Comparator|hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
3051233|NCT02219035||stroke -haemorrhagic|no intervention
3014210|NCT02467491|Other|Physical Activity group|All the participants enrolled in the study will be part of the physical activity group in which they will perform a scheduled exercise program for 4 weeks using a new physical activity technology called Jintronix.
3014211|NCT02467478|Placebo Comparator|Placebo|Matching placebo 1 pill daily for 12 weeks
3014212|NCT02467478|Active Comparator|Linagliptin|Linagliptin 5mg once daily for 12 weeks
3014213|NCT02467465|Experimental|Physical therapy modalities|Manual therapy techniques aimed to relaxed gastrocnemius and soleus muscles tone, movilizations, stretching and home exercises.
3014214|NCT02467465|Experimental|Invasive Physical therapy modalities|Manual therapy techniques aimed to relaxed gastrocnemius and soleus muscles tone, movilizations, stretching and home exercises. Previously, DN will be applied in gastrocnemius and soleus muscles.
3014215|NCT02467452|Experimental|BDP/FF/GB|Drug: BDP/FF/GB Other name: CHF 5993 pMDI 100/6/12 mcg
3014216|NCT02467452|Active Comparator|FlF/VI + Tiotropium|FlF/VI + Tiotropium Other name: Relvar DPI 100/25 mcg + Spiriva 18 mcg capsule
3014217|NCT02467439|Active Comparator|Notification Cards|Includes two groups of newly diagnosed HIV-infected participants (ppt): Seropositive and Acutely Infected. After consent and a full survey, blood and urine sample are collected for viral genetic testing and future STI testing. Ppts will be given notification cards for their sexual partners, social contacts. Ppts will receive contract partner notification: if the named sexual partners do not present for testing within 7-14 days, community outreach workers will contact and counsel the partners to visit the clinic. Any returning sexual partner or social contact presenting to the clinic with the notification card linking to the original index ppt will be consented (HIV testing, blood and urine specimen collected for viral genetic testing and future STI testing if HIV positive). If HIV-infected, they will be in the active arm, and will receive partner notification and social contact referral cards. If they are HIV-seronegative they will be screened for acute HIV infection.
3014218|NCT02467439|No Intervention|Base Case Arm|consist of HIV seropositive and seronegative STI clinic patrons . After a brief survey to obtain demographics and sexual behavior, seronegative ppts will have blood collected for screening for acute HIV infection. If a person has acute HIV infection, they will be contacted by a community outreach worker and brought back in for counseling, and, if consenting, enrolled in the active arm. STI clinic patrons who are seropositive at screening will be given cards and asked to refer their sexual partners for evaluation using passive referral. Sexual partners presenting to the clinic with the notification card linking to the original index ppt in the base case arm will be consented to be in study (HIV testing, blood and urine specimen collected for viral genetic testing and future STI testing if HIV positive). If they are seropositive, these participants will be in the base case arm, and will receive partner notification cards for passive referral.
3014219|NCT02467426||Chemotherapy|intraarterial chemotherapy with cisplatin and mitoxantrone
3014220|NCT02467413|Active Comparator|BAC treatment group|BAC, topical application on external nasal skin, scalp, and neck, 30g/day, 2 times daily, for 12 weeks
3014221|NCT02467413|Placebo Comparator|BAC Matched vehicle|BAC Matched vehicle, topical application on external nasal skin, scalp, and neck, 30g/day, 2 times daily, for 12 weeks
3014222|NCT02467400|Placebo Comparator|placebo|Sugar pill 2/day for 20 weeks; The once daily groups will receive a placebo as the second dose
3014223|NCT02467400|Active Comparator|Atenolol|Atenolol 50 mg 1/day for 20 weeks
3014224|NCT02467400|Active Comparator|Nebivolol|Nebivolol 5 mg/day for 20 weeks
3014225|NCT02467400|Active Comparator|Propranolol 40 mg|Propranolol 20 mg bid for 20 weeks
3014226|NCT02467400|Active Comparator|Propranolol 80 mg|Propranolol 40 mg bid for 20 weeks
3014227|NCT02467387|Experimental|Experimental: Human (aMBMC)|Intervention: One time intravenous infusion of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more.
3014228|NCT02467387|Placebo Comparator|Placebo:Lactated Ringer's Solution (LRS)|Intervention: One time intravenous infusion of 1.5mL/kg Lactated Ringer's Solution (LRS) administered at a constant rate of approximately 2mL/min.
3014229|NCT02467374|Active Comparator|Immediate Behavior Therapy|If assigned to the immediate BT condition, patients will be asked to make about 24 visits to our clinics at MGH, including an initial assessment, 12 therapy visits over 12 weeks, and 1 booster session (Week 16). Patients will be asked to come to the clinic for assessments during weeks 4 and 6 and after the treatment (week 12), as well as 1 follow-up visit (week 24). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
3014230|NCT02467374|Active Comparator|Waitlist Behavior Therapy|Patients will wait for 12 weeks before starting BT. In this case, they will be asked to make about 21 visits to our clinics, including an initial assessment visit, 12 therapy visits, and 1 booster session. Patients will be asked to come to the clinic for assessments during (weeks 4 and 6) and after the waiting period (week 12). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
3014231|NCT02467361|Experimental|Combo with Ipilimumab|
3014232|NCT02467361|Experimental|Combo with Nivolumab|
3014233|NCT02467361|Experimental|Combo with Pembrolizumab|
3014234|NCT02467348|Experimental|Albumin|MVP (Modest Volume Paracentesis) of less than 5 litres with intravenous albumin at a dose 8 gms/l of ascitic fluid.
3014235|NCT02467348|Active Comparator|No Albumin|MVP (Modest Volume Paracentesis) of less than 5 litres without albumin.
3014236|NCT02467335|Active Comparator|Healthy Subjects|Healthy subjects will receive a single, oral dose of BMS-663068 on Day 1.
3014237|NCT02467335|Active Comparator|Hepatic Impaired Subjects - Mild Rating|Mildly impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
3014238|NCT02467335|Active Comparator|Hepatic Impaired Subjects - Moderate Rating|Moderately impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
3014239|NCT02467335|Active Comparator|Hepatic Impaired Subjects - Severe Rating|Severly impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
3014240|NCT02467322|Experimental|Albumin|MVP (Moderate Volume Paracentesis) of less than 5 liters with iv albumin at a dose 8 gms/l of ascitic fluid.
3014241|NCT02467322|Active Comparator|No Albumin|MVP(Moderate Volume Paracentesis) of less than 5 liters without albumin.
3014242|NCT02467296|Active Comparator|A: 1.5 gr of Sodium|Meal Plans with 1.5 gr of Sodium
3014243|NCT02467296|Active Comparator|B: 3 gr of Sodium|Meal Plans with 3 gr of Sodium
3014244|NCT02467283||Patients with Chronic Periodontitis|"All subjects were free of systemic diseases and to be included, individuals had to be older than 18 years of age.~Chronic periodontitis was diagnosed according to American Academy of Periodontology 1999 Consensus Report."
3014245|NCT02467283||Control Patients|"Control subjects had no radiographic evidence of bone loss or any sign of past and present periodontitis.~All subjects were free of systemic diseases and to be included, individuals had to be older than 18 years of age."
3014246|NCT02467270|Experimental|Cohort A|ponatinib 45 mg once daily starting dose
3014247|NCT02467270|Experimental|Cohort B|ponatinib 30 mg once daily starting dose
3014248|NCT02467270|Experimental|Cohort C|ponatinib 15 mg once daily starting dose
3014249|NCT02467257|Experimental|Intrevention arm|Patients received Gum Arabic as intervention
3014250|NCT02467244||Euthyroid group|Fifty (50) age and sex matched euthyroid subjects will serve as the control group. Control euthyroid subjects will be evaluated once at baseline and after 12 weeks.
3014251|NCT02467244||Hypothyroid group|Fifty (50) hypothyroid patients attending the outpatient department of General Medicine, AIIMS, Bhubaneswar, will be recruited for the present study following inclusion and exclusion criteria.
3014252|NCT02467231||Exposed|Females ages 11-35 to be exposed to alkylating agent chemotherapy
3014253|NCT02467218|Experimental|Immediate Hyperbaric Oxygen Treatment|If a participant is randomized to the group receiving the intervention, the participant will be receiving a baseline assessment functional magnetic resonance imaging (fMRI) and subsequently receiving hyperbaric oxygen treatment for 90 minutes, once daily, five times a week for 8 consecutive weeks (40 treatments with 100% oxygen at 2.0 ATA). A follow-up fMRI will be performed after the last day of treatment.
3014254|NCT02467218|Experimental|Delayed Hyperbaric Oxygen Treatment|If the participant is assigned to the cross group, the participant will also receive a baseline assessment functional magnetic resonance imaging (fMRI). However, it will be followed-up in a controlled manner for 3 months. After 3 months, the participant will be receiving hyperbaric oxygen treatment identical to Group A and a follow-up fMRI will be performed after the last treatment.
3014255|NCT02467205|Other|Intervention|pedometer supported walking and education A ;pedometer will be given to each person in the intervention group at the first education session. Participants will be encouraged to use the pedometer for a 6 month period Educational component; participants will attend six weekly sessions in small groups of up to six people; the content of the sessions will be based on educational cognitive behavioural programme development, In addition, participants will receive education material in the first education session. The intervention group will receive two booster sessions, after 3 and 6 months.
3014256|NCT02467205|No Intervention|Control|participants randomly allocated to the comparison group will receive one education session (visit 2) regarding the importance of exercise and healthy diet and will be given education material similar to intervention group and encouraged to read it.
3014257|NCT02467192|Experimental|Low dose CT|All patients will have Thoracic CT scan
3014258|NCT02467179|Active Comparator|Manual Catheter Manipulation|25 subjects will be randomized to this arm. Manual catheter ablation of the cavo-tricuspid isthmus will be performed.
3014259|NCT02467179|Experimental|Amigo™ Robotic Catheter Manipulation|25 subjects will be randomized to this arm. Robotic catheter ablation of the cavo-tricuspid isthmus with the Amigo Catheter System will be performed.
3014260|NCT02467166|Experimental|Circa™ Probe|The Circa™ Probe will be used during the RFCA to monitor esophageal temperature. Following ablation, the esophagoscopy will be performed to examine the esophagus for resulting thermal lesions.
3014261|NCT02467153|Experimental|RET + vitamin D3|Resistance Exercise Training (RET) + vitamin D3 given orally as tablets at a dosage of 800 International Units (IU)/day for 6 months.
3014262|NCT02467153|Placebo Comparator|RET + placebo|Resistance Exercise Training (RET) + placebo given orally as tablets; 1 tablet per day for 6 months.
3014263|NCT02467140|Active Comparator|Self-fixating mesh|During surgery, the Parietex ProGrib mesh will be used.
3014264|NCT02467140|Active Comparator|Tack fixation|During surgery, the mesh will be fixated with tacks.
3014265|NCT02467127|No Intervention|control group|Patients without headache. No drugs will be administered
3014266|NCT02467127|Experimental|Chronic Headache|Patients with headache > 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
3014267|NCT02467127|Experimental|Chronic headache with drug overuse|Patients with headache > 6 months related to drug treatment, i.e. non steroidal antinflammatory drugs. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
3014268|NCT02467127|Experimental|Acute Headache|Patients without chronic headache but with an history of headache < 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
3014269|NCT02467114|Experimental|All study participants|Stimulation with TMS, a sham coil & no intervention
3014270|NCT02467101|Experimental|Corticosteroid/Saline|"Corticosteroid/Saline~Patients with diagnosis of frontal fibrosing alopecia are included in the study. The diagnosis is based on the clinical findings of frontal and temporoparietal hairline recession with loss of follicular ostia.~In the same patient, intralesional triamcinolone acetone will be injected to half-head (in the active border of hairline) and in the other half-head the patient will be injected with saline solution (placebo).~The intralesional triamcinolone acetone (40 mg/ml)l) of 0,1 mL/1cm, is given along the frontal and frontoparietal hairline every 4 weeks (3 sessions).~This study includes 4 visits: 3 visits of treatment (with 1-month interval) and 1 visit of follow-up (month 6)."
3014271|NCT02467088|Experimental|Individualised Homoeopathic Remedy|Each participant will receive an individualised homoeopathic remedy, in a vehicle of sucrose pillules, according to the symptoms of their PMS. Although different individualised remedies may be dispensed, each remedy will be homoeopathic. Each individualised homoeopathic remedy will have an individualised dosage, frequency and duration based on the laws of individualised homoeopathic prescribing as outlined by De Schepper.
3014272|NCT02467075|Active Comparator|Iopamidol 300 (Contrast)|Subjects scheduled for a clinical CT will be randomized to receive weight-based low-osmolality iodinated contrast with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
3014334|NCT02466633|Experimental|Change in in-hospital cardiac monitoring method|Pre- and post-intervention, where the intervention is a change in in-hospital cardiac monitoring method
3051234|NCT02219035||stroke: not confirmed|no intervention
3014273|NCT02467075|Placebo Comparator|Placebo (Normal Saline)|Subjects scheduled for a standard of care CT will be randomized to receive weight-based normal saline instead of contrast material with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
3014274|NCT02467062|Active Comparator|4Dflow MRI parallel imaging|4D flow MRI with conventional parallel imaging
3014275|NCT02467062|Other|4D flow ktARC parallel imaging|4D flow MRI kt ARC spatiotemporal parallel imaging
3014276|NCT02467049|Active Comparator|ECG-guided insertion of PICC|Placement of the PICC (Peripherally Inserted Central Catheter ) ECG-guided insertion.
3014277|NCT02467049|Experimental|ULTRASOUND-guided insertion of PICC|Placement of the PICC (Peripherally Inserted Central Catheter ) ULTRASOUND-guided.
3014278|NCT02467036|Experimental|Family Based Behavioral Treatment Egg|The FBT+Egg group will participate in group-based FBT and will be assigned to eat eggs a minimum of 5 days a week for breakfast. Families are provided eggs each week to facilitate compliance, along with recipes
3014279|NCT02467036|Active Comparator|Family Based Behavioral Treatment Cereal|The FBT+Cereal group will participate in group-based FBT and will be assigned to eat cereal a minimum of 5 days a week for breakfast. Families are provided cereal each week to facilitate compliance.
3014280|NCT02467023|Experimental|effective muscle stimulation group|Subjects in this arm will be in the study for up to 28 days or until discharge from the ICU. They will receive lower extremity muscle stimulation with Niveus medical stimulator, multiple measurement of maximal isometric twitch strength, muscle biopsy with muscle biopsy medication fentanyl, muscle biopsy medication versed, muscle biopsy medication lidocaine, and blood and urine sampling.
3014281|NCT02467023|Active Comparator|ineffective muscle stimulation group|Subjects assigned to this arm will be studied for up to 28 days or until discharge and will receive a sham muscle stimulation with Niveus medical stimulator, multiple measurement of maximal isometric twitch strength blood and urine samples, and a muscle biopsy sample with muscle biopsy medication fentanyl, muscle biopsy medication versed, and muscle biopsy medication lidocaine.
3014282|NCT02467010|Experimental|Bortezomib, cyclophosphamide, dexamethason|"To assess the efficacy of bortezomib, cyclophosphamide and dexamethasone during re-induction and in maintenance therapy.~To assess the safety of bortezomib, cyclophosphamide and dexamethasone during re-induction and in maintenance therapy in patients with refractory or relapsed multiple myeloma."
3014283|NCT02466997|Experimental|Tacrolimus group|Target-lesion will be treated with the study treatment BID. The batch of treatment (Tacrolimus ointment 0.1% or placebo) will be randomized. All the patients will be treated during 6 months. Counselling on natural daylight exposition will also be given to all patients. During the 6-month observation period, relapse (worsening of VASI ≥ 25%) will be re-treated by the study treatment
3014284|NCT02466997|Placebo Comparator|Control group|"In the Control group, patients will receive the placebo ointment to be applied twice a day during 24 weeks.~Counselling on natural light exposure during the duration of the trial will be given."
3014285|NCT02466984|Experimental|metoclopramide subcutaneous|every two days, first from 10 to 20 and then from 20 to 30 mg/d
3014286|NCT02466984|Active Comparator|metoclopramide intravenous|first from 10 to 20 and then from 20 to 30 mg/d
3014287|NCT02466971|Active Comparator|Arm I (cisplatin, IMRT or RT, brachytherapy)|Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, 30, (and day 36 or 37 at the treating physician's discretion). Patients then undergo EBRT (either conventional RT or IMRT) QD 5 days a week for 25 fractions followed by LDR or HDR brachytherapy according to institution's standards. Treatment continues in the absence of disease progression or unacceptable toxicity.
3014288|NCT02466971|Experimental|Arm II (cisplatin, IMRT or RT, brachytherapy, triapine)|Patients receive cisplatin and undergo EBRT followed by brachytherapy as in Arm I. Patients also receive triapine IV over 2 hours on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Treatment continues in the absence of disease progression or unacceptable toxicity.
3014289|NCT02466958|Active Comparator|levomilnacipran (FETZIMA)|All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.
3014290|NCT02466958|Placebo Comparator|Placebo|All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.
3014291|NCT02466945|Other|V063B-DP3003|all patients will received the study product (V063B-DP3003)
3014292|NCT02466932||Birth Weight|
3014293|NCT02466919|Experimental|Levofloxacin-based concomitant|Pantoprazole 40 mg BID day1~day10 Amoxicillin 1000 mg BID day1~day10 Metronidazole 500 mg BID day1~day10 Levofloxacin 500 mg QD day1~day10
3014294|NCT02466919|Active Comparator|Sequential|Pantoprazole 40 mg BID day1~day10 Amoxicillin 1000 mg BID day1~day5 Metronidazole 500 mg BID day6~day10 Clarithromycin 500 mg BID day6~day10
3014295|NCT02466906|Experimental|rhGM-CSF group|rhGM-CSF was injected subcutaneously perioperation.
3014296|NCT02466906|Placebo Comparator|placebo group|Placebo was injected subcutaneously perioperation.
3014297|NCT02466893|Other|ADAPT Technique/Standard SR Group|
3014298|NCT02466880|Experimental|Telemedicine|Diabetes education and support via telemedicine
3014299|NCT02466880|Active Comparator|Usual care|Diabetes education and support in person
3014300|NCT02466867|Experimental|Naftin® Cream, 2% (younger pediatric cohort)|Subject aged 2 years to 5 years, 11 months with tinea corporis
3014301|NCT02466867|Experimental|Naftin® Cream, 2% (older pediatric cohort)|Subject aged 6 years to 11 years, 11 months with tinea corporis
3014302|NCT02466841||Patients undergoing cubital tunnel release surgery|Patients undergoing cubital tunnel release surgery will be enrolled. All enrolled subjects will be followed regardless of the technique used by surgeon.
3014303|NCT02466828|Experimental|Single patient group receiving Feraheme®|Newly diagnosed GBM patients with no prior treatment will receive Feraheme® as MRI contrast agent
3014335|NCT02466607|Other|RETeval color flicker ERG|Compare implicit times and amplitudes of electroretinograms obtained from series of color flashes to those obtained from white flashes.
3014419|NCT02466048|Experimental|SurgiFill™ on Spinal Fusion|In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
3014304|NCT02466815|Experimental|Treatment A, then Treatment B and then Treatment C|Participants will receive treatment A (JNJ-42756493 10 milligram [mg] tablet, current clinical formulation [G-018] which uses milled active pharmaceutical ingredient [API]) in period 1, treatment B (JNJ-42756493 10 mg tablet, Prototype Formulation I [G-025] which uses coarser API) in period 2 and then treatment C (JNJ-42756493 10 mg tablet, Prototype Formulation II [G-025] which uses coarser API) in period 3.
3014305|NCT02466815|Experimental|Treatment B, then Treatment C and then Treatment A|Participants will receive treatment B in period 1, treatment C in period 2 and then treatment A in period 3.
3014306|NCT02466815|Experimental|Treatment C, then Treatment A and then Treatment B|Participants will receive treatment C in period 1, treatment A in period 2 and then treatment B in period 3.
3014307|NCT02466815|Experimental|Treatment A, then Treatment C and then Treatment B|Participants will receive treatment A in period 1, treatment C in period 2 and then treatment B in period 3.
3014308|NCT02466815|Experimental|Treatment B, then Treatment A and then Treatment C|Participants will receive treatment B in period 1, treatment A in period 2 and then treatment C in period 3.
3014309|NCT02466815|Experimental|Treatment C, then Treatment B and then Treatment A|Participants will receive treatment C in period 1, treatment B in period 2 and then treatment A in period 3.
3014310|NCT02466802|Experimental|A: regorafenib and sildenafil citrate|Patients receive regorafenib and sildenafil citrate by mouth every day (PO QD) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014311|NCT02466776|Active Comparator|Stainless steel staples|Patients in this arm will receive stainless steel staples for skin closure at time of cesarean section.
3014312|NCT02466776|Active Comparator|Absorbable subcuticular Suture|Patients will receive absorbable subcuticular suture for skin closure at time of cesarean section.
3014313|NCT02466763|Active Comparator|round window|Half of the participants will be randomized to the round window technique of cochlear implant device electrode insertion. Intervention for participants randomized to the round window arm include having the round window technique used for the electrode insertion during the participant's cochlear implant surgery. Participants in this arm of the study will also have a post operative CT scan at about three months after surgery.
3014314|NCT02466763|Active Comparator|cochleostomy|Half of the participants will be randomized to the cochleostomy technique of cochlear implant device electrode insertion. For the participants randomized to the cochleostomy arm, the surgeon will use a cochleostomy technique for the electrode insertion during the participant's cochlear implant surgery. Participants in this arm of the study will also have a post operative CT scan at about three months after surgery.
3014315|NCT02466750|Experimental|Primary vaccine|Subjects receive 3 doses off WEE vaccine on Day 0, Day 7 ± 2 days, and Day 28-35 days. A booster will be administered on Day 180 ± 14 days and a sample collected for PRNT80 28-35 days later.
3014316|NCT02466750|Experimental|Booster series|Subjects who previously received the WEE vaccine under another protocol and have a PRNT80 < 1:40. Boosters (and follow-up titers 28-35 days later) may continue while the subject has titers of < 1:40 for a maximum of 4 booster doses in a year. If the titer remains < 1:40 after 4 booster doses in 1 year, the subject will not be given WEE vaccine for 1 year. If the titer is < 1:40 after that interval, one booster dose will be given and the titer will be assayed. If the immune response to the last booster dose is < 1:40, the subject will be considered to have completed the study as a nonresponder.
3014317|NCT02466737|Experimental|no axillary surgery|
3014318|NCT02466737|Active Comparator|sentinel lymph node biopsy|standard arm in first randomization
3014319|NCT02466737|Experimental|sentinel lymph node biopsy alone|
3014320|NCT02466737|Active Comparator|completion axillary lymph node dissection|standard arm in second randomization
3014321|NCT02466724|Experimental|Web Group|Patients given web site (aiddly) instructions for colonoscopy
3014322|NCT02466724|No Intervention|Paper Group|Patients given paper instructions for colonoscopy
3014323|NCT02466711|Active Comparator|Relamorelin|
3014324|NCT02466711|Placebo Comparator|Placebo|
3014325|NCT02466698|Experimental|Intestinal Lavage|A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
3014326|NCT02466698|Active Comparator|Usual Care|Patients will receive usual care for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The usual care group will receive the same antibiotic doses as the experimental arm of the study. For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
3014327|NCT02466685|Experimental|JNJ-18038683|Subjects will be randomized to receive JNJ-18038683 or placebo after the completion of the baseline assessments. Subjects randomized to JNJ-18038683 will receive 10 mg for one week, then titrate to 20 mg for the duration of the trial, with the provision for a single, downward dose adjustment for intolerance, based upon investigator judgment.
3014328|NCT02466685|Placebo Comparator|Placebo|Placebo treatment for 8 weeks.
3014329|NCT02466659|Experimental|CIAO Therapy|Intervention with wearing 3-hour daily CIAO therapy glasses
3014330|NCT02466659|No Intervention|Observation|To observe as one kind of standard care for IXT.
3014331|NCT02466646|Active Comparator|Full-mouth Disinfection IPT|Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Sprey 0,2% and Klorhex® rinse 0,2% for 3 weeks).
3014332|NCT02466646|Experimental|Conventional IPT|Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
3014333|NCT02466646|Experimental|Full-mouth IPT|Initial periodontal treatment was performed in 2 sessions within 24 hours.
3014336|NCT02466607|Other|RETeval dilated versus un-dilated flicker ERG|Compare implicit times and amplitudes of ERGs obtained from cd/m2/sec stimulation (used with dilated pupils) to those obtained from troland stimulation (used with un-dilated pupils).
3014337|NCT02466594|Other|Hilotherm Clinic®|Intervention: Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
3014338|NCT02466581|Active Comparator|Arm 1|"Patients keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. one of the four below:~Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids~Cimzia plus Methotrexate and steroids~Orencia plus Methotrexate and steroids~RoActemra plus Methotrexate and steroids~This intervention is de-escalated starting at randomization."
3014339|NCT02466581|Active Comparator|Arm 2|"Patients keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. one of the four below:~Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids~Cimzia plus Methotrexate and steroids~Orencia plus Methotrexate and steroids~RoActemra plus Methotrexate and steroids~This intervention is de-escalated starting 24 weeks after randomization."
3014340|NCT02466568|Experimental|Phase I and Phase II Treatment Arm|Participants will receive nivolumab and GM.CD40L. Treatment will be administered on an outpatient basis. The nivolumab will be given first followed by the GM.CD40L vaccine for those enrolled on this arm.
3014341|NCT02466568|Active Comparator|Phase II Control Arm|Nivolumab treatment without GM.CD40L. Nivolumab will be given every 2 weeks at a dose of 3mg/kg.
3014342|NCT02466555|Experimental|Music Therapy Group|Music therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Music therapy is an established health profession in which music is used within a therapeutic relationship to address physical, emotional, cognitive, and social needs of individuals (American Music Therapy Association [AMTA], 2013, para 1 and 2).
3014343|NCT02466542|Placebo Comparator|Placebo group|Patients in placebo group will receive general balanced inhaled anesthesia with sevoflurane and remifentanil and a saline 0,9% infusion pump.
3014344|NCT02466542|Active Comparator|Esmolol group|Patients in esmolol group will receive general balanced inhaled anesthesia with sevoflurane and remifentanil and a bolus infection of esmolol 500 mgc/kg followed by a continuous infusion of esmolol 100 mcg/kg/min
3014345|NCT02466529||type 1 spinal muscular atrophy|The age of onset of patients with type 1 SMA is below 6 months of age.
3014346|NCT02466516|Experimental|GS-4997 6 mg|GS-4997 6 mg for 24 weeks
3014347|NCT02466516|Experimental|GS-4997 18 mg|GS-4997 18 mg for 24 weeks
3014348|NCT02466516|Experimental|GS-4997 6 mg+SIM 125 mg|GS-4997 6 mg plus SIM 125 mg for 24 weeks
3014349|NCT02466516|Experimental|GS-4997 18 mg+SIM 125 mg|GS-4997 18 mg plus SIM 125 mg for 24 weeks
3014350|NCT02466516|Experimental|SIM 125 mg|SIM 125 mg for 24 weeks
3014351|NCT02466503|Experimental|Synflutide HFA MDI, 250/25 mcg/dose|Synflutide HFA MDI(Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
3014352|NCT02466503|Active Comparator|SeretideTM EvohalerTM, 250/25 mcg/dose|SeretideTM EvohalerTM (Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
3014353|NCT02466490|Experimental|Fimasartan 60 mg Tablets|FMS 60 mg tablets once a day during the initial 8 treatment weeks of the study
3014354|NCT02466490|Active Comparator|Fimasartan 120 mg Tablets|FMS 120 mg tablets once a day during 4 weeks (treatment weeks 8 to 12)
3014355|NCT02466490|Active Comparator|Fimasartan; Hydrochlorothiazide 60/12.5|FMS 60 mg + HCTZ 12.5 mg tablets (fixed dose combination) once a day during 4 weeks (treatment weeks 8 to 12)
3014356|NCT02466490|Experimental|Fimasartan; Hydrochlorothiazide 120/12.5|FMS 120 mg + HCTZ 12.5 mg tablets (fixed dose combination) once a day during 12 weeks (treatment weeks 12 to 24)
3014357|NCT02466477|Experimental|GeneSight Psychotropic (GEN)|The GeneSight Psychotropic (GEN) product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection. More specifically, patients are tested for clinically important genetic variants of multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to metabolize, tolerate or respond to medications.
3014358|NCT02466477|Experimental|Enhanced-GeneSight Psychotropic (E-GEN)|The current GEN test lacks predictive genes for antipsychotic-induced weight gain (AIWG), a major complication of antipsychotic drug use. Therefore, the Enhanced-GeneSight Psychotropic (E-GEN), which is an enhanced version of the GEN test, was developed by incorporating 6 new genes (represented by 7 SNPs) that are predictive for AIWG, to those used in the GEN algorithm. An increasing risk level associated with AIWG is estimated by an increasing number of risk genotypes that a given patient possesses among the 7 SNPs.
3014359|NCT02466477|Active Comparator|Treatment as Usual (TAU)|"The comparator chosen for this study provides a real world comparison of standard of care for patients who receive no pharmacogenomics guidance.~Patients randomized to the TAU arm will also have their DNA collected and a pharmacogenomic-based interpretive report will be generated using GEN testing. However, this report will not be shared with the treating clinicians until completion at 12 months of the study. Therefore, patients in this arm will receive clinical treatment as usual, without the use or knowledge of genotyping results by their treating clinicians."
3014360|NCT02466464|Active Comparator|Microporous Polysaccharide Hemospheres (MPH)|Subjects with acute epistaxis will receive microporous polysaccharide hemospheres (Arista) powder. In the event that Arista fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the control group and will receive Merocel.
3014361|NCT02466464|Active Comparator|Merocel (Control)|Subjects with acute epistaxis will receive standard-of-care treatment, nasal tampon (Merocel). In the event that Merocel fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the MPH group and will receive Arista powder.
3014391|NCT02466243|Experimental|JBT-101|"Part A: JBT-101 20 mg capsule once a day on Days 1-28, then 20 mg capsule twice a day on Days 29-84.~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE."
3014392|NCT02466243|Placebo Comparator|Placebo|"Part A: Placebo capsule once a day on Days 1-28, then placebo capsule twice a day on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE."
3014458|NCT02465814|Experimental|Arm 2 - Placebo + BAY1002670|Placebo once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)
3014362|NCT02466451||Children operated at birth on CDH and EA|Standardized Questionnaires:For not collaborative patients,< 4 years:Standardized questionnaire collecting anamnestic-clinical data;Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents) For collaborative patients, >4 years:Standardized questionnaire collecting anamnestic-clinical data;Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar);Spirometry;6-minutes walk test (WT 6'); Prick tests;Children Quality of life questionnaire (KINDL questionnaire);Psychological test (Raven Matrices);Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents).
3014363|NCT02466438|Experimental|Piperacillin-tazobactam|"Piperacillin-tazobactam administration (fixed combination, ratio piperacillin:tazobactam = 8:1).~Recruitment stratified by age group and pediatric populations to ensure good representation of those subgroups. Maximum dose: 16g/day. Treatment duration: up to 14 days depending to the treating physician.~Patients with Normal Renal function:~Pediatric and surgery units: 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)~Pediatric intensive care unit (PICU): 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)~Haematology-oncology unit: 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)~Patients with Acute Kidney injury:~Pediatric and surgery units: 2 months-6 years (10)~PICU: 2 months-6 years (10)~Haematology-oncology unit: 2 months-6 years (10)"
3014364|NCT02466425|Experimental|SHP465|Subjects will receive SHP465 (12.5mg and 25mg capsules) or matching placebo. Subjects will take 1 capsule daily throughout the study at approximately 7:00am (+/- 2 hours)
3014365|NCT02466425|Placebo Comparator|Placebo|Subjects will receive SHP465 (12.5mg and 25mg capsules) or matching placebo. Subjects will take 1 capsule daily throughout the study at approximately 7:00am (+/- 2 hours)
3014366|NCT02466412|Active Comparator|CHTP 1.1 M then mCC|"Each subject will follow the below study design:~Day -1 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of CHTP 1.1 M)~Day 2 = Wash-out~Day 3 = 2nd intervention (single product use of mCC)."
3014367|NCT02466412|Active Comparator|mCC then CHTP 1.1 M|"Each subject will follow the below study design:~Day -1 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mCC)~Day 2 = Wash-out~Day 3 = 2nd intervention (single product use of CHTP 1.1 M)."
3014368|NCT02466399|Experimental|POLAT-001|Latanoprost liposome ophthalmic injection
3014369|NCT02466399|Active Comparator|Latanoprost ophthalmic solution|latanoprost ophthalmic solution 0.005%
3014370|NCT02466386|Experimental|Roll-over Participants|Participants who has completed the antecedent study (SPD489-211 or SPD489-347) will be included in this arm. Participants will begin with once daily oral dosing of 5 mg of SPD489 and should be titrated in a step wise fashion until an optimal dose is reached with 10, 15, 20, and 30 mg capsules.
3014371|NCT02466386|Experimental|Directly Enrolled Participants|Participant will be directly enrolled in this study and did not participate in antecedent study SPD489-211 or SPD489-347. Participants will begin with once daily oral dosing of 5 mg of SPD489 and should be titrated in a step wise fashion until an optimal dose is reached with 10, 15, 20, and 30 mg capsules.
3014372|NCT02466373|No Intervention|No clonidine|No clonidine is administered. The outcome measures are recorded, to compare them with the outcome measures of the other clonidine arms
3014373|NCT02466373|Experimental|Clonidine 600mcg|4 patients receive 600 µg/day of clonidine without loading schedule. 4 patients receive 600 µg/day of clonidine with a loading schedule of 300 µg in 4 h.
3014374|NCT02466373|Experimental|Clonidine 1200mcg|"4 patients receive 1200 µg/day of clonidine without loading schedule.~4 patients receive 1200 µg/day of clonidine with a loading schedule of 600 µg in 4 h."
3014375|NCT02466373|Experimental|Clonidine 1800mcg|"4 patients receive 1800 µg/day of clonidine without loading schedule.~4 patients receive 1800 µg/day of clonidine with a loading schedule of 900 µg in 4 h."
3014376|NCT02466360||chronic lower back pain|
3014377|NCT02466347|Experimental|Synflutide HFA MDI, 250/25 mcg/dose|Synflutide HFA MDI(Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
3014378|NCT02466347|Active Comparator|SeretideTM EvohalerTM, 250/25 mcg/dose|SeretideTM EvohalerTM (Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
3014379|NCT02466334|Active Comparator|Active|1.5µg/min IV calcitonin-gene related peptide for 20 minutes
3014380|NCT02466334|Placebo Comparator|Placebo|IV placebo for 20 minutes
3014381|NCT02466321|Experimental|Inverse / Reverse Shoulder|Patient treated with a inverse / reverse shoulder device.
3014382|NCT02466308|Experimental|SAM Ultrasound Diathermy Device|SAM (sam Professional System) 3 MHz ultrasound diathermy device: 4 hours/day, at least 5 days per week, for 6 weeks
3014383|NCT02466295|Experimental|Volume-controlled ventilation|The patient's lungs will be mechanically ventilated using the volume-controlled ventilation with tidal volume 8 ml/kg.
3014384|NCT02466295|Experimental|Pressure-controlled ventilation|The patient's lungs will be mechanically ventilated using the pressure-controlled ventilation with tidal volume 8 ml/kg.
3014385|NCT02466282|Active Comparator|Angiography-guidance|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
3014386|NCT02466282|Experimental|OCT-guidance|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
3014387|NCT02466269||the preauricular approach|A classic preauricular incision was used to treat diacapitular condylar fractures
3014388|NCT02466256|Placebo Comparator|Autosert Group|Procedure / Surgery : Intraocular lens implantation with Autosert injector
3014389|NCT02466256|Placebo Comparator|Royale Group|Procedure / Surgery : Intraocular lens implantation with Royale Injector
3014390|NCT02466256|Placebo Comparator|Monarch III Injector|Procedure / Surgery : Intraocular lens implantation with Monarch III group
3014523|NCT02465450|Experimental|JBT-101 (lenabasum) 5 mg|JBT-101 5 mg once a day on Days 1-28
3014393|NCT02466230|Experimental|Active rTMS|Subjects in the active rTMS arm will receive daily active repetitive transcranial magnetic stimulation (rTMS) treatments for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system will be administered. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
3014394|NCT02466217||1: AID groups|Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus/Antiphospholipid Syndrome, FMF, Cryopyrin-Associated Periodic Syndromes (CAPS)/TNF-receptor Associated Periodic Syndrome (TRAPS), Vasculitis, Uveitis, Myositis, Crohn's Disease, Ulcerative colitis, Type 1 Diabetes
3014395|NCT02466217||2: Control groups|knee arthritis, hip arthritis, muscular dystrophy, healthy subject
3014396|NCT02466204|Active Comparator|corifollitropin alfa (long action FSH)|corifollitropin alfa 150 mcg subcutaneous injection. Seven days after, combines with recombinant FSH 300 IU daily subcutaneous injection
3014397|NCT02466204|Active Comparator|Follitropin Beta (recombinant FSH)|300 IU of recombinant FSH, daily subcutaneous injection
3014398|NCT02466191|Experimental|memantine first|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
3014399|NCT02466191|Experimental|gabapentin first|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
3014400|NCT02466178||Serene RF System|Percutaneous delivery of radiofrequency (RF) energy to create a temporary conduction block to the corrugator and/or procerus muscles.
3014401|NCT02466165|Experimental|MS patients intervention group|the feasibilty and influence of high intense interval exercise on the cardiometabolic risk state in MS patients will be investigated in a pilot trial.
3014402|NCT02466165|No Intervention|healthy controls|To identify whether MS patients have a higher cardiometabolic risk state than healthy controls, this project discovers the prevalence of cardiometabolic risk factors (dyslipidemia, hypertension, body fat, glucose tolerance/IR, inflammation and heart function), in MS and referent subjects.
3014403|NCT02466165|No Intervention|larger group of MS patients|To identify whether MS patients have a higher cardiometabolic risk state than healthy controls, this project discovers the prevalence of cardiometabolic risk factors (dyslipidemia, hypertension, body fat, glucose tolerance/IR, inflammation and heart function), in MS and referent subjects.
3014404|NCT02466152|Experimental|GSK2894512 2.0% Cohort|Subjects will apply a thin layer of GSK2894512 2.0% topical cream twice daily (morning and evening) for 20 days and only in morning on day 21, to all affected skin areas (15-35% BSA) identified at baseline, excluding the scalp and around the eyes
3014405|NCT02466152|Experimental|GSK2894512 1.0% Cohort|Subjects will apply a thin layer of GSK2894512 1.0% topical cream twice daily (morning and evening) for 20 days and only in morning on day 21, to all affected skin areas (15-35% BSA) identified at baseline, excluding the scalp and around the eyes
3014406|NCT02466126|Experimental|bCBT/Direct Referral|A brief cognitive behavioral therapy intervention that offers 6 active- treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to maintain changes.
3014407|NCT02466126|No Intervention|Enhanced Usual Care (EUC)|Participants are provided with educational information on depression and will be encouraged to seek additional depression care options through their primary care providers.
3014408|NCT02466113|Experimental|An experimental group|A 6 microRNA stratified tool is applied in this group.Investigators defined high risk patient and low risk patient according to the microRNA stratified tool.The high risk group should receive adjuvant chemotherapy while the low risk group observation.
3014409|NCT02466113|Other|A control group|A classic stratified tool is applied in this group. Investigators defined high risk and low risk patient according to classical pathological features.The high risk group should receive adjuvant chemotherapy while the low risk group observation.
3014410|NCT02466100|Experimental|Goc Intervention|Patient education materials, study nurse phone call, tip sheet, provider tip sheet
3014411|NCT02466100|No Intervention|usual care|care as usual in the community
3014412|NCT02466087|Experimental|Mg Cl|
3014413|NCT02466087|No Intervention|Control|
3014414|NCT02466074|Experimental|Acetazolamide|Acetazolamide in oral daily divided dose administered for 6 consecutive months
3014415|NCT02466074|Placebo Comparator|Placebo|Placebo in oral daily divided dose administered for 6 consecutive months
3014416|NCT02466061|Experimental|Arm A: Telemedicine Group|"Telemedicine Weight Management plus Wi-Fi Scale (Arm A) Participants in the Telemedicine Group will receive a Wi-Fi Scale that measures weight, lean mass, and fat mass. Participants will receive 15-20 minute telephone counseling sessions by phone. Sessions will occur at routine intervals during the six month intervention period.~All Aim 1 participants, including those randomized to Arm A, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).~Month 12 followup weight data also will be collected through medical record abstraction."
3014417|NCT02466061|Experimental|Arm B: Text for Diet (Text4Diet) Group|"Text for Diet (Text4Diet) Group (Arm B) The intervention in this Arm involves delivery of Short Message Service (SMS) text messages to participants each day over the course of a 6 month intervention period. Participants will also receive a digital scale to track weight on a weekly basis. SMS text messages will be sent 2-3 times per day and will provide feedback, support, prompting, and strategies to adhere to behaviors associated with long-term weight management.~All Aim 1 participants, including those randomized to Arm B, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).~Month 12 follow up weight data also will be collected through medical record abstraction."
3014418|NCT02466061|Active Comparator|Arm C: Enhanced Usual Care Group|"Enhanced Usual Care Group (Arm C) Participants will be provided with handouts based on American Cancer Society guidelines on healthy eating and exercise.~All Aim 1 participants, including those randomized to Arm C, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).~Month 12 follow up weight data also will be collected through medical record abstraction."
3014524|NCT02465450|Placebo Comparator|Placebo|Placebo once a day on Days 1-28.
3014420|NCT02466048|Active Comparator|Autograft on Spinal Fusion|In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
3014421|NCT02466035|Experimental|Lactobacillus GG|Treatment with Lactobacillus rhamnosus GG
3014422|NCT02466035|No Intervention|Other formula|Children assuming other hypoallergenic formulas
3014423|NCT02466022|Experimental|Dexmedetomidine|Patients will receive one 0.5ug/kg bolus of Dexmedetomidine over 10 minutes for sedation prior to spinal anesthetic (12.75mg of heavy Bupivicaine and 10ug of Fentanyl) and 0-4mg of Midazolam for rescue sedation
3014424|NCT02466022|Placebo Comparator|Normal Saline|Patients will receive 0.1cc/kg Normal Saline bolus delivered over 10 minutes for control arm prior to spinal anesthetic (12.75mg of heavy Bupivicaine and 10ug of Fentanyl) and 0-4mg of Midazolam for rescue sedation
3014425|NCT02466009|Experimental|Regorafenib|"120 mg qd, 3 weeks on/1 week off (each cycle is 28 days)~Three 40 mg tablets should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (< 30% fat) breakfast."
3014426|NCT02465996|Other|postprandial distress syndrome (PDS)|"FD patients fulfilled Rome III criteria were subclassified into postprandial distress syndrome (PDS) or epigastric pain syndrome (EPS).~pCLE examination was performed in PDS patients, and then those who were willing to receive Puyuanhewei to treat FD were given 4 pills three times a day for 4 weeks after pCLE examination."
3014427|NCT02465996|Other|epigastric pain syndrome (EPS)|pCLE examination was performed in EPS patients, and then those who were willing to receive Puyuanhewei to treat FD were given 4 pills three times a day for 4 weeks after pCLE examination.
3014428|NCT02465983|Experimental|CART-meso-19 T cells|A single dose of CART-meso-19 T cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting.
3014429|NCT02465970|Experimental|TDCS session|Intervention : Stimulation is applied during a 60 min session with STARSTIM
3014430|NCT02465970|Placebo Comparator|TDCS Placebo|Intervention : Stimulation is not applied during a 60 min session with STARSTIM
3014431|NCT02465957|Experimental|aNK (NK-92)|aNK (activated NK-92, formerly Neukoplast)
3014432|NCT02465944|Experimental|FFP104 - 2.5 mg/kg|FFP104
3014433|NCT02465944|Experimental|FFP104 - 5.0 mg/kg|FFP104
3014434|NCT02465944|Placebo Comparator|Placebo|Placebo
3014435|NCT02465931|Other|Paper-Based Non-Intervention|Paper-based informed consent form paired with verbal overview of key points
3014436|NCT02465931|Experimental|Tablet-Based Consent Intervention|Paper informed consent form paired with tablet-based consent tool which contains visual and audio components
3014437|NCT02465918|Active Comparator|Original Setting- MCS 30 min off/0 min off|Patients at baseline with their original MCS settings: on 30 minutes, off 0 minutes in any single half-hour.
3014438|NCT02465918|Experimental|MCS 25 min on/5 min off|Patient MCS settings programmed to: on 25 minutes, off 5 minutes in any single half-hour.
3014439|NCT02465918|Experimental|MCS 20 min on/10 min off|Patient MCS settings programmed to: on 20 minutes, off 10 minutes in any single half-hour.
3014440|NCT02465918|Experimental|MCS 15 min on/15 min off|Patient MCS settings programmed to: on 15 minutes, off 15 minutes in any single hour.
3014441|NCT02465905|Active Comparator|Raw milk|For raw milk immunotherapy (RMI), fixed dose of raw milk was daily administered at home, determined using tolerated threshold dose during the DBPCFC. Augmentation was made every 5 weeks in the allergy clinic.
3014442|NCT02465905|Active Comparator|Heated milk|For heated milk immunotherapy (HMI), families were asked to weekly increase the daily dose of milk at home using industrial preparations. Milk included in the preparation was less and less heated among time. Passage from heated-milk to half-heated milk and then raw milk was performed in the allergy clinic.
3014443|NCT02465892|No Intervention|Standard Care|Subjects in this group will continue receiving standard care from their provider team.
3014444|NCT02465892|Experimental|Pillars4Life|Subjects in this group will complete the Pillars4Life online coping skills curriculum.
3014445|NCT02465879|Experimental|Therapist Triage|All subjects in this group will be triaged by an extended role occupational or physical therapist prior to their visit with the rheumatologist.
3014446|NCT02465866|Experimental|Treatment A: CL-108 (Fasted)|CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition
3014447|NCT02465866|Experimental|Treatment B: CL-108 (Fed)|CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition
3014448|NCT02465866|Active Comparator|Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)|Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition
3014449|NCT02465866|Active Comparator|Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)|Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition
3014450|NCT02465853|Placebo Comparator|Placebo group|Injection 0.9% Physiological saline solution<2.5 ml and physical therapy and occupational therapy
3014451|NCT02465853|Experimental|Hyaluronic Acid|injection Hyaluronic Acid 2.5ml and physical therapy and occupational therapy
3014452|NCT02465840|Placebo Comparator|Immobilization programs|custom-made protective hand splint physical therapy and occupational therapy
3014453|NCT02465840|Experimental|Kleinert programs|custom-made dynamic hand splint physical therapy and occupational therapy
3014454|NCT02465827|Active Comparator|Saphenous and obturator nerve block|"5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of ropivacaine 0,75% for the obturator nerve block.~Ropivacaine 0.75% for nerve blockades for both nerves mentioned."
3014455|NCT02465827|Active Comparator|Saphenous nerve block|"5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.~Ropivacaine 0.75% for the saphenous nerve block and saline for the obturator nerve block"
3014456|NCT02465827|Placebo Comparator|Placebo nerve block|"5 ml of isotonic saline for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.~Saline for nerve blockades for both nerves mentioned."
3014457|NCT02465814|Experimental|Arm 1 - BAY1002670 + BAY1002670|Vilaprisan (BAY1002670) 2 mg once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)
3051431|NCT02217917|Experimental|Cohort 3|Multiple ascending dose
3014459|NCT02465814|Experimental|Arm 3 - BAY1002670 + BAY1002670|Vilaprisan 2 mg once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily (12 weeks)
3014460|NCT02465814|Experimental|Arm 4 - Placebo+BAY1002670|Placebo once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily(12 weeks)
3014461|NCT02465814|Active Comparator|Arm 5 - Ulipristal + Ulipristal|Ulipristal 5 mg once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)
3014462|NCT02465814|Active Comparator|Arm 6- Placebo + Ulipristal|Placebo once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)
3014463|NCT02465814|Active Comparator|Arm 7- Ulipristal + Placebo|Ulipristal 5 mg once daily (12 weeks), treatment break, Placebo once daily (12 weeks)
3014464|NCT02465801|Experimental|Group 1|"Intervention: HSA-GCSF 1.2 mg~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（1.2mg）will be injected subcutaneously at night o`clock a.m. in the 3rd and 7th day of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration."
3014465|NCT02465801|Experimental|Group 2|"Intervention:HSA-GCSF 1.5 mg~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（1.5mg）will be injected subcutaneously at night o`clock a.m. in the 3rd and 7th day of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration.~Intervention: Drug: TE or TEC"
3014466|NCT02465801|Active Comparator|Group 3|"Intervention: GCSF~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Granulocyte Colony-Stimulating Factor Injection (5μg/kg/day) will be injected subcutaneously at night o`clock a.m. from the 3rd of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. The maximum of usage was continuous 14 days.~Intervention: Drug: TE or TEC"
3014467|NCT02465788|Experimental|755nm alexandrite laser with bipolar RF|GentleTouch (Helos) combines 755nm alexandrite laser energy with bipolar RF energy.
3014468|NCT02465775|Experimental|UltraShape treatment in all subjects|UltraShape treatment for fat reduction to unilateral flank for all subjects with untreated flank as control.
3014469|NCT02465762|Experimental|ultrashape fat reduction treatment|all patient undergo non-invasive fat and circumference reduction at the flanks area
3014470|NCT02465749|Experimental|Continuous Oxygen|Continuous oxygen intake and routine drug treatment .
3014471|NCT02465749|Experimental|Blue Light Deprivation|Wearing blue light-absorbing sunglasses at daily time and routine drug treatment
3014472|NCT02465749|Experimental|Continuous Oxygen Therapy Combined With Blue Light Deprivation|Continuous oxygen intake , Wearing blue light-absorbing sunglasses at daily time and routine drug treatment
3014473|NCT02465749|Other|control|Routine drug treatment
3014474|NCT02465736|Experimental|A (DP-RT)|"• Arm A consists of the concurrent chemoradiotherapy prior to surgery. The patient will receive 4 weeks of radiation therapy and 4 weekly cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Chemotherapy is given by intravenous infusion on days 1, 8, 15, and 22.~Interventions:~Radiation: (44 Gy/20 fractions)~Drug: Docetaxel~Drug: Cisplatin"
3014475|NCT02465736|Experimental|B (NP-RT)|"• Arm B consists of the concurrent chemoradiotherapy followed by surgery. The patient will receive 4 weeks of radiation therapy and 2 cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Each cycle of chemotherapy lasts 21 days/3 weeks. The drugs include Vinorelbine and Cisplatin.~Interventions:~Radiation: (44 Gy/20 fractions)~Drug: Vinorelbine~Drug: Cisplatin"
3014476|NCT02465723|Experimental|MRI with IVIM DW-MRI|Upon enrollment in the study, each patient will undergo a standard pre-treatment evaluation in the Radiation Oncology Clinic. Imaging will include MRI with IVIM DW-MRI (as a research exam). MR imaging will begin within 30 minutes (+/- 15 mins) of the completion of single-dose radiation or the first dose for patients treated with a multifractioned regime. Patients will have corresponding serum samples collected at approximately 1 hour before and 18-24 hours after the first radiation treatment. If radiation therapy occurs on a Friday, the collection of the serum 18-24 hours post-treatment may still be feasible. Patients will be treated with radiation therapy according to our standard clinical guidelines using one of several Varian megavoltage linear accelerators with on-board kilovoltage image-guidance capabilities, using established immobilization devices that are specific to the anatomical site treated at MD's discretion.
3014477|NCT02465710||pelvic organ prolapse|All women who underwent surgical treatment of pelvic organ prolapse in this study.
3014478|NCT02465697|Experimental|BPD Emotion Regulation Training|Guided practice in reappraisal
3014479|NCT02465697|No Intervention|BPD Control|no training in reappraisal
3014480|NCT02465697|Experimental|APD Emotion Regulation Training|Guided practice in reappraisal
3014481|NCT02465697|No Intervention|APD Controls|no training in reappraisal
3014482|NCT02465697|Experimental|Healthy Controls Emotion Regulation Training|Guided practice in reappraisal
3014483|NCT02465697|No Intervention|Healthy Controls|no training in reappraisal
3014484|NCT02465684|Experimental|tourniquet|UKA surgery with tourniquet
3014485|NCT02465684|Experimental|no tourniquet|UKA without tourniquet
3014486|NCT02465671||Patients group|All patients with acute spontaneous basal ganglia hemorrhage admitted to the Jinhua People's Hospital within the first 24 h from stroke during the same period were enrolled.
3014525|NCT02465450|Experimental|JBT-101 (lenabasum) 20 mg QD|JBT-101 20 mg once a day on Days 29-84.
3014526|NCT02465450|Experimental|JBT-101 (lenabasum) 20 mg BID|JBT-101 20 mg twice daily on Days 29-84.
3014487|NCT02465645|Experimental|Carvedilol + Simvastatin|"Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min.~Simvastatin will be administered orally at a start dose of 20 mg for 15 days followed by 40 mg OD for the next 3 months. Along with Simvastatin, Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min."
3014488|NCT02465645|Active Comparator|Carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min.
3014489|NCT02465632|Experimental|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|apply a thin layer of gel to the face
3014490|NCT02465632|Active Comparator|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|apply a thin layer of the gel to the face
3014491|NCT02465632|Placebo Comparator|Placebo topical gel|apply a thin layer of the gel to the face
3014492|NCT02465619||Severe acute hepatitis|Severe acute hepatitis without ascites.
3014493|NCT02465619||Non-cirrhotic|
3014494|NCT02465619||Cirrhotic patients with ascites|
3014495|NCT02465619||decompensated cirrhosis|
3014496|NCT02465606|Experimental|Group 1: Lebrikizumab Dose Level 1|Lebrikizumab will be administered by subcutaneous (SC) injection
3014497|NCT02465606|Active Comparator|Group 2: Topical Corticosteroids|Topical corticosteroid (TCS) cream only
3014498|NCT02465593|Experimental|PEP503+5-FU/capecitabine+Radiotherapy|Patients will receive PEP503 given as intratumor injection on Day 1, followed by preoperative radiation therapy.
3014499|NCT02465580|Active Comparator|hrIL-2 active|Intervention：Add hrIL-2 according to the protocol to original treatment. HrIL-2 active: 1 million U doses of human recombinant interleukin-2 s.c. injection
3014500|NCT02465580|Placebo Comparator|hrIL-2 placebo|1 million U doses of placebo s.c. injection
3014501|NCT02465567|Experimental|BGF (PT010) MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler [MDI])
3014502|NCT02465567|Experimental|BGF (PT010) MDI 160/14.4/9.6 μg|BGF MDI 160/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler [MDI])
3014503|NCT02465567|Experimental|BFF (PT009) MDI 320/9.6 μg|BFF MDI 320/9.6 μg Budesonide, Formoterol Fumarate Aerosol Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)
3014504|NCT02465567|Experimental|GFF (PT003) MDI 14.4/9.6 μg|GFF MDI 14.4/9.6 μg Glycopyrronium, Formoterol Fumarate Aerosol Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)
3014505|NCT02465554||No atherosclerosis cohort|"This group will have patients who have undergone clinically-indicated CT coronary angiography (CT-A) and who have no plaque and an Agatston score of 0. They will then undergo a myocardial contrast echocardiography study during vasodilator stress to subdivide risk further into No atherosclerosis/endothelial function normal and No atherosclerosis/endothelial function abnormal. Blood will then be collected for metabolomics, lipidomic and whole genome sequencing."
3014506|NCT02465554||Atherosclerosis cohort|"This group will have patients who have undergone clinically-indicated CT coronary angiography (CT-A) and who have non-critical plaque (<50% diameter) and at least 1 high risk feature according to the ROMICAT indices. They will then undergo a myocardial contrast echocardiography study during vasodilator stress to subdivide risk further into atherosclerosis/endothelial function normal and atherosclerosis/endothelial function abnormal. Blood will then be collected for metabolomics, lipidomic and whole genome sequencing."
3014507|NCT02465541|Experimental|Arm I (gentle yoga and dietary counseling)|Participants undergo onsite gentle yoga once weekly over 45-60 minutes for 8 weeks and home-based gentle yoga for 6 weeks. Participants also undergo dietary counseling over 8 weeks.
3014508|NCT02465541|Active Comparator|Arm II (enhanced usual care)|Participants undergo enhanced usual care designed to educate on best practices for exercise, diet and lifestyle change once weekly for 14 weeks.
3014509|NCT02465528|Experimental|Ceritinib (LDK378)|
3014510|NCT02465515|Experimental|Albiglutide|Albiglutide once weekly by subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed. Albiglutide will be administered in addition to standard therapy for diabetes and cardiovascular health.
3014511|NCT02465515|Placebo Comparator|Placebo|Placebo once weekly by subcutaneous injection. Placebo will be administered in addition to standard therapy for diabetes and cardiovascular health.
3014512|NCT02465502|Experimental|Regorafenib (BAY73-4506)|Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
3014513|NCT02465489|Experimental|ER, fasting conditions|A single 1000 mg dose of deferiprone extended release tablet formulation administered under fasting conditions
3014514|NCT02465489|Experimental|ER, fed conditions|A single 1000 mg dose of deferiprone extended release tablet formulation administered under fed conditions
3014515|NCT02465489|Experimental|ER half-tablets, fed conditions|A single 1000 mg dose of deferiprone extended release tablet formulation (one 1000 mg tablet divided in two) administered under fed conditions
3014516|NCT02465489|Active Comparator|IR, fasting conditions|A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fasting conditions
3014517|NCT02465489|Active Comparator|IR, fed conditions|A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fed conditions
3014518|NCT02465476|No Intervention|normal care|patient who will have normal treatment pathway
3014519|NCT02465476|Experimental|telemedicine|patient who will have telemedicine
3014520|NCT02465463|Experimental|FMT arm|Patients in the experimental arm with undergo a fecal microbiota transplant (FMT) after finishing a course of antibiotics.
3014521|NCT02465463|No Intervention|Control|Patients in the non-interventional group will not receive a FMT but will be followed over the course of 6 months to assess for recurrence of C.difficile.
3014522|NCT02465450|Experimental|JBT101 (lenabasum) 1 mg|JBT-101 1 mg once a day on Days 1-28
3051559|NCT02217072|No Intervention|Control|Control
3014528|NCT02465437|Experimental|JBT-101 5 mg/20 mg bid|JBT-101 5 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg twice a day (bid) on Days 29-84.
3014529|NCT02465437|Experimental|JBT-101 20 mg/20 mg bid|JBT-101 20 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg bid on Days 29-84.
3014530|NCT02465437|Experimental|JBT-101 20 mg bid/20 mg bid|JBT-101 20 mg bid on Days 1-84.
3014531|NCT02465437|Placebo Comparator|Placebo|Placebo bid on Days 1-84.
3014532|NCT02465437|Experimental|Part B Open-label|JBT-101 20 mg bid on Days 1-364
3014533|NCT02465424||questionnaire order|the order of presentation of the 4 quality of life questionnaires to the patients will be randomised to reduce the impact of boredom and habituation on responses
3014534|NCT02465411|Experimental|Long-term CGM|Continuous glucose monitoring with DexCom G4 platina or later generations during 12 months following participation in the CGMMDI trial
3014535|NCT02465398|Other|Fracture device|Patient were treated with an Anatomical Shoulder Fracture device.
3014536|NCT02465385|Experimental|Intervention|Linaclotide 290mcg
3014537|NCT02465372|Experimental|CSPAP|Schools in this arm will receive the Comprehensive School Physical Activity Program training.
3014538|NCT02465372|No Intervention|Control|Standard practice.
3014539|NCT02465359|Experimental|Immune globulin subcutaneous (Human)|lmmune Globulin Subcutaneous(Human) 20% Liquid (Hizentra) will be given weekly
3014540|NCT02465346|Experimental|MSU-based stroke management|The Mobile Stroke Unit (MSU) and the conventional emergency medical Service (EMS) will meet at the emergency site. The patient's medical history, the physical examination will directly be performed by a physician. Laboratory tests will be analyzed by a point of care laboratory. CT will be performed. After performance of the acute stroke diagnostic work-up the patients and, if indicated thrombolysis, the patient will be transported according to the diagnostic results: Stroke due to large vessel occlusion or to intracranial hemorrhage-> Neurovascular centre; Stroke without large vessel occlusion or without hemorrhage-> primary hospital with regional stroke unit.
3014541|NCT02465346|Active Comparator|Control stroke management|After performing patient's medical history, physical examination (reassessment of the extended Face Arm Speech Time score) and glucose testing by the (stroke trained) emergency personnel, the patient will be transported according to current best clinical practice and relevant guidelines to the next stroke unit or neurovascular centre. The hospital stroke team will be prenotified by the EMS. According to the patients needs the patient might be further transferred.
3014542|NCT02465333|Other|Pathway A|"Screening visit followed by heel fat grafting procedure with local anesthetic and visits at:~1 week Post op study visit 2 (1 month) Post op study visit 3 (2 month) Post op study visit 4 (6 month) Post op study visit 5 (12 month) Crossover to standard podiatry visits Study visit 6 (18 months) Study visit 7 (24 months)"
3014543|NCT02465333|Other|Pathway B|"Screening visit followed by:~Study visit 1 (6 months) Study Visit 2 (12 months) Crossover to Pathway A~Heel fat grafting procedure and local anesthetic and visits at:~1 week Post op study visit 2 (1 month post procedure) Post op study visit 3 (2 month post procedure) Post op study visit 4 (6 month post procedure) Post op study visit 5 (12 month post procedure)"
3014544|NCT02465320|Active Comparator|COL-1077|lidocaine bioadhesive gel, 10%
3014545|NCT02465320|Placebo Comparator|Placebo|placebo bioadhesive gel
3014546|NCT02465307||Delirium group|ICU patients with a positive Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).
3014547|NCT02465307||Control group|ICU patients with a negative Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).
3014548|NCT02465307||Healthy control group|Healthy subjects that sleep in their home environment; observational using accelerometers, cortisol swabs, and Internet Pod (iPod)
3014549|NCT02465294|Placebo Comparator|Potato starch and magnesium stearate|This arm will be used as a control to asses the efficacy of the other probiotic arms. The placebo will contain encapsulated potato starch and magnesium stearate which is used the matrix in the probiotic supplements. The placebo refers only to the intervention supplement, not the behavioral lifestyle intervention. All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
3014550|NCT02465294|Experimental|Lactobacillus|Lactobacillus will be taken as a capsule once daily for 12 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
3014551|NCT02465294|Experimental|Mix of Bifidobacterium and Lactobacillus|A blend of Bifidobacterium and Lactobacillus will be taken as a capsule once daily for 12 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
3014552|NCT02465281||Stroke patients|20 patients who are at least 6 months post stroke. Device: 3T scanner with MRI-compatible robot
3014553|NCT02465281||Healthy volunteers|80 age-matched healthy volunteers
3014554|NCT02465268|Experimental|pp65-shLAMP DC with GM-CSF and Td|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
3014555|NCT02465268|Experimental|pp65-flLAMP DC with GM-CSF and Td|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
3014556|NCT02465268|Placebo Comparator|unpulsed PBMC and Saline|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
3014557|NCT02465255|Experimental|Ketorolac|Ketorolac 0.5 mg/kg administrated by sublingual route
3014558|NCT02465255|Active Comparator|Tramadol|Tramadol 2.0 mg/kg administrated by sublingual route
3014559|NCT02465255|Active Comparator|Acetaminophen (paracetamol)|Acetaminophen (paracetamol) 20.0 mg/kg administrated by sublingual route
3014595|NCT02465060|Experimental|Subprotocol I (PIK3CA mutation)|Patients with PIK3CA mutation without RAS mutation or PTEN loss receive taselisib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014560|NCT02465242||NPi greather than 3|All patients will undergo initial pupillometry evaluation with recording of the NPi in the initial evaluation in the emergency department as per standard evaluation of all trauma patients. If pupils are unequal, group assignment will be determined by lowest pupil reading. Patients with an NPi greater than 3 will be assigned to this group. Pupillometry readings will be gathered for the first 7 days of hospital admission or until discharge. 30, 60, and 90 day post-injury outcomes will be collected.
3014561|NCT02465242||NPi less than or equal to 3|All patients will undergo initial pupillometry evaluation with recording of the NPi in the initial evaluation in the emergency department as per standard evaluation of all trauma patients. If pupils are unequal, group assignment will be determined by lowest pupil reading. Patients with an NPi less than or equal to 3 will be assigned to this group. Pupillometry readings will be gathered for the first 7 days of hospital admission or until discharge. 30, 60, and 90 day post-injury outcomes will be collected.
3014562|NCT02465229|Experimental|Diagnostic methods of indeterminate biliary stricture|
3014563|NCT02465216|Experimental|2 mcg ID93 + 2 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and low dose of adjuvant.
3014564|NCT02465216|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. High dose of antigen and low dose of adjuvant.
3014565|NCT02465216|Experimental|10 mcg ID93 + 5 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. High dose of antigen and high dose of adjuvant.
3014566|NCT02465216|Placebo Comparator|Placebo|Two intramuscular injections of normal saline at Days 0 and 56.
3014567|NCT02465203|Other|Follow up from feeder studies|Follow up arm
3014568|NCT02465164|Other|Cook catheter|Control
3014569|NCT02465164|Active Comparator|Cook catheter plus low dose oxytocin|Test group
3014570|NCT02465151|Experimental|No Protein|
3014571|NCT02465151|Experimental|Low Protein|
3014572|NCT02465151|Experimental|Medium Protein|
3014573|NCT02465151|Experimental|High Protein|
3014574|NCT02465138|Placebo Comparator|Placebo|Normal Saline will be administered prior to procedure.
3014575|NCT02465138|Active Comparator|Toradol|Intravenous ketorolac prior to ERCP
3014576|NCT02465125|Active Comparator|Low transfusion trigger|Intervention group. Low or restrictive transfusion trigger: hemoglobin < 5 mmol/L (approx. 8 g/dl or a hematocrit of 25%) This trigger is what is recommended by the Danish Health and Medicines Authority for stable patients with chronic heart disease.
3014577|NCT02465125|Active Comparator|High transfusion trigger|Control group. High or liberal transfusion trigger: hemoglobin < 6 mmol/L (approx. 10 g/dl or a hematocrit of 30%) This trigger reflects the practice among Danish vascular anesthesiologists and correspond to the transfusion trigger recommended by the European society for vascular surgery
3014578|NCT02465112|Experimental|metabolic radiotherapy|In111-Pentetréotide at 12, 18 and 24 weeks after surgery,
3014579|NCT02465112|Active Comparator|No metabolic radiotherapy - simple monitoring|No metabolic radiotherapy - simple monitoring without theraoy
3014580|NCT02465099|Active Comparator|Electrocautery Dissection (ED)|Patients meeting the study criteria, scheduled to undergo posterior spinal fusion (PSF) using monopolar electrocautery and metal Cobb elevator (considered the current standard) for soft tissue dissection and removal from vertebral surfaces.
3014581|NCT02465099|Experimental|Ultrasonic Dissection (UD)|Patients meeting the study criteria, scheduled to undergo PSF using ultrasonic dissection and metal Cobb elevator for soft tissue dissection and removal from vertebral surfaces.
3014582|NCT02465086|Experimental|Training|This arm, which is a half of the sample size, will be receiving training of linguistic recursion
3014583|NCT02465086|No Intervention|No training|The no intervention group, which is a half of the sample size, will not be recieving training in linguistic recursion.
3014584|NCT02465073|Active Comparator|NXTSC|This group will receive the NXTSC gel only. The NXTSC wound gel and its active agents are applied on the wound bed. A synthetic microfiber dressing will be applied to the surface of the wound
3014585|NCT02465073|Active Comparator|NXTSC plus SOC|This group will receive the NXTSC wound gel plus Standard of Care. The NXTSC wound gel is applied to the wound bed. Local wound management will consist of diagnosing the wound biofilm and providing specific measures to suppress the wound biofilm to allow host healing.
3014586|NCT02465073|Active Comparator|SOC|This group will receive Standard of Care only. The Standard of Care is based on wound management to remove wound slough by frequent debridement. Moist interactive wound care with multiple strategies to suppress biofilm is instituted.
3014587|NCT02465060|Experimental|Subprotocol A (EGFR activating mutation)|Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014588|NCT02465060|Experimental|Subprotocol B (HER2 activating mutation)|Patients with HER2 activating mutation receive afatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014589|NCT02465060|Experimental|Subprotocol C1 (MET amplification)|Patients with MET amplification receive crizotinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014590|NCT02465060|Experimental|Subprotocol C2 (MET exon 14 deletion)|Patients with MET exon 14 deletion receive crizotinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014591|NCT02465060|Experimental|Subprotocol E (EGFR T790M or rare activating mutation)|Patients with EGFR T790M or rare activating mutation receive osimertinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014592|NCT02465060|Experimental|Subprotocol F (ALK translocation)|Patients with ALK translocation receive crizotinib PO twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014593|NCT02465060|Experimental|Subprotocol G (ROS1 translocation or inversion)|Patients with ROS1 translocation or inversion receive crizotinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014594|NCT02465060|Experimental|Subprotocol H (BRAF V600E/R/K/D mutation)|Patients with BRAF V600E/R/K/D mutation receive dabrafenib PO BID and trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014596|NCT02465060|Experimental|Subprotocol J (HER2 amplification >= 7 copy numbers)|Patients with HER2 amplification >= 7 copy numbers receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3014597|NCT02465060|Experimental|Subprotocol L (mTOR mutation)|Patients with mTOR mutation receive sapanisertib PO daily on days 1-28. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3014598|NCT02465060|Experimental|Subprotocol M (TSC1 or TSC2 mutation)|Patients with TSC1 or TSC2 mutation receive sapanisertib PO daily on days 1-28. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3014599|NCT02465060|Experimental|Subprotocol N (PTEN mutation or deletion and PTEN expression)|Patients with PTEN mutation or deletion and PTEN expression receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014600|NCT02465060|Experimental|Subprotocol P (PTEN loss)|Patients with PTEN loss receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014601|NCT02465060|Experimental|Subprotocol Q (HER2 amplification)|Patients with HER2 amplification receive trastuzumab emtansine intravenously (IV) over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3014602|NCT02465060|Experimental|Subprotocol R (BRAF fusion or BRAF non-V600 mutation)|Patients with BRAF fusion or BRAF non-V600 mutation receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014603|NCT02465060|Experimental|Subprotocol S1 (NF1 mutation)|Patients with NF1 mutation receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014604|NCT02465060|Experimental|Subprotocol S2 (GNAQ or GNA11 mutation)|Patients with GNAQ or GNA11 mutation receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014605|NCT02465060|Experimental|Subprotocol T (SMO or PTCH1 mutation)|Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014606|NCT02465060|Experimental|Subprotocol U (NF2 inactivating mutation)|Patients with NF2 inactivating mutation receive defactinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014607|NCT02465060|Experimental|Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)|Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3014608|NCT02465060|Experimental|Subprotocol W (FGFR pathway aberrations)|Patients with FGFR1-3 mutation or translocation receive FGFR Inhibitor AZD4547 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014609|NCT02465060|Experimental|Subprotocol X (DDR2 S768R, I638F, or L239R mutation)|Patients with DDR2 S768R, I638F, or L239R mutation receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014610|NCT02465060|Experimental|Subprotocol Y (Akt mutation)|Patients with Akt mutation receive Akt inhibitor AZD5363 PO BID on days 1-4, 8-11, 15-18, and 22-25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014611|NCT02465060|Experimental|Subprotocol Z1A (NRAS mutation in codon 12, 13, or 61)|Patients with NRAS mutation in codon 12, 13, or 61 receive binimetinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014612|NCT02465060|Experimental|Subprotocol Z1B (CCND1, 2, or 3 amplification with Rb by IHC)|Patients with CCND1, 2, or 3 amplification that have tumor Rb expression by IHC receive palbociclib PO QD for 21 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014613|NCT02465060|Experimental|Subprotocol Z1C (CDK4 or CDK6 amplification and Rb protein)|Patients with CDK4 or CDK6 amplification and tumor Rb protein receive palbociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014614|NCT02465060|Experimental|Subprotocol Z1D (Loss of MLH1 or MSH2 by IHC)|Patients with mismatch repair deficiency (loss of MLH1 or MSH2 by IHC) receive nivolumab IV over 60 minutes on days 1 and 15 for 4 courses and then on day 1 every 28 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014615|NCT02465060|Experimental|Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)|Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive trk inhibitor LOXO-101 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3014616|NCT02465060|Experimental|Subprotocol Z1I (BRCA1 or BRCA2 gene mutation)|Patients with BRCA1 or BRCA2 gene mutation receive WEE1 inhibitor AZD1775 PO QD for 5 days for 2 weeks. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3014617|NCT02465047|Experimental|Self-help booklet|The intervention consists of a brief A5 self-help stress management booklet with an audio Compact Disk.
3014618|NCT02465047|No Intervention|Delayed Intervention|Participants do not receive the intervention until one month after the initial assessment.
3014619|NCT02465034|Active Comparator|Subcortical stroke|Subjects with subcortical stroke in the chronic phase of recovery with mild-moderate impairment of arm function will undergo noninvasive targeting of cortical locations by stereotactic neuronavigation using Transcranial Magnetic Stimulation (TMS), median nerve stimulation and arm motor function assessments. A paired associative stimulation (PAS) protocol using noninvasive stimulation will also be used which will be one of the following, a traditional or a corticocortical or a sham paired associative stimulation protocol. The subjects will also undergo median nerve stimulation.
3014620|NCT02465034|Active Comparator|Healthy Control|Healthy individuals matched for age, gender and handedness with the subcortical stroke group will undergo noninvasive targeting of cortical locations by stereotactic neuronavigation using Transcranial Magnetic Stimulation (TMS), median nerve stimulation and arm motor function assessments. A paired associative stimulation (PAS) protocol using noninvasive stimulation will also be used which will be one of the following, a traditional or a corticocortical or a sham paired associative stimulation protocol.
3014621|NCT02465021|Experimental|Snack bar 1|Dietary intervention: 190 Kcal, 12g fat, 14g carbohydrate, 5g fibre, 6g sugar, 10g protein
3014625|NCT02465021|Experimental|Control 2|Dietary intervention: White bread (190 Kcal, 2g fat, 37g carbohydrate, 2g fibre, 3g sugar, 6g protein)
3014626|NCT02465021|Experimental|Control 3|Dietary intervention: Soft baked pretzel (190 Kcal, 2g fat, 38g carbohydrate, 2g fibre, 6g sugar, 4g protein)
3014627|NCT02465008|Experimental|levobupivaciane group|Levobupivacaine group (L- bupivacaine 0,25% -2,5 mg/ml-) 60 ml. Total dosis in topical use 150 mg (administered irrigation 30 ml into the surgical pocket bilaterally intraoperatively).
3014628|NCT02465008|Placebo Comparator|Placebo Comparator (saline solution)|Placebo group (saline solution) 60 ml (administered irrigation 30 ml into the surgical pocket bilaterally intraoperatively).
3014629|NCT02464995|Experimental|Thermoplasty group|Procedure: Bronchial thermoplasty with the Alair System and conventional therapy
3014630|NCT02464995|No Intervention|Control group|Conventional therapy
3014631|NCT02464982||Women with 1 year non-invasive technology areola tattoo|Women with 1 year non-invasive technology areola tattoo realized in standard care as part of 1 breast mammary reconstruction following an operated breast cancer
3014632|NCT02464969|Experimental|Apixaban|Subjects between 3 month to <18 years will be dosed on a body weight tiered regimen. Subjects > or = 35 kg will receive 10 mg twice daily for 7 days followed by 5 mg twice daily thereafter;<35 kg to 25 kg will receive 8 mg twice daily for 7 days followed by 4 mg twice daily thereafter; <25 to 18 kg will receive 6 mg twice daily for 7 days and then 3mg twice daily thereafter; <18 to 12 kg will receive 4 mg twice daily for 7 days and then 2 mg twice daily thereafter; <12 to 9 kg will receive 3 mg twice daily for 7 days and then 1.5 mg twice daily thereafter; <9 kg to 6 kg will receive 2 mg twice daily for 7 days and 1 mg twice daily thereafter.
3014633|NCT02464969|Active Comparator|Standard of Care|Subjects will receive a dose and dosing regimen of anticoagulation treatment based on usual and customary care per local practices.
3014634|NCT02464930||No-GERD Controls|"NERD controls will be enrolled from subjects presenting to the endoscopy unit who are being evaluated for reasons other than GERD or BE surveillance. These are patients who are referred to the endoscopy unit for: evaluation of anemia, dysphagia, occult blood positivity, gastrointestinal blood loss etc.~No history of GERD~Response no to presence of symptoms on a standardized GERD questionnaire~No prescriptions for acid suppressive medication over the past 2 years as documented in electronic pharmacy records.~Normal endoscopy that does not find Barrett's esophagus, hiatus hernia or erosive esophagitis."
3014635|NCT02464930||GERD Controls|"Respond yes to the presence of symptoms on a standardized GERD questionnaire~Prescriptions for acid suppressive medication as documented in electronic pharmacy records."
3014636|NCT02464930||BE Cases|• Patients who present for evaluation of reflux symptoms and are found to have at least 1 cm of columnar lined esophagus on endoscopy with intestinal metaplasia on biopsies. This will include patients with esophageal adenocarcinoma
3014637|NCT02464917|Experimental|Supplemental oxygen|Subjects in this arm will receive 10L/min via simple facemask
3014638|NCT02464917|No Intervention|Room air|This control arm will receive no supplemental oxygen
3014639|NCT02464904|Experimental|Cryotherapy|Cryospray and biopsies
3014640|NCT02464904|Other|Control|Biopsies
3014641|NCT02464891|Experimental|CCX168|Study medication will be administered as hard gelatin capsules containing 10 mg CCX168. Patients will take 30 mg CCX168, given as 3 x 10 mg capsule, twice daily for 15 days.
3014642|NCT02464865|Experimental|Thiamine 1|presence of severe symptoms and signs of thiamine deficiency: heart failure, convulsion, coma, loss of ankle and knee jerks with muscular wasting and paralysis (typically symmetrical foot- and wrist-drop)
3014643|NCT02464865|Other|Non-thiamine|no symptoms and signs of thiamine deficiency
3014644|NCT02464865|Experimental|Thiamine 2|presence of mild symptoms and signs of thiamine deficiency; peripheral neuropathy alone (paraesthesia of hands and feet)
3014645|NCT02464852|Other|Snood|All recruited participants will try out the snood
3014646|NCT02464839||Hallux valgus patients|All of participants will perform a potassium hydroxide (KOH) examination and fungal culture to prove a fungal nail and feet fungal infection
3014647|NCT02464826|Experimental|Edit arms|Nailprotex apply to the abnormal nail twice daily
3014648|NCT02464813|Active Comparator|Pregabalin|Pregabalin in hard capsule 2mg/kg rounded up to next 25mg twice daily, max 150mg x 2, for 5 days.
3014649|NCT02464813|Placebo Comparator|Sugar pill|Same hard capsule and same amount of tablets twice daily for 5 days.
3014650|NCT02464800||Higher cutting rate group|Vitrectomy with higher cutting rate instruments (5000 cut per minute) were performed in 174 eyes for proliferative diabetic retinopathy
3014651|NCT02464800||Conventional cutting rate group|Vitrectomy with conventional instruments (2500 cut per minute) were performed in 219 eyes for proliferative diabetic retinopathy
3014652|NCT02464787|Experimental|Medical Students|Medical students willing to maintain the increased consumption of LifePak Nano dietary supplements, two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period, to maintain the logs and to report at each of the times that measurements will be made.
3014653|NCT02464774|Experimental|Breast-Conserving Therapy|"Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.~Within 4-8 weeks after surgery, patients receive adjuvant chemotherapy as follows:~TC for stage I: Docetaxel 75 mg/m + Cyclophosphamide 600 mg/m, cycled every 21 days for 4 cycles.~TAC for stage II: Docetaxel 75 mg/m + Doxorubicin 50 mg/m + Cyclophosphamide 500 mg/m, cycled every 21 days for 6 cycles.~Within 4-8 weeks after completion of chemotherapy, patients undergo radiation therapy as follows:~N0: Radiation therapy to whole breast (+boost to tumor bed). N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes."
3014654|NCT02464774|Active Comparator|Mastectomy|"Patients undergo mastectomy (MT) with surgical axillary staging.~Within 4-8 weeks after surgery, patients receive adjuvant chemotherapy as follows:~TC for stage I: Docetaxel 75 mg/m + Cyclophosphamide 600 mg/m, cycled every 21 days for 4 cycles.~TAC for stage II: Docetaxel 75 mg/m + Doxorubicin 50 mg/m + Cyclophosphamide 500 mg/m, cycled every 21 days for 6 cycles."
3014655|NCT02464761|Experimental|Dose escalating PDT|
3014656|NCT02464748|Experimental|Intervention|Patients and their primary carer will use a weekly telehealth system. This involves a series of questions on a tablet computer that is transmitted to their regional MND care centre for review and action.
3014657|NCT02464748|No Intervention|Control|Usual care
3014658|NCT02464722|Experimental|Dexmedetomidine|"Before induction of Anesthesia, 1 mcg/kg iv loading dose of dexmedetomidine over 10 minutes.~Anesthesia was induced with propofol 2 mg kg-1 , rocuronium 0.6 mg kg-1~After Mask ventilation with 6 vol% desflurane in 100% oxygen for 3 minutes, tracheal intubation was done~Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min. The infusion rate was adjusted according to the patient's response, to achieve a mean arterial pressure between 60 and 80 mmHg.~Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.~At the end of surgery, discontinuation of desflurane and dexmedetomidine, sending recovery room."
3014659|NCT02464722|Active Comparator|Remifentanil|"Anesthesia was induced with propofol 2 mg kg-1 , rocuronium 0.6 mg kg-1~Mask ventilation with 6 vol% desflurane in 100% oxygen for 2 minutes.~After 1 mcg/kg iv loading dose of remifentanil over a period of 1 minutes. tracheal intubation was done.~Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min. The infusion rate was adjusted according to the patient's response, to achieve a mean arterial pressure between 60 and 80 mmHg.~Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.~At the end of surgery, discontinuation of desflurane and remifentanil, sending recovery room."
3014660|NCT02464709|Experimental|Actinic keratosis patients|Participant's AKs in facial skin or scalp are first clinically graded and demarcated in two symmetric treatment areas on different sides of face. The areas will be curettaged thinly and next a SPF20 sun protection cream is applied on all sun-exposed areas of the skin. Then a 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid) gel is applied on one treatment side and MAL (methyl 5-aminolevulinate) cream on the other side. The sides will be randomized and the participant doesn't know which side is treated with which light sensitizer. After appropriate absorption time of 30 minutes the patients will be taken to the hospital balcony or yard for 2 hour illumination with natural daylight to accomplish the phototoxic reaction. Maximum dosage of light sensitizer will be 2 grams.
3014661|NCT02464696|Experimental|Non-Invasive Positive Pressure Ventilation (NIPPV)|"Participants placed on intermittent NIPPV oxygen therapy delivered through a mask. Supplemental oxygen administered during periods off of NIPPV. Settings and FIO2 titrated to maintain an SpO2 > 92%.~If at any time participant develops a contraindication to NIPPV, NIPPV therapy discontinued and participant will remain on supplemental oxygen therapy."
3014662|NCT02464696|Active Comparator|High Flow Oxygen Therapy|"Participants maintained on high flow nasal cannula oxygen therapy.~Participants can receive NIPPV if they develop evidence of accessory muscle use with breathing or at the discretion of the treating physician(s) at any time (assuming no contraindications to NIPPV exist)."
3014663|NCT02464683|Placebo Comparator|Placebo|The patient will take a single tablet of placebo daily for 60 days. Each patient will go to the hospital in order to take the blood sample.
3014664|NCT02464683|Experimental|VitaminD|The patient will take a single tablet of Vitamin D (200 International Units) daily for 60 days. Each patient will go to the hospital in order to take the blood sample.
3014665|NCT02464670|Experimental|Group 1|INO-4201 IM + EP, 2 mg, 3 doses
3014666|NCT02464670|Experimental|Group 2|INO-4202 IM + EP, 2 mg, 3 doses
3014667|NCT02464670|Experimental|Group 3|INO-4201 ID + EP 0.2A, 2 mg, 3 doses
3014668|NCT02464670|Experimental|Group 4|INO-4212 IM + EP, 4 mg, 3 doses
3014669|NCT02464670|Experimental|Group 5|INO-4212 + INO-9012 IM + EP, 4+1 mg, 3 doses
3014670|NCT02464670|Experimental|Group 6|INO-4201 ID + EP 0.2A, 1 mg, 3 doses
3014671|NCT02464670|Experimental|Group 7|INO-4201 ID + EP 0.2A, 2 mg, 2 doses
3014672|NCT02464670|Experimental|Group 8|INO-4201 ID + EP 0.2A, 1 mg, 2 doses
3014673|NCT02464670|Experimental|Group 9|INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 3 doses
3014674|NCT02464670|Experimental|Group 10|INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 2 doses
3014675|NCT02464670|Experimental|Group 11|INO-4201 + INO-9012 ID + EP 0.2A, 0.8 + 0.2 mg, 3 doses
3014676|NCT02464670|Experimental|Part II: Group 3A|INO-4201 ID + EP 0.2A, 2 mg, 3 doses
3014677|NCT02464670|Experimental|Part II: Group 3B|INO-4201 ID + EP 0.1A, 2 mg, 3 doses
3014678|NCT02464657|Experimental|Nivolumab + Idarubicin + Cytarabine|"Phase I starting dose of Nivolumab 1 mg/kg by vein on Day 24 of a 28 day cycle. Dose of Nivolumab escalated in successive cohorts of patients. After 2 cycles, if the disease appears to get better, participants receive Nivolumab by vein about every 2 weeks for up to 1 year.~Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.~Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I."
3014679|NCT02464644|Experimental|People with HHT|"People with HHT will identify themselves within the questionnaire, first by statement of what they think is their diagnosis, and second by provision of the HHT diagnostic criteria within specific questions.~They will be directed to appropriate questions, according to answers to the previous questions."
3014680|NCT02464644|Other|Controls without HHT|"People without HHT will identify themselves within the questionnaire, first by statement of what they think is their diagnosis, and second by provision of the HHT diagnostic criteria within specific questions.~They will be directed to appropriate questions, according to answers to the previous questions."
3014681|NCT02464631|Active Comparator|Sofosbuvir + Ribavirin 1|Sofosbuvir + Ribavirin x 24 weeks
3014682|NCT02464631|Experimental|Sofosbuvir + Ribavirin 2|Sofosbuvir + Ribavirin x 36 weeks
3014683|NCT02464631|Experimental|Sofosbuvir + Ribavirin 3|Sofosbuvir + Ribavirin x 48 weeks
3014684|NCT02464618|No Intervention|Usual care|The social contact of patients in this arm will not be contacted
3014685|NCT02464618|Active Comparator|Social contact intervention|The social contact of patients in this arm will be contacted and asked to facilitate the endoscopy care plan of the patient
3014686|NCT02464605|Experimental|SEL-037 (pegsiticase)|Pegylated uricase
3014687|NCT02464592|Active Comparator|Biopsy with Cryoprobes|Transbronchial lung biopsy with a cryoprobe.
3014688|NCT02464592|Active Comparator|Biopsy with Conventional Forceps|Transbronchial lung biopsy with conventional forceps.
3014716|NCT02464384|Other|cohort study|Collection of blood samples and ultrasound / MRI and x-ray examination.
3014934|NCT02462811|Placebo Comparator|Placebo|CL-108 formulation without API
3051884|NCT02214966|Active Comparator|Telmisartan/Ramipril, fasted|
3014689|NCT02464566|Experimental|L Group|"Weekly individual session in obesity clinic (15 to 20 min.) for the first 4 weeks then one individual session in obesity clinic (10 to 20 min.) every two weeks (week 5 to week 12).~Total sessions in 12 weeks: 8 (including the final data collection visit). The components of the program:~1) Low carbohydrate (aim to achieve spontaneous reduction in calorie intake) 2) increased physical activity; 3) behavioural strategies to facilitate adherence to diet and activity prescriptions."
3014690|NCT02464566|Active Comparator|C Group|One session regarding diet restriction and physical activity with printed health education papers.
3014691|NCT02464553|Experimental|Group A|1x periradicular therapy in one intervertebral space, corresponding with pain radiating dermatome
3014692|NCT02464553|Experimental|Group B|2x periradicular therapy in two intervertebral spaces, the first corresponding with pain radiating dermatome the second according magnetic resonance visualization where stenosis is situated
3014693|NCT02464540|Active Comparator|Light-cured resin cement|Laminate veneers luted using light-cured resin cement
3014694|NCT02464540|Active Comparator|Light-cured flowable composite|Laminate veneers luted using light-cured flowable composite
3014695|NCT02464527|Experimental|Stimulus-stimulus pairing (SSP)|Minimally verbal children between 2.0 and 3.9 years with autism spectrum disorder (ASD) and who do not emit vocalizations, will be randomly assigned to the treatment group and will begin the stimulus-stimulus pairing (SSP) procedure. Subjects will be recorded by a vocal recorder at home by the parent/guardian at home or in the community setting.
3014696|NCT02464527|Active Comparator|Waitlist Control (Delayed Treatment)|Minimally verbal children between 2.0 and 3.9 years with autism spectrum disorder (ASD) and who do not emit vocalizations will be randomly assigned to the Waitlist Control group. During the waitlist control subject's assigned session block of six weeks, s/he will not receive any treatment. The subjects will receive the stimulus-stimulus pairing procedure (delayed procedure) after the completion of the assigned 6-week block as a waitlist control participant. Subjects will be recorded by a vocal recorder at home by the parent/guardian at home or in the community setting.
3014697|NCT02464514|Other|Healthy obese children|High carbohydrate meal High fat meal
3014698|NCT02464514|Other|Children with Prader Willi Syndrome|High carbohydrate meal High fat meal
3014699|NCT02464501|Experimental|OPC Treatment|Paclitaxel administration using the OPC for the prevention of restenosis in infrainguinal de novo and restenotic femoropopliteal lesions. Subjects will be treated with the endovascular intervention selected by the treating physician in reference vessels ranging from 4mm to 7mm in diameter. Following the achievement of optimal interventional results (less than thirty (30) percent residual stenosis without stenting) the OPC will be placed at the interventional treatment area and paclitaxel will be delivered to the treated segment. Data will be collected to assess acute safety, long-term safety and durability to demonstrate the safety and efficacy of paclitaxel delivered with the ACT, Inc. OPC device.
3014700|NCT02464488||Main cohort (only cohort of the study)|Patients aged 80 years or older under treatment with dabigatran, rivaroxaban or apixaban because atrial fibrillation. All patients will have plasma drug concentrations measured and will be followed afterwards similarly
3014701|NCT02464475|Experimental|OMT|
3014702|NCT02464475|Sham Comparator|Sham|
3014703|NCT02464462|Experimental|CaD Group|This arm received total of 1800 IU of vitamin D3 and 720 mg of calcium
3014704|NCT02464462|Placebo Comparator|Placebo Group|This arm received rice powder pills
3014705|NCT02464449|Experimental|AI CBT|AI CBT engine will make recommendations to step-down or step-up intensity of CBT FU based on what patient reports and what other similar patients report. Stepped care model.
3014706|NCT02464449|Active Comparator|Standard telephone CBT|Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
3014707|NCT02464436|Experimental|human retinal progenitor cells (hRPC)|Single subretinal administration of human retinal progenitor cells (hRPC)
3014708|NCT02464423|No Intervention|Control|"Usual care: WE-ACTx For Hope and CHUK offer a host of services for HIV+ young people, and these will represent the usual care condition for the study. Both clinics provide adolescent-friendly environments with multidisciplinary teams that offer weekly or monthly support groups, peer education, medical services, mental health screenings, sports activities, HIV and health education sessions, and outreach to parents and guardians. The services youth in the usual care condition receive will be carefully tracked."
3014709|NCT02464423|Active Comparator|Treatment|Culturally-adapted, trauma-informed cognitive behavioral therapy (TI-CBT) intervention: The components of the TI-CBT include a) psychosocial health education b) relaxation training c) cognitive restructuring d) adherence barriers e) caregiver psycho-education. The TI-CBTe will be administered in groups of 8-10 weekly for 2 hours for 3 Sundays each month over 2 months. Two IYL will co-lead each intervention, and two IYL will rate fidelity.
3014710|NCT02464410|Experimental|Motivational Intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT) and uses the structure of ME brief interventions. The motivational session is overlaid on the VA long-term opioid therapy informed consent process.
3014711|NCT02464410|Active Comparator|Enhanced Usual Care|In addition to covering the VHA's long-term OA informed consent process, the enhanced usual care (EUC) condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic. This EUC condition will include some information related to risks of opioid use as part of the informed consent and will consequently have sufficient face validity as an intervention on opioid safety to effectively blind participant to randomization. However, the EUC therapist will not use the motivational enhancement approach of discussing strategies for avoiding these risks. It is designed to be equal in length to the motivational intervention.
3014712|NCT02464397|Experimental|OPTIMAX-BAS 1|Titanium-nitride-oxide coated cobalt-chromium OPTIMAX™ bio-active stent (BAS). Patients will have OCT follow-up 1 month after the index procedure.
3014713|NCT02464397|Active Comparator|SYNERGY-EES 1|SYNERGY™ everolimus eluting stent (EES). Patients will have OCT follow-up 1 month after the index procedure.
3014714|NCT02464397|Experimental|OPTIMAX-OCT 6|Titanium-nitride-oxide coated cobalt-chromium OPTIMAX™ bio-active stent (BAS). Patients will have OCT follow-up 6 months after the index procedure.
3014715|NCT02464397|Active Comparator|SYNERGY-EES 6|SYNERGY™ everolimus eluting stent (EES). Patients will have OCT follow-up 6 months after the index procedure.
3014851|NCT02463357|Experimental|Quercetin|Quercetin: 500mg pill, twice daily for 5 days
3014717|NCT02464371||ICU acquired muscle weakness (IAMW) group +|"The Medical Research Council score (MRC score) is lower than 48, defining an ICU acquired muscle weakness (IAMW).~Kinetic of microRNAs is measured"
3014718|NCT02464371||ICU acquired muscle weakness (IAMW) group -|The Medical Research Council score (MRC score) is higher than 48. Kinetic of microRNAs is measured
3014719|NCT02464358|Experimental|IMB Intervention Group|"The IMB group received an HPV Vaccination Information Statement (VIS) often given to individuals prior to vaccination. In addition, they received the following:~Additional educational content related to HPV, Cervical Cancer, and HPV vaccination,~Motivational content to help identify and problem-solve benefits and barriers to vaccination,~Skills-building content, including brief communication skills training and ways to access the vaccine."
3014720|NCT02464358|Active Comparator|Attention Control Group|The attention control group also received an HPV Vaccination Information Statement (VIS) often given to individuals prior to vaccination. In addition, to maintain consistency with the treatment's presentation format, participants watched a set of short video clips encompassing aspects of women's general and sexual health.
3014721|NCT02464345|Experimental|HAPIFED|HAPIFED therapy
3014722|NCT02464345|Active Comparator|CBT-E|CBT-E therapy
3014723|NCT02464332|Experimental|BLZ-100|"All participants in the study will receive the investigational drug product BLZ-100.~In part 1 of the study, two dose levels of BLZ-100 will be evaluated (3 mg and 12 mg) in 6 subjects, with a 2-3 post-dose imaging window.~In part 2 of the study up to 15 additional subjects will be randomized to one of three imaging interval groups (up to 6 subjects/interval): Early Imaging (within 1 day post-BLZ-100 dose), Intermediate Imaging (2 - 3 days post- BLZ-100 dose), and Late Imaging (4 - 7 days post- BLZ-100 dose)."
3014724|NCT02464319|Active Comparator|Experimental: hrIL-2 active|Intervention：Add hrIL-2 according to the protocol to original treatment. HrIL-2 active: 1 million U doses of human recombinant interleukin-2 s.c. injection
3014725|NCT02464319|Placebo Comparator|Placebo Comparator: hrIL-2 placebo|1 million U doses of placebo s.c. injection
3014726|NCT02464306|Experimental|SOT Recipients|SOT recipients (heart, lung, kidney, liver, kidney-pancreas, and pancreas) with a first-episode of CDI. Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days. The rate of sustained clinical response (SCR; cure without recurrence at 30 days) will be assessed.
3014727|NCT02464306|No Intervention|Historical Cohort|Historical cohort of SOT recipients who received standard of care therapy for CDI at our institution.
3014728|NCT02464293|Experimental|mindfulness-based cognitive therapy|
3014729|NCT02464280||Patients scheduled for lung imaging|"Patients with lung changes and scheduled for lung imaging will undergo:~the scheduled conventional X-ray examination~the scheduled CT scan~the tomosynthesis scan"
3014730|NCT02464280||Patients scheduled for wrist imaging|"Patients with wrist fracture or with osteoprotetic material in the wrist and scheduled for wrist imaging will undergo:~the scheduled conventional X-ray examination~the scheduled CT scan~the tomosynthesis scan"
3014731|NCT02464254|Experimental|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and the positive affect component
3014732|NCT02464254|Active Comparator|Physical activity plus education|Subjects will be randomized to a physical activity goal and education
3014733|NCT02464241||normal control|normal control
3014734|NCT02464241||patients|patients with optic or macular pathology or amblyopia
3014735|NCT02464228|Experimental|Tipifarnib|tipifarnib, oral
3014736|NCT02464215|Active Comparator|open surgery|Conventional procedure,Open surgery
3014737|NCT02464215|Experimental|laparoscopic surgery|Minimum invasive procedure，Laparoscopic surgery
3014738|NCT02464202|Experimental|stereolithography tooth replica|stereolithographic tooth replica used as a guide for tooth autotransplantation decreases extra-alveolar time and reduces trauma to periodontal ligament tissue therefore increasing the success rate after transplantation
3014739|NCT02464189||Children with asthma|
3014740|NCT02464176|Experimental|4 mg dexamethasone group|Following lumbar plexus nerve block administration using bupivacaine and epinephrine, 4 mg of systemic dexamethasone will be administered to this group intravenously. The volume given intravenously will be identical for all groups.
3014741|NCT02464176|Experimental|8 mg dexamethasone group|Following peripheral nerve block using bupivacaine and epinephrine administration, 8 mg of systemic dexamethasone will be administered to this group intravenously. The volume given intravenously will be identical for all groups.
3014742|NCT02464176|Placebo Comparator|Control Group|Normal saline will be used as a placebo control group given at the same time and in the same manner as the experimental groups following peripheral nerve block administration. The volume given intravenously will be identical for all groups.
3014743|NCT02464163|Experimental|Panblok 30µg in 2% SE|30µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
3014744|NCT02464163|Experimental|Panblok 15µg in 2% SE|15µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
3014745|NCT02464163|Experimental|Panblok 7.5µg in 2% SE|7.5µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
3014746|NCT02464163|Experimental|Panblok 30µg (No Adjuvant)|30µg recombinant hemagglutinin (no adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
3014747|NCT02464150|Experimental|Participants|Participants are subjected to gluten intervention in an unblinded fashion.
3014748|NCT02464137|Experimental|Radiation|Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.
3014749|NCT02464124|Experimental|lactulose plus nitazoxanide|"Nitazoxanide dosing: 500 mg tablets twice daily~Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day"
3014750|NCT02464124|Active Comparator|Lactulose alone|Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
3014751|NCT02464111|Experimental|Group 1|Treatment 1: Control - no supplement given Treatment 2: Bolus - LNS supplement provided in one dose Treatment 3: Divided Dose - LNS supplement provided in 3 doses
3014852|NCT02463357|Experimental|Nifedipine+Methazolamide|Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days
3014752|NCT02464111|Experimental|Group 2|Treatment 1: Control - no supplement given Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 2: Bolus - LNS supplement provided in one dose
3014753|NCT02464111|Experimental|Group 3|Treatment 2: Bolus - LNS supplement provided in one dose Treatment 1: Control - no supplement given Treatment 3: Divided Dose - LNS supplement provided in 3 doses
3014754|NCT02464111|Experimental|Group 4|Treatment 2: Bolus - LNS supplement provided in one dose Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 1: Control - no supplement given
3014755|NCT02464111|Experimental|Group 5|Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 2: Bolus - LNS supplement provided in one dose Treatment 1: Control - no supplement given
3014756|NCT02464111|Experimental|Group 6|Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 1: Control - no supplement given Treatment 2: Bolus - LNS supplement provided in one dose
3014757|NCT02464098||Group 1|Participants with diagnosis of hematological malignancy or solid tumor.
3014758|NCT02464098||Group 2|Participants undergoing hematopoietic stem cell transplantation (HSCT).
3014759|NCT02464085||Longitudinal evaluation of recovery|Stroke survivors with subacute and severe upper limb disability
3014760|NCT02464072|Experimental|Subtotal Parathyroidectomy|Patients will be submitted to subtotal parathyroidectomy. The intention is to leave a parathyroid remanent equivalent to two normal parathyroid glands in situ. The type of the operation is the intervention. No drugs or devices are tested.
3014761|NCT02464072|Active Comparator|Total Parathyroidectomy + 45 autografts|Patients will be submitted to a total parathyroidectomy and 45 fragments of parathyroid tissue are grafted in the forearm. This is the current standard treatment at the institution for severe secondary hyperparathyroidism.The type of operation is the intervention itself. No new device or drug is involved.
3014762|NCT02464072|Experimental|Total Parathyroidectomy + 90 autografts|Patients will be submitted to a total parathyroidectomy and 90 fragments of parathyroid tissue are grafted in the forearm. The type of operation is the intervention. No new device or drug is involved. .
3014763|NCT02464059|Experimental|Vitamin D3|Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks
3014764|NCT02464046|Experimental|JNJ-42847922 then Placebo|Participants receive 2*20 milligram (mg) tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive matching placebo from Day 1 to Day 5 of period 2.
3014765|NCT02464046|Experimental|Placebo then JNJ-42847922|Participants will receive matching placebo from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive 2*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 2.
3014766|NCT02464033|Experimental|A|All patients will from Day 1 receive 2 000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
3014767|NCT02464020|Experimental|primary sclerosing cholangitis|Two week course of oral vancomycin 500mg twice a day.
3014768|NCT02464020|No Intervention|Control group|A control group of participants without Primary Sclerosing Cholangitis. Control group will consist of both healthy subjects and subjects with Inflammatory Bowel Disease.
3014769|NCT02464007|Experimental|sSIFN-co|Dose escalation of rSIFN-co
3014770|NCT02463994|Experimental|MPDL3280A + HIGRT|
3014771|NCT02463981|Experimental|neurofeedback training|Neurofeedback training group receives neurofeedback from their own anterior insula.
3014772|NCT02463981|Sham Comparator|sham control|Sham control group receives sham neurofeedback from a large control brain region.
3014773|NCT02463968||CHRONIC CHIKUNGUNYA|Twenty participants with chronic chikungunya defined as continued knee joint effusion at least three months after diagnosis of chikungunya will be enrolled in the study.
3014774|NCT02463968||ACUTE CHIKUNGUNYA|Ten participants with acute chikungunya defined as clinical symptoms of chikungunya with acute fever and joint pain within 10 days the onset of symptoms.
3014775|NCT02463968||HEALTHY CONTROLS|Five healthy controls will have only blood drawn once.
3014776|NCT02463955|Experimental|Thoracoscopy|"experimental intervention (flexible video endoscope)~reference procedure (video-rigid thoracoscope)"
3014777|NCT02463942|Active Comparator|Doxycycline, Doxy®|Beside symptomatic therapy, patients will receive oral doxycycline 100 mg (Doxy®) twice daily. Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
3014778|NCT02463942|Other|No antibiotics|Patients will receive symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
3014779|NCT02463942|Other|Healthy controls|"Patients will be asked to refer a spouse to serve as a control. If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control.~Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia."
3014780|NCT02463929|Experimental|diphenhydramine|Subject sedated with sevoflurane, and given bilateral extraoral infraorbital block with 0,125% bupivacaine. Subject injected 0,5mg/kg diphenhydramine intravenously, 15 minutes prior to discontinuation of sevoflurane. If subject develop agitation, 0,1 mg/kg ketamine is administered
3014781|NCT02463929|Placebo Comparator|control|Subject sedated with sevoflurane, and given bilateral extraoral infraorbital block with 0,125% bupivacaine. Subject injected 0,5cc/kg normal saline intravenously, 15 minutes prior to discontinuation of sevoflurane. If subject develop agitation, 0,1 mg/kg ketamine is administered
3014782|NCT02463916|Active Comparator|Immediate exercise|This group will immediately commence an 8 week exercise programme.
3014783|NCT02463916|Active Comparator|Delayed exercise|This group will continue regular activities for 8 weeks and then commence 8 week exercise programme.
3014853|NCT02463357|Experimental|Metformin|Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)
3014854|NCT02463357|Placebo Comparator|Placebo|Sugar pill manufactured to look like all other investigational products
3014855|NCT02463357|Experimental|Nitrite|Nitrite: 20mg pill, three times daily for 5 days
3015098|NCT02461771|Experimental|APL-2 Cohort 2|10 mg of APL-2 100 μL IVT injection
3014784|NCT02463903|Experimental|Coping effectiveness Training (CET)|The intervention consists of Coping Effectiveness Training (CET), a manual-based group intervention based on a cognitive transactional theory of stress and coping. The purpose of CET is to improve skills to appraise stress, teach a number of techniques to cope with stress, and to give an opportunity to interact with other people with similar experiences of living with CHF. The CET program will, in this study, be modified for patients with CHF. The intervention consists of seven, 90-minute weekly sessions led by a nurse with a Masters degree in nursing science and extensive experience in heart failure care in collaboration with a professional psychologist. Each group consisted of 8 to 12 patients.
3014785|NCT02463903|No Intervention|Control|The control group will receive standard health care and will not take part of the intervention.
3014786|NCT02463890|Experimental|Training|"In this group, patients will perform 3 sessions of one hour per week of the NeuroGyV training program. It is a physical activity program with one session of Nordic walking, one session of aquagym and one session of gymnastic. Program lasts 9 months."
3014787|NCT02463890|Other|Control|In this group, patients will receive only diets and physical activity counselling
3014788|NCT02463877|Other|Minimally-Invasive Procedure|single-arm study of laparoscopic cytoreduction and HIPEC
3014789|NCT02463864|Experimental|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercise sessions
3014790|NCT02463864|Sham Comparator|Sham exercise|Twice daily, individual, stretching and relaxation exercise sessions
3014791|NCT02463851|Active Comparator|AF-Ablation with Multi-electrode catheter|Regular AF-ablation with a multi-electrode ablation catheter
3014792|NCT02463851|Active Comparator|AF-Ablation with Contact Force single-tip electrode|Regular AF-ablation with a regular Contact Force single-tip ablation catheter
3014793|NCT02463838|Experimental|Care Support Intervention|Eligible members are assigned a CareSupport Coordinator who carries a caseload of 25-35 members. A team of 5 Coordinators is supervised by a master's level Social Worker. Community Coordinators work with members to conduct standardized assessments to develop a Care Plan shared with other providers within and outside of SFHP. Coordinators provide members advocacy and navigation across systems of care, to improve coordination focus on treatment goals. Coordinator focus on prevention and early intervention around disease management, advocacy, appointment reminders and accompaniment, home visits, and regular communication with primary care and other providers. Coordinators are encouraged to be accountable for coordinating and following through on all aspects of a member's needs.
3014794|NCT02463838|No Intervention|Usual Care|All eligible SFHP members randomized to usual care will receive medical and health plan by virtue of enrollment in the SFHP and Medi-Cal. Services include assignment to a primary care physician and access to all services available through Medi-Cal in the county of San Francisco.
3014795|NCT02463825|Experimental|Group 1 Pimozide (2mg per day)|Pimozide will be initiated at 1 mg twice daily and maintained on 2mg/day for 50 days. End of study dose reduction will begin following the Final Outcome Measure Visit (Day 65). Pimozide will then be stopped.
3014796|NCT02463825|Experimental|Group 2 Pimozide (4mg per day)|Pimozide will be initiated at 1 mg twice daily then increased by 1mg twice daily every five days to 4 mg/day) for 45 days. End of study dose reduction will begin following the Final Outcome Measure Visit (Day 65). Pimozide will be titrated by reducing the dose by 1 mg twice daily every day to full discontinuation (over 2 days).
3014797|NCT02463825|Placebo Comparator|Group 3 Placebo (Lactose tablet)|Placebo tablets will be utilized and administered in an identical manner for subjects in Group 3
3014798|NCT02463812|Experimental|Intralipid|Patients will receive Intralipid infusion in the recovery room.
3014799|NCT02463812|Placebo Comparator|Control|Patients will receive infusion of normal saline in the recovery room.
3014800|NCT02463799|Experimental|sipuleucel-T and radium 223 combination|"Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20~Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10"
3014801|NCT02463799|Active Comparator|sipuleucel-T alone|Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10
3014802|NCT02463773|Experimental|Ultrasound|Adults older than 18 years old who develop ARDS, as defined by the Berlin criteria, within 72 hours of ICU admission.
3014803|NCT02463747|Experimental|Prolonged Infusion of antibiotics|"Prolonged (4 hours) Infusion of antibiotics.~Intervention:~Primary care would be one of three options:~Piperacillin/tazobactam : 4.5gr, TID, I.V.~Or~Fortum (Ceftazidim): 2.0gr, TID, I.V. - for penicillin-sensitive patients.~Or~Meropenem: 1.0gr, TID, I.V.~Supplementation of Vancomycin will be at the discretion of the treating physician."
3014804|NCT02463747|Active Comparator|Fixed time infusion of antibiotics|"Fixed time (half and hour) infusion of antibiotics.~Intervention:~Primary care would be one of three options:~Piperacillin/tazobactam : 4.5gr, TID, I.V.~Or~Fortum (Ceftazidim): 2.0gr, TID, I.V. - for penicillin-sensitive patients.~Or~Meropenem: 1.0gr, TID, I.V.~Supplementation of Vancomycin will be at the discretion of the treating physician/"
3014805|NCT02463721|Other|SBP patients|ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
3014806|NCT02463708||BHL COTP Caregivers|Caregivers participate in the BHL COTP, which provides support, education, and care management services from a Behavioral Health Provider (BHP) in addition to the Telehealth Education Program (TEP), a manualized program that consists of various modules that seek to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
3014807|NCT02463695|Experimental|vestibular deficit|"Initial clinical assessment including otoneurological examination, pure tone audiometry, tympanometry vestibular screening tests and Magnetic Resonance Imaging as clinically indicated.~The cortical vestibular evoked potentials will add approximately add an extra 30 minutes to the test sequence but is minimally invasive and will not cause any pain or discomfort. It will be conducted on both the affected and non-affected ears."
3014808|NCT02463695|Active Comparator|otologically normal controll|Normative data will be collected from 36 normal ears from subjects that have no history of audiovestibular symptoms and are not being investigated for any balance disorders. The cortical vestibular evoked potentials will be recorded from both ears
3014809|NCT02463682|Active Comparator|Sensor-Augmented Pump Open-Loop Care (Week 1)|The subjects Sensor-Augmented Pump Open-Loop Care for the first week of the study before any adjustments to pump settings.
3014810|NCT02463682|Experimental|Closed-Loop Control System with Zone MPC and HMS|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device.
3014811|NCT02463643|Experimental|Z-215 10 mg/day|Drug: Z-215 10mg Drug: Z-215 Placebo Drug: Rabeprazole Sodium Placebo
3014812|NCT02463643|Experimental|Z-215 20 mg/day|Drug: Z-215 20mg Drug: Z-215 Placebo Drug: Rabeprazole Sodium Placebo
3014813|NCT02463643|Experimental|Z-215 40 mg/day|Drug: Z-215 20mg Drug: Z-215 20mg Drug: Rabeprazole Sodium Placebo
3014814|NCT02463643|Active Comparator|Rabeprazole Sodium 10 mg/day|Drug: Z-215 Placebo Drug: Z-215 Placebo Drug: Rabeprazole Sodium
3014815|NCT02463630|Experimental|Compression distraction reduction|All the participants in this group will be performed Posterior Compression Distraction Reduction Technique for reduction of basilar invagination and atlantoaxial dislocation
3014816|NCT02463617|Other|PD patients|
3014817|NCT02463604|Experimental|Remote Ischemic Preconditioning|"A blood pressure cuff is placed on upper arm and inflated to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle is repeated 3 times in total.~The procedure has to be completed between 5 and 60 minutes prior coronary angiography."
3014818|NCT02463604|Sham Comparator|Control|"A blood pressure cuff is placed on upper arm and inflated to 10 mmHg for 5 minutes and then deflated for 5 minutes. This cycle is repeated 3 times in total.~The procedure has to be completed between 5 and 60 minutes prior coronary angiography."
3014819|NCT02463591|Experimental|Beriplex 50 IU/Kg|Cross over design: After therapy with Dabigatran Etexilate 300mg BID for 2.5 days, subjects will receive a single dose of Beriplex 50 IU/Kg. After a 10 day minimum wash-out period subjects will receive the alternative treatment (Placebo).
3014820|NCT02463591|Placebo Comparator|Placebo|Cross over design: After therapy with Dabigatran Etexilate 300mg BID for 2.5 days, subjects will receive a single dose of Placebo identically in appearance to Beriplex 50 IU/Kg. After a 10 day minimum wash-out period subjects will receive the alternative treatment (Beriplex).
3014821|NCT02463565||hospitalized patients|
3014822|NCT02463552|Placebo Comparator|Placebo|
3014823|NCT02463552|Experimental|Naproxen|
3014824|NCT02463526|Experimental|Group 1 - MWM condition/Sham condition|Subjects will receive treatment for 4 times with Mulligan's Mobilization with Movement (MWM) condition, and after 72 hrs, will be treated 4 times with the sham condition.
3014825|NCT02463526|Experimental|Group 2 - Sham condition/MWM condition|Subjects will receive treatment for 4 times with sham condition, and after 72 hrs, will be treated 4 times with the Mulligan's Mobilization with Movement (MWM) condition.
3014826|NCT02463513|Placebo Comparator|Treatment 1|
3014827|NCT02463513|Active Comparator|Treatment 2|
3014828|NCT02463513|Active Comparator|Treatment 3|
3014829|NCT02463500||DFU with/without osteomyelitis|Patients of the investigators. Male and female, age 18 and older (up to age 89), of any race or ethnicities, who have diabetes (Type I or II) and a foot ulceration.
3014830|NCT02463487|Active Comparator|Cardinal Pro +Simultaneous Irrigation (NPWTi)|• Negative Pressure Wound Therapy with Irrigation
3014831|NCT02463487|Active Comparator|Cardinal Pro (NPWT) Therapy|• Negative Pressure Wound Therapy without Irrigation
3014832|NCT02463474|Experimental|mHealth Intervention|Each week for 10 weeks, participants will receive two text messages on their cell phone. The first text message will contain a link to a culturally tailored, informational video clip about living with breast cancer. The second text message that provides a supportive message about the video content.
3014833|NCT02463461|Experimental|ActiSleep Activity Monitor|Subjects placed in this group will given an ActiSleep Activity Monitor for the one night of the study.
3014834|NCT02463461|Experimental|Jawbone Activity Monitor|Subjects placed in this group will given a Jawbone Activity Monitor for the one night of the study.
3014835|NCT02463461|Experimental|Actiwatch 2 Activity Monitor|Subjects placed in this group will given an Actiwatch 2 Activity Monitor for the one night of the study.
3014836|NCT02463461|Experimental|FitBit Activity Monitor|Subjects placed in this group will given a FitBit Activity Monitor for the one night of the study.
3014837|NCT02463461|Experimental|Actigraph by Ambulatory Monitoring Activity Monitor|Subjects placed in this group will given an Actigraph by Ambulatory Monitoring Activity Monitor for the one night of the study.
3014838|NCT02463448|Experimental|Autologous Muscle Derived Cells|Autologous Muscle Derived Cells are obtained by needle biopsy from the subject's own thigh muscle. These cells are sent to a special lab for growth and processing. When ready the cells are sent to the treatment location for injection into the bladder wall.
3014839|NCT02463435|Active Comparator|Nutritional intervention|Patients under only nutritional intervention for weight loss
3014840|NCT02463435|Experimental|Nutritional intervention plus olive oil|Patients under conventional treatment (nutritional intervention) plus extra virgin olive oil supplementation
3014841|NCT02463435|Experimental|Olive oil|Patient under habitual food consumption plus extra virgin olive oil supplementation
3014842|NCT02463422||San Diego, CA|Toddlers detected with ASD and other disorders based on the Get SET Early Model in San Diego.
3014843|NCT02463422||Phoenix, AZ|Toddlers detected with ASD and other disorders based on the Get SET Early Model in Phoenix.
3014844|NCT02463409|Experimental|Theophylline|Patients will receive a 24 hour continuous infusion of intravenous theophylline.
3014845|NCT02463396|Experimental|Mindfulness Based Cognitive Therapy (MBCT) for ADHD|Adapted MBCT for ADHD
3014846|NCT02463396|No Intervention|Treatment as usual (TAU)|Usually medication & psycho-education
3014847|NCT02463383|Experimental|Sequence 1|"Ibuprofen Tab 400MG~Placebo Tab"
3014848|NCT02463383|Experimental|Sequence 2|"Placebo tab~Ibuprofen Tab 400MG"
3014849|NCT02463370|Experimental|Group II|Group II patients will receive local anesthetic infiltration in two injections on each side of the face at the maxillary and infra-orbital areas and the remaining injections are placebo (saline).
3014850|NCT02463370|Experimental|Group V|Group V patients will receive local anesthesia in five injections on each side of the face at the infra-orbital area, supratrochlear area, medial to the medial canthus, nasal still and anterior septum. The remaining maxillary injection is placebo.
3014856|NCT02463344||MA09-hRPE|"Experimental: Subretinal injection of MA09-hRPE~Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
3014857|NCT02463331|Active Comparator|chloroquine plus prednisone|Chloroquine diphosphate 250mg/day associated to prednisone in variable doses
3014858|NCT02463331|Experimental|azathioprine plus prednisone|azathioprine in variable doses (50-150mg/day) associated to prednisone in variable doses
3014859|NCT02463318|Experimental|Multiple slerosis|Melatonin,,one millimolar,one micromolar,one nanomolar, 12 hr treatment.
3014860|NCT02463318|Experimental|Healthy subjects|Melatonin,one millimolar,one micromolar,one nanomolar, 12 hr treatment. hydrogen peroxide, 250 micromollar,2 hr treatment
3014861|NCT02463305|Experimental|Treatment arm|6 patients with mild-moderate ulcerative colitis treated with creatine monohydrate 21 grams per day in three divided doses taken with water for 8 weeks.
3014862|NCT02463305|Placebo Comparator|Placebo arm|6 patients with mild-moderate ulcerative colitis treated with placebo (matching creatine monohydrate) 21 grams per day in three divided doses taken with water for 8 weeks.
3014863|NCT02463305|Experimental|Optional Open-Label Treatment arm|Up to 6 patients, who were randomized to the placebo arm, will be given the option to continue with open-label creatine monohydrate treatment at 21 grams per day in three divided doses, taken with water, for 8 weeks. Only non-invasive testing will be performed.
3014864|NCT02463292||patient group|The patient group will consist of a maximum of 350 patients (male and female subjects,18 years to 30 years of age, in command of the German language)) with congenital heart disease (Tetralogy of Fallot, Transposition of the great arteries, univentricular heart disease, ventricular septal defect) treated at the cardiologic department of the University Hospital Zurich. Eligible patients will be contacted by the study nurse during the outpatient consultation at the university hospital. No intervention.
3014865|NCT02463292||peer control group|The control group will be recruited as good friends (same gender, approx. same age of the patients, in command of the German language). The patients will be given a study information for controls to hand this to their good friend and ask the friend to contact the study nurse for participation in the study. No intervention.
3014866|NCT02463279|Experimental|SinuSys Dilation System|Opening of previously constrained frontal recess and/or sphenoid sinus ostia via dilation procedure (sinuplasty)
3014867|NCT02463266|Active Comparator|SUSTAIN Clinical Monitoring|SUSTAIN Clinical Program participants who agree to follow-up Monitoring.
3014868|NCT02463266|Active Comparator|SUSTAIN Clinical Care Management|SUSTAIN Clinical Program participants who agree to Care Management.
3014869|NCT02463253||Phase 1|"A. OBJECTIVE: The objective of this phase of the study is to allow the clinical site to gain familiarity with patient recruitment, sample and data collection, and interpretation of the proteogenomic biomarker report provided, through retrospective analysis. This phase of the study will provide a platform for the transplant physicians to gain confidence with the format, logistics, and potential use of the biomarker tests on blood and tissue.~B. STUDY DESIGN: Enroll 20 subjects who are post-transplant and are undergoing kidney transplant biopsies at the UC Davis transplant center. Ten subjects will be enrolled who are receiving surveillance protocol biopsies and 10 subjects."
3014870|NCT02463227|Experimental|VRC01|Participants received an IV infusion of 40 mg/kg of VRC01 on study days 0, 21, and 42.
3014871|NCT02463214|No Intervention|Standard Room|Standard bone marrow transplant recovery, single occupancy, room
3014872|NCT02463214|Experimental|Engineered Room|Single occupancy bone marrow transplant recovery room, engineered with touchless devices, and surfaces coated with either copper or titanium dioxide.
3014873|NCT02463201||Obese children and adolescents|Attending a weightloss programme, that consist of lifestyle counseling, dietary restriction and exercise. The prevalence of obstructive sleep apnea (OSA) will be investigated in group. Children diagnosed with OSA will be followed to investigate if weight loss changes the condition.
3014874|NCT02463188|Experimental|Sleep Fitness Intervention|The intervention consists of 5-7 sessions on sleep science, the connection between sleep and substance use, behavior change strategies, and motivation to change behavior.
3014875|NCT02463188|No Intervention|Psychoeducation (PE)|The control classes will receive an 1-session psycho-educational (PE) intervention that provides information on sleep but does not provide guidance for implementing behavior change and does not explicitly teach about sleep's relationship to substance use.
3014876|NCT02463175|Experimental|Intervention group|Fluid management, boluses of 5ml/kg of plasmalyte, will follow a specific goal-directed fluid therapy (GDT) protocol guided by transesophageal doppler measurement
3014877|NCT02463175|Experimental|Control group|Fluid management, using boluses of 5ml/kg of plasmalyte, will follow the current standard of care guided by clinical judgment
3014878|NCT02463162|No Intervention|Control|"This group will receive usual care which is to receive no intervention."
3014879|NCT02463162|Experimental|Intervention|This group will receive the intervention which is two Conversations Matter videos about Advance Care Planning and Goals of Care Designations respectively
3014880|NCT02463149|Experimental|Youth Chef Academy|Receives intervention
3014881|NCT02463149|No Intervention|Control|Usual classroom curriculum
3014882|NCT02463136|Experimental|Behaviour and brain training|fMRI-based neurofeedback
3014883|NCT02463110|Experimental|1: Sertraline|ACS, depression
3014884|NCT02463110|Placebo Comparator|2: Placebo|ACS, depression
3014885|NCT02463110|Other|3: Control|ACS, no depression, no treatment
3014886|NCT02463097|Experimental|Study Arm|All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm
3014887|NCT02463084|Experimental|Low Diet|Diet intervention consisting of foods with low saturated fats, low glycemic index and low salt
3014888|NCT02463084|Experimental|High Diet|Diet intervention consisting of foods with high saturated fats, high glycemic index and high salt
3014889|NCT02463071|Experimental|AZD0585 2g group|AZD0585 1g × 2 capsules and AZD0585 placebo 1g × 2 capsules once daily
3014890|NCT02463071|Experimental|AZD0585 4g group|AZD0585 1g × 4 capsules once daily
3014891|NCT02463071|Placebo Comparator|Placebo control group|AZD0585 placebo 1g × 4 capsules once daily
3014932|NCT02462811|Experimental|CL-108|CL-108 hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
3014933|NCT02462811|Active Comparator|Active Comparator: Norco|Commercial product containing hydrocodone 7.5 mg, acetaminophen 325 mg
3014892|NCT02463058|Experimental|Research arm|"10 young and healthy civilian volunteers will participate in this study. The subjects will undergo 5 experiment days:~Recruitment , medical examination and VO2max test.~Acclimatization day by performing moderate exercise protocol under hot and humid climate.~3 days of performing moderate exercise under hot and humid conditions protocol, each day dressed with different protective garment:~Protective garment in current use + NBC mask.~The new BC protective undergarment + standard combat uniforms~The new BC protective undergarment + standard combat uniforms + NBC mask"
3014893|NCT02463045|Experimental|TOP1288 1mg (or placebo)|TOP1288 1mg single dose or placebo
3014894|NCT02463045|Experimental|TOP1288 10mg (or placebo)|TOP1288 10mg single dose or placebo
3014895|NCT02463045|Experimental|TOP1288 100mg (or placebo)|TOP1288 100mg single dose or placebo
3014896|NCT02463045|Experimental|TOP1288 200mg single dose or placebo|TOP1288 200mg single dose or placebo
3014897|NCT02463045|Experimental|TOP1288 400mg dose or placebo|TOP1288 400mg (200mg bid) dose or placebo
3014898|NCT02463045|Experimental|TOP1288 A mg or placebo|TOP1288 A mg daily for 4 days
3014899|NCT02463045|Experimental|TOP1288 B mg or placebo|TOP1288 B mg daily for 4 days
3014900|NCT02463045|Experimental|TOP1288 C mg or placebo|TOP1288 C mg daily for 4 days
3014901|NCT02463045|Experimental|TOP1288 D mg or placebo|TOP1288 D mg bid for 4 days
3014902|NCT02463045|Experimental|TOP1288 Xmg or placebo|TOP1288 X mg od or bid for 4 days
3014903|NCT02463032|Experimental|GTx-024 9 mg|Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg
3014904|NCT02463032|Experimental|GTx-024 18 mg|Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg
3014905|NCT02463019|Other|Tenofovir|Tenofovir Disoproxil Fumarate 300mg daily for 3 years
3014906|NCT02463006|Experimental|porous bone graft group|Intervention: Flap surgery procedure with porous bone grafting (Periooglass)
3014907|NCT02463006|Active Comparator|Non-porous bone gaft group|Intervention: Flap surgery procedure with non-porous bone grafting (Novabone morsels)
3014908|NCT02462993|Experimental|Aloe vera group|Group recieving scaling and root planing and aloe vera gel local drug delivery
3014909|NCT02462993|No Intervention|SRP group|Group recieving only scaling and root planing
3014910|NCT02462980|Experimental|AcQMapping|Mapping and ablation of atrial fibrillation guided by the AcQMap System
3014911|NCT02462967|Active Comparator|2 mg/kg GR MD 02|GR MD 02 in a dose of 2 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions
3014912|NCT02462967|Active Comparator|8 mg/kg GR MD 02|GR MD 02 in a dose of 8 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions
3014913|NCT02462967|Placebo Comparator|Placebo|Phosphate buffered saline solution administered every other week over a 52 week period for a total of 26 infusions
3014914|NCT02462954|Experimental|ContraGel|ContraGel, a personal lubricant has a Conformite Europeenne (CE) mark and has been used with barrier devices in Europe and other countries outside the US, but it is not currently approved by the US FDA.
3014915|NCT02462954|Placebo Comparator|HEC Placebo|The placebo gel is supplied by CONRAD in pre-filled individual applicators, each applicator containing 4.0 mL of HEC gel. Placebo gel contains HEC as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide.
3014916|NCT02462941|Experimental|Adenosine|After cardiac catheterization, the study protocol will begin with 12.5µg/kg of adenosine (one eighth the recommended starting clinical dose), and will double to 25µg/kg, 50µg/kg, 100µg/kg and finally 200µg/kg (not to surpass the total maximum dose of 12mg). A pacing catheter will be placed within the right ventricle prior to medication administration. Escalating doses will stop if ventricular pacing is required due to a ventricular pause greater than 12 seconds or if atrioventricular block is demonstrated with a ventricular pause less than 12 seconds. If there is no prolonged pause requiring pacing and no demonstration of medication effect the subsequent dose will be given.
3014917|NCT02462928|Experimental|abicipar pegol 2 mg (group A)|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on day 1, week 4, and week 8, followed by injections every 8 weeks through week 96. A sham procedure to the study eye will be performed every 4th week that an injection of abicipar pegol is not performed.
3014918|NCT02462928|Experimental|abicipar pegol 2 mg (group B)|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on day 1, week 4, and week 12, followed by injections every 12 weeks through week 96. A sham procedure to the study eye will be performed every 4th week that an injection of abicipar pegol is not performed.
3014919|NCT02462928|Active Comparator|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 96.
3014920|NCT02462915|Experimental|i-gel, an brand of supraglottic airway device|a supraglottic airway devices with a gastric suction channel
3014921|NCT02462915|Experimental|endotracheal tube|traditional use for protect airway during the surgery
3014922|NCT02462902|Experimental|5% albumin Infusion|(250 ml over 15 to 30 minutes)
3014923|NCT02462902|Active Comparator|0.9% sodium chloride solution|0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minute)
3014924|NCT02462889|Experimental|Intravitreal aflibercept injection|Subjects will be randomized to receive intravitreal aflibercept injection every three months for 24 months.
3014925|NCT02462889|Placebo Comparator|Placebo|Subjects will be randomized to receive sham injection every three months for 24 months.
3014926|NCT02462863|Experimental|Immunonutrient treatment|Administration of arginine and fish oil.
3014927|NCT02462850|Experimental|CL-108|CL-108 Hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
3014928|NCT02462837|Experimental|Treatment Arm|after stent placement, patient will be given Mirabegron 50 mg, PO, once daily, for 2 weeks
3014929|NCT02462837|Placebo Comparator|Placebo Arm|after stent placement, patient will be given placebo PO, once daily, for 2 weeks
3014930|NCT02462824|Experimental|Home-based exercise intervention|PAD Participants randomized to the home-based exercise intervention will be asked to take part in walking exercise to determine whether a patient-centered home-based exercise program improves walking ability, mobility, pain, and social functioning.
3014931|NCT02462824|No Intervention|Usual care group|PAD participants randomized to usual care will not receive any study interventions. Rather, they will receive usual care from their own physicians.
3014935|NCT02462798|Placebo Comparator|Whole grain rye bread|Whole grain rye bread, 200 g/d. Control intervention.
3014936|NCT02462798|Experimental|Whole grain sourdough rye bread|Whole grain rye bread, 200 g/d. Experimental intervention.
3014937|NCT02462785|Active Comparator|In-Class Instruction|This group of adolescents will receive carbohydrate counting instruction through an in-person, in class session led by a registered dietician. This represents the usual standard of care at the Diabetes Clinic at The Hospital for Sick Children (SickKids).
3014938|NCT02462785|Experimental|Internet-Based Teaching|This group of adolescents will receive carbohydrate counting instruction through an online teaching tutorial.
3014939|NCT02462772|Experimental|Cabotegravir|Women randomised to the cabotegravir arm will receive daily oral cabotegravir (30 mg tablets) for approximately 30 days and thereafter will receive intra-muscular gluteal injections of cabotegravir LA (800 mg, administered as two 400 mg injections) every 12 weeks
3014940|NCT02462772|Placebo Comparator|Placebo|Women randomised to the placebo arm will receive daily oral tablets (30 mg tablets) for approximately 30 days and thereafter will receive intra-muscular gluteal injections of Intralipid® 20% every 12 weeks
3014941|NCT02462759|Experimental|Nusinersen|Administered by intrathecal injection.
3014942|NCT02462759|Sham Comparator|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
3014943|NCT02462746|No Intervention|No supplement|This group subjects will not receive the supplement
3014944|NCT02462746|Active Comparator|1.5 gram of l-cysteine|Intervention: single dose of 1.5 g L-Cysteine.
3014945|NCT02462746|Active Comparator|3 grams of l-cysteine|Intervention: single dose of 3.0 g L-Cysteine.
3014946|NCT02462733|Active Comparator|Tools of the Mind (TOM)|These 10 classrooms will be exposed to the TOM program.
3014947|NCT02462733|Active Comparator|Playing to Learn (PTL)|These 10 classrooms will be exposed to the PTL program.
3014948|NCT02462720|Experimental|Varithena®, then Radiofrequency Ablation|Varithena (polidocanol injectable foam) supplied as polidocanol solution 180 mg/18 mL (10 mg/mL) to be activated before use. Once activated, Varithena is a white injectable foam delivering a 1% polidocanol solution. Each milliliter of Varithena injectable foam contains 1.3 mg of polidocanol. Up to 5 mL per injection or 15 mL per treatment session could be used. This was followed by RFA treatment.
3014949|NCT02462720|Active Comparator|Radiofrequency ablation then Varithena|RFA procedures were conducted in accordance with the physician's standard of care and according to the manufacturer's instructions for use. This was followed by treatment with Varithena.
3014950|NCT02462707|Experimental|PF-03084014|
3014951|NCT02462694|Active Comparator|Treatment as Usual|Treatment as usual (TAU): Standard psychological, psychopharmacology and case management services
3014952|NCT02462694|Experimental|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT): weekly individual sessions, skills training group and telephone coaching as needed
3014953|NCT02462681|Active Comparator|bupivacaine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% paravertebrally, divided into 3-4 ml in each level
3014954|NCT02462681|Active Comparator|bupivacaine + 0.5 mg/kg ketamine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% + 0.5 mg/kg ketamine paravertebrally divide into 3-4 ml in each level
3014955|NCT02462681|Active Comparator|bupivacaine + 1 mg/kg ketamine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% + 1mg/kg ketamine paravertebrally divide into 3-4 ml in each level
3014956|NCT02462668|Placebo Comparator|Control|"Preoxygenation with Bag-mask ventilation before fibreoptic bronchoscopy assisted intubation.~Intervention: Bag-mask ventilation."
3014957|NCT02462668|Experimental|NIPPV|"The NIPPV group preoxygenation with noninvasive positive pressure ventilation(NIPPV), And then receives fibreoptic bronchoscopy intubation through a face mask (there is a small hole allow to insert the tracheal tube through the mask into trachea) during NIPPV.~Intervention: noninvasive positive pressure ventilation(NIPPV)"
3014958|NCT02462655|Experimental|Pre-lipid apheresis|Blood samples will be taken just before the start of the lipid apheresis treatment.
3014959|NCT02462655|Experimental|Post-lipid apheresis|Blood samples will be taken following the lipid apheresis treatment.
3014960|NCT02462642|Experimental|Brahmi - 36 subjects|36 subjects both male and female will consume 2 capsules of Brahmi for 84 days.
3014961|NCT02462642|Placebo Comparator|Placebo- 36 subjects|36 subjects male and female who will take 2 capsules of placebo every day
3014962|NCT02462642|Experimental|Brahmi - 8 Subjects|For PK part of the study 8 male subjects will be taken for treatment arm. Each volunteer will consume 2 capsules of Brahmi each day for 84 days.
3014963|NCT02462642|Placebo Comparator|Placebo- 4 subjects|4 male subjects in PK part will be in the placebo arm. Each volunteer will consume 2 capsules of Brahmi each day for 84 days.
3014964|NCT02462629|Experimental|BLZ-100|
3014965|NCT02462616||Dr.Tang's research group|Dr.Tang's research group for clinical risk analysis of human complex disease
3014966|NCT02462603|Experimental|EPI-589 500 mg bid|All enrolled subjects will receive treatment with EPI-589
3014967|NCT02462590|Active Comparator|Lactobacillus rhamnosus GG|Patients allocated to the intervention group will receive 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule suspended in tap water, administered through a nasogastric (or orogastric) or nasoduodenal (or oroduodenal) tube twice daily while patients are in the ICU. The first dose will be within 72 hours of intubation. Patients in the ICU who await discharge and can swallow pills will take the capsules orally.
3014968|NCT02462590|Placebo Comparator|Placebo|Patients allocated to the placebo group will receive a capsule identical in appearance to the L. rhamnosus GG capsule, but containing microcrystalline cellulose. The placebo will also be suspended in tap water and similarly administered twice a day. When suspended in water, the placebo has identical appearance and consistency as the probiotic. The placebo will be prepared by the manufacturer of L. rhamnosus GG, Culturelle, and has been used successfully in a recent RCT in the ICU population [Morrow 2010]. This has also been used successfully in the PROSPECT Pilot Trial.
3014969|NCT02462577|Active Comparator|local instillation of morphine 5 mg|5 ml plain bupivacaine 0.5% and 5 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
3015096|NCT02461784||Control|Male subjects with IBD diagnosis not exposed to methotrexate (MTX) as treatment for their disease.
3014970|NCT02462577|Active Comparator|local instillation of morphine 10 mg|5 ml plain bupivacaine 0.5% and 10 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
3014971|NCT02462577|Active Comparator|local instillation of morphine 15 mg|5 ml plain bupivacaine 0.5% and 15 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
3014972|NCT02462577|Placebo Comparator|local instillation of local anesthetics|5 ml plain bupivacaine 0.5% .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
3014973|NCT02462564||postoperative cognitive dysfunction|Z score>1.96
3014974|NCT02462564||non-postoperative cognitive dysfunction|Z score<1.96
3014975|NCT02462551|Experimental|FEAST|Patients with treatment-resistant depression will undergo 3 sessions of focal electrically administered seizure therapy for two to six weeks. The complete parameter range of the stimulus delivered (Freq: 20-120 Hz; PW: 0.2-2 ms; Duration: 0.1 to 8 s; Current: 0.5-0.8A; charge: 1-576 mC) is determined by an initial titration session and the PI (as an expert in neuromodulation treatments).
3014976|NCT02462538|Experimental|Brentuximab vedotin and Imatinib|Brentuximab vedotin (every 3 weeks i.v., 1.8 mg/kg) and imatinib (200mg daily orally, escalated from 100mg daily) for up to 48 weeks
3014977|NCT02462525|Experimental|ABBV-838 dose escalation|Varying doses of ABBV-838
3014978|NCT02462525|Experimental|ABBV-838 plus pomalidomide/dexamethasone|ABBV-838 to be evaluated with pomalidomide/dexamethasone.
3014979|NCT02462512||FNAB of Thyroid nodule|The Patients with thyroid nodule who are scheduled for FNAB
3014980|NCT02462499|Experimental|Treatment|Treatment: Eplerenone (Inspra) All patients will receive 25mg eplerenone once a day for a week, followed by 50mg once a day, for a total of 4-12 weeks.
3014981|NCT02462486|Experimental|abicipar pegol 2 mg (group A)|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on day 1, week 4, and week 8, followed by injections every 8 weeks through week 96. A sham procedure to the study eye will be performed every 4th week that an injection of abicipar pegol is not performed.
3014982|NCT02462486|Experimental|abicipar pegol 2 mg (group B)|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on day 1, week 4, and week 12, followed by injections every 12 weeks through week 96. A sham procedure to the study eye will be performed every 4th week that an injection of abicipar pegol is not performed.
3014983|NCT02462486|Active Comparator|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 96.
3014984|NCT02462473|Experimental|Cohort 1|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in this cohort at a given site have completed their study participation.
3014985|NCT02462473|Experimental|Cohort 2|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will be provided to the clinician as they become available.
3014986|NCT02462473|Experimental|Cohort 3|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in cohorts 2 and 3 at a given site have completed participation in the active assessment phase.
3014987|NCT02462460||Patients with BRCA mutation|The purpose of this study is to optimize rapid pancreatic and ovarian MR screening protocols using T1, T2 and DW imaging sequences in BRCA mutation carriers. Each screening MR protocol is considered optimized if we reach 5 consecutive patients with technically adequate image quality. We will enroll up to 60 patients to perform the MR screening protocol, if the initial MR sequence parameters do not yield technically adequate MR images in a single patient, we will stop and modify our imaging protocol. We will continue to modify the technique until we reach 5 consecutive patients with technically adequate MR images for both on all imaging sequences. Thus, it is possible we will optimize different imaging sequences at different time points in our study. We plan to enroll at least 5 patients, and up to 60 patients with BRCA mutation who undergo breast MRI for this study. Participants will receive a copy of the questionnaire on the day of their Breast MRI.
3014988|NCT02462447||Prostate Cancer|Subjects will receive two PET/CT examinations, one with 11C-sarcosine and one with 11C-choline. These scans will take 30-45 minutes each.
3014989|NCT02462447||Healthy Volunteer|Subjects will receive one PET/CT examination, with 11C-sarcosine. This scan will take approximately 90 minutes.
3014990|NCT02462434|Experimental|Early palliative care team consultation|Early pediatric palliative care team consultation for single ventricle patients will occur in this group following birth but prior to the first stage palliative surgery.
3014991|NCT02462434|No Intervention|Usual care|Usual care for single ventricle patients will be provided with palliative care team consultation occurring at any point (if it is determined the child and family would benefit from palliative care consultation) during the child's neonatal hospital stay.
3014992|NCT02462421|Active Comparator|Wild type genotype|Research subjects with wild type genotypes at three candidate genes encoding sodium-dependent glucose transporter-3, sodium-dependent glucose transporter-4, and glucose transporter-9 (abbreviated as SLC5A4, SLC5A9, SLC2A9, respectively) will be studied before and after canagliflozin treatment.
3014993|NCT02462421|Experimental|Nonsense mutation in SLC5A4|Research subjects who are homozygous for nonsense mutation in SLC5A4 (sodium-dependent glucose transporter-3) will be studied before and after canagliflozin treatment.
3014994|NCT02462421|Experimental|Nonsense mutation in SLC5A9|Research subjects who are homozygous for nonsense mutation in SLC5A9 (sodium-dependent glucose transporter-4) will be studied before and after canagliflozin treatment.
3014995|NCT02462421|Experimental|Missense variant in SLC2A9|Research subjects who are homozygous for nonsynonymous variant in glucose transporter-9 (SLC2A9) will be studied before and after canagliflozin treatment.
3014996|NCT02462408|Experimental|Posterior approach|The main difference between this block approach and the conventional infraclavicular approach is the site and angle of needle insertion. Otherwise, the end point of local anaesthetic injection remained the same for both approaches.
3014997|NCT02462408|Active Comparator|Conventional approach|The main difference between this block approach and the conventional infraclavicular approach is the site and angle of needle insertion. Otherwise, the end point of local anaesthetic injection remained the same for both approaches.
3014998|NCT02462395|Experimental|Cefaly tDCS|Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.
3014999|NCT02462382|Active Comparator|Ropivacaine infusion|270cc of Ropivacaine infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
3015000|NCT02462382|Placebo Comparator|Saline infusion|270cc of Normal Saline infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
3015001|NCT02462382|Other|Rotator cuff repair|During arthroscopic rotator cuff repair procedure, the surgeon inserts a small camera, called an arthroscope, into your shoulder joint. The camera displays pictures on a television screen, and your surgeon uses these images to guide miniature surgical instruments to repair the torn ligament. It is after this procedure that pain control will be assessed.
3015002|NCT02462369|Experimental|Saxagliptin|Saxagliptin 5mg/d, 52 weeks
3015003|NCT02462369|Active Comparator|glimepiride|glimepiride 1~4mg/d,52 weeks
3015004|NCT02462356|Active Comparator|Conventional VATS|Via conventional VATS lobectomy and systematic lymph node dissection for lung cancer
3015005|NCT02462356|Experimental|Uniportal VATS|Via uniportal VATS lobectomy and systematic lymph node dissection for lung cancer
3015006|NCT02462343|Other|2 minute walk test|
3015007|NCT02462343|Other|6 minute walk test|
3015008|NCT02462330|Placebo Comparator|Placebo comparator|injection of human albumin 4%
3015009|NCT02462330|Experimental|Autologous MSC from bone marrow|intramyocardial injection of 6.10e7 stem cells
3015010|NCT02462317|Active Comparator|botulinum A toxin|Patients are injected with botulinum toxin in a standardized protocol and received placebo baclofen tablets (120 patients)
3015011|NCT02462317|Active Comparator|Baclofen|Patients are injected with placebo in a standardized protocol and received baclofen tablets (120 patients)
3015012|NCT02462317|Placebo Comparator|double Placebo|Patients are injected with placebo in a standardized protocol and received placebo baclofen tablets (60 patients)
3015013|NCT02462304|Experimental|Combination Anti-VEGF and EPM laser|Subjects will receive both anti-VEGF injections and EPM laser.
3015014|NCT02462304|Active Comparator|Anti-VEGF monotherapy|Subjects will receive anti-VEGF injections monotherapy.
3015015|NCT02462291|Experimental|Experimental group (TR)|A group of 80 patients with AD will perform a program of EET for 2 hours a day, 5 days a week for a total of 6 months.
3015016|NCT02462291|No Intervention|Control group (CTRL)|A group of 80 patients with AD will be treated with the standard therapy.
3015017|NCT02462278|Experimental|TempuRing|Women will wear the continuous temperature sensor, TempuRing, for 3 menstrual cycles.
3015018|NCT02462265|Experimental|'Oshadi D & Oshadi R; salvage therapy'|Oshadi D (180mg/tid) & Oshadi R (180mg/tid) will be administrated orally; Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days) will be administrated
3015019|NCT02462252|Experimental|BL-8040 plus hATG, methylprednisolone, cyclosporine|"BL-8040 0.75mg/kg will be administered Subcutaneously (SC ) on Days 1-10, then on first 5 days of months 2-6.~Standard therapy: hATG: Days 11-14: 40mg/kg/day IV over 6-8 hours, in all AA subjects, or in MDS subjects less than 55 years old. 35mg/kg/day IV over 6-8 hours in MDS subjects 55 years and older.~Standard therapy: methylprednisolone: Days 11-14: 40mg/kg/day IV over 6-8 hours, in all AA subjects, or in MDS subjects less than 55 years old. 35mg/kg/day IV over 6-8 hours in MDS subjects 55 years and older.~Standard therapy: cyclosporine: 5mg/kg/day orally, given in 2 divided doses, starting on day 11 and continuing through Month 6 Day 30 (end of treatment)"
3015020|NCT02462239|Experimental|Whole-body FDG PET-CT|Whole-body FDG PET-CT (Experimental arm)
3015021|NCT02462239|No Intervention|No PET-CT|No PET-CT (Control arm)
3015022|NCT02462226|Active Comparator|Arm Precaution|"Patients assigned to Education #1 will receive arm precaution self-care strategies. The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb. Exercises to promote limb mobility will also provided. Only the patients in the control group will be given access to Arm Precautions section.~Patients will be given access to the website to learn about the arm precaution program."
3015023|NCT02462226|Experimental|The-Optimal-Lymph-Flow|"The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI.~Patients will be given the access to the website to learn about the The-optimal-Lymph-Flow program"
3015024|NCT02462213||Amyloidosis|Patients being managed for amyloidosis without prior history of cardiac involvement
3015025|NCT02462213||Cardiac amyloidosis|Patients being managed for cardiac amyloidosis
3015052|NCT02462057|Active Comparator|Input from a diabetes expert|This group will receive a message that includes a quote from a South African physician who specializes in diabetes. The quote emphasises the financial benefit and the two specific diabetes health benefits of the HealthyFood program included in the other messages. It concludes with the doctor's recommendation of the benefit for all individuals with diabetes.
3015026|NCT02462200|Active Comparator|BCS Arm (breast-conserving surgery - standard of care)|"Defined as partial mastectomy, lumpectomy, or local excisional biopsy with or without needle/wire localization~The ICG will be prepared per manufacturer instructions and diluted to allow for intravenous dosing up to 0.5 mg/kg (except for those patients with iodine or seafood allergies or in cases where the goggles are unavailable for use).~Following the BCS procedures, the surgeon or a study team member will don the goggles and state the NIR fluorescence margin information of the excised primary tumor specimen and of and CSM that are taken."
3015027|NCT02462200|Experimental|CSM Arm (breast-conserving surgery with cavity shave margins)|"Partial mastectomy, lumpectomy, or local excisional biopsy with or without needle/wire localization with the addition of additional tissue specimens from all 6 margins (anterior, posterior, superior, inferior, medial, lateral) of the wound cavity if possible. In cases where an additional margin would involve the skin at the anterior margin and/or the pectoral muscle at the posterior margin, only the 4 (or 5) remaining margins should be obtained~A margin thickness of 1 cm will be the defined goal to establish uniformity among different surgeons and allow for appropriate pathological evaluation~The ICG will be prepared per manufacturer instructions and diluted to allow for intravenous dosing up to 0.5 mg/kg (no iodine or seafood allergies).~Following the BCS procedures, the surgeon or a study team member will don the goggles and state the NIR fluorescence margin information of the excised primary tumor specimen and of any CSM that are taken."
3015028|NCT02462187|Experimental|NVN1000 8% Gel twice daily|NVN1000 8% Gel twice daily
3015029|NCT02462187|Experimental|NVN1000 8% Gel once daily|NVN1000 8% Gel once daily
3015030|NCT02462187|Experimental|NVN1000 16% Once daily|NVN1000 16% Gel once daily
3015031|NCT02462187|Placebo Comparator|Vehicle Gel|Vehicle Gel at frequency to match active
3015032|NCT02462187|Experimental|NVN1000 24% once daily|NVN1000 24% once daily
3015033|NCT02462174|Active Comparator|Topical ketamine and topical bupivacaine|0.5 mg/ kg ketamine in 0.3 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) administered directly around the spermatic cord in the wound after end of surgery and before closure of the wound.
3015034|NCT02462174|Active Comparator|Caudal ketamine and caudal bupivacaine|0.5 mg/ kg ketamine in 1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) administered by caudal epidural route after anesthesia and before the start of surgery.
3015035|NCT02462161|Experimental|Insulin Aspart|Fifteen randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive twice daily intranasal administrations of insulin aspart (20 IU) for 12 weeks.
3015036|NCT02462161|Placebo Comparator|Placebo|Fifteen randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive twice daily intranasal administrations of placebo (saline) for 12 weeks.
3015037|NCT02462148|Experimental|4 mg Perineural Dexamethasone Group|4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
3015038|NCT02462148|Experimental|1 mg Perineural Dexamethasone Group|1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
3015039|NCT02462148|Placebo Comparator|Placebo Group|This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
3015040|NCT02462135|Experimental|Virtual interactive memory training|Training sessions of the VIMT group are divided into initial training and booster training. Each training session is 45 minutes/day, 3 sessions/week, for 12 weeks for both initial training and booster training (36 sessions each).
3015041|NCT02462135|Active Comparator|Passive information activities|The training of active control group is the same as VIMT group (45 min/day, 3 days/week, for 12 weeks, for a total of 36 sessions). The active control group receives only the initial training.
3015042|NCT02462122|Experimental|IDP-118 Lotion|Lotion
3015043|NCT02462122|Active Comparator|IDP-118 Vehicle Lotion|Vehicle Lotion
3015044|NCT02462109|Experimental|Lorazepam|"Children with confirmed Nodding syndrome that had 2 or more of the symptoms on the 10-item Kampala Catatonia Panel (KCP) scale were recruited to undergo the catatonia test using oral Lorazepam EG® (n.v. Eurogenerics s.a. Brussels, Belgium) using the 1 mg formulation tablets. The amount of Lorazepam (LZP) drug given orally was based on the weight of the child. The lower dose (0.5 mg) was used as starting dose for patients with <30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with >30 kg body weight.~A positive response to a catatonia test consisted of a reduction in catatonic symptoms, 60 minutes later, by at least 50% assessed by the KCP (using all 10 items). If no response to the initial dose of LZP, was observed after one hour, a second administration of the same medication at double the dose was given. Catatonia was again assessed at 60 minutes thereafter. If no response was observed, the test was considered negative."
3015045|NCT02462096|Experimental|Treatment|Subject to undergo the ReLeaf study procedure.
3015046|NCT02462083|Experimental|IDP-118 Lotion|halobetasol propionate [HP], tazarotene [Taz]
3015047|NCT02462070|Experimental|IDP-118 Lotion|Lotion
3015048|NCT02462070|Active Comparator|IDP-118 Vehicle Lotion|Vehicle Lotion
3015049|NCT02462057|No Intervention|Control Arm|This arm will represent current practice. This group will receive no contact from the research team. They may receive information regarding the benefit from the Vitality marketing team during the intervention period and can enroll in the benefit at any time during the study period.
3015050|NCT02462057|Active Comparator|Diabetes-specific|This group will receive a message which simply cites the two specific benefits of the eating more healthy foods for individuals with diabetes. This message contains a link to start the enrolment process.
3015051|NCT02462057|Active Comparator|Experience of another member|This group will receive a message that includes a quote from the perspective of a Vitality member with diabetes who uses the HealthyFood benefit. Given the need to standardise message content across study arms, the quote was written by the study team and not an actual member. The quote emphasizes the positive impact the benefit has had for the member—both the financial benefit, as well as the two specific diabetes health benefits.
3015094|NCT02461797|Other|AR patients without medication|biopsy of nasal mucosa allergic rhinitis to house dust mite without any use of medication for symptom control
3015095|NCT02461784||Case|Male subjects with IBD diagnosis currently taking methotrexate (MTX) as treatment for their disease.
3015053|NCT02462057|Active Comparator|Enhanced active choice|"This group will receive a message whose first portion is identical to those in the diabetes-specific message group. The second portion of the message differs in that instead of just asking recipients to click on the provided link if interested, the message asks people to choose and click on one of following possible responses:~Yes! I want to active the HealthyFood benefit and get up to 25% cash back on the healthy food I buy at Pick n Pay or Woolworths~No, I'd prefer not to activate and continue paying full price for my healthy food purchases"
3015054|NCT02462044|Experimental|240|Group 240 will receive CM with 240 mg Iodine/ml IDR 2.0 gI/s
3015055|NCT02462044|Experimental|300|Group 300 will receive CM with 300 mg Iodine/ml IDR 2.0 gI/s
3015056|NCT02462044|Experimental|370|Group 370 will receive CM with 370 mg Iodine/ml IDR 2.0 gI/s
3015057|NCT02462031|Experimental|KD101|
3015058|NCT02462031|Placebo Comparator|KD101 placebo|
3015059|NCT02462018|Experimental|WalkAide|
3015060|NCT02462005||ALL COMERS|Patients implanted or scheduled for an implant with a Ranger Drug coated balloon.
3015061|NCT02461992|Experimental|Intravenous infusion of Xyntha|observation arm
3015062|NCT02461979|Other|Hepatocellular carcinoma (HCC)|The VDR genotype in 20 HCV cirrhotic patient with HCC
3015063|NCT02461979|Other|Liver cirrhosis|The VDR genotype in 20 HCV cirrhotic patient without HCC
3015064|NCT02461979|Other|Control group|The The VDR genotype in 10 healthy individuals as control
3015065|NCT02461966|Other|Hepatocellular carcinoma (HCC)|Estimation of serum aflatoxin level in 40 patients with hepatocellular carcinoma (HCC)
3015066|NCT02461966|Other|20 cirrhotic patients|Estimation of serum aflatoxin level in 20 patients with liver cirrhosis
3015067|NCT02461966|Other|Control group|Estimation of serum aflatoxin level in 15 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study
3015068|NCT02461953|Experimental|low flux hemodialysis|low flux hemodialysis alone, 3 times a week, 4 hours per session
3015069|NCT02461953|Experimental|high flux hemodialysis|high flux hemodialysis alone, 3 times a week, 4 hours per session
3015070|NCT02461953|Experimental|low flux hemodialysis + hemoperfusion|low flux hemodialysis 2times a week and the HD+HP once a week
3015071|NCT02461953|Experimental|high flux hemodialysis + hemoperfusion|high flux hemodialysis 2times a week and the HD+HP once a week
3015072|NCT02461940|No Intervention|Standard care|The control group will receive the standard care provided by the STI clinic.
3015073|NCT02461940|Active Comparator|Adolescent Behavioral intervention|Participants allocated to the intervention arm receive 4 on-site personalised counselling and 2 phone/online sessions over a 12-month period, targeting individual, relational, sociocultural and environmental factors pertaining to the acquisition of STI/HIV.
3015074|NCT02461927|Experimental|Ketamine + Naltrexone|Subjects in this arm will receive (1) intravenous ketamine treatment once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular naltrexone once a month (a total of 2 injections).
3015075|NCT02461927|Experimental|Ketamine + Placebo|Subjects in this arm will receive (1) intravenous ketamine treatment once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular placebo once a month (a total of 2 injections).
3015076|NCT02461927|Placebo Comparator|Placebo (psychoactive placebo midazolam) + Placebo|Subjects in this arm will receive (1) intravenous placebo treatment (psychoactive placebo midazolam) once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular placebo once a month (a total of 2 injections).
3015077|NCT02461914|Experimental|Warfaring and PEX168(200µg)|Warfarin: 5mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
3015078|NCT02461901||Fidaxomicin treatment|Patients being treat with fidaxomicin (on the decision of their treating physician)
3015079|NCT02461901||Metronidazole or vancomycin treatment|Patients being treated with metronidazole or vancomycin (on the decision of their treating physician)
3015080|NCT02461888|Experimental|Ixazomib, CD|"Ixazomib, cyclophosphamide and dexamethasone (ICD) will be administered as part of a 28 days cycle until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~Ixazomib 4mg orally on days 1, 8 and 15~Cyclophosphamide 500mg orally on days 1, 8 and 15~Dexamethasone 40mg orally on days 1-4 and 12-15"
3015081|NCT02461888|Active Comparator|CD|"Cyclophosphamide and dexamethasone (CD) will be administered as part of a 28 days cycle until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~Cyclophosphamide 500mg orally on days 1, 8 and 15~Dexamethasone 40mg orally on days 1-4 and 12-15"
3015082|NCT02461875|Active Comparator|Cabergoline group|Cabergoline is administered starting on the day of HCG administration.
3015083|NCT02461875|Experimental|GnRH antagonist rescue & cabergoline group|Converting a long GnRH agonist cycle to an GnRH antagonist cycle (GnRH antagonist rescue) and Cabergoline is administered starting on the day of HCG administration.
3015084|NCT02461862||Intra Uternine Device|Women who came to the medical service, to insert an intra uterine Device (IUD) of Cu or a Levonorgestrel Intra Uterine System( Lng- IUS) after have been attended in the Family Planning Service of Federal University of São Paulo . All patient have had the pain evaluated by Application of the Visual Analog Scale of Pain (VAS), and also their vital signs ( Evaluation of blood pressure,Evaluation of radial pulse) evaluated pre and five minutes after the IUD/ IUS insertion.
3015085|NCT02461849|Experimental|Imatinib|Imatinib 400mg qd daily Until disease progression, patient's refusal
3015086|NCT02461836|Experimental|Chemo|adjuvant chemotherapy using Gemcitabine for 6 rounds
3015087|NCT02461836|Experimental|Chemo+SBRT|SBRT is delivered prior to adjuvant chemotherapy with Gemcitabine for 6 rounds
3015088|NCT02461823|Experimental|Z Crown|A Zirconia crown will be provided to patients.
3015089|NCT02461823|Active Comparator|PFM Crown|A Porcelain metal crown will provided to patients.
3015090|NCT02461810|Experimental|SpineJack® system|VCF treatment system Vertebral fracture surgery
3015091|NCT02461810|Active Comparator|Balloon Kyphoplasty|VCF treatment system Vertebral fracture surgery
3015092|NCT02461797|Other|healthy controls|biopsy of nasal mucosa healthy controls
3015093|NCT02461797|Other|AR patients with use of nasal corticoid spray|biopsy of nasal mucosa allergic rhinitis to house dust mite with nasal corticosteroid spray
3015097|NCT02461771|Experimental|APL-2 Cohort 1|4 mg of APL-2 100 μL IVT injection
3015099|NCT02461771|Experimental|APL-2 Cohort 3|20 mg of APL-2 100 μL IVT injection
3015100|NCT02461758|Other|Control Group|A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled. All healthy individuals will receive standard dose influenza vaccine SDIV.
3015101|NCT02461758|Other|Vedolizumab Group|A group of 20 patients who are currently on vedolizumab. All individuals in this group will receive SDIV
3015102|NCT02461758|Other|TNF Monotherapy Group|This arm will be a double blind randomized controlled trial of high dose influenza vaccine (HDIV) vs. SDIV for IBD patients on TNF monotherapy. 40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.
3015103|NCT02461745|Active Comparator|Genotype 1a|ombitasvir, paritaprevir/r, dasabuvir + ribavirin
3015104|NCT02461745|Active Comparator|Genotype 1b|ombitasvir, paritaprevir/r, dasabuvir
3015105|NCT02461732|Active Comparator|CBT for Substance Dependence|Standard CBT for substance use disorders
3015106|NCT02461732|Experimental|Integrated CBT for PTSD and Substance Dependence|Integrated CBT for PTSD and substance use disorders, combining elements of cognitive processing therapy for PTSD with coping skills and relapse prevention for substance use disorders
3015107|NCT02461719|Experimental|CYPORIN N EYE DROPS 0.05%(TJCS eye drop)|CYPORIN N EYE DROPS 0.05%(TJCS eye drop) 1 drop twice/day for 12 weeks to both eyes
3015108|NCT02461719|Active Comparator|Restasis eye drop|Restasis eye drop(Cyclosporine ophthalmic solution 0.05%) 1 drop twice/day for 12 weeks to both eyes
3015109|NCT02461693|Experimental|Caffeine|One-time treatment with 200mg caffeine pill
3015110|NCT02461693|Placebo Comparator|Placebo|One-time treatment with lactose-based placebo pill
3015111|NCT02461680|Experimental|Tangential resection|the tendon's injury is treated with a tangential resection
3015112|NCT02461680|Active Comparator|Suture|The tendon's injury is sutured
3015113|NCT02461667|Placebo Comparator|placebo|SRP plus placebo SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
3015114|NCT02461667|Active Comparator|Metformin|SRP plus Metformin SRP was done for all the subjects. metformin was delivered in the pocket subgingivally
3015115|NCT02461667|Active Comparator|Alendronate|SRP plus Alendronate SRP was done for all the subjects. Alendronate was delivered in the pocket subgingivally
3015116|NCT02461641|Other|Standard of Care|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe.
3015117|NCT02461641|Experimental|NuShield|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe. In addition, wounds will be treated with a dehydrated amnion-chorion membrane, NuShield, for up to 4 weeks.
3015118|NCT02461641|Experimental|Affinity|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe. In addition, wounds will be treated with a fresh hypothermically stored amniotic membrane, Affinity, for up to 4 weeks.
3015119|NCT02461628|Experimental|Malaria RDT & conditional voucher|In the intervention arm, trained community health volunteers (CHVs) will offer eligible household members a free malaria rapid diagnostic test (RDT) and a voucher allowing the purchase of a qualified ACT at a reduced fixed price in the retail sector conditional on a positive test.
3015120|NCT02461628|No Intervention|Comparison Arm|Individuals in the comparison arm will only receive standard community health volunteer (CHV) visits.
3015121|NCT02461615||Registry Participants|All participants who participate in the National PAP Registry will be put into this cohort and observed over approximately 5 years.
3015122|NCT02461589|Experimental|Semaglutide 0.05 mg/day|
3015123|NCT02461589|Active Comparator|Liraglutide 0.3 mg/day|
3015124|NCT02461589|Placebo Comparator|Placebo 50 µL|
3015125|NCT02461589|Experimental|Semaglutide 0.05/0.1 mg/day|
3015126|NCT02461589|Active Comparator|Liraglutide 0.3/0.6 mg/day|
3015127|NCT02461589|Placebo Comparator|Placebo 50/100 µL|
3015128|NCT02461589|Experimental|Semaglutide 0.05/0.1/0.2 mg/day|
3015129|NCT02461589|Active Comparator|Liraglutide 0.3/0.6/1.2 mg/day|
3015130|NCT02461589|Placebo Comparator|Placebo 50/100/200 µL|
3015131|NCT02461589|Experimental|Semaglutide 0.05/0.1/0.2/0.3 mg/day|
3015132|NCT02461589|Active Comparator|Liraglutide 0.3/0.6/1.2/1.8 mg/day|
3015133|NCT02461589|Placebo Comparator|Placebo 50/100/200/300 µL|
3015134|NCT02461589|Experimental|Semaglutide flexible escalation from 0.05 mg/day to 0.3 mg/day|
3015135|NCT02461576||HIV-1 infected|this is a study comparing Xpert HIV-1 VL assay quantitation to an already FDA approved HIV-1 quantitative HIV-1 RNA assay in known HIV-1 infected individuals
3015136|NCT02461563|Experimental|GT1: 200 mg MK-1075|Fasted GT1 participants are administered 200 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
3015137|NCT02461563|Experimental|GT1: 400 mg MK-1075|Fasted GT1 participants are administered 400 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
3015138|NCT02461563|Experimental|GT1: 800 mg MK-1075|Fasted GT1 participants are administered 800 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
3015139|NCT02461563|Experimental|GT3: 200 mg MK-1075|Fasted GT3 participants are administered 200 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
3015140|NCT02461563|Experimental|GT3: 400 mg MK-1075|Fasted GT3 participants are administered 400 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
3015141|NCT02461563|Experimental|GT3: 800 mg MK-1075|Fasted GT3 participants are administered 800 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
3015142|NCT02461550|Experimental|IRE procedure|The IRE procedure will be performed in the operating room at the time of scheduled clinical resection of colorectal lung metastases by the surgeon with guidance from the Interventional Radiologist.
3015143|NCT02461537|Active Comparator|RIST(remission induction)|high-dose cytarabine 3 g/m2 (days 1-3)/mitoxantrone 10mg/m2 (days 3-5)
3015144|NCT02461537|Experimental|DISC (disease control)|low-dose cytarabine 20 mg/ m2 and /or mitoxantrone 10mg/m2
3015145|NCT02461524|Other|Endovasculair repair|Endurant Evo AAA Stent graft system
3015146|NCT02461511||Therapeutic Education + Documentation|diabetic patient hospitalized patient particpating in therapeutic education program
3015147|NCT02461511||No Therapeutic Education No Documents|diabetic patient hospitalized patient without therapeutic education program no documentation submitted
3015148|NCT02461511||Documentation, No Therapeutic Education|diabetic patient hospitalized patient without therapeutic education program documentation submitted
3015149|NCT02461485|Experimental|1=BOW_01|1= Fermented Milk Product containing Probiotics
3015150|NCT02461485|Experimental|2=BOW_01 + fiber C|2= Fermented Milk Product containing Probiotics + Fibers C
3015151|NCT02461485|Experimental|3 =BOW_01 + fiber W|3= Fermented Milk Product containing Probiotics + Fibers W
3015152|NCT02461485|Placebo Comparator|4 = Control|4= Non fermented Milk Product with same color, texture and organoleptic properties as investigational products 1 to 3.
3015153|NCT02461472||Dr.Tang's research group|Dr.Tang's research group for clinical risk analysis of human complex disease
3015154|NCT02461459||Tuberous Sclerosis Complex|Tuberous Sclerosis Complex
3015155|NCT02461446||PTEN ASD|PTEN participants with Autism Spectrum Disorder group
3015156|NCT02461446||PTEN no ASD|PTEN participants without Autism Spectrum Disorder group
3015157|NCT02461446||PTEN Macrocephaly|PTEN participants with Macrocephaly group
3015158|NCT02461446||Controls|Healthy control group
3015159|NCT02461433|Experimental|Prevena|After surgery this group will receive the Prevena device (negative pressure wound therapy).
3015160|NCT02461433|Active Comparator|Standard dressing|After surgery this group will receive standard of care dressings on their surgical wound.
3015161|NCT02461420||Phelan-McDermid Syndrome|Phelan-McDermid Syndrome
3015162|NCT02461407|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3015163|NCT02461407|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3015164|NCT02461381||Dr.Tang's research group|This group included diabetic participants with completed both the short-term HRV test and Ewing's test.
3015165|NCT02461368|Experimental|anterior approach|Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
3015166|NCT02461368|Active Comparator|posterior approach|Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
3015167|NCT02461355|Experimental|Anodal tDCS|Anodal tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
3015168|NCT02461355|Sham Comparator|Sham tDCS|Sham tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
3015169|NCT02461342||Dr.Tang's research group|Dr.Tang's research group for genetic, environment and its interaction analysis of human complex disease
3015170|NCT02461329|Experimental|Gelatine solution|"Gelofusine will be administrated like fluid challenge - 250ml of solution will be infused within 5 minutes in case of hypotension ( mean arterial pressure - MAP below 65 mmHg or below 70mmHg in patient with chronic hypertension disease).~The blood pressure and heart rate before and after fluid challenge will be recorded."
3015171|NCT02461329|Experimental|Balanced Crystaloid solution|"Ringerfundin will be administrated like fluid challenge - 250ml of solution will be infused within 5 minutes in case of hypotension ( mean arterial pressure - MAP below 65 mmHg or below 70mmHg in patient with chronic hypertension disease).~The blood pressure and heart rate before and after fluid challenge will be recorded."
3015172|NCT02461316||Combination Treatment in Chronic Lymphocytic Leukemia (CLL)|All participants receiving combination treatment in Chronic Lymphocytic Leukemia (CLL)
3015173|NCT02461290||Combination Therapy|Rituximab 375mg/m2, on day 1 of each cycle of chemotherapy, total of 8 infusions. Chemotherapy according to standard regimens.
3015174|NCT02461277|Active Comparator|Fast-track protocol|Before surgery, patients are informed about the surgical procedure, anesthesia and rehabilitation protocol. The surgery occurs in accordance with the principles of the Fast-track: minimal invasive surgery, epidural anesthetic management, avoiding the need opioid in postoperatory analgesia and use of an standardized postoperatory management protocol to an early oral intake and early mobilization.
3015175|NCT02461277|No Intervention|Conventional care|Usual care routine postoperative
3015176|NCT02461264|Active Comparator|ARM A|Two packed red blood cells will be transfused in patient with anemia defined as a hemoglobin level below 8 g / dL. Clinical and biological monitoring will be carried out later each day. If the hemoglobin is <8 g / dL, two new packed red blood cells are transfused and so on.
3015177|NCT02461264|Experimental|ARM B|Single red blood packed cells Transfusion will be administered in patient with anemia defined as a hemoglobin level below 8 g/dL. Clinical and biological monitoring will be carried out later each day. If the hemoglobin is <8 g / dL, a single unit is transfused and so on.
3015178|NCT02461251|Experimental|Rotational thromboelastometry (ROTEM)|"Rotational thromboelastometry results are used to guide the treatment of major obstetric hemorrhage, eg. administration of prothrombin complex concentrate, fresh-frozen plasma, fibrinogen concentrate or platelets. In case of massive hemorrhage, shock packs of blood products in 1:1:1 ratio are administered."
3015179|NCT02461251|No Intervention|Standard care|"Patients are treated according to clinical decision making and conventional coagulation tests, and in case of massive hemorrhage, shock packs are administered."
3015180|NCT02461238|Active Comparator|Vouchers|Families included in the Voucher arm will receive vouchers for fruits and vegetables by mail every month for a period of 1 year coupled to nutritional education from a dietician
3015181|NCT02461238|Other|Control|Families included in the control arm will only receive nutritional education
3015182|NCT02461212|Experimental|Liver MRI|Liver MRI imaging will be performed on subjects undergoing a liver biopsy
3015237|NCT02460965||Patients with hearing impairment|
3015238|NCT02460965||Patients with visual loss|
3015183|NCT02461212|Experimental|Liver MRI repositioned|Liver MRI imaging will be performed on subjects undergoing a liver biopsy and then they will be repositioned and will repeat the MRI
3015184|NCT02461199||Fecal microbiota transplantation|Patients with proven gut colonization status with following bacteria: Klebsiella pneumoniae resistant to carbapenems, Pseudomonas aeruginosa resistant to carbapenems, Enterococcus faecalis VRE (vancomycin-resistant enterococcus), Enterococcus faecium VRE, Enterobacter cloacae resistant to carbapenems or other MDR species. Gut colonization proven by conventional microbiological culture and/or molecular methods.
3015185|NCT02461186|Experimental|Arterolane maleate-piperaquine phosphate (Synriam)|
3015186|NCT02461186|Experimental|Dihydroartemisinin-piperaquine phosphate (Duocotexin)|
3015187|NCT02461173|Active Comparator|Stimulated IUI|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3nd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
3015188|NCT02461173|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
3015189|NCT02461173|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
3015190|NCT02461160|Experimental|Single Rising Dose (SRD) Cohort 1: TAK-915 30 mg|TAK-915 30 mg (Dose A) suspension, orally, once on Day 1.
3015191|NCT02461160|Experimental|SRD Cohort 2: TAK-915 Dose B|TAK-915 suspension Dose B, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1. TAK-915 dose will be determined based on data from Cohort 1 of the study.
3015192|NCT02461160|Experimental|SRD Cohort 3: TAK-915 Dose C|TAK-915 suspension Dose C, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from previous Cohorts. TAK-915 dose will be determined based on data from previous Cohorts of the study.
3015193|NCT02461160|Experimental|SRD Cohort 4: TAK-915 Dose D|TAK-915 suspension Dose D, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from previous Cohorts. TAK-915 dose will be determined based on data from previous Cohorts of the study.
3015194|NCT02461160|Experimental|SRD Cohort 5: TAK-915 TBD Dose E|TAK-915 suspension Dose E, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from previous Cohorts. TAK-915 dose will be determined based on data from previous Cohorts of the study.
3015195|NCT02461160|Experimental|SRD Cohort 6: TAK-915 Dose F|TAK-915 suspension Dose F, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from previous Cohorts. TAK-915 dose will be determined based on data from previous Cohorts of the study.
3015196|NCT02461160|Experimental|Multiple Rising Dose (MRD) Cohort 7: TAK-915 30 mg|TAK-915 30 mg (Dose A) suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension ,orally, once on Days 8 to 14 following review of safety, tolerability and pharmacokinetic (PK) data from previous Cohorts.
3015197|NCT02461160|Experimental|MRD Cohort 8: TAK-915 Dose X|TAK-915 suspension Dose X, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 suspension, orally, once on Days 8 to 14 following review of safety, tolerability and pharmacokinetic (PK) data from previous Cohorts. TAK-915 dose will be determined based on data from previous Cohorts of the study.
3015198|NCT02461160|Experimental|MRD Cohort 9: TAK-915 Dose Y|TAK-915 suspension Dose Y, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 suspension, orally, once on Days 8 to 14 following review of safety, tolerability and pharmacokinetic (PK) data from previous Cohorts. TAK-915 dose will be determined based on data from previous Cohorts of the study.
3015199|NCT02461160|Experimental|MRD Cohort 10: TAK-915 Dose Z|TAK-915 suspension Dose Z, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 suspension, orally, once on Days 8 to 14 following review of safety, tolerability and pharmacokinetic (PK) data from previous Cohorts. TAK-915 dose will be determined based on data from previous Cohorts of the study.
3015200|NCT02461160|Experimental|Drug-Drug Interaction Cohort 8A: TAK-915 + Midazolam 2 mg|Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 suspension Dose X, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 suspension Dose X, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915) following review of safety, tolerability and pharmacokinetic (PK) data from previous Cohorts. TAK-915 dose will be determined based on data from previous Cohorts of the study.
3015201|NCT02461160|Placebo Comparator|Placebo: Cohorts 1-10, 8A|Placebo-matching TAK-915 suspension, orally on Day 1 in the SRD Cohorts 1-6. Placebo-matching TAK-915 suspension, orally, once on Day 1, followed by a 7-day washout period, followed by placebo-matching TAK-915 suspension, orally, once on Days 8 to 14 in the MRD Cohorts 7-10. Midazolam 2 mg solution, orally, once on Day 1, followed by placebo-matching TAK-915 suspension orally, once on Day 3, followed by a 7-day washout period, followed by placebo-matching TAK-915 suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 in Cohort 8A.
3015202|NCT02461160|Experimental|Bioavailability/Food Effect (BA/FE) Cohort 11 Group 1: A,B,C|Regimen A TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1, followed by Regimen B TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3. There will be a 6 to 14-day washout between each period.
3015203|NCT02461160|Experimental|BA/FE Cohort 11 Group 2: B,C,A|Regimen B TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 in Period 1, followed by Regimen C TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 2, followed by Regimen A TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 3. There will be a 6 to 14 day washout between each period.
3015239|NCT02460965||Patients with Parkinson's Disease|
3015240|NCT02460965||Patients with Alzheimer's Disease|
3015241|NCT02460965||Patients with dementia with Lewy Bodies|
3015204|NCT02461160|Experimental|BA/FE Cohort 11 Group 3: C,A,B|Regimen C TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 1, followed by Regimen A TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen B TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 3. There will be a 6 to 14-day washout between each period.
3015205|NCT02461160|Experimental|Elderly Subject Single Dose (ESSD) Cohort 12: TAK-915 50 mg|TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.
3015206|NCT02461147||Validation cohort|All patients of the study (single group, single arm) will undergo initial cholecystectomy with intraoperative cholangiogram, followed if required by ERCP, according to the standard protocol of treatment previously implemented at the investigators institution.
3015207|NCT02461134|Experimental|Ponesimod|Study treatment consists of 3 consecutive periods: 5 mg ponesimod treatment period (including up-titration), 10 mg treatment period (including up-titration) and a 20 mg treatment period.
3015208|NCT02461121|Experimental|MST（microtransplantation）|The microtransplantation conditioning regimen included high-dose Ara-C chemotherapy (2.0 to 2.5 g/m2 per 12 hours intravenously on days -4 to -2) followed by an infusion of HLA mismatched stem cell 24 hours (day 0) after the completion of cytarabine.
3015209|NCT02461121|Active Comparator|NST（nonmyeloablative transplantation）|The NST（nonmyeloablative transplantation）conditioning regimen consisted of 30 mg/m2/d fludarabine for days -6 to -2, 1.5-2 mg/kg/d anti-lymphocyte globulin for days -5 to -2, 40 mg/kg/d cyclophosphamide for days -4 and -2 and 2.0-3.0 g/m2/d cytarabine for days -6 to -4，followed by an infusion of HLA matched stem cell after the completion of regimen. The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
3015210|NCT02461108|Experimental|Price difference|Introduce a 10% price difference between foods labeled as nutritious and foods labeled as less nutritious and frame the price difference as either a Subsidy, Tax, or combination of a Tax and Subsidy.
3015211|NCT02461108|No Intervention|No price difference|No price difference between nutritious and less nutritious foods.
3015212|NCT02461095|Active Comparator|Impairment based approach|The intervention will address the patients impairments found during evaluation. Treatment will based on the Physical therapist evaluation and will be individualized to each patient.
3015213|NCT02461095|Experimental|PFPS algorithm|The Patellofemoral Syndrome algorithm is designed to determine what deficits a patient may have and addressing these sequentially. This subgrouping first assesses a patient fear avoidance beliefs, flexibility, body mechanics, and then strength and functional ability. The reason for sequential treatment is that there is evidence that without adequate flexibility a patient will be unable to perform exercises with proper body mechanics, and without proper mechanics strengthening and functional activity can cause increased stress on the patellofemoral joint. Progression through each specific subgroup is based on objective goals. Once the patient has met these goals they are progressed to the next treatment subgroup until discharge.
3015214|NCT02461082|Other|EMST and sham-TMS|Active expiratory muscle strength training in combination with sham transcranial magnetic stimulation
3015215|NCT02461082|Other|sham-EMST and TMS|Sham expiratory muscle strength training in combination with active transcranial magnetic stimulation
3015216|NCT02461082|Other|EMST and TMS|Active expiratory muscle strength training in combination with active transcranial magnetic stimulation
3015217|NCT02461082|Other|sham-EMST and sham-TMS|Sham expiratory muscle strength training in combination with sham transcranial magnetic stimulation
3015218|NCT02461069|Active Comparator|Dimethyl fumarate treatment arm (A)|All patients will receive dimethyl fumarate (Tecfidera®) according to national recommendations (Krankheitsbezogenes Kompetenznetz Multiple Sklerose, KKNMS) from week 0 to week 24 (EOS-1) in the core study.
3015219|NCT02461069|No Intervention|Healthy subject arm (B)|Healthy subjects will not receive any treatment for RRMS during the study.
3015220|NCT02461056|Active Comparator|Ibuprofen|Ibuprofen: Patients receive ibuprofen 50 mg, 100 mg, 200 mg, 400mg or 800 mg intravenously once at post-anesthesia care unit.
3015221|NCT02461056|Active Comparator|hydromorphone|Hydromorphone: Patients receive hydromorphone 0.25 mg, 0.5 mg, 1 mg, 1.5 mg, or 2 mg intravenously once at post-anesthesia care unit.
3015222|NCT02461056|Active Comparator|ibuprofen+hydromorphone|Ibuprofen+Hydromorphone: Patients receive ibuprofen 25 mg + hydromorphone 0.125 mg, ibuprofen 50 mg + hydromorphone 0.25 mg, ibuprofen 100 mg + hydromorphone 0.5 mg, ibuprofen 200 mg + hydromorphone 0.75 mg, or ibuprofen 400 mg + hydromorphone 1 mg intravenously once at post-anesthesia care unit.
3015223|NCT02461043|Experimental|Arm A|chemotherapy and radiotherapy
3015224|NCT02461043|Active Comparator|Arm B|radiotherapy
3015225|NCT02461030|Experimental|CSPR + NS treatment|"In-office and at home Colgate sensitive pro-relief - CSPR~Intervention: Non-surgical periodontal treatment (full-mouth debridement, scaling and root planing with ultrasonic/hand instruments) associated with In-office application of Colgate Sensitive Pro-Relief (CSPR) + tooth brushing with at home CSPR toothpaste during 8 weeks."
3015226|NCT02461030|Placebo Comparator|Villevie® + NS treatment|"In-office Villevie® prophy paste + Colgate Toothpaste~Treatment: In-office application of a Villevie® (fluoride-free) prophy paste + tooth brushing with a Colgate Cavity Protection Toothpaste during 8 weeks, after non-surgical periodontal treatment. (Full-mouth debridment/ Scaling and root planing with ultrasonic/hand instruments)"
3015227|NCT02461017||Endotracheal Leak|Assess for Audible Endotracheal Leak; Assess for Endotracheal Leak with direct visualization under rigid bronchoscope
3015228|NCT02461004|Experimental|TR group|CKD-391 and combination dose of Atrovastatin and Ezetimibe in order
3015229|NCT02461004|Experimental|RT group|combination dose of Atrovastatin and Ezetimibe and CKD-391 in order
3015230|NCT02460991|Experimental|DEB-TACE|ONCO-DOX (Doxorubicin loaded Microspheres) up to 150 mg per treatment; treatments can be repeated every 4-8 weeks until complete tumor response is achieved.
3015231|NCT02460991|Active Comparator|Sorafenib|200 mg Sorafenib twice daily; continue until unacceptable toxicity or unequivocal tumor progression
3015232|NCT02460978|Experimental|Dapagliflozin 5 mg|Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
3015233|NCT02460978|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
3015234|NCT02460978|Placebo Comparator|Placebo|Placebo tablet orally, once daily for 52 weeks
3015235|NCT02460965||Patients with schizophrenia|
3015236|NCT02460965||Patients with borderline personality disorder|
3015243|NCT02460926|Experimental|Scaling & Root Planing - Quadrant|Periodontal treatment (PT), consisting in both supra- and sub-gingival mechanical instrumentation of the root surface (scaling and root planing), was performed by a single periodontist . Treatment was provided using both hand and ultrasonic instrumentation with fine tips. Local anaesthesia was used when needed and no time constraints were enforced. Q-SRP patients received four quadrants sessions of PT with an interval of 1 week between sessions
3015244|NCT02460926|Experimental|Scaling & Root Planing - Full Mouth|Periodontal treatment (PT), consisting in both supra- and sub-gingival mechanical instrumentation of the root surface (scaling and root planing), was performed by a single periodontist . Treatment was provided using both hand and ultrasonic instrumentation with fine tips. Local anaesthesia was used when needed and no time constraints were enforced. FM-SRP patients received treatment within 24 hrs in two separate sessions, one side of the mouth for each session: two quadrants were instrumented in an afternoon session, whereas the other two were instrumented the following morning
3015245|NCT02460913|Experimental|Acupuncture|patients received a 20 to 30 minutes session of acupuncture
3015246|NCT02460913|Active Comparator|IV Morphine|patients received an intravenous titration of morphine every 5 minutes.
3015247|NCT02460900|Active Comparator|Varenicline and Standard of Care|Participants will received varenicline and standard of care
3015248|NCT02460900|Placebo Comparator|Placebo and Standard of Care|Participants will received placebo and standard of care
3015249|NCT02460900|Active Comparator|Positively Smoke Free and Placebo|Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Placebo
3015250|NCT02460900|Active Comparator|Positively Smoke Free and Vareniclinc|Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Placebo
3015251|NCT02460887|Experimental|Experimental|Induction chemotherapy+IMRT gemcitabine and cisplatin regimen Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT).
3015252|NCT02460887|Active Comparator|Active Comparator|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with weekly cisplatin 40 mg/m² up to 7cycles.
3015253|NCT02460874|Experimental|Pilot Portion|"Step 1: Patients with 1-10 brain metastases requiring SRS and not taking corticosteroids 5 days prior to treatment planning MRI~Step 2: Take Glyburide 1.25mg (twice a day by mouth) beginning 5 days prior to treatment planning MRI. Receive glucose monitoring materials and blood glucose education- begin glucose monitoring (4 times a day)~Step 3: On day of SRS, undergo MRI for treatment planning~Step 4: 1 week after SRS, return to clinic to review glucose logs- continue glyburide and blood glucose monitoring~Step 5: 1 month after SRS, discontinue both glyburide and blood glucose monitoring, undergo MRI~Step 6: 3 months after SRS, undergo MRI"
3015254|NCT02460874|Placebo Comparator|Randomized Portion|"Step 1: Patients with 1-10 brain metastases requiring SRS and not taking corticosteroids 5 days prior to treatment planning MRI~Step 2: Randomization (1:1)~Group 1: take Glyburide (1.25mg, twice a day by mouth) beginning 5 days prior to treatment planning MRI. Receive glucose monitoring materials and blood glucose education. Begin glucose monitoring (once a day) {This portion will be double blinded}~Group 2: Take Placebo (1 pill, twice a day by mouth) beginning 5 days prior to treatment planning MRI. Receive glucose monitoring materials and blood glucose education. Begin glucose monitoring (once a day) {This portion will be double blinded}~Step 3: On day of SRS, undergo MRI for treatment planning~Step 4: 1 week after SRS, return to clinic to review glucose logs, continue investigation medication, but discontinue glucose monitoring~Step 5: 1 month after SRS, discontinue investigation medication, undergo MRI~Step 6: 3 months after SRS, undergo MRI"
3015255|NCT02460861|Active Comparator|PCA Magdeburg|Prostate cancer conducted for RPVE with curative Intention, biopsies of the prostatic fossa in Magdeburg
3015256|NCT02460861|Active Comparator|Non-prostate cancer Magdeburg/Gronau|Conducted for CE in Male with bladder cancer or other indication for cystectomy but without prostate cancer in Magdeburg or Gronau, biopsies of the prostatic fossa in Gronau
3015257|NCT02460861|Active Comparator|PCA Gronau|Prostate cancer conducted for ETRARP with curative Intention, biopsies of the prostatic fossa
3015258|NCT02460848|Experimental|Outpatient therapeutic program, counseling and cash transfer|Ten outpatient therapeutic program sites (OTP) will be randomly allocated to unconditional cash transfer for children admitted for treatment of SAM according to the integrated management of acute malnutrition national protocol which will be associated with counseling on infant and young child feeding (IYCF).
3015259|NCT02460848|Active Comparator|Outpatient therapeutic program and counseling|Ten outpatient therapeutic program sites (OTP) will be randomly allocated for children admitted for treatment of SAM according to the integrated management of acute malnutrition national protocol which will be associated with counseling on infant and young child feeding (IYCF).
3015260|NCT02460835|Experimental|Adaptive Radiation Therapy|
3015261|NCT02460822|Experimental|MyChemoCare|Participants will receive access to the the MyChemoCare iPad application, which allows them to track cancer and chemotherapy related symptoms daily, and suggests strategies that may help the participant deal with these symptoms. While using the application, high symptom severity scores will be reported to the participant's medical team, who may intervene to help relieve the symptom. Participants will also be contacted if they have not checked in for 48 hours to make sure they are coping well with their chemotherapy regimen.
3015262|NCT02460809|Active Comparator|In-lab tDCS|Three people with chronic stroke will participate in finger tracking training while receiving transcranial direct current stimulation (tDCS) in a controlled laboratory environment with an investigator.
3015263|NCT02460809|Experimental|In-home tDCS|Three people with chronic stroke will participate in finger tracking training while receiving transcranial direct current stimulation (tDCS) in their own home. Patients will be taught how to use a blue-tooth enabled telerehabilitation module that is being controlled by an investigator in the lab on the University campus. For safety, an investigator will be in the home with each patient during tDCS use and finger tracking training but will only be supervising procedures.
3015264|NCT02460796||hippotherapy group or study group|8 weeks of hippotherapy therapy: Familiarization sessions were initially 15 minutes and gradually evolved to 30 minutes in order to allow all participants to adapt to the horse's rhythmic movements and to the act of mounting the horse. Each session had warm up before the training and exercises for relaxation in the end of each session.
3015265|NCT02460796||control group|8 weeks of Parkinson's disease lectures: this group did not hippotherapy classes in the same period.
3015266|NCT02460783|Experimental|5-2 CR|Healthy living diet for 5 days/week;
3015267|NCT02460783|Active Comparator|Healthy Living|Healthy living diet for 7 days/week
3015268|NCT02460770|Experimental|autologous mesenchymal stem cells|After bone-marrow aspiration by an authorized person, Mesenchymal Stem Cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of Mesenchymal Stem Cells during Left Ventricular Assist Device surgery
3015269|NCT02460757||Patients with COPD|
3015270|NCT02460757||Patients with interstitial lung disease|
3015271|NCT02460757||Healthy subjects|
3015272|NCT02460744|Experimental|Single arm treatment with radiation|Patients with breast cancer will be given adjuvant hypofractionated radiotherapy
3015273|NCT02460731|Experimental|Fresh Frozen Plasma|Fresh Frozen Plasma [young (<30 years of age) healthy male donors]
3015274|NCT02460718|No Intervention|control group|Participants received 1-hour group diabetes education class covering diabetes basics, healthy eating, stress reduction, physical activity, social support, and how to get the most out of their doctors visit. Participants also received a diabetes report card showing their Hba1c, blood pressure, ldl cholesterol, and body weight.
3015275|NCT02460718|Experimental|Encourage study|"Participants in the intervention arm were paired with a peer coach, interacting by telephone weekly for the first 8 weeks and then monthly for a total of 10 months.~Participants also received 1-hour group diabetes education class covering diabetes basics, healthy eating, stress reduction, physical activity, social support, and how to get the most out of their doctors visit. Participants also received a diabetes report card showing their Hba1c, blood pressure, ldl cholesterol, and body weight."
3015276|NCT02460705|Experimental|IBD patients receiving FMT|IBD patients receiving biologically active human fecal material sourced from OpenBiome. The physician will administer 250 mL of the fecal suspension in aliquots of 50-60 mL, through the endoscope. The material will be delivered to the most proximal point of insertion.
3015277|NCT02460692|Placebo Comparator|Placebos|The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
3015278|NCT02460692|Active Comparator|Dronabinol|A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
3015279|NCT02460692|Experimental|Vaporized Cannabis 3.7% THC/5.6% CBD|The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
3015280|NCT02460679|Experimental|EPI-589|EPI-589
3015281|NCT02460666|Experimental|Tai-Chi Chih Classes|Participants will engage in 12 weekly 120 minute Tai-Chi-Chih classes.
3015282|NCT02460666|Active Comparator|Health Education and Wellness Classes|Participants will engage in 12 weekly 120 minute Health Education and Wellness classes.
3015283|NCT02460653|No Intervention|Current|Current level of HFNC support
3015284|NCT02460653|Experimental|Low|Low flow range per kg.
3015285|NCT02460653|Experimental|Medium|Medium flow range per kg.
3015286|NCT02460653|Experimental|High|High flow range per kg
3015287|NCT02460640|Active Comparator|Tap Block|the intervention will be tap block after induction of anesthesia with ropivacaine 0,5% 15ml and continuous patient-controlled analgesia with morphine
3015288|NCT02460640|Active Comparator|No Tap Block|the patients who not receive tap block but they will be as intervention intravenous Patient controlled analgesia
3015289|NCT02460627|Experimental|Lidocaine adhesive tape|
3015290|NCT02460627|Placebo Comparator|Adhesive tape|
3015291|NCT02460614|Experimental|Rhinopharyngeal clearance + 0.9% saline|The retrograde rhinopharyngeal clearance (RRC) is based on the inspiratory reflex that follows a slow and prolonged expiration (passive exhalation technique performed using a slow thoracic-abdominal compression that begins at the end of a spontaneous exhalation and continues until the expiratory reserve volume). At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver. The instillation of saline (0.9%) preceded this step, resulting in the inhalation of the substance during the forced inspiration, contributing to the nasopharyngeal clearance.
3015292|NCT02460614|Active Comparator|Aspiration + 0.9% saline|Nasopharyngeal aspiration consisted in the introduction of a catheter that, by using negative pressure (vacuum), promotes the suction of secretion from the airways. In order to do that, a sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient. The saline instillation of 0.9% was used for humidification before the procedure.
3015293|NCT02460601|Experimental|Qizhiweitong granule|2.5g/time,tid,oral administration,6 weeks
3015294|NCT02460601|Placebo Comparator|Placebo|2.5g/time,tid,oral administration,6 weeks
3015295|NCT02460588|Placebo Comparator|Corticosteroid with placebo|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~All patients will receive non experimental medication with high dose of corticosteroid."
3015296|NCT02460588|Experimental|Corticosteroid associated with Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~All patients will receive non experimental medication with high dose of corticosteroid.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
3015297|NCT02460575|Experimental|Lactobacillus|Active Product: Description Lactobacillus reuteri 17938 suspended in sunflower oil, medium chain triglyceride oil, silicone dioxide. Total viable count of L. reuteri 17938 1 x 108 CFU/5 drops.
3015298|NCT02460575|Placebo Comparator|Placebo|Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
3015299|NCT02460562|Active Comparator|PMMA resin|A denture base will be made with PMMA resin as a standard material.
3015300|NCT02460562|Experimental|PMMA resin & S-PRG filler|A denture base will be made from PMMA resin & S-PRG filler for subject to wear.
3015301|NCT02460549|Experimental|therapeutic education program|patients attend three sessions of therapeutic education
3051885|NCT02214953|Experimental|BI 11634 ER formulation A|
3015302|NCT02460536|Experimental|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
3015303|NCT02460536|Active Comparator|Exposure only +ABMT|Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
3015304|NCT02460536|Active Comparator|Attention training only +ABMT|Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
3015305|NCT02460536|Placebo Comparator|Placebo group|Identical discrimination task including a single non-emotional stimulus in each trial.
3015306|NCT02460523|Active Comparator|conservative|"1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen ) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones.~Improvement: If the stone spontaneously passes to the duodenum and CBD is clear completely from the stones proved by US, the patient will undergo laparoscopic cholecystectomy (LC) within 3 days.~No improvement: the patient will undergo ERCP and then LC."
3015307|NCT02460523|Active Comparator|ERCP (endoscopic)|"2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.cholecystectomy (LC) within 3 days.~b- No improvement: the patient will undergo ERCP and then LC."
3015308|NCT02460510|Experimental|Mannitol|Treatment with mannitol intravenous (IV) bolus over 20 to 30 minutes. The dose is 0.25 g/kg IV as a 20% solution repeated every 4th hourly.(8) Mannitol infusion to be stopped if s osmolarity >320mm
3015309|NCT02460510|Active Comparator|3% hypertonic saline|Treatment with 3% hypertonic saline as continuous infusion. Continuous 3% NaCl infusion to be started at a rate of 25ml /hr and titrated q4hrs per sliding scale to achieve a target serum sodium level of <160 mmol/L.
3015310|NCT02460497|Experimental|Treatment|
3015311|NCT02460484|Experimental|Cord Blood Infusion|Autologous cord blood infusion
3015312|NCT02460471|Experimental|palliative radiation therapy|25 Gy in 5 daily fractions
3015313|NCT02460458||Type 3 VWD|Diagnosis of Type 3 von Willebrand Disease
3015314|NCT02460445|Experimental|Intervention|Premenopausal women with functional hyperandrogenism under combined oral contraceptive pill qd as usual clinical practice who will undergo a scheduled standard phlebotomy every 3 months from month 3 to 12 of follow-up.
3015315|NCT02460445|Active Comparator|Control|Premenopausal women with functional hyperandrogenism under standard combined oral contraceptive pill qd as usual clinical practice.
3015316|NCT02460432|Experimental|Paclitaxel-eluting metal Stent|Niti-S Mira-Cover III Biliary Stent (TaeWoong Medical Co., Ltd. Korea)
3015317|NCT02460432|Active Comparator|Covered Metal Stent|ComVi Biliary Covered Stent (TaeWoong Medical Co., Ltd. Korea)
3015318|NCT02460419|Experimental|maintenance capecitabine|maintenance capecitabine plus best supportive care(BSC)
3015319|NCT02460419|Other|best supportive care|Best supportive care and following-up every 6-8 weeks
3015320|NCT02460406|Other|control group|traditional physiotherapy (stretching, normal range of movement, walking)
3015321|NCT02460406|Active Comparator|intervention group|progressive functional strength training protocol on lower extremities consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball & heel-rise exercises.
3015322|NCT02460393|Placebo Comparator|Placebo group|The arm is as a control group to study the tolerance, safety and pharmacokinetic characteristics of Subcutaneous injection of different doses of humanized TNFα monoclonal antibody.
3015323|NCT02460393|Experimental|experimental group|The arm is as an experimental group to study the tolerance, safety and pharmacokinetic characteristics of Subcutaneous injection of different doses of humanized TNFα monoclonal antibody.
3015324|NCT02460380|Active Comparator|Vitamin D3|Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
3015325|NCT02460380|Placebo Comparator|Placebo|Women in the placebo group received once capsule of placebo once weekly for eight weeks.
3015326|NCT02460367|Experimental|Dose Level 1|"Tergenpumatucel-L given every 3 weeks for up to a total of 18 immunizations~Indoximod given TID every day until disease progression or significant toxicity.~Docetaxel given every 3 weeks until disease progression or significant toxicity."
3015327|NCT02460367|Experimental|Dose Level 2|"Tergenpumatucel-L given every 3 weeks for up to a total of 18 immunizations~Indoximod given TID every day until disease progression or significant toxicity.~Docetaxel given every 3 weeks until disease progression or significant toxicity."
3015328|NCT02460354|Experimental|Metformin|Subjects with congenital nephrogenic diabetes insipidus (NDI) will receive one metformin 500 mg pill orally
3015329|NCT02460341|Experimental|ondansetron-8|Single dose of 8 mg ondansetron (crossover with single dose of placebo)
3015330|NCT02460341|Experimental|ondansetron-16|Single dose of 16 mg ondansetron (crossover with single dose of placebo)
3015331|NCT02460341|Experimental|ondansetron-24|Single dose of 24 mg ondansetron (crossover with single dose of placebo)
3015332|NCT02460315|Active Comparator|early cholecystectomy|group (A) will be managed by early laparoscopic cholecystectomy after clearness ERCP
3015333|NCT02460315|Active Comparator|late cholecystectomy|group (B) will be managed by late LC one month after ERCP.
3015334|NCT02460302|Experimental|Vaginal Progesterone|"In the experimental arm, the participants will be randomized (1:1 allocation) to receive a vaginal progesterone suppository (100mg) as the intervention.~Participants will be instructed to insert the vaginal suppository into the vagina, as high as is comfortable for the patient. They are to insert the drug three days per week, on Monday, Wednesday and Fridays, preferably at bedtime. Patients will record the use of their medications. This will be done for the study period of 12 weeks."
3015335|NCT02460302|Placebo Comparator|Placebo Comparator|"In the placebo arm, the participants will be randomized (1:1 allocation) to receive a vaginal suppository (100mg) containing hard fat without any active hormonal ingredient as the intervention.~Participants will be instructed to insert the vaginal suppository into the vagina, as high as is comfortable for the patient. They are to insert the placebo three days per week, on Monday, Wednesday and Fridays, preferably at bedtime. Patients will record the use of their medications. This will be done for the study period of 12 weeks."
3015336|NCT02460289|Experimental|Treatment|
3015337|NCT02460276|Experimental|Lenalidomide, ibrutinib and rituximab.|
3015338|NCT02460263|Placebo Comparator|In-Center|Staff administered treatments in-center using the device
3015339|NCT02460263|Experimental|In-Home|Patient administered treatments in-home using the device
3015340|NCT02460250|Experimental|Fibroscan|All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked. Liver recipients will be followed up during one year. Biological and medical data used by all transplant sites for the follow-up of transplant patient will be collected
3015341|NCT02460237|Experimental|Arm I (intervention)|Participants receive a study kit that includes culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing. Participants are asked to complete the HPV self-test and return the test for HPV testing.
3015342|NCT02460237|Active Comparator|Arm II (control)|Participants receive a study kit that includes standard instructions for using and returning the HPV self-test device and a standard information sheet about HPV and cervical cancer. Participants are asked to complete the HPV self-test and return the test for HPV testing.
3015343|NCT02460224|Experimental|Arm A|Single agent treatment arm with LAG525
3015344|NCT02460224|Experimental|Arm B: combination of LAG525 and PDR001|Combination treatment arm with LAG525 and PDR001
3015345|NCT02460224|Experimental|Arm C|Single agent treatment arm with LAG525 in Japanese pts
3015346|NCT02460211|Active Comparator|Treatment|Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation.
3015347|NCT02460211|Placebo Comparator|Placebo/Control Arm|Those randomized to the control arm will receive three oral placebo doses.
3015348|NCT02460198|Experimental|Cohort A: Pembrolizumab|Cohort A participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to 35 cycles (up to approximately 2 years).
3015349|NCT02460198|Experimental|Cohort B: Pembrolizumab|Cohort B participants receive pembrolizumab 200 mg IV on Day 1 Q3W for up to 35 cycles (up to approximately 2 years).
3015350|NCT02460185|No Intervention|Control|Without maternal physical exercise practice
3015351|NCT02460185|Active Comparator|Study Group|Behavioral: 30 minutes of walking, 3 times a week at 4 Km/h. Induction of labor was performed at 41 weeks.
3015352|NCT02460172|Active Comparator|Zip Surgical Skin Closure|Subject will be randomized to receive one knee (right or left) closed with Zip Surgical Skin Closure and the other knee closed with steel staples.
3015353|NCT02460172|Active Comparator|Steel Staples|Subject will be randomized to receive one knee (right or left) closed with steel staples and the other knee closed with Zip Surgical Skin Closure.
3015354|NCT02460159|Experimental|EZ 10 mg/Atorva 10 mg FDC|one EZ 10 mg/Atorva 10 mg fixed-dose combination (FDC) tablet orally with food once daily for 52 weeks.
3015355|NCT02460159|Experimental|EZ 10 mg/Atorva 20 mg FDC|one EZ 10 mg/Atorva 20 mg fixed -dose combination (FDC) tablet orally with food once daily for 52 weeks.
3015356|NCT02460146|Active Comparator|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
3015357|NCT02460146|Placebo Comparator|CXA-10 placebo|The placebo contains olive oil with BHT (0.08% to 0.10%).
3015358|NCT02460133|Other|HCV Genotype 1, with and without cirrhosis|
3015359|NCT02460120|Experimental|Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System
3015360|NCT02460107|Placebo Comparator|Normal saline|Normal saline
3015361|NCT02460107|Active Comparator|Botulinum toxin type A 50U|Botulinum toxin 50U
3015362|NCT02460107|Active Comparator|Botulinum toxin type A 100U|Botulinum toxin 100U
3015363|NCT02460094|Experimental|Panel 1: BMS-986168/ Placebo|BMS-986168 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
3015364|NCT02460094|Experimental|Panel 2: BMS-986168/ Placebo|BMS-986168 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
3015365|NCT02460094|Experimental|Panel 3: BMS-986168/ Placebo|BMS-986168 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
3015366|NCT02460081|Experimental|PDA-002 -3x10^6 cells|Subjects will be treated with Investigational Product (IP) administered intramuscular (IM) on Study Days 1, 29 and 57.
3015367|NCT02460081|Experimental|PDA-002 - 30X10^6 cells|Subjects will be treated with IP administered IM on Study Days 1, 29 and 57.
3015368|NCT02460081|Placebo Comparator|Placebo|Subjects will be treated with Placebo administered IM on Study Days 1, 29 and 57.
3015369|NCT02460068|Active Comparator|fotemustine|fotemustine alone
3015370|NCT02460068|Experimental|fotemustine and ipilimumab|fotemustine in combination with ipilimumab
3015371|NCT02460068|Experimental|ipilimumab and nivolumab|ipilimumab in combination with nivolumab
3015372|NCT02460055|Active Comparator|Endotracheal tube|Following routine inhalation induction with 8% sevoflurane in oxygen and nitrous oxide, 100% oxygen will be administered and intravenous access will be secured. Intravenous administration of Propofol 3mg/kg and Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation with an age appropriate endotracheal tube. Presence of an audible air leak around the endotracheal tube will be addressed by inflating the cuff with air until the audible leak is no longer appreciated. The endotracheal tube will not be lubricated prior to intubation. Other medications that will be administered during the procedure include Dexamethasone at a dose of 0.15mg/kg up to 20 mg and Ondansetron 0.15mg/kg up to 4mg.
3015373|NCT02460055|Active Comparator|No Endotracheal tube|Those not receiving endotracheal intubation will undergo an inhalation induction, have intravenous access secured and intravenous propofol 3mg/kg with Fentanyl 1mcg/kg will be administered prior to placement of the nasal trumpet and connection to the anesthesia circuit.patients will receive a general anesthetic consisting of sevoflurane in oxygen and air at routine concentrations for maintenance of anesthesiaOther medications that will be administered during the procedure to both arms of patients include Dexamethasone which will be administered at a dose of 0.15mg/kg up to 20 mg and Ondansetron 0.15mg/kg up to 4mg for post operative nausea and vomiting prophylaxis.
3015374|NCT02460016|Experimental|AK0529|AK0529 pellets
3015375|NCT02460003|Experimental|Physiotherapy program|Physiotherapy program and usual drugs
3015376|NCT02460003|Active Comparator|Home exercise program|Home exercise program and usual drugs
3051886|NCT02214953|Experimental|BI 11634 ER formulation B|
3015377|NCT02459977|Experimental|No basiliximab group|The investigators omit basiliximab induction therapy in one to three-HLA mismatched living donor renal transplants.
3015378|NCT02459977|Active Comparator|Basilixiab group|Age and sex matched patients who underwent one to three-HLA mismatched living donor renal transplants with basiliximab induction therapy (Control group)
3015379|NCT02459964|Experimental|Fentanyl Nasal Spray|"Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h).~Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study."
3015380|NCT02459964|Active Comparator|Hydromorphone Hydrochloride|"Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).~Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study."
3015381|NCT02459951||clenched fist|Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.
3015382|NCT02459938|Experimental|ZP-Glucagon 0.5 mg|glucagon applied to the ZP transdermal microneedle patch system at a dose of 0.5 mg applied by means of a purpose built reusable applicator and worn for 30 minutes
3015383|NCT02459938|Experimental|ZP-Glucagon 1.0 mg|glucagon applied to the ZP transdermal microneedle patch system at a dose of 1.0 mg applied by means of a purpose built reusable applicator and worn for 30 minutes
3015384|NCT02459938|Active Comparator|Glucagon by injection, 0.5 mg|glucagon applied as GlucaGen (NovoNordisk) injector system at a dose of 0.5 mg
3015385|NCT02459938|Active Comparator|Glucagon by injection, 1.0 mg|glucagon applied as GlucaGen (NovoNordisk) injector system at a dose of 0.5 mg
3015386|NCT02459925|Active Comparator|CBT- Mental Health Program|Cognitive Behavioral Therapy. Manualized Stress Management class; brief individual behavioral counseling.
3015387|NCT02459925|Active Comparator|MOMS GROW|MOMS GROW (Generating Real Opportunities for Work) Teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage.
3015388|NCT02459912|Other|Unilateral Nerve-Sparing Cryoablation|Unilateral Nerve-Sparing Cryoablation of the Prostate using Galil Medical Precise Cryoablation System with IceRod Needles.
3015389|NCT02459899|Placebo Comparator|Placebo|Placebo (fasted conditions)
3015390|NCT02459899|Experimental|Treatment A|Low dose Sotagliflozin (fasted conditions)
3015391|NCT02459899|Experimental|Treatment B|Middle dose Sotagliflozin (fasted conditions)
3015392|NCT02459899|Experimental|Treatment C|High dose Sotagliflozin (fasted conditions)
3015393|NCT02459886|Experimental|Cohort 1|Single intravenous (IV) low dose infusion with staggered participant dosing
3015394|NCT02459886|Experimental|Cohort 2|Single IV ascending dose infusion with staggered participant dosing
3015395|NCT02459886|Experimental|Cohort 3|Single IV ascending dose infusion with staggered participant dosing
3015396|NCT02459886|Experimental|Cohort 4|Single IV ascending dose infusion with staggered participant dosing
3015397|NCT02459886|Experimental|Cohort 5|Single IV ascending dose infusion with staggered participant dosing
3015398|NCT02459886|Experimental|Cohort 6|Single IV ascending dose infusion with staggered participant dosing
3015399|NCT02459886|Experimental|Cohort 7|Single IV ascending dose infusion with staggered participant dosing
3015400|NCT02459873|Experimental|Computer games to assess change in executive function skills|Children in Intervention group get to train using executive function games at more difficult levels.
3015401|NCT02459873|Active Comparator|Easy games as active comparators for executive function skills|Children in Non-intervention group get to play executive function games at an easy level.
3015402|NCT02459860|Experimental|Problem Solving Treatment|Problem Solving Treatment Individual, face-to-face PST sessions over a span of 8 weeks and 3 monthly booster sessions. The PST protocol is highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies.
3015403|NCT02459860|Active Comparator|Enhanced Usual Care|Enhanced Usual Care EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
3015404|NCT02459847|Experimental|Mindfulness|Two sessions, each lasting 60-minutes total. The first session involves standard hand therapy care for the entire session. The second session begins with the participant listening to a 19-minute audio-recorded body scan (i.e., mindfulness training), followed by standard care.
3015405|NCT02459847|Experimental|Biofeedback|Two sessions, each lasting 60-minutes total. The first session involves standard hand therapy care for the entire session. The second session begins with the participant receiving 20 minutes of visual biofeedback training using sonographic imaging (i.e., sonographic biofeedback), followed by standard care.
3015406|NCT02459834|Experimental|Allulose + 75g OGTT|Allulose added to a 75 g OGTT of 500 mL at 2 doses (5g and 10g). The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
3015407|NCT02459834|Experimental|Fructose + 75g OGTT|Fructose added to a 75 g OGTT of 500 mL at 2 doses (5g and 10g). The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
3015408|NCT02459834|Active Comparator|75g OGTT (Control)|A 75 g OGTT (alone) of 500 mL will be given to each participant. The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
3015409|NCT02459821|Experimental|Robot-assisted gait training group|The first group will be subjected to RAGT for 9 weeks (2 sessions/ week) with a total of 18 sessions by mean of GE-O System (9). During each session, the patients will practice 15 to 20 min of simulated floor walking followed by 5 to 10 min of repetitive simulated stair climbing up and down. Breaks will be optional, but uninterrupted training intervals of at least 5 min for simulated floor walking and 3 min of simulated stair climbing will be required. When the patient reaches the maximum amount of time, speed of gait will then be progressively increased. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
3015597|NCT02458586|Active Comparator|PUFA|daily intake of 50 g of canola oil (rapeseed oil) over a period of 8 weeks
3015410|NCT02459821|Active Comparator|Conventional training group|The group will be subjected to conventional gait training for 9 weeks (2 sessions/week) with a total of 18 sessions. Each session will last altogether 50 minutes, the first 30 minutes will be dedicated to gait and stair climbing up and down training while the last 20 minutes to stretch the lower limb's muscles.
3015411|NCT02459808||GBS Patients|Patients with Guillain-Barré syndrome
3015412|NCT02459795|Experimental|Test product|Ingenol Mebutate (Perrigo)
3015413|NCT02459795|Active Comparator|Reference product|Ingenol Mebutate (Reference)
3015414|NCT02459795|Placebo Comparator|Placebo product|Placebo gel
3015415|NCT02459782|Other|US Guided Dual Quadrant Peribulbar block|Ultrasound guided Dual Quadrant Peribulbar Anaesthesia
3015416|NCT02459769|Active Comparator|Dyadic Exercise Intervention|Progressive walking and resistance exercise treatment, prescribed to both cancer survivors and their caregivers (daily walking and 3 times/week resistance prescription for 6 weeks). Cancer survivor and caregiver are also asked to discuss ways they can support one another in a) remaining adherent to exercise, and b) dealing with stress, including LGBT-specific minority stress.
3015417|NCT02459769|Other|Individual Exercise Intervention|Progressive walking and resistance exercise treatment, prescribed solely to cancer survivors (daily walking and 3 times/week resistance prescription for 6 weeks). The caregiver is told not to change his/her exercise behavior in any way.
3015418|NCT02459756|Active Comparator|Intervention|Spray dried blackcurrant powder dissolved in water
3015419|NCT02459756|Placebo Comparator|Placebo|(sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)
3015420|NCT02459743||Patients with hematological malignancies|Patients with a conclusive diagnosis of haematological malignancies according to WHO criteria referred to the Rete Ematologica Lombarda (REL) clinical network will be enrolled. The investigators will analyse genomic DNA extracted from hematopoietic cells at different time points of patient disease. The study contemplates the use of two optimized molecular platforms aimed at the identification of recurrent mutations in myeloid and lymphoid neoplasms, respectively. Screening of gene mutations by NGS will be prospectively implemented in the context of REL clinical network. Patient samples will be analyzed at diagnosis and sequentially during the course of the disease at specific timepoints.
3015421|NCT02459730|Experimental|ART with GIC containing 1.25% CHX|The cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
3015422|NCT02459730|Active Comparator|ART with GIC|The cavities were filled with the press finger technique using KetacMolar Easymix® (control group).
3015423|NCT02459717|Experimental|Probiotics and prebiotic|fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
3015424|NCT02459717|Placebo Comparator|Placebo|pasteurized fermented milk (125 grams) without prebiotics
3015425|NCT02459704|Experimental|SCPF + EMD (TEST)|Semilunar coronally positioned flap with Enamel matrix derivative (Emdogain)
3015426|NCT02459704|Active Comparator|SCPF (CONTROL)|Semilunar coronally positioned flap alone
3015427|NCT02459691|Active Comparator|Usual Care Only|Patients assigned to this group will continue medical care as usual.
3015428|NCT02459691|Experimental|Vida Sana|Patients assigned to this group will continue medical care as usual and in addition will receive the culturally adapted intervention.
3015429|NCT02459678|Other|Standard of Care|The MOH-recommended approach is opt out HIV testing in pregnancy followed by immediate initiation of ART for HIV-infected pregnant women. ART initiation is accompanied with counseling geared to educate and prepare women to take up and be retained on ART lifelong. Women who do not return for clinical or drug refill visits are traced by phone or in person.
3015430|NCT02459678|Experimental|Enhanced adherence package|The enhanced adherence package will be designed on the basis of the results of formative research. The intervention will support women who are eligible for ART under Option B+.
3015431|NCT02459665|No Intervention|Group 1|Negative control group: After initial treatment for BV/TV, no intervention.
3015432|NCT02459665|Other|Group 2|Positive control group: After initial treatment for BV/TV, metronidazole pills (500 mg) twice per week for 2 months.
3015433|NCT02459665|Active Comparator|Group 3|After initial treatment for BV/TV, Ecologic Femi vaginal capsule (a vaginal probiotic) once per day for 5 days immediately after the initial treatment followed by thrice weekly for two months.
3015434|NCT02459665|Active Comparator|Group 4|After initial treatment for BV/TV, Gynophilus vaginal tablet (a vaginal probiotic) once every 4 days for two months.
3015435|NCT02459652|Experimental|Neoadjuvant S-1/RT|This is a single arm prospective study. All eligible subjects will receive neoadjuvant S-1 and concurrent radiation followed by surgical resection. Subjects may receive adjuvant chemotherapy after surgical resection at the clinical discretion of the medical oncologists.
3015436|NCT02459639||Anthroposophic integrative care|"Inclusion criteria are: Pain patients with a primary diagnosis corresponding to ICD-10 M79, or long-term pain for a period of over 3 months in neck/shoulders and/or low back, or generalised pain, fluency in Swedish and allowing for co-morbidity/ multiple secondary diagnoses.~The exclusion criteria are: psychotic illness, schizophrenia, bipolar disorder, substance dependency problems, and cancer."
3015437|NCT02459639||Multimodal pain rehabilitation|"Inclusion criteria are: Pain patients with a primary diagnosis corresponding to ICD-10 M79, or long-term pain for a period of over 3 months in neck/shoulders and/or low back, or generalised pain, fluency in Swedish and allowing for co-morbidity/ multiple secondary diagnoses.~The exclusion criteria are: psychotic illness, schizophrenia, bipolar disorder, substance dependency problems, and cancer."
3015438|NCT02459626||HFpEF and servere diastolic dysfuntion|Left ventricular ejection fraction (LV-EF) > 50%, echocardiographic criteria for diastolic dysfunction, New York Heart Association classification (NYHA)=>2, Diagnostic P-V-loops and MRI
3015439|NCT02459626||HFpEF no servere diastolic dysfuntion|LV-EF > 50%, no echocardiographic criteria for diastolic dysfunction, NYHA=>2, Diagnostic P-V-loops and MRI
3015440|NCT02459626||No HF or diastolic dysfunction|LV-EF > 50%, no diastolic dysfunction, no heart failure, Diagnostic P-V-loops and MRI
3015441|NCT02459613|Experimental|Imaging|99mTc Annexin V-128 SPECT
3015442|NCT02459600|Experimental|All participants|"The measurement will be done at all the participants. the results will the divides in the following way:~Refraction measurements under general anesthesia without cycloplegic eye drops.~Refraction measurements under general anesthesia with cycloplegic eye drops."
3015445|NCT02459574|Active Comparator|Group 3-Conventional AF Ablation|This will involve an ablation procedure carried out in the usual manner. The patient will have three sheaths placed in the leg veins. Catheters will be passed up to the patient's heart from these veins. Two crossing are required into the left atrium. The ablation will involve freeze technology using the Advance Cryoballoon. It will include measuring the electrical signals and may also involve radiofrequency or 'burning' technology in addition.
3015446|NCT02459574|Active Comparator|Group 2-Anti-arrhythmic therapy|Anti-arrhythmic drugs: On the treatment start date the patient will have a new tablet prescribed or a change in the dosage of the medication. The patient will be reviewed at 8wks (visit 1) later to see if the medication is working. If the tablets are working, the patients medication will be left unchanged. If not, an alternative tablet or a higher dose will be used.
3015447|NCT02459574|Experimental|Group 1-AVATAR-AF Ablation Protocol|AF ablation with pulmonary vein isolation. The patient will have two sheaths in their leg veins instead of the usual three sheaths. Catheters will be passed up to the heart from these leg veins. The single crossing into the left atrium will be by the usual method. Veins will be ablated using freeze technology known as the Advance Cryoballoon. After the ablation is completed the patient will have scans on their heart and checks of the leg veins. If all the checks are satisfactory at six hours after the procedure the patient will be allowed to go home on the same day. The patient will be reviewed in clinic in 8 weeks (visit 1) after the procedure and if it has been successful, will be reviewed again a month later (visit 2) and if all is well, the patient will be discharged from clinic.
3015448|NCT02459561|Experimental|EndoBarrier Arm|The EndoBarrier Gastrointestinal Liner device received CE Mark for 12 months implant duration on 11 December 2009 and is a single use, minimally invasive device, used to achieve weight loss and improve Type 2 Diabetes status in subjects who are obese. The intent of the EndoBarrier Gastrointestinal Liner is to mimic portions of the standard Roux-en-Y bypass procedure. The device consists of 3 components: the implant, the delivery system, and the removal system. At study visit 4, after eight hours fasting, 80 subjects will arrive to the pre- assessment unit as part of the theatres at St. Mary's Hospital or Southampton Hospital and receive the EndoBarrier TM Gastrointestinal Liner as part of the EndoBarrier Arm Intervention.
3015449|NCT02459561|Other|Medical Therapy Arm|"The standard medical therapy arm will be carried out in accordance with the guidelines of the American Diabetes Association. These guidelines have been chosen as they are applicable to an International audience and thus would adhere to the current best worldwide practice that would still be likely to be relevant when the results are published following study completion.~Diabetes reviews appointments with a Diabetologist/Endocrinologist will be performed with the control arm patients at visits 2, 4, 6, 7, 9, 11, 12, 13 and 15.~At study visit 4, 80 subjects will arrive at Mary's Hospital or Southampton Hospital and receive the best Medical Care and dietary advice as part of the Medical Therapy Arm Interventions."
3015450|NCT02459548|Experimental|Primary Care Group|This group will be follow up in Primary Care at 1, 3 and 6 month. At each visit patients receive advice on CPAP treatment, management of adverse effects associated with CPAP, making anthropometric and blood pressure measurements and also were asked to complete questionnaires.
3015451|NCT02459548|Other|Sleep Unit Group|This group will be follow up in Sleep unit at 1, 3 and 6 month. At each visit patients receive advice on CPAP treatment, management of adverse effects associated with CPAP, making anthropometric and blood pressure measurements and also were asked to complete questionnaires.
3015452|NCT02459535|Active Comparator|Glucose only|oral ingestion of 54 g Glucose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
3015453|NCT02459535|Active Comparator|Glucose + Saccharin|oral ingestion of 54 g Glucose + 0,112 g Saccharin in 300 ml water at t=0 in fasted state; blood samples over 120 mins
3015454|NCT02459535|Active Comparator|Saccharin only|oral ingestion of 0,112 g Saccharin in 300 ml water at t=0 in fasted state; blood samples over 120 mins
3015455|NCT02459535|Active Comparator|Glucose + Aspartame|oral ingestion of 54 g Glucose 0,197 g Aspartame in 300 ml water at t=0 in fasted state; blood samples over 120 mins
3015456|NCT02459535|Active Comparator|Aspartame only|oral ingestion of 0,197 g Aspartame in 300 ml water at t=0 in fasted state; blood samples over 120 mins
3015457|NCT02459535|Active Comparator|Glucose + Sucralose|oral ingestion of 54 g Glucose + 0,088 g Sucralose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
3015458|NCT02459535|Active Comparator|Sucralose only|oral ingestion of 0,088 g Sucralose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
3015459|NCT02459522||Dr.Tang's research group|This group included participants with completed both the short-term HRV test and Ewing's test.
3015460|NCT02459509|Active Comparator|Dexmedetomidine 2 mcg/kg|2 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction
3015461|NCT02459509|Active Comparator|Dexmedetomidine 4 mcg/kg|4 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction
3015462|NCT02459496|Active Comparator|low-carb diet, followed by conventional DGE diet|subjects receive dietary consulting for a first phase of 3 weeks, being represented by a very-low calory low-carb ketogenic diet (VLCKD, below 40 g carbs per day), followed by an isocaloric or moderate hypocaloric low-carb diet (below 40 kcal% carbs per day)
3015463|NCT02459496|Active Comparator|very-low calory diet, followed by conventional diet|subjects receive dietary consulting for a first phase of 3 weeks, being represented by a very-low calory diet (VLCD; MODIFAST substitute, approx. 1200 kcal/day), followed by a conventional isocaloric or moderate hypocaloric diet under DGE guidelines
3015464|NCT02459483|Experimental|Nurse phone call|a nurse will interview patients by phone every 14 +/- 2 days for 6 months
3015465|NCT02459483|No Intervention|Control Group|Common practice
3015466|NCT02459470|Experimental|SVV and PPV|"SVV(stroke volume variation): recorded using the Flotrac/Vigileo system (Edwards Lifesciences)~PPV(pulse pressure variation): recorded using philips Intelivue MP70 monitors (Philips Medical System)~Intervention: Other: Fluid loading using HES 130/0.4; voluven; Fresenius Kabi; Stans, Switzerland"
3015467|NCT02459457|Active Comparator|Paclitaxel and Cisplatin (TP)|Patients receive TP concurrent with radiotherapy (1.8Gy/d, d1-5/week, 34Fx) Paclitaxel: 175mg/m2/d, ivgtt over 3 hours, d1; Cisplatin: 25mg/m2/d, ivgtt, d1-3, q4w*4
3015468|NCT02459457|Active Comparator|Paclitaxel and Fluorouracil (TF)|Patients receive TF concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; 5-FU 300mg/m2, civ 96h, d1-4, qw*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; 5-FU 1800mg/m2, civ 72h, d1-3, q4w*2
3015469|NCT02459457|Active Comparator|Paclitaxel and Carboplatin（TC）|Patients receive TC concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=2, ivgtt, d1, qw*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=5, ivgtt, d1, q4w*2
3015470|NCT02459444|Experimental|IMT group and physiotherapy|Inspiratory muscle training with POWERBREATHE an approximate load of 50 % of MIP , for 1 set of 30 breaths twice a day, 7 days a week for 4 weeks ( total 56 sessions). Associated with physiotherapy program.
3015471|NCT02459444|Placebo Comparator|Sham IMT group|Inspiratory muscle training with the same device in the experimental group , however without charge , for 1 set of 30 breaths twice a day, 7 days a week for 4 weeks ( total 56 sessions). Associated with physiotherapy program.
3015472|NCT02459431|Active Comparator|21G needle group|21 gauge endobronchial ultrasound guided transbronchial aspiration needle ( Vizishot, Olympus ) would be used to perform endobronchial ultrasound guided Transbronchial needle aspiration
3015473|NCT02459431|Active Comparator|22G needle group|22 gauge endobronchial ultrasound guided transbronchial aspiration needle ( Vizishot, Olympus ) would be used to perform endobronchial ultrasound guided Transbronchial needle aspiration
3015474|NCT02459418|Experimental|Afolia - US Gonal-f® (Sequence A) Arm|During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive treatment sequence: (Sequence A): Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.
3015475|NCT02459418|Active Comparator|US Gonal-f® - Afolia (Sequence B) Arm:|During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive treatment sequence (Sequence B): Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27
3015476|NCT02459405|Experimental|NIR anastomotic perfusion assessment|"Patient will have their anastomosis assessed after they receive 7.5 to 9 mg of Indocyanine green intravenously (at a concentration of 2.5mg/ml).~The microvascularisation assessment will be performed using a near infrared device(Pinpoint device), allowing to increase reality.~This procedure will be repeated twice during the surgery, the first time before and the second time after the anastomosis has been done."
3015477|NCT02459392|Other|Epiduroscopy mechanical lysis|Epiduroscopy only mechanical lysis
3015478|NCT02459392|Experimental|Epiduroscopy combination|Epiduroscopy together mechanical lysis of epidural adhesions together with epidural drug administration Hyaluronic acid 150 IU and Depo-Medrol 80mg
3015479|NCT02459366||control|establish the reliability of measurement of lumbopelvic asymmetry, mechanical and physical properties of thoracolumbar fascia, and the norm of different age
3015480|NCT02459366||low back pain|compare the differences among asymptomatic subjects and patients with and without lumbopelvic asymmetry, and investigate whether lumbopelvic symmetry, core muscle contractility, proprioception and standing balance change after manipulating thoracolumbar fascia tissue by physical therapy
3015481|NCT02459353|Experimental|dapagliflozin 10mg|a group which treated with dapagliflozin 10mg plus basal insulin therapy
3015482|NCT02459353|Placebo Comparator|placebo 10mg|a group which treated with dapagliflozin placebo plus basal insulin therapy
3015483|NCT02459340|Experimental|patient group|"Inpatient setting (cPTSD, DDNOS, DIS): Trauma-adapted psychotherapy (individual and group setting), body-related, cognitive stabilization groups, pharmacotherapy, and other non-verbal treatment modalities (e.g. music, art, and occupational therapy)~Outpatient setting (PTSD, cPTSD, DDNOS, DIS): Trauma-specific psychiatric as well as psychotherapeutic treatment~Inpatient setting (BPD): Patients receive Dialectic Behavioral Therapy (DBT) and Schema-Therapy, pharmacotherapy, and non-verbal therapies (music, art, occupational, and body therapy)"
3015484|NCT02459340|No Intervention|healthy control group|passive control group
3015485|NCT02459327|Experimental|VIP/FCU|VIP (Video Interaction Project) will be offered to all families assigned to the treatment group. FCU (Family Check Up) will be offered to families identified as high risk within the treatment group. Both treatments are parenting interventions.
3015486|NCT02459327|No Intervention|Control|
3015487|NCT02459314|Placebo Comparator|soymilk|Soymilk (SM) contained 5 gm soy protein and 6.5 gm sugar per 180 mL package.
3015488|NCT02459314|Active Comparator|sterol/fiber-enriched soymilk|PLant sterol and soluble fiber-enriched soymilk (SFSM) contained 1 gm free plant sterol, 5 gm inulin (soluble fiber), 5 gm soy protein and 6.5 gm sugar per 180 mL package
3015489|NCT02459301|Experimental|IPH2201|"Part 1: 1, 4 or 10mg/kg, IV, 1 hour duration on Day 1 every 2 weeks.~Part 2: Patients will receive single agent IPH2201 as above with the actual dose dependent on the outcome of Part 1"
3015490|NCT02459288|Experimental|Clopidogrel first|Clopidogrel (Plavix) 75 mg qd, 2 weeks; followed with Ticagrelor (Brilinta) 90 mg bd, 2 weeks
3015491|NCT02459288|Experimental|Ticagrelor first|Ticagrelor (Brilinta) 90 mg bd, 2 weeks; followed with Clopidogrel (Plavix) 75 mg qd, 2 weeks
3015492|NCT02459275|Experimental|PEP uP Protocol|Semi-elemental tube feeds are started at the hourly goal rate as determined by the 24 hour volume goal. Protein supplements will be started at the initiation of tube feeds to target a daily delivery of 2 g/kg/day. A promotility agent will be started empirically concomitant with EN initiation. GRV will be checked every 4 hours and will be reinfused to the patient each time it is checked. GRV threshold is 500 ml. Once the patient shows tolerance of semi-elemental formula, the tube feeds will then be converted to standard polymeric formula. Daily, the patient will be reassessed for the need to continue promotility agents.
3015493|NCT02459275|No Intervention|Standard of Care|Standard formula polymeric tube feeds started at a rate of 20 ml/hour. Gastric residual volume (GRV) will be checked every 4 hours. GRV is reinfused to the patient each time it is checked. GRV threshold is 200-500 ml. If the patient is tolerating tube feeds as determined by measuring the GRV, the rate is advanced by 20 ml/hour every 4 hours up to the goal rate.
3015494|NCT02459262|Active Comparator|GBS-NN Vaccine|GBS-NN vaccine administered either adsorbed to Alhydrogel® or alone.
3015495|NCT02459262|Placebo Comparator|Sterile dilution buffer with Alhydrogel|The placebo will contain either Alhydrogel® or buffer alone.
3015528|NCT02459041||Pancreatic cancer|"Consecutively admitted patients with pancreatic cancer confirmed by EUS-guided FNA.~EG-EUS and CE-EUS will be applied in all patients."
3015529|NCT02459041||Benign pancreatic masses|"Consecutively admitted patients with benign pancreatic masses with negative EUS-guided FNA.~EG-EUS and CE-EUS will be applied in all patients."
3015496|NCT02459249|Experimental|Healthy Lifestyle|A physician and a nutritionist will be give recommendations for diet and exercise emphasizing the importance of a healthy lifestyle (suggesting moderate-intensity activity at least 150 minutes/week and to eat less sodium, fat, sugar, portions and calories). Verbal and written individualized recommendations from trained professionals (nutritionists, and physician) will be provided. Monthly sessions of at least 30 minutes covering diet, exercise, and behavior modifications were held. The first was a one-to-one meeting and was followed by group sessions based on behavioral counseling
3015497|NCT02459249|Placebo Comparator|Treatment of Mexican Health Minister|General and unspecific recommendations of diet and physical activity for the metabolic syndrome treatment, given for a physician
3015498|NCT02459236|Experimental|CERC-301 12mg|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
3015499|NCT02459236|Experimental|CERC-301 20mg|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
3015500|NCT02459236|Placebo Comparator|Placebo|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
3015501|NCT02459223|Active Comparator|Test Group|Treated with nutritional biscuits and khichadi. Nutritional biscuits providing 2.5 to 3 gm Protein and 90-100kcal/kg body Weight/day, as well as local food Khichadi (Rice and hulled split green gram cooked together with spices) for the three months period.
3015502|NCT02459223|Active Comparator|Control Group|Treated with only local food Khichadi (Rice and hulled split green gram cooked together with spices) for the three months period.
3015503|NCT02459210|Experimental|CLUES|active treatment
3015504|NCT02459210|Active Comparator|therapy and computer games|supportive therapy + computer games
3015505|NCT02459197|Active Comparator|T4P1001|
3015506|NCT02459197|Sham Comparator|Placebo|
3015507|NCT02459184|Experimental|Early intervention|Participants will meet with the Income Security Health Promoter immediately.
3015508|NCT02459184|Active Comparator|Late intervention|Participants will meet with the Income Security Health Promoter at 6 months.
3015509|NCT02459171||Participants|"Subjects who meet eligibility requirements and consent to participate.~Interventions: Blood sample, nasal wash, throat swab, questionnaire"
3015510|NCT02459158|Experimental|Low dose of ME1100|
3015511|NCT02459158|Experimental|High dose of ME1100|
3015512|NCT02459145|Active Comparator|Graduated Exercise Protocol|Intervention involves exercise starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation. The exercise protocol includes treadmill speed and track minutes per lap conversion, rate of perceived exertion and talk test for each stage of exercise plus total time to execute for 5 days each week.
3015513|NCT02459145|Other|Rest followed by Protocol|No activity in weeks 1 - 8. In week 9 we will begin their intervention phase as described in graduated exercise protocol
3015514|NCT02459132|Experimental|Exercise Group|Subjects in the exercise group will attend supervised exercise sessions three times a week, for 12 weeks. The exercise intervention will consist of uphill walking or jogging on a treadmill between 50% and 95% of VO2peak for 35 minutes (including a 5-minute warm up and cool down). The participants will complete four, 4-minute, high-intensity intervals at 85-95% of VO2peak. The work period intervals will be interspersed with three, 3-minute periods of active recovery at an intensity below that of their ventilatory threshold.
3015515|NCT02459132|No Intervention|Usual Care|The usual care group will not receive an intervention, and they will be asked to maintain baseline physical activity levels throughout the observation period.
3015516|NCT02459119|Experimental|Regorafenib|Regorafenib will be administered orally to all patients on study. The drug will be taken once a day for 3 of every 4 week cycle (3 weeks on/1 week off). The dose is 120 mg once daily for the first cycle, then 160 mg once daily from the second cycle if no significant Regorafenib-associated toxicities occur during the first cycle. Drug dosage may be modified if toxicities occur. Patients will undergo up to 4 cycles of treatment and may continue on additional at the discretion of the investigator.
3015517|NCT02459106||Healthy lean insulin-sensitive individuals|This group will be studied by measuring the adipose tissue miRNA release, adipose tissue-released miRNA will be profiled, and these effects will be examined.
3015518|NCT02459106||Obese insulin-resistant individuals|This group will be studied by measuring the effect of adipose tissue-release miRNA on skeletal muscle biology and insulin sensitivity, adipose tissue-released miRNA will be profiled, and these effects will be examined on obese insulin-resistant individuals on skeletal muscle biology and insulin sensitivity.
3015519|NCT02459093|Experimental|poliglecaprone 25 suture|Subcuticular skin approximation with poliglecaprone 25 suture at cesarean birth surgery
3015520|NCT02459093|Experimental|polyglactin 910 suture|Subcuticular skin approximation with polyglactin 910 suture at cesarean birth surgery
3015521|NCT02459080|Active Comparator|TD-4208-1|88 mcg
3015522|NCT02459080|Active Comparator|TD-4208-2|175 mcg
3015523|NCT02459080|Placebo Comparator|Placebo|Placebo
3015524|NCT02459067|Experimental|ImmuniCell®|Subjects will receive 6 cycles of ImmuniCell®, one infusion over an hour, at two-week intervals. During Stage 1, intra-patient dose escalation to achieve a total dose of 30 x 109 γδ T cells.
3015525|NCT02459054|Experimental|Primary Pediatric Arm|Cardiac transplant-eligible pediatric patients at imminent risk of death from biventricular failure who are 10 - 18 years old at time of TAH-t implant. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
3015526|NCT02459054|Experimental|Primary Adult Arm|Cardiac transplant-eligible adult patients at imminent risk of death from biventricular failure who are 19 - 75 years old at time of TAH-t implant. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
3015527|NCT02459054|Experimental|Secondary Arm|Cardiac transplant-eligible pediatric and adult patients at imminent risk of death from biventricular failure who do not meet enrollment criteria for a Primary Arm, but meet less restrictive enrollment criteria for the Secondary Arm. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
3015530|NCT02459041||Malignant lymph nodes|"Consecutively admitted patients with malignant lymphnodes confirmed by EUS-guided FNA.~EG-EUS will be applied in all patients."
3015531|NCT02459041||Benign lymph nodes|"Consecutively admitted patients with benign lymphnodes with negative EUS-guided FNA.~EG-EUS will be applied in all patients."
3015532|NCT02459028|Experimental|T3P Intervention group|"Intervention group: Participants are instructed to practice 4 out of 10 different Positive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks."
3015533|NCT02459028|Active Comparator|Control group|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
3015534|NCT02459015|Experimental|Reaxon® Nerve Guide|Implantation of Reaxon® Nerve Guide: If the subject is randomized to the Reaxon® Nerve Guide group, the surgeon will implant a Reaxon® Nerve Guide of ≤ 30 mm to bridge a nerve defect of ≤ 26 mm according to the method described in the instructions for use.
3015535|NCT02459015|Active Comparator|Autologous Nerve Graft|Implantation of an autologous nerve graft: If the subject is randomized to the conventional treatment, the surgeon will repair the nerve by interposing an autologous nerve graft of ≤ 26 mm between the nerve ends.
3015536|NCT02459002||NSCLC - Current Palliative Care Referral Practices|Early palliative consultation impact assessment via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
3015537|NCT02459002||Primary Caregiver|Caregiver satisfaction with quality of care and early palliative consultation impact assessed via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
3015538|NCT02459002||NSCLC - After Early Palliative Care Consult System|Palliative consultation impact assessment via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
3015539|NCT02458989|Active Comparator|Scalpel|Use of a scalpel as a first incision during thyroid operation.
3015540|NCT02458989|Experimental|Electrocautery|Use of an electrocautery as a first incision during thyroid operation.
3015541|NCT02458976|Experimental|PDL|Pre-treatment of surgical area with PDL
3015542|NCT02458963|Active Comparator|IVF group|Women will undergo one full IVF cycle
3015543|NCT02458963|Active Comparator|Gonadotropin group|Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol.
3015544|NCT02458937||Osteonecrosis|"Observational measures of functional outcomes will be obtained from all participants who consent to and complete the study.~Interventions: Functional Mobility Assessment (FMA), GAITRite® System, and Range of Motion."
3015545|NCT02458924|Active Comparator|Schizophrenia|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
3015546|NCT02458924|Active Comparator|Bipolar disorder|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
3015547|NCT02458924|Active Comparator|First degree relatives|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
3015548|NCT02458924|Active Comparator|Health controls|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
3015549|NCT02458898|Experimental|Text Message Intervention|A series of 45 unique educational text messages sent over a period of 3 months in the evenings. Text messages include humorous reminders, links to online celiac disease resources, and bidirectional questions.
3015550|NCT02458898|No Intervention|Control (No Text Messages)|Routine care by primary gastroenterologist with no text messages.
3015551|NCT02458872|Experimental|Intervention Arm|Safety huddle alarm intervention.
3015552|NCT02458872|No Intervention|Control Arm|Usual care.
3015553|NCT02458859|Active Comparator|PICO|PICO Negative Pressure Wound Therapy (NPWT) system
3015554|NCT02458859|No Intervention|Standard care|Standard care
3015555|NCT02458846|Experimental|Early Vision Screening Group|Students in the early screening group will be screened at the beginning of the year with all four methods and those who fail on any measure will receive a full eye examination within 1-2 months .
3015556|NCT02458846|Experimental|Late Vision Screening Group|Students in the late screening group will receive the same four tests at the end of the school year. Those who pass the early screening, as well as the students in the late screening group (pass or fail), will receive an eye examination at the end of the school year.
3015557|NCT02458833|Experimental|Intervention|Behavioral: Home Plate intervention
3015558|NCT02458833|Experimental|Delayed Entry Control|This Arm will receive the Home Plate intervention 3 months after the Intervention Arm completes the intervention.
3015559|NCT02458820|No Intervention|Usual Care|Patients will be recorded and interpreted as per standard of care. If a seizure is noted by the neurology service, the standard seizure treatment protocol will be used by the clinical team.
3015560|NCT02458820|Experimental|DSA EEG + Usual Care|Patients will undergo at least hourly interpretation of DSA by the ICU bedside care provider. If the bedside care provider is concerned that there is a seizure on DSA they will contact the EEG tech on call for confirmation. If a seizure is confirmed by neurology, the standard seizure treatment protocol will be used by the clinical team.
3015561|NCT02458794|Active Comparator|LMA SupremeTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
3015562|NCT02458794|Active Comparator|Ambu-Aura GainTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
3015596|NCT02458586|Placebo Comparator|MUFA|daily intake of 50 g of olive oil over a period of 8 weeks
3015563|NCT02458781|Placebo Comparator|Placebo|"Placebo capsule:~To be provided by BAMC Pharmacy. It will be made and stored by BAMC pharmacy. The matching placebo will be a gelatin capsule filled with methylcellulose powder only. Patient will take 2 capsules two times a day for 14 days."
3015564|NCT02458781|Active Comparator|Ciprofloxacin|"Ciprofloxacin 250mg capsule:~To be provided by BAMC pharmacy. It will be made and stored by BAMC Pharmacy. Ciprofloxacin 250mg tablet will be encapsulated with a gelatin capsule filled with methylcellulose. Patient will take 2 capsules of Ciprofloxacin 250mg two times a day for 14 days."
3015565|NCT02458781|Active Comparator|Metronidazole|"Metronidazole 250mg capsule:~To be provided by BAMC pharmacy. It will be made and stored by BAMC Pharmacy. Metronidazole 250mg will be encapsulated with a gelatin capsule filled with methylcellulose. Patient will take 2 capsules of metronidazole 250mg two times a day for 14 days."
3015566|NCT02458768|Experimental|IVF-M HP Inj.|"administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.~Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results)."
3015567|NCT02458768|Active Comparator|Menopur® Inj.|"administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.~Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results)."
3015568|NCT02458755|Experimental|High-dose statin treatment|Atorvastatin (40mg) or Rosuvastatin (20mg)
3015569|NCT02458742|Experimental|Morphine|0.5%Bupivacaine 2 ml with morphine 50 mcg for spinal anesthesia
3015570|NCT02458742|Placebo Comparator|Placebo|0.5%Bupivacaine 2 ml for spinal anesthesia
3015571|NCT02458729|Placebo Comparator|Placebo Group|Primary total knee replacement with 0.9% normal saline 20ml administration intravenously twice, five minutes before deflation of the tourniquet and 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
3015572|NCT02458729|Active Comparator|One-dose TXA Group|Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously five minutes before deflation of the tourniquet. and then 0.9% normal saline 20ml administration intravenously 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
3015573|NCT02458729|Active Comparator|Two-dose TXA Group|Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously twice, five minutes before deflation of the tourniquet and 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
3015574|NCT02458716|Experimental|Surgery followed by hormone therapy (ADT)|Patients undergo Robotic Assisted Radical Prostatectomy (RARP) or conventional open retropubic radical prostectomy (RRP). Immediately following surgery, patients receive the standard systemic androgen deprivation therapy.
3015575|NCT02458703|Experimental|Patients with pulmonary AVMs and no airflow obstruction|30 patients with pulmonary AVMs and no airflow obstruction will undergo cardiopulmonary exercise testing
3015576|NCT02458703|Experimental|Patients with pulmonary AVMs and airflow obstruction|30 patients with pulmonary AVMs and airflow obstruction will undergo cardiopulmonary exercise testing
3015577|NCT02458690|Experimental|eIMPACT|eIMPACT is a collaborative stepped care intervention involving a multidisciplinary team delivering evidenced-based treatments consistent with patient preference. Intervention approaches include antidepressant medications, a computerized cognitive-behavioral therapy called Beating the Blues (BtB), and telephonic cognitive-behavioral therapy called Problem Solving Treatment in Primary Care (PST-PC).
3015578|NCT02458690|Active Comparator|Usual Care|Patients and their primary care providers are informed of the positive depression screen, and follow-up is encouraged.
3015579|NCT02458677|Experimental|PRX003|
3015580|NCT02458677|Placebo Comparator|Placebo|
3015581|NCT02458664||Colo-rectal cancer|All patients undergoing curative colorectal cancer in general and digestive surgery department at Saint-Antoine hospital
3015582|NCT02458651||Tier 1 and North|Site as described by tier level of the city where the site is located and by geographical location: Tier 1 city in northern region of China
3015583|NCT02458651||Tier 1 and South|Site as described by tier level of the city where the site is located and by geographical location: Tier 1 city in southern region of China
3015584|NCT02458651||Tier 2 and Middle|Site as described by tier level of the city where the site is located and by geographical location: Tier city in middle region of China
3015585|NCT02458651||Tier 2 and North|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in northern region of China
3015586|NCT02458651||Tier 2 and South Eastern|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in south eastern region of China
3015587|NCT02458651||Tier 2 and South Western|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in south western region of China
3015588|NCT02458638|Experimental|Atezolizumab|The dose of atezolizumab in this study will be 1200 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
3015589|NCT02458625|Active Comparator|Iron sucrose 500 mg|One treatment arm will receive a single dose of I.V iron sucrose 500 mg.
3015590|NCT02458625|Active Comparator|Iron sucrose 500 mg+60 mg Iron bisglycinate|Second treatment arm will receive a single dose of I.V iron sucrose 500 mg and oral treatment with 60 mg Iron bisglycinate for 6 weeks after giving birth.
3015591|NCT02458612|Other|control group|We will apply only upper limbs exercises with traditional therapy.
3015592|NCT02458612|Active Comparator|intervention group|We will apply mirror therapy and progressive strength training for upper extremities.
3015593|NCT02458599|Experimental|Test product|One ready-to-drink beverage of 500 milliliter (mL) volume, containing 20 gram (g) protein will be administered orally, twice daily for four days.
3015594|NCT02458599|Active Comparator|Reference product 1|One ready-to-drink beverage of 500 mL volume, containing 20 g carbohydrate will be administered orally, twice daily for four days.
3015595|NCT02458599|Placebo Comparator|Reference product 2|One ready-to-drink beverage of 500 mL volume, containing 0 g carbohydrate will be administered orally, twice daily for four days.
3015598|NCT02458573|Experimental|continuous epidural analgesia group|
3015599|NCT02458573|Active Comparator|continuous intravenous analgesia group|
3015600|NCT02458560|Experimental|single-arm|
3015601|NCT02458547|Experimental|Group D|General anesthesia with desflurane
3015602|NCT02458547|Active Comparator|Group P|General anesthesia with propofol total intravenous anesthesia
3015603|NCT02458547|Active Comparator|Group S|Spinal anesthesia with 0.5% bupivacaine
3015604|NCT02458534|Experimental|Mcgrath Mac videolaryngoscope|Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
3015605|NCT02458534|Experimental|C-MAC videolaryngoscope|Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
3015606|NCT02458534|Active Comparator|Macintosh laryngoscope|Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
3015607|NCT02458521|Experimental|Transcranial Magnetic Stimulation|TMS sessions will consist of both 10Hz left pre-frontal stimulation for 3,500 pulses followed by 1Hz right pre-frontal stimulation for 1,500 pulses per session, for a total stimulation time of approximately one hour per session.
3015608|NCT02458521|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7.
3015609|NCT02458508||GBM patients|patients with diagnosis of glioblastoma treated with concomitant radio-chemotherapy with temozolomide as Stupp protocol will be evaluated for pharmacogenetic evaluation
3015610|NCT02458495|No Intervention|Standard of Care Control Group|"Participants will be granted access to a generic Diabetes website. Participants will complete the same eligibility and baseline self-report as the intervention group. The 1 month and 3 month self-report survey will omit mention of the Diabetes MAP website and will reference the generic diabetes website.~Participants will be provided with access to a generic Diabetes website. Participants will complete the same eligibility, baseline and self-report surveys as the intervention group."
3015611|NCT02458495|Experimental|Diabetes MAP Intervention Group|Participants will be granted access to the Diabetes MAP website. Participants will complete the same eligibility and baseline self-report as the control group. The 1 month and 3 month self-report will refer to the Diabetes MAP website specifically.
3015612|NCT02458482|Active Comparator|Standard Nebulizer Mask Group|"Patients randomized to this Control or standard therapy group are to receive current institutional standard therapy for moderate asthma exacerbation which includes 10 mg Albuterol combined with 1.5mg Ipratropium nebulized therapy over one hour."
3015613|NCT02458482|Experimental|AccuPAP Group|"Patients randomized to this group must also have moderate asthma exacerbation and will use an investigational device called AccuPAP to receive three allotments of Albuterol and Ipratropium in nebulized form."
3015614|NCT02458469|Active Comparator|Buspirone|This drug will be taken for two week period
3015615|NCT02458469|Active Comparator|Trazodone|This drug will be taken for two week period
3015616|NCT02458469|Placebo Comparator|Placebo|A placebo pill will be taken at bed time for two week period
3015617|NCT02458456|Sham Comparator|IHG 5% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 5% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
3015618|NCT02458456|Experimental|IHG 30% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 30% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
3015619|NCT02458456|Experimental|IHG 30% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 30% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
3015620|NCT02458456|Sham Comparator|IHG 5% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 5% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
3015621|NCT02458456|Experimental|IHG 10% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 10% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
3015622|NCT02458456|Experimental|IHG 10% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 10% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
3015623|NCT02458443|Sham Comparator|IHG 5% Un-medicated|Participants with high blood pressure (greater than 120/80) who are not medicated for blood pressure control will conduct isometric handgrip (IHG) exercise at 5% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
3015624|NCT02458443|Sham Comparator|IHG 5% BB|Participants with high blood pressure (greater than 120/80) who are currently taking beta blockers for blood pressure control will conduct isometric handgrip exercise at 5% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
3015625|NCT02458443|Experimental|IHG 30% Un-medicated|Participants with high blood pressure (greater than 120/80) who are not medicated for blood pressure control will conduct isometric handgrip exercise at 30% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
3015658|NCT02458196|Experimental|Prednisone|Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.
3015626|NCT02458443|Experimental|IHG 30% BB|Participants with high blood pressure (greater than 120/80) who are currently taking beta blockers for blood pressure control will conduct isometric handgrip exercise at 30% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
3015627|NCT02458417|Active Comparator|Full surface CO2 laser 200mJ + ReCell|This test region will receive full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 200 mJ (depth 209 µm) and density 3. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
3015628|NCT02458417|Experimental|Full surface CO2 laser 150mJ + ReCell|This test region will receive full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 150 mJ (depth 144 µm) and density 3. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
3015629|NCT02458417|Experimental|Fractional CO2 laser 7.5mJ 20% + ReCell|This test region will receive pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
3015630|NCT02458417|No Intervention|Control|No intervention
3015631|NCT02458391|Experimental|Treatment 2x/wk|Participants will receive standard of care complete decongestive therapy 2x/wk for 4 weeks.
3015632|NCT02458391|Experimental|Treatment 4x/wk|Participants will receive standard of care complete decongestive therapy 4x/wk for 4 weeks.
3015633|NCT02458365|Experimental|Teen Choices|Teen Choices: A Program for Healthy Nonviolent Relationships
3015634|NCT02458365|Other|Comparison|Health In Motion
3015635|NCT02458352|Other|Standard dose CT|Standard dose non-contrast enhanced CT
3015636|NCT02458352|Other|Ultra-low dose CT|Ultra low dose non-contrast enhanced CT
3015637|NCT02458339|Experimental|Experimental|3 consecutive cycles of intraventricular methotrexate infusions into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle, each cycle will be of 4 weeks duration. During the first 3 weeks, methotrexate will be infused twice weekly on days 1 and 4 (+/- 2 days). The 4th week is a rest week.
3015638|NCT02458326|Experimental|Aerobic Training|The experimental group will follow the protocol: performing heating for 5 minutes at low speed on a treadmill; after heating, the speed is increased gradually until the patient reaches the proper heart rate for aerobic training obtained during cardiopulmonary exercise testing, maintaining the same for 20 minutes to perform the aerobic workout; completed, the velocity will be decreased to regain speed heating maintained for 5 minutes and finishing training. It is envisaged that in practice using the FC to ensure proper aerobic exercise for 20-60 minutes at a frequency of 3-5 times per week are effective in increasing the functional capacity of individuals with low fitness
3015639|NCT02458326|Other|Control Training|In the control group, these women will be guided to perform 10 minutes of heating on the treadmill with a low speed that does not cause patient effort (monitored by the Borg scale and FC close to the basement).
3015640|NCT02458313|Experimental|DMXB-A|150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
3015641|NCT02458313|Placebo Comparator|Placebo|Placebo capsules b.i.d. for 12 weeks.
3015642|NCT02458300|Placebo Comparator|Control Arm|Nebulized hypertonic saline. Aspiration of secretions
3015643|NCT02458300|Active Comparator|Intervention Arm.|Nebulization of hypertonic saline. Application of Prolonged slow expiration technique (PSE) expiratory volume. Patient coughing Provocation (TP) Inspiratory maneuver to rhinopharyngeal cleaning DRR Aspiration of secretions
3015644|NCT02458287|Experimental|Bococizumab 150mg|Bococizumab 150mg autoinjector (pre-filled pen)
3015645|NCT02458287|Experimental|Bococizumab 75mg|Bococizumab 75mg autoinjector (pre-filled pen)
3015646|NCT02458287|Placebo Comparator|Bococizumab 150mg placebo|Bococizumab 150mg placebo autoinjector (pre-filled pen)
3015647|NCT02458287|Placebo Comparator|Bococizumab 75mg placebo|Bococizumab 75mg autoinjector (pre-filled pen)
3015648|NCT02458274||Patient without bronchiolitis obliterans syndrome|Lung transplanted patient without bronchiolitis obliterans syndrome
3015649|NCT02458274||Patient with bronchiolitis obliterans syndrome|Patient with bronchiolitis obliterans syndrome three years after lung transplantation.
3015650|NCT02458248|Experimental|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day).
3015651|NCT02458248|No Intervention|Usual care|For all participants, standard care will be provided at the nephrology clinic at GUH or by local general practitioners, and includes treatment of hypertension, underlying comorbidities and optimizing the metabolic profile. Participants randomized to usual care will also attend a dietitian-developed healthy eating guidance session but will not receive specific recommendations targeting sodium intake.
3015652|NCT02458235|Experimental|Azacitidine/donor lymphocyte infusion|Patients will be stratified according to risk categories (low, standard and high), defined by GVHD status, mixed versus full donor chimerism, and positive versus negative Minimal Residual Disease (MRD) results. Patients will receive up to 7 cycles of low-dose azacitidine (40mg/m2 IV/SC daily x 4 days) at 6 weekly intervals, except for low risk ALL patients who may not receive treatment after withdrawal of immunosuppression. Standard risk patients will receive an additional 6 cycles of azacitidine alone. High risk patients will receive an additional 6 cycles of azacitidine plus escalating DLI.
3015653|NCT02458222|Experimental|game therapy then standard therapy|participants will take part in language game therapy followed by standard aphasia therapy
3015654|NCT02458222|Experimental|standard therapy then game therapy|participants will have standard aphasia therapy first then will take part in language game therapy
3015655|NCT02458209|Active Comparator|Treatment A|150 mg SC dose administered in a prefilled syringe using drug substance manufactured at Pfizer Andover
3015656|NCT02458209|Experimental|Treatment B|• Treatment B: 150 mg SC dose administered in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma
3015657|NCT02458209|Experimental|Treatment C|150 mg SC dose administered in a prefilled pen using drug substance manufactured at Pfizer Andover.
3016243|NCT02454400|Other|Waiting-list|Standard information by the orthopedic surgeon
3015659|NCT02458196|Experimental|Prednisone and Mycophenolate mofetil|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months."
3015660|NCT02458183|Experimental|DTaP-IPV combination vaccine|Dosage and administration: A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of right thigh at the age of 2, 4, and 6 months
3015661|NCT02458183|Active Comparator|DTaP vaccine and IPV vaccine|"Product name: : Boryung DTaP Vaccine Inj. (Prefilled syringe) (Absorbed diphtheria, tetanus toxoid, and purified pertussis combination vaccine) Dosage and administration: A 0.5-mL dose is administered 3 times intramuscularly in the anterolateral aspect of right thigh at the age of 2, 4, and 6 months.~Product name: IPVAX INJ. PREFILLED SYRINGE INJ. Dosage and administration: A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of left thigh at the age of 2, 4, and 6 months."
3015662|NCT02458157|Experimental|Forced Fluid Removal|"The experimental intervention is guided by a therapeutic goal of average negative fluid balance ≥ 1 ml/kg/h and safety variables indicating inadequate circulation (lactate ≥ 4, MAP < 50 or mottling beyond the edge of kneecaps).~The effect of fluid removal is evaluated three times daily (06:00. 14:00 and 22:00), while the safety variables are evaluated continuously. Resuscitation is started if one or more signs of inadequate circulation is present.~The first choice for fluid removal is diuretic therapy with furosemide, which is continued for a minimum of 8 hours. If the therapeutic goal (negative fluid balance ≥ 1 ml/kg/h) is not achieved and/or maintained by furosemide alone, then fluid removal with continuous renal replacement therapy (CRRT) is initiated."
3015663|NCT02458157|Active Comparator|Usual Care|Usual Care at the discretion of the treating clinicians, except for the initiation of renal replacement therapy (RRT).
3015664|NCT02458144|Other|"MIS anterior group"|"Total Hip Arthroplasty anterior surgical approach"
3015665|NCT02458144|Other|"MIS anterolateral group"|"Total Hip Arthroplasty anterolateral surgical approach"
3015666|NCT02458131|Experimental|TEEN HEED|Adolescent pre-diabetics will receive 8-12 weekly peer-led diabetes prevention educational workshops in community sites. The in-person group workshops will be supplemented by support through mobile health technologies such as text messaging and social media.
3015667|NCT02458131|No Intervention|Wait List Control|Adolescent pre-diabetics in this group will not receive any intervention until collection of all follow up data and will then be offered the same intervention as the participants in the experimental arm.
3015668|NCT02458118|Experimental|Secretin|Secretin 1 IU/kg over 3 min
3015669|NCT02458105|Experimental|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
3015670|NCT02458105|Active Comparator|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
3015671|NCT02458092|Experimental|50 ug of FMP010 antigen in 0.5 mL AS01B adjuvant|
3015672|NCT02458092|Experimental|Rabies Vaccine Rabipur|
3015673|NCT02458079|Experimental|Pentoxiphylline|
3015674|NCT02458079|Active Comparator|Stool Microbiota Transplantation|
3015675|NCT02458066|Active Comparator|Bendiocarb|IRS: bendiocarb
3015676|NCT02458066|Active Comparator|Deltamethrin|IRS: deltamethrin
3015677|NCT02458053|Experimental|TEAM Enhanced|The enhanced intervention will include group sessions where the participant attends with partner ( including a couples skill training session), weekly tailored feedback, and weekly lessons.
3015678|NCT02458053|Active Comparator|TEAM Traditional|The intervention will include group sessions where the male attends alone, weekly tailored feedback, and weekly lessons.
3015679|NCT02458040||Biomarker-positive patients|
3015680|NCT02458040||Biomarker-negative patients|
3015681|NCT02458040||All patients|
3015682|NCT02458027|Experimental|20g Hemp Protein Shake|Hemp protein shake, 20 grams, given once at beginning of acute trial.
3015683|NCT02458027|Experimental|40 g Hemp Protein Shake|Hemp protein shake, 40 grams, given once, at beginning of acute trial.
3015684|NCT02458027|Active Comparator|20 g Soybean Protein Shake|Soybean protein shake, 20 grams, given once, at beginning of acute trial.
3015685|NCT02458027|Experimental|40 g Soybean Protein Shake|Soybean protein shake, 40 grams, given once, at beginning of acute trial.
3015686|NCT02458027|Placebo Comparator|Control Shake|Non-protein control shake, given once, at beginning of acute trial.
3015687|NCT02458014|Experimental|Blinatumomab|"Patients receive Blinatumomab as continuous intravenous infusion at a dose of 28 Mcg/24 hours over 4 weeks followed by a treatment-free period of 2 weeks, defined as one 6-week treatment cycle. In the first induction cycle, the initial dose of blinatumomab is 9 Mcg/day for the first 7 days of treatment (to mitigate for potential CRS and CNS events associated with introduction to blinatumomab) which then will be escalated (dose step) to 28 Mcg/day starting on day 8 (week 2) through day 29 (week 4). For all subsequent cycles, 28 Mcg/day is the dose for all 4 weeks of continuous treatment.~Participants called by study staff 1 time each month for up to 18 months after all participants have been enrolled in the study."
3015688|NCT02458001|Experimental|SAFFRON stepped care|3 level intervention: level 1:Self help booklet level 2: CNS delivered intervention level 3: psychologist delivered intervention
3015689|NCT02458001|No Intervention|enhanced treatment as usual (ETU)|level 1 intervention: self help booklet Non study trained CNS will offer assessment, advice, vaginal dilator training where appropriate, arrange topical oestrogens or other creams
3015690|NCT02457988|Experimental|Vivify Kit|Patients with cirrhosis will undergo home monitoring for 30 days post-discharge through the use of the Vivify kit which contains a wireless tablet with daily medication/diet/symptom questionnaires and vital sign monitoring.
3015691|NCT02457988|No Intervention|Standard of Care|Patients with cirrhosis will undergo standard of care, which includes a post-discharge lab check and follow-up clinic appointment. Otherwise, no day-to-day monitoring of these patients will occur.
3015692|NCT02457949|No Intervention|Treatment As Usual (TAU)|Receipt of social assistance on government cheque issue days for 6 income assistance cycles (approx 26 weeks).
3015693|NCT02457949|Experimental|Staggered Arm|Receipt of social assistance once monthly on a randomly assigned day that does not fall during the week of government cheque issue (Non-synchronized social assistance receipt), for 6 income assistance cycles (approx 26 weeks).
3016546|NCT02452489|Other|Single point group (Zhongwan)|Patients will be acupuncture with Zhongwan(RN12).
3015694|NCT02457949|Experimental|Staggered and Split Arm|Receipt of social assistance twice monthly on equally spaced randomly assigned days that do not fall during the week of government cheque issue (Non-synchronized social assistance receipt, cheque divided into two equal disbursements), for 6 income assistance cycles (approx 26 weeks).
3015695|NCT02457936|Experimental|Mindfulness Based Cognitive Therapy (MBCT)|This group will receive 8 weeks of Mindfulness Based Cognitive Therapy
3015696|NCT02457936|Active Comparator|Waiting list|This group will be tested twice 8-10 weeks apart and then receive 8 weeks of Mindfulness Based Cognitive Therapy
3015697|NCT02457923|Experimental|Mobile phone counselling|"The intervention will include:~An App for real time data collection of mothers by ASHAs, data transfer, and, display of counselling messages and health video during ASHAs monthly home visit.~Weekly voice and text messages from server at a prescribed time to provide targeted information on infant feeding counselling.~Server generated reminders and alerts, delivered to the mother, ASHA and ANM.~An App for field supervisor to monitor ASHAs~Women will receive fortnightly mobile phone counselling calls by an ANM at times they recommend. Need based counselling will also be provided"
3015698|NCT02457923|No Intervention|Usual health care services|The control clusters to receive usual health care services at PHC. The existing data collection methods will be continued in these clusters. Routine IYCF counseling is provided in existing level of care and its frequency is consistent with the visit schedule described in the intervention group: at antenatal clinics; at delivery; and at immunization clinics postnatal.
3015699|NCT02457910|Experimental|Arm I (taselisib, enzalutamide)|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
3015700|NCT02457910|Active Comparator|Arm II (enzalutamide)|Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may crossover to Arm I.
3015701|NCT02457884|Active Comparator|Temporal Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
3015702|NCT02457884|Active Comparator|Spatial Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
3015703|NCT02457884|Active Comparator|Combined Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
3015704|NCT02457884|Placebo Comparator|Control Group|Receive 6 weekly 1-hour training sessions of leisure reading activities
3015705|NCT02457871|Experimental|Ecological Nurse Case Managemnt|Ecological Nurse Case Management (ENCM) group receives 6 months of ENCM services in addition to their usual primary care services at the study site.
3015706|NCT02457871|No Intervention|Comparison|Usual Clinical Care - is the usual primary care services delivered at the site of the study, a free clinic.
3015707|NCT02457858|Experimental|BMX-010 treated islets|Islet isolation using BMX-010
3015708|NCT02457845|Experimental|HSV G207|"Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI. If G207 is safe in the first two cohorts of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor defined by MRI followed by a 5 Gy dose of radiation to the tumor given with 24 hours of virus inoculation.~Intervention: Biological: G207"
3015709|NCT02457832|Experimental|Internal guidance training (IG)|Adapted tango dancing is a sophisticated, yet accessible system of tactile communication that conveys motor intentions and goals between a leader and follower. Those in IG training will choose direction, timing and amplitude of each successive step, and will communicate this information to their partner through moving their frame and center of mass.
3015710|NCT02457832|Experimental|Externally guided training (EG)|Those in EG will learn to attend to sensory cues for movement direction, timing and amplitude of steps, communicated from their partner to them via the frame and center of mass. The 'follower' will wait to receive the movement cue before moving.
3015711|NCT02457832|Active Comparator|Behavioral Control (BC)|BC participants will attend group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety. Participants in this training will be instructed not to change their habitual exercise routines. After completing health education, participants will be assigned to an IG or EG training class but will not undergo evaluations.
3015712|NCT02457832|No Intervention|Normal Control (NC)|Age-matched controls without Parkinson's disease will come in for a single assessment including MRI.
3015713|NCT02457819|Experimental|Dasotraline|Dasotraline 2, 4, 6 mg
3015714|NCT02457806|Experimental|Kovacaine Mist|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in each nostril (bilateral dosing) administered 4 minutes apart
3015715|NCT02457806|Active Comparator|Kovacaine Mist and Placebo|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in the right nostril and three sprays of placebo in the left nostril (right-sided unilateral dosing) administered 4 minutes apart
3015716|NCT02457806|Active Comparator|Placebo and Kovacaine Mist|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in the left nostril and 3 sprays of placebo in the right nostril (left-sided dosing) administered 4 minutes apart
3015717|NCT02457806|Placebo Comparator|Placebo spray|3 sprays of placebo in each nostril administered 4 minutes apart
3015718|NCT02457793|Experimental|Not assigned|One participant was assigned to receive intermittent cobimetinib 80 milligrams (mg) + GDC 0994 200 mg) and did receive study drug. However, the participant diary was not returned, and the site was unable to document study dose administration.
3015719|NCT02457793|Experimental|COB 20 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 20 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
3015720|NCT02457793|Experimental|COB 40 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 40 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
3015721|NCT02457793|Experimental|COB 80 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
3015722|NCT02457793|Experimental|COB 80 mg + GDC 400 mg|Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 400 mg for 21 consecutive days, followed by 7 days off.
3015723|NCT02457793|Experimental|COB 100 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 100 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
3015724|NCT02457780|Experimental|Relaxation Response Resiliency Program|The Relaxation Response Resiliency Program (3RP) is an 8-session (90min/session) group based intervention which includes a variety of skills and techniques designed to address chronic stress. Techniques used include psychoeducation on healthy lifestyle behaviors, goal-setting, CBT skills, relaxation training and self-monitoring.
3015725|NCT02457780|Active Comparator|Health Enhancement Program|The Health Enhancement Program (HEP) is an 8-session (90min/session) group based intervention which includes psychoeducation and self-monitoring of health behaviors (e.g., sleep hygiene, nutrition, exercise, substance use etc).
3015726|NCT02457728|Experimental|Inguinal herniation|In patients with bilateral herniations it should be explored if one glue device (LiquiBandFix8) for mesh fixation and closure of peritoneum is sufficient.
3015727|NCT02457715||Prostate Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
3015728|NCT02457715||Renal Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
3015729|NCT02457715||Brain Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
3015730|NCT02457715||Amyotrophic Lateral Sclerosis (ALS)|Subjects will use a Jawbone Up24 for 14 weeks.
3015731|NCT02457702|Experimental|Orally administered Labeled Glycerol|Patients will receive an oral mixture of [U-13C3]glycerol (25 mg/kg) plus unlabeled glycerol (25 mg/kg). The total dose of glycerol will be 50 mg/kg in 100 milliliters of water.
3015732|NCT02457689|Placebo Comparator|Group 1 (Transcutaneous and Placebo)|Group 1 (Transcutaneous and Placebo) Participants will receive 1.0ml intramuscular injections of the vaccine Sodium Chloride BP into the upper thigh. Participants will also have a further 0.2ml of Sodium Chloride BP delivered transcutaneously. An area of skin of approximately 4 x 4cm will be photographed and prepared first. During this preparation, the area is shaved to remove the hair, and then superglue is applied to remove the top layer of skin (like waxing). The vaccine is spread onto the skin surface. Once applied, the area is covered with a comfeel bandage, the investigator will ask volunteers to not engage in strenuous exercise, shower, or bathe for 24 hours afterwards.
3015733|NCT02457689|Active Comparator|Group 2 (Transcutaneous and Active)|Group 2 (Transcutaneous and Active) Participants will receive 1.0ml intramuscular injections of the GTU®-MultiHIV B Clade Vaccine (2 mg/ml) into the upper thigh. Participants will also have a further 0.2ml of the vaccine (2mg/ml) delivered transcutaneously. An area of skin of approximately 4 x 4cm will be photographed and prepared first. During this preparation, the area is shaved to remove the hair, and then superglue is applied to remove the top layer of skin (like waxing). The vaccine is spread onto the skin surface. Once applied, the area is covered with a comfeel bandage, the investigator will ask volunteers to not engage in strenuous exercise, shower, or bathe for 24 hours afterwards.
3015734|NCT02457689|Placebo Comparator|Group 3 (Electroporation and Placebo)|Group 3 (Electroporation and Placebo) Participants will receive 1.0ml intramuscular injections of Sodium Chloride BP into the upper thigh using the ICHOR TriGridTM delivery system for intramuscular (TDS-IM) delivery with electroporation. Electroporation (EP) improves the delivery of the product into muscle cells, by delivering an electrical pulse with the injection using a hand held device that is pressed against your thigh. This will cause a muscle twitch with a sharp cramp-like feeling in the thigh lasting a few seconds. Once the procedure is carried out, the muscle will feel sore for up to 72 hours. The investigator will ask volunteers not to engage in any strenuous exercise for at least 24 hours after the procedure.
3015735|NCT02457689|Active Comparator|Group 4 (Electroporation and Active)|Group 4 (Electroporation and Active) Participants will receive 1.0ml intramuscular injections of the GTU®-MultiHIV B Clade Vaccine (2mg/ml) into the upper thigh using the ICHOR TriGridTM delivery system for intramuscular (TDS-IM) delivery with electroporation. Electroporation (EP) improves the delivery of the product into muscle cells, by delivering an electrical pulse with the injection using a hand held device that is pressed against your thigh. This will cause a muscle twitch with a sharp cramp-like feeling in the thigh lasting a few seconds. Once the procedure is carried out, the muscle will feel sore for up to 72 hours. The investigator will ask volunteers not to engage in any strenuous exercise for at least 24 hours after the procedure.
3015736|NCT02457676|Experimental|Alert Program for Self-Regulation|Participants with FASD who received the Alert Program for Self-Regulation therapy between the two testing periods.
3015737|NCT02457676|No Intervention|FASD Alert Waitlist|Participants with FASD who did not receive therapy between the two testing periods but were provided intervention on study completion.
3015738|NCT02457676|No Intervention|Typically Developing Control|Normally developing controls not exposed to alcohol in utero who were not treated between the two testing periods.
3015739|NCT02457650|Experimental|Anti-NY ESO-1 TCR-transduced T cells|Patients will receive a lymphodepleting conditioning regimen followed by an infusion of anti-NY-ESO-1 TCR-transduced T cells.
3015740|NCT02457637||chronic liver disease patients with ALI or AD|
3015741|NCT02457624||Experienced endoscopists|All the experienced endoscopists will receive education and feedback on the diagnosis for premalignant lesion of chronic atrophic gastritis and intestinal metaplasia
3015742|NCT02457611|Experimental|LDV/SOF|LDV/SOF FDC for 6 weeks
3015743|NCT02457598|Experimental|Tirabrutinib + idelalisib (Combination I)|"Dose Escalation:~Participants will receive a single dose of tirabrutinib on Day 1 of Cycle 1 and tirabrutinib + idelalisib on Day 2 and remainder of Cycle 1. For all subsequent cycles, participants will receive tirabrutinib + idelalisib. Based on DLTs observed in subsequent cohorts, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.~Dose Expansion:~Additional participants will receive tirabrutinib + idelalisib for a maximum of 2 years."
3015744|NCT02457598|Experimental|Tirabrutinib + entospletinib (Combination II)|"Dose Escalation:~Participants will receive a single dose of tirabrutinib on Day 1 of Cycle 1 and tirabrutinib + entospletinib on Day 2 and remainder of Cycle 1. For all subsequent cycles, participants will receive tirabrutinib + entospletinib. Based on DLTs observed in subsequent cohorts, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.~Dose Expansion:~Additional participants will receive tirabrutinib + entospletinib for a maximum of 2 years."
3015777|NCT02457325|Experimental|Surgery with 2% articaine|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, under local anesthesia with articaine 2% (with 1:200,000 adrenaline).
3015745|NCT02457598|Experimental|Tirabrutinib + idelalisib + obinutuzumab (Combination III)|"Dose escalation:~Participants will receive tirabrutinib + idelalisib + obinutuzumab (doses will depend on results of Combination I data). Based on DLTs observed, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.~Dose Expansion:~Additional participants will receive tirabrutinib + idelalisib + obinutuzumab for a maximum of 2 years."
3015746|NCT02457598|Experimental|Tirabrutinib + entospletinib + obinutuzumab (Combination IV)|"Dose escalation:~Participants will receive tirabrutinib + entospletinib + obinutuzumab (doses will depend on results of Combination II data). Based on DLTs observed, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.~Dose Expansion:~Additional participants will receive tirabrutinib + idelalisib + obinutuzumab for a maximum of 2 years."
3015747|NCT02457598|Experimental|Single agent tirabrutinib (Combination V)|Participants with relapsed or refractory CLL may be enrolled to receive tirabrutinib once daily.
3015748|NCT02457585|Experimental|experimental group|"anti Tumor necrosis factor treatment group : treatment with remicade 5mg/kg as scheduled (0, 2, 6, 14, 22, 30, 38, 46, 54weeks).~evaluation of response at 30weeks by PET CT, acute phase reactants, symptom~No placebo group"
3015749|NCT02457572||Valsalva maneuver|This is an observational study and as a diagnostic intervention, subjects in the study would receive valsalva maneuver. Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration. The investigators perform this procedure to every patients and do not assign this intervention to the subjects of the study.
3015750|NCT02457559|Experimental|Tirabrutinib|Participant will receive tirabrutinib once or twice daily for up to 4 years.
3015751|NCT02457546|Experimental|EVICEL Fibrin Sealant|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen
3015752|NCT02457546|Active Comparator|Hydrogel sealant|The sealant is composed of two solutions, a polyethylene glycol (PEG) ester solution and a trilysine amine solution
3015753|NCT02457533|No Intervention|Control|Only SF-36 and CAT
3015754|NCT02457533|Active Comparator|Active|Lifestyle behavioral. Health plan, telephone support
3015755|NCT02457520|Experimental|Single treatment arm|ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.
3015756|NCT02457507|Experimental|Vitamin B12|Vitamin B12, 1mg, daily, 27 months
3015757|NCT02457507|Placebo Comparator|Placebo|Placebo comparator
3015758|NCT02457481|Experimental|Embryo Culture medium|Embryos from each patient are randomly allocated to culture in the commercial or experimental embryo culture medium (half of the embryos in commercial and half in experimental medium).
3015759|NCT02457468||Stenosis patients treated with coflex|Patients with a primary diagnosis of lumbar spinal stenosis treated with coflex after decompression
3015760|NCT02457455||Sick passangers|Passengers or cabincreew whom needed urgent medical supports during flights with completed medical records. (Aforementioned Flight Company records complaints, symptoms and diagnoses, demographic data, the mortality of those who request medical aid, whether medical treatment is performed by the cabin crew or by a medical professional on the plane, as well as those conditions which resulted in an emergency landing and dead). All ages are included.
3015761|NCT02457442|Active Comparator|PR1|Propofol-Remifentanil: Prop high, Remi low. Changing Remi (up-and-down)
3015762|NCT02457442|Active Comparator|PR2|Propofol-Remifentanil: Prop low, Remi high. Changing Prop (up-and-down)
3015763|NCT02457442|Active Comparator|SR1|Sevoflurane-Remifentanil: Sevo high, Remi low. Changing Remi (up-and-down)
3015764|NCT02457442|Active Comparator|SR2|Sevoflurane-Remifentanil: Sevo low, Remi high. Changing Sevo (up-and-down)
3015765|NCT02457442|Active Comparator|SPR1|Sevoflurane-Propofol-Remifentanil: Sevo plus Remi intermediate, Remi intermediate; changing Propofol.
3015766|NCT02457442|Active Comparator|SPR2|Sevoflurane-Propofol-Remifentanil: Sevo plus Remi intermediate, Remi intermediate; changing Sevoflurane.
3015767|NCT02457429|Other|Routine oesophageal pH monitoring|Routine oesophageal pH investigation involves the trans-nasal placement of a microelectrode into the distal oesophagus as per hospital protocol. Examining the oropharynx and confirming visualisation of the red LED at the catheter tip in the correct position just below the soft palate will confirm its position in the oropharynx. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours.
3015768|NCT02457416|Active Comparator|Peanut oral immunotherapy|Oral immunotherapy with peanut
3015769|NCT02457416|No Intervention|Controls|Avoid peanut exposure
3015770|NCT02457403|Experimental|ROTEM|
3015771|NCT02457403|Active Comparator|Conventional|
3015772|NCT02457390|Experimental|CE-LUS|"Laparoscopic ultrasound examination (LUS) of the liver during robot assisted CRC surgery. The liver is systematically scanned for unrecognized liver metastases.~After the laparoscopic LUS procedure, the liver is then systematically scanned with contrast enhancement with SonoVue® containing Sulphurhexafluoride. A bolus of 2.5 ml is injected into a peripheral vein followed by 10 ml of isotonic saline. The liver is then systematically scanned in 3 phases (arterial, venous and parenchymatous phase) searching for unrecognized liver metastases. The procedure is repeated after 5 minutes.~The time it takes to do the scan is measured and any technical challenges are reported. Time, challenges and findings of liver metastases (number, segment and size) are entered on a registration form."
3015773|NCT02457377|Experimental|Laparoscopic cerclage|The vesico-uterine peritoneum is opened & the urinary bladder is dissected downwards . Both needles are passed through the lower uterine tissue medial to uterine vessels on the right & left sides . Then, both needles are passed through the remaining cervical tissue medial to uterosacral ligaments towards the posterior vaginal fornix (on the right & left sides) guided by laparoscopic illumination . When the needles' blunt ends pierce the vaginal vault, the assistant pull them through the posterior vaginal fornix . After trimming of both needles, the Mersilene tape is tied tightly behind the intravaginal segment of the cervix with five knots &
3015774|NCT02457351|Experimental|Roniciclib + Itraconazole|Pharmacokinetics and safety in patients with advanced solid tumor
3015775|NCT02457338|Experimental|Supplement Group|This group will receive probiotic B. infantis supplementation, plus standard care and lactation consultation.
3015776|NCT02457338|No Intervention|Control Group|This group will receive standard care plus lactation consultation only.
3015778|NCT02457325|Experimental|Surgery with 4% articaine|The same fifty healthy volunteers underwent removal of the other symmetrically positioned lower third molars, under local anesthesia with articaine 4% (with 1:200,000 adrenaline).
3015779|NCT02457312|Active Comparator|Letrozole group|Letrozole 10 mg daily for 7 days before suction evacuation
3015780|NCT02457312|Placebo Comparator|Placebo group|Placebo tablets (look identical to letrozole tablets) daily for 7 days before suction evacuation
3015781|NCT02457299|Active Comparator|Two Stage Esophagectomy|Ischemic gastric preconditioning performed 7-10 prior to esophagectomy
3015782|NCT02457299|Active Comparator|One Stage Esophagectomy|Esophagectomy alone
3015783|NCT02457286|Experimental|Metformin|Metformin is being compared to exercise and diet modifications. The study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe
3015784|NCT02457286|Experimental|Lifestyle modification|The researchers are interested in learning if the addition of metformin to lifestyle modifications is more helpful in treating participants condition or disorder. The study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe
3015785|NCT02457273|Experimental|Assigned Interventions|TLC 388
3015786|NCT02457260|Experimental|Healthy control|10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
3015787|NCT02457260|Experimental|HFpEF|10 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
3015788|NCT02457260|Experimental|HFrEF|10 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
3015789|NCT02457247|Experimental|Test Group 1: Sequence AB|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) [A], chewable tablets, orally, twice, daily, on Days 1 through 14, followed by Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3) [B], chewable tablets, orally, twice, daily, on Days 15 through 28.
3015790|NCT02457247|Experimental|Test Group 1: Sequence BA|Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 1 through 14, followed by, Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 15 through 28.
3015791|NCT02457247|Experimental|Test Group 2: Sequence CD|Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3) [C], chewable tablets, orally, once, daily, on Days 1 through 14, followed by Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3) [D], chewable tablets, orally, once, daily, on Days 15 through 28.
3015792|NCT02457247|Experimental|Test Group 2: Sequence DC|Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 1 through 14, followed by, Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 15 through 28.
3015793|NCT02457234|Experimental|Cultural Immersion Children's Day Camp|Participants in this group received four culturally adapted nutrition lessons within a cultural immersion context as part of the camp program.
3015794|NCT02457234|Active Comparator|University Children's Day Camp|Participants in this group received four culturally adapted nutrition lessons in addition to camp activities that did not include cultural immersion.
3015795|NCT02457234|No Intervention|Recreational Children's Sports Day Camp|Participants in this group participated in existing camp activities that were exclusively physical activity.
3015796|NCT02457221|Experimental|Tacrolimus group|Tacrolimus capsules + steroid
3015797|NCT02457221|Active Comparator|Cyclophosphamide group|Cyclophosphamide injections + steroid
3015798|NCT02457208|Experimental|2HRZE/4HR|"2HRZE/4HR~Intensive phase: 2 months HRZE - once daily~Continuation phase: 4 months HR - once daily~Adults will be treated with fixed dose combination (FDC) tablets containing:~Intensive phase (content per tablet)~Isoniazid -75 mg,~Rifampicin - 150 mg,~Pyrazinamide - 400 mg,~Ethambutol - 275 mg~Continuation phase (content per tablet)~Isoniazid 150 mg~Rifampicin 300 mg~*Drug dosing will be adjusted by patient body weight."
3015799|NCT02457195|Experimental|Admnistration of granisetron|Preoperative administration of granisetron transdemal patch
3015800|NCT02457182|Experimental|Mindfulness-based Stress Reduction (MBSR)|Will receive usual care continuing current treatments in addition to MBSR
3015801|NCT02457182|Placebo Comparator|Usual Care|Will receive usual care and continue current treatments
3015802|NCT02457169|Experimental|Parent Engagement Intervention group|This group of parents will receive the brief, 2-4 hour intervention which will utilize motivational interviewing principles to enhance parents' preschool engagement as their children transition from Early Intervention to preschool.
3015803|NCT02457169|Other|Attention Control|Waitlist Control Group: This group will receive the brief, 2-4 hour intervention which will utilize motivational interviewing principles to enhance parents' preschool engagement as their children transition from Early Intervention to preschool after a 3 month delay.
3015804|NCT02457156|Experimental|Blumgart Anastomosis|"Re-construction of the pancreatic remnant following pancreatico-duodenectomy using a Blumgart method of pancreatico-jejunostomy.~Octreotide will be administered."
3015805|NCT02457156|Active Comparator|Cattell-Warren Anastomosis|"Re-construction of the pancreatic remnant following pancreato-duodenectomy using a Cattell-Warren method of pancreatico-jejunostomy.~Octreotide will be administered."
3015806|NCT02457143|Experimental|Letter|Patients will receive a reminder letter signed by their family physician which indicates which cancer screening tests they are overdue for and encourages them to book an appointment for screening.
3015807|NCT02457143|Experimental|Phone call|Patients will receive a phone call from a member of the practice staff. The call will inform them about which cancer screening tests they are overdue for and will encourage them to book an appointment for screening.
3015808|NCT02457130|Experimental|Group A|"After providing written informed consent, eligible subjects will be randomized in a 1:1 fashion to group A or B.~Ticagrelor (180-mg loading dose the first day followed by 90-mg b.i.d. maintenance dose) for one week; washout period of 2-4 weeks; crossover to clopidogrel (600-mg loading dose the first day followed by 75-mg daily maintenance dose) for one-week."
3015909|NCT02456545||representative population cohort|"representative population cohort from the IMAGEN study~anticipated n = 500"
3015809|NCT02457130|Experimental|Group B|"After providing written informed consent, eligible subjects will be randomized in a 1:1 fashion to group A or B.~Clopidogrel (600-mg loading dose the first day followed by 75-mg daily maintenance dose) for one-week; washout period of 2-4 weeks; crossover to ticagrelor (180-mg loading dose the first day followed by 90-mg b.i.d. maintenance dose) for one week."
3015810|NCT02457104||normal weight individuals not taking PPI|
3015811|NCT02457104||normal weight individuals taking PPI|
3015812|NCT02457104||obese individuals not taking PPI|
3015813|NCT02457104||obese individuals taking PPI|
3015814|NCT02457091|Active Comparator|Stretching exercise|The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
3015815|NCT02457091|Experimental|Resistance exercise|The resistance condition will consist of 1-3 sets, 10-15 repetitions of 12 exercises targeting lower body, upper body, and core muscle groups performed 2 days per week.
3015816|NCT02457078|Experimental|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
3015817|NCT02457078|Placebo Comparator|Control Supplement|Control Supplement: Capsule containing soybean oil and α-tocopheryl (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
3015818|NCT02457065|Experimental|Receive Plaque|Treatment
3015819|NCT02457065|No Intervention|Do Not Receive Plaque|Control
3015820|NCT02457052|Experimental|DATP +|Introduction of a device allowing a custom sitting to help patients with swallowing disorders .
3015821|NCT02457052|No Intervention|DATP -|No introduction of a device allowing a custom sitting to help patients with swallowing disorders .
3015822|NCT02457039|Active Comparator|Comprehensive acupuncture (CAI)|Breast cancer patients receiving Cytoxan-containing chemotherapy regimens (Chemo) will receive Dense cranial electroacupuncture stimulation (DCEAS) and Body acupuncture (BA).
3015823|NCT02457039|Sham Comparator|Least acupuncture stimulation (LAS)|Breast cancer patients receiving Cytoxan-containing chemotherapy regimens (Chemo) will receive Least acupuncture stimulation (LAS)
3015824|NCT02457026|Experimental|Adjunctive PDT + Aflibercept|Participants will receive adjunctive verteporfin PDT at Study Visit 1 as well as intravitreal aflibercept at Study Visits 1, 2, 3. At Study Visit 4, participants will have repeat assessment of disease activity. If disease activity is resolved or trivial, the individual will be maintained on aflibercept injections. If PDA remains unresolved, the individual will undergo repeat verteporfin PDT at Study Visit 4, as well as intravitreal aflibercept at Study Visits 4, 5, and 6. Disease activity will be reassessed at Study Visit 7. If disease activity is resolved or trivial, the individual will be switched to aflibercept injections once every three months. If PDA remains unresolved, then the individual will default to a standard-of-care treatment strategy with aflibercept (monthly injections).
3015825|NCT02457026|Active Comparator|Aflibercept Alone|"Participants in this group will receive intravitreal aflibercept at Study Visits 1, 2, and 3. At Study Visit 4, participants will have repeat assessment of disease activity. From Study Visit 4 onwards, aflibercept will be administered according to a treat-and-extend strategy. If disease activity is considered to be resolved or trivial, then the interval between treatments can be initially extended from every 28 days to every 42 days. If disease activity remains stable, treatments can be extended in 14-day increments, up to 10 weeks between treatments. For individuals who have PDA that remains unresolved, aflibercept will continue to be administered every days, but if disease quiescence is achieve at a later time point, the treatment period can be extended at that time."
3015826|NCT02457013|Experimental|HFNC treatment|HFNC : High flow nasal canula 24hours Patients will be treated by a High flow nasal canula (HFNC: 2l/kg/min) for the initial management of their bronchiolitis (24 hours)
3015827|NCT02457013|Active Comparator|nCPAP treatment|nCPAP : nasal NCPAP Patients will be treated by a nasal CPAP (n-CPAP: 7 cmH2O) for the initial management of their bronchiolitis (24 hours)
3015828|NCT02457000||Normal, healthy volunteers|Normal, healthy volunteers without any skin pathology will be asked to undergo various procedures to evaluate their sleep and skin health.
3015829|NCT02457000||Volunteers with skin pathology|Volunteers with skin pathology including but not limited to eczema, psoriasis, acne, and other inflammatory dermatoses will be asked to undergo various procedures to evaluate their sleep and skin health.
3015830|NCT02456987|Experimental|Intervention|Patients that qualify for the intervention will receive the Samsung Gear virtual reality experiences and will participate in a brief survey about their opinions and preferences once the experiences are completed.
3015831|NCT02456987|No Intervention|Control|Age and sex matched control participants will be asked to answer a series of satisfaction questions after the study recruitment period is over. These individuals will have been inpatients during the same time as the intervention participants.
3015832|NCT02456974||amoxicillin-clavulanate|Patients receiving amoxicillin-clavulanate as part of routine clinical care.
3015833|NCT02456974||piperacilline-tazobactam|Patients receiving piperacilline-tazobactam as part of routine clinical care.
3015834|NCT02456974||vancomycin|Patients receiving vancomycin as part of routine clinical care.
3015835|NCT02456974||teicoplanin|Patients receiving teicoplanin as part of routine clinical care.
3015836|NCT02456974||meropenem|Patients receiving meropenem as part of routine clinical care.
3015837|NCT02456974||ciprofloxacin|Patients receiving ciprofloxacin as part of routine clinical care.
3015838|NCT02456974||amikacin|Patients receiving amikcain as part of routine clinical care.
3015839|NCT02456961|Active Comparator|Standard epithelium-off CXL|Removing the central 8-10mm of the epithelium and applying a riboflavin solution (0.1% riboflavin-5-phosphate and 20% dextran T-500) to the corneal surface 30 minutes before irradiation and at 5 minutes intervals during the course of a 30 minute exposure to 370 nm UVA with an irradiance of 3 mWcm-2 (UFalink, Russian Federation)
3015875|NCT02456740|Experimental|Erenumab 70 mg QM|Participants received erenumab 70 mg QM by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
3015910|NCT02456532|Placebo Comparator|Placebo|Intervention: Six months of nightly placebo
3015840|NCT02456961|Experimental|Transepithelial CXL via iontophoresis of riboflavin|"impregnation of the cornea with a riboflavin 0.1% hypotonic solution is performed by using an iontophoresis device (galvanizator; Potok-1, Russian Federation). The passive electrode (anode) was applied to the inferior part of the cervical vertebrae. The active electrode (cathode), a bath tube (glass or plastic - 10-12 ml) is applied to the open eye,then r the tube is taped to the skin of the orbital margins and filled with riboflavin 0.1%. The current intensity is initially 0.2 mA and then gradually increased to 1.0 mA at 0.2 mA for 1 minute at 10-second intervals increments to determine individual tolerance. The total time that the riboflavin administration is 10 minutes.~Standard surface UVA irradiation (370 nm, 3 mW/cm2) using UFalink device, (Russian Federation) is then applied at a 5-cm distance for 30 minutes with continuing hypotonic riboflavin drops every 2 minutes"
3015841|NCT02456948|Experimental|Minocycline|Minocycline and standard antidepressant treatment (es-/citalopram, venlafaxine or mirtazapine monotherapy)
3015842|NCT02456948|Placebo Comparator|Placebo|Placebo and standard antidepressant treatment (es-/citalopram, venlafaxine or mirtazapine monotherapy)
3015843|NCT02456935|Experimental|CJ-12420 100 mg QD|CJ-12420 100 mg, tablet, once daily, oral administration for up to 8 weeks
3015844|NCT02456935|Active Comparator|Esomeprazole 40 mg QD|Esomeprazole 40 mg, tablet, once daily, oral administration for up to 8 weeks
3015845|NCT02456922|Other|Group A|Subjects wearing Harmony 1 Sensor for up to 10 days.
3015846|NCT02456909|Experimental|Cues|The PCA pump will be programmed to provide a cue to the end of the lockout period.
3015847|NCT02456909|Placebo Comparator|No Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period (current standard of care).
3015848|NCT02456896|No Intervention|Healthy control|Twenty five (25) age and sex matched healthy individuals will serve as the control group. Control subjects will be evaluated at baseline only.
3015849|NCT02456896|Experimental|Oxcarbazepine|Twenty five (25) patients of bipolar mania will be prescribed oxcarbazepine for 4 weeks.
3015850|NCT02456883|Experimental|gilteritinib and 14C-labeled gilteritinib|Gilteritinib will be taken once daily on study days 1 through 14 and days 16 through 47. On day 15, each participant will be given a single dose of 14C-labeled gilteritinib.
3015851|NCT02456870|Other|MA|Middle-aged overweight and obese men (age 25-40yr)
3015852|NCT02456870|Other|OA|Older overweight and obese men (age 55-75yr)
3015853|NCT02456857|Experimental|Bevacizumab + Liposomal Doxorubicin + Everolimus|"On Day 1 of each cycle, participants receive Liposomal Doxorubicin by vein over about 3 hours, and Bevacizumab and Temsirolimus by vein over about 90 minutes each (6 hours total). To reduce the possibility of side effects from surgery, participants will not receive Bevacizumab during the 4th cycle. Participants take Everolimus by mouth at about the same time every day during the cycle.~Participants receive 4 cycles of chemotherapy before surgery. Each cycle is 21 days."
3015854|NCT02456844|Experimental|Group 1|Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142
3015855|NCT02456844|Experimental|Group 2|Methotrexate,Leucovorin and BMS-986142
3015856|NCT02456831|Active Comparator|Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
3015857|NCT02456831|Experimental|Experimental Infant Formula 1|Experimental Ready-to-Feed Soy Formula
3015858|NCT02456831|Experimental|Experimental Infant Formula 2|Experimental Ready-to-Feed Soy Formula
3015859|NCT02456831|Experimental|Experimental Infant Formula 3|Experimental Ready-to-Feed Soy Formula
3015860|NCT02456818||Centers using contact isolation|"Isolation triggered by the detection of ESBL-EC at hospital admission in surveillance screening or during the hospitalization by weekly screening or clinical cultures~Contact isolation terminated, after at least two negative consecutive fecal screening cultures~Contact isolation resumed, if subsequent ESBL-EC positive cultures are identified for the same patient including readmissions~Contact isolation must include:~Patient placement in single rooms~Cohorting only possible, when no single rooms available and corresponding ESBL-EC strains are phenotypically identical~Staff and visitors wearing gloves and gowns as contact precautions when entering the room, patient when leaving the room"
3015861|NCT02456818||Centers using no contact isolation|"not regularly isolating for ESBL-EC~ESBL-EC colonized or infected patients with urinary or fecal incontinence or diarrhea (>3 loose bowel movements/day) isolated in single rooms with above described contact precautions"
3015862|NCT02456805|Active Comparator|Infant Formula 1|A standard commercial milk-based infant formula
3015863|NCT02456805|Experimental|Infant Formula 2|A standard commercial soy-based infant formula.
3015864|NCT02456792|Active Comparator|IVF group|Women will undergo one full IVF cycle
3015865|NCT02456792|Active Comparator|LOD group|Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
3015866|NCT02456779||Erosive Esophagitis|"Patients diagnosed with GERD with erosive esophagitis present on routine endoscopy during the previous 6 months.~RDQ greater or equal to 12~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire"
3015867|NCT02456779||non erosive reflux disease|"Patients diagnosed with GERD with erosive esophagitis not present on routine endoscopy during the last 6 months.~RDQ greater or equal to 12~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire"
3015868|NCT02456779||healthy controls|"No GERD symptoms RDQ = 0 RSI = 0-9~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire intervention: questionnaire"
3015869|NCT02456766||F0|Liver Steatosis Grade: <5%
3015870|NCT02456766||F1|Liver Steatosis Grade: 5-33%
3015871|NCT02456766||F2|Liver Steatosis Grade: 34-66%
3015872|NCT02456766||F3|Liver Steatosis Grade: > 66%
3015873|NCT02456753||trans-perineal ultrasonography|"Patients included are women about to give birth, they undergo a clinical examination done by midwives. Followed by a trans-perineal ultrasonography examination done by a technical operator in order to measure the perineal-cephalic distance.~These examination are done the day of enrollment, they last for a few minutes and no further tests will be done afterwards."
3015874|NCT02456740|Placebo Comparator|Placebo|Participants received placebo once a month (QM) by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
3015876|NCT02456740|Experimental|Erenumab 140 mg QM|Participants received erenumab 140 mg QM by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
3015877|NCT02456727|Active Comparator|Individual Acupuncture|Participants will be treated weekly with individual acupuncture treatment sessions for 12 consecutive weeks. Quality of life assessments will be taken at baseline, and weeks 6, 12, and 24 post treatment initiation.
3015878|NCT02456727|Active Comparator|Group Acupuncture|Participants will be treated weekly with group acupuncture treatments sessions for 12 consecutive weeks. Quality of life assessments will be taken at baseline, and weeks 6, 12, and 24 post treatment initiation.
3015879|NCT02456714|Experimental|Progressive cholangiocarcinoma, second line treatment|FOLFIRINOX
3015880|NCT02456701|Experimental|Combination of Vemurafenib and KTN3379|Vemurafenib 960 mg po bid KTN3379 1000 mg IV q2weeks
3015881|NCT02456688|Experimental|Patients with im paired hepatic function|One dose of Imrecoxib followed by 5 days' pharmacokinetic sample collection.
3015882|NCT02456688|Experimental|Healthy Volunteers|One dose of Imrecoxib followed by 5 days' pharmacokinetic sample collection.
3015883|NCT02456675|Experimental|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
3015884|NCT02456675|Experimental|INCB040093 and itacitinib (INCB039110) Combination Therapy|Subjects allocated to Group B will be given INCB040093 BID in combination with itacitinib SR tablets. The dose of itacitinib will be orally given once daily (QD). Doses should be taken in the morning on an empty stomach if possible.
3015885|NCT02456662|Placebo Comparator|Placebo|150 Patients will randomly be assigned, using sealed numbered opaque envelopes to receive placebo tablet 30 minutes prior to taking 200mg PO doxycycline
3015886|NCT02456662|Active Comparator|Ondansetron|150 Patients will randomly be assigned, using sealed numbered opaque envelopes to receive 8mg ondansetron tablet 30 minutes prior to taking 200mg PO doxycycline
3015887|NCT02456649|Experimental|MarginProbe|Single arm study - MarginProbe in addition to standard procedure
3015888|NCT02456636|Active Comparator|Fee-for-Service Model|Participants will receive individual counseling from their physician or other healthcare professional during regular clinic visits.
3015889|NCT02456636|Active Comparator|Patient Centered Medical Home|Participants will take part in group weight-management counseling during in-person group visits and then by group telephone calls.
3015890|NCT02456636|Active Comparator|Disease Management|Participants will take part in group weight-management counseling by telephone.
3015891|NCT02456623|Experimental|Intervention|Behavioral intervention that targets the parent of a preschool age child who is overweight. The intervention is 8 sessions in length. Each session is expected to last 1-1.5 hours and will be carried out in the participant's home over 4 months. The sessions will target the nutrition and physical activity knowledge of parents and their motivation for changing parenting related to these factors. Intervention content for the parent will be based on Motivational Interviewing principles.
3015892|NCT02456623|Active Comparator|Attention Control|The attention control condition includes 1 initial Motivational Interviewing (MI) session conducted in the home. The content of the MI session will be the same as for the intervention participants. Following this session, parents will receive bi-monthly newsletters that will include content similar to what intervention participants receive. AC participants will receive a total of 7 newsletters; 2 on nutrition, 2 on physical activity, 2 on parenting behavior and 1 on community resources. AC participants will also receive a monthly 20-min phone call designed to review newsletter content and answer parent questions.
3015893|NCT02456610|Experimental|Infusion of CMV/EBV specific CTLs|Repetitive CTLs infusion to treat CMV/EBV activation and infection
3015894|NCT02456597|Active Comparator|lidocainhydrochlorid|Lidocaine 20mg/ml, 15 ml injected perineural at the sciatic nerve
3015895|NCT02456597|Placebo Comparator|Isotonic saline|0.9% Saline Solution, 15ml injected perineural at the contralateral sciatic nerve
3015896|NCT02456584|Experimental|DMPA 150|single subcutaneous injection of 150mg/mL of DMPA in the abdomen
3015897|NCT02456584|Experimental|DMPA 300|single subcutaneous injection of 300mg/2mL of DMPA in the abdomen
3015898|NCT02456584|Active Comparator|DMPA 104|two injections, given at three months intervals, of 104mg/0.65mL of DMPA in the abdomen
3015899|NCT02456571||Group A|men with mCRPC starting sipuleucel-T (Provenge) with or without abiraterone acetate or enzalutamide will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, 4-12 weeks after completion of sipuleucel-T, and at progression.
3015900|NCT02456571||Group B|men with mCRPC with visceral or high risk disease pre-abiraterone/enzalutamide will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, and progression.
3015901|NCT02456571||Group C|men with high volume metastatic castration sensitive prostate cancer (mCSPC) starting hormonal therapy and docetaxel chemotherapy or who decline docetaxel chemotherapy will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, and progression.
3015902|NCT02456571||Group D|men with enzalutamide or abiraterone acetate resistant mCRPC will have CTC enumeration and immune checkpoint characterization at baseline (i.e. progression on enzalutamide or abiraterone acetate) and 4-12 weeks after completion of next therapy (ex. radium-223 or chemotherapy)
3015903|NCT02456558|Experimental|Intravenous deferiprone, 1.5 g|Subjects in this arm will receive an infusion of intravenous deferiprone at a dose of 1.5 g, twice-daily
3015904|NCT02456558|Experimental|Intravenous deferiprone, 2 g|Subjects in this arm will receive an infusion of intravenous deferiprone at a dose of 2 g, twice-daily
3015905|NCT02456558|Placebo Comparator|Placebo|Subjects in this arm will receive an infusion of placebo twice-daily for 10 days, at a volume equivalent to that of the active product in the respective cohort
3015906|NCT02456545||help-seekers at-risk|"persons consulting collaborating Early Recognition Centers presenting with hints for ≥ 1 potential risk factor for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse, ADHD)~anticipated n = 500"
3015907|NCT02456545||patients with depressive syndrome|"in- and outpatients with depressive syndrome (SCID)~anticipated n = 500"
3015908|NCT02456545||patients with ADHD|"in- and outpatients with Attention-Deficit/Hyperactivity-Disorder (ADHD)~anticipated n = 150"
3015911|NCT02456532|Active Comparator|Zolpidem CR|Intervention: Six months of zolpidem cr 12.5 mg nightly use
3015912|NCT02456532|Active Comparator|Eszopiclone|Intervention: Six months of eszopiclone 3 mg nightly use
3015913|NCT02456519||PaedQoR-15 Questionnaire|Questionnaire to be completed by all participants
3015914|NCT02456506|Experimental|Hyperfractionated IMRT Group|IMRT (total dose of 65Gy, division 54 times, twice a day, once 1.2Gy, irradiation interval of 6-8 hours)
3015915|NCT02456506|Active Comparator|Conventional Fraction IMRT Group|IMRT (total dose of 60Gy, division 27 times, once a day, every 2.2Gy)
3015916|NCT02456493||increased carotid IMT group|Patients who have increased carotid IMT (intima media thickness)
3015917|NCT02456493||normal carotid IMT group|Patients who have normal carotid IMT
3015918|NCT02456480|Experimental|CLS001 topical gel, 2.5%|
3015919|NCT02456480|Experimental|CLS001 topical gel 1%|
3015920|NCT02456480|Placebo Comparator|Vehicle gel|
3015921|NCT02456467||Cardiac Surgery Patients|Intervention: Procedure: Blood specimen collection
3015922|NCT02456454|Experimental|Risp|Risperidone, PO 0.25-2 mg/day
3015923|NCT02456454|Experimental|Valproic|Valproic Acid PO to achieve plasma levels of 85-100
3015924|NCT02456454|Placebo Comparator|PCB|Liquid placebo PO matched for color and taste.
3015925|NCT02456441|Experimental|Intervention group|Will be obtained the evolution parasympathetic and sympathetic system 10 minutes after TENS application, through Heart Hate Variability analysis.
3015926|NCT02456441|Placebo Comparator|Placebo group|Will be obtained the evolution parasympathetic and sympathetic system 10 minutes after placebo current application, through Heart Hate Variability analysis. p. The placebo group will receive transcutaneous electric stimulation, for 30 seconds and then will gradually decrease by 15 seconds to not pass any current. This approach will aim to masking of the subject.
3015927|NCT02456428||Treated with incretins|Current use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) alone or in combination with other anti-diabetic drugs (if the prescription overlaps with the index or event day with a 30-day grace period).
3015928|NCT02456428||Treated with insulin|Current use of insulins between base cohort entry and the index or event day (alone or in combination with other anti-diabetic drugs) and no current use of incretin-based drugs.
3015929|NCT02456428||Treated with ≥2 oral hypoglycemic agents|Current use of 2 or more non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescriptions overlap with the index or event day with a 30-day grace period), and no current use of incretin-based drugs or insulins.
3015930|NCT02456428||Treated with single oral agent|Current use of any single non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescription overlaps with the index or event day with a 30-day grace period) and no current use of more than 2 OHAs, incretin-based drugs, or insulins.
3015931|NCT02456428||Not currently exposed group|All patients not currently exposed to: incretin-based drugs, insulins, ≥2 OHAs, or a single OHA.
3015932|NCT02456415|Experimental|K-MET™ Bioresorbable Bone screw|The K-MET™ Bioresorbable Bone Screw, intended to be used for trauma therapy, consists of Cortex screws, Cannulated headless screws. For Headless screw and Cannulated headless screws, the design is similar to normal headless compression screws but the compression function was achieved by using different lengths for the front and rear pitches. These screws are dynamic and allow therewith the fracture at the Carpal, metacarpal, and small hand bone.
3015933|NCT02456402|Experimental|Drug Coated Balloon|PCB (SeQuent Please®, paclitaxel-coated balloon catheter, B. Braun, Melsungen, Germany)
3015934|NCT02456402|Active Comparator|Bare Metal Stent|BMS (Vision®)
3015935|NCT02456389|Active Comparator|Standard perioperative management|Standard postoperative care
3015936|NCT02456389|Experimental|Risk-based, perioperative management|Preoperative risk stratification Postoperative risk stratification Risk-based, escalating levels of care Risk-based, escalating levels of monitoring Risk-based, escalating levels of co-management
3015937|NCT02456376|Experimental|Children with Cerebral palsy|"Sensory integration testing~SR stimulation and Sensory integration testing"
3015938|NCT02456376|Active Comparator|Children with Typical Development|"Sensory integration testing~SR stimulation and Sensory integration testing"
3015939|NCT02456363|Experimental|NSAIDs(+) and sulfasalazine(+)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine
3015940|NCT02456363|Experimental|NSAIDs(+) and sulfasalazine(-)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine
3015941|NCT02456363|Experimental|NSAIDs(-) and sulfasalazine(+)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of sulfasalazine and no NSAIDs
3015942|NCT02456363|Experimental|NSAIDs(-) and sulfasalazine(-)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) neither NSAIDs nor sulfasalazine
3015943|NCT02456350|Experimental|Anti-CD19-CAR transduced T cells|Patients will receive a lymphodepleting preconditioning regimen followed by anti-CD19- CAR-transduced T cells.
3015944|NCT02456337|Experimental|CAF+MC+EMD|Coronally Advanced Flap with Mucograft and Emdogain
3015945|NCT02456337|Active Comparator|CAF+MC|Coronally Advanced Flap with Mucograft
3015946|NCT02456337|Active Comparator|CAF+EMD|Coronally Advanced Flap with Emdogain
3015947|NCT02456337|Active Comparator|CAF|Coronally Advanced Flap alone
3015948|NCT02456324|Experimental|Treatment Group|Patients Treated with PICS-AF device
3015949|NCT02456324|Other|Historical Controls|Patients Treated with Commercially Available Fistula Plug Devices at Same Sites
3015950|NCT02456311|Other|Harmonic Ace+7|Pulmonary ARtery sealing with Harmonic Ace+7 in open lobectomy
3015951|NCT02456298|Active Comparator|Standard FA+FCT|Parents are coached via weekly telehealth visits to use Functional Analysis (FA) to assess problem behavior and Functional Communication Training (FCT) to treat the problem behavior identified.
3016025|NCT02455817||Bare metal stents|Access rate of angina including degree, post PCI up to 1 year for bare metal stents.
3016101|NCT02455362|Experimental|Morphine sulfate (8, 16, 24 mg)|Morphine 8 mg per day week one, morphine 16 mg per day week two, and morphine 24 mg per day week three.
3015952|NCT02456298|Experimental|Pragmatic FA+FCT|Parents are coached via weekly telehealth visits to use a brief, streamlined version of Functional Analysis (FA) to assess problem behavior and to follow that assessment with Functional Communication Training (FCT) to treat the problem behavior identified. The version of FCT used in the Pragmatic arm involves significantly less data scoring and graphing than the version used in the Standard arm.
3015953|NCT02456272|Experimental|External hearing aid & Otosclerosis surgery|Trying an hearing aid for at least two months and then undergo otosclerosis surgery
3015954|NCT02456259||Neck cannula group|Patients in this group are indicated for neck cannula insertion due to tzpu of cardiac surgery (MICS)
3015955|NCT02456259||Central venous catheter only group|Patients in this group are indicated for central venous catheter insertion only.
3015956|NCT02456246|Experimental|FLT-PET|"Cohort 1: Patients in this cohort would be treatment naïve and will be planned for SBRT treatment according to established institutional practices. FLT-PET in this subgroup will be performed before radiation therapy.~Cohort 2: Patients who have had SBRT and demonstrate typical or stable lung fibrosis on follow up CT~Cohort 3: Patients who have had SBRT and demonstrate findings suspicious for recurrence on follow up CT or who have biopsy demonstrating disease recurrence."
3015957|NCT02456233|Active Comparator|Conventional AF Ablation with PVI|These patients will be treated by conventional AF ablation by pulmonary vein isolation (PVI) alone.
3015958|NCT02456233|Experimental|FIRM-guided ablation plus PVI|These patients will be treated by ablation of patient-specific rotors and focal sources (FIRM). Conventional ablation (PVI) will then be performed as part of the standard of care procedure.
3015959|NCT02456220|Experimental|Herbst Group|Patients treated with Herbst appliance.
3015960|NCT02456220|No Intervention|Comparison Group|Patients that received only teeth movement (alignment and leveling before Herbst insertion), without any orthopedic intervention.
3015961|NCT02456207|Experimental|Experimental|SCT400:375 mg/m2, iv, one infusion
3015962|NCT02456207|Active Comparator|Active Comparator|Rituximab: 375 mg/m2, iv, one infusion
3015963|NCT02456194|Experimental|Calcium Sulfate + Antibiotics + Internal Fixation|
3015964|NCT02456181|Experimental|JumpMath|"The JUMP method focuses more on the mental activity involved in constructing mathematical knowledge. There is a strong emphasis on symbolic math (numbers, letters, mathematical symbols). Manipulatives are used prescriptively, in lessons carefully scaffolded to help students connect the objects (e.g., three buttons) to what they are intended to stand for (the magnitude 3)."
3015965|NCT02456168||SLE|
3015966|NCT02456168||Healthy control|
3015967|NCT02456155|Experimental|ultrasound group|using B ultrasound as a instruction technique to place Nasal Jejunal Tube
3015968|NCT02456155|Placebo Comparator|endoscope group|Conventional methods for placing Nasal Jejunal Tube
3015969|NCT02456142|Experimental|caudal bupivacaine|1ml/kg of 0.125% caudal bupivacaine given over 2 minutes will be given at the end of surgery
3015970|NCT02456142|Active Comparator|intravenous morphine|0.05mg/kg intravenous morphine given over 5 minutes
3015971|NCT02456129|Experimental|Vilaprisan + Itraconazole|Vilaprisan (BAY1002670)
3015972|NCT02456116|Experimental|acupuncture/PCA/NSAID|"standard program with defined points:~Ear acupuncture needles bitten once (day 0-5)~Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released"
3015973|NCT02456116|Sham Comparator|sham acupuncture/PCA/NSAID|"standard program with defined points:~Ear sham-acupuncture needles bitten once (day 0-5)~Body sham-acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5"
3015974|NCT02456116|Other|PCA/NSAID|minimal intervention (included in every arm) standard boli of morphine by pressing a button of PCA availability in the postoperative period (day 0-4) readout once a day NSAID (non-steroid antiinflammatory drug) 2x i.v. (75mg diclofenac-sodium, 30 mg orphenadrine citrate) (day 0-4)
3015975|NCT02456103|Experimental|Ataluren|Ataluren will be orally administered at a dose of 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for up to 96 weeks.
3015976|NCT02456077|Experimental|Intervention Practices|Intervention offices will adopt a multi-modal vaccine program to increase their patients' vaccine rates.
3015977|NCT02456077|No Intervention|Control Practices|Control offices will offer usual health care related to immunizations throughout the duration of the study.
3015978|NCT02456064|Experimental|Lifestyle counseling|"In this group we will make an intensive program based on: workshops, educational talks, group medical practices and expert patient among others conduct auditions."
3015979|NCT02456064|No Intervention|Normal group|In this group will be controlled as usual in the consultations.
3015980|NCT02456051||High AM|Newly diagnosed diabetic patients with high Adrenomedullin serum levels
3015981|NCT02456051||Low AM|Newly diagnosed diabetic patients with low Adrenomedullin serum levels
3015982|NCT02456038|Experimental|Asfotase Alfa (ALXN1215)|Asfotase Alfa (ALXN1215) is administered 6mg/kg in total per week, divided into 3 times.
3015983|NCT02456025|Active Comparator|Topical tacrolimus|20 eyes with active Vernal Keratoconjunctivitis
3015984|NCT02456025|Placebo Comparator|Placebo|20 eyes with active Vernal Keratoconjunctivitis
3015985|NCT02456012|Experimental|The D group|After 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment, patients receive oral esomeprazole 20 mg twice daily for 36 weeks.
3015986|NCT02456012|Experimental|The S group|After 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment, patients receive oral esomeprazole 20 mg once daily for 36 weeks.
3015987|NCT02456012|No Intervention|The C group|The cohort control group includes patients from a previous study who had peptic ulcer bleeding and Rockall scores ≥ 6 but who did not receive esomeprazole or other proton pump inhibitors after 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment.
3015988|NCT02455999|Experimental|SYL1001 eye drops dose C|SYL1001 eye drops dose C administration via the ophthalmic route
3015989|NCT02455999|Experimental|SYL1001 eye drops dose D|SYL1001 eye drops dose D administration via the ophthalmic route
3015990|NCT02455999|Placebo Comparator|Placebo|Placebo eye drops administration via the ophthalmic route
3016098|NCT02455362|Experimental|Morphine sulfate (8, 8, 8 mg)|Morphine 8 mg per day during all three treatment weeks.
3016099|NCT02455362|Experimental|Morphine sulfate (8, 8, 16 mg)|Morphine 8 mg per day week one and two and morphine 16 mg per day week three.
3015991|NCT02455986|Experimental|Intervention|"The intervention group includes 150 participants aged 12-14 across three schools. Each participant has been given a Fitbit Zip pedometer to wear for a six month period and enrolled on the StepSmart challenge. Participants within the intervention group will take part in two competitions during this period.~School and team based competition. 27/05/15 - 22/06/15 (8 weeks)~Individually focused competition. 22/06/15 - 26/10/15 (18 weeks)~Prizes of low monetary value will be given to participants based on competition performance"
3015992|NCT02455986|No Intervention|Control|The control group for the study involves approximately 90 participants aged 12 - 14. across two schools. Participants within the control group will complete the same measures as the intervention group including wearing an actigraph GT3X accelerometer for a seven day period and completing all questionnaires at the same time points as the intervention group.
3015993|NCT02455973|Experimental|Transtheoretical model of change|In this type of intervention, the focus will be the development of skills through educational activities on health based on interdisciplinary motivational strategies.
3015994|NCT02455973|Placebo Comparator|Health information|In this type of intervention, the focus will be the development of skills through educational activities on health using the pedagogy of transmission.
3015995|NCT02455960|Experimental|Arginine|Participants need to take arginine 3 g/day orally for 3 days before CT with contrast media injection
3015996|NCT02455960|Placebo Comparator|Placebo|Participants need to take placebo (corn powder) 3 g/day orally for 3 days before CT with contrast media injection
3015997|NCT02455947|Experimental|Inquiry Based Stress Reduction (IBSR)|"IBSR intervention is the clinical implementation of a mindful-process, named The Work developed by Byron Katie.It teaches the individual to identify and question the thoughts that causes stress and suffering through four questions and turnarounds."
3015998|NCT02455947|No Intervention|Control group|A non interventional group/ The participants completed questionnaires before and after the intervention.
3015999|NCT02455934|Placebo Comparator|Sucrose|Sucrose 50 g
3016000|NCT02455934|Active Comparator|SAlloulose2.5|Sucrose 50 g + D-allulose (psicose) 2.5 g
3016001|NCT02455934|Active Comparator|SAllulose5|Sucrose 50 g + D-allulose (psicose) 5 g
3016002|NCT02455934|Active Comparator|SAllulose7.5|Sucrose 50 g + D-allulose (psicose) 7.5 g
3016003|NCT02455934|Active Comparator|SAllulose10|Sucrose 50 g + D-allulose (psicose) 10 g
3016004|NCT02455921|Active Comparator|sugammadex|iv sugammadex 2 mg/Kg
3016005|NCT02455921|Active Comparator|neostigmine - atropine|"iv neostigmine 0,05 mg/Kg - atropine 0,02 mg/kg~Efficacy, safety and effect on cognitive and behavioural function"
3016006|NCT02455908|Experimental|Proleukin®|"Subcutaneous administration of low doses of IL2 (Proleukin) following the therapeutical scheme indicated for crioglobulinemic nephropathy:~cycle1: IL2 1x106 /m2 s.c for 5 consecutive days cycle2: IL2 1.5 x106 / m2 s.c for 5 consecutive days, starting from 3 weeks after the first cycle.~cycle3: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 6 weeks after the first cycle.~Cycle 4: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 9 weeks after the first cycle."
3016007|NCT02455895|Active Comparator|iLid Cleanser (Avenova)|iLid Cleanser - applied 2 times per day for 10 days
3016008|NCT02455895|Placebo Comparator|iLid Cleanser Vehicle|iLid Cleanser Vehicle - applied 2 times per day for 10 days
3016009|NCT02455882||Neoadjuvant|Patients initiating standard of care treatment with primary systemic therapy for breast cancer
3016010|NCT02455882||Adjuvant|Patients initiating standard of care treatment with surgery followed by adjuvant chemotherapy for breast cancer
3016011|NCT02455882||Recurrence|Patients with a history of breast cancer who are diagnosed with disease recurrence
3016012|NCT02455869|Placebo Comparator|Placebo group|SRP plus placebo SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
3016013|NCT02455869|Active Comparator|Atorvastatin group|SRP plus Atorvastatin SRP was done for all the subjects. Atorvastatin was delivered in the pocket subgingivally
3016014|NCT02455869|Active Comparator|Alendronate Group|Alendronate SRP plus Alendronate SRP was done for all the subjects. Alendronate was delivered in the pocket subgingivally
3016015|NCT02455856|Experimental|JNJ-42847922 plus Itraconazole|Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter [mL] oral solution on Day 1 and Day 6 and itraconazole as 200 mg (2*100 mg capsule) from Day 2 to Day 6.
3016016|NCT02455843|Experimental|Microwave plus chemotherapy|In combination group, patients will be treated with microwave ablation in primary tumor sites followed by chemotherapy （For non-squamous cell lung cancer，patients will be treated with pemetrexed，500mg/m2, d1, ivdrip, or docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, ivdrip,or novelbine 25mg/m2 d1 d8, ivdrip, paclitaxel 175mg/m2 d1 ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip. For squamous cell lung cancer，patients will be treated with docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip；repeated every 3 weeks and up to 6 cycles are administrated ）
3016017|NCT02455843|Placebo Comparator|chemotherapy|In chemotherapy group,patients will be treated with chemotherapy alone（For non-squamous cell lung cancer，patients will be treated with pemetrexed，500mg/m2, d1, ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with a area uder the curve of 5 d1 ivdrip. For squamous cell lung cancer，patients will be treated with docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, novelbine 25mg/m2 d1 d8, ivdrip, paclitaxel 175mg/m2 d1 ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip；repeated every 3 weeks and up to 6 cycles are administrated ）
3016018|NCT02455830||Cell-treated|Infants with encephalopathy who receive autologous umbilical cord blood cell therapy along with therapeutic hypothermia.
3016019|NCT02455830||Cooled only|Infants with encephalopathy who receive therapeutic hypothermia only.
3016020|NCT02455817||Cypher|Access rate of angina including degree, post PCI up to 1 year for the Cypher stent.
3016021|NCT02455817||Taxus Express|Access rate of angina including degree, post PCI up to 1 year for the Taxus Express stent.
3016022|NCT02455817||Xience V|Access rate of angina including degree, post PCI up to 1 year for the Xience V stent.
3016023|NCT02455817||Promus Element|Access rate of angina including degree, post PCI up to 1 year for the Promus stent.
3016024|NCT02455817||Resolute|Access rate of angina including degree, post PCI up to 1 year for the Resolute stent.
3016026|NCT02455804|Other|Single Arm|This is a prospective, post-marketing, non-randomized, multi-center, single-arm clinical study that will be conducted at up to 15 sites in the United States (US). All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
3016027|NCT02455791|Experimental|Ultrasound-Guided Biopsy of Tumor Site|Ultrasound-guided biopsy of the tumor site performed before scheduled surgery.
3016028|NCT02455778|Experimental|Cinnamon|3 grams of oral cinnamon per day in form of capsules (6) along with standard diet and exercise protocol
3016029|NCT02455778|Placebo Comparator|Placebo|2.5 grams of wheat flour per day in form of capsules ( 6) along with standard diet and exercise protocol
3016030|NCT02455765|Experimental|White rice control|Subjects will consume white rice as control (50g carbohydrate)
3016031|NCT02455765|Experimental|co-ingest low dose of amino acid|Subjects will receive 68 ml of amino acid mixture together with white rice
3016032|NCT02455765|Experimental|co-ingest high dose of amino acid|Subjects will receive 136 ml of amino acid mixture together with white rice
3016033|NCT02455765|Experimental|pre-load low dose15 min|Subjects will receive 68 ml of amino acid mixture 15 min before consumption of white rice
3016034|NCT02455765|Experimental|pre-load low dose 30 min|Subjects will receive 68 ml of amino acid mixture 30 min before consumption of white rice
3016035|NCT02455765|Experimental|pre-load high dose 15 min|Subjects will receive 136 ml of amino acid mixture 15 min before consumption of white rice
3016036|NCT02455765|Experimental|pre-load high dose 30 min|Subjects will receive 136 ml of amino acid mixture 30 min before consumption of white rice
3016037|NCT02455752|Active Comparator|Reroperitoneal Group|LE-TME
3016038|NCT02455739|Experimental|chewing gum positive|chewing gum group will chew gum
3016039|NCT02455739|No Intervention|chewing gum negative|chewing gum group will not chew gum
3016040|NCT02455726|Experimental|Mg-group|"Standard therapy plus magnesium oxide.~Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.~A rescue dose: paracetamol 1g (maximum dose 3 g per day)."
3016041|NCT02455726|Placebo Comparator|C-group|"Standard therapy plus fructose.~Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.~A rescue dose: paracetamol 1g (maximum dose 3 g per day)."
3016042|NCT02455713||Intervention|Alter PEEP and PIP and measure hemodynamic outcomes.
3016043|NCT02455700|Active Comparator|Hand driven enamel reduction|This group will have enamel reduction in the lower incisor region carried out using hand held devices
3016044|NCT02455700|Active Comparator|Rotary ( motor driven) device|This group will ahve enamel reduction in the lower incisor region carried out using a rotary (motor driven) device
3016045|NCT02455687|Active Comparator|1|Group one will receive two doses of intravenous magnesium sulfate with inhaled budesonide.
3016046|NCT02455687|Placebo Comparator|2|Group two will receive two doses of intravenous magnesium sulfate with inhaled normal saline.
3016047|NCT02455687|Active Comparator|3|Group three will receive single dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with inhaled budesonide.
3016048|NCT02455687|Placebo Comparator|4|Group four will receive single dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with inhaled normal saline
3016049|NCT02455674||Age under 6 years|"All children 1 to 6 years~Used formula for weight calculation:~Children 1-5 years: Weight (kg) = (2 × age in years) + 8"
3016050|NCT02455674||Age over 6 years|"All children 6 to 12 years~Used formula for weight calculation:~Children 6-12 years: Weight (kg) = (3 × age in years) + 7"
3016051|NCT02455661|Experimental|Radial PCI with TR Band (TM)|Patients with a PCI using the radial approach and the above radial compression device.
3016052|NCT02455661|Active Comparator|Femoral PCI with AngioSeal(R)|Patients with a PCI using the femoral approach and the above femoral vascular closure device.
3016053|NCT02455648|Experimental|ESD/EMR plus Cell Sheet|Patients receive both mucosal buccal biopsy and insertion of cell sheets during/after ESD/EMR
3016054|NCT02455648|Sham Comparator|ESD/EMR|patients receive both mucosal biopsy but no placement of cell sheets during/after ESD
3016055|NCT02455635|Active Comparator|women with pain|women who felt pain at time of office hystroscopy at time of saline infusion and for 15 minutes after end of procedure
3016056|NCT02455635|Active Comparator|women without pain|women who didn't feel pain at time of office hystroscopy at time of saline infusion and for 15 minutes after end of procedure
3016057|NCT02455622|Experimental|Enrolled Patients|Patients who are receiving treatment with Elaprase in this study (SHP-ELA-401), who are <6 years of age, and were previously treatment-naïve. Patients who are not enrolled in this study (SHP-ELA-401) but are enrolled in the Hunter Outcome Survey (HOS) patient registry and were < 6 years of age at start of Elaprase treatment. While not enrolled in the present Study SHP-ELA-401, their height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
3016058|NCT02455609|Active Comparator|dexmedetomidine (I)|intrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine in 1 ml volume.
3016059|NCT02455609|Active Comparator|ketamine (II)|intrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume.
3016060|NCT02455609|Active Comparator|Dexmedetomidine + Ketamine group (III)|intrathecal drug administartion of patients in this arm received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine plus 0.1 mg/kg of Ketamine in 1 ml volume.
3016061|NCT02455596|Experimental|Experimental|Recombinant anti-tumor and anti-virus protein for injection(Novaferon), three times per week.
3016062|NCT02455583|No Intervention|Standard of Care|All Form 1 learners at 25 of the 50 schools will receive HIV prevention sessions from the Botswana life skills education program for junior secondary school students called LIVING.
3016063|NCT02455583|Experimental|Intervention|Form 1 learners at the 25 intervention schools will receive the Project AIM intervention and LIVING (standard of care).
3016100|NCT02455362|Experimental|Morphine sulfate (8, 16, 16 mg)|Morphine 8 mg per day week one and morphine 16 mg per day week two and three.
3016064|NCT02455557|Experimental|Treatment (SurVaxM, temozolomide)|Patients receive the first priming dose of SVN53-67/M57-KLH peptide vaccine in emulsion with montanide ISA 51 SC and sargramostim SC within 7-28 days after completion of chemoradiation. Treatment repeats every 2 weeks for a total of 4 doses in the vaccine priming phase and then every 12 weeks during the adjuvant phase in the absence of disease progression or unacceptable toxicity. Patients also receive standard adjuvant temozolomide PO or IV on days 1-5. Treatment repeats every 28 days for 6 courses or more (at the discretion of the investigator) in the absence of disease progression or unacceptable toxicity. Patients may then receive maintenance SVN53-67/M57-KLH peptide vaccine in emulsion with montanide ISA 51 SC and sargramostim SC every 12 weeks in the absence of disease progression or unacceptable toxicity.
3016065|NCT02455544||Pregnant Women|Any pregnant women that is referred to or presents to our tertiary care facility with concern for preeclampsia, will have a Congo Red Dot test preformed by research nurses. The research nurses are not involved in patient management and the results are blinded to the clinical providers and have no impact on clinical diagnosis or patient management.
3016066|NCT02455531||Transplant-free survivors|Transplant-free survivors of the SVR cohort (All SVR survivors are eligible to be followed for vital status.)
3016067|NCT02455518|Active Comparator|Oxycodone/acetaminophen|Oxycodone/acetaminophen (5 mg/325 mg)
3016068|NCT02455518|Active Comparator|Hydrocodone/acetaminophen|Hydrocodone/acetaminophen (5 mg/300 mg)
3016069|NCT02455518|Active Comparator|Codeine/acetaminophen|Codeine/acetaminophen (30 mg/300 mg)
3016070|NCT02455518|Active Comparator|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen (400 mg/1000 mg)
3016071|NCT02455505||Risk Screening tool & Cognitive Interview|
3016072|NCT02455479|Other|Cohort 1: 100µg|Subjects will receive 100µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
3016073|NCT02455479|Other|Cohort 2: 316 µg|Subjects will receive 316 µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
3016074|NCT02455479|Other|Cohort 3: 1000µg|Subjects will receive 1000 µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
3016075|NCT02455453|Experimental|Diagnostic FFNP-PET/CT Scan|"(2) 18F-FFNP-PET/CT scans~First one prior to estradiol challenge test~Second one immediately following one day of estradiol challenge test~(1) FDG-PET/CT scan at screening~The estradiol challenge test will consist of administering a total of 6 mg of estradiol dosed orally as three 2 mg tablets with each tablet being administered approximately 8 hours apart and within a 24 hour period. This estradiol medication will be provided to the patient by the study."
3016076|NCT02455440|Active Comparator|Esmolol|500 mcg/kg of esmolol bolus 10 min before induction of anesthesia, followed by additional 200 mcg/kg/min of esmolol until 30 minutes after extubation.
3016077|NCT02455440|Placebo Comparator|control|Control group did not receive esmolol or other b-blocker in the perioperative period.
3016078|NCT02455427|Active Comparator|Active tDCS+ Physical Therapy|Active tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After active session of tDCS, the patient will receive physical therapy for 60 minutes. Number of treatment sessions: 6 (3 times a week, for 2 weeks)
3016079|NCT02455427|Sham Comparator|Sham tDCS+Physical Therapy|"Sham tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After sham session of tDCS, the patient will receive physical therapy for 60 minutes.~Number of treatment sessions: 6 (3 times a week, for 2 weeks)"
3016080|NCT02455414||Wolfram Syndrome Group|"Participant has confirmation of a WFS1 mutation OR~Both of the following conditions: diabetes mellitus requiring insulin and optic nerve atrophy diagnosed by a physician. Both conditions diabetes mellitus and optic nerve atrophy had to be diagnosed at age younger than 18 years old"
3016081|NCT02455414||WFS Pre-symptomatic Sibling Group|"Has had genotyping~Willingness to share result of genotyping~Participant has confirmation of WFS1 (+/+) mutation but is asymptomatic."
3016082|NCT02455414||WFS Control Sibling Group|"Has had genotyping~Willingness to share result of genotyping~Patient has confirmation of NO WFS1 mutation (-/-) or confirmation as a carrier (+/- or -/+)."
3016083|NCT02455414||T1DM Group|"Age within the 0-28 yrs age range of WS participant~Dx of T1 diabetes mellitus"
3016084|NCT02455414||Healthy Control (HC) Group|• Age within the 0-28 yrs age range of WFS participants
3016085|NCT02455414||Proxy Group|Adult Biological parent(s), biological caregiver or non-biological caregiver of adult and minor participants in the any of the groups.
3016086|NCT02455401|Experimental|high dose remifentanil group|Intervention: high dose remifentanil will be administrated.
3016087|NCT02455401|Experimental|low dose remifentanil group|Intervention: low dose remifentanil will be administrated
3016088|NCT02455401|Placebo Comparator|No remifentanil group|Intervention: no remifenatnil will be administrated
3016089|NCT02455388|Experimental|Low, then high added sugar diet|Participants will consume a low added sugar (5% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a high added sugar (25% total energy) diet for 7 consecutive days.
3016090|NCT02455388|Experimental|High, then low added sugar diet|Participants will consume a high added sugar (25% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a low added sugar (5% total energy) diet for 7 consecutive days
3016091|NCT02455388|No Intervention|Dietary recall and fingerstick|Participants will complete 4 in-person 24-hr dietary recalls and 2 fingerstick blood samples at Visit 1 and 3 within 3 weeks.
3016092|NCT02455375||Cases|"Case group = group of patients positive with reference tests including serological (ELISA, IF neutralization) and/or molecular assays:~detection of PUUV RNA in plasma collected at admission.~or/and detection of IgM and IgG against PUUV in serum collected at admission,~or/and detection of a seroconversion in IgG against PUUV from admission and late sera"
3016093|NCT02455375||Controls|Control group = group of patients who do not have the criteria listed above
3016094|NCT02455362|Placebo Comparator|Placebo|Double-blind placebo capsule, looking identical to capsules with active treatment, during all three treatment weeks.
3016095|NCT02455362|Experimental|Morphine sulfate (0, 0, 8 mg)|Placebo during treatment week one and two and morphine 8 mg per day week three.
3016096|NCT02455362|Experimental|Morphine sulfate (0, 8, 8 mg)|Placebo during treatment week one and morphine 8 mg per day week two and three.
3016097|NCT02455362|Experimental|Morphine sulfate (0, 8, 16 mg)|Placebo week one, morphine 8 mg per day week two, and morphine 16 mg per day week three.
3016206|NCT02454673||Group A|"3-4 cycles of preoperative chemotherapy~Surgery"
3016102|NCT02455362|Experimental|Morphine sulfate (16, 16, 16 mg)|Morphine 16 mg per day during all three treatment weeks.
3016103|NCT02455362|Experimental|Morphine sulfate (16, 16, 24 mg)|Morphine 16 mg per day week one and two, and morphine 24 mg per day week three.
3016104|NCT02455362|Experimental|Morphine sulfate (16, 24, 24 mg)|Morphine 16 mg per day week one and morphine 24 mg per day during week two and three.
3016105|NCT02455362|Experimental|Morphine sulfate (16, 24, 32 mg)|Morphine 16 mg per day week one, morphine 24 mg per day week two, and morphine 32 mg per day week three.
3016106|NCT02455336|Experimental|Fenofibrate|Twenty subjects with adverse TG concentrations (i.e., paraplegia: >/=135 mg/dl; tetraplegia >/=115 mg/dl) will be randomized to receive once daily fenofibrate therapy (i.e., 145 mg) for 4 months
3016107|NCT02455336|Other|No Intervention|Ten subjects with adverse TG concentrations (i.e., paraplegia: >/=135 mg/dl; tetraplegia >/=115 mg/dl) will be randomized to receive no therapy for 4 months
3016108|NCT02455323|Experimental|Suboccipital inhibitory|Suboccipital inhibitory pressure technique. According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues.
3016109|NCT02455323|Experimental|Spinal Manipulative|Suboccipital inhibitory pressure technique. This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility.
3016110|NCT02455323|Experimental|Combined treatment|Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.
3016111|NCT02455323|Placebo Comparator|Control group|The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
3016112|NCT02455310||Outpatients with dementia|Medication use will be evaluated among outpatients with dementia in intervention and control counties, as well as statewide to evaluate the long-term effectiveness of the statewide intervention.
3016113|NCT02455310||Nursing home residents|Medication use and behavioral outcomes will be evaluated among nursing home residents in intervention and control counties, as well as statewide to evaluate the long-term effectiveness of the statewide intervention.
3016114|NCT02455297|Experimental|Copanlisib|Copanlisib (BAY80-6946) solution for IV infusion
3016115|NCT02455284|Experimental|Healthy subjects|MRI and neuropsychological evaluation
3016116|NCT02455271||Participants with insomnia|Participants with insomnia who will receive eszopiclone per approved label.
3016117|NCT02455258|Experimental|Dance/Movement Therapy (DMT)|
3016118|NCT02455258|Active Comparator|Aerobics Exercise (AE)|
3016119|NCT02455258|No Intervention|Waiting List|This group is placed on a waiting list and asked to refrain from making any changes to their current lifestyle.
3016120|NCT02455245|Active Comparator|Carboplatine and Vincristine|"Induction: 10 weeks of Carboplatin and Vincristine therapy. Carboplatin 175 mg/m2 give an an IV infusion weeks 1, 2, 3, 4, 7, 8, 9, 10. Vincristine 1.5mg/m2 (0.05 mg/kg if child less than 12 kg) (maximum dose 2.0 mg) give as an IV bolus infusion on weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.~Maintenance: Maintenance consists of 8, 6-week cycles of chemotherapy. It begins week 12 of Induction or when peripheral counts recover with ANC >1,000/µL and platelet count >100,000/µL. Each cycle will consist of 4 weekly doses of carboplatin, three weekly doses of vincristine (given concomitantly with the first 3 weeks of carboplatin), followed by two weeks of rest for a total of 6 weeks. Maintenance will continue for a total of 8 cycles.~Carboplatin 175 mg/m2 as an IV continuous infusion over 60 minutes on Week 1, 2, 3, 4 of each cycle. Vincristine 1.5 mg/m2 (0.05 mg/ kg for children <12 kg) (maximum dose 2.0 mg) IV bolus infusion on Week 1, 2, 3 of each cycle."
3016121|NCT02455245|Experimental|Carboplatin alone|"Carboplatin is given once every four weeks, Each 4-week period is considered a cycle. Regimen B will last for 13 cycles which is equivalent to one year (52 weeks).~Carboplatin 560 mg/m2 (or 19 mg/kg for children weighing less than 12 kg) IV over 1 hour every 4 weeks"
3016122|NCT02455232|Experimental|hemiplegic patient|muscle participation in upper limb spasticity
3016123|NCT02455206|Active Comparator|Usual Care|outpatient pulmonary Rehabilitation program
3016124|NCT02455206|Experimental|Counseling|outpatient pulmonary Rehabilitation program plus physical activity counseling
3016125|NCT02455193|Experimental|Exercise intervention|10 weeks of a moderate exercise intervention
3016126|NCT02455193|Active Comparator|Diet intervention|10 weeks of a diet intervention
3016127|NCT02455180|Experimental|4x 1 gram bolus (q12H) dosage regimen|1 gram of intravenous Vitamin C (ascorbic acid) is given 4 times at 12 hour intervals (total dose 4 grams).
3016128|NCT02455180|Experimental|4x 5 grams bolus (q12H) dosage regimen|5 grams of intravenous Vitamin C (ascorbic acid) is given 4 times at 12 hour intervals (total dose 20 grams).
3016129|NCT02455180|Experimental|4 gram continuous dosage regimen|1 gram per 12 hours of intravenous Vitamin C (ascorbic acid) is given continuously for 48 hours
3016130|NCT02455180|Experimental|20 gram continuous dosage regimen|5 gram per 12 hours of intravenous Vitamin C (ascorbic acid) is given continuously for 48 hours
3016131|NCT02455167|Experimental|HCV positive group|A single arm study of 'Simeprivir (SMV), Sofosbuvir (SOF) and Ribavirin (RBV) in an HCV positive population.
3016132|NCT02455154|Placebo Comparator|Letrozole|"Early Breast Cancer patients receiving adjuvant endocrine therapy~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po."
3016133|NCT02455154|Active Comparator|Letrozole + Xinglinggubao|"Early Breast Cancer patients receiving adjuvant endocrine therapy plus Xianlinggubao~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po.~Xinglinggubao: 0.5g bid po"
3016134|NCT02455154|Active Comparator|Letrozole + Zhongyaofufang|"Early Breast Cancer patients receiving adjuvant endocrine therapyplus Zhongyaofufang (Traditional Chinses Medicine)~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po.~Zhongyaofufang: qow po"
3016135|NCT02455141|Active Comparator|Taxanes|Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel
3016136|NCT02455141|Experimental|Taxanes plus carboplatin|Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel + Carboplatin
3016137|NCT02455128|Experimental|Experimental Group|This group will receive the therapeutic listening.
3016138|NCT02455128|No Intervention|Control Group|This group will receive usual care offered by the hospital where the study will be conducted.
3016139|NCT02455115|Experimental|60 mmHg|Alternating mean arterial pressure by lowering of the infusion rate of norepinephrine
3016140|NCT02455115|Experimental|75 mmHg|Alternating mean arterial pressure by adjust of the infusion rate of norepinephrine
3016141|NCT02455115|Experimental|90 mmHg|Alternating mean arterial pressure by augmentation of the infusion rate of norepinephrine
3016142|NCT02455102|Active Comparator|Electronic alert|Physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will receive an electronic warning alert.
3016143|NCT02455102|No Intervention|No electronic alert|Physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will receive no electronic warning alert.
3016144|NCT02455089|Experimental|Test group|"250 SLE patients : All SLE patients included in the study. Intervention : Blood analysis including GADD34 RNA level measurement every 3 months up to 1 year.~They will provided a blood sample every 3 months during a year. The result of GADD34 RNA level in mononuclear blood cells will be correlated to the clinical assessment of a SLE flare during the next 3 months.~A flare occurence will the group"
3016145|NCT02455076|Active Comparator|Exenatide|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
3016146|NCT02455076|Active Comparator|Exenatide plus glargine insulin|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide twice daily and glargine once daily. Glargine insulin will be given once daily at the same time. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
3016147|NCT02455076|Active Comparator|Basal bolus regimen|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive the Basal Bolus Regimen with Glargine and Rapid-Acting Insulin Analogs. Patients treated with insulin previously will receive 80% of total home daily insulin dose as the basal bolus. Half of the total daily dose will be given as glargine and half as rapid-acting insulin analogs. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
3016148|NCT02455076|Active Comparator|Exenatide with oral antidiabetic drugs|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive Exenatide with oral antidiabetic drugs.
3016149|NCT02455076|Active Comparator|Glargine with oral antidiabetic drugs|Patients with T2D treated with diet, oral antidiabetic drugs, or low-dose insulin will receive glargine with oral antidiabetic drugs. Patients receiving no drug therapy prior to admission will be discharged on glargine once daily at 50% of hospital dose.
3016150|NCT02455076|Active Comparator|Glargine without oral antidiabetic drugs|Patients with T2D treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive glargine without the addition of oral antidiabetic drugs. Patients receiving no drug therapy prior to admission will be discharged on glargine once daily at 50% of hospital dose.
3016151|NCT02455050|Other|New Eye Drop Formulation then Systane®|1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks.
3016152|NCT02455050|Other|Systane® then New Eye Drop Formulation|1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.
3016153|NCT02455050|Other|Genteal® then New Eye Drop Formulation|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.
3016154|NCT02455050|Other|New Eye Drop Formulation then Genteal®|1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks.
3016155|NCT02455037|No Intervention|Body Strengthening (Only)|All participants will complete a general resistance exercise training program.
3016156|NCT02455037|Experimental|Body Strengthening + Neck Strengthening|Participants assigned to the neck strengthening group will complete additional supervised exercises specifically designed to strengthen the neck.
3016157|NCT02455011|Experimental|REMD-477 Treatment A|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
3016158|NCT02455011|Placebo Comparator|Matching placebo|Placebo administered as single and repeated SC doses in subjects with Type 2 Diabetes
3016159|NCT02455011|Experimental|REMD-477 Treatment B|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
3016160|NCT02455011|Experimental|REMD-477 Treatment C|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
3016161|NCT02455011|Experimental|REMD-477 Treatment D|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
3016162|NCT02455011|Experimental|REMD-477 Treatment E|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
3016163|NCT02454998|Experimental|Orthodontic treatment arm|Previous to the surgical alveolar bone grafting, orthodontic treatment is performed several months before surgery
3016164|NCT02454998|No Intervention|No orthodontic treatment arm|No orthodontic treatment previous to surgical alveolar bone grafting
3016165|NCT02454972|Experimental|lurbinectedin (PM01183)|lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
3016166|NCT02454959|Experimental|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
3016167|NCT02454959|Experimental|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
3016168|NCT02454933|Experimental|MEDI4736 & AZD9291 Combination|10mg/kg q2w (IV) infusion & once daily tablet 80 mg
3016169|NCT02454933|Experimental|AZD9291 Monotherapy|Once daily tablet 80 mg
3016170|NCT02454907|Active Comparator|Control|One kind of communication with the clinic will be used.
3016171|NCT02454907|Experimental|Experimental|A different kind of communication with the clinic will be used.
3016172|NCT02454894|Experimental|Group 1|no anesthesia; postoperative management
3016173|NCT02454894|No Intervention|Group 2|no anesthesia; lying without the pillow and fasting water and food for four hours after lumbar puncture
3016174|NCT02454894|Experimental|Group 3|surface anesthesia with lidocaine; postoperative management
3016175|NCT02454894|Experimental|Group 4|surface anesthesia with lidocaine; lying without the pillow and fasting water and food for four hours after lumbar puncture
3016176|NCT02454881|Active Comparator|Placebo|Oxycodone 1 mg / ml alone
3016177|NCT02454881|Active Comparator|Dexmedetomidine 2.5|Oxycodone 1 mg / mL + Dexmedetomidine 2,5 μg / mL
3016178|NCT02454881|Active Comparator|Dexmedetomidine 5|Oxycodone 1 mg / mL + Dexmedetomidine 5 μg / mL
3016179|NCT02454881|Active Comparator|Dexmedetomidine 10|Oxycodone 1 mg / mL + Dexmedetomidine 10 μg / mL
3016180|NCT02454868|Experimental|Study arm|There is a single study arm. Remifentanil will be infused before intubation. The first patient will receive remifentanil 2mg/kg. If a success occurs the next patient's dose will be decreased by 0.25mg/kg and else it will be increased by 0.25mg/kg. This rule will apply recursively as Dixon's Up-And-Down Method.
3016181|NCT02454855|Experimental|"Group Melatonin"|standard chemotherapy + 3-month of melatonin supplementation
3016182|NCT02454855|Placebo Comparator|"Group Placebo"|standard chemotherapy + placebo (3 months)
3016183|NCT02454842|Experimental|TH-4000 (Tarloxotinib)|TH-4000 (Tarloxotinib), 150 mg/m2 will be administered by IV infusion on Days 1, 8, 15, and 22 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity
3016184|NCT02454829||Adults, gonadotoxic treatment|Women 18 years of age or older who underwent ovarian cortex cryopreservation before gonadotoxic treatment (chemotherapy, radiotherapy)
3016185|NCT02454829||Girls, gonadotoxic treatment|Girls under 18 years of age who underwent ovarian cortex cryopreservation before gonadotoxic treatment (chemotherapy, radiotherapy)
3016186|NCT02454829||Adults, ovarian pathology|Women 18 years of age or older who underwent ovarian cortex cryopreservation for an ovarian pathology not requiring gonadotoxic treatment but surgery
3016187|NCT02454829||Girls, ovarian pathology|Girls under 18 years of age who underwent ovarian cortex cryopreservation for an ovarian pathology not requiring gonadotoxic treatment but surgery
3016188|NCT02454829||Adults, genetic disorders|Women 18 years of age or older who underwent ovarian cortex cryopreservation in the context of a genetic risk of premature ovarian failure
3016189|NCT02454829||Girls, genetic disorders|Girls under 18 years of age who underwent ovarian cortex cryopreservation in the context of a genetic risk of premature ovarian failure
3016190|NCT02454816|Experimental|Single HIV RDT and single syphilis RDT|It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
3016191|NCT02454816|Active Comparator|Dual HIV/syphilis RDT|It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
3016192|NCT02454777|Experimental|ARM I (HIT group)|Participants undergo HIT exercises over 30 minutes, thrice weekly for 8 weeks.
3016193|NCT02454777|Active Comparator|Arm II (Delayed group)|Participants maintain their current sedentary activity level (< 60 minutes of total exercise per week) for 8 weeks. Participants document their weekly activity in an exercise log. Following completion of all study visits, participants are given the option to complete the HIT program as in Arm I.
3016194|NCT02454764|Experimental|Tenofovir + Interferon alpha 2 b|
3016195|NCT02454764|Active Comparator|Tenofovir|
3016196|NCT02454751|Experimental|Pre-fentanyl dose/fentanyl dose|Crossover: 6-six minute walk test, subjective rating of dyspnea, heart rate, respiratory rate, oxygen saturation and participants' general appearance measured before and after a dose of fentanyl.
3016197|NCT02454738|Experimental|Chest CT scan|Two follow-up ultralow dose chest CT scans will be taken 3 months and 1 year after the initial ultralow dose chest CT scan in close contact at high risk for developing multidrug- or extensively drug-resistant tuberculosis.
3016198|NCT02454725|Experimental|Social Network|Leaders of social networks will communicate messages endorsing regular HIV testing to network members.
3016199|NCT02454725|Active Comparator|Comparison|HIV counseling and testing
3016200|NCT02454712|Experimental|PF614|PF614 is the drug under evaluation. Doses may range from 15 mg to 640 mg. N=6 subjects per cohort. For Cohort 7, N=16 subjects in crossover study ± naltrexone.
3016201|NCT02454712|Active Comparator|Oxycodone extended-release (OxyContin)|Initial dose (Cohort 1) will be 10 mg. Subsequent doses will be 10, 20, 40, or 80 mg. N=2 subjects per cohort. Active comparator will not be used in Cohort 7.
3016202|NCT02454699|Experimental|1000mg MBX400|6 subjects receive 1000 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
3016203|NCT02454699|Experimental|100mg MBX400|6 subjects receive 100 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
3016204|NCT02454699|Experimental|350mg MBX400|6 subjects receive 350 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
3016205|NCT02454699|Experimental|750mg MBX400|6 subjects receive 750 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
3016207|NCT02454673||Group B|"3-4 cycles of induction chemotherapy~Radiotherapy with concurrent chemotherapy for 5 weeks~Surgery"
3016208|NCT02454660|Experimental|SMS (Text messaging)|This group will receive text messages during their entire enrollment period in the study.
3016209|NCT02454660|No Intervention|No SMS (No text messages)|This group will not receive text messages during their entire enrollment period in the study.
3016210|NCT02454634|Experimental|IDH1 peptide vaccine|The IDH1 peptide vaccine is a 20mer peptide encompassing the IDH1R132H-mutated region emulsified in Montanide®. It is injected subcutaneously and administered in combination with topical imiquimod. The vaccine is administered 8 times every 2 or 4 weeks.
3016211|NCT02454621|Active Comparator|Control|"Participants read a brief statement designed to encourage them to quit smoking (We want you to plan to quit smoking). Participants are presented with a table with two columns and twenty rows. Twenty critical situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to smoke and identifying ways to overcome those temptations had been shown to promote smoking cessation and are asked to tick critical situations/appropriate responses that might be useful to them."
3016212|NCT02454621|Experimental|Volitional help sheet|"Participants read a brief statement designed to encourage them to quit smoking (We want you to plan to quit smoking). Participants are presented with a table with two columns and twenty rows. Twenty critical situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to smoke and identifying ways to overcome those temptations had been shown to promote smoking cessation. Implementation intentions are formed by linking critical situations with appropriate responses by drawing lines between critical situations and appropriate responses."
3016213|NCT02454608|Experimental|Treatment|Verapamil HCl, capsules for oral administration, 80mg, TID, for 8 weeks
3016214|NCT02454608|Placebo Comparator|Control|Placebo, capsules for oral administration, TID, for 8 weeks
3016215|NCT02454608|Experimental|Open Label|Verapamil HCl, capsules for oral administration, 80mg, TID, for 1 year
3016216|NCT02454582|Other|Group 1|15min without CPAP, then 15min with CPAP NIRS measurement, Somanetics INVOS Cerebral Oxymeter 5100C
3016217|NCT02454582|Other|Group 2|15min with CPAP, then 15min without CPAP NIRS measurement, Somanetics INVOS Cerebral Oxymeter 5100C
3016218|NCT02454556|Experimental|FOLITIME®|Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.
3016219|NCT02454556|Active Comparator|Gonal-F®|Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.
3016220|NCT02454543|Other|Radical prostatectomy and BST|BST plus radical prostatectomy with ext. lymphadenectomy
3016221|NCT02454543|Other|Best Systemic Therapy (BST)|e.g. Androgen deprivation therapy, chemotherapy, others
3016222|NCT02454530||Cancer patients treated with Nivestim®|
3016223|NCT02454517|Experimental|Arm I (diet and exercise lifestyle intervention)|The goals of the diet and exercise lifestyle intervention is for patients to lose 7% total body weight. Patients meet with a nutritionist 11 times during the first 6 months to receive the structured diet and exercise instruction. Participants complete exercise sessions supervised by an exercise specialist, and will wear a heart rate monitor periodically during the study.
3016224|NCT02454517|Active Comparator|Arm II (control)|Patients receive an informational intervention along with a 20-30 minute individual session with a dietitian and a goal of 30 minutes of physical activity 5 days a week.
3016225|NCT02454504|Active Comparator|sugammadex|this arm will receive sugammadex at the end of the surgery
3016226|NCT02454504|Active Comparator|neostigmine|this arm will receive neostigmine at the end of the surgery
3016227|NCT02454491|Active Comparator|standard of care|intraradial heparin (5000 UI) immediately after a 6 F sheath insertion
3016228|NCT02454491|Experimental|experimental therapy|intraradial verapamil (5 mg) immediately after a 6 F sheath insertion
3016229|NCT02454478|Experimental|Lenvatinib plus Everolimus|
3016230|NCT02454465|Experimental|Intervention group|The first group at the top of the waiting list will receive the Acceptance and Commitment Therapy group intervention, which is 1 hour per week for six weeks.
3016231|NCT02454465|No Intervention|Waiting list group|The outcomes of those on the waiting list will be compared with those in the intervention group. Once the intervention group completes, those on the waiting list will be invited to attend the Acceptance and Commitment Therapy group intervention.
3016232|NCT02454452|Active Comparator|Saphenous vein stripping|Saphenous venous stripping surgical technique
3016233|NCT02454452|Active Comparator|CHIVA|conservative hemodynamic treatment venous insufficiency (CHIVA)
3016234|NCT02454452|Experimental|Radiofrequency|Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
3016235|NCT02454439|Experimental|CRT-D or CRT-P ON|This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
3016236|NCT02454439|Other|CRT-D or CRT-P OFF|This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
3016237|NCT02454426|Experimental|Open-Label Treatment|Patients will be initiated on vortioxetine 5 mg/day for 4 days, then increased to 10 mg/day. After the week 2 visit, patients will then be increased to 20 mg/day for the remainder of the study
3016238|NCT02454413|Sham Comparator|brush + water|denture brushing with water and soap + overnight storage in water
3016239|NCT02454413|Active Comparator|brush + cleansing tablet|denture brushing with water and soap + overnight storage in water with a cleansing tablet
3016240|NCT02454413|Sham Comparator|ultrasonic cleaning + water|ultrasonic denture cleaning + overnight storage in water
3016241|NCT02454413|Active Comparator|ultrasonic cleaning + cleansing tablet|ultrasonic denture cleaning + overnight storage in water with a cleansing tablet
3016242|NCT02454400|Other|Pre-surgery physiotherapy|Twice a week, in 9 weeks
3016244|NCT02454387|Experimental|Experimental: ONO-4474 Part A1|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
3016245|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part A1|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
3016246|NCT02454387|Experimental|Experimental: ONO-4474 Part A2|Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
3016247|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part A2|Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
3016248|NCT02454387|Experimental|Experimental: ONO-4474 Part B|Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
3016249|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part B|Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
3016250|NCT02454387|Experimental|Experimental: ONO-4474 Part C|NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
3016251|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part C|NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
3016252|NCT02454387|Experimental|Experimental: ONO-4474 Part D|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
3016253|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part D|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
3016254|NCT02454374|Experimental|Knee Loading|Progressive joint loading intervention will be taught by a program of exercises by the treating physiotherapist. The intervention consists of knee flexion (bending) and knee extension (straightening). Participants will be assessed for their immediate response to treatment during each assessment or treatment session and advised on the appropriate level of self-directed exercises to be performed twice daily. The clinician will review the patient at follow up appointments during the treatment period, progressing to the next level of exercises or by increasing intensity, duration or repetitions as appropriate. The physiotherapist will encourage compliance during the treatment period and beyond
3016255|NCT02454374|Active Comparator|Routine physiotherapy care|Normal care delivered to the control group will be based on current NICE guidelines (2014) for non-pharmacological management of OA which includes verbal and written advice/education; education regarding weight loss; exercise to include local muscle strengthening and general aerobic fitness; with or without manual therapy. Clinicians will be asked to refrain from using the progression of techniques specifically documented in the progressive loading protocol (not currently considered to constitute 'normal care'). Treating clinicians will be asked to record specific exercises and manual therapy techniques employed in the patient's records. Participants will be asked to complete a home treatment record sheet.
3016256|NCT02454361|Experimental|KBP-7072 cohort 1|KBP-7072 by mouth once
3016257|NCT02454361|Experimental|KBP-7072 cohort 2|KBP-7072 by mouth once
3016258|NCT02454361|Experimental|KBP-7072 cohort 3|KBP-7072 by mouth once
3016259|NCT02454361|Experimental|KBP-7072 cohort 4|KBP-7072 by mouth once
3016260|NCT02454361|Experimental|KBP-7072 cohort 5|KBP-7072 by mouth once
3016261|NCT02454361|Experimental|KBP-7072 Fed Group|KBP-7072 by mouth once to the fed group
3016262|NCT02454348|Active Comparator|Norepinephrine and vasopressin|Norepinephrine (0.05 to 0.5 mcg/kg/min) and vasopressin (0.04 units/min) will be given by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg).
3016263|NCT02454348|Active Comparator|Norepinephrine|Norepinephrine (0.05 to 0.5 mcg/kg/min) will be given by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg).
3016264|NCT02454335|Active Comparator|Anterior Approach|For the anterior approach, an incision will be made in the 1 to 2 o'clock position of the esophageal wall.
3016265|NCT02454335|Active Comparator|Posterior Approach|For the posterior approach, a mucosal incision will be made at the 5 to 6 o'clock position
3016266|NCT02454322||Magnesium|Hypertensive Disorder of Pregnancy (gestational hypertension or preeclampsia) Treated with Magnesium Sulfate
3016267|NCT02454322||No Magnesium|Hypertensive Disorder of Pregnancy (gestational hypertension or preeclampsia) Not Treated with Magnesium Sulfate
3016268|NCT02454309|Experimental|Cranberry concentrate|Each capsule contains 500 mg of cranberry powder at a concentration ratio of 36:1 (36 grams of cranberries equals 1 gram of concentrate)
3016269|NCT02454309|Placebo Comparator|Placebo|A capsule containing control formulation
3016270|NCT02454296|Active Comparator|Paracervical Block with lidocaine|A paracervical block will be done prior to the placement of laminaria with 1% lidocaine and sodium bicarbonate.
3016271|NCT02454296|Sham Comparator|Sham paracervical block|A sham block will be done prior to the placement of laminaria using a capped needle
3016272|NCT02454283|Experimental|Vanoxerine HCl|Vanoxerine HCl, 400 mg (2 x 200 mg capsules), orally, single dose
3016273|NCT02454283|Placebo Comparator|Placebo|identically matching placebo capsules, orally, single-dose
3016274|NCT02454270|Experimental|Dose Escalation: Participants With Certain B-Cell Malignancies|During accelerated dose titration in Group 1, participant will receive duvortuxizumab starting at 0.5 nanogram per kilogram (ng/kg) for biweekly dosing. Dose will be increased by half logarithmic steps in subsequent Dose Level (DL). After safety stopping criteria are met, Dose Escalation (DE) in Group 1 will transition to 3+3 design, and will continue until the Maximum tolerated Dose (MTD) is defined. DE in Groups 2 and 3 will follow 3+3 design, begin after initial dose level in Group 1 is deemed safe and recommended phase 2 doses (RP2D) for Part 1 of study can be decided. Duvortuxizumab at a starting dose of 50 ng/kg weekly will also be investigated in Group 1 and will follow 3+3 study design continue until the MTD or Maximum administered dose (MAD) is reached. Disease-specific dose escalation in Group 2 and 3 will not be initiated until dose in Group 1 is determined safe.
3016275|NCT02454270|Experimental|Dose Expansion: Diffuse-Large B-Cell Lymphoma Participants|Participants with Diffuse-Large B-Cell Lymphoma (DLBCL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
3016276|NCT02454270|Experimental|Dose Expansion: Follicular Cell Lymphoma Participants|Participants with Follicular Cell Lymphoma (FL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
3016277|NCT02454270|Experimental|Dose Expansion: Mantle Cell Lymphoma Participants|Participants with Mantle Cell Lymphoma (MCL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
3016278|NCT02454270|Experimental|Dose Expansion: Chronic Lymphocytic Leukemia Participants|Participants with Chronic Lymphocytic Leukemia (CLL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
3016279|NCT02454270|Experimental|Dose Expansion: Acute Lymphoblastic Leukemia Participants|Participants with Acute Lymphoblastic Leukemia (ALL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
3016280|NCT02454257||Admission to ICU|Patients admitted to an adult critical care unit or cardiothoracic critical care unit
3016281|NCT02454257||In-hospital cardiac arrest|Patients experiencing an in-hospital cardiac arrest
3016282|NCT02454244|Experimental|Amygdala Retraining Technique (ART) with Mindfulness|Consists of 10 weekly sessions, followed by 3 monthly sessions
3016283|NCT02454244|Experimental|Mindfulness Compassion|Includes the attentional training aspect of mindfulness and meditation practices, proved to bring benefits in relation to fibromyalgia and CFS symptoms, as fatigue and pain. Compassion training focuses on the ability to be kind to participants and their own experience, specifically to their experience of suffering. The protocol consists of 10 weekly sessions, followed by 3 following monthly sessions
3016284|NCT02454244|Active Comparator|Relaxation|Consists of 10 weekly sessions, followed by 3 monthly sessions
3016285|NCT02454231|Experimental|peripheral blood EPC injection|
3016286|NCT02454231|Active Comparator|bone marrow MNC injection|
3016287|NCT02454218|Active Comparator|Transcranial Direct Current Stimulation|The intensity of the asset is little perceived and painless.
3016288|NCT02454218|Placebo Comparator|Simulation Transcranial Current|Will receive only simulation.
3016289|NCT02454205|Active Comparator|Conventional treatment 21-24 months|"Participants will receive a six to eight month intensive phase of:~Kanamycin IM 500-750mg (40-50kg) or 1000mg (51-90kg) daily, Moxifloxacin 400mg od, Pyrazinamide 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily, Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.~The continuation phase of 4 oral drugs will start after two consecutive negative sputum cultures and continue for 18 months with Moxifloxacin, PZA, Ethionamide and Terizidone. Other WHO group 5 drugs will used if considered necessary by the attending clinician."
3016290|NCT02454205|Experimental|Interventional treatment 6-9 months|"Participants will receive six to nine months of oral:~Linezolid 600mg daily (reduce to 300mg if toxicity occurs), Bedaquiline 400mg for 2 weeks, followed by 200mg three times per week, Levofloxacin 750mg (<50kg) or 1000mg (>50kg) daily, PZA 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 15mg/kg (max 900mg) daily, or high-dose Isoniazid 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily, or Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.~A gene-directed diagnostic approach will be used in the interventional arm to individualise therapy and to inform on the use of high dose INH versus ethionamide. Treatment will stop after 3 consecutive negative sputum cultures."
3016291|NCT02454192|Other|CHAMPS Intervention|Tailored asthma education and counseling for children with moderate to severe asthma who have confirmed allergies to environmental triggers present in their homes provided through a combination of clinic and home visits
3016292|NCT02454192|No Intervention|Usual Care|Usual asthma care and management
3016293|NCT02454179|Experimental|Arm 1|pembrolizumab
3016294|NCT02454179|Experimental|Arm 2|acalabrutinib in combination with pembrolizumab
3016295|NCT02454153|Active Comparator|REMStar Postive Airway Pressure|Positive pressure therapy is the standard of care for managing obstructive sleep apnea.
3016296|NCT02454153|Other|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
3016297|NCT02454140|Experimental|Cohort 1|SBRT 40 Gy in 5 fractions
3016298|NCT02454140|Experimental|Cohort 2|SBRT 45 Gy in 5 fractions (starting dose level)
3016299|NCT02454140|Experimental|Cohort 3|SBRT 50 Gy in 5 fractions
3016300|NCT02454140|Experimental|Cohort 4|SBRT 55 Gy in 5 fractions
3016301|NCT02454140|Experimental|Cohort 5|SBRT 60 Gy in 5 fractions
3016302|NCT02454127|Active Comparator|Atkins Diet|Atkins Diet (dietary counseling)
3016303|NCT02454127|Active Comparator|Zone Diet|Zone Diet (dietary counseling)
3016304|NCT02454127|Active Comparator|Weight Watchers Diet|Weight Watchers Diet (dietary counseling)
3016305|NCT02454127|Active Comparator|Ornish Diet|Ornish Diet (dietary counseling)
3016306|NCT02454114|Active Comparator|Standard Hospital Care (SHC)|All management and discharge decisions will be made by the patient's usual hospital team. Clinical tests will be performed at the discretion of the medical team. If any significant or concerning clinical issues are noted during study team's visits, the usual medical team will be alerted. Patients receiving SHC will be discussed at weekly case note MDT meeting and followed-up on discharge in the 'Respiratory Infection' out-patient clinic (in the patient's own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.
3016307|NCT02454114|Active Comparator|HOMEFIRST|"Patients randomised to HOMEFIRST care will initially receive up to twice daily visits for the first 48 hours. After this, the frequency and duration of visits will depend on clinical need but not exceed 5 days. The study nurse will establish the need for the involvement of other MDT members. Laboratory tests will be performed as clinically indicated. Venepuncture will be performed for clinical purposes as needed.~Patients will be discussed at a weekly case-note MDT meeting and followed-up on discharge in the 'Respiratory Infection' out-patient clinic (in the patient's own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.~Patients are either discharged from HOMEFIRST, readmitted or handed over to their community care team at the end of the intervention."
3016308|NCT02454101|Other|cord milking|milking of the umbilical cord 5 times toward the neonate
3016309|NCT02454101|Other|delayed cord clamping|delayed cord clamping for 120 seconds
3016310|NCT02454088|Active Comparator|Triamcinolone acetate|Injection of Calcium hydroxylapatite with Triamcinolone acetate
3016311|NCT02454088|Placebo Comparator|Placebo|Injection of Calcium hydroxylapatite with a placebo
3016312|NCT02454075|Experimental|Eligible patients|The dose will be 100 mg YF476 once daily. When 6 patients have completed 12 weeks' treatment with that dose, it may be increased to 150 or 200 mg once daily. Patients will have type II gastric carcinoids and/or ECL cell hyperplasia/dysplasia.
3016744|NCT02451267|Active Comparator|negative CPR: control group|physical therapy treatment
3016313|NCT02454062|Experimental|Dose Escalation TAS-114 (PART 1)|Each cycle will be 21 days: 14 days of treatment and 7 days recovery. TAS-114 and S-1 will be escalated according to a defined dosing table and specific DLT criteria.
3016314|NCT02454062|Experimental|Expansion phase TAS-114 (PART 2)|"The TAS-114 and S-1 MTD established in the Dose Escalation Phase will be administered BID for 14 days followed by a 7 day recovery period.~This regimen is repeated every 21 days thereafter. Approximately 40 to 60 evaluable patients will be enrolled in the Expansion Phase. PGx, PD and PK analysis will be performed based on specific criteria."
3016315|NCT02454049|Active Comparator|beetroot juice|beetroot juice containing 6mmol nitrate, ingested 3hours before the exercise test
3016316|NCT02454049|Active Comparator|sodium nitrate|6mmol sodium nitrate dissolved in plain water, ingested 3hours before the exercise test
3016317|NCT02454049|Placebo Comparator|water|85ml of plain water, ingested 3 hours before the exercise test
3016318|NCT02454036|Experimental|BBI Intervention|Biobehavioral Intervention
3016319|NCT02454023|Active Comparator|Standard of care|Patients receive usual standard of care for investigating obstructive sleep apnea after stroke/transient ischemic attack, which is in-laboratory polysomnography.
3016320|NCT02454023|Experimental|Portable sleep monitor (ApneaLink Air)|Patients will undergo screening for obstructive sleep apnea using the ApneaLink Air portable sleep monitor.
3016321|NCT02454010|Experimental|Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101
3016322|NCT02454010|Experimental|2X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 2X the lowest dose
3016323|NCT02454010|Experimental|3X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 3X the lowest dose
3016324|NCT02454010|Experimental|4X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 4X the lowest dose
3016325|NCT02454010|Experimental|5X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 5X the lowest dose
3016326|NCT02453984|Experimental|1|89Zr-MPDL3280A-PET scan
3016327|NCT02453971|Experimental|eCHUG-D|The eCHUG group is requested to conduct the German Version of eCHECKUP TO GO and to fill in their code on the last page of the program.
3016328|NCT02453971|No Intervention|control|It is an assessment only condition.
3016329|NCT02453958|Experimental|mTBI-diagnosed group|Subjects diagnosed with mTBI were assessed with a multi-modal assessment system.
3016330|NCT02453958|Experimental|non mTBI-diagnosed group|Non-concussed subjects were assessed with a multi-modal assessment system.
3016331|NCT02453945|Experimental|Medical Support Bra|ClearPoint Medical Support Bra worn by patients during their post-cardiac surgery hospital stay (approximately 5-7days).
3016332|NCT02453945|No Intervention|Control|Usual Care
3016333|NCT02453932|Experimental|Tianzhi granule|Tianzhi granule and placebo identified to donepezil
3016334|NCT02453932|Active Comparator|Donepezil|Donepezil and placebo identified to Tianzhi granule
3016335|NCT02453932|Placebo Comparator|Placebo|Placebo identified toTianzhi granule and placebo identified to donepezil
3016336|NCT02453919||RECOVIH|"Complete cardiac examination including echocardiography, ischemia tests, and ambulatory blood pressure monitoring.~Collection of clinical information and biochemical laboratory results."
3016337|NCT02453906|Experimental|healthy subjects|they receive XNKQ acupuncture, as well as control 1, control 2, and control 3 in a randomized order.
3016338|NCT02453893|Experimental|oral iloperidone|2~12mg/day for 2 weeks,12~24mg/day for 6 weeks.
3016339|NCT02453893|Active Comparator|oral risperidone|1~3mg/day for 2 weeks,3~6mg/day for 6 weeks.
3016340|NCT02453880|Experimental|Web-based Cognitive Behavioral Therapy|"Participants will be directed to a web-based CBT self-help program with weekly modules."
3016341|NCT02453867|Active Comparator|Standard immunosuppression|starting immunosuppression: tacrolimus (Advagraf) (target trough levels >5 ng/ml), mycophenolate mofetil >1g/d in MMF or >720 mg/d in mycophenolic acid, steroids from month 1-3 dosing according to local practice; 200 pts are planned to carry on with standard immunosuppression (tacrolimus (Advagraf), Mycophenolate, steroids) as stated above according to international guidelines for kidney transplant recipients from month 3 posttransplant to month 12 posttransplant
3016342|NCT02453867|Experimental|Reduced immunosuppression|"The Intervention is stopping medication:~200 pts are planned to receive a reduced immunosuppression after month 3: carry on with tacrolimus (Advagraf; trough levels >5 ng/ml) steroids stop at month 3 mycophenolate stop at month 6"
3016343|NCT02453854|Active Comparator|Treatment as Usual|A Treatment as Usual (TAU) group received a psycho-educational programme for weight management over one year
3016344|NCT02453854|Experimental|Group Motivational Intervieiwng|A Motivational interviewing group received one year of programme using motivational interviewing as the approach for treatment.
3016345|NCT02453841|Active Comparator|FESS|Patients undergoing functional endoscopic sinus surgery and receiving oxymetazoline as part of their surgery.
3016346|NCT02453841|Active Comparator|Turbinates|Patients undergoing turbinate reduction surgery and receiving oxymetazoline as part of their surgery.
3016347|NCT02453841|Active Comparator|Adenoidectomy|Patients undergoing an adenoidectomy and receiving oxymetazoline as part of their surgery.
3016348|NCT02453828|Experimental|Checklist|after non-cardiac surgery, patients will have current standard-of-care anesthesia handover during anesthesia transitions in care with an additional, electronically pre-populated checklist displayed on the anesthesia record keeping system
3016349|NCT02453828|Active Comparator|Standard of Care|after non-cardiac surgery, patients will have current standard-of-care anesthesia handover during anesthesia transitions in care
3016350|NCT02453815|Experimental|arterial catheter|If a patient is randomized by the web-based system before non-cardiac surgery to receive an arterial catheter at surgery, then the subject will be placed in the experimental arm of the study.
3016351|NCT02453815|Placebo Comparator|no arterial catheter|If a patient is randomized by the web-based system before non-cardiac surgery to not receive an arterial catheter at the time of surgery, then the subject will be placed in the placebo comparator arm of the study.
3016746|NCT02451254|Active Comparator|control|patients electively admitted for SVT ablation
3016352|NCT02453802|Active Comparator|Topic TXA group|"Primary total knee replacement with intravenous 0.9% normal saline (20 ml) administration before deflation of the tourniquet and intraarticular application of Tranexamic Acid 5%,5ml/amp 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
3016353|NCT02453802|Active Comparator|IV TXA group|"Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously before deflection of the tourniquet and topical 160 ml 0.9% normal saline application after closure of joint capsule.~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
3016354|NCT02453802|Placebo Comparator|Control group|"Primary total knee replacement with 0.9% normal saline administration intravenously before deflation of the tourniquet and topical 160 ml 0.9% normal saline application after closure of joint capsule.~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
3016355|NCT02453789|Active Comparator|Alginate oligosaccharide|Inhalation of a dry powder OligoG in the first treatment period, and placebo in the second period
3016356|NCT02453789|Placebo Comparator|Placebo|Inhalation of placebo dry powder in the first treatment period, and OligoG in the second period
3016357|NCT02453776|Experimental|PRECISION dosing|Infliximab may vary between 1-10 mg/kg and the interval between 4 and 12 weeks.
3016358|NCT02453776|No Intervention|Conventional dosing of Infliximab|Infliximab 5 mg/kg every 8 or 6 weeks
3016359|NCT02453763||Transcranial direct current stimulation|All participants will receive transcranial direct current stimulation and an magnetic resonance imaging (MRI).
3016360|NCT02453750|Experimental|Hypersaline and Bronchodilator Response|After the subject has performed post-bronchodilator spirometry, they will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer.
3016361|NCT02453737|Other|Catheter-based brachytherapy APBI|7 Gy x 3 fractions
3016362|NCT02453737|Other|3D-CRT APBI|7.3 Gy x 3 fractions
3016363|NCT02453737|Other|Proton APBI|7.3 Gy x 3 fractions
3016364|NCT02453711|Experimental|Sema 0.05 mg|Dose 0.05 mg
3016365|NCT02453711|Experimental|Sema 0.1 mg|Dose 0.05 or 0.1 mg with dose escalation every fourth week
3016366|NCT02453711|Experimental|Sema 0.2 mg|Dose 0.05, 0.1 or 0.2 mg with dose escalation every fourth week
3016367|NCT02453711|Experimental|Sema 0.3 mg|Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every fourth week
3016368|NCT02453711|Experimental|Sema 0.4 mg|Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every fourth week
3016369|NCT02453711|Experimental|Sema 0.3 mg (fast dose escalation)|Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every second week
3016370|NCT02453711|Experimental|Sema 0.4 mg (fast dose escalation)|Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every second week
3016371|NCT02453711|Active Comparator|Lira 3.0 mg|Dose 0.6, 1.2, 1.8, 2.4, 3.0 mg with dose escalation every week
3016372|NCT02453711|Placebo Comparator|Placebo Sema 0.05 mg|Placebo arm matching active arm Sema 0.05 mg
3016373|NCT02453711|Placebo Comparator|Placebo Sema 0.1 mg|Placebo arm matching active arm Sema 0.1 mg
3016374|NCT02453711|Placebo Comparator|Placebo Sema 0.2 mg|Placebo arm matching active arm Sema 0.2 mg
3016375|NCT02453711|Placebo Comparator|Placebo Sema 0.3 mg|Placebo arm matching active arm Sema 0.3 mg
3016376|NCT02453711|Placebo Comparator|Placebo Sema 0.4 mg|Placebo arm matching active arm Sema 0.4 mg
3016377|NCT02453711|Placebo Comparator|Placebo Sema 0.3 mg (fast dose escalation)|Placebo arm matching active arm Sema 0.3 mg (fast dose escalation)
3016378|NCT02453711|Placebo Comparator|Placebo Sema 0.4 mg (fast dose escalation)|Placebo arm matching active arm Sema 0.4 mg (fast dose escalation)
3016379|NCT02453711|Placebo Comparator|Placebo Lira 3.0 mg|Placebo arm matching active arm Lira 3.0 mg
3016380|NCT02453698|Experimental|Methylphenidate|
3016381|NCT02453698|Placebo Comparator|Control Group|
3016382|NCT02453685|Experimental|BIAsp|
3016383|NCT02453685|Active Comparator|IGlar + IAsp|
3016384|NCT02453672|Experimental|SB8|SB8, single dose of 3 mg/kg, IV infusion
3016385|NCT02453672|Active Comparator|EU Sourced Avastin®|EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
3016386|NCT02453672|Active Comparator|US Sourced Avastin®|US Sourced Avastin®, single dose of 3 mg/kg, IV infusion
3016387|NCT02453659|Experimental|Distress Tolerance Treatment for Weight Concern (DT-W)|DT-W is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes distress tolerance intervention for weight concern plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
3016388|NCT02453659|Active Comparator|Health Education (HE)|HE is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes smoking health education program plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
3016389|NCT02453646|Experimental|NexSite HD Patients|NexSite HD patient catheter device placement
3016390|NCT02453633|Experimental|Emotional SMS text|Patients in this arm will receive an emotion-based SMS reminder of their scheduled outpatient clinic appointment.
3016391|NCT02453633|Active Comparator|Standard SMS text|Patients in this arm will receive the standard SMS reminder of their scheduled outpatient clinic appointment.
3016392|NCT02453620|Experimental|Treatment (entinostat, nivolumab, ipilimumab)|Patients receive entinostat PO on days -14 and -7 and then weekly, nivolumab IV over 60 minutes on day 1 and then every 2 weeks, and ipilimumab IV over 90 minutes on day 1 and then every 6 weeks for 4 doses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3016393|NCT02453607||CD Monotherapy|Crohn's disease treated with infliximab (monotherapy)
3016394|NCT02453607||CD Combo therapy|Crohn's disease treated with infliximab in combination with thiopurine (a 6MP metabolite) (combo therapy)
3016395|NCT02453594|Experimental|Cohort 1|Participants with RRcHL who failed to achieve a response or progressed after auto-SCT and have relapsed after treatment with or failed to respond to BV post auto-SCT received pembrolizumab, 200 mg, intravenously (IV) every 3 weeks (Q3W) on Day 1 of each 21-day cycle for up to 24 months.
3051887|NCT02214953|Experimental|BI 11634 ER formulation M|
3016396|NCT02453594|Experimental|Cohort 2|Participants with RRcHL who were unable to achieve CR or PR to salvage chemotherapy and did not receive auto-SCT, but have relapsed after treatment with or failed to respond to BV received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months.
3016397|NCT02453594|Experimental|Cohort 3|Participants with RRcHL who failed to achieve a response to or progressed after auto-SCT and have not received BV post auto-SCT received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months. These participants may or may not have received BV as part of primary treatment or salvage treatment.
3016398|NCT02453581|Experimental|OZ439 100mg|OZ439 100mg Powder for Oral Suspension
3016399|NCT02453581|Experimental|OZ439 200mg|OZ439 200mg Powder for Oral Suspension
3016400|NCT02453581|Experimental|OZ439 500mg|OZ439 500mg Powder for Oral Suspension
3016401|NCT02453555|Active Comparator|Linagliptin|patient to receive 5 mg linagliptin once daily
3016402|NCT02453555|Experimental|Empagliflozin + linagliptin low dose|patient to receive one tablet once daily
3016403|NCT02453555|Experimental|Empagliflozin + linagliptin high dose|patient to receive one tablet once daily
3016404|NCT02453529|Experimental|WCK 4873|Oral tablets
3016405|NCT02453516|Experimental|Serratus Block Group|Patients will receive a preoperative ultrasound-guided serratus block with 0.4ml/kg (max.30ml) of ropivacaine 0.5% with 1:4000,000 epinephrine injected between the serratus anterior (superficial) and external intercostal (deep) muscles followed by subsequent general anesthesia
3016406|NCT02453516|Placebo Comparator|Placebo Block - Control Group|Patients will receive a preoperative placebo injection with a subcutaneous injection of 1ml normal sterile saline solution in the midaxillary line and the ultrasound probe will be used to simulate the pressure and block duration associated with the serratus block. These patients will then receive general anesthesia.
3016407|NCT02453503|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
3016408|NCT02453503|Experimental|Licorice|Licorice mucoadhesive films 1 mg every 6 hours for two weeks.
3016409|NCT02453490|Experimental|Raltitrexed-based chemotherapy|Raltitrexed plus Oxaliplatin/Raltitrexed plus Irinotecan
3016410|NCT02453490|Active Comparator|5-fluorouracil-based chemotherapy|5-fluorouracil plus Oxaliplatin/5-fluorouracil plus Irinotecan
3016411|NCT02453477|Experimental|Adults|"≥18 years (3 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.~The product will be injected intraosseously."
3016412|NCT02453477|Experimental|Elderly children|"8-17 years (3 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.~The product will be injected intraosseously."
3016413|NCT02453477|Experimental|Younger children|"3-7 years (4 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.~The product will be injected intraosseously."
3016414|NCT02453464|Experimental|Sevacizumab+FOLFIRI|Two weeks as one cycle. Cycle 1: FOLFIRI on day1-2, Sevacizumab on day3; Cycle 2 and after: Sevacizumab on day 1, and then FOLFIRI on day1-2
3016415|NCT02453451|Experimental|2D-/3D-TTE; 3D-TEE, Walking Test|6 months after the MitraClip procedure
3016416|NCT02453425|Active Comparator|60 mmHg|Norepinephrine adjusted to reach MAP 60 mmHg
3016417|NCT02453425|Active Comparator|75 mmHg|Norepinephrine adjusted to reach MAP 75 mmHg
3016418|NCT02453425|Active Comparator|90 mmHg|Norepinephrine adjusted to reach MAP 90 mmHg
3016419|NCT02453412|No Intervention|Control|Standard care in operative planning in AVF creation, that is physical examination and extensive duplex examination of the arm vasculature carried out by an experience vascular technician.
3016420|NCT02453412|Experimental|Simulation|Standard care with the intervention of advisement of the preferred AVF-configuration, based on computational model simulation for predicting postoperative flow (AVF-simulation).
3016421|NCT02453386|Experimental|Tozadenant 60 mg BID|"During Part A, patients will take two (2) tablets, one 60 mg tozadenant and one placebo, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
3016422|NCT02453386|Experimental|Tozadenant 120 mg BID|"During Part A, patients will take two (2) tablets of 60 mg tozadenant, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
3016423|NCT02453386|Placebo Comparator|Placebo BID|"During Part A, patients will take two (2) tablets of placebo, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
3016424|NCT02453373|Experimental|ThermoSuit Cooling Induction|Induction of therapeutic hypothermia (32-34 degrees C) using the LRS ThermoSuit System. Prior to initiating hypothermia, Magnesium Sulfate will be administered intravenously to control shivering and tPA administered intravenously (if indicated). Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort. Neurothrombectomy will be performed if indicated.
3016425|NCT02453373|No Intervention|Historical Control|Historical patients treated for ischemic stroke using conventional medical treatments, but without induced hypothermia.
3016426|NCT02453360|Experimental|5 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
3016510|NCT02452775|Experimental|Arm 3|subjects in ARM3 will receive vaccination with OC-L admixed with 1 mg poly-ICLC (Hiltonol)
3016427|NCT02453360|Experimental|10 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
3016428|NCT02453360|Experimental|20 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
3016429|NCT02453347|Experimental|CES Therapy|All participants will complete CES treatment over the course of four weeks. Assessments will take place at baseline and at post-test four weeks later.
3016430|NCT02453334|Experimental|Injectafer|2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.
3016431|NCT02453334|Placebo Comparator|Normal Saline|Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.
3016432|NCT02453321|Active Comparator|Cont. Femoral Block - Low Dose Group|Arm is named by the intervention the group receives. Continuous Femoral Block - Low Dose. The Block/catheter is placed about 5cm below groin at ultrasonographic apex of femoral triangle. Rate of 2ml/hr of bupivacaine 0.0625% until morning of POD#2.
3016433|NCT02453321|Experimental|Cont. Femoral Block - Higher Dose|Place the CPNB in same manner as low-dose group, but rate will be 4ml/hr. Hypothesis is that this group may experience better pain control, but likely will have more dense motor blockade of thigh and less participation in physical therapy
3016434|NCT02453321|Experimental|Continuous Adductor Canal|Placed at mid-thigh in proximal adductor canal near femoral artery with a bupivacaine infusion rate of 4ml/hr. Hypothesis is that this group may experience less motor blockade of thigh but may have more pain than the femoral nerve groups.
3016435|NCT02453308|Active Comparator|ACT-arms|"1.1 Artemether-lumefantrine for 3 days.~1.2 Dihydroartemisinin-piperaquine for 3 days~1.3 Artesunate-Mefloquine for 3 days"
3016436|NCT02453308|Active Comparator|TACT-arms|"2.1: Artemether-lumefantrine for 3 days.plus: Amodiaquine for 3 days.~2.2: Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days.~2.3 Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days."
3016437|NCT02453295|Experimental|Intervention Group|The IG will meet weekly for 2 hours for 8 weeks. All workshops will be recorded and transcribed, then analyzed qualitatively. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will take place over the phone. The questionnaires will be administered 3 days prior to workshop 1 (T0), between workshop 4 and 5 (T1), and 3 days following the completion of the intervention (T2). The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2.
3016438|NCT02453295|No Intervention|Comparison Group|The CG will receive LE treatment as usual, without the hope intervention. They will be administered the same questionnaires (by phone) as the IG at the same timepoints. Potential participants (n=46) will be screened based MIQ. The individuals scoring in the top ~30% (n=16) will be excluded from the study. The remaining 30 individuals scoring the lowest level of hope will be admitted into the study.
3016439|NCT02453282|Experimental|Monotherapy|PD-L1 monoclonal Antibody monotherapy.
3016440|NCT02453282|Experimental|Combination Therapy|PD-L1+Tremelimumab combination therapy
3016441|NCT02453282|Active Comparator|Standard of Care|Standard of Care chemotherapy treatment
3016442|NCT02453269|Experimental|Transdisciplinary program|"Children in G1 were submitted to a transdisciplinary intervention once a week. Each child received a nutritional education kit including four games (Cool Diet, a board game, a memory game and a word search puzzle) and an interactive booklet containing)."
3016443|NCT02453269|No Intervention|Control group|The children in the control group (G2) were not exposed to interventions.
3016444|NCT02453256|Placebo Comparator|Double-Blind Placebo|Participants will receive double-blind matching placebo from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
3016445|NCT02453256|Experimental|Double-Blind Tocilizumab|Participants will receive double-blind tocilizumab from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
3016446|NCT02453243|No Intervention|Baseline|Retrospective Chart Reviews will be conducted for the period between the original ED-SAFE and the new study to test the long-term sustainability of nurse administered universal screening implemented in the original study.
3016447|NCT02453243|Other|Intervention|"Safety Plan Intervention: Clinician training in safety planning, and~A Lean Implementation Strategy: The Implementation of the safety planning guided by Lean~Combine, this is expected to increase safety planning by clinicians."
3016448|NCT02453243|No Intervention|Maintenance|Test sustainability of safety planning during the Maintenance phase.
3016449|NCT02453230|Active Comparator|light on|BPP done with lights on
3016450|NCT02453230|No Intervention|light off|Biophysical profile examinations done with the light off
3016451|NCT02453217|Experimental|Chinese CHIP|Chinese Health Improvement Profile (CHIP) screening and intervention
3016452|NCT02453217|No Intervention|Treatment as usual|Routine community mental health care and medical outpatient appointments
3016453|NCT02453204|Experimental|Sitting|Participants will remain sitting throughout the test period whilst undertaking typical sedentary behaviours such as watching TV, using a computer, reading and writing. Walking and standing will be restricted.
3016454|NCT02453204|Experimental|Standing|Participants will be asked to break their sitting time by standing for five minutes every 30 minutes. Participants will be asked to stand in the same position with no further instructions provided. In total, individuals will accumulate 12 bouts (60 minutes) of standing throughout the test period.
3016455|NCT02453204|Experimental|Walking|The walking condition will be identical to standing, but the breaks in sitting time will be punctuated with five minute bouts of self-paced walking rather than standing.
3016456|NCT02453191|Experimental|Treatment|talimogene laherparepvec in combination with radiotherapy
3016511|NCT02452775|Experimental|Arm 4|subjects in ARM 4 will receive vaccination with OC-L admixed with both Montanide and 1 mg poly-ICLC.
3016457|NCT02453178|Experimental|Steady state moderate intensity cycling|Moderate intensity exercise training will be a 12-week supervised cycling program, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes moderate intensity cycling and 30 minutes passive cycling, and 5 minute cool-down per session, for 3 sessions/week. In each additional week, we will add 6 minutes of moderate intensity cycling per session, until the total time for moderate intensity is 50 minutes per session by the start of week 5 (with additional 5 minute warm-up and 5 minute cool-down).
3016458|NCT02453178|Active Comparator|Intermittent cycling|The intermittent cycling group will come to the exercise lab for the same duration and frequency each week and complete primarily passive cycling such that a motor in the stationary bicycle moves the pedals for them. To maintain interest in this intervention, we will include short bouts of moderate intensity activity. The short bouts of moderate intensity cycling will be designed to be ineffective for substantially increasing cardiorespiratory fitness over the course of the intervention.
3016459|NCT02453165|Experimental|TRANSVAGINAL SUTURE|INTERVENTION: Transvaginal suturE of the vaginal vault at the end of a total laparoscopic hysterectomy using vaginal valves and needleholders.
3016460|NCT02453165|Active Comparator|LAPAROSCOPIC SUTURE|INTERVENTION: Laparoscopic suturE of the vaginal vault at the end of a total laparoscopic hysterectomy using with laparoscopic needleholders.
3016461|NCT02453152||Males with X-linked myotubular myopathy|History and physical, Tidal breathing, Maximal respiratory pressures, Peak cough flow, Pediatric Evaluation of Disability Inventory, PedsQL Multidimensional Fatigue Scale, Review of ventilation requirements
3016462|NCT02453139|Experimental|Exercise group|6 month supervised and home based moderate intensity aerobic exercise programme
3016463|NCT02453139|No Intervention|Control|Non-exercising control group receiving usual care
3016464|NCT02453113|Other|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
3016465|NCT02453100|Experimental|Exercise|"Women will be included in group mobility and pelvic floor exercise classes for one and a half hours twice weekly for 12 weeks and encouraged to carry out independent exercises each day when there is no group session.~A research paramedics will meet with the woman each month for six months from the initial training session to encourage her continued participation and adherence to the individual exercise program. At this meeting the research paramedic will also provide and reinforce simple education about how to manage urinary incontinence."
3016466|NCT02453100|Placebo Comparator|Education|On recruitment and each month for six months a research paramedic will meet with each woman to provide and reinforce simple education about how to manage urinary incontinence.
3016467|NCT02453087|Experimental|DCDS0780A Monotherapy|Participants will receive escalating doses of DCDS0780A as intravenous infusion as monotherapy on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
3016468|NCT02453087|Experimental|DCDS0780A + Rituximab|Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with rituximab at a dose of 375 milligrams per square meter (mg/m^2) of body surface area as intravenous infusion on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
3016469|NCT02453087|Experimental|DCDS0780A + Obinutuzumab|Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion on Days 1, 8, and 15 of Cycle 1, and from Cycle 2 onwards on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
3016470|NCT02453061|Placebo Comparator|Placebo group|Subjects will receive safflower oil at 1g/kg/day for 6 months (months 0 - 6) and triheptanoin oil at 1g/kg/day for 6 months (months 7 - 12)
3016471|NCT02453061|Active Comparator|Triheptanoin group|Subjects will receive triheptanoin oil at 1g/kg/day for 6 months (months 0 - 6) and triheptanoin oil at 1g/kg/day for 6 months (months 7 - 12)
3016472|NCT02453048|Experimental|BPZE1 - 10,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
3016473|NCT02453048|Experimental|BPZE1 - 100,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
3016474|NCT02453048|Experimental|BPZE1 - 1,000,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
3016475|NCT02453048|Experimental|BPZE1 - High Antibody 1,000,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 at a Dose 2 x 0.4 mL (0.4 mL per nostril).
3016476|NCT02453035||PTCA - Desolve Scaffold|Patients with coronary artery stenosis who have been treated with a DESolve bioresorbable coronary scaffold
3016477|NCT02453022|Experimental|Danirixin HBr + Danirixin FB + Omeprazole|Subjects will receive danirixin FB 50 milligram (mg) immediate release (IR) tablet, single dose, in the fed state (treatment A), danirixin HBr 50 mg IR tablet, single dose, in the fed state (treatment B), danirixin HBr 50 mg IR tablet, single dose, in the fasted state (treatment C), or danirixin HBr 50 mg IR tablet, single dose, in the fed state (treatment D) as per randomization in period 1 to 4. In treatment Period 5, subjects will receive danirixin HBr 50 mg IR table, single dose, in the fed state with concomitant, steady state OMP (40 mg once daily for 5 days) (treatment E). Subject will receive treatment with washout period of 5 days in one of the four sequence DCABE, ADBCE, BACDE, CBDAE.
3016478|NCT02453009|Experimental|Arm A|Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks plus oral enzalutamide 160 mg daily for 24 weeks
3016479|NCT02453009|Active Comparator|Arm B|Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks
3016480|NCT02452996|Active Comparator|6 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
3016481|NCT02452996|Active Comparator|18 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
3016482|NCT02452996|Active Comparator|36 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
3016483|NCT02452983|Experimental|Sertraline|Sertraline tablets 100mg daily for 4 (28-day) cycles
3016484|NCT02452970|Experimental|RRx-001 the cisplatin and gemcitabine|Patients with advanced and metastatic biliary tract adenocarcinoma (cholangiocarcinoma) who had been treated with and failed first-line chemotherapy will be treated with RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
3016485|NCT02452957||Device: Simpliciti™ System|"The Simpliciti™ nucleus is a humeral prosthesis intended for total and hemi shoulder arthroplasty in patients with a severely painful and/or disabled joint resulting from osteoarthritis or traumatic arthritis.~The implant is sized to match and replicate the anatomy of the proximal humerus, while maintaining a bone conserving approach. It does not extend beyond the metaphysis, leaving the humeral canal untouched. Fixation is enhanced through a porous coating with a high coefficient of friction; resulting in a solid initial fit and long term fixation.~The Simpliciti™ nucleus is designed to receive a humeral head. The Simpliciti™ system is authorized to bear the CE mark and will be investigated within this clinical study in accordance with its intended use."
3016486|NCT02452944|Experimental|US-IFI group|"ultrasound-guided obturator nerve block with interfascial injection approach group (US-IFI; experimental group)~The stimulating needle without nerve stimulator advanced via an ultrasound to position the needle tip on the fascia between adductor longus and adductor brevis muscles. 10mL of local anesthetics were slowly injected. The needle was reinserted to position the needle tip on the fascia between adductor brevis and adductor magnus muscles, another 5mL of LA was injected.~After that, the needle was reinserted to the same spots attached with nerve stimulator at 1.0 mA. If adductor muscle twitching was shown, another 5mL of LA was injected, and it was documented as 'fail'."
3016487|NCT02452944|Active Comparator|US-NS group|ultrasound-guided obturator nerve block with nerve stimulating approach group (US-NS; control group) The stimulating needle attached to a nerve stimulator advanced via an ultrasound to position the needle tip on the fascia between adductor longus and adductor brevis muscles. The nerve stimulator was then turned on, and the stimulation current started at 0.5 mA. If adductor muscle twitching was observed on the sonogram even at the stimulation current 0.3mA, 10mL of local anesthetics were slowly injected. The needle was reinserted to position the needle tip on the fascia between adductor brevis and adductor magnus muscles. The stimulation current started at 0.5 mA. If adductor muscle twitching was visualized on the sonogram even at 0.3mA, another 5mL of LA was injected.
3016488|NCT02452931|Experimental|Assigned Intervention|Leuprolide acetate 45 mg will be administered as a subcutaneous injection at 6-month intervals for the 12 month study period.
3016489|NCT02452918|Experimental|oritavancin|oritavancin, a single 1200mg IV dose, over 3 hours
3016490|NCT02452905|Active Comparator|Nitazoxanide|Nitazoxanide 7.5mg/kg oral/nasogastric/nasoenteric tube three times per day for five days.
3016491|NCT02452905|Placebo Comparator|Placebo|The placebo is identical to the active drug described above except that it does not contain the active compound nitazoxanide. It is reconstitutes, administered and dosed as per the active study drug.
3016492|NCT02452892|Sham Comparator|LFMS Sham|For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered. Low field magnetic stimulation (no magnetic field for sham) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
3016493|NCT02452892|Active Comparator|LFMS 20 minutes|LFMS 20 minutes + Sham 40 min.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
3016494|NCT02452892|Active Comparator|LFMS 60 minutes|LFMS 60 minutes.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
3016495|NCT02452892|Other|LFMS 120 min|Week 2 subjects may be re-randomized to receive LFMS 120 minutes. Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
3016496|NCT02452879|Experimental|Electroacupuncture group|Needle on bilateral BL33 acupoint 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day. The treatment period lasts eight weeks. totally 24 times.30min/time.
3016497|NCT02452879|Placebo Comparator|Placebo group|with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
3016498|NCT02452879|Active Comparator|Solifenacin Succinate group|Solifenacin Succinate Tablets (made by the Anse Tailai Pharmaceutical (China) R & D limited company) 5mg, 1 tablets each time, 1 times / day, oral administration of 30min before meal, even for 8 weeks.
3016499|NCT02452866|Experimental|SYM-1219|
3016500|NCT02452853|Experimental|HR combined with FOLFOX4|"HR ;~FOLFOX4 4 weeks after HR"
3016501|NCT02452840||NVAMD Patients with PDA|NVAMD Patients with PDA
3016502|NCT02452827||Primary Chronic Neck Pain|Patients suffering for at least 3 years from neck pain without any underlying pathology who have undergone MRI. Biomechanical parameters of neck movements will be investigated.
3016503|NCT02452827||Control|Patients without neck pain who have undergone MRI for any reason. Biomechanical parameters of neck movements will be investigated.
3016504|NCT02452814||Cohort|
3016505|NCT02452801|Experimental|ALKS 5461|Sublingual tablet
3016506|NCT02452788|Other|Intervention|Pharmaceutical care with educational intervention provided by a pharmacist to ambulatory hemodialysis patients
3016507|NCT02452788|No Intervention|Usual Care|Usual Care
3016508|NCT02452775|Experimental|Arm 1|Subjects in ARM 1 will receive the vaccination with OC-L alone
3016509|NCT02452775|Experimental|Arm 2|subjects in ARM 2 will receive vaccination with OC-L admixed with Montanide,
3016512|NCT02452762|Experimental|Enteral Loading Arm|Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)
3016513|NCT02452762|Placebo Comparator|Placebo Arm|Patients will receive a placebo solution equivalent in volume to the dose of cholecalciferol administered to patients in the enteral loading arm.
3016514|NCT02452749|Experimental|Cardiovascular Health Dietary Supplement|The cardiovascular health dietary supplement will be administered at a dosage of 1 caplet po per day for a period of 6 months
3016515|NCT02452736|Experimental|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|This is a Single arm, Non-randomized Study. All patients meet the eligibility criteria and sign the informed consent form will participate in this study.
3016516|NCT02452723|Experimental|ISC-hpNSC|
3016517|NCT02452710|Experimental|Open-Label Placebo|- Placebo Tablets-Twice a day for 3-4 weeks
3016518|NCT02452710|No Intervention|NT-Control|- No Placebo Tablets
3016519|NCT02452697|Active Comparator|Cohort A - NK cell enriched-DLI only|Patients with a 7-8/8 human leukocyte antigen (HLA)-matched related or unrelated donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) only
3016520|NCT02452697|Experimental|Cohort A - NK-DLI + DUK-CPG-001|Patients with a 7-8/8 human leukocyte antigen (HLA)-matched related or unrelated donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) and investigational DUK-CPG-001
3016521|NCT02452697|Active Comparator|Cohort B - NK cell enriched-DLI only|Patients with a 4-6/8 human leukocyte antigen (HLA)-matched related donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) only
3016522|NCT02452697|Experimental|Cohort B - NK-DLI + DUK-CPG-001|Patients with a 4-6/8 human leukocyte antigen (HLA)-matched related donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) and investigational DUK-CPG-001
3016523|NCT02452684||Participants with insomnia|Participants with insomnia who will receive eszopiclone, per approved label.
3016524|NCT02452658|Experimental|Changed menu|All participants will be exposed to the same changed menu after making their hypothetical choice. Changes will include reduced calorie labels, reduced prices, and changes to item descriptions.
3016525|NCT02452645|Experimental|Intervention|The intervention will integrate: a) support from peer counselors with child care experience who will serve as team leaders for groups of FCCPs; b) tailored print and video materials; and c) a set of portable active toys to elicit changes to the nutrition and physical activity environments of family child care homes.
3016526|NCT02452645|Active Comparator|Comparison|The comparison intervention will provide print materials and videos on literacy and school readiness to children and books in both English and Spanish. Participants will also receive support from peer counselors with child care experience.
3016527|NCT02452632|Experimental|ASP1941 group|once daily over a 24 week treatment
3016528|NCT02452632|Placebo Comparator|Placebo group|once daily over a 24 week treatment
3016529|NCT02452619||Brain trauma|Patients with chronic brain injury that have been treated with Hyperbaric oxygen therapy and underwent MRI imaging and cognitive tests before and after the treatment
3016530|NCT02452606|Experimental|Stalevo®|Participants who are assigned to Stalevo Arm will take Stalevo® at bedtime for 3 month.
3016531|NCT02452593|Active Comparator|"Tibial Nerve Stimulation"|"This group will do transcutaneous electrical stimulation of the tibial nerve at home.~Development of an innovative portable equipment, with domestic technology for home application of the posterior tibial nerve stimulation technique using the type SSP surface electrodes (Silver Spike Point). Frequency: 20 Hz, Pulse width: 200 us; duration: 15min daily"
3016532|NCT02452593|Active Comparator|"Pelvic Floor Exercises"|This group will make pelvic muscle training 3 times a day . In decubit dorsal posture, legs flexed and abductee. Perform pelvic floor contractions keeping 2 seconds and relaxing 4 seconds for 10 times, and contractions keeping 4 seconds and relaxing 8 seconds for 10 times.
3016533|NCT02452580||Family Centered Care Unit|Cohort of premature infants and their families receiving Family Centered Care hospitalized at VVHF
3016534|NCT02452580||Open-bay Care Unit|Cohort of premature infants and their families receiving and traditional open-bay care hospitalized at HUH
3016535|NCT02452567|Experimental|Metabolically abnormal lean|Moderate (8-10%) diet-induced weight loss.
3016536|NCT02452554|Experimental|Treatment (lorvotuzumab mertansine)|Patients receive lorvotuzumab mertansine IV over 1-1.5 hours on days 1 and 8. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
3016537|NCT02452541|Other|Prognostic evaluation|Prognostic tests/exams performed according to a determined schedule during the acute phase of care following admission in the intensive care unit.
3016538|NCT02452528|Experimental|ARC-520|"Intravenous administration of 1.0 mg/kg ARC-520 once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.~Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of study drug."
3016539|NCT02452528|Placebo Comparator|Placebo|"Intravenous administration of normal saline (0.9%) once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.~Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of placebo."
3016540|NCT02452515|Experimental|BAY1142524 (5 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
3016541|NCT02452515|Experimental|BAY1142524 (10 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
3016542|NCT02452515|Experimental|BAY1142524 (25 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
3016543|NCT02452515|Experimental|BAY1142524 (50 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
3016544|NCT02452502|Active Comparator|moderate dose|Drug: Atorvastatin Atorvastatin 20 mg daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months Other Name: Lipitor
3016545|NCT02452502|Experimental|high dose|Drug: Atorvastatin Atorvastatin 80 mg daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months Other Name: Lipitor
3016547|NCT02452489|Other|Combination of He-Mu points group|Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12).
3016548|NCT02452489|Other|Control group|Patients in Control group,will be acupuncture with at the junction of deltoid and biceps.
3016549|NCT02452476|Experimental|CHF5633|Single dose within 24 hours from birth
3016550|NCT02452476|Active Comparator|Poractant alfa|Single dose within 24 hours from birth
3016551|NCT02452463|Experimental|Arm I (nintedanib)|Beginning 4-6 weeks after completion of radiation therapy, patients receive nintedanib PO BID on days 1-30. Treatment repeats every 30 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3016552|NCT02452463|Placebo Comparator|Arm II (placebo)|Beginning 4-6 weeks after completion of radiation therapy, patients receive placebo PO BID on days 1-30. Courses repeat every 30 days in the absence of disease progression or unacceptable toxicity.
3016553|NCT02452450|Experimental|Ibuprofen lysine|
3016554|NCT02452450|Experimental|Ibuprofen sodium|
3016555|NCT02452450|Experimental|Ibuprofen liquid capsules|
3016556|NCT02452450|Active Comparator|Ibuprofen acid|
3016557|NCT02452450|Active Comparator|Paracetamol|
3016558|NCT02452437|Experimental|control|Oxycodone will be administered and subjects will undergo hemodialysis
3016559|NCT02452437|Experimental|hemodialysis|Oxycodone will be administered and subjects will undergo hemodialysis
3016560|NCT02452424|Experimental|PLX3397 and Pembrolizumab|"Part 1: Open-label, sequential PLX3397 dose escalation with a fixed dose of pembrolizumab in approximately 24 patients with advanced solid tumors.~(Enrollment complete- 35 enrolled)~Part 2: Extension cohort at the RP2D of PLX3397 in combination with pembrolizumab in approximately 376 patients with advanced solid tumors~(Enrollment Complete- 45 enrolled)"
3016561|NCT02452411|Experimental|Homework assignments using TEO system|Experimental: Homework assignments using TEO system. It is an internet-based system which allows the therapist to create homework sessions using multimedia materials (videos, images, texts, and narratives) and to offer and present this material to the patients through the Internet. Participants receive a CBT treatment for adjustment disorder supported by virtual reality and they do the homework assignments component using TEO at home over the Internet.
3016562|NCT02452411|Experimental|Homework assignments using Traditional method|The traditional way of applying homework assignments consists of reading and writing materials and audio session records. Participants receive a CBT treatment supported by virtual reality for adjustment disorder and they do the homework assignments component at home using traditional materials.
3016563|NCT02452398|Experimental|Treatment Group|Hair removal treatment using Venus Versa IPL energy
3016564|NCT02452385|Experimental|CM082 tablet|Escalating dose of CM082 tablet starting at 25mg once a day
3016565|NCT02452372|Active Comparator|givosiran (ALN-AS1)|
3016566|NCT02452372|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3016567|NCT02452359|Experimental|Treatment Group|Group receiving treatment with Venus Versa IPL energy
3016568|NCT02452346|Experimental|All Patients|Tosedostat 120 mg PO once daily will be administered.
3016569|NCT02452333|Experimental|Evidence-based Oncoplastic Algorithm|Oncoplastic Approach Excisional Breast Biopsy, Tezel Method of Breast Volume Measurement and Cosmetic Assessment
3016570|NCT02452333|Experimental|Control|- Conventional Excisional Breast Biopsy, Tezel Method of Breast Volume Measurement and Cosmetic Assessment
3016571|NCT02452320|Placebo Comparator|Control|Subjects randomized into the control group will not receive study medication, they will receive a placebo administered at the same schedule as the active drug in the other arm.
3016572|NCT02452320|Active Comparator|Randomized|Subjects randomized into the active treatment group will receive intravenous acetaminophen
3016573|NCT02452307|Experimental|Peptide vaccine|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51
3016574|NCT02452307|Experimental|Peptide vaccine + GM-CSF|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with Granulocyte macrophage colony stimulating factor (GM-CSF)
3016575|NCT02452307|Experimental|Peptide vaccine + local hyperthermia|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with local hyperthermia
3016576|NCT02452307|Experimental|Peptide vaccine + Imiquimod|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with Imiquimod
3016577|NCT02452307|Experimental|Peptide vaccine + mRNA/Protamin|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with mRNA/Protamin
3016578|NCT02452294|Experimental|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events.
3016579|NCT02452281|Experimental|ipilimumab + HSPPC-96|"Ipilimumab is administered intravenously at a dose of 3 mg/kg one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.~HSPPC-96 is administered at a dose of 25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab.~Length of Treatment: 4 cycles of ipilimumab and at least 6 cycles of HSPPC-96 up to 12 doses.~Booster doses of HSPCC-96 following 6 administrations on subsequent cycles will be administered every 21-23 days according to availability of vaccine."
3016580|NCT02452268|Experimental|NIZ985|"Single treatment arm, dose escalation administered subcutaneously (SC) on MWF for 2 consecutive weeks.~Cycle length 28 days.~Occurrence of a dose-limiting toxicity (DLT) leads to the expansion to 6 subjects.~MTD is the dose prior to the dose level where ≥ 2/6 subjects have a DLT.~Following identification of the MTD / RDE, dose expansion will follow."
3016581|NCT02452268|Experimental|NIZ985 + PDR001|"The phase Ib dose escalation portion of the study will consist of a fixed dose (400 mg, IV infusion, Q4W) of PDR001 and escalating doses of NIZ985 (hetIL-15) to evaluate safety, tolerability and determine the MTD and/or RDE of the combination to be used in expansion cohorts.~On days when PDR001 and NIZ985 are administered on the same day, PDR001 will be administered first. NIZ985 will be administered after the PDR001 infusion has been completed.~Information on the preparation and administration of PDR001 is found in the PDR001 pharmacy manual."
3016582|NCT02452255|Active Comparator|Fenofibrate|Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
3016583|NCT02452255|Active Comparator|Fenofibrate and Propranolol|Fenofibrate and Propranolol by mouth given throughout hospitalization for up to 12 months
3016584|NCT02452255|Placebo Comparator|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months.
3016585|NCT02452255|Active Comparator|Propranolol|Propranolol by mouth given throughout hospitalization for up to 12 months
3016586|NCT02452242|Experimental|ABX464|
3016587|NCT02452242|Placebo Comparator|Placebo|
3016588|NCT02452229||Burn patients|The included patient are burn victims who sustained a burn of at least 1 % total body surface are (TBSA); with no restriction on age.
3016589|NCT02452216|Experimental|Ferumoxytol group|All subjects in the experimental arm will have a single intravenous dose of ferumoxytol (5 mg Fe/kg), to be administered 24 hours before the subject undergoes ferumoxytol-enhanced magnetic resonance imaging (MRI). These subjects will subsequently undergo surgery, and tissue analysis of surgically resected samples (specifically the number of iron-containing and non-iron-containing macrophages) will be correlated with imaging features on ferumoxytol-enhanced MRI.
3016590|NCT02452203|Experimental|Floating|The participant will float supine in water with a high concentration of Epsom salt for 90 minutes.
3016591|NCT02452203|Placebo Comparator|Chair|The participant will lay in the supine position while reclined in a zero-gravity chair for 90 minutes.
3016592|NCT02452190|Experimental|Reslizumab|Reslizumab
3016593|NCT02452190|Placebo Comparator|Placebo|Matching Placebo
3016594|NCT02452177|Experimental|Vitamin D|Patients in this group were treated with oral vitamin D at a dose of 1200 IU per day for 2 months.
3016595|NCT02452177|Placebo Comparator|Placebo|
3016596|NCT02452164|Active Comparator|Teaching group|Parents are taught to conduct cellphone otoscopy and if necessary study physician removes cerumen from childrens´ ear canals at the first study visit.
3016597|NCT02452164|Other|Control group|Families receive the cellphone otoscope as if they had bought it themselves from the internet. After the first study week, parents are taught to conduct cellphone otoscopy and if necessary study physician removes cerumen from childrens´ ear canals.
3016598|NCT02452151|Experimental|Infliximab-biosimilar|Infliximab-Biosimilar (Inflectra) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment. In total 4 to 6 doses of the study drug will be administered while continuing patient's dosing intervals, ranging between 6 to 10 weeks.
3016599|NCT02452151|Active Comparator|Infliximab-Innovator|Infliximab-Innovator (Remicade) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment. In total 4 to 6 doses of the study drug will be administered while continuing patient's dosing intervals, ranging between 6 to 10 weeks.
3016600|NCT02452138||Low EAA|Endotoxin Activity Assay [EAA] level < 0.40 EAA units
3016601|NCT02452138||Intermediate EAA|Endotoxin Activity Assay [EAA] level between 0.40-0.59 EAA units
3016602|NCT02452138||High EAA|Endotoxin Activity Assay [EAA] level >= 0.60 EAA units
3016603|NCT02452125|Experimental|Nicotine Gum|Nicotine chewing gum administered for 30 minutes
3016604|NCT02452112|Active Comparator|Lidocaine|Active arm with administration of active 5% Lidocaine patch
3016605|NCT02452112|Placebo Comparator|Placebo|Placebo arm with administration of placebo patch
3016606|NCT02452099|Other|5% DMSO|
3016607|NCT02452099|Other|7.5% DMSO|
3016608|NCT02452099|Other|10% DMSO|
3016609|NCT02452086|Active Comparator|Low Level Laser Therapy|"In laser therapy group, group who received interventions was the patients received laser with 2 Joule/centimeters2, 90 milliwatt~, 3 days/week, for 4 weeks (12 sessions)"
3016610|NCT02452086|Placebo Comparator|Placebo|In the placebo group, the treatment procedure was the same as that the LLLT group, but the laser light was off and Guiding light was laser was on
3016611|NCT02452073||CRE group|patients with chronic radiation enteritis
3016612|NCT02452073||malignancy group|patients with some kinds of malignant tumors but had not previously received radiotherapy
3016613|NCT02452073||control group|age-matched healthy volunteers
3016614|NCT02452060|Placebo Comparator|treatment/placebo|saline infusion
3016615|NCT02452060|Experimental|treatment|ketamine (0.4mg/kg)
3016616|NCT02452047|Experimental|Group 1: Imipenem+Cilastatin/Relebactam|Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours and placebo for colistimethate sodium IV infusion once every 12 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
3016617|NCT02452047|Active Comparator|Group 2: Colistimethate sodium + Imipenem+Cilastatin|Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive colistimethate sodium IV infusion once every 12 hours and imipenem+cilastatin IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
3016618|NCT02452047|Experimental|Group 3: Imipenem+Cilastatin/Relebactam|Participants with documented imipenem-resistant and colistin-resistant bacterial infections may be eligible to receive open-label imipenem+cilastatin/relebactam IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
3016619|NCT02452034|Experimental|Young Children 3.5 mg/kg POS|Children 2 to less than 7 years of age will receive POS at 3.5 mg/kg by intravenous (IV) solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by powder for oral suspension (PFS) for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
3016620|NCT02452034|Experimental|Young Children 4.5 mg/kg POS|Children 2 to less than 7 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
3016649|NCT02451891|Active Comparator|Group 4|ChAd3-EBO Z (2.5 +/- 1.2 x 10^10 vp) and MVA-EBO Z (1.5 x 10^8 pfu) after 28 days
3016745|NCT02451254|Experimental|Atrial Fibrillation|Atrial Fibrillation patients electively admitted for circumferential ablation of the pulmonary veins.
3016621|NCT02452034|Experimental|Older Children 3.5 mg/kg POS|Children 7 to 17 years of age will receive POS at 3.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
3016622|NCT02452034|Experimental|Older Children 4.5 mg/kg POS|Children 7 to 17 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
3016623|NCT02452034|Experimental|Young Children 6 mg/kg POS|Children 2 to less than 7 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
3016624|NCT02452034|Experimental|Older Children 6 mg/kg POS|Children 7 to 17 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
3016625|NCT02452008|Experimental|Arm 1: Enzalutamide with LY2157299|
3016626|NCT02452008|Experimental|Arm 2: Enzalutamide alone|
3016627|NCT02451995|Experimental|Ripple Mapping guided AT ablation|Ripple Mapping (Imperial College) software (Biosense Webster) will be used to diagnose the mechanism of AT and guide ablation
3016628|NCT02451995|Active Comparator|Conventional AT Ablation|Standard activation mapping and entrainment will be used to guide ablation.
3016629|NCT02451982|Experimental|Arm A: CY/GVAX alone|Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 courses.
3016630|NCT02451982|Experimental|Arm B: CY/GVAX with nivolumab|Patients receive low-dose cyclophosphamide and nivolumab IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide and nivolumab IV on day 0 and the vaccine on day 1. Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide and nivolumab IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide, nivolumab, and the vaccine repeats every 28 days for 4 courses.
3016631|NCT02451969|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~Intervention: investigational 23-valent PPV"
3016632|NCT02451969|Active Comparator|Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0~Intervention: control 23-valent PPV"
3016633|NCT02451956|Experimental|AZD5363 in combination with paclitaxel|AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week that paclitaxel is given + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.If paclitaxel therapy is stopped then AZD5363 can be given on a 4on/3off continuous schedule.
3016634|NCT02451943|Experimental|Doxorubicin + Olaratumab|75 milligrams per meter squared (mg/m^2) doxorubicin administered intravenously (IV) on day 1 of each 21 day cycle for 8 cycles plus 20 milligrams per kilogram (mg/kg) dose of olaratumab administered IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab administered IV on day 1 and day 8 of cycles 2-8. Beginning with cycle 9, 15 mg/kg olaratumab administered IV on day 1 and day 8 of each subsequent 21 day cycle until documented progressive disease (PD) or discontinuation for any other reason.
3016635|NCT02451943|Placebo Comparator|Doxorubicin + Placebo|75 mg/m^2 doxorubicin administered IV on day 1 of each 21 day cycle for 8 cycles plus placebo (equivalent volume) administered IV on day 1 and day 8 for 8 cycles. Beginning with cycle 9, placebo (equivalent volume) administered on days 1 and 8 of each subsequent 21 day cycle until PD or discontinuation for any other reason.
3016636|NCT02451930|Experimental|Necitumumab + Pembrolizumab|"(Part A) Escalating doses of necitumumab administered intravenously (IV) on day 1 and day 8 every 3 weeks (Q3W) in combination with pembrolizumab IV on day 1 Q3W. Treatment may continue until discontinuation criterion is met.~(Part B) Necitumumab dose identified in part A administered IV on day 1 and day 8 Q3W in combination with pembrolizumab IV on day 1 Q3W. Treatment may continue until discontinuation criterion is met.~(Part C) Confirmation of necitumumab dose identified in part A administered IV on day 1 and day 8 Q3W in combination with pembrolizumab IV on day 1 Q3W in Japanese participants. Treatment may continue until discontinuation criterion is met."
3016637|NCT02451917|Experimental|Glargine insulin|This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin. At the end of the study, all data acquired during the use of insulin glargine, regardless of the sequence were grouped as glargine.
3016638|NCT02451917|Active Comparator|NPH insulin|"This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin.~At the end of the study, all data acquired during the use of NPH insulin, regardless of the sequence were grouped as NPH."
3016639|NCT02451904||Severe/Cerebral Malaria|Intensive monitoring
3016640|NCT02451904||Uncomplicated Malaria|Intensive monitoring
3016641|NCT02451904||Sepsis|Intensive monitoring
3016642|NCT02451904||Acidosis|Intensive monitoring
3016643|NCT02451904||Encephalitis|Intensive monitoring
3016644|NCT02451904||Healthy Individuals|Monitoring
3016645|NCT02451891|Active Comparator|Group 1a|MVA-EBO Z (1 x 10^8 pfu)
3016646|NCT02451891|Active Comparator|Group 1b|MVA-EBO Z (1.5 x 10^8 pfu)
3016647|NCT02451891|Active Comparator|Group 2|ChAd3-EBO Z (2.5 +/- 1.2 x 10^10 vp) and MVA-EBO Z (1 x 10^8 pfu) after 14 days
3016648|NCT02451891|Active Comparator|Group 3|ChAd3-EBO Z (2.5 +/- 1.2 x 10^10 vp) and MVA-EBO Z (1 x 10^8 pfu) after 28 days
3016650|NCT02451878|Experimental|Intervention|The E-Couch self-help social anxiety module which is based on cognitive behavioural therapy principles. This module contains a literacy section and 5 toolkits comprising exposure practice, cognitive restructuring (modifying your thinking), attention practice, social skills training and relaxation. E-Couch is designed to be completed at the participant's own pace. It is free to use, browser-based and widely accessible on a range of connected devices.
3016651|NCT02451878|No Intervention|Control|Wait list control (WLC)
3016652|NCT02451865|Experimental|Treatment (binimetinib and docetaxel)|Patients receive binimetinib PO BID on days 1-21 and docetaxel IV on day 21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have stable disease or better after completing 6 courses of binimetinib and docetaxel may continue receiving binimetinib PO BID in the absence of disease progression or unacceptable toxicity.
3016653|NCT02451839||Crohn's disease|Patients with Crohn's disease
3016654|NCT02451839||Rheumatoid arthritis|Patients with rheumatoid arthritis
3016655|NCT02451839||Psoriasis|Patients with psoriasis
3016656|NCT02451826|Active Comparator|1.5 mg tablet LNG after 12 weeks|CVR delivering 2,500 µg of Ulipristal acetate per day and a single dose of levonorgestrel delivered in a 1.5 mg tablet after 12 weeks of CVR use
3016657|NCT02451826|Active Comparator|1.5 mg tablet LNG every 4 weeks|CVR delivering 2,500 µg of Ulipristal acetate per day and one 1.5 mg tablet levonorgestrel every 4 weeks of CVR use (three times).
3016658|NCT02451813|Experimental|Intervention|"A 22 GA 5 cm nerve block needle will be advanced to the following conditions:~Needle tip slightly indenting the fascia iliaca~Needle tip advanced through fascia iliaca~Needle tip slightly indenting the anterior surface of the femoral nerve~Needle tip withdrawn 1 mm from nerve.~At each of these conditions, 1 ml of dextrose solution will be injected and spread of injectate observed sonographically. A blinded observer will measure injection pressure. If opening pressure reaches 15 psi, this investigator will halt the injection. In addition, minimum threshold current required to elicit a motor response will be recorded for conditions 3 and 4."
3016659|NCT02451800|Experimental|in-class yoga|"The intervention is a in-class yoga course taught by yoga instructors for 3 times per week for 3 months. This class is based on Peggy Cappy's Program: More Yoga for Every Body. Class is taught at Sanford Wellness Centers in Sioux Falls, South Dakota and Fargo, North Dakota. Each class in 1 hour in length."
3016660|NCT02451800|Active Comparator|yoga by DVD|"For the intervention participants are asked to do yoga at home following the Peggy Cappy's Program: More Yoga for Every Body DVD. They are asked to complete these exercises 3 times per week for 3 months. The DVD is 1 hour in length."
3016661|NCT02451800|Active Comparator|stretching by DVD|"For the intervention participants are asked to do stretching exercises at home following Bob Anderson's DVD-Stretching: the DVD. They are asked to complete these exercises 3 times per week for 3 months. The DVD is 1 hour in length."
3016662|NCT02451787|Experimental|Active|vitamin D supplementation group (2500 IU day for 3 months)
3016663|NCT02451787|Placebo Comparator|Control|no vitamin D supplementation
3016664|NCT02451774|Experimental|Pentoxifylline Plus Chemotherapy|"Pentoxifylline: 10-20 milligrams per kilogram, doses daily by oral, for 30 days.~Chemotherapy: Prednisone, Vincristine, Daunorubicin, L-asparaginase, Cyclophosphamide, Cytarabine, 6-Mercaptopurine, Methotrexate, Hydrocortisone and Cytarabine"
3016665|NCT02451774|Placebo Comparator|Placebo Plus Chemotherapy|Placebo: double blind period, one doses daily for 30 days. Chemotherapy: Prednisone, Vincristine, Daunorubicin, L-asparaginase, Cyclophosphamide, Cytarabine, 6-Mercaptopurine, Methotrexate, Hydrocortisone and Cytarabine
3016666|NCT02451761||Sequencing|Blood sampling will be carried out in all patients ; molecular analysis and sequencing will be performed on these samples
3016667|NCT02451748|Other|DMARD's Responder and Non-Responder|In the first group of subjects, blood samples will be obtained from (50) RA subjects with Disease modifying anti rheumatic drugs (DMARDs) such as methotrexate, plaquenil and/or prednisone that achieve remission (DAS28<2.6). The subjects that achieve remission (DAS28<2.6), blood will only be taken once at the subjects routine visit. Subject's that are non-responder to DMARDS will go onto group 2.
3016668|NCT02451748|Other|DMARD's plus Cimzia|"The second group will consist of (150) RA subjects that did not respond to DMARDs. These patients will further receive (DMARDs) such as methotrexate, plaquenil and/or prednisone as well as Cimzia®. In this Arm, blood samples will be collected onset of the study as well as 3 and 6 months after treatment with Cimzia at subject's visit through our collaboration with the aforementioned rheumatologists."
3016669|NCT02451735|No Intervention|Intervention Development|Psychoeducational Intervention (PEI) development. PEIs include printed and DVD materials, and represent a commonly used and effective approach to implement theoretically based individual-level interventions. These materials serve as important sources of information for the general public, cancer patients, and survivors from a variety of backgrounds, including populations with limited health literacy. An interview and feedback collection process will take place to provide data to improve current PEI materials.
3016670|NCT02451735|Experimental|Intervention Pilot - Intervention Group|The intervention group will receive the PEI materials: video and booklet. Self-reported feedback will be collected and reviewed to compare response with the control group.
3016671|NCT02451735|Active Comparator|Intervention Pilot - Control Group|The control group will receive a patient factsheet about Genetic Counseling (GC). Self-reported feedback will be collected and reviewed to compare response with the intervention group.
3016672|NCT02451722|Active Comparator|Healthy subjects|"Kyboot shoes will be administered to the healthy subjects.~Pressure distribution and gait parameters will be recorded in comparison with their normal footwear."
3016673|NCT02451722|Active Comparator|Diabetic patients|"Kyboot shoes will be administered to the diabetic patients.~Pressure distribution and gait parameters will be recorded in comparison with their normal footwear."
3016702|NCT02451514|Experimental|MenACWY Group (B1)|"Subjects who received MenACWY vaccine in the parent study and received no subsequent meningococcal vaccines, who will receive 2 doses of MenABCWY+OMV vaccine, one month apart, in the current study.~Blood samples will be collected from subjects at Day 1 (before vaccination), Day 4, Day 31 (before vaccination) and Day 61."
3016703|NCT02451514|Experimental|MenACWY Group (B2)|"Subjects who received MenACWY vaccine in the parent study and received no subsequent meningococcal vaccines, who will receive 2 doses of MenABCWY+OMV vaccine, one month apart, in the current study.~Blood samples will be collected from subjects at Day 1 (before vaccination), Day 8, Day 31 (before vaccination) and Day 61."
3016674|NCT02451709|Experimental|Feedback and alarms|"Standard education about importance of inhaled steroids and regular adherence to inhaled steroids after recruitment to study.~Randomized to receive an electronic adherence device ( activated smartinhaler or smartturbo - Nexus 6) with twice daily alarm reminders activated. Patient decides times, different times on weekdays and weekends if required. This device fitted to their regular preventer inhaler, patient aware of its presence and its purpose in the context of the study.~Reviewed in standard asthma clinic every 3 months for 12 months. At each clinic visit, adherence information downloaded from device and data shared with patient and family (feedback of adherence data). Discussion about adherence rates, and action planning for the next 3 months to improve adherence if necessary."
3016675|NCT02451709|Active Comparator|No feedback or alarms|"Standard education about importance of inhaled steroids and regular adherence to inhaled steroids after recruitment to study.~Randomized to receive an electronic adherence device. Deactivated Smartinhaler or Smartturbo.~Device not activated to play reminder alarms. This device fitted to their regular preventer inhaler, patient aware of its presence and its purpose in the context of the study.~Reviewed in standard asthma clinic every 3 months for 12 months. At each clinic visit, adherence information downloaded from device but data not shared with patient, and no adherence discussion."
3016676|NCT02451696|Experimental|Treated Subjects|This group will be treated with everolimus 7-28 days prior to surgery
3016677|NCT02451696|No Intervention|Reference Subjects|This group will be enrolled as reference subjects, and will be undergoing routine surgery as part of standard of care treatment. No intervention will be provided to these subjects as part of the study.
3016678|NCT02451683|Other|Electrophysiology Assessment of Time Domain|Assessment of electrophysiology in the time domain to examin temporal organization of corticospinal function
3016679|NCT02451683|Experimental|Electrophysiology Assessment of Location|Assessment of electrophysiology to examine spatial organization of corticospinal function
3016680|NCT02451683|Active Comparator|Training with some stimulation|Training with non-invasive stimulation and training with sham stimulation
3016681|NCT02451670|No Intervention|Usual Care|Patients in the usual care arm of the study do not receive the Wizard patient and provider display which prompts cardiovascular reduction discussion during a primary care visit, and do not receive a study-initiated assessment regarding high Body Mass Index and obesogenic medication.
3016682|NCT02451670|Experimental|Wizard algorithm risk reduction advice|Patients in the intervention arm of the study who meet study criteria (a qualifying serious mental illness and not at goal for any of the six cardiovascular risk areas) will receive Wizard algorithm individual-specific written and verbal advice as to prioritized treatment and lifestyle changes, prompted by an Electronic Medical Record based alert and printed display of risks, during their primary care visit. The patients who have a high Body Mass Index and are on an obesogenic medication will also be contacted for a possible change in medication to a less-obesogenic medication, if appropriate.
3016683|NCT02451657||Cohort|
3016684|NCT02451644|Experimental|high risk for PTD with pedometer|Patient with high risk for preterm delivery including short cervix or rapture of membranes
3016685|NCT02451631|Active Comparator|Traditional care|Traditional care with paper(SMBG) and healthcare staff advice in office
3016686|NCT02451631|Experimental|Health-On G App.+ Physician web portal|Patient self-mgmt using Health-On G Application on smartphone; Healthcare staffs monitoring through physician web to review data
3016687|NCT02451618||Epidermal Electronic System|EES, wireless tattoo electrode
3016688|NCT02451618||Hydrogel electrode|EKG electrode, looking at hairline placement of electrodes.
3016689|NCT02451605|Active Comparator|Femoral nerve blockade|In this group, patient will benefit of an ultrasound guided femoral nerve blockade with continuous catheter infusion as (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for total knee replacement surgery.
3016690|NCT02451605|Active Comparator|Adductor canal blockade|In this group, patient will benefit of an ultrasound guided adductor canal blockade with continuous catheter infusion (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for for total knee replacement surgery.
3016691|NCT02451605|Active Comparator|Subgluteal sciatic nerve blockade|In this group, patient will benefit of an ultrasound guided subgluteal sciatic nerve blockade with continuous catheter infusion (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for total knee replacement surgery.
3016692|NCT02451579|Active Comparator|Cetirizine Hydrochloride|Prophylactic use of cetirizine hydrochloride prior to and after Topical 5-aminolevulinic Acid Photodynamic Therapy
3016693|NCT02451579|Placebo Comparator|Placebo|Prophylactic use of placebo prior to and after Topical 5-aminolevulinic Acid Photodynamic Therapy
3016694|NCT02451566||Fast-Track Group|Includes subject who complete the Fast-Track EVAR protocol.
3016695|NCT02451566||Standard P-EVAR Group|Includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are completed with bilateral percutaneous access.
3016696|NCT02451566||Standard EVAR Group|Includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are not completed with bilateral percutaneous access (i.e. converted to femoral cutdown or open surgical repair).
3016697|NCT02451553|Experimental|Treatment (afatinib dimaleate, capecitabine)|Patients receive afatinib dimaleate PO QD on days 1-21 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3016698|NCT02451540|Active Comparator|Roflumilast|Patient will take Roflumilast (500 micrograms) once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months of treatment
3016699|NCT02451540|Placebo Comparator|Placebo|Patient will take the Placebo of Roflumilast once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months.
3016700|NCT02451527|Experimental|Digoxin and PEX168|A single dose of 0.5mg digoxin administered on Day 1 followed by 5 weekly subcutaneous injections of a single dose of 200ug PEX168, followed by a further single dose of 0.5mg digoxin on Day 38.
3016701|NCT02451514|Experimental|MenABCWY+OMV Group (A)|"Subjects in this group who received 2 doses of MenABCWY+OMV vaccine in the parent study and received no subsequent meningococcal vaccines, who will receive a booster dose of MenABCWY+OMV vaccine in the current study.~Blood samples will be collected from subjects at Day 1 (before vaccination), Day 4, Day 8 and Day 31."
3016743|NCT02451267|Active Comparator|positive CPR: control group|physical therapy treatment
3016704|NCT02451514|Experimental|Naive Group (C1)|"Subjects who have not previously received any meningococcal vaccine, who will receive 2 doses of MenABCWY+OMV vaccine, one month apart, in the current study.~Blood samples will be collected from subjects at Day 1 (before vaccination), Day 31 (before vaccination), Day 34 and Day 61."
3016705|NCT02451514|Experimental|Naive Group (C2)|"Subjects who have not previously received any meningococcal vaccine, who will receive 2 doses of MenABCWY+OMV vaccine, one month apart, in the current study.~Blood samples will be collected from subjects at Day 1 (before vaccination), Day 31 (before vaccination), Day 38 and Day 61."
3016706|NCT02451501|Experimental|Lying|Nebulization in lying position
3016707|NCT02451501|Active Comparator|Sitting|Nebulization in sitting position
3016708|NCT02451488|Experimental|GM-CSF|Patients will be treated with 14 days of GM-CSF self-administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on the day of enrollment. Patients will be instructed in the self-administration of GM-CSF and after they have demonstrated competency with the procedure, they will self-administer the treatment at home. Patients will undergo surgery within 1 day to 5 days after cessation of the GM-CSF therapy.
3016709|NCT02451488|Other|Standard of Care|no neo-adjuvant therapy prior to surgical intervention
3016710|NCT02451475|Other|Amitriptyline|Amitriptyline 25 mg/day
3016711|NCT02451475|Active Comparator|Venlafaxine|Venlafaxine 75 mg/day
3016712|NCT02451475|Active Comparator|Paroxetine|Paroxetine 25 mg/day
3016713|NCT02451462|Experimental|Zoledronic acid arm|Zoledronic acid
3016714|NCT02451462|No Intervention|placebo arm|placebo
3016715|NCT02451436|Active Comparator|Sleep and Media Use Intervention|The sleep intervention group will receive four sessions including cognitive behavioral training aimed at increasing sleep duration, education on the effects of media use on sleep and problem solving with the participant and parent about increasing sleep duration and decreasing nighttime media use.
3016716|NCT02451436|Active Comparator|Study Skills Control Group|The control group will receive four sessions of study skills training.
3016717|NCT02451423|Experimental|MPDL3280A|MPDL3280A: Intravenously; Day 1 of each 21-day Cycle
3016718|NCT02451410|Experimental|Nutrition and physical activity|This arm includes all preschool classes receiving the educational and behavioral intervention to improve nutrition and physical activity
3016719|NCT02451397||Dr.Tang's research group|Chinese lifestyle associated with osteoporosis
3016720|NCT02451384|Experimental|routine surgery|In this arm the patients will be performed routine surgery to remove the tumors. And then we compare their circulating tumor cell countings in the pre and post-operation.
3016721|NCT02451384|Experimental|no-touch surgery|In this arm the patients will be performed no-touch surgery to remove the tumors. And then we compare their circulating tumor cells countings in the pre and post-operation.
3016722|NCT02451384|Experimental|laparoscopy surgery|In this arm the patients will be performed laparoscopy surgery to remove the tumors. And then we compare their circulating tumor cells countings in the pre and post-operation.
3016723|NCT02451371|Experimental|tDCS|Patients with schizophrenia to receive tDCS treatment
3016724|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 1: 6 to 35 Months|Participants aged 6 to 35 months received 2 doses of 0.25 mL QIV (2016-2017 NH formulation) intramuscularly, 1 injection each at Day 0 and 28.
3016725|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 2: 3 to 8 Years|Participants aged 3 to 8 years received 2 doses of 0.5 mL QIV (2016 SH formulation) intramuscularly, 1 injection each at Day 0 and 28.
3016726|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 3: 9 to 17 Years|Participants aged 9 to 17 years received 1 dose of 0.5 mL QIV (2015-2016 NH formulation) intramuscularly, at Day 0.
3016727|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 4: >=18 Years|Participants aged >=18 years received 1 dose of 0.5 mL QIV (2015 SH formulation) intramuscularly, at Day 0.
3016728|NCT02451345|Experimental|Intervention|Personalized risk model+website+phone coaching
3016729|NCT02451332|Experimental|vaccinated|These women will have received the seasonal influenza vaccine.
3016730|NCT02451319|Active Comparator|first group|Patients undergoing Retrograde Intrarenal Surgery with 20w holmium laser device who have 1-2 cm diameter kidney stones
3016731|NCT02451319|Active Comparator|second group|Patients undergoing Retrograde Intrarenal Surgery with 30w holmium laser device (working over 20w power) who have 1-2 cm diameter kidney stones
3016732|NCT02451319|Active Comparator|third group|Patients undergoing Retrograde Intrarenal Surgery with 30w holmium laser(working under 20w power) device who have 1-2 cm diameter kidney stones
3016733|NCT02451306|Experimental|Quetiapine|"18 patients of the risk-group will receive quetiapine (Seroquel Prolong (c)) for 8 weeks in adjunction to their antidepressant standard therapy. Group allocation is randomised and double-blind.~Dosages: 50mg (day 1-3), 100mg (day 4-6) and 150mg (from day 7 onwards). Administration: Quetiapine will be given once daily before bedtime, not together with a meal and swallowed as a whole."
3016734|NCT02451306|Placebo Comparator|Placebo|"18 patients of the risk-group will receive placebo for 8 weeks in adjunction to their antidepressant standard therapy. Group allocation is randomised and double-blind.~The placebo does not contain any psychoactive substance."
3016735|NCT02451306|No Intervention|Control-group|18 depressive patients without a heightened risk for BPD will not receive any medication apart from their standard antidepressant therapy (control-group).
3016736|NCT02451293|Active Comparator|Melatonin (N-acetyl-5-methoxytryptamine)|Melatonin (N-acetyl-5-methoxytryptamine) 25 mg oral administration 1 hour before bedtime for 12 weeks.
3016737|NCT02451293|Placebo Comparator|Placebo|Comparable placebo pill, oral administration 1 hour before bedtime for 12 weeks.
3016738|NCT02451280|Experimental|Unilateral Hybrid Intervention Group|Participants will receive 6 weeks of bilateral RT training using the BMT and UAT training in each session.
3016739|NCT02451280|Experimental|Bilateral Hybrid Intervention Group|Participants will receive 6 weeks of bilateral RT training using the BMT and BAT training in each session.
3016740|NCT02451280|Experimental|Robot-Assisted Training Group|Participants will receive 6 weeks of RT training using the BMT in each session.
3016741|NCT02451267|Experimental|positive CPR: research group|physical therapy treatment with aerobic exercise
3016742|NCT02451267|Experimental|negative CPR: research group|physical therapy treatment with aerobic exercise
3051888|NCT02214953|Experimental|BI 11634 ER formulation C|
3016747|NCT02451241|Sham Comparator|sham acupuncture|group will be submitted to placebo electroacupuncture for 20 minutes, two times a week for 5 weeks. Each session lasts about 40 min.
3016748|NCT02451241|Experimental|acupuncture|group will be submitted to electroacupuncture for 20 minutes, two times a week for 5 weeks. Each session lasts about 40 min.
3016749|NCT02451228||Single-group|No intervention; Observational study of 300 pregnant women receiving Indomethacin therapy for risk of preterm birth
3016750|NCT02451215|Experimental|Laser interstitial thermotherapy (LITT) treated patients|All patients enrolled on the trial will undergo LITT therapy per protocol. Side-effects and outcomes will be monitored and compared with disease matched historical controls.
3016751|NCT02451202|Experimental|Deep Neuromuscular Blockade arm|"After initial doses of 0.6 mg Rocuronium, a continuous infusion can be initiated to maintain 0 responses to train-of-four (TOF) stimulation or 1-2 responses to Post-Tetanic Count (PTC) (Deep NMB). The pump rate will vary and depends on the PTC value. The initial pump rate will be set at 0.5 mg/kg per hour. In case of a deviation from the required PTC value the pump rate can be increased or decreased. This was left to the discretion of the attending anaesthetist. Deep NMB should be maintained throughout the operation.~The infusion of Rocuronium will be discontinued and Sugammadex will be given 4 mg/kg at the end of surgery, which is from deep NMB (PTC = 1-2)."
3016752|NCT02451202|Active Comparator|Moderate Neuromuscular Blockade arm|"After evidence of early spontaneous recovery (< 10% of control T1) from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain 1 to 2 responses to train-of-four stimulation (Moderate NMB). The initial pump rate will be set at 0.5 mg/kg per hour. In case of a deviation from the required TOF value the pump rate can be increased or decreased. This was left to the discretion of the attending anaesthesiologist. Moderate paralysis should be maintained throughout an operation.~At the end of surgery, the infusion of Rocuronium will be discontinued and Sugammadex 2 mg/kg via bolus injections]will be administered at least reappearance of T2."
3016753|NCT02451189|Experimental|Inulin acetate ester|Inulin acetate ester, 10g/day for 30 days
3016754|NCT02451189|Experimental|Inulin propionate ester|Inulin propionate ester, 10g/day for 30 days
3016755|NCT02451189|Experimental|Inulin butyrate ester|Inulin butyrate ester, 10g/day for 30 days
3016756|NCT02451176|Active Comparator|Active Comparator: Davol Bard ®Soft Mesh|Device: Davol Bard ®Soft Mesh Synthetic mesh for open ventral hernia repair for clean-contaminated or contaminated abdominal wall hernias Other Name: synthetic mesh SoftMesh™ (CR Bard)
3016757|NCT02451176|Active Comparator|Active Comparator: LifeCell Strattice®|Device: LifeCell Strattice® Reconstructive Tissue Matrix Biologic mesh for open ventral hernia repair for clean-contaminated or contaminated abdominal wall hernias Other Name: Biologic mesh Strattice
3016758|NCT02451163|Active Comparator|polysaccharides from wheat|12.0 g powder containing 10.0 g active ingredient (wheat polysaccharides) as well as 2.0 g filling substance (maltodextrin) stirred in milk or filtered apple juice (200 ml each).
3016759|NCT02451163|Placebo Comparator|control product|12.0 g maltodextrin stirred in milk or filtered apple juice (200 ml each).
3016760|NCT02451150|Experimental|Azilsartan 5 mg|Weight <50 kg: azilsartan 5 mg, tablets, orally, once, after breakfast on Day 1.
3016761|NCT02451150|Experimental|Azilsartan 10 mg|Weight ≥50 kg: azilsartan 10 mg, tablets, orally, once, after breakfast on Day 1.
3016762|NCT02451137|Experimental|Toujeo|Toujeo once daily on top of non-insulin antidiabetic agents in a real world setting
3016763|NCT02451137|Active Comparator|Levemir or Lantus|Levemir or Lantus once or twice daily according to label on top of non-insulin antidiabetic agents in a real world setting
3016764|NCT02451124|Experimental|Screening: non-endoscopic inflatable balloon for the esophagus|Patients undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus over 30-60 minutes followed by a standard esophagogastroduodenoscopy. Questionnaire administration will provide self-reported data on patient experiences. laboratory biomarker analysis of biopsy will confirm diagnosis.
3016765|NCT02451111|Active Comparator|Rituximab/Ibrutinib|Ibrutinib capsules for 24 months (104 weeks) daily (always at the same time) in a dose of 560 mg (4 x 140 mg capsules)
3016766|NCT02451111|Placebo Comparator|Rituximab/Placebo|Placebo as comparator for 24 months (4 capsules daily always at the same time)
3016767|NCT02451098|Experimental|Atorvastatin10mg, Ezetimibe10mg|Atorvastatin10mg, Ezetimibe10mg will be administered (Duration 8 weeks)
3016768|NCT02451098|Active Comparator|Atorvastatin10mg, Ezetimibe placebo|Atorvastatin10mg, placebo will be administered (Duration 8 weeks)
3016769|NCT02451098|Experimental|Atorvastatin20mg, Ezetimibe10mg|Atorvastatin20mg, Ezetimibe10mg will be administered (Duration 8 weeks)
3016770|NCT02451098|Active Comparator|Atorvastatin20mg, Ezetimibe placebo|Atorvastatin20mg, placebo will be administered (Duration 8 weeks)
3016771|NCT02451098|Experimental|Atorvastatin40mg, Ezetimibe10mg|Atorvastatin40mg, Ezetimibe10mg will be administered (Duration 8 weeks)
3016772|NCT02451098|Active Comparator|Atorvastatin40mg, Ezetimibe placebo|Atorvastatin40mg, placebo will be administered (Duration 8 weeks)
3016773|NCT02451085|Experimental|remote rehabilitation group|'training with video therapy' a domestic exercise plan through remote rehabilitation system based on short film. (http://videotherapy.co/vt/home.php), the plan will include installation of exercises adapted according to the physical condition of the patient. The content of each exercise is dynamic and variable. The difference between each exercise and the other depends on the feedback that the patient fills at the end of each exercise and sends to the therapist. Before each exercise, it is shown with explanations about the importance of performing it the way of performing. Furthermore, during the training, the patient listens to vocal explanation about the quality and importance of performing the exercise, and a vocal counting is heard and then a positive feedback is given.
3016774|NCT02451085|Other|conventional exercise group|will receive instruction for self-training as accepted today through exercise sheet. The exercises will be suited to the ones provided to the patients in the intervention group. Moreover, a follow-up sheet will be given to the patients to fill in order to receive a feedback at the end of experiment. The training duration will be identical in both groups and will last for 30-45 minutes, three times a week.
3016775|NCT02451072|Experimental|Placebo, LSD, Ketanserin/LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but three treatment conditions in the same subject
3016903|NCT02450214|Experimental|Ketamine group (K)|50 mL syringe with ketamine (50mg / 50ml), plus 1 flask of 100 mL saline (Ketamine)
3016776|NCT02451059|Experimental|Intervention-WE CARE|"The WE CARE survey is used to identify unmet material needs; it will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age.~Providers will be trained to review the WE CARE survey at health supervision visits and generate our WE CARE community resource handouts (referrals) through the EMR.~Peer patient navigators will offer personalized guidance to families with accessing community resources. A patient navigator will be available for at least 1 1/2 days per week at each intervention health center to meet with families and offer guidance. Families will also have the opportunity to contact a peer navigator at any time via the hotline number listed on the referral information sheets."
3016777|NCT02451059|No Intervention|Control-Standard of Care|Participants in the delayed-intervention control group will receive standard pediatric care. However, since the health centers share a common EMR, and for ethical reasons, investigators will also embed the health IT referral mechanism into the EMR at the control sites. Control providers will be made aware of this prior to the start of the study. Although this may potentially reduce the effect size, the investigator's prior study found that the impact on referral rates of provider access to resource information was minimal. Families at control health centers will not receive the WE CARE surveys at health supervision visits and will not have access to the peer patient navigators
3016778|NCT02451033|Active Comparator|standard medical therapy|Standard medical therapy
3016779|NCT02451033|Active Comparator|G-CSF|Standard medical therapy plus G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year.
3016780|NCT02451033|Active Comparator|G-CSF plus growth hormone|Standard medical therapy plus G-CSF plus Growth Hormone therapy. Growth Hormone will be given in low dose of 1unit sc daily for 1 year.
3016781|NCT02451020|Experimental|Altitude exposure|Stay at 3200 m for 3 weeks
3016782|NCT02451007|Experimental|A (lurbinectedin)|lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
3016783|NCT02450994|Active Comparator|Dexamethasone|Dexamethasone 4 mg capsules, twice per day, orally
3016784|NCT02450994|Placebo Comparator|Placebo|Placebo capsules twice per day, orally
3016785|NCT02450981|Experimental|BCD-021 group|BCD-021 (bevacizumab) at a dose of 1.25 mg, administered as single intravitreal injection every 28 days up to 12 months.
3016786|NCT02450968|Active Comparator|Dexamethasone|Dexamethasone 4 mg capsules, twice per day, orally
3016787|NCT02450968|Placebo Comparator|Placebo|Placebo capsules twice per day, orally
3016788|NCT02450955|Active Comparator|Massage|A superficial massage was performed for 10 minutes in the cervical region consisting of gentle rubbing and kneading.
3016789|NCT02450955|Experimental|Occiput-Atlas-Axis Technique|The technique is applied in two stages: in the first stage, a light core decompression is performed and then small circumductions are made with the aim of increasing viscoelasticity of tissues. Subsequently the appropriate joint barrier is sought by selective tension and high-velocity rotation manipulation is performed in a cranial helical motion without raising the subjects head.
3016790|NCT02450942|Experimental|18F-FDS injection and PET/CT scan|The patients were intravenously injected with 18F-FDS and underwent PET/CT scan 1 h after the injection.
3016791|NCT02450929||Standard Barrel-Cuff ETT|Standard Barrel-Cuff ETT use in surgical patients
3016792|NCT02450929||Taperguard ETT|Taperguard ETT use in surgical patients
3016793|NCT02450903|Experimental|LDK378|Oral LDK378 750mg once daily
3016794|NCT02450890|Placebo Comparator|Placebo First, then ORADUR®|Placebo once daily for 2 weeks in Period 1 and ORADUR®-Methylphenidate oral capsule at the optimal dose once daily for 2 weeks in period 2. (No washout period between two treatment periods)
3016795|NCT02450890|Experimental|ORADUR® First, then Placebo|ORADUR®-Methylphenidate oral capsule at the optimal dose once daily for 2 weeks in Period 1 and Placebo once daily for 2 weeks in period 2. (No washout period between two treatment periods)
3016796|NCT02450877|Experimental|Azacitidine Treatment|: Subjects randomized to the experimental arm will receive up to 3 cycles of IV azacitidine on Days 1 through 7 at the dose selected from the safety run-in part.
3016797|NCT02450877|Other|Control Arm: 'Watch and Wait'|Subjects randomized to the control arm will undergo 'watch and wait' until clinical relapse (defined as at least 5% blasts in PB (peripheral blood) and/or BM (bone marrow) and/or proven histological extramedullary relapse).
3016798|NCT02450864|Experimental|patient with ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
3016799|NCT02450864|Sham Comparator|patient without ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
3016800|NCT02450851||Undiagnosed disorders|Patients with rare, undiagnosed disorders
3016801|NCT02450838|Experimental|Adjuvanted V180 vaccine|Participants will receive one intramuscular (IM) injection of adjuvanted (with Alhydrogel™) V180 at study entry.
3016802|NCT02450838|Experimental|Nonadjuvanted V180 vaccine|Participants will receive one IM injection of nonadjuvanted V180 at study entry.
3016803|NCT02450838|Placebo Comparator|Placebo|Participants will receive one IM injection of placebo at study entry.
3016804|NCT02450825|Other|Mechanically ventilated patients|Mechanically ventilated patients who underwent a computed tomographic scan for dyspnea or hypoxemia will undergo a standardized lung ultrasound examination on Day 1 and Day 2 to 4. The GE Vivid ultrasound system will be used to perform the lung ultrasound examination.
3016805|NCT02450825|Other|Spontaneously breathing patients|Spontaneously breathing patients who underwent a computed tomographic scan for dyspnea or hypoxemia will undergo a standardized lung ultrasound examination on Day 1 only. The GE Vivid ultrasound system will be used to perform the lung ultrasound examination.
3016806|NCT02450812||Radium-223-dichloride (Xofigo, BAY88-8223)|patients with mCRPC with symptomatic bone metastases
3016807|NCT02450799|Experimental|AcrySof IOL|Acrylic IOL, prior implantation (1994-2000) in one or both eyes
3016808|NCT02450799|Active Comparator|Silicone IOL|Silicone IOL, prior implantation (1994-2000) in one or both eyes
3016809|NCT02450799|Active Comparator|PMMA IOL|PMMA IOL, prior implantation (1994-2000) in one or both eyes
3016810|NCT02450786|Experimental|Donepezil group|Donepezil is started in 5mg for 8 weeks followed by dose escalation to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
3016811|NCT02450786|No Intervention|control group|No administration of any therapeutic medications for dementia including cholinesterase inhibitor or NMDA receptor blocking agents. Standard treatment protocol of Parkinson's disease with mild cognitive impairment would be fulfilled including dopaminergic or nondopaminergic medications as well as nootropic drugs.
3016812|NCT02450773|Experimental|Furosemide/Potassium chloride|40 mg furosemide; 20 meq potassium chloride
3016813|NCT02450773|Placebo Comparator|Placebo|Placebo #1, Placebo #2
3016814|NCT02450760|Other|Control|Subjects will take their blood pressure twice daily using the provided Withings blood pressure cuff. If subjects miss blood pressure readings, they will receive automated alerts reminding them to take their blood pressure. Subjects will also receive weekly emails with their blood pressure data for the week.
3016815|NCT02450760|Other|Social Incentive|Subjects will take their blood pressure twice daily using the provided Withings blood pressure cuff. Subjects in this arm will also identify a social supporter who may help subjects adhere to daily blood pressure readings. If the subject misses blood pressure readings, they will receive automated alerts reminding them to take their blood pressure. The identified social supporter will also receive these alerts, with the expectation that the social supporter will remind the subject to take their blood pressure. Both the subject and the social supporter will also receive weekly emails with their blood pressure data for the week.
3016816|NCT02450747|Experimental|Multifocal Test Contact Lens|Subjects will wear the etafilcon A Multifocal test lens in a daily wear modality.
3016817|NCT02450734||Carotid endarterectomy|Realisation of an ultrasound-guided intermediate cervical plexus block for anesthesia of carotid endarterectomy
3016818|NCT02450721||Acute stroke|"Patients in the acute phase of atherothrombotic stroke or TIAs with 50-99% ACAS within the first 3 days af vascular event.~Interventions to be administered: Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE, National Institutes of Health Stroke Scale (NIHSS)"
3016819|NCT02450721||Stable carotid artery stenosis|"Patients with 50-99% ACAS without history of vascular events during one month before enrollment.~Interventions to be administered: Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE"
3016820|NCT02450721||Control group|Healthy volunteers without ACAS Interventions to be administered:Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE
3016821|NCT02450708||For patients with 1 HLA-compatible donor for URD HCT|For patients with 1 URD: donor KIR genotyping will be performed on the donor. Because donor selection will not depend on KIR/HLA genotyping, completion of donor KIR genotyping is not required prior to transplant.
3016822|NCT02450708||For patients with >1 HLA-compatible donor for URD HCT|For patients with 1 or more donor candidates, KIR genotyping may be performed for up to 5 donors. For patients with HLA-B alleles harboring the Bw4 epitope, KIR3DL1 allele typing will be performed at MSKCC.
3016823|NCT02450695|Experimental|Active rTMS|"In rTMS, a device called a stimulator provides energy to a magnetic coil. The coil is a handheld unit that delivers magnetic pulses. The coil is placed against the scalp on the top of your head. Sessions will occur once a day, 5 days/week, for 3 weeks."
3016824|NCT02450695|Sham Comparator|Sham rTMS|The coil in the sham rTMS phase will be positioned 90 degrees off the scalp, with one wind of the coil touching the scalp. This will ensure that the participant will not be affected by the machine during this time. All other factors will be similar to the active rTMS phase.
3016825|NCT02450682|Active Comparator|Apixaban|30 participants prescribed Apixaban 3-14 days before and 28 days after CIED procedure.
3016826|NCT02450682|Other|Warfarin|30 participants will take stable dose of warfarin and go through the procedure without drug interrupt. The dose is adjusted by INR level. Length of treatment is 42 days, 14 days before and 28 days after the procedure.
3016827|NCT02450656|Experimental|Afatinib plus selumetinib|Combination of afatinib and selumetinib at the optimal dose and regimen as determined in the phase I part of this study
3016828|NCT02450656|Active Comparator|Control|Standard-of-care second line treatment for non small cell lung cancer (docetaxel)
3016829|NCT02450643|Active Comparator|Test then Control|Subjects will perform a DBPCFC with the Test formula followed by the Control formula
3016830|NCT02450643|Active Comparator|Control then Test|Subjects will perform a DBPCFC with the Control formula followed by the Test formula
3016831|NCT02450630|Experimental|training on diagnosis, treatment and referral of children|Intervention Arm : training in diagnosis, treatment and referral of sick children
3016832|NCT02450630|No Intervention|Presumptive treament of sick children|Control Arm - Training of private providers in completing study tools i.e. filling in register and referral forms. No training in diagnosis, treatment and referral and no community awareness on referral
3016833|NCT02450617|Experimental|Stabilizing group treatment for PTSD|Group treatment, 20 sessions psychoeducation and skills-training. In combination with conventional individual treatment.
3016834|NCT02450617|Active Comparator|Conventional Individual treatment - PTSD|Conventional individual treatment.
3016835|NCT02450617|Experimental|Stabilizing group treatment for Dissociative disorders|Group treatment, 20 sessions psychoeducation and skills-training. In combination with conventional individual treatment.
3016836|NCT02450617|Active Comparator|Conventional Individual treatment - Dissociative disorders|Conventional individual treatment.
3016837|NCT02450604|Other|Patients with chronic pains of unknown aetiology|
3016838|NCT02450591|Experimental|Oligometastatic Non-Small Cell Lung Cancer|Patients will be placed on EGFR-TKI for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will undergo induction TKI for 12 weeks. At the conclusion of 12 weeks on erlotinib, patients without disease progression [partial response (PR) or stable disease (SD)] will undergo definitive local treatment to all remaining sites of disease. After local therapy, erlotinib will be resumed until progression of disease (POD) by RECIST criteria. All assessments completed during the 12 week TKI induction phase are to be performed per protocol with a ± 7 day window.
3016839|NCT02450578|Experimental|Cohort 1a: DSM265/placebo, sporozoite inoculum|DSM265 400mg / placebo Day -1, sporozoite inoculum Day 0
3016840|NCT02450578|Active Comparator|Cohort 1b: Malarone, sporozoite inoculum|Malarone daily for 9 days from Day -1 to Day 7, sporozoite inoculum Day 0
3016841|NCT02450578|Experimental|Cohort 2: DSM265/placebo, sporozoite inoculum|DSM265 400mg / placebo Day -7, sporozoite inoculum Day 0
3016842|NCT02450578|Experimental|Cohort 3: DSM265 / placebo, sporozoite inoculum|DSM265 400mg / placebo Day -X, sporozoite inoculum Day 0
3016843|NCT02450565||Neuropathic pain subjects|The diagnosis of neuropathic pain will be made by pain specialists based on a detailed history, physical examination, investigation results and medical records.
3016844|NCT02450565||Nociceptive pain subjects|The diagnosis of nociceptive pain will be made by pain specialists based on a detailed history, physical examination, investigation results and medical records.
3016845|NCT02450552|Experimental|Oral ezogabine 600 mg/day|
3016846|NCT02450552|Experimental|Oral ezogabine 900 mg/day|
3016847|NCT02450552|Placebo Comparator|Placebo|
3016848|NCT02450539|Experimental|Abemaciclib|200 milligram (mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3016849|NCT02450539|Active Comparator|Docetaxel|75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3016850|NCT02450526|Experimental|AbobotulinumtoxinA|Dysport, 50 Units, divided into five injections into the glabellar area. Administered in double blind fashion at cycle 1 followed by up to 4 cycles Dysport, 50 Units administered with an interval period depending on response, no less than 12 weeks between each treatment cycle.
3016851|NCT02450526|Active Comparator|OnabotulinumtoxinA|Botox will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
3016852|NCT02450526|Placebo Comparator|AbobotulinumtoxinA Placebo|Dysport placebo will be administered in treatment cycle 1 only. On Day 1, 50 Units, divided into five injections into the glabellar area.
3016853|NCT02450526|Placebo Comparator|OnabotulinumtoxinA Placebo|Botox placebo will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
3016854|NCT02450513||Single-group study|Subjects with active refractory Crohn's disease naïve to TNF antagonists starting adalimumab therapy.
3016855|NCT02450500|Experimental|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging.
3016856|NCT02450487|Experimental|Interventional group|100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control after lower third molar surgery
3016857|NCT02450474|Other|A: baseline - IPC|"A: baseline - IPC - washout - NMES - washout - follow up~The baseline phase, washout phase and follow up phase will consist of treatment as normal. IPC phase will consist of normal care plus IPC of the lower limbs for the duration of each dialysis session."
3016858|NCT02450474|Other|B: baseline - NMES|"B: baseline - NMES - washout - IPC - washout follow up~The baseline phase, washout phase and follow up phase will consist of treatment as normal. NMES phase will consist of normal care plus stimulation of the foot and calf muscles for a period of one hour during dialysis."
3016859|NCT02450461||Asthma|20 patients with asthma
3016860|NCT02450461||Controls|20 control subjects with no apparent lung disease and normal lung function testing. Matched for gender, age and smoking history.
3016861|NCT02450448||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
3016862|NCT02450448||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
3016863|NCT02450448||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
3016864|NCT02450448||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
3016865|NCT02450435||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
3016866|NCT02450435||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
3016867|NCT02450435||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
3016868|NCT02450435||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
3016869|NCT02450422||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
3016870|NCT02450422||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
3016871|NCT02450422||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
3016872|NCT02450422||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
3016901|NCT02450227|Experimental|Spinach - Minced (10 mg lutein)|"2-1: Group given minced spinach as first intervention Minced spinach (10 mg lutein) given every second day for a 15 days period.~Followed by:~Whole leaf spinach (10 mg lutein) given every second day for a 15 days period."
3016873|NCT02450409|Active Comparator|gap technique (GT)|"The patients receive a total knee arthroplasty using the established gap technique (gold standard serving as control). The intervention is the implantation of a total knee arthroplasty with this specific technique.~Implantation of TKA using the gap technique is the intervention. Intervention is not a drug but a specific operative technique."
3016874|NCT02450409|Experimental|anatomical alignment (AA)|"The patients receive a total knee arthroplasty using the new anatomical alignment technique (experimental). The intervention is the implantation of a total knee arthroplasty with this specific technique.~Implantation of TKA using anatomical alignment Intervention is not a drug but a specific operative technique."
3016875|NCT02450383|Active Comparator|Control|Autologous subepithelial connective tissue graft
3016876|NCT02450383|Experimental|Experimental|Acellular Dermal Matrix
3016877|NCT02450370|Active Comparator|Conventional IBS diet group|Subjects in this group will follow a conventional diet for up to 10 weeks. They will receive 3 dietetic consultations at week 0,6 and 10. This diet will focus on small frequent meals, no skipping meals and dietary adjustments for bloatedness, diarrhea and constipation. Advice on intake of caffeine and alcohol will also be given. Dietary leaflets will be provided.
3016878|NCT02450370|Experimental|Low FODMAP diet group|Subjects in this group will follow a low FODMAP diet for up to 10 weeks. Foods that are high in oligosaccharides, disaccharides, monosaccharides and polyols will be avoided. They will receive 3 dietetic consultations at week 0,6 and 10. Dietary leaflets, including meal samples and Yes/No food lists will be provided.
3016879|NCT02450357||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
3016880|NCT02450357||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
3016881|NCT02450357||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
3016882|NCT02450357||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
3016883|NCT02450344|Experimental|Internet intervention|Interactive health promotion
3016884|NCT02450344|Active Comparator|Conventional intervention|Passive health promotion
3016885|NCT02450331|Experimental|Atezolizumab|Participants will receive intravenous (IV) atezolizumab on Day 1 of each 21-day cycle for 16 cycles (up to 1 year).
3016886|NCT02450331|No Intervention|Observation|Participants will undergo observation starting on Day 1 for 16 cycles (up to 1 year).
3016887|NCT02450318|Experimental|Slow-paced walking|Subjects will complete 47 minutes of walking at slow pace.
3016888|NCT02450305||Treated with HBO|QOL questionnaires at 5 time points for those having HBO therapy at least one year post radiation therapy for head and neck cancer, daily x6 weeks
3016889|NCT02450305||Not treated with HBO|QOL questionnaires for those at least one year post radiation therapy for head and neck cancer at 5 times points.
3016890|NCT02450279|Active Comparator|Nebulization with a vibrating-mesh nebulizer|Nebulization performed with a vibrating-mesh nebulizer
3016891|NCT02450279|Active Comparator|Nebulization with a jet nebulizer|Nebulization performed with a jet nebulizer
3016892|NCT02450266|Active Comparator|A: Transrectal ultrasound-guided biopsy|Patients of arm A receive a systematic transrectal ultrasound-guided prostate biopsy (12-18 biopsy cores depending on individual prostate volume)
3016893|NCT02450266|Experimental|B: MRI/ultrasound fusion-guided biopsy|Patients of arm B receive a targeted MRI/ultrasound fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
3016894|NCT02450253|Active Comparator|Active Treatment|Tadalafil 20mg Capsule Stat single dose 2 x MRI scans (pre and post dose) Neuropsychological tests pre and post IMP dose Cognitive functioning prior to 1st MRI scan of that visit
3016895|NCT02450253|Placebo Comparator|Control|Matched placebo Capsule Stat single dose 2 x MRI scans (pre and post dose) Neuropsychological tests pre and post IMP dose Cognitive functioning prior to 1st MRI scan of that visit
3016896|NCT02450240||Depression and Anxiety Disorders|"350 subjects who screen positive for anxiety or depressive symptoms on the Patient Health Questionnaire (PHQ-9) ≥ 10 and/or Overall Anxiety Severity and Impairment Scale (OASIS) ≥ 8.~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
3016897|NCT02450240||Eating Disorders|"350 subjects who screen positive for problems related to eating behavior on the Eating Disorder Screen (SCOFF), score ≥ 2.~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
3016898|NCT02450240||Substance Use Disorders|"350 subjects who screen positive for problems related to substance use on the Drug Abuse Screening Test (DAST-10), score > 2.~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
3016899|NCT02450240||Healthy Controls|"150 subjects who do not screen positive for anxiety and depression symptoms or problems related to eating behavior and/or substance use.~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
3016900|NCT02450227|Active Comparator|Spinach - Whole leaf (10 mg lutein)|"1-2: Group given whole leaf as first intervention Whole leaf spinach (10 mg lutein) given every second day for a 15 days period.~Followed by:~Minced spinach (10 mg lutein) given every second day for a 15 days period."
3016902|NCT02450214|Sham Comparator|Control group (C)|50 mL syringe with saline, plus 1 flask of 100 mL saline (Saline)
3051889|NCT02214953|Active Comparator|BI 11634 IR tablet|
3016904|NCT02450214|Experimental|Magnesium + ketamine group (MGK)|50mL syringe with ketamine (50mg / 50ml), plus a flask of 100ml of saline with 5 g of magnesium sulfate (Ketamine + magnesium)
3016905|NCT02450201|Experimental|Part 1: Reproducibility|Pyruvate injection followed by an MRI scan. 2-3 weeks after imaging #1: a second pyruvate injection followed by an MRI scan.
3016906|NCT02450201|Experimental|Part 2: Treatment Response|Pyruvate injection followed by an MRI scan. 2 months after imaging #1: a second pyruvate injection followed by an MRI scan.
3016907|NCT02450188|Active Comparator|vardenafil|The study includes a total period of 10 week with a total of 3 visits for vardenafil Group (at the beginning, at 5th week and at the end). In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.
3016908|NCT02450188|Active Comparator|vardenafil+cbst|"The study includes a total period of 10 week with a total of 10 visits for vardenafil+cbst Group (one weekly visit).~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings."
3016909|NCT02450175|No Intervention|Cases|Patients with cancer whose platelets are examined
3016910|NCT02450175|Placebo Comparator|Control|Patients without cancer whose platelets are examined for comparison
3016911|NCT02450162||conventional lateral rectus recession|This is the standard technique for recession with two single-armed sutures.Exposure of the rectus muscle insertion includes freeing the insertion and proximal muscle borders sufficiently to place the sutures. And the needle is passed through the tendon avoiding the anterior ciliary arteries. If the sutures are passed as shown a true knot is formed, and the muscle is detached. Then a caliper measures from the limbus or the original insertion. A passage of the needle through sclera. The recessed muscle is ideally parallel to the old insertion (or nearly so). Conjunctival incision was finally sutured.
3016912|NCT02450162||hang-back lateral rectus recession|"The hang-back recession has been described as a simple, safe alternative to conventional recession. The procedure is said to be less likely to result in scleral perforation because needles are placed through relatively thicker sclera near the insertion site. It is the modified techique for recession with one double-armed sutures."
3016913|NCT02450149|Experimental|Sorafenib|Sorafenib 400 mg will be administered orally twice a day for 28 days.
3016914|NCT02450136|Experimental|pazopanib|pazopanib 800 mg will be administered orally once a day 28 days.Study treatment will be continued until objective disease progression.
3016915|NCT02450123|Experimental|sunitinib|sunitinib 50mg will be administered orally once a day 42 days.Study treatment will be continued until objective disease progression.
3016916|NCT02450110|Experimental|Intervention|Spinal cord stimulation on top of standard treatment
3016917|NCT02450110|No Intervention|Control|Standard treatment
3016918|NCT02450097|Other|Lifestyle counseling|"Intermittent Caloric restriction in 3 Groups:~I- 40 patients with diabetes type 2 BMI 25.1-37 II- 40 non diabetic over weight subjects with BMI 25.1-37 III- 20 non diabetic subject with BMI 23.1 - 25 and visceral fat"
3016919|NCT02450084|Experimental|Rectus sheath block|Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl 800 µg for 48 hours postoperatively.
3016920|NCT02450084|Sham Comparator|Control|Patients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl 800µg for 48 hours postoperatively.
3016921|NCT02450058|Active Comparator|FEC|5-Fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, intravenously on day 1, every 21 days
3016922|NCT02450058|Active Comparator|EP|Epirubicin 90 mg/m2 and paclitaxel 175 mg/m2, 3-hour infusion on day 1, every 21 days
3016923|NCT02450045|Active Comparator|Femoral nerve block|Patients will receive a pre-operative continuous femoral nerve block.
3016924|NCT02450045|No Intervention|Control|Patients will receive standard care without a continuous femoral nerve block.
3016925|NCT02450032|Experimental|G17DT|Treatment with 500µg/ 0.4mL dose of G17DT administered by intramuscular injection at 0, 2, and 6 weeks.
3016926|NCT02450019|Other|Traditional to protective ventilation|Traditional ventilation will be set with 9 ml/kg with predicted body weight of tidal volumes and no PEEP. Arterial CO2 partial pressure will be maintained between 30 and 35 mmHg. After intracranial pressure measurement ventilation will be switched to protective.
3016927|NCT02450019|Other|Protective to traditional ventilation|Protective ventilation will be set with 7 ml/kg tidal volume, 5 cm H2O PEEP, and 0.4 inspired O2 fraction (FiO2). Arterial CO2 partial pressure will be maintained between 30 and 35 mmHg. After intracranial pressure measurement ventilation will be switched to traditional.
3016928|NCT02449993||MammaTyper™|MammaTyper™ will be used to assess tumor material of patients treated with neo-adjuvant therapy.
3016929|NCT02449980|Active Comparator|Primary Surgery Group|Patients randomized to the primary surgical intervention group will undergo VATS (video-assisted thoracoscopic surgery), apical blebectomy and mechanical pleurodesis during the initial hospital admission by the admitting staff surgeon. The general principles of the surgical technique consist of a 3-port thoracoscopic approach, stapled blebectomy, apical mechanical pleurodesis, and placement of chest tube . Variations of this technique will be at the discretion of the surgeon.
3016966|NCT02449759|Experimental|ACT Intervention Group|This group will receive an ACT self-help manual to be completed over the course of 6 weeks. They will also receive two brief telephone calls during the reading of the manual by a member of the research team.
3016967|NCT02449759|No Intervention|Control Group|This group will receive no intervention
3017097|NCT02448940|Placebo Comparator|lactose|2 capsule/day Containing lactose
3016930|NCT02449980|Active Comparator|Initial Non-operative management|Those randomized to the control group will be admitted and their chest tube or percutaneous drainage catheter managed according to standard protocol. This consists of a minimum of 48 hours of Pleur-Evac suction and daily chest radiographs. The drainage tube is then placed to water seal when resolution of the pneumothorax is documented by x-ray, as well as absence of an air leak. If there are no clinical or radiographic changes after a water seal period, the chest tube is then removed. A post-removal chest radiograph is obtained and the patient is discharged if clinical and radiographic criteria are met.
3016931|NCT02449967|Experimental|HepaSphere|pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
3016932|NCT02449967|Placebo Comparator|control|pancreatic cancer patients did not receive any interventional therapy
3016933|NCT02449954|Active Comparator|morphine group|intravenous 0.1mg/kg morphine
3016934|NCT02449954|Active Comparator|tramadol group|intravenous 2 mg/kg tramadol
3016935|NCT02449954|Active Comparator|ketorolac group|intravenous30 mg ketorolac
3016936|NCT02449941||Helicobacter pylori(HP) positive|Participants who are diagnosed with Helicobacter Pylori infection through ESD(endoscopic submucosal dissection) will be treated with PPI (proton pump inhibitor).
3016937|NCT02449928|Active Comparator|lactate group,|
3016938|NCT02449928|Active Comparator|control group|
3016939|NCT02449915|Experimental|Bupivacaine Arm|Those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
3016940|NCT02449915|Placebo Comparator|Placebo Arm|Those subjects in the placebo arm will have 30 mL sterile normal saline injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected into the port site wounds in the abdomen (5 sites, 4 mL per incision).
3016941|NCT02449902|Active Comparator|Treatment 1|Estradiol 10 μg vaginal softgel capsule
3016942|NCT02449902|Placebo Comparator|Treatment 2|Placebo vaginal softgel capsule
3016943|NCT02449889|Experimental|HP-hCG IM|highly purified human chorionic gonadotropin, intramuscularly (IM)
3016944|NCT02449889|Experimental|HP-hCG SC|highly purified human chorionic gonadotropin, subcutaneously (SC)
3016945|NCT02449889|Active Comparator|rhCG|recombinant human chorionic gonadotropin
3016946|NCT02449876|Experimental|Neuroscience Education|"Subjects will have 2 sessions of education 2 weeks apart. After the first session subjects will be given a 50 page book Why Do I Hurt by Adriaan Louw. Session 1 will last approximately 60 minutes and session approximately 30 minutes."
3016947|NCT02449863||Low risk ultrasound|Patients with a low risk ultrasound
3016948|NCT02449863||High risk ultrasound|Patients with a high risk ultrasound
3016949|NCT02449850|No Intervention|Observation only|Observation only
3016950|NCT02449850|Experimental|Food intervention|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age
3016951|NCT02449850|Experimental|Skin care|Intervention: regular baths with bath-oil 0.5-9 months of age
3016952|NCT02449850|Experimental|Food intervention and skin care|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age Intervention: regular baths with bath-oil 0.5-9 months of age
3016953|NCT02449837||Head and Neck Cancer|Patient with locally advanced head and neck cancer but no distant metastasis scheduled to receive radiotherapy to the head and neck region with or without chemotherapy/targeted therapy (palliative or curative intent).
3016954|NCT02449837||Cervical Cancer|Patients with locally advanced cervical cancer without distant metastasis scheduled for radiotherapy to the pelvic region with or without chemotherapy/targeted therapy (palliative or curative intent).
3016955|NCT02449837||Non-Small Cell Lung Cancer|Patients with stage I to III non-small cell lung cancer, without distant metastasis, scheduled to receive stereotactic body radiotherapy for early stage lung disease and/or external beam radiotherapy for locally advanced lung disease, with or without concurrent/sequential chemotherapy and/or targeted therapy (curative intent).
3016956|NCT02449837||Rectal Cancer|Patients with locally advanced rectal cancer (no distant metastasis) scheduled to receive neoadjuvant chemoradiotherapy (curative intent).
3016957|NCT02449837||Metastatic Prostate Cancer|Patients with metastatic prostate cancer scheduled for palliative radiotherapy, or biochemically recurrent prostate cancer following radical prostatectomy scheduled for salvage prostatic fossa radiotherapy, with or without androgen deprivation.
3016958|NCT02449837||Oligometastatic Disease|Patients with oligometastatic cancer, defined as any solid malignancy with< 5 measurable sites of metastatic disease, limited to a maximum of 3 anatomic organ systems, excluding the primary tumor and regional lymph nodes. At least 1 site of metastatic disease, but as many as all 5 sites, in addition to the primary tumor and regional lymph nodes, is amenable to local ablative therapy with external beam radiation, stereotactic cranial radiosurgery or stereotactic body radiotherapy. Treatment will be guided by multi-disciplinary evaluation and may also include surgery, chemotherapy or target agents at the discretion of the primary oncologists. Patients may present with oligometastatic disease or have oligometastatic disease recurrence after definitive therapy for localized disease.
3016959|NCT02449824||magnetic resonance imaging|Participants will undergo MRI at baseline, after 1 cycle, 3 cycles and at completion of neoadjuvant chemotherapy.
3016960|NCT02449811||Perindopril|Treatment period 1: Perindopril 5mg, oral, once daily, for 4 weeks Treatment period 2: Perindopril 10mg, oral, once daily, for 4 weeks
3016961|NCT02449811||Olmesartan|Treatment period 1: Olmesartan 20mg, oral, once daily, for 4 weeks Treatment period 2: Olmesartan 40mg, oral, once daily, for 4 weeks
3016962|NCT02449811||Amlodipine|Treatment period 1: Amlodipine 5mg, oral, once daily, for 4 weeks Treatment period 2: Amlodipine 10mg, oral, once daily, for 4 weeks
3016963|NCT02449811||Hydrochlorothiazide|Treatment period 1: Hydrochlorothiazide 25mg, oral, once daily, for 4 weeks Treatment period 2: Hydrochlorothiazide 50mg, oral, once daily, for 4 weeks
3016964|NCT02449798|Experimental|"AccuCath 2.25 BC Intravascular Catheter"|"Use of AccuCath 2.25 BC peripheral IV device for difficult IV access in emergency room patients who have had 2 previous attempts, identified as difficult IV access from patient history or non-palpable, non-visible veins."
3016965|NCT02449785|Experimental|Cystic fibrosis adults|
3016989|NCT02449616|Experimental|Study Drug|MST-188
3016968|NCT02449746|Active Comparator|Intravenous Immunoglobulin (IVIG)|"Intravenous Immunoglobulin IVIG is a pooled blood product from 3000-100,000 human blood donors with direct immunomodulatory effects.~IVIG will be given at a dose of 2g/kg over 4 days. Dosing at 2g/kg is established in neurological disorders, with limited evidence that lower doses are less effective although adequate dosing studies have not been performed."
3016969|NCT02449746|Active Comparator|Plasma Pheresis / Plasma Exchange (PLEX)|Plasma Exchange (PLEX) is a procedure in which the subject's blood is passed through a medical device which separates out plasma from the other blood components, and replaces the plasma with albumin or plasma or other colloid. PLEX therefore removes circulating pathogenic antibodies, and its use was first reported in myasthenia gravis in 1976, and furthermore therapeutic benefit after PLEX supports an antibody mediated pathogenesis of disease. In PLEX, 200-250 mL plasma per kg body weight is exchanged typically over 7-14 days using 5% albumin as replacement, often at alternate days which increases the amount of immunoglobulin removed due to equilibrium effects . PLEX modality (centrifugation or filtration), type of anticoagulation, and dose scheduling will be determined by local centre practice
3016970|NCT02449733|Experimental|HIV+ subjects|Men who test positive for HIV will receive a comprehensive package of HIV prevention services, including condom choices, condom-compatible lubricant choices, risk-reduction counseling, couples HIV counseling and testing, and linkage to care
3016971|NCT02449733|Experimental|HIV- subjects|"Men who test negative for HIV will receive a comprehensive package of HIV prevention services, including condom choices, condom-compatible lubricant choices, enhanced HIV testing options, risk-reduction counseling, couples HIV counseling and testing, linkage to care, and screening for and offering of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP).~If men test positive for HIV during the study, they will be transitioned into the HIV+ subjects arm."
3016972|NCT02449720|Active Comparator|Laparoscopic Bowel Surgery: IPLA|Participants will undergo laparoscopic bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of IPLA (0.2% Ropivacaine) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of IPLA (0.2% Ropivacaine, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
3016973|NCT02449720|Placebo Comparator|Laparoscopic Bowel Surgery: Control|Participants will undergo laparoscopic bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of Control (0.9% Saline, 20mg/hr) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of Control (0.9% Saline, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
3016974|NCT02449720|Active Comparator|Open Bowel Surgery: IPLA|Participants will undergo open bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of IPLA (0.2% Ropivacaine) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of IPLA (0.2% Ropivacaine, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
3016975|NCT02449720|Placebo Comparator|Open Bowel Surgery: Control|Participants will undergo open bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of Control (0.9% Saline, 20mg/hr) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of Control (0.9% Saline, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
3016976|NCT02449707|Active Comparator|Control|Lateral Window Technique Augmentation for Maxillary Sinus without the use of Ultrasound activated resorbable poly-D-L-lactide pins for the stabilization of membrane. Placement of Purus® Cancellous Allograft, stabilized by Biomend ™ Collagen membrane. Cone Beam CT image of the sinus will be taken to evaluate the bone formation. Trephine Biopsy will be performed after 1 year, at the time of placement of implant to check the quality of bone formed.
3016977|NCT02449707|Experimental|Ultrasonic Pins|Lateral Window Technique Augmentation for Maxillary Sinus with the use of Ultrasound activated resorbable poly-D-L-lactide pins for the stabilization of the Purus® Cancellous Allograft, and Resorb X Membrane.Cone Beam CT image of the sinus will be taken to evaluate the bone formation. Trephine Biopsy will be performed after 1 year, at the time of placement of implant to check the quality of bone formed.
3016978|NCT02449694|Experimental|OCS Liver|OCS Liver will be used to preserve the donor liver
3016979|NCT02449681|Experimental|TH-4000 (Tarloxotinib)|
3016980|NCT02449668|Sham Comparator|Acupuncture on sham points (SA)|The control group received treatment with acupuncture needles on sham points (SA).
3016981|NCT02449668|Experimental|True acupuncture (TA)|The intervention group received treatment with true acupuncture techniques (TA) on a selection of points described as effective in the literature.
3016982|NCT02449655|Experimental|AZD5363 plus paclitaxel|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week that paclitaxel is given + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
3016983|NCT02449655|Active Comparator|AZD2014 plus paclitaxel|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
3016984|NCT02449642||group 1|group 1 include 10 women in which blood tests will be taken on the day of oocyte pick up
3016985|NCT02449642||group 2|group 2 include 10 women in which blood tests will be taken on the day of embryo transfer
3016986|NCT02449629||TGMY in HIV Care|TGMY (16-24 years of age) currently in HIV care at an Adolescent Medicine Trials Unit (AMTU) site or elsewhere.
3016987|NCT02449629||TGMY Not in HIV Care|TGMY (16-24 years of age) not currently in care who are living with HIV, not living with HIV, or those who are unaware of their HIV status.
3016988|NCT02449629||Health Care and Social Service Providers|Health care and social service providers who work with TGMY at AMTU sites or elsewhere that serve TGMY within the AMTU cities.
3016990|NCT02449603|Experimental|Exenatide|Exenatide (Colorless transparent liquid, comes in a prefilled pen.5ug/10ug, AstraZeneca) should be initiated, 60 minutes pre-breakfast and pre-supper, at 5ug twice a day for 4 weeks and then titrated up at 10ug twice a day until the completion of the study.
3016991|NCT02449603|Active Comparator|Biphasic insulin Aspart 30|Biphasic insulin Aspart 30 (Colorless transparent liquid, 100u/mL, 3ml each, Novo Nordisk), subcutaneous injection, starting at a dose of 0.2-0.4 IU/kg, or 10～12 IU/d assigned in pre-breakfast and pre-supper in a 1:1 ratio. The adjustment of insulin dose is instructed to achieve an optimal balance between glycaemic control and risk of hypoglycaemia as dictated by best clinical practice, titrated to glucose targets of fasting plasma glucose (FPG) and pre-supper <7 mmol/L.
3016992|NCT02449590|Active Comparator|Onion powder|Initial test meal contained 20g freeze dried onion powder in hot meals (1 potato soup and 1 meatball-meal daily). Subsequent daily meals contained 20g onion powder in the same meal formats.
3016993|NCT02449590|Placebo Comparator|Placebo|Hot meals (1 potato soup and 1 meatball-meal daily)containing 8.5 g sucrose and 2 g soy protein instead of onion powder
3016994|NCT02449577|Experimental|Beverage sequence ABCD|Each participant randomized to this arm is exposed to 4 test meals in the order ABCD with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
3016995|NCT02449577|Experimental|Beverage sequence CADB|Each participant randomized to this arm is exposed to 4 test meals in the order CADB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
3016996|NCT02449577|Experimental|Beverage sequence DACB|Each participant randomized to this arm is exposed to 4 test meals in the order DACB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
3016997|NCT02449577|Experimental|Beverage sequence CBAD|Each participant randomized to this arm is exposed to 4 test meals in the order CBAD with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
3016998|NCT02449577|Experimental|Beverage sequence ABDC|Each participant randomized to this arm is exposed to 4 test meals in the order ABDC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
3016999|NCT02449577|Experimental|Beverage sequence DABC|Each participant randomized to this arm is exposed to 4 test meals in the order DABC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
3017000|NCT02449577|Experimental|Beverage sequence DCAB|Each participant randomized to this arm is exposed to 4 test meals in the order DCAB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
3017001|NCT02449577|Experimental|Beverage sequence DBCA|Each participant randomized to this arm is exposed to 4 test meals in the order DBCA with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
3017002|NCT02449577|Experimental|Beverage sequence ADCB|Each participant randomized to this arm is exposed to 4 test meals in the order ADCB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
3017039|NCT02449317|Experimental|Bioimpedance guided|"Bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water~extracellular water/total body water < 0.36 : 4 ml/kg/hr~extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr~extracellular water/total body water > 0.4 : 1 ml/kg/hr"
3017128|NCT02448719|Placebo Comparator|Cohort 1-placebo|Single oral administration of TAK-792 30 mg placebo in Japanese participants
3017003|NCT02449577|Experimental|Beverage sequence BADC|Each participant randomized to this arm is exposed to 4 test meals in the order BADC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
3017004|NCT02449577|Experimental|Beverage sequence ACDB|Each participant randomized to this arm is exposed to 4 test meals in the order ACDB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
3017005|NCT02449564|Experimental|sirolimus|sirolimus 1mg daily
3017006|NCT02449551|Experimental|Volitinib|Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
3017007|NCT02449538|Experimental|everolimus|everolimus 10 mg qd daily
3017008|NCT02449525|Experimental|perfusion of flaps by a bypass system|Support of perfusion of microvascular free flaps until ingrowth of vessels from the wound bed has taken place. The System works with a pressure controlled bypass to ensure low grade perfusion.
3017009|NCT02449512||complete|individuals with somato-sensory complete spinal cord injury
3017010|NCT02449512||incomplete|individuals with somato-sensory incomplete spinal cord injury
3017011|NCT02449499||therapy|patients who meet inclusion criteria, continue to work with individual therapist, and participate in adjunct weekly group therapy
3017012|NCT02449499||control|patients who meet inclusion criteria, continue to work with individual therapist, and are eligible for group therapy participation but cannot participate in group due to schedule constraints
3017013|NCT02449486|Active Comparator|Ropivacaine|Ropivacaine 4 ml/h (8 mg/h) continuous infusion for 48 hours
3017014|NCT02449486|Placebo Comparator|Placebo|Saline infusion 4 ml/h for 48 hours
3017015|NCT02449473|Experimental|Tralokinumab Dose Regimen|Tralokinumab Subcutaneous Injection
3017016|NCT02449473|Placebo Comparator|Placebo Dose Regimen|Placebo Subcutaneous Injection
3017017|NCT02449447|Experimental|Blended treatment|10 weeks of four face-to-face Cognitive behavioral therapy sessions and internet-based CBT as a complement and support to the four sessions.
3017018|NCT02449447|Active Comparator|Treatment as usual|Usual course of antidepressants and management in primary care (e.g medication and supportive counselling).
3017019|NCT02449434||Severe Tooth Wear|
3017020|NCT02449434||Without Tooth Wear|
3017021|NCT02449421|Experimental|Fidelity-oriented Learning Community|The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
3017022|NCT02449421|Experimental|Quality Improvement Learning Community|The Quality Improvement Learning Community arm will include clinicians who set goals related to CPT delivery, execute a plan, study results, refine plan, and continue each cycle until goals are met.
3017023|NCT02449408||Overweight or Obese|Children being seen in consultation or follow-up within the Duke Division of Pediatric Endocrinology and Diabetes who are overweight or obese.
3017024|NCT02449408||Premature or Small for Gestational Age|Infants hospitalized in the Duke Transitional Care Nursery who were born prematurely or small for gestational age.
3017025|NCT02449382|Active Comparator|continuous venovenous hemofiltration|CVVH was mainly determined by the differences of sodium concentration between serum and replacement fluid. The rate of decline serum sodium could be real-time adjusted using different-sodium-concentration replacement fluid according to the updated serum sodium concentration.
3017026|NCT02449382|Active Comparator|Control group|Treatment of hypernatremia is correction of water deficit.
3017027|NCT02449369|Active Comparator|Control|Preop acetaminophen IV 1000 mg, Postop oral oxycodone & acetaminophen (5/325 mg) 1 to 2 tabs every 4 hours PRN, and Postop hydromorphone IV 0.5 mg every 4 hours PRN
3017028|NCT02449369|Active Comparator|Standard|Preop acetaminophen IV 1000 mg, Preop orphenadrine IV 60 mg, Postop oral orphenadrine 100 mg every 12 hours for 3 doses, Postop oral oxycodone & acetaminophen (5/325 mg) 1 to 2 tabs every 4 hours PRN, Postop hydromorphone IV 0.5 mg every 4 hours PRN
3017029|NCT02449369|Experimental|IVAM|Preop acetaminophen IV 1000 mg, Preop orphenadrine IV 60 mg, Postop acetaminophen IV 1000 mg every 6 hours for 7 doses, Postop orphenadrine IV 60 mg every 12 hours for 3 doses, Postop oral oxycodone 5 mg 1 to 2 tabs every 4 hours PRN, Postop hydromorphone IV 0.5 mg every 4 hours PRN
3017030|NCT02449356|Experimental|prone position endotracheal tube(PPT)|the subjects of this arm are given the prone ventilation endotracheal tube which contains fixed device, fixed rope.
3017031|NCT02449356|No Intervention|traditional endotracheal tube(TT)|the subjects of this arm are given the routine endotracheal tube.
3017032|NCT02449343|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3017033|NCT02449343|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3017034|NCT02449330|Experimental|Teneligliptin in the inhibition test|Patients showing E/e' by echocardiography less than 8 at base line and assigned as Teneligliptin treatment by randomization
3017035|NCT02449330|No Intervention|Other agents in the inhibition test|Patients showing E/e' by echocardiography less than 8 at base line and assigned as anti-diabetic agents except for DPP-4 inhibitors treatment by randomization
3017036|NCT02449330|Experimental|Teneligliptin in the improvement test|Patients showing E/e' by echocardiography more than 8 at base line and assigned as Teneligliptin treatment by randomization
3017037|NCT02449330|No Intervention|Other agents in the improvement test|Patients showing E/e' by echocardiography more than 8 at base line and assigned as anti-diabetic agents except for DPP-4 inhibitors treatment by randomization
3017038|NCT02449317|Other|Control|standard hydration : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
3017240|NCT02448056||Post-treatment one month|All enrolled HCC patients.
3017040|NCT02449304|Experimental|Endometrial Ablation (4th gen)|A single-centre uncontrolled observational study is proposed. All women presenting to the gynaecology outpatient clinic with heavy menstrual bleeding (HMB) in the absence of recognizable pelvic pathology, as determined by one or all of a normal pelvic ultrasound, hysteroscopy and / or endometrial biopsy, refractory to medical therapy that persists despite treatment with recommended pharmacological agents, who have no desire to preserve their fertility and are willing to have an endometrial ablation will be invited to participate. Eligible women with HMB will undergo RFA G4 endometrial ablation in either an inpatient or outpatient setting according to their preference.
3017041|NCT02449291|Experimental|APD421 standard|Single (standard) dose IV APD421
3017042|NCT02449291|Experimental|APD421 high|Single (high) dose IV APD421
3017043|NCT02449291|Placebo Comparator|Placebo|Single IV placebo
3017044|NCT02449278|Experimental|ISRT group|"Six cycles Chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals) .~Consolidation involved-site radiotherapy (ISRT) following in patient with complete or partial response beginning 1 month after last cycle of chemotherapy."
3017045|NCT02449278|Active Comparator|IFRT group|"Six cycles Chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-field radiotherapy (IFRT) following in patient with complete or partial response beginning 1 month after last cycle of chemotherapy."
3017046|NCT02449265|Experimental|ISRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) +prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-site radiotherapy (ISRT) following in patients with complete or paratial response beginning 1 month after the last cycle of chemotherapy."
3017047|NCT02449265|Active Comparator|IFRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) +prednisone 60mg/square meter on day 1 through 5,repeated at 21-day intervals ).~Consolidation involved-field radiotherapy (IFRT) following in patients with complete or paratial response beginning 1 month after the last cycle of chemotherapy."
3017048|NCT02449252|Experimental|ISRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maxomal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-site radiotherapy (ISRT) following in patients with complete or partial response beginning 1 month after the last cycle of chemotherapy."
3017049|NCT02449252|Active Comparator|IFRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maxomal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-field radiotherapy (IFRT) following in patients with complete or partial response beginning 1 month after the last cycle of chemotherapy."
3017050|NCT02449239|Experimental|Vicinium|"Induction - 30 mg of Vicinium in 50 mL of saline administered twice weekly (BIW) for 6 weeks followed by once weekly for 6 weeks, for a total of 12 weeks.~Maintenance - 30 mg of Vicinium in 50 mL of saline administered once weekly every other week for up to 104 weeks."
3017051|NCT02449200|Experimental|Multimodal physiotherapy group|4 week multimodal physiotherapy treatment programme provided by an experienced musculoskeletal physiotherapist
3017052|NCT02449200|No Intervention|Advice to stay active group|Advice to stay active and continue use of prescribed medication as appropriate, via weekly phone calls from a physiotherapist over a 4 week period.
3017053|NCT02449187|Experimental|JLP-1310, Fasted followed by fed|"JLP-1310 dosing in the fasted state followed by fed dosing~Interventions:~Drug: JLP-1310"
3017054|NCT02449187|Experimental|JLP-1310, Fed followed by fasted|"JLP-1310 dosing in the fasted state followed by fed dosing~Interventions:~Drug: JLP-1310"
3017055|NCT02449174|Active Comparator|Frozen Microbiota|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was kept at -80C labeled with ID and expiration date which was 6 months after preparation. Intervention - Frozen Microbiota will be delivered via enema
3017056|NCT02449174|Active Comparator|Lyophilized Microbiota|Lyophilized Microbiota_Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was starting lyophilization process within 30 minutes after completion of stool filtration. Lyophilized microbiota products were kept at 4C and were used within 6 months after preparation. Intervention - Lyophilized Microbiota will be delivered orally
3017057|NCT02449161|Experimental|MPA|medroxyprogesterone acetate, 10 mg/day, for 90 days, following endometrial ablation
3017058|NCT02449161|Placebo Comparator|placebo|1 placebo/day, for 90 days, following endometrial ablation
3017059|NCT02449148|Experimental|Intermittent Calorie Restriction|2 days per week fasting with 25 % energy intake and 5 days per week at 100% energy intake
3017060|NCT02449148|Experimental|Continuous Calorie Restriction|daily energy intake of 80 %
3017061|NCT02449148|No Intervention|Healthy Nutrition|general advice on healthy nutrition
3017062|NCT02449135|Experimental|Nano drug|Pancreatic cancer patients received nano drug interventional therapy using digital subtraction angiography（DSA）. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
3017063|NCT02449135|Active Comparator|Drug microspheres|Pancreatic cancer patients received drug microspheres (HepaSphere Microspheres) interventional therapy using digital subtraction angiography（DSA）.
3017064|NCT02449135|No Intervention|Control|Pancreatic cancer patients never received any interventional therapy.
3017065|NCT02449122|Experimental|Nano drug|Lung cancer patients received nano drug interventional therapy using digital subtraction angiography（DSA）. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
3017066|NCT02449122|Active Comparator|Drug MicroSpheres|Lung cancer patients received drug microspheres (HepaSphere Microspheres) interventional therapy using digital subtraction angiography（DSA）.
3017067|NCT02449122|No Intervention|Control|Liver cancer patients never received any interventional therapy.
3017068|NCT02449109|No Intervention|Control|Liver cancer patients never received any interventional therapy.
3017069|NCT02449109|Experimental|Nano drug|Liver cancer patients received nano drug interventional therapy using digital subtraction angiography（DSA）. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
3017070|NCT02449109|Active Comparator|Drug microspheres|Liver cancer patients received drug microspheres (HepaSphere Microspheres) interventional therapy using digital subtraction angiography（DSA）.
3017071|NCT02449096|Other|ORIF group|"No arthroscope ORIF = Open reduction and internal fixation~All Patients will be operated following a standardized protocol of our foot and ankle department:~Posterior malleolus: ORIF of the posterior malleolus fractures will be performed using a one-third tubular plate in an antiglide-technique.~Lateral malleolus: If the patients suffer a fracture of the posterior and lateral malleolus, a posterolateral approach will be performed. After posterior fracture fixation a lag screw and a one-third tubular plate will be used laterally. In special cases a locking plate will be used. If the patient only suffers a lateral malleolus fracture, we utilize the standard lateral incision.~Medial malleolus: We perform a curved incision and two cannulated leg screws/tension wiring or locking plate for fixation.~Syndesmotic complex: After all, the stability of the syndesmotic complex is tested and reduction will be performed if necessary."
3017072|NCT02449096|Active Comparator|AORIF group|Arthroscope AORIF = Arthroscopically assisted open reduction and internal fixation Our standard operative protocol is described above. Intervention: In case of randomization to the AORIF group, the arthroscopic procedure will be performed as the first step during the surgery before internal fixation. No distraction device will be used for the ankle. To avoid lesions of the cartilage and soft tissue, the joint will first be inflated with saline, and the portals will be created by blunt dissection. A 2.7mm, 30° arthroscope will be inserted into the ankle through a standard anteromedial portal. Fluid will be aspirated and the cavity filled with water. Afterwards the standard anterolateral portal will be performed in the same way. A standardized systematic examination as described by Ferkel and Fasulo will be performed to inspect the internal structures. At this stage loose bodies and disrupted ligaments extending into the joint will be removed.
3017073|NCT02449083||Arm 1|Patients with indication for MRI and coronary angiography
3017074|NCT02449083||Arm 2|Patients with atrioseptal or ventriculoseptal Shunt with indication to coronary angiography
3017075|NCT02449083||Arm 3|Patients with chronic obstructive pulmonary disease with indication to coronary angiography
3017076|NCT02449070|Experimental|Nicorandil|Receive nicorandil before primary PCI and thereafter for 6 months along with the standard therapy.
3017077|NCT02449070|No Intervention|Control|Receive primary PCI and the standard therapy.
3017078|NCT02449057|Experimental|JUST|Juveniles Under Supervision and Treatment. This entails swift, certain, and modest sanctions for violations of terms of community supervision.
3017079|NCT02449057|No Intervention|Probation-as-Usual|Juvenile probation-as-usual.
3017080|NCT02449044|Experimental|Tolvaptan|Enrolled subjects began treatment with 15 mg tolvaptan QD. A titration between target doses of 15 mg, 30 mg, or 60 mg of trial medication was based on the subject's change in serum sodium concentration and clinical tolerance of the trial medication.
3017081|NCT02449031||TOBI Podhaler cohort|
3017082|NCT02449031||non-TOBI Podhaler cohort|Approximately 250 patients treated with other FDA-approved inhaled antipseudomonal antibacterial drugs at enrollment
3017083|NCT02449018|Experimental|QBW251|QBW251 will be provided to participants during 70 days
3017084|NCT02449018|Placebo Comparator|Placebo|Placebo will be provided to participants during 70 days
3017085|NCT02449005|Experimental|Group A|Group A (BM-MSCs/fibrin glue/collagen fleece) will receive regenerative treatment using autologous bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue
3017086|NCT02449005|Experimental|Group B|in Group B (Fibrin glue/collagen fleece), a collagen fleece enriched with autologous fibrin glue devoid of stem cells will fill the osseous defect
3017087|NCT02449005|Active Comparator|Group C|Group C will receive open flap debridement retaining the soft tissue wall of the pocket
3017088|NCT02448992|Experimental|PCI via hippocampal-sparing WBRT|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25‐mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of WBRT, the technique of volumetric modulated arc therapy (VMAT) via Linac‐based RapidArc® or TrueBeamTM is employed in our treatment planning. All treatment plans are delivered by using the Linac Varian‐iX or TrueBeamTM. In terms of dose prescription, a dose of 30 Gy in 15 fractions is prescribed to whole‐brain planning target volume (PTV) under the setting of prophylactic cranial irradiation for NSCLC patients.
3017089|NCT02448992|No Intervention|observation without PCI|
3017090|NCT02448979|Active Comparator|Left thoracotomy|Esophagectomy through left side transthoracic approach, with esophagogastric anastomosis above aortic arch and two-field lymphadenectomy (thoracic and abdominal lymph node)
3017091|NCT02448979|Active Comparator|Right thoracotomy|Esophagectomy through right side transthoracic approach, with esophagogastric anastomosis above azygos vain arch or on the top of chest cavity and two-field lymphadenectomy (thoracic and abdominal lymph node)
3017092|NCT02448966||Traditional open esophagectomy|Treated by traditional three-incision esophagectomy in the centers with enough experience in esophagectomy via right thoracotomy and the volume ≧50 cases each year.
3017093|NCT02448966||Minimally invasive eophagectomy|treated by minimally invasive thorascopic/laparoscopic esophagectomy in the centers with enough experience in VATS esophagectomy and the volume≧50 cases each year.
3017094|NCT02448953|Active Comparator|negative lymph node|lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination
3017095|NCT02448953|Active Comparator|positive lymph node|lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination
3017096|NCT02448940|Experimental|Species of Lactobacillus|2 capsule/day of Lactofem Containing Species of Lactobacillus
3017098|NCT02448927|Other|TAVI patients without balloon aortic valvuloplasty|Patients that will not undergo balloon aortic valvuloplasty (BAV) before transcatheter aortic valve intervention (TAVI) with the Medtronic Evolut R (or CoreValve).
3017099|NCT02448927|Active Comparator|TAVI patients with balloon aortic valvuloplasty|Patients that will undergo balloon aortic valvuloplasty (BAV) before transcatheter aortic valve intervention (TAVI) with the Medtronic Evolut R (or CoreValve).
3017100|NCT02448914|Experimental|TRIGEL first, then Duodopa|"First Intervention (Day 1): TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).~Second Intervention (Day 2): Duodopa, intestinal gel (20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate).~Both TRIGEL and Duodopa treatment consists of 3 individually adjusted and pre-defined doses: a morning dose, a continuous 14 h infusion, and extra bolus doses (if required).~All TRIGEL doses correspond to 80% of the pre-study individually optimised doses of Duodopa. All Duodopa doses correspond to 100% of the pre-study individually optimized doses of Duodopa.~Administration is done through duodenal or upper jejunal infusion via the patient's permanently inserted gastrojejunostomy tube by means of an ambulatory infusion pump."
3017101|NCT02448914|Experimental|Duodopa first, then TRIGEL|"First Intervention (Day 1): Duodopa, intestinal gel (20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate).~Second Intervention (Day 2): TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).~Both TRIGEL and Duodopa treatment consists of 3 individually adjusted and pre-defined doses: a morning dose, a continuous 14 h infusion, and extra bolus doses (if required).~All TRIGEL doses correspond to 80% of the pre-study individually optimised doses of Duodopa. All Duodopa doses correspond to 100% of the pre-study individually optimized doses of Duodopa.~Administration is done through duodenal or upper jejunal infusion via the patient's permanently inserted gastrojejunostomy tube by means of an ambulatory infusion pump."
3017102|NCT02448888|Experimental|Adapted exercise|The experimental group is going to follow a home-exercise program designed specifically to compensate the overloads and strength necessities of the workplace, the patient enter the description of the workplace in a mobile application and the APP shows the specific exercise that the patient needs to practice and general exercise recommendations.
3017103|NCT02448888|Experimental|General exercise recommendations|The control group is going to receive general exercise recommendations (ACSM recommendations) with the same kind of APP to control the amount of exercise that each patient performs during the week.
3017104|NCT02448875|Active Comparator|CyPass Micro-Stent|Subjects in this arm of the study will receive the CyPass Micro-Stent
3017105|NCT02448875|Active Comparator|CyPass Micro-Stent + 60 ul viscoelastic|Subjects in this arm of the study will receive the CyPass Micro-Stent followed by targeted delivery of ophthalmic viscoelastic
3017106|NCT02448862||Elderly patients|Patients aged over 70 who had used fentanyl based IV-PCA for postoperative pain.
3017107|NCT02448862||Young adults|Patients aged 20 to 39 who had used fentanyl based IV-PCA for postoperative pain.
3017108|NCT02448849|Experimental|MSC recipients|The patients with nonunion fracture who underwent percutaneous implantation of bone marrow derived mesenchymal stem cells in combination with platelet lysate product.
3017109|NCT02448849|Placebo Comparator|Placebo|The patients with nonunion fracture who underwent percutaneous injection of placebo.
3017110|NCT02448836|Experimental|Active dTMS treatment|In each menstrual cycle, patients will undergo 8 sessions of dTMS active treatment for two weeks (4 sessions every week) with dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil. The post ovulation phase is the luteal and symptomatic phase of PMDD patients.
3017111|NCT02448836|Sham Comparator|Sham dTMS treatment|In each menstrual cycle, patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week) with dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil. The post ovulation phase is the luteal and symptomatic phase of PMDD patients.
3017112|NCT02448823|Experimental|Stylish Events and Mass Media|Mass Media (radio, posters) and annual Stylish Man/Stylish Living Event (SMLEvent), a multimedia event promoting CHP.
3017113|NCT02448823|Active Comparator|Control arm: mass media only|Mass media
3017114|NCT02448810|Experimental|Part 1: Subjects with mutated tumor (mt) (KRAS or NRAS)|Subjects stratified according to their mutation status.
3017115|NCT02448810|Experimental|Part 1: Subjects with wild-type (wt) tumor (KRAS and NRAS wt)|Subjects stratified according to their mutation status.
3017116|NCT02448810|Experimental|Part 2: Subjects with KRAS or NRAS mutated|Subjects stratified according to their mutation status.
3017117|NCT02448810|Experimental|Part 2: Subjects with KRAS and NRAS wt tumor|Subjects stratified according to their mutation status.
3017118|NCT02448810|Active Comparator|Part 2: Standard of Care- Subjects with KRAS or NRAS mutated|Subjects stratified according to their mutation status.
3017119|NCT02448810|Active Comparator|Part 2: Standard of Care- Subjects with KRAS and NRAS wt tumor|Subjects stratified according to their mutation status.Subjects stratified according to their mutation status.
3017120|NCT02448797|Experimental|icotinib|125 mg three times daily (375 mg per day) orally for two years.
3017121|NCT02448797|Active Comparator|chemotherapy|"Vinorelbine 25 mg/m^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles.~cisplatin 75 mg/m^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles.~For adenocarcinoma: pemetrexed (500 mg/m^2, day 1)/cisplatin (75 mg/m^2, day 1) for 4 cycles."
3017122|NCT02448784||Participants with DLB|Participants with DLB who will receive donepezil hydrochloride per approved label.
3017123|NCT02448771|Experimental|Palbociclib in Combination with Bazedoxifene|"After the screening procedures confirm eligibility participate in the research study.~Palbociclib Oral, predetermined time per cycle, predetermined dosage per protocol.~Bazedoxifene Oral, daily per cycle, predetermined dosage per protocol."
3017124|NCT02448745|No Intervention|Control|21 clusters composed of one or more villages with a total number of 30 to 70 children under 5 years old. Routine distribution of long-lasting insecticidal nets is the only malaria control intervention.
3017125|NCT02448745|Experimental|Intervention|21 clusters composed of one or more villages with a total of 30 to 70 children under 5 years old. Routine distribution of long-lasting insecticidal nets is available and in addition insecticide treated wall lining is installed in all sleeping areas with homeowner consent. All 4 walls and the ceiling are covered with lining.
3017126|NCT02448732|Experimental|ACM-1 team|intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
3017127|NCT02448719|Experimental|Cohort 1-active|Single oral administration of TAK-792 30 mg in Japanese participants
3017129|NCT02448719|Experimental|Cohort 2-active|Single oral administration of TAK-792 100 mg in Japanese participants
3017130|NCT02448719|Placebo Comparator|Cohort 2-placebo|Single oral administration of TAK-792 100 mg placebo in Japanese participants
3017131|NCT02448719|Experimental|Cohort 3-active|Single oral administration of TAK-792 250 mg in Japanese participants
3017132|NCT02448719|Placebo Comparator|Cohort 3-placebo|Single oral administration of TAK-792 250 mg placebo in Japanese participants
3017133|NCT02448719|Experimental|Cohort 4-active|Single oral administration of TAK-792 500 mg in Japanese and Caucasian participants
3017134|NCT02448719|Placebo Comparator|Cohort 4-placebo|Single oral administration of TAK-792 500 mg placebo in Japanese and Caucasian participants
3017135|NCT02448719|Experimental|Cohort 5-active|Single oral administration of TAK-792 750 mg in Japanese and Caucasian participants
3017136|NCT02448719|Placebo Comparator|Cohort 5-placebo|Single oral administration of TAK-792 750 mg placebo in Japanese and Caucasian participants
3017137|NCT02448719|Experimental|Cohort 6-active|Single oral administration of TAK-792 1250 mg in Japanese and Caucasian participants
3017138|NCT02448719|Placebo Comparator|Cohort 6-placebo|Single oral administration of TAK-792 1250 mg placebo in Japanese and Caucasian participants
3017139|NCT02448706|Active Comparator|Hearing Aid Fitting A|High level of signal manipulation
3017140|NCT02448706|Active Comparator|Hearing Aid Fitting B|Low level of signal manipulation
3017141|NCT02448693|Experimental|WLE-NBI|Participants will be evaluated by same endoscopist, tandem colonoscopy. It consists of two revisions of the polypectomy scar using firstly High Definition White Light Endoscopy (WLE) and secondly Narrow Band Imaging. All suspected neoplasia will be classified macroscopically and resected and differentiated from both techniques. The rest of the gut will be inspected following conventional standards.
3017142|NCT02448693|Experimental|NBI-WLE|Participants will be evaluated by same endoscopist, tandem colonoscopy. It consists of two revisions of the polypectomy scar using firstly Narrow Band Imaging and secondly High Definition White Light Endoscopy (WLE). All suspected neoplasia will be classified macroscopically and resected and differentiated from both techniques. The rest of the gut will be inspected following conventional standards.
3017143|NCT02448680|Active Comparator|Coagulation Factor VIIa (Recombinant): 75 µg/kg|75 µg/kg treatment regimen for 3 months
3017144|NCT02448680|Active Comparator|Coagulation Factor VIIa (Recombinant): 225 µg/kg|225 µg/kg treatment regimen for 3 months
3017145|NCT02448667|Experimental|FAXE Kondi - a sugary soft-drink|100 ml FAXE Kondi (10 grams of carbohydrates per 100 ml) is ingested every ten minutes during exercise plus 400 ml before exercise start.
3017146|NCT02448667|Placebo Comparator|FAXE Kondi Free - a sugarfree soft-drink|100 ml FAXE Kondi Free (0 grams of carbohydrates per 100 ml) is ingested every ten minutes during exercise plus 400 ml before exercise start.
3017147|NCT02448654|Active Comparator|Tolcapone|100mg tolcapone three times a day for 7 days then 100mg once a day on day 8
3017148|NCT02448654|Placebo Comparator|Sugar Pill|Sugar pill
3017149|NCT02448641|Experimental|SB623 Implant (2.5M)|2.5 million SB623 cells
3017150|NCT02448641|Experimental|SB623 Implant (5.0M)|5 million SB623 cells
3017151|NCT02448641|Sham Comparator|Sham Control|Sham surgery
3017152|NCT02448628|Experimental|CS-3150|CS-3150 1.25 to 5.0 mg , orally, once daily after breakfast for 12 weeks
3017153|NCT02448615||Birth Cohort|The cohort will comprise approximately 1500 pregnant women and their unborn babies, enrolled to participate in the control arm of a cluster-randomized controlled intervention trial (NCT02208960).
3017154|NCT02448602|Other|Single point group (Shenmen)|Patients will be acupuncture with Shenmen(HT7).
3017155|NCT02448602|Other|Sancai coordinated points group|Patients in Sancai coordinated points group, will be acupuncture with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6).
3017156|NCT02448602|Other|Control group|Patients in Control group, will be acupuncture with at the junction of deltoid and biceps.
3017157|NCT02448589|Experimental|TAS-119 Monotherapy|"Dose Escalation:~A Monotherapy Dose-Escalation Phase Performed in Approximately 5 Dose Levels (3 to 12 Patients Per Dose Level) to Determine the MTD for TAS-119 Given Orally (PO), Twice-Daily (BID) in a 28-Day Treatment Cycle; and:~Dose Expansion:~A Monotherapy Expansion Phase in Which Approximately 40 Additional Patients will be Enrolled to Further Evaluate the Recommended Phase II Dose (RP2D)"
3017158|NCT02448576|Experimental|PCI group|Receiving prophylactic cranial irradiation after response to first line chemotherapy.
3017159|NCT02448576|No Intervention|observation group|Patients in the observation group do not receive prophylactic cranial irradiation after response to first line chemotherapy.
3017160|NCT02448563|Experimental|Intervention|Weekly, in-person, support groups providing nutrition and physical activity education
3017161|NCT02448563|No Intervention|Control|Standard of care - one counseling visit with a study dietitian
3017162|NCT02448550|Experimental|bivalirudin|Bivalirudin will be used for PCI with bailout glycoprotein 2b3a inhibitor use permitted.
3017163|NCT02448550|Active Comparator|unfractionated heparin|Unfractionated heparin will be used for PCI with bailout glycoprotein 2b3a inhibitor use permitted.
3017164|NCT02448537|Experimental|PM01183 and Doxorubicin|"Anthracycline-naïve patients will receive combination of PM01183 and Doxorubicin per cycle.~PM01183 predetermined dose daily via IV per cycle~Doxorubicin predetermined dose daily via IV per cycle"
3017165|NCT02448537|Experimental|PM01183 and Gemcitabine|"Prior anthracycline exposure and without prior gemcitabine exposure~PM01183 predetermined dose given twice via IV per cycle~Gemcitabine predetermined dose given twice via IV per cycle"
3017166|NCT02448537|Experimental|Single Agent PM01183|"Patients who have received at least both prior anthracycline and prior gemcitabine~-PM01183 predetermined dose once via IV per cycle"
3017167|NCT02448524|Experimental|MiStentTM|MiStentTM coronary drug eluting stent (MiStent SES) consists of four parts: a bare-metal stent (BMS), a delivery system, resorbable polymer coating and anti-proliferative drug (sirolimus).
3017168|NCT02448524|Active Comparator|TIVOLI|TIVOLI stent is a mature and fully degradable coating on a cobalt-chromium alloy drug-eluting stent on the market, findings of four years fully demonstrated the efficacy and safety of sirolimus-coated TIVOLI stent.
3017169|NCT02448511|Experimental|Ozone|this group received local application of ozone gas in addition to conventional treatment.
3051890|NCT02214940|Experimental|BI 11634|multiple rising dose
3017170|NCT02448511|Sham Comparator|Placebo|This group received sham treatment in addition to conventional treatment
3017171|NCT02448498|Experimental|Strength Training Only|Participants in the strength-training only group will take part in a 9-month exercise intervention at a local exercise facility. They will engage in strength training 3 days per week for approximately 60 minutes each exercise session.
3017172|NCT02448498|Experimental|Aerobic Training Only|Participants in the aerobic training only group will take part in a 9-month exercise intervention at a local exercise facility. They will engage in aerobic training over 3 -5 days per week to achieve the targeted dose of 12 kcal/kg per week at a training intensity between 50-80% VO2 max.
3017173|NCT02448498|Experimental|Combination (Strength and Aerobic) Training|Participants in the combination (strength and aerobic training) group will take part in a 9-month exercise intervention at a local exercise facility. They will engage aerobic training that will expend 10 kcal/kg/week in combination with strength-training, 3 days per week.
3017174|NCT02448485||Aortic Valve Intervention|Consecutive symptomatic patients who underwent aortic valve intervention (SAVR or TAVI) for the treatment of severe AS since 2010
3017175|NCT02448485||Conservative Treatment|Asymptomatic patients with aortic stenosis followed conservatively at our department
3017176|NCT02448459|Experimental|COOL-COS|All women will receive Letrozole, Clomiphene, and Corifollitropin Alfa for controlled ovarian stimulation
3017177|NCT02448446|Active Comparator|Diabetic macular edema treatment group (Group 1)|Treatment using intravitreal ranibizumab 0.3mg based on the DRCR protocol I 4:2:7 strategy based on the presence of macular edema.
3017178|NCT02448446|Active Comparator|Diabetic macular edema and lipid treatment group (Group 2)|Continued treatment with intravitreal ranibizumab 0.3mg until, not only the macular edema is resolved, but also until the lipid exudate is resolved.
3017179|NCT02448433|Other|Phototherapy|
3017180|NCT02448420|Experimental|Arm A|"ER negative, HER2 positive patients who will receive palbociclib plus trastuzumab.~Trastuzumab: 8 mg/kg in the first dose, followed by 6 mg/kg every 3 weeks. Palbociclib: oral dose of 200 mg/day for 2 weeks, followed by 1 week off. Cycles will be 3 weeks long."
3017181|NCT02448420|Experimental|Arm B1|ER positive, HER2 positive patients who will receive palbociclib plus trastuzumab Trastuzumab: 8 mg/kg in the first dose, followed by 6 mg/kg every 3 weeks. Palbociclib: oral dose of 200 mg/day for 2 weeks, followed by 1 week off. Cycles will be 3 weeks long.
3017182|NCT02448420|Experimental|Arm B2|ER positive, HER2 positive patients will receive palbociclib plus trastuzumab. Trastuzumab: 8 mg/kg in the first dose, followed by 6 mg/kg every 3 weeks. Palbociclib: oral dose of 200 mg/day for 2 weeks, followed by 1 week off. Letrozole: daily oral dose of 2.5 mg. Cycles will be 3 weeks long.
3017183|NCT02448407|Experimental|Platelet rich plasma|Three intraarticular injection, one each fifteen days
3017184|NCT02448407|Active Comparator|Hyaluronic acid|Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1 % solution, administered by intraarticular injection (3 doses, one each fifteen days)
3017185|NCT02448394|Experimental|Intervention|At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. Strong preference will be given to matching CSWs and clients from the same kebele (village or neighborhood of residence). CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
3017186|NCT02448394|No Intervention|Standard of Care|At control sites, patients will receive standard of care facility-based medical care and counseling, consistent with general standards of care offered to HIV patients throughout the country as determined by the Ethiopian Ministry of Health.
3017187|NCT02448381|Active Comparator|SGX301|"Three treatment cycles, each six (6) weeks followed by a two (2) week rest period. Treatment uses 0.25% SGX301 in USP Hydrophilic Ointment (or placebo) applied twice per week followed by fluorescent light therapy.~Cycle 1: Patients randomized 2:1 to active/placebo will have three (3) index lesions treated and evaluated.~Cycle 2: All patients will have three (3) index lesions treated and evaluated with active SGX301 ointment.~Cycle 3: All patients will be given the opportunity to enter an open-label cycle of active SGX301 ointment treatment for all lesions (index and non-index)."
3017188|NCT02448381|Placebo Comparator|Placebo|Placebo ointment is indistinguishable from ointment containing active SGX301 and is only used in Cycle 1. Treatment paradigm (ointment application and fluorescent light therapy) is identical.
3017189|NCT02448368|Experimental|Treatment A|RDEA3170, 5 mg (FN24), administered in the fasted state.
3017190|NCT02448368|Experimental|Treatment B|RDEA3170, 5 mg (FN24), administered in the fed state (high-fat, high-calorie meal).
3017191|NCT02448368|Experimental|Treatment C|RDEA3170, 10 mg (FN25), administered in the fasted state.
3017192|NCT02448368|Experimental|Treatment D|RDEA3170, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal).
3017193|NCT02448368|Experimental|Treatment E|RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
3017194|NCT02448368|Experimental|Treatment I|RDEA3170, 10 mg (FN26), administered in the fasted state.
3017195|NCT02448368|Experimental|Treatment J|RDEA3170, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).
3017196|NCT02448368|Experimental|Treatment K|RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
3017197|NCT02448355|Experimental|Patient undergoing carotid endarterectomy|"All patients undergoing carotid endarterectomy in Shaare Zedek Medical Center Visual acuity measurement (Snellen) SS-OCT (DRI-Atlantis, Topcon) 3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.~On pre-op visit (Monday)~Day 1 post-surgery~Discharge day~Week 1 post-surgery~Month 1 post-surgery"
3017198|NCT02448342|Experimental|ReDS Guided Treatment|After discharge from hospital, patient will perform daily ReDS measurement. Data is automatically transmitted to the secured web portal. Treating physician will follow up on patients' measurements through a secured dedicated web site. Notification messages will be automatically sent by the system to the physician if certain thresholds are crossed (thresholds are physician adjustable). Medications will be adjusted according to defined guidelines. During the study a service center will monitor and support patient adherence and investigators attending to patients' notifications.
3017199|NCT02448342|Active Comparator|Standard of Care- Control arm|After discharge from hospital, patient will be followed up and medically managed according to standard of care guidelines.
3017200|NCT02448329|Experimental|AZD1775 in Combination With Paclitaxel|AZD1775 225 mg BID q 12 hours (x 5 doses, 2.5 days) administered days 1~3 Weekly paclitaxel 80 mg/m2 IV on 1, 8 and 15 of a four week l cycle is an widely used dose of paclitaxel given on this schedule in gastric adenocarcinoma patients as second-line therapy.
3017201|NCT02448316|Active Comparator|endoscopic surgery|Endoscopic operation through 2 portals profound for the fascia plantaris
3017202|NCT02448316|Active Comparator|conservative treatment|The standard treatment here acting as controle treatment . All patients are informed to decrease activity level, use shoes with good shock absorption and are recommended to use insoles (standard orthoses) for increased shock absorption. Training is supervised every third week by a physiotherapist (week 1,3,6,9), and daily training is carried out at home. Glucocorticoid injections of 1 ml Glucocorticosteroid (methylprednisolon 40 mg) and 1 ml of Lidokaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris are given every month until the fascia thickness is below 4 mm (max 3 injections).
3017203|NCT02448303|Experimental|Arm 1|pembrolizumab
3017204|NCT02448303|Experimental|Arm 2|acalabrutinib plus pembrolizumab
3017205|NCT02448290|Experimental|docetaxel+selumetinib|Selumetinib 75 mg will be administered orally twice a day with continuous dosing schedule Docetaxel 60 mg/m2 will be administered via intravenous access every 3 weeks.
3017206|NCT02448277|Experimental|Macintosh Laryngoscope|experimental Macintosh Laryngoscope group: laryngoscope is used to assist for nasotracheal intubation.
3017207|NCT02448277|Experimental|Pentax Airway scope|experimental Pentax Airway scope group:Pentax Airway scope is used to assist for nasotracheal intubation.
3017208|NCT02448277|Experimental|Glidescope|experimental Glidescope group:Glidescope is used to assist nasotracheal tube into trachea
3017209|NCT02448264|Experimental|BCX7353|BCX7353 capsules administered orally
3017210|NCT02448264|Placebo Comparator|Placebo|Placebo to Match BCX7353 capsules, administered orally
3017211|NCT02448251|Experimental|single dose per day (QD)|Phase I Arm 1: AC0010MA orally taking once daily, starting from 100 mg per day.
3017212|NCT02448251|Experimental|two doses per day (BID)|Phase I Arm 2: AC0010MA orally taking twice daily, starting from 200 mg per day (100 mg BID). Arm 2 will be initiated once the drug plasma t1/2 is 10 hours or below in the first dose cohort (100 mg QD).
3017213|NCT02448238|Experimental|probiotic|This is a single arm study all subjects will receive the study VSL#3 probiotic. Subjects will take 1 sachet of powder orally daily for 12 weeks
3017214|NCT02448225|Experimental|Diagnostic (18F-FDG PET/CT, 18F-FSPG PET/CT)|Patients undergo 18F-FDG PET/CT scan per standard of care. Within 15 working days, patients also undergo 18F-FSPG PET scan over 60 minutes followed by an 18F-FSPG PET/CT scan over 30 minutes.
3017215|NCT02448212|Experimental|PART 1 (Test/Retest)|Dosing with [11C]TASP0410699 for PET imaging without dosing of TS-121
3017216|NCT02448212|Experimental|PART 2 (PET Receptor Occupancy Study)|Dosing with [11C]TASP0410699 for PET imaging with dosing of TS-121
3017217|NCT02448199|Experimental|Kit 1 ( ML + CG ) + P|One sachet meloxicam and glucosamine and 1 placebo tablet once a day for 12 weeks One sachet
3017218|NCT02448199|Active Comparator|Kit 2 ( ML + P)|One tablet of meloxicam and one sachet of placebo once per day for 12 weeks
3017219|NCT02448199|Active Comparator|Kit 3 ( P+ GC)|One sachet of glucosamine and one tablet placebo once a day for 12 weeks
3017220|NCT02448186|Experimental|ESTEEM|cognitive behavioral treatment adapted to improve depression, anxiety, and co-occurring health risks (i.e., alcohol use, sexual compulsivity, condomless sex) among young adult gay and bisexual men by reducing minority stress processes that underlie sexual orientation-related mental health disparities
3017221|NCT02448186|No Intervention|Waitlist|3-month waitlist control
3017222|NCT02448173|Experimental|OncoVAX and Surgery|Autologous Specific Immunotherapy given intradermally following surgical resection of Stage II colon cancer
3017223|NCT02448173|Active Comparator|Surgery|Surgical resection of Stage II colon cancer
3017224|NCT02448160|Experimental|alfapump with albumin treatment|patients implanted with an alfapump, receiving intermittent salt-poor Human Albumin solution treatment
3017225|NCT02448147|Active Comparator|Interval training|
3017226|NCT02448147|Active Comparator|Continuous training|
3017227|NCT02448147|No Intervention|Control|
3017228|NCT02448134|Experimental|Youth Access|"Youth Engagement in Prosocial Alcohol-Free Activities Participate in the Reward and Reminder program in their community"
3017229|NCT02448134|No Intervention|Control|Student will receive regular information and programs.
3017230|NCT02448121|Experimental|Autologous bone marrow stem cell graft|Autologous bone marrow stem cell implantation
3017231|NCT02448108|Experimental|i-IPSRT|Participants randomized to this arm will complete bi-weekly i-IPSRT modules over the course of 12 weeks and they will track their mood and SRM's via smartphones or computer.
3017232|NCT02448108|Experimental|i-IPSRT + CH|Participants randomized to this arm will complete bi-weekly i-IPSRT modules over the course of 12 weeks and they will track their mood and SRM's via smartphones or computer. Additionally, i-IPSRT support will be delivered by Clinical Helpers, who will reach out to participants in this arm via 5-10 minute weekly phone calls.
3017233|NCT02448108|Other|CC (Controlled Condition)|Participants randomized to this arm will receive brief written psychoeducational material that includes information about social rhythm regularity. This information will be either mailed or e-mailed to them.
3017234|NCT02448095||CML ph+ patients|Chronic myeloid leukemia patients who are philadelphia positive
3017235|NCT02448082|Placebo Comparator|Shampoo (inactive)|Shampoo containing no active anti-dandruff ingredients will be used to wash the participants' hair every second day, starting from day 1 to day 15. Each participant in the placebo group will wash their hair with 25ml of the placebo shampoo per hair washing session.
3017236|NCT02448082|Experimental|Sodium shale oil sulponate 1% shampoo|Shampoo containing sodium shale oil sulponate 1% will be used to wash the participants' hair every second day, starting from day 1 to day 15. Each participant in the experimental group will wash their hair with 25ml of the sodium shale oil sulponate 1% shampoo per hair washing session.
3017237|NCT02448069|Experimental|Argatroban treatment|Intravenous Argatroban delivered at 100mcg/kg bolus, then 12-hour infusion initiated at 3mcg/kg/min.
3017238|NCT02448056||Pre-treatment|All enrolled HCC patients.
3017239|NCT02448056||Post-treatment one week|All enrolled HCC patients.
3017241|NCT02448043|Active Comparator|Bimatoprost 0.01% drops|Bimatoprost 0.01% drops placed on the proximal nail folds of the randomized hand digits two times per day for 30 days.
3017242|NCT02448043|Placebo Comparator|Placebo|Saline solution drops placed on the proximal nail folds of the hand digits opposite from the study hand two times per day for 30 days.
3017243|NCT02448030|Experimental|Functional electric stimulation|Other: The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively.
3017244|NCT02448030|Placebo Comparator|Isometric exercise|For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test.
3017245|NCT02448017|Active Comparator|The Herbst appliance|Orthodontic functional appliance
3017246|NCT02448017|Active Comparator|Twin block appliance|Orthodontic functional appliance
3017247|NCT02448004|Experimental|JNJ-63623872|Participants will receive a single 600-milligram (mg) dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
3017248|NCT02447991|Placebo Comparator|Placebo|During the Treatment Phase, three placebo capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
3017249|NCT02447991|Experimental|Rizatriptan|During the Treatment Phase, three Rizatriptan capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
3017250|NCT02447978||PCR-positive pertussis cases|Cases will be all individuals who tested PCR-positive for pertussis and negative for parapertussis during the study period and who received 5 doses of DTaP vaccines (either manufactured by GSK or any brand, depending on study objective) through 84 months of age before testing PCR-positive.
3017251|NCT02447978||PCR-negative pertussis controls|Controls will consist of persons who tested PCR-negative for both pertussis and parapertussis and who received 5 DTaP doses (either manufactured by GSK or any brand, depending on study objective) before testing PCR negative.
3017252|NCT02447978||KPNC-matched controls|Controls will consist of all KPNC members of the same sex, age (year and quarter of birth), race or ethnic group (7 groups; 6 for reported, 1 for imputed), and medical centre as each pertussis case and who were members on the date the case tested PCR-positive (anchor date).
3017253|NCT02447965|Active Comparator|Bupivacaine|Will have 20ml of bupivacaine injected into each rectus sheath.
3017254|NCT02447965|Placebo Comparator|Normal Saline|Will have 20ml of normal saline injected into each rectus sheath.
3017255|NCT02447952|Experimental|Pilot and Core Study Phase|During Pilot phase,subjects will attend clinic at least once to perform a series of set reference tasks while wearing the accelerometer and electrode. Subjects will also continuously wear the accelerometer and electrode in their routine home-life setting for approximately 3 days after the clinic visit (home monitoring). During 48 week Core Study, subjects will attend 5 clinic visits to perform gold standard measures of function (ALS Functional Rating Scale-Revised and Forced Vital Capacity) and perform a series of set reference tasks while wearing the accelerometer and electrode. Subjects will also continuously wear the accelerometer and electrode in their routine home-life setting for approximately 3 days after the clinic visits (home monitoring). In between clinic visits, subjects will attach the accelerometer and electrode and wear it for approximately 3 days in their home. A telephone contact with the subject will be made by the site at the end of each 3-day home monitoring period
3017256|NCT02447939|Experimental|Dabrafenib and Trametinib|Subject will be assigned in 2 cohorts, in cohort A, subjects will be administered dabrafenib (150 mg BID) monotherapy from Day1 to Day 21 (first part), followed by dabrafenib (150 mg BID) and trametinib (2mg QD) combination (second part, starting from day 22). After the last subject in cohort A has finished the last pharmacokinetic sampling(1st part ), another 10 subjects will be enrolled in cohort B with administration of dabrafenib (150 mg BID) in combination with oral trametinib (2mg QD).
3017257|NCT02447926|Other|Single Arm Treatment|Leukapheresis. All subjects will receive the same treatment arm.
3017258|NCT02447913|Experimental|Voucher|
3017259|NCT02447913|No Intervention|Control|
3017260|NCT02447900|Other|Treatment|
3017261|NCT02447887|Experimental|Ixazomib and pegylated IFN alfa - 2b|Ixazomib capsules and pegylated IFN alfa 2b injections weekly. Ixazomib will be taken for the last 3 weeks of 28 day cycle. Pegylated IFN alfa 2b injection will be administered weekly, each week of the 28 day cycle.
3017262|NCT02447874|Experimental|Standard dose|Subjects with sickle cell disease (SCD) and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first
3017263|NCT02447874|Experimental|Loading dose + standard dose|Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first
3017264|NCT02447874|Experimental|Loading dose + continuous infusion|Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive a continuous intravenous (IV) infusion of 300 mg/kg/24hr for 7 days or until discharged from the hospital, whichever occurs first
3017265|NCT02447861||3q29 deletion|Individuals with 3q29 deletion
3017266|NCT02447861||3q29 duplication|Individuals with 3q29 duplication
3017267|NCT02447861||Unaffected siblings|Unaffected siblings of 3q29 deletion or duplication individuals
3017268|NCT02447861||Healthy Controls|Unrelated age-matched controls without 3q29 deletion or duplication
3017269|NCT02447848|Experimental|sufentanil sublingual tablet 30 mcg|Patients may be administered one tablet every 60 minutes as needed during the study period
3017270|NCT02447835|Active Comparator|Olanzapine|Olanzapine administration
3017271|NCT02447835|Placebo Comparator|Placebo|Placebo administration
3017272|NCT02447822|Active Comparator|6.0ATG|Recipients who have 6.0 mg/kg Thymoglobulin as induction therapy
3017273|NCT02447822|Active Comparator|4.5ATG|Recipients who have 4.5 mg/kg Thymoglobulin as induction therapy
3017274|NCT02447809|Experimental|Regular DAPT(IPA≤60%)|ASA and Clopidogrel
3017275|NCT02447809|Active Comparator|Regular DAPT(IPA>60%)|ASA and Clopidogrel
3017276|NCT02447796|Active Comparator|Propofol|Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24)
3017277|NCT02447796|Active Comparator|Dexmedetomidine (DEX)|DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24)
3017278|NCT02447783|Placebo Comparator|Control, Flavanol-free intervention|Intake of flavanol-free, macro- and micro-nutrient matched control capsules
3017279|NCT02447783|Active Comparator|CF intervention|Intake of capsules containing Mars Cocoa Extract Capsules manufactured by the Cocoapro® process and providing 500 mg of cocoa flavanols per capsule
3017280|NCT02447770|Experimental|Cocoa Flavanol intake escalation|Ingestion of increasing number of capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process (500 mg of cocoa flavanols/capsule) during 6 weeks followed by a 2 week of washout (no capsule intake)
3017281|NCT02447757||Parturients with remifentanil analgesia|Parturients after induction of remifentanyl analgesia during the delivery
3017282|NCT02447744|Experimental|MBSR group|Mindfulness based stress reduction intervention will be provided to this group.
3017283|NCT02447744|Other|Waitlist control|This arm waits while the MBSR group receives their intervention, and then gets the Mindfulness based stress reduction intervention after their waiting period.
3017284|NCT02447731||Sonic Gas Exchange|"Gas exchange rates in the lungs of subjects breathing through a mouthpiece will be compared with their gas exchange rates after addition of sound pressure vibrations into the supplied gas. 'Induction of sound waves in lungs by sonic oscillator' can be as loud as a human screaming or singing very loudly (about 95 dB). The effects of these pressure oscillations on gas exchange will be assessed using 3 tests as explained in the section under detailed description."
3017285|NCT02447718|Active Comparator|Experimental|Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.
3017286|NCT02447718|No Intervention|Healthy Control|Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.
3017287|NCT02447705|No Intervention|Lamivudine group|continue Lamivudine
3017288|NCT02447705|Experimental|Telbivudine group|Telbivudine replaces Lamivudine
3017289|NCT02447692|Active Comparator|PSV ventilation strategy|The control is the standard of care PSV ventilation strategy, designed to adjust the level of support according to usual clinical parameters.
3017290|NCT02447692|Active Comparator|PAV+ ventilation strategy|The intervention is a PAV+ ventilation strategy, designed to adjust the level of support (gain) to target a predefined range of respiratory muscle pressure.
3017291|NCT02447679|Experimental|thalidomine|"Thalidomide 400mg/day for 1 year~tegafur-uracil 2 tables for 1 year."
3017292|NCT02447666|Experimental|Azacitidine Myelodysplastic Syndrome (MDS)|Azacitidine 75 mg/m2 by Intravenous (IV) or Subcutaneous (SC) administration once daily (QD) on Days 1 to 7 of a 28-day cycle for a minimum of 3 cycles and a maximum of 6 cycles.
3017293|NCT02447666|Experimental|Azacitidine Juvenile Myelomonocytic Leukemia (JMML)|Azacitidine 75 mg/m2 by Intravenous (IV) or Subcutaneous (SC) administration once daily (QD) on Days 1 to 7 of a 28-day cycle for a minimum of 3 cycles and a maximum of 6 cycles.
3017294|NCT02447653|Experimental|Hydroxyapatite Coating|G7 HA Acetabular component will be implanted
3017295|NCT02447653|Active Comparator|Plasma Porous Spray|G7 PPS Acetabular component will be implanted
3017296|NCT02447640|Experimental|Part 1|A receptor occupancy dose curve will be obtained by using an adaptive design in this arm.
3017297|NCT02447640|Experimental|Part 2|In this arm, the time course of the receptor occupancy will be studied for the dose which gives 70% receptor occupancy as determined in Part 1.
3017298|NCT02447627||Part A|Cohort 1- Participants with severe SCD (4-10 VOC/year) Cohort 2- Participants with milder SCD (<4-10 VOC/year) Cohort 3- Healthy volunteers Part A and B can occur in parallel
3017299|NCT02447627||Part B|Adults with SCD receiving chronic red blood cell exchange transfusion Part A and B can occur in parallel
3017300|NCT02447614|Experimental|Surgery|Adenotonsillectomy
3017301|NCT02447614|Experimental|Conservative treatment|Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists
3017302|NCT02447614|Experimental|no treatment|just regular follow-up
3017303|NCT02447601|Experimental|Simvastatin and PEX168(200µg)|Simvastatin: 40mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
3017304|NCT02447588|Other|Group 1|Intrauterine insemination with sperm donor (IAD) at 36 hours post-hCG. Cases where the IAD is scheduled at 36 hours post-administration of hCG.
3017305|NCT02447588|Experimental|Group 2|Intrauterine insemination with sperm donor (IAD) at 24 hours post-hCG. Cases where the IAD is scheduled at 24 hours post-administration of hCG.
3017306|NCT02447575|Other|Pre-Education Use of MDI|Patients perform metered dose inhaler (MDI) technique, attaching the Cognita electronic flowmeter to show measurements during the MDI use. These are evaluated by study staff prior to an education demonstration. The intervention is a short education presentation on correct use of the MDI.
3017307|NCT02447562|Active Comparator|G_AH|Usual care group
3017308|NCT02447562|Other|G_SP|Phone-based care
3017309|NCT02447562|Experimental|G_NOMHAD|Intervention group with a health platform NOMHADchronic
3017310|NCT02447549|Active Comparator|WBRT|Standard dose whole bladder radiotherapy
3017311|NCT02447549|Experimental|SART|Standard dose Adaptive tumour focused radiotherapy (SART)
3017312|NCT02447549|Experimental|DART|Dose escalated Adaptive tumour boost radiotherapy (DART)
3017313|NCT02447536|Active Comparator|BCG-DENMARK|"Infants randomised to receive BCG-DENMARK at dismissal from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine BCG-Denmark 1331 (Statens Serum Institute) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.~NOTE: By 1st of July 2016, infants in this arm has received BCG-Japan due to a worldwide shortage of BCG-Denmark because of a halt in production of this vaccine at the Statens Serum Institut in Copenhagen."
3051891|NCT02214940|Placebo Comparator|Placebo|
3017314|NCT02447536|Active Comparator|BCG-RUSSIA|Infants randomised to receive BCG-RUSSIA at dismissal from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-Russia-I (Serum Institute of India) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.
3017315|NCT02447523||Patients with metabolic syndrome|Patients fulfilling criteria to establish the diagnosis of metabolic syndrome
3017316|NCT02447523||Patients without metabolic syndrome|Patients not fulfilling criteria of the metabolic syndrome
3017317|NCT02447510|Other|group 1|bone substitute grafting material applied to the defect site control (n=10)
3017318|NCT02447510|Other|group 2|experimental platelet rich growth factor PRGF applied to the defect site (n=10) G2
3017319|NCT02447510|Other|group 3|platelet rich fibrin PRF applied to the defect site (n=10) G3.
3017320|NCT02447497|Experimental|3M CHG/IPA|Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70%
3017321|NCT02447497|Placebo Comparator|Normal Saline|0.9% sodium chloride with applicator
3017322|NCT02447484|Experimental|Mujer Segura Siempre|Twice-daily safer-sex and safer-drug-use text messages, 5 days per week, for 24 months. Text message content based on 8 different constructs of behavior-maintenance theory and tailored to specific preferences and motivators provided by participant.
3017323|NCT02447484|Active Comparator|General Health Message Texts|Twice-daily text messages, 5 days per week, for 24 months. Text message content centered on general health promotion, including getting regular medical checkups and maintaining good dietary and exercise habits.
3017324|NCT02447471||study group|all participants
3017325|NCT02447458|Experimental|Cohort 1: MLN3126 300 mg|MLN3126 300 mg tablets, orally, fasting, once on Day 1.
3017326|NCT02447458|Experimental|Cohort 2: MLN3126 600 mg|MLN3126 600 mg tablets, orally, fasting, once on Day 1.
3017327|NCT02447458|Experimental|Cohort 3: MLN3126 1000 mg|MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.
3017328|NCT02447458|Experimental|Cohort 4: MLN3126 1500 mg|MLN3126 1500 mg administered orally as tablets, once on Day 1.
3017329|NCT02447458|Experimental|Cohort 5: MLN3126 2000 mg|MLN3126 2000 mg tablets, orally, fasting, once on Day 1.
3017330|NCT02447458|Experimental|Cohort 6|Did not take place due to termination of the study.
3017331|NCT02447458|Placebo Comparator|Placebo: Cohort 1-6|Placebo-matching MLN3126 tablets, orally, once on Day 1.
3017332|NCT02447445||Older inpatient at MOP|The group includes older patients who are admitted to one of the Medicine for Older Patients (MOP) wards. Grip strength will be part of the routine assessment of older patient when admitted to MOP.
3017333|NCT02447432|Experimental|10Pn_4d Group|Subjects received 10Pn-PD-DIT, in its investigational 4-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
3017334|NCT02447432|Active Comparator|10Pn Group|Subjects received 10Pn-PD-DIT, in its licensed 1-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
3017335|NCT02447419|Experimental|Gefitinib|Gefitinib 250 mg will be administered orally daily
3017336|NCT02447406|Experimental|AZD6094 (Volitinib) in combination with docetaxel|"Phase Ib:Volitinib should be administered at least 200mg orally once a day in 21 days for achieving appropriate antitumor activity.~Phase II: Subjects will receive Volitinib once daily ( at the MTD determined from Phase Ib) for 21 days as one cycle.~Docetaxel 60 mg/m2 will be administered via intravenous access once every 3 weeks."
3017337|NCT02447393|Other|levocetirizine|Study Drug
3017338|NCT02447393|Other|cetirizine|Study Drug
3017339|NCT02447393|Other|placebo|Study Drug
3017340|NCT02447380|Experimental|AZD6094 (Volitinib) in combination with docetaxel|"Subjects will receive Volitinib once daily (at the MTD determined from Phase Ib) for 21 days as one cycle.~Docetaxel 60 mg/m2 will be administered via intravenous access once every 3 weeks."
3017341|NCT02447367|Experimental|JLP-1207, Fasted followed by fed|JLP-1207 dosing in the fasted state followed by fed dosing
3017342|NCT02447367|Experimental|JLP-1207, Fed followed by fasted|JLP-1207 dosing in the fed state followed by fasted dosing
3017343|NCT02447341||In patients|
3017344|NCT02447341||Out patients|
3017345|NCT02447328|Experimental|Single Arm|Faslodex treated in the study
3017346|NCT02447315|Experimental|Treatment Sequence ABCDD|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence ABCDD. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
3017347|NCT02447315|Experimental|Treatment Sequence BDACC|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence BDACC. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
3017348|NCT02447315|Experimental|Treatment Sequence CADBB|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence CADBB. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
3017349|NCT02447315|Experimental|Treatment Sequence DCBAA|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence DCBAA. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
3017350|NCT02447302|Experimental|Etrasimod (APD334) Low Dose|oral, low dose, daily for 12 Weeks
3017351|NCT02447302|Experimental|Etrasimod (APD334) High Dose|oral, high dose, daily for 12 weeks
3017352|NCT02447302|Placebo Comparator|Placebo|oral, placebo, daily for 12 weeks.
3017353|NCT02447289|Experimental|Experimental|Intranasal administration of ketamine (4.0 mg/kg, max. 100 mg) and midazolam (0.2 mg/kg, max. 5 mg)
3017354|NCT02447289|Active Comparator|Comparator|Oral administration of ketamine (4.0 mg/kg, max. 100 mg) and midazolam (0.5 mg/kg, max. 20 mg)
3017355|NCT02447289|Active Comparator|Control|Oral administration of midazolam (1.0 mg/kg, max. 20 mg)
3017356|NCT02447276|Experimental|Group A|Group A will receive REGN475 dosing regimen 1
3017357|NCT02447276|Experimental|Group B|Group B will receive REGN475 dosing regimen 2
3017358|NCT02447276|Experimental|Group C|Group C will receive REGN475 dosing regimen 3
3017359|NCT02447276|Experimental|Group D|Group D will receive REGN475 dosing regimen 4
3017360|NCT02447276|Experimental|Group E|Group E will receive matching placebo
3017361|NCT02447263|Experimental|HepaSphere|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
3017362|NCT02447263|No Intervention|control|liver cancer patients did not receive any interventional therapy
3017363|NCT02447250|Experimental|Single Arm: varied albuterol dose response|Subjects will be evaluated in three sessions. The sessions will occur within a 7 day time span, beginning between 14-28 days of life. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a sinlge dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
3017364|NCT02447237|Experimental|liquid food|dietary counselling in fulfilling need of protein and energy through liquid food
3017365|NCT02447237|Other|solid food|dietary counselling in fulfilling need of protein and energy through solid food
3017366|NCT02447224|Experimental|Antibiotics|Once-a-day dose of IV/IM ertapenem for at least two days and cefdinir and metronidazole, to complete 10 days total antibiotic therapy.
3017367|NCT02447224|Active Comparator|Appendectomy|Patients in the surgery therapy arm will only receive one dose of IV ertapenem prior to surgery.
3017368|NCT02447211|Active Comparator|doxepin cream|Patients use doxepin cream 5% twice daily for two weeks
3017369|NCT02447211|Placebo Comparator|Placebo|Patients use cream without doxepin ingredient twice daily for two weeks
3017370|NCT02447185|Experimental|Ranibizumab|"A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.~During operation all subjects in this group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in this group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation."
3017371|NCT02447185|Active Comparator|Triamcinolone Acetonide|"A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetonide group will receive Triamcinolone Acetonide 4mg/0.1 ml intravitreal injection.~During operation all subjects in this group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in this group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation."
3017372|NCT02447172|Experimental|Gentamicin sponge group|Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
3017373|NCT02447172|Placebo Comparator|Placebo sponge group|Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
3017374|NCT02447172|No Intervention|No sponge group|Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
3017375|NCT02447159|Experimental|Intervention|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
3017376|NCT02447159|No Intervention|Control|Antenatal care utilization data will be extracted from the administrative records. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
3017377|NCT02447146|Experimental|Training group|9-week resistance training program
3017378|NCT02447146|Other|Control group|'Lectures on the disease'
3017379|NCT02447133|Experimental|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Maestro device
3017380|NCT02447120|Experimental|Normal Eyes|Subjects with no known ocular diseases will be scanned with the Maestro device
3017381|NCT02447107||Outpatients|Outpatients enrolled in this study are required to complete study assessments on mobile applications and through questionnaires. A daily electronic diary will be completed through the Ohmage app. The Mobility app will be used to track the patients' movement and activity. Patients will be administered a questionnaire at the 1 and 2 week endpoints.
3017382|NCT02447094||Exposed|AIS patients evaluated through RTP and who receive i.v. tPA
3017383|NCT02447094||Un-exposed|AIS patients evaluated through RTP and who do not receive i.v. tPA
3017384|NCT02447081||Subjects implanted with Amulet Device|All subjects who receive the Amulet device will be followed.
3017385|NCT02447068|No Intervention|Non-treatment Control|Control arm will not have any intervention
3017386|NCT02447068|Active Comparator|Occlusive Dressing|An off-the-shelf dressing occlusive dressing will be used as an active comparator.
3017387|NCT02447068|Active Comparator|Luma Light|A NBUVB light will be used as an active comparator.
3017388|NCT02447068|Experimental|Luma Light System|The experimental arm will be a combination of an occlusive dressing and NBUVB light.
3017389|NCT02447055|Experimental|Arm 1 (Flu/Mel/PT-Cy & Tac/MMF for certain cases)|"Fludarabine 30 mg/m^2 intravenously (IV) on Days -5, -4, -3, and -2~Melphalan 140 mg/m^2 IV on Day -2~Tocilizumab 8 mg/m^2 (capped at 800 mg) IV on Day -1~Stem cell infusion on Day 0~Cyclophosphamide 50 mg/kg IV on Days +3 and +4~Tacrolimus 1 mg/day IV on Day +5 (for unrelated & haploidentical cases)~Mycophenolate mofetil 15 mg/kg orally three times per day on Day +5 (for unrelated & haploidentical cases)~Filgrastim 10 ug/kg/day subcutaneously until neutrophil recovery starting on Day +5"
3017390|NCT02447042|Experimental|2 ml/Kg|Fluid challenge with crystalloids (2 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
3017391|NCT02447042|Experimental|3 ml/Kg|Fluid challenge with crystalloids (3 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
3017392|NCT02447042|Experimental|4 ml/kg|Fluid challenge with crystalloids (4 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
3017393|NCT02447042|Experimental|5 ml/Kg|Fluid challenge with crystalloids (5 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
3017394|NCT02447029|Experimental|Active Comparator|Drug: vaginal 2% Xylocaine
3017395|NCT02447029|Other|standard lidocaine paracervical block|standard lidocaine paracervical block
3017396|NCT02447016|Experimental|eviplera (complera)|Tab eviplera QD
3017397|NCT02447016|Active Comparator|atripla|Tab Atripla QD
3017398|NCT02447003|Experimental|Pembrolizumab|Participants receive pembrolizumab, 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 24 months.
3017399|NCT02446990|Experimental|Ivabradine|
3017400|NCT02446990|Placebo Comparator|Placebo|
3017401|NCT02446977|Experimental|Vitamin B2 Streuli®|20mg IV
3017402|NCT02446977|Placebo Comparator|Solution for injection|4ml IV
3017403|NCT02446964|Experimental|Treatment (TMLI, chemotherapy, transplant, GVHD prophylaxis)|"CONDITIONING: Patients undergo TMLI BID on days -7 to -4 or -3 (depending on the dose level). Patients also receive fludarabine phosphate IV on days -7 to -3 and cyclophosphamide IV on days -7, -6, 3, and 4.~TRANSPLANT: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0.~GHVD PROPHYLAXIS: Patients receive tacrolimus* IV QD or PO BID on days 5-180. Patients also receive mycophenolate mofetil PO TID or IV on days 5-35. Treatment with tacrolimus and mycophenolate mofetil may continue in the presence of active GVHD.~*NOTE: Patients intolerant of tacrolimus may receive cyclosporine."
3017404|NCT02446951||ED Jaundice Patients|Patients presenting to the ED in either the implementation period or pre-implementation period.
3017405|NCT02446925|Experimental|Surefire® Infusion System|Patients randomized to the Surefire® Infusion System treatment arm will undergo Y-90 glass microsphere embolization with a Surefire catheter.
3017406|NCT02446925|Active Comparator|Standard End-hole catheter|Patients randomized to the standard end-hole catheter treatment arm will undergo Y-90 glass microsphere embolization with a standard end-hole catheter.
3017407|NCT02446912|Experimental|Anifrolumab - higher dose|Anifrolumab
3017408|NCT02446912|Placebo Comparator|Placebo|Placebo
3017409|NCT02446912|Experimental|Anifrolumab - lower dose|Anifrolumab
3017410|NCT02446899|Experimental|Anifrolumab|Anifrolumab
3017411|NCT02446899|Placebo Comparator|Placebo|Placebo
3017412|NCT02446886|Active Comparator|Group A|"MS patients enrolled in this study will be randomized into:~Intervention for Group A: 80 units/day ACTH (H.P. Acthar®)for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.)"
3017413|NCT02446886|Experimental|Group B|Intervention for Group B: 80 units/day ACTH (H.P. Acthar®) for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.), followed by monthly 80 units/day ACTH for 3 days for 12 months of treatment.
3017414|NCT02446873|No Intervention|Control|Control group
3017415|NCT02446873|Experimental|Treatment|Egg supplementation
3017416|NCT02446860|Experimental|Nivolumab|Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit
3017417|NCT02446847|Experimental|Group A: 3BNC117 IV + ART Interruption|Two intravenous infusions of 3BNC117 (30 mg/kg) at day 0 and day 21, with interruption of antiretroviral treatment (ART) at day 2.
3017418|NCT02446847|Experimental|Group B: 3BNC117 IV + ART interruption|Four intravenous infusions of 3BNC117 (30 mg/kg) at day 0, day 14, day 28, and day 42 with interruption of antiretroviral treatment (ART) at day 2.
3017419|NCT02446834|Experimental|intensive lifestyle intervention|3 months intensive lifestyle intervention, including low GI diet and exercise.
3017420|NCT02446834|Experimental|GLP-1 Receptor Agonists|3 months GLP-1 Receptor Agonists treatment
3017421|NCT02446834|Experimental|metformin|3 months metformin treatment
3017422|NCT02446834|Experimental|acarbose|3 months acarbose treatment
3017423|NCT02446821|Experimental|VeraCept IUD System|All women will receive VeraCept.
3017424|NCT02446808|Experimental|Intraoperative nerve monitoring|Patients for which intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
3017425|NCT02446795|Experimental|Experimental Arm|Phase I Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Isoquercetin: 225mg twice a day (at 08 a.m. and at 4 p.m). Phase II Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Isoquercetin: 450 mg twice a day (at 08 a.m. and at 4 p.m).
3017426|NCT02446795|Placebo Comparator|Placebo Arm|Phase I Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Placebo: 225mg twice a day (at 08 a.m. and at 4 p.m). Phase II Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Placebo: 450 mg twice a day (at 08 a.m. and at 4 p.m).
3017427|NCT02446782|Experimental|Cefazolin|A single dose of intravenous cefazolin 2 gms will be administered over 10 minutes, dissolved in 100 mL of normal saline between 15 and 30 minutes before the incision. This will be preceded by an intradermal test dose to check for hypersensitivity to the drug. If hypersensitivity is present, the patient will be administered a single dose of intravenous Clindamycin 900 mg.
3017428|NCT02446782|Placebo Comparator|saline|100 mL normal saline will be administered intravenously over a period of 10 minutes between 15 and 30 minutes before the incision. An intradermal test dose with normal saline will be administered to this group.
3017429|NCT02446769|Experimental|AVAPS-AE Non-invasive ventilation therapy|Participants will be initiated on AVAPS-AE therapy (intervention arm) for 60 days. AVAPS-AE is a mode of therapy (Philips Respironics Inc, Monroeville, Pa) with potential advantages over the currently established modes of non-invasive positive pressure ventilation (CPAP and bilevel therapy). This mode of therapy incorporates AVAPS (automated adjustable IPAP setting to maintain target ventilation with a settable rate of change), Auto EPAP and Auto Back up Rate.
3017430|NCT02446769|No Intervention|Standard of Care Group|Evaluation and treatment of the participant's sleep disordered breathing will be per their participant's health care provider's usual care pathway.
3017431|NCT02446756|Experimental|acupuncture group|Acupuncture treatment was given once every other day and 20min each time for four weeks.
3017432|NCT02446756|Active Comparator|physiotherapy group|Physiotherapy treatment was given five times a week and 30min each time for four weeks.
3017433|NCT02446743|Experimental|Group 3B|Subjects who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during studies V72P10 (NCT00661713) or V72_41(NCT0142384), and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.
3017434|NCT02446743|Active Comparator|Group B_0_1|Subjects who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.
3017435|NCT02446730|Active Comparator|BES with Prasugel 5mg|Biolimus-eluting stent with Prasugrel 5mg once daily MD
3017436|NCT02446730|Active Comparator|BES with Clopidogrel 75mg|Biolimus-eluting stent with Clopidogrel 75mg once daily MD
3017437|NCT02446717|Experimental|Arm A|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
3017438|NCT02446717|Experimental|Arm B|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD plus ribavirin (RBV) for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
3017439|NCT02446717|Experimental|Arm C|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
3017440|NCT02446717|Experimental|Arm D|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks in HCV genotypes 1- or 4-6- infected participants with or without cirrhosis.
3017441|NCT02446717|Experimental|Arm E|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 16 weeks in HCV genotype 1- or 4-6- infected participants with or without cirrhosis.
3017442|NCT02446704|Experimental|Olaparib and Temozolomide|"- Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation. Once the MTD is determined, the study will move to the phase II portion.~Olaparib- Oral, on determined days per cycle~Temozolomide- Oral, on determined days per cycle"
3017443|NCT02446691|Experimental|Menveo Group|Approximately 135 subjects will receive 4 doses of the study vaccine at 2, 4, 6 and 12 months of age.
3017444|NCT02446678|Active Comparator|Capsule group: PillCam ESO2|Perform capsule endoscopy and esophagogastroduodenoscopy will be preformed within 24 hours after capsule ingestion
3017445|NCT02446678|No Intervention|Standard group|Perform standard esophagogastroduodenoscopy
3017446|NCT02446665|Experimental|PSC Patients|MR Elastography, Fibroscan and standard of care biopsy
3017447|NCT02446665|Active Comparator|Non-PSC Patients|MR Elastography, Fibroscan and standard of care biopsy
3017448|NCT02446652|Experimental|Hydralazine/Magnesium valproate + QT|This group will receive TRANSKRIP® (Hydralazine/Magnesium valproate) + Carboplatin plus Paclitaxel
3017449|NCT02446652|Placebo Comparator|placebo + QT|This group will receive placebo + Carboplatin plus Paclitaxel
3017450|NCT02446626|Active Comparator|1|Patients with Lyme disease, post treatment
3017451|NCT02446626|Active Comparator|2|Patients with post-Lyme disease complaints at least 12 months from initial treatment
3017452|NCT02446626|Active Comparator|3|Acute erythema migrans patients (possible positive control)
3017453|NCT02446626|Active Comparator|4|Lyme Arthritis patients (possible positive control)
3017454|NCT02446626|Active Comparator|5|Healthy Volunteers (negative control)
3017455|NCT02446613|Other|Nasal allergen challenge|Subjects do not receive study medication in this study 204509. Subjects who carried from study TL7116958 treatment group GSK2245035 will undergo NAC with pollen allergen extract.
3017456|NCT02446600|Active Comparator|Arm I (platinum-based chemotherapy)|"REGIMEN I: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.~REGIMEN II: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 for at least 4 courses in the absence of disease progression or unacceptable toxicity.~REGIMEN III: Patients receive pegylated liposomal doxorubicin hydrochloride IV and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for at least 4 courses in the absence of disease progression or unacceptable toxicity."
3017457|NCT02446600|Experimental|Arm II (olaparib)|Patients receive olaparib PO BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3017458|NCT02446600|Experimental|Arm III (olaparib, cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3017459|NCT02446587||Stroke with Mechanical Thrombectomy|Eligible patients will be adults ≥18 with the final diagnosis of an acute ischemic infarction and large artery occlusion in anterior circulation strokes who undergo endovascular therapy with mechanical thrombectomy utilizing stent retrievers
3017460|NCT02446587||Stroke without Mechanical Thrombectomy|Patients who would have large artery occlusion treated with best medical management (IV-tPA if eligible) and not receiving endovascular therapy will be collected for a secondary analysis as a comparison group and to evaluate the selection methods in them as well
3017461|NCT02446574|Experimental|Arm A|"During the Phase I it will administered weekly paclitaxel(dose escalation) and cisplatin with concurrent radiation therapy~During the Phase II it will administered weekly paclitaxel(dose according to phase I) and cisplatin with concurrent radiation therapy"
3017462|NCT02446561|Active Comparator|MRXXX|Active comparator
3017463|NCT02446561|Experimental|MR1XXX|MR1XXX
3017464|NCT02446561|Experimental|MR2XXX|MR2XXX
3017465|NCT02446561|Experimental|MR3XXX|MR3XXX
3017466|NCT02446548|Experimental|aliskiren - placebo - losartan|aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
3017467|NCT02446548|Experimental|losartan - placebo - aliskiren|aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
3017468|NCT02446535|Experimental|BIA DW assessment|All patients have undergone a Clinical DW assessment. Then, they undergo HD sessions in which BIA DW is determined reducing body weight (kg): when flattening of the BIA resistance occurs, the BIA DW is achieved and compared with the Clinical DW
3017469|NCT02446522|Active Comparator|Open vein harvesting|Patients with IHD, who were underwent open vein harvest method (OVH)
3017470|NCT02446522|Active Comparator|Endoscopic vein harvesting|Patients with IHD, who were underwent edoscopic vein harvestingopen vein harvest method (EVH).
3017471|NCT02446509|Experimental|Experimental Group|The experimental group will receive a 7-week group psychoeducation intervention. Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.
3017472|NCT02446509|Active Comparator|Wait List Control Group|Subjects in the wait list control group will receive the same 7 psychoeducation sessions after the experimental group receives these sessions.
3017473|NCT02446496|Experimental|Group A|Subjects will receive a single oral dose of cefadroxil tablet manufactured by GSK under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of cefadroxil tablet manufactured by NP under fasting condition in treatment period 2
3017474|NCT02446496|Experimental|Group B|Subjects will receive a single oral dose of cefadroxil tablet manufactured by NP under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of cefadroxil tablet manufactured by GSK under fasting condition in treatment period 2
3017475|NCT02446483|Experimental|Group A|Thirty subjects will receive a single oral dose of idiazole 20mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fasting condition in treatment period 2.
3017476|NCT02446483|Experimental|Group B|Thirty subjects will receive a single oral dose of PARIET 20 mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of idiazole 20mg DR tabs under fasting condition in treatment period 2.
3017477|NCT02446470|Experimental|Sinus Tarsi approach|The Sinus Tarsi approach is the surgical approach for the incision.
3017478|NCT02446470|Active Comparator|Extensile Lateral approach|The Extensile Lateral approach is the surgical approach for the incision.
3017479|NCT02446457|Experimental|Rituximab + Pembrolizumab|"Refractory Follicular Lymphoma (FL) Participants~Participants receive Rituximab 375 mg/m2 by vein weekly for 4 weeks, and Pembrolizumab 200 mg by vein every 3 weeks for a maximum of 16 infusions. Study cycle is 21 days."
3017480|NCT02446457|Experimental|Rituximab + Pembrolizumab + Lenalidomide|"2/09/18 This cohort is now closed.~Relapse or Refractory Follicular Lymphoma (FL) and DLBCL~Participants receive Rituximab 375 mg/m2 by vein on Days 1, 8, 15 of Cycle 1, and Day 1 of Cycle 2. Pembrolizumab 200 mg by vein on Day 2 of Cycle 1 and every 3 weeks for up to 2 years.~Dose Escalation Phase Starting dose of Lenalidomide 5 mg on Days 1-14 of each cycle for up to 12 cycles.~Dose Expansion Phase Starting Dose of Lenalidomide is maximum tolerated dose from Phase 1."
3017481|NCT02446444|Experimental|Enzalutamide|Enzalutamide 160 mg daily, by mouth, for 24 months from randomisation. All participants are treated with a LHRHA for 24 months from randomisation and external beam radiation therapy started approximately 16 weeks after randomisation (+/- brachytherapy boost)
3017482|NCT02446444|Active Comparator|Conventional Non-steroidal Anti-androgen (NSAA)|"Conventional Non-steroidal Anti-androgen (NSAA), by mouth, for 6 months from randomisation.~All participants are treated with a LHRHA for 24 months from randomisation and external beam radiation therapy started approximately 16 weeks after randomisation (+/- brachytherapy boost)"
3017483|NCT02446431|Experimental|Metronomic Therapy|"There is only one arm in this study. All subjects receive the same therapy for a period of 420 days (42 day cycles x 10 cycles).~Bevacizumab: IV, 10 mg/kg, Days 1, 8~Cyclophosphamide: PO, 25 mg/m2 Days 1-14 (max dose = 50mg/dose)~Valproic Acid: PO, 5 mg/kg, three times per day (TID), Days 22-35~Temsirolimus: IV, 25 mg/m2, Days 22, 29"
3017484|NCT02446418|Experimental|Fluticasone Furoate/Vilanterol|Subjects will receive FF/VI 92 micrograms (mcg)/22 mcg or FF/VI 184 mcg/22 mcg as decided by the investigator QD via ELLIPTA DPI for 24 weeks.
3017485|NCT02446418|Active Comparator|FP/S OR BUD/F|Subjects will receive FP/S (250 mcg/50 mcg or 500 mcg/50mcg) twice daily via DISKUS or BUD /F (200 mcg/6mcg or 400 mcg/12mcg one or two inhalations) twice daily via TURBUHALER DPI as decided by the investigator for 24 weeks.
3017486|NCT02446405|Experimental|Enzalutamide|"Enzalutamide is 160 mg daily, by mouth, until clinical disease progression or prohibitive toxicity.~All participants are to receive standard background therapy with a LHRHA or surgical castration, as per standard of care. The choice of the LHRHA or surgical castration is at the discretion of the treating clinician."
3017487|NCT02446405|Active Comparator|Conventional NSAA|"Conventional NSAA, by mouth until clinical disease progression or prohibitive toxicity.~All participants are to receive standard background therapy with a LHRHA or surgical castration, as per standard of care. The choice of the LHRHA or surgical castration is at the discretion of the treating clinician."
3017488|NCT02446379||EnLightTM and LightPathTM Imaging Systems arm|"Patients will first be injected intravenously with 2-5 MBq/kg, up to a maximum 300 MBq of the marketed product 18F-fluorodeoxyglucose (FDG) and after this undergo tumour excision surgery according to standard of care.~The surgical cavity will be imaged by the EnLightTM system and the tumour excision specimen will be imaged by both the EnLightTM and LightPathTM Imaging Systems. The EnLightTM and LightPathTM Imaging Systems results will not influence any surgical or clinical decision-making. The tumour excision specimen will be analysed according to standard of care pathology. Patients will be followed-up (Visit 3) 2-14 days after the end of surgery for adverse events (AEs)."
3017489|NCT02446366|Experimental|Treatment (hypofractionated SBRT)|Patients undergo 5, 10, or 15 fractions of hypofractionated SBRT daily over 1-3 weeks.
3017490|NCT02446353|Experimental|Megace : fed|Megace / Apetrol ES : comparator / test, fed
3017491|NCT02446353|Experimental|Apetrol ES : fed|Apetrol ES / Megace : test / comparator, fed, cross-over
3017492|NCT02446353|Experimental|Megace : fasting|Megace / Apetrol ES : comparator / test, fasting
3017493|NCT02446353|Experimental|Apetrol ES : fasting|Apetrol ES / Megace : test / comparator, fasting, cross-over
3017494|NCT02446340|Experimental|dalazatide 5ug|8 subjects, 6 given active agent and 2 given placebo
3017495|NCT02446340|Experimental|dalazatide 15ug|8 subjects, 6 given active agent and 2 given placebo
3017496|NCT02446340|Experimental|dalazatide 30ug|8 subjects, 6 given active agent and 2 given placebo
3017497|NCT02446340|Experimental|dalazatide 60ug|8 subjects, 6 given active agent and 2 given placebo
3017498|NCT02446327|Other|Diastolic heart failure cohort|This is a prospective cohort of patients with diastolic heart failure. Blood sampling for biomarker assessment
3017499|NCT02446314|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
3017500|NCT02446314|Experimental|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine + 2.5 mg L-Glutathione + 250 mg placebo powder, once daily, in a 2-hard capsule regimen
3017501|NCT02446314|Experimental|Wild Blueberry Powder - 900 mg|Formulation containing containing 450 mg wild blueberry powder + 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
3017502|NCT02446314|Experimental|Wild Blueberry extract 100mg|Formulation containing containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
3017503|NCT02446301|Experimental|Period I (reference drug)|Before administration of investigational products, subjects should be fasted for 10 hours. On the dosing day, subjects will be confined after administration and won't be discharged until after completion of sample collections for 24 hours following dosing in Period I (Bain® IM injection).
3017504|NCT02446301|Experimental|Period II (Test drug)|Subjects will be back to the clinical site to join Period II (SDE IM injection) and will be discharged after completion for sample collections for 24 hours post drug administration.
3017505|NCT02446288|Active Comparator|TMJ Next Generation|The TMJ NextGeneration device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. They are constructed from methacrylate polymers - the same material as has been used in hearing aids. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the individuals' ear canals when the jaw is in the open position and permit full passage of sound into each ear. The proposed mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
3017506|NCT02446288|Active Comparator|DSG Relaxer|The occlusal splint to be used in this study will be the DSG Relaxer™. The DSG Relaxer™ is a device that has been FDA cleared for the treatment of medically diagnosed migraine pain as well as migraine associated tension-type headaches and relieving bruxism and TMJ syndrome through the reduction of trigeminally innervated muscular therapy.
3017507|NCT02446275|Experimental|Sternocleidomastoid MTRP and stretching|The sternocleidomastoid was treated with ischemic compression.
3017508|NCT02446275|Experimental|Trapezius MTRP and stretching|The central MTRP of the trapezius was treated as described above for the sternocleidomastoid.
3017509|NCT02446249|Experimental|single arm dose escalation|single arm dose escalation
3017510|NCT02446236|Experimental|Dose Escalation Study|Ibrutinib 560 mg/daily rituximab 375mg/m2 IV Day 1 Lenalidomide 10-25 mg PO days 1-21
3017511|NCT02446223|Experimental|Active|
3017512|NCT02446210|Active Comparator|Healthy Controls Group|Magstim 200 magnetic stimulator for Transcranial Magnetic Stimulation and Peripheral Nerve Stimulation
3017513|NCT02446210|Active Comparator|Spinal Cord Injury Group|Magstim 200 magnetic stimulator for Transcranial Magnetic Stimulation and Peripheral Nerve Stimulation
3017514|NCT02446197|Experimental|Patient Directed Exercise Group|Participants will complete a combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
3017515|NCT02446197|No Intervention|Standard of care|Standard of care comprehensive inpatient rehabilitation program.
3017516|NCT02446184|Experimental|Fetal cystoscopy|Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.
3017517|NCT02446184|Active Comparator|Vesicoamniotic shunt|The fetal vesicoamniotic shunt is considered the standard prenatal therapy for severe LUTO. Amnioinfusion and vesicoamniotic shunt placement will be performed under ultrasound guidance.
3017518|NCT02446184|No Intervention|No fetal intervention group|Those patients that refuse fetal intervention and do not elect to terminate the pregnancy will be followed as part of the no fetal intervention group.
3017519|NCT02446171|Experimental|Treatments A-D-B-C sequence|Treatment A in Period 1, Treatment D in Period 2, Treatment B in Period 3 and Treatment C in Period 4
3017520|NCT02446171|Experimental|Treatments B-A-C-D sequence|Treatment B in Period 1, Treatment A in Period 2, Treatment C in Period 3 and Treatment D in Period 4
3017521|NCT02446171|Experimental|Treatments C-B-D-A sequence|Treatment C in Period 1, Treatment B in Period 2, Treatment D in Period 3 and Treatment A in Period 4
3017522|NCT02446171|Experimental|Treatments D-C-A-B sequence|Treatment D in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment B in Period 4
3017523|NCT02446158|Experimental|Chlorhexidine gluconate|PD (peritoneal dialysis) paitents with daily chlorhexidine exit site care
3017524|NCT02446158|No Intervention|Control group|PD (peritoneal dialysis) patients with usual (Normal saline) exit site care
3017525|NCT02446145|Experimental|Experimental intervention arm|"Eltrombopag daily from day 1: 200 mg/day p.o. (100 mg for east asian patients) dose modification 100 mg up to 300 mg/d p.o. (50 - 150 mg for east asian patients)~concomitant medication: Decitabine days 1-5 of each cycle: 20 mg/qm i.v. over 30 minutes~one cycle lasts 28 days"
3017526|NCT02446145|Placebo Comparator|Control intervention arm|"Placebo daily from day 1: 200 mg/day p.o. (100 mg for east asian patients) dose modification 100 mg up to 300 mg/d p.o. (50 - 150 mg for east asian patients)~concomitant medication: Decitabine days 1-5 of each cycle: 20 mg/qm i.v. over 30 minutes~one cycle lasts 28 days"
3017779|NCT02444338|Active Comparator|Control Group|optimal standard of care therapy
3017527|NCT02446132|Experimental|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 52-week period
3017528|NCT02446132|Experimental|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 52-week period
3017529|NCT02446132|Experimental|AVP-786 (dose 3)|AVP-786 dose 3; capsules administered twice a day over a 52-week period
3017530|NCT02446119||Gastroparesis|"Inclusion criteria:~1. Subjects will be of either sex, 18 to 70 years of age.~patients with an established diagnosis of gastroparesis, either diabetic or idiopathic etiology. The gastroparesis subjects will have delayed gastric emptying on gastric scintigraphy defined as greater than 60% retention at 2 hours and/or greater than 10% retention at 4 hours. This gastric emptying test would have been done prior to the endoscopy and is not part of the research study. Patients will undergo EndoFlip during upper endoscopy."
3017531|NCT02446119||Normals|"Inclusion criteria:~1. Subjects will be of either sex, 18 to 70 years of age.~control subjects will be nondiabetic patients without gastroparesis or gastroesophageal reflux symptoms undergoing upper endoscopy. Patients will undergo EndoFlip during upper endoscopy."
3017532|NCT02446106|Active Comparator|Soup with MSG|0.5% MSG incorporated into a soup preload
3017533|NCT02446106|Placebo Comparator|Control Soup|Negative control match for sodium (no MSG + 0.635% salt)
3017534|NCT02446093|Experimental|Test Arm|GMCI + mFOLFIRINOX + Gemcitabine + Radiation + Surgery
3017535|NCT02446093|Active Comparator|Control Arm|mFOLFIRINOX + Gemcitabine + Radiation + Surgery
3017536|NCT02446080|Experimental|Probiotic Group|Milk drink with probiotic culture (150 mL/daily) for 60 days.
3017537|NCT02446080|Active Comparator|Control Group|Milk drink (150 mL/daily) for 60 days.
3017538|NCT02446067|No Intervention|Healthy control|No Repetitive Transcranial Magnetic Stimulation (rTMS)
3017539|NCT02446067|Active Comparator|Active rTMS group|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
3017540|NCT02446067|Sham Comparator|Sham rTMS group|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
3017541|NCT02446054|Experimental|One Arm Study|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
3017542|NCT02446041||ICS/LABA Patients|ICS/LABA Patients following standard of care
3017543|NCT02446028|Experimental|BIOD-531|BIOD-531 injected twice daily
3017544|NCT02446028|Active Comparator|Humalog® Mix 75/25|Humalog® Mix 75/25 injected twice daily
3017545|NCT02446015|Experimental|Systane Ultra QID|SYSTANE® ULTRA lubricant eye drops,1 drop in each eye, 4 times per day (QID) for 28 days
3017546|NCT02446015|Active Comparator|Systane Ultra PRN|SYSTANE® ULTRA lubricant eye drops, 1 drop in each eye, as needed (PRN) for 28 days
3017547|NCT02446002|Experimental|Lofexidine + Naltrexone|
3017548|NCT02445989|Active Comparator|Cyclic NuvaRing CVR Use|CVR use for 3 weeks, remove for 1 week, then replace
3017549|NCT02445989|Experimental|Continuous NuvaRing CVR Use|CVR use for 4 weeks, then replace
3017550|NCT02445976|Experimental|Prior Abiraterone or Enzalutamide|Seviteronel: given orally once daily in 28-day cycles
3017551|NCT02445976|Experimental|Prior Abiraterone and Enzalutamide|Seviteronel: given orally once daily in 28-day cycles
3017552|NCT02445963|Active Comparator|10 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
3017553|NCT02445963|Active Comparator|50 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
3017554|NCT02445963|Active Comparator|250 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
3017555|NCT02445963|Active Comparator|500 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
3017556|NCT02445950|Experimental|Technology-aided counseling|Customers receive intervention via technology-aided phone wellness counseling. The intensive phase lasts 13 weeks and includes 5 phone calls. The customers are able to view their change change needs and choose tasks/goals for the coaching. The independent phase lasts 13 weeks and coaching is done via a digital tool.
3017557|NCT02445950|Active Comparator|Traditional counseling|Customers receive intervention via traditional phone wellness counseling. The intensive phase lasts 13 weeks and includes 5 phone calls. Change needs and goals are set during the phone calls. The independent phase lasts 13 weeks and includes 3 phone calls.
3017558|NCT02445937|No Intervention|Control|The control group will receive usual care, in which the frequency and content of physician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
3017559|NCT02445937|Experimental|Behavioral: The PARTNER II Intervention|"The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists."
3017560|NCT02445924||Control group 1|ten non smoker volunteers
3017561|NCT02445924||Control group 2|ten smoker volunteers
3017562|NCT02445924||NSCLC patients|twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy
3017563|NCT02445911|Experimental|KQ-791 Dose 1|Single loading dose on day 1, followed by single doses on days 8, 15, 22, 29
3017564|NCT02445911|Experimental|KQ-791 Dose 2|Single loading dose on day 1, followed by a daily dose for 28 days
3017565|NCT02445911|Experimental|KQ-791 Dose 3|Single loading dose on day 1 or days 1-2, followed by a daily dose for 28 days
3017566|NCT02445911|Placebo Comparator|Placebo|Multiple ascending doses matching KQ-791 dose
3017567|NCT02445898|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
3017568|NCT02445898|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
3017569|NCT02445885|Experimental|Acute PCI|Acute re-opening of the occluded coronary artery including premedication as for primary PCI within 12 hours
3017641|NCT02445391|Active Comparator|Arm A (observation) (closed to accrual 05/16/2016)|Patients undergo observation.
3017570|NCT02445885|Active Comparator|Subacute PCI|Standard subacute re-opening of the occluded coronary artery including premedication as for subacute PCI within 72 hours
3017571|NCT02445872|Experimental|Arm A|Aprepitant: 125mg PO on day1, 80mg PO on day2 and day3. Palonosetron (a 5-HT3 receptor antagonist): 0.25 mg IV push on day 1 only. Dexamethasone: 5mg IV push once daily from day 1 to day 3,and 3.75mg PO on days 4-5.
3017572|NCT02445872|Active Comparator|Arm B|Palonosetron: 0.25 mg IV push on day 1 only. Dexamethasone: 5mg IV push once daily from day 1 to day 3,and 7.5mg PO on days 4-5.
3017573|NCT02445859|Active Comparator|Standard regimen|Cefuroxime 1.5grams pre-operatively Repeated every 4 hours
3017574|NCT02445859|Experimental|Interventioanl regimen|Cefuroxime continuous infusion targeting 64mg/l serum concentrations.
3017575|NCT02445846||Pregnant women|Pregnant women, regardless of HIV status, seeking antenatal care at clinics in Lusaka, Zambia
3017576|NCT02445833|Experimental|Lifestyle on-line intervention|"The self-applied on-line intervention will received acces to the web and the Vivir mejor modules."
3017577|NCT02445820||HES|Balanced HES 130/0.4 used as and pump prime and for intraoperative fluid therapy.
3017578|NCT02445820||Crystalloid|Balanced Crystalloid used as a pump prime and for intraoperative fluid therapy.
3017579|NCT02445807|Experimental|DFD-06 cream|DFD-06 Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
3017580|NCT02445807|Placebo Comparator|Vehicle Cream|Vehicle Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
3017581|NCT02445794|Experimental|RT001, oral, 1.8 g/day|RT001, oral, 1.8 g QD for 28 days or matching comparator
3017582|NCT02445794|Experimental|RT001, oral, 9 g/day|RT001, oral, 4.5 g BID for 28 days or matching comparator
3017583|NCT02445781|Experimental|90 mg/dl glucose clamp|Glucose clamp intervention of 90 mg/dl maintained for 90 minutes.
3017584|NCT02445781|Experimental|70 mg/dl glucose clamp|Glucose clamp intervention of 70 mg/dl maintained for 90 minutes.
3017585|NCT02445781|Experimental|60 mg/dl glucose clamp|Glucose clamp intervention of 60 mg/dl maintained for 90 minutes.
3017586|NCT02445781|Experimental|50 mg/dl glucose clamp|Glucose clamp intervention of 50 mg/dl maintained for 90 minutes.
3017587|NCT02445768|Active Comparator|Cognitive multisensory rehabilitation|The treatment group will receive the cognitive multisensory rehabilitation that uses motor imagery and sensory discrimination exercises
3017588|NCT02445768|Active Comparator|3T scanner with MRI-compatible robot|Device: 3T scanner with MRI-compatible robot
3017589|NCT02445742|Experimental|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
3017590|NCT02445729|Active Comparator|Dressing Removal at 24 Hours|These patients are randomly assigned to have their dressing removed 24 hours after cesarean section.
3017591|NCT02445729|Active Comparator|Dressing Removal at 48 Hours|These patients are randomly assigned to have their dressing removed 48 hours after cesarean section.
3017592|NCT02445716|Active Comparator|Testosterone 500 mcg / Biolipid B2|"The arm, is part of a randomized, double-blind, placebo-controlled, parallel group trial.~The arm have 35 women. It consists of a 12-week treatment phase involving three study visits and one telephone contact at week 7 of the treatment."
3017593|NCT02445716|Placebo Comparator|Placebo|"The arm, is part of a randomized, double-blind, placebo-controlled, parallel group trial.~The arm have 35 women. It consists of a 4-week screening period plus a 12-week treatment phase involving three study visits and one telephone contact at week 7 of the treatment.~Participants will be attended at the Federal University of São Paulo / Post Graduation Program in São Paulo, Brazil for their study visits."
3017594|NCT02445703|Experimental|Group 1 (HAV + HAV)|"Intervention: Inactivated Hepatitis A vaccine (HAV);~Subjects in this group each received 2 doses of inactivated HAV with a 6-month interval (day 0, month 6);~Route of administration: intramuscular injection in deltoid region;"
3017595|NCT02445703|Experimental|Group 2 (HAV + HABV)|"Intervention: Inactivated Hepatitis A vaccine (HAV) and Combined hepatitis A and hepatitis B vaccine (HABV);~Subjects in this group each received 1 dose of inactivated HAV at day 0, and 1 dose of HABV at month 6.~Route of administration: intramuscular injection in deltoid region;"
3017596|NCT02445703|Experimental|Group 3 (HABV + HABV)|"Intervention: Combined hepatitis A and hepatitis B vaccine (HABV);~Subjects in this group each received 2 doses of HABV with a 6-month interval (day 0, month 6);~Route of administration: intramuscular injection in deltoid region;"
3017597|NCT02445690||Clinical remission without inflammation|Patients with Crohn's disease in clinical remission and no inflammation in the colonoscopy
3017598|NCT02445690||Clinical remission with inflammation|Patients with Crohn's disease in clinical remission and active inflammation in the colonoscopy
3017599|NCT02445677|Experimental|Active TENS|Receiving active transcutaneous electrical nerve stimulation (TENS) treatments during the rehabilitation sessions (only the first half of the rehabilitation period, i.e. 4 to 6 weeks.
3017600|NCT02445677|Placebo Comparator|Simulated TENS|Receiving simulated transcutaneous electrical nerve stimulation (TENS) treatments during the rehabilitation sessions (only the first half of the rehabilitation period, i.e. 4 to 6 weeks.
3017601|NCT02445664|Experimental|Video intervention|A tablet-administered educational video (10 minutes duration).
3017602|NCT02445664|No Intervention|Control|No intervention (no video)
3017603|NCT02445651|Other|Oral and IV N acetyl Cysteine Cohort|Administration of Intravenous (IV) and Oral N-acetyl Cysteine (NAC) Intervention: IV NAC infusion: Dose: 50mg in 200ml of D5W, frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 600 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
3017604|NCT02445651|No Intervention|Control Cohort|Standard of Care Treatment
3017605|NCT02445638|Active Comparator|Whole egg|Subjects will be provided with a daily breakfast meal containing the equivalent of 2 whole eggs for 4 weeks.
3017606|NCT02445638|Placebo Comparator|Yolk-free egg|Subjects will be provided with a daily breakfast meal containing the equivalent of 2 yolk-free eggs for 4 weeks.
3017607|NCT02445625|Experimental|BCI to train joint attention in ASD|We are using Brain Computer Interfaces implemented by EEG in 16 ASD subjects
3017608|NCT02445612||Experimental: MA09-hRPE|Sub-retinal transplantation of MA09-hRPE cells
3017707|NCT02444897|Active Comparator|IV PCA group|Intravenous patient-controlled analgesia
3051892|NCT02214927|Experimental|BI 11634 single rising dose|tablet
3017609|NCT02445599|Experimental|Diclofenac group|"Diclofenac 100 mg tablet were administered orally and Midazolam 5 mg + Atropine 0.5 mg were administered intramuscularly as premedication, 60 minutes before surgical interventions.~Every patient recieved additional thoracic epidural analgesia during and after the surgery.~As rescue medication patients get nalbuphine 10-20mg, diclofenac 75 mg + orphenadrine 30 mg (NEODOLPASSE infusion), metamizole-sodium 2g, tramadol 50-100mg as needed postoperatively."
3017610|NCT02445599|Experimental|Control group|"Midazolam 5 mg + Atropine 0.5 mg were administered intramuscularly as premedication 60 minutes before surgical interventions.~Every patient recieved additional thoracic epidural analgesia during and after the surgery.~As rescue medication patients get nalbuphine 10-20mg, diclofenac 75 mg + orphenadrine 30 mg (NEODOLPASSE infusion), metamizole-sodium 2g, tramadol 50-100mg as needed postoperatively."
3017611|NCT02445586|Experimental|Pertuzumab in Combination with Trastuzumab and Docetaxel|Participants will receive pertuzumab in combination with trastuzumab and docetaxel every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
3017612|NCT02445573|Active Comparator|EA group|
3017613|NCT02445573|Placebo Comparator|Sham EA group|
3017614|NCT02445560|Experimental|Probiotic capsule and Fiber sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
3017615|NCT02445560|Experimental|Probiotic capsule and Placebo sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
3017616|NCT02445560|Experimental|Placebo capsule and Fiber sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
3017617|NCT02445560|Placebo Comparator|Placebo capsule and Placebo sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
3017618|NCT02445547|Experimental|UC-MSCs|UC-MSCs by peripheral intravenous infusion
3017619|NCT02445547|Active Comparator|control|received hormone maintenance therapy
3017620|NCT02445521||PKU (low phe-level)|A subject diagnosed with phenylketonuria (PKU) with low phenylalanine levels, defined as 1-5 mg/dL
3017621|NCT02445521||PKU (mid phe-level)|A subject diagnosed with phenylketonuria (PKU) with middle phenylalanine levels, defined as 6-10 mg/dL
3017622|NCT02445521||PKU (high mid phe-level)|A subject diagnosed with phenylketonuria (PKU) with high middle phenylalanine levels, defined as 11-15 mg/dL
3017623|NCT02445521||PKU (high phe-level)|A subject diagnosed with phenylketonuria (PKU) with high phenylalanine levels, defined as 16-20+ mg/dL
3017624|NCT02445521||Control|A normal subject without phenylketonuria (PKU)
3017625|NCT02445508|Placebo Comparator|Placebo+Placebo|Oral ingestion of sevelamer placebo powder combined with intravenous infusion of isotonic saline.
3017626|NCT02445508|Active Comparator|Placebo+Cholecystokinin|Oral ingestion of sevelamer placebo powder combined with intravenous infusion of cholecystokinin.
3017627|NCT02445508|Active Comparator|Sevelamer+Placebo|Oral ingestion of sevelamer powder combined with intravenous infusion of isotonic saline.
3017628|NCT02445508|Active Comparator|Sevelamer+Cholecystokinin|Oral ingestion of sevelamer powder combined with intravenous infusion of cholecystokinin.
3017629|NCT02445469|Other|Parkinson's disease|MRI exam of the brain
3017630|NCT02445469|Other|Multiple System Atrophy|MRI exam of the brain
3017631|NCT02445469|Other|Progressive Supranuclear Palsy|MRI exam of the brain
3017632|NCT02445469|Other|Vascular parkinsonism|MRI exam of the brain
3017633|NCT02445469|Other|Healthy volunteers|MRI exam of the brain
3017634|NCT02445456|Experimental|Ex-vivo|Patients with relatively advanced rectal cancer who are scheduled to undergo radical surgery to excise rectal tumour and mesorectum. They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery. They will then undergo surgery to excise rectal cancer. The excised specimen will be examined using the Sentimag probe and by standard histology to assess for lymph nodes ex-vivo.
3017635|NCT02445456|Experimental|In-vivo|Patients with early rectal cancer scheduled to undergo local excision of a rectal tumour by transanal endoscopic microsurgery (TEM). They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery, and have an MRI scan to assess tracer spread. They will then undergo TEM surgery to excise the rectal cancer. During surgery the Sentimag probe will be used to locate the sentinel lymph node so it can be surgically removed. The excised specimen will be examined by standard histology.
3017636|NCT02445443||LEGION Hinge Knee System|This group will be receiving the LEGION Hinge device.
3017637|NCT02445417||EES|Epidermal Electronic System
3017638|NCT02445417||Hydrogel Electrode|Hydrogel based EEG electrode
3017639|NCT02445404|Active Comparator|CHOP|cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1~5 every 3 weeks
3017640|NCT02445404|Experimental|Fractionated ICED|ifosfamide, 1.67 g/m² IV day1~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1~3 dexamethasone 40 mg PO or IV day1~4 every 3 weeks
3017642|NCT02445391|Experimental|Arm B (cisplatin or carboplatin)|Patients receive cisplatin IV or carboplatin IV on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
3017643|NCT02445391|Experimental|Arm C (capecitabine)|Patients receive capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3017644|NCT02445378|Experimental|Group I (aromatherapy and essential oils week 1)|Patients select between 3 scented essential oils: peppermint, lavender, or chamomile which is diffused in the hospital room from approximately 9 PM in the evening until morning during week 1 and placebo intervention using rose water during week 2.
3017645|NCT02445378|Experimental|Group II (aromatherapy and essential oils week 3)|Patients undergo placebo intervention using rose water during week 1 and aromatherapy and essential oils as in Group I during week 2.
3017646|NCT02445365|Experimental|Active RIC|Daily remote ischemic conditioning for 10 days. Remote ischemic conditioning is induced by placing a blood pressure cuff around the right or left arm. The cuff is inflated to 200 mmHg and the pressure is kept for 5 minutes. Hereafter the cuff is deflated for 5 minutes completing one cyclus. This cyclus is repeated 4 times.
3017647|NCT02445365|Sham Comparator|Sham|As above with a cuff pressure of 20 mmHg
3017648|NCT02445352|Active Comparator|Rosuvastatin 5mg & Placebo & Placebo|Once a day, administration of rosuvastatin 5mg and two types of placebo for 20 weeks
3017649|NCT02445352|Experimental|DP-R207 5/10mg & Placebo & Placebo|Once a day, administration of DP-R207 5/10mg and two types of placebo for 20 weeks
3017650|NCT02445352|Active Comparator|Rosuvastatin 10mg & Placebo & Placebo|Once a day, administration of rosuvastatin 10mg and two types of placebo for 20 weeks
3017651|NCT02445352|Experimental|DP-R207 10/10mg & Placebo & Placebo|Once a day, administration of DP-R207 10/10mg and two types of placebo for 20 weeks
3017652|NCT02445352|Active Comparator|Rosuvastatin 20mg & Placebo & Placebo|Once a day, administration of rosuvastatin 20mg and two types of placebo for 20 weeks
3017653|NCT02445352|Experimental|DP-R207 20/10mg & Placebo & Placebo|Once a day, administration of DP-R207 20/10mg and two types of placebo for 20 weeks
3017654|NCT02445339|Active Comparator|Intervention Arm: XR-NTX+CM|XR-NTX+CM (Extended Release Naltrexone + Care Management)
3017655|NCT02445339|No Intervention|Standard Care Arm|Standard Care/Alcohol-Medical Management (MM) Only
3017656|NCT02445326|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
3017657|NCT02445326|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
3017658|NCT02445313||Control|Normal, healthy participants
3017659|NCT02445313||AMD|Age-related Macular Degeneration participants
3017660|NCT02445300|Active Comparator|AQUACEL® Ag Surgical dressing|AQUACEL® Ag Surgical dressing is used to cover the surgical wound in the OR. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer.
3017661|NCT02445300|Active Comparator|Sofra-Tulla® dressing|The Sofra-Tulle® dressing was used in the OR and routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine.
3017662|NCT02445287|Experimental|Predicate & Invest.- Cadavers 2D & 3D|Radiation - Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT).
3017663|NCT02445287|Experimental|Investigational - Human Subjects 3D|Radiation - Human subjects will be imaged with 3D investigational device CARESTREAM Cone Beam Computed Tomography (CBCT) only.
3017664|NCT02445274|Experimental|Capsule-reserved surgical procedure|"In this group, the anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.~Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group."
3017665|NCT02445274|No Intervention|Conventional surgical procedure|In this group, the anterior lens capsule was not reserved or attached onto the posterior lens capsule.
3017666|NCT02445261|Active Comparator|normal growth|120 woman with normal fetal growth will be subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound will be done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone. UA resistance indices, number of fetal kicks, the loss of acceleration and variability, and the appearance of decelerations were assessed
3017667|NCT02445261|Active Comparator|growth restricted group|70 woman with l growth restricted fetus will be subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound will be done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone. UA resistance indices, number of fetal kicks, the loss of acceleration and variability, and the appearance of decelerations
3017668|NCT02445248|Experimental|CTL019|Single arm
3017669|NCT02445222|Other|Previously treated CART CD19 patients|Patients who previously were exposed to lentiviral-based CT19 directed CART cell therapy
3017670|NCT02445209|Active Comparator|EOX|"Epirubicin 50mg/m2 IV on day 1; Oxaliplatin 130mg/m2 IV on day 1; Capecitabine 625mg/m2/day PO BID days 1-21; Cycled every 21 days. Cycled every 3 weeks for a maximum of 8 cycles initially (24 weeks of treatment).~Patients who experienced a long term response to the initial 8 cycles of EOX chemotherapy, could be rechallenged with the same regimen."
3017671|NCT02445209|Active Comparator|mDCF|"Docetaxel 40 mg/m2 IV od day 1; Leucovorin 400 mg/m2 IV on day 1; 5fluorouracyl 400 mg/m2 IV on day 1; 5fluorouracil 1000 mg/m2/d IV continuous infusion days 1-2; Cisplatin 40 mg/m2 IV on day 3; Cycled every 2 weeks for a maximum of 12 cycles initially (24 weeks of treatment).~Patients who experienced a long term response to the initial 12 cycles of mDCF chemotherapy, could be rechallenged with the same regimen"
3017708|NCT02444884|Experimental|Stratum A1|Establish MTD in patients with solid tumors MLN8237 orally, once daily on Days 1-7
3017709|NCT02444884|Experimental|Stratum A2|MTD determined in Stratum A1in patients with solid tumors MLN8237 orally, twice daily on Days 1-7
3052094|NCT02213653|Active Comparator|Epoietin zeta|
3017672|NCT02445196|Experimental|PTSD Coach|Subjects assigned to this condition receive information about how to download the research app, PTSD Explorer. This research version of PTSD Coach functions exactly the same, however we have the ability to track individual usage of the app. The app contains contains psycho-education about PTSD and the management of symptoms of PTSD along with activities and techniques to address symptoms. Subjects are told to use the app as much or as little as they want over the next three months.
3017673|NCT02445196|Active Comparator|Waitlist Control|"Subjects assigned to this condition are told: You have been randomly assigned to Group 2, the group that does not use the app.~Following their completion of the post-intervention assessment at 3 months, they are told how to access to the publicly available PTSD Coach app in the Apple App Store or Android Play Store, just so that they are made aware of the resources available to them."
3017674|NCT02445183||Lung Cancer|Confirmed diagnosis of lung cancer
3017675|NCT02445183||No Lung Cancer Controls|Unconfirmed lung cancer diagnosis, false positive
3017676|NCT02445170||Below-knee amputees|The present group consists of diabetic below-knee prosthetic user
3017677|NCT02445170||Transmetatarsal amputees|The present group consists of diabetic transmetatarsal amputees
3017678|NCT02445157||IPF_Reliability|Patients diagnosed with IPF according to NICE guidelines.
3017679|NCT02445144||SCA Patients|Asymptomatic sickle cell anemia patients will undergo imaging/neurocognitive testing and be compared to controls
3017680|NCT02445144||Control Patients|Asymptomatic sickle cell anemia patients will undergo imaging/neurocognitive testing and be compared to controls
3017681|NCT02445131|Experimental|Bendamustine + GA101 + CAL-101|Bendamustine: 70 mg/m2 i.v. GA101: 1000 mg CAL-101: 150 mg p.o.
3017682|NCT02445118||Adipose Allograft Matrix Injection|AAM injected to create a 2 to 3mm raised wheal on the proximal dorsal wrist of the non-dominant hand
3017683|NCT02445105|Active Comparator|Autism Navigator Enhanced Practice|A 6-hour training will be provided to community service providers with the Autism Navigator for Primary Care professional development course and use of a web-based platform that includes an automated communication and autism screening and monthly electronic monitoring.
3017684|NCT02445105|Experimental|Family Engagement plus Autism Navigator|A 6-hour training will be provided to community service providers on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler, in addition to Autism Navigator Enhanced Practice.
3017685|NCT02445092|Experimental|Catheter prewashing|"Intervention: prewashing the catheter before IUI.~450 patients randomly included in this group will have their insemination catheter prewashed with the same media used to wash the sperm, prior to performing the insemination using the washed catheter."
3017686|NCT02445092|No Intervention|Control group|450 patients randomly assigned in this group will have their insemination performed routinely, without washing the insemination catheter..
3017687|NCT02445079||HIV infected|HIV infected sub-group
3017688|NCT02445079||HIV uninfected|HIV uninfected sub-group, age and gender matched to the HIV-infected group
3017689|NCT02445066|Other|Open label|Vitamin D3 - 4,000 IU/day for 4 months
3017690|NCT02445040|Experimental|Babylog VN500 in HFOV mode|Subjects will be treated with HFOV provided by the Babylog VN500 - the investigational device - for up to 14 days.
3017691|NCT02445027|Experimental|MGH OCT Imaging Capsule|Subject will swallow the OCT capsule and images will be acquired using the OCT Imaging system.
3017692|NCT02445014|Experimental|MGH SECM Imaging Capsule|Subject will swallow the SECM imaging capsule and images will be acquired using the SECM Imaging system.
3017693|NCT02445001|Experimental|ICG loaded erythrocytes|Ability to directly visualize erythrocyte dynamics within the retinal and choroidal microcirculations would facilitate focused investigations into the relationships between vasomotion (i.e., pulsatile erythrocyte movement through capillaries) and oxygen distribution to localized tissue regions.
3017694|NCT02444988|Active Comparator|0.9% Saline|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
3017695|NCT02444988|Active Comparator|Physiologically-balanced|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
3017696|NCT02444975|Experimental|Increased water intake+coaching program|Women in the intervention group will be asked to increase their mineral water intake of 1.5L/day
3017697|NCT02444975|Other|No intervention|No intervention
3017698|NCT02444962|Experimental|HAVD implant|
3017699|NCT02444949|Experimental|endostar+DF+IMRT|patient first receive one periodicity chemotherapy(DDP (25mg/m2/d; ivgtt; d1～3)+5-FU (600mg/m2/d; ivgtt; d1～5)+endostar (150mg/5d; civ; d1～5)), then given IMRT (5 times per week, 6 weeks). After rest 4 weeks, continue to give the chemotherapy (21 days for a periodicity, 3 periodicities).
3017700|NCT02444949|Other|DF+IMRT|patient first receive one periodicity chemotherapy(DDP (25mg/m2/d; ivgtt; d1～3)+5-FU (600mg/m2/d; ivgtt; d1～5)), then given IMRT (5 times per week, 6 weeks). After rest 4 weeks, continue to give the chemotherapy (21 days for a periodicity, 3 periodicities).
3017701|NCT02444936|Active Comparator|ZOSTAVAX|ZOSTAVAX shingles vaccine Zoster vaccine live Single 0.65mL subcutaneous injection
3017702|NCT02444936|No Intervention|Control|There is no drug given in this arm.
3017703|NCT02444923|Experimental|start with scleral RGP contact lenses|The experimental intervention is scleral rigid gas permeable contact lenses will . These lenses are designed to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with corneal contact.
3017704|NCT02444923|Placebo Comparator|start with corneal RGP contact lens|The control intervention is corneal rigid gas permeable contact lens. Corneal lenses are considered the gold standard in the management of the visual disability due to keratoconus and other related irregular cornea disorders.
3017705|NCT02444910|Experimental|KDT501|Experimental drug, KDT501, is administered at 600mg for 10 consecutive days. On days 11 and 21 (+/- 1 day), based on the KDT501 drug exposure level, the subject will be provided instructions on dose adjustment of KDT501. Dose adjustments will be administered at 800mg for 10 consecutive days, determined at day 11; followed by 1,000mg for 8 consecutive days if determined at day 21.
3017706|NCT02444897|Experimental|Epidural PCA group|Epidural patient-controlled analgesia group
3017710|NCT02444884|Experimental|Stratum B|Expand MTD in patients with neuroblastoma MLN8237 orally, once daily on Days 1-7
3017711|NCT02444858|Experimental|UCMSC group|Human umbilical cord MSCs are administrated to patients by intravenous injection
3017712|NCT02444858|Other|Control group(Normal saline)|Patients will receive normal saline at the same time points as that in experimental group.
3017713|NCT02444845||Study Population|Hypertensive and diabetic patients who meet eligibility criteria will be enrolled and evaluated for the presence of anemia secondary to CKD. The first visit will capture medical history including risk factors for CKD; laboratory assessments will be performed at the second and third visits to evaluate glomerular filtration rate (eGFR) and anemia profile, respectively. Participants who are not diagnosted with CKD based upon the second visit will not return for the third visit.
3017714|NCT02444819|Experimental|HM61713|Subjects who entered the study will be administered HM61713 800 mg per day.
3017715|NCT02444806|Active Comparator|Full Polysomnography|Patients will have NIV settings established using overnight full polysomnography.
3017716|NCT02444806|Active Comparator|Oximetry-capnography|Patients will have NIV settings established using only Oximetry-capnography and subjective sleep comfort.
3017717|NCT02444793|Experimental|PF-05082566 + KW-0761|During Parts 1 & 2 Mogamulizumab and PF-05082566 will be administered at appropriate intervals. Part 1: PF-05082566 dose escalation; increased doses of PF-05082566 IV are administered with mogamulizumab IV. Part 2: patients will be treated with the maximum tolerated dose established in Phase 1 for the combination.
3017718|NCT02444780||elective cardiac surgery patients|consecutive patients who undergo elective cardio-thoracic surgery during a 6 to 8 week period
3017719|NCT02444767|Experimental|13mg Bimatoprost Insert|Subjects in this arm have 13mg Bimatoprost Ocular Inserts placed in both eyes for 7 days.
3017720|NCT02444754||Observational (surveys, questionnaire, chart review)|Patients complete survey items across a number of domains (patient characteristics, access to health care, perceived quality of care, clinical trial knowledge and attitudes, and cancer related health needs). Patients also complete questionnaires to obtain demographics information including age, education, race and ethnicity, marital status, employment status, insurance coverage, and income, as well as health status/indicators. Cancer-related characteristics, including diagnosis, stage, time since diagnosis, and treatments received are obtained self-report and patients' medical records.
3017721|NCT02444741|Experimental|Pembrolizumab + SBRT|"Phase I: Participants receive Pembrolizumab at a dose depending on when they join this study. Starting dose of MK-3475 100 mg by vein on Day 1 of each 3-week cycle.~Participant receives stereotactic body radiation therapy (SBRT) to a total dose of 50 Gy in 12.5 Gy fractions (4 fractions total)."
3017722|NCT02444741|Experimental|Group 1: Pembrolizumab + SBRT|"Phase II: Participants receive Pembrolizumab by vein on Day 1 of each 3-week cycle at the maximum tolerated dose from Phase I.~Stereotactic body radiation therapy (SBRT) delivered at 50 Gy in 4 daily fractions."
3017723|NCT02444741|Experimental|Group 2: Pembrolizumab|"Phase II: Participants receive Pembrolizumab by vein on Day 1 of each 3-week cycle at the maximum tolerated dose from Phase I.~If disease progresses after 5 weeks, participant may be able to also start receiving stereotactic body radiation therapy (SBRT). If treating physician thinks it would be safer, participant may receive wide-field radiation therapy (WFRT) instead of SBRT."
3017724|NCT02444741|Experimental|Group 3: Pembrolizumab + WFRT|"Phase II: Participants receive Pembrolizumab by vein on Day 1 of each 3-week cycle at the maximum tolerated dose from Phase I.~Wide-field radiation therapy (WFRT) delivered at 45 Gy in 15 daily fractions."
3017725|NCT02444741|Experimental|Group 4: Pembrolizumab + Possible WFRT|"Phase II: Participants receive Pembrolizumab by vein on Day 1 of each 3-week cycle at the maximum tolerated dose from Phase I.~If disease progresses after 5 weeks, participant may be able to also start receiving wide-field radiation therapy (WFRT). WFRT delivered at 45 Gy in 15 fractions."
3017726|NCT02444741|Experimental|Pembrolizumab + WFRT|"Phase I: Participants receive Pembrolizumab at a dose depending on when they join this study. Starting dose of MK-3475 100 mg by vein on Day 1 of each 3-week cycle.~Participants receive either SBRT or conventional radiation therapy, depending on what type of radiation therapy the doctor thinks is better for them."
3017727|NCT02444741|Experimental|Group 5: Pembrolizumab + WFRT or SBRT|Patients with lesion(s) amenable to SBRT or WFRT, assigned to this group. Treatment will consist of MK-3475 and WFRT: 45 Gy in 15 fractions to the primary lesions and low dose radiation (500-1000cGy) radiation to other lesions or SBRT: 50 Gy in 4 fractions to the primary lesions and low dose radiation (500-1000cGy) to the other lesions.
3017728|NCT02444728|Active Comparator|Group1:Hydroxychloroquine|Hydroxychloroquine: 100 mg tablets by mouth, 400mg everyday for 12 months Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months
3017729|NCT02444728|Active Comparator|Group 2:Cyclophosphamide|"Cyclophosphamide, Azathioprine & Methylprednisolone Cyclophosphamide: 200mg powder intravenous infusion, 1000mg every month for 6 month.~Azathioprine: 100 mg tablets by mouth, everyday for 6 months. Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months"
3017730|NCT02444715|Active Comparator|Standard care (SC)|
3017731|NCT02444715|Experimental|Interventional care (IC)|
3017732|NCT02444702||CLBP and degenerative lumbar spine|Participants with CLBP (>12 weeks) and degenerative changes of the lumbar spine confirmed by CT imaging who were recommended surgery and chose to undergo surgery will be recruited from the department of Orthopedic Surgery at the Meir Medical Center, Kfar-Saba, Israel. Included participants will be men or women, aged 40-80 years, of any race or ethnic background. Participants' diagnosis may include unstable degenerative spondylolisthesis, radicular pain, or documented stenosis with referred pain.
3017733|NCT02444689|Experimental|Electronic Media Application|Participants will receive an age-appropriate behavioral intervention designed to promote weight loss, improved diet quality, and exercise.
3017734|NCT02444689|Active Comparator|Control|Participants will receive standard of care education and feedback on how to implement a heart healthy lifestyle to promote weight loss, improved diet quality and exercise.
3017735|NCT02444663|Active Comparator|Clinician Valgus|Clinician performed fluoroscopic valgus and varus stress X-rays
3017736|NCT02444663|Active Comparator|Clinician Varus|Clinician performed fluoroscopic varus stress X-rays
3017737|NCT02444663|Experimental|Device Valgus|Device performed fluoroscopic valgus stress X-rays
3017738|NCT02444663|Experimental|Device Varus|Device performed fluoroscopic varus stress X-rays
3017739|NCT02444637|Experimental|Rivastigmine (Exelon) Patch|For the first 4 weeks of the study, subjects will receive Rivastigmine patch 4.6mg/24 hours. Thereafter, subjects will receive Rivastigmine patch 9.5mg/24 hours.
3017740|NCT02444624||not necrotizing enterocolitis group|not necrotizing enterocolitis preterm neonates matched with necrotizing enterocolitis preterm neonates
3017741|NCT02444624||necrotizing enterocolitis group|necrotizing enterocolitis preterm neonates of gestational age less than or equal to 31+6 weeks of amenorrhoea with confirmed NEC diagnosis (Bell stage II or III)
3017742|NCT02444611|Active Comparator|Group 1|BCG vaccine, 0,05ml intradermally at birth
3017743|NCT02444611|Active Comparator|Group 2|BCG vaccine, 0,05ml intradermally at birth Hepatitis B vaccine, 5 micrograms, intramuscularly at birth
3017744|NCT02444611|Active Comparator|Group 3|Hepatitis B vaccine, 5 micrograms, intramuscularly at birth
3017745|NCT02444611|No Intervention|Group 4|No birth vaccines
3017746|NCT02444598|Experimental|Negative-pressure wound therapy|Vaccum Assisted Closure device. Patients will receive negative-pressure wound therapy according to manufacturer treatment guidelines.
3017747|NCT02444598|Active Comparator|Standard|Patients will be treated with conventional wound dressings according to local treatment protocols.
3017748|NCT02444585|Experimental|Denosumab|Drug for prevention of bone loss
3017749|NCT02444585|Placebo Comparator|Control|Hip Replacement Patient without Drug
3017750|NCT02444572|Experimental|ENOXA group|"patients going on Enoxa 4000 IU* according to randomization:~Administer the dose of 4,000 IU per day, regardless of the patient's weight to the inclusion of patients~Start injections 8-12 hours after the surgical procedure~Administer subcutaneously~The administration should be daily at a fixed time according to clinical practice for 30 successive days.~IU: international unit"
3017751|NCT02444572|Active Comparator|LOVENOX group|"patients going on Lovenox 4000 IU* according to randomization:~Administer the dose of 4,000 IU per day, regardless of the patient's weight to the inclusion of patients~Start injections 8-12 hours after the surgical procedure~Administer subcutaneously~The administration should be daily at a fixed time according to clinical practice for 30 successive days.~IU: international unit"
3017752|NCT02444559|Experimental|Ropivacaine+Clonidine|Adductor Canal Block Ropivacaine 20ml 5mg/ml+ Clonidine 150ug
3017753|NCT02444559|Placebo Comparator|Ropivacaine+Placebo|Adductor Canal Block Ropivacaine 20ml 5mg/ml+ saline
3017754|NCT02444546|Experimental|Treatment (sargramostim, wild-type reovirus)|Patients receive sargramostim SC daily on days 1 and 2 and wild-type reovirus IV over 60 minutes on days 3-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3017755|NCT02444533|Active Comparator|Liposomal Bupivacaine|Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy
3017756|NCT02444533|No Intervention|No treatment|Patient will not be given any medications in the tonsillar fossae after tonsillectomy
3017757|NCT02444520|Experimental|Integrated GP Care|"GP training in utilising cognitive behavioural skills during 10-minute consultations;~GP Supervision;~Audio-visual and written materials/guidelines for GP's;~Copies of self-help materials for patients;• Integrated case management discussion prior to secondary care referral. GPs will be encouraged to consult with a colleague before making a referral;~Booklets for patients once consent gained."
3017758|NCT02444520|No Intervention|Waiting List Control Group|Patients in the waiting list control group will continue to receive treatment as usual (TAU), and will be crossed over to receive 'Integrated GP Care' at 6 months post randomization.
3017759|NCT02444507|Active Comparator|Reference Drug: Nexium|Name: Nexium powder for injection and infusion 40 mg, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
3017760|NCT02444507|Active Comparator|Test Drug: Esomelone|Name: Esomelone Powder for Solution for Injection / Infusion 40 mg Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
3017761|NCT02444481|Experimental|Polygynax, antibiotic, vaginal treatment|Polygynax combinaison of nystatine, polymyxin, neomycin, Local treatment of vaginal infection during 12 days. One vaginal capsule every evening.
3017762|NCT02444468|Experimental|IPC and bandage|Pneumatic device and bandage
3017763|NCT02444468|Active Comparator|Bandage only|Bandage only
3017764|NCT02444455|Experimental|UCMSC group|Human umbilical cord MSCs are administrated to patients by intravenous infusion
3017765|NCT02444442|Active Comparator|Renal Denervation|participants randomised to undergo renal denervation
3017766|NCT02444442|Sham Comparator|Sham control|participants randomised to undergo sham procedure
3017767|NCT02444429|Experimental|Sub-study A experimental arm|"This experimental arm corresponds to patients with borderline infiltrates at 3 months, who will be randomized to receive a treatment for rejection (intensification of the corticotherapy with corticosteroid boluses = Corticosteroid boluses Methylprednisolone )"
3017768|NCT02444429|Active Comparator|Sub-study A control arm|"This control arm corresponds to patients with borderline infiltrates at 3 months, who will be randomized to not change their immunosuppressive treatment (No therapeutic modification)"
3017769|NCT02444429|Experimental|Sub-study B experimental arm|This experimental arm corresponds to patients without significant infiltrates 3 months, who will be randomized to stop maintenance corticotherapy (Stop maintenance corticotherapy )
3017770|NCT02444429|Active Comparator|Sub-study B control arm|This control arm corresponds to patients without significant infiltrates 3 months, who will be randomized to not change their immunosuppressive treatment (No therapeutic modification)
3017771|NCT02444403|Other|Police Education Program (PEP)|The entire police force mandated for periodic refresher training will be assigned to classes which receive one PEP course over 2 years.
3017772|NCT02444390|Other|Exemestane+everolimus|Exemestane+everolimus are administered as per their approved indication
3017773|NCT02444377|Experimental|High-intensity interval -2min|5 bouts of 2 min cycling at varying intensities of VO2peak (80-100%) with 1 min recovery.
3017774|NCT02444377|Experimental|High-intensity interval -1min|10 bouts of 1 min cycling at 90% of VO2peak with 1 min rest periods
3017775|NCT02444377|No Intervention|Control|No exercise
3017776|NCT02444364|Experimental|Sitagliptin|Subjects will receive 90 tablets of 100mg sitagliptin
3017777|NCT02444351|Active Comparator|control group|
3017780|NCT02444338|Experimental|Device Group|MitraClip device plus optimal standard of care therapy
3017781|NCT02444325|No Intervention|Routine Prenatal Care|Subjects randomized to routine care will receive their care in the usual diabetic clinic attended by residents and faculty. They will receive consultation with the diabetes educator at diagnosis and as needed. Patients are seen every 2 weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits are 10-15 minutes and focus on routine screening tests and review of blood sugar logs/medication titration. Each subject's medical chart will be reviewed for demographics, antenatal management, maternal and neonatal outcomes.
3017782|NCT02444325|Experimental|Group prenatal care|Group visits will be held every 2 weeks in a continuous cycle through a four session curriculum. Women will have weekly visits beginning at 37 weeks with traditional prenatal visits on the weeks when the group does not meet. Groups of 4-12 women will meet for two hour visits and much of that time will be spent on pregnancy, behavioral health, diabetes and nutrition education. Groups will be co-facilitated by 2 CenteringPregnancy trained providers at each site and an obstetric provider. Women may be instructed to have additional visits in the traditional clinic at the discretion of the obstetric provider.
3017783|NCT02444312|Experimental|Benefit-finding Writing Activity|For two weeks, on six days of their choice, caregivers will be instructed to write about their thoughts and feelings in a diary/ notebook about the benefits of caring.
3017784|NCT02444312|Active Comparator|Neutral Writing activity|For two weeks, on six days of their choice, caregivers will be instructed to write about a neutral topic.
3017785|NCT02444286||standard care group|optimal standard of care therapy
3017786|NCT02444286||device group|Follow-up of MitraClip device implantation plus optimal standard of care therapy
3017787|NCT02444273|No Intervention|Control Group|Subjects will receive standard care both pre and post transplant.
3017788|NCT02444273|Experimental|Exercise Group|Subjects will receive a personalized home exercise program and regular phone calls from a therapist to monitor and promote activity.
3017789|NCT02444260|Sham Comparator|Intravenous Normal Saline|Intravenous Normal Saline plus Lignocaine HCl (1%) - administered by wound infiltration to a maximum dose of 4.5mg/kg ; Bupivocaine HCl (0.25%) - administered by wound infiltration to a maximum dose of 2 mg/kg plus i
3017790|NCT02444260|Active Comparator|Midazolam|Lignocaine HCl (1%) - administered by wound infiltration to a maximum dose of 4.5mg/kg Bupivocaine HCl (0.25%) - administered by wound infiltration to a maximum dose of 2 mg/kg plus Midazolam - administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg.
3017791|NCT02444247|Other|High Dose Exercise vs Sedentary Option|Relative Reinforcing Value of high dose exercise (300 kcal expenditure per session) versus sedentary activity will be determined.
3017792|NCT02444247|Other|Low Dose Exercise vs Sedentary Option|Relative Reinforcing Value of low dose exercise (150 kcal expenditure per session) versus sedentary activity will be determined.
3017793|NCT02444247|Other|No Exercise vs Sedentary Option|Relative Reinforcing Value of no exercise (0 kcal expenditure per session) versus sedentary activity will be determined.
3017794|NCT02444234|Experimental|Tedizolid PO/IV|Tedizolid phophate 200mg tablet with crossover to IV
3017795|NCT02444234|Experimental|Tedizolid IV/PO|Tedizolid phophate 200mg IV with crossover to PO
3017796|NCT02444208|Experimental|Cocaine Inhibitory Control Training|This group will receive active inhibitory control training.
3017797|NCT02444208|Placebo Comparator|Neutral Inhibitory Control Training|This group will receive neutral inhibitory control training.
3017798|NCT02444195|Experimental|Guided Imagery|Guided Imagery With Audio Media
3017799|NCT02444195|No Intervention|Routine Postoperative Care|Subjects will receive routine pre-operative, intra-operative, post-operative, chemotherapy, and radiation care as dictated by pathologic diagnosis.
3017800|NCT02444182|Experimental|Probiotics|participants will receive a lozenge containing mixture of probiotic bacteria BB-12 and LGG
3017801|NCT02444182|Placebo Comparator|Control - No probiotics|Participants will receive a control lozenge containing no probiotics. all lozenges are sugar-free; sweetened by xylitol (0.5 g xylitol per piece)
3017802|NCT02444156|Experimental|Exercise training|All participants will receive usual care, including standard advice about diet and physical activity. In addition to usual care, participants will be asked to take part in a 12-week exercise programme. Participants will use an indoor rower (Concept 2, Model E) three times per week at Leicester Diabetes Centre. Each session will be supervised and the investigators will liaise with the participants to arrange convenient times to exercise, including mornings and evenings. The supervisors will teach the participants how to row correctly.
3017803|NCT02444143|Active Comparator|IBW|tacrolimus extended release 0.15 mg/kg/day based on Ideal Body Weight (IBW)
3017804|NCT02444143|Experimental|ABW|tacrolimus extended release 0.15 mg/kg/day based on adjusted Body Weight (aBW)
3017805|NCT02444104||Patients with atrial fibrillation|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with atrial fibrillation.
3017806|NCT02444104||Patients with highly reduced LV function|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with a highly reduced left ventricular function (LV function)
3017807|NCT02444104||Patients with aortic stenosis|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with severe aortic stenosis
3017808|NCT02444104||Patients with LVAD|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with left ventricular assist-device (LVAD)
3017809|NCT02444091|Experimental|Cyclophosphamide|Cyclophosphamide, intravenous infusions four weeks apart. Six infusions in total. First infusion: 600 mg/m2. Infusions 2 to 6: 700 mg/m2
3017810|NCT02444078|Experimental|Exercise|Exercise sessions will be done in groups of three-to-eight persons; whilst being a group-based exercise program, participants will be guided and the exercises will be adapted in an individual basis, which may increase adherence and compliance rates.
3018050|NCT02442557|Active Comparator|single dose 25 mg|a single intravenous injection of 25 mg DC-TAB
3017811|NCT02444078|Active Comparator|Social activity|Participants in this group will participate in group-based activities such as music (percussion instruments), arts and board games; no intervention on physical activity will be provided to these participants.
3017812|NCT02444065|Experimental|Cognitive Behavior Therapy (CBT)|In this arm, participants receive the Cognitive behavior therapy (CBT) intervention as an augmentative treatment to standard day hospital treatment as usual.
3017813|NCT02444065|Active Comparator|Motivational Interviewing (MI)|In this arm, participants receive the Motivational Interviewing intervention as an augmentative treatment to standard day hospital treatment as usual.
3017814|NCT02444052|Experimental|Zimmer Puros Cancellous Allograft|Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
3017815|NCT02444052|Experimental|Nobel Biocare Creos Cancellous Allograft|Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
3017816|NCT02444039||Any Willing and Able Person for Ocular Imaging|Any Willing and Able Person for Ocular Imaging
3017817|NCT02444026|Experimental|iCBT for Insomnia|The Internet intervention offered is the SHUT-i program (Sleep Healthy Using The Internet), which is based on the existing consensus concerning non-pharmacological treatment of insomnia and builds on previous validated CBT's for insomnia (CBT -I)
3017818|NCT02444026|No Intervention|Control|The control group will be offered the intervention AFTER the study
3017819|NCT02444013|Active Comparator|Folic acid|Oral folic acid (5 mg, tid) were given at least two days before CTA/angiography/angioplasty and continued for two days after.
3017820|NCT02444013|Placebo Comparator|Placebo|Oral placebo (1 tablet, tid) were given at least two days before CTA/angiography/angioplasty and continued for two days after.
3017821|NCT02444000|Experimental|experimental|Administration of 6 cycles of PCV chemotherapy PCV chemotherapy is given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally
3017822|NCT02444000|Active Comparator|control|radiotherapy followed by 6 cycles of PCV chemotherapy given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally
3017823|NCT02443987|Experimental|Received intravenous fluids|The patient will receive 500ml of 0.9% NaCl fluid intravenously during the operation.
3017824|NCT02443987|No Intervention|Control Arm|The patient will receive no intravenous fluid as per current routine protocol
3017825|NCT02443974|Experimental|Knee brace group|Patients received knee brace with hinges (Fisiotensor®) and were instructed to use it in daily activities, every day, during six months
3017826|NCT02443974|Experimental|Knee sleeve group|Patients received knee sleeve without hinges (Fisiotensor®) and were instructed to use it in daily activities, every day, during six months
3017827|NCT02443974|No Intervention|Control group|Keep medication usual
3017828|NCT02443961|Experimental|Mesenchymal Stem Cell (MSC) therapy|There will only be one treatment arm to evaluate the security of the treatment with MSC.
3017829|NCT02443948||adjuvant/follow up setting|
3017830|NCT02443948||neo-adjuvant setting|
3017831|NCT02443948||advanced disease|
3017832|NCT02443935|Experimental|MGN1703|TLR-9 agonist MGN1703 administered to HIV-1 positive patients on cART
3017833|NCT02443922|Experimental|Glimepiride|Glimepiride 2mg qam
3017834|NCT02443922|Experimental|Sitagliptin|Sitagliptin 100mg qam
3017835|NCT02443922|Active Comparator|Metformin|Metformin as prescribed
3017836|NCT02443909|Active Comparator|first group|Patients undergoing Retrograde Intrarenal Surgery with 20w Holmium laser device who have 2-3 cm kidney stones
3017837|NCT02443909|Active Comparator|second group|Patients undergoing Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power) who have 2-3 cm kidney stones
3017838|NCT02443909|Active Comparator|third group|Patients undergoing Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power) who have 2-3 cm kidney ston
3017839|NCT02443896|Experimental|Sealant applied to molars|"All 'sealable' permanent molars will be sealed: Occlusal fissures and where appropriate, buccal pits (on lower molars) and palatal pits (on upper molars) will be sealed.~If patient compliance is adequate, a resin based sealant will be used as the first choice material. The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard."
3017840|NCT02443896|Sham Comparator|No sealant applied to molars.|No molars will be sealed.
3017841|NCT02443883|Experimental|Ramucirumab Regimen 1|Standard dose of ramucirumab given intravenously (IV) on day 1 and day 15 of each cycle (28 day cycles) until discontinuation criteria are met.
3017842|NCT02443883|Experimental|Ramucirumab Regimen 2|Experimental dose of ramucirumab given IV on day 1 and day 15 of each cycle (28 day cycles) until discontinuation criteria are met.
3017843|NCT02443883|Experimental|Ramucirumab Regimen 3|Experimental dose of ramucirumab given IV on day 1, 8, 15 and 22 of each cycle (28 day cycles) until discontinuation criteria are met.
3017844|NCT02443883|Experimental|Ramucirumab Regimen 4|Experimental dose of ramucirumab given IV on day 1 and day 8 of each cycle (21 day cycles) until discontinuation criteria are met.
3017845|NCT02443857|Experimental|ChARMin|Single-arm only
3017846|NCT02443844|Active Comparator|First group|Patients taken tamsulosin for benign prostate hyperplasia who have non muscle invasive bladder cancer
3017847|NCT02443844|Active Comparator|Second Group|Patients taken transurethral resection prostatectomy for benign prostate hyperplasia who have non muscle invasive bladder cancer
3017848|NCT02443831|Experimental|CD19 CAR T-cells|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19CAR T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19CAR T-cells.
3017849|NCT02443805|Active Comparator|300 IR|300 IR tablet of HDM Allergen Extracts
3017850|NCT02443805|Placebo Comparator|Placebo|Placebo tablet
3017851|NCT02443792|Experimental|Unicirc with tissue adhesive|Unicirc under topical anesthetic w/ cyanoacrylate wound sealing
3017852|NCT02443792|Active Comparator|Open Surgical|Open surgical circumcision under local anesthetic with suturing
3017944|NCT02443129|Experimental|mydramide only|"Patients in the clinics undergoing pupil dilation~Intervention:~Tropicamide instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon"
3017853|NCT02443779||Early Parkinson's disease patients|All subjects will undergo a complete neuro-ophthalmological examination, including assessment of best-corrected visual acuity, ocular motility, pupillary reflexes, slit-lamp biomicroscopy, intraocular pressure (IOP) measurement, and dilated fundus examination, followed by an optical coherence tomography study. Subjects will also have a DaTscan for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging. A clinical examination will also be performed in order to document motor and cognitive functioning.
3017854|NCT02443779||Advanced Parkinson's disease patients|All subjects will undergo a complete neuro-ophthalmological examination, including assessment of best-corrected visual acuity, ocular motility, pupillary reflexes, slit-lamp biomicroscopy, intraocular pressure (IOP) measurement, and dilated fundus examination, followed by an optical coherence tomography study. Subjects will also have a DaTscan for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging. A clinical examination will also be performed in order to document motor and cognitive functioning.
3017855|NCT02443766||Healthy Subjects|Healthy subjects will attend the weeklong meditation retreat.
3017856|NCT02443753|Experimental|Device|Subjects who receive the device
3017857|NCT02443740|Experimental|Single Ascending Dose-1 (Part A)|Single ascending doses of PF-05251749 administered to healthy volunteers in a cross over study design
3017858|NCT02443740|Experimental|Single Ascending Dose-2 (Part A)|Single ascending doses of PF-05251749 administered to healthy volunteers in a cross over study design
3017859|NCT02443740|Experimental|Single Dose Cerebrospinal Fluid (Part B)|Single maximum dose from Part A of PF-05251749 administered to healthy volunteers to assess the PK of PF-05251749 in CSF
3017860|NCT02443727|Experimental|Intranasal oxytocin group|Participants will self-administer a single dose of 24 IU oxytocin (Syntocinon, Novartis; three puffs per nostril, each with 4 IU oxytocin, 6 puffs total).
3017861|NCT02443727|Placebo Comparator|Placebo group|"The placebo is identical to the oxytocin formulation with the exception of the active compound.~Participants will self-administer three puffs per nostril of placebo (6 puffs total)."
3017862|NCT02443714|Experimental|Needle-free jet injection|Jet injectors deliver insulin at a high velocity (typically.100 m/s) across the skin in the subcutaneous tissue and may dispense the insulin over a larger area than insulin injected with a syringe.
3017863|NCT02443714|Experimental|Conventional pen|Conventional insulin administration with insulin pens.
3017864|NCT02443701|Experimental|Exercise|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump).
3017865|NCT02443701|Experimental|NEMES|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump).The healthy athletes electrical stimulation group will perform the same training program described above, but strength training is associated with electrical stimulation, medium frequency current (1kHz), modulated at 70Hz, cycle Work 10%, intensity used will vary according to the capacity and tolerable for each individua. The stimulated muscle group will be the quadriceps femoris
3017866|NCT02443701|Experimental|Phototherapy|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump). The 12 healthy athletes participating in the phototherapy group will undergo a phototherapy protocol before performing the strength and jump training. Phototherapy will be conducted through a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J. The application sites will be six points on the belly of the quadriceps femoris muscles bilaterally.
3017867|NCT02443688|Experimental|50 mg CTX-4430|Once daily oral capsule for 48 weeks
3017868|NCT02443688|Experimental|100 mg CTX-4430|Once daily oral capsule for 48 weeks
3017869|NCT02443688|Placebo Comparator|Matching Placebo|Once daily oral capsule for 48 weeks
3017870|NCT02443649|Experimental|Sleep hypnosis plus sleep hygiene|Those randomized into this group will receive the sleep hygiene program plus hypnosis.
3017871|NCT02443649|Active Comparator|Sleep hygiene only|Those randomized into this group will receive the Optimizing Sleep Hygiene program during the intervention visit and hypnosis recording after the follow-up visit.
3017872|NCT02443623|Experimental|Single Arm Vaccinated with ACAM2000|"To vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers. The collection of donor plasma will be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).~To ensure the safety of plasma donors vaccinated with ACAM2000 through the implementation of risk factor screening procedures and the collection of post-vaccination safety data."
3017873|NCT02443597||obese pregnant women|"With the use of trans-abdominal ultrasound, the following measurements will be recorded:~Fetal nuchal translucency thickness.~Nasal bone.~Fetal facio-maxillary angle.~The flow across the tricuspid valve as normal or regurgitated.~A-wave in the ductus venosus as normal or reversed."
3017874|NCT02443597||lean pregnant women|"With the use of trans-abdominal ultrasound, the following measurements will be recorded:~Fetal nuchal translucency thickness.~Nasal bone.~Fetal facio-maxillary angle.~The flow across the tricuspid valve as normal or regurgitated.~A-wave in the ductus venosus as normal or reversed."
3017875|NCT02443584|Other|4-Week Group|Pharmacogenetic testing released to physician at 4 weeks following enrollment into study
3017876|NCT02443584|Other|12-Week Group|Pharmacogenetic testing released to physician at 12 weeks following enrollment into study
3017877|NCT02443558|Experimental|Complete Injury|"Patients suffering from complete injury at the cervical spinal cord level (ASIA Impairment Scale A).~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms."
3017878|NCT02443558|Experimental|Incomplete Injury|"Patients suffering from incomplete injury at the cervical spinal cord level (ASIA Impairment Scale B,C,D,E).~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
3017879|NCT02443558|Active Comparator|Non-cervical injury|"Patients suffering from complete or incomplete injury of the spinal cord at a level other than the cervical (thoracic or lumbar).~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
3017880|NCT02443558|Active Comparator|Healthy participants|"Healthy participants, age and sex matched to those of the other Arms.~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
3017881|NCT02443545|Experimental|Group 1: Deferiprone 3 years|Patients in this group are those who were randomized to the deferiprone arm in study LA38-0411, and hence will receive deferiprone for a total of 3 years (1 year in the initial study plus 2 years in the extension study)..
3017882|NCT02443545|Experimental|Group 2: Deferiprone 2 years|Patients in this group are those who were randomized to the deferoxamine arm in study LA38-0411, and hence will receive deferiprone for 2 years (both of them in the extension study).
3017883|NCT02443532|Experimental|Structured Group education|Six weekly interactive group sessions of 4 hours each, providing information and developing skills for diabetes self-management, including eating habits, food composition, calculation of bolus insulin, information on physical exercise, blood glucose self-monitoring, management of hypoglycemia.
3017884|NCT02443532|Other|Individual education|Usual care (individual consultations as routinely performed)
3017885|NCT02443519|Experimental|MBCT for Migraine|In this arm, participants will receive 8 weeks of the manualized treatment Mindfulness Based Cognitive Therapy (MBCT; Day & Thorn). Participants will attend weekly 75-90 minute individual sessions for eight weeks. At each weekly session one of eight broad topics are addressed and discussed (Automatic-Pilot, Dealing with Barriers, Mindfulness of Breath, Staying Present, Allowing/Letting Be, Cognitive Restructuring, Self Care, Application to Headache Pain). Homework is assigned each week, and participants are expected to develop a daily formal mindfulness practice (body scan meditation, seated meditation, breathing meditation, etc). Participants are provided with a course manual, reading materials, and audio recordings to facilitate meditation practice.
3017886|NCT02443519|No Intervention|Wait List/Treatment as Usual|Patients will continue with standard care. Patients will be offered MBCT after the primary endpoint.
3017887|NCT02443506|Experimental|AMG 623|Single dose of AMG 623 administered as subcutaneous and intravenous doses
3017888|NCT02443506|Placebo Comparator|Placebo|Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
3017889|NCT02443493|Experimental|Treatment group|Treatment group (receives low-level laser therapy (2x/week) in combination with standard skin care starting from day 1 of radiotherapy)
3017890|NCT02443493|Sham Comparator|Control group|Control group (receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy)
3017891|NCT02443467||HER2-positive early breast cancer|Human Epidermal Growth Factor Receptor 2 (HER2)-positive early breast cancer treated with loading dose of Herceptin (trastuzumab) administered as 6 mg/kg followed by once in 3 weeks administration at 4 mg/kg up to 12 months of treatment
3017892|NCT02443454||Patients after kidney transplantation|Short and Long-term results containing first 10 years after KTx.
3017893|NCT02443454||Healthy subjects|Medical staff: medical doctors, nurses
3017894|NCT02443428||Eribulin Mesilate|Participants will be treated in accordance with normal clinical practice. The recommend dose of eribulin is 1.23 mg/m2 administered intravenously on days 1 and 8 of every 21-day cycle. Treatment with eribulin is continued until disease progression, onset of unacceptable drug toxicities, or participant/physician's request to discontinue.
3017895|NCT02443415||Healthy Controls|Non-diabetic subjects
3017896|NCT02443415||Diabetics without DKA|Diabetic subjects (recent(< 1 year) diagnosis of diabetes) without a history of diabetic ketoacidosis (DKA)
3017897|NCT02443415||First episode of DKA|Diabetic subjects that just had their primary event of diabetic ketoacidosis (DKA)
3017898|NCT02443415||Three or more DKA episodes|Diabetic subjects who have had three or more diabetic ketoacidosis (DKA) episodes
3017899|NCT02443402|Experimental|Sitagliptin|Subjects undergoing cardiac surgery with no history of diabetes and with normal blood glucose (BG) will be randomized to take sitagliptin. Subjects with stress hyperglycemia (defined as a BG >180 mg/dL) in the intensive care unit (ICU) will continue to receive sitagliptin and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
3017900|NCT02443402|Placebo Comparator|Placebo|Subjects undergoing cardiac surgery with no history of diabetes and with normal blood glucose (BG) will be randomized to take a placebo. Subjects with stress hyperglycemia (defined as a BG >180 mg/dL) in the intensive care unit (ICU) will continue to receive a placebo and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
3017901|NCT02443389||Neonates admitted to NICU|Retrospective cohort of neonates admitted to NICU with stated inclusion and exclusion criteria
3017902|NCT02443376||Hemodialysis patients|Stable end-stage renal disease patients on maintenance conventional hemodialysis received 4-5 hours of treatment thrice weekly. Pulse wave velocity and central aortic pressure was measured before and after the midweek dialysis session.Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM) was measured before the midweek dialysis session just after Complior device
3017903|NCT02443376||Healthy subjects|Medical staff: medical doctors, nurses
3017904|NCT02443363||Patients After Kidney Transplantation|A total of 300 consecutive patients admitted to routine visit in Transplant Centre with functioning graft longer than 3 months to 10 years
3018051|NCT02442557|Active Comparator|single dose 37.5 mg|a single intravenous injection of 4 mg DC-TAB
3017905|NCT02443337|Experimental|LY3023414 + Necitumumab|200 milligrams (mg) LY3023414 administered orally twice daily and 800 mg necitumumab administered intravenously (IV) on day 1 and day 8 of each cycle (21 day cycles). Participants may continue to receive treatment until discontinuation criteria are met.
3017906|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1a Schedule 1)|Gastric-GEJ, BTC: Ramucirumab given intravenously (IV) on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
3017907|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1a Schedule 2)|Gastric, NSCLC, Urothelial: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
3017908|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A)|Gastric-GEJ: Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
3017909|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A1)|BTC: Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
3017910|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A2)|Gastric-GEJ (first line only): Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
3017911|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort B)|Gastric-GEJ: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
3017912|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort C)|NSCLC: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
3017913|NCT02443324|Experimental|Experimental: Ramucirumab + Pembrolizumab (Phase 1b Cohort D)|Urothelial: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
3017914|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort E)|NSCLC: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
3017915|NCT02443311|Experimental|Group I|Pimecrolimus 1% cream (Elidel, Novartis Pharmaceuticals, East Hanover, NJ)+ custom made hydrophilic Adhesive gel base (Department of Pharmaceutics and Industrial Pharmacy. Faculty of Pharmacy. Ain Shams University) 4 Times/day for 4 weeks
3017916|NCT02443311|Active Comparator|Group II|Betamethasone 17-valerate 0.1% cream (Betnovate, GlaxoSmithKline, Cairo, Egypt)+ custom made hydrophilic Adhesive gel base (Department of Pharmaceutics and Industrial Pharmacy. Faculty of Pharmacy. Ain Shams University) 4 Times/day for 4 weeks
3017917|NCT02443298|Experimental|ABBV-066|Single dose
3017918|NCT02443298|Placebo Comparator|Placebo|
3017919|NCT02443285|Active Comparator|Cefotaxime|cefotaxime 2gm every 12 hours daily for 5 days
3017920|NCT02443285|Active Comparator|Ceftriaxone|ceftriaxone 2 gm every 24 hours for 5 days.
3017921|NCT02443272|Active Comparator|Control Arm|Receive standard incision and drainage
3017922|NCT02443272|Experimental|Intervention Arm|Receive minimal invasive loop drainage using the Vesi-loop device
3017923|NCT02443259||late preterms from pre eclamptic mothers|late preterms born to pre eclamptic mothers
3017924|NCT02443259||late preterms|late preterm neonates
3017925|NCT02443246|Experimental|Vitamin D deficiency|Group 1
3017926|NCT02443246|Experimental|Vitamin D deficiency (Low)|Group 2
3017927|NCT02443233||Maternal hepatitis B carrier|
3017928|NCT02443233||Paternal hepatitis B carrier|
3017929|NCT02443220|Experimental|distal-proximal group|"TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Hegu"
3017930|NCT02443220|Active Comparator|regional group|"TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Juque"
3017931|NCT02443220|Sham Comparator|control group|"no TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Hegu ."
3017932|NCT02443194|Active Comparator|Group # 1- ACTIVE|"Patients who underwent resection or biopsy of glioblastoma (newly diagnosed glioblastoma), will randomization ratio of 1: 1 by the pharmacist (by age, KPS, the degree of tumor resection) two research groups:~Group # 1: consisting of 50 patients who will be treated immediately after diagnosis, 30 mg Cymbalta duloxetine -morning for a week and then a dose exceeding 60 mg for 3 months."
3017933|NCT02443194|Placebo Comparator|Group # 2-PLACEBO|Group # 2 will include 50 patients treated immediately after diagnosis with placebo for 3 months
3017934|NCT02443181|Experimental|Activa PC+S|Patients will be implanted with standard DBS electrodes for treatment of essential tremor, at the Vim nucleus of the thalamus, and an additional subdural electrode array overlying hand motor cortex.. The patient will receive standard of care programming for thalamic stimulation for essential tremor. During research study visits, implementation and evaluation of closed-loop DBS using the PC+S system will be performed.
3017935|NCT02443168|Experimental|100-mg AG-221 oral solution + a microtracer of [14C]-AG- 221|Subjects will receive a 100 mg AG-221 to be swallowed with 240 mL of room-temperature, non-carbonated water.
3017936|NCT02443168|Experimental|100-mg AG-221 tablet + 100 micrograms [14C] AG-221|Formulated tablet containing 100 mg AG-221 + IV solution containing 100 micrograms [14C] AG-221
3017937|NCT02443155|Experimental|NNC0114-0006 + Liraglutide|
3017938|NCT02443155|Experimental|NNC0114-0006 + Placebo|
3017939|NCT02443155|Active Comparator|Liraglutide + Placebo|
3017940|NCT02443155|Placebo Comparator|Placebo|
3017941|NCT02443142|Experimental|Ibuprofen|Ibuprofen is a nonselective NSAID that inhibits both COX-1 and COX-2 isoenzymes. COX-2 inhibition prevents arachidonic acid from converting to vasoactive prostaglandins and reactive oxygen species in brain cell. The analgesic, antipyretic, and antiinflammatory activity of ibuprofen operates mainly through inhibition of COX-2. The experimental treatment oral doses of either ibuprofen (800 mg three times per day). Subjects will receive the first medication dose in the emergency department and will be given the remaining 5 doses to take over 48 hours as outpatients.
3017942|NCT02443142|Active Comparator|Acetaminophen|Acetaminophen is a poor inhibitor of both COX isoenzymes in the CNS and has significantly weaker antiinflammatory effects than NSAIDs. Acetaminophen does not inhibit COX in peripheral tissues and is less effective in the presence of peroxides. The active comparator treatment is oral doses of acetaminophen (1000 mg three times per day). Subjects will receive the first medication dose in the emergency department and will be given the remaining 5 doses to take over 48 hours as outpatients.
3017943|NCT02443129|Experimental|control group|"18-99 year old male + female~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
3052208|NCT02212938|Experimental|BI 14332 CL fasted|
3017945|NCT02443129|Experimental|mydramide and ephrine 10%|"Patients in the clinics undergoing pupil dilation~Intervention:~Tropicamide and ephrine 10% instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon"
3017946|NCT02443129|Experimental|All patients presenting with RD|"Patients with retinal detachment~Intervention:~RD surgery DRI-1 Swept source OCT, Atlantis, Topcon"
3017947|NCT02443129|Experimental|Impact of previous grid treatment|"Patients after grid laser~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
3017948|NCT02443129|Experimental|Effect of glaucoma medications|"Patients requiring new intraocular presssur (IOP)-lowering treatment Patients with long-term IOP-lowering treatment~Intervention:~If needed, start of new IOP-lowering treatment DRI-1 Swept source OCT, Atlantis, Topcon"
3017949|NCT02443129|Experimental|Effect of arteritic/non-arteritic AION|"About 180 living patients diagnosed at ShaareZedek with anterior ischemic optic neuropathy (AION).~Longitudinal arm with newly diagnosed patients for 2 years follow-up~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
3017950|NCT02443129|Experimental|NVAMD poorly responsive to Rx|"Patients with neovascular age-related macular degeneration and epiretinal membreane/vitreomacular traction who do not respond to first course of Avastin~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
3017951|NCT02443129|Experimental|Retrospective analysis|"All patients pictured with DRI-OCT~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
3017952|NCT02443116|Experimental|NGM282 Dose 1|NGM282
3017953|NCT02443116|Experimental|NGM282 Dose 2|NGM282
3017954|NCT02443116|Experimental|NGM282 Dose 3|NGM282
3017955|NCT02443116|Experimental|NGM282 Dose 4|NGM282
3017956|NCT02443116|Placebo Comparator|Placebo|Placebo
3017957|NCT02443116|Experimental|NGM282 Dose 5|NGM282
3017958|NCT02443103|Experimental|Guanabenz|
3017959|NCT02443090|Experimental|Fispemifene 450 mg|Fispemifene capsules will be taken orally each morning immediately after eating a meal
3017960|NCT02443090|Placebo Comparator|Placebo|Placebo capsules will be taken orally each morning immediately after eating a meal
3017961|NCT02443077|Experimental|Arm I (ibrutinib, chemotherapy, autoHCT)|"CONDITIONING REGIMEN: Investigators may choose to use either the BEAMi or CBVi regimen.~BEAMi: Patients receive ibrutinib PO on days -6 to -1, carmustine IV over 2 hours on day -6, etoposide IV BID over 1-2 hours and cytarabine IV BID over 1-2 hours on days -5 to -2, and melphalan IV over 20-30 minutes on day -1.~CBVi: Patients receive ibrutinib PO on days -6 to -1, carmustine IV over 2 hours on day -6, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2.~TRANSPLANT: In both arms, patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0.~CONTINUATION REGIMEN: Beginning 30-60 days after transplant, patients receive ibrutinib PO on days 1-28. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity."
3017962|NCT02443077|Placebo Comparator|Arm II (placebo, chemotherapy, autoHCT)|"CONDITIONING REGIMEN: Patients receive placebo PO on days -6 to -1 and receive 1 of the 2 conditioning regimens as in Arm I.~TRANSPLANT: Patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0.~CONTINUATION REGIMEN: Beginning 30-60 days after transplant, patients receive placebo PO on days 1-28. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover Arm I."
3017963|NCT02443064|Experimental|MRSA blood stream infection patient|"Intervention:Vancomycin~Dosing:~15-20mg/kg, IV,q 12~8h (or 1 g, IV, q12~8h) for adult patient with normal renal function; Dosage should be adjusted by blood creatinine clearance in patients with impaired renal function; Administration route： 1~2 h/ dosing, IV~Drug combination:~Drug combination is not recommended for patients with simple MRSA infection; Rifampicin can be combined in case of MRSA artificial valve endocarditis; Anti-G- antibacterial agents can be combined in case of concurrent G- bacterial infections.~Duration:~Septicemia: 2~4 weeks Endocarditis: 6~8 weeks"
3017964|NCT02443051|Experimental|Attention Bias Modification|Training in bias modification for 80% of experimental trials
3017965|NCT02443051|Active Comparator|Control|Bias modification for 50% of trials
3017966|NCT02443038|Active Comparator|Home Exercise|Participants will practice 10 minutes of yoga in addition to 5 minutes of relaxation exercises at home each day when not in class.
3017967|NCT02443038|Placebo Comparator|Relaxation Exercise|Participants will practice 5 minutes of relaxation exercises at home each day when not in class.
3017968|NCT02443025|Experimental|Intervention|Classes receive anti-tobacco presentations from Teens Against Tobacco Use members
3017969|NCT02443025|No Intervention|Wait list control|Classes continue as usual without receiving anti-tobacco presentations from Teens Against Tobacco Use members until the end of the year, when data collection is complete.
3017970|NCT02443012|Experimental|Nevanac|Patients with CSME treated with argon laser photocoagulation (focal/grid laser) and Topical Gutt Nepafenac 0.1% given 8 hourly interval for 3 months
3017971|NCT02443012|Placebo Comparator|Laser|Patients with CSME treated with argon laser photocoagulation (focal/grid laser)
3017972|NCT02442999|No Intervention|Usual care|
3017973|NCT02442999|Experimental|Screen for Sleep Apnea|Screen for sleep apnea, treat with continuous positive airway pressure (CPAP) if diagnosed with sleep apnea
3017974|NCT02442986||Septic Shock or severe sepsis|Septic patients on ICU with severe sepsis or septic shock.
3017975|NCT02442986||Non-Septic, Surgical Patients|Non-septic patients after surgical treatment and anesthesia on ICU.
3017976|NCT02442986||Non-Septic, Non-Surgical Patients|Patients without sepsis criteria treated on ICU, non-surgical patients.
3017977|NCT02442973||Control group (CG):|Standard practice group
3017978|NCT02442973||Ultrasound group (UG):|"SpineView3D™ anatomical scouting approach"
3017979|NCT02442960|Active Comparator|Cohort 1|Herbal treatment (SA100) 500 mg/day (250 mg twice per day)
3017980|NCT02442960|Active Comparator|Cohort 2|Herbal treatment (SA100) 1.5 g/day (750 mg twice per day)
3018003|NCT02442817|Active Comparator|Linagliptin control group|This group will be made up of 10 control participants with no diagnosis of mental disorder; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day.
3018004|NCT02442804|Experimental|Stroke - POMx|Pomegranate supplement (1g) by mouth twice per day for 7 days
3018005|NCT02442804|Placebo Comparator|Stroke - Placebo|Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
3017981|NCT02442947|Experimental|Research arm|"1 day which will include: physician examination,ECG,anthropometric measurements and Vo2max test.~6 acclimatization days carried out by a standard protocol including a daily 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% HR) and when dressed in shorts.At the sixth day, the subjects will be dressed in a standard work uniform as a baseline exposure. Core (rectal) and skin temperature and heart rate will be monitored continuously.~4 experiment days carried out by the following protocol: 2 hour walk on a treadmill (5 Km/h,2% incline) under heavy heat stress conditions (30 deg. centigrade,60% RH) and when dressed each time with different clothing out of 4 options:~NBC protective garment (charcoal base).~combat garment.~2 different types of work uniforms. physiological stress will be examined based on rectal temperature and heart rate measurements."
3017982|NCT02442934|Experimental|Multicomponent program|Multicomponent intervention to reduce perceived discomforts in critically ill patients : the IPREA3 program
3017983|NCT02442934|Active Comparator|Standard Care|Standard care
3017984|NCT02442921|Experimental|Colchicine|20 patients will receive up to 2 mg of colchicine for 18 months
3017985|NCT02442921|Placebo Comparator|Placebo|20 patients will receive placebo for 18 months
3017986|NCT02442908|Experimental|NF Cachexia|Nutrifriend Cachexia, an Omega-3 enriched fruit juice (non complete dietary formula).
3017987|NCT02442908|Placebo Comparator|Placebo|An isocaloric placebo comparator
3017988|NCT02442895||Long luteal protocol|Subcutaneous administration of GnRH agonist (Triptorelina pamoato 0.1 mg/ml) in the medium-luteal phase (21th day) of the cycle before the stimulation. The next menstruation, in the presence of estradiol level (E2)<30pg/ml and in the absence of follicular cysts, the gonadotropin stimulation was begun. In the presence of at least three follicles of diameter ≥18mm was induced final oocyte maturation by administration of human chorionic gonadotropin (hCG).
3017989|NCT02442895||Daily antagonist protocol|GnRH antagonist (cetrorelix acetate 0.25 mg) was administered subcutaneously with a fixed protocol from the day +6 of stimulation or with a flexible protocol from the day in which at least one follicle reached a diameter of 14mm. In both protocols GnRH antagonist was administered until the day of the assumption of hCG. Recombinant Follicle Stimulating Hormone (rFSH) was administered from the 3rd day of menstruation at a dose of 150-300 IU/die according to the characteristics of women. The hCG was administered when at least three follicles had reached 18 mm in diameter and estradiol levels were higher than 150 pg/mL/dominant follicle.
3017990|NCT02442895||Depot antagonist protocol|"GnRH antagonist (Cetrorelix acetate 0.25 mg) was administered subcutaneously with a fixed or flexible protocol until the day of the assumption of hCG. Corifollitropila alfa was used at dose of 100μg (in women with weight ≤60 kg and age ≤36 years) or 150μg (in women with weight> 60 kg of any age or weight ≥50 kg and age greater than 36 years). Corifollitropina alfa was administered subcutaneously in the day +3 and in the day +5 or +6 was supplemented with rFSH at doses 112-300 IU/day.~The hCG was administered when at least three follicles had reached 18 mm in diameter and estradiol levels were higher than 150 pg/mL/dominant follicle."
3017991|NCT02442882||Boxers|Individuals who participate in a boxing tournament will be tested on balance, neuropsychological, and visual functions before and after the tournament.
3017992|NCT02442869|Experimental|Phase I TAU plus Phase II CAMS|"Treatment as usual [TAU] -- treatment typically provided by counselor for 4-8 weeks~If participant is responding, treatment ends. If participant is not responding, he is then re-randomized to~Collaborative Assessment and Management of Suicidality (CAMS) long for 4-16 weeks"
3017993|NCT02442869|Experimental|Phase I TAU plus Phase II DBT|"Treatment as usual [TAU] -- treatment typically provided by counselor for 4-8 weeks~If participant is responding, treatment ends. If participant is not responding, he is then re-randomized to~Dialectical Behavioral Therapy (DBT) long for 4-16 weeks"
3017994|NCT02442869|Experimental|Phase I CAMS plus Phase II repeat CAMS|"Collaborative Assessment and Management of Suicidality (CAMS) short for 4-8 weeks~If participant is responding, treatment ends. If participant is not responding, he is then re-randomized to~Collaborative Assessment and Management of Suicidality (CAMS) long for 4-16 weeks"
3017995|NCT02442869|Experimental|Phase I CAMS plus Phase II DBT|"Collaborative Assessment and Management of Suicidality (CAMS) short for 4-8 weeks~If participant is responding, treatment ends. If participant is not responding, he is then re-randomized to~Dialectical Behavioral Therapy (DBT) long for 4-16 weeks"
3017996|NCT02442856|Experimental|Intervention|We will measure dCA with both TCD and DCS during acute changes in mean arterial pressure using thigh cuff deflation techniques in vascular risk factor subjects. Measurements will be compared between TCD and DCS in order to validate DCS as a tool to measure dCA in this population.
3017997|NCT02442843|Experimental|active tDCS|Investigators will use cathodal tDCS to inhibit the brain regions that may be associated with symptoms of PTSD (temporal cortex). Active tDCS will be provided at 2 miliamps (mA) for 20 minutes (with gradual increase and withdraw of stimulation during the first and last minute).
3017998|NCT02442843|Sham Comparator|sham tDCS|Participants randomized to the sham condition will receive stimulation during the first and final minutes of the 20 minute period (with gradual increase and removal of current during that time).
3017999|NCT02442843|No Intervention|Combat Controls|Participants without PTSD will undergo neuropsychological testing and a single fMRI scan.
3018000|NCT02442830|Experimental|Early Video Capsule Endoscopy|The intervention for subjects in this arm will be to have a video capsule deployed as soon as possible after presentation to the emergency department. Information from the video capsule will be obtained and reviewed to determine location of bleeding. Once that information has been obtained a decision will be made on which endoscopic test is most pertinent in finding and treating the source of bleeding.
3018001|NCT02442830|No Intervention|Standard of Care Workup Group|"In this arm, patients will receive standard of care workup for non-hematemesis gastrointestinal bleeding. This could include upper endoscopy, colonoscopy, and additional capsule or small bowel enteroscopy depending on the subject's presentation and the results of the workup performed by the gastroenterology team. For patients requiring a video capsule endoscopy as part of standard of care workup the patients will be given the same Olympus video capsule that is used in the Early Capsule group."
3018002|NCT02442817|Active Comparator|Linagliptin patients with schizophrenia|This group will be made up of 8 participants with schizophrenia and minimal thought disorder who have been stable and taking their prescribed antipsychotics; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment.
3018006|NCT02442791|Experimental|GLP-1|"Half of the participants will receive the study drug, that will be given as follows:~250 mL isotonic sodium chloride added 1.5 mL of 20% Human Albumin added 25 microg Byetta (Lilly, Exenatide).~The study drug infusion is initiated as soon as possible at rate of 72ml/hour (0.12 μg/min) for 15 min (set volume at 18 ml), followed by 26ml/hour (0.043 μg/min) to be continued for 6 hours (set volume at 156 ml). This concludes the pharmacological intervention."
3018007|NCT02442791|Placebo Comparator|Placebo|"Half of the participants will receive placebo, that will be given as follows:~250 mL isotonic sodium chloride added 1.5 mL of 20% Human Albumin. The placebo infusion is administered exactly the same way as the study drug infusion."
3018008|NCT02442778|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
3018009|NCT02442778|Experimental|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 12-week period
3018010|NCT02442778|Experimental|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 12-week period
3018011|NCT02442765|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
3018012|NCT02442765|Experimental|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 12-week period
3018013|NCT02442765|Experimental|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 12-week period
3018014|NCT02442752|Experimental|Regimen A: Dexlansoprazole 10 mg|Dexlansoprazole 10 mg, delayed-release capsules, orally, once daily for 8 weeks.
3018015|NCT02442752|Experimental|Regimen B: Dexlansoprazole 15 mg|Dexlansoprazole 15 mg, delayed-release capsules, orally, once daily for 8 weeks.
3018016|NCT02442752|Experimental|Regimen C: Dexlansoprazole 20 mg|Dexlansoprazole 20 mg, delayed-release capsules, orally, once daily for 8 weeks.
3018017|NCT02442752|Experimental|Regimen D: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release capsules, orally, once daily for 8 weeks.
3018018|NCT02442739|Experimental|Ketamine|oral ketamine 0.5 mg/kg mixed with syrup
3018019|NCT02442739|Placebo Comparator|Placebo|oral placebo (syrup)
3018020|NCT02442726|Active Comparator|Thermal Injury|A first degree heat injury is induced by a contact thermode (12.5 cm2; 47C; 420 s) applied at the skin at the lower leg. CO2-Laser stimulation (Laser Stimulation Device, SIFEC)
3018021|NCT02442726|Sham Comparator|Sham Injury|"A sham injury is induced by a contact thermode (12.5 cm2; 38C; 420 s) applied at the skin at the lower leg. CO2-Laser stimulation (Laser Stimulation Device, SIFEC) is used to assess"
3018022|NCT02442713|Experimental|fluvoxamine|fluvoxamine: 50-300mg/day
3018023|NCT02442700|Experimental|Treatment sequence A, B|Treatment visits were seperated by a 2-week washout period. Treatment A = administration pitavastatin for 12 weeks; Treatment B = administration placebo for 12 weeks
3018024|NCT02442700|Experimental|Treatment sequence B, A|Treatment visits were seperated by a 2-week washout period. Treatment B = adminstration placebo for 12 weeks; Treatment A = adminstration pitavastatin for 12 weeks
3018025|NCT02442687|Active Comparator|A|JKB 121, 5 mg twice daily
3018026|NCT02442687|Active Comparator|B|JKB 121, 10 mg twice daily
3018027|NCT02442687|Placebo Comparator|C|Identical appearing placebo
3018028|NCT02442674|Active Comparator|Tolvaptan|Tolvaptan (3.75 mg, 7.5 mg, 15 mg, 30 mg, 60 mg dose daily depending on age and weight)
3018029|NCT02442674|Placebo Comparator|Placebo|Placebo tablet matching active drug
3018030|NCT02442648|Experimental|Group A (5-8 patients) - Carfilzomib|Two cycles of carfilzomib desensitization given.
3018031|NCT02442648|Experimental|Group B (5-8 patients) - Carfilzomib/plasmapheresis|Two cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
3018032|NCT02442648|Experimental|Group C (5-8 patients) - Rituximab/Carfilzomib/plasmapheresis|1 dose of rituximab prior to two cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
3018033|NCT02442648|Experimental|Group D (5-8 patients) - Rituximab/Carfilzomib/plasmapheresis|1 dose of rituximab prior to three cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
3018034|NCT02442635|Experimental|Condition 1|Yoga Breathing
3018035|NCT02442635|Experimental|Condition 2|Static Yoga
3018036|NCT02442635|Experimental|Condition 3|Flowing Yoga
3018037|NCT02442622|Active Comparator|Occupational therapy|Traditional therapy for de Quervain's Tenosynovitis
3018038|NCT02442622|Experimental|Occupational therapy with ASTYM|Traditional therapy for de Quervain's Tenosynovitis plus ASTYM
3018039|NCT02442609||patient|patient schedulled for elective surgery, adult (> 18yrs), non emergency procedure, able to read questionaire
3018040|NCT02442596||One Group|This is a prospective observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
3018041|NCT02442583|No Intervention|Arm 1: Phase 1, Step 1|In this part, 15 early stage colorectal cancer survivors will fill out surveys and have a recorded phone interview regarding their physical activity and sedentary behaviors, to inform the creation of a brochure about sedentary behaviors.
3018042|NCT02442583|No Intervention|Arm 2: Phase 1, Step 2|5 early stage colorectal cancer survivors will have recorded telephone interviews to provide feedback about the brochure.
3018043|NCT02442583|Experimental|Arm 3: Phase 2|15 early stage colorectal cancer survivors will complete a baseline survey about sedentary behaviors, then wear an Actigraph device and self-report their sedentary activities for one week. They will receive feedback regarding their activity, and one month after receiving the feedback will participate in a phone survey regarding use of the brochure, physical activity and sedentary behaviors.
3018044|NCT02442570|Active Comparator|DC-TAB 7.5 mg|three intravenous injections of 7.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
3018045|NCT02442570|Active Comparator|DC-TAB 12.5 mg|three intravenous injections of 12.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
3018046|NCT02442570|Active Comparator|DC-TAB 17.5 mg|three intravenous injections of 17.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
3018047|NCT02442570|Placebo Comparator|placebo|three intravenous injections of placebo, 2 months apart
3018048|NCT02442557|Active Comparator|single dose 4 mg|a single intravenous injection of 4 mg DC-TAB
3018049|NCT02442557|Active Comparator|single dose 12.5 mg|a single intravenous injection of 12.5 mg DC-TAB
3052209|NCT02212938|Experimental|BI 14332 CL fed|
3018052|NCT02442557|Placebo Comparator|single dose placebo|a single intravenous injection of placebo
3018053|NCT02442557|Active Comparator|multiple dose 10 mg|three consecutive daily intravenous injections of 10 mg DC-TAB
3018054|NCT02442557|Active Comparator|multiple dose 25 mg|three consecutive daily intravenous injections of 25 mg DC-TAB
3018055|NCT02442557|Active Comparator|multiple dose 37.5 mg|three consecutive daily intravenous injections of 37.5 mg DC-TAB
3018056|NCT02442557|Placebo Comparator|multiple dose placebo|three consecutive daily intravenous injections of placebo
3018057|NCT02442544|Placebo Comparator|Placebo|maltodextrin 3.3 g orally/ day for 12 weeks
3018058|NCT02442544|Experimental|Prebiotic|1:1 oligofructose: inulin 8 g orally /day for 12 weeks
3018059|NCT02442531|Experimental|CriPec® docetaxel|Docetaxel containing nanoparticle
3018060|NCT02442518||women with placenta praevia|women with placenta previa diagnosed at antenatal ultrasound in the third trimester of pregnancy (lower placental edge within 20 mm from the internal os above 26 week's gestation)
3018061|NCT02442492|Active Comparator|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
3018062|NCT02442492|Placebo Comparator|Placebo|Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
3018063|NCT02442479|Active Comparator|HHH3|High-resistance concentric-eccentric training (H) 3 d/wk (HHH3).
3018064|NCT02442479|Experimental|HLH3|3 d/wk mixed model consisting of high-resistance concentric-eccentric training 2 d/wk separated by 1 bout of low-resistance, high-velocity, concentric only training (L) (HLH3).
3018065|NCT02442479|Experimental|HH2|High-resistance concentric-eccentric training 2 d/wk (HH2).
3018066|NCT02442479|Experimental|HL2|2 d/wk mixed model consisting of high-resistance concentric-eccentric training 1 d/wk and low-resistance, high-velocity, concentric only training 1 d/wk (HL2).
3018067|NCT02442466|Experimental|Endothelin receptor B inhibitor BQ-788|Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788)
3018068|NCT02442466|Experimental|PBS|Intra-lesion administration of vehicle
3018069|NCT02442453|Active Comparator|curcuma longa|"curenext gel containing curcuma longa i.e. turmeric has strong antioxidant and antiinflammatory properties.~Test group:Topical application twice daily for ten minutes after brushing for four weeks."
3018070|NCT02442453|Placebo Comparator|Placebo gel|Placebo gel consists of corbopol 934 polymer and triethonalamine. Control group:Topical application twice daily for ten minutes after brushing for four weeks.
3018071|NCT02442440|Experimental|anisodamine group|administration of the drug
3018072|NCT02442440|No Intervention|control group|these arm do not use anisodamine, other resuscitation protocol is as usual.
3018073|NCT02442427|Active Comparator|Palivizumab|A single dose of IV palivizumab
3018074|NCT02442427|Placebo Comparator|Placebo|An equivalent volume of 0.9% normal saline.
3018075|NCT02442414|Experimental|KBP-5209|Dose escalation for KBP-5209 will initially follow a modified accelerated titration design with a starting dose of 20 mg QD. Early dose escalation will proceed with one-patient cohorts and 100% dose increments (ie, dose doubling) until a patient experiences a DLT, at which point the cohorts will move to a 3+3 design. Treatment will continue until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. A cycle is defined as continuous treatment for 28 days.
3018076|NCT02442401|Experimental|NPWT group|Negative pressure wound therapy was used to prevent donor site seroma formation
3018077|NCT02442401|No Intervention|Control group|Conventional method was used to the donor site
3018078|NCT02442388|Experimental|Hand file|Instrumentation technique
3018079|NCT02442388|Experimental|ProTaper file|Instrumentation technique
3018080|NCT02442388|Experimental|Wave-One file|Instrumentation technique
3018081|NCT02442375|Active Comparator|standard dose prescription|"FDG-PET-scan in treatment mask for radiotherapy planning~Accelerated radiotherapy IMRT/VMAT with SIB (34 fraction in 5.5 weeks)"
3018082|NCT02442375|Experimental|FDG‐PET guided gradient dose prescription|"FDG-PET-scan in treatment mask for radiotherapy planning~Accelerated radiotherapy IMRT/VMAT with SIB (34 fraction in 5.5 weeks)"
3018083|NCT02442362|Active Comparator|TOF Group|"Patients in the TOF group received chemotherapy with paclitaxel+oxaliplatin+fluorouracil"
3018084|NCT02442362|Experimental|SOX Group|The patients in the SOX group received chemotherapy with 'oxaliplatin+S1'
3018085|NCT02442349|Experimental|AZD9291|Once daily tablet 80 mg
3018086|NCT02442336|Experimental|My Journey AHead|Several internet modules will be developed to address mouth and swallowing concerns, oral care, healthy eating, speech problems, coping with cancer, pain management, and physical therapy.
3018087|NCT02442323|Experimental|Walking Intervention|Intervention patients will receive a 12-week home-based walking program, which includes a personalized instruction booklet and pedometer. The walking program consists of 3 phases and will be individualized for each patient based on their physical condition and baseline assessment. Patients are instructed to walk 3 to 5 times each week at home or other safe environment. Patients will be instructed on a gradual increase in walking time over the course of the intervention.
3018088|NCT02442323|No Intervention|Usual Care|Usual care patients will receive standard of care. They will not receive any instruction on walking or other physical activity other than what is normally provided by their physician or clinical staff.
3018089|NCT02442310|Experimental|Delayed release, fed conditions|A single 1200 mg dose of deferiprone delayed release tablet formulation administered following a high-fat breakfast
3018090|NCT02442310|Experimental|Delayed release, fasting conditions|A single 1200 mg dose of deferiprone delayed release tablet formulation, administered following a 10-hour fast
3018091|NCT02442310|Experimental|Delayed release half-tablets|A single 1200 mg dose of deferiprone delayed release tablet formulation, following a high-fat breakfast
3018092|NCT02442310|Active Comparator|Oral solution, fasting conditions|A single 1200 mg dose of deferiprone oral solution, administered following a 10-hour fast
3018093|NCT02442297|Experimental|HER2-specific T cells|To determine the safety profile of autologous HER2-specific T cells administered into the tumor or tumor resection cavity
3018131|NCT02442037|Experimental|UCMSC group|Human umbilical cord MSCs are administrated to patients by three intravenous infusion
3018094|NCT02442284|Experimental|3-DAA ± RBV for 12 or 24 weeks|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on genotype and presence of cirrhosis.
3018095|NCT02442271|Experimental|3-DAA ± RBV|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks.
3018096|NCT02442258|Experimental|Group 1 - Mild Renal Impairment|Subjects with mild renal impairment. eGFR (by MDRD equation) range 60 - 89 mL/min/1.73 m2 as determined at Screening.
3018097|NCT02442258|Experimental|Group 2 - Moderate Renal Impairment|Subjects with moderate renal impairment. eGFR (by MDRD equation) range 30 - 59 mL/min/1.73 m2 as determined at Screening.
3018098|NCT02442258|Experimental|Group 3 - Severe Renal Impairment|Subjects with severe renal impairment. eGFR (by MDRD equation) range 15 - 29 mL/min/1.73 m2 as determined at Screening.
3018099|NCT02442258|Experimental|Group 4 - End Stage Renal Disease, Not Yet on Dialysis|Subjects with end stage renal disease, not yet on dialysis. eGFR (by MDRD equation) range < 15 mL/min/1.73 m2 as determined at Screening.
3018100|NCT02442258|Experimental|Group 5 - Normal Renal Function|Subjects with normal renal function. eGFR (by MDRD equation) range ≥ 90 mL/min/1.73 m2 as determined at Screening.
3018101|NCT02442258|Experimental|Group 6 - End Stage Renal Disease, Requiring Dialysis.|Subjects with end stage renal disease, requiring dialysis. eGFR (by MDRD equation) < 15 mL/min/1.73 m2 as determined at Screening.
3018102|NCT02442245|Placebo Comparator|Placebo|Placebo group will receive microcrystalline cellulose
3018103|NCT02442245|Active Comparator|Treatment|Treatment group will get 2 g daily of XSurge in microcrystalline cellulose
3018104|NCT02442245|Sham Comparator|Control Group|The control group will be included to quantify or describe the effects of the acute exercise training but will not receive any supplement
3018105|NCT02442232||Normotensive|
3018106|NCT02442232||Hypertensive taking ACEi|
3018107|NCT02442232||Hypertensive not taking ACEi|
3018108|NCT02442219||Coeliac|Persons with coeliac disease on a gluten free diet where diagnosis is confirmed by duodenal biopsy.
3018109|NCT02442219||Non coeliac gluten sensitive|Persons on a gluten free diet where coeliac disease is excluded by duodenal biopsy.
3018110|NCT02442219||Healthy control group|Persons on a gluten containing diet without known coeliac disease.
3018111|NCT02442206|Experimental|Treatment sequence 1|QVA149 from day 1 to day 15 followed by Placebo from day 29 to day 43
3018112|NCT02442206|Experimental|Treatment sequence 2|Placebo from day 1 to day 15 followed by QVA149 from day 29 to day 43
3018113|NCT02442193|Experimental|Individual Placement and Support|Individual Placement and Support
3018114|NCT02442193|No Intervention|Treatment as Usual|Treatment as Usual is comprised of routine clinical care.
3018115|NCT02442180|Experimental|G-CSF + steroid in partial responder|Patients who are randomized to prednisolone plus G-CSF treatment group in patients with partial responder to prednisolone therapy.
3018116|NCT02442180|Placebo Comparator|Placebo + steroid in partial responder|Patients who are randomized to prednisolone plus placebo treatment group in patients with partial responder to prednisolone therapy.
3018117|NCT02442180|Experimental|G-CSF in null responder to steroid|Patients who are randomized to G-CSF treatment group in patients with null responder to prednisolone therapy.
3018118|NCT02442180|Placebo Comparator|Placebo in null responder to steroid|Patients who are randomized to placebo treatment group in patients with null responder to prednisolone therapy.
3018119|NCT02442154|Experimental|Early tracheostomy|To do an early tracheostomy within 24hours of admission of the severely head injured patients
3018120|NCT02442154|No Intervention|standard of care|To use the standard of care of mulago hospital for the management of the severely head injured patients
3018121|NCT02442128|Active Comparator|Group1|comparison of different dosages of drugs ( Fentanyl / Propofol), fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
3018122|NCT02442128|Active Comparator|Group 2|comparison of different dosages of drug ( Fentanyl / Propofol) ,fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
3018123|NCT02442115||ASD with GID|Children with Autism Spectrum Disorder with Functional Constipation will be treated with standard of care defined by NASPGHAN by a pediatric gastroenterologist, and evaluated at 4 visits over 1 year for their medical condition. These children will be enrolled in some ASD treatment program by their parents. The treatment program is not part of the current study. Measures of ASD symptoms will be done at each visit to determine social communication, emotional and cognitive improvement due to the FC treatment. Measures of F2-isoprostane, a marker of oxidative stress, will be done at each visit to determine if FC treatment and ASD symptom improvement relates to improvement in a child's physiology.
3018124|NCT02442115||ASD without GID|Children Autism Spectrum Disorder without Functional Constipation will be evaluated for their ASD symptoms at 4 times over 1 year. These children will be enrolled in some ASD treatment program by their parents. The treatment program is not part of the current study. Measures of F2-isoprostane, a marker of oxidative stress, will be done at each visit to determine if ASD symptom improvement relates to improvement in a child's physiology.
3018125|NCT02442102|Experimental|Exercise and sensory stimulation|60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
3018126|NCT02442089|No Intervention|No Intervention|The intervention arm subjects will not receive the automated interactive voice reminder before their appointment.
3018127|NCT02442089|Experimental|Intervention|The intervention arm subjects will receive the automated interactive voice reminder before their appointment.
3018128|NCT02442063|Experimental|Radium Ra 223 dichloride|Radium Ra 223 dichloride (Xofigo, BAY88-8223)
3018129|NCT02442050|Experimental|del Nido solution|Administering of cardioplegia using del Nido solution in eligible patients.
3018130|NCT02442050|Active Comparator|Blood-based cardioplegia|Administering of cardioplegia using current standard of care blood-based cardioplegia protocol.
3018132|NCT02442037|Other|Control group(Normal saline)|Patients will receive normal saline at the same time points as that in experimental group.
3018133|NCT02442024|Experimental|Modified diet|This group will follow a modified diet over a period of two months.
3018134|NCT02442024|Active Comparator|Standard diet|This group will follow a standardized diet over a period of two months.
3018135|NCT02441985|Experimental|Real rTMS Stimulation|rTMS will be delivered over each cerebellar hemisphere, using a 70mm figure-of-eight coil connected to a Magstim RapidStim2 machine while positioned 3 cm lateral to the inion on the line joining the inion and the external auditory meatus. 900 pulses will be delivered consecutively to each side with a frequency of 1 Hz and at an intensity of 90% of the resting motor threshold (RMT) for a total duration of 15 min for each cerebellar hemisphere. The RMT will be defined as the lowest stimulation intensity required to evoke a 50 μV potential in a target muscle. The inion will be taken as the boundary between the posterior cerebellum and the occipital cortex. Therefore the area stimulated will be caudal to the inion to stimulate the posterior cerebellum.
3018136|NCT02441985|Sham Comparator|Sham rTMS Stimulation|Patients randomized to receive sham treatment will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using sham Magstim RapidStim2 Placebo which produces discharge noise and vibration similar to the real coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. The investigator will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp. The investigator will use an electromyography to administer electrical shocks to the scalp simultaneous to each simulated rTMS train.
3018137|NCT02441972|Experimental|18F-Al-NOTA-PRGD2 PET/CT|Imaging with 18F-Al-NOTA-PRGD2 PET/CT.
3018138|NCT02441959|Active Comparator|Endoscopic Discectomy|Randomized to Endoscopic Discectomy Lumbar discectomy Endoscopic Intervention type is lumbar endoscopic surgery- no device or drug
3018139|NCT02441959|Active Comparator|Open Discectomy|Randomized to Open Discectomy Lumbar discectomy Open Intervention type is lumbar open surgery- no device or drug
3018140|NCT02441959|Other|Open Discectomy-Cross Over Arm|Randomized to Endoscopic Discectomy Cross over to lumbar discectomy open based on surgeons assessment pre or post incision Intervention type is lumbar open surgery- no device or drug
3018141|NCT02441946|Experimental|Abemaciclib + Anastrozole|"Abemaciclib was given orally every 12 hours (Q12H) plus anastrozole orally once daily (QD) for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.~All participants received abemaciclib orally Q12H plus anastrozole QD for an additional 14 weeks. Total treatment duration was 16 weeks."
3018142|NCT02441946|Experimental|Abemaciclib|"Abemaciclib was given orally Q12H for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.~All participants received abemaciclib orally Q12H plus anastrozole QD for an additional 14 weeks. Total treatment duration was 16 weeks."
3018143|NCT02441946|Active Comparator|Anastrozole|"Anastrozole is given orally QD for 2 weeks.~All participants received abemaciclib orally Q12H plus anastrozole QD for an additional 14 weeks. Loperamide was given as a prophylaxis for the first 2 weeks of the combination treatment and then at physician discretion. Total treatment duration was 16 weeks."
3018144|NCT02441933|Active Comparator|control group|
3018145|NCT02441933|Experimental|carboplatin group|
3018146|NCT02441920||Patients with rheumatoid arthritis|The inception cohort of 400 patients will be followed up for 20 years following recruitment.
3018147|NCT02441907|Other|aflibercept treatment|aflibercept, 40 mg/mL Solution for Intravitreal Injection
3018148|NCT02441894|Experimental|Cabazitaxel|"25 mg/m^2 of cabazitaxel is given intravenously in combination with prednisolone 10 mg orally per day. PEG-G-CSF is administered subcutaneously 24 hours after the completion of cabazitaxel infusion once every 3 weeks.~Antihistamine (dexchlorpheniramine or diphenhydramine), corticosteroids (dexamethasone), and H2 antagonist (ranitidine) premedications will be administered by IV infusion at least 30 minutes prior to each dose of cabazitaxel. A prophylactic antiemetic treatment (metoclopramide, granisetron, or ondansetron) should be given to the patients in all cycles."
3018149|NCT02441881|Active Comparator|Venefit|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
3018150|NCT02441881|Active Comparator|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
3018151|NCT02441881|Active Comparator|Endovenous Radiofrequency|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
3018152|NCT02441868|Experimental|Intervention|all participants will receive the training
3018153|NCT02441855||pneumonia|patients with community-acquired pneumonia
3018154|NCT02441855||control|patients admitted to emergency department with shortness of breath
3018155|NCT02441842|Active Comparator|Group A : Atenolol|oral atenolol (50mg)
3018156|NCT02441842|Placebo Comparator|Group C: Placebo|glucose tablet (10mg)
3018157|NCT02441842|Active Comparator|Group L: Lisinopril|oral lisinopril (5mg)
3018158|NCT02441829|Experimental|Mild Renal Impairment (CLcr 60-89 mL/min)|Participants with mild renal impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
3018159|NCT02441829|Experimental|Moderate Renal Impairment (CLcr 30-59 mL/min)|Participants with moderate impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
3018160|NCT02441829|Experimental|Severe Renal Impairment (CLcr 15-29 mL/min)|Participants with severe renal impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
3018161|NCT02441816|Other|Eylea Treatment|The intravitreal dose of Eylea will be 2mg (in 0.05ml) per injection. The medication will be supplied in single use vials. Given monthly for 3 months and then every 8 weeks in the first year of treatment before applying a treat and extend paradigm to patient visits in year 2. This is an open-label study.
3018162|NCT02441803|Experimental|Matched Sibling Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Stem cell infusion performed on Day 0."
3018163|NCT02441803|Experimental|Haploidentical Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Total body irradiation (TBI) delivered at 2Gy on Day -2. Stem cell infusion performed on Day 0. Cyclophosphamide 50 mg/kg by vein on Days +3 and +4. Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5. Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100."
3018164|NCT02441803|Experimental|Matched Unrelated Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2. Stem cell infusion performed on Day 0."
3018165|NCT02441790|Experimental|Early Active Range of Motion|Early Active Range of Motion (EAROM) 3-9 days following hand fracture
3018166|NCT02441790|Active Comparator|Standard Immoblization|Standard immobilization with plaster splint for 21-27 following hand fracture
3018167|NCT02441777|Experimental|Control: Healthy|Polarization Sensitive Optical Coherence Tomography (PS-OCT) Imaging will be used to look at the nerve fiber layer (NFL) in the healthy retina.
3018168|NCT02441764||Halaven|Participants who are prescribed with Halaven per approved prescribing information of Halaven.
3018169|NCT02441751||bleeding|intraoperative blood loss > 500 ml
3018170|NCT02441751||no bleeding|intraoperative blood loss < 500 ml
3018171|NCT02441738|Active Comparator|Hybrid Ablation|Epicardial surgical ablation performed thoracoscopically with occlusion/removal of the LAA combined with percutaneous endocardial ablation (one-stage).
3018172|NCT02441738|Active Comparator|Catheter Ablation|Percutaneous endocardial catheter ablation, with optional repeated catheter ablation(s).
3018173|NCT02441725|Other|Pulmonary Rehabilitation Patients|"Validation of the 1-minute sit-to-stand test; for participants who consent including a extended daily assessment period of physical activity and patient-reported symptoms of exacerbations:~Male and female COPD inpatients (≥40 years of age) from two pulmonary rehabilitation clinics (Klinik Barmelweid and Zürcher Höhenklinik Wald)"
3018174|NCT02441725|Other|Acute Care Hospital Patients|"Validation of the 1-minute sit-to-stand test, including daily assessment of physical activity and patient-reported symptoms of exacerbations:~Male and female COPD inpatients from two acute care hospitals (≥40 years of age; Stadtspital Waid and Spital Uster)"
3018175|NCT02441712|Experimental|Motor PENS|Motor PENS will be a strong tri-phasic stimulation pattern to the hip, quadriceps, hamstring, and adductors for strength training (50Hz impulses for 200ms every 1500 ms). The stimulus will be administered for 15-minutes followed by the impairment rehabilitation program.
3018176|NCT02441712|Sham Comparator|Subsensory PENS|Subsensory PENS will be a sub sensory stimulus also administered by a tri-phasic stimulation pattern to the hip, quadriceps, hamstring, and adductors (50Hz impulses for 200ms every 1500ms). The stimulus will be administered for 15-minutes followed by the impairment rehabilitation program
3018177|NCT02441699||Intervention group|Rural villages in which Gram Vikas has fully implemented its water supply and sanitation (Mantra) intervention. Intervention villages must: 1) be within 3 hours travel to the study office in Brahmapur, 2) have started the intervention by January 2003, and 3) have completed the intervention by January 2013.
3018178|NCT02441699||Control group|Rural villages that have been matched with intervention villages on demographics and other criteria. The sampling frame for control villages is limited to those: 1) within 3 hours travel to the study office in Brahmapur, and 2) within Gram Panchayats which do not include an intervention village and are not adjacent to an intervention village, to minimize spillover effects. In addition, both intervention and control villages must appear in the Government of India Census in 2001.
3018179|NCT02441686|Experimental|Bortezomib, Lenalidomide, Dexamethasone|"After the screening procedures confirm eligibility to participate in the research study: Each participant will be given a study drug-dosing diary for each treatment cycle. The diary will also include special instructions for taking the study drugs.~- Study Drugs:~Bortezomib- subcutaneous injection on predetermined days of each cycle~Lenalidomide oral daily on predetermined days of each cycle.~Dexamethasone oral on predetermined days of each cycle"
3018180|NCT02441673|Active Comparator|Nefopam|"Premedication of IV (Intravenous)10mg Metoclopramide and 50mg Ranitidine would be given morning of surgery to all patients.~0.15mg/kg of Acupan(Nefopam) would be administered IV after the initiation of the subarachnoid block (Time 0) and presence and severity of shivering (the primary outcome) would be looked out for.~IV Ephedrine in 3mg alliquots would be given if hypotension occurs; IV oxytocin 30-50mg would be given after delivery of the baby to all patients and IV Pethidine 25mg would be given to abate any residual shivering if a repeat dose of Acupan is not satisfactory."
3018181|NCT02441673|Active Comparator|Tramadol|"Premedication of IV (Intravenous)10mg Metoclopramide and 50mg Ranitidine would be given morning of surgery to all patients.~1mg/kg of tramadol would be administered after the initiation of the subarachnoid block (Time 0) and presence and severity of shivering (the primary outcome) would be looked out for.~IV Ephedrine in 3mg alliquots would be given if hypotension occurs; IV oxytocin 30-50mg would be given after delivery of the baby to all patients and IV Pethidine 25mg would be given to abate any residual shivering if a repeat dose of Tramadol is not satisfactory."
3018182|NCT02441660|Experimental|experimental group|Qutenza, Capsaicin 8% Patch will be used
3018183|NCT02441660|Active Comparator|control group|Active control with low dose capsaicin
3018184|NCT02441647|Experimental|Experimental group|
3018185|NCT02441621|Other|Passive leg raising|
3018186|NCT02441621|Other|premedication|
3018187|NCT02441621|Other|intubation and mechanical ventilation|
3018188|NCT02441621|Other|central venous catheter|
3018189|NCT02441621|Other|arterial catheter|Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
3018190|NCT02441621|Other|transesophageal echocardiography|
3018191|NCT02441621|Other|transpulmonary thermodilution catheter|
3018230|NCT02441348||CTT group|CTT will be initiated in a prospective fashion to study population
3018192|NCT02441608|Experimental|Experimental group|This study is designed as a single group assignment, because the 4 dressings (3 placebos and 1 containing the product) will be applied in all volunteers. This means that the region in which the tested product will be applied will be compared with the other placebo regions in the same volunteer.
3018193|NCT02441595|Experimental|MBCP intervention|The intervention involves eight 2.5 h weekly group sessions in which exercises in mindfulness are practiced and associated theory is taught to increase metacognition, emotional regulation and body awareness.
3018194|NCT02441595|Active Comparator|Control condition|Participants in the control condition are being offered a standardized course in psychoprophylaxis.
3018195|NCT02441582|Experimental|Telemetry|In this group, participants will have a prehospital 12 lead ECG taken and sent through to the receiving facility.
3018196|NCT02441582|Other|Non-Telemetry|In this group, participants will have a prehospital 12 lead ECG taken which will not be sent through to the receiving facility.
3018197|NCT02441569|Experimental|Common factors intervention|Children and parents in this arm will be cared for by a provider who has received brief training in common factors patient engagement skills (the intervention) for use in addition to standard anxiety-related advice. Thus this arm will receive common factors engagement training for provider.
3018198|NCT02441569|Active Comparator|Control|Children and parents in this arm will be cared for by a provider who is able to offer standard pediatric anxiety-related advice (the control intervention). Families will receive standard pediatric advice for childhood anxiety.
3018199|NCT02441556|Active Comparator|standard medical therapy|Patients receive standard medical therapy alone.
3018200|NCT02441556|Experimental|endovascular + standard medical therapy|Patients receive endovascular treatment plus standard medical therapy.
3018201|NCT02441530|Experimental|vitamin D|667 unit of vitamin D once a day ,two days before the expected date of menstruation and continued through the first three days of bleeding.
3018202|NCT02441530|Experimental|vitamin E|200 unit of vitamin E once a day ,two days before the expected date of menstruation and continued through the first three days of bleeding.
3018203|NCT02441530|Experimental|ibuprofen|400 mg ibuprofen twice a day, two days before the expected date of menstruation and continued through the first three days of bleeding.
3018204|NCT02441517|Experimental|Enzalutamide|Participants received 160 mg enzalutamide orally once daily until radiographic or clinical progression, or unacceptable toxicity.
3018205|NCT02441504|Active Comparator|Low intensity exercise|physical inactivity
3018206|NCT02441491|Experimental|Cyclophosphamide|"Cyclophosphamide will be given by vein once a day for four straight days.~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, will be given by vein once every day to try to help your blood cells grow faster."
3018207|NCT02441478|Experimental|Patients|
3018208|NCT02441478|Active Comparator|Controls|
3018209|NCT02441465|Experimental|Vemurafenib|Participants will receive oral vemurafenib BID from Day 1 to Day 28 and a single IV infusion of 14C-labeled vemurafenib on Day 21.
3018210|NCT02441452|Active Comparator|Early rehabilitation|one day before surgery, patients and their families were instructed by physiotherapists than explained the importance to perform physical exercises and breath exercises in postoperative. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation.
3018211|NCT02441452|No Intervention|Conventional care|Usual care routine postoperative.
3018212|NCT02441439|Other|Iron sucrose 200 mg|first arm will be treated with iron sucrose 200 mg 2-3 times a week
3018213|NCT02441439|Active Comparator|Iron sucrose 500 mg|Second arm will be treated with iron sucrose 500 mg once a week
3018214|NCT02441426||Bangladesh|"Birth cohort study community in Bangladesh is urban, and located in the Mirpur neighborhood of Dhaka.~Case control study is being conducted in the same catchment area. Cases defined as children 6-24 months of age with <-2WAZ (weight for age) score, controls are age and community matched with >-1WAZ."
3018215|NCT02441426||Brazil|"Birth cohort study community in Brazil is urban, and located within the Papoco area of Fortaleza.~Case control study is being conducted in the same area as the cohort study. Cases are children 6 - 24 months of age, with <-2 WAZ (weight for age) score, controls are age and community matched children with >-1 WAZ."
3018216|NCT02441426||India|Birth cohort study community in India is urban, and located in the southern state of Tamil Nadu, specifically in Vellore.
3018217|NCT02441426||Nepal|Birth cohort study community in Nepal is semi-urban, and located in Bhaktapur, approximately 25km from Kathmandu.
3018218|NCT02441426||Pakistan|Birth cohort study community in Pakistan is rural, and located in Naushero Feroze, Sindh.
3018219|NCT02441426||Peru|Birth cohort study community in Peru is rural, and located approximately 15km from Iquitos in Loreto.
3018220|NCT02441426||South Africa|Birth cohort study community in South Africa is rural/peri-urban, and comprised of nine settlements within Limpopo Province.
3018221|NCT02441426||Tanzania|Birth cohort study community in Tanzania is rural, and located within Haydom.
3018222|NCT02441413|Experimental|HRCT scans|HRCT scan will be taken
3018223|NCT02441400||EndoStim LES Stimulation System implant.|Registry subjects whom have been implanted commercially with the EndoStim LES Stimulation System device.
3018224|NCT02441387||Antidepressant treatment|"According to their previous treatment history and clinical presentation, patients may take:~Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year."
3018225|NCT02441387||Antidepressant treatment & Psychoeducation intervention|Antidepressant treatment and psych education program (10 weekly sessions).
3018226|NCT02441374|Experimental|Forced Use Therapy|Constriction (through the tubular mesh) of non paretic upper limb for a period of 12 and 24 hours, 5 days per week for 4 weeks.
3018227|NCT02441374|Active Comparator|Classical Kinesiotherapy|Rehabilitation of classical kinesiotherapy,at least 2 times a week for 4 weeks.
3018228|NCT02441361|No Intervention|control|Subjects will undergo bariatric surgery and no exercise training will be prescribed.
3018229|NCT02441361|Experimental|exercise training|Subjects will undergo bariatric surgery and exercise training will be prescribed.
3018231|NCT02441335||Group 1 (Preterm labor, PPROM, cervical insufficiency)|Singleton pregnancy between 20 0/7 36 6/7 weeks gestational age who is admitted with PTL or cervical insufficiency (Equal or greater than 2 cm dilated) or PPROM
3018232|NCT02441335||Group 2 (Term labor)|Admitted to the hospital with spontaneous labor (regular contractions, cervical dilation) or spontaneous rupture of membranes
3018233|NCT02441322|Experimental|Methods to identify treatment response|The investigators will study how well these advanced MRI methods are in accurately identifying response to Novo-TTF in comparison to standard MRI methods for evaluation of treatment response. Using advanced MRI imaging techniques may help assess treatment response earlier than changes in tumor volume which can be measured with standard MRI methods.
3018234|NCT02441309|Experimental|A. Mifamurtide only|"Patients receive Mifamurtide only.~Treatment Weeks 1-6 (post 1st biopsy/resection):~Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.~Treatment Weeks 7-12 (post 2nd biopsy/resection):~Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.~Treatment Weeks 13-36:~Mifamurtide 2mg/m2, IV infusion, once/week."
3018235|NCT02441309|Experimental|B. Ifosfamide (Followed by Mifamurtide)|"Patients receive Ifosfamide alone initially, followed by ifosfamide plus mifamurtide, then mifamurtide alone.~Treatment Weeks 1-6: Day 1 of 21: Ifosfamide 12-15g/m2 IV infused over 4-5 days as per local practice. Repeated every 21 days for 2 cycles (3 weeks=1 cycle).~Treatment Weeks 7-12 (post 2nd biopsy/resection): Day 1 of 21: Ifosfamide 12-15g/m2 IV infused over 4-5 days once every 21 days for two cycles (3 weeks=1 cycle). Ifosfamide administered as per local practice, including concurrent dosing with mesna. Plus mifamurtide 2mg/m2, IV infusion, twice/week. Ifosfamide infusion must be started 24 hours prior to mifamurtide. Mifamurtide should be given on day 2 and either day 5 or day 6.~Treatment Weeks 13-18: Mifamurtide 2mg/m2, IV infusion, twice/week. Treatment Weeks 19-42: Mifamurtide 2mg/m2, IV infusion, once/week."
3018236|NCT02441309|Experimental|C. Ifosfamide + Mifamurtide|"Patients receive mifamurtide combined with ifosfamide initially.~Treatment Weeks 1-6:~Day 1 of 21: Ifosfamide 12-15g/m2 IV infusion infused over 4-5 days once every 21 days for two cycles (3 weeks=1 cycle).~Plus Mifamurtide 2 mg/m2, IV infusion, twice per week, with each infusion given at least 3 days apart, for 6 weeks.~Ifosfamide infusion must be started 24 hours prior to mifamurtide. Mifamurtide should be given on day 2 and either day 5 or day 6.~Treatment Weeks 7-12 (post 2nd biopsy/resection):~Day 1 of 21: Ifosfamide 12-15g/m2 IV infusion infused over 4-5 days once every 21 days for two cycles (3 weeks = 1 cycle).~Plus Mifamurtide 2mg/m2, IV infusion, twice per week, with each infusion given at least 3 days apart, for 6 weeks. Ifosfamide infusion must be started 24 hours prior to mifamurtide. Mifamurtide should be given on day 2 and either day 5 or day 6.~Treatment Weeks 13-36: Mifamurtide 2mg/m2, IV infusion, once/week."
3018237|NCT02441296|Experimental|Formula with lactose|Carbohydrate-free formula with added lactose
3018238|NCT02441296|Experimental|Formula with maltodextrins|Carbohydrate-free formula with added maltodextrins
3018239|NCT02441296|No Intervention|Breastfeeding|Breastfed reference group
3018240|NCT02441283|No Intervention|All subjects enrolled in the study|Follow up study that includes sample collection (diagnostic intervention) procedures only and no treatment
3018241|NCT02441270|Experimental|Cyclophosphamide|
3018242|NCT02441257|Experimental|control ventilation|patients are scheduled to receive control or spontaneous ventilation
3018243|NCT02441244|Experimental|Probiotic Group|Visbiome experimental group (900 billion bacteria daily; 2 sachets daily)
3018244|NCT02441244|Placebo Comparator|Placebo Group|Placebo comparator group
3018245|NCT02441231|Experimental|Probiotic Group|Visbiome probiotic group (900 billion bacteria daily; 2 sachets daily)
3018246|NCT02441231|Placebo Comparator|Placebo Group|Placebo comparator group
3018247|NCT02441218|Experimental|Ivabradine|
3018248|NCT02441218|Placebo Comparator|Placebo|
3018249|NCT02441205|Experimental|HIIT Aging|all subjects will undergo high intensity interval training 3 x per week for 10-12 weeks. the intervals of high-intensity (~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes
3018250|NCT02441192|Experimental|Training resistance|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
3018251|NCT02441192|Experimental|Training aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
3018252|NCT02441192|Experimental|Training resistance+aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
3018253|NCT02441179|Experimental|Acute Intermittent Hypoxia Arm|AIH protocol: it consists of 15, 90-second hypoxic episodes (FiO2=0.09) interspersed with 15, 90-second normoxic intervals (FiO2=0.21) for a total time of 45 minutes. This protocol will be repeated every day for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks. After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
3018254|NCT02441179|Placebo Comparator|Normoxia Arm|Sham protocol: it consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
3018255|NCT02441166|Other|Mastocytosis diagnosis|For each enrolled subject, 5 mL sample of peripheral blood and 1 mL sample of BM aspirate will be collected the same day to do diagnosis mastocytosis tests (quantification of the kit mutations by qPCR, plasma tryptase level, immunophenotyping of BM mastocytes by flow cytometry, BM tryptase level, degree of dilution of the BM aspirate...) using the WHO criteria as the reference standard.
3018256|NCT02441153||Group 1(Extended Timing)|Surgery will be performed at 10-11 weeks after the completion of chemoradiotherapy.
3018257|NCT02441153||Group 2 (Non-extended timing)|Surgery will be performed at 6-7 weeks after completion of chemoradiotherapy.
3018258|NCT02441140|Experimental|Culdocentesis|"Patients with known or highly likely ovarian cancer (i.e. highly elevated CA-125, ascites, pelvic mass) scheduled for cytoreductive surgery will be identified during preoperative consultation and offered participation in the study.~During Surgery:~Blood Collection~Vaginal Swab~Chromopertubation~Culdocentesis~Tissue Collection"
3019047|NCT02435511|No Intervention|Control arm|The control group will receive usual care, no HealtheRx.
3018259|NCT02441127|Experimental|Diode laser group|In the test sites, an aluminum, gallium, and arsenide diode laser (wavelength 810 nm and power of 1W) was applied in continuous mode.
3018260|NCT02441127|Active Comparator|Scalpel control group|The surgical technique used in the control group was a FGG harvested by two horizontal and two vertical incisions by scalpel defining the area to be harvested .
3018261|NCT02441114|Experimental|Inhalation of HCP0910 and HGP1011|"Single, twice and triple inhalation of HCP0910 and HGP1011 (open-label, single-arm, dose-escalation) at period 1, 2, and 3, respectively.~The periods were separated with a washout period of 14 days."
3018262|NCT02441101|Experimental|RV DDD(R)-60 with AV optimization|RBBB pacing
3018263|NCT02441101|Placebo Comparator|RV DDD(R)-60|Standard demand pacing
3018264|NCT02441088|Experimental|PRRT with 90Y--DOTA-tyr3-Octreotide|A radiopharmaceutical, 90Y--DOTA-tyr3-Octreotide, and a renal protectant, Aminosyn II, in a dosimetry-guided theranostics trial for both children and adults with neuroendocrine and other somatostatin receptor positive tumors. Radiopharmaceutical will be administered IV in 3 doses, 6 weeks apart, with Aminosyn II administered concomittantly with each dose. Two followup visits are required at three and 6 months following third dose of 90Y-DOTA-tyr3-Octreotide.
3018265|NCT02441075|Experimental|70% Ethanol|The study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
3018266|NCT02441062|Other|68Ga-DOTATOC PET/CT|Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study. Subjects may receive a second 68Ga-DOTATOC PET/CT for restaging after therapy 12-36 months following the first scan.
3018267|NCT02441049|Experimental|Home-based promotora intervention|Study participants and their families received the home-based promotora family intervention
3018268|NCT02441049|No Intervention|Delayed treatment control|Study participants received intervention materials after the final study evaluation measures were taken, 10 months post-baseline.
3018269|NCT02441036|Active Comparator|Group 1 - 1-3 hours prior|Subjects will receive Ultherapy treatment 1-3 hours prior to tissue resection.
3018270|NCT02441036|Active Comparator|Group 2 - 1 day prior|Subjects will receive Ultherapy treatment 1 day prior to tissue resection.
3018271|NCT02441036|Active Comparator|Group 3 - 3 days prior|Subjects will receive Ultherapy treatment 3 days prior to tissue resection.
3018272|NCT02441036|Active Comparator|Group 4 - 7 days prior|Subjects will receive Ultherapy treatment 7 days prior to tissue resection.
3018273|NCT02441036|Active Comparator|Group 5 - 45 days prior|Subjects will receive Ultherapy treatment 45 days prior to tissue resection.
3018274|NCT02441023|Experimental|Nutritional therapy and education|"Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.~Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials."
3018275|NCT02441023|No Intervention|Nutritional Therapy|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.
3018276|NCT02441010|No Intervention|Group 1|Participants without suboptimal health status are randomly grouped into the group without monitor (Group 1) and the monitor group (Group 2 or Group 3). Thus, no monitoring or intervention technologies are used in Group 1.
3018277|NCT02441010|Sham Comparator|Group 2|Group 2 are participants without metabolic abnormality in the monitor group. Group 2 use the monitoring device with three months.
3018278|NCT02441010|Sham Comparator|Group 3|Group 3 are participants with metabolic abnormality in the monitor group. Group 3 use the monitoring device and the health information push technology with three months.
3018279|NCT02441010|Active Comparator|Group 4|All of participants with suboptimal health status use the monitoring device with three months, and are randomly grouped into the non-intervention group (Group 4 or Group 5) and the intervention group using the meridian therapy instrument (Group 6 or Group 7). Group 4 are participants without metabolic abnormality in the non-intervention group. No intervention technologies are used in Group 4.
3018280|NCT02441010|Active Comparator|Group 5|Group 5 are participants with metabolic abnormality in the non-intervention group. Group 5 use the health information push technology with three months.
3018281|NCT02441010|Experimental|Group 6|Group 6 are participants without metabolic abnormality in the intervention group. Group 6 use the meridian therapy instrument with two weeks. If the suboptimal health status is not improved, then the meridian therapy instrument will continue to be used with an interval of one week.
3018282|NCT02441010|Experimental|Group 7|Group 7 are participants with metabolic abnormality in the intervention group. Group 7 use the health information push technology with three months and the meridian therapy instrument with two weeks. Similar with Group 6, if the suboptimal health status is not improved after the treatment of the meridian therapy instrument, then the instrument will continue to be used with an interval of one week.
3018283|NCT02440997|Placebo Comparator|foot bath only|10 minute foot bath with addition of jojoba only
3018284|NCT02440997|Experimental|foot bath and aromatherapy|10 minute foot bath with addition of jojoba with added Mentha piperita
3018285|NCT02440984|Other|Enteric nervous system dysfunction|colonic biopsies and usual care
3018286|NCT02440958|Experimental|modified FOLFIRINOX|
3018287|NCT02440945|Experimental|collection of blood|160 old people for the collection of blood
3018288|NCT02440932|Experimental|Phenylketonuria-type diet|"Breakfast: one pouch of amino acid supplement (174 mls supplemented drink PKU cooler 20, Vitaflo®; 20 g protein, 9.4 g carbohydrates, 0.7 g Fat) Lunch: cheese sandwich [low protein bread (Juvela, UK), no protein vegan cheese (Viotros, UK)], low protein crackers (Vitaflo, UK), and low protein cookies (Juvela, UK).~Dinner: ad libitum buffet meal"
3018289|NCT02440932|Other|Normal diet|Breakfast: 174 ml of milk (20 g protein, 9.4 g carbohydrates, 0.7 g Fat) Lunch: cheese sandwich, crackers, and cookies (regular foods) Dinner: ad libitum buffet meal
3018290|NCT02440919|Other|Hyperoxygenation - 100% FiO2|Hyperoxygenation involved supplying 100% fraction of inspired oxygen (FIO2).
3018291|NCT02440919|Other|Hyperoxygenation - 20% FiO2|Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
3018292|NCT02440919|Other|Hyperinflation - Basal FiO2|Ventilator hyperinflation, with keeping the oxygen already offered to the patient.
3018293|NCT02440919|Other|Hyperinflation - 20% FiO2|Ventilator hyperinflation and hyperoxygenation involved supplying 20% oxygen.
3018294|NCT02440906|Experimental|Intervention|A person-centered wellness intervention that includes a patient-directed wellness account. Enrollees meet with a patient Navigator to develop a wellness plan. The enrollee can then use the flexible wellness account to make purchases that are consistent with the goals of the wellness plan. Health Navigators have monthly phone contact with enrollees and meet quarterly with them to discuss goals and spending with the express goal of improving self-management, use of preventive services, satisfaction with care, healthcare utilization and expenditures and quality of care.
3018295|NCT02440906|No Intervention|Control|Control group participants receive a monthly mailing requesting updated contact information. They can send this card via mail, or by calling the toll free number.
3018296|NCT02440906|No Intervention|Comparison|These are STAR+PLUS enrollees who meet the same enrollment criteria as the intervention and control but reside outside of the Harris Service Area. The purpose of the comparison group is to follow them and their outcomes. This group will help us to better compare the outcomes we see with those enrolled in the WIN Project to a comparable group for whom we already house data.
3018297|NCT02440893||Corus CAD (ASGES) Post-metformin|Corus CAD (ASGES) second sample draw results to compare to Corus CAD (ASGES) first draw results (per patient).
3018298|NCT02440880|Placebo Comparator|CONTROL|TAP block without Dexamethasone neither intravenous nor in combination with the block
3018299|NCT02440880|Experimental|Group 2 (TD8IS)|Dexamethasone in combination with TAP block in dose of 8 mg
3018300|NCT02440880|Experimental|Group 3(TD4IS)|Dexamethasone in addition to TAP block in dose of 4 mg
3018301|NCT02440880|Experimental|Group 4 (TSID8):|Dexamethasone intravenous in addition to TAP block in dose of 8 mg
3018302|NCT02440880|Experimental|Group5(TSID4)|Dexamethasone intravenous 4mg+ TAP block
3018303|NCT02440867|No Intervention|Healthy subjects|Multimodal imaging data acquisitions Clinical data acquisitions
3018304|NCT02440867|Experimental|TBS-MPC|"Intervention with active TBS aiming Medial Prefrontal Cortex in 6 patients with schizophrenia~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Continuous actimetry acquisition"
3018305|NCT02440867|Active Comparator|TBS-CPDLF|"Intervention with active TBS aiming Dorsolateral Prefrontal Cortex in 6 patients with schizophrenia~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Continuous actimetry acquisition"
3018306|NCT02440867|Sham Comparator|TBS-Sham|"Intervention with Sham TBS in 8 patients with schizophrenia~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Continuous actimetry acquisition"
3018307|NCT02440854||Afatinib|
3018308|NCT02440841|Experimental|fedovapagon and itraconazole|Two daily doses of fedovapagon and once daily doses of itraconazole
3018309|NCT02440841|Experimental|fedovapagon and rifampicin|Two daily doses of fedovapagon and once daily doses of rifampicin
3018310|NCT02440828|Experimental|tobramycin inhalation|twice daily tobramycin inhalation (Bramitob) 300 mg and standard intravenous antibiotics treatment
3018311|NCT02440828|Placebo Comparator|Placebo|twice daily placebo inhalation and standard intravenous antibiotics treatment
3018312|NCT02440815|Other|Problem Solving Therapy|Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD. The problem solving therapy includes 12 weekly in person 50 minute sessions.
3018313|NCT02440802||Gonadoliberin antagonist treatment|Single arm study, all patients are treated the same way. Saliva sample collection for genetic analyses.
3018314|NCT02440789|Experimental|Sirolimus 0.025 mg/kg/day initial dose for 20 weeks|For subjects on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen
3018315|NCT02440789|Experimental|Sirolimus 0.05 mg/kg/day initial dose for 20 weeks|For subjects who are on an NNRTI regimen with the exception of RPV
3018316|NCT02440763||Spinocerebellar ataxia type 1,2,3 and 6|Spinocerebellar ataxias (SCA) are autosomal dominantly inherited progressive ataxia disorders. An epidemiological study performed in the Netherlands found a prevalence of 3.0 : 100,000 (van de Warrenburg et al. 2002). The SCA´s are genetically and clinically heterogeneous disorders with SCA1, SCA2, SCA3 and SCA6 being the most frequent genotypes worldwide. While SCA1, SCA2 and SCA3 have a complex phenotype, SCA6 patients usually present with pure cerebellar ataxia (Schols et al. 2004). Although precise knowledge of the rate of disease progression is a prerequisite for the biometrical design of future therapeutical trials, prospective studies of the natural history of SCA´s have not been performed. Similarly, the occurrence and evolution of accompanying non-ataxia symptoms have not been studied prospectively.
3018317|NCT02440750|Experimental|Dienogest|Women selected for operative hysteroscopy that received for 21 days dienogest 2 mg/die
3018318|NCT02440750|Experimental|Ulipristal acetate|Women selected for operative hysteroscopy that received for 21 days ulipristal acetate 5 mg/die
3018319|NCT02440737|Experimental|NEST Intervention|Patients (PTs) and their caregivers (CGs) receive educational intervention, follow-up care, psychosocial assessment and care, and questionnaire administration interventions by completing psychosocial questionnaires and meeting with a nurse practitioner (NP) or nurse navigator (NN) for an initial survivorship care planning session to review the expected course of therapy and recovery, identify resources that may be needed and provide recommendations for follow-up. At the end of their treatment EOT), PTs and their CGs complete a 2nd set of questionnaires and meet with the NP/NN for a booster survivorship care planning session. They will receive an individualized final survivorship care plan and related materials. 2 months after EOT, PTs and their CGs complete a final set of questionnaires.
3018320|NCT02440724|Experimental|winged stent group|participants who are assigned to winged-stent group will be treated with deployment of a winged stent(partially covered or uncovered SEMS).
3018321|NCT02440711|Experimental|mRSF-ESF|Study participants in Arm 1 will first receive the Modified running specific foot (mRSF) and then the Energy storing foot (ESF). Outcomes will be assessed (in each condition) after 1 month of use. Order of interventions will be randomly assigned.
3018322|NCT02440711|Experimental|ESF-mRSF|Study participants in Arm 2 will first receive the Energy storing foot (ESF) and then the Modified running specific foot (mRSF). Outcomes will be assessed (in each condition) after 1 month of use. Order of interventions will be randomly assigned.
3018323|NCT02440685|Experimental|ASN002 Dose Escalation|Multiple ascending doses of ASN002 will be administered to determine the maximum tolerated dose (MTD). Arm Closed
3018324|NCT02440685|Experimental|ASN002 Recommended dose (RD) - DLBCL|ASN002 administered at the recommended dose in subjects with DLBCL. Arm Closed
3018325|NCT02440685|Experimental|ASN002 RD - Mantle Cell Lymphoma|ASN002 administered at the recommended dose in subjects with MCL. Arm Closed
3018326|NCT02440685|Experimental|ASN002 RD - Follicular Lymphoma|ASN002 administered at the recommended dose in subjects with FL.
3018327|NCT02440685|Experimental|ASN002 RD - Peripheral T-cell Lymphoma|ASN002 administered at the recommended dose in subjects with PTCL.
3018328|NCT02440685|Experimental|ASN002 RD - Myelofibrosis|ASN002 administered at the recommended dose in subjects with MF.
3018329|NCT02440685|Experimental|ASN002 RD - Chronic Lymphocytic Leukemia|ASN002 administered at the recommended dose in subjects with CLL.
3018330|NCT02440672|Other|Device:JOURNEY™ II CR Total Knee System (J II CR TKS)|Subjects having TKA with JOURNEY™ II CR Total Knee System
3018331|NCT02440659||Hemodialysis (HD)|Patients who have chronic kidney disease (CKD) and are currently on hemodialysis.
3018332|NCT02440659||Peritoneal Dialysis (PD)|Patients who have chronic kidney disease (CKD) and are currently on peritoneal dialysis.
3018333|NCT02440646||CTA group|All-comers admitted to the chest-pain outpatient center with or without acute coronary syndrome underwent functional tests and coronary computed tomography angiography (CTA) (with intravenous contrast) with or without further quantitative coronary angiography (QCA) and percutaneous intervention (PCI).
3018334|NCT02440646||3D QCA group|All-comers admitted to the chest-pain outpatient center with or without acute coronary syndrome underwent functional tests and 3D quantitative coronary angiography (QCA) with or without implantation of stent.
3018335|NCT02440633|Experimental|14C-OPS-2071|Suspension containing 50 mg of 14C-OPS-2071
3018336|NCT02440607|Experimental|Electronic aid|The dynamic aid will consist of a centralized electronic aid embedded within a simulated EMR.
3018337|NCT02440607|Active Comparator|Static Cognitive aid|The static aid represents the standard algorithm put forth by a leading clinical care organization.
3018338|NCT02440594|Experimental|Enhanced BHL Program|The Enhanced Program includes: 1) Enhanced Monitoring Module, which consists of the Standard Monitoring Module enhanced with a discussion of continuing versus discontinuing the medication 2) Enhanced Care Management Module, which consists of Care Management services with a BHP or 3) Enhanced BHL Telehealth Education Program (TEP), which consists of various modules which seek to provide both education and psychosocial support for individuals caring for older adults with moderate to severe cognitive impairment.
3018339|NCT02440594|No Intervention|Standard Clinical Monitoring|The Standard Clinical Monitoring Module is a service designed to help provide evidence-based care for individuals receiving new antidepressant, anxiolytic, or antipsychotic prescriptions. Monitoring consists of up to 4 brief (5-10 minutes), structured assessments following the Core assessment. These follow-up contacts are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks). These brief interviews monitor adherence, side effects, and response to treatment. A progress report is provided to the prescribing clinician following each interview to help in treatment planning and to alert the clinician of special issues.
3018340|NCT02440581|No Intervention|Control, low turnover|No intervention in low turnover osteoporosis control group.
3018341|NCT02440581|Experimental|Treatment, low turnover|Low turnover osteoporosis group treated with teriparatide and cinacalcet.
3018342|NCT02440581|No Intervention|Control, high turnover|No intervention in high turnover osteoporosis control group.
3018343|NCT02440581|Experimental|Treatment, high turnover|High turnover osteoporosis group treated with alendronate.
3018344|NCT02440568|Experimental|Patients with newly diagnosed AML|Patients will receive Omacetaxine, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
3018345|NCT02440555||patients included|fulfill the self-administered questionnaire.
3018346|NCT02440542||Postoperative Popliteal nerve block|All patients in the cohort are receiving a postoperative popliteal nerve block as part of their surgical plan. Outcomes including length of stay, Visual Analog Scale Scores, narcotic intake, and patient satisfaction will be collected as the intervention.
3018347|NCT02440529|Active Comparator|(Intervention Group)|The discussion about how smoking cigarettes impacts patient orthopaedic management plus aid
3018348|NCT02440529|Active Comparator|(Control Group)|The discussion about how smoking cigarettes impacts patient orthopaedic management.
3018349|NCT02440516|Active Comparator|Neurorehabilitation program|Standardized comprehensive ambulatory neurorehabilitation program
3018350|NCT02440516|Placebo Comparator|Waiting list|Waiting list
3018351|NCT02440490|Experimental|Computerised cognitive training|The cognitive training protocol will be run using pre-validated software, HappyNeuronPro, that delivers cognitive training games. The games are designed to be visually interesting and engaging, and are varied so that each session will comprise multiple different games, to avoid boredom. They begin with easy-to-follow instructions and demonstrations, then as the participant progresses, the difficulty is automatically increased in correspondence with their performance, to avoid ceiling or plateau effects. Participants will be assigned a program targeting multiple facets of cognition found to be compromised in chronic pain states, including divided attention, working memory, mentally planning a sequence of items to form a pattern or complete a puzzle, and response inhibition.
3019135|NCT02434861|Experimental|Part B|Rolapitant IV and Sulfasalazine
3018352|NCT02440490|Active Comparator|Video watching|This group will be provided with a variety of videos to watch, the content of which will be in the style of documentaries on general interest topics such as nature, travel, culture, and history. Each video is followed by multiple-choice questions that participants will answer, to ensure attention was engaged. The videos are visually stimulating and engaging, but involve no increment in difficulty or requirement to improve skills. They may provide some distraction from pain and may be relaxing, interesting and informative.
3018353|NCT02440477||partial rotator cuff tears|50 subjects with shoulder pain who are diagnosed with partial rotator cuff degenrative tears by ultrasound. All patients will be measured for their body weight and height and their hand dominance will be notified. Following reliability trials on the first 10 subjects, all subjects will be tested for pain provocation and level of pain (VAS) in both shoulders with 3 commonly used clinical shoulder tests for the diagnosis of rotator cuff diseases Empty can ,Neer test and Hawkins-Kennedy test in 3 sitting postures; normal resting posture, slouched posture, and upright posture with scapular retraction. In addition, the rotator cuff muscle strength tests during shoulder abduction, internal rotation and external rotation will be measured for the 2 shoulders using a hand-held dynamometer.
3018354|NCT02440477||control group|50 volunteering subjects without any pain in the upper quadrant.All patients will be measured for their body weight and height and their hand dominance will be notified. Following reliability trials on the first 10 subjects, all subjects will be tested for pain provocation and level of pain (VAS) in both shoulders with 3 commonly used clinical shoulder tests for the diagnosis of rotator cuff diseases Empty can ,Neer test and Hawkins-Kennedy test in 3 sitting postures; normal resting posture, slouched posture, and upright posture with scapular retraction. In addition, the rotator cuff muscle strength tests during shoulder abduction, internal rotation and external rotation will be measured for the 2 shoulders using a hand-held dynamometer.
3018355|NCT02440464|Experimental|Ixazomib Maintenance|Allogeneic HSCT and Fludarabine/Melphalan/Bortezomib conditioning followed by Ixazomib maintenance
3018356|NCT02440464|Placebo Comparator|Placebo|Allogeneic HSCT and Fludarabine/Melphalan/Bortezomib conditioning followed by placebo
3018357|NCT02440451|Experimental|Neurofeedback using BCI|16 (13 + 3 in case of dropoffs) ASD subjects
3018358|NCT02440438|Experimental|Clostridium difficile infection|
3018359|NCT02440425|Experimental|Combination Therapy|Combination Therapy: Pembrolizumab (experimental use) and Paclitaxel (standard use). All trial treatments will be administered on an outpatient basis. One cycle equals 21 days. The first cycle is 28 days with Pembrolizumab given on day 8 in order to determine paclitaxel tolerance.
3018360|NCT02440412|Experimental|Massage Therapy|A 45 minutes massage therapy (manual) standardized session, based in Swedish techniques.
3018361|NCT02440412|Placebo Comparator|Rest condition|45 minutes of rest in supine position, listening music with headphones, and warm condition.
3018362|NCT02440412|No Intervention|Control|Normal working condition, as a office workers (secretaries and managements employees)
3018363|NCT02440399|Experimental|Fix protocol - Oral treatment|"During 48 hours following surgery pain medications will be given as followed (listed in brackets are the generic names of each medication):~At patient arrival to the department: Intravenous Tramadol hydrochloride 100 milligrams + TAB. Paracetamol 500 milligrams + TAB. Diclofenac 100 milligrams~After 6 hours from patient arrival and every 6 hours: TAB. Zaldiar (Paracetamol 650 milligrams + Tramadol 75 milligrams).~After 12, 24 and 48 hours from patient arrival: TAB. Diclofenac 100 milligrams.~Rescue medication: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)as necessary up to 4 times per day.~The total amount of paracetamol is limited to 4 gr per day."
3018364|NCT02440399|Experimental|Spinal morphine|The women will receive 150 mcg morphine with the spinal anesthesia given in the cesarean section
3018365|NCT02440386|No Intervention|Control|The control arm receives standard of care. Standard of care involves referral for ART services and follow-up calls (maximum of 6) to assess whether linkage to care has occurred.
3018366|NCT02440386|Experimental|Incentive|The incentive arm receives standard of care plus a R300 voucher. The R300 voucher can be exchanged for cash if the participant starts ART at any clinic of their choice within three months from study enrollment.
3018367|NCT02440360|Active Comparator|Permanent Supportive Housing|Permanent Supportive Housing (PSH) is subsidized housing with closely linked or on-site supportive services that typically include case management, physical and mental health care, substance use treatment services and vocational support.
3018368|NCT02440360|Placebo Comparator|Usual Care|Usual Care consists of public benefits (e.g., General Assistance and CalFresh), integrated medical and behavioral health services provided by Valley Medical Center and the rest of the County Health & Hospital System including those offered by Valley Homeless Healthcare Program, specialty mental health and substance abuse treatment services and housing programs, and approximately 2,000 year-round beds of emergency shelter and transitional housing.
3018369|NCT02440347|Experimental|Computer controlled anesthetic delivery by Anaeject|Patients received single dose of 0.6 ml of 4% articaine with epinephrine (1:100.000) by computer controlled anesthetic delivery system (C-CLADS) for AMSA nerve block
3018370|NCT02440347|Active Comparator|Conventional anesthetic delivery by carpule syringe|Patients received single dose of 0.6 ml of 4% articaine with epinephrine (1:100.000) by conventional anesthetic delivery for AMSA nerve block
3018371|NCT02440334|Experimental|Contrast Ultrasound Reccurence Screening|Patients scheduled for MRI/CT follow up of a renal cancer previously treated by cryoablation therapy who will also undergo a contrast-enhanced ultrasound exam. This is a one-time imaging study and contrast ultrasound exams will be compared to the clinically scheduled MRI/CT.
3018372|NCT02440321|Experimental|parent-child interactive program|The parent-child interactive program is designed by three phase: precontemplation/ contemplation stage, preparation stage, and action/maintenance stage. In phase 1, the main focus is to promote motivation through information providing and being aware of children's perception toward ETS and smoking. In phase 2, the main focus is strengthening parents/children's ability to plan and implement smoke-free home. In phase 3, intervention focus is on maintaining behavioral change and smoke-free home by continuously strengthening implementing ability, identifying and eliminating barriers, and reinforcing successful experience. Parent-child interaction is designed through three phases, and parents perceive children's feedback through all phases.
3018373|NCT02440321|Active Comparator|written materials|The mailed materials included information on ETS and its adverse effects, smoking behavior that causes ETS at home, and a workbook for smoking cessation.
3018374|NCT02440308|Experimental|68Ga-DOTA-Bombesin PET/MRI|Patients receive 68Ga-DOTA-Bombesin IV and then undergo PET/MRI approximately 1 hour later.
3018375|NCT02440295||Lower Extremity Amputations|"All patients >= 18 years of age requiring Below Knee Amputation (BKA) or Above Knee Amputation (AKA) cared for by the Spectrum Health vascular surgery service will be assessed for eligibility.~Subjects with a history of allergies to iodides or iodinated contrast agents, pregnant or nursing women, subjects who are unable to provide consent, and prisoners will be excluded. Eighteen subjects will be enrolled in the pilot study. No special population subjects will be enrolled."
3018376|NCT02440282||Group A|patients undergo general anesthesia
3018377|NCT02440282||Group B|spinal anesthesia
3018378|NCT02440282||Group C|ultrasound-guided sciatic nerve block
3018379|NCT02440269||A：day|the patients who receive surgery and anesthesia during 8:00 am to 6:00 pm
3018380|NCT02440269||B：night|the patients who receive surgery and anesthesia during 10:00 pm to 5:00 am next day
3018381|NCT02440256|Other|Cluster 1|Cluster 1 is the first OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the sixth month of the trial. Cluster 1 will be a 'no intervention' arm in the first 6 months of the study, and will cross-over to an experimental arm for months 6-24.
3018382|NCT02440256|Other|Cluster 2|Cluster 2 is the second OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the twelfth month of the trial. Cluster 2 will be a 'no intervention' arm in the first 12 months of the study, and will cross-over to a experimental arm for month 12-24.
3018383|NCT02440256|Other|Cluster 3|Cluster 3 is the final OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the 18th month of the trial. As such, Cluster 3 will be a 'no intervention' arm in the first 18 months of the study, and will cross-over to an experimental arm for months 18-24.
3018384|NCT02440243|Active Comparator|Patients active|Purethal Grass
3018385|NCT02440243|Placebo Comparator|Patients placebo|Placebo
3018386|NCT02440230|Experimental|OFS + Anastrozole|Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Anastrozole.
3018387|NCT02440230|Active Comparator|OFS + Exemestane|Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Exemestane.
3018388|NCT02440217||DCM-AGT|Subjects with both dilated cardiomyopathy (DCM) and abnormal glucose tolerance (AGT, either impaired glucose tolerance or type 2 diabetes).
3018389|NCT02440217||DCM-NGT|Subjects with dilated cardiomyopathy (DCM) and normal glucose tolerance (NGT).
3018390|NCT02440217||N-AGT|Subjects without dilated cardiomyopathy (N) with abnormal glucose tolerance (AGT, either impaired glucose tolerance or type 2 diabetes).
3018391|NCT02440204|Active Comparator|Remifentanil 1.0 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
3018392|NCT02440204|Active Comparator|Remifentanil 1.5 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
3018393|NCT02440204|Active Comparator|Remifentanil 2.0 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
3018394|NCT02440191|Active Comparator|3DCRT|conventional 3-dimensional conformal radiotherapy on the breast, 50.4 Gy/28 fx and tumor bed boost, 9 Gy/5 fx will be irradiated for 6.5 weeks.
3018395|NCT02440191|Experimental|IMRT (Intensity modulated radiotherapy)|"Intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) on the whole breast, 50.4 Gy/28 fx and tumor bed, 57.4 Gy/28 fx will be irradiated for 5.5 weeks.~Unlike 3DCRT, concomittant boost technique is used in the IMRT arm."
3018396|NCT02440178|Experimental|micafungin prophylaxis|
3018397|NCT02440165|Experimental|Experimental|"The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:~Information and advice;~Examples of energy and protein rich meals;~patients will be asked to register their nutritional intake for two days at home;~after a week, the nurse will call the patients to answer questions and to give advice.~This nutrition care plan will be tailored to the individual patient requirements.~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care."
3018398|NCT02440165|No Intervention|Usual care|All participants, both in the intervention group and the control group, receive usual care containing a regular visit to a nurse who will perform a malnutrition screening with the MUST (Malnutrition Universal Screening Tool). If patients are 'malnourished', a visit to the dietician is suggested.
3018399|NCT02440152|Experimental|Deep brain stimulation|
3018400|NCT02440139|No Intervention|Arm 1|Participating radiologists will perform clinical reading on ~300 cases. They will mark all locations of concern (clinically actionable nodules) on conventional thoracic CT images. Computer will measure time, readers score regions according to action and suspiciousness.
3018401|NCT02440139|Active Comparator|Arm 2|Participating radiologists will perform clinical reading on ~300 cases. They will mark all locations of concern (clinically actionable nodules) on thoracic CT images aided by ClearRead CT Insight software as the intervention. Computer will measure time, readers score regions according to action and suspiciousness.
3018402|NCT02440126||Group A: Natalizumab Naïve|This group will consist of up to 10 people who are naïve to natalizumab (haven't received the drug before) and are just beginning therapy. These participants will meet with the study staff at Week 0 (Baseline) prior to their natalizumab infusion. They will then have a follow up appointment every 3 months for the first 12 months of their natalizumab infusions, for a total of 5 visits. Natalizumab concentration and other biomarkers will be measured at each visit.
3018432|NCT02439996|Active Comparator|IVIG(2g/kg.once)|The KD children will be randomly assigned to three groups. The patients in group A will receive IVIG 2g/kg once.
3018433|NCT02439983|Placebo Comparator|Placebo|
3018403|NCT02440126||Group B: Intracycle Regular Dosing|This group will consist of at least 50 people who are on a regular infusing cycle of 28-31 days. These participants will be consented at Week 0 (Baseline) and asked to come back each week during their regular cycle at Week 1, Week 2, and Week 3, for a total of 4 study visits. Natalizumab concentration and other biomarkers will be measured during their participation in the study.
3018404|NCT02440126||Group C: Intracycle Extended Dosing|This group will consist of up to 60 people who are on an extended infusing cycle of greater than 30 days. These participants will be consented at Week 0 (Baseline) and asked to come back each week for a blood draw to measure Natalizumab concentration and other biomarkers during their extended cycle at Week 2, and Week 4, for a total of 3 study visits.
3018405|NCT02440126||Group D: Transition Dosing|This group will consist of up to 10 people who are on a regular infusing cycle of 28-30 days who will be transitioning to an extended dosing cycle. The decision to transition will be made by their treating neurologist. These participants will be consented at Week 0 (Baseline) and will be followed for 8 cycles. Natalizumab concentration will be measured at each cycle. During certain cycles, other biomarkers will be measured.
3018406|NCT02440113||Nellix|Patients with endovascular Nellix repair
3018407|NCT02440100|Experimental|Multiple Doses PF-06648671 (Cohort1)|Healthy subjects receive 14-day repeated dose once a day at 4 mg of PF-06648671 or matching placebo
3018408|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 2)|Healthy subject receive 14-day repeated dose once a day at 12 mg of PF-06648671 or matching placebo
3018409|NCT02440100|Experimental|Multiple doses PF-06648671 (cohort 3)|Healthy subject receive 14-day repeated dose once a day at 40 mg of PF-06648671 or matching placebo and CSF LP is collected at baseline and steady state predose on day 1 and 14
3018410|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 4)|Healthy subject receive 14-day repeated dose once a day at 40 mg of PF-06648671 or matching placebo
3018411|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 5)|Healthy subject receive 14-day repeated dose once a day at 100 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 15, 24 hours after last dosing on day 14
3018412|NCT02440100|Experimental|Multiple Doses in Healthy Elderly (cohort 7)|Healthy Elderly subjects receive 14-day repeated dose once a day at MTD PF-06648671 defined in healthy adult subjects (part 1)
3018413|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 8)|Healthy subjects receive 14-day repeated dose once a day at 360 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 15, 24 hours post last dose
3018414|NCT02440100|Experimental|Midazolam DDI (optional cohort 9)|Healthy Subjects receive single dose of 2 mg midazolam in period 1 followed by 14 days PF-06648671 once a day and coadministration of PF-06648671 and midazolam 2 mg in period 2 (Optional cohort)
3018415|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 6)|Healthy subject receive 14-day repeated dose once a day at 200 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 25, 24 hours after last dosing on day 14
3018416|NCT02440074|Experimental|MSV autologous transplantation|
3018417|NCT02440061|Active Comparator|Study Group: Type 2 Diabetes Mellitus (T2DM)|Subjects with Type 2 Diabetes Mellitus (T2DM). Subjects will receive AG and saline infusions, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.
3018418|NCT02440061|Active Comparator|Control Group|Control group of healthy subjects. Subjects will receive AG and saline, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.
3018419|NCT02440048|Experimental|HA ®Bond-apatite|10 extraction sockets will be preserved with Bond Apatite synthetic bone substitutes as test group
3018420|NCT02440048|Active Comparator|BioOss bovine bone substitute|10 extraction sockets will be preserved with BioOss particles bovine bone substitute as a positive control
3018421|NCT02440048|No Intervention|extraction|10 extraction sockets with no use of bone substitute as negative control.
3018422|NCT02440035|Experimental|Group 1|Two subsequent Intramuscular injections of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on Day 1, Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10^10 vp) on Day 169.
3018423|NCT02440035|Experimental|Group 2|Intramuscular injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 1, an intramuscular injection of placebo control on Day 85 and an injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 169.
3018424|NCT02440035|Experimental|Group 3|One intramuscular injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 1 and an intramuscular injection of placebo control on Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10^10 vp) on Day 169.
3018425|NCT02440035|Experimental|Group 4|Two subsequent intramuscular injections of placebo control on Day 1, Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 169.
3018426|NCT02440022|Experimental|Lutonix DCB|Percutaneous transluminal angiography (PTA) will be performed using the Lutonix AV drug coated balloon.
3018427|NCT02440022|Active Comparator|Standard Balloon Angioplasty Catheter|Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.
3018428|NCT02440009|Active Comparator|Glucocorticoid group|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
3018429|NCT02440009|Experimental|Itraconazole plus glucocorticoid group|Oral itraconazole 200 mg BD for 6 months AND oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma.
3018430|NCT02439996|Experimental|IVIG(1g/kg,once)|The KD children will be randomly assigned to three groups. The patients in group C will receive IVIG 1g/kg once.
3018431|NCT02439996|Experimental|IVIG(1g/kg,twice)|The KD children will be randomly assigned to three groups. The patients in group B will receive IVIG 1g/kg for 2 days continuousl.
3018439|NCT02439944|Experimental|Experimental Arm|Escalating nicotine patch dose to satiety over 6 weeks with dosage depending on the number of cigarettes smoked per day and the occurrence of adverse effects
3018440|NCT02439944|Active Comparator|Positive Control Arm|Nicotine patch dose of 21mg coupled with nicotine mouthspray which is to be used as needed.
3018441|NCT02439931|Experimental|Remote psychosocial intervention|10 sessions of remotely delivered psychoeducation and support
3018442|NCT02439905|Experimental|Dexmedetomidine group|
3018443|NCT02439905|Placebo Comparator|Normal saline group|
3018444|NCT02439892|Experimental|Early rehabilitation|Exercise and nutrition during radiotherapy: Physical exercise, nutritional advice and oral nutritional supplements.
3018445|NCT02439892|Active Comparator|Late rehabilitation|Multidimensional rehabilitation after radiotherapy: Physical exercise, nutritional advice, oral nutritional supplements and patient education
3018446|NCT02439879|Active Comparator|alpha lipoic acid treatment|After a decrease in the total symptoms score >3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks 600 mg orally once a day of alpha lipoic acid
3018447|NCT02439879|No Intervention|alpha lipoic acid withdrawal|After a decrease in the total symptoms Score >3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks no treatment
3018448|NCT02439866|Placebo Comparator|prescription placebo|control Group consisted of 30 patients who received gelatinous capsules filled with sugar as placebo
3018449|NCT02439866|Active Comparator|prescription Intravenous methylprednisolone|Group 2 or steroid consisted of 30 patients received methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day
3018450|NCT02439866|Active Comparator|prescription normobaric oxygen with face mask|Thirty patients in group 3 or oxygen received 100% normobaric oxygen with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
3018451|NCT02439853|Experimental|Check-In group|Subjects in the Check-In group will undergo three check-in sessions with the speech therapist. These sessions will happen remotely, via video-chat, and will last less than an hour. They will occur at 3-, 4-, and 5-months from the subject's enrollment date.
3018452|NCT02439853|No Intervention|Control Arm|Subjects in the Control arm will not undergo three check-in sessions with the speech therapist.
3018453|NCT02439840||Light sedation|Light sedation is defined as RASS of +1 to -2.
3018454|NCT02439840||Deep sedation|Deep sedation is defined as RASS of -3 to -5
3018455|NCT02439827|Experimental|"Fortaleça sua Saúde program"|The intervention program was structured into four main components: (i) training and activities in general curriculum; (ii) training and activities in Physical Education classes; (iii) active opportunities in the school environment; (iv) health education in school community.
3018456|NCT02439827|No Intervention|Control|Schools from the control group carried out one semester with the regular and conventional activities of a full-time school. In general, the control schools had two weekly Physical Education classes that include content and activities according to the perspective of their teachers. The conventional Programa Saúde na Escola were also performed in these schools.
3018457|NCT02439814|Experimental|Pregnenolone|
3018458|NCT02439814|Placebo Comparator|Placebo|
3018459|NCT02439801||Compliance|"Pulmonary compliance (or lung compliance) is a measure of the lung's ability to stretch and expand. In clinical practice it is separated into two different measurements, static compliance and dynamic compliance. Static lung compliance is the change in volume for any given applied pressure. Dynamic lung compliance is the compliance of the lung at any given time during actual movement of air.~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on static and dynamic compliance levels will be investigate."
3018460|NCT02439801||Pulmonary Function tests|"Pulmonary function testing has diagnostic and therapeutic roles and helps clinicians answer some general questions about patients with lung disease.~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on pulmonary function test values will be investigate."
3018461|NCT02439801||volatil agent elimination time|"Volatile anaesthetics are eliminated in the terminal phase via the lungs. A low blood:gas partition coefficient is therefore necessary for quick removal of the anaesthetic.~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on volatil agent elimination time will be investigate."
3018462|NCT02439788|Experimental|GINAKIT Cells plus chemotherapy|Patients receive chemotherapy with Fludarabine and Cyclophosphamide and then an infusion of the GINAKIT cells (iC9-GD2.CD28.OX40.zeta Natural Killer T cells)
3018463|NCT02439775|Experimental|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
3018464|NCT02439775|Sham Comparator|Sham Procedure|Renal angiography
3018465|NCT02439762|Experimental|Cognitive Behavioral Therapy (CBT)|The CBT condition will cover topics such as orienting the patient to the cognitive model of suicidal thoughts, plans and behaviors and the role of substance use in increasing the likelihood of suicidal behaviors and presenting tools to help patients better manage responses to suicide-related triggers.
3018466|NCT02439762|Active Comparator|Supportive Psycho-education (SPC)|The SPC condition is designed to match the CBT condition in terms of level of attention and the non-specific aspects of receiving support for a suicidal crisis and substance misuse. Specific content related to suicide risk will consist of general information about suicide-related resources available, while content related to substance use is based on a modified psycho-educational attention control treatment for alcoholism. The sessions will help patients to better understand the resources available during a suicidal crisis and how substance use impacts in their life. However, topics related to identifying thoughts and behaviors associated with suicidal crises and possible coping mechanisms will not be a part of the formal content of these SPC sessions.
3018467|NCT02439749|Experimental|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
3018468|NCT02439749|Sham Comparator|Sham Procedure|Renal angiography
3018469|NCT02439736||CT positive for acute intracranial lesion|
3018470|NCT02439723|Experimental|Regorafenib|All patients will be treated with 160 mg regorafenib taken orally once daily for the first 21 days of each 28-day cycle. Doses are to be taken immediately following a light breakfast. During the seven-day break period of cycle 1, patients will start pantoprazole 40 mg twice daily for 8 days
3018471|NCT02439697|Experimental|Darbepoetin alfa (NESP®) same dose|Patients on stable low dose Aranesp® (darbepoetin alfa manufactured by Amgen®) (on 20mcg preparations or on 40mcg every 2 weeks or less) will be converted to the same dose of NESP® (darbepoetin alfa manufactured by Kirin®)
3018472|NCT02439697|Experimental|Extended dosing Darbepoetin alfa (NESP®)|Patients on stable dose of Aranesp® (darbepoetin alfa manufactured by Amgen®) will be converted to higher dose preparation of NESP® (darbepoetin alfa manufactured by Kirin®) 40 or 120 mcg preparations) with extended dosing intervals. The total dose of Darbepoetin alpha remains the same.
3018473|NCT02439697|Experimental|Darbepoetin alfa (NESP®) 120mcg|Patients on Aranesp® 100 mcg preparation (darbepoetin alfa manufactured by Amgen®) will be switched to the NESP® (darbepoetin alfa manufactured by Kirin®)120mcg preparation with slight increase in dosing interval according to the conversion
3018474|NCT02439671|Experimental|Immediate intervention|Participant assigned to McGill Transition Support Program in next available session
3018475|NCT02439671|No Intervention|Waiting List control|Participant assigned to waiting list for one session prior to receiving McGill Transition Support Program in following session
3018476|NCT02439658||Dofetilide patients|Patients admitted for dofetilide initiation
3018477|NCT02439658||Sotalol patients|Patients admitted for sotalol initiation
3018478|NCT02439632|Experimental|prulifloxacin|"Prulifloxacin film-coated tablet : 600 mg/tablet, oral administration of a single tablet.~Placebo of levofloxacin hydrochloride tablet without active components."
3018479|NCT02439632|Active Comparator|Levofloxacin|"Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.~Placebo of prulifloxacin film-coated tablet, without active components."
3018480|NCT02439619|Experimental|Feasibility Trial|
3018481|NCT02439606|Active Comparator|Glide Rite Rigid Stylet group|Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.
3018482|NCT02439606|Experimental|Parker-Flex-It Directional Stylet group|Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It Directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
3018483|NCT02439593|Active Comparator|Chemoradiotherapy (CTRT) (Control Group)|"Intervention type:~Drug and Radiation~Intervention name:~Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT)~Intervention description:~Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2"
3018484|NCT02439593|Experimental|Thermochemoradiotherapy (CTRTHT)|"Intervention type:~Drug, Radiation and Hyperthermia~Intervention name:~Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT) Hyperthermia (Loco-regional hyperthermia),~Intervention description:~Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2 Hyperthermia: Weekly Local hyperthermia before radiotherapy on D1 of every week, 41-43°C for 60 mins, once every week"
3018485|NCT02439580|Experimental|Annona muricata extract|Annona muricata ethanol-soluble fraction of water extract capsule, 300 mg/day, for eight weeks
3018486|NCT02439580|Placebo Comparator|Placebo|Maltose capsule, 300 mg/day, for eight weeks
3018487|NCT02439567|Experimental|Patients|Treatment with new oral antiviral drugs for HCV infection, Fibroscan: Liver and Spleen elastography
3018488|NCT02439541|Experimental|UCMSC group|Patients in this arm received umbilical cord MSCs by intracoronary injection
3018489|NCT02439541|No Intervention|Control group|Patients in this arm did not receive any intervention.
3018490|NCT02439528|Other|Combined pulmonary fibrosis and emphysema syndrome|Genetic analysis on patients with combined pulmonary fibrosis and emphysema syndrome.
3018491|NCT02439528|Other|Pulmonary fibrosis|Genetic analysis on patients with pulmonary fibrosis.
3018492|NCT02439528|Other|Emphysema|Genetic analysis on patients with emphysema.
3018493|NCT02439528|Other|Healthy subject|Genetic analysis on healthy subject.
3018494|NCT02439515|Experimental|Biofeedback training|"It consists of 15 daily sessions of voluntary cycling training augmented by functional electrical stimulation (FES) followed by 15 daily sessions of balance training (multimodal biofeedback training). Both cycling and balance training are supported by a visual biofeedback and last about 20 minutes.~In addition to cycling or balance training, subjects perform standard physical therapy in order to reach 90 minutes of training per day."
3018495|NCT02439515|Active Comparator|Usual Care|It consists of 30 daily sessions of standard physical therapy. Each session last about 90 minutes.
3018496|NCT02439502|Experimental|open label|Upper and Lower digestive tract diagnostic. The Fuse® system is intended for diagnostic visualization of the digestive tract. The system also provides access for therapeutic interventions using standard endoscopy tools. Fuse Colonoscopies are indicated for use within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) for adult subjects and for the upper digestive tract (including the esophagus, stomach, and duodenum).
3018497|NCT02439489|Experimental|BKM120-CIS|BKM120 (60, 80 100 mg po continuously) and Cisplatin (iv 75 mg/m2)
3018498|NCT02439489|Experimental|BKM120-CARBO|BKM120 and (60, 80 100 mg po continuously) and Carboplatin (iv AUC 5)
3018499|NCT02439476||Relapsed multiple myeloma patients who are considered eligible|Patients mobilized using G-CSF+Plerixafor according to Plerixafor label in France will be included. Apheresis will be performed according to standard practice and local guidelines. Once the autologous stem cell product becomes available, patients will undergo ASCT conditioned by high dose Melphalan according to standard practice in each centre
3018500|NCT02439450|Experimental|Viagenpumatucel-L + Nivolumab|Patients will receive a combination of weekly viagenpumatucel-L (HS-110) given as injections of 1x10^7 cells and Nivolumab for 18 weeks or until treatment discontinuation.
3018501|NCT02439437|Active Comparator|Psychosocial Intervention|Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
3018502|NCT02439437|No Intervention|Treatment as usual|Treatment as usual
3018503|NCT02439424|Experimental|Reactive ATP|"all enrolled subjects will have the Reactive ATP feature in their ICD turned on"
3018504|NCT02439411||Dabrafenib|
3018505|NCT02439411||Dabrafenib plus Trametinib|Patients treated with Dabrafenib plus Trametinib
3018506|NCT02439398|Experimental|Allogeneic human cardiac stem cells|After randomization, subjects will received a suspension of allogeneic human cardiac stem cells (35 millions of CSCs - cell medicine) infused into the coronary artery responsible for the ischemic event.
3018507|NCT02439398|Placebo Comparator|Placebo: Human Serum Albumin-HSA 5%|After randomization, subjects will received placebo (which is also the cell medicine diluent). The placebo consists of a final administered volume of human serum albumin 5% in saline solution equivalent to the reconstituted cell medicine (18 mL). The placebo to be used is a marketed product (HSA 5%).
3018508|NCT02439385|Experimental|Avastin/FOLFIRI with curcumin|Patients will receive first line Avastin/FOLFIRI in combination with curcumin-containing supplement
3018509|NCT02439359|Placebo Comparator|Placebo|Placebo
3018510|NCT02439359|Experimental|CF-301|CF-301
3018511|NCT02439346|Experimental|BAY1143269 5 mg|Subjects received BAY1143269 5 milligram (mg) tablet orally, once daily (QD) from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
3018512|NCT02439346|Experimental|BAY1143269 10 mg|Subjects received BAY1143269 10 mg (2*5 mg) tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
3018513|NCT02439346|Experimental|BAY1143269 25 mg|Subjects received BAY1143269 25 mg tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
3018514|NCT02439346|Experimental|BAY1143269 50 mg|Subjects received BAY1143269 50 mg (2*25 mg) tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
3018515|NCT02439333|Active Comparator|Nasal high flow therapy|AECOPD patients with no severe respiratory insufficiency are given NHF therapy for at least 15 hours per day.
3018516|NCT02439333|Active Comparator|Conventional oxygen therapy|AECOPD patients with no severe respiratory insufficiency are given conventional oxygen therapy such as nasal catheter or venturi mask for at least 15 hours per day.
3018517|NCT02439320|Experimental|Lasmiditan 100 mg|Oral tablet. Lasmiditan 100 mg plus placebo (to match 200 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
3018518|NCT02439320|Experimental|Lasmiditan 200 mg|Oral tablet. Lasmiditan 200 mg plus placebo (to match 100 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
3018519|NCT02439320|Placebo Comparator|Placebo|Oral tablet. Placebo tablets match lasmiditan 100 mg and lasmiditan 200 mg. One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
3018520|NCT02439307|Active Comparator|Rifaximin|Patients will receive per day 1200 mg of rifaximin
3018521|NCT02439307|Placebo Comparator|Placebo|Patients will receive a placebo of rifaximin
3018522|NCT02439294|Other|Without Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
3018523|NCT02439294|Other|Mild or moderate Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
3018524|NCT02439294|Other|Severe Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
3018525|NCT02439281|Active Comparator|Ropivacaine Group|Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilaterally in the posterior rectus sheath, at the umbilicus location.
3018526|NCT02439281|Experimental|Ropivacaine/ Clonidine Group|Ropivacaine/ Clonidine Group will receive ropivacaine 0.5% (10 ml) and clonidine (2mcg/kg) injected bilaterally in the posterior rectus sheath, at the umbilicus location.
3018527|NCT02439255|Experimental|Arm I (BRB nectar)|Participants receive BRB nectar PO QD for 12 weeks.
3018528|NCT02439255|Placebo Comparator|Arm II (placebo nectar)|Participants receive placebo nectar PO QD for 12 weeks.
3018529|NCT02439216|Experimental|Dose 1|Edasalonexent 67 mg/kg/day. Capsules taken by mouth two times per day
3018530|NCT02439216|Experimental|Dose 2|Edasalonexent 100 mg/kg/day. Capsules taken by mouth three times per day
3018531|NCT02439216|Placebo Comparator|Placebo|Matching placebo
3018532|NCT02439203|Experimental|JM-010|JM-010
3018533|NCT02439203|Placebo Comparator|Placebo|Placebo
3018534|NCT02439190|Active Comparator|Treatment A: BMS-986120|BMS-986120 on specified days
3018535|NCT02439190|Active Comparator|Treatment B: Aspirin and Clopidogrel|Aspirin and Clopidogrel on specified days
3018536|NCT02439177|Experimental|Omnitest 3|Blood glucose monitoring system
3018537|NCT02439177|Experimental|Omnitest 5|Blood glucose monitoring system
3018538|NCT02439164|Experimental|Glioma group|Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.
3018539|NCT02439164|Active Comparator|non-neurosurgical group|patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.
3018540|NCT02439151|Experimental|New Strategy|New Strategy: use transpulmonary pressure guide new lung ventilation strategy in ECMO for severe ARDS patients
3018541|NCT02439151|Other|Conventional Strategy|Conventional Strategy: use conventional ventilation strategy (ELSO guide ventilation strategy) in ECMO for severe ARDS patients
3018542|NCT02439138|Experimental|GS-1101|"After the screening procedures confirms eligibility to participate in the research study. Treatment will be administered on an outpatient basis.~-- Idelalisib (GS-11-01) orally, predetermined dose twice daily per cycle for up to 6 cycles. After this initial 6 month period, for Cycles 7 and beyond, Idelalisib will be administered once a day until disease progression."
3052210|NCT02212925|Experimental|BI 14332 CL|
3018543|NCT02439125|Experimental|Eltoprazine HCl 2.5 mg|Eltoprazine HCl 2.5 mg capsules to be taken orally b.i.d. (ie, 5 mg/day) for 3 weeks
3018544|NCT02439125|Experimental|Eltoprazine HCl 5.0 mg|Eltoprazine HCl 5.0 mg capsules to be taken orally b.i.d. (ie, 10 mg/day) for 3 weeks
3018545|NCT02439125|Experimental|Eltoprazine HCl 7.5 mg|Eltoprazine HCl 7.5 mg capsules to be taken orally b.i.d. (ie, 15 mg/day) for 3 weeks
3018546|NCT02439125|Placebo Comparator|Placebo|Placebo capsules to be taken orally b.i.d. for 3 weeks
3018547|NCT02439112|Active Comparator|Exercise|Supervised exercise combined with home based exercise and physical activity
3018548|NCT02439112|No Intervention|Control|Usual care consisting of advice regarding exercise, physical activity, person lifting and moving.
3018549|NCT02439099||MDD|Currently unmedicated patients with a depressive episode in the context of unipolar major depression
3018550|NCT02439099||Control|Healthy Controls
3018551|NCT02439099||Alzheimer's Disease|Patients with Alzheimer's disease
3018552|NCT02439099||Alcoholism|Subjects with alcoholism
3018553|NCT02439099||Schizophrenia|Subjects with before and schizophrenia prior to and during medication with clozapine, olanzapine or aripiprazole
3018554|NCT02439086|Experimental|Long Course Radiotherapy|all patients diagnosed with rectal cancer, amenable for neoadjuvant chemoradiotherapy, who agree to participate in this study will undergo 2 PET-CT scans: at baseline and 9 weeks after commencing therapy.
3018555|NCT02439073|Experimental|early initiated rehabilitation|A supervised 12-week rehabilitation program, initiated two weeks post surgery, containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.
3018556|NCT02439073|Active Comparator|late initiated rehabilitation|A supervised 12-week rehabilitation program, initiated 14 weeks post surgery, containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.
3018557|NCT02439060|Experimental|Arm I (biologic mesh)|Patients undergo placement of biologic mesh during radical cystectomy and placement of the ileal conduit.
3018558|NCT02439060|No Intervention|Arm II (no intervention)|Patients undergo standard of care radical cystectomy and placement of the ileal conduit.
3018559|NCT02439047|Experimental|Biological samples collection|"-Peritoneal samples : will be collected during abdominal surgery~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum~-Adipose tissue samples : will be collected during surgery for breast reconstruction"
3018560|NCT02439034|Active Comparator|Arm A|Paracetamol
3018561|NCT02439034|Experimental|Arm B|Paracetamol + Ketoprofen
3018562|NCT02439021|Experimental|CobraPLA|Patients will randomly assign to either LMA or Cobra PLATM
3018563|NCT02439021|Experimental|LMA|Patients will randomly assign to either LMA or Cobra PLATM
3018564|NCT02439008|Experimental|Blood samples collection|"Nine blood samples will be collected in each patient before, during and after radiotherapy treatment.~Interventions :~Blood samples collection before radiotherapy (T0)~Blood samples collection during radiotherapy (T1-T3)~Blood samples collection after radiotherapy (T4-T8)"
3018565|NCT02438995|Experimental|Cetuximab with Radiation Therapy|For subjects receiving radiation therapy, the treatment schedule will consist of a re-irradiation dose of approximately 70 Gy over 6-7 weeks. This experimental treatment arm will add IA Cetuximab administration every three weeks up to 2 doses to this radiation schedule.
3018566|NCT02438995|Experimental|Cetuximab Alone|For subjects who are not candidates for re-irradiation, this experimental treatment arm will include only IA Cetuximab administration every three weeks up to 2 doses.
3018567|NCT02438982|Active Comparator|Tacrolimus|Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
3018568|NCT02438982|Experimental|Rituximab|Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If >5 B cells per mm3 , it will be measured again after 1 week. If count is still >5 B cells per mm3, third & fourth doses of rituximab will be given.
3018569|NCT02438956|Placebo Comparator|Crystalline Cellulose|looks like and is given in the same way as the experimental treatment but contains no active ingredient
3018570|NCT02438956|Experimental|Glutathione supplement|500 mg/day Setria glutathione supplement
3018571|NCT02438943|Active Comparator|Audit and Physician intervention|The intervention will comprise the feedback of the results of the baseline audit, training in motivational interviewing for clinic staff, use of a physician reminder stamp in the patients' charts and distribution of patient education cards
3018572|NCT02438943|Sham Comparator|Audit only|The intervention will comprise the feedback of the results of the baseline audit only
3018573|NCT02438930|Experimental|Motivational interviewing counseling|"The brief intervention is adapted from the OPTIONS project, which is a brief client-centered risk reduction intervention for HIV-positive patients in clinical care. The OPTIONS intervention content is based upon the IMB model of health behavior change, and uses motivational interviewing techniques to create client-centered discussions in which HIV counselors and patients collaborate to identify patients' HIV transmission risk behaviors and to mutually identify strategies and goals for reducing the patient's risky behavior.~The brief intervention will be facilitated by health care providers (nurses, lab technicians) specifically trained in the intervention protocol and will consist of 2 brief counseling sessions occurring during the same-day rapid HIV-testing procedure"
3018574|NCT02438930|Active Comparator|Standard of care counseling|Participants in this study condition will receive standard-of-care counseling that is usually implemented during HIV testing.
3018575|NCT02438917||Hepatitis C|Patients who are about to begin HCV treatment
3018576|NCT02438904|Experimental|CD34 Positive Stem Cell Infusion|Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells. If the first infusion is not effective, an additional infusion may be given 4 - 6 weeks after the first infusion.
3018577|NCT02438891|Experimental|CBT course|8-week internet-based cognitive behavioral therapy and sound therapy course
3018608|NCT02438683|Placebo Comparator|1 Placebo|2 x single doses (1x resting conditions, 1 x exercise conditions)
3018578|NCT02438878|Experimental|Baby Behavior|"The intervention is comprised of 2 components: HCP and medical staff training and participant education. The trainings will be video-based and aim to build providers' knowledge and skills to support parents' recognition and understanding of common healthy infant behaviors that may be misinterpreted by parents. The intervention does not include any specific recommendations for infant feeding, nor does it include any information related to the assessment, diagnosis or treatment for any medical condition.~After completion of the intervention trainings, health care providers and medical staff will be asked to use what they learned with the mothers of infants in their care. Short handouts for mothers will be provided as tools to reinforce the verbal education. All educational materials will be focused only on supporting parents' abilities to recognize and understand common, healthy infant behaviors."
3018579|NCT02438878|No Intervention|Control|The control arm will continue with standard well-baby visit practices during the intervention period and will be offered the option to complete the Baby Behavior online trainings for continuing education credits.
3018580|NCT02438865|Active Comparator|Single instillation group|will receive single intravesical dose of epirubicin intravesical therapy (50 mg) within 48 hours of radical nephroureterectomy with open bladder cuff excision.
3018581|NCT02438865|Active Comparator|Maintainance therapy group|will receive a single intravesical dose of epirubicin and an additional 6 weekly doses of intravesical therapy (50 mg) after surgery then monthly maintenance therapy for 1 year.
3018582|NCT02438852|Experimental|Arm I (ropivacaine hydrochloride)|Patients receive ropivacaine hydrochloride IV continuously over 72 hours after radical cystectomy.
3018583|NCT02438852|Placebo Comparator|Arm II (placebo)|Patients receive normal saline (placebo) IV continuously over 72 hours after radical cystectomy.
3018584|NCT02438826|Experimental|LY2951742|LY2951742 administered by subcutaneous (SQ) injection every 30 days for 12 weeks. Open label extension with LY2951742 administered by SQ injection every 30 days for 12 months.
3018585|NCT02438826|Placebo Comparator|Placebo|Placebo administered by SQ injection every 30 Days for 12 weeks. Open label extension with LY2951742 administered by SQ injection every 30 days for 12 months.
3018586|NCT02438800|No Intervention|Standard Counseling|Women in this arm will receive standard contraceptive counseling routinely provided during prenatal care. All participants will receive information regarding access to free LARC methods in the postpartum period.
3018587|NCT02438800|Experimental|Video Counseling|Women in this arm will receive LARC First video-based contraceptive counseling in addition to standard contraceptive counseling routinely provided during prenatal care. All participants will receive information regarding access to free LARC methods in the postpartum period.
3018588|NCT02438787|Placebo Comparator|Group 1 (placebo)|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 24 all participants (with the exception of participants who qualified for early escape [EE]) will be re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52. Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52.
3018589|NCT02438787|Experimental|Group 2 (ustekinumab 45 mg)|Ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
3018590|NCT02438787|Experimental|Group 3 (ustekinumab 90 mg)|Ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
3018591|NCT02438774|Active Comparator|Routine agriculture extension services|Routine agriculture extension services alone
3018592|NCT02438774|Experimental|Post-harvest intervention package|Post-harvest intervention package and routine agriculture extension services
3018593|NCT02438761|Experimental|PF-05212384|150 mg Intra-venous every week
3018594|NCT02438748||Patients|Individuals undergoing Repetitive Transcranial Magnetic Stimulation treatment for major depressive disorder.
3018595|NCT02438748||Controls|Healthy age-, and sex-matched control individuals.
3018596|NCT02438735||Endometrioma|Reproductive aged women diagnosed with endometrioma. Conservative follow up for six months.
3018597|NCT02438735||Healthy Controls|"Women with regular menstrual cycles and without ovarian pathology will be recruited from physicians, nurses and other staff of the same hospital.~Controls will be matched for age with the women in the endometrioma group. They will be conservatively followed up for six months."
3018598|NCT02438735||Historical controls who underwent surgical excision|20 women who underwent surgical excision of endometrioma in the same clinic had serum AMH levels measured preoperatively and on post operative sixth month. Their values will be compared with that of endometrioma group. These data were priorly published in detail (Uncu et al. 2013).
3018599|NCT02438722|Experimental|Arm I (afatinib dimaleate, cetuximab)|Patients receive afatinib dimaleate PO QD on days 1-28 and cetuximab IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3018600|NCT02438722|Active Comparator|Arm II (afatinib dimaleate)|Patients receive afatinib dimaleate as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3018601|NCT02438709|Experimental|COX-2 Inhibitor|Patients who take COX-2 inhibitor
3018602|NCT02438696|Experimental|3 BI 1060469 low dose|TF2 followed by iFF followed by TF1
3018603|NCT02438696|Experimental|1 BI 1060469 high dose|TF1 followed by TF2 followed by iFF
3018604|NCT02438696|Experimental|2 BI 1060469 high dose|iFF followed by TF1 followed by TF2
3018605|NCT02438696|Experimental|3 BI 1060469 high dose|TF2 followed by iFF followed by TF1
3018606|NCT02438696|Experimental|1 BI 1060469 low dose|TF1 followed by TF2 followed by iFF
3018607|NCT02438696|Experimental|2 BI 1060469 low dose|iFF followed by TF1 followed by TF2
3018609|NCT02438683|Experimental|2 BI 409306|2 x single doses (1 x resting conditions, 1 x exercise conditions)
3018610|NCT02438683|Experimental|3 BI 409306|2 x single doses (1 x resting conditions, 1 x exercise conditions)
3018611|NCT02438670|No Intervention|Open-Loop Care|The subjects Open-Loop Care for the 24-hour period prior to each study sessions assessed for time in the target range 70-180 mg/dL, and frequency of hypoglycemia and hyperglycemia as assessed by CGM.
3018612|NCT02438670|Experimental|PID algorithm with HMS|"Subjects will be treated with closed-loop care for 27.5h using a proportional-integral-derivative (PID) control algorithm, incorporating a personalized model of glucose-insulin dynamics.~The health monitoring system (HMS) predicts impending hypoglycemia, and will be used in both experimental arms as an important safety feature of the device."
3018613|NCT02438670|Experimental|MPC algorithm with HMS|"Subjects will be treated with closed-loop care for 27.5h using a model predictive control (MPC) control algorithm with HMS, using the identical model as in the first experimental arm.~The health monitoring system (HMS) predicts impending hypoglycemia, and will be used in both experimental arms as an important safety feature of the device."
3018614|NCT02438657|Experimental|median nerve block|"An ultrasound-guided nerve block with dextrose 5% hydrodissection is performed in each case. The first patient will receive a 2 mL local anesthetic solution. For following patients, the volume of local anesthetic depends on the clinical result of the previous patient:~increase of the volume (0.5 mL) in case of failure,~no change or decrease (0.5 mol) in case of success; a randomization is made in this case (BCD method, Stylianou M, Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics 2002;58:171-7)"
3018615|NCT02438644||Study Population|Patients who are prescribed vismodegib in Argentina, according to standard of care and in line with the current SPC and local labeling, are eligible for observation. Dosing and treatment duration of vismodegib are at the discretion of the physician in accordance with local clinical practice and local labeling. Only patients with laBCC or mBCC will be considered in the effectiveness analysis.
3018616|NCT02438618|Experimental|Minimally invasive punch technique|New surgical technique for Ponto bone anchored hearing implants
3018617|NCT02438618|Other|Hultcrantz technique|Standard surgical technique for bone anchored hearing implants
3018618|NCT02438605||Treatment group|Patients eligible for AAA repair using Nellix and willing to participate in this trial.
3018619|NCT02438579|Experimental|Nasal Irrigation & Gargling|"Videos on how to collect nasal swabs, prepare and perform hypertonic saline nasal irrigation and gargling (HSNIG) are shown. A nasal swab is collected. Participant chooses the highest concentration of hypertonic saline he/she is comfortable with (from 1.5, 2.0, 2.5 and 3.0%) and performs HSNIG under observation. Nasal swabs are to be collected first thing in the morning on 4 consecutive days and posted using the Royal Mail Safebox. Daily diaries are to be completed (online / paper form) until they document not unwell for two consecutive days; or a maximum of 14 days or if they need medical attention for the URTI. Swabs are tested in parallel to detect change in viral shedding."
3018620|NCT02438579|No Intervention|Control|"The control group are advised to manage the URTI as they normally do. A video on how to collect nasal swabs is shown. A nasal swab is collected. Nasal swabs are to be collected first thing in the morning on 4 consecutive days and posted using the Royal Mail Safebox. Daily diaries are to be completed (online / paper form) until they document not unwell for two consecutive days; or a maximum of 14 days or if they need medical attention for the URTI. Swabs are tested in parallel to detect change in viral shedding."
3018621|NCT02438566|Active Comparator|Oral Tranexamic Acid (OTA)|Subjects will be randomized 1:1 to receive either IVTA or OTA with corresponding placebos. OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
3018622|NCT02438566|Active Comparator|Intravenous Tranexamic Acid (IVTA)|Subjects will be randomized 1:1 to receive either IVTA or OTA with corresponding placebos. IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
3018623|NCT02438553|Experimental|OSTNS Neurostimulator|Combined Occipital & Supraorbital Transcutaneous Neurostimulator.
3018624|NCT02438553|Placebo Comparator|Placebo OSTNS Neurostimulator|Placebo Combined Occipital & Supraorbital Transcutaneous Neurostimulator.
3018625|NCT02438540|Experimental|metformin & acupuncture|Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and acupuncture treatment including electro body acupuncture and Auricular acupuncture for 30 minutes, 10 times, every other day, for 3 weeks.
3018626|NCT02438540|Placebo Comparator|metformin & placebo|Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and placebo acupuncture treatment, needling not in right acupoints and EA machine was switched off during 30 minutes of therapeutic time. For ear acupuncture was just used sticky layers without seeds. All placebo treatment used for 30 minutes, 10 times, every other day, for 3 weeks.
3018627|NCT02438527|Experimental|Chest Compressions Only|"After recruitment and consenting, volunteers in the chest compressions only arm will receive a chart with a description of Basic Life Support without mouth to mouth ventilations. The participants will be asked to perform Cardiopulmonary Resuscitation according to the chart for a period of 5minutes on a manikin in a simulated cardiac arrest scenario."
3018628|NCT02438527|Experimental|Standard CPR|"After recruitment and consenting, volunteers in the standard CPR arm will receive a chart with a description of Basic Life Support. The participants will be asked to perform Cardiopulmonary Resuscitation according to the chart (including the initial check, chest compressions and mouth to mouth ventilations) for a period of 5minutes on a manikin in a simulated cardiac arrest scenario."
3018629|NCT02438501|Experimental|LD-IFRT group|Chemotherapy / Low-dose involved-field radiotherapy
3018630|NCT02438501|Active Comparator|IFRT group|Chemotherapy / Involved-field radiotherapy
3018631|NCT02438475|Active Comparator|Mynx Vascular Closure System|Where subjects will have venous hemostasis attempted to be achieved using the Mynx Vascular Closure system alone
3018632|NCT02438475|Other|Manual Compression|Where patients will have venous hemostasis attempted to be achieved using manual compression alone
3018633|NCT02438462||Group with PE|"The criteria for confirmation of PE are:~PE on spiral computed tomography (CT)~proximal deep vein thrombosis on ultrasound (US)~thromboembolic events objectively confirmed during the follow up"
3018863|NCT02436850|Experimental|Intervention group|The intervention group will receive large volume thoracentesis.
3018634|NCT02438462||Group without PE|"The criteria for exclusion of PE are:~low or moderate clinical probability and D-dimer ELISA <0.50 µg/mL or <10xage in patients older than 50 years and negative follow up~low and moderate clinical probability and negative CT and negative follow up~high clinical probability and negative CT, US and follow up."
3018635|NCT02438449||Abdominal-based Autogenous Tissue (AAT)|The AAT-based breast reconstruction surgery will include any of the following techniques: pedicled transverse rectus abdominis myocutaneous (TRAM) flap, Free TRAM, muscle-sparting TRAM flap, deep inferior epigastric perforator (DIEP) flap, superficial inferior epigastric artery (SIEA) flap, and Rubens flap.
3018636|NCT02438449||Tissue Expander-Implants (TE/I)|The TE/I approach will include two-stage breast reconstruction surgery. In the initial stage, immediately after mastectomy and with or without sentinel node biopsy, an expander will be placed in the subpectoral plane and the defect closed. Two weeks after the surgery, the expansion of the TE will commence until the desired volume of the respective expander is achieved. The second stage will include removal of the TE and the placement of a permanent implant which may be either saline or gel. The delayed method will be similar to the immediate reconstruction with the exception of the incision, which will be relatively smaller as the mastectomy was performed previously with breast cavity being fully closed.
3018637|NCT02438436|Experimental|simo decoction|Patients will receive simo decoction (10 mL/piece,three times per day) and bilateral tsusanli acupoint injections with vitamin B1 two times per day, starting in the first day after resection until flatus.
3018638|NCT02438436|Active Comparator|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
3018639|NCT02438436|No Intervention|empty control|
3018640|NCT02438423|Experimental|IIV delivered by MN patch by study staff|Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff
3018641|NCT02438423|Active Comparator|IIV delivered IM by study staff|Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff
3018642|NCT02438423|Experimental|IIV delivered by MN patch by subject|Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch self-administered by subject
3018643|NCT02438423|Placebo Comparator|Placebo MN patch by study staff|Placebo delivered by microneedle patch administered by study staff
3018644|NCT02438397|Active Comparator|metformin+premix insulin|metformin:500mg tid
3018645|NCT02438397|Experimental|acarbose+premix insulin|acarbose:100mg tid
3018646|NCT02438384|No Intervention|Usual care|Pts will receive education and follow-up based on judgment of emergency provder.
3018647|NCT02438384|Experimental|Video|Patients will watch 10 minute educational video
3018648|NCT02438384|Experimental|Video plus Phone Follow-up|Patients will watch 10 minute educational video and receive phone call follow-up at 3 days to assess pain symptoms. Patients with a pain score of 4 or more will receive another call with advice from a geriatric pain specialist.
3018649|NCT02438371|Active Comparator|Single|They will receive nifedipine for the treatment of preterm labor
3018650|NCT02438371|Active Comparator|Combination|They will receive nifedipine plus indomethacin
3018651|NCT02438358|Experimental|LUM Imaging System|No dose or a single dose of LUM015 (0.5 mg/kg or 1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. The dose administered in Phase B will be determined based on results of Phase A. All subjects will have intraoperative imaging using the LUM 2.6 Imaging Device.
3018652|NCT02438345|Active Comparator|Treatment Arm 1|PRO 140: one SC dose, 350 mg, weekly for 24 weeks
3018653|NCT02438345|Placebo Comparator|Treatment Arm 2|PRO 140: one SC dose, placebo, weekly for 24 weeks
3018654|NCT02438332||NATRELLE® INSPIRA® TruForm® 1 (Smooth)|Subjects receiving primary breast augmentation with smooth NATRELLE® INSPIRA® TruForm® 1 breast implants
3018655|NCT02438332||NATRELLE® INSPIRA® TruForm® 1 (Textured)|Subjects receiving primary breast augmentation with textured NATRELLE® INSPIRA® TruForm® 1 breast implants
3018656|NCT02438332||NATRELLE® INSPIRA® TruForm® 2 (Smooth)|Subjects receiving primary breast augmentation with smooth NATRELLE® INSPIRA® TruForm® 2 breast implants
3018657|NCT02438332||NATRELLE® INSPIRA® TruForm® 2 (Textured)|Subjects receiving primary breast augmentation with textured NATRELLE® INSPIRA® TruForm® 2 breast implants
3018658|NCT02438319||patients with open angle glaucoma|patients with open angle glaucoma who had their optic discs routinely documented by fundus photography. Optic disc photographs will be analyzied by manual planimetry or automated planimetry.
3018659|NCT02438306|Experimental|CardiAMP cell therapy|Placement of an introducer guidewire, performance of a left ventriculogram, and treatment with autologous cell therapy.
3018660|NCT02438306|Sham Comparator|Sham Comparator|Placement of an introducer guidewire and performance of a left ventriculogram with no autologous cell therapy treatment.
3018661|NCT02438293||children undergoing cardiac surgery|paediatric patients with a congenital heart disease undergoing elective cardiac surgery
3018662|NCT02438280|Experimental|Active Vibration|Use of Active Vibration (AcceleDent device) 20 minutes each day during treatment with aligners
3018663|NCT02438280|Active Comparator|Sham Vibration|Use of Sham Vibration (Sham AcceleDent device) 20 minutes each day during treatment with aligners
3018664|NCT02438267||Non-NC group|Enrolled subjects who did not have evidence of NC on renal ultrasound
3018665|NCT02438267||NC group|Enrolled subjects who did have evidence of NC on renal ultrasound
3018666|NCT02438254||FH+|Young adults with at least one parent with an alcohol or other drug use disorder history.
3018667|NCT02438254||FH-|Young adults with no histories of alcohol or other drug use disorders in any parents or grandparents.
3018668|NCT02438241|Active Comparator|Conventional physiotherapy Group|Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.
3018669|NCT02438241|Placebo Comparator|Placebo TENS Group|Will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
3018670|NCT02438241|Experimental|TENS group|Patients randomized to this group will receive conventional physical therapy for the control group, and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.
3018671|NCT02438228|Other|Cardiac output measurement|
3018672|NCT02438215|Experimental|IRX4204|IRX4204 20 mg QD for Days 1-30
3018673|NCT02438202|Experimental|Electroconvulsive Therapy (ECT)|A modified Electroconvulsive Therapy Series in Patients with Alzheimer's Disease. Device for the intervention ECT will be the Thymatron IV device (Somatics, LLC. Lake Bluff, Illinois, USA).
3018674|NCT02438189|Active Comparator|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
3018675|NCT02438189|No Intervention|Predictive Low Glucose Suspend|The control algorithm will run passively and not dose additional insulin. If hypoglycemia is predicted, the system will suspend the pump.
3018676|NCT02438176|Experimental|single puncture group|single trans-septal puncture
3018677|NCT02438176|Active Comparator|conventional group|conventional bilateral groin puncture
3018678|NCT02438163|Experimental|Patients with MDD|the group of depressed patients undergo 2 Theta Burst Stimulations : iTBS and cTBS. There is one session per stimulation. Cerebral Plasticity is measured after each stimulation for each session
3018679|NCT02438163|Experimental|healthy Controls|the group of healthy controls undergo 2 Theta Burst Stimulations : iTBS and cTBS. There is one session per stimulation. Cerebral Plasticity is measured after each stimulation for each session
3018680|NCT02438150|Experimental|Intervention|Will receive hospital fire video training
3018681|NCT02438150|Placebo Comparator|Control|Will receive non-fire video training
3018682|NCT02438137|Active Comparator|Dimethyl Fumarate (Tecfidera®) capsules|The starting dose for dimethyl fumarate (Tecfidera®, http://www.tecfidera.com/pdfs/full-prescribing-information.pdf) is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day, though slower dose escalations are possible to increase tolerability, if necessary. Participants randomized to dimethyl fumarate will be instructed to take this medication twice a day with breakfast and dinner for a period of 4 months.
3018683|NCT02438137|Placebo Comparator|Placebo|The placebo is an inert product that looks like a pill and is identical to dimethyl fumarate capsules, but it contains no medicine. Participants randomized to placebo will be instructed to take placebo twice a day with breakfast and dinner for a period of 4 months.
3018684|NCT02438124|Experimental|Patient|Patient with Parkinson's Disease with walking test and neuropsychological evaluation
3018685|NCT02438124|Experimental|Contrôle|normal control with walking test and neuropsychological evaluation
3018686|NCT02438111||age related macular degeneration|metagenome AMD
3018687|NCT02438111||controls|metagenome controls
3018688|NCT02438098|Other|Rivaroxaban arm|Pharmacokinetics / Pharmacodynamics
3018689|NCT02438085||ACS patients|prospective collection of data and follow-up
3018690|NCT02438072|Other|Overall population|
3018691|NCT02438059|Experimental|Intervention|Access to the SoSu-liv website and app for 38 weeks.
3018692|NCT02438059|No Intervention|Control|No treatment for 38 weeks.
3018693|NCT02438046|Experimental|Palatal wound bandage by PRF|Intervention: In the test group (n=20 patients) the palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes
3018694|NCT02438046|Placebo Comparator|Palatal wound bandage by gelatin sponge|Intervention: The control group patients (n=20) will have their palatal wound medicated by absorbable gelatin sponge.
3018695|NCT02438033|Experimental|Treatment Arm|All patients will be implanted with the investigational device in an open-label fashion
3018696|NCT02438020|Experimental|Metformin|500 mg metformin oral intake before main meal
3018697|NCT02438020|Placebo Comparator|Placebo|Placebo tablet before main meal.
3018698|NCT02438007|Experimental|Galeterone|
3018699|NCT02438007|Active Comparator|Enzalutamide|
3018700|NCT02437994|Experimental|Pulmonary Rehabilitation|The rehabilitation program will be multidisciplinary and will include supervised exercise training (interval exercise and resistance exercises), breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability.
3018701|NCT02437994|No Intervention|Control|In addition, a control group (Group C) which will not participate in the rehabilitation program (usual care) will be include at the same time as patients in Group A and B so as to be able and independently address study objectives 2 and 3 and 4. Group C will also randomized to those into paper-pencil version and electronic version.
3018702|NCT02437968|Experimental|Wave 1|South New Jersey school service providers.
3018703|NCT02437968|Experimental|Wave 2|Philadelphia suburbs and surrounding community service providers
3018704|NCT02437968|Experimental|Wave 3|Mississauga, ON (Canada) school district service providers.
3018705|NCT02437955|Experimental|FESO4+T|Ferrous sulfate fortified bread with tea
3018706|NCT02437955|Experimental|FESO4+W|Ferrous sulfate fortified bread with water
3018707|NCT02437955|Experimental|FeFu+T|Ferrous fumarate fortified bread with tea
3018708|NCT02437955|Experimental|FeFu+W|Ferrous fumarate fortified bread with water
3018709|NCT02437942|Experimental|Biomechanics led physical therapy rehabilitation|Physical therapy exercise rehabilitation
3018710|NCT02437929||Patients receiving standard procedures|
3018711|NCT02437916|Experimental|AMG 228 monotherapy|Part 1 and Part 2 of the study will both be with single agent AMG 228 in different selected tumor types.
3018712|NCT02437903|Other|JUVÉDERM VOLUMA™ XC|Subjects will be injected with JUVÉDERM VOLUMA™ XC to their right and left facial temporal regions at the baseline visit.
3018713|NCT02437890|Placebo Comparator|Group 1|Placebo, at week 0 and every 2 weeks thereafter up to and including week 46
3018714|NCT02437890|Experimental|Group 2|"ALX-0061 Dose A at week 0 and every 4 weeks thereafter up to and including Week 44.~Placebo at week 0 and every 2 weeks thereafter up to and including week 46"
3018715|NCT02437890|Experimental|Group 3|"ALX-0061 Dose B at week 0 and every 4 weeks thereafter up to and including Week 44.~Placebo at week 0 and every 2 weeks thereafter up to and including week 46."
3018716|NCT02437890|Experimental|Group 4|"ALX-0061 Dose B at Week 0 and every 2 weeks thereafter up to and including Week 46.~Placebo at week 0 and every 2 weeks thereafter up to and including week 46."
3018717|NCT02437890|Experimental|Group 5|ALX-0061 Dose C at Week 0 and every 2 weeks thereafter up to and including Week 46.
3018718|NCT02437877||Mouth Breather|Mouth Breathers Children from 7 to 13 years old
3018719|NCT02437877||Nasal Breather|Nasal breathers children from 7 to 13 years old
3018720|NCT02437864|No Intervention|Baseline Group|Airway management (intubation) undertaken immediately after anesthetic induction, without simultaneous supplemental oxygen via nasal cannula.
3018721|NCT02437864|Experimental|With-Cannula Group|Airway management (intubation) undertaken immediately after anesthetic induction, with simultaneous supplemental oxygen via nasal cannula.
3018722|NCT02437851|Experimental|Treatment (surgery)|Participants undergo therapeutic conventional surgery to remove anal or perianal cancer (SISCCA). Any HSIL remaining is treated with the goal for complete eradication in accordance with clinician and participant preference.
3018723|NCT02437825|Experimental|octreotide treatment|The studied drug Octreotide 100 mcg will be administered I.V in the evening prior to surgery and for two weeks on a thrice daily basis.
3018724|NCT02437825|Placebo Comparator|placebo treatment|plasebo will be administrated I.V in the evening prior to surgery and two weeks on a thrice daily basis
3018725|NCT02437812|Experimental|Paclitaxel, carboplatin and metformin|"Drug: Metformin (850 mg) Drug: Carboplatin (AUC 5 or 6) Drug: Paclitaxel (80 mg/m2)~The regimen will be administered as a dose dense schedule."
3018726|NCT02437799||Caesarean section spinal anaesthesia|Dicrotic Wave analysis of pulse oximeter of Women undergoing planned caesarean section under spinal anaesthesia.
3018727|NCT02437786|Experimental|GRAZAX|GRAZAX
3018728|NCT02437773|Active Comparator|Cognitive Behavioral Therapy - Adolescents|12 Cognitive-Behavioral Therapy sessions scheduled weekly over a 12-week period.
3018729|NCT02437773|Other|Stress Management Therapy - Adolescents|"12 SMT sessions scheduled weekly over a 12-week period.~After study completion, the OCD subjects who received SMT may derive benefit for non-OCD anxiety symptoms. They will be offered a 12-week course of CBT with a study therapist to directly target OCD symptoms (i.e., a partial cross-over)."
3018730|NCT02437773|Active Comparator|Cognitive Behavioral Therapy - Adults|12 CBT sessions scheduled weekly over a 12-week period.
3018731|NCT02437773|Other|Stress Management Therapy - Adults|"12 SMT sessions scheduled weekly over a 12-week period.~After study completion, the OCD subjects who received SMT may derive benefit for non-OCD anxiety symptoms. They will be offered a 12-week course of CBT with a study therapist to directly target OCD symptoms (i.e., a partial cross-over)."
3018732|NCT02437773|Other|Healthy Control - Adolescents|Healthy control adolescents matched to gender, race and socioeconomic status (SES) with adolescent patients with OCD will be enrolled. These healthy adolescents will be scanned with fMRI before and after 12 weeks, but without any intervention (i.e., no therapy).
3018733|NCT02437773|Other|Healthy Control - Adults|Healthy control adults matched to gender, race and socioeconomic status (SES) with adult patients with OCD will be enrolled. These healthy adults will be scanned with fMRI before and after 12 weeks, but without any intervention (i.e., no therapy).
3018734|NCT02437773|Other|Optional CBT - Adolescents|OCD adolescent participants who were randomized to the SMT and have completed all study procedures will be offered an additional 12 weeks of Optional Cognitive-Behavioral Therapy.
3018735|NCT02437773|Other|Optional CBT - Adults|OCD adult participants who were randomized to the SMT and have completed all study procedures will be offered an additional 12 weeks of Optional Cognitive-Behavioral Therapy.
3018736|NCT02437747|Experimental|SRP+ Aloe Group|Scaling and root planing was done along with application of aloe vera gel as an adjunct in selected sites.
3018737|NCT02437747|Sham Comparator|SRP Group|Only scaling and root planing was done on the opposite side.
3018738|NCT02437734|Other|Coronary angiography|Selected patients will be asked to undergo Coronary angiography with cardiac magnetic resonance imaging before and after Percutaneous Coronary Intervention. Clinical data collection will happen over a 30 month period.
3018739|NCT02437721|Active Comparator|infant formula containing folic acid|Infant formula including folic acid within the range stipulated by European legislation on infant formula
3018740|NCT02437721|Experimental|infant formula containing MTHF|Infant formula including MTHF instead of folic acid
3018741|NCT02437721|No Intervention|Breast milk|non randomized reference group
3018742|NCT02437708|Experimental|REP with L-PRF|The first REP session will be performed as described by Diogenes et al. (2013). For the second REP-session a venipunction will be performed before the endodontic treatment. 2 to 4 tubes of blood will be collected per tooth. These blood samples will be put into a centrifuge for 12 minutes at 2700 rpm. Fibrin clots will be collected after centrifugation and inserted in the root canal with endodontic pluggers. Medcem Portlandcement (GmbH, Swiss) will be used instead of mineral trioxide aggregate in the second session, to prevent tooth discoloration.
3018743|NCT02437708|Active Comparator|REP|A REP will be performed on immature infected permanent teeth, as described in the protocol of Diogenes et al. (2013). Medcem Portlandcement (GmbH, Swiss) will be used instead of mineral trioxide aggregate in the second session, to prevent tooth discoloration.
3018744|NCT02437669|Experimental|Intranasal hydromorphone|Hydromorphone, intranasal. 2 mg/mL concentration. Initial dose: 0.03 mg/kg, maximum single dose 4 mg. Rescue dose: 0.015 mg/kg, maximum single dose 2 mg.
3018745|NCT02437656|Experimental|Metformin treatment|"J1 : dosimetric scan~J3 : initiation of the Metformin therapy (at a dosage of 1700 mg / day)~J10 : increasing the dose of Metformin (2550 mg / day) + initiation of the radiochemotherapy~J44 : end of the radiochemotherapy~Between J86 and J100 : surgery (discontinuation of the Metformin therapy 48 hours before surgery)"
3018746|NCT02437643|Placebo Comparator|WL-LoEX|10% Weight loss diet plus low intensity exercise (protein ~0.8g/kg). Participants will be provided one serving of dairy protein daily.
3018864|NCT02436850|No Intervention|Control group|The control group will be taped with an 18 gauge and 20 gauge venflons and drain will not be placed.
3018747|NCT02437643|Active Comparator|Pro-WL-LoEX|Protein-enhanced 10% Weight loss diet plus low intensity exercise (protein ~1.2 g/kg with > 30g per meal and >60% as dairy). Participants will be provided at least 8 servings of dairy protein daily.
3018748|NCT02437630||Patients with COPD|Patients with COPD aged >40 years with Gold stage II as measured by standard lung function testing or worse and at least 10 pack year history of smoking who will have insertion of an oesophageal balloon to measure intra-thoracic pressure, fibre-optic laryngoscopy to observe movement of the larynx during respiration and facemask pneumotachograph measurement of airflow and volumes at the mouth. The facemask which will be used to deliver a positive airway pressure (continuous positive airways pressure(CPAP) This will provide face mask CPAP with variation of mouth pressure with CPAP
3018749|NCT02437630||normal subjects without copd|Subjects without COPD and normal lung function as measured by standard lung function tests who will have insertion of an oesophageal balloon to measure intra-thoracic pressure, fibre-optic laryngoscopy to observe movement of the larynx during respiration and facemask pneumotachograph measurement of airflows and volumes at the mouth which will be used to deliver a positive airway pressure (continuous positive airways pressure CPAP) This will provide face mask CPAP with variation of mouth pressure with CPAP
3018750|NCT02437617||Control Group #1|Participants who have had tumor molecular analysis performed with the similar clinical characteristics and genomic aberrations but who receive therapy not matched to their aberrations, or who have received results from Foundation Medicine that fail to demonstrate any molecular alteration.
3018751|NCT02437617||Control Group #2|Participants from historical archives of MD Anderson, no older than two years, who received therapy not matched to their aberrations and are matched not only on the basis of the clinical characteristics, but also, as much as possible, on the basis of genomic aberrations.
3018752|NCT02437617||Matched Targeted Therapy Group|Participants with tumor aberrations who received matched targeted therapy.
3018753|NCT02437604|Experimental|Treatment A|Fp MDPI 200 mcg, 1 inhalation
3018754|NCT02437604|Experimental|Treatment B|FS MDPI 200/12.5 mcg, 1 inhalation
3018755|NCT02437604|Active Comparator|Treatment C|fluticasone propionate (FLOVENT DISKUS) 250 mcg, 2 inhalations
3018756|NCT02437604|Active Comparator|Treatment D|fluticasone propionate/salmeterol (ADVAIR DISKUS) 500/50 mcg, 1 inhalation
3018757|NCT02437591|Experimental|fidaxomicin|tablet twice daily
3018758|NCT02437578||Infertile couples|Infertile couples referred to Dansk fertilitetsklinik (Danish Fertility clinic) for IUI, IVF and ICSI treatment
3018759|NCT02437565|Active Comparator|Control|Placement of stainless steel crown under general anesthesia without the use of an occlusal template
3018760|NCT02437565|Experimental|Impression|Placement of stainless steel crown under general anesthesia with the use of an occlusal template prepared after making an impression of the teeth using a fast setting polyvinyl siloxane material
3018761|NCT02437552|Placebo Comparator|Control group: routine physiotherapy|Are patients who carry out the routine already established the Unit, consisting of the first post surgery, the patient lying down doing the breathing exercises, active exercises ends and active-assisted upper (UL) and lower limbs (LL),
3018762|NCT02437552|Active Comparator|Intervention group: ergometer cycle exercise|Are the patients who will carry out the exercises routine over the cycle ergometer twice daily from 3 PO for 5 minutes with its progressiveness at discharge for ward for 10 minutes
3018763|NCT02437539|Experimental|68Ga-NOTA-AE105 PET|One injection of 68Ga-NOTA-AE105 (app. 200 MBq) followed by 3 PET/CT scans 10 minutes, 1 hour and 2 hours post injection
3018764|NCT02437526|Experimental|Treatment interruption|Antiretroviral therapy will be discontinued under close laboratory monitoring and clinical supervision.
3018765|NCT02437513||NewBreez|"The study group is composed only of patients who have already opted to receive the NewBreez device as part of their routine care from their physician.~Patients who have the device implanted, and consent to be part of the 12 week observational study, will be enrolled and have standard clinical parameters measured over the 12 week period as well as complete quality of life assessments in the form of patient questionnaires."
3018766|NCT02437487|Experimental|SER-109|SER 109 (1 × 108 SporQs)
3018767|NCT02437487|Placebo Comparator|Placebo|Placebo
3018768|NCT02437474||Omnivorous diet|Participants are consuming meat, fish, milk/milk products, eggs, plant products.
3018769|NCT02437474||Lacto-ovo-vegetarian diet|Participants are consuming milk/milk products, eggs, plant products but no meat, fish or by-products.
3018770|NCT02437474||Vegan diet|Participants are consuming plant products but no meat, fish, milk/milk products, eggs or by-products as well as honey.
3018771|NCT02437461|Active Comparator|single dose 20 mg|Intraarticular injection of triamcinolone hexacetonide
3018772|NCT02437461|Experimental|single dose 40 mg|Intraarticular injection of triamcinolone hexacetonide
3018773|NCT02437448||Idiopathic lung fibrosis|20 IPF patients
3018774|NCT02437448||Controls|20 subjects with no apparent lung disease and normal lung function testing. Matched for gender, age and smoking history.
3018775|NCT02437435|Experimental|Reproductive Technique Gimilio|"Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.~Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.~Hand therapist will keep in touch at all times on the suprapubic region of the patient."
3018776|NCT02437435|Placebo Comparator|Placebo technique|The researcher puts his right hand on the right shoulder of the patient for 20 times Metronome.
3018777|NCT02437422|Experimental|SANGUINATE|Single infusion of SANGUINATE
3018778|NCT02437396||Treatment naive GD1|Type 1 Gaucher disease subjects who are naive to any treatment
3018779|NCT02437396||Treated GD1|Type 1 Gaucher disease who are stable on therapy (on the specific ERT and/or SRT and specific dose for at least 2 years)
3018780|NCT02437396||Healthy Volunteers|Age matched healthy controls
3018781|NCT02437383|Active Comparator|Propranolol ER|Propranolol hydrochloride extended release (ER) capsules; 60 mg (Visit 1 and Visit 4); 120 mg (Visit 2 and Visit 3) given orally as: 60 mg once/day (Visit 1 and Visit 4) and 60 mg twice/day (Visit 2 and Visit 3).
3018782|NCT02437383|Placebo Comparator|Placebo|Capsules, identical in appearance to active comparator (propranolol), to be administered orally in exactly the same manner as propranolol at Visit 1 (once/day), Visit 2 (twice/day), Visit 3 (twice/day), and Visit 4 (once/day).
3018783|NCT02437370|Experimental|Arm A (pembrolizumab, docetaxel)|pembrolizumab IV over 30 minutes on day 1 and docetaxel IV over 60 minutes on day 1.
3018784|NCT02437370|Experimental|Arm B (pembrolizumab, gemcitabine hydrochloride)|pembrolizumab IV as in Arm A and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8.
3018785|NCT02437357|Experimental|Metacognitive Training|D-MCT is conceptualized as a variant of cognitive behavioral therapy (CBT) that uses a metacognitive perspective to focus on the modification of cognitive biases by using creative and engaging strategies (e.g., multimedial presentation). The training seeks to enable group members to recognize and correct the often automatic and unconscious depressive thought patterns, in part by viewing this depressive thought process at a distance (i.e., depersonalizing). Besides dysfunctional assumptions about one's thought processes, more general cognitive biases, which have been identified by basic research are at the core of the D-MCT. Finally, dysfunctional coping-strategies (i.e., thought suppression, rumination as problem-solving) are discussed and modified.
3018786|NCT02437357|Active Comparator|Positivity Training|"Positivity Training (PT) is a euthymic therapy group based on cognitive behavioral therapy (CBT) with a focus on the education and training of sensual enjoyment and pleasure. Aim of the training is to reduce depressive symptomatology by increasing the ability to enjoy and to (re-)install positive sensory experiences. Therefore, group members are informed about the impact of positive experiences on well-being and the awareness of the five senses is trained in different practical exercises (hearing, sight, smell, taste, and touch)."
3018787|NCT02437344|Experimental|CI-581aa|CI-581aa will be administered 24 hours after last opioid use, and followed by naltrexone dosing
3018788|NCT02437331||advanced heart failure|the patients was diagnostic on Chronic heart failure with NYHA class 3 and 4, AHA stage D, or LVEF<40%.
3018789|NCT02437318|Experimental|fulvestrant + alpelisib|Alpelisib (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)
3018790|NCT02437318|Placebo Comparator|fulvestrant + placebo|Placebo (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)
3018791|NCT02437305|Experimental|ABCDEs of Melanoma Skin Cancer|"A modified melanoma educational intervention that uses the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation but also incorporates the nomenclature melanoma skin cancer; indicates that melanoma is relevant for everyone regardless of race and ethnicity; includes images of melanoma on ethnic skin; informs people of the likelihood of melanoma developing in acral, subungual and mucosal surfaces; and provides guidance on self-skin examinations."
3018792|NCT02437305|Active Comparator|ABCDEs of Melanoma|"A conventional melanoma educational intervention using the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation."
3018793|NCT02437292|Experimental|Ischemic compression with stretching|The participants will receive the ischemic compression with stretching onto the trapezius muscle
3018794|NCT02437292|No Intervention|Control|Rest on the bed
3018795|NCT02437279|Active Comparator|Arm A|Post-surgery infusion for 12 weeks with the combination of ipilimumab+nivolumab
3018796|NCT02437279|Active Comparator|Arm B|A split design 6 weeks upfront surgery and 6 weeks post-surgery infusion with the combination of ipilimumab+nivolumab
3018797|NCT02437266|Experimental|Scapular mobilization|The participants will receive a twenty minutes session of scapular mobilization onto the scapular
3018798|NCT02437266|No Intervention|Control|Rest on the bed for twenty minutes
3018799|NCT02437253|Experimental|Adalimumab first, then Placebo|Participants first received Adalimumab 20 mg subQ every other week (weight 15 to <30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks.
3018800|NCT02437253|Experimental|Placebo first, then Adalimumab|Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to <30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.
3018801|NCT02437240|Experimental|Pilates-based CPT|incorporated the concept of pilates training into cardiopulmonary physical therapy after cardiac surgery
3018802|NCT02437240|Active Comparator|Traditional CPT|usual bed side cardiopulmonary physical therapy after cardiac surgery
3018803|NCT02437227|Experimental|Experimental: CCT3833|The starting dose of CCT3833 is 20 mg, taken as two 10 mg capsules. The starting schedule is a once daily continuous dosing schedule, but other dosing regimens may be considered depending on tolerability and exposures.The first dose of continuous dosing defines Cycle 1 Day 1. All treatment cycles have a duration of 28 days.
3018804|NCT02437214|Experimental|Use of music for anxiety in children|Children in the Exp group received the usual medical care in combination with the intervention. The intervention was started by the patients nurse without the knowledge of the research associate. In the intervention group, music was played until the CT scan was completed.
3018805|NCT02437214|No Intervention|Control|Children in the Con group received the usual medical care without listening to the music intervention.
3018806|NCT02437201|Experimental|Liberty Group|Weekly intensive support group for women with children who have suffered or are still suffering from domestic abuse (DA).
3018807|NCT02437201|No Intervention|Control group|
3018808|NCT02437188|Experimental|ACT plus TAU|"Participants randomized to receive ACT will be scheduled to attend a 1-day training session before their preoperative clinic visit. The intervention will incorporate both experiential learning and didactic content, will include a summary of the main concepts at the end of the day, and a manual of the main concepts will be sent home with participants so they can practice the exercises prior to and after surgery. Participants will also receive an individualized phone call booster intervention 2 weeks after surgery to address any issues and reinforce the information that was given during the workshop. This will be done to facilitate the participant's use of the skills during the postoperative period."
3018865|NCT02436837|Active Comparator|young|20 to 30 years old individuals used as a comparator for elderly group
3018866|NCT02436837|Experimental|elderly|target of treatment to improve the balance.
3052211|NCT02212925|Placebo Comparator|Placebo|
3018809|NCT02437188|No Intervention|TAU|Current pre-surgery treatment includes a nurse-led patient education class covering the post-operative course and what to expect for pain control and recovery. Patients may be taking analgesia (i.e. opioids and/or non-opioids) preoperatively for a chronic pain condition and are prescribed analgesics, sedatives and/ or anxiolytics immediately prior to surgery. Intraoperatively, regional (i.e., spinal and femoral) anesthesia and analgesia is given and patients receive opioids, non-opioids, anticonvulsants and/or anxiolytics during the immediate postoperative period. Other pain treatments may be used, such as cryotherapy, music therapy, relaxation, imagery, etc. Patients are sent home with analgesia (often a combination medication of an opioid and acetaminophen) for breakthrough pain.
3018810|NCT02437175|Placebo Comparator|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
3018811|NCT02437175|Experimental|Trace elements|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
3018812|NCT02437162|Placebo Comparator|Group 1 (Placebo)|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 24 all participants (with the exception of participants who qualified for early escape [EE]) will be re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100. Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 100.
3018813|NCT02437162|Experimental|Group 2 (Ustekinumab 45 mg)|Ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by every 12 week dosing, with the last administration of study agent at Week 100. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 100.
3018814|NCT02437162|Experimental|Group 3 (Ustekinumab 90 mg)|Ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 100.
3018815|NCT02437149|Experimental|Video and Brochure|Real stories video presentation and a brochure with information about distracted driving will be given to the participant.
3018816|NCT02437149|Experimental|Power Point and Brochure|Brief power point presentation and a brochure with information about distracted driving will be given to the participant.
3018817|NCT02437149|Experimental|Brochure Only|Only a brochure with information about distracting driving will be given to the participant.
3018818|NCT02437136|Experimental|Ph 2 NSCLC (squamous or adeno)|Cohort 1: Patients with Non-Small Cell Lung Cancer, with squamous cell or adenocarcinoma histology who have not been treated with a PD-1 or PD-L-1 blocking antibody (entinostat + pembrolizumab)
3018819|NCT02437136|Experimental|Ph 2 NSCLC pre-treated PD-1/LD-L1|Cohort 2: Patients with NSCLC (any histology) who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)
3018820|NCT02437136|Experimental|Ph 2 Melanoma pre-treated PD-1/PD-L1|Cohort 3: Patients with melanoma who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)
3018821|NCT02437136|Experimental|Ph 2 Mismatch Repair-Proficient CRC|Cohort 4: Patients with CRC (mismatch repair-proficient) who have not been previously treated with a PD-1 or PD-L1 blocking antibody
3018822|NCT02437123|Experimental|The Cedar Project mHealth Intervention|The Cedar Project mHealth intervention consists of a package of culturally-safe supports, including a mobile phone and long-distance cellular plan, weekly two-way text messaging, and support from community-based Cedar Advocates.
3018823|NCT02437123|No Intervention|Comparison group|The comparison group will be sampled from The Cedar Project, an ongoing cohort study of young Indigenous people who use drugs under its existing informed consent with no change whatsoever to their participation in the overall study.
3018824|NCT02437097|Experimental|Aerobic Exercise|Participants will perform 30 minutes of cycling at an intensity of 60 to 70% of maximum heart rate based on 220 - their age. The aerobic exercise will utilize a Monarch 818E Monarch Lower Body Ergometer (Monark Exercise, Stockholm, Sweden). Participant's heart rate will be monitored using Polar heart rate monitor.
3018825|NCT02437097|Experimental|Video Gaming|Participants will play Brain Age: Train Your Brain in Minutes a Day! on Nintendo 3DS for 30 minutes in a seated resting position.
3018826|NCT02437097|Experimental|Aerobic Exercise and Video Gaming|Participants will perform 30 minutes of cycling at an intensity of 60 to 70% of maximum heart rate based on 220 minus their age on a Monarch ergometer while playing Brain Age: Train Your Brain in Minutes a Day! on a Nintendo 3DS. Participant's heart rate will be monitored using Polar heart rate.
3018827|NCT02437097|Placebo Comparator|Control|Participants will sit quietly for 30 minutes
3018828|NCT02437084|Other|Elevated LDL|Those with elevated LDL =/> 130 mg will receive 40 mg of atorvastatin
3018829|NCT02437084|Other|Elevated LDL and Triglycerides|Those with elevated LDL =/> 130 mg and elevated triglycerides =/> 150 mg will receive 40 mg of atorvastatin
3018830|NCT02437071|Experimental|Pembrolizumab Plus Radiotherapy|pembrolizumab plus RT in subjects with metastatic CRC who are undergoing RT as standard therapy
3018831|NCT02437071|Experimental|Pembrolizumab Plus Ablation|pembrolizumab plus ablation in subjects with metastatic CRC who are undergoing ablation as standard therapy
3018832|NCT02437045|Active Comparator|Meropenem|Meropenem 1g every 8 hrs IV to day 4
3018833|NCT02437045|Experimental|Piperacillin-tazobactam combination product|Piperacillin tazobactam 4.5g every 6 hrs IV to day 4
3018867|NCT02436824|Experimental|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days.
3018868|NCT02436824|Placebo Comparator|Placebo patch|Identical in size and shape to the AB001 patch. Two placebo patches will be applied to the low back once daily for 14 days.
3018903|NCT02436577|Experimental|Sequence BAC|Treatment B in Period 1, Treatment A in Period 2 and Treatment C in Period 3
3018834|NCT02437032|Active Comparator|Group 1: recombinant FSH|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of rFSH (Gonal-F®, Merck-Serono, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously
3018835|NCT02437032|Active Comparator|Group 2:urinary FSH|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of urinary FSH (uFSH) (Fostipur®, Angelini, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously.
3018836|NCT02437032|Active Comparator|Group 3: with hMG|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of hMG (HMG-Lepori®, Angelini, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously, and transvaginal oocyte retrieval was performed 36 h later.
3018837|NCT02437006|No Intervention|rehabilitation|half an hour physical and half an hour occupational therapy in rehabilitation
3018838|NCT02437006|Experimental|Low-intensity exercise|Low-intensity exercise plus rehabilitation
3018839|NCT02437006|Experimental|High-intensity exercise|High-intensity exercise plus rehabilitation
3018840|NCT02436993|Experimental|Carboplatin+Paclitaxel+Bevacizumab (HER2-)|Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Bevacizumab every other week, 5 doses
3018841|NCT02436993|Experimental|Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)|Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Trastuzumab weekly 12 doses Pertuzumab every 3 weeks, 4 doses
3018842|NCT02436980|Active Comparator|tramadol|1mg/kg of tramadol drop (Contramal® drop, Abdi Ibrahim Ilaç San.,istanbul) was administered orally in 10 mL of cherry juice without particles in preparation room before intervention, Group T who were separated randomly to two premedication groups.
3018843|NCT02436980|Active Comparator|midazolam|0.15 mg/kg of midazolam (Dormicum®, ampoule, Roche Products A.Ş., istanbul) was administered orally in 10 mL of cherry juice without particles in preparation room before intervention, to Group M who were separated randomly to two premedication groups.
3018844|NCT02436954|Placebo Comparator|CO2 insufflation at intra-abdominal pressure 8 mmHg|CO2 insufflation with intra-abdominal pressure 8 mmHg during deep-NMB
3018845|NCT02436954|Active Comparator|CO2 insufflation at intra-abdominal pressure 12 mmHg|CO2 insufflation with intra-abdominal pressure 12 mmHg during deep-NMB
3018846|NCT02436928|Experimental|AT-501 High Dose vaccine|Inactivated H7N9 High Dose Antigen
3018847|NCT02436928|Experimental|AT-501 High Dose vaccine with Adjuvant|Inactivated H7N9 High Dose Antigen with Adjuvant
3018848|NCT02436928|Experimental|AT-501 Low Dose vaccine|Inactivated H7N9 Low Dose Antigen
3018849|NCT02436928|Experimental|AT-501 Low Dose vaccine with Adjuvant|Inactivated H7N9 Low Dose Antigen with Adjuvant
3018850|NCT02436915|Experimental|Real tDCS|"The real tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation (tDCS) at a target current intensity of 1.5 mA."
3018851|NCT02436915|Sham Comparator|Sham tDCS|"The sham tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation, except current will only be applied for the first 60 seconds of each session."
3018852|NCT02436902|Experimental|TACE|Transarterial chemoembolization (TACE) is performed two to four weeks after hepatic resection.
3018853|NCT02436902|Active Comparator|sorafenib|Patients will receive sorafenib at a dose of 400 mg twice daily after 2 weeks of hepatic resection.
3018854|NCT02436902|Other|TACE plus sorafenib|Patients will receive sorafenib at a dose of 400 mg twice daily after 2 weeks of hepatic resection. At the same time, TACE is performed two to four weeks after hepatic resection.
3018855|NCT02436902|No Intervention|empty control|This group patients will receive best supportive care.
3018856|NCT02436889|Experimental|Mirabegron|Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
3018857|NCT02436889|Active Comparator|Tolterodine Tartrate|Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
3018858|NCT02436876|Experimental|Cohort 1|Single, intra-wound local administration of MBN-101; dosage = 0.5 µg/cm2; randomized 3:1 with placebo
3018859|NCT02436876|Experimental|Cohort 2|Single, intra-wound local administration of MBN-101; dosage = 1.5 µg/cm2; randomized 3:1 with placebo
3018860|NCT02436876|Experimental|Cohort 3|Single, intra-wound local administration of MBN-101; dosage = 5.0 µg/cm2; randomized 3:1 with placebo
3018861|NCT02436863||Surgical perfomance (Laminoplasty)|After the lesions inside the spinal canal were surgical removed by laminectomy, the lamina and spinous process were replanted with titanium plates and screws.
3018862|NCT02436863||Surgical perfomance (Internal fixation)|After the lesions inside the spinal canal were surgical removed by laminectomy, the pedicle screws (Thoracic and lumbar vertebra) or lateral mass (Cervical vertebra) and sticks were used for internal fixation.
3019045|NCT02435524|Experimental|A&T Intervention Communes|
3018869|NCT02436811|Experimental|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
3018870|NCT02436811|Experimental|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
3018871|NCT02436811|Experimental|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
3018872|NCT02436798||Pediatric patients|"Children <6 months to 18 years of age receiving ondansetron for management of:~Post-operative nausea and vomiting~Chemotherapy-induced nausea and vomiting"
3018873|NCT02436798||Female patients|"Pregnant patients or women of a reproductive age (18-45 years) receiving ondansetron for management of:~Hyperemesis gravidarum~Post-operative nausea and vomiting"
3018874|NCT02436785|Active Comparator|Music Therapy|The music therapy group will run for approximately an hour (twice a week) and will involve in-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.
3018875|NCT02436785|Active Comparator|Music Listening|The control group will also run for approximately an hour (twice a week) and will involve listening to relaxing music on a CD player.
3018876|NCT02436759|Experimental|RVL-1201|RVL-1201 Ophthalmic Solution 0.1% 1 drop per eye QD for 6 weeks
3018877|NCT02436759|Placebo Comparator|RVL-1201 Vehicle Placebo|RVL-1201 Ophthalmic Solution vehicle (placebo) 1 drop per eye QD for 6 weeks
3018878|NCT02436746||Neurofibromatosis type I (NF1)|Monozygotic twin pairs with genetically confirmed Neurofibromatosis type I
3018879|NCT02436746||Tuberous Sclerosis Complex (TSC)|Monozygotic twin pairs with genetically confirmed Tuberous Sclerosis Complex
3018880|NCT02436733|Experimental|Immediate pleurectomy/decortication|immediate P/D followed by three cycles of pemetrexed 500mg/m2 IV and cisplatin 75 mg/m2 IV, both drugs given on day 1, every three weeks for non-progressing patients
3018881|NCT02436733|Active Comparator|Delayed pleurectomy/decortication|three cycles of pemetrexed 500mg/m2 IV and cisplatin 75 mg/m2 IV, both drugs given on day 1, every three weeks followed by P/D, for non-progressing patients.
3018882|NCT02436707|Active Comparator|R-GDP|"Rituximab - 375 mg/m2 IV, 1.5 - 6 hours D1 (prior to cisplatin);~Gemcitabine - 1000 mg/m2, IV 30 min D1, D8;~Dexamethasone - 40 mg daily PO D1 - D4;~Cisplatin - 75 mg/m2 IV, 1 hour D1;"
3018883|NCT02436707|Experimental|Ibrutinib plus R-GDP (ACCRUAL COMPLETE)|"Ibrutinib 560 mg PO -- D1 - D21~Rituximab 375 mg/m2 IV 1.5 - 6 hours D1 (prior to cisplatin)~Gemcitabine 1000 mg/m2 IV 30 min D1, D8~Dexamethasone 40 mg daily PO -- D1 - D4~Cisplatin 75 mg/m2 IV 1 hour D1"
3018884|NCT02436707|Experimental|R-DICEP|"Rituximab 375 mg/m2 IV 1.5-6hrs Day 1 and Day 5 prior to Cisplatin~Mesna 1.75 g/m2 IV 24 hour Cycle 1, Day 2, Day 3 and Day 4~Cyclophosphamide, 1.75 g/m2 IV 2 hours, Day 2, Day 3 and Day 4~Etoposide 350 mg/m2 IV 2 hours, Day 2, Day 3 and Day 4~Cisplatin 35 mg/m2 IV, 2 hours, Day 2, Day 3 and Day 4~G-CSF 300 mcg (<60kg); 480 mcg (60-90kg); 600 mcg (>90kg); SC, Daily, starting Day 15 until apheresis completed."
3018885|NCT02436694|Active Comparator|Local Anesthetic ropivacaíne|Femoral nerve block with ropivacaine 0.375% and sciatic nerve block with ropivacaine 0.2%
3018886|NCT02436694|Experimental|Perineural Dexamethasone|Femoral nerve block with ropivacaine 0.375% and perineural dexamethasone and sciatic nerve block with ropivacaine 0.2% and perineural dexamethasone
3018887|NCT02436681|Other|MIROMESH|Single-arm study. MIROMESH will be used in the surgical repair of hiatal hernias.
3018888|NCT02436668|Active Comparator|Ibrutinib|"Ibrutinib daily in combination with:~Nab-paclitaxel and gemcitabine"
3018889|NCT02436668|Placebo Comparator|Placebo|"Placebo daily in combination with:~Nab-paclitaxel and gemcitabine"
3018890|NCT02436655|No Intervention|conventional drug treatment|conservative treatment and watchful waiting till symptom onset (then aortic valve replacement). Other indications for aortic valve replacement include reduced left ventricular systolic function
3018891|NCT02436655|Active Comparator|elective aortic valve replacement|elective aortic valve surgery (replacement) within 4 weeks after randomization
3018892|NCT02436629|Active Comparator|Nitrate-rich concentrated beetroot juice|Dietary supplement: 800 mg of nitrate in 140 mL of concentrated beetroot juice (Beet-IT)
3018893|NCT02436629|Placebo Comparator|Nitrate-depleted conc. beetroot juice|Placebo: 140 mL of nitrate-depleted concentrated red beetroot juice
3018894|NCT02436616||EEG monitoring|All subjects enrolled in this observational study will undergo EEG monitoring using the microEEG device.
3018895|NCT02436603|Other|Nutrition/Mind-Body Coaching|The intervention will consist of weekly group sessions lasting 75-90 minutes during which participants will receive training in the FODMAP diet and mind-body skills.
3018896|NCT02436603|No Intervention|Waitlist Control Group|Waitlist subjects. At the end of the 12-week study period, waitlist subjects will be offered the four-week nutrition and mind-body intervention.
3018897|NCT02436590|Active Comparator|Active PEMF|Subjects have a 2 out of 3 chance to get the active device which emits a Pulsed Electromagnetic Field (PEMF) from the Physio-Stim Model 3315OA device. Double blind randomization
3018898|NCT02436590|Placebo Comparator|Control/no PEMF|Subjects have a 1 out of 3 chance of getting the control/placebo device which does not emit Pulsed Electromagnetic Field (PEMF) from the Physio-Stim Model 3315A device. Double blind randomization
3018899|NCT02436577|Experimental|Sequence ABC|Treatment A in Period 1, Treatment B in Period 2 and Treatment C in Period 3
3018900|NCT02436577|Experimental|Sequence BCA|Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3
3018901|NCT02436577|Experimental|Sequence CAB|Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3
3018902|NCT02436577|Experimental|Sequence ACB|Treatment A in Period 1, Treatment C in Period 2 and Treatment B in Period 3
3018904|NCT02436577|Experimental|Sequence CBA|Treatment C in Period 1, Treatment B in Period 2 and Treatment A in Period 3
3018905|NCT02436551||Pregnant women in Tajikistan|
3018906|NCT02436538||Mullerian duct anomalies|Anti Mullerian hormone level; Mullerian duct anomaly type
3018907|NCT02436525|Active Comparator|Group I:|will be treated using conventional stainless steel orthodontic brackets ligated with stainless steel ligature. Oromco - USA.
3018908|NCT02436525|Experimental|Group II|: will be treated using passive self-ligating stainless steel orthodontic brackets Oromco - USA.
3018909|NCT02436525|Experimental|Group III:|will be treated by active self-ligating stainless steel orthodontic brackets Oromco - USA .
3018910|NCT02436512|Experimental|Inhaled Nitric Oxide|Active Comparator: Nitric Oxide
3018911|NCT02436499|Experimental|Treatment with Botox and fMRI screening|"Following baseline screening, participants will receive two subsequent treatments with botulinum-A toxin, each separated by 12 weeks. Participants will receive standardized botulinum-A toxin dosing for chronic migraine prophylaxis, comprised of 155 total units given at 31 specified sites across 7 head/neck muscles (protocol to be explicitly described in full protocol). Second dose of botulinum-A toxin will either be maintained at 155 total units as dosed initially, or be increased to 195 total units, depending on response to clinical questionnaires and examination to evaluate response and efficacy (to be described in full protocol, consistent with the Follow-the-Pain Injection Paradigm)."
3018912|NCT02436486|Placebo Comparator|Placebo|
3018913|NCT02436486|Experimental|Idalopirdine 120 mg|Therapeutic dosages
3018914|NCT02436486|Experimental|Idalopirdine 360 mg|Supra-therapeutic dosages
3018915|NCT02436486|Active Comparator|Moxifloxacin 400 mg|Positive Control
3018916|NCT02436473|Experimental|Test fluoride toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods
3018917|NCT02436473|Placebo Comparator|Fluoride free (0ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
3018918|NCT02436473|Active Comparator|Low dose fluoride (250ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
3018919|NCT02436473|Active Comparator|Fluoride (1150ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
3018920|NCT02436460|Experimental|AbGn-168H|AbGn-168H will be administered once weekly for four weeks via intravenous infusion.
3018921|NCT02436447|Experimental|Normal renal function|
3018922|NCT02436447|Experimental|Mild renal impairment|
3018923|NCT02436447|Experimental|Moderate renal impairment|
3018924|NCT02436447|Experimental|Severe renal impairment|
3018925|NCT02436434|Active Comparator|pulsed radiofrequency|Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
3018926|NCT02436434|Sham Comparator|Sham pulsed radiofrequency|Sham intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in controlled joint
3018927|NCT02436421|Other|Atrial Fibrillation BPA|The alert will notify providers when patients with atrial fibrillation are not on anticoagulation
3018928|NCT02436421|Other|Hypertension BPA|The alert will notify providers when patients have elevated blood pressure
3018929|NCT02436421|Other|Atrial Fibrillation and Hypertension BPA|Providers in this arm will receive both alerts
3018930|NCT02436408|Experimental|Vismodegib|150mg taken orally once daily
3018931|NCT02436395|Experimental|Group A (povidone-iodine group)|"The surgical incision is washed by the mixed solution with 400ml 9% normal saline and 100ml 5% povidone-iodine solution.~We declare that we have no conflicts of interest."
3018932|NCT02436395|Experimental|Group B (normal saline group)|"The surgical incision is washed by the 500ml 0.9% normal saline.~We declare that we have no conflicts of interest."
3018933|NCT02436382|No Intervention|Ambient Temperature of 67F|These patients will have an operating room temperature of 67F for cesarean delivery, the standard of care at our institution.
3018934|NCT02436382|Active Comparator|Ambient Temperature of 73F|These patient will have an operating room temperature of 73F for cesarean delivery, a temperature more consistent with WHO recommendations.
3018935|NCT02436369|Experimental|low fat yogurt enriched with flaxseed|200 gr low fat yogurt enriched with 30 gr flaxseed
3018936|NCT02436369|Placebo Comparator|low fat yogurt|200 gr low fat yogurt
3018937|NCT02436356|Active Comparator|Distal Radius Fracture Operative Group|Fracture group patients will undergo DXA and MRI scans, along with Osteoprobe indentation.
3018938|NCT02436356|Active Comparator|Healthy Volunteers (Non Fracture Group)|Healthy volunteers will undergo DXA and MRI scans.
3018939|NCT02436356|Active Comparator|Distal Radius Fracture Non-operative Group|Fracture group patients will undergo DXA and MRI scans, but will not undergo Osteoprobe indentation.
3018940|NCT02436343||obese pregnant women|"pregnant women wit body mass index more than or equal to 30 kg/m2 will be subjected to four serial echocardiograms in the 3 trimesters of pregnancy and in the postpartum state.~Height, weight, systolic and diastolic blood pressures will be measured at each echocardiographic evaluation."
3018941|NCT02436343||lean pregnant women|"pregnant women wit body mass index less than or equal to 25kg/m2 will be subjected to four serial echocardiograms in the 3 trimesters of pregnancy and in the postpartum state.~Height, weight, systolic and diastolic blood pressures will be measured at each echocardiographic evaluation."
3018942|NCT02436330|Experimental|Exergaming and Didactic health teaching|Participation of child and parent/guardian in 6 months of weight management programming consisting of exergaming combined with didactic teaching.
3018943|NCT02436330|Active Comparator|Didactic health teaching|Participation of child and parent/guardian in 6 months of weight management programming consisting only of didactic teaching.
3018944|NCT02436317|Experimental|Study group|"All patients included in intervention group will be examined with an ultrasound machine with cardiac probe and vascular probe [Saote/ Mylab 5/ Italy] using both 2 dimensional and color Doppler imaging modalities according to our local point of care ultrasonography protocol.~Including demographic and medical data collection. Also, a wellbeing questionnaire will be filled by the investigator."
3018945|NCT02436317|No Intervention|Control group|All patients included in the control group won't be examined with an ultrasound machine. Participation including demographic and medical data collection. Also, a wellbeing questionnaire will be filled by the investigator.
3018946|NCT02436304|Experimental|EXE844 for 7 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops, twice daily (BID) in each ear for 7 days after Tympanostomy Tube Insertion
3018947|NCT02436304|Experimental|EXE844 for 3 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops BID in each ear for 3 days after Tympanostomy Tube Insertion
3018948|NCT02436304|Active Comparator|Tubes Only|Bilateral myringotomy and tympanostomy tube insertion
3018949|NCT02436291|Experimental|CURE-EX device|twice daily treatment with CURE-EX device for 24-30 weeks
3018950|NCT02436278||IPF_MORT|Patients diagnosed with Idiopathic Pulmonary Fibrosis according to NICE guidelines.
3018951|NCT02436265|Sham Comparator|Group 1 Ropivacaine|Group 1 Ropivacaine (N=47) Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine
3018952|NCT02436265|Active Comparator|Group 2 Ropivacaine and Dexamethasone|Group 2 Ropivacaine/dexamethasone Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine and 0.1mg/kg of intravenous dexamethasone immediately after caudal placement
3018953|NCT02436252|Experimental|DSP-7888|
3018954|NCT02436239|Experimental|Vilazodone|
3018955|NCT02436226|Active Comparator|Clomiphene citrate-HCG group|Women will receive clomiphene citrate and human chorionic gonadotropin (HCG)
3018956|NCT02436226|Active Comparator|Clomiphene citrate group|Women will receive clomiphene citrate alone
3018957|NCT02436213|Experimental|Healthy control|A group of up to 30 healthy controls will be recruited to have a cardiopulmonary exercise test and a blood test.
3018958|NCT02436213|Experimental|Pulmonary AVM|A group of up to 30 pulmonary AVM patients will be recruited to have a cardiopulmonary exercise test, and a blood test.
3018959|NCT02436213|Experimental|HHT but no pulmonary AVM|Most patients with pulmonary AVMs have underlying hereditary hemorrhagic telangiectasia (HHT). If there is a difference between pulmonary AVM and control groups that does not correct following embolization of pulmonary AVMs, a group of up to 30 people with HHT but no evidence of pulmonary AVMs will be selected to have a cardiopulmonary exercise test and a blood test.
3018960|NCT02436200|Experimental|Intervention|Patients receiving neuromuscular electrical stimulation.
3018961|NCT02436174||study group|patients undergoing cesarean under epidural anesthesia
3018962|NCT02436161|Experimental|"Care management program PROMIC"|care management program provided by a multidisciplinary team that optimizes care with the main role of nurses acting as coaches of patients and carers, within the primary care teams
3018963|NCT02436161|No Intervention|Usual care|Patients in the control group belongs to different Primary health care centres from the intervention group and are treated as usual by their Primary Care team and by cardiologists different from the intervention group
3018964|NCT02436135|Experimental|Idelalisib Dose Escalation|Four successive cohorts of participants will each be started on a fixed dose of idelalisib. Based on safety data after the third participant completes Day 28, the cohort may be expanded to enroll an additional 3 participants. After the sixth participant completes Day 56, the next cohort will be open to enrollment after safety and PK data at this dose have been evaluated. For the successive 3 cohorts, enrollment will be expanded based on cumulative safety and PK data. Participants will continue ruxolitinib dosing during screening and throughout the study treatment period.
3018965|NCT02436109||study group|elective cesarean delivery patients
3018966|NCT02436096|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8mg Tablet taken sublingually each day at bedtime for 12 weeks
3018967|NCT02436096|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks
3018968|NCT02436083|No Intervention|control|no antibiotics
3018969|NCT02436083|Active Comparator|experimental group|drug administration (antibiotic)
3018970|NCT02436070|Active Comparator|Control|Subjects receive general, health-related text messages applicable for children with asthma.
3018971|NCT02436070|Experimental|Test group|Subjects receive specific, targeted text messages for post-emergency department discharge asthma care.
3018972|NCT02436057|No Intervention|Usual care|Individuals in this arm will undergo usual care with their physician.
3018973|NCT02436057|Experimental|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Individuals in the AEGIS arm will be invited to use AEGIS/My GI Health prior to their clinic visit. For those who complete AEGIS/My GI Health, their physician will have access to their AEGIS symptom report (includes a GI symptom heat map and GI history) and tailored education prescription.
3018974|NCT02436031|Active Comparator|Desipramine First, Placebo Second|Desipramine 200 mg administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching desipramine administered 2 hours before normal sleep time on second study night.
3018975|NCT02436031|Experimental|Placebo First, Desipramine Second|Placebo-matching desipramine administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then desipramine administered 2 hours before normal sleep time on second study night.
3018976|NCT02436018|No Intervention|Control group|Oxygen(2L/min) supplied with nasal catheter
3018977|NCT02436018|Experimental|Nasopharyngeal airway group|Oxygen(2L/min) supplied directly through WEI NASAL JET without jet ventilator
3018978|NCT02436018|Experimental|WEI NASAL JET group|Oxygen supplied through WEI NASAL JET with a manual jet ventilator
3018979|NCT02435992|Experimental|RPC1063 (Ozanimod)|1mg, daily oral administration during Induction and Maintenance periods.
3018980|NCT02435992|Placebo Comparator|Placebo|Daily oral administration during Induction and Maintenance periods.
3019046|NCT02435524|No Intervention|Control Communes|
3018981|NCT02435979|Experimental|Proximal strengthening + hand therapy|Patients in this group will perform traditional hand therapy for 30 minutes and proximal strengthening of the core, cervical spine, and shoulder complex for up to 30 minutes
3018982|NCT02435979|Active Comparator|Traditional hand therapy|This group will receive traditional hand therapy for 45-60 minutes each session.
3018983|NCT02435966|Experimental|Manual therapy + Dry needling|Manual therapy + Dry needling: 2 sessions, after a 7 days interval
3018984|NCT02435966|Other|Manual therapy + Sham Dry needling|Manual therapy + Sham Dry needling: after a 7 days interval
3018985|NCT02435966|No Intervention|Untreated control|Natural history of the condition
3018986|NCT02435953|Experimental|TACE-RFA|1-2 times of TACE treatment, then followed by RFA treatment.
3018987|NCT02435953|Active Comparator|TACE alone|TACE treatment several times till tumor progress to advance stage
3018988|NCT02435927|Experimental|ASLAN001 + CAPOX|ASLAN001 + CAPOX: ASLAN001 twice daily in combination with oxaliplatin 130 mg/m2 intravenously on day 1 and capecitabine 850 mg/m2 orally twice daily on days 1 to 14 every 3 weeks
3018989|NCT02435927|Experimental|ASLAN001 + mFolfox6|ASLAN001 + mFolfox6: ASLAN001 twice daily in combination with mFolfox6 (oxaliplatin 85 mg/m2 intravenously on day 1 and 5-FU bolus 400mg/m2 i.v on day 1 and as a continuous infusion 2400mg/ m2 over 46h and leucovorin 400mg/2 i.v on day 1) every 2 weeks
3018990|NCT02435914|Experimental|AGN-223575 Dose A|1 drop of AGN-223575 Dose A ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose A ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
3018991|NCT02435914|Experimental|AGN-223575 Dose B|1 drop of AGN-223575 Dose B ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose B ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
3018992|NCT02435914|Experimental|AGN-223575 Dose C|1 drop of AGN-223575 Dose C ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose C ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
3018993|NCT02435914|Placebo Comparator|AGN-223575 Vehicle|1 drop of Vehicle to AGN-223575 ophthalmic solution administered in each eye twice daily for 14 day followed by 1 drop of vehicle to AGN-223575 ophthalmic solution in each eye once daily for 7 days.
3018994|NCT02435901|Experimental|Reduced Intensity Regimen|Administration of reduced doses of alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by daily dose of 10mg/dose on Day -19 to Day -17 for patients <10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients > 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. On Day -1 Cyclosporine OR Tacrolimus will be initiated along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. On Day 0 the Human Leukocyte Antigen (HLA) matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused.
3018995|NCT02435888||Polycystic ovary syndrome|
3018996|NCT02435875||hypertensive|Patients with confirmed hypertension or systolic blood pressure≥140 mmHg or diastolic blood pressure≥90 mmHg without antihypertensive treatment.After anesthesia induction,baroreflex sensitivity will be measured by nitroglycerin.
3018997|NCT02435875||nonhypertensive|systolic blood pressure <140 mmHg and diastolic blood pressure<90 mmHg.After anesthesia induction,baroreflex sensitivity will be measured by nitroglycerin.
3018998|NCT02435862|Experimental|1.0mg Luminate®|1.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
3018999|NCT02435862|Experimental|2.0mg Luminate®|2.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
3019000|NCT02435862|Experimental|3.0mg Luminate®|3.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
3019001|NCT02435862|Placebo Comparator|Balanced Salt Solution 0.10cc|Balanced Salt Solution 0.10cc injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
3019002|NCT02435849|Experimental|Single dose of CTL019|2 to 5 x 10(6) autologous CTL019 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
3019003|NCT02435836|Experimental|Aripiprazole|All subjects began open-label treatment with 30 mg aripiprazole on the first day of participation in the current trial. Once a subject stabilized at the 30 mg per day dose, the investigator could adjust the dose within the range of 10 to 30 mg per day as needed (throughout this long-term trial), to manage AEs.
3019004|NCT02435823|Experimental|PulseRider|Endovascular treatment of intracranial aneurysms
3019005|NCT02435797|Active Comparator|Nicorandil|Nicorandil for injection
3019006|NCT02435797|Placebo Comparator|normal saline|normal saline
3019007|NCT02435784|Active Comparator|2-COM group|Patients will use the Two-Way Communication Checklist (2-COM) once in a psychiatric consultation.
3019008|NCT02435784|Placebo Comparator|TAU group|Treatment as usual (TAU) group.
3019009|NCT02435771|Experimental|BMI <25|Normal BMI
3019010|NCT02435771|Experimental|BMI 25-35|Overweight and obese by BMI
3019011|NCT02435771|Experimental|BMI >35|Obese by BMI
3019012|NCT02435758|Experimental|Preservation of Denonvilliers Fascia|Preservation of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery for male mid-low rectal cancer patients
3019013|NCT02435758|No Intervention|Excision of Denonvilliers Fascia|Standard TME surgery (excision of Denonvilliers fascia) in Laparoscopy-assisted pelvic autonomic nerve preservation surgery for male mid-low rectal cancer patients
3019014|NCT02435745||Ehlers-Danlos Syndrome|Patients with the diagnosis of Ehlers-Danlos syndrome
3019015|NCT02435745||Controls|Patients/Subjects without the diagnosis of Ehlers-Danlos syndrome
3019016|NCT02435732|Placebo Comparator|Control group|Standard donor management + vehicle treatment (n=9)- placebo saline solution
3019017|NCT02435732|Experimental|CINRYZE 200 U/Kg IV|Intervention is CINRYZE 200 U/Kg IV single dose
3019018|NCT02435732|Experimental|200 units/kg IV CINRYZE with Heparin 20 U/kg/h IV|CINRYZE 200 units/kg IV single dose with Heparin at 20 units/kg/h IV maintenance until organ recovery
3019019|NCT02435706|Experimental|Flapless group|Flapless immediate implant placement: Flapless placement of immediate implant and temporary crown
3019020|NCT02435706|Active Comparator|Flap group|Flap assisted immediate implant placement: Flap elevation prior to placement of immediate implant and temporary crown
3019021|NCT02435693|Experimental|PHARMACEUTICAL CARE programe|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
3019022|NCT02435693|Other|control|without pharmaceutical care programe (control)
3019023|NCT02435680|Experimental|Arm 1: MCS110+carboplatin+gemcitabine|MCS110+carboplatin+gemcitabine
3019024|NCT02435680|Active Comparator|Arm 2: carboplatin+gemcitabine|carboplatin+gemcitabine
3019025|NCT02435667|Experimental|Resistance Exercise Training|Entails 36 supervised resistance exercise training sessions (3 sessions per week for 12 weeks). Each exercise session will be supervised by a trained, certified Exercise Physiologist specializing in Cardiac Rehabilitation. The specific resistance exercise training will include Aerobic Exercise, Resistance Exercise, and Core Strengthening Exercises. Other baseline and follow-up tests include: DEXA bone scan, Blood Draw, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, and a Submaximal Exercise Test.
3019026|NCT02435667|Placebo Comparator|Standard Care|No resistance exercise training. Patients will stay on their current healthcare regimen as previously assigned by their physician. Patients will still undergo baseline and follow-up tests similar to the Resistance Exercise Training group, including: DEXA bone scan, Blood Draw, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, and a Submaximal Exercise Test.
3019027|NCT02435654|Experimental|Treatment group|All EOS patients will receive olanzapine treatment with flexible dose(2.5 to 20 mg/day)according to standard body weight,olanzapine will be initiated at 2.5 or 5 mg/day and the dose could be increased by 2.5 or 5 mg/day dose increments at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,the investigator could decrease the dose at any time and in any number of dose decrements if patients experienced an adverse event.
3019028|NCT02435641||ICU Questionnaires|"After enrollment, all subjects (patients and their primary caregiver) will be given baseline measures assessing: sociodemographics, depression, anxiety, distress, stress, PTSD, coping, mindfulness, quality of life, satisfaction with life, resiliency/self efficacy (patient only), patient caregiver interaction, caregiver preparedness (caregiver only), caregiver self efficacy (caregiver only), quality of adherence measure, and health care satisfaction.~Subjects will complete the same measures again at time 2 (3 months) and time 3 (6 months). The study endpoint is time 3 follow up (6 months)."
3019029|NCT02435628||Satisfaction Questionnaires|"After enrollment, subjects will be given baseline measures to assess demographics, psychosocial factors, and health literacy. This assessment will occur online via Computerized Assessment Center. Participants will complete the PROMIS battery of measures assessing: depression, anxiety, anger, fatigue, pain behavior and interference, physical function, satisfaction with discretionary social activities, satisfaction with social roles, and health literacy. Participants will also complete the FFFHL scale.~Upon completion of the baseline assessments, the participant will meet with their doctor at the NF clinic for a routine appointment. Post-treatment assessments will be administered immediately after completion of the medical visit. This assessment will evaluate the participant's satisfaction with the appointment in the NF clinic using the MISS and CAHPS surveys. This will be done online via REDCap."
3019030|NCT02435615|Experimental|Study group|There is one group of patients which are those presenting to the hospital with suspected clinical case of dengue fever for diagnosis. This group will have oral fluid collected via the SaniSal oral fluid collector and a pipette, and blood collected via venipuncture.
3019031|NCT02435602|Active Comparator|NBI endoscopy|"GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy~Biopsy at the visually abnormal lesions~Pathologic examination of all biopsy tissue specimens~Advises of endoscopic/surgical or oncological treatment will be given to participants who will be diagnosed with ESCC or high grade dysplasia of the esophagus."
3019032|NCT02435602|Active Comparator|lugol chromoendoscopy|"GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy~Biopsy at the unstained lesions >= 5 mm diameter~Pathologic examination of all biopsy tissue specimens~Advises of endoscopic/surgical or oncological treatment will be given to participants who will be diagnosed with ESCC or high grade dysplasia of the esophagus."
3019033|NCT02435589|Experimental|Intervention group|"Intervention:~systematic pain assessment~Notification of results of assessments to nurses and physicians. Pain Assessments will be done with the use of 2 different behavioral pain tools by independent assessors and the results of the assessments will be notified to the nurses and physicians and their respond will be observed and documented"
3019034|NCT02435589|Active Comparator|Control Group|Intervention. Systematic pain assessments. Assessments of pain will be done by independent assessors but results will not be notified to nurses or physicians
3019035|NCT02435563|Experimental|Ticagrelor 180 mg|Single dose of 180mg ticagrelor administered orally
3019036|NCT02435563|Experimental|Ticagrelor adjusted dose+ritonavir 100mg|adpated dose of ticagrelor calculated after PK modelisation with the Simcyp® simulator administered simultaneously with 100 mg ritonavir
3019037|NCT02435550|Experimental|Acute Myeloid Leukemia|Patients with acute myeloid leukemia will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
3019038|NCT02435550|Experimental|Acute Lymphoblastic Leukemia|Patients with acute lymphoblastic leukemia will have blood, bone marrow aspirate , and saliva collected from them as part of routine care.
3019039|NCT02435550|Experimental|Myelodysplastic Syndrome|Patients with myeloplastic syndrome will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
3019040|NCT02435550|Experimental|Myelofibrosis|Patients with myelofibrosis will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
3019041|NCT02435550|Experimental|Multiple Myeloma|Patients with multiple myeloma will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
3019042|NCT02435537|Active Comparator|Intrathecal Bupivacaine|intrathecal injection of 10 mg hyperbaric bupivacaine 0.5% in 2 ml volume and 1ml of saline 0.9%
3019043|NCT02435537|Active Comparator|Intrathecal Morphine|intrathecal injection of 10mg bupivacaine 0.5% in 2ml volume intrathecal injection of 0.5 mg morphine in 1ml volume
3019044|NCT02435537|Active Comparator|Intrathecal Morphine-Dex|intrathecal 10mg bupivacaine 0.5% in 2 ml volume intrathecal 0.5 mg morphine intrathecal 5 µg of dexmedetomidine in 1ml volume .
3019048|NCT02435511|Experimental|Intervention arm|The intervention arm will receive the intervention, a HealtheRx, which includes a list of resources in their community tailored to their health needs.
3019049|NCT02435498|Experimental|Interactive website|The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
3019050|NCT02435498|Active Comparator|Video|The online video will contain the same information within the website.
3019051|NCT02435498|Active Comparator|Standard of care|Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
3019052|NCT02435485|Experimental|spondylolisthesis with balance training|Intervention: 1. Biodex balance training including weight shift training and random control training, 2. Regular rehabilitation including core spinal stabilization exercise.
3019053|NCT02435485|Active Comparator|spondylolisthesis, no balance training|Intervention: Regular rehabilitation including core spinal stabilization exercise
3019054|NCT02435485|Active Comparator|lumbar spondylitis|Intervention: Regular rehabilitation including core spinal stabilization exercise
3019055|NCT02435472|Experimental|Arm A (Exercise)|Arm A will engage in up to 4 walking sessions per week at 55% to 75% of the individually determined exercise capacity (VO2peak; determined from the cardiopulmonary exercise test performed at baseline) for 16 weeks. This exercise prescription will be achieved through ~ 4 sessions / week. Men are provided with a heart rate monitor to help ensure they exercise in their target zone. At baseline & week 16(-7, +7 days), all patients will complete: (1) lifestyle and quality-of-life questionnaires, (2) measurement of weight and waist circumference (3) collection of research fasting blood sample, (4) transrectal ultrasound-guided clinical biopsy, and (5) cardiorespiratory fitness testing.
3019056|NCT02435472|No Intervention|Arm B (Usual Care)|"Arm B will receive usual care (physical activity information) This group will receive general physical activity information (Moving through Cancer - A Guide to Exercise for Cancer Survivors) at baseline, but no specific exercise program or goals. At the conclusion of the 16 weeks, subjects in this group will be provided with a free sessions with an exercise physiologist and an individualized aerobic exercise program based on their cardiorespiratory fitness test results."
3019057|NCT02435472|No Intervention|Non-Randomized Group|There is also a non-randomized observational component to the study where we will collect biospecimens, survey, data, and administer one CPET. Individuals who will be enrolled to this group include those who do not meet all eligibility criteria for the RCT, or those who do not wish to be in a RCT, but are interested to participate in some lifestyle research. This group provides us with a larger more heterogeneous population to follow long term to examine associations between exercise, biomarkers, fitness metrics, and clinical and psychosocial outcomes.
3019058|NCT02435459|Placebo Comparator|No lining|No lining material placed under amalgam dental restoration
3019059|NCT02435459|Active Comparator|Calcium hydroxide cement|Placement of calcium hydroxide cement under amalgam dental restorations
3019060|NCT02435459|Active Comparator|Bonding agent|Placement of Resin bonding agent under amalgam dental restorations
3019061|NCT02435459|Active Comparator|RMGI cement|Placement of rmgi lining under amalgam dental restorations
3019062|NCT02435446|Experimental|Eligible patients for cone-beam|A cone-beam computed tomography will be offered to the patients undergoing a CT scan for the diagnosis and/or the pre-operative assessment of an otosclerosis, fulfilling the inclusion criterias and without any exclusion criteria.
3019063|NCT02435433|Experimental|Ramucirumab|8 milligrams per kilogram (mg/kg) ramucirumab administered as an intravenous (IV) injection on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
3019064|NCT02435433|Placebo Comparator|Placebo|"Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.~Participants still on treatment at the time of study completion may have the option to crossover to the ramucirumab arm."
3019065|NCT02435433|Experimental|Open Label Ramucirumab|8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
3019066|NCT02435433|Experimental|Ramucirumab ME2 Cohort|8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
3019067|NCT02435433|Placebo Comparator|Placebo ME2 Cohort|"Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.~Participants still on treatment at the time of study completion may have the option to crossover to the ramucirumab arm."
3019068|NCT02435420||EMPERION Modular Primary Stem subjects|All subjects have previously been implanted with the EMPERION Modular Primary Stem for primary total hip arthroplasty.
3019069|NCT02435407|Experimental|SOS arm|The Sequential Oral Sensory (SOS) approach treatment protocol, involving systematic desensitization hierarchy of skills needed to build feeding skills.
3019070|NCT02435407|Active Comparator|Education arm|Parents will participate in educational talks around the cause and management of feeding difficulties in children with autism spectrum disorder.
3019071|NCT02435394|Experimental|Remote Coach plus Asthma Module|The intervention is for practices to have remote coach support for patients with asthma in addition to doctors using CHADIS-Asthma module. Practices will start sequentially for a time series analysis.
3019072|NCT02435394|Experimental|Asthma Module- No Coach|The intervention is for practices to use CHADIS-Asthma module to improve patient care without a remote coach assisting patient adherence.
3019073|NCT02435394|Active Comparator|CHADIS- no Asthma module|Practices using CHADIS but no Asthma module as a control condition.
3019074|NCT02435381|Placebo Comparator|Placebo|Participants will receive placebo from days 2- 4.
3019075|NCT02435381|Active Comparator|Carisbamate|Participants will receive carisbamate 600mg qd from days 2- 4.
3019076|NCT02435355|No Intervention|standard support|All patients in this study underwent this procedure, which is the regular procedure in France.
3019077|NCT02435355|Experimental|coached group|In the coached group (CG), patients received standard support completed by 5 sessions (day 3, 10, 30, 60, 90 with equipment at home) of telephone-based counselling session by competent staff. Sessions were performed by a qualified person in education, qualifies by a university degree (Paul Sabatier University, Toulouse, France). The dates of phone calls were planned with the patient availabilities.
3019078|NCT02435342|Experimental|30ug dalazatide|12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks.
3019079|NCT02435342|Experimental|60ug dalazatide|12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks.
3019080|NCT02435329||Healthy volunteers|"10 healthy volunteers~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
3019081|NCT02435329||Type 2 diabetes without neuropathy|"10 patients~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
3019082|NCT02435329||Type 2 diabetes with painful neuropathy|"10 patients~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
3019083|NCT02435329||Type 2 diabetes with painless neuropathy|"10 patients~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
3019084|NCT02435329||Type 2 diabetes with Charcot foot|"10 patients~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
3019085|NCT02435316|Active Comparator|Group 1|Group 1 will receive 1 hour of compare-contrast basic science teaching of cell recognition to enhance recognition of those photographs, followed by 1 hour Case vignette-based teaching of cell recognition 2 weeks later
3019086|NCT02435316|Active Comparator|Group 2|Group 2 will receive 1 hour of Case vignette-based teaching of cell recognition followed by compare-contrast basic science teaching of cell recognition 2 weeks later
3019087|NCT02435303|Experimental|Sildenafil|Sildenafil 20mg tid for six months (* consider open-label extension study for 1 year)
3019088|NCT02435303|Placebo Comparator|Placebo|Placebo tablets do not contain an active ingredient but are identical in shape with each active tablet of Sildenafil
3019089|NCT02435290||patients with malignant cancer receiving chemotherapy|five hundred patients suffering malignant cancer from eight wards ( breast , GIT ,gynecological , genitourinary , lung , head and neck, lymphoma and myeloma ,skin and melanoma) ,receiving various chemotherapy protocols .
3019090|NCT02435277|Experimental|Low Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
3019091|NCT02435277|Experimental|Mid Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
3019092|NCT02435277|Experimental|High Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
3019093|NCT02435277|Active Comparator|Metformin Monotherapy|3 Capsules BID each containing 283.3 mg of metformin BID (1,700 mg/Day) at Day 14.
3019094|NCT02435264|Experimental|Healthier Dining Program Intervention|Food centers that receive the Healthier Dining Program (HDP)
3019095|NCT02435264|No Intervention|Control centers|Food centers that do not receive the Healthier Dining Program (HDP)
3019096|NCT02435225|Experimental|Mindfulness group|Participation in a 12 week mindfulness therapy group.
3019097|NCT02435212|Active Comparator|Arm 1|
3019098|NCT02435212|Experimental|Arm 2|
3019099|NCT02435199|Experimental|EMA401 600mg|2 X 150mg BID
3019100|NCT02435199|Placebo Comparator|Placebo|Placebo to match, 2 capsules BID
3019101|NCT02435186|Experimental|p53 gene plus chemotherapy|Intraperitoneal p53 gene plus cisplatin, and paclitaxel iv
3019102|NCT02435186|Active Comparator|chemotherapy|Intraperitoneal cisplatin, and paclitaxel iv
3019103|NCT02435173|Other|CDZ173|Part I was with-in patient dose escalation with CDZ173 10, 30 and 70 mg bid. Part II is randomized placebo-controlled with CDZ173 70 mg bid and matching placebo
3019104|NCT02435173|Placebo Comparator|Placebo|Part II is placebo controlled
3019105|NCT02435160|Experimental|Ulcerative Colitis|
3019106|NCT02435134||Healthy participants|
3019107|NCT02435121|Experimental|SAR125844|Given intravenously weekly at the dose of 570 mg/m^2 for at least 18 weeks
3019108|NCT02435108|Experimental|crizotinib arm|crizotinib medication
3019109|NCT02435095|Active Comparator|Maintenance treatment (Control)|287 female and male patients with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) will be directed randomly to the maintenance treatment group (control). Patients will be treated according to the current clinical standard of long-term maintenance antipsychotic treatment. Study related procedures include safety assessments (physical examination, questionaires), laboratory assessments (blood sampling, urine analysis), efficacy assessments (questionaires) and volumetric Magnetic Resonance Imaging (structural MRI incl. volumetry). Study procedures are the same for both study groups (control/experimental).
3019136|NCT02434861|Experimental|Part C|Rolapitant IV and Cooperstown Cocktail
3019137|NCT02434848|Active Comparator|Engerix B|15 subjects per group (n = 30 in total)
3019110|NCT02435095|Experimental|Intermittent Treatment (Experimental)|"287 female and male patients with schizophrenia according to DSM-V will be directed randomly to the intermittent treatment group (experimental). Patients directed to this group will be tapered off medication.~Study related procedures include safety assessments (physical examination, questionaires), laboratory assessments (blood sampling, urine analysis), efficacy assessments (questionaires) and volumetric Magnetic Resonance Imaging (structural MRI incl. volumetry). Study procedures are the same for both study groups (control/experimental)."
3019111|NCT02435082||Concussion with TCD|Any patient (adolescent/adult) receiving a Transcranial Doppler (TCD) for a head injury, suspected concussion, or suspected mild traumatic brain injury (sports related or not).
3019112|NCT02435069|Experimental|NS and USP Glycerin - Dose Response|Randomize NS and Glycerin to treatment sequence. Begin NS 10mL/kg or glycerin 20 mL every other day. Titrate dose in 10 mL increments to achieve continence so as not to exceed 20 mL/kg or a maximum dose of 1000 mL daily. Titrate USP glycerin in 5 mL increments so as not to exceed 50 mL of USP glycerin daily. For side effects greater than Wong Bailey Faces Pain Rating Scale (WBFPRS) level 4, decrease NS by 2.5 mL/kg to the lowest dose of 5 mL/kg daily. Decrease glycerin by 5 mL increments to the lowest dose of 5 mL daily. If the dose necessary to minimize side effects results in episodes of fecal soiling or there are side effects greater than WBFPRS level 4 at the lowest dose of administration, the child will be dropped from the study.
3019113|NCT02435069|Experimental|NS and USP Glycerin - Effectiveness|To prevent statistical bias from subject loss due to treatment failure, each child will be randomized to a second treatment sequence once they have achieved continence on optimal dosing with minimal side effects.This arm will evaluate the long term effectiveness of NS and glycerin at optimal dose and administration frequency for 4 weeks and serve as comparison between flush solutions. The study will conclude with the child being placed back on 2 weeks of the initial flush in the randomized sequence.
3019114|NCT02435056|No Intervention|Classic Approach|Patient fills in a paper diary in order to quantify parameters of MOH (days with headache, acute drugs consumed, etc.)
3019115|NCT02435056|Experimental|IEPR Approach|Patient has to use the electronic diary to record days with headache, acute drugs consumed, etc.
3019116|NCT02435043|Experimental|Nature based rehabilitation|ten weeks of nature-based rehabilitation, as add-on to standard management
3019117|NCT02435043|Active Comparator|Treatment as usual|standard management after stroke
3019118|NCT02435030||NP-C Patients|NPC type 1 or 2 patients aged 2-18 years
3019119|NCT02435017||Adults 20-85 years|Data from adults 20-85 years old will be evaluated for serum phosphorus concentration.
3019120|NCT02435004|Other|Spinal Modulation Axium™|Spinal Modulation Axium™: an external trial neurostimulator (TNS) is used for the trial period, followed by an implanted neurostimulator (INS) if the TNS is successful. The TNS and INS are a pacemaker-sized devices that send out mild electrical pulses. The stimulator contains a battery and electrical components. Both TNS and INS are constant voltage devices. The TNS is used first and is worn on the outside of the clothing. The INS is implanted under the skin and support:
3019121|NCT02434991|Experimental|Barostat|The barostat (a thin tube, with a deflated balloon attached at the end) will be placed through your mouth down your esophagus (swallowing tube) to where your stomach and esophagus meet. The 10-cm long balloon will then be inflated with step by step pressure increases of 4mmHg for 30 seconds each to a maximum pressure of 50mmHg. The patient will rate discomfort during each step of inflation
3019122|NCT02434978|Active Comparator|Supplementary doppler-guided endoscopic therapy|
3019123|NCT02434978|Placebo Comparator|control group|
3019124|NCT02434965|Experimental|Autologous Cord Blood and HPDSC|Autologous cord blood and placental blood will be collected after birth of child and administered in divided aliquots during the first week of life.
3019125|NCT02434952|Experimental|DHA PP plus primaquine, G6PD deficiency|"Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.~Target dose of 0.25mg/kg primaquine given orally with first dose only of DHA PP, dosing by weight for children <18 years and standard 15mg primaquine dose for all adults ≥18 years. Small children (<25kg) will receive a primaquine suspension, adults receive 7.5mg or 15mg primaquine tablets."
3019126|NCT02434952|Active Comparator|DHA PP plus primaquine, G6PD normal|"Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.~Target dose of 0.25mg/kg primaquine given orally with first dose only of DHA PP, dosing by weight for children <18 years and standard 15mg primaquine dose for all adults ≥18 years. Small children (<25kg) will receive a primaquine suspension, adults receive 7.5mg or 15mg primaquine tablets."
3019127|NCT02434952|Active Comparator|DHA PP alone, G6PD deficiency|Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
3019128|NCT02434952|Active Comparator|DHA PP alone, G6PD normal|Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
3019129|NCT02434939|Experimental|Low dose ketamine|Low dose ketamine 1mg/kg given as an IV infusion via syringe pump over 10 minutes. Maximum of 2 doses to be given during study period that will last 2 hours.
3019130|NCT02434939|Active Comparator|Morphine|Morphine 0.1mg/kg given as an IV infusion via a syringe pump over 10 minutes. Maximum of 2 doses to be given during the study period that will last 2 hours.
3019131|NCT02434887|Experimental|Experimental group|
3019132|NCT02434874|Experimental|Immediate Activation|Subjects randomized to this group will have the StimGuard Sacral Nerve Stimulator System activated immediately.
3019133|NCT02434874|Other|Delayed Activation|Subjects randomized to this group will have the StimGuard Sacral Nerve Stimulator System activated after 90 days.
3019134|NCT02434861|Experimental|Part A|Rolapitant IV and Digoxin
3019138|NCT02434848|Active Comparator|Fendrix|15 subjects per group (n = 30 in total)
3019139|NCT02434835|Experimental|[14C]KWA-0711|
3019140|NCT02434822|Experimental|Study Group 1|Participants aged 1 through 4 years at enrollment
3019141|NCT02434822|Experimental|Study Group 2|Participants aged 5 through 14 years at enrollment
3019142|NCT02434822|Experimental|Study Group 3|Participants aged 15 years and above at enrollment
3019143|NCT02434809|Experimental|Patients with lung cancer|Physician evaluation of patient setup accuracy will be performed using all available images and adjustments will be made as per standard practice. In addition, a respiration motion-corrected CBCT (daily for SBRT, weekly for standard fractionation) will be used to confirm the accuracy of Calypso-based setup. Patients will return for follow up at 3,6 and 12 months (+/- 4 weeks) following completion of radiation therapy. The following assessments will be performed at these visits: history and physical exam, diagnostic CT chest, and toxicity assessment.
3019144|NCT02434796|Experimental|Arm 1 Male Peer Groups (MPG)|Women participate in savings groups and male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. This intervention aims to improve knowledge and attitudes about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals (e.g. caring for one's family) and to challenge gender stereotypes (e.g. women are not equal to men); and the ability to formulate positive outcome expectations regarding IPV (intolerance of violence perpetrated by themselves or others) and healthy relationships with their spouses and communities.
3019145|NCT02434796|Experimental|Arm 2 MPG & Community Dialogues|This arm will include women participants in savings groups, male peer groups and community dialogues. Village community leaders will engage in community dialogues on gender norms, IPV and HIV prevention.
3019146|NCT02434783||1st level of arterial insufficiency|asymptomatic PAD patients
3019147|NCT02434783||2nd level of arterial insufficiency|Intermittent claudication patients
3019148|NCT02434783||3rd level of arterial insufficiency|Critical limb ischemia patients
3019149|NCT02434783||No arterial insufficiency|Healthy individuals (control)
3019150|NCT02434770|Experimental|TiantanBio bOPV lot 1|2 drops liquid bOPV manufactured by TiantanBio, lot 1; contains types 1 and 3 attenuated polioviruses (Sabin), with at least 106 CCID50/dose and 105.8 CCID50/dose, respectively
3019151|NCT02434770|Experimental|TiantanBio bOPV lot 2|2 drops liquid bOPV manufactured by TiantanBio, lot 2; contains types 1 and 3 attenuated polioviruses (Sabin), with at least 106 CCID50/dose and 105.8 CCID50/dose, respectively
3019152|NCT02434770|Active Comparator|PQ bOPV|Bivalent Type 1 & 3 Oral Poliomyelitis Vaccine (BioFarma) 2 drops liquid bOPV manufactured by BioFarma; contains types 1 and 3 attenuated polioviruses (Sabin), with at least 106 and 105.8 infective units per dose, respectively
3019153|NCT02434757|Experimental|Acthar 40 U|Acthar 40 U (0.5mL)
3019154|NCT02434744|Experimental|Cohort 1 100 mg KD026 BID|100 mg KD026 twice a day (BID) in combination with Metformin for 12 weeks
3019155|NCT02434744|Experimental|Cohort 2 150 mg KD026 BID|150 mg KD026 BID in combination with Metformin for 12 weeks
3019156|NCT02434744|Experimental|Cohort 3 200 mg KD026 BID|200 mg KD026 BID in combination with Metformin for 12 weeks
3019157|NCT02434744|Experimental|Cohort 4 100 mg KD026 TID|100 mg KD026 three times a day (TID) in combination with Metformin for 12 weeks
3019158|NCT02434744|Placebo Comparator|Cohort 1 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
3019159|NCT02434744|Placebo Comparator|Cohort 2 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
3019160|NCT02434744|Placebo Comparator|Cohort 3 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
3019161|NCT02434744|Placebo Comparator|Cohort 4 Placebo|Matched Placebo Dose TID in combination with Metformin for 12 weeks
3019162|NCT02434731|Experimental|Buzzy® device|The Buzzy® device will be applied just above the selected site of the venipuncture; a ice pack will be attached under the device; the device will be turned on and after 15 second the procedure will be carried out.
3019163|NCT02434731|No Intervention|No intervention|No intervention for pain relief
3019164|NCT02434718|Experimental|Cohort 1|IV infusion in cohorts assigned to low dose 1; 1 participant per cohort will receive placebo
3019165|NCT02434718|Experimental|Cohort 2|IV infusion in cohorts assigned to low dose 2; 1 participant per cohort will receive placebo
3019166|NCT02434718|Experimental|Cohort 3|IV infusion in cohorts assigned to high dose; 1 participant per cohort will receive placebo
3019167|NCT02434718|Experimental|Cohort 4|IV infusion in cohorts assigned to mid dose; 1 participant per cohort will receive placebo
3019168|NCT02434705||Antigen (wheat base soy sauce) spray|"Ten patients with active and ten with inactive eosinophilic esophagitis (defined by consensus guidelines) undergoing clinically indicated endoscopy and esophageal biopsies will participate in this study.~During the endoscopy two biopsies will be taken from the esophageal body, 10 cm above the gastroesophageal junction.~After biopsies are taken, approximately 10 cc of wheat based soy sauce (antigen spray) will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction."
3019169|NCT02434692|Experimental|Single-arm intervention ARGOS-IO system|The ARGOS-IO Pressure sensor will be additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery.
3019170|NCT02434666|Experimental|CPC-201|
3019171|NCT02434653|Experimental|Postpartum anemia diagnosis following symptoms|Post partum anemia will be assessed by taking hemoglobin level following symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL in the first 5 days following delivery
3019172|NCT02434653|Experimental|Postpartum anemia diagnosis following patients screening|Post partum anemia will be assessed by taking hemoglobin level in patients at increased risk to develop post-partum anemia in the first 5 days following delivery, defined as patients with initial (before or immediately after delivery) hemoglobin level of 10.5 g/dl or less regardless of symptoms, or in cases of severe post partum hemorrhage.
3019173|NCT02434640|Experimental|BAY1128688 [Dose1]|BAY1128688 dose level 1
3019174|NCT02434640|Experimental|BAY1128688 [Dose2]|BAY1128688 dose level 2
3019175|NCT02434640|Experimental|BAY1128688 [Dose3]|BAY1128688 dose level 3
3019176|NCT02434640|Experimental|BAY1128688 [Dose4]|BAY1128688 dose level 4
3019177|NCT02434640|Placebo Comparator|Placebo|Placebo to match arm 1,2, 3 and 4
3019178|NCT02434627|Experimental|Sodium Nitrate (Beetroot Juice)|Sodium nitrate in the form of beetroot juice will be administered orally. Patients will be assessed with a number of functional muscle assessments.
3019179|NCT02434614|Experimental|Induction CT+IMRT alone|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT )alone
3019180|NCT02434614|Active Comparator|Induction CT+IMRT Combined Concurrent CT|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT ) Combined Concurrent Chemotherapy
3019181|NCT02434601|Other|Treatment of Dentin Surface|Treatment of Dentin Surface: Restoration made following the protocol recommended by the manufacturer of the materials.
3019182|NCT02434601|Experimental|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
3019183|NCT02434601|Experimental|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
3019184|NCT02434588|Experimental|Bhattacharjee ring|
3019185|NCT02434575||PAE|Men with LUTS BPE who have opted for PAE at a participating site, and have consented to take part in the UK ROPE Register Study.
3019186|NCT02434575||TURP|Men with LUTS BPE who have consented to TURP at a participating site, and have consented to the UK ROPE Register Study.
3019187|NCT02434575||Other|Men with LUTS BPE who have had an Open Prostatectomy or laser surgery at a participating site, and have consented to the UK ROPE Study.
3019188|NCT02434562||Medical castration|Patients treated with androgen deprivation therapy (e.g. for hypersexuality, transgender subjects, ...)
3019189|NCT02434562||Male hypogonadism|Patients treated with testosterone replacement therapy (e.g. for late-onset hypogonadism, secondary hypogonadism)
3019190|NCT02434562||Thyroid disorders|Patients treated for hyperthyroidism or hypothyroidism (incl. during treatment for thyroid cancer)
3019191|NCT02434562||Obesity and weight loss|Patients treated for obesity with weight loss interventions (mainly bariatric surgery)
3019192|NCT02434562||Miscellaneous|Various disorders associated with alterations in SHBG, androgens and/or estrogens
3019193|NCT02434549|Active Comparator|Botulinum toxin-A (Dysport®)|Intramuscular injections of Botulinum toxin-A in spastic muscles with regional muscle-related pain
3019194|NCT02434549|Placebo Comparator|Normal saline|Intramuscular injections of normal saline solution in spastic muscles with regional muscle-related pain
3019195|NCT02434523|Experimental|amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler)
3019196|NCT02434523|Placebo Comparator|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
3019197|NCT02434510||Sterile Water bath|Standard of Care group using a sterile water instrument bath
3019198|NCT02434510||CHG group|Study group using the 0.05% CHG solution in the instrument bath
3019199|NCT02434497|Experimental|Single Arm|One treatment period for all patients (<1 year and 10 months), with the possibility to up-titrate dose to 40 mg of rosuvastatin for non-Asian patients.
3019200|NCT02434484||Symbenda|Subjects who are prescribed with Symbenda per approved prescribing information of Symbenda will be enrolled in the study.
3019201|NCT02434471|No Intervention|Breath hold Liver Acquisition with Volume Acquisition (LAVA)|Subjects will undergo abdominal MRI with LAVA with conventional breath holds (typically four or more breath holds) per standard of care.
3019202|NCT02434471|Active Comparator|Respiratory-triggered T1w DISCO LAVA|The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.
3019203|NCT02434458||Fibromyalgia case group|Patients diagnosed with fibromyalgia from the department of rheumatology will be subject to sudoscan evaluation and NCS studies.
3019204|NCT02434458||Control|Healthy control subjects
3019205|NCT02434458||Rheumatoid arthritis group|Patients diagnosed with rheumatoid arthritis at the department of rheumatology will be subject to sudoscan evaluation and NCS studies.
3019206|NCT02434445||Hepatorenal syndrome group|Patients with advanced cirrhosis who develope hepatorenal syndrome
3019207|NCT02434445||Non-hepatorenal syndrome group|Patients with advanced cirrhosis who do not hepatorenal syndrome
3019208|NCT02434432|Experimental|condition 1|Infants in this arm will receive their mother's choice of music recorded on an Mp player and delivered via headphones.
3019209|NCT02434432|Active Comparator|condition 2|Infants in this arm wil receive a recorded Lullaby music delivered to the infant via headphones.
3019210|NCT02434432|No Intervention|Condition 3|Infants in this arm will have the headphones applied but no music played.
3019211|NCT02434419|Experimental|PENS with training|Patients undergoing percutaneous electrostimulation (PENS) of the pectoral muscle combined with specific training during 12 weeks postoperatively
3019212|NCT02434419|Active Comparator|Specific training|Patients undergoing specific training during 12 weeks postoperatively
3019213|NCT02434419|No Intervention|No intervention|No specific treatment was assigned to these patients postoperatively
3019214|NCT02434406|Experimental|Web-based intervention|Participants get access to the web-based intervention and are asked to work through the 8 modules of the intervention within eight weeks. The intervention program sends automated weekly email reminders about the current session. In addition, users are offered weekly optional 30-minute telephone support with a trained intervention coach.
3019215|NCT02434406|No Intervention|Wait-list control|Participants get standard care and will be offered access to the web-based intervention at 8-weeks post-randomization.
3019216|NCT02434393||Late Life Depression|120 participants who meet the criteria for Major Depression or Late Life Depression (LLD)
3019217|NCT02434380|Active Comparator|Low dose vitamin D|Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.
3019218|NCT02434380|Active Comparator|High dose vitamin D|Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
3019219|NCT02434367|Experimental|Arm A|Women randomized to the WWE program will receive a workbook, and a daily walking log, the latter to be completed during the study.
3019220|NCT02434367|No Intervention|Arm B|Patients randomized to the usual care arm will receive a document with information on exercise to improve fatigue during radiotherapy
3019221|NCT02434354|Experimental|Arm 1|
3019222|NCT02434341||septic patients|wake septic patients on mechanical ventilation
3019223|NCT02434341||COPD patients|wake COPD patients on mechanical ventilation
3019224|NCT02434328|Experimental|RTH258|RTH258 solution for IVT injection, single injection at Day 0, Week 4, and Week 8, then as specified in the protocol up to Week 92
3019225|NCT02434328|Active Comparator|Aflibercept|Aflibercept solution for IVT injection, single injection at Day 0, Week 4, and Week 8, then as specified in the protocol up to Week 92
3019226|NCT02434315|Active Comparator|Group A - Control|FreeStyle Libre Pro 3 sensor wears
3019227|NCT02434315|Experimental|Group B - Intervention|FreeStyle Libre Pro 4 sensor wears, 2 with reviews
3019228|NCT02434315|Experimental|Group C - Intervention|FreeStyle Libre Pro 6 sensor wears, 4 with reviews
3019229|NCT02434289|Experimental|Resistance exercise and protein products|Practice intervention trial including resistance exercise training and intake of dietary protein products in (frail) elderly, implemented by health care professionals.
3019230|NCT02434276|Experimental|Vaccine Dose Group 8 mcg dose|VAX2012Q, 8 mcg dose
3019231|NCT02434276|Experimental|Vaccine Dose Group 12 mcg dose|VAX2012Q, 12 mcg dose
3019232|NCT02434276|Active Comparator|Control|Fluzone Quadrivalent vaccine
3019233|NCT02434263|Experimental|Hydra TAVI|Percutaneous Replacement of the Diseased Aortic Valve
3019234|NCT02434250|Experimental|SLT arm|Patient receiving 'Selective Laser Trabeculoplasty' (SLT) due to failed Phacoemulsification Cataract Extraction with Intraocular Lens Implantation combined with Eximer Laser Trabeculectomy (phaco-ELT) in Open Angle Glaucoma and Ocular Hypertension to control intraocular pressure and/or glaucoma progression.
3019235|NCT02434237||patients|
3019236|NCT02434237||healthy subjects|
3019237|NCT02434224|Experimental|music therapy|two to three sessions per week: The therapist will stay with one hand on the infants` chest (or back) in order to continuously assess the infants` breathing pattern. Based on and oriented towards the assessed breathing pattern, the infants` behavioral state, facial and gestural expression, the therapist transforms the infants` rhythms and subtle expressions into infant-directed improvised humming.
3019238|NCT02434224|No Intervention|control|standard care
3019239|NCT02434211|Experimental|Questionnaire and Focus group|The children complete the questionnaire to better know their knowledge and cancer individual conceptions. Then, they will be interviewed during one hour in groups for the pre-testing phase. And after, for the testing phase, they just complete the questionnaire.
3019240|NCT02434172||Screening|There are no arms to the study. All participants will undergo screening. Preemptive treatment will only be provided to those who are CrAg positive.
3019241|NCT02434159|Active Comparator|Scan|Heart scan prior to device insertion
3019242|NCT02434159|No Intervention|No scan|No heart scan prior to device insertion
3019243|NCT02434146|Experimental|Supportive care (topical phenylephrine solution)|Patients undergoing a cyclophosphamide and total body irradiation regimen receive topical phenylephrine solution via spray to the oral mucosa 15-20 minutes prior to each cyclophosphamide infusion, 25-30 minutes after the beginning of each cyclophosphamide infusion, and 15-20 minutes prior to each radiation treatment.
3019244|NCT02434133||Case (Group A)|Group A (Immunomodulator) currently taking azathioprine or 6- mercaptopurine (Blood Draw)
3019245|NCT02434133||Case (Group B)|"Group B (Biologic group) currently taking anti-TNF therapy (infliximab, golimumab, adalimumab, or certolizumab).~(Blood Draw)"
3019246|NCT02434133||Case (Group C)|Group C (Combination therapy) currently taking anti-TNF therapy and an immunomodulator (including methotrexate) (Blood Draw)
3019247|NCT02434133||Control|"Individuals will be obtained from patients without an IBD diagnosis coming to Digestive Health Center for endoscopic procedures or clinic visits.~(Blood Draw)"
3019248|NCT02434107|Experimental|Completion Lymphadenectomy|Completion Lymphadenectomy and monitoring afterwards
3019249|NCT02434107|Experimental|Clinical Monitoring (Palpation and node ultrasound)|Monitoring only
3019250|NCT02434094||T1DM Clinicians|Clinicals currently teaching T1DM patients how to use insulin pumps and continuous glucose monitors will be asked to complete the eDAPT on-line training program.
3019251|NCT02434094||T1DM Subjects with DiAs experience|T1DM subjects will prior DiAs experience will be asked to complete the eDAPT on-line training program.
3019252|NCT02434094||T1DM Subjects with no prior DiAs experience|T1DM subjects will no prior DiAs experience will be asked to complete the eDAPT on-line training program.
3019253|NCT02434081|Experimental|Chemo-radiotherapy with concurrent nivolumab|4 doses of nivolumab 360mg concurrently with standard chemo-radiotherapy, followed by 480mg for up to 1 year from start of nivolumab treatment.
3019254|NCT02434068||stone residuals|all patients are going to be submitted to the same intervention: CT, US, KUB
3019255|NCT02434042|Active Comparator|BB536|Bifidobacterium longum BB536 (9 log CFU/day) and dextrin
3019256|NCT02434042|Placebo Comparator|Placebo|100% dextrin
3019257|NCT02434029|Experimental|Budesonide|Budesonide 1mg orodispersible tablet twice daily
3019258|NCT02434029|Placebo Comparator|Placebo|Placebo orodispersible tablet twice daily
3019259|NCT02433990||Adult Congenital Heart Disease|18 years and older with congenital heart disease
3019260|NCT02433977|Experimental|Conjugated Linolenic Acid + NOx|"This is a single arm study~Conjugated Linolenic Acid (CLA)- daily oral dose 4.56 g/day~Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)~Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)"
3019292|NCT02433782|Experimental|Experimental group|Treatment through myofascial therapy for the treatment of pain and restricted mobility in patients with hemophilic arthropathy of the knee and ankle
3019293|NCT02433782|No Intervention|Control group|No myofascial intervention. Patients continue their treatment with FVIII or FIX concentrates, normally
3019294|NCT02433769|Active Comparator|TOf-Watch-SX|Train-of-four (TOF) ratios will be measured with the TOF-Watch-SX and compared to TOF ratios measured simultaneously with the TOFscan
3019295|NCT02433769|Experimental|TOFscan|Train-of-four (TOF) ratios obtained from the TOFscan will be compared to TOF ratios measured simultaneously with the TOF-Watch-SX
3019261|NCT02433964|Experimental|LED group|Treated by a device LED - LED: power 60mW, 627nm wavelength ± 10nm and 1,3cm2 beam output. The energy density used was 10J / cm2 with time of 2 minutes and 47 seconds per flash of the beam, which is unique for each ten points in the lateral region of the ankle edema. The volunteers underwent previous cleaning application points with cotton soaked in 70% alcohol, positioned for high stretcher in the supine position and wearing goggles. The LED was applied in a timely manner, wherein the skin contact surfasse at an angle of 90 °, the ten points were irradiated in a 1cm2 area selected by a single investigator. One session was performed every 24 hours for six consecutive days. Ice applications were made associated with semi-rigid compression bandage, with the patient lying supine and the affected limb in elevation under a foam wedge in the same period.
3019262|NCT02433964|Placebo Comparator|Placebo group|Both volunteers LED group and the placebo group were treated with the same procedure, with the LED device in the placebo group remained off.
3019263|NCT02433951||healthy individuals|Age, gender and BMI matched healthy subjects without any chronic disease or physical disability, and being sedentary.
3019264|NCT02433951||CABG patients|Age, gender and BMI matched CABG patients, without neurologic, nephrologic, respiratory disease.
3019265|NCT02433951||endo-ACAB patients|Age, gender and BMI matched endo-ACAB patients without neurologic, nephrologic, respiratory disease.
3019266|NCT02433938|Experimental|Underwent tibial nerve stimulation|Patients that underwent standard postoperative protocol + tibial nerve stimulation for 3 days
3019267|NCT02433938|Sham Comparator|Did not undergo tibial nerve stimulation|Patients that underwent standard postoperative protocol + sham tibial nerve stimulation (standard postoperative protocol+sham tns)
3019268|NCT02433925|Active Comparator|Supplement B|Administration of 500mg of trans-resveratrol per day, for 4 weeks
3019269|NCT02433925|Placebo Comparator|Supplement A|Administration of 500mg of placebo per day, for 4 weeks
3019270|NCT02433912|Experimental|Test - Laterally positioned flap|Incisions were made in mesial and distal aspects of the recession, in order to remove the epithelial attachment. The root surface was then instrumented. The flap design was outlined by two vertical incisions which extended from the horizontal incision which was performed either at the gingival, or 1 - 2mm apically, following the marginal gingival contour. The flap was rotated laterally in order to completely cover the recession defect and extend for approximatelly 1mm coronal to the CEJ. Careful flap suturing was performed in order to position and secure the soft tissues over the root surface by means of sling and simple sutures.
3019271|NCT02433912|Active Comparator|Control - Coronally advanced flap|The CAF was designed performing two vertical releasing incisions at both the mesial and distal aspects of the recession to be treated, in such a way that both the proximal papillae were not included as part of the flap. The vertical incisions were joined by an intrasulcular incision. A combined mucoperiosteal-mucosal flap was elevated. Thorough root planning was performed. A complementary horizontal incision was performed on the apical aspect of the flap, releasing it from the attached periosteum. This allowed the elongation and free coronal positioning of the flap. The flap was coronally positioned and maintained in place by means of individual 5.0 monofilament sutures.
3019272|NCT02433899|Experimental|Test - Microsurgical semilunar flap|"Semilunar coronally repositioned flap performed under magnification with a surgical microscope.~SLI was carried out following the outline of the gingival margin with a microsurgical blade under (8x) magnification. An ISI was performed mid-facially. Then, a split-thickness dissection was performed from the initial incision coronally until connecting to the ISI. The mid-facial tissue was completely released, positioned coronally to the CEJ and held in place against the tooth. A cyanoacrilate adhesive (CAA) was applied over the post-surgical gingival margin and tooth enamel to stabilize the flap."
3019273|NCT02433899|Active Comparator|Control - Conventional Semilunar flap|Semilunar coronally repositioned flap performed without magnification. A semilunar incision (SLI) was carried out with a 15c surgical blade. An ISI was performed mid-facially. Then, a split-thickness dissection was performed from the initial incision coronally until connecting to the ISI. The mid-facial tissue was completely released, positioned coronally to the CEJ and held in place against the tooth. A cyanoacrilate adhesive (CAA) was applied over the post-surgical gingival margin and tooth enamel to stabilize the flap.
3019274|NCT02433886|Experimental|Gamma Ventral Capsulotomy|
3019275|NCT02433873|Placebo Comparator|Placebo|Ingredients that are in the placebo are: high maltose corn syrup (Satin Sweet™), water, and mannitol. Both Supplement A and Supplement B will be compared to this placebo arm.
3019276|NCT02433873|Experimental|Supplement A|Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Supplement A and B differ by degrees of polymerization.
3019277|NCT02433873|Experimental|Supplement B|Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Supplement A and B differ by degrees of polymerization.
3019278|NCT02433860|Experimental|pregnant nicotine users|watch video and tobacco cessation counselling using SCRIPT protocol
3019279|NCT02433847|Experimental|mosapride|
3019280|NCT02433834|Experimental|GP MDI 28.8 μg|GP MDI (PT001) 28.8 μg
3019281|NCT02433834|Experimental|GP MDI 14.4 μg|GP MDI (PT001) 14.4 μg
3019282|NCT02433834|Experimental|GP MDI 7.2 μg|GP MDI (PT001) 7.2 μg
3019283|NCT02433834|Experimental|GP MDI 3.6 μg per|GP MDI (PT001) 3.6 μg
3019284|NCT02433834|Experimental|GP MDI 1.9 μg|GP MDI (PT001) 1.9 μg
3019285|NCT02433834|Placebo Comparator|Placebo|Placebo
3019286|NCT02433834|Active Comparator|Serevent® Diskus® 50 μg per inhalation|Serevent® Diskus® 50 μg per inhalation
3019287|NCT02433821|Experimental|Pilates Group|The group will realize 2 classes per week, lasting one our, of Pilates under supervision of a trained instructor. The training program will last 3 months.
3019288|NCT02433821|No Intervention|Control group|The patients will keep the drug treatment and will be keep in a waiting list. After the 180 days of study the will be invited to realize the Pilates training.
3019289|NCT02433808|Experimental|Neostigmine Group|Neostigmine will be administered at the conclusion of the surgical procedure
3019290|NCT02433808|Placebo Comparator|No Neostigmine group|Saline will be administered at the conclusion of the surgical procedure
3019291|NCT02433795|Experimental|Bendamustine plus rituximab(BR)|Intravenous bendamustine plus rituximab intravenously at 1st cycle and subcutaneously from 2nd cycle (to maximum 8th cycle).
3054080|NCT02200757|Experimental|Aldoxorubicin|
3019296|NCT02433743|No Intervention|Control|Control group (n=33) didn't received intervention. The received the standard hospital diet
3019297|NCT02433743|Experimental|Ready-to-use therapeutic food (RUTF)|RUTF group (n=32) received the standard hospital diet combined with 100 g/day of RUTF
3019298|NCT02433730|Active Comparator|placebo|intramuscular injection
3019299|NCT02433730|Active Comparator|testosterone|intramuscular injection
3019300|NCT02433717|Experimental|Paliperidone ER|Six-week paliperidone ER
3019301|NCT02433704|Active Comparator|Intraosseous Administration|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
3019302|NCT02433704|No Intervention|Systemic Intravenous Administration|Historical controls will be used and will have received systemic dosing of cefazolin within one hour of the incision.
3019303|NCT02433691|Active Comparator|Sequential Exercise and Memory Training|Aerobic exercise via stationary bicycling followed by memory training.
3019304|NCT02433691|Experimental|Simultaneous Exercise & Memory Training|Simultaneous aerobic exercise via stationary bicycling while receiving memory training.
3019305|NCT02433691|Placebo Comparator|Stretching and Toning|Anerobic stretching and toning followed by memory training
3019306|NCT02433678|Placebo Comparator|Placebo|Patients will be treated for 12 weeks with placebo once daily
3019307|NCT02433678|Active Comparator|Dapagliflozin|10 mg daily for the 12 weeks
3019308|NCT02433665|Active Comparator|Fixed dose|100 of the first 200 subjects will be randomized to a fixed dose of contrast material.
3019309|NCT02433665|Active Comparator|Customized dose|100 of the first 200 subjects will be randomized to a customized dose of contrast material based on the experimental algorithm. The second group of 300 subjects will receive a customized dose of contrast material based on the experimental algorithm.
3019310|NCT02433652|Experimental|Trivalent dengue vaccine admixture + rDEN2Δ30-7169|Participants will receive the trivalent dengue vaccine admixture at Day 0 and the rDEN2Δ30-7169 vaccine at Day 180.
3019311|NCT02433652|Experimental|Placebo + rDEN2Δ30-7169|Participants will receive a placebo vaccine at Day 0 and the rDEN2Δ30-7169 vaccine at Day 180.
3019312|NCT02433639|Experimental|treatment|single arm study: TH-302 monotherapy is given
3019313|NCT02433626|Experimental|COTI2|COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week; 1 cycle will be defined as 4 weeks of treatment as described (5 days on, 2 days off per week). Participants will remain on treatment until they experience a lack of benefit.
3019314|NCT02433600|Active Comparator|Cow's milk-based infant formula|
3019315|NCT02433600|Experimental|Cow milk-based infant formula with enriched protein fractions|
3019316|NCT02433587|Experimental|Short Term|The short term group will continue Aspirin 81mg and Clopidogrel 75mg for 1 month after the intervention. After that, they will continue Aspirin 81mg only.
3019317|NCT02433587|Experimental|Long Term|The long term group will continue Aspirin 81mg and Clopidogrel 75mg for 6 months after the intervention. After this time, they will continue on Aspirin 81mg only.
3019318|NCT02433574|Experimental|Neoadjuvant stereotactic body radiation|Single arm study. Four cohorts of 5 patients will undergo neo-adjuvant SBRT for lung cancer. Eligible patients will have operable, borderline resectable lung cancer , they will be treated with SBRT, prior to undergoing surgical resection.
3019319|NCT02433561|Active Comparator|Intraplexic catheter|Intraplexic approach (Patients will have the catheter placed within the plexus, classical approach)
3019320|NCT02433561|Experimental|Extraplexic catheter|Extraplexic approach (Patients will have the catheter placed out of the plexus.)
3019321|NCT02433548|Experimental|Fascia iliaca block|Fascia iliaca block (Injection of 30 mLs of bupivacaine 0.5% with epinephrine 5 mcg/mL below the fascia iliaca, Carbostesin®)
3019322|NCT02433548|Sham Comparator|Sham injection|No fascia iliaca block (Sham injection = Subcutaneous injection of 5 cc of normal saline, no intervention)
3019323|NCT02433535|Experimental|Simvastatin|Simvastatin 40 mg daily will be given for 12 weeks.
3019324|NCT02433535|Placebo Comparator|Placebo|A placebo capsule will be given daily for 12 weeks.
3019325|NCT02433522|Experimental|Rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months
3019326|NCT02433522|Placebo Comparator|Placebo|Placebo infusion at the randomization visit and every 6 months for 18 months
3019327|NCT02433509|Experimental|HUCB cells combine with Mannitol treatment in acute stroke|"The cord blood need to be infusion within 72 hours after the onset of stroke, and the cord blood mononuclear cells 200 million ~ 500 million will used.~20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion ."
3019328|NCT02433496||Physician coaching|This group includes 4 intervention primary care clinics that are part of the University of Wisconsin's Department of Family Medicine. These clinics will receive an organizational coaching intervention that includes in-person site visits and phone/email communication. Each participating clinic will designate one primary care physician to act as a clinic lead in working with the coach to coordinate an initial site visit (during project month 13, July 2015), a follow-up site visit (month 15, October, 2015), and communicating with the coach throughout the 6-month follow-up period via phone and email.
3019329|NCT02433496||Control Group|This group includes 4 control primary care clinics that will not receive any intervention. A de-identified dataset will be created to examine differences in outcome variables between intervention and control clinics.
3019330|NCT02433483|Experimental|Myeloid Malignancies|"Includes participants with AML and MDS. Participants receive chemotherapy based on diagnosis followed by infusion of donor HPC-A.~Participants with CNS disease receive weekly age-adjusted intrathecal triples therapy until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).~Interventions:~Cycle 1: cytarabine, HPC-A donor infusion~Cycle 2: Participants who have at least a partial response to Cycle 1 are eligible to receive Cycle 2: cytarabine, HPC-A infusion"
3019331|NCT02433470|Active Comparator|Active tDCS|Active transcranial direct current stimulation
3019332|NCT02433470|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
3019333|NCT02433457|Experimental|CC-292 SDD (Spray Dried Dispersion)300mg - Fasted Condition|Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets)
3019422|NCT02432898||Normal Healthy Eyes|Normal healthy eyes with no known ocular diseases
3019334|NCT02433457|Experimental|CC-292 SDD 300mg - Fed Condition|Single oral dose of 300 mg CC-292 SDD under fed conditions (100 mg SDD x 3 tablets)
3019335|NCT02433457|Experimental|375mg P22 - Fasted condition|Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3)
3019336|NCT02433457|Experimental|375mg P22 Fed Condition|Single oral dose of 375 mg P22 under fed conditions (125 mg P22 x 3)
3019337|NCT02433457|Experimental|CC-292 SDD 100 mg Fasted Condition|Single oral dose of 100 mg CC-292 SDD under fasted conditions
3019338|NCT02433457|Experimental|SDD plus OMP (Oral Omeprazole)|Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets) in the presence of 40 mg
3019339|NCT02433457|Experimental|P22 plus OMP|Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3) in the presence of 40 mg oral OMP
3019340|NCT02433444||Patients receiving ERCP|Patients receiving Endoscopic retrograde cholangiopancreatography (ERCP) at Cedars-Sinai Medical Center.
3019341|NCT02433431|Active Comparator|Mindfulness Training|14-lesson audio-guided mindfulness training program instructing present-moment attention and an orientation of acceptance
3019342|NCT02433431|Active Comparator|Mindful Attention Only Training|14-lesson audio-guided mindfulness training program instructing present-moment attention only
3019343|NCT02433431|Active Comparator|Analytic Thinking Training|14-lesson audio-guided analytic thinking program encouraging reflection on one's thoughts, feelings, and behaviors, but not instructing mindfulness
3019344|NCT02433418|Active Comparator|Tubal flushing with Urografin®|Women will have HSG using water soluble media
3019345|NCT02433418|No Intervention|Control group|Women will not receive any intervention
3019346|NCT02433405||Group 1|Chronic Periodontitis-serum amyloid A, Fetuin-A
3019347|NCT02433405||Group 2|Plaque induced Gingivitis-serum amyloid A, Fetuin-A
3019348|NCT02433405||Group 3|Control Group-serum amyloid A, Fetuin-A
3019349|NCT02433392|Experimental|CM-BC2|Patients diagnosed with recurrent, surgically resectable glioblastoma multiforme will receive up to 75 mg irinotecan delivered by drug-eluting beads (CM-BC2).
3019350|NCT02433379|Experimental|Single Arm|Subjects implanted with an EMBLEM S-ICD with rate zones set at 200 bpm and 250 bpm per protocol.
3019351|NCT02433366||Patients|
3019352|NCT02433366||Physicians|
3019353|NCT02433353|Experimental|EMDR + Venlafaxine XR|Participants will receive 12 one-hour sessions of EMDR while taking venlafaxine XR 150mg or 225mg for the duration of the 6 month study.
3019354|NCT02433353|Placebo Comparator|EMDR + Placebo|Participants will receive 12 one-hour sessions of EMDR while taking placebo 150mg or 225mg for the duration of the 6 month study.
3019355|NCT02433340|Experimental|ABT-122 120 mg EOW|All subjects receive open-label ABT-122 120 mg EOW subcutaneously, with the first dose administered at the last visit of Study M12-963 randomized controlled trial.
3019356|NCT02433327|Active Comparator|PEWS - trigger tool|"Paediatric Early Warning Score:~Children randomized to PEWS - trigger tool"
3019357|NCT02433327|Active Comparator|RM - trigger tool|"Paediatric Early Warning Score:~Children randomized to Central Denmark Region (RM)- trigger tool"
3019358|NCT02433288|Other|Active app|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
3019359|NCT02433288|Other|Control app|a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
3019360|NCT02433262|Placebo Comparator|WHO (World Health Organisation)|"Participants will undergo oral glucose tolerance test involving drinking of 75g glucose and blood taking for fasting and 2 hours post glucose intake. Diagnosis of GDM will be made based on these criteria:~Fasting glucose >6 2 hour glucose >7.7"
3019361|NCT02433262|Active Comparator|IADPSG|Participants will undergo oral glucose tolerance test involving drinking of 75g glucose and blood taking for fasting and 2 hours post glucose intake. Diagnosis of GDM will be made based on these criteria: (International Association of Diabetes & Pregnancy Study Group) Fasting glucose >5 2 hour glucose >8.4
3019362|NCT02433249|Active Comparator|1 Physical Activity|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. All participant receive Fitbit Ones and are asked to use them on a daily basis.
3019363|NCT02433249|Experimental|2 Interpersonal Motivation|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the interpersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
3019364|NCT02433249|Experimental|3.Intrapersonal Motivation|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the intrapersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
3019365|NCT02433249|Experimental|4.Full Intervention|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the intrapersonal and interpersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
3019366|NCT02433236|Experimental|Fostamatinib Disodium tablet 100 mg|Fostamatinib Disodium tablet 100 milligram (mg) by mouth twice a day for 15 months
3019458|NCT02432664|Experimental|ODM-108 Part I|Oral capsules dosage 0.2 - 240 mg once daily for one day
3019367|NCT02433236|Experimental|Fostamatinib Disodium tablet 150 mg|Fostamatinib Disodium tablet 150 milligram (mg) by mouth twice a day for 15 months
3019368|NCT02433223||2006 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation
3019369|NCT02433223||2011 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 results.
3019370|NCT02433223||2013 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 & 2011 results.
3019371|NCT02433223||2015 Patients|Group added to reflect recency of practice. Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 & 2011 results.
3019372|NCT02433210|Active Comparator|Solute Clearance|Solute clearance at 60 minutes for urea, creatinine, phosphate, beta 2 microglobulin, and myoglobin will be determined three times for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers at the 60 minute time point.
3019373|NCT02433210|Active Comparator|Hemocompatibility|Hemocompatibility will be determined using the markers C3a, C5a, thrombin/anti-thrombin complex and complete blood count with platelets will be determined one time for each dialyzer at session 2 and at time points 0, 15, 30, 60, and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers ..
3019374|NCT02433210|Active Comparator|Solute removal rate|Solute (urea, creatinine, phosphate, beta 2 macroglobulin, and myoglobin) removal rate will be determined time points 0 and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers .
3019375|NCT02433197|Experimental|Aerobic program|Individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants.
3019376|NCT02433197|No Intervention|Control group|They will be instructed to continue their current activities and not to increase objectively levels of physical activity performed during the 8-week intervention.
3019377|NCT02433184|Experimental|Etanercept|Treatment Arm 1 will receive etanercept and methotrexate combination therapy administered for a total duration of 48 weeks.
3019378|NCT02433184|Active Comparator|Methotrexate-treat to target|Treatment Arm 2 will receive initial methotrexate monotherapy with adoption of a treat to target protocol (standard care involving monthly DAS28-ESR assessment with escalation to combination sDMARD therapy if not achieving LDA at, or after, 8 weeks) and step-up to etanercept and methotrexate at 24 weeks if failing to achieve clinical remission
3019379|NCT02433171||Melanoma Brain Metastases|Stage 4 cancer patient population with melanoma with brain metastases previously treated with SRS
3019380|NCT02433171||Lung Cancer Brain Metastases|Stage 4 cancer patient population with non-small cell lung cancer with brain metastases previously treated with SRS
3019381|NCT02433158|Experimental|Cohort 1|includes one adult stratum (>18 years old) and one pediatric stratum (12-17 years old)
3019382|NCT02433158|Experimental|Cohort 2|includes one pediatric stratum (6-11 years old).
3019383|NCT02433132|Other|Diagnostic test|Diagnostic test will be perform on cell from nasal brushing
3019384|NCT02433119|Experimental|Amlodipine orotate & Valsartan|Amlodipine orotate 6.91mg (5mg as amlodipine) and Valsartan 160 mg, tablet, once a day for 8 weeks
3019385|NCT02433119|Active Comparator|Valsartan & Hydrochlorothiazide|Valsartan 160mg and Hydrochlorothiazide 12.5mg, tablet, once a day for 8 weeks
3019386|NCT02433106|Experimental|Intervention|GAA 15 Specific neuromuscular exercise training
3019387|NCT02433106|Active Comparator|Control|Control Usual training
3019388|NCT02433093|Experimental|Basimglurant: Healthy Cohort (1)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. Cohort 1 will receive a prespecified titration scheme; however, adaptive titration schemes may be applied in subsequent cohorts.
3019389|NCT02433093|Experimental|Basimglurant: Healthy Cohort (2)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 2 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in Cohort 1.
3019390|NCT02433093|Experimental|Basimglurant: Healthy Cohort (3)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 3 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1 and 2.
3019391|NCT02433093|Experimental|Basimglurant: Healthy Cohort (4)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 4 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1, 2, and 3.
3019392|NCT02433093|Experimental|Basimglurant: MDD Cohort (5)|Participants with MDD assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 5 may differ from those previously evaluated; however, the titration steps and the highest dose tested will remain equal to or lower than the doses tested in Cohorts 1 to 4.
3019393|NCT02433093|Placebo Comparator|Placebo: Healthy Cohorts (1 to 4)|Healthy participants will receive a 22-day regimen of matching placebo capsules.
3019394|NCT02433093|Placebo Comparator|Placebo: MDD Cohort (5)|Participants with MDD will receive a 22-day regimen of matching placebo capsules.
3019395|NCT02433080|Active Comparator|Shape-Up following cancer treatment|"In addition to usual care, cancer survivors in the intervention group will participate in a behaviour change programme, called Shape-Up following cancer treatment: a self-help programme on eating well and being active. Participants will be allocated to groups of eight to ten. These groups will meet every week for eight weeks and each session will last approximately 90 minutes. The programme focuses on strategies for improving diet and physical activity in a self-help and peer education format. Each week, one participant will volunteer to present a new concept (e.g. regular eating, being active, eating a balanced diet, keep an eye on portion sizes, and manage internal and external triggers, and understanding food labeling) to the rest of the group."
3019423|NCT02432885|Experimental|ACE inhibitor|ACE inhibitor (enalapril up to 20mg BID), in patients with preserved EF (LVEF grater than 50%) and with detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance, randomized to therapy or not.
3019424|NCT02432885|No Intervention|Control|Patients with preserved EF (LVEF grater than 50%) and with no detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance
3019396|NCT02433080|No Intervention|Control intervention|"Participants in the control group will be offered usual care until the 24-week follow-up. Quantifying usual care is challenging, but preliminary qualitative work suggested that most survivors do not received any unsolicited advice about healthy eating and physical activity from their health care professionals after treatment.~During the course of their participation in the trial, participants will be contacted only for the assessments. After the completion of the 24-week follow-up, participants will receive the booklet Healthy living after cancer; a brief self-help manual produced by the World Cancer Research Fund. Providing only this information aims to match the currently offered usual care as accurately as possible but also meet ethical standards."
3019397|NCT02433067|Experimental|Physical activity intervention|"- Arm A standard oncologic care coupled with physical activity intervention (3 times / week)  during 3 months"
3019398|NCT02433067|Active Comparator|Control group|"- Arm B (control group) standard oncologic care"
3019399|NCT02433054||CE-certified dedicated venous stents|Patients receiving self-expanding venous nitinol stents.
3019400|NCT02433041|Active Comparator|Haloperidol|Haloperidol 0.005mg/kg at induction of anesthesia
3019401|NCT02433041|Active Comparator|Ketamine|Ketamine 1mg/kg at induction of anesthesia
3019402|NCT02433041|Active Comparator|Haloperidol + Ketamine|Combination of Haloperidol + Ketamine in same dosage at induction of anesthesia
3019403|NCT02433041|Placebo Comparator|Saline solution (NaCl 0.9%)|Placebo
3019404|NCT02433015|Active Comparator|Tobacco Cigarette Group|This group will not receive an electronic cigarette and will continue to smoke combustible tobacco cigarettes as previously.
3019405|NCT02433015|Experimental|Electronic Cigarette Group|This group will receive an electronic cigarette to use for the duration of the study.
3019406|NCT02433002||Main study|1300 participants will undergo baseline (month 0) and final (month 36) reference GFR, estimated GFR (eGFR) and urinary albumin-to-creatinine ratio (ACR) tests. Additionally they will provide ACR and eGFR tests at 6-monthly intervals.
3019407|NCT02433002||Sub-study of patterns of progression|A subset of the cohort (n=375) will receive annual reference GFR tests.
3019408|NCT02433002||Biological variability study|In a further sub-study 20 participants will undergo the reference test four times over four weeks.
3019409|NCT02432989|No Intervention|Resting Control Group|Patients will receive standard concussion management, but will be asked not to exercise for the first 7 days after their concussion.
3019410|NCT02432989|Experimental|Exercise Group|Patients will receive standard concussion management, but will be asked to exercise on a stationary bike on two different occasions (once for 15 minutes and again for 30 minutes) in their first week of recovery. This group will also be asked to complete a 30 minute leisurely walk at their convenience on the two days they are not tested at UBC or Fortius.
3019411|NCT02432976|Experimental|Exenatide group|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
3019412|NCT02432976|Active Comparator|Insulin group|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
3019413|NCT02432963|Experimental|Treatment (p53MVA, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes followed by modified vaccinia virus Ankara vaccine expressing p53 SC at least 30 minutes later once in weeks 1, 4, and 7. Patients may receive additional doses of pembrolizumab in weeks 10, 13, 16, and 19, for a maximum of 7 doses if there are no signs of progressive disease. Treatment continues in the absence of disease progression or unacceptable toxicity.
3019414|NCT02432950|Experimental|Supportive care (PNP)|Patients participate in the PNP intervention, which begins with a baseline meeting with a diet and lifestyle instructor to discuss baseline testing results, begin an educational plan, determine an individualized eating plan, and print out food choices. Patients also undergo automated glucometry every 15 minutes, review their individual food choices and blood glucose levels 90 minutes after eating, keep a daily nutrition and lifestyle journal log, fill out a daily meal discovery card log, and attend weekly meetings with a diet and lifestyle instructor for 12 weeks.
3019415|NCT02432937|Placebo Comparator|Corever middle dose|
3019416|NCT02432937|Placebo Comparator|Corever high dose|
3019417|NCT02432937|Placebo Comparator|Placebo|
3019418|NCT02432924|Experimental|Feedback Group|Participants randomised into the intervention group will be invited to return to the university for a one-off 60 minute set-up session once their physical activity monitor has been returned and processed. Within this session the participant will be given detailed instructions on how to use and wear the activity monitor and real time display and upload their data to and navigate the multidimensional feedback web platform (See materials section for details). They will also be introduced to the concept of goal setting and talked through the different aspects of the instantaneous feedback display and how that might benefit them. Following this visit the participant will be given licence to wear and use the physical activity monitoring devices for a 6-week period and encouraged to self-monitor their behaviour using the combined instantaneous and multidimensional feedback.
3019419|NCT02432924|No Intervention|Waiting List Control Group|Participants who have been randomised into the control arm will be put on a 3 month waiting list to receive the intervention described above. They will still attend assessment visits at week 6 and week 12 while they are not receiving any advice or feedback. Following their 12 week assessment, participants in the control arm will be invited to attend the same 60 minute set-up session as received by the intervention group and then provided with the armband monitor and display to then receive the intervention in full. No further post-intervention or follow-up assessments will be taken from these participants.
3019420|NCT02432911|Experimental|CAG regimen|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
3019421|NCT02432911|Active Comparator|Low dose cytarabine|cytarabine 20mg bid for 10 days.
3019425|NCT02432872|Experimental|escalated daunorubicin|Daumorubicin 60mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.
3019426|NCT02432872|Active Comparator|standard daunorubicin|Daunorubicin 45mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.
3019427|NCT02432872|Experimental|medium dosage cytarabine|1g/m2 q12h for 3 days as consolidation therapy.
3019428|NCT02432872|Active Comparator|standard dosage cytarabine|100mg/m2 cytarabine for 6 days combined with aclacinomycin 20mg per day for 6 days as consolidation therapy.
3019429|NCT02432859|Active Comparator|Electrical stimulation|In the electrical stimulation group, group who received direct current ES at sensory threshold intensity for 1 h/day, 3 days/week, for 4 weeks (12 sessions)
3019430|NCT02432859|Placebo Comparator|Placebo|In the placebo group, the treatment procedure was the same as that the ES group, but the current intensity was zero
3019431|NCT02432846|Experimental|Intuvax+ Nephrectomy+Sunitinib|Two Intuvax (ilixadencel) vaccinations (10 milj cells/vaccination) 14 days apart before nephrectomy, followed by Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
3019432|NCT02432846|Active Comparator|Nephrectomy+Sunitinib|Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
3019433|NCT02432833|Experimental|Envarsus® (tacrolimus)|prolonged-release tablets once daily and orally
3019434|NCT02432833|Active Comparator|Prograf or Advagraf|Prograf® hard capsules, twice daily, oral formulation or Advagraf® prolonged-release hard capsules, once daily, oral formulation
3019435|NCT02432807|Experimental|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1% dosed approximately 1 cm of ointment QID for 7 days
3019436|NCT02432807|Placebo Comparator|Placebo|Vehicle (placebo) ophthalmic ointment dosed approximately 1 cm of ointment QID for 7 days
3019437|NCT02432794|Experimental|delay phenomenon by arteriography|"intervention: delay phenomenon by arteriography. Patients who will be subjected a delay phenomenon by arteriographic procedure before esophageal resection surgery minimum 14 days before surgery.~An angiogram of the celiac trunk is performed through a femoral access before and after the embolization. A 4-5 Fr Simmons or Cobra catheter is used for the catheterization and embolization of the left gastric artery, and 0.035-inch platinum coils are proximally placed from the main trunk in the splenic artery. When accessory left gastric arteries are present, they are catheterized and embolized as well. The right gastric artery catheterization is realized by a 4-5 Fr catheter and coils or microcoils are proximally placed in the artery as well."
3019438|NCT02432794|No Intervention|control group|Patients who will be operated directly without gastric ischemic conditioning. The investigators don't performed any arteriography before the esophageal surgical resection
3019439|NCT02432781|Experimental|Carbohydrate group|Carbohydrate-rich drink 400 mL 3 h before surgery
3019440|NCT02432781|Active Comparator|Control group|10% dextrose solution mixed with insulin 16 unit 100 mL/h
3019441|NCT02432768|Active Comparator|Triheptanoin|14 days on Triheptanoin treatment including a 7 days titration period and a 7 days full dose treatment of 1mL/kg/day.
3019442|NCT02432768|Placebo Comparator|Placebo oil|14 days of diet on a placebo oil including 7 days titration period and 7 days full dose treatment of 1mL/kg/day.
3019443|NCT02432755|Experimental|home-based MTOT|Home-based mirror therapy combined with task-oriented training (MTOT)
3019444|NCT02432755|Active Comparator|hospital-based therapy|hospital-based individualized occupational therapy
3019445|NCT02432755|Experimental|hospital-based MTOT|hospital-based mirror therapy combined with task-oriented training (MTOT)
3019446|NCT02432742|Experimental|Restylane Perlane|Single injection and optional touch up injection with Restylane Perlane in NLF
3019447|NCT02432742|Active Comparator|Restylane|Single injection and optional touch up injection with Restylane in NLF
3019448|NCT02432729||Study population|"Adult smokers who are motivated to quit smoking within the next 30 days at the Screening Visit will be asked to continuously quit smoking for 1 year.~Smokers who are not continuously abstinent from smoking or any nicotine tobacco containing product from the actual quit date will be discontinued from the study."
3019449|NCT02432716|Experimental|Insulin (glulisine)|Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril), once per study
3019450|NCT02432716|Placebo Comparator|Placebo|Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril), once per study
3019451|NCT02432703|Experimental|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
3019452|NCT02432703|Placebo Comparator|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
3019453|NCT02432690|Experimental|Arm A|
3019454|NCT02432677|Experimental|Remifentanil + Active tDCS|"tDCS session: the procedure will initiate by placing an anode electrode on the primary motor cortex (contralateral to the dominant cortex) and the cathode electrode on the contralateral supra-orbital region. The current employed is 2mA of transcranial direct-current stimulation administered for 20 minutes.~Remifentanil - 0,06mcg.kg.min - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
3019455|NCT02432677|Other|Placebo + Active tDCS|"tDCS session: the procedure will initiate by placing an anode electrode on the primary motor cortex (contralateral to the dominant cortex) and the cathode electrode on the contralateral supra-orbital region. The current employed is 2mA of transcranial direct-current stimulation administered for 20 minutes.~Placebo: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
3019456|NCT02432677|Other|Remifentanil + Sham tDCS|"Sham tDCS: consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.~Remifentanil - 0,06mcg.kg.min - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
3019457|NCT02432677|Other|Placebo + Sham tDCS|"Sham tDCS: consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.~Placebo: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
3019459|NCT02432664|Placebo Comparator|Placebo Part I|Oral capsules given once daily for one day
3019460|NCT02432664|Experimental|ODM-108 Part II|Oral capsules 4 dose levels to be decided after Part 1 of the study. 1 - 4 times a day for 7 days
3019461|NCT02432664|Placebo Comparator|Placebo Part II|Oral capsules 1 - 4 times per day for 7 days
3019462|NCT02432664|Experimental|ODM-108 Part III|Oral capsules 1-4 times daily for 7 to 10 days
3019463|NCT02432664|Active Comparator|Midazolam|Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
3019464|NCT02432651|Other|6 mg xanthohumol per day vs. placebo|All participants take 6 mg xanthohumol daily and placebo in a crossover design with a washout period.
3019465|NCT02432651|Other|12 mg xanthohumol per day vs. placebo|All participants take 12 mg xanthohumol daily and placebo in a crossover design with a washout period.
3019466|NCT02432651|Other|24 mg xanthohumol per day vs. placebo|All participants take 24 mg xanthohumol daily and placebo in a crossover design with a washout period.
3019467|NCT02432612|Experimental|Sativex|Sativex will be administered by trained, clinical trial personnel, via a pump action oromucosal spray. Sativex will be administered as 2 actuations (sprays) under the tongue or inside the cheeks every 4 minutes until 6 sprays have been administered. Following the administration of the first and second set of 2 actuations, patients will be offered 50 mL water to drink; and following the final set of 2 actuations, 100 mL of water will be offered (i.e., a total of 200 mL water will be offered during the Sativex dosing). There must be a period of at least 2 minutes and no more than 3 minutes between Sativex administration and consumption of water. Patients will not be permitted their regular medication until 2 hours post dose of investigational medicinal product (IMP) to minimize any possible drug interactions.
3019468|NCT02432599|Experimental|F18-choline PET|F18-choline PET examination will be performed before surgery
3019469|NCT02432586|Other|Intensive Education|Attendance of 2 intensive education sessions
3019470|NCT02432573|No Intervention|Standard care|Postpartum patients that receive physician rounding at current time
3019471|NCT02432573|Experimental|Delayed rounding|Postpartum patients that receive physician rounding at a delayed time
3019472|NCT02432560||Everolimus|women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking everolimus as part of their clinical care
3019473|NCT02432560||Sirolimus|women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking sirolimus as part of their clinical care
3019474|NCT02432547|Active Comparator|Aflibercept Monotherapy|Intravitreal aflibercept injections according to a treat and extend regimen.
3019475|NCT02432547|Experimental|Targeted laser therapy with Aflibercept|Targeted laser photocoagulation therapy to areas of peripheral retinal ischaemia and intravitreal aflibercept injections using a treat and extend regimen.
3019476|NCT02432534|Experimental|UVB + treatement|The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months.
3019477|NCT02432534|Other|UVB|The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
3019478|NCT02432508|Active Comparator|laser acupuncture|One hundreds of hemodialysis patients include and give intervention with laser acupuncture (50mW) for 4 weeks. After 4 weeks of wash out period, these patients cross over to shame laser acupuncture treatment (5mW).
3019479|NCT02432508|Sham Comparator|sham laser acupuncture|One hundreds of hemodialysis patients include and give intervention with sham laser acupuncture (5mW) for 4 weeks. After 4 weeks of wash out period, these patients cross over to laser acupuncture treatment (50mW).
3019480|NCT02432495||Anterior screw fixation|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
3019481|NCT02432495||Halo immobilization|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone of halo immobilization of type II odontoid fractures
3019482|NCT02432482|Active Comparator|Standard care|Brief advice to quit (less than 5 minutes) Self-help brochure Offer of nicotine patches
3019483|NCT02432482|Experimental|mobile Positively Smoke Free (mPSF)|"mPSF: a targeted, intensive behavioral cessation intervention for PLWH smokers~offer of nicotine patches"
3019484|NCT02432469|Experimental|Intervention group|APP specific for this study, with reminder, education materials and feedback mechanism for improving secondary medications
3019485|NCT02432469|No Intervention|Control group|Usual Care
3019486|NCT02432456|Placebo Comparator|Placebo Infusion|"Subjects in this arm will receive the institutional standard of care for rib fractures along with a placebo (NaCl) infusion.~All patients will undergo Intercostal Nerve Blockade with administration of scheduled medications including acetaminophen, ibuprofen, pantoprazole, and methocarbamol. All subjects will receive adjunct opioids."
3019487|NCT02432456|Experimental|Ketamine Infusion|"Subjects in this arm will receive the institutional standard of care for rib fractures along with a ketamine infusion.~All patients will undergo Intercostal Nerve Blockade with administration of scheduled medications including acetaminophen, ibuprofen, pantoprazole, and methocarbamol. All subjects will receive adjunct opioids."
3019488|NCT02432443|Experimental|Motor and pre-literacy program|First group to receive the motor and pre-literacy program.
3019489|NCT02432443|Active Comparator|Wait-list comparison|Second group to receive the motor and pre-literacy program after the experimental arm has completed the program.
3019490|NCT02432430|Experimental|quality improvement technical support|QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage. Participants receive a Vaccinator Toolkit and attend 6 virtual QI Learning Sessions and 12 monthly conference calls with a coach and other participant teams. On a monthly basis for 11 months, participants collect, submit and review immunization data of 10-20 of their patients ages 3 months to 18 months. After 12 months, participants attend a virtual QI Debriefing Session.
3019491|NCT02432430|Active Comparator|pay for performance|Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage. Participants receive a Vaccinator Toolkit and are informed of a tiered incentives structure. Practices receive bonuses for both improvement in individual practice coverage as well as improvement in coverage for all practices allocated to this study arm.
3019529|NCT02432183||Control group|Age-matched controls are recruited (exercising at a recreational level, >4 hours).
3019852|NCT02430181|Experimental|lonafarnib 300 mg BID|lonafarnib 300 mg BID; n=3
3019853|NCT02430181|Experimental|lonafarnib 100 mg TID|lonafarnib 100 mg TID; n=3
3019492|NCT02432417|No Intervention|Standard|Radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 30 daily fractions of 2 Gray (Gy) or 33 daily fractions of 1.8 Gy to the tumor and surrounding margin in combination with TMZ 75 mg/m² Per os daily (po qd) and six adjuvant cycles of TMZ 150 - 200 mg/m² po qd.
3019493|NCT02432417|Experimental|Experimental arm|"Radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 30 daily fractions of 2 Gray (Gy) or 33 daily fractions of 1.8 Gy to the tumor and surrounding margin in combination with TMZ 75 mg/m² Per os daily (po qd) and six adjuvant cycles of TMZ 150 - 200 mg/m² po qd.~In addition this treatment will be combined with a daily intake of the recommended phase two dose (RPTD) of chloroquine (CQ)."
3019494|NCT02432404|Active Comparator|Cyclic NuvaRing CVR Use|CVR use for 3 weeks, remove for 1 week, then replace
3019495|NCT02432404|Experimental|Continuous NuvaRing CVR Use|CVR use for 4 weeks, then replace
3019496|NCT02432391|No Intervention|Routine Care|Participants continue their routine medical care for type 2 diabetes
3019497|NCT02432391|Experimental|GEM|Participants receive the GEM (Glycemic load, Exercise, and Monitoring blood glucose) lifestyle modification program and continue their routine medical care for type 2 diabetes.
3019498|NCT02432378|Experimental|Cisplatin + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
3019499|NCT02432378|Experimental|Cisplatin + CKM + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
3019500|NCT02432365|Experimental|Weekly paclitaxel and cisplatin|7-day cycle schedule of paclitaxel (60 mg/m2) combining with cisplatin (40 mg/m2) NAC regimen followed by radical hysterectomy and bilateral pelvic lymphadenectomy
3019501|NCT02432352|Experimental|Intervention|Families are randomly allocated to a behavioral intervention arm (called Our Family Our Future) focusing on reducing sexual risk behavior in adolescents and reducing or maintaining symptoms that fall below the clinically significant range for depression. Arms will be allocated using urn randomization.
3019502|NCT02432352|No Intervention|Control|Families are randomly allocated to the control arm (which receives standard usual care, and then offered the intervention after outcome assessments as a wait-list) using urn randomization.
3019503|NCT02432339|Experimental|mycophenolate mofetil (MMF)|Mycophenolate Mofetil (MMF) 500 mg tablet twice a day for 7 1/2 days.
3019504|NCT02432339|Placebo Comparator|Placebo|Placebo (sugar pill) in the same size capsule that the MMF is used in - twice a day for 7 1/2 days.
3019505|NCT02432326|Experimental|Arm A|
3019506|NCT02432313|Experimental|Modified Release Formulation x (MRx)|Various formulations of Modified Release anatabine citrate tablets
3019507|NCT02432300|Experimental|Intervention|Treatment sessions with a virtual treatment program called Emotion Builder
3019508|NCT02432287|Experimental|Metformin|Metformin, an FDA approved first-line drug for the treatment of type 2 diabetes, has known beneficial effects on glucose metabolism.
3019509|NCT02432287|Experimental|Placebo|Placebo
3019510|NCT02432274|Experimental|Cohort 1: Single-Agent Dose-Finding|Children and adolescents with relapsed or refractory solid malignant tumors.
3019511|NCT02432274|Experimental|Cohort 2A: Single-agent Expansion (DTC)|Children and adolescents with 131 iodine-refractory DTC.
3019512|NCT02432274|Experimental|Cohort 2B: Single-agent Expansion (Osteosarcoma)|Participants with relapsed or refractory osteosarcoma.
3019513|NCT02432274|Experimental|Cohort 3A: Combination Dose-finding|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
3019514|NCT02432274|Experimental|Cohort 3B: Combination Expansion|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
3019515|NCT02432261|Experimental|Group 1|5.0 mL of the 1.62% Nestorone® /testosterone gel (containing 8.3 mg NES + 62.5 mg T) applied each day on the arms and shoulders
3019516|NCT02432261|Experimental|Group 2|4.4 mL of the 1.62% Testosterone only gel (AndrogelTM) (containing 62.7 mg T) applied each day to the arms and shoulders
3019517|NCT02432248|Experimental|Dehydroepiandrosterone|DHEA is considered as health supplement and is available over the counter. Side effects are minimal at present dosage (25mg or 50mg tds).
3019518|NCT02432248|Placebo Comparator|Placebo|Medical starch is considered as medicine components. Side effects are minimal at present dosage.
3019519|NCT02432235|Experimental|ADCT-301|"In Part 1 (dose-escalation), patients will receive a 1-hour intravenous infusion of ADCT-301 on Day 1 every 3 weeks (21-day cycle). Dose escalation will be conducted according to a continual reassessment method.~In Part 2 (expansion), patients will be assigned to receive the recommended dose(s) of ADCT-301 as determined by the Dose Escalation Steering Committee (DESC)."
3019520|NCT02432222|Experimental|Music Training|Music training
3019521|NCT02432222|Experimental|Visual Arts Training|Visual arts training
3019522|NCT02432222|No Intervention|Control|Waitlist control
3019523|NCT02432209|Active Comparator|Intensive Lifestyle Mod. Intervention|The intensive lifestyle modification intervention will consist of caloric restriction (consumption of approximately 1200-1500 kcal/d), use of an over-the-counter weight loss medication (Alli, which is brand name Orlistat, a gastric lipase inhibitor that limits gut fat absorption), and moderate physical activity (goal of reaching 10,000 steps a day). The pretreatment intervention will last 16 weeks and is designed to promote a weight loss of approximately 7% of total body weight.
3019524|NCT02432209|Placebo Comparator|Standard Lifestyle Intervention|Women in the standard lifestyle intervention (standard) will receive publicly available written materials that promote engagement in moderate physical activity with target of 10,000 steps a day. Detailed instruction of physical activity will not be provided.
3019525|NCT02432196|Experimental|Mitral Valve Repair|Implanting ePTFE sutures as artificial chordae tendineae using the TSD-5
3019526|NCT02432183||Football players|Football players of the first grade of high school are recruited from the topsportschool in Leuven.
3019527|NCT02432183||Basketball players|Basketball players of the first grade of high school are recruited from the topsportschool in Leuven.
3019528|NCT02432183||Swimmers|Swimmers of the first grade of high school are recruited from the future team of the Flemish Swimming Federation
3019530|NCT02432170|Experimental|Foot/Ankles imaged with tomosynthesis|"Intervention: Digital Tomosynthesis of Foot and Ankle~The intervention, digital tomosynthesis of the foot and ankle, will be done on eligible participants. The resulting images will be compared to radiography and weight-bearing CT images from the same participants."
3019531|NCT02432157|Experimental|Hypertonic saline (HTS)|A protocol of prophylactic 3% HTS as a volume expander with bolus (over 30 minutes) of 3% HTS at a dose of 250 ml every 6 hours for 7 days. This will be given through a central line as soon as possible and within 72 hours of onset of SAH symptoms.
3019532|NCT02432157|Active Comparator|Standard fluid|Routine fluid management strategy as pre-specified by our SAH management protocol at Jefferson University Hospital according to the American Heart Association and Neurocritical Care Guidelines for the management of SAH (this includes conventional intravenous fluids or normal saline solutions to maintain a normal hydration status and guided by the treating doctor and daily assessments of fluid balance).
3019533|NCT02432144|Experimental|4 mg/kg of UX003|All subjects will receive 4 mg/kg UX003 every other week (QOW) unless data from prior studies define a different dose either for that subject or the use of UX003 in general.
3019534|NCT02432131||Divers with PFO|
3019535|NCT02432131||Divers without PFO|
3019536|NCT02432118|Experimental|Diagnostic (radiofrequency-guided localization)|Patients undergo radiofrequency-guided localization comprising RFID tag placement before lumpectomy and interactive detection of tag using RFID reader during lumpectomy.
3019537|NCT02432105|Experimental|EXE844 for 7 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops, twice daily (BID) in each ear for 7 days after Tympanostomy Tube Insertion
3019538|NCT02432105|Experimental|EXE844 for 3 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops BID in each ear for 3 days after Tympanostomy Tube Insertion
3019539|NCT02432105|Active Comparator|Tubes Only|Bilateral myringotomy and tympanostomy tube insertion
3019540|NCT02432092||Affected|participants with cardiomyopathy
3019541|NCT02432092||Family Members of affected|Family members of participants with cardiomyopathy (can be affected or unaffected)
3019542|NCT02432079||Heterotaxy and congenital heart defects|Patients and family members with heterotaxy and related congenital heart defects
3019543|NCT02432066|Active Comparator|GTS-21|Participants in the GTS-21 arm will receive 150 mg/BID GTS-21 over the course of 7 weeks. All participants will receive repeated neurobehavioral testing, laboratory assessment of cardiovascular and liver function, and provide weekly updates regarding smoking behavior, mood states, and side effects.
3019544|NCT02432066|Placebo Comparator|Placebo|Participants in the Placebo arm will receive placebo compound twice daily over the course of 7 weeks. All participants will receive repeated neurobehavioral testing, laboratory assessment of cardiovascular and liver function, and provide weekly updates regarding smoking behavior, mood states, and side effects.
3019545|NCT02432053|Experimental|Transplantation|Advagraf
3019546|NCT02432040|Experimental|Atorvastatin|Atorvastatin 40 mg once a day at night Patients asked to apply Betamethasone valerate 0.1% ointment twice a day, 3 weeks on, 1 week off, at the most
3019547|NCT02432040|Placebo Comparator|Placebo|Placebo tablets But patients are still asked to apply Betamethasone valerate 0.1% ointment twice a day, 3 weeks on, 1 week off, at the most
3019548|NCT02432027|Experimental|IMP 1|C-82 Topical Gel, 1%
3019549|NCT02432027|Placebo Comparator|IMP 2|C-82 Topical Gel, placebo
3019550|NCT02432027|Active Comparator|IMP 3|Daivonex cream
3019551|NCT02432027|Active Comparator|IMP 4|Diprosis gel
3019552|NCT02432014|Other|PMTO-PTC Group clinic-based|PMTO-PTC = Oregon Parent Management Training program, Parenting Through Change groups provided at a clinic.
3019553|NCT02432014|Other|PMTO Individual home-based|PMTO = Oregon Parent Management Training program, delivered individually in the home.
3019554|NCT02432014|Other|PMTO Individual clinic-based|PMTO = Oregon Parent Management Training program, delivered individually at a clinic.
3019555|NCT02432014|Other|Services as Usual|Usual child-centered services (i.e. therapy) provided by the agencies at a clinic.
3019556|NCT02432001||Image-Guided Biopsies|Image-guided biopsies will be performed at the Dream Team Site enrolling the patient. Lesions will be chosen based upon the strength of the evidence suggesting the presence of metastasis and with the goal of minimizing patient risk. Soft tissue lesions and lesions with documented radiologic progression should be prioritized for biopsy. If the Radiologist in charge of the procedure cannot identify a lesion amenable for biopsy, the patient will be considered a screening failure.
3019557|NCT02431988|Experimental|CAR19 T-cells|"Patients will receive a single infusion of CAR19 T-cells following standard pre-conditioning with cyclophosphamide and fludarabine.~The CAR19 T-cells are to be administered on day 0."
3019558|NCT02431975|Experimental|Early ART|All infants enrolled in the trial, regardless of maternal PMTCT regimen, will be initiated on a triple ARV regimen consisting of nevirapine (NVP), zidovudine (ZDV) and lamivudine (3TC) presumptively based on the initial positive result. This regimen will be continued to 42 weeks post menstrual age (PMA). At this time, infants will be switched to LPV/r, ZDV and 3TC to be continued to 104 weeks or longer unless otherwise preferred by the treating clinician or if any clinical or laboratory contraindications are identified.
3019559|NCT02431962|Experimental|Screening arm|Annual low dose screening chest CT scan x 3.
3019560|NCT02431962|Experimental|Smoking cessation counseling|Active smokers randomized to this arm will be contacted by a trained smoking cessation counselor and offered cessation support and advice.
3019561|NCT02431962|Active Comparator|Smoking cessation control|Active smokers randomized to this arm will receive general information on available smoking cessation resources.
3019562|NCT02431949||Controls|Participants without a psychosis disorder diagnosis.
3019563|NCT02431949||Patients|Participants with a psychosis disorder diagnosis- recruited from the BC Psychosis Program.
3019564|NCT02431936|Experimental|Prazosin|Prescription for 1mg oral Prazosin twice per day will be administered for 71/2 days.
3019565|NCT02431936|Placebo Comparator|Placebo|Prescription for placebo identical to Prazosin dosage will be administered for twice daily for 71/2 days.
3019566|NCT02431910|No Intervention|Control group|The control group remains at rest for 10 minutes, which is not applied KT in the RF, VL and VM muscles. The volunteers of this group perform all evaluation without the application of KT
3019675|NCT02431364|Experimental|Cohort 4|40 mg verdinexor on Days 1 and 3
3019567|NCT02431910|Placebo Comparator|Placebo group|The Kinesio Taping (KT) is applied on the vastus lateralis (VL), vastus medialis (VM) and rectus femoris (RF) muscles longitudinally from proximal to the distal. For the RF proximal anchor is applied 5cm below the anterior superior iliac spine and the distal anchor the upper edge of the patella. VL in the proximal and distal anchor will be fixed in greater trochanter of the femur and the lateral edge of the patella. As for the VM muscle proximal anchor will be applied to the middle third from the medial region of the thigh and the distal anchor on the medial edge of the patella. The anchors are applied with 0% tension and therapy area will follow on the belly of the muscles with a 0%.
3019568|NCT02431910|Experimental|Kinesio Taping group|The Kinesio Taping (KT) is applied on the vastus lateralis (VL), vastus medialis (VM) and rectus femoris (RF) muscles longitudinally from proximal to the distal. For the RF proximal anchor is applied 5cm below the anterior superior iliac spine and the distal anchor the upper edge of the patella. VL in the proximal and distal anchor will be fixed in greater trochanter of the femur and the lateral edge of the patella. As for the VM muscle proximal anchor will be applied to the middle third from the medial region of the thigh and the distal anchor on the medial edge of the patella. The anchors are applied with 0% tension and therapy area will follow on the belly of the muscles with a 50%. This application will be held with subjects standing on one foot, with the hip of the non-dominant limb at 0º and knee flexed at 90º.
3019569|NCT02431897|Experimental|Estrogen Cream|
3019570|NCT02431897|Placebo Comparator|Placebo Cream|
3019571|NCT02431884||body fluids/tissues & history|collect body fluids/tissues & med history from subjects with polycystic ovary syndrome(PCOS), congenital uterine malformations, endocrine malfunctions, endometriosis, and infertility;
3019572|NCT02431871||Treated for DDH in childhood|Subjects have had DDH in childhood. DDH has been diagnosed before age of 1,5 years and treated for.
3019573|NCT02431871||Control|Age an sex matched controls of DDH patients
3019574|NCT02431858|Experimental|Catheter Over Needle|"The femoral nerve catheter used will be the E-Catheter (Pajunk) device which is a novel catheter over needle system."
3019575|NCT02431858|Active Comparator|Catheter through needle|"The femoral nerve catheter used will be the Sonolong catheter (Pajunk) which is a traditional catheter through needle system."
3019576|NCT02431845|Experimental|SSRIs treatment as usual OCD gruop|SSRIs treatment as usual fluoxetine 40~80 mg dose equivalent (fluoxetine, paroxetine, sertraline, fluvoxamine, escitalopram, clomipramine)
3019577|NCT02431832|Experimental|Augmentin tab|
3019578|NCT02431819|Experimental|contention socks|Patients wear evolutive contention socks during 15 days.
3019579|NCT02431806|Placebo Comparator|Placebo|Patients randomized to the placebo arm will take placebo capsules once daily orally during the double-blind treatment period.
3019580|NCT02431806|Experimental|Levomilnacipran ER 40 mg|Patients randomized to the levomilnacipran ER 40 mg arm will take over-encapsulated levomilnacipran ER 40 mg capsules once daily orally during the double-blind treatment period.
3019581|NCT02431806|Experimental|Levomilnacipran ER 80 mg|Patients randomized to the levomilnacipran ER 80 mg arm will take two over-encapsulated levomilnacipran ER 40 mg capsules once daily orally during the double-blind treatment period.
3019582|NCT02431806|Active Comparator|Fluoxetine 20 mg|Patients randomized to the fluoxetine 20 mg arm will take over-encapsulated fluoxetine 20 mg tablets once daily orally during the double-blind treatment period.
3019583|NCT02431793|No Intervention|Usual Care|Employ the standard of care, no intervention
3019584|NCT02431793|Experimental|EMC2 strategy|"Patients of providers randomized to EMC2 arm will received educational tool from the ED to support the understanding and safe use of opioids.~A single-page medication information sheet with content from a patients perspective and following health literacy best practices.~Prescribing instructions will be adapted to the Universal Medication Scheduled Take-Wait-Stop regimen for both the prescribing and dispensing of the medicine. This format uses simplified text and numeric characters to detail dose.~Provider counseling prompts: The providers for patients in this arm will be prompted to encourage counseling both in the ED and at follow-up time points. These prompts include: 1) An automated prompt to the ED physician upon signing the order; 2) an automated inbox message to the PCP (if an in-system PCP) notifying them of the ED visit, new prescription, and counseling request; and 3) a request for the pharmacist to counsel patient printed automatically on the prescription."
3019585|NCT02431793|Experimental|EMC2 strategy + SMS Text Reminders|In addition to the EMC2 Strategy Arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
3019586|NCT02431780|No Intervention|non ANSeR Software System|Routine clinical EEG monitoring
3019587|NCT02431780|Experimental|ANSeR Software System|The intended use of the ANSeR Software System is to provide a real time decision support tool to assist in the diagnosis of seizures in neonates (between 36 weeks and 44 weeks corrected age) and to provide a review tool for EEG and seizure analysis. ANSeR is intended to provide a reliable, effective, objective and intuitive means of identifying seizures
3019588|NCT02431767|Experimental|Group 1: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.6 mg admixed with IL-12 DNA 0.2 mg to be administered as 0.1 mL by intradermal (ID) injection over either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
3019589|NCT02431767|Placebo Comparator|Group 1: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
3019590|NCT02431767|Experimental|Group 2: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.8 mg to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
3019591|NCT02431767|Placebo Comparator|Group 2: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
3019592|NCT02431767|Experimental|Group 3: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.8 mg admixed with IL-12 DNA 0.2 mg to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
3019593|NCT02431767|Placebo Comparator|Group 3: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
3019676|NCT02431364|Experimental|Cohort 5|60 mg verdinexor on Days 1 and 3
3019594|NCT02431767|Experimental|Group 4: Treatment|Participants will receive the PENNVAX®-GP vaccine 8 mg admixed with IL-12 DNA 1 mg to be administered as 1 mL intramuscular (IM) injection in either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 5P EP system.
3019595|NCT02431767|Placebo Comparator|Group 4: Placebo|Participants will receive placebo to be administered as 1 mL IM in either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 5P EP system.
3019596|NCT02431754|Experimental|Tadalafil|"5 milligrams (mg) tadalafil administered once daily orally for 8 weeks in one of two treatment periods.~0.2 mg tamulosin once daily or 4 mg silodosin twice daily.~Participants will remain on stable dose of alpha1 blocker through both treatment periods."
3019597|NCT02431754|Placebo Comparator|Placebo|"Placebo administered once daily orally for 8 weeks in one of two treatment periods.~0.2 mg tamulosin once daily or 4 mg silodosin twice daily.~Participants will remain on stable dose of alpha1 blocker through both treatment periods."
3019598|NCT02431741|Experimental|Mepilex Transfer Ag|Non controlled investigation
3019599|NCT02431728|Active Comparator|Melatonin|capsule containing 5mg melatonin plus cellulose
3019600|NCT02431728|Placebo Comparator|Matched Placebo|capsule containing cellulose
3019601|NCT02431702|Active Comparator|Part-1: Oral Antipsychotics (OAP)|All Participants will receive Paliperidone Extended Release (ER) 1.5 to 12 milligram (mg) or risperidone 1 to 6 mg once daily orally for 2 months. Subjects who tolerate paliperidone ER/risperidone but find it inadequately efficacious after treatment for an adequate duration at an adequate dosage (per clinical judgment), may be switched to another protocol-specified OAP at the discretion of the investigator.
3019602|NCT02431702|Experimental|Part-2: Paliperidone Palmitate (PP)|Participants who will complete Part-1 will be randomized to receive oral Paliperidone Palmitate (PP) treatment. Participants will receive 5 doses of PP1M (paliperidone palmitate once-monthly injection). First dose at a starting dose of 234 mg on Day 1 and thereafter second dose in second week and then, every month up to Day 92. Participants will be subsequently switched to PP3M (paliperidone palmitate three-monthly injection) following a minimum of 5 injections of PP1M. Participants receiving PP3M may go back to treatment with PP1M (monthly injections of 78, 117, 156 or 234 mg, flexibly dosed) for further dose adjustment or for the duration of the study with the approval of the medical monitor.
3019603|NCT02431702|Active Comparator|Part-2: OAP|Participants who will complete Part-1 will be randomized to receive Oral Antipsychotics for 9 months.
3019604|NCT02431702|Experimental|Part-3: PP - PP|Participants who will complete Part-2 (with PP treatment) will continue to receive Paliperidone Palmitate for 9 months.
3019605|NCT02431702|Experimental|Part-3: OAP - Delayed Start Paliperidone Palmitate (PP)|Participants who will complete Part-2 (with OAP treatment) will be randomized to receive PP treatment for 9 months. PP treatment includes PP1M and PP3M. Participants will be subsequently switched to PP3M following a minimum of 5 injections of PP1M. Participants receiving PP3M may go back to treatment with PP1M (monthly injections of 78, 117, 156 or 234 mg, flexibly dosed) for further dose adjustment or for the duration of the study with the approval of the medical monitor.
3019606|NCT02431702|Active Comparator|Part-3: OAP - OAP|Participants who will complete Part-2 (with OAP treatment) will be randomized to receive OAP treatment for additional 9 months.
3019607|NCT02431689|Active Comparator|Antagonist|"Antagonist protocol (fixed) for IVF/ICSI, with starting dose of human menopausal gonadotrophins (HMG) from 300-450 IU from day 1 of the cycle, antagonist start from day 6 stimulation. Follow-up by ultrasound and serum estradiol will be done. Triggering of ovulation using human chorionic gonadotrophin (HCG) 10000 IU I.M. when at least 2-3 follicles reach 17mm in diameter.~Cryopreservation of all embryos at will be done. Frozen embryo transfer in the following cycle will be attempted using estradiol valerate (6mg) for endometrial preparation after pituitary down regulation using long acting GnRH analogue . A maximum of 3 good quality embryos will be transferred."
3019608|NCT02431689|Active Comparator|Short|"Short protocol for IVF/ICSI, gonadotrophin releasing hormone analogue (GnRHa) starts from day 1 of the cycle, HMG starts in a dose from 300-450 IU from day 3, Follow-up by ultrasound and serum estradiol will be done. Triggering of ovulation using human chorionic gonadotrophin (HCG) 10000 IU I.M. when at least 2-3 follicles reach 17mm in diameter.~Cryopreservation of all embryos at will be done. Frozen embryo transfer in the following cycle will be attempted using estradiol valerate (6mg) for endometrial preparation after pituitary down regulation using long acting GnRH analogue . A maximum of 3 good quality embryos will be transferred."
3019609|NCT02431676|Active Comparator|Self-Directed|In this group, the study staff will meet with you once at the beginning of the study to give you written information about weight management.
3019610|NCT02431676|Experimental|Coach Directed Behavioral Weight Loss|The Remote Lifestyle Coaching intervention is based on the Call Center Directed intervention to help you loss weight
3019611|NCT02431676|Experimental|Metformin|This group will be given the study drug called Metformin. Metformin comes in tablet form that you take with meals
3019612|NCT02431663|Experimental|ketamine up to 100 mcg/kg/min|Two intravenous boluses of 2-3 mg/kg each of ketamine will be administered 5 minutes apart and immediately followed by a continuous infusion of 5-10 mcg/kg/min. Based on both clinical or electrographic responses, dosage will be increased every 10 minutes or longer, using 2 to 10 mcg/kg/ min increments, up to 60 mcg/kg/min. Maximum duration of infusion will be of 7 days.
3019613|NCT02431663|Active Comparator|midazolam & thiopental & propofol|"Midazolam intravenous will be increased every 5 minutes, using 2 mcg/kg/min increments, up to 12 mcg/kg/min and Thiopental intravenous will be increased every 30 minutes or longer, using 1 mg/kg/h increments, up to 6 mg/kg/h and Propofol intravenous will be increased every 5 minutes or longer, using 1 mg/kg/h increments, up to 5 mg/kg/h.~Maximum duration of infusion for each drug will be 48 hours."
3019614|NCT02431650|Experimental|OZ439|"Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants is ≥ 5,000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood stage parasitemia. When gametocytemia is at the peak (approximately 15 days after administration of piperaquine), participants will be randomised to receive either OZ439 or a control group (primaquine treatment).~In the first cohort 500 mg OZ439 will be administered as a single dose. Doses used in subsequent cohort(s) will be determined following a review of observed safety and pharmacodynamic drug effects."
3019677|NCT02431364|Experimental|Cohort 6|80 mg verdinexor on Days 1 and 3
3019678|NCT02431364|Experimental|Cohort 7|100 mg verdinexor on Days 1 and 3
3019615|NCT02431650|Active Comparator|Primaquine|"Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants is ≥ 5,000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood stage parasitemia. When gametocytemia is at the peak (approximately 15 days after administration of piperaquine), participants will be randomised to receive either OZ439 or a control group (primaquine treatment).~Primaquine is a positive control for OZ439, to be administered 15 mg as a single dose."
3019616|NCT02431637|Experimental|Piperaquine Phosphate after infected blood malaria challenge|Volunteers will receive a dose of 480 mg piperaquine phosphate (PQP) approx. 7 days after a challenge with P. falciparum infected red blood cells. The effects of PQP on gametocyte carriage (assessed by PCR) and infectivity to mosquitos after direct and indirect feeding on blood from volunteers will be assessed.
3019617|NCT02431624|Experimental|Test treatment|BTDS 40 milligram
3019618|NCT02431624|Active Comparator|Reference treatment|BTDS 20 milligram
3019619|NCT02431611|Active Comparator|Control condition|Control behavioral phone-based smoking cessation intervention
3019620|NCT02431611|Experimental|Biomarker Feedback Intervention|Biomarker feedback plus behavioral phone-based smoking cessation intervention
3019621|NCT02431598|Active Comparator|Eovist (gadoxetate disodium)|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
3019622|NCT02431598|Active Comparator|Dotarem (gadoterate dimeglumine)|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
3019623|NCT02431598|Active Comparator|Saline|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
3019624|NCT02431585|Other|rechallenge|Double blind placebo controlled cross over
3019625|NCT02431572|Experimental|Metastatic Melanoma to the Brain (Cohort A)|"Assess Inflammation (PBR PET)~Immunotherapy~Assess Inflammation (PBR PET)"
3019626|NCT02431572|Experimental|Primary Brain Tumor (Cohort B)|"Assess Inflammation (PBR PET)~Immunotherapy~Assess Inflammation (PBR PET)"
3019627|NCT02431572|Experimental|Primary Brain Tumor (Cohort C)|"Chemoradiation~Assess inflammation (PBR PET)~Follow Patients"
3019628|NCT02431559|Experimental|Phase 1|"Phase 1 Dose escalations and de-escalations for the determination of the MTD (or highest tolerable dose tested) will be performed based on the available dose levels and the respective rules for a standard 3 + 3 study design.~All subjects will be treated with PLD intravenously, MEDI4736 intravenously subcutaneously during each 28-day cycle according to the treatment schedule below:~Cycles 1-12 Day 1: PLD (IV) Day 3: MEDI4736 (IV)"
3019629|NCT02431559|Experimental|Phase 2|Phase 2 subjects will be treated at the highest tolerable dose level determined in phase 1.
3019630|NCT02431546|Experimental|Mobile Health Application Group|"VIDA is a mobile technology that is well positioned to provide healthcare coaching. After completing the CR program, each participant will have access to the VIDA mobile phone platform for the 12-week intervention, and be instructed to download the app on his/her smart phone. VIDA will assign an individual professional health coach selected from a pool of well-trained and experienced health professionals-nutritionists, fitness trainers, nurses and health educators. Each coach will engage their patient in a productive and meaningful health mentorship on a daily basis. The coach and patient work as a team to successfully set goals and make small changes that add up to significant improvements in the patients' dietary choices, physical activity, medication management, as well as understanding of their health status.~Physical Activity: A goal of total number of steps to attain daily will be provided by the Duke study team to the patient and monitored using a Fitbit activity tracker."
3019631|NCT02431546|No Intervention|Usual Care Group|Participants randomized to the usual care control arm will follow standard care as ordered by their individual, treating physician. Participants in the UC control arm will not receive any specific lifestyle recommendations from study personnel. They may, however, receive any lifestyle recommendations deemed appropriate by their usual clinical care providers. All participants will be contacted by study personnel in order to schedule visits at baseline and 12-weeks for the outcome assessments.
3019632|NCT02431533|Experimental|Probiotic PX0612|PX0612 is a probiotic contained in a veggie capsule.
3019633|NCT02431533|Placebo Comparator|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
3019634|NCT02431520|Experimental|Self-collection|Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for Hybrid Capture II (HCII).
3019635|NCT02431520|Active Comparator|Gynecologist collection|Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
3019636|NCT02431507|Experimental|Treatment Arm with Magnetic Apnea Device|The treatment arm with magnetic apnea device includes: surgical implantation of the magnetic apnea device(MAGNAP) to treat obstructive sleep apnea in each eligible enrolled subject . A custom fitted external brace will be created for wear throughout the 13 months of treatment and evaluated for improvement of symptoms..
3019637|NCT02431494|Active Comparator|BLP arm (Blue Light Phototherapy)|In this arm participants will receive 5 BLP sessions at 1 week intervals. The duration of each session will be approximately 20 minutes. At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes.
3019638|NCT02431494|Active Comparator|MCT arm (Microcurrent Therapy)|In this arm participants will receive 5 MCT sessions 1 week intervals using MCT machine. The duration of each session will be approximately 45 minutes. The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated.
3019679|NCT02431351|Experimental|Selinexor|60 mg once weekly
3019854|NCT02430181|Experimental|100 mg BID lonafarnib/PEG IFN-a|lonafarnib 100 mg BID + PEG IFN-a 180 ug QW; n=3
3019639|NCT02431494|Active Comparator|Combination of BLP and Microcurrent|In this arm participants will receive 5 BLP and 5 MCT sessions at 1 week intervals. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
3019640|NCT02431481|Experimental|Normal renal function|Normal renal function; matched demography to renal impariment cohorts
3019641|NCT02431481|Experimental|Severe renal impairment|Severe decrease in GFR (15-29 ml/min)
3019642|NCT02431481|Experimental|End Stage Renal Disease|End stage renal disease not on dialysis; GFR <15 ml/min
3019643|NCT02431481|Experimental|Mild renal impairment|Mild decrease in GFR (60-89 ml/min)
3019644|NCT02431481|Experimental|Moderate renal impairment|Moderate decrease in GFR (30-59 ml/min)
3019645|NCT02431468|Experimental|Bryostatin 1 20ug|Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
3019646|NCT02431468|Experimental|Bryostatin 1 40ug|Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
3019647|NCT02431468|Placebo Comparator|Placebo|Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.
3019648|NCT02431455|Active Comparator|Incentive Spirometry|Incentive spirometry 10 times per hour while awake
3019649|NCT02431455|Experimental|No Incentive Spirometry|No incentive spirometer provided
3019650|NCT02431442|Active Comparator|Cohort 1: RM-493 SC Infusion 14 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 14 days (1 panel, all male subjects)
3019651|NCT02431442|Active Comparator|Cohort 2: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
3019652|NCT02431442|Active Comparator|Cohort 3: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
3019653|NCT02431442|Active Comparator|Cohort 4: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.015 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
3019654|NCT02431442|Active Comparator|Cohort 5: RM-493 SC Injection 14 days|Double-blind RM-493 will be administered at a dose of 0.0075 mg/kg every 12 hours via a subcutaneous injection for 14 days (1 panel)
3019655|NCT02431442|Active Comparator|Cohort 6: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel, heterozygous MC4R subjects)
3019656|NCT02431442|Placebo Comparator|Cohort 1: Placebo SC Infusion 14 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 14 days (1 panel, all male subject)
3019657|NCT02431442|Placebo Comparator|Cohort 2: Placebo SC Infusion 28 Days|Double-blind Placebo will be via subcutaneous continuous infusion for 14 days (1 panel)
3019658|NCT02431442|Placebo Comparator|Cohort 3: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel)
3019659|NCT02431442|Placebo Comparator|Cohort 4: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel)
3019660|NCT02431442|Placebo Comparator|Cohort 5: Placebo SC Injection 14 days|Double-blind Placebo will be administered via a subcutaneous injection every 12 hours for 14 days (1 panel)
3019661|NCT02431442|Placebo Comparator|Cohort 6: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel, heterozygous MC4R subjects)
3019662|NCT02431429||miltefosine|miltefosine: target of 2.5 mg/kg/day for 28 days
3019663|NCT02431416|Active Comparator|Gonadotropin releasing hormone (GnRH)|A single intravenous injection of gonadotropin releasing hormone GnRH (Relefact LHRH 0,1 mg/mL). Dose: 100 micrograms per square meter body surface. Maximal dose: 100 micrograms.
3019664|NCT02431416|Placebo Comparator|Sodium chloride|A single intravenous injection of sodium chlorid (9 mg/mL). Dose: the same volume as the volume given/to be given with GnRH, that is maximal dose = 1 mL = 9 mg sodium chlorid.
3019665|NCT02431403|Experimental|ESHAP-Imatinib 100mg|"Imatinib 100 mg combined with ESHAP~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
3019666|NCT02431403|Experimental|ESHAP-Imatinib 200mg|"Imatinib 200 mg combined with ESHAP~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
3019667|NCT02431403|Experimental|ESHAP-Imatinib 400mg|"Imatinib 400 mg combined with ESHAP~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
3019668|NCT02431403|Experimental|ESHAP-Imatinib 300mg|"Imatinib 300 mg combined with ESHAP~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
3019669|NCT02431390|Experimental|RAPAELⓇ Smart Glove group|The experimental group includes 40 stroke patients. The group will receive the conventional occupational therapy(30min per session, 5 times per week, during 4 weeks of hand dexterity training) and RAPAELⓇ Smart Glove digital treatment system training. RAPAELⓇ Smart Glove digital treatment training will consist of games and play to facilitate the function of upper limbs and brain plasticity. RAPAELⓇ Smart Glove group will be provided the 20 training session. (30min per session, 5 times per week, during 4 weeks)
3019670|NCT02431390|Active Comparator|Additional occupation therapy group|The active comparator group includes 40 stroke patients.The occupational therapy group will receive the conventional occupational therapy(30min per session, 5 times per week, during 4 weeks of hand dexterity training) sessions twice. Additional conventional occupational therapy sessions are comprised of the training for upper limb and cognition. The additional occupational therapy group will be provided the 20 additional session (30min per session, 5 times per week, during 4 weeks)
3019671|NCT02431377|Experimental|S-26 Gold|Standard Infant Formula containing enriched with alpha-lactalbumin
3019672|NCT02431364|Experimental|Cohort 1|5 mg verdinexor on Days 1 and 3 or Placebo
3019673|NCT02431364|Experimental|Cohort 2|10 mg verdinexor on Days 1 and 3
3019674|NCT02431364|Experimental|Cohort 3|20 mg verdinexor on Days 1 and 3
3019680|NCT02431338|Experimental|Intervention group|Remote ischemic conditioning through intermittent arm ischemia with four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff performed in the ambulance during transport to primary percutaneous coronary intervention.
3019681|NCT02431338|No Intervention|Control group|Standard treatment with primary percutaneous coronary intervention alone.
3019682|NCT02431325|Experimental|Teduglutide|Teduglutide, subcutaneous injection, 0.05 mg/kg/day, 6 months duration
3019683|NCT02431325|Placebo Comparator|Placebo|Placebo, subcutaneous injection, 6 months duration
3019684|NCT02431312|Experimental|Group A, low dose, standard regimen|0.3mg INO-1800 delivered by EP in a standard regimen (either 3 or 4 doses) while continuing treatment with nucleos(t)ide analogue treatment
3019685|NCT02431312|Experimental|Group A, mid dose, standard regimen|2mg INO-1800 delivered by EP in a standard regimen (either 3 or 4 doses) while continuing treatment with nucleos(t)ide analogue treatment
3019686|NCT02431312|Experimental|Group A, high dose, standard regimen|9mg INO-1800 delivered by EP in a standard regimen (either 3 or 4 doses) while continuing treatment with nucleos(t)ide analogue treatment
3019687|NCT02431312|Experimental|Group B, mid dose, standard regimen|2mg INO-1800 + 0.25mg INO-9112 delivered by EP in a standard regimen (either 3 or 4 doses) while continuing treatment with nucleos(t)ide analogue treatment
3019688|NCT02431312|Experimental|Group B, high dose, standard regimen|9mg INO-1800 + 0.25mg INO-9112 delivered by EP in a standard regimen (either 3 or 4 doses) while continuing treatment with nucleos(t)ide analogue treatment
3019689|NCT02431312|Active Comparator|Active Control|Continue treatment with nucleos(t)ide analogue treatment
3019690|NCT02431286|Experimental|Aprepitant|patient will receive aprepitant 80 mg per os one hour before surgery; palonosetron and dexamethasone will be intravenously administered during surgery
3019691|NCT02431286|Placebo Comparator|placebo|patient will receive placebo per os one hour before surgery; palonosetron and dexamethasone will be intravenously administered during surgery
3019692|NCT02431273|Experimental|TDF (Single IVR)|"All subjects will be asked to wear Single (TDF) IVRs for 7 days."
3019693|NCT02431273|Experimental|TDF-FTC (Dual IVR)|"If the TDF IVR is determined as safe, study participants will be asked to replace it with Dual (TDF-FTC) IVRs for 7 days. There will be follow-up visit between removal of a single IVR and replacing it with a dual IVR."
3019694|NCT02431273|Experimental|TDF-FTC-MVC (Triple IVR)|"If the TDF-FTC IVR is determined as safe, study participants will be asked to replace them with Triple (TDF-FTC-MVC) IVRs for 7 days. There will be follow-up visit between removal of a dual IVR and replacing it with a triple IVR."
3019695|NCT02431260|Experimental|INCB054329 Monotherapy|
3019696|NCT02431247|Experimental|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide|Subject will receive a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching and FTC/TDF FDC-matching placebo tablets once daily up to Week 48 analysis unblinding visit (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding visit, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.
3019697|NCT02431247|Active Comparator|DRV/COBI fixed dose combination (FDC) and FTC/TDF FDC|Subject will receive DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48 analysis unblinding (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.
3019698|NCT02431221|Experimental|Intervention|Perhexiline maleate will be supplied in 100 mg and 25 mg tablets. It will be initially administered at a dose of 200 mg once a day in tablet form for at least six months. After initiation of dosing, perhexiline dosing will be determined using plasma level guided dose adjustment. Dosing decisions will be made by an unblinded dose control center.
3019699|NCT02431221|Placebo Comparator|Placebo|Placebo will be administered once a day in tablet form for at least six months. Tablets will be identical in size and shape to perhexiline tablets. Adjustments in placebo dosing will be made by an unblinded dose control center to mimic decisions made for subjects in the experimental arm.
3019700|NCT02431208|Experimental|Cohort A: ATZ (Run-In)|Cohort A will involve a safety run-in to evaluate atezolizumab administered as a single agent in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort has been completed.
3019701|NCT02431208|Experimental|Cohort B1: ATZ + LEN (Dose Escalation)|Cohort B1 will involve a dose escalation to evaluate atezolizumab administered in combination with ascending-dose lenalidomide in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort has been completed.
3019702|NCT02431208|Experimental|Cohort C: ATZ + LEN (Post-ASCT):|Cohort C will evaluate atezolizumab administered in combination with lenalidomide in participants with MM who have measureable disease after ASCT. NOTE: This cohort is closed to enrollment.
3019703|NCT02431208|Experimental|Cohort D1: ATZ + DAR (Run-in)|Cohort D1 will involve a safety run-in to evaluate atezolizumab administered in combination with daratumumab in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment.
3019704|NCT02431208|Experimental|Cohort D2: ATZ + DAR (Expansion)|Cohort D2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab in participants with relapsed or refractory MM who have received 2 but no more than 3 lines of prior treatment that must have included a PI and IMiD and are refractory to the last line of treatment.
3019705|NCT02431208|Experimental|Cohort D3: ATZ + DAR (Progressed)|Cohort D3 will involve an expansion to evaluate atezolizumab in combination with daratumumab in participants with relapsed or refractory MM who have received 2 or more lines of prior treatment and have progressed with an anti-cluster of differentiation (CD) 38 monoclonal antibody, either alone or in combination, and are refractory to both a proteasome inhibitor (PI) and immunomodulatory drug (IMiD).
3019706|NCT02431208|Experimental|Cohort E1: ATZ + DAR + LEN (Dose Escalation)|Cohort E1 will involve a dose escalation to evaluate atezolizumab administered in combination with daratumumab and ascending-dose lenalidomide in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort is closed to enrollment.
3019855|NCT02430181|Experimental|200 mg BID lonafarnib/PEG IFN-a|lonafarnib 200 mg BID + PEG IFN-a 180 ug QW; n=3
3019707|NCT02431208|Experimental|Cohort E2: ATZ + DAR + LEN (Expansion)|Cohort E2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab and the maximum tolerated dose (MTD) of lenalidomide determined in Cohort E1 in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort is closed to enrollment.
3019708|NCT02431208|Experimental|Cohort F1: ATZ + DAR + POM (Dose Escalation)|Cohort F1 will involve a dose escalation to evaluate atezolizumab administered in combination with daratumumab and ascending-dose pomalidomide in participants with relapsed or refractory MM who have received 4 or more lines of prior treatment and are refractory to the last line of treatment. NOTE: This cohort has been completed.
3019709|NCT02431208|Active Comparator|Cohort F2: ATZ + DAR + POM (Expansion)|Cohort F2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab and the MTD of pomalidomide determined in Cohort F1 in participants with relapsed or refractory MM who have received 4 or more lines of prior treatment and are refractory to the last line of treatment. NOTE: This cohort is randomized.
3019710|NCT02431208|Active Comparator|Cohort F3: DAR + POM + Dexamethasone|Cohort F3 is an expansion control arm for cohort F2. Participants will receive daratumumab in combination with pomalidomide at the MTD and dexamethasone. NOTE: This cohort is randomized.
3019711|NCT02431182|Experimental|Memory training group|"Memory training:The intervention consists of twelve 90-minutes group sessions given once a week by a specialized psychologist.~The groups are formed by around 15 people. Each session has its own objectives, material and activities. The content of the intervention is based on memory training from different perspectives as cognitive and emotional aspects or social and individual skills."
3019712|NCT02431182|No Intervention|Control group|No intervention will be administred until the delayed post-test is finished
3019713|NCT02431156||monovision|Presbyopic patients that underwent mini-monovision correction with bilateral implantation of monofocal intraocular lenses. Their visual capacity in ADLs will be assessed.
3019714|NCT02431143|Experimental|Miltefosine|allometric dosing
3019715|NCT02431130|Experimental|Low-fidelty instructor driven simulation training|participants receive simulation training
3019716|NCT02431130|No Intervention|No simulation training|
3019717|NCT02431104|Experimental|Laser Treatment|Treatment to unwanted tattoo using a 532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser
3019718|NCT02431091|Experimental|Definite Case|"Patients with abnormal response on both the screening questions and at least one of the cognitive screening tests.~Optical Coherence Tomography is performed in all definite cases"
3019719|NCT02431091|Active Comparator|Control B|Patients with abnormal response on the screening questions but normal cognitive screening tests Optical Coherence Tomography is performed in matched control B patients
3019720|NCT02431091|Active Comparator|Control A|"Patients with normal response on both the screening questions and all the cognitive screening tests.~Optical Coherence Tomography is performed in matched control A patients"
3019721|NCT02431078||ZEB1 high-expression group|Participants with ZEB1 high-expression(ZEB1 expression values＞the ZEB1 cut‑off point) in CTCs for gastric cancer will be assigned to this group.The ZEB1 cut‑off point was set at the top quartile.Routine comprehensive treatment will be performed.
3019722|NCT02431078||ZEB1 low-expression group|Participants with ZEB1 low-expression(ZEB1 expression values＜the ZEB1 cut‑off point) in CTCs for gastric cancer will be assigned to this group.The ZEB1 cut‑off point was set at the top quartile.Routine comprehensive treatment will be performed.
3019723|NCT02431065|Experimental|Group 3, Direct injection group|Test group 2, Rectus sheath block will be performed under direct visualization. Ropivacaine (0.75%, 10ml) will be directly injected into the right and left rectus sheath at the end of the operation.
3019724|NCT02431065|Active Comparator|Group 2, ultrasonography group|Test group 1, Rectus sheath block will be performed under sonographic guidance. Ropivacaine (0.75%, 10ml) will be injected into the right and left rectus sheath under ultrasonographic guidance at the end of the operation.
3019725|NCT02431065|Placebo Comparator|Group 1|Control group, Rectus sheath block will be performed under sonographic guidance. Normal saline 10 ml will be injected into the right, left rectus sheath under ultrasonography guidance at the end of the operation.
3019726|NCT02431052|Experimental|Treatment A|DRM01
3019727|NCT02431052|Experimental|Treatment B|DRM01
3019728|NCT02431052|Experimental|Treatment C|DRM01
3019729|NCT02431052|Placebo Comparator|Treatment D|Vehicle
3019730|NCT02431052|Placebo Comparator|Treatment E|Vehicle
3019731|NCT02431039|Experimental|NEOSORB PLUS|Subjects who are treated by NEOSORB PLUS
3019732|NCT02431039|Active Comparator|NEOSORB|Subjects who are treated by NEOSORB
3019733|NCT02431026|Experimental|Cooling present|"Cooling pack activated before start of MRI scan for the condition cooling present."
3019734|NCT02431026|No Intervention|No cooling present|"Cooling pack will not be activated in the condition no cooling present."
3019735|NCT02431013|Experimental|Simvastatin+Cilostazol|Simvastatin 40 mg on Day 1. Cilostazol 100 mg twice a day for 6 days. Simvastatin 40 mg and Cilostazol 100 mg twice a day on Day 8.
3019736|NCT02431013|Active Comparator|Pravastatin+Cilostazol|Pravastatin 20 mg on Day 1. Cilostazol 100 mg twice a day for 6 days. Pravastatin 20 mg and Cilostazol 100 mg twice a day on Day 8.
3019737|NCT02431000||Male Chemo/Radiotherapy Candidates|"Adult and post-pubertal males, 13 years of age or older, presenting to clinic because diagnosed with cancer, who wish to preserve their future fertility. Sperm and blood collected for analysis. If minors, parents or guardians have to give consent to the procedure while the boys give their assent.~This is a prospective observational cohort study."
3019738|NCT02430987||desire disorder group|with carrier hypoactive sexual desire disorder diagnosis with female sexual function index questionnaire
3019739|NCT02430987||no desire disorder|no carrier hypoactive sexual desire disorder diagnosis with female sexual function index questionnaire
3019740|NCT02430974|No Intervention|Chemotherapy|patients received four cycles of platinum-based doublet chemotherapy (150 mg/m2 paclitaxel plus 80 mg/m2 nedaplatin or 30mg/m2 lobaplatin on day one of a three-week cycle).
3019771|NCT02430818|Experimental|Ketamine|Ketamine is a dissociative agent that is thought to modulate pain by binding to NMDA receptors. Participants assigned to the ketamine arm will be given 0.4 mg/kg IV of ketamine (40 mg maximum).
3019856|NCT02430181|Experimental|300 mg BID lonafarnib/PEG IFN-a|lonafarnib 300 mg BID + PEG IFN-a 180 ug QW; n=3
3019741|NCT02430974|Experimental|Chemotherapy & Icotinib|patients received four cycles of platinum-based doublet chemotherapy (150 mg/m2 paclitaxel plus 80 mg/m2 nedaplatin or 30mg/m2 lobaplatin on day one of a three-week cycle).Two weeks after chemotherapy completed, patients assigned to the consolidation therapy group began oral icotinib treatment (125 mg, thrice daily). Icotinib treatment continued for four to eight months, or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity.
3019742|NCT02430948|Active Comparator|Standard Support Outreach|Providers receive standard written screening recommendations and do not receive academic detailing (educational outreach)
3019743|NCT02430948|Experimental|Standard materials and academic detailing|Providers receive standard written screening recommendations and receive academic detailing (educational outreach)
3019744|NCT02430948|Experimental|Color-coded materials and no academic detailing|Providers receive color-coded written screening recommendations and do not receive academic detailing (educational outreach)
3019745|NCT02430948|Experimental|Color-coded materials and academic detailing|Providers receive color-coded written screening recommendations and receive academic detailing (educational outreach)
3019746|NCT02430935|Experimental|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a standardized approach to the use of environmental supports for improving multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia.
3019747|NCT02430935|Active Comparator|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
3019748|NCT02430922|Experimental|iVolution stent|Patient's treated with the iVolution stent from iVascular for the treatment of femoropopliteal lesions.
3019749|NCT02430909|Placebo Comparator|CZP / CZP + PBO / CZP|"Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two weeks) until Week 30~+Placebo from Week 8 to Week 18"
3019750|NCT02430909|Experimental|CZP / CZP + UCB4940 / CZP|"Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two weeks) until Week 30~+ UCB4940 from Week 8 until Week 18"
3019751|NCT02430909|Other|CZP / CZP/ CZP|Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two Weeks) until Week 30
3019752|NCT02430896||ADHD group|Children and adolescents who met the Diagnostic and Statistical Manual IV Text Revision (DSM-IV-TR) diagnostic criteria for ADHD and needed pharmacotherapy. Subjects will be taking Methylphenidate or Atomoxetine for 52 weeks.
3019753|NCT02430896||Normal control group|Children and adolescents will be recruited by advertisement, and will be assigned to normal group if they do not meet the Diagnostic and Statistical Manual IV Text Revision (DSM-IV-TR) diagnostic criteria for ADHD .
3019754|NCT02430883|Active Comparator|first group|patients who have upper pole kidney stones treated with flexible renoscopy
3019755|NCT02430883|Active Comparator|second group|patients u who have mid pole kidney stones treated with flexible renoscopy
3019756|NCT02430883|Active Comparator|third group|patients who have lower pole kidney stones treated with flexible renoscopy
3019757|NCT02430883|Active Comparator|forth group|patients who have kidney stones in pelvis treated with flexible renoscopy
3019758|NCT02430883|Active Comparator|fifth group|patients who have multiple calixes kidney stones treated with flexible renoscopy
3019759|NCT02430870|Experimental|Part 1 Cohort 1: TAK-648 0.35 mg|Participants with T2DM on a stable dose of metformin in study Part 1, Cohort 1 received TAK-648 0.35 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
3019760|NCT02430870|Experimental|Part 1 Cohort 2: TAK-648 0.80 mg|Participants with T2DM on a stable dose of metformin in study Part 1, Cohort 2 received TAK-648 0.80 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
3019761|NCT02430870|Placebo Comparator|Part 1: Placebo Cohort 1-2|Participants with T2DM on a stable dose of metformin in study Part 1 received placebo-matching TAK-648, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
3019762|NCT02430870|Experimental|Part 2 Cohort 1: TAK-648 0.05 mg|Healthy participants of Japanese descent in study Part 2, Cohort 1 received TAK-648 0.05 mg, solution , orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
3019763|NCT02430870|Experimental|Part 2 Cohort 2: TAK-648 0.15 mg|Healthy participants of Japanese descent in study Part 2, Cohort 2 received TAK-648 0.15 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
3019764|NCT02430870|Experimental|Part 2 Cohort 3: TAK-648 0.35 mg|Healthy participants of Japanese descent in study Part 2, Cohort 3 received TAK-648 0.35 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
3019765|NCT02430870|Experimental|Part 2 Cohort 4: TAK-648 0.80 mg|Healthy participants of Japanese descent in study Part 2, Cohort 4 received TAK-648 0.80 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
3019766|NCT02430870|Placebo Comparator|Part 2: Placebo Cohort 1-4|Healthy participants of Japanese descent in study Part 2, received TAK-648 placebo-matching solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
3019767|NCT02430857|Experimental|OMT-Group|The OMT-group will get an osteopathic treatment once a week for 1 hour for 5 weeks. The blood will be screened again after the treatment.
3019768|NCT02430857|No Intervention|Controll Group|This group will receive no treatment. A blood screening is made again after 5 weeks.
3019769|NCT02430831|Active Comparator|Reuteri group|Milk formula added with probiotic L reuterii DSM 17938
3019770|NCT02430831|Placebo Comparator|Placebo|Milk formula without probiotic L reuterii DSM 17938
3019848|NCT02430194|Experimental|lonafarnib/ritonavir/PEG IFN-a - VIII|lonafarnib 25 mg BID + ritonavir 100 mg BID + PEG IFN-a 180 ug QW;
3019772|NCT02430818|Experimental|Morphine|Morphine is an opioid that acts on opioidergic receptors to modulate pain. Participants in the opioid arm will receive 0.1 mg/kg IV of morphine (10 mg maximum).
3019773|NCT02430805|Other|NOE|multicentric family-based cohort. prospective and transversal study
3019774|NCT02430792|Active Comparator|Football|Recreational football 1-hour twice weekly in a local football club on a disease specific team
3019775|NCT02430792|No Intervention|Control|A 15-30-minute guidance session upon group allocation to encourage engagement in the standard rehabilitation offered by the municipality
3019776|NCT02430779|Experimental|IRE Group|irreversible electroporation for Unresectable Renal Pelvic and Ureteral Neoplasms
3019777|NCT02430766|Experimental|IRE Group|irreversible electroporation for Unresectable Lymph Node Metastase
3019778|NCT02430753|Experimental|IRE Group|irreversible electroporation for Lung Neoplasms accompanied by Respiratory Function Insufficiency
3019779|NCT02430740|Other|control group|standard care recFSH
3019780|NCT02430740|Experimental|study group|modified dosage of recFSH for controlled ovarian stimulation based on AMH, BMI and AFC
3019781|NCT02430714||Arm 1|A prospective, centrally registered investigation will be conducted. The new administering participants are to be registered at the time of administration.
3019782|NCT02430701|Experimental|IRE Group|irreversible electroporation for Unresectable Esophageal Neoplasms
3019783|NCT02430688|Experimental|IRE Group|irreversible electroporation for Unresectable Extremities Neoplasms
3019784|NCT02430675|Experimental|Group A|irreversible electroporation for Unresectable Laryngeal Neoplasms
3019785|NCT02430662|Experimental|IRE Group|irreversible electroporation for Unresectable Gallbladder Neoplasms
3019786|NCT02430649|Experimental|IRE Group|irreversible electroporation for Unresectable Prostatic Neoplasms
3019787|NCT02430636|Experimental|IRE Group|irreversible electroporation for Unresectable Stomach Neoplasms
3019788|NCT02430623|Experimental|IRE Group|irreversible electroporation for Unresectable Urinary Bladder Neoplasms
3019789|NCT02430610|Experimental|IRE Group|irreversible electroporation for Unresectable Uterine Cervical Neoplasms
3019790|NCT02430597|Experimental|IRE Group|irreversible electroporation for Unresectable Hilus Pulmonis Neoplasms
3019791|NCT02430558|Experimental|OD-PHOENIX|treatment of 1 to 5 osteochondral allograft cylinders in mosaic
3019792|NCT02430545|Experimental|Glasdegib, Rifampin|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
3019793|NCT02430532|Experimental|Dimethyl fumarate|BG00012 120 mg (1 BG00012 120 mg capsule + 1 matching placebo capsule) orally twice daily (BID) for 1 week, followed by BG00012 240 mg orally BID thereafter.
3019794|NCT02430532|Experimental|Placebo|BG00012 120 mg capsule orally once a day supplemented with matching placebo capsules for the first 4 weeks of treatment, as an additional blinding measure. Matched placebo capsules only thereafter.
3019795|NCT02430519|Experimental|11 Patients with Grade II Manibular Molar Furcation|Group A- Furcation Treatment with PRF
3019796|NCT02430519|Experimental|11 Patients with Grade II Mandibular Molar Furcation D|Group B- Furcation Treatment with Allograft and GTR
3019797|NCT02430506|Placebo Comparator|Placebo|1.0 mL sterile buffer administered by intramuscular (IM) injection to deltoid area on days 0 and 56.
3019798|NCT02430506|Experimental|AERAS-402|1.0 mL containing 3 x 10^10 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non-animal source) and water. Administered intramuscular (IM) injection to deltoid area on days 0 and 56.
3019799|NCT02430493||ticagrelor|Chinese subjects aged over 18, diagnosed as ACS and treated with ticagrelor at least one tablet
3019800|NCT02430480|Experimental|1/Arm 1|Patients will have an mpMRI guided biopsy, then receive enzalutamide and goserelin SC treatment for 6 months followed by a second mpMRI examination.
3019801|NCT02430467|Active Comparator|Caregiver-guided pain management training protocol (CG-PMT)|Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques
3019802|NCT02430467|Active Comparator|Enhanced treatment-as-usual (TAU)|Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
3019803|NCT02430454|Experimental|Experimental|Subjected to increased cognitive load
3019804|NCT02430454|No Intervention|Control|Not subjected to increased cognitive load
3019805|NCT02430428|Experimental|VisuMax lenticule removal|VisuMax femtosecond laser sphere-only or spherocylindrical treatment
3019806|NCT02430415|Experimental|Group A|laryngoscope-assisted lightwand intubation - traditional lightwand intubation
3019807|NCT02430415|Experimental|Group B|traditional lightwand intubation - laryngoscope-assisted lightwand intubation
3019808|NCT02430402|Experimental|Climate therapy|Climate therapy consisting of 3 week stay at rehabilitation facility in Spain
3019809|NCT02430402|No Intervention|Usual care|Usual care provided as needed / agreed between patient and health care providers
3019810|NCT02430389|Experimental|Remifentanil|Intravenous bolus of 10 mL of remifentanil (0.7 mcg/kg based on ideal body weight) will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
3019811|NCT02430389|Placebo Comparator|Normal Saline|Intravenous bolus of 10 mL normal saline from study syringe will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
3019849|NCT02430194|Experimental|lonafarnib/ritonavir/PEG IFN-a - IX|lonafarnib 50 mg BID + ritonavir 100 mg BID
3019850|NCT02430194|Experimental|lonafarnib/ritonavir - X|lonafarnib 25 mg BID + ritonavir 100 mg BID
3019812|NCT02430363|Active Comparator|MK-3475|"Pembrolizumab (MK-3475) is a humanized monoclonal antibody. Information from these studies suggests that Pembrolizumab (MK-3475) may be beneficial in Glioblastoma / Gliosarcoma.~Patients enrolling in phase 1 receive MK-3475 every 3 weeks, with the dose to be determined.~MK-3475 will be given intravenously over the course of 30 minutes"
3019813|NCT02430363|Experimental|Suppressor of the PI3K/Akt pathways|"Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ. Patients will take the Pictilisib (capsules) orally with food. The dose should be taken every 3 weeks.~BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor. Inhibits ATR whileshown to be a poor inhibitor to Akt and PDK1.~Patients will take the BEZ235 (capsules) orally with food. The dose should be taken every 3 weeks.~Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 .~Patients will take the Ipatasertib (capsules) orally with food. The dose should be taken every 3 weeks.~The suggested dosage of inhibitors of the PI3K/Akt pathway orally as a single dose in capsule and Packed in plastic boxes, so that preparations can be taken at home"
3019814|NCT02430350|Experimental|Compound Edaravone|Compound Edaravone Injection 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days
3019815|NCT02430350|Active Comparator|Edaravone|Edaravone Injection 30 mg/dose, one dose every 12 hours, continues for 14 days
3019816|NCT02430337|Experimental|Technology-Assisted SafeCare|A modified version of SafeCare, using a tablet and online program to complete a portion of the session
3019817|NCT02430337|Active Comparator|SafeCare-as-usual|SafeCare as it is usually delivered
3019818|NCT02430324||TBI, no cerebral infarction|patients with moderate or severe brain injury that do not develop posttraumatic cerebral infarction
3019819|NCT02430324||TBI, posttraumatic cerebral infarction|patients with moderate or severe brain injury that develops posttraumatic cerebral infarction
3019820|NCT02430311|Experimental|Cohort 1|Treat 15 patients, single dose olaparib 300mg followed by multiple dose olaparib 300mg twice a day
3019821|NCT02430311|Experimental|Cohort 2|Treat 15 patients, single dose olaparib 100mg followed by multiple dose olaparib 100 mg twice a day and then in combination with paclitaxel (80mg/m2 weekly on days 1, 8 and 15 of a single 28-day cycle)
3019822|NCT02430298|Placebo Comparator|Matched placebo|Drug: match placebo Drug: placebo suspension gargle for 2 minutes before radiation 15 minutes and placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
3019823|NCT02430298|Active Comparator|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
3019824|NCT02430285|Other|Endoscopic Ultrasound|All consecutive patients entering the emergency department due to acute abdominal pain and showing biochemical and/or radiological findings consistent with possible acute biliary pancreatitis, undergo Endoscopic Ultrasound with linear array Olympus 180 series echoendoscopes (Olympus Europa Holding, Hamburg, Germany).
3019825|NCT02430272|Experimental|Anticholinergic premedication|Premedication with 0.005mg/Kg of glycopyrrolate
3019826|NCT02430272|No Intervention|Control group|Same volume of normal saline
3019827|NCT02430259|Experimental|Weekly Isoniazid / Rifapentine|Weekly INH / RRT given by DOT
3019828|NCT02430259|No Intervention|No preventive treatment|Follow up without intervention
3019829|NCT02430246|Experimental|Primary prevention - Urex Plus|Patients with Normal vaginal flora in the experimental arm will be treated with UREX PLUS
3019830|NCT02430246|Placebo Comparator|Primary prevention - Placebo|Patients with Normal vaginal flora in the Placebo arm will be treated with a capsule without active ingredient
3019831|NCT02430246|Experimental|Secondary prevention - Urex Plus|Patients with abnormal vaginal flora in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given UREX PLUS
3019832|NCT02430246|Placebo Comparator|Secondary prevention - Placebo|Patients with abnormal vaginal flora in the Placebo arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given placebo without active ingredient
3019833|NCT02430246|Experimental|Eradication - Urex Plus|Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the experimental arm will be treated with UREX PLUS
3019834|NCT02430246|Placebo Comparator|Eradication - Placebo|Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the placebo arm will be treated with placebo without active ingredient
3019835|NCT02430246|Other|Lactobacilli transfer - probiotic capsule|Patients with Normal vaginal flora will be treated with a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months afterwhich they will receive no treatment for additional two months. Lactobacili colonization in the vaginal flora will be tested
3019836|NCT02430246|Other|Lactobacilli transfer - probiotic capsule after 2 months|Patients with Normal vaginal flora will be followed for two months without intervention afterwhich they will receive a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months. Lactobacili colonization in the vaginal flora will be tested.
3019837|NCT02430233|Experimental|micronized progesterone 400 mg|participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
3019838|NCT02430233|No Intervention|No treatment|No treatment
3019839|NCT02430207|Experimental|Femoral Vein|patients receiving temporary pacing via femoral vein
3019840|NCT02430207|Experimental|Subclavian Vein|patients receiving temporary pacing via subclavian vein
3019841|NCT02430194|Experimental|lonafarnib/ritonavir - I|lonafarnib 100 mg BID + ritonavir 100 mg QD;
3019842|NCT02430194|Experimental|lonafarnib/ritonavir - II|lonafarnib 150 mg QD + ritonavir 100 mg QD;
3019843|NCT02430194|Experimental|lonafarnib/ritonavir - III|lonafarnib 75 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW on Week 12
3019844|NCT02430194|Experimental|lonafarnib/ritonavir - IV|lonafarnib 50 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW on Week 12
3019845|NCT02430194|Experimental|lonafarnib/ritonavir - V|lonafarnib 100 mg BID + ritonavir 50 mg BID;
3019846|NCT02430194|Experimental|lonafarnib/ritonavir - VI|lonafarnib 100 mg QD + ritonavir 100 mg QD;
3019847|NCT02430194|Experimental|lonafarnib/ritonavir - VII|lonafarnib 50 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW;
3019851|NCT02430181|Experimental|lonafarnib 200 mg BID|lonafarnib 200 mg BID; n=3
3019857|NCT02430181|Experimental|lonafarnib/ritonavir|lonafarnib 100 mg BID + ritonavir 100 mg QD; n=3
3019858|NCT02430168|Active Comparator|RIRS|Retrograde intrarenal surgery
3019859|NCT02430168|Active Comparator|PCNL|Percutaneous nephrolithotomy
3019860|NCT02430155|Active Comparator|Bakri balloon group|The women in this group will be managed by Bakri balloon
3019861|NCT02430155|Active Comparator|Condom loaded Foley's catheter group|The women in this group will be managed by condom loaded Foley's catheter
3019862|NCT02430142||Vasoocclusive testing in sepsis|Septic patients defined according to the Surviving Sepsis Campaign (SSC)
3019863|NCT02430142||Vasoocclusive testing in severe sepsis|Severe septic patients defined according to the Surviving Sepsis Campaign (SSC)
3019864|NCT02430142||Vasoocclusive testing in sepsic shock|Septic shock patients defined according to the Surviving Sepsis Campaign (SSC)
3019865|NCT02430129|Active Comparator|Total knee arthroplasty/Persona|Total knee arthroplasty with Zimmer Persona posterior cruciate retaining prosthesis (Zimmer, Warsaw, IN)
3019866|NCT02430129|Experimental|Unicompartment knee arthroplasty/Oxford|Unicompartmental knee arthroplasty with Biomet Oxford mobile-bearing unicompartmental knee prosthesis (Biomet, Warsaw, IN)
3019867|NCT02430116|No Intervention|negative control group|The myocardial tissues of the right atrial appendage were obtained at 3 min before CPB was established in the NEG group.
3019868|NCT02430116|Active Comparator|I/R group|The myocardial tissues of the right atrial appendage were obtained at 45 min after opening the aorta in the I/R group.
3019869|NCT02430116|Experimental|I-postC group|The procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
3019870|NCT02430103||Chemotherapy plus GnRHa|Patients of the group will receive (neo)chemotherapy plus GnRHa ( Goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration).
3019871|NCT02430103||Chemotherapy|Patients of the group will receive (neo)chemotherapy merely.
3019872|NCT02430090|Experimental|Levobupivacaine|"Levobupivacaine, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.~Injection Surgical anaesthesia~Adult: Epidural block: 50-100 mg (10-20 ml) of a 0.5% solution or 75-150 mg (10-20 ml) of a 0.75% solution. Caesarean section: 75-150 mg (15-30 ml) of a 0.5% solution. Spinal block: 15 mg (3 ml) of a 0.5% solution. Max: 150 mg/dose; 400 mg/day. Injection Peripheral nerve block~Read more: http://www.ndrugs.com/?s=levobupivacaine#ixzz3Xvp0iS5T"
3019873|NCT02430090|Experimental|Levobupivacaine + fentanyl|"Fentanyl - Used for: Producing anesthesia for surgery and treating pain before, during, and after surgery.Fentanyl is a narcotic (opioid) analgesic. It works in the brain and nervous system to cause anesthesia and decrease pain.~Indications:~Adult: PO Breakthrough cancer pain As a loz: Initially, 200 mcg over 15 minutes for an episode of breakthrough pain; may repeat once after 15 minutes if needed. Not more than 4 unit doses/day. IV Adjunct to general anesth Patients w/ spontaneous resp: Initial: 50-200 mcg, w/ supplements of 50 mcg. Patients w/ assisted ventilation: Initial: 300-3,500 mcg (up to 50 mcg/kg), w/ supplements of 100-200 mcg depending on response.~Read more: http://www.ndrugs.com/?s=fentanyl#ixzz3XvpAcULL"
3019874|NCT02430090|Experimental|Levobupivacaine + sufentanil|"Sufentanil is a synthetic opioid analgesic. Sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation.~Maintenance: Additional doses of 0.5-10 mcg/kg may be given if needed. Max (total dose): 30 mcg/kg. Post-op pain Initial: 30-60 mcg. Additional doses of up to 25 mcg may be given at intervals of ≥1 hr if needed. Epidural Pain relief during labour and delivery W/ bupivacaine: 10-15 mcg w/ or w/o epinephrine. May repeat dose twice at intervals of ≥1 hr till delivery. Max (total dose): 30 mcg.~Read more: http://www.ndrugs.com/?s=sufentanil#ixzz3XvqVyLzx"
3019875|NCT02430077|Experimental|Active capsule of Obeticholic acid|Patient will receive obeticholic acid (OCA) in the dose of 25 mg/day for a period of 4 months.
3019876|NCT02430077|Placebo Comparator|Pacebo for Obeticholic acid|Patient will recieve placebo in the dose of 25 mg/day for a period of 4 months.
3019877|NCT02430064|Experimental|Low PAMP diet then high PAMP diet|All subjects on study proceed from 7 days low PAMP diet to 4 days high PAMP diet
3019878|NCT02430051|No Intervention|Regular Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Regular dental environment no sensory characteristics of the dental environment are altered, the cleaning is conducted as per usual.
3019879|NCT02430051|Experimental|Sensory Adapted Dental Environment|In the Sensory Adapted Dental Environment the sensory characteristics of the dental environment are altered (visual, auditory, tactile adaptations).
3019880|NCT02430038||Acceptability and feasibilty|Where vaginal examinations are best avoided e.g. vaginismus or contraindicated (PPROM) with controls
3019881|NCT02430038||Predictive Model|Nulliparous term labouring women with cephalic presentation
3019882|NCT02430025||control subjects|people had no clinical history of cardiovascular diseases,no family history of premature cardiovascular diseases.
3019883|NCT02430025||coronary atherosclerosis|Subjects with CAD also had at least one ＜50% stenotic lesion on coronary angiography.
3019884|NCT02430025||stable coronary artery disease|Subjects with stable CAD had clinically established atherosclerotic vascular disease but had been stable for ≥3 months.
3019885|NCT02430025||acute coronary syndrome|Subjects with CAD also had at least one ≥50% stenotic lesion on coronary angiography or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting. All subjects with ACS exhibited acute ECG changes consistent with myocardial ischemia or elevated troponin levels. ACS was confirmed with urgent coronary angiography; all subjects had at least one ≥50% stenotic lesion with ruptured plaque or thrombus.
3019886|NCT02430012|Active Comparator|Intervention group|The intervention group will take the secondary prevention quality improvement strategies into implementation.
3019887|NCT02430012|No Intervention|Control group|The control goup will maintain the routine practice pattern.
3019888|NCT02429999|Active Comparator|Letrozole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75 international unit(IU) /day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till human chorionic gonadotrophin (hCG) injection.
3019889|NCT02429999|Active Comparator|Standered protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225 international unit/day) from day 2. We will give them at first 225 international unit FSH for 5 days.
3019890|NCT02429986|Other|ASV Arm|The measures are performed during the annual consultation required by the French Social Security for the renewal of the reimbursement of the ASV care.
3019891|NCT02429973|Experimental|Experimental|6 cycles of gemcitabine plus rapamycin
3019892|NCT02429960|Other|Analgesia monitoring|Remifentanil is increased step-by-step according to the study protocol. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli consisting of the intracutaneous pain model and tetanic stimulation for the time period of 30 s with 80 milliampere, 50 Hz are applied. All stimulations are accompanied by the measurement of the analgesic monitoring-devices (PhysioDoloris®, SPI® and AlgiScan®). Moreover the investigators measure and inspect changes in heart rate and blood pressure as well as occurrence of defensive movements of the patients.
3019893|NCT02429947||INC Contact Registry Participants|Adult CMT patients who have self-registered at the Inherited Neuropathies Consortium (INC) Contact Registry, a web-based contact registry developed and supported by the Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Consortium (RDCRN), located at the University of South Florida.
3019894|NCT02429934|Active Comparator|Abatacept|32 SLE patients to be treated with subcutaneous abatacept 125mg sq once a week for 16 weeks.
3019895|NCT02429934|Placebo Comparator|Placebo|32 SLE patients to be treated with subcutaneous placebo once a week for 16 weeks.
3019896|NCT02429921|Experimental|low-Se lentils|50 mg of low-selenium lentils per person consumed as soups
3019897|NCT02429921|Experimental|high-Se lentils|50 mg of high-selenium lentils per person consumed as soup
3019898|NCT02429908|Other|Post market study of TM-Ardis Interbody|TM-Ardis TLIF MIS or Open single or multi level implant for lumbar fusion
3019899|NCT02429895|Experimental|All subjects (open-label extension)|All subjects will start treatment with ABT-122
3019900|NCT02429882|Experimental|Brodalumab|
3019901|NCT02429882|Placebo Comparator|Placebo|
3019902|NCT02429869|Experimental|Everolimus|
3019903|NCT02429856|Active Comparator|PCS|SCORPIO™ Posterior Cruciate Ligament Substituting TKA prosthesis
3019904|NCT02429856|Active Comparator|PCR|SCORPIO™ Posterior Cruciate Ligament Retaining TKA prosthesis
3019905|NCT02429843|Experimental|Standard treatment + TRC105|In addition to standard treatment of paclitaxel, carboplatin, and bevacizumab, dosing of TRC105 will begin at 8 mg/kg. However a lower dose level has also been included (6 mg/kg) and will be enrolled if 8 mg/kg is found to exceed the maximum tolerated dose. Following the appropriate pre-medication regimen, the first weekly TRC105 dose (cycle 1 day 8) will be split into two doses whereby 3 mg/kg is administered on cycle 1 day 8 and the balance (e.g., 5 mg/kg for Dose Level 1) is administered on cycle 1 day 11. Beginning with cycle 1 day 15 and thereafter, the full TRC105 dose will be administered intravenously each week during the 21-day cycle. Intra-patient dose reductions are allowed beginning in cycle 2.
3019906|NCT02429830|Other|Single arm study|Previous LSG patient will be treated with the LINX device and serve as their own control
3019907|NCT02429817|Active Comparator|Aeroneb Solo|Subjects inhaled radiolabelled aerosol via the Aeroneb Solo connected to the high flow nasal cannula.
3019908|NCT02429817|Active Comparator|Standard Jet Nebulizer|Subjects inhaled radiolabelled aerosol via the jet nebulizer connected to the high flow nasal cannula.
3019909|NCT02429804|Experimental|Diagnostic (18F NaF/18F FDG PET/MRI, contrast-enhanced MRI)|Patients receive 18F NaF and 18F FDG IV over 30 seconds-1 minute and then undergo PET/MRI and contrast-enhanced MRI after 45-60 minutes. Patients undergo imaging at baseline, after course 3 (12 weeks), and after course 6 (24 weeks) of treatment with Ra-223.
3019910|NCT02429791|Active Comparator|CAR|Participants will receive CAR from Day 1 to Week 52 (Early Switch Phase), and eligible participants will switch to DTG 50 mg + RPV 25 mg once daily from Week 52 to 148 (Late Switch Phase).
3019911|NCT02429791|Experimental|DTG 50 mg + RPV 25 mg|Participants will receive DTG 50 mg + RPV 25 mg once daily from Day 1 through Week 148 (Early and Late Switch Phase).
3019912|NCT02429778|Experimental|BREATHE|4 weeks DVD-delivered relaxation intervention program called breathe. The experimental intervention includes progressive muscle relaxation, diaphragmatic breathing, and home practice of the skills. Following the 4 weeks of treatment, participants will be asked to continue to practice at home for 4 weeks.
3019913|NCT02429778|No Intervention|Wait List|8 week wait list period. Participants assigned to wait list will have the opportunity to receive BREATHE arm after 8 weeks if interested.
3019914|NCT02429765|Active Comparator|ACL/FOR|The evening dose of twice-daily dual bronchodilator medication will consist of aclidinium/formoterol 400/12mcg . After 2-weeks of treatment with twice-daily aclidinium/formoterol 400/12mcg, subjects will be randomized to receive an evening dose consisting of active drug or placebo.
3019915|NCT02429765|Placebo Comparator|Placebo|The evening dose of twice-daily dual bronchodilator medication will consist of a placebo inhaler. After 2-weeks of treatment with twice-daily aclidinium/formoterol 400/12mcg, subjects will be randomized to receive an evening dose consisting of active drug or placebo.
3019916|NCT02429752|Experimental|Inspiratory Muscle Training|Subjects will receive 8 weeks of IMT
3019917|NCT02429739|Experimental|Working Memory Training|Behavioral: Cogmed RM working memory training. After baseline assessment participants will be randomized to active training or treatment as usual (waiting). The active group will start immediately and will have 6 weeks to perform the 25 training sessions.
3019918|NCT02429739|No Intervention|Passive control group|"The control group will receive treatment as usual (Ordinary school days, special education if normally received)."
3019919|NCT02429726|Experimental|rAdp53|2 x 10^12 viral particles of rAdp53 gene are given in 40 ml of saline by intra-cavity infusion at day of 7, 15 and 21
3019920|NCT02429726|Active Comparator|cisplatin|cisplatin 40 mg in 40 ml of saline are given by intra-cavity infusion at day of 7, 15 and 21
3019921|NCT02429726|Experimental|rAdp53 plus cisplatin|2 x 10^12 viral particles of rAdp53 gene and cisplatin 40 mg in 40 ml of saline are given by intra-cavity infusion at day of 7, 15 and 21
3019922|NCT02429713|Experimental|Short-duration tourniquet group|The tourniquet was inflated immediately before cement application and deflated after its hardening
3054081|NCT02200757|Active Comparator|Topotecan|
3019923|NCT02429713|Active Comparator|Long-duration tourniquet group|The tourniquet was inflated immediately before incision and deflated after the hardening of the cement
3019924|NCT02429700|Experimental|PT (Arm 1)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3019925|NCT02429700|Active Comparator|BEP (Arm 2)|"Patients receive bleomycin IV per week, etoposide IV daily for days 1-5, cisplatin IV for days 1-5. Treatment repeats every 21 days for 3 or 4* courses in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients who have good risk will have 3 courses and those who have poor risks will have 4 courses."
3019926|NCT02429687|Experimental|PT (Arm 1)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3019927|NCT02429687|Active Comparator|BEP (Arm 2)|"Patients receive bleomycin IV per week, etoposide IV daily for days 1-5, cisplatin IV for days 1-5. Treatment repeats every 21 days for 3 or 4* courses in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients who have good risk will have 3 courses and those who have poor risks will have 4 courses."
3019928|NCT02429674|Other|TranS-C and IPT-A|12 sessions of weekly outpatient psychotherapy for adolescent depression.
3019929|NCT02429661|Experimental|RC (Girls First Resilience Curriculum)|The Girls First Resilience Curriculum is delivered in peer support groups of 12-15 students per group over 23 weekly 1-hour sessions. The curriculum draws from fields such as positive psychology, emotional competence/intelligence, and restorative practices, and aims to improve students' psychosocial assets and wellbeing.
3019930|NCT02429661|Experimental|HC (Girls First Health Curriculum)|The Girls First Health Curriculum is delivered in peer support groups of 12-15 students per group over 21 weekly 1-hour sessions. The curriculum covers topics such as nutrition, sexual and reproductive health, clean water, hygiene, and common diseases, and aims to improve students' physical health and wellbeing.
3019931|NCT02429661|Experimental|RC+HC (Girls First)|Girls First is a combination of the Girls First Resilience Curriculum (RC) and the Girls First Health Curriculum (HC).
3019932|NCT02429661|No Intervention|SC (School-as-usual control)|Participants receive no intervention and attend school as they usually would.
3019933|NCT02429648|Active Comparator|PVI performed in Normal Sinus Rhythm|DCC first then PVI
3019934|NCT02429648|Active Comparator|PVI performed in Atrial Fibrillation|PVI then DCC after if patient remains in Atrial Fibrillation
3019935|NCT02429635|Experimental|My exercise|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshp.~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan."
3019936|NCT02429635|Experimental|Control group - delayed intervention|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team workshops and training groups The control groups will consist of teams that will receive the team-based health promotion measures about 9 months after the Team-based health promotion measures group."
3019937|NCT02429622|Experimental|Radical 2.14|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
3019938|NCT02429622|Experimental|Radical 2.17|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.17Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
3019939|NCT02429622|Experimental|Radical 2.21|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.21Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
3019940|NCT02429622|Experimental|Neoadjuvant 2.14|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 4 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity. Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
3019966|NCT02429453|Active Comparator|Fresh Frozen Plasma|Administration of a single dose of fresh frozen plasma based on INR per the following regimen: 2U for INR of 2-2.5; 3U for INR of 2.5-3; 4U for INR of 3-3.5; 5U for INR of 3.5-4; 6U for INR of 4+
3019967|NCT02429453|Experimental|Four Factor Prothrombin Complex Concentrate|Administration of a single dose of four factor prothrombin complex concentrate per the following dosing regimen: 25 U/kg for INR of 2-4; 35 U/kg for INR of 4-6; 50 U/kg for INR of 6+; maximum dosing weight of 100kg, patients may be dispensed +/- 10% of ordered dose
3054082|NCT02200744||Dislocation reduction using propofol|
3019941|NCT02429609|Experimental|Keratoconic subjects|"Short clinical interview (Questions pertaining to ocular and systemic health, medications, family history and date of birth). (approx. 2 minutes)~Visual acuity measurement using EDTRS chart at 4 m (approx. 4 minutes)~Refraction: retinoscopy and subjective, at 4m (approx. 10 minutes)~Anterior eye examination (approx. 4 minutes)~Fundus examination using binocular indirect ophthalmoscopy or a standard ophthalmoscope - to screen for eye disease that is likely to affect visual ability in this study. (approx. 5 minutes)~Corneal topography measurement with an Oculus Pentacam (Oculus Gmbh., Germany). (approx. 5 minutes)~Two measurements of visual acuity will be made:~Standard ETDRS logMAR acuity measurement (5 minutes)~Vanishing Optotype logMAR acuity measurement (5 minutes)"
3019942|NCT02429609|Experimental|Healthy subjects|"Short clinical interview (Questions pertaining to ocular and systemic health, medications, family history and date of birth). (approx. 2 minutes)~Visual acuity measurement using EDTRS chart at 4 m (approx. 4 minutes)~Refraction: retinoscopy and subjective, at 4m (approx. 10 minutes)~Anterior eye examination (approx. 4 minutes)~Fundus examination using binocular indirect ophthalmoscopy or a standard ophthalmoscope - to screen for eye disease that is likely to affect visual ability in this study. (approx. 5 minutes)~Corneal topography measurement with an Oculus Pentacam (Oculus Gmbh., Germany). (approx. 5 minutes)~Two measurements of visual acuity will be made:~Standard ETDRS logMAR acuity measurement (5 minutes)~Vanishing Optotype logMAR acuity measurement (5 minutes)"
3019943|NCT02429596|Experimental|Experimental Treatment|AED(s) currently taken (CBZ, VPA, TPM, OXC, LEV, LTG) will be substituted, starting with the morning dose on day 2, with an equivalent formulation available in the market. Namely, a brand product will be switched to a generic, randomly chosen among those available in the market, while maintaining unaltered the dosing regimen and times of administration.Likewise, a generic product will be switched to the brand or another generic.
3019944|NCT02429596|No Intervention|No Experimental Treatment|When the randomized allocation requires continuation on the same product (control), the AED product(s) currently taken will be continued unaltered, with the same dosing regimen and times of administration.
3019945|NCT02429583|Active Comparator|Recombivax in HCV infected individuals|Recombivax vaccine administered IM to HCV-infected individuals
3019946|NCT02429583|Active Comparator|Recombivax in healthy volunteers|Recombivax vaccine administered IM to healthy individuals
3019947|NCT02429570|Experimental|Meclofenamate|All enrolled patients will receive the study drug, meclofenamate at 100 mg PO BID.
3019948|NCT02429557|Experimental|Abdominal compression and placebo pill|Abdominal compression with an inflatable abdominal binder (up to 40 mmHg) during head up tilt, and placebo pill given 1 hour before the second head up tilt
3019949|NCT02429557|Sham Comparator|Sham abdominal compression and placebo|Sham abdominal compression with an inflatable abdominal binder (~5 mmHg) during head up tilt, and placebo pill given 1 hour before the second head up tilt
3019950|NCT02429557|Experimental|Abdominal compression and midodrine|Abdominal compression with an inflatable abdominal binder (up to 40 mmHg) during head up tilt, and midodrine 2.5-10 mg PO given 1 hour before the second head up tilt
3019951|NCT02429557|Active Comparator|Sham abdominal compression and midodrine|Sham abdominal compression with an inflatable abdominal binder (~5 mmHg) during head up tilt, and midodrine 2.5-10mg PO given 1 hour before the second head up tilt
3019952|NCT02429544|Experimental|Experimental Support Group (ESG) - Residential Program|"Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.~Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
3019953|NCT02429544|Experimental|Standard Support Group (SSG) - Residential Program|"Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.~Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
3019954|NCT02429544|Other|Standard of Care Group (SOC) - No Residential Program|"Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
3019955|NCT02429531|Experimental|Healthy controls|Healthy volunteers who consented to participate in the study will be immunized with both Pneumovax 23 and Typhim Vi .
3019956|NCT02429531|Experimental|Patients|Patients presenting for immune evaluation because of recurrent ENT/lung infection or invasive infection with encapsulated bacteria, in whom evaluation of pneumococcal antibody response is indicated, will be immunized with both Pneumovax 23 and Typhim Vi .
3019957|NCT02429518||miltefosine|miltefosine: target of 2.5 mg/kg/day for 28 days
3019958|NCT02429505||miltefosine|
3019959|NCT02429492|Experimental|ALS patients|Patients with amyotrophy lateral sclerosis (ALS)
3019960|NCT02429492|Experimental|Control subjetcs|Neurologically intact subjects sex and age-matched to ALS patients
3019961|NCT02429479|Active Comparator|Standard ACP/Patient Alone|Patients (without their family caregiver) complete a standard living will form online.
3019962|NCT02429479|Experimental|Decision Aid/Patient Alone|Patients (without their family caregiver) complete Making Your Wishes Known, an online decision aid for advance care planning.
3019963|NCT02429479|Active Comparator|Standard ACP/Together|Patients and their family caregiver together complete a standard living will form online.
3019964|NCT02429479|Experimental|Decision Aid/Together|Patients and their family caregiver together complete Making Your Wishes Known, an online decision aid for advance care planning.
3019965|NCT02429466|Experimental|Guadecitabine (SGI-110)|
3019968|NCT02429440|Experimental|Study Arm 1|Intradermal application of peptide vaccine in combination with Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
3019969|NCT02429440|Active Comparator|Study Arm 2|Intradermal application of peptide vaccine with Montanide ISA-51
3019970|NCT02429427|Experimental|Celecoxib|Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
3019971|NCT02429427|Placebo Comparator|Placebo|Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
3019972|NCT02429414|Experimental|Non-Video Double Lumen Tube (DLT) Group|Participants receive a non-video DLT for lung isolation before surgery. Once non-video DLT is in correct place, its final position before surgery checked with a fiberoptic bronchoscopy (FOB).
3019973|NCT02429414|Experimental|Video Double Lumen Tube (VDLT) Group|Participants receive a VDLT for lung isolation before surgery. Once VDLT is in correct place, its final position before surgery checked with the camera inside the tube.
3019974|NCT02429401|Experimental|Culturally adapted brief intervention|
3019975|NCT02429401|Active Comparator|Non-adapted brief intervention|
3019976|NCT02429388|Experimental|High dose spironolactone|This arm of the study will include addition of high dose spironolactone upto 100mg twice daily in adjunct to usual care of hospitalized acute decompensated heart failure patients with loop diuretics.
3019977|NCT02429388|No Intervention|Usual Care|This arm of the study will continue the usual care of hospitalized acute decompensated heart failure patients with loop diuretics.
3019978|NCT02429375|Experimental|Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35)|Patients with relapsed or refractory Hodgkin lymphoma will receive brentuximab vedotin combined with mocetinostat. For the phase I portion of the study, patients will be enrolled in a traditional 3 + 3 phase 1 design on sequential dosing cohorts in order to determine the maximum tolerated dose (MTD) of mocetinostat when given with brentuximab vedotin. Once the MTD is determined, (up to) an additional 26 patients will be enrolled on to the phase II portion of the study at the MTD to determine the response rate and toxicity associated with treatment. The phase Ib and II study will include a lead-in with mocetinostat alone for 1 week followed by the combined treatment beginning day 15 following initiation of mocetinostat.
3019979|NCT02429362||Pregnant Women & their stillborn infants|All English speaking female patients who are seen in the Regional One Health perinatal clinics and/or deliver at Regional One Health are the group of study's focus. Likewise, when a delivery results in a stillbirth, the stillborn baby will also be an additional group of our study's focus.
3019980|NCT02429349|Experimental|Diagnostic Procedure|Surgery - Unilateral surgical removal of ovary, freezing of tissue, post cancer cure autotransplant
3019981|NCT02429323|Active Comparator|sevoflurane concentration 8%|sevoflurane concentration 8% from the start
3019982|NCT02429323|Active Comparator|incremental sevoflurane (1-8%)|incremental increase of the concentration each few breaths from 1% to 8%
3019983|NCT02429310|No Intervention|Supervised Exercise Only|This is the cohort of patients with Intermittent Claudication that will receive standard care of a supervised exercise programme only.
3019984|NCT02429310|Experimental|NMES + Supervised Exercise|This cohort of patients with Intermittent Claudication will receive the standard care of supervised exercise plus the use of a Revitive IX neuromuscular electrical stimulation device (Intervention) as per the protocol. The adjunctive benefit of the latter intervention compared to standard treatment alone will then be assessed.
3019985|NCT02429297|Experimental|Patient Only - HITCM-only|Patients enrolling without a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team.
3019986|NCT02429297|Experimental|Patient & CarePartner - HITCM-only|Patients enrolling with a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team.
3019987|NCT02429297|Experimental|Patient & CarePartner - HITCM+CP|Patients enrolling with a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team plus updates to their CarePartner via phone or email.
3019988|NCT02429284||Patients newly diagnosed with CTEPH|Patients newly diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group IV Classification for Pulmonary Hypertension.
3019989|NCT02429271|Active Comparator|Ticagrelor|1st day 270 mg & from then onwards 180 mg per day
3019990|NCT02429271|Active Comparator|Clopidogrel|1st day 300 mg & from then onwards 75 mg per day
3019991|NCT02429258|Experimental|Farxiga with metformin or insulin|Farxiga with metformin (>/=1500mg/day) or insulin (>/=30 units/day) and up to 2 OAD medications
3019992|NCT02429258|Placebo Comparator|Placebo with metformin or insulin|Placebo with metformin (>/=1500mg/day) or insulin (>/=30 units/day) and up to 2 OAD medications
3019993|NCT02429232|Experimental|Pioglitazone|Pioglitazone 30 mg once daily will be administered orally for total 48 weeks.
3019994|NCT02429232|Active Comparator|Linagliptin|Linagliptin 5 mg once daily will be administered orally for total 48 weeks.
3019995|NCT02429219|Active Comparator|Transurethral Resection|Transurethral Resection of the Prostate in Saline irrigation with ethanol
3019996|NCT02429219|Experimental|Photoselective vaporisation|Photoselective vaporisation of the Prostate in Saline irrigation with ethanol
3019997|NCT02429206|Active Comparator|Positive Control|Each volunteer will be asked to self-apply a standard moisturizing cream (Glaxal Base) on one side of their body. Application twice a day during 14 days.
3019998|NCT02429206|Experimental|Experimental Cream|Each volunteer will be asked to self-apply the experimental product (SQIN with CanSATs technology) on the other side of their body. Application twice a day during 14 days.
3019999|NCT02429193|Experimental|Abiraterone / enzalutamide|Abiraterone + prednisone; Enzalutamide
3020040|NCT02428868|Experimental|Tranexamic acid - intravenous iron|"IV iron (Ferroven®) : 2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.~IV Tranexamic acid (Exacyl®): 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later."
3020140|NCT02428140|Experimental|Implanted Loop Recorder|long-term implantable ECG (Medtronic Reveal LINQ) coupled with remote monitoring (MyCareLink) for 12 months
3020000|NCT02429180|Experimental|Rehabilitation training|"ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.~Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals~Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.~Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme~Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression."
3020001|NCT02429180|No Intervention|Control|Control: treatment as usual plus receipt of a UK Stroke Association booklet on exercise after stroke.
3020002|NCT02429154|Active Comparator|Normocapnia|The Child will be ventilated in order to achieve an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa). Measurements will be performed after steady state condition. Then the ventilation will be reduced to allow ETCO2 to reach 6.5 kPa before repeating the measurements. Finally, the child will be again ventilated to obtain a normocapnia condition.
3020003|NCT02429154|Other|Mild Hypercapnia|The Child will be ventilated in order to achieve a ETCO2 of 6.5 kPa. Measurements will be performed after steady state condition. Then the ventilation will be increased to allow ETCO2 to reach 5.5 kPa before repeating the measurements. Finally, the child will be again ventilated to obtain a mild hypercapnic condition
3020004|NCT02429141|Experimental|US-guided periarterial techique|Axillary brachial plexus block by an ultrasound-guided periarterial technique
3020005|NCT02429141|Experimental|US-guided multi-injection technique|Ultrasound-guided multi-injection perineural technique for axillary brachial plexus
3020006|NCT02429128|Active Comparator|Lean PCOS training|14 weeks exercise training
3020007|NCT02429128|Other|Lean healthy controls|14 weeks exercise training
3020008|NCT02429115|Experimental|Face-to-face peer mentoring|Will receive 6 months of face-to-face peer mentoring by a trained peer mentor.
3020009|NCT02429115|Experimental|Online peer mentoring|Will receive 6 months of face-to-face peer mentoring by a trained peer mentor.
3020010|NCT02429115|No Intervention|Control|Will not receive peer mentoring.
3020011|NCT02429102|Experimental|Single ascending dose, MT-8554 or Placebo|
3020012|NCT02429102|Experimental|Multiple ascending dose, MT-8554 or Placebo|
3020013|NCT02429089|Experimental|Group I|The patients will receive the same molecules (cetuximab and LEE011) but this phase I study will determine the DLTs by dose escalation of LEE011 (400 mg and 600mg).
3020014|NCT02429076|Experimental|Propofol|Subjects in this arm will receive propofol general anesthesia
3020015|NCT02429076|Experimental|Sevoflurane|Subjects in this arm will receive sevoflurane general anesthesia
3020016|NCT02429063|Experimental|Bright White Light|Participants use the bright white light intervention for 30 minutes upon waking each morning for 60 days.
3020017|NCT02429063|Experimental|Dim Red Light|Participants use the dim red light intervention for 30 minutes upon waking each morning for 60 days.
3020018|NCT02429050|Active Comparator|intervention|sustained release morphine
3020019|NCT02429050|Placebo Comparator|control|placebo
3020020|NCT02429037|Experimental|rAd-p53 plus radiation and chemotherapy|rAd-p53 tumor injection combined with radio- and chemo-therapy.
3020021|NCT02429037|Active Comparator|radiation and chemotherapy|radiation combined with chemotherapy
3020022|NCT02429024|No Intervention|Control|Subjects with type 1 and type 2 diabetes will be provided with the OneTouch Verio® Flex BGM system only over a period of 24 weeks.
3020023|NCT02429024|Experimental|Intervention|Subjects with type 1 and type 2 diabetes will be provided with the OneTouch Verio® Flex BGM and the OneTouch Reveal® Mobile APP system over a period of 24 weeks.
3020024|NCT02429011||MDD|patients with current MDD
3020025|NCT02429011||Healthy Control (HC)|healthy control volunteers
3020026|NCT02428998|Experimental|Korean Red Ginseng|Patients receive oral Korean Red Ginseng twice daily for 24 weeks. Treatment repeats every 4, 12, 24 weeks for 3 courses
3020027|NCT02428998|Placebo Comparator|Placebo|Patients receive oral placebo twice daily for 24 weeks. Treatment repeats every 4, 12,24 weeks for 3 courses
3020028|NCT02428985||Riociguat|Riociguat treatment group
3020029|NCT02428972|Experimental|intravenous anesthesia|propofol infusion @ 100-200 mcg/kg/min for maintenance of anesthesia
3020030|NCT02428972|Active Comparator|inhalational anesthesia|sevoflurane MAC between 0.8-1.2 for maintenance of anesthesia
3020031|NCT02428959|Experimental|Amyl Nitrite|Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle.The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
3020032|NCT02428946|Active Comparator|Morning bromocriptine|Bromocriptine is taken in the morning
3020033|NCT02428946|Active Comparator|Evening bromocriptine|Bromocriptine is taken in te evening
3020034|NCT02428933|Other|Before and after bromocriptine|Subjects will be investigated before and after the use of bromocriptine. They will use bromocriptine for two weeks in the evening (1.25mg/day during the first week and 2.5mg/day during the second week).
3020035|NCT02428920|Experimental|Peer Groups|Individuals in Intervention Group Arm will attend biweekly or monthly peer support groups (approximately 10 people per group) for evaluating changes and promoting mutual support. 12-month duration.
3020036|NCT02428920|No Intervention|Control Arm|The control arm, will attend the initial educational group lectures at baseline assessment and will receive no intervention thereafter.
3020037|NCT02428894||LVAD recipients|
3020038|NCT02428881|Experimental|Complete retention- onabotulinumtoxinA|Women in complete urinary retention receiving onabotulinumtoxinA
3020039|NCT02428881|Experimental|Obstructed voiding- onabotulinumtoxinA|Women with obstructed voiding receiving onabotulinumtoxinA
3020041|NCT02428868|Active Comparator|Tranexamic acid|IV Tranexamic acid (Exacyl®): 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later.
3020042|NCT02428868|Placebo Comparator|Placebo|20 mL saline, in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
3020043|NCT02428855|Experimental|Dasatinib|"Patients with advanced intrahepatic cholangiocarcinoma who have either IDH1 or IDH2 mutations and have received at least one prior platinum containing regimen~Dasatinib, oral, daily, predetermined dosage per cycle~Radiologic Response Assessment every 2 cycles"
3020044|NCT02428842|Other|Tumor biopsies and blood sampling|"Patient will undergo standard care with tumor and blood sampling before and after treatment.~Blood and tumor sampling will also be performed at disease progression/relapse."
3020045|NCT02428829|Experimental|Intervention|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
3020046|NCT02428829|Active Comparator|Control|Control group will receive standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively
3020047|NCT02428816|Experimental|Patients with Parkinson's Disease|Patients with PD will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)
3020048|NCT02428816|Experimental|Patients with MSA|Patients with MSA will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)
3020049|NCT02428790||ABI Patients|Patients with acquired brain injury.
3020050|NCT02428777|Active Comparator|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
3020051|NCT02428777|Active Comparator|Diclofenac|Women will receive oral diclofenac 100 mg 1 hour before the procedure
3020052|NCT02428777|Placebo Comparator|Placebo|Women will receive an oral placebo 1 hour before the procedure
3020053|NCT02428764|Experimental|Intervention group|Patients were assigned to receive neoadjuvant nimotuzumab plus gemcitabine and carboplatin followed by surgery.
3020054|NCT02428751|Active Comparator|R-CHOP|This group received R-CHOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Doxorubicin, 50mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.
3020055|NCT02428751|Experimental|R-CDOP|This group received R-CDOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Pegylated liposomal doxorubicin, 30mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.
3020056|NCT02428725|Experimental|Acute coronary syndrome patient|Acute coronary syndrome patient undergoing PCI and eligible for ticagrelor therapy according to the guidelines accepting blood samples measuring platelets reactivity
3020057|NCT02428712|Experimental|PLX8394|"Group A: Phase 1-Dose Escalation: Adult patients.~Phase 2a-RP2D Confirmation (Formulation 2): Adult and pediatric patients.~Phase 2a-Dose Extension: Adult patients with advanced unresectable solid tumors will be enrolled among two cohorts.~Cohort 1: Activating BRAF V600 mutations~Cohort 2: Activating BRAF non-V600 mutations~Group B: Phase 1-Dose Escalation: Pediatric patients.~Phase 2a-Dose Extension: Pediatric patients with advanced unresectable BRAF-mutated tumors, including LCH."
3020058|NCT02428699|Experimental|Test|30mL Test contains 10%w/w cod oil + 10%w/w cod liver oil in an emulsion formulation
3020059|NCT02428699|Active Comparator|Control|5.8mL of cod liver oil in a free flowing non-emulsified formulation
3020060|NCT02428686|Experimental|epoetin beta|
3020061|NCT02428673|Other|Load-measuring platform|A load-sensing platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.
3020062|NCT02428660|Other|Controls (no analysis or testing)|MTM alone (i.e. Treatment As Usual)
3020063|NCT02428660|Experimental|Group 1|MTM + software-based drug & gene interaction risk analysis + pharmacogenetic testing
3020064|NCT02428660|Active Comparator|Group 2|MTM + software-based drug & gene interaction risk analysis only
3020065|NCT02428647|Active Comparator|micronutrient powder (MNP)|preventive zinc supplements provided as MNP (containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate,) plus ORS and therapeutic placebo supplements for diarrhea
3020066|NCT02428647|Placebo Comparator|placebo powder|placebo powder plus ORS and therapeutic placebo supplements for diarrhea
3020067|NCT02428647|Active Comparator|preventive zinc supplements|preventive zinc supplements provided as dispersible zinc tablets (containing 7 mg zinc, to be given between meals) plus ORS and therapeutic placebo supplements for diarrhea
3020068|NCT02428647|Active Comparator|therapeutic zinc supplements|preventive placebo supplements provided as dispersible tablets plus ORS and dispersible therapeutic zinc tablets (containing 20 mg zinc) for diarrhea
3020069|NCT02428634|Experimental|Program SI! for Elementary 6 levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. The intervention is implemented during all the elementary levels (PSIE13+PSIE46).
3020070|NCT02428634|No Intervention|Normal curriculum|The schools on the control group keep their normal curriculum and don't join any school program about health until the end of the study.
3020071|NCT02428634|Experimental|Program SI! for Elementary first levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. To evaluate the effects of different exposures to the program, the intervention is implemented in the first three levels (PSIE13).
3020072|NCT02428634|Experimental|Program SI! for Elementary last levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. To evaluate the effects of different exposures to the program, the intervention is implemented in the last three levels (PSIE46).
3020073|NCT02428621|Experimental|Twicare® appliance|Group treated with the Twicare® appliance. This appliance is a removable mandibular propulsive adjustable preformed medical device. It is made out of soft and stiff thermoplastics. Its two gutters are linked to each other according to different antero-posterior positions. It is EC marked since 2011.
3020074|NCT02428621|Active Comparator|Removable Herbst appliance|Group treated with the removable Herbst appliance. This appliance is a medical device measured made composed of telescopic metallic hinges and resin gutters made-to-measure based on dental impression.
3020075|NCT02428621|No Intervention|Untreated|Children will not wear any interceptive activator. They will have a routine follow-up with their orthodontist waiting for the placing of a fixed appliance.
3020076|NCT02428608|Experimental|Botulinum toxin, Tyoe A|DWP-450 (Botulinum toxin, Type A)
3020077|NCT02428595|Experimental|Treatment|Eclipse™ System
3020078|NCT02428582|Active Comparator|bare stent inserted|Standard bare stent will be placed
3020079|NCT02428582|Experimental|Covered stent inserted|Covered stent will be placed
3020080|NCT02428569|No Intervention|Usual Care|Participants randomized to this arm of the study will receive usual care from their physician.
3020081|NCT02428569|Experimental|PREPARED Decision Support|Participants randomized to this arm of the study will receive the PREPARED educational book and video.
3020082|NCT02428556|Active Comparator|Facts only|"Scenario describes study results without breakthrough language, promising language, no cautions about conditional approval"
3020083|NCT02428556|Active Comparator|promising language|"study description describes drug as promising; no warning about conditional approval"
3020084|NCT02428556|Active Comparator|"breakthrough with may warning"|"study describes drug as breakthrough; warning that continued approval may be contingent on subsequent verification of clinical benefit in confirmatory trials"
3020085|NCT02428556|Active Comparator|"breakthrough with is warning"|"study describes drug as breakthrough; warning that continued approval may be contingent on subsequent verification of clinical benefit in confirmatory trials"
3020086|NCT02428556|Experimental|breakthrough only|"Scenario describes study results with breakthrough language, no cautions about conditional approval"
3020087|NCT02428543|Experimental|Ponatinib arm|dose-escalation Arm _ 15, 30, 45mg Ponatinib per day. Each cohort will consist of 3 evaluable patients
3020088|NCT02428517||Young/MSD|Patients who are <55 years old, and will receive alloHCT for Young/MSD
3020089|NCT02428517||Young/MUD&FMD|Patients who are <55 years old, and will receive alloHCT for Young/MUD&FMD
3020090|NCT02428517||Old/MSD|Patients who are >=55 years old, and will receive alloHCT for Old/MSD
3020091|NCT02428517||Old/MUD&FMD|Patients who are >=55 years old, and will receive alloHCT for Old/MUD&FMD
3020092|NCT02428504||End of life decision|
3020093|NCT02428491|Experimental|DTaP-IPV-HB-PRP~T Vaccine|All participants will receive 3 doses of 0.5 mL DTaP-IPV-HB-PRP~T combined vaccine, intramuscularly, at 2, 3 and 4 months of age (primary series), followed by a booster dose approximately 12 months after the completion of the primary series (at 16 to 17 months of age).
3020094|NCT02428478|Active Comparator|Desipramine First, Placebo Second|Desipramine 200 mg administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching desipramine administered 2 hours before normal sleep time on second study night.
3020095|NCT02428478|Active Comparator|Placebo First, Desipramine Second|Placebo-matching desipramine administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then desipramine administered 2 hours before normal sleep time on second study night.
3020096|NCT02428465|Experimental|Purposeful Parenting|Families randomized to the intervention group will receive their pediatric provider's usual anticipatory guidance plus Purposeful Parenting.
3020097|NCT02428465|No Intervention|Control Group|Families randomized to the control group will receive usual anticipatory guidance, delivered at the discretion of their pediatric provider, at each well-child visit in the first 12 months of life.
3020098|NCT02428452|Experimental|Treatment|Six-month Social ABCs parent-training program received immediately
3020099|NCT02428452|No Intervention|Control|Participants randomized to the Control group do not receive the Social ABCs parent training program for the 6-month control phase. Control participants may access other approved community services as outlined in the study protocol and consent during the Control Phase, which is considered 'treatment as usual'. After the 6-month Control Phase, participants are offered the Social ABCs parent training program.
3020100|NCT02428439||Increased suicidality|Increase in suicidal ideation after taking the standardized pharmacotherapy (bupropion or lamotrigine) during 8 weeks.
3020101|NCT02428439||Non-increased suicidality|Non-increase of suicidal ideation after taking the standardized pharmacotherapy (bupropion or lamotrigine) during 8 weeks.
3020102|NCT02428426||gastric intestinal metaplasia|patients were diagnosed gastric intestinal metaplasia
3020103|NCT02428426||gastritis|patients were diagnosed non atrophic gastritis
3020104|NCT02428413|Active Comparator|Standard oxygen mask|Standard face mask to provide supplemental oxygen
3020105|NCT02428413|Active Comparator|ISO-Gard Mask|Face mask to scavenge waste anesthetic gases from patient during recovery from general anesthesia and to provide supplemental oxygen.
3020106|NCT02428400|Experimental|TG1050|"TG1050 SD cohort, administered SC as a single injection: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles~TG1050 MD cohort, administered SC as 3 once weekly injections:9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles~TG1050 Part B cohort, dose(s) and schedule to be determined"
3020138|NCT02428179||Group with Study intervention|Group with Study intervention
3020139|NCT02428153|Experimental|cases|static and dynamic stretching exercises
3020215|NCT02427698|Active Comparator|cryolipolysis plus subcision|
3020107|NCT02428400|Placebo Comparator|Placebo|"Placebo SD cohort, administered SC as a single injection: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles~Placebo MD cohort, administered SC as 3 once weekly injections: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles~Placebo Part B cohort, dose(s) and schedule to be determined"
3020108|NCT02428387|Experimental|Intervention|"The intervention group (Group 1) will receive instructions on how to access My Tools 4 Care for 3 months."
3020109|NCT02428387|No Intervention|Educational Control|An educational control group (Group 2) will receive a copy of the Alzheimer's Society' The Progression of Alzheimer's Disease - Overview Booklet.
3020110|NCT02428374|Active Comparator|rosuvastatin plus clopidogrel|rosuvastatin 40 mg and clopidogrel 75 mg
3020111|NCT02428374|Active Comparator|Rosuvastatin plus ticagrelor|Rosuvastatin 40 mg plus ticagrelor 90 mg bid
3020112|NCT02428374|Active Comparator|simvastatin plus clopidogrel|Simvastatin 40 mg plus clopidogrel 75 mg
3020113|NCT02428374|Active Comparator|Simvastatin plus ticagrelor|Simvastatin 40 mg plus ticagrelor 90 mg bid
3020114|NCT02428361|Experimental|Pouchitis patients receiving FMT|Pouchitis patients receiving biologically active human fecal material sourced from OpenBiome.The physician will administer 250 mL of the fecal suspension in aliquots of 50-60 mL through the endoscope. The material will be delivered to the most proximal point of insertion.
3020115|NCT02428348|Experimental|Interview|Interview of epilepsy patients and their family about their opinion on different EEG-cap models in development.
3020116|NCT02428322|Experimental|Intervention|2,000iu vitamin D3 per day for 15 weeks
3020117|NCT02428322|Placebo Comparator|Placebo|An identical placebo capsule daily for 15 weeks.
3020118|NCT02428309|Experimental|Low Dose Treg Cohort|3-6 participants will receive a single infusion of 1 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
3020119|NCT02428309|Experimental|Medium Dose Treg Cohort|Sequential dose escalation, 3-6 subjects will receive a single infusion of 4 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
3020120|NCT02428309|Experimental|High Dose Treg Cohort|Sequential dose escalation, 3-6 participants will receive a single infusion of 16 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
3020121|NCT02428283|Experimental|Nerve block|Scalp nerve block was performed with 0.25% ropivacaine.
3020122|NCT02428283|Active Comparator|Control|Remifentanil was administered intravenously.
3020123|NCT02428270|Experimental|GSK2256098 and Trametinib|"GSK2256098, orally, at 0.375 or 0.5 mg, once daily, continuously every 28 day cycles.~Trametinib, orally at 250 mg or 500 mg, twice daily, continuously every 28 day cycles."
3020124|NCT02428257|Experimental|hypobaric|continuous spinal anesthesia with 2,5 mg boluses of hypobaric bupivacaine, prepared diluting each 1 ml of 0.5% isobaric bupivacaine with 1 ml of sterile water.
3020125|NCT02428257|Active Comparator|isobaric|continuous spinal anesthesia with 2,5 mg boluses of 0.5% isboaric bupivacaine
3020126|NCT02428244|No Intervention|Arm 1, Control|Standard of care intervention: All patients at the University as a standard of care receive informational materials about smoking cessation. They are referred to the patient resource center at our institution. Patients will be provided this, also they will be provided with a smoking cessation Quitline Brochure
3020127|NCT02428244|Experimental|Standard of care + brief counseling|Patients who are randomized into this arm will receive the standard of care (outlined above). Additionally, patients will also receive a smoking education/counseling session. Patients will receive 10-30 minutes of guided discussion regarding the risks and benefits with regards to smoking and the healing of their traumatic injuries. The smoking educators, who will be trained in accordance with the guidelines provided by MdQuit.org will utilize motivational interviewing techniques to enhance interest in quitting. Patients will receive a description of the quitline, and the quitlined will be the recommended resource. If patients elect to enroll in the quitline, they will be consented using the standardized quitline protocols.
3020128|NCT02428244|Experimental|Standard of care + counseling/follow-up|"Patients who are randomized into this arm will receive the same intervention as patients in Arm 2, except when patients arrive for their follow-up, the smoking educator will check-in with their progress for approximately 5 minutes. The techniques utilized during this check-in visit will include repetition of previously described motivational interviewing, at this point patients who elect to be referred to the quitline will be given this opportunity."
3020129|NCT02428231|Active Comparator|Standard Treatment (One-Week Titration)|120 mg DMF twice daily for 1 week, then 240 mg (as 2 120-mg capsules) DMF twice daily for 11 weeks
3020130|NCT02428231|Experimental|Slow Up-Titration (Six-Week Titration)|120 mg DMF once daily (morning dose) and placebo once daily (evening dose) for 2 weeks, then 120 mg DMF twice daily for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF in the morning and 120 mg in the evening for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF twice daily for 6 weeks
3020131|NCT02428218|Experimental|BG00012|Participants will receive 120 mg capsule(s) BG00012 taken orally.
3020132|NCT02428218|Experimental|Placebo|Participants will receive matching placebo capsule(s) taken orally.
3020133|NCT02428205|Experimental|Propranolol arm|Propranolol will be administered in the form of a liquid dose via oral syringe by the participants' parent/caregiver an hour before each EIBI session. To minimize risk, the bodyweight adjusted minimum dose of propranolol used safely for test anxiety in healthy adults (10mg) will be used: participants weighing > 30 kg will be given 4 mg, participants weighing 22.5 - 30 kg will be given 3 mg, participants weighing 15 - 22.5 kg will be given 2 mg. Participants weighing < 15 kg will be excluded for safety reasons.
3020134|NCT02428205|Placebo Comparator|Placebo arm|Placebo will be administered in the form of a liquid dose via oral syringe by the participants' parent/caregiver an hour before each EIBI session.The same bodyweight adjusted doses specified in the propranolol arm will be used for this arm.
3020135|NCT02428192|Experimental|Cohort A (nivolumab - closed to accrual on 21-Oct-2015)|Patients receive nivolumab IV over approximately 60 minutes once every 2 weeks for up to 46 doses in the absence of disease progression or unacceptable toxicity.
3020136|NCT02428192|Experimental|Cohort B (nivolumab and Ipilimumab)|Patients receive nivolumab IV over approximately 60 minutes followed by a saline flush and ipilimumab IV over 90 minutes. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3020137|NCT02428179||Control group without Study intervention|Control group without Study intervention
3054334|NCT02198768||Ankle Fracture|Patients with isolated ankle fractures.
3020141|NCT02428140|Experimental|External Loop Recorder|external event-triggered ECG loop recorder (Sorin Spiderflash-t) for 30 days
3020142|NCT02428127|Experimental|Test|20g Carbohydrate powder fortified with multiple micronutrients, reconstituted as a beverage in 200mL lukewarm water. This will be administered twice a day
3020143|NCT02428127|Active Comparator|Calorie matched protein powder|20g Calorie matched protein powder with 80% protein, reconstituted as a beverage in 200mL lukewarm water. This will be administered twice a day
3020144|NCT02428127|Placebo Comparator|Control|200mL lukewarm water given twice a day
3020145|NCT02428114||5 days of filgrastim|Standard of care
3020146|NCT02428114||7 days of filgrastim|Standard of care
3020147|NCT02428114||10 days of filgrastim|Standard of care
3020148|NCT02428088|Experimental|Dasotraline 2 mg|Dasotraline 2 mg
3020149|NCT02428088|Experimental|Dasotraline 4 mg|Dasotraline 4 mg
3020150|NCT02428088|Placebo Comparator|Placebo|Placebo
3020151|NCT02428075|Experimental|FCHV visit-normotensive|
3020152|NCT02428075|No Intervention|FCHV no visit-normotensive|
3020153|NCT02428075|Experimental|FCHV visit-prehypertensive|
3020154|NCT02428075|No Intervention|FCHV no visit-prehypertensive|
3020155|NCT02428075|Experimental|FCHV visit-hypertensive|
3020156|NCT02428075|No Intervention|FCHV no visit-hypertensive|
3020157|NCT02428062|No Intervention|Standard-of-Care|The intraoperative hemodynamic management of the patients assigned to this arm will be left to the discretion of the anesthesiologist, without any indication as to the intraoperative hemodynamic strategy to be adopted.
3020158|NCT02428062|Experimental|Treatment|The anesthesiologist will have as hemodynamic target for patients assigned to this arm the maintenance of mean arterial blood pressure within 10% of the baseline blood pressure value (recorded at the preoperative evaluation). The strategy to reach this hemodynamic target will be left to the clinical judgment of the anaesthesiologist in charge. The possible strategies include a vasoconstrictor agent (either phenylephrine, ephedrine, epinephrine, norepinephrine or dopamine), intravenous fluids, patient's positioning or reduction of depth of anesthesia.
3020159|NCT02428062|No Intervention|Control|"Subjects assigned to this arm will undergo the same geriatric, neuropsychologic and audiologic evaluations administered to patients of the Standard-of-Care and Treatment arms at the same time points (baseline, 3 months and 1 year). These subjects will not undergo any surgical procedure and will therefore not be evaluated for post-operative complications or delirium occurrence."
3020160|NCT02428049||Lung cancer patients|Lung cancer patients in stages IA-IIIA destined to have stereotactic or conventional radiotherapy and chemotherapy in curative intent
3020161|NCT02428049||Control group|COPD patients
3020162|NCT02428036|Experimental|TBI-1401(HF10) - Cohort 1|Oncolytic virotherapy, intratumoral administrations of TBI-1401(HF10)
3020163|NCT02428036|Experimental|TBI-1401(HF10) - Cohort 2|Oncolytic virotherapy, intratumoral administrations of TBI-1401(HF10)
3020164|NCT02428023||GrThalasaemia|estimation of IMT of the carotides arteries and calcium scoring
3020165|NCT02428023||GrNormal|estimation of IMT of the carotides arteries and calcium scoring
3020166|NCT02428010|Experimental|Treatment|TMVR Implant
3020167|NCT02427997|Experimental|Treadmill training with virtual reality|The TT+VR patients (i.e., the experimental arm) will receive 18 sessions (3 times per week x 6 weeks) of training that will consist of walking on a treadmill while wearing a safety harness (without body weight support, recall Figure 1), and while being provided with feedback from the system.
3020168|NCT02427997|Active Comparator|Treadmill training alone|TT alone will receive conventional treadmill training with no feedback from the system. They will train with a safety harness 18 sessions (3 times per week x 6 weeks).
3020169|NCT02427984||Metal on Metal (MoM)|Patients wearing MoM hip prosthesis
3020170|NCT02427984||Ceramic on Ceramic (CoC)|Patients wearing CoC hip prosthesis
3020171|NCT02427984||Controls|Patients free from hip devices
3020172|NCT02427971||Perseus|Use of Perseus® A 500 with VaporView® mode that gives the evolution of inspired (Fi) and end-tidal (Fe) fractions of halogenated agents for 20 minutes based on the delivered fraction (Fd). FGF remains adjusted manually by the practitioner. This mode also makes it possible to maintain a low FGF (0.5 L/min)
3020173|NCT02427971||Aysis|Use of Aysis® Cs2 ventilator with automated control of end-tidal inhalation anesthetic concentration, EtControl® mode.
3020174|NCT02427958|Experimental|Leuprorelin|Participants with body weight greater than or equal to (>=) 20 kilogram (kg) will receive the recommended dose of leuprorelin 3.75 milligram (mg), injection, subcutaneously, once every 4 weeks for 96 weeks. Participants with body weight less than (<) 20 kg will receive leuprorelin 1.88 mg, injection, subcutaneously, once every 4 weeks for 96 weeks.
3020175|NCT02427945|Experimental|Control|Provision of information on safe water
3020176|NCT02427945|Experimental|Treatment traditional|Provision of information on safe water and child nutrition. The information will be targeted to the mother of the child aged between 6 and 24 months old.
3020177|NCT02427945|Experimental|Treatment couple|Provision of information on safe water and child nutrition. The information will be targeted to the mother of the child aged between 6 and 24 months old, and her husband.
3020178|NCT02427932||Pregnant/Ampicillin|pregnant participants who will receive Ampicillin for conditions such as Group B Streptococcus
3020179|NCT02427932||Non-pregnant/Ampicillin|non-pregnant participants who will receive Ampicillin for a qualifying hospital admission
3020180|NCT02427932||Pregnant and Non-pregnant/Ampicillin and Gentamicin|pregnant participants who will receive Ampicillin and Gentamicin for conditions such as chorioamnionitis; non-pregnant participants who will receive Ampicillin and Gentamicin for a qualifying hospital admission
3020181|NCT02427932||Non-Pregnant/Gentamicin|non-pregnant participants who will receive Gentamicin for a qualifying hospital admission
3020182|NCT02427919|Experimental|Early G-CSF use|"Refractory AML undergoing salvage chemotherapy (MEC regimen in AML). After finishing application of chemotherapy, G-CSF will be started post chemotherapy D+7~D+10 when blasts disappear from peripheral blood smear.~When blasts reappear on peripheral blood smear, G-CSF will be discontinued.~Intervention type : Drug Intervention name : G-CSF (Filgrastim)~-> Comparison of the effect of G-CSF (Filgrastim) use"
3020264|NCT02427373|Active Comparator|fish oil triglyceride|1.3g/d dose of DHA+EPA in fish oil TG (6 capsules) administered for 4 weeks
3020183|NCT02427919|Active Comparator|No or delayed G-CSF use|"Refractory AML undergoing salvage chemotherapy (MEC regimen in AML). After finishing application of chemotherapy, G-CSF will not be applied at least post chemotherapy D+25~D+28. If patient suffers from severe infectious complication and when no blasts are detected on peripheral blood smear, G-CSF can be started then.~Intervention type : Drug Intervention name : G-CSF (Filgrastim)~-> Comparison of the effect of G-CSF (Filgrastim) use"
3020184|NCT02427906||TIPS group|patients who have transjugular intrahepatic portosystemic shunt
3020185|NCT02427906||Non-TIPS group|patients who have endoscopic variceal ligation
3020186|NCT02427893|Active Comparator|Cohort 1|Ten patients begin Vemurafenib monotherapy, after 10 days, begin combination therapy by adding Cobimetinib.
3020187|NCT02427893|Active Comparator|Cohort 2|Ten patients begin Cobimetinib monotherapy, after 10 days, begin combination therapy by adding Vemurafenib.
3020188|NCT02427880|Experimental|Acetazolamide|Each patient receives 250 mg of acetazolamide and 50 mg of hydrochlorothiazide daily for 1 week. Then they are prescribed 40 mg of furosemide daily for 2 weeks.
3020189|NCT02427880|Active Comparator|Furosemide|Each patient is prescribed 40 mg of furosemide and 50 mg of hydrochlorothiazide daily for 1 week. Then they receive 40 mg of furosemide daily for 2 weeks.
3020190|NCT02427867|Experimental|remote ischemic preconditioning|Three cycles of 5 minutes ischemia will be applied to the upper left arm (or right arm or legs if the left arm will not be deemed suitable by the attending physician), achieved by inflation of a blood-pressure cuff to 200 mm Hg, followed by 5 minutes reperfusion while the cuff will be deflated.
3020191|NCT02427867|Placebo Comparator|no ischemic preconditioning|The cuff will be placed around the arm but not inflated.
3020192|NCT02427854|No Intervention|No training|Incidence of obstetric perineal injuries in the participating hospitals before implementation of the manual perineal protection method.
3020193|NCT02427854|Active Comparator|Education by animated training video|Incidence of obstetric perineal injuries in the participating hospitals, after the delivery unit staff has been educated and trained to a perineal support by an animated training video only.
3020194|NCT02427854|Active Comparator|Interactive hands on bedside training|Incidence of obstetric perineal injuries in the participating hospitals, after the delivery unit staff has been educated and trained to a perineal support by an animated training video and additionally by an interactive hands-on bedside training.
3020195|NCT02427841|Experimental|Treatment (chemotherapy, chemoradiation therapy, surgery)|"PRE-OPERATIVE (NEOADJUVANT) CHEMOTHERAPY: Patients receive nab-paclitaxel IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo IG-IMRT 5 days a week for 28 fractions and receive fluorouracil IV continuously on days 1-7 for 6 weeks.~SURGICAL RESECTION: Patients undergo surgery 4-10 weeks after the last dose of chemoradiation.~POST-OPERATIVE (ADUJUVANT) CHEMOTHERAPY: Beginning within 8-12 weeks after surgery, patients receive nab-paclitaxel IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4 additional courses in the absence of disease progression or unacceptable toxicity."
3020196|NCT02427828|Active Comparator|Treatment Group|Assessment of Visensia Respiration Rate Estimation Service (product) to provide Respiration Rate from PPG signal, providing 3 vital signs (heart rate, oxygen saturation and respiration rate) to facilitate continuous Safety Index (VSI) calculation by Visensia, alongside standard routine intermittent observations (vital signs every 4 - 6 hours).
3020197|NCT02427828|No Intervention|Control Group|Using standard routine intermittent observation (vital signs every 4 - 6 hours) and calculation of NEWS/MEWS scores for early detection of patient deterioration.
3020198|NCT02427802|Experimental|Gentamicin sponge group|Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
3020199|NCT02427802|Placebo Comparator|Placebo sponge group|Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
3020200|NCT02427802|No Intervention|No sponge group|Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
3020201|NCT02427789|No Intervention|Control|In this group patients will not have physical exercises
3020202|NCT02427789|Active Comparator|Physical Exercise|In this group patients will make physical exercise
3020203|NCT02427776|Experimental|IMP|
3020204|NCT02427763|Active Comparator|Retainer use|"The volunteer use a thermoplastic appliance (Essix) for 8hours~Interventions:~hours of use~collect biofilm~collect saliva~collect epithelium"
3020205|NCT02427763|Active Comparator|Aligner use|"The volunteer use thermoplastic appliance (Essix) for 22 hours~Interventions:~hours of use~collect biofilm~collect saliva~collect epithelium"
3020206|NCT02427750|Experimental|Trivalent Influenza Vaccine|One injection of Agrippal®
3020207|NCT02427737|Experimental|Comfort Talk® Training|Six MRI clinical sites form the experimental group. Their personnel will be trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests at the onset of the study.
3020208|NCT02427737|No Intervention|Control|Six MRI sites will not be trained in Comfort Talk®.
3020209|NCT02427724|Active Comparator|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
3020210|NCT02427724|Active Comparator|lidocaine 7%/tetracaine 7% topical anesthetic|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
3020211|NCT02427724|Placebo Comparator|placebo vehicle|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
3020212|NCT02427711|Active Comparator|Bipolar sealer|Prospective use of bipolar sealer for skin and knee capsule incision revisions of non-septic knee arthroplasty.
3020213|NCT02427711|Placebo Comparator|Scalpel|Conventional surgical incision with scalpel - data extracted from a retrospective group.
3020214|NCT02427698|Active Comparator|cyrolipolysis|
3020216|NCT02427672|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal bilateral transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex. tDCS will be delivered by a battery-driven, constant-current stimulator connected to three saline-soaked surface sponge electrodes. Two anodal electrodes (25cm2) will be placed over the dorsolateral prefrontal cortex bilaterally and one cathodal electrode (35cm2) will be placed at the back of the neck. Scalp electrodes will be positioned over the F3 and F4 according to the 10-20 EEG international system. A current of 1mA will be applied for 20 minutes and the current will be ramped up and down at the beginning and end of the stimulation period.
3020217|NCT02427672|Sham Comparator|Sham stimulation|The sham transcranial direct current stimulation condition will involve the same placement of the electrodes, current intensity, and ramp time as the real tDCS condition, but stimulation will only last for 30 seconds.
3020218|NCT02427659|Other|Virtual Reality Distraction|The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
3020219|NCT02427659|Other|Audio (sounds of nature)|"The subjects will listen to an audio recording called Sounds of Nature during their wound care. The nurse will be doing the wound care."
3020220|NCT02427659|Other|control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
3020221|NCT02427646|Experimental|Essential tremor treatment|
3020222|NCT02427646|Experimental|Parkinson disease tremor treatment|
3020223|NCT02427633|No Intervention|Control|Randomized to standard care (control group) - observations only
3020224|NCT02427633|Experimental|UKRC 1997|Randomized to modified UKRC 1997 - Intervention and Observations
3020225|NCT02427633|Experimental|UKRC 2010|Randomized to modified UKRC 2010 - Intervention and Observations
3020226|NCT02427620|Experimental|Ibrutinib + Rituximab with Hyper-CVAD Consolidation|"In Part 1, participants receive the combination of Ibrutinib and Rituximab. Depending on participant's response in Part 1, they will receive 2 alternating combinations of drugs (the first combination in the first cycle, then the second combination in the second cycle, and so on) for 2-8 cycles. Each cycle will be 28 days.~In Part 2, participants are consolidated with Rituximab plus Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD) alternating every 28 days with Rituximab plus high-dose Methotrexate-Cytarabine (MTX-AraC)."
3020227|NCT02427607|Experimental|Perampanel|Participants started the study with the dose that they were receiving at the end of their participation in the previously participated Study E2007-G000-332 (Study 332) [NCT02307578]. Doses of perampanel were allowed to be adjusted based on clinical judgment. A minimum perampanel dose of 2 milligram (mg) per day was required to continue in the study. The maximum daily dose of perampanel permitted was 12 mg per day.
3020228|NCT02427594|Experimental|Controlled diet first|In this arm participants will first consume a controlled diet plus added table salt (sodium chloride) for one week. They will then consume an identical controlled diet plus sodium bicarbonate for one week. Sodium bicarbonate will be dosed as 2,600 mg divided three times daily if ideal body weight is <70 kg or 3,250 mg divided three times daily if ideal body weight is ≥70 kg. Added table salt will match the sodium content of the sodium bicarbonate dose (i.e. 31 or 39 mEq/day).
3020229|NCT02427594|Experimental|Sodium bicarbonate first|In this arm participants will first consume a controlled diet plus sodium bicarbonate for one week. They will then consume an identical controlled diet plus added table salt (sodium chloride) for one week. Sodium bicarbonate will be dosed as 2,600 mg divided three times daily if ideal body weight is <70 kg or 3,250 mg divided three times daily if ideal body weight is ≥70 kg. Added table salt will match the sodium content of the sodium bicarbonate dose (i.e. 31 or 39 mEq/day).
3020230|NCT02427581|Experimental|Arm 1 - personlized synthetic long peptide vaccine|"Each subject will receive a single synthetic long peptide vaccine on Days 1, 4, 8, 15, 22, 50, and 78.~The first five injections must take place within +/- 1 day window and the remaining injections must take place within a +/- 2 week window.~The synthetic long vaccine is reconstituted in up to four pools (A, B, C, and D). At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, and D - Left Leg) by subcutaneous (SC) injection. Alternative anatomical locations for patients who are status post complete axillary or inguinal lymph node dissection or other contraindications that prevent injections to a particular extremity are the left and right midriff, respectively. The same pool should be administered to the same limb across doses."
3020231|NCT02427568|Placebo Comparator|Placebo|Inactive placebo administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by supplement half the size of the initial dose.
3020232|NCT02427568|Active Comparator|MDMA|125 mg 3,4-methylenedioxymethamphetamine (MDMA) administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.25 to 2.5 hours later by a supplemental dose of 62.5 mg MDMA.
3020233|NCT02427555|Experimental|Barley kernel bread|
3020234|NCT02427555|Sham Comparator|Whit wheat flour bread|
3020235|NCT02427542|Active Comparator|CBT for DP|Six sessions of CBT covering psycho-education, formulation, enhancing coping strategies (including grounding) and cognitive restructuring techniques.
3020236|NCT02427542|Placebo Comparator|Treatment as usual|Participants will continue to receive their normal treatment - in most cases, this will be care coordination/case management delivered through a community mental health team and may include medication.
3020237|NCT02427529|Experimental|HCG Group|This group received daily subcutaneous injections of Human Chorionic Gonadotropin while eating a very low calorie diet of 500 calories per day.
3020238|NCT02427529|Placebo Comparator|Saline/Placebo|This group received daily subcutaneous injections of saline while eating a very low calorie diet of 500 calories per day.
3020239|NCT02427516||NVAF-VKA cohort|NVAF patients who initiate a VKA treatment
3020240|NCT02427516||VTE-VKA cohort|VTE patients who initiate a VKA treatment
3020241|NCT02427503||Asthma with NP and require surgery|Patients receiving standardized treatment for nasal polyposis, according to the POLINA guidelines and for persistent asthma who will undergo FESS-BP.
3020242|NCT02427503||Asthma with NP and NOT require surgery|Patients receiving standardized treatment for nasal polyposis, according to the POLINA guidelines and for persistent asthma who will NOT undergo FESS-BP.
3020265|NCT02427373|Active Comparator|krill oil|1.3g/d dose of DHA+EPA in krill oil (6 capsules) administered for 4 weeks
3020243|NCT02427490|Active Comparator|Unenhanced Monitoring|Family caregivers of cancer patients receiving outpatient palliative care will complete standardized questionnaires at the time of study enrollment and two, four, and eight weeks after study enrollment.
3020244|NCT02427490|Experimental|Problem-Solving Intervention|Family caregivers of cancer patients receiving outpatient palliative care will use videoconferencing tools to participate in three problem-solving sessions with a member of the research team.
3020245|NCT02427477|Experimental|senofilcon A/ delefilcon A/ senofilcon A|Subjects were randomized to one two lens wear sequences. Subjects randomized to this sequence first wore the senofilcon A contact lens, then wore the delefilcon A contact lens second and then wore the senofilcon A contact lens third.
3020246|NCT02427477|Active Comparator|delefilcon A/senofilcon A/ delfilcon A|Subjects were randomized to one two lens wear sequences. Subjects randomized to this sequence first wore the delefilcon A contact lens then wore the senofilcon A contact lens second and then wore the Control lens delefilcon A contact lens third.
3020247|NCT02427464|Experimental|VM202|"Subjects randomized to the VM202 treatment arm will receive the following intramuscular injections in each calf:~Day 0 - 16 injections of 0.5mL of VM202 / calf~Day 14 - 16 injections of 0.5mL of VM202 / calf~Day 90 - 16 injections of 0.5mL of VM202 / calf~Day 104 - 16 injections of 0.5mL of VM202 / calf"
3020248|NCT02427464|Placebo Comparator|Placebo|"Subjects in the placebo control group will receive the following intramuscular injections in each calf:~Day 0 - 16 injections of 0.5mL of VM202 vehicle / calf~Day 14 - 16 injections of 0.5mL of VM202 vehicle / calf~Day 90 - 16 injections of 0.5mL of VM202 vehicle / calf~Day 104 - 16 injections of 0.5mL of VM202 vehicle / calf"
3020249|NCT02427451|Experimental|Treatment (obinutuzumab, ibrutinib, Bcl-2 inhibitor GDC-0199)|Patients receive obinutuzumab IV on day 1 (days 1, 2, 8, and 15 for course 1 only) every 28 days for up to 8 courses. Beginning in course 2, patients receive ibrutinib PO QD on days 1-28. Beginning in course 3, patients receive Bcl-2 inhibitor GDC-0199 PO QD on days 1-28. Treatment repeats every 28 days for up to 14 courses in the absence of disease progression or unacceptable toxicity.
3020250|NCT02427438|Active Comparator|Video Home Program Education|Subjects in this group will complete the same 8 weeks of home program exercises for lumbar instability. The home program exercises will be completed using a video with verbal instruction for guidance of proper technique and repetitions.
3020251|NCT02427438|Active Comparator|Handout Home Program Education|Subjects will complete the same 8 weeks of home program exercises for lumbar instability. The home program exercises will be completed using a handout with two dimensional pictures and written instructions for guidance of proper technique and repetitions.
3020252|NCT02427425|Experimental|TENS group|It was applied conventional TENS with FIV effect, frequency of 100 Hertz, a pulse width of 60μs and intensity adjusted according to the individual baseline for each patient without causing muscular contraction. The electrodes were arranged in a cross shape in the paravertebral region (levels T12-L1 and L5 - S1). Treatment consisted of 10 sessions (2x / week / 5 weeks), with each session lasting 30 '.
3020253|NCT02427425|Placebo Comparator|Placebo group|In Placebo group the same procedures of the TENS group were adopted, but did not occur electrical stimulus.
3020254|NCT02427412|Active Comparator|IA Tranexamic acid + IV Tranexamic Acid|3 gram of Tranexamic acid diluted into 30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.
3020255|NCT02427412|Placebo Comparator|IA Saline Water + IV tranexamic Acid|30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.
3020256|NCT02427399|No Intervention|Usual care / opportunistic screening|This group will not be contacted by the study team in any way and will receive the general standard of care at Fenway. Patient charts are reviewed by the provider and medical team shortly before a scheduled visit to determine if the patient is due for a Pap, and if so, the patient is offered a Pap during the visit or the chance to schedule one for another date. Any proactive outreach occurs infrequently and at an ad-hoc basis, but should any proactive outreach occur, the study team will not interfere.
3020257|NCT02427399|Experimental|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests. If the patient does not contact Fenway within 1 month to schedule an appointment, an additional letter will be sent at 1 month, and similarly again at 2 months. These letters will be the same, except that letters two and three will mention that previous attempts have been made at contact. Based on best practices in the literature, the letters will be signed by the patient's primary care provider.
3020258|NCT02427399|Experimental|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders. The email will be sent from the provider's email account. The email will have an informational sheet attached or included in the body of the email. The emails will be sent through MyFenway, the secure, Health Insurance Portability and Accountability Act (HIPAA)-compliant patient contact system at Fenway.
3020259|NCT02427399|Experimental|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. As per HIPAA regulations, if the patient does not answer, a voicemail will be left saying that a Fenway representative has called and request that the patient calls back, but a reason will not be given. Some, but not all of the information contained in the info sheet will be provided during the call (see phone script). The script used is consistent with the scripts used currently for patient outreach. A voicemail will still count as one outreach attempt out of three. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
3020260|NCT02427399|Experimental|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called. If a patient randomly selected for this group does not have an email listed, she will receive one letter and two phone calls.
3020261|NCT02427386|Active Comparator|dynamized estrogen in alcohol solution|Dynamized estrogen (17-beta estradiol) in the 12cH, 24cH and 18cH potencies.
3020262|NCT02427386|Placebo Comparator|placebo (alcohol solution)|This arm received alcohol solution during the 24-week study duration.
3020263|NCT02427373|Active Comparator|fish oil ethyl ester|1.3g/d dose of DHA+EPA in fish oil EE (6 capsules) administered for 4 weeks
3020330|NCT02426957|No Intervention|Treatment As Usual|Treatment As Usual on inpatient psychiatric unit
3020266|NCT02427347|Experimental|Intervention group|Intervention including acupuncture treatment and healthy education.
3020267|NCT02427347|Other|Control group|Healthy education is given as a baseline treatment.
3020268|NCT02427334|Active Comparator|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
3020269|NCT02427334|Active Comparator|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
3020270|NCT02427334|Placebo Comparator|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
3020271|NCT02427321||Cystoscopy cohort|"Video recording of flexible cystoscopic examination. All participants enrolled on the study will have video from their flexible cystoscopic examination recorded.~Diagnosis and pathology information will be collected from the participants medical notes for a period of eight weeks following the recorded cystoscopy."
3020272|NCT02427308||miltefosine patients that become pregnant|
3020273|NCT02427295|Experimental|Group 2: Surgery + Medical treatment|"MRI : residual tumor 6 months post-op : IGF-1 >600 ng/ml~medical treatment : Sandostatin (Octreotide Acetate)"
3020274|NCT02427295|No Intervention|Group 3 : Rescue group|If IGF-1 levels fails to normalize till post-op 18 months post-op, medical treatment will be added.)
3020275|NCT02427295|No Intervention|Gruop1 : Surgery only group|"MRI : without residual tumor 6months post-operation~and IGF-1 <600ng/ml"
3020276|NCT02427282|Active Comparator|MS. Frog|miniscrew-supported frog molar distalizing appliance
3020277|NCT02427282|Experimental|Stand. Frog|Standard Frog appliance
3020278|NCT02427269||Barrett's Esophagus (BE) Surveillance|Patients who have never received ablative therapy for Barrett's Esophagus and are receiving routine care surveillance upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
3020279|NCT02427269||Barrett's Esophagus (BE) Pre-Ablation|Patients who are receiving routine care upper endoscopy with ablative therapy for their Barrett's Esophagus for the first time. Subjects will have esophageal biopsies, blood, and data collected for this study.
3020280|NCT02427269||Barrett's Esophagus (BE) Post-Ablation|Patients with a history of Barrett's Esophagus who are status post ablation and are receiving routine care follow-up EGD for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
3020281|NCT02427269||Esophageal Cancer(ECA/IMC)|Patients with esophageal cancer who are receiving routine care upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
3020282|NCT02427269||Squamous Cell Carcinoma (SCC)|Patients with squamous cell cancer of the esophagus who are receiving routine care upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
3020283|NCT02427256||Non-Pathologic Adults age 18-28 yrs|
3020284|NCT02427256||Non-Pathologic Adults age 29-80 yrs|
3020285|NCT02427256||Pathologic Adults age 29-80 yrs|
3020286|NCT02427243|Experimental|Crenezumab Formulation 2|A single dose given as two subcutaneous injections on Day 1
3020287|NCT02427243|Experimental|Crenezumab Formulation 3|A single dose given as two subcutaneous injections on Day 1
3020288|NCT02427230|Active Comparator|Pelvic floor muscle training (PFMT)|Pelvic floor muscle training daily during 12 weeks.
3020289|NCT02427230|Active Comparator|PFMT and electrical stimulation|Pelvic floor muscle training and intravaginal neuromuscular electrical stimulation daily during 12 weeks.
3020290|NCT02427217||Fibrinogen Concentrate, Human (FCH)|A cohort of subjects who have retrospectively received FCH for the treatment of bleeding, routine prophylaxis and/or use in surgery, and who may continue to prospectively receive FCH at the discretion of the treating physician.
3020291|NCT02427191|Experimental|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
3020292|NCT02427191|Placebo Comparator|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
3020293|NCT02427178|Experimental|Open label|"Hematopoietic allogeneic stem cells will be transplanted:~HLA testing will be performed on potential stem cell donors. HLA 10/10 matched donors are eligible, however there are additional criteria that will be applied to determine an acceptable donor. Patients will receive 2 X10 6 CD34 cells/kg weight."
3020294|NCT02427165|Placebo Comparator|Placebo|Single dose of nebulised placebo solution
3020295|NCT02427165|Experimental|RPL554 Dose 1|0.4 mg single dose nebulised RPL554
3020296|NCT02427165|Experimental|RPL554 Dose 2|1.5 mg single dose nebulised RPL554
3020297|NCT02427165|Experimental|RPL554 Dose 3|6 mg single dose nebulised RPL554
3020298|NCT02427165|Experimental|RPL554 Dose 4|24 mg single dose nebulised RPL554
3020299|NCT02427165|Active Comparator|Salbutamol Dose 1|2.5 mg single dose nebulised salbutamol
3020300|NCT02427165|Active Comparator|Salbutamol Dose 2|7.5 mg single dose nebulised salbutamol
3020301|NCT02427152||Lean|body mass index: 18-25 kg/m²
3020302|NCT02427152||Overweight/Obese|body mass index: >25 kg/m²
3020303|NCT02427139|Experimental|ANSiStim|"The ANSiStim device is designed to administer auricular point stimulation treatment over several days. The advantage of using the ear for this treatment is that it provides numerous points for stimulation within a small area. Stimulation is performed by electrical pulses emitted through strategically positioned needles.~Three zinc air batteries with 1.4 V provide the required stimulation energy for 96 hours. This constant current source guarantees equivalent stimulation energy regardless of the individual impedance of the skin. The treatment period varies based on the severity of the pain. To minimize the risk of adaption or tolerance to the electrical stimulation, it is applied for 3 hours, followed by a pause of 3 hours."
3020304|NCT02427126|Experimental|Apixaban|Apixaban 5mg b.i.d. Study treatment: 12 months Follow-up: 30 days after last study drug intake
3020305|NCT02427126|Active Comparator|Aspirin|Acetylic Salicylic Acid 100mg o.d.; Study treatment: 12 months Follow-up: 30 days after last study drug intake
3020306|NCT02427113|Active Comparator|Self-Select Music|Participants will be randomized to two groups. Self-select music will be used as treatment for managing pain. They will be required to listen to their preferred songs for 30 minutes per 7 days, recommended 5, for 3 weeks.
3020331|NCT02426944|Experimental|LAAO group|Patients will be treated interventionally by left atrial appendage occlusion (LAAO). LAAO will be done using Amulet or Watchman device.
3054431|NCT02198079||Cystic Fibrosis|Children with Cystic Fibrosis
3020307|NCT02427113|Active Comparator|Sound Oasis Vibrating Chair|Participants will be randomized to two groups. Vibroacoustic therapy will be administered in the form of a vibrating chair. They will be required to listen to their preferred songs for 30 minutes per 7 days, recommended 5, for 3 weeks.
3020308|NCT02427100|No Intervention|Control Group|Control participants will be paid for assessments. They will receive study newsletters and a pedometer with advice after the final follow-up visit.
3020309|NCT02427100|Active Comparator|Intervention Group|Intervention participants will receive 4 weekly newsletters, a pedometer with walking advice, and twice daily fruit/vegetable snacks during weekdays.
3020310|NCT02427087|Active Comparator|Continuous Aerobic training|Aerobic training continuous (n=19 patients) carry a protocol continuous aerobic training twice a week for 24 weeks and the session will last 60 minutes/2 days/week with recommendation for healthy diet.
3020311|NCT02427087|Active Comparator|Healthy diet|Diet group (n=21 patients) only recommendation for healthy diet.
3020312|NCT02427074|Active Comparator|Balloon Compression Rhizotomy|Patients that are submitted to Balloon Compression Rhizotomy
3020313|NCT02427074|Active Comparator|Radiofrequency Thermal Coagulation Rhizotomy|Patients that are submitted to Radiofrequency Thermal Coagulation Rhizotomy
3020314|NCT02427061|Experimental|Intervention Program (Manhood 2.0)|"Curricular Content: The 18 hour content will be spread over 3 to 6 sessions (3 weeks duration up to a 2 month period). Youth are guided to explore social constructions of masculinity, describe healthy relationships, discuss healthy sexual behaviors, identify coercive and disrespectful behaviors, and practice skills to intervene when witnessing peers' disrespectful and harmful behaviors, with repeated reflection on gender norms throughout these sessions.~Module One focuses on themes of gender and masculinity. Module Two focuses on themes of violence and sexual consent. Module Three focuses on themes of sexual health and decision making."
3020315|NCT02427061|Active Comparator|Control Program (Job Skills Training)|"Youth in the control arm receive the same amount of time with an intervention -- 18 hours of curriculum divided into 3 to 6 sessions, over 3 weeks up to 2 months duration.~The control intervention focuses on job skills development."
3020316|NCT02427048|No Intervention|Pre-Intervention|Delayed feedback and peer comparison
3020317|NCT02427048|Experimental|Feedback with Peer Comparison|Individualized adherence feedback with peer comparison
3020318|NCT02427035|Experimental|Low|A low dose of either CSL112 or placebo is to be administered as a single intravenous (IV) infusion. The placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
3020319|NCT02427035|Experimental|High|A high dose of either CSL112 or placebo is to be administered as a single intravenous (IV) infusion. The placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
3020320|NCT02427022|Experimental|Online CTI Training|Services providers in this group received a novel online CTI training. The enhanced course combines depth of knowledge among trainers, skills-based and practical approaches to learning, new technologies, and opportunities for social networking. The course is divided the knowledge, skills, and tools associated with CTI into four two-week modules. The total instruction time for the course was 24 hours.
3020321|NCT02427022|Active Comparator|Face-to-Face CTI Training|Service providers in the group received 1.5-days of face-to-face CTI training at each study site with one trainer. There were a total of 8 hours of instructor led training per site. Face-to-face training sessions were followed by three assignments with feedback from trainers, and eight 60-minute telephone consultation sessions.
3020322|NCT02427009|Experimental|The study population|"The study population consists of adult women requiring an epidural blood patch for the treatment of post-dural puncture headache following vaginal delivery. Women who delivered by cesarean section are not included due to the discomfort of the prone position while there is an abdominal scar.~Intervention: Prone position for 1 hour after blood patch"
3020323|NCT02426996|Experimental|Study population|"The patients included have been operated for chronic anterior shoulder instability by a Latarjet-type bone block procedure using the SEM (Science Et Medecine) positioning tool within the past 3 months.~Intervention: Scan of shoulder"
3020324|NCT02426983|Active Comparator|Direct Current Stimulation active|Electrodes will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks.
3020325|NCT02426983|Sham Comparator|Direct Current Stimulation sham|In sham sessions, the device will have the same placement and intensity, but will only be turned on for 30 seconds. The DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. This will occur in two separate sessions, occurring within weeks.
3020326|NCT02426983|Active Comparator|NMDA antagonist active|Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON). Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink. This same dose will be delivered in two separate sessions, occurring within weeks.
3020327|NCT02426983|Placebo Comparator|NMDA antagonist placebo|Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink. This same dose will be delivered in two separate sessions, occurring within weeks.
3020328|NCT02426970||Lumbar spine pain inpatients|The study population corresponds to inpatient rehabilitative care for lumbar spine pain in the Departments of Physical Medicine and Functional Rehabilitation at the Nîmes and Montpellier University Hospitals.
3020329|NCT02426957|Experimental|Motivational Enhancement Therapy|The 60-90 minute intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets. Personalized feedback for the intervention will be derived from the assessment battery and will be provided in both written and graphic formats. In addition to the 60-90 minute MI intervention delivered to the adolescent, a 30-45 minute intervention will be conducted with the adolescent and parent(s) the following day, in which the adolescent will review the goals, strategies, and change plan worksheets with the parent(s), facilitated by the therapist.
3020332|NCT02426944|Experimental|NOAC group|Patients will be treated by novel anticoagulants (NOAC).
3020333|NCT02426931|Experimental|tf-URS|Participants in tf-URS group undergo ureteroscopy using the tip-flexible ureterorenoscope.
3020334|NCT02426931|Active Comparator|f-URS|Participants in f-URS group undergo ureteroscopy using the classic flexible ureteroscope.
3020335|NCT02426918|Experimental|Debio 1450 320/480 mg|After 2 doses of Debio 1450 IV (intravenous) therapy, the Debio 1450 320/480 mg daily dose group receives 240 mg Debio 1450 Oral + Linezolid Placebo twice daily (BID).
3020336|NCT02426918|Experimental|Debio 1450 160/240 mg|After 2 doses of Debio 1450 IV therapy, the Debio 1450 160/240 mg daily dose group receives 120 mg Debio 1450 Oral + Debio 1450 Oral Placebo + Linezolid Placebo BID.
3020337|NCT02426918|Placebo Comparator|Placebo|After 2 doses of Vancomycin IV, the Placebo comparator group receives Debio 1450 Oral Placebo + Linezolid 600 mg BID.
3020338|NCT02426905|No Intervention|Retrospective|
3020339|NCT02426905|Other|Prospective|
3020340|NCT02426892|Experimental|ISA101 + Nivolumab|"HPV-16 vaccination (ISA 101) administered subcutaneously at 100 mcg for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.~Nivolumab administered intravenously at 3 mg/kg every 2 weeks beginning on day 8 after the first vaccine dose.~There are 3 weeks in Cycle 1 and 2 weeks in Cycles 2 and beyond."
3020341|NCT02426879|Other|surgery|esophagectomy with three-field lymphnode dissection
3020342|NCT02426866||Patient with Efavirenz exposure|Patient with Efavirenz exposure
3020343|NCT02426866||Patient without Efavirenz exposure|Patient without Efavirenz exposure
3020344|NCT02426853|Experimental|Group 1 - UV Photography Group|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education. Participants given handouts that discusses skin cancer prevention, sun protection, and how to avoid tanning beds. At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.
3020345|NCT02426853|Active Comparator|Group 2 - Comparison Group|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education. Participants given handouts that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
3020346|NCT02426840|Experimental|High dose vitamin D and calcium|Fixed-dose combination (FDC) of 1,500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3, administered orally twice daily plus vitamin D2 (20,000 IU/cap) administered once weekly (a total of 1,200 mg of elemental calcium and 3,200 IU of vitamin D daily)
3020347|NCT02426840|Active Comparator|Normal dose vitamin D and calcium|Fixed-dose combination (FDC) of 1,500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3, administered orally twice daily (a total of 1,200 mg of elemental calcium and 400 IU of vitamin D daily)
3020348|NCT02426827|Experimental|SCS in CV|
3020349|NCT02426814|Sham Comparator|Standard Care with Medication Monitoring|"Patients will be given an inhaler sensor to monitor medication use and a sham version of the mobile app that will not include reminders or incentives.~Intervention: inhaler sensor"
3020350|NCT02426814|Experimental|Medication Monitoring and Mobile App|"Patients will be given an inhaler sensor to monitor medication use and a mobile phone application with reminders to allow self-management of medication use.~Interventions: inhaler sensor and mobile application for asthma adherence"
3020351|NCT02426801|No Intervention|Control|Patients in this arm were given no intervention. Their self-reported medication adherence was assessed at the baseline (week 0) and follow-up (week 12) visits but during the study period they did not receive any intervention.
3020352|NCT02426801|Sham Comparator|Medication Sensor Only|"These patients received the medication use sensor (sham intervention) and downloaded a sham version of the mobile app. Thus, the medication use from these patients was able to be recorded but the patients did not receive reminders or incentives or the ability to see their medication use via the real mobile app.~Intervention: inhaler sensor"
3020353|NCT02426801|Experimental|Medication Sensor and Mobile App|"These patients received the medication use sensor and the mobile app with reminders (intervention arm).~Interventions: inhaler sensor and mobile application for asthma adherence"
3020354|NCT02426788|Experimental|CBT+SMC|"Cognitive behavioural therapy + Standard Medical Care (cognitive-behavioural therapy+SMC):~8 hour-long manual-based CBT sessions with a therapist, weekly or fortnightly."
3020355|NCT02426788|No Intervention|Standard Medical Care (SMC)|Participants assigned to the SMC group (i.e., control group) will receive all the treatment and support they would otherwise receive outside of a research trial.
3020356|NCT02426775|No Intervention|Methylmalonic Acidemia Control Arm|patients with Methylmalonic Acidemia will receive standard therapy only (protein restricted diet, L-carnitine, metronidazole and vitamin B12)
3020357|NCT02426775|Experimental|Methylmalonic Acidemia Active arm|patients with Methylmalonic Acidemia will receive Carglumic Acid in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12)
3020358|NCT02426775|No Intervention|Propionic Acidemia Control Arm|patients with Propionic Acidemia will receive standard therapy only (protein restricted diet, L-carnitine, metronidazole and biotin)
3020359|NCT02426775|Experimental|Propionic Acidemia Active arm|patients with Propionic Acidemia will receive Carglumic Acid in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and biotin)
3020360|NCT02426762|Experimental|Sealant skin closure|A quick skin sealant would be applied after laparoscopic surgery. All abdominal wounds are sealed by smearing the quick sealant (skin adhesive) twice. No additional gauges should be appended on wound areas. No further wound care should be applied unless any effusion or bleeding emerged around it.
3020361|NCT02426749|Active Comparator|Active Coil|Participants of this arm will receive active rTMS intervention (treatment).
3020362|NCT02426749|Sham Comparator|Sham|Participants of this arm will receive sham rTMS intervention (treatment).
3020363|NCT02426736|Active Comparator|Low dose intravenous dexamethasone|4 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
3020364|NCT02426736|Active Comparator|High dose intravenous dexamethasone|8 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
3020365|NCT02426736|Active Comparator|Low dose perineurial dexamethasone|4 milligrams dexamethasone administered once perineurally with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
3020366|NCT02426736|Active Comparator|High dose perineurial dexamethasone|8 milligrams dexamethasone administered once perineurally with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
3020367|NCT02426723|Experimental|CWP232291|"Phase 1a: single administration of CWP232291 ,~Phase 1b: CWP232291 combination with Lenalidomide and Dexamethasone"
3020368|NCT02426710|Experimental|Flutter ablation with intracardiac echocardiography|Atrial flutter ablation will be done using intracardiac echocardiography.
3020369|NCT02426710|Active Comparator|Flutter ablation without intracardiac echocardiography|Atrial flutter ablation will be done without intracardiac echocardiography.
3020370|NCT02426697|Experimental|Pecfent|Patients will receive 100 µg of transmucosal Pecfent before radiotherapy session (or 200 µg in patients with a stable opioid background pain treatment)
3020371|NCT02426697|Placebo Comparator|Placebo|Patients will receive 100 µg of transmucosal placebo before radiotherapy session or 200 µg in patients with a stable opioid background pain treatment)
3020372|NCT02426684|Experimental|IdeS®|First ten patients will receive 0.24mg/kg, if no PK/PD/safety/tolerability issues are observed, dose will increased to 0.5mg/kg IdeS on day 0 for final 10 patients. (n=20)
3020373|NCT02426671|Experimental|MuteButton sensory stimulation device|"Participants will be asked to use the Mutebutton, neuro-modulation device every day for 60 minutes for 12 weeks. Use of the device involves placing a 'lollipop' type sensor on the tongue and wearing earphones. The participant will hear pink noise through the earphones and will receive neuro-stimulation through the sensor. The participant will not feel any discomfort whilst using the MuteButton device."
3020374|NCT02426658|Experimental|Treatment (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Quality-of-Life Assessment and Laboratory Biomarker Analysis.
3020375|NCT02426632|Experimental|Session 1: Sequence 1|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
3020376|NCT02426632|Experimental|Session 1: Sequence 2|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
3020377|NCT02426632|Experimental|Session 1: Sequence 3|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
3020378|NCT02426632|Experimental|Session 1: Sequence 4|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
3020379|NCT02426632|Experimental|Session 1: Sequence 5|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
3020380|NCT02426632|Experimental|Session 1: Sequence 6|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
3020381|NCT02426632|Experimental|Session 2: Sequence 7|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
3020382|NCT02426632|Experimental|Session 2: Sequence 8|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
3020383|NCT02426632|Experimental|Session 2: Sequence 9|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
3020384|NCT02426632|Experimental|Session 2: Sequence 10|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
3020385|NCT02426632|Experimental|Session 2: Sequence 11|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
3020386|NCT02426632|Experimental|Session 2: Sequence 12|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
3020387|NCT02426619|Experimental|SDF regular|3 applications of a 30% SDF solution will be applied onto the surface of dental caries lesions by a small brush regularly once a year
3020388|NCT02426619|Experimental|SDF intensive|3 applications of a 30% SDF solution will be applied onto the surface of dental caries lesions by a small brush at weekly interval at baseline
3020389|NCT02426619|Active Comparator|NaF varnish|3 applications of a 5% NaF varnish will be applied onto the surface of dental caries lesions by a small brush at weekly interval at baseline
3020390|NCT02426606|Experimental|White bread|
3020391|NCT02426606|Experimental|Lentil 1 + white rice|
3020392|NCT02426606|Experimental|Lentil 2 + white rice|
3020393|NCT02426606|Experimental|Lentil 3 + white rice|
3020394|NCT02426606|Experimental|White rice|
3020395|NCT02426606|Experimental|Lentil 1 + potato|
3020396|NCT02426606|Experimental|Lentil 2 + potato|
3020397|NCT02426606|Experimental|Lentil 3 + potato|
3020398|NCT02426606|Experimental|Potato|
3020399|NCT02426593||Subjects without heart failure|
3020400|NCT02426580|Experimental|Intervention with wechat group|The wechat model will provide information of protein, calcium, phosphorus and sodium intake, which were suggested by the current KDIGO/ KDOQI guideline.
3020401|NCT02426580|No Intervention|Controlled group|Only conventional education every 3 months during routing clinical visit
3020402|NCT02426567|Experimental|Healthy Adult Participants A|Participants who will get two interventional diets, for 7 days each, but allocated to start with Exclusive Enteral Nutrition (EEN)
3020403|NCT02426567|Experimental|Healthy Adult Participants B|Participants who will get two interventional diets, for 7 days each, but allocated to start with Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)
3020404|NCT02426554|Active Comparator|Group 1|
3020405|NCT02426554|Placebo Comparator|Group 2|
3020406|NCT02426541|Experimental|Dapagliflozin|Dapagliflozin Once Daily 10 mg
3020407|NCT02426541|Placebo Comparator|Placebo|Matching placebo for Dapagliflozin Once Daily 10 mg
3020408|NCT02426528|Experimental|Cultural and Social exposure A|Cultural and Social exposure
3020409|NCT02426528|No Intervention|Cultural and Social exposure B|Non Intervention (Control Group)
3020410|NCT02426515|Experimental|Hilotherm® Device|Patients undergo removal of lower third molar with Hilotherm® cooling device applied.
3020411|NCT02426515|No Intervention|Control|Patients undergo removal of lower third molar without the Hilotherm® cooling device applied.
3020412|NCT02426502|Experimental|Conversion to once daily dosing|The conversion to a once daily dosing regimen will be accomplished in three phases (1-conversion to Advagraf; 2-conversion of non-immunosuppressant drugs and; 3-conversion of patients taking twice daily MPA to once daily MPA). No control group.
3020413|NCT02426489|No Intervention|Diagnostic accuracy with MRI alone|The MRI of the breast lesion will be examined. Measures of performance accuracy will be evaluated, including diagnostic sensitivity (true positives divided by true positives and false negatives), diagnostic specificity (true negatives divided by true negatives and false positives), and diagnostic accuracy, defined as the number of correct assessments divided by the number of all assessments.
3020414|NCT02426489|Experimental|Diagnostic accuracy with MRI + PEM image|The combined PEM/MRI image will be examined.
3020415|NCT02426476|Experimental|active HRVB training|Heart rate variability biofeedback training
3020416|NCT02426476|Sham Comparator|sham HRVB training|passive relaxation
3020417|NCT02426463|Active Comparator|Propofol|Plasma samples and patient data are collected prospectively from 40 neonates who receive propofol as part of their care in the neonatal intensive care unit at the Turku University Hospital, Turku, Finland.
3020418|NCT02426463|Active Comparator|Oxycodone|Plasma samples and patient data are collected prospectively from 40 neonates who receive oxycodone as part of their care in the neonatal intensive care unit at the Turku University Hospital, Turku, Finland.
3020419|NCT02426450|Experimental|RFA+FOLFOX4|"RFA:~RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).~Oxaliplatin + 5-Fluorouracil/Leucovorin:~4 weeks after RFA; Drug: Oxaliplatin + 5-Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
3020420|NCT02426437|Other|Early Pulmonary Rehabilitation (EPR)|Patients randomized to EPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 1 month of discharge. They will proceed through the program in a typical fashion.
3020421|NCT02426437|Other|Late Pulmonary Rehabilitation (LPR)|Patients randomized to LPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 3 months of discharge. They will proceed through the program in a typical fashion.
3020422|NCT02426437|Other|Usual Care|Usual care patients will be followed-up by their most responsible physician as determined by the admitting team.
3020423|NCT02426424|Experimental|Investigatory 1|The sleep study will be performed via Watchpat during the index hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP both during the hospital stay and after discharge for three months.
3020424|NCT02426424|Experimental|Investigatory 2|The sleep study will be performed via Watchpat at home three months after hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP for three months.
3020425|NCT02426411|Experimental|EMA401 200 mg|2 X 50 mg capsules BID
3020426|NCT02426411|Experimental|EMA401 600 mg|2 X 150 mg capsules BID
3020427|NCT02426411|Placebo Comparator|Placebo|Placebo to match 2 capsules BID
3020428|NCT02426398||People with Alzheimer's disease|People with Alzheimer's disease
3020429|NCT02426398||Healthy volunteers|Healthy volunteers
3020430|NCT02426385||1POD26PFT|Patients implanted with the POD 26% FineVision Toric
3020431|NCT02426385||2POD26PT|Patients implanted with the POD 26% Toric
3020432|NCT02426372|Experimental|QBECO SSI 0.02 mL|0.02 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
3020433|NCT02426372|Experimental|QBECO SSI 0.05 mL|0.05 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
3020434|NCT02426372|Experimental|QBECO SSI 0.1 mL|0.1 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
3020435|NCT02426359|Experimental|Q301 Cream|Q301 Cream
3020436|NCT02426359|Placebo Comparator|Vehicle|Vehicle
3020437|NCT02426346|Active Comparator|JOIN FOR ME|The JOIN for ME curriculum includes 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Weekly meetings are scheduled for 60 minutes and are facilitated by a YMCA coach. Interventions include behavioral weight control and parent-based incentives. Parents attend group at weeks 1, 2 and 16 with their teen.
3020438|NCT02426346|Experimental|TEEN JOIN|Similar to the JOIN FOR ME condition, adolescents in the TEEN JOIN condition attend 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Interventions include behavioral weight control, group-based physical activity, and group-based incentives. Parents attend separate meetings at weeks 1, 2, and 16.
3020439|NCT02426333||Abiraterone Acetate|abiraterone treatment, 1000mg, tablets, once daily, treatment is not adapted for the study
3020440|NCT02426320|Active Comparator|Sedation Interruption Protocol + standard sedation protocol|Nurse directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
3020441|NCT02426320|Active Comparator|Standard sedation protocol|Nurse directed protocol for administering sedation and/or analgesia.
3020442|NCT02426307||Transcatheter Aortic Valve Replacement|TAVR: Portico (St Jude Medical), CoreValve (Medtronic), Lotus (Boston Scientific), Edwards Sapien 3 (Edwards LifeSciences),
3020443|NCT02426307||Surgical aortic valve replacement|SAVR: Perimount (Edwards), Epic (St Jude Medical), Trifecta (St Jude Medical)
3020444|NCT02426294|Experimental|Pioglitazone|Pioglitazone is a Pioglitazone hydrochloride, and white circle-shaped tablet. It is administered once-daily with 15mg, with or without meals. The once-daily administration begins with 15mg, and if need increase, researchers can increase up to 30mg at week 12.
3020445|NCT02426294|Active Comparator|Glimepiride|The generic name of Glimepiride is Glimepiride, and it is a green snowman-shaped tablet. The once-daily administration begins with 2mg, and if need increase, researchers can increase up to 4mg at week 12.
3020446|NCT02426281|Experimental|nab-paclitaxel in combination with gemcitabine|nab-paclitaxel in combination with gemcitabine nab- paclitaxel 125mg/m2 in combination with gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
3020447|NCT02426255||ICU patients|Patients with severe trauma (with or without brain injury) or Patients with hemorrhagic shock Data concerning the ICU stay will be collected for these patients
3020448|NCT02426242||ICU PATIENTS|Patients with brain-injury
3020449|NCT02426229|Experimental|dabigatran 75mg|dabigatran etexilate 75mg orally twice daily for 6 months
3020450|NCT02426216||Group A|Group A: Subjects who fullfil all eligibility criteria of the MCS-8 protocol and consent to enroll the study.
3020451|NCT02426216||Group B|Group B: Subjects who fullfil the definition of elevated risk for prostate cancer by the MCS-8 protocol but did not sign up for the MCS-8 study.
3020452|NCT02426203||Pulmonary Endarterectomy patients|Patients undergoing pulmonary endarterectomy surgery at Papworth Hospital
3020453|NCT02426190|Active Comparator|Arm 1|Patients in Arm 1 receive standard of care rehabilitation protocol using a recumbent or Nu-step bike during warm-up, followed by individualized therapeutic exercise, and cool-down protocols.
3020454|NCT02426190|Experimental|Arm 2|Patients in Arm 2 will use AlterG treadmill during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
3020455|NCT02426190|Experimental|Arm 3|Patients in Arm 3 will use a recumbent or Nu-step bike along with the PENS neuromuscular stimulation modality during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
3020456|NCT02426190|Experimental|Arm 4|Patients in Arm 4 will use both the AlterG treadmill and the PENS neuromuscular stimulation modality during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
3020457|NCT02426177|Active Comparator|group A|tab.labetalol is given to the patient with postpartum hypertension in dose of 100 mg 6 hourly increased to maximum 600 mg in 24 hours
3020458|NCT02426177|Active Comparator|group B|tab.nifedipine is given to the patient with postpartum hypertension in the dose of 10 mg twice a day to maximum dose of 60 mg per 24 hours
3020459|NCT02426164|Active Comparator|Liposomal bupivacaine|Periarticular infiltration of 20cc of liposomal bupivacaine with 20cc of normal saline administered prior to cementation of knee implants
3020460|NCT02426164|Active Comparator|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone administered prior to cementation of knee implants
3020461|NCT02426151|Experimental|BEPO-A|Single subcutaneous injection of BEPO-A 4000 IU (Bioreactor manufacturing process)
3020462|NCT02426151|Active Comparator|REPO-A|Single subcutaneous injection of REPO-A 4000 IU (Roller bottle manufacturing process)
3020463|NCT02426138|Experimental|Immediate|Participants will receive 12 weeks of medically tailored meal delivery, comprising approximately half of their weekly caloric intake and consisting of foods prepared under the supervision of a registered dietitian to be compatible with a diabetes diet. They will also receive usual diabetes care and a Choose MyPlate healthy eating brochure.
3020464|NCT02426138|Active Comparator|Usual Care + Choose Myplate|Participants will receive usual diabetes care and a Choose MyPlate healthy eating brochure for 12 weeks.
3020465|NCT02426125|Experimental|Ramucirumab + Docetaxel|Ramucirumab intravenously (IV) plus docetaxel IV in 21 day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
3020466|NCT02426125|Placebo Comparator|Placebo + Docetaxel|Placebo IV plus docetaxel IV in 21 day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
3020467|NCT02426112|Active Comparator|Azithomycin|"Azithromycin tablets 250 mg, 30mg/kg/week by mouth, once a week for 12 months.~10-20 kg: 250 mg~20-29 kg: 500 mg~30-39 kg: 750 mg~40-49 kg: 1250 mg"
3020468|NCT02426112|Placebo Comparator|Placebo|"Placebo tablets 250 mg, 30 mg/kg/week by mouth, once a week for 12 months.~10-20 kg: 250 mg~20-29 kg: 500 mg~30-39 kg: 750 mg~40-49 kg: 1250 mg"
3020469|NCT02426099|Experimental|Low dose Spironolactone|Add-on low dose 25 mg Spironolactone to current hypertension treatment
3020470|NCT02426099|Active Comparator|Routine|Routine intensification of anti hypertensive treatment based on existing guidelines
3020471|NCT02426086|Experimental|Imetelstat 9.4 milligram/kilogram (mg/kg)|Participants will receive imetelstat intravenously as 9.4 mg/kg every 3 weeks. Study drug will be administered intravenously until disease progression, unacceptable toxicity, or study end. Once the end of the main study has been reached, participants who are receiving benefit from study treatment may continue to receive imetelstat during the Extension Phase until there is loss of benefit or unacceptable toxicity, as determined by the investigator according to local standard of care.
3020472|NCT02426086|Experimental|Imetelstat 4.7 mg/kg|Participants will receive imetelstat intravenously as 4.7 mg/kg every 3 weeks. Study drug will be administered intravenously until disease progression, unacceptable toxicity, or study end. Participants will have an option to continue the treatment at the current dose or at an escalated dose of 9.4 mg/kg based on investigator's discretion. Once the end of the main study has been reached, participants who are receiving benefit from study treatment may continue to receive imetelstat during the Extension Phase until there is loss of benefit or unacceptable toxicity, as determined by the investigator according to local standard of care.
3020473|NCT02426073||HE|Healthy elderlies
3020474|NCT02426073||DM|Elderlies with type 2 diabetes
3020475|NCT02426073||SA|Elderlies with sarcopenia
3020476|NCT02426073||DS|Elderlies with both type 2 diabetes and sarcopenia
3020478|NCT02426047|Experimental|Modified Atkins diet plus betaquik®|Participants will continue on the modified Atkins diet (with a 20 net grams carbohydrate per day limit) and add betaquik® (a liquid emulsion of medium chain triglycerides) for 10 days per month for 5 months. The days chosen are based on their particular catamenial pattern (there are 3 types that have been identified in the literature).
3020479|NCT02426034|Experimental|Apatinib(ATAN)|apatinib 850 mg qd p.o.
3020480|NCT02426021|Experimental|Cohort J1: MLN1202 (75 mg)|Single subcutaneous administration of MLN1202 (75 mg) in 6 healthy Japanese male adults
3020481|NCT02426021|Experimental|Cohort J1: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
3020482|NCT02426021|Experimental|Cohort J2:MLN1202 (105 mg)|Single subcutaneous administration of MLN1202 (105 mg) in 6 healthy Japanese male adults
3020483|NCT02426021|Experimental|Cohort J2: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
3020484|NCT02426021|Experimental|Cohort J3: MLN1202 (150 mg)|Single subcutaneous administration of MLN1202 (150 mg) in 6 healthy Japanese male adults
3020485|NCT02426021|Experimental|Cohort J3: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
3020486|NCT02426021|Experimental|Cohort J4: MLN1202 (450 mg)|Single subcutaneous administration of MLN1202 (450 mg) in 6 healthy Japanese male adults
3020487|NCT02426021|Experimental|Cohort J4: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
3020488|NCT02426021|Experimental|Cohort C1: MLN1202 (75 mg)|Single subcutaneous administration of MLN1202 (75 mg) in healthy Causacian male adults
3020489|NCT02426021|Experimental|Cohort C2: MLN1202 (150 mg)|Single subcutaneous administration of MLN1202 (150 mg) in healthy Causacian male adults
3020490|NCT02426008|Experimental|Culture media plus growth factor|Growth factors adding to culture media to detect the deference and monitor the embryological outcome.
3020491|NCT02426008|Experimental|Culture media with growth factors and Cytokine|Growth factors and Cytokine adding to culture media to detect the deference and monitor the embryological outcome.
3020492|NCT02426008|Placebo Comparator|In Vitro culture media|culture media to monitor the embryological outcome as control group
3020493|NCT02425995|Experimental|Arthroscopic intercondylar and posteromedial portal|
3020494|NCT02425982||Conservative treatment|Patients who will opt conservative treatment or patients treated conservatively by surgeon decision.
3020495|NCT02425982||Operative treatment|Patients who opt for surgery when offered.
3020496|NCT02425969|Experimental|Optimal Medical Therapy|Patients will receive secondary prevention and optimal medical therapy to control their anginal symptoms according to international guidelines without PCI of their grey-zone FFR lesion
3020497|NCT02425969|Active Comparator|PCI with Optimal Medical Therapy|Patients will undergo PCI of their grey-zone FFR lesion as well as appropriate secondary prevention. Anti-anginal therapy will be administered as per clinical requirements according to international guidelines.
3020498|NCT02425956|Experimental|MRI imaging of liver|GE Optima/Discovery® MRI imaging data of the liver and surrounding tissues will be acquired using 1.5T and 3.0T GE Healthcare (GEHC) IDEAL IQ scans and commercially available 1.5T MRI scans conducted according to the FerriScan®
3020499|NCT02425943|Experimental|Sculptra Aesthetic|
3020500|NCT02425930||C3 Depletion|Patients with persistent low-level of complement C3 within the perioperative period would be assigned into this main observational group. After a careful multidisciplinary treatment (MDT) discussion, a radical operation with gastrectomy plus D2 lymphadenectomy would be performed, followed by an adjuvant chemotherapy if required. Generally, SOX chemo regimen (S-1+Oxaliplatin) would be first considered for the candidates.
3020501|NCT02425930||Non-C3 depletion|Patients with normal plasma values of complement C3 within the perioperative period would be assigned into this control group. Those patients would undergo the same decision making process to determine the final treatment plan.
3020502|NCT02425917|Experimental|geko|
3020503|NCT02425917|Active Comparator|ipc-calf|intermittent pneumatic compression of the calf
3020504|NCT02425904|Experimental|A-Recurrent Low-Risk Multi-System LCH|"- Participants with multi-focal or low-risk multi-system disease who have recurred after standard treatment with prednisone and vinblastine.~Clofarabine administered via IV on days 1-5, 25 mg/m2/day, per cycle.~Evaluation of disease response will be performed after 2 cycles of Induction Therapy. In the absence of disease progression, participants will be eligible to receive up to 4 cycles of Maintenance Therapy, which is identical to the Induction Therapy."
3020505|NCT02425904|Experimental|B-R/R High-Risk Multi-System LCH|"-Patients with high-risk multi-system disease (risk-organ involvement) who have recurred (or have refractory disease) after treatment with prednisone and vinblastine, and cladribine/cytarabine, or who are not considered to be eligible for treatment on those regimens.~Clofarabine administered via IV on days 1-5, 25 mg/m2/day, per cycle.~Evaluation of disease response will be performed after 2 cycles of Induction Therapy. In the absence of disease progression, participants will be eligible to receive up to 4 cycles of Maintenance Therapy, which is identical to the Induction Therapy."
3020506|NCT02425904|Experimental|C-LCH-related disorders|"Participants with LCH-related disorders who require systemic chemotherapy including:~Participants with RDD who have not responded to or recurred after treatment with corticosteroids. ECD subjects who have confirmed presence of BRAF V600E mutation must have not responded to, have recurred after, or be unable to receive treatment with a BRAF inhibitor.~Clofarabine administered via IV on days 1-5, 25 mg/m2/day, per cycle.~Evaluation of disease response will be performed after 2 cycles of Induction Therapy. In the absence of disease progression, participants will be eligible to receive up to 4 cycles of Maintenance Therapy, which is identical to the Induction Therapy."
3020507|NCT02425891|Experimental|Atezolizumab Plus Nab-Paclitaxel|Participants assigned to atezolizumab plus nab-paclitaxel will receive both agents until loss of clinical benefit, unacceptable toxicity, symptomatic deterioration attributed to disease progression, or death.
3020508|NCT02425891|Placebo Comparator|Placebo Plus Nab-Paclitaxel|Participants assigned to placebo plus nab-paclitaxel will receive both agents until loss of clinical benefit, unacceptable toxicity, symptomatic deterioration attributed to disease progression, or death.
3020509|NCT02425878|Experimental|Experimental|Ulipristal Acetate 10 mg, Oral administration. Dose: 10 mg per day, single dose, duration 12 weeks
3020510|NCT02425878|Placebo Comparator|Control|Placebo, 10 mg, Oral administration. Dose: 10 mg per day, single dose, duration 12 weeks
3020511|NCT02425865|Other|open-label, uncontrolled trial|All patients will receive Standard regimen with golimumab 50 mg Q4W, or 100 mg Q4W if > 80 kg
3020512|NCT02425852|Active Comparator|Combination therapy arm|Infliximab 5 mg/kg plus Azathioprine 2-2.5 mg/kg/day. Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible to 2.5 mg/kg/d, or to 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake.
3020513|NCT02425852|Active Comparator|Azathioprine arm|"Intravenous steroids will be continue until day 2. Then, steroid therapy will be orally administered at a dose of 40-60 mg/day ou 1 mg/kg/day prednisolone (or equivalent) and progressively reduced by 10mg step every week to 20mg per day, and then reduced by 5mg step every week until stopped. Hydrocortisone intake to prevent steroid weaning will be authorized until supradrenal function normalization.~In patients with clinical response at day 7, Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible of 2.5 mg/kg/d, or of 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake."
3020514|NCT02425839|Experimental|Experimental group|"ultrasound exam by Supersonic Shear Imaging® technique~EMG examination by electromyograph Keypoint system."
3020515|NCT02425826|Experimental|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
3020516|NCT02425826|Placebo Comparator|Placebo|Placebo tablets BID during Weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 36 weeks (from week 16 to week 52)
3020517|NCT02425813|Experimental|Treatment (methylprednisolone sodium succinate, budesonide)|"STUDY AGENT: Patients receive methylprednisolone sodium succinate IA QD on days 1-3.~CONVENTIONAL THERAPY: Patients also receive conventional therapy comprising methylprednisolone sodium succinate IV every 12 hours on for 7-14 days beginning on day 1 and budesonide PO on days 1-56. Patients with response by day 7-14 may begin taper and receive methylprednisolone PO on days 28-56. Treatment continues in the absence of disease progression or unacceptable toxicity.~IST: Patients receive conventional IST or continue their previous prophylactic regimen beginning on day 1 to 56 (or beyond) at the discretion of the treating physician."
3020518|NCT02425800||Ancillary-Correlative (human prostate tissue model)|Tissue samples are collected from patients with benign prostatic hyperplasia for decellularization and preparation as human extracellular matrix for growing human prostate CSCs. Tissue samples are also collected from patients with prostate cancer for the analysis of TROP2+ cells by flow cytometry. Cytology Specimen Collection Procedure. Laboratory Biomarker Analysis.
3020519|NCT02425787||Parents of deceased children (no BMT)|"Participants will be parents who have lost a child at St. Jude Children's Research Hospital (SJCRH). They will participate in a 60-90 minute interview.~(Not recruiting)"
3020520|NCT02425787||Parents of deceased children (haploidentical BMT)|Participants will be parents whose child died after receiving a haploidentical bone marrow transplant at St. Jude Children's Research Hospital (SJCRH), and who have not previously participated in an interview through this study. They will participate in a 60-90 minute interview.
3020521|NCT02425787||Parents of deceased children (non-haploidentical BMT)|Participants will be parents whose child died after receiving a non-haploidentical bone marrow transplant at St. Jude Children's Research Hospital (SJCRH), and who have not previously participated in an interview through this study. They will participate in a 60-90 minute interview.
3020522|NCT02425787||Parents of deceased children (not interviewed)|Participants will be parents who have lost a child at SJCRH, who have not previously participated in an interview through this study.They will participate in a 60-90 minute focus group.
3020523|NCT02425787||Hematology/Oncology Fellows|Participants will be Hematology/Oncology Fellows at SJCRH. They will participate in a 60-90 minute focus group.
3020524|NCT02425774|Placebo Comparator|Sham stimulation + Placebo|"no stimulation~1 placebo tablet at two different timepoints before surgery"
3020525|NCT02425774|Active Comparator|Vagus stimulation + placebo|"Stimulation at the beginning and the end of the surgery~1 placebo tablet at two different timepoints before surgery"
3020526|NCT02425774|Active Comparator|Prucalopride + sham stimulation|"1 prucalopride tablet at two different timepoints before surgery~no stimulation"
3020527|NCT02425761|Active Comparator|Anterior Entry SIte|"Anterior entry site is defined as shunt surgery with catheter entry into the brain from an opening near the coronal suture, on the top of the head and near the front. Specifically, anterior entry is defined as ventricular catheter entry less than 1 centimeter anterior to the coronal suture near the mid-pupillary line.~Subjects randomized to this arm will undergo ventriculoperitoneal shunt insertion surgery using an anterior entry site."
3020528|NCT02425761|Active Comparator|Posterior Entry Site|"Posterior entry site is defined as shunt surgery with catheter entry into the brain from an opening near the lambdoid suture, on the back of the head. Specifically, posterior entry is defined as ventricular catheter entry 4 to 7 centimeters above the external occipital protuberance (inion), near the mid-pupillary line.~Subjects randomized to this arm will undergo ventriculoperitoneal shunt insertion surgery using a posterior entry site."
3020529|NCT02425748|Experimental|Group A|DC-CIK cells will be used against tumor cells.
3020530|NCT02425748|Experimental|Group B|γδ T cells will be used against tumor cells.
3020531|NCT02425748|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
3020532|NCT02425735|Experimental|Group A|DC-CIK cells will be used against tumor cells.
3020533|NCT02425735|Experimental|Group B|γδ T cells will be used against tumor cells.
3020534|NCT02425735|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
3020535|NCT02425722|Experimental|ASP0456 lowest dose group|
3020536|NCT02425722|Experimental|ASP0456 low dose group|
3020537|NCT02425722|Experimental|ASP0456 middle dose group|
3020538|NCT02425722|Experimental|ASP0456 high dose group|
3020539|NCT02425722|Placebo Comparator|Placebo group|
3020540|NCT02425709|Active Comparator|Diclofenac|women will receive oral diclofenac 50 mg 1 hour before the procedure.
3020541|NCT02425709|Active Comparator|Tramadol|Women will receive oral tramadol 50 mg 1 hour before the procedure.
3020542|NCT02425709|Placebo Comparator|Placebo|Women will receive a placebo 1 hour before the procedure.
3020543|NCT02425696||group 1|Normal individuals without migraine
3020544|NCT02425696||group 2|Migraineurs
3020661|NCT02424851|Active Comparator|Arm A (BBD)|Bortezomib, Bendamustine and Dexamethasone
3020545|NCT02425683|Experimental|Regorafenib|Regorafenib 120 or 160 mg by mouth every day for the first 21 days of each 28-day cycle. If the dose is tolerated during the first 2 cycles in the 120 mg group, in Cycle 3 the 120 mg dose will be increased to 160 mg by mouth each day for the first 21 days of each 28-day cycle for 4 more cycles for a total of 6 cycles or 6 months of therapy.
3020546|NCT02425683|No Intervention|Standard of Care (No Treatment)|No study drug (which is the standard care for Stage IIIC colorectal cancer patients after they've received FOLFOX chemotherapy).
3020547|NCT02425670|Experimental|Bone marrow derived stem cells (BMSCs)|BMSCs 30-500 million plus conventional management
3020548|NCT02425670|No Intervention|Control|Control: conventional management
3020549|NCT02425657||Junior Doctors|Surgical trainees (PGY1, 2 and 3 - Danish equivalents: introduktionsstilling, hoveduddannelse 1, 2).
3020550|NCT02425644|Experimental|ponesimod|20 mg administered orally once daily in the morning
3020551|NCT02425644|Active Comparator|teriflunomide|14 mg administered orally once daily in the morning
3020552|NCT02425618|Active Comparator|Volume-controlled ventilation|The patient's lungs will be mechanically ventilated using the volume-controlled ventilation with tidal volume 8 ml/kg.
3020553|NCT02425618|Experimental|Pressure-controlled ventilation|The patient's lungs will be mechanically ventilated using the pressure-controlled ventilation with tidal volume 8 ml/kg.
3020554|NCT02425605|Experimental|CCRT-sorafenib group|
3020555|NCT02425592||Men on Active Surveillance|This study will include men between age 30-80 with Gleason 6 prostate cancer, prostate specific antigen (PSA) <20, clinical stage <cT3, and a life expectancy of at least ten years. To be eligible, men must have undergone an MRI-USG fusion prostate biopsy for an elevated PSA or abnormal prostate examination that demonstrates Gleason 6 prostate cancer. If a man is already on active surveillance, the MRI-USG fusion biopsy may be negative or confirm Gleason 6 prostate cancer. Eligible men will be approached at their post fusion-biopsy visit to discuss the biopsy results and offered enrollment in the trial.
3020556|NCT02425579|Experimental|Cohort 1|Inhaled Carbon Monoxide at 100 ppm for up to 90 minutes daily for 5 days
3020557|NCT02425579|Placebo Comparator|Cohort 1 (placebo)|Inhaled Medical Air for up to 90 minutes daily for 5 days
3020558|NCT02425579|Experimental|Cohort 2|Inhaled Carbon Monoxide at 200 ppm for up to 90 minutes daily for 5 days
3020559|NCT02425579|Placebo Comparator|Cohort 2 (Placebo)|Inhaled Medical Air for up to 90 minutes daily for 5 days
3020560|NCT02425579|Experimental|Cohort 3|Open-label algorithm-specified dose of iCO (not to exceed 500 ppm) to achieve a COHb of 6-8% for up to 90 minutes daily for 5 days
3020561|NCT02425566|Experimental|Study day with trimethaphan|After baseline measurements, autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min.
3020562|NCT02425566|Experimental|Radionuclide Study day with nitroglycerin|Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements. Outcome measurements will be repeated within 10 min after the nitroglycerin has dissolved
3020563|NCT02425553||Faculty and Delegates of Ascona II Meeting|
3020564|NCT02425540||patients with unclassified ovarian mass|
3020565|NCT02425527|Experimental|The rehabilitation gaming|The rehabilitation gaming group (n=30) will use an internet browser-based digital brain training program CogniFit (https://www.cognifit.com), with a selection of about 33 games.The participants will use the rehabilitation gaming for at least 30 min per day over a period of 8 weeks.
3020566|NCT02425527|Active Comparator|The entertaining gaming|The entertaining gaming group (n = 30) will use commercial digital games with Sony Playstation 3 (PS3) consoles, played with wireless Sony DualShock gamepad controllers. The participants will be guided to play the console for at least 30 min per day over a period of 8 weeks
3020567|NCT02425527|No Intervention|"Do-nothing"|"The passive control group Do-nothing group (n = 30) will not have gaming activities organized by the project."
3020568|NCT02425514|Experimental|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs(TM), which is the PEEK cage filled with b-TCP.
3020569|NCT02425514|Experimental|NovoMax™|The ACDF surgery will be carried out with NovoMax™, which is the bioactive glass ceramic intervertebral spacer
3020570|NCT02425501||Aflibercept (Eylea,BAY86-5321)|Decision of EYLEA treatment is made by attending investigator according to the Japanese Package Insert
3020571|NCT02425488|Experimental|Nursing therapeutics education|People who are educated by the nurse (Behavioral intervention: Nursing therapeutics education) and follow all the program (12 months)
3020572|NCT02425488|No Intervention|Non NET|People who receive basic information without follow the educational program but clinically controlled
3020573|NCT02425475||Mole|Patients with suspicious moles
3020574|NCT02425462||Cohort 1|Asian patients at least 18 years of age with clinical or surgical diagnosis of endometriosis, and patients with endometriosis associated pelvic pain.
3020575|NCT02425449|Experimental|01 mg/kg|Succinylcholine 0.1 mg/kg will be administered and TOF ratio measured before and after the administration until stable
3020576|NCT02425449|Experimental|0.15 mg/kg|Succinylcholine 0.15 mg/kg will be administered and TOF ratio measured before and after the administration until stable
3020577|NCT02425449|Experimental|0.2 mg/kg|Succinylcholine 0.2 mg/kg will be administered and TOF ratio measured before and after the administration until stable
3020578|NCT02425449|Experimental|0.25 mg/kg|Succinylcholine 0.25 mg/kg will be administered and TOF ratio measured before and after the administration until stable
3020579|NCT02425449|Experimental|0.3 mg/kg|Succinylcholine 0.3 mg/kg will be administered and TOF ratio measured before and after the administration until stable
3020580|NCT02425436|Active Comparator|Ginkgo Biloba Extract group|This group received Ginko Biloba, two tablets per day
3020581|NCT02425436|Placebo Comparator|Placebo group|This group received placebo two tablets per day .
3020582|NCT02425423|Experimental|New thickened infant formula|
3020583|NCT02425410||Isis-Virus|T1D patients of the Isis-Diab cohort with genetic data (GWAS) and specific environmental data on viral events during childhood
3020584|NCT02425397||patients with grade 3 or 4 Brock ototoxicity|
3020585|NCT02425397||patients controls with no signs of ototoxicity|
3020662|NCT02424851|Active Comparator|Arm B (BTD)|Thalidomide, Bendamustine and Dexamethasone
3054499|NCT02197585|Active Comparator|Suture|Mesh fixation with suture
3020586|NCT02425384|Experimental|Intervention Group|This group is provided an activity meter that tracks the amount and intensity of one's physical activity and is linked to a motivational website. On the website, activity data from the activity meter can be viewed after uploading information from the meter to the website. The reward website allots points for participants based on the amount and intensity of physical activity. Points can be redeemed for rewards on the website, such as gift cards and digital badges.
3020587|NCT02425384|Active Comparator|Active Control|This group is provided an activity meter that tracks the amount and intensity of one's physical activity and a copy of the game Dance Dance Revolution (DDR). The activity meter will upload data to a secure server but will not be linked to the motivational website used by the intervention group. DDR is a dancing video game in which players view arrows timed to music on a TV screen and gain points by stepping on the corresponding arrows on a floor mat. Players obtain points in the game by stepping on the correct arrows at the right time to the beat of the music. The points earned with DDR cannot be redeemed for rewards.
3020588|NCT02425384|Placebo Comparator|Passive Control|This group is provided with an activity meter and will be asked to carry it with them as they go about their normal daily activities. Like in the Active Control group, participants in the Passive Control group will not have access to the motivational website. For this group, the activity meter functions solely as a monitor to track their activity levels. No other product or intervention will be introduced to the control group.
3020589|NCT02425371|Experimental|Intervention|screening and treatment of comorbidities
3020590|NCT02425371|Placebo Comparator|Control|No screening of comorbidity
3020591|NCT02425358|Experimental|BMC therapy within 24 hours|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 24 hours after successful primary PCI.
3020592|NCT02425358|Experimental|BMC therapy within 3-7 days|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 3-7days after successful primary PCI.
3020593|NCT02425358|Experimental|BMC therapy within 7-30 days|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 7-30days after successful primary PCI.
3020594|NCT02425358|Active Comparator|PCI only|Patients with acute myocardial infarction who were performed successful primary PCI.
3020595|NCT02425345|Experimental|Physical Activity Intervention|The Physical Activity Intervention Group will receive guidance on being physically active, including aerobics, flexibility, balance, strength, and decreased sedentary time. The primary resource is the National Institute of Aging Go4Life exercise and physical activity materials. The materials are based on the United States national guidelines for physical activity for older adults
3020596|NCT02425345|No Intervention|Usual Activity Control|Usual activity
3020597|NCT02425332|Experimental|Lokomat assessment|
3020598|NCT02425319||patients with CapFlex-PIP© implant|
3020599|NCT02425319||patients with silicone implant|
3020600|NCT02425319||patients with healthy PIP joints|
3020601|NCT02425306|Experimental|Arm A:6MHP + Montanide ISA-51|Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.
3020602|NCT02425306|Experimental|Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide|"Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:~Day -6 (Cycle 1)~Day 8 (Cycle 2)~Day 22 (Cycle 3)~Day 36 (Cycle 4)~Day 50 (Cycle 5)"
3020603|NCT02425306|Experimental|Arm C:6MHP + polyICLC + Montanide ISA-51|Part 1: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.
3020604|NCT02425306|Experimental|Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide|"Parts 1 and 2: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:~Day -6 (Cycle 1)~Day 8 (Cycle 2)~Day 22 (Cycle 3)~Day 36 (Cycle 4)~Day 50 (Cycle 5)"
3020605|NCT02425293|Experimental|Intervention|Patients participating in a patient education seminar
3020606|NCT02425293|No Intervention|Control|Patients not participating in a patient education seminar
3020607|NCT02425280|Experimental|Narrative Exposure Therapy|For the intervention group receiving Narrative Exposure Therapy treatment, the intervention will last for approximately three months and include 10-12 weekly sessions of 60-90 minutes. The course of the intervention will follow the NET manual (Schauer et al., 2011).
3020608|NCT02425280|Active Comparator|Treatment as Usual|For the TAU control group, participants will receive the usual care for posttraumatic stress symptoms currently offered by each unit.
3020609|NCT02425267|Experimental|Telerehabilitation|Telerehabilitation at home from a clinic
3020610|NCT02425267|Active Comparator|Face-to-face intervention in a clinic|Conventional physiotherapy
3020611|NCT02425254|Experimental|Preemptive paracetamol|1000mg intravenous paracetamol given ≥15 minutes before surgical incision and intravenous saline 15 minutes before the end of surgery
3020612|NCT02425254|Active Comparator|Postincision paracetamol|Intravenous saline ≥15 minutes before surgical incision and 1000mg intravenous paracetamol given 15 minutes before the end of surgery
3020613|NCT02425241|Experimental|CPHPC|"CPHPC infusion over 26 hours to deplete SAP at weeks 0,4 and 8. pSG2.HIVconsv DNA vaccine 4 mg at weeks 0, 4 and 8 after 24 hours of CPHPC infusion.~ChAdV63.HIVconsv booster vaccine 5 x 10^10 vp at week 12. MVA.HIVconsv booster vaccine 2 x 10^8 pfu at week 20"
3020614|NCT02425241|Placebo Comparator|0.9% w/v saline solution|"Placebo (normal saline) infusion over 26 hours at weeks 0,4 and 8. pSG2.HIVconsv DNA vaccine 4 mg at weeks 0, 4 and 8 after 24 hours of placebo infusion.~ChAdV63.HIVconsv booster vaccine 5 x 10^10 vp at week 12. MVA.HIVconsv booster vaccine 2 x 10^8 pfu at week 20"
3020615|NCT02425202|Active Comparator|Ketamine infusion|Ketamine infusion at 0.1 mg/kg/hr up to maximum of 10 mg/hr
3020616|NCT02425202|Placebo Comparator|Saline infusion|Saline infusion
3020617|NCT02425189||LQT Positive (Group 1)|"Gene-positive LQTS patients~Gene negative LQTS patients with confirmed phenotypic diagnosis of LQTS (Schwartz score ≥4)"
3020618|NCT02425189||Asyptomatic Patients (Group 2)|Asymptomatic patients, those free of syncope on beta blocker, or gene negative unaffected family members
3020900|NCT02423083|Experimental|Treatment arm|
3020619|NCT02425176|Active Comparator|Botulinum toxin A (BoNT-A) 50U|"Drug dilution and dosage:~Prepare a mother solution of 500 U/ml by diluting Botulinum toxin A Dysport® with 1 ml of 0.9% saline.~Prepare in 1 ml syringe to get 50U/ml :0.1 ml drawn from the mother solution and add 0.9 ml of 0,9% saline. Total volume of 1 ml.~Intervention: Botulinum toxin A (BTX-A) 50U are divided equally into 4 salivary glands, 12.5U each gland"
3020620|NCT02425176|Active Comparator|Botulinum toxin A (BoNT-A) 100U|"Drug dilution and dosage:~1. Prepare a mother solution of 500 U/ml by diluting Botulinum toxin A Dysport® with 1 ml of 0.9% saline. 2. Prepare in 1 ml syringe to get 100U/ml :0.2 ml drawn from the mother solution and add 0.8 ml of 0.9% saline. Total volume of 1 ml.~Intervention: Botulinum toxin A (BTX-A) 100U are divided equally into 4 salivary glands, 25U each gland"
3020621|NCT02425176|Active Comparator|Botulinum toxina A (BoNT-A) 200U|"Drug dilution and dosage:~1. Prepare a mother solution of 500 U/ml by diluting Botulinum ToxinA Dysport® with 1 ml of 0.9% saline. 2. Prepare in 1 ml syringe to get 200U/ml :0.4 ml is drawn from the mother solution and 0.6ml of 0.9% saline is added. Total volume of 1 ml.~Intervention: Botulinum toxin A (BTX-A) 200U are divided equally into 4 salivary glands, 50U each gland"
3020622|NCT02425163|Active Comparator|suspicious for Prostate Cancer|"PSA >4ng/ml or PSA-Velocity >0.75ng/ml/a or suspicious rectal examination or Status after external beam therapy of the prostate in prostate cancer.~Patients who are able for transrectal ultrasound examination. Transrectal shear wave elastography of the prostate for Transrectal random biopsy of the prostate."
3020623|NCT02425150|Experimental|Corneal reshaping/crosslinking (CRXL)|Corneal crosslinking with compression of the cornea using a sutured rigid contact lens during the treatment.
3020624|NCT02425150|Active Comparator|Corneal crosslinking (CXL)|Standard corneal crosslinking using the Dresden protocol.
3020625|NCT02425150|No Intervention|Control group to CRXL|Healthy subjects, age- and sex-matched to the CRXL group.
3020626|NCT02425150|No Intervention|Control group to CXL|Healthy subjects, age- and sex-matched to the CXL group.
3020627|NCT02425137|Experimental|S-1/Gemcitabine|single-arm
3020628|NCT02425124|Active Comparator|Control|PC101 Enhanced usual primary health care where non-physician clinicians have been equipped with the basic skills to identify stress and depression/anxiety but with limited access to doctors authorized to prescribe antidepressant medication, and with no specific psychosocial interventions.
3020629|NCT02425124|Experimental|Intervention|PC101 + Mental Health Facility-based stepped care intervention combining stress and depression case detection and management by non-physician clinicians and referral pathways for anti-depressant medication and/or group/individual counselling delivered by lay-health workers for patients with depression.
3020630|NCT02425111|Experimental|Vedolizumab 300 mg|Part A: Vedolizumab 300 mg, intravenously (IV), once on Day 1 and Weeks 2, 6, 14 and 22, followed by Part B: Vedolizumab 300 mg, intravenously (IV), once at Weeks 30, 38, and 46.
3020631|NCT02425098|Experimental|HD-TDV|High-dose Tetravalent Dengue Vaccine Candidate [HD-TDV], 0.5 mL, subcutaneous injection on Day 1.
3020632|NCT02425098|Experimental|TDV|Tetravalent Dengue Vaccine Candidate [TDV], 0.5 mL, subcutaneous injection on Day 1.
3020633|NCT02425085|Experimental|multi-endodiathermy retinectomy group|Patients receive multi-endodiathermy retinectomy
3020634|NCT02425085|Active Comparator|relaxing retinectomy|Patients receive relaxing retinectomy
3020635|NCT02425072|Experimental|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
3020636|NCT02425059|Experimental|IRE Group|irreversible electroporation for Unresectable Rectal Neoplasms
3020637|NCT02425046|Experimental|health coaching and community screening|Family Health Coaching and community benefits screening
3020638|NCT02425046|Other|community screening|community benefits screening only
3020639|NCT02425033|Experimental|Intervention|Patients undergoing POEM for spastic esophageal disorders such as achalasia at the University Health Network, Toronto, Canada
3020640|NCT02425020|Experimental|Meat protein|Post workout (training days) or breakfast (non training days) 20g of meat protein mixed with 250ml of orange juice and water
3020641|NCT02425020|Experimental|Whey Protein|Post workout (training days) or breakfast (non training days) 20g of whey protein isolate mixed with 250ml of orange juice and water
3020642|NCT02425020|Active Comparator|Carbohydrate|Post workout (training days) or breakfast (non training days) maltodextrin mixed with 250ml orange juice and water
3020643|NCT02425007|Experimental|Spiro|Incentive spirometry
3020644|NCT02425007|No Intervention|Control|Control group
3020645|NCT02424981|Experimental|inspiratory muscle training|Muscle training
3020646|NCT02424981|No Intervention|control|Control group
3020647|NCT02424968|Experimental|Treatment (TLI, ATG, transplant, CD8+ memory T-cells)|Patients undergo TLI on days -11 to -7 and -4 to -1 and receive ATG per standard institutional practice on days -11 to -7. Patients also receive cyclosporine PO daily starting on day -3 and will continue for at least 6 months post-transplant. Patients undergo non-myeloablative allogeneic HSCT on day 0. Patients also receive mycophenolate mofetil PO daily beginning on day 0 and continue until day 28. Based on the patient's status after the initial transplant, patients receive CD8+ memory T-cells IV over 10-20 minutes sometime between day 30 and day 60.
3020648|NCT02424955|Experimental|3D Perfusion Ultrasound|undergo 3D ultrasound perfusion imaging with perflutren
3020649|NCT02424942|Experimental|GZ389988|Single intraarticular injection of GZ389988 in the knee joint
3020650|NCT02424942|Placebo Comparator|Placebo|Single intraarticular injection of placebo for GZ389988 in the knee joint
3020651|NCT02424929|Other|Awake|"Original surgery intervention.~Patient will have DBS surgery done in the normal fashion. Asleep for the drilling of the burr holes, then awakened for the placement of the electrodes. No intervention will be given."
3020652|NCT02424929|Other|Asleep|"Sedation intervention.~Surgical intervention, anesthesia will be administered during entire placement of the system. Patient will not be awake at any point during procedure. All other aspects of surgery will be conducted normally."
3020653|NCT02424916|Experimental|Autologous somatic cell therapy|Patients treated with melanoma antigens-specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
3020654|NCT02424903||with prosthetic joint infection|Patients admitted for a septic revision surgery
3020655|NCT02424903||without prosthetic joint infection|Patients admitted for an aseptic revision surgery
3020656|NCT02424890|Active Comparator|Repetitive Sim Group|9 simulation sessions
3054579|NCT02197078||Sulfonylurea|
3020663|NCT02424838|Active Comparator|22 gauge with suction|EUS-FNA of pancreatic masses will be performed with a 22 gauge needle using suction.
3020664|NCT02424838|Active Comparator|22 gauge without suction|EUS-FNA of pancreatic masses will be performed with a 22 gauge needle without suction.
3020665|NCT02424838|Active Comparator|25 gauge with suction|EUS-FNA of pancreatic masses will be performed with a 25 gauge needle using suction.
3020666|NCT02424838|Active Comparator|25 gauge without suction|EUS-FNA of pancreatic masses will be performed with a 25 gauge needle without suction.
3020667|NCT02424825|Experimental|Rouxbe|Subjects will attend a one-month online cooking course, and be followed before, during, and after their participation for quality-of-life, fatigue, and blood biomarker changes.
3020668|NCT02424812|Experimental|Intervention|school based handwashing education programme
3020669|NCT02424812|No Intervention|Control|no intervention
3020670|NCT02424799|Experimental|Part A: Dose group 1|Subjects will be treated topically with 0.5 % GSK2646264 cream and placebo cream on an area of approximately 12 x 3 centimetre (cm) on the volar aspect of the arm which approximates to 0.2% total body surface area (BSA), on each arm. On Day 2 and Day 3 subjects will receive active treatment and placebo on the same arms as on Day 1, with the percentage BSA being 1% on Day 2 and 5% on Day 3.
3020671|NCT02424799|Experimental|Part A: Dose group 2|Subjects will be treated topically with 1 % GSK2646264 cream and placebo cream on the morning and evening of Day 1 starting at the final % BSA dosed at Day 3 in group 1 which is anticipated to be 5%. In dose group 2, the starting BSA will increase to 10% at Day 3 and then 20% by Day 5. Administration of the evening (PM) dose will be dependent on the data from Part A Dose group 1.
3020672|NCT02424799|Experimental|Part B|Cold urticaria subjects will receive treatment to 4 defined areas (right and left arms and legs). Subjects will be treated with maximum tolerated strength of GSK2646264 cream (0.5% or 1%) and placebo cream in morning or in morning and evening to 2 specified areas of ~5% BSA on the subject's legs for the CU assessment and to 2 specified areas of 0.2% BSA on the volar aspect of the arm. The maximum tolerated strength and evening dosing will be dependent on the data from the Part A
3020673|NCT02424799|Experimental|Part C|Chronic spontaneous urticaria subjects will be treated with the maximum tolerated strength of GSK2646264 cream from Part A (0.5% or 1%) and placebo cream onto defined areas (right and left arms and, legs and front torso) from Days 1 to 7. The total % BSA for an individual subject will be decided by the investigator prior to randomization. The maximum % BSA and the frequency of dosing will be decided after part A of the study.
3020674|NCT02424786|Other|Intervention group|"Medication lists from the patients randomized in the intervention group will be evaluated by the research physician with the help of STOPP/START criteria.~Feedback of this screening will be given to the team responsible for patient treatment."
3020675|NCT02424786|No Intervention|Control|Patients in this arm will receive standard pharmacological treatment
3020676|NCT02424773|Active Comparator|Venturi group|Venturi group : Oxygen is delivered using oxygen Venturi mask FiO2 is started at 60% (15l/min) and modified to maintain SpO2 over 94%.
3020677|NCT02424773|Experimental|HFNC group|HFNC group : Oxygen is delivered using HFNC. HFNC is started with FIO2 =1 and modified to maintain SpO2 over 94%, flow is settled at 40-50l/min.
3020678|NCT02424747||De Novo Acute Kidney Injury|Patients who developed Acute Kidney Injury during intensive care admission and not previously diagnosed with chronic kidney disease or end stage renal disease.
3020679|NCT02424747||No Acute Kidney Injury.|Intensive care patients not diagnosed with acute kidney Injury during admission and not previously diagnosed with Chronic Kidney Disease or End Stage Renal Disease.
3020680|NCT02424734|Experimental|Ceftaroline Fosamil|Ceftaroline Fosamil
3020681|NCT02424708|Placebo Comparator|Placebo|The study medication is packaged in sterile 1 ml pre-filled syringes, containing saline, which will be delivered intranasally.
3020682|NCT02424708|Active Comparator|Reduced Glutathione 100mg|The study medication is packaged in sterile 1 ml pre-filled syringes, containing 100 mg/ml of reduced glutathione (GSH), which will be delivered intranasally.
3020683|NCT02424708|Active Comparator|Reduced Glutathione 200mg|The study medication is packaged in sterile 1 ml pre-filled syringes, containing 200 mg/ml of reduced glutathione (GSH), which will be delivered intranasally.
3020684|NCT02424695|Experimental|Single Gabapentin Enacarbil Arm|"Gabapentin Enacarbil (Gen) 600 mg will be administered once daily for 4 weeks~Matching placebo will be administered once daily for one week prior initiation of treatment with GEn"
3020685|NCT02424682||HER 2 positive metastatic breast cancer|HER 2 positive metastatic breast cancer treated with Herceptin as per registered indication, until disease progression.
3020686|NCT02424669|Experimental|recently diagnosed ALS patients|
3020687|NCT02424669|Experimental|not recently diagnosed ALS patients|
3020688|NCT02424669|Active Comparator|patients with peripheral neuropathy, recently diagnosed|
3020689|NCT02424656||1|"Patients with TBI and DOC.~Experimental measures (MRI, TMS-EEG, and clinical scales) will be performed at 4 time points: within 2 weeks of admission, 6-10 weeks after admission, at discharge, 1-year follow-up after TBI episode. FDG-PET will be performed in a subset of 25 patients at 3 time points: at admission, at discharge, and at 1-year follow-up."
3020690|NCT02424656||2|"Healthy patient-matched controls.~Experimental measures (MRI, TMS-EEG, and FDG-PET) will be performed at 2 time points: within patient admission, and within patient discharge."
3020691|NCT02424643|No Intervention|No Incentive|Participants in this arm will receive no compensation for taking the online survey.
3020692|NCT02424643|Experimental|Monetary Incentive|Participants in this arm will receive a $20 Amazon.com incentive for participating in the online survey.
3020693|NCT02424643|Experimental|Altruistic Incentive|Participants in this arm will receive altruistic messages throughout the length of the survey in hopes of improving survey completion.
3020694|NCT02424643|Experimental|Dashboard Incentive|Participants in this arm will receive a dashboard at the end of the survey that will compare their data entered into the survey to other participants who have taken the survey. A preview of this dashboard will be shown at the beginning of the survey as a teaser in the hopes to improve survey completion.
3020695|NCT02424630|Experimental|ISB with SSNB|During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL ropivacaine.
3054580|NCT02197078||Within-class comparators|
3020696|NCT02424630|Placebo Comparator|ISB alone|During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL normal saline.
3020697|NCT02424617|Active Comparator|Arm A|designed to determine the maximum dose of BGB324 that can be safely administered in combination with erlotinib administered at the approved oral dose level of 150 mg daily. It is anticipated that a maximum of three BGB324 dose levels will be evaluated, with up to approximately 18 patients enrolled. In the absence of unacceptable toxicity, patients will be allowed to continue receiving BGB324 in combination with erlotinib until disease progression.- (Arm completed)
3020698|NCT02424617|Active Comparator|Arm B|will incorporate a Simon-like two-stage design with relaxed stopping for futility to evaluate the safety, pharmacokinetics and clinical activity of BGB324 in combination with erlotinib in patients with an activating EGFR mutation who have progressed after receiving prior erlotinib.( Open to enrolment)
3020699|NCT02424617|Active Comparator|Arm C|will evaluate the safety, pharmacodynamics and clinical activity of BGB324 when administered in combination with erlotinib in patients with an activating EGFR mutation who have received at least twelve weeks of erlotinib without disease progression.(Open to enrolment)
3020700|NCT02424617|Other|Run in Arm|The primary goal of the Run-in Cohort is to establish the safety and tolerability of BGB324 administered as a single agent. Eligible patients will have either exhausted existing licensed therapies or be unsuitable for treatment with existing licensed therapies for NSCLC. BGB324 will be administered at a loading dose of 600 mg on Day 1 and Day 2 of Cycle 1, followed by 200 mg daily thereafter (Arm completed)
3020701|NCT02424591|Active Comparator|Ketamine|ketamine group will be infused after intubation and terminated at the start of skin closure
3020702|NCT02424591|Placebo Comparator|Placebo|placebo group will have standard of care rather than ketamine infusion
3020703|NCT02424578|Experimental|Diclofenac Capsules low dose|Diclofenac Capsules low dose three times daily for up to three days
3020704|NCT02424578|Experimental|Diclofenac Capsules high dose|Diclofenac Capsules high dose three times daily for up to three days
3020705|NCT02424565|Experimental|Test|2 ± 0.2 g of product will be gently rubbed for 15 seconds on the affected knee joint.
3020706|NCT02424565|Placebo Comparator|Placebo|2 ± 0.2 g of product will be gently rubbed for 15 seconds on the affected knee joint.
3020707|NCT02424552|Experimental|Vitamin D3|Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks
3020708|NCT02424552|Placebo Comparator|Placebo|Amount of Placebo capsules corresponding to initial single dose of Vitamin D3, beginning from the second day amount of capsules corresponding to daily dose of Vitamin D for 24 weeks
3020709|NCT02424539|Experimental|FFNS 55 mcg Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing either FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 55 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.
3020710|NCT02424539|Experimental|FFNS 110 mcg Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 110 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.
3020711|NCT02424539|Placebo Comparator|Placebo Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing only placebo. Subject's on their own or with assistance from parent/guardian will administer one intranasal spray of placebo, from Device A and Device B, once daily into each nostril in the morning for 4 Weeks.
3020712|NCT02424526|Active Comparator|high-intensity group|Children will engage in home-based treadmill training 5 days/week, twice daily for 10-20 min for 6 weeks
3020713|NCT02424526|Active Comparator|low-intensity group|Children will engage in home-based treadmill training 2 days/week, once daily for 10-20 minutes for 6 weeks
3020714|NCT02424513|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg.
3020715|NCT02424487||Intracuff pressure during one-lung ventilation|Measurement of changes in intracuff pressure with one-lung ventilation during thoracic surgery.
3020716|NCT02424474|Experimental|Genetic NIPT and regular serum screening|All woman will be tested using the two tests, genetic NIPT (Non Invasive Prenatal Testing) and regular serum screening.
3020717|NCT02424461|Active Comparator|7 day-antibiomicrobial treatment|"Ceftriaxone : 1 injection 1 g per day for 2 days~Ofloxacine : 400 mg/jour (200 mg/ jour in case of renal failure) for seven days~Placebo of ofloxacine for 7 days"
3020718|NCT02424461|Active Comparator|14-day antibiomicrobial treatment|"Ceftriaxone : 1 injection 1 g per day for 2 days~Ofloxacine : 400 mg/jour (200 mg/ jour in case of renal failure) for 14 days"
3020719|NCT02424448||Metastatic CRPC|Patients with metastatic prostate cancer post maximal androgen blockade (MAB) with primary or metastatic cancer deposits amenable to biopsy. Patients will have biopsies, blood and urine samples taken.
3020720|NCT02424435|Experimental|Methylprednisolone|This is an open-label study of methylprednisolone in patients with FRDA. Subjects will begin oral administration of 48 mg methylprednisolone at day 1 and will decrease their administered dose by 8 mg per day. After 6 days, subjects will spend 22 days off medication before repeating the same treatment cycle. Last dosing cycle of methylprednisolone will be administered at 24 weeks after baseline. Visits will occur at weeks 2, 6, 14, 26, and 30 following baseline.
3020721|NCT02424409|Active Comparator|1: Control|
3020722|NCT02424409|Experimental|2: Intervention|
3020723|NCT02424396|Experimental|1 : IL2|Interleukin-2 (ILT-101)
3020724|NCT02424396|Placebo Comparator|2 : Placebo|Placebo
3020725|NCT02424383||PTA (Lutonix® 035 DCB Catheter)|Treatment with the Lutonix 035 DCB will be per the investigational site's standard of care and adhering to the IFU.
3020726|NCT02424357|Experimental|5% povidone iodine ophthalmic solution|patient received 1 drop of 5% povidone-iodine instilled over the adjustable suture noose in addition to routine antibiotic/steroid ointment to operated eye at surgery completion
3020727|NCT02424357|Active Comparator|no povidone-iodine ophthalmic solution|patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
3020728|NCT02424344|Experimental|Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg|8 weeks, double blind treatment period
3020729|NCT02424344|Placebo Comparator|Placebo to Aclidinium/Formoterol|8 weeks, double blind treatment period
3020730|NCT02424331|Experimental|Quiet Breathing or Pursed Lips Breathing|Free or natural breathing for six minutes.
3020731|NCT02424318|Experimental|Topiramate|topiramate 25mg twice for 1 week -> topiramate 50mg twice for 7 weeks
3020732|NCT02424305|Experimental|face: LEO 43204 gel 0.018%|3 days treatment (once daily) on face: LEO 43204 gel 0.018%
3020733|NCT02424305|Experimental|arm: LEO 43204 gel 0.1%|3 days treatment (once daily) on arm: LEO 43204 gel 0.1%
3020734|NCT02424305|Experimental|scalp: LEO 43204 gel 0.037%|3 days treatment (once daily) on scalp: LEO 43204 gel 0.037%
3020735|NCT02424292||Physical activity|Physical activity in a personalised program
3020736|NCT02424279|Active Comparator|Surgical treatment|Patients from the first group will undergo thoracoscopic splanchnicectomy. The surgery will be performed in general anaesthesia, with tracheal intubation in prone position. The greater splanchnic nerve will be identified at its origin in sympathetic trunk, dissected together with all collaterals all the way down to the diaphragm and excised. Additional splanchnic nerves (smaller, minimus) will be incised or excised if connected to the greater splanchnic nerve. Single sutures will be applied to the skin. Then the procedure will be repeated on the contralateral side.
3020737|NCT02424279|No Intervention|Conservative Treatment|Patients from the second group will be offered best available conservative pain treatment. The list of medication on stage 1 will include: paracetamol, ibuprofen, diclofenac. On stage 2: stage 1 + codeine and tramadol. On stage 3: stage 2 + morphine, fentanyl, oxycodone, pethidine. Oral and transcutaneous routes will be preferred to intravenous, intramuscular and subcutaneous. A need for elevation to the next step of analgesic ladder will be considered when the pain will be stronger than 6 points in Numeric Rating Scale (NRS) and will be present for more than 5 days.
3020738|NCT02424266||Healthy subjects|None invasive imaging of the tear film for subjects with no eye disease
3020739|NCT02424266||keratoconjunctivits sicca (KCS) and Dry Eye Syndrome (DES)|None invasive imaging of the tear film for KCS and DES patients as confirmed by a cornea specialist
3020740|NCT02424253|Experimental|ZPL-3893787|30mg once daily
3020741|NCT02424253|Placebo Comparator|Placebo|Once daily
3020742|NCT02424240||IGF-I/ IGFBP-3 ratio group|
3020743|NCT02424240||IGF-1 and IGFBP-3|
3020744|NCT02424227||Kidney Transplant Recipients|Adult living and deceased donor kidney transplant recipients will be eligible to participate in this study.
3020745|NCT02424214|Experimental|Ca Ionophore group|Artificial Oocyte activation with Ca Ionophore for 20 min after Intracytoplasmic Sperm Injection
3020746|NCT02424214|Experimental|Strontium Chloride group|Artificial Oocyte activation with Strontium Chloride for 60 min after Intracytoplasmic Sperm Injection
3020747|NCT02424214|No Intervention|Only Intracytoplasmic Sperm Injection|after Intracytoplasmic Sperm Injection Oocytes will cultured and incubated
3020748|NCT02424201|Experimental|study|Intramuscular oxytocin 10 units, 400 micrograms of misoprostol
3020749|NCT02424201|Other|control|Intramuscular oxytocin 10 units, 2 tablets of placebo which will be vitamin c
3020750|NCT02424188|Experimental|TRIUMPH intervention|Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
3020751|NCT02424188|No Intervention|Treatment as Usual|referral to quit line
3020752|NCT02424175|Experimental|Patients with PSC|This is an open label study. All patients enrolled will receive a fecal microbiota transplantation.
3020753|NCT02424162|Experimental|2.75 group|Patients with 2.75 diopters multifocal intraocular lens
3020754|NCT02424162|Active Comparator|3.25 group|Patients with +3.25 diopters multifocal intraocular lens
3020755|NCT02424149|No Intervention|Control|No preoperative phenazopyridine
3020756|NCT02424149|Experimental|Phenazopyridine|Preoperative phenazopyridine
3020757|NCT02424136|Other|Entire group|Children aged 2-17 years with suspected peanut allergy who require peanut food challenge to confirm clinical allergy, will be recruited for the study. They will undergo a preceding questionnaire, peanut skin prick testing, spirometry, fraction of exhaled nitric oxide (FeNO) measurement, serum peanut and Ara h2 specific immunoglobulin E (sIgE) antibodies, and collection of blood biomarker prior to food challenge. The primary endpoint will be anaphylaxis at open label peanut challenge, with the primary exposure of interest will be the serum biomarker.
3020758|NCT02424123||The study population|The study population is composed of patients between 18 and 60 years of age, of both sexes, recruited during consultations for a first epileptic seizure at the emergency department of Nîmes and Marseille Hospitals (CHRU).
3020759|NCT02424110|Experimental|Argon beam coagulator ablation group|In the bipolar left atrial radiofrequency ablation, when the linear ablation was performed through along the lower edge of interatrial groove incision up to the mitral annulus, there is a gap between the ends of the ablation line and the mitral annulus And in the bipolar right atrial radiofrequency ablation, when the linear ablation was performed along the lower edge of the coronary sinus ostium up to the inferoseptal commissure and through the vertical incision on anterior wall of the right atrium up to the tricuspid annulus. There also have gaps between ends of the ablation line and the tricuspid annulus. In the experimental group the investigators plan to use conventional bipolar radiofrequency ablation and use argon beam coagulator to ablate these gaps.
3020760|NCT02424110|Experimental|Bipolar radiofrequency ablation group|Only use conventional bipolar radiofrequency ablation and do not deal with these gaps.
3020761|NCT02424097|Experimental|MI Paste & MI Varnish|MI past will be applied by the patient every night; MI varnish will be applied every three months in the office
3020762|NCT02424097|Active Comparator|Standard of Care|Subjects will use at home regal toothpaste every night and F-mouth rinse as recommended
3020763|NCT02424084|Experimental|Intact scaphoid bone|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3020764|NCT02424084|Experimental|Intact metacarpal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3055017|NCT02194244|Active Comparator|Tablet Fasted|
3020765|NCT02424084|Experimental|Fractured scaphoid bone|"Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3020766|NCT02424084|Experimental|Fractured metacarpal bone|"Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3020767|NCT02424084|Experimental|Intact metatarsal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metatarsal bone.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3020768|NCT02424071|Active Comparator|Melatonin group|Patients will receive a pill containing 5mg of melatonin on the evening before the surgery. Patients will receive another pill containing 5mg of melatonin two hours prior to surgery.
3020769|NCT02424071|Placebo Comparator|Placebo group|Patients will receive a pill containing placebo on the evening before the surgery. Patients will receive another pill containing placebo two hours prior to surgery.
3020770|NCT02424058||Neck pain|Patients aged between 18 and 65 years with persistent neck pain for more than 3 months
3020771|NCT02424058||Healthy|Acceptance to participate in the study, no previous neck oain (lifetime-to-date), no spinal surgery or deformity, and no radiological abnormalities detected
3020772|NCT02424045|Other|BCD chemotherapy|"All patients are scheduled to receive 2 cycles of three-weekly Bendamustine, carboplatin and dexamethasone combination chemotherapy(BCD Chemotherapy).~D1,D2 Bendamustine 80mg/m2 IV over 30-60min D1 Carboplatin AUC 5.0 IV D1-4 Dexamethasone 40mg #2 PO or IV"
3020773|NCT02424032|Experimental|Exercise and connective tissue massage|Stabilization exercise and connective tissue massage have been applied
3020774|NCT02424032|Active Comparator|Exercise|Only stabilization exercise has been applied
3020775|NCT02424019|Experimental|ILUVIEN 0.19 MG|All patients will receive ILUVIEN (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg.
3020776|NCT02424006|Experimental|RHCIII-MPC cornea|Patients of this arm will undergo RHCIII-MPC bioengineered cornea transplantation using anterior lamellar keratoplasty technique
3020777|NCT02424006|Active Comparator|Donor cornea|Patients of this arm will undergo human donor cornea transplantation using anterior lamellar keratoplasty technique
3020778|NCT02423993|Experimental|SAP + Group Education|Patients will be transferred from MDI to sensor-augmented pump (SAP) in group using specialised structured education program. CGM will be used for self monitoring of blood glucose permanently within 4 month.
3020779|NCT02423993|Active Comparator|SAP + Standard Education|Patients will be transferred from MDI to sensor-augmented pump (SAP) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
3020780|NCT02423993|Experimental|CSII + Group Education|Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) using specialised structured education program.
3020781|NCT02423993|Active Comparator|CSII + Standard Education|Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
3020782|NCT02423980|Experimental|Glucagon|1 mg G-Pen™ (glucagon injection) first, followed by 0.5 mg
3020783|NCT02423967|Active Comparator|Transplant uses fresh familial stool|Undergoes Fecal Microbial Transplant using fresh stool from a screened family member Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
3020784|NCT02423967|Experimental|Transplant uses frozen anonymous stool|Undergoes Fecal Microbial Transplant using stool collected from screened anonymous donor that has been frozen until time of Fecal Microbial Transplant Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
3020785|NCT02423954|Experimental|Arm 1|Temsirolimus 25 mg every 14 days + nivolumab
3020786|NCT02423954|Experimental|Arm 2|Irinotecan 150 mg/m2 every 14 days + nivolumab
3020787|NCT02423954|Experimental|Arm 3|Irinotecan + capecitabine + nivolumab irinotecan 175 mg/m2 on day 1 every 14 days + capecitabine 1000 mg PO BID days 1-5 on, days 6-7 off, each 7 day period
3020788|NCT02423941|Experimental|Retrograde reperfusion|During the transplant procedure the liver is initially reperfused retrogradely via hepatic veins. Venting of 300 ml blood is allowed via donor portal vein. After completion the portal vein anastomosis and retrograde venting of another 100 ml blood the antegrade portal reperfusion is performed.
3020789|NCT02423941|Active Comparator|Antegrade reperfusion|During the transplant procedure the liver is reperfused conventionally, antegradely via portal vein after completion of caval and portal anastomoses. Venting of 300 ml blood is allowed via tube placed in infrahepatiс caval anastomosis before unclamping the vena cava.
3020790|NCT02423928|Experimental|Cryoimmunotherapy|Patients with castration resistant prostate cancer and imaging proven metastases will be treated by autologous dendritic cell based cryoimmunotherapy of the prostatic tumor tissue assisted by immunomodulation consisting of low-dose metronomic cyclophosphamide for all patients plus ipilimumab for the latter half of all patients.
3020791|NCT02423915|Experimental|Phase I: Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Mesna administered on Day -8 immediately following completion of the Fludarabine.~Total body radiation 2 Gy delivered on Day -4.~3rd party CB Treg infusion on Day -1.~Three (3) participants treated at cell dose level 1: 1 x 10^6/kg fucosylated T-reg cells. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD transplant on Day 0.~Mycophenolate 15 mg/kg by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
3020901|NCT02423057|Experimental|1|TdCyd will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles
3020792|NCT02423915|Experimental|Phase I: Non-Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Total body radiation 2 Gy delivered on Day -4.~3rd party CB Treg infusion on Day -1.~Ten (10) participants treated with non-fucosylated T-reg cells at dose level 2: 1 x 10^7/kg T-reg cells. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD infused on Day 0.~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
3020793|NCT02423915|Experimental|Phase II: Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Total body radiation 2 Gy delivered on Day -4.~Seventeen (17) participants treated with Fucosylated T-reg cells at dose level 2: 1 x 10^7/kg. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD infused on Day 0.~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
3020794|NCT02423915|Experimental|Phase II: Non-Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Total body radiation 2 Gy delivered on Day -4.~Seventeen (17) participants treated with Non-Fucosylated T-reg cells at dose level 2: 1 x 10^7/kg. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD infused on Day 0.~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
3020795|NCT02423902|Experimental|Ad-RTS-hIL-12 + Veledimex|Intratumoral injection of Ad-RTS-hIL-12 in combination with veledimex
3020796|NCT02423889|Experimental|1|Stereotactic radiotherapy with a total dose of 36.25 Gy in 5 fractions (7.25 Gy per fraction, 2 fractions per week) in low risk prostate cancer patients is delivered to evaluate acute and subacute toxicty
3020797|NCT02423876|Experimental|Arm I (epidural placement, ERP)|Patients undergo epidural placement in the First Day Surgery pre-operative area or similar areas suitable for insertion of epidural catheters. In the post-operative anesthesia care unit, patients may receive medication via the epidural on an as needed basis, as determined by the anesthesia team. Dosing and rate of standardized medication will be managed by the anesthesia team until the epidural is removed. Patients complete the ERP comprising increased activity, dietary restrictions, fluid balance, as well as anti-nausea, anti-inflammatory and pain medications at specific times. Patients will have access to additional pain medications as needed to control their pain.
3020798|NCT02423876|Active Comparator|Arm II (ERP)|Patients complete the ERP comprising increased activity, dietary restrictions, fluid balance, as well as anti-nausea, anti-inflammatory and pain medications at specific times. Patients will have access to additional pain medications as needed to control their pain.
3020799|NCT02423863|Experimental|Hiltonol Poly-ICLC|This is an adaptive design protocol. A total of 100 study subjects will be enrolled. Ten study subjects each with one of the four indications above will be treated in stage I of the protocol. At the end of stage I, an interim analysis will be conducted and one of the four indications will be selected for enrollment of an additional 60 patients, for a total of 100 patients in the study. Enrolled study subjects will receive three cycles of Poly-ICLC treatment. Each priming and boosting treatment course will constitute one cycle.
3020800|NCT02423850||Diabetic foot ulcers or venous leg ulcers|
3020801|NCT02423824|Active Comparator|Insulin Resistance|Adjunctive Liraglutide 1.2-1.8mg/day
3020802|NCT02423824|Active Comparator|Non-Insulin Resistance|Adjunctive Liraglutide 1.2-1.8mg/day
3020803|NCT02423811|Experimental|CCRT plus Fursultiamine|"Fursultiamine 100mg tid, po Radiotherapy 36Gy/18Fx Chemotherapy will include Cisplatin and 5-FU. Cisplatin 60-75 mg/m2 on days 1 and 29 with standard prehydration and antiemetic therapy.~5-FU 600-1000 mg/m2day administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1 through 4 and 29 through 32"
3020804|NCT02423798|Other|Open-label, single-sample design|"The trial has an open label design with a glucose sensor intervention. Only 1 sensor system is used in the trial (no comparator).~As all subjects will receive identical devices and undergo the same experimental procedures, no randomization will be performed. Furthermore, neither subjects nor clinical staff will be blinded to the sensor readings, as knowing the sensor glucose readings will not affect the accuracy endpoint."
3020805|NCT02423772|Experimental|Intervention|Treatment as usual, plus 12 weeks of group based intervention to improve functioning and decrease problematic effects of opioid use.
3020806|NCT02423772|No Intervention|Treatment as Usual|
3020807|NCT02423759|Active Comparator|ciprofloxacin|standard chemoprophylaxis [500mg ciprofloxacin twice daily for 3 days]
3020808|NCT02423759|Experimental|ciprofloxacin and gentamycine|Augmented Chemoprophylaxis [standard chemoprophylaxis plus 160mg]
3020809|NCT02423759|Experimental|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
3020810|NCT02423746|Placebo Comparator|Control Group|"The control group will include 3 hearing aid (HA) and 3 cochlear implant (CI) caregiver-child dyads.~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
3020902|NCT02423018|Active Comparator|Pregabalin|Pregabalin titrated up to, and tapered from, 225mg/day in divided doses for 10 days
3020811|NCT02423746|Experimental|Intervention Group|"The intervention group will include 3 hearing aid (HA) and 3 cochlear implant (CI) caregiver-child dyads.~Intervention parents receive the initial assessment session followed by the 3-session Family Check Up Behavioral Parenting Training Program (BPT) within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
3020812|NCT02423733|No Intervention|Control|In addition to their usual clinical care will also be given written information about web sites that provide information on depression but will not be specifically directed to The Journal.
3020813|NCT02423733|Experimental|Computerized Therapy|In addition to their usual clinical care they will receive an invitation to use The Journal supported by an e-therapy coach who will provide patients with weekly email or telephone contact. The e-therapy coach will have a guideline script for each lesson of The Journal to reinforce the topic of each lesson, help identify and support patients in their goals and to coach them in goal setting and the techniques of problem solving.
3020814|NCT02423720|Other|Study Intervention|Audio-based mindfulness intervention A 8-week single arm pilot study will be conducted among Helen Diller Famiily Comprehensive Cancer Center (HDFCCC) patients with metastatic colorectal cancer receiving chemotherapy and their caregivers (44 participants, total). Participants will receive an informational booklet containing a practice log and an MP3 player containing an introductory lecture and guided meditations. Practice reminders will be sent via text messages. Weekly emails will contain practice instructions and links to validated questionnaires.
3020815|NCT02423707|Active Comparator|ALK Alutard Birch and/or 5-grasses|3 intralymphatic injections with dose 1000 SQ-U and dose interval 4 weeks.
3020816|NCT02423707|Placebo Comparator|ALK diluent|3 intralymphatic injections with dose interval 4 weeks.
3020817|NCT02423694|Experimental|Electroacupuncture|"Baihui, Yintang, Guanyuan(dual), Zigong(dual), Sanyinjiao(dual), Hegu(dual), Taichong(dual).~Insert needles to the acupoints mentioned above after sterilized.Needle handles of Baihui and Yintang are connected with the electroacupuncture instrument wire. And needle handles of bilateral Zigong are conneted with the electroacupunture instrument wire. And needle handles of bilateral Tianshu are connected with the electroacupunture instrument wire. Density wave, frequency of 10/50Hz and current intensity is 0.5~1.0 mA for 30 minutes. 3 times per week. Each treatment interval of more than 24 hours, continuous treatment for 12 weeks."
3020818|NCT02423694|Active Comparator|escitalopram oxalate tablets|0.5 hour after breakfast oral taking 10mg escitalopram oxalate tablets, continuous treatment for 12 weeks.
3020819|NCT02423681|Active Comparator|Heated humidification as first intention (HH1st)|Subjects receive heated humidification as first intention with ThermoSmart
3020820|NCT02423681|Placebo Comparator|Non-heated humidification|Subjects will receive no humidification. However they can be switched to the humidification group if patients complains of nasal dryness, congestion, nose bleed or if they had significant leak that cannot be resolved by two changes of mask.
3020821|NCT02423668||50% Partial adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. Second eye refinement in the intra-ocular lens power selection for the second eye was performed using a theoretical 50% partial adjustment of the PE1. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
3020822|NCT02423668||No adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. The intra-ocular lens power selection for the second eye was performed irrespective of the first eye prediction error. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
3020823|NCT02423668||Full adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. Second eye refinement in the intra-ocular lens power selection for the second eye was performed using a theoretical 100% partial adjustment of the PE1. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
3020824|NCT02423655|Experimental|Deffered Dialysis Initiation|"Algorithm for deferred dialysis intervention:~initiating dialysis in the absence of symptoms in patients with an eGFR of 5 ml/min /1.73 m2 or less"
3020825|NCT02423655|Active Comparator|Routine dialysis Initiation|"Algorithm for routine dialysis intervention:~initiating dialysis in the absence of symptoms in patients with an eGFR of 7 ml/min /1.73 m2 (which is the average GFR for patients in Beijing to start dialysis )"
3020826|NCT02423642|Experimental|AKI requring CRRT and use regional citrate anticoagulation|CRRT use regional citrate anticoagulation
3020827|NCT02423642|Experimental|AKI requring CRRT and not use regional citrate anticoagulation|CRRT not use regional citrate anticoagulation
3020828|NCT02423629|Other|Agili C™|Candidates will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
3020829|NCT02423616|Experimental|Healthy individuals|Study population was consisted by healthy volunteers from hospital staff of physical therapy department, Intensive Care Unit, and cleaning service. All subjects were men and women aged between 20 and 65 years old, who never had major problems with the respiratory system or with the hand flexors.
3020830|NCT02423603|Active Comparator|Paclitaxel + AZD5363|"Patients receive Paclitaxel on Day 1, Day 8 and Day 15 plus AZD5363/Placebo on Days 2-5, Days 9-12, and Days 16-19.~Upon Paclitaxel withdrawal,~Patient receive AZD5363/Placebo on Days 2-5, Days 9-12, Days 16-19 and Days 23-27."
3020903|NCT02423018|Placebo Comparator|Placebo|Placebo for 10 days
3022898|NCT02410356|Experimental|TV-1106|TV-1106 to be injected once weekly.
3020831|NCT02423603|Placebo Comparator|Paclitaxel + Placebo|"Patients receive Paclitaxel on Day 1, Day 8 and Day 15. plus AZD5363/Placebo on Days 2-5, Days 9-12, and Days 16-19.~Upon Paclitaxel withdrawal,~Patient receive AZD5363/Placebo on Days 2-5, Days 9-12, Days 16-19 and Days 23-27."
3020832|NCT02423590|Active Comparator|Gemcitabine/Carboplatin|"Gemcitabine/carboplatin will be administered as standard 21-day treatment cycles according to normal clinical practice.~Gemcitabine will be given by 30 minute intravenous infusions on Day 1 and Day 8 of each 21-day Cycle.~On Day 1, carboplatin (AUC5) will be given by infusion over 30-60 minutes."
3020833|NCT02423590|Experimental|Gemcitabine/carboplatin + Apatorsen|"Apatorsen (OGX-427) will be administered as an intravenous infusion over 2 hours.~Apatorsen (OGX-427) treatment will begin with a loading dose period prior to the initiation of chemotherapy. Patients will receive three loading doses of 400 mg within a 9-day period with at least 48 hours between infusions and between the last loading dose infusion and Day 1 of initiating chemotherapy. Chemotherapy must be initiated within 7 calendar days once the last loading dose infusion has been completed.~Following the loading dose period, Apatorsen (OGX-427) will be given weekly at a dose of 400 mg by 2 hour intravenous infusions. On days when both chemotherapy and Apatorsen (OGX-427) are given, Apatorsen (OGX-427) should be given first followed by chemotherapy."
3020834|NCT02423577|Experimental|FF-3 dry powder|FF-3
3020835|NCT02423577|Placebo Comparator|Placebo|
3020836|NCT02423564|Active Comparator|Healthy Population with Digesta Lac|Digesta Lac is Lactobacillus bulgaricus LB-51 at 2.0 billion cfu with non-medicinal ingredients: cellulose, potato powder, chick pea extract, vitamin c, L-leucine, vegetable capsule (hypromellose)
3020837|NCT02423564|Placebo Comparator|Healthy Population with Placebo|Placebo contains: cellulose, Organic Whole Grain Brown Rice Milk Concentrate, L-Leucine, potato powder, vegetable capsule (hypromellose)
3020838|NCT02423551|No Intervention|Control|Usual diet
3020839|NCT02423551|Experimental|MRE|MRE consumption
3020840|NCT02423538|Experimental|single ascending doses|single ascending doses, oral tablets
3020841|NCT02423538|Placebo Comparator|Placebo|Placebo Comparator, oral tablets
3020842|NCT02423525|Experimental|Afatinib|"Four dosing cohorts are planned, with the option to enroll additional cohorts based on safety and PK data. Afatinib tablets are taken by mouth every 4 days.~Dose Level 1: 80 mg Dose Level 2: 120 mg Dose Level 3: 180 mg Dose Level 4: 200 mg"
3020843|NCT02423512||Anti-TNF Exposure|Inflammatory Bowel Disease (IBD) patients scheduled to start vedolizumab therapy who have been previously exposed to anti-TNF therapy
3020844|NCT02423512||anti-TNF Naive|IBD patients scheduled to start vedolizumab therapy who have not been previously exposed to anti-TNF therapy
3020845|NCT02423499||Autism Spectrum Disorder|Autism Spectrum Disorder adults without intellectual disability
3020846|NCT02423499||Bipolar Disorder|Bipolar Disorder adults during normothymic phase of illness
3020847|NCT02423499||Healthy Volonteers|Healthy adults
3020848|NCT02423486|Experimental|Electromagnetic stimulation therapy|Electromagnetic stimulation therapy group
3020849|NCT02423486|Experimental|Electromagnetic stimulation therapy with biofeedback|Electromagnetic stimulation therapy with biofeedback group
3020850|NCT02423473|Active Comparator|Connective tissue graft (CTG)|After local anesthesia, the surgical procedure performed was the trapezoidal-type of CAF (de Sanctis & Zucchelli, 2007). After the flap was raised, the exposed root surface was gently scaled and planed until it became smooth. Afterward, a thin and small connective tissue graft that was sutured over the root surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
3020851|NCT02423473|Experimental|Connective tissue graft plus composite resin restoration.|After local anesthesia, the surgical procedure performed was the trapezoidal-type of CAF (de Sanctis & Zucchelli, 2007). After the flap was raised, a sterile rubber dam was placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M ESPE - St. Paul, MN, USA), following the manufacturer's instructions. Afterward, a thin and small connective tissue graft that was sutured over the restoration surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
3020852|NCT02423460|Experimental|Threonine requirement|The threonine requirement in healthy male subjects and in patients with Crohn's disease and Ulcerative colitis
3020853|NCT02423447|Active Comparator|Electro-Flo Arm|The patients were randomized to a series of airway clearance sessions with Electro-Flo on Day 1 and G5 on Day 2.
3020854|NCT02423447|Active Comparator|G5 Arm|The patients were randomized to a series of airway clearance sessions with G5 on Day 1 and Electro-Flo on Day 2.
3020855|NCT02423434||Corneal Confocal Microscopy subjects|
3020856|NCT02423421|Active Comparator|Treatment group|The treatment group will have faecal microbiota transplantation performed using stool from a healthy human donor
3020857|NCT02423421|Placebo Comparator|Placebo group|The placebo group will have autologous faecal microbiota transplantation performed.
3020858|NCT02423408|Experimental|TNX-201|4 X 35 mg capsules to be taken when qualifying tension-type headache occurs
3020859|NCT02423408|Placebo Comparator|Placebo|4 X placebo capsules to be taken when qualifying tension-type headache occurs
3020860|NCT02423395|Experimental|Orphenadrine(Norflex)|100 patients will be treated with orphenadrine 100 mg twice daily for 1 month
3020861|NCT02423395|Placebo Comparator|Placebo|100 patients will be given placebo
3020862|NCT02423382|Other|3-6 months group|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for 3-6 months.
3020863|NCT02423382|Other|6-9 months|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for 6-9 months.
3020864|NCT02423382|Other|>9 months|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for more than 9 months.
3020865|NCT02423369|Experimental|neonates and infants requiring surgery|neonates and infants in whom blood samples for measurement of S-100 B protein in serum and NSE protein in serum are taken pre-operatively and 1-st, 2-nd and 3-rd post-operatively. During anesthesia cerebral near infrared spectroscopy is continuously applied until the wound closure.
3020866|NCT02423356||Echocardiography|All patients will receive 4 echocardiograms and 4 blood draws. The blood draws and echocardiograms will occur at the same visits.
3020938|NCT02422810||New to aspirin|Subjects newly started on aspirin during their visit
3020867|NCT02423343|Experimental|Galunisertib + Nivolumab (Phase 1b)|Galunisertib in escalating dose cohorts given orally daily or twice a day (BID) for the first 14 days of each 4 week cycle in combination with nivolumab given intravenously (IV) every 2 weeks for 2 cycles.
3020868|NCT02423343|Experimental|Galunisertib + Nivolumab (NSCLC) (Phase 2)|Galunisertib given orally BID for the first 14 days of each 4 week cycle in combination with nivolumab given IV every 2 weeks of each 4 week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
3020869|NCT02423343|Experimental|Galunisertib + Nivolumab (HCC) (Phase 2)|Galunisertib given orally BID for the first 14 days of each 4 week cycle in combination with nivolumab given IV every 2 weeks of each 4 week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
3020870|NCT02423330|Experimental|Strattice-LIFT|
3020871|NCT02423317|Active Comparator|Intubation with Miller's blade|After induction and muscle paralysis, Miller's blade was introduced in the patient's mouth. After visualization of vocal cord, patient was intubated with appropriate sized tracheal tube.
3020872|NCT02423317|Experimental|Intubation with Airtraq laryngoscope|After induction and muscle paralysis, Airtraq laryngoscope's blade was introduced in the patient's mouth. After visualization of vocal cord as a reflected image in the viewfinder of the device, patient was intubated with appropriate sized tracheal tube.
3020873|NCT02423304||test|"50 periodontitis patients~• Patients will be categorized by Periodontal Disease Index (PDI) by P. Ramfjord(1959) blood samples collected from all patients serum separated and evaluated for77A/G AND 11A/12A associated gene polymorphism of Matrix Metallo Proteinase( MMP)-13 in all the patients. studies showing that there is co relation of these genes with increase inflammation."
3020874|NCT02423304||control|50 periodontally healthy individuals blood samples collected from all patients serum separated and evaluated for77A/G AND 11A/12A associated gene polymorphism of Matrix Metallo Proteinase (MMP)-13 in all the patients
3020875|NCT02423291|Experimental|Vial for IV infusion|This is a single-arm, open-label, multicenter, Phase 2 clinical trial to evaluate the efficacy and safety of Brentuximab vedotin as a single agent in patients with relapsed or refractory PMLBCL who have previously received a first line of treatment with chemotherapy or immunotherapy.20 patients will be treated in this study and All patients will receive 1.8 mg/kg Brentuximab vedotin administered as a single outpatient IV infusion on Day 1 of each 21-day treatment cycle. Patients may continue on study treatment until disease progression or unacceptable toxicity. Patients who achieve stable disease or better as assessed by investigator should receive a minimum of 8, but no more than 16 cycles of study treatment.
3020876|NCT02423278|Experimental|D4 Lymphadenectomy|"This is the interventional group in which additional para-aortic lymph nodes are dissected meanwhile.~Under this arm, main therapeutic measures are listed as follows:~three-cycle SOX chemo regimen (S-1+Oxaliplatin) as neoadjuvant chemotherapy~radical gastrectomy plus D4 lymphadenectomy~five-cycle SOX chemo as adjuvant chemotherapy~five-year follow-up program to evaluate the prognosis."
3020877|NCT02423278|Experimental|D2 Lymphadenectomy|"This is the control group in which a classic surgical procedure for gastric cancer is performed.~Under this arm, main therapeutic measures are included as follows:~three-cycle SOX chemo regimen (S-1+Oxaliplatin) as neoadjuvant chemotherapy~radical gastrectomy plus D2 lymphadenectomy (Without para-aortic lymph nodes dissection)~five-cycle SOX chemo as adjuvant chemotherapy~five-year follow-up program to evaluate the prognosis."
3020878|NCT02423265|Active Comparator|Ranolazine|500mg bd ranolazine for 1 week then uptitrated to 1000mg bd to continue for 8 weeks
3020879|NCT02423265|Placebo Comparator|Placebo|Matching placebo, with up titration after 1 week as in active treatment arm
3020880|NCT02423252|Experimental|Intervention group|Intervention: Massage, Relaxation, imagery, music. Patients in Intervention group will receive standard care plus massage, relaxation, guided imagery and music listening
3020881|NCT02423252|No Intervention|Control|Patients in control group will receive standard care only. Same records and outcome measures with intervention group will apply for control group as well.
3020882|NCT02423239|Experimental|Relapsed or refractory advanced tumours|Patients with selected relapsed or refractory tumour types to receive single agent dexanabinol.
3020883|NCT02423239|Experimental|Newly diagnosed hepatocellular carcinoma|Patients with hepatocellular carcinoma to receive dexanabinol in combination with standard chemotherapy.
3020884|NCT02423239|Experimental|Newly diagnosed pancreatic cancer|Patients with pancreatic cancer to receive dexanabinol in combination with standard chemotherapy
3020885|NCT02423226|Active Comparator|CT alone|Treated with systemic chemotherapy alone (FOLFIRI).
3020886|NCT02423226|Experimental|CT+BT|Treated with systemic chemotherapy (FOLFIRI) plus computed tomography guided radioactive seeds implant.
3020887|NCT02423200|Experimental|VX-745 dose level 1|Active Group 1: VX-745 dose level 1 twice daily
3020888|NCT02423200|Experimental|VX-745 dose level 2|Active Group 1: VX-745 dose level 2 twice daily
3020889|NCT02423187||Arm 1|Participants with combination therapy (rabeprazole and low-dose aspirin)
3020890|NCT02423174||Total Mesorectal Excision|Patients with an indication for surgical intervention for a total mesorectal excision
3020891|NCT02423148|Experimental|FluoSCOPE device|"All study interventions will occur intraoperatively during the subject's planned surgery. No deviation from standard of care will be performed with the exception of the following specific interventions:-~Intraoperative injection of indocyanine green (ICG) around tumor and imaging with the FluoSCOPE NIR endoscopic imaging system~Treatment will be administered on an inpatient basis"
3020892|NCT02423135|Experimental|Blood bags without DEHP|Intervention : Autologous blood transfusion
3020893|NCT02423135|Experimental|Blood bags with DEHP|Intervention : Autologous blood transfusion
3020894|NCT02423122|Experimental|VX-745 dose 1|Active Group 1: VX-745 40 mg twice daily
3020895|NCT02423122|Experimental|VX-745 dose 2|Active Group 2: VX-745 125 mg twice daily
3020896|NCT02423109|Experimental|fanfilcon A|Each subject randomized to wear either the test or control as a matched pair and cross over to the second matched pair.
3020897|NCT02423109|Active Comparator|enfilcon A|Each subject randomized to wear either the test or control as a matched pair and cross over to the second matched pair.
3020898|NCT02423096||Schizophrenia|Patients with schizophrenia will be treated with antipsychotic drugs as routine care (i.e., risperidone, haloperidol, sulpiride, olanzapine, quetiapine).
3020899|NCT02423096||Healthy controls|No special intervention will be provided for healthy controls.
3020904|NCT02423005|Experimental|Neurotech Vital Compact|The Neurotech Vital Compact will be used by subjects with Stress Urinary Incontinence 5 days per week for 30 minutes per session for 12 weeks followed by 14 weeks of Kegel exercises.
3020905|NCT02423005|Active Comparator|itouch Sure Pelvic Floor Exerciser|The itouch Sure Pelvic Floor Exerciser will be used by subjects with Stress Urinary Incontinence 7 days per week for 20 minutes per session for 12 weeks followed by 14 weeks of Kegel exercises.
3020906|NCT02422992||PD|100 PD patients were patients diagnosed with Parkinson's disease
3020907|NCT02422992||Controls|242 Controls were subjects free of neurodegenerative diseases, matched by age and gender to the PD patients
3020908|NCT02422979|Experimental|Combination Study: RM-1929 & Photoimmunotherapy|RM-1929 & Photoimmunotherapy
3020909|NCT02422966|Experimental|Paracetamol|Paracetamol intravenous solution 15 mg/kg (corresponding to 1.5 ml/kg) per dose every 6 hours for 3 days, for a total amount of 12 doses.
3020910|NCT02422966|Active Comparator|Ibuprofen|Ibuprofen intravenous solution at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 5 mg/kg at 48 h.
3020911|NCT02422953|Experimental|Intervention|Wheat Soya Blend, Wawa Mum, Micronutrient Powders, Behavior change and preventive health massages
3020912|NCT02422953|No Intervention|Control|Control group will receive routine public and private health services available in the area.
3020913|NCT02422940|Active Comparator|dalfampridine-ER 7.5 mg|"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.~Subjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study."
3020914|NCT02422940|Active Comparator|dalfampridine-ER 10 mg|"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.~Subjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study."
3020915|NCT02422927|Placebo Comparator|Standard of Care + Placebo|low-cholesterol/low-saturated fat diet and a regular aerobic physical activity schedule + once daily placebo
3020916|NCT02422927|Active Comparator|Nutraceutical combination|low-cholesterol/low-saturated fat diet and a regular aerobic physical activity schedule + Nutraceutical combination
3020917|NCT02422914|Experimental|Nicotine|Smoking cessation program TFC and activity tracker. Three months low intensity counselling at distance program. Subject will also undergo a 3-months TFC (with nicotine) program; subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity tracker and ad-hoc items.
3020918|NCT02422914|Placebo Comparator|Nicotine-free|Smoking cessation program TFC-free and activity tracker. Three months low intensity counselling at distance program. Subject will also undergo a 3-months TFC (nicotine-free) program; subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity trackerand ad-hoc items.
3020919|NCT02422914|Active Comparator|No-cig|Smoking cessation program and activity tracker. Three months low intensity counselling at distance program;subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity tracker and ad-hoc items.
3020920|NCT02422901||Vit C deficiency in acute diseases|Patients with vitamin C deficiency due to a acute underlying disease treated with Pascorbin® 7.5 g
3020921|NCT02422901||Vit C deficiency in chronic diseases|Patients with vitamin C deficiency due to a chronic underlying disease treated with Pascorbin® 7.5 g
3020922|NCT02422888|Experimental|Ticagrelor|Ticagrelor 90 mg twice a day, tablet Duration: 1 year after PCI
3020923|NCT02422888|Active Comparator|Prasugrel|Prasugrel 10 mg once a day, tablet Duration: 1 year after PCI
3020924|NCT02422875||Healthy Controls|Subjects are healthy persons without any autoimmune conditions or infectious diseases
3020925|NCT02422875||Autoimmune Disease|Subjects diagnosed with autoimmune disease including but not limited to: Systemic Lupus Erythematosus (SLE), Sjögren's Syndrome (SS), Scleroderma, Myositis, Juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis (RA), inflammatory arthritis, undifferentiated connective tissue disease, idiopathic thrombocytopenic purpura (ITP), Graft vs Host Disease (GVHD), Autoimmune Lymphoproliferative Syndrome (ALPS) and IgG4-related disease
3020926|NCT02422875||Infectious Disease|Subjects diagnosed with an infectious disease including but not limited to: Hepatitis C, Epstein Barr Virus (infectious mononucleosis - EBV), Sepsis, Guillain-Barre syndrome (GBS), Mycoplasma pneumoniae or Human Immunodeficiency Virus (HIV)
3020927|NCT02422875||Autoimmune - Family|Subjects have a brother, sister, mother, father, or child with an autoimmune disease
3020928|NCT02422875||Vaccination|Subjects have received or will receive a vaccination as part of regular standard of care from their healthcare provider or other outside source
3020929|NCT02422862|Experimental|UC-TSM|Upper cervical translatoric spinal mobilization (UC-TSM). UC-TSM is a physical therapy technique used to improve range of movement, consisting on a manual stretching of the cervical spine of the patient during 30 minutes.
3020930|NCT02422862|No Intervention|Control|The control group receive no treatment intervention during 30 minutes (a similar time as the UC-TSM group).
3020931|NCT02422849|Other|own GP|The patient is cared for by own General Practitioner in the acute stage
3020932|NCT02422849|Other|Hospital specialist|The patient is cared for by a hospital specialist in the acute stage
3020933|NCT02422836|Experimental|Three Product Anti-Aging Regimen|"Three Product Anti-Aging Treatment Regimen:~Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks"
3020934|NCT02422823|Experimental|injection of 1.8mL|injections of 1.8 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
3020935|NCT02422823|Experimental|injection of 3.6mL|injections of 3.6 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
3020936|NCT02422810||No aspirin|Subjects who have not taken aspirin or other blood thinners in the previous 10 days
3020937|NCT02422810||Aspirin Daily|Subjects who have taken aspirin daily for the previous 10 or more days
3020939|NCT02422797|Active Comparator|CAR|Participants will receive CAR from Day 1 to Week 52 (Early Switch Phase), and eligible participants will switch to DTG 50 mg + RPV 25 mg once daily from Week 52 to 148 (Late Switch Phase).
3020940|NCT02422797|Experimental|DTG 50 mg + RPV 25 mg|Participants will receive DTG 50 mg + RPV 25 mg once daily from Day 1 through Week 148 (Early and Late Switch Phase).
3020941|NCT02422784|Placebo Comparator|Control|Participants will be instructed to consume 240 mL of iced-tea daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
3020942|NCT02422784|Active Comparator|Rooibos Tea - Vitamin D3|Participants will be instructed to consume 240 mL of iced-tea fortified with 1000 IU water-soluable vitamin D3 daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
3020943|NCT02422784|Active Comparator|Rooibos Tea- Vitamin D3 & Calcium|Participants will be instructed to consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water-soluable vitamin D3 and 360 mg of calcium daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
3020944|NCT02422771|No Intervention|Control group|Athletes in this group will continue with their usual warm-up for the duration of the indoor soccer season.
3020945|NCT02422771|Experimental|Intervention group|FIFA 11+ warm-up
3020946|NCT02422758|Experimental|Active Prewarming 3M™ BairHugger™Blanket|Patients will have the whole body covered with the3M™ Bair Hugger™ Preoperative & Outpatient Care Blanket of forced air warming system for 20 minutes, at average power.Tympanic temperature will be measured, through electronic infrared tympanic thermometer GENIUS 2. Patients will be warmed with 3M™ Bair Hugger™ Upper Body Blanket, during intraoperative period.
3020947|NCT02422758|Placebo Comparator|Passive Prewarming|Passive prewarming with a cotton sheet and blanket for 20 minutes. Tympanic temperature will be measured, through electronic infrared tympanic thermometer GENIUS 2. Patients will be warmed with 3M™ Bair Hugger™ Upper Body Blanket, during intraoperative period.
3020948|NCT02422745|Active Comparator|Cocoa extract + multivitamin|
3020949|NCT02422745|Active Comparator|Cocoa extract + multivitamin placebo|
3020950|NCT02422745|Active Comparator|Cocoa extract placebo + multivitamin|
3020951|NCT02422745|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|
3020952|NCT02422732|Other|Children with reading disability|Children with NF1, with reading disability if their performances on reading assessment (Alouette Test) present a delay of at least 18 months, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis
3020953|NCT02422732|Other|Children without reading disability|Children with NF1, without reading disability if their performances on reading assessment (Alouette Test) present a less than 18-month delay, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis.
3020954|NCT02422719|Experimental|Radotinib|Radotinib treatement single arm
3020955|NCT02422706|Active Comparator|group I|"Metronidazole(MTZ) 500mg twice daily ,Omeprazole 20 mg twice daily as (Proton Pump Inhibitor (PPI)& Clarithromycin 500 mg twice daily .for 14 days .~40 patients"
3020956|NCT02422706|Experimental|Group II|"Nitazoxanide(NTZ)500 mg twice daily ,PPI 20 mg twice daily & Clarithromycin 500 mg twice daily for 14 days.~40 patients."
3020957|NCT02422706|Experimental|Group III|"Levofloxacin 250 mg once daily,Omeprazole 40mg once daily(PPI),Nitazoxanide (NTZ) 500mg twice daily & Doxicycline 100 mg once daily (LOND).~40 patients"
3020958|NCT02422693|Experimental|Aquatic exercises|Warm-up, lumbar mobilization, stretching and relaxation. 3x-week (9 weeks), indoor pool, 32o.C/89.6o.F.
3020959|NCT02422693|Active Comparator|Aquatic exercises + Deep-water running|Same as AEG with addition of 20 minutes of running without touch the ground, 3x-week (9 weeks), indoor pool, 30o.C/86o.F.
3020960|NCT02422680||Patients referred to colonscopy|A min. of 500 patients referred to colonoscopy at Aalborg University Hospital. The 500 patients are from the out patient clinic. A mix of screening and non-screening patients.
3020961|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle A|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
3020962|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle B|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
3020963|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle C|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
3020964|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle D|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
3020965|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle E|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
3020966|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle A|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
3020967|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle B|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
3020968|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle C|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
3020969|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle D|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
3020970|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle E|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
3020971|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle A|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
3020972|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle B|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
3020973|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle C|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
3020974|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle D|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
3020975|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle E|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
3020976|NCT02422641|Experimental|High-dose Methotrexate (8 gm/m2; HD-MTX)|Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
3020977|NCT02422628||EGFR mutation postive|Blood samples every 3 months till disease progression or intolerable due to side effect.
3020978|NCT02422628||EGFR mutation wild type|Blood samples before treatment once.
3020979|NCT02422628||Healthy Volunteers|Blood samples once.
3020980|NCT02422615|Experimental|Ribociclib + fulvestrant|Riblociclib 600mg daily oral (days 1 to 21 in a 28-day Cycle) in combination with fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
3020981|NCT02422615|Placebo Comparator|Ribociclib placebo + fulvestrant|Riblociclib placebo 600mg daily oral (days 1 to 21 in a 28-day Cycle) in combination with fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
3020982|NCT02422602|Active Comparator|Taking conventional charge|No further information is given to the patient during the first and only contact with the nurse of the coordinator center. A time will be dedicated by the IDE to answer questions of the patient.
3020983|NCT02422602|Experimental|Personalized information intervention|The intervention of personalized information will be made as appropriate to the patient's needs and will include: Personalized telephone information carried by a nurse trained in therapeutic education. A time will be dedicated by the IDE to answer questions of the patient. The delivery of paper documents, a list of recommended websites and phone remote monitoring will be performed by the nurse at J30 and J45 to check understanding of the information provided, the actual reading of the paper documents, or effective consultation of websites. A time will be dedicated by the IDE to answer questions at the remote monitoring of the patient to J30 and J45.
3020984|NCT02422589|Experimental|Ceritinib|
3020985|NCT02422576|Active Comparator|Control + Product 1|Control product (Thicken Up clear: TUC) + natural ingredient 1 (cinnamon extract)
3020986|NCT02422576|Active Comparator|Control + Product 2|Control product (Thicken Up clear: TUC) + natural ingredient 2 (lemon extract)
3020987|NCT02422576|Active Comparator|Control + Product 3|Control product (Thicken Up clear: TUC) + natural ingredient 3 (lemon extract+eucalyptus extract)
3020988|NCT02422563|Experimental|Arm A: NACT+radical hysterectomy|Arm A includes patients for dose dense chemotherapy using TP (paclitaxel, carboplatin) or TIP (cisplatin, paclitaxel, ifosfamide) weekly for six cycles. Radical hysterectomy is performed after the 6th week + lymphadenectomy
3020989|NCT02422563|Other|Arm B: Chemoradiation|Arm B includes patients undergoing primary cisplatin based chemo-radiation
3020990|NCT02422550||participants undergoing radiation therapy & normal volunteers|
3020991|NCT02422537|Active Comparator|Unmodified wheat bran|One single dose om 20 g
3020992|NCT02422537|Active Comparator|Wheat bran with reduced particle size|One single dose of 20 g
3020993|NCT02422537|Active Comparator|Destarched pericarp-enriched wheat bran|One single dose of 20 g
3020994|NCT02422537|Other|No bran-based dietary platform|No wheat bran fractions is administered
3020995|NCT02422524|Experimental|Child-Pugh A (Mild hepatic impairment)|6 Subjects will receive a single oral dose of 200mg PA-824 tablets on day 1
3020996|NCT02422524|Experimental|Child-Pugh B (Moderate hepatic impairment)|6 Subjects will receive a single oral dose of 200mg PA-824 tablets on day 1
3020997|NCT02422524|Experimental|Child-Pugh C (Severe hepatic impairment)|6 Subjects will receive a single oral dose of 200mg PA-824 tablets on day 1
3020998|NCT02422524|Experimental|Non-hepatically impaired controls|18 matched Subjects will receive a single oral dose of 200mg PA-824 tablets on day 1
3020999|NCT02422511|Other|Well Infant Cohort, No Sequencing|Healthy infants and their parents enrolled through the Brigham and Women's Hospital (BWH) Well Newborn Nursery who are randomized not to receive sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, and any potentially medically relevant findings from the baby's medical history/physical exam.
3021000|NCT02422511|Other|Well Infant Cohort, Sequencing|Healthy infants and their parents enrolled through Brigham and Women's Hospital (BWH) Well Newborn Nursery who are randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby's medical history/physical exam, and the results of the genomic sequencing report.
3021001|NCT02422511|Other|Sick Infant Cohort, No Sequencing|Infants and their parents enrolled through Boston Children's Hospital (BCH) and the BWH Neonatal Intensive Care Unit who are randomized not to receive sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, and any potentially medically relevant findings from the baby's medical history/physical exam.
3021002|NCT02422511|Other|Sick Infant Cohort, Sequencing|Infants and their parents enrolled through Boston Children's Hospital and the BWH Neonatal Intensive Care Unit who are randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby's medical history/physical exam, and the results of the genomic sequencing report.
3021003|NCT02422498|Experimental|Concurrent Cisplatin & Radiation Therapy|
3021004|NCT02422485|Experimental|Salsalate|All participants will be administered 2,250 mg daily [1,500 mg every day before noon (every AM) and 750 mg every night at bedtime (every HS)] for 6 months.
3021005|NCT02422472|No Intervention|Standard|Standard of care ultrasound guided peripheral IV placement
3021006|NCT02422472|Experimental|Experimental|Ultrasound guided peripheral IV placement with the use of a guidewire
3021007|NCT02422459|Experimental|COMMENCE|ChrOnic pain self-ManageMent support with pain science EducatioN and exerCisE (COMMENCE)
3021008|NCT02422459|No Intervention|Wait-list control|No treatment assigned
3021216|NCT02421107|Other|all patients|all patients
3021009|NCT02422446|Experimental|EPA arm|EPA arm will receive 4 grams per day of EPA (icosapent ethyl) taken twice a day
3021010|NCT02422446|No Intervention|Control|Control group will not receive EPA
3021011|NCT02422433|Experimental|OFDI Capsule Marking and Imaging|Subject will swallow the OFDI capsule, marking will be performed by making superficial cautery marks on the tissue. This will be followed by imaging using the OFDI Imaging system.
3021012|NCT02422420|Experimental|Individual Incentive|Participants receive a financial incentive every time they attend a class session and goal-based incentives for attending 75% of Core sessions, 75% of Post-Core sessions, separately achieving 5%, 7%, and 10% weight loss during the Core period (i.e. separate financial incentives for each goal reached at any point during the Core period), and 5%, 7%, or 10% weight loss by the end of Post-Core Session 8 (i.e., one financial incentive based on final weight loss).
3021013|NCT02422420|Experimental|Group Incentive|This arm receives the same routine attendance incentives as the Individual Incentive arm. Group goal-based incentives include 5% weight loss by an individual during the Core period and, separately, during the Post-Core period. Financial incentives are also received if the entire DPP group achieves 75% Core session attendance, 75% of Post-Core session attendance, 7% or 10% weight loss from baseline during the Core, and 7% or 10% weight loss from baseline at the end of the Post-Core period.
3021014|NCT02422420|Other|Minimal Incentive|Participants receive the full Diabetes Prevention Program (DPP), but receive a nominal $25 financial incentive for attendance only at the first DPP session and no other incentives for attendance or weight loss.
3021015|NCT02422407||Subgroup 1|Healthy Volunteers - subset of which 10 will receive salivary gland biopsy.
3021016|NCT02422407||Subgroup 2|Diagnosis of pSS based on the criteria of the American-European Consensus Criteria for Sjögren's Syndrome (AECCSS) with positive biopsy result.
3021017|NCT02422407||Subgroup 3|Diagnosis of pSS based on the criteria of the American-European Consensus Criteria for Sjögren's Syndrome (AECCSS) with negative biopsy result.
3021018|NCT02422407||Subgroup 4|Presenting with sicca but not satisfying the criteria of the AECCSS for diagnosis of pSS.
3021019|NCT02422394|Experimental|Eltrombopag|"Phase 1: Eltrombopag 50 mg/day for 3 weeks. At the end of these 3 weeks of treatment: platelet count higher than 100 x10e9/L and no spontaneous bleeding, end therapy. In the other cases, treatment with eltrombopag 75 mg/day for 3 additional weeks.~Phase 2: Eltrombopag will be administered for 16 weeks. Eltrombopag will be initially given at 25 mg/day for 4 weeks. Every 4 weeks, the dosage will be modified as follows. (1) Bleeding score (WHO bleeding scale) 0-1 and platelet count between 30 and 100 x10e9/L: continue at the current dose; (2) Bleeding score 0-1 and platelet count higher than 100 x10e9/L: switch to the next lower dose; (3) Bleeding score 2-4 or platelet count lower than 30 x 10e9/L: switch to the next higher dose. The following dosages of eltrombopag are considered: 12.5 mg/day; 25 mg/day; 50 mg/day; 75 mg/day."
3021020|NCT02422381|Experimental|MK-3475 + Gemcitabine|200mg MK-3475 200 given by IV infusion every 3 weeks, for 2 years, or until disease progression and Gemcitabine 1250 mg/m2 iv Days 1, 8 every 3 weeks, for maximum 6 cycles.
3021021|NCT02422368|Experimental|Methylprednisolone + ASTED|"ASTED (Antioxidant Supplements for Thyroid Eye Disease) includes : B-Carotene (6 mg)+ Vit.C (200 mg) + Vit.E (200 mg) + Nicotinamide(20mg) + Selenium(200mic.) + Zinc oxide (8 mg) + Copper gluconate or oxide (1mg) + Manganese chloride (1.8 mg), Twice a day for 6 months~Methylprednisolone includes :~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow up."
3021022|NCT02422368|Placebo Comparator|Methylprednisolone + Placebo|Placebo Twice a day for 6 months Methylprednisolone prescribes as the same as arm 1
3021023|NCT02422355||Femoral Neck Fractures AO/OTA 31-B1:3|Fixation using the implant FNS.
3021024|NCT02422329|Experimental|Educational Video|Participants complete self-administered numerical rating scale (NRS) constipation questionnaire at baseline. Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements. Participants then complete three self-administered questionnaires, post-educational material, Modified Rome III questionnaire, and Overall satisfaction of the educational material.
3021025|NCT02422329|Experimental|Fact Sheet|Participants complete self-administered numerical rating scale (NRS) constipation questionnaire at baseline. Participants read educational material describing symptoms of constipation and importance of regular bowel movements. Participants then complete three self-administered questionnaires, post-educational material, Modified Rome III questionnaire, and Overall satisfaction of the educational material.
3021026|NCT02422303|Active Comparator|Ketamine Group|This group will receive ketamine 0.5mg/kg IV at induction of general anesthesia.
3021027|NCT02422303|No Intervention|No ketamine group|This group will not receive ketamine at induction of general anesthesia.
3021028|NCT02422290|Experimental|Adolescents and young adults with OCD|All participants will be receive the intravenous ketamine infusion.
3021029|NCT02422277|Active Comparator|LI-ESWT group|Intervention include that patients will undergo penile low-intensity extracorporeal shock wave therapy, 6-12 sessions, 1500 shocks per session, two sesssions per week for 3 weeks then 3 weeks break and then 2 sessions per week for 3 weeks.
3021030|NCT02422277|Active Comparator|PDE-5 inhibitors group|"Intervention include that patients will intke oral tablets of PDE-5 inhibitors :~- Oral intake of 50 mg once daily for 6 months."
3021031|NCT02422277|No Intervention|Control group|Patients will be only followed up without any therapy for assisting erection.
3021032|NCT02422264|Experimental|Boostrix Group|This group will consist of infants born to mothers belonging to the dTpa Group in study 116945 [DTPA (BOOSTRIX)-047] i.e. who received a single dose of BoostrixTM during pregnancy and a dose of placebo immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.
3021033|NCT02422264|Active Comparator|Control Group|This group will consist of infants born to mothers belonging to the Control group in study 116945 [DTPA (BOOSTRIX)-047], i.e. who received a single dose of placebo during pregnancy and a dose of BoostrixTM immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.
3021217|NCT02421094|Active Comparator|GR-MD-02|Active
3021218|NCT02421094|Placebo Comparator|Placebo|Placebo
3021034|NCT02422251|Experimental|Mobile high congruency bearing|Device B Braun Columbus total knee system using a rotating platform tibia and high congruency mobile bearing.
3021035|NCT02422251|Experimental|Fixed high congruency bearing|Device B Braun Columbus total knee system using a fixed tibial platform and high congruency bearing.
3021036|NCT02422251|Experimental|Fixed low congruency bearing|Device B Braun Columbus total knee system using a fixed tibial platform and low congruency bearing.
3021037|NCT02422251|No Intervention|Control|Healthy control group
3021038|NCT02422225|Experimental|Eldith DC-STIMULATOR group|"Intervention:~20-minutes of transcranial Direct Current Stimulation (tDCS) application 5 days a week for 2 weeks (30 applications for each 3 groups: total 90 applications)"
3021039|NCT02422225|Sham Comparator|sham-Eldith DC-STIMULATOR group|Intervention: 20-minutes of sham-tDCS application 5 days a week for 2 weeks (total 30 applications)
3021040|NCT02422212|Active Comparator|healthy weight group|Postop RYGBP patients who underwent surgery at least 2 years previously and have healthy weight (at least 50% loss of excess weight) (HW group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
3021041|NCT02422212|Other|Obese group|Clinically severe obese patients (Body Mass Index greater than 40 kg/m2, without co-morbidities and greater than 35 kg/m2 with co-morbidities) (OB group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
3021042|NCT02422212|Active Comparator|weight regain group|Patients who suffered weight regain after RYGBP (at least 10% above the minimum weight after surgery and less than 50% loss of preop excess weight) (WR group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
3021043|NCT02422199|Experimental|pyrotinib plus capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
3021044|NCT02422199|Active Comparator|lapatinib plus capecitabine|lapatinib (1250 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
3021045|NCT02422186|Experimental|Intranasal Esketamine plus Oral Antidepressant|Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase. All participants will start with first dose (Day 1 as 28 milligram [mg]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability. In addition participants will simultaneously initiate a new, open-label oral antidepressant (Duloxetine, Escitalopram, Sertraline, or Venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
3021046|NCT02422186|Active Comparator|Placebo plus Oral Antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in Double-Blind Induction Phase using the same titration as Esketamine. In addition participants will simultaneously initiate a new, open-label oral antidepressant (Duloxetine, Escitalopram, Sertraline, or Venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
3021047|NCT02422173|Experimental|Anodal tDCS|Participants in the acute post-stroke stage will receive anodal transcranial direct current stimulation
3021048|NCT02422173|Experimental|Cathodal tDCS|Participants in the acute post-stroke stage will receive cathodal transcranial direct current stimulation
3021049|NCT02422173|Experimental|Bilateral tDCS|Participants in the acute post-stroke stage will receive bilateral transcranial direct current stimulation
3021050|NCT02422173|Sham Comparator|Sham tDCS|Participants in the acute post-stroke stage will receive sham transcranial direct current stimulation
3021051|NCT02422147||Ablation of PCL|Patients with pancreatic cysts will undergo ablation using alcohol under EUS-guidance
3021052|NCT02422134|Active Comparator|Cytokine plus Hyalurinan embryo transfer arm|To monitor the pregnancy and implantation of the patients in this arm after adding Cytokine to the embryo transfer medium.
3021053|NCT02422134|No Intervention|Hyalurinan embryo transfer group|To transfer the embryos using a Hyaluronan enriched medium only
3021054|NCT02422121|Experimental|RNS60|RNS60, 4 ml twice daily
3021055|NCT02422121|Placebo Comparator|Placebo|Normal Saline, 4 ml twice daily
3021056|NCT02422108|Experimental|intervention|Denosumab (Prolia) 60 mg s.c.
3021057|NCT02422095||EUS of pancreatic cyst lesions|Data collected for this registry will include patient demographics, procedural indications, EUS features of pancreatic cyst, Fine needle aspiration and pathology details, complications, outcomes and follow-up.
3021058|NCT02422082|Active Comparator|L. reuteri|Lactobacillus reuteri (L. reuteri) ATCC PTA 6475 at a dose of 5 000 000 000 CFU as a powder in a stick-pack, orally twice daily (morning and evening) yielding a total daily dose of 10 000 000 000 CFU per day, for 12 months.
3021059|NCT02422082|Placebo Comparator|Placebo|Placebo product identical to the active product (L. reuteri) in taste and appearance but without the active component, orally twice daily, for 12 months.
3021060|NCT02422069||Study Population|Gynecology outpatients who meet eligibility criteria will be enrolled and evaluated for the presence of PMO at screening. Women diagnosed with PMO will complete an additional visit to document the prescribed management plan.
3021061|NCT02422056|Placebo Comparator|Placebo|Saline infusion: Group receiving saline as placebo during the surgical procedure
3021062|NCT02422056|Experimental|Intervention|Tranexamic acid infusion: Group that received a Tranexamic acid bolus of 10mg / kg, followed by continuous infusion of 1 mg / kg / hr until the end of the procedure.
3021063|NCT02422043|Experimental|type 1 diabetes adolescents cohort|The participants of the prospective cohort of adolescents will be 12 to 17 years of age, type 1 diabetics with insulin, included in TPE program
3021064|NCT02422030|Experimental|Group1: TreatmentA+TreatmentB+TreatmentC|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
3021065|NCT02422030|Experimental|Group2: TreatmentC+TreatmentA+TreatmentB|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
3021295|NCT02420561|Experimental|Motivational Interviewing|"The motivational interviewing (MI) intervention consisted of one 45-minute in-person MI session followed by two 15-minute telephone booster sessions"
3021066|NCT02422030|Experimental|Group3: TreatmentB+TreatmentC+TreatmentA|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
3021067|NCT02422030|Experimental|Group4: TreatmentC+TreatmentB+TreatmentA|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
3021068|NCT02422030|Experimental|Group5: TreatmentB+TreatmentA+TreatmentC|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
3021069|NCT02422030|Experimental|Group6: TreatmentA+TreatmentC+TreatmentB|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
3021070|NCT02422017|Experimental|Timolol|Patients will receive one drop of timolol every 6cm ² every other day for twelve weeks in combination with dressings and compression.
3021071|NCT02422017|Other|Control|Local care treatment only (dressing and compression applied every other day)
3021072|NCT02422004|Active Comparator|Control|This constitutes the currently accepted regime and is therefore consider the control group (CTRL) with early range of motion and early weight bearing. The control group was allowed to have partial weight-bearing from day 0 and full weight-bearing from week 4. Furthermore, they were instructed in tendon strain exercise identical with the range of motion group.
3021073|NCT02422004|Experimental|Range of motion|Early range of motion and delayed weight bearing (ROM). The range of motion group was restricted completely from weight-bearing until week 6, allowed partial weight-bearing after 6 weeks and full weight-bearing after 8 weeks. In addition to this, the patients were instructed to perform tendon strain exercises, five times a day, from week 2. The exercises were performed by removing the foot from the brace and then perform light dorsal ankle movement, 25 repetitions/time, when sitting on a table.
3021074|NCT02422004|Experimental|Immobilization|Delayed weight-bearing or range of motion (IMMOB). The immobilization group was restricted completely from weight-bearing until week 6, allowed partial weight-bearing after 6 weeks and full weight-bearing after 8 weeks.
3021075|NCT02421991|Experimental|TALK study group|This is the experimental arm of the study. This includes 5 weekly sessions of experimental therapy via telephone. Therapy description withheld to protect the integrity of the study.
3021076|NCT02421991|Active Comparator|TALK control group|This is the control arm of the study. This includes 5 weekly sessions of control therapy via telephone.Therapy description withheld to protect the integrity of the study.
3021077|NCT02421978||Chemotherapy-treated breast cancer group|Female subjects with Stage I-III breast cancer treated with chemotherapy will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
3021078|NCT02421978||Non-Chemotherapy-treated breast cancer group|Non-chemotherapy treated female subjects with Stage I-III breast cancer will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
3021079|NCT02421978||Control group|Age and race-matched healthy women will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
3021080|NCT02421965|Experimental|FOCUS (Smartphone Application)|FOCUS is a smartphone application system designed to improve illness self-management and facilitate recovery in individuals with serious mental illness. It delivers both system initiated (i.e. pre-programmed) and patient initiated (i.e. on demand) real-time assessment to individuals in their own environment.
3021081|NCT02421965|Active Comparator|WRAP (Wellness Recovery Action Planning)|WRAP is a clinic-based intervention designed to improve illness self-management and facilitate recovery in individuals with serious mental illness. It is conducted in group sessions that are delivered by trained facilitators with lived experience, using lecture, group discussion, and exercises.
3021082|NCT02421952||BARF Scale|an instrument used to measure nausea in children
3021083|NCT02421952||Visual Analog Scale (VAS)|an Instrument used to measure nausea
3021084|NCT02421939|Experimental|ASP2215|Administered once daily
3021085|NCT02421939|Active Comparator|Salvage chemotherapy|Options for salvage chemotherapy are limited to the following: Low- Dose Cytarabine (LoDAC), Azacitidine, MEC Induction Chemotherapy, FLAG-IDA Induction Chemotherapy
3021086|NCT02421926||IDEAL-E observational group|Subjects who were newly diagnosed as chronic phase chronic myelogenous leukemia, were enrolled to 'IDEAL' study, finished the total study period of 'IDEAL' study or were dropped during the study period.
3021087|NCT02421913|Active Comparator|S(+)-ketamine group (SG)|Five minutes before surgery, patients in the SG group received an intravenous continuous infusion containing 0.3 mg.kg-1.h-1 of S(+)-ketamine
3021088|NCT02421913|Placebo Comparator|placebo group (PG)|PG received the same dose of saline.
3021089|NCT02421900||group 1|Atrial fibrillation patients
3021090|NCT02421887|Active Comparator|Antioxidant Supplement|Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
3021091|NCT02421887|Placebo Comparator|Placebo|
3021092|NCT02421874|Experimental|Use of electronic health record / outcomes monitoring|Use of electronic health record / outcomes monitoring via a specified electronic behavioral health information system
3021093|NCT02421874|Active Comparator|education about outcomes monitoring|Care coordination as usual with education about fidelity and outcomes monitoring but no use of EBHIS
3021094|NCT02421861|Experimental|Anxiety Management (AM)|
3021095|NCT02421861|Placebo Comparator|Usual Care (UC)|
3021096|NCT02421848||Cirrhotic Patients With Ascites|Cirrhotic Patients With Ascites
3021097|NCT02421835|Placebo Comparator|Placebo control|2 capsules of 350 mg maltodextrin to be consumed daily for 12 weeks
3021098|NCT02421835|Active Comparator|Olive leaf extract|2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily for 12 weeks
3021099|NCT02421835|Placebo Comparator|Physical activity|2 capsules of 350 mg maltodextrin to be consumed daily combined with gradually increase physical activity levels over 12 weeks
3021100|NCT02421835|Active Comparator|Physical activity and olive leaf extract|2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily combined with gradually increase physical activity levels over 12 weeks
3021101|NCT02421822|Experimental|Fitwits Intervention|Fitwits office tool and games
3021102|NCT02421809||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
3021103|NCT02421809||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group.
3021104|NCT02421809||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group.
3021105|NCT02421796||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
3021106|NCT02421796||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group.
3021107|NCT02421796||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group.
3021108|NCT02421783||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
3021109|NCT02421783||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group
3021110|NCT02421783||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group
3021111|NCT02421770|Experimental|Experimental Chamaemelum Nobile|"Experimental Chamaemelum Nobile 2% gel During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel twice daily with occlusion on the affected are"
3021112|NCT02421770|Placebo Comparator|Placebo|During the 6-week double-blind phase, all patients will be randomly assigned to receive vehicle ( placebo)twice daily with occlusion on the affected are
3021113|NCT02421757|Experimental|Transcutaneous Magnetic Stimulation|Transcutaneous Magnetic Stimulation
3021114|NCT02421757|Placebo Comparator|Sham|Sham
3021115|NCT02421744|Experimental|Task Oriented Circuit Training|TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
3021116|NCT02421744|Active Comparator|Delayed Onset TOCT|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
3021117|NCT02421731|Experimental|Robot-assisted gait training|This group will receive rehabilitation treatment based on robot-assisted gait training.
3021118|NCT02421731|Active Comparator|Conventional therapy|This group will receive conventional rehabilitation therapy.
3021119|NCT02421705|Other|Sample collection|Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
3021120|NCT02421692|No Intervention|Usual Care|SNF rehabilitation therapists provide all patients with usual standard of care.
3021121|NCT02421692|Experimental|Progressive Rehabilitation|SNF rehabilitation therapists have been trained on principles of progressive rehabilitation strategies and will implement to all eligible patients as new standard of care.
3021122|NCT02421679|Experimental|TNX-102 SL|TNX-102 SL taken daily at bedtime for 12 weeks
3021123|NCT02421666|Experimental|behavioral PNMI|eligible patients will receive patient navigator led plus mobile phone text messaging intervention(PNMI) or standard care. Bilingually trained patient navigators will be recruited from our existing patient navigator training network and receive intensive training on HBV prevention, diagnosis and treatment management. The PN-led plus mobile phone text messaging intervention will offer three education sessions and serve as a liaison with respective clinics. The phone-based, text messaging will be designed by and for HBV patients who will craft appropriate reminders for follow up appointments or treatment, educational and motivational messages
3021124|NCT02421666|No Intervention|control|eligible chronic HBV patients will receive usual care
3021125|NCT02421653|Experimental|MNP90 + INERT OIL|Daily micronutrient powders (14 micronutrients) containing 90 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;
3021126|NCT02421653|Experimental|MNP45 + INERT OIL|Daily micronutrient powders (14 micronutrients) containing 45 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;
3021127|NCT02421653|Experimental|IODISED OIL + INERT MNP|Daily inert powder (maltodextrin, no micronutrients) plus one oral dose of 200 mg iodine as iodised poppy seed oil at the study start
3021128|NCT02421653|Active Comparator|NON-IODISED MNP + INERT OIL|Daily micronutrient powders (14 micronutrients) without iodine plus one inert oil capsule without iodine at the study start.
3021129|NCT02421640|Experimental|Cisplatin+TIL|Cisplatin concurrent chemoradiotherapy(CCRT) combined with tumor-infiltrating lymphocyte (TIL)
3021130|NCT02421640|Active Comparator|Cisplatin|Cisplatin concurrent chemoradiotherapy(CCRT) only
3021272|NCT02420730|Placebo Comparator|Cohort 1: AGN-232411 Vehicle|One drop of Vehicle for AGN-232411 topical ophthalmic solution administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants.
3021131|NCT02421627|Experimental|Moxibustion group|Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral);using mild-warm moxibustion，keep transcutaneous temperature maintained at 43 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks of moxibustion treatment. After the treatment, subjects were followed up in the 12 weeks and 18 weeks.
3021132|NCT02421627|Placebo Comparator|Placebo moxibustion group|Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral);using mild-warm moxibustion，keep transcutaneous temperature maintained at 37 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks of moxibustion treatment. After the treatment, subjects were followed up in the 12 weeks and 18 weeks.
3021133|NCT02421614|Experimental|high olive oli|A high fat (45%) low carbohydrate (35%) enteral feeding will be administered to acute respiratory failure patients. The percentage of olive oil will be half of total fat.
3021134|NCT02421614|Experimental|high sunflower oil|A high fat (45%) low carbohydrate (35%) enteral feeding will be administered to acute respiratory failure patients. The total fat will be sunflower oil.
3021135|NCT02421614|No Intervention|kitchen formula|A high protein kitchen diet for tube feeding will be administered to acute respiratory failure patients.
3021136|NCT02421601|Experimental|SI-6603|SI-6603: SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
3021137|NCT02421588|Experimental|Arm A|lurbinectedin (PM01183)
3021138|NCT02421588|Active Comparator|Arm B|"pegylated liposomal doxorubicin~OR~topotecan"
3021139|NCT02421575|Experimental|Group I, Arm I (lower dose hydroxychloroquine)|Patients receive hydroxychloroquine PO QD for 14 days and then undergo prostatectomy.
3021140|NCT02421575|Experimental|Group I, Arm II (higher dose hydroxychloroquine)|Patients receive hydroxychloroquine PO TID for 14 days and then undergo prostatectomy.
3021141|NCT02421575|Experimental|Group II (mid-dose hydroxychloroquine)|Patients receive hydroxychloroquine PO QD. Treatment continues until the beginning of local therapy or for up to 1 year.
3021142|NCT02421562|Experimental|training in hypnoanalgesia|training nurses in hypnoanalgesia to perform painful procedure in children
3021143|NCT02421549|Active Comparator|Interrogation with unpaired remote monitoring transmitter|Interrogation with unpaired remote monitoring transmitter Interrogation with an unpaired remote monitoring transmitter for devices that are compatible.
3021144|NCT02421549|No Intervention|Interrogation with Programmer|Interrogation with programmer Interrogation with programmer according to usual standard of care
3021145|NCT02421536|Experimental|Vibrent Smartphone Application|"We propose to pilot the application of the mobile application VibrentTM (research procedure) during a course of head and neck radiotherapy for eligible study subjects. Study subjects will be prospective consented and enrolled and will have baseline out of clinic assessment with the Vibrent smartphone application (research procedure)."
3021146|NCT02421523|Experimental|Aim 2 Exercise group|The 10 subjects randomized to the experimental group will participate in an isometric exercise strengthening intervention of the knee extensor and knee flexor muscles in both legs with a frequency of ~three times/week for 12 weeks.
3021147|NCT02421523|Active Comparator|Aim 2 Control group|The 10 subjects randomized to the control group will not participate in any exercise program during the 12 weeks and will be instructed to continue with their normal activities.
3021148|NCT02421523|Experimental|Aim 1 Exercise Dosing|In order to implement a pilot home exercise intervention, the dose response and safety of this intervention must first be determined. We will enroll 12 boys with DMD for this aim and testing will be performed on the right leg.
3021149|NCT02421510|Experimental|Treatment A|High dose Sotagliflozin (fasted conditions)
3021150|NCT02421510|Experimental|Treatment B|Low dose Sotagliflozin (fasted conditions)
3021151|NCT02421510|Placebo Comparator|Treatment C|Placebo (fasted conditions)
3021152|NCT02421497||Normal Healthy Volunteer|
3021153|NCT02421497||Non-CKD Control|
3021154|NCT02421497||Chronic Kidney Disease (CKD)|
3021155|NCT02421497||Dialysis Patients|
3021156|NCT02421497||Renal Transplant Recipients|
3021157|NCT02421484|Experimental|allogeneic mesenchymal stromal cells|This is a Phase 1 dose escalation clinical trial that constitutes 3 dose cohorts with 3 participants per cohort who will receive intravenous doses of allogeneic bone marrow derived allogeneic mesenchymal stromal cells--0.3 million cells/kg, 1.0 million cells/kg, and 3.0 million cells/kg. We will proceed from the lower dose to the next higher dose if there are no safety concerns for each cohort.
3021158|NCT02421471||Ingenol mebutate treatment cohort|Patients who are prescribed ingenol mebutate gel for the first time by investigator's medical judgment.
3021159|NCT02421458|Active Comparator|arm 1: 6 fractions of radiation|radiation in a 6 fractions scheme and a daily dose of 6 Gy
3021160|NCT02421458|Active Comparator|arm 2: 16 fractrions of radiation|radiation in a 16 fractions scheme and a daily dose of 3.125 Gy
3021161|NCT02421432|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
3021162|NCT02421419|Active Comparator|Corticosteroid alone (CS) Group|1 cc dexamethasone sodium phosphate (4mg/ml) injectable
3021163|NCT02421419|Active Comparator|Corticosteroid/Lidocaine (CSL) Group|1 cc dexamethasone sodium phosphate (4 mg/ml) injectable and 1 cc 1% Xylocaine (lidocaine) injectable
3021164|NCT02421419|Active Comparator|Corticosteroid/Saline (CSS) Group|1 cc dexamethasone sodium phosphate (4mg/ml) injectable and 1 cc 0.9% injectable Sodium Chloride (saline)
3021165|NCT02421406|Experimental|Internet Behavioral Intervention|Participants receive a 12-week Internet-based eating and activity intervention including multimedia lessons and enhanced self-monitoring of weight loss behaviors with automated feedback
3021166|NCT02421406|Active Comparator|Internet Education Intervention|Participants receive 12 weekly Internet-based weight loss lessons containing information for modification of diet and activity behaviors, but not behavioral strategies for changing these behaviors.
3021167|NCT02421393|Experimental|Exercise|Supervised exercise training on top of standard care (exercise, EXE, group; n=100)
3021168|NCT02421393|No Intervention|Control|Standard care including advises to maintain a physically active lifestyle, according to current guidelines, by performing any type of commuting, occupational, home and and leisure-time physical activity (PA) (control, CON, group; n=100).
3021296|NCT02420561|Active Comparator|Control|Participants received a brochure on alcohol and drug use risks.
3021169|NCT02421380|Experimental|Hyperpolarized Pyruvate MRI Reproducibility|This is a reproducibility study of hyperpolarized [1-13C] pyruvate MRI in patients with solid tumors. A total of 100 patients will be enrolled, 50 of whom will be imaged using 1D MR spectroscopy and the other 50 with 3D imaging sequence.
3021170|NCT02421367|Experimental|TDENV-PIV (0-1)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 0 and Day 28. The placebo will be administered on Day 84 and Day 168."
3021171|NCT02421367|Experimental|TDENV-PIV (0-1-6)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 0, Day 28, and Day 168. The placebo will be administered on Day 84."
3021172|NCT02421367|Experimental|TDENV-PIV (0-3)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 84 and Day 168. The placebo will be administered on Day 0 and Day 28."
3021173|NCT02421354|Experimental|Nivolumab|Nivolumab 3 mg/kg given by vein every 2 weeks for 8 doses followed by a maintenance regimen of one dose every 12 weeks. Quality of life questionnaire routinely completed from baseline and thereafter.
3021174|NCT02421341|Experimental|Drug - Fentanyl|Study visit 1 you will be asked to get a blood draw, DEXA bone scan, perform pulmonary function tests, and exercise on a stationary bike at maximal exertion while breathing into a mouth piece. Study visits 2 and 3 you will be asked to again exercise at maximal exertion while breathing into a mouth piece. During these two visits you will be receiving an intrathecal injection of either fentanyl or placebo, randomly selected and you will be blinded as to which you are receiving. Catheters will also be placed in an artery in your arm and a vein in your leg, helping us to measure blood flow, blood pressure and draw blood. You will also perform a chemosensitivity test, breathing in and out your own air, after you are done exercising.
3021175|NCT02421341|Placebo Comparator|Placebo|Study visit 1 you will be asked to get a blood draw, DEXA bone scan, perform pulmonary function tests, and exercise on a stationary bike at maximal exertion while breathing into a mouth piece. Study visits 2 and 3 you will be asked to again exercise at maximal exertion while breathing into a mouth piece. During these two visits you will be receiving an intrathecal injection of either fentanyl or placebo, randomly selected and you will be blinded as to which you are receiving. Catheters will also be placed in an artery in your arm and a vein in your leg, helping us to measure blood flow, blood pressure and draw blood. You will also perform a chemosensitivity test, breathing in and out your own air, after you are done exercising.
3021176|NCT02421328|Active Comparator|CPAP first|Infant will be given nasal CPAP for 60 minutes and then put on HHHFNC for another 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on nasal CPAP and HHHFNC. After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
3021177|NCT02421328|Active Comparator|HHHFNC first|Infant will be given HHHFNC for 60 minutes and then switched to nasal CPAP for another 30 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on HHHFNC and nasal CPAP. After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
3021178|NCT02421315|Experimental|OCD|Participants will have a current diagnosis of OCD.
3021179|NCT02421302|No Intervention|Well-nourished HIV+ ART naive|These children aged between 6months-12years will be followed up for 12weeks to look at their nutrition, immune and pharmacological responses. They will receive routine nutritional and ART adherence counseling
3021180|NCT02421302|Active Comparator|Moderately-malnourished HIV+; RUTF|These children aged between 6months - 12years, ART naive or experienced, will be initiating ready-to-use-therapeutic(RUTF) food and will be followed up for 12 weeks to see the effect of nutrition supplementation on immune and pharmacological responses
3021181|NCT02421302|Active Comparator|Severely acute-malnourished HIV+; RUTF|These children aged between 6months - 12years, ART naive or experienced, will be initiating ready-to-use-therapeutic(RUTF) food and will be followed up for 12 weeks to see the effect of nutrition supplementation on immune and pharmacological responses
3021182|NCT02421289|Experimental|CYP2B6 guided group|Patients were assigned to perform CYP2B6 study before ART initiation. If CYP2B6 *6/*6 was found in CYP2B6 *6/*6, the patients will be initiated a low dose of 400 mg of efavirenz (2 tablets of 200 mg) with tenofovir 300 mg and lamivudine 300 mg.
3021183|NCT02421289|No Intervention|control group|Patients were promptly ART initiation regardless CYP2B6 results. Treatments were efvirenz 600 mg, tenofovir 300 mg and lamivudine 300 mg.
3021184|NCT02421276|Other|Persons without Down syndrome|White blood cell analysis from persons without Down syndrome assessed by absence of trisomy 21.
3021185|NCT02421276|Other|Persons with Down syndrome|White blood cell analysis from persons with Down syndrome assessed by presence of trisomy 21.
3021186|NCT02421263|Experimental|Immediate Participation Group|Participants will begin psilocybin intervention immediately after study enrollment.
3021187|NCT02421263|Active Comparator|Delayed Participation Group|Participants will begin the psilocybin intervention 6 months after study enrollment.
3021188|NCT02421250|Experimental|Radical-7 Non-invasive Hgb Monitor|We use the Radical-7 Noninvasive Hgb Monitor device (provided by Masimo Corporation from Irvine USA) to measure hemoglobin levels in patients in the experimental group.
3021189|NCT02421250|No Intervention|Control|We will use standard-of-care for control group and not use the SpHb monitor.
3021190|NCT02421237|Experimental|Experimental condition|Narrative enhancement and cognitive therapy (NECT) groups. Structured psychoeducational and skills-training groups focused on self-stigma and its impact on people with schizophrenia
3021191|NCT02421237|Active Comparator|Control condition|Supportive group therapy groups. Unstructured supportive groups not focused on self-stigma.
3021297|NCT02420548|Active Comparator|Services as Usual|Participants continue with any services they may be receiving outside of the study.
3021192|NCT02421224|Active Comparator|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
3021193|NCT02421224|Experimental|Deposits|Same as Usual Care, plus participants will have to deposit a certain amount of their own money as an incentive to quit smoking. Participants will be able to make additional voluntary deposits above the minimum amount. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
3021194|NCT02421224|Experimental|Small Individual Bonus|Same as Usual Care, plus each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
3021195|NCT02421224|Experimental|Large Individual Bonus|Same as Usual Care, plus each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
3021196|NCT02421224|Experimental|Team Bonus|Same as Usual Care, plus each participant will be randomly assigned one teammate to provide social support during the quit attempt. If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
3021197|NCT02421224|Experimental|Deposits plus Small Individual Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will follow the protocol for the monetary bonus as described for the Small Individual Bonus group.
3021198|NCT02421224|Experimental|Deposits plus Large Individual Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will follow the protocol for the monetary bonus as described for the Large Individual Bonus group.
3021199|NCT02421224|Experimental|Deposits plus Teammate|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will be randomly assigned one other participant to serve as a teammate who provides social support during the quit attempt.
3021200|NCT02421224|Experimental|Deposits plus Team Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group, will be randomly assigned a teammate, and will follow the protocol for the monetary bonus as described for the Team Bonus group.
3021201|NCT02421211|Experimental|Panel 1|Participants will receive Simeprevir (SMV) 150 milligram (mg) capsule (Treatment A) along with Sofosbuvir (SOF) 400 mg tablet, orally, once daily (Treatment C) from Day 1 until Day 14 followed by SMV 150 mg capsule (Treatment A) along with fixed dose combination (FDC) tablet of 90 mg Ledipasvir (LDV)/400 mg SOF (Treatment B), orally, once daily from Day 15 until Day 70.
3021202|NCT02421211|Experimental|Panel 2|Participants will receive FDC tablet of 90 mg LDV/400 mg SOF (Treatment B), orally, once daily from Day 1 until Day 14 followed by SMV 150 mg capsule (Treatment A) along with FDC tablet of 90 mg LDV/400 mg SOF (Treatment B), orally, once daily from Day 15 until Day 56.
3021203|NCT02421198|Experimental|face-to-face|Delivery and testing of YMCA Family Diabetes Prevention Program (YFDPP) delivered face-to-face by YMCAs over 12 weeks to children age 9-12 and one parent/guardian.
3021204|NCT02421198|Experimental|face-to-face + mobile hybrid|Delivery and testing of YMCA Family Diabetes Prevention Program (YFDPP) delivered face-to-face and via a mobile platform by YMCAs over 12 weeks to children age 9-12 and one parent/guardian.
3021205|NCT02421185|Experimental|Part 1: Dose Escalation and Part 2: Dose Expansion|"Part 1: First, participants will receive 8 milligram (mg) (starting dose) tablet of JNJ-42756493 (erdafitinib) orally once daily from Day 1 to 7, then Day 15 to 21 of 28 days cycle or 8 mg orally once daily from Day 1 to 21 of 28 days cycle (intermittent dosing). After recommended Phase 2 dose (RP2D) is identified, enrollment of continuous dosing schedule will be open, starting at 8mg. In this cohort, participants will receive 8mg (starting dose) tablet of JNJ42756493 (erdafitinib) orally once daily from Day 1 to Day 28 in a 28-day cycle. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine RP2D.~Part 2: Participants will receive RP2D JNJ-42756493 (erdafitinib) dose determined in Part 1. Participants who are tolerating study drug treatment and achieve clinical responses or stable disease will continue to receive study drug at the same dose until disease progression, unacceptable toxicity, or withdrawal of consent."
3021206|NCT02421172|Experimental|Arm 1|CJM112 high dose in period 1; placebo in period 2
3021207|NCT02421172|Experimental|Arm 2|Placebo in period 1; CJM112 low dose in period 2
3021208|NCT02421172|Experimental|Arm 3|Placebo in period 1; CJM112 high dose in period 2
3021209|NCT02421146|Sham Comparator|Sham tDCS - Healthy Controls|The sham group session will contain 20 minute sessions of transcranial direct current stimulatio , but only the first minute will be with 2mA, then unbeknownst to the subject, the unblinded research assistant will turn off the stimulation.
3021210|NCT02421146|Active Comparator|tDCS - Healthy Controls|will receive real transcranial direct current stimulation. Real tDCS stimulation will involve ten 20 minute stimulations daily (at 2 mA anode over the left DLPFC while cathode over the right suborbital region) on 5 weekdays of two consecutive weeks
3021211|NCT02421146|Sham Comparator|Sham tDCS - Patients|The sham group session will contain 20 minute sessions of transcranial direct current stimulation as well, but only the first minute will be with 2mA, then unbeknownst to the subject, the unblinded research assistant will turn off the stimulation.
3021212|NCT02421146|Active Comparator|tDCS - Patients|will receive real transcranial direct current stimulation . Real tDCS stimulation will involve ten 20 minute stimulations daily (at 2 mA anode over the left DLPFC while cathode over the right suborbital region) on 5 weekdays of two consecutive weeks
3021213|NCT02421133|Experimental|Transitional care program.|The transitional care program from hospital to home will be implemented at three steps: during the patient's stay in hospital, the day of the discharge and during 4 weeks after discharge.
3021214|NCT02421133|Other|standard care program|No intervention liable to affect the care provided to the patients, the organization of care or the practices of health care professionals will be implemented during the control period (time steps without intervention).
3021215|NCT02421120|Experimental|Ceftolozane/Tazobactam|Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses
3021219|NCT02421081|Active Comparator|having arteriel cut|30 patients who refer to Erciyes University emergency department because of wrist laceration with radial and/or ulnar artery incision,will be presenting to the study.All patient's flow rate will be evaluated by Doppler ultrasonography before surgery,as well as the healthy side and side of the cuts.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.Then after patients received surgery,under a microscope using microsurgical techniques and polyamide suture will be held vascular repair.Patients will be assessed by Doppler ultrasonography again 4 weeks after surgery;flow velocity and vessel diameter will be measured at the anastomoses line and patient will be divided to 4 groups. Among these groups serum CD34,CD133,CD309 levels and distribution of lymphoid cells measured by immunohistochemistry; The relationship between the anastomosis opening will be evaluated statistically.
3021220|NCT02421081|Active Comparator|having tendon cut|10 patients having similar age and sex with first group, who refer to Erciyes University emergency department because of wrist laceration without radial or ulnar artery cutting,will be taken to compare with first group.All patient's flow rate will be evaluated by Doppler ultrasonography before surgery,as well as the healthy side and side of the cuts.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.Then after patients received surgery to repair tendons and/or nerves. Among these groups serum CD34,CD133,CD309 levels and distribution of lymphoid cells measured by immunohistochemistry; and will compare with first group.
3021221|NCT02421081|No Intervention|healthy control|10 healty having similar age and sex with first group,controls who accept to give blood to determine normal range of serum CD34,CD133 and CD 309 will be taken to compare with first group.All patient's flow rate will be evaluated by Doppler ultrasonography.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.
3021222|NCT02421068||Preterm neonates|All neonates that receive at least one of the 9 drugs (phenobarbital, paracetamol, levetiracetam, midazolam, sildenafil, fentanyl, doxapram, ibuprofen, fluconazole) are included in the studied cohort
3021223|NCT02421055||Group 1|Roux-en-Y Gastric Bypass
3021224|NCT02421055||Group 2|Sleeve Gastrectomy
3021225|NCT02421042|Experimental|Lenvatinib|Subjects determined to be eligible for the protocol will receive either a 5- or 10-mg single oral dose of lenvatinib on Day 1, depending on their hepatic status [Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)].
3021226|NCT02421029|Experimental|edetate calcium disodium|Subjects who had a gadolinium-enhanced MRI within 1-4 weeks or within 3-6 months before enrollment will receive a single dose of edetate calcium disodium to evaluate levels of gadolinium in their urine, pre and post infusion.
3021227|NCT02421016|Experimental|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
3021228|NCT02421016|Active Comparator|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
3021229|NCT02421003|Experimental|Patients|Patients undergoing heart surgery
3021230|NCT02420990|Active Comparator|Behavioral Only- Treatment|All participants will receive behavioral interventions (CASH-AA): family psycho-education in ADHD symptoms, executive functioning, and developmental impacts; family-based motivation and ADHD accommodation interventions; and academic training focused on home environment support and organizational skills.
3021231|NCT02420990|Experimental|Integrated Treatment|Half of the participants will also receive medication decision-making interventions (MIP): ADHD medication psychoeducation, family decision-making interventions, and (for those who elect to start medication) coordinated medication management.
3021232|NCT02420977|Experimental|DCFPyL PET-MRI fusion or PET/MRI|"Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT~Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"
3021233|NCT02420964|Other|Nurse instruction|Traditional injection teaching method. No video instruction
3021234|NCT02420964|Other|Video instruction|Video instruction that can be paused/repeated by subject
3021235|NCT02420951|Experimental|Injection|Will receive injection of 30ml of .5% bupivacaine solution prior to catheter removal
3021236|NCT02420951|Active Comparator|No Injection|Will not receive injection of bupivacaine prior to catheter removal
3021237|NCT02420938|Experimental|Rituximab + Urelumab|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course. Urelumab 8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the course. Urelumab doses administered approximately 24 hours after the Rituximab doses. Up to two 12-week courses of treatment administered (total of maximum 12 doses of Rituximab and 8 doses of Urelumab).
3021238|NCT02420925|Experimental|Celiac Plexus Block|There is one treatment arm who undergoes celiac plexus block.
3021239|NCT02420912|Experimental|Cohort 1: Not Previously on Ibrutinib|"Cohort 1: Determine the response rate (complete response (CR)/complete response with incomplete marrow recovery(CRi)) by 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria. Participants consists of those who were refractory to or relapsed after at least one prior standard therapy or untreated with del(17p) by FISH.~Cohort 1: Participants receive Nivolumab 3 mg/kg by vein monotherapy for the first cycle to assess for monotherapy toxicities of Nivolumab. Nivolumab continues for up to 24 cycles (96 weeks; 48 infusions).~Ibrutinib 420 mg given by mouth daily at the start of Course 2 on Days 1 and 15 of Cycles 1-24. Cycle of therapy is 28 days."
3021240|NCT02420912|Experimental|Group 2: Currently on Ibrutinib|"Cohort 2: Determine the conversion rate from PR to CR/CRi by 2008 IWCLL criteria.~Cohort 2: Participants receive Nivolumab 3 mg/kg by vein monotherapy for the first cycle to assess for monotherapy toxicities of Nivolumab. Nivolumab continues for up to 24 cycles (96 weeks; 48 infusions).~Participants to have been on Ibrutinib for >9 months. Ibrutinib given by mouth daily, at same dose currently receiving, on Days 1 and 15 of Cycles 1-24. Cycle of therapy is 28 days."
3021273|NCT02420730|Experimental|Cohort 2A: AGN-232411 Dose A|One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease.
3021274|NCT02420730|Experimental|Cohort 2B: AGN-232411 Dose B|One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose A in Cohort 2A is acceptable.
3022899|NCT02410356|Active Comparator|dGH|dGH to be given as daily injections.
3021241|NCT02420912|Experimental|Cohort 3: Not Previously on Ibrutinib|"Cohort 3: Determine the response rate (CR/CRi).~Determine the response rate (complete response (CR)/complete response with incomplete marrow recovery(CRi)) by 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria. Participants consists of those who who were refractory to or relapsed after at least one prior standard therapy or untreated with del(17p) by FISH.~Cohort 3: Participants receive Nivolumab 3 mg/kg by vein monotherapy for the first cycle to assess for monotherapy toxicities of Nivolumab. Nivolumab continues for up to 24 cycles (96 weeks; 48 infusions).~Ibrutinib 420 mg given by mouth daily at the start of Course 2 on Days 1 and 15 of Cycles 1-24. Cycle of therapy is 28 days."
3021242|NCT02420899|Experimental|Statins,lipid-lowering drugs|rosuvastatin 10mg or 20mg per day，pro
3021243|NCT02420886|Active Comparator|Cytokines supplemented In Vitro single culture media|We will add Cytokines (LIF, HB-EGF and GM-CSF) to LIFEGLOBAL culture media and assess the embryogenesis and pregnancy.
3021244|NCT02420886|No Intervention|Traditional Single step culture media|
3021245|NCT02420873|Experimental|Cohort 1: CD56 Expressing Hematological Malignancies|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
3021246|NCT02420873|Experimental|Cohort 2: Myelofibrosis|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
3021247|NCT02420873|Experimental|Cohort 3: Blastic Plasmacytoid Dendritic Cell Neoplasm|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
3021248|NCT02420860|Experimental|Elotuzumab + Lenalidomide|"Elotuzumab dosed at 10 mg/kg by vein on Days 1, 8, 15, and 22 for the first 2 cycles, then on Day 1 each cycle after that.~Dexamethasone 28 mg by mouth between 3-24 hours prior to the start of Elotuzumab infusion or as a split dose 12-24 hours and 3 hours prior to Elotuzumab. Dexamethasone 8 mg by vein on day of Elotuzumab infusion prior to the start of infusion.~Diphenhydramine 12.5-50 mg by mouth or vein prior to Elotuzumab.~Famotidine 20 mg by vein prior to Elotuzumab.~Lenalidomide dosed at 10 mg/day; after three cycles, provided the ANC is >/= 1000/mL, platelet count >/= 100,000/mL and all non-hematologic toxicity is </= grade 1, dose may be increased to 15 mg/day at discretion of physician.~Treatment with Lenalidomide and Elotuzumab use a cycle length of 28 days.~Symptom questionnaire completion on Day 1."
3021249|NCT02420847|Experimental|Ixazomib + Gemcitabine + Doxorubicin|"Phase I~Starting dose of Ixazomib 4.0 mg by mouth on Day 1 of every 14-day cycle. Starting dose of Gemcitabine 10 mg/m2/min by vein on Day 1 of each 14 day cycle.~Starting dose of Doxorubicin 33 mg/m2 by vein on Day 1 of each 14 day cycle.~Phase II Starting doses of Ixazomib, Gemcitabine, and Doxorubicin is maximum tolerated dose (MTD) from Phase I."
3021250|NCT02420834|Experimental|Tear Supplement Hypromellose 0.15%|Preservative free Hypromellose Eye Drops BP 0.15% applied as required for 1 month
3021251|NCT02420834|Experimental|Tear Supplement Hypromellose 0.4%|Preservative free Hypromellose Eye Drops BP 0.4% applied as required for 1 month
3021252|NCT02420834|Experimental|Tear Supplement Carboxymethylcellulose|Tear Supplement 3: Preservative free 0.25% Carboxymethylcellulose, electrolyte balanced (Theratears) applied as required for 1 month
3021253|NCT02420834|Experimental|Tear Supplement Liposomal spray|Preservative free Phospholipid liposomal spray (Tears Again) applied as required for 1 month
3021254|NCT02420821|Experimental|Atezolizumab + Bevacizumab|Participants will receive both atezolizumab and bevacizumab until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression, withdrawal of consent, or death, whichever occurs first.
3021255|NCT02420821|Active Comparator|Sunitinib|Participants will receive sunitinib until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression, withdrawal of consent, or death, whichever occurs first.
3021256|NCT02420795|Experimental|Arm A: ONC201 - Once every 3 Weeks|Phase I starting dose of ONC201 125 mg taken orally Day 1 of every 21-day cycle (enrollment in Arm A stopped February 2016). After end-of-dosing visit, study staff will call participant every 3 months for 1 year.
3021257|NCT02420795|Experimental|Arm B: ONC201 - Once a Week|Phase I starting dose of ONC201 125 mg taken orally Day 1 of every week. Dose escalation will continue until MTD is reached for recommended Phase 2 Dose. After end-of-dosing visit, study staff will call participant every 3 months for 1 year.
3021258|NCT02420782|Experimental|ASP6282 single ascending dose (fasted)|Part 1
3021259|NCT02420782|Placebo Comparator|Placebo single ascending dose (fasted)|Part 1
3021260|NCT02420782|Experimental|ASP6282 single dose (fed)|Part 1
3021261|NCT02420782|Placebo Comparator|Placebo single dose (fed)|Part 1
3021262|NCT02420782|Experimental|ASP6282 single dose (fasted)|Part 1 Period 1
3021263|NCT02420782|Experimental|Itraconazole multiple dose and ASP6282 single dose (fasted)|Part 1 Period 2
3021264|NCT02420782|Experimental|ASP6282 multiple ascending dose (nonelderly and elderly)|Part 2. Germany only: once daily dosing, optional twice daily dosing. Midazolam dosing elderly only, exploratory for DDI purpose
3021265|NCT02420782|Placebo Comparator|Placebo multiple ascending dose (nonelderly and elderly)|Part 2. Germany only: once daily dosing, optional twice daily dosing
3021266|NCT02420782|Experimental|ASP6282 and pilocarpine|Part 3
3021267|NCT02420782|Other|Placebo and pilocarpine|Part 3
3021268|NCT02420769||Threatened abortion|Pregnant patients > 8 weeks gestation coming to the ANC clinic with mild vaginal bleeding but healthy viable intrauterine pregnancy. Vaginal color doppler for uterine artery and corpus luteum together with serum progesterone and CA125 will be assessed.
3021269|NCT02420730|Experimental|Cohort 1A: AGN-232411 Dose A|One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants.
3021270|NCT02420730|Experimental|Cohort 1B: AGN-232411 Dose B|One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose A in Cohort 1A is acceptable.
3021271|NCT02420730|Experimental|Cohort 1C: AGN-232411 Dose C|One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose B in Cohort 1B is acceptable.
3021294|NCT02420574|Active Comparator|ALB-OVIS|albendazole, 400 mg, single-oral dose, (OVIS)
3022965|NCT02409927|Experimental|MCT homogenate 10 g|Meal with 10 g of MCT homogenate mixed in
3021275|NCT02420730|Experimental|Cohort 2C: AGN-232411 Dose C|One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose B in Cohort 2B is acceptable.
3021276|NCT02420730|Placebo Comparator|Cohort 2: AGN-232411 Vehicle|One drop of Vehicle for AGN-232411 topical ophthalmic solution administered to the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease.
3021277|NCT02420717|Experimental|Ruxolitinib + Chemotherapy|Based on the molecular profile, participants stratified into 2 cohorts. For patients who fail to respond to a single agent ruxolitinib by 3 weeks (earlier if evidence of progressive disease), Hyper-CVAD chemotherapy added. Single-agent ruxolitinib cycle is cycle 0. Hyper-CVAD intensive cycles labelled cycles 1-8. The hyper-CVAD regimen consists of an intensive phase comprised of 8 cycles of chemotherapy alternating courses of hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone) with courses of high-dose methotrexate and cytarabine every 21 days. Maintenance phase chemotherapy with POMP (6-mercaptopurine, vincristine, methotrexate, and prednisone) commences after the completion of the intensive phase of chemotherapy. Ruxolitinib given continuously concurrently with the intensive and maintenance phases.
3021278|NCT02420717|Experimental|Dasatinib + Chemotherapy|Based on the molecular profile, participants stratified into 2 cohorts. For patients who fail to respond to a single agent dasatinib by 3 weeks (earlier if evidence of progressive disease), Hyper-CVAD chemotherapy added. Single-agent dasatinib cycle is cycle 0. Hyper-CVAD intensive cycles labelled cycles 1-8. The hyper-CVAD regimen consists of an intensive phase comprised of 8 cycles of chemotherapy alternating courses of hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone) with courses of high-dose methotrexate and cytarabine every 21 days. Maintenance phase chemotherapy with POMP (6-mercaptopurine, vincristine, methotrexate, and prednisone) commences after the completion of the intensive phase of chemotherapy. Dasatinib given continuously concurrently with the intensive and maintenance phases.
3021279|NCT02420704||Cleavage stage-thin endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness ≤7mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
3021280|NCT02420704||Cleavage stage-medium endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness 8-13mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
3021281|NCT02420704||Cleavage stage-thick endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness ≥14mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
3021282|NCT02420704||Blastocyst stage-thin endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness ≤7mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
3021283|NCT02420704||Blastocyst stage-medium endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness 8-13mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
3021284|NCT02420704||Blastocyst stage-thick endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness ≥14mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
3021285|NCT02420691|Experimental|LEE011|Patients treated with LEE011 600 mg by mouth daily 3 weeks on/1 week off in 28 day cycles. Participants allowed to remain on study until disease progression or unacceptable toxicities
3021286|NCT02420665|Experimental|High-Resolution Microendoscopy (HRME) + Colposcopy|Visual inspection of cervix performed using 3 - 5% acetic acid to the cervix. Participants undergo standard colposcopy and abnormal lesions noted by quadrant. Then 0.01% proflavine applied topically to the cervix. High-resolution microendoscopy (HRME) then performed. HRME images obtained from one visually normal site and from up to 3 visually abnormal lesions based on visual exam and/or colposcopic findings. Study staff follow up with participant by phone one month after procedure.
3021287|NCT02420652|Experimental|Arm I (metformin hydrochloride, aspirin)|Patients receive metformin hydrochloride PO BID and aspirin PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
3021288|NCT02420652|Placebo Comparator|Arm II (metformin hydrochloride placebo, aspirin placebo)|Patients receive metformin hydrochloride placebo PO BID and aspirin placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
3021289|NCT02420639|Experimental|Intervention|The placement of the Esophageal Cooling Device will follow standard recommendations as per Instructions for Use. The Esophageal Cooling Device will be connected to the appropriate console (Meditherm III, Blanketrol II, or Blanketrol III).
3021290|NCT02420613|Experimental|Newly Diagnosed DIPG Group|"Participants receive radiation therapy with Vorinostat followed by adjuvant therapy with Vorinostat and Temsirolimus for 10 cycles.~Dose Escalation Phase Starting Dose of Vorinostat: 230 mg /m2 by mouth daily. During radiation, participants receive Vorinostat daily from Mon-Friday along with radiation. After radiation therapy, participant rests for 4 weeks in which no radiation therapy or study drug received .~Radiation therapy (RT) administered in single daily fractions of 1.8 Gy for 30 treatments over 6-7 weeks. Total dose of radiation 54 Gy.~Maintenance Phase Starting Dose for Vorinostat: 230 mg/m2/dose by mouth once daily in a 28 day cycle.~Maintenance Phase Starting Dose for Temsirolimus: 25 mg/m2 by vein on Day 1 and Day 8 of a 28 day cycle."
3021291|NCT02420613|Experimental|Progressive DIPG Group|"Participants receive 12 cycles of therapy with each cycle being repeated every 28 days.~Dose Escalation Phase Starting Dose of Vorinostat: at 230 mg/m2 by mouth from Day 1 to Day 8.~Dose Escalation Phase Starting Dose of Temsirolimus: 25mg/m2 by vein on Day 1 and Day 8.~Maintenance Phase Starting Dose for Vorinostat: 230 mg/m2/dose by mouth once daily of a 28 day cycle.~Maintenance Phase Starting Dose for Temsirolimus: 25 mg/m2 by vein on Day 1 and Day 8 of a 28 day cycle."
3021292|NCT02420587|Experimental|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles. Participants receive AMG 208 until radiographic progression of disease and/or unequivocal clinical progression. Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
3021293|NCT02420574|Active Comparator|ALB-BENDEX|albendazole, 400 mg, single oral dose, (BENDEX)
3021298|NCT02420548|Experimental|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
3021299|NCT02420535|Experimental|Immediately Receive Tool|Caregiver/Care Recipient Dyad will be randomly assigned to immediately receive the WeCareAdvisor Tool for 4 weeks.
3021300|NCT02420535|Active Comparator|One Month Delay|Caregiver/Care Recipient Dyad will be randomly assigned to a 4 week delay (usual care activities only) before receiving the WeCareAdvisor Tool for 4 weeks.
3021301|NCT02420522|Experimental|Active-first|Patients in this arm will receive one week of active Repetitive Transcranial Magnetic Stimulation prior to one week of Sham Transcranial Magnetic Stimulation, separated by at least one week.
3021302|NCT02420522|Experimental|Sham-first|Patients in this arm will receive one week of Sham Transcranial Magnetic Stimulation prior to one week of active Repetitive Transcranial Magnetic Stimulation, separated by at least one week.
3021303|NCT02420509||systemic chemotherapy after CRS/HIPEC|Single-arm, prospective study of systemic chemotherapy after CRS/HIPEC. Subjects will be given twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery. CTRI Biostatistics Core personnel will assist in conducting analyses using the latest version of R (R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/).
3021304|NCT02420496|Experimental|Enteral fish oil|Infants will receive enteral fish oil at a dose of 1mg/kg/day divided in two daily doses given enterally.
3021305|NCT02420496|Active Comparator|UDCA (ursodeoxycholic acid)|Infants will receive UDCA at a dose of 10mg/kg/dose in two daily doses given enterally
3021306|NCT02420496|Placebo Comparator|Placebo|Infant will receive placebo in two daily doses given enterally
3021307|NCT02420483|Experimental|Patients|Cardiopulmonary resuscitation with measurement of tidal volume, airway pressure and flow by a pneumotachograph and airway, oesophageal pressure sensors
3021308|NCT02420470||healthy control group|fasting plasma glucose(FPG)＜6.11mmol/L，and 2-h plasma glucose(2hPG)＜7.77mmol/L；
3021309|NCT02420470||prodromal diabetes group|IFG：fasting plasma glucose(FPG) ≥5.6mmol/L (100mg/dl)，and<7.0mmol/L (126mg/dl)，oral glucose tolerance test(OGTT) 2-h plasma glucose(2hPG) <7.8 mmol/L ；IGT：oral glucose tolerance test(OGTT) 2-h plasma glucose(2hPG) ≥7.8mmol/L (140mg/dl)，and<11.1mmol/L (200mg/dl)，fasting plasma glucose(FPG)< 5.6mmol/L
3021310|NCT02420470||diabetes group|fasting plasma glucose(FPG)>7.0mmol/L, or 2-h plasma glucose(2hPG)>11.1mmol/L
3021311|NCT02420457||Back pain receiving epidural injection|Patients who have chronic back pain and are scheduled for an epidural injection to treat this pain will be receive a transforaminal epidural steroid injection as determined by routine care provider
3021312|NCT02420444|Placebo Comparator|BCG SSI prime with Placebo|"All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42.~Placebo containing 0,8 mL sterile buffer consisting of 10 mmol Tris and 169 mmol NaCl aqueous solution was administered on Study Days 0, 56, and 231."
3021313|NCT02420444|Experimental|BCG SSI prime with Placebo and AERAS-404|"All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42.~Placebo on Study Day 0 followed by AERAS-404 50/500 on Study Days 56 and 231.~AERAS-404 50/500 was a fixed dose combination of H4 50 mcg and IC31 500 nmol (KLK equivalent). H4 and IC31 adjuvant were supplied as separate single-dose vials containing frozen product as follows:~H4 antigen: 500 mcg/mL (100 mcg/0.2 mL), in 10 mmol/L Tris-HCl, pH 8.3.~IC31 adjuvant: 1250 nmol/mL (1000 nmol/0.8 mL) KLK equivalent, in 10 mmol/L Tris-HCl and 169 mmol/L NaCl."
3021314|NCT02420444|Experimental|BCG SSI prime with AERAS-404|"All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42.~AERAS-404 50/500 on Study Days 0, 56, and 231.~AERAS-404 50/500 was a fixed dose combination of H4 50 mcg and IC31 500 nmol (KLK equivalent). H4 and IC31 adjuvant were supplied as separate single-dose vials containing frozen product as follows:~H4 antigen: 500 mcg/mL (100 mcg/0.2 mL), in 10 mmol/L Tris-HCl, pH 8.3.~IC31 adjuvant: 1250 nmol/mL (1000 nmol/0.8 mL) KLK equivalent, in 10 mmol/L Tris-HCl and 169 mmol/L NaCl."
3021315|NCT02420431|Experimental|metacognitive therapy plus CR|Group psychological treatment focused on reducing worry and rumination and modifying beliefs about thinking in addition to treatment as usual (standard cardiac rehabilitation)
3021316|NCT02420431|Active Comparator|CR alone (control)|Usual group-based cardiac rehabilitation (treatment as usual) involving stress management, exercise, education
3021317|NCT02420418|Active Comparator|NAC ( baseline )and 12 week|"subjects with tobacco use disorder (TUD) and bipolar disorders who will receive N-acetyl-cysteine (NAC) or placebo at baseline for a period of 12 weeks The participants with TUD (n=72) and they will receive a 1800mg per day of NAC or matching placebo .~There will be asses laboratory examinations for inflammatory and oxidative stress biomarkers at baseline and at 12 week"
3021318|NCT02420418|Placebo Comparator|placebo ( baseline ) and 12 week|"subjects with tobacco use disorders (TUD and bipolar disorders who will receive N-acetyl-cysteine (NAC) or placebo for a period of 12 weeks.~The participants with TUD and bipolar disorders (n=72) and they will receive a 1800mg per day of NAC or matching placebo .~There will be assessed laboratory examinations for inflammatory and oxidative stress biomarkers at baseline and at 12 week"
3021319|NCT02420405|Placebo Comparator|Routine gene testing|Routine gene testing of EGFR, ROS1 and ALK will be performed on those diagnosed with nonsquamous NSCLC.
3021320|NCT02420405|Experimental|Next-generation sequencing|Routine gene testing was performed in those diagnosed with nonsquamous NSCLC. NGS will be performed on these that have adequate rest tissues.
3021321|NCT02420392|Experimental|Dapagliflozin treatment|Test incretin sensitivity after dapagliflozin treatment in type 2 diabetes patients
3021322|NCT02420392|No Intervention|Normal glucose tolerance|Test incretin sensitivity in subjects with normal glucose tolerance
3021323|NCT02420379|Experimental|Open-Label|Approximately 20 patients will receive weekly infusions of eteplirsen 30 mg/kg .
3021324|NCT02420379|No Intervention|Control Group|Approximately 20 patients with DMD not amenable to exon 51 skipping will be observed for 96 weeks.
3021325|NCT02420353|Active Comparator|Somatropin|Somatropin of rDNA origin
3021326|NCT02420353|Placebo Comparator|Placebo|A placebo vehicle that contains somatropin diluent but no active hormone.
3055018|NCT02194244|Active Comparator|Tablet Fed|
3021327|NCT02420340|Other|HOPES Group|Participants will participate in twice weekly sessions of the HOPES program until curriculum is completed (approximately 1 year) or discharge from Glencliff home
3021328|NCT02420327|Experimental|Placebo patch and placebo capsule|On the double-placebo test day, participants receive a placebo patch and a placebo capsule.
3021329|NCT02420327|Experimental|Nicotine patch and placebo capsule|On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.
3021330|NCT02420327|Experimental|Placebo patch and galantamine capsule|On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.
3021331|NCT02420327|Experimental|Nicotine patch and galantamine capsule|On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.
3021332|NCT02420314|Experimental|Ascorbate, paclitaxel, carboplatin|Paclitaxel, administered once per cycle (3 weeks) Carboplatin, administered once per cycle (3 weeks) Pharmacological ascorbate (ascorbic acid) infusions, 2 times per week for 3 weeks
3021333|NCT02420301|Experimental|Exercises on real points|Self administered exercises were done in real treatment points
3021334|NCT02420301|Placebo Comparator|Exercises on false points|Self administered exercises were done in false treatment points
3021335|NCT02420288|No Intervention|Control Group|Pregnant women not participating in supervised physical exercise program. The subjects in this group will be monitored during pregnancy to know if they make any kind of exercise on your own, to know which are really sedentary pregnant women.
3021336|NCT02420288|Experimental|Exercise Group|Pregnant women participating in supervised physical exercise program.
3021337|NCT02420275|Placebo Comparator|Severe brain injury patient|Severe brain injury patients with placebo
3021338|NCT02420275|Experimental|Severe brain injury patient with device|"Severe brain injury patients withe with Luminette,Lucimed Belgium"
3021339|NCT02420262|Experimental|IDegLira|
3021340|NCT02420262|Active Comparator|IGlar plus IAsp|
3021341|NCT02420249|Experimental|Qigong training group|Participants assigned to the Qigong group will receive Qigong training. The Qigong training programme will be run for 3 months with two supervised 1-hour sessions per week. Participants will learn the 18 Forms of Tai Chi Internal Qigong. The training sessions will be conducted by a qualified Qigong instructor from the Natural Health Qigong Association. Participants in the control group will receive no Qigong training during the study period. They will receive an 18 Forms of Tai Chi Internal Qigong training package after the study.
3021342|NCT02420249|No Intervention|Control group|Participants in the control group will receive no Qigong training.
3021343|NCT02420236|Experimental|High-intensity resistance training|Full body, progressive strength training with Theraband® Elastic bands. Three times per week for 12 weeks - 3 weeks with supervised sessions at the clinic, and 9 weeks of home training. Three guided sessions will be offered during the home training period.
3021344|NCT02420236|Active Comparator|General physical activity|12 weeks of general physical activity - 3 weeks with supervised sessions at the clinic, and 9 weeks of individually adjusted home training. This include circle-training, low-intensity resistance exercises, endurance exercises, ball playing, body awareness, stretching, and relaxation techniques, and similar activities. Neither moderate nor high-intensity resistance exercise is included for participants in this group.Three guided sessions will be offered during the home training period.
3021345|NCT02420223|Experimental|Propranolol|Patient's randomized to the Propranolol arm will be starting 7 days prior to transplant and continuing through 28 days post-transplant. Propranolol will start at 20mg twice daily and will be titrated to 40mg twice daily as tolerated. Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for up to 7 total weeks for patient's on the Propranolol arm.
3021346|NCT02420223|No Intervention|Control Arm|Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for 6 total weeks for patient's on the control arm.
3021347|NCT02420210|Experimental|Treatment (bendamustine, obinutuzumab, dexamethasone)|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2, obinutuzumab IV over 4 hours on days 1 or 2, 8, and 15 (on both days 1 and 2 in course 1 only), dexamethasone PO daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3021348|NCT02420197|Experimental|High-intensity resistance training|Full body, progressive strength training with Theraband® Elastic bands. Three times per week for 12 weeks - 3 weeks with supervised sessions at the clinic, and 9 weeks of home training.Three guided sessions will be offered during the home training period.
3021349|NCT02420197|Active Comparator|General physical activity|12 weeks of general physical activity - 3 weeks with supervised sessions at the clinic, and 9 weeks of individually adjusted home training. This include circle-training, low-intensity resistance exercises, endurance exercises, ball playing, body awareness, stretching, and relaxation techniques, and similar activities. Neither moderate nor high-intensity resistance exercise is included for participants in this group.Three guided sessions will be offered during the home training period.
3021350|NCT02420184|Experimental|CPAP Therapy|Participants will receive standard medical care for CKD as well as CPAP therapy for the duration of the study (1 year).
3021351|NCT02420184|Placebo Comparator|No CPAP|Participants will receive standard medical care for CKD.
3021352|NCT02420171|Active Comparator|In Vitro culture media with insulin|We will add insulin to the single step culture media to monitor the embryogenesis
3021353|NCT02420171|No Intervention|In Vitro culture media without insulin m|The embryos will be cultured in the media without insulin and compare this arm as the control arm with the interventional one.
3021354|NCT02420158|Experimental|Vagal nerve stimulation|Trans-cutaneous vagal nerve electrical stimulation during 6 months
3021355|NCT02420145|Experimental|Yoga|This group will participate in 12 weeks of yoga
3021356|NCT02420145|No Intervention|Waitlist|No intervention
3021421|NCT02419729|Sham Comparator|Placebo of CO2 laser & Estrogen|Placebo fractional CO2 laser therapy and effective estrogen vaginal cream.
3021357|NCT02420132||Main Study|Decentralized participant recruitment, participant and local ophthalmologist compliance, and use of the mVT mobile medical application in a more geographically diverse, decentralized cohort of participants with DME or nAMD receiving intravitreal ranibizumab therapy as part of standard-of-care treatment.
3021358|NCT02420132||Traditional Substudy|"Subset of participants enrolled through a single investigator who will determine visual acuity and anatomical markers of disease status using clinical gold standard assessments (certified ETDRS protocol visual acuity and macula OCT)."
3021359|NCT02420106|Active Comparator|OMM alone|Subjects who are not receiving botulinum treatment consenting to Osteopathic Manipulative Medicine intervention
3021360|NCT02420106|Active Comparator|OMM plus Botulinum|Subjects who are receiving botulinum treatment and will have osteopathic manipulative medicine intervention.
3021361|NCT02420093|Experimental|Experimental Group|"The experimental group will use the Pelvis Support Assembly per US Patent number US 8,857,906 B2, in the seat of their work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting."
3021362|NCT02420093|No Intervention|Control Group|"The control group will not use the Pelvis Support Assembly per US Patent number US 8,857,906 B2 but will continue in their current sitting arrangement during the same 3 week interval"
3021363|NCT02420080||Cohort A|"The primary endpoint for subjects in Cohort A is time to progression of AdV disease through Week 24 post initial AdV diagnosis, with progression of AdV disease defined as time to the following outcomes:~Clinical progression to probable or definitive disseminated AdV disease Death"
3021364|NCT02420080||Cohort B|The primary endpoint for subjects in Cohort B is time to all-cause mortality through Week 36 post diagnosis of disseminated AdV disease
3021365|NCT02420054|Active Comparator|Intermittent fasting|Intermittent fasting conducted by a group of subjects with type 2 diabetes mellitus and an age- and BMI matched control group.
3021366|NCT02420054|Active Comparator|Time control|A time control period.
3021367|NCT02420041|Active Comparator|Fluoroscopic Guidance|Patients referred to the Naval Medical Center-San Diego Pain Medicine Clinic. Need a history and physical showing objective findings of sacroiliac joint (SIJ) dysfunction. If the patient meets inclusion / exclusion criteria, they will be presented with the study. After accepting and being consented, they will then be scheduled. The day of the appointment they will be randomised to Group A or B. In Group A : Fluoroscopy will be used to Guide Needle Placement to inject Steroid into joint. Then complete the multidimensional pain inventory (MPI) and rate their pain on the NRS from 0-11. After procedure, they will rate their pain from 0-10 in the recovery area and then be discharged to home. They will complete an MPI, Patient Global Impression of Change (PGIC), numerical rating scale (NRS), and adverse events questionnaire 1-2 weeks post-procedure and 3 months post-procedure.
3021368|NCT02420041|Experimental|Ultrasound Guidance|Patients referred to the Naval Medical Center-San Diego Pain Medicine Clinic. Need a history and physical showing objective findings of SIJ dysfunction. If the patient meets inclusion / exclusion criteria, they will be presented with the study. After accepting and being consented, they will then be scheduled. The day of the appointment they will be randomised to Group A or B. In Group B Ultrasound will be used to Guide Needle Placement to inject steroid into joint. Then complete the MPI and rate their pain on the NRS from 0-11. After procedure, they will rate their pain from 0-10 in the recovery area and then be discharged to home. They will complete an MPI, Patient Global Impression of Change (PIGC), NRS, and adverse events questionnaire 1-2 weeks post-procedure and 3 months post-procedure.
3021369|NCT02420028|Experimental|OptiVein IV catheter|Insertion of an IV catheter into the patient's vein, defined as placement of the catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
3021370|NCT02420028|Active Comparator|Vasofix Certo IV catheter|Insertion of an IV catheter into the patient's vein, defined as placement of the catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
3021371|NCT02420015|Experimental|iCOMMIT|The components of the intervention include 1) behavioral therapy in the form of mobile contingency management (mCM) designed to increase early abstinent rates; 2) pharmacotherapy for smoking cessation [including nicotine replacement therapy (NRT) and bupropion]; 3) four sessions of guideline based cognitive-behavioral smoking cessation counseling designed to increased coping skills specific to smoking cessation; 4) a smart-phone based relapse prevention application (the Stay Quit Coach) that is populated during the counseling sessions; and 5) SMS text messaging reminders to increase medication adherence.
3021372|NCT02420015|Active Comparator|Control Group|The components of the intervention include 1) pharmacotherapy for smoking cessation [including nicotine replacement therapy (NRT) and bupropion]; and 2) four sessions of guideline based cognitive-behavioral smoking cessation counseling designed to increased coping skills specific to smoking cessation.
3021373|NCT02420002|Active Comparator|Usual care (MEOPA)|"Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing.~Intervention: Use of MEOPA during suturing Intervention: Stitch removal"
3021374|NCT02420002|Experimental|Experimental arm (Hypnosis)|"Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing will therefore take place under hypnosis (and MEOPA if necessary).~Intervention: Use of Hypnosis during suturing Intervention: Stitch removal"
3021375|NCT02419989||CF patients|Male and female subjects with CF age 6 years and older who meet diagnostic criteria for NTM disease through participation in the PREDICT (Part A) study who are being offered NTM treatment.
3021376|NCT02419976|Experimental|fasting breath analysis|Individuals consenting to participation of this study will be asked to provide a breath analysis using the Aeonose. Following their scheduled standard of care endoscopic procedure the patient will repeat the breath analysis
3021377|NCT02419963|Other|IBS-D patients|Subjects on this arm will have an endoscopy for tissue biopsy, and provide blood samples and stool samples.
3021378|NCT02419963|Other|Healthy Controls|Subjects on this arm will have an endoscopy for tissue biopsy, and provide blood samples and stool samples.
3021379|NCT02419950||No fixation of mesh in TEP|Patient having no mechanical fixation of the mesh in TEP. This will include both no fixation at all och glue fixation of the mesh in total extraperitoneal placement of mesh by endoscopic technique
3021422|NCT02419703||Patients receiving Targeted Radiofrequency Ablation (t-RFA)|
3021380|NCT02419950||Fixation of mesh in TEP|Patients having fixation of the mesh using mechanical, non absorbable fixating devices.This will include mechanical fixation of the mesh in total extraperitoneal placement of mesh by endoscopic technique
3021381|NCT02419937|Active Comparator|Tocilizumab|Blinded subjects will be randomized to tocilizumab 162 mg subcutaneously once.
3021382|NCT02419937|Placebo Comparator|Placebo|Blinded subjects will be randomized to placebo
3021383|NCT02419924|Experimental|Experimental|Pelvic floor support device to treat refractory constipation.
3021384|NCT02419911|Other|FloShield|FloShield Air Laparoscopic Cleaning and Defogging System used during laparoscopic surgery
3021385|NCT02419911|Other|Clearify|Clearify Visualization System used during laparoscopic surgery
3021386|NCT02419898||Feasibility Study|Nulliparous women of reproductive age (18-40 years), who are not pregnant but could have a planned or unplanned pregnancy during the duration of the study.
3021387|NCT02419872||Patient Participants|Patients are confirmed to have either Persistent Asthma or COPD
3021388|NCT02419859|Experimental|PaQ® Insulin Delivery Device|The intervention is continuous subcutaneous U 100 Insulin, Asp(B28)-rapid-acting insulin, at a constant basal rate of either 20, 24, 32, 40 or 50 U per day over 3 days and and bolus insulin as needed at meals in 2 U increments.
3021389|NCT02419846|Experimental|Men over 40: Screening with intervention|Participants over the age of 40 complete an educational intervention comprising a 10-20 minute PowerPoint presentation given by an experienced healthcare professional that discusses prostate cancer facts, screening guidelines, risks, benefits, and consequences. Participants may undergo a screening exam comprising a prostate specific antigen level and digital rectal exam.
3021390|NCT02419846|Experimental|Men 18-39: Educational intervention|Participants between 18 and 39 complete an educational intervention comprising a 10-20 minute PowerPoint presentation given by an experienced healthcare professional that discusses prostate cancer facts, screening guidelines, risks, benefits, and consequences.
3021391|NCT02419833|Experimental|Immediate invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission
3021392|NCT02419833|Active Comparator|Delayed invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and within 2-72 hours of admission
3021393|NCT02419820|Experimental|APD791 10mg single dose|APD791 10mg single dose
3021394|NCT02419820|Experimental|APD791 20mg single dose|APD791 20mg single dose
3021395|NCT02419820|Experimental|APD791 40mg single dose|APD791 40mg single dose
3021396|NCT02419820|Experimental|APD791 10mg|APD791 10mg single dose + Aspirin + Clopidogrel
3021397|NCT02419820|Experimental|APD791 20mg|APD791 20mg single dose + Aspirin + Clopidogrel
3021398|NCT02419820|Experimental|APD791 40mg|APD791 40mg single dose + Aspirin + Clopidogrel
3021399|NCT02419820|Experimental|APD791 80mg|APD791 80mg single dose + Aspirin + Clopidogrel
3021400|NCT02419820|Experimental|APD791 160mg|APD791 160mg single dose + Aspirin + Clopidogrel
3021401|NCT02419820|Experimental|APD791 240mg|APD791 240mg single dose + Aspirin + Clopidogrel
3021402|NCT02419820|Experimental|APD791 320mg|APD791 320mg single dose + Aspirin + Clopidogrel
3021403|NCT02419820|Placebo Comparator|APD791 Placebo|APD791 placebo for single dose + Aspirin + Clopidogrel
3021404|NCT02419820|Experimental|APD791 2mg MD|APD791 2mg multiple dose + Aspirin + Clopidogrel
3021405|NCT02419820|Experimental|APD791 5mg MD|APD791 5mg multiple dose + Aspirin + Clopidogrel
3021406|NCT02419820|Experimental|APD791 10mg MD|APD791 10mg multiple dose + Aspirin + Clopidogrel
3021407|NCT02419820|Experimental|APD791 20mg MD|APD791 placebo for multiple dose + Aspirin + Clopidogrel
3021408|NCT02419820|Placebo Comparator|APD791 placebo MD|APD791 placebo for multiple dose + Aspirin + Clopidogrel
3021409|NCT02419807|Experimental|Diagnostic (indocyanine green, 99mTc-labeled radiotracer)|Patients receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, patients also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Patients then undergo Axillary Lymph Node Biopsy and surgery.
3021410|NCT02419794||Group with endovascular treatment|Group with additional endovascular treatment
3021411|NCT02419794||Group without endovascular treatment|Group without additional endovascular treatment
3021412|NCT02419781|Active Comparator|Group with endovascular treatment|Group with additional endovascular treatment
3021413|NCT02419781|Active Comparator|Group without endovascular treatment|Group without additional endovascular treatment
3021414|NCT02419768|Experimental|Physical Exercise|All patients will receive a circuit-group training including a specific work of balance, posture, gait, fitness, dual tasks and stretching.
3021415|NCT02419768|No Intervention|Control|All patients will not change their physical activities
3021416|NCT02419755|Experimental|Stratum 1: Myeloid Malignancies|Participants receive cytarabine, bortezomib, vorinostat, methotrexate, hydrocortisone, mitoxantrone as described in the Detailed Study Description.
3021417|NCT02419755|Experimental|Stratum 2: ALL and MLM|Participants in Stratum 2 [Acute Lymphoid Leukemia (ALL) and Mixed Lineage Malignancies (MLM)] receive mitoxantrone, PEG-L-Asparaginase (or Erwinia L-asparaginase), dexamethasone, bortezomib, vorinostat, cytarabine, methotrexate, hydrocortisone, mercaptopurine, and doxorubicin as described in the Detailed Study Description.
3021418|NCT02419742|Experimental|Trastuzumab|Participants will receive trastuzumab as a part of either AC-TH or TCH treatment regimen. The choice of the regimen will be based on investigator's discretion referring the local prescribing document of trastuzumab. AC-TH consists of doxorubicin and cyclophosphamide followed by either paclitaxel or docetaxel. TCH consists of docetaxel and carboplatin. Trastuzumab will be common in both treatment regimens and could be administered weekly or every 3 weeks, as per investigator discretion. Each cycle will be of 3 weeks.
3021419|NCT02419729|Experimental|CO2 laser & Estrogen|Effective fractional CO2 laser therapy and effective estrogen vaginal cream
3021420|NCT02419729|Active Comparator|CO2 laser & Placebo of Estrogen|Effective fractional CO2 laser therapy and placebo of estrogen vaginal cream.
3021617|NCT02418429|Active Comparator|waxy maize starch and whey protein|pancake test meal - waxy maize starch and whey protein
3021423|NCT02419690|No Intervention|Usual Care|The current standard of care in the clinic is a preventive care physical examination every 1-2 years and/or treatment for presenting medical conditions. The frequency and content of reproductive health is not standardized between clinicians, but it is expected that all clinicians will address sexuality during routine visits. Additionally, sexually active teens are encouraged to have urine screening tests for chlamydia, gonorrhea and pregnancy as indicated. Teens may also see a reproductive health educator at the clinic as well. Available contraceptive methods are oral contraceptive pills, contraceptive patches, Depo-Provera, diaphragms, condoms, implants and intrauterine devices (IUDs).
3021424|NCT02419690|Active Comparator|text message intervention|Subjects in the intervention arm will receive usual care plus text messages that have been developed to promote overall teen sexual health.
3021425|NCT02419677|Other|RFA alone|Patients undergo radiofrequency ablation alone.
3021426|NCT02419677|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA.
3021427|NCT02419664|Experimental|Ga-68 DOTATOC PET in pituitary adenomas|"To give Ga-68 DOTATOC in pituitary patients doing PET/CT~They are compared with Ga-68 DOTATOC PET performed in another study on patients with no pituitary disease."
3021428|NCT02419651|Active Comparator|Tramadol|Women will receive oral Tramadol 100 mg before the procedure
3021429|NCT02419651|Active Comparator|Diclofenac|Women will receive oral diclofenac 100 mg before the procedure
3021430|NCT02419651|Placebo Comparator|Placebo|Women will receive oral placebo 1 hour before the procedure.
3021431|NCT02419638||Randomized Treatment Arm: Rebif|120 patients treated with Rebif (IFN β-1a subcutaneous three times per week)
3021432|NCT02419638||Randomized Treatment Arm: Tecfidera|120 patients treated with Tecfidera (dimethyl fumarate)
3021433|NCT02419625|Other|subgroup‐specific HEV in Israel|The study will involve patient interviews using questionnaires
3021434|NCT02419612|Experimental|Saxagliptin 5 mg/ dapagliflozin 10mg or Placebo|Saxagliptin 5 mg /dapagliflozin 10 mg Placebo once a day orally
3021435|NCT02419612|Experimental|Glimepiride or Placebo|Glimepiride or placebo 1mg or 2mg or 3mg or 4mg or 6mg once a day orally
3021436|NCT02419599|Experimental|Group A|The group who will receive high energy density, low volume oral nutritional supplement, to be taken for 4 weeks (28 days)
3021437|NCT02419599|Active Comparator|Group B|The group who will receive the standard energy density oral nutritional supplement, to be taken for 4 weeks (28 days)
3021438|NCT02419586|Experimental|bubble gum chewing and routine care|Start chewing gum on postoperative day at three times daily with no more than 30 minutes till discharged
3021439|NCT02419586|No Intervention|routine care|Non interventional group will receive existing routine care as usual
3021440|NCT02419573|Active Comparator|Endotracheal Intubation|The insertion of a plastic breathing tube through the mouth and into the trachea.
3021441|NCT02419573|Active Comparator|Laryngeal Tube (King)|Insertion of a supraglottic airway (SGA)
3021442|NCT02419560|Experimental|ABT-199 and Ibrutinib Combination|Participants will take ABT-199 (dose 100-400 mg) and Ibrutinib (dose 280-560 mg).
3021443|NCT02419547|Other|Anesthesia Induction|Patients undergoing ventricular tachycardia ablation will undergo programmed stimulation (PS) with minimal sedation (Versed, Fentanyl), with intravenous agents (propofol) , and finally with volatile inhalational agent (sevoflurane).
3021444|NCT02419534|Active Comparator|Polyethylene glycol|In our study parents will be asked to start at 1g per day if they are less than 1 year of age and 2g per day in divided doses if they are older and will be asked to titrate the does according to the response up to the a maximum does of .5g/kg/day. In titrating the dose parent will be asked to increase the dose every 2 days until the child pass one normal BM per day without significant efforts. They should titrate down or hold treatment if the child developed lose BM or diarrhea. Caregiver will be asked to use placebo ointment by applying 5mm on fingertip to the anal verge area twice a day for the duration of the study.
3021445|NCT02419534|Active Comparator|Polyethylene glycol with Diltiazem|Parents will be instructed to apply 5 mm of ointment on a fingertip at the anal verge twice daily for the duration of the study
3021446|NCT02419521|Other|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Stent System
3021447|NCT02419508|Experimental|SIMBRINZA + PGA|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
3021448|NCT02419508|Other|Vehicle + PGA|Brinz/brim vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
3021449|NCT02419495|Experimental|Arm A: Selinexor + Carboplatin|"Selinexor escalated in combination with a fixed dose of carboplatin to evaluate the safety, tolerability, and MTD in patients with advanced solid tumors. In the expansion phase, there will be at least one histology-independent cohort of up to 9 patients that will be enrolled at the previously established safe dose for additional safety and correlative studies to establish the recommended phase 2 dose (RP2D) for this combination.~Selinexor given orally once a week for 3 weeks or Days 1, 8, and 15 of each 21-day cycle, and Carboplatin given at the fixed dose of 6 area under curve (AUC) intravenously (IV) every 3 weeks for 6 cycles then Selinexor can be given as a single agent until disease progression."
3021450|NCT02419495|Experimental|Arm B: Selinexor + Paclitaxel|"Dose escalation phase, dose of Selinexor escalated in combination with fixed dose of paclitaxel to evaluate the safety, tolerability, and MTD in patients with advanced solid tumors. In expansion phase, there will be two tumor-specific cohorts of 25 patients each (ovarian carcinoma and metastatic breast cancer) enrolled at the previously established safe dose for additional safety and correlative studies to establish the RP2D for this combination.~Selinexor given orally twice a week for the first two weeks of each 3-week (21-day) cycle. Paclitaxel given intravenously at a fixed dose of 80 mg/m2 on Day 1 and Day 8 of every 21-day cycle (weekly for 2 weeks on and 1 week off) for up to 8 cycles then Selinexor can be given as a single agent until disease progression."
3021493|NCT02419196||abdominal surgery|27 patients undergoing abdominal surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
3021494|NCT02419196||limb surgery|27 patients undergoing upper and lower limb surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
3055283|NCT02192697|Experimental|Phase II group|Oral administration
3021451|NCT02419495|Experimental|Arm C: Selinexor + Eribulin|"In dose escalation phase, dose of Selinexor escalated in combination with a fixed dose of eribulin to evaluate the safety, tolerability, and MTD in patients with advanced solid tumors. In expansion phase, there will be at least one histology-independent cohort of up to 9 patients enrolled at the previously established safe dose for additional safety and correlative studies to establish the RP2D for this combination.~Selinexor given orally once a week for 3 weeks or Days 1, 8, and 15 of each 21-day cycle. Eribulin given intravenously at a fixed dose of 1.0 mg/m2 on Days 1 and 8 of every 21-day cycle for 6 cycles then Selinexor can be given as a single agent until disease progression."
3021452|NCT02419495|Experimental|Arm D: Selinexor + Doxorubicin + Cyclophosphamide|"In dose escalation phase, dose of Selinexor escalated in combination with fixed dose of combination doxorubicin and cyclophosphamide to evaluate the safety, tolerability, and MTD in patients with advanced solid tumors. In expansion phase, there will be at least one histology-independent cohort of up to 9 patients enrolled at the previously established safe dose for additional safety and correlative studies to establish the RP2D for the combination.~Selinexor given orally once a week for 3 weeks or Days 1, 8, or 15 of each 21 day cycle. Doxorubicin given at fixed dose of 60 mg/m2 by vein and cyclophosphamide given at fixed dose of 600 mg/m2 by vein every 3 weeks for 6 cycles then Selinexor can be given as a single agent."
3021453|NCT02419495|Experimental|Arm E: Selinexor + Carboplatin + Paclitaxel|"Dose escalation phase Selinexor dose escalated with fixed dose of carboplatin and paclitaxel up to dose level 2 to evaluate safety, tolerability, and MTD in patients with advanced solid tumors. There will be an additional dose level 3 using fixed dose of carboplatin but escalating the paclitaxel. In expansion phase, there will be one tumor-specific cohort of 25 ovarian carcinoma patients and one tumor-specific cohort of 25 non-small cell lung cancer patients.~Selinexor given orally once a week for 3 weeks in a 21 day cycle. Carboplatin 5 AUC by vein and paclitaxel given at doses of 175 or 200 mg/m2 by vein every 3 weeks for 6 or up to 8 cycles dependent on cancer type. After completion of carboplatin and paclitaxel treatment, Selinexor can be given as a single agent until disease progression."
3021454|NCT02419495|Experimental|Arm F: Selinexor + Carboplatin + Pemetrexed|"Dose escalation phase Selinexor dose escalated with fixed dose of combination carboplatin and pemetrexed to evaluate safety, tolerability, and MTD in patients with advanced solid tumors. In expansion phase, there will be at least one histology-independent cohort of up to 9 patients enrolled at the previously established safe dose for additional safety and correlative studies to establish the RP2D for this combination.~Selinexor given orally once a week for 3 weeks in a 21 day cycle. Carboplatin 6 AUC by vein, and pemetrexed 500 mg/m2 by vein every 3 weeks for up to 6 cycles. After completion of carboplatin and pemetrexed treatment, pemetrexed and Selinexor or single agent Selinexor can be given as a combination maintenance therapy until disease progression. Participants with mesothelioma continue with pemetrexed and Selinexor treatment, participants with other histological malignancies continue with single agent Selinexor."
3021455|NCT02419495|Experimental|Arm G: Selinexor + Topotecan|"In dose escalation phase, dose of Selinexor escalated in combination with escalated dose of topotecan to evaluate the safety, tolerability, and MTD in patients with advanced solid tumors. In expansion phase, at least one tumor-specific cohort of up to 25 ovarian carcinoma patients enrolled at previously established safe dose for additional safety and correlative studies to establish the RP2D for the combination.~Selinexor given orally once a week for 3 weeks or Days 1, 8, and 15 of each 21-day cycle, and topotecan given at starting dose of 0.5 mg/m2 by vein daily for 5 days every 3 weeks (Days 1-5 of every 21-day cycle) for up to 8 cycles, then Selinexor given as a single agent until disease progression."
3021456|NCT02419495|Experimental|Arm H: Selinexor + FOLFIRI|"In dose escalation phase, dose of Selinexor escalated in combination with a fixed dose of FOLFIRI (irinotecan and 5-FU) to evaluate the safety, tolerability, and MTD in patients with advanced solid tumors. In expansion phase, at least one tumor-specific cohort of up to 25 colorectal carcinoma patients enrolled at previously established safe dose for additional safety and correlative studies to establish the RP2D for this combination.~Selinexor given orally once a week for 4 weeks or Days 1, 8, 15, and 22 of each 28-day cycle, and the FOLFIRI regimen given at the fixed dose every 2 weeks or Days 1 and 15 of each 28-day cycle for 6 cycles (12 doses of FOLFIRI) then Selinexor given as a single agent until disease progression."
3021457|NCT02419495|Experimental|Arm I: Selinexor + Irinotecan|"In dose escalation phase, dose of Selinexor escalated in combination with fixed dose of irinotecan to evaluate the safety, tolerability, and MTD in patients with advanced solid tumors. In expansion phase, at least one tumor-specific cohort of up to 25 colorectal carcinoma patients enrolled at the previously established safe dose for additional safety and correlative studies to establish the RP2D for this combination.~Selinexor given orally once a week for 3 weeks or Days 1, 8, and 15 of each 21-day cycle, and irinotecan given at fixed dose of 125 mg/m2 by vein on Days 1 and 8 of each 21-day cycle (2 weeks on and 1 week off) for 8 cycles then Selinexor can be given as a single agent until disease progression."
3021458|NCT02419495|Experimental|Arm J: Selinexor + XELOX|"In dose escalation phase, dose of Selinexor escalated in combination with a fixed dose of XELOX (capecitabine and oxaliplatin) to evaluate the safety, tolerability, and MTD in patients with advanced solid tumors. In expansion phase, at least one tumor-specific cohort of up to 25 colorectal carcinoma patients enrolled at the previously established safe dose for additional safety and correlative studies to establish the RP2D for this combination.~Selinexor given orally once a week for 3 weeks or Days 1, 8, and 15 of each 21-day cycle. Capecitabine given at fixed dose of 900 mg/m2 orally twice daily for Days 1-14 of each cycle, and oxaliplatin given at the fixed dose of 130 mg/m2 by vein every 3 weeks for 8 cycles then Selinexor can be given as a single agent until disease progression."
3021459|NCT02419495|Experimental|Arm K: Selinexor + Olaparib|"In dose escalation phase, dose of Selinexor escalated in combination with fixed dose of olaparib to evaluate the safety, tolerability, and MTD in patients with advanced solid tumors. In expansion phase, at least one tumor-specific cohort of up to 25 ovarian carcinoma patients enrolled at the previously established safe dose for additional safety and correlative studies to establish the RP2D for this combination.~Selinexor given orally twice weekly (e.g. Monday/ Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) for 4 weeks of each 28-day cycle, and olaparib given at fixed dose of 400 mg/m2 taken orally twice daily continuously for as many cycles at the discretion of the attending physician, then Selinexor can be given as a single agent until disease progression."
3021495|NCT02419196||flail chest|10 patients undergoing an operative stabilization of a flail chest will be examined by perioperative pulmonary function tests
3021618|NCT02418429|Active Comparator|resistant starch|pancake test meal - resistant starch
3021460|NCT02419495|Experimental|Arm L: Selinexor + Pembrolizumab|"In dose escalation phase, dose of Selinexor escalated in combination with a fixed dose of pembrolizumab to evaluate the safety, tolerability, and MTD in patients with advanced solid tumors. In expansion phase, at least one tumor-specific cohort of up to 25 melanoma patients and up to 25 NSCLC patients enrolled at the previously established safe dose for additional safety and correlative studies to establish the RP2D for this combination.~Selinexor given twice weekly (e.g. Monday/ Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) for 3 weeks of each 21-day cycle, and pembrolizumab given at fixed dose of 2 mg/kg by vein every 3 weeks for as many cycles at the discretion of the attending physician, then Selinexor can be given as a single agent until disease progression."
3021461|NCT02419495|Experimental|Arm M: Selinexor + Nivolumab|"In dose escalation phase, dose of Selinexor escalated in combination with with a fixed dose of Nivolumab.~Selinexor 40 mg taken orally twice weekly, either on Monday and Wednesday or on Tuesday and Thursday or on Wednesday and Friday or Thursday/Saturday or Friday/Sunday, for 4 weeks. One cycle is defined as 28 days or 8 doses.~Nivolumab 240 mg by vein every 2 weeks or Days 1 and 15 of each 28-day cycle."
3021462|NCT02419482|Experimental|4x4 minutes interval training|4x4 minutes high intensity interval training with 4 minute intervals
3021463|NCT02419482|Experimental|10x1 minute interval training|10x1 minute high intensity interval training with 1 minute intervals
3021464|NCT02419482|No Intervention|control|Physical activity recommended
3021465|NCT02419469|Experimental|Augmented BFM Therapy + Ofatumumab or Rituximab|Participants receive the study drugs in Induction, Consolidation, and Maintenance Courses.
3021466|NCT02419456|Experimental|MK-2048A Intravaginal Ring (IVR) (Low Dose)|The MK-2048A IVR (Low Dose) will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
3021467|NCT02419456|Experimental|MK-2048A IVR (Original Dose)|The MK-2048A IVR (Original Dose) will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
3021468|NCT02419443|Placebo Comparator|Placebo|Patients randomized to the placebo-group were administered placebo-pills orally one hour prior to surgery, then three times a day for a maximum of 6 total doses.
3021469|NCT02419443|Active Comparator|Gabapentin|Patients randomized to the gabapentin-group were administered 300 mg orally one hour prior to surgery, then three times a day for a maximum of 6 total dose.
3021470|NCT02419430|Active Comparator|MBRT ClassRoom and Phone Application|MBRT ClassRoom and Phone Application
3021471|NCT02419430|Active Comparator|Phone application only|Phone application only
3021472|NCT02419430|Active Comparator|Questionnaires|Questionnaires
3021473|NCT02419417|Experimental|Monotherapy Treatment|Patients treated at various doses and schedules
3021474|NCT02419417|Experimental|Combination Therapy|Patients treated at selected doses and schdules
3021475|NCT02419404||Patients having cardiac surgery|Patients having cardiac surgery who have a pulmonary artery catheter will be eligible for inclusion in this study
3021476|NCT02419391|Experimental|Group 1|18-49 year old healthy subjects, receiving either 1x10E7TCID50 MVA BN RSV or Placebo
3021477|NCT02419391|Experimental|Group 2|18-49 year old healthy subjects, receiving either 1x10E8TCID50 MVA BN RSV or Placebo
3021478|NCT02419391|Experimental|Group 3|50-65 year old healthy subjects, receiving either 1x10E8TCID50 MVA BN RSV or Placebo
3021479|NCT02419378|Experimental|alemtuzumab|"Administration of 2 courses of alemtuzumab at an interval of 1 year. Course 1: Intravenous infusion of 12 mg alemtuzumab per day on 5 consecutive days.~Course 2: Intravenous infusion of 12 mg alemtuzumab per day on 3 consecutive days."
3021480|NCT02419365||PCD|Individuals with Primary Ciliary Dyskinesia will be assessed in a pure observational design without intervention
3021481|NCT02419352|Active Comparator|Sugammadex|Sugammadex is administered to reverse rocuronium-induced neuromuscular blockade at the end of elective surgery.
3021482|NCT02419352|Active Comparator|Neostigmine/atropine|Neostigmine combined to atropine is administered to reverse rocuronium-induced neuromuscular blockade at the end of elective surgery.
3021483|NCT02419326|Experimental|Couples|The patient and their significant other receive psychotherapy treatment for the patient's BED.
3021484|NCT02419313|Active Comparator|Placebo, then Xeomin|Subjects randomized to receive the placebo ( saline) will receive an equivalent volume as the active study drug (1cc). The injections will be into -10 hand and forearm muscles. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. The subject will then cross over to an Active Intervention arm to receive incobotulinumtoxinA which will be injected in the same pattern as the saline.
3021485|NCT02419313|Active Comparator|Xeomin, then Placebo|Subjects will all receive injections with incobotulinumtoxinA injections, 100unit/cc into 6-10 muscles of the forearm. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. These subjects will then cross over and receive placebo ( saline) in the same distribution as their second treatment.
3021486|NCT02419287|Experimental|crizotinib|250mg BID
3021487|NCT02419261|Active Comparator|Adductor Canal Blockade|In this group, patient will benefit of an ultrasound guided adductor canal blockade (20 ml of Ropivacaine 0.75%) as analgesic nerve blockade for their surgery of anterior cruciate ligament repair
3021488|NCT02419261|Active Comparator|Femoral Nerve Blockade|In this group, patient will benefit of an ultrasound guided femoral nerve blockade (20 ml of Ropivacaine 0.75%) as analgesic nerve blockade for their surgery of anterior cruciate ligament repair
3021489|NCT02419235|Placebo Comparator|20% Ethanol|Ten drops of unmedicated 20% ethanol must be administered under the tongue, three times per day, thirty minutes before or after meals, for six weeks.
3021490|NCT02419235|Experimental|Homoeopathic complex|Ten drops of 20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrum muriaticum 6cH and Scutellaria lateriflora 6cH will be administered under the tongue, three times per day, thirty minutes before or after meals, for six weeks.
3021491|NCT02419222|Experimental|Prism Adaptation|Prism Adaptation Treatment is 20 minutes long, administered 10 consecutive days
3021492|NCT02419209|Experimental|Individualised Homeopathic Remedy|A single individualised homeopathic remedy will be administered to each participant in the form of medicated sucrose pillules. The potency, dosage and frequency of administration will be individualised for each participant in accordance with the laws that govern homeopathic prescribing.
3022966|NCT02409927|Experimental|MCT homogenate 20 g|Meal with 20 g of MCT homogenate mixed in
3021496|NCT02419183||Sequence A|Participants will receive a computer administered Word List Recall (WLR) [SAMSTAR] on Test Day 1 and an examiner addminstered WLR [RAVLT] on Test Day 2 of the study.
3021497|NCT02419183||Sequence B|Participants will receive an examiner-administered WLR [RAVLT] on Test Day 1 and a computer adminstered WLR [SAMSTAR] on Test Day 2 of the study.
3021498|NCT02419170|Experimental|Surgery/Apheresis/Cyclophosphamide/Vaccine|"Standard of care surgery~Apheresis (between Day -28 and Day -7) approximately 12 weeks after surgery~Cyclophosphamide 300 mg/m^2 intravenously (Day -4)~Personalized vaccine (Day 1)~Booster dose of personalized vaccine (Day 43)~Booster dose of personalized vaccine (Day 85)"
3021499|NCT02419157|Active Comparator|Clearfil SE Bond Etch (CSE-E)|"CSE-E (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Enamel margins were selectively etched with 36% phosphoric acid for 15s and subsequently thoroughly rinsed and air-dried. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~Selective enamel etching with 36% phosphoric acid"
3021500|NCT02419157|Active Comparator|Xeno V+ Etch (XV-E)|"XV-E (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Enamel margins were selectively etched with 36% phosphoric acid for 15s and subsequently thoroughly rinsed and air-dried. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~Selective enamel etching with 36% phosphoric acid"
3021501|NCT02419157|Active Comparator|Clearfil SE Bon Non-etch (CSE-NE)|"CSE-NE (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~No selective enamel etching with 36% phosphoric acid"
3021502|NCT02419157|Active Comparator|Xeno V+ Non-etch (XV-NE)|"XV-NE (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~No selective enamel etching with 36% phosphoric acid"
3021503|NCT02419144|Active Comparator|AMI followed by campaigns|Behavioral interventions
3021504|NCT02419144|Active Comparator|Campaigns followed by AMI|Behavioral interventions
3021505|NCT02419131|Experimental|Behavioral Headache Therapy|A standard, manualized behavioral intervention for primary headache disorders
3021506|NCT02419131|Experimental|Cognitive Processing Therapy|A gold-standard treatment for PTSD, called Cognitive Processing Therapy
3021507|NCT02419131|Active Comparator|Treatment as Usual|Treatment as usual, receiving standard care for PTHA
3021508|NCT02419118|Experimental|Dara len dex|Daratumumab in combination with lenalidomide and dexamethasone
3021509|NCT02419118|Active Comparator|Len dex|Lenalidomide in combination with dexamethasone
3021510|NCT02419105|Active Comparator|Testosterone + Vitamin D|Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
3021511|NCT02419105|Active Comparator|Testosterone + Placebo|Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
3021512|NCT02419105|Active Comparator|Placebo + Vitamin D|Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
3021513|NCT02419105|Placebo Comparator|Control|Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
3021514|NCT02419092||Obstructive Sleep Apnea|Subjects scheduled to undergo bariatric surgery and with Obstructive Sleep Apnea
3021515|NCT02419092||No Obstructive Sleep Apnea, controls|Subjects scheduled to undergo bariatric surgery and without Obstructive Sleep Apnea, control group
3021516|NCT02419066||men and women with CD4 >=350|electronic monitoring of ARV adherence in men and women with CD4 >=350
3021517|NCT02419066||pregnant women with CD4 >=350|electronic monitoring of ARV adherence in pregnant women with CD4 >=350
3021518|NCT02419066||men and women with CD4 <200|electronic monitoring of ARV adherence in men and women with CD4 <200
3021519|NCT02419053||Pre-checklist|Surgical interventions performed for children before the introduction of the surgical safety checklist in Ontario, from October 2008 to September 2009.
3021520|NCT02419053||Post-checklist|Surgical interventions performed for children after the introduction of the surgical safety checklist in Ontario, from October 2010 to September 2011.
3021521|NCT02419040|Experimental|Barbotage|Ultrasound guided needling, lavage and steroid/lidocain injection (20 mg Triamcinolon/9 ml Lidocain 1%) Ultrasound guided lidocain injection (10 ml Lidocain 1%, sham group) and home exercises
3021522|NCT02419040|Active Comparator|Corticosteroid injection|Ultrasound guided steroid/lidocain injection (20 mg Triamcinolon/9 ml Lidocain 1%) and home exercises
3021523|NCT02419040|Sham Comparator|Lidocain injection (sham)|Ultrasound guided lidocain injection (10 ml Lidocain 1%, sham group) and home exercises
3021614|NCT02418468|Experimental|Indacaterol 150 mcg|Indacaterol 150 mcg capsules for inhalation once daily delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
3021524|NCT02419027|Experimental|GI Flora|Lactobacillus acidophilus LA1 1.312% Lactobacillus rhamnosus LR5 0.656% Lactobacillus paracasei LPC5 0.656% Bifidobacterium lactis BL3 1.312% Bifidobacterium breve BR3 1.312% Pediococcus pentosaceus SL4 1.312% Prolac-T(heat-killed L. acidophilus LA1) 24.286% Dextrose 60.000% Maltodextrin 7.154% Lemon flavor 1.000% Mg-stearate 1.000% TOTAL 100% (1.4g)%
3021525|NCT02419027|Placebo Comparator|placebo|Dextrose 89.846% Maltodextrin 7.154% Lemon flavor 1.000% Mg-stearate 1.000% TOTAL 100% (1.4g)%
3021526|NCT02419014|No Intervention|Usual Care|Participants in this group will continue receiving their previously prescribed therapy during the 8 week data collection period.
3021527|NCT02419014|Active Comparator|Active CES Device|The Alpha-Stim® device is a Class II FDA-approved device for the delivery of cranial electrotherapy using microcurrents that are delivered via two electrodes worn on the earlobes. Active CES devices will be pre-programmed by the manufacturer to deliver a bipolar, asymmetric rectangular waveform at a current of 100 µa, a level that is generally undetectable by the wearer of the device. At these settings, the manufacturer recommends a treatment duration of 60 minutes. Participants will not be able to alter the settings in any way.
3021528|NCT02419014|Placebo Comparator|Sham CES Device|The inactive (sham) devices look identical to the active device but are inactivated by the manufacturer so as not to deliver any electrical current.
3021529|NCT02419001|Experimental|Period 1 - Treatment Sequence AB|"Treatment Sequence AB:~Period 1: Ceftriaxone 1 g infused IV over 30 minutes~[Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg (1 x 75 mg capsule) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion]"
3021530|NCT02419001|Experimental|Period 1 - Treatment Sequence AC|"Period 1: Ceftriaxone 1 g infused IV over 30 minutes~[Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg (2 x 75 mg capsules) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion]"
3021531|NCT02419001|Experimental|Period 2 - Treatment Sequence AB|"Treatment Sequence AB:~[Period 1: Ceftriaxone 1 g infused IV over 30 minutes]~Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg (1 x 75 mg capsule) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion"
3021532|NCT02419001|Experimental|Period 2 - Treatment Sequence AC|"[Period 1: Ceftriaxone 1 g infused IV over 30 minutes]~Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg (2 x 75 mg capsules) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion"
3021533|NCT02418988|Experimental|TACE plus rAd-p53|TACE plus rAd-p53 artery injection'
3021534|NCT02418988|Active Comparator|TACE|TACE will be applied alone
3021535|NCT02418975|Experimental|Very low-calorie protein-based diet|Patients will receive a homemade very low-calorie (~5 kcal/kg of ideal body weight /day) protein-based formula (milk proteins; 1.2 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
3021536|NCT02418975|Active Comparator|Hypocaloric diet|Patients will receive a commercial balanced enteral formula (~20 kcal/kg of ideal body weight /day; protein content, 1.0 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
3021537|NCT02418962|Experimental|Group 1 (pilot group)|Group 1 will be comprised of 3 volunteers who will be vaccinated first before the rest for demonstration of safety. The safety volunteers will receive 2 escalating doses of PfSPZ vaccine at a two week interval, 1.35x10^5 and 2.7x10^5 PfSPZ.
3021538|NCT02418962|Experimental|Group 2|The second group of 14 - 20 volunteers will receive three vaccinations of 2.7x10^5 PfSPZ Vaccine that will be given at 0, 8 and 16 weeks
3021539|NCT02418962|Placebo Comparator|Group 3|The third group of 7 - 10 volunteers will act as control group for group 2 and will receive three injections of normal saline at 0, 8 and 16 weeks respectively.
3021540|NCT02418949|Experimental|Cyproheptadine + AMP|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of Active movement practice (AMP) treatment (1 hour sessions 3x/week). Dose will be titrated down to zero in the 2 weeks following treatment."
3021541|NCT02418949|Placebo Comparator|Placebo for Cyproheptadine + Stretching|"Placebo for Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of passive cyclical stretching treatment (1 hour sessions 3x/week). Each session will involve 20 min of stretching followed by 10 minutes of rest.~Dose will be titrated down to zero in the 2 weeks following treatment."
3021542|NCT02418949|Active Comparator|Cyproheptadine + Stretching|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of passive cyclical stretching treatment (1 hour sessions 3x/week). Each session will involve 20 min of stretching followed by 10 minutes of rest.~Dose will be titrated down to zero in the 2 weeks following treatment."
3021543|NCT02418949|Active Comparator|Placebo for Cyproheptadine + AMP|"Placebo for Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of Active movement practice (AMP) treatment (1 hour sessions 3x/week). Dose will be titrated down to zero in the 2 weeks following treatment."
3021544|NCT02418936||WS|WS diagositic kit
3021545|NCT02418936||LVAS|LVAS diagositic kit
3021546|NCT02418910||bipolar outpatients in any clinical state|Patients with Bipolar Disorder. Study does not provide a treatment intervention.
3021547|NCT02418884|Other|CAD+DM|Using self controlled study to validate the hypothesis that the treatment of rosuvastatin could increase the score of CAC density in CAD patients with diabetes mellitus.
3021548|NCT02418871|Experimental|Single arm|
3021549|NCT02418858|Active Comparator|Awake DBS Surgery|"Deep brain stimulation surgery: Essential tremor patients undergoing traditional awake DBS surgery utilizing microelectrode recordings and intraoperative stimulation."
3021615|NCT02418455|Experimental|4 mg/kg of UX003|Initial treatment period 48 weeks. Continuation period up to 240 weeks.
3055322|NCT02192463|Experimental|NVP ER 300 mg (ECR 20%) Fast Release|
3021550|NCT02418858|Active Comparator|Asleep DBS Surgery|Deep brain stimulation surgery: Essential tremor patients undergoing DBS surgery under general anesthesia utilizing intraoperative imaging to verify the stereotactic accuracy of DBS electrode placement at the time of surgery.
3021551|NCT02418845|Experimental|SYM-1219|Administered orally
3021552|NCT02418845|Placebo Comparator|Placebo|Administered orally
3021553|NCT02418832|Other|Men with Azoospermia, sperm cell aspiration and TEFNA|Men between 16-80 with Obstructive and Non-Obstructive Azoospermia; Sperm cell aspiration,TEFNA and Ultrasound Guidance
3021554|NCT02418819|Experimental|PF-06412562 3mg|PF-06412562 3mg BID
3021555|NCT02418819|Experimental|PF-06412562 9mg|PF-06412562 9mg BID
3021556|NCT02418819|Experimental|PF-06412562 45mg|PF-06412562 45mg BID
3021557|NCT02418819|Placebo Comparator|Placebo|Placebo BID
3021558|NCT02418806|Experimental|Therapy group with follow up sessions|Weekly psychotherapy groups during 4 months with a monthly follow up period (12 months)
3021559|NCT02418806|Experimental|Therapy group without follow up sessions|Weekly psychotherapy groups during 4 months
3021560|NCT02418806|Active Comparator|Active comparator group|Weekly self-help groups during 4 months with a monthly follow up period (12 months)
3021561|NCT02418793|Experimental|Dose Cohort 1|Lowest MOD-5014 dose tested in the study
3021562|NCT02418793|Experimental|Dose Cohort 2|MOD-5014 Dose cohort 2
3021563|NCT02418793|Experimental|Dose Cohort 3|MOD-5014 Dose cohort 3
3021564|NCT02418793|Experimental|Dose Cohort 4|MOD-5014 Dose cohort 4
3021565|NCT02418793|Experimental|Dose Cohort 5|MOD-5014 Dose cohort 5
3021566|NCT02418793|Experimental|Dose Cohort 6|Highest MOD-5014 dose tested in the study
3021567|NCT02418780|Experimental|Tai Chi|6-month Tai Chi training program combined with usual medical care
3021568|NCT02418780|No Intervention|Usual Care|Waitlist control group receiving usual medical care alone
3021569|NCT02418767|Experimental|Low dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
3021570|NCT02418767|Experimental|Mid dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
3021571|NCT02418767|Experimental|High dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
3021572|NCT02418754|Experimental|Group 1|Group 1 will receive REGN2176-3 dosing regimen 1
3021573|NCT02418754|Experimental|Group 2|Group 2 will receive REGN2176-3 dosing regimen 2
3021574|NCT02418754|Experimental|Group 3|Group 3 will receive Intravitreal Aflibercept Injection (IAI) monotherapy
3021575|NCT02418741|Experimental|Degree of neck flextion|Two degrees of neck flexion were achieved using a 4 cm or 8 cm height of pillow
3021576|NCT02418728||persons with obesity|
3021577|NCT02418728||lean persons|
3021578|NCT02418715|Experimental|Water Aerobics Training|The training period was composed by a 12-week macrocycle with two sessions per week. The macrocycle was divided into three four-week mesocycles that were, in turn, divided into four one-week microcycles composed by two training sessions. Each training session took 45 min. Nine different water-aerobics exercises were used during the training period. These exercises were performed alternating the right and left limbs. Exercise intensities were controlled using the Borg Scale. Interval training was used alternating intensities ranged between 9 (easy) and 15 (hard). During the first mesocycle, participants performed sets of 3min at intensity 13 interspersed by 2min at intensity 9; during the second mesocycle, sets of 3min at intensity 15 followed by 2min at intensity 9 were performed; finally, sessions of the third mesocycle were composed by sets of 3min at intensity 15 followed by 2min at intensity 11.
3021579|NCT02418715|No Intervention|Control|No training, no intervention.
3021580|NCT02418702|Experimental|0.2mg/kg ketamine|After being assessed, and giving informed consent, participants would receive 0.2mg/kg ketamine. Their suicidal thinking, depression, and other symptoms would be monitored acutely for 240 min after drug infusion, and the for lasting changes the next day, at hospital discharge, 2 weeks, and 10 weeks.
3021581|NCT02418702|Placebo Comparator|placebo|After being assessed, and giving informed consent, participants would receive a placebo. Symptoms will be monitored.
3021582|NCT02418689|Experimental|NOV120101 (Poziotinib)|Single arm study with NOV120101(poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval
3021583|NCT02418676|Experimental|Gel with HPβCD-I complex|A quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
3021584|NCT02418676|Active Comparator|Gel with insulin|A quantity of 5 grams of gel with insulin was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
3021585|NCT02418676|Placebo Comparator|Control gel|A quantity of 5 grams of gel without active was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
3021586|NCT02418663|Other|Postoperative elective surgical patients|Patients undergoing major elective thoracic and abdominal, the latter group including upper gastrointestinal, esophageal, and colorectal procedures. In this group FR will predicted by administering a fluid challenge of 250 ml of Lactated Ringer's solution and measuring SV with the ccNexfin
3021587|NCT02418650|Experimental|Part 1|A single oral 300 mg tablet of ODM-201 followed by single intravenous 100 microg of 14C-ODM-201 containing not more than 37 kBq (1000 nCi)14C
3021588|NCT02418650|Experimental|Part 2|A single oral solution of 300 mg 14C-ODM-201 containing no more than 6.3 MBq (171 microCi) 14C
3021589|NCT02418637|Experimental|Farm workers|This is a one arm intervention including farm workers and owners
3021590|NCT02418624|Experimental|Dose escalation|carboplatin, olaparib
3021591|NCT02418598|Experimental|Cohort1|The target putamen for AAV-hAADC-2 infusion is identified on MRI image that has been taken prior to the operation, and then subjects will be bilaterally infused with a total volume of 200 µL at a total of 4 sites (2 sites in left putamen, 2 sites in right putamen; 50 µL per site) at a flow rate of 3 µL per minute.
3021592|NCT02418598|Experimental|Cohort2|The target putamen for AAV-hAADC-2 infusion is identified on MRI image that has been taken prior to the operation, and then subjects will be bilaterally infused with a total volume of 600 µL at a total of 4 sites (2 sites in left putamen, 2 sites in right putamen; 150 µL per site) at a flow rate of 3 µL per minute.
3021593|NCT02418585|Experimental|Intranasal Esketamine plus oral antidepressant|Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase. All participants will start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg per investigator's discretion. On Days 8 and 11 the dose may be increased to 84 mg (from 56 mg), remain same, or be reduced to 56 mg (from 84 mg) per investigator's discretion. On Day 15, a dose reduction from 84 mg to 56 mg is permitted, if required for tolerability; no dose increase permitted. After Day 15, dose must remain stable (unchanged). In addition participants will simultaneously initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
3021594|NCT02418585|Active Comparator|Placebo plus oral antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (ie, duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
3021595|NCT02418572|Experimental|Transdermal testosterone gel|"Patients will receive once daily application of 0.55 gr TTG (Testosterone gel 1%; Laboratories Besins International,Paris,France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~Pituitary down-regulation will be induced by daily injections of 0.1mg triptorelin started on day 21 of the next cycle following enrollment in the study, up to and including the day of hCG administration.~After 2 weeks of down-regulation, daily SC injections of HP-hMG (Menopur®) (300 IU/day) will be administered up to the day of hCG administration.~Ovulation triggering will be induced with 250μg rhCG (Ovidrelle®) followed by oocyte pick-up ~36 hours later and ICSI. A maximum of 2 embryos, following each center's national criteria of single embryo transfer, will be transferred 3 days later.~Luteal phase support with be performed with progesterone tablets ( Utrogestan®) (200mg x3, intravaginally)."
3021596|NCT02418572|Placebo Comparator|Placebo transdermal gel|"Patients will receive once daily application of 0.55 gr identical placebo gel starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~Pituitary down-regulation will be induced by daily injections of 0.1mg triptorelin started on day 21 of the next cycle following enrollment in the study, up to and including the day of hCG administration.~After 2 weeks of down-regulation, daily SC injections of HP-hMG (Menopur®) (300 IU/day) will be administered up to the day of hCG administration.~Ovulation triggering will be induced with 250μg rhCG (Ovidrelle®) followed by oocyte pick-up ~36 hours later and ICSI. A maximum of 2 embryos, following each center's national criteria of single embryo transfer, will be transferred 3 days later.~Luteal phase support with be performed with progesterone tablets ( Utrogestan®) (200mg x3, intravaginally)."
3021597|NCT02418559|Experimental|JNJ-63623872 (300 mg) or Placebo|Participants will receive JNJ-63623872 300 milligram (mg) or placebo tablet orally once on Day 1 under fasted conditions.
3021598|NCT02418559|Experimental|JNJ-63623872 (600 mg) or Placebo|Participants will receive JNJ-63623872 600 mg (2*300 mg) or placebo tablet orally once on Day 1 under fasted conditions.
3021599|NCT02418559|Experimental|JNJ-63623872 (1200 mg) or Placebo|Participants will receive JNJ-63623872 1200 mg (4*300 mg) or placebo tablet orally once on Day 1 under fasted conditions.
3021600|NCT02418546|Active Comparator|In-Person Nutritional Counseling|Participants in the in-person nutritional counseling arm will meet with a Registered Dietitian at every clinic visit and will also receive regular phone calls to monitor weight and food intake. Participants' individual dietary needs will be calculated using baseline calorie consumption, weight history, disease status and current activity level.
3021601|NCT02418546|Experimental|E-Health App for Nutritional Counseling|Participants randomized to the e-Health App arm with receive nutritional counseling using the e-Health Application. Participants will enter weights at home and complete electronic food records using the App. Participants' individual dietary needs will be calculated using baseline calorie consumption, weight history, disease status and current activity level. Participants will receive these calorie recommendations through the Application.
3021602|NCT02418546|No Intervention|Standard Care|Participants are allowed to receive all usual treatments and medications. Participation in other research studies is allowed.
3021603|NCT02418533|Experimental|Mono-menotropin protocol|Stimulation Group 1: Mono-Menotropin Protocol Fifty patients will undergo the standard of care COS for IVF using Menopur only. Patients will receive 300 IU of Menopur injected subcutaneously daily for the first five days of stimulation. Thereafter, Menopur may be adjusted (to optimize ovarian response by patient's physician) in 75 IU increments up to a total of 450 IU Menopur daily up to and including day of hCG trigger.
3021604|NCT02418533|Experimental|rFSH protocol|Stimulation Group 2: Recombinant follicle stimulating hormone (rFSH) Protocol Fifty patients will undergo the standard of care COS for IVF using Gonal-f (EMD Serono, USA) Protocol. Patients will receive Gonal-f (300 IU) administered subcutaneously daily for the first five days of stimulation. Thereafter, Gonal-f may be adjusted (to optimize ovarian response by the patient's physician) in 75 IU increments up to a total of 450 IU daily up to and including day of hCG trigger.
3021605|NCT02418520|Experimental|Miswak chewing|Chewing Sticks
3021606|NCT02418520|No Intervention|H.Pylori|Oral H.Pylori
3021607|NCT02418507|Active Comparator|Proprietary Probiotic Blend|A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
3021608|NCT02418507|Placebo Comparator|Placebo|The placebo is administered to randomized healthy participants
3021609|NCT02418494||Observational (ANCHOR HRQoL interview, cognitive interview)|Participants complete the ANCHOR HSIL HRQoL interview over 45-60 minutes, comparing the list of symptoms, concerns, or HRQOL impacts related to HSIL diagnosis and treatment. Some patients also undergo a cognitive interview for up to 3 sessions.
3021610|NCT02418481|Experimental|Group A|DC-CIK cells will be used against tumor cells.
3021611|NCT02418481|Experimental|Group B|γδ T cells will be used against tumor cells.
3021612|NCT02418481|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
3021613|NCT02418468|Experimental|Placebo|Matching placebo indacaterol capsules for inhalation once daily delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
3021616|NCT02418429|Active Comparator|waxy maize starch|pancake test meal - waxy maize starch
3021619|NCT02418429|Active Comparator|resistant starch and whey protein|pancake test meal - resistant starch and whey protein
3021620|NCT02418416|Experimental|Double activation|The Oocytes in this arm will undergo double activation with Ca ionophore 5 micro mol for 20 min them Strontium chloride 10 micro mol for 60 min.
3021621|NCT02418416|No Intervention|Control arm|The Oocytes will undergo Intracytoplasmic sperm injection only
3021622|NCT02418403|Active Comparator|PREPARE|"Access to Prepare for Your Care website and written encouragement to discuss ACP with one's PCP."
3021623|NCT02418403|Experimental|PREPARE+financial incentive|"Access to Prepare for Your Care website and written encouragement to discuss ACP with one's PCP; offer of $50 to complete the website and entry into $1000 lottery for discussing ACP with one's PCP."
3021624|NCT02418390|No Intervention|No prophylactic central dissection|Patients underwent total thyroidectomy for papillary thyroid carcinoma, without prophylactic central lymph node dissection
3021625|NCT02418390|Active Comparator|Prophylactic central dissection|Patients underwent total thyroidectomy for papillary thyroid carcinoma, with prophylactic central lymph node dissection
3021626|NCT02418377||Obese children|"The obese subject must meet all of the following inclusion criteria to participate in this study:~Ideal body weight for height (WFH) of at least 140% or BMI for age above 97th percentile~Overweight before 10 years of age~Informed consent from both obese children subject and legal representative e.g. parents"
3021627|NCT02418377||Family members of obese children|"Family member must meet all of the following inclusion criteria to participate in this study:~Must be parent or direct sibling of obese subject~Informed consent from both subject and parent is subject is below 21 years of age"
3021628|NCT02418364|Placebo Comparator|placebo reflexology|Placebo reflexology treatment
3021629|NCT02418364|No Intervention|control group|Data will be taken from questionnaires
3021630|NCT02418364|Experimental|reflexology treatment|Reflexology treatment
3021631|NCT02418351|Experimental|Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC)|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
3021632|NCT02418338|Experimental|dmd children|echocardiography
3021633|NCT02418338|Other|healthy children|echocardiography
3021634|NCT02418325|Experimental|AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
3021635|NCT02418312|Active Comparator|histamine-2 receptor antagonist group|famotidine (40 mg qd) plus thienopyridine for 6 months.
3021636|NCT02418312|Placebo Comparator|Placebo group|placebo plus thienopyridine for 6 months.
3021637|NCT02418299|Experimental|IncontiLase Er:YAG laser treatment|Er:YAG laser treatment for stress and mixed urinary incontinence
3021638|NCT02418286||Low Back Pain Participant Registry|Patients with low back pain in traditional Korean medicine rehabilitation clinic
3021639|NCT02418273|Experimental|Denosumab|These subjects will receive two sequential doses of denosumab
3021640|NCT02418273|No Intervention|No drug intervention|These subjects do not receive denosumab
3021641|NCT02418260|Active Comparator|Open reduction and plate osteosynthesis|Open reduction and internal fixation with DCP 4.5mm plate.
3021642|NCT02418260|Experimental|Bridge Plate|Patients will be submitted to closed reduction and anterior bridge plate osteosynthesis (narrow 4.5mm DCP plate will be used)
3021643|NCT02418260|Experimental|Intramedullary nail|Patients will be submitted to closed reduction and locked intramedullary nail osteosynthesis.
3021644|NCT02418247|Active Comparator|low dose RAI|Low dose RAI (radioactive iodine I-131, 30mCi) will be given to ablate remnant thyroid tissue.
3021645|NCT02418247|Sham Comparator|diagnostic RAI|Diagnostic RAI (radioactive iodine I-123, 2-6mCi) will be given to achieve postRAI scan.
3021646|NCT02418221|Experimental|DAOSiN®/ Placebo & ProvokAmin® Ingestion|A sample of blood is drawn from Patient, blood pressure & pulse are recorded. Patient will ingest 2 capsules of either DAOSiN® or Placebo, followed by 2 tablets of ProvokAmin 20 minutes later. After an additional 40 minutes blood pressure and pulse are recorded and another sample of blood is drawn. Patient is handed a questionaire for self-evaluation to record any symptoms for the following After between 7 and 15 days the whole cycle is repeated switching between active treatment and Placebo.
3021647|NCT02418208||Test retest- 2 visits|Eligible participants will arrive for 2 testing visits a week apart and an optional third visit within 6-12 months.
3021648|NCT02418208||Single Visit|Eligible participants will arrive for a single testing visit
3021649|NCT02418195|Active Comparator|MDD with recent Suicide Attempt|All subjects with Major Depressive Disorder with a recent Suicide Attempt (in the past 2 weeks) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
3021650|NCT02418195|Active Comparator|MDD with Suicidal Ideation no attempt|All subjects with Major Depressive Disorder with recent Suicidal Ideation (in the past 7 days) without a recent Suicide Attempt (in the past 6 months) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
3021651|NCT02418195|Active Comparator|MDD without Suicidal Ideation no attempt|All subjects with Major Depressive Disorder without recent Suicidal Ideation (in the past 7 days) without a recent Suicide Attempt (in the past 6 months) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
3021652|NCT02418195|No Intervention|Healthy Controls|Healthy Control subjects without a psychiatric diagnosis will have a one-time blood draw to examine miRNAs.
3021653|NCT02418182|Placebo Comparator|Control|Control group participants will receive unlabelled 2 non-active placebo tablets approximately 1 hour prior to transvaginal oocyte retrieval procedure.
3021654|NCT02418182|Experimental|Experimental|Experimental group participants will receive 2 acetaminophen 500mg tablets approximately 1 hour prior to transvaginal oocyte retrieval procedure.
3021655|NCT02418169||retrospective, severe traumatic brain injury|All patients in 2010-2014 with severe traumatic brain injury admitted to Turku University Central Hospital (TUCH)
3021656|NCT02418169||retrospective, craniofacial fracture|All patients in 2010-2014 with craniofacial fracture admitted to TUCH.
3021657|NCT02418169||prospective, severe traumatic brain injury|All patients in 2015-2017 with severe traumatic brain injury admitted to Turku University Central Hospital (TUCH)
3021658|NCT02418169||prospective, craniofacial fracture|All patients in 2015-2017 with craniofacial fracture admitted to TUCH.
3021659|NCT02418156||Single arm|Observation of subjects undergoing femoral arterial reconstruction using CorMatrix ECM for vascular repair.
3021660|NCT02418143||Implantable electronic device placement|CorMatrix CanGaroo ECM envelope for an implantable electronic device placement following a battery change out or upgrade.
3021661|NCT02418130|Experimental|UDCA004|UDCA004
3021662|NCT02418130|Placebo Comparator|Placebo of UDCA004|Placebo of UDCA004
3021663|NCT02418117|Experimental|Stereolitographic template's accuracy|Evaluating the accuracy of stereolitographic template comparing the final implant insertion to the planned implant position at coronal and apical level
3021664|NCT02418104|Experimental|CHS-1701|CHS-1701 followed by CHS-1701
3021665|NCT02418104|Active Comparator|Neulasta|Neulasta followed by Neulasta
3021666|NCT02418091|Experimental|Intervention Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
3021667|NCT02418091|No Intervention|Control/No Intervention|Group of subjects that will serve as a comparison group. These subjects will not be approached/enrolled for this study.
3021668|NCT02418078||Geriatri|patients ageing ≥ 65 yr undergoing herniorrhaphy with local infiltration anesthesia and sedation
3021669|NCT02418078||non-geriatri|patients ageing 19-64 yr undergoing herniorrhaphy with local infiltration anesthesia and sedation
3021670|NCT02418065|Experimental|treated group|testosteron, oral nutritional supplementation, n3 polyunsaturated fatty acid, training on ergonomic bicycle
3021671|NCT02418065|Other|control group|oral nutritional supplementation
3021672|NCT02418052|Experimental|neck flexion group|Patients who fixed in neck flexion position after MIE
3021673|NCT02418052|No Intervention|control group|Patients without posture intervention after MIE
3021674|NCT02418039|Placebo Comparator|MHE and normal protein diet|Normal protein content (0.8 g/kg/day)
3021675|NCT02418039|Experimental|MHE and high protein diet|Patients with minimal hepatic encephalopathy will received a high protein diet (1.5 g/kg/day)
3021676|NCT02418026|No Intervention|Control|women who attended the obstetrics department for a scheduled or unplanned cesarean section and who benefited from general care
3021677|NCT02418026|Experimental|Hypnosis|women who attended the obstetrics department for a scheduled or unplanned cesarean section and who benefited from a hypnosis session during the surgery in addition to general care
3021678|NCT02418013|Experimental|Fresh cord blood(experimental group A)|16 males and 16 females are assigned to the experimental group A. Dropout is 20 percent in each gender.
3021679|NCT02418013|Experimental|Frozen cord blood(experimental group B)|16 males and 16 females are assigned to the experimental group B. Dropout is 20 percent in each gender.
3021680|NCT02418013|Experimental|Frozen plasma(experimental group C)|16 males and 16 females are assigned to the experimental group C. Dropout is 20 percent in each gender.
3021681|NCT02418013|Placebo Comparator|Placebo group|16 males and 16 females are assigned to the Placebo group. Dropout is 20 percent in each gender. Total participants are 64 in males and 64 in females.
3021682|NCT02418000|Experimental|Lowest dose of E6201 weekly|Lowest dose of E6201 administered as an IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle)
3021683|NCT02418000|Experimental|Highest dose of E6201 weekly|Highest dose of E6201 administered as an IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle)
3021684|NCT02418000|Experimental|Lowest dose of E6201 twice weekly|Lowest dose of E6201 administered as an IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle)
3021685|NCT02418000|Experimental|Highest dose of E6201 twice weekly|Highest dose of E6201 administered as an IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 22 and 25, repeated every 28 days (= 1 cycle)
3021686|NCT02418000|Experimental|Mid dose of E6201 twice weekly|Mid dose of E6201 administered as an IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22, 25, repeated every 28 days (= 1 cycle)
3021687|NCT02417987|Active Comparator|High Volume injection|"A total volume of 50 ml:~10 mls 0.5% bupivacaine hydrochloride and~20 mg of Depomedrol (hydrocortisone)~40 mls saline (NaCl) HVI is injected one time at baseline and thereafter the group received sham treatment at 2 weeks, 4 weeks and after 6 weeks."
3021688|NCT02417987|Active Comparator|Autologous conditioned plasma (ACP)|"Whole blood was drawn from the patients using arthrex system (total of 10 mls whole blood). After that the whole blood is spined for 5 minutes and ACP with platelets and growth factors is separated from the red and white blood cells (4 mls).~The ACP is injected 4 times (at baseline, 2 weeks, 4 weeks and after 6 weeks)"
3021689|NCT02417987|Sham Comparator|Placebo|A few drops of saline is injected in the soft tissue away from the tendon.
3021690|NCT02417974|Experimental|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT) via colonoscopy
3021691|NCT02417974|No Intervention|Control|No Fecal Microbiota Transplant (FMT) via colonoscopy
3021692|NCT02417961|Experimental|Benralizumab 30 mg|Benralizumab administered subcutaneously every 4 weeks
3021693|NCT02417948|Experimental|Arm I (educational brochure, online educational tutorial)|Participants receive a skin cancer educational and preventive brochure distributed by the National Cancer Institute and watch a 30-minute online tutorial video called X-Plain about skin cancer, preventative behaviors, and skin self-examinations.
3021694|NCT02417948|Active Comparator|Arm II (educational brochure)|Participants receive an educational brochure as in Arm I.
3021695|NCT02417935|Experimental|Duloxetine|20 milligrams (mg) duloxetine orally once a day (QD) for one week and then 40 mg duloxetine orally QD for 3 weeks. Duloxetine dosage may be increased up to 60 mg QD at week 4 or week 8. Placebo will be given with duloxetine for blinding. Dosage will be tapered down during the final week of the study.
3021696|NCT02417935|Active Comparator|Pregabalin|150 mg pregabalin orally twice a day (BID) for 1 week and then 300 mg pregabalin orally BID for 3 weeks. Pregabalin dosage may be increased up to 450 mg BID at week 4 or 8, and increased up to 600 mg BID at week 8. Placebo will be given with pregabalin for blinding. Dosage will be tapered down during the final week of the study.
3021697|NCT02417922|Experimental|Autologous conditioned plasma (ACP)|"Whole blood was drawn from the patients using arthrex system (total of 10 mls whole blood). After that whole blood spinning is conducted for 5 minutes and ACP with platelets and growth factors is separated from the red and white blood cells (around 4 mls).~ACP is injected at baseline, 2 weeks, 4 weeks and after 6 weeks from injury date."
3021698|NCT02417922|Placebo Comparator|Saline|Saline (4 mls) is injected around the ruptured achilles tendon at baseline, 2 weeks, 4 weeks and after 6 weeks from injury date.
3021699|NCT02417909||Healthy volunteers|This group is composed of healthy teenagers that volunteered to participate in the trial and that will answer questionnaires about quality of life. Parents will anwser questionnaires too.
3021700|NCT02417909||Obese teenagers|This group is composed of obese teenagers that have been recruited to participate in the trial and that will answer different questionnaires quality of life. Parents will anwser questionnaires too.
3021701|NCT02417896|Experimental|Spironolactone|The intervention group will receive spironolactone. The drug will be administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently, three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3.
3021702|NCT02417896|No Intervention|No spironolactone|Cardiac surgical patients requiring cardiopulmonary bypass and aortic cross clamp, randomised not to receive spironolactone will be followed for 10 days after surgery.
3021703|NCT02417883|Experimental|Furosemide Stress Test|Furosemide stress test will be perform to patients scheduled for kidney bipsy. The test consist in 1.5 miligrams per kilogram of weight of intravenous furosemide administration, along with urinary output follow up and measurement for 6 hours. The urinary output will be replaced intravenously with normal saline to avoid dehydration and/or hypotension.
3021704|NCT02417870|Experimental|aldesleukin|
3021705|NCT02417857|Experimental|Laparoscopic Cholecystectomy (SILC)|Group 1: Single Incision Laparoscopic Cholecystectomy (Intervention)
3021706|NCT02417857|Experimental|Laparoscopic Cholecystectomy (CLC)|Group 2: Conventional Laparoscopic Cholecystectomy (Intervention)
3021707|NCT02417844|Active Comparator|Tamsulosin HCl|
3021708|NCT02417844|Active Comparator|Tamsulosin|
3021709|NCT02417831|Active Comparator|tamsulosin capsules|
3021710|NCT02417831|Active Comparator|tamsulosin HCl capsules|
3021711|NCT02417818|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Plasma Therapy (PlasmaDerm)"
3021712|NCT02417818|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.~Intervention: Plasma Therapy (PlasmaDerm)"
3021713|NCT02417818|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Plasma Therapy (PlasmaDerm)"
3021714|NCT02417818|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Plasma Therapy (PlasmaDerm)"
3021715|NCT02417818|Experimental|Second-Degree Burn (repetitive)|"Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
3021716|NCT02417818|Experimental|Skin Excision (for Skin Graft) (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
3021717|NCT02417818|Experimental|Chronic Wound (repetitive)|"Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
3021718|NCT02417818|Active Comparator|Intact Skin (repetitive)|"Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
3021719|NCT02417818|Experimental|Hypertrophic burn scar|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
3021720|NCT02417818|Experimental|Hypertrophic burn scar (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
3021721|NCT02417818|Experimental|Flap|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
3021722|NCT02417818|Experimental|Flap (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
3021723|NCT02417805|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
3022139|NCT02415335|Placebo Comparator|Placebo|Injection of 2 ml isotonic NaCl intravenously minimum 30 minutes preoperative.
3055323|NCT02192463|Experimental|NVP ER 400 mg (KCR 20%) Medium Release|
3021724|NCT02417805|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
3021725|NCT02417805|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
3021726|NCT02417805|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
3021727|NCT02417792||control|group of healthy participants
3021728|NCT02417792||Topical psoriasis treatment|Group of patients who are treated with topical medications for psoriasis
3021729|NCT02417792||Systemic psoriasis treatment|Group of patients who are treated with systematic medications for psoriasis
3021730|NCT02417779|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3021731|NCT02417779|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size must not be less than 1% of TBSA.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3021732|NCT02417779|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3021733|NCT02417779|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3021734|NCT02417779|Experimental|Second-Degree Burn (repetitive)|"Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3021735|NCT02417779|Experimental|Skin Excision (for Skin Graft) (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size must not be less than 1% of TBSA.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3021736|NCT02417779|Experimental|Chronic Wound (repetitive)|"Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3021737|NCT02417779|Active Comparator|Intact Skin (repetitive)|"Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3021738|NCT02417779|Experimental|Hypertrophic burn scar|"Group I (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn scar.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3021739|NCT02417779|Experimental|Hypertrophic burn scar (repetitive)|"Group J (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn scar.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3021740|NCT02417779|Experimental|Flap|"Group K (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3021741|NCT02417779|Experimental|Flap (repetitive)|"Group L (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
3021742|NCT02417753|Experimental|AZD9150 in People with Malignant Ascites|AZD9150 over a 28 day cycle
3021743|NCT02417701|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3021744|NCT02417688|Experimental|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of 4-8 mCi of Cu[64]-25%-CANF-Comb with a mass no more than 100 μgrams followed by PET-MR Imaging
3021745|NCT02417675|Active Comparator|Standard of Care (SOC)|"Women who choose the SOC will receive postpartum antiretroviral therapy (ART) services at their nearest primary care clinic, following the Standard of Care for Mothers. Details are provided in the intervention description.~Infants receive the same care in each arm, according to the Standard of Care for Infants."
3021746|NCT02417675|Experimental|Intervention (AC)|"Women who choose the Community-based Adherence Clubs (AC) will receive postpartum antiretroviral therapy (ART) services at an AC, rather than at their nearest primary care clinic as in the SOC arm. Details are provided in the intervention section.~Infants receive the same care in each arm, according to the Standard of Care for Infants."
3021747|NCT02417662|Active Comparator|Chemotherapy alone|Standard platinum-based doublet chemotherapy
3021748|NCT02417662|Experimental|Chemotherapy + Radical Radiotherapy (Conventional RT and SABR)|Standard platinum-based doublet chemotherapy followed by radical RT (conventional or SABR) to the primary and SABR to the metastatic sites
3021749|NCT02417649|Experimental|Ismigen|Treatment over 3 successive months. One sublingual tablet every day on the first ten days of each month, followed by twenty days of rest.
3021750|NCT02417649|Placebo Comparator|Placebo|Treatment over 3 successive months. One sublingual tablet every day on the first ten days of each month, followed by twenty days of rest.
3021815|NCT02417272|Experimental|Anterior Cervical Decompression and Fusion (ACDF)|Interbody fusion by replacing disc space with a cage packed with bone substitute, and inserted into the anterior portion of the interspace.
3021902|NCT02416713|Experimental|Opt-in Blocking|Participants will have to initiate Cellcontrol DriveID device when entering the vehicle; the blocking settings will be pre-set to block all calls and text messages when the car is in motion.
3055324|NCT02192463|Experimental|NVP ER 400 mg (KCR 30%) Slow Release|
3021751|NCT02417636|Experimental|Nurse-initiated and monitored ART|This is an experimental task shifting of ART initiation and monitoring from a clinician-led model to a nurse-led model. Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
3021752|NCT02417636|Active Comparator|Clinician - initiated and monitored ART|This is Standard of Care for the Uganda Ministry of Health to compared with the experimental task shifting. Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Clinicians (Clinical Officer or Medical Officer) and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually.
3021753|NCT02417623|Experimental|Smartphone intervention group|The experimental group will receive the standard diet intervention for weight loss plus free Smartphone app plus a wearable device.
3021754|NCT02417623|No Intervention|Control group|Control group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline
3021755|NCT02417610|Experimental|Polynucleotide - PNHA - Newart|50 patients will be enrolled and treated with three weekly injections of polynucleotide plus hyaluronic acid
3021756|NCT02417610|Active Comparator|Hyaluronic acid - HA - Ialart|50 patients will be enrolled and treated with three weekly injections of hyaluronic acid
3021757|NCT02417597|Experimental|Experimental Group|Participants in this arm are aged over 65 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
3021758|NCT02417597|Active Comparator|Immunogenicity Control Group|Participants in this arm are aged beteen 18-65 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
3021759|NCT02417597|No Intervention|Safety Control Group|Participants in this arm are aged over 65 years.
3021760|NCT02417584|Experimental|positive airway pressure (PAP)|Treatment with positive airway pressure (PAP)
3021761|NCT02417571|Experimental|ABPM group|"Ambulatory blood pressure monitoring (ABPM) performed at 3, 6 months after randomization; adjusting drugs/doses based on ABPM results.~Target BP: daytime ABP < 135/85 mm Hg according to British NICE clinical guideline 127."
3021762|NCT02417571|No Intervention|Office BP group|"Conventional BP management using office BP according to KDIGO guideline on BP management.~Target BP: <140/90 mm Hg."
3021763|NCT02417558|Experimental|Alterniity Augmented Reality (AAR)|AAR training Participants use the patent pending AAR exercise and gaming (exergaming) platform that combines a physical training component (PTC) and a cognitive training component (CTC) in closed-feedback loop with Personalized Brain Network Activity (PBNA) test from a portable EEG.
3021764|NCT02417558|No Intervention|Passive Control Participants|Passive Control Participants do not receive an intervention serving as passive controls
3021765|NCT02417558|Active Comparator|Active|Active Control Participants receive an alternative cognitive training scheme; software was built on purpose by the Aristotle University of Thessaloniki. The software is called VideoGrade and uses videos from Youtube (YouTube) documentaries (VideoGrade).
3021766|NCT02417532|Experimental|Rehabilitation using REX|Exercises using Rex mobility assist device
3021767|NCT02417519|Experimental|Sequence A|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance A was DAR-LIR-CTR
3021768|NCT02417519|Experimental|Sequence B|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance B was DAR-CTR-LIR
3021769|NCT02417519|Experimental|Sequance C|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance C was LIR-DAR-CTR
3021770|NCT02417519|Experimental|Sequence D|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance D was LIR-CTR-DAR
3021771|NCT02417519|Experimental|Sequence E|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance E was CTR-DAR-LIR
3021772|NCT02417519|Experimental|Sequence F|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance F was CTR-LIR-DAR
3021773|NCT02417506|Experimental|E-OA-07 (Lanconone)|500 mg two capsules to be taken stat at the site
3021774|NCT02417506|Active Comparator|Ibuprofen|200 mg two capsule to be taken stat at the site
3021775|NCT02417493|Experimental|Simulation of Epinephrine Self-Injection|The patient will self-inject an empty syringe into his/her thigh simulating a self-injection of epinephrine during a routine outpatient visit to the allergist.
3021776|NCT02417493|No Intervention|Control Group|The patient will be encouraged to speak to their physician about self-injection, but will not undergo the self-injection protocol during a routine outpatient visit to the allergist.
3021777|NCT02417480|Active Comparator|Vegan arm|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. Researchers will ask participants on a vegan diet to follow their usual diet and exercise habits consistent for the two week study period.
3021778|NCT02417480|Experimental|Omnivorous arm|A diet containing all food groups. Researchers will ask participants on an omnivorous diet to follow habitual, usual diet and exercise habits for the first week. During the second week, participants will be asked to switch to a vegan diet for one week and to maintain their usual exercise habits.
3021816|NCT02417246|Active Comparator|Study Group A|This group will start with the brand name Toprol XL for 7 to 28 days, and then switch to Wockhardt metoprolol for 7 days, then they will switch back to Toprol XL for 7 to 28 days, and then they will be switch to Activas metoprolol for 7 days. During the times the switch will take place the following tests will be performed: 24-hour pharmacokinetic parameters, 24-hour heart rate, 24-hour blood pressure, 24-hour holter monitor, exercise treadmill to induced heart rate, and a 24-hour gastric pH through SmartPill Capsule.
3022101|NCT02415530|Placebo Comparator|Term infant control|term infant without intervention
3055325|NCT02192463|Experimental|NVP ER 400 mg (KCR 40%) Slow Release|
3021779|NCT02417467|Experimental|Nicotine E-Cigarette and Counseling|"As with standard nicotine replacement therapies, participants are expected to self-regulate administration of nicotine e-cigarettes according to their withdrawal symptoms. The manufacturer recommends each vaping session to last approximately 10 puffs, with one puff every 30 seconds over a span of approximately 4.5 minutes.~Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development."
3021780|NCT02417467|Other|Non-Nicotine E-Cigarette and Counseling|"Participants are expected to self-regulate administration of e-cigarettes. The manufacturer recommends each vaping session to last approximately 10 puffs, with one puff every 30 seconds over a span of approximately 4.5 minutes.~Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development."
3021781|NCT02417467|Other|Counseling|Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development.
3021782|NCT02417454|Experimental|Probiotic|Participants will undergo the same study procedures as for the comparator; however, the product given will be the active probiotic supplement (ProbioStick).
3021783|NCT02417454|Placebo Comparator|Placebo|Participants will undergo the same study procedures as for the probiotic; however, the product given will be a placebo, identical to the probiotic in taste, smell, colour, and comprised only of the same non-active ingredients in the probiotic supplement
3021784|NCT02417441|Experimental|EEVA™|
3021785|NCT02417441|No Intervention|Non-EEVA|
3021786|NCT02417428|Experimental|Citrulline|Participants that will be randomized in the first arm will be divided in either citrulline plus HIIT (CIT + HIIT or group A) or citrulline alone (CIT or group B).
3021787|NCT02417428|Placebo Comparator|Placebo|Participants that will be randomized in the second arm will be divided in either placebo plus HIIT (PLA + HIIT or group C) or placebo alone (PLA or group D).
3021788|NCT02417428|Experimental|Exercise|Participant that will be randomized in this arm will have an exercise program (HIIT) added to their respective dietary supplement.
3021789|NCT02417428|Other|Without exercise|Participant that will be randomized in this arm will not have an exercise program.
3021790|NCT02417415|Experimental|Local Heat Stress|Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
3021791|NCT02417415|Sham Comparator|Control (Non-heating)|Commercial heating pad applied over the abdomen and part of the torso but turned off
3021792|NCT02417402|Active Comparator|Untrained Physical Therapists|The patients allocated to the Control group will be treated by physical therapists who did not receive any training about clinical practice guidelines and pain management. These patients will receive the usual care from their physical therapists.
3021793|NCT02417402|Experimental|Trained Physical Therapists|The patients allocated to the Experimental group will be treated by physical therapists who received training about clinical practice guidelines and pain management.
3021794|NCT02417389|Experimental|cinacalcet|Phase 1 (12 months): all patients treated with cinacalcet alone; Phase 2 (12 months): all patients treated with cinacalcet plus alendronate
3021795|NCT02417376|Active Comparator|Experimental|"Periodontal intervention in the form of scaling and root planing by:~ultrasonic piezoelectric scaler (frequency of 28-36 KHz) and~gracey curets (set of 7 instruments number 1-14) to remove supra and subgingival calculus on teeth, is completed in two appointments of 45 to 60 min, within 24 hours"
3021796|NCT02417376|No Intervention|Control|No periodontal intervention in any form.
3021797|NCT02417363||Group A|the control group,healthy individuals
3021798|NCT02417363||Group B|patients with 1-4 stage K/DOQI (Kidney Disease Outcome Quality Initiative) chronic kidney disease, but healthy periodontium
3021799|NCT02417363||Group C|patients with periodontitis, but healthy renal conditions
3021800|NCT02417363||Group D|patients with 1-4 stage K/DOQI (Kidney Disease Outcome Quality Initiative) chronic kidney disease and periodontitis
3021801|NCT02417350|Experimental|Ketogenic diet first|Starting with ketogenic diet first and then switching to a NFA recommended diet
3021802|NCT02417350|Experimental|NFA recommended diet first|Starting with NFA recommended diet first and then switching to a ketogenic diet
3021803|NCT02417337|Active Comparator|Group I|paracetamol 1000mg
3021804|NCT02417337|Experimental|Group II|ibuprofen 600mg + paracetamol 1000mg,
3021805|NCT02417337|Experimental|Group III|Mefenamic acid 500mg + Paracetamol 1000mg
3021806|NCT02417337|Experimental|Group IV|Diclofenac K 50mg + paracetamol 1000 mg
3021807|NCT02417337|Placebo Comparator|Group V|No medication
3021808|NCT02417311||Control group|40 healthy volunteers will serve as control group. Skin biopsy, genotyping and disease phenotyping
3021809|NCT02417311||DCM patients|20 patients with dilated cardiomyopathy
3021810|NCT02417311||HCM patients|20 patients with hypertrophic cardiomyopathy
3021811|NCT02417298|Active Comparator|Ketamine|Ketamine 0.3 mg/kg intravenous push followed by ketamine infusion at 0.1 mg/kg/hr for 3 hours
3021812|NCT02417298|Placebo Comparator|Saline|Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
3021813|NCT02417285|Experimental|CC-122 in combination with Obinutuzumab|CC-122 will be administered orally QD starting on Day 1 for 5 consecutive days followed by 2 days off study drug every 7 days (5/7-day schedule) in each 28-day cycle in combination with Obinutuzumab administered as an intravenous (IV) infusion at a dose of 1000 mg on Days 2, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8.
3021814|NCT02417272|Experimental|Total disc replacement (TDR)|Total disc replacement with preserved segmental motion decreasing load on adjacent levels.
3021817|NCT02417246|Active Comparator|Study Group B|This group will start with the brand name Toprol XL for 7 to 28 days, and then switch to Activas metoprolol for 7 days, then they will switch back to Toprol XL for 7 to 28 days, and then they will be switch to Wockhardt metoprolol for 7 days. During the times the switch will take place the following tests will be performed: 24-hour pharmacokinetic parameters, 24-hour heart rate, 24-hour blood pressure, 24-hour holter monitor, exercise treadmill to induced heart rate, and a 24-hour gastric pH through SmartPill Capsule.
3021818|NCT02417233|No Intervention|Standard of Care|Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime) only. This group will not receive any additional engagement to care intervention.
3021819|NCT02417233|Active Comparator|SMS text message|"Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also automated bi-weekly check-in text messages that will trigger a phone call from clinic staff if the participant reports not being well."
3021820|NCT02417233|Active Comparator|SMS text message + Peer Navigation|Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also bi-weekly contact from an HIV-positive peer who provides personalized support and with health or other service systems navigation assistance.
3021821|NCT02417220|Active Comparator|Weight Watchers Online 2015|
3021822|NCT02417220|Experimental|Weight Watchers Online 2015 Enhanced|
3021823|NCT02417207|Sham Comparator|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 ~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
3021824|NCT02417207|Active Comparator|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
3021825|NCT02417181|No Intervention|General Practitioners Care|Usual medical care provided by a general practitioner at the out-of-hours primary care service
3021826|NCT02417181|Experimental|Physician Assistants Care|Medical care provided by the Physician Assistant at the out-of-hours primary care service
3021827|NCT02417155|Experimental|HTR|The `Hoftraining` group (HTR): a group of subjects (n=10) that will be trained extensively by mr. Hof and his team in both hyper/hypoventilation and strength ventilation breathing techniques. Total time training is 8 days.
3021828|NCT02417155|Active Comparator|EIN|The `extensive instruction` group (EIN): a group of subjects (n=10) that will receive an extensive instruction course supervised by the research team (in absence of Mr. Hof) in both hyper/hypoventilation and strength ventilation breathing techniques.
3021829|NCT02417155|Active Comparator|STR|The `short training` group (STR): a group of subjects (n=10) that will receive only a short training of 1 hour (immediately prior to the study) by Mr. Hof and his team in both hyper/hypoventilation and strength ventilation breathing techniques.
3021830|NCT02417155|Active Comparator|SIN|The `short instruction` group (SIN): a group of subjects (n=10) that will receive no training, but only an short instruction course of 1 hour (immediately prior to the study) supervised by the research team (in absence of Mr. Hof) in both hyper/hypoventilation and strength ventilation breathing techniques.
3021831|NCT02417142|Experimental|Experimental|"(existing treatment) + (Drug)~Intervention:~Drug: Exenatide"
3021832|NCT02417142|Placebo Comparator|Placebo|"(existing treatment) + (Placebo)~Intervention:~Drug: Placebo"
3021833|NCT02417129|Experimental|BI 695500|375 mg/m2; One intravenous infusion once a week for 4 weeks
3021834|NCT02417129|Active Comparator|Rituximab (US reference product)|375 mg/m2; One intravenous infusion once a week for 4 weeks
3021835|NCT02417116|Placebo Comparator|Control|Minims Saline (Preservative Free) lubricant eye drops - daily for 90 days
3021836|NCT02417116|Active Comparator|Hypromellose - standard treatment|Tear Supplement: Hypromellose 0.3% eye drops - daily for 90 days
3021837|NCT02417116|Active Comparator|Combination treatment|Tear Supplement 2: Hylo-Forte 0.2% Sodium Hyaluronate eye drops, Omega 3 nutrition supplement: Omega-3 tablets, Eye bag: TranquilEyes Moist Heat Lid Compresses - Daily for 90 days;
3021838|NCT02417103|Active Comparator|GLP-1 (Liraglutide)|Daily subcutaneous injection of Lirglutide over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg
3021839|NCT02417103|Placebo Comparator|Placebo Comparator|Daily subcutaneous injection of PL1/PR1 Placebo over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg
3021840|NCT02417090||Metformin therapy|9-year-old children whose mothers used metformin for gestational diabetes
3021841|NCT02417090||Insulin therapy|9-year-old children whose mothers used insulin for gestational diabetes
3021842|NCT02417077||Photographic Review|Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
3021843|NCT02417064|Experimental|Intranasal Esketamine 84mg plus Oral Antidepressant|As part of an initial titration, participants will self-administer 56 milligrams (mg) of esketamine intranasally on Day 1, and then 84 mg from Day 4 onwards, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
3021900|NCT02416726|Experimental|Metastatic lymph node|The gene testing of the metastatic lymph node tissue diagnosed with nonsquamous NSCLC will be performed with NGS technique using Illumina Nextseq500 sequencer.
3021844|NCT02417064|Experimental|Esketamine 56 mg plus Oral Antidepressant|Starting from Day 1, participants will self-administer 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
3021845|NCT02417064|Active Comparator|Placebo plus Oral Antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
3021846|NCT02417051|Experimental|Resiliency Training|Intervention: Disaster Worker Resiliency Training (DWRT) Program.
3021847|NCT02417051|No Intervention|Waitlist|Waitlist control: Participants to be offered the program after completion of the trial.
3021848|NCT02417025|Experimental|PE-HBT|Prolonged Exposure via home-based telehealth (i.e., completed using videoconferencing technology)
3021849|NCT02417025|Active Comparator|PE-SD|Prolonged Exposure via standard delivery (i.e., completed in person at the therapist's office)
3021850|NCT02417012|Experimental|U-TURN intervention|"The intervention group will receive an intensive lifestyle intervention including partly supervised aerobic and strength exercise, diet plans and counseling by clinical dietitians. All exercise will be supervised initially and the supervision will be reduced gradually across the 12-month intervention. Additionally, the participants will be offered educational classes on implementation of a healthy lifestyle and diabetes education and support by trained nurses.~Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines."
3021851|NCT02417012|Active Comparator|Standard care|"The reference group will receive diabetes education and support by trained nurses.~Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines."
3021852|NCT02416999|Experimental|patient group|
3021853|NCT02416973|Other|Sham of Provant|Sham of Provant
3021854|NCT02416973|Other|Active Treatment|Active Provant Treatment
3021855|NCT02416973|Other|Active Treatment with alternative settings|Active Provant Treatment with alternative settings
3021856|NCT02416960|Experimental|Low Glycemic Index Diet Group|Patients will follow a treatment with a hypocaloric diet with low glycemic index/load for 12 weeks, immediately before the in vitro fertilization cycle.
3021857|NCT02416960|Active Comparator|Conventional Diet Group|Patients will follow a treatment with a hypocaloric diet with high glycemic index/load for 12 weeks, immediately before the in vitro fertilization cycle.
3021858|NCT02416960|No Intervention|Control Group|Patients will follow their usual diet for 12 weeks, immediately before the in vitro fertilization cycle.
3021859|NCT02416947|Placebo Comparator|0g SCF|Subjects will consume 0 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
3021860|NCT02416947|Active Comparator|10 g SCF|Subjects will consume 10 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
3021861|NCT02416947|Active Comparator|20g SCF|Subjects will consume 20 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
3021862|NCT02416934|Experimental|Treatment 1; Dexamethasone|"Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses."
3021863|NCT02416934|Placebo Comparator|Treatment 0; Saline placebo|"Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses."
3021864|NCT02416921|Experimental|Weight-gain Prevention|Subjects in this group will engage in a 4-week weight-gain prevention curriculum delivered via Facebook
3021865|NCT02416921|Active Comparator|Women's Health|Subjects in this group will engage in a 4-week women's health curriculum delivered via Facebook
3021866|NCT02416908|Experimental|Phase I Schedule A (selinexor)|"Selinexor will be dosed on Days 1, 5, 10, and 12 of the 28-day cycle. All doses will be 60 mg each PO.~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.~G-CSF will be given 300 mcg SC once daily on Days 3-8.~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
3021867|NCT02416908|Experimental|Phase I Schedule B (selinexor)|"Selinexor will be dosed on Days 1, 5, 10, 12, 17, and 19 of the 28-day cycle. All doses will be 60 mg each PO.~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.~G-CSF will be given 300 mcg SC once daily on Days 3-8.~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
3021901|NCT02416713|Placebo Comparator|Education Only (Control)|The Cellcontrol DriveID device will run completely in the background with no observable changes to cellphone functions while driving. During Week Four, participants will be presented educational materials on the dangers of distracted driving.
3021868|NCT02416908|Experimental|Phase II (selinexor)|"Selinexor will be given at the schedule as determined in Phase 1.~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.~G-CSF will be given 300 mcg SC once daily on Days 3-8.~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
3021869|NCT02416895||Army recruits|Army recruits at the start of basic training will complete an in vivo immunity model
3021870|NCT02416882|Other|Aerobic Exercise vs Sedentary Option|Relative Reinforcing Value of aerobic exercise versus sedentary activity will be determined.
3021871|NCT02416882|Other|Resistance Exercise vs Sedentary Option|Relative Reinforcing Value of resistance exercise versus sedentary activity will be determined.
3021872|NCT02416869|Active Comparator|Intramuscular application|Intramuscular application of 4mg Dexamethasone
3021873|NCT02416869|Experimental|Submucosal application|Submucosal application of 4mg Dexamethasone
3021874|NCT02416869|Active Comparator|4mg Dexamethasone submucosal|4mg Dexamethasone submucosal application
3021875|NCT02416869|Experimental|8mg Dexamethasone submucosal|8mg Dexamethasone submucosal application
3021876|NCT02416869|Active Comparator|4mg Dexamethasone postoperative|4mg Dexamethasone postoperative application
3021877|NCT02416869|Experimental|4mg Dexamethasone preoperative|4mg Dexamethasone postoperative application
3021878|NCT02416843|Experimental|Lean|Consumption of a mixed meal relative to individual resting metabolic rate.
3021879|NCT02416843|Experimental|Overweight|Consumption of a mixed meal relative to individual resting metabolic rate.
3021880|NCT02416843|Experimental|Obese|Consumption of a mixed meal relative to individual resting metabolic rate.
3021881|NCT02416817|Experimental|Blood Products only.|This arm will receive 1:1:1 Red blood cells : Fresh Frozen Plasma : Platelets upon a major trauma triggers. 1:1:1 Ratio for packs of blood products. The patient will be re-evaluated every hour again for the major bleeding triggers and another 1:1:1 intervention may or may not occur.
3021882|NCT02416817|Experimental|Point of care guided|This arm will receive Red blood cells, Human Fibrinogen and Prothrombinic complex concentrates (PCC) based on thromboelastometry. The dosis of each drug will be determined by the analyses of the thromboelastometry curves.
3021883|NCT02416804|Experimental|Buprenorphine|Buprenorphine group : They will apply 3 days after the spine operation.
3021884|NCT02416804|Active Comparator|Tramadol|Tramadol group : They will take a pill of tramadol analgesics.
3021885|NCT02416791|Active Comparator|Active tDCS + robotic therapy + physical therapy|"Active tDCS (transcranial direct current stimulation) will be applied prior to the robotic training. After robot training, the patient will receive physical therapy for 40 minutes.~Number of treatment sessions: 18 (3 times a week, for 6 weeks)."
3021886|NCT02416791|Active Comparator|sham tDCS + robotic therapy + physical therapy|"Sham tDCS (transcranial direct current stimulation) will be applied prior to robotic training. After robot training, the patient will receive physical therapy for 40 minutes.~Number of treatment sessions: 18 (3 times a week, for 6 weeks)."
3021887|NCT02416791|Experimental|sham tDCS + physical therapy + occupational therapy|Sham tDCS (transcranial direct current stimulation) will be applied prior to conventional therapy (40 minutes of physical therapy and 40 minutes of occupational therapy) Number of treatment sessions: 18 (3 times a week, for 6 weeks).
3021888|NCT02416778|Experimental|Treatment Arm|Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion will be administered in patients with COPD
3021889|NCT02416765|Active Comparator|Sensor-augmented pump therapy|Patients will use conventional pump therapy and freely implement their usual basal rate and CHO-matching full prandial bolus to regulate glucose levels.
3021890|NCT02416765|Active Comparator|Single-hormone CLS with full boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
3021891|NCT02416765|Active Comparator|Single-hormone CLS with partial boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. A pre-meal partial prandial bolus will be given 10 minutes before the meal. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.
3021892|NCT02416765|Active Comparator|Dual-hormone CLS with full boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
3021893|NCT02416765|Active Comparator|Dual-hormone CLS with partial boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. A pre-meal partial prandial bolus will be given 10 minutes before the meal. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.
3021894|NCT02416752||remifentanil group|Group received intra op remifentanil infusion
3021895|NCT02416752||conventional opioid gropup|Group received only conventional opioids and No infusion of remifentanil
3021896|NCT02416739|Experimental|Nicotinamide|"Nicotinamide with EGFR-TKI:~gefitinib (250mg tab) or erlotinib (150mg tab) - per oral, once a day~nicotinamide (500mg tab) - per oral, twice a day, until the event or censoring occurs"
3021897|NCT02416739|Placebo Comparator|Placebo|"Placebo tablet with EGFR-TKI:~gefitinib (250mg tab) or erlotinib (150mg tab) - per oral, once a day~placebo tablet - per oral, twice a day, until the event or censoring occurs"
3021898|NCT02416726|Experimental|Peripheral blood|The peripheral blood sample will be extrated with DNA and performed NGS using Illumina Nextseq500 sequencer.
3021899|NCT02416726|Experimental|Primary tumor|The gene testing of the primary tumor tissue diagnosed with nonsquamous NSCLC will be performed with NGS technique using Illumina Nextseq500 sequencer.
3022102|NCT02415530|Placebo Comparator|VLBW infant control|very low birth weight infant without intervention
3021903|NCT02416713|Experimental|Opt-out Blocking|Cellcontrol DriveID device will automatically turn on when the teen begins driving and will be pre-set to block all calls and text messages when the car is in motion.
3021904|NCT02416713|Experimental|Opt-out Blocking with Notification|Cellcontrol DriveID device will automatically turn on when the teen begins driving and will be pre-set to block all calls and text messages when the car is in motion. If a participant overrides the blocking function, an email will be sent to a parent/guardian.
3021905|NCT02416700|Experimental|immediate implant surgery|Immediate implant surgery in one site.
3021906|NCT02416700|Active Comparator|conventional implant surgery|Conventional implant surgery in another site
3021907|NCT02416687|Active Comparator|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) was inserted in the first 48 h postpartum
3021908|NCT02416687|No Intervention|Control group|Postpartum women who used no contraceptive method in the first six weeks after delivery
3021909|NCT02416674|Experimental|Transplant recipients|The intervention is transplantatoin of abdominal wall tissues from an organ donor who is deceased to a recipient with a large abdominal wall defect.
3021910|NCT02416661||Observation|Patients with genetically confirmed diagnosis of Gaucher disease type 1 without treatment prior to enrollment
3021911|NCT02416648|Experimental|CCC Counseling; baseline and 2 months|Intervention group 1 received 2 CCC Counseling sessions; at baseline and at 2 months. The intervention was a 10 to 15 minute clinic based one on one counseling session between a clinician (counselor) and a HIV positive adult patient (client). Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
3021912|NCT02416648|Experimental|CCC Counseling; baseline|Intervention group 2 received a session CCC Counseling session at baseline only. The intervention was a 10 to 15 minute clinic based one on one counseling session between a clinician (counselor) and a HIV positive adult patient (client). Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
3021913|NCT02416648|No Intervention|Routine care|The control group received routine clinic care.
3021914|NCT02416635||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
3021915|NCT02416635||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
3021916|NCT02416635||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
3021917|NCT02416635||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
3021918|NCT02416622|Experimental|Groups 1A and 1B|Subjects at least 18 y/o treated with a lower dose of rAAV2tYF-CB-hRS1 study drug.
3021919|NCT02416622|Experimental|Groups 2 and 2A|Subjects at least 6 y/o treated with a middle dose of rAAV2tYF-CB-hRS1 study drug.
3021920|NCT02416622|Experimental|Group 3|Subjects at least 18 y/o treated with a higher dose of rAAV2tYF-CB-hRS1 study drug.
3021921|NCT02416622|Experimental|Group 4|Subjects at least 6 y/o treated with a maximum tolerated dose of rAAV2tYF-CB-hRS1 study drug determined for Groups 1A, 1B, 2 and 3.
3021922|NCT02416609|Experimental|Gem Ox with LDR & sequential SBRT|Four GemOx cycles will be administered concurrent with LDR. If no progression, three fractions of SBRT will be administered. Further two cycles of additional GemOx without LDR can be administered after SBRT.
3021923|NCT02416596|Experimental|Group Undergoing Hysterosopy|This group will include 340 women with unexplained primary infertility undergoing their first trial of IVF/ICSI (intracytoplasmic sperm injection). This group will undergo hysteroscopy in the mid luteal phase of the proceeding cycle.
3021924|NCT02416596|No Intervention|Group With No intervention|This group will include 340 women with unexplained primary infertility they will undergo their first trial of IVF/ICSI (intracytoplasmic sperm injection) without hysteroscopy in the mid Luteal phase of the proceeding cycle.
3021925|NCT02416583|Active Comparator|Oxytocin & Membrane sweeping|"Women assigned to Concurrent oxytocin with membrane sweeping had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, followed by oxytocin infusion the next day"
3021926|NCT02416583|Active Comparator|Oxytocin & Dinoprostone|"For women assigned to Concurrent oxytocin with dinoprostone vaginal insert: The 10mg dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening, followed by oxytocin infusion the next day"
3021927|NCT02416570|Active Comparator|Clarithromycin|Clarithromycin 250mg by mouth twice a day for 8 weeks
3021928|NCT02416570|Placebo Comparator|Placebo|Placebo matched capsule one capsule by mouth twice a day for 8 weeks
3021929|NCT02416557|Experimental|Group P|Patients using positive end-expiratory pressure (PEEP) of 10 cmH2O (centimeter of water) intraoperatively
3021930|NCT02416557|No Intervention|Group C|Patients using no positive end-expiratory pressure (zero PEEP) intraoperatively
3021931|NCT02416544|Experimental|Full participation|Participants in this group receive lunch which is calorie-restricted and low-salt during 12 weeks, the total duration of this study.
3021932|NCT02416544|Experimental|Two thirds participation|Participants in this group starts lunch which is calorie-restricted and low-salt after 4 weeks from the beginning of the study and maintain the diet during 8 weeks.
3021933|NCT02416544|Experimental|One thirds participation|Participants in this group starts lunch which is calorie-restricted and low-salt after 8 weeks from the beginning of the study and maintain the diet during 4 weeks.
3021934|NCT02416531|Active Comparator|Corticosteroid|Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
3021935|NCT02416531|Experimental|Photodynamic therapy|Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks.
3021936|NCT02416531|Experimental|Low level laser therapy|λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks.
3022967|NCT02409927|Experimental|MCT homogenate 30 g|Meal with 30 g of MCT homogenate mixed in
3021937|NCT02416505|No Intervention|Verbal Discussion: Control Group|"In this group, participants will receive a 10 minute Verbal Only Knee Osteoarthritis Steroid Injection Informed Consent discussion.~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
3021938|NCT02416505|Active Comparator|Verbal+Anatomic Model|"This intervention group will receive a 10 minute Knee Osteoarthritis Steroid Injection Informed Consent discussion with the aid of a Knee Model.~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
3021939|NCT02416505|Active Comparator|Verbal+Video Presentation|"This intervention group will receive a 10 minute Knee Osteoarthritis Steroid Injection Informed Consent discussion with the aid of a Video.~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
3021940|NCT02416492|Experimental|SB623 Cells|SB623 Cells: 2.5, 5 or 10 million cells surgically implanted adjacent to the injured cerebral region.
3021941|NCT02416492|Sham Comparator|Sham Surgery|Control Sham Surgery (partial burr hole only)
3021942|NCT02416479|Experimental|SystemCHANGE|SystemCHANGE supports patient-designed, interventionist-guided, small experiments to: 1) assess individual systems (including important others who shape medication taking) and the system's impact on medication taking and propose individual system solutions to improve MA, 2) implement the proposed individual systems' solutions to improve MA, 3) track MA data, and 4) evaluate MA data.
3021943|NCT02416479|Active Comparator|Patient-education attention-control|The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
3021944|NCT02416466|Experimental|anti-CEA CAR-T cells + Sir-Spheres|Three infusions of gene-modified anti-CEA T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach along with low dose IL-2. A single dose of Sir-Spheres will be given 2 weeks following the final T cell dose.
3021945|NCT02416453|Experimental|Group 1|Participants will receive intramuscular (IM) injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 29.
3021946|NCT02416453|Experimental|Group 2|Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 57.
3021947|NCT02416453|Experimental|Group 3|Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 85.
3021948|NCT02416440||screening for diabetes prevalence|blood samples
3021949|NCT02416427|Experimental|Arm A|Atorvastatin 80 mg/day for 3 weeks
3021950|NCT02416427|No Intervention|Arm B|Observation
3021951|NCT02416414||Solid Organ Transplant Recipients|Subjects who have received a Solid Organ Transplant.
3021952|NCT02416414||Healthy Controls|Healthy individuals.
3021953|NCT02416401|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, 4-5 times weekly, one hour each session.
3021954|NCT02416401|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, 4-5 times weekly, one hour each session.
3021955|NCT02416388|Experimental|R1-IDA|Idarubicin
3021956|NCT02416388|Active Comparator|R1-DAUNO|Daunorubicin
3021957|NCT02416388|Active Comparator|R2-HDAC|High dose cytarabine
3021958|NCT02416388|Experimental|R2-IDAC|Intermediate dose cytarabine
3021959|NCT02416388|Active Comparator|R3-MAC-MTX|Methotrexate and mycophenolic acid
3021960|NCT02416388|Experimental|R3-MAC-MPA|Cyclosporine and mycophenolic acid
3021961|NCT02416388|Active Comparator|R3-RIC-CICLO|Cyclosporine
3021962|NCT02416388|Experimental|R3-RIC-MPA|Cyclosporine and mycophenolic acid
3021963|NCT02416388|Experimental|R4-VOS-IDAC|Intermediate dose cytarabine and vosaroxin
3021964|NCT02416388|Active Comparator|R4-IDAC|Intermediate dose cytarabine
3021965|NCT02416375||Observation|Adult Cystic Fibrosis patients
3021966|NCT02416362|No Intervention|Control|The control group (No vibration) will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. The vibrating platform will remain off throughout intervention.
3021967|NCT02416362|Experimental|GE1|The GE1 (Vibration at 30 Hz) group will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 30 Hz.
3021968|NCT02416362|Experimental|GE2|The GE1 (Vibration at 50 Hz) group will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 50 Hz.
3021969|NCT02416349|Active Comparator|Respiratory Muscles Stretching|Respiratory Muscles Stretching Neck stretching, upper chest stretching, pectoralis major stretching and lateral chest stretching.
3021970|NCT02416349|Placebo Comparator|Control Group|All volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
3022103|NCT02415530|Experimental|VLBW infant intervention|Combined home visiting and group intervention for very low birth weight infant
3021971|NCT02416336|Experimental|Sentinella intraoperative use|"Standard of care intraoperative protocol~Localize SLN with the Gamma Probe for In vivo count~Optional (time permitting during surgical prep). Image same SLN with Sentinella (Pre-incision)~Surgically remove/excise localized SLN~Ex vivo count - excised SLN with Gamma Probe~In vivo background/roaming count with Gamma Probe~Repeat step 1-5, until no SLNs are found with the Gamma Probe (negative reading)~Sentinella intraoperative imaging protocol~Survey surgical field/Post-excision control with Sentinella for remaining SLNs~If focal uptake seen in step 1, search for these occult SLNs with Gamma Probe and remove localized additional SLNs~Record information on data sheet for each excised SLN with Gamma Probe and Sentinella"
3021972|NCT02416323|No Intervention|Usual Care|Community therapist delivers routine care to participant child with no training in AIM HI.
3021973|NCT02416323|Other|AIM HI Training|Therapist enrolls in AIM HI training
3021974|NCT02416310|Experimental|TEAS group|TEAS are performed by a specific investigator on the specially acupoint.
3021975|NCT02416310|Sham Comparator|Sham group|TEAS are performed by a specific investigator on the non-acupoint.
3021976|NCT02416310|Placebo Comparator|Control group|Only place cutted electrodes but do not give any electrical stimulation.
3021977|NCT02416297|Experimental|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve accelerated orthodontic tooth movement. Topical and local anesthetic will be delivered in the area to be treated in accordance with standard practice.
3021978|NCT02416297|No Intervention|Control|Anterior retraction after premolars extraction will be done conventionally (slide mechanics)
3021979|NCT02416284|Experimental|NFBDG|Multi-faceted, 2 week intervention to increase compliance to the NFBDG.
3021980|NCT02416271|Experimental|Teriparatide|20 micrograms per day teriparatide subcutaneous (SC) injection plus oral placebo for 18 months.
3021981|NCT02416271|Active Comparator|Alendronate|10 milligrams/day alendronate orally plus SC injection placebo for 18 months.
3021982|NCT02416258|Active Comparator|LP0113 aerosol spray|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
3021983|NCT02416258|Placebo Comparator|Aerosol spray vehicle|No active ingredient, topical
3021984|NCT02416258|Active Comparator|LEO 90100 aerosol foam|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
3021985|NCT02416258|Active Comparator|Betamethasone dipropionate aerosol spray|Betamethasone (as dipropionate) 0.5 mg/g, topical
3021986|NCT02416258|Active Comparator|Calcipotriol aerosol spray|Calcipotriol (as monohydrate) 50 mcg/g, topical
3021987|NCT02416258|Active Comparator|Daivobet® gel|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
3021988|NCT02416245|Experimental|Test beverage powder|Test beverage powder is fortified with micronutrients and Bacopa monnieri extract. Each sachet contains 32g of treatmemt product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
3021989|NCT02416245|Placebo Comparator|Control beverage powder|Control beverage powder is the non-fortified isocaloric powder i.e. without micronutrients and Bacopa Monnieri extract. Each sachet contains 32g of placebo product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
3021990|NCT02416219||Cricoid Cartilage localization|The caregiver will be asked to palpate the cricoid cartilage and draw aline where he will apply cricoid pressure during rapid sequence induction
3021991|NCT02416206|Experimental|BeEAM|Bendaumustine, Etoposide, Cytrabine and Melphalan in autologous transplant for multiple myeloma
3021992|NCT02416193|Experimental|High Dose|50,000 IU cholecalciferol once weekly for three months
3021993|NCT02416193|Active Comparator|Low Dose|5,000 IU cholecalciferol once weekly for three months
3021994|NCT02416180|Experimental|SERETIDE EVOHALER|Subjects will switch from their current usual maintenance treatment of SERETIDE via DISKUS Inhaler to an equivalent dose of SERETIDE via the MDI (EVOHALER) at Visit 1. Subjects will use the MDI as 2 inhalations twice daily for approximately 14 days. Subjects will revert back to using SERETIDE DISKUS Inhaler again from Visit 2 (after 14 days) starting with the next scheduled dose.
3021995|NCT02416167|Active Comparator|FYU-981 High dose|Drug: FYU-981 High dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
3021996|NCT02416167|Active Comparator|FYU-981 High middle dose|Drug: FYU-981 High middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High middle dose arm receive active drug, FYU-981 High middle dose.
3021997|NCT02416167|Active Comparator|FYU-981 Middle dose|FYU-981 Middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
3021998|NCT02416167|Active Comparator|FYU-981 Low dose|Drug: FYU-981 Low dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
3021999|NCT02416167|Placebo Comparator|Placebo|Drug: Placebo, (Oral daily dosing for 12 weeks) Subjects randomized to the placebo arm receive placebo.
3022000|NCT02416154||Follicular phase|Normally cycling women in the follicular phase of menses
3022001|NCT02416154||Luteal phase|Normally cycling women in the luteal phase of menses
3022002|NCT02416141|Active Comparator|Fast release oro-dispersible tramadol|"This group receives a fast release oro-dispersible tramadol 30 minutes before the vacuum aspiration procedure. A paracervical block with a 27-gauge spinal needle with lidocaine will be injected at the the start of the procedure.~Intervention: use of fast release oro dispersible tramadol 50 mg"
3022003|NCT02416141|Placebo Comparator|Placebo-controlled arm|"This group receives a placebo 30 minutes before the vacuum aspiration procedure. A paracervical block with a 27-gauge spinal needle with lidocaine will be injected at the the start of the procedure.~Intervention: use of placebo"
3022004|NCT02416128|Active Comparator|Iritis prevention after LPI: prednisolone|To use prednisolone acetate after and peripheral laser iridotomy to determine efficacy and side effects compared to arm 2.
3022005|NCT02416128|Experimental|Iritis prevention after LPI: euphrasia|To use euphrasia after and peripheral laser iridotomy to determine efficacy and side effects compared to arm 1.
3022006|NCT02416115|Active Comparator|R group|Thirty minutes before end of surgery, patients in R group (n=30) received 0.3 mg ramosetron. In the post anesthetic care unit, patients in R group received PCA morphine 1 mg/ml
3022007|NCT02416115|Active Comparator|N group|Thirty minutes before end of surgery, patients in N group (n=30) received normal saline. In the post anesthetic care unit, group N received PCA mixture of naloxone 1μg/ml and morphine 1 mg/ml.
3022008|NCT02416115|Experimental|RN group|Thirty minutes before end of surgery, patients in Ramosetron and naloxone (RN) group (n=30) received 0.3 mg ramosetron. In the post anesthetic care unit, group RN received PCA mixture of naloxone 1μg/ml and morphine 1 mg/ml.
3022009|NCT02416102|Experimental|losartan 50 mg|10 COPD ex-smokers (>10 pack-years of cigarette smoking) and 10 active smokers not treated with ARBs will receive 50 mg of losartan for 4 weeks
3022010|NCT02416102|Experimental|losartan 100 mg|10 COPD ex-smokers (>10 pack-years of cigarette smoking) and 10 active smokers not treated with ARBs will receive 100 mg of losartan for 4 weeks
3022011|NCT02416089|Experimental|Tampostat|Tampostat™ is a self-regulating, low cost, pressure based emergency obstetric device designed specifically for use in low-resource settings. It has 6 parts: probe, condom, O ring, nerve centre, tube and bulb pump. It offers significant benefits over the current model by simplifying the insertion process, reducing the need for constant monitoring, eliminating leakage and the need for sterile saline, and using a pressure-based mechanism to apply consistent pressure to all women regardless of uterus size.Women who develop PPH even after applying AMTSL at the hospital or women who visit the hospital with PPH within 24 hours after delivery will be managed by Tampostat for the intervention arm or by the condom catheter tamponade in the control arm(172 patients in each arm)
3022012|NCT02416089|Active Comparator|Condom catheter tamponade|Condom catheter tamponade have been used by medical professionals for several years in the management of atonic (primary) PPH. In this approach, Sterile rubber catheter fitted with a condom as a tamponade balloon device and using normal saline to inflate the condom.
3022013|NCT02416076|Active Comparator|Group A - LT side simulines Ulthera treatment at EL2|Ulthera treatment using simulines transducers on the LEFT side of the face and standard transducers on the RIGHT of the face at the default Energy Level [EL2].
3022014|NCT02416076|Active Comparator|Group B - RT side simulines Ulthera treatment at EL2|Ulthera treatment using simulines transducers on the RIGHT side of the face and standard transducers on the LEFT side of the face at the default Energy Level [EL2] .
3022015|NCT02416076|Active Comparator|Group C - LT side simulines Ulthera treatment at EL4|Ulthera treatment using simulines transducers on the LEFT side of the face and standard transducers on the RIGHT of the face at a higher Energy Level [EL4].
3022016|NCT02416076|Active Comparator|Group D - RT side simulines Ulthera treatment at EL4|Ulthera treatment using simulines transducers on the RIGHT side of the face and standard transducers on the LEFT side of the face at a higher Energy Level [EL4] .
3022017|NCT02416076|Active Comparator|Group E - LT side simulines/standard Ulthera treatment at EL4|Ulthera treatment using a 4-4.5 simulines transducer and 7-3.0 standard transducer on the LEFT side of the face and standard transducers on the RIGHT of the face at a higher Energy Level [EL4].
3022018|NCT02416076|Active Comparator|Group F - RT side simulines/standard Ulthera treatment at EL4|Ulthera treatment using a 4-4.5 simulines transducer and 7-3.0 standard transducer on the RIGHT side of the face and standard transducers on the LEFTof the face at a higher Energy Level [EL4].
3022019|NCT02416063|Active Comparator|caudal Dexmedetomidine|"Drug:Caudal Bupivacaine 0.25% 1ml/kg .~Drug:caudal Dexmedetomidine 1μg /kg.~Intravenous :10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
3022020|NCT02416063|Active Comparator|Intravenous Dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Drug: Intravenous dexmedetomidine 1µg/kg in a 10 ml volume normal saline~Anesthesia was induced and maintained with sevoflurane"
3022021|NCT02416063|Placebo Comparator|Placebo|"Caudal: bupivacaine 0.25% 1ml/kg .~Intravenous: 10 ml Normal saline~Anesthesia was induced and maintained with sevoflurane"
3022022|NCT02416037|Experimental|Prone Proseva|
3022023|NCT02416037|Active Comparator|Prone Talmor|
3022024|NCT02416024||ACE inhibitor|Patient who has been taking ACE inhibitor for longer than 3 months
3022025|NCT02416024||Control|Patient who is not on any blood pressure medication
3022026|NCT02416011|No Intervention|Assessment Only (ASSESS)|Participants in this condition will not receive any intervention materials. They will participate solely in the repeated assessments. Including this comparison condition controls for the effect of repeated assessments and allows for the most meaningful evaluation of the efficacy effect size as well as the cost-effectiveness of the eTARGET intervention. This condition will also be the primary source of data for the secondary surveillance aim regarding naturalistic changes in smoking and e-cigarette use over time.
3022027|NCT02416011|Active Comparator|Generic Self-Help (GENERIC)|This will allow us to evaluate our novel self-help intervention for e-cigarette users (our If you Vape booklets) against a matched non-targeted intervention that has demonstrated efficacy for cigarette smokers in general. Such a comparison controls for the possibility that e-cigarette users are sufficiently primed to quit smoking and that even a generic, non-targeted intervention would be effective. This possibility will be directly tested by comparing this condition against both the ASSESS and eTARGET conditions in terms of clinical outcomes and cost-effectiveness.
3022028|NCT02416011|Experimental|Targeted Self-Help (eTARGET)|Participants in this condition will receive the intervention created as the product of Study I.
3022029|NCT02415998||TEE|
3022030|NCT02415985|Other|rifabutin 150|rifabutin 150 mg (1 capsule) once daily
3022031|NCT02415985|Other|rifabutin 300|rifabutin 150 mg (2 capsules) 300 mg 3 times a week
3022032|NCT02415972||All study participants|Patients with Stroke
3022033|NCT02415959|Experimental|Creon IR low dose|Creon IR 300 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
3022034|NCT02415959|Experimental|Creon IR medium dose|Creon IR 1,200 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
3022035|NCT02415959|Experimental|Creon IR high dose|Creon IR 2,400 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
3022036|NCT02415959|Experimental|Creon IR maximum dose|Creon IR 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
3055326|NCT02192463|Experimental|NVP ER 400 mg (ECR 20%) Fast Release|
3022037|NCT02415959|Active Comparator|Creon® (DR/GR)|Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
3022038|NCT02415946|Active Comparator|Sinus floor augmentation (lateral)|Maxillary sinus floor elevation using a lateral approach
3022039|NCT02415946|Experimental|Sinus floor augmentation (transcrestal)|Maxillary sinus floor elevation using a transcrestal approach (Smart Lift technique; Trombelli et al. 2008)
3022040|NCT02415933|Experimental|Trickle Up|Economic empowerment
3022041|NCT02415933|Experimental|Trickle Up Plus|Economic empowerment + child rights sensitization
3022042|NCT02415933|No Intervention|Wait-list|Women in villages assigned to the control arm do not receive any intervention during the study period, but are placed on a wait-list to receive the intervention upon completion of the evaluation phase.
3022043|NCT02415920|Experimental|Experimental|These participants will receive 24 international units (IU) of oxytocin via a nasal spray.
3022044|NCT02415920|Placebo Comparator|Control - Placebo|These participants will receive 24 international units (IU) of a saline solution via a nasal spray.
3022045|NCT02415907|Experimental|Idalopirdine|"Period I: Initial administration of Lu AF67709 single dose at baseline.~Period II: Administration of Lu AF67708 single dose (week 4)"
3022046|NCT02415881|Experimental|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye800 prior to their scheduled surgery.
3022047|NCT02415868||Low pH|Post Menopausal women with vaginal pH of 4.5 or below
3022048|NCT02415868||High pH|Post Menopausal women with vaginal pH of 5.5 or above
3022049|NCT02415842||H1N1 Group|Serum samples from subjects 19-40 years of age (in H1N1 cohort of primary completed study) who were administered unadjuvanted pandemic vaccine with 15 microgram HA (hemagglutinin) at Days 21 and 42.
3022050|NCT02415842||H1N1_AS Group|Serum samples from subjects 19-40 years of age (in H1N1 cohort of primary completed study) who were administered adjuvanted pandemic vaccine with 3.75 microgram HA (hemagglutinin) at Days 21 and 42.
3022051|NCT02415842||Adult H5N1_AS Group|Serum samples from subjects 18-49 years of age (in H5N1 cohort of primary completed study) who were administered adjuvanted pandemic vaccine with 3.75 microgram HA (hemagglutinin) at Days 21 and 42.
3022052|NCT02415842||Adult H5N1 Group|Serum samples from subjects 18-49 years of age (in H5N1 cohort of primary completed study) who were administered unadjuvanted pandemic vaccine with 15 microgram HA (hemagglutinin) at Days 21 and 42.
3022053|NCT02415842||H9N2_375_AS_1 Group|Serum samples from subjects 18-64 years of age (in H9N2 cohort of primary completed study) who were administered adjuvanted pandemic vaccine with 3.75 microgram HA (hemagglutinin) at Days 0 and 21 and saline placebo at Day 182.
3022054|NCT02415842||H9N2_375_AS_2 Group|Serum samples from subjects 18-64 years of age (in H9N2 cohort of primary completed study) who were administered adjuvanted pandemic vaccine with 3.75 microgram HA (hemagglutinin) at Days 0, 21 and 182.
3022055|NCT02415842||H9N2_1500_1 Group|Serum samples from subjects 18-64 years of age (in H9N2 cohort of primary completed study) who were administered unadjuvanted pandemic vaccine with 15 microgram HA (hemagglutinin) at Days 0 and 21 and with saline placebo at Day 182.
3022056|NCT02415842||H9N2_1500_2 Group|Serum samples from subjects 18-64 years of age (in H9N2 cohort of primary completed study) who were administered unadjuvanted pandemic vaccine with 15 microgram HA (hemagglutinin) at Days 0, 21 and 182.
3022057|NCT02415842||Pediatric H5N1_AS Group|Serum samples from subjects 6-35 months of age (primary completed study with pediatric H5N1 cohort) who were administered adjuvanted pandemic vaccine with 1.9 microgram HA (hemagglutinin) at Days 21 and 42.
3022058|NCT02415829|Experimental|Neoadjuvant chemotherapy|A total of 55 cases of locally advanced colon cancer will be enrolled in this arm. After radiological staging, patients were treated first with 3 cycles of neoadjuvant chemotherapy consisting of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen), followed by tumor resection, and then with another 5 cycles of adjuvant chemotherapy with the XELOX regimen. Radiological response was evaluated after 2 cycles of neoadjuvant chemotherapy . A total of 3 cycles neoadjuvant chemotherapy was completed unless there was unacceptable toxicity, emergency operation condition or tumor progression during the period. Tumor responses, toxicities, and surgical complications were recorded. The pathological tumor response in the primary tumor was evaluated according to tumor regression grade (TRG) score.
3022059|NCT02415816|Experimental|Participants|All patients who consent to participate in this protocol. They will have diffusion weighted magnetic resonance imaging performed at several time points.
3022060|NCT02415803|Experimental|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients with non-ST-elevation acute coronary syndrome
3022061|NCT02415803|Active Comparator|conventional-dose ticagrelor|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose ticagrelor.
3022062|NCT02415803|Active Comparator|clopidogrel|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose clopidogrel.
3022063|NCT02415790|Experimental|Part A: PK of E2027 in healthy adults|Part A consists of 6 sequential cohorts of healthy adults. There will be 8 participants in each cohort, with 6 participants randomized to E2027 and 2 participants to placebo.
3022064|NCT02415790|Experimental|Part B: PK and PD of E2027 in healthy adults|Part B consists of 4 sequential cohorts of healthy adult participants. There will be 8 participants in the 1st cohort, with 6 participants randomized to E2027 and 2 participants to placebo. In the 2nd to 4th cohorts, there will be 7 participants in each cohort, with 6 participants randomized to E2027 and 1 participant to placebo. Participants in the 2nd cohort will then receive placebo/the same dose of E2027 again after their washout period in the fed state for the evaluation of food effect.
3022065|NCT02415790|Experimental|Part C: PK of E2027 in elderly cohorts|In Part C, 1 cohort of 8 healthy elderly participants will be enrolled, with 6 participants randomized to E2027 and 2 participants to placebo.
3022066|NCT02415790|Experimental|Part D: PK of E2027 in healthy Japanese adults|In Part D, there will be 3 cohorts of 7 healthy adult Japanese participants, with 6 participants randomized to E2027 and 1 participant to placebo.
3022067|NCT02415777|Experimental|udca003|udca003
3022068|NCT02415777|Placebo Comparator|placebo|placebo of udca003
3022104|NCT02415517|Experimental|Experimental group|Intervention: Cognitive Training
3022105|NCT02415517|Active Comparator|Active control group|Intervention: Test of general knowledge
3022069|NCT02415764|Other|Pilot test Intervention OnTrack>The Game|"Consumers who have been referred to OnTrackNY sites at Washington Heights Community Service or Mental Health Association Westchester in the past six months will be recruited to participate in a product evaluation of OnTrack>The Game.~Intervention: This is a behavioral/attitudinal intervention, using OnTrack>The Game, which will include each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes)."
3022070|NCT02415751||self-care education|All patients in the study will receive self-care education
3022071|NCT02415725|Experimental|lymphofluoroscopy|Indocyanine Green intradermal injection before surgery, and after 3, 6 and 12 monthes
3022072|NCT02415712||Fomepizole Intravenous Infusion|Fomepizole Intravenous Infusion
3022073|NCT02415699|Experimental|DC-CIK Immunotherapy Plus Chemotherapy|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy will receive 12 cycles of DC-CIK therapy in this group
3022074|NCT02415699|Active Comparator|Chemotherapy Alone|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy alone.
3022075|NCT02415673|Experimental|NiTi Af 37ºC|Patients were treatment with fixed orthodontics appliance and arch wire. Two nickel-titanium alignment and leveling sequences were employed - NiTi archwire: 0.012 in and 0.019 X 0.025 in; and thermal activated NiTi archwires: 0.018 in and 0.016 X 0.022 in with different austenite finish temperatures (37ºC).
3022076|NCT02415673|Experimental|NiTi Af 35ºC|Patients were treatment fixed orthodontics appliance and arch wire. Two nickel-titanium alignment and leveling sequences were employed - NiTi archwire: 0.012 in and 0.019 X 0.025 in; and thermal activated NiTi archwires: 0.018 in and 0.016 X 0.022 in with different austenite finish temperatures (35ºC)
3022077|NCT02415660|Experimental|SMT and TDN|Thoracic spinal manipulation and trigger point dry needling using Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm. Exercise program consists of cervical range of motion exercises and posterior neck muscle activation exercise.
3022078|NCT02415660|Sham Comparator|SMT and Sham TDN|Thoracic spinal manipulation and trigger point dry needling sham. Exercise program consists of cervical range of motion exercises and posterior neck muscle activation exercise.
3022079|NCT02415647||Child Proband with Psychiatric Disorder|Affected group of child probands with psychiatric disorders (ages 6-12 years).
3022080|NCT02415647||Normal Comparison Group|Non-disordered psychiatrically normal comparison group (ages 6-12 years).
3022081|NCT02415634|Experimental|Intervention|Intervention Participants in the experimental group will receive usual care plus the RECAP with ICU therapist follow up after ICU discharge. This will be provided for a period of 3 weeks after intensive care unit discharge.
3022082|NCT02415634|Active Comparator|Control|Control Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
3022083|NCT02415621|Other|Abiraterone Acetate Therapy|Study schedule involves stopping FDA Approved abiraterone after participants achieve a good PSA response (50% or more decline of pre-abiraterone PSA) and then restarting abiraterone after their PSA reaches the level of pre-abiraterone PSA.
3022084|NCT02415608|Experimental|Treatment (Ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving an unconfirmed or confirmed CI, PR, or CR by the end of course 6 will be permitted to continue maintenance courses of ibrutinib on an ongoing basis until loss of response/progressive disease, or unacceptable toxicity. Quality-of-Life Assessments will be performed at each cycle start and EOT to evaluate changes in symptom scores. Laboratory Biomarker Analysis will be performed to evaluate changes in histopathology, and Pharmacological Studies to evaluate the pharmacokinetic profile of ibrutinib.
3022085|NCT02415595|Experimental|Arm 1: BMS-955176 60 mg + TDF/FTC|BMS-955176 at 60 mg active dose per day + BMS-955176 placebo matching 120 mg + efavirenz (EFV) placebo matching 600 mg + tenofovir/emtricitabine (TDF/FTC) 300/200 mg per day, orally
3022086|NCT02415595|Experimental|Arm 2: BMS-955176 120 mg + TDF/FTC|BMS-955176 placebo matching 60 mg + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC 300/200mg per day, orally
3022087|NCT02415595|Experimental|Arm 3: BMS-955176 180 mg + TDF/FTC|BMS-955176 at 60mg active dose per day + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC at 300/200mg per day, orally
3022088|NCT02415595|Active Comparator|Arm 4: EFV + TDF/FTC|BMS-955176 placebo matching 60mg + BMS-955176 placebo matching 120mg + EFV at 600mg per day + TDF/FTC 300/200mg per day
3022089|NCT02415582|Experimental|Aerobic exercise|Aerobic exercise on treadmill at 65-70% of the heart rate reserve during a session.
3022090|NCT02415582|Experimental|Combined exercises|A session combines resistance and aerobic exercises, with aerobic exercise on treadmill at 65-70% of the heart rate reserve, followed by 60 minutes for cardiorespiratory recovery, and resistance exercise.
3022091|NCT02415582|Sham Comparator|Control|Participants do not exercise and remain sitting for 45 minutes
3022092|NCT02415569|Experimental|group1|Subjects whose bristol stool forms are type 1 or 2, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.
3022093|NCT02415569|Experimental|group2|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure. ( 2L PEG-ELP and 10mg bisacodyl )
3022094|NCT02415569|Active Comparator|group3|Subjects whose bristol stool forms are type 3 to 7, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.
3022095|NCT02415556|Experimental|Type 2 Diabetes Mellitus - Insulin|40 IU of regular human insulin once daily over 24 weeks
3022096|NCT02415556|Placebo Comparator|Type 2 Diabetes Mellitus - Placebo|Intranasal sterile saline once daily over 24 weeks
3022097|NCT02415556|Experimental|Control - Insulin|40 IU of regular human insulin once daily over 24 weeks
3022098|NCT02415556|Placebo Comparator|Control - Placebo|Intranasal sterile saline once daily over 24 weeks
3022099|NCT02415543|Active Comparator|GROUP A|Group A will undergo SIL-TEP inguinal hernia repair with a single port LESS (12 to 15 mm paraumbilical)
3022100|NCT02415543|Active Comparator|GROUP B|Group B will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )
3022107|NCT02415504|Experimental|Enhanced care transition|The enhanced care transition will offer: (1) an integrated behavioural care plan, (2) an in- person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
3022108|NCT02415504|Other|Standard care transition|The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
3022109|NCT02415491|Experimental|ASO group|ASO group:Evaluation of Correlation of Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test for long term assessment after ASO and recommendation of physical activity of young adults after TGA
3022110|NCT02415465|Active Comparator|Combined Spinal Epidural|Spinal Intraoperative Anesthesia with standard Epidural (0.1% bupivacaine with fentanyl 5 mcg/mL running at 6mL/hr with 1mL q15 bolus) with standard post-operative analgesics.
3022111|NCT02415465|Active Comparator|General+Continuous Adductor Canal Block|General Intraoperative Anesthesia with standard post-operative Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr) with standard post-operative analgesics.
3022112|NCT02415465|Active Comparator|Spinal+Continuous Adductor Canal Block|Spinal Intraoperative Anesthesia with standard post-operative Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr) with standard post-operative analgesics.
3022113|NCT02415452||Acute Coronary Syndrome (ACS) patients|Acute coronary syndrome (ACS) patients who underwent coronary angiography ,drug-eluting stent (DES) implantation, and eye fundus examination.
3022114|NCT02415439|Experimental|VBP15- 0.1 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 0.1 mg/kg under fasted conditions.
3022115|NCT02415439|Experimental|VBP15- 0.3 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.
3022116|NCT02415439|Experimental|VBP15- 1.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions.
3022117|NCT02415439|Experimental|VBP15- 3.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions.
3022118|NCT02415439|Experimental|VBP15- 8.0 mg/kg Fasting SAD|Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions.
3022119|NCT02415439|Experimental|VBP15- 8.0 mg/kg Fed SAD|Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high fat/high high calorie meal.
3022120|NCT02415439|Experimental|VBP15- 20.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 20.0 mg/kg under fasted conditions.
3022121|NCT02415439|Placebo Comparator|Placebo - SAD|Subjects were orally administered a placebo under fasted conditions.
3022122|NCT02415439|Experimental|VBP15- 1.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 1.0 mg/kg for 14 days under fasted conditions.
3022123|NCT02415439|Experimental|VBP15- 3.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 3.0 mg/kg for 14 days under fasted conditions.
3022124|NCT02415439|Experimental|VBP15- 9.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 9.0 mg/kg for 14 days under fasted conditions.
3022125|NCT02415439|Experimental|VBP15- 20.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 20.0 mg/kg for 14 days under fasted conditions.
3022126|NCT02415439|Placebo Comparator|Placebo MAD|Subjects were orally administered placebo for 14 days under fasted conditions.
3022127|NCT02415413|Experimental|Carlizomib lenalidomide and low dose dexamethasone|"Induction treatment: patients included in the trial will receive an induction treatment for approximately 6 months (6 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)). After the third cycle of KRd, all patients will be mobilized with colony stimulating factor (G-CSF) alone to collect peripheral blood stem cell for the ASCT.~High dose therapy followed by autologous stem cell transplantation: patients will receive melphalan 200 mg/m2 via intravenous followed by autologous stem cell transplantation (HDT-ASCT).~Consolidation treatment: approximately 3 months after the autologous stem cell transplantation, patients will receive consolidation treatment for 2 months (2 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)).~Maintenance treatment: subsequently they will start a maintenance treatment that will be administered for approximately 24 months (24 cycles of lenalidomide and low dose dexamethasone"
3022128|NCT02415400|Active Comparator|Apixaban|5 mg or 2.5 mg Apixaban tablets orally twice per day
3022129|NCT02415400|Active Comparator|Vitamin K Antagonist|VKA tablets orally once daily
3022130|NCT02415400|Placebo Comparator|Acetylsalicylic acid film coated tablet|81 mg Acetylsalicylic acid film coated tablet orally once daily
3022131|NCT02415400|Placebo Comparator|Placebo matching Acetylsalicylic acid film coated tablet|Placebo matching Acetylsalicylic acid film coated tablet once daily
3022132|NCT02415387|Experimental|Arm I (inactive typhoid vaccine, placebo)|Patients receive inactive typhoid vaccine IM at visit 1 followed by placebo IM 30 days later at visit 2.
3022133|NCT02415387|Placebo Comparator|Arm II (placebo, inactive typhoid vaccine)|Patients receive placebo IM at visit 1 followed by inactive typhoid vaccine IM 30 days later at visit 2.
3022134|NCT02415374|Placebo Comparator|Low-AVA oat flour cookies|Three low-AVA oat flour cookies
3022135|NCT02415374|Experimental|High-AVA oat flour cookies|Three high-AVA cookies
3022136|NCT02415361|No Intervention|Arm A|"Standard care consists of:~a phone call from a CLP-nurse after the referral from the local birth hospital has been received~telephone service at parents request and at the staffs availability~invitation to a one-day-information course before surgery"
3022137|NCT02415361|Active Comparator|Arm B|"Systematic follow up by a special trained nurse consists of:~telephone contact with the parents shortly after birth~visit at the maternity ward within 36 hours after the referral has been received~telephone follow ups at specific times and at parents request~guidance and support in feeding and treatment~written information~cooperation with the staff at the maternity unit and the health centre~follow up in accordance with a check-list and log~invitation to a one-day-information course before surgery"
3022138|NCT02415348|Experimental|Fibroscan|Fibroscan under simultaneous cardiac monitoring
3022140|NCT02415335|Experimental|dexamethasone|Injection of 2 ml 4 mg/ml dexamethasone phosphate intravenously minimum 30 minutes preoperative.
3022141|NCT02415309|Active Comparator|2 mg Melatonin|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of 2mg melatonin.
3022142|NCT02415309|Active Comparator|10 mg Melatonin|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of 10mg melatonin.
3022143|NCT02415309|Placebo Comparator|Sugar Pill|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of two different levels of melatonin versus placebo as premedication in patients undergoing a lumbar medial branch block (LMBB) procedure.
3022144|NCT02415296||stage 1|French online gamblers.
3022145|NCT02415296||stage 2|Validation of problematic gamblers score on possible problematic gamblers.
3022146|NCT02415296||stage 3|240 problematic gamblers.
3022147|NCT02415283||HCC positive|¹³C-Octanoate Breath Test in 50 MRI proven HCC positive patients
3022148|NCT02415283||HCC negative|¹³C-Octanoate Breath Test in 50 MRI proven HCC negative patients
3022149|NCT02415270|Experimental|Reduced Nicotine Cigarettes|Participants will be randomized to receive low nicotine cigarettes to replace their usual high nicotine brand.
3022150|NCT02415270|Experimental|Reduced ROS/RNS|Participants will be randomized to receive Reduced Oxidative/Nitrogen Species (ROS/RNS) cigarettes to replace their usual cigarettes.
3022151|NCT02415270|Placebo Comparator|Control Group|Participants will be assigned to continue smoking their usual brand of cigarettes.
3022152|NCT02415257|Experimental|Gentamicin treated|"Installation of gentamicin in the middle ear 6 weeks prior to surgery + rehabilitation exercises before and after both treatment and surgery.~Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented and exclusion from exercises would not be approved by the ethical board"
3022153|NCT02415257|No Intervention|Non-gentamicin|Rehabilitation exercises before and after both treatment and surgery Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented and exclusion from exercises would not be approved by the ethical board
3022154|NCT02415244||Age 0 - 3|TEE visualization of the spinal cords in patients age between 0 - 3
3022155|NCT02415244||Age 4 - 18|TEE visualization of the spinal cords in patients age between 4 - 18
3022156|NCT02415244||Age 18 plus|TEE visualization of the spinal cords in patients age 18 or greater
3022157|NCT02415231|Experimental|humor|humor group will watch humor video for 20 minutes
3022158|NCT02415231|No Intervention|control non humor|control group did not watch humor, they sat quietly for 20 minutes.
3022159|NCT02415218|Experimental|Mucosal cell sheet transplantation|The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
3022160|NCT02415192||Patients treated with Levacalm|"In this group, the patients will be enrolled treated with Levacalm tab. as an anti-hypertensive drug.~The number of this group will be double than the control group to get more information about safety and efficacy."
3022161|NCT02415192||Patients treated with Valsartan/amlodipine|In this group, the patients will be enrolled treated with Valsartan/amlodipine combination drug as an anti-hypertensive drug.
3022162|NCT02415179|Experimental|Inhaled Mometasone/formoterol|Inhaled Mometasone/Formoterol (100/5 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
3022163|NCT02415179|Active Comparator|Inhaled Fluticasone/Salmeterol|Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
3022164|NCT02415166|Experimental|VACCINE MDD|SEASONAL INFLUENZA VACCINE (0.5ML) DELIVERED I.M.
3022165|NCT02415166|Placebo Comparator|PLACEBO MDD|SALINE (0.5ML) DELIVERED I.M.
3022166|NCT02415166|Experimental|VACCINE HC|SEASONAL INFLUENZA VACCINE (0.5ML) DELIVERED I.M.
3022167|NCT02415166|Placebo Comparator|PLACEBO HC|SALINE (0.5ML) DELIVERED I.M.
3022168|NCT02415153|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
3022169|NCT02415140||COPD|Spirometry confirmed COPD patients
3022170|NCT02415140||Control|normal geriatric patients without lung disease
3022171|NCT02415127|Experimental|Interferon γ-1b|Approximately 45 participants will receive subcutaneous (SC) doses of ACTIMMUNE® 3 times a week (TIW) for a total of 26 weeks.
3022172|NCT02415127|Placebo Comparator|Placebo|Approximately 45 participants will receive SC doses of placebo TIW for a total of 26 weeks.
3022173|NCT02415114|Active Comparator|Healthy Population|Healthy Population with Omega Q Plus Resveratrol (with 50mg CoQ10)
3022174|NCT02415114|Active Comparator|Population taking Statins|Population taking Statins with Omega Q Plus Resveratrol (with 50mg CoQ10)
3022175|NCT02415101|Active Comparator|Resective surgery after 4-6 weeks|Resective surgery 4-6 weeks after completed chemoradiotherapy (CRT)
3022176|NCT02415101|Active Comparator|Resective surgery after 10-12 weeks|Resective surgery 10-12 weeks after completed chemoradiotherapy (CRT)
3022177|NCT02415088|Active Comparator|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
3022178|NCT02415088|Active Comparator|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
3022179|NCT02415062|Experimental|high dose donepezil (23mg)|Patients with dementia in Parkinson's disease, who are treated with high dose donepezil (23mg)
3022180|NCT02415062|Active Comparator|standard dose denepezil (10mg)|Patients with dementia in Parkinson's disease, who are treated with standard dose donepezil (10mg)
3022181|NCT02415049|Active Comparator|Incremental|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
3022182|NCT02415049|Experimental|Ad-lib|This arm of patients is fed ad lib following surgery and can feed with formula or breast milk at any time and with any frequency up to 12.5ml/kg/feed
3022246|NCT02414581|Experimental|Chlorhexidine 2% & Ethyl Alcohol 7%|Chlorhexidine 2% and Ethyl Alcohol 7% mouthwashes 15ml by 30 seconds, once day for 3 days.
3055327|NCT02192463|Active Comparator|Nevirapine IR 1 tablet|
3022183|NCT02415036|Experimental|Melphalan/HDS treatment of patients with HCC|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System on patients with Hepatocellular carcinoma (HCC).~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 2 cycles of treatment."
3022184|NCT02415036|Experimental|Melphalan/HDS treatment of patients with ICC|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System on patients with Intrahepatic cholangiocarcinoma (ICC).~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 2 cycles of treatment."
3022185|NCT02415023|Experimental|fruquintinib+paclitaxel|fruquintinib combined with paclitaxel. Fruquintinib treatment: administration for 3 weeks followed by 1-week break, and administration every day for the first 21 days.Paclitaxel is administered once weekly in the first three weeks of each cycle.
3022186|NCT02414997|Experimental|RIPC group|Surround left upper limb with cuff, inflate cuff to 200 mmHg and maintain 5 minutes, than deflate to 0 mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
3022187|NCT02414997|Sham Comparator|Sham RIPC group|Surround left upper limb with cuff, inflate cuff to 20 mmHg and maintain 5 minutes, than deflate to 0 mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
3022188|NCT02414984||Golimumab|Participants with rheumatoid arthritis in Colombia, for whom the treating physician has decided to treat with golimumab prior to enrolment. All participants will be observed for 24 months. Any changes including addition of new medications or dose modifications of existing medications will be entirely according to the treating physician's judgment.
3022189|NCT02414971||Men with prostate cancer|men over 18 years of age diagnosed with prostate cancer receiving external beam radiation
3022190|NCT02414958|Experimental|Empagliflozin low dose|Empagliflozin tablets once daily
3022191|NCT02414958|Experimental|Empagliflozin high dose|Empagliflozin tablets once daily
3022192|NCT02414958|Placebo Comparator|Placebo|Placebo tablets matching empagliflozin once daily
3022193|NCT02414945|Experimental|TILs|"Lymphodepleting preparative regimen: Cyclophosphamide, intravenously, at 60mg/kg/day x 2 days, and Fludarabine, intravenously at 25mg/m2/day x 5 days~Autologous tumor infiltrating lymphocytes (TILs): Intravenously at 1x10^10 - 1.6x10^11 cells~Low-dose interleukin-2: Subcutaneously at 125,000 IU/kg per day, for 2 weeks (2 days rest between each week)."
3022194|NCT02414932|Experimental|Ketamine|Ketamine (ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland)) will be made up as a 50 ml colourless saline solution and administered as a slow infusion over 40 minutes using an intravenous infusion pump. A course of up to four once-weekly infusions will be administered. Infusions will be discontinued by the Anaesthetist if there are persisting haemodynamic changes (i.e. heart rate >110/minute or systolic/diastolic blood pressure (BP) >180/100 or >20% increase above pre-infusion BP for more than 15 minutes) that do not respond to beta-blocker therapy.
3022195|NCT02414932|Active Comparator|Midazolam|Midazolam (0.045 mg/kg; Roche Products Ireland Ltd) will be made up as a 50 ml colourless saline solution and administered as a slow infusion over 40 minutes using an intravenous infusion pump. A course of up to four once-weekly infusions will be administered.
3022196|NCT02414919||HERC|Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon)
3022197|NCT02414906|Experimental|Intervention group|Goal-directed therapy
3022198|NCT02414906|No Intervention|Control group|Control group
3022199|NCT02414893||Non obese|
3022200|NCT02414893||Morbidly obese|
3022201|NCT02414893||Sleeve gastrectomy|
3022202|NCT02414880|Active Comparator|Sugammadex/ Normal liver|"Patients with American Society of Anesthesiologists physical status (ASA) class I with normal preoperative liver functions undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg."
3022203|NCT02414880|Active Comparator|Neostigmine / Normal liver|"Patients with American Society of Anesthesiologists physical status (ASA) class I with normal preoperative liver functions undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg."
3022204|NCT02414880|Active Comparator|Sugammadex / Liver cirrhosis|"Patients with liver cirrhosis, Child classification A with a Model for End-Stage Liver Disease (MELD) score <10 undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg."
3022205|NCT02414880|Active Comparator|Neostigmine / Liver cirrhosis|"Patients with liver cirrhosis, Child classification A with a Model for End-Stage Liver Disease (MELD) score <10 undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg."
3022206|NCT02414867||1|Normal weight mothers
3022207|NCT02414867||2|Overweight/Obese mothers
3022208|NCT02414854|Placebo Comparator|Placebo (for Dupilumab 200 mg) q2w|2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection every 2 weeks (q2w) from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
3022209|NCT02414854|Experimental|Dupilumab 200 mg q2w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
3022210|NCT02414854|Placebo Comparator|Placebo (for Dupilumab 300 mg) q2w|2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
3055328|NCT02192463|Active Comparator|Nevirapine IR 2 tablets|
3022211|NCT02414854|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines . Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
3022212|NCT02414841|Active Comparator|Vonapanitase|Vonapanitase administered at the time of radiocephalic fistula creation
3022213|NCT02414841|Placebo Comparator|Placebo|Placebo administered at the time of radiocephalic fistula creation. The placebo is identical in appearance and composition of vonapanitase but lacks the active ingredient.
3022214|NCT02414828|Placebo Comparator|Placebo|Placebo control: 1.0 mL sterile buffer containing 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
3022215|NCT02414828|Experimental|AERAS-402 3 x 10^8 vp|AERAS-402: 1.0 mL containing 3 x 10^8 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
3022216|NCT02414828|Experimental|AERAS-402 3 x 10^9 vp|AERAS-402: 1.0 mL containing 3 x 10^9 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
3022217|NCT02414828|Experimental|AERAS-402 3 x 10^10 vp|AERAS-402: 1.0 mL containing 3 x 10^10 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
3022218|NCT02414815|Experimental|AF group|Atrial fibrillation
3022219|NCT02414802|Experimental|Combined thrombectomy device|A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis. Ten million U of urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy. Anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) at discharge
3022220|NCT02414802|Other|Catheter-directed thrombolysis|Participants will undergo catheter-directed thrombolysis alone. A total of 100,000 units urokinase will be pulse‑spray injected through the catheter once every 4‑6 h. Anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) at discharge
3022221|NCT02414789|Experimental|SRM / MS-MS|
3022222|NCT02414776|Experimental|hydroxychloroquine plus hormonal therapy|Add hydroxychloroquine to the current hormonal therapy
3022223|NCT02414763|No Intervention|Care as Usual|Participants will receive usual care services provided to suicide attempt survivors, including inpatient psychiatry, outpatient psychotherapy, and case management.
3022224|NCT02414763|Experimental|Teachable Moment Brief Intervention|The brief intervention consists of engaging the patient in conversation regarding suicidal ambivalence (desire to live vs. desire to die), collaborative discovery of primary and secondary drivers of suicidality, functional analysis of the suicidal ideation and behaviors, and crisis response planning. Participants will also receive usual care services provided to suicide attempt survivors, including inpatient psychiatry, outpatient psychotherapy, and case management.
3022225|NCT02414750|Experimental|Treatment with BRAF/MEK inhibitor|"Treatment with vemurafenib 2dd 960 mg 28/28 plus cobimetinib 1dd 60 mg 21/28. During treatment patient will undergo PET scanning with FLT and FDG, to compare both types of PET scanning.~During the study biopsies and blood will be taken from the patients."
3022226|NCT02414737|Experimental|corifollitrophin alfa|corifollitrophin alfa used as COH stimulant in IVF
3022227|NCT02414724|Experimental|Treatment (ribociclib, gemcitabine hydrochloride)|Patients receive ribociclib PO on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3022228|NCT02414711|Other|No depressed|"If the result of the HSCL25 scale is inferior than 1.75, then the patient is considered as no depressed.~50 of these patients have to have a psychological interview with the PSE9 questionary to validate the result of the HSCL25 scale."
3022229|NCT02414711|Other|Depressed|"If the result of the HSCL25 scale is superior or equal to 1.75, then the patient is considered as depressed.~50 of these patients have to have a psychological interview with the PSE9 questionary to validate the result of the HSCL25 scale."
3022230|NCT02414698|Active Comparator|Percutaneous Hydrodiscectomy|Percutaneous Hydrodiscectomy with the SpineJet Hydrodiscectomy System
3022231|NCT02414698|Active Comparator|TESI|Transforaminal Epidural Steroid Injections
3022232|NCT02414685|Experimental|intravenous chemotherapy|"TIP regimen:~Paclitaxel 250 mg/ m2 iv on day 1~Ifosfamide 1,2 g/ m2/ day iv x 5 days~Cisplatin 20 mg/ m2/ day iv x 5 days"
3022233|NCT02414672|Experimental|CareSTEPS|CareSTEPS provides skills training in six domains that are central to the caregiving role: self-care, stress management, symptom management, effective communication, problem-solving, and social support.
3022234|NCT02414672|No Intervention|Usual Medical Care (UMC)|Patients receive standard oncologic and generalist palliative care from their healthcare team.
3022235|NCT02414659||Cesarean delivery, cord blood collected|Cesarean delivery patient who opted for cord blood collection during procedure. Cord blood was collected in-utero after delivery and after clamping of the umbilical cord. After cord blood collection operation was continued.
3022236|NCT02414659||Cesarean delivery, control|Routine cesarean delivery patients.
3022237|NCT02414646|Experimental|Treatment (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.
3022238|NCT02414633||Humira|Subjects with an exposure
3022239|NCT02414620|Experimental|Dental Vibe|New oscillating device for reduction in pain during dental anesthesia
3022240|NCT02414607|Experimental|Elderberry Juice|Participants will drink 5ml of elderberry juice, diluted in 8oz of water, 3 times per day for three months.
3022241|NCT02414607|Placebo Comparator|Placebo|Participants will drink 5ml of colored water, diluted in 8oz of water, 3 times per day for three months.
3022242|NCT02414594|Experimental|IONIS-APO(a)-LRx|Drug: IONIS-APO(a)-LRx
3022243|NCT02414594|Placebo Comparator|Placebo (Normal Saline)|Drug: Sterile Normal Saline (0.9% NaCl)
3022244|NCT02414581|Experimental|Chlorhexidine 0.12% & Ethyl Alcohol 7%|Chlorhexidine 0.12% and Ethyl Alcohol 7% mouthwashes 15ml by 30 seconds, twice day for 9 days.
3022245|NCT02414581|Active Comparator|Ethyl Alcohol 7%|Ethyl Alcohol 7% without chlorhexidine mouthwashes 15ml by 30 seconds, twice day for 9 days.
3022247|NCT02414568|Experimental|PVAB regimen|Prednisone 40 mg/m2 (PO) Days 1-5 ; Vinblastine 6 mg/m2 (IV) Day 1 ; Doxorubicin 40 mg/m2 (IV) Day 1 ; Bendamustine 120 mg/m2 (IV) Day 1
3022248|NCT02414555|Active Comparator|NaCl 0.9% BBraun (normale saline)|154mmol/l sodium, 154mmol/l chloride
3022249|NCT02414555|Active Comparator|Elo-Mel Isoton (balanced acetat-based infusate)|sodium 140mmol/l, potassium 5.0mmol/l, calcium 2.5mmol/l, magnesium 1.5mmol/l, chlorid 108mmol/l, acetate 45mmol/l
3022250|NCT02414529|Placebo Comparator|Placebo group|"Placebo group B: single blinded to patients, receive 6 capsule PO (placebo) at once.~Subjects are blinded then they will crossover groups"
3022251|NCT02414529|Active Comparator|Treatment group|"Group A will receive 6 capsules (50.000 units/each) of vitamin D2(ergocalciferol) at once.~Subjects are blinded then they will crossover groups."
3022252|NCT02414516|Experimental|OBP-801|
3022253|NCT02414503|Active Comparator|8IU intranasal oxytocin|8IU intranasal oxytocin delivered with the OptiNose Breath Powered Bi directional liquid device
3022254|NCT02414503|Active Comparator|24IU intranasal oxytocin|24IU intranasal oxytocin delivered with the OptiNose Breath Powered Bi directional liquid device
3022255|NCT02414503|Placebo Comparator|Placebo|Placebo delivered with the OptiNose Breath Powered Bi directional liquid device
3022256|NCT02414477|Experimental|Smokeless tobacco study product|Smokeless tobacco product spiked with deuterated NNN.
3022257|NCT02414464|Experimental|35% hydrogen peroxide|Volunteers of this group will receive a gel with 35% hydrogen peroxide - Whiteness HP 35% for whitening treatment.
3022258|NCT02414464|Experimental|35% hydrogen peroxide with calcium|Volunteers of this group will receive a gel with 35% hydrogen peroxide with calcium - Whiteness HP Blue Calcium 35% for whitening treatment.
3022259|NCT02414464|Experimental|20% hydrogen peroxide with calcium|Volunteers of this group will receive a gel with 35% hydrogen peroxide with calcium - Whiteness HP Blue Calcium 20% for whitening treatment.
3022260|NCT02414451|Experimental|Propranolol arm|"Propranolol will be administered via oral capsule(s) daily for a period of 10 weeks, involving gradual titration up from 40mg to 100mg and subsequent tapering off of the drug. The titration/tapering schedule will be as follows:~Week 1: 40 mg propranolol (1 capsule, nightly) Week 2: 80 mg propranolol (2 40mg capsules, morning & night) Weeks 3 - 8: 100 mg propranolol (3 capsules, 40 mg/morning, 20mg/afternoon, & 40mg/night) Week 9: 60 mg propranolol (2 capsules, 40 mg/morning & 20mg/night) Week 10: 20 mg propranolol (1 capsule, nightly) Week 11: no capsules"
3022261|NCT02414451|Placebo Comparator|Placebo arm|"Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning & night Weeks 3 - 8: 3 capsules, morning, afternoon, & night Week 9: 2 capsules, morning & night Week 10: 1 capsule, nightly Week 11: no capsules"
3022262|NCT02414438|No Intervention|Current Practice Arm|Physicians follow current care procedures
3022263|NCT02414438|Experimental|FirstStep and NextStep Information|Providers receive informational webinar regarding FirstStepDx PLUS and NextStepDx PLUS between rounds and are able to order test results in Round 2
3022264|NCT02414438|Experimental|FirstStep and NextStep Results|Providers receive informational webinar regarding FirstStepDx PLUS and NextStepDx PLUS between rounds and are specifically prompted to order test results in Round 2
3022265|NCT02414425|Experimental|Rectal Injection of Botulinum toxin A|"Botulinum toxin A will be injected during rectoscopy for patient with rectal incontinence.~Anorectal manometry will be performed for evaluation of efficacy of experimental drug"
3022266|NCT02414425|Placebo Comparator|Rectal Injection of physiologic serum|"physiologic serum will be injected during rectoscopy for patient with rectal incontinence.~Anorectal manometry will be performed for evaluation of efficacy of placebo"
3022267|NCT02414412|Active Comparator|Ulmus|Ulmus macrocarpa water extract 250mg orally 2 times a day for 4 weeks
3022268|NCT02414412|Placebo Comparator|Placebo|placebo 250mg orally 2 times a day for 4 weeks
3022269|NCT02414399|Experimental|Azithromycin|Azithromycin 10mg/kg for one day, then 5mg/kg for four days, a total of five days of experimental treatment.
3022270|NCT02414399|Placebo Comparator|Placebo|5 days of taste/appearance/bottle-matched placebo
3022271|NCT02414386||Acute Kidney Injury - CRRT|Multi-organ failure with acute kidney injury critically ill patients admitted to the critical care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure. Biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels.
3022272|NCT02414386||Control|Multi-organ failure non acute kidney injury critically ill patients admitted to the critical care unit. Multi-organ failure is defined as a respiratory and circulatory failure. Biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels.
3022273|NCT02414373|Experimental|Ropivacaine|Ropivacaine 2mg/ml (ROPIVACAIN Sintetica 2 mg/ml ™, Sintetica-Bioren, Couvet, Schweiz)
3022274|NCT02414373|Active Comparator|Bupivacaine|Bupivicaine 1.25mg/ml (BUPIVACAIN Sintetica 0.125 % ™ (Bupivacain 1,25 mg/ml), Sintetica-Bioren, Couvet, Schweiz)
3022275|NCT02414360|Experimental|Shortened Format|Shortened format of a systematic review
3022276|NCT02414360|Active Comparator|Control|Full length systematic review
3022277|NCT02414347|Experimental|Experimental F 18 T807|
3022278|NCT02414334|Active Comparator|Immediate SABR|Immediate stereotactic ablative radiotherapy (standard arm)
3022279|NCT02414334|Experimental|Delayed SABR|Delayed stereotactic ablative radiotherapy (delayed= treatment six months after randomisation or at disease progression) (experimental arm)
3022280|NCT02414321||Fontan group|"Right heart catheterization:~pulmonary artery OCT analysis~dobutamine stress test~pulmonary vascular response test (nitric oxide)~trans-thoracic echocardiography"
3022281|NCT02414321||Control group|"Right heart catheterization:~- pulmonary artery OCT analysis"
3022282|NCT02414308|Experimental|Adipose tissue stem cell injection|The stem cell will be harvested by liposuction and injection will be at corpora cavernosa and dorsal penile artery
3022283|NCT02414295|Experimental|Mesenchymal stem cell injection|Bone marrow Mesenchymal stem cell injection in the testicular tubules and testicular artery
3022284|NCT02414282|Experimental|Experimental F 18 T807|
3022389|NCT02413567|Experimental|DMR Procedure|Subjects receive the endoscopic DMR procedure in this arm
3022285|NCT02414269|Experimental|modified T cells alone (without chemotherapy)|Following enrollment, leukapheresis product will be obtained in the blood donor facility at MSKCC and cryopreserved in the Cell Therapy and Cell Engineering Facility (CTCEF). Before protocol treatment, the leukapheresis product will be thawed, and T cell isolation, transduction, and expansion of iCasp928z T cells will be performed in the MSKCC CTCEF Facility. It is estimated that it will take approximately 3 to 6 weeks to generate T cells for treatment.
3022286|NCT02414269|Experimental|modified T cells with cyclophosphamide|Patients will receive cyclophosphamide intravenously (at 1.5 g/m^2) , 2 - 7 (Day (-7) -(-2) days before T cell infusion. On Day 1 , patients will be admitted to the MSKCC Thoracic Surgery Inpatient Service (if not already inpatients) for intravenous hydration, clinical monitoring, and blood work for immune monitoring. Standard MSKCC antiemetic therapy will be administered prior to chemotherapy to prevent nausea/vomiting. Administration of corticosteroids will be avoided as steroids may impede the efficacy of CAR T cells.
3022287|NCT02414243|Experimental|New Amino Acid formula|New Amino-Acid based Infant Formula
3022288|NCT02414243|Active Comparator|Control formula|Commercially available Amino Acid Formula
3022289|NCT02414230|Experimental|Experimental F 18 T807|
3022290|NCT02414217|Experimental|In-Person Diabetes Numeracy Education|"Participants randomized to the in-person education group attended four group classes, each addressing a specific set of diabetes self-care skills (i.e., understanding and using blood glucose numbers, counting carbohydrates, taking medications at the right dose and time). So that each class included a stable group of 8 and 16 participants, we ran classes in cohorts of 8-16 people. A participant always attended classes with his/her cohort."
3022291|NCT02414217|Experimental|Online Diabetes Numeracy Education|Participants randomized to the online education group attended a single session, at which he/she completed a computerized education module that addressed understanding blood sugar values and using them to examine the impact of food, exercise, and medicines on blood sugar.
3022292|NCT02414217|No Intervention|Control|Participants were given written educational materials about diabetes.
3022293|NCT02414204|Active Comparator|Sildenafil|20 mg twice a day orally
3022294|NCT02414204|Placebo Comparator|Placebo|Placebo twice a day orally
3022295|NCT02414191|No Intervention|Control|Participants in this study arm will receive no form of feedback.
3022296|NCT02414191|Other|Benchmarked Feedback|Participants in this study arm will receive benchmarked feedback regarding their perioperative temperature management.
3022297|NCT02414191|Other|Ranked Feedback|Participants in this study arm will receive ranked feedback regarding their perioperative temperature management.
3022298|NCT02414178|Experimental|Experimental F 18 T807|
3022299|NCT02414165|Experimental|Toca 511/Toca FC|"Resection followed by administration of 4 mL Toca 511 (vocimagene amiretrorepvec). Toca 511 is administered by injection into the wall of the subject's tumor resection cavity on Day 1 (approximately 40 injections of 0.1 mL)~Toca FC is an extended-release formulation of flucytosine. Toca FC will be administered at 220 mg/kg/day orally for 7-day courses beginning at least 6 weeks after resection and repeated approximately every 6 weeks."
3022300|NCT02414165|Active Comparator|Lomustine, Temozolomide, or Bevacizumab|"Investigator selects one of the following:~Bevacizumab: Beginning 6 weeks after tumor resection, bevacizumab will be administered by IV infusion at 10 mg/kg and repeated every 2 weeks. Refer to the prescribing information and to institutional guidelines for details on the administration procedure.~Lomustine: Beginning 6 weeks after tumor resection, lomustine will be administered as a single oral dose of 110 mg/m2 and repeated every 6 weeks. Refer to the prescribing information and to institutional guidelines for details regarding the administration procedure.~Temozolomide: Beginning 6 weeks after tumor resection, temozolomide will be administered per 1 of 2 options:~at a dose of 50 mg/m2 PO once daily continuously, or~at an initial dose of 150 mg/m2 IV or PO once daily for 5 consecutive days per 28-day treatment cycle that may be raised to 200 mg/ m2 once daily for 5 consecutive days in the following 28-day treatment cycles"
3022301|NCT02414152|Experimental|anakinra|100mg of Anakinra administered as a daily subcutaneous injection
3022302|NCT02414139|Experimental|cMET GCN ≥ 6|Pre-treated patients with cMET GCN ≥ 6 treated with INC280 at 400mg BID as second or third line
3022303|NCT02414139|Experimental|cMET GCN ≥ 4 and < 6|Pre-treated patients with cMET GCN ≥ 4 and < 6 treated with INC280 at 400 mg BID as second or third line
3022304|NCT02414139|Experimental|cMET GCN < 4|Pre-treated patients with cMET GCN < 4 treated with INC280 at 400mg BID as second or third line
3022305|NCT02414139|Experimental|cMET mutations|Pre-treated patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID as second or third line
3022306|NCT02414139|Experimental|cMET dysregulation - treatment-naïve|Treatment-naïve patients with cMET dysregulation treated with INC280 at 400mg BID
3022307|NCT02414139|Experimental|cMET dysregulation - second line|Pre-treated patients with cMET deregulation treated with INC280 at 400 mg BID as second line
3022308|NCT02414126|Active Comparator|Children with dilated cardiomyopathy with an ejection fraction|
3022309|NCT02414126|Active Comparator|Children with univentricular congenital heart disease|
3022310|NCT02414126|Active Comparator|Children with left valvulopathy|
3022311|NCT02414113||Low GNOS donors|
3022312|NCT02414113||High GNOS donors|
3022313|NCT02414100||Patient derived cancer cell lines|Patients receive gemcitabine hydrochloride IV qw 3/4 wk or gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV qw 3/4 wk in the absence of disease progression or recurrence per standard of care. Tissue and blood samples are collected for genetic analysis via sequencing.
3022314|NCT02414087|Active Comparator|study group|ICB Medical Insoles
3022315|NCT02414087|Placebo Comparator|control group|without ICB Medical insoles
3022316|NCT02414074|Other|Youth Behavioral Intervention|Teen Intervene Program
3022317|NCT02414074|Other|Parent Education|Everyday Parenting Program
3022318|NCT02414061|Experimental|Breakfast - Carbohydrate + Whey Protein|Addition of whey protein isolate (20 g dissolved in flavoured water) to breakfast meal composition
3022319|NCT02414061|Placebo Comparator|Breakfast - Carbohydrate|Only flavoured water consumed with breakfast meal
3022320|NCT02414061|No Intervention|No Breakfast|Only water consumed at breakfast time point
3022321|NCT02414048|Other|Pimonidazole|All patients will receive Pimonidazole to demarcate hypoxia regions in the tumour
3022322|NCT02414009|Experimental|CAPTEM|Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die bid from day 1 to day 14 every 28 days plus temozolomide 150 mg/mq/die bid starting on day 10 to 14 every 28 days. Treatment will continue for up to 6 cycles or up to disease progression, unacceptable toxicity or informed consent withdrawal.
3022323|NCT02414009|Active Comparator|FOLFIRI|"Patients in Arm B will receive FOLFIRI chemotherapy starting Day~1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU 7 (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days. Treatment will continue for up to 12 cycles in Arm B or up to disease progression, unacceptable toxicity or informed consent withdrawal."
3022324|NCT02413996|Experimental|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS) in addition to a knee continuous passive motion device ( Kinetec® continuous passive motion ( CPM )) and functional activities (e.g.,stairs, walking)
3022325|NCT02413996|Active Comparator|traditional rehabilitation|exercise therapy through a traditional rehabilitation training in addition to a knee continuous passive motion device ( Kinetec® continuous passive motion ( CPM )) and functional activities (e.g.,stairs, walking)
3022326|NCT02413983||CI (conventional incision)|The living liver donors underwent hepatectomy using right subcostal incision with a midline extension (conventional incision)
3022327|NCT02413983||MI (midline incision)|The living liver donors underwent hepatectomy using upper midline incision (10cm) without laparoscopic assistance
3022328|NCT02413983||TI (transverse incision)|The living liver donors underwent hepatectomy using transverse incision with laparosocpic assistance
3022329|NCT02413970|Experimental|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® UAS System.
3022330|NCT02413957|No Intervention|Controll-Group|Patient randomized to the Control-Group will receive the traditional care by physician and nurse on the ward.
3022331|NCT02413957|Experimental|MedRec-Group|Patient randomized to the MedRec-Group will receive the traditional care by physician and nurse on the ward and additional pharmacist led medication reconciliation.
3022332|NCT02413957|Experimental|AMTS-Group|Patient randomized to the AMTS-Group will receive the traditional care by physician and nurse on the ward and additional pharmaceutical care by a pharmacist.
3022333|NCT02413944|Experimental|healthy volunteers|ACTH stimulation test
3022334|NCT02413931||Patients with MDR-TB|Patients with multidrug-resistant tuberculosis admitted for treatment at the Marius Nasta Institute will be included
3022335|NCT02413918|Experimental|Open Label iloperidone|open label iloperidone (oral tablet, 6mg-24mg, QD, 20 weeks) as adjunct to current lithium, divalproex, or lamotrigine.
3022336|NCT02413905||Senegal|Stool samples on Children with and without severe acute malnutrition in Senegal recruited in 3 locations (Dakar, Dielmo and Ndiop)
3022337|NCT02413905||Niger|Stool samples Children with and without severe acute malnutrition in Niger recruited in Niamey
3022338|NCT02413879|Experimental|Treatment Group|All study subjects will be treated using the CleanCision device.
3022339|NCT02413866|Experimental|Calorie Restriction Only|Participants in this group will be decreasing their caloric intake to approximately 95% of their resting metabolic rate. We will provide one meal for 4 days of the week, and participants will be required to keep an accurate dietary record of all food and drink. Participants assigned to this group will be instructed to keep a fixed sleep schedule based on their own sleep/napping habits.
3022340|NCT02413866|Experimental|Sleep & Calorie Restriction|Participants in this group will decrease their caloric intake to approximately 95% of their resting metabolic rate in addition to reducing their total time in bed by 90 minutes 5 days a week.
3022341|NCT02413853|Experimental|Arm I (PRI-724, mFOLFOX6/bevacizumab)|Patients receive CBP/beta-catenin antagonist PRI-724 IV continuously on days 1-7, bevacizumab IV over 30 minutes, leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV over 46 hours on day 8. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3022342|NCT02413853|Experimental|Arm II (mFOLFOX6/bevacizumab)|Patients receive bevacizumab, leucovorin calcium, oxaliplatin, and fluorouracil as in Arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3022343|NCT02413840|Experimental|Baduanjin qigong group|Doing exercise of Baduanjin qigong under the guidance of medical staff;psychological counseling at the same time.
3022344|NCT02413840|No Intervention|control group|Psychological counseling only.
3022345|NCT02413827|Experimental|Phase l: varlilumab and ipilimumab|
3022346|NCT02413827|Experimental|Phase ll: varlilumab & ipilimumab, +/- CDX-1401 & poly-ICLC.|
3022347|NCT02413814|Experimental|Anger Reduction Treatment|The treatment consists of eight 30-minute IBM sessions. Participants will be presented with ambiguous scenarios and asked imagine themselves in these situations. In the first task, the scenario will be followed by a benign interpretation of the situation. Participants will answer a comprehension question designed to have participants endorse this benign interpretation. In the second task, participants will be presented with a word denoting an interpretation with either a negative/hostile or positive/benign connotation. Following this word, an ambiguous scenario will appear. Participants will indicate whether the word and the scenario were related. They will receive feedback training them to endorse positive interpretations and reject negative interpretations.
3022348|NCT02413814|Placebo Comparator|Control Condition|Participants assigned to the control condition will complete eight computerized sessions consisting of psychoeducation on healthy behaviors (i.e., topics of exercise, diet, hygiene, social support, healthy activities, and sleep, taken from protocols developed from our ongoing research). These participants will also view relaxing videos consisting of brief guided meditation instructions, pictures of nature scenes, and soft music. These sessions (psychoeducation and relaxing videos) will be matched for time with the active treatment condition, lasting 30 minutes each.
3022349|NCT02413801||Psoriasis|Individuals with psoriasis
3022350|NCT02413801||Healthy|Individuals that are healthy
3022351|NCT02413788|Experimental|combined group (treadmill and resisted)|- 10 minutes of warming, aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate) and resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs (36 sessions)
3056058|NCT02187705||Patients with essential hypertension at baseline|
3022352|NCT02413788|Active Comparator|aerobic group (treadmill)|10 minutes of warming, aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate) for 36 sessions
3022353|NCT02413762||NGT, no insulin resistance|Individuals with normal glucose tolerance without a diagnosis of IGF, IGT or Diabetes Mellitus. No intervention.
3022354|NCT02413762||IFG/IGT/T2DM|Individuals with a diagnosis of impaired glucose tolerance, impaired fasting glucose or type 2 diabetes mellitus. No intervention.
3022355|NCT02413762||Insulin resistance without IGT|e.g. polycystic ovarian syndrome. No intervention.
3022356|NCT02413762||IGT, no insulin resistance|e.g. T1DM. No intervention.
3022357|NCT02413762||Previous metabolic surgery|Previous metabolic surgery for weight loss or treatment of T2DM. No intervention.
3022358|NCT02413749||Stable PsA response to treatment|Individuals with psoriatic arthritis who are being treated standard of care with a stable DMARD or a biologic
3022359|NCT02413749||PsA inadequate response to DMARD|Individuals with psoriatic arthritis who have had an inadequate response to a DMARD and are being treated standard of care with a biologic.
3022360|NCT02413736|Experimental|Imatinib|Imatinib 400 mg/day for 24 months.
3022361|NCT02413736|No Intervention|No imatinib|No further imatinib.
3022362|NCT02413723|Active Comparator|Videolaryngoscope McGrath Mac|McGrath Mac videolaryngoscope will be used for laryngoscopy for patient's intubation
3022363|NCT02413723|Placebo Comparator|Standard laryngoscope|Macintosh laryngoscope will be used for laryngoscopy for patient's intubation
3022364|NCT02413710|Active Comparator|Usual Protein Group|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
3022365|NCT02413710|Experimental|Soy Protein Group|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the USDA MyPlate program (www.choosemyplate.gov) with the incorporation of two servings of study food providing soy protein per day.
3022366|NCT02413697|Active Comparator|Two-dimensional ultrasound|Two-dimensional ultrasound guided embryo transfer
3022367|NCT02413697|Experimental|Three-dimensional ultrasound|Three-dimensional ultrasound guided embryo transfer
3022368|NCT02413684|Other|Asthma Patients|Patient engagement toolkit
3022369|NCT02413671|Other|Lupin Protein|Subjects received a test meal rich in carbohydrates and supplemented with lupin protein.
3022370|NCT02413671|Other|Whey Protein|Subjects received a test meal rich in carbohydrates and supplemented with whey protein.
3022371|NCT02413671|Other|Reference|Subjects received a test meal rich in carbohydrates not supplemented with any protein.
3022372|NCT02413658|Active Comparator|Control|Dressings of best current clinical practice, sugar solution.
3022373|NCT02413658|Experimental|Phenytoin 1|Dressings using phenytoin solution 20mg/ml
3022374|NCT02413658|Experimental|Phenytoin 2|Dressings using phenytoin solution 40mg/ml
3022375|NCT02413645|Other|100 μg TriMix mRNA (TriMix_100)|"Cohort 1 (control group) 3 patients will receive 100 μg of mRNA (i.e. 100 μg TriMix mRNA).If two or more of the three patients have a dose limiting toxicity (DLT), DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
3022376|NCT02413645|Other|300 μg TriMix mRNA (TriMix_300)|"Cohort 2 (control group) 3 patients will receive 300 μg of mRNA (i.e. 100 μg TriMix mRNA).If two or more of the three patients have a DLT, DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
3022377|NCT02413645|Experimental|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 3 (experimental group) 3 patients will receive 600 μg of mRNA (300 μg HIV mRNA + 300 μg TriMix mRNA). If two or more of the three patients have a DLT, DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
3022378|NCT02413645|Experimental|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 4 (experimental group) 3 patients will receive 900 μg of mRNA (i.e. 600 μg HIV mRNA and 300 μg TriMix mRNA). If two or more of the three first patients have a DLT, then additional three patients will be enrolled at the previous level dose (dose will be reduced to 600 μg of mRNA per vaccination). If one or no patients have a DLT, additional three patients will be enrolled at 900 μg dose level. If two or more of the six patients receiving 900 μg of mRNA have a DLT, then additional 3 patients will be enrolled at the previous level dose (dose will be reduced to 600 μg of mRNA per vaccination). If one or no patients of the six patients have a DLT, six patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
3022379|NCT02413645|Experimental|1200μg mRNA(900 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 5 (experimental group) 6 patients will receive 1200 μg of mRNA (i.e. 900 μg HIV mRNA + 300 μg TriMix mRNA) in case one or no patients of the six patients at the previous dose level have a DLT.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
3022380|NCT02413632|Other|First period|"creation of a STIs score risk~pharyngeal swab+urinary collection+blood specimens+rectal Chlamydia trachomatis l Neisseria gonorrhoeae (CT/GC) testing"
3022381|NCT02413632|Other|Second period|"validation of a STIs score risk~pharyngeal swab+urinary collection+blood specimens+rectal Chlamydia trachomatis l Neisseria gonorrhoeae (CT/GC) testing"
3022382|NCT02413619|Active Comparator|Start cataract|Patients start having cataract surgery. After one month they undergo vitrectomy
3022383|NCT02413619|Active Comparator|start vitrectomy|Patients start having vitrectomy. After one month they undergo cataract surgery.
3022384|NCT02413619|Active Comparator|combined surgery|Combined cataract surgery and vitrectomy at the same time
3022385|NCT02413606|Experimental|Intervention|reduced follow-up schedule: 4 follow-up visits, after 3, 12, 24 and 36 months
3022386|NCT02413606|No Intervention|control|regular follow-up schedule according to the guideline, 10-13 visits during 5 years
3022387|NCT02413593|Experimental|LDV/SOF+RBV|LDV/SOF FDC plus RBV for 12 weeks
3022388|NCT02413580|Experimental|IGIV-C Treatment|An IV dose of 2 g/kg of IGIV-C will be administered in subjects with myasthenia gravis exacerbations.
3022390|NCT02413554|Experimental|Patch applied patients|"The investigators had enrolled consecutively the patients who were going to operation after femur neck fracture.~Participants were applied the 5 unit rivastigmine patches from 3 days before and 7 days after the femur neck operation."
3022391|NCT02413554|No Intervention|Patch non-applied patients|The participants who were going to operation after femur neck fracture were not applied the rivastigmine patches.
3022392|NCT02413541|Experimental|High EAA and use Polymyxin-B Hemoperfusion|EAA level > 0.6 or EAA = 0.6 and use Polymyxin-B Hemoperfusion
3022393|NCT02413541|Experimental|High EAA and not use Polymyxin-B Hemoperfusion|EAA level > 0.6 or EAA = 0.6 and not use Polymyxin-B Hemoperfusion
3022394|NCT02413541|Active Comparator|Low EAA|EAA level < 0.6 and not use Polymyxin-B Hemoperfusion
3022395|NCT02413528|Sham Comparator|Standard Care with Medication Monitoring|"Patients will be given an inhaler sensor to monitor medication use and a sham version of the mobile app that will not include reminders or incentives.~Intervention: Inhaler sensor"
3022396|NCT02413528|Experimental|Medication Monitoring and Mobile App|"Patients will be given an inhaler sensor to monitor medication use and a mobile phone application that will send them reminders and provide an opportunity to see their own medication use and win incentives for adherence.~Interventions: Inhaler sensor and mobile application for asthma adherence"
3022397|NCT02413515|Experimental|Arm 1|Single arm study,the eligible subjects will receive Nifedipine GITS 60mg for 8 weeks
3022398|NCT02413502|Experimental|Bacillus Calmette-Guérin (BCG)|Tice brand BCG used to vaccinate BCG-Naïve adults.
3022399|NCT02413489|Experimental|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram [mg/kg]) as intravenous infusion once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
3022400|NCT02413476|Experimental|Robotic-assisted Gastrectomy(RAG)|Robotic-assisted Gastrectomy will be performed for the treatment of patients assigned to this group.
3022401|NCT02413476|Active Comparator|Laparoscopic-assisted Gastrectomy(LAG)|Laparoscopic-assisted Gastrectomy will be performed for the treatment of patients assigned to this group.
3022402|NCT02413463|Active Comparator|augmented recession|Augmented recession of the medial rectus muscles
3022403|NCT02413463|Active Comparator|Faden with recession|medial rectus muscle recession with posterior scleral fixation
3022404|NCT02413437|Experimental|CEUS guided biopsy|Biopsy was operated under contrast-enhanced ultrasound-guided
3022405|NCT02413437|Other|US guided biopsy|Biopsy was operated under conventional ultrasound-guided
3022406|NCT02413424|Experimental|Drink Sucralose|Subjects will drink sucralose 10 min before drinking a glucose load
3022407|NCT02413424|Placebo Comparator|Drink Water|Subjects will drink water 10 min before drinking a glucose load
3022408|NCT02413424|Experimental|Taste and spit Sucralose|Subjects will taste and spit up sucralose 10 min before drinking a glucose load
3022409|NCT02413411|Experimental|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
3022410|NCT02413411|Active Comparator|Attention Control|Patients randomized to the attention control arm will receive an educational program (an NIH-developed booklet) that summarizes how to live with knee OA but does not specifically mention joint replacement. This booklet provides examples of exercises one could do to improve pain and reduce stiffness from knee OA.
3022411|NCT02413398|Experimental|Dapagliflozin|10 mg Tablets, Oral, Once daily, 24 weeks
3022412|NCT02413398|Placebo Comparator|Placebo|Matching placebo to Dapagliflozin 10 mg tablet. Oral, Once daily, 24 weeks
3022413|NCT02413385|Experimental|HealtheSteps Program|6 month evidence-based lifestyle Rx program: receive lifestyle Rx's for exercise, physical activity (step counts) and healthy eating and set goals around Rx's (in person sessions at set time points during 6-month period); take part in self-directed healthy living activities to achieve Rx's (Months 0-6); access to a suite of health technology support options for additional support and coaching (Months 0-6).
3022414|NCT02413385|No Intervention|Usual-care wait-list control|No active intervention (usual care).
3022415|NCT02413372|Experimental|Treatment Group A: BMS-986036|Administered as specified on specified days
3022416|NCT02413372|Experimental|Treatment Group B: BMS-986036|Administered as specified on specified days
3022417|NCT02413372|Placebo Comparator|Treatment Group C: Placebo|Administered as specified on specified days
3022418|NCT02413346|Experimental|Placebo/Sarecycline|Participants received placebo-matching sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 milligram(mg)/kilogram(kg) sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).
3022419|NCT02413346|Experimental|Sarecycline/Sarecycline|Participants received sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 mg/kg sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).
3022420|NCT02413333|Other|Clear Care Plus, then PeroxiClear|Clear Care Plus contact lens solution in Period 1, followed by PeroxiClear contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual silicone hydrogel contact lenses for approximately 30 cleaning cycles.
3022421|NCT02413333|Other|PeroxiClear, then Clear Care Plus|PeroxiClear contact lens solution in Period 1, followed by Clear Care Plus contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual silicone hydrogel contact lenses for approximately 30 cleaning cycles.
3022422|NCT02413320|Active Comparator|Carboplatin + Paclitaxel then Doxorubicin + Cyclophosphamide|Paclitaxel (80mg/m2) given IV every week x12 weeks and Carboplatin (AUC 6) given IV every 21 days x 4 cycles, followed by Doxorubicin (60mg/m2) given IV and Cyclophosphamide (600mg/m2) given IV every 14 days X 4 cycles
3022423|NCT02413320|Active Comparator|Carboplatin + Docetaxel|Carboplatin (AUC 6) given IV and Docetaxel (75mg/m2) given IV every 21 days x 6 cycles
3022485|NCT02413034|Active Comparator|Study group cefazolin|Classical antibiotic prophylaxis
3022424|NCT02413307|Experimental|Intervention Group|Self-practice compassion focused therapy intervention following written or audio scripts. This includes instructions, an explanation of compassion and aims of the intervention. It includes several exercises designed to increase self-compassion including breathing exercises and compassionate imagery exercises focused on self and others
3022425|NCT02413307|No Intervention|Waiting List Control|Participants on the waiting list for trauma specific therapy. These will be participants who have consented to engaging in the research project but their intervention phase has a delayed start.
3022426|NCT02413294|Experimental|Bright Light Intervention|Before the bright light intervention is initiated (and during the intervention), participants will wear two wrist bands which measure sleep quality and activity levels- the Fitbit and actigraphy watches. These will be worn for two weeks to assess individuals' baseline levels of sleep quality and will continue to be worn during the intervention. Following the baseline period, the re-timer glasses will be introduced and worn for a period of 30 to 50 minutes a day for two weeks.
3022427|NCT02413281|Experimental|ALKS 5461 Dose 1|Sublingual tablets
3022428|NCT02413281|Experimental|ALKS 5461 Dose 2|Sublingual tablets
3022429|NCT02413281|Experimental|ALKS 5461 Dose 3|Sublingual tablets
3022430|NCT02413281|Active Comparator|Buprenorphine Dose 1|Sublingual tablets
3022431|NCT02413281|Active Comparator|Buprenorphine Dose 2|Sublingual tablets
3022432|NCT02413281|Placebo Comparator|Placebo|Sublingual tablets
3022433|NCT02413268|Placebo Comparator|Placebo|Patient receives an antibiotic ointment with no vasoactive drug as a placebo for comparison.
3022434|NCT02413268|Active Comparator|Nitropaste|Nitroglycerin 2% ointment is applied above the compression surface on the skin, to evaluate its efficacy in reducing radial artery occlusion.
3022435|NCT02413255|Experimental|Part 1 Cohort 1: TAK-020 0.1 mg|TAK-020 0.1 milligram (mg), solution, orally or matching placebo, solution, orally, once on Day 1.
3022436|NCT02413255|Experimental|Part 1 Cohort 2: TAK-020 0.5 mg|TAK-020 0.5 mg, solution, orally or matching placebo, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.
3022437|NCT02413255|Experimental|Part 1 Cohort 3: TAK-020 2.5 mg|TAK-020 2.5 mg, solution, orally or matching placebo, solution, orally, once on Day 1 following review of safety, tolerability and PK data from Cohort 2.
3022438|NCT02413255|Experimental|Part 1 Cohort 4: TAK-020 4.4 mg|TAK-020 4.4 mg, solution, orally or matching placebo, solution, orally, once on Day 1 following review of safety, tolerability and PK data from Cohort 3.
3022439|NCT02413255|Experimental|Part 1 Cohort 5: TAK-020 8.8 mg|TAK-020 8.8 mg, solution, orally or matching placebo, solution, orally, once on Day 1 following review of safety, tolerability and PK data from Cohort 4.
3022440|NCT02413255|Experimental|Part 1 Cohort 6: TAK-020 17.5 mg|TAK-020 17.5 mg, solution, orally or matching placebo, solution, orally, once on Day 1 following review of safety, tolerability and PK data from Cohort 5.
3022441|NCT02413255|Experimental|Part 1 Cohort 7: TAK-020 35 mg|TAK-020 35 mg, solution, orally or matching-placebo, solution, orally, once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 6.
3022442|NCT02413255|Experimental|Part 1 Cohort 8: TAK-020 70 mg|TAK-020 70 mg, solution, orally or matching placebo, solution, orally, once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 7.
3022443|NCT02413255|Experimental|Part 1 Cohort 9: TAK-020 105 mg|TAK-020 105 mg, solution, orally or matching placebo, solution, orally, once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 8. TAK dose to be determined for actual dose level when PK data from previous cohort is available (TBD).
3022444|NCT02413255|Experimental|Part 2 Cohort 1: TAK-020 3.75 mg|TAK-020 3.75 mg, solution, orally or matching placebo, solution, orally, once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.
3022445|NCT02413255|Experimental|Part 2 Cohort 2: TAK-020 5.75 mg|TAK-020 5.75 mg, solution, orally or matching placebo, solution, orally, once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.
3022446|NCT02413255|Experimental|Part 2 Cohort 3: TAK-020 13 mg|TAK-020 13 mg, solution, orally or matching placebo, solution, orally, once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.
3022447|NCT02413255|Experimental|Part 2 Cohort 4: TAK-020 25 mg|TAK-020 25 mg, solution, orally or matching placebo, solution, orally, once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.
3022448|NCT02413255|Experimental|Part 2 Cohort 5: TAK-020 TBD|TAK-020 solution, orally or matching placebo, solution, orally, once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.
3022449|NCT02413255|Experimental|Part 2 Cohort 6: TAK-020 TBD|TAK-020 solution, orally or matching placebo, solution, orally, once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.
3022450|NCT02413255|Experimental|Part 2 Cohort 7: TAK-020 TBD|TAK-020 solution, orally or matching placebo, solution, orally, once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 6 in Part 2.
3022451|NCT02413242||ICU subjects, S. aureus+ at ICU admission|"Adult ICU patients, with a positive colonization status for S. aureus at ICU admission, who are mechanically ventilated within 24 hours of ICU admission and have an expected length of stay of 48h or more.~Colonization status will be measured at ICU admission using a nose swab and an ETA (or sputum/throat if unavailable). Positivity of either of the two qualifies the patient to be enrolled as a subject in this group."
3022452|NCT02413242||ICU subjects, S. aureus- at ICU admission|"Adult ICU patients, with a negative colonization status for S. aureus at ICU admission, who are mechanically ventilated within 24 hours of ICU admission and have an expected length of stay of 48h or more.~Colonization status will be measured at ICU admission using a nose swab and an ETA (or sputum/throat if unavailable). Negativity of both qualifies the patient to be enrolled as a subject in this group."
3022453|NCT02413229|Experimental|DSXS1411|DSXS applied once a day for a total of 28 days.
3022454|NCT02413229|Placebo Comparator|Placebo|Placebo (vehicle) applied once a day for a total of 28 days.
3022455|NCT02413216|Experimental|TicHelper|In this condition, participants will be provided with a secure username and login information for TicHelper.com. Participants will be asked to log in and use TicHelper.com for 8 weeks as instructed by the program (TicHelper recommends 30-60 minutes of website and therapeutic activity per day). TicHelper.com consists of 3 modules: Education, Assessment, and Intervention. The education module provides information about tic disorders and treatment. The assessment module tracks progress through the program. The intervention module uses interactive activities to teach tic management skills including habit reversal training (HRT). During HRT, patients learn to become more aware of tics and pre-tic sensations and to subsequently interrupt tics. Participants will also learn ways to interact with each other regarding tics, to identify and alter tic-worsening factors, and relaxation strategies to reduce stress.
3022456|NCT02413216|Active Comparator|Internet-Based Resources Condition|Participants who are assigned to the Internet-Based Resources (IBR) condition will receive a collection of materials with inks to the best available online resources about tic disorders and their treatment. The sites that are provided use a variety of online print, video, and animation materials to teach patients about various aspects of chronic tic disorders and their management. Participants will will be asked to explore and use the website information over the course of 8 weeks in any manner they find helpful. Participants will be asked to spend 30-60 minutes per day reviewing and discussing the information provided.
3022457|NCT02413203|Experimental|Celecoxib|Oral administration of a single pill of celecoxib (200 mg). Celecoxib pills will be over-encapsulated to match the placebo.
3022458|NCT02413203|Placebo Comparator|Placebo|Oral administration of a single placebo pill.
3022459|NCT02413177|Active Comparator|EEG-RTNF|Group 1 will receive EEG-RTNF training from the PCC. They will attend an 8 week MBSR class. This feedback will occur at weeks 3, 4, 6 and 7.
3022460|NCT02413177|Active Comparator|EEG-no RTNF|Group 2 will receive EEG (no RTNF feedback). They will attend an 8 week MBSR class. This feedback will occur at weeks 3, 4, 6 and 7.
3022461|NCT02413164|Experimental|Physical intervention group|12 weeks of groupal sessions of individualised multimodal physiotherapy programme of therapeutic exercises with education healthy-style-of-life based, 2 times for week.
3022462|NCT02413164|No Intervention|Control group|This group will receive usual care and will be in wait list status for the duration of study, later the intervention will be offered to this group.
3022463|NCT02413151|Experimental|Exercise Training Program|The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods.
3022464|NCT02413151|Active Comparator|Control|Regular lifestyle
3022465|NCT02413138|Experimental|Phase 2: Somavaratan (VRS-317)|Active treatment arm
3022466|NCT02413138|Experimental|Phase 3: Somavaratan (VRS-317)|Somavaratan long acting recombinant human growth hormone administered subcutaneously twice-monthly
3022467|NCT02413125|Experimental|ChitoRino irrigation solution|The study participants will be provided a NeilMed irrigation bottle and instructed to administer 1 packet of ChitoRhino irrigation solution (premixed from manufacturer containing sea salt, Chitosan, and sodium bicarbonate). An informational sheet regarding care and cleaning of the irrigation bottle will be provided during the initial visit. Participants will be instructed to complete up to three nasal saline irrigations daily for 1 month and keep a log to determine compliance. After 1 month of use, the irrigation bottle will be returned at a second study visit.
3022468|NCT02413125|Experimental|Normal saline solution|The study participants will be provided a NeilMed irrigation bottle and instructed to administer nasal saline (250mL of 0.9% sodium chloride) irrigation solution. An informational sheet regarding care and cleaning of the irrigation bottle will be provided during the initial visit. Participants will be instructed to complete up to three nasal saline irrigations daily for 1 month and keep a log to determine compliance. After 1 month of use, the irrigation bottle will be returned at a second study visit.
3022469|NCT02413112|Experimental|Training once per week|Subjects train once per week in the University gym. All training sessions are supervised by the researchers.
3022470|NCT02413112|Experimental|Training twice per week|Subjects train twice per week in the University gym. All training sessions are supervised by the researchers.
3022471|NCT02413112|Experimental|Thrice per week|Subjects train three times per week in the University gym. All training sessions are supervised by the researchers.
3022472|NCT02413112|No Intervention|Non-training Control group|Subjects continue with their normal daily lives, just performing measurements
3022473|NCT02413099|Experimental|KBMSI-2 6gm|Patients were instructed to take investigational products (KBMSI-2 6g) twice a day for 8weeks at least 1 hour after food intake
3022474|NCT02413099|Placebo Comparator|Placebo|Patients were instructed to take placebo twice a day for 8weeks at least 1 hour after food intake
3022475|NCT02413086|Experimental|Early-stage amputation+external herbs chitosan|Individuals with DFU were given early-stage amputation and wound was given herbs chitosan after amputation.
3022476|NCT02413086|Experimental|Early-stage amputation+traditional gauze|Individuals with DFU were given early-stage amputation and wound was given traditional gauze after amputation.
3022477|NCT02413086|Experimental|Amputation+external herbs chitosan|Individuals with DFU were given amputation and wound was given herbs chitosan after amputation.
3022478|NCT02413086|Experimental|Amputation+traditional gauze|Individuals with DFU were given amputation and wound was given traditional gauze after amputation.
3022479|NCT02413073|Sham Comparator|Sham of Whole Body Vibration|This group will receive placebo treatment on the platform we'll use a little engine that will produce a very small vibration stimulus in the platform.
3022480|NCT02413073|Experimental|Whole body vibration Group|This group will be a training na vibratory platform with 12 weeks (3 months), held twice a week on alternate days
3022481|NCT02413060|Experimental|Resistance training|Patients of treatment group will undergo resistance training every week sessions
3022482|NCT02413060|Other|Lifestyle counseling|Patients of control group will get the lifestyle counseling every 3 month
3022483|NCT02413047|Experimental|Immunomodulator|Azathioprine, 6 mercaptopurine or methotrexate.
3022484|NCT02413034|Placebo Comparator|Control group|no antibiotic prophylaxis group
3056059|NCT02187705||Patients with isolated hypertension at baseline|
3022486|NCT02413021|Experimental|deferasirox + cytarabine|deferasirox + cytarabine group will receive oral deferasirox at 20 mg/kg per day and cytarabine at20 mg/m^2 , SC , two times a day for 10 days every 30 days for 1 cycle.
3022487|NCT02413021|Active Comparator|cytarabine|cytarabine group will receive just cytarabine at 20 mg/m^2 , SC , two times a day for 10 days every 30 days for 1 cycle.
3022488|NCT02413008|Experimental|0.005% estriol vaginal gel|Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
3022489|NCT02413008|Placebo Comparator|placebo vaginal gel|Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
3022490|NCT02412995|Experimental|Meal sequence 1-2-3|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 1-2-3
3022491|NCT02412995|Experimental|Meal sequence 1-3-2|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 1-3-2
3022492|NCT02412995|Experimental|Meal sequence 2-3-1|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 2-3-1
3022493|NCT02412995|Experimental|Meal sequence 2-1-3|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 2-1-3
3022494|NCT02412995|Experimental|Meal sequence 3-1-2|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 3-1-2
3022495|NCT02412995|Experimental|Meal sequence 3-2-1|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 3-2-1
3022496|NCT02412982|No Intervention|Serum anti-Xa >= 0.1 IU/mL|Patients with serum anti-Xa level >= 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours
3022497|NCT02412982|Active Comparator|Anti-Xa <0.1 IU/mL:enoxaparin 40 mg q12h|Patients with serum anti-Xa level < 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 40 mg every 12 hours. If repeat steady state trough anti-Xa is subtherapeutic, dose will be increased to enoxaparin 50 mg every 12 hours.
3022498|NCT02412982|Active Comparator|Anti-Xa <0.1 IU/mL:enoxaparin 30 mg q8h|Patients with serum anti-Xa level < 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 30 mg every eight hours
3022499|NCT02412969|Active Comparator|Lumbar Epidural|Control group will have standard of care Lumbar Epidural
3022500|NCT02412969|Experimental|Dural Puncture Epidural|Will receive Dural Puncture Epidural
3022501|NCT02412956|No Intervention|Control|pamphlet
3022502|NCT02412956|Experimental|Intervention (text)|SmokefreeMOM text messaging program
3022503|NCT02412956|Experimental|Intervention Plus (text+quitline)|SmokefreeMOM text messaging program + state quitline
3022504|NCT02412943|Experimental|PAPP-A2 Enzyme Replacement|A 20 cc/kg transfusion of Fresh Frozen Plasma will be given over 3 hours on day 0.
3022505|NCT02412930|Active Comparator|Group Paravertebral Block|With ultrasound guidance at T10 to L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. 5 mL bupivacaine 0.5% was injected in each dermatome level.
3022506|NCT02412930|Placebo Comparator|Group tramadol|Patients in group T were given a loading dose of tramadol of 1 mgkg-1
3022507|NCT02412917|Experimental|FV-100 400 mg QD|FV-100 400mg QD
3022508|NCT02412917|Experimental|FV-100 400mg BID|FV-100 400mg BID(total daily dose of 800mg)
3022509|NCT02412917|Active Comparator|valacyclovir|valacyclovir 1000mg TID
3022510|NCT02412904|Other|drug to ovulation induction: rFSH|Patients submitted to IVF that will use rFSH (Puregon®, Organon Ltd., Ireland) for ovarian stimulation
3022511|NCT02412904|Other|drug to ovulation induction :HMG|Patients submitted to IVF that will use hMG (Menopur®, Ferring Pharmaceuticals, Denmark) for ovarian stimulation
3022512|NCT02412891|Active Comparator|Patients receive active UroShield device|Patients receive active UroShield device
3022513|NCT02412891|Sham Comparator|Patients receive inactive UroShield device|Patients receive inactive UroShield device
3022514|NCT02412878|Active Comparator|Arm A: Once-weekly Carfilzomib with Dexamethasone|"Carfilzomib 20 mg/m2 - Study Day 1 (Cycle 1)~Carfilzomib 70 mg/m2 - Study Days 8 and 15 (Cycle 1), Study Days 1, 8, and 15 (Cycles 2+)~Dexamethasone 40 mg (IV or PO) Study Days 1, 8, and 15 (all Cycles)~Dexamethasone 40 mg (IV or PO) Study Day 22 (Cycle 1-9 only)"
3022515|NCT02412878|Active Comparator|Arm B: Twice-weekly Carfilzomib with Dexamethasone|"Carfilzomib 20 mg/m2 - Study Days 1 and 2 (Cycle 1)~Carfilzomib 27 mg/m2 - Study Days 8, 9, 15, and 16 (Cycle 1), Study Days~1, 2, 8, 9, 15, and 16 (Cycles 2+)~Dexamethasone 40 mg (IV or PO) Study Days 1, 8, and 15 (all Cycles)~Dexamethasone 40 mg (IV or PO) Study Day 22 (Cycle 1-9 only)"
3022516|NCT02412865|Experimental|Intervention|quit4baby + text4baby
3022517|NCT02412865|Other|Control|text4baby
3022518|NCT02412852|Placebo Comparator|Placebo|One placebo tablet administered twice daily for 12 weeks.
3022519|NCT02412852|Active Comparator|40 mg TV1001sr|One 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
3022520|NCT02412852|Placebo Comparator|Placebo (2)|Two placebo tablets administered twice daily for 12 weeks.
3022521|NCT02412852|Active Comparator|80 mg TV1001sr|Two 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
3022522|NCT02412839||Group 20-39|Patients aged from 20 to 39 years old. 30 males and 30 females.
3022523|NCT02412839||Group 40-59|Patients aged from 40 to 59 years old. 30 males and 30 females.
3022524|NCT02412839||Group 60-79|Patients aged from 60 to 79 years old. 15 males and 15 females.
3022525|NCT02412826||Acute pancreatitis|Patients presenting to the hospital with acute pancreatitis that will receive AbStats sensor
3022526|NCT02412813|Active Comparator|LEGION OXINIUM femoral component|
3022527|NCT02412813|Active Comparator|LEGION Cobalt Chrome femoral components|
3022553|NCT02412644|Placebo Comparator|apremilast|after week 12 PASI 75 responders receive ampremilast 30mg bid or placebo bid
3022528|NCT02412800||Acute lung injury|Postoperative acute lung injury was diagnosed according to the latest 2012 Berlin definition of acute respiratory distress syndrome by the PaO2/FiO2< 300 and acute onset of bilateral infiltrates on the chest radiograph that were not fully explained by cardiac failure during postoperative day 1 to postoperative day 3.
3022529|NCT02412787|Experimental|Idursulfase-IT|All patients in this study will be treated with intrathecal idursulfase-IT in conjunction with Elaprase therapy. Patients who complete Visit Week 52 assessments of Study HGT HIT 094 and who meet the eligibility criteria and for whom informed consent is provided will be enrolled in this extension study. All patients will receive idursulfase-IT at the same dose and frequency (10 mg once every 28 days) as selected for the HGT-HIT-094 study. Patients who are younger than 3 years of age will continue to receive an adjusted dose.
3022530|NCT02412774|Experimental|Diet Beverages (DBs)|Diet beverages after the main meal+ Diet
3022531|NCT02412774|Experimental|Water|Water after the main meal+ Diet
3022532|NCT02412761|Active Comparator|lisinopril|lisinopril
3022533|NCT02412761|Active Comparator|amlodipine|amlodipine
3022534|NCT02412761|Active Comparator|hydrochlorothiazide|hydrochlorothiazide
3022535|NCT02412748|Active Comparator|Financial Literacy Program|"The Financial Literacy Program (FLP) attention control condition will not receive any information on fatherhood. They will participate in a nine-session financial education program, called Money Smart, which has modules that will be facilitated by a group leader that focus on banking, borrowing, checking accounts, money management, saving, establishing and repairing a credit history, using credit cards responsibly and learning about borrowing and home ownership. They will also receive a booster session 6 weeks after the final session that focuses on setting financial goals."
3022536|NCT02412748|Experimental|BBTF Intervention|"The Building Bridges to Fatherhood (BBTF) intervention employs the following key features: a collaborative model for working with parents; vignettes of father-child models engaged in situations typical of non-resident fathers with young children for stimulating discussion and problem-solving; group discussion format, which allows fathers to support one another and share ideas on using program principles to fit within the contexts of fatherhood; homework assignments that help fathers practice the new skills at home; weekly handouts summarizing the major points discussed each week, which can be shared with others and used to gain greater support from extended family; and a Leader's Manual that standardizes the program across groups and group leaders."
3022537|NCT02412735|Experimental|rexlemestrocel-L|"rexlemestrocel-L alone: 2.0 mL formulation of approximately 6 million rexlemestrocel-L cells"
3022538|NCT02412735|Experimental|rexlemestrocel-L + HA|"rexlemestrocel-L + HA: 2.0mL 6 million rexlemestrocel-L cells"
3022539|NCT02412735|Placebo Comparator|Placebo|saline control: 2.0 mL saline solution
3022540|NCT02412722|Experimental|Single-Agent QD: MLN0128 4 mg|"Pharmacokinetic (PK) Run-In Period: MLN0128 4 mg unmilled capsules, orally, once, under fasted conditions, on Day 1, followed by MLN0128 4 mg milled capsules, orally, once, after a high-fat breakfast, on Day 3, followed by MLN0128 4 mg unmilled capsules, orally, once, under fasted conditions, on Day 5, followed by the main treatment period within 14 days of Day 6 of the PK Run-In period.~Main Treatment Period: MLN0128 4 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, for up to 12 Cycles. The dose of MLN0128 may be modified based on safety and tolerability during each 28-day cycle."
3022541|NCT02412722|Experimental|Combination: MLN0128 6 mg + Paclitaxel 80 mg/m^2|MLN0128 6 mg milled capsules, orally, once, for 3 consecutive days following each Paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 12 Cycles, and Paclitaxel 80 mg/m^2, intravenously (IV), on Days 1, 8, and 15 in 28-day Cycle, for up to 12 Cycles. The dose of MLN0128 may be modified based on safety and tolerability during each 28-day cycle.
3022542|NCT02412722|Experimental|Single-Agent QW: MLN0128 4 mg|In Cohort 1, patients will receive 20 mg of MLN0128 capsules based on milled API once every week (QW). Based on safety and tolerability assessment of Cohort 1, the starting dose of MLN0238 milled API for Cohort 2 will either be increased to 30 mg QW or reduced to 15 mg QW.
3022543|NCT02412709|Experimental|Parent Performing ECG (PPE)|Parent Performing ECG (PPE) Group--When the baby is 2 weeks old, research staff will contact interested parents to schedule a home visit. During the visit, a research assistant will provide the parents with a kit that includes the QTScreen system and instructions. The parents will perform an ECG on their child using the QTScreen and instructions. If after attempting the ECG on their own parents encounter problems, parents can ask the research assistant for assistance.
3022544|NCT02412709|Active Comparator|Staff Performing ECG (SPE)|Staff Performing ECG (SPE) Group--When the baby is 2-4 weeks of age, research staff will contact the family to schedule a home visit. The QTScreen test will be done by a research assistant.
3022545|NCT02412696|Active Comparator|Positive Airway Pressure|Positive airway pressure and nasal dilator strips during sleep.
3022546|NCT02412696|Placebo Comparator|Nasal Dilator Strips|Nasal dilator strips during sleep.
3022547|NCT02412670|Experimental|Arm A (methotrexate, vinblastine, doxorubicin, cisplatin)|Patients receive methotrexate IV over 2-3 minutes, vinblastine IV, doxorubicin hydrochloride IV, and cisplatin IV over 4 hours on day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without metastatic disease undergo nephroureterectomy and lymph node dissection 21-60 days after completion of chemotherapy.
3022548|NCT02412670|Experimental|Arm B (gemcitabine, carboplatin)|Patients receive gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without metastatic disease undergo nephroureterectomy and lymph node dissection 21-60 days after completion of chemotherapy.
3022549|NCT02412657|Experimental|Dexamethasone 10 mg intravenous|Dexamethasone 10 mg diluted with Normal Saline 17,5 mL i.v. (20 mL total) injected slowly during 30 seconds immediately after performing interscalene brachial plexus block
3022550|NCT02412657|Experimental|Dexamethasone 4 mg intravenous|Dexamethasone 4 mg diluted with Normal Saline 19 mL i.v. (20 mL total) injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
3022551|NCT02412657|Placebo Comparator|Normal Saline 20 mL intravenous|Normal saline 20 mL injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
3022552|NCT02412644|Active Comparator|Apremilast|apremilast 30mg bid for 12 weeks. After 12 weeks apremilast 30 mg bid
3022554|NCT02412631|Placebo Comparator|Varenicline plus placebo|Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)
3022555|NCT02412631|Experimental|Varenicline plus lorcaserin|Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)
3022556|NCT02412618|Active Comparator|Mifepristone|Mifepristone 200mg oral tablet, once Misoprostol 400 mcg tablets, vaginally, once
3022557|NCT02412618|Placebo Comparator|Placebo|Placebo oral tablets, odorless, colorless and matched to Mifepristone appearance Misoprostol 400 mcg tablets, vaginally, once
3022558|NCT02412605||Fertile embryo biopsy|Fertile couples requesting sex selection for family balancing
3022559|NCT02412605||Infertile embryo biopsy|Infertile women having embryo biopsy
3022560|NCT02412605||IVF/ICSI|Infertile women undergoing IVF/ICSI without embryo biopsy
3022561|NCT02412579||Hepatocellular Carcinoma with Cirrhosis|Subjects with hepatocellular carcinoma and cirrhosis.
3022562|NCT02412579||Cirrhosis without Hepatocellular Carcinoma|Subjects with only cirrhosis.
3022563|NCT02412553|Active Comparator|Specific carbohydrate arm|The specific carbohydrate diet will be sufficient to meet 100% of the caloric requirements of the patient.
3022564|NCT02412553|Active Comparator|Elemental diet arm|The partial elemental diet will be sufficient to provide 50% of the daily caloric needs for each patient with the remainder from a standard low-residue diet
3022565|NCT02412540|No Intervention|Weight Loss Surgery|Adolescents who will have Weight Loss Surgery and had biopsy-confirmed NASH. The Weight Loss Surgery is not part of the study. The investigators are following the adolescents after the surgery.
3022566|NCT02412540|Experimental|Comprehensive Lifestyle Intervention|Comprehensive Lifestyle Intervention - Dietary, activity and behavioral interventions. Adolescents who have biopsy-confirmed NASH and wish to participate in a Comprehensive Lifestyle Intervention (26+ contact hours) including individual meetings with a study dietitian, group nutrition classes, behavior management modules and physical activity goals.
3022567|NCT02412527||Primary insomnia|Primary insomnia patients, without combined any other sleep disorders
3022568|NCT02412527||Periodic limb movement in sleep|Patients have periodic limb movement in sleep, without combined any other sleep disorders
3022569|NCT02412527||Simple snores|Simple snore patients, without combined any other sleep disorders
3022570|NCT02412527||Obstructive sleep apnea|Obstructive sleep apnea patients, including mild, moderate and severe types, without combined any other sleep disorders or CPAP treatment during PSG study
3022571|NCT02412514|Active Comparator|Arm A|Infants assigned to Arm A will receive bOPV at 6, 10, and 14 weeks of age and IPV at 6 weeks of age.
3022572|NCT02412514|Active Comparator|Arm B|Infants assigned to Arm B will receive bOPV at 10 and 14 weeks of age and IPV at 6 weeks of age.
3022573|NCT02412501|Other|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent
3022574|NCT02412488|Experimental|Out of CathLab setting|"The insertion of the Reveal LINQ device will be performed in the out-of-cathlab setting."
3022575|NCT02412475|Experimental|Treatment Plan - 2 treatment courses|Drug Method Used to Give Drug Days Cytarabine IT 0 or -1 Decitabine IV over 1 hour 1-5 Vorinostat PO 1-5 Fludarabine IV over 30 minutes 6-10 Cytarabine IV over 3 hours 6-10 Filgrastim (G-CSF) IV or SQ 5-12 Sorafenib PO 11-28
3022576|NCT02412462|Experimental|AB-16B5|Single-arm study of AB-16B5 given as a 60-minute intravenous weekly infusion. One cycle of treatment will consist of 21 days. The dose levels that will be assessed are 1.5, 3.0, 6.0, 9.0 and 12 mg/kg.
3022577|NCT02412449|Experimental|Treatment A|AKB-6548
3022578|NCT02412449|Experimental|Treatment B|AKB-6548
3022579|NCT02412449|Experimental|Treatment C|AKB-6548
3022580|NCT02412436|Experimental|Arm A: Depot medroxyprogesterone acetate|
3022581|NCT02412423|Experimental|treatment group|post-transplantation cyclophosphamide
3022582|NCT02412410|Experimental|Single|Single arm pilot study analyzing sleep data and calculated efficacy before and after fatigue avoidance education (comparator is same group after intervention)
3022583|NCT02412384||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
3022584|NCT02412384||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
3022585|NCT02412384||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
3022586|NCT02412384||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
3022587|NCT02412371|Experimental|RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Veliparib|This arm, concurrent radiotherapy (RT) + carboplatin (Carbo)/Paclitaxel (Pac) + veliparib followed by consolidation of Carbo/Pac + veliparib, is for both the Phase 1/dose escalation and Phase 2 portion of the study.
3022588|NCT02412371|Experimental|RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Placebo|This arm, concurrent radiotherapy (RT) + carboplatin (Carbo)/Paclitaxel (Pac) + veliparib followed by consolidation of Carbo/Pac + Placebo, is for the Phase 2 portion of the study.
3022589|NCT02412371|Placebo Comparator|RT + Carbo/Pac + Placebo followed by Carbo/Pac + Placebo|This arm, concurrent radiotherapy (RT) + carboplatin (Carbo)/Paclitaxel (Pac) + placebo followed by consolidation of Carbo/Pac + placebo, is for the Phase 2 portion of the study.
3022590|NCT02412358|Active Comparator|Pulsar|Patients use Pulsar toothbrush for plaque removal
3022591|NCT02412358|Active Comparator|Crossaction|Patients use Crossaction toothbrush for plaque removal
3022592|NCT02412358|Active Comparator|Butler|Patients use Butler toothbrush for plaque removal
3022593|NCT02412345|Experimental|Extracorporeal Shockwave therapy|Extracorporeal shockwave therapy at the penis. 6 sessions.
3022594|NCT02412345|Sham Comparator|Sham treatment|Extracorporal shockwave therapy with a placebo probe. 6 sessions
3022595|NCT02412332|No Intervention|Group 1 - Control|The patients will be followed during the course of 12 months and evaluated regarding disease progression. No interventions will be performed other than conventional (in-course) treatment.
3022652|NCT02411903|Active Comparator|atorvastatin and Clopidogrel|80 patients will be taking atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months。
3022596|NCT02412332|Experimental|Group 2 - BMMC|Patients will be submitted to bone marrow harvesting. Bone marrow mononuclear cells (BMMC) will be obtained by Ficoll separation and returned to patients by systemic infusion (1x10^8 BMMC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
3022597|NCT02412332|Experimental|Group 3 - ASC|Patients will be submitted to liposuction. The obtained fat tissue will be cultivated by 21 days and adipose-derived stem cell (ASC) will be returned to patients by systemic infusion (1x10^8 ASC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
3022598|NCT02412332|Experimental|Group 4 - BMMC + ASC|Patients will be submitted to liposuction and the obtained fat tissue will be cultivated by 21 days and adipose-derived stem cell (ASC) obtained. Patients will be submitted to bone marrow harvesting and bone marrow mononuclear cells (BMMC) will be obtained by Ficoll separation. BMMC and ASC will be returned to patients by systemic infusion (5x10^7 ASC + 5x10^7 BMMC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
3022599|NCT02412319|Experimental|Experimental Group|Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
3022600|NCT02412319|Placebo Comparator|Comparator Group|Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
3022601|NCT02412306|Experimental|Blinatumomab|
3022602|NCT02412293|Experimental|Intervention|"Health Education & Promotion: LHWs and CHWs will delivered the package via community awareness sessions and two one-to-one counselling sessions to pregnant women during third trimester and five newborn assessment visits in the neonatal period in intervention areas.~Training of Health Workers: The LHWs and CHWs will receive trainings on IMNCI-based training package.~Community Mobilization: For community mobilization and education, two types of tools will be used one group session by use of flip charts and group session by use of video."
3022603|NCT02412293|No Intervention|Control|Control areas will continue to receive the routine standard health services of governmental and non-governmental organizations in the area.
3022604|NCT02412267|Experimental|O-ICE|"O-ICE:~Ofatumumab 1000mg intravenous (IV) infusion on Day 1 and Day 8 of cycle 1 of the salvage chemotherapy, and thereafter on Day 1 of each cycle; Ifosfamide 1667 mg/m2 IV infusion over 2 hours on days 1,2,3 of each cycle; Carboplatin 5 x ((25 + Creatinine clearance (CrCl)) IV in 250 ml Normal Saline over 1 hour on day 1 of each cycle; Etoposide 100mg/m2/day IV infusion day 1,2,3 over 45 to 60 minutes of each cycle."
3022605|NCT02412254|Active Comparator|Hearing intervention|Best practices hearing rehabilitative treatment
3022606|NCT02412254|Placebo Comparator|Successful aging intervention|Successful aging intervention
3022607|NCT02412241|Other|LEF Measures|"PATIENT-REPORTED OUTCOME MEASURE: Validity of LSIDS-H&N will be assessed using 6 forms (e.g., Vanderbilt Head and Neck Symptom Survey (v2.0); Neck Disability Index; and Hospital Anxiety and Depression Scale).~CLINICIAN-REPORTED OUTCOME MEASURES: External LEF will be assessed using HN-LEF Grading Criteria, CTCAE (v4.03), and digital photos of the head and neck. Internal LEF will be scored using Modified Patterson Scale through an endoscopic exam. Both external/internal measures are re-assessed for intrarater and interrater reliability.~OBJECTIVE/TECHNICAL MEASURES: Patients undergo CT scans and ultrasound exams with results re-scored for intrarater and interrater reliability."
3022608|NCT02412228|Experimental|Ixazomib Regimen|"Cycle 1: Ixazomib: 4mg/day 1, 8, 15, Cyclophosphamide: 50 mg/day continuous daily, Dexamethasone: 20 mg/day 1, 8, 15 Cycles 2-6: Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18, Cyclophosphamide: 50 mg/day continuous, daily, Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18~Maintenance:~Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years"
3022609|NCT02412215|Experimental|Toric Nanoflex IOL|Phacoemulsification with toric Nanoflex IOL implantation
3022610|NCT02412202|Other|patients who undergo weaning from mechanical ventilation|consecutive mechanically ventilated critical ill patients who fulfil criteria for weaning will be included
3022611|NCT02412189|No Intervention|control|Ordinary anesthesia, mean arterial pressure allowed to decrease to 60 mmHg. If it is lower the patients will receive a norepinephrine infusion in order to raise the mean arterial pressure to 60 mmHg.
3022612|NCT02412189|Active Comparator|Maintained blood pressure|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
3022613|NCT02412176|Experimental|Pacing site - right ventricular apex|The intervention will be the implantation of the lead into the right ventricular apex
3022614|NCT02412176|Experimental|Pacing site - septum|The intervention will be the implantation of the lead into the septum.
3022615|NCT02412163||IM HTO Nail|Implant with the Ellipse IM HTO Nail
3022616|NCT02412150|Experimental|Dexmedetomidine (Group D)|"After induction of anesthesia, anesthesia is maintained with desflurane and remifentanil during thyroidectomy.~Fifteen minutes before the end of surgery, infusion of remifentanil for surgery is discontinued.~Then, dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr). Vital signs and complications of testing drugs are measured before and after infusion of testing drugs.~Five minutes before the end of surgery, anesthetic gas (desflurane) is discontinued.~After patient has awake, extubation has done. Extubation time and Recovery time,Cough reflex,Ramsay Sedation Scale, Visual analogue scale, and surgical outcomes such as postoperative bleeding, time to remove drainage and duration of hospital staying, postoperative complications are measured until POD#3."
3022617|NCT02412150|Placebo Comparator|Normal Saline (Group N)|"After induction of anesthesia, anesthesia is maintained with desflurane and remifentanil during thyroidectomy.~Fifteen minutes before the end of surgery, infusion of remifentanil for surgery is discontinued. Then, normal saline has started infusion for 15 min (same rate as Group D). Vital signs and complications of testing drugs are measured before and after infusion of testing drugs.~Five minutes before the end of surgery, anesthetic gas (desflurane) is discontinued.~After patient has awake, extubation has done. Extubation time and Recovery time,Cough reflex,Ramsay Sedation Scale, Visual analogue scale, and surgical outcomes such as postoperative bleeding, time to remove drainage duration of hospital staying, postoperative complications are measured until POD#3."
3022653|NCT02411903|Experimental|rosuvastatin and Clopidogrel|80 patients will be taking rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months。
3023750|NCT02404480|Experimental|Cohort 4|PTC 596 administered twice daily-Dose level 5.2mg/kg
3022618|NCT02412137|Experimental|Counseled Patients|The counseled cohort will have their brace wear compliance documented on the Brace Progress Report after the Orthotist downloads the time/temperature data onto a laptop from the sensor reader (A piece of computer hardware which the sensor clips into and is attached to the laptop via the USB port). The Orthotist will then reset the temperature logger discs and reinstall them into the padding in the inside front of the brace in order to monitor the next period of brace wear. This group will then be counseled for about 10 minutes or less regarding their brace-wear using the Brace Progress report as a checklist.
3022619|NCT02412137|Placebo Comparator|Non-counseled patients|The non-counseled cohort will have their brace wear compliance documented on the Brace Progress Report after the Orthotist downloads the time/temperature data onto a laptop from the sensor reader (A piece of computer hardware which the sensor clips into and is attached to the laptop via the USB port). The Orthotist will then reset the temperature logger discs and reinstall them into the padding in the inside front of the brace in order to monitor the next period of brace wear. This group will not be counseled, and will only receive standard clinical care.
3022620|NCT02412124|Experimental|Supportive care (W2W program)|Patients participate in the W2W program for which they are matched with a trained mentor and followed throughout treatment by phone, email, and/or in person.
3022621|NCT02412111|Active Comparator|VX-661/ ivacaftor|"AM: VX-661 100-mg/ivacaftor 150-mg fixed-dose tablet ivacaftor matching placebo tablet oral~PM: ivacaftor 150-mg tablet oral"
3022622|NCT02412111|Active Comparator|ivacaftor|"AM: VX-661/ivacaftor matching placebo tablet ivacaftor 150-mg tablet oral~PM: ivacaftor 150-mg tablet oral"
3022623|NCT02412098|Experimental|Moderate hepatic impairment|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
3022624|NCT02412098|Experimental|Severe hepatic impairment|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
3022625|NCT02412098|Experimental|Mild hepatic impairment|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
3022626|NCT02412085|Experimental|Golimumab|Subcutaneous golimumab
3022627|NCT02412059|Experimental|Prednisolone|Pred Forte (prednisolone acetate ophthalmic suspension, USP) 1% sterile
3022628|NCT02412059|No Intervention|Control|Patients in control group will not be given a corticosteroid as per usual standard of care.
3022629|NCT02412046|Active Comparator|Time of the first biopsy: H0|For the patients in arm H0, the first biopsy is done as soon as the patient is lying on the air mattress.
3022630|NCT02412046|Active Comparator|Time of the first biopsy: H1|For a patient in arm H1, it is done after 1 hour lying on the air mattress.
3022631|NCT02412046|Active Comparator|Time of the first biopsy: H2|For a patient in arm H2, it is done after 2 hour lying on the air mattress.
3022632|NCT02412046|Active Comparator|Time of the first biopsy: H3|For a patient in arm H3, it is done after 3 hour lying on the air mattress.
3022633|NCT02412033|Active Comparator|Misoprostol group|Going to receive 400 µg misoprostol vaginally 3 hours before IUD insertion.
3022634|NCT02412033|Placebo Comparator|Placebo group|Going to receive placebo.
3022635|NCT02412020|Experimental|PA101|PA101, 40 mg administered via inhalation three times daily for 14 days
3022636|NCT02412020|Placebo Comparator|Placebo|Placebo PA101, administered via inhalation three times daily for 14 days
3022637|NCT02412007|Experimental|Group A|"Individualized comprehensive home centred activity based programme. Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to (a) Standing up from squatting position to catch an object of interest.~(b) Squatting from standing position to pick an object of interest. (c) Walking to reach an object of interest. (d) Climbing up steps to get an object of interest. (e) Climbing down steps to keep the above object of interest. (f) Cycling (g) Kicking a football (h) Dancing"
3022638|NCT02412007|Active Comparator|Group B|"Conventional Physiotherapy Conventional physiotherapy would include and would not be limited to~Passive stretching exercises for spasticity reduction~Gait exercises~Walking on treadmill~Lower limb strengthening exercises~Exercises for balance improvenet"
3022639|NCT02411994|Experimental|Pyronaridine-artesunate|pyronaridine-artesunate: recommended dose according to body weight, once a day for three days.
3022640|NCT02411994|Active Comparator|Artemether-lumefantrine|artemether-lumefantrine: recommended dose according to body weight, twice a day for three days.
3022641|NCT02411981|Other|Autogenic drainage|"The autogenic drainage will be the chest physiotherapy technique used for this study.~Autogenic drainage is an airway clearance technique that attempts to obtain the optimal airflow to evacuate the secretions. This technique uses modulation of inspiratory and expiratory airflow at different breathing level within the vital capacity."
3022642|NCT02411968||111In-Girentuximab DOTA SPECT|Patients >50 years of age with renal tumours ≤4 cm highly suspicious for a malignancy planned to undergo cryotherapy will undergo 111In-Girentuximab DOTA SPECT scanning.
3022643|NCT02411955|Experimental|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% (Taro Pharmaceuticals Inc.)
3022644|NCT02411955|Active Comparator|Tazorac®|Tazorac® (tazarotene cream 0.1%) (Allergan LLC)
3022645|NCT02411955|Placebo Comparator|Placebo|Placebo (Vehicle of the test product) (Taro Pharmaceuticals Inc.)
3022646|NCT02411942|Experimental|Adapalene Gel 0.3%|Adapalene Gel 0.3% (Taro Pharmaceuticals Inc.)
3022647|NCT02411942|Active Comparator|Differin®|Differin® (adapalene gel 0.3%) (Galderma Laboratories, LP, US)
3022648|NCT02411942|Placebo Comparator|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
3022649|NCT02411929|Experimental|Ertugliflozin|Period 1: Oral dose of 15 mg unlabeled ertugliflozin + intravenous (IV) dose of 100 µg 14^C-labeled ertugliflozin containing approximately 400 nCi 14^C. The 14^C IV dose will be administered as an infusion over approximately 5 minutes starting at 55 minutes after the unlabeled oral dose. → Period 2: Oral dose 15 mg unlabeled ertugliflozin + oral dose of 100 µg 14^C-labeled ertugliflozin containing approximately 400 nCi 14^C. Both the unlabeled and 14^C-ertugliflozin will be administered at the same time (no more than 5 minutes apart). Dosing in Periods 1 and 2 will be separated by a washout of at least 11 days.
3022650|NCT02411916|Experimental|intervention cases|patient receiving misoprostol
3022651|NCT02411916|No Intervention|controls|patients not receiving misoprostol
3022654|NCT02411890|Experimental|Adductor canal block|Adductor canal block (active) + Femoral nerve block (sham block)
3022655|NCT02411890|Active Comparator|Femoral nerve block|Femoral nerve block (active) + Adductor canal block (sham block)
3022656|NCT02411877|Active Comparator|Normothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using the Trevo Pro Retriever (Stryker), after which normothermia will attempt to keep core body temp between 38 and 36.5 degrees centigrade.
3022657|NCT02411877|Experimental|Mild hypothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using the Trevo Pro Retriever (Stryker). Subjects will also have a catheter placed in the femoral vein (Zoll Thermogard XP technology with the Quattro catheter) and temperature brought to 33 degrees centigrade as quickly as possible. They will stay in mild hypothermia for 12 hours, and then be rewarmed very slowly.
3022658|NCT02411864||Group 1|Low b=(0,50,150,200)，NEX=(1,3,2,2)
3022659|NCT02411864||Group 2|Low b=(0,30,50,100,200)，NEX=(1,3,3,2,2)
3022660|NCT02411864||Group 3|Low b=(0,30,60,90,120,150,180,200)，NEX=(1,3,3,3,2,2,2,2)
3022661|NCT02411864||Group 4|Low b=(0,30,60,90,120,150,180,200)，NEX=(1,1,1,1,1,1,1,1)
3022662|NCT02411864||Group 5|Low b=(0,20,40,60,80,100,120,140,160,180,200)NEX=(1,3,3,3,3,2,2
3022663|NCT02411851|Active Comparator|Ingenol mebutate alone|At Visit 1, ingenol mebutate 0.015% alone on the second 25 cm2 treatment area. The treatment area receiving ingenol mebutate 0.015% alone will apply the medication as directed per approved drug labeling. Patients will apply ingenol mebutate gel on Day 2 and Day 3.
3022664|NCT02411851|Experimental|Ingenol mebutate and dermasil lotion|At Visit 1, ingenol mebutate 0.015% and dermasil lotion on one 25 cm2 treatment area. The treatment area receiving both ingenol mebutate 0.015% and dermasil lotion, will first apply ingenol mebutate 0.015% allow the gel to dry completely as per drug labeling on Day 1. The patient will allow at least 6 hours between the application of ingenol mebutate and dermasil lotion on Day 2 and 3. Patients will apply dermasil lotion daily on Day 2 until at least Day 8. At Day 8, the physician will reassess whether dermasil application should be continued to Day 15 or ceased. At Day 15, the physician will reassess whether dermasil application should be continued to Day 29 or ceased.
3022665|NCT02411838|No Intervention|Control group|Steroid treatment (10 total days), which is a standard therapy for significant MS relapses.
3022666|NCT02411838|Experimental|Calorie restriction|"The intervention in this group will be to undergo a regimen of calorie restriction through fasting every other day (named alternate day fasting).~Specifically this group will undergo alternate day fasting plus the same steroid regimen as the control group (CR GROUP).~During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of IVMP) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point."
3022667|NCT02411825|Experimental|SAR425899 (healthy subjects)|Once daily SC doses of SAR425899
3022668|NCT02411825|Placebo Comparator|Placebo (healthy subjects)|Once daily SC doses of placebo
3022669|NCT02411825|Experimental|SAR425899 (T2DM Patients)|Once daily SC doses of SAR425899 and two up titration steps in each dose cohort with metformin as background therapy
3022670|NCT02411825|Placebo Comparator|Placebo (T2DM Patients)|Once daily SC doses of placebo and two up titration steps in each dose cohort with metformin as background therapy
3022671|NCT02411812|Experimental|Herbst appliance with skeletal anchorage|Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.
3022672|NCT02411812|Active Comparator|Herbst appliance with dental anchorage|Group treated with the conventional Herbst appliance with dental anchorage.
3022673|NCT02411812|Active Comparator|Twin-Block appliances|Group treated with Twin-Block appliance.
3022674|NCT02411786|Experimental|pTVG-AR biweekly|pTVG-AR (dose: 100 µg) alone without rhGM-CSF. Administered at weeks 0, 2, 4, 6, 8, and 10 (biweekly) for 6 doses, then administered at week 12, week 24, week 36, and week 48 (quarterly) for 4 doses, or 10 total doses.
3022675|NCT02411786|Experimental|pTVG-AR staggered biweekly|pTVG-AR (dose: 100 µg) alone without rhGM-CSF. Administered at weeks 0, 2, 12, 14, 24, 26, 36, 38, 48 and 50 (staggered biweekly schedule) for 10 total doses.
3022676|NCT02411786|Experimental|pTVG-AR with rhGM-CSF biweekly|pTVG-AR (dose: 100 µg) with rhGM-CSF (200 µg). Administered at weeks 0, 2, 4, 6, 8, and 10 (biweekly) for 6 doses, then administered at week 12, week 24, week 36, and week 48 (quarterly) for 4 doses, or 10 total doses.
3022677|NCT02411786|Experimental|pTVG-AR with rhGM-CSF staggered biweekly|pTVG-AR (dose: 100 µg) with rhGM-CSF (200 µg). Administered at weeks 0, 2, 12, 14, 24, 26, 36, 38, 48 and 50 (staggered biweekly schedule) for 10 total doses.
3022678|NCT02411773|Active Comparator|Exercise Training/Sodium Bicarbonate|Subjects with CKD will undergo exercise training on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each exercise session three times a week.
3022679|NCT02411773|Active Comparator|Exercise Training/Placebo|Subjects with CKD will undergo exercise training on a stationary bicycle,for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.
3022680|NCT02411773|Active Comparator|Stretching/Sodium Bicarbonate|Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each stretching session three times a week.
3022681|NCT02411773|Placebo Comparator|Stretching/Placebo|Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.
3022682|NCT02411773|No Intervention|Control|Healthy subjects without CKD will not receive any interventions.
3022683|NCT02411747|Experimental|Testing+endoscopic simulation training|Endoscopic training in flexible cystoscopy by directed self-regulated training with knowledge of a test afterwards, max. time cap 1h45min. 15 minutes of testing with a expert in the procedure. Total max time: 2 hours.
3022684|NCT02411747|Active Comparator|Oral lecture+endoscopic simulation training|Endoscopic training in flexible cystoscopy by directed self-regulated training, max. time cap 1h45min after a 15 minute oral theoretical lecture by a expert in the procedure. Total max. time: 2 hours.
3022685|NCT02411721|Experimental|Animal assisted intervention|The Effects of Dog Intervention on Anxiety Levels in Children. The experimental group will receive standard training on the imaging process by the MRI technician plus intervention activity with a dog
3022686|NCT02411721|No Intervention|control group|The control group will receive the standard training on the imaging process by the MRI technician.
3022687|NCT02411708|Experimental|SANGUINATE|320 mg/kg
3022688|NCT02411708|Placebo Comparator|Placebo|Normal saline IV infusion
3022689|NCT02411695|Experimental|Cohort 1|0.5 mg, Brexpipraxzole (OPC-34712)
3022690|NCT02411695|Experimental|Cohort 2|1mg, Brexpipraxzole (OPC-34712)
3022691|NCT02411695|Experimental|Cohort 3|2mg, Brexpipraxzole (OPC-34712)
3022692|NCT02411695|Experimental|Cohort 4|3 mg, Brexpipraxzole (OPC-34712)
3022693|NCT02411695|Experimental|Cohort 5|4mg, Brexpipraxzole (OPC-34712)
3022694|NCT02411682|Active Comparator|YesB|On YesB day the patients will consume breakfast , lunch and dinner
3022695|NCT02411682|Experimental|NoB|On NoB Day The patient will consume only lunch and dinner
3022696|NCT02411669||Health care professionals|Physicians, nurses and managerial staff
3022697|NCT02411656|Experimental|MK-3475|"MK-3475 200 mg administered on Day 1 of each 21 day cycle as a 30 minute infusion by vein for up up to 24 months.~Follow up or phone call about 1-3 months after last dose of study drug."
3022698|NCT02411643|Other|topical calcipotriene 0.005% ointment|Calcipotriene 0.005% applied to affected areas twice daily to all enrolled subjects
3022699|NCT02411630||Interactive Questionnaire System (iQS)|An Interactive Questionnaire System (iQS) will be administered twice. First at study entry (ATN 110/113 week 24 visit) and second at week 24 (ATN 110/113 week 48 visit). The questionnaire will assess adherence as well as how structural (physical settings) and partnership factors affect adherence of YMSM to PrEP with FTC/TDF (Truvada®).
3022700|NCT02411617|Active Comparator|Single drain in modified radical mastectomy|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
3022701|NCT02411617|Active Comparator|Double drain in modified radical mastectomy|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
3022702|NCT02411591|Experimental|Necitumumab + Abemaciclib|"Part A: Necitumumab administered intravenously (IV) on Days 1 and 8, followed by abemaciclib given orally Q12H on Days 1 to 21. (21 day cycles.) Treatment may continue until discontinuation criterion is met.~Part B: Necitumumab administered IV on Days 1 and 8, followed by abemaciclib given orally Q12H on Days 1 to 21. (21 day cycles.) Abemaciclib dose determined by Part A. Treatment may continue until discontinuation criterion is met."
3022703|NCT02411578|Experimental|G-Pen Mini™ (glucagon injection)|"Participants are to check blood glucose (BG) with study meter once their continuous glucose monitor (CGM) reads <70 mg/dl or they experience symptoms. Participants will be instructed to treat using mini-dose glucagon for certain phases/periods when BG is 40 to 69 mg/dl (considered a non-severe hypoglycemic event).~For every event, participant will check BG with meter 3 times and treat according to protocol instructions based on BG measurement."
3022704|NCT02411578|Active Comparator|Glucose Tabs|"Participants are to check their blood glucose (BG) with study meter once their continuous glucose meter reads <70 mg/dl or they experience symptoms. Participants will be instructed to treat using oral glucose tablets for certain phases/periods when BG is 40 to 69 mg/dl (considered a non-severe hypoglycemic event).~For every event, participant will check BG with meter 3 times and treat according to protocol instructions based on BG measurement."
3022705|NCT02411565|Active Comparator|Fermented Wheat Germ Extract (FWGE)|FWGE administration 2 - 4 weeks prior to planned surgery, + Quality of Life (QoL) Surveys: FACT-O.
3022706|NCT02411565|Placebo Comparator|Placebo Administration|Placebo administration 2 - 4 weeks prior to planned surgery, + Quality of Life (QoL) Surveys: FACT-O.
3022707|NCT02411552||Intervention schools|These schools were promoting 4 strategies to increase physical activity in students.
3022708|NCT02411552||Control schools|These schools continued with standard programming for activity during year 1, and implemented intervention during years 2 and 3.
3022709|NCT02411539|Experimental|Arm A: VRC01 followed by placebo|Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo (normal saline) at Weeks 6 and 9.
3022710|NCT02411539|Experimental|Arm B: placebo followed by VRC01|Participants received an infusion of placebo (normal saline) at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
3022711|NCT02411526|Experimental|Cohort 1|60 mg of ZX003 administered 4 times (every 4 weeks)
3022712|NCT02411526|Experimental|Cohort 2|90 mg of ZX003 administered 4 times (every 4 weeks)
3022713|NCT02411526|Experimental|Cohort 3|120 mg of ZX003 administered 4 times (every 4 weeks)
3022714|NCT02411526|Active Comparator|Cohort 4|Risperdal Consta administered 5 times (once every 2 weeks) NOTE: Oral risperidone 2 mg will be given with the first injection of Risperdal Consta and continued for 3 weeks (and then discontinued) to ensure adequate therapeutic plasma concentrations from Risperdal Consta.
3022715|NCT02411513|Experimental|Active|60 minutes of CEFALY stimulation as acute treatment of an on-going attack
3022716|NCT02411500|Experimental|Formulation A|
3022717|NCT02411500|Experimental|Formulation B|
3022718|NCT02411500|Experimental|Formulation C|
3022719|NCT02411500|Experimental|Formulation D|
3022720|NCT02411500|Experimental|Formulation E|
3022721|NCT02411500|Experimental|Formulation F|
3022722|NCT02411474||With or without newly diagnosed chronic GVHD after SCT|The patients developed chronic GVHD after SCT/ The patients did not developed chronic GVHD after SCT
3022723|NCT02411461||Pseudohypoparathyroidism type 1a|Study group
3022724|NCT02411461||Healthy siblings|Control group
3022725|NCT02411461||Obese patients|Control group
3022726|NCT02411448|Experimental|Ramucirumab + Erlotinib|"(Part A) 10 milligrams per kilogram (mg/kg) ramucirumab every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met.~(Part B) 10 mg/kg ramucirumab every 2 weeks IV in combination with 150 mg erlotinib daily orally . Participants may continue to receive treatment until discontinuation criteria are met."
3022780|NCT02411058|Experimental|Informed about Incentives and Purpose|Condition 2
3022781|NCT02411045|Active Comparator|Group 1: Control|Ask participants to take a picture of themselves
3022727|NCT02411448|Placebo Comparator|Placebo + Erlotinib|"(Part A) Not Applicable~(Part B) Placebo every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met."
3022728|NCT02411448|Experimental|(Part C) Ramucirumab + Gefitinib or Osimertinib|"(Period 1) Ramucirumab given IV and gefitinib given orally.~(Period 2) Ramucirumab given IV and osimertinib given orally."
3022729|NCT02411435|Experimental|Treatment A(CAB 30mg)+B (RIF 600mg)+C (CAB 30mg and RIF 600mg)|Subjects will receive a single dose of CAB 30 mg on day 1. Subjects will then receive RIF 600 mg once daily on days 8-28 with co-administration of a single dose of CAB 30 mg on day 21.
3022730|NCT02411422|Experimental|Intubation using laryngoscope|"Intubation using Macintosh laryngoscope. we will check procedure time according to kind of endotracheal tube, separately.~Two kinds of endotracheal tube will be used~Conventional endotracheal tube~Reinforced endotracheal tube"
3022731|NCT02411422|Experimental|i-gel blind intubation|"i-gel blind intubation means that blind endotracheal intubation will be performed after i-gel insertion.~i-gel will be used as a conduit. we will check procedure time according to kind of endotracheal tube, separately.~Two kinds of endotracheal tube will be used~Conventional endotracheal tube~Reinforced endotracheal tube"
3022732|NCT02411422|Experimental|i-gel bronchoscopic intubation|"i-gel bronchoscopic intubation means that bronchoscopic endotracheal intubation will be performed after i-gel insertion.~i-gel will be used as a conduit. we will check procedure time according to kind of endotracheal tube, separately.~Two kinds of endotracheal tube will be used~Conventional endotracheal tube~Reinforced endotracheal tube"
3022733|NCT02411409|Experimental|Intervention group|This group of patients receives the HealtheRx.
3022734|NCT02411409|No Intervention|Control group|This group of patients does not receive the HealtheRx
3022735|NCT02411396||VOC in patients with SCD|This is an observational study comparing patient centered outcomes for patients treated for uncomplicated VOC in ICs and EDs.
3022736|NCT02411383|Experimental|NeuRx Diaphragm Pacing System (DPS)®|The NeuRx Diaphragm Pacing System (DPS)® is placed in the diaphragm during lung transplant.
3022737|NCT02411357|Active Comparator|Treatment as usual|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
3022738|NCT02411357|Experimental|WHO contraception protocol|The WHO contraception protocol condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits.
3022739|NCT02411357|Experimental|WHO contraception protocol + incentives|The WHO + incentives condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits, but will also receive financial incentives contingent on attending those follow-up visits.
3022740|NCT02411344|Experimental|Pertuzumab, Trastuzumab, Letrozole|
3022741|NCT02411331|Experimental|Experimental group|90 patients will receive 10 injections of ethanol lock solution in implantable venous access port during the first 10 days of the study.
3022742|NCT02411331|Other|control group|90 patients will receive 10 injections of vancomycin lock solution in implantable venous access port during the first 10 days of the study
3022743|NCT02411318|Experimental|Cardiovascular Exercise|Subjects will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes. For example, a 30 year old will have a target heart rate zone of 95-162 beats per minute. A baseline blood sample will be acquired before the subject begins exercising. In the following 30 minutes, subjects will ride the exercise bike, and their heart rate and general status will be assessed continuously. Specifically, heart rate will be monitored using a chest strap heart rate monitor. Two additional lancet punctures will be performed after the exercise to measure the changes in neutrophil function: one immediately following the 30 minute exercise period and one 30 minutes after the exercise has been completed.
3022744|NCT02411318|Experimental|Caffeine Consumption|Subjects will be exposed to a moderate dose of caffeine (200 mg capsule in one sitting) from a common commercial product. After consent and screening, a baseline blood sample will be acquired using the lancet puncture procedure. The subject will then be instructed to swallow a 200 mg caffeine capsule. Two additional lancet punctures will be performed after the caffeine ingestion: one after 30 minutes post-ingestion and another one after 60 minutes.
3022745|NCT02411318|Experimental|Ethanol Ingestion|Subjects will be weighed and their required alcohol dose determined according to the equation used by the Madison Police Department during alcohol training workshops: 1 mL of 80 proof (40%) alcohol per pound of body weight. Subjects will be permitted to consume the drink at their own pace, although no slower than one drink per hour. Breath Alcohol Concentration (BAC) will be tested 20 minutes after drinking has ceased in order to clear mouth alcohol that may affect the BAC reading. Subjects at 0.05 BAC and above will have blood drawn via lancet puncture. In addition to the lancet puncture done once the alcohol level is reached, an additional lancet puncture will be performed 1 hour later.
3022746|NCT02411305||PCRC Palliative Care Clinicians|
3022747|NCT02411292|Experimental|Enoxaparin metabolism|Eligible patients will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
3022748|NCT02411279||Groupe 1: experimental group|Equiped group with telemedicine systems
3022749|NCT02411279||Groupe 2: control group|Non equiped group with telemedicine systems
3022750|NCT02411266|Placebo Comparator|control|Subjects in this group will undergo sham preconditioning. A blood pressure cuff will be placed around the leg and inflated just lightly to a pressure of 30mmHg, not enough to affect arterial circulation. This will be maintained for 10min followed by 5min of deflation. This will constitute one conditioning cycle. There will be 3 sham conditioning cycles per treatment session.
3022751|NCT02411266|Active Comparator|treatment group|Study personnel will place a blood pressure cuff around the subject's leg and use it to interrupt the circulation to the leg for 10 minutes followed by release of the blood pressure for 5 minutes. This will be repeated for a total of 3 times every 24 to 48 hours up to 14 days. The cuff will be inflated for 10 minutes and then deflated for 5 minutes. There will be 3 cycles of this. The cuff will be inflated to 200mmHg to induce ischemia, confirmed by palpation of pedal pulses.
3022968|NCT02409914||POLYCYSTIC OVARY SYNDROME (PCOS)|Women with PCOS diagnosed during a clinical examination using the Rotterdam criteria.
3022752|NCT02411253|Experimental|rhIL-2|"0.5 MIU/m²/day of IL2 with a maximum of 1MIU/day in a volume of 1 ml for children and adolescents,~1MIU/day for adults.~Subcutaneous injection every day (5 days) then:~Regimen A injection every two weeks between D15 and D351,~Regimen B injections every week between D15 and D351"
3022753|NCT02411253|Placebo Comparator|Placebo|"Placebo with a identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 days) then:~Regimen A injection every two weeks between D15 and D351~Regimen B injections every week between D15 and D351"
3022754|NCT02411240|Other|Air filtering in the living room|GENANO tubes, GENANO Benelux; Heusen-Zolder, Belgium
3022755|NCT02411227|Experimental|1|Immediate Intervention
3022756|NCT02411227|No Intervention|2|Wait list
3022757|NCT02411214||<12 years|children under 12 years diagnosed with cancer questionnaire survey
3022758|NCT02411214||12-18 years|adolescents diagnosed with cancer questionnaire survey
3022759|NCT02411214||parents|parents of children and adolescents diagnosed with cancer questionnaire survey
3022760|NCT02411201|Experimental|DOTAREM|
3022761|NCT02411188|Experimental|STEP Program Group|Arm: Intervention: The 12-week STEP Program intervention will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
3022762|NCT02411188|No Intervention|Usual Care Group|The usual care group will follow the routine model of care for post-discharge patients who do not participate in a CRP. Usual care group participants will be given the opportunity/option to participate in the STEP Program in 6 months.
3022763|NCT02411175|Experimental|20% Ethanol|20% ethanol will be medicated with the individualised homeopathic remedy as determined by the researcher and administered as drops. The potency, dose and frequency of the medicated 20% ethanol drops will be determined for each prescription, in accordance with the laws that govern homeopathic prescribing.
3022764|NCT02411162|Experimental|Open Label Arm|In Cohort 1, study medication (Cream A, 1%) will be applied as a thin layer onto a predefined area of the volar region of the forearm that is large enough to image and collect 3 biopsies (4 mm per biopsy). Vehicle will be applied on Day 1 only, onto a symmetrical location on the opposite forearm from Cream A. In cohort 2, subjects will be enrolled to evaluate Cream A (1%) and a different GSK2894512 Cream, Cream B (1%). Cream A, 1% and Cream B, 1% will be applied as a thin layer to the opposite forearms of the subject. Vehicle will be applied only on Day 1 to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied. Both Cream A and Cream B will continue to be applied OD to the same area of the same forearm for 7 days.
3022765|NCT02411149|Placebo Comparator|Local Inflitration Only|"This group will receive LIA and saline solution (placebo) in the adductor canal block with NO morphine in the spinal anesthesia:~30 ml normal saline~3ml 0.5% preservative-free bupivacaine"
3022766|NCT02411149|Active Comparator|Adductor Canal Block|"This group will receive LIA and the standard local anesthetic in the ACB with NO morphine in the spinal anesthetic:~ropivacaine 0.5% with 1:400,000 epinephrine~3ml 0.5% preservative-free bupivacaine"
3022767|NCT02411149|Active Comparator|Adductor Canal Block with Morphine|"This group will receive LIA with local anesthetic in the ACB and morphine in the spinal anesthetic:~ropivacaine 0.5% with 1:400,000 epinephrine~3ml 0.5% preservative-free bupivacaine with 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)"
3022768|NCT02411136|Experimental|AMG 623|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
3022769|NCT02411136|Placebo Comparator|Placebo|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
3022770|NCT02411123|Experimental|IDgenetix Neuropsychiatric Test Panel Intervention|The medical provider for the IDgenetix Neuropsychiatric Test Panel-guided group will make treatment recommendations based on test results. Patient outcomes will be measured throughout the duration of the study.
3022771|NCT02411123|No Intervention|control|The medical provider for the control group will not receive IDgenetix Neuropsychiatric Test Panel results and will make treatment recommendations as usual. Patient outcomes will be measured throughout the duration of the study.
3022772|NCT02411110|Experimental|LiRIS® (Treatment Period 1)/LiRIS® (Treatment Period 2)|Treatment Period 1: continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 1. Treatment Period 2: optional continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 2.
3022773|NCT02411110|Other|LiRIS Placebo (Treatment Period 1)/LiRIS® (Treatment Period 2)|Treatment period 1: Matching placebo device to LiRIS inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 1. Treatment Period 2: optional continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 2.
3022774|NCT02411097|Experimental|femoral nerve block|femoral nerve block will be administered before or after the surgery
3022775|NCT02411084|Experimental|BEGEDINA® (Begelomab)|BEGEDINA® (Begelomab) (murine monoclonal antibody against CD26). Dose is 2.7 mg/m2/day i.v. infusion for 5 consecutive days (Study Days 1, 2, 3, 4, 5) and then single dose on each of Study Days 10, 14, 17, 21, 24 and 28, for a total of 11 doses. BEGEDINA® is supplied as 1 mg/mL concentrate for solution for infusion in vials of 6 mL (5.4 mg of active substance) for reconstitution. The total volume to be administered should be further diluted in 100 mL of 0.9% sodium chloride solution for injection prior to administration. The infusion lasts 60 minutes. Subjects are eligible for a single treatment for flare after study Day 28
3022776|NCT02411084|Active Comparator|Conventional Second-line Treatment|Subjects in the conventional treatment arm will receive a second line treatment, which is to be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center. Currently no treatments for this life-threatening disease have been approved in either the USA or Europe. The recommendations of the American Society for Blood and Marrow Transplantation (ASBMT) confirm that no treatment for acute steroid-refractory GvHD can be considered gold standard in terms of TRM or survival as results remain unsatisfactory and this approach has been agreed by the FDA and the EMA.
3022777|NCT02411071||Patients starting cART|Patients starting cART. Grouping according to the time needed to reach viral loads below 1000, 500, 400, 200, 50 copies/ml, respectively.
3022778|NCT02411071||Patients with cART|Patients with cART. Grouping in patients without and with low-level-viremia (LLV) defined as two consecutive viral loads between 40 copies/ml and 200 copies/ml, 400 copies/ml, 500 copies/ml and 1000 copies/ml, respectively.
3022779|NCT02411058|Experimental|Uninformed|Condition 1
3022782|NCT02411045|Experimental|Group 2: Dress for Success|Ask participants to take a picture of themselves while wearing their workout gear
3022783|NCT02411045|Experimental|Group 3: Exercise for Success|Ask participants to take a picture of themselves while wearing their workout gear and complete a 30-minute workout
3022784|NCT02411032|Experimental|Reminder control|Customers receive a mailing on a random day, which does not coincide with any of the predictable fresh start events.
3022785|NCT02411032|Experimental|Birthday framed|Customers receive a mailing on the most recent Wednesday before the customers' birthday, and the mailing frames the customers' birthday by emphasizing a fresh start associated with the customers' birthday.
3022786|NCT02411032|Experimental|New Year's framed|Customers receive a mailing on 1/21/15, and the mailing frames the customers' birthday by emphasizing a fresh start associated with the customers' birthday.
3022787|NCT02411032|Experimental|Birthday un-framed|Customers receive a mailing on the most recent Wednesday before the customers' birthday, but the mailing does not frame the customers' birthday.
3022788|NCT02411032|Experimental|New Year's un-framed|Customers receive a mailing on 1/21/15, but the mailing does not frame New Year's.
3022789|NCT02411019||Observational group|Subjects in the period less than 24 weeks after the final administration of GX-188E
3022790|NCT02411006|No Intervention|Usual care control|No intervention, just usual care from the insurance company
3022791|NCT02411006|Experimental|Reminder control|Send a reminder to subjects every month
3022792|NCT02411006|Experimental|Anonymous prediction|Ask subjects to anonymously predict their upcoming medication adherence
3022793|NCT02411006|Experimental|Anonymous commitment|Ask subjects to anonymously commit to their upcoming medication adherence
3022794|NCT02411006|Experimental|Identified prediction|Ask subjects to predict their upcoming medication adherence and report it
3022795|NCT02411006|Experimental|Identified commitment|Ask subjects to commit to their upcoming medication adherence and report it
3022796|NCT02410993||CABG surgery|Candidates for CABG surgery for left main disease, three-vessel disease or two-vessel disease with proximal LAD stenosis indicated by current practice guideline
3022797|NCT02410980|Experimental|Tretinoin cream 0.1%|Assessment of the skin change
3022798|NCT02410967|Experimental|Attention Bias Modification|Attention Bias Modification is a computer-based attention training program.
3022799|NCT02410967|Placebo Comparator|Placebo Attention Task|The Placebo Attention Task uses the same computer-based format and stimuli as the Attention Bias Modification Task, but does not train attention toward or away from stimuli.
3022800|NCT02410954|Experimental|tDCS electrode configuration|Three rounds of tDCS using NeuroConn Direct Current stimulator Multiple Channel -4, Rogue Resolutions treatment optimization where each round includes identifying a promising electrode configuration based on electric field modeling using a realistic head model and capitalizing on the experience with the prior round (for rounds 2 and 3) and testing that electrode placement by administering a series of electrical doses of tDCS with that tDCS electrode configuration (carrying out a dose titration) in a cohort of 10 healthy control subjects to see if we can find an electrical dose which is well-tolerated, safe, suppresses the AOT pupil response and is below recommended current density safety limits (the safety limit in terms of Amperage varies depending on the electrode configuration)
3022801|NCT02410954|Placebo Comparator|Using tDCS to reduce acute fear|Administration of 7.5% CO2 to see if this elicits symptoms of Acute Fear and activates LC and whether tDCS safely inhibits the LC response to 7.5% CO2 compared with sham in a pilot cross-over trial (N=10). A 3-year double-blind, randomized, controlled trial where clinical symptoms of Acute Fear, the primary outcome are elicited with 7.5% CO2 in healthy volunteers is the final study component.
3022802|NCT02410941|Experimental|Decision-support for MTBI|Clinical decision support will be provided on ordering CT scans for patients suspected to have Minor Traumatic Brain Injury (MTBI) to treating physicians randomized into this group. This arm will also serve as a control for the PE group.
3022803|NCT02410941|Experimental|Decision-support for PE|Clinical decision support will be provided on ordering CT scans for patients suspected to have Pulmonary Embolism (PE) to treating physicians randomized into this group. This arm will also serve as a control for the MTBI group.
3022804|NCT02410928|Experimental|fiberoptic nasal laringoscopy|the vocal cords ill be visualized with fiberoptic nasal laringoscopy
3022805|NCT02410928|Experimental|ultrasonography|the vocal cords ill be visualized with ultrasonography
3022806|NCT02410928|Active Comparator|Direct laringoscopy|the vocal cords ill be visualized with direct laringoscopy
3022807|NCT02410915|Experimental|Study Group|Intervention: Hybrid Assistive Limb (HAL); gait training in combination with conventional training. Training with the exosceleton Hybrid Assistive Limb (HAL) is performed in 1 session per day, 4 days per week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective time). Training with HAL is performed in combination with body-weight support system and on a treadmill. The training program is performed by 2 physiotherapists, who have been trained in the HAL method.
3022808|NCT02410915|Active Comparator|Control Group|Intervention: Conventional gait training is individualized and performed according to current practice (approximately 30-60 minutes/session, 5 days a week) and may include standing, weight shifting, stepping, over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support. Conventional gait training is offered to both study groups.
3022809|NCT02410902|Experimental|CM-AT|Active substance in single unit dose powder
3022810|NCT02410902|Placebo Comparator|Placebo|Placebo powder of inactive substance
3022811|NCT02410889||Patients with Epilepsy|A group of patients with a variety of types of epilepsy.
3022812|NCT02410876||controls|no lower urinary tract symptoms undergoing cystoscopy in anesthesia for stone treatment or microhematuria assessment.
3022813|NCT02410876||spinal cord injury/acontractile|"Patients with traumatic spinal cord injury (SCI) with no (neither spontaneous nor provoked) detrusor activity during the filling phase of urodynamics.~Bladder biopsy 6 weeks after trauma 6 months later urodynamic study and bladder biopsy"
3022814|NCT02410876||spinal cord injury/Detrusor overactivity|"SCI patients with proven detrusor (urodynamics) overactivity during the filling phase.~Bladder biopsy 6 weeks after trauma 6 months later urodynamic study and bladder biopsy"
3022897|NCT02410369|Placebo Comparator|Placebo|Subjects with HLA-A*2402 in the placebo arm will receive the subcutaneous administration of placebo.
3022815|NCT02410876||prostatic obstruction/acontractile|"Low flow to no flow, no measurable detrusor activity on urodynamic evaluation, cystoscopy in line with obstruction.~Bladder biopsy at TURP (transurethral resection prostate) 3 months later urodynamic study and bladder biopsy"
3022816|NCT02410876||prostatic obstruction/ obstructed|Obstruction according to Schäfer nomogram on urodynamic evaluation. Bladder biopsy at TURP 3 months later urodynamic study and bladder biopsy
3022817|NCT02410863|Experimental|Cohort A (BRAFi naïve)|Dabrafenib (BRAFi) and trametinib (MEKi) will be administered orally at their recommended doses for combination therapy of 150 mg twice daily (BID) and 2 mg daily.
3022818|NCT02410863|Experimental|Cohort B (BRAFi / MEKi rechallenge)|Dabrafenib (BRAFi) and trametinib (MEKi) will be administered orally at their recommended doses for combination therapy of 150 mg twice daily (BID) and 2 mg daily
3022819|NCT02410850||University of Montreal|Patients from University of Montreal in Canada
3022820|NCT02410850||University of Antwerp|Patients from University of Antwerp in Belgium.
3022821|NCT02410850||University of Sydney|Patients from University of Sydney in Australia.
3022822|NCT02410850||Angers University Hospital|Patients from Angers University Hospital in France.
3022823|NCT02410850||University of Gronigen|Patients from University of Gronigen in Netherlands.
3022824|NCT02410850||Kaiser Permanente|Patients from Kaiser Permanente from USA.
3022825|NCT02410850||Stanford University|Patients from Stanford University from USA.
3022826|NCT02410850||Laval University|Patients from Laval University in Canada.
3022827|NCT02410850||Cambridge University|Patients from Cambridge University in UK.
3022828|NCT02410850||Kyushu University|Patients from Kyushu University in Japan
3022829|NCT02410850||Japan Somnology Center|Patients from Japan Somnology Center in Japan.
3022830|NCT02410850||Uniformed Services University|Patients from the Uniformed Services University in USA.
3022831|NCT02410850||University of British Columbia|Patients from the University of British Columbia in Canada.
3022832|NCT02410824|Experimental|stenfilcon A toric lens|Participants were randomized to wear stenfilcon A toric lens for one week during the cross over study.
3022833|NCT02410824|Active Comparator|etafilcon A toric lens|Participants were randomized to wear etafilcon A toric lens for one week during the cross over study.
3022834|NCT02410811||Age Stratum A|"Age 6 to 13.99 years~Cardiac magnetic resonance imaging (CMR)"
3022835|NCT02410811||Age Stratum B|"Age 14 to 20.99 years~Detectible and quantifiable TRJV with reported value~Cardiac magnetic resonance imaging (CMR)"
3022836|NCT02410811||Age Stratum C|"Age ≥21 years~Detectible and quantifiable TRJV with reported value~Cardiac magnetic resonance imaging (CMR)"
3022837|NCT02410811||Age Stratum D|"Age ≥6 years.~Current use of disease-modifying therapy [hydroxyurea, chronic transfusions, or both (given concurrently, sequentially, or both)] that was initiated at <3 years of age, and for which there has been no interruption of therapy for >6 consecutive months since the initiation of disease-modifying therapy.~Cardiac magnetic resonance imaging (CMR)"
3022838|NCT02410798|Experimental|TransLoc electrode|Electrode placement
3022839|NCT02410785|Active Comparator|Medical device polyglucosamine|2 times daily 2 tablets with the two main meals with the highest fat content. Participants follow the German guideline with a hypo-caloric (-500 kcal daily) lifestyle and increased physical activity.
3022840|NCT02410785|Placebo Comparator|Placebo|2 times daily 2 tablets with the two main meals with the highest fat content. Participants follow the German guideline with a hypo-caloric (-500 kcal daily) lifestyle and increased physical activity.
3022841|NCT02410772|Active Comparator|Regimen 1|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifampin, 600 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg"
3022842|NCT02410772|Experimental|Regimen 2|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and ethambutol, followed by Nine weeks of daily treatment with rifapentine and isoniazid~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg"
3022843|NCT02410772|Experimental|Regimen 3|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; moxifloxacin, 400 mg"
3022844|NCT02410759|Active Comparator|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly IM
3022845|NCT02410759|Active Comparator|Ergometrine|100 women with atonic PPH will receive Ergometrine 0.5mg IM
3022846|NCT02410746|Active Comparator|standard chirocaine infiltration|non-targeted infiltration of 10ml 0.25% Chirocaine into breast pocket
3022847|NCT02410746|Experimental|targeted chirocaine pec block|pectoral muscle block with 10ml 0.25% chirocaine
3022848|NCT02410733|Experimental|Lipo-MERIT|7 dose escalation cohorts (3 +3 design) and 3 expanded cohorts
3022849|NCT02410720|Active Comparator|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
3022850|NCT02410720|Experimental|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
3022851|NCT02410707|Experimental|Nitrous Oxide Arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
3022852|NCT02410694|Experimental|Ixazomib-Thalidomide-Dexamethasone|"Combination therapy of:~Ixazomib 4.0mg at days 1, 8, 15, Thalidomide 100mg at days 1 to 28 (50mg in patients aged ≥75 years), Dexamethasone 40mg (20mg in patients aged ≥75 years) at days 1, 8, 15 of a 28-day treatment cycle.~After 8 cycles of ITD therapy, maintenance treatment with 4.0mg ixazomib (3.0mg in patients aged ≥ 75 years at first day of maintenance phase) on days 1, 8, 15 of 28-day cycles will be administered to patients with ≥ MR for a maximum period of 12 months."
3022853|NCT02410668|Active Comparator|Flaxseed|30 grams Flaxseed powder combine with dietary and exercise recommendation
3022854|NCT02410668|Placebo Comparator|control|dietary and exercise recommendation
3022855|NCT02410655|Active Comparator|Conventional standard of care|Traditional administration of oxytocin at Lutheran Medical Center involves the use of two 20 IU / 1000 mL bags hung sequentially at a flow rate of 125 mL / hour each after the delivery of the anterior shoulder. This will total no more than 16 hours.
3022856|NCT02410655|Active Comparator|Evidence based protocol|The proposed evidence based protocol involves utilizing a single 30IU / 500mL bag of oxytocin. After the delivery of the anterior shoulder, an initial rapid infusion bolus of 50mL of the 30IU / 500mL at 999mL / hour. Three minutes after rapid infusion, uterine tone should be assessed. If inadequate uterine tone persists, a second rapid infusion at the same dose and rate as above should be given. If inadequate uterine tone persists, a third rapid infusion may be given. If adequate uterine tone is achieved after any rapid infusion, the remainder of the bag should be administered at a rate of 100mL / hour until finished. If adequate tone is not achieved, the remainder of the bag should be administered at 100mL / hour and additional uterotonic agents should be considered.
3022857|NCT02410629|Experimental|Music Glove|Music Glove is a glove with sensors attached to the tips of all 5 fingers. The glove is connected to a software musical program like guitar hero. Participants will follow the rhythm or musical notes of the songs and move their fingers accordingly. Participants are reinforced with biofeedback that includes visual and auditory cues when the correct sequences are achieved.
3022858|NCT02410629|Active Comparator|Conventional Hand Exercise Program|Conventional Hand Exercise Program includes range of motion exercises, strengthening exercises, coordinating exercises of the hand and fingers. This exercise program is designed by an occupational therapist and is a general exercise program that a stroke patient will receive when he/she is being discharged from the hospital.
3022859|NCT02410616|Experimental|Blended CBT|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psychoeducation, (2) behavioural activation, (3) cognitive restructuring, and (4) relapse prevention.
3022860|NCT02410616|Active Comparator|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the secondary care system. The investigators will not interfere with treatment as usual but they will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report.
3022861|NCT02410590|Experimental|Rocuronium + Sugammadex|Participants will receive rocuronium administered at a dosage adequate to make intubation possible and provide deep NMB (defined as no response to train-of-four stimulation but at least one response to five post-tetanic count [PTC]) for the duration of surgery, until the end of the procedure. Sugammadex will be administered to participants once at a dosage of 4 mg/kg real body weight (RBW) IV at the end of surgical procedure. Sugammadex will be used as the only reversal drug in all participants who receive rocuronium as a neuromuscular blocker.
3022862|NCT02410590|Active Comparator|Succinylcholine + Cisatracurium + Neostigmine/Atropine|After receiving succinylcholine 1.0 mg/kg RBW for intubation, participants will receive cisatracurium administered at dosage adequate to have a moderate NMB (defined as a target of TOF ratio = 10% with a range: 2-3 twitches to TOF ratio of 20%) for the duration of surgery, until the end of the procedure. Neostigmine/Atropine will be administered to participants once at respective dosage of 0.05 mg/kg RBW and 0.01 mg/kg RBW at least after the reappearance of T2 after surgery completion. The maximum allowed dosage for Neostigmine is 5 mg. Neostigmine will be used as only reversal drug in all participants who received Cisatracurium as neuromuscular blocker.
3022863|NCT02410577|Experimental|89Zr-J591|Patients will not be required to fast prior to imaging with 89Zr-J591 injection or imaging. The total dose of humanized mAb J591 will be 20mg. Patients will first receive an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody (IND11407) followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg). Administration of the cold antibody will be followed by the labeled compound.
3022864|NCT02410564|Active Comparator|CBTI treatment|cognitive behavioral therapy for insomnia (CBTI) treatment is a validated web based version of CBT-I, which will take place over seven weeks and will include a combination of face-to-face and telephone sessions, and email updates
3022865|NCT02410564|Placebo Comparator|Waitlist control condition|No advice regarding sleep will be given to the control group and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
3022866|NCT02410551|Experimental|Pacritinib + Allogeneic Stem Cell Transplantation|Participants start Pacritinib 200 mg by mouth twice a day. Participants proceed to transplant after 60 days of Pacritinib but not more than 180 days. Pacritinib stopped 21 days prior to starting preparative regimen for standard of care stem cell transplantation (SOC Allo TP). SOC transplant conditioning with Fludarabine and Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days. Questionnaires about symptoms and quality of life completed at baseline, 1, 3, 6, and 12 months after transplant. Phone calls made by study staff to participant on second and third week of each month.
3022867|NCT02410538||"families that received the list of FAQ"|"The intervention consists of the delivery to the relatives of ICU patients a list of 21 key issues in intensive care during the first 48h period of ICU stay, only for intubated and mechanically ventilated patients A formal interview is scheduled to relatives of ICU patients on D3 of inclusion"
3022868|NCT02410538||families that received information as usual|A formal interview is scheduled relatives of ICU patients on D3 inclusion
3022869|NCT02410525|Experimental|[11C]PF-06427878|Single intravenous infusion of [11C]PF-06427878 in Periods 1, 2 and 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
3056576|NCT02184338|Placebo Comparator|Placebo|
3022870|NCT02410525|Experimental|PF-06427878 10 mg|Single oral dose of 10 mg PF-06427878 in Period 2 or 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
3022871|NCT02410525|Experimental|PF-06427878 600 mg|Single oral dose of 600 mg PF-06427878 in Period 2 or 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
3022872|NCT02410512|Experimental|Dose Escalation: MOXR0916 + Atezolizumab|Cohorts of at least 3 participants each will be treated at escalating doses of MOXR0916 in combination with a fixed dose of atezolizumab to determine the MTD or maximum administered dose (MAD).
3022873|NCT02410512|Experimental|Expansion: MOXR0916 + Atezolizumab|Approximately 250-580 participants will be enrolled in the expansion stage to better characterize the safety, tolerability, pharmacokinetic variability, biomarkers of anti-tumor activity, and preliminary efficacy of MOXR0916 + atezolizumab in different cancer types.
3022874|NCT02410499|Placebo Comparator|Placebo|MLN1202 placebo-matching solution, subcutaneous injection (SC), once, on Day 1 (loading dose), followed by MLN1202 placebo-matching solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
3022875|NCT02410499|Experimental|MLN1202 75 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 75 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
3022876|NCT02410499|Experimental|MLN1202 105 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 105 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
3022877|NCT02410499|Experimental|MLN1202 150 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 150 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
3022878|NCT02410486||EOS infant / mother with chorio|Infant with EOS (Gram-positive or Gram-negative) and mother with Chorioamnionitis
3022879|NCT02410486||EOS infant / mother without chorio|Infant with EOS (Gram-positive or Gram-negative) and mother without Chorioamnionitis
3022880|NCT02410486||EOS Gram-neg infant / mother with chorio|Infant with Gram-negative EOS and mother with Chorioamnionitis
3022881|NCT02410486||Gram-neg infant / mother without chorio|Infant with Gram-negative EOS and mother without Chorioamnionitis
3022882|NCT02410486||Gram-pos infant / mother with chorio|Infant with Gram-positive EOS and mother with Chorioamnionitis
3022883|NCT02410460|Other|PKA-BIS (intravenous anesthesia)|"Received the following medications:~clonidine 0.1-0.2mg glycopyrrolate 0.2mg propofol infusion titrated to BIS of 60-75 ketamine 50mg + additional ketamine not to exceed 200mg aggregate dosage throughout the case local anesthetic (lidocaine/marcaine mix)"
3022884|NCT02410460|Other|Inhalational anesthesia|"Received the following:~Pre-operatively:~famotidine 20mg scopolamine 1.5mg transdermal patch midazolam 2mg ondansetron 8mg metoclopramide 10mg glycopyrrolate - dose determined by anesthesiologist~During the case, medication choices and dosing were dependent on the anesthesiologist - all general anesthesia cases received inhalational anesthetic (type of anesthetic - desfluorane vs. sevofluorane - also varied based on anesthesiologist's choice)"
3022885|NCT02410447|Experimental|Treatment Group|"Defocused shock waves were provided by an electromagnetic generator (DUOLITH® SD1 - Storz Medical AG, Tägerwilen, Switzerland).~The protocol consisted of a series of 3 sessions in 2 weeks, 2 treatments a week. For each patient, a different number of impulses per session was delivered, depending on wound size (300 impulses + 100 impulses per cm2 wound-surface), at an energy flux density of 0.15 mJ/mm2 and a frequency of 5 pulses/s."
3022886|NCT02410434|Experimental|LGBT Stigma Reduction Intervention|Participants will complete a pre-test, followed by a performance ethnography where they will watch theatre performances that illustrate stigma experienced by LGBT persons in Swaziland and Lesotho. They will have the opportunity to participate in these theatre performances to demonstrate reduced stigma and increased acceptance of LGBT persons. They will then complete a post-test, followed by a 6 week follow up survey.
3022887|NCT02410421|Experimental|Individualized rTMS protocol|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 80). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The therapeutic protocol will be design to correct the rCBF anomaly first by defining each point where to deliver the stimulation than the stimulation protocol for each point (180% of active motor threshold, 4-second 10 Hz train duration, with 26-second intertrain interval for a total of 3000 pulses). The whole target will be homogeneously stimulated.~The active motor threshold will be assessed. The programmed protocol will be delivered while a figure of eight coil will be positioned by a robotic device (Axilum Robotics).~The procedure will be repeated twice a day for 10 days over 2 weeks."
3022888|NCT02410421|Active Comparator|High frequency rTMS as usual|"rTMS will be performed as usual using a figure-eight coil: Defining the active motor threshold. For each session positioning the coil 5 cm ahead of the abductor pollicis brevis muscle, stimulating at 180% of active motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session), twice a day for 10 days over 2 weeks.~Coil and stimulator will remain the same between individualized and as usual proceedures."
3022889|NCT02410421|Active Comparator|Trans-cranial direct current stimulation (tDCS)|tDCS will be performed as usual: After controlling for skin healthiness, the anode and the cathode will be respectively placed over F3 and F4. A commercial devices (MagStim), will deliver a constant current of 2 mA through 25 cm2 saline-soaked rubber sponges for 20 min per session. The procedure will be repeated twice a day for 10 days over 2 weeks.
3022890|NCT02410408|Active Comparator|Control|Information package about patient safety certification or how to conduct Root Cause Analysis
3022891|NCT02410408|Experimental|Experimental|Apps: Root Cause Analysis or patient safety ISO certification
3022892|NCT02410395|Active Comparator|Conventional technique|Closure of the uterotomy with a conventional two-layer technique
3022893|NCT02410395|Experimental|Modified technique|Closure of the uterotomy with a modified two-layer technique
3022894|NCT02410382|Placebo Comparator|Arm 1 Placebo|Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to placebo bid for 14 days
3022895|NCT02410382|Active Comparator|Arm 2 Dexamethesone|Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to dexamethasone 4 mg bid for 14 days
3022896|NCT02410369|Active Comparator|S-588410|Subjects with HLA-A*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
3022900|NCT02410343|Placebo Comparator|Placebo|Placebo was injected subcutaneously once weekly on the same day and time for 24 weeks. To maintain the blind, placebo could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 to match the effect of dose titration.
3022901|NCT02410343|Experimental|TV-1106|TV-1106 was injected subcutaneously once weekly on the same day and time for 24 weeks. A common starting dose was 5.0 mg. Doses could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
3022902|NCT02410330||Group I|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with Therapeutic ultrasound with 20 usec: custom designed high mechanical index (MI) impulses at 4-20 usec and >1.0 MI designed for the 1.7 MHz S5-1 transducer while waiting for percutaneous coronary intervention. Treatment will continue after procedure untill complete a total of 60 minutes.
3022903|NCT02410330||Group II|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with repeated diagnostic high mechanical index impulses (all <2 usec pulse duration; MI=1.0) whenever very low MI perfusion imaging detected microbubbles within the microvasculature. Treatment will be applied while patient waits for percutaneous coronary intervention. Treatment will continue after procedure untill complete a total of 60 minutes.
3022904|NCT02410330||Group III|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) while few limited diagnostic high MI impulses (n<5 per patient) will be applied to assess myocardial perfusion before and after percutaneous coronary intervention (PCI).
3022905|NCT02410317|Experimental|Continuous wound infusion group|Patients receive analgesia through a multiorifice wound catheter connected to ropivacaine infusion. Saline solution is given in the epidural bolus.
3022906|NCT02410317|Active Comparator|Epidural morphine group|Patients receive epidural analgesia through an epidural bolus of morphine. Saline solution is perfused through the wound catheter.
3022907|NCT02410304|Other|Arm C (Clinical)|No drug and no placebo were used in this arm. Patients were followed only by clinical évaluation.
3022908|NCT02410304|Other|Arm B (Clinical + Ultrasound)|No drug and no placebo were used in this arm. Patients were followed by Clinical evaluation in combination with ultrasound (in B mode).
3022909|NCT02410304|Other|Arm D (Ultrasound)|No drug and no placebo were used in this arm. Patients were followed by Ultrasound approach in D mode.
3022910|NCT02410291|Experimental|Experimental group|Patients will receive the standard are to prepare them for their planning CT scan. They will be presented with the flyer that will be developed based on information about the importance of rectal and bladder preparation that is currently provided to patients and will also watch a youtube video on how to prepare for their CT simulation appointment. A few days before the CT planning appointment, patients in this group will be called by the radiation therapist or RA, reminding them about the rectal preparation for the appointment. Each patient will also be reminded to watch the instructional video on YouTube. Patients will be asked not to share the video link with other patients during the study.
3022911|NCT02410291|No Intervention|Control group|Patients in this group will receive the standard care to prepare them for their planning CT scan. They will be presented with the flyer at the consultation. A few days before the CT appointment, patients in this group will also be called and reminded about the required preparations, but will not be told about the video. In addition to the statistics about patient preparedness collected by the radiation therapist conducting the CT scan and stored and secured in an OCC Pinnacle planning system, we will also evaluate: patients' satisfaction with the preparation instructions, their knowledge (knowledge questionnaire) about the video content and importance of understanding the rectal emptying procedures, and radiation therapists' satisfaction with patients' rectal preparation.
3022912|NCT02410278|Experimental|DMF plus montelukast|DMF as described in the United States Prescribing Information (USPI) plus 10mg montelukast tablet once daily according to the prevailing product label (Singulair)
3022913|NCT02410278|Experimental|DMF plus placebo|DMF as described in the USPI plus matched placebo
3022914|NCT02410265|Experimental|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
3022915|NCT02410265|Experimental|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
3022916|NCT02410265|No Intervention|Delayed Program|Subject assigned to this arm will receive one of the online programs in 9 months.
3022917|NCT02410252|Experimental|iThermonitor|Participants are asked to use the iThermonitor device for two weeks to monitor their temperature. Participants are asked to wear the device for as many hours as they can but at a minimum to wear while sleeping.
3022918|NCT02410239|Experimental|Mesenchymal Stem Cell|Third party donor Mesenchymal Stem Cells (MSC) will be administered via intrathecal administration at the assigned dose on days 0, 7 and 14. Dose escalation will be guided by a fast track design. One patient is entered per dose level until a DLT is experienced. At that point, two additional patients will be enrolled at the same dose level. Dose levels will be 2.5 x 10e6 MSC/kg per dose, 5 x 10e6 MSC/kg per dose or 7.5 x 10e6 MSC/kg per dose.
3022919|NCT02410226|Active Comparator|Palpation|Double-space combined spinal-epidural anesthesia, Sham ultrasound procedure
3022920|NCT02410226|Experimental|Ultrasound|Double-space combined spinal-epidural anesthesia, Preprocedure spinal ultrasound
3022921|NCT02410213|Experimental|Ferric Carboxymaltose (FCM)|FCM at 7.5 mg/kg or 15 mg/kg to a maximum single dose of 750 mg iron, whichever is smaller
3022922|NCT02410200|Experimental|BG00012|Oral BG00012 120 mg twice daily (BID) for the first 7 days followed by 240 mg BID for 24 weeks.
3022923|NCT02410187|Active Comparator|Arm 1|systemic therapy+palliative RT
3022924|NCT02410187|Experimental|Arm 2|systemic therapy+SBRT
3022925|NCT02410174|Experimental|Stereotactic Body Radiotherapy (SBRT)|Starting dose of 48Gy in 3 fractions, will escalate dose by 2 Gy per fraction (a 6Gy total dose) to a maximum dose of 20Gy x 3 fractions (TD 60 Gy in 3 fractions).
3023751|NCT02404480|Experimental|Cohort 5|PTC 596 administered twice daily-Dose level 10mg/kg
3022926|NCT02410161|Experimental|4 week ALA treatment|Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
3022927|NCT02410148|Active Comparator|Papilledema|non-invasive aICP measurement in patientes with papilledema
3022928|NCT02410148|Active Comparator|open angle glaucoma|non-invasive aICP measurement in patients with glaucoma
3022929|NCT02410135||Patients with symptomatic LUTS and disordered sleep|Patients exhibiting symptoms of LUTS and disordered sleep and who meet all inclusion/exclusion criteria will be prescribed Mirabegron for 12 weeks.
3022930|NCT02410109|Experimental|SCRIPT intervention|
3022931|NCT02410109|No Intervention|Historical Control|
3022932|NCT02410096|Active Comparator|Oil supplementation verum|30 patients aged 12-44 years with a diagnosis of exercise induced asthma undergo a methacholine challenge and a prick test. After randomization patients will receive in double blind approach ones daily 1190 mg of middle-chain and polyunsaturated fatty acids for four weeks. Before and after supplementation an exercise challenge in a cold chamber will be performed.
3022933|NCT02410096|Placebo Comparator|Oil supplementation placebo|30 patients aged 12-44 years with a diagnosis of exercise induced asthma undergo a methacholine challenge and a prick test. After randomization patients will receive in double blind approach placebo for four weeks. Before and after placebo treatment an exercise challenge in a cold chamber will be performed.
3022934|NCT02410083|Experimental|Clopirin 1|Clopirin single-administration. Before this clinical trial Clopidogrel/Aspirin co-administration.
3022935|NCT02410083|Active Comparator|Clopidogrel/Aspirin co-administration 1|Clopidogrel-aspirin co-administration. Before this clinical trialClopidogrel/Aspirin co-administration.
3022936|NCT02410083|Experimental|Clopirin 2|Clopirin single-administration. Before this clinical trial Aspirin single-administration.
3022937|NCT02410083|Active Comparator|Clopidogrel/Aspirin co-administration 2|Clopidogrel-aspirin-co-administration. Before this clinical trial Aspirin single-administration.
3022938|NCT02410070|Experimental|Though Volar Minimal Incision|Patients in group A were treated through a small Incision.
3022939|NCT02410070|Active Comparator|Though Convectional Incision|Patients in group B were treated through the conventional Incision
3022940|NCT02410057|Active Comparator|Standard infant formula|Standard infant formula
3022941|NCT02410057|Experimental|Protein-reduced whey formula|Protein-reduced whey formula with higher level of α-lactalbumin than in standard infant formula
3022942|NCT02410057|Experimental|Protein-reduced α-lactalbumin formula|Protein-reduced formula with level of α-lactalbumin more similar to breast milk and higher than in experimental whey formula
3022943|NCT02410057|No Intervention|Breast-feeding|Exclusive breast-feeding
3022944|NCT02410031||Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)|Prescribers of Diane-35 who agree and fulfill the criteria inclusion to participate in the survey
3022945|NCT02410018|Experimental|Cohort 1 - Uterine Artery Embolization|"Women treated with OCL 503 proceeding to hysterectomy 1 week post embolization.~OCL 503 will be administered by catheter to the uterine artery(ies) to achieve blood flow stasis."
3022946|NCT02410018|Experimental|Cohort 2 - Uterine Artery Embolization|"Women treated with OCL 503 proceeding to hysterectomy 1 month post embolization.~OCL 503 will be administered by catheter to the uterine artery(ies) to achieve blood flow stasis."
3022947|NCT02410005|Active Comparator|Losartan alone|In the losartan alone group, subjects are prescribed: losartan 50mg twice daily.
3022948|NCT02410005|Experimental|Losartan and Calcitriol|In the losartan plus calcitriol group, subjects are prescribed: losartan 50mg twice daily and calcitriol 0.25mcg daily.
3022949|NCT02409992|Experimental|Parent Training plus Emotion Coaching|This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting intervention.
3022950|NCT02409992|Active Comparator|Parent Training Only|This intervention will consist of a parent management training program called Helping the Noncompliant Child.
3022951|NCT02409979|Active Comparator|Carbon dioxide method|Colonoscopy performed as usual, with the minimal CO2 insufflation required to aid insertion and adequate distension during withdrawal for exploration. Washing allowed as needed. Considered to be standard procedure.
3022952|NCT02409979|Experimental|Water Exchange-CO2|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for opaque water. Air pockets and residual feces will be always aspirated. Withdrawal phase done using carbon dioxide insufflation.
3022953|NCT02409979|Experimental|Water Exchange-AI|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for opaque water. Air pockets and residual feces will be always aspirated. Withdrawal phase done using air insufflation.
3022954|NCT02409966|Active Comparator|Quadrant-wise scaling|Patients underwent quadrant scaling under local anesthesia in four weekly sections.
3022955|NCT02409966|Experimental|Full-mouth 24-hour scaling|Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours.
3022956|NCT02409953|Experimental|Bath|
3022957|NCT02409953|Placebo Comparator|Bed|
3022958|NCT02409940|Experimental|Autologus Mesenchymal Stem Cells|This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant recipient's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.
3022959|NCT02409940|Active Comparator|Allogeniec Mesenchymal Stem Cells|This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant donor's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.
3022960|NCT02409940|No Intervention|Control without Mesenchymal Stem Cells|This group would get no stem cell infusion.
3022961|NCT02409927|Placebo Comparator|Control|Placebo meal without any active ingredient
3022962|NCT02409927|Active Comparator|MCT oil 10 g|Meal with 10 g of MCT oil mixed in
3022963|NCT02409927|Active Comparator|MCT oil 20 g|Meal with 20 g of MCT oil mixed in
3022964|NCT02409927|Active Comparator|MCT oil 30 g|Meal with 30 g of MCT oil mixed in
3056741|NCT02183233|Placebo Comparator|Eschscholtzia Californica Placebo|
3022969|NCT02409901|Experimental|Exercise Rehabiliation|12 month personalized exercise rehabilitation in addition to standard clinical care
3022970|NCT02409901|No Intervention|Control|Standard clinical care only
3022971|NCT02409888|Experimental|Intervention|Study participants receive either motivational enhancement therapy (MET) or cognitive behavioral therapy (CBT).
3022972|NCT02409888|Experimental|Assessment|IB Assessment study participants receive semi-annual assessments specific to their alcohol and other drug use and FC Assessment study participants receive quarterly assessments specific to diverse areas of functioning (e.g., alcohol and other drug use, social, occupational, legal, psychological/psychiatric, marital).
3022973|NCT02409875||Risk groups|"For families that both parents have BMI>=24 or at least one of them BMI>=28, then calculated as high-risk group.~For families that both parents have BMI<24 or one parents with BMI<24 and one with 24<=BMI<28, then grouped as low-risk group."
3022974|NCT02409862|Experimental|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
3022975|NCT02409862|Placebo Comparator|Placebo spray|This group will receive the single dose of 24 IU saline, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
3022976|NCT02409849|No Intervention|control group|
3022977|NCT02409849|Experimental|Octreotide LAR treatment|The patients with unresectable or metastatic GEP or esophageal NEC who got CR/PR/SD after chemotherapy with IP or EP regimen qualified with the inclusion criteria are enrolled. All the patients enrolled in our study will be randomly assigned to receive octreotide LAR (group A) as maintenance treatment or follow up (group B) to disease progression.
3022978|NCT02409836|Active Comparator|Crest Cavity Protection|Marketed Dentifrice
3022979|NCT02409836|Active Comparator|Crest for Kids Hawaiian Punch Paste|Marketed Dentifrice
3022980|NCT02409836|Active Comparator|Crest for Kids Bubble Gum Paste|Marketed Dentifrice
3022981|NCT02409823||patients on atypical antipsychotics|
3022982|NCT02409810|Experimental|PCA-DEX Patients|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10mins by nurse staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg.
3022983|NCT02409797|Experimental|Flexion-Distraction spinal manipulation|Participants will receive Flexion-Distraction treatment from a licensed doctor of chiropractic. During the procedure the participant lies prone on a specially designed treatment table. The table is equipped with a movable lower body section, which can be directed by the study doctor to lower the participants legs, move them from side to side, or in a traction motion. Table movements can occur in combination with other motions, depending on the diagnosis and characteristics specific to the participant's condition. During this procedure, the doctor will also touch the lower or upper part of the participants back or neck with their hands to direct treatment toward specific spinal regions.
3022984|NCT02409784|No Intervention|Control|TEP study without any intervention
3022985|NCT02409784|Experimental|Ketogenic diet|TEP study with a 4 days ketogenic diet
3022986|NCT02409771|Experimental|Intervention arm|Bilateral implantation with PRECIZON Presbyopic intraocular lens
3022987|NCT02409758|Active Comparator|VFE voice therapy|Voice therapy: Vocal Function Exercises applied during 6 weeks
3022988|NCT02409758|Experimental|CVRP voice therapy|Voice therapy: Comprehensive Voice Rehabilitation Program applied during 6 weeks
3022989|NCT02409745|Experimental|Young age group-Luteal phase|Endometrial injury in luteal phase (previous menstrual cycle) for patients undergoing Frozen thawed embryo transfer.
3022990|NCT02409745|Active Comparator|Young age group-Early follicular phase|Endometrial injury in early follicular phase for patients undergoing Frozen thawed embryo transfer.
3022991|NCT02409745|Experimental|Advanced age group-Luteal phase|Endometrial injury in luteal phase (previous menstrual cycle) for patients undergoing Frozen thawed embryo transfer.
3022992|NCT02409745|Active Comparator|Advanced age group-Early follicular phase|Endometrial injury in early follicular phase for patients undergoing Frozen thawed embryo transfer.
3022993|NCT02409732|Experimental|PDT|PDT with aminolevulinic acid hydrochloride (HCl) and blue light to the affected area of the lips every six weeks for up to three treatments
3022994|NCT02409719|No Intervention|Control|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given.
3022995|NCT02409719|Experimental|Study|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
3022996|NCT02409693||Myringotomy with tube insertion|Patients who received surgically inserted ear tubes.
3022997|NCT02409680|Active Comparator|Intervention Arm|Women will be randomized equally to receive daily low dose aspirin (LDA) [also known as acetylsalicylic acid (ASA)] of 81 mg beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
3022998|NCT02409680|Placebo Comparator|Placebo Arm|Women will be randomized equally to receive an identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
3022999|NCT02409667|Active Comparator|Secukinumab 300mg in PASI 90 responders (every 4 weeks)|570 patients with moderate to severe plaque psoriasis who have reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks will be treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.
3023000|NCT02409667|Experimental|Secukinumab 300mg in PASI 90 responders (longer intervals)|570 patients with moderate to severe plaque psoriasis who have reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks will be treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 at a longer dosing interval.
3023121|NCT02408835|Active Comparator|PICO™|Use of PICO™ system negative pressure wound therapy device on surgical wound for up to seven days.
3023001|NCT02409667|Experimental|Secukinumab 300mg in PASI 75-90 responders (shorter intervals)|105 patients with moderate to severe plaque psoriasis who have reached PASI 75-90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks will be treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 at a shorter dosing interval.
3023002|NCT02409667|Active Comparator|Secukinumab 300mg in PASI 75-90 responders (every 4 weeks)|105 patients with moderate to severe plaque psoriasis who have reached PASI 75-90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks will be treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.
3023003|NCT02409654|Active Comparator|Individualized stroke prevention|(i) Patient education (ii) Assess individual risk of stroke using the CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii) Recommendation of evidence-based stroke prevention therapy based on international guidelines (iv) Patient audit and follow-up (v) Patients not on appropriate OAC without adequate explanation will be referred to Cardiology Outpatient Clinic for second opinion
3023004|NCT02409654|Placebo Comparator|Routine Care|The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.
3023005|NCT02409641|Experimental|30 healthy male and female subjects|30 healthy male and female subjects , age 18-35 years
3023006|NCT02409628|Experimental|EktoTherix|One application of the EktoTherix scaffold to a fresh wound resulting from a full thickness excision of skin cancer.
3023007|NCT02409615|Active Comparator|Hypnosis Group|Hypnosis Group: fifteen participants will receive Hypnosis therapy in addition to the standard postoperative pain management protocol
3023008|NCT02409615|Active Comparator|Healing Touch Group|Healing Touch Group: fifteen participants will receive Healing Touch therapy in addition to the standard postoperative pain management protocol
3023009|NCT02409615|No Intervention|Control Group|Control Group will receive standard postoperative pain management protocol
3023010|NCT02409602||Women with BIIAL|Women who underwent bilateral internal iliac artery ligation due to postpartum hemorrhage within last 2 months
3023011|NCT02409602||Healthy puerperal women|Age-matched healthy puerperal women who delivered within last 2 months
3023012|NCT02409589|Experimental|ECG-guided PICC Tip Placement|New intracavitary ECG guiding method
3023013|NCT02409589|Active Comparator|Conventional|Surface prediction length method
3023014|NCT02409576|Experimental|Expanded, activated NK Cells(NKEXPSARC)|Intravenous infusion of expanded, activated NK Cells Donor cell will be expanded and activated in the cGMP compliant TECT lab for 10 to 12 days prior to infusion into the patient.
3023015|NCT02409563|Experimental|Budesonide nasal (100 mcg bid)|The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: N1 (n = 8) = Budesonide nasal spray 100 mcg, 2 v / d; Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)
3023016|NCT02409563|Experimental|Budesonide nasal (50 mcg bid)|The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: ; N2 (n = 31) = Budesonide nasal spray 50 mcg, 2 v / d. Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)
3023017|NCT02409550||113 patients with concomitant asthma and allergic rhinitis|113 patients with concomitant asthma and allergic rhinitis followed up from at least 3 months will be enrolled for the validation process at outpatient clinic of Pediatric Allergology & Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy.
3023018|NCT02409537|Active Comparator|non cholesterolemic individuals|Individuals with normal cholesterol levels will consume red wine for 1 month. There will be 1 month of wash out period. After 1 month of wash out period resveratrol will be consumed for 1 month and finally after 1 month wash out period placebo will be administered for 1 month.
3023019|NCT02409537|Active Comparator|Asymptomatic Hypercholesterolemics|individuals with high levels of cholesterol with no cardiovascular disease Those individuals will consume red wine for 1 month. There will be 1 month of wash out period. After 1 month of wash out period resveratrol will be consumed for 1 month and finally after 1 month wash out period placebo will be administered for 1 month.
3023020|NCT02409524|Experimental|Treatment|The treatment schedule of AlloVax includes: (1) Priming segment with ID injections of AlloStim on Days 0, 3, 7 and 10. (2) Vaccination segment with ID injections of AlloStim+CRCL on Days 14, 17, 21 and 24. (3) Activation segment with IV push infusion of AlloStim on Day 28. (4) Booster Segment with monthly (every 28 days) ID injections of CRCL alone beginning on Day 56. These injections will continue until all the vaccine is used or the death of the subject
3023021|NCT02409511||Type 1 diabetic, retinopathy, non cardiovascular disease|Type 1 diabetic patients with microalbuminuria, diabetic retinopathy and without cardiovascular disease
3023022|NCT02409511||Non-diabetic, hipertension|Non-diabetic patients with hypertension and microalbuminuria
3023023|NCT02409511||Type 2 diabetic, non diabetic retinopathy|Type 2 diabetic patients without diabetic retinopathy and microalbuminuria
3023024|NCT02409511||Type 2 diabetic with diabetic retinopathy|Type 2 diabetic patients with diabetic retinopathy and microalbuminuria
3023025|NCT02409511||Type 2 diabetic, with proven nephropathy|Type 2 diabetic patients with biopsy proven diabetic nephropathy.
3023026|NCT02409498|Active Comparator|pudendal block|preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine. 10 ml of Bupivacaine will be injected on either side using the pudendal nerve block tray.
3023027|NCT02409498|Placebo Comparator|no pudendal block|Saline
3023122|NCT02408835|No Intervention|Conventional wound care|Usual wound dressings will be used as comparison group.
3056742|NCT02183220|Experimental|Metamizol high & Placebo|
3023028|NCT02409485|Experimental|Couples Skill-Training (CST)|CST provides education about acute and long-term side-effects of HNC and teaches: 1) self-management skills to control/prevent side-effects; 2) communication skills to facilitate coordination of care; and, 3) strategies to improve communal coping and confidence in the ability to work as a team.
3023029|NCT02409485|No Intervention|Usual Medical Care (UMC)|Patients receive standard symptom management education by their health care team.
3023030|NCT02409472|Other|minimal surveillance|Minimal program for colon cancer: Office visit and CEA at 4,8,12,16,20,24,30,36,42,48, and 60 months. Colonoscopy at 12, and 48 months. Liver echography* at 8, and 20 months.
3023031|NCT02409472|Other|intensive surveillance|Intensive program for colon cancer: Office visit, complet blood count (CBC), CEA+ Carbohydrate Antigen (CA) 19.9 at 4,8,12,16,20,24,30,36,42,48, and 60 months. Colonoscopy at 12, 24, 36, 48,and 60 months. Liver echography* at 4,8,12,16,24,36,48, and 60 months. Chest X-ray at 12,24,36,48,and 60 months.
3023032|NCT02409459|Experimental|Injectafer|15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
3023033|NCT02409459|Placebo Comparator|Placebo|15 cc of Normal Saline IV push at 2 ml/minute
3023034|NCT02409446|Experimental|Anthocyanin|34 patients will receive anthocyanin. We will analyze their blood samples both prior and after taking anthocyanin.
3023035|NCT02409446|No Intervention|Controls|Healthy Controls, 20 persons. Will be giving blood samples at study start and study end.
3023036|NCT02409433|Experimental|lacosamide|The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours.
3023037|NCT02409433|Active Comparator|phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day. Levels will be checked accordingly.
3023038|NCT02409420|Experimental|PACT|PACT: a brief physiotherapy intervention based on ACT principles optimised to promote self-management. ACT aims to promote the acceptance of pain, the belief that it is not always necessary to change pain to move forward and the understanding that focusing on pain avoidance.
3023039|NCT02409420|No Intervention|Control|Usual care
3023040|NCT02409407|Experimental|Oral Misoprostol|oral misoprostol ( prostaglandins E1 analogue) will be administered at a dose of 600 µg (200 µg every 8 hours), starting 24 hours before office hysteroscopy.
3023041|NCT02409407|Experimental|Vaginal Misoprostol|vaginal misoprostol ( prostaglandins E1 analogue)will be administered at a dose of 400 µg (200 µg 12 hours apart, starting 24 hours before office hysteroscopy)
3023042|NCT02409407|Placebo Comparator|Placebo|oral placebo (one pill every 8 hours) will be administered starting 24 hours before the office hysteroscopy.
3023043|NCT02409394|Experimental|hetrombopag 7.5mg fasted to fed|Hetrombopag tablet, fasting conditions on day 1; 9 days wash-out; Than subjects will be crossover to have hetrombopag tablet with high fat, high calorie breakfast on day 11.
3023044|NCT02409394|Experimental|hetrombopag 7.5mg fed to fasted|Hetrombopag tablet with high fat, high calorie breakfast on day 1; 9 days wash-out; Than subjects will be crossover to have hetrombopag tablet, under fasting condition on day 11.
3023045|NCT02409381|Experimental|Motore|Curcuma longa complexed with phosphatidylcholine - 250 mg (Motore®), two (02) capsules orally every twelve (12) hours
3023046|NCT02409381|Active Comparator|Alivium|Ibuprofen 600 mg (Alivium®), one (01) coated tablet orally, every six (06) hours.
3023047|NCT02409368|Experimental|Cohort A: Treatment - Nivolumab|Nivolumab IV infusion
3023048|NCT02409355|Experimental|Atezolizumab|Participants will receive intravenous (IV) infusion of atezolizumab once on Day 1 of each 21-day cycle until loss of clinical benefit.
3023049|NCT02409355|Active Comparator|Gemcitabine + Cisplatin/Carboplatin|Participants will receive IV infusion of gemcitabine + cisplatin or gemcitabine + carboplatin once on Day 1 of each 21-day cycle for four or six cycles as per local standard of care.
3023050|NCT02409342|Active Comparator|(Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)|Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months). Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).
3023051|NCT02409342|Experimental|Atezolizumab|Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
3023052|NCT02409329|Experimental|REACH|"Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence and targeted to address other self-care behaviors) for 12 months.~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
3023053|NCT02409329|Experimental|REACH + FAMS|"In addition to the REACH text messages tailored to user's individual barriers to adherence, participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months. After six months, participants in this arm will receive REACH text messages only.~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
3023054|NCT02409329|Active Comparator|Helpline and A1c results|"Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).~All participants will receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
3023055|NCT02409316|Experimental|FES PET/CT|All subjects will receive an [18F]FES PET/CT scan.
3023056|NCT02409303|Experimental|Screen-Refer-Treat Intervention|PCPs and EI Providers receive training workshops on validated, evidence-based practices (i.e., Online M-CHAT-R/F, STAT, and RIT) and then receive TA (i.e., Screen-Refer-Treat Intervention). At the county level, providers are randomized to the order/timing at which they will receive this system intervention
3023057|NCT02409303|No Intervention|Control|No intervention received.
3023058|NCT02409290|Active Comparator|Regimen A|"Regimen A locally-used WHO-approved MDR-TB regimen~Regimen A, is the locally-used WHO-approved MDR-TB regimen in a country or site. It will be used in the secondary analysis of the study only."
3023059|NCT02409290|Active Comparator|Regimen B|"Product and dose for [<33 kg, 33-50kg, >50 kg] respectively:~Moxifloxacin [400mg, 600mg, 800mg]; Clofazimine [50mg,100mg,100mg]; Ethambutol [800mg,800mg,1200mg]; Pyrazinamide [1000mg,1500mg, 2000mg]; Isoniazid 300mg, 400mg, 600mg]; Prothionamide [250mg,500mg,750mg]; Kanamycin [15mg per kilogram body weight (maximum 1g)]."
3023060|NCT02409290|Experimental|Regimen C|"Product and dose for [<33kg, 33-50kg, >50 kg] respectively:~Bedaquiline 400mg once daily for first 14 days/200 mg thrice weekly thereafter; Levofloxacin [750mg, 750mg,1000mg]; Clofazimine [50mg, 100mg, 100mg]; Ethambutol [800mg, 800mg, 1200mg]; Pyrazinamide [1000mg,1500mg, 2000mg]; Isoniazid [300mg, 400mg, 600mg]; Prothionamide [250mg, 500mg,750mg]."
3023061|NCT02409290|Experimental|Regimen D|"Product and dose for [<33kg, 33 to<40kg, 40-50kg, >50-60 kg, >60 kg] respectively:~Bedaquiline 400mg once daily for first 14 days/200mg thrice weekly thereafter; Levofloxacin [750mg, 750mg, 750mg, 1000mg, 1000mg]; Clofazimine [50mg, 100mg, 100mg, 100mg, 100mg]; Pyrazinamide [1000mg,1500mg, 1500mg, 2000mg, 2000mg]; Isoniazid [400mg, 500mg, 600mg, 800mg, 900mg]; Kanamycin [15 mg per kilogram body weight (maximum 1g)]."
3023062|NCT02409277|Experimental|Standard e-AT Intervention|Patients in Standard e-AT or standard intervention group will receive a daily (if a participant forgets to complete his/her weekly assessment) email and text reminders with a link to the e-AT website to help patient/parent participants to comply with their weekly assessment of patient's level of asthma control. Note: patient/parent participants are required to complete their asthma control assessment 1x/week. The e-AT is now set up to send a weekly reminder to participants with a link to the website. If a participant does not complete an assessment within a week of the last assessment, the reminder will be sent daily until the patient/parent complies and the system resets to weekly.
3023063|NCT02409277|Experimental|Intensive e-AT Intervention|Participants in the intensive e-AT or adherence support intervention will receive everything as those in Standard Intervention. In addition, they will see a progress bar display, which adds 25 points each time they complete an assessment. When this bar reaches 100 points, a pop-up message with fireworks will appear to congratulate them about the milestone. The progress bar resets to zero after it reaches 100 points. Participants will also see a leader board allowing them to compare themselves with the 5 best users to increase compliance.
3023064|NCT02409277|No Intervention|Usual Care (Non-Randomized Cohort)|Both arms (Intensive and standard e-AT interventions) will be compared to each other as well as to a non-randomized cohort who did not receive the e-AT interventions. These non-randomized cohort will be matched 2:1 to each randomized individuals.
3023065|NCT02409264|Experimental|Individualised Homeopathic Remedy|Sucrose pillules will be medicated with the determined individualised homeopathic remedy, in the potency decided by the researcher in accordance with the laws that govern homeopathic prescribing. The dose and repetition of the remedy will be determined by the researcher in accordance with the aforementioned laws. A remedy will be prescribed every 2 weeks, after its determination by the researcher. No remedy will be prescribed after week 8.
3023066|NCT02409251|Experimental|Education and feedback|The intervention consisted of a one-hour, small group educational session. During this session information on rational ANA testing was provided and feedback on current ANA testing was provided to the rheumatologists. A booster session with the same components was held 6 months after the first session.
3023067|NCT02409238|Experimental|Lifestyle Intervention and Metformin|Intensive lifestyle interventions at Lifestyle Intervention Centres and Metformin (if Diabetic)
3023068|NCT02409238|Active Comparator|Standard Level of Care|Standard lifestyle recommendations for the Control groups
3023069|NCT02409225|Experimental|Home Monitoring|Remote monitoring od ICD/CRT-D function and patient condition. Device: HM provided by St Jude Medical, Biotronik or Medtronic.
3023070|NCT02409225|Active Comparator|HM option not active.|Regular visits in outpatient clinic. Device: no HM
3023071|NCT02409212|Experimental|Intervention|12 months of aerobic exercise training with behaviour change support
3023072|NCT02409212|Placebo Comparator|Comparison|Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
3023073|NCT02409199|Experimental|apatinib|Apatinib 850 mg qd po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3023074|NCT02409199|Active Comparator|Docetaxel|Docetaxel 60mg/m2 ivgtt every 3 weeks, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3023075|NCT02409186|Active Comparator|Nimotuzumab plus chemoradiotherapy|Nimotuzumab：400mg/w，d1, week 1-7 Paclitaxel：45mg/m2, d1, week 1-7 Cisplatin：20mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
3023076|NCT02409186|Placebo Comparator|placebo plus chemoradiotherapy|placebo：400mg/w，d1, week 1-7 Paclitaxel：45 mg/m2, d1, week 1-7 Cisplatin：20 mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
3023077|NCT02409173|Experimental|Noninvasive Ventilation and Surgery|Noninvasive positive airway pressure flow generator device by full face or nasal mask and bariatric surgery.
3023078|NCT02409173|No Intervention|Control Group|
3023079|NCT02409160|Experimental|Bariatric Surgery|Standard laparoscopic Roux-en-Y gastric bypass technique resulting in a gastric pouch with a volume of about 25 mL, a 100-cm-long Roux-limb, and a 75-cm-long biliopancreatic limb.
3023080|NCT02409160|No Intervention|Control Group|
3023081|NCT02409147|Experimental|Patients|Healthy female volunteers wishing to have a childbirth via uterine transplantation
3023082|NCT02409121|Experimental|Open label|All participants will receive a tablet educational intervention (health IT platform) during the patient inpatient hospitalization for autologous or allogeneic transplant
3023083|NCT02409108|Experimental|Exatherm-TBH system|One treatment of Total Body Hyperthermia
3056743|NCT02183220|Experimental|Metamizol low & Placebo|
3023084|NCT02409095|Experimental|DISPOSABLE-SYRINGE JET INJECTOR (DSJI)|Subjects in this arm will be given three deep intramuscular doses, 0.5 mL each dose 4 weeks apart, of Serum Institute of India Ltd.'s DTP-HB-Hib vaccine (Brand name: Pentavac) via Disposable Syringe Jet Injector (Brand Name:Stratis) of Pharmajet Inc
3023085|NCT02409095|Active Comparator|NEEDLE & SYRINGE (N-S)|Subjects in this arm will be given three deep intramuscular doses, 0.5 mL each dose 4 weeks apart, of Serum Institute of India Ltd.'s DTP-HB-Hib vaccine (Brand name: Pentavac) via conventional needle and Syringe
3023086|NCT02409069|Experimental|Transcutaneous vagus nerve stimulation (Nemos®, Cerbomed GmbH)|Stimulation of the ramus auricularis of the vagus nerve (ear)
3023087|NCT02409069|Sham Comparator|Sham stimulation (Nemos®, Cerbomed GmbH)|Stimulation of the earlobe
3023088|NCT02409069|No Intervention|No stimulation|No stimulation
3023089|NCT02409056|Experimental|workplace-tailored CDSMP|Group will receive the CDSMP program which has been modified to fit the unique characteristics of the workplace.
3023090|NCT02409056|Active Comparator|CDSMP usual care|Group will receive the standard CDSMP program which is currently being offered in a variety of community settings.
3023091|NCT02409056|No Intervention|control|Group will receive no intervention for the first 6 months (pre / post), then be randomly assigned to one of the above interventions.
3023092|NCT02409043||Control|Non-stroke participants. Blood drawn for analysis of biomarkers.
3023093|NCT02409043||Ischemic Stroke|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, and MRI infarct size assessed in hospital. 3 month modified Rankin scale score collected by phone interview.
3023094|NCT02409043||Hemorrhagic Stroke|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, and MRI infarct size assessed in hospital. 3 month modified Rankin scale score collected by phone interview.
3023095|NCT02409043||Stroke Mimic|Participants presenting at the University of Florida Shands Emergency Department with signs and symptoms resembling a stroke, but which are determined to be from another cause. Blood drawn during initial emergency room evaluation.
3023096|NCT02409030||Cognitively Healthy controls|"The neuropsychological test assessment must confirm that there is no cognitive impairment.~In the case of the cognitively healthy controls, CerebroSpinal Fluid tests performed within 24 months of inclusion will be accepted."
3023097|NCT02409030||Alzheimer Disease|Patients with AD will be classified based on currently valid and updated diagnostic algorithms in the NIA-Alzheimer's Association of America Clinical Guidelines (2011).
3023098|NCT02409030||Frontotemporal dementia|Inclusion criterion used will be prior diagnosis based on the diagnostic guidelines published by Dr. Rackovsky (Brain, 2011) for the behavioural variant; and those published by Prof. D. Neary (Neurology, 1998) for primary aphasia. A clinical and neuropsychological assessment is required, with the optional presence of alterations to the progranulin gene (and others) and there must be a compatible, previously performed imaging test (MRI, PET or SPECT) (predominantly frontal or frontotemporal atrophy).
3023099|NCT02409017|Active Comparator|Protocol A|Our current standard during labor
3023100|NCT02409017|Active Comparator|Protocol B|Another commonly accepted alternative for insulin drip management during labor
3023101|NCT02409004|Experimental|Ataluren|Ataluren 1375 mg powder for oral suspension administered once daily on Days 1 and 11 Rifampin 300 mg capsules administered twice daily on Day 3 to Day 12
3023102|NCT02408991|Experimental|AA and Neopogen|Patient undergoes treatment with Art-assist device and Neupogen
3023103|NCT02408978|Experimental|OXP005|1g naproxen
3023104|NCT02408978|Active Comparator|naproxen|1g naproxen
3023105|NCT02408965|Experimental|MM|Methergine group
3023106|NCT02408965|Placebo Comparator|Placebo|Placebo group
3023107|NCT02408952|Experimental|Primary Care Physician|If the adolescent is identified at risk for substance use, the screening and brief intervention referral to treatment delivered is by the primary care physician
3023108|NCT02408952|Experimental|Behavioral Medicine Specialist|If the adolescent is identified at risk for substance use, the screening and brief intervention referral to treatment delivered by the behavioral medicine specialist
3023109|NCT02408952|No Intervention|Usual Care|Care is administered as usual
3023110|NCT02408939||Intervention|Patients resuscitated from in-hospital cardiac arrest and treated with stress-dose hydrocortisone for postresuscitation shock
3023111|NCT02408939||Control|Patients resuscitated from in-hospital cardiac arrest and treated according to contemporary standards that did not include stress-dose steroids for postresuscitation shock
3023112|NCT02408926|Experimental|Group A|Women will be vaccinated with an acellular pertussis containing vaccine (Boostrix) between 27 and 36 weeks of gestation. Children born from these mothers will be vaccinated according to the official recommendations in Thailand at 2, 4, 6 and 18 months with a hexavalent acellular pertussis containing vaccine (Infanrix hexa).
3023113|NCT02408926|Active Comparator|Group B|Women will be vaccinated with an acellular pertussis containing vaccine (Boostrix) between 27 and 36 weeks of gestation. Children born from these mothers will be vaccinated according to the official recommendations in Thailand at 2, 4, 6 and 18 months with a pentavalent whole cell pertussis containing vaccine (Quinvaxem). OPV (oral poliovirus vaccine) will also be administered at 2, 4, 6 and 18 months.
3023114|NCT02408913|Experimental|Group1|MVA-EbolaZ 1x10(7) PFU
3023115|NCT02408913|Experimental|Group 2|MVA-EbolaZ 1x10(8) PFU
3023116|NCT02408913|Experimental|Group 3|cAd3-EBO 2x10(11) PU followed by MVAEbolaZ 1x10(8) PFU at 8 weeks
3023117|NCT02408913|Experimental|Groups 4 to 7|MVA-EbolaZ 1x10(8) PFU administered in VRC 208 to participants who received cAd3-EBO or cAd3-EBOZ in VRC 207.
3023118|NCT02408887|Active Comparator|1|pCND plus TT
3023119|NCT02408887|Active Comparator|2|TT alone
3023120|NCT02408861|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 60 minutes on day 1. Patients in dose level 2 also receive ipilimumab IV over 90 minutes on day 1 of every third course of nivolumab, and patients in dose level -2 also receive ipilimumab IV over 90 minutes on day 1 of every sixth course of nivolumab. Courses repeat every 14 days for up to 46 courses of nivolumab (with ipilimumab if receiving dose level 2 or -2) in the absence of disease progression or unacceptable toxicity.
3023123|NCT02408822|Active Comparator|PBA (Plain Balloon Angioplasty)|"Patient receiving endovascular treatment of a vascular access stenosis by plain balloon angioplasty (mechanical action, without drug)~2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure"
3023124|NCT02408822|Experimental|PTX|(PacliTaXel-coated balloon angioplasty) Patient receiving endovascular treatment of a vascular access stenosis by drug-eluting balloon angioplasty (mechanical action + antiproliferative drug - Paclitaxel) 2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
3023125|NCT02408809|Active Comparator|Control|
3023126|NCT02408809|Active Comparator|Intervention|
3023127|NCT02408796|Experimental|OTO-201|6 mg OTO-201
3023128|NCT02408770|Experimental|treatment|ulipristal acetate 5mg daily for 3 months
3023129|NCT02408757||All study participants|The study population consists of consecutive patients undergoing clamping of EVD/LD treated at the Departments of Neurosurgery or Intensive Care Medicine at the University Hospital Bern
3023130|NCT02408744|Experimental|Pirfenidone|Pirfenidone 1200 mg in the form of prolonged-released tablets, orally administered two times a day (b.i.d.) to yield a daily dose of 2400 mg during three years.
3023131|NCT02408731|Experimental|Single dose of 0.005 mg/kg of PMZ-2010|A single dose of 0.005 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
3023132|NCT02408731|Experimental|Single dose of 0.01 mg/kg of PMZ-2010|A single dose of 0.01 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
3023133|NCT02408731|Experimental|Single dose of 0.05 mg/kg of PMZ-2010|A single dose of 0.05 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
3023134|NCT02408731|Experimental|Single dose of 0.10 mg/kg of PMZ-2010|A single dose of 0.10 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
3023135|NCT02408731|Experimental|3 doses equivalent to MTD of PMZ-2010|Three equally divided doses (total dose/day equivalent to MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days
3023136|NCT02408731|Experimental|3 doses equivalent to 2*MTD of PMZ-2010|Three equally divided doses (total dose/day equivalent to 2*MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days
3023137|NCT02408718|Active Comparator|Training group|Subjects randomized to this group will receive a 6 week Assistive Device Training program in the use of their assistive device. They will have mobility assessments taken at baseline, after the training program has been completed, and 3 months later. During this time, their falls will be recorded monthly using prospective falls calendars. Members of this group will also receive MRI scans at baseline and after the completion of the training program.
3023138|NCT02408718|No Intervention|Wait-list control|Subjects in this group will participate in the same mobility assessments and completion of the falls calendars, but will receive no intervention during this time. These subjects will have the opportunity to receive the training sessions when all assessment visits have been completed. These subjects will not receive MRI scans.
3023139|NCT02408705|Active Comparator|Liraglutide|3-month treatment of liraglutide
3023140|NCT02408705|Placebo Comparator|Placebo|3-month treatment of placebo
3023141|NCT02408692|Active Comparator|Normal BMI ECx1|5 normal weight women (BMI<25 kg/m2) taking 1.5mg LNG
3023142|NCT02408692|Active Comparator|Obese BMI ECx1|5 obese women (BMI >30 kg/m2) taking 1.5mg LNG
3023143|NCT02408692|Active Comparator|Obese BMI ECx2|5 obese women (BMI >30 kg/m2) taking 3mg LNG
3023144|NCT02408679||All subjects|300 eligible subjects will perform a blood sampling for a dosage of serum vitamin D and will fill up a study questionnaire during one visit.
3023145|NCT02408666|Other|Interview|"Interview of epilepsy patients and their family about their experience with epilepsy, EEG registrations and daily life.~Interview of EEG-technologists and neurologists about their experience with EEG registrations and expections when thinking of a ideal EEG-cap."
3023146|NCT02408653|Active Comparator|conventional EEG-registration type 1|conventional EEG-registration with wet bridge electrodes and conductive gel
3023147|NCT02408653|Active Comparator|conventional EEG-registration type 2|conventional EEG-registration with wet cup electrodes and collodion
3023148|NCT02408653|Experimental|EEG-registration with dry electrodes|EEG-registration with dry electrodes
3023149|NCT02408640|Experimental|Intervention group|"Individuals randomized to the intervention group will directly after randomization answer questions about alcohol and drug use (other than alcohol and cannabis), depression, anxiety, a sense of context and whether they during the last 12 months has received professional help to reduce or quit their cannabis use or during the same period have raised this issue with their relatives or friends.~Further, they will fill out a survey about Internet-based services for individuals who wish to reduce or quit their cannabis use. The study participants will then be informed that they, within two days, will gain access to an internet based treatment program designed to help them quit their cannabis use and that they through the program will be able to communicate with a therapist. Within the next two days, they will gain access to the internet-based treatment program, they will have access to it for two months and they will be contacted again after three months to complete the follow-up."
3023150|NCT02408640|No Intervention|Control group|"Individuals randomized to the control group will undergo exactly the same procedure as the intervention group. The difference is that the control group will be informed that they in about three months will gain access to an internet based treatment program designed to help them quit their cannabis use (i.e. when the data collection for follow-up is completed).~Otherwise, participants in both groups will have the opportunity to use factual information that is available to everyone on Cannabishjalpen.se."
3023151|NCT02408627|Active Comparator|conventional EEG-registration type 1|conventional EEG-registration with wet bridge electrodes and conductive gel
3023152|NCT02408627|Active Comparator|conventional EEG-registration type 2|conventional EEG-registration with wet cup electrodes and collodion
3023153|NCT02408627|Experimental|EEG-registration with dry electrodes|EEG-registration with dry electrodes
3023154|NCT02408614||Slow-paced walking|Subjects will complete 47 minutes of walking at slow pace.
3023155|NCT02408614||Moderate-paced walking|Subjects will complete 47 minutes of walking at a moderate pace.
3023156|NCT02408614||Interval training|Subjects will complete 40 minutes of walking alternating between a moderate and fast pace.
3023184|NCT02408367||Exercise|30 minutes of active training at 75% of the Maximum heart rate achieved in a cardiopulmonary exercise test
3023185|NCT02408367||Relaxation|30 Minutes of passive relaxation
3023752|NCT02404480|Experimental|Cohort 6|PTC 596 administered twice daily-Dose level 7mg/kg
3023157|NCT02408601|Active Comparator|Group 1|"split mouth study. one side of the arch that is the lower left permanent 1st molar will be receiving resin based sealants.~Application of the resin sealants as per the standard instructions of the manufacturer~Helioseal -F ( Resin based sealant)~isolate the tooth surface~etch the fissure anatomy with 37% phosphoric acid for 20 seconds~wash the tooth surface and dry it. No salivary contamination is accepted~using a syringe based system, apply the sealant onto the fissures, do not overfill the fissures, run an explorer along the fissures to avoid any air entrapment.~light cure the sealant~check for high points and the occlusion"
3023158|NCT02408601|Experimental|Group 2|"split mouth study. one side of the arch that is the lower right permanent 1st molar will be receiving ART sealants.~Application of the ART sealants as per the standard instructions of the manufacturer~isolate the tooth surface~condition the fissure anatomy using a GC conditioner for 10 seconds~wash the conditioner by using a cotton pellet for a couple of times, do not use a three way syringe.~dry the tooth surface~mix the GIC according to the standard powder: liquid ratio~place the mix onto the fissures using a plastic spatula~apply pressure on the occlusal surface with a gloved index finger( the gloved index finger must be coated with petroleum jelly)~apply pressure for 10-15 sec and withdraw the finger in a sideways motion~scrap out the excess material~check for the high points and the occlusion~apply petroleum jelly onto the GIC mix~advice patient not to eat or drink for 30 minutes."
3023159|NCT02408588||Childbirth and epidural|Pregnant women giving childbirth who receive an epidural.
3023160|NCT02408588||Childbirth and general anesthesia|Pregnant women giving childbirth who receive general anesthesia
3023161|NCT02408588||Fetal Intervention and epidural|Pregnant women receiving fetal intervention and an epidural
3023162|NCT02408588||Fetal Intervention and general anesthesia|Pregnant women receiving fetal intervention and general anesthesia
3023163|NCT02408575|Experimental|Notched filtering (verum)|"The Hearing aid with notched amplification filters frequencies in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.~Intervention: Device: Conventional hearing aid type Carat 7bx with M-Receiver; Adjustment by Connexx 7.3"
3023164|NCT02408575|Experimental|No filtering (placebo)|"Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3~No notched filtering~Intervention: Device: Conventional hearing aid type Carat 7bx with M-Receiver; Adjustment by Connexx 7.3"
3023165|NCT02408562|Experimental|sNN0031|sNN0031 Infusion Solution (in aCSF) for intracerebroventricular (i.c.v.) administration by an implanted infusion pump
3023166|NCT02408562|Placebo Comparator|Placebo|Articifial Cerebro Spinal Fluid (aCSF) for intracerebroventricular (i.c.v.) administration by an implanted infusion pump
3023167|NCT02408549|Experimental|Lacosamide|"Start dose~SP982 completers at V1:~LCM 10 mg/kg/day for pediatric subjects weighing <30 kg~LCM 8 mg/kg/day for pediatric subjects weighing ≥ 30kg to <50 kg~LCM 400 mg/day (200 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg~SP982 Baseline failures at V1:~LCM 2 mg/kg/day for pediatric subjects weighing <50 kg~LCM 100 mg/day (50 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg~Oral solution (pediatric subjects <50 kg):~Minimum LCM dose: 4 mg/kg/day~Maximum LCM dose: 12 mg/kg/day~Tablets (pediatric subjects ≥50kg):~Minimum LCM dose: 200 mg/day~Minimum LCM dose: 600 mg/day~Tablets (adult subjects):~Minimum LCM dose: 200 mg/day~Maximum LCM dose: 800 mg/day"
3023168|NCT02408536||Single cohort|Retrospective analysis of all patients diagnosed, from 01/01/2000 to 01/01/2014, with low-grade serous ovarian cancer or invasive recurrence after surgery for borderline serous carcinoma
3023169|NCT02408523|Experimental|Lacosamide|"Lacosamide 50 mg tablets (Starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400 mg/day for adult subjects and pediatric subjects >= 50 kg.~Lacosamide oral solution 10 mg/ml (Starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects < 30 kg.~Lasosamide oral solution 10 mg/ml Starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30 kg to < 50 kg."
3023170|NCT02408523|Placebo Comparator|Placebo|"Placebo 50 mg tablets (Starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400mg/day for adult subjects and pediatric subjects >= 50kg.~Placebo oral solution 10 mg/ml (Starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects < 30kg.~Placebo oral solution 10 mg/ml Starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30kg to < 50kg."
3023171|NCT02408484|Experimental|Octafibrin|Plasma-derived fibrinogen concentrate
3023172|NCT02408471|Other|Ascension® MCP Finger Implant|Single arm study, patient treated with Ascension® PyroCarbon MCP implant.
3023173|NCT02408458|Other|MIROMESH|Single-arm study. MIROMESH will be used in the surgical repair of ventral hernia.
3023174|NCT02408445|Experimental|Testosterone treatment|Testosterone cypionate (200 mg/ml) intramuscular injection
3023175|NCT02408445|No Intervention|No treatment|Subjects will not receive any testosterone during the study period.
3023176|NCT02408432|Experimental|Multipotent Mesenchymal Stromal Cells (MSCs)|Participants receive human mesenchymal stem cells (hMSCs) by vein delivered as 2 x 10^6 cells/Kg per week (one cycle) over 4 weeks. Participants also treated with routine heart failure medical therapy.
3023177|NCT02408432|Other|Standard of Care|Participants receive routine heart failure medical therapy.
3023178|NCT02408419|Experimental|Local anesthetic|15 ml. of local anesthetic
3023179|NCT02408419|Placebo Comparator|Saline|15 ml. of saline
3023180|NCT02408406|Experimental|Arm I (PatientCareAnywhere program system)|Patients are encouraged to use the PatientCareAnywhere program at least once weekly either in the clinic or at home. Patients receive reminder emails after 1 week of inactivity. If patients indicate they are experiencing moderate to severe symptoms, an alert message is sent to at least 1 member of the patient's support team along with a list of expected response times.
3023181|NCT02408406|Active Comparator|Arm II (usual care)|Patients receive usual care, including a one-time use of SupportScreen, a touchscreen questionnaire system that identifies patient issues before appointments, at the clinic during the first treatment consultation after diagnosis. Consultation, printed education materials, and specialist referrals may be generated based on SupportScreen responses.
3023182|NCT02408393|Placebo Comparator|Placebo|Saline (30 mL maximum)
3023183|NCT02408393|Experimental|Ropivacaine|Ropivacaine 7.5 mg/mL (0.35 mL/kg of solution)
3023186|NCT02408354|Active Comparator|Triheptanoin|"Triheptanoin/ Placebo Randomized to receive active Triheptanoin first for 12 weeks. At cross-over, participants will receive placebo for 12 weeks.~Each drug will be dispensed successively. A one-month wash out period is planned for 4 weeks between triheptanoine and placebo phases."
3023187|NCT02408354|Placebo Comparator|Placebo|"Placebo / Triheptanoin Randomized to receive active Placebo first for 12 weeks. At cross-over, participants will receive Triheptanoin for 12 weeks.~Each drug will be dispensed successively. A one-month wash out period is planned for 4 weeks between placebo and triheptanoin phases."
3023188|NCT02408341||Routine clinical practice of induction anesthesia|There was no intervention, just monitoring of clinical routine practice using non-invasive Doppler tissue imaging.
3023189|NCT02408328|Active Comparator|Inpatient Observation|Continued inpatient monitoring of apnea, bradycardia, and/or desaturation until an event free period of time (5 days per the current standard of care at each participating institution) has been established and deemed appropriate for discharge home per the discretion of the responsible provider.
3023190|NCT02408328|Active Comparator|Caffeine and Outpatient Monitoring|Patients will receive a loading dose of caffeine on day 1 with a daily maintenance dose thereafter. Infants will then receive continued inpatient monitoring of apnea/bradycardia/desaturation until an event free period of time has been established and deemed appropriate for discharge home per the discretion of the responsible provider. Infants discharged home on caffeine therapy will receive instructions regarding use of a home monitor. Follow up in the pulmonary clinic will be arranged at 42-43 weeks gestational age. At 43 weeks corrected gestational age, caregivers will be instructed to discontinue caffeine therapy. An outpatient recorded oximetry study will be arranged at least 1 week after discontinuation of caffeine therapy. Home pulse oximetry monitoring will be discontinued if no significant events, as previously defined, are recorded.
3023191|NCT02408315|Placebo Comparator|misoprostol/placebo using buccal|Randomized for buccal route of administration/ placebo
3023192|NCT02408315|Placebo Comparator|misoprostol/placebo using vaginal|Randomized for vaginal route of administration/ placebo
3023193|NCT02408302|Active Comparator|oral midazolam|oral midazolam 0.5-0.7 mg/kg maximum 10 mg. one dose only before the invasive procedure.
3023194|NCT02408302|Active Comparator|intranasal midazolam|intranasal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure
3023195|NCT02408302|Active Comparator|buccal midazolam|buccal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure
3023196|NCT02408289|Placebo Comparator|Lo-Flav|Low-flavonoid cocoa powder with 0 mg of procyanidins and 0 mg epicatechin per kg of body weight will be consumed as a beverage
3023197|NCT02408289|Active Comparator|Hi-Flav|Cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.
3023198|NCT02408289|Active Comparator|Epicatechin|Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage.
3023199|NCT02408289|Active Comparator|Procyanidins|Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.
3023200|NCT02408276||dGEMERIC MRI technique|All tests and imaging are part of standard of care except follow up MRI, which will be performed in a random group from within the cohort and paid for through this grant.
3023201|NCT02408263||Total Hip Replacement (THR) and Total Knee Replacement (TKR)|25 patients receiving a THR and 25 patients receiving aTKR. The investigators are using Skin Conductance Algesimeter (SCA) to measure pain by analyzing changes in skin conductance.
3023202|NCT02408237|Active Comparator|tDCS Ambulatory & Sham|Active tDCS Ambulatory: 1 mA of current of active tDCS applied for 20 minutes, single session of stimulation. Sham tDCS Ambulatory: applied for 20 minutes, single session of stimulation.
3023203|NCT02408237|Active Comparator|tDCS home use & Sham|Active tDCS home use: 11 active tDCS sessions: single session in the hospital and the remaining 10 in the subject's home, with duration of each active tDCS session of 20 min. Sham tDCS home use: 11 sessions of tDCS: single session in the hospital and the remaining 10 in the subject's home, with duration of each sham tDCS session of 20 min.
3023204|NCT02408224||one arm|patients on Ticagrelor
3023205|NCT02408198|Experimental|Immediate therapy|Therapy will be delivered for a period of 6 weeks immediately after randomisation
3023206|NCT02408198|No Intervention|Delayed therapy|Therapy will be delayed until 10 weeks following randomisation, and then delivered over a 6 week period
3023207|NCT02408185|Experimental|Colistin 6 million units + 240mg/8h|Loading dose of 6 million units of colistin+ 240mg/8h maintenance
3023208|NCT02408185|Experimental|Colistin 6 million units + 360mg/12h|Loading dose of 6 million units of colistin+ 360mg/12h maintenance
3023209|NCT02408172|Experimental|OSA-amlodipine|To observe the effects of amlodipine (5mg) on blood pressure variation after 12 weeks of treatment
3023210|NCT02408172|Experimental|OSA-metoprolol|To observe the effects of metoprolol (47.5mg) on blood pressure variation after 12 weeks of treatment
3023211|NCT02408159|Experimental|Varicella Zoster Vaccine|Sterile, lyophilized white to off-white compact crystalline plug in a single-dose vial. Each vial contains one dose of lyophilized vaccine (approximately 0.65 mL when reconstituted as directed). The diluent (0.7 mL) is a sterile, clear, colorless fluid supplied separately in a 3 mL single-dose vial. A single dose will be administered to subjects at baseline.
3023212|NCT02408159|Placebo Comparator|0.9% Sodium Chloride|"United States Pharmacopeia (USP), preservative free for injection supplied in a single dose vial.~A single dose will be administered to subjects at baseline."
3023213|NCT02408146|Experimental|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia.
3023214|NCT02408146|Experimental|parecoxib|The second group has oral celecoxib before surgery, then receives parecoxib sodium intravenously guttae after surgery.
3023215|NCT02408146|Experimental|new intravenous infusion pump|The third group uses new intravenous infusion pump of patient-controlled analgesia after surgery.
3023216|NCT02408133|No Intervention|Control|The control group will be accompanied according to the service routine.
3023217|NCT02408133|Experimental|Exercise|The group will be instructed to perform home exercises autonomously for range of motion and muscular fitness
3023251|NCT02407860|Experimental|treatment|one single osteopathic treatment in addition to usual breastfeeding counselling
3023252|NCT02407860|Active Comparator|control|usual breastfeeding counselling. Osteopathic evaluation of entire body
3023218|NCT02408120|Active Comparator|Insulin Aspart for BG > 140 mg/dL|Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels >140 mg/dL.
3023219|NCT02408120|Active Comparator|Insulin Aspart for BG > 260 mg/dL|Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels >260 mg/dL.
3023220|NCT02408107|Experimental|Physical activity intervention|Received a 30 min physical activity counselling session which employed motivational interviewing to encourage the adoption of current recommended physical activity guidelines. This arm also received 3 support phone calls (1 at the end of months 1, 2 and 3) and a physical activity reminder postcard on months 4 and 5.
3023221|NCT02408107|No Intervention|Usual care|This arm received usual care (i.e. no physical activity counselling, support phone calls or post-cards).
3023222|NCT02408081|No Intervention|Treatment as usual|Pharmacological treatment, patient information and counselling according to international and national guidelines by health professionals specialized in elderly medical patients.
3023223|NCT02408081|Experimental|Family Focused Nursing|Family Focused Nursing and treatment as usual
3023224|NCT02408068|Active Comparator|Chronocort : fed|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and receive a high fat, high calorie breakfast on the morning of Day 1. Thirty minutes after the start of the breakfast they will receive 20mg of modified release hydrocortisone with 200 millilitres of water, and no further food for 4 hours, water will be allowed from 1 hour after the food. Further dexamethasone doses will be given at 06:00, 12:00, 18:00 and 22:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken starting prior to the dose and then over 24 hours (29 samples).
3023225|NCT02408068|Active Comparator|Immediate release hydrocortisone: fasted|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and take 20mg immediate release hydrocortisone with 200 millilitres of water on the morning of Day 1. Water will be allowed 1hr after the study drug, but no food for at least 4hrs post dose. Further dexamethasone doses will be given at 06:00, 12:00 and 18:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken prior to the dose, and then afterwards for over a 12 hour period (16 samples)
3023226|NCT02408068|Active Comparator|Chronocort: fasted|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and take 20mg modified release hydrocortisone with 200millilitres of water on the morning of Day 1. Water will be allowed 1hr after the dose, but no food for at least 4hrs post dose. Further dexamethasone doses will be given at 06:00, 12:00, 18:00 and 22:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken prior to the dose, and then afterwards for over a 12 hour period (16 samples)
3023227|NCT02408055|Experimental|Radiolabelled TA-8995|
3023228|NCT02408042|Active Comparator|RICE and Pembrolizumab|non-Hodgkin's lymphoma patients requiring 2nd line or beyond therapy and eligible to receive RICE (rituximab, ifosfamide, carboplatin, and etoposide)
3023229|NCT02408042|Active Comparator|ICE and Pembrolizumab|classical Hodgkin's lymphoma requiring 2nd line or beyond therapy and eligible to receive ICE (ifosfamide, carboplatin, and etoposide)
3023230|NCT02408042|Active Comparator|brentuximab vedotin and Pembrolizumab|classical Hodgkin's lymphoma that have progressed after high-dose chemotherapy with autologous stem cell rescue or progressed on at least 2 lines of therapy and are eligible to receive brentuximab vedotin
3023231|NCT02408029||Trauma Patients Group|Patients undergoing treatment for injuries and trauma.
3023232|NCT02408016|Experimental|Arm I, Stage I (T lymphocytes, cyclophosphamide, IL-2)|Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on days 0 and 14, cyclophosphamide IV on days 11 and 12, and aldesleukin SC BID for 14 days. Patients who have received radiation to the chest/lung tissue may receive gene-transduced T lymphocytes 90 days after completion of radiation.
3023233|NCT02408016|Experimental|Arm I, Stage II (T lymphocytes, cyclophosphamide, IL-2)|Patients receive cyclophosphamide IV on days -3 and -2, autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on day 0, and aldesleukin SC BID for 14 days.
3023234|NCT02408016|Experimental|Arm II (T lymphocytes, IL-2, surgery)|Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV between 24-96 hours after the last dose of chemotherapy and receive aldesleukin SC BID for 14 days. Patients then undergo surgery within 3-4 weeks after the T-cell infusion.
3023235|NCT02408003|Experimental|Levosimendan|"st dose: 12 µg/kg iv bolus for 10 min followed by 0,1 µg/kg/min for 20 min.~nd dose: 12 µg/kg iv bolus for 10 min followed by 0,2 µg/kg/min for 20 min."
3023236|NCT02408003|Experimental|Milrinone|"st dose: 48 µg/kg iv bolus for 10 min followed by 0,4 µg/kg/min for 20 min.~nd dose: 48 µg/kg iv bolus for 10 min followed by 0,8 µg/kg/min for 20 min."
3023237|NCT02407990|Experimental|BGB-A317 Phase 1A|
3023238|NCT02407990|Experimental|BGB-A317 Phase 1B|
3023239|NCT02407951|Experimental|CBIT group|
3023240|NCT02407951|Placebo Comparator|Psycho-Educational group|
3023241|NCT02407938|Experimental|rice meal|High resolution manometry will be performed. Esophageal function will be tested using liquid swallows, solid swallows and a test meal (200g rice)
3023242|NCT02407925||Endoscopists|Approximately 35 endoscopists whom are certified to perform colonoscopies on FIT-positive patients in the Dutch population screening program
3023243|NCT02407925||Colonoscopies|Colonoscopies on FIT-positive patients in the Dutch population screening program
3023244|NCT02407925||Device|Olympus colonoscopes with Narrow Band Imaging
3023245|NCT02407912|Experimental|Cisplatin|75 mg of body surface area of ciplatin in distilled water is injected in to the chest through a chesttube.
3023246|NCT02407912|No Intervention|Control|No intervention was applied.
3023247|NCT02407899|Experimental|insulin + saxagliptin|Patients who have diagnosed LADA are assigned to receive Saxagliptin tablets 5 mg and insulin for 104-week.
3023248|NCT02407899|Experimental|insulin + saxagliptin + vitamin D3|Patients who have diagnosed LADA are assigned to receive Saxagliptin tablets 5 mg , vitamin D drop 2000IU,and insulin for 104-week.
3023249|NCT02407899|Active Comparator|insulin|Patients who have diagnosed LADA are assigned to receive insulin for 104-week.
3023250|NCT02407873||Cardiac surgery|
3023253|NCT02407847|No Intervention|General Practitioners Care|Usual medical care provided by General Practitioners at the Primary Out-of-Hours Service.
3023254|NCT02407847|Experimental|Nurse Practitioners Care|Medical care provided by both Nurse Practitioners and General Practitioners at the Primary Out-of-Hours Service.
3023255|NCT02407834|Experimental|S1 - 0.25% sodium hypochlorite|Brushing with specific brush and neutral soap, three times a day. After, immesion in 0.25% sodium hypochlorite during 20 minutes, once a day. This protocol was used during 7 days.
3023256|NCT02407834|Experimental|S2 - 0.5% sodium hypochlorite|Brushing with specific brush and neutral soap, three times a day. After, immesion in 0.5% sodium hypochlorite during 20 minutes, once a day.This protocol was used during 7 days.
3023257|NCT02407834|Experimental|S3 - 10% Ricinus communis|Brushing with specific brush and neutral soap, three times a day. After, immesion in 10% Ricinus communis solution during 20 minutes, once a day. This protocol was used during 7 days.
3023258|NCT02407834|Placebo Comparator|S4 - saline solution|Brushing with specific brush and neutral soap, three times a day. After, immesion in saline solution during 20 minutes, once a day. This protocol was used during 7 days.
3023259|NCT02407821|Active Comparator|Escitalopram|
3023260|NCT02407821|Placebo Comparator|Placebo|
3023261|NCT02407808|Active Comparator|THC|Active THC (0.0015mg/kg-0.03mg/kg) administered over 20 minutes.
3023262|NCT02407808|Placebo Comparator|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
3023263|NCT02407795|Active Comparator|Arm 1|Conventional radiotherapy, 1x8Gy
3023264|NCT02407795|Experimental|Arm 2|Stereotactic radiotherapy, 1x20Gy
3023265|NCT02407782|Experimental|Ivermectin|
3023266|NCT02407782|Experimental|Permethrin|
3023267|NCT02407769|Experimental|Branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during the late evening (after 19:00 hours) daily by two months.
3023268|NCT02407769|Sham Comparator|Late evening snack|The patients will eat a snack with similar nutrimental facts that food supplement (480 Kcal, 19g of proteins and they were based in casein and vegetable proteins; 17g of lipids and 63g of carbohydrates) during the late evening (after 19:00 hours) daily by two months.
3023269|NCT02407756|Experimental|Cohort 1|Cohort 1 will receive dupilumab dosing regimen 1
3023270|NCT02407756|Experimental|Cohort 2|Cohort 2 will receive dupilumab dosing regimen 2
3023271|NCT02407743||Surgical patients' clinical progression|Patients undergoing non-ambulatory surgery will be asked questions and complete surveys in an effort to characterize postoperative pain experience profiles. A blood sample will be obtained for genetic markers exploring a variety of pain-related genes.
3023272|NCT02407704|Experimental|Aerobic Exercise + Venlafaxine XR|"Venlafaxine (Effexor) Extended-Release (XR) comes in capsule form and is taken by mouth. Target dose will be 150mg/d, with a maximum dose of 300mg/d (response dependent) for a minimum of 12 weeks.~Exercise will include walking on a treadmill 1 hour 3 times/week for 12 weeks. Heart rate will be closely monitored during sessions. The intensity of the exercise will start at 50% of the age-based maximum for the first week and then increase and be maintained at 60-70% of the age-based maximum for the remainder of the intervention.~Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. This will be administered in pill form (2mg or less per 24 hours)."
3023273|NCT02407704|Active Comparator|Venlafaxine XR Only|"Venlafaxine (Effexor) XR comes in capsule form and is taken by mouth. Target dose will be 150mg/d, with a maximum dose of 300mg/d (response dependent) for a minimum of 12 weeks.~Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. This will be administered in pill form (2mg or less per 24 hours)."
3023274|NCT02407691|Experimental|Primary Care 101 Enhanced guideline|Primary Care 101 guideline with enhanced mental health
3023275|NCT02407691|Active Comparator|Standard of care|Primary Care 101 standard version guideline
3023276|NCT02407678|Experimental|Treatment|Treated eye undergoes AAV-mediated REP1 gene replacement. AAV vector is delivered by subretinal injection.
3023277|NCT02407678|No Intervention|Control|Untreated eye
3023278|NCT02407665|Experimental|Tai Chi|Participants who practice Tai Chi 2X/week for 12-weeks
3023279|NCT02407665|No Intervention|Healthy Control|24 healthy controls
3023280|NCT02407652|Experimental|cognitive control training|internet-delivered, 2 weeks
3023281|NCT02407652|Active Comparator|low cognitive load training|internet-delivered, 2 weeks
3023282|NCT02407639|Active Comparator|co2 arm|insufflation with CO2
3023283|NCT02407639|Placebo Comparator|air arm|insufflation with air
3023284|NCT02407626|Experimental|Sevoflurane|Volatile anesthesia for elective cardiac surgery
3023285|NCT02407626|Active Comparator|Propofol|Total intravenous anesthesia for elective cardiac surgery
3023286|NCT02407613|Experimental|MR-HIFU ablation|Ten patients undergo MR-HIFU ablation with the Philips Sonalleve MR-HIFU Breast Tumor Therapy System. According to a treat-and-resect protocol, these patients also undergo breast cancer surgery after 1 tot 2 weeks after MR-HIFU treatment.
3023287|NCT02407600|Active Comparator|Fosparepitant administered in 1st cycle|Fosaprepitant (Emend) for Injection 150 mg is administered, one time, intravenously on day 1 only, as an infusion with a duration of 30 minutes. It will be initiated approximately 30 minutes prior to the subjects first chemotherapy cycle. An intravenous saline placebo will be administered on day 1 of the second chemotherapy cycle, in the same manor as EMEND for Injection.
3023288|NCT02407600|Sham Comparator|Fosaprepitant administered in 2nd cycle|Subject will receive a saline Placebo intravenously on day 1 of their first chemotherapy cycle. For the subject's second chemotherapy cycle, EMEND for Injection 150 mg is administered, one time, intravenously on day 1, as an infusion with a duration of 30 minutes. It will be initiated approximately 30 minutes prior to the subjects second chemotherapy cycle.
3023289|NCT02407587|Experimental|unilateral cochlear implants|"Study Group~PET scans for the mature patients with unilateral cochlear implants and preserved hearing~4 states and each state will be repeated 3 times Cochlear implant only Residual hearing only Combination of implant and residual hearing No auditory stimulation"
3023290|NCT02407587|No Intervention|Healthy volunteers|4 states and each state will be repeated 3 times Auditory stimulation Left ear only Auditory stimulation right ear only Binaural auditory stimulation Silence
3023291|NCT02407574|Experimental|Spontaneous rhythm first|Stepwise preload increase by repeated administration of 100 mL of fluid during spontaneous rhythm and then stepwise preload reduction by repeated drainage of 100 mL of fluid during atrial pacing.
3023292|NCT02407574|Experimental|Atrial pacing first|Stepwise preload increase by repeated administration of 100 mL of fluid during atrial pacing and then stepwise preload reduction by repeated drainage of 100 mL of fluid during spontaneous rhythm.
3023293|NCT02407548|Experimental|combined group|each coenzyme Q10 vitamin E softgel contain CoQ 10 30mg + vitamin E 16mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 and 64mg vitamin per day. The duration is 24 weeks.
3023294|NCT02407548|Experimental|CoQ10 group|each softgel contain CoQ 10 30mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 per day. The duration is 24 weeks.
3023295|NCT02407548|Other|placebo group|each softgel contain no vitamin E, no CoQ10; The subjects in this arm take 2 softgels after lunch and supper respectively per day. The duration is 24 weeks.
3023296|NCT02407535|Experimental|Endometrial carcinoma patient|
3023297|NCT02407522|Experimental|black rice group|Each subject in the experimental group will be provided with black rice (50 g/day).According to the clinical requirements, no specific rules are needed for other treatments of the two groups.
3023298|NCT02407522|Placebo Comparator|white rice group|individuals in the control group will be subjected to follow-up. According to the clinical requirements, no specific rules are needed for other treatments of the two groups.
3023299|NCT02407509|Experimental|Twice weekly|RO5126766 will be administered initially as a single daily dose of 4mg using a twice weekly dosing schedule. A cycle of treatment will comprise 28 days.
3023300|NCT02407509|Experimental|Three times weekly|RO5126766 will be administered initially as a single daily dose of 4mg using a 3 times per week dosing schedule. A cycle of treatment will comprise 28 days.
3023301|NCT02407496||ADHD|Adults with Attention Deficit Hyperactivity Disorder (ADHD)
3023302|NCT02407496||Control|Healthy individuals without ADHD
3023303|NCT02407483|Experimental|Laser Visual Guidance group|Will be tested using simulated laparoscopic tasks with the use of laser visual guidance
3023304|NCT02407483|Active Comparator|Normal 2D vision group|Will be tested using simulated laparoscopic tasks without the use of laser visual guidance
3023305|NCT02407470|Active Comparator|Rabbit antithymoglobulin （ATG）|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 with the goals of ablating host repressive T cells.
3023306|NCT02407470|Experimental|Rabbit ATG & AD-MSCs|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own adipose derived mesenchymal stem cells (AD-MSCs) at a dose of 3000000/kg/d on day 1 to 3.
3023307|NCT02407470|Experimental|Rabbit ATG & AD-HSCs|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own AD-MSC transdifferentiated HSCs (AD-HSCs) at a dose of 3000000/kg/d from day 1 to 4.
3023308|NCT02407457|Active Comparator|AFX EVAR AAA Graft System|Subjects randomized to receive the Endologix AFX Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
3023309|NCT02407457|Active Comparator|FDA Approved EVAR AAA Graft Systems|Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
3023310|NCT02407444|Experimental|Physiotherapy treatment & leg cycling|"This group will receive conventional physiotherapy treatments, each session will last 30 minutes. Treatments include muscles strength exercises for upper and lower extremities, static and dynamic balance training in standing ,pain relief techniques and functional training (including transfers, sit to stand, walking and climbing stairs). The treatment program shall be consistent with the patient's problems and the degree of difficulty will rise depending on progress.~In addition this group will have cycling training with leg cycle ergometer for 20 minutes.~This treatment protocol will last for three weeks, five days a week, 50 minutes each session per day."
3023311|NCT02407444|Active Comparator|Physiotherapy treatment & music listening|"This group will receive conventional physiotherapy treatments, each session will last 30 minutes .Treatments include muscles strength exercises for upper and lower extremities, static and dynamic balance training in standing ,pain relief techniques and functional training (including transfers, sit to stand, walking and climbing stairs). The treatment program shall be consistent with the patient's problems and the degree of difficulty will rise depending on progress.~In addition this group will listen to music (while sitting on a chair) for 20 minutes.This treatment protocol will last for three weeks, five days a week, 50 minutes each session per day."
3023312|NCT02407418|Active Comparator|Spinal Manipulation|In a repeated measures, crossover design, all subjects received spinal manipulation during the second or third session. The selection of spinal manipulation or sham was randomized.
3023313|NCT02407418|Sham Comparator|Sham Manipulation|In a repeated measures, crossover design, all subjects received the sham manipulation during the second or third session. The selection of spinal manipulation or sham was randomized.
3023314|NCT02407405|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID (approximately every 12 hours) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3023315|NCT02407392|Active Comparator|Non targeted quadrantic biopsies|Patients undergo current gold standard Barrett's surveillance with quadrantic Seattle protocol biopsies
3023316|NCT02407392|Experimental|Acetic Acid targeted biopsies|Patients undergo dye spray gastroscopy with Acetic Acid and targeted biopsies for areas of dysplasia.
3023317|NCT02407379|Active Comparator|PAPD+SRP Quadrant|This quadrant, randomly selected in each patients, undergoes treatment with PAPD+ SRP
3023318|NCT02407379|Sham Comparator|Sham-laser + SRP|This quadrant, randomly selected in each patients, undergoes treatment with sham-laser + SRP
3023319|NCT02407366|Experimental|Icotinib with concurrent radiotherapy|Icotinib (125 mg ,three times daily)with concurrent thoracic radiotherapy(TRT) (66 Gy/33 fractions), followed by maintenance icotinib (125 mg ,Three times daily) until disease progression or unacceptable toxicity.
3023366|NCT02407067|Active Comparator|Voice Amplifier|Participant will be fit with a voice amplifier (ChatterVox) and it will be used during speech testing and during regular conversations over a one week period.
3023399|NCT02406872|Experimental|Remimazolam Tosilate 3|intravenous pumping of Remimazolam Tosilate at 18mg/kg/h for anesthesia induction
3023320|NCT02407366|Active Comparator|Chemoradiotherapy|Pemetrexed(500mg/m2) + carboplatin (AUC，5) every 21 days for three cycles with concurrent thoracic radiotherapy(TRT) (66 Gy/33 fractions), followed by consolidation chemotherapy with two cycles of pemetrexed(500mg/m2) + carboplatin (AUC，5) every 21 days.Maintenance pemetrexed(500mg/m2) will be administered after consolidation chemotherapy until disease progression or unacceptable toxicity .
3023321|NCT02407353|Experimental|PF-06648671 High dose group|subjects receive a single oral dose of PF-06648671 at 300 mg
3023322|NCT02407353|Experimental|PF-06648671 Low dose group|Subjects receive a single oral dose of PF-06648671 lower than 300 mg dose
3023323|NCT02407353|Placebo Comparator|Placebo group|Subjects receive matching placebo
3023324|NCT02407353|Experimental|PF-06648671 Low dose group (2)|Optional arm. Subjects receive a single oral dose of PF-06648671 at second lower dose if 300 mg dose is not repeated in cohort 2
3023325|NCT02407340|Active Comparator|Oxytocin|intranasal oxytocin - 40 International Units (IU) dose administered 3 times daily for 1 week
3023326|NCT02407340|Placebo Comparator|Placebo|Intranasal placebo administered 3 times daily for 1 week
3023327|NCT02407314|Sham Comparator|Aspirin only|Clopidogrel 75 mg + aspirin 81 mg for the first month followed by aspirin 81 mg alone for months 2-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT) ankle brachial index (ABI) and six minute walk distance.
3023328|NCT02407314|Experimental|Aspirin + Ticagrelor|ticagrelor 90 mg bid + aspirin 81 mg for months 1-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT)ankle brachial index (ABI) and six minute walk distance.
3023329|NCT02407301||Laryngeal function in cough|cough airflow measure, vocal tasks, true vocal fold movement, spirometry test, and maximum expiratory pressure (MEP) assessment will be performed in this group.
3023330|NCT02407288|Active Comparator|active tDCS|patients will received 2 sessions per day for 5 consecutive days. Each session will last 20 minutes. The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
3023331|NCT02407288|Placebo Comparator|SHAM tDCS|The same procedure will be applied except that the tDCS device will only deliver a current stimulation for the 10 first seconds.
3023332|NCT02407275|Other|biological sample|Genomic & culturomic analyses
3023333|NCT02407262|Active Comparator|Treatment|"Black seed oil capsules~1g/day for 4 weeks"
3023334|NCT02407262|Placebo Comparator|Placebo|"Placebo (olive oil) capsules~1g/day for 4 weeks"
3023335|NCT02407236|Placebo Comparator|Induction Study - Placebo Intravenous (IV)|Participants will be randomized to receive single dose of placebo as Intravenous (IV: into the vein) infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study, but will not be randomized.
3023336|NCT02407236|Experimental|Induction Study - Ustekinumab 130 milligram (mg) IV|Participants will be randomized to receive single dose of ustekinumab 130 mg as IV infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study and will be randomized.
3023337|NCT02407236|Experimental|Induction Study - Ustekinumab 6 mg/kg IV|Participants will be randomized to receive ustekinumab approximating 6 mg/kg of body weight, as intravenous infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study and will be randomized.
3023338|NCT02407236|Other|Induction Study- Placebo- Nonresponsders at Week 8|Participants without clinical response to placebo at Week 8 will receive a single IV infusion of ustekinumab approximating 6mg/kg along with matching subcutaneous (SC) placebo (to maintain the blind). Participants in clinical response at Week 16 will be eligible to enter Maintenance study and will be randomized.
3023339|NCT02407236|Other|Induction study-Ustekinumab Nonresponders at Week 8|Participants without clinical response to ustekinumab (130 mg or 6 mg/kg [IV]) at Week 8 will receive a single dose of ustekinumab 90 mg subcutaneously along with matching placebo intravenously (to maintain the blind). Participants in clinical response at Week 16 (that is, delayed responders) will be eligible to enter Maintenance study, but will not be randomized.
3023340|NCT02407236|Placebo Comparator|Maintenance Study - Placebo Subcutaneous (SC)|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44.
3023341|NCT02407236|Experimental|Maintenance Study - Ustekinumab 90mg SC every 12 weeks|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive ustekinumab 90 mg subcutaneously every 12 weeks, beginning Week 0 of Maintenance study through Week 44.
3023342|NCT02407236|Experimental|Maintenance Study - Ustekinumab 90mg SC every 8 weeks (q8w)|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive ustekinumab 90 mg subcutaneously every 8 weeks, beginning Week 0 of Maintenance study through Week 44.
3023343|NCT02407236|Other|Maintenance Study - Placebo IV - Responder - Placebo SC|Participants in clinical response to Induction treatment with IV Placebo will receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44. Participants are not randomized.
3023344|NCT02407236|Other|Maintenance Study-Delayed Responder-Ustekinumab 90mg SC q8w|Participants without clinical response to induction treatment ustekinumab (130 mg or 6 mg/kg [IV]) at Week 8 but in clinical response at Week 16 after receiving Induction Ustekinumab at week 8 (delayed responders) will receive ustekinumab 90 mg subcutaneously every 8 weeks, beginning Week 0 of Maintenance study through Week 44. Participants are not randomized.
3023367|NCT02407067|Experimental|Personal Communication System|Participant will be fit with a personal communication system (Easy Listener FM system) and it will be used during speech testing and during regular conversations over a one week period.
3023368|NCT02407054|Experimental|LY3023414 + Enzalutamide|Lead In- LY3023414 orally twice daily in first week for pharmacokinetics (PK); thereafter LY3023414 orally twice daily in combination with enzalutamide orally once daily for 28-day cycles. Randomization- LY3023414 orally twice daily in combination with enzalutamide orally once daily for 28-day cycles. Participants may remain on treatment until discontinuation criteria are met.
3023400|NCT02406872|Active Comparator|Propofol|single IV bolus of Propofol at 2.0-2.5mg/kg for anesthesia induction
3023345|NCT02407223|Placebo Comparator|Group 1: Placebo|Participants will receive placebo subcutaneously (SC) at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 milligram (mg) SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with < 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88. NOTE: Intervention Description should have no more than 800 characters.
3023346|NCT02407223|Experimental|Group 2: Ustekinumab 45 milligram (mg)|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
3023347|NCT02407223|Experimental|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
3023348|NCT02407210|Experimental|azilsartan group|Once-daily oral administration of 20 or 40 mg tablet before or after breakfast
3023349|NCT02407210|Active Comparator|olmesartan medoxomil group|Once-daily oral administration of 20 or 40 mg tablet before or after breakfast
3023350|NCT02407184|No Intervention|Scheduled C-section|Babies that are scheduled to be born in a hospital via standard C-section procedure.
3023351|NCT02407184|No Intervention|Vaginal Delivery|Babies that are born via vaginal delivery, either at home, at a birthing center or hospital. Drugs may be administered during labor.
3023352|NCT02407184|Experimental|Scheduled C-section with Exposure|Babies that are scheduled to be born in a hospital via standard C-section procedure, as well as are swabbed with gauze containing their mother's vaginal microbiota just after delivery. The intervention: Newborn exposure to mother vaginal microbiota.
3023353|NCT02407171|Experimental|Non Small Cell Lung Cancer, Phase I|Dose escalation cohort for patients with Non Small Cell Lung Cancer (NSCLC). The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction). If there is dose-limiting toxicity at the lowest cohort, that arm will be closed and SBRT to that site will be discontinued.
3023354|NCT02407171|Experimental|Non-Lung, Phase I|Dose escalation cohort for non lung cancer patients. The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction). If there is dose-limiting toxicity at the lowest cohort, that arm will be closed and SBRT to that site will be discontinued.
3023355|NCT02407171|Experimental|Melanoma Expansion Cohort|Phase 2a expansion cohort for patients with melanoma. Patients will be treated at the maximum tolerated dose discovered in phase I.
3023356|NCT02407171|Experimental|Non Small Cell Lung Cancer Expansion Cohort|Phase 2a expansion cohort for patients with NSCLC. Patients will be treated at the maximum tolerated dose discovered in phase I.
3023357|NCT02407145||PVDF retropubic midurethral sling|Women with urodynamic stress urinary incontinence having a retropubic polyvinylidene fluoride midurethral sling (DynaMesh®-SIS soft).
3023358|NCT02407132|No Intervention|Traditional DSME|Traditional diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
3023359|NCT02407132|Experimental|Family Model DSME|Participants assigned to this arm will received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
3023360|NCT02407119|Active Comparator|7 day H.pylori eradication|Treatment: Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
3023361|NCT02407119|Placebo Comparator|Placebo|Omeprazole 20 mg or Rabeprazole 10 mg bid + Placebo for two antibiotics (clarithromycin and amoxicillin) bid for 7 days
3023362|NCT02407106|Experimental|BLIS K12 treatment|Once daily tablet of Streptococcus Salivarius BLIS K 12 to be slowly dissolved orally every evening for six month
3023363|NCT02407093|Experimental|High-Intensity Functional Training|CrossFit will be the HIFT intervention framework with training elements, exercise programming, and scheduling set by CrossFit staff. Workouts will be comprised of one or more of three exercise modalities: aerobic/monostructural (e.g., running), gymnastics (e.g., pullups), and weightlifting/resistance training with workouts designed to maximize use of equipment available in deployed environments (e.g.,vehicle tires). All workouts will be individually scaled to each soldier's current level of fitness by a certified trainer. Sessions will be standardized across the 6 months of intervention so that each cluster will receive exactly the same training.
3023364|NCT02407093|Active Comparator|Army Physical Readiness Training|"The APRT program has combat readiness as the primary focus and is mandated for active duty personnel. For this study, APRT sessions have been standardized across the 6 months of the intervention according to FM 7-22 Army Physical Readiness Training manual so each cluster will receive the same training program using the Reset Phase. Sessions will consist of preparation, activities and recovery and will include strength, endurance, and mobility exercises that involve on-ground (e.g., running), off-ground (e.g., climbing), and combatives (e.g., striking and grappling) training, with supervision by a certified trainer."
3023365|NCT02407080|Experimental|RG7388|"Part A: RG7388 as a single agent; given at a starting dose of 100 mg each day for five days for the first cycle which will be 56 days.~Part B: combination of RG7388 and Pegasys if subject does not achieve at least a PR by the end of 3 cycles of single agent RG7388"
3056744|NCT02183220|Active Comparator|Acetylsalicylic acid & Placebo|
3023369|NCT02407054|Active Comparator|Enzalutamide + Placebo|Enzalutamide orally once daily in combination with matching LY3023414 placebo orally twice daily for 28-day cycles. Participants may remain on treatment until discontinuation criteria are met.
3023370|NCT02407041|Experimental|GR-MD-02|active arm
3023371|NCT02407028|Experimental|Hyperbaric Oxygen|Patients in this arm will be assigned to one of three different pressures of hyperbaric oxygen with or without normobaric hyperoxia
3023372|NCT02407028|Active Comparator|NBH|Patients will be assigned to normobaric hyperoxia only
3023373|NCT02407028|Placebo Comparator|Placebo|Patients will be assigned to usual care
3023374|NCT02407015|Active Comparator|3D gameplay|Participants will play a game for 30 minutes on the Nintendo 3DS in 3D.
3023375|NCT02407015|Active Comparator|2D gameplay|Participants will play a game for 30 minutes on the nintendo 3DS in 2D.
3023376|NCT02406989|Experimental|MS-553|MS-553 oral tablet BID x 14 days
3023377|NCT02406989|Placebo Comparator|Placebo|Placebo oral tablet BID x 14 days
3023378|NCT02406976|Experimental|G1- EXERCISE|The group will Participate in an physical exercise program twice a week. This program consists of 20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.
3023379|NCT02406976|Experimental|G2- EXERCISE AND LIFESTYLE|"This groups will receive the same intervention of G1 group, associated with the weekly group with a psychologist.~These groups worked techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors, as well as the reduction or elimination of undesirable conduct."
3023380|NCT02406976|Active Comparator|G3- CONTROL|This group will keep the routine treatment in outpatient of bariatric surgery. This treatment consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
3023381|NCT02406963|Active Comparator|TTC|Current standard of care- a telephone call with the NP in the event of a post-operative concern where advice/interventions/reassurance is provided based on information provided by family
3023382|NCT02406963|Experimental|PEC|Experimental arm, the standard telephone call with the NP and the addition of a digital photograph of the surgical site for assessment prior to the administration of advice
3023383|NCT02406950|Experimental|Sitagliptin|All participant will exam brachial artery endothelium-dependent flow-mediated dilatation (FMD). After then, pneumatic cuff wiil be inflated to 200 mmHg for 15 minutes to induce brachial artery ischemia. At the end of ischemia, 15 minutes of reperfusion was performed to induce reperfusion injury. After ischemia-reperfusion (IR) injury, brachial artery FMD will be measured again. After randomization, sitagliptin group will be treated by single dose of sitagliptin (Januvia) 50mg. In 2 hours later, brachial artery FMD measurement, IR injury and brachial artery FMD measurement will be measured again.
3023384|NCT02406950|Placebo Comparator|Placebo|After brachial artery FMD measurement, IR injury for each 15 minutes will be performed, and brachial artery FMD will be measured again. After randomization, placebo group will be treated by nothing. In 2 hours later, brachial artery FMD measurement, IR injury and brachial artery FMD measurement will be measured again.
3023385|NCT02406950|Other|Sitagliptin and glibenclimide|If sitagliptin treatment show preventive effects of IR injury, the investigator will perform additional experiment to explore the mechanism (Protocol 2 study). Additional 15 healthy volunteers will be treated 5 mg of glibenclamide (Euglucon) 1 hour before administration of 50 m g of sitagliptin. In 2 hours after sitagliptin administration, FMD measurement before and after IR injury will be performed as described above.
3023386|NCT02406937|Experimental|Feihe New Formula|Oral intake of Feihe new formula with hydrolyzed protein supplied by Arla Foods Ingredients.
3023387|NCT02406937|Active Comparator|Feihe Stage 1 Formula|Oral intake of Feihe stage 1 formula
3023388|NCT02406937|Placebo Comparator|Breast Feeding|Oral intake of breast milk
3023389|NCT02406924|Experimental|Sausage graft|Bone graft performed with a mixture of particulated autogenous and lyophilized bovine bone, stabilized with collagen membrane and pins.
3023390|NCT02406924|Active Comparator|Bone block graft|Bone graft performed with a block of autogenous bone stabilized by a screw associated with lyophilized bovine bone and collagen membrane.
3023391|NCT02406911|Experimental|Ticagrelor 90 mg|After randomization, an initial loading dose of ticagrelor (180 mg) was given and low dose ticagrelor (ticagrelor 90 mg once a day) was treated for 14 days.
3023392|NCT02406911|Active Comparator|Ticagrelor 180 mg|After randomization, an initial loading dose of ticagrelor (180 mg) was given and usual dose ticagrelor (ticagrelor 90 mg twice a day) was treated for 14 days.
3023393|NCT02406898|Experimental|hysteroscopic surgery with morcellation technic|"The hysteroscope with the MH system will be introduced. Resection of fibroids or both will be realized. The procedure will end or when the fibroids will be completely resected.~the procedure may be suspended before complete resection of fibroids or uterine perforation or higher operating time to 90 minutes or amount of liquid used distension than 9 liters or distension fluid deficit of more than one liter ."
3023394|NCT02406898|Active Comparator|conventional hysteroscopy technic with resection.|"The hysteroscope with conventional resection system will be introduced. Resection of fibroids or both will be realized. The procedure will end or when the fibroids will be completely resected.~the procedure may be suspended before complete resection of fibroids or uterine perforation or higher operating time to 90 minutes or amount of liquid used distension than 9 liters or distension fluid deficit of more than one liter (4 )."
3023395|NCT02406885|Active Comparator|APB study: Apixaban Pharmacokinetics in VSG|To determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index (BMI) of 35 kg/m2 or greater pre vs. post surgery for patients undergoing vertical sleeve gastrectomy
3023396|NCT02406885|Active Comparator|APB study: Apixaban Pharmacokinetics in RYGB|To determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index (BMI) of 35 kg/m2 or greater pre vs. post surgery for patients undergoing Roux-en Y gastric bypass.
3023397|NCT02406872|Experimental|Remimazolam Tosilate 1|IV pumping of Remimazolam Tosilate at 6mg/kg/h for anesthesia induction
3023398|NCT02406872|Experimental|Remimazolam Tosilate 2|intravenous pumping of Remimazolam Tosilate at 12mg/kg/h for anesthesia induction
3023401|NCT02406859|Experimental|Anorectal Manometry|Part 1 [Anorectal Manometry]: Fifty SCI subjects and 15 AB subjects will undergo anorectal manometry and a baseline assessment of level of constipation or frequency of fecal incontinence (FI). Additional 10 able-bodied subjects will be enrolled to serve as controls. The 10 Question Bowel Survey and Incontinence Scale will be administered.
3023402|NCT02406859|Experimental|Bowel Biofeedback Training|Part 2 [Bowel Biofeedback]: A subgroup of 20 subjects who participated in the first arm of the study (Anorectal Motility) and report either constipation or fecal incontinence will be asked to participate in 12 weeks of twice weekly, biofeedback training. The biofeedback training will consist of in-lab exercises that are paired with a visual feedback. Anorectal manometry and bowel surveys will be repeated after the training session to assess the effects of bowel biofeedback on anorectal function.
3023403|NCT02406846||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
3023404|NCT02406846||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
3023405|NCT02406846||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
3023406|NCT02406846||cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
3023407|NCT02406833|Experimental|TGF-β2 antisense oligonucleotide|"Core Study: Administered intravitreally at the time of trabeculectomy at escalating doses~Post-Study Follow-up: until 1 year after administration"
3023408|NCT02406820||No Indwelling PAC, Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is not clinically indicated and who are registered to twice daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
3023409|NCT02406820||Indwelling PAC, Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is clinically indicated and who are registered to three times daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
3023410|NCT02406820||No Indwelling PAC, No Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is clinically indicated and who are registered to no daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
3023411|NCT02406807|Experimental|HVLA manipulation|Osteopathic high velocity, and low amplitude spinal lumbar manipulation
3023412|NCT02406807|Sham Comparator|Sham Spinal lumbar manipulation|Just position in the side lying and not performed the high velocity and low amplitude
3023413|NCT02406794|Experimental|Neuromuscular taping|The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
3023414|NCT02406794|No Intervention|No Kinesio taping|No Kinesio taping
3023415|NCT02406781|Experimental|Combination of MK3475 with Metronomic CP|Combination of MK3475 with Metronomic CP. MK3475 will be administered intraveinously Metronomic CP (Cyclophosphamide) will be adminstered orally.
3023416|NCT02406768||HIV negative unexposed|HIV negative controls
3023417|NCT02406768||HIV negative exposed|HIV-negative children born to HIV-infected mothers
3023418|NCT02406755|No Intervention|Control|This control group will not receive an intervention.
3023419|NCT02406755|Active Comparator|one-sensory self care|Daily moisturizing body care with an odorless moisturizer (Todo Dia® - Natura) for 30 days.
3023420|NCT02406755|Active Comparator|bi-sensory self care|Daily moisturizing body care with a moisturizer with cotton fragance (Todo Dia® - Natura) for 30 days.
3023421|NCT02406755|Active Comparator|multisensory self care|Daily moisturizing body care with a moisturizer with cotton fragance (Todo Dia® - Natura) for 30 days, and will watch a video with music and images of nature during self-care.
3023422|NCT02406742|Experimental|CC-122 Single Agent|An intrasubject dose escalation design was selected to determine the safety of single agent CC-122 (Arm A) in order to reach an optimal, clinically active dose and to mitigate the risk of early tumor flare reactions, based on earlier experience with lenalidomide monotherapy in CLL.
3023423|NCT02406742|Experimental|CC-122 in combination with ibrutinib|Ascending fixed dose cohorts evaluated in a 3 + 3 dose-finding design will be used to determine the safety and tolerability of the combination of CC-122 and ibrutinib to determine the NTD, MTD, and Recommended Phase 2 Dose (RP2D). An intrasubject dose escalation cohort may also be evaluated at the discretion of the Safety Review Committee. The RP2D of the combination may be evaluated in ibrutinib-naïve and high-risk CLL patients in the dose expansion phase to continue to evalute safety and efficacy.
3023424|NCT02406742|Experimental|CC-122 in combination with obinutuzumab|Ascending fixed dose cohorts evaluated in a 3 + 3 dose-finding design will be used to determine the safety and tolerability of the combination of CC-122 and obinutuzumab to determine the , MTD, and Recommended Phase 2 Dose (RP2D). An intrasubject dose escalation cohort may also be evaluated at the discretion of the Safety Review Committee.. The RP2D of the combination may be evaluated in CLL patients who failed a B-cell receptor pathway inhibitor or venetoclax in the dose expansion phase to continue to evalute safety and efficacy.
3023425|NCT02406729|Experimental|Dengue 1,2,3,4 (attenuated) vaccine|Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC
3023426|NCT02406729|Placebo Comparator|Placebo|Placebo Single dose, SC
3023427|NCT02406716||HF|Heart failure patients
3023428|NCT02406716||Controls|Healthy donors
3023429|NCT02406703||Chloroprocaine|Patient undergoing popliteal block with chloroprocaine
3023430|NCT02406703||Mepivacaine|Patient undergoing popliteal block with mepivacaine
3023431|NCT02406690||Case Group|Patients who failed to achieve adequate endometrial lining during a synthetic embryo transfer. This group will undergo a Leuprolide prep cycle using estradiol valerate, progesterone in oil and subsequently undergo an endometrial biopsy and uterine aspiration.
3023432|NCT02406690||Control Group|Patients who have achieved an adequate endometrial lining. This group will undergo a Leuprolide prep cycle using estradiol valerate, progesterone in oil and subsequently undergo an endometrial biopsy and uterine aspiration.
3056745|NCT02183220|Placebo Comparator|Placebo|
3023433|NCT02406677|Experimental|Copayment Intervention Arm|Sites in the intervention arm will provide patients with a study voucher card to offset any patient copayments or medication card for the filling of any prescriptions of clopidogrel or ticagrelor.
3023434|NCT02406677|No Intervention|Usual Care Arm|For hospitals randomized to the control arm, all patients receive usual care and no study intervention is performed.
3023435|NCT02406664|Experimental|Obese patients|15 Obese patients (BMI>30) having one of comorbidity (type 2 diabetes, dyslipidemia, or hypertension) and morbid obese patients (BMI>35) accepted for bariatric surgery.
3023436|NCT02406664|No Intervention|Control patients|15 matched controls receiving Intensive medical therapy
3023437|NCT02406651|Experimental|F-652 and systemic coritcosteroids|Subjects will be dosed once a week for four weeks with Recombinant Human Interleukin-22 IgG2-Fc (F-652). Dosing will be concurrent with systemic corticosteroids.
3023438|NCT02406638||TVT Group|Women who underwent to stress urinary incontinence surgery using Gynecare TVT 3 years before clinical and 3D pelvic floor ultrasound evaluation.
3023439|NCT02406638||TVT-O Group|Women who underwent to stress urinary incontinence surgery using Gynecare TVT Obturator System, inside-out approach, 3 years before clinical and 3D pelvic floor ultrasound evaluation.
3023440|NCT02406638||TVT-S Group|"Women who underwent to stress urinary incontinence surgery using GynecareTVT-Secur System, in U approach, 3 years before clinical and 3D pelvic floor ultrasound evaluation."
3023441|NCT02406625|Experimental|Diaclectical Behavioral Therapy|15 adolescents with history of suicidal behaviors receiving Dialectical Behavioral Therapy.
3023442|NCT02406625|Experimental|Support Therapy|15 adolescents with history of suicidal behaviors receiving Support Therapy.
3023443|NCT02406625|No Intervention|Controls|A group of 15 healthy controls that are not receiving any kind of therapy.
3023444|NCT02406612|Experimental|X-Seal 6F Vascular Closure Device|The X-Seal 6F Vascular Closure device will be used to achieve hemostasis in both diagnostic and interventional procedures using up to a 6F procedure sheath.
3023445|NCT02406599|Other|SOC + Device|The surgeon will perform routine standard of care lumpectomy with adjunctive MarginProbe device use on the main ex-vivo lumpectomy specimen.
3023446|NCT02406599|Other|SOC + Additional Inspection|The surgeon will perform routine standard of care lumpectomy with additional inspection on the main ex-vivo lumpectomy specimen.
3023447|NCT02406586|Experimental|Salsalate|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one salsalate 750 mg tablet twice daily for two weeks. If the subject has no side effects, the dose will be increased to two salsalate 750 mg tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
3023448|NCT02406586|Experimental|Carvedilol|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one carvedilol 3.125 mg tablet twice daily for two weeks. If the subject has no side effects, the dose will be increased to two carvedilol 3.125 mg tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
3023449|NCT02406586|Placebo Comparator|Placebo|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one placebo tablet twice daily for two weeks. The dose will be increased to two placebo tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
3023450|NCT02406573|Active Comparator|Crest® Sensi-Stop™ Strips|Professionally Applied
3023451|NCT02406560|Experimental|4 tablets of 12.2 mg tafamdis free acid|
3023452|NCT02406560|Experimental|4 tablets of 12.2 mg tafamidis free acid|
3023453|NCT02406560|Experimental|5 tablets of 12.2 mg tafamidis free acid|
3023454|NCT02406547|Experimental|WLE-NBI|Participants will be evaluated by same endoscopist, back-to-back tandem colonoscopy. It consists of two withdrawal from the cecum to sigmoid colon using firstly High Definition White Light Endoscopy (WLE) and secondly Narrow Band Imaging (NBI). All detected polyps will be classified macroscopically and resected in each withdrawal.
3023455|NCT02406547|Experimental|NBI-WLE|Participants will be evaluated by same endoscopist, back-to-back tandem colonoscopy. It consists of two withdrawal from the cecum to sigmoid colon using firstly Narrow Band Imaging (NBI) and secondly High Definition White Light Endoscopy (WLE). All detected polyps will be classified macroscopically and resected in each withdrawal.
3023456|NCT02406534||Normal Pulmonary Function|
3023457|NCT02406534||Reduced Pulmonary Function|
3023458|NCT02406521|Experimental|Arm A: Pazopanib with Radium-223|"No prior targeted therapy~Pazopanib oral, daily and at predetermined dosage per cycle~Radium-223 predetermined dosage via IV, per cycle"
3023459|NCT02406521|Experimental|Arm B: Sorafenib with Radium-223|"At least one line of prior targeted therapy:~Sorafenib at predetermined dosage, mouth twice daily~Radium-223 predetermined dosage via IV, per cycle"
3023460|NCT02406508|Experimental|Hepatic Delivery System Treatment followed by Sorafenib|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System.~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 3 cycles of treatment.~After the Melphalan/HDS treatment patients will be treated with sorafenib according to the package prescribing information."
3023461|NCT02406495|Experimental|filcon IV 1 and ocufilcon D|Habitual wearers of filcon IV 1 sphere lenses refitted with asphere ocufilcon D lenses.
3023462|NCT02406482|Experimental|HIVRR + MF|Four sessions of education and intervention (Behavioral: HIV risk reduction (HIVRR)) followed by financial literacy, micro-savings and vocational training (Behavioral: Microfinance intervention (MF)).
3023463|NCT02406482|Active Comparator|HIVRR only|Four sessions of education and intervention (Behavioral: HIV risk reduction (HIVRR)).
3023464|NCT02406469|Experimental|Sequence A1-A2|Oral consumption of milk containing both A1 and A2 type beta casein in intervention phase 1 and milk containing only A2 type beta casein in intervention phase 2.
3023465|NCT02406469|Placebo Comparator|Sequence A2-A1|Oral consumption of milk containing only A2 type beta casein in intervention phase 1 and milk containing both A1 and A2 type beta casein in intervention phase 2.
3023466|NCT02406456|Experimental|Neurofeedback|
3023467|NCT02406443|Experimental|Experimental arm|sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
3023468|NCT02406443|Placebo Comparator|Placebo arm|placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
3023469|NCT02406417|Experimental|Investigation for pituitary dysfunction|Further investigation for pituitary dysfunction by blood tests, dynamic function tests and pituitary imaging e.g. CT Scan with contrast. Patients identified as being at high risk of having pituitary dysfunction based on preliminary blood tests will have further tests added. If these results point to a likely pituitary dysfunction, the patient will be referred to the Endocrine team for further investigations including dynamic function tests and/or imaging.
3023470|NCT02406404|Experimental|spirometer training group|incentive spirometer training group
3023471|NCT02406404|Placebo Comparator|No intervention group|no intervention group
3023472|NCT02406365|Experimental|Standard of care plus imaging with research devices|"Eligible patients who consent to participate in the research study will receive their standard of care colposcopy or treatment with the Loop Electrosurgical Excision Procedure (LEEP). Additionally, cervical images will be taken using the diagnostic imaging aid. The cervical images will be compared to the histopathology from the biopsies taken as part of the patients' standard of care for colposcopy. If the patient is presenting for the LEEP procedure, then she will be asked if one or two biopsies can be obtained prior to the procedure but after anesthesia has been administered.~The imaging device is not being used to make a diagnosis, but rather to develop an algorithm to make more efficacious and timely diagnoses of cervical neoplasias in the future."
3023473|NCT02406352|Experimental|Routine colposcopy and MDC with probe|The intervention which consists of obtaining cervical images with the MDC and spectroscopic data with the probe will be applied to all participants who agreed to participate in the study during their visit for a colposcopy exam or treatment with a LEEP procedure. A control biopsy will also be obtained from patients who agree to provide it. The control biopsy is a biopsy of cervical tissue that does not appear to have atypical changes when observed through a standard of care colposcope.
3023474|NCT02406339|No Intervention|Control|Are not subject to any intervention.
3023475|NCT02406339|Experimental|Electrotherapy|The athletes will be submitted to NMES of bilateral quadriceps. The stimulation will be held in order to induce the move flexion / extension involuntary knee in extension machine, with resistance of 30% of maximum voluntary strength.
3023476|NCT02406339|Experimental|Electrotherapy + Vascular Occlusion|The same as in Electrotherapy group, athletes are subjected to NMES associated total vascular occlusion of the members below the level of the groin.
3023477|NCT02406313|Experimental|CTS + ETP|Patients following a standardized thermal cure (CTS) follow an additional program called Fibr'eaux (ETP) that consists in discussion groups and physical activities allowing patients to learn how to manage their illness.
3023478|NCT02406313|Active Comparator|CTS alone|Patients follow a standardized thermal cure that is a sedative, relaxing, antalgic and mobilizing treatment based on muds application, hydrotherapy and physiotherapy. The cure is made of 72 treatments selected among a list including muds application, massages, reeducation in thermal pool, baths and showers.
3023479|NCT02406300|Active Comparator|Subarachnoid anesthesia|"Patients submitted to subarachnoid anesthesia for proximal femur fracture surgical repair.~Up to 12.5 mg of bupivacaine or levobupivacaine will be used"
3023480|NCT02406300|Active Comparator|PNB/GA|Patients are submitted to a femoral, a lateral cutaneous nerve of the thigh and an anterior obturator nerve blocks with ropivacaine and an inhalational general anesthesia with sevoflurane or desflurane
3023481|NCT02406287|Experimental|Active|Netarsudil (AR-13324) Ophthalmic Solution
3023482|NCT02406287|Placebo Comparator|Placebo|Netarsudil (AR-13324) Ophthalmic Solution Placebo
3023483|NCT02406274|Experimental|Contrast Enhanced Spectral Mammography|
3023484|NCT02406261|Experimental|Cohort A|"500 microgram (mcg) midazolam, single oral dose on Days 1, 17, and 35;~20 mg simvastatin, single oral dose on Days 2 and 36;~250 microgram (mcg) midazolam, intravenous (IV) on Days 3 and 37;~50 mg lanabecestat, single oral dose on Day 4;~50 mg lanabecestat, single oral dose, Days 10 to 37"
3023485|NCT02406261|Experimental|Cohort B|"5 mg donepezil, single oral dose on Day 1, Period 1;~50 mg lanabecestat, single oral dose Days 1 to 43, Period 2;~5 mg donepezil, single oral dose on Day 28, Period 2"
3023486|NCT02406248|Experimental|single arm|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
3023487|NCT02406222|Active Comparator|Pomalidomide and Dexamethasone|"Pomalidomide and Dexamethasone will be administered as part of a 28 day cycle. Patients will continue with their treatment until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~Pomalidomide 4mg orally on days 1-21~Dexamethasone 40mg orally on days 1, 8, 15 and 22"
3023488|NCT02406222|Experimental|Pomalidomide Dexamethasone Cylcophosphamide|"Pomalidomide, Dexamethasone and Cyclophosphamide will be administered as part of a 28 day cycle. Patients will continue with their treatment until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~Pomalidomide 4mg orally on days 1-21~Dexamethasone 40mg orally on days 1, 8, 15 and 22~Cyclophosphamide 500mg orally on days 1, 8 and 15"
3023489|NCT02406209|Experimental|NS2|NS2 ophthalmic drops (0.5%) in the affected eye
3023490|NCT02406209|Experimental|NS2 and Pred Forte|NS2 ophthalmic drops (0.5%) and Prednisolone acetate ophthalmic suspension (1%) in the affected eye
3023491|NCT02406209|Active Comparator|Pred Forte|Prednisolone acetate ophthalmic suspension (1%) in the affected eye
3023492|NCT02406183|Experimental|Treatment (SBRT, Ipilimumab)|"Drug: Ipilimumab Dosage: Ipilimumab will be administered intravenously at 3 mg/kg every 3 weeks for 4 cycles,~Radiation: Stereotactic Body Radiotherapy Radiation therapy 24 Grays in 8 Grays fractions, Radiation therapy 30 Grays in 10 Grays fractions, Radiation therapy 36 Grays in 12 Grays fractions"
3023493|NCT02406170|Experimental|Regorafenib+Paclitaxel|Regorafenib tolerability will be tested in a dose escalation scheme with a cytotoxic backbone of paclitaxel 80mg/m2.
3023494|NCT02406157|Experimental|577-MPL|577nm micropulse laser photocoagulation(577MPL) treatment to the macular area of retinal thickening with a focal or grid pattern
3023495|NCT02406157|Active Comparator|532-SLP|532nm subthreshold laser photocoagulation(532-SLP) treatment to the macular area of retinal thickening with a focal or grid pattern
3023496|NCT02406144|Active Comparator|Lenalidomide|Oral administration of 15 mg/day of oral lenalidomide on days 1-21, and 20 mg/day of dexamethasone administered orally on days 1-4 and 9-12 for a period of two years
3023672|NCT02404922|Experimental|CTP-730 Low Dose or Matching Placebo|Capsule, once daily.
3023497|NCT02406144|Experimental|MLN9708 plus Lenalidomide|MLN9708 during the two year maintenance period, at a dose of 4 mg/day on days 1, 8 and 15 of the cycle.
3023498|NCT02406131|No Intervention|Control Group:|This group will be getting all the routine work up including Duplex scan . we will add request for inflammatory and coagulation markers in their blood samples before and after intervention . The pre-op blood sample will be collected within the 24 hours before intervention and the post intervention in the 24 hrs after (second RIPC window). The repeated duplex scan will be schedule after 6 months.
3023499|NCT02406131|Active Comparator|RIPC Group|Remote Ischemic Preconditioning Group (RIPC):This group will have all the tests as for the control group with the additional component will be preconditioning. One hour prior to procedure candidates in this group will have structured intermittent periods of induced remote ischaemic preconditioning using standard blood pressure cuffs. The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles, which needs 40 minutes.
3023500|NCT02406118|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
3023501|NCT02406105|Experimental|Radiosurgical thalamotomy|Cyber Knife based functional radiosurgical thalamotomy, photons 6MV, single dose 70-110 Gy
3023502|NCT02406092|Experimental|Rituximab|Participants with FL and DLBCL will receive rituximab SC 1400 milligrams (mg) once a month for a minimum of 4 cycles as induction therapy. Participants with FL will continue to receive rituximab once in 2 months for a minimum of 6 cycles as maintenance therapy according to local standards of care. Participants will also receive standard chemotherapy regimen (CHOP [cyclophosphamide+doxorubicin+vincristine+prednisone], CVP [cyclophosphamide+vincristine+prednisone] or FC [fludarabine+cyclophosphamide]) during induction.
3023503|NCT02406079|Experimental|tracheotomy|
3023504|NCT02406066|Placebo Comparator|Placebo|Subjects will receive capsules containing no active pharmaceutical ingredients.
3023505|NCT02406066|Active Comparator|Low Dose (Cohort 1)|270 mg metyrapone and 12 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
3023506|NCT02406066|Active Comparator|Medium Dose (Cohort 2)|540 mg metyrapone and 24 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
3023507|NCT02406066|Active Comparator|High Dose (Cohort 3)|720 mg metyrapone and 24 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
3023508|NCT02406053||OSAS|Obstructive sleep apnea syndrome
3023509|NCT02406053||COPD|Chronic obstructive pulmonary disease
3023510|NCT02406053||LC|Lung cancer
3023511|NCT02406053||HC|Healthy controls
3023512|NCT02406040|Experimental|High Protein|2.4g protein/kg/d. The macronutrient composition will be 50:15:35 (carbohydrates:fat:protein) during Energy Restriction
3023513|NCT02406040|Experimental|Adequate Protein|1.2g protein/kg/d. The macronutrient composition will be 50:35:15 (carbohydrates:fat:protein) during Energy Restriction
3023514|NCT02406027|Experimental|Double-blind Treatment Phase: JNJ-54861911, 10 mg|Participants will continue with their current treatment regimen (10 milligram [mg] of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 10 milligram (mg) of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
3023515|NCT02406027|Experimental|Double-blind Treatment Phase: JNJ-54861911, 25 mg|Participants will continue with their current treatment regimen (25 mg of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 25 mg of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
3023516|NCT02406027|Placebo Comparator|Double-blind Treatment Phase: Placebo|Participants will continue with their current treatment regimen established in the parent study of JNJ-54861911. Participants will receive placebo matching to JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
3023517|NCT02406027|Active Comparator|Open-label Phase: JNJ-54861911, 5 mg|Participants who were receiving JNJ-54861911, 10 mg and placebo in the DB treatment phase, will receive the 5 mg JNJ-54861911 once daily up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) in Open-label phase.
3023518|NCT02406027|Active Comparator|Open-label Phase: JNJ-54861911, 25 mg|Participants who were receiving JNJ-54861911, 25 mg in the DB treatment phase, will continue to receive the same regimen in open-label treatment phase. Participants who were receiving placebo in the DB treatment phase will be randomly assigned to receive 25 mg of JNJ-54861911 once daily up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) in the open-label treatment phase.
3023519|NCT02406014|Active Comparator|Treatment Group A|Ingenol mebutate gel 0.015%, once daily for 3 consecutive days for the first treatment course. At 8 weeks after treatment initiation, subjects who present with existing AKs or newly emergent AKs in the treatment area will receive one more treatment course of ingenol mebutate gel 0.015%, daily for 3 consecutive days.
3023520|NCT02406014|Active Comparator|Treatment Group B|Diclofenac sodium gel 3%, (0.5 grams), twice daily for 90 days.
3023521|NCT02406001|Experimental|Tigran PTG|Surgical intervention: open flap debridement and implantation of bone grafting material
3023522|NCT02406001|Other|Control|Surgical intervention: open flap debridement
3023523|NCT02405988|Experimental|Intravenous naloxone|0,4 mg/ml Naloxone B Braun 2,5 ML intravenously
3023524|NCT02405975|No Intervention|Control|These participants will not receive the educational intervention
3023525|NCT02405975|Experimental|Intervention|"These participants will receive the online educational intervention SCRIPT"
3023526|NCT02405962|Placebo Comparator|An educational talk (Usual care group)|Parents of children with asthma, will receive one session of asthma educational talk as an usual care, plus three weekly sessions of assessment only by telephone.
3023527|NCT02405962|Experimental|ACT group|In addition to asthma educational talk as usual care, parents of children with asthma will receive four sessions of group-based ACT integrated with asthma education.
3023528|NCT02405949||T2D 40%EWL|15 pacients who had type 2 diabetes before bariatric surgery and presented with less than 40% of the excess weight loss after 12 month from surgery.
3023529|NCT02405949||nonT2D40%EWL|15 pacients without type 2 diabetes before bariatric surgery and presented with less than 40% of the excess weight loss after 12 month from surgery.
3023530|NCT02405949||T2D75%EWL|35 pacients who had type 2 diabetes befor bariatric surgery and presented with more than 75% of the excess weight loss after 12 month from surgery.
3023531|NCT02405949||nonT2D75%EWL|35 pacients without type 2 diabetes befor bariatric surgery and who presented with more than 75% of the excess weight loss after 12 month from surgery.
3023532|NCT02405923|Experimental|HRF (Rice formula)|Hydrolyzed Rice Protein Formula (HRF)
3023533|NCT02405923|Placebo Comparator|eHF (Extensive Hydrolysed Formula)|Extensive Hydrolysed Cow's Milk Protein Formula (eHF)
3023534|NCT02405910|Experimental|A - Nab-paclitaxel 100mg + Gemcitabine 1250mg|Nab-paclitaxel 100 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on days 1, 8 and 15 of a 21 day cycle. On days 1 and 8 of each cycle, nab-paclitaxel administration will be followed by the administration of gemcitabine 1250 mg/m2 as a 30 minute infusion (maximum 40 minutes).
3023535|NCT02405910|Experimental|B - Nab-paclitaxel 125mg + Gemcitabine 1000mg|Nab-paclitaxel 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on days 1, 8 and 15 of a 28 day cycle. Each nab-paclitaxel administration will be followed by the administration of gemcitabine 1000 mg/m2 as a 30 minute infusion (maximum 40 minutes) on days 1, 8 and 15. Treatments will be repeated until progression or intolerance.
3023536|NCT02405897|Experimental|Cup forceps|4 biopsies (transbronchial lung biopsy) with Cup forceps
3023537|NCT02405897|Active Comparator|Alligator forceps|4 biopsies (transbronchial lung biopsy) with Alligator forceps
3023538|NCT02405884|Other|measurement of intraocular pressure|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
3023539|NCT02405858|Experimental|Abiraterone Acetate|Participants will receive abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily, concomitantly with oral prednisolone 10 mg per day. No food should be consumed for at least 2 hours before the dose of abiraterone acetate is taken and for at least one hour after the dose of abiraterone acetate is taken. A 28-daily dosing cycle will continue until disease progression or unacceptable toxicity is observed up to 2 years.
3023540|NCT02405845|No Intervention|CT Angiogram|A research CTA scan may be required if there is no change of the imaging on the 3 CTA scans prior.
3023541|NCT02405832|Experimental|Zinc - active arm|Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
3023542|NCT02405832|Placebo Comparator|Placebo|Placebo lozenge, with sweetener and citrus flavor, administered orally
3023543|NCT02405819|Other|Patient Directed|We will collect baseline data, including sociodemographic information for the patients and an assessment of each patient's baseline supportive care needs and knowledge about survivorship care. Sociodemographic information will be self completed. All other data collection will be interviewer administered. The instruments used at baseline and follow-up are adapted from previously published surveys (Hodgkinson et al, 2007; Sprague et al, 2013; Griggs et al). The research team will direct patients to their assigned condition by providing a hand-out directing them to the planning tool. After 2 months, we will re-contact all randomized patients to determine whether the survivorship care planning occurred as intended.
3023544|NCT02405819|Other|Clinician Directed|We will collect baseline data, including sociodemographic information for the patients and an assessment of each patient's baseline supportive care needs and knowledge about survivorship care. Sociodemographic information will be self completed. All other data collection will be interviewer administered. The instruments used at baseline and follow-up are adapted from previously published surveys (Hodgkinson et al, 2007; Sprague et al, 2013; Griggs et al). The provider will be provided a hand-out with their patient's assigned condition and is responsible for implementing the survivorship care plan process. After 2 months, we will re-contact all randomized patients to determine whether the survivorship care planning occurred as intended.
3023545|NCT02405806|Experimental|low carbohydrate food|"The subjects will be given a diet with moderate, low carbohydrate content for 3 months, or as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum as described previously.~Intervention: Food: Low carbohydrate food"
3023546|NCT02405806|Active Comparator|standard food|The subjects will be given a diet with standard food as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum, as described Intervention: Food: Standard food
3023547|NCT02405793|Experimental|Meloxicam low dose test capsule|Meloxicam SoluMatrix Capsules - low dose QD
3023548|NCT02405793|Experimental|Meloxicam high dose test capsule|Meloxicam SoluMatrix Capsules - high dose QD
3023549|NCT02405793|Active Comparator|Meloxicam tablets|Meloxicam Tablets QD
3023550|NCT02405780|Experimental|FKB327|Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
3023551|NCT02405780|Active Comparator|Humira®|Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
3023552|NCT02405767|Experimental|Foot ulcer impedance|Diabetic patients with a diabetic foot ulcer
3023553|NCT02405754||Treatment Group|Patients receiving Age/Sex/Gene Expression Score (ASGES) or Corus CAD test
3023554|NCT02405728|Experimental|Peripherally inserted central catheters|Peripherally inserted central catheters (PICCs) - Most commonly used vascular access in hematological patients - Randomization between CICCs and PICCs
3023555|NCT02405728|Active Comparator|Centrally inserted central catheter|Centrally inserted central catheter (CICCs) - New vascular access, with the aim to reduce the complications - Randomization between CICCs and PICCs
3023556|NCT02405715|Placebo Comparator|Placebo Spray And Interpersonal Psychotherapy|Participants will receive 6 sprays of a placebo nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total).
3023557|NCT02405715|Experimental|Oxytocin Spray And Interpersonal Psychotherapy|Participants will receive 6 sprays of a oxytocin nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total). Each spray will contain 4IU of oxytocin, for a total dose of 24IU.
3023558|NCT02405689|Active Comparator|remifentanil|In the remifentanil group, anesthesia was maintained with 0.5-1.5% sevoflurane and 0.125-0.25 μg/kg/min remifentanil infusion during surgery
3023559|NCT02405689|Active Comparator|dexmedetomidine|In the dexmedetomidine group anesthesia was maintained with 0.5-1.5% sevoflurane and 0.5 μg/kg dexmedetomidine loading dose during 10 minute and then 0.3-0.9 μg/kg/min infusion.
3023560|NCT02405676|Other|Risk group 1|Complete resection of stage I or II disease: 3 courses (A-B-A) and 3 intrathecal injections(Cytarabine/Methotrexate/Dexamethasone, age adjusted);
3023561|NCT02405676|Other|Risk group2|Not or incompletely resected stage I/II disease and LDH <2 times NL: 5 courses (A--B--A--B--A) and 8 intrathecal injections;
3023562|NCT02405676|Other|Risk group3|Stage III with high LDH < 4 times NL, or Stage I,II with LDH >=2 times NL: Preface followed by 6 courses (P(Cyclophosphamide/Vincristine/Prednisone)-A-BB-AA-BB-AA-BB) and 13 intrathecal injections; Dosage of Cytarabine, Methotrexate and Etoposide was increased in AA or BB compared with A or B. Vindelsine was used in AA/BB instead of Vincristine in A/B.
3023563|NCT02405676|Other|Risk group4|Stage III with LDH≥4N, or Stage IV, or B-AL: Preface followed by 4 dose of rituximab (375mg/m2) combined 6 courses of chemotherapy, together with 13 intrathecal injections: P-A-(Rituximab)BB-(Rituximab)AA-(Rituximab)BB-(Rituximab)AA-BB; rituximab is at D0 of each course.
3023564|NCT02405663|Experimental|manual removal group|Group will be assigned for manual removal of the placenta as the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby by caesarean section
3023565|NCT02405663|Experimental|cord traction group|Group will be assigned for controlled cord traction as the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery after the delivery of the baby by caesarean section
3023566|NCT02405650||CRIC VAP cohort|"If eligible, the participant will have additional testing at regular annual CRIC Visit. The following will occur:~abdominal and pelvic Magnetic Resonance Imaging (MRI) scan~400 meter walk test for physical fitness"
3023567|NCT02405637|Experimental|SAFE group|simulated amniotic fluid 20cc/kg/day enterally divided according to number of feds (syringe for every fed). This amount provides enteral 4.5μg rhG-CSF / kg/day and enteral 88IU rhEPO / kg/day.
3023568|NCT02405637|Placebo Comparator|placebo|distilled water 2.5 ml/kg every 3 hours enterally
3023569|NCT02405624|Experimental|CPAP training|Patients will be instructed and follow the continuous positive airway pressure (CPAP) training procedure
3023570|NCT02405611|Active Comparator|active control|mothers and children are in active control group and only receive the questionnaires
3023571|NCT02405611|Experimental|mother and student|an intervention group in which mothers and children receive the intervention and questionnaires
3023572|NCT02405611|Experimental|children|only the children receive the intervention and mothers and children receive the questionnaires
3023573|NCT02405598|Experimental|Salbutamol|"age 2-6 year: 0.1mg/kg tid x 2 weeks, then gradually increase to 0.2mg/kg tid (daily total maximal12mg)~age 6-12 year: 2mg tid x 2 weeks, then gradually increase to 4mg tid (daily total maximal 24mg)~age 12 year and above: 4mg tidx 2 weeks, then gradually increase to 8mg tid (daily total maximal 32mg)"
3023574|NCT02405585|Experimental|mFOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy|"SOC mFOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy~Day 93-100 Disease evaluated: Progressive disease = salvage therapy off study. Day 93-100 Disease evaluated: Stable disease or better = SBRT + HAPa on days 1 and 15 of radiotherapy Post SBRT: surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for 6 cycles.~Post adjuvant therapy: 6 monthly immunizations with HAPa"
3023575|NCT02405572|Active Comparator|Formula 1|infant formula
3023576|NCT02405572|Active Comparator|Formula 2|infant formula
3023577|NCT02405559|Experimental|Lymphatic occlusion pressure lower limb|injection of 100µg Indocyanine Green in the first interdigital space and application of increasing pressure around the leg to visualize at which pressure lymph flow is interrupted.
3023578|NCT02405546|Experimental|Pre-Rotated Technique (Group R)|90° counterclockwise rotation of bevel of ETT
3023579|NCT02405546|Active Comparator|No rotation|No rotation of bevel of ETT
3023580|NCT02405533|Experimental|Group 1|AHCC 3 grams once a day on an empty stomach x 6 months then placebo once a day x 56 months.
3023581|NCT02405533|Placebo Comparator|Group 2|Placebo once a day on an empty stomach x 12 months
3023582|NCT02405520|Experimental|low dosage HPV Vaccine|Participants in this arm would receive low dosage of HPV vaccines.
3023583|NCT02405520|Experimental|medium dosage HPV Vaccine|Participants in this arm would receive medium dosage of HPV vaccines.
3023584|NCT02405520|Experimental|high dosage HPV Vaccine|Participants in this arm would receive high dosage of HPV vaccines.
3023585|NCT02405520|Placebo Comparator|Placebo|Participants in this arm would receive placebo (Aluminium Adjuvant).
3023586|NCT02405507|Experimental|wheat bread with wheat germ|wheat bread with wheat germ supplementation
3023587|NCT02405507|Placebo Comparator|wheat bread without wheat germ|wheat bread without wheat germ supplementation
3023588|NCT02405494|Other|Beverage 1|Liquid foam consisting of 37 ml liquid with 73% overrun (total volume 65 ml).
3023589|NCT02405494|Other|Beverage 2|Liquid foam consisting of 37 ml liquid with 427% overrun (total volume 197 ml).
3023590|NCT02405494|Other|Beverage 3|Liquid foam consisting of 98 ml liquid with 73% overrun (total volume 169 ml).
3023591|NCT02405494|Other|Beverage 4|Liquid foam consisting of 98 ml liquid with 427% overrun (total volume 514 ml).
3023592|NCT02405494|Other|Beverage 5|Liquid foam consisting of 25 ml liquid with 250% overrun (total volume 88 ml).
3023593|NCT02405494|Other|Beverage 6|Liquid foam consisting of 110 ml liquid with 250% overrun (total volume 385 ml).
3023594|NCT02405494|Other|Beverage 7|68 ml beverage consisting of 68 ml liquid with 0% overrun (total volume 68 ml).
3023595|NCT02405494|Other|Beverage 8|Liquid foam consisting of 68 ml liquid with 500% overrun (total volume 405 ml).
3023596|NCT02405494|Other|Beverage 9|Liquid foam consisting of 68 ml liquid with 250% overrun (total volume 236 ml).
3023597|NCT02405481|No Intervention|Wait List Control|
3023673|NCT02404922|Experimental|CTP-730 Mid Dose or Matching Placebo|Capsule, once daily
3023674|NCT02404922|Experimental|CTP-730 High Dose or Matching Placebo|Capsule, once daily.
3023675|NCT02404909||Patients with liver tumors candidate to hepatectomy|
3023676|NCT02404896|Experimental|Metreleptin|Metreleptin, SC
3023677|NCT02404883|No Intervention|control group|care as usual (fertility preservation counseling)
3023598|NCT02405481|Experimental|SEPA III Intervention|SEPA brings together two important theoretical perspectives that will be effective and sustainable for HIV/AIDS prevention among Hispanic women in an inner city environment. The content and learning strategies of SEPA are based on the social cognitive theory and of HIV/AIDS prevention that prior research has shown to be the most effective in increasing HIV/AIDS prevention behaviors, modified to take into account the special needs of Hispanic women related to gender inequality and cultural values and practices. SEPA's conceptual framework integrates the Social Cognitive Model of behavioral change with Freire's Pedagogy of the Oppressed that guides the delivery and contextual tailoring.
3023599|NCT02405468||case|patients with a myocardial infarction within one month to one year before the inclusion
3023600|NCT02405468||control|"patients without history of myocardial infarction, free of coronary disease in the view of one of the following test performed within one year before the inclusion : Effort test Echocardiographic stress test Myocardial perfusion scintigraphy Coronarography with >= 2 major cardiovascular risk factors :~Treated hypertension~Treated dyslipidemia~Current smoking~Diabetes mellitus"
3023601|NCT02405455|Experimental|Cerclage|Cervical cerclage.
3023602|NCT02405455|Experimental|Cervical pessary|Cervical pessary
3023603|NCT02405442|Placebo Comparator|Group A (Blinded Treatment)|Placebo weekly for 8 weeks
3023604|NCT02405442|Experimental|Group B (Blinded Treatment)|GS-5745 150 mg alternating with placebo weekly for 8 weeks
3023605|NCT02405442|Experimental|Group C (Blinded Treatment)|GS-5745 150 mg weekly for 8 weeks
3023606|NCT02405442|Experimental|Group D (Blinded Treatment)|GS-5745 300 mg weekly for 8 weeks
3023607|NCT02405442|Experimental|Open Label Extension GS-5745|All enrolled participants will be eligible to enroll in the Open Label Extension to receive GS-5745 150 mg weekly for an additional 44 weeks.
3023608|NCT02405442|Experimental|Extended Treatment Phase GS-5745|Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with GS-5745 for an additional 156 weeks.
3023609|NCT02405416|Experimental|IIVCC group|The portal triad and infrahepatic inferior vena cava are dissected and taped with a vessel loop, respectively. During liver parenchymal resection，portal triad and infrahepatic inferior vena cava clampings are performed at the specified transection depth from liver surface successively.
3023610|NCT02405416|Active Comparator|SHVE group|In this group, the portal triad clamping and selective hepatic vascular exclusion of major hepatic veins are used. Different major hepatic veins are occluded by clamping forcep depending on the site of tumors. The clamping timepoints are same as the IIVCC group.
3023611|NCT02405403|Experimental|amyotrophic lateral sclerosis (ALS)|[18F]DPA-714 PET
3023612|NCT02405390|Experimental|Video Laryngoscopy|Some patients will be intubated with a video laryngoscope 'Storz C-Mac® laryngoscope'
3023613|NCT02405390|Active Comparator|Direct Laryngoscopy|Some patients will be intubated with a direct (conventional) laryngoscope
3023614|NCT02405377|Experimental|CVP guided hydration|The fluid rate was adjusted according to the CVP dynamically
3023615|NCT02405377|Active Comparator|Control|The control group was hydrated at 1 mL/kg per h.
3023616|NCT02405364|Experimental|Front line therapy|Induction: 4 cycles of 28 days of Carfilzomib/Lenalidomide/Dexamethasone Stem Cell Harvest+Intensification Consolidation 4 cycles of 28 days of Carfilzomib/ Lenalidomide/Dexamethasone Maintenance: Lenalidomide 13 cycles of 28 days
3023617|NCT02405351|Experimental|Training Group|Participants will be 10 individuals post stroke, living in the community. The intervention, adaptive working memory training, is a dual n-back working memory task. This training will take place once for 30 minutes per day, 5 days a week for 6 weeks, with one week dedicated for familiarizing participants to the program in the very beginning (i.e., Week 1).
3023618|NCT02405338|Experimental|WT1/PRAME vaccination|
3023619|NCT02405325|Experimental|Physical Activity|The program will be run by peer Leaders and senior center staff with the support of UCSD staff. Participants will work towards a 2000 increase in daily steps through self-paced incidental walking and peer led group walks.
3023620|NCT02405325|No Intervention|Usual Care|Measurement at baseline, 6, 12, 18 and 24 months only with a health related event at each time point.
3023621|NCT02405312|Experimental|advance care planning|nephrologist empowers social worker to meet with patient and family.
3023622|NCT02405299|Experimental|Experimental Group|neuropsychological reeducation disorder specific of inhibition (bottom-up and top-down protocol): 24 bi-weekly sessions (30 subjects)
3023623|NCT02405299|Placebo Comparator|Control Group|non-specific and general cognitive neuropsychological reeducation (comprehension, syntactic, visuospatial) : 24 bi-weekly sessions (30 subjects)
3023624|NCT02405286||Upeer gastrointestinal bleeding|"Adult Egyptian patients.~Patients with acute upper G.I hemorrhage.~Informed consent."
3023625|NCT02405273|Experimental|Interventional Group|Pulmonary rehabilitation
3023626|NCT02405273|Active Comparator|Control Group|Standard Care
3023627|NCT02405260|Experimental|TTP399 400 mg|TTP399 once daily
3023628|NCT02405260|Experimental|TTP399 800 mg|TTP399 once daily
3023629|NCT02405260|Active Comparator|Sitagliptin 100 mg|Sitagliptin once daily
3023630|NCT02405260|Placebo Comparator|Placebo|Placebo once daily
3023631|NCT02405247||NSCLC without T790M mutation|NSCLC patients who have failed first line TKI treatment (defined radiological documentation of disease progression during treatment for advanced or metastatic NSCLC with an approved EGFR-TKI e.g. gefitinib, afatinib or erlotinib) and are screened for the AURA3 study and determined to be lacking the T790M mutation as determined using the AURA3 designated central laboratory using the cobas® EGFR Mutation Test (Roche Molecular Systems).
3023632|NCT02405234|Experimental|Carbon Modular Radial Head|PyroCarbon Modular Radial Head replacement
3023633|NCT02405234|Active Comparator|Metal Radial Head|Metal Radial Head replacement
3023634|NCT02405221|Experimental|Group A|TA-CIN administration via thigh
3023635|NCT02405221|Experimental|Group B|TA-CIN administration via arm
3023636|NCT02405208||Primary cohort|Primary cohort will receive the PyroTITAN HRA device
3023678|NCT02404883|Experimental|intervention group|Intervention: use of an online decision-aid tool after fertility preservation counseling
3023679|NCT02404870|Experimental|1|Canagliflozin
3023680|NCT02404870|Placebo Comparator|2|Placebo
3056880|NCT02182401|Experimental|BI 207127 NA|fixed sequence
3023637|NCT02405182||Patients|ALS patients (as well as patients with other motor neuron diseases such PLS and PMA) will be recruited from ALS clinics under the direction of ALS neurologists who are participating in this study. ALS patients should meet research criteria for possible, probable, probable laboratory-supported, or definite ALS. Patients with a history of CNS disease (e.g. stroke, head injury) or significant psychiatric disease will be ineligible. Patients must be able to undergo a brain MRI for approximately an hour.
3023638|NCT02405182||Controls|Healthy controls who are age and gender matched to patients will be recruited. Controls with a history of CNS disease (e.g. stroke, head injury) or significant psychiatric disease will be ineligible. Controls must be able to undergo a brain MRI for approximately an hour.
3023639|NCT02405169|Experimental|Test -4 implants-|Evaluate marginal bone level (MBL) changes at implants that are placed in total edentulous patient when they are treated with four with titanium Cad/Cam framework.
3023640|NCT02405169|Active Comparator|Control -6 implants-|Evaluate marginal bone level (MBL) changes at implants that are placed in total edentulous patient when they are treated with six with titanium Cad/Cam framework
3023641|NCT02405156|Experimental|letrozole + misoprostol|Women will receive three tablets of letrozole vaginal as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) for three days and will be followed by 200 mcg vaginal misoprostol or 100mcg vaginal misoprostol (according gestational age) soaked with saline every six hours up to maximum four doses.
3023642|NCT02405156|Placebo Comparator|placebo + misoprostol|Women will receive three tablets of placebo vaginal as a single dose, for three days and will be followed by 200 mcg vaginal misoprostol or 100 mcg vaginal misoprostol (according gestational age) soaked with saline every six hours up to maximum four doses.
3023643|NCT02405143|Experimental|Active tACS using DC-Stimulator MC|15 to 30 patients will be randomized to the arm receiving the active transcranial alternating current stimulation (tACS) treatment using DC-Stimulator MC.
3023644|NCT02405143|Sham Comparator|Sham stimulation using DC-Stimulator MC|The same number of patients as in the active arm, 15 to 30, will be randomized to receive sham stimulation using DC-Stimulator MC.
3023645|NCT02405130|Active Comparator|epinephrine|intracoronary epinephrine is two ampoules each of 1:1000 epinephrine (1 μg/mL) diluted into 100 mL of normal saline (to 20 μg/mL epinephrine solution); a 5 ml syringe prepared will then contain 100 μg
3023646|NCT02405130|Other|no intracoronary epinephrine|no epinephrine
3023647|NCT02405117|Experimental|LiveWell System|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study.
3023648|NCT02405117|No Intervention|Treatment As Usual|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will be asked to provide limited self-report data via the phone.
3023649|NCT02405104|Active Comparator|THA+Klorz|All patients in this arm are treated surgically with a THA and medically with Chlorzoxazone
3023650|NCT02405104|Placebo Comparator|THA+Placebo|All patients in this arm are treated surgically with a THA and medically with placebo
3023651|NCT02405104|Active Comparator|TKA+Klorz|All patients in this arm are treated surgically with a TKA and medically with Chlorzoxazone
3023652|NCT02405104|Placebo Comparator|TKA+Placebo|All patients in this arm are treated surgically with a TKA and medically with placebo
3023653|NCT02405091|Experimental|Dose Group 1|Fixed dose of NBI-98854 administered once daily for 48 weeks
3023654|NCT02405091|Experimental|Dose Group 2|Fixed dose of NBI-98854 administered once daily up to 48 weeks
3023655|NCT02405078|Experimental|FDG PET/CT Imaging + Blood Draws|Participants receive 2 cycles of high dose chemotherapy (RICE or RDHAP) at discretion of treating physician. Four FDG PET/CT scans, five blood-based detection of tumor-specific clonotype tests, and five blood-based evaluations of the metabolic profile performed for each participant. With day 1 designated as start of chemotherapy, FDG PET/CT scans performed sequentially between day -21 - day 0 (baseline PET), day 4 (interim PET1, after completion of 1st high dose chemotherapy), day 21 (interim PET2, after completing 1st cycle of chemotherapy), and day 42 (end of therapy PET). Blood-based detection of tumor-specific clonotype and metabolic profile testing collected on day -5 - 0, day 4, day 8, day 21 and day 42.
3023656|NCT02405065|Experimental|HM95573|single arm
3023657|NCT02405052||Patients|Emergency department patients with unexplained chest pain
3023658|NCT02405039|Active Comparator|Active Comparator: EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day
3023659|NCT02405039|Placebo Comparator|Placebo or Vehicle control Comparator|One of two study arms: placebo or vehicle control topical administered 3 times per day
3023660|NCT02405026||HIV infected patients|HIV infected patients with asthma
3023661|NCT02405026||HIV uninfected patients|HIV uninfected patients with asthma
3023662|NCT02405026||HIV infected non-asthmatic patients|HIV infected patients without asthma
3023663|NCT02405013|Experimental|Sofosbuvir+Ribavirin|Sofosbuvir 400mg QD (Sovaldi®) + Ribavirin weight-adjusted dosing (1000mg BID in patients < 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
3023664|NCT02405013|Experimental|Sofosbuvir+Ledipasvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
3023665|NCT02405000|Experimental|Intraoperative CT imaging|
3023666|NCT02404987||Nutritional Supplement|Free living and residing and nursing home malnourished patients
3023667|NCT02404974|Experimental|Exercise|This is a single arm pilot study. All participants who answer yes to interest in exercise question on the web-based osteoarthritis preference tool will be included in the exercise intervention. After completing baseline measures, they will be put in contact with the Fitness Instructor and follow the protocol described.
3023668|NCT02404961||Control (no vulvodynia)|Clinically-confirmed as a woman with no history of vulvodynia.
3023669|NCT02404961||Vulvodynia Case|Clinically-confirmed as a woman with vulvodynia.
3023670|NCT02404935|Experimental|Arm A cetuximab|cetuximab 500 mg/m2 (every 2 weeks) until progression
3023671|NCT02404935|Other|Arm B observation|observation until progression
3023681|NCT02404857|Experimental|Chronic post-stroke|Patients >6 months post-stroke with little to no hand movement. use of EEG based BCI in the neurorehabilitation process
3023682|NCT02404844|Experimental|BKM120 + Tamoxifen|"BKM120 (Buparlisib): 100 mg/day, orally, on a continuous dosing schedule without interruption starting on day 1 in 28 day cycle~Tamoxifen: 20 mg/day, orally, on a continuous dosing schedule without interruption starting on day 1 in 28 day cycle"
3023683|NCT02404831|Active Comparator|Traditional hospital-based PR|Class based pulmonary rehabilitation
3023684|NCT02404831|Experimental|Web-based PR|web-based pulmonary rehab
3023685|NCT02404818||Survivors of Hodgkin's lymphoma|Cardiac Magnetic Resonance Imaging and Echocardiogram
3023686|NCT02404805|Experimental|Sequence 1a|Sequence 1,2,3: simeprevir only, then dolutegravir only, then both simeprevir and dolutegravir.
3023687|NCT02404805|Experimental|Sequence 1b|Sequence 1,3,2: simeprevir only, then both simeprevir and dolutegravir, then dolutegravir only.
3023688|NCT02404805|Experimental|Sequence 2a|Sequence 2,1,3: dolutegravir only, then simeprevir only, then both simeprevir and dolutegravir.
3023689|NCT02404805|Experimental|Sequence 2b|Sequence 2,3,1: dolutegravir only, then both simeprevir and dolutegravir, then simeprevir only.
3023690|NCT02404805|Experimental|Sequence 3a|Sequence 3,1,2: both simeprevir and dolutegravir, then simeprevir only, then dolutegravir only.
3023691|NCT02404805|Experimental|Sequence 3b|Sequence 3,2,1: Both simeprevir and dolutegravir, then dolutegravir only, then simeprevir only.
3023692|NCT02404792|Active Comparator|HIV-uninfected|HIV-uninfected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
3023693|NCT02404792|Experimental|HIV-infected|HIV-infected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
3023694|NCT02404779|Experimental|CISATRACURIUM|To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo.
3023695|NCT02404779|Placebo Comparator|PLACEBO|To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo.
3023696|NCT02404766|Experimental|Intervention group|C0-C1 dorsal glide mobilization in the cervical neutral position.
3023697|NCT02404766|Experimental|Intervention group 2|C7-T1 ventral cranial glide mobilization in the cervical neutral position
3023698|NCT02404766|No Intervention|Control group|Not receiving any intervention
3023699|NCT02404753|Experimental|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer after neoadjuvant chemotherapy.
3023700|NCT02404753|Active Comparator|Open gastrectomy|Open distal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer after neoadjuvant chemotherapy.
3023701|NCT02404740||VP shunt functioning|No intervention, just a physiological category--patients with VP shunts that are functioning normally.
3023702|NCT02404740||VP shunt malfunctioning|No intervention, just a physiological category--patients with VP shunts that are malfunctioning.
3023703|NCT02404740||No known intracranial pathology|No intervention, just a physiological category--patients without VP shunts that have no known intracranial pathology.
3023704|NCT02404727|Active Comparator|cup fixation cemented|30 of the 60 patients will be randomized to cemented cup fixation
3023705|NCT02404727|Active Comparator|cup fixation cementless|30 of the 60 patients will be randomized to cementless cup fixation
3023706|NCT02404714||CF/CRMS|"Subject's with a previous cystic fibrosis or cystic fibrosis related metabolic syndrome (CRMS) diagnosis will receive the institution's standard iontophoresis sweat testing (Gibson-Cooke or Wescor Macroduct) to provide a diagnosis.~The patient will also receive a sweat test provided by the new CF Quantum Sweat Test System which includes the same process and principal of operation of iontophoretic stimulation, collection and analysis of sweat compared to the standard. The results of the new sweat test and the standard sweat test will be compared. The new sweat test will not be used to diagnose, treat or mitigate the patient's condition. Results are used only to compare to the standard of care."
3023707|NCT02404714||NON CF/CRMS|"Subject's without a previous cystic fibrosis or cystic fibrosis related metabolic syndrome (CRMS) diagnosis but referred to the sweat test lab on a clinical observation basis by a physician will receive standard iontophoresis sweat testing (Gibson-Cooke or Wescor Macroduct) to provide a diagnosis.~The patient will also receive a sweat test provided by the new CF Quantum Sweat Test System which includes the same process and principal of operation of iontophoretic stimulation, collection and analysis of sweat compared to the standard. The results of the new sweat test and the standard sweat test will be compared. The new sweat test will not be used to diagnose, treat or mitigate the patient's condition. Results are used only to compare to the standard of care."
3023708|NCT02404701|Experimental|Aloe vera with cactus|1 capsule (500 mg), 2 times/day
3023709|NCT02404701|Experimental|Cranberry|3 capsules (810 mg), 2 times/day
3023710|NCT02404701|Experimental|Green tea extract|2 capsules (630 mg), 2 times/day
3023711|NCT02404701|Experimental|Bilberry|1 softgel (1000 mg), 2 times/day
3023712|NCT02404701|Experimental|Cinnamon|1 capsule (500 mg), 2 times/day
3023713|NCT02404701|Experimental|Milk thistle|1 capsule (250 mg), 3 times/day
3023714|NCT02404701|Experimental|Turmeric|1 capsule (450 mg turmeric + 50 mg turmeric extract), 1 time/day
3023715|NCT02404701|Experimental|Aloe vera|1 capsule (470 mg), 2 times/day
3023716|NCT02404688|Experimental|Active THC and Placebo Ethanol|
3023717|NCT02404688|Experimental|Active THC and Active Ethanol|
3023718|NCT02404688|Experimental|Placebo THC and Active Ethanol|
3023719|NCT02404688|Placebo Comparator|Placebo THC and Placebo Ethanol|
3023720|NCT02404675|Experimental|21 icotinib (250mg)|Patients with EGFR 21 exon positive are randomly assigned to higher dose icotinib group to receive icotinib with a dose of 250 mg three times per day, till progressive disease or unaccepted toxicity.
3023749|NCT02404480|Experimental|Cohort 3|PTC 596 administered twice daily-2.6mg/kg
3023721|NCT02404675|Active Comparator|21 icotinib (125mg)|Patients with EGFR 21 exon positive are randomly assigned to routine dose icotinib group to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
3023722|NCT02404675|Experimental|19 icotinib (125mg)|Patients with EGFR del 19 exon positive are assigned to routine dose icotinib group to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
3023723|NCT02404662|Experimental|Supportive text messages intervention|Patients in the intervention group will receive twice daily supportive text messages to their mobile phone for 6 months following discharge from a 4-week in-patient dual diagnosis treatment programme. The messages will be sent by a computer programme at 10am and 7pm each day and will be set up and monitored by the research worker who will not participate in follow-up assessments. They will receive a fortnightly text message thanking them for participating in the study, and a brief phone call every 2 weeks to ensure that they are still using their phone and that they have received some messages. The intervention group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
3023724|NCT02404662|Active Comparator|Control group|Patients in the control group will receive a fortnightly text message thanking them for participating in the study, and a brief phone call every 2 weeks to ensure that they are still using their phone and that they have received some messages. The control group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
3023725|NCT02404649|Active Comparator|Bone Augmention|Two implant designs in a Sinus Bone Augmentation Procedure. Sinus bone augmentation with Puros Cortico-Cancellous Particulate Allograft (70% Cortico and 30% Cancelleous) (Zimmer Dental- Carlsbad, CA, USA)- one implant will be TMDI (Zimmer Dental- Carlsbad, CA, USA) and the second will be Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA). Implant stability will be determined by the initial insertion torque and RFV values at time of implant placement and after 1 month of healing on a monthly basis up until 12 months post implant placement. Thickness of bone surrounding implant body positioned in the sinus will be measured.
3023726|NCT02404649|Active Comparator|Sinus elevation only|Two implant designs in a Sinus Floor Elevation Procedure. Placement of two dental implants as mentioned above in sinus bone augmentation by sinus elevation procedure, blood clot and CopiOs Pericardium Membrane (Zimmer Dental- Carlsbad, CA, USA) only. One implant will be TMDI (Zimmer Dental- Carlsbad, CA, USA) and the second will be Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA). Implant stability will be determined by the insertion torque and RFV values at time of implant placement and after 1 month of healing on a monthly basis up until 12 months post implant placement. Thickness of bone surrounding implant body positioned in the sinus will be measured.
3023727|NCT02404636||Alcoholic hepatitis|Individuals admitted to hospital with acute alcoholic hepatitis, defined as acute onset of jaundice in the context of recent hazardous alcohol use and the absence of other liver disease
3023728|NCT02404636||Hazardous alcohol use|Individuals admitted to hospital for any cause who drink hazardous quantities of alcohol but without evidence of alcoholic hepatitis or advanced liver disease
3023729|NCT02404623|Experimental|Intervention Group|800 IU of Vitamin D once daily
3023730|NCT02404623|Other|Control Group|400 IU of Vitamin D once daily, the standard of care
3023731|NCT02404610|Experimental|Moderate Procedural Sedation|Subjects will undergo procedural sedation for an indicated urgent medical procedure with a target sedation level of moderate sedation. Moderate procedural sedation is a specific term referring to procedural sedation with a target depth of moderate.
3023732|NCT02404610|Experimental|Deep Procedural Sedation|Subjects will undergo procedural sedation for an indicated urgent medical procedure with a target sedation level of deep sedation. Deep procedural sedation is a specific term referring to procedural sedation with a target depth of deep.
3023733|NCT02404597|Experimental|NICOM|"Subjects with burns greater than 20% total body surface area (TBSA) will have a NICOM placed on them after the first 24 hours of admission if subject has an episode of hypotension (mean arterial pressure < 65 or a systolic blood pressure < 90mmHg). The NICOM will generate a number that reflects stroke volume of the heart. If the number is greater than 10 percent, subject will be given a bolus of crystalloid fluids. If the number is less than 10 percent, subject will start a medication to raise the blood pressure.~Physicians may also use traditional endpoints of resuscitation include base deficit values and urine output goals of 0.5cc/kg/hr as indications of adequate intravenous fluid resuscitation."
3023734|NCT02404597|No Intervention|Control|This is a retrospective comparison control group of patients with burns greater than 20% total body surface area (TBSA) admitted to the hospital from 7/1/2014-12/31/2014.
3023735|NCT02404584||The study population|"Patients with kidney cancer and will be starting treatment via sunitinib at the study start will be included.~Intervention: Blood drawn for genotyping Intervention: Blood drawn for pharmacokinetic measures"
3023736|NCT02404571|Experimental|GDP chemotherapy|GDP chemotherapy: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
3023737|NCT02404558|Experimental|Sarilumab|Single subcutaneous (SC) dose of sarilumab
3023738|NCT02404558|Active Comparator|Tocilizumab|Single SC dose of tocilizumab
3023739|NCT02404545|No Intervention|Group 1 - Ideal Conduit No Mesh|No mesh will be placed at the time of radical cystectomy and ileal conduit.
3023740|NCT02404545|Active Comparator|Group 2 - Ileal Conduit with Mesh|Ethicon Physiomesh will be placed at the time of radical cystectomy and ileal conduit.
3023741|NCT02404532|Experimental|1|
3023742|NCT02404519|Active Comparator|Menaquinone-7|Menaquinone-7 180 microgram tablet, by mouth, daily for 1 year
3023743|NCT02404519|Placebo Comparator|Placebo|Placebo tablet, by mouth, daily for 1 year
3023744|NCT02404506|Experimental|Arm: Eribulin mesilate|
3023745|NCT02404493|Active Comparator|EpiCeram Skin Barrier Emulsion|Marketed. Apply in a thin layer to the affected skin areas two times per day (or as needed) and massage gently into the skin.
3023746|NCT02404493|Experimental|1% Colloidal Oatmeal Balm|Not Yet Marketed. Apply in a thin layer to the affected skin areas at least once at night or more if needed (anytime), and massage gently into the skin.
3023747|NCT02404480|Experimental|Cohort 1|PTC 596 administered twice daily- Dose level 0.65mg/kg
3023748|NCT02404480|Experimental|Cohort 2|PTC 596 administered twice daily-Dose level 1.3mg/kg
3023753|NCT02404480|Experimental|Cohort 7 (Bio Marker cohort)|PTC 596 administered twice daily-Dose level 5.2mg/kg
3023754|NCT02404467||Patients receiving tranfermoral TAVI|TF TAVI
3023755|NCT02404454|Experimental|hysteroscopic metroplasty|women undergoing hysteroscopic metroplasty for uterine septum resection
3023756|NCT02404441|Other|patients with solid tumors|Phase I Dose escalation cohorts
3023757|NCT02404441|Other|Selected tumor types|Phase II expansion: Selected tumor types: melanoma, NSCLC, triple negative breast cancer, anaplastic thyroid cancer
3023758|NCT02404428|Active Comparator|standard broccoli soup|one portion (300 g each) per week of a soup containing standard broccoli
3023759|NCT02404428|Experimental|beneforte extra broccoli soup|one portion (300 g each) per week of a soup containing glucoraphanin-enriched broccoli named for the study 'Beneforte extra'
3023760|NCT02404402|Experimental|Active LED|Active LED Treatment
3023761|NCT02404402|Sham Comparator|Sham LED|Inactive (sham) LED Treatment
3023762|NCT02404389|Experimental|LFX453 0.1% NMC|LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications
3023763|NCT02404389|Experimental|LFX453 0.15% LCC|LFX453 0.15% liquid crystal cream (LCC) Twice daily applications
3023764|NCT02404389|Placebo Comparator|Vehicle to NMC|Vehicle to nanomedicinal cream (NMC) Twice daily applications
3023765|NCT02404389|Placebo Comparator|Vehicle to LCC|Vehicle to liquid crystal cream (LCC) Twice daily applications
3023766|NCT02404389|Active Comparator|Aldara|Aldara cream 3 applications per week
3023767|NCT02404376|Active Comparator|Remote Ischemic Conditioning|Remote Ischemic Conditioning + placebo
3023768|NCT02404376|Active Comparator|Combined treatment|Remote Ischemic Conditioning + exenatide
3023769|NCT02404376|Placebo Comparator|Placebo|Sham Remote Ischemic Conditioning + placebo
3023770|NCT02404376|Active Comparator|Exenatide|Sham Remote Ischemic Conditioning + exenatide
3023771|NCT02404363|Experimental|Clopidogrel|Clopidogrel tablets 75 mg for six months:
3023772|NCT02404363|Placebo Comparator|Comparator|Placebo tablet 75 mg for six months:
3023773|NCT02404350|Experimental|Secukinumab 150 mg load (Group 1)|"Secukinumab 150 mg sc injection every week for 4 weeks followed by Secukinumab 150 mg every 4 weeks for 100 weeks~Beginning at Week 52, for subjects whose signs and symptoms are not fully controlled, and who the investigator believes may improve further with an increase in dose, may have the secukinumab dose increased to 300mg s.c. every 4 weeks."
3023774|NCT02404350|Experimental|Secukinumab 150 mg no load (Group 2)|"Secukinumab 150 mg sc injection every 4 weeks for 100 weeks~Beginning at Week 52, for subjects whose signs and symptoms are not fully controlled, and who the investigator believes may improve further with an increase in dose, may have the secukinumab dose increased to 300mg s.c. every 4 weeks."
3023775|NCT02404350|Experimental|Secukinumab 300 mg load (Group 3)|Secukinumab 300 mg sc injection every week for 4 weeks followed by Secukinumab 300 mg every 4 weeks for 100 weeks
3023776|NCT02404350|Placebo Comparator|Placebo arm 1 (Group 4)|"Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders will be switched to Secukinumab either 150 or 300 mg sc injection every two weeks until week 100. Responders at week 16 will continue receiving placebo until week 24, then will be switched to secukinumab 150 or 300 mg sc injection every 4 weeks for 100 weeks. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)~Beginning at Week 52, for subjects whose signs and symptoms are not fully controlled, and who the investigator believes may improve further with an increase in dose, may have the secukinumab dose increased to 300mg s.c. every 4 weeks."
3023777|NCT02404350|Placebo Comparator|Placebo arm 2 (Group 4)|"Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders will be switched to Secukinumab either 150 or 300 mg sc injection every two weeks until week 100. Responders at week 16 will continue receiving placebo until week 24, then will be switched to secukinumab 150 or 300 mg sc injection every 4 weeks for 100 weeks. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)~Beginning at Week 52, for subjects whose signs and symptoms are not fully controlled, and who the investigator believes may improve further with an increase in dose, may have the secukinumab dose increased to 300mg s.c. every 4 weeks."
3023778|NCT02404337|Experimental|100 mg/kg of Betaine|Dose 1 : 100 mg/kg of Betaine
3023779|NCT02404337|Experimental|250 mg/kg of Betaine|Dose 2 : 250 mg/kg of Betaine
3023780|NCT02404324|Experimental|spectacles|"Esotropia is treated by full optical correction (spectacles prescription) in all children with refractive errors. Special attention is paid to astigmatism up to 0.5 Dptr.~Intervention: Prescription of spectacles"
3023781|NCT02404311|Experimental|Vacine|"ALVAC-HIV (vCP2438) as a lyophilized vaccine for injection at a viral titer ≥ 1 × 10E6 cell culture infectious dose (CCID)50 and < 1 × 10E8 CCID50 (nominal dose of 10E7 CCID50) and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose.~Bivalent Subtype C gp120/MF59® -- 2 recombinant monomeric proteins, each at a dose of 100 mcg, mixed with MF59® adjuvant (an oil-in-water emulsion) delivered as a 0.5 mL IM injection"
3023782|NCT02404311|Placebo Comparator|Placebo|"ALVAC-HIV placebo: a sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for injection as a single dose IM~Bivalent gp120/MF59® placebo: sodium chloride for injection, 0,9% delivered as a 0.5 mL IM injection"
3023783|NCT02404298|Experimental|IVIg|
3023784|NCT02404285|Placebo Comparator|Vehicle|"Subjects will be treated with once daily vehicle and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:~Lesions will be counted and right, left and forward facing photographs will be taken~Investigator Global Assessment~Acne Quality of Life Questionnaire~Treatment Area Assessment by Investigator"
3023785|NCT02404285|Active Comparator|NAG (Next Science Acne Gel)|"Subjects will be treated with once daily NAG and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:~Lesions will be counted and right, left and forward facing photographs will be taken~Investigator Global Assessment~Acne Quality of Life Questionnaire~Treatment Area Assessment by Investigator"
3023786|NCT02404272||Preterm neonates|All preterm neonates of less than 34 weeks' of gestation admitted to the Neonatology and Neonatal Intensive Care unit of an university hospital located in Lyon, France
3023787|NCT02404259|Other|non-nucleoside reverse transcriptase inhibitor (NNRTI)|Efavirenz
3023788|NCT02404259|Other|ritonavir-boosted protease inhibitor|lopinavir/ritonavir atazanavir/ritonavir
3023789|NCT02404246|Experimental|Intervention Arm|Intervention evaluated the feasibility, acceptability, and effectiveness of a structured peer support intervention based on the Certified Peer Specialist Program of the Depression and Bipolar Support Alliance (DBSA).
3023790|NCT02404246|No Intervention|Usual Care|Usual Care
3023791|NCT02404233|Experimental|Darunavir/ cobicistat and Rilpivirine|"Single arm study:~Darunavir/ cobicistat 800/ 150 mg tablet once daily taken with food Rilpivirine tablet 25 mg once daily taken with food"
3023792|NCT02404220|Experimental|Entospletinib|"Dose Escalation:~Lead-in (7 day): Entospletinib up to 400 mg twice daily~Cycle 1 and 2 (28 days each): Entospletinib up to 400 mg twice daily+ VCR up to 2 mg once weekly + CNS prophylaxis on Day 28 + dexamethasone 20 mg twice daily on days 8-11 and 22-25 (Cycle 1) and Days 1- 4 and 15-18 (Cycle 2)~Cycle 3 (up to 36 maintenance cycles): Entospletinib up to 400 mg twice daily + VCR up to 2 mg on Day 1+ dexamethasone 20 mg once daily on Days 1- 4 and 15-28 of each 28 day cycle"
3023793|NCT02404207|Active Comparator|Soybean oil|
3023794|NCT02404207|Experimental|High-oleic soybean oil|
3023795|NCT02404207|Experimental|High-oleic soybean oil + fully hydrogenated soybean oil|
3023796|NCT02404207|Active Comparator|Palm olein + palm stearin|
3023797|NCT02404194|Experimental|Targeted Cognitive Training|40 hours of computerized cognitive training
3023798|NCT02404194|Placebo Comparator|Computer Games|40 hours of computer games
3023799|NCT02404168|Active Comparator|lamotrigine brand tablet1|lamotrigine tablet Lamictal
3023800|NCT02404168|Experimental|lamotrigine generic tablet1|lamotrigine tablet Teva
3023801|NCT02404168|Active Comparator|lamotrigine brand tablet2|lamotrigine tablet Lamictal
3023802|NCT02404168|Experimental|lamotrigine generic tablet2|lamotrigine tablet Teva
3023803|NCT02404155|Experimental|Clozapine|
3023804|NCT02404142|Placebo Comparator|Control group (saline isotonic solution)|saline isotonic solution
3023805|NCT02404142|Experimental|Curar (Atracurium) group|Curar (Atracurium)
3023806|NCT02404129|Other|Non-fallers|"The subjects had to report having no difficulties with mobility, activities of daily living, or turning while walking and had no falls for a year period. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
3023807|NCT02404129|Other|In a risk to fall|"Subjects who report about 1-2 falls in a year period. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
3023808|NCT02404129|Other|Multiple fallers|"Subjects who reported to have more than two falls per year. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
3023809|NCT02404116|Experimental|Metacognitive Therapy|12 weeks of Metacognitive Therapy
3023810|NCT02404116|Other|Wait List Control|The Waiting list control will control for time and repeated assessments during an initial 12 week period
3023811|NCT02404103|Active Comparator|Flunisolide 160 mcg per day|Patients will receive inhaled Flunisolide HFA 80 mcg twice per day for a total of 160 mcg per day over the 6 week study period
3023812|NCT02404103|Active Comparator|Flunisolide 320 mcg per day|Patients will receive inhaled Flunisolide HFA 160 mcg twice per day for a total of 320 mcg per day over the 6 week study period
3023813|NCT02404077||Clonidine|Patients who received clonidine following prolonged dexmedetomidine infusions
3023814|NCT02404064|Other|Antibiotics perioperative|dose of perioperative antibiotics (cefamezin 1g IV; metronidazole 500 mg IV) This is the standard of care of the department
3023815|NCT02404064|Placebo Comparator|placebo - No Antibiotics perioperative|The intervention is No Antibiotics perioperative
3023816|NCT02404051|Experimental|ARM 1|Everolimus plus Exemestane -> progression disease (PD) -> fulvestrant (ARM 1)
3023817|NCT02404051|Experimental|ARM 2|Fulvestrant -> progression disease (PD) -> everolimus plus exemestane (ARM 2)
3023818|NCT02404038|Active Comparator|Arm A: Injectable|This arm will receive Nur-Isterate administered as an intramuscular injection administered bi-monthly (every 8 weeks).
3023819|NCT02404038|Active Comparator|Arm B: Intra-vaginal|This arm will receive the Nuvaring a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days.
3023820|NCT02404038|Active Comparator|Arm C: Oral|This arm will receive Triphasil a daily oral contraceptive of 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle
3023821|NCT02404025|Experimental|Eltrombopag+rabbit ATG/CsA arm|Subjects will receive rabbit ATG diluted by 500 mL of saline or 5% glucose injection at a dose of 2.5 to 3.75 mg per kilogram (kg) per day for 5 days as a slow intravenous infusion over 6 hours. CsA will be administered at a dose of 3 mg per kg twice a day from day 0. The dose level will be adjusted based on the monitoring of blood level or renal function. Eltrombopag will be initiated on day 14 and it can be delayed up to 2 weeks if the subject has infection, serum sickness, or other adverse events. Eltrombopag will be administered orally once a day at fasting at an initial dose of 75 mg, and adjust the dose every 2 weeks according to the platelet count. Eltrombopag and CsA are continued until Week 26.After Week 26, eligible subjects will receive eltrombopag; and CsA will be tapered or maintained as per the investigator's discretion.
3023822|NCT02404012|Active Comparator|Ferrous sulfate|Ferrous sulfate 65 mg. t.i.d is the standard of care for oral supplementation for iron deficiency
3023823|NCT02404012|Experimental|AspironTM 65 mg t.i.d.|AspironTM, an organic formulation of iron, is the experimental treatment for oral supplementation of iron deficiency
3023824|NCT02403999|Experimental|Test shampoo|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
3023825|NCT02403999|Experimental|Test bath foam|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
3023826|NCT02403999|Experimental|Test head to toe Wash|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
3023827|NCT02403986|Experimental|R. Vital Skinboosters Lidocaine (three)|Treatment with three initial sessions
3023828|NCT02403986|Experimental|R. Vital Skinboosters Lidocaine (two)|Treatment with two initial sessions
3023829|NCT02403973|Other|Patient hotel group|
3023830|NCT02403973|Other|Ward group|
3023831|NCT02403960|Active Comparator|probiotic|The participants of the probiotic group were asked to let a probiotic tablet dissolve on their tongue 2 times a day for 3 months.
3023832|NCT02403960|Placebo Comparator|placebo|The participants of the control group were asked to let a placebo tablet dissolve on their tongue 2 times a day for 3 months.
3023833|NCT02403947|Experimental|Mesenchymal stem cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
3023834|NCT02403947|Placebo Comparator|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
3023835|NCT02403908|Experimental|PADN groups (radiofrequency denervation)|An 8-F long sheath will be inserted through the femoral vein and advanced to the main PA (MPA). The nMARQ Circular or Crescent (Biosense Webster) catheter will be advanced along this long sheath. After gently withdrawing the sheath and pushing the PADN catheter, the tip will be released from the sheath. Then, the tip of the catheter will be positioned first at the ostium of the left PA (Level 1 of ablation, <2 mm distal to orifice. After ablation at this level, the catheter tip will be positioned at the ostium of right PA (Level 2 of ablation, <2mm proximal to the bifurcation level). Finally, denervation of main pulmonary artery will be done by pulling the denervation catheter back into Level 3 of ablation (<2 mm proximal to both ostia of right and left PA-s) into main pulmonary artery.
3023836|NCT02403908|No Intervention|SHAM group|non-treated patients (controls)
3023837|NCT02403895|Experimental|Open-label AZD2014|Open-label AZD2014 given twice daily 3 days on, 4 days off during weekly paclitaxel
3023838|NCT02403882|Experimental|Order|The investigators arrange the placement of the targeted good to see if the order affects selection.
3023839|NCT02403882|Experimental|Packaging|The investigators adjust the packaging of the targeted good to determine the effects on selection.
3023840|NCT02403882|Experimental|Pricing|In food pantries, few products are priced. The investigators use pricing of products to determine its effect on selection.
3023841|NCT02403882|Experimental|Relative Proportions|The investigators adjust the proportion of the products to determine the effect on the selection of the targeted product.
3023842|NCT02403882|Experimental|Default Option|The investigators provide a targeted product to subjects at one point. Later, investigators offer subjects the possibility to exchange the targeted product for a close substitute.
3023843|NCT02403869||Group 1|MBC patients starting treatment with monochemotherapy for second line of quimiotherapy treatment for metastatic disease
3023844|NCT02403856|Experimental|Experimental group (Sodium Chloride 0.9%)|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
3023845|NCT02403856|Active Comparator|Control group (Methylprednisolone Acetate)|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
3023846|NCT02403843||Evaluation|A group of subjects with the RNS System implanted who elect to continue to receive RNS System responsive stimulation for the long term.
3023847|NCT02403830|Experimental|Methylnaltrexone|Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
3023848|NCT02403830|Placebo Comparator|Placebo|Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
3023849|NCT02403817|Experimental|Eye Movement Game Control|Cognitive Training Eye Motor Training
3023850|NCT02403817|Active Comparator|Hand Movement Game Control|Cognitive Training Hand Motor Training
3023851|NCT02403804|Other|All subjects|"All 3 weeks will occur during luteal phase of menstrual cycle with a two-to-three week washout period between weeks.~Week 1: Phosphatidylcholine 3600 mg qam and 2700 mg qpm~Week 2: Betaine anhydrous 588 mg qam and 412 mg qpm~Week 3: Betaine anhydrous 1000 mg BID"
3023852|NCT02403791|Experimental|Lung Ultrasound|In infants allocated to this arm Lung ultrasound for detection of ARDS will be performed before chest radiography.
3023853|NCT02403791|Active Comparator|Chest Radiography|In infants allocated to this arm chest radiography will be performed for the detection of indirect signs of ARDS without ultrasound evaluation.
3023854|NCT02403778|Active Comparator|Ipilimumab|Arm A (No VESANOIDTherapy) will receive the standard of care treatment with ipilimumab only, receiving the standard 4 doses of either 3 or 10 mg/kg ipilimumab every 3 weeks.
3023855|NCT02403778|Experimental|VESANOID|Arm B (VESANOID Therapy) will receive the standard 4 doses of either 3 or 10 mg/kg ipilimumab every three weeks plus the supplemental treatment of 150 mg/m2 of VESANOID orally for 3 days surrounding each dose of ipilimumab (day -1, day 0, day +1) for a total of 12 days of VESANOID treatment.
3023856|NCT02403765||Family cases|Family-based Parkinson patients carrying genetic variants associated with the disease
3023857|NCT02403765||Family controls|Family-based Control subjects
3023858|NCT02403752|Experimental|exercise intervention|"Exercise protocol based on the PLIÉ protocol, developed in consultation with experts worldwide, incl. traditional strength-building exercises, yoga, Tai Chi and Feldenkrais, that engage the muscles most needed to maintain independence--including lower body strength, balance, upper body strength, fine motor exercises , and pelvic floor exercises- combined them into a unique integrative exercise program, to be purposeful and to build procedural ('muscle') memory.~To be practiced at home in dyads of affected individuals and caregivers, called Paired PLIE Program."
3023859|NCT02403726||osteoporosis associated vertebral fractures|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures.
3023860|NCT02403713|Experimental|Test Treatment|Fluticasone/formoterol 125/5 µg BAI
3023861|NCT02403713|Active Comparator|Active Comparator 1|Fluticasone/formoterol 125/5 µg pMDI with spacer
3023862|NCT02403713|Active Comparator|Active Comparator 2|Fluticasone/formoterol 125/5 µg pMDI without spacer
3023863|NCT02403713|Active Comparator|Active Comparator 3|Fluticasone/formoterol pMDI (125/5 μg) without spacer, low dose
3023864|NCT02403713|Active Comparator|Active Comparator 4|Formoterol (12 µg) without spacer
3023865|NCT02403700||All study participants|One group observation study
3023866|NCT02403674|Experimental|MK-1439A|Treatment-naive HIV-infected participants will receive MK-1439A, a single-tablet FDC containing doravirine 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg, q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding.
3023867|NCT02403674|Active Comparator|ATRIPLA™|Treatment-naive HIV-infected participants will receive ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to MK-1439A q.d. by mouth for 96 weeks in order to maintain blinding.
3023868|NCT02403661|Active Comparator|Post surgical electrical stimulation|Balanced AC pulse at 20 Hz with less than 30V and 0.01 ms duration will be delivered for 1 hour.
3023869|NCT02403661|Placebo Comparator|Sham stimulation|Stimulation with the same parameters delivered only for 5 s.
3023870|NCT02403648|Experimental|BIOD-961, 1 mg IM|Intramuscular delivery of BIOD-961.
3023871|NCT02403648|Active Comparator|Lilly Glucagon, 1 mg IM|Intramuscular delivery of Lilly glucagon.
3023872|NCT02403648|Active Comparator|Novo Glucagon, 1 mg IM|Intramuscular delivery of Novo glucagon.
3023873|NCT02403648|Experimental|BIOD-961, 1 mg SC|Subcutaneous delivery of BIOD-961,
3023874|NCT02403648|Active Comparator|Lilly Glucagon, 1 mg SC|Subcutaneous delivery of Lilly glucagon.
3023875|NCT02403648|Active Comparator|Novo Glucagon, 1 mg SC|Subcutaneous delivery of Novo glucagon.
3023876|NCT02403635|Other|Midazolam + ASP2151|400 mg ASP2151 followed by 7.5 mg midazolam
3023877|NCT02403609|Experimental|BPT, Computerized Assessment|Participants will first take the Brain Performance Test (BPT) on two consecutive days
3023878|NCT02403596|Experimental|Group 1: Exacyl®: Standard treatment|Intravenous use. 1g Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g Exacyl® at H+3 then 1g Exacyl® placebo at H+7 and H+11
3023879|NCT02403596|Experimental|Group 2: Exacyl®: Extended treatment|Intravenous use. 1g Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g Exacyl® at H+3 / H+7 and H+11
3023880|NCT02403596|Placebo Comparator|Group 3: Placebo|This group will receive a placebo of Exacyl®: 1g placebo of Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g placebo of Exacyl® at H+3 / H+7 and H+11
3023881|NCT02403583|Other|Intervention- Home visits|Participants randomized to intervention arm receive 3 home visits conducted by one female and one male lay health worker.
3023882|NCT02403583|No Intervention|Standard Care|Participants will receive current standard clinic-based services including the option for women and partners to return to the clinic for male partner HIV testing or CHCT.
3023883|NCT02403570||Multiple Sclerosis|Brain MRI using advanced MR techniques
3023884|NCT02403557|Experimental|Tailored Internet-delivered CBT|Tailored Internet-delivered CBT during 8 weeks.
3023885|NCT02403557|Active Comparator|Waitlist|Weekly check-up.
3023886|NCT02403544|Experimental|CCRT Arm|Patients recruited will be treated by concurrent chemoradiotherapy with IGRT and two cytotoxic agents: capecitabine and oxaliplatin. Capecitabine will be taken orally twice a day, from D1 to D14 while oxaliplatin will be given intravenously on D1 and D8, every 21 days. The doses of the two drugs will be escalated alternatively in each level group. The radiation will be given by IGRT and the dose is between 45 to 54Gy, 1.8-3Gy per fraction.
3023887|NCT02403531|Active Comparator|Concurrent chemoradiotherapy|Patients assigned to this Arm received concurrent chemoradiotherapy. The prescribed dose of radiotherapy is generally 50-60 Gy/25-28fr. The concomitant chemotherapy is docetaxel 20 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1, repeated weekly during radiation.
3023888|NCT02403531|Experimental|Induction chemotherapy plus chemoradiotherapy|Patients assigned to this Arm first received two cycles of 3-weekly schedule of IC before definitive chemoradiotherapy, consisting of docetaxel 75 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1. The prescribed dose of radiotherapy is generally 50-60 Gy/25-28fr. The concomitant chemotherapy is docetaxel 20 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1, repeated weekly during radiation.
3023889|NCT02403518|Active Comparator|Back Pain Only|Pain localized to the low back or buttocks.
3023890|NCT02403518|Active Comparator|Leg Pain Only|Pain localized to unilateral pain of the leg (thigh, knee, calf, or foot).
3023891|NCT02403518|Active Comparator|Back and Leg Pain|Pain localized to both the low back and legs (back, buttocks, thigh, knee, calf, or foot).
3023892|NCT02403505|Experimental|ABIRATERONE - Group 1|"ZYTIGA - ABIRATERONE ACETATE TABLET~Combined Chemotherapy~DELTASONE- PREDNISONE TABLET~XTANDI - ENZALUTAMIDE CAPSULE"
3023893|NCT02403505|Experimental|ABIRATERONE - Group 2|"ZYTIGA - ABIRATERONE ACETATE TABLET~Combined Chemotherapy~DELTASONE- PREDNISONE TABLET~NILANDRON - NILUTAMIDE TABLET"
3023894|NCT02403492|No Intervention|Observational (No OSAS)|Comprised of obese children are not found to have obstructive sleep apnea and do not require cPAP
3023895|NCT02403492|Experimental|Experimental - cPAP, Continuation|Comprised of those obese children who are diagnosed with obstructive sleep apnea, requiring cPAP, who continue using cPAP during the 2 week RCT
3023896|NCT02403492|Experimental|Experimental - cPAP Discontinuation|Comprised of those obese children who are diagnosed with obstructive sleep apnea, requiring cPAP, who discontinue using cPAP during the 2 week RCT
3023897|NCT02403479|Active Comparator|Control|Cross-over control Each participant does 6 weeks of topical nasal saline, followed by 6 weeks of topical nasal silver colloid (Dose= 6.7mcg silver daily; Frequency= 2 sprays in each nostril daily; Route= Topical intra-nasal spray; Duration= 3 months)
3023898|NCT02403479|Active Comparator|Experimental|Each participant receives the full 12 weeks of topical nasal silver colloid (Dose= 6.7mcg silver daily; Frequency= 2 sprays in each nostril daily; Route= Topical intra-nasal spray; Duration= 3 months)
3024019|NCT02402608|Active Comparator|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture (32 g)
3023899|NCT02403466|Experimental|Resident Handoff Bundle|bundle of interventions designed to improve handoff, including: training of residents in teamwork and handoff techniques; redesign of verbal handoff processes; implementation of handoff mnemonic (I-PASS); implementation of structured written / computerized handoff tool; faculty training in handoffs
3023900|NCT02403440|Experimental|Hetrombopag Olamine|Hetrombopag Olamine 2.5mg, 5mg and 7.5mg
3023901|NCT02403427|Experimental|VoiceDiab expert system|the VoiceDiab system using before every main meal; three times per day.
3023902|NCT02403427|No Intervention|manual calculation|manula insulin calculation before every main meal; three times per day
3023903|NCT02403401|Experimental|Levonorgestrel (BAY98-7196)|Vaginal ring containing 170 mg levonorgestrel
3023904|NCT02403388||Multiprofessional primary care offices with PRisM|25 multiprofessional primary care offices. Each professional of care of the offices (about 10 FTE / office) have to declare each adverse event that occurs in their office during 18 months.
3023905|NCT02403388||Multiprofessional primary care offices without PRisM|25 multiprofessional primary care offices. Each professional of care of the offices (about 10 FTE / office) have to declare each adverse event that occurs in their office during 18 months.
3023906|NCT02403375|Experimental|Continuous Subcutaneous Insulin Infusion (CSII)|Continuous Subcutaneous Insulin Infusion (CSII) in Children and Adolescents 2-17 Years of Age
3023907|NCT02403362|Experimental|EPO-018B 0.025 mg/kg|EPO-018B starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
3023908|NCT02403362|Experimental|EPO-018B 0.05 mg/kg|EPO-018B starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
3023909|NCT02403362|Experimental|EPO-018B 0.08 mg/kg|EPO-018B starting dose of 0.08 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
3023910|NCT02403349|Experimental|Fimasartan|fimasartan potassium 60mg, 1 tablet by mouth, every day Angiotensin ll receptor blocker
3023911|NCT02403349|Active Comparator|Valsartan|valsartan 80mg, 1 tablet by mouth, every day angiotensin II receptor antagonists
3023912|NCT02403349|Active Comparator|Atenolol|atenolol 50mg, 1 tablet by mouth, every day beta-blocker
3023913|NCT02403336|Experimental|Behavioral group intervention|Professionals: 3 training sessions for updating the knowledge and learning skills. Patients: Health education workshop.
3023914|NCT02403336|Active Comparator|Usual clinical practice|Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
3023915|NCT02403323|Experimental|Part 1 Open-label Extension|
3023916|NCT02403323|No Intervention|Part 2 Safety Monitoring|
3023917|NCT02403310|Experimental|Dose Escalation - Selinexor|"Dose escalation of selinexor with fixed doses of daunorubicin and cytarabine.~Induction Therapy may be followed by Consolidation Phase and Maintenance Phase as outlined in the Detailed Description and Intervention Descriptions."
3023918|NCT02403297||Healthy|"Saliva will be collected from 58 subjects determined to be healthy according to the protocol."
3023919|NCT02403297||Gingivitis|Saliva will be collected from 58 subjects determined to have gingivitis according to the protocol.
3023920|NCT02403297||Periodontal disease|Saliva will be collected from 58 subjects determined to have periodontal disease according to the protocol.
3023921|NCT02403284|Experimental|Liraglutide|Liraglutide titration up to 1.8 mg/d over approximately 3 weeks
3023922|NCT02403284|Placebo Comparator|Sugar pill|matching placebo and titration
3023923|NCT02403271|Experimental|Phase 1b/2|"Phase 1b: Subjects will receive ibrutinib daily in combination with Durvalumab (MEDI4736) IV at various dose levels to determine the Recommended Phase II dose level.~Phase 2: Subjects will receive ibrutinib daily in combination with Durvalumab (MEDI4736) IV at the Recommended Phase II dose level."
3023924|NCT02403258|Experimental|Plum-blossom needle group|Patients randomized into this group will receive plum-blossom needle as treatment. DU 20, DU 16, GB 20, EX-HN5, BL 15, BL 18, BL 23 will be selected as acupoints. Each point will be tapped gently one by one by plum blossom needle until the skin get slightly redness. The treatments will be given two sessions per week, consistently for 12weeks (24 sessions in all).
3023925|NCT02403258|Active Comparator|HRT group|Patients randomized into this group will receive habit reversal training (HRT) as treatment. Habit reversal training will consist of the following 4 parts: (1) self-monitoring, (2) competing responses, (3) relaxation training and (4) contingency management. The training will be given weekly in the 12 weeks (totally 12 sessions) by a special rehabilitation therapist, first two sessions 1.5 h, and remaining sessions 1 h for each treatment.
3023926|NCT02403245|Experimental|Psychosocial stimulation|One session of a social stimulation
3023927|NCT02403245|No Intervention|Control group|Residents are in a social controlled condition but without direct stimulation.
3023928|NCT02403232|Experimental|ASCs injection|Autologous adipose-derived stem cells (ASCs) injection with LIPOGEMS system.
3023929|NCT02403219|Experimental|Botulinum toxin type A injection|An injection of 4 international units of botulinum toxin type A will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
3023930|NCT02403219|Sham Comparator|Sham injection|An injection of 4 international units of sham will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
3023931|NCT02403206|Experimental|Laser|Femtosecond laser assisted capsulotomy and corneal incision performed during cataract surgery
3023932|NCT02403206|Active Comparator|Manual|Continuous curvilinear capsulorhexis performed during cataract surgery
3023933|NCT02403193|Experimental|PBF-509_80 mg|
3023934|NCT02403193|Experimental|PBF-509_160 mg|
3023935|NCT02403193|Experimental|PBF-509_320 mg|
3023936|NCT02403193|Experimental|PBF-509_640 mg|
3023937|NCT02403193|Experimental|PBF509_160 mg +PDR001|
3023938|NCT02403193|Experimental|PBF509_320 mg+PDR001|
3023939|NCT02403193|Experimental|PBF509_640 mg +PDR001|
3023940|NCT02403193|Experimental|RP2D (PBF-509+PDR001)_immuno naïve|Immunotherapy naïve patients will be treated at the combination RP2D previously determined in the phase Ib, dose escalation portion of the trial.
3023941|NCT02403193|Experimental|RP2D (PBF-509+PDR001)_immuno treated|Patients previously treated with immunotherapy (previous immune checkpoint inhibitors; anti-CTLA-4, anti-PD-1, anti-PD-L1 and/or combinations) will be treated at the combination RP2D previously determined in the phase Ib, dose escalation portion of the trial.
3023942|NCT02403180|Other|DACP MF, then PROCLEAR 1D MF|DACP MF (nelfilcon A) multifocal contact lenses worn in Period 1, followed by PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
3023943|NCT02403180|Other|PROCLEAR 1D MF, then DACP MF|PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 1, followed by DACP MF (nelfilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
3023944|NCT02403154|Experimental|Randomized to Internal Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention will be internal fixator.
3023945|NCT02403154|Experimental|Randomized to External Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention will be external fixator.
3023946|NCT02403154|Other|Observational - Internal Fixator|Patient signed consent but did not want to randomize their procedure and either the treating physician selected the internal fixator intervention based on their preference for the specific case or the patient chose the internal fixator.
3023947|NCT02403154|Other|Observational - External Fixator|Patient signed consent but did not want to randomize their procedure and either the treating physician selected the external fixator intervention based on their preference for the specific case or the patient chose the external fixator.
3023948|NCT02403141||Normal glucose tolerance|Patients with normal fasting glucose. Blood glucose less than 5.6mmol/L
3023949|NCT02403141||Impaired fasting glycaemia|Patients with blood glucose between 5.6mmol/L - 7mmol/L
3023950|NCT02403141||Type 2 diabetes|Patients with blood glucose higher than 7mmol/L and negative IA2 and GAD antibodies.
3023951|NCT02403141||Type 1 diabetes|Patients on insulin and with positive IA2 and/or GAD antibodies.
3023952|NCT02403128|Experimental|Patients with macular edema from RAM|Intravitreal aflibercept 2.0 mg injection for eyes meeting eligibility criteria will be administered at baseline. Reinjection of the drug for protocol-defined criteria at least two months after previous injection.
3023953|NCT02403115||Lupus Nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies.
3023954|NCT02403115||Incident SLE without nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies, in order to evaluate the presence of nephritic manifestations.
3023955|NCT02403115||Prevalent SLE without nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to evaluate the presence of nephritic manifestations.
3023956|NCT02403115||Rheumatoid arthritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to evaluate the presence of nephritic manifestations.
3023957|NCT02403115||Membranous glomerulonephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to exclude secondary forms of the disease.
3023958|NCT02403089||neonates|neonates 24-41 weeks gestational age
3023959|NCT02403089||children|hematopoietic stem cell transplant recipient children (< 18 years old, donor source: cord blood or genoidentical donor)
3023960|NCT02403063|Active Comparator|sugammadex|Selective relaxant binding agent
3023961|NCT02403063|Active Comparator|neostigmine|Acetylcholinesterase inhibitor
3023962|NCT02403063|Experimental|neostigmine-sugammadex|Acetylcholinesterase inhibitor followed by a selective relaxant binding agent
3023963|NCT02403050||Fiducial Markers Prospective cohort|2 fiducial markers (Visicoils) to be placed in the tumor area at the routine endoscopic ultrasound (EUS) appointment.
3023964|NCT02403050||Retrospective cohort|Images and clinical data from a retrospective group of patients without fiducial markers
3023965|NCT02403037|Experimental|True Auricular Acupressure Group|Participants in this group will receive standard antiemetics before and during chemotherapy, and a 5-day auricular acupressure treatment protocol for controlling nausea and vomiting during the first cycle of chemotherapy.
3023966|NCT02403037|Sham Comparator|Sham Auricular Acupressure Group|Participants in this group will receive standard antiemetic medications before and during chemotherapy, and a 5-day sham auricular acupressure intervention protocol during the first cycle of chemotherapy.
3023967|NCT02403037|Other|Standard Care Group|Participants in this group will only receive standard anti-emetic treatment before and during chemotherapy.
3023968|NCT02403024|Experimental|InterWalk|The intervention program will prescribe that patients performing 150 min of interval training per week.
3023969|NCT02403024|Other|Waiting list Control|Patients allocated to the waiting-list control group will receive usual care control for the first 12 weeks of the study and will receive the same instructions for download and use of the InterWalk app in the final 12 weeks.
3023970|NCT02403011|Experimental|Soft tissue mobilization group|soft tissue mobilization was applied three times in a week and home program exercises were recommended which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
3023971|NCT02403011|Experimental|Home program controlled once six weeks|Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations were recommended
3023972|NCT02402998|Experimental|Eltrombopag|Eltrombopag 50 mg/daily.
3023973|NCT02402985|Other|High animal protein diet group AP|6-weeks diet intervention with high animal protein
3023974|NCT02402985|Other|High plant protein diet group PP|6-weeks diet intervention with high plant protein
3023988|NCT02402946|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patienst will take a pill of placebo and receive no instructions about controlling muscular activity.
3056881|NCT02182388|Experimental|BI 207127 NA|single rising dose part
3023975|NCT02402972|Experimental|IPC plus AC|"patients treated with intraoperative intraportal chemotherapy (IPC) plus adjuvant chemotherapy (AC; mFOLFOX6).; IPC: During the operation, one dose of fluorodeoxyuridine (FUDR) 1000 mg and oxaliplatin 100 mg were administered as a bolus into the regional vein within 5 minutes just before ligation.~AC: All patients received mFOLFOX6 adjuvant chemotherapy, consisting of a 2-h infusion of 85 mg/m2 oxaliplatin given simultaneously with a 2-h infusion of 400 mg/m2 LV, followed by a bolus of 400 mg/m2 5-FU, and then a continuous infusion of 2000 mg/m2 5-FU given on 2 consecutive days by intravenous pumping every 14 days for 12 cycles.[1] Adverse events were categorized according to National Cancer Institute Common Toxicity Criteria, version 3.0."
3023976|NCT02402972|Active Comparator|AC|patients treated with adjuvant chemotherapy (AC; mFOLFOX6) alone after surgery; Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy, consisting of a 2-h infusion of 85 mg/m2 oxaliplatin given simultaneously with a 2-h infusion of 400 mg/m2 LV, followed by a bolus of 400 mg/m2 5-FU, and then a continuous infusion of 2000 mg/m2 5-FU given on 2 consecutive days by intravenous pumping every 14 days for 12 cycles.[1] Adverse events were categorized according to National Cancer Institute Common Toxicity Criteria, version 3.0.
3023977|NCT02402959||Cohort 1|Based on the first TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
3023978|NCT02402959||Cohort 2|Based on the second TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
3023979|NCT02402959||Cohort 3|Based on the third TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
3023980|NCT02402959||Cohort 4|Based on the fourth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
3023981|NCT02402959||Cohort 5|Based on the fifth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
3023982|NCT02402959||Cohort 6|Based on the sixth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
3023983|NCT02402959||Cohort 7|Based on the seven TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
3023984|NCT02402959||Cohort 8|Based on the eighth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
3023985|NCT02402959||Cohort 9|Based on the nineth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
3023986|NCT02402959||Cohort 10|Based on the tenth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
3023987|NCT02402946|Experimental|Biofeedback|Abdomino-thoracic muscle activity after a challenge meal will be recorded by EMG and the signal will be displayed on a monitor but not showed to the patients; in the biofeedback group, patients will be instructed to control, abdomino-thoracic muscle activity
3024016|NCT02402634||Mechanical ventilatory lung care|liver transplantation recipients under mechanical ventilatory lung care
3023989|NCT02402933|Experimental|Nasal Glucagon|A single dose of 3mg glucagon nasal powder administered using a nasal powder delivery device for the treatment of moderate or severe hypoglycemic events; a maximum of 4 events per participant during the study.
3023990|NCT02402920|Experimental|Limited Stage SCLC Group: MK-3475 + Radiation|"Part A: Participants receive MK-3475 by vein on Day 1 of Cycles 1-16. The dose of MK-3475 given by vein depends on when the participants joins this study.~Participants receive chemotherapy with either Cisplatin and Etoposide or Carboplatin and Etoposide. During cycles 1-4, Etoposide 100 mg/m^2 given by vein on Days 1, 2, and 3 of each 3 week cycle. During cycles 1-4 of the induction phase, participants for whom Cisplatin/Etoposide has been selected as chemotherapy receive Cisplatin 80 mg/m^2 by vein on Day 1 of each 3 week cycle. Cisplatin given for up to four cycles.~During cycles 1-4 of the induction phase, participants for whom Carboplatin/Etoposide has been selected as chemotherapy receive Carboplatin by vein at AUC 5 on Day 1 of each 3 week cycle. Carboplatin given for up to four cycles.~Radiation therapy delivered to chest at 45 Gy twice a day for 15 days."
3023991|NCT02402920|Experimental|Extensive Stage SCLS Group: MK-3475 + Radiation|Part B: After second chemotherapy cycle, the dose of MK-3475 given by vein will depend on when the participants joins this study. Consolidation radiation therapy delivered after 1-6 cycles of chemotherapy. Radiation therapy delivered to chest at 45 Gy once a day for 15 days.
3023992|NCT02402907|Experimental|CHG cloth|2% chlorhexidine gluconate (CHG) cloth
3023993|NCT02402907|Placebo Comparator|Placebo cloth|A fragrance free cleansing cloth
3023994|NCT02402881|Experimental|Intervention|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
3023995|NCT02402868|Experimental|Intranasal ketamine and saline|Intranasal ketamine (each single dose, 8 mg/kg prepared in 0.9% NS in 3 mL syringe and atomizer, to a maximum of 6.4 mL) PLUS IV 0.9% NS 0.02 mL/kg
3023996|NCT02402868|Active Comparator|Intravenous ketamine and saline|Intravenous ketamine (single dose, 1 mg/kg, to a maximum 100 mg) PLUS intranasal 0.9% NS 0.08 mL/kg divided to both nares
3023997|NCT02402855|Experimental|Group Intervention: Financial support|
3023998|NCT02402855|Active Comparator|Group Control: no financial support|
3023999|NCT02402842|Experimental|DCF regimen|docetaxel 75 mg/m2 day, Cisplatin75 mg/m2 and 5Fluorouracil at 750 mg/m2/day for 5 days
3024000|NCT02402829||Hemophilia Patients|Subjects diagnosed with moderate or severe Hemophilia A or B who use a central venous line (CVL) for regular prophylaxis factor infusions and are at the clinic for a standard of care visit. As part of the study all subjects will have blood drawn through their CVL and will also undergo a peripheral vein blood draw.
3024001|NCT02402816|Experimental|MPP ON|Patients will be randomized to the MPP-ON Arm vs Standard ICD
3024002|NCT02402816|Active Comparator|Standard ICD|Patients will be randomized to the MPP-ON Arm vs Standard ICD
3024003|NCT02402764|Experimental|Selinexor Treatment|"Screening period (which may last up to 28 days), followed by Selinexor treatment for qualified participants.~During the treatment period, participants will undergo physical examination every 2 weeks until Cycle 6 Day 1 (C6D1), and then every 4 weeks and assessment of tumor response every 8 weeks.~Participants will be treated until progression of disease or the development of unacceptable toxicities. All participants will then undergo a final visit (end of treatment visit)."
3024004|NCT02402751|Experimental|Acquisition of normative database|Development, implementation and initiation of normative database (image and data) quantitative ultra high field MRI paramaters
3024005|NCT02402738|Experimental|Interpersonal and Social Rhythm Therapy|Participants may be randomized to receive up to 20 outpatient sessions of Interpersonal and Social Rhythm Therapy, provided as an adjunct to community treatment as usual. Intervention sessions begin during pregnancy and continue through 8 weeks postpartum.
3024006|NCT02402738|Active Comparator|Enhanced Treatment as Usual|Those randomized to the Enhanced Treatment as Usual arm will follow their usual treatment plans in the community, with enhanced monitoring of symptoms and functioning through regular study assessments. With a release of information, we will provide community clinicians with a monthly standardized report that summarizes level of symptom severity and risk, designed to aid in continuity of care.
3024007|NCT02402725|Experimental|Ultra-high dose dexamethasone|Ultra-high dose dexamethasone administered intravenously and orally
3024008|NCT02402712|Experimental|Herceptin SC + Perjeta IV + docetaxel IV|Single arm
3024009|NCT02402699||Unresectable, recurrent or metastatic melanoma patients|All adult unresectable, recurrent, or metastatic melanoma patients with HBV or HCV treated with at least 1 dose of ipilimumab therapy in Taiwan
3024010|NCT02402686||Tocilizumab for RA in Routine Clinical Practice|Participants from routine clinical practice in Hungary who are receiving treatment for RA with tocilizumab SC according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling and who have no contraindication to tocilizumab therapy as per the local label are eligible for observation.
3024011|NCT02402673|Other|Intervention|
3024012|NCT02402660|Experimental|ALK-001|Daily, oral administration of one capsule. See details below.
3024013|NCT02402660|Placebo Comparator|Placebo|Daily, oral administration of one capsule. See details below.
3024014|NCT02402647|Experimental|CREST|"Compensatory Cognitive Training (CCT) is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
3024015|NCT02402647|Active Comparator|ET|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
3024017|NCT02402621|Active Comparator|Conventional analgesic group|fentanyl
3024020|NCT02402608|Placebo Comparator|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
3024021|NCT02402595|Experimental|Sequence 1 - Period 1|AVP-923 and placebo matching AVP-786- BID Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
3024022|NCT02402595|Experimental|Sequence 1 - Period 2 (after 3-week washout)|AVP-786 and placebo matching AVP-923 - BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
3024023|NCT02402595|Experimental|Sequence 2 - Period 1|AVP-786 and placebo matching AVP-923 - BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
3024024|NCT02402595|Experimental|Sequence 2 - Period 2 (after 3-week washout)|AVP-923 and placebo matching AVP-786- BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
3024025|NCT02402582|Experimental|Family-Centered Empowerment Model|Have the same in-patient, pre-intervention, and post-intervention follow-up care as Control Group. However, rather than routine care and follow-up during the intervention period, they recieved than 4 stage intervention using the Family Centered Empowerment Model.
3024026|NCT02402582|Active Comparator|Control|Same in-patient, pre-intervention, and post-intervention follow-up care as Experimental Group. However, rather than 4 stage intervention they receive routine care and follow-up.
3024027|NCT02402569|Experimental|Multi-electrodes / single electrode|Multi stimulation / single stimulation
3024028|NCT02402569|Experimental|Single-electrode / Multi electrodes|Single stimulation / Multi stimulation
3024029|NCT02402556|Experimental|MOCEP|MOCEP is implemented over a period of 25 weeks, through weekly group meetings that last approximately three hours.
3024030|NCT02402556|Active Comparator|Waitlist Control Group|For ethical reasons, no one recruited will be excluded from the opportunity to benefit from the intervention. MOCEP group will be the primary intervention group and the second group will act as the wait-listed control group. Although the families in the wait-listed control group will start out as a control group (not receiving the intervention), they will have the opportunity to participate in the intervention in a later round of implementation, after the intervention group has completed the program.
3024031|NCT02402543|Placebo Comparator|Control Arm|In pre-op, the subject is administered four placebo pills PO containing confectioners sugar, which are matched in color, size, and shape to the active pills.
3024032|NCT02402543|Experimental|Experimental Arm|In pre-op, the subject is administered four pills PO containing a total of 1000 mg of acetaminophen and 600 mg of gabapentin, which are matched in color, size, and shape to the placebo pills.
3024033|NCT02402530|Placebo Comparator|Placebo|Matching placebo administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10
3024034|NCT02402530|Experimental|125 mg Neridronic acid|Neridronic acid 62.5 mg administered as intravenous infusion on Day 1 and Day 4; matching placebo administered as intravenous infusion on Day 7 and Day 10
3024035|NCT02402530|Experimental|250 mg Neridronic acid|Neridronic acid 62.5 mg administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10
3024036|NCT02402517|Placebo Comparator|Extruded snack control|100% corn flour
3024037|NCT02402517|Experimental|Extruded snack with small particle size pea flour|60% corn flour and 40% small particle size pea flour
3024038|NCT02402517|Experimental|Extruded snack with large particle size pea flour|60% corn flour and 40% large particle size pea flour
3024039|NCT02402517|Experimental|Extruded snack with lentil flour|60% corn flour and 40% lentil flour
3024040|NCT02402517|Experimental|Extruded snack navy bean flour|60% corn flour and 40% navy bean flour
3024041|NCT02402517|Experimental|Extruded snack with pinto bean flour|60% corn flour and 40% pinto bean flour
3024042|NCT02402504|Placebo Comparator|Extruded snack control|100% corn flour
3024043|NCT02402504|Experimental|Extruded snack with small particle size pea flour|60% corn flour and 40% small particle size pea flour
3024044|NCT02402504|Experimental|Extruded snack with large particle size pea flour|60% corn flour and 40% large particle size pea flour
3024045|NCT02402504|Experimental|Extruded snack with lentil flour|60% corn flour and 40% lentil flour
3024046|NCT02402504|Experimental|Extruded snack navy bean flour|60% corn flour and 40% navy bean flour
3024047|NCT02402504|Experimental|Extruded snack with pinto bean flour|60% corn flour and 40% pinto bean flour
3024048|NCT02402491|Active Comparator|24 months of P2Y12 receptor antagonist|Receive 24 months of dual antiplatelet therapy (with a P2Y12 receptor antagonist in addition to aspirin) after index procedure. All subjects receive aspirin for the duration of study.
3024049|NCT02402491|Placebo Comparator|12 months of P2Y12 receptor antagonist|Receive 12 months of dual antiplatelet therapy (with a P2Y12 receptor antagonist in addition to aspirin) after index procedure. All subjects receive aspirin for the duration of study.
3024050|NCT02402478||Stable coronary artery disease|Patients with chest pain
3024051|NCT02402465|Placebo Comparator|Placebo|Placebo nasal spray that is similar to Dymista in all respects except the active ingredient
3024052|NCT02402465|Experimental|Fluticasone propionate|Fluticasone propionate nasal spray provided in a bottle similar to placebo and dymista
3024053|NCT02402465|Experimental|Dymista (fluticasone/azelastine)|Dymista is also provided as a nasal spray in bottles similar to the other two agents
3024054|NCT02402452|Experimental|Normal Renal Function|Participants will receive a single dose of GS-9857 on Day 1.
3024055|NCT02402452|Experimental|Severe Renal Impairment|Participants will receive a single dose of GS-9857 on Day 1.
3024056|NCT02402439|Experimental|Islet Transplant|Islet transplantation into the gastrointestinal submucosa
3024057|NCT02402413|Experimental|PCOS women|
3024058|NCT02402400|Active Comparator|Oral Ticagrelor|
3024059|NCT02402400|Experimental|Sub Lingual Ticagrelor|
3024060|NCT02402387|Active Comparator|Neutral|The patient's head will be in neutral position.
3024061|NCT02402387|Experimental|Flexed|The patient's head will be flexed.
3024062|NCT02402387|Experimental|Extended|The patient's head will be extended.
3024063|NCT02402387|Experimental|Rotated|The patient's head will be rotated.
3024064|NCT02402374|Experimental|PRP gel|Autologous platelet rich plasma gel
3024065|NCT02402374|Placebo Comparator|Placebo|Saline gel
3024066|NCT02402348|Experimental|Metformin|Metformin 850 mg orally once a day for 3 days, then 850 mg orally twice daily starting day 4 until 24hrs before surgery.
3024067|NCT02402335||1 Fracture of vertebra|Osteoporotic fracture of the vertebra
3024068|NCT02402335||2 Nerve Compression|Osteochondria, Spinal disc herniation, Nerve compression
3024069|NCT02402322|Active Comparator|Non-scheduled support|Participants received an Web-based cognitive behavioral treatment for Panic Disorder with the support of a therapist via phone when they required it.
3024070|NCT02402322|Experimental|Scheduled support|Participants received an Web-based cognitive behavioral treatment for Panic Disorder with the support of a therapist via phone weekly.
3024071|NCT02402322|No Intervention|Waiting list|Participants in a waiting list.
3024072|NCT02402309|Experimental|Active topical NS2 1% dermatologic cream|NS2 1% topical cream for dermal application
3024073|NCT02402309|Placebo Comparator|Topical vehicle dermatologic|Vehicle placebo for dermal application
3024074|NCT02402296|Active Comparator|Group II (test group)|Included those patients who received a systemic β-1,3/1,6-D-glucan (100 mg capsule) once/ day for 40 days after scaling and root planing.
3024075|NCT02402296|Placebo Comparator|Group I (control group)|Was assigned for patients who had scaling and root planing and empty capsules filled with carbohydrates (placebo) for 40 days.
3024076|NCT02402283|Experimental|Test Product|Metronidazole benzoate oral granules
3024077|NCT02402283|Active Comparator|Reference Product|Flagyl 400 mg Tablets
3024078|NCT02402270|Experimental|ECP-019 A (Group A)|
3024079|NCT02402270|Experimental|ECP-019 B (Group B)|
3024080|NCT02402270|Experimental|ECP-019 C (Group C)|
3024081|NCT02402270|Active Comparator|Group D|
3024082|NCT02402270|Active Comparator|Group E|
3024083|NCT02402257||Traditionally-trained|Patients who undergo CVC procedures by traditionally-trained providers who have not undergone simulation-based mastery learning. This could be retrospective (before the study started) or at a site where the training was not implemented.
3024084|NCT02402257||CVC Train the Trainer|Patients who undergo CVC procedures by providers who have participated in simulation-based mastery learning.
3024085|NCT02402244||Observational (Project: Every Child)|Patients undergo medical data review to create a Childhood Cancer Registry. Patients also undergo collection of bio-specimen samples (e.g., tissue, blood, bone marrow, plasma, serum, buccal cells, saliva, cerebrospinal fluid, or urine).
3024086|NCT02402231|Experimental|Omalizumab|Omalizumab is given to protect the study object from severe allergic reactions while they are going through oral immunotherapy with peanuts. There wïll be only one arm. The study objects are their own controls by also having allergy to airborne allergens. The dose is calculated by the study objects body mass and number of total IgE antibodies.
3024087|NCT02402218|Active Comparator|Usual Care|Participants receive standard of care for Hepatitis C in the clinic.
3024088|NCT02402218|Experimental|Usual care plus peer-mentors|In addition to receiving standard of care for HCV in the clinic, this is an investigational strategy in which participants assigned to this group will be asked to interact with a peer-mentor who is someone who has been cured of their HCV infection.
3024089|NCT02402218|Experimental|Usual care plus incentives|In addition to receiving standard of care for HCV in the clinic, this is an investigational strategy in which participants assigned to this group will be given incentives after completing certain goals during the course of the study.
3024090|NCT02402205|Experimental|Web Implementation of TF-CBT|"Web implementation (W)provides only web-based (distance learning) training and consultation to mental health therapists providing TF-CBT treatment to adjudicated youth in RTF. Therapists access the initial 10 hour training course(www.musc.edu/tfcbt) and follow-up consultation (www.musc.edu/tfcbtconsult) at their own convenience and as needed during the course of the study, with RTF administrators guaranteeing that therapists have time to do so. This implementation strategy is free and more convenient to therapists and administrators as it can be accessed whenever desired."
3024091|NCT02402205|Experimental|Web + Live Implementation of TF-CBT|"Web + Live (W+L) implementation provides web-based training and consultation as described in W, and also provides 1) face-to-face training and 2) twice monthly phone consultation with an expert TF-CBT trainer. W+L requires greater resource commitment from therapists and administrators and is less convenient, but provides more specific consultation on the therapists' personal TF-CBT treatment cases."
3024092|NCT02402192|Active Comparator|Corifollitropin alfa|Under current practice, 67 participants will be stimulated with a single injection of 100 mg, sc of Corifollitropin alpha (Elonva®). From day 6 stimulation and even prior to induction of ovulation day, 0.25 mg / day was administered sc ganirelix (Orgalutran®). From day 8 stimulation and depending on the ovarian response, you can add recombinant FSH (Puregon) up to 150 IU by Puregon Pen® device. In the presence of 3 or more follicles ≥17 mm, ovulation is induced with a single dose of 0.2 mg Decapeptyl 6500u or hCG (Ovitrelle) if there is no risk of OHSS, and 36 hours later he held the follicular puncture oocyte retrieval.
3024093|NCT02402192|Active Comparator|recombinant FSH|Under current practice, 67 participants will be stimulated with a daily dose of recombinant FSH. Administration of recombinant FSH (Puregon) starts at an initial dose of 150-225 IU / day by the Puregon Pen® device. From day 6 stimulation 0.25 mg / day administered sc ganirelix (Orgalutran®). From this day may also vary the dose of recombinant FSH according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.2 mg or Decapeptyl hCG 6500u (Ovitrelle) is given if there is no risk of OHSS, and 36 hours then held follicular puncture for recovering oocytes.
3024094|NCT02402192|Active Comparator|HP- hMG|Under current practice, 67 participants will be stimulated with HP-hMG, following the same pattern described for the group of recombinant FSH. In this case, the initial dose is 225-300 IU / day of HP-hMG (Menopur®). From day 6 stimulation 0.25 mg / day administered sc ganirelix (Orgalutran®). From this day may also vary the dose of HP-hMG according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.2 mg Decapeptyl 6500u or hCG (Ovitrelle) is given if there is no risk of OHSS and 36 hours then held the follicular puncture for oocyte retrieval .
3024095|NCT02402179|Experimental|Tryptophan Amino Acid|13.2, 26.4, 39.7, 52.9% of the mean tryptophan requirement of 3.78 mg/kg/d will be given to subjects.
3024096|NCT02402166|Experimental|Single Arm|There are 4 periods in this study: 1)screening and washout; 2) Dose Optimization; 3) Dose Maintenance; 4) Safety Follow-up. SPD489 will be used to treat all subjects.
3056882|NCT02182388|Placebo Comparator|Placebo|
3024097|NCT02402153|Other|Sydvestjysk hospital|Observational EEG recording with the Hyposafe device
3024098|NCT02402140|Experimental|1 with pharmaceutical intervention|"Patients allocated to group 1 with pharmaceutical intervention received instructions on the proper use of immunosuppressants as dosage, frequency and administration schedules, importance of immunosuppressive drugs and the risk of rejection.~No more interventions were applied."
3024099|NCT02402140|No Intervention|2 without pharmaceutical intervention|"Standard following of the Hospital do Rim, without pharmaceutical intervention. This group was just followed by the nurses of the hospital, but without a standardized intervention.~It was not a intervention, it was the control group"
3024100|NCT02402127|Other|TruEye, MyDay, clariti 1day|Narafilcon A contact lenses in Period 1, followed by stenfilcon A contact lenses in Period 2 and somofilcon A contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 1 day (16 hours).
3024101|NCT02402127|Other|TruEye, clariti 1day, MyDay|Narafilcon A contact lenses in Period 1, followed by somofilcon A contact lenses in Period 2 and stenfilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
3024102|NCT02402127|Other|MyDay, TruEye, clariti 1day|Stenfilcon A contact lenses in Period 1, followed by narafilcon A contact lenses in Period 2 and somofilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
3024103|NCT02402127|Other|MyDay, clariti 1day, TruEye|Stenfilcon A contact lenses in Period 1, followed by somofilcon A contact lenses in Period 2 and narafilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
3024104|NCT02402127|Other|Clariti 1day, TruEye, MyDay|Somofilcon A contact lenses in Period 1, followed by narafilcon A contact lenses in Period 2 and stenfilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
3024105|NCT02402127|Other|Clariti 1day, MyDay, TruEye|Somofilcon A contact lenses in Period 1, followed by stenfilcon A contact lenses in Period 2 and narafilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
3024106|NCT02402114|Experimental|Intervention|Subject randomized to this group receives 1 oral dose of Hydrocortisone 120 mg
3024107|NCT02402114|Placebo Comparator|Placebo|Subject randomized to this group will receive an oral sugar/placebo pill that looks similar to the Hydrocortisone pill.
3024108|NCT02402101|Active Comparator|active tDCS|Intensity : 2mA Duration : 20 minutes ramp up/ramp down 30sec anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
3024109|NCT02402101|Placebo Comparator|sham tDCS|Placebo built-in mode (30 sec ramp periods at the beginning and the end of the sham stimulation to mimic the somatosensory artifact of real tDCS) Same electrode montage than in the active group.
3024110|NCT02402088|Active Comparator|Normal Weight|BMI18.5-24.9 (normal range)
3024111|NCT02402088|Experimental|Overweight|body mass index between 25.0 - 29.9 (overweight range)
3024112|NCT02402088|Experimental|Obese|body mass index between 30 and 35 (obese range)
3024113|NCT02402075||Brain tumor|patients with glioma
3024114|NCT02402062|Experimental|TH-302 + Sunitinib|TH-302 + Sunitinib. Single arm Study.
3024115|NCT02402049|Active Comparator|1: Natrum muriaticum 30C|Natrum muriaticum 30C
3024116|NCT02402049|Active Comparator|2: Lachesis 30C|Lachesis 30C
3024117|NCT02402049|Active Comparator|3: Sepia 30C|Sepia 30C
3024118|NCT02402049|Active Comparator|4: Nux vomica 30C|Nux vomica 30C
3024119|NCT02402049|Active Comparator|5: Pulsatilla 30C|Pulsatilla 30C
3024120|NCT02402049|Active Comparator|6 Folliculinum 30C|Folliculinum 30C
3024121|NCT02402049|Placebo Comparator|1: Placebo Natrum muriaticum|Placebo Natrum muriaticum
3024122|NCT02402049|Placebo Comparator|2: Placebo Lachesis|Placebo Lachesis
3024123|NCT02402049|Placebo Comparator|3: Placebo Sepia|Placebo Sepia
3024124|NCT02402049|Placebo Comparator|4: Placebo Nux vomica|Placebo Nux vomica
3024125|NCT02402049|Placebo Comparator|5: Placebo pulsatilla|Placebo pulsatilla
3024126|NCT02402049|Placebo Comparator|6: Placebo Folliculinum|Placebo Folliculinum
3024127|NCT02402036|Experimental|Regorafenib|Regorafenib 120 mg orally daily for 21 days out of a 28 day cycle
3024128|NCT02402023|Active Comparator|Standard Care (SC)|Patients in the SC arm will receive 4 counseling sessions and nicotine patches as part of typical cessation measures delivered to patients.
3024129|NCT02402023|Experimental|Contingency Management (CM)|Patients in the CM arm will receive monetary payment contingent on smoking abstinence (in addition to SC: 4 counseling sessions and nicotine patches).
3024130|NCT02402010|Experimental|Adjunctive Yoga|Participants may be randomized to receive up to 10 weeks of group yoga class, as an adjunct to medication treatment as usual provided by community clinicians.
3024131|NCT02402010|Other|Enhanced Treatment as Usual|Those randomized to the Enhanced Treatment as Usual arm will follow their usual treatment plans in the community, with enhanced monitoring of symptoms and functioning through regular study assessments. With a release of information, we will provide community clinicians with a standardized report that summarizes level of symptom severity and risk, designed to aid in continuity of care.
3024132|NCT02401997|Active Comparator|sexual abstinence period group I|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group I male partners have sexual abstinence period of 2 days or less.
3024133|NCT02401997|Active Comparator|sexual abstinence period group II|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group II male partners have sexual abstinence period of 2 to 4 days.
3024134|NCT02401997|Active Comparator|sexual abstinence period group III|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group II male partners have sexual abstinence period of more than 4 days
3024135|NCT02401984||Screening|A Screening tool will be administered to the participants.
3024136|NCT02401971|Experimental|Arm A (thalidomide+CPT-11)|Patients will receive CPT-11 180 mg/m^2 ivgtt ,over 90 minutes on day 1, every 21 days for one cycle, four cycles ,and oral thalidomide 100 mg/d qn. Maintenance therapy with thalidomide in the same dose is performed until disease progression.
3056883|NCT02182388|Experimental|BI 207127 NA, fasted or fed|
3024137|NCT02401971|Experimental|Arm B (CPT-11)|Patients will receive CPT-11 180 mg/m^2 ivgtt ,over 90 minutes on day 1, every 21 days for one cycle, four cycles.
3024138|NCT02401958|Experimental|Rheumatoid Arthritis Group|Resistance Training
3024139|NCT02401958|Active Comparator|Healthy control Group|Resistance Training
3024140|NCT02401945|Experimental|DE-120 Monotherapy|DE-120 intravitreal injection given as monotherapy on a PRN basis
3024141|NCT02401945|Experimental|Eylea® and DE-120 Concomitant Therapy|DE-120 intravitreal injection given on a PRN basis after Aflibercept (Eylea®) injection as an induction therapy.
3024142|NCT02401932||Hemophagocytosis|The group includes patients who have the evidence of hemophagocytosis in their bone marrow or other sites.
3024143|NCT02401919|Experimental|Tell-us Card Intervention|Patients in the experimental arm will receive a Tell-us Card on a daily basis during their stay in the hospital. With this card patients are invited to state what is important to them for that day or before discharge from the ward.
3024144|NCT02401919|No Intervention|Care as usual|In the control arm, patients will receive care as usual.
3024145|NCT02401880|Active Comparator|Empagliflozin plus Linagliptin|Linagliptin 5mg to be adminstered for 30 days in T2DM patients on stable metformin and Empagliflozin
3024146|NCT02401880|Placebo Comparator|Empagliflozin plus Placebo|Placebo to be adminstered for 30 days in T2DM patients on stable metformin and Empagliflozin
3024147|NCT02401880|Other|Empagliflozin|Empagliflozin 25mg will be adminstered for 30 days in T2DM patients
3024148|NCT02401841||Sugammadex|Patients treated with Sugammadex
3024149|NCT02401841||Neostigmine|Patients treated with Neostigmine
3024150|NCT02401828|Experimental|Group A - Direct Switch|Direct switch from cART to Dolutegravir mono-therapy at baseline. Dolutegravir single tablet 50mg QD, once a day. Duration = 48 weeks
3024151|NCT02401828|Experimental|Group B - Delayed Switch|Delayed switch from cART to Dolutegravir mono-therapy at week 24 from baseline. Dolutegravir single tablet 50mg QD, once a day. Duration = 48 weeks
3024152|NCT02401815|Experimental|Part 1|Open-label, sequential cohort PLX9486 single-agent Dose Escalation in patients with solid tumors.
3024153|NCT02401815|Experimental|Part 2a|Single-agent PLX9486 RP2D in patients with GIST who have failed or progressed on imatinib mesylate/KIT directed TKI therapy
3024154|NCT02401815|Experimental|Part 2b|Open-label, sequential cohort PLX9486 combined with PLX3397 Dose Escalation in patients with advanced solid tumors (including GIST)
3024155|NCT02401815|Experimental|Part 2c|RP2D of the PLX9486/PLX3397 combination in patients with GIST who have failed or progressed on second-line or greater therapy.
3024156|NCT02401815|Experimental|Part 2d|Single-agent PLX9486 RP2D in patients with advanced, unresectable, or metastatic solid tumors with KIT mutations who have failed or progressed on prior therapy.
3024157|NCT02401815|Experimental|Part 2e|Open-label, sequential cohort PLX9486 combined with Sunitinib Dose Escalation in patients with solid tumors (including GIST).
3024158|NCT02401815|Experimental|Part 2f|RP2D of the PLX9486/Sunitinib combination in patients who have advanced solid tumors (including GIST).
3024159|NCT02401802|Experimental|Low-residue diet|The experimental group will receive 4 days of low-residue diet Laxative 4 liters polyethylene glycol 4000 in split fashion.
3024160|NCT02401802|Active Comparator|Usual care|"The control group will receive 3 days of low-residue diet followed by 24 hours of liquid diet.~Laxative 4 liters polyethylene glycol 4000 in split fashion."
3024161|NCT02401789|Experimental|test - implant placement|The possibility of counteracting unfavourable ridge modelling after multiple tooth extractions by placing implants in the fresh extraction sites
3024162|NCT02401789|No Intervention|control- natural healing|
3024163|NCT02401776|Experimental|small dose monster energy drink|This will be a small dose of monster energy drink
3024164|NCT02401776|Experimental|medium dose monster energy drink|This will be a medium dose of monster energy drink
3024165|NCT02401776|Active Comparator|coffee|This will be a coffee group and will drink Starbuck's K-cup Breakfast Blend. This will be mixed according to packing instructions and will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 11 ounce cup of coffee for a person weighing 75 kg).
3024166|NCT02401763||Nasopharyngeal carcinoma and salivary gland tumor|patients diagnosed and treated in National Taiwan University Hospital
3024167|NCT02401750|Experimental|Oxycodone Naltrexone (a)|Double-Blind Oxycodone/Naltrexone, 1 capsule by mouth every 6 hours for 48 hours
3024168|NCT02401750|Experimental|Oxycodone Naltrexone (b)|Double-Blind Oxycodone/Naltrexone , 1 capsule by mouth every 6 hours for 48 hours
3024169|NCT02401750|Placebo Comparator|Placebo|Double-Blind Placebo to experimental Oxycodone/Naltrexone, 1 capsule every 6 hours for 48 hours
3024170|NCT02401737|Experimental|NVR 3-778|NVR 3-778 in varying doses of capsules by mouth for 28 days
3024171|NCT02401737|Placebo Comparator|Placebo for NVR 3-778|Placebo for NVR 3-778 in varying doses of capsules by mouth for 28 days
3024172|NCT02401737|Experimental|NVR 3-778 and Pegasys|NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days
3024173|NCT02401737|Active Comparator|Pegasys|Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days
3024174|NCT02401724|Active Comparator|Action Training|Training exercise which involves patients lifting up rods of different sizes and shifting their grip if this is too far to one side
3024175|NCT02401724|Experimental|tDCS|A constant 1mA current will be applied to the left (undamaged) side of the scalp with an electrode covered with a damp cotton pad (25 cm2). The current will be applied for 15 minutes per day, with a total of 10 sessions over 3 weeks.
3024176|NCT02401724|Experimental|Action Training + tDCs|This will involve the same procedure as in action training only but with tDCS applied for 15 minutes during the rodlifting.
3024177|NCT02401724|Placebo Comparator|Control training|For the control training, patients will be asked to simply reach for the right hand side of each rod with their right (unaffected) hand and lift it
3024178|NCT02401711|Active Comparator|Online training|Residents randomized to the control group will only participate in the Breakthroughs in Patient Safety (BIPS) online training (Education - BIPS course). All residents in the comparison arm will receive evaluations on their non-technical skills, but the results will not be fed back to them until after the study has been completed.
3024307|NCT02400697||<30 wks gestation or 1500 grams|Preterm infants born at participating hospitals
3024179|NCT02401711|Experimental|Online training & Safety curriculum & Evaluation and feedback|Those in the intervention group will participate in a formal safety education curriculum in addition to the currently required Breakthroughs in Patient Safety (BIPS) online training. The intervention will have three components: (1) the mandatory online BIPS course (Education - BIPS course), (2) the formal safety curriculum, and (3) ongoing evaluation and feedback of operating room performance.
3024180|NCT02401685|Experimental|Adjuvant therapy alone|Women in this arm will have adjuvant therapy but no treatment to their armpit after surgery. Axillary and supraclavicular fossa radiotherapy is not allowed when randomised to this arm.
3024181|NCT02401685|Active Comparator|Adjuvant therapy plus axillary treatment|Women in this arm will have adjuvant therapy plus treatment to their armpit after surgery. Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
3024182|NCT02401672|Active Comparator|Active TMS|Repetitive TMS pulse stimulation
3024183|NCT02401672|Sham Comparator|Sham TMS|The sham TMS system will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
3024184|NCT02401659||naïve with CareLink|patients with a first implant of an implanted cardiac device naïve in CareLink or patients with a refill who have not used CareLink until the implant
3024185|NCT02401659||users of CareLink|patients with an implanted cardiac device who have used CareLink for more than one year
3024186|NCT02401646|Experimental|Polygoni Multiflori Radix complex|Participants randomized to the experimental group will take one capsule of Polygoni Multiflori Radix complex extract (250mg) twice a day, 30 minutes after breakfast and dinner for 4 weeks.
3024187|NCT02401646|Placebo Comparator|Starch|Participants randomized to the placebo group will take one capsule of placebo(250mg) twice a day, 30 minutes after breakfast and dinner for 4 weeks.
3024188|NCT02401633|Experimental|CO-CPR Bystander|Instructions by dispatcher to bystander to provide CPR with chest-compressions only
3024189|NCT02401633|Active Comparator|S-CPR Bystander|Instructions by dispatcher to bystander to provide CPR with chest-compressions and rescue breaths in a 30:2 ratio
3024190|NCT02401620||single-group studies|Patients with RA diagnosed
3024191|NCT02401594|Experimental|Group 1: Rivaroxaban treatment|Rivaroxaban active substance plus a placebo of enoxaparin
3024192|NCT02401594|Active Comparator|Grouyp 2: Enoxaparine treatment|Enoxaparin active substance plus a placebo tablet of Rivaroxaban
3024193|NCT02401581|Experimental|rate of early removal of the catheter|In our study, we propose to evaluate the failure rate of an early removal of the catheter 3 hours post-operative after a PVP procedure with GL 180 W/XPS in selected patients on general anesthesia or spinal anesthesia for limiting autonomic effects on the bladder and ensure fastest possible recovery of voiding .
3024194|NCT02401568|Other|Normal subjects|"No morphologic changes in carpal ligaments or clinical signs of wrist instability.~Dynamic CT of the wrist will be performed before and after arthrography."
3024195|NCT02401568|Other|Wrist instability|Morphologic ligament changes (e.g. partial or complete rupture) Dynamic CT of the wrist will be performed before and after arthrography.
3024196|NCT02401555||Known HIV1 positives|Individuals known to the HIV1 positive tested with Geenius HIV1/2 Supplemental Assay
3024197|NCT02401555||Known AIDS|Individuals known to meet diagnostic criteria for AIDS tested with Geenius HIV1/2 Supplemental Assay
3024198|NCT02401555||Low risk (negatives)|Individuals at low risk for HIV infection tested with Geenius HIV1/2 Supplemental Assay
3024199|NCT02401542|Active Comparator|B-701 plus docetaxel|IV infusion B-701, 25 mg/kg plus docetaxel, 75 mg/m2 on day one of each 21-day cycle
3024200|NCT02401542|Placebo Comparator|Placebo plus docetaxel|IV infusion placebo plus docetaxel, 75 mg/m2 on day one of each 21-day cycle
3024201|NCT02401542|Experimental|B-701|IV infusion B-701, 25 mg/kg
3024202|NCT02401529|Experimental|IV dexamethasone and oral Prednisolone|Single dose of intravenous dexamethasone given immediately following surgery (0.15 mg/kg), followed by oral Prednisolone (0.25mg/kg/day for 7 days then tapering for next 7 days) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
3024203|NCT02401529|Active Comparator|Placebo|Placebo (IV saline) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
3024204|NCT02401516|Active Comparator|Reprogramming Insoles|EG - experimental group. Subjects will be subjected to the use of insoles with the artifact in the postural reprogramming insole that emits a electrogalvanic stream. Volunteers of this research must use the insole for at least 12 hours a day and have usage control through a daily chart.
3024205|NCT02401516|Placebo Comparator|Neutral Insoles|CG - control group. Subjects will be subjected to the use of insoles likewise the ones used by EG, but instead the artifact in the postural reprogramming insole made of metal, will be made of cork.
3024206|NCT02401503|Experimental|Bendamustine + GA101 + ABT-199|Bendamustine: 70mg/m² i.v. GA101: 1000 mg i.v. ABT-199: 20 - 400 mg p.o.
3024207|NCT02401490|Active Comparator|Human albumin|human albumin in the 24-48 hours after the hospitalization and at 48+/- 24 hours after the first dose.
3024208|NCT02401490|Placebo Comparator|placebo|saline serum 0.9%
3024209|NCT02401477|Experimental|Ilaprazole + Amoxicillin|Noltec(Ilaprazole) 10mg 4 tablets BID + Ildong-Amoxicillin 500mg 1capsule and 250mg 1capsule QID by oral for 14 days
3024210|NCT02401464|Experimental|Dry syrup formulation (Group a)|One pack of the dry syrup formulation of TAK-536, containing 10 milligram (mg) of TAK-536, will be orally administered with water (200 milliliter [mL]) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
3024271|NCT02400996||Pancreatic Endocrine Neoplasms|We did an observational analysis from a prospectively maintained database of patients who underwent pancreatic surgery for neoplasms of the pancreas at Sir Ganga Ram Hospital, New Delhi, India from 1995 to 2013 and using pathological reports and preoperative CT scan as gold standard, we identified 40 patients with PENs.
3024272|NCT02400957|Experimental|Silver nanoparticles|Half of the mouth was applied silver nanoparticles. Allocation was randomized.
3024211|NCT02401464|Experimental|Dry syrup formulation (Group b)|One 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one pack of the dry syrup formulation of TAK-536, containing 10 mg of TAK-536, will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
3024212|NCT02401464|Experimental|Granule formulation (Group a)|One pack of the granule formulation of TAK-536, containing 10 mg of TAK-536,will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
3024213|NCT02401464|Experimental|Granule formulation (Group b)|One 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one pack of the granule formulation of TAK-536, containing 10 mg of TAK-536, will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
3024214|NCT02401451|Experimental|ECG acquisition|"ECG acquisition using the standard ECG machine~Intervention: An ECG will be performed on every participant using the novel device called the 'RhythmPadGP'"
3024215|NCT02401438||pregnant women with preterm delivery|5D LB and 2D ultrasounds will be done to pregnant women between 28 and 34 weeks planned for termination of pregnancy for obstetric or medical causes.
3024216|NCT02401425|Active Comparator|letrozole|Women will receive three tablets of letrozole(FemaraR, NOVARTIS) as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) for two days at home and will be told to bring back the empty packs. The third dose will be given on admission to hospital on day three and will be followed by 4 tablets of vaginal misoprostol (200 mcg) (MisotacR,SIGMA)soaked with saline every three hours up to maximum 2 doses.
3024217|NCT02401425|Placebo Comparator|placebo|Women will receive three tablets of placebo as a single dose, for two days at home and will be told to bring back the empty packs. The third dose will be given on admission to hospital on day three and will be followed by 4 tablets of vaginal misoprostol (200 mcg) (MisotacR,SIGMA)soaked with saline every three hours up to maximum 2 doses.
3024218|NCT02401412|Other|Test Ostomy Barrier|The test product is a new Hollister ostomy barrier.
3024219|NCT02401412|Other|Control Ostomy Barrier|The control product is a currently marketed Hollister ostomy barrier.
3024220|NCT02401399|Placebo Comparator|regular diet|The patients receive regular diet of 900 Kcal/day during 15 days before surgery
3024221|NCT02401399|Active Comparator|high protein formula|The patients receive high protein formula during 15 days before surgery
3024222|NCT02401399|Experimental|Immunonutrition|The patients receive Immunonutrition during 15 days before surgery
3024223|NCT02401386|Experimental|EB group|Trained and guided by EB certified physicians, patients in EB group received closely supervised, group-format EB program and practiced EB for one hour, twice weekly for 12 weeks in the Guang'anmen Hospital.
3024224|NCT02401386|No Intervention|Control group|The participants in usual therapy-controlled group will stay on their previous treatment through 12 weeks. As compensation, they will be invited to receive LEB training for 12 weeks after the end of the study.
3024225|NCT02401373|Experimental|low dose|30 participants will be firstly recruited and assigned to receive the low dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).
3024226|NCT02401373|Experimental|High dose|After the safety of the low dose vaccination is confirmed, another 30 participants will be recruited and assigned to receive the high dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).
3024227|NCT02401360|Experimental|Experimental Group|Oral care regimen
3024228|NCT02401360|Placebo Comparator|Control Group|Toothbrush and toothpaste
3024229|NCT02401347|Experimental|Cohort A - Triple-negative Breast Cancer|"Participants with advanced triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD) based on the Myriad HRD Assay.~Participants receive talazoparib 1 mg by mouth daily."
3024230|NCT02401347|Experimental|Cohort B - HER2-negative solid tumor|"Participants with advanced HER2-negative solid tumor with a deleterious hereditary or cancer somatic mutation in one of the following genes:~PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, RAD51C, RAD51D, MRE11, ATR, Fanconi anemia complementation group of genes.~Participants receive talazoparib 1 mg by mouth daily."
3024231|NCT02401334|Experimental|Hernia Repair|Surgical repair for hernia with implantation of the Cook® Antimicrobial Hernia Repair Device.
3024232|NCT02401321|Experimental|Supportive care (Taking Care of Her program)|Patients and spouse caregivers complete the Taking Care of Her Program comprising 5 telephone-delivered intervention sessions over 45-60 minutes every 2 weeks. The intervention sessions are designed to provide training for spouse caregivers and patients to better manage the impact and emotional toll of recently diagnosed ovarian cancer, including its impact on their interpersonal communication and support about the cancer.
3024233|NCT02401308|Active Comparator|Awake DBS Surgery|"Deep brain stimulation surgery: Parkinson's patients undergoing traditional awake DBS surgery utilizing microelectrode recordings and intra-operative stimulation"
3024234|NCT02401308|Active Comparator|Asleep DBS Surgery|Deep brain stimulation surgery:Parkinson's patients undergoing DBS surgery under general anesthesia utilizing intraoperative imaging to verify the stereotactic accuracy of DBS electrodes placement at the time of surgery.
3024273|NCT02400957|Experimental|Placebo|Half of the mouth was applied placebo. Allocation was randomized.
3024274|NCT02400944||patients with bladder cancer|
3024275|NCT02400931|Active Comparator|mask ventilation|Mask ventilation will be performed before the tracheal intubation.
3024276|NCT02400931|Experimental|no mask ventilation|Mask ventilation will not be performed before the tracheal intubation.
3024308|NCT02400697||30 wks to <34 wks gestation|Preterm infants born at participating hospitals
3024407|NCT02399982|Experimental|CBT-GSH + Noom Monitor|CBT-GSH with smartphone application for self-monitoring
3024235|NCT02401295|Experimental|ATRA/celecoxib/itraconazole|"All maintenance drugs will be given on days 1-21 of each cycle, followed by 14 days off treatment. Cycles will be repeated every 35 days (+/- 3 days) for a total of five cycles.~Each patient enrolled will receive ATRA 20mg twice per day by mouth. Dose modifications are not allowed unless excessive toxicity occurs. In this case, ATRA will be de-escalated by 50% to 10mg twice per day by mouth.~The dose of celecoxib for all patients enrolled will be 400 mg twice per day by mouth. If creatinine level increases to more than 2 mg/dl and cannot be corrected by increased oral fluid intake or other measures, the dose of celecoxib will be decreased by 50%. If creatinine level does not drop below 2 mg/dl on the reduced dose, celecoxib will be discontinued.~The dose of itraconazole for all patients enrolled will be 200 mg twice per day by mouth. Dose modifications are not allowed."
3024236|NCT02401282|Experimental|ABM|Attention bias modification
3024237|NCT02401282|Placebo Comparator|Placebo|Dot-probe task
3024238|NCT02401269|Experimental|Aspirin|Aspirin 325mg daily
3024239|NCT02401269|Placebo Comparator|Placebo|Placebo
3024240|NCT02401256|Experimental|CYP2B6|"This is a fixed-order, open label prospective cohort study to determine: a) the contribution of CYP2B6 autoinhibition/autoinduction processes to variable CYP2B6 activity and efavirenz exposure; b) the impact of CYP2B6 genetic variants on these processes; and c) drug interactions that ensue.~Included drugs:~Efavirenz (600mg) - The volunteers will receive it in two of three inpatient visits and also during 17 days at home~Bupropion (100mg), Montelukast (10mg) and Rosuvastatin (5mg) - These drugs will be administrated on 3 occasions (at the begging each inpatient visit of Phase 1, 2 and 4)."
3024241|NCT02401243|Experimental|Cohort 1 (INSIGHT titration algorithm)|INSULIN GLARGINE (U300): self-titration of insulin glargine 300 units/mL (U300) will be increased daily by 1 unit until fasting SMPG reaches the target range of 4.4 to 5.6 mmol/L
3024242|NCT02401243|Experimental|Cohort 2 (EDITION titration algorithm)|INSULIN GLARGINE (U300): titration of insulin glargine 300 units/mL (U300) will be adjusted weekly or not more than every 3 days to achieve the target range of fasting SMPG of 4.4 to 5.6 mmol/L
3024243|NCT02401230|Active Comparator|Rectal Gel Lubricant|Subjects will insert 5 mL of lubricant in rectum for seven consecutive days
3024244|NCT02401230|Active Comparator|Truvada|Subjects will take one Truvada tablet orally for seven consecutive days
3024245|NCT02401230|Active Comparator|Rectal Gel Lubricant + Truvada|Subjects will insert 5 mL of lubricant in rectum and take one Truvada tablet orally for seven consecutive days
3024246|NCT02401217|Experimental|Phase 1-Arm 1 Infant Formula|Milk-based infant formula manufactured by an alternative method. Non-commercially available formula. To be fed ad libitum.
3024247|NCT02401217|Active Comparator|Phase 2- Arm 2 Infant Formula|Milk-based infant formula using current manufacturing and ingredients. Non-commercially available formula. To be fed ad libitum.
3024248|NCT02401217|Experimental|Phase 2- Arm 3 Infant Formula|Milk-based infant formula using a new protein. Non-commercially available formula. To be fed ad libitum.
3024249|NCT02401204||Neonates admitted to QSNICH NICU|All neonates admitted to the QSNICH NICU over a period of one year from March 2015 to March 2016 meeting the inclusion and exclusion criteria will be enrolled in the study. Readmitted neonates will be eligible to be enrolled again into the study.
3024250|NCT02401191|Experimental|FEX60/PE10|Internal use of FEX60/PE10 combination tablet will be administered twice daily (1 tablet per intake) for 2 weeks
3024251|NCT02401178||Well baby|"For cross-sectional study design:~The dependent variables are LCPUFA composition from buccal. The independent variables are 17 SNP from FADS genes.~For extended cross-sectional study design:~The dependent variable is atopic dermatitis, while independent variables are:~17 SNP; LCPUFA and FLG gene mutation"
3024252|NCT02401165|Other|patient|patient
3024253|NCT02401152|Placebo Comparator|Placebo group|Sports drink containing maltodextrin
3024254|NCT02401152|Active Comparator|Sports drink 1|Sports drink with a specific source of carbohydrates (CHO).
3024255|NCT02401152|Active Comparator|Sports drink 2|Sports drink with a specific source of CHO.
3024256|NCT02401139|Active Comparator|Treatment arm|Ketamine
3024257|NCT02401139|Placebo Comparator|Placebo arm|Placebo
3024258|NCT02401126|Active Comparator|Nitrate supplementation|Concentrated nitrate-rich beetroot juice
3024259|NCT02401126|Placebo Comparator|Placebo|Nitrate-depleted beetroot juice
3024260|NCT02401113|Experimental|UA group|UA group who takes Ursolic acid of Loquat Extract , 500 mg/ day during 12 weeks for treatment of muscle function improvement with relatively health adults
3024261|NCT02401113|Placebo Comparator|placebo group|placebo group who takes a placebo, 500 mg/day for 12 weeks
3024262|NCT02401074|Experimental|Segmental bronchoprovocation with Allergen (SBP-Ag)|Following nasopharyngeal anesthesia, the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During SBP-Ag challenge, 15% of the Ag-PD20 allergenic extract will be instilled into the segment.
3024263|NCT02401061|Experimental|PRTX-100|Patients will be assigned to consecutive PRTX-100 interventions as they are enrolled into the study. Between two and six patients will be enrolled per intervention level. Intervention levels range from one (1) to twenty four (24) micrograms of PRTX-100 per kilogram of patient weight. Patients may receive up to four weekly infusions of PRTX-100 over the study treatment period. PRTX-100 doses ≤ 500 μg will be infused intravenously over 30 minutes. PRTX-100 doses > 500 μg will be infused over 60 minutes. Patients will remain under observation for 4 hours after completion of PRTX-100 dosing for safety management.
3024264|NCT02401048|Experimental|Phase 1|Dose determination safety cohort
3024265|NCT02401048|Experimental|Phase 2: Follicular lymphoma expansion cohort:|Will use the recommended Phase 2 doses determined in the Phase 1 portion
3024266|NCT02401048|Experimental|Phase 2: Diffuse large B-cell lymphoma expansion cohort:|Will use the recommended Phase 2 doses determined in the Phase 1 portion
3024267|NCT02401035|Experimental|IV pantoprazole|Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight.
3024268|NCT02401022|Active Comparator|AZD8529 low dose|1.5 mg
3024269|NCT02401022|Active Comparator|AZD8529 high dose|40mg
3024270|NCT02401009||HCT, cell therapy, marrow toxic injuries|All recipients of HCT or other cellular therapies, both domestic and international, and marrow toxic injuries reported to the CIBMTR
3024306|NCT02400710|Active Comparator|Self-Managed PTSD Coach|One in-person 10-minute session that provides instructions on how to use the PTSD Coach app.
3024277|NCT02400918|Experimental|Workbook|They will be directed to use the 8-week plan included in The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming & Kocovski, 2013), an ACT-based self-help book and to access mindfulness audio files located on the publisher's website (as described in the book).
3024278|NCT02400918|No Intervention|Control|Waitlist control
3024279|NCT02400905|Experimental|BioMimics 3D Stent|Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System
3024280|NCT02400892||PFO|Subjects with a bedside Transthoracic Echocardiogram (TTE) bubble study positive for a PFO
3024281|NCT02400892||Control|Subjects with a bedside TTE bubble study negative for a PFO
3024282|NCT02400879|Active Comparator|Remifentanil|For anesthesia maintenance, TCI-remifentanil (fixed Cp of 20 ng/ml) and TCI-propofol (variable Ce < 2.0 µg/ml) for maintaining BIS 40-60
3024283|NCT02400879|Placebo Comparator|sevoflurane and sufentanil|TCI-sufentnail (Cp of 0.4-0.8 ng/ml) and sevoflurane (< 1.5 MAC) for maintaining 80-120 % of preoperative value and BIS < 60
3024284|NCT02400866|Placebo Comparator|Control|palonosetron + dexamethasone + placebo
3024285|NCT02400866|Experimental|Experimental|palonosetron + dexamethasone + olanzapine
3024286|NCT02400853|Experimental|preterm infants with intracranial hemorrhage|Cord blood analysis of preterm infants with radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed
3024287|NCT02400853|Active Comparator|preterm infants without intracranial hemorrhage|Cord blood analysis of preterm infants without radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed
3024288|NCT02400840|Experimental|Heart graft rejection|Assessment of cardiac allograft recipient with rejection by Cardiac MRI with gadobenic acid intravenous injection 0.2 ml/kg one time
3024289|NCT02400840|Active Comparator|No rejection|Assessment of cardiac allograft recipient without any rejection by Cardiac MRI with gadobenic acid intravenous injection 0.2 ml/kg one time
3024290|NCT02400827||cryopreservation|
3024291|NCT02400814|Experimental|Arm I (concurrent cohort)|Patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of course 1, patients also undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions.
3024292|NCT02400814|Experimental|Arm II (induction cohort)|Patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of course 3, patients also undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions.
3024293|NCT02400814|Experimental|Arm III (sequential cohort)|Patients undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions beginning on day 1 of course 1. After completion of SAR (beginning on day 1 of course 2), patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3024294|NCT02400801|Active Comparator|oral oestroprogestogen pre-treatment|preparation with oral oestroprogestogens prior to downregulation in an assisted reproductive technology treatment (ART) cycle
3024295|NCT02400801|Experimental|gonadotropin-releasing hormone (GnRH) pre-treatment|preparation with gonadotropin-releasing hormone (GnRH) analogues prior to downregulation in an assisted reproductive technology treatment (ART) cycle
3024296|NCT02400788|Experimental|Resminostat + Sorafenib|oral administration
3024297|NCT02400788|Active Comparator|Sorafenib|oral administration
3024298|NCT02400775|Experimental|Azilsartan|Azilsartan orally once daily in the morning, either before or after breakfast
3024299|NCT02400749|Experimental|Apremilast|Patients will receive Apremilast until week 32.
3024300|NCT02400749|Placebo Comparator|Placebo followed by Apremilast|Patients will receive Placebo until week 16 and then receive Apremilast until week 32
3024301|NCT02400736|Experimental|Individual Placement and Support (IPS)|"Individual Placement and Support (IPS) is supported employment and involves the following domains: 1) Competitive Employment: The IPS intervention assists participants to enter into competitive jobs; 2) Eligibility Based on Client Choice, i.e. zero exclusion; 3) Integration of IPS and Treatment Team, i.e. the PACT; 5) Personalized Benefits Counseling: IPS specialists help Veterans obtain information about their VA, Social Security, Medicaid, and other government entitlements; 6) Rapid Job Search: IPS specialists use a rapid job search, rather than providing lengthy pre-employment assessment, training, counseling; 7) Systematic Job Development: IPS specialists build an employer network based on Veterans' interests; 8) Time-Unlimited and Individualized Support: follow-along IPS supports are individualized and continue for as long as needed during the 12-month study."
3024302|NCT02400736|Active Comparator|Usual Care/Transitional Work Program (TWP)|Transitional Work Program (TWP) involves 1) Time-limited Set-Aside Employment: short-term transitional work experiences in a brokered or set-aside work setting; 2) Eligibility Criteria: no strict entrance criteria other than general medical clearance; 3) Limited Integration of TWP and Clinical Services: not integrated within PACT; 4) Less Patient-Centered: TWP jobs are pre-arranged, set-aside jobs are less likely to have a meaningful relationship to the Veterans' preferences; 5) Personalized Benefits Counseling: TWP specialists help Veterans obtain information about their VA, Social Security, Medicaid, and government entitlements; 6) Job Search: The TWP specialists provide variable and limited guidance for competitive job search; 7) Limited Job Development: TWP specialists do not engage in community based job development for a specific Veteran; 8) Time Limited Support: The TWP specialist does not provide long-term follow-up after the first job is obtained.
3024303|NCT02400723|Experimental|BREATHE|Four weeks of DVD-delivered behavioral intervention. Intervention consists of diaphragmatic breathing and progressive muscle relaxation.
3024304|NCT02400723|Placebo Comparator|Psychoeducation|Four weeks of DVD-delivered psychoeducation as an attention placebo control.
3024305|NCT02400710|Experimental|Clinician-Supported PTSD Coach|Four 20-minute sessions (2 in-person, 2 by phone) focused on instructions for use, setting symptom reductions goals, and assigning specific PTSD Coach activities (i.e., assessments, management strategies, psycho-educational readings) for the participant to complete on their own.
3024309|NCT02400684||Deep endometriosis|The population is a female population, above 18 years and under 38 years who have stage III or IV endometriosis (which will remain to be confirmed after inclusion by intra-operative observations), and who undergo operative laparoscopy in our center, with only deep endometriosis without endometriomas.
3024310|NCT02400684||Deep endometriosis and endométriomas|The population is a female population, above 18 years and under 38 years who have stage III or IV endometriosis (which will remain to be confirmed after inclusion by intra-operative observations), and who undergo operative laparoscopy in our center, with deep endometriosis and endometriomas.
3024311|NCT02400671|Experimental|Two-way SMS|Participants will receive weekly push SMS messaging with a questions and have the ability to text back to the study nurse
3024312|NCT02400671|Experimental|One-Way SMS|Participants will receive weekly push SMS messaging
3024313|NCT02400671|No Intervention|Control|
3024314|NCT02400658|Experimental|IORT with CT-Guided HDR Brachytherapy|Patients will receive IORT with CT-guided HDR brachytherapy at the time of breast surgery.
3024315|NCT02400645|Active Comparator|Group A: pre-incisional bupivacaine|Intervention: Pre-incisional wound infiltration with bupivacaine plain 0.25%. Ketorolac 30mg IV will be given following surgical procedure.
3024316|NCT02400645|Active Comparator|Group B: laparoscope to place TAP block|Intervention: laparoscope to place TAP block with liposomal bupivacaine and bupivacaine plain 0.25%. Ketorolac 30 mg IV will be given following surgical procedure.
3024317|NCT02400632|Experimental|MAGIC-TOUCH Drug-eluting balloon|in-stent restenosis treated with drug-eluting balloon
3024318|NCT02400619|Active Comparator|shock waves|A comparative study with patients with spasticity in gastrocnemius and soleus where a group start having shockwave treatment and receive three sessions at weekly intervals, gastrocnemius and soleus applied in 2000 impacts at a frequency of 8hz and energy intensity is proposed between 2.2-2.4 Bars (0,10-0,12mj ). Swiss dolor clast EMS. The other group will receive botulinum toxin Type A in the same muscles. The dose of toxin is in accordance with the weight of each patient, the dose normally used with each user and always with the same brand is always respected, Botox (4-8-12 U/Kg) Patients will be assessed before treatment, after three weeks, two months and three months after three months when the groups exchange the therapy.
3024319|NCT02400619|Active Comparator|botulinum toxin|A comparative study with patients with spasticity in gastrocnemius and soleus where a group start having shockwave treatment and receive three sessions at weekly intervals, gastrocnemius and soleus applied in 2000 impacts at a frequency of 8hz and energy intensity is proposed between 2.2-2.4 Bars (0,10-0,12mj ). Swiss dolor clast EMS.The other group will receive botulinum toxin type A in the same muscles. The dose of toxin is in accordance with the weight of each patient, the dose normally used with each user and always with the same brand is always respected. Botox (4-8-12 U/Kg)Patients will be assessed before treatment, after three weeks, two months and three months after three months when the groups exchange the therapy.
3024320|NCT02400606|Experimental|Intervention|The intervention group were presented with a short case overview introducing four cardiopulmonary VP cases as well as the final diagnosis and had to complete the history, physical findings, and lab results, i.e. constructing VP cases.
3024321|NCT02400606|Active Comparator|Control|The participants were presented with a short case overview introducing four cardiopulmonary VP cases to be solved, i.e. solving VP cases.
3024322|NCT02400593|Experimental|Lovingkindness|A six-week formal meditation workshop for 1 hour per week.
3024323|NCT02400593|Placebo Comparator|Mindfulness|A six-week formal meditation workshop for 1 hour per week.
3024324|NCT02400580|Experimental|Intravenous IV acetaminophen|The patients in the treatment arm will receive 1000mg of IV acetaminophen.
3024325|NCT02400580|Placebo Comparator|Normal Saline|The patients in the placebo arm will receive normal saline.
3024326|NCT02400567|Active Comparator|Chemotherapy|3 cycles of FEC 100 followed by 3 cycles of Docetaxel Drugs: Fluorouracile, Epirubicine, Cyclophosphamide, Docetaxel
3024327|NCT02400567|Experimental|Letrozole Palbociclib|Drugs: letrozole + palbociclib combination
3024328|NCT02400554|No Intervention|Wait List Control|Participants wait one year before receiving the intervention. Three assessments are taken over this period: Month 3, Month 9, and Month 12.
3024329|NCT02400554|Experimental|Yappalli|Yappalli: Participants attend a 12-month behavioral intervention.
3024330|NCT02400541|Experimental|Cognitive remediation therapy|10 sessions of the cognitive remediation therapy program conducted during five weeks
3024331|NCT02400541|Placebo Comparator|relaxation therapy|10 relaxation sessions during 5 weeks
3024332|NCT02400528|Other|Patients With Profound and Multiple Disabilities|
3024333|NCT02400515|Other|Moderate Exercise|Aerobic physical exercise was applied during 3 months, 3x/week on women with type 2 diabetic. The evaluation occurred before and after exercise in the same (and only) group, considering that this is a quasi-experimental study.
3024334|NCT02400502|Experimental|I-CAT Therapy|Integrated Coping and Awareness Therapy is a six-month intervention designed to examine the physiological, biological, and psychological effects of meditation and mindfulness practice on individuals diagnosed with a psychotic disorder.
3024335|NCT02400476|Experimental|Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Loperamide daily for two 28-day cycles and then as needed.
3024336|NCT02400476|Experimental|Budesonide and Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Anti-inflammatory treatment for 1 cycle and Loperamide to be administered daily for two 28-day cycles and then as needed, thereafter.
3024337|NCT02400476|Experimental|Colestipol and Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Colestipol for 1 cycle and loperamide to be administered 1 cycle and then as needed, thereafter.
3024338|NCT02400476|Experimental|Colestipol with Loperamide as needed|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Colestipol for 1 cycle and loperamide to be administered as needed.
3024339|NCT02400476|Experimental|Neratinib dose escalation|120 mg Neratinib for Week 1, followed by 160 mg Neratinib starting for Week 2, followed by 240 mg Neratinib starting at Week 3 and thereafter (C1D15 to End of Treatment). Loperamide administered as needed.
3024340|NCT02400463|Experimental|Ruxolitinib|"Ruxolitinib 15 mg by mouth twice daily.~For patients unable to ingest tablets, ruxolitinib suspended in water may be administered through a nasogastric (NG) or percutaneous endoscopy gastrostomy (PEG) tube."
3024405|NCT02399995||patients following hepatectomy|
3024341|NCT02400450|Experimental|Functional Ingredient Group|Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix. The food items will contain a standardized amount of functional ingredients.
3024342|NCT02400450|Placebo Comparator|Control Ingredient Group|The control group will receive a comparable set of food items that contain an equivalent amount of calories per portion but without the added functional ingredients.
3024343|NCT02400437|Experimental|IDR|"- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity~Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.~Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase~Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase~Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase"
3024344|NCT02400424|Experimental|SBRT|Study treatment = SBRT for peripheral primary tumor.
3024345|NCT02400411|Experimental|Wheat bread|Bread-based meal
3024346|NCT02400411|Experimental|Wheat bread with margarine and ham|Bread-based meal
3024347|NCT02400411|Experimental|Wheat bread with margarine, ham and soup|Bread-based meal
3024348|NCT02400411|Experimental|Rye bread|Bread-based meal
3024349|NCT02400411|Experimental|Rye bread with margarine and ham|Bread-based meal
3024350|NCT02400411|Experimental|Rye bread with margarine, ham and soup|Bread-based meal
3024351|NCT02400398||Tube feeding with peptide-base formula|The peptide-based formula (Peptamen) will be administered through a gastrojejunal or jejunal feeding tube and dosing will be calculated using the Mifflin St. Jeor equation. It will be administered for three 28-day cycles.
3024352|NCT02400385|Experimental|Treatment|Sunitinib 50mg/day, 4 weeks on and 2 weeks off, and concurrent nivolumab 3mg/kg iv every 2 weeks, both for three years if tolerated.
3024353|NCT02400372|Experimental|research group|Medihoney Dressing
3024354|NCT02400372|No Intervention|control group|Paraffin gauze with saline Dressing
3024355|NCT02400372|No Intervention|3. Comparison group|Polymem dressing
3024356|NCT02400359|Placebo Comparator|Placebo|Subjects will be randomized to either placebo or Lorcaserin HCl.
3024357|NCT02400359|Active Comparator|Active|Subjects will be randomized to either placebo or Lorcaserin HCl.
3024358|NCT02400346|Experimental|Adjunct brexpiprazole|All patients continue their current antidepressant treatment (ADT) and receive brexpiprazole in addition
3024359|NCT02400333|Experimental|Treatments A-D-B-C sequence|Treatment A in Period 1, Treatment D in Period 2, Treatment B in Period 3 and Treatment C in Period 4
3024360|NCT02400333|Experimental|Treatments B-A-C-D sequence|Treatment B in Period 1, Treatment A in Period 2, Treatment C in Period 3 and Treatment D in Period 4
3024361|NCT02400333|Experimental|Treatments C-B-D-A sequence|Treatment C in Period 1, Treatment B in Period 2, Treatment D in Period 3 and Treatment A in Period 4
3024362|NCT02400333|Experimental|Treatments D-C-A-B sequence|Treatment D in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment B in Period 4
3024363|NCT02400320|Active Comparator|Topical Spray|Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
3024364|NCT02400320|Experimental|Topical Gel|Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
3024365|NCT02400320|Other|Saline|Saline
3024366|NCT02400307|Experimental|Severe Renal Impairment|Participants with severe renal impairment and matched healthy controls will receive a single dose of GS-9883.
3024367|NCT02400307|Experimental|Moderate Renal Impairment|Participants with moderate renal impairment and matched healthy controls will receive a single dose of GS-9883.
3024368|NCT02400307|Experimental|Mild Renal Impairment|Participants with mild renal impairment and matched healthy controls will receive a single dose of GS-9883.
3024369|NCT02400281|Experimental|Arm 1 crenolanib besylate combination|Arm 1 patients will receive crenolanib besylate, combined with standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine, FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin
3024370|NCT02400281|Experimental|Arm 2 crenolanib besylate combination|Arm 2 patients will receive crenolanib besylate and azacytidine.
3024371|NCT02400268|Experimental|7 days course of antibiotic treatment|Accepted antibiotic indicated for enterobacteriaceae infections, according to sensibility test performed and daily practice protocols or local guidelines.
3024372|NCT02400268|Active Comparator|14 days course of antibiotic treatment|Accepted antibiotic indicated for enterobacteriaceae infections, according to sensibility test performed and daily practice protocols or local guidelines.
3024373|NCT02400255|Experimental|Cohort A|Cohort A will include patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) while in first or second complete remission with count recovery. Crenolanib besylate maintenance therapy will start at the earliest time no sooner than 45 days but no later than 90 days after allogeneic HSCT.
3024374|NCT02400255|Experimental|Cohort B|Cohort B will include patients who underwent HSCT with incomplete count recovery although they had ≤%10 bone marrow blasts at the time of HSCT. Crenolanib besylate maintenance therapy will start at the earliest time no sooner than 45 days but no later than 90 days after allogeneic HSCT.
3024375|NCT02400242|Experimental|ACY-241, Pomalidomide, and dexamethasone|Open label dosing cohorts will evaluate oral ACY-241 (dosing ranging from 180 mg to 480 mg days 1-21) in combination with oral pomalidomide (4 mg days 1-21), and oral dexamethasone (40 mg qd on days 1, 8, 15, 22).
3024376|NCT02400229|Experimental|Computed Tomography Angiography (CTA)|Computed Tomography Angiography including coronary calcium scoring and coronary computed tomography angiography
3024377|NCT02400229|Active Comparator|Invasive coronary angiography (ICA)|Invasive coronary angiography
3024378|NCT02400203|Active Comparator|Control|54 grams of hulled sesame seeds, consumed in 2 daily 27 gram portions, and 30 grams of soybean oil per day
3024379|NCT02400203|Experimental|Hemp foods|60 grams of hulled hemp seeds,consumed in 2 daily 30 gram portions, and 30 grams of hemp oil per day
3024380|NCT02400190|Experimental|Endocrine therapy alone|Patients receive endocrine therapy alone without radiotherapy
3024406|NCT02399982|Active Comparator|CBT-GSH|Traditional CBT-GSH with paper and pencil self-monitoring
3024517|NCT02399137|No Intervention|Observational Group|
3024381|NCT02400177|Experimental|Emotion regulation training|This is a 4 sessions group workshop and 1 session individual pre-screening about parental emotion regulation and emotion co-regulation. In this study the facilitators will give information about efficient strategies to regulate parent emotions and their children's emotions.
3024382|NCT02400177|No Intervention|Control group|"In this condition we will take all the measurement before and after the waiting list period.~This group will go through the workshop after the measurements will be taken."
3024383|NCT02400164|Experimental|alfapump system|The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
3024384|NCT02400151|Other|Non-Obese group|"Non-obese patients will be recruited and frequency matched to obese groups according to sex and level of sexual maturation.~Intervention: Normal control"
3024385|NCT02400151|Experimental|Obese group, Vitamin D|"Subjects randomized to this group will receive vitamin D supplementation. They are recruited from the St Pierre Institute at Palavas-les-Flots, France.~Intervention: 3 months lifestyle and dietary management Intervention: Vitamin D supplementation"
3024386|NCT02400151|Placebo Comparator|Obese group, placebo|"Subjects randomized to this group will receive a placebo supplement. They are recruited from the St Pierre Institute at Palavas-les-Flots, France.~Intervention: 3 months lifestyle and dietary management Intervention: Placebo"
3024387|NCT02400138|Experimental|Respiratory training|Respiratory training will include training of the inspiratory and expiratory muscles seven times per week over eight weeks, during 40 minutes per day, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve device, regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
3024388|NCT02400138|Sham Comparator|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring, which will be also concealed. The control group will also attend the weekly sessions and undergo the same procedures, except for the load adjustments. If the training proves to be effective, the control subjects will be informed and have the choice to receive the training with proper loads.
3024389|NCT02400125||1|Patients underwent isolated or combined coronary artery bypass grafting surgery
3024390|NCT02400125||2|Patients underwent isolate or combined surgical treatment for heart valve disease
3024391|NCT02400112|Experimental|Vancomycin Powder|If the patient randomizes to the experimental group (vancomycin powder), the patient will receive open fracture care identical to the control group except that, prior to closure, 1 gram of vancomycin powder will be applied locally to the open fracture bed. The traumatic and surgical wounds will be closed over a sterile drain and dressed, and the extremity will be immobilized.
3024392|NCT02400112|No Intervention|Standard Treatment|If the patient randomizes to the control group (standard treatment), the patient will receive irrigation and debridement of the fracture site and surrounding soft tissues. The fracture will then be stabilized in standard fashion determined by fracture personality. Once stabilized, a sterile drain will be placed in the open fracture bed and the traumatic and surgical wounds will be closed and dressed. The extremity will then be immobilized.
3024393|NCT02400099|Active Comparator|High-protein low calorie diet (HPLC)|900 Kcal; Protein 90 g (39%); CHO 75 g (30%); Lipid 32 g (31%)
3024394|NCT02400099|Placebo Comparator|Control low calorie diet (CLC)|900 Kcal; Protein. 50 g (22%); CHO 119 g (48%); Lipid 31 g (30%)
3024395|NCT02400073|Experimental|AutoSet for Her PAP device|Patients in this study will use the AutoSet for Her: A new AutoSetting Positive Airway Pressure (PAP) device designed specifically to treat female OSA
3024396|NCT02400060|Experimental|Supportive (text messages and interactive exchanges)|Patients receive daily text messages reminding them to take AHT and weekly interactive surveys delivered by a smart phone app for 3 months.
3024397|NCT02400047|Experimental|Dexamethasone 0.2 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.2 mg / kg after general anesthesia induction and before surgery incision.
3024398|NCT02400047|Experimental|Dexamethasone 0.4 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.4 mg / kg after general anesthesia induction and before surgery incision.
3024399|NCT02400047|Active Comparator|Ketoprofen 1 mg/kg|Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
3024400|NCT02400034|Active Comparator|FAST voiding trial method|1) Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water. 2) catheter is removed; 3) Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction). 4) The patient will subjectively quantify their FOS via VAS scale. 5) If VAS scale >50 (=50%) the catheter will remain out, patient is discharged home without measuring a PVR 6) If VAS scale is from 0-49 (= 0-49%) a PVR will be checked via bladder scan. If PVR is <500 the patient will be discharged WITHOUT a catheter; If PVR is >500 the patient will be discharged WITH a catheter. If she is discharged with an indwelling foley catheter, she will have an in-office retrograde voiding trial in 2-5 days
3024401|NCT02400034|Active Comparator|Retrograde fill voiding trial method|1) Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water. 2) catheter is removed; 3) Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction). 4) The patient will subjectively quantify their FOS via VAS scale (however this information will only be used for research purposes). 5) If she voids >/= 2/3 (200cc) the catheter will remain out as she will have passed her voiding trial. If she voids < 200cc she will be discharged home with a catheter and instructed to follow-up in 2-5 days for an in-office retrograde voiding trial in 2-5 days.
3024402|NCT02400021|Experimental|Prometrium|Prometrium (progesterone capsules) intervention
3024403|NCT02400021|No Intervention|No treatment|no treatment arm
3024404|NCT02400008|Experimental|Patient with bilateral vocal fold paralysis|Patient with bilateral vocal fold paralysis in a closure position between 6 months to 36 months before et who has been treated by endoscopic treatment without satisfying result (voice or breathing).
3024408|NCT02399969|Experimental|Battlefield Acupuncture Plus Standard of Care|Patients with low back pain that will receive ear acupuncture based on the Battlefield Acupuncture protocol.
3024409|NCT02399969|No Intervention|Standard of Care Alone|Patients with low back pain that will receive standard of care without study intervention.
3024410|NCT02399956||Survivors|"Participants will be recruited from the St. Jude Lifetime Cohort (SJLIFE protocol) and the After Completion of Therapy (ACT) Clinic at St. Jude Children's Research Hospital.~Intervention: Survey"
3024411|NCT02399943|Experimental|Trametinib and Panitumumab|"Trametinib: 2 mg QD, orally, continuously.~Panitumumab: 6 mg/kg, intravenously, Q2W"
3024412|NCT02399917|Experimental|5-azacytidine + Lirilumab|"5-azacytidine administered subcutaneously (SQ) or intravenously (IV) for 7 days of every cycle (Days 1-7) as determined by treating physician.~Lirilumab administered as 60 minute IV infusion on Day 8 (+/-2 days) of each 5-azacytidine cycle.~One cycle of therapy is defined as 28 days.~Phase I dose of lirilumab and 5-azacytidine depends on when participants joined study; Phase II doses begin at the highest dose tolerated in Phase I."
3024413|NCT02399904|Experimental|1|
3024414|NCT02399891||Retrospective|MI prior to December 11, 2011
3024415|NCT02399891||Prospective|MI on or after December 11, 2011
3024416|NCT02399878||Patients undergoing surgery|All non-cardiothoracic surgical patients aged 18 years or above receiving general anesthesia at Massachusetts General Hospital between January 2007 and August 2014.
3024417|NCT02399865|Experimental|YSBNT Group|Six 50 minute YSBNT sessions (delivered by a trained YSBNT practitioner) for over a maximum period of 12 weeks
3024418|NCT02399865|No Intervention|Treatment as Usual Group|Usual care delivered by treatment-as-usual practitioners
3024419|NCT02399826|Other|Standard of Care|Surgical debridement of diabetic foot ulcer, followed by collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice offloading, reassessment weekly at office visit
3024420|NCT02399826|Experimental|Amniotic Membrane / Amnioband|Application of Amnioband with dressing application, to be changed weekly following surgical debridement. Patient will practice offloading. If the ulcer is not closed completely Amnioband will be applied weekly at weeks 2-11
3024421|NCT02399813|Experimental|ADXS11-001|
3024422|NCT02399800|Experimental|EUS with Celiac Block|Celiac Block with triamcinolone and bupivicaine Intra Plexus Triamcinolone and Bupivicaine Injection
3024423|NCT02399800|Active Comparator|EUS without Celiac Block|Patients will undergo EUS but no celiac block will be performed
3024424|NCT02399787||infertile patients|Infertile patients with more than 5 oocytes retrieved and no endometriosis
3024425|NCT02399774|Experimental|Post-partum primi and multiparous women|"Post-partum primipara and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~Control group: participants will not receive any device for breastfeeding pain control"
3024426|NCT02399774|Experimental|Post-partum women that have already begun breast feeding|2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
3024427|NCT02399735|Experimental|Arm A|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
3024428|NCT02399735|Experimental|Arm B|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
3024429|NCT02399735|Experimental|Arm C|Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
3024430|NCT02399722|Active Comparator|VAC mono therapy|negative pressure wound therapy alone
3024431|NCT02399722|Active Comparator|WICVAC combined therapy|Polymeric membrane dressing combined with negative pressure wound therapy
3024432|NCT02399709|Experimental|simvastatin|oral administration, capsule of 20mg.
3024433|NCT02399709|Placebo Comparator|microcrystalline cellulose|oral administration, capsule of 20mg
3024434|NCT02399696|Experimental|Primary Care-Brief Mindfulness Program|A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum.
3024435|NCT02399696|Active Comparator|Primary Care-Treatment as Usual|Typical VA primary care treatment, including mental health services delivered by primary care staff.
3024436|NCT02399683||Trichuris trichiura eggs|One healthy volunteer
3024437|NCT02399670||Decrease femoral offset|The FO of operated side was reduced more than 5mm compared with the contralateral side.
3024438|NCT02399670||Restored femoral offset|The FO of operated side was within 5mm restored compared with the contralateral side.
3024439|NCT02399670||Increased FO|The FO of operated side was increased more than 5mm compared with the contralateral side.
3024440|NCT02399657|Experimental|Intravitreal dexamethasone implant|Intravitreal dexamethasone 0.7mg implant (Ozurdex)
3024441|NCT02399644|Experimental|ACT|Acceptance and Commitment Therapy is a version of Cognitive behavioral Therapy that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
3024442|NCT02399644|Experimental|Physical activity|Participants are going to participate in a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
3024443|NCT02399644|No Intervention|Experience based discussion group|Participants are going to discuss their experiences of long term pain. The discussions is supervised by a heath care professional and is based on beforehand defined subjects, i.e. relations, spare time, economics, occupation. The meetings are hold for 7 weeks, 2 hours a week.
3024444|NCT02399631|Experimental|ERAS group|early recovery program with no preoperative mechanical bowel preparation, early diet initiation, and prevention of postoperative ileus after elective laparoscopic colon cancer surgery
3024445|NCT02399631|No Intervention|Congrol group|Traditional, conventional perioperative treatment
3024821|NCT02396979|Experimental|Methadone Maintenance|Methadone induction and management provided
3024446|NCT02399618|Experimental|Capsulized freeze-dried FMT|Reconstitution of normal flora with capsulized freeze-dried fecal inoculum
3024447|NCT02399605|No Intervention|Control|No intervention, group control.
3024448|NCT02399605|Experimental|Stimulation|Subcutaneous Electrical Intervention
3024449|NCT02399592|Experimental|Bevacizumab and Tocotrienol|
3024450|NCT02399579|Experimental|HypoScore|Provocation test. Recording symptoms of cat allergic participants with the cat owner's cat: Before and after petting the cat.
3024451|NCT02399566|Experimental|Experimental|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy
3024452|NCT02399566|Active Comparator|Comparator|followed classical chemotherapy for 4 cycles, use Pemetrexed interventional for the maintenance therapy
3024453|NCT02399553|Experimental|Soccer 2G|Soccer players who trained in second generation artificial turf
3024454|NCT02399553|Experimental|Soccer 3G|Soccer players who trained in third generation artificial turf
3024455|NCT02399553|Experimental|Soccer NG|Soccer players who trained in natural grass
3024456|NCT02399553|Experimental|Soccer NON-NG|Soccer players who trained in non-natural grass
3024457|NCT02399553|No Intervention|Control group|
3024458|NCT02399540|Sham Comparator|Sham|Day 1: sham stimulation Day 2: sham stimulation
3024459|NCT02399540|Active Comparator|Conventional Paired tDCS|Day 1: sham stimulation Day 2: conventional tDCS
3024460|NCT02399540|Active Comparator|Conventional Unpaired tDCS|Day 1: conventional tDCS Day 2: sham stimulation
3024461|NCT02399540|Experimental|Late LTP-like Plasticity tDCS|Day 1: late LTP-like Plasticity tDCS Day 2: sham stimulation
3024462|NCT02399514|Other|RePneum coils|Patients who needed lung volume reduction with RePneum coils
3024463|NCT02399501|Experimental|uterine lesion ultrasound, hysteroscopy|evaluation of female with proved uterine lesion by two dimensional ultrasound, three dimensional ultrasound, saline sonohysterography and hysteroscopy
3024464|NCT02399475|Experimental|Levothyroxine First|Participants will start on the thyroid hormone Levothyroxine prior to crossing over to Liothyronine
3024465|NCT02399475|Experimental|Liothyronine First|Participants will start on the thyroid hormone Liothyronine prior to crossing over to Levothyroxine
3024466|NCT02399462|Experimental|Study Drug Arm|Acthar SC injections
3024467|NCT02399449|Active Comparator|sodium ferric gluconate (brand)|brand-name sodium ferric gluconate
3024468|NCT02399449|Active Comparator|sodium ferric gluconate (generic)|generic sodium ferric gluconate
3024469|NCT02399436|Experimental|School-Based Healthy Snacking Campaign|Students who attend middle and high schools in the experimental county that participate in the healthy snacking campaign intervention.
3024470|NCT02399436|No Intervention|Comparison Schools|Students who attend middle and high schools in the comparison county, which does not receive any intervention components.
3024471|NCT02399436|Experimental|Community Cooking Classes|Adults in the intervention county who enroll in group cooking classes (single-group pretest-posttest)
3024472|NCT02399423|Other|South Asian participants|30 South Asian male participants
3024473|NCT02399423|Other|European participants|30 European male participants
3024474|NCT02399410|Experimental|bevacizumab and CRS with oxaliplatin|Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin
3024475|NCT02399397|Active Comparator|Control group|Adult patients(18-50 years old) ASA I-II without sepsis submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
3024476|NCT02399397|Experimental|Sepsis group|Adult patients (18-50 years old) ASAII and III with sepsis, systemic inflammatory response syndrome or septic shock submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
3024477|NCT02399397|Experimental|Elderly group|Elderly patients (> 65 years old) ASA I-II without sepsis submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
3024478|NCT02399384||HIV+/CAD+|HIV+/CAD+
3024479|NCT02399384||HIV+/CAD-|HIV+/CAD-
3024480|NCT02399384||HIV-/CAD+|HIV-/CAD+
3024481|NCT02399384||HIV-/CAD-|HIV-/CAD-
3024482|NCT02399371|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may be eligible for up to 1 year of additional pembrolizumab therapy if they progress after stopping pembrolizumab.
3024483|NCT02399358||High-dose Cyclophosphamide|Patients requiring infusion of high-dose cyclophosphamide in the period 2015-2017 will be included. After informed consent, patients will de follow up from the infusion of cyclophosphamide to 30 days after hospital discharge.
3024484|NCT02399345|Experimental|Ombitasvir/Paritaprevir/r, Dasabuvir, and SOF plus RBV|Ombitasvir/paritaprevir/ritonavir (ombitasvir/paritaprevir/r) (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) and sofosbuvir (SOF) (400 mg once daily), plus weight-based ribavirin (RBV) (dosed 1,000 or 1,200 mg daily divided twice a day) for 6 weeks.
3024485|NCT02399332|Experimental|Community Pharmacist Involvement|"Patients would have a complex care plan completed by their clinical team, which will involve chronic disease management nurse and the family physician. This complex care plan would also involve discussion with the patient's community pharmacist who would follow-up with the patient monthly and send a report to the patient's physician. Patients would also continue to receive routine care at the clinic.~The monthly follow-ups with the community pharmacist would involve review of the goals of complex care plan and monitoring clinical targets, medication review and discussing adherence as well as patient education. This follow-up can be completed in person or by telephone. The pharmacist would then send a monthly report to patient's family physician."
3024486|NCT02399332|No Intervention|Usual care|Patients have a complex care plan completed by their clinical team, which will involve the chronic disease management nurse and the family physician and then receive routine care and follow up. They will receive usual care from their community pharmacist.
3024487|NCT02399319|Experimental|Randomized to Internal Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention would be internal fixator.
3024488|NCT02399319|Experimental|Randomized to Symphyseal Plate|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention would be internal plating of the symphysis.
3024489|NCT02399319|Active Comparator|Observational - Internal Fixator|Patient signed consent but did not want to randomize their procedure and the treating physician selected the internal fixator intervention based on their opinion of how best to treat the specific case.
3024490|NCT02399319|Active Comparator|Observational - Symphyseal Plate|Patient signed consent but did not want to randomize their procedure and the treating physician selected internal plating of the symphysis based on their opinion of how best to treat the specific case.
3024491|NCT02399306|Experimental|Arm A|chemoradiotherapy with Enteral Nutrition intervention
3024492|NCT02399306|Placebo Comparator|Arm B|chemoradiotherapy
3024493|NCT02399293|Experimental|Patient N-back|Patients training the N-back task
3024494|NCT02399293|Active Comparator|Patient Visual Search|Patients training the Visual-Search task
3024495|NCT02399293|Experimental|Non-impaired N-back|Non-impaired training the N-back task
3024496|NCT02399293|Active Comparator|Non-impaired Visual Search|Non-impaired training the Visual-Search task
3024497|NCT02399280|Experimental|Lunch|Lunch as main meal(LM)+ Diet
3024498|NCT02399280|Experimental|Dinner|Dinner as main meal(DM)+ Diet
3024499|NCT02399267|Active Comparator|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
3024500|NCT02399267|Experimental|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
3024501|NCT02399267|Active Comparator|PS SBTs|In the 'PS SBTs arm', RTs will conduct SBTs using only PS =< 8 cm H2O with PEEP =< 5 cm H2O. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
3024502|NCT02399267|Active Comparator|T-piece SBTs|In the 'T-piece SBTs arm', RTs will conduct SBTs using only T-piece. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
3024503|NCT02399254||Pulmonary Rehabilitation|COPD patients following pulmonary rehabilitation
3024504|NCT02399241|Experimental|Remote telemonitoring of clinical data|Bluetooth enabled nebuliser device (I-neb) providing breathing parameters and adherence data.
3024505|NCT02399228|Experimental|0.25% EISO Mouth Rinse|"A mouth rinse containing 0.25% East Indian sandalwood oil (EISO), a candidate botanical drug substance. The rinse will be used three times a day for up to ten weeks. The material will not be ingested but used to swish, gargle and spit."
3024506|NCT02399215|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3024507|NCT02399202|Experimental|osilodrostat ( LCI699)|Each participant will undergo a 28 day screening /baseline period (day-28 to Day -1), followed by a 4 day treatment period ( a single 30 mg dose of LCI699 (Day 1) with 4 days of PK smple collection
3024508|NCT02399189|Experimental|R-MT followed by auto-HSCT|"R-MT followed by auto-HSCT Rituximab 375 mg/m2 d1 MTX 3.5g/m2 d2(0.5g/m2 15min,3g/m2 3h） TMZ 100 mg/m2 d2-6 Q21d*4cycles~Auto-HSCT conditioning regimen:~BCNU 400mg/m2 d1; Thiotepa 5mg/kg q12h，d2-3"
3024509|NCT02399176|Experimental|Yoga of minimal intensity|Does Yoga: At least 4 times/week.
3024510|NCT02399163|Experimental|Placebo dentifrice/Fluoride rinse|Twice daily brushing with a non-fluoride (placebo) toothpaste followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride
3024511|NCT02399163|Placebo Comparator|Placebo dentifrice/No rinse|Twice daily brushing with a non-fluoride (placebo) toothpaste
3024512|NCT02399163|Active Comparator|Fluoride dentifrice/No rinse|Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride
3024513|NCT02399163|Experimental|Fluoride dentifrice/Fluoride rinse|Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride, followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride.
3024514|NCT02399150||Acute Abdominal Pain|patients presenting to the ED with acute abdomen
3024515|NCT02399137|Experimental|Arm A (Experimental Arm)|MM-141 in combination with nab-paclitaxel and gemcitabine
3024516|NCT02399137|Active Comparator|Arm B (Comparator Arm)|Placebo in combination with nab-paclitaxel and gemcitabine
3024518|NCT02399124|Other|single arm, open label, treatment|single arm, open label, treatment; ProSenseTM Cryoablation treatment, post marketing surveillance
3024519|NCT02399111|No Intervention|Not obese:BMI<30; Standard Care|Standard Wound Care
3024520|NCT02399111|No Intervention|Obese:BMI≥30; Standard Care|Standard Wound Care
3024521|NCT02399111|Other|Not Obese:BMI<30; Wound Vac|Using Prevena Incision Management System
3024522|NCT02399111|Other|Obese:BMI≥30; Wound Vac|Using Prevena Incision Management System
3024523|NCT02399098|Experimental|External focus group|This group will be given instructions on how to focus on the external cue relevant to the task (e.g., focus on the center of the dart board).
3024524|NCT02399098|Experimental|Internal focus group|This group will be instructed how to focus on the arm movements (e.g., feel the bend in your elbow).
3024525|NCT02399098|No Intervention|Control|This group will be given general instructions on throwing techniques (e.g., hold the dart with four fingers and make sure it is in a stable position) but no attentional focus instructions will be given.
3024526|NCT02399085|Experimental|Treatment (MOR00208, lenalidomide)|"MOR00208 Fc-Optimized Anti-CD19 Antibody, intravenous Infusion, weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), 4 weeks cycles, until disease progression or unacceptable toxicity or discontinuation due to any other reason.~Lenalidomide (Revlimid®), PO, daily, 4 weeks cycles, lenalidomide is used 3 of the 4 weeks. Up to 12 cycles in the absence of disease progression or unacceptable toxicity."
3024527|NCT02399072|Other|Geographic Atrophy Participants|Participants with unilateral GA or GA in one eye and choroidal neovascularization (CNV; active or treated) with or without GA, in the contralateral eye, will be evaluated for the progression of GA for up to approximately 60 months.
3024528|NCT02399059|Experimental|Antibiotic lavage|Peritoneal irrigation with Gentamycin - clndamycin solution
3024529|NCT02399059|Active Comparator|Normal saline lavage|Peritoneal irrigation with normal saline
3024530|NCT02399046|Experimental|Total Knee System made in China|Patinet in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured in China
3024531|NCT02399046|Active Comparator|Total Knee System made outside of China|Patient in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured Outside of China
3024532|NCT02399033|No Intervention|the control group|Patients in Control group were not received Xihuang Capsules.
3024533|NCT02399033|Experimental|Xihuang Capsules group|Patients in Xihuang Capsules group were received Xihuang Capsules (2g, bid), Continuously taking to cancer recurrence or death.
3024534|NCT02399020|Experimental|SCIT group|Social Cognition and Interaction Training intervention group
3024535|NCT02399007|Experimental|Total Hip System made in China|Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured in China
3024536|NCT02399007|Active Comparator|Total Hip System made outside of China|Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured Outside of China
3024537|NCT02398994|Active Comparator|Intravenous Methylprednisolone|"Paediatric patients - 30mg/kg or 500mg/m2 up to a maximum daily dose of 1g/day for 5 days.~Adult patients - 1g/day for 5 days."
3024538|NCT02398994|Experimental|Intravenous Immunoglobulin|"Paediatric patients <41.2kg - total dose of 2g/kg in divided doses over 2 days.~All other patients - total dose of 2g/kg in divided doses over 5 days.~PLUS Intravenous Methylprednisolone~Pediatric patients - 30mg/kg or 500mg/m2 up to a maximum daily dose of 1g/day for 5 days.~Adult patients - 1g/day for 5 days."
3024539|NCT02398981|No Intervention|Baseline|Baseline data collection ( 20 patients per ICU)
3024540|NCT02398981|Experimental|Checklist|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist 40 patients per ICU
3024541|NCT02398968|Active Comparator|RURTI+IDA+iron therapy|children with iron deficiency anemia on therapeutic iron fumerate therapy (6mg/kg/d) for 3 months, then maintained on iron fumerate supplementation(1mg/kg/d) for 12 months
3024542|NCT02398968|Active Comparator|B1:RURTI+no anemia+iron maintenance|children with recurrent upper respiratory tract infection and no anemia receiving oral iron fumerate (1mg/kg/d) for 12 months
3024543|NCT02398968|Placebo Comparator|B2:RURTI+no anemia|children with recurrent upper respiratory tract infection and no anemia receiving placebo for 12 months
3024544|NCT02398955||Study cohort|All comers patients with coronary artery disease treated with percutaneous coronary intervention and at least one Biomime stent
3024545|NCT02398942||Proximal Pole Fracture of the Scaphoid|QuickDASH 6 months after injury CT scan 6 months after injury
3024546|NCT02398929|Other|Bisoprolol 2.5 mg|Bisoprolol 2.5 mg will be given once daily following run-in placebo for 2 weeks
3024547|NCT02398916|Experimental|Music|"Listening to relaxing music for the entire period starting from waiting period in the surgical waiting area until the end of the LEEP procedure~Undergoing LEEP according to the usual protocol"
3024548|NCT02398916|No Intervention|Control|- Undergoing LEEP according to the usual protocol without listening to music
3024549|NCT02398903||Obese women SG|Obese women operated by sleeve gastrectomy
3024550|NCT02398903||Normal weight women|Normal weight women
3024551|NCT02398903||Obese women GBP|Obese women operated by Rougastric bypass
3024552|NCT02398877|Experimental|Depression with early trauma|stress
3024553|NCT02398877|Experimental|Depression without early trauma|stress
3024554|NCT02398877|Experimental|Healthy with early trauma|stress
3024555|NCT02398877|Experimental|Healthy without early trauma|stress
3024556|NCT02398864|Experimental|endobronchial ultrasound bronchoscopy|EBUS with TBNA
3024557|NCT02398851|Other|TacTIC care model|Compare the 30-day readmission rate in adult patients who receive care in a trans-disciplinary chronic disease continuity of care model with integrated technology (mobile devices such as tablets, iPads and smartphones)
3024558|NCT02398851|Other|Standard of Care|Compare standard practice (patient-centered, coordinated care model without the integration of technology
3024559|NCT02398838|Experimental|Home administration of mifepristone|Home administration of 200 mg mifepristone. Choice of home or clinic administration of 400 mcg buccal misoprostol.
3024560|NCT02398838|Active Comparator|Clinic administration of mifepristone|Clinic administration of 200 mg mifepristone. Choice of home or clinic administration of 400 mcg buccal misoprostol.
3024561|NCT02398825|Experimental|Ponatinib|
3024562|NCT02398812|Active Comparator|Active comparator|In addition to usual care, participants allocated to intervention group will receive medication assessment and treatment plan based on it
3024563|NCT02398812|No Intervention|Usual care|Usual care (reference group).
3024564|NCT02398799|No Intervention|control|The dyads in the control group received care as usual including traditional care in hospital and outpatient education and support. The care is mainly focused on the patient's needs. The partner is not systematically involved in the follow-up focusing on education and psychosocial support.
3024565|NCT02398799|Experimental|Psycho edcuactional support|The intervention psychoeducational support to the patient-partner dyads was delivered in 3 sessions through nurse-led face-to-face counseling, a computer-based CD-ROM program and other written teaching materials. All sessions lasted at least 60 minutes and were conducted in the dyads' homes or in the heart failure clinic. The first session 2 weeks after discharge and the two remaining sessions 6- and 12-weeks following discharge. Each session included education on heart failure and development of problem- solving skills to assist the dyads in recognizing and modifying factors that contribute to psychological and emotional distress. The intervention focused on changing thoughts and behaviors and implementing strategies for self-care.
3024566|NCT02398773|Experimental|Diagnostic (FES PET/CT)|Between 0 to 30 days before start of endocrine therapy, patients receive F-18 16 alpha-fluoroestradiol IV over 2 minutes and undergo PET/CT. Patients may undergo a second FES-PET/CT study at least 24 hours after the first study and no later than 10 days after the initial study.
3024567|NCT02398760|Experimental|Motor Control Exercises|(Costa LOP et al. 2009; Hodges PW et al. 2009)
3024568|NCT02398747|Experimental|AZD2014 50mg, 125mg, 25mg and 50mg intermittent BD|50mg BD continuous dosing, 125mg BD intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
3024569|NCT02398734|Experimental|Sonolysis|In patients randomized into sonolysis group, middle cerebral artery segment in a depth of 55 mm will be continuously monitored during intervention using a diagnostic 2-MHz transcranial Doppler probe with a maximal diagnostic energy. The probe will be fixed in a required position using a special helmet and sonolysis will start before the carotid intervention and will be stopped after the intervention, but at latest after 120 minutes. Transcranial Doppler machine with a 2-MHz diagnostic transcranial Doppler probe will be used. This non-diagnostic transcranial Doppler monitoring will be performed without detection of microembolic signals or detection of changes in blood flow. Device sound and Doppler wave imaging will be switched off. Only sonographer will be unblinded to the procedure.
3024570|NCT02398734|Sham Comparator|Shame sonolysis|In patients randomized into control group, the transcranial Doppler probe will be fixed in a required position using a special helmet as in sonolysis group patients, but middle cerebral artery segment in a depth of 55 mm will be only localized using a diagnostic 2-MHz transcranial Doppler probe with a maximal diagnostic energy and the transcranial Doppler monitoring will be stopped afterwards. Patients in the control group will undergo a sham procedure in which further sonolysis (transcranial Doppler monitoring) will not be conducted.
3024571|NCT02398721|Other|FNAC|patients will then be randomized routine FNAC strategy
3024572|NCT02398721|No Intervention|No FNAC|patients will be randomized to watchful observation strategy (no FNAC)
3024573|NCT02398708||Chronic Graft-Versus-Host Disease|This group will have questionnaires, clinical data, a blood sample and a stool sample collected to be compared with the other group.
3024574|NCT02398708||No Chronic Graft-Versus-Host Disease|This group will have questionnaires, clinical data, a blood sample and a stool sample collected to be compared with the other group.
3024575|NCT02398695||Caries Free|Participants who do not have caries (cavities) will have oral samples collected.
3024576|NCT02398695||Caries Active|Participants who do have caries (cavities) will have oral samples collected.
3024577|NCT02398682|Experimental|After study Intervention arm Heartlands|"The trial has 4 arms in a Before and After design:~Arm 3. After/Heartlands area patients receiving the experimental intervention~Patients who have AKI and are either inpatients in the Intervention hospital or living within the surrounding catchment area are eligible. The intervention will be in the form of a telephone call to the primary clinician or visit to the patient. The intervention will include:~Rapid diagnosis of AKI cause; Rapid treatment of AKI cause; Stopping 'nephrotoxic' drugs; Early nephrology followup for stage 3 AKI survivors; and preventing recurrent AKI."
3024578|NCT02398682|Active Comparator|After study Control arm Good Hope|"The trial has 4 arms in a Before and After design:~Arm 4. After/Good Hope area patients observed whilst receiving active comparator~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Good Hope Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
3024579|NCT02398682|Active Comparator|Before study Heartlands area|"The trial has 4 arms in a Before and After design:~Arm 1. Before/Heartlands area patients observed whilst receiving active comparator~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Heartlands Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
3024580|NCT02398682|Active Comparator|Before study Good Hope area|"The trial has 4 arms in a Before and After design:~Arm 2. Before/Good Hope area patients observed whilst receiving active comparator~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Good Hope Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
3024581|NCT02398669|Experimental|lorcaserin 10 mg|Cohort 1 - obese pediatric participants between age group of 6 and 8 years (inclusive) Cohort 2 - obese pediatric participants between age group of 9 and 11 years (inclusive)
3024582|NCT02398656|Experimental|Tenecteplase (tNK)|Experimental: TNK-tPA (0.25mg/kg) given as a single, intravenous bolus immediately upon randomization. Experimental treatment will be administered as a single intravenous bolus over 1-2 minutes as per the standard manufacturers' instructions for use. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, has a longer half-life, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor than alteplase.
3024648|NCT02398214|Experimental|Sleep hygiene & standard care|Participants receive a light, activity, and sleep training (LAST) intervention consists of behavioral and educational strategies for increasing light exposure and physical activity to minimize sleep disturbance.
3024583|NCT02398656|Active Comparator|Control (Antiplatelet Agents)|Control: Patients will be treated with standard of care based antiplatelet treatment - choice at the discretion of the investigator. Low dose aspirin (single agent) will be the choice of most physicians, some will chose to use the combination of aspirin and clopidogrel. As this is a multi-centre, international trial where local practices will vary, rather than mandating a specific antiplatelet agent, we will allow the local investigator to chose which antithrombotic regime should be used. Standard of care medication(s) should be given immediately upon randomization.
3024584|NCT02398643|Other|Early Pulmonary Education (EPE)|Patients randomized to EPE will receive focused education sessions by a Certified Respiratory Educator. Education sessions will start within two weeks of discharge from hospital.
3024585|NCT02398643|Other|Usual Care|Patients randomized to usual care will receive general education sessions by a Certified Respiratory Educator within the month of being discharged.
3024586|NCT02398630|Other|Open Label|"This is a single arm open label study.~Its procedures involve:~Transvaginal Echography~Conventional Virtual Histerosalpingography~Virtual Histerosalpingography by MRI~Blood draw for Antimullerian Hormone Dosing"
3024587|NCT02398617|Other|Decision Making Intervention|At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.
3024588|NCT02398604|Experimental|Group A - Allo-hMSCs|Group A: Fifteen (20) patients will be treated with Allogenic human mesenchymal stem cells (Allo-hMSCs): A concentration of 5 million cells/ml delivered in a dose of 2.5 x 10^5 cells per kg of recipient (5 million/20kg) Allo-hMSCs. The entire dose of the cells will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.
3024589|NCT02398604|Placebo Comparator|Group B|Group B: Fifteen (10) patients will be treated with a placebo comparator. The placebo will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.
3024590|NCT02398591|Experimental|JNJ 53718678 250 milligram (mg)|Participants will receive either single oral dose of 250 mg of JNJ 53718678 or matching placebo on Day 1.
3024591|NCT02398591|Experimental|JNJ 53718678 500 mg|Participants will receive either single oral dose of 500 mg of JNJ 53718678 or matching placebo on Day 1.
3024592|NCT02398591|Experimental|JNJ 53718678 1000 mg|Participants will receive either single oral dose of 1000 mg of JNJ 53718678 or matching placebo on Day 1.
3024593|NCT02398578|Experimental|Amphora OAB Device|Specialized cystoscope that facilitates visualization and radiofrequency (RF) therapy for the treatment of OAB.
3024594|NCT02398565||Cohort|"Patients with a history of ventral hernia repair (umbilical/epigastric and incisional) with subsequent pregnancy~Ventral hernia repair - perioperative factors of interest:~- mesh vs sutured repair, age, planned vs emergency repair, open vs laparoscopic approach,~Pregnancy and delivery - factors of interest:~- vaginal vs caesearan section, single vs multiple pregnancy~Subgroup of patients with mesh repair:~- subanalysis on main attributes~Subgroup of patients with sutured repair:~- mono- vs multifilament, slowly vs rapidly absorbable"
3024595|NCT02398552|Active Comparator|Sunitinib 50mg/day schedule 4/2|Sunitinib 50mg/day 4 weeks on/2 weeks off per 6 weeks till disease progression or intolerable toxicity.
3024596|NCT02398552|Experimental|Sunitinib 50mg/day schedule 2/1|Sunitinib 50mg/day 2 weeks on/1 week off per 6 weeks till disease progression or intolerable toxicity.
3024597|NCT02398539|Active Comparator|Group 1|Silver nitrate treatment will include weekly applications in the pediatric surgery office by a clinician.
3024598|NCT02398539|Active Comparator|Group 2|Triamcinolone cream, 0.5% applied three times per day by the patient's caregiver.
3024599|NCT02398526||Radium-223 dichloride|Male patients with a diagnosis of CRPC with symptomatic bone metastases without known visceral metastases will be enrolled after the decision for treatment with Radium-223 has been made by the attending physician according to his/her medical practice.
3024600|NCT02398513|Experimental|Regorafenib (Stivarga, BAY73-4506)|Patients enrolled in the study will start treatment with Regorafenib160 mg (given by four 40 mg tablets of Regorafenib) on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, Regorafenib 160 mg QD will be administered for 21 days, followed by 7 days off treatment. Treatment with Regorafenib will continue until the patient either progresses or meets one of the criteria for withdrawal prespecified in the study protocol.
3024601|NCT02398500|Experimental|LMG324|SAD: LMG324 administered as a single IVT injection in 1 eye (study eye) in 1 of 4 doses, with 15-day follow-up
3024602|NCT02398500|Experimental|LMG324 + sham|Expansion: LMG324 administered as a single IVT injection in 1 eye (study eye), followed by sham injections, until implementation of SoC therapy as specified in the protocol, for 24 weeks
3024603|NCT02398500|Active Comparator|Lucentis + sham|Expansion: Ranibizumab 0.5 mg administered as monthly IVT injections in 1 eye (study eye) with interim sham injections, for 24 weeks
3024604|NCT02398487|Active Comparator|Personal Vaporizer|Personal Vaporizer loaded with nicotine
3024605|NCT02398487|Active Comparator|Cigalike|Cigalike loaded with nicotine
3024606|NCT02398487|No Intervention|Usual smoking|
3024607|NCT02398474|Experimental|iliac crest bone graft with a TFP block|Regional anesthesia (RA) for the upper or lower limb depending on the surgery + general anesthesia (GA) + TFP block
3024608|NCT02398474|Active Comparator|local anesthetic infiltration of the surgical site.|RA for the upper or lower limb depending on the surgery + GA + ropivacaine infiltration of the iliac crest bone
3024609|NCT02398461|Experimental|rHIgM22|Patients will be enrolled sequentially in 2 separate cohorts, representing escalating dose levels. Each dose cohort will comprise 15 subjects, randomly assigned to receive either rHIgM22 (n=10) or placebo (n=5).
3024610|NCT02398461|Placebo Comparator|Placebo|Patients will be enrolled sequentially in 2 separate cohorts, representing escalating dose levels. Each dose cohort will comprise 15 subjects, randomly assigned to receive either rHIgM22 (n=10) or placebo (n=5).
3024649|NCT02398214|No Intervention|Standard care|Participants receive usual care.
3024650|NCT02398201|Experimental|Interventional|Bezafibrate tablets (200-600mg) three times daily for 12 weeks.
3024611|NCT02398448|Experimental|Zyloprim® 300 mg and three dissolution test formulations|Regimen A: Zyloprim® 300 mg; Regimen B: Allopurinol 300 mg; undergranulated, high hardness condition; Regimen C: Allopurinol 300 mg; alternative condition 2; Regimen D: Allopurinol 300 mg; alternative condition 3
3024612|NCT02398435|Experimental|Cohort 80 mg|Cohort 1 included 10 patients. Patients received Tadekinig alfa s.c with a dosage of 80mg. Safety assessments were conducted by data safety monitoring board. Non-responder patients were upscaled to next dose (160mg) after 3 weeks of treatment.
3024613|NCT02398435|Experimental|Cohort 160 mg|Cohort 2 included 13 patients. all patients were treated with Tadekinig alfa s.c with a dosage of 160mg. Safety was evaluated by data safety monitoring board.
3024614|NCT02398422|Experimental|Filtered Music Intervention|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
3024615|NCT02398422|Experimental|Nonfiltered Music Intervention|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention (nonfiltered music). The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
3024616|NCT02398422|No Intervention|Assessment-only|The assessment-only group will participate in all pre- and post-intervention assessments, but will not receive the Listening Project Protocol.
3024617|NCT02398409|Experimental|ANSWERS-VA|"8 week telephone intervention with nurse case manager using Acquiring New Skills While Enhancing Remaining Strengths (ANSWERS)"
3024618|NCT02398409|Other|Control|8 week telephone usual care with education with nurse case manager
3024619|NCT02398396|Experimental|Open Label: 4CMenB (Bexsero®)|
3024620|NCT02398383|Experimental|CF with Normal Glucose Tolerance|Individuals with CF without cystic fibrosis related diabetes
3024621|NCT02398383|Experimental|Cystic Fibrosis Related Diabetes|Individuals with cystic fibrosis and cystic fibrosis related diabetes
3024622|NCT02398383|Active Comparator|Control|Age matched control subjects
3024623|NCT02398370|Experimental|Injection of PMD-MSCs into the penis|Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based patient reported treatment satisfaction.
3024624|NCT02398357|No Intervention|Control|No anticoagulation，just routine follow-up
3024625|NCT02398357|Experimental|Anticoagulation|Nadroparin Calcium and Warfarin
3024626|NCT02398344|Experimental|1- tDCS ACTIVE|1. Transcranial stimulation ( tDCS ) will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes, intensity 2mA With Simulator anodic electro stimulation from bloodstream on right and left temporal cortex region (T3 area) and cathodic position in contralateral supraorbital region to anode (Fp2), associated Cardiac Frequency Variability (HRV) as measured by spectral analysis by spectral analysis Polar RS800 cx.
3024627|NCT02398344|Experimental|2- tDCS SHAM|Placebo tDCS will be administered using Tct Research 1 CH tdcs Simulator model 101 and will follow the same procedures as active tDCS active, but the tDCS device will only be switched on for 30 seconds.
3024628|NCT02398331|Experimental|arm|Standardised information and education on sexuality in women with spinal cord injury
3024629|NCT02398331|No Intervention|Control arm|Usual care (no structured information or education on sexuality)
3024630|NCT02398318|Active Comparator|Bilateral Nucleus Accumbens DBS|6 month period of active bilateral nucleus accumbens DBS
3024631|NCT02398318|Sham Comparator|Sham Bilateral Nucleus Accumbens DBS|6 month period of sham bilateral nucleus accumbens DBS
3024632|NCT02398305|Active Comparator|TR Band accelerated|Diminishing air pressure in the TR Band using accelerated protocol
3024633|NCT02398305|Other|TR band standard|Diminishing air pressure in the TR band according to standard care
3024634|NCT02398292|Other|M3 Program|Non-randomized experimental group. The program is a six-week multi-modal intervention, including nutrition education and cooking classes, physical activity, and mindfulness. Outcomes will be compared to a non-randomized control group.
3024635|NCT02398292|Other|Control|Non-randomized control group. Outcomes will be compared at same time points (baseline, 6 weeks, 12 weeks).
3024636|NCT02398279|Experimental|L-Arginine-First|For the first three weeks, L-Arginine 3 g bid (500mg capsules 6 x 2), one week wash-out, then for the next three weeks placebo capsules (6 x 2)
3024637|NCT02398279|Experimental|Placebo-First|For the first three weeks, placebo capsules (6 x 2), one week wash-out, then for the next three weeks L-Arginine 3 g bid (500 mg capsules 6 x 2)
3024638|NCT02398266|Experimental|Healthy subjects|Intervention: administration of ultrasound contrast agent (drug) to assess muscle perfusion. Normal healthy subjects (n=10) will be used for optimization of dose and acoustic settings for performing real-time contrast ultrasound perfusion imaging of the limb.
3024639|NCT02398266|Experimental|Patients with PAD and ABI 0.4-0.6|Intervention: administration of ultrasound contrast agent (drug) to assess muscle perfusion. Patients with moderate to severe PAD (ABI 0.4 to 0.6) will be evaluated with contrast ultrasound perfusion imaging using methods optimized in the first Arm to determine whether symptoms better correlate with perfusion imaging than other measures of PAD severity.
3024640|NCT02398266|Experimental|Patients with PAD Undergoing Revascularization|Intervention: administration of ultrasound contrast agent (drug) to assess change in muscle perfusion produced by revascularization (surgical or percutaneous procedure). Patients with symptomatic PAD will be evaluated with contrast ultrasound perfusion imaging using methods optimized in the first Arm before and within 1 month of revascularization to determine whether improvement in symptoms correlate with perfusion imaging data.
3024641|NCT02398253|Experimental|CBT + Hypo-energetic Diet|
3024642|NCT02398253|Experimental|Hypo-energetic Diet only|
3024643|NCT02398240|Experimental|Low Risk|Low Risk Patients (Stage IA, IIA; no bulky disease or extension): 3 cycles of chemotherapy
3024644|NCT02398240|Experimental|Intermediate Risk|Intermediate Risk Patients (Stage IA bulk/E, IB, IIA bulk/E, IIB, IIIA): 4 cycles of chemotherapy
3024645|NCT02398240|Experimental|High Risk|High Risk Patients (Stage IIIA bulk/ E, IIIB, IVA/B): 6 cycles of chemotherapy
3024646|NCT02398227|Experimental|HOPE|Cognitive Behavioral Treatment Program for PTSD
3024647|NCT02398227|Active Comparator|PCT|Present Centered Therapy for PTSD
3024653|NCT02398175||Pediatric polytraumatized patients with thoracic injuries|Pediatric polytraumatized patients (age < 18), (ISS > 16) with thoracic injuries
3024654|NCT02398162||STP|Scrub Typhus Patients (STP, n=60) Cohort. Blood samples will be collected at baseline (the day of presentation to hospital), 2 weeks later in hospital, 12 weeks after baseline at the clinic visit and 1 year later. Data on clinical presentation and relapses will be recorded. Eschar swab specimens and a non-invasive specimen of the dark crust will be also collected from STP group on the day of enrollment.
3024655|NCT02398162||STE|Scrub Typhus Exposed (STE, n=80) Cohort. Single blood sample collection.
3024656|NCT02398162||STH|Scrub Typhus Healthy (STH, n=30) Cohort. Single blood sample collection
3024657|NCT02398149||PwMS receiving care at the Mandell Center|
3024658|NCT02398136|Experimental|Ketamine|Intranasal ketamine up to 75 mg, delivered over 20 minutes, frequency: 3x/week for 4 weeks.
3024659|NCT02398136|Active Comparator|Midazolam|Intranasal midazolam 3.75mg, delivered over 20 minutes, frequency: 3x/week for 4 weeks.
3024660|NCT02398123|Active Comparator|Transversus abdominis plane block|Transversus Abdominis Plane block
3024661|NCT02398123|Placebo Comparator|Caudal block|Caudal block
3024662|NCT02398110|Experimental|transvaginal NOTES nephrectomy|A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity
3024663|NCT02398110|Active Comparator|conventional laparoscopic nephrectomy|One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin
3024664|NCT02398097|Active Comparator|Agripal|28 trivalent subunit inactivated intramuscular vaccine (Agripal) recipients: one vaccine injection administered on Day 0
3024665|NCT02398097|Active Comparator|IDflu9μg|30 reduced-content intradermal split vaccine (IDflu9μg) recipients: one vaccine injection administered on Day 0
3024666|NCT02398097|Active Comparator|IDflu15μg|28 standard-content intradermal split vaccine (IDflu15μg) recipients: one vaccine injection administered on Day 0
3024667|NCT02398084|Experimental|Chewing of nuts|8 samples (4-5 g) of nuts (cashews or walnuts) on two separate visit days.
3024668|NCT02398071|Experimental|PEP interventon|Participants performed 6 PEP breaths using a water pressure threshold device (BreatheMAX) with expiratory load set at 5 cmH2O
3024669|NCT02398071|Sham Comparator|Sham intervention|Participants performed 6 PEP breaths using a water pressure threshold device (BreatheMAX) with expiratory load set at 0 cmH2O
3024670|NCT02398058|Experimental|Trabectedin plus olaparib|"All patients will be treated with trabectedin and olaparib in an open-label fashion.~The dosage of the drugs at which each patient is treated depends on the dose level reached at the time of enrollment."
3024671|NCT02398045|Experimental|Computerised CBT|Computerised CBT for OCD
3024672|NCT02398032|Experimental|CPAP nasal|Nasal continuous positive airway pressure, during the night
3024673|NCT02398032|Sham Comparator|sham CPAP nasal|Nasal sham continuous positive airway pressure, during the night
3024674|NCT02398019|Experimental|CPB-OXIRIS®|Non emergent cardiac surgery patients with CPB requirement.
3024675|NCT02398019|No Intervention|CPB-Standard|Non emergent cardiac surgery patients with CPB requirement.
3024676|NCT02398006|Active Comparator|Group 1: a standard arm sling|Group 1: the orthopaedic surgeon will apply a standard arm sling that will be used for four weeks; however, during these weeks, participants will be encouraged to discard the sling when their pain has subsided. After four weeks the same orientations of group 1 will be done to this group.
3024677|NCT02398006|Active Comparator|Group 2: a figure-of-eight bandage|Group 2: a figure-of-eight bandage will be used for four weeks, and every week the participants will return to check and adjust the immobilisation. In this way, the dominant hand can remain free and simple activities will be allowed (writing, keyboarding and other). After four weeks, participants will be encouraged to discard the bandage, but load bearing will not be allowed before osseous consolidation (around 10 weeks).
3024678|NCT02397993||FNA, blood collection|blood collection prior to fine needle aspiration Endoscopic ultrasonography-guided fine needle aspiration of the pancreas blood collection after to fine needle aspiration
3024679|NCT02397980|No Intervention|Control|Basic information about dementia
3024680|NCT02397980|Active Comparator|Behavioral intervention|"Individual, 90 min a day, with an interval of 2 weeks~Education about dementia~psychological counselling~cognitive behavioral therapy"
3024681|NCT02397967|Experimental|Children NF1|Children diagnosed with NF1 according the NIH criteria Neuropsychological assessments
3024682|NCT02397967|Placebo Comparator|Control group|Control group children without NF1 with the same reading level Neuropsychological assessments
3024683|NCT02397954|Experimental|Zimura + Anti-VEGF|Subjects will receive monthly intravitreous injections of Zimura in combination with either Lucentis, Avastin or Eylea.
3024684|NCT02397941||non-pregnant women|20 non-pregnant women, BMI < 30 kg/m2, Nulligravidas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound
3024685|NCT02397941||pregnant women|40 pregnant women, BMI < 30 kg/m2 before pregnancy, Primigravidas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound, consecutive measurement during the course of pregnancy
3024686|NCT02397941||women who deliverd|20 pregnant women, BMI < 30 kg/m2 before pregnancy, Primiparas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound, measurement after delivery (10 after spontaneous delivery, 10 after elective cesarean section)
3024687|NCT02397928|Experimental|TTFields concomitant to pemetrexed plus cisplatin/carboplatin|Patients will be treated continuously with TTFields, in addition to pemetrexed plus cisplatin/carboplatin
3024688|NCT02397915|Experimental|Fluticasone Furoate|Subjects will receive a single dose of intranasal FF (total dose of 110 mcg) as 2 sprays per nostril / 4 sprays in total.
3024689|NCT02397915|Experimental|Mometasone Furoate|Subjects will receive a single dose of intranasal MF (total dose of 200 mcg) nasal spray as 2 sprays per nostril / 4 sprays in total.
3024690|NCT02397902|Experimental|Dairy|Add 4 daily servings of high fat dairy to diet for a period of 4 weeks
3024691|NCT02397902|Active Comparator|Plant-based|Add 4 daily servings of fruit to diet and/or plant-based milk, remove all dairy from diet for a period of 4 weeks
3024692|NCT02397889|Experimental|Experimental ketamine group|This arm will receive 0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).
3024693|NCT02397889|Active Comparator|Active control midazolam group|This arm will receive 0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).
3024694|NCT02397876|Experimental|partially hydrolyzed whey formula|The group of patients who pass an oral food challenge to partially hydrolyzed whey formula and will be continued on it through out the study
3024695|NCT02397876|No Intervention|No intervention|Patients who do not pass an oral food challenge to partially hydrolyzed whey formula will continue on their prior diet of cows milk avoidance.
3024696|NCT02397850|Experimental|30 min or 50 min|Patients receive either seven 30 minutes or 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
3024697|NCT02397837|Experimental|Pramipexole|Pramipexole, by mouth. Dosing will be initiated at 0.25 mg on night one, followed by 0.25 mg twice-a-day day two onward, and increased every week to a target of 4.5 mg/day for the 12-week duration of the study.
3024698|NCT02397837|Placebo Comparator|Placebo|Placebo, by mouth. Dosing will be initiated at 0.25 mg on night one, followed by 0.25 mg twice-a-day day two onward, and increased every week to a target of 4.5 mg/day for the 12-week duration of the study.
3024699|NCT02397811|Experimental|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
3024700|NCT02397811|Experimental|Liposomal Astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 2.66 grams per dose
3024701|NCT02397811|Experimental|Standard Softgel|Standard softgel containing 4 mg per softgel. 3 softgels per dose
3024702|NCT02397811|Experimental|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
3024703|NCT02397811|Experimental|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
3024704|NCT02397811|Experimental|Standard Softgel with Astaxanthin Gel|Statndard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 softgels per dose
3024705|NCT02397798|Experimental|Intervention|Person-centered high-intense training three times a week under supervision (supervision two times a week) during 5 months
3024706|NCT02397798|Active Comparator|Control|Introduction to health-enhancing physical activity, personalized exercise program to perform at home three times a week during 5 months
3024707|NCT02397785|Experimental|ApexM Device|InControl Medical created a line of products FDA approved for urinary incontinence and fecal incontinence (10). These devices are non-implanted, customizable, battery-operated vaginal probes made of medical grade silicon and provide electrical stimulation to the pelvic floor. One of the devices, ApexM™ provides electrical stimulation at frequencies alternating between 13 Hz and 50 Hz and allows the clinician to adjust the intensity as well as the duration of the electrical stimulation. The investigators propose the use of low power electrical stimulation for the treatment of pain in patients diagnosed with CPP. The electrical stimulation is delivered using ApexM™, adjusting the power to a sensory threshold to prevent muscle contraction.
3024708|NCT02397785|Sham Comparator|Sham Device|"Subjects in the control arm will use a sham ApexM device. The original ApexM device will be modified to disable its electrical stimulation functionality. Otherwise, the devices are indistinguishable and possess identical dimensions. Although the sham device can be powered on, the circuitry will be disconnected so that electrical stimulation is disabled."
3024709|NCT02397772|Active Comparator|Annual school-based deworming|Pre-school and school children (typically 2-14 years) will receive albendazole treatment from trained school teachers, as part of the ongoing national school-based deworming programme.
3024710|NCT02397772|Experimental|Annual community-based deworming|Standard school-based deworming supplemented by annual community-based deworming (2-99 years). All household members who are not enrolled in school will receive albendazole treatment from trained community health workers.
3024711|NCT02397772|Experimental|Biannual|Biannual school- and community-based deworming (2-99 years). All household members who are not enrolled in school will receive albendazole treatment from trained community health workers
3024712|NCT02397759|Experimental|Patients with severe SAH and vasospasm|Patients with severe SAH from ruptured aneurysm requiring the establishment of an external ventricular derivation (EVD) and presenting vasospasm
3024713|NCT02397759|Experimental|Patients with severe SAH without vasospasm|Patients with severe SAH from ruptured aneurysm requiring the establishment of an external ventricular derivation (EVD) without vasospasm
3024714|NCT02397759|Active Comparator|Patients with severe SAH without external ventricular derivati|Patients with severe severe SAH from ruptured aneurysm without necessitating a EVD subarachnoid hemorrhage
3024715|NCT02397746||Total Hip Arthroplasty|Single group previously implanted with the following combination of components: PROFEMUR® Gladiator femoral stem, MicroPort acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.
3024716|NCT02397733|Active Comparator|Prophylactic cranial irradiation (PCI)|Radiation. Prophylactic cranial irradiation : 25 Gy in 10 daily fractions, five times a week
3024717|NCT02397733|Experimental|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation. 25 Gy in 10 daily fractions, five times a week
3024718|NCT02397720|Experimental|Azacitidine + Nivolumab|"Dose Escalation Phase: Participants receive Azacitidine by vein over about 1 hour or as an injection under the skin. Participants receive this drug either on Days 1-7 of each cycle, or on Days 1-5 and then 8 and 9 of each cycle.~Participants receive Nivolumab by vein over about 1 hour on Days 1 and 14 of Cycles 1-4 and then on Day 1 only of Cycles 5 and beyond.~Dose Expansion Phase: Participants receive the maximum tolerated dose of Azacitidine and Nivolumab from Dose Escalation Phase."
3024719|NCT02397720|Experimental|Azacitidine + Nivolumab + Ipilimumab|"Dose Escalation Phase: Participants receive Azacitidine by vein over about 1 hour or as an injection under the skin. Participants receive this drug either on Days 1-7 of each cycle, or on Days 1-5 and then 8 and 9 of each cycle.~Participants receive Nivolumab by vein over about 1 hour on Days 1 and 14 of Cycles 1-4 and then on Day 1 only of Cycles 5 and beyond.~Participants receive Ipilimumab by vein starting on Day 1 and every 6 (or 12) weeks after that. Participants receive a total of 4 doses of Ipilimumab every 6 (or 12) weeks and then stop therapy. If participant has evidence of relapse or seems to be benefitting, Ipilimumab may continue every 6 (or 12) weeks.~Dose Expansion Phase: Participants receive the maximum tolerated dose of Azacitidine and Nivolumab from Dose Escalation Phase."
3024720|NCT02397720|Experimental|Phase II Salvage Cohort|"Cohort consists of participants with relapsed/refractory AML.~Participants receive the maximum tolerated dose of Azacitidine and Nivolumab from Dose Escalation Phase."
3024721|NCT02397720|Experimental|Phase II Frontline Older Cohort|"Cohort consists of newly diagnosed older AML participants (age ≥ 65).~Participants receive the maximum tolerated dose of Azacitidine and Nivolumab from Dose Escalation Phase."
3024722|NCT02397707|Experimental|Moderate Hepatic Impaired|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of GS-9857 on Day 1.
3024723|NCT02397707|Experimental|Severe Hepatic Impaired|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of GS-9857 on Day 1.
3024724|NCT02397694|Experimental|BIC + F/TAF|"Participants will receive BIC + F/TAF FDC + DTG placebo for 48 weeks.~Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF."
3024725|NCT02397694|Active Comparator|DTG + F/TAF|"Participants will receive DTG + F/TAF FDC + BIC placebo for 48 weeks.~Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive B/F/TAF until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF."
3024726|NCT02397681|Experimental|Experimental|
3024727|NCT02397668|Experimental|CorMatrix ECM Tricuspid valve|Tricuspid valve replacement in patients for the surgical management of tricuspid valve disease, including tricuspid valve disease secondary to congenital heart disease.
3024728|NCT02397642|Active Comparator|Dual trigger|GnRH agonist plus 1000 IU of HCG to trigger final maturation
3024729|NCT02397642|Active Comparator|Booster HCG dose|GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
3024730|NCT02397629||Patients Undergoing Prostate Biopsy|Men referred for biopsy because of an abnormal or suspicious PSA digital rectal exam, or both.
3024731|NCT02397603|Active Comparator|bupivacaine saline group|This group of patients will receive 20 ml bupivacaine plus 0.5 ml normal saline perineurally in the paravertebral catheter
3024732|NCT02397603|Active Comparator|Dexmedetomidine- bupivacaine group|This group of patients will receive 20 ml bupivacaine plus 0.5 ml (50 microgram) dexmedetomidine administered perineurally in the paravertebral catheter.
3024733|NCT02397590|Other|A Group|Fimasartan (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days)
3024734|NCT02397590|Other|B Group|Fimasartan (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days)
3024735|NCT02397590|Other|C Group|Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days)
3024736|NCT02397590|Other|D Group|Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days)
3024737|NCT02397590|Other|E Group|Fimasartan+Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days) → wash out (7days) → Atorvastatin (7 days)
3024738|NCT02397590|Other|F Group|Fimasartan+Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days)
3024739|NCT02397577|Other|gastric emptying measurements|
3024740|NCT02397564|Experimental|1|Enroll 20 patients for nonsurgical treatment of surgical scars. Half of each scar will be treated with the Er:YAG laser on the traditional ablative setting and the other half of the scar will receive Er:YAG treatment with the fractional ablative setting. The patients will receive 3 treatments at monthly intervals. They will follow up at 1 and 2 months after the treatment.
3024741|NCT02397551|Active Comparator|Small doses of HCG|Supplementing the luteal phase with three small doses (500 IU) of HCG after trigger with GnRH agonist in antagonist IVF/ICSI cycles in high responders
3024742|NCT02397551|Active Comparator|Booster HCG dose|Booster HCG dose GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
3024743|NCT02397538|Other|Cohort1|Treatment AB → ABC Treatment A+B (10days) → Treatment A+B+C (6days) Treatment A: Fimasartan Treatment B: Amlodipine Treatment C: Rosuvastatin
3024744|NCT02397538|Other|Cohort2|Treatment C → ABC Treatment C (6days) → Treatment A+B+C (10days) Treatment A: Fimasartan Treatment B: Amlodipine Treatment C: Rosuvastatin
3024745|NCT02397525|Experimental|LIPO-202|
3024746|NCT02397512|Experimental|Lactulose group|Subjects will ingest 50g of lactulose once
3024747|NCT02397512|Placebo Comparator|Control group|Subjects will ingest 50g of sucrose once
3024748|NCT02397499|Experimental|LIPO-202|Experimental arm
3024749|NCT02397499|Placebo Comparator|Placebo|Placebo comparator
3024750|NCT02397486|Experimental|Intervention Group|"Platinum based concurrent chemoradiotherapy [cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks] .~Pentoxifylline 400 mg oral tablets twice daily for 7 weeks. Vitamin E 1000 mg oral capsules once daily for 7 weeks."
3024751|NCT02397486|Active Comparator|Control Group|Platinum based concurrent chemoradiotherapy [cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks] .
3024752|NCT02397473|Experimental|LY2951742|LY2951742 administered subcutaneously (SC) every 30 days during an 8 week treatment period.
3024753|NCT02397473|Placebo Comparator|Placebo|Placebo administered SC every 30 days during an 8 week treatment period.
3024754|NCT02397460|Experimental|Gefapixant|Gefapixant 50 mg tablets administered as a single dose
3024755|NCT02397460|Placebo Comparator|Matching placebo for gefapixant|Matching placebo tablets administered as a single dose
3024756|NCT02397447|Experimental|Momordica charantia|Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days
3024757|NCT02397447|Placebo Comparator|Placebo|Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days
3025235|NCT02394041|Sham Comparator|Sham acupuncture|The same as active arm but with sham needles.
3024758|NCT02397434|Experimental|Adjuvant EBRT|Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to positive lymph nodes will be delivered.
3024759|NCT02397421|Active Comparator|Treatment|Dapagliflozin 10mg once daily
3024760|NCT02397421|Placebo Comparator|Control|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
3024761|NCT02397408|Other|Choline PET/MR|11C-Choline: 370MBq Intravenously 18F-Choline: 3MBq/kg Intravenously
3024762|NCT02397395|Experimental|Simeprevir Co-administered with Daclatasvir|All participants will receive Simeprevir (SMV) 150 milligram (mg) capsule co-administered with Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks. Participants should take the study drugs (SMV and DCV together) orally and once daily with food.
3024763|NCT02397382|Experimental|Guselkumab and Cytochrome P450 Probe Cocktail|Participants will be administered single dose of Guselkumab 200 milligram (mg) by subcutaneous injection (2*100 mg) on Day 8 and Cytochrome P450 probe cocktail consist of midazolam, warfarin/vitamin K, omeprazole, dextromethorphan and caffeine orally once on Day 1,15 and 36.
3024764|NCT02397369|Experimental|Tobacco users: Self Help|Self-help intervention is defined as any manual or programme to be used by individuals to assist a quit attempt not aided by counsellors or group support.They include written materials on the health effects of tobacco, audio-or video tape or computer programmes.
3024765|NCT02397369|Experimental|Tobacco users:Telephonic counseling|Telephone counseling is a way of providing individual counseling via telephone conversation or telephone hotlines. It can be proactive or reactive.
3024766|NCT02397369|Experimental|Tobacco users:Behavioural therapy Only|Behavioural therapy includes multiple sessions of Focus Group Discussion (FGD) and individual tobacco cessation counseling sessions. The participants in this group will be given advice to quit tobacco via multisession formal cognitive-behavioural therapy as per the Tobacco Cessation Clinic (TCC) guidelines.
3024767|NCT02397369|Experimental|Tobacco users:Pharmacologic|Pharmacotherapy in the form of Nicotine Replacement Therapy based on individual need assessment to relieve withdrawal symptoms in tobacco users when trying to quit.
3024768|NCT02397356|Experimental|Ketamine first AB|Patients in this group will first receive a dose of ketamine in the nebulised form when they ask for pain relief. The second time they ask for pain relief, they will receive physiological salt in the nebulised form.
3024769|NCT02397356|Active Comparator|Placebo first BA|Patients in this group will first receive physiological salt in the nebulised form form when they ask for pain relief. The second time they ask for pain relief, they will receive a dose of ketamine in the nebulised.
3024770|NCT02397343|Other|Session 1|HBO given the first day of study period and sensory test battery performed. 4 weeks later no intervention is given but the sensory test battery performed.
3024771|NCT02397343|Other|Session 2|No intervention first day of study period and sensory test battery performed. 4 weeks later HBO intervention is given and the sensory test battery performed.
3024772|NCT02397330|Active Comparator|group BIS|scheduled for ultrasound guided interscalene blockade with 30 ml of bupivacaine 0.25%
3024773|NCT02397330|Experimental|group BS|scheduled for selective blockade of the ultrasound guided suprascapular (15 ml bupivacaine 0.25%) and supraclavicular (15 ml bupivacaine 0.25%) nerves blocks
3024774|NCT02397317|Experimental|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
3024775|NCT02397304|Experimental|Pre-exercise food|Pre-exercise food provision
3024776|NCT02397304|Experimental|Post-exercise food|Post-exercise food provision
3024777|NCT02397291|Placebo Comparator|Part 1: Measurements of maternal and fetal concentrations|"At the time of the elective cesarean section, a blood sample of 0.5 ml will be obtained from a maternal heated hand vein at the time the umbilical cord is clamped. Then, the umbilical cord will be doubly clamped to isolate a segment. The umbilical artery and vein will be sampled for 0.5 ml of blood. There are no stable isotopes infused. Heating the maternal hand vein allows it to be arterialized. These patients are separate from those required for the stable isotope studies listed below."
3024778|NCT02397291|Active Comparator|Part 2: Stable Isotope Studies|Prior to the elective cesarean section, 2 samples from the patient's heated hand vein are obtained to establish a baseline for the compounds. Next, a primed constant infusion containing the stable isotopes of mannose and myoinositol is begun in a peripheral IV of the mother. This is continued approximately 2 hours until the Cesarean section is complete and the umbilical cord samples are obtained. An additional 3 samples are obtained from the patient's heated hand vein: 1 at the start of the cesarean section, 1 at the time the fetus is delivered, and 1 at the time the umbilical cord samples are obtained.
3024779|NCT02397278|Active Comparator|Platelet rich plasma (PRP)|Patients will receive three PRP injections into the symptomatic knee; they will also be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
3024780|NCT02397278|No Intervention|Conventional therapy|Patients will be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
3024781|NCT02397265|Experimental|Bihormonal closed loop|Bi-hormonal closed loop pump will be used in the exercise and mixed meal substudies
3024782|NCT02397265|Active Comparator|Standard opened loop pump|Standard opened loop pump will be used in the exercise and mixed meal substudies
3024783|NCT02397252|Experimental|Eve Medical self-collection system©|Device: Self-sampling swab from Eve Medical for collection of vaginal cells.
3024784|NCT02397252|Placebo Comparator|cobas® PCR Female swab self-sampling|Device: Regular polyester swab for collection of vaginal cells.
3024785|NCT02397252|Placebo Comparator|Physician-collected sampling|Routine colposcopy sample collected by a physician.
3024786|NCT02397239||Six cycles|Maintenance pemetrexed 500 mg/m2 every 3 weeks for six cycles
3024787|NCT02397239||Until disease progression|Maintenance pemetrexed 500 mg/m2 every 3 weeks until disease progression
3024788|NCT02397226|Active Comparator|Radiofrequency ablation|Treatment with radiofrequency ablation using radiofrequency ablation catheter. This intervention implies tumescent anesthesia.
3024789|NCT02397226|Active Comparator|High ligation/stripping|Treatment with high ligation/stripping using a vein stripping catheter. This intervention implies general anesthesia.
3024790|NCT02397213|Placebo Comparator|Placebo|All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
3024791|NCT02397213|Active Comparator|Ciclosporin|Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection.
3024792|NCT02397200|Experimental|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
3024793|NCT02397200|Placebo Comparator|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and minerals.
3024794|NCT02397187|Experimental|LOOP intervention|"Patients enrolled in this arm will be treated by the LOOP interventional technique.~The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
3024795|NCT02397187|Active Comparator|TAU|Patients enrolled in this arm will be TAU, which is based upon short-term supportive PT.
3024796|NCT02397174|Experimental|Mediterranean Diet|The diet programme will be characterized by carbohydrates (60 %); proteins (20 %, half comprised of vegetable proteins); total fat (20 %; saturated fat < 10 %). After calculating the patient's energy need, the amount of calories will be successively adjusted to create an 800 kcal deficit per day.
3024797|NCT02397174|Active Comparator|hypocaloric diet|The diet programme will be characterized by carbohydrates (50%),total lipids (30%) and proteins (20%). After calculating the patient's energy need, the amount of calories will be successively adjusted to create an 800 kcal deficit per day.
3024798|NCT02397161|Experimental|AT-NMT|AT-NMT group - will receive a 12-week EEG biofeedback mental attention-neuromuscular training
3024799|NCT02397161|Experimental|NMT alone|NMT group - will receive a 12-week neuromuscular training
3024800|NCT02397161|Experimental|AT alone|AT group - will receive a 12-week EEG biofeedback mental attention training
3024801|NCT02397161|No Intervention|Control|Control group - no intervention for 12 weeks
3024802|NCT02397148|Experimental|patients with sinonasal pathology|Computed Tomography Cone Beam Computed Tomography
3024803|NCT02397122|Experimental|PRF+CAF+CTG|platelet-rich fibrin + coronally advanced flap + connective tissue graft
3024804|NCT02397122|Active Comparator|CAF+CTG|coronally advanced flap + connective tissue graft
3024805|NCT02397096|Experimental|Immediate Switch to MK-1439A|Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a NNRTI (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for >=6 months with undetectable HIV-1 RNA will switch on Day 1 to MK-1439A single tablet by mouth once daily for 48 weeks in the Base Study and, optionally, for up to an additional 4 years in the Study Extensions
3024806|NCT02397096|Active Comparator|Delayed Switch to MK-1439A|Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a NNRTI (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for >=6 months with undetectable HIV-1 RNA will continue on this therapy until Week 24, at which time they will switch to MK-1439A single tablet by mouth once daily for 24 weeks in the Base Study and, optionally, for up to an additional 4 years in the Study Extensions
3024807|NCT02397083|Experimental|Levonorgestrel Intrauterine Device (LIUD)|"Participants undergo treatment with the LIUD. Placement of LIUD done at the time of the dilation and curettage (D&C) or during a routine clinic visit.~At 3 months after procedure, participants whose disease has completely responded to treatment, randomized to remain on study for 3 more months using LIUD alone.~Quality of life (QOL) questionnaire completed at baseline visit."
3024808|NCT02397083|Experimental|Levonorgestrel Intrauterine Device (LIUD) + Everolimus|"Participants undergo treatment with the LIUD. Placement of LIUD done at the time of the dilation and curettage (D&C) or during a routine clinic visit.~At 3 months after procedure, participants whose disease has completely responded to treatment, randomized to continue the LIUD in combination with Everolimus. Everolimus administered at 10 mg taken by mouth daily for three months.~Quality of life (QOL) questionnaire completed at baseline visit."
3024809|NCT02397070|Experimental|Jaw exercise program|
3024810|NCT02397070|Active Comparator|Occlusal splint and counseling|
3024811|NCT02397057|Active Comparator|Injectafer|Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.
3024812|NCT02397057|Placebo Comparator|Normal Saline|IV Placebo (15ml of Normal Saline) IV push at 2ml/minute
3024813|NCT02397044||Implant loading Immediate|Dental implant surgery with immediate loading
3024814|NCT02397044||Implant Loading Early|Dental implant surgery with delayed loading
3024815|NCT02397031|Experimental|Mindfulness|As proposed in dialectical behavioral therapy, mindfulness training consist of a set of behavioral skills that aim at improving patient`s attentional control and emotional regulation.
3024816|NCT02397031|Active Comparator|Interpersonal effectiveness|Interpersonal effectiveness skills are focused on improving interpersonal relationships and enhancing patient`s ability to display social effective behavior.
3024817|NCT02397018|Experimental|Allogeneic Umbilical Cord Blood Infusion|All subjects in this study will receive an intravenous infusion of ABO/Rh matched umbilical cord blood.
3024818|NCT02397005|Active Comparator|ZL-2102|Planned to be administrated in an ascending manner: 5,20,60,150,300,500,750mg
3024819|NCT02397005|Placebo Comparator|Placebo|Placebo matching ZL-2102
3024820|NCT02396992|Other|Minimal-Massive Intervention|The minimal/basic intervention for a massive number of hospitalized patients.
3056949|NCT02181972|Experimental|Gingko biloba|
3024822|NCT02396979|Experimental|Holistic Health Recovery Program|Administration of the Holistic Health Recovery Program (HHRP-M), which is an eight-session substance abuse relapse prevention and harm reduction program administered by a trained substance abuse counselor.
3024823|NCT02396979|Experimental|Methadone Maintenance and Holistic Health Recovery Prorgram|Methadone induction and management provided in combination with the Holistic Health Recovery Program (HHRP-M).
3024824|NCT02396979|No Intervention|Standard of Care|Standard of care provided for substance abuse treatment. No methadone maintenance or holistic health recovery program intervention provided.
3024825|NCT02396953|Experimental|lanreotide PRF|One single dose of lanreotide PRF (via subcutaneous injection) either 180mg or 270mg or 360mg.
3024826|NCT02396940|Placebo Comparator|2D HD laparoscopy|Elective laparoscopic inguinal hernia repair performed with the use of Olympus ENDOEYE FLEX in the 2DHD viewing mode
3024827|NCT02396940|Active Comparator|3D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 3DHD viewing mode
3024828|NCT02396927|Placebo Comparator|2D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 2DHD viewing mode
3024829|NCT02396927|Active Comparator|3D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 3DHD viewing mode
3024830|NCT02396901|Experimental|GDT group|Patients randomized to the GDT Group will care from a protective strategy with the suspension of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) 48 hours before surgery and receive hydration with lactated Ringer's solution at the rate of 1 mL/kg/h in the night before the surgery until the surgical procedure and perioperative hemodynamic therapy.
3024831|NCT02396901|Placebo Comparator|Control group|Patients randomized to the control group will be treated in accordance with the care in the institution's routine.
3024832|NCT02396888|Experimental|Insulin|Half of the wound surface was treated daily with intermediate insulin. Allocation was randomized.
3024833|NCT02396888|Placebo Comparator|Placebo|Half of the wound surface was treated daily with normal saline. Allocation was randomized.
3024834|NCT02396875|Experimental|Group 1|40 patients undergoing CRT will have venous samples taken from two CS tributaries, peripheral venous and peripheral arterial sites at the time of CRT insertion at the time of device implant. Blood samples will be analysed for metabolites and novel biomarkers They will then undergo repeat sampling at 6 months to assess for changes in the biomarker profile including CS sampling.
3024835|NCT02396875|Active Comparator|Group 2|A control arm of 15 patients with heart failure and no dyssynchrony will undergo peripheral venous sampling for novel biomarkers and this will be repeated at 6 months. These samples will allow for control against the dyssynchronous heart failure group and also for temporal changes in biomarker expression.
3024836|NCT02396875|Active Comparator|Group 3|A control arm of 15 patients with normal hearts will undergo peripheral venous sampling for novel biomarkers and this will be repeated at 6 months. These samples will allow for control against the dyssynchronous heart failure group and also for temporal changes in biomarker expression.
3024837|NCT02396875|Experimental|Group A|"10 patients from Group 1~On the day preceding the CRT implant will attend hospital for a temporary invasive catheter study. The patient will have a radial sheath positioned in the arterial system. A pacing protocol will be performed using a pacing wire inserted into the right atrium. Coronary sinus venous blood sampling will be performed using a catheter placed via the femoral or internal jugular vein. At the chief investigator's discretion a specially designed exercise bicycle that allow supine exercise in the catheter lab will be used rather than the atrial pacing wire.~6 months post implant the patients will return to the catheter laboratory for a further study. This will repeat the protocol but with the device having been on for 6 months. This will require further study as described above."
3024838|NCT02396875|Active Comparator|Group B|"5 patients form Group 2.~Patients will undergo a pacing or exercise protocol and have venous, coronary sinus and arterial blood sampled. They will revert to Group 2 for 6 month follow up"
3024839|NCT02396875|Active Comparator|Group C|"5 patients form Group 3~Patients will undergo a pacing or exercise protocol and have venous, coronary sinus and arterial blood sampled. They will revert to Group 3 for 6 month follow up"
3024840|NCT02396862||Patients with moderate to severe Hemophilia A / Cohort 1|Patients aged over 16 years, with documented physician-confirmed diagnosis of moderate or severe Hemophilia A (severity defined as moderate = FVIII activity 1% to 5% and severe = FVIII activity ≤1%)
3024841|NCT02396849|Experimental|CPAP|Use of a CPAP machine for at least 5 days per week for 28 days
3024842|NCT02396849|Sham Comparator|CPAP Sham|Use of a sham CPAP machine for at least 5 days per week for 28 days
3024843|NCT02396836|Active Comparator|6 step hand hygiene technique|Hand decontamination with alcohol hand rub using the World Health Organisations 6 step technique
3024844|NCT02396836|Experimental|3 step hand hygiene technique|Hand decontamination with alcohol hand rub using the 3 step technique
3024845|NCT02396823|Experimental|Respiratory Muscle Training|Each training session will last about 45-60 min and will occur five times weekly during one month. During the RMT sessions, the patient will remain in their personal wheelchair. They will be asked to breath through a special device with regulated resistance to breathing air. In the 20 sessions starting from the lowest resistance, the goal will be to train the muscles they use to breathe by slowly increasing this resistance. They will perform six work sets, 5 minutes in duration, separated by rest intervals lasting 1-3 minutes.
3024846|NCT02396823|No Intervention|Control|Following screening process and recruiting, subjects from both Healthy Control and SCI Control groups will undergo the same procedures as subjects from SCI group excluding the training intervention.
3024847|NCT02396810|Placebo Comparator|No intra-operative MRI|Patients undergo transsphenoidal surgery without an intra-operative MRI.
3024848|NCT02396810|Experimental|intra-operative MRI|Patients undergo transspheonidal surgery followed by intra-operative MRI.
3024849|NCT02396797|Experimental|The new atWork intervention|The intervention group will receive the new atWork intervention, which include a management course and workplace courses for all employees targeting mental health complaints and musculoskeletal complaints.
3024850|NCT02396797|Active Comparator|The original atWork intervention|The control group will receive the original atWork intervention, targeting musculoskeletal complaint, and peer support.
3025236|NCT02394041|No Intervention|control group|Standard care, no acupuncture session.
3024851|NCT02396784||High risk|One parent has a BMI of greater than or equal to 28, or both parents have a BMI of greater than or equal to 24
3024852|NCT02396784||Normal risk|Both parents have a BMI of smaller than 24
3024853|NCT02396771|Experimental|Massage|Women allocated to the uterine massage group will be provided with 2 minutes of trans-abdominal uterine massage starting promptly after placental delivery.
3024854|NCT02396771|Experimental|Compression|Women allocated to the uterine compression group will be provided with 2 minutes of sustained trans-abdominal uterine compression starting promptly after placental delivery.
3024855|NCT02396758|Active Comparator|2 hours APT Procedure and 4/8 mg rtPA|2 hr treatment with EkoSonic Endovascular System and either 4 or 8 mg of rtPA
3024856|NCT02396758|Active Comparator|4 hours APT Procedure and 4/8 mg rtPA|4 hr treatment with EkoSonic Endovascular System and either 4 or 8 mg of rtPA
3024857|NCT02396758|Active Comparator|6 hours APT Procedure and 6/12 mg rtPA|6 hr treatment with EkoSonic Endovascular System and either 6 or 12 mg of rtPA
3024858|NCT02396758|Active Comparator|6 hours APT Procedure and 12/24 mg rtPA|6 hr treatment with EkoSonic Endovascular System and either 12 or 24 mg of rtPA
3024859|NCT02396758|Active Comparator|tbd|x hr treatment with EkoSonic Endovascular System and either x or x mg of rtPA
3024860|NCT02396745|Experimental|TECR & ECM|Subjects undergoing TECR with ECM placement
3024861|NCT02396732|Experimental|LMWH + ASA|Group will get both enoxaparin (standard of care) and aspirin (intervention).
3024862|NCT02396732|Active Comparator|LMWH Alone|Group will get only enoxaparin (standard of care).
3024863|NCT02396719||LenSx|Phacoemulsification cataract surgery in at least 1 eye using LenSx® Laser technology
3024864|NCT02396706|Active Comparator|Ivy Leaves Cough Liquid|Ivy Leaves Cough Liquid
3024865|NCT02396706|Placebo Comparator|Placebo|Placebo
3024866|NCT02396693|Experimental|NIPPV|NIPPV - Newborns randomized to this group underwent NIPPV, in noninvasive ventilation support intermittent, in TIME mode of the respirator.
3024867|NCT02396693|Placebo Comparator|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, in noninvasive ventilation continuous, in bubble NCPAP.
3024868|NCT02396693|Placebo Comparator|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, in noninvasive ventilation continuous, in NCPAP mode of the respirator.
3024869|NCT02396680||TR006 Subjects|Subjects that have previously been randomised into study TR006
3024870|NCT02396667||pregnant women with macrosomia|Pregnant wo.en between 37 and 42 weeks with fetal macrosomia as suspected by clinical estimation and 2D ultrasound.
3024871|NCT02396654||normal pregnant women|Normal pregnant women between 37 and 42 weeks gestation.
3024872|NCT02396641|Experimental|Single Study Arm|This study arm consists of providers who will identify their baseline in Best Supportive Care, then have the intervention of using a Best Supportive Care checklist.
3024873|NCT02396628|Experimental|Experimental intervention|Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines.
3024874|NCT02396628|Active Comparator|Standard treatment|Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of August 2015). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
3024875|NCT02396615|Active Comparator|Active|Satin pineapple. Active juice with fibre and ginseng
3024876|NCT02396615|Placebo Comparator|Control|SATIN pineapple control. Control juice - normal juice prpoducts without added active ingredients
3024877|NCT02396602|Experimental|Intervention|After completing baseline the baseline questionnaire, women randomized to the intervention group will receive an iPad, along with a brief tutorial on iPad navigation, and use the miPlan app for up to 15 minutes. They will complete a post-intervention survey before proceeding to standard of care contraceptive counseling.
3024878|NCT02396602|No Intervention|Control|After completing baseline the baseline questionnaire, women randomized to the control arm will proceed to standard of care contraceptive counseling.
3024879|NCT02396589|Active Comparator|Education Group|Participants in the Education group receive five 90 minute tailored stroke education sessions in the home.
3024880|NCT02396589|Experimental|Home Modifications Group|Participants in the treatment group receive a home assessment and home modifications tailored to functional abilities (pre discharge) and then five 90 minute occupational therapy treatment sessions at home (post discharge) to improve functional abilities and community participation.
3024881|NCT02396576|No Intervention|Usual Care|NEVHC has two main Department of Mental Health (DMH) contracted clinical partners where the majority of the patients are referred to -these are Child and Family Guidance Center (CFGC) in the San Fernando Valley and Child and Family Center (CFC) in the Santa Clarita Valley.
3024882|NCT02396576|Experimental|Telehealth Intervention|The telehealth model will enhance patient coordination as well as clinician communication via live videoconferencing. Developmental behavioral services will be provided by a Developmental Behavioral Pediatrician (DBP) housed at UCLA from Children's Hospital Los Angeles (CHLA). Mental Health services will be provided by Child Family Center (CFC) and Child Family Guidance Center (CFGC). The location of the telehealth visit will be at the same clinic location as the index PCP visit with a telehealth coordinator facilitating the encounter between patient and clinicians.The clinician communication will be enhanced through monthly telehealth topic-based educational sessions as well as case-based educational sessions for the transfer cases.
3024883|NCT02396563||epidural analgesia|women in labor with epidural analgesia
3024884|NCT02396563||no epidural analgesia|
3024885|NCT02396550|Experimental|Positive Expectations|Procedure/Surgery: Mobilization with movement in patients with lateral epicondylalgia with modification of its expectations into positive
3024886|NCT02396550|Experimental|Neutral Expectations|Procedure/Surgery: Mobilization with movement in patients with lateral epicondylalgia with modification of its expectations into neutral
3024887|NCT02396537|Experimental|Intranasal Lidocaine|Patient to receive 4% lidocaine intranasally prior to midazolam
3024888|NCT02396537|Placebo Comparator|Intranasal 0.9% saline|Patient to receive 0.9% Saline intranasally prior to midazolam
3024889|NCT02396524|Experimental|Hockey FIT program|12-week active phase - exercise and healthy living program (1x/week; 90 minutes/session); 40-week maintenance phase (individualized approach)
3024890|NCT02396524|No Intervention|Usual-care wait-list control|No active intervention (usual care)
3024891|NCT02396511|Experimental|TRC105 and Bevacizumab|TRC105 weekly intravenous infusion bevacizumab every 2 weeks intravenous infusion
3024892|NCT02396498|Placebo Comparator|D2 radical gastrectomy+Systemic chemotherapy|8 cycles of systemic chemotherapy were performed for stage Ⅲ patients after D2 gastrectomy .Systemic chemotherapy(SP): Cisplatin: 60mg/m^2, d1 , Intravenous infusion, every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks .Subjects should be given maximum 8 cycles, or progression/intolerance.
3024893|NCT02396498|Experimental|D2 radical gastrectomy+HIPEC|8 cycles of hyperthermic intraperitoneal chemotherapy (cisplatin) and S-1(oral) were performed after D2 radical gastrectomy. HIPEC was conducted in d1 and d3: Normal saline 2000ml-5000ml, Cisplatin 60mg/m^2, 43°C, 60min. every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks.Subjects should be given maximum 8 cycles, or progression/intolerance.
3024894|NCT02396485|Experimental|Early Feeding Arm|Patients will be started on regular diet within 6 hrs postoperative.
3024895|NCT02396485|No Intervention|Late Feeding Group|Patients will be remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs as standard postoperative protocol in the investigators' institution.
3024896|NCT02396472|Placebo Comparator|Order by time and topic|"Volunteers from the American Cancer Society's Cancer Survivors' Network (CSN) will see some of their messages delivered using CSN's default ordering, which shows messages within a conversational thread ordered by time stamp. Conversational threads are nested within a broad topic-based forum, like breast cancer or colorectal cancer survivors.~Note that this is a within-participant trial, so that all participants participate in all arms of the trial. Messages, not people, are randomly assigned to condition."
3024897|NCT02396472|Active Comparator|Order by information relevance|In this condition some messages will be highlighted if they match the type of content the user has previously shown interest in, by previously contributing or reading semantically similar material.
3024898|NCT02396472|Active Comparator|Order by social relationship|In this condition some messages will be highlighted because they come from people the user has previously shown interest in, by previously reading their posts or communicating with them.
3024899|NCT02396472|Active Comparator|Order by help giving|In this condition some messages will be highlighted because they seek help and therefore provide an opportunity for participants to provide social support to others.
3024900|NCT02396472|Active Comparator|Order by self-disclosure|In this condition some messages will be highlighted because in them the writer is self-disclosing, and they provide provide an opportunity for participants to self-disclose in return.
3024901|NCT02396459|Experimental|AHDS patients|Triac treatment
3024902|NCT02396446||Intervention group|Inpatients at CSMC whose abdominal acoustic sounds will be measured using the AbStats device.
3024903|NCT02396433|Experimental|Carboplatin, eribulin, and E7449|This is a phase I/II clinical trial of the combination of carboplatin, eribulin, and E7449.
3024904|NCT02396420|Experimental|Treatment arm|Patients will receive prostate artery embolization (PAE) with Embosphere Microspheres.
3024905|NCT02396407|Active Comparator|Combined water, sanitation, and hygiene|Water quality, Sanitation, Handwashing
3024906|NCT02396407|No Intervention|Non-intervention arm|None. Households will continue their usual practices.
3024907|NCT02396394|Experimental|Two-Step Adherence Feedback|Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is <95%.
3024908|NCT02396381|Experimental|THS 2.2|Ad libitum use of THS 2.2
3024909|NCT02396381|Active Comparator|CC|Ad libitum use of CC
3024910|NCT02396368|Experimental|Radium 223 and Tasquinimod|"During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day.~Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks)."
3024911|NCT02396355||All subjects|This is a single arm study. Samples from each subject will be tested with the Investigational BD FACSPresto System, the BD FACSCalibur flow cytometer, and the Sysmex hematology analyzer KX-21.
3024912|NCT02396342|Experimental|Cohort 1|AAV5-hFIX 5 × 10E12 gc/kg intravenous single infusion
3024913|NCT02396342|Experimental|Cohort 2|AAV5-hFIX 2 × 10E13 gc/kg intravenous single infusion
3024914|NCT02396329|Experimental|chlorhexidine _based antisepsis|Including cases undergoing elective&non elective caesarean section.Patients will be were prepared similarly by three applications of 2%chlorhexidine solution time given between each application about 30 seconds followed by drying with a sterile towel and three applications of 70% alcohol after one minute The area scrubbed was from the xiphoid to the knee, reaching the midaxillary line laterally. In both groups, patients received preoperative prophylactic i.v antibiotics (cefotrixone 1 gm) one hour before skin incision.
3024915|NCT02396329|Active Comparator|povidone_iodine based antisepsis|Including cases undergoing elective&nonelective caesarean section.Patients will be scrubbed preoperative with an applicator that contain 10%povidone-iodine scrub aqueous solution(3 consecutive applications)followed by drying with sterile towel and 3 application of 70% alcohol after one minute The area scrubbed was from the xiphoid to the knee, reaching the midaxillary line laterally. In both groups, patients received preoperative prophylactic i.v antibiotics (cefotrixone 1 gm) one hour before skin incision
3024916|NCT02396316|Experimental|Aflibercept|Aflibercept 2 mg Intravitreal (IVT) injection group
3024917|NCT02396316|Sham Comparator|Sham Injection|Sham injection group
3024918|NCT02396303|Experimental|Patient receiving carbetocin|Experimental group subjects will receive intravenous Carbetocin during third stage of labour.
3024919|NCT02396303|Active Comparator|Patient receiving oxytocin|Comparator group subjects will receive intramascular Oxytocin during third stage of labour.
3024920|NCT02396290|Experimental|fractional CO2 laser with PRP|fractional carbon dioxide laser followed by intradermal injection of platelet rich plasma
3024921|NCT02396290|Active Comparator|fractional CO2 laser with NS|fractional carbon dioxide laser followed by intradermal injection of NS
3024922|NCT02396264|Experimental|Mediterranean Diet|The diet programme will be characterized by carbohydrates (60 %); proteins (20 %, half comprised of vegetable proteins); total fat (20 %; saturated fat < 10 %). After calculating the patient's energy need, the amount of calories will be successively adjusted to mantain the same weight of the time of recruitment
3024923|NCT02396264|Active Comparator|normocaloric diet|50% carbohydrates, 30% total lipids and 20% proteins. After calculating the patient's energy need, the amount of calories will be successively adjusted to mantain the same weight of the time of recruitment
3024924|NCT02396251|Experimental|HA experimental|HA experimental only
3024925|NCT02396251|Active Comparator|HA comparator|HA experimental + HA comparator
3024926|NCT02396238|Experimental|Adipose Derived Regenerative Cells|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs administered in 2 injections per digit on both hands.
3024927|NCT02396238|Placebo Comparator|Placebo|Sterile Lactated Ringers Solution mixed with small amount of study subject's own freshly drawn blood and administered in 2 injections per digit on both hands.
3024928|NCT02396225|Experimental|Inhaled voriconazole|12 patients inhale voriconazole 40 mg b.i.d for two days
3024929|NCT02396225|Active Comparator|Oral Voriconazole|12 patients ingest voriconazole tablets 400 mg b.i.d for one day followed by 200 mg b.i.d for one day
3024930|NCT02396212|Experimental|Canakinumab 4 mg/kg every 4 weeks|All patients will receive canakinumab (ACZ885) as open-label study medication. Patients will be administered canakinumab 4 mg/kg every 4 weeks. The maximal total single dose of canakinumab allowed is 300 mg.
3024931|NCT02396199|Experimental|Endovascular|Endovascular treatment using the Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents
3024932|NCT02396173|Experimental|Risk Score for non-return to work|The WORRK model is a predictive tool (19 items) of the non-return to work risk useful for all kinds of orthopaedic trauma and for patients needing vocational rehabilitation. It is constructed with variables independent of the patient's education and language fluency. It is a short patient's bedside tool and takes less than 20 minutes.
3024933|NCT02396173|No Intervention|Control group|In this group the medical staff will not be informed about the risk score (WORRK).
3024934|NCT02396160|Active Comparator|Treatment|2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
3024935|NCT02396160|Placebo Comparator|Placebo|identical placebo vegetarian capsule containing color-matched cellulose
3024936|NCT02396147|Experimental|Arm 1: T2-A + T4B-B + T4B-C|T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation B Regimen B (T4B-B) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation B Regimen C (T4B-C) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was a 10-day washout period between each dose.
3024937|NCT02396147|Experimental|Arm 2: T2-A + T4C-D + T4C-E|T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation C Regimen D (T4C-D) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation C Regimen E (T4C-E) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was 10-day washout period between each dose.
3024938|NCT02396134|Experimental|Arm I (CMVpp65-A*0201 peptide vaccine)|Patients receive CMVpp65-A*0201 peptide vaccine SC on days 28 and 56 after HCT.
3024939|NCT02396134|Placebo Comparator|Arm II (placebo)|Patients receive placebo SC on days 28 and 56 after HCT.
3024940|NCT02396121|Experimental|Interventional|Administration of 1 bottle of an oral nutritional supplement, Renutryl® Booster (600 kcal), during 28 days.
3024941|NCT02396108|Experimental|Paclitaxel + Carboplatin + ASLAN001|"Phase I:~A modified 3+3 study de-escalating dose design will be employed for dose determination. Subjects will receive treatment in 21-day cycles until disease progression, intolerable toxicities or withdraws consent. In the presence of intolerable toxicities to one or more of the drugs in the regimen (but not all 3), the drug in question may be discontinued and the other drugs continued with the patient remaining in the study, if the patient is deemed to be benefiting, after discussion with the Principal Investigator.~Phase II:~Patients with stage I-III HER2-positive breast cancer with a primary breast tumour of 2cm or greater will receive up to 4 cycles of pre-operative ASLAN001 and weekly paclitaxel/ carboplatin delivered in 21-day cycles. Prior to administration of chemotherapy, there will be lead-in dosing of single-agent ASLAN001 administered daily for 2 weeks at the recommended phase II dose."
3024942|NCT02396082|Experimental|MIND-S Intervention|Participants (persons with dementia (PWD) and their family caregiver (CG)) in this group will receive up to 18 months of the MIND-S dementia care coordination intervention by an interdisciplinary team comprised of trained memory care coordinators (non-clinical), a psychiatric nurse, and geriatric psychiatrist. The intervention involves 4 key components: identification of needs and individualized care planning (PWD and CG needs); dementia education and skill building; coordination, referral and linkage of services; and care monitoring.
3024943|NCT02396082|Other|Augmented Usual Care|Participants (persons with dementia (PWD) and their family caregiver (CG)) and their primary care physicians in this group will receive an initial in-home needs assessment and then a written report indicating any unmet care needs identified and potential recommendations of care for meeting those needs. They will be able to pursue any interventions or treatments they or their treating physicians deem appropriate. They will also receive a standardized Aging and Caregiver Resource Guide developed in the previous MIND trial. The study team will perform another in-home needs assessment at 18 months and the written report along with recommendations for care will be provided to the family and the PWD's primary care physician.
3024944|NCT02396069|Experimental|JPI-289|Each cohort, volunteers will be infused JPI-289 for 60 min. (6 volunteers per each cohort, total 3 cohort)
3024945|NCT02396069|Placebo Comparator|Placebo|Each cohort, volunteer will be infused placebo for 60 min. (2 volunteers per each cohort, total 3 cohort)
3024946|NCT02396056|Sham Comparator|Occlusive Membrane (OM)|Five patients will be randomly assigned to the OM group.
3024947|NCT02396056|Experimental|Modified Perforated Membrane (MPM)|Five patients will be randomly assigned to the MPM group.
3024948|NCT02396043|Experimental|Modifed BFM-95|"Modifed BFM-95:~First patients were stratified into two therapy arms according to the disease stage. Patients with stage I or II disease received induction, protocol M and maintenance therapy. Patients with stage III or IV disease received induction, protocol M, reinduction and maintenance therapy.Maintenance therapy included oral 6-mercaptopurine (6-MP), 50 mg/m 2 daily, and MTX, 20 mg/m 2 once a week.Note that there were four additional doses of HD-MTX every 3 months during the maintenance phase. All patients received regular intrathecal chemotherapy.The treatment lasted 2.0 years."
3024949|NCT02396030|Active Comparator|Magnesium sulfate 50% - 1g/h|After loading dose of 6g of magnesium sulfate, patients will receive the maintenance dose of 1g/hour of intravenous magnesium sulfate, for 24 hours
3024950|NCT02396030|Experimental|Magnesium sulfate 50% - 2g/h|After loading dose of 6g of magnesium sulfate, patients will receive the maintenance dose of 2g/hour of intravenous magnesium sulfate, for 24 hours
3024951|NCT02396017|Active Comparator|Single-dose Polyethylene Glycol regimen|Drug: Polyethylene Glycol Intervention: 2 liters of Polyethylene Glycol will be given in the day before Capsule Endoscopy ingestion.
3024952|NCT02396017|Experimental|Split-dose Polyethylene Glycol regimen|Drug: Polyethylene Glycol Intervention: 1 liter of Polyethylene Glycol will be given in the day before Capsule Endoscopy ingestion and another 1 liter Polyethylene Glycol will be given in the same day of Capsule Endoscopy ingestion.
3024953|NCT02395991||Observe1|Patients who are referred to MR unit for hepatocyte-specific contrast (gadoxetic acid) enhanced liver magnetic resonance imaging (MRI)
3024954|NCT02395978|Experimental|2 PDC-1421 Capsule|2 PDC-1421 Capsule TID, p.o. after meal for 28 days
3024955|NCT02395978|Experimental|1 PDC-1421 Capsule plus 1 placebo|1 PDC-1421 Capsule plus 1 placebo TID, p.o. after meal for 28 days
3024956|NCT02395978|Placebo Comparator|2 placebo|2 placebo TID, p.o. after meal for 28 days
3024957|NCT02395952|Active Comparator|Lubrication|
3024958|NCT02395952|Active Comparator|Bandage Contact Lens|Acuvue Oasys Contact Lens
3024959|NCT02395952|Active Comparator|Prokera|Wet amniotic membrane mounted on plastic retaining ring
3024960|NCT02395952|Active Comparator|Ambiodisk|Freeze dried amniotic membrane
3024961|NCT02395939|Active Comparator|CT guided core biopsy|In patients allocated to this arm a CT guided core biopsy will be performed
3024962|NCT02395939|Active Comparator|Cryo-biopsy via Radial EBUS navigation|"If the patient is randomised to this arm, the lesion will be located via R-EBUS.~Each patient will have 3 cryo biopsies and 3 forceps biopsies. The order of the cryo biopsy and forcep biopsy will be randomly allocated at the time of initial randomisation."
3024963|NCT02395926|Active Comparator|R|Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
3024964|NCT02395926|Experimental|T1|HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
3024965|NCT02395926|Experimental|T2|HT-003 600mg*2tab, administration 1 times per 1 day 8:00 a.m.
3024966|NCT02395913|Active Comparator|R|
3024967|NCT02395913|Experimental|T1|
3024968|NCT02395913|Experimental|T3|
3024969|NCT02395913|Experimental|T4|
3024970|NCT02395900|Active Comparator|Flaxseed|30 grams Flaxseed powder
3024971|NCT02395900|Placebo Comparator|control|dietary and exercise recommendation
3024972|NCT02395887||Intervational|Patients with back or neck pain who are a candidates for operational intervention.
3024973|NCT02395887||Control|Men or women who haven't seek for spine surgery consultation.
3024974|NCT02395874|Experimental|verum-tDCS|verum-tDCS+ speech therapy
3024975|NCT02395874|Sham Comparator|sham-tDCS|sham-tDCS + speech therapy
3024976|NCT02395861|Experimental|Electrophysiologic analyses|
3024977|NCT02395848|Experimental|Fidaxomicin|30-day Fidaxomicin ( 200mg twice daily x 10 days and 200mg once daily x 20 days.
3024978|NCT02395835||Normal weight (NW) pregnant women|"Pregnant women with Body Mass Index (BMI) > = 30. Body weight and height were measured in an overnight fasting status using an adult scale (Seca, Hamburg, Germany). Prepregnancy BMI was calculated as weight in kg divided by height in meters squared based on the prenatal chart or on the self-reported weight of women with no prenatal chart.~Dietetic treatment was calculated according to height, weeks of gestation, and weight, considering an energy intake of 30 kcal/kg of ideal weight and a macronutrient distribution of: 55-65% carbohydrates, 10-20% fat, and the remainder as proteins."
3024979|NCT02395835||Overweight (OW) pregnant women|"Pregnant women with Body Mass Index (BMI) < 30. Body weight and height were measured in an overnight fasting status using an adult scale (Seca, Hamburg, Germany). Prepregnancy BMI was calculated as weight in kg divided by height in meters squared based on the prenatal chart or on the self-reported weight of women with no prenatal chart.~Dietetic treatment was calculated according to height, weeks of gestation, and weight, considering an energy intake of 30 kcal/kg of ideal weight and a macronutrient distribution of: 55-65% carbohydrates, 10-20% fat, and the remainder as proteins."
3024980|NCT02395822|Experimental|Preparative Regimen and SubQ rHuIL-15|"Preparative Regimen of Fludarabine and Cyclophosphamide~IL-15 Activation of Donor NK Cells:~IL-15 to Facilitate NK Cell Survival and Expansion"
3024981|NCT02395809|Active Comparator|LIS group|Lateral internal shincterotomy: A blade knife (No 11) was inserted between internal and external sphincter. The tip of the blade was angled medially pointing just above the dentate line and IS was divided. When the knife was felt beneath the intact mucosa, it was withdrawn.
3024982|NCT02395809|Active Comparator|TENS group|Posterior tibial nerve stimulation by transcutaneous electrical nerve stimulation by through a stimulating TENS unit.
3024983|NCT02395796|Experimental|Epidural Pressure Waveform|"Study Population:~Term pregnancy~in labour~18 years of age or older."
3024984|NCT02395783|Active Comparator|Melatonin dose1|Melatonin 10 µg
3024985|NCT02395783|Active Comparator|Melatonin dose2|Melatonin 20 µg
3024986|NCT02395783|Placebo Comparator|Placebo|Placebo
3024987|NCT02395770|Experimental|Subacromial pain group|Rehabilitation Program: The program was developed to target the deficits described in individuals with SPS. It included movement training, manual therapy, strengthening and stretching exercises, and patient education. Each supervised session lasted around 30 minutes, with 75% of the session for movement training. Three treating physiotherapists supervised the program and initially attended a training session to standardize the program.
3024988|NCT02395757|Experimental|Microperimetry|Microperimetry exam performed in addition to the usual ophthalmological examinations for monitoring AMD.
3024989|NCT02395744|Experimental|OPC Treatment|Paclitaxel administration using the OPC for the prevention of restenosis in infrapopliteal de novo and restenotic lesions and occlusions using a novel catheter, the OPC. Subjects will be treated with the endovascular intervention selected by the treating physician in reference vessels ranging from 2mm to 4mm in diameter. Following the achievement of optimal interventional results (≤ 30 percent residual stenosis without stenting and without flow-limiting dissection) the OPC will be placed at the interventional treatment area and paclitaxel will be delivered to the treated segment.
3024990|NCT02395731|Experimental|MIND at Home- Plus Intervention|MIND at Home-Plus is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND-Plus systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, occupational therapist, and physician.
3024991|NCT02395718|Experimental|QDU|Patients will undergo a fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation. Patients will have immediate access to all diagnostic tests and treatments that will be carried out all day (24 hours) on demand from the responsible physician. The QDU is both organisationally and physically integrated in the ED. Point of care ultrasonography can be performed round the clock. Additionally the Department of Radiology provides the QDU with more advanced diagnostic procedures such as e.g. CT scans or MRI scans on a fast track basis. There is access to additional specialist evaluations from the ED staff or from various in house specialists, when needed. Simultaneously to the medical treatment, physical therapists and occupational therapists train and optimise patients' level of functioning, including prevention of loss of function.
3024992|NCT02395718|Active Comparator|DIM|Patients in the control group are treated as conventionally at one of seven wards at the DIM. After initial admission including initial diagnostics and treatment have been carried out in the ED, patients are transferred to the DIM. Usually patients are seen primarily by the on-call physician for evaluation of acute symptoms. The following day, a Chief physician will work out a plan for further diagnostics and treatment. Treatment by physiotherapists and occupational therapists is available on request from a physician. Analyses of blood samples are performed at the central laboratory and radiological procedures at the Department of Radiology.
3024993|NCT02395705|Experimental|Neo-adjuvant chemotherapy group|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.~Surgery:~2-3weeks after Neo-adjuvant chemotherapy~Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
3024994|NCT02395705|No Intervention|Surgery alone group|"Surgery:~2-3weeks after Neo-adjuvant chemotherapy~Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
3024995|NCT02395692|Experimental|Treatment (methoxyamine, temozolomide)|Patients receive methoxyamine PO QD and temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3024996|NCT02395679|Experimental|MesoCancerVac|Autologous dendritic cells loaded with a mixture of 5 allogenic mesothelioma tumor cell lysates 3 to 5 vaccinations with 10x10e6, 25x10e6 or 50x10e6 loaded dendritic cells i.d. and i.v. administration every two weeks
3024997|NCT02395666|Experimental|DFMO twice daily|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
3024998|NCT02395653|Experimental|SSEC Fentanyl|SSEC fentanyl iontophoretic transdermal system, 40 mcg fentanyl per activation.
3024999|NCT02395640|Experimental|XELOX|oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
3025000|NCT02395640|Active Comparator|EOX|Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
3025001|NCT02395627|Experimental|Pembrolizumab Cycle 1 (Group A)|Tamoxifen: 20 mg daily orally (starting at Cycle 1) Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 1)
3025002|NCT02395627|Experimental|Pembrolizumab Cycle 2 (Group B)|Tamoxifen: 20 mg daily orally (starting at Cycle 1) Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 2)
3025003|NCT02395627|Experimental|Pembrolizumab Cycle 1 (Group C)|Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 1)
3025004|NCT02395614|Experimental|Chlorhexidine irrigation|0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles for irrigation. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
3025005|NCT02395614|Active Comparator|triple antibiotic irrigation|triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and 80 mg of gentamicin in 500 mL of normal saline (NS). If the patient is allergic to either component - the allergen will not be used in the solution - for irrigation. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
3025006|NCT02395601|Experimental|CPI-1205|
3025007|NCT02395588||Guideline based care|"Prior to discharge. Survey data will include descriptive characteristics, depression, heart failure knowledge. After patient education is complete prior to discharge patients will complete a readiness for discharge scale and heart failure self-care survey.~Phone call 48 hours after discharge. Discharge instructions will be reinforced.~Phone call 7 days after discharge. Survey data will include self management, complications, and satisfaction care.~Secondary data 30 days post discharge. The hospital electronic medical record system will be queried to determine if the patient has been readmitted within 30 days of discharge for heart failure or non-heart failure causes."
3025008|NCT02395562||OTR and viral reactivation|Organ transplant recipients with and without viral reactivation and skin cancer
3025009|NCT02395549|Experimental|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
3025010|NCT02395549|Experimental|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
3025011|NCT02395549|Experimental|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
3025012|NCT02395549|Placebo Comparator|Vehicle Control Gel|Vehicle Control Gel will be applied bid to the whole face for 12 weeks.
3025013|NCT02395536|Experimental|In office Outside walls of hospital|Reveal LINQ insertions will be performed in office setting. The in office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not an ambulatory surgery center.
3025014|NCT02395536|Other|Traditional Hospital Setting|Reveal LINQ insertions will be performed in a traditional setting. The traditional hospital setting includes an operating room or electrophysiology laboratory.
3025015|NCT02395523|Experimental|Proton Beam Therapy|"Definition of target volume:~Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan~Clinical target volume (CTV) = GTV + internal target volume~Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week~Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
3025016|NCT02395510|Other|Flexible, open label dosing|Flexible dosing 5-20mg
3025017|NCT02395497|Experimental|Treatment: Transplantation|Penile transplantation with an immunomodulatory protocol consisting of monoclonal antibody induction therapy of humanized anti CD52 followed by donor bone marrow infusion and tacrolimus monotherapy.
3025018|NCT02395484||constipation|collect stool samples from constipation patients
3025019|NCT02395484||healthy controls|collect stool samples from healthy controls patients
3025020|NCT02395471||Patient wth Barrett's|Subjects presenting for routine endoscopic BE surveillance examinations
3025021|NCT02395471||Patients with GERD|Subjects with gastroesophageal reflux disease (GERD) symptoms undergoing upper endoscopy for screening for BE
3025022|NCT02395458|Experimental|Sequential therapy|Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
3025023|NCT02395458|Active Comparator|Triple therapy|Patient receive Omeprazole plus clarithromycin and amoxicillin during 14 days
3025024|NCT02395445|Active Comparator|Totaltrack|Indirect laryngoscopy
3025025|NCT02395445|Active Comparator|Macintosh Laryngoscope|Direct laryngoscopy
3025026|NCT02395432|Active Comparator|Totaltrack|OTI with Totaltrack
3025027|NCT02395432|Active Comparator|Macintosh Laryngoscope|OTI with Macintosh Laryngoscope
3025028|NCT02395419|Active Comparator|Totaltrack|OTI with TotalTrack
3025029|NCT02395419|Active Comparator|Airtraq|OTI with Airtraq
3025030|NCT02395406|Active Comparator|Totaltrack|OTI with Totaltrack
3025031|NCT02395406|Active Comparator|Airtraq|OTI with Airtraq
3025032|NCT02395393|Other|Lung transplant recipients|In patients scheduled for bronchoscopy as part of regular clinical care/diagnostic workup, the investigators will offer the patient concurrent confocal microscopy imaging to be performed during the bronchoscopic procedure. A 1.4mm or 1.9mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli.
3025033|NCT02395380|Experimental|C-reactive protein dosage|
3025034|NCT02395354|Other|Placing a self-expanding metallic stent|Placing a self-expanding metallic stent
3025035|NCT02395354|Other|A balloon dilatation|A balloon dilatation
3025036|NCT02395328|Experimental|Care worker home visitation|Care Workers provide biweekly home visits and offer residing caregivers and children information and psychosocial support, and encourage their awareness and accessing of external health and social services.
3025037|NCT02395328|No Intervention|Wait List|Access to homework classes are made available to all participants' children at schools supported by the implementing organization.
3025038|NCT02395315||Well-controlled diabetic (WC)|well-controlled diabetic controls (HbA1c ≤ 7.0%), individuals will receive a single 4.1 Titanium-Zirconia, hydrophilic (Roxolid) implant placed in the posterior mandible, a bone core will be taken for histologic and histomorphometric analysis.
3025039|NCT02395315||Poorly controlled diabetics (PC)|Poorly controlled diabetics (HbA1c >7.5% & <10%), individuals will receive a single 4.1 Titanium-Zirconia, hydrophilic (Roxolid) implant placed in the posterior mandible, a bone core will be taken for histologic and histomorphometric analysis.
3025040|NCT02395302|Experimental|Dual Action Pneumatic Compression|Dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an alternating current (AC) outlet.
3025041|NCT02395289|Experimental|Cognitive-Based Compassion Training (CBCT)|HIV-1 positive subjects on antiretroviral therapy (ART) will be randomized to receive an 8-week program of Cognitive-Based Compassion Training (CBCT).
3025042|NCT02395289|Active Comparator|Health Discussion Control|HIV-1 positive subjects on antiretroviral therapy (ART) will be randomized to attend a health discussion group for 8 weeks.
3025043|NCT02395276|Active Comparator|Whole body hypothermia|Children that had an event suspected for hypoxic ischemic brain injury, according to the inclusion criteria, will be randomly allocated for whole body hypothermia therapy. Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Whole body hypothermia will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
3025044|NCT02395276|Placebo Comparator|Whole body normothermia|Children that had an event suspected for hypoxic ischemic brain injury, according to the inclusion criteria, will be randomly allocated for normothermia therapy. Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 36-37 °C . Treatment period will be 72 hrs.
3025125|NCT02394756|Experimental|Marketed Soft Contact Lens (Test)|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
3056950|NCT02181972|Placebo Comparator|Placebo|
3025045|NCT02395276|No Intervention|Control|A group of children that underwent a cardiac surgery and was not suspected to have an hypoxic ischemic brain injury. This group will be undergo the similar biomarkers collection as arm 1 and 2. The information will be used to measure the change in biomarkers between surgeries with no HII to those in arm 1+2.
3025046|NCT02395263|Experimental|Yuxintine 200mg per day|Yuxintine 200mg oral, once a day, 6 weeks
3025047|NCT02395263|Experimental|Yuxintine 300mg per day|Yuxintine 300mg oral, once a day, 6 weeks
3025048|NCT02395263|Experimental|Yuxintine 400mg per day|Yuxintine 400mg oral, once a day, 6 weeks
3025049|NCT02395263|Placebo Comparator|Placebo|Placebo oral, once a day, 6 weeks
3025050|NCT02395250|Experimental|anti-GPC3 CAR T|
3025051|NCT02395237|Experimental|Amaryl® M IR 2/1000 (manufactured in India)|Investigational products :Reference formulation Trade Name: Amaryl® M IR 2/1000 (manufactured in India) Dosage Form: Film coated tablet 1x1 Active Substance: Glimepiride/metformine HCl 2 mg/1000 mg Manufacturer: Goa, India
3025052|NCT02395237|Experimental|Amaryl® M IR 2/1000 (manufactured in Turkey)|Dosage form: Film coated tablet 1x1 Active substance : Glimepiride/metformine HCl 2 mg/1000 mg Manufacturer: Zentiva TR, Lüleburgaz
3025053|NCT02395211|Active Comparator|Usual Physiotherapy|
3025054|NCT02395211|Experimental|Gloreha device|
3025055|NCT02395198||HCV negative or in HCV treatment at T1|This group will be followed up at T2
3025056|NCT02395185|Experimental|Milk|Milk bottle administration
3025057|NCT02395185|Experimental|Water|Water bottle administration
3025058|NCT02395185|Experimental|Sucrose|Sucrose bottle administration
3025059|NCT02395172|Experimental|Avelumab|
3025060|NCT02395172|Active Comparator|Docetaxel|
3025061|NCT02395159|Experimental|Prevena™ IMS|The patients in the experimental arm will be treated with the Prevena™ IMS seven days after the surgery
3025062|NCT02395159|Other|sterile plaster dressings|The wound will be treated with the conventional wound management method of sterile plaster dressing.
3025063|NCT02395146|Experimental|Monitoring|intraoperative EBSLN monitoring will take place
3025064|NCT02395146|No Intervention|Non-Monitoring|No intraoperative EBSLN monitoring will take place (standard practice)
3025065|NCT02395133|Experimental|Group 1|Participants who received treatment regimen 1 of SC dupilumab in the initial treatment studies will be randomized to group 1 and receive 1 of 4 treatment regimens
3025066|NCT02395133|Experimental|Group 2|Participants who received treatment regimen 2 of SC dupilumab in the initial treatment studies will be randomized to group 2 and receive 1 of 4 treatment regimens
3025067|NCT02395120|Active Comparator|Standard letter|Modified standard letter will be sent to caregivers.
3025068|NCT02395120|Experimental|Intervention letter|The CSM-based referral letter alone will be sent to caregivers
3025069|NCT02395120|Experimental|Reduced intervention letter|"The reduced (removing text corresponding to timeline) CSM-based referral letter alone will be sent to caregivers."
3025070|NCT02395120|Experimental|Intervention letter+DIG|The CSM-based referral letter with the dental information guide will be sent to caregivers.
3025071|NCT02395120|Experimental|Reduced intervention letter+reduced DIG|The reduced CSM-based referral letter with the reduced dental information guide will be sent to caregivers.
3025072|NCT02395094|No Intervention|Group 1 (Standard Procedure)|Group 1 (Standard Procedure) will receive BCCH standard care, which consists of topical anesthetic cream, waiting with parents in the playroom in the surgical daycare unit preoperatively, parental presence in the OR, the BCCH 'parent hug' and standard distraction techniques
3025073|NCT02395094|Experimental|Group 2 (Child Life)|Group 2 (Child Life) will receive Child Life intervention applicable to the individual patient, on the day of surgery in addition to standard practices
3025074|NCT02395081|Placebo Comparator|600 IU|Women will receive prenatal vitamins containing 600 IU of Vitamin D.
3025075|NCT02395081|Experimental|2000 IU|Women will receive prenatal vitamins containing 2000 IU of Vitamin D.
3025076|NCT02395081|Experimental|4000 IU|Women will receive prenatal vitamins containing 4000 IU of Vitamin D.
3025077|NCT02395068|Experimental|Single-dose PK|single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation. 1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.
3025078|NCT02395068|Experimental|Weekly fixed dose|Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks.
3025079|NCT02395068|Experimental|Bioweekly fixed dose PK|Nimotuzumab 600mg, administered once every 2 weeks for 8 weeks. Dosing regimens can be adjusted according to the results of preliminary experiments. Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h
3025080|NCT02395055|Experimental|BCD-057 group|BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
3025081|NCT02395055|Active Comparator|Humira group|Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
3025082|NCT02395042|Experimental|LiRIS®, LiRIS® (Tx 1)/LiRIS® (Tx 2)|Treatment period 1: continuous release of lidocaine inserted into the bladder by cystoscopy. Treatment Period 2: optional of continuous release of lidocaine inserted into the bladder by cystoscopy.
3025083|NCT02395042|Other|LiRIS Placebo, LiRIS Placebo (Tx 1)/LiRIS® (Tx 2)|Treatment period 1: Matching placebo device to the LiRIS inserted into the bladder by cystoscopy. Treatment Period 2: optional of continuous release of lidocaine inserted into the bladder by cystoscopy.
3025084|NCT02395042|Other|LiRIS Placebo, LiRIS® (Tx 1)/ LiRIS® (Tx 2)|Treatment period 1: continuous release of lidocaine and matching placebo inserted into the bladder by cystoscopy. Treatment Period 2: optional of LiRIS placebo inserted into the bladder by cystoscopy.
3025085|NCT02395029|Experimental|Injection of PMD-MSCs into the penis|Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based on ultrasound guided measurements of penile plaque(s) post treatment and on patient reported treatment satisfaction.
3025189|NCT02394379||Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
3025086|NCT02395016|Experimental|Nimotuzumab and Gemcitabine|"nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.~Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test."
3025087|NCT02395016|Placebo Comparator|Placebo and Gemcitabine|"placebo,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.~Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test."
3025088|NCT02395003||High VAT/SAT high Palmitate Diet|Subjects with a high ratio of visceral to subcutaneous fat consuming high Palmatite oil diet for 12 weeks
3025089|NCT02395003||Low VAT/SAT|Subjects with a low ratio of visceral to subcutaneous fat
3025090|NCT02395003||Lean Controls|Lean control
3025091|NCT02395003||High VAT/SAT- low Palmitate Diet|Subjects with a high ratio of visceral to subcutaneous fat consuming low Palmatite oil diet for 12 weeks
3025092|NCT02394990|Experimental|Violence Brief Intervention|Participants receive a standard of care brief motivational intervention (BMI) to address alcohol consumption (ABI) based on self reported use and their relationship between consumption and behavior, followed by an additional BMI to address how involvement in violence (VBI) impacts their life, relationship to social norms, and strategies to avoid violence.
3025093|NCT02394990|Active Comparator|Control|Participants receive only ABI
3025094|NCT02394977|Experimental|Compression with Feedback|CPR performed according to established international standards with chest compressions performed with the assistance of the Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) compression feedback device.
3025095|NCT02394977|Active Comparator|Standard chest compression|CPR performed according to established international standards with standard manual chest compression
3025096|NCT02394964||Systemic Lupus Erythematosus|Blood, stool, and swab samples will be collected at baseline, week 4, and week 8 and compared with control samples
3025097|NCT02394964||Subacute Cutaneous Lupus Erythematosus|Blood, stool, and swab samples will be collected at baseline, week 4, and week 8 and compared with control samples
3025098|NCT02394964||Control|Blood, stool, and swab samples will be collected for comparison to each disease group
3025099|NCT02394964||Cutaneous T-Cell Lymphoma|Blood and swab samples will be collected for comparison to each disease group
3025100|NCT02394964||Autoimmune Disorders|Blood, stool, and swab samples will be collected for comparison to each disease group
3025101|NCT02394951|Experimental|Pregabalin|Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
3025102|NCT02394951|Placebo Comparator|Placebo|Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
3025103|NCT02394938|Experimental|MUSIC|In addition to the standard care, heart failure patients assigned to the music group will listen recorded classical music.
3025104|NCT02394938|No Intervention|CONTROL|Heart Failure patients assigned to the control group will receive standard care only. The standard care will consist in nursing and medical counselling, self-care education and medication.
3025105|NCT02394925|Experimental|Multifocal Test Contact Lens|Subjects will wear the test lenses at least six hours per day, at least five days per week
3025106|NCT02394912|Experimental|Single-arm|
3025107|NCT02394899|No Intervention|Control|The control dyad will receive usual care.
3025108|NCT02394899|Experimental|Intervened|Parents receive training in problem solving skills and play therapy with their infants.
3025109|NCT02394886|Experimental|ALLO-ASC-DFU|ALLO-ASC-DFU treatment with conventional care
3025110|NCT02394873|Experimental|ALLO-ASC-DFU|
3025111|NCT02394860||blood and cardiological examination|
3025112|NCT02394847|Other|propofol|dose of propofol according to the number of therapies
3025113|NCT02394834|Experimental|Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
3025114|NCT02394834|Active Comparator|Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg/ mFOLFOX6 + panitumumab combination therapy, once every two weeks
3025115|NCT02394821|Experimental|Metronidazole|metronidazole 0.8% solution - topical
3025116|NCT02394821|Experimental|Polihexanide|Polihexanide 2%
3025117|NCT02394808|Experimental|Test Lens 1|senofilcon A (Approved contact lens material)
3025118|NCT02394808|Active Comparator|Test Lens 2|lotrafilcon B (Approved contact lens material)
3025119|NCT02394795|Experimental|Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
3025120|NCT02394795|Active Comparator|Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg/ mFOLFOX6 + bevacizumab combination therapy, once every two weeks
3025121|NCT02394782||Relapsing-remitting Multiple Sclerosis|
3025122|NCT02394769|Placebo Comparator|Placebo (For Aspirin)|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose, once daily, until the final visit. Duration not to exceed 12 weeks.
3025123|NCT02394769|Active Comparator|Low Dose Aspirin|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose (81 mg/d), once daily, until the final visit. Duration not to exceed 12 weeks.
3025124|NCT02394769|Active Comparator|Standard Dose Aspirin|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose (325mg/d), once daily, until the final visit. Duration not to exceed 12 weeks.
3025355|NCT02393261|Active Comparator|B 2000mlGroup|use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
3025126|NCT02394756|Active Comparator|AIR OPTIX® AQUA|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
3025127|NCT02394756|Active Comparator|Biofinity®|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
3025128|NCT02394743||eGFR > 90|group whose eGFR is more than 90
3025129|NCT02394743||60 < eGFR <90|group whose eGFR is between 60 and 90
3025130|NCT02394743||eGFR < 60|group whose eGFR is less than 60
3025131|NCT02394730|Experimental|vorapaxar|2.5mg of vorapaxar po qd
3025132|NCT02394730|Placebo Comparator|Placebo|sugar pill po qd
3025133|NCT02394717|Other|Intervention|All YMCA programs will receive the Healthy Eating and Physical Activity Intervention throughout the study. All programs will receive the HEPA Strategies intervetion to assist them with achievement of the HEPA Standards.
3025134|NCT02394704|Experimental|Graded sensory attention training|Sensory stimuli will begin at a maximal tolerable intensity and decrease in intensity throughout the training, to shift from involuntary to voluntary attentional focus.
3025135|NCT02394704|Active Comparator|Non-graded sensory attention training|Sensory stimuli will begin and be maintained at a minimal detectable intensity to maximize voluntary attentional training.
3025136|NCT02394691|Active Comparator|anodal stimulation|Patients receive an anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after the tDCS session. A final CRS-R is performed 8 week after the end of the session to assess the potential long term effects of tDCS.
3025137|NCT02394691|Placebo Comparator|sham stimulation|Patients receive a sham tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 5 secondes at the begining and the end of the stimulation to mimic the effects of tDCS). A CRS-R is performed at baseline (before the first stimulation) and after the tDCS session. A final CRS-R is performed 8 week after the end of the session to assess the potential long term effects of tDCS.
3025138|NCT02394678|Experimental|Intervention - clot removal|Patients will undergo rheolytic thrombectomy for intraventricular hemorrhage
3025139|NCT02394665|Experimental|Group 1: SIB + IMRT|"Simultaneous Integrated Boost (SIB) plus Fractionated Intensity Modulated Radiation therapy (IMRT), with concurrent Temozolomide therapy for 6 weeks;~3D MRSI during week 3, end of RT and other protocol-defined time points during adjuvant Temozolomide therapy;~Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire administered at protocol-defined time points;~Adjuvant Temozolomide Therapy for up to 12 cycles."
3025140|NCT02394665|Experimental|Group 2: SRS Boost + IMRT|"For patients with High-Risk Tumor Volumes (HTV) <= 4cm; or multiple HTVs <= 3 cm:~Stereotactic Radiosurgery Boost (SRS Boost) followed one week later by Fractionated Intensity Modulated Radiation therapy (IMRT), and concurrent Temozolomide therapy for 6 weeks;~3D MRSI during week 3, end of RT and other protocol-defined time points during adjuvant Temozolomide therapy;~Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire administered at protocol-defined time points;~Adjuvant Temozolomide Therapy for up to 12 cycles."
3025141|NCT02394652|Experimental|Experimental: Metformin with Standard Chemoradiation|"Metformin: About 1 week prior to the start of chemoradiation, take 850 mg of metformin, orally, once a day for 3 days, followed by 850 mg twice a day and continued for the duration of external radiation.~Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation.~FAZA-PET scan at baseline and after about 1 week of metformin (just prior to the start of chemoradiation)"
3025142|NCT02394652|Active Comparator|Standard Chemoradiation|"Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation.~FAZA-PET scan at baseline and about 1 week later (just prior to the start of chemoradiation)."
3025143|NCT02394639|Active Comparator|conventional video-EEG monitoring|conventional video-EEG monitoring with cup-electrodes and collodion
3025144|NCT02394639|Experimental|video-EEG monitoring with prototype|video-EEG monitoring of 5 hours with EEG-cap with dry electrodes
3025145|NCT02394626|Experimental|Surgery followed by adjuvant second-line therapy|Surgery followed by adjuvant second-line therapy
3025146|NCT02394626|Active Comparator|Second-line therapy alone|Second-line therapy alone
3025147|NCT02394613|Experimental|ANX776|Using and increasing dose storer design, GLAUCOMA and NORMAL patients will be randomly grouped to received the intervention (0.1 mg, 0.2 mg, 0.4 mg, 0.5 mg). 1 NAION patient will receive each dose once it has been proven safe in GLAUCOMA and NORMAL patients, as part of the secondary objective of this trial.
3025148|NCT02394600|Experimental|Grastek®|48 participants will receive Grastek® once per day for 120 days. Grastek® is a standardized sublingual immunotherapy (SLIT) tablet containing 2800 BAU of standardized allergen extract from Timothy grass (Phleum pretense). This SLIT product is approved by Health Canada and the Food and Drug Administration (FDA) for the treatment of grass-pollen induced allergic rhinoconjunctivitis (AR) in Canada and the United States respectively.
3025149|NCT02394600|Placebo Comparator|Placebo|48 participants will receive placebo once per day for 120 days.
3025150|NCT02394587|Experimental|Mindfulness-Based Stress Reduction|Subjects assigned to the experimental group will participate in a MBSR foundation program, which includes weekly telephonic, group-based, 60-minute MBSR sessions for 6 weeks. The foundation program will introduce subjects to the concept of mindfulness with each week focusing on a different facet. Modeled after Kabat-Zinn's original program, breath awareness (focus on breath and observing thoughts without fighting or following them), body scan (promoting mindfulness of sensations in different parts of body), walking meditation (walking as form of meditation), loving kindness (projection of friendliness and kindness towards oneself and others), and choiceness awareness (awareness of all sensations with equal interest) will be taught.
3025183|NCT02394431||Healthy patients|This is the control group for the sickle cell disease patients: each sickle cell disease patient will be matched with a healthy patient of the same sex and of similar age.
3025184|NCT02394418|Active Comparator|Sevoflurane|Treatment of delirium by inhaled sevoflurane
3025185|NCT02394418|Active Comparator|Propofol|Treatment of delirium by propofol i.v. infusion
3025186|NCT02394418|Active Comparator|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
3025187|NCT02394405||on-pump surgery|
3025188|NCT02394405||off-pump surgery|
3025151|NCT02394587|Other|Wait-listed control group|Subjects assigned to the wait-listed control group will not receive the MBSR program, but will receive weekly reminders of their study participation, be asked to complete the same questionnaires (per telephone script) once every three weeks, and receive the same financial incentives as the MBSR group. Upon completion of the 6-week session, the wait-list control group will be offered the same MBSR program. At that time, a new series of MBSR sessions will be scheduled and offered to the wait-listed control patients. Subjects who elect to participate in MBSR will receive the same packet of materials and measures received by the intervention group and be asked to complete the measures again at baseline, 1, 3, and 6 weeks.
3025152|NCT02394574|Active Comparator|Clean Cookstove|Subjects will use ethanol stoves using bioethanol
3025153|NCT02394574|Other|Traditional Cookstove|Subjects will use traditional firewood or kerosine cookstove and receive education on how to reduce air pollution exposures
3025154|NCT02394561|Experimental|Secukinumab|This is a multicenter, prospective study involving Cw6-negative and Cw6-positive patients affected by moderate to severe chronic plaque psoriasis. Patients will be centrally tested and stratified into two cohorts (Cw6-negative and Cw6-positive patients). Both patients and investigators will be blinded to the results with respect to Cw6. After a full screening visit, each eligible patient will be treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response will be eligible to continue on secukinumab for an additional 8 weeks. The total duration of the study is 24 weeks.
3025155|NCT02394548|Experimental|Contralateral Esophagus Sparing Technique (CEST)|IMRT with CEST and concurrent chemotherapy (any standard-of-care regimen)
3025156|NCT02394535|Experimental|Abraxane (Nab-Paclitaxel) + Capecitabine + Radiation Therapy|"Phase I study and a standard 3+3 design used to determine maximum tolerated dose (MTD) dose of Abraxane with Radiation Therapy and Capecitabine. Up to 3 dose levels of Abraxane tested. First group of participants receive lowest dose level. Each new group receives a higher dose than the group before it, if no intolerable side effects were seen. This continues until highest tolerable dose of Abraxane is found. Once MTD identified an expansion cohort of 12 patients enrolled.~Starting dose of Abraxane 50 mg/m2 by vein weekly Day 1, 8, 15, 22 and 29. Capecitabine 825 mg/m2 by mouth twice a day only on days of radiation. Radiation Therapy delivered at a dose of 50.4 Gy in 1.8 Gy fractions 1 time each day on Monday through Friday for 5½ weeks.~Symptom and Quality of Life (QOL) Questionnaire completed at baseline, and 4 - 6 weeks after radiation therapy."
3025157|NCT02394522|Placebo Comparator|Placebo|Spatial Repellent product without active ingredient (SHIELD)
3025158|NCT02394522|Active Comparator|Intervention|Spatial Repellent product with active ingredient (SHIELD)
3025159|NCT02394509|Experimental|HOBSCOTCH-IP (in person)|Participants will receive the HOBSCOTCH intervention consisting of a first session conducted in-person, 3 weekly followed by 3 bi-weekly telephone coaching sessions, and a final session conducted in-person.
3025160|NCT02394509|Experimental|HOBSCOTCH-V (virtual)|Participants will receive the HOBSCOTCH intervention consisting of a first session conducted virtually, 3 weekly followed by 3 bi-weekly telephone coaching sessions, and a final session conducted virtually.
3025161|NCT02394509|Other|Control|Participants will be wait listed and given an option whether they prefer to enroll into HOBSCOTCH-IP or HOBSCOTCH-V. Subjects in Group 3 will receive HOBSCOTCH following a 6 month wait period.
3025162|NCT02394496|Experimental|ARM 1|Fulvestrant + Placebo Lapatinib
3025163|NCT02394496|Experimental|ARM 2|Fulvestrant + Aromatase Inhibitors + Placebo Lapatinib
3025164|NCT02394496|Experimental|ARM 3|Fulvestrant + Lapatinib
3025165|NCT02394496|Experimental|ARM 4|Fulvestrant + Lapatinib + Aromatase Inhibitors
3025166|NCT02394483|Experimental|Cohort A active|2 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
3025167|NCT02394483|Placebo Comparator|Cohort A placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
3025168|NCT02394483|Experimental|Cohort B active|4 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
3025169|NCT02394483|Placebo Comparator|Cohort B placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
3025170|NCT02394483|Experimental|Cohort C active|6 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
3025171|NCT02394483|Placebo Comparator|Cohort C placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
3025172|NCT02394483|Experimental|Cohort D active|8 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
3025173|NCT02394483|Placebo Comparator|Cohort D placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
3025174|NCT02394483|Experimental|Cohort E active|10 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
3025175|NCT02394483|Placebo Comparator|Cohort E placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
3025176|NCT02394470|Other|Acute heart failure HF,Chronic HF,Advanced chronic HF|patient admitted to the hospital for acute heart failure (de-novo or exacerbation of chronic heart failure), for Chronic HF and for Advanced chronic heart failure
3025177|NCT02394457|Experimental|Intravenous Cosyntropin Group A|Cosyntropin 500 mcg in 1000cc Normal Saline
3025178|NCT02394457|Active Comparator|Epidural Blood Patch Group B|Epidural Blood Patch and I000cc Normal Saline
3025179|NCT02394444|Experimental|Preterm intervention TRT group|"Parents with premature infants received the intervention called Triadic parent-infant's Relationship Therapy (TRT) :~the psychological intervention included home visits twice month during the first four months and then monthly visits in the neonatal ward until the 18 months corrected age resulting in a total of 22 visits during the whole intervention; TRT gave attention to emotional distress and the promotion of parenting skills and attachment security; The three sessions of intervention targeted objectives specific to each child's development; A basic manual was designed to ensure uniformity of the defined themes during each session"
3025180|NCT02394444|No Intervention|Preterm control group|Parents with premature infants without intervention program TRT (Triadic parent-infant's Relationship Therapy) received routine follow-up medical care with monthly visits to a practitioner for the first six months and then very three months
3025181|NCT02394444|No Intervention|Full-term control group|Parents with full-term infants without intervention program TRT
3025182|NCT02394431||Sickle cell disease patients|Sickle cell disease patients
3025190|NCT02394366|Experimental|Active|Original Healing Salve (Puremedy, Inc.) including 1x homeopathic dilutions of Calendula, Echinacea, and Sambucus extracts, plus extracts from pine and Balsam fir; acute effects only
3025191|NCT02394366|Placebo Comparator|Control|Original Health Salve olive oil and beeswax base only without homeopathic or herbal extracts; acute effects only
3025192|NCT02394353|Active Comparator|Sleeve Gastrectomy|Patients undergoing the sleeve gastrectomy surgery
3025193|NCT02394353|Active Comparator|Gastric Bypass|Patients undergoing the gastric bypass surgery
3025194|NCT02394340|Experimental|Luliconazole Cream 1%|Each subject will receive Luliconazole Cream 1% for one week to cover the entire affected surface areas and adjacent areas, beginning 24 hours after initial Omeprazole dosing (40mg)
3025195|NCT02394327|Active Comparator|Endoscopic nasogallbladder drainage|If GB cannulation was achieved and the wire was coiled in the GB, 5 to 7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA) was placed into the GB
3025196|NCT02394327|Active Comparator|Endoscopic gallbladder stenting|If GB cannulation was achieved and the wire was coiled in the GB, 7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA) was placed into the GB
3025197|NCT02394314|Placebo Comparator|Placebo|Placebo administered subcutaneously
3025198|NCT02394314|Experimental|MEDI0382|MEDI0382 administered subcutaneously
3025199|NCT02394288||Adults without cardiac disease|Extremity orthopedic or trauma surgery
3025200|NCT02394275|Experimental|Single arm:|Eligible patients with receive intervention: frozen fecal microbiota transplantation (FMT), kept at -20 oC and will be thawed prior to administration. Patients on antibiotic to control CDI will discontinue antibiotic 24 hours prior to FMT.
3025201|NCT02394262|Experimental|Serial CCTA and atherothrombosis markers|Sequential coronary CT-angiography and assesment of biomarkers involved in atherothrombosis after 1 year follow-up.
3025202|NCT02394249|Experimental|Sitting regime|The subjects will follow the sitting regime during four days. Each day: 14 hours sitting, 1 hour walking and 1 hour standing and 8 hours sleeping.
3025203|NCT02394249|Experimental|Sit Less regime|Subjects will follow the sit less regime during four days. Each day will consist of 9 hours sitting, 4 hours walking, 3 hours standing and 8 hours sleeping. The walking and standing will be done in a minimum of eight bouts with a time interval of >1 hour. The subjects will be instructed to walk on a slow pace, i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.
3025204|NCT02394236|Experimental|Continuous exercise training|The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
3025205|NCT02394236|Experimental|interval exercise training|The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
3025206|NCT02394223||Full Field Optical Coherence Tomography (FFOCT) procedure|
3025207|NCT02394210||Group 1|Patients in relapse/biological progression (under the criteria of the IMW (International Myeloma Workshop) Consensus Panel 1 not receiving treatment until clinical relapse.
3025208|NCT02394210||Group 2|"Patients in relapse/biological progression receiving anti-MM treatment at the time of relapse/biological progression): Patients in this group may receive conventional anti-myeloma treatment as per routine clinical practice at the participating site:~Upon relapse/biological progression, defined as per the criteria of the IMW (International Myeloma Workshop) Consensus Panel Panel1 Or~Upon a significant relapse of paraprotein, defined as:~Duplication of M-component in two consecutive readings taken ≤2 months apart; or~An increase in absolute levels of serum M-protein ≥1 g/dL or M-protein in urine at ≥500 mg/24h, or~Increase in light chain levels ≥20 mg/dL with an abnormal ratio in two consecutive readings taken ≤2 months apart), which suggests the presence of biological progression/relapse criteria, but without including any clinical details of those involved in clinical relapse."
3025209|NCT02394197|Active Comparator|14-day treatment (T14)|"The operational treatment-dose was administered by mouth. The number of tablets of Chloroquine phosphate of 150 mg for three days (x-x-x/ number of tablets of Primaquine (15mg or 5 mg)), daily during 14 days. For 1 year old subjects only chloroquine (1-½-½/ ½ of 5 mg); for 2-5 years old (1-¾-1/ 1 of 5 mg); 6-12 years old (2-1-2/ 2 of 5 mg); 13 years old and over with about 60 kg of body weight (3-2-2/ 1 of 15 mg) and above 60 kg of body weight (4-3-3 / 1 of 15 mg).~According to the age group as indicated by the Mexican guidelines for vector borne diseases control (http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html) (Table 10)"
3025210|NCT02394197|Experimental|Intermittent single doses (ISD)|"The single dose medication was administered orally according to age group as the operational table: (number of tablets of chloroquine phosphate of 150 mg / number of tablets of primaquine (15mg or 5 mg)): for 1 year old (½ / 1 of 5 mg); for 2¬-5 years old (1 / 2 of 5 mg); 6-12 years old (2 / 4 of 5 mg); 13 years old and over of about 60 kg of body weight (3 / 2 of 15 mg), and above 60 kg of body weight (4 / 3 of 15 mg).~It is administered on Days 0 (after the detection of infection by microscopy), and Days 30, 60, 180, 210, 240 and 360 as indicated in the National guidelines for vector borne diseases control (http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html)."
3025211|NCT02394184||patients with bicuspid aortic valve stenosis|
3025212|NCT02394171|Experimental|Physical Activity|Women completed a physical activity group cohesion intervention which included six content intensive intervention sessions over a 24 week period that focused on specific group dynamics team building strategies to increase physical activity. A small team structure was used for peer problem solving and support throughout the intervention. Teams were given weekly physical activity goals, with slowly increasing weekly minutes milestones to gradually meet recommended amounts of physical activity. Sessions included brief instructions, team-based activities, and discussion with the entire group lead by a trained health educator. The intervention sessions ended with the health educator leading the teams in a brisk 15-minute walk.
3025233|NCT02394054|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
3025234|NCT02394041|Experimental|acupuncture|"The first session of acupuncture treatment will be performed at the inclusion visit, 2 additional acupuncture sessions will be scheduled as 1 session per week for the next 2 weeks.~One or more additional session will be performed in the delivery room."
3056951|NCT02181959|Experimental|Pharmaton® with DMAE|
3025213|NCT02394171|Active Comparator|Fruit and Vegetable|Women completed a fruit and vegetable group cohesion intervention which involved six content intensive intervention sessions over a 24 week period that focused on specific group dynamics team building strategies to increase fruit and vegetable consumption. A small team structure was used for peer problem solving and support throughout. Teams were given weekly fruit and vegetable consumption goals at each session, with slowly increasing weekly servings milestones to gradually meet recommended amounts of fruit and vegetable consumption. Sessions included brief instructions, team-based activities, and discussion with the entire group lead by a trained health educator. The intervention sessions ended with the health educator leading the teams in a fruit and vegetable taste test.
3025214|NCT02394158|Active Comparator|Intervention arm Metformin|Metformin (500mg tablets) to start at a dose of 500mg once daily with an increase of 500mg every five days until the maximum dose of 1000mg twice daily is reached.
3025215|NCT02394158|Placebo Comparator|Control arm placebo|Matched placebo tablets (500mg) to start at a dose of 500mg once daily with an increase of 500mg every five days until the maximum dose of 1000mg twice daily is reached.
3025216|NCT02394145|Experimental|Ticagrelor 180mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of ticagrelor (180 mg) and maintenance doses (ticagrelor 90 mg twice daily) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
3025217|NCT02394145|Active Comparator|Clopidogrel 75mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 75 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
3025218|NCT02394145|Active Comparator|Clopidogrel 150mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 150 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
3025219|NCT02394145|Active Comparator|Ticagrelor 180mg in normal kidney|After randomization, patients with normal kidney function will be treated by an initial loading dose of ticagrelor (180 mg) and maintenance doses (ticagrelor 90 mg twice daily) for 14 days. Platelet reactivity and genetic polymorphism will be assessed
3025220|NCT02394145|Active Comparator|Clopidogrel 75mg in normal kidney|After randomization, patients with normal kidney function will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 75 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
3025221|NCT02394132|Experimental|Imiquimod|"Topical imiquimod 5% cream~application to treatment area for 5 days/week for a total of 12 weeks~dispensed at baseline visit along with patient diary"
3025222|NCT02394132|Experimental|Radiotherapy|"Radiotherapy~treatment regimen determined by treating radiation oncologist and as per standard practice at local institution~treatment to commence within 8 weeks of randomisation"
3025223|NCT02394119|Experimental|Ofatumumab|"Drug Name: Ofatumumab~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities~Procedures: methylprednisolone 2 mg/kg infused in 30' IV diluted in 100 ml of normal saline (NaCl 0,9%); oral paracetamol 15 mg/kg ; cetirizine 0,4 mg/kg IV infused slowly in 5 ml of normal saline (NaCl 0,9%) prior to Ofatumumab infusion to reduce common reactions~How: Ofatumumab IV: 1500 mg/1.73m2 at 12 ml/hour in the first 30'. Thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 200 ml/hour.~When and how much: once; diluted in 1000 ml of normal saline."
3025224|NCT02394119|Active Comparator|Rituximab|"Drug Name: Rituximab (RTX)~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities~Procedures: the same as for Ofatumumab Arm~How: Rituximab IV: 375 mg/m2; for dosage between 100 and 250 mg RTX will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg RTX will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg RTX will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.~When and how much: once; diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg."
3025225|NCT02394106|Experimental|Ofatumumab|"Drug Name: Ofatumumab~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities~Procedures: methylprednisolone 2 mg/kg infused in 30' IV diluted in 100 ml of normal saline (NaCl 0,9%); oral paracetamol 15 mg/kg ; cetirizine 0,4 mg/kg IV infused slowly in 5 ml of normal saline (NaCl 0,9%) prior to Ofatumumab infusion to reduce common reactions~Who provides: registered nurse~How: Ofatumumab IV at 12 ml/hour in the first 30'. Thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 200 ml/hour.~Where: in Hospital~When and how much: once; diluted in 1000 ml of normal saline~Tailoring: 1500 mg/1.73m2~How well: expert nurse would assist administration"
3025226|NCT02394106|Placebo Comparator|Placebo|"Drug Name: Normal Saline (NaCl 0,9%)~Why: standard therapy could not be used as comparator for Ofatumumab, given its toxicity and lack of effectiveness. Moreover, although Rituximab, a chimeric monoclonal anti-CD20 antibody, is increasingly being used as a steroid-sparing treatment option for children with certain forms of INS (those that respond to and are dependent of steroids), this drug does not work in DR-INS and could not be used as a comparator.~Materials and Procedures: The placebo arm will receive the same infusion as the Ofatumumab Arm with the exception of the Ofatumumab."
3025227|NCT02394093|Experimental|Aspirin dry powder|500 mg Acetylsalicylic Acid (ASA) dry powder
3025228|NCT02394093|Active Comparator|Aspirin coated tablet|500 mg ASA coated tablet
3025229|NCT02394093|Active Comparator|Aspirin effervescent tablet|500 mg ASA effervescent tablet
3025230|NCT02394080|Experimental|Photodynamic Bone Stabilization System (PBSS)|The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.
3025231|NCT02394067||Idiopathic Intracranial Hypertension|All participants of our study will be in this arm. These will be patients with a diagnosis of IIH. These patients will be followed throughout their standard of care treatment, with neuro-radiological imaging.
3025232|NCT02394054|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
3025237|NCT02394028|Experimental|Induction Phase: Etrolizumab 105 Milligrams (mg)|Participants will receive subcutaneous (SC) injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and etrolizumab matching placebo at Week 2 during 14-week Induction Phase.
3025238|NCT02394028|Experimental|Induction Phase: Etrolizumab 210 mg|Participants will receive SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during 14-week Induction Phase.
3025239|NCT02394028|Placebo Comparator|Induction Phase: Placebo|Participants will receive SC injection of etrolizumab matching placebo at Weeks 0, 2, 4, 8 and 12 during 14-week Induction Phase.
3025240|NCT02394028|Experimental|Maintenance Phase: Etrolizumab 105 mg|Participants will receive SC injection of etrolizumab (105 mg every 4 weeks [Q4W]) during 52-week Maintenance Phase.
3025241|NCT02394028|Placebo Comparator|Maintenance Phase: Placebo|Participants will receive SC injection of etrolizumab matching placebo (Q4W) during 52-week Maintenance Phase.
3025242|NCT02394015||Trabectedin+ PLD|Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC.
3025243|NCT02394002|Experimental|Brain surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
3025244|NCT02394002|Experimental|Spine surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
3025245|NCT02394002|Active Comparator|General surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
3025246|NCT02393989|Experimental|Active comparator|posterior restorations
3025247|NCT02393976|Other|CONTROL|STANDARD NUTRITION
3025248|NCT02393976|Experimental|IMMUNONUTRITION|INMUNONUTRITION
3025249|NCT02393963|Experimental|Tranexamic Acid|Intra-articular administration of low dose Tranexamic acid
3025250|NCT02393963|Placebo Comparator|Placebo|Sodium Chloride
3025251|NCT02393950|Experimental|Drug: ODM-106|Oral capsules dosage 2-800mg once daily for one day
3025252|NCT02393950|Placebo Comparator|Drug: Placebo|Oral capsules given once daily for one day
3025253|NCT02393937|Experimental|Test: Metronidazole Gel 1%|Metronidazole Gel 1% once daily for 70 days.
3025254|NCT02393937|Active Comparator|Reference: Metronidazole Gel 1%|Metronidazole Gel, 1% (MetroGel) Galderma S.A. once daily for 70 days.
3025255|NCT02393937|Placebo Comparator|Placebo|Placebo Gel once daily for 70 days.
3025256|NCT02393924||Participants With HER2-Positive Breast Cancer|Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.
3025257|NCT02393911|Active Comparator|Study A - with diet|Patients with LPV, treated by Low Oxalate Diet for three months.
3025258|NCT02393911|Active Comparator|Study B- no diet|Patients with LPV, not treated by Low Oxalate Diet for three months.
3025259|NCT02393911|Active Comparator|Control|Healthy women without LPV, not treated by Low Oxalate Diet
3025260|NCT02393898||Elderly Participants with Ovarian Cancer|Elderly participants aged 70 years and older administered frontline treatment for International Federation for Gynecology and Obstetrics (FIGO) stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer with bevacizumab in combination with chemotherapy according to standard of care.
3025261|NCT02393885|Experimental|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System at day 1 of surgical procedure followed by endocardial catheter ablation procedure to occur at approximately 90 days after day 1 of surgical procedure.
3025262|NCT02393872|Experimental|High-risk families component|School-based intervention and counselling sessions.
3025263|NCT02393872|Experimental|All-families component|School-based intervention.
3025264|NCT02393872|No Intervention|Control|Control group.
3025265|NCT02393859|Experimental|Blinatumomab|Subjects will be randomized to receive either blinatumomab or standard consolidation chemotherapy.
3025266|NCT02393859|Active Comparator|Conventional Consolidation Chemotherapy|Subjects will be randomized to receive either blinatumomab or standard consolidation chemotherapy.
3025267|NCT02393846|Experimental|ketoprofen|Topical ketoprofen (gel) is the experimental drug that is applied to the ankle in a dose of 2 gr.
3025268|NCT02393846|Placebo Comparator|Placebo|Topical placebo (gel) is identical in colour, form and smell with the ketoprofen gel.
3025269|NCT02393833|Active Comparator|Induction chemotherapy|Approved induction CT regimen after randomization
3025270|NCT02393833|Experimental|Induction chemotherapy followed by CM maintenance|Approved induction chemotherapy followed by 12 months of CM maintenance
3025271|NCT02393820|Experimental|pazopanib|Pazopanib per os, 800mg daily until progression
3025272|NCT02393807|Experimental|Open label single dose crossover study of PF-06260414|This will be a Phase 1, open label, randomized, single dose, 3 period, 3 way crossover study to evaluate the relative bioavailability of solid dose formulation of PF 06260414 under fasted conditions compared to the nanosuspension under fasted conditions
3025273|NCT02393794|Experimental|Romidepsin (8mg/m2) + Cisplatin (75mg/m2)|Romidepsin 8mg/m2 IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
3025274|NCT02393794|Experimental|Romidepsin (10mg/m2) + Cisplatin (75mg/m2)|Romidepsin 10mg/m2 IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
3025275|NCT02393794|Experimental|Romidepsin (12mg/m2) + Cisplatin (75mg/m2)|Romidepsin 12mg/m2 IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
3025276|NCT02393794|Experimental|Romidepsin Dose Expansion|Romidepsin maximum tolerated dose (MTD) from Phase I IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle Nivolumab 360mg on day 1 of each 21 day cycle
3025277|NCT02393768||patients|patients with documented atherosclerosis on a CCTA
3025278|NCT02393768||controls|patients without atherosclerosis on a CCTA
3025376|NCT02393131|Experimental|Hippocampal avoidance WBRT|Conformal whole brain radiotherapy with hippocampal avoidance
3026101|NCT02388152|Experimental|Lu AF20513, low dose (Cohort 1)|10 Patients with mild Alzheimer's.
3025279|NCT02393755|Experimental|Treatment (capecitabine, nintedanib)|Patients receive capecitabine PO BID (every 12 hours) on days 1-14 and nintedanib PO BID (every 12 hours) on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3025280|NCT02393742|Experimental|Sodium Nitrite Supplementation|80 mg/day (40 mg 2x/day) slow release sodium nitrite (TheraVasc, Inc) for 3 months
3025281|NCT02393742|Placebo Comparator|Placebo|placebo 2x/day for 3 months
3025282|NCT02393729|Other|children with DCD|Children with Developmental Coordination Disorder (DCD) will have neuropsychological assessment and MRI study
3025283|NCT02393729|Other|children with DD|Children with Developmental Dyslexia (DD) will have neuropsychological assessment and MRI study
3025284|NCT02393729|Other|children with DCD + DD|Neuropsychological assessment and MRI study
3025285|NCT02393729|Other|control children|Neuropsychological assessment and MRI study
3025286|NCT02393716|Other|Endovascular repair|Endurant Evo AAA Stent Graft System
3025287|NCT02393690|Experimental|Arm I (selumetinib, iodine I-131)|Patients receive selumetinib PO BID starting on week 1, day 1 and continuing through 2 days after iodine I 131 therapy has been administered. Approximately 3 weeks after beginning treatment with selumetinib, patients receive iodine I-131 PO.
3025288|NCT02393690|Active Comparator|Arm II (placebo, iodine I-131)|Patients receive placebo PO BID starting on week 1, day 1 and continuing through 2 days after iodine I-131 therapy has been administered. Approximately 3 weeks after beginning treatment with placebo, patients receive iodine I-131 PO.
3025289|NCT02393677|Placebo Comparator|Ropivacaine|amide local anesthetic
3025290|NCT02393677|Active Comparator|Ropivacaine with Dexmedetomidine|combination of amide local anaesthetic and alpha2 agonist
3025291|NCT02393664|Experimental|Nonintubated group|Patients undergoing thoracoscopic surgery using nonintubated technique with propofol and bupivacaine.
3025292|NCT02393664|Active Comparator|Intubated group|Patients undergoing thoracoscopic surgery using intubated general anesthesia with sevoflurane and rocuronium.
3025293|NCT02393651|Placebo Comparator|Sham|Motor training of the affected upper extremity combined with sham tDCS.
3025294|NCT02393651|Experimental|tDCS|Motor training of the affected upper extremity combined with dual transcranial direct current stimulation (tDCS).
3025295|NCT02393638|Experimental|study group|Simulation and lecture
3025296|NCT02393638|Active Comparator|control group|Lecture only
3025297|NCT02393625|Experimental|Dose Escalation|
3025298|NCT02393625|Experimental|Dose Expansion|
3025299|NCT02393612|Experimental|DP-R202|Patients administrate DP-R202 (Sarpogrelate 300mg) once a day for 12 weeks
3025300|NCT02393612|Active Comparator|Anplag tab|Patients administrate Anplag tab (Sarpogrelate 100mg) 3 times a day for 12 weeks
3025301|NCT02393599|Experimental|Lorcaserin|Lorcaserin (10mg) will be administered 2 times per day from Days 3 to 9 and only one time on Day 10
3025302|NCT02393599|Placebo Comparator|Placebo|Placebo will be administered 2 times per day from Days 3 to 9 and only one time on Day 10
3025303|NCT02393586|Experimental|Faropenem/augmentin|Faropenem 600mg plus amoxicillin/clavulanic acid 500mg/125mg
3025304|NCT02393586|Experimental|Rifampicin/faropenem/augmentin|Rifampicin 10mg/kg plus faropenem 600mg plus amoxicillin/clavulanic acid 500mg/125mg
3025305|NCT02393586|Experimental|Rifampicin|Rifampicin 10mg/kg
3025306|NCT02393573|Active Comparator|Metformin|Metformin will be administered as pills to be taken orally with an initial dose of 850 mg on the first day; the dose will be increased to 850 mg every 12 hours and 850mg every 8 hours respectively on the second day and then on the days to follow up to the morning of the surgery. Metformin will be discontinued on the day of surgery and will be restarted immediately after surgery.
3025307|NCT02393573|Placebo Comparator|Placebo|Placebo will be administered exactly in the similar way to Metformin
3025308|NCT02393560||Gout subjects on stable dose of allopurinol (at least 300mg)|
3025309|NCT02393547|Experimental|Varenicline + Lorcaserin|Open label all subjects receive both Varenicline and Lorcaserin
3025310|NCT02393534|No Intervention|Usual Care|Eligible patients that are randomized to the usual care arm will have a standard in-person clinic visit with their primary care provider.
3025311|NCT02393534|Experimental|Telephone visit|Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
3025312|NCT02393521|Experimental|Vibration group|Patients in the vibration therapy group received 10 self-administered sessions of vibration therapy (45-50 Hz), one session per day, remaining on their Shindo® vibration mattress at home in supine for 15 min.
3025313|NCT02393521|No Intervention|Control group|Subjects in the control group did not receive vibration therapy
3025314|NCT02393508|Active Comparator|Fresh Human Red Blood Cells|Participants will receive transfusion of human donor red blood cells that are less than or equal to 7 days of age from the time of donation.
3025315|NCT02393508|Active Comparator|Aged Human Red Blood Cells|Participants will receive transfusion of human donor red blood cells that are greater than 21 days and up to a maximum of 42 days of age from the time of donation.
3025316|NCT02393495|Experimental|Ultrasound guided group|the female will be asked to be full bladder. the trans-abdominal probe will be placed by an assistant on the suprapubic region. under speculum examination, the intrauterine device IUD (TCu 380A) will be placed till it reaches the fundus of the uterus and then released.
3025317|NCT02393495|Experimental|Non ultrasound guided group|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound.
3025318|NCT02393482|Active Comparator|Balanced estroprogestins|Women assigned to this arm will assume balanced monophasic estroprogestins (etinil-estradiol 100 mcg/levonorgestrel 20 mcg), one tablet orally daily, for 180 days.
3025319|NCT02393482|Active Comparator|GnRHa|Women assigned to this arm will assume Leuprorelin acetate (3,75 mg/2ml), one intramuscular administration every 28 days. After 45 days of treatment, therapy will be implemented with Tibolone 5 mg, one tablet daily orally, and Calcium carbonate/colecalciferol (500 mg/400 UI), one tablet daily orally. This therapy will be prosecuted for the remaining 135 days of treatment.
3025377|NCT02393131|Active Comparator|Conformal WBRT|Conformal whole brain radiotherapy without hippocampal avoidance
3025378|NCT02393118|Experimental|BrainPort V200 Device|Single Arm
3056952|NCT02181959|Active Comparator|Pharmaton® without DMAE|
3025320|NCT02393469|Placebo Comparator|Group phase 1|Two months of education and self-management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
3025321|NCT02393469|Experimental|Group phase 2|Pulmonary rehabilitation for two months: The same patients enter phase 1 phase 2 performing this two months of pulmonary rehabilitation are also included new patients who participate directly in phase 2
3025322|NCT02393469|Experimental|Group phase 3|Pulmonary rehabilitation for ten months: Participate participants of phases 1 + 2 and 2, as well as new participants enter directly in phase 3
3025323|NCT02393456|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
3025324|NCT02393456|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
3025325|NCT02393443|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
3025326|NCT02393443|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
3025327|NCT02393430|Experimental|experimental|The experimental group were treated with rebamipide 0.1g tid and optimization of life style.
3025328|NCT02393430|Placebo Comparator|control|The control group were only optimized their life style.
3025329|NCT02393417|Experimental|Cohort 1|0.3 mL of CANDIN administered intralesionally in the largest common wart
3025330|NCT02393417|Experimental|Cohort 2|0.5 mL of CANDIN administered intralesionally in the largest common wart
3025331|NCT02393417|Experimental|Cohort 3|0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
3025332|NCT02393417|Placebo Comparator|Pooled Placebo|0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
3025333|NCT02393404|Experimental|PT-FMT|Functional movement-power training group
3025334|NCT02393404|Experimental|FMT alone|Functional movement training group
3025335|NCT02393404|No Intervention|Control|No intervention control group
3025336|NCT02393391|Active Comparator|NIBS tDCS/tACS stimulation|Each patient will undergo initial diagnosis with NIBS algorithm utilizing EEG measurements combined with TMS. Initial diagnosis will last 10 minutes in which EEG measurement will be recorded 5 minutes and then in combination with TMS for another 5 minutes with no more than 500 TMS stimuli applied to cortex at low frequency of up to 5Hz. EEG recording will be analyzed by NIBS algorithm which will propose a course of treatment with the following limitations: stimulation of 2mA (32, 33) current after 30 seconds ramp up of 0.1mA increments, 20 min for each session, twice a week
3025337|NCT02393391|Placebo Comparator|inactive electrodes|diagnosis and monitoring will be performed as in active treatment, but during treatment anodal/cathodal/alternate stimulation will begin and automatically stop after 30 seconds leaving subject with an inactive electrodes in place for the remainder of treatment duration
3025338|NCT02393378|Experimental|Namilumab 150 mg|Namilumab 150 mg x 2, subcutaneous(SC) at week 0 followed therafter by 150mg SC.at weeks 2 through 22 (at intervals specified in the protocol) as an add-on to weekly existing stable MTX and Folic acid.
3025339|NCT02393378|Active Comparator|Adalimumab 40 mg|Adalimumab 40 mg, subcutaneous (SC) on weeks 0 through 22 (at intervals specified in the protocol) as an add-on to weekly existing stable MTX and Folic acid.
3025340|NCT02393365|Other|HCV screening|All patients admitted to the one day clinic for surgery and gastroenterology.
3025341|NCT02393352|Experimental|Dry Needling Therapy|The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
3025342|NCT02393352|Active Comparator|Electrical Stimulation Therapy|Diadynamic fixed current phase in active trigger points, with pulses of 10msec, and intervals of equal duration.
3025343|NCT02393339|Active Comparator|study group|Study group will receive syrup paracetamol (15 mg/kg) 15 min before the dental treatment
3025344|NCT02393339|Placebo Comparator|controll group|Control group will receive placebo syrup, designed to mimic paracetamol syrup, similar in color and viscosity, 15 min before dental treatment.
3025345|NCT02393326|Experimental|Partial pulpotomy with biodentine|Biodentine is gently applied to the pulp stumps
3025346|NCT02393326|Other|Formocresol pulpotomy|A cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min.
3025347|NCT02393313|Experimental|Cataract surgery toric intraocular lens|Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
3025348|NCT02393300|Placebo Comparator|Group1|60 Milliliters（ml）Normal saline (0.9% sodium chloride) will be applied by soaking the knee cavity for at least 3 minutes before wound closure and then sucked away.
3025349|NCT02393300|Experimental|Group2|two-dose intravenous tranexamic acid will be applied as follow: 10mg/kg of Tranexamic Acid in 100 Milliliters（ml) normal saline (0.9% sodium chloride),the first dose 15' before the tourniquet deflation and the second dose at 180' after the first dosage
3025350|NCT02393300|Experimental|Group 3|3g Tranexamic Acid diluted to 60 Milliliters（ml） with normal saline (0.9% sodium chloride) will be applied by soaking the knee cavity for at least 3 minutes before wound closure and then sucked away.
3025351|NCT02393287||Reproline|this is an observational trial ; there is no intervention
3025352|NCT02393274||28-day Survival|survive for at least 28 days after placement of extra-corporeal membrane oxygenation life support
3025353|NCT02393274||28-day Nonsurvival|not survive for 28 days after placement of extra-corporeal membrane oxygenation life support
3025354|NCT02393261|Experimental|A 2500mlGroup|use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night
3025356|NCT02393248|Experimental|Dose Escalation|"Open-label dose escalation with an accelerated titration design based on observing each dose level for a period of 21 days.~Dose Expansion~Combination therapy:~Gemcitabine + Cisplatin + INCB054828~Pembrolizumab + INCB054828~Docetaxel + INCB054828~Trastuzumab + INCB054828"
3025357|NCT02393235||unexplained infertility(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
3025358|NCT02393235||tubal infertility(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
3025359|NCT02393235||fertile group(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
3025360|NCT02393222||Patients with ESRD on HD|Adult patients with ESRD on HD. Observing the effect of a single HD session on cerebral blood flow (assessed by transcranial doppler) and cognitive function (assessed by neurocognitive questionnaires). Subgroup to undergo brain MRI.
3025361|NCT02393209|Experimental|TAK-117 200 mg + Docetaxel (36 mg/m^2)|TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m^2, intravenous (IV) infusion, on Days 1 and 8 of the 21-day cycle up ro Cycle 9 (approximately 189 days).
3025362|NCT02393209|Experimental|TAK-117 300 mg + Docetaxel 36 mg/m^2|TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m^2, IV infusion, on Days 1 and 8 of the 21-day cycle up to 6 cycles (approximately 126 days).
3025363|NCT02393209|Experimental|Phase 2 - TAK-117 + Docetaxel 36 mg/m^2|TAK-117 tablets, at the dose determined in the dose escalation phase, on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of a 21-day cycle plus Docetaxel 36 mg/m^2 IV infusion on Days 1 and 8 of a 21-day cycle.
3025364|NCT02393209|Experimental|Phase 2 - Docetaxel 75 mg/m^2|Docetaxel 75 mg/m^2, IV infusion once every 3 weeks (per approved prescribing information) with dosing on Day 1 of each 21-day cycle.
3025365|NCT02393196|Active Comparator|Group Preloading (Group P)|Group Preloading (Group P): 500 mL hydroxyethyl starch (6% HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible before spinal anesthesia.
3025366|NCT02393196|Active Comparator|Group Coloading (Group C)|Group Coloading (Group C): After the patients have been monitored, spinal anesthesia will be performed. Recognizing the cerebrospinal fluid, 500 mL hydroxyethyl starch (%6 HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible.
3025367|NCT02393183|Experimental|ASTED|"Antioxidant Supplements for TED:~to evaluate the effect of selected antioxidant vitamins and minerals supplement B-Carotene (6 mg) + Vit.C (200 mg) + Vit.E (200 mg) + Vit. Nicotinamide (20 mg) + Selenium (200 mic.)+ Zinc oxide (8 mg) + Copper oxide (1mg) +Mangeneschloride (1.8 mg)"
3025368|NCT02393183|Active Comparator|Selenium|Selenium (200mic)
3025369|NCT02393183|Placebo Comparator|Placebo|Placebo
3025370|NCT02393170|Experimental|self-training using video-games|Participants will receive a video-game console and will be asked to play video-games for one hour a day X 6 days a week for 5 weeks.
3025371|NCT02393170|Active Comparator|traditional self-training|Participants will receive a manual and kit of a traditional self-training program and will be asked to perform the program one hour a day X 6 days a week for 5 weeks.
3025372|NCT02393157|Experimental|Central Nervous System (CNS) Negative|All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients without CNS involvement will receive one dose of Liposomal cytarabine for CNS prophylaxis on day -13. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting one day prior to the Liposomal cytarabine. Dexamethasone 0.15 mg/kg/dose (max 4mg) IV BID will be given days -14 to -10. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
3025373|NCT02393157|Experimental|CNS Positive|All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients with positive CSF prior to enrollment will receive treatment with two doses of Liposomal cytarabine during the prephase portion of therapy. Liposomal cytarabine will be given intrathecally on days -13 and -5. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting the day prior to the Liposomal cytarabine. Dexamethasone will be given days -14 to -10 and days -6 through -2. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
3025374|NCT02393144|Other|Spontaneous labor arm|Women with term pregnancies whose labor started spontaneously. Spontaneous labor is determined by either spontaneous rupture of membranes at term and/or powerful, regular uterine contractions that cause cervical change. Women will be admitted to labor ward after initial assessment via transperineal ultrasonography. Labor augmentation will be performed for women with inadequate uterine contractions, i.e. contractions measuring less than Montevideo units, irregular weak uterine contractions. Analgesia will be provided via administration of 50 mg intramuscular meperidine at 2 hour intervals as required. Amniotomy will be performed for women with adequate cervical dilatation and fetal head-descent. Transperineal ultrasonography will be performed at irregular intervals to assess cervical dilatation, angle of progression and fetal head position. After birth, birth time, birth weight, APGAR scores, degree of perineal trauma, episiotomy use will be recorded.
3025375|NCT02393144|Other|Induced labor arm|Women with term pregnancies who are induced for birth before the onset of spontaneous labor. Labor will be induced with either oxytocin infusion for women with high Bishop score, or labor will be induced with dinoprostone pessary for women requiring cervical ripening, i.e. poor. Women will be admitted to labor ward after initial assessment via transperineal ultrasonography. Analgesia will be provided via administration of 50 mg intramuscular meperidine at 2 hour intervals as required. Amniotomy will be performed for women with adequate cervical dilatation and fetal head-descent. Transperineal ultrasonography will be performed at irregular intervals to assess cervical dilatation, angle of progression and fetal head position. After birth, birth time, birth weight, APGAR scores, degree of perineal trauma, episiotomy use will be recorded.
3025379|NCT02393105||Breast cancer survivor|Females finished primary breast cancer treatment including surgical operation, radiation therapy and chemotherapy.
3025380|NCT02393092|Experimental|BVA Only|Study participants in this arm will only receive a Brief Violence Awareness (BVA) intervention.
3025381|NCT02393092|Experimental|BVP Only|Study participants in this arm will only receive a Brief Violence Prevention (BVP) intervention.
3025382|NCT02393092|Experimental|Emerging Leaders plus BVP|Study participants in this arm will participate in the Emerging Leaders: East End curriculum at the Boys and Girls Club of Metro Richmond, Martin Luther King Jr. Middle School site. They will also receive a Brief Violence Prevention (BVP) intervention.
3025383|NCT02393079|Experimental|Active helmet LED|15 patients will undergo 18 sessions of transcranial LED therapy (ACTIVE HELMET) with 30 minutes duration each. The sessions take place over 6 weeks. The therapy will be performed with a helmet that covers the frontal and parietal region.
3025384|NCT02393079|Sham Comparator|Sham group|15 patients will undergo 18 sessions of transcranial LED therapy (INACTIVE HELMET) with 30 minutes duration each. The sessions take place over 6 weeks. The therapy will be performed with a helmet that covers the frontal and parietal region.
3025385|NCT02393066|Active Comparator|propofol|these patients are sedated with propofol infusion during ICU admission
3025386|NCT02393066|Active Comparator|dexmedetomidine|these patients are sedated with dexmedetomidine infusion during ICU admission
3025387|NCT02393053|Sham Comparator|subepithelial connective tissue graft|Surgery: Treatment with subepithelial connective tissue graft for gingival recession
3025388|NCT02393053|Experimental|non-pedicled buccal fat pad graft|Surgery: Treatment with non-pedicled buccal fat pad graft for gingival recession
3025389|NCT02393040|Experimental|PRP/Saline|"PRP/Saline~Briefly, for PRP preparation, approximately 18 mL of blood from each patient is drawn into a tube containing 3,8 % sodium citrate. The tubes were centrifuged at 450 g for 8 minutes, resulting in three basic layers: an erythrocyte layer at the bottom of the tube, a PRP layer in the middle, and a platelet-poor plasma (PPP) layer at the top of the tube. After removing the platelet-poor plasma (PPP) layer, the PRP is obtained, activated with 10 % calcium chloride.~In the same patient, PRP will be injected to half-head and in the other half-head will be injected with saline solution (placebo).~This study includes 4 visits: 3 visits (with 1-month interval) and 1 visit of follow-up (month 6)."
3025390|NCT02393027|Experimental|patients|10 idopathic parkinson disease
3025391|NCT02393027|Active Comparator|controls subjects|10 healthy controls (no parkinson disease)
3025392|NCT02393014|Experimental|Low fall risk|low fall risk patients
3025393|NCT02393014|Experimental|Medium fall risk|medium fall risk patients
3025394|NCT02393014|Experimental|High fall risk|high fall risk patients
3025395|NCT02393001||Dermatology patients|Patients seen in the dermatology clinic with suspicious skin lesion to be biopsied will have 4 skin swabs, 2 of the skin lesion and 2 of an area of unafflicted skin.
3025396|NCT02392988|Placebo Comparator|Group receives sham treatment|Sham treatment will be given on points on the back, points that are not acupuncture points, so that the patient will not be able to know whether she is receiving sham treatment or a real treatment. The treatment will be every 48-72 hours, a maximum of three treatments.
3025397|NCT02392988|Experimental|Group receives acupuncture treatment|The women in this group will receive acupuncture treatment every 48-72 hours, a maximum of three treatments.
3025398|NCT02392988|No Intervention|Group doesn't receive any treatment|The women in this group will come for a follow-up check a week later, unless a spontaneous birth will develop.
3025399|NCT02392975|Experimental|Fast magnetic resonance imaging (Fast MR)|All subjects will undergo fast MR in addition to Computerized Tomography (CT) (the current criterion standard). Fast MR will be interpreted independently for research purposes by 2 blinded radiologists. Consensus interpretation will be compared to the clinical reading of the CT.
3025400|NCT02392962|Experimental|Experimental I|This group performed static stretching
3025401|NCT02392962|Active Comparator|Experimental II|This group performed dynamic stretching
3025402|NCT02392949|Experimental|Experimental group|Passive mobilization on cervical spine
3025403|NCT02392949|Placebo Comparator|Control|Placebo exercise on arms
3025404|NCT02392910|Other|Group A|Placebo
3025405|NCT02392910|Other|Group B|Iron Sucrose
3025406|NCT02392897|Experimental|High Eating Frequency|6 Eating Occasions
3025407|NCT02392897|Experimental|Low Eating Frequency|3 Eating Occasions
3025408|NCT02392884|Active Comparator|EON-MEM|Intervention: Cognitive Rehabilitation and compensatory strategies will be taught to subjects to help them remember routes, viral load count, CD4 count, faces of providers and managing their schedules. Over the course of 5 visits, subjects will receive this intervention.
3025409|NCT02392884|Active Comparator|Compensatory Cognitive Training|Cognitive Rehabilitation and physical reminders, such as calendars, smart phones, self-notes and other methods to help subjects remember to attend all medical appointments and take their HIV medication. Subject will be exposed to 5 sessions of this particular training.
3025410|NCT02392884|No Intervention|Psychoeducation|The psychoeducation group, which aims to teach subjects the importance of taking medications and attending all doctor's appointment for HIV treatment. If you subjects are assigned to this group, they will be followed and receive the care generally followed for individuals with this condition.
3025411|NCT02392871|Experimental|Radiotherapy|"Palliative radiotherapy in combination with dabrafenib and trametinib Eligible subjects are patients who have been on dabrafenib and trametinib for more than 2 weeks, as the current standard management for advanced stage melanoma.~Palliative RT will be delivered to symptomatic or bulky (>2cm) soft tissue, nodal or bony metastases concurrently with dabrafenib and trametinib. Up to 3 areas of disease can be irradiated at the same time.~Following RT, dabrafenib and trametinib alone will be continued until disease progression according to RECIST 1.1 criteria."
3025412|NCT02392858|Other|Control group|Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.
3025413|NCT02392845|Experimental|Combination of Docetaxel (DTX) and Epirubicin (EPI)|
3056953|NCT02181959|Placebo Comparator|Placebo|
3025414|NCT02392832|Experimental|Intervention arm|Fourstar® granule formulation, 90day and 180 day briquettes Bti/Bs in larval habitats of malaria vectors.
3025415|NCT02392832|No Intervention|Control arm|No larvicide application.
3025416|NCT02392819|Experimental|test product|Arm: Panax ginseng
3025417|NCT02392819|Placebo Comparator|placebo product|Arm: a placebo with similar appearance but without Panax ginseng. The tablet include all the other non-active bulk ingredients.
3025418|NCT02392806|Active Comparator|BabiPlus, Respiralogics|Infants randomized to the BabiPlus device will be extubated to BabiPlus Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the B&B Bubbler device for 24 hours
3025419|NCT02392806|Active Comparator|B&B Bubbler, B&B medical Technologies|Infants randomized to the B&B Bubbler device will be extubated to B&B Bubbler Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the BabiPlus device for 24 hours
3025420|NCT02392793|Active Comparator|Arm A: Talazoparib Plus Irinotecan|"Talazoparib will be administered orally on day 1 either once or twice per day depending on the dose level of the enrolled patient. Both oral talazoparib and IV irinotecan will then be administered daily, on days 2-6. Each cycle will last 21 days. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy.~Arm A is closed to enrollment."
3025421|NCT02392793|Active Comparator|Arm B: Talazoparib Plus Irinotecan Plus Temozolomide|Once the maximum tolerated doses (MTDs) for talazoparib and irinotecan are determined, a second arm of the study will open administering talazoparib, irinotecan and temozolomide. Talazoparib will be given orally, days 1-6. Intravenous irinotecan and oral temozolomide will be given days 2-6. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy.
3025422|NCT02392780|Experimental|Cannabidiol|
3025423|NCT02392767|Active Comparator|Verum|2 times 2 tablets a day for 4 weeks.
3025424|NCT02392767|Placebo Comparator|Placebo|2 times 2 tablets a day which cornstarch. Tablets look identical like verum tablets.
3025425|NCT02392754|Experimental|Screening|The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
3025426|NCT02392754|No Intervention|Control|The control group receives standard care for 6 months (including a pulse check and heart auscultation by a physician at 6 months).
3025427|NCT02392741|No Intervention|Control|The control group will follow the IMIP prenatal routine.
3025428|NCT02392741|Experimental|Physical exercise program|The intervention group witch will be submitted to an exercise program consisting of daily post prandial, 10' after breakfast, lunch and dinner.
3025429|NCT02392728|Experimental|Intervention VE|Session of Immersive Virtual Reality (VR) and Session of Guided Imagery
3025430|NCT02392728|Active Comparator|Intervention GI|Session of Immersive Virtual Reality (VR) and Session of Guided Imagery
3025431|NCT02392715|Experimental|Intervention cohort|"36 sessions of 60 - 75 minutes with a frequency of 3x/week~30' endurance training, 15' strength training, 15' inspiratory muscle training with Threshold by Respironics~Inspiratory muscle training intensity: 15% of maximal inspiratory pressure (PiMax) during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax."
3025432|NCT02392715|Sham Comparator|Control cohort|"36 sessions of 60 - 75 minutes with a frequency of 3x/week~30' endurance training, 15' strength training, 15' sham inspiratory muscle training with Threshold by Respironics~Sham inspiratory muscle training intensity : 5 centimeters of water (cmH20)"
3025433|NCT02392702|Active Comparator|C-10355, 25 mg|single oral dose.
3025434|NCT02392702|Active Comparator|C-10358, 25 mg|single oral dose.
3025435|NCT02392702|Active Comparator|C-10355 or C-10358, 75 mg|single oral dose.
3025436|NCT02392702|Active Comparator|C-10355 or C-10358, 150 mg|single oral dose.
3025437|NCT02392702|Active Comparator|Kalydeco, 150 mg|single oral dose.
3025438|NCT02392702|Active Comparator|C-10355 or C-10358, 300 mg|single oral dose.
3025439|NCT02392689|Experimental|PCT-guided|"Blood samples are taken on day 0 and day 1 of the study. Procalcitonin (PCT) is measured and used support the decision on antibiotic therapy.~PCT levels above 0.2 ng/ml: antibiotic therapy is recommended PCT levels equal/below 0.2 ng/ml: antibiotic therapy is not recommended"
3025440|NCT02392689|No Intervention|Standard of Care|Blood samples are taken on day 0 and day 1 and stored for later analysis. The investigator treats the patients according to standard of care.
3025441|NCT02392676|Experimental|1/OLAPARIB|olaparib 300 mg oral tablets; twice daily
3025442|NCT02392676|Placebo Comparator|2/PLACEBO|placebo matching olaparib 300 mg oral tablets; twice daily
3025443|NCT02392663|Active Comparator|Hypertonic saline solution|"Hypertonic saline (7%) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).~Both patients and physiotherapist will be blind to the intervention."
3025444|NCT02392663|Active Comparator|Hyaneb solution|"Hyaneb (acid hyaluronic + hypertonic saline [7%]) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).~Both patients and physiotherapist will be blind to the intervention."
3025445|NCT02392663|Placebo Comparator|Isotonic saline solution|"Isotonic saline (0,9%) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).~Both patients and physiotherapist will be blind to the intervention."
3025446|NCT02392637|Experimental|Gemcitabine + Cisplatin + Abraxane (Nab-Paclitaxel)|"All 3 drugs administered intravenously on Day 1 and Day 8 of the cycle. Nab-Paclitaxel given at 100 mg/m2, followed by Cisplatin at 25 mg/m2 and then Gemcitabine at 800 mg/m2 for 2 weeks in a row followed by a week of rest. Cycles are 21 days.~Participant receives phone call from study staff 30 days after last dose of study drugs, and every 12 weeks thereafter."
3025468|NCT02392520|Placebo Comparator|Conventional|Women with severe early OHSS will be treated with conventional treatment, such as intravenous albumin administration, paracentesis of ascitic fluid, either on an outpatient or inpatient basis.
3025447|NCT02392624|Experimental|Omalizumab|Participants will receive open-label omalizumab treatment at 300 mg SC Q4W for 24 weeks. After 24 weeks open-label treatment, eligible participants will be randomized to receive omalizumab treatment at 300 mg SC Q4W for next 24 weeks (up to Week 48). Participants randomized to omalizumab may, at the discretion of the investigator, be transitioned from blinded study drug to open-label omalizumab at 300 mg SC Q4W if they experience clinically significant worsening in their CIU (as judged by the investigator). Participants who are transitioned to open-label omalizumab will continue to receive open-label omalizumab as study drug until Week 48.
3025448|NCT02392624|Placebo Comparator|Placebo|Participants will receive open-label omalizumab treatment at 300 mg SC Q4W for 24 weeks. After 24 weeks open-label treatment, eligible participants will be randomized to receive placebo SC Q4W for next 24 weeks (up to Week 48). Participants randomized to placebo may, at the discretion of the investigator, be transitioned from blinded study drug to open-label omalizumab at 300 mg SC Q4W if they experience clinically significant worsening in their CIU (as judged by the investigator). Participants who are transitioned to open-label omalizumab will continue to receive open-label omalizumab as study drug until Week 48.
3025449|NCT02392611|Experimental|GS-5829 (Group 1)|Cohorts will be sequentially enrolled at progressively higher dose levels to receive GS-5829 once daily. Participants in the first 3 cohorts will receive a single dose of GS-5829 and then approximately 7 days later, initiate dosing once daily. Each dose level will enroll 1 participant until a ≥ Grade 2 treatment-related toxicity is observed within the initial dosing period (Day 1 to Day 28). At Dose Level 5 or if a ≥ Grade 2 treatment-related toxicity is observed (whichever occurs first), the dose level will be expanded to 3 participants. Once a dosing level has expanded to 3 participants, a standard 3+3 study design will begin and dose escalation will be performed with cohort sizes of 3 to 6 participants.
3025450|NCT02392611|Experimental|Combination GS-5829 (Group 2)|Participants will receive escalating doses of GS-5829 in combination with either exemestane or fulvestrant.
3025451|NCT02392611|Experimental|Lymphoma Expansion (Group 3)|Participants with aggressive non-hodgkin's lymphoma (NHL) may be enrolled to receive GS-5829 at a dose no higher than the maximum tolerated dose (MTD).
3025452|NCT02392585|Active Comparator|Single tourniquet|
3025453|NCT02392585|Active Comparator|Triple tourniquet|
3025454|NCT02392572|Experimental|Arm A: ONC201 Once Every 3 Weeks|"ONC201 dosed orally once every three weeks. One cycle defined as 21 days (3 weeks).~Phase I: Cohorts consisting of one new patient per dosing level treated sequentially at rising dose levels starting at 125 mg. Enrollment at each dose level requires that all patients enrolled at the prior dose level have completed one cycle of treatment (21 days) and that dose level is deemed safe. Dose escalation continues until an maximum tolerated dose (MTD) is reached or dose level 5 is reached (625 mg), which will be declared the maximum administered dose (MAD).~Phase II: Starting dose is MTD dose from Phase I."
3025455|NCT02392572|Experimental|Arm B: ONC201 Once Every 1 Week|"ONC201 dosed orally once every 1 week. One cycle defined as 21 days (3 weeks).~Phase I: Cohorts consisting of one new patient per dosing level treated sequentially at rising dose levels starting at 125 mg. Enrollment at each dose level requires that all patients enrolled at the prior dose level have completed one cycle of treatment (21 days) and that dose level is deemed safe. Dose escalation continues until an maximum tolerated dose (MTD) is reached or dose level 5 is reached (625 mg), which will be declared the maximum administered dose (MAD).~Phase II: Starting dose is MTD dose from Phase I."
3025456|NCT02392572|Experimental|Arm C: ONC201 On First Two Consecutive Days of Every Week|"ONC201 dosed orally on the first two consecutive days of every week. One cycle defined as 21 days (3 weeks).~Phase I: Cohorts consisting of one new patient per dosing level treated sequentially at rising dose levels starting at 125 mg. Enrollment at each dose level requires that all patients enrolled at the prior dose level have completed one cycle of treatment (21 days) and that dose level is deemed safe. Dose escalation continues until an maximum tolerated dose (MTD) is reached or dose level 5 is reached (625 mg), which will be declared the maximum administered dose (MAD).~Phase II: Starting dose is MTD dose from Phase I."
3025457|NCT02392572|Experimental|Arm D: ONC201 Once Daily|"ONC201 dosed orally once daily. One cycle defined as 21 days (3 weeks).~Phase I: Cohorts consisting of one new patient per dosing level treated sequentially at rising dose levels starting at 125 mg. Enrollment at each dose level requires that all patients enrolled at the prior dose level have completed one cycle of treatment (21 days) and that dose level is deemed safe. Dose escalation continues until an maximum tolerated dose (MTD) is reached or dose level 5 is reached (625 mg), which will be declared the maximum administered dose (MAD).~Phase II: Starting dose is MTD dose from Phase I."
3025458|NCT02392572|Experimental|Arm E: ONC201 Once Daily + Cytarabine|"ONC201 orally once daily in combination with low Cytarabine 20 mg subcutaneous twice daily for 10 days. One cycle defined as 28 days (4 weeks).~Once the highest dose for Arm D (625 mg) are deemed safe (<2/6 DLTs) or the MTD is reached before that, then Phase I part of the study for Arm E will begin. The starting dose of ONC201 will be 625 mg or the MTD with the same schedule as that in Arm D. 3 + 3 algorithm will be applied for dose de-escalation."
3025459|NCT02392559|Experimental|QM evolocumab|Evolocumab subcutaneous injection every 4 weeks (QM)
3025460|NCT02392559|Placebo Comparator|Placebo|Matching subcutaneous injection every 4 weeks (QM)
3025461|NCT02392546|Experimental|Elobixibat 10 mg|elobixibat
3025462|NCT02392546|Experimental|Elobixibat 15 mg|elobixibat
3025463|NCT02392546|Experimental|Elobixibat 20 mg|elobixibat
3025464|NCT02392546|Placebo Comparator|Placebo|placebo
3025465|NCT02392533||Pre cohort group|Following 3 months of data collection (pre-cohort group), education regarding the documented intervertebral space versus the actual intervertebral space that the neuraxial anesthetic was administered will be provided to each anesthesiologist and resident. Following delivery of this information, an additional 3 months of data collection will be performed (post-cohort group) (the same as the first 3 months) to evaluate whether a practice change took place.
3025466|NCT02392533||Post cohort group.|Following 3 months of data collection (pre-cohort group), education regarding the documented intervertebral space versus the actual intervertebral space that the neuraxial anesthetic was administered will be provided to each anesthesiologist and resident. Following delivery of this information, an additional 3 months of data collection will be performed (post-cohort group) (the same as the first 3 months) to evaluate whether a practice change took place.
3025467|NCT02392520|Experimental|Antagonist|0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
3025469|NCT02392507|Experimental|Necitumumab + Nab-Paclitaxel + Carboplatin|"Induction: Necitumumab intravenously (IV) on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel IV on day 1, 8 and 15 of each cycle; carboplatin IV on Day 1 of each cycle, for a maximum of 4 cycles.~Maintenance: Necitumumab IV on day 1 and 8 of each cycle; nab-paclitaxel IV on day 1 and 8 of each cycle. Participants may continue to receive treatment until discontinuation criteria are met."
3025470|NCT02392494|Experimental|MK-1075 100 mg|HCV-infected participants will receive a single 100 mg dose of MK-1075.
3025471|NCT02392494|Experimental|MK-1075 200 mg|HCV-infected participants will receive a single 200 mg dose of MK-1075.
3025472|NCT02392494|Experimental|MK-1075 400 mg|HCV-infected participants will receive a single 400 mg dose of MK-1075.
3025473|NCT02392494|Experimental|MK-1075 800 mg|HCV-infected participants will receive a single 800 mg dose of MK-1075.
3025474|NCT02392481||Healthy subjects|
3025475|NCT02392481||Mild asthma|
3025476|NCT02392481||Moderate asthma|
3025477|NCT02392481||Severe asthma|
3025478|NCT02392468|Experimental|BI 409306 low dose|low dose of BI 409306
3025479|NCT02392468|Experimental|BI 409306 high dose|high dose of BI 409306
3025480|NCT02392455||A|
3025481|NCT02392442|Experimental|A|A lung segment (either in the lingual of the left upperlobe or the right middle lobe) will be selected. Saline (10 mL) will be instilled into the one side using a balloon tipped catheter placed into a lung subsegment and then endotoxin (4 ng/kg in final volume of 2 ml) will be instilled using a balloon tipped catheter into theopposite lung subsegment and then flushed with 10mL of saline. A second BAL will be performed at either 6, 24, or 48 hours after Endotoxin instillation.
3025482|NCT02392442|Other|B|Bronchoalveolar lavage performed with a total of 180of normal saline instilled in six 30 mL aliquots into the left (lingual) and right (middle lobe) lung segments (360 mL total).
3025483|NCT02392429|Experimental|Diagnostic (anthracycline, cytarabine, FLT PET/CT)|Patients receive anthracycline IV on days 1-3 and cytarabine IV on days 1-7 for up to 2 courses. Patients then undergo FLT PET/CT within 3 days before or after the nadir bone marrow biopsy (between days 10-17 after initiation of first induction cycle and prior to reinduction). Patients may undergo an optional FLT PET/CT prior to induction chemotherapy if it does not interfere with commencement of treatment.
3025484|NCT02392403|Experimental|Nucleus CI532 cochlear implant|
3025485|NCT02392390|Experimental|The study population|"A total of 10 leg ulcer patients will be recruted for this study. All will have the experimental treatment.~Intervention: Topical Dynamic Phototherapy (TDP)"
3025486|NCT02392377|Experimental|Arm I (paclitaxel, carboplatin, radiation therapy, surgery)|"INDUCTION: Patients receive chemotherapy with carboplatin and paclitaxel. Patients receive carboplatin (AUC=2) and paclitaxel (90 mg/m2) intravenously on days 1 and 8 of a 21 day treatment cycle for two cycles (total of 6 weeks).~CHEMORADIATION THERAPY: Patients receive carboplatin (AUC=2) and paclitaxel (50 mg/m2) intravenously once weekly for five weeks throughout the duration of their radiation which is daily (Monday through Friday).~SURGERY: Approximately 4-10 weeks after completion of chemoradiation therapy, patients undergo esophagectomy at the discretion of the treating team."
3025487|NCT02392377|Experimental|Arm II (combination chemotherapy, radiation therapy, surgery)|"INDUCTION: Patients receive mFOLFOX6 where they get oxaliplatin 85 mg/m2 intravenously on day 1, leucovorin 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV on day 1 and then 5FU at 2400 mg/m2 IV to be administered over a 46 hour period. This is repeated every 2 weeks for 3 cycles (total of 6 weeks).~CHEMORADIATION THERAPY: Patients receive oxaliplatin 85 mg/m2 IV on day 1 every 2 weeks for a total of 3 cycles (6 weeks) as well as 5FU 300 mg/m2/day over 96 hours via continuous infusion each week of radiation for a total of 6 weeks.~SURGERY: Approximately 4-10 weeks after completion of chemoradiation therapy, patients undergo esophagectomy at the discretion of the treating team."
3025488|NCT02392364|Active Comparator|Variable Treatment Dosing Arm|Group 1 will receive injections every 4 weeks until diabetic macular edema on the OCT is decreased and stable. At that point, the length of time between injections may increase, depending on how the study eye is doing. The interval between study eye treatments may maintain, increase, or decrease once the variable treatment dosing has begun. This will be determined by an algorithm designed into a computer program
3025489|NCT02392364|Active Comparator|Monthly Treatment Arm|Group 2 will receive 5 intravitreal injections, monthly, for the first 5 months of the study. After those initial injections, visits/treatment will be every 8 weeks.
3025490|NCT02392351|Experimental|Renal Denervation|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator (Vessix Renal Denervation System).
3025491|NCT02392351|Sham Comparator|Masked Procedure|Percutaneous renal angiography
3025492|NCT02392338|No Intervention|Thoracoscopic ablation group|Patients who will undergo thoracoscopic ablation only
3025493|NCT02392338|Active Comparator|Hybrid procedure|Patients who will undergo hybrid procedure (thoracoscopic ablation and eletrophyologic study with or without additional ablation)
3025494|NCT02392325|Experimental|rDEN1Δ30 and rDEN2Δ30-7169|Participants will receive the rDEN1Δ30 vaccine at Day 0. They will receive the rDEN2Δ30-7169 vaccine at Day 270.
3025495|NCT02392325|Experimental|Placebo and rDEN2Δ30-7169|Participants will receive placebo vaccine at Day 0. They will receive the rDEN2Δ30-7169 vaccine at Day 270.
3025496|NCT02392312||ATF-Fresenius S|intravenous
3025497|NCT02392286|Active Comparator|Weight-based|Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
3025498|NCT02392286|Active Comparator|Fixed dose|Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
3025499|NCT02392260|Experimental|Vasculight prototype zero level|
3025500|NCT02392247||Cardiac Surgery Patients|Single cohort of 50 consecutive cardiac surgery patients undergoing cardiopulmonary bypass. The study compares output of two technologies for determination of point of care coagulation function: thromboelastography (TEG; current care option) and the new technology Sonic Estimation of Elasticity via Resonance (SEER) Sonorheometry
3025501|NCT02392234|Experimental|VX-661/Ivacaftor combination|
3025502|NCT02392234|Experimental|Ivacaftor monotherapy|
3025503|NCT02392234|Placebo Comparator|Placebo|
3025504|NCT02392208|Other|Telavancin Before Hemodialysis|Stage 5 Chronic Kidney Disease patients receive a single dose of telavancin before their normally scheduled hemodialysis session.
3025616|NCT02391415|Active Comparator|HIV-exposed infants BCG|HIV-exposed infants vaccinated with BCG
3025505|NCT02392208|Other|Telavancin After Hemodialysis|Stage 5 Chronic Kidney Disease patients receive a single dose of telavancin immediately after their normally scheduled hemodialysis session.
3025506|NCT02392195||Single arm; Non-interventional|A convenience sample of 10-15 infants born at term gestation, that are </= 6 months of age with significant DP (defined as head flattening requiring helmet therapy) and no major health issues will be recruited into this phase 1 descriptive pilot study
3025507|NCT02392182||healthy volunteers|no intervention to be administered in this observational study, although all participants will undergo fiberoptic bronchoscopy.
3025508|NCT02392156||rFVIIIFc for hemophilia A|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
3025509|NCT02392156||non-Fc (fusion protein) replacement products for hemophilia A|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
3025510|NCT02392156||rFIXFc for hemophilia B|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
3025511|NCT02392156||non-Fc factor replacement products for hemophilia B|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
3025512|NCT02392143|Active Comparator|Printed Education Material|Participants received printed education materials (PEM) sent by first class mail.
3025513|NCT02392143|Active Comparator|Academic Detailing|Participants' primary care physicians (PCPs) received academic detailing (AD) to improve colorectal cancer screening referral and follow-up practices.
3025514|NCT02392143|Active Comparator|Academic Detailing+Telephone Education|Participants' primary care physicians (PCPs) received academic detailing (AD) to improve colorectal cancer screening referral and follow-up practices and participants received tailored telephone education (TTE).
3025515|NCT02392130|Active Comparator|Active Drug|Clobetasol propionate 0.05% ointment
3025516|NCT02392130|Experimental|Experimental Drug|LEO 130852A gel 1%
3025517|NCT02392130|Placebo Comparator|Placebo Drug|LEO 130852A placebo gel
3025518|NCT02392117||Insulin degludec|
3025519|NCT02392104|Experimental|Intervention Arm|All patients in the study will be in the intervention arm.
3025520|NCT02392091||critically ill patients|critically ill patients at the age ≥18, expected to stay in the ICU for ≥24h, with the clinical necessity for a urinary catheter and the absence of anuria
3025521|NCT02392052|Experimental|Reinvention Protocol Participants|This group will receive 6 instructor-led 2 hour long didactic presentations regarding 8 key principles of self-efficacy and experiential exercises, including goal setting and problem solving with extensive group discussion. At the end of each session, tasks are assigned to participants to be completed outside the group during the week between sessions. Experiences from these activities and practice implementing the intervention principles will be shared and discussed each week, providing additional opportunities for problem solving and positive feedback.
3025522|NCT02392052|Other|Waitlist Group|This group will include individuals randomized to receive no treatment for the 18 weeks during which the interventional group will receive the active treatment and have their progress tracked.
3025523|NCT02392039|Experimental|Group 1 - Loratadine|"Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.~Cycle 1 and 3:~Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Cycle 2 and 4:~Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs."
3025524|NCT02392039|Experimental|Group 2 - Placebo|"Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.~Cycle 1 and 3:~Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Cycle 2 and 4:~Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs."
3025525|NCT02392026|Experimental|Metronidazole Gel|Metronidazole Vaginal Gel
3025526|NCT02392013|Experimental|Home Modification Group|A tailored home-modification (home-hazard removal) intervention delivered in the home by occupational therapists over three visits and with a booster session at six months.
3025527|NCT02392013|No Intervention|Usual Care Group|Usual care by an Area Agency on Aging
3025528|NCT02392000|Experimental|WatchPAT and CBT-i Coach mobile app|Individuals use the WatchPAT sleep monitor and the CBT-i Coach app to self-manage insomnia
3025529|NCT02391987|Active Comparator|Tele-Monitoring|Tele-monitoring and health coaching in addition to standard health care
3025530|NCT02391987|No Intervention|Standard Care|Standard health care
3025531|NCT02391974|Experimental|PERIOSYAL FILL|n=15
3025532|NCT02391974|No Intervention|No treatment (untreated control)|n=15
3025533|NCT02391961|Experimental|dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo. Within the trial, each patient serves as his own control.
3025534|NCT02391961|Placebo Comparator|placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo. Within the trial, each patient serves as his own control.
3025535|NCT02391935|Experimental|RCS-01|Cultured, autologous hair follicle cells suspended in cryomedium
3025536|NCT02391935|Placebo Comparator|Placebo|cryomedium
3025537|NCT02391922|No Intervention|No first aid course, No dipatch instruction|Participants' first aid skills are tested in two scenarios without prior first aid course and no dispatch instructions during the scenarios
3025538|NCT02391922|Active Comparator|First aid course, No dispatch instructions|Participants' first aid skills are tested in two scenarios 4 to 5 months after receiving a first aid course and no dispatch instructions during the scenarios
3025617|NCT02391415|Experimental|HIV-exposed infants VPM1002|HIV-exposed infants vaccinated with VPM1002
3026102|NCT02388152|Experimental|Lu AF20513, medium dose (Cohort 2)|10 Patients with mild Alzheimer's.
3025539|NCT02391922|Active Comparator|First aid course, dispatch instructions|Participants' first aid skills are tested in two scenarios 4 to 5 months after receiving a first aid course and they are given instructions from emergency dispatch by phone during the test scenarios
3025540|NCT02391922|Active Comparator|No first aid course, dispatch instructions|Participants' first aid skills are tested in two scenarios without prior first aid course, and they are given instructions from emergency dispatch by phone during the test scenarios
3025541|NCT02391909||Group A|Vivotif 6.9-10.0 x109 CFU/capsule
3025542|NCT02391909||Group B|Vivotif 4.0-6.8 x109 CFU/capsule
3025543|NCT02391896|Other|Digital Tomosynthesis|Patient will get tomosynthesis scan
3025544|NCT02391896|Other|Dual energy|Patient will get dual energy scan
3025545|NCT02391883||Clopidogrel|Patients in Clopidogrel or Dual Antiplatelet Therapy (Clopidogrel+Acetylsalicylic acid) at the time of admission AND who are operated <24 hours after admission.
3025546|NCT02391883||Control|Patients NOT in anticoagulation treatment (Except acetylsalicylic acid) AND who are operated <24 hours after admission.
3025547|NCT02391870|Experimental|MBCT-PD|Mindfulness-based cognitive therapy adapted for perinatal women (MBCT-PD)
3025548|NCT02391857|Experimental|EGDgroup|Intervention (gastric decompression by naso(oro)-gastric tube insertion) was performed
3025549|NCT02391844|Other|Oxycodone|Xartemis XR - Oxycodone with Acetaminophen Extended Release Tablet
3025550|NCT02391818||Breast Cancer Patients receiving ACT|Adraimycin/Cytoxan/Taxol
3025551|NCT02391818||Breast Cancer patients receiving RT only|radiation therapy
3025552|NCT02391805|Placebo Comparator|Placebo, Every Other Day (QOD)|Placebo orally (PO) QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
3025553|NCT02391805|Placebo Comparator|Placebo, Once a Week (QWk)|Placebo PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
3025554|NCT02391805|Experimental|RO6864018, 1200 milligrams (mg) QOD|RO6864018 1200 mg PO QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
3025555|NCT02391805|Experimental|RO6864018, 1200 mg QWk|RO6864018 1200 mg PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
3025556|NCT02391805|Experimental|RO6864018, 800 mg QOD|RO6864018 800 mg PO QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
3025557|NCT02391805|Experimental|RO6864018, 800 mg QWk|RO6864018 800 mg PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
3025558|NCT02391792||patients|patients with septic shock
3025559|NCT02391792||control|patients without septic shock
3025560|NCT02391792||healthy volunteers|
3025561|NCT02391779|Experimental|BeneFlax® + walking training (Dash)|BeneFlax (0.8 g, twice a day) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
3025562|NCT02391779|Placebo Comparator|Placebo + walking training (Dash)|Placebo (whey powder isocaloric to BeneFlax) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
3025563|NCT02391779|Experimental|BeneFlax® + flexibility training (Dash)|BeneFlax (0.8 g, twice a day) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
3025564|NCT02391779|Sham Comparator|Placebo + flexibility training (Dash)|Placebo (whey powder isocaloric to BeneFlax) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
3025565|NCT02391766|Active Comparator|empowerment group|empowerment intervention by us for us guides
3025566|NCT02391766|Placebo Comparator|no treatment group|dementia patients treatment as usual
3025567|NCT02391727|Other|SYN004|open label study
3025568|NCT02391714|Placebo Comparator|Oxygen (Placebo)|"100% oxygen will be administered via disposable scented nasal masks 2 minutes before, throughout and 3-5 minutes after procedure.~If you are randomized to this group, you will undergo the IUD insertion (including Povidone-Iodine or Chlorhexidine swab) using standard technique."
3025569|NCT02391714|Experimental|Nitrous Oxide (NO)|"Nitrous Oxide in a fixed dose ratio of 50% nitrous/50% oxygen will be administered via disposable scented nasal masks 2 minutes before and throughout the procedure; 100% oxygen will be given after the procedure for 3-5 minutes.~If you are randomized to this group, you will undergo the IUD insertion (including Povidone-Iodine or Chlorhexidine swab) using standard technique."
3025570|NCT02391701|Experimental|Diet group|Diet program 1 day a month for 3 months in 120-minute diet sessions + Freely they receive AD food: vegetables, cheese, olive oil, mussels and wine.
3025571|NCT02391701|No Intervention|Control|No intervention
3025572|NCT02391688|Experimental|Treatment A|"Oral intake of:~caffeine 50 mg dextromethorphan 10 mg omeprazole 10 mg flurbiprofen 10 mg midazolam 1 mg"
3025573|NCT02391688|Experimental|Treatment B|"Oral intake of:~fexofenadine 25 mg"
3025574|NCT02391688|Experimental|Treatment C|"Oral intake of:~bupropion 20 mg"
3025575|NCT02391688|Experimental|Treatment D|"Oral Intake of Geneva cocktail (A+B+C):~caffeine 50 mg dextromethorphan 10 mg omeprazole 10 mg flurbiprofen 10 mg midazolam 1 mg fexofenadine 25 mg bupropion 20 mg"
3025576|NCT02391675||Appendicitis patients|Patients presenting with acute appendicitis
3025577|NCT02391662|Experimental|Nab-paclitaxel plus Gemcitabine|Nab-paclitaxel 125 mg/m2 plus Gemcitabine 1000 days 1, 8 & 15 in a 28 days cycle
3025578|NCT02391649|Experimental|Bibliotherapy program|The participants in the Problem-solving Based Bibliotherapy Program will complete the bibliotherapy (self-help) and problem-solving manual developed by the research team for caregivers of people with schizophrenia spectrum disorders over 20 weeks. In addition to the orientation, understanding about schizophrenia and its care and final review sessions (4 sessions in 3 weeks) facilitated by the research nurse, the caregivers will work independently through the modules over 15-17 weeks.
3025635|NCT02391311|Experimental|Active tDCS + Cognitive Remediation|Subjects in the active arm will be administered active transcranial direct current stimulation (tDCS) (i.e., 2.0 mA tDCS will be administered for 20 minutes and then will automatically turn off). Active group will have identical intervention engagement in 10 1-hour computerized cognitive remediation therapy sessions during active tDCS as with the sham tDCS condition.
3025579|NCT02391649|Active Comparator|Psycho-education|Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the psychoeducation group, which is guided by a validated treatment protocol based on the research team's and McFarlane and his colleagues' psychoeducation programs for schizophrenia. The program consists of 12 two-hour sessions held weekly/biweekly (similar to the bibliotherapy program, completed in 5 months), with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and ''review and future plan'.
3025580|NCT02391649|No Intervention|Routine community care|Participants in the control group (and 2 treatment groups) will receive routine psychiatric outpatient and family services.
3025581|NCT02391636|Experimental|Carbetocin arm|100 μg intravenous injection at delivery of the anterior shoulder
3025582|NCT02391636|Active Comparator|oxytocin arm|5 IU intravenous injection at delivery of the anterior shoulder
3025583|NCT02391623|Experimental|Cohort 1|Single dose level of PF-06427878 at 5 mg or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3025584|NCT02391623|Experimental|Cohort 2|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 1 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3025585|NCT02391623|Experimental|Cohort 3|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 2 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3025586|NCT02391623|Experimental|Cohort 4|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 3 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3025587|NCT02391623|Experimental|Cohort 5|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 4 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3025588|NCT02391623|Experimental|Cohort 6|Single dose level of PF-06427878 (with the same total daily dose as Cohort 5) or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3025589|NCT02391584|Experimental|XprESS|Balloon dilation of the Eustachian tube
3025590|NCT02391584|Other|Control|Continued medical management
3025591|NCT02391571|Experimental|Oxycodone/Naltrexone|Oxycodone/Naltrexone Capsules (over-encapsulated), on days 6-10, every 6 hours (at 09:00, 15:00, 21:00)
3025592|NCT02391571|Active Comparator|Oxycodone|Oxycodone Tablets (Over-encapsulated), on Days 6-10, every 6 hours (at 09:00, 15:00, 21:00)
3025593|NCT02391571|Other|Placebo Lead-In|Placebo Lead-In: Placebo Capsules (matching to Active and Experimental) on days 4-5, every 6 hours (at 09:00, 15:00, 21:00)
3025594|NCT02391545|Experimental|IPI-145 and Rituximab|"IPI-145 is administered orally and supplied as 5 mg and 25 mg formulated capsules. IPI-145 will be administered orally, twice daily, in 28-day cycles.~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26."
3025595|NCT02391545|Experimental|IPI-145 and Obinutuzumab|"IPI-145 is administered orally and supplied as 5 mg and 25 mg formulated capsules.IPI-145 will be administered orally, twice daily, in 28-day cycles.~Obinutuzumab 1000 mg will be administered intravenously (IV) beginning at Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26."
3025596|NCT02391532|Active Comparator|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA lozenges twice daily for 12 weeks
3025597|NCT02391532|Placebo Comparator|Placebo|Placebo lozenges twice daily for 12 weeks
3025598|NCT02391519||High Altitude (3000 m)|Collection of myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
3025599|NCT02391519||Low Altitude (1600 m)|Collection of myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
3025600|NCT02391506|Experimental|Cartiva|Synthetic Cartilage Implant
3025601|NCT02391493|Experimental|healthy early bilinguals|healthy early bilinguals functional magnetic resonance imaging
3025602|NCT02391493|Experimental|healthy late bilinguals|healthy late bilinguals functional magnetic resonance imaging
3025603|NCT02391493|Experimental|bilingual patients|bilingual patients suffering from low-grade glioma in the language areas functional magnetic resonance imaging
3025604|NCT02391480|Experimental|ABBV-075|Dose escalation cohorts of ABBV-075 monotherapy
3025605|NCT02391480|Experimental|ABBV-075 and venetoclax combination|Expansion cohorts of ABBV-075 and venetoclax combination therapy
3025606|NCT02391480|Experimental|ABBV-075 expansion|Expansion cohorts of ABBV-075 monotherapy
3025607|NCT02391454|Other|Group A|usual care
3025608|NCT02391454|Experimental|Group B|usual care + RunKeeper app
3025609|NCT02391441||Pulmonary arterial hypertension|Patients who are on the waiting list for double-LTX for pulmonary arterial hypertension.
3025610|NCT02391441||Control group|Control patients without increased pulmonary artery pressure (i.e. RV peak pressure <35 mmHg measured with echocardiography) who are on the waiting list for double-LTX.
3025611|NCT02391428|Experimental|Children who diagnosed with ADHD|The ADHD children will be asked to consume omega3 capsules for 6 months. Blood will be taken for omega3 analysis in day 0, after 3 and 6 months.
3025612|NCT02391428|Experimental|Control group of children without ADHD|"Blood test:~The control group of 30 children (age and gender match) without ADHD and related neuropsychiatric syndromes, who were hospitalized due to surgical or orthopedic problems. Only when blood will be taken for clinical purposes, the investigators will ask the children and their parents to allow the collection of an additional small blood tube."
3025613|NCT02391415|Experimental|HIV-unexposed infants VPM1002|HIV-unexposed infants vaccinated with VPM1002
3025614|NCT02391415|Active Comparator|HIV-unexposed infants BCG|HIV-unexposed infants vaccinated with BCG
3025615|NCT02391415|Experimental|HIV-unexposed infants VPM1002(Hyg+)|HIV-unexposed infants vaccinated with VPM1002(Hyg+)
3025618|NCT02391402|Experimental|CABA|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
3025619|NCT02391402|Placebo Comparator|TAU|"Treatment as Usual (TAU) is the usual care that patients would normally receive at the VA. TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
3025620|NCT02391389|Experimental|CPAP or PPV during DCC|Infant will receive CPAP or PPV from 30 to 90 seconds after birth while attached to the placenta, and then the umbilical cord will be cut at 90 seconds
3025621|NCT02391376|Experimental|moist heat pack group|Three sessions of 15 minutes of superficial heat through a moist heat pack on the lower back of healthy subjects
3025622|NCT02391376|Experimental|seed pack group|Three sessions of 15 minutes of superficial heat through a seed pack on the lower back of healthy subjects
3025623|NCT02391376|Experimental|gel pack group|Three sessions of 15 minutes of superficial heat through a gel pack on the lower back of healthy subjects
3025624|NCT02391363|Experimental|Calmer Life|Cognitive behavior treatment for anxiety
3025625|NCT02391363|Active Comparator|Enhanced Community Care|Enhanced information and referral services for mental health and basic needs
3025626|NCT02391350|Active Comparator|Usual Care|Patients will be managed by primary care provider with a stepped care approach supported by current practice guidelines. Initial management will include education and re-assurance for the first 4 weeks following the primary care visit. Patients in will be recommended to follow-up with their primary care provider if unsatisfied with their progress after 4 weeks. At that time decisions on further treatments and/or referrals will be made by the primary care provider in consultation with the patient consistent with usual care.
3025627|NCT02391350|Experimental|Early Intervention|Patients will receive education and re-assurance in the same manner as the usual care group and will receive physical therapy during the initial 4 weeks following enrollment. Physical therapy will be based on evidence and prior research evaluating a centralizing treatment program for patients with LBP and sciatica. The first physical therapy session will be scheduled within 3 days after enrollment and 6-8 sessions will be administered in the first 4 weeks. Each session will include a brief assessment, treatment with centralizing exercises and spinal mobilizations. Mechanical traction is an optional component. Patients will be provided handouts and instructed to perform assigned exercises at home every 4-5 hours on days between sessions.
3025628|NCT02391337|Active Comparator|Beta-blocker|In Group B, oral bisoprolol will be commenced at either 1.25mg, 2.5mg or 5mg according to the treatment schedule and uptitrated, as required, to 15mg daily. Recommended additional therapy in this arm includes diltiazem. Use of digoxin is explicitly discouraged but will not terminate participation in the study. If intolerance to bisoprolol occurs, investigators will be advised to try an alternate beta-blocker of their choosing (typically carvedilol, nebivolol, or metoprolol) at equivalent dosage.
3025629|NCT02391337|Active Comparator|Digoxin|In Group A, the maintenance dose of oral digoxin will be either 62.5mcg or 125mcg according to the pre-defined treatment schedule and uptitrated, as required, to 250mcg daily. A single loading dose of four tablets (250 or 500mcg according to target maintenance dose) will be prescribed in digoxin-naïve participants, where necessary. Recommended additional therapy in this arm includes the calcium-channel blocker diltiazem. Use of beta-blockers is explicitly discouraged but will not terminate participation in the study.
3025630|NCT02391324|Experimental|Lokomat (LOK)|Two 50-minute sessions per week. The manualized LOK walking protocol provides methods for progressing/tracking including a 5-minute overground walking session after the LOK to facilitate transfer of motor learning from the LOK to usual walking devices. The goal-based LOK program uses a standardized approach to progressing LOK body weight and guidance support and includes upper body activities while walking to encourage dual tasking and improved posture, and motor imagery practice.
3025631|NCT02391324|Experimental|Gait focused physical therapy (fPT)|Two 50-minute sessions per week. Each weekly fPT session consists of 50 minutes of active treatment, a 'dose' equivalent to time spent in active treatment in the LOK arm. Techniques that focus on body structure changes will be not be permitted (e.g., inhibitive casting, kinesiotaping, functional electrical stimulation).
3025632|NCT02391324|Experimental|LOK + fPT|Two 50-minute sessions per week. Children will receive both the LOK and the fPT protocols (content as described above for each) for the duration of the 8 to 10 week intervention phase. These will be given as two sessions of LOK one week alternating with two sessions of fPT the next week. The fPT will build on motor learning principles because the activities will allow the child to practice motor skills in a variety of different activities. Techniques focusing on body structure changes will be prohibited.
3025633|NCT02391324|No Intervention|Maintenance therapy|Consists of maintenance therapy and a weekly email from the centre's research assistant to monitor any co-interventions. Maintenance may include range of motion/stretching and basic isometric strength home program as well as up to 10 minutes per day of exercise bicycle or treadmill or general walking practice.
3025634|NCT02391311|Active Comparator|Sham tDCS + Cognitive Remediation|Subjects in the sham arm will be administered sham transcranial direct current stimulation (tDCS) (i.e., tDCS will be administered for 30 seconds and then will automatically turn off). Sham group will have identical intervention of engagement in 10 1-hour computerized cognitive remediation therapy sessions during sham tDCS as with the active tDCS condition.
3025674|NCT02390973|Active Comparator|Roux-en-Y Gastric Bypass|
3025675|NCT02390973|Active Comparator|Biliopancreatic Diversion|
3025676|NCT02390973|Active Comparator|Control|the best medical management of their diabetes, non-surgical group
3025636|NCT02391298|Experimental|Mindfulness Meditation|All participants will complete baseline assessments of variables of interest (i.e., levels of mindfulness, contrast sensitivity, cognitive inhibition, and emotional regulation skills). Participants will then undergo 8 weeks of self-directed mindfulness training with re-assessments of variables of interest completed at week 4 and week 8. All participants will be given access to meditation recordings and asked to practice the exercises in a progressive manner from mindfulness of breath to a loving/kindness meditation (each exercise twice per week). Participants will be asked at the end of study for feedback on the acceptability of the program.
3025637|NCT02391285|Experimental|pelvic floor dynamometry|
3025638|NCT02391272|Experimental|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
3025639|NCT02391259|Experimental|AMG 557|AMG 557 administered as subcutaneous and intravenous doses.
3025640|NCT02391259|Placebo Comparator|Placebo|No active drug
3025641|NCT02391246||Positron Emission Tomography Imaging|Dual time point imaging with 250 MBq of 18F-Fluorodeoxyglucose (18F-FDG)
3025642|NCT02391233|Experimental|HIV/STI Risk Reduction|This intervention tests the comparative effectiveness of E-WORTH, streamlined HIV Testing and a 5-week multimedia intervention on primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
3025643|NCT02391233|Active Comparator|Streamlined HIV Testing Alone|This intervention tests the comparative effectiveness of streamlined HIV Testing alone on primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
3025644|NCT02391220|Active Comparator|Symbiotic|LCA symbiotic fermented milk, 180 g pot, twice daily.
3025645|NCT02391220|Placebo Comparator|Placebo|heat-treated fermented milk, 180 g pot, twice daily.
3025646|NCT02391207||patients having at least one CLM|Hepatic vein-sparing hepatectomy guided by intraoperative ultrasonography
3025647|NCT02391194|Experimental|AVB-620|Eligible subjects will receive a single dose of AVB-620 as an intravenous infusion before the surgical procedure.
3025648|NCT02391181|Experimental|test product|Iron sucrose injection solution 100mg (5 mL single dose ampoule 20mg/mL elemental iron as iron sucrose in water for injection)
3025649|NCT02391181|Active Comparator|reference product|Iron sucrose injection solution 100mg (5 mL single dose vial 20mg/mL elemental iron as iron sucrose in water for injection)
3025650|NCT02391155|Active Comparator|single lumen|Single lumen needle in oocyte retrieval
3025651|NCT02391155|Active Comparator|double lumen|Double lumen needle with follicle flushing during oocyte retrieval
3025652|NCT02391142|Experimental|cardiac sympathetic nerve block|lidocaine or ropivacaine epidural injection
3025653|NCT02391142|No Intervention|non-cardiac sympathetic nerve block|
3025654|NCT02391129||Hyperion Prosthesis|Patients treated with the second generation long-stem revision prosthesis
3025655|NCT02391129||Helios Prosthesis|Patients treated with the first generation long-stem revision prosthesis
3025656|NCT02391129||Locking compression plate|Patients treated with LCP
3025657|NCT02391116|Experimental|Copanlisib (BAY80-6946)|Copanlisib (BAY80-6946) solution for IV infusion (test drug/investigational medicinal product)
3025658|NCT02391103|Experimental|NMES group|Anterior muscles of both thighs were electrically stimulated twice a day (2×30 minutes of NMES with a break of at least 30 minutes between both sessions) 7 days a week during the entire ICU stay but no longer than 14 days, starting on postoperative day 1. Highest tolerable intensity was applied.
3025659|NCT02391103|Sham Comparator|Control group|In the control group, the electrodes were applied, connected to the stimulator, but no electricity was delivered.
3025660|NCT02391090|Experimental|hypoxia|"The hypoxia group receives normobaric hypoxic air while sitting in a hypoxic chamber simulating 2800 meter above sea level.~Interventions: hypoxia in hypoxic chamber, asthma and Quality of Life Questionnaires, lung function testing, blood taking, FeNO measurement, pulse oximetry"
3025661|NCT02391090|Sham Comparator|sham hypoxia|"The sham group receives normal air while sitting in a hypoxic chamber in about 360 meter above sea level (Graz, Austria).~Interventions: sham hypoxia in hypoxic chamber, asthma and Quality of Life Questionnaires, lung function testing, blood taking, FeNO measurement, pulse oximetry"
3025662|NCT02391077|No Intervention|Control Arm|Standard PrePex Procedure
3025663|NCT02391077|Experimental|Arm 1 - Maximal intervention|"Foreskin disinfection with Povidone-Iodine~Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus~Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days"
3025664|NCT02391077|Experimental|Arm 2 - Medium intervention|"Foreskin disinfection with Povidone-Iodine~Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus"
3025665|NCT02391064|Experimental|Patient|MS Relapsing-remitting under interferon beta-1b treatment in inclusion, Secondary progressive and Primary progressive MS forms
3025666|NCT02391064|Experimental|Control|healthy subject
3025667|NCT02391051|Experimental|Focal Brachytherapy|HDR-Brachytherapy, 2 fractions within at least 24 but max. 30 hours, each 13,5 Gy
3025668|NCT02391038|Experimental|MLN0264|"Phase 1: MLN0264 1.2 milligram per kilogram (mg/kg) starting dose, Intravenous (IV), on Day 1 of 3 week cycles, for up to 1 year or until disease progression or unacceptable toxicity. Dosage of MLN0264 will be increased to 1.5 mg/kg then 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 Dose (RP2D).~Phase 2: MLN0264, IV, on Day 1 of 3 week cycles, for up to 1 year or until disease progression or unacceptable toxicity. Dosage for this phase will be determined from results of Phase 1 MTD/RP2D."
3025669|NCT02391025|No Intervention|Gallium-68 citrate|
3025670|NCT02391012|Experimental|Fecal microbial l transplantation|patients with active colitis who will undergo treatment by fecal microbial transplantation
3025671|NCT02390999|No Intervention|24 hours of therapeutic hypothermia|24 hours of therapeutic hypothermia to a target temperature of 32-34 degrees in comatose cardiac arrest patients is standard treatment in Denmark.
3025672|NCT02390999|Experimental|48 hours of therapeutic hypothermia|48 hours of therapeutic hypothermia to a target temperature of 32-34 degrees
3025673|NCT02390973|Active Comparator|Sleeve gastrectomy|
3025677|NCT02390960|Active Comparator|Sildenafil|Sildenafil (SST-6006) is a preserved, white to off-white, topical cream. The active ingredient is 5% sildenafil citrate by weight. During the SST-6006 dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. The plethysmography session will be approximately 75 minutes. This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
3025678|NCT02390960|Placebo Comparator|Placebo|Placebo cream will be the same as SST-6006 without the active ingredient, sildenafil citrate. It will be matched in appearance, smell, consistency, and color to SST-6006 topical sildenafil cream. During the placebo cream dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. The plethysmography session will be approximately 75 minutes. This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
3025679|NCT02390947|Experimental|Famitinib arms|Famitinib 25 mg p.o. qd and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
3025680|NCT02390947|Placebo Comparator|Control arms|Placebo 25 mg p.o. qd and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
3025681|NCT02390934|Experimental|Radium 223|Radium-223 (Xofigo®) will be supplied in vials as a ready-to-use solution for intravenous administration. The activity (administered radioactivity) will be 50 kBq/kg b.w., and multiple treatment activities up to 6 injections will be administered at intervals of 4 weeks.
3025682|NCT02390921|Active Comparator|Liosomated iron therapy|Fisiogen Ferro Forte 28mg every day po, during 3 months
3025683|NCT02390921|Experimental|Endovenous Iron Therapy|Venofer 300mg endovenously every 3 months
3025684|NCT02390908|Experimental|Immediate PLUS intervention|Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
3025685|NCT02390908|Active Comparator|wait-list PLUS condition|Received the PLUS intervention at 12 months post baseline
3025686|NCT02390895|Experimental|Minimally-invasive endoscopic repair|endoscopic repair of myelomeningocele before 26 SA
3025687|NCT02390895|Other|surgery at birth|Non eligible pregnant women because of foetal or maternal reasons or women refusing the prenatal surgery
3025688|NCT02390882|Placebo Comparator|Placebo|Tamsulosin placebo (12 weeks)
3025689|NCT02390882|Experimental|Treatment 1|HGP0412 capsule (12 weeks)
3025690|NCT02390882|Experimental|Treatment2|HIP1402 capsule (12 weeks)
3025691|NCT02390869|Experimental|R2-MANT|A) Rituximab B) Lenalidomide
3025692|NCT02390869|Active Comparator|R-MANT|A) Rituximab
3025693|NCT02390856|Active Comparator|Volar Plate|Patients in this group will undergo distal radius fracture fixation with a traditional volar plate.
3025694|NCT02390856|Experimental|Conventus DRS|Patients in this group will undergo distal radius fracture fixation with the Conventus DRS intramedullary fixation device.
3025695|NCT02390843|Experimental|simvastatin + topotecan/cyclophosphamide|During dose escalation (phase I), standard 3+3 design will be followed.
3025696|NCT02390830|Experimental|Intervention|Participants in the intervention group received at least 25-45' of balance treatment. The balance treatments were aimed at improving participants' control of the position and movement of the center of mass and body segments during static, dynamic and transitional tasks.
3025697|NCT02390830|Active Comparator|Control|Participants in the control group were treated to reduce limitations at body function and activity levels, while treatment for balance disorders was restricted to a maximum of 10' per session. Treatment mainly focused on increasing range of joints motion, reducing of muscle contractures and strength training.
3025698|NCT02390817|Active Comparator|Sugammadex|At the wakeup status Sugammadex 2 mg/kg single dose will perform.
3025699|NCT02390817|Placebo Comparator|Neostigmine|At the wakeup status Neostigmine 0,04 mg/kg single dose will perform.
3025700|NCT02390804|Experimental|single-port laparoscopic hysterectomy|total laparoscopic hysterectomy via transumbilical single port
3025701|NCT02390804|Active Comparator|multi-port laparoscopic hysterectomy|total laparoscopic hysterectomy via multi-port (3 port)
3025702|NCT02390791|Experimental|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
3025703|NCT02390791|Active Comparator|treatment as usual standard portal|Standard version of myADHDportal.com web software
3025704|NCT02390778|Experimental|Debrief Group|The debrief group participated in 3 consecutive face-to-face group debriefing sessions lasting 1.5-2 hrs each. Each session started with a fun ice-breaker to create a relaxed atmosphere and group cohesion. Session 1 focused on encouraging group participation, discussing primary trauma encountered and emotional reactions to these stories. Session 2 connected current experiences with the group members' own trauma histories and life experiences. The last session focussed on societal and community responses to violence, and employing personal agency to find constructive ways to address violence in communities.
3025705|NCT02390778|Placebo Comparator|Control Group|The control group was assigned to a leisure activity (film showing), for every session of debriefing undergone by the intervention group. The films were chosen for their light-hearted uplifting content and presented as a fun and relaxing activity.
3025706|NCT02390752|Experimental|1|Take oral drug daily for 28 day cycle
3025707|NCT02390739|Experimental|Single Arm|All patients will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine followed by antithyroglobulin mTCR PBL and aldesleukin.
3025708|NCT02390726|Sham Comparator|Control|Sham FMT and Sham Microbial Maintenance plus standard therapy
3025709|NCT02390726|Experimental|Treatment|FMT and microbial maintenance plus standard therapy
3025710|NCT02390713|Experimental|MID-AVR|Tolerance and functionality of MID-AVR during surgery (Phase A) and after surgery (Phase B)
3025711|NCT02390700||Golimumab Intravenous|Participants with rheumatoid arthritis (RA) in Canada, will be observed for 24 months. Only data available from source documentation will be collected.
3025712|NCT02390687|Placebo Comparator|Placebo Arm|Placebo Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
3025713|NCT02390687|Experimental|Probiotic Arm|L. brevis CD2 Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
3025714|NCT02390674|Active Comparator|Ciclosporin|Single intravenous administration of ciclosporin (2.5mg per kilogram body weight) immediately prior to reperfusion during primary percutaneous coronary intervention. Ciclosporin is dissolved in saline (maximum concentration 2.5mg per millilitre)
3025715|NCT02390674|Placebo Comparator|Saline|Single intravenous administration of placebo (saline) immediately prior to reperfusion during primary percutaneous coronary intervention
3025716|NCT02390661|No Intervention|No drain|Control group
3025717|NCT02390661|Experimental|Penrose drain placement|Placement of a penrose drain after irradiation catheter is removed
3025718|NCT02390648|Experimental|Ginger|Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
3025719|NCT02390648|Placebo Comparator|Placebo|Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
3025720|NCT02390635|Experimental|PET/CT + Whole Body MRI|Participants receive an injection of 18F-FDG prior to whole body magnetic resonance imaging (MRI). MRI images taken, then participants receive an injection of gadolinium contrast agent 2 mL/sec and 0.1 mmol/kg of body weight followed by a 20-cc saline flush. MRI images are then completed. Immediately following whole body MRI, standard positron emission tomography/ computed tomography (PET/CT) performed.
3025721|NCT02390622|Other|FMT treatment|Treat the patients by fecal microbiota transplantation
3025722|NCT02390609|Experimental|Group 1: Sequence 1 (ABC)|Participants will receive Treatment A (Ibrutinib 560 milligram [mg] capsules [reference] under fasted conditions) in Period 1; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 2; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 3. A washout period of 7 (plus [+] / minus [-] 2) days will be maintained between each treatment period.
3025723|NCT02390609|Experimental|Group 1: Sequence 2 (BCA)|Participants will receive Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 1; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
3025724|NCT02390609|Experimental|Group 1: Sequence 3 (CAB)|Participants will receive Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
3025725|NCT02390609|Experimental|Group 1: Sequence 4 (ACB)|Participants will receive Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 1; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 2; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
3025726|NCT02390609|Experimental|Group 1: Sequence 5 (BAC)|Participants will receive Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
3025727|NCT02390609|Experimental|Group 1: Sequence 6 (CBA)|Participants will receive Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 1; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
3025728|NCT02390609|Experimental|Group 2: Sequence 1 (AFDE)|Participants will receive Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 1; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 2; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 3; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
3025729|NCT02390609|Experimental|Group 2: Sequence 2 (DAEF)|Participants will receive Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 3; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
3025730|NCT02390609|Experimental|Group 2: Sequence 3 (EDFA)|Participants will receive Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 1; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 2; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 3; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
3025731|NCT02390609|Experimental|Group 2: Sequence 4 (FEAD)|Participants will receive Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 1; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
3025732|NCT02390596|Experimental|Anakinra|
3025733|NCT02390583|Active Comparator|control|CBT treatment of internet dependence each two weeks during 3 months
3025734|NCT02390583|Experimental|intervention|CBT treatment of internet dependence plus CBT treatment of sleep disorders during 3 months
3025735|NCT02390570|Experimental|Implementation Arm|
3025736|NCT02390557|No Intervention|Control - Standard Practice|Standard measures of quality as scheduled through One Care demonstration
3025802|NCT02390154|Experimental|Arm 2|Open label non-randomized non controlled multiple dose study in Cycle 2 and subsequent cycles
3025737|NCT02390557|No Intervention|Survey Arm|Consumer surveyed with Persons with Disabilities Quality Survey (PDQ-S) Results given to provider along with standard quality metric data as scheduled through One Care
3025738|NCT02390557|Experimental|YES Health|Initiative created by persons with disabilities for persons with disabilities to actively engage in collecting, analyzing and reporting on quality of care from the consumer perspective. The purpose is to engage eligible enrollees to answer brief surveys surrounding various themes about the care and experiences they receive through One Care. Subsequent brief, actionable reports are fed back to primary care provider practices randomized to this arm.
3025739|NCT02390544|Experimental|Melphalan in Patients Receiving HSCT|"The investigators will recruit approximately 30 patients who are scheduled to undergo allogeneic transplant with reduced intensity conditioning that includes melphalan. Approximately 10 patients who will receive melphalan as part of their conditioning regimen for an autologous transplant will also be recruited.~A test dose of melphalan will be administered prior to the start of the HSCT preparative regimen. The test dose will equal 10% of the standard dose. Blood samples will be drawn for pharmacokinetic measurement prior to and after the administration of the test dose and again around the full standard dose of melphalan. Urine samples will also be collected around the test dose and full standard dose of melphalan to measure markers of kidney injury."
3025740|NCT02390531|Experimental|Bevacizumab|Dosage if injected Bevacizumab to be studied
3025741|NCT02390518|Experimental|Stereotactic Radiosurgery|
3025742|NCT02390505|Experimental|Vitamin C|Patients receive vitamin C at a daily dose of 500 mg orally: 7 days before and during 6 weeks after surgery
3025743|NCT02390505|Placebo Comparator|Placebo|Patients receive placebo at a daily dose of 500 mg orally: 7 days before and during 6 weeks after surgery
3025744|NCT02390492|Experimental|Ipatasertib/[14C]-ipatasertib|
3025745|NCT02390479|Active Comparator|Chronic periodontitis|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
3025746|NCT02390479|Placebo Comparator|clinically healthy periodontium|GCF samples were taken at baseline Intervention: oral hygiene instructions
3025747|NCT02390466|Experimental|VAC-3S|32µg/ml corresponding to 16µg/vaccination
3025748|NCT02390453|Experimental|Combined Cognitive and Physical|This consists of 45 minutes of Cognitive arm + 45 minutes of Physical arm (90 minutes total), 3 days a week for 12 weeks (36 sessions).
3025749|NCT02390453|Active Comparator|Cognitive|This consists of 45 minutes of cognitive modules from Posit Science, 3 days a week for 12 weeks (36 sessions).
3025750|NCT02390453|Active Comparator|Physical|This consists of 45 minutes of multi-modal physical exercise, 3 days a week for 12 weeks (36 sessions).
3025751|NCT02390453|Sham Comparator|Control|This consists of 45 minutes of group discussion and instruction in health self-management and successful aging, 2 days a week for 12 weeks (24 sessions).
3025752|NCT02390440|Experimental|EXPAREL|single dose, 266mg (20mL) of EXPAREL injected to slowly infiltrate the soft tissue around the site of fracture
3025753|NCT02390427|Experimental|Arm A|"Arm A~- Taselisib with Trastuzumab emtansine (also called T-DM1)~Taselisib administered orally, daily in each treatment cycle (3 weeks).~Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks)."
3025754|NCT02390427|Experimental|Arm B|"Arm B~-Taselisib with T-DM1 and Pertuzumab~Taselisib is administered oral, daily or every other day per treatment cycle (3 weeks).~Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks).~Pertuzumab- administered once via IV per treatment cycle (3 weeks)."
3025755|NCT02390427|Experimental|Arm C|"Arm C:~Taselisib with Pertuzumab and Trastuzumab~Cohort C will not open without additional authorization from Genentech~Taselisib is administered oral, daily in each treatment cycle (3 weeks).~Trastuzumab administered once via IV per treatment cycle (3 weeks).~Pertuzumab- administered once via IV per treatment cycle (3 weeks)."
3025756|NCT02390427|Experimental|Arm D|"Arm D~Taselisib with Pertuzumab, Trastuzumab, and Paclitaxel~Cohort will not be opened without additional authorization from Genentech~Taselisib- administered oral, daily in each treatment cycle (3 weeks).~Pertuzumab- administered once via IV per treatment cycle (3 weeks).~Trastuzumab administered once via IV per treatment cycle (3 weeks).~Paclitaxel- administered via IV, weekly for 3 weeks within each cycle."
3025757|NCT02390414||HSCT|Patients with higher-risk myelodysplastic syndrome (MDS) aged 60-75 who are fit for HSCT and actually undergo HSCT.
3025758|NCT02390414||No HSCT|Patients with higher-risk myelodysplastic syndrome (MDS) aged 60-75 who are fit for HSCT but do not undergo HSCT.
3025759|NCT02390401|Experimental|Vacuum-assisted closure (VAC)|Prevena (VAC) device
3025760|NCT02390401|Active Comparator|Standard sterile dressing|Standard sterile dressing
3025761|NCT02390388|Active Comparator|pudendal block group|nerve stimulated pudendal nerve block performed under general anesthesia
3025762|NCT02390388|Active Comparator|Caudal block group|caudal block performed under general anesthesia
3025763|NCT02390375|Experimental|A|DW-0929
3025764|NCT02390375|Active Comparator|B|Rosuvastatin
3025765|NCT02390362|Experimental|Rituximab|Rituximab 375 mg/m2 will be administered intravenously on Study weeks 1 & 3.
3025766|NCT02390362|Active Comparator|Mycophenolate Mofetil (MMF)|Mycophenolate Mofetil will be continued in the patients in the MMF arm at a standard oral dose of 600 mg/m2 PO, BID starting on Study week 1 and continuing for 12 months
3025767|NCT02390349|Experimental|CuraMed (BCM-95)|67 patients, treatment with CuraMed (BCM-95), one capsule (500 mg) orally, three times daily for 12 weeks
3025768|NCT02390349|Experimental|Curamin|67 patients, treatment with Curamin, one capsule (500 mg) orally, three times daily for 12 weeks
3025769|NCT02390349|Placebo Comparator|Placebo|67 patients, treatment with placebo, one capsule (500 mg) orally, three times daily for 12 weeks
3025770|NCT02390336|Experimental|Real mobilization-with-movement (MWM)|"In each volunteer of this group, the blind assessor will perform the pre-intervention measurements of intensity of pain, range of motion and physical function tests.~Next, the therapist will performed the real mobilization-with-movement. Then, all measurements, before described, will be repeated, by the assessor."
3025803|NCT02390141|Experimental|ZP4207|Five multiple doses of ZP4207 in ascending doses
3025804|NCT02390141|Placebo Comparator|Placebo|Five multiple doses of corresponding placebo in ascending doses
3025805|NCT02390128||mothers and babies|pregnant mothers (UK resident) and their babies (observational, not an intervention)
3025771|NCT02390336|Sham Comparator|Sham mobilization-with-movement (MWM)|"In each volunteer of this group, the blind assessor will perform the pre-intervention measurements of intensity of pain, range of motion and physical function tests.~Next, the therapist will performed the sham mobilization-with-movement. Then, all measurements, before described, will be repeated, by the assessor."
3025772|NCT02390323|Experimental|Lumbar Sympathetic Block|Patients receiving a Lumbar Sympathetic Block as treatment for lower extremity pain. Skin conductance algesimeter will be used to measure sympathetic activity.
3025773|NCT02390310|Active Comparator|Phase 1 - 7 Day Removal|Shang Ring No Flip Technique: Removal of Shang Ring and assessment of healing 7 days after circumcision with no-flip technique.
3025774|NCT02390310|Active Comparator|Phase 1 - Delayed Removal|Shang Ring No Flip Technique: Removal of ring or assessment of spontaneous detachment at more than 7 days to assess occurrence and safety following circumcision with the no-flip technique.
3025775|NCT02390310|Active Comparator|Phase 2 - Topical Anesthesia|Comparison of Anesthesia methods for Shang Ring circumcision: Assessment of pain during and after surgery using topical anesthesia.
3025776|NCT02390310|Active Comparator|Phase 2 - Injectable Anesthesia|Comparison of Anesthesia methods for Shang Ring circumcision: Assessment of pain during and after surgery when using injectable anesthesia.
3025777|NCT02390297||Single|Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
3025778|NCT02390284|No Intervention|Abnormal PERG Untreated|Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to not receive therapy or intervention.
3025779|NCT02390284|Experimental|Abnormal PERG Treated|"Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to receive one or more drops in each eye in order to reduce the intraocular pressure by 20%.~Drugs could be:~Latanoprost 1 drop Once a day (QD) Bimatoprost 1 drop QD Travoprost 1 drop QD Timolol 1 drop Twice a day (BID) Dorzolamide 1 drop Three times a day (TID) Brinzolamide 1 drop BID Acetazolamide and Methazolamide depends on clinicians evaluation.~If Clinicians consider necessary, he/she might combine 2 drugs in order to get the desired intraocular pressure."
3025780|NCT02390284|No Intervention|Normal|Patients with a normal PERG test that will go through the study under observation.
3025781|NCT02390271|Experimental|emotion focused therapy training CCT|The general training includes in an individual adjusted way the following techniques: biofeedback-assisted breathing classes that erase negative emotion involving the cardiac and limbic neural pathways, control one's own and other's emotions, mastering positive cognition and enhance self-concept, anchoring positive memories, learning how to recognize psychological reversal in others
3025782|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 1|8 subjects (6 receiving 10mg XEN-D0103, 2 receiving placebo)
3025783|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 2|8 subjects (6 receiving 30mg XEN-D0103, 2 receiving placebo)
3025784|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 3|8 subjects (6 receiving 60mg XEN-D0103, 2 receiving placebo)
3025785|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 4|8 subjects (6 receiving 120mg XEN-D0103, 2 receiving placebo)
3025786|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 5|8 subjects (6 receiving 200mg XEN-D0103, 2 receiving placebo)
3025787|NCT02390258|Experimental|Part 2: Fed-Fasted|17 subjects receiving 200mg XEN-D0103 with either a high fat meal or following an overnight fast.
3025788|NCT02390258|Experimental|Part 3: Multiple Ascending Dose - Cohort 1|10 subjects (8 receiving 30mg XEN-D0103 twice daily, 2 receiving placebo twice daily)
3025789|NCT02390258|Experimental|Part 3: Multiple Ascending Dose - Cohort 2|10 subjects (8 receiving 60mg XEN-D0103 twice daily, 2 receiving placebo twice daily)
3025790|NCT02390258|Experimental|Part 3: Multiple Ascending Dose - Cohort 3|10 subjects (8 receiving 150mg XEN-D0103 once daily, 2 receiving placebo once daily)
3025791|NCT02390245|Experimental|Enhanced Intervention Group|Use of patient navigation and social worker: Patients randomized to Group 1 will be referred to a general ophthalmologist close to the current health center or PCP office where they received the undilated eye exam. Prior to all follow-up visits, patients in the enhanced group who have scheduled an appointment will receive a personal phone call reminding them to attend. These patients will receive any necessary interpretation services and educational materials.
3025792|NCT02390245|No Intervention|Usual care group|Patients randomized to Group 2 will be recommended to follow-up for eye care with a local ophthalmologist. These patients will be scheduled for their initial follow-up visit based on the recommendations of our study physicians so the research team is able to track outcomes. Group 2 represents a realistic choice currently available for patients. Practice patterns will vary depending on the resources, staff time, and services available within each local ophthalmology practice.
3025793|NCT02390232||NAFLD with simple steatosis|Patients with NAFLD with simple steatosis: collection of stools, blood sample and liver biopsy
3025794|NCT02390232||NAFLD with steatohepatitis|Patients with NAFLD with steatohepatitis: collection of stools, blood and liver biopsy
3025795|NCT02390219|Experimental|Lumacaftor/Ivacaftor combination|Lumacaftor 400 milligram (mg) and ivacaftor 250 mg combination tablet orally twice daily for 24 weeks.
3025796|NCT02390206||Botulinum toxin type A (BoNT-A) injection Naïve|Subjects naïve to BoNT-A treatment. Investigators follow their individual injection protocol for treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines).
3025797|NCT02390193|Experimental|Hemodialysis|Chronic kidney disease patients undergoing hemodialysis will be recruited consecutively and screened for eligibility using a standardised protocol.
3025798|NCT02390180||Sorting all tastes|This group will receive 15 samples to taste and sort into groups. The samples included: a blank solution, hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, sodium chloride (2), citric acid, acetic acid, quinine, urea, monosodium glutamate, and inosine monophosphate.
3025799|NCT02390180||Sorting bitter tastes|This group will receive 12 samples to taste and sort into groups. The samples included: blank solutions (2), decenoic acid, oleic acid, linoleic acid, quinine (2), urea (2),caffeine, sucrose octaacetate, and propylthiouracil.
3025800|NCT02390167|Experimental|Persons With Diabetes|Untrained Subjects WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System).
3025801|NCT02390154|Experimental|Arm 1|Open label non-randomized non-controlled mass balance study in Cycle 1
3025806|NCT02390115|Active Comparator|Elastic Tape|"Tape placing will consider as the initial anchor the acromioclavicular joint, and as the final one the point immediately below the insertion of the deltoid muscle. Two centimeters anchor will be considered for all the participants, and the active zone will be equivalent to the distance between two anchors. The first tape will be placed to the anterior portion of the deltoid with the shoulder at 30° passive extension. The second tape will be placed to the middle portion of the deltoid with the shoulder at 30° of passive horizontal adduction. For placing the third tape to the posterior deltoid, the limb will be positioned at 90° of passive flexion of the shoulder. The elastic tape tension will be placed as previously described as paper tension and it is equivalent to 10-15% of the total elastic tape tension."
3025807|NCT02390115|Sham Comparator|Sham|The sham elastic tape will be placed using the same tape to the paretic shoulder. However, the rigid tape will be placed without tension with the upper limb supporting at 90 degree elbow flexion, 0 degrees abduction and adduction of the shoulder.
3025808|NCT02390102|Active Comparator|Erythropoietin|Dose: darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose Administered at days 10 (±4) and 1 (±1) before the index procedure.
3025809|NCT02390102|Placebo Comparator|Placebo|Dosage: Saline solution 0.9% Administered at days 10 (±4) and 1 (±1) before the index procedure.
3025810|NCT02390089|Active Comparator|Healthy control|Healthy age-matched adult participants with no history of Parkinson's disease Participants in this group will receive capsaicin vapor cough provocation test. The vapor will be delivered using a small hand-held nebulizer.
3025811|NCT02390089|Experimental|Parkinson's disease - no PA|People with Parkinson's disease without penetration or aspiration during swallowing; based on results of videofluoroscopic swallow evaluation. Participants in this group will receive capsaicin vapor and fog cough provocation test using a small, hand-held nebulizer.Participants in the group will also receive a fluoroscopic swallow evaluation.
3025812|NCT02390089|Experimental|Parkinson's disease - PA|People with Parkinson's disease with penetration or aspiration during swallowing;based on results of videofluoroscopic swallow evaluation.Participants in this group will receive capsaicin vapor and fog cough provocation test using a small, hand-held nebulizer. Participants in the group will also receive a fluoroscopic swallow evaluation.
3025813|NCT02390076|Active Comparator|Left active LLLT|Active LLLT targeting the left forehead
3025814|NCT02390076|Active Comparator|Right active LLLT|Active LLLT targeting the right forehead
3025815|NCT02390076|Sham Comparator|Sham LLLT|Sham LLLT targeting the right forehead
3025816|NCT02390063|Experimental|CHAMVA standard regime|ChAdOx1.5T4 prime followed by two boost of MVA.5T4 vaccine at 4 week intervals until radical prostatectomy
3025817|NCT02390063|Experimental|CHAMVA+CTX standard regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by two boost of MVA.5T4 at 4 week intervals until radical prostatectomy.
3025818|NCT02390063|Active Comparator|MVA standard regime|Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
3025819|NCT02390063|Active Comparator|MVA+CTX standard regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination.Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
3025820|NCT02390063|Experimental|CHAMVA accelerated regime|ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
3025821|NCT02390063|Experimental|CHAMVA+CTX accelerated regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
3025822|NCT02390063|Experimental|CHAMVA accelerated regime AS|ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later. Patients continue on active surveillance.
3025823|NCT02390063|Experimental|CHAMVA+CTX accelerated regime AS|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later. Patients continue on active surveillance.
3025824|NCT02390050|Active Comparator|Bexagliflozin tablets, 5 mg|Bexagliflozin tablets, 5 mg, once daily by mouth before breakfast
3025825|NCT02390050|Active Comparator|Bexagliflozin tablets, 10 mg|Bexagliflozin tablets, 10 mg, once daily by mouth before breakfast
3025826|NCT02390050|Active Comparator|Bexagliflozin tablets, 20 mg|Bexagliflozin tablets, 20 mg, once daily by mouth before breakfast
3025827|NCT02390050|Placebo Comparator|Bexagliflozin tablets, placebo|Bexagliflozin tablets, placebo, once daily by mouth before breakfast
3025828|NCT02390024||Critically ill patients|Mechanical Ventilation
3025829|NCT02390011||MRI|Day 1
3025830|NCT02389998|Experimental|Placebo|Arm 1: Subjects take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary for a period of three weeks. Subjects will also have access to hyoscyamine as a rescue medication.
3025831|NCT02389998|Other|No Treatment|Arm 2: Subjects receive no treatment but have access to hyoscyamine as a rescue medication.
3025832|NCT02389985|Experimental|CRLX101 and weekly paclitaxel|CRLX101 and weekly paclitaxel administered by IV on days 1 and 15 of a 28 day cycle. Paclitaxel only is administered by IV on day 8.
3025833|NCT02389972||CML patients treated with dasatinib|Cohort of chronic myeloid leukemia patients treated with second-line dasatinib (Sprycel)
3025834|NCT02389959|Experimental|Bevacizumab|The Stanford Hospital Investigational Pharmacy will perform all randomization, drug storage and management, as well as mixing and packaging for double-blinded injection of bevacizumab or saline control. Patients will undergo standard-of-care bipolar electrocautery of nasal telangiectasias in the Stanford Surgery Center operating room. At the time of electrocautery, patients will receive intranasal injection of either study drug or saline control. The surgeon performing the injection will be blinded to whether injection is composed of bevacizumab or saline control. Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose. Injections will be performed according to the standardized four-point injection protocol (0.5mL/site) based on the vascular anatomy of the nose published in 2012 by Dheyauldeen et al.
3025897|NCT02389504|Active Comparator|Standard Physical Therapy Protocol|Regular Physical Therapy Protocol. Standard treadmill running, monitoring heart rate
3025985|NCT02388919|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
3025986|NCT02388919|Placebo Comparator|Placebo|Placebo p.o, qd and it should be continued until disease progress or patients withdraw consent
3025835|NCT02389959|Placebo Comparator|Saline Control|The Stanford Hospital Investigational Pharmacy will perform all randomization, drug storage and management, as well as mixing and packaging for double-blinded injection of bevacizumab or saline control. Patients will undergo standard-of-care bipolar electrocautery of nasal telangiectasias in the Stanford Surgery Center operating room. At the time of electrocautery, patients will receive intranasal injection of either study drug or saline control. The surgeon performing the injection will be blinded to whether injection is composed of bevacizumab or saline control. The saline control placebo will be mixed by the Stanford Hospital Pharmacy to a total dose of 4mL in order to be identical in quantity and appearance to the mixed doses of bevacizumab, and 2mL will be injected into each side of the nose. Injections will be performed according to the standardized four-point injection protocol (0.5mL/site) based on the vascular anatomy of the nose published in 2012 by Dheyauldeen et al.
3025836|NCT02389946|Experimental|Orsiro sirolimus coronary stent system|Intervention with a Orsiro DES.
3025837|NCT02389946|Active Comparator|Xience everolimus coronary stent system|Intervention with a Xience DES.
3025838|NCT02389920|Experimental|Nilotinib|nilotinib 400mg BID for 12 months
3025839|NCT02389907||Total Hip Replacement Group|Adults who have undergone a total hip replacement
3025840|NCT02389907||Hysterectomy Group|Adults who have undergone a hysterectomy
3025841|NCT02389894|Active Comparator|Embol-X Embolic Protection Device|The surgeon may use either the EMBOL-X® Access Device/Aortic Cannula or a standard cannula with the EMBOL-X® filter deployed through a separate introducer sheath.
3025842|NCT02389894|Active Comparator|CardioGard Cannula|The Cardiogard embolic protection device is a curved tip 24-French aortic perfusion cannula.
3025843|NCT02389894|No Intervention|Standard Cannula|Patients in this arm will receive the standard of care surgical procedure using a cannula of the surgeon's choosing.
3025844|NCT02389881|Experimental|Cohort 1 Non-elderly Healthy: TAK-058 25 mg|TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
3025845|NCT02389881|Experimental|Cohort 2 Non-elderly Healthy: TAK-058 75 mg|TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
3025846|NCT02389881|Experimental|Cohort 3 Non-elderly Healthy: TAK-058 150 mg|TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
3025847|NCT02389881|Experimental|Cohort 4 Elderly Healthy: TAK-058 25 mg|TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.
3025848|NCT02389881|Placebo Comparator|Cohort 5 Non-elderly Healthy: TAK-058 300 mg|TAK-058 300 mg solution, orally, once daily on Day 1, in non-elderly healthy participants.
3025849|NCT02389881|Placebo Comparator|Cohorts 1, 2, 3 and 5 Non-elderly Healthy: Placebo|TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10 (Cohorts 1, 2 and 3), or TAK-058 placebo-matching solution, orally, once on Day 1 (Cohort 5), in non-elderly healthy participants.
3025850|NCT02389881|Placebo Comparator|Cohort 4 Elderly Healthy: Placebo|TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
3025851|NCT02389868|Experimental|Lovastatin|
3025852|NCT02389842|Experimental|Palbociclib + Taselisib|The starting dose of palbociclib in combination with taselisib will be 100mg OD of palbociclib and 2mg taselisib OD, administered orally 21-days-on and 7-days-off, as part of a 28 day cycle.
3025853|NCT02389842|Experimental|Palbociclib + Pictilisib|The starting dose of palbociclib in combination with pictilisib will be 100mg OD of palbociclib and 195 mg pictilisib OD, administered orally 21-days-on and 7-days-off, as part of a 28 day cycle.
3025854|NCT02389829|Active Comparator|Hydromorphone|Hydromorphone 1mg, administered as intravenous drip over 5 minutes. Patients can receive second 1mg dose at 1 hour.
3025855|NCT02389829|Active Comparator|Prochlorperazine|"Prochlorperazine 10mg, administered as intravenous drip over 5 minutes. Diphenhydramine 25mg co-administered.~Patients can receive second 10mg dose at 1 hour."
3025856|NCT02389816|Placebo Comparator|Placebo|placebo tablets, orally, once daily
3025857|NCT02389816|Experimental|Lu AA21004 10 mg|Lu AA21004 10 mg tablets, orally, once daily
3025858|NCT02389816|Experimental|Lu AA21004 20 mg|Lu AA21004 10 mg tablets, orally, once daily for 1 week and then 20 mg tablets, orally, once daily for the last 7 weeks in the double-blind condition
3025859|NCT02389803|Experimental|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
3025860|NCT02389803|Placebo Comparator|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and mineral
3025861|NCT02389790|Experimental|MT-1303|
3025862|NCT02389777|No Intervention|Control UV burn|No treatment of the UV Light burn will be given
3025863|NCT02389777|Active Comparator|ACCS treated UV burn immediately|Amnion-derived Cellular Cytokine Solution will be applied topically immediately by spray to the UV light burn wound
3025864|NCT02389777|Active Comparator|ACCS treated UV burn delayed|Amnion-derived Cellular Cytokine Solution will be applied topically by spray to the UV light burn beginning 6 - 12 hours after the burn
3025865|NCT02389764|Experimental|BIBF 1120|Initial dose of BIBF 1120 is 200 mg twice daily orally for a 28 day cycle. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit.
3025866|NCT02389751|Experimental|Ganetespib + Chemoradiation|Ganetespib administered concurrently with chemoradiation once-weekly by vein in a dose-escalated manner, from the first week of chemoradiation to the last week of chemoradiation. Starting dose of Ganetespib 80 mg/m2. Carboplatin administered at an AUC=2 weekly by vein and Paclitaxel at 50 mg/m2 weekly by vein. Radiotherapy administered once-daily, 5 days a week, for 5.5 weeks, or a total of 28 treatments. Total dose 50.4 Gy (@ 1.8 Gy/fx/day) prescribed to the periphery of the planning target volume (PTV).
3025925|NCT02389322|Experimental|10μg/ml ESAT6-CFP10 after BCG immunization|A within group paired comparison of 10μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 10μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after BCG immunization, according to a randomisation scheme .
3056954|NCT02181946|Experimental|Fluconazole with and without Nevirapine|
3025867|NCT02389738|Experimental|BBB disruption with regadenoson|"This is an exploratory (pilot) study to assess whether Regadenoson can disrupt the BBB, change the barrier permeability, to enhance the temozolomide delivery to brain.~Five evaluable patients will be studied in this trial. The sample size justification is not based on statistical rationale but clinical affordability. If the investigators detect ≥ 50% increase in temozolomide brain interstitium concentrations after Regadenoson, then the investigators will consider future studies evaluating additional patients."
3025868|NCT02389725|Active Comparator|disposable elastic tourniquet|
3025869|NCT02389725|Active Comparator|manual blood pressure cuff|manual blood pressure cuff inflated to 60mmHg
3025870|NCT02389712|Active Comparator|Lamotrigine|Subjects on this arm will be randomized to Lamotrigine.
3025871|NCT02389712|Active Comparator|Fluoxetine|Subjects on this arm will be randomized to Fluoxetine.
3025872|NCT02389699|Experimental|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
3025873|NCT02389699|Active Comparator|whole breast radiation|WRT:whole breast radiation after BCS with 46-50 Gy
3025874|NCT02389686|No Intervention|Without Radiotherapy|Patients just accept nipple-sparing mastectomy (NSM) without radiotherapy.
3025875|NCT02389686|Experimental|Intraoperative Radiotherapy|Followed by nipple-sparing mastectomy (NSM),INTRABEAM IORT was carried out with a single dose of 16 Gy for nipple-areola complex (NAC).
3025876|NCT02389673|No Intervention|Without Radiotherapy|Patients just accept breast-conversing surgery without radiotherapy.
3025877|NCT02389673|Experimental|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
3025878|NCT02389660|Experimental|Blended CBT|Internet based blended depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, and (4) relapse prevention. These will be delivered over 13 sessions (6 online and 7 face-to-face, session sequence - alternate, online platform - Moodbuster).
3025879|NCT02389660|Active Comparator|Treatment as usual|Treatment as usual (TAU) will be defined as the routine care CBT that subjects receive when they are diagnosed with depression in the setting of recruitment. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report (including TIC-P measurements).
3025880|NCT02389647||Endovascular group|Subjects undergoing elective endovascular catheterization for coiling of unruptured cerebral aneurysms. Four blood draws of 5mL each: (1) prior to initiation of procedure; (2) at the time of catheterization of major cerebral vessels, (3) immediately after the procedure, and (4) 24-hours after the procedure.
3025881|NCT02389647||Ischemic stroke group|Subjects who present to the emergency department with ischemic infarcts of <6 hours. Four blood draws of 5mL each: (1) at time of enrollment but prior to tPA, (2) 6 hours post-tPA, (3) 12 hours post-tPA, and (4) 24 hours post-tPA.
3025882|NCT02389647||Intracranial hemorrhage|Subjects who present to the emergency department with intracranial hemorrhage. One 5mL blood draw within 24 hours of onset.
3025883|NCT02389621|Experimental|Lusutrombopag|Lusutrombopag 3 mg once daily for up to 7 days.
3025884|NCT02389621|Placebo Comparator|Placebo|Placebo once daily for up to 7 days.
3025885|NCT02389608|Experimental|1- tDCS 2--FES|"Transcranial stimulation ( tDCS ) will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes and intensity 2mA associated active contraction of the TA muscle. Placebo tDCS will follow the same procedures as active tDCS with active, but the tDCS device will only be switched on for 20 seconds.~Functional electrical stimulation (FES) will be administered using QUARK® FES VIF 995 DUAL device. The duration of active FES will be 20 minutes, associated with active contraction of the TA muscle. The pulse width will be 250 µs, modulated at a frequency of 50 Hz, with one to two stimulation cycles (6 seconds on and 12 seconds off) and the intensity will be increased until reaching the motor threshold. Placebo FES will follow the same procedures as active FES , but the FES device will only be switched on for 20 seconds, following which the intensity will be gradually reduced to 0 mA."
3025886|NCT02389595||HIV positive subjects|This group will provide a blood sample.
3025887|NCT02389595||Non-infected control subjects|This group consist of de-identified blood samples from a commercial source.
3025888|NCT02389582|Experimental|Dabigatran|Dabigatran 150mg twice a day for five days
3025889|NCT02389582|Active Comparator|Enoxaparin|Enoxaparin 1mg/kg/day twice a day for five days
3025890|NCT02389569|Experimental|Adhesive system treatment|Four groups ( Two will be treat with Etch-and-Rinse Adhesive System and two will be treated with two step Self-Etch Adhesive System).
3025891|NCT02389569|Experimental|Restoration protocol|Four groups ( Two will be treat with experimental Biosilicate and two will be the control groups).
3025892|NCT02389543|Experimental|A: Selinexor (1x/week), Lenalidomide, & Dexamethasone|Lenalidomide will be dosed initially at 15 mg daily, and if that dose is tolerated per dose-limiting toxicity (DLT criteria,) it will be increased to 25 mg for that arm. Selinexor will be started at 80 mg (~45 mg/m2) once weekly in combination with dexamethasone 40 mg once weekly with each dose of selinexor. If the selinexor 80 mg dose is tolerated per DLT criteria, the dose will be increased to 100 mg (~60 mg/m2) and evaluated for MTD, tolerability and efficacy.
3025893|NCT02389543|Experimental|B: Selinexor (2x/week), Lenalidomide, & Dexamethasone|Lenalidomide will be dosed initially at 15 mg daily, and if that dose is tolerated per DLT criteria, it will be increased to 25 mg for that arm. Selinexor will be started at 60 mg (~35 mg/m2) twice weekly in combination with dexamethasone 20 mg twice weekly with each dose of selinexor; dexamethasone 20 mg will also be given, without selinexor, on Days 22 and 24. If the selinexor 60 mg dose is tolerated per DLT criteria, the dose will be increased to 80 mg (~45 mg/m2) and evaluated for MTD, tolerability and efficacy.
3025894|NCT02389530||interventional group|All participants will receive the study intervention, intravenous administration of fluorescein dye prior to brain tumor removal.
3025895|NCT02389517|Experimental|Arm I (ixazomib citrate, lenalidomide, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only).
3025896|NCT02389517|Active Comparator|Arm II (lenalidomide)|Patients receive lenalidomide PO as in Arm I.
3025957|NCT02389114|Experimental|High Protein Preload|The subjects consumed soybean curd preload containing high protein content.
3025898|NCT02389504|Experimental|Exertion Physical Therapy Protocol|Exertional Physical Therapy Protocol. Dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
3025899|NCT02389491|Active Comparator|normal density formula (Neocate)|In control group,infants intake normal density formula (Neocate,67kcal/100ml) when starting enteral nutrition after operation and continue for 7days
3025900|NCT02389491|Experimental|high density formula (Infatrini)|In the intervention group,infants intake high density formula (Infatrini, 100kcal/100ml) when starting enteral nutrition after operation and continue for 7days
3025901|NCT02389478|Experimental|colostrums|Oropharyngeal administration of colostrums, every 4 hours，continue for 7days
3025902|NCT02389478|Other|Normal saline|Oropharyngeal administration of Normal saline,every 4 hours，continue for 7days
3025903|NCT02389465|No Intervention|Control|This arm is for participants who are not depressed.
3025904|NCT02389465|Experimental|Experimental - treatment|Depressed participants will receive an antidepressant (escitalopram) AND either a non-steroidal anti-inflammatory drug (celecoxib) OR placebo (sugar pill) for 6 weeks.
3025905|NCT02389452|Experimental|Synvisc-One|Single 6 mL IA injection of Synvisc-One (48 mg of cross-linked hylan polymer) at Day 0 (Initial Treatment). Participants received repeat injection based on physician's discretion of safety and efficacy (no major safety concerns and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 subscore [measurement of pain while walking on flat surface] between 40-80 mm, measured on a 0-100 mm scale with 0 represents no pain and 100 represents worst possible pain) at Week 26, 39 or 52 (Repeat treatment).
3025906|NCT02389439|Experimental|Pyronaridine-artesunate|"Pyronaridine-artesunate (Pyramax®, Shin Poong Pharmaceuticals). One tablet contains 60mg artesunate+ 180mg pyronaridine. Dosing will be according to body weight.~It will be taken orally with water, once daily for 3 days. Each dose will be administered under the supervision. A dose will be repeated in full if vomiting occurs within 30 minutes of administration of the first day of administration only.~20 - < 24 kg = 1 tab 24 - < 45 kg = 2 tabs 45 - < 65 kg = 3 tabs 65 and above = 4 tabs"
3025907|NCT02389426|Experimental|Patients with Multiple Sclerosis|One examination with TCD baseline and with NIRS baseline, and a second examination with TCD after bosentan administration and with NIRS after bosentan administration will be performed; The examination will be repeated only in the patients with MS (i.e. not in control subjects) 4 h after the oral intake of one tablet 62.5 mg bosentan (Tracleer®) (when peak plasma concentrations are expected).
3025908|NCT02389426|Experimental|Healthy controls|Only one examination with TCD baseline and NIRS baseline will be performed, without administration of bosentan.
3025909|NCT02389413|Experimental|PQ912 oral|PQ912 will be administered orally twice daily for 12 weeks.
3025910|NCT02389413|Placebo Comparator|Placebo|Placebo will be administered orally twice daily for 12 weeks.
3025911|NCT02389400|Experimental|Experimental arm|methotrexate,1g/m2,iv.d1 cytosine arabinoside,0.1g/m2,iv.,d1-5
3025912|NCT02389387|No Intervention|Control|Two hundred twenty (220) dialysis facilities will follow standard of care practices in their management of ESRD patients. They will not receive interventions, but they will have access to standard educational materials and quality improvement through End Stage Renal Disease Network 6.
3025913|NCT02389387|Experimental|Intensive Intervention|Two hundred twenty (220) dialysis facilities will follow standard of care practices and the intensive intervention in their management of ESRD patients. The intensive intervention will consist of 1) A multi-module, secure, web-enabled software application called Transplant Referral EXchange (T-REX) to enhance coordination between dialysis and transplant staff and track ESRD patients through the seven primary steps to transplant , 2) educational webinars/seminars for staff, 3) facility-specific performance feedback reports, 4) assistance with and review of center-specific action plans to increase transplant referral, 5) scheduled bi-annual phone calls with an SETC member to monitor progress, 6) patient education on transplant via creation of an Education Station in facility lobby, and 7) development of a Peer Mentor program.
3025914|NCT02389374|Other|chloroquine primaquine 14days|P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
3025915|NCT02389374|Other|artemether-lumefantrine primaquine 1day|P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
3025916|NCT02389374|Other|artemether-lumefantrine primaquine 14days|mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
3025917|NCT02389361|Experimental|Group Z|Postoperative Analgesia with Zaldiar
3025918|NCT02389361|Active Comparator|Group PT|Postoperative Analgesia with Paracetamol-Tramadol
3025919|NCT02389348|Experimental|combination OZ439 and DSM265|"Subjects will receive 1800 P falciparum infected red blood cells. Development of parasitemia will be monitored by quantitative PCR. When the parasitemia reached the threshold of 1000 p/ml subjects will receive a single oral dose of OZ439 and DSM265.~Subsequent doses in subsequent cohort(s) will be determined following a review of observed OZ439 and DSM265 safety, and pharmacokinetic and pharmacodynamic interaction outcomes as well as the activity of the drugs as defined by parasite clearance kinetics."
3025920|NCT02389335||Group 1a|Patients with type 1 diabetes who have undetectable c-peptide ( ≤0.1 ng/mL) levels after mixed meal tolarance test: group 1a
3025921|NCT02389335||Group 1b|Patients with type 1 diabetes who have c-peptide levels between 0.1-0.8 ng/mL after mixed meal tolerance test: group 1b
3025922|NCT02389335||Group 1c|Patients with type 1 diabetes who have c-peptide levels ≥0.8ng/mL after mixed meal tolerance test: group 1c
3025923|NCT02389335||Control|Healthy subjects
3025924|NCT02389322|Experimental|5μg/ml ESAT6-CFP10 after BCG immunization|A within group paired comparison of 5μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 5μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after BCG immunization, according to a randomisation scheme .
3025958|NCT02389114|Experimental|High Protein with Polydextrose Preload|The subjects consumed soybean curd preload containing high protein content and polydextrose.
3025959|NCT02389101|Experimental|Lymphoma|
3058207|NCT02173535|Experimental|etafilcon test contact lens Variant VC|
3025926|NCT02389322|Placebo Comparator|5μg/ml ESAT6-CFP10 after placebo immunization|A within group paired comparison of 5μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 5μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after placebo controlled immunization, according to a randomisation scheme .
3025927|NCT02389322|Placebo Comparator|10μg/ml ESAT6-CFP10 after placebo immunization|A within group paired comparison of 10μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 10μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after placebo controlled immunization, according to a randomisation scheme.
3025928|NCT02389309|Experimental|Dasatinib + Temsirolimus + Cyclophosphamide|"Dasatinib will be given twice daily by mouth along with Cyclophosphamide by mouth once daily for 21 consecutive days followed by a one week break.~Temsirolimus is given intravenous once weekly at day 1, 8 and 15 of the cycle. Each course of therapy is 28 days."
3025929|NCT02389296||Forensic Psychiatric Nurses in Mental Health Centers|Psychiatric nurses working in forensic wards in mental health centers
3025930|NCT02389296||Psychiatric Nurses in General Hospitals|Psychiatric nurses working in general hospitals
3025931|NCT02389283||Rheumatoid arthritis(RA) patients|The patients will be evaluated according to clinical practice (clinical evaluation and inflammation markers) at baseline and 3 and 6 months after the initiation of the treatment with the biologic DMARD.
3025932|NCT02389270||Healthy children|Healthy children without lower urinary tract diseases, history of urinary tract infection, chronic diseases, anomalies of urinary or genital tract, and remarkable clinical examination.
3025933|NCT02389257|Experimental|MINIMAG / MEG|Cerebral magnetic fields
3025934|NCT02389257|Experimental|MINIMAG / ECG|Cardiac magnetic fields
3025935|NCT02389244|Experimental|Regorafenib|"For adult patients (≥ 18 years old) : 160 mg/d once daily for the 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent .~For children Age ≥ 10 years to < 18 years old and BSA ≥ 1.30 m2, regorafenib (82 mg/m²) once daily for the 3 weeks on/1 week off (without exceeding 160mg/day) plus Best Supportive care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent."
3025936|NCT02389244|Placebo Comparator|placebo|Placebo plus BCS until progression (according to RECIST V1.1) intolerance or withdrawal of consent. Patients who have received placebo will receive open-label regorafenib after objective tumor progression.
3025937|NCT02389231|Experimental|Low doses of Interleukine-2|Low doses of Interleukine-2 over a 9 week treatment period
3025938|NCT02389218|Experimental|Cryoablation|Cryoballoon single ablation (as described in the reference) at entry after randomization to this group. Single procedure,not to be repeated.
3025939|NCT02389218|Active Comparator|Drug|Conventional, available anti arrhythmic drugs (propafenone, sotalol or flecainide), in a first stage, sequential, with amiodarone in second stage
3025940|NCT02389205|Placebo Comparator|control group|physical therapy
3025941|NCT02389205|Active Comparator|kinesio group|kinesio taping for ankle joint
3025942|NCT02389192|Experimental|OPEN|healthy volunteers between the ages of 18-50 to receive a one-time infusion of Zmapp at a dose of 50mg/kg.
3025943|NCT02389179|Active Comparator|25 000 IU monthly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd). The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
3025944|NCT02389179|Active Comparator|50 000 IU monthly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd).The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
3025945|NCT02389179|Active Comparator|50 000 IU bi-weekly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd).The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
3025946|NCT02389166|Experimental|Optiflow group|
3025947|NCT02389166|Active Comparator|Control group|
3025948|NCT02389153|Experimental|collaborative care, CHD|Participants start with the collaborative care intervention at baseline directly after inclusion.
3025949|NCT02389153|Active Comparator|collaborative care CHD - waitlist|Participants start with the intervention 6 months after baseline, in the meantime they receive tau.
3025950|NCT02389140|Experimental|Trigger point treatment|Trigger point release
3025951|NCT02389140|Sham Comparator|Ultrasound|Sham US at Trigger point
3025952|NCT02389127||Group A|"Cirrhosis, either clinically- or biopsy-proven~Child-Pugh-Turcotte (CTP) A, B, and C (only biopsy-proven in the case of CTP-A)~Random glucose <200 mg/dL on at least 3 occasions~No use of insulin or any hypoglycemic agent~(Group A) patients with cirrhosis and varying degrees of liver dysfunction but no prior diagnosis of T2DM will have an OGTT performed after overnight fasting (8-12-hours). HbA1c will be obtained before OGTT along with the following tests: HbA1c, fructosamine, insulin, CBC, HFP, GGT, OP Chem 7, INR, and prealbumin."
3025953|NCT02389127||Group B|"Cirrhosis, either clinically- or biopsy-proven~Child-Pugh-Turcotte (CTP) A, B, and C (only biopsy-proven in the case of CTP-A)~Prior diagnosis of T2DM as based on any of ADA criteria~Use of insulin or any hypoglycemic agent~(Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (?Dexcom, ?Medtronic) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks. On the day the continuous monitor is retrieved by the investigators, patients will have the following blood tests performed after overnight fasting (8-12-hours): HbA1c, fructosamine, CBC, HFP, GGT, BMP, INR, and prealbumin."
3025954|NCT02389127||Control|"Age 18 to 75~No known chronic liver disease~Prior diagnosis of T2DM as based on any of ADA criteria~Use of insulin or any hypoglycemic agent"
3025955|NCT02389114|Active Comparator|Low Protein Preload|The subjects consumed soybean curd preload containing low protein content.
3025956|NCT02389114|Experimental|Low Protein with Polydextrose Preload|The subjects consumed soybean curd preload containing low protein content and polydextrose.
3026023|NCT02388646|Active Comparator|Bracing + Exercises|Reaction Web brace and home exercises.
3025960|NCT02389088|No Intervention|Phase I|"9 PCOS women will be studied. On study day one, r-FSH will be administered I.V. at a dose of 150 IU (FSH stimulation test). Blood samples will be obtained before and after FSH administration. After the FSH stimulation test, each subject will receive an I.M. injection of Lupron 3.75 mg. This dose has a duration effect of one month.~The FSH stimulation test will be repeated, as described above, at 5 weeks (early resumption of ovarian function) and 6 weeks (moderate resumption of ovarian function)."
3025961|NCT02389088|Active Comparator|Phase II|"Women that participated in Phase I will be studied again after a washout of 2 months. On study day one, an FSH stimulation test will be performed as described above.~After the FSH stimulation test, each subject will receive an I.M. injection of Lupron 3.75 mg. This dose has a duration effect of one month. Four weeks after administration of Lupron, each subject will receive Letrozole 5mg for 14 days. The FSH stimulation test will be repeated at 5 weeks (early resumption of ovarian function) and 6 weeks (moderate resumption of ovarian function)."
3025962|NCT02389075||Ankylosing Spondylitis|Subjects with a diagnosis of ankylosing spondylitis undergoing routine colonoscopy or willing to undergo a flexible sigmoidoscopy for research purposes only. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
3025963|NCT02389075||Inflammatory Bowel Disease|Subjects with a diagnosis of inflammatory bowel disease undergoing routine colonoscopy. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
3025964|NCT02389075||Healthy Controls|Subjects without any major autoimmune diseases or pathologies undergoing routine colonoscopy. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
3025965|NCT02389062|Experimental|Placebo controlled group|This is a group of same number of subjects as in other arms, who will be given equivalent dose of placebo- cornstarch capsules i.e 5 capsules containing neutral substance- cornstarch(placebo) to be taken daily by mouth for a period of 12 weeks.
3025966|NCT02389062|Experimental|High dose gluten capsules|This group of subjects will be given high dose i.e 2.5 g of gluten containing capsules, 5 capsules to be taken daily by mouth, for a period of 12 weeks.
3025967|NCT02389062|Experimental|Low dose gluten capsules|This group of subjects will be given low dose i.e 0.5 g of gluten containing capsules, 5 capsules to be taken daily by mouth, for a period of 12 weeks.
3025968|NCT02389036|No Intervention|Control group- standard care|Standard care- In Australia there are no national guidelines so local policy is determined by each ICU. We are recommending (but not mandating) that control and SDD group management be in line with these national guidelines. We will recommend control and SDD group management is in line with current national standards of practice that may or may not include a VAP bundle. We will monitor record data regarding the nature and delivery of the control and SDD group co-interventions.
3025969|NCT02389036|Experimental|SDD intervention group|"The intervention will entail:~A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx~A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube~A four-day course of an IV antibiotic. Patients not already receiving a therapeutic antibiotic will be prescribed cefotaxime 1g six-hourly or ceftriaxone 1g daily, with dose adjusted as appropriate for organ dysfunction. Ciprofloxacin (400mg 12-hourly) may be used as an alternative if there is a contraindication to cephalosporins (e.g. allergy). Patients already receiving an alternative IV antibiotic to treat infection will not receive this additional IV antibiotic, but will continue the prescribed antibiotic for the usual duration of therapy."
3025970|NCT02389023|Other|standard gauze dressing|a standard post-operative dressing consisting of dry gauze and tape will be placed over the surgical site
3025971|NCT02389023|Other|Prevena Incision Management System|the Prevena™ Incision Management System (PIMS) or ActiVAC® with the PrevenaTM Dressings (Peel and Place™ or Customizable™) will be placed over the surgical site. The Prevena dressing is not considered experimental and has FDA approval for coverage of at risk closed-surgical incisions. The dressing is already in clinical use for vascular surgery bypass operations at the University of Vermont Medical Center.
3025972|NCT02389010|Experimental|Allogeneic Cord Blood Platelet Gel-CBPG|For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
3025973|NCT02389010|Active Comparator|Standard Local Medications-SLM|1 administration every 3-4 days for 4 weeks. Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
3025974|NCT02388997|Active Comparator|Mild asthmatics treated with omalizumab|Subjects with mild asthma will be treated with omalizumab for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. Omalizumab will be given subcutaneously every 2 to 4 weeks according to the manufacturer's recommendations.
3025975|NCT02388997|Placebo Comparator|Mild asthmatics treated with placebo medication|Subjects with mild asthma will be treated with placebo medication for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. The placebo mediation will consist of the same diluent used for suspending the omalizumab without omalizumab added.
3025976|NCT02388984|Experimental|Compound danshen dripping pills|Compound danshen dripping pills,20pills,tid. Duration: 24 weeks.
3025977|NCT02388984|Placebo Comparator|Placebo|Placebo,20pills,tid. Duration: 24 weeks.
3025978|NCT02388971|Experimental|MLN1202 Dose|MLN1202 Dose, intravenously (IV), once on Days 1, 29 and 57.
3025979|NCT02388971|Experimental|MLN1202 Placebo|MLN1202 placebo, intravenously (IV), once on Days 1, 29 and 57.
3025980|NCT02388958||Women with GDM|
3025981|NCT02388958||Women without GDM|
3025982|NCT02388945|Experimental|A APDGroup|PDGO APD machines used in the PD patients for 8 weeks
3025983|NCT02388945|Active Comparator|B CAPDGroup|CAPD used in the PD Patients for 8 weeks
3025984|NCT02388932|Experimental|Treatment (SBRT)|Patients undergo Stereotactic Body Radiation Therapy in 5 fractions at least 40 hours apart over 10-18 days.
3026100|NCT02388165|Placebo Comparator|Placebo|Diluent (sterile water) for Placebo
3025987|NCT02388906|Experimental|Ipilimumab and Placebo matching Nivolumab|Ipilimumab IV infusion and Placebo as specified
3025988|NCT02388906|Experimental|Nivolumab and Placebo matching Ipilimumab|Nivolumab IV infusion and Placebo as specified
3025989|NCT02388880|Experimental|ITPR|Use of the ITPR for 240 minutes.
3025990|NCT02388867|Experimental|Group I|Intervention: Polytetrafluoroethylene (PTFE) bypass grafting.
3025991|NCT02388867|Experimental|Group II|Intervention: Autogenous vein bypass grafting.
3025992|NCT02388854||Endometriosis|Women with histological diagnosis of endometriosis
3025993|NCT02388854||Controls|Healthy blood donors
3025994|NCT02388841||Pulmonary embolism|Distribution of the characteristics of Pulmonary Embolism patients according to thrombus localization
3025995|NCT02388841||tomographic pulmonary angiography|Distribution of the characteristics of Pulmonary Embolism patients according to the localization of thrombi in the most proximal level of Main pulmonary artery and other arterial branches as confirmed by Computed tomographic pulmonary angiography
3025996|NCT02388828||Subjects who have received lentiviral-based CARTmeso therapy|
3025997|NCT02388815|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
3025998|NCT02388802|Experimental|Uterine transplant|10 patients will be appropriately selected to undergo oocyte retrieval and freezing. Subsequently deceased donor allograft excision will take place prior to uterine transplantation. Immunosuppressive agents will be used to optimise graft success until successful In-vitro fertilisation and subsequent delivery by Caesarean Section
3025999|NCT02388789|Experimental|active movement|use a light treadmill run to raise feet temperature
3026000|NCT02388776|Experimental|ROTEM|Clinical burn ICU Inpatients receiving blood draws for ROTEM analysis and fibrinogen levels.
3026001|NCT02388763|Other|MyDay, then 1DAVTE|Stenfilcon A contact lenses, followed by narafilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
3026002|NCT02388763|Other|1DAVTE, then MyDay|Narafilcon A contact lenses, followed by stenfilcon A contact lenses. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
3026003|NCT02388750|Other|No previous nausea and vomiting|"Palonosetron 0.5 mg oral capsule given for the length of radiation treatment~No previous nausea and vomiting 24 hours prior to radiotherapy"
3026004|NCT02388750|Other|Previous nausea and/or vomiting|"Palonosetron 0.5 mg oral capsule given for the length of radiation treatment~Previous nausea and/or vomiting 24 hours prior to radiotherapy"
3026005|NCT02388737|Experimental|Vonoprazan 10 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Vonoprazan 10 mg, tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg placebo-matching, capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing."
3026006|NCT02388737|Experimental|Vonoprazan 20 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Vonoprazan 20 mg, tablets, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg, placebo-matching capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing"
3026007|NCT02388737|Active Comparator|Lansoprazole 15 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Lansoprazole 15 mg, capsules, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing."
3026008|NCT02388724|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg, tablet, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily for up to 8 weeks.
3026009|NCT02388724|Active Comparator|Lansoprazole 30 mg|Lansoprazole 30 mg, capsule, orally, once daily and vonoprazan placebo-matching tablet, orally, once daily for up to 8 weeks.
3026010|NCT02388711|Experimental|Usual Care with C-TraC Intervention|Patients/caregivers randomized to this group will receive all routine hospital discharge education/materials (same as usual care group), but will also be enrolled in the C-TraC Program. C-TraC is a low-resource, telephone-based, protocol-driven program designed to reduce 30-day rehospitalizations and to improve care transitions during the early post-hospital period.
3026011|NCT02388711|No Intervention|Usual Care|Usual care group patients will receive all routine University of Wisconsin Hospital and Clinics (UWHC) discharge education/materials. This includes pharmacy-led medication teaching, physician discussions and routine nursing education. No post hospital education/contact is performed by these providers. Caregivers are sometimes, but not always, involved. Patients may receive home health services, depending on their physician's discharge plan.
3026012|NCT02388698|Experimental|Cervical Swab, PET-CT and plasma HPV|Participants will have a cervical swab, and plasma HPV at baseline. In addition, a plasma HPV test drawn after completion of radiation. 3 months post chemoradiation, patients will have a PET-CT and plasma HPV completed. Plasma HPV will be drawn at progression/recurrence, if applicable.
3026013|NCT02388685|Experimental|Home exercise|Patients will undergo home exercise therapy under the supervision of the exercise laboratory
3026014|NCT02388685|No Intervention|No exercise|Patients will continue with usual care
3026015|NCT02388672|Experimental|Drink high-CGA|Participants will drink once 250ml of decaffeinated coffee enriched with chlorogenic acid (CGA) (6g decaffeinated coffee (5 mg caffeine) with high total CGA (560 mg)).
3026016|NCT02388672|Placebo Comparator|Drink low-CGA|6g decaffeinated coffee (250 ml) with normal total CGA (224 mg)
3026017|NCT02388672|Experimental|Capsules high-CGA|6g decaffeinated coffee (250 ml) with normal total CGA and 800mg green coffee bean extract supplement with total CGA (560mg)
3026018|NCT02388672|Placebo Comparator|Capsules low-CGA|6g decaffeinated coffee (250 ml) with normal total CGA and placebo
3026019|NCT02388672|No Intervention|Control|No treatment control group
3026020|NCT02388659||Brain MRI/MRS Patients|3 Tesla Scanning: MRI/MRS of glioma and non-glioma patients.
3026021|NCT02388646|Active Comparator|Exercise Only|Home exercise program.
3026022|NCT02388646|Active Comparator|Brace Only|Reaction Web brace.
3026024|NCT02388633||Plasmapharesis|Patients undergoing apheresis for elevated LDL. Patients will undergo contrast ultrasound perfusion imaging at rest and during forearm exercise at before and immediately after apheresis.
3026025|NCT02388620|Experimental|Normal Hepatic Function|Normal hepatic function; matched demography to hepatic impairment cohorts
3026026|NCT02388620|Experimental|Mild Hepatic Impairment|Child-Pugh Classification A (score 5-6)
3026027|NCT02388620|Experimental|Moderate Hepatic Impairment|Child-Pugh Classification B (score 7-9)
3026028|NCT02388620|Experimental|Severe Hepatic Impairment|Child-Pugh Classification C (score 10-15)
3026029|NCT02388607||assessing attention span|"Electrophysiological measurements (evocated potentials and spectral densities)~Clinical scales and subjective assessments of difficulty of the tasks performed, and commitment to the task"
3026030|NCT02388594|Experimental|ZFN Modified CD4+ T Cell|ZFN Modified CD4+ T Cell
3026031|NCT02388594|Experimental|ZFN Modified CD4+ T Cell with Cyclophosphamide|ZFN Modified CD4+ T Cell with Cyclophosphamide
3026032|NCT02388581|Experimental|Anti-H. pylori Therapy|Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole
3026033|NCT02388568|Active Comparator|Lorcaserin plus Lifestyle Modification|
3026034|NCT02388568|Placebo Comparator|Placebo plus Lifestyle Modification|
3026035|NCT02388555||Pre-operative group|Respectively recruited patients with DLS. Patients in this group were not surgically treatment. Only pre-operative radiographic parameters were measured.
3026036|NCT02388555||Surgically treated group|All DLS patients received posterior osteotomy correction of spinal deformity. The immediate post-operative radiographic measurements were performed.
3026037|NCT02388542|Experimental|lifestyle counseling|we will have a trained peer mentor educating employees regarding lifestyle modification for control of cardiovascular disease risk factors and following them up for a duration of 3 months
3026038|NCT02388529|Experimental|Low dose|
3026039|NCT02388529|Experimental|Intermediate dose|
3026040|NCT02388529|Experimental|High dose|
3026041|NCT02388529|Placebo Comparator|Placebo|
3026042|NCT02388516|Placebo Comparator|Group A|Prenatal Period 0 IU; Postpartum Period 0 IU (placebo) Overall: The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery. The Postpartum Period will last from delivery until 6 months postpartum.
3026043|NCT02388516|Experimental|Group B|Prenatal Period 4,200 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
3026044|NCT02388516|Experimental|Group C|Prenatal Period 16,800 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
3026045|NCT02388516|Experimental|Group D|Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
3026046|NCT02388516|Experimental|Group E|Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 28,000 IU/week
3026047|NCT02388503|Placebo Comparator|Reference|No added fruit extract
3026048|NCT02388503|Active Comparator|Active 1|lowest dose of fruit extract
3026049|NCT02388503|Active Comparator|Active 2|low dose of fruit extract
3026050|NCT02388503|Active Comparator|Active 3|medium dose of fruit extract
3026051|NCT02388503|Active Comparator|Active 4|high dose of fruit extract
3026052|NCT02388490|Experimental|Brentuximab vedotin|Brentuximab vedotin is an antibody-drug conjugate (ADC) composed of the anti-CD30 chimeric immunoglobulin G1 (IgG1) monoclonal antibody cAC10 and the potent antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker. cAC10 binds to the CD30 antigen, which has a very low expression on normal cells but is found on some tumor cells.
3026053|NCT02388477|Active Comparator|Doxycycline|oral doxycycline, 2 weeks, twice a day,
3026054|NCT02388477|Placebo Comparator|sugar pill|sugar pill, same size, shape, and color as comparator, twice a day for 2 weeks.
3026055|NCT02388464|Experimental|Low dose|
3026056|NCT02388464|Experimental|Intermediate dose|
3026057|NCT02388464|Experimental|High dose|
3026058|NCT02388464|Experimental|Placebo|
3026059|NCT02388451|Experimental|Feuerstein Program|15 subjects conforming to inclusion and exclusion criteria with a known clinical diagnosis of MCI and who provide informed consent will undergo cognitive and functional assessment to confirm the diagnosis of MCI. Baseline assessment using the Mindstreams Mild Cognitive Impairment Computerized Assessment Battery will be performed. Subjects will then participate 30 twice weekly meetings of 90 minutes duration each (for a total of 15 weeks). Mindstreams testing will be repeated after 15 sessions and at completion of the study.
3026060|NCT02388438|Experimental|Demineralized bone matrix|Applied demineralized bone matrix when investigator conduct hallux valgus surgery.
3026061|NCT02388412||Vulnerable plaque in optical coherence tomogrpahy|OCT-derived vulnerable plaque is defined as composite of thin-cap fibrous atheroma (cap thickness in optical coherence tomography < 60um), prominent macrophage, or prominent microvessels.
3026062|NCT02388412||Non-vulnerable plaque in Optical coherence tomogrpahy|OCT-derived vulnerable plaque is defined as composite of thin-cap fibrous atheroma (cap thickness in optical coherence tomography < 60um), prominent macrophage, or prominent microvessels. OCT-derived non-vulnerable plaque is defined as a plaque without any of the findings
3026063|NCT02388399||OCT and Pressure wire pullback tracing|This study is pilot study evaluating the feasibility of invasive measurement and estimation of hemodynamic stress acting on plaque as well as co-registration of hemodynamic data with plaque geometric data, which is obtained by optical coherence tomography
3026064|NCT02388386|Experimental|PROTEUS-SENSOR|The current study is a prospective interventional design with a single experimental arm. The intervention consists of two components: an edible sensor and a wearable receiver health monitor.
3026065|NCT02388373|Active Comparator|Seretide 250|Seretide® Evohaler® 25 microgram /50 microgram per metered dose pressurised inhalation, suspension. 25 micrograms of salmeterol (as salmeterol xinafoate) and 250 micrograms of fluticasone propionate. This is equivalent to a delivered dose (ex actuator) of 21 micrograms of salmeterol and 220 micrograms of fluticasone propionate. 2 puffs twice daily for 12 weeks Phase 1.
3026066|NCT02388373|Active Comparator|Flutiform 250|flutiform® 250 microgram/10 microgram per actuation pressurised inhalation, suspensions. 250 micrograms of fluticasone propionate and 10 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 230 microgram of fluticasone propionate/9.0 microgram of formoterol fumarate dihydrate. 2 puffs twice daily for 12 weeks in Phase 1 and 12 weeks in Phase 2.
3026067|NCT02388373|Active Comparator|Flutiform 125|flutiform 125 microgram/5 microgram per actuation pressurised inhalation, suspensions. 125 micrograms of fluticasone propionate and 5 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 115 microgram of fluticasone propionate/4.5 microgram of formoterol fumarate dihydrate. 2 puffs twice daily for 12 weeks in Phase 2.
3026068|NCT02388360|Other|topical prostaglandin analogs|
3026069|NCT02388347|Placebo Comparator|Placebo|Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
3026070|NCT02388347|Experimental|MEDI7836 Dose 1|Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
3026071|NCT02388347|Experimental|MEDI7836 Dose 2|Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
3026072|NCT02388347|Experimental|MEDI7836 Dose 3|Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
3026073|NCT02388347|Experimental|MEDI7836 Dose 4|Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
3026074|NCT02388321|Experimental|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
3026075|NCT02388321|Active Comparator|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
3026076|NCT02388308||Patient volunteers|Patients who have received radiotherapy for prostate cancer which included a planning CT scan, or who are currently receiving radiotherapy including a CT scan.
3026077|NCT02388308||Gold fiducial marker group|Patients receiving radiotherapy for prostate cancer as part of a clinical trial or standard care which includes gold FM or EM insertion, or patients who have previously received RT for prostate cancer which included EM insertion.
3026078|NCT02388308||Electromagnetic marker group|Patients receiving radiotherapy for prostate cancer as part of a clinical trial or standard care which includes gold FM or EM insertion, or patients who have previously received RT for prostate cancer which included EM insertion.
3026079|NCT02388308||General patients|Patients who are receiving radiotherapy for prostate cancer and who are not receiving FMs. Attempts will be made to match Group 4 patients BMI and time receiving hormone therapy to patients in group 2 and 3 (see below, section 6.1 recruitment.
3026080|NCT02388295|Experimental|AZD3241|Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.
3026081|NCT02388295|Placebo Comparator|Placebo to match AZD3241|Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.
3026082|NCT02388269|Active Comparator|gammaCore®-G|"The user/operator applies the gammaCore®-G device to the skin on the right side and left side of the neck. The 2 stimulations should be performed on the same side of the neck before stimulating the other side. This is also applies with the doses increase in the open label phase. The user applies conductive gel to the stimulation surfaces to maintain an uninterrupted conductive path from the stimulation surfaces to the skin.~The device is capable of delivering multiple patient treatments (doses). Each dose consists of 90 seconds of stimulation; for each dose, the device is active for 120 seconds before automatically stopping stimulation.The extra 30 seconds allows ."
3026083|NCT02388269|Sham Comparator|gammaCore®-G sham|"The sham device is a hand-held portable device that appears identical to the gammaCore®-G, in look, weight, visual and audible feedback, user application and control. It passes a low frequency (0.1 Hz) biphasic DC signal into the tissue, which can be felt as a tingling sensation but does not stimulate the vagus nerve or cause muscle contraction. Similar to the active device, the sensation becomes more pronounced as the amplitude is increased, until it is uncomfortable, at which point the amplitude is decreased slightly until tolerable.~Like the active device, the sham device is a multi-use device capable programmed to deliver up to 150, 90-second treatments with a 30-second margin for set-up and operator adjustment of the stimulation intensity."
3026084|NCT02388256|Experimental|Acupuncture|Manual and electroacupuncture
3026085|NCT02388256|Active Comparator|Enhanced recovery program after surgery|Enhanced recovery program after surgery
3026086|NCT02388243|Experimental|Brief Intervention in Public Clinic|Written information after screening; 15 minutes or so brief intervention at recruitment with follow-up visit of about the same length after one month; in public clinic.
3026087|NCT02388243|Active Comparator|Screening results in Public Clinic|Written information after screening; No brief intervention; in public clinic.
3026088|NCT02388243|Experimental|Brief Intervention in Private Clinic|Written information after screening; 15 minutes or so brief intervention at recruitment with follow-up visit of about the same length after one month; in private clinic.
3026089|NCT02388243|Active Comparator|Screening results in Private Clinic|Written information after screening; No brief intervention; in private clinic.
3026090|NCT02388230||Patients 4 or more years post radiotherapy|IMPORT or FAST trial patients who received breast RT previously and are receiving four years (or more) follow-up assessment and have hardening of their breast as a result of breast radiotherapy.
3026091|NCT02388230||Patients 0 to 2 years post breast radiotherapy|Patients who are (1) undergoing, or undergone recently breast RT (general population) and have undergone a clinical assessment either during RT or at 3 month follow-up that found moderate or severe oedema, or (2) IMPORT patients who have received RT and are receiving one or two year follow-up, at which moderate or severe oedema is reported.
3026092|NCT02388204|Experimental|Parkinson's disease patients|Group description: PD patients with locomotion problems as the primary complain with no interventions other than medication and rehabilitation therapies Intervention: Implantable spinal cord stimulation.
3026093|NCT02388204|Experimental|DBS Parkinson's disease patients|"Group description: PD patients with locomotion problems as the primary complain after cardinal symptoms are controlled by DBS.~Intervention: Implantable spinal cord stimulation."
3026094|NCT02388191|Experimental|Naproxen sodium|550 mg naproxen sodium
3026095|NCT02388191|Placebo Comparator|Placebo|Placebo
3026096|NCT02388178|Placebo Comparator|Fluoride free, silica based toothpaste|Control toothpaste containing no anti-cavity ingredients
3026097|NCT02388178|Experimental|fluoride + amino acid in a silica toothpaste|Experimental toothpaste containing fluoride and amino acid (arginine)
3026098|NCT02388178|Active Comparator|1450 ppm fluoride in a silica base toothpaste|Fluoride toothpaste containing fluoride as the anti-cavity ingredient
3026099|NCT02388165|Active Comparator|SA4Ag|Staphylococcus aureus 4-antigen Vaccine
3026103|NCT02388152|Experimental|Lu AF20513, high dose (Cohort 3)|15 Patients with mild Alzheimer's.
3026104|NCT02388152|Experimental|Lu AF20513, double high dose (Cohort 4)|15 Patients with mild Alzheimer's.
3026105|NCT02388126|Experimental|MRI|Comparison of targeted transrectal ultrasound guided prostate biopsies based on 3T multiparametric MRI findings to systematic non-targeted transrectal ultrasound guided prostate biopsies
3026106|NCT02388113|Experimental|accumulated exercise|12 exercise sessions of 10 minutes each week, 2 per day, 1 day rest
3026107|NCT02388113|Active Comparator|traditional exercise|4 exercise sessions of 30 minutes each week, 3 in the training laboratory, 1 at home.
3026108|NCT02388087|Active Comparator|ROX COUPLER|Iliac arterio-venous anastamosis created by insertion of ROX coupler device.
3026109|NCT02388087|Sham Comparator|ROUTINE CARE|Right heart catheterisation and Routine care of Neurally mediated syncope.
3026110|NCT02388074|Experimental|CyPath® Assay of Deep-Lung Sputum Sample|Deep-lung sputum was obtained from healthy individuals who had no known lung disease, was labeled with TCPP and evaluated to detect red fluorescent [ie, cancer] cells (RFCs) from deep-lung sputum samples.
3026111|NCT02388061|Experimental|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).
3026112|NCT02388061|Active Comparator|Intravenous tissue plasminogen activator (tPA)|Patients will receive intravenous t-PA at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
3026113|NCT02388048|Experimental|Ibrutinib + Ofatumumab|"IBRUTINIB 420 mg PO daily in 28-day cycles for a total of 7 cycles (28 weeks).~OFATUMUMAB 300 mg on day 1 of cycle 2 of Ibrutinib, followed by 2000 mg on D8, 15, 22 of cycle 2, D1, 8, 15, 22 of cycle 3, and Day 1 of cycle 4-7.~After induction treatment patients with HLA identical sibling or fully matched MUD donor will be addressed to reduced intensity allogeneic bone marrow transplant, while patients without a suitable donor or who refuse the transplant procedure will receive maintenance treatment by BTK inhibitor (IBRUTINIB 420 mg PO daily in 28-day cycles). Treatment will continue until disease progression or unacceptable toxicity."
3026114|NCT02388035|Experimental|SBP-group 1|Spontanous bacterial peritonitis
3026115|NCT02388035|Experimental|CNNA-group 2|Culture negative neutrocytic ascites
3026116|NCT02388035|Experimental|MNBA-group 3|monomicrobial non-neutrocytic ascites
3026117|NCT02388035|No Intervention|group 4|no evidence of ascitic fluid infection
3026118|NCT02388022||degenerative disc disease|Patients who have had a transforaminal lumbar interbody fusion at 1-2 contiguous levels with the CALIBER® expandable spacer and have completed at least 2 year follow-up.
3026119|NCT02388009|Active Comparator|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
3026120|NCT02388009|Active Comparator|Flexyn2a plus adjuvant|2 doses of 10 μg of Flexyn2a plus adjuvant will be injected intramuscularly 4 weeks apart
3026121|NCT02388009|Placebo Comparator|Placebo|2 doses of saline buffer plus adjuvant will be injected intramuscularly 4 weeks apart
3026122|NCT02387996|Experimental|Nivolumab|Nivolumab intravenous infusion as specified
3026123|NCT02387983|Experimental|Posaconazole|Posaconazole 300 mg tablet (3 x 100 mg tablets) once every 12 hours on Day 1 and once-daily on Days 2 to 28
3026124|NCT02387970|Active Comparator|Immediate provisionalization|Individuals will receive temporary dental crowns supported by NobelParallel CC implant at the same day as implant surgery
3026125|NCT02387970|Active Comparator|Delayed provisionalization|Individuals will receive temporary dental crowns supported by NobelParallel CC implant 3 months after implant surgery
3026126|NCT02387957|Experimental|Fovista® plus bevacizumab|Fovista® 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection
3026127|NCT02387957|Experimental|Fovista® plus ranibizumab|Fovista® 1.5 mg intravitreal injection + 0.5 mg ranibizumab intravitreal injection
3026128|NCT02387957|Experimental|Fovista® plus aflibercept|Fovista® 1.5 mg intravitreal injection + 2.0 mg aflibercept intravitreal injection
3026129|NCT02387944||Cardiopulmonary bypass|Children with congenital heart defect undergoing surgery on cardiopulmonary bypass
3026130|NCT02387944||cardiac catheterism|Children with congenital heart defect undergoing cardiac catheterism
3026131|NCT02387931|Experimental|Vitamin D|Vitamin D3 2000 IU daily taken for 6 months
3026132|NCT02387931|Experimental|Fish Oil|Fish Oil 1000 mg daily for 6 months
3026133|NCT02387931|Placebo Comparator|Placebo|Placebo taken daily for 6 months.
3026134|NCT02387918|Active Comparator|Dexamethasone|Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
3026135|NCT02387918|Active Comparator|Acupuncture|Acupuncture at point Neiguan (Pericardium-6) bilaterally and at point CV13 (Shang Wen) with acupuncture needles (0.25x25 mm) to a depth of approximately 7 mm will be performed on the children immediately after induction of anaesthesia and removed after 20 minutes
3026136|NCT02387905|Active Comparator|Stereotactic Spinal Radiosurgery (SSRS)|Participants receive CT-guided spinal stereotactic radiosurgery using intensity modulated radiation therapy. Treatment planning based on group's current standards for organ-at-risk dose constraints; however, final target volume and treatment plan at discretion of attending physician. Pain assessment performed utilizing Brief Pain Inventory assessment form. Quality of life assessment performed utilizing MD Anderson Symptom Inventory - Spine Tumor (MDASI-SP) form. Both assessments completed at baseline and every 3 months for 2 years after treatment.
3026137|NCT02387905|Experimental|Vertebral Body Cement Augmentation + SSRS|Participants receive CT-guided spinal stereotactic radiosurgery using intensity modulated radiation therapy. Participants receive prophylactic cement augmentation to spine within 4 weeks (before or after) radiosurgery treatment. Treatment planning based on group's current standards for organ-at-risk dose constraints; however, final target volume and treatment plan discretion of attending physician. Pain assessment performed utilizing Brief Pain Inventory assessment form. Quality of life assessment performed utilizing MD Anderson Symptom Inventory - Spine Tumor (MDASI-SP) form. Both assessments completed at baseline and every 3 months for 2 years after treatment.
3026138|NCT02387892|Placebo Comparator|Control|Cheese & yogurt
3026139|NCT02387892|Experimental|Treatment|Cheese & yogurt + Vitamin D
3026174|NCT02387645|Experimental|Patients prior to surgery for EC/suspicion|Patient undergoing surgery for strong suspicion of EC
3026458|NCT02385695||Posterior Dynamic Stabilization|Surgical treatment with posterior dynamic stabilization
3026140|NCT02387879||Group 1|"Subjects should be chosen among relapse/refractory multiple myeloma patients who have received at least one prior antimyeloma chemotherapy regimen (excluding treatment regimens with steroid only) with adequate dose and duration (≥2 cycles) or who have relapse/refractory multiple myeloma after stem cell transplantation.~Patients who are eligible for the study will be consecutively enrolled in the study until the targeted patient number is reached. The responsible investigator will be requested to keep a log of subjects who are invited to enter the study. In the case of any of these subjects will not be enrolled in the study, this information will be documented together with its reason"
3026141|NCT02387866|Experimental|50 mg AG-221 tablet|50 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
3026142|NCT02387866|Experimental|100 mg AG-221 tablet|100 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
3026143|NCT02387866|Experimental|300 mg AG-221 tablet|300 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
3026144|NCT02387853|Experimental|LEO 90100|
3026145|NCT02387840|Experimental|NF1-associated Optic Pathway Glioma (OPG)|Patients with neurofibromatosis type 1 (NF1) associated OPG will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
3026146|NCT02387840|Experimental|NF1 without brain tumor|Patients with NF1 without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
3026147|NCT02387840|Experimental|Without NF1 and with brain tumor exposed to therapy|Patients without NF1 and with low grade gliomas exposed to therapy will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
3026148|NCT02387840|Experimental|Without NF1 and with untreated low grade brain tumors|Patients without NF1 and with untreated low grade gliomas will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
3026149|NCT02387840|Experimental|Without NF1 and without brain tumors|Patients without NF1 and without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
3026150|NCT02387840|Experimental|Brain tumors of assorted pathology|Patients with brain tumors of assorted pathologies will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
3026151|NCT02387827|Experimental|Diet+ short -term physical activity (DST)|
3026152|NCT02387827|Experimental|Diet+ long -term physical activity (DLT)|
3026153|NCT02387814|Experimental|Abemaciclib: Normal Hepatic Function|Single dose of Abemaciclib administered orally on Day 1 to participants with normal hepatic function.
3026154|NCT02387814|Experimental|Abemaciclib: Mild Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with mild hepatic impairment.
3026155|NCT02387814|Experimental|Abemaciclib: Moderate Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with moderate hepatic impairment.
3026156|NCT02387814|Experimental|Abemaciclib: Severe Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with severe hepatic impairment.
3026157|NCT02387801|Experimental|Ixekizumab Dosing Q2W|160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q2W) every 2 weeks through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44.
3026158|NCT02387801|Experimental|Ixekizumab Dosing Q4W|160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q4W) every 4 weeks through week 44.
3026159|NCT02387788|Experimental|15 mg AKB-9778 BID for 84 days|Subcutaneous AKB-9778 15 mg BID (total dose of 30 mg/day) for 84 days
3026160|NCT02387775|Experimental|Esophageal temperature control|The Esophageal Cooling Device (ECD) will be inserted and utilized for temperature control for up to 36 hours in this arm. The ECD will be used for all three phases of therapeutic hypothermia; induction, maintenance, and rewarming. Conventional cooling or warming techniques (e.g. cold saline, ice packs, cooling or warming blankets) will still be made available to the treating ICU team to be used at their discretion.
3026161|NCT02387762|Experimental|Treatment Group 1|ACP-196
3026162|NCT02387762|Placebo Comparator|Treatment Group 2|Placebo
3026163|NCT02387749|Experimental|mesenchymal stem cells|The BM aspirate will be diluted at 6:1 ratio with phosphate buffer saline with 2 ml EDTA (30 ml BM aspirate+ 5 ml PBS/EDTA buffer).MNCs will be separated under aseptic conditions using a Ficoll. Hypaque desity gradient by centrifugation at 1800 rpm for 20 min then the MNCs will be plated in 40 ml(αMEM), serum free media; mesencult(MSCs culture),penicillin (100 U/ml),streptomycin(10 mg/ml),0.5 ml amphotericin B(all from Gibco BRL) and 10 ng/ml basic fibroblast growth factor (b-FGF)(R&D system, Minneapolis, MN) and will be incubated at 370 c in a humidified atmosphere containing 5% CO2 .after one day ,nonadherent cells will be cultured in the presence of Mesenchymal media for 3 weeks changed every week. After reaching 80% confluence the MSCs will be placed in 10 ml saline and infused IV.
3026164|NCT02387736|Experimental|DBT-6|6 months of standard dialectical behaviour therapy treatment.
3026165|NCT02387736|Active Comparator|DBT-12|12 months of standard dialectical behaviour therapy treatment
3026166|NCT02387723|Experimental|Stem cell therapy|Treatment with direct intra-myocardial Injection of 100 million allogeneic adipose derived stem cells (CSCC_ASC) into the heart
3026167|NCT02387710|Active Comparator|Tiagabine|Tiagabine PO 12 mg before sleep
3026168|NCT02387710|Placebo Comparator|Placebo|Placebo PO before sleep
3026169|NCT02387697|Experimental|Group A|Transfemoral implantation of an Edwards Sapien XT Valve into the vena cava inferior (VCI). For better stability and for downsizing of the VCI diameter the valve will be implanted after preparation of a landing zone. This includes implantation of one or two self expandable stents into the VCI prior to the final deployment of the valve.
3026170|NCT02387697|No Intervention|Group B|Control group (no surgery) with optimal medical treatment.
3026171|NCT02387671|Experimental|mHealth Platform|The primary interventions employed in the study are wifi enabled tracking devices, text message communications and behavioral counseling.
3026172|NCT02387658||final TLG </=11 mmHg|includes all patients who have a final mean translesional gradient measurement (TLG) < 11 mmHg regardless if revascularization is done or not.
3026173|NCT02387658||final TLG > 11 mmHg|includes all patients who have a final mean translesional gradient measurement (TLG) > 11 mmHg regardless if revascularization is done or not.
3026175|NCT02387619|Experimental|Group 1 of part 1|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T during the period 1 and Rosuvastatin 20mg 1T and Telmisartan/Amlodipine 40/5mg 2T during the period 2
3026176|NCT02387619|Experimental|Group 2 of part 1|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Rosuvastatin 20mg 1T during the period 2
3026177|NCT02387619|Experimental|Group 1 of part 2|Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 2
3026178|NCT02387619|Experimental|Group 2 of part 2|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Telmisartan/Amlodipine 40/5mg 2T during the period 2
3026179|NCT02387606|Experimental|Cohort 1|Participants will receive placebo or JNJ-53718678 500 milligram (mg) or 200 mg once daily for 7 days.
3026180|NCT02387606|Experimental|Cohort 2|Participants will receive placebo or JNJ-53718678; dosing regimen in Cohort 2 will be decided based on Cohort 1 results.
3026181|NCT02387606|Experimental|Cohort 3|Participants will receive placebo or JNJ-53718678, 75 mg once daily for 7 days.
3026182|NCT02387593|Experimental|colonoscopy with endocuff|To the usual colonoscopy will place a endocuff at the tip of the colonoscope
3026183|NCT02387593|No Intervention|standard colonoscopy without endocuff|Routine colonoscopy without endocuff
3026184|NCT02387580|Active Comparator|Regimen A: OZ439 + TPGS and PQP|800 mg OZ439 + TPGS granules (oral suspension 240 mL volume and 100 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
3026185|NCT02387580|Experimental|Regimen B: OZ439 Prototype 1 and PQP - 110mL|800 mg OZ439 Prototype 1 granules (oral suspension 60 mL volume and 50 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
3026186|NCT02387580|Experimental|Regimen C: OZ439 Prototype 3 and PQP - 110mL|800 mg OZ439 Prototype 3 granules (oral suspension 60 mL volume and 50 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
3026187|NCT02387580|Active Comparator|Regimen D: OZ439 + TPGS and PQP|800 mg OZ439 + TPGS granules (oral suspension 240 mL volume and 100 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
3026188|NCT02387580|Experimental|Regimen E: OZ439 Prototype 1 or 3 and PQP - XmL|800 mg OZ439 Prototype 1 or 3 granules (oral suspension and rinse volume to be determined) and 960 mg (3 × 320 mg) PQP tablets
3026189|NCT02387580|Experimental|Regimen F: OZ439 Prototype 1 or 3 and PQP - XmL|800 mg OZ439 Prototype 1 or 3 granules (oral suspension and rinse volume to be determined) and 960 mg (3 × 320 mg) PQP tablets
3026190|NCT02387567|Experimental|Lidocaine|Paraspinal infusion of 3ml lidocaine at 1%, once a week for three weeks, combined with standard treatment.
3026191|NCT02387567|Sham Comparator|Sham lidocaine|Sham Injection, without lidocaine, combined with standard treatment.
3026192|NCT02387567|Active Comparator|Standard treatment only|The only intervention is the standard treatment. No lidocaine or shame injection was used.
3026193|NCT02387554|Experimental|HGP0904+HGP0608+HGP1405|amlodipine + losartan + chlorthalidone
3026194|NCT02387554|Active Comparator|HGP0904|amlodipine
3026195|NCT02387554|Active Comparator|HGP0608|losartan
3026196|NCT02387554|Active Comparator|HGP1405|chlorthalidone
3026197|NCT02387528|Experimental|Mindfulness Intervention|Group will participate in a Minfulness Intervation
3026198|NCT02387528|Active Comparator|Control Group meetings|Group will practice relaxation
3026199|NCT02387515|Experimental|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology.
3026200|NCT02387502|Experimental|Intubation with Macintosh laryngoscope|40 patients were intubated with Macintosh laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
3026201|NCT02387502|Active Comparator|Intubation with MacCoy laryngoscope|40 patients were intubated with MacCoy laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
3026202|NCT02387502|Active Comparator|Intubation with Airtraq laryngoscope|40 patients were intubated with Airtraq laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
3026203|NCT02387489|Active Comparator|NBI|Nurse-delivered Brief Intervention
3026204|NCT02387489|Experimental|CBI|Computerized Brief Intervention
3026205|NCT02387476|Experimental|FRESCA mask first night|"FRESCA mask first night (experimental device) | CPAP second night (active comparator)"
3026206|NCT02387476|Experimental|CPAP Mask first night|"CPAP Mask first night (active comparator)| FRESCA mask second night (experimental device)"
3026207|NCT02387450|Active Comparator|Treated group|Sildenafil, oral, 100mg per day
3026208|NCT02387450|Placebo Comparator|Control group|placebo oral
3026209|NCT02387437|Experimental|SI recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
3026210|NCT02387437|Experimental|IP recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
3026211|NCT02387437|Experimental|PCV recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
3026212|NCT02387424|Experimental|MBCT-PD|Mindfulness-based cognitive therapy adapted for perinatal women (MBCT-PD)
3026213|NCT02387424|Active Comparator|OAR|Ongoing Assessment and Referral (OAR)
3026214|NCT02387411|Active Comparator|Interval group|high-intensity interval exercise training
3026215|NCT02387411|Active Comparator|Combined group|combined exercise training
3026216|NCT02387398|Experimental|Interventional|Early Angiography with purpose of coronary revascularization within 120 minutes of admission to ED, post out-of-hospital cardiac arrest, suspicious for cardiac etiology and no ST segment elevation on ECG
3026379|NCT02386280|Sham Comparator|Psicoeducation|General information about drugs and ways of prevention
3026217|NCT02387398|No Intervention|Control Group|Standard of care treatment including therapeutic hypothermia in subjects post resuscitation, out-of-hospital cardiac arrest, suspicious for cardiac etiology and no ST segment elevation on ECG.
3026218|NCT02387385|Active Comparator|Intervention|Whole body cooling to 33 degrees C to 34 degrees C
3026219|NCT02387385|No Intervention|Standard of Care|Standard of care
3026220|NCT02387372|Experimental|Mechanically Ventilated|"Participants with proven or suspected pneumonia, undergoing mechanical ventilation will receive 4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:~Those with Creatinine clearance (CLCR) > 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours~Those with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours~Those with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"
3026221|NCT02387372|Experimental|Critically Ill|Critically ill participants with CLCR ≥180 mL/min (as calculated by the Cockcroft-Gault equation) will receive a single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion.
3026222|NCT02387359|Active Comparator|3.0 mg plecanatide|Plecanatide 3.0 mg dosed daily for 12 weeks
3026223|NCT02387359|Active Comparator|6.0 mg plecanatide|Plecanatide 6.0 mg dosed daily for 12 weeks
3026224|NCT02387359|Active Comparator|Matching placebo|Placebo dosed daily for 12 weeks
3026225|NCT02387346|Experimental|Real Stimulation|Participants in this group will receive Repetitive Transcranial Magnetic Stimulation, characterized by 900 pulses at 1Hz over the medial cerebellum at 120% resting motor threshold of the right first dorsal interosseous.
3026226|NCT02387346|Sham Comparator|Sham Stimulation|Participants will receive Sham Repetitive Transcranial Magnetic Stimulation by having the coil angled at 90 degrees to the scalp; this will allow adequate noise output from the stimulator in the absence on real magnetic stimulation.
3026227|NCT02387333|Experimental|Study group|in this arm -study group- : patients will receive mesh stoma reinforcement technique with ileal conduit urinary diversion.
3026228|NCT02387333|Sham Comparator|Control group|in this arm -sham comparator- : patients will not receive mesh stoma reinforcement technique with ileal conduit urinary diversion.
3026229|NCT02387320|Experimental|Self-Care Toolkit|Women randomized to self-care toolkit group will receive a toolkit which includes a spiral-bound instruction manual, a section of the manual that can be used as a journal, a portable mp3 player with 8 audiofile tracks with guided meditations to reduce stress and anxiety, and two acupressure wristbands to help prevent nausea.
3026230|NCT02387320|No Intervention|Standard Care|Women randomized to the standard care group will be informed that they will continue to receive standard of care as delivered by the SAMMC Oncology Department. The research team will inform women randomized to standard care that they will receive the self-care toolkit at their two week post-operative visit and will be able to use it subsequently if they choose to.
3026231|NCT02387307|Experimental|Cohort: Dose-Escalation and Expansion|"Dose-Escalation: Dose escalation in solid tumors utilizing a 3+3 design with intra-subject dose escalation. 3 dose levels of rSIFN-co are planned for determining the RD. Dose of rSIFN-co: 15, 21, 24, 27 and 30 ug.~Dose-Expansion: The Expansion Cohort will be initiated at the RD. Depending on the RD, the lead in period will occur accordingly. After the lead in period, a period from Cycle 1 to the final administration will be performed as the Treatment Phase during which subjects will undergo a standardized evaluation for the safety and efficacy of rSIFN-co at the RD. Follow-up evaluations will be performed 28 days (±5 days) after the last rSIFN-co administration."
3026232|NCT02387294|Experimental|Children and adolescents|"Intervention:~Vaccination with Fluval AB Novo.~Dosage:~Children (3-11 years): 0,25 ml (half dose of) a single intramuscular injection of Fluval AB Novo suspension for injection.~Adolescents (12-18 years): 0,5 ml (one dose of) a single intramuscular injection of Fluval AB Novo suspension for injection."
3026233|NCT02387281||"PD with FOG on"|"Subjects diagnosed with Parkinson disease (PD) and sub-categorized as on freezing of gait (FOG) based on evaluation using motion capture"
3026234|NCT02387281||"PD with FOG off"|"Subjects diagnosed with Parkinson disease (PD) and sub-categorized as off freezing of gait (FOG) based on evaluation using motion capture"
3026235|NCT02387281||PD without FOG|Subjects with Parkinson disease (PD) and an absence of freezing of gait (FOG)
3026236|NCT02387281||Non-PD with FOG|Subjects with freezing of gait (FOG) and an absence of Parkinson disease (PD) (exception granted for those with FOG and atypical parkinsonism: PSP or MSA)
3026237|NCT02387268|Experimental|CleanC|Standard colonoscopy procedure using the CleanC system
3026238|NCT02387255||Normal Volunteers|60 normal volunteers will be recruited. Each volunteer will undergo a single MRE scan (with Resoundant driver System ) of their abdominal aorta.
3026239|NCT02387255||Patients with AAA|Fifty to sixty five patients with AAA will be recruited. These patients will undergo MRE (with Resoundant driver system) of their AAA every six months for three years, or until the study ends or until the time of surgical repair or death due to rupture of AAA or other causes.
3026240|NCT02387255||Open Surgical Repair Patients|Fifty to sixty five patients patients undergoing open surgical repair will be recruited and undergo MRE (with Resoundant driver system) prior to surgery
3026241|NCT02387242|Experimental|Group 1|10mg/kg Rifampicin
3026242|NCT02387242|Experimental|Group 2|20mg/kg Rifampicin
3026243|NCT02387242|Experimental|Group 3|30mg/kg Rifampicin
3026244|NCT02387229|Active Comparator|Rivaroxaban|Rivaroxaban 15 mg/ Acetylsalicylic acid Placebo tablets, orally, once daily, preferably at the same time of the day throughout the study.
3026245|NCT02387229|Active Comparator|Acetylsalicylic acid|Acetylsalicylic acid 100 mg/ Rivaroxaban Placebo tablets, orally, once daily, preferably at the same time of the day throughout the study.
3026246|NCT02387216|Experimental|Arm A: Experimental Arm|MM-121 in combination with Docetaxel
3026247|NCT02387216|Active Comparator|Arm B: Comparator Arm|Docetaxel alone
3026248|NCT02387203|Experimental|PrevPac|All eligible patients with a PMP diagnosis, undergoing CRS/HIPEC treatment, who consent to study participation will have a urea breath test prior to the first course of PrevPac. After surgery, when tolerated, each patient will take a second course of PrevPac. Patients will be seen for follow-up as clinically indicated until year 5.
3026249|NCT02387203|No Intervention|PMP Historical Control|The historical control group will consist of all PMP patients who did not receive perioperative antibiotic treatment.
3026250|NCT02387190|Experimental|Telenursing monitoring|The protocol for telenursing allows the realization of standardized professional contacts with the patient and educational approach It is possible through questions and answers coded, that indicate the need for educational intervention or reinforcement of appropriate health behavior.1) Contact the patient by telephone, weekly; 2) Distribution and explanation of the educational booklet; 3) Filling a diary of symptoms and signs; 4) Record, management and markdown visits in case of non-elective visits, hospitalization or fatal episodes. Also, the following aspects shall be observed: help requests associated with illness, adaptations for living with the disease, effects of drugs in daily life, availability of financial resources for disease management, self-image; emotional and social support.
3026251|NCT02387190|No Intervention|Control group|Placebo is considered as standardized education
3026252|NCT02387177|Experimental|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
3026253|NCT02387177|Experimental|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
3026254|NCT02387164|Experimental|Alum-GAD, Vitamin D3|Two doses à 20 microgram of subcutaneous alum-GAD (Diamyd), 30 Days apart. Vitamin D 2000 U/Daily with start 30 days before the first injection of Diamyd. Vitamin D treatment will continue throughout the whole study period of 5 years.
3026255|NCT02387164|Placebo Comparator|Placebo, Vitamin D3|Two doses of subcutaneous placebo, 30 Days apart. Vitamin D 2000 U/Daily with start 30 days before the first injection of Diamyd. Vitamin D treatment will continue throughout the whole study period of 5 years
3026256|NCT02387151|Experimental|mesenchymal stromal cells|allogeneic mesenchymal stromal cell infusion
3026257|NCT02387138|Experimental|SIRINOX|"S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels).~Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle G-csf : d8 to d13 systematically"
3026258|NCT02387125|Experimental|Part 1 Dose Escalation of CMB305|Patients with melanoma, NSCLC, ovarian cancer, or sarcoma will be enrolled. Patients will receive CMB305, a sequential regimen of LV305 and G305. Two cohorts are planned based on LV305 dose.
3026259|NCT02387125|Experimental|Part 2 Expansion of CMB305|Arm A will enroll up to 9 patients each with NSCLC or ovarian cancer, or up to 18 patients with the sarcoma subtypes, synovial sarcoma or MRCL. Arm B will enroll up to 9 additional patients with selected sarcoma subtypes to explore subcutaneous (SC) dosing of LV305 and G305 on the same schedule. Arm C will enroll up to 9 patients with synovial sarcoma or MRCL for treatment with CMB305 and with oral metronomic CPA. Arm D will enroll up to 9 patients with synovial sarcoma or MRCL at selected sites for treatment with CMB305 and IT G100. Arm E will enroll up to 6 patients with soft tissue sarcoma any subtype for treatment with a higher dose of CMB305 than previous arms.
3026260|NCT02387112|Experimental|Early VAD implantation|The experimental intervention is early implantation of a left ventricular assist device (early VAD). Patients randomized to early VAD implantation will obtain a VAD within 28 days after randomization.
3026261|NCT02387112|No Intervention|Emergency VAD implantation|The control intervention is conservative heart failure treatment, with LVAD implantation in the case of worsening heart failure (emergency VAD). All patients randomized to the control intervention will be treated according to standard medical practice. In brief, these patients are closely monitored (scheduled regular visits to outpatient department depending on the patient's condition and at least every 6 months). If the condition worsens the patient may qualify for high urgency (HU) listing and/or for VAD implantation.
3026262|NCT02387099|Active Comparator|Conventional Everolimus dosing according to label|"everolimus 10 mg/day, week 1-3: 4x2.5 mg/day (blinded); week 4-24: 10mg/day (open according to label)~+ further treatment according to standard of care"
3026263|NCT02387099|Experimental|3 week Dose Induction of Everolimus|"an escalating dose of everolimus as follows: week 1: 1x2.5 mg verum + 3x placebo/day; week 2: 2x2.5 mg verum + 2x placebo/day; week 3: 3x2,5 mg verum + 1x placebo/day; week 4-24: 10 mg/day (open according to label)~+ further treatment according to standard of care"
3026264|NCT02387086|Experimental|A:gefitinib and thalidomide/aspirin|intervention: drug: gefitinib and thalidomide/aspirin: gefitinib will be administered at 250mg QD continuously; thalidomide will be administered at 100mg QD at night continuously; aspirin will be administered at 100mg QD continuously;
3026265|NCT02387086|Placebo Comparator|B:Placebo|intervention: drug: gefitinib and placebo/aspirin: gefitinib will be administered at 250mg QD continuously; placebo will be given to patients in the same way as the thalidomide; aspirin will be administered at 100mg QD continuously;
3026266|NCT02387073||Electrical version|Electrical version patient reported outcome questionnaire was used for patients who had filled-up same questionnaire in a paper version
3026267|NCT02387060|Experimental|H-Bupivacaine 11.5 mg + fentanyl 25 mcg.|Intrathecal administration of Hyperbaric Bupivacaine 1.5 ml 0.75% plus fentanyl 25 mcg.
3026268|NCT02387060|Active Comparator|H-Bupivacaine 11.5 mg.|Intrathecal administration of Hyperbaric Bupivacaine 1.5 ml 0.75%
3026269|NCT02387034|Experimental|Physical activity on prescription (PAP)|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
3026270|NCT02387034|Other|General advice|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about being active with cardiovascular exercise such as walking, cycling or otherwise in 30 minutes three times a week and do strength training functional during the day such as walk in stairs and getting up from a chair without hand support.
3026271|NCT02387021|Active Comparator|Continous femoral nerve block|Patients will receive ultrasound-guided (USG) continuous femoral nerve block with 20 ml ropivacaine 0.2% and USG Continuous adductor canal block with 20 ml of saline and USG infragluteal SNB with 20 ml of saline .
3026459|NCT02385695||Internal Fixation and Fusion|Surgical treatment with internal fixation and fusion
3026272|NCT02387021|Experimental|Continuous adductor canal block|Patients will receive ultrasound-guided continuous adductor canal block with 20 ml ropivacaine 0.2% and USG infragluteal SNB with 20 ml ropivacaine 0.2% and USG continuous FNB with 20 ml of saline .
3026273|NCT02387008|Active Comparator|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
3026274|NCT02387008|Active Comparator|GUIDOR® membrane alone|horizontal bone augmentation with synthetic GUIDOR® membrane
3026275|NCT02387008|Active Comparator|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
3026276|NCT02386995||BIS and Entropy monitoring|Depth of anesthesia monitoring (BIS and entropy) are compared with standard clinical monitoring in patients with deep brain stimulators inserted at internalization whilst they are having a general anesthesia.
3026277|NCT02386982|Experimental|HMS5552 dose 1|HMS5552 75mg.Oral administration,twice per day.
3026278|NCT02386982|Experimental|HMS5552 dose 2|HMS5552 75mg.Oral administration,once per day.
3026279|NCT02386969|Experimental|Active rTMS then sham rTMS|Active rTMS in 1st period and sham rTMS in 2nd period
3026280|NCT02386969|Experimental|Sham rTMS then active rTMS|Sham rTMS in 1st period and active rTMS in 2nd period
3026281|NCT02386956|Experimental|Active stretching|10 minutes of Postural Global Reeducation for the posterior muscle chain
3026282|NCT02386956|Experimental|Dynamic Stretching|10 minutes of sciatic nerve manual movilization in two legs
3026283|NCT02386956|Placebo Comparator|Control|10 minutes with the patient lying on a machine off of magnetotherapy
3026284|NCT02386943|Experimental|Sitagliptin|Subjects are assigned to take one pill of sitagliptin(100mg po once) at 7am on experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
3026285|NCT02386943|Experimental|Saxagliptin|Subjects are assigned to take one pill of saxagliptin(5mg po once) at 7am on experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
3026286|NCT02386943|Experimental|Blank control|Subjects take no medication for blank control at experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
3026287|NCT02386930|Experimental|Behavrioal Lifestyle modification|
3026288|NCT02386930|No Intervention|Control|
3026289|NCT02386917|Active Comparator|Gastric bypass|40 patients will undergo gastric bypass
3026290|NCT02386917|Active Comparator|Very low calorie diet|40 patients will undergo a very low calorie diet
3026291|NCT02386917|No Intervention|Gall bladder operation|20 patients will be asked to undergo one pharmacokinetic study only, and then finish the study. They will not undergo any weight loss intervention.
3026292|NCT02386904|Experimental|Phosphate Enema|Phosphate Enema consisting on Monobasic Sodium Phosphate (USP) 19.2 gm /120 ml and Dibasic Sodium Phosphate (USP) 7.2 gm/120 ml Dosage Form: Enema Frequency: One time; 30 minutes before Sigmoidoscopy
3026293|NCT02386891|Experimental|Cold|The cold treatment was 18-20°C (64.5-68°F), which is at the lower end of the thermalneutral zone in healthy adults.
3026294|NCT02386891|Experimental|Warm|The warm treatment was 25-27°C (77-80.6°F), which is above the range of the thermalneutral zone.
3026295|NCT02386878|Experimental|Interpersonal Psychotherapy for Groups (IPTG)|The intervention consists of 16 weekly 60 to 90 minute psychotherapy sessions, implemented once a week by a trained lay facilitator.
3026296|NCT02386878|Experimental|Vhutshilo 2|The intervention consists of 13 group sessions, implemented once a week by a trained lay facilitator.
3026297|NCT02386878|Experimental|IPTG and Vhutshilo|Participants receive the IPTG intervention first, followed by Vhutshilo 2.
3026298|NCT02386878|No Intervention|No Intervention|No intervention
3026299|NCT02386852|Experimental|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (ginseng: group 1; ginkgo biloba: group 2).
3026300|NCT02386852|Experimental|Ginseng|Participants in the ginseng group received a medium, and higher dose of ginseng in addition to placebo capsules.
3026301|NCT02386852|Experimental|Ginkgo Biloba|Participants in the ginkgo biloba group received a medium, and higher dose of ginkgo in addition to placebo capsules.
3026302|NCT02386839||Group 1|Participants who had short-term exposure to rhIGF-I/rhIGFBP-3 in previous study ROPP-2008-01 (NCT01096784)
3026303|NCT02386839||Group 2|Participants who received standard neonatal care in previous study ROPP-2008-01(NCT01096784)
3026304|NCT02386826|Experimental|INC280 + Bevacizumab|"Dose Escalation: 18 GBM patients received bevacizumab 10 mg/kg intravenously (IV) once every 2 weeks in combination with INC280 given by mouth (PO) starting at 100 mg twice daily and escalating on a 3+3 escalation pattern until the maximum tolerated dose (MTD) was determined.~Dose Expansion: Up to 45 GBM patients enrolled in 3 Cohorts:~Cohort A: 20 GBM patients - progressed during or after standard 1st-line therapy; Cohort B: 15 GBM patients - progressed during or after 2nd-line bevacizumab therapy; Cohort C: 10 unresectable GBM patients.~INC280: PO twice daily at the MTD. Bevacizumab: 10 mg/kg IV once every 2 weeks for Cohorts A and B; 15 mg/kg IV every 4 weeks for Cohort C Treatment cycles will be repeated every 28 days (4 weeks)."
3026305|NCT02386813||Training cohort|"Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31, 2013;~Patients treated with non-anthracycline based therapy as an initial treatment."
3026306|NCT02386813||Validation cohort|"Patients diagnosed with ENKTL, nasal type between January 1, 1998 and December 31, 2014;~Patients treated with non-anthracycline based therapy as an initial treatment."
3026307|NCT02386800|Experimental|Ruxolitinib|
3026308|NCT02386787|Experimental|SEMI EMERGENCY SURGERY PATIENT|patient undergoing a non-elective surgery and having a preoperative fasting period of six hours.
3026309|NCT02386774|Other|an ocular or ocular adnexa disease|patient presenting with an ocular or ocular adnexa disease in the Dermatology or Ophthalmology ward.
3026310|NCT02386774|Other|diabetic patients|
3026311|NCT02386761|Experimental|Single Ascending Dose (SAD)|"Dose 1 (SAD1): 6 inhalations of CHF 6001 400 µg giving a total dose of 2400 µg~Dose 2 (SAD2): 10 inhalations of CHF 6001 400 µg giving a total dose of 4000 µg~Dose 3 (SAD3): 12 inhalations of CHF 6001 400 µg giving a total dose of 4800 µg Placebo (P): the number of placebo inhalations will match that of the active CHF 6001 pertaining to the same dose period.~In case the actual doses are modified, the number of inhalations will be adapted accordingly."
3026380|NCT02386267|Experimental|L-leucine pills|L-leucine , dose- 700mg/m2 , per os, three time a day, course duration 6 months
3026544|NCT02385149|Experimental|whole grain wheat|98g whole grain wheat per day for 12 weeks
3026312|NCT02386761|Experimental|Multiple Ascending Dose (MAD)|"Dose 1 (MAD1): Multiple doses of CHF 6001 - Total daily dose 2400 µg or placebo~Dose 2 (MAD2): Multiple doses of CHF 6001 - Total daily dose 4000 µg or placebo~Dose 3 (MAD3): Multiple doses of CHF 6001 - Total daily dose 4800 µg or placebo~Duration 14 days b.i.d."
3026313|NCT02386748|Experimental|Chewing gum|Chewing sugarless gum
3026314|NCT02386748|Active Comparator|Oral fluids|Clear oral fluids
3026315|NCT02386748|Other|Intravenous fluids|No chewing gum No oral fluids Only intravenous fluids (Lactated Ringer's solution)
3026316|NCT02386735|Experimental|Investigational treatment|Patients included in the placebo group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for three days followed by two days of placebo.
3026317|NCT02386735|Active Comparator|Standard treatment|Patients included in the control group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for five days as recommended in current guidelines.
3026318|NCT02386722|Experimental|Intervention group|Patients assigned to the intervention group will receive a Smartinhaler/POEMS, which will contain an audio reminder function. If the alarm function is on, a ring tone will be generated, after the time predesigned for inhalation. If the use of rescue medication doubles or if the inhaled medication is not inhaled as prescribed for more than two consecutive days, the investigator will call them to see if they need help and to find out the reason for non-adherence.
3026319|NCT02386722|No Intervention|Control group|Patients in the control group will receive a Smartinhaler/POEMS, which only records their adherence. The alarm function of the devices will be switched off, and these participants will not be reminded to take their inhalers. This group will not receive any calls, if they do not comply with the prescribed medication schedule or if they use their rescue medication too frequently.
3026320|NCT02386696|Experimental|Ultrasound findings|"Thoracic ultrasound examinations in the following conditions:~Apnea;~Spontaneous regular breathing;~Valsalva maneuver, during which each subject will be asked for performing three forced expirations with closed glottis after one forced inspiration;~Muller maneuver, during which each subject will be asked for performing three forced inspirations after one forced expiration;~Hyperventilation."
3026321|NCT02386683|Active Comparator|Group L|lung-protective ventilation applied in anesthesia
3026322|NCT02386683|No Intervention|Group T|traditional ventilation applied in anesthesia
3026323|NCT02386670|Experimental|tDCS + CR|"Intervention sessions are administered 5 days/week for 8 weeks (induction phase). Then, for 5 days every 6 months (consolidation phase).Transcranial Direct Current Stimulation (tDCS) session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 minutes/session. Cognitive Remediation (CR) sessions follow tDCS sessions and last 2 hours in a group supervised by trained interventionists. Participants also complete CR exercises online at home. CR consists of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. Strategic monitoring and bridging discussions promotes transfer of cognitive gains to everyday tasks."
3026324|NCT02386670|Sham Comparator|sham tDCS + sham CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes.~CR sessions will follow the tDCS session and last 2 hours in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels."
3026325|NCT02386657||Emergency admitted sickle cell disease patients|Sickle Cell Disease Patients admitted inside the Emergency Department of the Brugmann Hospital for a vaso-occlusive crisis.
3026326|NCT02386644|Experimental|Suspected Membrane Rupture Arm|Women with suspected membrane rupture will be subject to following interventions; Ultrasound amniotic fluid index measurement, ultrasound transperineal assessment, nitrazine test, speculum examination, PAMG-1 Immunoassay
3026327|NCT02386631|Experimental|Orthotic|Custom made orthotic provided for study
3026328|NCT02386618|Other|Local residual neoplasia|Patients with local residual neoplasia in 3 months after endoscopic resection of colorectal lateral spreading tumors diagnosed endoscopically and/or histologically
3026329|NCT02386605|Experimental|Treatment|Motivational Interviewing Treatment group
3026330|NCT02386605|Active Comparator|Control|Relaxation Skills Training group
3026331|NCT02386592|Experimental|Intervention|Infection control package consisting of alcohol hand rub hand hygiene (HH), 2% chlorhexidine gluconate (CHG) body washes, infection control training, and text messages with basic Infection control reminders via SMS text
3026332|NCT02386579||Diabetics with Charcot foot|
3026333|NCT02386579||Diabetics without charcot foot|
3026334|NCT02386566||natalizumab|natalizumab 300 mg intravenous (IV) every 4 weeks; according to the approved product label of Tysabri in Switzerland
3026335|NCT02386553|Experimental|Nusinersen|Nusinersen administered as an intrathecal injection
3026336|NCT02386540|Experimental|Health Coaching|Patients randomized to the experimental arm receive six months of post-ED health coaching from the Alameda County Health Coach Program (ACHCP) in addition to usual care in the emergency department at enrollment.
3026337|NCT02386540|No Intervention|Usual Care|Patients randomized to the control arm receive usual care in the emergency department at enrollment.
3026338|NCT02386501|Experimental|ADXS31-164|
3026339|NCT02386488|Experimental|Vortioxetine 10 mg single dose|8 men and 8 women
3026340|NCT02386488|Experimental|Vortioxetine 20 mg single dose|8 men and 8 women
3026341|NCT02386488|Experimental|Vortioxetine 10 mg multiple dose|8 men and 8 women
3026342|NCT02386488|Experimental|Vortioxetine 20 mg multiple dose|8 men and 8 women
3026343|NCT02386475|Placebo Comparator|Placebo|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
3026344|NCT02386475|Active Comparator|citalopram 20 mg|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
3026345|NCT02386475|Active Comparator|sinemet plus 100 mg|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
3026346|NCT02386475|Active Comparator|Sinemet Plus + citalopram group|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
3026347|NCT02386462|Experimental|Dexmedetomidine|After an injection of pre-determined bolus dose of dexmedetomidine over 10 min, anaesthesia was induced with propofol 2.0 mg/kg. The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg).
3026348|NCT02386449|Experimental|Picoprep|sodium picosulfate, magnesium oxide and citric acid
3026349|NCT02386449|Active Comparator|Mannitol and Bisacodyl|
3026350|NCT02386436|Experimental|Cohort 1- GSK2330811(0.1 mg/kg)|Subjects will be randomised to receive either 0.1 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
3026351|NCT02386436|Experimental|Cohort 2- GSK2330811(0.3 mg/kg)|Subjects will be randomised to receive either 0.3 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
3026352|NCT02386436|Experimental|Cohort 3- GSK2330811(1 mg/kg)|Subjects will be randomised to receive either 1 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
3026353|NCT02386436|Experimental|Cohort 4- GSK2330811(3 mg/kg)|Subjects will be randomised to receive either 3 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
3026354|NCT02386436|Experimental|Cohort 5- GSK2330811(6 mg/kg)|Subjects will be randomised to receive either 6 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
3026355|NCT02386423|Experimental|RESTIFFIC|RESTIFFIC™ Brand Pressure Application System
3026356|NCT02386410|Experimental|Group parent training|The intervention Group parent training for anxious parents is delivered in groups of about five, in 90 minutes per session, for eight consecutive weeks. The parent training is delivered by a licensed psychologist.
3026357|NCT02386410|Experimental|Internet delivered parent training|In the internet delivered parent training for anxious parents, parents are asked to work with one chapter each week, for eight consecutive weeks. Each chapter mirrors a session in the group format. Parents are able to e-mail a licensed psychologist during the intervention.
3026358|NCT02386410|No Intervention|Wait-list|Parents in the wait-list condition will receive the intervention after 12-month follow-up.
3026359|NCT02386397|Experimental|Treatment|"Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment mGEMOX: infusion on days 1 and 8~Gemcitabine 900 mg/m² IV in 30 minutes~Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine"
3026360|NCT02386384||Control|Normal fertile
3026361|NCT02386384||Implantation Failure|Failure to conceive
3026362|NCT02386384||Recurrent Pregnancy Loss|2 or more unexplained miscarriages
3026363|NCT02386371|Experimental|surgery and Intra Operative Radiotherapy|"Surgery :~Tumorectomy will be performed according to the current standards, obtaining clear margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams.~Intra Operative Radiotherapy (IORT):~After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure."
3026364|NCT02386358|Active Comparator|Benznidazole|Benznidazole pills of 100 mg, dose 5 mg/Kg/day, twice a day during 60 days
3026365|NCT02386358|Placebo Comparator|Placebo|Placebo pills 100 mg, dose 5mg/Kg/day, twice a day, during 60 days
3026366|NCT02386332||umbilical cord blood transplant (UCBT)|Patients to receive umbilical cord blood transplant (UCBT) are conditioned with the myeloablative conditioning regimen (preparative therapy with thiotepa, fludarabine, intravenous busulfan and anti-thymocyte globulin.). Also receive GVHD prophylaxis with cyclosporine A and prednisone and Additional Supportive Care
3026367|NCT02386332||HLA-haploidentical hematopoietic stem cell transplantation|Patients to receive HLA-haploidentical hematopoietic stem cell transplantation are conditioned with the myeloablative conditioning regimen (preparative therapy with thiotepa, fludarabine, intravenous busulfan). Also receive GVHD prophylaxis with cyclophosphamide, cyclosporine A and mycophenolate mofetil and Additional Supportive Care
3026368|NCT02386319|Active Comparator|Melatonin|"Melatonin 10 mg, gelatin capsules. Pharmacokinetic study: 10 mg x 2. In the morning before surgery and in the evening after surgery.~Analgesic study: 10 mg x 4. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery."
3026369|NCT02386319|Placebo Comparator|Placebo|Gelatin capsules. Analgesic study. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.
3026370|NCT02386306|Experimental|Treatment Cohort 1|Each study participant will be administered with one 1mg dose capsule per day of GC021109 for 28 days.
3026371|NCT02386306|Placebo Comparator|Placebo Cohort 1|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
3026372|NCT02386306|Experimental|Treatment Cohort 2|Each study participant will be administered with one dose per day of GC021109 for 28 days. Dose levels will be determined following a review of cohort 1 safety data through day 14
3026373|NCT02386306|Placebo Comparator|Placebo Cohort 2|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
3026374|NCT02386306|Experimental|Treatment Cohort 3|Each study participant will be administered with one dose per day of GC021109 for 28 days. Dose levels will be determined following a review of cohort 2 safety data through day 14
3026375|NCT02386306|Placebo Comparator|Placebo Cohort 3|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
3026376|NCT02386293|Placebo Comparator|Placebo|Sugar pill identical to Avapro provided for 7 day prescription
3026377|NCT02386293|Active Comparator|Irbesartan|150 mg of Avapro once daily for 7 days.
3026378|NCT02386280|Experimental|Motivational Interviewing for Change of Parenting Styles|After measured parental style across the scale, the motivational interviewing will be applied in order to modify the parenting styles of risk for involvement with drug use and maintenance of protective factors. This approach will occur in 5 segments .
3026381|NCT02386215|Experimental|HIV Self-test|Following a baseline interview, participants in the intervention group will be shown how to correctly use the self-tests and given two HIV self-tests. Subsequently, we will contact participants periodically over a 3 month period to see if they have used the test(s) with their sexual partners and conduct a follow-up interview.
3026382|NCT02386215|No Intervention|Control|Following the baseline interview, participants in the control group will be given referral vouchers for themselves and their partners to obtain HIV testing at Voluntary Counseling & Testing (VCT) centers. We will contact the participants at the end of 3 months to see if they and/or their partner(s) have sought HIV testing.
3026383|NCT02386202||Patients with hemorrhagic stroke|All patients with hemorrhagic stroke admitted to the neurosciences ICU are eligible for study enrollment.
3026384|NCT02386189|No Intervention|Usual Care|Veterans randomized to usual care will not receive any training on using their patient portal(s) to access and share information. They will be contacted via phone and/or secure messaging to remind him/her to take the VA or non-VA provider packet to their appointment. At the conclusion of the study, Veterans assigned to usual care will be provided the training information on the VA health summary for their own reference.
3026385|NCT02386189|Active Comparator|Care Coordination|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
3026386|NCT02386150|Experimental|Group 1: 10 μg|10 μg RVEc is to be administered given in the volar surface of the forearm by ID injection (in alternate arms for each vaccination unless there is a medical reason not to alternate arms) with a needle and syringe (ID adapter may be used) (0.1 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
3026387|NCT02386150|Experimental|Group 2: 20 μg|20 μg RVEc is to be administered given in the volar surface of the forearm by ID injection (in alternate arms for each vaccination unless there is a medical reason not to alternate arms) with a needle and syringe (ID adapter may be used) (0.1 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
3026388|NCT02386137|Experimental|Patient|Woman aged more than 18 years having one or two symptomatic fibroid with size < 15cm.
3026389|NCT02386124|Other|frailty evaluation|"all consecutive patients admitted to hospital for acute cardiac disease aged more than 69 years will be evaluated with Short Portable Mental Status Questionnaire (SPMSQ), handgrip and Short Physical Performance Battery (SPPB).~These three tests (SPMSQ, SPPB and handgrip) are the intervention of the study. They are the assays to establish the frailty status"
3026390|NCT02386111|Experimental|Varlilumab and Sunitinib|
3026391|NCT02386098|Experimental|Arm 1: BMS-955176 + ATV + RTV + DTG|BMS-955176 at 120 mg tablet per day + Atazanavir boosted with ritonavir (ATV/r) 300/100 mg tablets per day + DTG 50 mg tablet per day, orally
3026392|NCT02386098|Other|Arm 2: TDF + ATV + RTV + DTG|TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally
3026393|NCT02386098|Experimental|Arm 3: BMS-955176 + ATV + DTG|BMS-955176 at 120 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally
3026394|NCT02386098|Experimental|Arm 4: BMS-955176 + ATV + DTG|BMS-955176 at 180 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally
3026395|NCT02386098|Other|Arm 5: TDF + ATV + RTV + DTG|TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally
3026396|NCT02386085||Osteopathic manipulative treatment (OMT)|All participants will have received OMT to be eligible and will be followed for 1 week after treatment.
3026397|NCT02386072||1. patients diagnosed with OAB taking mirabegron|patients diagnosed with OAB whose physician has decided to prescribe mirabegron as part of routine clinical practice
3026398|NCT02386072||2. patients diagnosed with OAB taking an antimuscarinic|patients diagnosed with OAB whose physician has decided to prescribe an antimuscarinic as part of routine clinical practice
3026399|NCT02386059|Placebo Comparator|PLACEBO Group|Received normal saline
3026400|NCT02386059|Active Comparator|DEXAMETHASONE Group|Received 4 mg Dexamethasone.
3026401|NCT02386059|Active Comparator|ONDANSETRON|Received 4 mg Ondansetron
3026402|NCT02386059|Active Comparator|DEXAMETHASONE + ONDANSETRON|Received 4mg Dexamethasone + 4mg Ondansetron
3026403|NCT02386046||Reference Group|Late preterm infants without any pathology. Intervention: Pulse oxymeter measurements at the hospital and weekly thereafter until 46 weeks postconceptional age.
3026404|NCT02386046||Study Group|Infants born 26-35 weeks requiring caffeine. Intervention: Pulse oxymeter measurements at the hospital before and after caffeine instituted, and weekly thereafter until 46 weeks postconceptional age.
3026405|NCT02386046||Control Group|Infants born 26-35 weeks not requiring caffeine. Intervention: Pulse oxymeter measurements at the hospital and weekly thereafter until 46 weeks postconceptional age.
3026406|NCT02386033|Placebo Comparator|SRP plus placebo|SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
3026407|NCT02386033|Active Comparator|SRP plus Atorvastatin|SRP was done for all the subjects. Atorvastatin was delivered in the pocket subgingivally
3026408|NCT02386020|Placebo Comparator|Placebo|After SRP, placebo gel was delivered subgingivally into periodontal pockets.
3026409|NCT02386020|Active Comparator|Aloe vera|After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.
3026410|NCT02386007|Experimental|DW-3101_150mg|150mg a day
3026411|NCT02386007|Experimental|DW-3101_300mg|300mg a day
3026412|NCT02386007|Experimental|DW-3101_600mg|600mg a day
3026413|NCT02386007|Placebo Comparator|a tablet same as experimental agents in formation and shape|Placebo
3026414|NCT02385994|Experimental|enLighten Laser Treatment|Melasma, Cohort I or Lentigines, Cohort II will be treated with dual-pulse duration, dual-wavelength 532nm KTP/1064nm Nd:YAG laser.
3026415|NCT02385994|No Intervention|Control|Melasma subjects randomized to non-treatment will receive no treatments.
3026416|NCT02385981|Experimental|Stivax|an intermittent stimulation of afferent vagus nerve at earlap
3026417|NCT02385955|Experimental|Myeloablative dUCBT|Myeloablative conditioning with (1) TBI, cyclophosphamide, and cytarabine, or (2) thiotepa, busulfan, and fludarabine, followed by double unit umbilical cord blood transplant
3026418|NCT02385942|Other|Tele-consultation system|compare the Live assessed wound size with the transmitted Smart phone-based wound size through Tele-consultation system
3026419|NCT02385929|Experimental|Swallowing therapy & resistance training|"Mouth opening and swallowing exercise intervention by occupational therapist for half an hour 3 times a week for 5-6 weeks during radiotherapy.~Progressive resistance training by physiotherapist for 1 hour twice weekly for 5-6 weeks during radiotherapy."
3026420|NCT02385929|No Intervention|Standard Care|Patients in this arm are randomized to usual care / control group
3026421|NCT02385916|Experimental|EstroSense®/MD|3 capsules per day during the study period
3026422|NCT02385916|Placebo Comparator|Placebo|3 capsules per day during the study period
3026423|NCT02385903|Other|Standard dressing procedure|One arm receive standard dressing procedure according to the wound
3026424|NCT02385903|Active Comparator|Flammacerium|"Necrosis covering with Flammacerium 3 mm thick each day during one week then one day on two.~On each dressing, remove excess and add flammacerium. Not to remove crust forming until eliminating furrow appears.~Cover Flammacerium by compress."
3026425|NCT02385890|Experimental|Bagel control|100% wheat flour
3026426|NCT02385890|Experimental|Bagel with pea flour|Pea flour
3026427|NCT02385890|Experimental|Bagel with pea fibre|Pea fibre
3026428|NCT02385890|Experimental|Bagel with pea protein|Pea protein
3026429|NCT02385890|Experimental|Bagel with pea flour + pea protein|Pea flour + pea protein
3026430|NCT02385890|Experimental|Bagel with pea fibre + pea protein|Pea fibre + pea protein
3026431|NCT02385877|Experimental|Protocol 1: [18F]4F-MHPG|Subjects (n = 4) will be injected one time with 6.5 mCi of 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and receive a 90 minute PET scan.
3026432|NCT02385877|Experimental|Protocol 1: [18F]3F-PHPG|Subjects (n = 4) will be injected one time with 6.5 mCi of 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) and receive a 90 minute PET scan.
3026433|NCT02385877|Experimental|Protocol 2: Biodistribution Studies|Subjects (n = 4) will be injected one time with 6.5 mCi of either [18F]4F-MHPG or [18F]3F-PHPG (whichever is selected based on Protocol 1 studies) and receive four whole-body PET scans, starting at 5 min, 60 min, 150 min and 360 min after tracer injection.
3026434|NCT02385851|Experimental|CHS-1701/Neulasta|CHS-1701 followed by Neulasta (crossover)
3026435|NCT02385851|Experimental|Neulasta/CHS-1701|Neulasta followed by CHS-1701 (crossover)
3026436|NCT02385838|Experimental|5-Color Nutrition Label (5-CNL)|The 5-CNL front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
3026437|NCT02385838|Experimental|Mutiple Traffic Lights (MTL)|The MTL front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
3026438|NCT02385838|Experimental|Guidelines Daily Amounts (GDA)|The GDA front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
3026439|NCT02385838|Experimental|Green Tick (Tick)|The Tick front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
3026440|NCT02385838|No Intervention|No label|No front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
3026441|NCT02385825|Experimental|Group 1: 10 μg RVEc|10 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
3026442|NCT02385825|Experimental|Group 2: 50 μg RVEc|50 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
3026443|NCT02385825|Experimental|Group 3: 75 μg RVEc|75 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
3026444|NCT02385812|Experimental|High lung cancer risk|Individuals with lung cancer risk >= 1.5% over 6 years
3026445|NCT02385812|Experimental|Low lung cancer risk|Individuals with lung cancer risk <1.5% over 6 years
3026446|NCT02385799|Placebo Comparator|Sertraline Liquid Placebo|The placebo will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid placebo once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid placebo once per day for a period of six months.
3026447|NCT02385799|Active Comparator|Sertraline Active Medication|Liquid sertraline (20 mg/cc) will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid sertraline once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid sertraline once per day for a period of six months.
3026448|NCT02385786|Experimental|Mindfulness-Based Cognitive Therapy|Adult Participants with Major Depressive Disorder who Enroll in an open clinical trial of MBCT as Mono-therapy
3026449|NCT02385773|Experimental|PTM202|PTM202
3026450|NCT02385773|Placebo Comparator|Enfamil Puramino|Formal Placebo
3026451|NCT02385760|Experimental|Active|CTX-4430 oral capsule, 100 mg, once-daily for 12 weeks
3026452|NCT02385760|Placebo Comparator|Placebo|Placebo: identical oral capsule, without active ingredient, once-daily for 12 weeks
3026453|NCT02385747|Experimental|women with anbormal bleeding|women with perimenopausal and postmenopausal bleeding who will be evaluated with transvaginal ultrasound, saline sonohysterography,hystroscopy and endometrial currettage
3026454|NCT02385734|Experimental|Concentrated growth Factor Membrane|Autogenous platelet and leukocyte fibrin material was obtained from blood.
3026455|NCT02385734|Active Comparator|Coronally Advanced Flap|Periodontal plastic surgery procedure in the treatment of gingival recession
3026456|NCT02385708|Active Comparator|Standard of Care|Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery
3026457|NCT02385708|Active Comparator|Treatment Arm|Patients will receive detailed instruction for use of 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative till discharge
3026460|NCT02385682||ST-segment elevation AMI|ST-segment elevation acute myocardial infarction teated with percutaneous coronary intervention
3026461|NCT02385682||Non-ST-segment elevation AMI|Non-ST-segment elevation acute myocardial infarction teated with percutaneous coronary intervention
3026462|NCT02385669|Experimental|6MHP and ipilimumab|"The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 43, 64, and 85. All peptide vaccines are administered intradermally and subcutaneously.~Ipilimumab will be administered in accord with the official prescribing information: 3 mg/kg intravenously once every 3 weeks, for 4 doses. Ipilimumab will be administered on days 1, 22, 43, and 64."
3026463|NCT02385656|Experimental|Intervention group|Subjects who take modafinil for cancer-related fatigue for 4 weeks.
3026464|NCT02385643|Experimental|Intervention group|This group of subjects receives mobile support system and conventional treatment
3026465|NCT02385643|No Intervention|Control group|This group of patients receive conventional treatment only
3026466|NCT02385630|Experimental|Esophagectomy|"Serial assessment:~Fasting gut hormones, post-prandial gut hormone response to a standardized 400kcal meal"
3026467|NCT02385630|Experimental|Gastrectomy|"Serial assessment:~Fasting gut hormones, post-prandial gut hormone response to a standardized 400kcal meal"
3026468|NCT02385617|Experimental|Esophagectomy|Double blind single dose placebo-octreotide crossover
3026469|NCT02385617|Experimental|Total gastrectomy|Double blind single dose placebo-octreotide crossover
3026470|NCT02385617|Active Comparator|Control - no surgery|Double blind single dose placebo-octreotide crossover
3026471|NCT02385617|Experimental|Pancreaticoduodenectomy|Double blind single dose placebo-octreotide crossover
3026472|NCT02385591|Experimental|Telephone Support|Participants will receive bi-weekly 20 minute telephone calls from a trained professional facilitator offering physical activity advice with the goal of increasing moderate-to-vigorous intensity physical activity.
3026473|NCT02385591|Experimental|SMS Support|Participants will receive weekly text messages (3-5 text messages per week) offering physical activity advice with the aim of increasing moderate-to-vigorous intensity physical activity.
3026474|NCT02385591|No Intervention|Attention-control|Participants will receive telephone-based general nutrition advice.
3026475|NCT02385578|No Intervention|The control group|no intervention
3026476|NCT02385578|Experimental|The experimental group|an educational intervention
3026477|NCT02385565|Experimental|high fat diet|10 % proteins, 30 % lipids, 60 % carbohydrates
3026478|NCT02385565|Placebo Comparator|Normal fat diet|10 % proteins, 45 % lipids, 45 % carbohydrates
3026479|NCT02385552||Experienced endoscopists|All of the experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rate every 3 months
3026480|NCT02385539|Active Comparator|Levobupivacaine (LB) 6 mg|Patients will be stratified into three groups (80 patients) according to doses of Levobupivacaine (6, 8 or 12 mg, Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients who will receive 6 mg of Levobupivacaine will be randomized to one of four treatment groups (each 20 patients), by dose of intrathecal opioids: 25, 35 mcg of Fentanyl (Fentanyl, Janssen Cilag, amp. 50 mcg/ml) or 5, 7 mcg of Sufentanil (Sufenta, Janssen-Pharmaceutica, amp. 5 mcg/ml). The groups will be named according to dose and combination of Levobupivacaine and Fentanyl or Sufentanil that will be given intrathecally as LB6F25 (LB 6 mg, Fentanyl 25 mcg), LB6F35 (LB 6 mg, Fentanyl 35 mcg), LB6S5 (LB 6 mg, Sufentanil 5 mcg), LB6S7 (LB 6 mg, Sufentanil 7 mcg). Hemodynamic and opioid's side effects will be recorded. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered
3026481|NCT02385539|Active Comparator|Levobupivacaine (LB) 8 mg|Patients will be stratified into three groups (80 patients) according to doses of Levobupivacaine (6, 8 or 12 mg, Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients who will receive 8 mg of Levobupivacaine will be randomized to one of four treatment groups (each 20 patients), by dose of intrathecal opioids: 25, 35 mcg of Fentanyl (Fentanyl, Janssen Cilag, amp. 50 mcg/ml) or 5, 7 mcg of Sufentanil (Sufenta, Janssen-Pharmaceutica, amp. 5 mcg/ml). The groups will be named according to dose and combination of Levobupivacaine and Fentanyl or Sufentanil that will be given intrathecally as LB8F25 (LB 8 mg, Fentanyl 25 mcg), LB8F35 (LB 8 mg, Fentanyl 35 mcg), LB8S5 (LB 8 mg, Sufentanil 5 mcg), LB8S7 (LB 8 mg, Sufentanil 7 mcg). Hemodynamic and opioid's side effects will be recorded after intrathecal injection. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered
3026482|NCT02385539|Placebo Comparator|Levobupivacaine (LB) 12 mg|"Patients will be stratified into three groups by 80 patients: those who will receive 6, 8 or 12 mg of Levobupivacaine intrathecally (Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients will receive 12 mg of Levobupivacaine alone intrathecally.~Hemodynamic side effects will be recorded after intrathecal injection. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered"
3026483|NCT02385526||Group A|Vagus Nerve Stimulation Therapy Standard Titration
3026484|NCT02385526||Group B|Vagus Nerve Stimulation Therapy Alternate Titration 1
3026485|NCT02385526||Group C|Vagus Nerve Stimulation Therapy Alternate Titration 2
3026486|NCT02385513|Active Comparator|6 + 10 weeks of age PCV10 priming|10 valent pneumococcal conjugate vaccine administered (PCV10) at 6 and 10 weeks of age with a booster at9 months of age and routine vaccines administered as per the Nepal EPI schedule
3026487|NCT02385513|Active Comparator|6 + 14 weeks of age PCV10 priming|10 valent pneumococcal conjugate vaccine administered (PCV10) at 6 and 14 weeks of age with a booster at 9 months of age and routine vaccines administered as per the Nepal EPI schedule
3026488|NCT02385500|Placebo Comparator|Placebo|Subjects will be started on placebo tablets, similar to fesoterodine 4 mg, and will have the option to escalate as well.
3026489|NCT02385500|Experimental|Fesoterodine|Drug intervention of fesoterodine 4 mg once a day in the morning after the two-week washout period. They will have the option to escalate to 8 mg (2 tablets of 4 mg each) after 4 weeks on fesoterodine. Patients will have the option to go back to one tablet (i.e., 4 mg) at any time in the study.
3026490|NCT02385487||Critical illness and type 2 MI|Critically ill adults with abnormal serum troponin I during hospitalization for critical illness.
3026491|NCT02385487||Critical illness without type 2 MI|Critically ill adults without an elevation in troponin I complicating critical illness.
3026492|NCT02385474|Experimental|38% SDF semi-annual|semi-annual application of 38% SDF
3026493|NCT02385474|Experimental|38% SDF annual|annual application of 38% SDF
3026494|NCT02385474|Active Comparator|12% SDF semi-annual|semi-annual application of 12% SDF
3026495|NCT02385474|Active Comparator|12% SDF annual|annual application of 12% SDF
3026496|NCT02385461||Inherited Thrombophilia|Women with Common Inherited Thrombophilias and previous foetal loss
3026497|NCT02385461||Other Thrombophilias with Pregnancy loss|Women with Thrombophilias other than common inherited thrombophilias and previous foetal loss
3026498|NCT02385461||No thrombophilia|Women without thrombophilias and previous foetal loss
3026499|NCT02385448|Experimental|Dienogest|
3026500|NCT02385448|Active Comparator|Combined oral contraceptive pills|
3026501|NCT02385435|Active Comparator|Bupivacaine|single shot caudal plain bupivacaine at a dose of 2mg/kg is used as a reference control drug.
3026502|NCT02385435|Active Comparator|dexmedetomidine 1μg.kg-1|Single shot Caudal dexmedetomidine 1μg.kg-1 used as the second arm intervention
3026503|NCT02385435|Active Comparator|dexmedetomidine 2μg.kg-1|Single shot Caudal dexmedetomidine 2 μg.kg-1 used as the second arm intervention
3026504|NCT02385422|Experimental|Carvedilol|Carvedilol，6.25mg-25mg/d,oral,6 months
3026505|NCT02385422|Active Comparator|Propranolol|Propranolol,30mg-160mg/d,oral,6 months
3026506|NCT02385409||Elective Total Hip- or Knee arthroplasty patients|Patients scheduled for elective Hip- or knee replacement at Hvidovre Hospital, Denmark.
3026507|NCT02385396|Placebo Comparator|Group I|60 patients diagnosed with PCOS, not myo-inositol treated undergoing ICSI
3026508|NCT02385396|Experimental|Group II|52 patients diagnosed with PCOS undergoing ICSI, taking Inofolic (myo-inositol + folic acid)
3026509|NCT02385396|Placebo Comparator|Group III|105 patients not diagnosed with PCOS undergoing ICSI, not taking myo-inositol
3026510|NCT02385383||Patients with preoperative anemia following treatment protocol|Patients with preoperative anemia according to the WHO definition and treated with a protocol of Iitravenous iron prior to surgery
3026511|NCT02385383||Patients with preoperative anemia - Historical control|Cohort of preoperative anemic patients from the Lundbeckcentre Database. Serving as a historical control
3026512|NCT02385370|Active Comparator|using standard method of applying MMC|applying MMC 0.02 % soaked sponges under conjunctival space for 1 to 3 minutes
3026513|NCT02385370|Active Comparator|intratendon injection of MMC|intratendon injection of 0.1 cc MMC 0.01% at the beginning of the procedure
3026514|NCT02385357|Placebo Comparator|Control|330 ml of commercial protein-enriched drink (2.5 g/100 ml of protein)
3026515|NCT02385357|Experimental|Experimental|330 ml of protein-enriched drink (6 g/100 ml of protein)
3026516|NCT02385318|Experimental|Test Product|Ingenol Mebutate
3026517|NCT02385318|Active Comparator|Reference product|Ingenol Mebutate
3026518|NCT02385318|Placebo Comparator|Placebo product|Placebo gel
3026519|NCT02385305|Other|Pressure support ventilation|Usual anesthesia management
3026520|NCT02385292|Experimental|Intranasal application of the device|Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator
3026521|NCT02385292|Active Comparator|Extranasal application of the device|Extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator
3026522|NCT02385279|Experimental|MiStent®|Percutaneous Coronary Intervention with the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent. It is a balloon expandable sirolimus eluting stent with an absorbable polymer coating.
3026523|NCT02385279|Active Comparator|XIENCE EES|Percutaneous Coronary Intervention with the XIENCE EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating.
3026524|NCT02385266|Experimental|D-Cycloserine and Acetominophen|D-cycloserine 200mg/bid and Acetaminophen prn
3026525|NCT02385266|Placebo Comparator|Placebo and Acetominophen|Placebo capsules (lactose)/bid and Acetaminophen prn
3026526|NCT02385253|Active Comparator|Educational training program|PCPs randomized to the intervention group will receive the educational training program at the beginning of the study, extending over a maximum of five months.
3026527|NCT02385253|No Intervention|Control|PCPs randomized to the control group will have the option of receiving the educational training program at the end of the study.
3026528|NCT02385240|Experimental|Test product|Brimonidine Topical Gel, 0.33 percent
3026529|NCT02385240|Active Comparator|Reference Product|Brimonidine Topical Gel, 0.33 percent (Reference)
3026530|NCT02385240|Placebo Comparator|Placebo gel|Placebo
3026531|NCT02385227|Experimental|Cohort A1|Exclusive blu™ e-cigarette A1
3026532|NCT02385227|Experimental|Cohort A2|Exclusive blu™ e-cigarette A2
3026533|NCT02385227|Experimental|Cohort A3|Exclusive blu™ e-cigarette A3
3026534|NCT02385227|Experimental|Cohort B1|Dual blu™ e-cigarette and usual brand B1
3026535|NCT02385227|Experimental|Cohort B2|Dual blu™ e-cigarette and usual brand B2
3026536|NCT02385227|Experimental|Cohort B3|Dual blu™ e-cigarette and usual brand B3
3026537|NCT02385227|Experimental|Cohort C|Nicotine product cessation C
3026538|NCT02385214|Experimental|Arm A Wide Local Excision = 1cm Margin|"ARM A: Experimental Arm Wide Local Excision = 1cm Margin + Sentinel Lymph Node Biopsy~+/- Reconstruction"
3026539|NCT02385214|Active Comparator|Arm B Wide Local Excision = 2cm Margin|"ARM B:Control Arm Wide Local Excision = 2cm Margin + Sentinel Lymph Node Biopsy~+/- Reconstruction"
3026540|NCT02385201|Experimental|Senza|Subjects with chronic, intractable pain of the upper limbs and/or neck will be implanted with a Senza Spinal Cord Stimulation (SCS) system designed to deliver electrical stimulation to the spinal cord.
3026541|NCT02385188|Experimental|Imiquimod|Topical 5% imiquimod cream will be applicated to the vulvar skin lesion 3 times a week during 16 weeks.
3026542|NCT02385175||Adults with suspected Eustachian tube dysfunction|Age 18+ with possible Eustachian tube dysfunction on the basis of symptoms and examination findings.
3026543|NCT02385162||Observation|Patients with a diagnosis of Glycogen storage diseases based upon biochemical and/or genetic criteria or profound suspicion for Glycogen storage disease
3026545|NCT02385149|Experimental|refined wheat|coloured refined wheat control intervention
3026546|NCT02385136|Experimental|WBRT plus TMZ arm|whole brain radiotherapy (WBRT) concomitantly with temozolomide (TMZ)
3026547|NCT02385136|No Intervention|WBRT|whole brain radiotherapy (WBRT)
3026548|NCT02385123|Experimental|Seasonal flu vaccine|N=50
3026549|NCT02385110|Experimental|Group 1: Alemtuzumab + Etoposide + Dexamethasone|"Induction Phase: Participants receive Alemtuzumab daily on Days 1 - 4 with weekly Etoposide, and Dexamethasone by vein on Days 1-7 during the 8-week induction phase. Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.~Dexamethasone by vein on Days 1-7 of the induction phase.~Maintenance Phase: The maintenance phase will last 16 weeks and starts after the Induction Phase. Participants receive Alemtuzumab once every 4 weeks and Dexamethasone three times per week during the maintenance phase. Participants who have evidence of budding relapse during the maintenance phase may revert back to receiving Etoposide.~If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes."
3026550|NCT02385110|Experimental|Group 2: Etoposide + Dexamethasone + Tocilizumab|"Induction Phase: Participants receive Tocilizumab by vein over 60 minutes on Day 1 or Day 2 of the Induction phase. Participants receive Alemtuzumab daily on Days 1 - 4 with weekly Etoposide and Dexamethasone by vein on Days 1-7 during the 8-week induction phase. Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.~Maintenance Phase: The maintenance phase will last 16 weeks and starts after the Induction Phase. Tocilizumab not given in the Maintenance Phase. Dexamethasone three times per week during the maintenance phase.~If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes"
3026551|NCT02385097|Experimental|Chloroprocaine HCl 2% (20 mg/mL)|Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL
3026552|NCT02385097|Active Comparator|Ropivacaine 0.75% (7.5 mg/mL)|Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL
3026553|NCT02385084|Experimental|Part A: LY2409021 Capsule|Single oral dose of LY2409021 capsule in one of three study periods.
3026554|NCT02385084|Experimental|Part A: LY2409021 Tablet Pre-commercial|Single oral dose of LY2409021 tablet (pre-commercial formulation) in one of three study periods.
3026555|NCT02385084|Experimental|Part A: LY2409021 Tablet Commercial|Single oral dose of LY2409021 tablet (commercial formulation) in one of three study periods.
3026556|NCT02385084|Experimental|Part B: LY2409021 Capsule|Single oral dose of LY2409021 capsule in one of two study periods.
3026557|NCT02385084|Experimental|Part B: LY2409021 Tablet Commercial|Single oral dose of LY2409021 tablet (commercial formulation) in one of two study periods.
3026558|NCT02385071|Experimental|Panel1: Sequence 1 (ABC)|Participants will receive Treatment A (150 milligram (mg) simeprevir (SMV) capsule with water under fed conditions) in Period 1; followed by Treatment B (3*50 mg capsules of SMV [including 50 mini-tablets of 1 mg each] with water under fed conditions) in Period 2; followed by Treatment C (3*50 mg dispersible SMV tablets dispersed in water under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3026559|NCT02385071|Experimental|Panel1: Sequence 2 (BCA)|Participants will receive Treatment B in Period 1; followed by Treatment C in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3026560|NCT02385071|Experimental|Panel1: Sequence 3 (CAB)|Participants will receive Treatment C in Period 1; followed by Treatment A in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3026561|NCT02385071|Experimental|Panel1: Sequence 4 (CBA)|Participants will receive Treatment C in Period 1; followed by Treatment B in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3026562|NCT02385071|Experimental|Panel1: Sequence 5 (BAC)|Participants will receive Treatment B in Period 1; followed by Treatment A in Period 2; followed by Treatment C in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3026563|NCT02385071|Experimental|Panel1: Sequence 6 (ACB)|Participants will receive Treatment A in Period 1; followed by Treatment C in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3026564|NCT02385071|Experimental|Panel 2: Sequence 1 (DEF)|Participants will receive Treatment D (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with water or 3*50 mg dispersible SMV tablets dispersed in water under fed conditions) in Period 1; followed by Treatment E (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with water or 3*50 mg dispersible SMV tablets dispersed in water under fasted conditions) in Period 2; followed by Treatment F (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with yoghurt or 3*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3026565|NCT02385071|Experimental|Panel 2: Sequence 2 (EFD)|Participants will receive Treatment E in Period 1; followed by Treatment F in Period 2; followed by Treatment D in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3026566|NCT02385071|Experimental|Panel 2: Sequence 3 (FDE)|Participants will receive Treatment F in Period 1; followed by Treatment D in Period 2; followed by Treatment E in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3026567|NCT02385071|Experimental|Panel 2: Sequence 4 (FED)|Participants will receive Treatment F in Period 1; followed by Treatment E in Period 2; followed by Treatment D in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3026568|NCT02385071|Experimental|Panel 2: Sequence 5 (EDF)|Participants will receive Treatment E in Period 1; followed by Treatment D in Period 2; followed by Treatment F in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3026569|NCT02385071|Experimental|Panel 2: Sequence 6 (DFE)|Participants will receive Treatment D in Period 1; followed by Treatment F in Period 2; followed by Treatment E in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3026601|NCT02384876|Experimental|Ephedrine, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG|Dose escalation: 6 successive cohorts with a maximal increasing dose
3026570|NCT02385058|Experimental|Mebendazole + Quinfamide|Participants will receive mebendazole 600 milligram (mg) and quinfamide 200 mg tablets orally once starting on Day 1 and 21 in both Phase 1 and 2.
3026571|NCT02385058|Experimental|Mebendazole + Quinfamide + Placebo|Participants will receive mebendazole 600 mg and quinfamide 200 mg tablets orally once starting on Day 1 in Phase 1 and placebo tablets orally once starting on Day 21 in Phase 2.
3026572|NCT02385045|Placebo Comparator|Narrow band imaging|Narrow band imaging function (Olympus endoscopes)
3026573|NCT02385045|Experimental|i-scan imaging|i-scan imaging (Pentax endoscopes)
3026574|NCT02385032|Experimental|AB|Ursodiol followed by URSO Forte
3026575|NCT02385032|Experimental|BA|URSO Forte followed by Ursodiol
3026576|NCT02385019|Experimental|Administration of 0.5 x 10ˆ6 donor Treg/kg|First group of 5 patients will receive a total of 0.5 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
3026577|NCT02385019|Experimental|Administration of 1.0 x 10ˆ6 donor Treg/kg|Second group of 5 patients will receive a total of 1.0 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
3026578|NCT02385019|Experimental|Administration of 2.0-3.0 x 10ˆ6 donor Treg/kg|Third group of 5 patients will receive a total of 2.0-3.0 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
3026579|NCT02385019|Experimental|Administration of MTD of donor T reg|Preliminary Phase 2 study will include another 5 to 10 patients at the MTD identified in the Phase 1 study
3026580|NCT02385006|Other|Arm kidney transplanted|Arm kidney transplanted: all patients who receive kidney transplantation
3026581|NCT02385006|Other|Arm pancreas-kidney transplanted|Arm pancreas-kidney transplanted: all patients who receive pancreas-kidney transplantation
3026582|NCT02384993|Experimental|Enhanced Physical Activity|Those assigned to the enhanced physical activity group will train 3-4 days per week with the goal of attaining current public health recommendations of 150 minutes of moderate intensity exercise by the 7th week of training, and maintaining this level of exercise for the remainder of the 26-week intervention. A gradual increase in exercise intensity and duration will be used throughout this twenty-six week exercise intervention, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Training will occur in individual sessions supervised by exercise specialists with the appropriate education and experience. Each training session will begin with an appropriate warm-up, slowly build up, and end with an appropriate cool down period.
3026583|NCT02384993|No Intervention|Usual Physical Activity|"All study participants randomized to the usual physical activity group will receive education from study staff about the importance of maintaining a healthy and active lifestyle. They will receive standardized literature such as Exercise & Physical Activity: Your Everyday Guide from the National Institute on Aging. These booklets provide vetted and reliable information for older adults on how to exercise. Participants assigned to the usual physical activity group will not be provided additional support or guidance with an exercise program."
3026584|NCT02384980|No Intervention|Walk Group|This group of patients are part of the walk group. They will be encouraged to walk and will receive standard care, defined as conservative (non-surgical) management of signs and symptoms, including prescriptive medications to improve circulation and manage pain, determined by their attending physician on a case by case basis.
3026585|NCT02384980|Experimental|FES + Walk Group|This group of patients will participate in Functional Electrical Stimulation (FES) and exercise. This group will receive functional electrical stimulation as an intervention. The FES device will stimulate (activate) the calf and shin leg muscles of both legs while the patient is walking. This group will also receive standard care, defined as conservative (non-surgical) management of signs and symptoms, including prescriptive medications to improve circulation and manage pain, determined by their attending physician on a case by case basis.
3026586|NCT02384967|Experimental|Darunavir 400mg/d|Tri-therapy containing Darunavir at dose of 400 mg/d.
3026587|NCT02384954|Experimental|Phase I/II ALT-803 w/rituximab for rel/ref iNHL|
3026588|NCT02384941|Experimental|Treatment A|High dose Sotagliflozin (fasted conditions)
3026589|NCT02384941|Experimental|Treatment B|Low dose Sotagliflozin (fasted conditions)
3026590|NCT02384941|Placebo Comparator|Treatment C|Placebo (fasted conditions)
3026591|NCT02384928|Experimental|Shinbaro pharmacopuncture group|The Shinbaro pharmacopuncture group will receive 8 interventional sessions of Shinbaro pharmacopuncture at one Hyeopcheok (Huatuo Jiaji, EX B2) point and acupuncture at 5 acupoints (GB30, BL40, BL25, BL23, GB34) 2 times/week over 4 weeks. All groups will take 4 educational program sessions supervised by physicians once a week.
3026592|NCT02384928|Active Comparator|Acupuncture group|The acupuncture group will receive 8 interventional sessions of acupuncture at one Hyeopcheok (Huatuo Jiaji, EX B2) point and 5 other acupoints (GB30, BL40, BL25, BL23, GB34) 2 times/week over 4 weeks. All groups will take 4 educational program sessions supervised by physicians once a week.
3026593|NCT02384928|Active Comparator|Usual care group|The usual care group will receive conventional medicine 2 times/day and 2 sessions/week of physical therapy over 4 weeks. Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics, which include aceclofenac, tramadol hydrochloride, talniflumate, diclofenac sodium, and loxoprofen sodium. All groups will take 4 educational program sessions supervised by physicians once a week.
3026594|NCT02384915|Experimental|Spinal anesthesia|Intrathecal injection of 2 ml (40 mg) of 2% hyperbaric prilocaine at L3-L4 interspaces through a 100mm Sprotte 25 G spinal needle (Pencan, b-brawn, Germay) in lateral decubitus position, (with limb to operate declive).
3026595|NCT02384915|Active Comparator|peripheral nerve block|Ultrasound-guided sciatic-femoral nerve block injecting 25 ml of a 2% mepivacaine solution,15 ml on femoral nerve and 10 ml on sciatic nerve through a 80 mm 22g eco-reflex needle (Sonoplex, Pajunk, Germany)
3026596|NCT02384902|Experimental|low GI|low GI: participants were asked to consume low GI foods (GI<55) in abundant, medium GI in moderate and high GI (GI>70) rarely.
3026597|NCT02384902|Experimental|low GL|low GL: participants were asked to consume low GI foods and the amount of carbohydrate was controlled.
3026598|NCT02384902|Experimental|conventional diet|conventional diet: all carbohydrate were treated as the same.
3026599|NCT02384889|Experimental|Difluoromethylornithine|Subjects may be given daily dose of DFMO
3026600|NCT02384889|Placebo Comparator|Placebo|Subjects may be given daily dose of placebo
3026602|NCT02384876|Active Comparator|Ephedrine, dose : 0.1 mg/kG, reference dose|Reference dose
3026603|NCT02384850|Experimental|Selinexor + mFOLFOX6|Different Dose Levels of Selinexor will be evaluated in combination with mFOLFOX6 (see interventions)
3026604|NCT02384837||TCFA|EXCEL biodegradable polymer-coated sirolimus-eluting stent was implanted on lesions which include TCFA (>=1)
3026605|NCT02384837||NO-TCFA|EXCEL biodegradable polymer-coated sirolimus-eluting stent was implanted on lesions which is not include TCFA
3026606|NCT02384811|Experimental|Radiation group|Radiation therapy
3026607|NCT02384798|Experimental|ventilatory support|noninvasive ventilatory support to 5cmH2O used before the session of interval training and resistance exercises performed three times a week for 12 weeks
3026608|NCT02384798|Active Comparator|interval training|sessions of interval training and resistance exercises performed three times a week for 12 weeks
3026609|NCT02384785||Spinal Cord Stimulation|"Patients who underwent implantation of electrodes spine for treatment in chronic pain.~'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation (one after another)"
3026610|NCT02384759|Experimental|A|Aflibercept + LV5FU2
3026611|NCT02384759|Active Comparator|B|LV5FU2
3026612|NCT02384746|Experimental|Combination Treatment|Fulvestrant (500mg) + MLN9708 (2.3, 3, and 4mg)
3026613|NCT02384733|Experimental|Hypofractionated loco-regional RT|40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions weekly
3026614|NCT02384733|Active Comparator|Normofractionated loco-regional RT|50 Gy / 25 fractions, 2.00 Gy per fraction, 5 fractions weekly
3026615|NCT02384720||A|Gender: 10 Males, 10 Females
3026616|NCT02384720||B|Gender: 10 Males, 10 Females
3026617|NCT02384720||C|Gender: 10 Males, 10 Females
3026618|NCT02384707|Experimental|allergic food|"Reintroduction procedure for small doses :~Administration of the first dose the first dose must be allergic food or placebo~Clinical monitoring for 45 minutes~Administration of the second dose"
3026619|NCT02384694|Experimental|Intervention|Zumba dance intervention
3026620|NCT02384681||Exposed|Medical regulation assistants working with headset
3026621|NCT02384681||Non-Exposed|Participants working without headset
3026622|NCT02384668|Active Comparator|Cholecalciferol|Cholecalciferol 70 mcg per day Other name: Vitamin D3.
3026623|NCT02384668|Placebo Comparator|Placebo|"Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.~The placebo regimen is identical to the vitamin D3 regimen."
3026624|NCT02384655|Experimental|Fenugreek|Mothers will take fenugreek for 14 days
3026625|NCT02384642|Active Comparator|COMPASS|The COMPASS program will involve a structured intervention for girls between the ages of 10-14 that is intended to engage adolescent girls, those who are influential in their lives, service providers and other stakeholders, with the ultimate goal of co-creating environments in which girls are valued and safe. The program is centered on establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
3026626|NCT02384642|Experimental|COMPASS plus parenting|In the COMPASS plus parenting intervention arm, girls will receive the COMPASS intervention, and In addition to the safe spaces for girls, the COMPASS project will also implement structured activities for the parents and caregivers of participants. The study will examine the relative impact of the parenting initiative in addition to the program for adolescent girls. The study will seek to determine whether the structured intervention with girls' parents has an added impact on outcomes improve girls' safety and well-being.
3026627|NCT02384629|Experimental|AXXESS stent1|AXXESS stent (OCT-guided)
3026628|NCT02384629|Experimental|Conventional DES1|Conventional DES (Biomatrix flex stent, OCT-guided)
3026629|NCT02384629|Active Comparator|AXXESS stent2|AXXESS stent (Angio-guided)
3026630|NCT02384629|Active Comparator|Conventional DES2|Conventional DES (Biomatrix flex stent, Angio-guided)
3026631|NCT02384616|Active Comparator|Group High FiO2|Children will receive Fi02 100% during induction of anesthesia until end tidal oxygen concentration (Et 02) of 90% before intubation, anesthesia will be maintained with Fi02 of 80%. Then, shortly before the planned extubation, Fi02 will be increased to 100%.
3026632|NCT02384616|Active Comparator|Group Low FiO2|Children will receive Fi02 80% until Et 02 70% before intubation, anaesthesia will be maintained with Fi02 35%. Then, shortly before the planned extubation, Fi02 will be increased again to 80%.
3026633|NCT02384603|Experimental|GPR and CBT|Global postural reeducation associated with cognitive behavioral therapy; 01 session per week for 10 weeks
3026634|NCT02384603|Active Comparator|SMSE and CBT|Segmental muscle stretching exercises associated with cognitive behavioral therapy; 01 session per week for 10 weeks
3026635|NCT02384590|Experimental|CCBT + Care Manager Arm|Patients will be given a tablet device with unlimited data. The device will be pre-installed with a pain and mood diary app that will prompt them to enter their pain severity (0-10), pain location, and mood (0-10), once a day. They will also be registered on to the Beating the Blues website and asked to use the tablet device to complete eight 1-hour Beating the Blues CBT sessions, over the next 3-months. They will also be introduced to a care manager who will contact them on a weekly basis by telephone and throughout the week by email or text, for one-month and then as needed for two additional months. At the conclusion of 3 months participants will only have care manager support upon request but are free to continue using the Beating the Blues program for as long as they like.
3026636|NCT02384590|No Intervention|Treatment As Usual|Similar to the treatment arm, patients will be given a tablet device with unlimited data that comes pre-loaded with a pain and mood diary app. The app will prompt the usual care patients to complete diary data daily. No other activities are required as part of the study but the patients are free to use the tablet as much as they like for their own leisure. At the end of 3-months, patients who continue to report depressive or anxiety symptoms are invited to cross-over to the treatment arm where they will be registered for the Beating the Blues program and given care manger support.
3026637|NCT02384577||Single group prospective treatment|
3026638|NCT02384564|Experimental|Ambu King Vision Video Laryngoscope aBlade System|The trachea will be intubated using the Ambu King Vision Video Laryngoscope with the appropriate sized blade (size 1 or 2) based on manufacturer guidelines and clinical judgement.
3026710|NCT02384031|Active Comparator|Traumatic group|Traumatic needle
3026711|NCT02384031|Active Comparator|Atraumatic group|Atraumatic needle
3026639|NCT02384564|Active Comparator|Direct Laryngoscope|The trachea will be intubated via direct laryngoscopy using a traditional straight blade laryngoscope, with appropriately sized blade based on manufacturer guidelines and clinical judgement.
3026640|NCT02384551|Active Comparator|HTHS|High total carbohydrate with high total simple carbohydrate diet
3026641|NCT02384551|Experimental|HTLS|High total carbohydrate with low total simple carbohydrate diet
3026642|NCT02384551|Experimental|LTHS|Low total carbohydrate with low total simple carbohydrate diet
3026643|NCT02384551|Experimental|LTLS|Low total carbohydrate with low total simple carbohydrate diet
3026644|NCT02384538|Placebo Comparator|Placebo|Placebo for ABT-981 every two weeks (Q2W) for 24 weeks.
3026645|NCT02384538|Experimental|ABT-981|ABT-981 200 mg every two weeks (Q2W) for 24 weeks.
3026646|NCT02384525|Experimental|clinical-based ultrafiltration|
3026647|NCT02384525|Active Comparator|BIA-based ultrafiltration|
3026648|NCT02384499|Experimental|ALLO-ASC group|Allogenic-adipose-derived mesenchymal stem cell (ALLO-ASC) with fibrin glue injection to the anal sphincter
3026649|NCT02384499|Placebo Comparator|Normal saline group|0.9% normal saline with fibrin glue injection to the anal sphincter
3026650|NCT02384486|Experimental|intervention group|"intervention group will receive the Training to Reduce Stress in Mothers of Children with (ASD)"
3026651|NCT02384486|Other|control group|control group will receive nothing but for ethical purposes will receive the same intervention after the end of the trial for the intervention group
3026652|NCT02384473|Experimental|Real-time CEUS and SWE|Patients undergo real-time CEUS and SWE at baseline, 6 weeks after initiation of neoadjuvant therapy, and 9 weeks after initiation of neoadjuvant therapy (prior to surgery).
3026653|NCT02384460|Experimental|SD-101-6.0 cream|SD-101-6.0 cream applied topically, once a day to the entire body for a period of 90 days
3026654|NCT02384460|Placebo Comparator|SD-101-0.0 cream|SD-101-0.0 (placebo) cream applied topically, once a day to the entire body for a period of 90 days
3026655|NCT02384447||Knee Amputation|Patients that are scheduled to undergo above knee amputation due to complications associated with diabetes will be enrolled
3026656|NCT02384434|Other|Single Arm|Low Level Laser Therapy
3026657|NCT02384421|Experimental|Activa PC+S Neurostimulator|Participants will be own controls and undergo both adaptive and continuous deep brain stimulation testing paradigms using Nexus D research tool
3026658|NCT02384408|Placebo Comparator|Control|Control Group: Women without hormone replacement therapy. Transvaginal Ultrasound - Endometrial Thickness; Endometrial Biopsy. Endometrial Immunohistochemical Study
3026659|NCT02384408|Experimental|Hormone treatment|"Group Drospirenone: To whom a continuous combined treatment with drospirenone 2 mg and 17β-estradiol 1 mg (DRSP/E2) will be administered daily for 24 weeks.~Group Tibolone: To whom treatment with tibolone 1.25 mg (Tib) will be administered daily for 24 weeks.~Transvaginal Ultrasound - Endometrial Thickness; Endometrial Biopsy. Endometrial Immunohistochemical Study"
3026660|NCT02384395|Experimental|DTG/3TC/ABC FDC|Dolutegravir (DTG 50 mg), abacavir sulfate (ABC 600 mg) and lamivudine (3TC 300 mg) formulated in a single tablet fixed dose combination (FDC) (DTG/ABC/3TC, GSK2619619), administered orally, once daily
3026661|NCT02384382|Experimental|Enzalutamide monotherapy|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily
3026662|NCT02384369|Experimental|SNC-102 sustained release tablet|SNC-102 sustained release tablet for oral administration, 1600 mg BID for 8 weeks
3026663|NCT02384369|Placebo Comparator|Placebo|Placebo tablet for oral administration, BID for 8 weeks
3026664|NCT02384343|Active Comparator|Dexmedetomidine|Dexmedetomidine 4 mcg/ml, 30 mcg (7,5 ml), single intravenous bolus
3026665|NCT02384343|Placebo Comparator|Normal saline|NaCl 0,9% 7,5 ml, single intravenous bolus
3026666|NCT02384330||Dysport® (abobotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
3026667|NCT02384330||Botox® (onabotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
3026668|NCT02384330||Xeomin® (incobotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
3026669|NCT02384317|Experimental|CCX168|BID for 84 days
3026670|NCT02384304|Experimental|Choice|A self help program consisting of 8 modules. Patients will have access to therapist support through either messages or chat sessions
3026671|NCT02384304|Experimental|Messages|A self help program consisting of 8 modules. Patients will have access to therapist support through messages
3026672|NCT02384304|Active Comparator|Self help|A relapse intervention program consisting of 8 modules. Patients will have no access to therapist support
3026673|NCT02384291|Experimental|Alpha-Bios GRAFT Natural Bovine Bone treatment|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
3026674|NCT02384291|Active Comparator|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
3026675|NCT02384278|Experimental|Internet-based CBT for alcohol problems|A 12-week internet-based cognitive behavior treatment (CBT) and relapse prevention program. The subjects will have access to a psychologist guiding them through the program.
3026676|NCT02384265|Experimental|IM/SMS + Incentive Condition|"Participants in the intervention condition will consist of the PWD and their two STMs. The PWD and STM will receive the same protocols that the Usual Care participants receive, including an introductory educational session, written materials on diabetes, a blood glucose log, and a physical activity monitoring log. The PWDs in this condition will also receive training in action planning with their STMs. They will also receive SMS messages supporting diabetes self-care from the study team. The study team will also encourage the STMs to interaction in person and via text messages with the PWD."
3026712|NCT02384018|No Intervention|Control|Patients will receive standard islet transplantation.
3026713|NCT02384018|Experimental|autologous mesenchymal stromal cell|Patients will receive MSCs together with standard islet transplantation.
3026714|NCT02384005|Other|Self-anal exam arm|Study only has one arm.
3058208|NCT02173535|Experimental|etafilcon test contact lens Variant LA|
3026677|NCT02384265|No Intervention|Control|Control group participants will consist of the person with diabetes (PWD) and their two support team members (STM). The PWD will receive regular medical care from their usual providers. They will also receive an introductory educational session and written materials on diabetes, the importance of its control, and diabetes self-care strategies, and a blood glucose and physical activity monitoring log. They will be invited for study visits at 3, 6, and 12 months to measure cholesterol, A1c (for those with diabetes), blood pressure, height, and weight measurement. PWDs and STMs in the control condition will receive generic health promotion information during in-person visits or by mail. They will receive follow-up messages by text to remind them about study related events.
3026678|NCT02384252||obese patients|patients with BMI > 30
3026679|NCT02384252||no obese patients|norma weight patient (BMI<25) overweight patients ( 25< BMI >30)
3026680|NCT02384239|Experimental|Palbociclib 100mg|Treatment arm palbociclib dose 100mg + fulvestrant or tamoxifen
3026681|NCT02384239|Experimental|Palbociclib 125mg|Treatment arm palbociclib dose 125mg + fulvestrant or tamoxifen
3026682|NCT02384200|Experimental|Antibiotic|"1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily starting 1 week prior to planned kidney stone surgery (PCNL).~In addition, each patient receives a a dose of ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 60 minutes of surgery start time. Patients with penicillin allergy will receive vancomycin IV (1 g) instead of ampicillin and patients with gentamicin/aminoglycoside allergy will receive ceftriaxone IV (2 g) instead of gentamicin."
3026683|NCT02384200|Active Comparator|No preoperative oral antibiotics|Each patient does receive a a dose of ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 60 minutes of surgery start time. Patients with penicillin allergy will receive vancomycin IV (1 g) instead of ampicillin and patients with gentamicin/aminoglycoside allergy will receive ceftriaxone IV (2 g) instead of gentamicin.
3026684|NCT02384187|Placebo Comparator|Group C|Patients in this group will receive 0.3 ml/kg of a placebo solution identical in taste, shape and color to the study medication two hours before the induction of anesthesia.
3026685|NCT02384187|Experimental|Group GAB|Patients in this group will receive 0.3 ml/kg (16 mg/kg) oral gabapentin solution (Neurontin 50 mg/ml, Pfizer Pharmaceutical) as premedication two hours before the induction of anesthesia
3026686|NCT02384174|Experimental|Resistant starch (RS)|Resistant starch (RS3)
3026687|NCT02384174|Experimental|Dietary fibre|Dietary fibre (Arabinogalactan, gum guar, pectin)
3026688|NCT02384161|Experimental|Total RBF + Exercise Isometric|"Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant member associated with a total obstruction of blood flow, which will be conducted through a cuff pressure applied to the proximal region of the dominant limb."
3026689|NCT02384161|Experimental|Partial RBF + Exercise Isometric|"Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant member associated with a partial obstruction of blood flow, which will be conducted through a cuff pressure applied to the proximal region of the dominant limb."
3026690|NCT02384161|Placebo Comparator|Free BR + Exercise Isometric|Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant limb with the free blood flow. A 'cuff' pressure on the member of the proximal region, but with a pressure that will not interfere with blood flow will be applied.
3026691|NCT02384148||Healthy|Healthy volunteers with no inflammation diseases, no neoplasia, no allergy to lidocaine.
3026692|NCT02384148||Type 2 diabetic non obese|Type 2 diabetic patients with HbA1c>6.5%, body mass index 19-30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
3026693|NCT02384148||Type 2 diabetic obese|Type 2 diabetic patients with HbA1c>6.5%, body mass index >30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
3026694|NCT02384148||obese|Obese non diabetic patients with HbA1c<6.5%, body mass index >30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
3026695|NCT02384135|Other|interventional|Patients with D-dimer levels between the usual cutoff and the age-adjusted cutoff will be left untreated and followed-up for three months
3026696|NCT02384122|Active Comparator|Octreotide|Drug: Sandostatin LAR Sandostatin LAR 40 mg will be administered once every 4 weeks as a intramuscular injection
3026697|NCT02384122|No Intervention|Standard of care|Patients receive standard of care without a placebo.
3026698|NCT02384109|Experimental|Intervention|Pharmacist-coordinated shared decision making about treatment for pre-diabetes (lifestyle change and/or metformin), using a decision tool
3026699|NCT02384109|Placebo Comparator|Usual Care|Usual care for patients with a diagnosis of pre-diabetes
3026700|NCT02384096|Active Comparator|Conventional Programming, then Advanced Programming|Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received conventional single source programming followed by Precision Spectra SCS System advanced programming.
3026701|NCT02384096|Active Comparator|Advanced Programming, then Conventional Programming|Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received Precision Spectra SCS System advanced programming followed by conventional single source programming.
3026702|NCT02384083|Experimental|Filanesib, pomalidomide and dexamethasone|28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 & 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 & 22
3026703|NCT02384070|Experimental|Group 1|Received upstream aspirin plus clopidogrel with no intra-procedural anticoagulation for the FFR calculation with a saline bolus and drip used for placebo anticoagulation during the procedure to blind the operator
3026704|NCT02384070|Active Comparator|Group 2|Received upstream aspirin and clopidogrel plus intra-procedural anticoagulation with bivalirudin for FFR calculation
3026705|NCT02384070|Experimental|Group 3|Received only upstream single anti-platelet therapy with aspirin plus intra-procedural anticoagulation for the FFR calculation with bivalirudin
3026706|NCT02384057|Experimental|C8 sciences|cognitive rehabilitation with C8 sciences
3026707|NCT02384057|Active Comparator|Conventional cognitive rehabilitation|cognitive rehabilitation with conventional methods
3026708|NCT02384044|Active Comparator|Crest® Sensi-Stop™ Strips|Professionally Applied
3026709|NCT02384044|Active Comparator|Colgate® Sensitivity Relief Pen|Professionally Applied
3026715|NCT02383992|Active Comparator|Hydrogen Peroxide|Post-operative wound will be treated with 3% H2O2 solution, Subjects will also clean the sutured wounds with 3% H2O2 solution or twice daily then dress the wounds with petroleum jelly and a bandage.
3026716|NCT02383992|Active Comparator|Saline|Post-operative wound will be treated with 0.9% normal saline. Subjects will also clean the sutured wounds with normal saline twice daily then dress the wounds with petroleum jelly and a bandage.
3026717|NCT02383979|Sham Comparator|Plasma Ball (Control)|"Subjects randomized to standard therapy will participate 14 days of daily mirror therapy sessions preoperatively which will consist of undergoing a sham therapy with a 22 plasma globe involving contralateral limb interaction with the sphere."
3026718|NCT02383979|Experimental|Experimental|Subjects randomized to the mirror therapy limb will undergo 14 days of daily mirror therapy sessions preoperatively which will consist of observing the unaffected limb reflected for 30 minutes in a mirror positioned in the midline to block the view of the affected limb.
3026719|NCT02383979|No Intervention|Non-Surgical|Subjects will undergo 3 questionnaires and one functional fMRI exam. Imaging protocol will be identical to preoperative imaging protocol for amputation subjects. This data will aid in establishing baseline fMR activation values for all fMR paradigms tested. The control group will not be randomized to receive either perioperative plasma ball (sham) or mirror therapy.
3026720|NCT02383966|Experimental|Cetuximab + Cisplatin/Carboplatin + 5-FU|
3026721|NCT02383966|Active Comparator|Cisplatin/Carboplatin + 5-FU|
3026722|NCT02383940|Experimental|Treatment A|Sotagliflozin (fasted conditions)
3026723|NCT02383940|Placebo Comparator|Treatment B|Placebo (fasted conditions)
3026724|NCT02383927|Experimental|Cohort 1|Thyroid Cancer
3026725|NCT02383927|Experimental|Cohort 2|Squamous Head and Neck Cancer
3026726|NCT02383914||Subscapularis rupture|
3026727|NCT02383888|Placebo Comparator|Matching placebo for each dose groups|
3026728|NCT02383888|Experimental|BI 425809 Active dose group 1|
3026729|NCT02383888|Experimental|BI 425809 Active dose group 2|
3026730|NCT02383888|Experimental|Bi 425809 Active dose group 3|
3026731|NCT02383875|Experimental|Opticourses education intervention|People living in the northern districts of Marseille with in very deprived social situation: very low incomes, heavy financial dependence on social benefits, over-representation of people covered by arrangements for controlling poverty and people covered by free social security
3026732|NCT02383862|Experimental|Feedback Group|Patients whose clinician received baseline PROMIS symptom scores at the time of their clinic visit
3026733|NCT02383862|No Intervention|Control Group|Patients whose clinician did not receive baseline PROMIS symptom scores at the time of their clinic visit
3026734|NCT02383849||Arm 1|Breastfeeding infants 7 to 14 days of age with birth weight less than or equal to 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected and TB negative; infant receiving NVP prophylaxis but not TB prophylaxis or treatment
3026735|NCT02383849||Arm 2|Breastfeeding infants 7 to 14 days of age with birth weight less than or equal to 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected with active TB disease; infant receiving NVP prophylaxis plus isoniazid (INH) but not rifampicin (RIF) for TB prophylaxis
3026736|NCT02383849||Arm 3|Breastfeeding infants 7 to 14 days of age with birth weight less than or equal to 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected with active TB disease; infant receiving NVP prophylaxis plus INH plus RIF for TB prophylaxis or treatment
3026737|NCT02383849||Arm 4|Breast or formula feeding infants 7 to 14 days of age with birth weight less than or equal to 2500 grams born to HIV-uninfected mothers with active TB disease; infant receiving INH alone or INH plus RIF for TB prophylaxis
3026738|NCT02383849||Arm 5|Breast or formula feeding infants newly diagnosed with HIV infection weighing less than or equal to 2500 grams at birth and are less than or equal to 12 weeks of age. Infants who were enrolled in Arms 1, 2 or 3 and later determined to be HIV infected are then are eligible to enroll in Arm 5 if started on an LPV/r regimen. Infants initiating treatment with LPV/r plus 2 NRTIs, and not receiving RIF (but may be receiving INH)
3026739|NCT02383849||Arm 6|Breast or formula feeding infants newly diagnosed with HIV infection weighing less than or equal to 2500 grams at birth and are less than or equal to 12 weeks of age. Infants who were enrolled in Arms 1, 2 or 3 and later determined to be HIV infected are then are eligible to enroll in Arm 6 if started on an LPV/r regimen. Infants initiating treatment with LPV/r plus 2 NRTIs, and receiving RIF (and may be receiving INH)
3026740|NCT02383823|Active Comparator|Estrogens in menopausal women|Crossover of estrogens or placebo in random order, either 2 mg estradiol or placebo in three months in random sequence, age span 45-55
3026741|NCT02383823|No Intervention|Menopausal men|comparative to menopausal women, age span 45-55
3026742|NCT02383823|No Intervention|Elderly women|comparative to menopausal women, age span 65-80
3026743|NCT02383823|No Intervention|Elderly men|comparative to menopausal women, age span 65-80
3026744|NCT02383823|Placebo Comparator|Placebo in menopausal women|Crossover of estrogen or placebo in random order, either 2 mg estrogen or placebo in three months in random sequence, age span 45-55
3026745|NCT02383810|Active Comparator|Elsiglutide 10 mg - target population|Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
3026746|NCT02383810|Active Comparator|Elsiglutide 20 mg - target population|Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving F-FU based chemotherapy
3026747|NCT02383810|Active Comparator|Elsiglutide 40 mg - target population|Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
3026748|NCT02383810|Placebo Comparator|Placebo - target population|Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
3026749|NCT02383810|Active Comparator|Elsiglutide 10 mg - additional population|Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
3026750|NCT02383810|Active Comparator|Elsiglutide 20 mg - additional population|Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
3026811|NCT02383303|No Intervention|Comparison|The comparison group cannot enter the Individual Development Account program.
3026751|NCT02383810|Active Comparator|Elsiglutide 40 mg - additional population|Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
3026752|NCT02383810|Placebo Comparator|Placebo - additional population|Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
3026753|NCT02383797|Experimental|Cartilage-hair hypoplasia (CHH)|Selected CHH patients will be vaccinated against varicella with Varilrix, one dose of 0,5 ml subcutaneously. If no response is documented to the first dose, the second dose of 0,5 ml can be administered.
3026754|NCT02383784|Experimental|Low-GI diet|Low glycemic index diet
3026755|NCT02383784|Experimental|High-GI diet|High glycemic index diet
3026756|NCT02383771|Experimental|Single Anti-platelet Treatment|Ticagrelor
3026757|NCT02383771|Experimental|Dual Anti-platelet Treatment|Aspirin + Ticagrelor
3026758|NCT02383771|Sham Comparator|Control|No Drug
3026759|NCT02383771|Other|CAD undergoing PCI|Patients with coronary artery disease undergoing percutaneous coronary intervention and receiving dual anti-platelet therapy (ticagrelor 90mg bid + aspirin 100mg daily)
3026760|NCT02383758|Experimental|Treatment Program|Pediatric subjects with autistic spectrum disorder will begin treatment immediately. The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, subjects will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
3026761|NCT02383758|Active Comparator|Waitlist Control|Pediatric subjects with autistic spectrum disorder will wait for 8 weeks and then be offered treatment at that time.The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, participants will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
3026762|NCT02383732|Experimental|Treatment|Pediatric subjects between the age of 4-12 years with autistic spectrum disorder and elopement will begin the Elopement Prevention and Safety Training (EPST) program. EPST includes up to 12 120-minute weekly sessions delivered over approximately 12-14 weeks. EPST is a modular treatment, with three components: 1) Universal Safety Measures (USM), 2) Proximity training, and 3) Check-in training. All participants receive the USM module in the first two sessions. They then receive either the Proximity training or Check-in training module depending on the type of elopement exhibited by the child (i.e., bolting vs. wandering).
3026763|NCT02383732|Active Comparator|Waitlist Control|Pediatric subjects between the age of 4-12 years with autistic spectrum disorder and elopement will be assigned to the Waitlist Control group. The subjects will be offered the intervention after completion of the 12-week waiting period. The subjects will then begin the Elopement Prevention and Safety Training (EPST) program. EPST includes up to 12 120-minute weekly sessions delivered over approximately 12-14 weeks. EPST is a modular treatment, with three components: 1) Universal Safety Measures (USM), 2) Proximity training, and 3) Check-in training. All participants receive the USM module in the first two sessions. They then receive either the Proximity training or Check-in training module depending on the type of elopement exhibited by the child (i.e., bolting vs. wandering).
3026764|NCT02383719|Experimental|Oro-nasal mask|All patients are included in this arm. Patients in this group receive the experimental oro-nasal mask during non-invasive ventilation
3026765|NCT02383706||Subjects|Pregnant women, BMI greater than or equal to 40 undergo questionnaires, physical exam, and ApneaLink Air, at home, overnight polysomnography study.
3026766|NCT02383693|Active Comparator|repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 4 weeks
3026767|NCT02383693|Sham Comparator|Sham comparator|Placebo Comparator: Placebo Treatment 5 days/week for up to 4 weeks
3026768|NCT02383680||Patients under low dose methotrexate therapy|Patients with various underlying conditions (e.g. rheumatic diseases, dermatologic diseases) who have an indication for yellow fever vaccination
3026769|NCT02383680||Healthy controls|Healthy travelers who have an indication for yellow fever vaccination
3026770|NCT02383667||Patients with Electrocardiograms|"Any patient within the hospital either for procedure or for admission will be screened. Patients will be simultaneously be hooked up to two ambulatory Holter monitors for the period of time to be not less than one hour.~One holter will use standard electrodes in a standard electrode distribution. The second holter will use dry electrodes in a derived; data will be collected for 1-6 hours. After the data is collected the Holters will be removed and the data will be downloaded into the reading software to be scanned."
3026771|NCT02383654|Other|Compassionate Treatment|ALS patients are received Intravenous and intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells (ADSCs), Rehabilitation.
3026772|NCT02383641||Observation|Patients with Wolman disease or high-grade suspicion for Wolman disease
3026773|NCT02383615|Active Comparator|DTSNB|Distal transsartorial saphenous nerve block
3026774|NCT02383615|Active Comparator|ACSNB|Adductor canal saphenous nerve block
3026775|NCT02383602||Retention strategies|In addition to telephone call(s) made within 1 week prior to scheduled visit, participants will receive at least biweekly communications from the study staff in order to establish and maintain a good relationship between participants and study sites. These communications will make use of various social networking tools (for example, Grindr, LINE and/or WhatsApp and/or SMS and/or Facebook and/or electronic mail).
3026776|NCT02383589|Active Comparator|A: Mycophenolate Mofetil|Participants will receive MMF orally twice daily (every 12 hours, Q12H) from Day 1 to Week 52. Participants will also receive rituximab matching placebo by intravenous (IV) infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria have been met.
3026928|NCT02382510|Experimental|TRN-157|
3026777|NCT02383589|Experimental|B: Rituximab|Participants will receive rituximab by IV infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria have been met. Participants will also receive MMF matching placebo orally Q12H from Day 1 to Week 52.
3026778|NCT02383576||Bevacizumab|Participants who received bevacizumab in IMELDA (MO22223) P-trial and were in maintenance phase were observed.
3026779|NCT02383576||Bevacizumab and Capecitabine|Participants who received bevacizumab and capecitabine in IMELDA (MO22223) P-trial and were in maintenance phase were observed.
3026780|NCT02383563|Active Comparator|Metformin Treatment Arm|500 mg metformin Extended Release tablets - one tablet daily increased at 4 weeks to 2 tablets (1000 mg) daily.
3026781|NCT02383563|No Intervention|Observational Arm|Observation only
3026782|NCT02383537||Pregnant women with diabetes|Pregnant women with diabetes type 1, type 2 or gestational diabetes
3026783|NCT02383537||Healthy pregnant women|Healthy pregnant women with no underlying illness
3026784|NCT02383524||Chronic Low Back Pain (Lumbar Facet Joints Mediated Pain)|
3026785|NCT02383511|Other|Sequence 1|Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)
3026786|NCT02383511|Other|Sequence 2|Drug: SMT C1100 or placebo 3-treatment (Period 1,2, and 3)
3026787|NCT02383511|Other|Sequence 3|Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)
3026788|NCT02383498|Experimental|Vaccine|Radiation + GI-6301 Vaccine + Actigraph
3026789|NCT02383498|Placebo Comparator|Placebo|Radiation + GI-6301 Placebo + Actigraph
3026790|NCT02383485|Experimental|After-school exercise program|40 min/day vigorous aerobic games after school
3026791|NCT02383485|Active Comparator|Sedentary after-school program|Attention-control condition similar to experimental condition with the exception of exercise
3026792|NCT02383472|Experimental|MedX Health Console model 1100|The treatment group will receive LED treatments over 6 weeks, 3 times per week, totaling 18 visits. All treatments will take place at Boston Children's Hospital. The cluster heads are applied to frontal, parietal, and temporal areas. Each cluster head is applied to the forehead/scalp areas for up to 10 minutes. There will be two 10-minute LED/placebo treatment periods per visit, each with different cluster head placements on the head/scalp.
3026793|NCT02383472|Placebo Comparator|MedX Health Console model 1100-placebo|Subjects enrolled in the placebo group will be on the same schedule as the treatment group. The placebo group will receive LED placebo over 6 weeks, 3 times per week, totaling 18 visits. All placebo patients will take place at Boston Children's Hospital. The cluster heads are applied to frontal, parietal, and temporal areas. Each cluster head is applied to the forehead/scalp areas for up to 10 minutes. There will be two 10-minute LED/placebo treatment periods per visit, each with different cluster head placements on the head/scalp.
3026794|NCT02383446|Experimental|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
3026795|NCT02383433|Experimental|Treatment (regorafenib, gemcitabine hydrochloride)|Patients receive regorafenib PO QD on days 1-21 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3026796|NCT02383420|Experimental|Predicate & Invest-GOS|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
3026797|NCT02383420|Experimental|Predicate & Invest-CsI|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
3026798|NCT02383420|Experimental|Predicate & Invest.-Cadavers GOS & CsI|Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
3026799|NCT02383407|Experimental|Stimulation group 2 Hz|Patient will be randomized to a stimulation group of 2 Hz using Medtronic deep brain stimulation device
3026800|NCT02383407|Experimental|Stimulation group 5 Hz|Patient will be randomized to a stimulation group of 5 Hz using Medtronic deep brain stimulation device
3026801|NCT02383394||aborted women|women who got pregnant and have 2nd trimesteric abortion, follow up antenatal care by ultrasound and clinical monitoring
3026802|NCT02383394||continued women|women who got pregnant and completed her pregnancy follow up antenatal care by ultrasound and clinical monitoring
3026803|NCT02383368|Experimental|ASP4132 dose escalation|"Subjects will receive a single dose of the study drug on Day -4 (Single-Dose Period), followed by PK sampling prior to Multiple-Dose Period where they will receive the same dose as they received in the Single-Dose Period on one of four schedules:~Continuous - daily dosing for 28 days, Intermittent: Schedule A: 3 days on / 4 days off; Schedule B: 1 days on / 6 days off; Schedule C: 3 days on / 11 days off."
3026804|NCT02383368|Experimental|ASP4132 dose expansion|Subjects in Part 2 will be treated with ASP4132 at the MTD and dosing schedule identified from Part 1.
3026805|NCT02383355|Experimental|Switch group|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy for 10 weeks
3026806|NCT02383355|Active Comparator|Continuation group|Individuals in the continuation group will continue the regimen, which consists of antiretroviral therapy as indicated in the inclusion criteria
3026807|NCT02383329|Experimental|Oral Nutritional Supplement (ONS)|Diet consultation for the child/family + ONS
3026808|NCT02383329|No Intervention|No Oran Nutritional Supplement (ONS)|Diet consultation for the child/family
3026809|NCT02383316|Experimental|Noonan Syndrome Children|"Children with Noonan Syndrome will be compared with age- and sex-matched healthy children. We hypothesize than Noonan Syndrome children have an increased insulin sensitivity compared to GHD children.~Study parameters will be collected including: clinical measurements (height, weight, body mass index, waist circumference, and blood pressure), glucose and insulin levels at baseline and after an oral glucose tolerance test (OGTT), body composition measured by dual-energy x-ray absorptiometry (DXA)."
3026810|NCT02383303|Experimental|Program|The program group is eligible to participate in the Individual Development Account savings program.
3026812|NCT02383290|Experimental|Decision support|This is a feasibility trial so all patients will give a saliva sample and the pharmacist/ Family Physician will use the decision support for generating prescription recommendations
3026813|NCT02383277|Experimental|Stretching and Exercise|This group undergo a session of stretching aiming flexibility of the rib cage and later at an exercise test with constant load up to the limit of tolerance for exercise bike
3026814|NCT02383277|Sham Comparator|Control and Exercise|This group will carry out the exercise test with constant load up to the limit of tolerance for exercise bike after a period of rest under the same environmental conditions and the experimental group time. During this time the therapist will place their hands but not performing the stretch.
3026815|NCT02383264||feeding intolerance|Development of feeding intolerance, defined as enteral feeding withholding for at least 1 day due to the onset ofgastrointestinal clinical symptoms
3026816|NCT02383264||normal feeding tolerance|no evidence of feeding intolerance during the hospitalization
3026817|NCT02383251|Experimental|Pazopanib/Paclitaxel association|"Arm 1 :~Pazopanib alone during 1 week at 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.~Then:~Pazopanib 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.~Paclitaxel 65 mg/m2 i.v. on days 1, 8, 15 every 28 days until progression of disease or toxicity"
3026818|NCT02383251|Active Comparator|Paclitaxel alone|"Arm 2 :~Paclitaxel 80mg/m2 i.v. on days 1, 8, 15~every 28 days until progression of disease or toxicity"
3026819|NCT02383238|Active Comparator|Dapagliflozin|Dapagliflozin, 10 mg/day, oral administration, 6 weeks
3026820|NCT02383238|Placebo Comparator|Placebo|Placebo, oral administration, 6 weeks
3026821|NCT02383225|Experimental|Condition A|Substance use resistance skills; no Lakota language enhancement, no FaceBook supplement
3026822|NCT02383225|Experimental|Condition B|FaceBook supplement; no Lakota language enhancement; no Substance Use resistance skills
3026823|NCT02383225|Experimental|Condition C|Lakota language enhancement; no FaceBook supplement; no Substance Use resistance skills
3026824|NCT02383225|Experimental|Condition D|Lakota language enhancement; FaceBook supplement; Substance Use resistance skills
3026825|NCT02383212|Experimental|Monotherapy Cohort|REGN2810 will be administered alone
3026826|NCT02383212|Experimental|Dual Combination Cohorts|"Doses of REGN2810 will be administered in combination with hypofractionated radiotherapy~Doses of REGN2810 will be administered in combination with Cyclophosphamide~Doses of REGN2810 will be administered in combination with Docetaxel"
3026827|NCT02383212|Experimental|Triple Combination Cohorts|"Doses of REGN2810 will be administered in combination with hypofractionated radiotherapy plus Cyclophosphamide~Doses of REGN2810 will be administered in combination with hypofractionated radiotherapy plus GM-CSF~Doses of REGN2810 will be administered in combination with Carboplatin plus Paclitaxel~Doses of REGN2810 will be administered in combination with Carboplatin plus Pemetrexed~Doses of REGN2810 will be administered in combination with Carboplatin plus Docetaxel"
3026828|NCT02383212|Experimental|Quadruple Combination Cohorts|Doses of REGN2810 will be administered in combination with hypofractionated radiotherapy plus GM-CSF plus Cyclophosphamide
3026829|NCT02383186|Active Comparator|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
3026830|NCT02383186|Active Comparator|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
3026831|NCT02383173|Active Comparator|Basic Implementation Approach|Basic approach to implementing a Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams
3026832|NCT02383173|Experimental|Enhanced Implementation Approach|Enhanced approach to implementing a Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams
3026833|NCT02383160|Active Comparator|Exogen 4000 Active Unit|Exogen low-intensity pulsed ultrasound treatment 20 minutes/day until the fracture is deemed united clinically and on CT scan.
3026834|NCT02383160|Sham Comparator|Exogen 4000 Sham Unit|Exogen sham device treatment 20 minutes/day until the fracture is deemed united clinically and on CT scan.
3026835|NCT02383147|Experimental|Tomographic Neurofeedback (TONF)|15x Neurofeedback Trainings, 1-2 times per week
3026836|NCT02383147|Active Comparator|Non Tomographic Neurofeedback (NTE)|15x Neurofeedback Trainings, 1-2 times per week
3026837|NCT02383121||No patients|Study has been withdrawn
3026838|NCT02383108|Active Comparator|Standard of Care group (SOC)|triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI
3026839|NCT02383108|Experimental|DTG+DRV/r|NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
3026840|NCT02383095|Experimental|Art-therapy|16 Art-therapy sessions
3026841|NCT02383095|Active Comparator|Metacognitive therapy|16 Metacognitive therapy sessions
3026842|NCT02383069|Experimental|Intervention Group|The intervention group will have supervised rehabilitation program held twice a week, each session will have 60 minutes duration, with minimum interval of 24 hours, for a period of 8 weeks. Each session will consist of three parts: aerobic training, strength training and respiratory physiotherapy. The aerobic training will be held for 35 minutes (10 min of warm up, 20 min on target load and 5 min of slowdown) with initial intensity of 60% of the maximum load obtained in the maximal cardiopulmonary exercise testing or in incremental shuttle walk test (ISWT). The intensity will be gradually increased up to 80%, so that fatigue or dyspnea values are kept between 4 and 6, according to the modified Borg scale.
3026843|NCT02383069|Active Comparator|Control Group|The control group will be subjected to supervised respiratory physiotherapy and stretching exercises twice a week, each session with duration of 60 minutes, with minimum interval of 24 hours, for a period of 8 weeks. The oral high-frequency oscillation device (Flutter®) will be used for 10 minutes, 5 minutes in each lateral decubitus, followed by the stretching of upper and lower limbs for 40 minutes. All exercises will be active, performed in sitting and lying positions without increasing the heart rate. The remaining 10 minutes will be used to discuss doubts about the disease and the use of the booklet.
3026844|NCT02383056|Sham Comparator|Sham Group (Group 1)|This group will receive 4 sessions of Omnilux sham light, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
3026845|NCT02383056|Experimental|Treatment group (Group 2)|This group will receive 4 treatment sessions with Omnilux 633nm LED, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
3026846|NCT02383043|Experimental|Active Treatment|Cocaine choice during d-amphetamine maintenance
3026847|NCT02383043|Placebo Comparator|Placebo Treatment|Cocaine choice during placebo maintenance
3026848|NCT02383030|Experimental|Fulvestrant|In Arm A maintenance Fulvestrant will be given until disease progression, unacceptable toxicity or refused of patient to the treatment.
3026849|NCT02383030|No Intervention|No intervention|Patients will be randomized to receive fulvestrant (experimental arm) or no treatment
3026850|NCT02383017|Experimental|Shroom Tech Sport|Shroom Tech Sport is a multi-ingredient performance supplement taken, in pill form, prior to work outs to enhance workout performance.
3026851|NCT02383017|Placebo Comparator|Placebo|The placebo is a calorie matched sugar pill that will be taken in the same fashion as the STS pill.
3026852|NCT02383004|Experimental|Acupuncture|"Same premedication, induction and maintenance protocol as the No Acupuncture (Standard of Care) group.~The intervention will be placement of 4 acupuncture needles. The needles will be placed after inhalational anesthesia induction and removed prior to leaving the operating room. A total of 4 needles will be placed, one in each wrist at the HT7 point and one in each ear at the shen men point."
3026853|NCT02383004|No Intervention|No Acupuncture (Standard of Care)|"If needed, the patient will receive a standard does of oral midazolam (0.5 mg /kg or less, up to 15mg) plus acetaminophen 12.5 mg/kg (V group). If the patient does not require premedication with midazolam, oral acetaminophen 12.5mg/kg will be given alone (NV group).~Induction of anesthesia by mask ventilation with sevoflurane in 50% nitrous oxide mixed with 50% oxygen. Sevoflurane will be incrementally titrated from 0% up to 8%. Nitrous oxide will be discontinued after induction. Anesthesia will be maintained with sevoflurane in an oxygen/air mixture. Sevoflurane concentration will be titrated to maintain the adequate depth of anesthesia. Prior to leaving the operating room, a dose of ketorolac 0.5mg/kg will be given intramuscularly."
3026854|NCT02382991|Other|NMPK-3C60|D0 + 30 days: evaluation with the non-microprocessor knee. D1 + 90 days: evaluation with the 3C60 knee.
3026855|NCT02382991|Other|3C60-NMPK|"D0 + 90 days: evaluation with the 3C60 knee. A period of 10 days of wash out. D1 + 30 days: evaluation with the non-microprocessor knee."
3026856|NCT02382978|Experimental|nurse-provided well child care visit|these children will be seen by a nurse only for their regular, pre-scheduled well child care visit
3026857|NCT02382965|Experimental|ultrasound|
3026858|NCT02382952|Experimental|Differential Dissector|For patients in the study device group, blunt dissection will be performed with the Differential Dissector whenever the surgeon believes its use is appropriate.
3026859|NCT02382952|Active Comparator|Standard Dissection Method|For patients in the control group, blunt dissection will be performed by standard method.
3026860|NCT02382939|Experimental|somapacitan|
3026861|NCT02382939|Active Comparator|hGH (somatropin)|
3026862|NCT02382926|Experimental|contactless heart-, breathing rate, ECG|
3026863|NCT02382913|Experimental|Group 1|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: low dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
3026864|NCT02382913|Experimental|Group 2|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: medium dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
3026865|NCT02382913|Experimental|Group 3|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: high dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart
3026866|NCT02382913|Experimental|Group 4|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, low dose of D (diphteria) toxoid, fixed dose of T (tetanus) toxoid, followed by one administration of saline solution one month apart.
3026867|NCT02382913|Experimental|Group 5|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3026868|NCT02382913|Experimental|Group 6|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3026869|NCT02382913|Experimental|Group 7|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3026870|NCT02382913|Experimental|Group 8|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart
3026871|NCT02382913|Experimental|Group 9|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3026872|NCT02382913|Active Comparator|Group 10|Subject received one dose of a licensed TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) followed by one administration of saline solution one month apart
3026873|NCT02382900|Experimental|Cohort 1|11 year old boys enrolled in fifth grade of 40 public elementary schools of Mexico City, from the political demarcations of Azcapotzalco, Gustavo A. Madero, Iztacalco, Miguel Hidalgo, Venustiano Carranza, Iztacalco and Tlalpan, reciving a two-dose vaccination scheme (0-6). 250 subjects will be recruited.
3026874|NCT02382900|Active Comparator|Cohort 2|Historical cohort of young women 18-24 years old recruited by Lazcano et. al. receiving a standard vaccination schedule (0-1-6 months). 500 subjects were recruited.
3026929|NCT02382510|Placebo Comparator|Placebo|
3026930|NCT02382510|Active Comparator|Tiotropium|
3026875|NCT02382900|Active Comparator|Cohort 3|11 year old girls enrolled in fifth grade of 40 public elementary schools of Mexico City, from the political demarcations of Azcapotzalco, Venustiano Carranza, Iztacalco and Tlalpan, reciving a two-dose vaccination scheme (0-6). 250 subjects will be recruited.
3026876|NCT02382887|Active Comparator|Tracheal intubation with Fiberscopy|tracheal intubation with a fiberscope
3026877|NCT02382887|Experimental|Tracheal intubation with Airtraq|tracheal intubation with an Airtraq
3026878|NCT02382874|Experimental|AD-MSC|The patients with FSGS who underwent intravenous injection of AD-MSC.
3026879|NCT02382861|Experimental|NAVA group|Management of the difficult weaning from mechanical ventilation by the NAVA.
3026880|NCT02382861|Active Comparator|Control group|Conventional management of the difficult weaning from mechanical ventilation, with the pressure ventilation.
3026881|NCT02382848|Active Comparator|Pazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
3026882|NCT02382848|Placebo Comparator|Placebo|Placebo will be given for a 3 consecutive week period during the 7 week study period.
3026883|NCT02382835||Metal-on-Metal Hip Replacement|
3026884|NCT02382835||Other Hip Replacement|Other types of hip replacement, such as metal-on-polyethylene or ceramic-on-ceramic
3026885|NCT02382822||HIV infected|Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, mouth wash, eNO assessment, ankle brachial pressure index, fibroscan, blood sampling
3026886|NCT02382822||HIV uninfected|Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, eNO assessment, ankle brachial pressure index, fibroscan, blood sampling
3026887|NCT02382809|Experimental|DC071 (0.2% chlorhexidine digluconate)|
3026888|NCT02382809|Placebo Comparator|Placebo|
3026889|NCT02382796|Experimental|Dacomitinib|3 dose strengths (45 mg, 30 mg, and 15 mg), continuous oral daily dosing
3026890|NCT02382783|Other|FLARE Intervention Group|"In the FLARE Intervention Group, we ask that you participate in all of the following, over the course of two years:~Baseline Study Visit~Monthly: Complete FLARE Questionnaires, at home, and report results. The last question on this questionnaire will ask you if you feel you are having a flare of your disease.~FLARE Study Visit (if applicable): We will schedule you to be seen when/if you feel you are having a flare of your disease.~Follow-up Visits (minimum of every 6 months): These are done as the standard of care for your RA.~At one time-point, during your first return visit after the baseline visit you will have an examination by ultrasound~Patient Satisfaction Surveys at three time-points: Baseline, 1 year, 2 year~Also, your rheumatology health care provider (RHCP) will be asked to participate in the study by completing three satisfaction surveys over the course of two years."
3026891|NCT02382783|No Intervention|Standard of Care (SOC) Group|"If you are randomized to the SOC Group, your care will not be any different than your usual care of rheumatoid arthritis (RA). You will be seen by a rheumatologist at a minimum of every six months, which is the standard of care for RA.~Additionally (for research), we ask the following of you...~At one time-point, during your first return visit after the baseline visit you will have an examination by ultrasound~Patient Satisfaction Surveys at three time-points: Baseline, 1 year, 2 year~Also, your rheumatology health care provider (RHCP) will be asked to participate in the study by completing three satisfaction surveys over the course of two years."
3026892|NCT02382770||Open Abdomen patients|All patients underwent to open abdomen procedure
3026893|NCT02382757||Children|
3026894|NCT02382744|Experimental|Ultrasound Guidance|Saphenous nerve block placed using ultrasound guidance alone
3026895|NCT02382744|Experimental|Ultrasound Guidance + nerve stimulation|Saphenous nerve block placed using ultrasound guidance and nerve stimulation
3026896|NCT02382731|No Intervention|Usual care|Usual care (no intervention)
3026897|NCT02382731|Experimental|Usual care + letters|Usual care plus a series of postal educational reminders (including information for patients to share with clinicians)
3026898|NCT02382731|Experimental|Usual care + letters + automated calls|Usual care plus a series of postal educational reminders (including information for patients to share with clinicians), plus automated reminder interactive voice response phone calls to identify patients at being at risk for non-adherence and a trained lay health worker to provide additional support and navigation for such patients via telephone.
3026899|NCT02382718|Experimental|FAST fish mCyp c 1|"Subcutaneous injections of investigational medicinal product mCyp c 1 formulated in a solution (suspension) with aluminium.~Up-dosing (build-up) phase: each subject will receive 10 injections of active or placebo treatment. The first three injections will be given on the first day. For those on active treatment the dosing will begin at 6ng and conclude on week 8 with the administration of 60μg.~Maintenance phase: the maintenance dose of 60μg will be repeated once at two weeks and then monthly for a period of four months (four monthly injections)."
3026900|NCT02382718|Placebo Comparator|Placebo|Subcutaneous injections of exactly the same dosage, frequency and duration as Active Arm but all injections will be performed with placebo (has the same composition as the active drug suspension but no allergen mCyp c 1 is added).
3026901|NCT02382679|Placebo Comparator|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
3026902|NCT02382679|Experimental|Experimental: Vitamin Mixture|Vitamin coenzyme Q10, magnesium, riboflavin and omega-3-fatty acid combination.
3026903|NCT02382666|Experimental|Rolapitant Cohort 1|Investigational Product: Rolapitant Dose 1 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
3026904|NCT02382666|Experimental|Rolapitant Cohort 2|Investigational Product: Rolapitant Dose 2 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
3026905|NCT02382666|Experimental|Rolapitant Cohort 3|Investigational Product: Rolapitant Dose 3 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
3026906|NCT02382666|Experimental|Rolapitant Cohort 4|Investigational Product: Rolapitant Dose 4 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
3026907|NCT02382666|Experimental|Rolapitant Cohort 5|Investigational Product: Rolapitant Dose 5 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
3026908|NCT02382666|Experimental|Rolapitant Cohort 6|Investigational Product: Rolapitant Dose 6 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
3026909|NCT02382653|Other|oral perixicam|50 patients with Breakthrough pain will receive oral prioxicam for treament of breakthrough pain.
3026910|NCT02382653|No Intervention|oral fentanyl|50 patients with Breakthrough pain will receive sublingual fentanyl for treament of breakthrough pain.
3026911|NCT02382640|Experimental|Sequence 1: ABDC|Experimental: Sequence 1: ABDC Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and 20 mL Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL (hereafter referred as Maalox) or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 1 (A), followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 2 (B), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 3 (D), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 4 (C).
3026912|NCT02382640|Experimental|Sequence 2: DACB|Experimental: Sequence 2: DACB Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 3, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 4.
3026913|NCT02382640|Experimental|Sequence 3: CDBA|Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 3, followed by a 7-day washout period, followed by Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 4.
3026914|NCT02382640|Experimental|Sequence 4: BCAD|Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 3, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 4.
3026915|NCT02382614|Experimental|Spiration Valve System|The treatment group will have valves deployed to achieve leak isolation.
3026916|NCT02382614|No Intervention|Medical Management|The control group for this study will receive standard chest tube drainage management and standard-of-care interventions. This group will be evaluated and followed in the same manner as the treatment group, but without having valves placed.
3026917|NCT02382601||Small for Gestational Age Pregancies (controls)|Small for gestational age (SGA) pregnancies that do not develop IUGR will be considered controls. Each subject will have an ultrasound, MRI, maternal blood and cord blood collection, placental analysis, neurological function assessments (infant), and body fat measurements (infant).
3026918|NCT02382601||IUGR Pregnancies (cases)|Small for gestational age (SGA) pregnancies that do develop IUGR will be considered cases. Each subject will have an ultrasound, MRI, maternal blood and cord blood collection, placental analysis, neurological function assessments (infant), and body fat measurements (infant).
3026919|NCT02382588|Experimental|Gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
3026920|NCT02382588|Placebo Comparator|hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
3026921|NCT02382575|Active Comparator|Tacrolimus|Tacrolimus: Standard dose with oral Tacrolimus 0.2 mg/kg/day in two divided doses till 6 month of relapse free survival.
3026922|NCT02382575|Experimental|Rituximab|Two to four rituximab infusions (over 2-4 weeks) will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2)depending on circulating B cells level.
3026923|NCT02382562|Experimental|Brief Behavioral Activation Intervention|All eligible participants will undergo the Brief Behavioral Activation Intervention.
3026924|NCT02382549|Experimental|6MHP and dabrafenib and trametinib|"The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 36, 57, 78. All peptide vaccines are administered intradermally and subcutaneously.~Dabrafenib is a small molecular BRAF inhibitor and will be administered in accordance with the prescribing information: 150 mg orally twice daily taken at least 1 hour before or at least 2 hours after a meal; the doses will be approximately 12 hours apart. Trametinib is a small molecular MEK1 and MEK2 inhibitor and will be administered in accordance with the prescribing information: 2 mg orally once daily taken at least 1 hour before or at least 2 hours after a meal. The medication will be taken at the same time each day with either the morning or evening dose of dabrafenib."
3026925|NCT02382536||Infusion set|Each subject will receive a total of 4 simultaneous subcutaneous infusions of insulin diluent, two using the investigational device (BD Scarlett Infusion Set) and two using the the comparator (Medtronic QuickSet Infusion Set).
3026926|NCT02382523|Experimental|Acthar injection 2 times per week|Acthar 80 unit injection 2 times a week
3026927|NCT02382523|Experimental|Acthar injection 3 times per week|Acthar 80 unit injection 3 times a week
3026931|NCT02382497|Experimental|AN Active tDCS|"Treatment as usual plus experimental treatment"
3026932|NCT02382497|Sham Comparator|AN Sham tDCS|"Treatment as usual plus placebo treatment"
3026933|NCT02382497|Experimental|BED Active tDCS|"Treatment as usual plus experimental treatment"
3026934|NCT02382497|Sham Comparator|BED Sham tDCS|"Treatment as usual plus placebo treatment"
3026935|NCT02382484|Experimental|Treatment|"The study was a single arm, unblinded, treatment only study. Each patient served as his or her own control.~Treatment delivered by a dual chamber pacing system (BackBeat Medical) which was able to generate stimulating patterns with characteristics that are different than the common pacemaker.~The study was limited to hypertensive patients who were also already scheduled to undergo an invasive electrophysiology procedure."
3026936|NCT02382471|Placebo Comparator|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
3026937|NCT02382471|Active Comparator|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
3026938|NCT02382458|Experimental|Lifestyle intervention|Participants will receive a year-long comprehensive, dietary, exercise, and stress management intervention. They will be asked to bring a partner of their choosing with them for support. The intervention will include a behavioral program to reduce inflammation.
3026939|NCT02382458|Active Comparator|Information intervention|Participants will receive a year-long intervention that will involve receiving weekly (for the first 3 months) and then monthly (for the following 9 months) newsletters on cancer prevention and control (via e-mail or mail) that will provide the participant with information about cancer prevention and control strategies.
3026940|NCT02382445|Experimental|Anesthesia depth monitor|Anesthesia depth is aimed to be between BIS 50-60
3026941|NCT02382445|Sham Comparator|Control group|Anesthesia depth is monitored but blinded to the anesthesiologist
3026942|NCT02382432|Active Comparator|Pethidine 0.4mg/kg iv|interventional: Pethidine 0.4mg/kg intravenous bolus once to be repeated if shivering incompletely abolished.
3026943|NCT02382432|Active Comparator|DEX. I|Interventional:Dexmedetomidine (Precedex) 0.5µg/kg intravenous bolus once to be repeated if shivering incompletely abolished.
3026944|NCT02382432|Active Comparator|DEX. II|Interventional: Dexmedetomidine (PRECEDEX) 0.3µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.
3026945|NCT02382432|Active Comparator|DEX III|Interventional: Dexmedetomidine (PRECEDEX) 0.2µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.
3026946|NCT02382419|Experimental|Arm I (carrageenan-containing gel)|Participants apply carrageenan-containing gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.
3026947|NCT02382419|Placebo Comparator|Arm II (placebo gel)|Participants apply placebo gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.
3026948|NCT02382406|Experimental|Arm A: Phase I Dose Finding Cohort|"Twelve subjects will be enrolled and treated with carboplatin AUC 6 IV on Day 1, nab-paclitaxel 100 mg/m^2 IV on Day 1, Day 8, and Day 15, pembrolizumab 2* mg/kg IV on Day 1 for 4 cycles. pembrolizumab (Phase I) treatment for Cohort 1 will continue for a maximum duration of 4 21-day cycles~Phase I, Cohort 1 Maintenance Therapy:~Participants who have confirmed CR, PR, or SD (non-progression) after 4 cycles, maintenance therapy with MK-3475 2* mg/kg will continue on D1 of each 21-day cycle. Treatment will continue until progression of disease, unacceptable toxicity, or a maximum of 2 years from C1D1.~If unacceptable toxicity is seen in Phase I Cohort 1, 12 additional participants will be enrolled in Cohort 2 and treated with carboplatin AUC 6 IV on D1, nab-paclitaxel 100 mg/m2 IV on D1, D8, and D15, MK-3475 2*mg/kg IV on D1 starting C2. MK-3475 (Phase 1) treatment for Cohort 2 will continue for a maximum duration of 3 21-day cycles (C2-4 only)."
3026949|NCT02382406|Experimental|Arm B: Phase II Investigational Treatment|"Subjects will be treated with carboplatin AUC 6 given IV on Day 1, nab-paclitaxel 100 mg/m^2 given IV on Day 1, Day 8, and Day 15, and pembrolizumab 200mg IV on Day 1 of each cycle. Pembrolizumab Phase II treatment will continue for a maximum duration of 4 cycles (cycle = 21 days).~Maintenance Therapy For participants who have confirmed CR, PR, or SD (non-progression) after 4 cycles of induction therapy, maintenance therapy with MK-3475 2* mg/kg will continue on Day 1 of each 21-day cycle. Treatment will continue until progression of disease, unacceptable toxicity, or for a maximum of 2 years from C1D1.~*As additional data from ongoing trials becomes available, the dose of MK-3475 may be adjusted."
3026950|NCT02382393|Experimental|BPT, Computerized Assessment|Participants will first take the Brain Performance Test (BPT) and then a third party validated assessment battery.
3026951|NCT02382393|Experimental|Computerized Assessment, BPT|Participants will take a third party validated assessment battery and then the Brain Performance Test (BPT).
3026952|NCT02382380|Experimental|Gadoterate|Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
3026953|NCT02382380|Other|No Gadoterate|Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. MRI protocols utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
3026954|NCT02382367|Experimental|Pulmonary emphysema|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
3026955|NCT02382354|Experimental|i-gel|I-gel insertion was attempted during propofol and remifentanil anesthesia .
3026956|NCT02382354|Active Comparator|laryngeal mask airway|LMA insertion was attempted during propofol and remifentanil anesthesia .
3026957|NCT02382341||Observational|BIOSURE™ HEALICOIL™ PK Interference Screw
3026958|NCT02382328|Experimental|alpha lipoic acid|600mg/24 oral pills alpha lipoic acid 28 days before and 120 days after carpal tunnel release.
3026959|NCT02382328|Placebo Comparator|Placebo|Oral pills of mangensium inactivated 28 days before and 120 days after carpal tunnel release.
3026960|NCT02382315|Experimental|Intervention Group|Fear of Cancer Recurrence Intervention.
3027227|NCT02380391||People living with HIV (HIV+)|Adults experiencing first episode of ACS treated with percutaneous coronary intervention.
3026961|NCT02382315|No Intervention|Wait-list Control Group|Patients assigned to this arm will be asked to wait 6 weeks before being offered the fear of cancer recurrence intervention.
3026962|NCT02382302|Experimental|Telemedicine system|Telemedicine system
3026963|NCT02382289|Active Comparator|bipolar RF 6 points|Six RF needles will be put between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. After sensory and motor stimulation, bipolar lesion RF at 80oc for 90 sec will be applied between each successive pairs of needles.
3026964|NCT02382289|Active Comparator|monopolar RF 6 points|RF needle is inserted at six levels in the area between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. after sensory and motor stimulation, monopolar lesion RF at 80oc for 90 sec will be applied.
3026965|NCT02382289|Active Comparator|monopolar RF 3 points|RF needle is inserted at three levels in the upper , middle and lower part of the area between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. after sensory and motor stimulation, monopolar lesion RF at 80oc for 90 sec will be applied.
3026966|NCT02382276|Experimental|Nalmefene hydrochloride 20 mg|As-needed; tablets, orally
3026967|NCT02382263|Experimental|Arm B|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4
3026968|NCT02382263|Experimental|Arm C|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
3026969|NCT02382263|Experimental|Arm D|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4
3026970|NCT02382263|Experimental|Arm E|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
3026971|NCT02382250||Catheterization Group|These are patients recruited from Bellevue Hospital and NYU Hospital Cardiac Catheterization Laboratories
3026972|NCT02382237|Other|PET/TDM|Evaluation by PET/TDM at 2 times
3026973|NCT02382224|Experimental|Worry Exposure for GAD|WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
3026974|NCT02382224|Placebo Comparator|12-week Waitlist|Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
3026975|NCT02382198|Active Comparator|Active Group|This arm will receive the study drug glycopyrrolate.
3026976|NCT02382198|Placebo Comparator|Placebo Group|Control arm to receive placebo
3026977|NCT02382185|Experimental|Usual care|No intervention apart from application of clearsight monitor. Prior to induction of anaesthesia the control group will have a Clearsight cardiac monitor probe placed on a suitable finger and baseline haemodynamic measurements will be taken. All fluid management and administration of vasopressor therapy will be at the discretion of the anaesthetist as per the current practice at the host institution. Data on stroke volume, heart rate, blood pressure, cardiac output, oxygen saturations, will be recorded at baseline and then every 5 minutes.
3026978|NCT02382185|Experimental|Fluid optimisation|Application of clearsight monitor, optimisation of blood pressure and fluid optimisation. A Clearsight cardiac probe is attached and after induction of anaesthesia stroke volume is optimised using 250ml boluses of Hartmann's solution. The SV measurement prior to the final fluid bolus will be the optimal SV. Mean arterial blood pressure will be maintained within 30% of baseline values using a phenylephrine infusion.Data on haemodynamics will be recorded at baseline and then every 5 minutes, as well as before and after a fluid bolus. Haemoglobin will be maintained at>10g/dL with blood transfusion as required.
3026979|NCT02382172|Experimental|Social Cognition and Interaction Training for Autism (SCIT-A)|The measures the investigators are giving assess participants' initial level of social deficits and the extent to which the therapy did or did not help their social skills. The research team will compare the level of difficulty that participants first reported with their subjective evaluation of their experience in the group sessions to determine whether the program is clinically useful for further development. The investigators will also have the participants complete eye tracking paradigms to assess possible changes in social functioning after completing the Social Cognition and Interaction Training for Autism (SCIT-A) program.
3026980|NCT02382172|Other|Treatment As Usual (TAU)|Continuation of services being given upon study entry.
3026981|NCT02382146|Experimental|dexamethasone and ondansetron|dexamethasone 8 mg with ondansetron 4mg administered in group DO
3026982|NCT02382146|Active Comparator|dexamethasone and dimenhydrinate|dexamethasone 8 mg with dimenhydrinate 1mg/kg administered in group DD
3026983|NCT02382133|Other|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
3026984|NCT02382120||Patients undergoing cardiovascular surgery|Patients ASA 3-4 undergoing cardiac surgery.
3026985|NCT02382094|Experimental|Arm AA(anti-androgen)|Bicalutamide 150 mg per os daily + if needed Tamoxifen 10 mg against breast tenderness/gynecomasti.
3026986|NCT02382094|Other|Arm TAB (Total androgen blockade)|Bicalutamide 50 mg orally daily + Goserelin 3.6 mg subcutaneously every 28±2 days + if needed Tamoxifen 10 mg against breast tenderness/gynecomasti.
3026987|NCT02382081|Experimental|Patient-initiated shared care|"Patient-initiated shared care hospital reviews in which there were one planed hospital review every year and if needed additional reviews initiated by the patient.~Access to nurse-run telephone helpline with direct access to a contact nurse."
3026988|NCT02382081|No Intervention|Control|Traditional, routine hospital reviews every three-fourth month.
3026989|NCT02382068|Experimental|Supportive care (intratympanic dexamethasone)|Patients receive dexamethasone via intratympanic injection in one ear and placebo via intratympanic injection in the other ear. Cisplatin standard of care treatment.
3026990|NCT02382055|Experimental|REACH|Psychotherapy
3026991|NCT02382055|Active Comparator|Supportive Psychotherapy|Psychotherapy
3026992|NCT02382042|Active Comparator|Intensive Referral Intervention|
3026993|NCT02382042|No Intervention|Standard Care|
3026994|NCT02382029|Active Comparator|clonazepam|Twenty two patients took clonazepam two times a day (0.5 mg) in the morning and after two weeks one tablet (0.5 mg) in the morning and another tablet (0.5 mg) in the evening during the next two weeks.
3027030|NCT02381691|Placebo Comparator|no odor|In a second control group, venipuncture was performed to the neonate with an odorless diffusor.
3026995|NCT02382029|Experimental|acupuncture|"Traditional Chinese acupuncture was performed on 20 participants 3 times during one week for four weeks. Intervention was performed on acupuncture points as follows: the points ST 8 (stomach- tou wei), GB 2, TE 21, SI 19 (small intestine- ting gong), SI 18 (small intestine- quan liao), LI 4 (large intestine-Yuan) on both sides of the body as well as GV 20 (Governing vessel-bai hui).~Each session lasted half an hour. Sterile acupuncture needles made from surgical stainless steel silicone coated with spring handle were used. The dimensions of the chosen needles were 0.25 in diameter and 30 mm length, inserted at the depth of the 0.5-1 cm. The elicited response was of the type de qi accompanied by redness and a feeling of numbness around the needles."
3026996|NCT02382016|Experimental|Investigational treatment|Macitentan film-coated tablet 10 mg once daily.
3026997|NCT02382016|Placebo Comparator|Placebo|Matching placebo tablet once daily.
3026998|NCT02382003|Experimental|Positive Training+Anxious Imagery Prime|Positive Cognitive Bias Modification - Interpretation training paired with a preceding Anxious Imagery Prime
3026999|NCT02382003|Experimental|Positive Training+Neutral Imagery Prime|Positive Cognitive Bias Modification - Interpretation training paired with a preceding Neutral Imagery Prime
3027000|NCT02382003|Active Comparator|50/50 Training+Anxious Imagery Prime|50/50 Cognitive Bias Modification - Interpretation (half positive & half negative scenarios) paired with a preceding Anxious Imagery Prime
3027001|NCT02382003|Active Comparator|50/50 Training+Neutral Imagery Prime|50/50 Cognitive Bias Modification - Interpretation (half positive & half negative scenarios) paired with a preceding Neutral Imagery Prime
3027002|NCT02382003|Other|No Scenario+Anxious Imagery Prime|No scenarios paired with a preceding Anxious Imagery Prime
3027003|NCT02382003|Other|No Scenario+Neutral Imagery Prime|No scenarios paired with a preceding Neutral Imagery Prime
3027004|NCT02381964|Placebo Comparator|Placebo|Matched placebo
3027005|NCT02381964|Experimental|1RDA+CoQ10|Supradyn® (1RDA+CoQ10) containing vitamins and minerals at levels up to 100% of the 2008 European Union recommended dietary allowances (RDAs), plus 4.5 mg CoQ10 (1RDA+CoQ10).
3027006|NCT02381964|Experimental|3RDA|Supradyn® (3RDA) containing vitamins and minerals at levels up to 300% of the 1990 European Union RDAs (3RDA).
3027007|NCT02381951|Experimental|Spinal cord stimulation|
3027008|NCT02381938|Experimental|Intervention|6-month intervention to increase physical activity and improve other health related behaviors
3027009|NCT02381938|Other|Control|6-month intervention to educate and improve financial health
3027010|NCT02381912||Hematuria - NMIBC|Primary hematuria due to NMIBC.
3027011|NCT02381912||Hematuria - other cause|Other non-malignant cause of hematuria.
3027012|NCT02381899||BR in CLL|Patients receive bendamustine hydrochloride 90mg/m2 IV on days 1 and 2 each cycle. Patients also receive rituximab 375 mg/m2 IV on day 1 at first cycle and 500 mg/m2 on day 1 all subsequent cycles.
3027013|NCT02381886|Experimental|IDH305|
3027014|NCT02381860|Placebo Comparator|Placebo|The PLA supplement consisted of a commercially available, less than 5% fruit, cordial (Protein - Trace, Carbohydrate 260 mg•mL−1, Sodium 0.02 mg•mL−1, Fibre-Trace and Anthocyanins-Trace for colour), mixed with water, whey protein isolate (Arla Foods Ltd., Leeds, UK) and maltodextrin (MyProtein Ltd., Northwich, UK) until matched for carbohydrate and calorie content of the MC.
3027015|NCT02381860|Active Comparator|60mL of cherry concentrate with 100ml water|One bolus of 60mL of tart Montmorency cherry (MC) juice mixed with 100mL of water. Independent analysis of MC (Atlas Biosciences, 2010) provided the following compositional data; Fat 0.028 mg•mL−1, Protein 31.47 mg•mL−1, Carbohydrate 669.4 mg•mL−1, Cholesterol < 0.01 mg•mL−1, Sodium 0.691 mg•mL−1, Calcium 0.137 mg•mL−1 and Iron 0.026 mg•mL−1. Additionally, according to the manufacturers guidelines (Cherry Active, Hanworth, UK),
3027016|NCT02381847|No Intervention|without HIPEC|Patients will be treated with a D2 radical gastrectomy for advanced gastric cancer and postoperative chemotherapy (SOX or XELOX).
3027017|NCT02381847|Experimental|with HIPEC|"Patients will be treated with a D2 radical gastrectomy for advanced gastric cancer and intraperitoneal chemoperfusion with cisplatin and postoperative chemotherapy as described for the control group.~Cisplatin: 75mg/m2 (max 150mg/m2 max 5L )"
3027018|NCT02381834|Experimental|Bladder stimulation technique|This is a two-person technique. A health care aide or nurse (RN) begins by holding the infant under the axillae with its legs dangling. A second RN or physician then performs bladder stimulation by gentle finger tapping on the lower abdomen in the midline just above the pubic symphysis at a frequency of 100 taps/min. If this is unsuccessful after 30 seconds, lower back stimulation in the lumbar paravertebral zone is performed by light massage in a circular motion using both thumbs. This too is performed for 30 seconds maximum. These two manoeuvres are repeated in succession, for a maximum of 5 minutes total, until urination occurs. Unsuccessful attempts at midstream urine collection will be followed by further feeding/fluid administration and bladder catheterization.
3027019|NCT02381821||pregnant|women undergoing ICSI who became pregnant
3027020|NCT02381821||Not pregnant|women undergoing ICSI who fail to achieve pregnancy
3027021|NCT02381795|Experimental|Nasal Carbon Dioxide|0.17 liters (L) of carbon dioxide (CO2) will be delivered through two 10 second administrations in each nostril, up to 6 times, to treat one attack (total of 1.0 L CO2). Subjects may treat up to three cluster headache attacks during the treatment phase of this study (total of 3.0 L (CO2).
3027022|NCT02381769|Experimental|Parenteral Nutrition|Soybean based lipid emulsion
3027023|NCT02381743|No Intervention|Group 1|Weekly non-medical SMS messages
3027024|NCT02381743|Experimental|Group 2|Receipt of a daily SMS text message describing various aspects of clinical practice
3027025|NCT02381743|Experimental|Group 3|Receipt of a daily SMS text message describing various aspects of clinical practice, but phrased as multiple choice question
3027026|NCT02381730|Experimental|Aflibercept|
3027027|NCT02381717|Experimental|ultra-sound guided femoral nerve block|Patients in this arm will receive a bed-side ultrasound guided femoral nerve block with analgesia 0.5% bupivacaine (2mg/kg)
3027028|NCT02381717|Active Comparator|standard of care- IV morphine|Patients in this arm will have the femoral nerve block block with no ultrasound for guidance with analgesia (IV morphine)
3027029|NCT02381691|Experimental|maternal breast milk odor|"In the first group breast milk, venipuncture was performed to the neonate while his mother's milk odor was being diffused."
3058418|NCT02172144|Active Comparator|Moxifloxacin (Avalox®)|
3027031|NCT02381678||Subjects implanted with Perimount Heart Valve|Only one group was set for this study, including all enrolled subjects who implanted with Perimount Heart Valve during 2001 to 2007
3027032|NCT02381665|Experimental|Group A|Patient enrolled in this group will receive a device for effective interferential current stimulation.
3027033|NCT02381665|Placebo Comparator|Group B|Patient enrolled in this group will receive a device that does not deliver current stimulation
3027034|NCT02381652|Experimental|Cingal®|Subjects will receive a single injection of Cingal® (Hyaluronic Acid plus Triamcinolone Hexacetonide)
3027035|NCT02381639|Other|Patients|patients followed in the addiction service of the University Hospital of Nantes (consultations and / or hospitalizations) for restrictive anorexia nervosa
3027036|NCT02381639|Other|Healthy volunteers|control subjects matched for age and sex with the patients
3027037|NCT02381626|Experimental|Intervention Group|During the first 2 weeks, measurements (e.g. biological markers and air monitoring) will be taken under usual conditions. At the end of the initial two weeks, portable HEPA air purifiers (136) will be placed in the Intervention Group drivers' cars and the air monitoring and biological parameters will be repeated for another 2-week period, to determine changes in PM levels and physiological measurements as a result of this targeted intervention.
3027038|NCT02381626|Experimental|Wait-list Control Group|During the first 2 weeks, measurements (e.g. biological markers and air monitoring) will be taken under usual conditions. The Wait-list Control Group drivers will not receive a HEPA air purifier at this time, but will also have the air monitoring and biological parameters repeated for another 2 weeks. At the end of the 1 month period of measurements for both groups of drivers, the Wait-list drivers will then receive a HEPA air purifier, so that they may also potentially benefit from the intervention being tested in this study, but no further measurements will be taken.
3027039|NCT02381613|Active Comparator|Baked beef|A meal based on baked beef
3027040|NCT02381613|Experimental|Baked herring|A meal based on baked herring
3027041|NCT02381613|Experimental|Pickled herring|A meal based on pickled herring
3027042|NCT02381600|Experimental|Intervention group- vitamin D|Include patients aged 65 years and older that are found to have below-normal serum levels of vitamin D on routine laboratory testing. After providing informed consent (the study was submitted for approval by the Ethics Committee of the Clalit Health Services) eligible subjects will undergo cognitive and affective assessment
3027043|NCT02381561|Experimental|Treatment (ropidoxuridine, IMRT)|Beginning 30 minutes to 2 hours before radiation therapy, patients receive ropidoxuridine PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. Beginning on day 8, patients undergo IMRT 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity.
3027044|NCT02381548|Experimental|Treatment (belinostat, WEE1 inhibitor AZD1775)|Patients receive belinostat IV over 30-90 minutes QD on days 1-5 and 8-12 and WEE1 inhibitor AZD1775 PO QD on days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Responding patients with CR, CRi, CRc, or CRm and do not go on to have stem cell transplant may only continue treatment for 3-4 additional courses after response.
3027045|NCT02381535|Experimental|Treatment (onalespib, cisplatin, IMRT)|Patient receive onalespib IV over 1 hour on days -7, 3, 10, 24, 31, and 38 and cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, 36 and 43. Patients also undergo IMRT QD, 5 days a week over 7 weeks for a total of 35 fractions. Treatment continues in the absence of disease progression or unacceptable toxicity.
3027046|NCT02381522|Active Comparator|Remote Ischemic Pre-conditioning|Remote Ischemic Pre-conditioning group will receive 4 cycles of lower extremity occlusion of perfusion by blood pressure cuff inflated to 20 mmHg higher than systolic and confirmed by doppler.
3027047|NCT02381522|Sham Comparator|Sham RIPC|Sham procedure group will receive 4 cycles of inflation of lower extremity blood pressure cuff but it will be 20mmhg lower than systolic BP and hence not occlude the vessel.
3027048|NCT02381509||IVC Filter|IVC filter for the prevention of PE
3027049|NCT02381496|Experimental|Part A: Cohort A1: ACT-453859 1 mg|"ACT-453859 1 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
3027050|NCT02381496|Experimental|Part A: Cohort A2: ACT-453859 3 mg|"ACT-453859 3 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
3027051|NCT02381496|Experimental|Part A: Cohort A3: ACT-453859 10 mg|"ACT-453859 10 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
3027052|NCT02381496|Experimental|Part A: Cohort A4: ACT-453859 30 mg|"ACT-453859 30 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
3027053|NCT02381496|Experimental|Part A: Cohort A5: ACT-453859 100 mg|"ACT-453859 100 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo~After a washout period of 10-20 days subjects will return for a second study period to receive the same treatment received in the first session but under fed conditions"
3027054|NCT02381496|Experimental|Part A: Cohort A6: ACT-453859 300 mg|"ACT-453859 300 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
3027055|NCT02381496|Experimental|Part A: Cohort A7: ACT-453859 800 mg|"ACT-453859 800 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
3027056|NCT02381496|Experimental|Part B: Cohort B1: ACT-453859 10 mg|"ACT-453859 10 mg or placebo, once a day for 7 days, administered orally in the fasted state~Three male subjects will receive ACT-453859~Three female subjects will receive ACT-453859~One male subject will receive matching placebo~One female subject will receive matching placebo"
3027057|NCT02381496|Experimental|Part B: Cohort B2: ACT-453859 100 mg|"ACT-453859 100 mg or placebo, once a day for 7 days, administered orally in the fasted state~Three male subjects will receive ACT-453859~Three female subjects will receive ACT-453859~One male subject will receive matching placebo~One female subject will receive matching placebo"
3027119|NCT02381067|Other|NuCel with Allograft Bone|NuCel will be used with allograft bone for the surgical treatment of one, two or three level degenerative disease of the cervical spine.
3058424|NCT02172105|Placebo Comparator|Placebo|
3027058|NCT02381496|Experimental|Part B: Cohort B3: ACT-453859 800 mg|"ACT-453859 800 mg, once a day for 7 days, administered orally in the fasted state~Three male subjects will receive ACT-453859~Three female subjects will receive ACT-453859~One male subject will receive matching placebo~One female subject will receive matching placebo"
3027059|NCT02381496|Experimental|Part C: Treatment Periods I & II: Setipiprant|"Setipiprant 500 mg, twice daily for 7 days, administered orally in Treatment Period I (TPI) and setipiprant 1000 mg, twice daily for 7 days, administered orally in Treatment Period II (TPII)~Four male subjects will receive setipiprant 500 mg twice a day in TPI and 1000 mg twice a day in TPII.~Four female subjects will receive setipiprant 500 mg twice a day in TPI and 1000 mg twice a day in TPII.~There will be a washout period of 10 days between TPI and TPII"
3027060|NCT02381483|Experimental|Lean|Cold exposure
3027061|NCT02381483|Experimental|Obese|Cold exposure
3027062|NCT02381470|Experimental|Faropenem+amoxicillin/clavulanic acid|Faropenem 400mg with amoxicillin/clavulanic acid (500mg/125mg) each three times daily for 5 days
3027063|NCT02381470|Active Comparator|Pyrazinamide|Pyrazinamide 2g (1.5g if weight <50kg) once daily for 5 days
3027064|NCT02381470|Active Comparator|Isoniazid|Isoniazid 300mg once daily for 5 days
3027065|NCT02381457||Pregnancies undergoing prenatal microdeletion screening|"Pregnant women undergoing non-invasive prenatal screening for microdeletion and aneuploidy syndromes.~No drug will be administrated, this cohort will undergo a non invasive prenatal blood test and then follow up data and specimens will be collected for research analysis."
3027066|NCT02381444||Standard of Care|Participants with advanced Parkinson's Disease
3027067|NCT02381444||Levodopa Carbidopa Intestinal Gel|Participants with advanced Parkinson's Disease
3027068|NCT02381431|Experimental|Thermal Imaging|imaging using a thermal camera
3027069|NCT02381418|Experimental|1|"Trivalent influenza subunit vaccine Influvac. 3x 15mcg Hemagglutinin Antigen (HA) per 0.5 ml,trivalent one injection at Day 1 "
3027070|NCT02381405|Active Comparator|A|Enterade beverage
3027071|NCT02381405|No Intervention|B|Standard of care
3027072|NCT02381392|Experimental|AV400|The nurse will use the Accuvein AV400 to assist with intravenous access. If the nurse cannot place the catheter after 2 tries (two needle sticks into the skin) then the nurse will attempt to put in the catheter without using the device. While the nurse is putting in the catheter, a member of the study team will record the number of tries, the type of catheter and where the catheter is successfully put in. Afterwards the parent and nurse will be surveyed on their satisfaction and the nurse will be asked specific questions about using the AV400.
3027073|NCT02381392|No Intervention|Standard|The nurse will use the standard technique for intravenous access (not using the Accuvein AV400). If the nurse cannot place the catheter after 2 tries (two needle sticks into the skin) then the nurse will attempt to put in the catheter with the help of the Accuvein AV400. While the nurse is putting in the catheter, a member of the study team will record the number of tries, the type of catheter and where the catheter is successfully put in. Afterwards the parent and nurse will be surveyed on their satisfaction and the nurse will be asked specific questions about using the AV400 if they crossed over to the AV400 after two failures.
3027074|NCT02381379|Active Comparator|Peginterferon-α-2a (Pegasys®)|Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year
3027075|NCT02381379|No Intervention|Observation|Stop tyrosine kinase inhibitor that was on and no active medication that might affect CML, for example any immune-modulatory agents, traditional herbs or medications, chemotherapeutic agents, growth factors, or colony stimulating factors is allowed during the trial period.
3027076|NCT02381366|Experimental|PNEUMOSTEM®|Dose A: PNEUMOSTEM® 10 million cells per kg Dose B: PNEUMOSTEM® 20 million cells per kg
3027077|NCT02381353|Active Comparator|Plain bupivacaine|Intraoperative injection of local anesthetic agent, standard of care
3027078|NCT02381353|Experimental|Exparel (sustained release bupivacaine)|Intraoperative injection of local anesthetic agent, long acting agent
3027079|NCT02381327|Experimental|Binge Eating Disorder|Patients with Binge Eating Disorder will use Mandometer as an intervention to reduce food intake and speed of eating.
3027080|NCT02381327|Experimental|Control|Normal weight, healthy control subjects will use Mandometer to obtain data for comparison with the patients with Binge Eating Disorder.
3027081|NCT02381314|Experimental|enoblituzumab plus ipilimumab|Enoblituzumab: Fc-optimized, humanized monoclonal antibody. Ipilimumab: Yervoy; recombinant, fully humanized IgG-1 CTLA-4 blocking antibody approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of unresectable or metastatic melanoma.
3027082|NCT02381301||Venous blood sampling prior to CCTA.|In patients undergoing routine Cardiac Computed Tomography Angiography (CCTA) and given written informed consent blood sampling will be performed. The samples will be stored for a period of 15 years at the Biobank for future analyses.
3027083|NCT02381288|Experimental|TAK-448 0.1 mcg|TAK-448 0.1 mcg, injection, subcutaneously, once daily on Days 1 through 42.
3027084|NCT02381288|Experimental|TAK-448 0.3 mcg|TAK-448 0.3 mcg, injection, subcutaneously, twice-weekly on Days 1 through 39.
3027085|NCT02381288|Experimental|TAK-448 1.0 mcg|TAK-448 1.0 mcg, injection, subcutaneously, once-weekly on Days 1 through 36.
3027086|NCT02381288|Placebo Comparator|Placebo|TAK-448 placebo matching injection, subcutaneously, either once daily on Days 1 through 42, or twice weekly on Days 1 through 39 or once weekly on Days 1 through 36.
3027087|NCT02381262|Experimental|Intervention|"At the 2 week post-surgical visit, subjects will receive and be trained in the use of the Fitbit and data interface and meet with the exercise physiologist or research coordinator to initiate MyLGHealth, lifestyle/activity data collection.~Subsequent data collection time-points correspond with follow-up post-surgical appointments either at each visit or the 2 week, 1 month, 4 month, 8 month or 12 month visit."
3027088|NCT02381262|No Intervention|Control|"At the 2 week post-surgical visit, all subjects will then meet with the exercise physiologist or research coordinator to initiate MyLGHealth, lifestyle/activity data collection.~Subsequent data collection time-points correspond with follow-up post-surgical appointments either at each visit or the 2 week, 1 month, 4 month, 8 month or 12 month visit.~The control group will receive a current version of the Fitbit device at the end of their completion of the 12 month visit."
3027197|NCT02380573|Placebo Comparator|Healthy Aging Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
3027089|NCT02381262|No Intervention|Historical Control|The investigators will extract historical control data from the electronic health record using electronic queries and manual data extraction. Historical controls will have surgery and 12-month follow-up completed prior to the start of the RCT.
3027090|NCT02381249|Experimental|Esophagectomy|Double-blind single dose octreotide-placebo crossover
3027091|NCT02381249|Experimental|Gastrectomy|Double-blind single dose octreotide-placebo crossover
3027092|NCT02381249|Active Comparator|Unoperated healthy control|Double-blind single dose octreotide-placebo crossover
3027093|NCT02381249|Experimental|Pancreaticoduodenectomy|Double-blind single dose octreotide-placebo crossover
3027094|NCT02381236|Experimental|G-202|G-202 administered by intravenous infusion on 3 consecutive days of a 28-day cycle
3027095|NCT02381210||CLINICALLY CONFIRMED PREECLAMPSIA|Pregnant women with clinical diagnosis of preeclampsia (severe, mild or superimposed) will provide a urine sample to determine the presence or absence of proteinuria using the Congo Red Dot test.
3027096|NCT02381210||CLINICALLY HEALTHY|Pregnant women admitted to the hospital for delivery of a healthy normal baby at term (induction of labor or an elective Caesarean Section) will provide a urine sample to determine the presence or absence of proteinuria using the Congo Red Dot test.
3027097|NCT02381197||pregnant women|Women presenting for prenatal care will provide urine samples at each antenatal care visit. The sample will be used to perform a Congo Red Dot test.
3027098|NCT02381184|Active Comparator|Clomiphene Citrate group (Group A)|Group A (n =68) assigned to receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
3027099|NCT02381184|Active Comparator|laparoscopic ovarian drilling (LOD) Group B|Group B (n =68) underwent LOD. Laparoscopy was performed under general anesthesia, using three-puncture technique. Each ovary was cauterized perpendicular to its antimesenteric border at four points, each for 4 seconds at 40 W with a mixed current, using a monopolar electrosurgical needle (Karl Storz, ND, Germany). Each puncture was about 4 mm in diameter and 6-8 mm in depth. The ovary was cooled by irrigation with normal saline solution. Any, intraoperative or postoperative complication was reported. The follow-up was started from the next cycle after ovarian drilling up to 6 months
3027100|NCT02381171|Sham Comparator|Both Sham rTMS and Neuroacupuncture|Subjects will be randomized to receive 10 sessions of both sham treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMSat 10hHz (1600pulses) over the primary motor cortex area and neurofunctional electrical acupuncture without current connection over peripheral region.
3027101|NCT02381171|Sham Comparator|Active rTMS and sham Neuroacupuncture|Subjects will be randomized to receive 10 sessions of active rTMS and sham neurofunctional electrical acupuncture treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS at 10Hz (1600 pulses) over the primary motor cortex area and neurofunctional electrical acupuncture without current connection over peripheral region.
3027102|NCT02381171|Sham Comparator|Sham rTMS and Active Neuroacupuncture|Subjects will be randomized to receive 10 sessions of sham rTMS and active Neurofunctional Electrical Acupuncture. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS placebo coil over the primary motor cortex area and neurofunctional electrical acupuncture at 1Hz, continuous, 10mA current for 20 minutes over peripheral region.
3027103|NCT02381171|Active Comparator|Both Active rTMS and Neuroacupuncture|Experimental Subjects will be randomized to receive 10 sessions of both active treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS at 10 Hz (1600 pulses) over the primary motor cortex area and neurofunctional electrical acupuncture at 1Hz, continuous, 10mA current for 20 minutes over peripheral region.
3027104|NCT02381158|Experimental|Nebulized Beclomethasone dipropionate|Nebulized Beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg).
3027105|NCT02381145|Placebo Comparator|Placebo|micro-cellulose-filled Placebo
3027106|NCT02381145|Active Comparator|EGCG+RSV-supplementation|EGCG+RSV: 300mg/d + 80mg/d
3027107|NCT02381132|Active Comparator|MNK155|Hydrocodone Bitartrate/Acetaminophen Extended-Release Tablets
3027108|NCT02381132|Active Comparator|Norco 7.5mg/325mg|Norco 7.5mg/325mg
3027109|NCT02381119|Experimental|Personalized advice|Dietitian provides Personalized dietary advice (based on genetic, blood and food intake profiles) (the type of advice is the intervention)
3027110|NCT02381119|Active Comparator|Regular care|Dietitian provides regular care for diabetes type 2 (regular advice is the control condition)
3027111|NCT02381106||Women with preeclampsia|Women delivered by cesarian section and with preeclampsia
3027112|NCT02381106||Women with dysfunctional labor|Women delivered with cesarian section due to dtsfunctional labor
3027113|NCT02381106||Women with cesarian section due to maternal request|Women with cesarian section due to maternal request
3027114|NCT02381106||Women with preamture labor|Women with pemature labor undergoing cesarian section
3027115|NCT02381093|Active Comparator|Standard BLS Course|Participants will partake in a standard BLS course.
3027116|NCT02381093|Experimental|Contextual Interference|Participants will partake in a BLS course designed using contextual interference scheduling.
3027117|NCT02381080|Experimental|Part 1: Ibrutinib+Erythromycin+Voriconazole|Participants will receive oral treatment in six, 28-days cycles. In Cycle 1, participants will take ibrutinib 560 milligram (mg) (4*140 mg capsules) once daily (QD) from Days 1- 4; on Days 5-11 ibrutinib 140 mg capsule QD in combination with erythromycin 500 mg tablet 3 times daily (TID); on Days 12-13 ibrutinib 140 mg capsule QD; on Days 14-18 ibrutinib 560 mg (4*140 mg capsules) QD; on Days 19-25 ibrutinib 140 mg capsule QD in combination with voriconazole 200 mg tablet twice daily (BD); on Days 26-27 ibrutinib 140 mg capsule orally QD; and on Day 28 and in subsequent treatment Cycles (2-6) participants will continue oral treatment with ibrutinib 420 mg or 560 mg QD (depending on the subtype of B-cell malignancy).
3027118|NCT02381080|Experimental|Part 2: Ibrutinib+ Erythromycin+Voriconazole|Participants will receive oral treatment in six, 28-days cycles. In Cycle 1, participants will take ibrutinib 560 mg (4*140 mg capsules) QD from Days 1- 4; on Days 5-18 ibrutinib 560 mg (4*140 mg capsules) QD in combination with either erythromycin 500 mg tablet TID (Group 1) or voriconazole 200 mg tablet BD (Group 2); on Day 19 and in subsequent treatment Cycles (2-6) participants will continue oral treatment with ibrutinib 420 mg or 560 mg QD (depending on the subtype of B-cell malignancy).
3058472|NCT02171806|Experimental|BI 1744 CL medium dose, females|
3027120|NCT02381054||Translation and cross-cultural adaptation phase|In this phase 96 Italian-speaking patients who are receiving cancer treatment or who have completed treatment for cancer within the past six months at one of the participating sites will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the interviewer will elicit participants' feedback regarding item comprehension, symptomatic adverse event terms, attribute terms, 7-day recall period, and response options, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.
3027121|NCT02381054||Test-retest phase|In this phase a minimum of 59 Italian-speaking patients who are receiving cancer treatment will be asked to independently complete the Italian version PRO-CTCAE questionnaire on 2 consecutive business days.
3027122|NCT02381028|Experimental|Study area|Human milk and emollient: Apobase creme® (Actavis Norway AS)
3027123|NCT02381028|Active Comparator|Control area|Emollient: Apobase creme® (Actavis Norway AS)
3027124|NCT02381015|Experimental|Genetic Risk Score: Number Format|Genetic Risk Score: Number Format Subjects receive genetic risk scores in a number format.
3027125|NCT02381015|Experimental|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Subjects receive genetic risk scores in a number and pictograph format.
3027126|NCT02381015|Experimental|Family History: Number Format|Family History: Number Format Subjects receive family history risk in a number format.
3027127|NCT02381015|Experimental|Family History: Number + Pictograph|Family History: Number + Pictograph Subjects receive family history risk in a number and pictograph format.
3027128|NCT02381002|Experimental|Weight reduction|weight reduction program for 6 months
3027129|NCT02380989|Experimental|Ayurveda|
3027130|NCT02380989|Placebo Comparator|Placebo|
3027131|NCT02380976|Experimental|Test 1|First phase: DW330SR+DW1030 7 days after Second phase: DW340
3027132|NCT02380976|Experimental|Test 2|First phase: DW340 7 days after Second phase: DW330SR+DW1030
3027133|NCT02380963|Experimental|Colorado Diet with soy protein|
3027134|NCT02380963|Active Comparator|Colorado Diet|
3027135|NCT02380950|Other|250 ml alcohol consumption|"Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510."
3027136|NCT02380937|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device (catheter)
3027137|NCT02380924|Active Comparator|DSP loaded RBC using EryDex System|Autologous RBC loaded with DSP using the EDS process, and treated RBC are infused to the subject.
3027138|NCT02380924|Sham Comparator|Sham treated RBC using the EryDex System|Autologous RBC are treated with buffer using the EDS process, and treated RBC are infused to the subject.
3027139|NCT02380911|Experimental|Intervention Group|The intervention group will receive a multifaceted educational intervention targeting physicians and pharmacist assistants to improve detection, treatment and control of hypercholesterolemia among uninsured patients with moderate-high cardiovascular risk in Argentina.
3027140|NCT02380911|No Intervention|No Intervention Group|This group will continue with the usual care. Irrespective of the assignment of the clinic to the intervention or control group, all physicians from participating PCCs have received previous training on global cardiovascular risk management, given by the Ministry of Health
3027141|NCT02380898|Experimental|Ketorolac|
3027142|NCT02380898|Placebo Comparator|Normal saline 0.9%|
3027143|NCT02380885|Experimental|SCIT|Social Cognition and Interaction Training: psychosocial group intervention
3027144|NCT02380885|Experimental|TAFT|Therapeutic Alliance Focused Therapy
3027145|NCT02380885|No Intervention|TAU|Treatment as Usual
3027146|NCT02380872|Active Comparator|Connective tissue graft|Connective tissue graft Soft tissue harvested from palatum of the subjects.
3027147|NCT02380872|Experimental|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
3027148|NCT02380859|Active Comparator|visual adaptation|Both groups will receive goggles fitted with lenses that distort vision in slightly different ways. Group A is thought to reduce gait impairment
3027149|NCT02380859|Sham Comparator|Sham adaptation|Group B will alter vision but are not thought to reduce gait impairment
3027150|NCT02380846|Other|Rice|Control session - white rice (equivalent to 50g available carbohydrates)
3027151|NCT02380846|Active Comparator|Rice with chicken|Treatment 1 - White rice and steamed chicken breast (25g protein)
3027152|NCT02380846|Active Comparator|Rice with fish|Treatment 2 - White rice and steamed fish (25g protein)
3027153|NCT02380846|Active Comparator|Rice with egg white|Treatment 3 - White rice and egg white (25g protein)
3027154|NCT02380846|Active Comparator|Rice with beancurd|Treatment 4 - White rice and steamed beancurd (25g protein)
3027155|NCT02380833|Active Comparator|MyPlate|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations for eight weeks.
3027156|NCT02380833|Active Comparator|MyPlate + Exercise|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
3027157|NCT02380833|Active Comparator|Paleolithic|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations for eight weeks.
3027158|NCT02380833|Active Comparator|Paleolithic + Exercise|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
3027159|NCT02380820|Experimental|AirsoftDuo first|"Patients randomized to this arm will be placed on the Airsoft Duo mattress, and the investigator will proceed with 2 series (for reproductibility) of measures for 30 minutes with the bed headboard at 0°. A pause, consisting of ten minutes of sitting and 1 minute of verticalization is then carried out. The bed is then positioned at 30°, and the 2 series of measures over 30 minutes are repeated. The next day, all of the above are repeated with the Softform Premium mattress (in static mode). The patient will then continue his/her stay with the Softform Premium mattress (in static mode) for 1 month.~Intervention: Airsoft Duo mattress Intervention: Softform Premier mattress (in static mode)"
3027160|NCT02380820|Experimental|Softform Premium first|"Patients randomized to this arm will be placed on the Softform Premium mattress (in static mode), and the investigator will proceed with 2 series (for reproductibility) of measures for 30 minutes with the bed headboard at 0°. A pause, consisting of ten minutes of sitting and 1 minute of verticalization is then carried out. The bed is then positioned at 30°, and the 2 series of measures over 30 minutes are repeated. The next day, all of the above are repeated with the Airsoft Duo mattress. The patient will then continue his/her stay with the Airsoft Duo mattress for 1 month.~Intervention: Softform Premier mattress (in static mode) Intervention: Airsoft Duo mattress"
3027161|NCT02380807|Experimental|Dry Needling Therapy|Dry Needly Therapy will be assesses in trigger points on latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourum muscle.
3027162|NCT02380807|Active Comparator|Cross Tape Therapy|Cross Tape is a grid-shaped bandage easy aplicacionen different parts of the body that regulates the tension.
3027163|NCT02380794|Active Comparator|Danshen Gegen Capsule|3 capsules (500 mg per capsule) twice daily for 24 weeks
3027164|NCT02380794|Placebo Comparator|Placebo|3 capsules (500 mg per capsule) twice daily for 24 weeks
3027165|NCT02380781|No Intervention|Control|Patients will receive current standard postpartum contraceptive counseling.
3027166|NCT02380781|Experimental|Intervention|Patients will receive current standard postpartum contraceptive counseling and will be shown a 10 minute video from the CHOICE project which outlines the different contraceptive options
3027167|NCT02380768|Experimental|Ambu AuraGain|Subjects will receive the Ambu AuraGain size 1.5 or 2.0 based on manufacturer guidelines
3027168|NCT02380768|Active Comparator|LMA Supreme|Subjects will receive the Ambu AuraGain size 1.5 or 2.0 based on manufacturer guidelines
3027169|NCT02380755|Placebo Comparator|Placebo|One pill every other day during 12 weeks
3027170|NCT02380755|Active Comparator|Clomiphene Citrate|Clomiphene citrate 50 mg orally daily (Serophene) during 12 weeks
3027171|NCT02380742|Experimental|lidocaine-prilocaine|4 mL of lidocaine-prilocaine cream
3027172|NCT02380742|Placebo Comparator|Placebo|4 mL of placebo cream
3027173|NCT02380729||Index patients|"Children between birth and 18 years of age manifesting with a suspected genetic disorder.~Investigation: First Gene Panel Sequencing and if no mutation ist found > Whole Genome Sequencing (WGS)"
3027174|NCT02380729||Parents of the index patient|"Both parents of the index patient.~Investigation: Whole Genome Sequencing (WGS) if no mutation is found by Gene Panel Sequencing of the index patient."
3027175|NCT02380703|Experimental|Aggression Prevention Training (APT)|APT will use active learning tools, including didactics, role-playing, and multimedia (eg, books and DVDs) to educate and provide skill training for the caregiver. The 6-8 modules in the intervention will include 4 core modules that address 4 main aggression risk factors: a) recognizing pain, b) treating pain, c) increasing pleasant activities, and d) improving patient-caregiver communication. Caregivers can select 2 to 3 additional elective sessions; elective selection is guided by the needs of the dyad to further enhance skills related to these core topics. Sessions will take place in the patient's home.
3027176|NCT02380703|Placebo Comparator|Enhanced Usual Primary Care (EU-PC)|EU-PC provides the patient and caregiver educational materials on pain, notifies the primary care provider of the PWD's level of pain and depression, and provides 8 weekly supportive telephone calls to caregivers.
3027177|NCT02380690|Experimental|Peer Coach Assignment|Veteran participants will be assigned to a peer coach, who delivered self-management instruction one-on-one over a 6-month period.
3027178|NCT02380690|No Intervention|Control|"Veteran participants will attend a 2-hour class in pain basics and pain self-management. Veterans will aso be given a set of pamphlets related to pain self-management."
3027179|NCT02380677|Experimental|CRLX301|"CRLX301 given by intravenous infusion on either Schedule 1 (Day 1 of a 21-day Cycle) or Schedule 2 (Weekly with no break, or Weekly 3 weeks on, 1 week off).~In Phase 2a all patients will receive the MTD/RP2D dose level per dosing schedule determined in Phase 1."
3027180|NCT02380664|No Intervention|Swimmers|Swimmers that continue their normal swimming activity
3027181|NCT02380664|Experimental|WBV swimmers|Swimmers that perform a whole-body vibration training
3027182|NCT02380664|Experimental|Plyometric swimmers|Swimmers that perform a plyometric training
3027183|NCT02380664|No Intervention|Sedentary controls|Controls that do not perform swimming or other physical activities
3027184|NCT02380638|Experimental|DS-WBV|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform squat on a vibratory platform (3 times per week; 10 repetitions 30 to 60 seconds; Frequency: 25-30 Hz; Amplitude: 2 mm).
3027185|NCT02380638|No Intervention|DS-NONWBV|This group will continue with their day-to-day lifestyle during the course of the project.
3027186|NCT02380638|Experimental|NONDS-WBV|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform squat on a vibratory platform (3 times per week; 10 repetitions 30 to 60 seconds; Frequency: 25-30 Hz; Amplitude: 2 mm).
3027187|NCT02380638|No Intervention|NONDS-NONWBV|This group will continue with their day-to-day lifestyle during the course of the project.
3027188|NCT02380625|Experimental|Azithromycin|Azithromycin, IV fluids and laboratory testing
3027189|NCT02380625|Experimental|Sunitinib and Erlotinib|Sunitinib, Erlotinib, IV fluids and laboratory testing
3027190|NCT02380625|Experimental|Atorvastatin and Irbesartan|Atorvastatin, Irbesartan, IV fluids and laboratory testing
3027191|NCT02380625|Other|IV fluids and laboratory testing|no additional treatment
3027192|NCT02380612|Experimental|Area A|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
3027193|NCT02380612|Experimental|Area B|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
3027194|NCT02380599|Experimental|Experimental Group|Crossover assignment of mid-thoracic spinal manipulation, spinal mobilization, or sham ultrasound
3027195|NCT02380586||Women in labor undergoing anesthesia care|Women in labor undergoing anesthesia care
3027196|NCT02380573|Experimental|Healthy Aging MB|Methylene Blue (USP grade, 282mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
3027198|NCT02380573|Experimental|Mild Cognitive Impairment (MCI) MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
3027199|NCT02380573|Placebo Comparator|Mild Cognitive Impairment (MCI) Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
3027200|NCT02380573|Experimental|Mild Alzheimer's Disease (AD) MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
3027201|NCT02380573|Placebo Comparator|Mild Alzheimer's Disease (AD) Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
3027202|NCT02380573|Experimental|Health Middle Age MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
3027203|NCT02380573|Placebo Comparator|Health Middle Age Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
3027204|NCT02380560||pPROM|50 women with preterm premature rupture of membranes with gestational age from 24 to 34 weeks assessed by ultrasound examination
3027205|NCT02380560||term non-labor control|25 term non-labor control (T-CTR, n=25) with gestational age from 37 to 41 weeks assessed by ultrasound examination
3027206|NCT02380560||preterm non-labor control|25 preterm non-labor control (P-CTR, n=25) with gestational age from 24 to 34 weeks assessed by ultrasound examination
3027207|NCT02380534|Experimental|active procedure|High cardiovascular risk patients will undergo H.E.L.P. apheresis.
3027208|NCT02380521|Experimental|60 patients with T2DM|These patients will be treated with exenatide once weekly for a period of 8 months
3027209|NCT02380508|Experimental|Group 1|32 BCG-naïve subjects receiving BCG SSI or BCG Sii at standard dose (2-8x10^5 cfu) via Intradermal route.
3027210|NCT02380508|Experimental|Group 2|8-16 control volunteers receiving no vaccination.
3027211|NCT02380495||Allergic rhinitis with/without asthma, from 14 to 17 years age|600 adolescents with allergic rhinitis with/without asthma, from 14 to 17 years age, recruited from Pediatricians of the Italian territory.
3027212|NCT02380495||Without respiratory pathology|600 subject (5 for each participant Pediatrician) of the same age range, without respiratory pathology (patient family)
3027213|NCT02380482|Other|Traumatic brain injury|"Two dimensional and speckle tracking transthoracic echocardiography in traumatic brain injured patients~Glasgow score < or = 9 or~Glasgow score between 9 and 13 (included) and Following Traumatic Coma Data Bank Tomographic Damages:~diffuse injuries type III or IV or mass lesion over 25ml and/or neurosurgical injuries"
3027214|NCT02380482|Other|Controls|"Two dimensional and speckle tracking transthoracic echocardiography in control patients paired with traumatic brain injured patient on age, BMI and sex with the following criteria:~Intubated and mechanically ventilated~Undergoing urgent non severe surgery"
3027215|NCT02380469|Experimental|Immediate intervention|Immediately after enrollment in the project, caregivers and patients receive the intervention
3027216|NCT02380469|Other|Delayed intervention (3 weeks later)|This group receives the same intervention as in the experimental group, but after the outcome assessment at 2 weeks
3027217|NCT02380443|Experimental|Dosing Schedule A|"The priming step with ID injections of AlloStim on Days 0, 7, and 14~The vaccination step with cryoablation and IT (intratumoral) injection of AlloStim on Day 21~The activation step with IV infusion of AlloStim on Day 28~The booster step with two IV booster infusions of AlloStim on Days 56 and 84~Protocol follow-up procedures continue until day 112. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
3027218|NCT02380443|Experimental|Dosing Schedule B|"The priming step with ID injections of AlloStim on Days 0, 3 and days 7 and 10~The vaccination step with cryoablation and IT (intratumoral) injection of AlloStim on Day 14~The activation step with IV infusion of AlloStim on Day 21~The booster step with two IV booster infusions of AlloStim on Days 49 and 77~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
3027219|NCT02380443|Experimental|Dosing Schedule C|"The priming step with ID injections of AlloStim on Days 0, 3 and days 7 and 10~The vaccination step with cryoablation and IT (intratumoral) injection of AlloStim on Day 14 and an additional IT injection of AlloStim on Day 17~The activation step with IV infusion of AlloStim on Day 21~The booster step with two IV booster infusions of AlloStim on Days 49 and 77~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
3027220|NCT02380443|Experimental|Dosing Schedule D|"The priming step with ID and IV injections of AlloStim on Days 0, 3 and days 7 and 10~The vaccination step with cryoablation and IT injection of AlloStim on Day 14~The activation step with IV infusion of AlloStim on Day 21~The booster step with two IV booster infusions of AlloStim on Days 49 and 77~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
3027221|NCT02380443|Experimental|Dosing Schedule E|"The priming step with ID and IV injections of AlloStim on Days 0, 3 and days 7 and 10~The vaccination step with cryoablation and IT and IV injections of AlloStim on Day 14~The activation step with IV infusion of AlloStim on Day 21~The booster step with two IV booster infusions of AlloStim on Days 49 and 77~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
3027222|NCT02380443|Experimental|Dosing Schedule F|"The priming step with ID and IV injections of AlloStim on Days 0, 3 and days 7 and 10~The vaccination step with cryoablation and IT injection of AlloStim on Day 14 and IV injection of AlloStim on Day 17~The activation step with IV infusion of AlloStim on Day 21~The booster step with two IV booster infusions of AlloStim on Days 49 and 77~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
3027223|NCT02380430||ambulatory surgery description|Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
3027224|NCT02380417||Single lung transplant paravertebral catheter placement|Those patients who underwent single lung transplant either right or left.
3027225|NCT02380417||bilateral lung transplant paravertebral catheter placement|those patients who underwent bilateral lung transplantation
3027226|NCT02380404||Edentulous maxilla|Ibuprofen (600 mg - Film-coated Tablets) 3x/day before the surgery. Duration : 5 days Amoxicilline Teva (500 mg - dispersible tablets) 3x/day before the surgery. Duration : 16 days
3027228|NCT02380391||People without HIV (HIV-)|Adults experiencing first episode of ACS treated with percutaneous coronary intervention, matched to HIV+ on age, sex, known diabetes mellitus, and anti-platelet therapy.
3027229|NCT02380378||Myeloproliferative Neoplasms|Patients diagnosed with Myeloproliferative Neoplasms based on WHO 2008 criteria.
3027230|NCT02380365||Outpatients on the Waiting List and after Lung Transplantation|Electrocardiography
3027231|NCT02380352|Experimental|Short-course|5 days amoxicillin 90 mg/kg/day divided TID followed by 5 days placebo TID
3027232|NCT02380352|Active Comparator|Standard|5 days amoxicillin 90 mg/kg/day divided TID followed by alternate formulation 5 days amoxicillin 90 mg/kg/day divided TID
3027233|NCT02380339|Active Comparator|Psych-Educational and Bio Feedback (BF_|Participants in the control group will undergo Psych-Educational and BF sessions in which they will receive information about FOH and about ways of coping with FOH and BF training. More specifically, they will learn about factors associated with FOH, behavioral manifestations of FOH, negative consequences of these behavioral manifestations and about ways of coping with FOH. They will be instructed to practice BF for 15 minutes, at home for 5 initial training sessions during a week. After which they will receive another session of BF training and will be instructed to practice it at home for 10 sessions course, (5 weekly sessions for 2 weeks). Each session will be for 15 minutes.
3027234|NCT02380339|Experimental|Psych-Educational session and virtual reality (VR)|Participants in the intervention group will receive Psych-Educational session as the control group and in addition they will participate in training for VR system and will be asked to use it at home for 5 initial training sessions during a week. During this week, they will practice reducing their GSR levels as indicated by the BF device. Following this they will receive a combined biofeedback-virtual reality system and use it at home for a 10 sessions course, (5 weekly sessions for 2 weeks). Each session will be for 15 minutes.
3027235|NCT02380326||Lung transplant recipients|Lung transplant recipients with diffuse parenchymal abnormalities subjected to advanced endoscopic imaging modalities
3027236|NCT02380326||Diffuse intersitial lung disease|Patients suffering from diffuse intersitial lung disease without a certain diagnosis subjected to advanced endoscopic imaging modalities
3027237|NCT02380313|Experimental|Afuresertib 125 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 125mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
3027238|NCT02380313|Experimental|Afuresertib 150 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 150 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
3027239|NCT02380313|Experimental|Afuresertib 175 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 175 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
3027240|NCT02380313|Experimental|Afuresertib 200 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 200 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
3027241|NCT02380313|Experimental|Afuresertib 125 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 125mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
3027242|NCT02380313|Experimental|Afuresertib 150 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 150mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
3027243|NCT02380313|Experimental|Afuresertib 100 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 100 mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
3027244|NCT02380313|Experimental|RP2D of Afuresertib + enzalutamide 160 mg|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to plus enzalutamide 160 mg once daily.
3027245|NCT02380313|Experimental|Afuresertib RP2D + abiraterone 1000 mg + prednisone 5 mg|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to abiraterone 1000 mg once daily and continuous BID prednisone 5 mg coadministered per the labelled recommendations.
3027246|NCT02380313|Experimental|Afuresertib RP2D + abiraterone + prednisone in PK cohort|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to abiraterone 1000 mg once daily and continuous BID prednisone 5 mg coadministered per the labelled recommendations
3027247|NCT02380287|Experimental|Cohort no.1|This cohort includes just one subject who will receive the maximum safe starting dose of BCD-085 (0.05 mg/kg) subcutaneously. If the dose limitating toxicity occurs within the first seven days after injection the study will be stopped. If there is no DLT within mentioned above period then Cohort no.2 is included.
3027248|NCT02380287|Experimental|Cohort no.2|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.05 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 3 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 3."
3027316|NCT02379858|Experimental|Alvimopan (Entereg)|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
3027343|NCT02379663|Active Comparator|Oral direct Factor Xa inhibitor|Rivaroxaban
3058473|NCT02171793|Experimental|BI 1744 CL|
3027249|NCT02380287|Experimental|Cohort no.3|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 4 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 4."
3027250|NCT02380287|Experimental|Cohort no.4|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.825 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 5 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 5."
3027251|NCT02380287|Experimental|Cohort no.5|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 1.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 6 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 6."
3027252|NCT02380287|Experimental|Cohort no.6|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 1.75 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 7 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 7."
3027253|NCT02380287|Experimental|Cohort no.7|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 2.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 8 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 8."
3027254|NCT02380287|Experimental|Cohort no.8|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 3.0 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level."
3027255|NCT02380274||Patients with CRPC|Patients with CRPC
3027256|NCT02380261|Experimental|Systane|Systane® Lid Wipes, 1 per eyelid, used once and discarded after each use, for 21 days
3027257|NCT02380248|Experimental|Systane|Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops, 1 drop QID in each eye for 90 days
3027258|NCT02380235|Experimental|PEG-somatropin|0.12mg/kg/w
3027259|NCT02380235|Experimental|PEG-Somatropin|0.20mg/kg/w
3027260|NCT02380222||ASM|
3027261|NCT02380222||SM-AHNMD|
3027262|NCT02380222||MCL|
3027263|NCT02380222||SSM|
3027264|NCT02380222||ISM|
3027265|NCT02380209|Experimental|Optimization|CEST MRI of the breast for estimation of tumor pH.
3027266|NCT02380183|Experimental|Intervention|Civco needle guidance device will be used while the nerve block is performed.
3027267|NCT02380183|No Intervention|Standard of Care|Needle guidance device will not be used while nerve block is performed; nerve block is performed by hand alone.
3027268|NCT02380170||Urosepsis|Sepsis derived from the urinary tract infection
3027269|NCT02380157|Experimental|Kaleorid|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
3027270|NCT02380157|Placebo Comparator|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
3027271|NCT02380144|Experimental|Orange Fruit - Orange Juice|"Sequence of test foods during the intervention period:~1st: Orange fruit; 2nd: Orange juice"
3027272|NCT02380144|Experimental|Orange Juice - Orange Fruit|"Sequence of test foods during the intervention period:~1st: Orange juice; 2nd: Orange fruit"
3027273|NCT02380131|Experimental|Herceptin|"drug: Oxaliplatin;Capecitabine;Herceptin A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.~To explore the effect of herceptin with chemotherapy for potentially resectable HER-2 positive gastric cancer with liver metastasis"
3027274|NCT02380118|Experimental|Olanzapine|intramuscular olanzapine injection (zyprexa), 5 mg/dose, first dose and an optional second dose.
3027275|NCT02380118|Active Comparator|Haloperidol|intramuscular haloperidol injection, 5 mg/dose, first dose and an optional second dose.
3027276|NCT02380118|Active Comparator|Midazolam|intramuscular midazolam injection, 5 mg/dose, first dose and an optional second dose.
3027317|NCT02379858|Placebo Comparator|Suger Pill (Control)|Placebo, 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
3027318|NCT02379845|Experimental|Arm A|NBTXR3 + Radiotherapy
3027319|NCT02379845|Active Comparator|Arm B|Radiotherapy alone
3027320|NCT02379832||Cases|Nulliparous women recruited at diagnosis of preeclampsia No intervention, only observation of biochemical and ultrasonographic markers at recruitment and at delivery N= 45
3027277|NCT02380105|Experimental|Counseling Group|Patients allocated to the counseling group (Group I) were informed about possible etiological factors and educated to not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions, as a way of reinforcing the information provided during the initial consultation. In subsequent returns at 7, 15, 30 and 60 days of follow-up, the instructions were given again and patients were asked whether they had detected any habits related to the initiation and maintenance of painful symptoms of TMD, as a way to further highlight the association between the presence of these harmful behaviors and the worsening signs and symptoms of TMD.
3027278|NCT02380105|Active Comparator|Splint Group|Patients allocated to the splint group (Group II) were treated using interocclusal appliances, according to the following protocol: At baseline, an anterior bite plate (front-plateau) was made from acrylic resin that was placed in the maxillary arch to include the the canine to canine region and promote the disocclusion of the posterior teeth. Patients were instructed to use the device for 24 hours, interspersed with rests of equal length during the first week. After 7 days, the device was removed. A hard splint was then made. At 30 days of follow-up, the splint was fitted and the patients were also asked to use it when they were sleeping.
3027279|NCT02380079|Experimental|SCD-101|SCD-101 dosed TID for 28-days
3027280|NCT02380079|Placebo Comparator|Placebo|Placebo dosed TID for 28-days
3027281|NCT02380066|Experimental|Anyu Peibo 0.4g per day|Anyu Peibo Capsule, oral, 0.2g twice per day
3027282|NCT02380066|Experimental|Anyu Peibo 0.8g per day|Anyu Peibo Capsule, oral, 0.4g twice per day
3027283|NCT02380066|Experimental|Anyu Peibo 1.2g per day|Anyu Peibo Capsule, oral, 0.6g twice per day
3027284|NCT02380066|Experimental|Anyu Peibo 1.6g per day|Anyu Peibo Capsule, oral, 0.8g twice per day
3027285|NCT02380066|Placebo Comparator|Placebo|Placebo,oral, twice per day
3027286|NCT02380053|Experimental|Bisoprolol|2.5mg once daily for 2 weeks then 5mg once daily for 2 weeks.
3027287|NCT02380053|Experimental|Celiprolol|200mg once daily for 2 weeks then 400mg once daily for 2 weeks.
3027288|NCT02380040||Term|Normal Term Newborn Intervention: PPG
3027289|NCT02380040||Preterm|Preterm babies admitted to the NICU not suffering from the conditions to be studied Intervention: PPG
3027290|NCT02380040||PDA|Patent Ductus Arteriosus Intervention: PPG
3027291|NCT02380040||PPHN|Persistent Pulmonary Hypertension Intervention: PPG
3027292|NCT02380027|Experimental|MRI-arm|Men in this arm will undergo multi-parametric MRI. In the presence of a suspicious area, a man will undergo MRI-targeted biopsy with cores targeted to the suspicious lesion. In the absence of a suspicious area, no biopsy will be taken.
3027293|NCT02380027|Active Comparator|TRUS-biopsy arm|Men in this arm undergo standard 12-core trans-rectal ultrasound guided prostate biopsy
3027294|NCT02380001|Experimental|Dexketoprofen trometamol|A White round pill with 25 mg of dexketoprofen will be administered 30 minutes before the impacted third molar surgery start. Immediately after the surgery, a hard-gelatin capsule with placebo will be administered.
3027295|NCT02380001|Placebo Comparator|Preoperative control|A hard-gelatin capsule with placebo will be administered 30 minutes before the impacted third molar surgery start. Immediately after the surgery, a hard-gelatin capsule with 25mg of Dexketoprofen will be administered.
3027296|NCT02379988|Experimental|Verify radiation dose to heart and lung|Subjects will undergo the standard of care CT simulation, which includes an additional breath hold CT. Inspiratory gated breath-hold will be used. Two radiation plans will be generated: one for the CT scan performed free breathing, and one for the CT scan performed with inspiratory gated breath hold. The cardiac and lung doses will be determined. At the discretion of the treating physician, the plan with the lower cardiac and lung dose may be used to treat the patient.
3027297|NCT02379975|Experimental|rheumatoid arthristis|individuals with rheumatoid arthritis
3027298|NCT02379975|Active Comparator|health|healthy individuals
3027299|NCT02379949|Experimental|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
3027300|NCT02379949|Active Comparator|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
3027301|NCT02379949|No Intervention|Waitlist|Participants assigned to wait list were re-randomized to virtual reality exposure therapy or exposure group therapy following the waiting period.
3027302|NCT02379936|Active Comparator|The NeoHilda Point of care method|Evaluating baby including lactate dehydrogenase Levels measured in umbilical core blood using the fast point of care method called Neo Hilda
3027303|NCT02379936|Sham Comparator|No Measurement of LDH|Evaluating baby without Lactate dehydrogenase result
3027304|NCT02379923|Experimental|Crossing of Coronary Artery CTO|This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events
3027305|NCT02379910|Experimental|SAD 1|AM1030-CREAM
3027306|NCT02379910|Experimental|SAD 2|AM1030-CREAM
3027307|NCT02379910|Experimental|SAD 3|AM1030-CREAM
3027308|NCT02379910|Experimental|MAD 1|AM1030-CREAM
3027309|NCT02379910|Experimental|MAD 2|AM1030-CREAM
3027310|NCT02379897|Experimental|LowGI+ModCarb|Low glycemic index + moderate carbohydrate/moderate fat diet
3027311|NCT02379897|Experimental|LowGI+HighCarb|Low glycemic index + high carbohydrate/low fat diet
3027312|NCT02379897|Experimental|HighGI+ModCarb|High glycemic index + moderate carbohydrate/moderate fat diet
3027313|NCT02379897|Experimental|HighGI+HighCarb|High glycemic index + high carbohydrate/low fat diet
3027314|NCT02379871|Experimental|Experimental Group|While lying in supine, subjects will receive a single posterior to anterior directed spinal manipulation to the mid-thoracic region (T4-5).
3027315|NCT02379871|Sham Comparator|Sham Group|Sham group will procedures will be identical with the exception of the spinal manipulation intervention. Sham shall not receive the spinal manipulation intervention.
3027321|NCT02379832||Control|Nulliparous women recruited at the beginning of pregnancy. No intervention, only observation of biochemical and ultrasonographic markers at recruitment (1st trimester), 3 other times during pregnancy (2nd and 3rd trimester) and at delivery N= 45
3027322|NCT02379819|Experimental|Nucleus Hybrid L24 Implant|Adults age 18 and over who meet FDA criteria for unilateral implantation with the Nucleus Hybrid L24 Implant.
3027323|NCT02379806|Active Comparator|Active enoxaparin 40 mg|One 0.4 ml prefilled syringe containing 40 mg enoxaparin active substance administered once daily for 10 ± 4 days
3027324|NCT02379806|Placebo Comparator|Placebo of enoxaparin 40 mg|One 0.4 ml placebo syringe of enoxaparin 40 mg administered once daily for 10 ± 4 days
3027325|NCT02379793|Experimental|LEO 80185 gel, vehicle, liquid paraffin|Each subject has all 3 treatments applied topically at the same time. However, the location on which the treatments are applied is randomised in an investigator blinded manner.
3027326|NCT02379780|Active Comparator|USG guided Subcostal TAP block|after preparing the skin, ultrasound probe was placed obliquely on the upper abdominal wall along the subcostal margin near the midline. the rectus abdominis muscles, transversus abdominis muscles and the fascial plane (TAP) between rectus abdominis and transversus abdominis muscles were identified. after identification, the block needle was introduced anteriorly in the plane of the ultrasound beam. the needle was directed the transversus abdominis plane and 10 ml of bupivacaine (Marcaine 0,25 %) and 5 ml of lidocaine (2%) was injected after negative aspiration.
3027327|NCT02379780|Active Comparator|USG guided Paravertebral Block|prior to start surgery, was performed in the left lateral position. after preparing skin, ultrasound linear probe was placed, 2-3 cm lateral of the T7 / T8 level in the midline. After determining the transverse process and ribs as hyperechoic, the paravertebral space was identified as an area wedge-shaped bounded by the pleura and above the internal intercostal membrane.after identification of the paravertebral space, the block needle was introduced in plane / out of plane and 10 ml of bupivacaine (Marcaine 0,25 %) and 5 ml of lidocaine (2%) was injected after negative aspiration.
3027328|NCT02379767||Patients|Subjects aged between 18 and 60 years suffering from unipolar severe depression, who did not respond to conventional pharmacological antidepressant treatment (at least two adequate trials with antidepressants of different pharmacological classes over a minimum period of one month, equivalent to 150mg of tricyclic antidepressants). Concomitant psychotropic medication will be accepted during study participation, however, medication should remain stable throughout the study. Patients will undergo 6 to 14 ECT sessions in accordance with recent consensus statements and based on standard operation procedures (SOPs) of the Department of Psychiatry and Psychotherapy.
3027329|NCT02379767||Healthy subjects|Subjects will be age- and sex-matched to the patients and should present no psychiatric, or major neurological or internistic illness.
3027330|NCT02379754|Experimental|Gentamicin treated|"Installation of gentamicin in the middle ear 6 weeks prior to surgery + rehabilitation exercises before and after both treatment and surgery.~Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented, and exclusion from exercises would not be approved by the ethical board."
3027331|NCT02379754|No Intervention|Non-gentamicin|Rehabilitation exercises before and after surgery. Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented, and exclusion from exercises would not be approved by the ethical board.
3027332|NCT02379741|Experimental|ADC-1013 intratumoral|ADC-1013 (agonistic human monoclonal IgG1 anti-CD40 antibody) administered by intratumoral injection every second week for 8 weeks. Patients that do not progress will be offered continued treatment until complete response, confirmed progressive disease, or clinical deterioration.
3027333|NCT02379741|Experimental|ADC-1013 intravenous|ADC-1013 (agonistic human monoclonal IgG1 anti-CD40 antibody) administered by intravenous infusion every second week until complete response, confirmed progressive disease, or clinical deterioration.
3027334|NCT02379728|Experimental|PrenaBelt|"Participants will be instructed to use the PrenaBelt nightly for the remainder of their pregnancy in addition to receiving the local standard of care.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
3027335|NCT02379728|Experimental|PrenaBelt with Body Position Sensor (BPS)|"Participants will be instructed to use the PrenaBelt (with integrated BPS) nightly for the remainder of their pregnancy in addition to receiving the local standard of care. The BPS will be securely integrated into a small pocket on the PrenaBelt. The BPS is not expected to affect body position or sleep.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
3027336|NCT02379728|Sham Comparator|Control|"Participants will be instructed to use the sham-PrenaBelt nightly for the remainder of their pregnancy in addition to receiving the local standard of care.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
3027337|NCT02379728|Sham Comparator|Control with Body Position Sensor (BPS)|"Participants will be instructed to use the sham-PrenaBelt (with integrated BPS) nightly for the remainder of their pregnancy in addition to receiving the local standard of care. The BPS will be securely integrated into a small pocket on the sham-PrenaBelt. The BPS is not expected to affect body position or sleep.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
3027338|NCT02379715|Experimental|Remifentanil|When the particapants arrived into the operating room, the investigators applied standard monitoring and after preoxygenation, 2 mg remifentanil was diluted into 50 ml of normal saline (40 μg/ml solution) and was infused by Target concentration infusion (TCI) via syringe pump (Pilot Anesthesia 2. Fresenius vial, France) using the pharmacokinetic model. Investigator started to infuse remifentanil at 4 ng/ml and after the Ce of remifentanil reached the target concentration level, opened the dial of desflurane vaporizer at 4 vol%. After 30 seconds, increase the concentration of desflurane 8% and 12% at last. If there is no spontaneous respiration or loss of consciousness, the muscle relaxant esmerone 0.6mg/kg is injected and after 90 seconds the tracheal intubation is performed.
3027339|NCT02379689|Active Comparator|injectable placental tissue extract called BioDGenesis|This study will compare injectable placental tissue extract called BioDGenesis (Active Product)
3027340|NCT02379689|Placebo Comparator|Placebo|injectable Tissue Suspension Solution (TSS) (Placebo). The Active Product is supplied by BioD, LLC (BioD).
3027341|NCT02379676|Experimental|Ticagrelor|Ticagrelor 90mg twice daily
3027342|NCT02379676|Active Comparator|Clopidogrel|Clopidogrel 75mg once daily
3027344|NCT02379663|Active Comparator|Low molecular weight heparin|Enoxaparin
3027345|NCT02379663|Placebo Comparator|Normal Saline|Normal Saline
3027346|NCT02379650|Experimental|Hydroxychloroquine (HCQ)|Subjects in the experimental arm will take 400 mg hydroxychloroquine pills every day, starting before they get pregnant and continuing until 36 weeks of pregnancy or until the pregnancy is over.
3027347|NCT02379650|Placebo Comparator|Placebo|Subjects in the experimental arm will take placebo pills every day, starting before they get pregnant and continuing until 36 weeks of pregnancy or until the pregnancy is over.
3027348|NCT02379637|Experimental|A N-acetylcysteine|N-acetylcysteine
3027349|NCT02379637|Placebo Comparator|B Placebo|Placebo
3027350|NCT02379624|Placebo Comparator|EN group|5% glucose at a rate of 25 mL/h was given at day 1, followed with initial amount of EN (31.25g peptisorb dissolved in 250ml water) at 12.5 mL/h on day 2. From day 3 to day 6, the prescription is EN (62.5g peptisorb dissolved in 250ml water) at 12.5 mL/h. Since day 7, EN was began to advance to goal energy target as quickly as possibl
3027351|NCT02379624|Experimental|PEC/EN group|An additional amount of pectin was added 4 hours ahead of EN given from day 2 to day 6 (24g everday). Since day 7, EN was advanced to goal energy target as the same step
3027352|NCT02379611|Active Comparator|normally hearing children|
3027353|NCT02379611|Experimental|Congenital profound deaf children|
3027354|NCT02379598||Amino acid based formula|
3027355|NCT02379598||Whey protein formula|
3027356|NCT02379585|Active Comparator|HER2 negative breast cancer|Doxorubicin and cyclophosphamide every two weeks for four cycles (one cycle is defined as 14 days). After completing fourth cycle, paclitaxel every two weeks for an additional four cycles. The appropriate surgery will be done three to six weeks after completing the last cycle of paclitaxel.
3027357|NCT02379585|Active Comparator|HER2 positive breast cancer|Docetaxel, trastuzumab, and pertuzumab every three weeks for four cycles. Pegfilgrastim after docetaxel. Surgery three to six weeks after completing the last docatexel. If additional chemotherapy is needed patients will receive both doxorubicin and cyclophosphamide every three weeks for four cycles and after the fourth cycle then trastuzumab for one year
3027358|NCT02379572|Experimental|iMRI-guided surgery|Resection of Glioblastomas with iMRI-guidance
3027359|NCT02379572|Active Comparator|5-ALA-guided surgery|Resection of Glioblastomas with 5-ALA-fluorescence-guidance
3027360|NCT02379559|Experimental|Exercise Group|Eligible participants randomized into the intervention group will receive a mix of supervised moderate-intensity aerobic and light weight-resistance exercises.
3027361|NCT02379559|Active Comparator|Attention Control Group|Eligible participants randomized in the attention control group will be asked to maintain their current daily activities and exercise habits for 6-months.
3027362|NCT02379546|Experimental|BIS<50|Anaesthesia will be maintained with desflurane in a 50% O2-Air mixture by titrating the concentration according to the Bispectral index monitoring to keep the Bispectral index values below 50.
3027363|NCT02379546|Active Comparator|BIS≥50|Anaesthesia will be maintained with desflurane in a 50% O2-Air mixture by titrating the concentration according to the Bispectral index monitoring to keep the Bispectral index values above 50.
3027364|NCT02379533|No Intervention|sedentary control|
3027365|NCT02379533|Experimental|Home-based aerobic exercise|The training program will be conducted in accordance with the recommendations of the American College of Sports Medicine. All training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). The program will consist of 24 weeks with three sessions per week on alternate days. The aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. The intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. The intensity control was done by means of the heart rate value obtained at ventilatory threshold. The home-based exercise group exercise at home with telephone follow-up weekly and once a month will be held at the training center under the supervision of a physical education teacher.
3027366|NCT02379533|Active Comparator|Center-based aerobic exercise|The training program will be conducted in accordance with the recommendations of the American College of Sports Medicine. All training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). The program will consist of 24 weeks with three sessions per week on alternate days. The aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. The intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. The intensity control was done by means of the heart rate value obtained at ventilatory threshold. However, a group exercise held in the center on a treadmill with the direct supervision of a physical education teacher.
3027367|NCT02379520|Experimental|Group A|HPV Specific T Cells
3027368|NCT02379520|Experimental|Group B|HPV Specific T Cells plus lymphodepletion (Cytoxan and Fludarabine) and nivolumab
3027369|NCT02379507|Experimental|DEC033 Study Product|Apply twice a day
3027370|NCT02379481|Experimental|NS 550mg|NS 550mg/day
3027371|NCT02379481|Experimental|NS 1100mg|NS 1100mg/day
3027372|NCT02379481|Placebo Comparator|placebo|placebo
3027373|NCT02379468|Experimental|Pedyphar|Ointment
3027374|NCT02379468|Active Comparator|Panthenol|Ointment
3027375|NCT02379455|Experimental|Comprehensive drug review|
3027376|NCT02379455|No Intervention|Control group|"Follow-up by family physician as usual."
3027377|NCT02379442|Experimental|1|Target dose of 2 times 106 MSC/kg for up to 12 doses
3027378|NCT02379429||1|Adults with biopsy-proven or suspected urothelial cancer who require diagnostic or therapeutic intervention
3027379|NCT02379429||2|Healthy volunteers
3027380|NCT02379416|Experimental|1|The starting dose of nilotinib will be administered at 300 mg orally BID from cycle 1 day 2 and paclitaxel will be administered IV at 60 mg/m2 at dose level 1 on Days 1, 8, and 15 in 28-day cycles. For cycle 2 on, nilotinib will be administered from day 1. Dose escalation will follow a 3+3 design, with dose limiting toxicities defined during cycle 1.
3027381|NCT02379390|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m^2 intravenously in 1 hour every three weeks + prednisone 10 mg orally given daily. Treatment will continue until confirmed disease progression or unacceptable toxicity
3027382|NCT02379390|Active Comparator|Abiraterone acetate or Enzalutamide|Abiraterone acetate 1000 mg orally, once daily + prednisone 5 mg orally given twice daily OR Enzalutamide 160 mg orally, once daily. Treatment will continue until confirmed disease progression or unacceptable toxicity
3027383|NCT02379377|Experimental|Diagnostic (18F-FSPG PET, 11C-acetate PET)|Patients undergo 18F-FSPG PET and carbon-11 (11C)-acetate PET scans within 4-8 weeks of surgery or OLT. Patients may also receive a second 18F-FSPG PET scan following standard-of-care treatment.
3027384|NCT02379364|Experimental|Intervention group|Diacutaneous Fibrolysis treatment
3027385|NCT02379351|Experimental|In-Home Non-Stress Test Device|Patients with physician-ordered twice-weekly NSTs scheduled in the OB Diagnostic Center at University of Utah Hospital will be eligible for enrollment. After being taught how to use the Airstrip® Sense4Baby™ system machine, participants will use the device on a weekly basis (at home) until the time of delivery. Participants will also receive an in clinic NST once a week.
3027386|NCT02379338|Experimental|Dynamic Brain Cohort|The Dynamic Brain cohort will include up to 10 patients who will undergo a dynamic brain [18F]Fluortriopride PET/CT scan over a period of approximately 2 hours. Subjects in this cohort will also undergo a research brain MRI, generally on a separate day from the PET/CT.
3027387|NCT02379338|Experimental|Biodistribution Cohort|The Biodistribution cohort will include up to10 patients who will undergo a series of whole body biodistribution [18F]Fluortriopride PET/CT scans over a period of approximately 4 hours.
3027388|NCT02379325|Experimental|Lets Quit|Given text message
3027389|NCT02379325|Active Comparator|Pamplets education|Given pamplets on smoking and complication
3027390|NCT02379312|Active Comparator|Very low energy aerated beverage|Very low energy aerated beverage
3027391|NCT02379312|Active Comparator|Normal energy aerated beverage 1|Normal energy aerated beverage 1
3027392|NCT02379312|Active Comparator|Normal energy aerated beverage 2|Normal energy aerated beverage 2
3027393|NCT02379312|Active Comparator|Normal energy aerated beverage 3|Normal energy aerated beverage 3
3027394|NCT02379299|Active Comparator|Single-hormone closed-loop control|Closed-loop glucose control by use of insulin only by use of DiaCon single-hormone closed-loop glucose control algorithm
3027395|NCT02379299|Experimental|Dual-hormone closed-loop control|Closed-loop glucose control by use of insulin and glucagon by use of DiaCon dual-hormone closed-loop glucose control algorithm
3027396|NCT02379286||14 to 17 years old French teenager|14 to 17 years old French teenager representative of French population from whom parental consent to particpare to the study has been given
3027397|NCT02379273|Experimental|Hybrid L24 pivotal study subjects|Subjects implanted with the Nucleus Hybrid L24 Implant as part of the pivotal IDE study and who still have the device implanted will continue to be followed for 5 years post activation
3027398|NCT02379260|Other|Interview|Patients and urologists will be interview by a sociologist.
3027399|NCT02379260|Other|Focus Groups|Focus groups contain 5-7 patients. Groups will be stratified according to socio-economic levels and according to treatment (radical prostatectomy with conservation or without preservation of the neuro vascular strips).
3027400|NCT02379247|Experimental|Co-hort 1 BYL719 (250mg)+Nab-paclitaxel|"BYL719: 250mg daily on day 1-28~Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
3027401|NCT02379247|Experimental|Co-hort 2 BYL719 (300mg)+Nab-paclitaxel|"BYL719: 300mg by mouth daily on day 1-28 of each 28 day cycle~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
3027402|NCT02379247|Experimental|Co-hort 3 BYL719 (350mg)+Nab-paclitaxel|"BYL719: 350mg by mouth daily on day 1-28 of each 28 day cycle~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
3027403|NCT02379247|Experimental|BYL719 Dose Expansion|"BYL719: MTD from Phase I by mouth daily on day 1-28 of each 28 day cycle~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
3027404|NCT02379234|No Intervention|Control|"All nurses received a 4 hours formation, called conventional formation, given by a professional trainer, that included 2 hours of theorical formation and 2 hours of practical training, based on CVVH generator demonstration. In addition, the trainer was present in the ICU during the first week of CVVH implementation, to answer any questions and to help nurses with their first CVVH sessions"
3027405|NCT02379234|Experimental|Simulated|The 'Simulated formation',used high fidelity mannequin and CVVH generator, is composed of 3 training sessions of 2 hours each one. This formation is associated with the 'conventional formation'.
3027406|NCT02379221|Experimental|Injectable local anesthesia|Right side of face is injected with local anesthesia, left side is treated with topical anesthesia.
3027407|NCT02379221|Active Comparator|Topical Anesthesia|Left side of face is injected with local anesthesia, right side is treated with topical anesthesia.
3027408|NCT02379195|Experimental|A|"All patients receive the same treatment.~All patients are hospitalized during treatment (approximately 3 weeks) and receive treatment only once.~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine) on day -7 to day -1.~The TILs are infused on day 0 and Interleukin-2 therapy are administered on day 0 to day 5.~Interleukin-2 are administered in an i.v. continuous decrescendo regimen starting approximately 6 hours after TIL infusion with a duration of approximately 5 days~Subcutaneous injections of peginterferon alpha 2b are administered three time (day -2, day 7 and day 14)"
3027409|NCT02379182|Active Comparator|Control group|Will not receive any treatment procedure. Patients allocated in the control group will be treated according to the standard clinical care of patients with dysphagia at our center, that includes: adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary.
3027428|NCT02379065|Active Comparator|Control nebuliser treatment|"Both groups will receive the same bronchodilator pharmacotherapy, in keeping with National Institute of Clinical Excellence guidelines. For this arm, nebuliser will be standard of care.~Interventions:~Score on the Modified Borg Scale (an interval scale which runs from 0-10, with statements describing level of breathlessness as perceived by the patient) to be completed by both the patient and clinician~Heart rate (as a measure of severity of exacerbation and an indirect measure of salbutamol dosage)~Arterial blood gas changes - pH, pO2, pCO2"
3027571|NCT02378220|No Intervention|"Controls (not tested)"|Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
3027410|NCT02379182|Experimental|Sensory Group|Patients allocated in the sensory group will be treated with transcutaneous electrical stimulation at sensory level. In addition, they will receive the standard clinical care described in the control group. The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
3027411|NCT02379182|Experimental|Motor Group|Patients allocated in the motor group will be treated with transcutaneous electrical stimulation at motor level. In addition, they will receive the standard clinical care of patients with dysphagia described in the control group. The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
3027412|NCT02379169|Experimental|Sea buckthorn & lutein|Sea buckthorn oil complemented with lutein. Dose: 2 g/day as capsules taken twice/day for 6 months
3027413|NCT02379169|Placebo Comparator|Placebo|Triglycerides of medium-chain fatty acids. Dose: 2 g/day as capsules taken twice/day for 6 months
3027414|NCT02379156|Experimental|Cool Temperature Exposure / No Drug|Subjects are persons with tetraplegia: spinal cord lesion level C3 to T1, AIS levels A and B, ages 18-65 years or subjects are able-bodied controls matched for age and gender. Procedure is exposure to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 1).
3027415|NCT02379156|Experimental|Cool Temperature Exposure with Drug|Subjects are persons with tetraplegia who completed Visit 1 (no drug). Subjects are administered a 10 mg tablet of midodrine hydrochloride by a physician before being exposed to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 2).
3027416|NCT02379130|Experimental|Family Nurture Intervention Group|Children in the FNI group will continue to attend any intervention programs that they are already enrolled in. In addition, they will be asked to attend 1 clinic visit per week for 6 weeks over the course of 12 weeks. During each visit, the mother-child will meet with trained Nurture Specialists. The Nurture Specialists will facilitate and encourage the mother and child to engage in nurturing and calming activities, including sustained touch, vocal soothing, and an odor cloth exchange. FNI families will be asked to participate in a 6 month post-enrollment follow-up visit and a 12 month post-enrollment follow-up visit.
3027417|NCT02379130|Active Comparator|Play and Nutrition Intervention Group|Children in the PNI group will continue to attend any intervention programs that they are already enrolled in. They will be asked to attend 1 clinic visit per week for 6 weeks over the course of 12 weeks to meet with clinical personnel who will collect measures regarding the child's behavior and development. At each visit, study staff will meet with mothers to facilitate a lesson plan on appropriate play and nutrition. NPI families will be asked to participate in a 6 month post-enrollment follow-up visit and a 12 month post-enrollment follow-up visit.
3027418|NCT02379117||Crohn's Disease Patients|Patients with a diagnosis of Crohn's disease fitting the studies inclusion & exclusion criteria.
3027419|NCT02379117||Healthy Volunteers|For healthy volunteers the studies exclusion criteria apply.
3027420|NCT02379104||Healthy Volunteers|Healthy volunteers fulfilling inclusion/exclusion criteria for reference interval sample group are tested with ROTEM sigma
3027421|NCT02379104||Patients with expected coagulopathy|Patients with expected bleeding and coagulation problems during elective surgery or at the ICU, or trauma patients are tested with ROTEM sigma and ROTEM delta comparatively
3027422|NCT02379091|Experimental|Namilumab 20 mg/mL|Namilumab 20 mg/mL, subcutaneous (SC) injection, once on Days 1, 15, 43, 71 and every 4 weeks up to Week 24 and a stable dose of methotrexate tablets (15-25 mg weekly), and folic acid (at least 5 mg/week), orally, throughout the duration of the study.
3027423|NCT02379091|Experimental|Namilumab 80 mg/mL|Namilumab 80 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks up to Week 24 and a stable dose of methotrexate tablets (15-25 mg weekly), and folic acid (at least 5 mg/week), orally, throughout the duration of the study.
3027424|NCT02379091|Experimental|Namilumab 150 mg/mL|Namilumab 150 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks up to Week 24 and a stable dose of methotrexate tablets (15-25 mg weekly), and folic acid (at least 5 mg/week), orally, throughout the duration of the study.
3027425|NCT02379091|Placebo Comparator|Placebo|Namilumab placebo-matching, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks up to Week 24 and a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
3027426|NCT02379078|Experimental|Shared decision-making aid|"At study start (step 1: provider-directed intervention phase): Online shared decision-making aid, 1-page provider enabler, provider training video made available to health care providers~At 6 months (step 2: provider- and patient-directed phase): Online shared decision-making aid, 1-page patient enabler, patient training video also made available to patients (in addition to health care providers)"
3027427|NCT02379078|Placebo Comparator|Generic hard-copy diabetes resources|"At study start (step 1: Provider-directed intervention phase): A hard copy of the executive summary of the CDA CPG and postcard outlining online resources made available to health care providers~At 6 months (step 2: provider- and patient-directed phase): A CDA patient education pamphlet regarding diabetes self-management also made available to patients~In addition, provider- and patient-directed guideline dissemination tools (not incorporating SDM) will also be publicly accessible from the CDA website."
3027465|NCT02378909|No Intervention|Group 4|Diabetic neuroischemia with standard of care.
3027429|NCT02379065|Experimental|Treatment nebuliser treatment|"Both groups will receive the same bronchodilator pharmacotherapy, in keeping with National Institute of Clinical Excellence guidelines4. For this arm, nebuliser will be Aerogen.~Interventions:~Score on the Modified Borg Scale (an interval scale which runs from 0-10, with statements describing level of breathlessness as perceived by the patient) to be completed by both the patient and clinician~Heart rate (as a measure of severity of exacerbation and an indirect measure of salbutamol dosage)~Arterial blood gas changes - pH, pO2, pCO2"
3027430|NCT02379052|Experimental|Dupilumab SC|Participants will receive dupilumab SC from baseline (day 1) to week 11.
3027431|NCT02379052|Experimental|Placebo|Participants will receive placebo SC from baseline (day 1) to week 11.
3027432|NCT02379026|Experimental|Exercise & Protein Drink/Diet|High-protein (1.2-1.5 g protein per kg bodyweight; a milk-based protein drink will provide 50 g protein/day) energy-restricted (500 kcal deficit) diet and a multimodal exercise program (balance, flexibility, aerobic, resistance) 3 times/week, each lasting 1 hour. 1 tablet of Vitamin D3 (25 micrograms) x three days/week. Total duration 16 weeks.
3027433|NCT02379026|Active Comparator|Exercise|A multimodal exercise program (balance, flexibility, aerobic, resistance) will take place 3 times/week, each one lasting 1 hour. Participants in this group will follow their habitual diet. 1 tablet of Vitamin D3 (25 micrograms) x three days/week. Total duration 16 weeks.
3027434|NCT02379013|Experimental|Volunteer with MRI|All volunteer will be included in the arm MRI
3027435|NCT02379000|Active Comparator|Transpupillary therapy alone|Transpupillary thermotherapy is performed as monotherapy. It is performed with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor. TTT could be repeated at intervals of 6-8 weeks with the goal of achieving a complete resolution of fluid
3027436|NCT02379000|Active Comparator|TTT+Triamcinolone Acetonide|transpupillary thermotherapy followed by an intravitreal injection of triamcinolone. It is performed with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor. After an intravitreal injection of triamcinolone was perfomed under sterile conditions. TTT and triamcinolone injection could be repeated at intervals of 6-8 weeks with the goal of achieving a complete resolution of fluid.
3027437|NCT02378987||Typical developmental children|Normal children
3027438|NCT02378987||CP children with GMFCS level I and II|Children with CP were classified into Levels I-II based on the Gross Motor Function Classification System (GMFCS).
3027439|NCT02378987||CP children with GMFCS level III and IV|Children with CP were classified into Levels III-IV based on the Gross Motor Function Classification System (GMFCS).
3027440|NCT02378974|Other|Cohort 1|Cordstem-ST 2.0 x 10^8 cells or Placebo on day 0
3027441|NCT02378974|Other|Cohort 2|Cordstem-ST 2.0 x 10^8 cells or Placebo on day 0 and day 7
3027442|NCT02378961|Experimental|VOX+SOF/VEL 6 wk, TN, without cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
3027443|NCT02378961|Experimental|GS-9857+SOF/VEL 6 wk, TN, with cirrhosis|GS-9857 + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
3027444|NCT02378961|Experimental|VOX+SOF/VEL 8 wk, TN, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
3027445|NCT02378961|Experimental|VOX+SOF/VEL 8 wk,TE, without cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment experienced (TE), without cirrhosis)
3027446|NCT02378961|Experimental|VOX+SOF/VEL 12 wk, TE, without cirrhosis|VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
3027447|NCT02378961|Experimental|GS-9857+SOF/VEL 8 wk, TE, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment experienced, with cirrhosis)
3027448|NCT02378961|Experimental|VOX+SOF/VEL 12 wk, TE, with cirrhosis|VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
3027449|NCT02378948|Experimental|Early oral feeding|Liquid oral feeding directly after esophagectomy.
3027450|NCT02378948|No Intervention|Delayed oral feeding|Liquid oral feeding 5 days after esophagectomy
3027451|NCT02378935|Experimental|VOX+SOF/VEL 6 wk, TN, without cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
3027452|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, TN, without cirrhosis|VOX + SOF/VEL for 8 weeks (treatment naive, without cirrhosis)
3027453|NCT02378935|Experimental|VOX+SOF/VEL 6 wk, TN, with cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
3027454|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, TN, with cirrhosis|VOX + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
3027455|NCT02378935|Experimental|VOX+SOF/VEL+RBV 8 wk, TN, with cirrhosis|VOX + SOF/VEL+RBV for 8 weeks (treatment naive, with cirrhosis)
3027456|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, DAA-E, without cirrhosis|VOX + SOF/VEL for 8 weeks (direct-acting antiviral experienced (DAA-E), without cirrhosis)
3027457|NCT02378935|Experimental|VOX+SOF/VEL 12 wk, DAA-E, without cirrhosis|VOX + SOF/VEL for 12 weeks (direct-acting antiviral experienced, without cirrhosis)
3027458|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, DAA-E, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (direct-acting antiviral experienced, with cirrhosis)
3027459|NCT02378935|Experimental|VOX+SOF/VEL 12 wk, DAA-E, with cirrhosis|GS-9857 + SOF/VEL for 12 weeks (direct-acting antiviral experienced, with cirrhosis)
3027460|NCT02378935|Experimental|VOX+SOF/VEL 12 wk (GS-US-338-1121)|VOX + SOF/VEL for 12 weeks (participants who were previously enrolled in GS-US-338-1121 phase 1b study)
3027461|NCT02378922|Experimental|Treatment (gene-modified stem cells)|"CONDITIONING: Patients undergo high-dose chemotherapy or chemoradiotherapy according to institutional guidelines.~STEM CELL INFUSION: Patients undergo hematopoietic stem cell transplant on day 0.~Note: Patients continue to receive HAART throughout treatment, with a 7-day break for apheresis. Patients may be eligible for a structured treatment interruption of up to 12 weeks after autologous hematopoietic stem cell transplant with gene-modified cells."
3027462|NCT02378909|Active Comparator|Group 1|Diabetic Neuropathy with electrical stimulation device and standard of care.
3027463|NCT02378909|No Intervention|Group 2|Diabetic neuropathy with standard of care.
3027464|NCT02378909|Active Comparator|Group 3|Diabetic neuroischemia with electrical stimulation device and standard of care.
3027466|NCT02378896|Experimental|CBT + Personalized Computer Program|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy and training with a personalized computerized inhibitory training program
3027467|NCT02378883|Other|AVM treatment|Apollo™ Onyx™ Delivery Micro Catheter
3027468|NCT02378870|Experimental|A:Osteodex|3.0 mg/kg bodyweight solution for infusion
3027469|NCT02378870|Placebo Comparator|B: Placebo|NaCl 0.9% solution for infusion
3027470|NCT02378857||Patient group|Adolescents (15-18 years of age) With univentricular heart defects and Fontan type palliation.
3027471|NCT02378857||Control group|Age- and gender-matched healthy individuals
3027472|NCT02378844|Active Comparator|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
3027473|NCT02378844|Sham Comparator|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
3027474|NCT02378831||PSG and WatchPAT200 in subjects age12-17|Adolescents refered to a sleep lab for sleep lab for full night PSG
3027475|NCT02378818|Other|Schizophrenia patients|35 patients, Age between 18 and 65 years, with a diagnosis of schizophrenia and unchanged psychotropic treatment for at least three months before inclusion.
3027476|NCT02378818|Other|Healthy volunteers (schizophrenia)|35 healthy volunteers
3027477|NCT02378818|Other|Depressive patients|
3027478|NCT02378818|Other|Healthy volunteers (depression)|
3027479|NCT02378805||no-T: untreated patients|untreated patients, typically uncles or grandfathers of present patients. No Intervention (means no therapy until CKD stage V, on renal replacement therapy)
3027480|NCT02378805||T-III: late therapy in patients|patients treated with RAAS-Blockade after onset of renal failure (GFR below 60 ml/min) (starts at patients with CKD stages III and IV).
3027481|NCT02378805||T-II: early therapy in patients|therapy starts at patients with proteinuria >0.3 g/day or per gCreatinine
3027482|NCT02378805||T-I: very early tharpy in patients|starts at patients with microhematuria only (usually at birth) or microalbuminuria (30-300 mg protein per day or per gCreatinine in children).
3027483|NCT02378805||no therapy in heterozygous carriers|heterozygous carriers without therapy
3027484|NCT02378805||therapy in heterozygous carriers|heterozygous carriers with RAAS-blockade
3027485|NCT02378792|Experimental|Vagus Verve Stimulation is on|
3027486|NCT02378792|Sham Comparator|Placebo Vagus Verve Stimulation is off|
3027487|NCT02378779|Other|Interventional GP|"The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.~He must so answer to the questionary PEDT. Then the interventional GP group must use one of the six strategies to approach the subject of premature ejaculation.~There three strategies of attitude (Total attention, Humour, Take the drama out) and three investigative strategies (Question about premature ejaculation, Symptoms of premature ejaculation, Help to verbalize)."
3027488|NCT02378779|Other|Usual care|"The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.~He must so answer to the questionary PEDT. This classical GP group make a classical consultation like each day without use any strategies to speak about"
3027489|NCT02378766|Experimental|Website A|Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé.
3027490|NCT02378766|Other|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites.
3027491|NCT02378753|Experimental|rVSVΔG-ZEBOV (immediate vaccination)|One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10^7 plaque forming units)
3027492|NCT02378753|Experimental|rVSVΔG-ZEBOV (deferred vaccination)|One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10^7 plaque forming units) in participants randomized to receive deferred vaccination (18-24 weeks after enrollment).
3027493|NCT02378740|Placebo Comparator|Placebo|Placebo (.9 sterile normal saline) administered IV
3027494|NCT02378740|Active Comparator|Ketamine|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
3027495|NCT02378727|Active Comparator|A Standard Care Group (SCG)|Standard Care Conventional Group (SCG): 158 subjects to receive lumbar epidural procedure with the loss of resistance syringe used to identify the epidural space
3027496|NCT02378727|Experimental|Experimental Procedure Group (EPG).|158 of subjects to receive lumbar epidural procedure with the CompuFlo® Epidural System used to identify the epidural space
3027497|NCT02378714|Placebo Comparator|Standard treatment + placebo varenicline|Standard behavioral smoking cessation treatment plus placebo varenicline
3027498|NCT02378714|Experimental|BASC + placebo varenicline|Behavioral activation for smoking cessation plus placebo varenicline
3027499|NCT02378714|Active Comparator|Standard treatment + active varenicline|Standard behavioral smoking cessation treatment plus active varenicline
3027500|NCT02378714|Experimental|BASC + active varenicline|Behavioral activation for smoking cessation plus active varenicline
3027501|NCT02378701||Quality of Life in Myelodysplasia Scale (QUALMS-1)|Participants complete the Quality of Life in Myelodysplasia Scale (QUALMS-1) and the Anemia Subset of FACT (FACT-An), instrument twice: at the start of treatment, and after four cycles or discontinuation of treatment, whichever comes first.
3027502|NCT02378688|Experimental|MT-1303|
3027503|NCT02378688|Placebo Comparator|Placebo|
3027504|NCT02378675||Healthy (1)|Adipocytokine levels of patients suffering from GDM are compared to healthy pregnant women
3027505|NCT02378675||GDM (2)|Adipocytokine levels of patients suffering from GDM are compared to healthy pregnant women
3027506|NCT02378662|Experimental|Group A|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
3027507|NCT02378662|Experimental|Group B|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
3027566|NCT02378259|Active Comparator|Intense conservative treatment|Intense conservative treatment. 8 week LCD followed by outpatient visits 1/ month
3027508|NCT02378649|Experimental|Sildenafil|"PDEI or placebo will be administered in the surgical ICU 4-6 hours after arriving from the Operative Room. The initial Dose will be 20mg X 3 NG and can be increase to 40mg X 3, it will be administered PO if the patient extubated.~PDEI or placebo will continue up to 8 days or discharge."
3027509|NCT02378649|Placebo Comparator|Placebo|"PDEI or placebo will be administered in the surgical ICU 4-6 hours after arriving from the Operative Room. The initial Dose will be 20mg X 3 NG and can be increase to 40mg X 3, it will be administered PO if the patient extubated.~PDEI or placebo will continue up to 8 days or discharge."
3027510|NCT02378636|Experimental|600S|Modified 600C (axis marks) monofocal aspheric intraocular lens
3027511|NCT02378623|Active Comparator|Apixaban|Intervention group: Apixaban 5 mg by mouth two times daily in addition to usual medical therapy (or 2.5 mg two times daily for subjects who fulfilled any 2 of the following criteria: age≥80 years, body weight≤60kg, and/or serum creatinine≥1.5 mg/dL). Planned treatment duration is 2 years
3027512|NCT02378623|Placebo Comparator|Placebo|Control group: Matched placebo by mouth two times daily in addition to usual medical therapy. Planned treatment duration is 2 years.
3027513|NCT02378610||Observation in High-stressed|Saliva and fecal samples will be collected from High-stressed persons
3027514|NCT02378610||Observation in Low-stressed|Saliva and fecal samples will be collected from Low-stressed persons
3027515|NCT02378597|Active Comparator|Delayed Intervention: Control|Delayed intervention: Control was a a behavioral treatment for resiliency delivered in a single 4 hour session delivered in a delayed fashion (waitlist control)
3027516|NCT02378597|Experimental|Experimental: Intervention|Experimental: Intervention was a 4 hour behavioral resiliency intervention.
3027517|NCT02378584|Other|natural cycle|Ultrasound controls and endocrine blood test to asses the day of ovulation for embryo transfer
3027518|NCT02378584|Active Comparator|hormonal cycle|Ultrasound controls and endocrine blood test to asses the endometrium thickness for embryo transfer
3027519|NCT02378571|No Intervention|Usual care|Participants assigned to usual care will also be provided with a GlowCap prior to discharge and will be instructed to take their loop diuretic from this bottle and to notify the study team about prescribed dose changes. This information, however, will solely be used to measure medication adherence and will not be provided to a member of the study team nor to any of the participants' health care providers until the completion of the study period, at least 1 month later. Participants will not be provided with any advice on heart failure adherence.
3027520|NCT02378571|Experimental|Medication adherence telemonitoring|At discharge, participants in the intervention group will be instructed to take their loop diuretic exclusively from the GlowCap in the manner prescribed by their physician. A study team member will review the adherence data on a daily basis (except holidays and weekends) during the first 7 days after discharge, and then on, at minimum, a weekly basis. The study team member will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care. Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
3027521|NCT02378558|Experimental|Investigational Device|All patients will undergo breast localization and excision of a lesion using the MagneMark system. The radiologist will insert the MagneMarker clip into the area of concern using the MagneJector device. The surgeon will then locate the MagneMaker clip using the MagneProbe. The clip and breast tissue of concern will then be removed.
3027522|NCT02378545|Active Comparator|Hyperoxia|Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose. The oxygen delivery device will be set to deliver oxygen at 15 litres per minute. The oxygen will be continuously delivered throughout the patients stay in the Emergency Department.
3027523|NCT02378545|Active Comparator|normoxia|Oxygen will not be administered if a patient's oxygen saturations (as measured using a pulse oximeter) are less than 94%. If a patient's oxygen saturations are less than 94%, oxygen will be 'titrated' using a 'venturi' type oxygen delivery device to achieve target saturations of 94%. Following initial dynamic titration (to identify correct oxygen delivery level) the oxygen delivery device will be re-evaluated hourly during the patient's stay in the emergency department.
3027524|NCT02378532|Experimental|Radiotherapy/Temozolomide + Chloroquine|"Eligible patients will receive radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM.~Chloroquine will be escalated in 3 dose-levels (200mg, 400mg and 600mg) up each containing a minimum of 3 and a maximum of 6 patients."
3027525|NCT02378519|Experimental|Web-prog, followed by CBT + PT|This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
3027526|NCT02378519|Active Comparator|Base, followed by Web + CBT + PT|The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
3027527|NCT02378506|Experimental|ETN 50mg QW|
3027528|NCT02378493||Exposure: Concordance between tests|"The study population is composed of diabetic patients with foot wounds (at least stage >=2) that are infected by at least 1 strain of S. aureus. Patients whose antibiogrammes and Antibiofilmogrammes are concordant will fall into this group (the exposed group).~Upon inclusion, 1) all patients' wounds will be sampled, and 2) the associated bacterial strains identified via Vitek and 3) antibiograms performed; the latter are all part of routine procedure. 4) S. aureus isolates will be further analysed via an antiobiofilmogramme, which is an experimental element added by this research. At the end of the 1st regimen of antibiotics prescribed, if the treatment failed steps 1 to 4 can be repeated. 30 days after the end of the 1st regimen of antibiotics prescribed, steps 1 to 4 are systematically performed."
3027567|NCT02378246|Experimental|Iodine containing multivitamin|multivitamin tablet containing 150 ug iodine, 1 tablet daily
3027568|NCT02378246|Placebo Comparator|Placebo: non-iodine containing multivitamin|non-iodine containing multivitamin, 1 tablet daily
3027569|NCT02378233|Experimental|iodine|"iodine containing multivitamin~150 ug, 1 tablet daily"
3027570|NCT02378233|Placebo Comparator|placebo|placebo, 1 tablet Daily of a non-iodine containing multivitamin
3027529|NCT02378493||Non exposure: Not concordance between tests.|"The study population is composed of diabetic patients with foot wounds (at least stage >=2) that are infected by at least 1 strain of S. aureus. Patients who do not fall into the concordance (exposure) group, will fall into the non exposure group. The latter includes semi-concordance or discordance between antibiogrammes and Antiobiofilmogrammes.~Upon inclusion, 1) all patients' wounds will be sampled, and 2) the associated bacterial strains identified via Vitek and 3) antibiograms performed; the latter are all part of routine procedure. 4) S. aureus isolates will be further analysed via an antiobiofilmogramme, which is an experimental element added by this research. At the end of the 1st regimen of antibiotics prescribed, if the treatment failed steps 1 to 4 can be repeated. 30 days after the end of the 1st regimen of antibiotics prescribed, steps 1 to 4 are systematically performed."
3027530|NCT02378480|Experimental|Omadacycline|Omadacycline IV; Omadacycline tablets
3027531|NCT02378480|Active Comparator|Linezolid|Linezolid IV; Linezolid tablets
3027532|NCT02378467|Experimental|Active Treatment Group|7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
3027533|NCT02378467|Active Comparator|Control Group|0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks
3027534|NCT02378454||Cystic fibrosis adults (CF)|No treatment, comparison of LCI values obtained with two devices
3027535|NCT02378454||Healthy adults (HC)|No treatment, comparison of LCI values obtained with two devices Free of respiratory disease or others diseases likely to disturb respiratory system.
3027536|NCT02378441|Experimental|CJ-30056 20/750mg|fixed-dose combination of Atorvastatin 20mg and Metformin SR 750mg
3027537|NCT02378441|Experimental|Atorvastatin 20mg and Metformin SR 750mg|co-administration of Atorvastatin 20mg and Metformin SR 750mg
3027538|NCT02378428|Experimental|MIBG|Research participants with MIBG avid tumors
3027539|NCT02378415|Placebo Comparator|Normal Saline Infusion|A single IV bolus dose of normal saline solution.
3027540|NCT02378415|Experimental|Subanesthetic IV Bolus Ketamine|a single sub-anesthetic rapid IV bolus dose of ketamine administered to acutely depressed patients with or without suicidality
3027541|NCT02378402||Unstable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, currently LVEF<50%. Proton (1H-) magnetic resonance (MR) spectroscopy.
3027542|NCT02378402||Stable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, LVEF>=50%. Proton (1H-) magnetic resonance (MR) spectroscopy.
3027543|NCT02378402||Control group|Age- and gender-matched healthy volunteers recruited as normal control group. Proton (1H-) magnetic resonance (MR) spectroscopy.
3027544|NCT02378389|Experimental|Pyrotinib/Pyrotinib with Docetaxel|Subjects would be treated with Pyrotinib (Part 1) or Pyrotinib with Docetaxel (Part 2). A subject is only allowed to participant in one part of this trial.
3027545|NCT02378376|Experimental|Wheat derived fiber fraction 1|Arabinoxylan oligosaccharides
3027546|NCT02378376|Experimental|Wheat derived fiber fraction 2|Dietary fiber enriched bran
3027547|NCT02378363||Student 9 to 12 years|Students aged 9 to 12 years and enrolled in classes CM1, CM2 and 6th
3027548|NCT02378350|Active Comparator|ESRD patients receiving HD treatment|no investigational drug involved. Only observe therapy treatment
3027549|NCT02378350|Experimental|ESRD patients receiving PD treatment|no investigational drug involved. Only observe therapy treatment
3027550|NCT02378337||Retrospective development cohort|A total of 85 18F-FDG-PET adult studies were gathered over a 3-month period and retrospectively evaluated.
3027551|NCT02378337||Prospective validation cohort|To verify the application of methodology in clinical routine, we conducted a second phase of the study prospectively in 250 subjects (phase 2) using inclusion and exclusion criteria of the retrospective study (phase 1).
3027552|NCT02378324|Active Comparator|Intervention and control|Intervention arm: screening without fee.
3027553|NCT02378324|No Intervention|Control group|Control arm: screening with the regular fee, 100SEK.
3027554|NCT02378311||Cases|Those satisfying the inclusion & exclusion criteria whose injury involved impact with the handlebar end who have sustained an injury more severe than a skin or subcutaneous tissue contusion from an end-on handlebar impact
3027555|NCT02378311||Controls|Those satisfying the inclusion & exclusion criteria in whom the handlebars were not implicated in the mechanism of injury
3027556|NCT02378298|Active Comparator|Non-responder RTX+MTX|"Patients with moderate-severe TAO with an inflammatory CAS of ≥ 4 that do not respond to iv GC (deltaCAS <2 compared to baseline after 4 weeks of iv GC ) or do relapse (deltaCAS ≥2 and total CAS ≥4) after steroid treatment compared to previous CAS measurement at 12 weeks. Rituximab (1000 mg iv with 2 weeks in between) is combined with methotrexate (15-20 mg once a week) to minimize the risk of antibody developement. MTX is always combined with RTX and is never given as a monotherapy in this study.~rituximab and methotrexate"
3027557|NCT02378298|Active Comparator|Relapse RTX+MTX|Patients that respond to iv GC (Methylprednisolone iv) but relapse after 6 weeks will be randomised to either RTX+MTX or per oral GC (po GC+MTX) rituximab and methotrexate
3027558|NCT02378298|Active Comparator|Relapse po GC+MTX|"Patients that respond to iv GC but relapse after 6 weeks will be randomised to either RTX+MTX or per oral GC (po GC+MTX) This is the conventional therapy arm.~methotrexate and methylprednisolone"
3027559|NCT02378298|No Intervention|Responders without relapse|Patients that respond to iv GC and have no relapse at 18 weeks of study.
3027560|NCT02378298|Active Comparator|Methylprednisolone iv|All patients in the study have a 4 weeks period of 500 mg methylprednisolone iv/week. Depending of the response patients are classified as non- responders (and are given RTX and MTX) or responders. The responders continue with intravenous infusion of Methylprednisolone 500 mg /week in 2 weeks and thereafter 250 mg iv/week in 6 weeks.
3027561|NCT02378285|Active Comparator|PRP group|ACP infiltration: 2 mL at 0 and 4 weeks with ultrasound guidance
3027562|NCT02378285|Placebo Comparator|Saline solution group|Saline solution infiltration: 2mL at 0 and 4 weeks with ultrasound guidance
3027563|NCT02378272|Experimental|Care manager for depression|A district nurse will apply around 15-25% of working time as care coordinator (care manager for depression) at PCC for management of care for all recruited patients with depression
3027564|NCT02378272|No Intervention|Treatment As Usual|Management of recruited patients with depression continued as usually applied at PCC
3027565|NCT02378259|Experimental|Bariatric surgery|Roux-en-Y gastric bypass surgery
3027572|NCT02378220|Active Comparator|"Intervention (tested)"|"Patients in the tested group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug interactions (DDI), drug-gene interactions (DGI), and drug-drug-gene interactions (DDGI) using YouScript® to provide drug therapy recommendations to prescribers."
3027573|NCT02378207|Experimental|Group 1 H4:IC31|15 mcg H4/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
3027574|NCT02378207|Experimental|Group 2 H56:IC31|5 mcg H56/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
3027575|NCT02378207|Active Comparator|Group 3 BCG (2-8 x 105 CFU)|Administered ID as 0.1 mL in either deltoid muscle at Day 0.
3027576|NCT02378207|Placebo Comparator|Group 4 Control Sodium Chloride 0.9%|Administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
3027577|NCT02378194|Placebo Comparator|Placebo group|
3027578|NCT02378194|Experimental|HD-003 (800mg/day)|
3027579|NCT02378194|Experimental|HD-003 (1600mg/day)|
3027580|NCT02378181|Experimental|Toolkit (TK)|Patients in the TK condition will receive counseling sessions from participating counselors who have been trained to use the Health Education Toolkit (TK).
3027581|NCT02378181|Active Comparator|Treatment-as-usual (TAU)|Patients in the treatment-as-usual (TAU) condition will receive the same number of counseling sessions as patients in the TK condition from participating counselors who have not been trained to use the Health Education Toolkit. Counselors working with patients in this condition will receive a control training of the same length and intensity on recovery topics that are covered in the Health Education Toolkit, but will not be equipped with the Toolkit.
3027582|NCT02378168||cohort of RCT (StV 5-2007; NCT00924222)|Patient group with either sevoflurane or propofol sedation of the RCT (StV 5-2007; NCT00924222)
3027583|NCT02378155|Other|electrical cardioversion|Hemodynamic unstable patients with atrial fibrillation who are scheduled to undergo electrical reconversion to convert their irregular heart rhythm into a normal sinus rhythm. Cerebral tissue oxygen saturation is measured by means of SenSmart Model X-100, Nonin Medical.
3027584|NCT02378155|Other|pharmacological cardioversion|Patients who develop atrial fibrillation after cardiac surgery. Pharmacological treatment with amiodarone is started in order to convert their irregular heart rhythm into a normal sinus rhythm. Cerebral tissue oxygen saturation is measured by means of SenSmart Model X-100, Nonin Medical.
3027585|NCT02378142|Experimental|Arm 1|Pazopanib 800mg oral daily
3027586|NCT02378129|Experimental|Clinpro XT (3M ESPE, Minnesota, USA)|Resin-modified glass ionomer cement
3027587|NCT02378129|Active Comparator|Vidrion R (SS White, Gloucester, UK)|Conventional glass ionomer cement
3027588|NCT02378116|No Intervention|Control|On the control group is done MRI scans of the brain, and patients can be elected for monitoring and/or bicycle stress test to test for neurohormones.
3027589|NCT02378116|Active Comparator|Surgical Closure|During open heart surgery, the surgeon closes the left atrial appendage. The research group recommend a double closure with both a ligation and suture, but a single suture is also accepted.
3027590|NCT02378103||Case|Diagnosis of aortic dissection was based on history and physical examination, and confirmed by imaging, visualization at surgery, and/or postmortem examination. Simple aortic aneurysm and pseudoaneurysm were excluded. Simple aortic aneurysm and pseudoaneurysm were excluded. Surgical and endovascular treatments were the main interventions and performed in the case group.
3027591|NCT02378103||Control|As the control group, patients without AD were obtained from the hospitalized patients in the same period.
3027592|NCT02378077|Experimental|Lean or Obese, Non-Diabetic|To determine whether eosinophil content of adipose tissue is related to insulin sensitivity. We will use euglycemic clamps, fat biopsy (obtained during a scheduled abdominal surgery) and fat aspiration for analysis of subcutaneous (Sc) and omental (OM) adipose tissue from obese, insulin resistant and lean, insulin sensitive volunteers to test the hypothesis that, as in mice, eosinophil content in human subcutaneous and omental white adipose tissue, inversely correlates with body weight, with skeletal muscle and hepatic insulin sensitivity.
3027593|NCT02378077|Experimental|Fish oil supplementation|Determine whether, in adipose tissue, levels of, anti-inflammatory molecules correlate with insulin sensitivity and whether these levels are altered by a treatment designed to promote resolution of inflammation. Volunteers will take a fish oil supplement for three months.
3027594|NCT02378064|Experimental|Fimasartan and vytorin|fimasartan(60mg,QD)+Vytorin(10mg,QD)
3027595|NCT02378064|Experimental|Fimasartan and rosuvastatin|fimasartan(60mg,QD)+rosuvastatin(5mg,QD)
3027596|NCT02378064|Active Comparator|amlodipine and vytorin|amlodipine(5mg,QD)+Vytorin(10mg,QD)
3027597|NCT02378064|Active Comparator|amlodipine and rosuvastatin|amlodipine(5mg,QD+rosuvastatin(5mg,QD)
3027598|NCT02378051|Experimental|Staying Strong with Schools Intervention|The Staying Strong with Schools Intervention includes: (a) a training of all school professionals, and (b) a year-long training and supervision of the school guidance counselor (RSL), by a Liaison-Trainer (LT).
3027599|NCT02378051|Placebo Comparator|Waitlist Control|The waitlist control schools will receive an educational pamphlet outlining resources useful to support military-connected children to be distributed to all educators at the beginning of the Year 1. They will then receive the Staying Strong with Schools Intervention in Year 2.
3027600|NCT02378038|Experimental|PNT2258|PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle for 8 induction cycles followed by continuation phase therapy at a dose of 100 mg/m2 on days 1-4 of a 28-day cycle.
3027601|NCT02378025|Experimental|Yoga Group|Postures, meditation, breathing exercises
3027602|NCT02378025|Active Comparator|Pain Management Wellness Group|Behavioral medicine
3027603|NCT02378012|Active Comparator|GROUP A (participants provide own computer or tablet device)|A member of the research personnel helps the participants install Netflix, Spotify, and Skype applications on their computers if they wish to do so. Participants will be given subscriptions to each application and usernames for access on days -5 to 10.
3027604|NCT02378012|Experimental|GROUP B (Apple BuckiPad)|Participants receive an iPad for days -5 to 10. Participants also receive the BuckiPad manual for instructions on how to use the iPad and Netflix, Skype, and Spotify applications. Participants are also directed to the official Apple's iPad user's manual on their device and have questions answered by research personnel on day -5.
3027605|NCT02378012|No Intervention|GROUP C (no intervention)|Participants do not receive an iPad for days -5 to 10.
3027607|NCT02377986|Experimental|Experimental: BIT+In-home Decluttering|Patients who have not received the BIT workshop through our previous study (IRB 6681) will receive BIT+in-home decluttering practice.
3027608|NCT02377986|Experimental|Experiemental: In-home Decluttering|Patients who have already received the BIT workshop in our previous study (IRB 6681) will receive in-home decluttering practice.
3027609|NCT02377973||Growth and Development|Growth and Development og healthy young children born by Obese mothers
3027610|NCT02377960|Active Comparator|Usual care (Reference group)|Treatment is leaded by treating physician according to national guide lines with no study-specific medication or clinical appointment protocol.
3027611|NCT02377960|Experimental|An IMB model-based initiation of medication|"In addition to usual care, participants allocated to intervention group will receive~An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time"
3027612|NCT02377960|Experimental|Tailored SMS-text message support|"Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication.~After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments."
3027613|NCT02377947||Patients with cirrhosis (grade 3 & 4 per west haven cr.)|Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema
3027614|NCT02377921|Experimental|Aceneuramic Acid Extended-Release (Ace-ER)|Ace-ER 6 g/day, divided 3 times per day (TID) for 48 weeks.
3027615|NCT02377921|Placebo Comparator|Placebo|Matching placebo TID for 48 weeks.
3027616|NCT02377895|Experimental|Nasapaque Nasal Solution|250 ul in each nostril at Day 1 and Day 8
3027617|NCT02377895|Active Comparator|Placebo Saline Nasal Solution|250 ul in each nostril at Day 1 and Day 8
3027618|NCT02377856|Active Comparator|intervention|40 patients will receive pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks combination treatment, followed by 24 weeks of follow-up. 'pegylated interferon alpha 2a, ribavirin'
3027619|NCT02377856|No Intervention|observation|40 patients without treatment will be followed for the clinical course for 1.5 year
3027620|NCT02377843|Experimental|Participatory|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the participatory study arm will receive a 1-hour in-person communication training.
3027621|NCT02377843|Experimental|Efficient|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the efficient study arm will receive a 1-hour in-person communication training.
3027622|NCT02377843|No Intervention|Control|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the control study arm will not receive a 1-hour in-person communication training.
3027623|NCT02377830|Experimental|Early Cycling and routine physiotherapy|Patients will receive 30 minutes of in-bed cycling in addition to routine physiotherapy, 5 days per week, for the duration of their ICU stay
3027624|NCT02377830|Active Comparator|Routine physiotherapy|Patients will receive routine physiotherapy per current institutional practice
3027625|NCT02377817|Experimental|PrenaBelt on First Sleep Test Night|Participants will be randomized to treatment order: sham PrenaBelt on first night, then PrenaBelt on second night, or vice versa. This will avoid the potential impact of changes to sleep across the two nights resulting from familiarization with the polysomnography equipment, which could bias the results.
3027626|NCT02377817|Sham Comparator|Sham PrenaBelt on First Sleep Test Night|Participants will be randomized to treatment order: sham PrenaBelt on first night, then PrenaBelt on second night, or vice versa. This will avoid the potential impact of changes to sleep across the two nights resulting from familiarization with the polysomnography equipment, which could bias the results.
3027627|NCT02377804|Experimental|Experimental intervention|The experimental intervention will consist of 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity. In addition, during this intervention patients will also receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pectoralis mayor
3027628|NCT02377804|Active Comparator|Control intervention|The control intervention will consist of 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity.
3027629|NCT02377778|Experimental|Propofol|In this arm patients will be receiving propofol for anaesthesia at doses 3-5mg depending on the time needed to complete oocyte retrieval
3027630|NCT02377778|Active Comparator|Thiopental|In this arm patients will receive thiopental for anaesthesia at doses 7mg and a repeat dose of 2-3mg depending on the time needed to completed oocyte retrieval
3027631|NCT02377765|Active Comparator|Percutaneus Stimulation|PTNS performed bilaterally every 4 weeks within the Physiotherapy Department.
3027632|NCT02377765|Experimental|Transcutaneous Stimulation|TPTNS applied bilaterally, using two surface, self-adhesive, round electrodes (3 cm in diameter) in each leg at least 3 times per week.
3027633|NCT02377752|Experimental|Part A cohort 1: Olaratumab+Doxorubicin|olaratumab administered intravenously (IV) on Day 1 and Day 8, and 25 milligram per square meter (mg/m^2) of doxorubicin on Day 1, Day 2, and Day 3 of every 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3027634|NCT02377752|Experimental|Part A cohort 2: Olaratumab+Doxorubicin|olaratumab administered IV on Day 1 and Day 8, and 75 mg/m^2 of doxorubicin administered IV on Day 1 of every 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met
3028027|NCT02375178|Active Comparator|Sterile saline solution|sterile Saline solution 0,9%
3027635|NCT02377752|Experimental|Part B: Olaratumab|olaratumab administered IV on Day 1 and Day 8 of every 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met
3027636|NCT02377739|Experimental|non-invasive ventilation|patients will undergo about 14 nights of non-invasive ventilation during pulmonary rehabilitation
3027637|NCT02377726|Experimental|Internet self-help with support|eChange Alkoholhjälpen is an internet based self help program consisting of 5 modules. Patients will have access to Alkoholhjälpen counselor support through secure comments at every module they complete.
3027638|NCT02377726|Experimental|Internet self-help|eChange Alkoholhjälpen is an internet based self help program consisting of 5 modules.
3027639|NCT02377726|Active Comparator|Information|Brief information on resources that can be accessed through the open access website Alkoholhjälpen: Information on alcohol and health, where and how to find treatment and an internet discussion forum.
3027640|NCT02377713|Experimental|KHK6640|KHK6640
3027641|NCT02377713|Placebo Comparator|Placebo|Placebo
3027642|NCT02377700|Experimental|Xeltis Vascular Patch, Model COR-VP-001|Patients implanted with the vascular patch during staged bidirectional cava-pulmonary anastomosis.
3027643|NCT02377687||elderly >75 years|all patients aged ≥ 75 having an emergency GI laparotomy or laparoscopy
3027644|NCT02377674|Experimental|Vascular Graft, Model COR-VG-001|A surgically implanted vascular graft for pediatric patients undergoing extracardiac total cavopulmonary connection.
3027645|NCT02377661|No Intervention|Standard Care|Treatment of hypertension according to current guidelines
3027646|NCT02377661|Experimental|Experimental Care|Treatment of hypertension using a standardised and simplified titration regime with single pill combinations, comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide.
3027647|NCT02377648|Experimental|ABSORB Bioresorbable Vascular Scaffold|Everolimus-Eluting Bioresorbable Vascular Scaffold implantation
3027648|NCT02377635|Experimental|Treatment|Drug: Anhydrous selenite (Se-77), single dose 0.8mg, orally administered as a 100 ml purified water solution
3027649|NCT02377635|Placebo Comparator|Control|Drug: Placebo sodium chloride (table salt), orally administered as a 100 ml purified water solution
3027650|NCT02377622|Experimental|THERANOVA 400 dialyzer prototype AA|THERANOVA 400 dialyzer prototype AA in hemodialysis
3027651|NCT02377622|Experimental|THERANOVA 400 dialyzer prototype BB|THERANOVA 400 dialyzer prototype BB in hemodialysis
3027652|NCT02377622|Active Comparator|FX CorDiax 80 dialyzer|FX CorDiax 80 dialyzer in hemodialysis
3027653|NCT02377622|Active Comparator|FX CorDiax 800 dialyzer|FX CorDiax 800 dialyzer in high volume hemodiafiltration
3027654|NCT02377609||Kidney or Liver Transplant Patients|adult kidney or liver Advagraf® (tacrolimus) recipients
3027655|NCT02377596||Perceived Feeding Difficulties|To complete the study we will recruit at least 40 of the children perceived by their parents or guardian to have feeding difficulties.
3027656|NCT02377583||Diabetic children|"physical examination~Glucocorticoid sensitivity index~DNA sample~Anxiety and depression questionnaires~depression questionnaire~MRI"
3027657|NCT02377583||Controls|"physical examination~Glucocorticoid sensitivity index~DNA sample~Anxiety and depression questionnaires~depression questionnaire~MRI~Laboratory tests"
3027658|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype AA|THERANOVA 400 dialyzer prototype AA in hemodialysis treatment
3027659|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype BB|THERANOVA 400 dialyzer prototype BB in hemodialysis treatment
3027660|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype CC|THERANOVA 400 dialyzer prototype CC in hemodialysis treatment
3027661|NCT02377570|Active Comparator|FX CorDiax 80 dialyzer|FX CorDiax 80 dialyzer in hemodialysis treatment
3027662|NCT02377544|Placebo Comparator|Placebo|Saccharum lactis
3027663|NCT02377544|Experimental|Probiotic|Bifidobacterium animalis lactis
3027664|NCT02377531|Other|Early glucose screen group|Participants with high risk factors for gestational diabetes, will be randomly assigned to an early glucose screen group: it consists of an oral load of 50 grams of glucose followed by a measurement of serum glucose 1 hour later, and if abnormal (higher than 130mg/dl), will undergo a 100 gram oral load of glucose followed by serum glucose levels drawn 1,2 and 3 hours after the load. If abnormal according to Carpenter-Cousant criteria, the participant will undergo standard of care for Gestational Diabetes.
3027665|NCT02377531|Other|Standard glucose screen group|The participants in this group will be randomized to undergo the testing process previously described at 24 to 28 weeks.
3027666|NCT02377518|Experimental|oncologic patients|"Prediction of postoperative pulmonary function.~Patients with an operable lung cancer: dual energy computed tomography with Krypton will be tested to estimate the postoperative FEV1"
3027667|NCT02377518|Experimental|lung transplant recipients|"Detection of BOS~6 months+ lung transplant recipients will be tested using dual energy computed tomography with Krypton, with acquisition in the end-inspiratory and end-expiratory phase, in search of regional air trapping."
3027668|NCT02377505|Active Comparator|On-Stimulation|"Disease condition is assessed with stimulation turned on"
3027669|NCT02377505|Placebo Comparator|Off-Stimulation|"Disease condition is assessed with stimulation turned off"
3027670|NCT02377492|Experimental|Paracervical & Intramyometrial|Vasopressin will be placed paracervically (8mL, 4 units) and intramyometrial (8mL, 4 units)
3027671|NCT02377492|Active Comparator|Intramyometrial|Vasopressin will be placed intramyometrial (16mL, 8 units)
3027672|NCT02377479|Active Comparator|Clomiphene alone|The patient will take 100mg clomiphene orally from cycle days 3-7
3027673|NCT02377479|Active Comparator|Letrozole alone|The patient will take 5mg Letrozole orally from cycle days 3-7
3027674|NCT02377479|Experimental|Combination Clomiphene and Letrozole|The patient will take a dose of 5mg Letrozole every night and 100mg clomiphene every day after lunch from cycle days 3-7.
3027675|NCT02377466|Experimental|Retosiban|Retosiban treatment will be administered as a 6 mg IV loading dose over 5 minutes followed by a 6 milligram per hour (mg/hour) continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, another 6 mg loading dose will be administered and infusion rate will be increased to 12 mg/hour for the remainder of the 48 hour treatment period. The retosiban dosing regimen will require adjustment in subjects treated concomitantly with drugs that are strong Cytochrome 3A4 inhibitors or inducers.
3058474|NCT02171793|Placebo Comparator|Placebo|
3027676|NCT02377466|Placebo Comparator|Placebo|The placebo control will be a normal saline (0.9% sodium chloride [NaCl]) infusion matched for the loading dose and continuous infusion rates, including a dose increase in subjects with an inadequate response after the first hour of treatment.
3027677|NCT02377453||Control|Control: Healthy adult
3027678|NCT02377453||Experimental|Experimental: patients with stroke
3027679|NCT02377427|Experimental|Mepolizumab 40 mg in Part A and B|Participants with bodyweight < 40 kg will receive 0.4 milliliter (mL) of reconstituted mepolizumab subcutaneously, in upper arm or thigh.
3027680|NCT02377427|Experimental|Mepolizumab 100 mg in Part A and B|Participants with bodyweight >= 40 kg will receive 1.0 mL of reconstituted mepolizumab subcutaneously, in upper arm or thigh.
3027681|NCT02377414|Experimental|Cohort 1: Retosiban/placebo|Each subject in cohort 1 will receive an intravenous (IV) bolus infusion of 6 milligrams (mg) retosiban or placebo over 5 minutes, followed by a continuous infusion of 6 milligram per hour (mg/h) retosiban or placebo for 24 h. At 24 h of dosing, an additional 6 mg retosiban or placebo will be administered over 5 minutes followed by a 12 mg/h infusion over the next 24 h, for a total time of infusion of 48 h. Subjects administered with placebo will receive an equal volume of normal saline as an IV bolus as well as an equal rate of continuous infusion of normal saline as of retosiban.
3027682|NCT02377414|Experimental|Cohort 2: Retosiban|Each subject in cohort 2 will receive a bolus infusion of 6 mg retosiban over 5 minutes, followed by a continuous infusion of 6 mg/h retosiban for 24 h. At 24 h of dosing, an additional 6 mg retosiban will be administered over 5 minutes followed by a 12 mg/h infusion over the next 24 h, for a total time of infusion of 48 h.
3027683|NCT02377401|Experimental|Zanamivir 300 mg|Subjects will receive a single dose of IV zanamivir 300 mg on Day 1 morning. The repeat dose session will begin on Day 3 evening. Subjects will receive IV zanamivir 300 mg every 12 hours for 5 days. Each dose will be administrated intravenously at a constant rate over 30 minutes (500 milliliter per hour [mL/hr]).
3027684|NCT02377401|Experimental|Zanamivir 600 mg|Subjects will receive a single dose of IV zanamivir 600 mg on Day 1 morning. The repeat dose session will begin on Day 3 evening. Subjects will be receive IV zanamivir 600 mg every 12 hours for 5 days. Each dose will be administrated intravenously at a constant rate over 30 minutes (500 mL/hr).
3027685|NCT02377388|Active Comparator|treatment: DPP4 -i|"Use of DPP4-i :~sitagliptin 50 mg (if glomerular filtration rate-GFR <50 ml/min at randomization) or 100 mg (if GFR>50 ml/min at randomization),during 30 days,once-daily(OD)~OR~saxagliptin 2,5 mg (if glomerular filtration rate-GFR <50 ml/min at randomization) or 5 mg (if GFR>50 ml/min at randomization),during 30 days,once-daily(OD)"
3027686|NCT02377388|Placebo Comparator|control|placebo tablets identical to active comparator,administered according to GFR at randomization,during 30 days,OD
3027687|NCT02377375|Experimental|Micro-assisted|In each patient, one electrode will be implanted using the standard technique and one electrode will be implanted using the micro-electrode assisted technique. The side is randomized.
3027688|NCT02377375|Active Comparator|Standard|In each patient, one electrode will be implanted using the standard technique and one electrode will be implanted using the micro-electrode assisted technique. The side is randomized.
3027689|NCT02377362|Experimental|GLWL-01, Part A|Escalating dose in at least 2 of 3 periods, starting at 10 milligrams (mg)
3027690|NCT02377362|Placebo Comparator|Placebo, Part A|Escalating dose of placebo to match GLWL-01, in 1 period
3027691|NCT02377362|Experimental|GLWL-01, Part B|Multiple ascending daily doses of GLWL-01 at up to six dose levels, based on Part A
3027692|NCT02377362|Placebo Comparator|Placebo, Part B|Multiple daily doses of placebo to match GLWL-01
3027693|NCT02377362|Experimental|GLWL-01, Part C|Multiple daily doses of GLWL-01 at level based upon Part B
3027694|NCT02377362|Placebo Comparator|Placebo, Part C|Multiple daily doses of placebo to match GLWL-01
3027695|NCT02377349|Experimental|dTpa Group|This group will consist of pregnant women who will receive a single dose of Boostrix™ at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of the placebo post-delivery (within 72 hours).
3027696|NCT02377349|Placebo Comparator|Control Group|This group will consist of pregnant women who will receive a single dose of placebo at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of Boostrix™ post-delivery (within 72 hours).
3027697|NCT02377336|Experimental|GS-6615|GS-6615 30 mg (5 x 6 mg) on Day 1, followed by 6 mg twice daily
3027698|NCT02377336|Placebo Comparator|Placebo|Placebo to match GS-6615 (5 tablets) on Day 1, followed by placebo to match GS-6615 twice daily
3027699|NCT02377323|Other|Treatment with Rebif|Patients treated with Rebif only, for at least two years, and for up to 18 years
3027700|NCT02377323|Other|Never treated|Patients never treated with a disease-modifying drug (DMD)
3027701|NCT02377310||All patients|All patients will undergo coronary physiological study with measurement of resting Pd/Pa, iFR™, hyperaemic iFR and FFR.
3027702|NCT02377297|Active Comparator|Restoration with Fuji IX|The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
3027703|NCT02377297|Experimental|Restoration with Vitro Molar|The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
3027704|NCT02377297|Experimental|Restoration with Maxxion R|The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
3027705|NCT02377284|Experimental|Intervention (personalized chef card)|Restaurant employees received a personalized chef card, which included written information about a patron's food allergies and a photograph of the patron.
3027706|NCT02377284|No Intervention|Control (depersonalized chef card)|Restaurant employees received a depersonalized chef card, which included written information about a patron's food allergies, without a photograph of a patron.
3027707|NCT02377271|Experimental|Bosentan|Bosentan at a dose of 125 mg two times daily, will be administered orally, twice a day, during eight weeks
3027708|NCT02377271|Placebo Comparator|Placebo|placebo drug , twice a day, during eight weeks
3027709|NCT02377258||1|without previous or ongoing exposure to IS or biologics, (5ASA and Steroids are allowed)
3027710|NCT02377258||2|with on-going anti-TNF monotherapy
3027711|NCT02377258||3|with thiopurines monotherapy
3027712|NCT02377258||4|with on-going combination therapy
3027713|NCT02377258||5|patients on vedolizumab (1 on vedolizumab alone and 1 on combination therapy)
3027714|NCT02377245||Juvenile Inflammatory Rheumatism|Juvenile Inflammatory Rheumatism patients
3027715|NCT02377232|Active Comparator|Usual Care Outreach for Colon Cancer Screening|Receives standard of care outreach concerning colon cancer screening.
3027716|NCT02377232|Active Comparator|Decision Aid for Colon Cancer Screening|Receives colon cancer screening decision aid intervention in addition to outreach.
3027717|NCT02377219|Experimental|couples|couples attending an IVF or intra cytoplasmic sperm injection (ICSI) attempt have hormonal and blood analysis
3027718|NCT02377206|Experimental|Alzheimer Disease|Alzheimer Disease People ADAS-Cog evaluation PET imaging with [18F]DPA-714
3027719|NCT02377193|Experimental|Simulect|Simulect IV 40 mg D0 and D4
3027720|NCT02377193|Active Comparator|ATG Fresenius|ATG IV min dose 3 mg/ kg/ day D0, D1, D3, D5
3027721|NCT02377180|Experimental|Part 1|Intramuscular injection of capsaicin for the study of pain and hyperalgesia
3027722|NCT02377180|Active Comparator|Part 2|Pain arising from supraspinatus muscle vs. pain arising from trapezius muscle. Nerve block is only expected to be effective in the former.
3027723|NCT02377180|Active Comparator|Part 3|Suprascapular nerve block vs. intramuscular local anesthetic against pain arising from the supraspinatus muscle.
3027724|NCT02377167|Experimental|Early Tracheostomy|"Patients randomized to early tracheostomy receive (preferably dilatative) tracheostomy within 5 days from intubation.~Intervention: Procedure: Early Tracheostomy"
3027725|NCT02377167|Active Comparator|Prolonged Intubation|"Patients randomized to this arm will be tried to wean off the ventilator and get (an) extubation trial(s) if regarded feasible. In case of failure or non-feasibility, they receive tracheostomy after intubation day 10.~Intervention: Procedure: Late Tracheostomy"
3027726|NCT02377154|Other|Opthalmologically healthy individuals|Slit lamp, Autorefractor, IOLMaster 500, Pentacam HR, LenStar LS900, VERION Image Guided System
3027727|NCT02377141|Active Comparator|Endoscopic Variceal Band Ligation (EVBL)|Participants in this group will receive standard medical care consisting of vasoactive drugs (Terlipressin 2mg QDS (where there are no contraindications e.g. severe ischaemic heart disease), antibiotics, and entry into a variceal banding programme (in-patient or out-patient).
3027728|NCT02377141|Active Comparator|Early TIPSS|For those randomized to early TIPSS the Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure will be performed within 72 hours (and preferably within the first 24 hours) after initial endoscopy. Vasoactive drugs will be continued until the TIPSS is performed and antibiotics continued for 5-7 days.
3027729|NCT02377128|Experimental|Bilateral salpingectomy|Cesarean section with bilateral salpingectomy
3027730|NCT02377128|Active Comparator|Tubal ligation|Cesarean section with tubal ligation
3027731|NCT02377128|No Intervention|No intervention|Cesarean section with no additional intervention
3027732|NCT02377115|Other|Study cohort|Tablet computer application
3027733|NCT02377102|No Intervention|Observational|Patients will be asked to continue for 12 weeks of nonoperative medical management without physical therapy. At 12 weeks they will be reevaluated regarding the need for total knee arthroplasty.
3027734|NCT02377102|Active Comparator|Physical Therapy|Patients will be provided a prescription for 12 weeks of physical therapy at a location of their choice. No set protocol will be issued to allow for adjustments based on patient activity level and the therapist's professional choice. The physical therapy techniques, consisting of active and passive physiological and accessory movements and soft tissue mobilization, active range of motion exercises, muscle strengthening, muscle stretching, and exercises such as riding a stationary bicycle will be applied at the discretion of the treating physical therapist primarily to the knee and surrounding structures.
3027735|NCT02377089|Sham Comparator|Sham|The stimulators are the same device for the active and sham treatment conditions.
3027736|NCT02377089|Active Comparator|Active|The stimulators are the same device for the active and sham treatment conditions.
3027737|NCT02377076|Experimental|DAIRY|Dietary calcium supplementation
3027738|NCT02377076|Placebo Comparator|CONTROL|Control
3027739|NCT02377063|Other|Pressed Juice|Subjects will consume pressed juice supplementation for 3 days
3027740|NCT02377050|Active Comparator|Higher Volume Feeding Goal|Infants randomized to this group will have higher volume feeding goals of 180-200 ml/kg/day.
3027741|NCT02377050|No Intervention|Usual Volume Feeding Goal|Infants randomized to this group will have feeding goals of 140-160 ml/kg/day.
3027742|NCT02377037|Experimental|Sitting|Remain seated in a chair, with hands placed on top of the thighs for 10 minutes, remaining motionless in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured minute by minute.
3027743|NCT02377037|Experimental|Standing|Remain in an upright position (standing) with hands placed on the thighs for 10 minutes, remaining motionless in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured minute by minute.
3027744|NCT02377037|Experimental|Transitions sit/stand|The participant will perform one sit-to-stand followed by a stand-to-sit transition, every minute in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured.
3027745|NCT02377024|Experimental|TF 600mg|TF 600mg/day
3027746|NCT02377024|Experimental|TF 1200mg|TF 1200mg/day
3027747|NCT02377024|Placebo Comparator|placebo|placebo
3027748|NCT02377011|Experimental|PS CBT|"Problem solving cognitive behaviour therapy (PS CBT) will be delivered remotely by means of telephone or video calling by a cognitive behaviour therapist in addition to their usual care.~The duration of the intervention will be 10 sessions. Research measures will be completed at baseline, 3,6,9 and 12 months"
3027749|NCT02377011|No Intervention|Treatment as Usual|Participants will not receive any CBT therapy in addition to their usual care. Research measures will be completed at baseline,3,6,9 and 12 months.
3027750|NCT02376998|Experimental|Valiant™ endoluminal procedure|Data from early and long term complications following endoluminal stent-graft placement for thoracic endovascular aortic repair (TEVAR) procedure (Valiant™ endoluminal procedure) will be collected.
3027751|NCT02376985|Placebo Comparator|Brushing instruction group|"Drug: Everolimus and Exemestane Everolimus, 10 mg/day Exemestane, 25 mg/day Administration on consecutive days once daily after breakfast until tumor progression or for a minimum 8 weeks.~Oral treatment:~Brushing and gargling with saline after every meal (initially instructed by a dental/oral surgeon)."
3027870|NCT02376257|Active Comparator|250 mg DCS|Baseline assessment (week 1), two weekly sessions when 250mg DCS is administered, and final week (week 4) when retention is assessed.
3027752|NCT02376985|Experimental|Dental oral management group|"Drug: Everolimus and Exemestane Everolimus, 10 mg/day Exemestane, 25 mg/day Administration on consecutive days once daily after breakfast until tumor progression or for a minimum 8 weeks.~Oral treatment:~Scaling and enamel polishing will be performed by a dental and oral surgeon or dental hygienist before everolimus treatment, and once weekly after everolimus treatment.~Brushing and gargling with Neostelin Green 0.2% mouthwash solution after every meal (initially instructed by a dental/oral surgeon)."
3027753|NCT02376972|Experimental|RIFAXIMIN VAGINAL TABLET 25 MG|RIFAXIMIN VAGINAL TABLET 25 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
3027754|NCT02376972|Experimental|RIFAXIMIN VAGINAL TABLET 100 MG|RIFAXIMIN VAGINAL TABLET 100 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
3027755|NCT02376972|Placebo Comparator|PLACEBO VAGINAL TABLET|PLACEBO VAGINAL TABLET ADMINISTERED ONCE A DAY FOR 5 DAYS
3027756|NCT02376972|Active Comparator|METROGEL VAGINAL|METROGEL VAGINAL ADMINISTERED ONCE A DAY FOR 5 DAYS
3027757|NCT02376959|Placebo Comparator|Control Group|"Application of 8 spiritist passe simulation sessions by people without spiritist training at the same time and in the same environment as the treatment group."
3027758|NCT02376959|Active Comparator|"Treatment Group (Spiritist passe)"|"Application of 8 sessions of spiritist passe by spiritists with more than 2 years of experience in controlled environments for the same period as the control group."
3027759|NCT02376946|Active Comparator|Actipatch|The study group will be comprised of subjects that will receive PEMF ActiPatchTM treatment for postoperative management of pain and edema.
3027760|NCT02376946|Placebo Comparator|Placebo|The control group will be comprised of the subjects that will receive a placebo patch as treatment for postoperative management of pain and edema.
3027761|NCT02376933|Experimental|Vertebroplasty with Radiotherapy|Vertebroplasty with Radiotherapy is given in either order. Radiotherapy dosage is at the discretion of the treating physician. Vertebroplasty is applied to fractured vertebrae.
3027762|NCT02376907||EUS-BD or ERCP with duodenal SEMS|Patients who underwent endoscopic placement of a duodenal self-expandable metal stent (SEMS) for nonresectable malignant GOO and endoscopic biliary drainage for nonresectable distal MBO.
3027763|NCT02376881|Experimental|EPO|20,000 IU recombinant human erythropoietin IV infusion in 100 ml normal saline in 2 hr for 3 successive days
3027764|NCT02376881|Placebo Comparator|control group|100 ml normal saline in 2 hr for 3 successive days
3027765|NCT02376868|Other|Normal Eyes|Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
3027766|NCT02376868|Other|Glaucomatous Eyes|Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
3027767|NCT02376868|Other|Eyes with Retinal Diseases|Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
3027768|NCT02376855|No Intervention|Control|Providers in the Control group followed standard care protocols. If they deemed a patient was in need of cardiology consultation, a referral was created using the standard process. The referral was processed by a referral coordinator and transmitted to an appropriate cardiologist. An appointment was then scheduled for the patient to have an in-person consultation with a cardiologist.
3027769|NCT02376855|Experimental|eConsult|"The intervention consisted of an eConsult pathway and standardized protocol for PCPs to obtain cardiology consults using a secure messaging peer to peer (P2P) module embedded within the EHR. Intervention providers were asked to send all cardiology referrals for their adult patients through the eConsult system. Providers could bypass the eConsult pathway for patients with established relationships with a cardiologist or for whom providers felt a consult was urgent (required a face-to-face visit within a week or less). eConsults contain reason for consult, relevant test results, records or reports but are sent electronically to a Cardiology Consultant for review. eConsults were responded to within two business days. Responses were case-specific and generally contained recommendations for management, additional testing, or a face-to-face cardiology visit. The PCP was responsible for considering/acting upon recommendations and determining when an eConsult was complete."
3027770|NCT02376842|Active Comparator|Severe sepsis early warning best practice alert|Patients in this arm will actively generate the alert.
3027771|NCT02376842|Placebo Comparator|Standard care|This arm will be the current standard of care and will not generate the alert.
3027772|NCT02376829|Experimental|The Invisalign System|Class II correction of malocclusions
3027773|NCT02376816|Experimental|Cohort 1: Low Dose|The rAAVrh74.MCK.micro-Dystrophin vector will be injected to the Extensor Digitorum Brevis (EDB) muscle of a single foot at a total dose of 3E11 vg. The contralateral EDB muscle will injected with normal saline placebo as a comparator. Both physician and study team will be blinded as to which muscle received vector vs placebo. A minimum of three (3) patients with DMD will be enrolled in this cohort.
3027774|NCT02376816|Experimental|Cohort 2: High Dose|The rAAVrh74.MCK.micro-Dystrophin vector will be injected to the Extensor Digitorum Brevis (EDB) muscle of a single foot at a total dose of 1E12 vg. The contralateral EDB muscle will injected with normal saline placebo as a comparator. Both physician and study team will be blinded as to which muscle received vector vs placebo. A minimum of three (3) patients with DMD will be enrolled in this cohort.
3027775|NCT02376803|Experimental|Morning warfarin ingestion|Patients switch from taking warfarin in the evening to taking warfarin in the morning.
3027776|NCT02376803|Active Comparator|Evening warfarin ingestion|Patients continue taking warfarin in the evening as per their usual routine.
3027777|NCT02376790|Active Comparator|Etanercept & Methotrexate Combo|Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 20 mg weekly.
3027778|NCT02376790|Placebo Comparator|Etanercept Mono|Etanercept 50 mg weekly by subcutaneous injection plus oral placebo for methotrexate.
3027779|NCT02376790|Placebo Comparator|Methotrexate Mono|Oral methotrexate 20 mg weekly plus placebo for etanercept.
3027780|NCT02376777||Patient receiving NOAC|Follow up of patients receiving new oral anticoagulants (NOAC) medication
3027781|NCT02376777||Patient receiving VKA|Follow up of patients receiving vitamin K antagonist (VKA) medication
3027782|NCT02376725|Active Comparator|Phaco/IOL|Cataract extraction using phacoemulsification technique with intraocular lens implant
3027783|NCT02376725|Active Comparator|Phaco/IOL + goniosynechialysis|Cataract extraction using phacoemulsification technique with intraocular lens implant with goniosynechialysis
3028001|NCT02375360||Parents 0-12 - OIT|Parents to children aged 0-12 years with food allergy who are undergoing oral immunoterapy
3027784|NCT02376712||Pre-renal AKI|"Three definitions of pre-renal AKI will be used separately:~Hemodynamic instability (any sign of tissue hypoperfusion) on AKI identification, and AKI recovery in 24-72 hours following hemodynamic stabilization.~AKI recovery in less than 72 hours after AKI identification.~Decreased renal blood flow measured by transesophageal echocardiography (TEE)."
3027785|NCT02376712||Renal AKI|"Three definitions of renal AKI will be used separately:~Hemodynamically stable at AKI identification; or hemodynamically instability (any sign of tissue hypoperfusion) on AKI identification, and AKI persistence in 24-72 hours following hemodynamic stabilization.~AKI persistence 72 hours after AKI identification.~Normal or increased renal blood flow measured by TEE."
3027786|NCT02376699|Experimental|IV Monotherapy in Solid Tumors|SEA-CD40 administered IV
3027787|NCT02376699|Experimental|IV Monotherapy in Lymphomas|SEA-CD40 administered IV
3027788|NCT02376699|Experimental|Combination Therapy in Solid Tumors|SEA-CD40 (administered IV) + pembrolizumab
3027789|NCT02376699|Experimental|SC Monotherapy in Solid Tumors|SEA-CD40 administered SC
3027790|NCT02376699|Experimental|SC Monotherapy in Lymphomas|SEA-CD40 administered SC
3027791|NCT02376686|Experimental|Music intervention|Patient receives Music Intervention before going to sleep.
3027792|NCT02376686|No Intervention|treatment as usual|Patient receives Treatment as usual.
3027793|NCT02376673|Active Comparator|Brochures|Mothers in this arm will receive safe sleep education from home visitors using standard brochures (including 1-page handouts and pamphlets) that are customarily used in this home visiting program.
3027794|NCT02376673|Experimental|Children's Book|Mothers in this arm will receive safe sleep education from home visitors using a specially-designed children's book incorporating American Academy of Pediatrics safe sleep guidelines.
3027795|NCT02376660|Experimental|Oats|70 grams oats
3027796|NCT02376660|Placebo Comparator|usual diet and exercise|usual diet and exercise
3027797|NCT02376647|Experimental|Driving pressure limited ventilation|Driving pressure limited ventilation (≤13cmH2O)
3027798|NCT02376647|Active Comparator|Conventional ventilation|Mechanical ventilation with limited tidal volume (8mL/kg of predicted body weight) and plateau pressure (≤30cmH2O)
3027799|NCT02376634|Active Comparator|Hypnosis|"The hypnosis group will receive a semi-structured intervention by primary investigator. The intervention is somewhat individualized based on the recipients personal characteristics (e.g., age, gender, medical history). The intervention will begin with an induction phase during which the participant is guided to relax and to focus their attention on one stimuli. The intervention will then proceed with a suggestion phase. Suggestions used in this phase will all be directed toward decreasing the patient's anxiety and post-operative pain. Patients will be taught self-hypnosis to decrease distress and reframe painful experiences."
3027800|NCT02376634|No Intervention|Control|This group will receive the standard of care of Nationwide Children's Hospital.
3027801|NCT02376621|Active Comparator|PronovaPure 150:500 triglycerides|3 × PronovaPure 150:500 triglycerides (TG) European Union (EU)
3027802|NCT02376621|Active Comparator|Pronovum PRF-048|3 × Pronovum PRF-048
3027803|NCT02376621|Active Comparator|Pronovum PRF-037|3 × Pronovum PRF-037
3027804|NCT02376621|Active Comparator|PronovaPure 500:200 TG|3 × PronovaPure 500:200 TG EU
3027805|NCT02376621|Active Comparator|Pronovum PRF-047|3 × Pronovum PRF-047
3027806|NCT02376608|Active Comparator|Pronova Pure 150:500 EE EU|2 × PronovaPure 150:500 EE EU
3027807|NCT02376608|Active Comparator|Pronovum PRF-037|2 × Pronovum PRF-037
3027808|NCT02376608|Active Comparator|Pronovum PRF-041|2 × Pronovum PRF-041
3027809|NCT02376608|Active Comparator|Eskimo-3|3 × Eskimo-3
3027810|NCT02376595||Rocuronium Bromide|Rocuronium 0,3 mg/kg administered in less than five seconds, followed by a saline bolus.
3027811|NCT02376582|Experimental|DNA and protein|4mg DNA and 600 mcg protein formulated with Alum co-administration (IM) at Month 0, 1 and 6 in Schisto infected individuals
3027812|NCT02376582|Active Comparator|Vaccination without S. mansoni infection|DNA Protein
3027813|NCT02376556||Blepharoplasty|patients undergoing upper eyelid blepharoplasty
3027814|NCT02376556||blepharoplasty and muller muscle resection|patients undergoing a combined blepharoplasty and muller muscle resection surgery
3027815|NCT02376543|Active Comparator|19 Gauge EUS FNA BNX|Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 19 gauge technique (ARM 1) of EUS guided fiducial marker technique.
3027816|NCT02376543|Active Comparator|22 Gauge EUS FNA BNX|Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 22 gauge technique (ARM 2) of EUS guided fiducial marker technique.
3027817|NCT02376530|No Intervention|Usual shopping|No change in condition.
3027818|NCT02376530|Experimental|Nutrient profiling|Nutrient profiling system will be present during shopping session.
3027819|NCT02376530|Experimental|Price change|Price changes will be present during shopping session.
3027820|NCT02376530|Experimental|Nutrient profiling and price change|Nutrient profiling system and price changes will be present during shopping session.
3027821|NCT02376517|Active Comparator|Educational program|Participants randomized to the intervention group will receive the educational program at the baseline visit.
3027822|NCT02376517|No Intervention|Control|Participants randomized to the control group will receive the educational program at the follow-up visit.
3027823|NCT02376504|Experimental|Treadmill workstation|Participants will be provided with a treadmill workstation to be more active at the workplace Active Workplace
3027824|NCT02376504|Experimental|Sit-to-Stand workstation|Participants will be provided with a sit-to-stand workstation to be decrease sitting time at the workplace Active Workplace
3027825|NCT02376504|No Intervention|Control|Participants will be asked to engage in three 10 min walking bouts each work day
3027826|NCT02376491|Active Comparator|High Frequency Left repetitive|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4 weeks Magventure Cool B65 Coil with Magpro X100
3027827|NCT02376491|Experimental|intermittent Theta Burst Stimulation (iTBS)|intermittent Theta Burst Stimulation (iTBS) five days per week for 4 weeks Magventure Cool B65 Coil with Magpro X100
3027828|NCT02376478||TNF-alpha inhibitors|TNF-alpha Inhibitors: patients with psoriasis or inflammatory bowel diseases under TNF-alpha inhibitor monotherapy
3027829|NCT02376478||Purine/folic acid analogues|Purine/folic acid analogues: patients with psoriasis or inflammatory bowel diseases receiving monotherapy with purine or folic acid analogues, such as azathioprin, 6-mercaptopurine, or methotrexate
3027830|NCT02376478||Combination therapy|Combination therapy: patients with psoriasis or inflammatory bowel diseases receiving combination therapy with TNF-alpha blocker plus purine or folic acid analogues
3027831|NCT02376478||Alternative/no medication|Alternative/no medication: patients with psoriasis or inflammatory bowel diseases receiving alternate therapy, such as phototherapy, fumaric acid, mesalazine, or no medication
3027832|NCT02376465|Experimental|BLI4600 Regimen 1|Oral bowel preparation for colonoscopy
3027833|NCT02376465|Experimental|BLI4600 Regimen 2|Oral bowel preparation for colonoscopy
3027834|NCT02376465|Active Comparator|PEG based below preparation|Oral bowel preparation for colonoscopy
3027835|NCT02376452|Experimental|RALIRI|Raltitrexed combined with irinotecan
3027836|NCT02376452|Placebo Comparator|FOLFIRI|5-fluorouracil,folinate combined with irinotecan
3027837|NCT02376439||Siblings|Siblings will consume four test meals after 4 different exposures, including two types of koolaid, a control and a smell condition.
3027838|NCT02376426|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
3027839|NCT02376426|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
3027840|NCT02376426|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
3027841|NCT02376426|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
3027842|NCT02376413||Traditional BCS|Breast-conserving surgery. Modified radical mastectomy.
3027843|NCT02376413||Oncoplastic-BCS|"Breast-conserving surgery. Modified radical mastectomy. Oncoplastic-BCS based on surgeon preference and/or tumor location.~Superior pedicle mammoplasty / inverted T~Superior pedicle mammoplasty / V scar~Batwing~Inferior pedicle mammoplasty~Racquet mammoplasty/radial scar~vertical-scar mammoplasty"
3027844|NCT02376400|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
3027845|NCT02376400|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
3027846|NCT02376400|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
3027847|NCT02376400|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
3027848|NCT02376374|Experimental|10% OPV|In this arm, 10% of the households in this community will receive OPV.
3027849|NCT02376374|Experimental|30% OPV|In this arm, 30% of the households in this community will receive OPV.
3027850|NCT02376374|Experimental|70% OPV|In this arm, 70% of the households in this community will receive OPV.
3027851|NCT02376361|Active Comparator|Surveillance Group|Monthly blood flow surveillance by ultrasound dilution technique and standard of care.
3027852|NCT02376361|No Intervention|Control Group|Control group will receive standard monitoring (standard care).
3027853|NCT02376348|No Intervention|Control|Individuals receiving the standard Ministry of Health Package
3027854|NCT02376348|Experimental|Intervention|Individuals receiving the targeted demand creation strategy to increase adult men taking up VMMC
3027855|NCT02376335|Active Comparator|Rituximab infusion|Participants will be randomised to Rituximab therapy (1000 mg IV on days 1 and 15) or placebo (0.9% Sodium Chloride 250mls) control.
3027856|NCT02376335|Placebo Comparator|Placebo infusion|Participants will be randomised to Rituximab therapy (1000 mg IV on days 1 and 15) or placebo (0.9% Sodium Chloride 250mls) control.
3027857|NCT02376322|Experimental|Radiotherapy in bone metastases|The purpose of this one armed, phase II trial is to determine the efficacy and safety profile of a hypofractionated radiotherapy regimen, 16 Gy in 2 fractions with an interval of one week, for the palliation of complicated bone metastases in patients with poor performance status.
3027858|NCT02376309|Experimental|Leu during inactivity|Leucine supplements
3027859|NCT02376309|Experimental|ND during inactivity|Nandrolone injection
3027860|NCT02376296||hormone naïve|Subjects with hormone naïve metastatic prostate cancer that have high-volume disease and have been on androgen deprivation therapy for less than 120 days prior to starting docetaxel therapy.
3027861|NCT02376296||castrate resistant|Subjects with castrate resistant prostate cancer (CRPC) [defined as having evidence of prostate specific antigen (PSA) progression despite androgen deprivation therapy] that have had at least four weeks elapse between the withdrawal of anti-androgens (Bicalutamide, Flutamide or Nilutamide) and the initiation of docetaxel therapy.
3027862|NCT02376283|Other|STEMI prasugrel|Patients with diabetes mellitus admitted with STEMI who are under 75 years of age and greater than 60Kg in weight receiving Prasugrel Loading (60mg) and maintenance (10mg per day).
3027863|NCT02376283|Other|STEMI clopidogrel|Patients admitted with STEMI over the age of 75 or under 60 Kg receiving clopidogrel loading (600 mg) and then maintenance (75mg per day).
3027864|NCT02376283|Other|NSTEMI clopidogrel|Patients admitted with NSTEMI/UA over the age of 75 or under 60 Kg receiving clopidogrel loading (600 mg) and then maintenance (75mg per day).
3027865|NCT02376283|Other|Patients with NSTEMI|who are under 75 years of age and greater than 60Kg in weight receiving Prasugrel loading (60mg) however: - i. After sample collection patients treated with intracoronary stent placement on the same day as loading will receive prasugrel maintenance dose (10mg per day) as per licensing agreement for prasugrel ii. After sample collection patients who are not stented after loading will receive clopidogrel maintenance dose (75mg per day).
3027866|NCT02376283|Other|Patients admitted with STEMI receiving ticagrelor loading|Patients admitted with STEMI receiving ticagrelor loading (180 mg) and then maintenance (90mg bd per day)
3027867|NCT02376283|Other|Patients Admitted with NSTEMI receiving ticagrelor loading|Patients Admitted with NSTEMI receiving ticagrelor loading (180 mg) and then maintenance (90mg bd per day).
3027868|NCT02376270|Experimental|Pectin|This group will receive 7.5 grams of pectin supplements twice daily for four weeks.
3027869|NCT02376270|Placebo Comparator|Maltodextrin|This group group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
3028028|NCT02375178|Experimental|chlorhexidine|chlorhexidine 0,12% mouthwash
3027871|NCT02376257|Active Comparator|100 mg modafinil|Baseline assessment (week 1), two weekly sessions when 100 mg modafinil is administered, and final week (week 4) when retention is assessed.
3027872|NCT02376257|Placebo Comparator|Placebo|Baseline assessment (week 1), two weekly sessions when placebo is administered, and final week (week 4) when retention is assessed.
3027873|NCT02376244|Experimental|High intensity interval training (HIIT)|"Patients will undergo a 15-minute warm-up, followed by a 24-minute conditioning phase, and a 10-minute cool-down. The conditioning phase will include a combination of aerobic exercise (e.g. cycling or walking) and resistance exercise (e.g. squats, bicep curls). Patients will complete 5 intervals of 3 minutes with 2 minute rest periods interspersed. The intensity will correspond to 16-17 on the Borg 6-20 Rating of perceived exertion scale.~Patients will exercise once a week for 8 weeks."
3027874|NCT02376244|Active Comparator|Standard Care|"Patients assigned to this group will participate in usual standard care of cardiac rehabilitation.~Commonly, patients will undergo a 15-minute warm-up, followed by a 24-minute conditioning phase, and a 10-minute cool-down. The conditioning phase will include a combination of aerobic exercise (e.g. cycling or walking) and resistance exercise (e.g. squats, bicep curls). Patients will complete 5 intervals of 3 minutes with 2 minute rest periods interspersed. The intensity will correspond to 11-15 on the Borg 6-20 Rating of perceived exertion scale.~Patients will exercise once a week for 8 weeks."
3027875|NCT02376231|No Intervention|Standard Surgery without trial (PJ) device|Standard debulking surgery for EOC without interventional device
3027876|NCT02376231|Active Comparator|Surgery with trial (PJ) device|Debulking surgery for EOC with interventional trial device (PJ)
3027877|NCT02376218|Experimental|Hypertonic 50% dextrose pleurodesis|
3027878|NCT02376205|Experimental|bupivacaine hydrochloride 0.5% solution|Bupivacaine hydrochloride 0.5% 10 mL solution poured into the retropharyngeal space intraoperatively before wound closure during anterior cervical discectomy and fusion procedure
3027879|NCT02376205|Placebo Comparator|0.9% NaCl solution|0.9% NaCl 10 mL solution poured into the retropharyngeal space intraoperatively before wound closureduring anterior cervical discectomy and fusion procedure
3027880|NCT02376192|Experimental|Bolus Phenylephrine/Ephedrine Treatment'|Initial MicroScan® (Microvision Medical) SDF measurement are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia. In the operating room participants will receive a standard spinal anesthetic (hyperbaric bupivacaine, fentanyl and preservative free morphine) followed by a second comparative MicroScan® (Microvision Medical) SDF measurement within 10 minutes of initiation of spinal anesthetic. Participants who experience hypotension will receive bolus phenylephrine and/or ephedrine treatment as needed.
3027881|NCT02376192|Experimental|Phenylephrine Infusion Group|Initial MicroScan® (Microvision Medical) SDF measurement are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia. In the operating room participants will receive a standard spinal anesthetic (hyperbaric bupivacaine, fentanyl and preservative free morphine) followed by a second comparative MicroScan® (Microvision Medical) SDF measurement within 10 minutes of initiation of spinal anesthetic. Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
3027882|NCT02376179||Cuff ETT|
3027883|NCT02376166|Experimental|Metformin|850 mg PO once daily for 4 weeks
3027884|NCT02376153|Experimental|ABS deployed and active|Air Barrier System (ABS) will be deployed onto the surgical field and activated.
3027885|NCT02376153|Sham Comparator|ABS deployed and NOT active|Air Barrier System (ABS) will be deployed onto the surgical field and NOT activated. This is a sham comparator to reduce the influence of the presence of the device and provide user blinding.
3027886|NCT02376140||Women|Mothers of children 36-59 months old No intervention
3027887|NCT02376140||Children|Children 36-59 months old No intervention
3027888|NCT02376127||pts with known spinal metastases|(20 patients from any solid cancer) who are to undergo radiation treatment (RT) will be recruited. The patients will undergo DCE-MRI before and after RT. RT will be classified as success based on evidence of tumor contraction on conventional MRIs, negative PET, or stability for more than 11 months and blinded from DCE MRI sequencing. For each patient, a scanning profile for the first scan will be saved and used for the follow-up scans to acquire the same locations over time. Each patient will be scanned 4 times (one pre-treatment and 3 follow up post treatment) during their consecutive clinical visits. The DCE MRI sequence is a part of MR sequences for standard care. No additional scans will be added in the standard clinical sequences.
3027889|NCT02376114|Other|Ginkgo-Placebo|Patients receive Ginkgo biloba and then placebo afterwards.
3027890|NCT02376114|Other|Placebo-Ginkgo|Patients receive placebo and then Ginkgo biloba afterwards.
3027891|NCT02376101|Active Comparator|Standard ETT size|Their tracheas will be intubated with an appropriately sized ETT using the standard formula. The cuff will be inflated to achieve a seal by the air-leak test when holding CPAP of 20 cmH2O and the intracuff pressure will be measured using a manometer.
3027892|NCT02376101|Experimental|ETT one size smaller|Their tracheas will be intubated with an ETT that is one size smaller (instead of a 5.0 ETT, we would use a 4.0 ETT). The cuff will be inflated to achieve a seal by the air-leak test when holding CPAP of 20 cmH2O and the intracuff pressure will be measured using a manometer.
3027893|NCT02376088||GA1|subjects from coastal areas who initiated Methimazole treatment for the first time on enrollment
3027894|NCT02376088||GA2|subjects from coastal areas who were under Methimazole treatment and with an elevated TH level
3027895|NCT02376088||GA3|subjects from coastal areas who were under Methimazole treatment and with a normal TH level
3027896|NCT02376088||GB1|subjects from non-coastal areas who initiated Methimazole treatment for the first time on enrollment
3027897|NCT02376088||GB2|subjects from non-coastal areas who were under Methimazole treatment and with an elevated TH level
3027898|NCT02376088||GB3|subjects from non-coastal areas who were under Methimazole treatment and with a normal TH level
3027899|NCT02376088||NC|age-matched healthy checkup subjects
3027900|NCT02376075|Placebo Comparator|Placebo|Placebo, tablets, administered once daily as add on to pre-existing antihypertensive treatment
3027901|NCT02376075|Active Comparator|Linagliptin|Linagliptin, tablets containing 5 mg, administered once daily as add on to pre-existing antihypertensive treatment
3028002|NCT02375360||Parents 13-17 - OIT|Parents to teenagers aged 13-17 years with food allergy who are undergoing oral immunoterapy
3027902|NCT02376062|Experimental|Bundled Intervention|"On-site care coordinator and off-site psychiatric supervisors based in Nepal's capital, Kathmandu~Weekly case conferences~Surveys of clinicians and clinical supervisors in accordance with CME curriculum"
3027903|NCT02376049|Active Comparator|Pimecrolimus cream|Pimecrolimus 1% cream once daily for 14 days
3027904|NCT02376049|Active Comparator|Betamethasone dipropionate cream|Betamethasone dipropionate 0.05% cream once daily for 14 days
3027905|NCT02376049|Active Comparator|Clobetasol propionate cream|Clobetasol propionate 0.05% cream once daily for 14 days
3027906|NCT02376049|Placebo Comparator|Glaxal Base cream vehicle|Glaxal Base cream vehicle once daily for 14 days
3027907|NCT02376036|Experimental|MGD010|Subjects will receive MGD010 through IV infusion.
3027908|NCT02376036|Placebo Comparator|Placebo|Subjects will receive placebo through IV infusion.
3027909|NCT02376036|Experimental|MGD010 and HepA vaccine|Subjects will receive MGD010 through IV infusion and HepA vaccine through an IM injection.
3027910|NCT02376036|Placebo Comparator|Placebo and HepA vaccine|Subjects will receive placebo through IV infusion and HepA vaccine through an IM injection.
3027911|NCT02376023|Experimental|mHealth|Women in the mHealth group will receive text and voice messages, in addition to their habitual care from the health clinic they attend. The messages will remind them to schedule a PAP smear, and will be sent for 1 year following enrollment in the study.
3027912|NCT02376023|No Intervention|No mHealth|Women in the No mHealth group will not receive any text messages, and will only receive their habitual care from the health clinic they attend.
3027913|NCT02376010|Active Comparator|rivaroxaban|rivaroxaban will be given to this cohort, once daily orally (15 or 20 mg, depending on GFR)
3027914|NCT02376010|Active Comparator|warfarin|warfarin orally once a day, titrated to INR of 2-3
3027915|NCT02375997|Experimental|Standard oncology care plus palliative care|
3027916|NCT02375997|No Intervention|Standard oncology care|
3027917|NCT02375984|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro either as part of this treatment protocol or the JWCI procurement protocol. TIL from these cultures will be assessed for tumor-reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day X 2 days IV) and fludarabine (25 mg/m2/day IV X 5 days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 109 tumor-reactive lymphocytes (TIL) followed by high-dose intravenous IL-2 (600-720,000 IU/kg/dose every 8 hours for up to 12 doses).
3027918|NCT02375971|Experimental|Ranibizumab 0.2 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
3027919|NCT02375971|Experimental|Ranibizumab 0.1 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
3027920|NCT02375971|Active Comparator|Laser therapy|Laser treatment to each eye on Day 1 (Baseline), with supplementary treatments allowed
3027921|NCT02375958|Experimental|Triple Negative Breast Cancer|
3027922|NCT02375958|Experimental|Head and Neck Cancer|
3027923|NCT02375958|Experimental|Esophageal Cancer|
3027924|NCT02375945|Active Comparator|current compression stocking Comprinet®|"Immediately post operatively 24 hours compression therapy starts with Elastomull Haft ®, an elastic bandage, combined with a Comprinet stocking (BSM Medical®) for anti thrombotic purposes. The anti thrombosis stocking is worn 6 weeks post operatively. After 4 hours the patient is ambulated and the physical therapy starts."
3027925|NCT02375945|Experimental|New non-elastic compression kit|"Juxta Reduction Kit ® Immediately post operative compression starts with the Juxta Reduction Kit® for the knee region, combined with an anti thrombosis stocking (Struva 2, for prevention of trombo-embolism). Both the stocking and the Juxtra Pro are used for six weeks. After 4 hours the patient ambulated and the physical therapy starts.~For the first 24 hours and longer if necessary (depending on the skills of the patient) Juxta experienced staff will apply the device and the fit and the use of the device will be checked.~In the second phase between approximately 24 hours and 6 weeks patients may adjust the Juxta-pro according to their needs and comfort by themselves."
3027926|NCT02375932|Experimental|Pre-Visit Tool|Patients whose primary care physicians are allocated to the intervention arm will receive a secure electronic message shortly after scheduling an appointment with their provider asking them to complete a pre-visit prioritization survey using the kp.org patient portal
3027927|NCT02375932|Active Comparator|Usual Care Control|Patients whose primary care physicians are allocated to the control arm will continue with usual care
3027928|NCT02375919|No Intervention|Control|Emergency physician will assess low risk patients for PE with conventional strategy, using D-Dimer testing with subsequent CTPA if positive
3027929|NCT02375919|Other|Intervention|PERC based Strategy : Emergency physician will assess low risk patients for PE first with calculation of PERC score. If all PERC criteria are negative, then no further testing for PE is recommended. If at least one criterion is positive, then the patient undergoes D-Dimer testing with subsequent CTPA if positive
3027930|NCT02375893||Coronary patients|Feces, blood sample, clinical and biological data. Presence (1) of coronary disease defined as the presence of atheroma during the coronary angiogram
3027931|NCT02375893||Healthy subjects (2)|Feces, blood sample, clinical and biological data. Absence (2) of atheroma during the coronary angiogram
3027932|NCT02375880|Experimental|150 mg DKN-01 Part A|Patients will receive 150 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
3027933|NCT02375880|Experimental|300 mg DKN-01 Part A|Patients will receive 300 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
3027934|NCT02375880|Experimental|MTD mg DKN-01 Part B|Patients are treated at the maximum tolerated dose (MTD) of DKN-01 (or highest dose tested in Part A if the MTD is not defined) followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
3027935|NCT02375867|Active Comparator|prednisolone|This group includes patients with FHF without encephalopathy
3027936|NCT02375867|Active Comparator|methylprednisolone|This group includes patients with FHF with encephalopathy
3027937|NCT02375867|No Intervention|Non-intervention|FHF patients without any of the proposed intervention as controls
3027938|NCT02375854||Preterm infants|Less than 32 weeks' gestation
3027939|NCT02375841||Physicians, Patients, and Caregivers|This is a longitudinal study of patients with GBM with recurrent or multi-recurrent disease as determined by their neuro-oncologist (on the basis of clinical and/or radiological findings). Patients will indicate a single caregiver who will consent separately and perform separate assessments. The study assessments will evaluate the content of the discussion in which this change in disease status was communicated, as well as include patient-reported and caregiver-reported outcomes. We intend to accrue 160 total participants (80 patients and 80 caregivers) with complete post-discussion visit follow-ups over 18-24 months.
3027940|NCT02375828|Experimental|Patients with neonatal diabetes|Patients with neonatal diabetes
3027941|NCT02375815|Experimental|Statin Choice Implementation|
3027942|NCT02375802|Experimental|Experimental|Liposuction will be done to extract 50-100 cc of adipose tissue which will be processed to obtain the stromal cells. The adipose-derived stromal cells will be injected into a fibrin sealant applicator and applied to the wound (intervention), Patients will receive 5.0x106 ASCs per cubic centimeter of wound area. The wound will be dressed with an occlusive dressing and soft silicone dressing. The dressing will remain in place for one week (minimally, 3 days). Follow-up will occur weekly for 6 weeks.
3027943|NCT02375802|Placebo Comparator|Control|Liposuction will be done to extract 50-100 cc of adipose tissue which will be processed to obtain the stromal cells and then stored for the duration of the study. The fibrin sealant will be applied to the wound without the additive stromal cells. The wound will be dressed as the experimental group, with an occlusive dressing and soft silicone dressing. The dressing will remain in place for one week (minimally, 3 days). Follow-up will occur weekly for 6 weeks.
3027944|NCT02375789|Active Comparator|Active RhinoChill|"Following the initial 30 days (and minimum of 2 separate migraine attacks) of data collection the patient will be trained in the use and self administration of the RhinoChill device.~At the onset of an acute migraine, the patient will insert the RhinoChill Migraine Intranasal catheters and commence a 10 minute treatment on the Low Flow setting of the device.~During this time the patient will complete the basic data record sheets to document current symptoms and changes in severity throughout the period of treatment and then at specific time points thereafter.~The patient remains in the trial until two separate migraines have been treated."
3027945|NCT02375789|Placebo Comparator|Placebo RhinoChill|"The same procedure will be followed for the placebo comparator as in the active comparator. The RhinoChill device looks identical and functions in a very similar way to the active device however through some minor design changes the device has been altered to provide a sufficient placebo treatment.~At the onset of an acute migraine headache the patient will insert the RhinoChill Migraine Intranasal catheters and the 10 minute treatment is commenced on Low Flow.~During this time the patient will complete the basic data record sheets to document current symptoms and changes in severity throughout the period of treatment and then at specific time points thereafter.~The patient remains in the trial until two separate migraines have been treated."
3027946|NCT02375776|Experimental|Intervention|Download and use mobile health application - CORA- Device:smartphones for 12 weeks.
3027947|NCT02375776|No Intervention|Control|Usual Care - The control group will not use the study's mobile health application during the study.
3027948|NCT02375763|Experimental|Sortware suggestions|Children will fill a questionnaire regarding their dietary habits. Afterwards a dietary analysis will be performed using a computer software, and dietary instructions will be given to the children.
3027949|NCT02375763|Placebo Comparator|Traditional suggestions|
3027950|NCT02375750|Experimental|GBO and GBG|0.2 g-0,5 g GBO and 1 GBG once after decontamination of implant surface
3027951|NCT02375750|Active Comparator|Standard treatment|Decontamination of surface of implant
3027952|NCT02375737|Experimental|m-health|Patients will receive text message, emails, and monthly phone calls
3027953|NCT02375724|Experimental|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg twice daily by inhalation
3027954|NCT02375724|Placebo Comparator|Placebo|placebo twice daily by inhalation
3027955|NCT02375711|Experimental|Chronic Renal Failure|Patients with renal failure, with creatinine clearance between 60 and 15 ml/min. A blood sample is achieved at 0, 1, 3 and 6 months.
3027956|NCT02375698|Experimental|Gr 1 H56:IC31 5/500|5ug H56 + 500 ug IC31
3027957|NCT02375698|Placebo Comparator|Placebo|The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4.
3027958|NCT02375685|Experimental|gevokizumab|
3027959|NCT02375672|Experimental|Pembrolizumab (MK-3475) + mFOLFOX6|"Following the safety run-in cohort:~mFOLFOX6 Treatment D1 and D15 (every 2 weeks); Pembrolizumab (MK-3475) IV over 30 minutes (every 3 weeks)"
3027960|NCT02375659||Focus group|Each focus group (4 total) will be approximately 90 minutes in duration. A trained facilitator will pose 8 scripted questions to the focus group participants and manage the conversation, ensuring all participants have an opportunity to respond and steering the conversation to remain on task. A note-taker will also be present at the focus group to document via handwritten notes the flow and content of the focus group conversation. All focus groups will be audio taped and transcribed.
3027961|NCT02375646|Experimental|Continued Warfarin|continuous Warfarin therapy (aiming for therapeutic INR: 2-3) will be given throughout the study
3027962|NCT02375646|Active Comparator|LMW Heparin|Enoxaparin 1mg/kg SC bid (adjusted to renal function) will be given 5 days before the colonoscopy while withholding therapy with Warfarin. The day after procedure Warfarin therapy will be added, and Enoxaparin stopped when therapeutic INR will be reached
3027963|NCT02375633|Experimental|DW-330SR2|DW-330SR(Pelubiprofen) 45mg twice a day
3027964|NCT02375633|Active Comparator|Pelubiprofen|Active Comparator(Pelubiprofen) 30mg three times a day
3027965|NCT02375620|Experimental|PEG-somatropin: Low dose|0.1 mg/(kg.w), once per week for 52 weeks.
3027966|NCT02375620|Experimental|PEG-somatropin: High dose|0.2 mg/(kg.w), once per week for 52 weeks.
3027967|NCT02375607|Other|Algometer|Algometer used patients
3027968|NCT02375594|Experimental|Exercise in park equipment|Participants in the intervention arm will attend a 3-month long program of 2 weekly one-hour exercise sessions in the exercise park equipment, guided by a physical therapist. The sessions will comprise a combination of aerobic, strength, balance and flexibility exercises. Up to 20 participants exercising simultaneously in the equipment under the guidance of an experienced LAPPSET physical therapist.
3028003|NCT02375347|Experimental|Chickpea Enhanced Diet|Fed an enhanced Chickpea diet over a short term period (Chickpea Enhanced Diet Short Term)
3027969|NCT02375594|No Intervention|Control|Participants in the control arm will receive usual advice on healthy habits. During the study, they will be offered to attend the talks on healthy living for elderly periodically organised by their primary care centre (CAP Vallcarca - Sant Gervasi). At the end of the study, they will be invited to an exercise session at the exercise park equipment, conducted by the study physical therapist.
3027970|NCT02375581|Experimental|Icotinib & Radiotherapy|Icotinib, 125mg, Po, Tid, during the course of radiotherapy; Thoracic radiotherapy, 50-60Gy, conventional fraction, 3D-CRT/IMRT.
3027971|NCT02375581|Active Comparator|Radiotherapy alone|Thoracic radiotherapy alone, 50-60Gy, conventional fraction, 3D-CRT/IMRT.
3027972|NCT02375568||103024-F|For patients who have an operation of total knee replacement, two removed tissues (synovial membrane and infrapatellar fat pad) will be collected for mesenchymal stem cell isolation.
3027973|NCT02375555|Experimental|Elotuzumab, lenalidomide, bortezomib, and dexamethasone|"Participants will receive therapy with the combination of lenalidomide, bortezomib, and dexamethasone and elotuzumab (E-RVD). Induction cycles (1 to 8) are 21-day cycles.~Elotuzumab will be administered by intravenous (IV) infusion~Bortezomib as a subcutaneous injection~Lenalidomide single daily oral dose~Dexamethasone as oral tablets and IV infusion~Stem cell mobilization will be performed for all subjects at the end of Cycle 4.~Subjects may elect to stop E-RVD Cycle 4 and proceed to autologous SCT. Subjects who do not proceed to SCT may receive 8 cycles of induction therapy.~- The maintenance schedule (28 days) will start after 8 cycles of induction regimen for subjects not proceeding with SCT, or after recovery from SCT for subjects proceeding with it.~Maintenance therapy with E-RVD will be administered to all patients, with the specific maintenance regimen determined by risk category."
3027974|NCT02375542||Cardiac Reoperation|Patients who have previously undergone a cardiac operation with the use of BioGlue and are now undergoing a reoperation
3027975|NCT02375529|Experimental|Single Incision Cholesystectomy (SILC)|Single Incision Laparoscopic Cholecystectomy (SILC): The umbilicus is grasped and a 2 cm vertical skin and fascial incision is performed. A multiport (TriPort®) is inserted under direct vision. Principles of cholecystectomy are the same as traditional laparoscopic cholecystectomy.
3027976|NCT02375529|Active Comparator|Four Ports Cholecystectomy (4PCL)|Four Ports Conventional laparoscopic cholecystectomy (4PCL): A 10mm supraumbilical incision is made and the pneumoperitoneum insufflated through a Veress needle. 4 ports are introduced: 2 of 10mm in supraumbilical and left flank and 2 of 5mm in epigastric and right flank.
3027977|NCT02375516|Experimental|Prevention Program|Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions.
3027978|NCT02375516|No Intervention|Control group|Youths assigned to the control arm will receive no intervention.
3027979|NCT02375503|Experimental|Calcium/Vitamin D|Dietary supplement distributed and consumed as one calcium and vitamin D fortified snack bar per day
3027980|NCT02375503|Placebo Comparator|Placebo|Placebo distributed and consumed as one isocaloric, unfortified snack bar per day
3027981|NCT02375490|Experimental|Intervention arm|The intervention arm will participate in Healthy Start.
3027982|NCT02375490|No Intervention|Control arm|Control arm will pursue daily activities at early childcare center as usual.
3027983|NCT02375477|Experimental|Health services research (isolation protocol education)|Residents and nurses are given an educational intervention on isolation protocols for diarrhea and enteric pathogens approved by Infection Control and covering their recommendations.
3027984|NCT02375451||Radioiodine|Patients with a history of childhood treatment with radioiodine will be assessed for symptoms of salivary function and measurement of saliva production. These data will be compared to a normal control group.
3027985|NCT02375451||Control|Patients who are similar in age to those in the Radioiodine group, but who did not recieve I-131 therapy.
3027986|NCT02375438||Cohort Group|Patients with a clinical presentation suggestive of mitochondrial cytopathy, in whom mitochondrial deletions above 20% have been found in muscle are considered eligible if they are older than 18 years and are willing and able to give written informed consent.
3027987|NCT02375438||Control Group|Twenty healthy individuals matched for age and gender will be included in the study and considered as controls.
3027988|NCT02375425||No contraceptive use|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
3027989|NCT02375425||levonorgestrel IUD|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
3027990|NCT02375425||paraguard IUD|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
3027991|NCT02375425||DMPA|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
3027992|NCT02375412||Pre-operative HRV group|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery.
3027993|NCT02375386|Experimental|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI (fMRI), Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
3027994|NCT02375386|Sham Comparator|Therapeutic touch|"Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI (fMRI), Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment."
3027995|NCT02375373||Observational Chickpea Diet|Observed long-term to study legume intake and GI health (Observational Chickpea Diet)
3027996|NCT02375360||Children 8-12- control|Children aged 8-12 years with food allergy who are not undergoing oral immunoterapy
3027997|NCT02375360||Parents 0-12 - control|Parents to children aged 0-12 years with food allergy who are not undergoing oral immunoterapy
3027998|NCT02375360||Children 8-12 - OIT|Children aged 8-12 years with food allergy who are undergoing oral immunoterapy
3027999|NCT02375360||Teenagers 13-17 - OIT|Teenagers aged 13-17 years with food allergy who are undergoing oral immunoterapy
3028000|NCT02375360||Adults >18 - OIT|Adults> 18 years with food allergy who are undergoing oral immunoterapy
3028004|NCT02375334||Observational (medical chart review)|Patient lab and visit dates are monitored by the Cancer Center ORIS and EPIC based systems during the 42 days of the concurrent temozolomide and radiation therapy.
3028005|NCT02375321|Experimental|Group A|Study Group: patients with OSA and depressive symptoms treated with CPAP and psychological support
3028006|NCT02375321|No Intervention|Group B|Control Group: patients with OSA and depressive symptoms treated with CPAP
3028007|NCT02375308|Experimental|Hypnotherapeutic Treatment|HDT (Hypnotherapeutic Treatment of Depression) focuses on the hypnotic activation and strengthening of individual resources, the use of regression techniques to rebuild positive and negative experiences and the development of positive imaginations for the future.
3028008|NCT02375308|Experimental|Cognitive Behavioral Treatment|ACDT (Activation-focussed Cognitive Treatment of Depression) focuses on psychoeducation, behavior activation, the use of cognitive techniques, and the improvement of social skills.
3028009|NCT02375295|Experimental|Arm A: 2 weeks Abx post PCNL|Oral antibiotics: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin are administered for 2 weeks at full dose.
3028010|NCT02375295|Active Comparator|Arm B: 12 weeks/3 months Abx post PCNL|Oral antibiotics: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin are administered for 2 weeks at full dose followed by a suppressive dose for another 10 weeks (total = 12 weeks or 3 months).
3028011|NCT02375282|Experimental|Ambulation Orderly Intervention|Patients that are in this group are those randomized to receive visits from the ambulation orderly (ambulation group). The patients in this group will receive the visits from the ambulation orderly in addition to the standard of care that occurs with the rest of the hospital and with the control group.
3028012|NCT02375282|No Intervention|Control Group|This is for the patients who are randomized to receive the standard care of Baystate Medical Center. The standard of care will be nurse-directed ambulation, as is currently done in all other nursing floors at Baystate Medical Center. Nurses will be instructed to walk with the patients as they did before the initiation of the ambulation orderly and as they do when the orderly is on vacation, at conferences, training, or away for illness. These patients will not receive visits from the ambulation orderly.
3028013|NCT02375269|Experimental|RIPC (Remote Ischemic Preconditioning)|Preoperatively in the operation theater a tourniquet will be applied to the left arm and RIPC will performed. Therefore the tourniquet will be insufflated to suprasystolic pressure levels for 5 minutes, followed by 5 minutes reperfusion (deflated). Three cycles are planned. Duration of the procedure is 30 minutes.
3028014|NCT02375269|No Intervention|Control|Preoperatively in the operation theater a tourniquet will be applied to the left arm. The tourniquet will not be insufflated. The tourniquet will be removed after 30 minutes.
3028015|NCT02375256|Experimental|AERAS-402|3 x10^10 viral particles per 0.5 mL suspended in 10 mM Tris buffer, 1 mM MgCl2, 75 mM NaCl, 5% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80), 0.1 mM EDTA, 10 mM l-histidine, 0.5% v/v ethanol and water. The dose volume administered was 0.5 mL.
3028016|NCT02375256|Active Comparator|Placebo|1.0 mL sterile vaccine buffer containing 10mM Tris buffer, 1 mM MgCl2, 75 mM NaCl, 5% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80), 0.1 mM EDTA, 10 mM l-histidine, 0.5% v/v ethanol and water. The dose volume administered was 0.5 mL
3028017|NCT02375243|Experimental|cases|children who receive midazolam 0.05 mg/kg/h + morphine 10 mcg/kg/h + dexmedetomidne 0.5 mcg/kg/h. Midazolam in administered until extubation, while morphine and dexmedetomidine are administered until removal of surgical drains.
3028018|NCT02375243|No Intervention|controls|standard care: children who receive midazolam 0.1 mg/kg/h + morphine 20 mcg/kg/h. Midazolam in administered until extubation, while morphine is administered until removal of surgical drains.
3028019|NCT02375230|Placebo Comparator|Control|"Control group~Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise."
3028020|NCT02375230|Active Comparator|MR SOPA|"Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. Each participant will receive five minutes of training at the start of each shift.~The educator will teach mask adjustment, and airway reposition. If either of these first steps is unsuccessful the participant will learn about mouth and nose suction, open mouth and increase of airway pressure. All participants will also learn and practice alternative airways placement including intubation and laryngeal mask airway placement."
3028021|NCT02375217|Active Comparator|Group 1 : (NS)|"Group 1 Drug combination:~patients receive half of the recommended dose of sugammadex plus dose of neostigmine~Sugammadex IV= -1 mg/kg( moderate NMB) or~2 mg/kg (deep NMB)~neostigmine IV = 50mcg/kg~glycopyrrolate 10 mcg/kg"
3028022|NCT02375217|Active Comparator|Group 2 : (S)|"patients receive Full recommended dose of sugammadex~Sugammadex IV= 2mg/kg (Moderate NMB) 4mg/kg ( Deep NMB)"
3028023|NCT02375204|Other|Arm A: TIP|"Patients will receive treatment for 4 cycles administered every 21 days.~Cycles 1-4 (1 cycle = 21 days)~paclitaxel 250 mg/m^2 IV over 24 hours on Day 1 including premedication as defined in the protocol (eg, dexamethasone, diphenhydramine and H2 blocker)~ifosfamide 1500 mg/m^2 IV daily on Days 2-5 with mesna protection as defined in the protocol~cisplatin 25 mg/m^2 IV daily on Days 2-5~pegylated G-CSF 6 mg subcutaneous on Day 6 or 7 or G-CSF as defined in the protocol on Days 6-18~Patients may commence with each Arm A cycle provided they meet the criteria as defined in the protocol."
3028024|NCT02375204|Other|Arm B: TI-CE|"Patients will receive treatment for a total of 5 cycles.~Cycles 1-2 (1 cycle = 14 days)~paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 including premedication as defined in the protocol (eg, dexamethasone, diphenhydramine and H2 blocker)~ifosfamide 2000 mg/m^2 IV daily on Days 1-3 with mesna protection as defined in the protocol~G-CSF 10 µg/kg subcutaneously on Days 3-15 (cycle 1) and Days 3-14 (cycle 2) or pegylated G-CSF 6 mg subcutaneous on Day 4 or 6 (cycle 1) and Day 4 or 5 (cycle 2)~leukapheresis every 14 days, if there is an inadequate number of CD34+ cells/kg collected in cycle 1~Cycles 3-5 (1 cycle = 21 days)~carboplatin daily on Days 1-3~etoposide 400 mg/m^2 daily on Days 1-3~stem cell reinfusion on day 5~pegylated G-CSF 6 mg subcutaneously or G-CSF at approximately 5 µg/kg daily on Days 5-15~Patients may commence with each Arm B cycle provided they meet the criteria as defined in the protocol."
3028025|NCT02375191|Active Comparator|fentanyl|0.2% ropivacaine+ 1 mcg/kg fentanyl
3028026|NCT02375191|Experimental|dexmedetomidine|0.2% ropivacaine+1 mcg/kg dexmedetomidine
3028029|NCT02375178|Experimental|polyhexamethylene|polyhexamethylene biguanide 0,07% mouthwash
3028030|NCT02375165||Cohort with lymphedema|Participants with a history of acquired lymphedema of at least 6 months' duration, will have tissue sampling (skin punch biopsy) of affected and unaffected tissue and phlebotomy for serum and plasma.
3028031|NCT02375165||Cohort without lymphedema, risk factors|Participants who have undergone medical treatment that places them at risk of developing lymphedema e.g. lymph node dissection, radiation treatment; will have phlebotomy for serum and plasma.
3028032|NCT02375165||Cohort without lymphedema|Healthy volunteers; will have phlebotomy for serum and plasma.
3028033|NCT02375152|Experimental|Surgical Intervention|
3028034|NCT02375139|Experimental|DA-1229_01 → E+M|DA-1229_01 : Evogliptin/Metformin XR 2.5/500mg x 2 Tablets E : Evogliptin 5 mg M : Metformin XR 1000 mg
3028035|NCT02375139|Experimental|E+M → DA-1229_01|DA-1229_01 : Evogliptin/Metformin XR 2.5/500mg x 2 Tablets E : Evogliptin 5 mg M : Metformin XR 1000 mg
3028036|NCT02375126||Ages 18-35, no antidepressant use|Ages 18-35, up to 15 males and 15 females, no antidepressant use
3028037|NCT02375126||Ages 36-55, no antidepressant use|Ages 36-55, up to 15 males and 15 females, no antidepressant use
3028038|NCT02375126||Ages 18-55, with antidepressant use|Ages 18-55, up to 10 males and 10 females, taking antidepressants
3028039|NCT02375113|Experimental|Intervention|Soy supplementation: Isoflavones 160 mg/day + 25 gram soy protein / day
3028040|NCT02375113|Placebo Comparator|Control|Placebo capsules + 25 gram whey protein / day
3028041|NCT02375100|Active Comparator|Intrathecal bupivacaine&analgesics|Patients will be given standard care during perioperative period. They will undergo inguinal herniorraphy operation under spinal anesthesia (with 3ml of %0.5 hyperbaric bupivacaine intrathecally) and receive an parenteral pain regimen (acetaminophen for intravenous infusion in two doses routinely and intramuscular tramadol 50 mg when pain score is higher than 4) in postoperative period.
3028042|NCT02375100|Experimental|TAP Block with bupivacaine|In addition to standard perioperative care (spinal anesthesia and parenteral pain regimen) patients will receive transversus abdominis plane block (with 20ml of %0.25 isobaric bupivacaine) just before surgery is initiated.
3028043|NCT02375100|Experimental|IlNB with bupivacaine|In addition to standard perioperative care (spinal anesthesia and parenteral pain regimen) patients will receive Ilioinguinal nerve block (with 20ml of %0.25 isobaric bupivacaine) just before surgery is initiated.
3028044|NCT02375074|Experimental|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
3028045|NCT02375074|Experimental|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment.
3028046|NCT02375061|Experimental|e-BPS intervention|"Participants are asked to write and imagine about a future in which they have reached all their goals in four different domains: personal, professional, social and health domain. They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero & Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform (TEO-Emotional Therapy Online) in which they can visualize all the content they had developed previously."
3028047|NCT02375061|Placebo Comparator|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
3028048|NCT02375048|Active Comparator|Hypofractionated WBI|Patients treated with hypofractionated Whole Breast Irradiation received Simultaneous Integrated Boost irradiation of the whole breast and surgical bed at two different dose levels using external intensity - modulated radiotherapy (VMAT RA).
3028049|NCT02375048|Experimental|Accelerated Partial Breast Irradiation|Patients treated with Accelerated Partial Breast Irradiation received the irradiation on surgical bed using external intensity - modulated radiotherapy (VMAT RA).
3028050|NCT02375022|Experimental|Endostar and icotinib|Combination of drug: Endostar: 15mg CIV d1-9, Q3w and icotinib: 125mg TID po. If no progressive disease observed, combination treatment will continue until unacceptable toxicity or progressive disease.
3028051|NCT02375009|Experimental|Treatment Cohort|All subjects will receive bilateral 360 degree Selective Laser Trabeculoplasty therapy in a single session, but will be randomized to one of three treatment sessions at times 0, Month 3 and Month 6. Subjects will be washed out of current IOP-lowering therapy 4-6 weeks pre-SLT. Subjects continuing on meds beyond time 0 will provide a comparator to early SLT to quantify regression to the mean.
3028052|NCT02374996||APIGT|Bipolar subjects treated with antipsychotics and having impaired glucose tolerance
3028053|NCT02374996||APNGT|Bipolar subjects treated with antipsychotics and having normal glucose tolerance
3028054|NCT02374996||LINGT|Bipolar subjects treated with lithium and having normal glucose tolerance
3028055|NCT02374983||Research group|The group will consist of 100 patients (200 observations) receiving Gamma Knife treatment. Radiosurgery treatments will be re-planned using the convolution algorithm and compared to the TMR plans used to treat the patients.
3028056|NCT02374970|Experimental|Intervention group|Actual Lumbar stability exercises involving co-contraction of the transversus abdominis and Protocolized Physiotherapy (therapeutic exercises and thermotherapy during 12 sessions)
3028057|NCT02374970|Active Comparator|Control group|Protocolized Physiotherapy treatment: therapeutic exercises and thermotherapy during 12 sessions.
3028058|NCT02374957|Active Comparator|Cilostazol|Administer Cilostazol100 mg twice daily for 90 days.
3028059|NCT02374957|No Intervention|Control|No Cilostazol
3028060|NCT02374944|Experimental|Hardware Removal|Removal of hardware at 6 months.
3028061|NCT02374944|No Intervention|Hardware Retention|Retention of hardware at 6 months
3028062|NCT02374931|Experimental|Diagnostic (18F-FES PET/CT)|Patients undergo 18F-FES PET/CT imaging over 30 minutes.
3028063|NCT02374918|Experimental|mTBI wavelength-1 bright light|30 minutes daily light exposure for 6 weeks
3028064|NCT02374918|Placebo Comparator|mTBI wavelength-2 bright light|30 minutes daily light exposure for 6 weeks
3028065|NCT02374918|Experimental|HC wavelength-1 bright light|30 minutes of light exposure
3028066|NCT02374918|Placebo Comparator|HC wavelength-2 bright light|30 minutes of light exposure
3028067|NCT02374905|Experimental|Drinksmeter|Web-based application delivering Identification and Brief Advice of Alcohol Use
3028068|NCT02374905|Active Comparator|Brief Advice of Alcohol Use|Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
3028069|NCT02374892|Experimental|Intervention|"Adolescents will attend a single one-on-one session with a nurse. Sessions will be youth-oriented, interactive, and engaging. They will make a health passport, go over their cardiac anatomy, watch videos among other things.~The adolescent will be given a study email address and encouraged to contact the nurse by email or text messaging with follow-up."
3028070|NCT02374892|No Intervention|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies.
3028071|NCT02374879|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
3028072|NCT02374866|No Intervention|Conventional monitoring|The control group will follow the current center: every four months for a year, combined with monitoring by email or regular mail during the year.
3028073|NCT02374866|Experimental|Closer monitoring|"The experimental group will follow a closer monitoring than the control group : every two months for one year in,stead of every 4 months for a year.~Follow by email or mail is identical to the control group."
3028074|NCT02374853|Experimental|Vancomycin|During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in the following solution: 5 g vancomycin dissolved in 50 mL sterile water
3028075|NCT02374853|Placebo Comparator|Control|During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in 50 mL sterile water. No Vancomycin
3028076|NCT02374827|Active Comparator|Standard postpartum tubal ligation|In this arm, patients will receive the standard postpartum tubal ligation by accepted methods (procedure names are the following: Modified pomeroy technique or Parkland method). These methods are procedures for completing a partial salpingectomy.
3028077|NCT02374827|Experimental|Complete Salpingectomy|In this arm, patients will receive a complete salpingectomy by documented accepted methods.
3028078|NCT02374814|Active Comparator|Rabies vaccine IM 3 dose|This is standard FDA approved schedule
3028079|NCT02374814|Experimental|Rabies vaccine ID 3 dose|This is using alternative administration method
3028080|NCT02374814|Experimental|Rabies vaccine IM 2 dose|This is using alternative dose schedule
3028081|NCT02374814|Experimental|Rabies vaccine ID 2 dose|This is using alternative dose schedule and administration
3028082|NCT02374814|Placebo Comparator|Placebo IM 1 dose|Albumin and saline comparator
3028083|NCT02374814|Placebo Comparator|Placebo ID 1 dose|Albumin and saline comparator
3028084|NCT02374801|Experimental|Treatment|"This is a single-arm trial. All patients will be implanted with the PARADYM RF SONR CRT-D device and the SonRtip bipolar atrial lead. After successful implant, all patients will be programmed with the SonR automatic optimization feature turned ON (AV+VV)."
3028085|NCT02374788|Experimental|Group A|Participants in the intensive intervention group (A) receive a pedometer intervention and 12 group meetings over two years' time, with the majority of meetings being held in the first 6 months. The group meetings constitutes of a 30 min walk and 60 min group consulting based on techniques for behaviour change using an interactive program with positive feed-back following their steps on a website. One occasion is taking place at a gym with instruction for a home-based strength training program. Participants receive 10 individual consultations with a diabetes specialist nurse.
3028086|NCT02374788|Experimental|Group B|Participants in the pedometer group (B) receive a pedometer intervention. Henceforth they are left to continue by they own for two years.
3028087|NCT02374788|No Intervention|Group C|The control group (C) receive diabetes care as usual except for the extra measurements included in the study. Diabetes care as usual is meeting a diabetes specialist nurse and a general practitioner once a year receiving lifestyle advice and physical activity on prescription.
3028088|NCT02374775||Group A (Culprit lesion)|The plaque in the culprit vessel of acute myocardial infarction will be defined the Group A.
3028089|NCT02374775||Group B (Non-culprit lesion)|The plaque in the non-culprit vessel of acute myocardial infarction will be defined as internal control, Group B.
3028090|NCT02374762||Hemodialysis Patients with AVF|Hemodialysis patients that use an arteriovenous fistula (AVF) to receive their dialysis treatments will be invited to have their AVF recorded by a digital camera for one minute prior to cannulation.
3028091|NCT02374749|Active Comparator|comorbidities|Evaluation of the prevalence and the presence of the risks factors of the four most frequently observed comorbidities in spondyloarthritis (cardiovascular diseases, cancers, infections osteoporosis and gastro-intestinal) as it is recommended by the French Society of Rheumatology.
3028092|NCT02374749|Active Comparator|self-assessment|"During the initial visit, the clinical research nurse exempt a learning program of assessment of disease activity/severity :~for assessing the activity in SpA;~for the calculation of BASDAI and the ASDAS-CRP~for the transfer technique and for the calculation of the disease activity on a monthly basis during the next 12 months.~for the risk of tobacco exposure~for the benefit of an NSAID intake in case of painful episode of the disease~for the benefit of home exercises~for the spine and indication of a treatment under the supervision of a physiotherapist in case of severe disease~for learning the patient to calculate his BASDAI and ASDAS-CRP Then, the patient will return home with his calculator and his notebook. Each month, the patient will be asked to perform the BASDAI and ASDAS-CRP calculations and to report the data on the notebook. 12 months later, the patient comes for a visit in the current practice to assess both such program and comorbidities."
3028155|NCT02374281|Experimental|Glucose sucking|"The newborn will receive one minute before the painful care either a compress with sucrose.~The puncture made in the veins of the back of the hand, will be performed only once per patient per test.~Glucose 30% by oral route (1 ml)."
3028156|NCT02374281|Active Comparator|Water sucking|"The newborn will receive one minute before the painful care either a compress with water.~The puncture made in the veins of the back of the hand, will be performed only once per patient per test.~Sterile water by oral route (1 ml)."
3028093|NCT02374736|Experimental|Human normal immunoglobulin G (IgG > 98 % purity)|"All subjects will be treated for 6 months. The treatment will start the day of inclusion (M0).~Privigen will be given as 2 g/kg for 2 days/month. The maximum daily dose authorized will be 80g.~The infusion rates are the recommended rates for Privigen in other indications and are in line with the market authorization for Privigen:~Infusions should start at a rate of 0.5 mg/kg/min (0.005 mL/kg/min; 0.3 mL/kg/h; 30 mg/kg/h). If well tolerated within 30 min, the rate can be increased in a first step to 1.0 mg/kg/min (0.01 mL/kg/min; 0.6 mL/kg/h; 60 mg/kg/h) for another 30 min.~If well tolerated, a stepwise increase to a maximum of 8 mg/kg/min (0.08 mL/kg/min; 4.8 mL/kg/h; 480 mg/kg/h) is allowed at the discretion of the investigator."
3028094|NCT02374723|Experimental|NuCornea (Biosynthetic corneas)|6 patients will receive biosynthetic corneas when undergoing corneal transplantation
3028095|NCT02374723|Active Comparator|Donated human corneas|6 patients will receive a donated human cornea when undergoing corneal transplantation
3028096|NCT02374710|Experimental|ACL Reconstruction: Anterior Tunnel|During surgery prior to ACL reconstruction, a line will be measured to indicate 35% of the anterior-to-posterior (front to back) distance of the proximal tibia. The tibial tunnel will be placed anterior (in front) of the 35% line.
3028097|NCT02374710|Active Comparator|ACL Reconstruction: Posterior Tunnel|During surgery prior to ACL reconstruction, a line will be measured to indicate 35% of the anterior-to-posterior (front to back) distance of the proximal tibia. The tibial tunnel will be placed posterior (in back) of the 35% line.
3028098|NCT02374697||Before tele-expertise|Usual second opinion with pathological slides sent by mailing
3028099|NCT02374697||During Tele-expertise|Second opinion with tele-expertise
3028100|NCT02374684|Experimental|Methosulide|Methosulide, oral administration
3028101|NCT02374684|Placebo Comparator|Placebo|Placebo, oral administration
3028102|NCT02374671|Experimental|Treatment via Procedure/Surgery|The VisAbility Micro Insert treatment is for the improvement of near visual acuity in presbyopic patients. Subjects will receive the VisAbility Micro Inserts via a Procedure/Surgery.
3028103|NCT02374658|Experimental|Arts Intervention|This group will receive the weekly one-hour Living Through the Arts program in addition to their standard program of rehabilitation activities
3028104|NCT02374658|No Intervention|Control Group|This group of patients will only receive their standard program of rehabilitation activities
3028105|NCT02374645|Experimental|Volitinib 600mg + gefitinib 250 mg|Cohort 1: Volitinib（AZD6094） 600 mg od + gefitinib 250 mg od
3028106|NCT02374645|Experimental|Volitinib 800mg + gefitinib 250 mg|Cohort 2: Volitinib（AZD6094） 800 mg od + gefitinib 250 mg od
3028107|NCT02374632|Other|Low EBL|"Gastric bypass operated patients with low postoperative excess body weight loss (EBL) <50%.~Interventions: Meal tests after saline/octreotide injection in a randomized order, sham feeding."
3028108|NCT02374632|Other|High EBL|"Gastric bypass operated patients with high postoperative excess body weight loss (EBL) >70% matched with respect to age, gender and preoperative BMI in the LowEBL group.~Interventions: Meal tests after saline/octreotide injection in a randomized order, sham feeding."
3028109|NCT02374619|Experimental|Iron supplement|Oral supplementation
3028110|NCT02374619|Placebo Comparator|Control|Oral supplementation
3028111|NCT02374593|Experimental|Targeted dosing|Patients in this arm will receive targeted levothyroxine dosing based on thyroid anatomy on ultrasound as follows: 10 mcg/kg for normal gland, 12 mcg/kg for ectopic gland, 15 mcg/kg for athyreosis.
3028112|NCT02374567|Experimental|Psychiatric drugs|
3028113|NCT02374554|Other|Respiratory Rate Measurement Comparision|To demonstrate equivalence of the Thora-3Di Structured Light Plethysmography device and a Clinician Over-scored End Tidal C02 (COSC)derived from a BCI Capnograph 9004 (Smiths Medical) for measurement of Respiratory Rate
3028114|NCT02374541|Experimental|Patient Navigation|Assistance from Autism Patient Navigator (APN) to obtain diagnostic evaluation / eligibility determination for possible autism spectrum disorder and, if indicated, early intervention services.
3028115|NCT02374541|No Intervention|Control|Standard referral for diagnostic evaluation / eligibility determination for possible autism spectrum disorder and, if indicated, early intervention services.
3028116|NCT02374528|Experimental|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
3028117|NCT02374528|Active Comparator|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
3028118|NCT02374515|Active Comparator|Endocuff assisted Colonoscopy|Endocuff assisted Colonoscopy
3028119|NCT02374515|Active Comparator|Standard Colonoscopy|Standard colonoscopy
3028120|NCT02374502|Experimental|Brief Intervention Group|Participants in this intervention group will receive a twelve week 'Brief Intervention' delivered by a physiotherapist. Participants will have an initial consultation with a physiotherapist, followed by a number of follow-up sessions. The number and timing of follow-up sessions will be at the participant's discretion (a minimum of 3 and a maximum of 11 over the duration of the study). The follow-up sessions can be face-to-face, over the telephone, or video conferencing depending on participant preference. Participants may additionally opt-in for a weekly email or text message reminder of physical activity goals.
3028121|NCT02374502|No Intervention|Control Group|Participants in this control group will be asked to continue with their current levels of physical activity.
3028122|NCT02374489|Experimental|single-arm studies|"LDK378 in suitable patients:~Collect tumor tissue for immunohistochemistry staining to confirm the status of ROS1 or ALK expression. If the patient fits all criteria, LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle"
3028123|NCT02374476|Experimental|Bipolar Ablation|All patients who meet inclusion criteria and have VT not terminable with unipolar ablation will undergo bipolar ablation.
3028153|NCT02374294|Experimental|Epiflo|After the surgery, but before the application of dressing to the surgical site the kit containing the investigation device (and four cannula) is opened. The EPIFLO cannula (sterile package) is opened and applied to the surgical site and sealed with the dressings per protocol. The EPIFLO device is connected to the cannula after making sure the switch is in the ON position.The EPIFLO device is mounted on the patient's body in a convenient location using the Pouch and Arm band provided. At Treatment Visit 3 (Postoperative day #14, +/- 1 day) a new device is given and the old one disposed of. Intermittent dressing changes will take place as needed.
3028617|NCT02371356||Untreated (Depressed )|Screen positive for depression and receive no treatment.
3028124|NCT02374463|Experimental|MMBI|Multimodality Balance Intervention (MMBI): The Investigator's MMBI class will be held 3-times a week for an hour and will consist of a group dynamic balance class (30 minutes), a supervised obstacle course (10 minutes), and lower extremity and core strengthening (20 minutes). The group exercise classes will focus on dynamic weight shifts with an emphasis on the lateral and diagonal directions. Over the 6 months of class, the exercises will gradually increase in difficulty to challenge balance. A skilled instructor will lead each class and 1-2 assistants will be present to assist with fall risk prevention. The supervised obstacle course will focus on obstacle negotiation, gait over challenging surfaces, and moving in lateral, diagonal, and backward directions. Finally, strength training of the lower extremities and core will focus on strengthening major muscles of the lower extremity and core utilizing commonly available gym equipment, ankle weights and body weight.
3028125|NCT02374463|Active Comparator|Tai Chi|Tai Chi Intervention: The supervised Tai Chi class will be held 3-times a week for one hour. All Tai Chi classes will be taught in a group setting by an experienced instructor. The emphasis during the class will be on standing movements, body alignment, weight shift and changes of direction. Movements will be adapted as the class progresses to increase the difficulty of weight shift and change in direction over time so that participants balance is continually challenged throughout the 6 months. Chairs or hand rails will be available for the participants to use as needed for balance recovery.
3028126|NCT02374450|Other|Active and enhanced hospitalisation surveillance group|Children <18 months of age and living in the HDSS area (active surveillance group) and children <5 years of age and hospitalised at any time during the study, living in the HDSS area (enhanced hospitalisation surveillance group).
3028127|NCT02374437|Active Comparator|PART A (single dose)-200 mg|200 mg ARAMCHOL
3028128|NCT02374437|Active Comparator|PART A (single dose)-400 mg|400 mg ARAMCHOL
3028129|NCT02374437|Active Comparator|Part B ( food effect)- -Fasting|600 mg Aramchol tablets under fasting conditions (fasting for at least 10 hours before and 4 hours after dosing)
3028130|NCT02374437|Active Comparator|Part B ( food effect)- -Fed|600 mg Aramchol tablets under fed conditions (fasting for at least 10 hours before dosing, consumption of a high calorie high fat meal within 30 minutes prior to drug administration and no food for additional 4 hours after dosing)
3028131|NCT02374437|Active Comparator|Part C ( multiple doses)- 200 mg|200 mg Aramchol tablets for ten consecutive days.
3028132|NCT02374437|Active Comparator|Part C ( multiple doses)- 400 mg|400 mg Aramchol tablets for ten consecutive days.
3028133|NCT02374437|Active Comparator|Part C ( multiple doses)- 600 mg|600 mg Aramchol tablets for ten consecutive days.
3028134|NCT02374437|Placebo Comparator|Part C ( multiple doses)- Placebo|Placebo tablets for ten consecutive days.
3028135|NCT02374424|Experimental|GA101_DHAP|"Patients receive: GA101-DHAP x 2, restaging, mobilization and collection of peripheral blood stem cells, + GA101-DHAP x 2, restaging with PET and CT and consolidation with BEAM and ASCT in patients in response (CR+PR).~During the treatment period of four cycles, all patients will receive a total of four 28-day courses of chemotherapy."
3028136|NCT02374411||HIPEC surgeons|
3028137|NCT02374398|Active Comparator|Tranexamic Acid|TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes
3028138|NCT02374398|Active Comparator|Aquamantys System|The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts
3028139|NCT02374398|Active Comparator|TXA plus Aquamantys|"TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.~The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts."
3028140|NCT02374398|Placebo Comparator|Control|Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes
3028141|NCT02374385|Experimental|Group 1|1x10(5) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL
3028142|NCT02374385|Experimental|Group 2|5x10(5) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL
3028143|NCT02374385|Experimental|Group 3|3x10(6) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL.
3028144|NCT02374385|Placebo Comparator|Group 4|Group 4 will receive placebo (normal saline).
3028145|NCT02374372|Active Comparator|conventional hemodialysis|conventional hemodialysis
3028146|NCT02374372|Active Comparator|hemodiafiltration On-line|hemodiafiltration On-line
3028147|NCT02374359||atrial tachycardia group|Patients diagnosed of cryptogenic stroke with atrial tachycardia in holter
3028148|NCT02374359||Non atrial tachycardia group (control group)|Patients diagnosed of cryptogenic stroke with a normal holter
3028149|NCT02374333|Experimental|huCART19|CART19 cells transduced with a lentiviral vector to express humanized anti-CD19 administered by IV injection
3028150|NCT02374320|Experimental|Exparel|20 mL liposomal bupivacaine injected once
3028151|NCT02374307|Experimental|Exercise and education|This group will perform a 12-week individual tailored home exercise programme in accordance with the manual of Otaga exercise programme. Physiotherapist will visit the participants 5 times during the 12 weeks (at week 1,2,4,8 and 10) to prescribe and progress exercises. Motivational conversations on telephone will be performed the weeks when no visits are scheduled. Additionally, the participants will receive information on the first visit which will focus on motivation, importance of adherence and effectiveness of falls prevention. The participants are expected to do exercises on their own, and in that way perform exercises 3 times weekly. If safe, the participant will be provided with a walking plan and be encouraged to walk twice weekly.
3028152|NCT02374307|No Intervention|Control|The control group will perform activities as usual.
3028154|NCT02374294|No Intervention|Standard of Care|After the surgery, but before the application of dressing to the surgical site if upon opening, the kit contains only a weighted block, then, the regular wound dressing protocol, standard of care, will be followed. Intermittent dressing changes will take place as needed.
3058475|NCT02171780|Experimental|BI 1744 CL single rising doses|
3028157|NCT02374281|Placebo Comparator|No sucking|The puncture made in the veins of the back of the hand, will be performed only once per patient per test.
3028158|NCT02374268|Experimental|Exercise program alone|There will be 2 site sessions and 1 home session per week for 12 weeks. Each site exercise session will begin and end with a 5-10 minute warm-up and cool-down routine. The first part of the exercise program consists of 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body. To target the development of muscle power in both the lower and upper extremities, participants will be instructed to perform each concentric movement 'as rapidly as possible,' and the eccentric movement in a slow and controlled manner. A 5-minute rest period will be given prior to the start of the second part of the exercise program that consists of aerobic exercises such as ball games using fitballs or Taichi. Participants will be asked to spend an hour/week on home exercise. Thera-Bands and a leaflet showing the exercise procedures will be given to them and their caregivers.
3028159|NCT02374268|Experimental|Exercise program plus nutrition supplement|This group will receive both the exercise program as well as the nutrition supplement. The components of the exercise program will be same as those of the exercise program alone group. Participants will also be asked to consume two sachets of Ensure NutriVigor every day during the 12-week intervention period. Ensure NutriVigor (one sachet of 54.1 g powder) contains 231 calories, 8.61 g protein, 1.21 g hydroxyl-methyl-butyrate (HMB), 130 IU vitamin D, and 0.29 g omega 3 fatty acid per serving. Participants will be instructed on how to prepare the supplement.
3028160|NCT02374268|Other|Waitlist control group|This group will be asked to maintain their usual physical activities and dietary habits during the first 6 months of study period. After they complete the 24-week measurement, they will receive the same 12-week exercise program as of the exercise program alone group.
3028161|NCT02374255|Experimental|GoC intervention|Oncologists trained using OncoTalk to have Goals of Care discussions.
3028162|NCT02374255|No Intervention|Usual Care|
3028163|NCT02374242|Active Comparator|Cohort 1 Nivolumab Monotherapy|Nivolumab 3mg/kg every 2 weeks, until disease progression, withdrawn consent, unacceptable toxicity or death.
3028164|NCT02374242|Active Comparator|Cohort 2 Nivolumab Monotherapy|Nivolumab 3mg/kg every 2 weeks, until disease progression, withdrawn consent, unacceptable toxicity or death.
3028165|NCT02374242|Active Comparator|Cohort 3 Nivolumab and Ipilimumab|Nivolumab 1mg/kg every 3 weeks x four doses and ipilimumab 3mg/kg every 3 weeks x four doses. After 12 weeks, nivolumab 3mg/kg alone every 2 weeks until disease progression, withdrawn consent, unacceptable toxicity or death.
3028166|NCT02374229|Experimental|The study group|"Procedure: mitral valve surgery, surgical ablation of ganglion plexus pulmonary artery.~Will include 15 patients with mitral stenosis or insufficiency subject to correction, complicated by high pulmonary hypertension. During the operation, a standard surgical procedure for the treatment of heart valve disease will be complemented by the ablation zone of bifurcation of the pulmonary artery, surgical ablation of ganglion plexus pulmonary artery.~For mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement.~Procedure will be considered effective in the face of declining average pressure in the pulmonary artery for invasive monitoring of 10mm Hg and more."
3028167|NCT02374229|Active Comparator|The control group|"Procedure:mitral valve surgery. Will include 15 patients with mitral stenosis or insufficiency subject to correction, complicated by high pulmonary hypertension. Patients will be made standard procedure correction mitral valve disease without pulmonary artery denervation.~For mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement only."
3028168|NCT02374216|Other|Dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 and August 31st 2017
3028169|NCT02374203|Experimental|high protein enteral nutrition|supply protein over 1.5 gm/kg body weight
3028170|NCT02374190||Hospital Admitted AMI Patients|Patients admitted to hospital ('trust') for an acute coronary syndrome (ACS) within England and captured within the MINAP dataset. Final discharge diagnosis will be used to limit patient population to that with either a) an ST-segment elevation myocardial infarction (STEMI), or b) a non-ST-segment elevation myocardial infarction (NSTEMI). All patients captured within the MINAP dataset and meeting these inclusion/exclusion criteria will be included within this observational study (expected n = 60,000 / year).
3028171|NCT02374177||Propofol group|Patient anesthetized using propofol
3028172|NCT02374177||Sevoflurane group|Patients anesthetized using sevoflurane
3028173|NCT02374164|Experimental|Treatment Sequence ABC|Febuxostat extended release (XR) 80 mg, capsules, orally, once on Day 1 of Period 1 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.
3028174|NCT02374164|Experimental|Treatment Sequence BCA|Febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 3 after a high-fat meal.
3028175|NCT02374164|Experimental|Treatment Sequence CAB|Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.
3028176|NCT02374151||Women with IUPC|Women at term in second or third phase of labor who are indicated to have an IUPC during active labor
3028177|NCT02374138|Active Comparator|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
3028178|NCT02374138|Experimental|Intervention|Parental stress management in addition to IMPACT DC intervention of guideline-based clinical care, education, and short-term care coordination.
3028179|NCT02374125|Experimental|Fibrolysis Group|Actual Diacutaneous Fibrolysis and protocolized physiotherapy
3028180|NCT02374125|Experimental|Pressure Group|Trigger Point Pressure Release and protocolized physiotherapy
3028181|NCT02374125|Active Comparator|Control Group|Protocolized physiotherapy
3028182|NCT02374112|Experimental|Experimental|Creatine supplementation
3028183|NCT02374112|Placebo Comparator|Control|Placebo supplementation
3058476|NCT02171780|Placebo Comparator|Placebo|
3028184|NCT02374099|Experimental|CC-486 and fulvestrant|CC-486 300mg by mouth (PO) daily on days 1-21 of each 28 day cycle and Fulvestrant 500mg by intramuscular (IM) injection on Days 1 and 15 of cycle 1 and day 1 of each subsequent cycle every 28 days.
3028185|NCT02374099|Experimental|Fulvestrant|Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
3028186|NCT02374086|Experimental|Exercise Training|Subjects will exercise for 8 weeks
3028187|NCT02374073|Experimental|Intervention group|Treated with protocolized physiotherapy and functional massage
3028188|NCT02374073|Experimental|Control group|Treated with protocolized physiotherapy
3028189|NCT02374060|Active Comparator|Periocular triamcinolone 40mg|"Periocular triamcinolone acetonide (Kenalog), 40 mg Initial injection at Week 0~Second injection permitted at Week 8 IF:~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
3028190|NCT02374060|Active Comparator|Intravitreal triamcinolone 4mg|"(preservative-free preparation, Triescence at U.S. clinics; Triesence preferred at non-U.S. clinics but Kenalog allowed) (4 mg) Initial injection at Week 0~Second injection permitted at Week 8 IF:~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
3028191|NCT02374060|Active Comparator|Dexamethasoneintravitreal implant|"Dexamethasone intravitreal implant (Ozurdex) (0.7 mg) Initial injection at Week 0~Second injection permitted at Week 12 IF:~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
3028192|NCT02374047|Experimental|Cohort A1, Dose Level 1: CAT-2054 or placebo fasting|Single dose
3028193|NCT02374047|Experimental|Cohort A2, Dose Level 2: CAT-2054 or placebo fasting and fed|Single dose
3028194|NCT02374047|Experimental|Cohort A3, Dose Level 3: CAT-2054 or placebo fasting and fed|Single dose
3028195|NCT02374047|Experimental|Cohort A4, Dose Level 4: CAT-2054 or placebo fasting and fed|Single dose
3028196|NCT02374047|Experimental|Cohort A5, Dose Level 5: CAT-2054-C or placebo fasting and fed|Single dose
3028197|NCT02374047|Experimental|Cohort B1, Dose Level 1: CAT-2054 or placebo|Multiple dose for 14 days
3028198|NCT02374047|Experimental|Cohort B2, Dose Level 2: CAT-2054 or placebo|Multiple dose for 14 days
3028199|NCT02374047|Experimental|Cohort B3, Dose Level 3: CAT-2054 or placebo|Multiple dose for 14 days
3028200|NCT02374047|Experimental|Cohort B4, Dose Level 4: CAT-2054 or placebo|Multiple dose for 14 days
3028201|NCT02374047|Experimental|Cohort B5, Dose Level 5: CAT-2054 or placebo|Multiple dose for 14 days
3028202|NCT02374047|Experimental|Cohort B6, Dose Level 6: CAT-2054 with atorvastatin|Multiple dose for 14 days
3028203|NCT02374047|Experimental|Cohort B7, Dose Level 7: CAT-2054 or placebo|Multiple dose for 14 days
3028204|NCT02374034|Experimental|Treatment|Experimental group (n=20) completed a corrective exercise routine, as per the Egoscue Method, at least five days per week for two weeks.
3028205|NCT02374034|No Intervention|Control|The control group maintained their current lifestyle for the two-week duration of the study.
3028206|NCT02374021|Active Comparator|Triple therapy (MTX+SSZ+HCQ)|Sulfasalazine (SSZ) 1 g bid and hydroxychloroquine (HCQ) 200 mg twice daily, not to exceed 6.5mg/kg HCQ (in addition to concomitant methotrexate [MTX]).
3028207|NCT02374021|Active Comparator|TNF inhibitor (etanercept or adalimumab)|etanercept 50 mg subcutaneously weekly or adalimumab 40 mg subcutaneously every other week (in addition to concomitant methotrexate, plus hydroxychloroquine, for subjects who were taking this at screening). Biologic treatment will be assigned randomly.
3028208|NCT02374008|Experimental|Combined nerve block|Ropivacaine and Adrenalin, systemic Ketorolac and high dose Dexamethasone
3028209|NCT02374008|Active Comparator|Local infiltrationanalgesia|Ropivacaine, Adrenalin and Ketorolac combined with systemic high dose dexamethasone
3028210|NCT02373995|Active Comparator|LAB4|In addition to conventional Anti Thyroid Drug (ATD), LAB4 probiotic preparation will be administered at the 2 cps x 2/die dosing with food for 6 months. It is key to properly store LAB4 at 8°C.
3028211|NCT02373995|Placebo Comparator|Placebo|In addition to conventional Anti Thyroid Drug (ATD) a LAB4 placebo preparation will be administered at the 2 cps x 2/die dosing with food for 6 months. It is key to properly store placebo at 8°C.
3028212|NCT02373956|Experimental|MELECTIS G|"In addition to usual care as described for the other arm, patients randomized to this arm will have MELECTIS G added to their wound dressing according to the manufacturer's instructions.~Intervention: Usual care Intervention: MELECTIS G"
3028213|NCT02373956|Active Comparator|Usual care|"Patients randomized to this are will receive usual care according the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).~Intervention: Usual care"
3028214|NCT02373943|Experimental|β-carotene biofortified maize|Participants will ingest porridge bF: this will be the β-carotene fortified maize porridge where each 250 g will be made with 50 g of dry maize flour obtained from fortified corn seeds. The contents of β-carotene and other provitamin A carotenoids in this flour will be determined before preparing the porridges.
3028215|NCT02373943|Active Comparator|white maize supplemented with β-carotene|Participants will ingest porridge F: this will be also a β-carotene fortified maize porridge but in this case it will be made with 50 g of dry maize flour obtained from non fortified corn seeds and supplemented with a 500-1500 µg β-carotene reference dose. The exact dose of β-carotene that will be added to these porridges will be established according to the amount of β-carotene found in the flour used with porridges BF.
3028216|NCT02373943|Sham Comparator|white maize|Participants will ingest porridge N which will be the control porridge and will be made with 50 g of dry maize flour obtained from non fortified corn seeds.
3028243|NCT02373813|Experimental|etanercept monotherapy|etanercept for injection in pre-filled syringes with placebo for methotrexate
3028244|NCT02373813|Experimental|methotrexate monotherapy|Oral methotrexate with placebo for etanercept
3028217|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 1|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) and Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
3028218|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 2|Each subject will receive a single dose of Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) and Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
3028219|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 3|Each subject will receive a single dose of Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS), Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
3028220|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 4|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) and Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
3028221|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 5|Each subject will receive a single dose of Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), and Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
3028222|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 6|Each subject will receive a single dose of Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK), Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
3028223|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 1|Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fasted state, Treatment F (DTG/RPV FDC-1) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
3028224|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 2|Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment F (DTG/RPV FDC-1) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
3028225|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 3|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state, Treatment F (DTG/RPV FDC-1) in fasted state and Treatment F (DTG/RPV FDC-1) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
3028226|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 4|Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fasted state, Treatment G (DTG/RPV FDC-2) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
3028227|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 5|Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
3028228|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 6|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) fasted state and Treatment G (DTG/RPV FDC-2) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
3028229|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 7|Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fasted state, Treatment H (DTG/RPV FDC-3) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
3028230|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 8|Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
3028231|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 9|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) fasted state and Treatment H (DTG/RPV FDC-3) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
3028232|NCT02373917||study group|patient who in the biopsy showed lung cancer
3028233|NCT02373917||control group|patient who in the biopsy showed not to have lung cancer
3028234|NCT02373904|Experimental|Photodynamic Bone Stabilization System (PBSS)|The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.
3028235|NCT02373891|Experimental|T1|
3028236|NCT02373891|Experimental|T0|
3028237|NCT02373878|Active Comparator|Telecoaching plus plate|Telecoaching plus portion control plate
3028238|NCT02373878|Active Comparator|Usual Care|Usual Care
3028239|NCT02373865|Experimental|Arm A|Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)
3028240|NCT02373865|Active Comparator|Arm B|Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo
3028241|NCT02373839|Other|PlGF measurement|Determination of PlGF levels. If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks.
3028242|NCT02373839|No Intervention|Controls|induction of labour at 37 weeks of gestation.
3028245|NCT02373813|Experimental|etanercept plus methotrexate|etanercept for injection in pre-filled syringes and oral Methotrexate
3028246|NCT02373800||The study population|"The study population is composed of pregnant women with a medical indication for the induction of pre-term (37-42 weeks of gestation) labor and who are consulting in the participating center.~Intervention: Cervical ultrasound with elastography"
3028247|NCT02373787|Experimental|creos xenoprotect|resorbable collagen membrane
3028248|NCT02373787|Active Comparator|Bio-Gide|Bio-Gide, resorbable collagen membrane
3028249|NCT02373774|No Intervention|Standard Anatomic Palpation Technique|Participants randomized to this group will receive standard of care treatment with providers using the palpation technique to select an interspace to perform lumbar puncture.
3028250|NCT02373774|Experimental|Pre-Procedural Ultrasound|Participants randomized to this group will receive an ultrasound of the interspace selected via the palpation method prior to performance of the lumbar puncture to determine measurements of appropriate angle and depth and evaluation of any overlying vasculature.
3028251|NCT02373748|Experimental|BioGaming YuGo System|
3028252|NCT02373735|Active Comparator|Group A (SVV <10% group)|"infuse crystalloid (Hartmann`s solution) 6-10 ml/kg/hr continuously during surgery~infuse colloid (Volulyte) 200 ml if SVV is ≥ 10% during the surgery~Interventions: crystalloid (Hartmann`s solution), colloid (Volulyte)"
3028253|NCT02373735|Experimental|Group B (SVV 10-20% group)|"infuse crystalloid (Hartmann`s solution) 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy~infuse colloid (Volulyte) 200 ml if SVV is > 20%~infuse mannitol 0.5 g/kg or lasix 5 mg if SVV < 10%~Interventions: crystalloid (Hartmann`s solution), colloid (Volulyte), mannitol, lasix"
3028254|NCT02373722|Experimental|Group I (video, text message)|Patients watch an educational video about Mohs surgery before their surgery, a video about wound care after the surgery and receive text messages about wound care on days 1-5 after the surgery. Patients also receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are instructed to apply petroleum jelly BID to the wound area.
3028255|NCT02373722|Experimental|Group II (educational video)|Patients watch an educational video about Mohs surgery before their surgery, an educational video about wound care after the surgery and receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients apply petroleum jelly BID to the wound area
3028256|NCT02373722|Experimental|Group III (text message)|Patients receive text messages about wound care on days 1-5 after the surgery and receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly BID to the wound are.
3028257|NCT02373722|Experimental|Group IV (control)|Patients receive no video or text messages. Patients receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly BID to the wound area.
3028258|NCT02373709||Cases: Perinatal depression|Cases will be defined as those with a depressive episode with onset during the antenatal or postnatal period.
3028259|NCT02373709||Controls: No perinatal depression|Controls will be defined as those who score < 7 on Edinburgh Postnatal Depression Scale and/or no episode of clinical depression from pregnancy until 6 months postnatal.
3028260|NCT02373683|Experimental|Vapotherm-Heliox|Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
3028261|NCT02373683|No Intervention|Standard Care|Care dictated by clinical team.
3028262|NCT02373670|Experimental|Parent Mentor|Parent mentors using positive deviance findings to promote healthy behaviors
3028263|NCT02373670|Active Comparator|Education|Community health workers providing health education to promote healthy behaviors
3028264|NCT02373657|Experimental|WASH Intervention|"In these seven communities we built a well in a central location for all state team residents. We plan on providing tippy-taps (water and soap dispensers), instruction in soap-making, and hygiene education to these communities. We will also put fly traps in the communities to see if wells reduce flies. We plan on performing monitoring visits at 12 months and 24 months, in order to assess clinically active trachoma, ocular chlamydia infection, nasopharyngeal macrolide resistance, soil transmitted helminths, and childhood growth (height and weight). We will also perform assessments of the adequacy of the intervention, by conducting household surveys to assess hygiene behavior, access to water and latrines, and fly density."
3028265|NCT02373657|No Intervention|Control|In these seven communities, we plan to perform monitoring visits at 12 months and 24 months, in order to assess clinically active trachoma, ocular chlamydia infection, nasopharyngeal macrolide resistance, soil transmitted helminths, and childhood growth (height and weight). We will also perform assessments of the adequacy of the intervention, by conducting household surveys to assess hygiene behavior, access to water and latrines, and fly density.
3028266|NCT02373644|Experimental|HVLA Thrust Manipulation and DN|
3028267|NCT02373644|Active Comparator|Conventional Physical Therapy|
3028268|NCT02373631|Experimental|Dry Needling, Conventional PT|
3028269|NCT02373631|Active Comparator|Conventional PT|
3028270|NCT02373618|Experimental|Experimental: DN and Conventional PT|
3028271|NCT02373618|Active Comparator|Active Comparator: Conventional PT|
3028272|NCT02373605|Experimental|Dry Needling,Thrust Manipulation|
3028273|NCT02373605|Active Comparator|Exercise,Non-thrust Mobilization|
3028274|NCT02373592|Placebo Comparator|Thermometry-only group|"Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet.~Some alarm signs have been pre-specified: 1) thermal image shows yellow spots in any area of feet for two consecutive days, 2) thermal image shows different colors in contralateral areas of the feet for two consecutive days or, 3) a dermal lesion. In any of these three scenarios, subjects will be instructed to contact the study nurse by phone. (See Detailed Description for more detail on the actions after an alarm sign has been observed)"
3028335|NCT02373202|Experimental|Sarilumab 200 mg q2w|Participants received sarilumab 200 mg, SC injection, q2w for up to 52 weeks.
3028336|NCT02373189|Experimental|Bright light|
3028337|NCT02373176|Experimental|[14C] PRC-4016 (Icosabutate)|Investigational medicinal product (IMP), [14C] PRC-4016 (Icosabutate) solution (600 mg in 2 mL, 200.0 μCi [7.4 MBq]). The radiochemical purity of [14C]PRC-4016 will be at least 97%.
3058477|NCT02171767|Experimental|BIBW 2992 MA2 - single rising dose|
3028275|NCT02373592|Experimental|Thermometry plus SMS and voice messaging|"Thermometry-related intervention activities will be the same as those established for the thermometry-only group. In addition, this group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages has been developed and validated through both SMS and voice messaging.~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
3028276|NCT02373579|Active Comparator|Intervention arm with Omega 3 FA|"included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .~Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day ."
3028277|NCT02373579|Active Comparator|control group|control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
3028278|NCT02373566|Experimental|Dermal substitute with STSG|Novomaix dermal substitute in combination with STSG
3028279|NCT02373566|No Intervention|STSG alone|STSG alone
3028280|NCT02373553|No Intervention|Group 1( G1): CONTROL GROUP|not be submitted to intervention, only receive informations about health education.
3028281|NCT02373553|Experimental|Group 2(G2) : HEALTH EDUCATION|The family will receive a booklet of guidance of exercises to be performed at home.
3028282|NCT02373553|Experimental|Group 3(G3): EXERCISES IN OUTPATIENTS UNIT|The postural reeducation through lengthening of the anterior muscles and strengthening of the posterior muscles of the trunk.
3028283|NCT02373527|No Intervention|Standard - Strict Fasting|No food after midnight the night before the procedure and will be allowed to drink clear liquids up to 2 hours prior to the procedure.
3028284|NCT02373527|Experimental|Non Fasting|No Fasting prior to catheterization. Usual meal on the day of the procedure and allowed to drink as usual.
3028285|NCT02373514|Active Comparator|Paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with rapid infusion
3028286|NCT02373514|Active Comparator|Dexketoprofen|Intravenous 50 mg dexketoprofen in 100 ml saline with rapid infusion
3028287|NCT02373501|Experimental|intra-abdominal repair|intra-abdominal repair of uterine incision, after delivery of the fetus and the placenta.
3028288|NCT02373501|Experimental|extra-abdominal repair|extra-abdominal repair of uterine incision, after delivery of the fetus and the placenta.
3028289|NCT02373488|Other|control|lifestyle advice
3028290|NCT02373488|Active Comparator|intervention-1|connective tissue manipulation
3028291|NCT02373488|Active Comparator|intervention-2|abdominal massage
3028292|NCT02373475|Experimental|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
3028293|NCT02373475|Active Comparator|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
3028294|NCT02373462|Experimental|olmesartan group|olmesartan (20mg qd then 40mg qd for titrating BP <140/90 mmHg)
3028295|NCT02373462|Active Comparator|other group|other anti-hypertensive drug (titrating BP <140/90 mmHg)
3028296|NCT02373449|Experimental|RS-fMRI|All subjects will be instructed to keep their eyes closed but to remain awake during the fMRI measurement. Resting State fMRI (RS-fMRI) will be performed within four weeks of planned infusion of ketamine, immediately after the end of infusion of ketamine on the fifth (last) day of infusion, and on the one month follow-up appointment after the infusion.
3028297|NCT02373436|Experimental|Constraint Induced Therapy|"All participants will receive a glove that limits the use of the fingers and wrist, and can be placed by the participant. They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.~The intervention training will consist of 30 minutes of exposure of the transfer package, the interview with the items in the MAL, and 2 hours and 30 minutes with about four task Shaping, which may vary according to the needs of each individual, and Task Practice, standardized to be the same for all individuals."
3028298|NCT02373436|Other|Control|They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
3028299|NCT02373423|Experimental|Advocacy program|A series of commonly used advocacy actions which will incorporate a theory of change model. Each advocacy action is targeted to change organizational capability, opportunity, or motivation of food companies to reduce salt in processed packaged foods. The intervention will span 24 months from 2013-2015.
3028300|NCT02373423|No Intervention|Control|No intervention program
3028301|NCT02373410|Experimental|Umbilicus|The height of the operating table which set at the needle insertion point, is the level of umbilicus of the anesthesiologist in a standing posture.
3028302|NCT02373410|Active Comparator|Lowest rib margin|The height of the operating table which set at the needle insertion point, is the level of lowest rib margin of the anesthesiologist in a standing posture.
3028303|NCT02373410|Active Comparator|Xiphoid|The height of the operating table which set at the needle insertion point, is the level of xiphoid of the anesthesiologist in a standing posture.
3028304|NCT02373410|Active Comparator|Nipple|The height of the operating table which set at the needle insertion point, is the level of nipple of the anesthesiologist in a standing posture.
3028305|NCT02373397|Experimental|Cacicol20|Instillation of Cacicol20 eye drops after laser corneal surgery. 3 eye drops total, to be given once immediately after surgery, once 2 days after surgery, and a final time 4 days after surgery.
3028306|NCT02373397|Placebo Comparator|Placebo|Instillation of placebo eye drops (vehicle missing the active ingredient) after laser corneal surgery. 3 eye drops total, to be given once immediately after surgery, once 2 days after surgery, and a final time 4 days after surgery.
3028338|NCT02373163|Active Comparator|Diuretic|Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM
3028339|NCT02373163|Active Comparator|Calcium-channel blocker|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
3028340|NCT02373163|Active Comparator|Angiotensin Receptor Blocker|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
3028341|NCT02373150|Experimental|Group A1|Dose 1 or placebo
3028307|NCT02373384|Experimental|Study group|"Eligible patients, who fulfilled the study criteria, will be instructed For;~Oral alkalinization~Potassium citrate 20 mEq three times daily~Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females), will receive Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily.~Life style modification Adequate fluid intake in order to maintain urine volume between 2-3 L per day.~Dietary recommendations~In hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) ;~- Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables."
3028308|NCT02373371|Experimental|Daylight|Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline
3028309|NCT02373371|Active Comparator|Conventional treatment|Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline
3028310|NCT02373358|Experimental|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety & boundaries, strength & power, assertiveness, intuition, trust, & community) using mindfulness, breath work, and physical yoga poses.
3028311|NCT02373332||Healthy subjects|Healthy subjects for oxylipin effect Platelets from healthy donors will be assessed for regulation of platelet reactivity by fatty acids and 12-lipoxygenase oxylipins.
3028312|NCT02373332||Type 2 diabetes mellitus (T2DM) patients|T2DM patients for oxylipin effect Platelets from healthy donors will be assessed for regulation of platelet reactivity by fatty acids and 12-lipoxygenase oxylipins.
3028313|NCT02373319|Experimental|CV-screening-1 plus personalized|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
3028314|NCT02373319|Experimental|CV-screening-2 plus personalized|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
3028315|NCT02373319|Active Comparator|CV-screening-1 plus standard|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
3028316|NCT02373319|Active Comparator|CV-screening-2 plus standard|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
3028317|NCT02373306|Active Comparator|NIPS-sensitive group|Patients who had sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation.
3028318|NCT02373306|No Intervention|Control group|Patients who had no sustained or hemodynamically unstable arrhythmias induction during non-invasive programmed stimulation.
3028319|NCT02373280|Active Comparator|10 day sequential group|After proving H. pylori infection, the participant will receive the empirical 10 day sequential regimen (Esomeprazole, nexium® 40 mg bid 10 days (D1-D10)+amoxicillin® 1 g bid 5 days (D1-D5)+clarithromycin, klaricid® 500mg bid 5 days (D6-D10)+metronidazole, flasinyl® 500mg tid 5 days (D6-D10) for treatment of H. pylori infection in this group.
3028320|NCT02373280|Experimental|7 days tailored PPI triple therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day tailored regimen [PPI triple therapy (Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+amoxicillin® 1 g bid 7 days (D1-D7)+clarithromycin, klaricid® 500mg bid 7 days (D1-D7)] in this group.
3028321|NCT02373280|Experimental|7 days tailored MEA therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day moxifloxacin triple therapy [Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+Moxifloxacin, avelox® 400 mg qd 7 days (D1-D7)+Amoxicillin® 1 g bid 7 days (D1-D7)] in this group.
3028322|NCT02373280|Experimental|7 or 14 days tailored EBMT therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day bismuth quadruple therapy [Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, denol® 300 mg qid 7 days (D1-D7)+Metronidazole, flasinyl® 500 mg tid 7 days (D1-D7)+Tetracycline® 500 mg qid 7 days (D1-D7)] in this group. If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
3028323|NCT02373254|Active Comparator|Ibuprofen 400 mg|Ibuprofen 400 mg po q 8 hours as needed (PRN) for pain. Subjects will receive Norco, 5/525 mg po q 6 hours PRN if pain relief with Ibuprofen is not sufficient.
3028324|NCT02373254|Active Comparator|Ibuprofen 800 mg|Ibuprofen 800 mg po q 8 hours PRN pain. Subjects will receive Norco, 5/525 mg po q 6 hours PRN if pain relief with Ibuprofen is not sufficient.
3028325|NCT02373254|Active Comparator|Norco|Norco (acetaminophen/hydrocodone) 10/325 mg po q 6 hours PRN pain. If pain is not relieved, physician should be contacted.
3028326|NCT02373241|Active Comparator|Standard Blood Pressure Management|Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to <95th percentile
3028327|NCT02373241|Experimental|Experimental Blood Pressure Management|Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to <75th percentile
3028328|NCT02373228|Experimental|Compressive signal processing algorithm|Participants compare music signals with preprocessing to the same music signals without compressive preprocessing.
3028329|NCT02373215|Experimental|Cohort 1 - Groups 1-3|HD patients dosing up to 180mg BID
3028330|NCT02373215|Experimental|Cohort 1 - Group 4|HD patients dosing up to 240mg BID
3028331|NCT02373215|Experimental|Cohort 2|Healthy patients dosing up to 180mg BID
3028332|NCT02373202|Experimental|Sarilumab 150 mg q2w + DMARDs|Participants received sarilumab 150 mg, subcutaneous (SC) injection, once every two weeks (q2w) along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
3028333|NCT02373202|Experimental|Sarilumab 200 mg q2w + DMARDs|Participants received sarilumab 200 mg, SC injection, q2w along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
3028334|NCT02373202|Experimental|Sarilumab 150 mg q2w|Participants received sarilumab 150 mg, SC injection, q2w for up to 52 weeks.
3028344|NCT02373137|Other|DSAEK|Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
3028345|NCT02373137|Other|DMEK|Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
3028346|NCT02373124|Experimental|open-label|52 minute infusion of NMDA antagonist
3028347|NCT02373111|Active Comparator|Isoflavone and Astaxanthin|Each subject takes one active tablet per day for 24 weeks. Each tablet contains isoflavone 27mg and astaxanthin 4mg.
3028348|NCT02373111|Placebo Comparator|Placebo|Each subject takes one placebo tablet per day for 24 weeks.
3028349|NCT02373098|Experimental|FTY720|
3028350|NCT02373085|Experimental|A: Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria beyond 2 months after transplantation and during the first 2 years after transplantation
3028351|NCT02373085|No Intervention|B: no treatment|No treatment of any episode of asymptomatic bacteriuria beyond 2 months after transplantation in kidney transplant recipients.
3028352|NCT02373072|Experimental|Cohort 1|Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.
3028353|NCT02373072|Experimental|Cohort 2|Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.
3028354|NCT02373059|Experimental|Pharmaceutical care with shared decision making|Use of Diabetes Issue Cards Decision Aids
3028355|NCT02373059|Active Comparator|Usual Pharmaceutical care|Usual Care
3028356|NCT02373046|Experimental|Treatment A|1 × 400-mg LX4211 tablet (fasted conditions)
3028357|NCT02373046|Experimental|Treatment B|2 × 200-mg LX4211 tablets (fasted conditions)
3028358|NCT02373033|Active Comparator|Intervention: Natural food folate|Food group consumed folate-rich foods (providing additional 250 μg/d folate).
3028359|NCT02373033|Active Comparator|Intervention: Folic acid|Folic acid group received a folic acid supplement (providing additional 500 μg/d folic acid).
3028360|NCT02373033|Placebo Comparator|Intervention: Control|Control group received apple juice containing no folate or folic acid every day.
3028361|NCT02373020||group 1|colonoscopic biopsies from patients with colorectal cancer patients
3028362|NCT02373020||(Group 2|colonoscopic biopsies from healthy controls
3028363|NCT02373007|Other|Classic Scopinaro Surgery|Patients will get the Bariatric surgery using the Classic Scopinaro Techniques
3028364|NCT02373007|Other|Modified Scopinaro Surgery|Patients will get Bariatric surgery using the Modified Scopinaro Techniques
3028365|NCT02372994|Experimental|Intervention Group|The randomization is at the level of attending healthcare professional who identifies patients for recruitment. For each participant in the intervention arm, a secure space (called a Patient Loop) is created in the online clinical communication system. A Patient Loop can be accessed by the patient, their caregiver, and the healthcare providers who have permission to do so through an algorithm of invitation, authentication and careful partitioning. In each Patient Loop, team members can post messages that can be read and responded to by the entire team. Each Patient Loop consists of a patient, their caregiver and at least two healthcare professionals.
3028366|NCT02372994|No Intervention|Control Group|Participants receive usual care.
3028367|NCT02372981|Experimental|DG-HAL with mucopexy|Mucopexy with DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
3028368|NCT02372981|Active Comparator|mucopexy alone|Mucopexy without DG-HAL is performed using the same specific device consisting of a proctoscope equipped with a Doppler probe and a light source as described above.
3028369|NCT02372955|Experimental|dapagliflozin 10 mg daily|dapagliflozin, 10 mg daily for 16 weeks
3028370|NCT02372955|Active Comparator|glimpiride|glimpiride 4 mg daily for 16 weeks
3028371|NCT02372942|Experimental|Lattoferrin|Use of Lattoferin for prevention of preterm delivery
3028372|NCT02372942|Experimental|Progesterone|Use of Progesterone for prevention of preterm delivery
3028373|NCT02372929||Endoscopic Ultrasound Staging|Prospective study of esophageal cancer patients referred for endoscopic ultrasound
3028374|NCT02372916||Dry AMD|Patients with pre-existing GA secondary to AMD NOT requiring intravitreal injections (i.e. Dry AMD)
3028375|NCT02372916||Wet AMD and treatment-naive|Patients with pre-existing GA and CNV secondary to AMD requiring intravitreal injections (i.e. Exudative AMD) and are treatment-naïve patients
3028376|NCT02372916||Wet AMD with history of intravitreal injections|Patients with pre-existing GA and CNV secondary to AMD requiring intravitreal injections (i.e. Exudative AMD) and have received previous intravitreal injections
3028377|NCT02372903|Experimental|Endometriosis|Symptomatic patients with laparoscopic diagnosis of endometriosis
3028378|NCT02372890||All patients|Patients with head and neck squamous cell carcinoma with advanced primary tumor stages (cT3 or cT4), clinical suspicion of cervical lymph node metastases, cervical lymph node metastasis of unknown primary tumor (CUP) or patients with tumor recurrence scheduled for neck dissection.
3028379|NCT02372877|Experimental|Amicus Red Cell Exchange in SCD patients|Open arm. Patients with sickle cell disease (SCD) treated using one Amicus Red Cell Exchange procedure.
3028409|NCT02372682||Control|Any pediatric patient (0-18 years of age) undergoing evaluation with an abdominal ultrasound as standard of care for evaluation for a diagnosis other than liver disease and in whom the US shows a normal liver, gallbladder, pancreas, spleen, and biliary tree will then be asked to enroll in the research study by undergoing shear wave elastography.
3028410|NCT02372669|Experimental|Chitosan|Enrolled participants presenting with traumatic sensory nerve lesions of the hand without defect zone that were randomized to primary microsurgical repair with the additional use of a chitosan nerve tube.
3028380|NCT02372864|No Intervention|Care as usual|"All participants in the intervention and control group receive the care as usual. The care as usual consists of a clinic appointment with the research nurse. In this appointment the RRSO-induced menopausal complaints will be discussed in more detail. Depending on the complaints at hand, information, reassurance and life style advice will be offered. A leaflet with relevant information will be provided for. Furthermore, the usual medical care may include prescription of (non-)hormonal medicationsTwelve weeks after the clinic appointment, the research nurse will contact all participants per telephone to ask whether there are issues that remain to be addressed.~Participants are allowed to continue the use of all their current medication."
3028381|NCT02372864|Experimental|Mindfullness based stress reduction|
3028382|NCT02372851|Active Comparator|Pureit As+ Filter|Each household will receive one water filter and a replacement battery for free during distribution. The intervention will be distributed door-to-door by the implementation team. Households will be trained on use and maintenance of the device according to the manufacturer's instructions. Households will be advised to drink exclusively from the water filter and to carry water with them if attending school or work. Households will also be advised to clean and cook their rice with filtered water only.
3028383|NCT02372851|No Intervention|Control arm|The control arm will be advised to continue with their traditional drinking water and cooking practices. The control arm will receive the intervention at the end of the study period.
3028384|NCT02372812|Active Comparator|group1|12 mg( 3 mls) of dexamethasone given 15 mins after induction of anesthesia
3028385|NCT02372812|Placebo Comparator|group2|3 mls of placebo( normal saline) given 15 mins after induction of anesthesia
3028386|NCT02372799|Experimental|Vilazodone|Vilazodone tablets, 5mg, 10mg and 20mg. Oral administration, once per day.
3028387|NCT02372799|Placebo Comparator|Placebo|Dose-matched placebo tablets or capsules, oral administration, once per day.
3028388|NCT02372799|Active Comparator|Fluoxetine|Fluoxetine capsules, 10mg and 20 mg. Oral administration, once per day.
3028389|NCT02372786|Other|Acne Keloidalis Nuchae|2,5% lidocaine / 2,5% prilocaine cream and 7% lidocaine / 7% tetracaine cream will be applied for 60 minutes. After removal of the creams patients will recieve laser hair removal treatment using a neodymium-doped yttrium aluminium garnet (Nd:Yag) laser.
3028390|NCT02372786|Other|Tattoo|2,5% lidocaine / 2,5% prilocaine cream and 7% lidocaine / 7% tetracaine cream will be applied for 60 minutes. After removal of the creams patients will recieve laser tattoo removal treatment using a Q-switched nd Yag laser.
3028391|NCT02372773||Frontotemporal Dementia - MAPT|Frontotemporal Dementia with microtubule associated protein tau (MAPT) mutation
3028392|NCT02372773||Frontotemporal Dementia - PGRN|Frontotemporal Dementia with progranulin (PGRN; also known as granulin or GRN) mutation
3028393|NCT02372773||Frontotemporal Dementia - C9OR72|Frontotemporal Dementia with chromosome 9 open reading frame 72 (C9ORF72) mutation.
3028394|NCT02372773||Control|Member of family with a known mutation in one of the three major FTD related genes: MAPT, PGRN, and C9ORF72.
3028395|NCT02372760|Experimental|BA by spray catheter (Olympus PW-205V)|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V).
3028396|NCT02372760|Active Comparator|BA classic anesthesia|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.
3028397|NCT02372747|Experimental|Delta-shaped anastomosis group|The patients in DS group underwent Delta-shaped anastomosis after TLDG.
3028398|NCT02372747|Experimental|Billroth II anastomosis group|The patients in B-II group underwent Billroth-II anastomosis after TLDG.
3028399|NCT02372734||Sepsis with acute kidney injury (AKI)|Prior admission for sepsis with a diagnosis of AKI as a child. Intervention: The subjects will be administered the Peds QL survey.
3028400|NCT02372734||Sepsis without acute kidney injury (AKI)|Prior admission for sepsis without a diagnosis of AKI as a child. Intervention: The subjects will be administered the Peds QL survey.
3028401|NCT02372721||Sepsis with Severe AKI|"History of a pediatric admission with sepsis related AKI which lead to classification of injury or failure. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry."
3028402|NCT02372721||Sepsis without AKI|History of a pediatric admission with sepsis which lead to no classification of AKI. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry.
3028403|NCT02372721||Control|No history of an admission for AKI. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry.
3028404|NCT02372708||Experimental|diluted dinitrophenyl(DNP) Vaseline (which equaled to 2% DNP 0.1ml) was started to be directly spread on the surfaces of primary or metastatic tumors of malignant melanoma patients since the first day of every circle of chemotherapy, simultaneously laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2. The tumors were wrapped and blocked for two days to induce contact dermatitis. If lymph nodes had been cleared, sensibilization of 2×2cm was performed at occipital region. It was repeated once a week.
3028405|NCT02372708||Control|only diluted DNP Vaseline was spread and the operation were the same with the treatment group
3028406|NCT02372695|Experimental|Treatment|Patient will take one pill of paricalcitol a day.
3028407|NCT02372695|No Intervention|Usual treatment.|Patient allocated to this arm will only take his/her habitual treatment
3028408|NCT02372682||Test|"Any pediatric patient (0-18 years of age) with known liver disease in whom a liver biopsy is to be performed as standard of care to assess the degree of fibrosis will also undergo an abdominal ultrasound to evaluate the liver.~Underlying diagnoses include but are not limited to biliary atresia, congenital fibrosis-cholestasis, Alagille syndrome, Caroli's disease, choledochal cyst, alpha-1-antitrypsin deficiency, progressive familial intrahepatic cholestasis (PFIC), viral hepatitis, glycogenosis, fructosemia, Wilson disease, cystic fibrosis, autosomal recessive polycystic kidney disease (ARPCKD), mesenterico-caval shunt, post liver transplant, and nonalcoholic steatohepatitis (NASH)."
3028513|NCT02371980|Placebo Comparator|Double-blind: Placebo|Vortioxetine placebo-matching capsules, orally, once, daily, Week 17 through Week 44.
3058478|NCT02171754|Experimental|BIBW 2992 + Ritonavir|
3028411|NCT02372669|Active Comparator|Gold standard alone|Enrolled participants presenting with traumatic sensory nerve lesions of the hand without defect zone that were randomized to primary microsurgical repair without the additional use of a chitosan nerve tube.
3028412|NCT02372656|Placebo Comparator|Placebo Group|Placebo gel without active ingredient to be delivered at baseline, 3, 6 and 9 months.
3028413|NCT02372656|Active Comparator|1% Metformin|1% metformin gel to be delivered at baseline, 3, 6 and 9 months.
3028414|NCT02372656|Active Comparator|1.2% Simvastatin|1.2% Simvastatin to be delivered at baseline, 3, 6 and 9 months.
3028415|NCT02372643|Other|Sexually healthy women|20 sexually healthy volunteer women will be enrolled from subjects consulting our outpatient clinic (subjects free from sexual dysfunction). Hormonal and ultrasound parameters and self-administered questionnaires will be evaluated.
3028416|NCT02372630|Placebo Comparator|Placebo|Patients will be treated for 12 weeks with placebo once daily
3028417|NCT02372630|Active Comparator|Linagliptin 5mg per day|Patients will be treated for 12 weeks with Linagliptin 5mg once daily.
3028418|NCT02372617||Group A|bone graft - autologous
3028419|NCT02372617||Group B|bone graft - ceramic
3028420|NCT02372604|Active Comparator|Group1 : Regulatory dosage|"In a first time, every day, one tablet of 5 mg of levocetirizine is taken the morning and a second tablet of placebo is taken the evening, during 5 weeks (between visit 2 and 3).~In a second time,and after primary endpoint assessment, every day, one tablet of 10 mg of levocetirizine is taken the morning and a second tablet of 10 mg of levocetirizine is taken the evening, during 5 weeks (between visit 3 and 4)."
3028421|NCT02372604|Experimental|Group 2 : fourfold dosage|"In a first time, every day, one tablet of 10 mg of levocetirizine is taken the morning and a second tablet of 10 mg of levocetirizine is taken the evening, during 5 weeks (between visit 2 and 3).~In a second time, every day, one tablet of 5 mg of levocetirizine is taken the morning and a second tablet of placebo is taken the evening, during 5 weeks (between visit 3 and 4)."
3028422|NCT02372591|Placebo Comparator|Placebo|
3028423|NCT02372591|Active Comparator|Hydromorphone|
3028424|NCT02372591|Experimental|Buprenorphine|
3028425|NCT02372578|Experimental|ASP3662|ASP3662 once daily (QD) and pregabalin placebo 3 times daily (TID) for Weeks 1 - 6. ASP3662 placebo QD and pregabalin placebo TID for Week 7.
3028426|NCT02372578|Active Comparator|pregabalin|pregabalin TID and ASP3662 placebo QD for Weeks 1 - 7.
3028427|NCT02372578|Placebo Comparator|Placebo|ASP3662 placebo QD and pregabalin placebo TID for Weeks 1 - 7.
3028428|NCT02372565|Experimental|Facebook and Text Message|Participants randomized to the technology-based physical activity intervention will receive a culturally-relevant physical activity promotion intervention delivered via text messages and the social media website Facebook. The purpose of the intervention materials is to encourage participants to achieve a minimum of 150 minutes/week of moderate-intensity aerobic physical activity each week.
3028429|NCT02372565|Active Comparator|Standard Print-based Intervention|Participants randomized to the standard print-based physical activity intervention group will be mailed 4 self-help booklets promoting physical activity produced by the American Heart Association. Booklets will be mailed one at a time in 2 week intervals over the 1st 6-weeks of the intervention. These high quality booklets provide general information on the benefits of physical activity, tips and strategies to increase daily physical activity, and encourage recipients to perform a minimum of 10,000 steps per day.
3028430|NCT02372552|Experimental|CROMA|Microwave coagulation of small blood vessels
3028431|NCT02372539||Non-diabetes|Patients without diabetes will serve as the control group
3028432|NCT02372539||Diabetes|Patients with diabetes will be further stratified based upon antihyperglycemic medications (insulin versus oral medications)
3028433|NCT02372526||10 Roux-en-Y gastric bypass patients|Isocaloric amounts of specific macronutrients is mixed with 4 g vegetable bouillon and tested against each others ability to induce GLP-1 secretion. The mealtest takes place at 4 different days with 3-14 days separation.
3028434|NCT02372526||10 Healthy Control subjects|Isocaloric amounts of specific macronutrients is mixed with 4 g vegetable bouillon and tested against each others ability to induce GLP-1 secretion. The mealtest takes place at 4 different days with 3-14 days separation.
3028435|NCT02372500|Experimental|Chewing gum|Patients will chew sugar free gum three times a day
3028436|NCT02372500|No Intervention|Control|Normal post operative care
3028437|NCT02372487|Active Comparator|fluid therapy and sildenafil citrate|Patients in first group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour in addition to sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily during hospitalization. After discharge patients in first group will be asked to continue sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily plus a daily oral fluid intake of 2 liters
3028438|NCT02372487|Active Comparator|fluid therapy|Patients in second group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour. After discharge patients wil be asked to have 2 liters daily oral fluid
3028439|NCT02372474|Experimental|Stem Cell therapy in POF|POF cases were evaluated hormonally, HP and IH using ESS. Autologous MSC were prepared and laparoscopically transplanted.
3028440|NCT02372461|Placebo Comparator|Experimental|Placebo
3028441|NCT02372461|Active Comparator|Control|Amoxicillin Liquid
3028442|NCT02372448|Other|ALK-positive|ALK positive analysis on CTCs detected by ISET
3028443|NCT02372448|Other|ALK-negative|ALK negative analysis on CTCs detected by ISET
3028444|NCT02372435|Experimental|Short interval|"Re-Implantation of the prosthesis after a short interval of 2-3 weeks after explantation (fast-track-arm)."
3028445|NCT02372435|Active Comparator|Long interval|Re-Implantation of the prosthesis after a Long interval of 6-10 weeks (standard surgical treatment).
3028446|NCT02372422|Experimental|Transvaginal Cervical Length Group|Clinicians managing the patients were aware of the transvaginal cervical length ultrasound measurements.
3028447|NCT02372422|Other|Routine Care|Clinicians managing the patients were not aware of any transvaginal cervical length ultrasound measurements.
3028540|NCT02371759|Experimental|Diabetics: L+C maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia
3028618|NCT02371356||Untreated (Depressed with comorbidity)|Screen positive for depression and comorbidity and receive no treatment.
3028448|NCT02372409|Experimental|Arm A (MRI-guided laser ablation)|"MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.~Participants will undergo DCE and DSC-MRI imaging at the following time points:~no more than 3 weeks prior to MLA (OPTIONAL)~within approximately 4 days after MLA~2-4 weeks after MLA~Every 12 weeks (+/- 7 days) for the first year or until disease progression"
3028449|NCT02372409|Experimental|Arm B (MRI-guided laser ablation, doxorubicin, etoposide)|"MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.~Within 7 days of MLA (range 2-14 days) doxorubicin will be given intravenously on an outpatient basis weekly for 6 weeks at a dose of 25 mg/m^2 over 5-30 minutes~Following the completion of doxorubin, etoposide 50 mg/m^2/day will be given orally for 21 days of each 28-day cycle (treatment can continue up to 24 cycles)~Participants will undergo DCE and DSC-MRI imaging at the following time points:~no more than 3 weeks prior to MLA (OPTIONAL)~within approximately 4 days after MLA~2-4 weeks after MLA~every 8 weeks (+/- 7 days) until 2 years have elapsed or disease progression, whichever comes first"
3028450|NCT02372396|Experimental|Compassion Meditation|Compassion Meditation delivered in 10 2-hour group treatment sessions.
3028451|NCT02372396|Active Comparator|Relaxation|Relaxation delivered in 10 2-hour group treatment sessions.
3028452|NCT02372383|Experimental|Fasting|"Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
3028453|NCT02372383|Experimental|Food/Enzymes|"Subjects with CF will be given the antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
3028454|NCT02372383|Active Comparator|Healthy Controls|"Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
3028455|NCT02372370|Active Comparator|Interventions|All participants receive all interventions.
3028456|NCT02372357|Experimental|Posaconazole 120mg/m² tid|"Pediatric patients admitted to receive chemotherapy or hematopoietic stem cell transplantation for the treatment of a hematological malignancy are receiving Posaconazole prophylaxis 120 mg/m² tid.~At steady state, blood sampling will be performed: 9 blood samples will be taken during 1 dosing interval to evaluate the pharmacokinetics of posaconazole."
3028457|NCT02372344|Experimental|Fasting|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered at the end of a 10-hour fast.
3028458|NCT02372344|Experimental|Before meal|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered before consumption of a low calorie, low-fat breakfast (within 30 minutes before starting food intake).
3028459|NCT02372344|Experimental|After meal|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered after consumption of a low calorie, low-fat breakfast (within 30 minutes after starting food intake).
3028460|NCT02372331|No Intervention|Conventional perioperative management|"Preop usual biliary drainage~Preop smoking and alcohol~Preop parenteral nutrition~Oral bowel preparation (mechanical bowel preparation )~Preoperative fasting > 12 hours~Pre-anesthetic medication~Anti-thrombotic prophylaxis~Antimicrobial prophylaxis and skin preparation~Intravenous analgesia : PCA~Prevention of postoperative nausea and vomiting (PONV) (X)~Incision : surgeon direction~Avoiding hypothermia~Nasogastric intubation (O)~Postop glycemic control~Positive fluid balance~Perianastomotic drain removal over POD #5~Somatostatin analogues~Transurethral catheter removal~Delayed gastric emptying(DGE) (+) , parenteral nutrition (+)~Postop routine artificial nutrition (O), soft diet at POD #5~Early and scheduled mobilization"
3028461|NCT02372331|Experimental|ERAS perioperative management|"behavioral intervention (counselling, audit)~dietary supplement~procedure (preoperative and postoperative)~drug"
3028462|NCT02372318|Experimental|Nalmefene Challenge|Participants will receive 18mg Nalmefene two hours prior to fMRI measurement. During fMRI scanning alcohol cues will be presented.
3028463|NCT02372318|Placebo Comparator|Placebo|Participants will receive Placebo two hours prior to fMRI measurement. During fMRI scanning alcohol cues will be presented.
3028464|NCT02372305|Active Comparator|FlexHD|Patients randomly assigned to receive FlexHD for breast reconstruction.
3028465|NCT02372305|Active Comparator|Alloderm|Patients randomly assigned to receive Alloderm for breast reconstruction.
3028466|NCT02372292|Active Comparator|Group 1|Patients with type 1 cardiorenal syndrome who had improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
3028467|NCT02372292|Active Comparator|Group 2|Patients with type 1 cardiorenal syndrome who did not have improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
3028468|NCT02372279|No Intervention|No embryo observation (NEO)|Study group. No embryonic observation from day one to day five of embryo development.
3028469|NCT02372279|Experimental|Embryo observation (EO)|Control group. Conventional embryonic observations performed in day two, three and five of embryo development.
3028470|NCT02372266|Experimental|Early Discharge Group|If safety criteria were met, women and infants were discharged home from the hospital at 12 to 24 hours after delivery with a planned home health visit within 48 hours of the discharge.
3028471|NCT02372266|Active Comparator|Routine Stay Group|Women and newborns were discharged no sooner than 48 hours after delivery and could stay voluntarily up to 72 hours.
3028472|NCT02372253|Experimental|Verapamil|13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral verapamil for 12 months. The initial dose of verapamil will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The verapamil tablets will be encapsulated to match the placebo capsules
3028473|NCT02372253|Placebo Comparator|Placebo|13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral placebo for 12 months. The initial dose of placebo will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The placebo tablets will be encapsulated to match the verapamil capsules
3028474|NCT02372240|Experimental|VLX1570 and dexamethasone|"VLX1570 IV (0.05, 0.15, 0.3, 0.6, 1.2, 2.0 mg/kg) on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle~Dexamethasone 20 mg PO/IV"
3028475|NCT02372227|Experimental|VS-5584 and VS-6063|
3028476|NCT02372214|No Intervention|Group 1|30 patients/5 vascular surgery residents The residents of the last year of vascular surgery will perform the procedure under supervision of a senior surgeon
3028477|NCT02372214|Experimental|Group 2|30 patients/5 vascular surgery residents Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
3028478|NCT02372201|Experimental|Hydro Colon Therapy plus probiotic|Hydro Colon therapy including 2-5 washes in 3 weeks, probiotic intervention for 5 weeks after end of hydro Colon therapy
3028479|NCT02372188|Experimental|Water|125 mL water are administered during or before gastric pH measurement
3028480|NCT02372188|Experimental|Caffeine|150 mg Caffeine and 125 mL water are administered during or before gastric pH measurement
3028481|NCT02372188|Experimental|Caffeine + homoeriodictyol sodium salt|150 mg Caffeine + 30 mg homoeriodictyol sodium salt and 125 mL water are administered during or before gastric pH measurement
3028482|NCT02372188|Experimental|homoeriodictyol sodium salt|30 mg homoeriodictyol sodium salt and 125 mL water are administered during the gastric pH measurement
3028483|NCT02372175|Experimental|Low dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single low dose (0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
3028484|NCT02372175|Experimental|Medium dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single medium dose (0.5 mL of 6.5 x 10^4 PFU/mL) inoculated subcutaneously
3028485|NCT02372175|Experimental|High dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single high dose (0.5 mL of 6.5 x 10^5 PFU/mL) inoculated subcutaneously
3028486|NCT02372162||Group A - TACE|"Patients with transarterial chemoembolization (TACE) will get an Image Fingerprint and Molecular Fingerprint for tumor characterization in vivo."
3028487|NCT02372162||Group B - Sorafenib|"Patients with Sorafenib treatment will get an Image Fingerprint and Molecular Fingerprint for tumor characterization in vivo."
3028488|NCT02372149|Experimental|IVIg--Washout--0.9% NaCl (CROSSOVER)|"10% caprylate-chromatography purified intravenous immunoglobulin (IVIg) Initial dose: 1.0gm/kg/day for 2 days (maximum 80gm/day). Maintenance dose (monthly x3): 1.0mg/kg/day for 1 day (maximum 80gm/day)~Washout period~0.9% sodium chloride in water - equal volume to IVIg - Monthly x4"
3028489|NCT02372149|Experimental|0.9% NaCl--Washout--IVIg (CROSSOVER)|"0.9% sodium chloride in water - equal volume to IVIg - Monthly x4~Washout period~10% caprylate-chromatography purified intravenous immunoglobulin (IVIg) Initial dose: 1.0gm/kg/day for 2 days (maximum 80gm/day). Maintenance dose (monthly x3): 1.0mg/kg/day for 1 day (maximum 80gm/day)"
3028490|NCT02372136|Experimental|Individualized and Optimized Nutrition|Individualized nutrition Optimized nutrition
3028491|NCT02372136|Other|Optimized Nutrition|Optimized nutrition
3028492|NCT02372123|Other|control|lifestyle advice
3028493|NCT02372123|Active Comparator|intervention|connective tissue manipulation
3028494|NCT02372110|Experimental|HPA, ANS stimulation|Oral administration of 400mg caffeine and 20mg hydrocortisone will stimulate HPA axis and ANS activity, respectively
3028495|NCT02372110|Placebo Comparator|Two cellulose placebo capsules|two cellulose capsule filled with acidophilus powder will be administered orally
3028496|NCT02372097|Experimental|Group A|Participants in group A will be orally administered 2 tablets of SYR-472 25 mg in period 1 and 1 tablet of SYR-472 50 mg tablet in period 2, both in a single dose under fasting conditions in the morning.
3028497|NCT02372097|Experimental|Group B|Participants in group B will be orally administered 1 tablet of SYR-472 50 mg in period 1 and 2 tablets of SYR-472 25 mg tablets in period 2, both in a single dose under fasting conditions in the morning.
3028498|NCT02372084|Experimental|osilodrostat (LCI699)|Each participant will undergo a 28-day screening/baseline period (day -28 to day -1), followed by a 5 day treatment period (a single 30 mg dose of LCI699 ( Day 1) with 5 days of PK sample collection).
3028499|NCT02372071|Other|BiliCare|Two measurements with the BiliCare device
3028500|NCT02372058|Other|BiliCare|"Three non invasive measurements of TcB:~Two measurements with the BiliCare device and one measurement with a competitive FDA approved device"
3028501|NCT02372032|Experimental|PLD combined with ozone|Patients diagnosed as lumbar disc herniation undergoing percutaneous lumbar discectomy combined with ozone therapy.
3028502|NCT02372032|Active Comparator|pure PLD|Patients diagnosed as lumbar disc herniation undergoing percutaneous lumbar discectomy(PLD).
3028503|NCT02372019|Experimental|CBM With Active Fear Reactivation|
3028504|NCT02372019|Active Comparator|CBM With Inert Fear Reactivation|
3028505|NCT02372019|Placebo Comparator|Inert CBM With Inert Fear Reactivation|
3028506|NCT02372006|Experimental|afatinib|dose escalation
3028507|NCT02371993|Experimental|Choline 650 mg twice daily|See above
3028508|NCT02371993|Placebo Comparator|Placebo|See above
3028509|NCT02371980|Experimental|Open-label: Vortioxetine 10 mg|Vortioxetine 10 mg, capsules, orally, once, daily Week 1 through Week 16.
3028510|NCT02371980|Experimental|Double-blind: Vortioxetine 5 mg|Vortioxetine 5 mg, capsules, orally, once, daily, Week 17 through Week 44.
3028511|NCT02371980|Experimental|Double-blind: Vortioxetine 10 mg|Vortioxetine 10 mg, capsules, orally, once, daily, Week 17 through Week 44.
3028512|NCT02371980|Experimental|Double-blind: Vortioxetine 20 mg|Vortioxetine 20 mg, capsules, orally, once, daily, Week 17 through Week 44.
3028514|NCT02371967||No Gorlin Syndrome Participants With No Prior HPI Exposure|BCC participants with advanced disease and no Gorlin syndrome, and who have not been exposed previously to an Hedgehog Pathway Inhibitor (HPI) (e.g., Vismodegib, LDE225) prior to diagnosis of advanced disease; will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
3028515|NCT02371967||No Gorlin Syndrome Participants With Prior HPI Exposure|BCC participants with advanced disease and no Gorlin syndrome, and who have been exposed previously to an HPI (e.g., during clinical studies with vismodegib [SHH4476g {NCT00833417}, MO25616 {NCT01367665}] or LDE225); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
3028516|NCT02371967||Gorlin Syndrome Participants With/Without Prior HPI Exposure|BCC participants with advanced disease and Gorlin syndrome, and who have or have not been previously exposed to an HPI (e.g., during clinical studies); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
3028517|NCT02371954|Experimental|Health Promotion|Happy Older Latinos are Active (HOLA) is multicomponent health promotion intervention led by a community health worker (CHW). First component is a social and physical activation session. Participants meet individually with CHW for 30 minutes once at week 1, then again at week 8 (the midway point). Second component is a moderate intensity group walk. Groups will consist of 6 participants and will meet for one hour, 3 times a week, for 16 weeks. Third component is pleasant events scheduling during cool down phase of the group walk.
3028518|NCT02371954|Active Comparator|Psychoeducation|Participants will be given a fotonovela and will meet once a month after they receive the fotonovela to discuss their thoughts on the materials they received. These discussion groups will last one hour and will consist of 10 participants.
3028519|NCT02371941|Experimental|Oral cromolyn|"Subjects randomized to the experimental arm will receive oral cromolyn sodium. The dose will be per current package insert for oral cromolyn:~Subjects 2-12 years of age - 100 mg (1 ampule) 4 times daily Subjects 13-18 years of age - 200 mg (2 ampules) 4 times daily"
3028520|NCT02371941|Placebo Comparator|Placebo|Subjects randomized to placebo will receive normal saline ampules Subjects 2-12 years of age - 1 ampule 4 times daily Subjects 13-18 years of age - 2 ampules 4 times daily
3028521|NCT02371928|Active Comparator|Neuromuscular exercise program|"A 12-week physiotherapeutic, supervised exercise program with focus on neuromuscular shoulder control besides incorporation of kinetic chain exercises.~The exercise program contains the following focal points: Scapula and glenohumeral setting/control, dynamic shoulder stability, muscle co-contractions (weight-bearing upper extremity exercises) and proprioceptive training."
3028522|NCT02371928|Active Comparator|Standard home exercise program|"One physiotherapeutic-supervised instruction in 12 weeks of active exercises for the rotator cuff and scapular muscles.~Information about the shoulder injury and how to avoid pain provoking movements besides future implications is given. Also, participants receives one phone call after six weeks of training from a physiotherapist to ensure good compliance and answer any questions that the patient may have."
3028523|NCT02371915|Experimental|Videoconference follow-up|These subjects will remain in or near their home communities for rheumatology follow-up visits. Follow-up visits will occur via telehealth/videoconferencing, with a physiotherapist present, performing the in-person assessment, supported by the rheumatologist via videoconference.
3028524|NCT02371915|No Intervention|Control|These subjects will continue to travel into Saskatoon for the rheumatology visits, as they normally would for routine follow-up visits with their rheumatologist.
3028525|NCT02371902|Active Comparator|ESWT Group|Focused Extracorporeal Shock Wave Therapy: 3 sessions were carried out, with the time interval between sessions spanning between 48 and 72 hours. In each session, 2400 pulses were administered with energy flux density (EDF) ranging from 0.14 and 0.20 mJ/mm2
3028526|NCT02371902|Active Comparator|Cryo-US Group|Therapeutic cryoultrasound: 12 sessions was performed in a continuous emission modality, using an ultrasound emission power rating of 1,8 Watt/cm2, and a temperature of -2˚C, for a total of 12 sessions lasting 20 minutes each.
3028527|NCT02371889|Experimental|Topiramate + Medical Management|Topiramate 200 mg/day orally in two divided doses. Dose will be titrated upward over a six-week period, maintained for 6 weeks, then tapered over 6 days + Medical Management sessions for 15-25 minutes per study visit
3028528|NCT02371889|Placebo Comparator|Placebo Pill + Medical Management|Inactive placebo with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit
3028529|NCT02371876|Experimental|Users of the Monitoring System|Untrained subjects with diabetes used the ONYX PLUS Investigational Blood Glucose Monitoring System.
3028530|NCT02371850|Experimental|Nicoderm patch first, then Aveva patch|Each subject gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)
3028531|NCT02371837|Experimental|pilates group|Pilates based protocol for 6 weeks
3028532|NCT02371837|No Intervention|control group|No treatment group
3028533|NCT02371824||MRI Sequence|
3028534|NCT02371811|Experimental|v care group|In this group we will use (v care) uterine manipulator during abdominal hysterectomy.
3028535|NCT02371811|No Intervention|control group|In this group we will do abdominal hysterectomy without v care.
3028536|NCT02371798|Experimental|Double dose of Gadopentetate dimeglumine|Subjects with a clinical diagnosis of unilateral Meniere Disease (MD) will undergo 3T MR imaging with a double dose of intravenous (IV) gadolinium contrast injection: 0.2 mmol/kg of Gd-DTPA (Magnevist)
3028537|NCT02371785|Experimental|CorPath 200 System|CorPath 200 System for remote delivery and manipulation of guidewires and balloon catheters during percutaneous vascular intervention.
3028538|NCT02371772|Other|Self-management anticoagulation treatment|Trained to monitor INR and dose warfarin
3028539|NCT02371772|No Intervention|Conventional anticoagulation treatment|Before enrolment
3028619|NCT02371356||No depression|Screen negative for depression and comorbidities and receive no treatment.
3028541|NCT02371759|Experimental|Diabetics: L+C mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia
3028542|NCT02371759|Active Comparator|Diabetics: L+E maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia
3028543|NCT02371759|Active Comparator|Diabetics: L+E mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia
3028544|NCT02371759|Experimental|Healthy: L+C maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia
3028545|NCT02371759|Experimental|Healthy: L+C mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia
3028546|NCT02371759|Active Comparator|Healthy: L+E maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia
3028547|NCT02371759|Active Comparator|Healthy: L+E mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia
3028548|NCT02371746|Experimental|ENV515 Travoprost XR Dose A|Study Eye: Single dose of ENV515 travoprost XR Dose A administered on Day 1. Non-Study Eye: TRAVATAN Z administered once a day from Day 1 to Day 25.
3028549|NCT02371746|Experimental|ENV515 Travoprost XR Dose B|Study Eye: Single dose of ENV515 travoprost XR Dose B administered on Day 1. Non-Study Eye: TRAVATAN Z administered once a day from Day 1 to Day 25.
3028550|NCT02371746|Experimental|ENV515 Travoprost XR Dose C|Study Eye: Single dose of ENV515 travoprost XR Dose C administered on Day 1. Non-Study Eye: TRAVATAN Z administered once a day from Day 1 to Day 25.
3028551|NCT02371746|Experimental|ENV515 Travoprost XR Dose D|Study Eye: Single dose of ENV515 travoprost XR Dose D administered on Day 1. Non-Study Eye: TRAVATAN Z administered once a day from Day 1 to Day 25.
3028552|NCT02371746|Experimental|ENV515 Travoprost XR Dose E|Study Eye: Single dose of ENV515 travoprost XR Dose E administered on Day 1. Non-Study Eye: Timolol maleate ophthalmic solution 0.5% administered twice daily from Day 1 to Month 12, Month 18, or up to Month 21.
3028553|NCT02371746|Experimental|ENV515 Travoprost XR Dose F|Study Eye: Single dose of ENV515 travoprost XR Dose F administered on Day 1. Non-Study Eye: Timolol maleate ophthalmic solution 0.5% administered twice daily from Day 1 to Month 12, Month 18, or up to Month 24.
3028554|NCT02371746|Experimental|ENV515 Travoprost XR Dose G|Study Eye: Single dose of ENV515 travoprost XR Dose G administered on Day 1. Non-Study Eye: Timolol maleate ophthalmic solution 0.5% administered twice daily from Day 1 to Month 12, Month 18, or up to Month 24.
3028555|NCT02371733|Active Comparator|Training Group|Intervention:Training group will receive upper extremity aerobic exercise training using arm ergometer and breathing exercises.
3028556|NCT02371733|Sham Comparator|Control Group|Sham: Control group will receive alternative upper extremity exercises and breathing exercises.
3028557|NCT02371720|Experimental|Adults - Mobile DOT|Subjects with SCD that are older than 21 years old will receive comprehensive medication adherence management (Mobile DOT) after 1 month assessment period. The subjects will receive the Mobile DOT intervention for 24 months.
3028558|NCT02371720|Active Comparator|Adults - standard of care then Mobile DOT|Subjects with SCD that are older than 21 years old will receive standard of care for the first 12 months. They will then crossover to the comprehensive medication adherence management plan (Mobile DOT) after 1 month assessment period for the remaining 12 months.
3028559|NCT02371720|Experimental|Children - Mobile DOT|Subjects with SCD that are younger than 21 years old will receive comprehensive medication adherence management (Mobile DOT) after 1 month assessment period. The subjects will receive the Mobile DOT intervention for 24 months.
3028560|NCT02371720|Active Comparator|Children - standard of care then Mobile DOT|Subjects with SCD that are younger than 21 years old will receive standard of care for the first 12 months. They will then crossover to the comprehensive medication adherence management plan (Mobile DOT) after 1 month assessment period for the remaining 12 months.
3028561|NCT02371707|Experimental|Idalopirdine 60 mg formulation A (test)|
3028562|NCT02371707|Experimental|Idalopirdine 60 mg formulation B (reference)|
3028563|NCT02371694|Experimental|Fat Test drink (50g)|This drink contains 50g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
3028564|NCT02371694|Experimental|Fat Test drink (38g)|This drink contains 38g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
3028565|NCT02371694|Experimental|Fat Test drink (25g)|This drink contains 25g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
3028566|NCT02371694|Experimental|Fat Test drink (13g)|This drink contains 13g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
3028567|NCT02371694|Placebo Comparator|Fat Test drink (3g)|This drink contains no sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
3028568|NCT02371694|Active Comparator|Carbohydrate Test drink|This drink contains 20g of glucose from de-gassed lucozade energy.
3028569|NCT02371681|Experimental|1|TB drugs
3028570|NCT02371668|Experimental|2|CR6261, Investigational monoclonal antibody against influenza A viruses
3028571|NCT02371668|Placebo Comparator|1|Placebo, 5% dextrose (D-glucose) water
3028572|NCT02371655|Active Comparator|Diet included|Diet is included in bowel preparation
3028573|NCT02371655|Experimental|Diet not included|Diet is not included in bowel preparation
3028574|NCT02371629|Experimental|NVA237 o.d.|Participants will receive NVA237 once daily dosing during the 26-week treatment period. All participants will receive salbutamol as rescue medicine.
3028575|NCT02371629|Experimental|NVA237 b.i.d.|Participants will receive NVA237 twice daily dosing during the 26-week treatment period. All participants will receive salbutamol as rescue medicine.
3028576|NCT02371616|Experimental|Test dentifrice|Test dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium flouride
3028577|NCT02371616|Active Comparator|Comparator dentifrice|Comparator dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium monofluorophosphate
3028616|NCT02371356||Combination (Comorbidity)|Screen positive for depression and comorbidity and receive both antidepressants and psychotherapy.
3058479|NCT02171754|Active Comparator|BIBW 2992|
3028578|NCT02371603|Experimental|Part A: GSK1278863, pioglitazone and rosuvastatin|Subjects will receive single, oral 15 milligram (mg) pioglitazone, 10 mg rosuvastatin and 25 mg dose of GSK1278863 (Treatment A) or 15 mg pioglitazone and 10 mg rosuvastatin (Treatment B) on Day 1 and a 25 mg dose of GSK1278863 alone on Day 2 in two treatment periods as per treatment sequence AB or BA. The 2 treatment periods will be separated by a wash out period of approximately 7 days
3028579|NCT02371603|Experimental|Part B: GSK1278863 and trimethoprim|Subjects will receive a single, oral 25 mg dose of GSK1278863 on Day 1 and Day 6 morning. The subjects will also receive 200 mg dose of trimethoprim twice daily from Day 3 to 6, with Day 6 dosing being concomitant with morning dosing of GSK1278863
3028580|NCT02371590|Experimental|Lenalidomide-Obinutuzumab|All patients receive the combination of lenalidomide and obinutuzumab. There is no randomization or comparator arm.
3028581|NCT02371577|Experimental|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events.
3028582|NCT02371564|Active Comparator|High flow humidified oxygen first|High flow humidified oxygen then standard oxygenotherapy with a two-hour non invasive ventilation session in between.
3028583|NCT02371564|Active Comparator|Standard oxygen therapy first|Standard oxygenotherapy then high flow humidified oxygen with a two-hour non invasive ventilation session in between.
3028584|NCT02371551||1|All patients
3028585|NCT02371538|Experimental|Donor Breastmilk|Donated human milk is subjected to pasteurization prior to use. Milk consumption is to be overseen by a Registered Dietician. Oral or enteral milk feeding will begin at 180 ml/day and will be advanced as quickly as tolerated to a goal of 360 ml/day for 6 weeks. If symptoms and stool tests for norovirus do not improve after 6 weeks, milk administration may continue for an additional 6 weeks.
3028586|NCT02371525|No Intervention|Standard of Care|
3028587|NCT02371525|Experimental|Prepmate|
3028588|NCT02371512|Experimental|Percutaneous mitral valve repair (MitraClip system )|Percutaneous mitral valve repair (simultaneous left atrial and ventricular pressure assessment suggested) with MitraClip system (Abbott)
3028589|NCT02371512|Active Comparator|Mitral valve surgery|Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
3028590|NCT02371499|Experimental|1st Arm|Treatment with Lactobacillus casei DG (Enterolactis plus®)
3028591|NCT02371499|Placebo Comparator|2nd Arm|Treatment with equivalent product without bacteria (Enterolactis placebo)
3028592|NCT02371486|Experimental|Nich Repair|"Interventions to be administered:~Ultrasound Scan~Diagnostic Hysteroscopy~hysteroscopic repair of cesarean section defect~IVF cycle"
3028593|NCT02371486|Sham Comparator|No Repair|"Interventions to be administered:~Ultrasound Scan~Diagnostic Hysteroscopy~IVF cycle Operative hysteroscopy WILL NOT BE PERFORMED"
3028594|NCT02371473|Experimental|#1 (Acetazolamide-placebo)|The arm #1 consists of 6 eligible patients who receive Acetazolamide 250mg once daily an hour before sleep for first six nights and after two weeks washout they receive placebo for six nights in the same order. After each six-day period they undergo polysomnography.
3028595|NCT02371473|Experimental|#2 (Placebo-acetazolamide)|The arm #2 consists of 6 eligible patients who receive placebo once daily an hour before sleep for first six nights and after two weeks washout they receive acetazolamide 250mg for six nights in the same order. After each six-day period they undergo polysomnography.
3028596|NCT02371460|Experimental|DHA-rich algal oil|1200mg DHA per day
3028597|NCT02371460|Placebo Comparator|Placebo|No supplementation in DHA
3028598|NCT02371447|Experimental|VPM1002BC Induction|"Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)~Maintenance: 3 instillations of VPM1002BC at months 3, 6 and 12"
3028599|NCT02371434|Experimental|Treatment arm|"Patients in ONEnTreg13 will be treated with four immunosuppressive agents, all of which are classified as an Investigational Medicinal Products (IMPs):~nTregs~Prednisolone~MMF~Tacrolimus"
3028600|NCT02371421|Experimental|Allopurinol|Participants with history of gout indicated by the use of allopurinol or participants who have high serum uric acid without contraindication to use allopurinol.
3028601|NCT02371408|Experimental|1a: Treatment-naive patients, without ribavirin (RBV)|PPI-668 + sofosbuvir for 12 weeks
3028602|NCT02371408|Experimental|1b: Treatment-naive patients, with RBV|PPI-668 + sofosbuvir + ribavirin (RBV) for 12 weeks
3028603|NCT02371408|Experimental|2a: Non-cirrhotic previous non-responders, without RBV|PPI-668 + sofosbuvir for 12 weeks
3028604|NCT02371408|Experimental|2b: Non-cirrhotic previous non-responders, with RBV|PPI-668 + sofosbuvir + ribavirin for 12 weeks
3028605|NCT02371408|Experimental|3a: Cirrhotic previous non-responders 12 weeks|PPI-668 + sofosbuvir + ribavirin for 12 weeks
3028606|NCT02371408|Experimental|3b: Cirrhotic previous non-responders 16 weeks|PPI-668 + sofosbuvir + ribavirin for 16 weeks
3028607|NCT02371369|Experimental|Part 1 - Pexidartinib|Participants received blinded treatment of pexidartinib,1000 mg (5 capsules per day ) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks
3028608|NCT02371369|Placebo Comparator|Part 1 - Placebo|Participants received blinded treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks
3028609|NCT02371369|Experimental|Part 2 - All Pexidartinib|Participants received pexidartinib in Part 1 and in Part 2 at their prescribed dose
3028610|NCT02371369|Experimental|Part 2 - Placebo-Pexidartinib|Participants received placebo in Part 1 and pexidartinib in Part 2 at their prescribed dose
3028611|NCT02371356||Antidepressant only (Depressed )|Screen positive for depression and use only antidepressants during pregnancy
3028612|NCT02371356||Antidepressant only (Comorbidity)|Screen positive for depression and comorbidity and use only antidepressants during pregnancy
3028613|NCT02371356||Therapy only (Depressed)|Screen positive for depression and receive psychotherapy only.
3028614|NCT02371356||Therapy only (Comorbidity)|Screen positive for depression and comorbidity and receive psychotherapy only.
3028615|NCT02371356||Combination (Depressed)|Screen positive for depression and receive both antidepressants and psychotherapy.
3028620|NCT02371343|Active Comparator|Fish-Oil|"The pregnants with gestational diabetes given fish oil:~(Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, German) During third trimester of pregnancy, Once in a day"
3028621|NCT02371343|Placebo Comparator|Sunflower oil|"The pregnants with gestational diabetes given sunflower oil:~Sunflower oil capsules will be prepared in the pharmacy as the same size and colour with fish oil capsules During third trimester of pregnancy, Once in a day"
3028622|NCT02371317|Experimental|Mindfulness-Based Stress Reduction|The Mindfulness-Based Stress Reduction intervention includes eight 2.5-hour weekly group sessions and an all-day retreat.
3028623|NCT02371317|Active Comparator|Stress Management Education|The Stress Management Education intervention includes eight 2.5-hour weekly group sessions and an all-day retreat.
3028624|NCT02371317|Other|AHA Recommended Self-Care|All participants will receive the American Heart Association - Understanding and Controlling Your High Blood Pressure Brochure and information on the Dietary Approach to Stop Hypertension from the National Institutes of Health. These brochures describe ways that individuals can improve their lifestyle through better diet and exercise. Participants will get a chance to try and make healthy lifestyle changes on their own, using this information.
3028625|NCT02371304|Active Comparator|Total Mesorectal Excision|After local excision patients will receive additional TME surgery
3028626|NCT02371304|Experimental|Adjuvant chemoradiotherapy|After local excision. Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
3028627|NCT02371291|Experimental|Memory Flexibility Training|The MemFlex programme draws on cognitive bias modification and memory specificity training techniques (Raes et al., 2009; Dalgleish et al., 2014), and was developed by clinical psychologists. MemFlex is primarily self-guided and aims to reduce autobiographical memory biases associated with depression. The training material is presented over one face-to-face session and eight self-guided sessions. In the initial session, the researcher introduces cued-recall tasks which are used throughout the workbook, and guides the participant in completion of these tasks. When understanding of the basic principles is satisfactory, the researcher assists the participant to set a schedule for completion of the workbook over the following four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress.
3028628|NCT02371291|Placebo Comparator|Psychoeducation|The psychoeducation condition will also complete an initial face-to-face session. This session will cover the symptoms and causes of depression, and the workbook will be introduced. As in the MemFlex condition, the workbook will consist of eight self-guided sessions that the individual will be required to complete over four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress, and clarify any difficulties with the workbook material. The workbook content will cover the presentation of depression and basic information on factors associated with depression, such as worry, procrastination, and sleep difficulties. Each session consists of information on psychological theories of the topic, followed by a series of questions about the material to ensure participant engagement. The workbook was developed by clinical psychologists.
3028629|NCT02371278|Other|Higher daily protein|"Diets will provide protein intakes of 1.2 g/kg/d.~Placebo with meals for 3 days, and leucine with meals for 3 days."
3028630|NCT02371278|Other|Lower daily protein|"Diets will provide protein intakes of 0.8 g/kg/d.~Placebo with meals for 3 days, and leucine with meals for 3 days."
3028631|NCT02371265|Experimental|Adherence and retention intervention|Implementation of adherence and retention package
3028632|NCT02371265|No Intervention|Control|Clusters continue without intervention package
3028633|NCT02371252|No Intervention|Original alendronate (Fosamax)|The patients will be given the brand alendronate (Fosamax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
3028634|NCT02371252|Active Comparator|Generic alendronate (Bonmax)|The patients will be given the generic alendronate (Bonmax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
3028635|NCT02371239|Experimental|Sitting regime|The subjects will follow the sitting regime during four days. Each day: 14 hours sitting, 1 hour walking and 1 hour standing for daily care and 8 hours sleeping or lying.
3028636|NCT02371239|Experimental|Sit Less regime|Subjects will follow the sit less regime during four days. Each day will consist of 3 hours walking, 4 hours standing, 9 hours sitting and 8 hours sleeping or lying. The additional 2 hours of walking and 3 hours of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of > 1 hour. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.
3028637|NCT02371239|Experimental|Exercise regime|Subjects will follow the exercise regime during four days. Each day will consist of 13 hours and 15 minutes sitting, ± 45 minutes supervised cycling on an ergometer, 1 hour walking and 1 hour standing for daily care and 8 hours sleeping or lying.
3028638|NCT02371226|Experimental|Cohort 1|1 mg/kg AGT-181 (fusion protein of anti-human insulin receptor monoclonal antibody and alpha-L-iduronidase; HIRMAb-IDUA) administered once weekly x 8 weeks
3028639|NCT02371226|Experimental|Cohort 2|3 mg/kg AGT-181 (HIRMAb-IDUA) administered once weekly x 8 weeks
3028640|NCT02371226|Experimental|Cohort 3|6-9 mg/kg AGT-181 (HIRMAb-IDUA) administered once weekly x 8 weeks
3028641|NCT02371213|Experimental|social networking on mobile phone|Audio-video media via social networking on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly plus usual antenatal care group-health education
3028642|NCT02371213|No Intervention|no social networking on mobile phone|usual antenatal care group-health education
3028643|NCT02371200||Brain Sentinel Seizure Detection and Warning System|This study will compare accuracy of seizure detection by the study device to simultaneously collected data of seizure detection by video EEG.
3028644|NCT02371187|Experimental|Dapagliflozin|The dose of Dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
3058480|NCT02171741|Experimental|Docetaxel + BIBW 2992|
3028645|NCT02371187|Placebo Comparator|Placebo|Matching placebo for Dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
3028646|NCT02371174||HALAVEN treatment group of primary or secondary chemotherapy|Patients with HER2-negative recurrent breast cancer who have received 0 or 1 chemotherapy regimen for recurrent breast cancer.
3028647|NCT02371174||HALAVEN treatment group of tertiary or later chemotherapy|Patients with HER2-negative inoperable or recurrent breast cancer who have received 2 or more chemotherapy regimens for inoperable or recurrent breast cancer.
3028648|NCT02371161|Experimental|R-DHAP/R-ICE|High-dose myeloablative therapy (R-DHAP or R-ICE) and conditioning therapy (BEAM or FEAM) in elderly patients with relapsed NHL or resistant to firs line therapy
3028649|NCT02371148|Experimental|Bortezomib-Rituximab-Bendamustine|Bortezomib-Rituximab-Bendamustine (BRB) combination in patients with relapsed/refractory lymphoplasmocytic/lymphoplasmocytoid lymphoma/Waldenstrom macroglobulinemia after one line of therapy.
3028650|NCT02371135||patients having lower endoscopy|At least 2 weeks prior to scheduled lower endoscopy, consented study participants will be mailed a Brief Diet and Lifestyle Questionnaire, a stool collection kit with detailed instructions and a Stool Collection Data Sheet. No more than one week prior to the lower endoscopy but prior to initiation of bowel preparation, the consented participants will provide a stool specimen and fill out the two questionnaires. The routine lower endoscopy will be performed according to routine clinical procedures. Clinical biopsies of suspicious areas and/or lesions will be taken as per standard clinical care with all such tissue samples sent to pathology for routine clinical analysis. For the sole purposes of research, at the routine lower endoscopy, up to 8 additional colonic biopsies will be taken from normal appearing colon mucosa
3028651|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 1|Therapy Setting 1
3028652|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 2|Therapy Setting 2
3028653|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 3|Therapy Setting 3
3028654|NCT02371122|Sham Comparator|RestoreSensor or RestoreUltra Setting 4|Therapy Setting 4
3028655|NCT02371109||selftaken vs clinical taken swabs|
3028656|NCT02371096|Experimental|RGB-03|
3028657|NCT02371096|Active Comparator|MabThera (rituximab)|
3028658|NCT02371083|No Intervention|Routine|Subjects will continue with regular pessary care every 12 weeks.
3028659|NCT02371083|Experimental|Extended|Subjects will have extended time between pessary care visits which will occur every 24 weeks.
3028660|NCT02371070||Rivaroxaban|N=20
3028661|NCT02371070||Apixaban|N=20
3028662|NCT02371070||Dabigatran|N=20
3028663|NCT02371057||patients under follow-up known to have sleep apnoea|
3028664|NCT02371057||patients attending the sleep apnoea clinic for assessment|Patients who are attending clinic who have not yet been diagnosed.
3028665|NCT02371044||Rivaroxaban|N=20
3028666|NCT02371044||Apixaban|N=20
3028667|NCT02371044||Dabigatran|N=20
3028668|NCT02371031|Experimental|Arm 1: FDOPA-PET/MRI|"Patients with known or suspected brain gliomas that are non-enhancing or have substantial non-enhancing regions will undergo FDOPA-PET/MRI within 2 weeks prior to planned standard of care surgical resection and/or stereotactic biopsy. In the same planning session, the MRI alone will be reviewed and then the FDOPA-PET data will be added to the planning.~In the event that a patient cannot undergo MRI or PET/MRI is not available (e.g. due to maintenance), FDOPA-PET/CT can be performed instead at the discretion of the responsible physician.~When feasible and at the discretion of the neurosurgeon performing the resection, areas of suspected tumor identified on the FDOPA-PET/MRI study but not the MRI alone will undergo tissue sampling."
3028669|NCT02371018|No Intervention|Standard Hemodialysis|Participants will be monitored during their normal hemodialysis treatment with no intervention administered
3028670|NCT02371018|Experimental|Hemodialysis with Nutrition Supplement|Participants will be monitored during a normal hemodialysis treatment in which they consume 1-8oz can of Nepro.
3028671|NCT02371018|Experimental|Nutrition Supplement|Participants will be monitored while drinking 1-8oz can of Nepro with no hemodialysis treatment.
3028672|NCT02371005|Other|Measurement of the periodontal ligament space|Evaluation of the width of the ligament in patients with SSc and comparison to the width found in control.
3028673|NCT02371005|Other|Radiographic analysis of oro-facial manifestations|Establishment of a complete clinical phenotypic description of oral manifestations associated with SSc and comparison with the control group.
3028674|NCT02370992||Receiving I125 brachytherapy|I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
3028675|NCT02370979|Experimental|Dolutegravir|
3028676|NCT02370966|Placebo Comparator|Potato starch|Potato powder will be incorporated in the placebo product.
3028677|NCT02370966|Active Comparator|Berry powder|Several different berry powders including rose hip, bilberry, blackcurrant, sea buckthorn, and lingonberry will be prepared and studied.
3028678|NCT02370953|Experimental|VERION|In this group the VERION-tools (Digital Marker) are used for the alignment of the toric IOL
3028679|NCT02370953|Active Comparator|Conventional, manual ink-marking|In the group the conventional manual marking is used for the alignment of the toric IOL
3028680|NCT02370940|Experimental|High Phytate Diet|The high phytate diet group was required to consume a high phytate diet for 8 weeks. The high phytate foods were provided for subjects. They received whole grain ready-to-eat cereals, whole wheat pasta/spaghetti, tortillas, bagels, bread and dinner rolls, corn tortillas, brown rice, canned black beans, edamame and tofu, and were encouraged to consume generous amounts of nuts and other legume products high in phytate.
3028681|NCT02370940|Experimental|Low Phytate Diet|The low phytate diet group was required to consume a low phytate diet for 8 weeks. They received foods similar to those for the high phytate diet group but which were made from refined wheat and white rice, eggs and cheese, and were instructed to avoid high phytate foods.
3028682|NCT02370927|Placebo Comparator|Control|100% Wheat Flour
3028683|NCT02370927|Experimental|Cereal w/ pea protein|Pea protein
3028684|NCT02370927|Experimental|Cereal w/ pea starch|Pea starch
3028685|NCT02370927|Experimental|Cereal w/ pea starch + pea fibre|Pea starch + pea fibre: 5g
3028686|NCT02370927|Experimental|Cereal w/ pea protein + pea starch|Pea protein + pea starch: 10g
3028687|NCT02370927|Experimental|Cereal w/ pea protein + pea fibre + pea starch:|Pea protein + pea fibre + pea starch: 20g
3028688|NCT02370914|Experimental|Suspected Concussive Event (SCE)|When a subject is suspected of a concussion, a Nautilus NeuroWaveTM System recording is obtained from the subject and the recording is evaluated by a Jan Medical concussion algorithm. The subject is declared concussed or not per the algorithm. This is compared to a SCAT test.
3028689|NCT02370914|Experimental|Control|All subjects at the start of study have a baseline recording using the Nautilus NeuroWaveTM System. These subjects are enrolled into the study as non-concussed and these recordings serve as control recordings. Additionally, some subjects from this cohort will be recorded again at the end of the study to obtain end of season recordings. These results are compared to a SCAT test.
3028690|NCT02370901|Experimental|Helmet|Patients will be referred to a cranial orthotist who will create a custom cranial orthotic device. They will undergo adjustments monthly. At these appointments anthropometric measurements will be done by the cranial orthotist. The orthotist will be blinded and will not be informed of which patient is involved in the study.
3028691|NCT02370901|Experimental|home therapies|Patients will be referred to a physical therapist. They will be offered education, neck stretching exercises, and repositioning techniques, and reassurance.
3028692|NCT02370888|Experimental|Lenalidomide|"Lenalidomide will be administered for a total of 42 days.~The dose levels of lenalidomide will be as follows:~Dose Level 1: 2.5 mg PO QOD Day 1-21 for 28-day cycle X 2 cycles~Dose Level 2: 2.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles~Dose Level 3: 5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles~Dose Level 4: 7.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles"
3028693|NCT02370875|Experimental|Real rTMS stimulation|Repetitious transcranial magnetic stimulation (rTMS) will be delivered using the Magstim RapidStim2 over each anterior cingulate cortex, using a figure-of-eight coil. The investigators will apply rTMS with 0.2 Hz frequency to the ACC. 180 stimuli will be delivered with a stimulator output of 100% active motor threshold (AMT). AMT will be assessed at the tibialis anterior muscle with the coil. The AMT will be defined as the lowest stimulation intensity required to evoke a 150 μV potential in the target muscle. To determine the stimulation site for ACC, the coil will be placed over Fz and then moved over the midline of the brain in 0.5-cm steps anteriorly, until the point of maximum motor evoked potential in the orbicularis oculi (OO) muscle. The coil position will be marked on the skin. These rTMS sessions will be repeated daily for 10 days.
3028694|NCT02370875|Sham Comparator|Sham rTMS Stimulation|During sham repetitious transcranial magnetic stimulation (rTMS), subjects will undergo the same procedure for identifying stimulus location as used in patients receiving real rTMS using the sham Magstim RapidStim2 coil. This coil will be placed on the patient's head in an identical manner however will not be connected to the Magstim device. Instead another coil will be connected to provide stimulation sound. In each stimulation condition, the Magstim will be placed behind the patient and not visible to him or her. Placebo sham coil which produces discharge noise and vibration similar to a real coil without stimulating the cerebral cortex. During rTMS, all patients will continue to wear ear plugs as instructed during the real stimulation sessions.
3028695|NCT02370862|Experimental|Bowel Evacuation Study with NEO and GLY|The study design will consist of a screening visit to determine each individual's response to a previously established IV dose of NEO and GLY, followed by a dose titration study (two visits) of iontophoresed NEO and GLY. Study visits will be separated by no less than 2 days and no more than 14 days.
3028696|NCT02370849|Experimental|NCS|nimotuzumab plus cisplatin and S-1
3028697|NCT02370849|Active Comparator|CS|cisplatin and S-1
3028698|NCT02370836|Experimental|Psycho-oncological education|One 60 minute psycho-oncological education session on late effects, fatigue and stress management.
3028699|NCT02370836|No Intervention|Usual Care|Usual care includes completion of a symptom checklist by the nurse practitioner
3028700|NCT02370823||Knee OA Treated with Regenexx SD|20 subjects with unilateral knee osteoarthritis. Collection of synovial fluid from both knees will serve as the experimental condition, i.e. the osteoarthritic knee, and the matched control, i.e. the knee not demonstrating signs of osteoarthritis. Alterations in the concentration of the synovial fluid proteins and cellular components will be evaluated up to 6 weeks post-Regenexx® SD - Same Day Bone Marrow Concentrate Injection treatment.
3028701|NCT02370810|Experimental|experimental group|CBT-based internet-intervention for tinnitus The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
3028702|NCT02370810|No Intervention|weekly check-in group|will complete weekly measures and commence the treatment once the experimental group completes the intervention
3028703|NCT02370797|Experimental|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
3028704|NCT02370784|Active Comparator|Active Drug|atorvastatin 40 mg once daily for sixteen weeks
3028705|NCT02370784|Placebo Comparator|Placebo control|receive a placebo of similar appearance once daily for sixteen weeks
3028706|NCT02370771|Experimental|Patient with hand osteoarthritis|Biological sampling and Radiographic evaluation of patient with erosive and non erosive hand osteoarthritis
3028707|NCT02370758|Active Comparator|Low CMV CMI|Patients that show low levels of cell-mediated immunity against CMV will have their antiviral therapy (oral Valganciclovir or Intravenous Ganciclovir) continued for an additional 2 months at half dose.
3028708|NCT02370758|No Intervention|High CMV CMI|Patients that show high levels of cell-mediated immunity against CMV will have their antiviral therapy (oral Valganciclovir or Intravenous Ganciclovir) stopped.
3028709|NCT02370745|Experimental|Post absorptive insulin without GLP-1|"Subjects with receive post absorptive insulin concentrations while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.~The intervention in this group is Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition."
3028737|NCT02370628|Experimental|Percutaneous vertebroplasty (PV)|The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae.
3028710|NCT02370745|Experimental|Postabsorptive insulin with GLP-1|"Subjects will receive post absorptive insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.~The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L ."
3028711|NCT02370745|Experimental|Postprandial insulin without GLP-1|"Subjects will receive postprandial insulin concentrations without GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.~The intervention in this group is Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition"
3028712|NCT02370745|Experimental|Postprandial insulin with GLP-1|"Subjects with receive postprandial insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.~The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L ."
3028713|NCT02370745|Experimental|Oral amino acids-Young|"Gut hormones will be measured post oral drink containing 15 g of amino acids in young persons. This will cross over with the following 2 arms.~The intervention here is: 15g of mixed essential amino acid drink."
3028714|NCT02370745|Experimental|Intravenous (IV) amino acids- Young|"Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids in young persons.~The intervention in this group: Intravenous amino acids delivering iso-equivalent amount of 15g mixed essential amino acids"
3028715|NCT02370745|Experimental|IV amino acids, GLP-1, GIP -Young|"Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids, GLP-1, GIP in young persons.~The intervention in this group: Intravenous amino acids iso-equivalent to oral 15 g mixed essential amino acids, GLP-1 infusion and GIP infusion"
3028716|NCT02370745|Experimental|Oral amino acids- Older|"Gut hormones will be measured post oral drink containing 15 g of mixed essential amino acids in older persons.~The intervention in this arm: 15 gram of oral mixed essential amino acid drink"
3028717|NCT02370732|Other|Roux en Y Gastric Bypass|"Participants recruited for this protocol will be those planning to undergo Roux-en-Y Gastric Bypass (RYGB). Upon study screening completion, participants will take part in a total of 4 laboratory assessment days where a fixed dose of alcohol will be given.~2 pre-surgery research appointments where participants will be given alcohol: a driving simulator day and a cognitive testing and reinforcement testing day.~2 post-surgery (1 year) research appointments where you will be given alcohol: a driving simulator day and a cognitive testing and reinforcement testing day."
3028718|NCT02370719|Experimental|Intervention Group|Mobile application plus standard of care
3028719|NCT02370719|No Intervention|Control Group|Standard of care
3028720|NCT02370706|Experimental|Dose Escalation Arm 1|
3028721|NCT02370706|Experimental|Dose Escalation Arm 2|
3028722|NCT02370706|Experimental|Dose Escalation Arm 3|
3028723|NCT02370706|Experimental|Dose Expansion Arm 1|
3028724|NCT02370706|Experimental|Dose Expansion Arm 2|
3028725|NCT02370706|Experimental|Dose Expansion Arm 3|
3028726|NCT02370693|Active Comparator|bortezomib plus mycophenolate mofetil|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month and mycophenolate mofetil 1.5 g orally twice daily for 48 weeks
3028727|NCT02370693|Placebo Comparator|Placebo plus mycophenolate mofetil|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month and mycophenolate mofetil 1.5 g orally twice daily for 48 weeks
3028728|NCT02370680|Experimental|Durlaza™, 1 capsule|Aspirin run-in, followed with Durlaza™, one capsule QD (quaque die), for 14 ± 4 days and an in-patient visit
3028729|NCT02370680|Experimental|Durlaza™, 2 capsules|in a rollover with 10 subjects from the first arm, an aspirin run-in, followed by Durlaza™, two capsules QD, for 14 ± 4 days and an in-patient visit
3028730|NCT02370667|Experimental|Biomechanical Exercise (BE)|The participants in this arm will be asked to attend 3 group classes per week for 12 weeks at a local yoga studio taught by a certified yoga instructor. Four class times will be offered per week. These classes will include a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes will include clinical mobility; muscle and fat volumes, and cartilage morphology using MRI; pain; isometric leg strength; cardiovascular fitness; and gait analysis.
3028731|NCT02370667|Active Comparator|Traditional Exercise (TE)|The participants in this arm will be prescribed an aerobic and strengthening exercise program often prescribed to those with knee OA. The program will include 15 minutes of walking per class, closed kinetic chain strengthening exercises on machines, and a cool down consisting of stretching. Participants will be asked to come to class 3 times per week for 12 weeks. Certified Kinesiologists as well as student volunteers will be available during all class times for program completion and progression.
3028732|NCT02370667|Other|Meditation Control (M)|The participants in this arm will be asked to attend 3 meditation classes per week for 12 weeks taught by a certified yoga instructor with a specialization in meditation. This will take place at an alternate yoga studio to avoid contamination. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the control group will be offered a free exercise pass following completion of the study.
3028733|NCT02370654|Experimental|Tai Chi|12 week Tai chi intervention, 3 sessions per week, 90 minutes per session
3028734|NCT02370654|Active Comparator|Conventional exercise|12 week conventional exercise intervention, 3 sessions per week, 90 minutes per session
3028735|NCT02370641|Active Comparator|urolithin excretors|The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
3028736|NCT02370641|Active Comparator|non excretors|The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
3028738|NCT02370628|Active Comparator|Facet block|injection of anti-inflammatory and analgesic drugs
3028739|NCT02370615|Experimental|Cohort 1: TAK-272 + Itraconazole|TAK-272 40 mg, tablet, orally, once on Day 1 and 10, followed by Itraconazole 200 mg, solution, orally, twice on Day 4, further followed by Itraconazole 200 mg, solution, orally, once from Day 5 to 12.
3028740|NCT02370615|Experimental|Cohort 2: Midazolam + Digoxin + TAK-272|Midazolam 2 mg, syrup, and Digoxin 0.25 mg, tablet, orally, once on Day 1 and 7, followed by TAK-272 80 mg, tablet, orally, once from Day 3 to 8.
3028741|NCT02370602|Experimental|Pilot Cohort: [^11C]T-773 + TAK-063|[^11C]T-773 <8 μg; 400MBq ± 10%, intravenous (IV), once on Days 1 and 2 prior to PET scans and TAK-063 30 mg or 1000 mg, tablets, orally, once on Day 2 and after PET scan #2 and prior to PET scan #3 and [^11C]T-773 IV after TAK-063 and prior to PET scan #3 on Day 2.
3028742|NCT02370602|Experimental|Main Cohort: TAK-063 + [^11C]T-773|TAK-063 3 to 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 <8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2 .
3028743|NCT02370589|Experimental|Group A|Day 0: Base Dose EBOV GP Vaccine; IM Day 21: Base Dose EBOV GP Vaccine; IM
3028744|NCT02370589|Experimental|Group B|Day 0: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
3028745|NCT02370589|Experimental|Group C|Day 0: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
3028746|NCT02370589|Experimental|Group D|Day 0: 2x Base Dose EBOV GP Vaccine; IM Day 21: 2x Base Dose EBOV GP Vaccine; IM
3028747|NCT02370589|Experimental|Group E|Day 0: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
3028748|NCT02370589|Experimental|Group F|Day 0: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
3028749|NCT02370589|Experimental|Group G|Day 0: 4x Base Dose EBOV GP Vaccine; IM Day 21: 4x Base Dose EBOV GP Vaccine; IM
3028750|NCT02370589|Experimental|Group H|Day 0: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
3028751|NCT02370589|Experimental|Group J|Day 0: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
3028752|NCT02370589|Experimental|Group K|Day 0: 8x Base Dose EBOV GP Vaccine; IM Day 21: 8x Base Dose EBOV GP Vaccine; IM
3028753|NCT02370589|Experimental|Group L|Day 0: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
3028754|NCT02370589|Experimental|Group M|Day 0: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
3028755|NCT02370589|Placebo Comparator|Group N|Day 0: Placebo; IM Day 21: Placebo; IM
3028756|NCT02370576||control|Healthy women after elective cesarean section.Questionnaire/ rating scale application. Screening: protocol designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor).
3028757|NCT02370576||emergency|Healthy women after emergency cesarean section. Questionnaire/ rating scale application. Screening: protocol designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor).
3028758|NCT02370563|Experimental|Arm 1|18F-FSPG will be administered to 30 patients with brain tumors or brain metastases.
3028759|NCT02370550|Experimental|Cyclosporin A(CsA)+glucocorticoid|A. The efficacy/safety are evaluated at V3, V4, V5 and V6, and the treatment is adjusted accordingly. Patients who experienced treatment failure (FVC absolute decrease >15% of predicted values after 4 weeks of treatment) are suggested to switch to intravenous glucocorticoid + cyclophosphamide(CYC) 0.5-1 g/m2 every 4 weeks as the rescue therapy after unblinding, and continue to complete the subsequent follow-up. Each patient can only have one chance to be rescued. Patients who experience a second treatment failure should be withdrawn from the trial and be given empirical treatment. Patients who did not experience treatment failure continued to receive current treatment. B. For subjects with aggravated shortness of breath and dyspnea in between of two consecutive visits, the investigators should decide whether a visit should be increased to complete subsequent examinations.
3028760|NCT02370550|Placebo Comparator|placebo+glucocorticoid|A. The efficacy/safety are evaluated at V3, V4, V5 and V6, and the treatment is adjusted accordingly. Patients who experienced treatment failure are suggested to switch to glucocorticoid + CsA 2-3mg/kg/d, BID as the rescue therapy, and continue to complete the subsequent follow-up. Each patient can only have one chance to be rescued. Patients who did not experience treatment failure continued to receive current treatment. B. For subjects with aggravated shortness of breath and dyspnea in between of two consecutive visits, the investigators in each center should decide whether a visit should be increased.
3028761|NCT02370537|Experimental|Sequence AB|A single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 7.
3028762|NCT02370537|Experimental|Sequence BA|A single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 7.
3028763|NCT02370524|Experimental|[18F]T807|At the [18F]T807 PET imaging visit, subjects will be given a bolus injection of no more than 10 mCi (370 MBq) of [18F]T807
3028764|NCT02370511|Experimental|Native mitral valve with severe MAC|Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.
3028765|NCT02370511|Experimental|Valve-in-Ring|Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).
3028766|NCT02370511|Experimental|Valve-in-Valve|Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).
3028767|NCT02370498|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle, for up to 35 administrations (approximately 2 years)
3028768|NCT02370498|Active Comparator|Paclitaxel|Participants receive paclitaxel 80 mg/m^2 IV, on Days 1, 8, and 15 of each 28-day cycle.
3028769|NCT02370485|Experimental|LY2801653 Reference - Fasted|Single oral dose of LY2801653 (Reference Formulation) administered in fasted state in one of three study periods.
3028770|NCT02370485|Experimental|LY2801653 Test - Fasted|Single oral dose of LY2801653 (Test Formulation) administered in fasted state in one of three study periods.
3028771|NCT02370485|Experimental|LY2801653 Test - Fed|Single oral dose of LY2801653 (Test Formulation) administered with a high fat meal in one of three study periods.
3028772|NCT02370472|No Intervention|control group|complete pre-study form 10 minute familiarization time with equipment view video demonstration of task perform task 3 times assessed using scoring form - pretest assigned to group practice task again for 30 minutes proficiency noted final evaluation
3028773|NCT02370472|Experimental|Experimental|complete pre-study form 10 minute familiarization time with equipment view video demonstration of task perform task 3 times assessed using scoring form - pretest assigned to group practice task again for 30 minutes - subjects will use tool developed using cameras and a computer to visualize hand and needle movements as well as the position of the transducers along with the image from the ultrasound on a computer screen proficiency belief noted final evaluation
3028774|NCT02370459|No Intervention|control|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90 clinics. Clinics randomly assigned to this arm will receive no AFIX consultation.
3028775|NCT02370459|Experimental|AFIX in-person consultation|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90 clinics. Clinics randomly assigned to this arm will receive an in-person AFIX consultation. Consultations will be delivered by state health department staff.
3028776|NCT02370459|Experimental|AFIX webinar consultation|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90. Clinics randomly assigned to this arm will receive an AFIX consultation via interactive webinar. Consultations will be delivered by state health department staff.
3028777|NCT02370446||patient gets personalized medication log|Patients in the intervention group will receive a personalized medication log that includes all treatment medications (IV and oral), days of treatment and medication specific information such as timing or diet restrictions. The personalized medication log and patient education materials (fact cards) will be placed in a clear plastic envelope that the patient can carry with them throughout treatment.
3028778|NCT02370446||patient gets standard of care|Current MSKCC standards of professional nursing practice require the professional nurse to develop a plan of care that includes teaching the patient and support system the prescribed prescriptions / regimen and all doses, route, length of treatment, side effects and safety precautions.
3028779|NCT02370433|Experimental|Bowel Evacuation via IV|The study design will consist of an intravenous (IV) screening visit to determine each individual's response to neostigmine and glycopyrrolate (NG).
3028780|NCT02370433|Experimental|Bowel Evacuation Titration|This design will consist of a dose titration for those subjects who respond positively to IV. These subjects will receive either a low dose and/or a high dose of NG via iontophoresis to determine their responsiveness.
3028781|NCT02370433|Experimental|Bowel Evacuation Iontophoresis|This design will consist of the incorporation of iontophoresis administration into clinical bowel care. The subject will receive the exact dose they responded to during the titration 3x per week for 2weeks.
3028782|NCT02370420|Experimental|Unique application of PRP|Patients will be applied a unique application of platelet-rich plasma for knee osteoarthritis, and will be given rehabilitation exercises at home
3028783|NCT02370420|Active Comparator|Triple application of PRP|Patients will be applied a triple application of platelet-rich plasma for knee osteoarthritis, with a interval of two weeks between each, and will be given rehabilitation exercises at home
3028784|NCT02370407|Experimental|Laparoscopic simulator|20 study participants will be randomized to perform peg transfer task on a laparoscopic simulator 10 times (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA).
3028785|NCT02370407|Experimental|Mimic da Vinci robotic simulator|20 study participants will be randomized to perform peg board 1 exercise 10 times on a Mimic da Vinci robotic simulator (Mimic da Vinci Simulator, Intuitive Surgical, Sunnyvale, CA).
3028786|NCT02370394|Experimental|ROSE Program|Participants received a 35-40-minute intervention on the Tablet PC and an in-person 10-15-minute booster session conducted by interventionists within a month after the intervention. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.
3028787|NCT02370394|No Intervention|Control Condition|Control Condition consisted of a series of questions regarding television show preferences and then viewed a brief series of videos of popular entertainers/shows, with subsequent requests for ratings of subjective preference. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.
3028788|NCT02370381||Epistaxis|Patients with active anterior epistaxis
3028789|NCT02370368|Experimental|Dance Group|The Xbox Kinect Video Gaming System: Just Dance 2014 will be used to train the dance group. The training will last 45 minutes. This will be done three times per week for six weeks. The Xbox system will be connected to a multimedia projector and the participants will follow the dance routine conducted by the avatar that will be seen on a wall about six feet in front of them. Training will be done in an air conditioned room.
3028790|NCT02370368|Active Comparator|Ladder Drills|Ladder drills will be done three times per week for 6 weeks. each session will last 45 minutes. Training will be done in an indoor room at the Section of Physical therapy and Division of Sports Medicine.
3028791|NCT02370355||Group I (retrospective analysis)|Previously collected plasma samples are analyzed for ctDNA via PCR and NSG.
3028792|NCT02370355||Group II (prospective analysis)|Patients undergo collection of blood samples before and following systemic therapy for analysis of CTC enumeration, RNA expression, and ctDNA via PCR and NSG.
3028793|NCT02370342|Experimental|Treatment (robot-assisted laparoscopic HIFU)|Patients undergo robot-assisted laparoscopic HIFU thermal ablative therapy during partial nephrectomy.
3028794|NCT02370329|Experimental|Treatment (PEG-proline-interferon alpha-2b)|Patients receive PEG-proline-interferon alpha-2b SC on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3028795|NCT02370316|Experimental|MIT - SA|Metacognitive Interpersonal Therapy -standard approach (MIT-SA) is a cognitive behavior-based psychotherapeutic approach that works to increase metacognitive abilities and to improve interpersonal relationships
3028796|NCT02370316|Active Comparator|Clinical Structured Treatment (CST)|Clinical Structured Treatment (CST) is a structured case management and symptom-targeted medication
3028797|NCT02370290||Observational (QIM)|Patients' clinical and imaging data are collected from routine multiphase CECT imaging and used to establish and validate the classification/prediction rule for QIM.
3028798|NCT02370277||Group A (stool collection after adjuvant chemotherapy)|Patients undergo collection of stool samples at baseline (before surgery), at 1 week before initiation of adjuvant chemotherapy (after surgery), and at 1 and 4 months after completion of adjuvant chemotherapy.
3028799|NCT02370277||Group B (stool collection after adjuvant chemotherapy)|Patients undergo collection of stool samples at baseline (after surgery), at 1 week before initiation of adjuvant chemotherapy, and at 1 and 4 months after completion of adjuvant chemotherapy.
3028800|NCT02370277||Group C (stool collection after neoadjuvant chemotherapy)|Patients undergo collection of stool samples at baseline, 1 month after completion of neoadjuvant chemotherapy (before surgery), and at 1 and 4 months after surgery
3028801|NCT02370264|Experimental|Supportive care (musculoskeletal screening, quality of life)|Patients complete the DASH and FACT-B questionnaires over 30-45 minutes.
3028802|NCT02370251|Experimental|Omegaven|Children will receive Omegaven at a maximum of 1 g/kg/day upon enrollment in this arm.
3028803|NCT02370238|Experimental|paclitaxel+reparixin|"paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + reparixin oral tablets 1200 mg t.i.d.~continuing from D 1 to Day 21 of 28-day cycle"
3028804|NCT02370238|Active Comparator|paclitaxel+placebo|paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
3028805|NCT02370225|Experimental|aerobic exercise|Subjects were submitted to a supervised walking, 3 times a week for 16 weeks.
3028806|NCT02370225|No Intervention|no exercise|Subjects randomized to control group did not participate of the walking exercise initially, but after completing 16 weeks they were invited to participate of the training group.
3028807|NCT02370212|Experimental|Creatine|"Creatine will be ingested after interval training and at supper time on training days and in the morning and afternoon on non-training days (0.05 g/kg body mass of creatine with 0.05 g/kg flavoured dextrose per dose).~Both experimental and placebo groups will perform the same high intensity interval training protocols (3x/week for 4 weeks)."
3028808|NCT02370212|Placebo Comparator|Placebo|"The placebo will be ingested after interval training and at supper time on training days and in the morning and afternoon on non-training days (0.1 g/kg flavoured dextrose per dose, isocaloric to the creatine).~Both experimental and placebo groups will perform the same high intensity interval training protocols (3x/week for 4 weeks)."
3028809|NCT02370199|Experimental|670 nm light|Subjects will have baseline blood flow measured in the gastrocnemius using octafluoropropane infusion and ultrasound.After baseline flow measurements are obtained, a 670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2. Contrast images will be obtained up to 5 minutes after the commencement of light.
3028810|NCT02370173|Experimental|PTSD wavelength-1 bright light|30 minutes of daily light exposure for 6 weeks
3028811|NCT02370173|Placebo Comparator|PTSD wavelength-2 bright light|30 minutes of daily light exposure for 6 weeks
3028812|NCT02370160|Experimental|DT2219ARL|A recombinant bispecific antibody-targeted toxin.
3028813|NCT02370147|Experimental|Smoking reduction intervention arm|Smoking reduction intervention arm (SRI) consisting of a minimal face-to-face individual smoking reduction intervention lasted for about one minute, and five follow-up interventions lasted for about one minute each.
3028814|NCT02370147|Active Comparator|Control arm|Control arm (UC) consisting of a brief face-to-face individual exercise and dietetic advices lasted for the same intervention time as SRI, and five follow-up interventions lasted for about one minute each with different intervention contents.
3028815|NCT02370134|Experimental|Parkinson's glove|Parkinson's glove 14 days use with 4 times follow-up
3028816|NCT02370134|Placebo Comparator|sham glove|sham glove (with light and sound)14 days use with 4 times follow-up
3028817|NCT02370121|Placebo Comparator|Placebo|600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
3028818|NCT02370121|Experimental|Gymnema Sylvestre|600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
3028819|NCT02370108|Experimental|PD patient|Parkinson's disease patients will get the electrical muscle stimulation at the most tremulous hand at 50 Hz frequency, maximal tolerate pulse amplitude (not over 20 mA), duration of stimulation for 10 second.
3028820|NCT02370108|Experimental|OT patients|others tremor patients will get the electrical muscle stimulation at the most tremulous hand at 50 Hz frequency, maximal tolerate pulse amplitude (not over 20 mA), duration of stimulation for 10 second.
3028821|NCT02370095|Active Comparator|Treprostinil inhalation solution|Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
3028822|NCT02370095|Placebo Comparator|Placebo|Placebo administration will be administered as above for the active arm
3028823|NCT02370082|Experimental|SAVI SCOUT device|SAVI SCOUT device used to localize breast lesion which will then be removed surgically. The SAVI SCOUT is the intervention for localization of breast lesions.
3028824|NCT02370069|Active Comparator|Previous immunization with PPV23|Participants who have received a previous vaccination with 1 or more dose of PPV23 at least 12 months previously will receive one dose of 0.5 mL Prevnar 13 study vaccine.
3028825|NCT02370069|Active Comparator|Naive to PPV23|Participants who have never received a previous vaccination with PPV23 will receive one dose of 0.5 mL Prevnar 13 study vaccine.
3028826|NCT02370056|Experimental|3D Visualization|"3-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using 3D Laparoscopic Surgical Video System.~This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons.Effect of using 3D Laparoscopic Surgical Video System on operative outcomes will be evaluated."
3028827|NCT02370056|Active Comparator|2D Visualization|"2-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using conventional Laparoscopic Surgical Video System.~This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons and outcomes will be evaluated."
3058481|NCT02171728|Experimental|BIBW 2992|dose escalation
3028828|NCT02370043|Experimental|KQ-791|Escalating doses of KQ-791, starting at 15 milligrams
3028829|NCT02370043|Experimental|KQ-791 (after meal)|Single dose of KQ-791 in capsule form, after a meal
3028830|NCT02370043|Placebo Comparator|Placebo|Single dose of placebo matching KQ-791 dose
3028831|NCT02370030|Active Comparator|Intervention|Oral or nasogastric administration of 10 g citrulline malate daily. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
3028832|NCT02370030|Placebo Comparator|Placebo|10 g of maltodextrin will be substituted for the citrulline. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
3028833|NCT02370017|Experimental|ANKL combined with chemotherapy|combination of ANKL and doublet chemotherapy as 3rd and 4th course in patients who get stable response after initial x2 courses
3028834|NCT02370004|Experimental|Resistive Flexibility and Strength Training|Each subject will undergo Resistive Flexibility and Strength Training (RFST) with a trained practitioner.
3028835|NCT02369978|Experimental|Nifurtimox (NFX)|60 days of active treatment with full-dose, or 120 days of active treatment with half-dose (allocation ratio 1:1). The 60-day group will receive active treatment in the first or second half of a 120-day treatment window, as per random allocation. The active treatment period will be followed/preceded by matching placebo (see placebo arm below)
3028836|NCT02369978|Active Comparator|Benznidazole (BZN)|60 days of active treatment with full-dose, or 120 days of active treatment with half-dose (allocation ratio 1:1). The 60-day group will receive active treatment in the first or second half of a 120-day treatment window, as per random allocation. The active treatment period will be followed/preceded by matching placebo (see placebo arm below)
3028837|NCT02369978|Placebo Comparator|Placebo|120 days of treatment with matching placebo
3028838|NCT02369965|Experimental|albuvirtide, lopinavir-ritonavir|albuvirtide once a week and lopinavir-ritonavir twice daily for 48 weeks
3028839|NCT02369965|Active Comparator|lopinavir-ritonavir,tenofovir,lamivudine|lopinavir-ritonavir twice daily, tenofovir once daily and lamivudine once daily for 48 weeks
3028840|NCT02369939|Active Comparator|control arm|Irradiation 1.8Gy/d; T2N0 55.8Gy; T3N0-T4N0 59.4Gy Chemotherapy: Mitomycin C 10mg/m^2/d on d1 and 29; 5-Fluorouracil 1000mg/m^2/d on d1-5, 29-33
3028841|NCT02369939|Experimental|Experimental arm|Irradiation 1.8Gy/d; T2N0 55.8Gy; T3N0-T4N0 59.4Gy Chemotherapy: Mitomycin C 10mg/m^2/d on d1 and 29; 5-Fluorouracil 1000mg/m^2/d on d1-5, 29-33 Hyperthermia: 6
3028842|NCT02369926|Active Comparator|Group 1|Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 2.
3028843|NCT02369926|Active Comparator|Group 2|Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 1.
3028844|NCT02369913||Heart failure subjects|Heart failure subjects undergoing cardiac resynchronization will have a blood drawn for this study.
3028845|NCT02369913||Heart arrhythmia patients|Heart arrhythmia patients undergoing ablation will have a blood drawn for this study.
3028846|NCT02369900|Active Comparator|Esmolol infusion|"Esmolol infusion for 24 hours. Esmolol will be titrated to a heart rate of 80 - 94 per minute, starting at 10mcg/kg/min and subsequently increasing every 20 minutes in increments of 10 mcg/kg/min (or slower at the discretion of the team) until target is achieved. The maximum allowed dose will be 300mcg/kg/min.~Patients, irrespective of treatment group, will be managed at the discretion of the clinical team. BIDMC has internal guidelines for the management of septic shock which reflect the most recent 2012 Surviving Sepsis Campaign guidelines and are incorporated into the care of patients with septic shock in the ICUs"
3028847|NCT02369900|Placebo Comparator|Standard care, Saline|Standard care (no esmolol). Patients, irrespective of treatment group, will be managed at the discretion of the clinical team. BIDMC has internal guidelines for the management of septic shock which reflect the most recent 2012 Surviving Sepsis Campaign guidelines and are incorporated into the care of patients with septic shock in the ICUs
3028848|NCT02369874|Experimental|MEDI4736|MEDI4736 monotherapy
3028849|NCT02369874|Experimental|MEDI4736 + Tremelimumab|MEDI4736 + tremelimumab combination therapy
3028850|NCT02369874|Active Comparator|Standard of Care|Standard of Care
3028851|NCT02369861|Experimental|ACCS|Eye drops
3028852|NCT02369861|Placebo Comparator|Artificial tears|Refresh lubricant eye drops
3028853|NCT02369848|Experimental|Lithoplasty Treatment|Shockwave Lithoplasty System
3028854|NCT02369835|Experimental|Arm I (modified Dakin's solution)|Patients apply modified Dakin's solution topically to skin that will be irradiated for 10 minutes within 3 hours before each radiation treatment.
3028855|NCT02369835|Placebo Comparator|Arm II (placebo)|Patients apply placebo solution topically to skin that will be irradiated for 10 minutes within 3 hours before each radiation treatment.
3028856|NCT02369822|Experimental|Vitamin C supplemented|patients with refractory idiopathic epilepsy will receive vitamin C supplement according to age for 1 month
3028857|NCT02369822|No Intervention|None supplemented|followed up for 1 month
3028858|NCT02369809|Experimental|Neovasculgen®|Single group prospective treatment
3028859|NCT02369809|Active Comparator|standard care|
3028860|NCT02369796|Experimental|TAK-448 3 µg once weekly|TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
3028861|NCT02369796|Experimental|TAK-448 1 µg once weekly|TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
3028862|NCT02369796|Experimental|TAK-448 0.3 µg once weekly|TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
3028863|NCT02369796|Experimental|TAK-448 0.3 µg twice weekly|TAK-448 0.3 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.
3028864|NCT02369796|Experimental|TAK-448 0.1 µg twice weekly|TAK-448 0.1 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.
3028907|NCT02369471|Active Comparator|Group 2a|Subjects on inhibitor AEDs will administer GWP42006.
3028865|NCT02369783|Experimental|Questionnaire and interview|The patient complete the questionnaire on the tablet to better know their social situation and any difficulties. Then, he will be interview during thirty minutes with a social worker and a nurse navigator. At the end of this intervention we will be offered to the patient monitoring and appropriate resources to its situation.
3028866|NCT02369770|Experimental|Study group|Subjects in the Study group will receive stretching and active movement training with robotic guidance and intelligent control
3028867|NCT02369770|Experimental|Control group|Subjects in the Control group will receive stretching and active movement training without robotic guidance.
3028868|NCT02369757|Experimental|Intervention of navigators|Navigators accompany the target population towards OCCS.
3028869|NCT02369757|No Intervention|No Intervention|Population is not accompanied by navigators
3028870|NCT02369744|Active Comparator|Silodosin|Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks.
3028871|NCT02369744|Active Comparator|Tamsulosin|Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks.
3028872|NCT02369718|Experimental|Implanted subjects|Listening to 12 Fournier's lists of words
3028873|NCT02369718|Active Comparator|Normal hearing subjects|Listening to 48 Fournier's lists of words
3028874|NCT02369679|Experimental|Precast Adjustable Compression Wrap|Precast Adjustable Compression Wrap will be adjusted by the physiotherapist each visit
3028875|NCT02369679|Active Comparator|Multilayer Compression Bandages|Multilayer Compression Bandages will be adjusted by the physiotherapist each visit
3028876|NCT02369666|Experimental|LycoRed (code 40051) product|Dietary supplement, LycoRed (code 40051) product, experimental: Mixture of tomato-based carotenoids and phytochemicals in medium chain triglycerides (MCT). One capsule each day with the morning meal, for 4 weeks.
3028877|NCT02369666|Placebo Comparator|Placebo|Dietary supplement placebo: Only MCT oil. One capsule each day with the morning meal, for 4 weeks.
3028878|NCT02369653|Experimental|Apixaban|"Children aged 1 to <18 years weighing 6 to <35 kg randomized to apixaban will receive a fixed dose apixaban based on body weight tier twice a day for approximately 28 days.~Children aged 1 to <18 years weighing ≥ 35 kg will receive 2.5 mg of apixaban twice a day for approximately 28 days. Subjects ≥ 5 years may be administered either 2.5-mg, 0.5-mg tablets or oral solution apixaban. Subjects < 5years and < 35 kg may be administered 0.5-mg tablets only"
3028879|NCT02369653|Placebo Comparator|No systemic anticoagulant prophylaxis|No systemic anticoagulant prophylaxis
3028880|NCT02369640|Experimental|Error-avoidance training|Study group 1: Error-avoidance training (Focusing on achieving the highest possible metrics score by avoiding errors).
3028881|NCT02369640|Experimental|Error-management training|Study group 2: Error-management training (Focusing on making errors and thinking of them in a positive way).
3028882|NCT02369627|Experimental|Rapid HIV Self-Test|Participants will perform a rapid HIV self-test using the OraQuick® In-home HIV Test.
3028883|NCT02369627|Active Comparator|Conventional Home-Based HIV Test|Participants will perform a conventional home-based HIV test using the Home Access Express HIV-1 Test System.
3028884|NCT02369627|Active Comparator|Community/Medical-Based HIV Test|Participants will receive a link to a CDC website (https://gettested.cdc.gov) that allows them to search for HIV testing locations of their choice.
3028885|NCT02369614|Active Comparator|Active Comparator:1 Hz rTMS|Active Comparator: 1 Hz rTMS
3028886|NCT02369614|Active Comparator|Active Comparator:10 Hz rTMS|Active Comparator:10 Hz rTMS
3028887|NCT02369614|Sham Comparator|Sham Comparator:Sham rTMS|Sham Comparator: Sham rTMS
3028888|NCT02369614|No Intervention|OASIS treatment as usual|OASIS treatment as usual
3028889|NCT02369588|Experimental|100% Portion Sizes|Food portion size Test meal consists of baseline (100%) portion size of all foods
3028890|NCT02369588|Experimental|133% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 133% the size of baseline portions
3028891|NCT02369588|Experimental|167% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 167% the size of baseline portions
3028892|NCT02369588|Experimental|200% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 200% the size of baseline portions
3028893|NCT02369562||Dental implant patients|All patients rehabilitated with dental implants.
3028894|NCT02369549|Active Comparator|Micro-particle curcumin|"Three 30 mg capsules once daily, self-administered for 6 months.~Curcumin is a nutraceutical, which are products isolated or purified from foods. The rhizomes of the plant Curcuma longa produces turmeric, a spice commonly used in Indian cuisine. Turmeric is comprised of three curcuminoids, of which curcumin is the most abundant. Curcumin is a polyphenol molecule that has been investigated for anti-inflammatory and anti-neoplastic properties since the 1970s."
3028895|NCT02369549|Placebo Comparator|Placebo|"Three 30 mg capsules taken once daily, self-administered for 6 months.~Placebo capsules are identical to the curcumin capsules in color, taste, smell, size and shape."
3028896|NCT02369536|Active Comparator|nutraceutical mixture|Lifestyle counseling plus three month administration of nutraceutical mixture (2 soft gelatin capsules of 800 mg per day)
3028897|NCT02369536|Placebo Comparator|placebo|Lifestyle counseling plus three month administration of placebo formulation (2 soft gelatin capsules of 800 mg per day)
3028898|NCT02369523|Active Comparator|liposomal bupivacaine (LB) (Exparel)|Mixture of 50 milliliters (mL) of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
3028899|NCT02369523|Active Comparator|Ropivacaine cocktail (PIC)|400 milligrams (mg) Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
3028900|NCT02369523|Active Comparator|continuous femoral nerve blocks (cFNB)|"Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.~Sciatic nerve block - 0.125% bupivacaine"
3028901|NCT02369510|Experimental|Low-dose epinephrine|100micrograms of epinephrine group
3028902|NCT02369510|Experimental|High-dose epinephrine|200micrograms of epinephrine group
3028903|NCT02369510|Placebo Comparator|No epinephrine|0.2ml saline
3028904|NCT02369497||Primary cohort|Primary cohort of subjects who receive the HRA device.
3028905|NCT02369484|Other|Afatinib|Afatinib 40 mg p.o./day until tumour progression or lack of tolerability
3028906|NCT02369471|Experimental|Group 1a|Subjects on inducer AEDs will administer GWP42006.
3028908|NCT02369471|Experimental|Group 3a|Subjects on AEDs that are neither inducers nor inhibitors will administer GWP42006.
3028909|NCT02369471|Placebo Comparator|Group 1b|Matching placebo control for Group 1a.
3028910|NCT02369471|Placebo Comparator|Group 2b|Matching placebo control for Group 2a.
3028911|NCT02369471|Placebo Comparator|Group 3b|Matching placebo control for Group 3a.
3028912|NCT02369458|Experimental|Arm 1: p16+ OPSCC|"Mitomycin C given on Day 1 every 5 weeks (each cycle is 5 weeks).~Pegfilgrastim will be given on Day 2 of each cycle (subcutaneous injection)"
3028913|NCT02369458|Experimental|Arm 2: p16- HNSCC|"Mitomycin C given on Day 1 every 5 weeks (each cycle is 5 weeks).~Pegfilgrastim will be given on Day 2 of each cycle (subcutaneous injection)"
3028914|NCT02369445|Experimental|Moisture Pager (MP) Intervention Group|"This group receives the innovative toilet training intervention comprised of a wireless moisture pager (i.e., an app based on an iPod that communicates via electronic signal with a disposable moisture sensor located in the child's underwear)."
3028915|NCT02369445|Active Comparator|Standard Behavioral Intervention Group|This group receives standard-of-care intervention as presented in the Autism Treatment Network's Toilet Training Tool Kit (https://www.autismspeaks.org/site-wide/atn-tool-kits).
3028916|NCT02369432|Experimental|Group of healthy volunteers and group of patients|"Healthy volunteers: Microparticles will be applied to the skin of the forearm and then a skin biopsy of this area will be performed~Patients suffering from atopic dermatitis: Microparticles will be applied to the skin of the forearm both to an area affected by dermatitis and to an area deprived from the disease. A skin biopsy of these two areas will be performed"
3028917|NCT02369419||CRT|Patients over 70 years age, selected for CRT according to the ESC 2013 guidelines.
3028918|NCT02369406|Experimental|Antepartum Cohort|"30 children who test HIV-positive within 96 hours after birth (antepartum HIV infection) and are able to initiate ART < 7 days after birth. This cohort will include at least 15 children who start ART < 3 days after birth.~All infants in the antepartum cohort will initiate ART with Nevirapine, Zidovudine, Lamivudine, and later switch to Kaletra, Zidovudine, Lamivudine."
3028919|NCT02369406|Experimental|Peripartum Cohort|"20 children who test HIV-negative within 96 hours after birth but test HIV-positive within 42 days after birth (peripartum HIV infection) and who are able to initiate ART < 57 days after birth. This cohort will include at least 10 children who start ART < 21 days after birth.~The majority of infants in the peripartum cohort will be able to start Kaletra, Zidovudine, Lamivudine as their first regimen, but a minority may start Nevirapine, Zidovudine, Lamivudine and then switch to Kaletra, Zidovudine, Lamivudine."
3028920|NCT02369406|No Intervention|Control Cohort|20 HIV-infected children who initiated ART at later age ranges (30-365 days for antepartum infection, 57-365 days for peripartum infection or for those with unknown timing of infection) will be enrolled for a single visit that will occur between 24 and 36 months of age. These children will serve as a control group for virologic and immunologic comparisons with children in the prospective cohorts.
3028921|NCT02369393|Experimental|Behavioral Activation|BA treatment for depression is a simple, cost-effective method. There is evidence that the behavioral component may be the active mechanism of change in cognitive-behavioral treatments of clinical depression. One of the main objectives of the treatment is to systematically increase exposure to positive activities, and thereby improve affect and corresponding cognitions. Treatment will be delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components are: 1) psycho-education, 2) identifying important values and significant activities, 3) activity structuring and scheduling, 4) relapse prevention. These will be delivered over 4 modules. There will be a minimal therapist support.
3028922|NCT02369393|No Intervention|Waiting list control group|In the waiting list control group (WL), subjects will receive no treatment during 8 weeks. We will not interfere but we will monitor carefully through self-report. Then participants will be randomised to the two treatment groups.
3028923|NCT02369393|Experimental|Physical Activity|There is evidence to suggest that the addition of cognitive behavioral therapies, specifically exercise, can improve treatment outcomes for many patients. Exercise is a behavioral intervention that has shown great promise in alleviating symptoms of depression. The treatment will be delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the PA treatment are: 1) psychoeducation: understand the mental health benefits of physical activity, 2) learn about the types and amounts of physical activity recommended, 3) motivation to perform and maintain physical activities, 4) relapse prevention. These will be delivered over 4 modules. There will be a minimal therapist support.
3028924|NCT02369380|Experimental|Hyaluronic acid|Injections of hyaluronic acid under metatarsal heads
3028925|NCT02369367|Experimental|Irinotecan + Lenalidomide|Irinotecan 200 mg/m^2 intravenous once every 2 weeks on days 1 and 15; Lenalidomide orally 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
3028926|NCT02369354|No Intervention|Usual Care|Usual medical care at the Duke Kidney Transplant Clinic
3028927|NCT02369354|Other|TALKS|Usual Care plus TALKS Social Worker Intervention: Includes video, book, and Social Worker meetings
3028928|NCT02369354|Other|TALKS PLUS|Usual Care plus TALKS Social Worker Intervention: Includes video, book, and Social Worker meetings plus live donor financial assistance intervention
3028929|NCT02369341|Experimental|Fluarix Tetra (Southern Hemisphere) Adult Group|Subjects aged 18-60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
3028930|NCT02369341|Experimental|Fluarix Tetra (Southern Hemisphere) Elderly Group|Subjects aged >60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
3028931|NCT02369328|Experimental|multimodal MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) and clinical evaluation will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months for patients whom suffering stroke
3028932|NCT02369328|Active Comparator|multimocal MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) and clinical evaluation will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months for healthy subjects
3028933|NCT02369315|Experimental|Treatment (Invited entry 2012)|Children offered entry to music program in September 2012
3028934|NCT02369315|Experimental|Control (Invited entry 2013)|Children offered entry to music program delayed until September 2013
3028935|NCT02369302|Experimental|DWC20141|multiple dose of DWC20141
3028936|NCT02369302|Experimental|DWC20142|multiple dose of DWC20142
3028937|NCT02369302|Experimental|DWC20141+DWC20142|multiple dose of DWC20141 and DWC20142
3028938|NCT02369289||vegans|a vegan diet in the last 3 years
3028939|NCT02369289||omnivores|aminal-based diet, comsumption of aminal products at least 3 times a week
3028940|NCT02369276||post SND within 3 months|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within 3 months, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
3028941|NCT02369276||post SND within >3- 6months|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within >3- 6months, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
3028942|NCT02369276||post SND within 6 months -1 year|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within 6 months -1 year, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
3028943|NCT02369276||post SND within more than 1 year|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within more than 1 year, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
3028944|NCT02369276||without shoulder disability|20 Head and Neck Cancer(HNC) post SND without shoulder complication at the control group, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
3028945|NCT02369250|Placebo Comparator|OFD+ PLACEBO GEL|furcation defect site is surgically debrid and placed a placebo gel
3028946|NCT02369250|Active Comparator|OFD+ PRF + BONE GRAFT|Following surgical debridment of furcation site autologous PRF and bone graft is placed in defect as a competator drug used is platelet rich fibrin and porus hydroxyapatite bone graft
3028947|NCT02369250|Experimental|RSV1.2% gel + PRF+ BG|Following surgical debridment of furcation site Rosuvastatin 1.2% in situ gel combined with autologous PRF and bone graft is placed
3028948|NCT02369211|Experimental|Intravenous acetaminophen|Patient receives 1g intravenous acetaminophen after the incision
3028949|NCT02369211|Placebo Comparator|Placebo|Patient receives saline injection instead of the study drug
3028950|NCT02369198|Experimental|Single arm, open label TargomiRs|"TargomiRs are IV injected.~Phase 1 Planned dose levels~Dose level 1: 5 billion once a week Dose level 2: 5 billion twice a week Dose level 3: 5 billion once a week with cardiac monitoring Dose level 4: 2.5 billion twice a week with cardiac monitoring Dose level 5: as for dose level #3 with a dexamethasone challenge~All patients begin on a micro dose of one billion and increase their dose over 2 weeks and reach their phase 1 dose level on week 3.~Schedule of assessments includes laboratory and physical assessments in the 24 hours after each treatment as well as periodic assessments such as PET and CT scans for tumour assessment.~100% of the data will be source data verified. Analysis will be simple phase 1 analysis based on a 3+3 model."
3028951|NCT02369172|Other|Bupropion + ASP2151|400 mg ASP2151 followed by 150 mg Bupropion
3028952|NCT02369159|Experimental|Peramivir (IV)|"Subjects randomized to peramivir will receive an age appropriate single dose, diluted to a total volume of 100 mL in normal saline, administered as a short intravenous infusion over a minimum of 15 minutes.~Subjects ≥12 years will receive a dose of 600 mg.~Subjects <12 years will receive a dose of 12 mg/kg (to a maximum dose of 600 mg).~Subjects < 6 months will receive a dose of 8 mg/kg."
3028953|NCT02369159|Active Comparator|Oseltamivir|"Subjects randomized to oral oseltamivir will receive an age appropriate dose twice daily for 5 days.~Subjects ≥ 13 years will receive a 75mg dose administered as a capsule or oral suspension (twice daily for 5 days).~Subjects < 13 years of age will receive a weight-based dose administered as a capsule or oral suspension (twice daily for 5 days)."
3028954|NCT02369146|Experimental|cohort 1|Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly
3028955|NCT02369146|Experimental|cohort 2|Subjects will receive 8 doses of the UB-421 by intravenous infusion at 25 mg/kg weekly
3028956|NCT02369133|Active Comparator|Group Paracetamol (Group P),|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol
3028957|NCT02369133|Placebo Comparator|Group Saline (Group S)|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group S (n = 30) received 100 ml iv %0,9 saline
3028958|NCT02369120|Active Comparator|Normal care by GP|"Control group: Will follow conventional treatment provided by the family physician in primary care. This treatment is based on the clinical guidelines of the Institut Català de la Salut (http://www.gencat.cat/ics/professionals/guies/docs/guia_lumbalgies.pdf)."
3028959|NCT02369120|Experimental|Educational intervention using a website|This group of subjects will be given access to our web-site in where they will find information related to CLBP. This information will be provided in different formats: explanatory video by the author, animated video about the neurophysiology of pain, written format using metaphors, and FAQs. All this information will be based on the information provided by the subjects on QUAL. The aim of this educational intervention is to change patient´s misbeliefs about CLBP with the last outcome of reducing pain intensity, improving function, and reducing disability.
3028983|NCT02368912|Experimental|1. Single ascending dose (SAD), ASP1707 dose levels 1-7|healthy young male
3028984|NCT02368912|Experimental|2. Single ascending dose (SAD), placebo dose levels 1-7|healthy young male
3028985|NCT02368912|Experimental|3. Food effect (FE), ASP1707 fasted|Fasted healthy young male
3028986|NCT02368912|Experimental|4. Food effect (FE), ASP1707 fed|Fed healthy young male
3028960|NCT02369107|Experimental|Verum acupuncture and medicine|Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
3028961|NCT02369107|Sham Comparator|Sham acupuncture and medicine|Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
3028962|NCT02369094|Experimental|Acupressure Group|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
3028963|NCT02369094|Other|Waiting Control Group|"No acupressure therapy will be provided during the 1st 12 weeks' of study.The enrolled elderly will join a group activity, resembling the other group activities that held in that particular center, their caregivers will be requested to spend two 20 minutes sessions per week with the elderly doing homework assigned by the activity group and log down the timing in the log book.This arrangement is to account for the placebo effect of additional social interaction time and attention that the treatment group will receive during this period.~After completing the 1st 12 weeks' participation in the Waiting Control Group, the subject dyads in the waiting control group will receive the same training and treatment as the treatment group."
3028964|NCT02369081|Active Comparator|Spironolactone|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase.
3028965|NCT02369081|Placebo Comparator|Placebo|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
3028966|NCT02369081|Active Comparator|Doxazosin|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
3028967|NCT02369081|Active Comparator|Bisoprolol|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
3028968|NCT02369068|Experimental|Onabotulinumtoxin A|"Intervention is a one time 30 cc intravaginal injection totaling a dose of 200u of onabotulinumtoxin A and saline injected throughout the pelvic floor at 1, 3, 5, 7, 9 and 11 o'clock sites/locations.~An injection of 30 cc of ropivicaine (5cc/6 sites) will be used, followed by a mixture of 200 u of Onabotulinumtoxin A and 6 cc of saline (1cc/injection site)."
3028969|NCT02369068|Active Comparator|Kenalog|"Intervention is a one time 30 cc intravaginal injection totaling a dose of 40mg/cc of Kenalog (triamcinolone) and ropivicaine 0.5% (29cc) injected throughout the pelvic floor at 1, 3, 5, 7, 9 and 11 o'clock sites/locations.~A mixture of 40mg/1 cc of triamcinolone (40 mg) and 29cc of ropivicaine 0.5% (5cc/6 sites) will be used, followed by 6 cc of saline (1cc/injection site)."
3028970|NCT02369055||Patients with stroke|"All patients from UNN Tromso, Narvik and Harstad (Norway) and Aarhus (Denmark) are included.~For the in-depth interviews patients are strategically picked based on their answers in the quantitative study"
3028971|NCT02369042|Experimental|Cohort I|Patients admitted with the primary diagnosis of HF and are currently being assessed with clinically indicated hemodynamic monitoring.The Kyma device will be worn by the patient and data collected from the device will be compared to the data collected through hemodynamic monitoring. The device will be worn for 60 days post hospital discharge.
3028972|NCT02369042|Experimental|Cohort II|Patients admitted with the primary diagnosis of HF and are being assessed with or without hemodynamic monitoring. The Kyma device will be worn by the patient and data collected from the device will be compared to the data collected while the patient is hospitalized. The device will be worn for 60 days post hospital discharge.
3028973|NCT02369029|Experimental|Arm 1|To determine maximum tolerated dose (MTD) of BAY 1238097
3028974|NCT02369016|Experimental|Copanlisib (BAY 80-6946)|patients with rituximab-refractory iNHL
3028975|NCT02369003|Experimental|Peripheral Nerve Graft|The intervention includes the surgical implantation of autologous peripheral nerve graft into the substantia nigra of participants with Parkinson's Disease that are undergoing Deep Brain Stimulation (DBS).
3028976|NCT02368990||NSCLC T790M positive|NSCLC patients who have had 1st line treatment with an approved EGFR targeted TKI, who are known to be T790M mutation positive and who have been prescribed platinum based doublet chemotherapy (pemetrexed + cisplatin/carboplatin) as a 2nd line treatment as part of their standard care.
3028977|NCT02368977|Experimental|All subjects|All subjects will undergo examination with a Third Eye Panoramic device in conjunction with a standard colonoscope to evaluate the feasibility of using the study device to provide video imaging of areas of the colon that are difficult to evaluate with the colonoscope alone.
3028978|NCT02368964|Experimental|High dose hCG|The hCG group- will be triggered for final follicular maturation with high dose hCG (500 mcg)-38 hours prior to oocyte aspiration
3028979|NCT02368964|Experimental|Double trigger|Double trigger Group- will receive GnRH agonist (Decapeptyl 0.2mg) 40 hours prior to oocyte aspiration and hCG (250mcg) 34 hours prior to the oocyte aspiration
3028980|NCT02368951|Experimental|BAY1187982|"Dose-escalation phase:~Approximately 30 subjects will participate in the dose-escalation phase The total number of subjects will depend on the number of cohorts necessary to identify the MTD.~MTD expansion phase:~Once the MTD has been determined, two expansion cohorts in FGFR2 expressing indications are planned:~Cohort 1: Triple negative breast cancer (TNBC). This cohort will enroll 80 subjects (N=40 with low to moderate FGFR2 expression and N=40 with high FGFR2 expression) Cohort 2: Other indications expressing FGFR2. This cohort 40 subjects will be enrolled."
3028981|NCT02368938||Several communities in the north of Shanghai|
3028982|NCT02368925|Experimental|Ultherapy™ System|Ultherapy™ System
3028987|NCT02368912|Experimental|5. Multiple ascending dose (MAD), ASP1707 dose levels 1-4|healthy elderly male
3028988|NCT02368912|Experimental|6. Multiple ascending dose (MAD), Placebo, dose levels 1-4|healthy elderly male
3028989|NCT02368912|Experimental|7. Multiple ascending dose (MAD), ASP1707, dose levels 1-2|healthy pre-menopausal female
3028990|NCT02368912|Experimental|8. Multiple ascending dose (MAD), Placebo dose levels 1-2|healthy pre-menopausal female
3028991|NCT02368912|Experimental|9. Parallel multiple dose, ASP1707 dose levels 1-3|healthy pre-menopausal female
3028992|NCT02368912|Experimental|10. Parallel multiple dose, Placebo|healthy pre-menopausal female
3028993|NCT02368899|Experimental|Computerized Alcohol Misuse Intervention|Arm 1 is a cross-over randomized controlled trial (XRCT) comparing the short-term effects of the computerized alcohol misuse intervention (CAMI) vs. a generic health education attention-control (AC) condition in reducing past 30 day: (a) days of alcohol use, (b) days of heavy episodic drinking, (c) typical number of drinks consumed on a day of drinking, and (d) alcohol use in dangerous situations; (2) investigate changes in (a) patient motivation and (b) perceived norms as mediators of intervention effectiveness.
3028994|NCT02368899|Placebo Comparator|Attention Control (AC)|Arm 2 is not an active intervention but an attention control condition - it is not expected to exert any real intervention effect. Hence, any observed effects for the AC condition can be attributed to natural change via regression-to-the-mean, assessment reactivity, or a placebo effect. The effect size estimate of the intervention, both from an efficacy standpoint (i.e., above and beyond what change would have normally occurred) and an effectiveness standpoint (i.e., the magnitude of behavior change that can be expected in real-world implementation), can be readily calculated.
3028995|NCT02368886|Experimental|Arm A1 (lower-dose regorafenib, pre-emptive clobetasol)|Patients receive lower-dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate given topically BID for 12 weeks, beginning on day 1 of regorafenib.
3028996|NCT02368886|Experimental|Arm A2 (lower-dose regorafenib, reactive clobetasol)|Patients receive lower-dose regorafenib PO as in Arm A1 and reactive clobetasol propionate given topically BID beginning on day 1 per physician discretion upon occurrence of PPES grade >= 1.
3028997|NCT02368886|Experimental|Arm B1 (standard dose regorafenib, pre-emptive clobetasol)|Patients receive standard dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate as in Arm A1.
3028998|NCT02368886|Experimental|Arm B2 (standard dose regorafenib, reactive clobetasol)|Patients receive standard dose regorafenib PO as in Arm B1 and reactive clobetasol propionate as in Arm A2.
3028999|NCT02368873|Active Comparator|Intervention group|Patients with IPOM Dynamesh mesh around the straight permanent colostomy.
3029000|NCT02368873|No Intervention|Control group|Patients with the straight permanent colostomy without a mesh.
3029001|NCT02368860|Experimental|OXIRI|OXIRI regimen: oxaliplatin, irinotecan, capecitabine
3029002|NCT02368847|Other|Diagnostic tests|For any patient with a suspected urinary tract infection during the course of the study a basic questionnaire will have to be filled out and diagnostic tests (urine sample for culture, dipstick assay for the detection of nitrites and leukocyte- esterase and a POC CRP test) will have to be perform.
3029003|NCT02368834|Experimental|intervention group|A psychoeducation program was delivered to the parents/caregivers
3029004|NCT02368834|No Intervention|control group|This group waited for 3 months, only receiving general consultation.
3029005|NCT02368821||normal pregnancy|placental from normal pregnancy
3029006|NCT02368821||complacted pregnancy|placental from complicated pregnancy ( intrauterine growth restriction, preeclampsia , placenta accrete
3029007|NCT02368808|Experimental|Abangane Support Group|Bereavement support group for adolescents
3029008|NCT02368808|No Intervention|Wait List|Wait-listed adolescents will be able to participate in Abangane at the close of the study.
3029009|NCT02368795|Placebo Comparator|Pharmacological Prevention|Combination of rectal indomethacin, sublingual isosorbide dinitrate and intravenous hydration with Ringer's lactate serum without pancreatic stenting
3029010|NCT02368795|Active Comparator|Pancreatic Stent|Pancreatic Stent PLUS Pharmacological Prevention
3029011|NCT02368782||ketamine group|ketamine 2mg/kg bolus IV once
3029012|NCT02368782||propofol group|propofol 2mg/kg ıv bolus once
3029013|NCT02368769||During tele-expertise|Remote site interpretation of frozen section
3029014|NCT02368769||Before tele-expertise|Usual (on site) frozen section
3029015|NCT02368756|Other|Aflibercept|2 mg dose of Aflibercept given prn
3029016|NCT02368743||mesalazine|Treatment according to standard clinical practice.
3029017|NCT02368730||desmopressin|Treatment according to standard clinical practice.
3029018|NCT02368717|Experimental|Mesalazine|Mesalazine Enema
3029019|NCT02368717|Placebo Comparator|Placebo|Placebo Enema
3029020|NCT02368704||control|"control subjects with :~Nondiabetic subjects (blood glucose <7.0 mmol/l without hypoglycemic treatment).~The control subjects should be matched to patients for age (± 5 years), sex, and BMI (± 2 kg/m2)."
3029021|NCT02368704||case|"Diabetic patients with :~Having type 2 diabetes for at least 6 months~HbA1c ≤ 8%~Treat by lifestyle and dietary rules associated or not to a hypoglycemic therapy (metformin and / or sulfamid) and / or insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4): Vildagliptin, Sitagliptin, Saxagliptin~No modification of hypoglycemic therapy and / or insulin secretors for at least 3 months"
3029022|NCT02368691|Experimental|GTx-024|GTx-024 capsules, 18 mg PO once-daily for up to 12 months
3029023|NCT02368678|Active Comparator|Scaling and Root Planning (SRP)|Scaling and root planing (SRP) (n=15): the traditional mechanical periodontal therapy consisting of quadrant-wise (30 min. per quadrant) scaling and root planning performed at weekly sessions (one or two weeks of interval between session) and completed within 2 months.
3029024|NCT02368678|Active Comparator|Full Mouth Scaling (FMS)|Full mouth scaling (FMS) (n=15): the alternative mechanical periodontal therapy consisting of full-mouth scaling and root planning completed in a single stage within 24 hours; i.e two sessions (60 min. per session) in two consecutive days.
3029025|NCT02368665|Experimental|AML 5mg|- Amlodipine 5mg, once a day for 8 weeks
3029026|NCT02368665|Experimental|AML 5mg / CC 16mg|- Amlodipine 5mg and Candesartan cilexetil 16mg, once a day for 8 weeks
3029027|NCT02368665|Experimental|AML 10mg / CC 16mg|- After 8 weeks of treatment period, Amlodipine 10mg and Candesartan ceilexetil 16mg, once a day for 8 weeks
3029028|NCT02368652|Experimental|CC 16mg|Candesartan ceilexetil 16mg, once a day for 8 weeks
3029029|NCT02368652|Experimental|AML 10mg / CC 16mg|Amlodipine 10mg and Candesartan ceilexetil 16mg, once a day for 8 weeks
3029030|NCT02368639|Experimental|Positive airway pressure (PAP) device|Fisher & Paykel Healthcare PAP Device. Participants will sleep overnight using themodified positive airway pressure device. Their pressures will be titrated by a qualified sleep technician, they will then be optimised during the night.
3029031|NCT02368626|Experimental|RF ablation treatment|'EndyMed Pro™ RF Micro-Needles' - RF ablation treatments for wrinkle appearance reduction
3029032|NCT02368613|Placebo Comparator|placebo group|Placebo
3029033|NCT02368613|Active Comparator|test1 group|DW-3102 125mg
3029034|NCT02368613|Active Comparator|test2 group|DW-3102 250mg
3029035|NCT02368613|Active Comparator|test3 group|DW-3102 500mg
3029036|NCT02368600|Experimental|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
3029037|NCT02368600|No Intervention|Usual care|Women will have their first AN booking visit generally on or before 12 week gestation. For women who are primigravida, their AN visit appointments will be set at every 6 weeks before 24 weeks, every 4 weeks between 24-28 weeks, and every 2 weeks after 28 weeks. For women who are multigravida, the corresponding schedules will be set at every 6 weeks before 24 weeks, every 4 weeks between 24-36 weeks, and every 2 weeks after 36 weeks. Body weight of the pregnant woman will be monitored by nurses and basic nutrition advice will be briefly given by nurses in case she is slightly overweight. They will be provided with an educational pamphlet on diet and exercise during pregnancy. They will also be offered optional antenatal classes which subjected to quotas availability.
3029038|NCT02368587|Placebo Comparator|Intracoronary infusion WJMSCs|Intracoronary infusion WJMSCs or placebo in patients with ischemic heart failure
3029039|NCT02368587|Placebo Comparator|Intravenous infusion WJMSCs|Intravenous infusion WJMSCs or placebo in patients with ischemic heart failure.
3029040|NCT02368574|No Intervention|Class III hysterectomy Arm|Class III hysterectomy (radical hysterectomy): This procedure may be performed through laparotomy or laparoscope. Perivesical space and perirectal space should be opened, and the ureteral tunnel is completely separated and pushed down to the junction of ureter and urinary bladder. The uterine arteries are ligated at the level of internal iliac artery, and all the supporting ligaments and connective tissues around the uterus should be separated and abscised. The uterosacral ligament is removed near the sacrum, the cardinal ligament is removed near the pelvic wall, and the vagina is removed after the excision of peivaginal connective tissues, about 3-4cm from the cervical lesion. The pelvic lymph nodes are usually dissected at the same time.
3029041|NCT02368574|Experimental|Class II hysterectomy Arm|Class II hysterectomy (modified radical hysterectomy): This procedure may be performed through laparotomy or laparoscope. The scope of surgery is more extensive than Class I epifascial panhysterectomy, demanding the excision of more parametrium but reservation of the blood supply for distal ureter and urinary bladder. The ureter is separated from the ureteral tunnel, the vesicouterine ligament should be intact, and 1/2 uterosacral ligament and 1cm vagina are excised. The pelvic lymph nodes are usually dissected at the same time.
3029042|NCT02368561|Experimental|Hyaluronic Acid Injection|Hyaluronic Acid Injection in 20 adult patients with IAT
3029043|NCT02368548|Experimental|Pharmaceutical care program|"Initiated in the Emergency Department (ED):~Review of home medication and medication reconciliation based on Primary Care data~Patient interview. Assessment of the patient's knowledge on the pharmacological treatment~Development of the pharmacological history and registration in the medical record~Adequacy of drug therapy. Identification of Drug Related Problems including reconciliation errors (DRP) and communication to medical team~Pharmacotherapy monitoring~Treatment validation and medication reconciliation at discharge~During the hospitalization (if admission from the ED):~Treatment review and medication reconciliation~Pharmacokinetics monitoring~Retrospective validation of prescriptions and assessment of drugs appropriateness. DRP identification and communication to medical team~Pharmacotherapy monitoring~Validation and medication reconciliation at discharge~Patient education at discharge"
3029044|NCT02368548|Other|Standard Care|"Stages:~Pharmaceutical care program in the episode at the Emergency Department:~a. There was no monitoring of the patient by the pharmacist. Retrospective validation of the prescriptions was not performed.~During the hospitalization (if admission from the ED):~Pharmacokinetics monitoring~Retrospective validation of prescriptions and assessment of drugs appropriateness."
3029045|NCT02368522||Patients treated with and without exposure|
3029046|NCT02368509|Experimental|Bronchial cancer|Patients with bronchial cancer will perform sensory tests before and after a 6-week period of chemotherapy.
3029047|NCT02368509|Placebo Comparator|Control group|Healthy individuals will perform sensory tests before and after a 6-week period without chemotherapy.
3029048|NCT02368496|Experimental|Children and young adults on long-term parenteral nutrition|long-term parenteral nutrition : 2 years
3029049|NCT02368483|Experimental|Neuromuscular training|
3029050|NCT02368470|Active Comparator|Standard triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
3029051|NCT02368470|Experimental|Gemifloxacin-based triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
3029052|NCT02368457|Experimental|Pentoxifylline and Tocopherol|Drug: pentoxifylline with tocopherol Combination of pentoxifylline and tocopherol during a minimum of 6 months and a maximum of 24 months.
3029053|NCT02368457|No Intervention|CONTROL|No drug treatment
3029054|NCT02368444|Experimental|Intervention Group|Cognitive Behavioral Therapy and Yoga
3029119|NCT02368028||Caries Active|Participants who do have caries (cavities) will have oral samples collected.
3029219|NCT02367365||Newly Reactivated NVAMD Patients|Patients with newly reactivated NVAMD which has been previously quiescent off treatment
3029055|NCT02368431|Experimental|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind (Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose). Subjects may increase their dose to 600mg daily during the target treatment period if it is thought to be beneficial.
3029056|NCT02368431|Placebo Comparator|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group)
3029057|NCT02368418||PCP and SRS|participants had received two interventions (PCP and SRS)
3029058|NCT02368418||PCP only|participants had received PCP intervention only
3029059|NCT02368418||SRS only|participants had received SRS intervention only
3029060|NCT02368418||control group|participants had received usual care (neither PCP nor SRS)
3029061|NCT02368405|Active Comparator|Control|Control group will receive standard of care
3029062|NCT02368405|Experimental|Treatment|"Participants in the treatment group will receive six interactive nutrition lectures over the course of three weeks. The treatment program is titled Eat Smart, Live Better"
3029063|NCT02368392||Cardiac Arrest|Those who get in-hospital cardiac arrests
3029064|NCT02368392||Non Cardiac Arrest|Those who do not get in-hospital cardiac arrest
3029065|NCT02368379|Other|Assessment of Central Adrenal Insufficiency|Patients will undergo low dose ACTH stimulation test followed by overnight metyrapone test to assess for central adrenal insufficiency.
3029066|NCT02368366|Experimental|Therapist Guided Face to Face FPST|Therapist Guided Face to Face Family Problem Solving Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
3029067|NCT02368366|Experimental|Therapist Guided Online FPST|Therapist Guided Online Family Problem Solving Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
3029068|NCT02368366|Experimental|Self-Guided Online FPST|Self-Guided Online Family Problem Solving Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
3029069|NCT02368353|Experimental|Cognitive behavioral therapy group|weekly group stress-management CBT (SM-CBT) - 1/week 3 months
3029070|NCT02368353|Active Comparator|Reference group|weekly supportive therapy - 1/week 3 months
3029071|NCT02368340||Adults with pulmonary fibrosis|This group includes adults with HPS who have known pulmonary fibrosis. Subjects in this group will provide blood and urine specimens.
3029072|NCT02368340||Adults at-risk|"This group includes adults with HPS with subtypes at-risk for pulmonary fibrosis, but who do not have known pulmonary fibrosis.~Subjects in this group will undergo chest CT and pulmonary function testing, and provide blood and urine specimens."
3029073|NCT02368340||HPS adults not at-risk|"This group includes adults with HPS subtypes considered not at-risk for pulmonary fibrosis.~Subjects in this group will provide blood and urine specimens."
3029074|NCT02368340||Children with HPS at-risk|This group includes children with HPS subtypes at-risk for pulmonary fibrosis. Subjects in this group will undergo pulmonary function testing, and provide blood and urine specimens.
3029075|NCT02368327|Active Comparator|Fluad|Participants receive one dose of Fluad vaccine
3029076|NCT02368327|Active Comparator|Fendrix|Participants receive one dose of Fendrix vaccine
3029077|NCT02368327|Placebo Comparator|Placebo|Participants receive one dose of saline placebo
3029078|NCT02368314|Experimental|BCD-080|Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of BCD-080 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery.
3029079|NCT02368314|Active Comparator|Clexane|Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of Clexane 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery/
3029080|NCT02368288|Experimental|entecavir with PEG-IFN a-2a|after enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks.
3029081|NCT02368288|No Intervention|peginterferon alpha 2a|in this group, patients will be continue treated only with PEG-IFN a-2a for 48 weeks after enrolled.
3029082|NCT02368275||prospective cohort of patients undergoing mastectomy|Prospective cohort
3029083|NCT02368275||cross sectional cohort of patients|Cross sectional cohort
3029084|NCT02368262||CP- incontinent|Children with CP and daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
3029085|NCT02368262||CP- continent|Children with CP without daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
3029086|NCT02368262||NoDev - incontinent|Children with normal development with daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
3029087|NCT02368262||NoDev - continent|Children with normal development without daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
3029088|NCT02368249|Placebo Comparator|Control Group|Patients receiving post-operative placebo (Ringer lactate solution) treatment to preserve the renal function
3029089|NCT02368249|Experimental|Terlipressin Group|Patients receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
3058482|NCT02171715|Experimental|BIBW 2992 MA2, final formulation|
3029090|NCT02368236|Other|Intervention Group|Patients randomized to the intervention group will use CRIS. Then intervention group patients and their physicians will receive a tailored printout generated by the CRIS recommending risk-appropriate colorectal testing and ways to overcome perceived barriers to testing. A member of the research team will hand the patient a printout and will deliver the other printout to the physician.
3029091|NCT02368236|No Intervention|Comparison Group|Patients randomized to the comparison group will use CRIS, but receive a non-tailored standard information about multiple types of cancer screening (e.g., content from an American Cancer Society cancer screening brochure) while physicians receive standard electronic chart prompts indicating the patients were age-eligible but not currently adherent for colorectal cancer screening.
3029092|NCT02368236|No Intervention|True No-contact Control Group|A screening baseline for the true no-contact group will be established by conducting a retrospective chart review for patients who did not receive an invitation to participate in this study. The same randomization procedure will be used as the comparison and intervention groups. The purpose is to conduct analysis with the comparison and intervention group to see if individuals who participate in CRIS have a higher screening rate for colorectal cancer compared to the non-contact group.
3029093|NCT02368223|Experimental|YouGrabber training|Home-based YouGrabber training
3029094|NCT02368210|Experimental|122-0551 Foam|122-0511 Foam, topically applied twice daily
3029095|NCT02368210|Placebo Comparator|Vehicle Foam|Vehicle Foam, topically applied twice daily
3029096|NCT02368197|Active Comparator|Standard balloon angioplasty|Dilatation of stenosis with standard non drug eluting balloon catheter
3029097|NCT02368197|Experimental|Drug eluting balloon angioplasty|Dilatation of stenosis with paclitaxel eluting balloon catheter
3029098|NCT02368171||Obstructive sleep apnea with pulmonary hypertension|Patients with AHI> 5/h and pulmonary hypertension with RVSP>35 mmHg on Echo
3029099|NCT02368171||control|patients with AHI<5/h and RVSP<35 mmHg on Echo
3029100|NCT02368171||OSA with no Pulmonary hypertension|patients with AHI>5/h, but RVSP<35 mmHg on Echo
3029101|NCT02368158|Experimental|Cardiologic Patient|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors
3029102|NCT02368158|Experimental|Control Proband|"The same intervention as in arm cardiologic patients :Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors"
3029103|NCT02368132|No Intervention|Usual Care|Caregivers randomized to UC will be sent general material about VA and community resources for patients with dementia and their CGs. With the exception of this material, individuals in this group will receive usual care and will be contacted again at 3, 6, and 12 months for follow-up research assessments.
3029104|NCT02368132|Active Comparator|Individual Delivered TEP Arm|Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
3029105|NCT02368132|Active Comparator|Group Delivered TEP Arm|All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 5-8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.
3029106|NCT02368119|Experimental|Group 1|VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp (n=10) or VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp (n=10). Randomization to booster of MVA-EbolaZ or PBS placebo will be completed 4 to 16 weeks after priming dose.
3029107|NCT02368119|Experimental|Group 2|VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp (n=20) or VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp (n=20). Randomization to booster of MVA-EbolaZ or PBS placebo will be completed 4 to 16 weeks after priming dose.
3029108|NCT02368106||Radiation Therapy|Participants receiving one of the 11 listed therapy modalities.
3029109|NCT02368093|Experimental|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide; Detosiv Slow Release® (60mg per tablet, Lotus Pharmaceutical Company, Taipei, Taiwan), 120mg per day with once daily dose taken after breakfast]
3029110|NCT02368093|Placebo Comparator|Placebo|placebo pills with the same appearance as Detosiv tablets.
3029111|NCT02368080||Cystic fibrosis adults (CF)|No treatment, comparison of LCI values obtained with two devices
3029112|NCT02368080||Healthy adults (HC)|No treatment, comparison of LCI values obtained with two devices Free of respiratory disease or others diseases likely to disturb respiratory system.
3029113|NCT02368067|Active Comparator|Standard of Care Sentinal Node Dye|Surgery route, as determined by the patient and clinician, will determine which standard clinical dye will be used.
3029114|NCT02368067|Experimental|Installation of Study Sentinal Node Dye|Surgery route, as determined by the patient and clinician, will determine which study dye will be used for delivery by the experimental route.
3029115|NCT02368054|Active Comparator|Bupivacaine-adrenaline|Paracervical block. Bupivacaine 2,5 mg/ml Adrenaline 5 microg/ml; 20 ml
3029116|NCT02368054|Active Comparator|Bupivacaine|Paracervical block. Bupivacaine 2,5 mg/ml; 20 ml
3029117|NCT02368041||InSpectraTM StO2|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
3029118|NCT02368028||Caries Free|Participants who do not have caries (cavities) will have oral samples collected.
3058483|NCT02171715|Experimental|BIBW 2992 MA2, trial formulation II|
3029120|NCT02368015|Other|Patients with a large hepatic cyst|"During this study all subjects undergo aspiration sclerotherapy and receive antibiotic prophylaxis with a single dose of cefazolin (intravenous infusion 1000mg) following standard care.~In order to secure patient safety and allow accurate measurement of cefazolin concentrations, an additional peripheral intravenous cannula (IVC) will be placed to allow blood withdrawal at three timepoints."
3029121|NCT02368002|Experimental|Behavioral weight loss therapy|Emphasizes 1) identifying behaviors in need of change, 2) setting goals for change, 3) monitoring progress, 4) modifying environmental cues to facilitate change, and 5) modifying consequences to motivate change.
3029122|NCT02368002|Experimental|Meal replacements|Fifty percent of participants who have not lost the expected amount of weight will be re-randomized to receive meal replacements in addition to standard behavioral weight loss therapy.
3029123|NCT02368002|Experimental|Enhanced behavioral weight loss therapy|Fifty percent of participants who have not lost the expected amount of weight will be re-randomized to receive an enhanced version of behavioral weight loss therapy.
3029124|NCT02367989|Placebo Comparator|Control without fibre|"Intervention: 0g barley β-glucan no fibre.~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
3029125|NCT02367989|Experimental|low barley β-glucan|"Intervention: 2g barley β-glucan~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
3029126|NCT02367989|Experimental|medium barley β-glucan|"Intervention: 4g barley β-glucan~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
3029127|NCT02367989|Experimental|high barley β-glucan|"Intervention: 6g barley β-glucan~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
3029128|NCT02367989|Placebo Comparator|control with fibre|"Intervention: 0g barley β-glucan with fibre~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
3029129|NCT02367976|Experimental|rhprouk|rhprouk to be administrated in 60 minutes.
3029130|NCT02367976|No Intervention|controlled|The controlled arm patients will be administrated in 90 minutes after randomized.
3029131|NCT02367963|Experimental|Intervention|A Training period and a Peer-group intervention are asigned to this arm. Peer-group intervention is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.
3029132|NCT02367963|Other|Control|"A Training period intervention is asigned to this arm. Once the workshops have been carried out, the control group will be provided with written and visual documentation of risk factors and overall health habits. The members of this group will have access to the study website, where they will be able to find information on risk factors and health habits and links to the same websites related to health as the intervention group.~They won`t participate in the sessions of peer education group dynamics for a period of 12 months."
3029133|NCT02367950|Experimental|Single Arm Study|All participants receive active treatment (exercise) tailored to their level of health ad fitness
3029134|NCT02367937|Experimental|PRC-4016 (Icosabutate)|
3029135|NCT02367924||Yondelis|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
3029136|NCT02367911|Experimental|Active Arm|122-0551 Foam, topically applied twice daily for two weeks
3029137|NCT02367911|Placebo Comparator|Vehicle Arm|Vehicle Foam, topically applied twice daily for two weeks
3029138|NCT02367898|Experimental|Cognitive Training|Lumosity cognitive training program.
3029139|NCT02367898|Active Comparator|Crossword Puzzles|Timed online crossword puzzles
3029140|NCT02367885|Experimental|TAK-850 0.5 mL injection (13-19 years of age)|Single intramuscular injection of TAK-850 0.5 mL in participants aged 13-19 years
3029141|NCT02367885|Experimental|TAK-850 0.5 mL injection (3-12 years of age)|Two intramuscular injections of TAK-850 0.5 mL in participants aged 3-12 years old.
3029142|NCT02367885|Experimental|TAK-850 0.25 mL injection (6-35 months of age)|Two intramuscular injections of TAK-850 0.25 mL in participants aged 6-35 months old.
3029143|NCT02367872|Active Comparator|Participants with normal renal function: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 milligram (mg)
3029144|NCT02367872|Experimental|Participants with mild renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
3029145|NCT02367872|Experimental|Participants with moderate renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
3029146|NCT02367872|Experimental|Participants with severe renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
3029147|NCT02367872|Experimental|Hemodialysis participants: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
3029148|NCT02367872|Active Comparator|Participants with normal hepatic function: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
3029149|NCT02367872|Experimental|Participants with mild hepatic impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
3029150|NCT02367872|Experimental|Participants with moderate hepatic impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
3029151|NCT02367859|Experimental|Treatment (dabrafenib)|Patients receive dabrafenib PO BID every 12 hours plus trametinib daily PO for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients whose disease is judged to be not amenable to resection will continue dabrafenib and trametinib indefinitely as long as there has not been tumor progression.
3029170|NCT02367703|Experimental|standard instrument|That is why we propose a randomized comparative study between standard instrument and less than 3 millimeter diameter's instruments to achieve in daily practice laparoscopic hysterectomy
3029171|NCT02367703|Other|less than 3 millimeter diameter's instruments|That is why we propose a randomized comparative study between standard instrument and less than 3 millimeter diameter's instruments to achieve in daily practice laparoscopic hysterectomy
3029257|NCT02367040|Experimental|Copanlisib + Rituximab|Combination of the Copanlisib and rituximab
3029152|NCT02367846|Experimental|Combined Oral Contraceptive (COC)|We are testing the effects of a COC (Apri (Reclipsen); 30 µg EE, 150 µg desogestrel). On the first day of the intervention, the participants randomized to COC will begin taking the pill. One pill will be ingested orally at the same time each day for days 1-49 of the intervention. Pills ingested during days 1-21 and during days 29-49 will be active tablets. Pills ingested on days 22-28 will be tablets without active ingredients. Each participant in the COC group will ingest a pill from the first pack each day for the first 28 days then begin the second pack. If a participant is unable to collect a 24-h urine sample on day 49, she will take active tablets from the third pill pack until she has collected the 24-h urine sample.
3029153|NCT02367846|Experimental|Contraceptive Vaginal Ring (CVR)|We are testing the effects of the vaginal ring (Nuva Ring; 15 µg/d EE, 120 µg/d etonogestrel). When randomized to CVR, participants will insert the contraceptive ring into their vagina . The ring will be worn during weeks 1-3, and again during weeks 5-7. During week 4, no ring will be worn to allow for withdrawal bleeding. If a participant is unable to collect a 24-h urine sample on day 49, they will insert a third ring which will remain in the vagina until she has collected a 24-h urine sample.
3029154|NCT02367833|Experimental|Combined Oral Contraceptives (COC)|Apri (or generic equivalent - Reclipsen) (30µg/d EE, 150 µg/d desogestrel) is a monophasic dosing regimen of 21 active and 7 placebo pills. On Day 1 of the Intervention, participants in the COC group will begin taking the COC pill. Each participant in this group will ingest active pills from the first pack each day for the first 21 days. Pills ingested on days 22 through 28 are placebo pills. A second pill pack will begin on day 29 and pills with active ingredients will be ingested from the second pack each day for days 29-49. On day 50, the participants will immediately begin a 3rd pill pack, if the post-study testing is still occurring, and will ingest a pill with active ingredients from the third pack for days 50-56 (or for as long as the post-study testing is occurring).
3029155|NCT02367833|Experimental|Transdermal Contraceptive (TDC)|Participants in the TDC group will apply a 20 cm2 patch (Xulane: 20µg/d EE,150µg/d norelgestromin) to the abdomen, upper arm or buttock. The patch will be changed once weekly on the same day each week for weeks 1-3 (days 1-21, removed on day 22) and weeks 5-8 (days 29-56). Week 4 (days 22-28) will be a patch-free week. As soon as the post-study testing is complete, subjects will remove the patch.
3029156|NCT02367833|Experimental|Contraceptive Vaginal Ring (CVR)|Participants in the CVR group (NuvaRing - 15µg/d EE/120µg/d etonogestrel) will insert a vaginal ring into the vagina on Day 1 of the intervention. The vaginal ring will be removed and discarded after 3 weeks of continuous use (days 1-21 of continuous use and removed on day 22). There will be one week (days 22-28) that will be ring-free. A new ring will be inserted for days 29-49. On day 50, the second ring will be removed, and a third ring will be immediately inserted into the vagina (if the post-study testing is still occurring). The third ring will remain in the vagina for the last week of the post-study period (days 50-56). As soon as the post-study testing is complete, subjects will remove the ring.
3029157|NCT02367833|No Intervention|Control Group|The Control group will complete all procedures with the exception of contraceptive therapy.
3029158|NCT02367820|Experimental|NKTR-181|NKTR-181 twice daily (BID) tablets
3029159|NCT02367794|Experimental|Arm A: Atezolizumab + Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
3029160|NCT02367794|Experimental|Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; atezolizumab and carboplatin will be administered on Day 1 of each 21-day cycle. Nab-Paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
3029161|NCT02367794|Active Comparator|Arm C: Nab-Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; carboplatin will be administered on Day 1 of each 21-day cycle, nab-paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: nab-paclitaxel, then carboplatin. Participants who experience disease progression at any time during the induction phase will discontinue all study treatment. In the maintenance phase, participants will receive best supportive care.
3029162|NCT02367781|Experimental|Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)|Participants will receive intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants will receive IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
3029163|NCT02367781|Active Comparator|Arm B (Nab-Paclitaxel+Carboplatin)|Participants will receive IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
3029164|NCT02367755|Experimental|Propofol|propofol infusion at a rate of 3 mg/kg/hr during TH.
3029165|NCT02367755|Active Comparator|Lorazepam|lorazepam infusion at a rate of 0.5 mg/kg/hr during TH.
3029166|NCT02367742|Other|Endurance Activity (EA)|The subjects have followed a program of endurance (aerobic) activity (EA).
3029167|NCT02367742|Other|EA + Resistance Training (RT)|The subjects have followed a program of endurance activity (EA) and resistance training (RT).
3029168|NCT02367729|Experimental|Neurostimulator|Auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
3029169|NCT02367729|Sham Comparator|Sham Neurostimulator|Inactive auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
3029172|NCT02367690|Experimental|Cohort 1|"Cohort 1 will be randomized to one of the following treatment groups:~a) Standard-of-care (SOC) + Selinexor gel, 10 μM~, b) SOC + vehicle gel c) SOC alone."
3029173|NCT02367690|Experimental|Cohort 2|"Cohort 2 will be randomized to one of the following treatment groups:~Standard-of-care (SOC) + Selinexor gel, 30 μM~SOC + vehicle gel~SOC alone."
3029174|NCT02367690|Experimental|Cohort 3|"Cohort 3 will be randomized to one of the following treatment groups:~Standard-of-care (SOC) + Selinexor gel, 70 μM~SOC + vehicle gel~SOC alone."
3029175|NCT02367677||Clinical measurements|Measurements are made with a paper ruler
3029176|NCT02367677||Smartphone|Measurements are made with ImageJ from pictures taken with an iPhone 6
3029177|NCT02367677||Digital camera|Measurements are made with ImageJ from pictures taken with a Nikon D700
3029178|NCT02367664|Experimental|0.5ml experimental vaccine on day 0,7|0.5ml experimental vaccine on day 0,7 and a booster dose 12 months later
3029179|NCT02367664|Experimental|0.5ml experimental vaccine on day 0,28|0.5ml experimental vaccine on day 0,28 and a booster dose 12 months later
3029180|NCT02367664|Active Comparator|0.5ml active comparator vaccine on day 0,7|0.5ml active comparator vaccine on day 0,7 and a booster dose 12 months later
3029181|NCT02367651|Experimental|Pazopanib|Subjects will receive pazopanib 800 mg once daily during each 28-day treatment period until disease progression, unacceptable adverse event (AE)/serious adverse event (SAE), death or withdrawal of consent
3029182|NCT02367651|Placebo Comparator|Placebo|Subjects will receive placebo once daily during each 28-day treatment period until disease progression, unacceptable AE/SAE, death or withdrawal of consent
3029183|NCT02367638|Experimental|MG1111|
3029184|NCT02367638|Active Comparator|VARIVAX|
3029185|NCT02367625|Experimental|Arm 1|20 women with normal cervical cytology will be randomized to receive MedGYn MGC 200 therapy
3029186|NCT02367625|Active Comparator|Arm 2|20 women with normal cervical cytology will be randomized to receive MedGYn MGC 200 therapy
3029187|NCT02367612|Experimental|Fermented milk|Fermented milk with Lactobacillus paracasei CBA L74
3029188|NCT02367612|Placebo Comparator|Placebo|Placebo
3029189|NCT02367599|Active Comparator|Vitamin D Supplement + PrEP|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks in addition to their PrEP provided through the main study.
3029190|NCT02367599|No Intervention|PrEP Only|Subjects not enrolled into this sub-study will continue receiving PrEP through the main study. Subjects taking unsupplemented PrEP may still be used as matched controls to sub-study subjects.
3029191|NCT02367573|Active Comparator|2D TAPP|Trans-abdominal pre-peritoneal laparoscopic inguinal hernia repair operated with two dimensional view
3029192|NCT02367573|Experimental|3D TAPP|Trans-abdominal pre-peritoneal laparoscopic inguinal hernia repair operated with three dimensional view
3029193|NCT02367560|Active Comparator|NDSSI|Participants in this arm of the trial will be referred for Needle decompression with subacromial steroid (Depo medrol) injection (NDSSI) as their treatment for calcific tendinitis
3029194|NCT02367560|Active Comparator|SWT|Participants in this arm of the trial will be referred for Shockwave therapy (SWT) using an Ultrasound device, delivered by a physiotherapist, as their treatment for calcific tendinitis
3029195|NCT02367547|Experimental|Hexylaminolevulinate cream|2% Hexylaminolevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream
3029196|NCT02367547|Experimental|Aminolevulinic Acid Nano Emulsion|78 mg/g Aminolevulinic Acid Nano Emulsion
3029197|NCT02367547|Active Comparator|Methylaminolevulinate cream|160 mg/g Methylaminolevulinate cream
3029198|NCT02367534|Experimental|Umbilical vein|umbilical vein catheterization
3029199|NCT02367521|Experimental|LFR rTMS|Investigators propose to deliver 1200 pulses daily at 110% Motor threshold for 4 weeks using four trains of 300 pulses daily separated by an intertrain interval of 60 seconds.
3029200|NCT02367521|Placebo Comparator|Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
3029201|NCT02367508|Experimental|MODEL Care|Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) is a mindfulness meditation-based intervention to facilitate timely advance care planning (ACP) and end-of-life conversations with greater ease. Participants are taught a variety of mindfulness practices (e.g., breath awareness, sitting meditation, mindful movement through gentle yoga, and mindful communication) that can be used to enhance end-of-life coping.
3029202|NCT02367495|Experimental|PCB|Paclitacel-coated balloon (Agent, Boston Scientific)
3029203|NCT02367482||NovoTTF|NovoTTF treatment will be administered as usual during the imaging study either in monotherapy or in combination with other treatments (initiated prior to NovoTTF therapy). The treatment plan or intervention will not be altered in any way. Two AMT-PET scans will be added to the management scheme: a baseline PET shortly before and a follow-up PET scan 2-3 months after the start of NovoTTF treatment.
3029204|NCT02367469||Brain Tumors|Patients with newly diagnosed or recurrent brain tumors will be studied.
3029205|NCT02367456|Experimental|Arm A|MDS patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
3029206|NCT02367456|Experimental|Arm B|AML patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
3029207|NCT02367443|Experimental|one group|Radiation: Hypofractionated accelerated Radiotherapy with concomitant full dose Chemotherapy
3029208|NCT02367430|Experimental|Critical Time Intervention for Hoarding Disorder|Patients with Hoarding Disorder received CTI Model
3029209|NCT02367430|Active Comparator|Buried in Treasures|Patients with Hoarding Disorder received BIT
3029210|NCT02367404|No Intervention|Control|Keigel's exercise
3029211|NCT02367404|Active Comparator|Duloxetine|Duloxetine 60mg for 3 months
3029212|NCT02367404|Active Comparator|Duloxetine + PMFT|Duloxetine 60mg for 3 months PMFT weekly for 3 months
3029213|NCT02367404|Active Comparator|Pelvic Floor Muscle Training|PMFT weekly for 3 months
3029214|NCT02367391|Experimental|Motivational Text Messages|
3029215|NCT02367391|Sham Comparator|Control|
3029216|NCT02367378||MIS|Those who received minimally invasive surgical procedures
3029217|NCT02367378||Control|Those who received treatments which include surgical resection, chemotherapy, and radiotherapy.
3029218|NCT02367365||Treatment Naive NVAMD Patients|Patients with treatment naive NVAMD diagnosed in the last three months
3029220|NCT02367352|Experimental|Cohort 1 (Dose Escalation Phase)|Alisertib, 15 mg tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, intravenous (IV), on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity.
3029221|NCT02367352|Experimental|Cohort 2 (Dose Escalation Phase)|Alisertib, 25 mg tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, intravenous (IV), on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity. Dose of alisertib will be de-escalated to 20 mg if ≥ 2 participants experience a DLT.
3029222|NCT02367352|Experimental|Dose Expansion Cohort|Alisertib, MTD/RP2D determined in Dose Escalation Phase, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, IV on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity.
3029223|NCT02367326||Patients with Inflammatory Bowel Disease|patients with Crohn's Disease or Ulcerative Colitis meeting clinical, endoscopic and histological criteria and on thiopurines at stable doses for at least 3 months, monotherapy or combined with corticotherapy
3029224|NCT02367313|Placebo Comparator|Placebo|Placebo
3029225|NCT02367313|Active Comparator|Vapendavir 264 mg|Vapendavir 264 mg and matching placebo
3029226|NCT02367313|Active Comparator|Vapendavir 528 mg|Vapendavir 528 mg and matching placebo
3029227|NCT02367287||Sampling strata|Stratified analyses of primary and secondary outcomes based on variables of interest (e.g. sex, age, or BMI) may occur prior to achieving the target for total study enrollment.
3029228|NCT02367261|Experimental|SPI dental implant|Subjects implanted with SPI implant
3029229|NCT02367248|Active Comparator|Deferoxamine|Deferoxamine mesylate supplied in vials containing 500 mg of sterile, lyophilized, powdered deferoxamine mesylate. The drug will be reconstituted for injection, by dissolving in 20 ml of sterile water.
3029230|NCT02367248|Active Comparator|Xingnaojing injection|Xingnaojing injection supplied in vials containing 20 ml liquid xingnaojing.
3029231|NCT02367248|Placebo Comparator|Normal Saline|0.9% sodium chloride
3029232|NCT02367235|Experimental|Traditional vaginal positioning device|Patients will undergo their robotic-assisted sacrocolpopexy using a vaginally placed endo anal sizer.
3029233|NCT02367235|Experimental|Colpassist vaginal positioning device|Patients will undergo their robotic-assisted sacrocolpopexy using a vaginally placed Colpassist vaginal manipulator.
3029234|NCT02367222||Exposed to Arepanrix™ Cohort|All individuals with Manitoba Immunization Monitoring System (MIMS) record of H1N1 (Arepanrix™) and/or seasonal influenza vaccination during the influenza season 2009/2010 (15 September 2009 to 15 March 2010).
3029235|NCT02367222||Unexposed to Arepanrix™ Cohort|All individuals registered with Manitoba Health (MH) during the study period but with no MIMS record for H1N1 (Arepanrix™) and seasonal influenza vaccination during the influenza season 2009/2010 (15 September 2009 to 15 March 2010).
3029236|NCT02367196|Experimental|CC-90002 +/- Rituximab|CC-90002 by intravenous (IV) infusion on a 28 day cycle (PartA); CC-90002 in combination with Rituximab by intravenous (IV) infusion on a 28 day cycle in subjects with CD20-positive NHL (Part B)
3029237|NCT02367183|Experimental|GED-0301 160mg QD 12 WK|GED-0301 160 mg once daily (QD) for 12 weeks
3029238|NCT02367183|Experimental|GED-0301 160 mg QD 8 WK|GED-0301 160 mg QD for 8 weeks followed by 4 weeks of placebo
3029239|NCT02367183|Experimental|GED-0301 160 mg QD 4 WK|GED-0301 160 mg QD for 4 weeks followed by 8 weeks of placebo
3029240|NCT02367170|Experimental|IMST Intervention group|IMST will be conducted 5 days per week by study staff using a threshold inspiratory muscle training device (Respironics model 735). Prior to training, the tracheal cuff pressure is assessed to ensure no air leakage and appropriate inflation. The IMST training takes approximately 15 minutes to complete. To perform IMST, FiO2 is increased for 2 minutes prior to each training bout to maintain oxygen saturation more than 92%.
3029241|NCT02367170|Sham Comparator|SHAM group|SHAM training will also be conducted five days per week with an identical training device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout.
3029242|NCT02367157|Experimental|Experimental: Kinesio taping|Epicondilar and epitroclear muscle Kinesio Taping with a Space Correction on the wrist according Kenzo Kase Method
3029243|NCT02367157|No Intervention|No intervention: Control|
3029244|NCT02367131||Jardiance|
3029245|NCT02367118|Experimental|Prednisone|Intervention: prednisone 5 mg tablets taken orally, in decreasing doses. Beginning with 6 tablets (30 mg) daily for 7 days, then 3 tablets (15 mg) daily for 7 days, then 1 tablet (5 mg) daily for 7 days. Total days of treatment: 21 days.
3029246|NCT02367118|Placebo Comparator|Placebo|Intervention: placebo tablets taken orally (similar to prednisone), in decreasing doses. Beginning with 6 tablets daily for 7 days, then 3 tablets daily for 7 days, then 1 tablet daily for 7 days. Total days of treatment: 21 days.
3029247|NCT02367105|Active Comparator|Testosterone + Lifestyle Therapy|Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training
3029248|NCT02367105|Placebo Comparator|Placebo + Lifestyle Therapy|Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training
3029249|NCT02367092|Experimental|Exercise Program|The exercise intervention consists of a 30 minute exercise session led by an instructor through a DVD or a video available on the internet.
3029250|NCT02367092|No Intervention|Standard of care|Standard of care which consists of encouragement to exercise by the subject's transplant clinician.
3029251|NCT02367079|Active Comparator|Switched on diathermy|Switched on diathermy was used on DOMS compared to sham diathermy
3029252|NCT02367079|Sham Comparator|Switched OFF diathermy|Switched OFF diathermy was used on DOMS compared to REAL diathermy
3029253|NCT02367066|Experimental|AR-C165395XX + placebo|1st period AR-C165395XX 2nd period placebo
3029254|NCT02367066|Placebo Comparator|Placebo + AR-C165395XX|1st period Placebo for AR-C165395XX 2nd period AR-C165395XX
3029255|NCT02367053|Experimental|ZP4207|single dose of ZP4207 in ascending doses (s.c. and i.m.)
3029256|NCT02367053|Active Comparator|native glucagon|single fixed dose of glucagon
3029258|NCT02367040|Placebo Comparator|Placebo + Rituximab|Combination of Copanlisib placebo and rituximab
3029259|NCT02367027|Experimental|Arm 1 - BAY59-7939|10 mg oral suspension (dry powder) in fasted conditions
3029260|NCT02367027|Experimental|Arn 2 - BAY59-7939|20 mg oral suspension (dry powder) in fed conditions.
3029261|NCT02367027|Experimental|Arm 3 - BAY59-7939|10 mg oral suspension in fasted conditions
3029262|NCT02367027|Experimental|Arm 4 - BAY59-7939|10 mg tablet in fasted conditions.
3029263|NCT02367014|Experimental|Low Dose|
3029264|NCT02367014|Experimental|Intermediate dose|
3029265|NCT02367014|Experimental|High dose|
3029266|NCT02367014|Placebo Comparator|Placebo|
3029267|NCT02367001|Other|1: standard invitation|"Group 1: sending a standard invitation signed by the coordinating doctor (send by the structure responsible for organized screenings)~Intervention : Normal invitation"
3029268|NCT02367001|Experimental|2: Revised invitation|"Group 2: Sending a revised invitation ( text, layout) signed by the coordinating doctor (send by the structure responsible for organized screenings)~Intervention : revised invitation signed by the coordinating doctor"
3029269|NCT02367001|Experimental|3 : revised invitation signed by the attending physician|"Group 3: Sending a revised invitation signed by the attending physician (send by the structure responsible for organized screenings)~Intervention : Revised invitation signed by the attending physician"
3029270|NCT02366988|Active Comparator|Endoscopic Biliary Stenting|Temporary self-expandable metallic covered stent
3029271|NCT02366988|Active Comparator|Surgical treatment|Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
3029272|NCT02366975|No Intervention|Eugonadal patients|Patients without hypogonadism has been enrollend but not randomized
3029273|NCT02366975|Active Comparator|Hypogonadal patients A|Patients with hypogonadism has been randomized to testosterone gel solution 2%
3029274|NCT02366975|Placebo Comparator|Hypogonadal patients B|Patients with hypogonadism has been randomized to placebo solution gel
3029275|NCT02366962|Experimental|ASP7374 group|
3029276|NCT02366949|Experimental|Arm 1|Experimental Treatment (combination of BAY 1217389 with paclitaxel in an intermittent dosing schedule) Expansion Cohort - Maximum tolerated dose of BAY 1217389 and Paclitaxel
3029277|NCT02366949|Placebo Comparator|Arm 2|Standard Treatment (Single-agent Paclitaxel )
3029278|NCT02366936|Experimental|Use of Tortle midliner|This study will be an interventional, longitudinal study of 30 preterm infants using the Tortle Midliner.
3029279|NCT02366923|Experimental|stenfilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
3029280|NCT02366923|Active Comparator|delefilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
3029281|NCT02366910|Experimental|omafilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
3029282|NCT02366910|Active Comparator|delefilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
3029283|NCT02366897|Other|Tolerability and sensitivity|Stage 1: tolerability as per study design Stage 2: sensitivity as per study design - either quetiapine or risperidone. The intervention is the use of the Manus sensor pen
3029284|NCT02366884|Experimental|Anti-bacterial agents|Combination of two selected anti-bacterial agents with documented anti-cancer properties
3029285|NCT02366884|Experimental|Anti-fungal agents|Combination of two selected anti-fungal agents with documented anti-cancer properties
3029286|NCT02366884|Experimental|Anti-protozoal agents|Combination of two selected anti-protozoal agents with documented anti-cancer properties
3029287|NCT02366884|Experimental|Anti-bacterial + anti-fungal + anti-protozoal agents|Combination of six selected anti-bacterial agents, anti-fungal agents, and anti-protozoal agents with documented anti-cancer properties
3029288|NCT02366871|Experimental|Oral apixaban|Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
3029289|NCT02366871|Active Comparator|Subcutaneous enoxaparin|Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.
3029290|NCT02366858|Active Comparator|19 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle.
3029291|NCT02366858|Active Comparator|22 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle.
3029292|NCT02366845|Active Comparator|Clinician Chosen Dosing|"Admitted University of Colorado Hospital or Denver Health bleeding patients with chronic liver disease determined to receive fresh frozen plasma (FFP) for clinical indications as determined by hospital clinician. The total dose will be determined by the physician's judgment which is the current standard of care. The physician chosen dose will be utilized but physician will be unaware of which dosing strategy has been utilized.~An INR measurement will be performed within 1 hour after the entire transfusion of plasma has been administered. Primary and secondary outcome measures will be collected. No other transfused blood component, crystalloid or colloidal fluid will be infused between the first and second INR studies except plasma"
3029293|NCT02366845|Experimental|Algorithm Dosing|"Admitted University of Colorado Hospital or Denver Health bleeding patients with chronic liver disease determined to receive fresh frozen plasma (FFP) for clinical indications as determined by hospital clinician. This group will receive plasma doses based on the study dosing algorithm table.~A pre-transfusion INR and a target post-transfusion INR will be used to determine dose of FFP. The study table will reveal the dose in (ml/kg) of FFP to be transfused. An INR measurement will be performed within 1 hour after the entire transfusion of plasma has been administered. Primary and secondary outcome measures will be collected. No other transfused blood component,crystalloid or colloidal fluid will be infused between the first and second INR studies except plasma."
3029294|NCT02366832|Experimental|Cryoablation|Amputee subjects experiencing phantom limb syndrome (PLS) will receive cryoablation
3029319|NCT02366650||Vancouver ED|appr 100 patients at St Paul's hospital ED
3029320|NCT02366650||Bern ED|appr 100 patients at Bern ED
3029321|NCT02366637|Placebo Comparator|Placebo|Double blind placebo for PF-03715455
3029322|NCT02366637|Experimental|PF-03715455|
3029365|NCT02366364|Placebo Comparator|Drug: Placebo|Single oral administration on Day 1
3058484|NCT02171715|Active Comparator|BIBW 2992 MA 2 drinking solution|
3029295|NCT02366819|Experimental|Treatment (mFOLFIRINOX, surgery)|"PREOPERATIVE THERAPY: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours continuously on day 1. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo conventional surgery.~POST-OPERATIVE THERAPY: Beginning 5-10 weeks after surgery, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours continuously on day 1. Courses repeat every 2 weeks for 4 more courses in the absence of disease progression or unacceptable toxicity."
3029296|NCT02366806||In-Depth Education|A. Standard radiotherapy discussion including rationale, number of fractions, side effects, +/- beam arrangements, potential and likely short and long-term toxicity, status checks, skin care, nursing and physician accessibility B. Radiotherapy plan review to include, but not limited to: beam arrangement, total dose, dose per fraction, target area(s), description of isodose lines, DVH review and discussion of prescription constraints for OARs
3029297|NCT02366793|Experimental|Accessory joint mobilization|Humeral head slides, anterior, posterior and caudal slides.
3029298|NCT02366793|Experimental|Nerve mobilization|neural tissue longitudinal slide using the median neurodynamic test 1 (Butler).
3029299|NCT02366780|Experimental|Manual expression followed by electric pump|Mothers will be assigned to first express breast milk manually followed by electric pump
3029300|NCT02366780|Experimental|Electric pump followed by manual expression|Mothers will be assigned to first express breast milk by electric pump followed by manual expression
3029301|NCT02366767|Experimental|automatic closed-loop insulin delivery|The closed-loop arm will consist of participants wearing a sensor and transmitter which transmits sensor glucose data. The algorithm determines insulin delivery rates and this is delivered in microboluses every 5 minutes
3029302|NCT02366767|Active Comparator|Control|The subjects in the control arm will wear the 530G system using Enlite and MiniLink transmitter and threshold suspend.
3029303|NCT02366754|Experimental|Active rTMS|The intervention consists of 30 active rTMS sessions. Each session is comprised of 300 trains of paired pulses with the following parameters: 100µs paired pulses separated by 100ms inter-pulse-intervals and a five second inter-train-interval. Pulse intensity will be set at 110% of each participant's motor threshold. Active rTMS sessions will be provided two times per day with a 70mm figure-of-eight coil over the left dorsolateral prefrontal cortex. Two Magstim-2002 units and a Bistim2 module will be used to administer active rTMS. Participants assigned to the active rTMS group will receive a total of 1.8 seconds of stimulation. Active rTMS will be administered 2 times daily with the following weekly schedule: 2 days of rTMS, 1 day of rest, 2 days of rTMS, 2 days of rest.
3029304|NCT02366754|Sham Comparator|Placebo rTMS|The intervention consists of 30 placebo rTMS sessions. Each session is comprised of 300 paired-pulse trains with the following parameters: 100µs paired pulses separated by 100ms inter-pulse-intervals and a five second inter-train-interval. Placebo rTMS sessions will be provided two times per day with a 70mm figure-of-eight coil over the left DLPFC. Two Magstim-2002 units and a Bistim2 module will be used to administer placebo rTMS. The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. Participants assigned to the placebo rTMS group will receive 0 seconds of stimulation. Placebo rTMS will be administered with the following weekly schedule: 2 days of rTMS, 1 day of rest, 2 days of rTMS, 2 days of rest.
3029305|NCT02366741|Other|Pilot group|Five eligible patients will undergo WBRT with reduced dose to the hippocampi and will be evaluated prospectively by neuro cognitive testing, MRI scans and blood tests.
3029306|NCT02366728|Experimental|Group I: Unpulsed DC pre-conditioning|0.4 mLs of 1 x 10^6 autologous unpulsed DCs in saline will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the fourth human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies. All patients will be vaccinated with pp65 DCs in conjunction with subsequent TMZ cycles every 5 ± 1 weeks for a total of 6 to 12 cycles after RT.
3029307|NCT02366728|Experimental|Group II: Tetanus pre-conditioning|Tetanus diptheria toxoid (Td), 1 flocculation unit, will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the fourth human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies.All patients will be vaccinated with pp65 DCs in conjunction with subsequent TMZ cycles every 5 ± 1 weeks for a total of 6 to 12 cycles after RT.
3029308|NCT02366728|Experimental|Group III: Basiliximab and Tetanus pre-conditioning|Basiliximab infusions prior to human CMV pp65-LAMP mRNA-pulsed autologous DC vaccines #1 and #2 with Td pre-conditioning 1 flocculation unit, will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the fourth human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. All patients will be vaccinated with pp65 DCs in conjunction with subsequent TMZ cycles every 5 ± 1 weeks for a total of 6 to 12 cycles after RT.
3029309|NCT02366715|Experimental|HeatedHumidifiedHighFlowNasalCannula|Treatment for moderate-severe cases of Bronchiolitis while monitoring medical parameters
3029310|NCT02366702||Individuals with Bilateral Transfemoral Amputation|
3029311|NCT02366689|Active Comparator|Toothpaste|Triclosan/fluoride toothpaste
3029312|NCT02366689|Active Comparator|Toothpaste + mouthwash|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
3029313|NCT02366689|Placebo Comparator|Fluoride only Toothpaste + mouthwash|Fluoride only toothpaste + Fluoride only Mouthwash
3029314|NCT02366676|Experimental|Recurrent Cystitis group|Patients with Recurrent Cystitis Refractory to Escherichia Coli Extract
3029315|NCT02366663|Experimental|Arm I (ZBEAM)|Patients receive rituximab IV on days -21 and -14, and 90-yttrium ibritumomab tiuxetan IV on day -14. Patients also receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
3029316|NCT02366663|Active Comparator|Arm II (BEAM)|Patients receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
3029317|NCT02366650||Lund ED|appr 100-200 patients at Lund ED
3029318|NCT02366650||Helsingborg ED|appr 100-200 patients at Helsingborg ED
3029323|NCT02366611|Experimental|Transcranial Direct Current Stimulation (tDCS)|tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes—anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions: at each session a modular EEG recording cap will be placed on the participant's head and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
3029324|NCT02366611|No Intervention|Chemoradiotherapy Standard of Care|
3029325|NCT02366598|Experimental|20g Hemp protein shake|Hemp protein shake, 20 grams, given once at beginning of acute trial
3029326|NCT02366598|Experimental|40 g hemp protein shake|Hemp protein shake, 40 grams, given once, at beginning of acute trial
3029327|NCT02366598|Active Comparator|20 g Soybean protein shake|Soybean protein shake, 20 grams, given once, at beginning of acute trial
3029328|NCT02366598|Experimental|40 g Soybean protein shake|Soybean protein shake, 40 grams, given once, at beginning of acute trial
3029329|NCT02366598|Placebo Comparator|Control shake|non-protein control shake, given once, at beginning of acute trial
3029330|NCT02366585|Experimental|Treatment with Ciclosporin|Treatment of two periodontal pockets with ciclosporin gel Non-treatment of two periodontal pockets in same patient as comparator
3029331|NCT02366572|Placebo Comparator|Cereal control|100% Wheat Flour
3029332|NCT02366572|Experimental|Cereal with pea protein|Pea protein
3029333|NCT02366572|Experimental|Cereal with pea starch|Pea starch
3029334|NCT02366572|Experimental|Cereal w/ pea starch + pea fibre: 5g|Pea starch + pea fibre: 5g
3029335|NCT02366572|Experimental|Cereal w/ pea protein + pea starch: 10g|Pea protein + pea starch: 10g
3029336|NCT02366572|Experimental|Cereal w/ pea protein + pea fibre + pea starch: 20g|Pea protein + pea fibre + pea starch: 20g
3029337|NCT02366559|Active Comparator|electrocautery|Blocks of subjects' lesions will be randomized 1:1 to receive electrocautery or 532 nm Nd:YAG laser. Prior to treatment with either electrocautery or 532nm Q-switched Nd:YAG laser, a topical EMLA cream will be applied to the lesions for at least 60 minutes under occlusion at the area of treatment.
3029338|NCT02366559|Active Comparator|532 nm Nd:YAG laser|Blocks of subjects' lesions will be randomized 1:1 to receive electrocautery or 532 nm Nd:YAG laser. Prior to treatment with either electrocautery or 532nm Q-switched Nd:YAG laser, a topical EMLA cream will be applied to the lesions for at least 60 minutes under occlusion at the area of treatment.
3029339|NCT02366546|Experimental|Low dose TBI-1301 with pre-treatment 1|TBI-1301(5*10^8) single-dose administration with pre-treatment of cyclophosphamide alone.
3029340|NCT02366546|Experimental|High dose TBI-1301 with pre-treatment 1|TBI-1301(5*10^9) single-dose administration with pre-treatment of cyclophosphamide alone.
3029341|NCT02366546|Experimental|High dose TBI-1301 with pre-treatment 2|TBI-1301(5*10^9) single-dose administration with pre-treatment of cyclophosphamide and fludarabine.
3029342|NCT02366546|Experimental|TBI-1301 with pre-treatment 1 or 2|Arm1, 2 or 3, which is considered as optimal.
3029343|NCT02366533||Sites Implementing the LTC Program|This study will be conducted at the 15 ATN-funded clinical sites, known as the Adolescent Medicine Trial Units (AMTU). Each enrolling site must have the capability to input field data that can be used to evaluate the effectiveness of the Strategic Multisite Initiative for the Identification, Linkage, and Engagement in Care of Youth with Undiagnosed HIV Infection (SMILE in CARING for YOUTH) Project.
3029344|NCT02366520|No Intervention|control visit|The child receives dental treatment without the handheld mirror. The child cannot see the dental treatments that are conducted in his or her mouth.
3029345|NCT02366520|Experimental|intervention visit|The child receives dental treatment with handheld mirror. The child may see the dental treatments that are conducted in his or her mouth by the handheld mirror.
3029346|NCT02366494||Androgen blockade|Androgen DeprivationTherapy or Complete Androgen Blockade
3029347|NCT02366494||Chemo Hormonal therapy|Trelstar IM injection with Docetaxel (Taxorere) 75mg/m2 every 3 weeks for 10 cycles.
3029348|NCT02366481|Placebo Comparator|Placebo-Control|The placebo-control group will take two placebo softgel capsules every day for 8 weeks.
3029349|NCT02366481|Active Comparator|Low-Dose Vitamin K2 (90-mcg/d)|The low-dose vitamin K group will take one 90-mcg vitamin K2 (menaquinone-7) softgel capsule and one placebo softgel capsule every day for 8 weeks.
3029350|NCT02366481|Active Comparator|High-Dose Vitamin K2 (180-mcg/d)|The high-dose vitamin K group will take two 90-mcg vitamin K2 (menaquinone-7) softgel capsules every day for 8 weeks.
3029351|NCT02366468|Experimental|Discretion of the investigator (DI)|
3029352|NCT02366468|Active Comparator|Pro re nata (PRN)|
3029353|NCT02366455||Thoracic CT-Scan|Measurement of the length of the right main stem bronchus and of the right upper lobe bronchus antero-posterior angulation on consecutive thoracic CT-Scan reconstruction
3029354|NCT02366429|Experimental|ICBT|Internet-based CBT for antenatal depression
3029355|NCT02366429|Active Comparator|TAU|Treatment as usual provided at antenatal clinics and other health care instances
3029356|NCT02366416|Experimental|Exercise training|12 weeks of one hour exercise training twice weekly
3029357|NCT02366403|Experimental|SKY|a standardized meditation program
3029358|NCT02366403|Active Comparator|CPT-C|CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
3029359|NCT02366390|Experimental|Psychoeducative intervention|A psychoeducative dialogue and one telephone booster session
3029360|NCT02366390|No Intervention|Usual care|Usual care according to current guidelines.
3029361|NCT02366377|Experimental|SHR3824 Placebo|SHR3824 Placebo , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
3029362|NCT02366377|Experimental|SHR3824 5 mg|SHR3824 5 mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
3029363|NCT02366377|Experimental|SHR3824 10 mg|SHR3824 10 mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
3029364|NCT02366377|Experimental|SHR3824 20 mg|SHR3824 20mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
3029366|NCT02366364|Experimental|Drug: NRX-1074 375 mg|Single oral administration on Day 1
3029367|NCT02366364|Experimental|Drug: NRX-1074 500 mg|Single oral administration on Day 1
3029368|NCT02366364|Experimental|Drug: NRX-1074 750 mg|Single oral administration on Day 1
3029369|NCT02366351|Experimental|SHR3824 Placebo|once daily, 12 weeks
3029370|NCT02366351|Experimental|SHR3824 5 mg|once daily, 12 weeks
3029371|NCT02366351|Experimental|SHR3824 10 mg|once daily, 12 weeks
3029372|NCT02366351|Experimental|SHR3824 20 mg|once daily, 12 weeks
3029373|NCT02366325|Experimental|EPO-018B 0.025 mg/kg|EPO-018B starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
3029374|NCT02366325|Experimental|EPO-018B 0.05 mg/kg|EPO-018B starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
3029375|NCT02366325|Experimental|EPO-018B 0.08 mg/kg|EPO-018B starting dose of 0.08 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
3029376|NCT02366312|Experimental|vismodegib|The 150-mg vismodegib drug product is a hard gelatin capsule formulation for oral administration. This study involves one year of treatment with Erivedge (150 mg/day) plus two years of follow-up.
3029377|NCT02366299|Active Comparator|dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
3029378|NCT02366299|Active Comparator|propofol|Treatment of delirium by propofol i.v. infusion
3029379|NCT02366247|Experimental|PEG-Tα1|PEG-Tα1 (3.2 mg/ml, once a week, taken subcutaneously) and adefovir (10 mg, once daily, taken orally) for 48 weeks
3029380|NCT02366247|Placebo Comparator|Placebo to match PEG-Tα1|PEG-Tα1 placebo (1ml, once a week, taken subcutaneously) and adefovir (10 mg, once daily, taken orally) for 48 weeks
3029381|NCT02366234||Fracture of Distal Tubercle of Scaphoid|"Questionnaires~Quick DASH after trauma (< 2 weeks)~11-point ordinal measure of overall pain intensity 6 months after trauma~11-point ordinal measure of satisfaction with treatment 6 months after trauma"
3029382|NCT02366221||All subjects|Subjects with a history of complex arm trauma
3029383|NCT02366208|Experimental|PEG-Tα1|PEG-Tα1 (1.6 mg/ml, once a week, taken subcutaneously) for 24 weeks and adefovir (10 mg, once daily, taken orally) for 48 weeks
3029384|NCT02366208|Placebo Comparator|Placebo to match PEG-Tα1|PEG-Tα1 placebo (1ml, once a week, taken subcutaneously) for 24 weeks and adefovir (10 mg, once daily, taken orally) for 48 weeks
3029385|NCT02366195|Experimental|Talimogene Laherparepvec|Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL on day 1 followed by a dose of 10⁸ PFU/mL 21 days after the initial dose and every 14 days thereafter. Participants were treated with talimogene laherparepvec until they achieved a complete response, all injectable tumors had disappeared, clinically significant (resulting in clinical deterioration or requiring change of therapy) disease progression beyond 6 months of treatment, per modified World Health Organization (WHO) response criteria, or intolerance of study treatment, whichever occurred first.
3029386|NCT02366156|Placebo Comparator|Placebo|Inactive capsules
3029387|NCT02366156|Active Comparator|Low Dose Grape Blend|Low dose grape blend providing 375 mg whole grape extract + 375 mg grape seed extract/d (750 mg total botanical extracts/d).
3029388|NCT02366156|Active Comparator|High Dose Grape Blend|High dose grape blend providing 500 mg whole grape extract + 500 mg grape seed extract/d (1000 mg total botanical extracts/d)
3029389|NCT02366143|Experimental|Arm A (Atezolizumab+Paclitaxel+Carboplatin)|Participants will receive intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
3029390|NCT02366143|Experimental|Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)|Participants will receive IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
3029391|NCT02366143|Active Comparator|Arm C (Bevacizumab+Paclitaxel+Carboplatin)|Participants will receive IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
3029392|NCT02366130|Experimental|Ra-223 dichloride + Denosumab|"Ra-223 dichloride 55 kBq/kg administered as a bolus intravenous (IV) injection (over 1 minute) through a secure in-dwelling catheter on day 1 of the study and then every four weeks thereafter for 6 cycles.~Denosumab 120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.~A single hormonal agent (ie, Tamoxifen or Aromatase Inhibitor or Fulvestrant) administered daily while on study. Physician to decide what type of hormone therapy participant will receive."
3029393|NCT02366117|Experimental|Training|"Data collected during the first pahse of the study will be presented and discussed in a specialist focus group, which will work with the study team as advisors and trainers, to decide on the type of training to be developed.~This training intervention will be applied to the facilities presenting half the patient sample size."
3029394|NCT02366117|No Intervention|No Training|Facilities representing half the sample size will not be trained as in the Experimental Arm and continue their standard of care for these patients.
3029395|NCT02366091|Experimental|Methotrexate|Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily
3029396|NCT02366091|Experimental|Colchicine|Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily
3029397|NCT02366091|Experimental|Methotrexate & Colchicine|Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily
3029398|NCT02366091|Experimental|Placebo|Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily
3029399|NCT02366078|Experimental|Stress management|Participants will receive SMART traiing
3029400|NCT02366065|Experimental|Acetaminophen|study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
3029401|NCT02366052|Active Comparator|Nutritional Counseling|The nutritional counseling group will receive dietary counseling focusing on a reduction of fructose intake by a trained nutritionist for 12 weeks every 3 weeks.
3029402|NCT02366052|Experimental|Nutritional Counseling and LCS|The dietary supplement LCS (Lactobacillus casei shirota ) will be given 2 times a day for 12 weeks in addition to the nutritional counseling every 3 weeks.
3029403|NCT02366052|Experimental|Lactobacillus Casei Shirota|The dietary supplement LCS (Lactobacillus casei shirota ) will be given 2 times a day for 12 weeks.
3029404|NCT02366039||EMR|patients undergoing clinically indicated endoscopic mucosal resection as standard of care will be asked to participate for this observational study
3029405|NCT02366026|Experimental|IR103 REMUNE + AMPLIVAX 1.0|IR103 Vaccine contain the same active component as REMUNE® (Inactivated HIV-1 Antigen Drug Substance at 10 μg/mL p24 dose), and have one dose of Amplivax™ (HYB2055) Adjuvant (1.0 mg) added before emulsification in Incomplete Freund's Adjuvant (the same adjuvant and in the same ratio that is used in REMUNE).
3029406|NCT02366026|Placebo Comparator|AMPLIVAX 1.0 + IFA|AMPLIVAX 1.0 mg Amplivax™ (HYB2055) Adjuvant (1.0 mg) + IFA Incomplete Freund's Adjuvant (the same adjuvant and in the same ratio that is used in REMUNE).
3029407|NCT02366013|Experimental|Group 1|1 dose of rcAd26.MOS1.HIV-Env 1x10^8 vp or placebo
3029408|NCT02366013|Experimental|Group 2|1 dose of rcAd26.MOS1.HIV-Env 1x10^9 vp or placebo
3029409|NCT02366013|Experimental|Group 3|1 dose of rcAd26.MOS1.HIV-Env 1x10^10 vp or placebo
3029410|NCT02366013|Experimental|Group 4|1 dose of rcAd26.MOS1.HIV-Env 1x10^11 vp or placebo
3029411|NCT02366000|Experimental|Brief Parental Training Intervention|Participants will have to attend two 3-hour Brief Parental Training Intervention Programme, with three weeks apart. There will also be two telephone follow-up sessions to reinforce learnt strategies and skills for home practice between workshops.
3029412|NCT02366000|Other|Wait-list Group|Participants will receive the same Brief Parental Training Intervention Programme as the intervention group. However, they will wait until the questionnaires have been completed by the intervention group for the second time (i.e. immediately after intervention) before they receive their programme.
3029413|NCT02365987|Experimental|Interesterified|Interesterified blend of palm kernal and plam stearin. 50g fat.
3029414|NCT02365987|Active Comparator|Un-interesterified|Un-interesterified blend of palm kernal and plam stearin. 50g fat.
3029415|NCT02365974|Active Comparator|Transcutaneous Electrical Stimulation|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps (mA) will be adjusted depending on the sensitivity of each individual patient. The arrangement thereof will be parallel on each side of the C7 (channel 1) and T4 (channel 2) vertebral spinous processes.
3029416|NCT02365974|Sham Comparator|No Transcutaneous Electrical Stimulation|The sham group will be submitted to the procedure to fit the stimulation equipment without be submitted to stimulation.
3029417|NCT02365961|Experimental|FI Block|Fascia iliaca block consisting of up to 60 mL of 0.35% ropivicaine at a dose of 3 mg/kg (with adjuvants of 100 mcg clonidine [per 60 mL] and epinephrine 1:400,000)
3029418|NCT02365961|Active Comparator|Local Injection|Local anesthetic in the hip joint consisting of 30cc of 0.5% Noropin
3029419|NCT02365948|Experimental|Certolizumab Pegol 100 mg|"Subjects will receive100 mg of CZP given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment on Day 1.~To achieve an injectable CZP 100 mg dose, a manual process will be applied by the unblinded site pharmacist."
3029420|NCT02365948|Experimental|Certolizumab Pegol 200 mg|Subjects will receive 200 mg of CZP given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment staggered by a minimum of 14 days from CZP 100 mg. Dose escalation will be suspended according to the predefined criteria and process.
3029421|NCT02365948|Experimental|Certolizumab Pegol 400 mg|Subjects will receive 400 mg of CZP (two injections of CZP 200 mg) given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment staggered by a minimum of 14 days from CZP 200 mg. Dose escalation will be suspended according to the predefined criteria and process.
3029422|NCT02365948|Placebo Comparator|Placebo|For assessment of the Adverse Event (AE) profile, there are 2 placebo controls in each dose group. The placebo subjects receive the injection of saline (NaCl 0.9 %) at the same time (and of the same volume) as the CZP subjects.
3029423|NCT02365935|Experimental|Group A to administer 4 cycles|In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
3029424|NCT02365935|Experimental|Group B to administre 6 cycles|In Group B, all patients received instead 6 cycles of adjuvant chemotherapy every three weeks according to the same chemotherapic regimen.
3029425|NCT02365922||Patients with FTLD or family members|Participants with FTLD syndrome diagnoses and/or strong family histories of FTLD.
3029426|NCT02365909|Active Comparator|Acitve|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
3029427|NCT02365909|Placebo Comparator|Placebo|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
3029428|NCT02365896|Other|TLDG or LADG|To complete the distal gastrectomy with Billroth-II reconstruction and D2 lymphadenectomy for locally advanced gastric cancer with TLDG or LADG
3029429|NCT02365883||Prostate Cancer Group|
3029430|NCT02365870|Active Comparator|rotigotine|rotigotine transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks
3029431|NCT02365870|Placebo Comparator|placebo|placebo transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks
3029432|NCT02365857|Active Comparator|DEX-5|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 5 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
3029539|NCT02365233|Active Comparator|DPP4 inhibitor|Sitagliptin, 100 mg/day or Saxagliptin, 5 mg/day
3029433|NCT02365857|Active Comparator|DEX-10|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 10 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
3029434|NCT02365857|Active Comparator|DEX-15|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 15 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
3029435|NCT02365857|Active Comparator|Control|Bupivacaine Only. Patients will receive intrathecal 12.5 mg isobaric bupivacaine only using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
3029436|NCT02365831||Prospective|Observation of treatment management of patients with metastatic breast cancer that have been treated or not with hormonal therapy and candidate for a first line chemotherapeutic treatment in the years 2014-2015 will be observed until the end of the study.
3029437|NCT02365831||Retrospective|Observation of treatment management of patients with metastatic breast cancer that have been treated with a first, second or following line of chemotherapeutic treatment for metastatic disease in the years 2012-2013.
3029438|NCT02365818|Experimental|CG0070|Single arm intervention with CG0070 to be given at a dose of 1e12 vp weekly for six weeks. Patients who achieve a partial response or a complete response at 6 months post first intravesical intervention will be maintained with the same induction cycle of weekly times six. Patients will be followed every 3 months through Month 24.
3029439|NCT02365805|Active Comparator|Standard FEC Regimen|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
3029440|NCT02365805|Experimental|No or Low BRCA1 expression|Epirubicin + Cisplatin + Fluorouracil
3029441|NCT02365805|Experimental|Normal or High BRCA1 expression|Docetaxel + Ciclofosfamide
3029442|NCT02365792|Active Comparator|CDSS1|The CDSS1 will provide decision support according to existing protocols for clinical procedures and medical treatment, mainly starting from specific symptoms or diagnostic related patients groups. The symptom oriented approach is categorised in a specific list of predetermined conditions.
3029443|NCT02365792|Active Comparator|CDSS2|The CDSS2 will provide decision support according to existing protocols for clinical procedures and medical treatment, mainly starting from specific symptoms or diagnostic related patients groups. The symptom oriented approach is categorised in a specific list of predetermined conditions.
3029444|NCT02365792|Placebo Comparator|Booklet|The control group will provide prehospital patient care with usual decision support: a pocket-size booklet, backed by a mobile phone through which the PIT can get in contact with an Emergency Physician.
3029445|NCT02365779|Experimental|bilateral laparoscopic salpingectomy|
3029446|NCT02365766|Experimental|Arm A - Phase 1b Dose Finding Cohort:|Cisplatin-eligible subjects will receive pembrolizumab at starting dose of 200mg (dose level 0), and/or 120mg (dose level -1) in combination with gemcitabine and cisplatin. The MTD will be the highest pembrolizumab dose level in combination with gemcitabine/cisplatin every 21 days, repeated for 4 cycles. (Subjects with Ccr of 50-59 mL/min must follow split dosing of cisplatin over two days). Once the MTD is established, this portion of the study will close and the phase II will open to cohorts I and II at the recommended phase II dose (RP2D).
3029447|NCT02365766|Experimental|Arm B - Phase II Cohort I:|Cisplatin-eligible subjects receive gemcitabine/cisplatin every 21 days, repeated for 4 cycles. (Subjects with Ccr of 50-59 mL/min must follow split dosing of cisplatin over two days) . Pembrolizumab at RP2D is given every 21 days for 5 doses starting C1D8. Note: the last dose of pembrolizumab falls on what would be day 8 of a 5th 'chemo' cycle, however gemcitabine/cisplatin is NOT GIVEN. Subjects will then have consolidative surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
3029448|NCT02365766|Experimental|Arm C - Phase II Cohort II:|Cisplatin-ineligible subjects receive gemcitabine every week every 28 days for 3 cycles. Pembrolizumab at RP2D is given every 21 days for 5 doses starting C1D8. NOTE: due to the timing of gemcitabine cycles every 4 weeks, and every 3-week dosing of pembrolizumab, there are two doses of pembrolizumab given during cycle 2: D1 and D22. Additionally, the last dose of pembrolizumab falls on what would be D8 of a 4th 'chemo' cycle; however gemcitabine is NOT GIVEN. Subjects will then have consolidative surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
3029449|NCT02365753|Placebo Comparator|SofPulse nonfunctional device.|The Sofpulse non-functional device is placed over the incision after cesarean delivery and then turned on. The device only appears to be function correctly because the lights turn on, but does not emit a pulsed electromagnetic frequency..
3029450|NCT02365753|Active Comparator|Active|The Sofpulse Pulsed electromagnetic frequency device is placed over the incision after cesarean delivery and then turned on. Device appears to be operational and functions correctly.
3029451|NCT02365740|Experimental|Cases|gastric emptying test gut hormones determination Continuous Glucose Monitoring Insulin single bolus Insulin double-wave bolus
3029452|NCT02365740|Sham Comparator|Controls|gastric emptying test gut hormones determination
3029453|NCT02365727|Experimental|Exparel plus Adductor Canal Block|Adductor canal block with 20 cc 0.5% Ropivacaine with 1:400,000 epinephrine and 100mcg of clonidine
3029454|NCT02365727|Placebo Comparator|Exparel plus Placebo Block|Adductor canal block with 20 cc saline
3029455|NCT02365714|Other|Treatment-Radiation|CyberKnife (CK) Stereotactic Accelerated Partial Breast Irradiation. Adjuvant radiation therapy delivered to the region around the lumpectomy cavity. Patients will receive 30 Gy in 5 fractions over 5-14 days.
3029456|NCT02365701|Experimental|Motilitone 30mg|Motilitone will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 4 weeks.
3029457|NCT02365701|Placebo Comparator|Placebo|Placebo (same formulation as Motilitone but without the active ingredients) will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this tablet for 4 weeks.
3029458|NCT02365688|Other|Initial bolus pre-incision|Initial pre-incision bolus of 500 cc of fluids with hemodynamic response recorded
3029459|NCT02365675|Active Comparator|Cotton gauze with petrolatum|The dressing to be used is regular cotton gauze impregnated in petrolatum (a mixture of solid hydrocarbons) creating a film that reduces the adherence of the gauze to the wound.
3029540|NCT02365220|Active Comparator|No expectancy (control)|No expectancy instruction with regard to the efficacy of the daily smartphone-based training
3029460|NCT02365675|Active Comparator|Cellulose acetate with petrolatum|The dressing to be used is a mesh or tulle base of cellulose acetate polymers that do not easily adhere to the wound impregnated in petrolatum (a mixture of solid hydrocarbons).
3029461|NCT02365675|Active Comparator|Nanocrystalline silver|The dressing to be used consists of two layers of a silver-coated, high-density polyethylene mesh, enclosing a single layer of an apertured non-woven fabric of rayon and polyester. The three components are ultrasonically welded together to maintain the integrity of the dressing in use. Silver is applied to the polyethylene mesh by a vapour deposition process, which results in the formation of microscopic `nanocrystals' of metallic silver.
3029462|NCT02365675|Active Comparator|Carboxymethylcellulose with ionic silver|The dressing to be used is a soft, sterile, non- woven pad dressing made from sodium carboxymethylcellulose containing 1.2% silver in an ionic form.
3029463|NCT02365662|Experimental|Arm 1|Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
3029464|NCT02365649|Active Comparator|Induction Period ABT-494 Low Dose|Induction Period ABT-494 Low Dose orally dosed twice a day
3029465|NCT02365649|Active Comparator|Induction Period ABT-494 Low/Medium Dose|Induction Period ABT-494 Low/Medium Dose orally dosed twice a day
3029466|NCT02365649|Active Comparator|Induction Period ABT-494 Twice Daily Medium/High Dose|Induction Period ABT-494 Twice Daily Medium/High Dose orally dosed twice a day
3029467|NCT02365649|Active Comparator|Induction Period ABT-494 High Dose|Induction Period ABT-494 High Dose orally dosed twice a day
3029468|NCT02365649|Active Comparator|Induction Period ABT-494 Once Daily Medium/High Dose|Induction Period ABT-494 Once Daily Medium/High Dose orally dosed once a day
3029469|NCT02365649|Placebo Comparator|Induction Period Placebo|Induction Period Placebo orally dosed twice a day
3029470|NCT02365649|Active Comparator|Extension Phase ABT-494 Low Dose|Extension Phase ABT-494 Low Dose orally dosed twice a day
3029471|NCT02365649|Active Comparator|Extension Phase ABT-494 Medium Dose|Extension Phase ABT-494 Medium Dose orally dosed twice a day
3029472|NCT02365649|Active Comparator|Extension Phase ABT-494 High Dose|Extension Phase ABT-494 High Dose orally dosed twice a day
3029473|NCT02365636|Experimental|TV-45070 4%|applied topically and twice daily to the area of pain
3029474|NCT02365636|Experimental|TV-45070 8%|applied topically and twice daily to the area of pain
3029475|NCT02365636|Placebo Comparator|Placebo|applied topically and twice daily to the area of pain
3029476|NCT02365623|Experimental|TMC207 (bedaquiline) + Background Regimen (BR)|Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4*100 mg tablets once daily 2 weeks (14 days). From Week 3, participants will receive 200 mg (2 tablets) TMC207 (bedaquiline) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase. After TMC207 is stopped, the BR will be continued up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
3029477|NCT02365610|Experimental|GWP42006|GWP42006
3029478|NCT02365610|Placebo Comparator|Placebo control|Placebo
3029479|NCT02365597|Experimental|JNJ-42756493 (8 milligram)|Prior to interim analysis 1 (IA1), there were 2 treatment regimens: Regimen 1 (10 milligram [mg] once daily, 7 days on/7 days off); and Regimen 2 (6 mg once daily for 28 days). Following IA1, Regimen 1 is closed for further enrollment and starting dose of Regimen 2 is increased to 8 mg once daily for 28 days on a 28-day cycle (referred to as Regimen 3).
3029480|NCT02365584|Experimental|Standard care and Lanreotide Autogel|Standard care according to site clinical practice and Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
3029481|NCT02365584|No Intervention|Standard care|Standard care according to site clinical practice.
3029482|NCT02365571|Experimental|LY3154207 (Part A)|LY3154207 administered in ascending doses once orally in two of three study periods
3029483|NCT02365571|Placebo Comparator|Placebo (Part A)|Placebo matching LY3154207 administered once orally in one of three study periods.
3029484|NCT02365571|Experimental|LY3154207 (Part B)|LY3154207 administered once orally.
3029485|NCT02365571|Placebo Comparator|Placebo (Part B)|Placebo matching LY3154207 administered once orally.
3029486|NCT02365571|Experimental|LY3154207 (Part C)|LY3154207 administered once orally on Day 1
3029487|NCT02365571|Experimental|LY3154207 + Itraconazole (Part C)|Itraconazole administered orally (twice daily on Day 3 and then once daily to Day 12). LY3154207 co-administered once orally, on Day 9. Timing and duration of itraconazole dosing may be adjusted based on data from Part A.
3029488|NCT02365558|Experimental|Evacetrapib|Single oral dose of evacetrapib administered alone on Day 1 of Period 1.
3029489|NCT02365558|Experimental|Omeprazole + Evacetrapib|"In Period 2, participants will receive 40 mg oral dose of Omeprazole once daily (QD) on Days 8 through 20.~Evacetrapib will be co-administered once, orally on Day 14."
3029490|NCT02365532|Placebo Comparator|Placebo to match GS-6615|Placebo to match GS-6615 + dofetilide or placebo to match dofetilide twice daily
3029491|NCT02365532|Experimental|GS-6615|GS-6615 or placebo to match GS-6615 + dofetilide or placebo to match dofetilide twice daily
3029492|NCT02365519|Experimental|LME636|LME636 ophthalmic solution, 1 drop (approx. 40 µL; 2.4 mg) administered topically in each eye 3 times a day (TID) for 6 weeks
3029493|NCT02365519|Placebo Comparator|Vehicle|LME636 Vehicle, 1 drop administered topically in each eye TID for 6 weeks
3029494|NCT02365506|Experimental|Eleclazine Dose Level 1|Eleclazine dose level 1 + placebo to match eleclazine
3029495|NCT02365506|Experimental|Eleclazine Dose Level 2|Eleclazine dose level 2 + placebo to match eleclazine
3029496|NCT02365506|Placebo Comparator|Placebo|Placebo to match eleclazine for 4 days
3029535|NCT02365259|Placebo Comparator|Shame phototherapy|This arm is identical with experimental arm, except that participants will be exposed to non-UVB florescent light.
3029536|NCT02365246|Experimental|immunoadsorption group|All patients will be treated with 10 immunoadsorptions with an IgE-specific adsorption column :
3029537|NCT02365233|Active Comparator|Thiazolidinedione|(Pioglitazone, 15 mg/day)
3029538|NCT02365233|Active Comparator|Lantus Insulin|0.35 U per kg body weight once daily
3029497|NCT02365493|No Intervention|Standard therapy|"Intravenous vancomycin dosed as per Australian Therapeutic Guidelines (loading dose of 25 mg/kg followed by maintenance dose of 15-20 mg/kg every 12 hours) with subsequent adjustment to maintain trough levels at 15-20 mg/dL OR Intravenous daptomycin 6-10 mg/kg per day, adjusted for renal function (details of renally adjusted dosing provided in full protocol).~The choice of daptomycin or vancomycin is clinician-determined and may be influenced by such factors as local practice, the vancomycin minimum inhibitory concentration (MIC) of the isolate and evidence emerging during the course of the study"
3029498|NCT02365493|Experimental|Standard therapy + Beta-Lactam|In addition to standard treatment an intravenous Beta-Lactam (β-lactam) will be added for the first 7 calendar days following randomisation (randomisation is day 1 - hence patients will receive 6-7 days of β-lactam). This β-lactam will be intravenous flucloxacillin 2g every 6 hours in Australia and intravenous cloxacillin 2g every 6 hours in Singapore. For those with a history of minor allergy to any penicillin (rash or unclear history, but not anaphylaxis or angiooedema), it will be intravenous cefazolin 2g every 8 hours. For haemodialysis patients, it will usually be cefazolin 2g three times per week post dialysis, however clinicians are also free to choose intermittent (flu)cloxacillin, dosed as for glomerular filtration rate (GFR ) <10, if they desire.
3029499|NCT02365480|Experimental|Arm I (berberine chloride)|Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.
3029500|NCT02365480|Placebo Comparator|Arm II (placebo)|Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.
3029501|NCT02365467|Experimental|Treatment with Valiant Mona LSA device|
3029502|NCT02365454|Experimental|Thoracic Aortic Disease Single Arm Study|Thoracic Aortic Disease treated by Stent Graft Placement
3029503|NCT02365441|Active Comparator|Arm A|imatinib 400mg orally daily continuously
3029504|NCT02365441|Experimental|Arm B|alternating 28-day periods of imatinib 400mg orally daily for 21 to 25 days followed by a washout (drug free) period of 3 to 7 days, then regorafenib 160mg orally daily for 3 weeks followed by a 7 day washout (drug free) period.
3029505|NCT02365428|Experimental|Control: Group 1|The control group will receive three standard Text4Baby messages per week at noon on Mondays, Wednesdays, and Fridays.
3029506|NCT02365428|Experimental|Group 2|Intervention group 1 will receive two physical activity messages and one standard Text4Baby message each week at noon on Mondays, Wednesdays, and Fridays.
3029507|NCT02365428|Experimental|Group 3|Intervention group 2 will receive six physical activity messages and one standard Text4Baby message per week at a random time per day.
3029508|NCT02365428|Experimental|Group 4|Intervention group 3 will receive six physical activity messages and one standard Text4Baby message per week at a time of the participant's choice per day.
3029509|NCT02365415|Experimental|Sirolimus|Patients randomized to this arm will receive 8 weeks of enteral Rapamycin (sirolimus), with dosage titrated to achieve target blood levels.
3029510|NCT02365415|No Intervention|Control|No treatment.
3029511|NCT02365402|Experimental|entecavir with PEG-IFN a-2a|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow up after treatment.
3029512|NCT02365402|No Intervention|control group|In this group, patients will be continue treated only by PEG-IFN a-2a for 48 weeks after enrolled and receive 24 weeks of follow up.
3029513|NCT02365389|Active Comparator|Group A received in situ MTZ vaginal gel|Received in situ MTZ vaginal gel once daily for 5 days. Treatment in this group was offered in the form of a bottle of an aqueous liquid (100 mL of a preparation composed of 0.8% MTZ, 20% pluronic F-127, 10% pluronic F-68, and 0.01% benzalkonium chloride). Women were asked to put 5 cc of the liquid into the vagina once daily for 5 days using a graded syringe and 10-cm long soft applicator.
3029514|NCT02365389|Active Comparator|Group B received conventional MTZ vaginal gel|Group B (control group) received conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days, using the supplied nozzle, which applies about 5 gm of gel again in the same laying back position.
3029515|NCT02365363|Experimental|Bagel control|100% wheat flour
3029516|NCT02365363|Experimental|Bagel with pea flour|Pea flour (30%)
3029517|NCT02365363|Experimental|Bagel with pea fibre|Pea fibre (11g)
3029518|NCT02365363|Experimental|Bagel w/ pea flour + pea fibre|Pea flour (30%) + pea fibre (11g)
3029519|NCT02365363|Experimental|Bagel w/ pea flour + pea protein|Pea flour (30%) + pea protein (24g)
3029520|NCT02365363|Experimental|Bagel w/ pea flour + pea fibre + pea protein|Pea flour (30%) + pea fibre (11g) + pea protein (24g)
3029521|NCT02365350|Experimental|STEINER-TAN Needle®|All visible follicles regardless of size in both ovaries will be aspirated and flushed three times by the STEINER-TAN Needle.
3029522|NCT02365350|Active Comparator|17G single lumen needle|In the control group all visible follicles regardless of size in both ovaries will be aspirated by the 17G single lumen needle.
3029523|NCT02365337||vitamin D levels < 20ng/ ml|Vitamin D levels < 20ng/ ml
3029524|NCT02365337||vitamin D levels>20ng/ ml|Vitamin D levels >20ng/ ml
3029525|NCT02365324|Experimental|Peer-education Family Fitness Program|Peer educators (children in grade 8) recruited from the schools participating in the study will be trained and will then be implementing the 12 week Peer-education Family Fitness Program (PE-FFP) intervention to children in 6th and 7th grade.
3029526|NCT02365324|Other|Family Fitness Program (FFP)|Adult educators recruited from the University of Illinois Extension or the community will be trained and will then be implementing the 12 week Family Fitness Program (FFP) intervention to children in 6th and 7th grade.
3029527|NCT02365311|Experimental|one lung group|
3029528|NCT02365298|Experimental|etafilcon A|Worn in a daily disposable modality
3029529|NCT02365298|Active Comparator|nelfilcon A|Worn in a daily disposable modality
3029530|NCT02365285|Experimental|Galantamine 16 mg|Galantamine 16 mg po one time dose
3029531|NCT02365285|Placebo Comparator|Placebo|Placebo capsule po one time dose
3029532|NCT02365272|Active Comparator|amikacin standard dose|amikacin in a single standard dose
3029533|NCT02365272|Active Comparator|amikacin dose for critical care patients|amikacin in a single dose for critical care patients
3029534|NCT02365259|Experimental|Phototherapy|This arm involves exposure to a UVB phototherapy device 3 times per week over 8 weeks.
3058485|NCT02171702|Experimental|BIBW 2992|dose escalation
3029541|NCT02365220|Experimental|Prospective expectancy|"Prospective expectancy instruction (Training will have an effect on...) with regard to the efficacy of the daily smartphone-based training"
3029542|NCT02365220|Experimental|Retrospective expectancy|"Retrospective expectancy instruction (Training already had an effect on...) with regard to the efficacy of the daily smartphone-based training"
3029543|NCT02365220|Experimental|Prospective and retrospective expectancy|"Prospective (Training will have an effect on...) and retrospective (Training already had an effect on...) expectancy instruction with regard to the efficacy of the daily smartphone-based training"
3029544|NCT02365207|Experimental|BCG|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
3029545|NCT02365194|Other|Prehabilitation|physical conditioning and weight loss intervention done pre-operatively
3029546|NCT02365194|Other|Standard Counseling|initial clinic counseling
3029547|NCT02365181|Experimental|IAL|intra-articular local anesthetic infiltration with catheter
3029548|NCT02365181|Active Comparator|ISB|interscalene block with catheter
3029549|NCT02365168|Experimental|Food Challenge with cod|
3029550|NCT02365168|Experimental|Food Challenge with salmon|
3029551|NCT02365168|Experimental|Food Challenge with mackerel|
3029552|NCT02365168|Placebo Comparator|Food Challenge with placebo|
3029553|NCT02365155|Experimental|Intervention group.|Multicomponent training intervention; Nutrition intervention; Cognitive intervention; D-vitamin intervention; Occupational intervention; Heart failure follow up.
3029554|NCT02365155|Active Comparator|Control group.|Nutrition intervention; Cognitive intervention; D-vitamin intervention; Occupational intervention; Heart failure follow up.
3029555|NCT02365142|Active Comparator|Platelet Rich Plasma (PRGF)|Platelet Rich plasma (PRGF) 3 intraarticular onjections sepataded by 7 days.
3029556|NCT02365142|Active Comparator|BMMSC with Platelet Rich Plasma (PRGF)|Single intraarticular injection of 100 million Bone marrow mesenchimal stem cells and three intraarticular injections of plateler Rich Plasma (PRGF) separatede by 7 days.
3029557|NCT02365129|No Intervention|Usual care group (control)|Participants randomly assigned to the usual care (control) group will receive general advices from the exercise-training specialist about the positive effects of physical activity at the start of the study. The investigators will prepare informative pamphlets describing the benefits of physical activity that the investigators group has prepared for the Region of Andalucía (Southern Spain),http://www.juntadeandalucia.es/salud/servicios/contenidos/andaluciaessalud/docs/130/Guia_Recomendaciones_AF.pdf.
3029558|NCT02365129|Experimental|Moderate-intensity group|Exercise training based on recommendations for adults (WHO)
3029559|NCT02365129|Experimental|Vigorous-intensity group|Exercise training based on recommendations for adults (WHO)
3029560|NCT02365116|Experimental|Peer Mentorship intervention|A Peer Specialist will be making weekly follow-up contact with study participants in the community or by telephone for 3 months following hospital discharge. The content of the peer mentorship interactions will be based on the manual developed by the study team and will include components such as hope and belongingness.
3029561|NCT02365116|Active Comparator|Enhanced Usual Care|Patients will continue to receive usual care which typically consists of referral to an outpatient psychiatrist. Participants will also receive a phone call within 24-72 hours from a member of the inpatient unit clinical staff to assess barriers to follow-up care and safety. The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
3029562|NCT02365103|Other|Test meal I (given with water)|Test meal with water
3029563|NCT02365103|Other|Test meal II (simultaneously with tea)|Test meal with tea (simultaneously)
3029564|NCT02365103|Other|Test meal III (1 hour after test meal)|Test Meal with tea given 1 hour after test meal
3029565|NCT02365103|Other|Reference Iron Dose|Reference iron dose administered
3029566|NCT02365090|Active Comparator|patching (occlusion therapy)|2 hours per day patching of the sound eye (for strabismic, anisometropic, and combined mechanism amblyopia) or current patching regimen (deprivation amblyopia)
3029567|NCT02365090|Experimental|binocular games|1 hour per day (5 days per week) binocular game play
3029568|NCT02365077||Control|The patients of necrosis group was defined by a history of taking 1800 mg prednisolone or an equivalent over 4 week without the symptom of femur head necrosis after 1 year.
3029569|NCT02365077||Necrosis|The patients of necrosis group was defined by a history of taking 1800 mg prednisolone or an equivalent over 4 week with the diagnosis of femur head necrosis.
3029570|NCT02365064|Active Comparator|Continuous Positive Airway Pressure|Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.
3029571|NCT02365064|Experimental|Adaptive Servo-Ventilation|Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.
3029572|NCT02365051|No Intervention|usual care|Older adults with dementia and their family caregivers receive all services for which they are eligible in the Connecticut Home Care Program for Elders.
3029573|NCT02365051|Experimental|COPE plus usual care|Older adults with dementia and their family caregivers receive Usual care plus the intervention: Care of Persons with Dementia in their Environments.
3029574|NCT02365038|Experimental|Driving pressure limited ventilation|Driving pressure limited ventilation
3029575|NCT02365038|Active Comparator|Conventional ventilation|Mechanical ventilation as proposed in the ARDSNet protocol.
3029576|NCT02365025|Experimental|Experimental group|"Step 1: Patients and parents enrolment. Step 2: The parents of the children assigned to the experimental group will fill a questionaire related to familial and social background, electronic media exposure and sleep characteristics of their children.~Step 3: Parents of the children assigned to this group will participate in 6 meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.~Step 4: Re evaluation by questioners after the 6 meetings participation. Step 5: 3 months follow up after the intervention (Meetings)."
3058598|NCT02171052|Active Comparator|Digoxin|
3029577|NCT02365025|No Intervention|Control group|"Step 1: Patients and parents enrolment. Step 2: The parents of the children assigned to the control group will fill a questionaire related to familial and social background, electronic media exposure and sleep characteristics of their children.~Step 3: Parents of the children assigned to this group will not participate in the meetings as described in the experimental group.~Step 4: Re evaluation by questioners after the time that the experimental group participated in the meetings.~Step 5: 3 months follow up."
3029578|NCT02365012|Placebo Comparator|Placebo|Placebo given three times a day for 2 weeks
3029579|NCT02365012|Active Comparator|Midodrine|Midodrine 2.5 mg given three times a day for one week followed by 5 mg given three times a day for one week
3029580|NCT02364999|Experimental|Bevacizumab-Pfizer|Bevacizumab-Pfizer plus paclitaxel and carboplatin
3029581|NCT02364999|Active Comparator|Bevacizumab-EU|Bevacizumab-EU plus paclitaxel and carboplatin
3029582|NCT02364986|Experimental|Rebif/Avonex|Rebif® 44µg (day 1, 3, 5 and 8) s.c. Avonex 30µg (day 1 and 8) i.m.
3029583|NCT02364973||PET-MRI|Patients with chronic inflammatory bowel disease who are treated at Turku University hospital outpatient clinic or ward
3029584|NCT02364947|Experimental|Nalmefene hydrochloride 10 mg|As-needed; tablets, orall
3029585|NCT02364947|Experimental|Nalmefene hydrochloride 20 mg|As-needed; tablets, orall
3029586|NCT02364947|Placebo Comparator|Placebo|AS-needed; tablets, orall
3029587|NCT02364934||Propofol|Propofol is intravenously administrated during anesthesia maintenance in patients (18-65 years old)
3029588|NCT02364934||Sevoflurane|Sevoflurane (inhalation) is administrated during anesthesia maintenance in patients (18-65 years old)
3029589|NCT02364934||Propofol (elderly)|Propofol is intravenously administrated during anesthesia maintenance in patients (≥65 years old)
3029590|NCT02364934||Sevoflurane (elderly)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in patients (≥65 years old)
3029591|NCT02364934||Propofol (men)|Propofol is intravenously administrated during anesthesia maintenance in men (18-65 years old)
3029592|NCT02364934||Sevoflurane (men)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in men (18-65 years old)
3029593|NCT02364934||Propofol (women)|Propofol is intravenously administrated during anesthesia maintenance in women (18-65 years old)
3029594|NCT02364934||Sevoflurane (women)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in women (18-65 years old)
3029595|NCT02364921|Experimental|Two-layer compression bandage|Two multilayer compression bandage: Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.Measure the ankle circumference and choose the correct kit accordingly (ankle size 18-25cm or 25-32cm). Apply one to seven days
3029596|NCT02364921|Active Comparator|crepe bandage|Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
3029597|NCT02364908|Other|Patients with Systemic Lupus|
3029598|NCT02364895|Experimental|Male arm|Males control group: Deferred letter Males Group 1: Current CCC invitation letter Males Group 2: New letter with neutral gender content Males Group 3: New letter with male-specific content
3029599|NCT02364895|Experimental|Female arm|Females control group: Deferred letter Females Group 1: Current CCC invitation letter Females Group 2: New letter with neutral gender content
3029600|NCT02364882|Placebo Comparator|1|1 g (placebo) 0 mg sildenafil 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
3029601|NCT02364882|Active Comparator|2|1 g 50 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
3029602|NCT02364882|Active Comparator|3|2 g 100 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
3029603|NCT02364882|Active Comparator|4|4 g 200 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
3029604|NCT02364869|Experimental|Fructooligosaccharide|12g daily, for 12 weeks
3029605|NCT02364869|Placebo Comparator|Maltodextrin|12g daily, for 12 weeks
3029606|NCT02364856||Children with cerebral palsy|
3029607|NCT02364843|Experimental|Dietary Threonine Intake|Physiological establishment of enteral intake of amino acid threonine required by infants ages 1 - 6 mos
3029608|NCT02364830|Active Comparator|Anise-oil EC|Intervention Group: Anise-oil EC Capsule,One Cap(187mg)/day for 4 weeks. Patients will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
3029609|NCT02364830|Placebo Comparator|Placebo|Placebo Group: One Placebo Capsule/Day for 4 Weeks. Patients Will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
3029610|NCT02364830|Active Comparator|Colpermin®|Colpermin® Group: One Colpermin® Capsule/Day for 4 Weeks. Patients Will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
3029611|NCT02364817||Post-Detox Cohort|"All the patients included should meet Diagnostic and Statistical Manual 4th edition revised (DSM-IV-Tr) criteria for Alcohol Dependance. They are all recruited at the end of an inpatient alcohol detoxification process (see inclusion criteria).~The initial screening is performed just before the end of hospitalization. The subsequent follow-up is 12 weeks-long. There is no drug for abstinence maintenance during the study. The psychosocial intervention is based on the BRENDA model."
3029612|NCT02364791|Active Comparator|standard treatment|standard techniques to achieve air leak control after complex thoracic surgical procedures
3029613|NCT02364791|Experimental|standard treatment plus hemopatch|the addition of hemopatch to standard techniques to achieve air leak control after complex thoracic surgical procedures
3029614|NCT02364778||Provisional stenting strategy|Patients with stable coronary artery disease with angiographic main vessel lesion not involving side branch (SB) in whom provisional stenting strategy is planned.
3029615|NCT02364765|Other|Orthognatic surgery|Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour.
3029616|NCT02364752|Experimental|Healthy|Part 1: Blood is obtained from healthy participants on 3 consecutive days, and participants undergo Cardiac Magnetic Resonance Imaging (CMR) and two-dimensional speckle tracking echocardiography (2DSTE) on one of those 3 days.
3029725|NCT02363946|Experimental|Part A: 2.0 mg/kg|Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers
3029726|NCT02363946|Experimental|Part A: 3.0 mg/kg|Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers
3029617|NCT02364752|Experimental|Mild/moderate heart failure (HF)|Part 1: Blood is obtained from participants with mild/moderate HF on 3 consecutive days, and participants undergo CMR and 2DSTE on one of those 3 days. Part 2: Within 5 days of completing Part 1 participants have a 24 hour loop diuretic withdrawal, and 15 hour 0.9% normal saline infusion; followed by a blood draw, CMR and 2DSTE.
3029618|NCT02364752|Experimental|Severe HF|Part 1: Blood is obtained from participants with severe HF on 3 consecutive days, and participants undergo CMR and 2DSTE on one of those 3 days. Part 2: Within 5 days of completing Part 1 participants have a 24 hour loop diuretic withdrawal, and 15 hour 0.9% normal saline infusion; followed by a blood draw, CMR and 2DSTE.
3029619|NCT02364739|Experimental|Written information|Written information
3029620|NCT02364739|Experimental|Written and oral information|Written and oral information
3029621|NCT02364739|No Intervention|No intervention|Control
3029622|NCT02364726|Experimental|Acupuncture|"As part of routine clinical care, a chemotherapy nurse, research nurse, or physician will assess the patient's symptoms including CIPN based on the NCI-CTC 4.0 criteria to determine the grade of CIPN. Once these patients develop National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grade 2 CIPN, they will be recruited for the intervention phase of the study. Severity of CIPN as defined by NCI-CTC is listed in Appendix A. Patients who consent to the intervention phase of the study will then be treated with weekly acupuncture until the end of chemotherapy. No concomitant anti-neuropathy medication will be permitted.~Subjects will receive acupuncture in bilateral ear points: shen men, point zero, two additional auricular acupuncture point where electrodermal signal is detected and bilateral body acupuncture points: LI4, TE5, LI11, ST40, Ba Feng, Ba xie."
3029623|NCT02364713|Experimental|Arm A (MV-NIS)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IP over 30 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3029624|NCT02364713|Active Comparator|Arm B (DOXIL, GEM, TOPA, TAXOL)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15, or paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3029625|NCT02364700|Experimental|interventional group|This is a single group, interventional pilot study. All participants will receive 6-week hand training on the HOH device.
3029626|NCT02364687||Participants|Participants will have previously had an MRI scan and will undergo a CT scan.
3029627|NCT02364674|Experimental|HRCT scans|HRCT scan will be taken
3029628|NCT02364661|Experimental|Hepatitis B virus infected patients|HBV patients with detectable viremia will be analyzed for their level of viremia following an over-night starvation (fasting) versus fed state
3029629|NCT02364648|Experimental|MitoQ|4 week 20mg oral daily dose of MitoQ
3029630|NCT02364648|Placebo Comparator|Placebo|4 week 20mg oral daily placebo
3029631|NCT02364635|Experimental|Icosabutate dose 1|Dose 1
3029632|NCT02364635|Experimental|Icosabutate dose 2|Dose 2
3029633|NCT02364635|Experimental|Icosabutate dose 3|Dose 3
3029634|NCT02364635|Placebo Comparator|Placebo|Placebo (medium chain triglycerides)
3029635|NCT02364635|Experimental|Icosabutate dose 4|Dose 4
3029636|NCT02364622|Sham Comparator|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided double lumen endobronchial tube into the left main bronchus was facilitated by traditional fiberoptic bronchoscopy.
3029637|NCT02364622|Experimental|Modified fiberoptic bronchoscopy|The accurate placement of left-sided double lumen endobronchial tube into the left main bronchus was facilitated by modified fiberoptic bronchoscopy.
3029638|NCT02364622|Experimental|Flexible Trachway intubating stylet|We used Flexible Trachway intubating stylet to facilitate the accurate placement of left-sided double lumen endobronchial tube into the left main bronchus.
3029639|NCT02364609|Experimental|Arm I (afatinib dimaleate, pembrolizumab)|DOSE DE-ESCALATION COHORT: Patients receive afatinib dimaleate PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days (for up to 2 years for pembrolizumab) in the absence of disease progression or unacceptable toxicity.
3029640|NCT02364609|Experimental|Arm II (pembrolizumab, afatinib dimaleate)|EXPANSION COHORT: Patients receive pembrolizumab IV over 30 minutes on day 1 for 2 courses. Beginning course 3, patients receive afatinib dimaleate PO and pembrolizumab IV as in Arm I. Courses repeat every 21 days (up to 2 years for pembrolizumab) in the absence of disease progression or unacceptable toxicity.
3029641|NCT02364596|Experimental|1|SA4Ag vaccine
3029642|NCT02364583|Active Comparator|14 day dose regimen|0.5 mg/kg oral Primaquine administered daily for 14 days
3029643|NCT02364583|Active Comparator|7 day dose regimen|1.0 mg/kg oral Primaquine administered daily for 7 days
3029644|NCT02364583|Active Comparator|3.5 day dose regimen|1.0 mg/kg oral Primaquine administered twice daily (bd) for 3.5 days
3029645|NCT02364570|Active Comparator|Oral Glucose Tolerance Test|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (100 g). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
3029646|NCT02364570|Experimental|Glucose with Whole Eggs|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 1.5 whole eggs (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
3029727|NCT02363946|Experimental|Part A: 4.0 mg/kg|Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers
3029647|NCT02364570|Experimental|Glucose with Egg Whites|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 7 egg whites (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
3029648|NCT02364570|Experimental|Glucose with Egg Yolks|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 2 egg yolks (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
3029649|NCT02364557|No Intervention|Arm 1 (standard of care)|Patients continue to receive their current planned systemic therapy at the discretion of the treating physician.
3029650|NCT02364557|Experimental|Arm 2 (stereotactic radiosurgery, surgery)|Patients continue to receive their current planned systemic therapy at the discretion of the treating physician. Patients also undergo stereotactic radiosurgery in 1, 3, or 5 fractions within 3 weeks and/or surgery at the discretion of the treating physician.
3029651|NCT02364544|Other|Health Technology Program|"The components of the treatment model include: 1) Prescriber Decision Assistant (PDA) 2) relapse prevention plan, 3) the daily support website 4) FOCUS, an interactive smart phone text-messaging application 5) a web-based, cognitive-behavioral therapy (CBT) program~All patients will be provided with pharmacological treatment (PDA), brief in-person relapse prevention counseling, and an Android mobile phone. The other program components will be provided to patients using a shared decision-making approach to assess need and preference."
3029652|NCT02364531||Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry|Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
3029653|NCT02364518|Experimental|Snoreplasty|Treatment of Snoring and/or mild obstructive sleep apnea with snoreplasty.
3029654|NCT02364505|Experimental|Telemedicine mindfulness intervention|Participants are assigned to a telemedicine mindfulness intervention group. The protocol lasts 8 weeks and it is composed by one online course session each week and home exercises. The course sessions, with a synchronous communication, will be conducted by a trainer, through teleconferences, that will explain how to practice the exercises to develop mindfulness attitude, following the mindfulness-based intervention-multiple sclerosis protocol. Subjects will be able to take part of these sessions everywhere, through a computer, tablet o mobile. During these sessions, individuals will interact with the trainer with teleconference or textual communications.
3029655|NCT02364505|Active Comparator|Psycho-education control group|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
3029656|NCT02364492|Experimental|MAG-Tn3 + AS15|"3 escalating doses of MAG-Tn3 in combination with a fixed dose of AS15 adjuvant.~For each dose patient will receive 6 injections at 3 interval weeks."
3029657|NCT02364479|Experimental|etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week, Subcutaneous injection
3029658|NCT02364479|Experimental|etanercept (half dose)|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injectio, 25mg per week, Subcutaneous injection
3029659|NCT02364479|Placebo Comparator|placebo|placebo, Subcutaneous injection per week
3029660|NCT02364453|Experimental|Placebo to PACAP38|Pre-treatment with placebo. PACAP38 8pmol/kg/min
3029661|NCT02364453|Experimental|Clemastin 1 mg/ml to PACAP38 8pmol/kg/min|Pre-treatment with Clemastin 1 mg/ml PACAP38 8 pmol/kg/min
3029662|NCT02364440|Experimental|Ultherapy™ System|Ultherapy™ System
3029663|NCT02364427||Arterial stiffness|Arterial stiffness - Vicorder to measure pulse wave velocity
3029664|NCT02364414|Other|Cohort|Orthodontic patients, aged 11-18 who fulfill the inclusion/exclusion criteria and provide written informed consent to participate will undergo intra-oral scan. This will be repeated 2 weeks later.
3029665|NCT02364401|Experimental|Impedance Guided Ablation Group|Impedance guided ablation group performs pulmonary vein(PV) isolation guided by annotation criteria with minimum time of 10 seconds, maximum range of 2 mm, and minimum impedance decrease over 5 Ohms instead of CF parameters. In the impedance guided group, operators are blinded to contact force data during PV isolation.
3029666|NCT02364401|Active Comparator|Contact Forced Guided Ablation Group|Contact force(CF) guided ablation group performs pulmonary vein (PV) isolation guided by automated annotation criteria with minimum time of 10 seconds, maximum range of 2mm, CF over time of 50% and minimum CF of 10 g.
3029667|NCT02364388||Imagio scan|Female subjects that have an undiagnosed suspicious finding which may include more than one solid or complex cystic suspicious mass, classified by CDU as BI-RADS 4a or 4b within 3 weeks of their baseline Imagio Scan.
3029668|NCT02364362|Experimental|Famitinib + docetaxel|Low, medium and high dose of famitinib and 60 mg/m^2 docetaxel every 3 weeks
3029669|NCT02364349|Active Comparator|Bee Venom (BV) group|All subjects are injected with Bee Venom (BV, intervention), randomly assigned to the right or left forearm. Raw BV used dried BV prepared through collection from bee venom sacs and removal of impurities. The BV administration site on each subject was on the palmar side of the designated arm 5 cm below the middle of the elbow crease as it is convenient for observation and has high responsiveness. Pharmacopuncture sessions were also conducted in the morning for higher responsiveness.
3058599|NCT02171039|Experimental|dabigatran plus atorvastatin|
3029670|NCT02364349|Experimental|essential Bee Venom (eBV) group|All subjects are injected with essential Bee Venom (eBV, intervention), randomly assigned to the right or left forearm. eBV was prepared through the following methods: BV was collected from bee venom sacs and dried. LC/MS was used to analyze subdivisions of dried BV dissolved in purified water and passed through a sephadex G-25 column to collect histamine-free units. Collected units were filtered to eliminate allergenic substances including PLA2 of molecular weight 10 kDa or higher. The eBV administration site on each subject was on the palmar side of the designated arm 5 cm below the middle of the elbow crease as it is convenient for observation and has high responsiveness. Pharmacopuncture sessions were also conducted in the morning for higher responsiveness.
3029671|NCT02364323|Experimental|Personalized risk counselling|Intervention includes risk counseling to patients with diabetes on future risk of diabetic complications based on an established genetic counseling framework for common polygenic disorders which will be delivered to patient in a counselling sesssion 6 weeks after genetic testing
3029672|NCT02364323|Placebo Comparator|Normal usual care|Intervention includes normal usual care. General education on diabetes and diabetic complications
3029673|NCT02364310|Experimental|Baroreceptor stimulation on top of the best medical care|Baroreceptor stimulation with Barostim Neo TM
3029674|NCT02364310|No Intervention|Best medical care|Best medical care
3029675|NCT02364297|Active Comparator|Early TIPS|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic injection of tissue adhesives according to the center protocol.~Performance of TIPS in the first 5 days following acute gastric variceal bleeding."
3029676|NCT02364297|Placebo Comparator|Control|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic injection of tissue adhesives according to the center protocol.~Standard combined endoscopic and pharmacological therapy as a secondary prophylaxis (beta-blockers or carvedilol + repeated injection of tissue adhesives until the erradication of the fundal varices)."
3029677|NCT02364284||Urinary Tract Infection (cUTI)|Patients ≥18 years with diagnosis of urinary tract infection.
3029678|NCT02364284||Intra Abdominal Infection(cIAI)|Patients ≥ 18 years with diagnosis of Intra Abdominal Infection
3029679|NCT02364284||Nosocomial Pneumonia (NP)|Patients ≥ 18 years with diagnosis of Hospital acquired pneumonia
3029680|NCT02364271||MACE groups|"Patients with major adverse cardiac events occurred within 30-days or 6-months~Routine blood test for hs-cTnT and point-of-care test for H-FABP, Coronary CT angiography and Thrombolysis in myocardial infarction score were performed on study patients~Protocol amendment:~In October 2014, HEART score of the study patients was determined retrospectively"
3029681|NCT02364271||No MACE group|"Patients with no major adverse cardiac events occurred within 30-days or 6-months~Routine blood test for hs-cTnT and point-of-care test for H-FABP, Coronary CT angiography and Thrombolysis in myocardial infarction score were performed on study patients~Protocol amendment:~In October 2014, HEART score of the study patients was determined retrospectively"
3029682|NCT02364258|Experimental|Rosuvastatin|Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
3029683|NCT02364258|Experimental|Atorvastatin|Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
3029684|NCT02364245|Experimental|Kinect|Receive computer games training for 30 minutes and 30 minutes traditional OT.There are 3 sections for 1 week; the intervention period will be 8 weeks.
3029685|NCT02364245|Placebo Comparator|Traditional|The control group will receive traditional OT for 1 hour. There are 3 sections for 1 week; the intervention period will be 8 weeks.
3029686|NCT02364232|Experimental|Home-based|"Participants in home-based training graoup will receive 1.5 hours/ day, 3 days a week, for 4 contious weeks at home. Participants will receive 2 training stages, including bilateral training with mirror feedback for 30-45 minutes and functional training for 45-60 minutes. Each training stage hase to include above 2 activities.After the end of the home-based training, a four-week wash-out period followed. Then, patients will receive the clinic-based training for 4 continuous weeks.~Before and after the treatment, a total of 4 evaluations were conducted, including clinical assessments and blood test (each 9c.c.). One month after the end of the course of treatment will be assessed."
3029687|NCT02364232|Active Comparator|Clinic-based|"Participants in clinic-based training graoup will receive 1.5 hours/ day, 3 days a week, for 4 contious weeks at home. Participants will receive 2 training stages, including bilateral training with mirror feedback for 30-45 minutes and functional training for 45-60 minutes. Each training stage hase to include above 2 activities.After the end of the clinic-based training, a four-week wash-out period followed. Then, patients will receive the home-based training for 4 continuous weeks.~Before and after the treatment, a total of 4 evaluations were conducted, including clinical assessments and blood test (each 9c.c.). One month after the end of the course of treatment will be assessed."
3029688|NCT02364219|No Intervention|Standard|"Study arm in which patients are treated according to standard operating procedures. Acting as control arm."
3029689|NCT02364219|Experimental|Standard + Microdialysis|Study arm in which patients are treated according to standard operating procedures but also receive Microdialysis through a small catheter which is inserted into subcutaneous upper arm fatty tissue.
3029690|NCT02364219|Experimental|Prewarm|Study arm in which patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.
3029691|NCT02364219|Experimental|Prewarm + Microdialysis|Study arm in which patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia and Microdialysis through a small catheter which is inserted into subcutaneous upper arm fatty tissue
3029692|NCT02364206|Experimental|LY2228820 + TMZ + Radiotherapy|"addition of LY2228820 to standard radiotherapy and concomitant treatment by temozolomide (TMZ).~LY2228820 will be administered orally for two 28 day cycles, from one week before the beginning of radiotherapy, and during standard chemoradiotherapy. Three dose levels of LY2228820 will be tested.~After a 4 week break after concomitant treatment, patient were then received up to 6 cycles of adjuvant TMZ according to the standard 5-day schedule every 28 days ."
3029728|NCT02363946|Experimental|Part A: 5.0 mg/kg|Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers
3029729|NCT02363946|Experimental|Part A: 6.0 mg/kg|Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers
3058600|NCT02171039|Active Comparator|dabigatran|
3029693|NCT02364193|Experimental|Thoracic fluid status assessment|"Cardiac MRI by a 1.5 Tesla scanner:~Left ventricular ejection fraction (LVEF), tracing short axis endocardial borders.~CO, phase contrast angiography.~Fluid challenge by auto-transfusion by distal leg compression using inflatable cuffs (Lympamat Digital Gradient system).~DCE-MRI, bolus injection of Gd-CA intravenously by an injector. Each subject will receive repeated injections (10% of maximum dose).~BIS, impedance will be measured continuously using ImpediMed-SFB7 and surface electrodes on the thorax. ."
3029694|NCT02364180|Other|Electromyography|Subjects taking pyridostigmine bromide for more than 6 weeks for a condition other than myasthenia gravis were observed with Electromyography (EMG)
3029695|NCT02364167|Experimental|Verum acupuncture|Each patient will receive 16 permanent indwelling acupuncture needles, embedded in adhesive tape, bilaterally in addition to standard postoperative analgesia
3029696|NCT02364167|Placebo Comparator|Placebo acupuncture|Each patient will receive 16 adhesive tapes mimicking the indwelling acupuncture needles bilaterally in addition to standard postoperative analgesia
3029697|NCT02364167|Active Comparator|Standard therapy|Each patient will receive just standard postoperative analgesia
3029698|NCT02364154||Control group-Blood sampling|-subjects with a normal colonoscopy
3029699|NCT02364154||Study group-Blood sampling|- subjects with colorectal cancer after colonoscopy
3029700|NCT02364141|Experimental|Trunk restraint therapy|Reaching training with trunk restraint by a harness that limited the trunk movements.
3029701|NCT02364141|Active Comparator|Trunk unrestraint therapy|Unrestraint reaching training, only with verbal feedback to maintain the trunk right position.
3029702|NCT02364128|No Intervention|Control|Potential bariatric surgery patients who receive both the baseline questionnaire and follow-up questionnaire.
3029703|NCT02364128|Other|Decision Aid|Potential bariatric surgery patients who receive both the baseline questionnaire decision aid/conjoint analysis and follow-up questionnaire.
3029704|NCT02364115|Experimental|Stereotactic Body Radiotherapy|MRI-based, cone beam CT-guided SBRT delivery of a single dose of 18 Gray (Gy) on the visible metastasis, and 8 Gy on the bony compartment containing the metastasis (e.g. the affected vertebra or pedicle).
3029705|NCT02364115|No Intervention|Conventional Radiotherapy|Delivery of a single fraction of 8 Gy using virtual simulation
3029706|NCT02364089|Experimental|Surgery followed by intensive medical care|Laparoscopic surgical removal of the adrenal tumor
3029707|NCT02364089|Active Comparator|Intensive medical treatment only|Standardized medical treatment of hypertension by SAHR.
3029708|NCT02364076|Experimental|Pembrolizumab and Epacadostat|Pembrolizumab 200 mg intravenously every 3 weeks Epacadostat 100mg by mouth taken daily
3029709|NCT02364063|Experimental|Children with CP - Therapy|Children receive incontinence treatment during one year, after which a follow-up period of 6 months will be applied. Intervention includes standard urotherapy with or without pharmacotherapy/specific urotherapy
3029710|NCT02364063|No Intervention|Children with CP - Control|Children are followed for 6 months, not receiving any treatment. After this follow-up period, children also receive incontinence treatment for 6 months.
3029711|NCT02364063|Active Comparator|Children without CP|Children receive incontinence treatment during 1 year. Intervention includes standard urotherapy with or without pharmacotherapy/specific urotherapy
3029712|NCT02364050||Elderly patients with DLBCL|Elderly patients (Age ≥ 65 years) with large B-cell lymphoma classified FIT or UNFIT or FRAIL by Multidimensional Geriatric Assessment (MGA)
3029713|NCT02364037||Phase I Enhanced Care|For women in both phases of the prospective study, we will provide them with the comprehensive contraceptive counseling developed in the CHOICE project and follow them over time. Women in phase one (Enhanced Care) will have their contraceptive method covered by the mechanisms of usual care such as insurance or financial assistance programs.
3029714|NCT02364037||Phase II Complete CHOICE Model|Women in phase two of the prospective study (Complete CHOICE model) will also receive cost support for an IUD or implant if she chooses either as her contraceptive method. Immediately prior to the start of Phase II, clinicians will undergo a training session to discuss eligibility and same-day insertion considerations in an attempt to increase the number of patients who are receiving these methods, if desired.
3029715|NCT02364024||Arm A|Patients with no or low immune response (score 1 or 2) with linear quantification of CD3+ cells
3029716|NCT02364024||Arm B|Patients with high immune response (score 3 or 4) with linear quantification of CD3+ cells
3029717|NCT02363998|Other|Open Label Lofexidine|During this open-label study, subjects will be given the option to receive lofexidine tablets for 7 days and up to 14 days if requested.
3029718|NCT02363985|Other|Multiple vitamin A exposer|"55 children who are using~Mega-dose vitamin A supplementation~Food diversification (promotion and education on vitamin A rich food consumption)~Promotion of orange flash sweet potato production and consumption in collaboration with international potato center (CIP) in one of the study area"
3029719|NCT02363985|Other|Only vitamin A supplementation|"55 children who are using~Mega-dose vitamin A supplementation~Food diversification (promotion and education on vitamin A rich food consumption)"
3029720|NCT02363972|Experimental|Ellipsys Vascular Access Catheter|ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.
3029721|NCT02363959|Experimental|Hyperbaric Oxygen, Airway Biopsy|"The hyperbaric oxygen therapy (HBOT) will be performed with the standard HBOT protocol used at Duke for the treatment of compromised grafts and flaps. This is 2 hours of breathing >99% medical grade oxygen inside an air-pressurized chamber at atmospheric pressure of 2 (2 ATA) once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.~During standard bronchoscopies, an endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure."
3029722|NCT02363959|Other|No Hyperbaric Oxygen, Airway Biopsy|No hyperbaric oxygen therapy administered, but lung biopsy still completed during standard post-lung transplant bronchoscopies. An endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure.
3029723|NCT02363946|Experimental|Part A: 0.38 mg/kg|Single dose administration of ARC-AAT intravenous (IV) injection, 0.38 mg/kg in healthy volunteers
3029724|NCT02363946|Experimental|Part A: 1.0 mg/kg|Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers
3029730|NCT02363946|Experimental|Part A: 7.0 mg/kg|Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers
3029731|NCT02363946|Experimental|Part A: 8.0 mg/kg|Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers
3029732|NCT02363946|Placebo Comparator|Part A: Placebo|Single dose administration of 0.9% normal saline IV injection in healthy volunteers
3029733|NCT02363946|Experimental|Part B: 2.0 mg/kg|Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD
3029734|NCT02363946|Experimental|Part B: 4.0 mg/kg|Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD
3029735|NCT02363946|Experimental|Part B: 6.0 mg/kg|Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in participants with AATD
3029736|NCT02363946|Experimental|Part B: 7.0 mg/kg|Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in participants with AATD
3029737|NCT02363946|Placebo Comparator|Part B: Placebo|Single dose administration of 0.9% normal saline IV injection in participants with AATD
3029738|NCT02363933|Experimental|Perampanel + Current Anti-Epileptic Drug|Primary glioma patients will receive perampanel along with their current AED for a total of 20 weeks. Perampanel will be titrated from 2 mg in weeks 1 and 2 and up to 8 mg daily by week 5 if well tolerated by the patient. They will then receive a maintenance dose of 8 mg per day through 16 weeks. After 16 weeks, subjects will be tapered off perampanel over a 4 week period.
3029739|NCT02363920|Placebo Comparator|spontaneous breathing trial|the patients will be asked to breathe spontaneously using their acutal low oxygen flow
3029740|NCT02363920|Active Comparator|HOF20|the patients will be asked to breathe with HOF of 20 L/min
3029741|NCT02363920|Active Comparator|HOF30|the patients will be asked to breathe with HOF of 30 L/min
3029742|NCT02363920|Active Comparator|noninvasive mechanical ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
3029743|NCT02363894||Subjects enrolled in DEFINITIVE AR|
3029744|NCT02363868||CML subjects receiving Dasatinib|CML receiving dasatinib as first or second line therapy will be conducted to assess healthcare costs
3029745|NCT02363868||CML subjects receiving Nilotinib|CML receiving nilotinib as first or second line therapy will be conducted to assess healthcare costs
3029746|NCT02363855|Experimental|BAY 1841788(ODM-201)|Cohort 1: Safety, tolerability and PK of 300 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 28 days after start of multiple dose (MD) Cohort 2: Safety, tolerability and PK of 600 mg dose given twice daily
3029747|NCT02363842|Experimental|Skin IQ™ MCM Coverlet|Skin IQ™ MCM coverlet used over a commercially available pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
3029748|NCT02363842|Active Comparator|Pressure redistribution surface|Commercially available pressure redistribution surface already in use at participating study sites (SOC) to manage patients at risk for tissue breakdown
3029749|NCT02363803|Placebo Comparator|Normal saline infusion|Intravenous infusion of normal saline over a 40 minute period.
3029750|NCT02363803|Active Comparator|Lidocaine infusion|Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.
3029751|NCT02363790|Other|Bridging LVHR|"Laparoscopic ventral hernia repair without closure of central defect (bridging repair)~Upon completion of the lysis of adhesions, the margins of the hernia defect will be measured and marked. The hernia defect size will be measured with the abdomen completely desufflated and insufflated at 15 mm Hg externally (on the skin).~A coated mesh with at least four cm of overlap on all sides will be placed. Mesh will be secured with at least four but no more than eight trans-fascial sutures. Titanium tacks will be placed in a double crown technique where tacks are placed every 1 cm on the periphery and every 3 cm along the fascial edge (bridged or closed)."
3029752|NCT02363790|Other|LVHR PFC|Ventral hernia repairs in the primary fascial group will be performed similarly except prior to placement of the mesh, the defect will be closed. After the defect size is measured, the mesh will be chosen based upon the unclosed defect size and size will not be adjusted. The hernia defect will be closed as described previously 9,10 with 0-prolene transfascial sutures placed every 1-2 cm. The two caudal-most and cranial-most sutures will be placed. The abdomen will be desufflated and these sutures will be secured. The abdomen will be reinsufflated to 15 mm Hg and the defect progressively closed. Upon completion of fascial closure, the mesh will be placed in the standard fashion as describe above. The lateral overlap will be increased due to the fascial closure.
3029753|NCT02363777|Active Comparator|Standard of Care|Epidural placed for postoperative pain control
3029754|NCT02363777|Experimental|Experimental Intervention|Bilateral paravertebral catheters placed for postoperative pain control
3029755|NCT02363764||Expectorating CF patients|"(=able to expectorate sputum spontaneously)~Nasal swab~Cough swab~Spontaneous expectorated sputum~Questionnaire"
3029756|NCT02363764||Non-expectorating CF patients|"(=unable to expectorate sputum spontaneously)~Nasal swab~Cough swab~Induced sputum after inhalation of hypertonic saline (NaCl 6%)~Questionnaire"
3029757|NCT02363764||Bronchoscopy CF patients|"(=undergoing clinically indicated bronchoscopy)~Nasal swab~Cough swab~Induced sputum after inhalation of hypertonic saline (NaCl 6%)~Bronchoalveolar lavage (BAL)"
3029758|NCT02363751|Experimental|1|Patients will be treated for a maximum of 6 (21 days) chemotherapy cycles (Gemcitabine+platinium salt+bevcizumab)
3029759|NCT02363738|Experimental|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation
3029760|NCT02363738|Placebo Comparator|Saline (Placebo)|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.
3029761|NCT02363725|Other|Conventionnal treatment|"Optimal conventional treatment used for patients admitted for STEMI (ESC guidelines 2012):~Double anti-aggregation~IEC (or sartan) at best tolerated dose~Beta-blocker at best tolerated dose~High dose statin (usually atorvastatin 80 mg daily)~If ventricular dysfunction; inhibitor minérolcorticoïdes (the eplerenone more often)~Any other treatment will be logged."
3029762|NCT02363725|Experimental|Conventionnal + Colchimax®|Optimal conventional treatment + Colchimax®
3029763|NCT02363712|Experimental|APOS|APOS(All Phase Of Step)-shoe
3029764|NCT02363712|Sham Comparator|Sham APOS|Sham APOS(All Phase Of Step)-shoe
3029765|NCT02363699|Active Comparator|Lidocaine|Group treated with lidocaine solution
3029766|NCT02363699|Placebo Comparator|Placebo|Group treated with saline solution
3029767|NCT02363686|Other|FEES & Bedside Swallow Evaluation (BSE)|Subjects will receive a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), followed by a speech language pathologist (SLP) performing a bedside swallowing evaluation (BSE).
3029768|NCT02363673|Experimental|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy in aqua distilla according to their symptoms and characteristic manifestations of their disorder. Although different individualised remedies may be dispensed, each remedy will be homoeopathic. Remedies will be dispensed in aqua distilla. Each individualised homoeopathic remedy will have an individualised dosage, frequency and duration based on the laws of individualised homoeopathic prescribing.
3029769|NCT02363660|Experimental|Arm I|will receive standard dose (0.5mL) delivered by standard intramuscular injection using a needle and syringe.
3029770|NCT02363660|Experimental|Arm II|will receive standard dose (0.5mL) delivered by intramuscular injection using the Pharmajet needle-free Stratis device.
3029771|NCT02363660|Experimental|Arm III|will receive a reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device
3029772|NCT02363647|Experimental|Tumor Genomic Analysis|Personalized Therapy Plan Patients with Metastatic Medullary or Colon Cancer being treated with the Personalized Treatment Plan developed during the different tumor genomic analysis study.
3029773|NCT02363634|Active Comparator|Magnesium threonate (Magtein)|Those randomized to receive the Magtein
3029774|NCT02363634|Placebo Comparator|Placebo|Those randomized to placebo
3029775|NCT02363621|Active Comparator|Ranibizumab 0.3 Intravitreal injection|Intravitreal injection of Ranibizumab 0.3 mg once
3029776|NCT02363621|Active Comparator|Aflibercept 2.0 mg intravitreal injection|Intravitreal Aflibercept 2.0 mg once
3029777|NCT02363608||standard post surgery care|An initial cohort of consecutive patients admitted to the 15th floor of the hospital on a Monday or Tuesday will form the usual care control arm of the study. Once this cohort is completed, the Caring Canines program will start.
3029778|NCT02363608||Caring Canines program|Once the standard of care cohort is completed, the Caring Canines program will start making visits on the 15th floor and a second cohort of consecutive patients admitted to M15 on a Monday or Tuesday will form the intervention (experimental) arm of the study.patients admitted to M15 on a Monday or Tuesday will form the intervention (experimental) arm of the study.
3029779|NCT02363608||staff canine-assisted|For the staff portion of this study a longitudinal pre and post intervention design will be used. Baseline staff assessments will occur prior to the Caring Canine program being implemented on the unit. The assessments include questions about compassion satisfaction and compassion fatigue as well as some open ended questions about your thoughts on the Caring Canines program. Post assessment will occur after the program has been active on the unit for at least 6 weeks. Only staff who work at least one Monday - Friday day shift each week will be eligible to participate.
3029780|NCT02363595||Papillary Microcarcinoma|This clinical trial protocol describes implementation of a prospective observation protocol to standardize data collection and obtain permission to collect samples of PMC tumors in a cohort of PMC patients being followed with active surveillance. This will allow PMC tumors to be accurately classified as either stable or progressive over time and used for comprehensive molecular profiling if surgical removal is required during follow-up
3029781|NCT02363582|No Intervention|Breast fed|healthy term infants on exclusively breast feeding , enrollment age: 30-50days old
3029782|NCT02363582|Experimental|Formula fed|healthy term infants on exclusively formula fed , enrollment age: 30-50days old
3029783|NCT02363569||case-|"Pregnant women (age 18-40) at 4-23 weeks of pregnancy that have appealed to the Women ER 24 hours after bleeding or bleeding secretions due to intercourse."
3029784|NCT02363569||control|"Pregnant women (age 18-40) at 4-23 weeks of pregnancy that have appealed the women ER due to spontaneous bleeding or bleeding secretions"
3029785|NCT02363556|Experimental|Misoprostol Alone|Subjects enrolled into this arm of the study will receive misoprostol 400-mcg only.
3029786|NCT02363556|Experimental|Dilapan with Misoprostol|Subjects enrolled into this arm of the study will receive Dilapan with 400-mcg misoprostol.
3029787|NCT02363543|Active Comparator|Hyalomatrix|Sterile, single use, flexible, and conformable wound dressing comprised of a derivative of hyaluronic acid which acts as a three dimensional regenerative matrix.
3029788|NCT02363543|Active Comparator|Integra|Sterile, single use, wound care dressing comprised of a porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan
3029789|NCT02363530|Experimental|HPMC group|Patients use the intervention Hydroxypropyl ethylcellulose (HPMC) 2% gel during the cataract surgery.
3029790|NCT02363530|Placebo Comparator|BSS group|Patients use balanced salt solution (BSS) during the cataract surgery.
3029791|NCT02363517|No Intervention|Group A|"Primary (n=40) and secondary (n=100) participants will receive supportive care only (includes a clinical review, questionnaire and blood sample collected at baseline and weeks 12, 24, 36, 48, 60, 72 and 84).~Participants with HCV not allocated to treatment arms will receive deferred treatment at the end of the follow-up period."
3029792|NCT02363517|Active Comparator|Group B|"Primary participants (n=40) will be treated with 'Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) for 12 weeks. Secondary participants (n=100) will receive supportive care only.~Participants with HCV not allocated to treatment arms will receive deferred treatment at the end of the follow-up period."
3029793|NCT02363517|Active Comparator|Group C|Primary (n=40) and secondary participants with chronic HCV infection (approx. n=50%*100) will be treated with 'Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) for 12 weeks. Participants in Group C who have evidence of HCV re-infection will be offered re-treatment with SOF + LDP for 12 weeks.
3029794|NCT02363504||Healthy older controls|7 Tesla MRI with memory task and non-invasive neurostimulation
3029795|NCT02363504||Prodromal Alzheimer's disease patients|7 Tesla MRI with memory task and non-invasive neurostimulation
3029796|NCT02363491|Experimental|OPN-305|OPN-305
3029797|NCT02363478|Experimental|buspirone|4-weeks buspirone administration (20mg) in patients with SSc and esophageal involvement
3029798|NCT02363465||Participants aged 18-30 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 18-30 years.~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
3030305|NCT02359916||B|Healthier snacks sold at 25% or $0.25 discount, no delays
3029799|NCT02363465||Participants aged 31-40 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 31-40 years.~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
3029800|NCT02363465||Participants aged 41-50 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 41-50 years.~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
3029801|NCT02363465||Participants aged 51-65 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 51-65 years.~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
3029802|NCT02363452|Experimental|AGS|Reverse transcriptase inhibitors
3029803|NCT02363439|Experimental|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg 2xwk|Subcutaneous injection of IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly per Protocol 8400-401
3029804|NCT02363426|Other|Medical Device: INVOcell Culture Device|5 day oocyte incubation using INVOcell Culture Device within the vaginal cavity.
3029805|NCT02363426|Active Comparator|Medical Device: IVF Incubator|5 day oocyte incubation using traditional IVF incubation.
3029806|NCT02363413|Active Comparator|IniVAH|Initiation of the NIV in hospital : current care. 3 days hospitalization to start-up the NIV as usual.
3029807|NCT02363413|Experimental|IniVAD|Initiation of the NIV at home : experimental care.
3029808|NCT02363400|Experimental|Adjuvant Chemotherapy|MEP followed by oral Tegafur-uracil
3029809|NCT02363400|No Intervention|control arm|closely followed with frequency similar to the experiemental arm
3029810|NCT02363387|Experimental|Incentive Group|Incentive group participants will receive the standard HIV medical care offered in their clinic. In addition, Incentive group participants will receive incentives for viral suppression. These incentives will be presented if the participants maintain suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
3029811|NCT02363387|Other|Usual Care Group|Usual Care Control participants will receive the standard HIV medical care offered in their clinic.
3029812|NCT02363374|Active Comparator|Arm A: Chemotherapy -> Chemoradiotherapy|Induction chemotherapy followed by chemoradiotherapy before surgery
3029813|NCT02363374|Experimental|Arm B: Chemoradiotherapy -> Chemotherapy|Combined chemoradiotherapy followed by three cycles chemotherapy before surgery
3029814|NCT02363361|Experimental|Imatinib|Day 1. 800 mg, Day 2-14: 2 * 400 mg per day
3029815|NCT02363348|Placebo Comparator|Placebo (A)|"were administered 5 capsules per day each capsule contained 600 mg of magnesia calcinada. Duration: from week 20th of pregnancy until the end of the same.~dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner."
3029816|NCT02363348|Experimental|L arginine (B)|were administered 5 capsules per day each capsule contained 600 mg of L arginine. Duration: from week 20th of pregnancy until the end of the same dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner.
3029817|NCT02363335|Experimental|Sitagliptin|Randomized, double blind, placebo-controlled cross-over study
3029818|NCT02363335|Experimental|Roflumilast|Randomized, double blind, placebo-controlled cross-over study
3029819|NCT02363335|Placebo Comparator|Placebo|Randomized, double blind, placebo-controlled cross-over study
3029820|NCT02363335|Experimental|Roflumilast/Sitagliptin|Randomized, double blind, placebo-controlled cross-over study
3029821|NCT02363322|Active Comparator|A|Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting
3029822|NCT02363322|Experimental|B|ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.
3029823|NCT02363283|Experimental|Treatment (glembatumumab vedotin)|Patients receive glembatumumab vedotin IV over 90 minutes every 3 weeks in the absence of disease progression or unacceptable toxicity.
3029824|NCT02363270|Active Comparator|IV Push Group|Ketamine medication given via IV Push. IV Push is the intervention.
3029825|NCT02363270|Active Comparator|IV Drip Group|Ketamine medication given via IV Drip. IV Drip is the intervention.
3029826|NCT02363244||Pap group|Per speculum examination will be done.Pap test will be collected for the women as per allotement.A via (visual inspection with acedic acid)test will be done.A repeat cervical cell for pap test will be collected and send to laboratory for further evaluation.
3029827|NCT02363244||HPVDNA GROUP|Per speculum examination will be done.HPVDNA test will be collected for the women as per allotement.A via (visual inspection with acedic acid)test will be done.A repeat cervical cell for HPVDNA will be collected and send to laboratory for further evaluation.
3029828|NCT02363231||patients under mechanical ventilation|
3029829|NCT02363218|Experimental|CyberKnife|Hepatocellular Carcinoma Patients Treated With CyberKnife
3029830|NCT02363205|No Intervention|control|Weekly check-up
3029831|NCT02363205|Experimental|internet-delivered CBT|Tailored Internet-administrated CBT-Treatment
3029832|NCT02363192|Experimental|Pharmacist Intervention Group|
3029833|NCT02363192|No Intervention|Usual Care Group|
3029834|NCT02363179|No Intervention|Non Music Group|500 non-intervention patients will be consented to serve as the control group
3029835|NCT02363179|Experimental|Music Intervention Group|500 intervention patients will be consented to participate in the live preferential music intervention
3029836|NCT02363166||Acute Abscess Group|Adults and pediatric patients presenting to the UFHealth Shands Emergency Department with evidence of an acute abscess, or skin/soft tissue infection, which can be sampled for culture and sensitivity testing will be recruited.
3029877|NCT02362919||A cohort of elderly individuals|A cohort of elderly individuals between 65 and 80 years of age were vaccinated with Fluad, a seasonal inactivated trivalent adjuvanted influenza vaccine. Blood samples before (day 0) and at days 1/3, 7,21 and 70 after vaccination were collected.
3030189|NCT02360748|Experimental|single|Pilot Study in which patients will be adding food items to improve their nutritional status
3029837|NCT02363153|Experimental|Diet and Exercise|Patients will be given an individualized diet and exercise plan by a physical therapist and registered dietician. The diet and exercise plan will be carried out by the participant for 16 weeks. The exercise plan, an aerobic and strength training regimen, will be performed under the supervision of a personal trainer or certified exercise physiologist that is local to the participant. The participant will complete core-stabilizing exercises which can be performed at home or in an approved group class. The participant will wear an activity tracker at all times during this 16 week period, and will be asked to manually enter data into a phone app, such as daily food intake and weight.
3029838|NCT02363140|No Intervention|Group One patients in age group 18--20 years,|"Patients should be aged 18--20 years or 35--45years~Asymptomatic knee for past 6 months.~Painless flexion-extension movements at knee joint."
3029839|NCT02363140|Active Comparator|Group Two patients in age group 35-45 years,|"Patients should be aged 18--20 years or 35--45years~Asymptomatic knee for past 6 months.~Painless flexion-extension movements at knee joint."
3029840|NCT02363140|Active Comparator|Group Three Patients aged 75|"Patients should be aged 75 or older~Knee X-ray showing no more than Kellgren-Lawrence grade II osteoarthrtis~No clinical suspicion of meniscus tear~Painless flexion-extension movements at knee joint."
3029841|NCT02363140|Active Comparator|Group Four, any age due to undergo a surgical meniscus repair|1. Patients should have presented with clinical signs to suggest meniscus tear indicating potential need for surgical meniscus repair
3029842|NCT02363127|Experimental|Prolutex|Subcutaneous progesterone
3029843|NCT02363127|Active Comparator|Progeffik|Vaginal progesterone
3029844|NCT02363114||Stroke Prevention Clinic Patients|All consecutive patients presenting to six high volume Regional Stroke Prevention Clinics.
3029845|NCT02363088|No Intervention|No intervention, 24-29 years|No intervention, group 24-29 years. Women will receive the written invitation to screening only
3029846|NCT02363088|Experimental|Messenger text message reminder, 24-29|Messenger text message reminder, group 24-29 years.
3029847|NCT02363088|No Intervention|No intervention, 30-64 years|No intervention group 30-64 years, Women will receive the written invitation to screening only
3029848|NCT02363088|Experimental|Neutral text message reminder, 30-64|Neutral Text message, group 30-64 years
3029849|NCT02363088|Experimental|Messenger text message reminder, 30-64|Messenger text message reminder, group 30-64
3029850|NCT02363088|Experimental|Social Norms A reminder, 30-64|Social Norms (population proportion) text message reminder, group 30-64 years
3029851|NCT02363088|Experimental|Social Norms B reminder, 30-64|Social Norms (population total) text message reminder, group 30-64 years
3029852|NCT02363088|Other|Framed gain text reminder, 30-64|Framed gain text message reminder, group 30-64 years
3029853|NCT02363088|Experimental|Framed loss text reminder, 30-64|Framed loss text message reminder, group 30-64 years
3029854|NCT02363075|Experimental|Dexamfetamine sulphate|Dexamfetamine Sulphate 5 mg Tablets
3029855|NCT02363075|Placebo Comparator|placebo|Aspect tablets identical to the active
3029856|NCT02363049|Experimental|colectomy|surgery followed by chemotherapy +/- targeted therapy regime according to each centre
3029857|NCT02363049|Active Comparator|no colectomy|Chemotherapy +/- targeted therapy alone, regime according to each centre.
3029858|NCT02363036||Active labor|Women in active labor normal pregnancy at term.
3029859|NCT02363036||Planned Cesarian Section|Women, normal pregnancy at term who came for elective Cesarean Section without signs of labor (pain/contractions, etc).
3029860|NCT02363023||VAP suspects|Collect tracheal and pulmonary secretions. All patients (n: 72) will be submitted to endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage.
3029861|NCT02363010|Active Comparator|Standard Behavior Therapy for Weight Loss|Eighteen months of standard, group-based behavioral treatment for weight loss and weight loss maintenance.
3029862|NCT02363010|Experimental|Behavior Therapy for Weight Loss with PA emphasis|Six months of standard, group-based behavioral treatment for weight loss and weight loss maintenance, followed by 12 months of standard, group-based behavioral treatment for weight loss and weight loss maintenance with a larger emphasis on physical activity goals.
3029863|NCT02363010|Experimental|Acceptance-based Behavior Therapy with PA emphasis|Six months of standard, group-based behavioral treatment for weight loss and weight loss maintenance, followed by 12 months of group-based behavior therapy with acceptance-based strategies, and a larger emphasis on physical activity goals.
3029864|NCT02362997|Experimental|Diffuse large B cell lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
3029865|NCT02362997|Experimental|Classical Hodgkin lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
3029866|NCT02362997|Experimental|Peripheral T cell lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
3029867|NCT02362984|Placebo Comparator|Control Group|Placebo will be administered orally, 3 x 1 tablet daily, for 8 days of study period
3029868|NCT02362984|Experimental|DLBS1033 Group|DLBS1033 will be administered orally, 3 x 1 tablet daily, for 8 days of study period
3029869|NCT02362971||Included|Patients included into the randomized controlled trial
3029870|NCT02362971||Non-consenters|Patients eligible for participation in the randomized controlled trial but did not give their informed consent and thus excluded in the randomized controlled trial.
3029871|NCT02362971||Excluded|Patients, by different reasons excluded from participation in the randomized controlled trial.
3029872|NCT02362958|Experimental|Lapatinib and Capecitabine or Vinorelbine|Lapatinib 1250mg qd and Capecitabine 1000mg/m2 bid or Vinorelbine 25mg/m2 iv (d1,d8)
3029873|NCT02362945|Experimental|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl (sodium chloride)0.9% solution IV). ( the oxytocin is the routine practice in our department).
3029874|NCT02362945|No Intervention|Control:|Treatment with oxytocin after fetal extraction (10 units in 100ml NaCl 0.9% solution IV). as commonly given for Post-Partum Hemorrhage (PPH) at our obstetrical ward.Active Comparator: (this is the routine practice in our department).
3029875|NCT02362932|Experimental|Intervention|Sanitation
3029876|NCT02362932|No Intervention|Control|No sanitation
3029918|NCT02362633|Sham Comparator|Sham tDCS|Subjects will receive sham tDCS treatment for ten times for two weeks (five times per week).
3029919|NCT02362620||Docetaxel|Docetaxel 75mg/m2 IV every 3 weeks
3029878|NCT02362906|Experimental|Injection,medications and application|"Intravenous injection:~bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules; external application: Fu-xiong San."
3029879|NCT02362906|Experimental|Injection and medications|"Intravenous injection:~bacterial pneumonia：second generation cephalosporin; mycoplasma pneumonia：erythromycin or azithromycin; viral pneumonia：Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules."
3029880|NCT02362906|Experimental|Injection and application|"Intravenous injection:~bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; external application: Fu-xiong San."
3029881|NCT02362893|Experimental|Direct Observed Therapy|Direct Observed Therapy immediately followed by mounting of ambulatory blood pressure device and measurement of ambulatory blood pressure according to ESH 2013 guidelines.
3029882|NCT02362893|No Intervention|Control|Standard care
3029883|NCT02362880|Active Comparator|mutation carrier|
3029884|NCT02362880|Sham Comparator|mutation non-carrier|
3029885|NCT02362867|No Intervention|Total Knee Replacement|Total knee replacement is indicated for patients suffering from severe knee pain and disability. Specific indications include femoral, tibial and patellar replacement due to degenerative bone disease such as osteoarthritis, rheumatoid arthritis, primary and secondary traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral condyles, or complications from a previous prosthesis. The Balanced Knee System (BKS) will be used to treat patients undergoing a total knee replacement.
3029886|NCT02362854|Active Comparator|Conventional peri-implantitis treatment|Peri-implantitis treatment according to the Cumulative interceptive supportive (CIST) therapy.
3029887|NCT02362854|Experimental|DL application in peri-implantitis|Adjunct Diode Laser application.
3029888|NCT02362815|Active Comparator|Apple juice|Patient are allowed to drink up to 400 ml of apple juice
3029889|NCT02362815|No Intervention|Control|Patient are not allowed to drink
3029890|NCT02362802|Active Comparator|Antitachycardia Pacing|Implantable cardioverter defibrillator placement with Antitachycardia Pacing. Apart from that usual standard of care.
3029891|NCT02362802|No Intervention|No Antitachycardia Pacing|"Implantable cardioverter defibrillator placement without Antitachycardia Pacing.~Apart from that usual standard of care."
3029892|NCT02362789|Experimental|300 mg secukinumab|Randomization occurs at week 16 and only for patients with extensive remission. All other patients complete the study at week 16. All patients receive 300 mg secukinumab at weeks at weeks 0, 1, 2, 3, 4, 8, 12. Patients randomized to 300 mg secukinumab at week 16, receive secukinumab at weeks 16, 20, 24, 28.
3029893|NCT02362789|Placebo Comparator|Secukinumab followed by placebo|Randomization occurs at week 16 and only for patients with extensive remission. All other patients complete the study at week 16. All patients receive 300 mg secukinumab at weeks at weeks 0, 1, 2, 3, 4, 8, 12. Patients randomized to placebo at week 16, receive placebo at weeks 16, 20, 24, 28.
3029894|NCT02362776||breast cancer patients|
3029895|NCT02362776||lung cancer patients|
3029896|NCT02362776||control subjects|
3029897|NCT02362763|Experimental|Study group|Subjects received five acupuncture sessions designed to treat pain in the vulvar area
3029898|NCT02362763|Active Comparator|Controls|Controls received five acupuncture sessions designed for sedation
3029899|NCT02362750||Participating Program Administrators|Eligible survivorship program administrators at selected Commission on Cancer-accredited institutions will complete an organizational interview and organizational survey.
3029900|NCT02362750||Participating Cancer Survivors|"Survivors receiving follow-up care surveys at selected Commission on Cancer-accredited institutions will complete four surveys:~Survivor Survey (1): Pre-Visit Baseline Survivor Survey (2): 1 Week Post-Visit Survivor Survey (3): 3 Months Post-Visit Survivor Survey (4): 6 Months Post-Visit"
3029901|NCT02362750||Participating Clinicians|Survivorship clinicians from clinical survivorship programs at selected Commission on Cancer-accredited institutions will complete a clinician survey.
3029902|NCT02362737|Experimental|Active and Healthy Brotherhood (AHB)|16-week behavioral intervention
3029903|NCT02362737|No Intervention|Control|Usual care.
3029904|NCT02362711|Experimental|NPC-16 Standard Dosing Regimen Group|Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg
3029905|NCT02362711|Experimental|NPC-16 Continuous Dosing Regimen Group|Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg
3029906|NCT02362711|Placebo Comparator|Placebo Group|Placebo for NPC-16
3029907|NCT02362698|Experimental|electro-acupuncture|Receiving electro-acupuncture treatment once every other day, half an hour per treatment, 10 times as one treatment course, subjects received 2 courses of treatment.
3029908|NCT02362698|Active Comparator|psychological intervention|Receiving cognitive behavioral therapy once every four days, each time two hours. Five times intervention as one treatment course, subjects received 2 courses of treatment.
3029909|NCT02362685||metabolic exercise testing|All the subjects referred to performed a metabolic exercise testing.
3029910|NCT02362672|Experimental|NKTR-181|NKTR-181 twice daily (BID) tablets
3029911|NCT02362672|Placebo Comparator|Placebo|Placebo to match NKTR-181 twice daily (BID) tablets
3029912|NCT02362659||Antiplatelet agent plus anticoagulant|an antithrombotic regimen comprising one single antiplatelet agent plus an anticoagulant
3029913|NCT02362659||DAPT alone|an antithrombotic regimen consisting of dual antiplatelet therapy (DAPT) alone
3029914|NCT02362659||DAPT plus anticoagulant|an antithrombotic regimen consisting of DAPT plus anticoagulant therapy
3029915|NCT02362646|Experimental|MPC Intramyocardial Injection|Intramyocardial injections of 150 million MPCs
3029916|NCT02362646|Sham Comparator|Control Solution|Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
3029917|NCT02362633|Experimental|Real tDCS|Subjects will receive real tDCS treatment for ten times for two weeks (five times per week).
3029921|NCT02362607|Experimental|Integrated Diabetes Management Protocol|Smartphone apps for food diary, activity monitor, blood glucose will be used for three months.
3029922|NCT02362607|Active Comparator|Standard Diabetes Management Protocol|Subjects will receive standard diabetes management protocol with standard education and standard blood glucose measurement devices.
3029923|NCT02362594|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle for up to 1 year
3029924|NCT02362594|Placebo Comparator|Placebo|Participants receive placebo IV on Day 1 of each 21-day cycle for up to 1 year
3029925|NCT02362581|Experimental|On demand treatment, prophylaxis treatment|"On demand treatment arm:Patients received factorVIII concentrate(Hemofil M) when they had bleeding episodes.~Prophylaxis arm: patients received factorVIII concentrate (Hemofil M) 30-35 unit/kg once a week"
3029926|NCT02362568|No Intervention|Cervical ultrasound exploration|A cervical ultrasound exploration will be performed in all patients admitted for a planned surgery performed under general anesthesia during the stay in the postoperative room.
3029927|NCT02362555||ossification of nuchal ligament|check neck function, radiography characteristics and complete functional disability questionnaire
3029928|NCT02362555||Non ossification of nuchal ligament|check neck function, radiography characteristics and complete functional disability questionnaire
3029929|NCT02362542|Experimental|Sham tDCS|Subjects will receive tDCS two times, one is active stimulation and the other is sham stimulation. Both stimulations will be separated at least one week and the order of sham and active tDCS will be counterbalanced across subjects.
3029930|NCT02362542|Experimental|Real tDCS|Subjects will receive tDCS two times, one is active stimulation and the other is sham stimulation. Both stimulations will be separated at least one week and the order of sham and active tDCS will be counterbalanced across subjects.
3029931|NCT02362529|Experimental|Minocycline|The dose of minocycline would be 50mg per day on week 1, 50mg bid on week 2 and 100mg bid weeks 3-8. For tapering, the dose will be reduced to 50mg bid for a week, and then stopped.
3029932|NCT02362529|Placebo Comparator|Placebo|The number and appearance of the pills would be identical to those in the minocycline arm.
3029933|NCT02362529|Other|Celecoxib|This will be an open label trial for those with Hamilton Depression Rating Scale score ≥ 8 following the minocycline v. placebo trial or those not eligible for Phase 2. Dose of celecoxib will be 100 mg bid for the first week and 200mg bid for weeks 2-8. For tapering, the dose of celecoxib will be reduced to 100mg bid for one week, and then stopped.
3029934|NCT02362516|Experimental|BI 425809|
3029935|NCT02362503|Experimental|A1: BMS-663068|Phase 1: BMS-663068 600 mg tablets orally twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
3029936|NCT02362503|Active Comparator|B1: Placebo + BMS-663068|Phase 1: Placebo twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
3029937|NCT02362503|Experimental|BMS-663068|BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
3029938|NCT02362490|Experimental|peginterferon alpha 2a|in this group, patients who were on treatment of Nucleoside (Acid) Analogues and had achieved HBsAg level ≤250 IU/ml will switch to treatment of peginterferon alpha 2a for 72 week.
3029939|NCT02362490|No Intervention|control group|in this group, patients who were on treatment of Nucleoside(Acid) Analogues and had achieved HBsAg level ≤250 IU/ml will be continue to treatment of Nucleoside(Acid) Analogues for 72 week.
3029940|NCT02362477|Active Comparator|Control CPT|'Cognitive Processing Therapy in-person. Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
3029941|NCT02362477|Experimental|Experimental CPT via VTC|'Cognitive Processing Therapy through videoteleconference. Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
3029942|NCT02362464|Experimental|1|Stage D0 Prostate Cancer ME TARP
3029943|NCT02362451|Experimental|1-Lead-in TARP DC vaccine treatment|All patients to receive autologous multi-epitopeTARP DC vaccine before randomization
3029944|NCT02362451|Experimental|2-Active TARP DC vaccine treatment|Autologous multi-epitope TARP DC vaccine afterrandomization
3029945|NCT02362451|Placebo Comparator|3-Placebo|Autologous elutriated monocyte vaccine placeboafter randomization
3029946|NCT02362425|Active Comparator|1|N-acetylcysteine
3029947|NCT02362425|Placebo Comparator|2|
3029948|NCT02362412|Experimental|FK949E 50 MG / FK949E 150 MG|Participants who received the 50 mg tablet once daily during Treatment Period II (8 weeks) and 150 mg tablet once daily during Treatment Period III (8 weeks).
3029949|NCT02362412|Experimental|FK949E 150 MG / FK949E 50 MG|Participants who received the 150 mg tablet once daily during Treatment Period II (8 weeks) and 50 mg tablet once daily during Treatment Period III (8 weeks).
3029950|NCT02362399|Active Comparator|sildenafil citrate|50 mg single oral dose
3029951|NCT02362399|Active Comparator|placebo|single tablet of placebo
3029952|NCT02362373|Other|levonorgestrel IUS|all women in the study underwent placement of the levonorgestrel IUS in an open-label fashion, outcomes were compared before and after placement.
3029953|NCT02362360|Experimental|Coloplast Test Product then Comparator|The subject first tests the Coloplast Test Product and then tests the Comparator
3029954|NCT02362360|Experimental|Comparator then Coloplast Test Product|The subject first tests the Comparator and then tests the Coloplast Test Product.
3029955|NCT02362347|Active Comparator|Usual care + exercise|Usual care + exercise
3029956|NCT02362347|No Intervention|No care, no exercise|No care, no exercise
3029957|NCT02362347|Experimental|Usual care + exercise + compression vest|Usual care + exercise + London Health Sciences Centre - Compression Vest
3029958|NCT02362321|Experimental|Dexamethasone|Participants allocated to the treatment group received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
3029959|NCT02362321|Placebo Comparator|Control|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
3029960|NCT02362308|Other|Adrenalectomy|Subjects will undergo assessment before and after adrenalectomy for treatment of primary aldosteronism
3029961|NCT02362308|Other|Medical Therapy|Subjects will undergo assessment before and after medical treatment of primary aldosteronism
3029963|NCT02362282|Active Comparator|Gait plus cognitive training|Rehabilitation of walking/gait, combined with rehabilitation of cognitive function
3029964|NCT02362282|Active Comparator|Gait plus arm training|Rehabilitation of walking/gait, combined with rehabilitation of arm function
3029965|NCT02362269|Active Comparator|Control Group|The control group will receive 2500 IU of vitamin D3 daily.
3029966|NCT02362269|Experimental|Dosing Algorithm Group|The dosing algorithm group will initially receive 1000, 2500, or 4000 IU of vitamin D3 daily based on the baseline 25(OH)D. This group's dosing may be adjusted at the 3-month visit.
3029967|NCT02362256|Experimental|Intervention|"Opioid antagonist induction. Day 4. Duration 12-16 hours.~Naltrexone gradual increase from 50 µg p/o to a total dose of 12,5 mg according to a predefined protocol:~st hour 50 µg~nd hour 50 µg~rd hour 100 µg~th hour 100 µg~th hour 200 µg~th hour 400 µg~th hour 800 µg~th hour 1600 µg~th hour 3200 µg~th hour 6000 µg~Correction of symptoms for opioid abstinence:~Clonidine 150 µg p/o every 4 hours (Day 3 and Day 4) Lorazepam 5 mg p/o every 4 hours (Day 3 and Day 4), Lorazepam 2,5 mg po every 4 hours (Day 5, Day 6)"
3029968|NCT02362256|Active Comparator|Control|"Opioid antagonist induction. Day 4. Duration 12-16 hours. Naltrexone single dose 12,5 mg p/o~Correction of symptoms for opioid abstinence:~Clonidine 150 µg p/o every 4 hours (Day 3 and Day 4) Lorazepam 5 mg p/o every 4 hours (Day 3 and Day 4), Lorazepam 2,5 mg po every 4 hours (Day 5, Day 6)"
3029969|NCT02362243|Placebo Comparator|Control Group|Participants in the control arm will complete the placebo comparator intervention.
3029970|NCT02362243|Experimental|Supervised Exercise Group|Participants in the supervised exercise intervention arm will perform the experimental intervention under direct 1-on-1 supervision of an exercise specialist.
3029971|NCT02362243|Experimental|Web-based Exercise Group|Participants in the web-based exercise intervention arm will perform the experimental intervention with use of a web-based exercise system for exercise instruction and guidance, and without direct 1-on-1 on-site supervision.
3029972|NCT02362230|Experimental|Icotinib|Icotinib 125 mg BID
3029973|NCT02362217|Experimental|Group 1|"Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.~Subjects: 8 healthy volunteers."
3029974|NCT02362217|Experimental|Group 2|"Interventions: ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose ChAdV63.HIVconsv 5 x 10^10 vp at week 0 and 1 dose MVA.HIVconsv 2 x 10^8 pfu at week 8.~Subjects: 8 healthy volunteers."
3029975|NCT02362217|Experimental|Group 3|"Interventions: AdCh3NSmut1, MVA-NSmut, ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp and 1 dose ChAdV63.HIVconsv 5 x 10^10 vp at week 0, and 1 dose MVA-NSmut 1 x 10^8 pfu and 1 dose MVA.HIVconsv 1 x 10^8 pfu at week 8.~Subjects: 16 healthy volunteers."
3029976|NCT02362191|Experimental|tACS|Participants will receive 40 minutes of transcranial alternating current stimulation (tACS) produced by an alternating current stimulator.
3029977|NCT02362191|Sham Comparator|Sham stimulation|Participants will receive approximately 1 minute of tACS produced by the stimulator in order to maintain blinding.
3029978|NCT02362178|Experimental|Thromboelastography (TEG)|Patients in the TEG group received fresh frozen plasma at the dose of 10 ml/kg of ideal body weight, only if INR was higher than 1.8 and r time longer than 40 minutes. They received platelets at the amount of 1 apheresis Unit, only if platelets count was lower than 50000/μl and MA was shorter than 30 millimeter.
3029979|NCT02362178|Active Comparator|Standard of Care (SOC)|In the SOC group patients received fresh frozen plasma at the dose of 10 ml/kg of ideal body weight, when INR was higher than 1.8. They received platelets at the amount of 1 apheresis Unit, when platelets count was lower than 50000/μl.
3029980|NCT02362165|Experimental|CyBorD regimen|this arm will receive cyclophosphamide (500mg/d,once-weekly),bortezomib(1.3mg/㎡，once-weekly,subcutaneous injection), and dexamethasone (40mg/d,once-weekly)(CyBorD) as induction therapy.
3029981|NCT02362165|Active Comparator|PAD regimen|this arm will receive bortezomib(1.3mg/㎡，once-weekly,subcutaneous injection), dexamethasone (40mg/d,once-weekly), and doxorubicin (9mg/㎡，d1-4)(PAD) as induction therapy.
3029982|NCT02362152||Ingenol mebutate|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
3029983|NCT02362152||5-fluorouracil|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
3029984|NCT02362152||Imiquimod|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
3029985|NCT02362152||Diclofenac|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
3029986|NCT02362139|Experimental|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation<4cm).
3029987|NCT02362139|No Intervention|The control group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were not treated with IM Papverine
3029988|NCT02362126||Patients undergoing EFTR|Patients with non-lifting adenomas, adnomas at difficult anaotomic locations , T1-carcinomas or submucosal colorectal tumors
3029989|NCT02362113||Isfahani adults|GI/GL
3029990|NCT02362100|Placebo Comparator|nonoperative management|"Treatment will consist of sling immobilization for a period of 6 weeks. Details and treatment timeline as follows:~0 - 3 weeks: immobilization with a shoulder sling, range of motion of elbow, hand and wrist~3 - 6 weeks: same as 0-3 weeks, with addition of pendulum exercises every two hours~After 6 weeks: Active mobilization and removal of sling. Light activity permitted and physiotherapy for range of motion permitted as tolerated.~After 6 months: no further restriction will be placed. Full home and work activity permitted."
3029991|NCT02362100|Active Comparator|locking plate surgical fixation|"Standardized operative management protocol as follows:~Pre-operative medical clearance established via anesthesia consults if required for medically complex patients.~Provision of pre-operative intravenous (IV) antibiotic prophylaxis:~Administration of general anesthetic.~Patient positioning and preparation:~Patient is carefully placed in the beach-chair position,~Deltopectoral approach Fracture reduction and fixation with confirmation with intraoperative fluoroscopy images."
3029992|NCT02362074||Adalimumab subjects|Subjects starting Adalimumab treatment at time of enrollment.
3030031|NCT02361814|Experimental|Amniotic membrane allograft group|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
3029993|NCT02362061||pregnant|These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation and they became pregnant
3029994|NCT02362061||Non pregnant|These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation and they remained non pregnant
3029995|NCT02362048|Experimental|Experimental: Arm 1|ACP-196 alone
3029996|NCT02362048|Experimental|Experimental: Arm 2|ACP-196 in combination with pembrolizumab
3029997|NCT02362035|Experimental|Safety Review|The safety and preliminary efficacy of the combination of acalabrutinib and pembrolizumab will be reviewed
3029998|NCT02362022|Placebo Comparator|Group Saline|Group Saline (Group S) received i.v saline 0.9 % in 10 ml volume (n=30)
3029999|NCT02362022|Active Comparator|Group Morphine 1|Group Morphine 1 (Group M1) received i.v morphine 0.1 mg kg-1, in 10 ml volume (n=30)
3030000|NCT02362022|Active Comparator|Group Morphine 2|Group Morphine 2 (Group M2) received i.v morphine 0.2 mg kg-1, in 10 ml volume (n=30)
3030001|NCT02361996||Coronary Bypass Surgery|"inclusion criteria:~presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary bypass surgery.~list of medication timely related to the procedure~signed informed consent~exclusion criteria:~intolerance to contrast agent~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection~renal failure~severe arrhythmia~pregnancy~reduction of cognitive capabilities to understand the purpose and the extent of the study~participation in a medical-scientific study using X-rays in the last ten years~lack of Russian knowledge to fill the forms~lack of signed study agreement"
3030002|NCT02361996||Coronary Stenting|"inclusion criteria:~presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary vessel dilatation/stenting.~list of medication timely related to the procedure~signed informed consent~exclusion criteria:~intolerance to contrast agent~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection~renal failure~severe arrhythmia~pregnancy~reduction of cognitive capabilities to understand the purpose and the extant of the study~participation in a medical-scientific study using X-rays in the last ten years~lack of Russian knowledge to fill the forms~lack of signed study agreement"
3030003|NCT02361996||Aortic Valve Replacement|"inclusion criteria:~presence of aortic valve disease (stenosis) with clinical indication for aortic valve replacement without coronary vessel stenosis above 50%~list of medication timely related to the procedure~signed informed consent~exclusion criteria:~intolerance to contrast agent~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection~renal failure~severe arrhythmia~pregnancy~reduction of cognitive capabilities to understand the purpose and the extent of the study~participation in a medical-scientific study using X-rays in the last ten years~lack of Russian knowledge to fill the forms~lack of signed study agreement"
3030004|NCT02361983||DLT versus bronchial blockers|double lumen tube versus bronchial blockers
3030005|NCT02361970||severe sepsis and septic shock|patients were diagnosed severe sepsis or septic shock
3030006|NCT02361970||patient control|Patients after elective surgeries presented with SIRS but without sepsis
3030007|NCT02361970||volunteer|Health persons
3030008|NCT02361957|Active Comparator|Probiotics|Multispecies probiotic product Ecologic 825, 2x10-9 colony forming units per gram, 6 grams per day.
3030009|NCT02361957|Placebo Comparator|Placebo|Similar in appearance as the probiotics, but not containing any bacteria.
3030010|NCT02361944|Experimental|Normoxia|Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
3030011|NCT02361944|Active Comparator|Hyperoxia|Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
3030012|NCT02361931|Experimental|Treatment group (erythropoietin)|15 patients will receive erythropoietin (3000IU/ml) containing formula. Topically, five days a week for 12 weeks.
3030013|NCT02361931|Active Comparator|Standard Care group|5 patients will receive Hydrogel. Daily for three months.
3030014|NCT02361918||Anastomotic leakage|Patient had anastomotic leakage
3030015|NCT02361918||No anastomotic leakage|Patient had no anastomotic leakage
3030016|NCT02361905|Experimental|Ulipristal acetate|women will be treated with an oral dose of ulipristal acetate 5 mg/day for 3 months
3030017|NCT02361905|Active Comparator|Leuprolile acetate|Women will be treated with an intramuscular (IM) injection of leuprolide acetate 11.25 mg in the luteal phase
3030018|NCT02361892|Experimental|Ulipristal acetate|Women will be treated with 5mg/die of Ulipristal acetate for 2 courses of 3 months each
3030019|NCT02361879|Experimental|Ulipristal acetate|Womens will be treated with 5 mg/day of oral ulipristal acetate for 3 months
3030020|NCT02361879|Active Comparator|Leuprolile acetate|women will be treated with 1 IM injection of leuprolide acetate 11,25 mg in in the luteal phase
3030021|NCT02361866|Experimental|GC1107|0.5ml, intramuscular, a single dosing
3030022|NCT02361866|Active Comparator|Tetanus and Diphtheria(Td vaccine)|0.5ml, intramuscular, a single dosing
3030023|NCT02361853||Active labor at term|Women in active labor normal pregnancy at term
3030024|NCT02361853||Non-active labor at term|"Women, normal pregnancy at term who come for usual follow up without signs for labor ( contraction / show discharge/ rupture of membranes)."
3030025|NCT02361853||Active labor, pre-term|Women in active pre term labor (34- 37w) normal pregnancy.
3030026|NCT02361840||Exposed cohort: TI>0.05ng/ml|We call Exposed group to increased TI > or = 0.05ng/ml We call Event to the onset of ARDS
3030027|NCT02361840||No Exposed cohort: TI<0.05ng/ml|We cal no Exposed group to increased TI (<0.05ng/ml) We call Event to the onset of ARDS
3030028|NCT02361827||A, Vitamin D deficient|Vitamin D level on the day of HCG administraion < 20 ng/mL Embryo transfer after oocyte retrieval.
3030029|NCT02361827||B, Vitamin D insufficient|Vitamin D level on the day of HCG administraion 20-29.9 ng/mL Embryo transfer after oocyte retrieval.
3030030|NCT02361827||C, Vitamin D replete|Vitamin D level on the day of HCG administraion > 30 ng/mL Embryo transfer after oocyte retrieval.
3030032|NCT02361801|Active Comparator|Liberal dobutamine group|All patients will receive dobutamine at the cardiopulmonary bypass weaning
3030033|NCT02361801|Active Comparator|Restrictive dobutamine group|Patients will only receive dobutamine if they present clinical signs of cardiogenic shock
3030034|NCT02361775|Experimental|Paravertebral catheter|a paravertebral catheter is placed and an elastomeric pump is connected to infuse 0.2% ropivacaine postoperatively
3030035|NCT02361775|Active Comparator|IV PCA|opioid PCA consisting of hydromorphone is connected to patient in the post anesthesia care unit
3030036|NCT02361762|Experimental|Training|Computerized executive control training
3030037|NCT02361762|No Intervention|Waitlist|The waitlist group will not initially receive the training program. At the end of the study, the waitlist group will be offered training if it is efficacious.
3030038|NCT02361749|Active Comparator|Myectomy group|Subjects will undergo anal myectomy for their anal sphincter.
3030039|NCT02361749|Active Comparator|Botox Group|Subjects will undergo Botulinum toxin injection into their anal sphincter.
3030040|NCT02361736|Sham Comparator|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
3030041|NCT02361736|Experimental|Hydroxyethyl Starch|6% Hydroxyethyl Starch (HES) is intravenously administrated at a dose of 7.5ml/ kg in the first hour of surgery, and then, Lactate Ringers' is administrated to the patient until the end of the surgery
3030042|NCT02361723|Experimental|BGB-290|
3030043|NCT02361710||vitamin D deficient patients|Serum 25- (hydroxide) OH Vitamin D levels <20ng/L undergoing Frozen embryo transfer (Vitamin D levels are measured on the day of embryo transfer)
3030044|NCT02361710||vitamin D sufficient patients|Serum 25- (hydroxide) OH Vitamin D levels >20ng/L undergoing Frozen embryo transfer (Vitamin D levels are measured on the day of embryo transfer)
3030045|NCT02361697|Other|DTI-MRI|MRI of the brain with specific DTI-sequences according to a specific investigation protocol
3030046|NCT02361684|Experimental|Blended CBT treatment|
3030047|NCT02361684|Active Comparator|Treatment as usual|
3030048|NCT02361645|No Intervention|Control Group|No NSAIDs were administered prior to surgery
3030049|NCT02361645|Experimental|Ketorolac eyedrops|Ketorolac 0.5% eyedrops were administered prior to surgery
3030050|NCT02361645|Experimental|Indomethacin eyedrops|Indomethacin 0.5% eyedrops were administered prior to surgery
3030051|NCT02361645|Experimental|Nepafenac eyedrops|Nepafenac 0.1% eyedrops were administered prior to surgery
3030052|NCT02361645|Experimental|Bromfenac eyedrops|Bromfenac 0.09% eyedrops were administered prior to surgery
3030053|NCT02361632|Experimental|Group 1|"Dietary Supplement. Participants drink coffee with or without milk in following order:~Black coffee~Coffee with 20% milk added~Coffee with 50% milk added"
3030054|NCT02361632|Experimental|Group 2|"Dietary supplement. Participants drink coffee with or without milk in following order:~Coffee with 20% milk added~Black coffee~Coffee with 50% milk added"
3030055|NCT02361632|Experimental|Group 3|"Dietary supplement. Participants drink coffee with or without milk in following order:~Black coffee~Coffee with 50% milk added~Coffee with 20% milk added"
3030056|NCT02361619|Experimental|1|
3030057|NCT02361606|Experimental|Internet CBT intervention|Eligible candidates were offered to participate in an internet cognitive behavioral intervention.
3030058|NCT02361593|Experimental|Cap group|Patients will receive endoscopic sclerotherapy(lauromacrogol injection) for esophageal varices with assistance of a transparent cap in front of gastroscopy.
3030059|NCT02361593|Active Comparator|Control group|Patients will receive routine endoscopic sclerotherapy(lauromacrogol injection) for esophageal varices(no transparent cap involved).
3030060|NCT02361580|Experimental|Diary|Subjects that are randomized to the diary group will be told to keep a diary of their recovery. The study is focusing on the effect of keeping a diary on disability, rather than the content of the diary.
3030061|NCT02361580|No Intervention|No Diary|Control Group
3030062|NCT02361567|Active Comparator|Tramacet|Tramacet 1-2 tabs PO q4h prn
3030063|NCT02361567|Active Comparator|Percocet|Percocet (5/325) 1-2 tab PO q4h PRN
3030064|NCT02361554|Experimental|Deep Brain Stimulation Implant|Unblinded treatment arm, deep brain stimulation of the substantia nigra pars reticulata for treatment resistant schizophrenia.
3030065|NCT02361541||HCV screening|All adult patients of an existing HIV cohort
3030066|NCT02361528|Experimental|Leukine|Sargramostim: Leukine (Genzyme USA), 125µg/m2 , once per day during 5 days, by subcutaneous route
3030067|NCT02361528|Placebo Comparator|placebo|placebo, once per day during 5 days by subcutaneous route
3030068|NCT02361515|Active Comparator|Moderate Hypofractionated radiotherapy (62Gy)|20 fractions of 3.1Gy
3030069|NCT02361515|Experimental|Stereotactic radiotherapy (37.5Gy)|5 fractions of 7.5Gy)
3030070|NCT02361502|Placebo Comparator|placebo|mirabegron placebo qd
3030071|NCT02361502|Experimental|mirabegron|mirabegron 50mg qd
3030072|NCT02361489|Active Comparator|Titration Algorithm A|All patients that are initiated on a V-Go 20 will have a starting bolus dose of 6 clicks (12 units) during the day and all patients who are initiated on a V-Go 30 will have a starting bolus dose of 9 clicks (18 units) during the day. All patients randomized to Algorithm A will use a fixed starting dose of either 2 clicks per meal (if on the V-Go 20) or 3 clicks per meal (if on the V-Go 30).
3030073|NCT02361489|Active Comparator|Titration Algorithm B|All patients that are initiated on a V-Go 20 will have a starting bolus dose of 6 clicks (12 units) during the day and all patients who are initiated on a V-Go 30 will have a starting bolus dose of 9 clicks (18 units) during the day. All patients randomized to Algorithm B will have 50% of their initial bolus dose given at the largest meal with less bolus insulin at the other meals as noted below:
3030074|NCT02361476|Experimental|Intervention|Clonidine : injection og 3 micg/kg IV during the operation.
3030075|NCT02361476|Placebo Comparator|Placebo|Placebo : injection og equal amount of NaCl IV during the operation.
3030076|NCT02361463|Experimental|3D group|Will practice under 3D vision conditions on a laparoscopic virtual reality simulator
3030077|NCT02361463|Active Comparator|2D group|Will practice under 2D vision conditions on a laparoscopic virtual reality simulator
3030078|NCT02361450|Experimental|Retrograde Colonic Irrigation with usual care|In the experimental group, retrograde colonic irrigation sessions will be scheduled in addition to conventional treatment according to a progressive volume program.
3030306|NCT02359916||C|Less healthy snacks sold at equal pricing with delays
3030079|NCT02361450|Active Comparator|Usual Care|In the comparator group, patients will receive conventional care, according to each clinical center habits.
3030080|NCT02361437|Placebo Comparator|placebo|placebo
3030081|NCT02361437|Experimental|Vasculera|diosmin
3030082|NCT02361424|Experimental|PXT00864 Dose 1|1 orange capsule containing 0.4 mg of acamprosate , and 1 white capsule containing 6 mg of baclofen These 2 capsules are taken orally b.i.d. during 8 weeks.
3030083|NCT02361424|Experimental|PXT00864 Dose 2|"1 orange capsule containing 1 mg of acamprosate , and 1 white capsule containing 15 mg of baclofen .~These 2 capsules are taken orally b.i.d. during 8 weeks."
3030084|NCT02361424|Experimental|PXT00864 Dose 3|"1 orange capsule containing 20 mg of acamprosate , and 1 white capsule containing 12 mg of baclofen .~These 2 capsules are taken orally b.i.d. during 8 weeks."
3030085|NCT02361424|Placebo Comparator|Placebo of PXT00864|"1 orange capsule containing placebo of acamprosate , and 1 white capsule containing placebo of baclofen .~These 2 capsules are taken orally b.i.d. during 4 weeks"
3030086|NCT02361398|Experimental|EIT group|the Individualized PEEP titration by EIT was administered to the patients in the EIT group.
3030087|NCT02361398|No Intervention|oxygenation group|If patients are assigned to the oxygenation group, the Individualized PEEP Setting was by the best oxygenation as in the routines of the institution
3030088|NCT02361385||this is a pilot study|All patients will undergo PET-CT with PBR28, with the CT being localised to one group of joints only
3030089|NCT02361372|Experimental|Kefir and CaCO3|Kefir were administered 1,600 mg kefir-fermented milk per day and an accompanying supplement of 1,500 mg CaCO3 for 6 months
3030090|NCT02361372|Placebo Comparator|Placebo and CaCO3|Placebo and 1,500 mg of CaCO3 daily for 6 months
3030091|NCT02361346|Experimental|MT-3724 Phase 1 5 mcg/kg/dose|Phase 1: MT-3724 5 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
3030092|NCT02361346|Experimental|MT-3724 Phase 1b|Phase 1b: MT-3724 IV for 6 doses over 12 days for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Phase 1 portion of the study)
3030093|NCT02361346|Experimental|MT-3724 Phase 1 10 mcg/kg/dose|Phase 1: MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
3030094|NCT02361346|Experimental|MT-3724 Phase 1 20 mcg/kg/dose|Phase 1: MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
3030095|NCT02361346|Experimental|MT-3724 Phase 1 50 mcg/kg/dose|Phase 1: MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
3030096|NCT02361346|Experimental|MT-3724 Phase 1 100 mcg/kg/dose|Phase 1: MT-3724 100 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
3030097|NCT02361346|Experimental|MT-3724 Phase 1 75 mcg/kg/dose|Phase 1b: MT-3724 IV for 6 doses over 12 days for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Phase 1 portion of the study)
3030098|NCT02361333|Experimental|Teaching Intervention|Patients will be taught how to install and use a remote monitor.
3030099|NCT02361333|No Intervention|No Intervention|Patients will not be taught how to install and use a remote monitor
3030100|NCT02361320|Experimental|Computed Tomography Scans (CT)|Participants to receive 2 computed tomography (CT) scans that are part of their regular cancer care. One (1) scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist. Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit.
3030101|NCT02361307|Placebo Comparator|conventional ADL training|The control group receive the conventional ADL training programme
3030102|NCT02361307|Active Comparator|seamless ADL training|The experimental group receive the seamless ADL training programme which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training.
3030103|NCT02361294||Patient|Patients with a newly diagnosed deep venous thrombosis and/or pulmonary embolism. The thrombembolism is idiopathic or caused by immobilisation. Three blood samples are taken during the study period. A thrombophilia screening is carried out.
3030104|NCT02361294||Control|Patients that present with a suspicion of deep venous thrombosis which is excluded by duplex sonography. One to two blood samples are taken during the study period.
3030105|NCT02361281||Sarcoidosis patients|Clinically relevant sarcoidosis patients with different stages and treatments.
3030106|NCT02361281||Healthy controls|Healthy people without any pulmonary conditions
3030107|NCT02361268|Experimental|Intra-dialysis yoga|The experimental intervention in this study is intra-dialysis yoga.
3030108|NCT02361268|Active Comparator|Educational program|The active comparator for the study is an educational program.
3030109|NCT02361255||Drug-induced parkinsonism|subjects with drug-induced parkinsonism
3030110|NCT02361255||antipsychotic treated non-parkinsonian control|subjects treated with antipsychotic but without parkinsonism
3030111|NCT02361242|Experimental|PXT00864 Dose 1|1 orange capsule containing 0.4 mg of acamprosate and 1 white capsule containing 6 mg of baclofen are taken orally b.i.d during 24 weeks.
3030112|NCT02361242|Experimental|PXT00864 Dose 2|1 orange capsule containing 1 mg of acamprosate and 1 white capsule containing 15 mg of baclofen are taken orally b.i.d during 24 weeks.
3030113|NCT02361242|Experimental|PXT00864 Dose 3|1 orange capsule containing 20 mg of acamprosate and 1 white capsule containing 12 mg of baclofen are taken orally b.i.d during 24 weeks.
3030114|NCT02361216|Experimental|Ingenol mebutate gel|Treatment once daily for 3 days
3030115|NCT02361216|Placebo Comparator|Vehicle|Treatment once daily for 3 days
3030116|NCT02361203|No Intervention|No Exercise|
3030117|NCT02361203|Experimental|Exercise Pre|30 minutes of aerobic exercise before exposure therapy
3030118|NCT02361190|Placebo Comparator|Placebo nasal spray|Subjects will inhale approximately 40ml aqueous solution via intranasal route
3058601|NCT02171039|Active Comparator|atorvastatin|
3030119|NCT02361190|Experimental|Testosterone nasal spray|Subjects will inhale approximately 40ml aqueous, testosterone-containing solution via intranasal route
3030120|NCT02361177|Experimental|oxytocin|Intranasal 24 IU oxytocin self-administration.
3030121|NCT02361177|Placebo Comparator|placebo|Intranasal placebo. 125 mg of 0.5% cholorobutanol to 50 ml saline, with approximately 5 pH. The solution will then be sterilized using a 0.22 micron filter.
3030122|NCT02361164||Mother/child pair|Mother/child pair.
3030123|NCT02361151|Active Comparator|TECH (standard program)|"Receive 3-month healthy eating and physical activity intervention delivered via email newsletters and mobile apps plus self-monitoring with paper records; based on standard behavior change recommendations and materials (e.g., Diabetes Prevention Program)~Intervention: remotely-delivered evidence-based intervention to support healthy eating and physical activity; use of supporting app-based games and activities and self-monitoring."
3030124|NCT02361151|Experimental|TECH+ (enhanced program)|"Receive 3-month family-based healthy eating and physical activity intervention delivered via email newsletters and mobile apps plus self-monitoring with special study website~Intervention: remotely-delivered evidence-based intervention to support healthy eating and physical activity; use of supporting app-based games and activities; enhanced self-monitoring and family activities via special study website"
3030125|NCT02361138|Experimental|Cohort SHR3824/Placebo 1.25 mg|SHR3824 1.25 mg/day or placebo for 10 days.
3030126|NCT02361138|Experimental|Cohort SHR3824/Placebo 2.5 mg|SHR3824 2.5 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
3030127|NCT02361138|Experimental|Cohort SHR3824/Placebo 5 mg|SHR3824 5 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
3030128|NCT02361138|Experimental|Cohort SHR3824/Placebo 10 mg|SHR3824 10 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
3030129|NCT02361138|Experimental|Cohort SHR3824/Placebo 25 mg|SHR3824 25 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
3030130|NCT02361138|Experimental|Cohort SHR3824/Placebo 100mg|SHR3824 100 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
3030131|NCT02361125|Experimental|Methylphenidate|"Participants given a 7 day supply of 5 mg methylphenidate tablets (to take a maximum of 20 mg/day, for total of 28 tablets). Directions for use are to take one 5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue (maximum of 4 tablets/day).~Evaluation of fatigue, ability to sleep, and general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment."
3030132|NCT02361112|Experimental|pyrotinib combined with capecitabine|
3030133|NCT02361099|Experimental|Monitoring by SENTINEL application|Patients randomized to this arm will connect once a week to SENTINEL application to do a self-evaluation of several symptoms. A CT- scan will be scheduled only when there is an alert of the application.
3030134|NCT02361099|No Intervention|Conventional Monitoring|Patients randomized to this arm will have a CT-scan every 3 months.
3030135|NCT02361086|Experimental|Regimen 1: 7dayPM+DT|VT-464: given orally once daily in 28 day cycles. Dosing in the evening before bed 7-days a week with a 2-week dose titration.
3030136|NCT02361086|Experimental|Regimen 2: 7dayPM-DT|VT-464: given orally once daily in 28 day cycles. Dosing in the evening before bed 7-days a week without dose titration.
3030137|NCT02361086|Experimental|Regimen 3: 7dayAM+DT|VT-464: given orally once daily in 28 day cycles. Dosing in the morning 7-days a week with a 2-week dose titration.
3030138|NCT02361086|Experimental|Regimen 4: 7dayAM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the morning 7-days a week without dose titration.
3030139|NCT02361086|Experimental|Regimen 5: 5dayPM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the evening before bed 5-days a week without dose titration.
3030140|NCT02361086|Experimental|Regimen 6: 5dayAM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the morning 5-days a week without dose titration.
3030141|NCT02361073||Takotsubo|
3030142|NCT02361073||Healthy|
3030143|NCT02361073||ACS|
3030144|NCT02361060|Experimental|Sugammadex|sugammadex 4 mg/kg
3030145|NCT02361060|Active Comparator|Neostigmine + Atropine|Neostigmine 40µg/kg in combination with atropine 10µg/kg.
3030146|NCT02361047|Experimental|Phone Coaching Program|Participants will receive a nutrition and physical activity phone coaching program, in addition to standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
3030147|NCT02361047|No Intervention|Standard Care Control|Participants will receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
3030148|NCT02361034|Active Comparator|GRC 27864|Test treatment GRC 27864
3030149|NCT02361034|Placebo Comparator|Placebo|Placebo treatment
3030150|NCT02361008|Experimental|TPDC group|Patients who matched inclusion criteria and randomly divided into TPDC group underwent the TEE-guided perventricular device closure without CBP. But of them,who underwent TPDC failure during the procedure would be dropped out of the trial.
3030151|NCT02361008|Experimental|SR group|Patients who matched inclusion criteria and randomly assigned into SR group underwent the surgery repair with CBP.
3030152|NCT02360995|Active Comparator|Total Toothpaste|Triclosan/fluoride toothpaste
3030153|NCT02360995|Active Comparator|Toothpaste + Mouthwash|Stannous fluoride toothpaste & cetylpyridinium chloride Mouthwash
3030154|NCT02360995|Placebo Comparator|Control group|fluoride toothpaste +fluoride mouthwash
3030187|NCT02360761|Active Comparator|Lobectomy|Patients undergo lobectomy by thoracotomy or thoracoscopy/Video assisted thoracoscopic surgery(VATS).
3030188|NCT02360761|Experimental|Sublobar resection|Patients undergo sublobar resection(wedge resection or anatomic segmentectomy) by thoracotomy or thoracoscopy/VATS.
3058602|NCT02171026|Experimental|Dabigatran etexilate + Amiodarone|
3030155|NCT02360982||propofol and esmeron(rokuronyum)|In group G, anesthesia was induced with iv propofol (2 mg.kg-1) and maintained with 2% sevoflurane in a mixture of 65 % nitrous oxide and 35 % oxygen with a total gas flow rate of 6 L min-1. Neuromuscular relaxation was induced with iv rocuronium (esmeron) (0.5 mg.kg-1). Intravenous infusion of 0.9% saline was administered at a volume of 5 mL/kg/h. Patients received morphine (0.1mg/kg) for postoperative analgesia 30 minutes before the end of the operation. Anesthesia was terminated and neuromuscular blockade was antagonized with neostigmine (0.05 mg.kg-1)and atropine sulphate (0.01 mg.kg-1).
3030156|NCT02360982||marcaine and fentanyl|"We inserted a 18-G Tuohy needle at the L3/L4 or L2/L3 intervertebral epidural space using an epidural loss of resistance technique and thus performed needle-through-needle technique for subarachnoid injection of 2 mL bupivacaine (marcaine)(0.5%) and fentanyl (25 mcg) by 27-G spinal needle. After subarachnoid injection, epidural catheter was advanced and fixed.~At the end of the surgery 5 mL of bupivacaine 0.5% plus morphine (1 mg), adding to 4 mL saline was injected via epidural catheter for postoperative analgesia.Epidural catheter was removed at 24th hours"
3030157|NCT02360969||healthy subjects waiting for surgery|patients for whom surgery under general anesthesia with administration of curare is planned will be offered an examination of the eyes before and during surgery
3030158|NCT02360956|Experimental|Olmesartan medoxomil|Drug: Olmesartan medoxomil tablets(Daiichi Sankyo Inc, Japan). The initial dose is 20mg once daily. If blood pressure requiring further reduction after two weeks, olmesartan medoxomil may be increased to 40mg once daily.
3030159|NCT02360956|Active Comparator|Antihypertensive medication|"Drug:Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except angiotensin-Converting Enzyme Inhibitors inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs).~The drug dose must be individualized."
3030160|NCT02360943||PEAGE|Patients older than 75 years receiving an anticoagulant treatment for a symptomatic and confirmed PE
3030161|NCT02360930||Tanner Stage </=2|Patients will be stratified by phase of treatment, and they will be classified into Tanner stage ≤ 2 or ≥ 4, based on physical examination. We plan to have 15 patients in Tanner staging ≤ 2 and 15 patients in Tanner staging ≥ 4.
3030162|NCT02360930||Tanner Stage >/= 4|Patients will be stratified by phase of treatment, and they will be classified into Tanner stage ≤ 2 or ≥ 4, based on physical examination. We plan to have 15 patients in Tanner staging ≤ 2 and 15 patients in Tanner staging ≥ 4.
3030163|NCT02360917|Experimental|Intervention|Participants in the intervention group will undergo 6 weeks of psycho-educational classes provided in a live setting at Cedars Sinai and a web based setting at The University of Kansas. Each class will focus on a different realm of coping with chemo-brain.
3030164|NCT02360917|Other|Waitlist|Participants assigned to the control group will be placed on a wait list for the Haze program. While they are waiting for admittance to the program, they will receive the same surveys as the participants who are taking the Haze class. Additionally, participants assigned to the control group will receive the surveys again when taking the class in order to allow comparison of the effects of the program on the control group. Participants assigned to the wait list will be enrolled in the following Haze series.
3030165|NCT02360904|Experimental|start yoga classes immediately|12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training that will commence concurrently with the start of chemotherapy.
3030166|NCT02360904|Active Comparator|Start yoga classes after 3 months|12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training that will commence 3 months after start of chemotherapy
3030167|NCT02360891||patients|follow up of patients with amyotrophic lateral sclerosis from the first signs to the end of the disease
3030168|NCT02360891||neurological controls|patients with other neurological disease
3030169|NCT02360891||healthy controls|age matched healthy controls
3030170|NCT02360878||Non-diabetic subjects|Obese (BMI > 30 kg/m2) with normal glucose tolerance implanted with the EndoBarrier Gastrointestinal liner
3030171|NCT02360878||T2DM subjects|Obese (BMI > 30 kg/m2) with type 2 diabetes implanted with the EndoBarrier Gastrointestinal liner
3030172|NCT02360865|Experimental|COPD|Acute exercise bouts
3030173|NCT02360865|Active Comparator|Healthy|Acute exercise bouts
3030174|NCT02360852|Experimental|A4250|A4250 once daily
3030175|NCT02360839|No Intervention|Early|Study subjects (patients) undergoing endoscopic ultrasound (with or without FNA/TCB) for clinical reasons during 2005-2011.
3030176|NCT02360839|Other|Late|"Study subjects (patients) undergoing endoscopic ultrasound with EUS-guided sampling of various lesions for clinical reasons during 20012-2015.~Subjects sampled with both EUS-FNA and EUS-FNB on the same lesion. Randomization on first needle order."
3030177|NCT02360826|Experimental|Pravastatin|Pravastatin 20mg tablet (age 8-13 years), 40mg tablet (>14 years); 1 time dose given per oral at at the start of the study day.
3030178|NCT02360826|Experimental|Simvastatin|Simvastatin 10mg tablet (ages 8-13 years), 20mg tablet (>14 years); 1 time dose given per oral at the start of the study day.
3030179|NCT02360813|Experimental|Cognitive Remediation Therapy|Principle driven cognitive remediation therapy, cognitive rehabilitation, cognitive training, cognitive enhancement.
3030180|NCT02360813|Active Comparator|Treatment as Usual|Usual care.
3030181|NCT02360800|Experimental|TISSEEL|Spray Fibrin Sealant
3030182|NCT02360800|Active Comparator|CONTROL|Traditional hemostasis and chest closure routine
3030183|NCT02360787|Experimental|Energy restriction|Energy restriction (-500 kcal/day) (N=40), where participants will receive dietary counseling to reduce energy intake to achieve 500 kcal/day deficits to support weight loss. Participants will also be asked to avoid all nuts during the intervention period.
3030184|NCT02360787|Experimental|Energy restriction with almonds|Energy restriction (-500 kcal/day) with dry-roasted, lightly salted almonds supplying 15% of estimated energy requirement. Participants will receive dietary counseling to reduce energy intake to achieve 500 kcal/day deficits. Energy from almonds will be accounted for during dietary modeling so that a 500 kcal/day deficit is achieved.
3030185|NCT02360774|Experimental|Canagliflozin|Subjects will be randomized (1:1) to treatment with canagliflozin 300mg or placebo once daily for 18 weeks.
3030186|NCT02360774|Placebo Comparator|Placebo|Subjects will be randomized (1:1) to treatment with canagliflozin 300mg or placebo once daily for 18 weeks.
3030307|NCT02359916||D|Healthy snacks sold at 25% or $0.25 discount, plus delays on less healthy snacks
3030190|NCT02360735|Active Comparator|Control|Patients randomized to this arm will follow the current standard for post-operative care.
3030191|NCT02360735|Experimental|Experimental|Patients randomized to this arm will follow the current standard for post-operative care as well as 2 daily sessions of manual lymphatic drainage.
3030192|NCT02360722|Experimental|Oral Nutritional Supplement|ONS + Nutritional education
3030193|NCT02360722|Other|Control Group|Nutritional education only
3030194|NCT02360709||CRE8 group|CRE8 sirolimus-eluting stent
3030195|NCT02360696||Peds/Adol Pts w/ FD - CMH GI APT clinic|"Phase 1. Standard-of-Care Endoscopy to establish baseline data and immunohistochemistry studies. Additional biopsies taken for DNA and microarray analysis. If participant biopsies meet criteria (> or = 20/hpf) and no nodularity or tumors, s/he will be eligible to move to second phase.~Phase 2. Standard of care treatment of 3 mg/kg ranitidine bid and 20 mg. montelukast each AM for three weeks. Based on response to global assessment score, participants will be placed in non-responder or responder group. Participants from the responder group will move to final phase of the study.~Phase 3: Research endoscopy to measure response to montelukast therapy. Biopsies taken for cell density counts and immunohistochemistry studies. Additional biopsies taken for DNA and microarray analysis."
3030196|NCT02360683||patients with Parkinson's disease|Large population of Parkinson's patients who benefit from subthalamic stimulation
3030197|NCT02360670|Placebo Comparator|Control imaging (NCCT)|Standard imaging
3030198|NCT02360670|Experimental|additional multimodal imaging|CT + CTA + CTP
3030199|NCT02360657|Experimental|JNJ-54861911, 10 mg|JNJ-54861911, 10 milligram (mg) (2*5 mg tablet) orally once daily for 4 weeks.
3030200|NCT02360657|Experimental|JNJ-54861911, 50 mg|JNJ-54861911, 50 mg (2*25 mg tablet) orally once daily for 4 weeks.
3030201|NCT02360657|Placebo Comparator|Placebo|Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
3030202|NCT02360644|Experimental|Arm 1: Drug Metabolism and Transport|"The aim of Arm 1 is to determine the effect of vitamin D deficiency and repletion on xenobiotic clearance in vivo. The study will evaluate the in vivo function of targeted metabolism and transport pathways in 40 CKD and 18 healthy volunteer subjects (controls) under the influence of a vitamin D depleted state and repeated under a vitamin D replete state with cholecalciferol.~The function of two major phase I drug metabolizing enzymes (CYP2B6, CYP3A), and three transporters [P-gp, MRP2, and MATE1/2K] will be assessed by administering oral bupropion, midazolam, olmesartan, and fexofenadine."
3030203|NCT02360644|Experimental|Arm 2: Vitamin D Pharmacokinetics|The aim of Arm 2 is to determine the effect of CKD on the in vivo function of individual CYP450s responsible for vitamin D metabolism and their functional relevance on the pharmacokinetics of cholecalciferol. A total of 90 CKD subjects will be enrolled [30 per group: group I (CKD stage 1/2), group II (CKD stage 3), and group III (CKD stage 4/5, pre-ESRD)], as well as 30 healthy controls.
3030204|NCT02360631|Experimental|Chantix (varenicline)|Participants will receive 1mg pills to take twice a day for 12 weeks.
3030205|NCT02360631|Placebo Comparator|Placebo|Participants will receive a placebo pill to take twice a day for 12 weeks.
3030206|NCT02360618|Experimental|Metformin and Simvastatin Treatment|Patients in this group will receive 850 mg of Metformin and 20 mg of Simvastatin daily from the time they are enrolled in the study until the day before their surgery (approximately 12 weeks), in the absence of any safety or tolerability concerns.
3030207|NCT02360605|Active Comparator|automated telephone reminder arm|Patients will receive Health literacy appropriate education and demonstration of FIT kits with simplified instructions. Patients will receive reminders to complete their FIT screening kits by an automated call.
3030208|NCT02360605|Active Comparator|prevention coordinator arm|Patients will receive Health literacy appropriate education and demonstration of FIT kits with simplified instructions.Patients will receive reminders to complete their FIT screening kits by a prevention coordinator.
3030209|NCT02360592|Active Comparator|1, conventional control group|Entecavir 0.5 mg po daily for 72 weeks
3030210|NCT02360592|Experimental|2, combination and sequential group|Interferon alfa-2b 600wIU qod iH for 48 weeks plus Entecavir 0.5mg qd po for 8 weeks
3030211|NCT02360592|Experimental|3, multitarget group|Interferon alfa-2b 600wIU qod iH for 48 weeks plus Entecavir 0.5mg qd po for 8 weeks plus interleukin 2 25 wIU qod iH for 12 weeks plus Hepatitis B Vaccine 60ug qm im for 48 weeks
3030212|NCT02360579|Experimental|Cohort 1|Lifileucel (LN-144) without cryopreservation (Gen 1 infusion product) (Closed)
3030213|NCT02360579|Experimental|Cohort 2|Lifileucel (LN-144) with cryopreservation (Gen 2 infusion product)
3030214|NCT02360579|Experimental|Cohort 3|Retreatment cohort: patients from Cohort 1 or Cohort 2 may rescreen for a second TIL regimen therapy if they meet all Inclusion and Exclusion Criteria (except exclusion criterion b).
3030215|NCT02360566|Experimental|Participatory Video Intervention Group|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
3030216|NCT02360553|Experimental|Intervention|ObeseGO!-web-based intervention
3030217|NCT02360553|Other|Control|Given pamphlets education mainly on diet and physical activity
3030218|NCT02360527||Type 2 diabetic patients with AD|35 patients
3030219|NCT02360527||Type 2 diabetic patients with MCI|35 patients
3030220|NCT02360527||Type 2 diabetic patients controls|35 patients
3030221|NCT02360527||Non-diabetic patients with AD|35 patients
3030222|NCT02360514|Experimental|hantaan virus vaccine|
3030223|NCT02360501|Experimental|treatment arm|docetaxel 75mg/㎡,d1; cisplatin 25mg/㎡,d1-3; capecitabine 2g/㎡, d1-14. repeated every three weeks
3030297|NCT02359955|Experimental|Zero-Degree Teeth, then Anatomic Teeth|edentulous patients who were first treated with zero-degree teeth complete denture, then with anatomic teeth complete denture
3030377|NCT02359539|Experimental|MPP|Marginal periosteal pedicle
3030224|NCT02360488|Experimental|Telerehabilitation Therapy|The Telerehabilitation arm of this study will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During half of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
3030225|NCT02360488|Active Comparator|In-Clinic Therapy|The in-clinic arm of this study will deliver half of the rehabilitation treatment sessions at a study site providing traditional outpatient therapy, continuously supervised by a licensed therapist. The unsupervised therapy sessions will take place in the patient's home, and will be guided by an individualized booklet generated and printed by the Treatment Therapist and distributed to the subject during the first in-clinic therapy visit. The content of the unsupervised therapy sessions will be matched to the same exercise and training components provided during the subject's in-clinic supervised therapy sessions. In addition, at the start of each of the unsupervised sessions, all subjects will receive 5 minutes of stroke education.
3030226|NCT02360475|Experimental|RSV vaccine formulation 1 Group|Subjects in this group will receive a single dose of formulation 1 of the RSV vaccine
3030227|NCT02360475|Experimental|RSV vaccine formulation 2 Group|Subjects in this group will receive a single dose of formulation 2 of RSV vaccine
3030228|NCT02360475|Experimental|RSV vaccine formulation 3 Group|Subjects in this group will receive a single dose of formulation 3 of RSV vaccine
3030229|NCT02360475|Active Comparator|Boostrix Group|Subjects in this group will receive a single dose of Boostrix
3030230|NCT02360462|Experimental|Active tDCS|Active tDCS will be applied in the head of the patients in 20 minute sessions, twice. First session will be applied in the night before and the second session, in the morning before the surgical procedure. The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area, and it will use a 2 mA current
3030231|NCT02360462|Sham Comparator|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
3030232|NCT02360449|No Intervention|Wait List|
3030233|NCT02360449|Experimental|Social Initiation Motivation Intervention|
3030234|NCT02360423|Experimental|CRE8 group|CRE8 sirolimus-eluting stent system
3030235|NCT02360423|Active Comparator|RESOLUTE group|RESOLUTE zotarolimus-eluting stent system
3030236|NCT02360410|Experimental|Check Yourself App With Feedback|Adolescents complete Check Yourself, an electronic health screening app and receive personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers receive a summary report of health risk behaviors from Check Yourself prior to their adolescent patient's primary care appointment.
3030237|NCT02360410|No Intervention|Usual Care|Participants are asked to complete health risk screening on a tablet computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors.
3030238|NCT02360397|Experimental|Ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
3030239|NCT02360384|Placebo Comparator|Sham diet|The placebo intervention will be healthy eating advice in patients with irritable bowel syndrome of the alternating subtype for 28 days.
3030240|NCT02360384|Active Comparator|Lincalotide|All patients with constipation predominant IBS will receive linaclotide 280mcg po od for 28 days.
3030241|NCT02360384|Experimental|FODMAP diet|The FODMAP diet will be introduced in patients with irritable bowel syndrome of the alternating subtype for 28 days.
3030242|NCT02360371|Other|Within-subject design|All participants will complete several sessions and within-subject assessment of double-blind study drug will be examined during the study sessions. Order of sessions will be randomized and counter-balanced, but all participants will undergo the same study conditions. Although this is a clinical trial, it does not have an active intervention/treatment component.
3030243|NCT02360358|Experimental|autologous cultured skin|autologous cultured skin patches (Tiscover) is applied on wound in 2-step procedure with 1 week interval. Dosage: number of patches depends on wound size. Application week 0 is removed after one week (week1). Week 1: wound is completely covered with new Tiscover patches.
3030244|NCT02360358|Active Comparator|acellular donor dermis|"acellular donor dermis (AS210) is applied on wound in 2-step procedure with 1 week interval. Dosage: number of patches depends on wound size.~Application week 0 is removed after one week (week1). Week 1: wound is completely covered with new AS210 patches."
3030245|NCT02360345|Experimental|q1week schedule|ONX-0801 will be administered over a 1-hour IV infusion on Days 1, 8, 15 and 22 of repeated 28-day treatment cycles.
3030246|NCT02360345|Experimental|q2week schedule|ONX-0801 will be administered over a 1-hour IV infusion on Days 1 and 15 of repeated 28-day treatment cycles.
3030247|NCT02360332|Experimental|PS-ASD|Treatment Condition, participants assigned to this condition will receive the treatment, one school year (9 months) of Project SEARCH plus ASD Supports
3030248|NCT02360332|No Intervention|High School As Usual|Control Condition, Participants assigned to this condition will have no interaction or intervention with the research team with the exception of data collection at the specified time points.
3030249|NCT02360319|Active Comparator|Clinician's Choice|Prescribers are not limited in the choice of treatment they can administer to their clients to alleviate the symptoms of schizophrenia. Any FDA approved antipsychotic agent can be used. Clients in the study wil be followed for 2 years
3030250|NCT02360319|Experimental|Aripiprazole Once Monthly|Aripiprazole long acting injectable formulation, 400mg per dose is to be administered once monthly. Clients in the study will be followed for 2 years
3030298|NCT02359955|Experimental|Anatomic Teeth, then Zero-Degree Teeth|edentulous patients who were first treated with anatomic teeth complete denture, the with zero degree teeth complete denture
3030299|NCT02359942|Experimental|Citric acid group|Giving the citric acid (4g) as test meal before UBT
3030251|NCT02360306|Active Comparator|Conventional EBUS|Subjects in this arm will have endobronchial ultrasound bronchoscopy done by the conventional EBUS scope rather than the hybrid EBUS scope. Subjects in this arm, like in the Hybrid EBUS arm, may or may not receive transbronchial forcep biopsies, airway brusings, and/or radial EBUS, depending on clinical need.
3030252|NCT02360306|Experimental|Hybrid EBUS|Subjects in this arm will have endobronchial ultrasound bronchoscopy done by the hybrid EBUS scope rather than the conventional EBUS scope. Subjects in this arm, like in the conventional EBUS arm, may or may not receive transbronchial forcep biopsies, airway brusings, and/or radial EBUS, depending on clinical need.
3030253|NCT02360293|Experimental|Stay Strong w/coaching|participants in the Stay Strong w/coaching (Experimental) arm are provided a wearable device, scale, telephone coaching, tailored push notifications, personalized goals, and enhanced online/app support.
3030254|NCT02360293|Active Comparator|Stay Strong|participants in the Stay Strong (active comparison) arm will only be provided a wearable device with standard online/app support.
3030255|NCT02360280|Experimental|Six ketamine infusions|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
3030256|NCT02360280|Active Comparator|Single ketamine infusion preceded by 5 midazolam infusions|Single infusion of 0.5 mg/Kg of ketamine hydrochloride solution preceded by midazolam 0.045 mg/kg over 2 weeks.
3030257|NCT02360254||Patients shifting to insulin degludec|Patients shifting from twice daily glargine or detemir to once daily degludec. This change in therapy will have to be decided by the diabetologist and the patient, not done for the purpose of the study.
3030258|NCT02360254||Patients remaining on twice daily glargine/detemir|Patients continuing on twice daily glargine or detemir
3030259|NCT02360241|Experimental|Robot|A robot will be used and it's position will be evaluated
3030260|NCT02360228|Experimental|tACS (alpha)|20 participants: 10Hz tACS with a peak-to-peak amplitude of 2mA for 20 minutes twice daily
3030261|NCT02360228|Experimental|tDCS|20 participants: 2mA stimulation for 20 minutes twice daily
3030262|NCT02360228|Sham Comparator|Sham stimulation|20 participants: Will include 10 seconds of ramp in to 1 minutes of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation twice daily.
3030263|NCT02360215|Experimental|Arm I (memantine hydrochloride, WBRT)|Patients receive memantine hydrochloride PO BID for 24 weeks. Patients undergo WBRT daily over approximately 2 weeks (10 fractions).
3030264|NCT02360215|Experimental|Arm II (memantine hydrochloride, HA-WBRT)|Patients receive memantine hydrochloride as in Arm I. Patients undergo HA-WBRT using IMRT daily over approximately 2 weeks (10 fractions).
3030265|NCT02360202|Experimental|Bullous pemphigoid patient treated with clobetasol propionate|Impedance analysis in patient with bullous pemphigoid treated by Clobetasol Propionate cream treatment.
3030266|NCT02360176|Experimental|Sleeve gastrectomy single port|Sleeve gastrectomy single port
3030267|NCT02360176|Active Comparator|Sleeve gastrectomy multi trocar|Sleeve gastrectomy multi trocar
3030268|NCT02360163|Active Comparator|Landmark Technique Attempt|Patients will undergo an additonal TLT attempt
3030269|NCT02360163|Experimental|USGPIVA Technique Attempt|Patients will be offered a USGPIVA attempt after two failed attempts using the traditional landmark technique (TLT)
3030270|NCT02360150|Experimental|second propeller arm scanner|The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement to the inclusion visit.
3030271|NCT02360137||Patients with carotid plaque|Patients with carotid plaque treated using only drugs
3030272|NCT02360137||Patients with carotid stenosis|Patients with carotid stenosis indicated to carotid endarterectomy
3030273|NCT02360124|Placebo Comparator|control|instructions on oral hygiene (OHI) tailored to the individual's condition will be given, and a tube of toothpaste containing 1,000 ppm fluoride (the most popular type of adult toothpaste in the Hong Kong market) will be provided. The OHI and provision of toothpaste will be repeated at 6-month intervals. In addition, distilled water as placebo with a bitter flavor added (to mimic the bitter metallic taste of SDF) will be painted onto all exposed tooth root surfaces using a small disposable brush. This procedure will be repeated after 12 and 24 months.
3030274|NCT02360124|Experimental|silver diammine fluoride|the subjects will receive the same intervention as those provided to subjects in the control group except that a 38% SDF solution (Saforide, Toyo Seiyaku Kasei Co. Ltd, Osaka, Japan) instead of the placebo solution will be painted onto the exposed tooth root surfaces. This treatment will be repeated after 12 and 24 months.
3030275|NCT02360124|Active Comparator|silver diammine fluoride and KI|the subjects will receive the same treatment as those provided to subjects in the control group except that a 38% SDF solution instead of the placebo solution will be painted onto the exposed tooth root surfaces and followed by painting of a saturated potassium iodide solution. This treatment will be repeated after 12 and 24 months.
3030276|NCT02360111|Experimental|Post Transplant Cyclophosphamide|Melphalan 70 mg/m 2/d will be administered intravenously on d-6 and -5 Fludarabine 25 mg/m 2/d will be administered intravenously on d-6 thru -2 Day -1 will be a day or rest Cyclophosphamide and mesna will be given on d+3 and +4 Siro +/- MMF will be started in those patients who are to receive it on d+5. Neupogen will begin d+7.
3030277|NCT02360072||AR group|Allergic rhinitis without any typical asthma symptoms
3030278|NCT02360072||Asthma|Accompanied by typical asthma symptoms and Δ FEV1≥12% in response to a short-acting bronchodilator or bronchial hyperreactivity(BHR) in the methacholine provocation test (PC20≤2.504mg)
3030279|NCT02360072||AR+Asthma|Diagnosed allergic rhinitis concomitant asthma symptoms
3030280|NCT02360072||Control group|non-atopic subjects with neither a history of rhinitis nor asthma
3030300|NCT02359942|No Intervention|Controlled group|No use of test meal
3030301|NCT02359929|Experimental|Dose Level 1: Infusion of MSCs|First three subjects enrolled will receive a single infusion of mesenchymal stromal cells based on their individual weight
3030302|NCT02359929|Experimental|Dose Level 2: Infusion of MSCs|Subsequent subjects enrolled will receive two infusions (a week apart) of mesenchymal stromal cells based on their individual weight
3030303|NCT02359929|Experimental|Dose Level 3: Infusion of MSCs|Subsequent subjects enrolled will receive four infusions (a week apart) of mesenchymal stromal cells based on their individual weight
3030304|NCT02359916||A|Snacks sold under equal pricing, no delays
3058603|NCT02171026|Active Comparator|Amiodarone|
3030281|NCT02360059|Experimental|Metformin Group|"Participants take 1,000 mg Metformin by mouth twice daily for 12 weeks during Paclitaxel treatment.~Adaptation phase begins 12 days prior to the start of the Paclitaxel therapy. During this phase, study medication dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by the desired dose of 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit."
3030282|NCT02360059|Placebo Comparator|Placebo Group|"Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit."
3030283|NCT02360046|Other|Higher hydrocortisone dose|Established hydrocortisone replacement therapy plus 10mg of hydrocortisone
3030284|NCT02360046|Other|Lower hydrocortisone dose|Established hydrocortisone replacement therapy plus placebo
3030285|NCT02360033|Experimental|Systemic Therapy|Systemic Therapy deals with the experience in private social systems (e.g. couples. Family, friends) and organizational systems (e.g. work teams), their appraisals and the attitude of the members towards each other within the system. It is analyzed how these systems can lead to the development and maintenance of psychological disorders.
3030286|NCT02360033|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy deals with individual behavior as well as individual attitude, thoughts, appraisals and beliefs, which can have an influence on the development and maintenance of psychological disorders.
3030287|NCT02360020|Experimental|XLimus patients|participants must have symptomatic ischemic heart disease attributable to critical (that is, >70% visual estimate) stenotic lesions of native coronary arteries. Inclusion criteria are 1) chronic total occlusion (CTO), 2) severe calcification, and 3) severe tortuosity. CTO is defined as the presence of TIMI 0 flow within the occluded segment and angiographic or clinical evidence of an occlusion duration of ≥3 months. Calcification is defined severe when larger than 3x vessel diameter, and comprising the vessel wall totally in two perpendicular views. Tortuosity is defined severe when: one or more bends >= 90°, or three or more bends of 45-90° proximal to the diseased segment.
3030288|NCT02360007|Experimental|Interim Buprenorphine Treatment|IBT participants will visit the clinic every 2 weeks while receiving the IBT package. Our integrative IBT treatment package includes five key components, each strategically chosen to maximize patient access to pharmacotherapy for opioid dependence while minimizing nonadherence, abuse and diversion: (1) Buprenorphine (BUP), (2) Computerized adherence monitoring (CAM), (3) Mobile health clinical support, (4) Urinalysis and adherence monitoring, and (5) HIV+Hepatitis Education.
3030289|NCT02360007|No Intervention|Waitlist Control|WLC participants will remain on the waitlist for their treatment of choice but complete the same scheduled follow-up assessments as IBT participants.
3030290|NCT02359994|Experimental|Cardiac Surgery|For cardiac procedures, the site of evaluation for satisfaction of intraoperative eligibility criteria will be any bleeding sites on the epicardium, along an aortic anastomotic suture line, or an aortotomy suture line. For example, the surgeon will perform dissection of adhesions per his or her conventional methods and bleeding will be controlled using means continually employed by the surgeon prior to surgical closure. Prior to application along an aortic anastomotic suture line or an aortotomy suture line, suture line gaps > 2mm and large needle holes > 2mm will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the epicardium, or along an aortic anastomotic suture line, or an aortotomy suture line meeting the eligibility criteria will be evaluated for satisfaction. PerClot should be applied after drug reversal and the patient is taken off by-pass.
3030291|NCT02359994|Experimental|General Surgery|"For liver resection procedures, the resected liver surface will be the site of evaluation. The surgeon will perform resection of the diseased portion of the liver per his/her conventional methods. Bleeding from discrete vessels will be controlled using means conventionally employed by the surgeon. Vessels > 2mm in diameter will be ligated and any observed bile leaks controlled prior to assessment of intraoperative eligibility criteria.~For total splenectomy procedures, the site of evaluation for satisfaction of the intraoperative eligibility criteria will be the retroperitoneal surface. The surgeon will perform the splenectomy per his/her conventional methods. Vessels > 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria.~Any bleeding site on the retroperitoneal surface/cavity or exposed parenchymal surface will be evaluated for satisfaction of the eligibility criteria."
3030292|NCT02359994|Experimental|Urologic Surgery|"For on-clamp partial nephrectomies, the site of evaluation will be the kidney bed surface. The surgeon will perform resection of the kidney per his or her conventional methods. Vessels > 2mm in diameter will be ligated and entries into the collecting system controlled prior to assessment of intraoperative eligibility criteria. Any bleeding site on the kidney bed will be evaluated for satisfaction of the eligibility criteria after clamp release.~For radical nephrectomies, the site of evaluation will be the retroperitoneal surface/cavity. The surgeon will perform the procedure per his or her conventional methods. Vessels > 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the retroperitoneal surface/cavity will be evaluated for satisfaction of the eligibility criteria."
3030293|NCT02359981|Active Comparator|Generic suggestions|Control group participants received suggestions generated by the a nutritionist and exercise trainer. These suggestions didn't relate to user's life or their past behavior.
3030294|NCT02359981|Experimental|MyBehavior|Experiment group participants received personalized suggestions from MyBehavior that relates their life and past behavior.
3030295|NCT02359968|Active Comparator|FOLFOX|"Fluorouracil 400 mg/m², IV bolus dose on day 1, followed by continuous IV infusion of fluorouracil 1600 mg/m² over 2 days~Oxaliplatin 85 mg/m², 2-hr IV infusion on day 1~Folinic acid 200 mg/m² 2-hr IV infusion on day 1~3 cycles, q14"
3030296|NCT02359968|Experimental|CarboP-pacliT|"Carboplatin (carboP) AUC=2, given by intravenous infusion~Paclitaxel (pacliT) 50 mg/m², given by intravenous infusion~on days 1, 8, 15, 22 and 29"
3030308|NCT02359916||E|Less healthy snacks sold at 25% or $0.25 higher price, no delays
3030309|NCT02359916||F|Less healthy snacks sold at 25% or $0.25 higher price, plus delays
3030310|NCT02359916||G|Snacks sold under equal pricing, no delays
3030311|NCT02359903|Experimental|BCD-055 group|BCD-055 (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
3030312|NCT02359903|Active Comparator|Remicade group|Remicade (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
3030313|NCT02359890|Experimental|Treatment Group|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH® SF family of contact force sensing catheters (study device)
3030314|NCT02359877|Experimental|BCD-054|Pegylated interferon beta 1a Single doses - 60 mcg, SC/IM Single doses - 120 mcg, SC/IM Single doses - 240 mcg, SC/IM Single doses - 360 mcg, SC/IM Multiple doses - 180 mcg, SC/IM
3030315|NCT02359877|Active Comparator|Rebif|interferon beta 1a 44 mcg, SC, 3 times a week for 2 weeks
3030316|NCT02359877|Active Comparator|Avonex|interferon beta 1a 30 mcg, IM, once a week for 2 weeks
3030317|NCT02359864|Experimental|Cohort One|An initial 15 patients will be enrolled in the first treatment scheme (5 daily fractions of 2 Gy) and will be followed for 12 months after completion of treatment to assess safety and any toxicity/adverse events associated with treatment. 15 patients will be enrolled and each will be followed for 12 months to assess safety and toxicity/adverse events.
3030318|NCT02359864|Experimental|Cohort Two|"The second treatment arm will not be used until the last patient in the first dose arm has completed all follow up. At that point patients~#16-30 will be enrolled in the second dose arm (10 daily fractions of 2 Gy). 15 patients will be enrolled and each will be followed for 12 months to assess safety and toxicity/adverse events."
3030319|NCT02359851|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
3030320|NCT02359838|Other|Usual Care|Frail/pre-frail hematologic oncology patients receive usual care
3030321|NCT02359838|Active Comparator|Geriatrician Co-Management|Frail/pre-frail hematologic oncology patients receive co-management by a geriatrician
3030322|NCT02359825|No Intervention|standard epineural repair <24 hours|epineural repair following treatment with standard epineural repair alone in sensory nerve injuries in the upper extremity in short-term acute injuries (repaired <24 hours after injury); no medication used
3030323|NCT02359825|No Intervention|standard epineural repair >24 - 72 hours|epineural repair following irrigation with standard epineural repair alone in sensory nerve injuries in the upper extremity in short-term chronic injuries (>24-<72 hours after injury); no medication used
3030324|NCT02359825|No Intervention|epineural repair with autografting within 48 hours|epineural repair with auto grafting within 48 hours; no medication used
3030325|NCT02359825|Experimental|epineural repair <24 hours using PEG|epineural repair following treatment with standard epineural repair using PEG in sensory nerve injuries in the upper extremity in short-term acute injuries (repaired <24 hours after injury); PEG is used during the surgical procedure
3030326|NCT02359825|Experimental|epineural repair >24 but <72 hours using PEG|epineural repair following treatment with standard epineural repair using PEG in sensory nerve injuries in the upper extremity in short-term acute injuries (repaired >24 hours but < 72 hours after injury); PEG is used during the surgical procedure
3030327|NCT02359825|Experimental|epineural repair with autografting within 48 hours, using PEG|epineural repair with auto grafting within 48 hours
3030328|NCT02359812||Healthy|Healthy volunteers with no history of neurological disorders
3030329|NCT02359812||Stroke|Patients had a recent stroke, two weeks or earlier prior to enrollment
3030330|NCT02359799|Experimental|Lab group|Lab-based intervention includes 18 training sessions using the IntelliStretch in the lab .
3030331|NCT02359799|Experimental|Home group|Home-based intervention includes 18 training sessions using the IntelliStretch at home.
3030332|NCT02359786||Genetic Testing Subjects undergoing genetic testing|
3030333|NCT02359786||Topicals Subjects using topical compounds|
3030334|NCT02359786||Patients undergoing Spinal Surgery using IOM|
3030335|NCT02359786||Spine Patients undergoing cervical or lumbar surgery|
3030336|NCT02359786||Total Joint Patients undergoing knee and hip replacement|
3030337|NCT02359786||UDT (unrinary drug test) Patients who are given a UDT|
3030338|NCT02359773||Group 1 - Non ischemic chest pain|No coronary artery disease (CAD) as confirmed by myoview, MRI or stress echo. Subjects will receive one MCG scan (intervention) using the QI Model 1.0 Magentocardiogram. This will be in addition to their current care and it will not be used to support clinical decision making.
3030339|NCT02359773||Group 2 - Myocardial infarction|Myocardial infarction confirmed by a troponin test (>50ng/l) 12 hours after the onset of chest pain. Subjects will receive one MCG scan (intervention) using the QI Model 1.0 Magentocardiogram. This will be in addition to their current care and it will not be used to support clinical decision making.
3030340|NCT02359760|Experimental|Piezocision group|The experimental group will consist of 14 adults, subjects from 18 to 40 years-old (10 women, 4 men).
3030341|NCT02359760|No Intervention|conventional orthodontics|The control group will consist of 30 matched patients with the same inclusion and exclusion criteria, who have been already treated by conventional orthodontics in the orthodontic clinic of the University of Montreal.
3030342|NCT02359747||In Vitro Fertilization treatment|culture medium discarded after IVF treatment
3030343|NCT02359734||Brigham and Women's Hospital.|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Brigham and Women's Hospital. In these unit, the intervention bundle was implemented.
3030344|NCT02359734||Johns Hopkins University Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Johns Hopkins University Hospital. In these unit, the intervention bundle was implemented.
3030345|NCT02359734||Winchester Medical Center|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Winchester Medical Center. In these unit, the intervention bundle was implemented.
3030415|NCT02359357|Experimental|Food effect - fed|Single dose of FDL169 in fed conditions
3030346|NCT02359734||Central DuPage Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Central DuPage Hospital. In these unit, the intervention bundle was implemented.
3030347|NCT02359734||Vanderbilt University|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Vanderbilt University Medical Center. In these unit, the intervention bundle was implemented.
3030348|NCT02359734||Massachusetts General Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Massachusetts General Hospital. In these unit, the intervention bundle was implemented.
3030349|NCT02359734||University of California, San Diego|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at University of California, San Diego. In these unit, the intervention bundle was implemented.
3030350|NCT02359734||Maricopa Integrated Health System|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Maricopa Integrated Health System. In these unit, the intervention bundle was implemented.
3030351|NCT02359734||Danbury Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Danbury Hospital. In these unit, the intervention bundle was implemented.
3030352|NCT02359734||Candler Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Candler Hospital. In these unit, the intervention bundle was implemented.
3030353|NCT02359721|Experimental|test group|Base line scaling and root planing was done. Clarithromycin tablet 500 mg( Clarino-500) was given for a period of 7 days orally two times per day
3030354|NCT02359721|No Intervention|control|scaling and root planing
3030355|NCT02359708|Experimental|OR nurse group|OR nurses (14) who agreed to participate were asked to perform a surgical hand disinfection accordingly to clinic routine. When hands were dry cultures were first obtained at 3 sites, using a moist with saline nylon flocked swab (Copan ESwab, Italia SpA). After hand disinfection; 1) in right hand palm, 2) between index finger and middle finger, 3) nail/cuticle of index finger. When surgery were completed and before disposal of gloves and gown the fourth culture were taken where the glove cuff meets the gown sleeve, under and above, the inner glove of all OR nurses.When gloves were removed cultures were taken again at three sites on the hand, approximately 2-3 hours.
3030356|NCT02359708|Experimental|Non-hospital group|Non-hospital volunteers who agreed to participate were asked to perform a surgical hand disinfection accordingly to clinic routine. When hands were dry cultures were first obtained at 3 sites, using a moist with saline nylon flocked swab (Copan ESwab, Italia SpA). After hand disinfection; 1) in right hand palm, 2) between index finger and middle finger, 3) nail/cuticle of index finger. This group whore gowns and gloves for approximately 2-3 hours but not kept sterile. The Culture at the glove cuff were left out. When gloves were removed cultures were taken again at three sites on the hand.
3030357|NCT02359695|Experimental|GH cycle|Subsequent IVF cycle, supplemented with a low dose of growth hormone.
3030358|NCT02359682||Age 20-39|Patients aged from 20 to 39 years old.
3030359|NCT02359682||Age 40-59|Patients aged from 40 to 59 years old.
3030360|NCT02359682||Age 60-79|Patients aged from 60 to 79 years old.
3030361|NCT02359669|Active Comparator|Growing up milk (GUM)|GUM associated with StimuLearn intervention.
3030362|NCT02359669|Placebo Comparator|Skimmed Milk|Control group given skimmed milk without StimuLearn intervention.
3030363|NCT02359656|Other|non operative treatment|specif non operative treatment protocol
3030364|NCT02359656|Other|operative treatment|dorsal atlanto-axial C1-C2 Arthrodesis
3030365|NCT02359643|Placebo Comparator|with high dose aspirin|KD patients treated with high dose IVIG (2gm/kg) and high dose aspirin (>50mg/kg/day) since diagnosed, then taper to low dose aspirin (3-5mg/kg/day) when fever subside.
3030366|NCT02359643|Experimental|Without high dose aspirin|KD patients treated with high dose IVIG (2gm/kg) without high dose aspirin (>50mg/kg/day) since diagnosed, then low dose aspirin (3-5mg/kg/day) when fever subside.
3030367|NCT02359630|Active Comparator|EasyTube|Use of EasyTube during general anesthesia
3030368|NCT02359630|Experimental|Endotracheal tube|Use of endotrachel tube during general anesthesia
3030369|NCT02359617|Experimental|glucose sensing and insulin delivery|"Subcutaneous insulin delivery with an insulin pump plus glucose sensing with a continuous glucose sensor placed at the site of subcutaneous insulin delivery.~In parallel, capillary glucose determinations using a conventional glucose meter as well as glucose sensing in subcutaneous, insulin-unexposed tissue using a continuous glucose sensor."
3030370|NCT02359604|Other|Single Arm Study -microbiome|This is a single-arm study. The patients will serve as their own controls. The PPI administered for PPI-therapy is already FDA approved. A stool sample will be obtained for intestinal microbiome testing before PPI, under PPI and after PPI therapy.
3030371|NCT02359591||text-based or multimedia|Subject fills in a questionnaire regarding whether the child meets developmental milestones for his/her developmental age, both the text-based and the multimedia version. A total score will be calculated and compared.
3030372|NCT02359578|Experimental|Lymphatic occlusion pressure|injection of 100µg Indocyanine Green in the first interdigital space and application of increasing pressure around the arm to visualize at which pressure lymph flow is interrupted.
3030373|NCT02359565|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 34 courses in the absence of disease progression or unacceptable toxicity.
3030374|NCT02359552|Placebo Comparator|Placebo|"Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.~Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit)."
3030375|NCT02359552|Active Comparator|Rasagiline|"Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.~Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit)."
3030376|NCT02359539|Experimental|PRF|Platelets rich fibrin,
3030378|NCT02359526|Experimental|ILUVIEN 190 ug intravitreal implant|All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
3030379|NCT02359513|Experimental|boulimic|Analyse of serotoninergic brain activity (determined by positron emission tomography using [18F]MPPF) from bulimic patients treated with serotoninergic antidepressants during 3 months. The serotoninergic brain activity is measured before adnd after the serotoninergic antidepressant treatment.
3030380|NCT02359500|Experimental|68Ga-DOTATOC PET|patients with known or suspected somatostatin receptor positive neuroendocrine tumors (NETs)
3030381|NCT02359487|Experimental|Intervention|The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
3030382|NCT02359487|Placebo Comparator|Control|Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
3030383|NCT02359474|Experimental|Trabectedin with regional hyperthermia|Trabectedin 1.5 mg/m², 24 hrs continuous i.v. infusion, repetition after 21 days, until progress of disease Additional treatment with regional hyperthermia (RHT): RHT treatment of the tumor area and the surrounding tissue (41-44°C for 60 min treatment time) is applied at the end of Trabectedin infusion (+/- 4 hrs).
3030384|NCT02359474|Active Comparator|Trabectedin|Trabectedin 1.5 mg/m², 24 hrs continuous i.v. infusion, repetition after 21 days, until progress of disease
3030385|NCT02359461|Experimental|Stendo group|Subjects will be randomized into two groups determining the sequence: stendo then control, or control then stendo
3030386|NCT02359461|Other|control group|Subjects will be randomized into two groups determining the sequence: stendo then control, or control then stendo
3030387|NCT02359448|Experimental|Melatonin|Patients will be prescribed and dispensed from pharmacy sustained -release Melatonin (Circadin) 2mg. This will be taken every night for twelve weeks.
3030388|NCT02359435|Experimental|Reverse hybrid therapy|pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg for the first 7 days, followed by pantoprazole 40 mg and amoxicillin 1 g for another 5 days; with all drugs given twice daily
3030389|NCT02359435|Active Comparator|Standard triple therapy|pantoprazole 40 mg, clarithromycin 500 mg, and amoxicillin 1 g for 12 days; with all drugs given twice daily
3030390|NCT02359422|Experimental|Media Aware-Sexual Health|10-lesson middle school, comprehensive sexual health program developed based upon the Message Interpretation Processing model designed to increase critical thinking skills about media messages and reduce risky sexual behaviors.
3030391|NCT02359422|No Intervention|Wait-list control|
3030392|NCT02359409|Active Comparator|water immersion only|Colonoscopy will be performed using the water immersion technique.
3030393|NCT02359409|Experimental|water immersion with goggle balloon|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique
3030394|NCT02359396|Experimental|5.0g of MZRW|The participants will receive 5.0g of MZRW at 9 am .
3030395|NCT02359396|Experimental|7.5g of MZRW|The participants will receive 7.5g of MZRW at 9 am.
3030396|NCT02359396|Experimental|10g of MZRW|The participants will receive 10g of MZRW at 9 am.
3030397|NCT02359383|Active Comparator|Chest Physiotherapy group|Conventional medical treatment plus Chest Physiotherapy
3030398|NCT02359383|No Intervention|Control grup|Conventional medical treatment
3030399|NCT02359370|Active Comparator|Magnesium Group|Magnesium Sulphate was administered through continuous infusion, immediately before induction of anesthesia
3030400|NCT02359370|Active Comparator|Lidocaine Group|Lidocaine was administered through continuous infusion, immediately before induction of anesthesia
3030401|NCT02359357|Placebo Comparator|Placebo single dose|Placebo administered as a single dose
3030402|NCT02359357|Experimental|Single dose (Dose level 1)|FDL169 (Dose level 1) administered as a single dose
3030403|NCT02359357|Experimental|Single dose (Dose level 2)|FDL169 (Dose level 2) administered as a single dose
3030404|NCT02359357|Experimental|Single dose (Dose level 3)|FDL169 (Dose level 3) administered as a single dose
3030405|NCT02359357|Experimental|Single dose (Dose level 4)|FDL169 (Dose level 4) administered as a single dose
3030406|NCT02359357|Experimental|Single dose (Dose level 5)|FDL169 (Dose level 5) administered as a single dose
3030407|NCT02359357|Experimental|Single dose (Dose level 6)|FDL169 (Dose level 6) administered as a single dose
3030408|NCT02359357|Experimental|Single dose (Dose level 7)|FDL169 (Dose level 7) administered as a single dose
3030409|NCT02359357|Experimental|Single dose (Dose level 8)|FDL169 (Dose level 8) administered as a single dose
3030410|NCT02359357|Experimental|Additional single dose 1|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
3030411|NCT02359357|Experimental|Additional single dose 2|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
3030412|NCT02359357|Experimental|Additional single dose 3|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
3030413|NCT02359357|Experimental|Additional single dose 4|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
3030414|NCT02359357|Experimental|Food effect - fasted|Single dose of FDL169 in fasted conditions
3030416|NCT02359357|Placebo Comparator|Placebo - multiple dose|Repeat doses of placebo
3030417|NCT02359357|Experimental|Multiple dose - Dose level 1|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
3030418|NCT02359357|Experimental|Multiple dose - Dose level 2|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
3030419|NCT02359357|Experimental|Multiple dose - Dose level 3|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
3030420|NCT02359357|Experimental|Multiple dose - Dose level 4|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
3030421|NCT02359357|Experimental|Multiple dose - additional dose level 1|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
3030422|NCT02359357|Experimental|Multiple dose - additional dose level 2|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
3030423|NCT02359344|Experimental|CNV1014802|CNV1014802 150mg three times a day (tid) 7 days plus a single dose on day 8
3030424|NCT02359344|Placebo Comparator|Placebo|Placebo tid 7 days plus a single dose on day 8
3030425|NCT02359331|Active Comparator|14 days PBMT group|Giving the 14 days bismuth quadruple regimen as 2nd rescue therapy for eradication of persistent H. pylori infection Drug regimen Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
3030426|NCT02359331|Experimental|7 days tailored therapy group|According the antimicrobial susceptibility testing, the H. pylori isolates were resistant to moxifloxacin, 7 days PBMT regimen were prescribed; if the isolates were resistant to metronidazole, 7 days moxiflxacin based triple regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d) were prescribed.
3030427|NCT02359318|Experimental|Infiltration and Bonding|Brackets (Gemini metal brackets, 3M Unitek) are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. Brackets that were de-bonded in preparation of infiltration were not re-used, but replaced by new brackets. Infiltration was carried out according to the manufacturer's instruction, with a maximum of three times of prior etching. In accordance with the instructions, the numbers of etching intervals were adapted to the depth of the lesions by visual clinical evaluation. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.
3030428|NCT02359318|Other|No Infiltration|Brackets are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.
3030429|NCT02359318|Other|Control|Brackets are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.
3030430|NCT02359305||IV Acetaminophen|Acetaminophen administered by intravenous infusion.
3030431|NCT02359305||Rectal Acetaminophen|Acetaminophen administered by rectal suppository.
3030432|NCT02359292|Experimental|CHF 5993 HS 200/6/25 pMDI|High Strength fixed combination
3030433|NCT02359292|Active Comparator|CHF 5993 MS 100/6/25 pMDI|Medium Strength fixed combination
3030434|NCT02359292|Experimental|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|High Strength fixed combination plus Charcoal Block
3030435|NCT02359292|Active Comparator|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|Medium Strength fixed combination plus Charcoal Block
3030436|NCT02359292|Placebo Comparator|Placebo pMDI|Placebo
3030437|NCT02359279|Experimental|Contrast|All subjects will be in one group who will have a control radiograph before applying sodium iodide to interproximal surfaces of teeth when another radiograph will be taken to test for the presence of caries cavitation.
3030438|NCT02359266|Experimental|Vitamin D supplement|20,000 IU cholecalciferol p.o for the first 7 days, and weekly thereafter for 6 months
3030439|NCT02359266|No Intervention|Controls|These patients had normal vitamin D levels and did not receive any treatment with vitamin D.
3030440|NCT02359253|Experimental|IntelliArm with passive stretching|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
3030441|NCT02359253|Experimental|IntelliArm with passive movement|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will wear the IntelliArm for up to 30 minutes with gentle passive movement or little stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
3030442|NCT02359253|Experimental|The hand robot with passive stretching|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the hand robot.
3030443|NCT02359253|Experimental|The hand robot with passive movement|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will wear the hand robot for up to 30 minutes with gentle passive movement or little stretching, then followed by 45-60 minutes of active movement training with the hand robot.
3030444|NCT02359240||sepsis|Patients with a diagnosis of sepsis or severe sepsis,immobilization for 3 days at least. Therapy according to the SSC guidelines will be applied. therapy according to SSC guidelines and muscle biopsy
3030445|NCT02359240||Patients with femoral fractures|non septic patients with a femoral fracture,who need an fixation surgery.standard surgery for femoral fracture and muscle biopsy will be performed.
3030446|NCT02359227|Experimental|Cenderitide|Cenderitide will be administered as four, 48-hour, continuous, subcutaneous infusion rates of 0.5, 1.0, 2.0 and 3.0 ng/kg/min totaling up to eight sequential days of dosing.
3030447|NCT02359214|Active Comparator|Vitamin D3 Supplement|This group will receive a daily dose of 5000IU (125µg) vitamin D3 (which is half of the recommended safe tolerable upper intake level of vitamin D for healthy individuals) for eight weeks.
3030448|NCT02359214|Placebo Comparator|Placebo|This group will receive 100% lactose placebo daily for eight weeks.
3030449|NCT02359201|Experimental|Sequence 1|Treatment group sequence: Test Product (V0018) on Day 1 and Placebo on Day 2
3030450|NCT02359201|Experimental|Sequence 2|Treatment group sequence: Placebo on Day 1 and Test Product (V0018) on Day 2
3030451|NCT02359188|Active Comparator|tVNS|Transcutaneous vagal nerve stimulation with 25 Hz
3030452|NCT02359188|Sham Comparator|Sham-tVNS|Sham transcutaneous vagal nerve stimulation with 1 Hz
3030453|NCT02359175|Active Comparator|Active Epidural analgesia|Epidural catheter: Bupivacain 1,0 mg/ml + Fentanyl 2 micrograms/ml. Oral analgesia: Paracetamol, NSAID and placebo tablets.
3030454|NCT02359175|Active Comparator|Placebo Epidural analgesia|Epidural analgesia: Placebo. Oral analgesia: Paracetamol, NSAID and opioids tablets.
3030455|NCT02359162|Experimental|P-Gemox|"P-Gemox:gemcitabine :1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days.~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions."
3030456|NCT02359162|Active Comparator|EPOCH|"EPOCH:Patients received the EPOCH chemotherapy regimen every 3 weeks. The EPOCH regimen included a 24 h continuous infusion of etoposide (50 mg/m 2 /day), vincristine (0.4 mg/m 2 /day) and doxorubicin(10 mg/m 2 /day administered on days 1-4, followed by cyclophosphamide (750 mg/m2 /day) over 15 min intravenously on day 5 and prednisone (60 mg/m 2 /day) on days1- 5 orally.~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions."
3030457|NCT02359149|Experimental|nurse|intravitreal injections with anti-VEGF agents given by a nurse
3030458|NCT02359149|Active Comparator|physician|intravitreal injections with anti-VEGF agents given by a physician
3030459|NCT02359136|Placebo Comparator|LIA placebo|local infiltration anesthesia using saline i addition to multimodal analgesic regimen
3030460|NCT02359136|Experimental|LIA Ropivacaine|local infiltration anesthesia using Ropivacaine and Epinephrine i addition to multimodal analgesic regimen
3030461|NCT02359123|Experimental|Cannabics 5mg|Patients will be treated initially for 3-4 days with 1x5mg Cannabics capsules per day for gradual adaptation. From the 5th day, patients will be treated 2x5mg capsules per 24 hours for a period of 3 months. However, since some patients may suffer from side effects mainly, dizziness and or anxiety, dosage for these patients will be reduced to 5mg per day.
3030462|NCT02359110|Experimental|Drug 1|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
3030463|NCT02359110|Placebo Comparator|Drug 2|Patients will receive Methylcellulose based placebo tab less than 1 hour before surgery.
3030464|NCT02359097|Experimental|Diagnostic (DSC/DCE-CBV, SS-CBV mapping)|Patients receive 2 doses (2nd dose optional) of gadoteridol IV and undergo MRI including DSC or DCE-CBV mapping over approximately 45-60 minutes on day 1. Within 3 days, patients receive 3 doses of ferumoxytol non-stoichiometric magnetite IV and undergo MRI including DSC and SS-CBV mapping after each dose over approximately 90 minutes. Patients undergo MRI without contrast 24 hours after ferumoxytol non-stoichiometric magnetite over approximately 30 minutes. This 3 day series of imaging repeats at different stages of disease and may be performed up to 5 times: prior to surgery, prior to chemoradiation therapy, 4-6 weeks post-chemoradiation therapy, at time of progression on gadolinium MRI per RANO criteria, and again at time of progression (if the previous time of progression showed pseudoprogression).
3030465|NCT02359084|Experimental|Family Navigation|Families will work one-on-one with the navigator who provides off-site support - e.g. home visits or accompanying families to appointments. The goal of FN during the diagnostic evaluation period is to ensure timely completion of the evaluation. The focus of these interactions is to understand the structure and purpose of the evaluation, gather and complete required materials, and address logistic barriers related to the diagnostic visit. The navigator will continue to work with the family after the diagnostic evaluation to access recommended services and support the family's engagement in treatment.
3030466|NCT02359084|Active Comparator|Conventional Care Management|Families will be assigned to a care manager for the diagnostic evaluation and for 100 days thereafter. Consistent with a high quality medical home, the care manager will be responsible to ensure that the referral for the diagnostic evaluation has been made. She is also available for family-initiated support. The care manager will be responsible for ensuring that referrals are made and continue to provide family-initiated, clinic-based support to families for up to 100 days after the completion of diagnostic evaluation.
3030467|NCT02359071||Handovers with lower durations|equal or lower than 20 minutes
3030468|NCT02359071||handovers with higher durations|Higher than 20 minutes
3030469|NCT02359058|Other|Ramucirumab + Capecitabine + Cisplatin|Ramucirumab (8 milligram per kilogram (mg/kg) given intravenously (IV) on days 1 and 8 in combination with 1000 mg/square meter (m^2) capecitabine given orally twice a day on days 1 through 14 and 80 mg/m^2 cisplatin given IV on day 1 of each 21 day cycle (up to 6 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
3030470|NCT02359058|Other|Ramucirumab + S-1 + Cisplatin|Ramucirumab 8 mg/kg given IV on days 1 and 8 of 21 day in combination with 40 mg/m^2 tegafur/gimeracil/oteracil (S-1) given orally twice a day on days 1 through 21 and 60 mg/m^2 cisplatin given IV on day 8 of each 35 day cycle (up to 8 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
3030471|NCT02359058|Other|Ramucirumab + S-1 + Oxaliplatin|Ramucirumab 8 mg/kg given IV on days 1 and 8 in combination with 40 mg/m^2 S-1 given orally twice a day on days 1 through 14 and 100 mg/m^2 oxaliplatin given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3030472|NCT02359045|Experimental|Part 1: Treatment A-B-C-D|Subjects received a single dose of D1400147 (Treatment A: Omega-3-carboxylic acids 2000 mg uncoated capsules), D14000136 (Treatment B: Omega-3-carboxylic acids 2000 mg coated capsules coat 1), D14000137 (Treatment C: Omega-3-carboxylic acids 2000 mg coated capsules coat 2) and Epanova® (Treatment D: Epanova capsules 1000 mg) under fasted condition.
3030473|NCT02359045|Experimental|Part 2: Treatment A-B/C-D|Subjects received a single dose of D1400147 (Treatment A: Omega-3-carboxylic acids 2000 mg uncoated capsules), D14000136 (Treatment B: Omega-3-carboxylic acids 2000 mg coated capsules coat 1) or D14000137 (Treatment C: Omega-3-carboxylic acids 2000 mg coated capsules coat 2) and Epanova® (Treatment D: Epanova capsules 1000 mg) under fed condition.
3030474|NCT02359032|Experimental|Part 1: ASP6858 single ascending dose|ASP6858 arm
3030475|NCT02359032|Placebo Comparator|Part 1: Placebo single ascending dose|Placebo arm
3030476|NCT02359032|Experimental|Part 1: ASP6858 single ascending dose (fasting cohort)|ASP6858 arm
3030477|NCT02359032|Experimental|Part 2, Sequence 1: ASP6858 multiple ascending dose & placebo|ASP6858 and placebo arm
3030478|NCT02359032|Experimental|Part 2, Sequence 2: ASP6858 multiple ascending dose & placebo|ASP6858 and placebo arm
3030479|NCT02359019|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
3030480|NCT02359006|Active Comparator|minocycline|200mg minocycline
3030481|NCT02359006|Placebo Comparator|Placebo|Sugar pill
3030482|NCT02358993|Experimental|Methenamine|Methenamine hippurate is a medication that exhibits antibacterial activity by converting to formaldehyde in the presence of acidic urine. It is currently FDA approved for the prophylaxis of recurrent urinary tract infections. It has been previously used in studies for prevention of UTI after gynecologic surgery. Dosage will be methenamine hippurate 1g, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.
3030483|NCT02358993|Active Comparator|Ciprofloxacin|Ciprofloxacin is a commonly used antibiotic commonly used for prevention of UTI after catheterization. It belongs to a class of antibiotics known as the fluoroquinolones. Dosage will be ciprofloxacin 500 mg, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.
3030484|NCT02358980||Study group|Participants will receive FLC removal HD undertaken using an extended dialysis schedule on KIDNEY therapy system. Treatments (4 hours each) were carried out for 8 consecutive days and then every other day.
3030485|NCT02358967|Placebo Comparator|Placebo|Standard renal care + 300 mg placebo daily for 1 year
3030486|NCT02358967|Active Comparator|Treatment|Standard renal care + 300 mg TRF daily for 1 year
3030487|NCT02358954|Experimental|Vestibular Pain interactions|
3030488|NCT02358941|Experimental|Training in a school setting|"A minimum of 30 sessions (45 min.) over at least 12 weeks in the schools of the participants.~Half of the children will be assigned to NF training, the other half to CCT."
3030489|NCT02358941|Experimental|Training in a clinical setting|"A minimum of 30 sessions (45 min.) over approx. 12 weeks at the Department of Child and Adolescent Psychiatry (treatment as usual).~Half of the children will be assigned to NF training, the other half to CCT."
3030490|NCT02358928|Other|Low calorie diet|Calorie-restricted diet is composed of 50% carbohydrate, 15-20% protein and 30-35% fat.
3030491|NCT02358928|Other|Low carbohydrate diet|Carbohydrate-restricted diet is composed of 20% carbohydrates, 35% protein and 45% fat.
3030492|NCT02358915|Experimental|Peri-auricular muscles voluntary contraction training paradigm|The whole training paradigm consists of two steps. At the first step of training, the electrical stimulation (FastStart neuromuscular electrical stimulator) will be applied to facilitate the voluntary contractions of the ear muscles, and the motion of the outer ear in two directions (up/down, forward/backward) will be videotaped and played back to the participants so that they can get real-time visual feedback about their ear movement. At the second step of training, surface EMG electrodes will be placed on the skin around participants' ears. During the training, they are required to move a cursor to a specific target that will randomly appear on the computer screen. The cursor will be controlled by the electrical signal from the contraction of their bilateral peri-auricular muscles. In the computer game, contraction of the left ear muscles will move the cursor to the left side and contraction of your right ear muscles will move the cursor to the right side.
3030493|NCT02358902|Experimental|Group A|tDCS (tDCS - DC stimulator, Neurocom, Germany) / AE Group in which will receive active intervention of aerobic exercise training and active tDCS intervention
3030494|NCT02358902|Experimental|Group B|AE group which will receive active intervention of aerobic exercise and placebo tDCS (tDCS - DC stimulator, Neurocom, Germany)
3030495|NCT02358902|Experimental|Group C|tDCS group which will receive placebo AE and active intervention for tDCS (tDCS - DC stimulator, Neurocom, Germany)
3030496|NCT02358889|Experimental|hI-con1|Patients will receive monthly intravitreal hI-con1 as monotherapy (plus sham injection) for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
3030497|NCT02358889|Experimental|hI-con1 + ranibizumab|Patients will receive monthly intravitreal hI-con1 in combination with intravitreal ranibizumab for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
3030498|NCT02358889|Active Comparator|ranibizumab|Patients will receive monthly intravitreal ranibizumab as monotherapy (plus sham injection) for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
3030499|NCT02358863|Experimental|Chemotherapy|"Standard chemotherapy doublet based on molecular testing using one of the following interventions:~Modified FOLFOX6 Docetaxel/Capecitabine Cisplatin/Irinotecan Cisplatin/Docetaxel IRI/EPI EPI/Docetaxel Irinotecan/Docetaxel Docetaxel"
3030500|NCT02358850|Active Comparator|Tonsillectomy and Norco|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Norco (Hydrocodone and Acetaminophen)
3030501|NCT02358850|Active Comparator|Tonsillectomy and Percocet|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Percocet (Oxycodone and Acetaminophen)
3030502|NCT02358850|Active Comparator|Tonsillectomy and Dilaudid + Tylenol|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Dilaudid (hydromorphone) and Tylenol (Acetaminophen)
3030503|NCT02358837||Conventional Sonography|Conventional Sonography to detect breast lesion
3030504|NCT02358837||Ductosonography Technique|Ductosonography Technique to detect breast lesion
3030505|NCT02358824|Experimental|CKD-828(Fixed Dose Combination)|FDC tablet consisting of Telmisartan 80mg/S-Amlodipine 5mg
3030506|NCT02358824|Active Comparator|Combination Therapy|Coadministration of Telmisartan 80mg and S-amlodipine 5mg
3030507|NCT02358811||Eldery SAOS+|Patients with severe obstructive sleep apnea (AHI>30) 70 years old and more
3030508|NCT02358811||Eldery SAOS-|People without obstructive sleep apnea (AHI<10) 70 years old and more
3030509|NCT02358811||Adult SAOS+|Patients with severe obstructive sleep apnea (AHI>30) 18 < Age < 55 years old
3030510|NCT02358811||Adult SAOS-|People without obstructive sleep apnea (AHI<10) 18 < Age < 55 years old
3030791|NCT02356913|Experimental|Gum C|4 mg nicotine gum; single dose; chewed 30 minutes
3030511|NCT02358798|Experimental|Preschool aged children detected of CF in neonatal period|Preschool aged children detected of Cystic Fibrosis in neonatal period
3030512|NCT02358772||Pre-hospital thrombolysis|Patients with acute ischemic stroke who are cared in a specialized STroke Emergency MObile (STEMO) before admission to the Hospital and receive thrombolytic therapy (either in STEMO or in Hospital).
3030513|NCT02358772||In-hospital thrombolysis|Patients with acute ischemic stroke who receive thrombolytic therapy after admission to an University Hospital.
3030514|NCT02358759|Active Comparator|Giant Oocytes after ICSI|abnormally produced oocyte after ART or Controlled ovarian stimulation. Correction of abnormally fertilized oocytes using nucleus removal.
3030515|NCT02358759|Active Comparator|3PNs zygotes developed after ICSI|Abnormally developed embryos these produced 3PNs. Correction of abnormally fertilized oocytes using nucleus removal.
3030516|NCT02358746|Experimental|combined endo/epicardial approach|combining endocardial scar homogenization with epicardial scar homogenization in the first VT ablation approach
3030517|NCT02358746|Active Comparator|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
3030518|NCT02358733|Experimental|Treatment|Intra-cytoplasmic Morphologically-selected Sperm Injection (IMSI)
3030519|NCT02358733|Active Comparator|Control|Intracytoplasmic sperm injection (ICSI)
3030520|NCT02358720|Experimental|A: single fraction IMRT with 1 x 24 Gy|single fraction IMRT with 1 x 24 Gy on bone metastasis
3030521|NCT02358720|Active Comparator|B: fractionated RT with 10 x 3 Gy|fractionated RT with 10 x 3 Gy on bone metastasis
3030522|NCT02358707|Experimental|phonophoresis in knee osteoarthritis|Ibuprofen phonophoresis in patients with knee osteoarthritis
3030523|NCT02358694|Experimental|Active Treatment Group|Patients who weigh less than 40 Kg will receive 5 g daily (2.5 g PO BID) of Serum-derived bovine immunoglobulin/ protein isolate Patients who weigh 40 Kg or more will receive 10 g daily (5 g PO BID) of Serum-derived bovine immunoglobulin/ protein isolate
3030524|NCT02358694|Placebo Comparator|Placebo Arm|The placebo group will receive a hydrolyzed gelatin protein for next 4 weeks on a daily basis.
3030525|NCT02358681|Experimental|Ketorolac, intranasal|"Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route, single dose.~Placebo, intravenous."
3030526|NCT02358681|Active Comparator|Ketorolac, intravenous|"Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route, single dose.~Placebo, intranasal."
3030527|NCT02358668|Experimental|BTI320 4 grams|three times daily, oral for 16 weeks
3030528|NCT02358668|Experimental|BTI320 8 grams|three times daily, oral for 16 weeks
3030529|NCT02358668|Placebo Comparator|BTI320 matching placebo|2 tablets three times daily, oral for 16 weeks
3030530|NCT02358655|Other|Phase 1: Retrospective Chart Review|Retrospective chart review of all patients who presented to the emergency department (ED) with ECG-documented AF during 1 year prior to study commencement. The main purpose of Phase 1 is to determine if oral anticoagulants were prescribed for eligible AF patients at ED discharge.
3030531|NCT02358655|Other|Phase 2: Low-Intensity Intervention|Low-intensity intervention will be applied in the ED during 6 months, involving physician education, distribution of an AF patient education package, short-term oral anticoagulant prescription, and a follow-up letter to the patient's family physician.
3030532|NCT02358655|Other|Phase 3: High-Intensity Intervention|Phase 3 incorporates the Phase 2 intervention, and adds immediate follow-up (within 48-72 hours) in a community AF clinic run by a nurse/pharmacist who is supervised by a specialist in AF.
3030533|NCT02358642|Experimental|Angiotensin converting enzyme inhibitor|Angiotensin converting enzyme inhibitor (Lisinopril), 2.5mg, nocte, 26 weeks
3030534|NCT02358642|Placebo Comparator|Placebo|Placebo
3030535|NCT02358629|Experimental|Prospective, non-randomized|use the NovaCross™micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of femoropopliteal and infra-popliteal Chronic Total Occlusion (CTO) lesion
3030536|NCT02358616||Former VOICE (MTN-003) participants|Qualitative interviews and focus group discussions conducted on former VOICE participants. All participants to receive interviews.
3030537|NCT02358590|Experimental|HAPA menu-based mini-video|This group will watch mini-videos, which are multi-target menu-based interventions designed to deliver information about vitamin D adherence and its effect on osteoporosis
3030538|NCT02358590|Active Comparator|Standard care|This group will be advised by the treating physician to take vitamin D
3030539|NCT02358577|Experimental|Cycle ergometry|Participants will receive In-bed cycling for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first).
3030540|NCT02358577|Active Comparator|Usual care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization
3030541|NCT02358564|Active Comparator|Healthy Volunteers|Participants will receive a Gastrointestinal Permeability Test, Upper Endoscopy, Rectal Barostat and Infusion of Fats.
3030542|NCT02358564|Experimental|Irritable Bowel Syndrome Patients|Participants will receive a Gastrointestinal Permeability Test, Upper Endoscopy, Rectal Barostat and Infusion of Fats.
3030543|NCT02358551|Other|Axillary vein|Lead Placement Through the Axillary Vein Technique
3030544|NCT02358551|Other|Subclaivan vein|Lead Placement Through the Subclavian Vein Technique
3030545|NCT02358538|Experimental|Ganaxolone|Maximum of 1800 mg/day or 63 mg/kg/day
3030546|NCT02358512|Experimental|Intermittent enteral feeding|The intermittent feeding regimen will consist of six bolus feeds (one bolus every four hours).
3030547|NCT02358512|Active Comparator|Continuous enteral feeding|The continuous feeding regimen consists of the total volume of feed administered over 24 hours.
3030548|NCT02358499|Experimental|Posaconazole Injection|We will give a single dose of intravenous posaconazole and collect blood samples for pharmacokinetics (PK). The study pool will be enriched by selecting participants with known sequence variations. Every effort will be made to balance age and disease state (HSCT vs. non-HSCT).
3030549|NCT02358486|Experimental|Acupuncture|Participants in this group are given 10 times of real acupuncture treatment for 4 weeks.
3030550|NCT02358486|Sham Comparator|Sham acupuncture|Participants in this group are given 10 times of sham acupuncture treatment for 4 weeks.
3030792|NCT02356913|Active Comparator|Nicorette Freshmint|4 mg nicotine gum; single dose; chewed 30 minutes
3030551|NCT02358473|Experimental|mogamulizumab + docetaxel|"Mogamulizumab will be given as monotherapy in a 4-week run-in period. Subjects will then receive up to 6 cycles of mogamulizumab in combination with docetaxel at appropriate intervals.~Subjects may then continue to receive mogamulizumab, at the same dose administered in Cycle 1, once every 3 weeks as monotherapy."
3030552|NCT02358460|Active Comparator|Pressure-limited ventilation|
3030553|NCT02358460|Active Comparator|Volume-targeted ventilation|
3030554|NCT02358447||SPECT/CT before/after navigated TKR|SPECT/CT in patients before and after navigated TKR (assessment of bone tracer uptake, 3D CT component position)
3030555|NCT02358447||SPECT/CT before/after conventional TKR|SPECT/CT in patients before and after conventional TKR (assessment of bone tracer uptake, 3D CT component position)
3030556|NCT02358421||Initial cohort|Patients at risk of developing OHSS according to the inclusion criteria
3030557|NCT02358395|Experimental|BBI608 puls Sorafenib|
3030558|NCT02358382|No Intervention|Alpha Stat|Standard CPB blood gas management conditions
3030559|NCT02358382|Experimental|pH Stat|pH stat blood gas management conditions.
3030560|NCT02358369|Experimental|13mg Bimatoprost Insert|"13mg Bimatoprost Ocular Inserts (OU)~Note: subjects also self-administer placebo ophthalmic eye drops to both eyes twice a day."
3030561|NCT02358369|Experimental|2.2mg Bimatoprost Insert|"2.2mg Bimatoprost Ocular Inserts (OU)~Note: subjects also self-administer placebo ophthalmic eye drops to both eyes twice a day."
3030562|NCT02358369|Active Comparator|timolol drops|"0.5% timolol ophthalmic solution (OU, BID).~Note: subjects simultaneously wear placebo ocular inserts"
3030563|NCT02358356|Active Comparator|PRRT|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV) on day 1 every 8 weeks for 4 cycles.
3030564|NCT02358356|Active Comparator|CAPTEM|Oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 every 28 day cycle, up to 8 cycles.
3030565|NCT02358356|Experimental|PRRT/CAPTEM|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV) on day 10 every 8 weeks for 4 cycles, with concurrent oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 up to 4 cycles.
3030566|NCT02358343|Active Comparator|Engagement Interview|Subjects will be randomly assigned to engagement interview or a control visit.Trained CBT therapists at each of the three sites will conduct the engagement interview. The session will be aimed at improving the acceptance of the diagnosis of depression by patients and treatment for the same.
3030567|NCT02358343|No Intervention|Control Visit|Subjects will be randomly assigned to engagement interview or a control visit. Individuals assigned to control visit will be scheduled for a follow-up discussion with a member of the research team. During this session, they will be informed of the diagnosis of major depression or dysthymia, the options for treatment available through the clinical trial, and alternatives should they decline participation in the clinical trial.
3030568|NCT02358343|Active Comparator|Cognitive Behavioral Therapy|"The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization.~Individuals will undergo 10 CBT sessions of 60 minutes each, by a trained therapist in the dialysis facility (8 weekly sessions; then every other week x 2). The CBT will be administered while the patient is undergoing HD; however, alternative arrangements will be made upon individual patient's preferences."
3030569|NCT02358343|Active Comparator|Antidepressant Drug Therapy|The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization. Anti-Depressant Drug Therapy will be delivered with sertraline, a selective serotonin reuptake inhibitor, and the dose will be titrated using the Measurement Based Care Protocol.
3030570|NCT02358343|No Intervention|Obsevational Cohort|Subjects who (1) are not willing to participate in the clinical trial and (2) do not find any treatment acceptable outside the clinical trial will be invited to participate in the prospective observational cohort for serial assessment of depressive symptoms.These subjects will only undergo assessment of severity of depressive symptoms at weeks 0, 6, and 12 using QIDS-C.
3030571|NCT02358330||EHR Enhanced Clinic Referral|"A set of standard EHR modifications will be implemented in 18 clinics as part of the MBD (multiple baseline design) experiment.The key new EHR functions that will be implemented and tested are: 1) a modified screen for smoking sta-tus to enhance the identification and documentation of all smokers visiting targeted primary care clinics; 2) a Smoker Registry to track smokers, document their receipt of treatment services, and organize direct-to-consumer communications; 3) a 1-click referral system to evidence-based smoking treat-ment with UW-CTRI case managers; 4) a closed-loop feedback feature to communicate to the clinician the fate of a referral, documenting receipt of the referral and treatment engagement; and 5) EHR-based communication options to inform smokers of treatment resources"
3030572|NCT02358330||Standard care (control) clinics|10 control clinics will also be inducted into the study. These clinics will use existing EHR resources to identify smokers (e.g., the expanded vital signs) and to document their smoking status, and then use the standard paper fax-to-quit methods to refer patients to the Wisconsin Tobacco Quit Line
3030573|NCT02358317|Experimental|Video Game Motor Training|Participants in the treatment group will come to the University of Wisconsin lab for six weeks to train 3-5 days each week under research staff supervision. Each training session will last 30-60 minutes and will include playing our in-house Ninja Training game combined with balance games from the Wii Fit.
3030574|NCT02358317|Active Comparator|Sedentary Video Game Training|Participants randomly assigned to this condition will come to the lab for six weeks to play sedentary video games 3-5 days each week under research staff supervision. Each training session will last 30-60 minutes. Pre-and post assessments will be done identically to the Experimental group.
3030575|NCT02358304|Active Comparator|a:Patients with aggressive CGCG|Patients had been clinically with CGCG and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, size, and site of the lesions , duration of disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received nasal spray calcitonin 200 IU/ day for 3 months after surgical curettage was done.
3030576|NCT02358304|Placebo Comparator|b; Patients with aggressive CGCG|Patients had been clinically with CGCG and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, size, and site of the lesions , duration of disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups . second group received placebo after surgical curettage for 3 months
3030577|NCT02358291|Active Comparator|open discectomy|patients diagnosed as lumbar disc herniation undergoing open simple discectomy(OD)
3030578|NCT02358291|Active Comparator|microendoscopic discectomy|patients diagnosed as lumbar disc herniation undergoing microendoscopic discectomy(MED)
3030579|NCT02358291|Active Comparator|transforaminal endoscopic discectomy|patients diagnosed as lumbar disc herniation undergoing transforaminal endoscopic lumbar discectomy(TELD)
3030580|NCT02358265|Active Comparator|10 mg Rupatadine on demand|Rupatadine 10 mg, on demand
3030581|NCT02358265|Active Comparator|10 mg Rupatadin|Rupatadine 10 mg, continuously
3030582|NCT02358265|Active Comparator|20 mg Rupatadine|Rupatadine 20 mg, continuously
3030583|NCT02358265|Active Comparator|10 mg rupatadine on demand (sham upd.)|Rupatadine 10 mg, on demand (sham updosing to 20 mg)
3030584|NCT02358252||Orthostatic hypotension|"Collection of information of body mass index, modified Ashworth scale, maximal voluntary contraction(MVC), heart rate variability(HRV).~Tilt table test was used in this study to identify if the subjects with or without orthostatic hypotension."
3030585|NCT02358252||Non-orthostatic hypotension|Collection of information of body mass index, modified Ashworth scale, maximal voluntary contraction(MVC), heart rate variability(HRV) Tilt table test was used in this study to identify if the subjects with or without orthostatic hypotension.
3030586|NCT02358239|Experimental|Efficacy and safety of acupuncture for dizziness and vertigo|To evaluate the efficacy and safety of acupuncture in treating patients with dizziness and vertigo in ED.
3030587|NCT02358226|Experimental|Soccer League (SL)|In the SL arm, participants will be invited to participate in a Soccer League, led by coaches who meet the criteria of: 1) soccer skills, 2) being a role model, and 3) social competence. Coaches will undergo intensive training in ethics; role-playing the delivery of health messages; conducting brief interventions for alcohol; how to acquire information on HIV, TB, alcohol use and employment; linkages to local clinics, data collection; and Street Smart, an evidence-based intervention for high-risk youth. Coaches will provide pre- and post-game talks, incorporating the topics of alcohol and drugs; interacting positively with health care providers, partners and family members; HIV, diabetes; daily routines; healthy social networks; making and saving money; loyalty and national success.
3030588|NCT02358226|Experimental|Soccer League/Vocational Training (SL-V)|The SL-V arm will include both the SL intervention as well as access to Vocational Training through either Silulo Ulutho Technologies, which offers computer courses, or Zenzele Training and Development programs, which provides training in woodwork and wielding. Both programs are located in Khayelitsha, which is close to participants' homes, thus avoiding transport-related barriers. Additionally, the training programs occur in a mentor-mentee context so that participants can develop the interpersonal skills required for employment.
3030589|NCT02358226|No Intervention|Control Condition (CC)|Participants in the CC arm will routinely receive flyers with picture stories regarding HIV prevention strategies and how to access these strategies: HIV testing, circumcision, HIV treatment, including ARV, condoms and sexually transmitted diseases.
3030590|NCT02358213|Other|Procedure|5 ultrasounds were done on 20 patients by 5 different sonographers
3030591|NCT02358200|Experimental|Treatment|BMN-673: Oral, every day, Days 1-21; Carboplatin: intravenous, every week, 750 μg/day; Paclitaxel: intravenous, every week, 0.75 x Maximum Tolerated Dose μg/day
3030592|NCT02358187|Experimental|HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC|All subjects will receive vaccine plus Poly-ICLC. Injections will be given every 3 week for a total of 8 vaccines.
3030593|NCT02358174|Experimental|Group I|Patients with symptomatic hemorrhoids - Grade I to IV sec. Goligher. Grade III to IV underwent Hemorrhoidectomy. Blood sampling for MMPs and NGAL plasma levels evaluation will be performed. Tissue sampling (obtained during hemorrhoidectomy) for MMPs and NGAL tissue levels evaluation will be performed in grade III-IV patients.
3030594|NCT02358174|Experimental|Group II|Healthy subjects without hemorrhoids as control groups for MMPs and NGAL plasma evaluation will be performed by means of Blood sampling.
3030595|NCT02358161|Experimental|LDE225|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer.
3030596|NCT02358148||STEMI / NSTEMI|All patients (100%) admitted to the participating hospitals during the study period with the diagnosis of Acute ST Segment Myocardial Infarction (STEMI) or Non-ST Segment Myocardial Infarction (NSTEMI) will be selected for inclusion in the study. In order to assure rapid door-to-reperfusion times, Study Investigators will obtain consent and interview these patients AFTER cardiac catheterization and intervention. A minimum number of 25 STEMI and 25 NSTEMI patients will be enrolled in the study.
3030597|NCT02358148||Elective / Non-emergent Cardiac Cath|This group will include both admitted and outpatients, with possible diagnoses of Unstable Angina (UA), Low Risk Chest Pain (LRCP), and those having cardiac catheterization for any other reason (eg: elective, medical clearance for surgery, failed stress test, etc.). To maintain integrity of the study, these patients will be randomly selected, with written consent obtained, prior to cardiac catheterization.
3030598|NCT02358135|Other|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or ultraviolet therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from primary care practitioners or dermatologists, just as they would in the real world.
3030599|NCT02358135|Experimental|CCH Model|The intervention arm will be the collaborative connected health (CCH) model, which purports to increase access to specialists and improve outcomes. Specifically, CCH offers multiple modalities for patients and primary care providers (PCPs) to access dermatologists online directly and asynchronously. CCH also fosters team care and patient engagement through active sharing of management plans and multidirectional, informed communication among patients, PCPs, and dermatologists.
3030600|NCT02358122|Active Comparator|Refined wheat|Refined wheat grain, a variety of cereal foods providing no wholegrain
3030601|NCT02358122|Experimental|Wholegrain wheat|Wholegrain wheat grain, a variety of cereal foods providing >100g wheat wholegrain/day
3030602|NCT02358122|Experimental|Wholegrain rye|Wholegrain rye grain, a variety of cereal foods providing >100g rye wholegrain/day
3030603|NCT02358109|Experimental|Intervention arm|Intervention group receive directed classes of physical conditioning, 3 hours/week during a period of 16 weeks
3030604|NCT02358109|No Intervention|Control arm|Control group do not receive physical conditioning intervention but usual care advice and are measured at the beginning and at the end of the study
3030605|NCT02358096|Experimental|ASP8232|ASP8232 administered once daily
3030606|NCT02358096|Placebo Comparator|Placebo|Placebo administered once daily
3030607|NCT02358083|No Intervention|Arm 1. HPV + Control + Control|HPV is target vaccine. No message regarding relative safety of vaccine; Provider provides brief routine recommendation for vaccination.
3030608|NCT02358083|Experimental|Arm 2. HPV + Control + Strong|HPV is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination.
3030609|NCT02358083|Experimental|Arm 3. HPV + Control + Disclosure|HPV is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
3030610|NCT02358083|Experimental|Arm 4. HPV + Safety + Control|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides brief routine recommendation for vaccination.
3030611|NCT02358083|Experimental|Arm 5. HPV + Safety + Strong|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination.
3030612|NCT02358083|Experimental|Arm 6. HPV + Safety + Disclosure|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
3030613|NCT02358083|No Intervention|Arm 7. Flu + Control + Control|Flu is target vaccine. No message regarding relative safety of vaccine; Provider provides brief routine recommendation for vaccination.
3030614|NCT02358083|Experimental|Arm 8. Flu + Control + Strong|Flu is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination.
3030615|NCT02358083|Experimental|Arm 9. Flu + Control + Disclosure|Flu is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
3030616|NCT02358083|Experimental|Arm 10. Flu + Safety + Control|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides brief routine recommendation for vaccination.
3030617|NCT02358083|Experimental|Arm 11. Flu + Safety + Strong|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination.
3030618|NCT02358083|Experimental|Arm 12. Flu + Safety + Disclosure|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
3030619|NCT02358070||HCC group|
3030620|NCT02358070||control group|
3030621|NCT02358057|Experimental|Dexmedetomidine and Alfentanil|"Patients included in the study will receive an injection of dexmedetomidine via a TIVA Injectomat Agilia, specially programmed for the injection of dexmedetomidine.~At time zero, the patient will receive a bolus 1 mcg/ kg of dexmedetomidine during 10 minutes.~Patients over 65 years will receive a bolus of 0.5 mcg/kg of dexmedetomidine during 10 minutes.~Afterwards, the patient will receive a continuous injection of 0.6 mcg/kg/h of dexmedetomidine~Patients will also receive a dose of alfentanil 1 mcg /kg, 1 minute before the technical act.~A new alfentanil dose of 0.5 mcg / kg may be injected if pain reported by the patient corresponds to an EN > 50.~The maximum dose of alfentanil the patient can receive is 5 mcg / kg."
3030622|NCT02358044|Experimental|Grazoprevir + Elbasvir|Participants receive a fixed-dose combination (FDC) tablet of 100 mg grazoprevir and 50 mg elbasvir for 12 weeks, followed by 24 weeks of follow-up.
3030623|NCT02358044|Active Comparator|SOF + PR|Participants receive SOF (400 mg) combined with PegIntron (1.5 mcg/kg) plus RBV (1000-1200 mg weight-based dose) for 12 weeks, followed by 24 weeks of follow-up.
3030624|NCT02358031|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg, intravenously (IV) on Day 1 of each week in 3-week cycles for up to 24 months.
3030625|NCT02358031|Experimental|Pembrolizumab + Platinum + 5-FU|Participants receive pembrolizumab 200 mg, intravenously (IV) on Day 1 of each week in 3-week cycles for up to 24 months; plus cisplatin 100 mg/m^2 IV or carboplatin AUC 5 IV (Investigator's choice) on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 1000 mg/m^2/day IV continuous from Day 1-4 of each 3- week cycle (6 cycle maximum).
3030626|NCT02358031|Active Comparator|Cetuximab + Platinum + 5FU|Participants receive cetuximab on Day 1 at a dose of 400 mg/m^2 IV, and then 250 mg/m^2 IV on Day 1 of each week until disease progression or unacceptable toxicity; plus cisplatin 100 mg/m^2 IV or carboplatin AUC 5 IV (Investigator's choice) on Day 1 of each week in 3-week cycles (6 cycle maximum for platinum-based therapy); plus 5-FU 1000 mg/m^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum).
3030627|NCT02358005|Experimental|60mJ ESWT|ESWT (0.04 mJ/mm2, 1500 shock + sham stimulation 2500) / total dose per treatment : 60mJ
3030628|NCT02358005|Experimental|120mJ ESWT|ESWT (0.04 mJ/mm2, 4000 shock) / total dose per treatment : 160mJ
3030629|NCT02358005|Placebo Comparator|sham ESWT stimulation|ESWT (0 mJ/mm2, sham stimulation 4000) / total dose per treatment : 0mJ
3030630|NCT02357992|Experimental|Stereotactic Radiotherapy (SRT)|"Participants receive stereotactic body radiotherapy (SABR) once a day for 3-4 days in a row.~50Gy delivered in 4 fractions for central tumor, or 54Gy delivered in 3 fractions for peripheral tumor."
3030631|NCT02357979|Experimental|Laser & Fluoride|In the split mouth design the molar on one side of the mouth receives the intervention CO2 9.3 μm short pulsed laser treatment and fluoride varnish (experimental side) in the occlusal fissure areas.
3030632|NCT02357979|Active Comparator|Fluoride alone|In the split mouth design this arm (this side in the mouth - the contralateral tooth to the experimental site in the same jaw) will receive only fluoride varnish treatment. In the split mouth design this opposite side of the jaw is functioning as control.
3030633|NCT02357966|Experimental|514G3|Phase I of the study will include a single dose of 514G3 at three different dose levels. Phase II utilizes a single dose of 514G3 at the highest dose level. Standard antibiotic therapies will be used in both phases.
3030936|NCT02355795|Experimental|low-fat diet|Participants will be provided low-fat diet for 6 months
3030634|NCT02357966|Placebo Comparator|Placebo|Both Phase I and II will include a single dose of placebo in addition to standard antibiotic therapies.
3030635|NCT02357940|Experimental|Adult Tolerance Assessment|Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
3030636|NCT02357940|Experimental|Baby (infants, toddlers, young children) Tolerance Assessment|Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
3030637|NCT02357927|Placebo Comparator|control|simple general telephone call
3030638|NCT02357927|Experimental|Mini-AFTERc Intervention|20-30 minute structured conversation with breast cancer patient using Mini-AFTERc Manual
3030639|NCT02357914||Individuals with paraplegia|Individuals with a spinal cord injury below T1
3030640|NCT02357901|Experimental|RBP-6000 300mg/100mg|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given RBP-6000 300 mg injections on Days 1 and 29. Injections 3-6 are separated by 28 days (Day 57-Day 141) and contain RBP-6000 100 mg.~In addition, participants received individual drug counseling (IDC) at least once a week."
3030641|NCT02357901|Experimental|RBP-6000 300mg/300mg|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given six RBP-6000 300 mg injections on Days 1 to 141 with injections separated by 28 days.~In addition, participants received individual drug counseling (IDC) at least once a week."
3030642|NCT02357901|Placebo Comparator|Placebo Matching 300 mg/100 mg RBP-6000|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given placebo injections on Days 1 and 29 (matching the RBP-6000 300 mg dose volume). Injections 3-6 are separated by 28 days (Day 57-Day 141) and also contain placebo (matching the RBP-6000 100 mg volume).~In addition, participants received individual drug counseling (IDC) at least once a week."
3030643|NCT02357901|Placebo Comparator|Placebo Matching 300 mg RBP-6000|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given six placebo injections (volume-matched to RBP-6000 300 mg dose) on Days 1 to 141 with injections separated by 28 days.~In addition, participants received individual drug counseling (IDC) at least once a week."
3030644|NCT02357888|Experimental|Sequence 1|Treatment group sequence: Test Product on Day 1 and Placebo on Day 2
3030645|NCT02357888|Experimental|Sequence 2|Treatment group sequence: Placebo on Day 1 and Test Product on Day 2
3030646|NCT02357862||Mitral Valve Annuloplasty|All eligible patients
3030647|NCT02357849|Active Comparator|Aripiprazole|To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (2mg wk1, 5mg wk2, 10mg wk3, 5-30 mg wk4-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need (5-30mg).
3030648|NCT02357849|Active Comparator|Fluoxetine|To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (5mg wk1, 10mg wk2, 20mg wk3, 10-60mg wk3-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need(10-60mg).
3030649|NCT02357836|Other|Itraconazole|600 mg twice daily for 10-14 days
3030650|NCT02357823||Group 1|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 2 PCV13 doses received from more than 3 years that have prescription for a single booster dose of PCV13.
3030651|NCT02357823||Group 2|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 1 PPV23 dose received from more than 3 years that have prescription to receive 2 doses (priming + boost) of PCV13.
3030652|NCT02357823||Group 3|HIV- positive adults that have never received a pneumococcal vaccine (naive) and have a CD4+ cell count < 200 cells/ul that have prescription to be primed with a single dose of PCV13 then boosted with a single dose of PPV23.
3030653|NCT02357823||Group 4|Immunological and microbiological status of HIV- positive adults that have never received a pneumococcal vaccine (naive) and have a CD4+ cell count > 200 cells/ul that have prescription to be primed with a single dose of PCV13 then boosted with a single dose of PPV23.
3030654|NCT02357823||Group 5|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 1 PPV23 dose received from more than 3 years and that that have prescription to receive a single dose of PCV13.
3030655|NCT02357810|Experimental|Treatment (pazopanib hydrochloride, topotecan hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28 and topotecan hydrochloride PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3030656|NCT02357797|Active Comparator|Vortioxetine|Vortioxetine will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of vortioxetine can be lowered to 10 mg for tolerability reasons.
3030657|NCT02357797|Placebo Comparator|Placebo|Matching placebo pills will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of placebo can be lowered to 10 mg for tolerability reasons.
3031020|NCT02355119|Experimental|FOLFOXIRI|
3030658|NCT02357784|Experimental|Current Perception Threshold Testing|The subjects in this study will undergo Current Perception Threshold Testing and fill out several questionnaires both before their Sacral Nerve Modulator device implantation and again 3 months after the device implantation.
3030659|NCT02357771|Placebo Comparator|Placebo Arm|Placebo Lozenges (4 Lozenges per day; 2 lozenges in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
3030660|NCT02357771|Experimental|Probiotic Arm|Lactobacillus brevis CD2 Lozenges (4 Lozenges per day; 2 lozenges in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
3030661|NCT02357758|Active Comparator|Antibiotic Prophylaxis|Patients with RUTI receiving Septra (Trimethoprim dose 2mg/kg) or nitrofurantoin (dose 2 mg/kg) as determined by clinician.
3030662|NCT02357758|No Intervention|Healthy Population|
3030663|NCT02357758|No Intervention|Clinical Observation|Patients experiencing RUTI that do not require antibiotic prophylaxis as determined by clinician.
3030664|NCT02357745||Pre-menopausal with periodontitis|non surgical periodontal therapy ( scaling and root planing)
3030665|NCT02357745||Post-menopausal with periodontitis|non surgical periodontal therapy ( scaling and root planing)
3030666|NCT02357732|Experimental|Nivolumab and Dabrafenib Combination (doublets)|Level -1, Nivolumab 1mg/kg IV every 2 weeks (q2 weeks); Dabrafenib 100mg by mouth (PO) twice a day(BID) every day (QD); Level 1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Dabrafenib 150mg PO BID QD;
3030667|NCT02357732|Experimental|Nivolumab and Trametinib Combination (doublets)|Level -1, Nivolumab 1mg/kg IV q2 weeks; Trametinib 1mg PO QD; Level 1, Nivolumab 1mg/kg IV q2 weeks; Trametinib 2mg PO QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Trametinib 2mg PO QD;
3030668|NCT02357732|Experimental|Nivolumab, Dabrafenib and Trametinib Combination (triplet)|Level -1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 1mg PO QD; Level 1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 2mg PO QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 2mg PO QD;
3030669|NCT02357719|Experimental|VistaO2 FLUX device|This device combines the transcutaneous oxyhemoglobin saturation (allowing to compute the oxyhemoglobin desaturation index), the slow variations in heart rate, the nasal flow and an index of nocturnal respiratory events calculated by analyzing the movements of the chest performed by chest impedance variations.
3030670|NCT02357706|Active Comparator|Group 1|Patients will be randomised to either Group 1 or Group 2. Patients in this group (group 1) will use APAP A on the first night of the evaluation, and APAP B on the second night.
3030671|NCT02357706|Active Comparator|Group 2|Patients will be randomised to either Group 1 or Group 2. Patients in this group (group 2) will use APAP B on the first night of the evaluation and APAP A on the second night.
3030672|NCT02357693|Experimental|aprepitant|aprepitant 80 mg one hour before surgery
3030673|NCT02357693|Placebo Comparator|placebo|oral placebo one hour before surgery
3030674|NCT02357680|Experimental|Intervention group|"Relatives randomized to the intervention group is provied with a diary. Nurses advice relatives on how to write and use the diary under and after the patients stay in the ICU. A written description on how to use the diary is also provided.~At least two photographs of the patient is taken by nurses. Photographs will first be included in the diary when full consent from the patient has been obtained.~Patients and relatives recieve a questionaire 3 months after the patient has been dismissed from the ICU."
3030675|NCT02357680|No Intervention|Control group|Standard Care. Patients and relatives recieve a questionaire 3 months after the patient has been dismissed from the ICU.
3030676|NCT02357667||Exposed cases|African American women with concern for severe preterm (37 weeks gestation) preeclampsia who are admitted to the inpatient obstetrical unit at HUP.
3030677|NCT02357667||Unexposed controls|African American women without preeclampsia or medical comorbidity who are matched by gestational age, maternal age, and BMI in the outpatient setting.
3030678|NCT02357654|Experimental|GnRH agonist|
3030679|NCT02357654|Placebo Comparator|Placebo|
3030680|NCT02357641||Patients with thoracal disorder|"300 patients with thoracal disorder, cardiac or non- cardiac, are enrolled prospectively to undergo routinely examinations such as clinical and hemodynamic chemistry as well as echocardiography for strain analysis refering to myocardial deformation.~Especially analysis of strain data (circumferential and radial), regional and global left and right ventricular wall movement data and diastolic parameters will be analysed retrospectively to investigate a probable cut off value corresponding to acute coronary disease or non cardiac disorder (Intervention: retrospective echographic myocardial strain analysis refering to acute coronary syndrome)."
3030681|NCT02357628||Research Group I|Wound treatment with RO-NPT 40%
3030682|NCT02357628||Research Group II|Wound treatment with RO-NPT 60%
3030683|NCT02357628||Research Group III|Wound treatment with RO-NPT 40% and irrigation
3030684|NCT02357615|Experimental|nifedipine CR tablets (Xin Ran)|Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 8-week treatment period.
3030685|NCT02357615|Active Comparator|nifedipine CR tablets (Adalat)|Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 8-week treatment period.
3030686|NCT02357602|Experimental|1. GS-7340 25mg|The first 8 women on study will be assigned to take a single dose of 25mg TAF (1 tablet) orally.
3030687|NCT02357602|Experimental|2. GS-7340 10mg|The 2nd group of 8 women will be sequentially assigned to take a single dose of 10mg TAF (1 tablet) orally.
3030688|NCT02357602|Experimental|3. GS-7340 5mg|The final 8 women on study will be sequentially assigned to take a single dose of 5mg TAF (1/2 tablet) orally.
3030689|NCT02357589|Active Comparator|2D laparoscopic cholecystectomy|The normal laparoscopic cholecystectomy with two dimensional view
3030690|NCT02357589|Experimental|3D laparoscopic cholecystectomy|The normal laparoscopic cholecystectomy with three dimensional view
3030691|NCT02357576|Experimental|Reduced Lipid|Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
3030692|NCT02357576|Active Comparator|Standard Lipid|Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
3030693|NCT02357563|Experimental|Ulipristal acetate|Women will be treated with an oral dose of ulipristal acetate 5 mg/day for 2 courses of 3 months each
3030694|NCT02357563|Active Comparator|Leuprolile acetate|Women will be treated with an injection IM on leuprolide acetate 11,25 in the luteal phase repeated 3 months later
3030695|NCT02357550|Placebo Comparator|Control|Saline infusion. FDG-PET Scan. O2-PET scan. H2O-PET scan Muscle biopsy
3030696|NCT02357550|Experimental|Hyperketonaemia|Ketone infusion. FDG-PET Scan. O2-PET scan. H2O-PET scan Muscle biopsy
3030697|NCT02357537|Active Comparator|Traditional|"Subjects in Study Arm 1 will undergo a screening process, and if randomized, will follow a traditional, site-based clinical trial model and undergo a baseline visit and 3 more in-person visits with the Principal Investigator (total of 4 visits).~Subjects in each Study Arm will be randomized (2:1) to follow one of two dietary regimens during the study: the Combined Anti-Inflammatory Diet (CAID) or Control (standard nutritional advice)."
3030698|NCT02357537|Active Comparator|Remote|"Subjects in Study Arm 2 will undergo a screening process, and if randomized, will undergo one Baseline visit at the local Gastroenterologist's office and 4 video visits with the Principal Investigator. A mobile nurse will visit subjects at a distant location (such as their home) to obtain blood samples at visits 1 and 4.~Subjects in each Study Arm will be randomized (2:1) to follow one of two dietary regimens during the study: the Combined Anti-Inflammatory Diet (CAID) or Control (standard nutritional advice)."
3030699|NCT02357524|Experimental|Oritavancin|Subject will receive a single oritavancin dose of 1200 mg in 1000 mL of D5W administered as a constant rate IV infusion over 3 hours via a single dedicated peripheral venous line.
3030700|NCT02357511|Experimental|Study goup|Vital values are being measured for the time of two hours at postoperative setting at postanesthesia care unit. A novel method is compared to golden standard: invasive measurement. Also Saturation measurements are being compared between standard and study monitor.
3030701|NCT02357498|Active Comparator|microscopic|Microscopic transsphenoidal surgery, including endoscopic-assisted approach (350 subjects)
3030702|NCT02357498|Active Comparator|endoscopic|Fully endoscopic transsphenoidal surgery (350 subjects)
3030703|NCT02357485|Experimental|Treatment arm|Single injection of ADSC
3030704|NCT02357472|Experimental|High dose group|dehydroepiandrosterone,DHEA,capsule, 50mg/capsule, one capsule t.i.d..
3030705|NCT02357472|Experimental|Standard dose group|dehydroepiandrosterone,DHEA, capsule, 25mg/capsule, one capsule t.i.d.
3030706|NCT02357459|Experimental|FX006 32mg|Single 5 mL intra-articular (IA) injection Extended-release Formulation
3030707|NCT02357459|Placebo Comparator|Normal Saline|Single 5 mL intra-articular (IA) injection
3030708|NCT02357459|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection TCA IR 40 mg: Immediate-release formulation
3030709|NCT02357433|Experimental|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization
3030710|NCT02357433|No Intervention|Control Group|Standard practice
3030711|NCT02357420|Active Comparator|RM-131|RM-131 - also known as relamorelin
3030712|NCT02357420|Placebo Comparator|Placebo|
3030713|NCT02357407|Experimental|Patients in intensive care|30 patients in intensive care treated with ciprofloxacin IV
3030714|NCT02357407|Experimental|Osteoarticular infected patients|30 patients in orthopedics treated with oral ofloxacin
3030715|NCT02357381||TMS Treatment|TMS( transcranial magnetic stimulation) -treatment for headache
3030716|NCT02357368|Experimental|Depot medroxyprogesterone acetate (DMPA)|DMPA will be administered every 12 weeks at 150 mg IM at week 3 of study enrollment and repeated at week 15.
3030717|NCT02357368|Experimental|Etonogestrel impant (Eng-Implant)|A standard Nexplanon rod Implant will be placed at study week 3.
3030718|NCT02357368|Experimental|Levonorgestrel intrauterine device (Lng-IUD)|A standard Mirena IUD will be placed at study week 3.
3030719|NCT02357368|Experimental|ParaGard® T 380A Intrauterine Copper Contraceptive|A standard ParaGuard IUD will be placed at study week 3.
3030720|NCT02357355|Active Comparator|CMT 1A Group|Patients with CMT 1A will undergo a driving simulation study. The intervention will be the SIREN driving simulator.
3030721|NCT02357355|Active Comparator|Control Group|Patients without CMT 1A who are our normal controls will undergo a driving simulation study. The intervention will be the SIREN driving simulator.
3030722|NCT02357342|Experimental|Sirolimus|Intravitreal Sirolimus
3030723|NCT02357342|Active Comparator|Standard of Care intravitreal anti-VEGF|anti-VEGF intravitreal injections
3030724|NCT02357329||Taste and hedonic ratings of NEFA|Linoleic acid solutions from 0.005% to 1.58%. Participants swish and spit 10 - 7.5mL solutions.
3030725|NCT02357316||All participants|All individuals visiting the museum who want to participate and sign a consent form.
3030726|NCT02357303|Placebo Comparator|Placebo|Group A - 100mL of water by mouth, 15 to 30 minutes before endoscopy
3030727|NCT02357303|Active Comparator|Simethicone|Group B - 100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
3030728|NCT02357303|Active Comparator|Simethicone plus N-acetylcysteine|Group C - 100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
3030729|NCT02357290|Experimental|Open-label Treatment with NAC|"12-week, open-label treatment with NAC. Subjects will be treated with the following dose:~Subjects ages 5-12:~Week 1: 900mg po daily Weeks 2+: 900mg po QAM, 900mg po QPM~Subjects ages 13-17:~Week 1: 900mg po daily Weeks 2-3: 900mg po QAM, 900mg po QPM Weeks 4+: 1800mg po QAM, 900mg po QPM~In Weeks 3-12 for subjects ages 13-17, we will encourage twice per day dosing, but we will permit daily dosing if needed for adherence."
3030730|NCT02357277|Experimental|Budesonide 360 mcg|Budesonide dry powder inhaler 2 puffs of 90 mcg twice daily for 4 weeks
3030731|NCT02357277|Experimental|Budesonide 720 mcg|Budesonide dry powder inhaler 2 puffs of 180 mcg twice daily for 4 weeks
3030732|NCT02357277|Placebo Comparator|Placebo|Placebo inhaler 2 puffs twice daily for 4 weeks
3030733|NCT02357264||pre-eclampsia|Ultrasound of Pregnant Females 18+ with pre-Eclampsia
3030734|NCT02357264||No pre-eclampsia.|Ultrasound of Pregnant Females 18+ with no pre-eclampsia
3030735|NCT02357251|Active Comparator|Enhanced recovery protocol|Aspects of perioperative care will be standardized. Specific protocol for pre-operative, intra-operative, and post-operative care will be followed in this group.
3030822|NCT02356679|Experimental|Eupasidin-s tab.|three times per day, 1 tab for each time, PO, during 2weeks
3030736|NCT02357251|No Intervention|Standard of care|Treating physicians will determine all aspects of patients' perioperative care. Specifically, the individual surgeon, nurse, resident, fellow, and anesthesiologist caring for the patient will determine the patients' pre-operative counseling, bowel preparation, postoperative nausea and vomiting prophylaxis, IV fluid replacement, use of drains, timing of urinary catheter removal, mobilization, post-operative nutrition, pain medication, and bowel stimulation.
3030737|NCT02357238||Uveitis|Uveitis or infectious uveitis patients
3030738|NCT02357225|Experimental|Acute Dose of Pyridostigmine|Subjects will receive an acute administration of pyridostigmine bromide, calculated on their body weight at clinical exam (1 mg/kg, 60mg max starting dose), and will be monitored for 2 hours post administration. Subjects will also receive a pre- and post-administration single-fiber EMG, respiratory tests and strength tests in order to evaluate the function of the neuromuscular junction. All study subjects will be enrolled in this arm.
3030739|NCT02357225|Experimental|Prolonged Use of Pyridostigmine|This arm will evaluate the impact of pyridostigmine bromide on respiratory and skeletal muscle function during a 90-day administration period. On Days 1 - 7 subjects will receive 0.5mg/kg of the study drug every 4 hours while awake. On Days 8 - 90 subjects will receive 1.0 mg/kg every 4 hours while awake. Quality of life will also be measured with the SF-36 health survey. Data collection will occur at multiple time points (Days 30 and 90) throughout the study. Subjects will also be contacted at least weekly via telephone. All study subjects will be enrolled in this arm.
3030740|NCT02357212|Other|Early Invasive|Patients assigned to an early invasive strategy will undergo coronary angiography within 48 hours and have percutaneous coronary intervention or coronary artery bypass grafting performed as soon as possible during the initial hospitalization if deemed appropriate.
3030741|NCT02357212|Other|Conservative management|Patients assigned to conservative management will be treated with anti-anginal medications, aspirin, clopidogrel, atorvastatin, and other guideline recommended medicines. Patients will have an echocardiogram and adenosine stress testing
3030742|NCT02357199|Experimental|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
3030743|NCT02357199|No Intervention|Standard oral care|Standard oral care protocol consisting of referral by staff in the Department of Nephrology to general dental practitioner followed by patient self-administration of tooth brushing, fluoride toothpaste and oral lubricants.
3030744|NCT02357173|Active Comparator|cigarette group|This group (1/3 of the sample) will not receive electronic cigarettes to sample and will continue smoking their regular cigarettes as much or as little as they would like.
3030745|NCT02357173|Experimental|electronic cigarette|This group (2/3 of the sample) will be given electronic cigarettes for a 3-week period, to use as much or as little as they would like.
3030746|NCT02357160|Experimental|Choice|Patients given choice over artwork on wall
3030747|NCT02357160|Active Comparator|No choice|Patients not given choice over artwork on wall
3030748|NCT02357160|Placebo Comparator|No artwork|Patients not receiving any artwork on wall
3030749|NCT02357147|Experimental|Arm 1|"Combination Phase - Amatuximab + Pemetrexed and Cisplatin~Maintenance Phase - Amatuximab"
3030750|NCT02357147|Experimental|Arm 2|"Combination Phase - Placebo + Pemetrexed and Cisplatin~Maintenance Phase - Placebo"
3030751|NCT02357134|Experimental|Structured Exercise with High Flow Oxygen|"After screening, participants perform a cycle test using a stationary bicycle. Participants pedal with no resistance for 60 seconds. Participants perform the cycle test without receiving any air or oxygen for as long as they can. After a 2 hour rest, participant performs the cycle test again using low-flow air for as long as they can.~About 3 days after baseline cycle test, second cycle test performed using high flow oxygen.~Four symptom questionnaires completed at screening and after the second cycle test. This should take about 40 minutes to complete."
3030752|NCT02357134|Experimental|Structured Exercise with High Flow Air|"After screening, participants perform a cycle test using a stationary bicycle. Participants pedal with no resistance for 60 seconds. Participants perform the cycle test without receiving any air or oxygen for as long as they can. After a 2 hour rest, participant performs the cycle test again using low-flow air for as long as they can.~About 3 days after baseline cycle test, second cycle test performed using high flow air.~Four symptom questionnaires completed at screening and after the second cycle test. This should take about 40 minutes to complete."
3030753|NCT02357134|Experimental|Structured Exercise with Low Flow Oxygen|"After screening, participants perform a cycle test using a stationary bicycle. Participants pedal with no resistance for 60 seconds. Participants perform the cycle test without receiving any air or oxygen for as long as they can. After a 2 hour rest, participant performs the cycle test again using low-flow air for as long as they can.~About 3 days after baseline cycle test, second cycle test performed using low flow oxygen.~Four symptom questionnaires completed at screening and after the second cycle test. This should take about 40 minutes to complete."
3030754|NCT02357134|Experimental|Structured Exercise with Low Flow Air|"After screening, participants perform a cycle test using a stationary bicycle. Participants pedal with no resistance for 60 seconds. Participants perform the cycle test without receiving any air or oxygen for as long as they can. After a 2 hour rest, participant performs the cycle test again using low-flow air for as long as they can.~About 3 days after baseline cycle test, second cycle test performed using low flow air.~Four symptom questionnaires completed at screening and after the second cycle test. This should take about 40 minutes to complete."
3030755|NCT02357121|Experimental|Laser ablation|All patient will undergo focal ablation of prostate tissue utilizing laser energy.
3030756|NCT02357108|Active Comparator|Group 1: Video/Doctor Sequence 1|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
3030757|NCT02357108|Active Comparator|Group 2: Video/Doctor Sequence 2|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
3030758|NCT02357108|Active Comparator|Group 3: Video/Doctor Sequence 3|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
3030759|NCT02357108|Active Comparator|Group 4: Video/Doctor Sequence 4|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
3030760|NCT02357095|Experimental|hysteroscopic monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under hysteroscopic monitoring.The brand of hysteroscope machine is STORZ.
3030761|NCT02357095|Experimental|ultrasonography monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under ultrasonography monitoring.The brand of ultrasonograph is mindray(Z6).
3030762|NCT02357095|Experimental|no monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under no monitoring
3030763|NCT02357082||MRI Scan|Patients with a previously implanted Cardiac Implantable Electronic Device who are undergoing an MRI Scan for clinically indicated, diagnostic purposes.
3030764|NCT02357069|Experimental|LBEC0101|Etanercept
3030765|NCT02357069|Active Comparator|Enbrel|Etanercept
3030766|NCT02357056|Active Comparator|Wet Lab|Subjects in the wet lab group will perform dissections of the internal thoracic artery and placement of annuloplasty stitches in the mitral valve in pig models until time proficiency is reached based on the performance of our expert robotic surgeons.
3030767|NCT02357056|Active Comparator|Dry Lab|Subjects in the dry lab group will perform exercises form the fundamentals of laparoscopic surgery (FLS) program adapted for the daVinci robot. These exercises included, camera and clutching, peg transfer and intracorporeal knot tying. Participants will repeat these tasks until time proficiency is reached based on the performance of our expert robotic surgeons.
3030768|NCT02357056|Active Comparator|Virtual Reality|Subjects in the virtual reality group will perform exercises from a 9 task curriculum, on the daVinci Skills Simulator. These exercises included, camera and clutching, energy switching, peg board, energy dissection, matchboard, ringwalk, suture sponge, and vertical defect suturing. Participants will repeat these tasks all metrics are passed and an overall score is reached based on the performance of our expert robotic surgeons.
3030769|NCT02357056|No Intervention|Control|The control group will receive no training after they complete the initial assessment and undergo randomization. They will be invited back after several weeks to complete the final assessment to control for any improvement in performance from the initial assessment alone and normal progression through surgical training outside of this project.
3030770|NCT02357043|Experimental|Dario Blood Glucose Monitoring System|Subject will be requested to follow the device instructions and perform his/her own finger-stick test using the Dario Glucose Monitoring System (BGMS).
3030771|NCT02357030|Experimental|Methyl-P plus GWI Nutrient Formula|Methylphenidate hydrochloride plus a GWI Nutrient Formula (K-PAX Synergy), both taken twice daily.
3030772|NCT02357017|Active Comparator|Low salt diet|The low-salt meals will be formulated to provide 50 mmol of sodium per day. Two diets with different caloric amounts (2000 or 2500) will be available.
3030773|NCT02357017|Active Comparator|High salt diet|High dietary salt intake, NaCl tablets (6 grams/day) will added to the subject's study diet in order to increase dietary sodium intake to >250 mmol/day.
3030774|NCT02357004|Experimental|Carvedilol|Carvedilol CR 40 mg daily in addition to their normal BP medications. Subjects will be seen in follow-up at 2-week intervals for the duration of the 8-week intervention period. If the clinic BP remains elevated (>140/90 mmHg) at any of the follow-up visits, the study medication will be titrated up to carvedilol CR 80 mg daily (subjects will take 2 of the study pills).
3030775|NCT02357004|Experimental|Chlorthalidone|Chlorthalidone 12.5 mg daily in addition to their normal BP medications. Subjects will be seen in follow-up at 2-week intervals for the duration of the 8-week intervention period. If the clinic BP remains elevated (>140/90 mmHg) at any of the follow-up visits, the study medication will be titrated up to chlorthalidone 25 mg daily (subjects will take 2 of the study pills).
3030776|NCT02356991|Experimental|Famitinib|Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
3030777|NCT02356991|Placebo Comparator|Placebo|Placebo 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
3030778|NCT02356978|Experimental|Arm 1|"Each patient will be treated before using the active usual homemade device, and after using the experimental new DRAP device.~This new sheet was designed by weaving optical fibers connected to LEDs ( BROCHIER Technology). The LIGHTEX technology ® is a principle of weaving mill of optical fibres with side lighting connected to LEDs and allowing to realize flexible or stiff bright surfaces with very weak congestions, low consumption and high life cycle. The energy illumination of this device varies between 3 and 4 mW / cm ² ( average 3,6 mW / cm ².)"
3030779|NCT02356965|Experimental|Ketamine 70 mg Sublingual Wafer|Single dose of 70 mg ketamine sublingual wafer
3030780|NCT02356965|Experimental|Ketamine 100 mg Sublingual Wafer|Single dose of 100 mg ketamine sublingual wafer
3030781|NCT02356965|Placebo Comparator|Placebo|Single dose of placebo sublingual wafer
3030782|NCT02356952|Experimental|Mediterranean Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
3030783|NCT02356952|Experimental|Low Glycemic Index Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
3030784|NCT02356952|Experimental|Low Glycemic Index Mediterranean Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
3030785|NCT02356939|Experimental|Intraductal stent (IST)|"For intervention : intraductal removable stent In the IST group, the surgeon will place the IST in the bile duct, which is a custom-made segment (2 cm) of a 8 French T-tube. The stent is inserted in the biliary duct without suture fixation.~In the IST group, an endoscopic retrograde cholangio-pancreatography (ERCP) with sphincterotomy will be planned between the 4th and the 6th month post-transplantation."
3030786|NCT02356939|Experimental|Without intraductal stent (no IST)|For intervention : stent extraction by endoscopic retrograde cholangio-pancreatography (ERCP) Each center will perform its habitual postoperative follow up.
3030787|NCT02356926||Control|Usual care and routine management
3030788|NCT02356926||Cross checking|Systematic cross checking between emergency physicians at 11:30, 14:00 and 16:30
3030789|NCT02356913|Experimental|Gum A|4 mg nicotine gum; single dose; chewed 30 minutes
3030790|NCT02356913|Experimental|Gum B|4 mg nicotine gum; single dose; chewed 30 minutes
3030793|NCT02356900|Experimental|Hyperoxic, Hyperbaric|Hyperoxic hyperbaric interval exercise training Six sessions of 30 min.of High-intensity interval training completed on a 3-times a week basis at 1.4 ATA of oxygen in a hyperbaric chamber.
3030794|NCT02356900|Sham Comparator|Normoxic, Normobaric|Normoxic, normobaric, interval exercise training Six sessions of 30 min.of High-intensity interval training completed on a 3-times a week basis.
3030795|NCT02356874|Experimental|Exercise group|Exercise
3030796|NCT02356874|No Intervention|Control group|Participants in the control group will be asked to continue their usual physical activity habits
3030797|NCT02356861|Active Comparator|Real, Active LED Treatment Series|These participants will first receive a series of 12, sham LED treatments, At 1 week post completion of the Sham LED treatment series, participants in this group receive a series of 12 real LED treatments from the helmet housing LEDs that deliver photons of light in the infrared range.
3030798|NCT02356861|Sham Comparator|Sham LED Treatment Series|These participants will first receive an initial series of 12 sham LED treatments from the helmet containing the sham LEDs.
3030799|NCT02356848|Experimental|Tailored intervention (TI)|Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles. This arm will have biweekly calls for the first two months and then monthly calls for the next four months followed by texts or mailings for months 7-18 with the frequency determine by level of treatment adherence.
3030800|NCT02356848|Placebo Comparator|Current Practice (CP)|This group will receive all the enhancements that the VA has targeted to improve foot risk in diabetes including full EMR functionality, clinical reminders to improve care, and Patient-Centered Medical Home (PCMH) implementation with its benefits for diabetes care. To control for attention and preserve blinding, this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease. This arm will have biweekly calls for the first two months and then monthly calls for the next four months followed by texts or mailings for months 7-18 with the frequency determine by level of treatment adherence to general health recommendations
3030801|NCT02356835|Experimental|APT001|The APT001 is a medical device that generates a plasma flow containing nitric oxide intended to be applied topically to wound sites. The nitric oxide / plasma flow will be directed at the wound site and surrounding skin at a distance of 11.5 to 15 centimeters from the skin surface. Dose will be 10 seconds / cm2 wound surface area. Administration of the therapy will include a 2 cm border around the defined edges of the wound site.
3030802|NCT02356835|Sham Comparator|SHAM|Treatment with a sham device to deliver non-medicated, heated room air to the wound in the same manner and dose as the active treatment device.
3030803|NCT02356809|Experimental|pl-vegf165|Patients of this group will receive 2,4 mg of pl-vegf165 administered by intramuscular injection which is given in the hand
3030804|NCT02356809|No Intervention|standard care|Patients of this group will receive standard therapy accepted in a clinical centre
3030805|NCT02356796|Experimental|Multidisciplinary group treatment|"Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.~The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months."
3030806|NCT02356796|Active Comparator|Standard physiotherapy treatment|Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
3030807|NCT02356783|Other|Interlaminar|"Approach for lumbar epidural steroid injection for this arm will be interlaminar.~We will be implementing a wireless pedometer to each of the 15 patients in this group to measure our primary and secondary outcomes."
3030808|NCT02356783|Other|Transforaminal|"Approach for lumbar epidural steroid injection for this arm will be transforaminal.~We will be implementing a wireless pedometer to each of the 15 patients in this group to measure our primary and secondary outcomes."
3030809|NCT02356770|Experimental|Collagen Matrix 10808|Mucosal split-thickness flap in combination with the Collagen Matrix 10808.
3030810|NCT02356770|Other|Connective tissue graft (gold standard)|Mucosal split-thickness flap in combination with the connective tissue graft.
3030811|NCT02356757|Experimental|Personalized Behavioral Intervention (PBI)|The PBI is a 12-month long integrated, multicomponent counseling and dermal thermometry intervention targeting foot self-care, foot self-monitoring, diet, medication and physical activity. The intervention is based on self-regulation theory, the Transtheoretical Model and
3030812|NCT02356757|Placebo Comparator|Current Best Practice (CBP)|This group will receive all the enhancements that the VA has targeted to improve foot risk in diabetes and foot care, and will also receive counseling regarding preventing general health conditions.
3030813|NCT02356744||surgery done less than 1 year|Pregnant women who had bariatric surgery done within the last year before pregnancy. Ultrasound fetal monitoring,biophysical profile assessment and maternal follow up investigations and blood pressure monitoring through all pregnancy
3030814|NCT02356744||surgery done more than 1 year|Pregnant women who had bariatric surgery done more than 1 year before pregnancy. Ultrasound fetal monitoring,biophysical profile assessment and maternal follow up investigations and blood pressure monitoring through all pregnancy
3030815|NCT02356718|Experimental|Experimental|Computerized cognitive training activities
3030816|NCT02356718|Active Comparator|Control|Non-adaptive computerized cognitive training activities
3030817|NCT02356705|Placebo Comparator|Saline Placebo|Control patients will receive intranasal saline
3030818|NCT02356705|Active Comparator|Nasal Midazolam Only|Patients will receive 0.2 mg/kg of intranasal midazolam
3030819|NCT02356705|Active Comparator|Midazolam Plus Xylocaine|Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.
3030820|NCT02356692|Experimental|enfilcon A|participants randomized to wear the test lens in one eye and the control in the other eye (contralateral study)
3030821|NCT02356692|Active Comparator|senofilcon A|participants randomized to wear the test lens in one eye and the control in the other eye (contralateral study)
3030823|NCT02356679|Active Comparator|Stillen tab.|three times per day, 1 tab for each time, PO, during 2weeks
3030824|NCT02356653|Experimental|Expanded access to CliniMACs device for T cell depletion|access for patients who lack a fully HLA matched sibling, and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-open protocols that utilize CliniMACs technology for T depletion. Subjects will undergo transplant of stem cells with CD3+/CD19+ depletion.
3030825|NCT02356640|Active Comparator|EUS-guided celiac ganglion neurolysis|Endoscopic ultrasound guided celiac ganglion neurolysis would be performed
3030826|NCT02356640|Active Comparator|Percutaneous celiac plexus neurolysis|Percutaneous celiac plexus neurolysis would be performed
3030827|NCT02356627|Experimental|The Cancer Home Life Intervention|"One or more of the following:~prioritisation of resources and everyday activities~adaptation of activities~adaptation of posture and seating positioning~provision of assistive devices~modification of the physical home environment And usual care from hospital and municipality"
3030828|NCT02356627|No Intervention|Control|Usual care from hospital and municipality
3030829|NCT02356588|Experimental|Sufentanil Tablet 30 mcg|A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.
3030830|NCT02356588|Placebo Comparator|Placebo Tablet|A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.
3030831|NCT02356575|Active Comparator|Acupuncture Group|In the acupuncture group, patients will receive ten treatments of acupuncture over eight weeks.
3030832|NCT02356575|Active Comparator|CBT-I Group|In the CBT-I group, patients will receive seven sessions of CBT-I over eight weeks.
3030833|NCT02356562|Experimental|3-DAA with or without SOF and RBV|3-DAA (ombitasvir/paritaprevir/ritonavir once daily [QD] and dasabuvir twice daily [BID]) with and without sofosbuvir (SOF) QD and with or without ribavirin (RBV) BID for 12 or 24 weeks
3030834|NCT02356549|Active Comparator|GROUP 1: (EMR) Tailoring Alone|Patients will be randomized to receive tailored messages based on demographic and disease information extracted from Massey Cancer Center (MCC) electronic medical records (EMR) that will include a) demographic information: age, income, education and health insurance status, b) disease variables: cancer type and severity and c) trial variables: phase of trial being offered and prior trial participation.
3030835|NCT02356549|Active Comparator|GROUP 2:EMR Tailoring+Feedback|Patients will be randomized to receive tailored messages based on information extracted from the EMR as in Group 1. Physicians also receive a summary of tailored messages provided to patients.
3030836|NCT02356549|Active Comparator|GROUP 3:EMR+Survey Tailoring alone|Patients will be randomized to receive tailored messages based on EMR data as in Group 1. Patients will complete a survey that will be used to provide a deeper level of tailored messages
3030837|NCT02356549|Active Comparator|GROUP 4:EMR+Survey Tailoring+Feedback|Patients will be randomized to receive tailored messages based on information extracted from their EMR as in Group I. Patients will complete a survey that will be used to provide a deeper level of tailored messages as in Group 3. Physicians also receive a summary of tailored messages provided to patients as in Group 2.
3030838|NCT02356536|Experimental|Experimental|
3030839|NCT02356523||Cardiac Intensive Care Unit Patients|Patients admitted at Cardiac Intensive Care Unit for any condition
3030840|NCT02356510||Culprit lesion|Patients who underwent culprit lesion only PCI during primary intervention
3030841|NCT02356510||Culprit vessel|Patients who underwent culprit lesion only PCI during primary intervention
3030842|NCT02356484||CRP group|
3030843|NCT02356484||Procalcitonin group|
3030844|NCT02356484||Albumine group|
3030845|NCT02356484||Lactate group|
3030846|NCT02356471|Experimental|Supportive care (consumer-based activity monitor)|Patients wear Fitbit Zip (portable pedometer device) to track physical activity for 7 days before undergoing surgery and for 21 more days after undergoing surgery.
3030847|NCT02356458|Experimental|Ibrutinib & Bortezomib|Combination therapy (trial treatment of ibrutinib in combination with bortezomib) followed by ibrutinib maintenance therapy
3030848|NCT02356445||Cytotoxic drug|Patients treated for sarcoidosis
3030849|NCT02356432||NOACs group|Medication with dabigatran, rivaroxaban, apixaban, or edoxaban will not be assigned, but will be freely prescribed by each attending doctor based on assessment of the condition of each patient.
3030850|NCT02356432||Warfarin group|Medication with warfarin: PT-INR should be controlled in accordance with the JCS2008 guideline concerning the drug treatment of atrial fibrillation, that is, INR 2.0 to 3.0 in patients younger than 70 years, or INR 1.6 to 2.6 in patients not younger than 70 years.
3030851|NCT02356419|Experimental|experimental 0.5 ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
3030852|NCT02356419|Experimental|experimental 1.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
3030853|NCT02356419|Experimental|experimental 2.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
3030854|NCT02356419|Experimental|experimental 3.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
3030855|NCT02356406|Experimental|Celiac Plexus Radiosurgery|"The study has a prospective, single arm design. It will be composed from an initial run-in safety assessment that will include 6 patients and then continue as a phase II trial.~All eligible patients will receive the same protocol of celiac plexus radiosurgery"
3030892|NCT02356081|Experimental|ASyMS intervention Group|Patients in the intervention group will be instructed to use the ASyMS intervention once daily (and whenever they feel unwell) for up to 6 cycles of chemotherapy treatment.
3030856|NCT02356380|Experimental|Mobilization|"Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.~Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae."
3030857|NCT02356354|Other|Skin biopsy|On the same patient, a biopsy of post-burn scar is removed. A second one is removed from healthy skin.
3030858|NCT02356341||NovaTears®|
3030859|NCT02356328||NovaTears®|
3030860|NCT02356315||Healthy subjects|Functional magnetic resonance imaging of healthy subjects
3030861|NCT02356315||Chronic neck pain patients|Functional magnetic resonance imaging of chronic neck pain patients
3030862|NCT02356302|Experimental|Vicriviroc (MK-4176) Intravaginal Ring (IVR)|The vicriviroc (MK-4176) IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
3030863|NCT02356302|Experimental|MK-2048 IVR|The MK-2048 IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
3030864|NCT02356302|Experimental|MK-2048A IVR|The MK-2048A IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
3030865|NCT02356302|Placebo Comparator|Placebo IVR|The placebo IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
3030866|NCT02356289|Experimental|MYK-461|single-dose, tablet formulation
3030867|NCT02356289|Placebo Comparator|Placebo|single-dose, tablet formulation
3030868|NCT02356276|Experimental|HIPEC group|"Postoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is performed after radical surgery, followed by 6-8 cycles of systemic chemotherapy. The first HIPEC is conducted within 48 h after surgery: Paclitaxel 75 mg/m^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m^2, 43°C, 60min.~Systemic chemotherapy (XELOX or SOX regimens):~XELOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~If XELOX regimen is not conducted in some collaborators, SOX regimen is also permitted. The regimen is Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid, po, day 1-14, every 3 weeks for a total of 6-8 cycles."
3030869|NCT02356276|Placebo Comparator|Control group|"6-8 cycles of systemic chemotherapy (XELOX or SOX regimens) were performed after radical gastrectomy with D2 lymphadenectomy.~XELOX regimen is Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~If XELOX regimen is not conducted in some collaborators, SOX regimen as comment systemic chemotherapy in Asia is also permitted to treat the patients. The treatment bundles are listed as follows: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid (S-1: BSA <1.25m^2, 40mg bid, 1.25m^2≤ BSA ≤1.5m^2, 50mg bid, BSA>1.5m^2, 60 mg bid), po, day 1-14, every 3 weeks for a total of 6-8 cycles."
3030870|NCT02356250||PORTAL HYPERTENSION|PAIEBT WITH PORTAL HYPERTENSION
3030871|NCT02356237|Experimental|No episiotomy|Episiotomy will not be performed in this group. Deviation from protocol (i.e. episiotomy performance) will be allowed only according to the discretion of obstetrician in charge of the delivery, in cases of unequivocal benefit to the fetus.
3030872|NCT02356237|No Intervention|Selective episiotomy|The decision to perform episiotomy in this group will be based on routine delivery care, i.e. indistinguishable from any other delivery not participating in the trial.
3030873|NCT02356224|Experimental|Cohort 1|SHR3824 2.5 mg/day or placebo.
3030874|NCT02356224|Experimental|Cohort 2|SHR3824 5 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
3030875|NCT02356224|Experimental|Cohort 3|SHR3824 10 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
3030876|NCT02356224|Experimental|Cohort 4|SHR3824 25 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
3030877|NCT02356224|Experimental|Cohort 5|SHR3824 50 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
3030878|NCT02356224|Experimental|Cohort 6|SHR3824 100 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
3030879|NCT02356224|Experimental|Cohort 7|SHR3824 200 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
3030880|NCT02356211|Experimental|Treatment|Geriatric Multifactorial Falls Assessment Clinic
3030881|NCT02356211|Active Comparator|Comparator|Falls e-consult
3030882|NCT02356211|No Intervention|Control|Geriatric Evaluation and Management Service (GEM)
3030883|NCT02356198|Active Comparator|TAP block (EXPAREL)|After induction of anesthesia, the patients will receive a single injection with 133 mg of EXPAREL in the transversus abdominis plane (TAP), on each side, suspended in 20mL of injectable saline.
3030884|NCT02356198|Active Comparator|IT|single injection intrathecal hydromorphone analgesia given preoperatively
3030885|NCT02356159|Experimental|1/Phase 1: Dose escalation arm|Induction chemotherapy, then palifermin at escalating doses, then conditioning chemotherapy, then allogeneic stem cell transplant, then immunosuppression
3030886|NCT02356159|Experimental|2/ Phase II arm|Induction chemotherapy, then palifermin at the MTDdetermined in Phase 1, then conditioning chemotherapy, then allogeneic stem cell transplant, then immunosuppression
3030887|NCT02356146||All KT recipient|
3030888|NCT02356120||Suspected Pulmonary Embolus|Patients with suspected pulmonary embolus who are getting a CTPA
3030889|NCT02356107|Experimental|Open label treatment with 5-HTP and Creatine|
3030890|NCT02356094||Cases|Patients with primary open angle glaucoma, randomly selected from the Glaucoma Outpatient Clinic to be submitted to Pentacam examination
3030891|NCT02356094||Controls|Control group of age and central corneal thickness matched healthy subjects, randomly selected from the General Ophthalmology Outpatient Clinic to be submitted to Pentacam examination
3030893|NCT02356081|No Intervention|Control Group|Patients in the control group will receive standard care as is currently available at their clinical site.
3030894|NCT02356068||liver transplantation recepient|every patient who had a liver transplantation. 3 blood samples (2.7ml) for the ROTEM analysis
3030895|NCT02356055|Experimental|Intensive Protocol|"Participants in this group will receive the Skill-building through Task-Oriented Motor Practice (STOMP) intervention 3 hours/day, 5 days/week for 2 weeks. Participants will choose functional goals that have an identifiable beginning and concluding step for creation of practice-able steps for task-oriented training. Practice-able steps will embed both task modifications and assistive technology determined by the OT to support performance and will be situated contextually within the participant's habits and environment. Each group will practice the task as many times as possible during their allotted time in training. For the intensive protocol, each hour of training will focus on 1 of 3 identified goals and will include 50 minutes of intervention and a 10 minute break."
3030896|NCT02356055|Active Comparator|Less-Intensive Protocol|"Participants in this group will receive the Skill-building through Task-Oriented Motor Practice (STOMP) intervention 1 hour/day, 2 days/week for 2 weeks. Participants will choose goals that have an identifiable beginning and concluding step for creation of practice-able steps for task-oriented training. Practice-able steps will embed both task modifications and assistive technology determined by the OT to support performance and will be situated contextually within the participant's habits and environment. Each group will practice the task as many times as possible during their allotted time in training. In the less-intensive protocol, each of the 3 ADL goals will be practiced as many times as possible within 20 minutes of the scheduled hour."
3030897|NCT02356042||Nursing home residents practicing GIA activity|
3030898|NCT02356042||Nursing home residents no practicing GIA activity|
3030899|NCT02356029||EMS Healthcare Providers|Healthcare Providers working in Emergency Medical Services and directly involved in treatment of cardiac arrest patients (out-of-hospital or in the Emergency Department)
3030900|NCT02356016|Active Comparator|Whole body Electromyostimulation (WB-EMS)|18 min of WB-EMS/week (one session/week)
3030901|NCT02356016|Active Comparator|WB-EMS and Nutritional Supplements|18 min of WB-EMS/week (one session/week) and supplements with high protein (Leucin) contents
3030902|NCT02356016|Sham Comparator|Control|Monthly dietary counseling for 6 months
3030903|NCT02356003|Experimental|Low frequency rTMS|Eleven children (7-12 years of age) with Tourette syndrome will be undergo low frequency repetitive transcranial magnetic stimulation (5 times a week for three weeks).
3030904|NCT02355990|Experimental|MIMS|Minimally Invasive Micro Sclerostomy
3030905|NCT02355977|Active Comparator|surface and root planning|surface and root planning is performed in a single-visit, one-stage, full mouth pattern using periodontal ultrasonic scaler (Satelec, Mérignac, France)
3030906|NCT02355977|Active Comparator|locally delivered minocycline|Locally delivered minocycline is administered directly into the periodontal pocket up to the gingival margin of the selected teeth
3030907|NCT02355977|Experimental|surface and root planning+minocycline|surface and root planning+locally delivered minocycline is the combined administration of both surface and root planning and locally delivered minocycline.
3030908|NCT02355964|Experimental|exercise|exercise (Aerobe training) 3 times per week
3030909|NCT02355964|Experimental|Diet|A diet with an overall high protein content and a low glycemic index
3030910|NCT02355964|Experimental|Diet+Exercise|A diet with an overall high protein content and a low glycemic index combined with exercise (Aerobe training) 3 times per week.
3030911|NCT02355964|No Intervention|control|Regular lifestyle (no intervention)
3030912|NCT02355938|Experimental|Fidaxomicin Arm|Oral Fidaxomicin 200 mg every 12 hours (Placebo for 2 doses) for 10 days
3030913|NCT02355938|Active Comparator|Vancomycin Arm|Oral Vancomycin 125 mg every 6 hours for 10 days
3030914|NCT02355925|Experimental|uhCG|The patients who receive Intrauterine injection of 500 IU of uhCG (0.5ml) before embryo transfer
3030915|NCT02355925|Placebo Comparator|Placebo|The patients who underwent Intrauterine injection of placebo (normal saline 0.5 ml) before embryo transfer
3030916|NCT02355925|Other|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
3030917|NCT02355912|Experimental|Evaluate a real-time adaptive neural control system|The prosthesis will be tuned, for each subject: level-ground walking, walking up and down slopes and walking up and down stairs. We anticipate that participants will visit the laboratory approximately 6-9 times over 2 months (2-3 visits for socket duplications and modifications, 2-3 visits for control system tuning, and an additional 2-3 visits for practice using the tuned system). By the end of these visits, the goal is to have a properly fitting socket and for the subjects to ambulate proficiently with the powered prosthesis. After tuning, the subjects will complete 20 ambulation circuits (level ground walking, walking up and down slopes, up and down stairs). This will provide training data for our pattern recognition control systems.
3030918|NCT02355899|Experimental|PD P 506 A-PDT|One PD P 506 A-patch will be administered to each great toenail for 4 hours. After removal of the study medication the study nail(s) s will be illuminated with red light of defined wavelength (PDT).
3030919|NCT02355886|Experimental|Arm I (gabapentin)|Patients receive gabapentin PO TID for 48 hours after surgery.
3030920|NCT02355886|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO TID for 48 hours after surgery.
3030921|NCT02355873|Experimental|AN69ST|AN69ST:Surface-treated Polyacrylonitrile Membrane Hemofilter
3030922|NCT02355873|Active Comparator|AN69|AN69:original Polyacrylonitrile Membrane Hemofilter
3030923|NCT02355847|Other|Healthcare Worker Education|Educational Lectures
3030924|NCT02355834|Experimental|Group 1 (IBD Nurse CONSULT + BOOKLET)|IBD nurse intervention-Will have 3-4 x 30 minute face-to-face sessions over 3 months with an IBD specialist nurse specifically focusing on bowel control. Participants completing at least 3 sessions will be considered to have completed the intervention. They will also be given a booklet and access to all usual care, including nurse-led IBD helpline
3030925|NCT02355834|No Intervention|Group 2 (BOOKLET alone)|Will receive the same booklet and access to usual care as Group 1.
3030926|NCT02355821|Experimental|Moxonidine|0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID
3030927|NCT02355821|Active Comparator|Bisoprolol|5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID
3030928|NCT02355808|No Intervention|Non Superfast|
3030929|NCT02355808|Other|Non Superfast GP intervention|
3030930|NCT02355808|Other|Non Superfast Tailored Leaflet|
3030937|NCT02355795|Experimental|moderate-fat diet|Participants will be provided moderate-fat diet for 6 months
3030938|NCT02355795|Experimental|high-fat diet|Participants will be provided high-fat diet for 6 months
3030939|NCT02355756|Experimental|Active|Intradermal injection of maxadilan solution
3030940|NCT02355756|Placebo Comparator|Placebo|Intradermal injection of placebo (=vehicle) solution
3030941|NCT02355743|Experimental|rtPA lock therapy Recipients|rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks
3030942|NCT02355730|Experimental|Warfarin Patients|Single Arm - blood collection by venepuncture in patients undergoing Warfarin Therapy
3030943|NCT02355717||Prospective Cohort|400 otherwise healthy children and adolescents aged 9-15 years will be recruited to participate in a 2-year longitudinal study.
3030944|NCT02355704|Active Comparator|Atorvastatin|22 patients received oral atorvastatin 40 mg 1 time for day for 4 weeks
3030945|NCT02355704|Placebo Comparator|Placebo|22 patients received oral placebo 40 mg 1 time for day for 4 weeks
3030946|NCT02355691|Experimental|PREVENA Group|Patients will be treated with the PREVENA negative pressure device following total hip arthroplasty. This dressing will be used for a period of seven days.
3030947|NCT02355691|No Intervention|Standard group|Patients will be treated with the standard absorptive dressing following total hip arthroplasty.
3030948|NCT02355678|Experimental|IV Dex|dexamethasone 0.5 mg/kg IV with placebo pre-incision infiltration
3030949|NCT02355678|Experimental|Infiltration|The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 1.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 3 ml lidocaine 2%, 3 ml lidocaine 2% with epinephrine 1/200 000, 3 ml of bupivacaine 0.5%, 0.5 ml fentanyl 50 µg ml-1, and 0.3 ml clonidine 150 µg ml-1
3030950|NCT02355665|Experimental|Nicotine|Nicotine Spray
3030951|NCT02355665|Placebo Comparator|Placebo|Placebo to match Nicotine spray
3030952|NCT02355652|Active Comparator|Cemented TKA|
3030953|NCT02355652|Active Comparator|Uncemented TKA|
3030954|NCT02355639|Experimental|Clobetasol propionate 0.05 % ointment|Active drug
3030955|NCT02355639|Experimental|Betamethasone dipropionate 0.064 % ointment|Active drug
3030956|NCT02355639|Placebo Comparator|Petrolatum ointment|Placebo drug
3030957|NCT02355613|Active Comparator|Radiosurgery with Gamma Knife Perfexion|A single dose of 24 Gy at 50% isodose will be prescribed at metastases with diameter ≤ 20 mm, while a dose of 20 Gy at 50% isodose will be prescribed for metastases with diameter 21-30 mm
3030958|NCT02355613|Active Comparator|Linac-based Radiosurgery with EDGE|A single dose of 24 Gy will be prescribed at mean dose to PTV at metastases with diameter ≤ 20 mm, while a dose of 20 Gy will be prescribed for metastases with diameter 21-30 mm
3030959|NCT02355561|Experimental|Sequence 1 (ABC)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram [mg] formulation 1 [reference] under fasted conditions) in Period 1; followed by Treatment B (single oral dose of JNJ-54861911 25 mg formulation 2 [test] under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg formulation 2 under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3030960|NCT02355561|Experimental|Sequence 2 (ACB)|Participants will receive Treatment A in Period 1; followed by Treatment C in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3030961|NCT02355561|Experimental|Sequence 3 (BAC)|Participants will receive Treatment B in Period 1; followed by Treatment A in Period 2; followed by Treatment C in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3030962|NCT02355561|Experimental|Sequence 4 (BCA)|Participants will receive Treatment B in Period 1; followed by Treatment C in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3030963|NCT02355561|Experimental|Sequence 5 (CAB)|Participants will receive Treatment C in Period 1; followed by Treatment A in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3030964|NCT02355561|Experimental|Sequence 6 (CBA)|Participants will receive Treatment C in Period 1; followed by Treatment B in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3030965|NCT02355548||Outpatient Treatment|All patients eligible for the study will have their PE treated in the outpatient setting.
3030966|NCT02355535|Experimental|Open label|Using a dose-escalation design, PAC-1 is administered orally on days 1-21, at the assigned dose, of a 28-day cycle.
3030967|NCT02355522|Active Comparator|Lidocaine gel group|3ml of 2% lidocaine gel on the cervix and 5ml of intrauterine normal saline
3030968|NCT02355522|Active Comparator|Intrauterine lidocaine group|3ml of KY jelly on the cervix and 5ml of 2% intrauterine lidocaine
3030969|NCT02355522|Placebo Comparator|Placebo group|3ml of KY jelly on the cervix and 5mL of intrauterine normal saline
3030970|NCT02355509|Placebo Comparator|Placebo|A placebo drug is given for three months
3030971|NCT02355509|Experimental|Acarbose|Acarbose is given for three months
3030972|NCT02355496|Experimental|Displaying medicare fee data|The active arm is the intervention group of randomly selected inpatient laboratory tests (about 15 most frequently ordered and about 15 most expensive) that will have medicare fee data displayed in the computerized provider order entry system.
3030973|NCT02355496|No Intervention|Control Arm|The control arm is the group of randomly selected inpatient laboratory tests (about 15 most frequently ordered and about 15 most expensive) that will not have medicare fee data displayed.
3030974|NCT02355470|Experimental|Intervention|Participants will receive the GIFTSS intervention provided by college health center staff and clinicians
3030975|NCT02355470|Active Comparator|Control|Participants will receive a brief alcohol use reduction intervention based on NIAAA guidelines provided by college health center staff and clinicians
3030976|NCT02355457||Suspected acute myocardial infarction|Patients with recent onset symptoms suggesting acute myocardial infarction
3030977|NCT02355444|Experimental|High-dose blackberry polyphenol beverage|Each participant will consume a blackberry beverage with high-dose blackberry polyphenols (250mL/day for 6 weeks).
3030978|NCT02355444|Placebo Comparator|Low-dose blackberry polyphenol beverage|Each participant will consume a blackberry beverage with minimal blackberry polyphenols (250mL/day for 6 weeks).
3030979|NCT02355431|Experimental|INCB039110 plus erlotinib|
3030980|NCT02355431|Active Comparator|Placebo plus erlotinib|
3030981|NCT02355418||Patients for early surgery|A prospective, cross sectional comparison of asymptomatic patients before and after mitral valve repair surgery for chronic severe primary degenerative mitral regurgitation.Once established, it is our intention to restudy subjects in 5 years to provide information on late outcome following surgery.
3030982|NCT02355418||Patients against early surgery|In order to establish the natural history of diffuse fibrosis in mitral regurgitation, an additional cohort of patients with asymptomatic mitral regurgitation who do not wish to consider early repair will be followed.
3030983|NCT02355379|Experimental|GROUP1 -ARM A|LV5FU2 or capecitabine
3030984|NCT02355379|Experimental|GROUP1-ARMB|FOLFOX4 or XELOX
3030985|NCT02355379|Experimental|GROUP2- ARM C|Observation
3030986|NCT02355379|Experimental|GROUP2-ARM D|LV5FU2 or capecitabine
3030987|NCT02355366|Experimental|Family Focused Therapy (FFT)|Participants will receive Family-Focused Therapy (FFT). It will consist of twelve, 1-hour long sessions, over a period of 4 months. The 12 sessions will include psychoeducation (sessions 1-4), training in communication enhancement (sessions 5-8) and training in relation to problem-solving skills (sessions 9-12).
3030988|NCT02355366|Active Comparator|Brief Educational Treatment|Participants will be receive 1-2 educational sessions which will include diagnostic feedback, recommendations for further treatment and crisis intervention if required.
3030989|NCT02355353|Experimental|Imaging arm|
3030990|NCT02355340|Other|DXA and pQCT Scan|"Dual energy x-ray absorptiometry (DXA): Assessment of bone mineral density~Peripheral quantitative computed tomography (pQCT): Assessment of bone mineral density"
3030991|NCT02355327|Experimental|Laselle Kegel Exerciser|
3030992|NCT02355327|Active Comparator|Pelvic floor muscle exercises|
3030993|NCT02355314|Experimental|ICU patients requiring mechanical ventilation|
3030994|NCT02355301||patients with orthopedic disorders|Patients with muscular skeletal impairments receiving a treatment (A, B, C...). The investigators compare these treatments (A, B, C...) in function of ICF model in order to improve the quality of care in orthopedic department.
3030995|NCT02355288|Active Comparator|Minimally Invasive Coronary Bypass|Minimally invasive bypass surgery (MICS CABG) would be conducted to treat the left anterior descending (LAD) artery disease in diabetic patients. This would be a surgical intervention, and differs from the stent procedure arm.
3030996|NCT02355288|Active Comparator|Percutenous Coronary Intervention|Percutaneous coronary intervention (PCI) with drug eluting stents would be used to treat left anterior descending (LAD) artery disease in diabetic patients. This would be an intervention induced by cardiology, and differs from the surgical intervention arm.
3030997|NCT02355275|Experimental|Home Exercise Program|
3030998|NCT02355262||Arm I (Independent Tool Implementation)|Participants receive CATCH-UP tools which include a panel management/data aggregator system that identifies patients who may be eligible for public coverage but are not yet insured, or who are nearing coverage expiration, coupled with automated patient outreach and communication at baseline.
3030999|NCT02355262||Arm II (Tool Implementation with Interactive Facilitation)|Participants receive CATCH-UP tools which include a panel management/data aggregator system that identifies patients who may be eligible for public coverage but are not yet insured, or who are nearing coverage expiration, coupled with automated patient outreach and communication. Participants also receive additional implementation support such as trainings, assistance with workflows, and practice facilitation.
3031000|NCT02355249|Experimental|A group (MIE)|Via minimally invasive thoracol-laparoscopic esophagectomy.
3031001|NCT02355249|Active Comparator|B group (OE)|Via traditional three incisions esophagectomy.
3031002|NCT02355236|Experimental|Test Group|Naproxen/Esomeprazol 500/20mg and Comparator-Placebo for 12 weeks
3031003|NCT02355236|Active Comparator|Comparator Group|Celecoxib 200mg and Naxozol-Placebo for 12 weeks
3031004|NCT02355223|Other|FAST Implementation|This single center study will consist of introducing a TB screening program called FAST (Find cases Actively, Separate safely, and Treat Effectively) within the hospital among patients presenting for care who have cough or TB risk factors, and testing them for tuberculosis using a combination of rapid screening and diagnostics tools. The study will evaluate the process of implementation as well as the impact on reducing tuberculosis transmission to health care workers over successive years.
3031005|NCT02355210|Placebo Comparator|Placebo|5 g lactose given as a placebo
3031006|NCT02355210|Experimental|Probiotic 1|Bifidobacteria adolescentis BD1, 10^9
3031007|NCT02355210|Experimental|Probiotic 2|Bifidobacteria animalis subsp. lactis BB-12, 10^9
3031008|NCT02355210|Experimental|Prebiotic|galactooligosaccaride, 5 g
3031009|NCT02355210|Experimental|Synbiotic 1|galacto-oligosaccharide (5 g) and Bifidobacteria adolescentis BD1 (10^9)
3031010|NCT02355210|Experimental|Synbiotic 2|galacto-oligosaccharide (5 g) and Bifidobacteria animalis subsp. lactis BB-12 (10^9)
3031011|NCT02355197|Active Comparator|antioxidant|1 gram L-ascorbic acid (vitamin C capsule) orally once per day from the time of diagnosis until the time of delivery in addition to treatment for gestational diabetes mellitus in the form of diet and insulin
3031012|NCT02355197|No Intervention|control|Only treatment for gestational diabetes mellitus in the form of diet and insulin
3031013|NCT02355184|Experimental|PRO 140|PRO 140 350mg weekly SQ injection.
3031014|NCT02355158|Experimental|Active|Clonidine hydrochloride topical gel, 0.1%
3031015|NCT02355145||Patient group in moment 1 of evaluation|Study group enrolled in moment 1 of evaluation (Feb - Mar 2015)
3031016|NCT02355145||Patient group in moment 2 of evaluation|Study group enrolled in moment 2 of evaluation (Feb - Mar 2016) - 1 year distance from moment 1
3031017|NCT02355132||Insurance Intervention Arm|Oregon OCHIN patients that put their names on the reservation list for the Oregon Experiment and were randomly chosen to apply for insurance coverage via the Oregon Experiment
3031018|NCT02355132||Control|Oregon OCHIN patients that put their names on the reservation list for the Oregon Experiment and were not chosen to apply for insurance coverage via the Oregon Experiment
3031019|NCT02355119|Active Comparator|Gemcitabine|Gemcitabine 1000 mg/sqm on days 1,8,15 every 28 days
3031022|NCT02355093|Experimental|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
3031023|NCT02355093|Active Comparator|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
3031024|NCT02355080|Experimental|On-site bundled rapid HIV/HCV testing|Participants will receive the on-site bundled rapid HIV/HCV testing intervention. In the intervention group, all patients will receive an offer to participate in rapid HIV/HCV testing. Those who accept this offer will: receive pre-test information about testing procedures and education, be tested, receive results during the same visit as testing, and be provided post-test counseling and support services by trained test counselors. Patients with a preliminary positive (i.e., reactive) HIV and/or HCV test result(s) will be actively linked immediately to a health care provider for further evaluation and confirmatory HIV and/or HCV RNA testing.
3031025|NCT02355080|Active Comparator|Standard of care (SOC)|Participants will receive the standard of care (SOC) at the study sites. The SOC entails venipuncture whole blood HIV testing + venipuncture whole blood HCV testing. Blood draws are sent to an external laboratory for processing, and patients must return for test results in another visit. Patients may not receive pre-test information or results and post-test counseling, especially if non-reactive or negative test result(s). Reflex testing is not standard practice, therefore some patients may require another visit and blood draw for confirmatory HIV and/or HCV RNA testing. Linkage to care in the SOC is accomplished by referral to a health care provider, either within the participating substance use disorder treatment organization or passive referral to other health facilities.
3031026|NCT02355067|Experimental|Social Media Format|Social Media Intervention for women with postpartum depression (PPD) symptoms
3031027|NCT02355067|Active Comparator|In-Person Format|Traditional In-Person Intervention for Women with postpartum depression (PPD)
3031028|NCT02355041|Experimental|Meal Replacement-based Weight Loss Diet|Experimental participants will be instructed to replace 2 meals per day with a PROBAR meal replacement and consume a dinner under 1000 calories or a dinner under 800 calories and a 200 calorie snack for 90 days. No further nutritional advice or education shall be provided.
3031029|NCT02355041|Active Comparator|Educational Video|"Control participants will view The Weight of the World, a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web."
3031030|NCT02355028|Experimental|LHA510|LHA510 ophthalmic suspension administered topically in the study eye as specified in the protocol for 84 days, with ranibizumab ophthalmic solution for IVT injection as standard of care rescue therapy.
3031031|NCT02355028|Placebo Comparator|Vehicle|LHA510 vehicle administered topically in the study eye as specified in the protocol for 84 days, with ranibizumab ophthalmic solution for IVT injection as standard of care rescue therapy.
3031032|NCT02355002|Experimental|Active Transcranial Magnetic Stimulation (TMS) treatment|In this arm subjects will receive real, active TMS with a standard, water-cooled, figure-8 shaped TMS coil.
3031033|NCT02355002|Sham Comparator|Sham-TMS treatment|This arm serves as the sham/placebo control. In TMS a sham coil is used to create a sensory experience which is similar to active TMS, but in which the magnetic field is blocked by a metal shield built into the coil.
3031034|NCT02354989|Active Comparator|RR on first|Rate Response on first
3031035|NCT02354989|Active Comparator|RR off first|Rate Response off first
3031036|NCT02354976|Placebo Comparator|Placebo|
3031037|NCT02354976|Experimental|Omega-3 carboxylic acids 4g / day|
3031038|NCT02354976|Active Comparator|Fenofibrate 200mg|
3031039|NCT02354963|No Intervention|Control arm|No intervention is performed. Assessment of antral follicle count. IVF treatment.
3031040|NCT02354963|Experimental|Experimental arm|"Perform intervention described: Laparoscopy. In vitro fragmentation of the ovarian tissue.~Assessment of antral follicle count. IVF treatment."
3031041|NCT02354950|Experimental|Part 1 Cohort 1 (Moderate hepatic impairment subjects)|Subjects with moderate hepatic impairment will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
3031042|NCT02354950|Experimental|Part 1 Cohort 2 (Healthy control subjects)|Healthy control subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
3031043|NCT02354950|Experimental|Part 2 Cohort 3 (Mild hepatic impairment subjects)|Subjects with mild hepatic impairment will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
3031044|NCT02354950|Experimental|Part 2 Cohort 4 (Healthy control subjects)|Healthy control subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
3031045|NCT02354937|Experimental|Subjects with renal impairment|Subjects with severe renal impairment will receive single oral dose of 744 30 mg
3031046|NCT02354937|Active Comparator|Subjects with normal renal function|Subjects with normal renal function will receive single oral dose of 744 30 mg
3031047|NCT02354924|Experimental|Visco soft contact lens|Olifilcon A, Daily wear, monthly disposable soft contact lens
3031048|NCT02354924|Active Comparator|Biofinity soft contact lens|Comfilcon A, Daily wear, monthly disposable soft contact lens
3031110|NCT02354560|Experimental|Erythromycin|Oral treatment with Erythromycin 250-500mg (will be determined according to body weight) twice a day.
3031049|NCT02354911|Experimental|Immunoregulatory Dendritic Cells (iDC)|Biological intervention consisting of autologous dendritic cells treated in vitro to convert to active immunoregulatory dendritic cells.
3031050|NCT02354911|Placebo Comparator|Placebo Control|Saline injections administered blinded to subject and all study staff except for research pharmacist who is not involved in study conduct
3031051|NCT02354898|Experimental|BBI503, BBI503 and Sorafenib|
3031052|NCT02354885|No Intervention|Tranexamic Acid|TXA administered to multiple trauma patients in the helicopter or ambulance
3031053|NCT02354872|Experimental|Mini-Lozenge, BR, 5Rs, BA|1; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, 5Rs, BA
3031054|NCT02354872|Experimental|Mini-Lozenge, BR, 5Rs, No BA|2; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, 5Rs, No BA
3031055|NCT02354872|Experimental|Mini-Lozenge, BR, No 5Rs, BA|3; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, No 5Rs, BA
3031056|NCT02354872|Experimental|Mini-Lozenge, BR, No 5Rs, No BA|4; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, No 5Rs, No BA
3031057|NCT02354872|Experimental|Mini-Lozenge, No BR, 5Rs, BA|5; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, 5Rs, BA
3031058|NCT02354872|Experimental|Mini-Lozenge, No BR, 5Rs, No BA|6; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, 5Rs, No BA
3031059|NCT02354872|Experimental|Mini-Lozenge, No BR, No 5Rs, BA|7; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, No 5Rs, BA
3031060|NCT02354872|Experimental|Mini-Lozenge, No BR, No 5Rs, No BA|8; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, No 5Rs, No BA
3031061|NCT02354872|Experimental|No Mini-Lozenge, BR, 5Rs, BA|9; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, 5Rs, BA
3031062|NCT02354872|Experimental|No Mini-Lozenge, BR, 5Rs, No BA|10; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, 5Rs, No BA
3031063|NCT02354872|Experimental|No Mini-Lozenge, BR, No 5Rs, BA|11; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, No 5Rs, BA
3031064|NCT02354872|Experimental|No Mini-Lozenge, BR, No 5Rs, No BA|12; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, No 5Rs, No BA
3031065|NCT02354872|Experimental|No Mini-Lozenge, No BR, 5Rs, BA|13; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, 5Rs, BA
3031066|NCT02354872|Experimental|No Mini-Lozenge, No BR, 5Rs, No BA|14; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, 5Rs, No BA
3031067|NCT02354872|Experimental|No Mini-Lozenge, No BR, No 5Rs, BA|15; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, No 5Rs, BA
3031068|NCT02354872|Experimental|No Mini-Lozenge, No BR, No 5Rs, No BA|16; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, No 5Rs, No BA
3031069|NCT02354859|Active Comparator|5 day of infusion of gallium nitrate|Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device () using an ambulatory infusion pump infused over 24 hours for 5 sequential days.
3031070|NCT02354859|Placebo Comparator|5 day of infusion of normal saline|Placebo with be dispensed as 1,000 milliliters of 0.9% sodium chloride to match the reconstitution volume of the IV Ga
3031071|NCT02354833|Experimental|Phenylephrine|A continuous phenylephrine infusion at 0.1 mcg/kg/min
3031072|NCT02354833|Experimental|Norepinephrine|A continuous norepinephrine infusion at 0.05 mcg/kg/min
3031073|NCT02354820|No Intervention|Control|Patients are identified by the pre-screener form given to parents as having constipation or encopresis. No intervention is given to providers to help them with constipation management.
3031074|NCT02354820|Experimental|Experimental|Patients are identified by the pre-screener form given to parents as having constipation or encopresis. Evidence based reminders and patient educational materials are given to providers to help them with constipation management.
3031075|NCT02354807|Experimental|Experimental group|Subjects that undergo both cold exposure and one-time dose of 100mg of Mirabegron drug
3031076|NCT02354794|Experimental|Healthy subjects with 'hypertriglyceridemic waist'|"Subjects with overweight, elevated waist circumference and elevated fasting triglyceridemia.~Intervention: see below"
3031077|NCT02354781|Experimental|Experimental|The vector will be delivered to both limbs via multiple, direct intramuscular injections of rAAV1.CMV.huFollistin344; the number of injections per muscle will depend on the size of the patient. A total dose of 2.4E12 vg/kg (1.2E12vg/kg/limb) will be delivered to the lower limbs of 6 DMD subjects
3031078|NCT02354768|Experimental|lanreotide and anti-diarrheal treatments|"Lanreotide: 1 single injection at day 0 (lanreotide 120 mg)~Diosmectite (3 g) 6 / day for 72 hours (fromD0 to D3)~Chlorhydrate of Loperamide (2 mg capsule or tablet) 6 / day for 72 hours (D0 to D3)~hydration"
3031079|NCT02354768|Active Comparator|Current anti-diarrheal treatments alone|"Diosmectite (3 g) 6 / day for 72 hours (fromD0 to D3)~Chlorhydrate of Loperamide (2 mg capsule or tablet) 6 / day for 72 hours (D0 to D3)~Hydration"
3031080|NCT02354755||Cold room|Anesthesia providers intraoperatively placed in ambient room temperature of 65 degreees (cold room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
3031081|NCT02354755||Hot room|Anesthesia providers intraoperatively placed in ambient room temperature of 80 degreees (hot room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
3031171|NCT02354118|Experimental|Intervention Group|Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.
3031082|NCT02354755||Control Room|as a control placed Anesthesia providers in ambient room temperature of 75 degreees (neutral room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
3031083|NCT02354742|Active Comparator|Early Goal Directed Therapy (EGDT)|EGDT is currently standard of care in management of septic shock, so assignment to this treatment arm will confer no additional risk above that of standard of care. EGDT utilizes placement of a central venous catheter, an arterial catheter, and administration of intravenous fluid and vasoactive medications. EGDT uses central venous catheter to assess central venous pressure and ScVO2.
3031084|NCT02354742|Experimental|Echo Guided Fluid Resuscitation|The echo arm also utilizes placement of a central venous catheter, an arterial catheter, and administration of intravenous fluid and vasoactive medications, all of which are interventions found in standard care. The central venous pressure will not be monitored in this arm. Instead, decisions for giving fluids will be directed by the results of Echocardiography. Echocardiography poses no known risk to the patient, and it is non-invasive. The only risk of echocardiography is that of misdiagnosis.
3031085|NCT02354729|Experimental|Intervention|Participants received text messages and financial incentives after successfully documenting that they were carrying their epinephrine auto-injectors, based on principles of behavioral economics.
3031086|NCT02354729|No Intervention|Control|Participants received text messages.
3031087|NCT02354716||EndoFLIP Measurements|To define the role of a functional luminal imaging probe (EndoFLIP) in benign upper GI luminal narrowing. EndoFlip measurement of the cross sectional area of the narrowing will be obtained prior to and after endoscopic dilation. Patients will follow up for repeat endoscopy and dilation if indicated. EndoFLIP measurements will be made again before and after dilation. The use of EndoFlip may offer insight in to the clinical and endoscopic predictors of successful stricture dilation.
3031088|NCT02354703|Experimental|ondansetron|"ondansetron-0.33 mg bid + BBCET for 16 weeks arm equally divided between two genetic subgroups~at Maryland site: carriers of any of the following genotypes~5-HTTLPR:LL plu rs25531:AA (LALA genotype) in SLC6A4 gene; or~SLC6A4-rs1042173:TT, or~HTR3A-rs1150226:AG; or~HTR3A-rs1176713:GG; or~HTR3B-rs17619942: AC and carriers of any other genotype~At Pennsylvania site:~carriers of HTR3B- rs176744: CC or CT and carriers of HTR3B- rs176744: TT"
3031089|NCT02354703|Placebo Comparator|placebo|"BBCET for 16 weeks arm equally divided between two genetic subgroups~At Maryland site:~carriers of any of the following genotypes~5-HTTLPR:LL plu rs25531:AA (LALA genotype) in SLC6A4 gene; or~SLC6A4-rs1042173:TT, or~HTR3A-rs1150226:AG; or~HTR3A-rs1176713:GG; or~HTR3B-rs17619942: AC and carriers of any other genotype~At Pennsylvania site:~carriers of HTR3B- rs176744: CC or CT and carriers of HTR3B- rs176744: TT"
3031090|NCT02354690|Experimental|A|7 days before tumor harvest, patients will begin taking vemurafenib until admission for lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine, followed by TIL infusion and interleukin-2.
3031091|NCT02354677|Experimental|Heathy volunteers, smokers and COPD|
3031092|NCT02354664||Pompe subjects|These subjects will receive a thoracic MRI, spirometry, inspiratory load compensation, maximal inspiratory pressure, resting breathing pattern, respiratory muscle endurance test.
3031093|NCT02354664||Control subjects|These subjects will receive a thoracic MRI, spirometry, inspiratory load compensation, maximal inspiratory pressure, resting breathing pattern, respiratory muscle endurance test.
3031094|NCT02354651||Pompe subjects receiving NeuDx DPS|Patients will receive pulmonary function testing, resting breathing pattern evaluation, respiratory muscle endurance testing, phrenic nerve stimulation, maximal inspiratory pressure (MIP) testing, forced expiratory testing, and EMG.
3031095|NCT02354638|Experimental|Tobacco users: behavioural counseling|The cab drivers using tobacco will be invited to participate in the tobacco cessation programme at the TCC and will receive three monthly follow-up for one year. Thus intervention will be in the form of behavioural therapy and pharmacotherapy (if required)
3031096|NCT02354638|No Intervention|Non Users|The cab drivers who are not using tobacco in any form will not receive any type of intervention
3031097|NCT02354625|Experimental|ahSC transplantation|Autologous human Schwann cells
3031098|NCT02354612|Experimental|TRC105|Weekly or biweekly TRC105 i.v. in combination with companion therapy (if applicable) from the parent trial or single agent TRC105 as per the parent trial. Companion therapy includes but is not limited to: bevacizumab, capecitabine, pazopanib or axitinib
3031099|NCT02354599|Experimental|Cohort 1: MT203 80 mg|Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
3031100|NCT02354599|Placebo Comparator|Cohort 1: MT203 80 mg matching placebo|Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
3031101|NCT02354599|Experimental|Cohort 2: MT203 150 mg|Six Japanese participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
3031102|NCT02354599|Placebo Comparator|Cohort 2: MT203 150 mg matching placebo|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
3031103|NCT02354599|Experimental|Cohort 3: MT203 300 mg|Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
3031104|NCT02354599|Placebo Comparator|Cohort 3: MT203 300 mg matching placebo|Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
3031105|NCT02354599|Experimental|Cohort 4: MT203 150 mg|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
3031106|NCT02354599|Placebo Comparator|Cohort 4: MT203 150 mg matching placebo|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously
3031107|NCT02354586|Experimental|Niraparib|
3031108|NCT02354573|Active Comparator|Active arm|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
3031109|NCT02354573|Placebo Comparator|Placebo arm|All subjects will receive matching placebo tablets twice daily for 2 weeks in a double-blind randomized crossover design.
3058604|NCT02171013|Experimental|Dabigatran etexilate batch A|
3031111|NCT02354547|Experimental|SGT-53 with Topotecan/Cyclophosphamide|There will be 4-6 cycles (21 days/cycle) of therapy in this trial. In cycle 1, SGT-53 will be given as a single agent twice weekly starting at 1.4 mg/m² of DNA per infusion to evaluate single-agent toxicity. Pharmacokinetic studies will be performed. In the absence of dose limiting toxicity, patients will proceed to cycle 2 even if they have progressive disease. Starting in cycle 2, SGT-53 will be administered twice-weekly in combination with topotecan and cyclophosphamide administered daily for 5 days, days 1-5 of each cycle. Day 1 of each combination cycle is the first day on which topotecan and cyclophosphamide are administered with SGT-53. If a subject has at least stable disease after four cycles of therapy and is tolerating protocol therapy, two additional cycles may be considered.
3031112|NCT02354534|Experimental|50 mg Artesunate suppositories, 1 cycle|Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
3031113|NCT02354534|Experimental|200 mg Artesunate suppositories, 1 cycle|Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
3031114|NCT02354534|Experimental|200 mg Artesunate suppositories,2 cycles|Subjects enrolled in this cohort will receive 2 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
3031115|NCT02354534|Experimental|200 mg Artesunate suppositories,3 cycles|Subjects enrolled in this cohort will receive 3 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
3031116|NCT02354508|Experimental|Pasireotide LAR|Patients who qualify for the core phase of the study will be treated with pasireotide LAR 40 mg initially. Patients not achieving biochemical control can be up-titrated to pasireotide LAR 60 mg.
3031117|NCT02354495|Experimental|Diet intervention arm|Individualized diet prescription following food record, indirect calorimetry (for energy requirement) and body composition assessments. repeat assessments after 12 weeks on interventional diet.
3031118|NCT02354482||Patients|Patients undergoing care transitions; e.g. from hospital to home.
3031119|NCT02354482||Caregivers|Caregivers assisting patients undergoing care transitions
3031120|NCT02354469||Contact/Collision Sport Athletes|Collegiate athletes who participate in contact or collision sports will be assessed on a comprehensive battery of tests during pre-season and post-season assessments.
3031121|NCT02354469||Non-contact Sport Athletes|Collegiate athletes who participate in non-contact sports will be assessed on a comprehensive battery of tests during pre-season and post-season assessments.
3031122|NCT02354469||Post-Concussion|Collegiate athletes who sustain a concussion will be assessed on a comprehensive battery of tests from the time of injury and incrementally throughout the following year post-injury.
3031123|NCT02354469||Healthy Control|Collegiate athletes who do not sustain a concussion but match the demographic profile of an individual enrolled as a post-concussion subject, will be assessed on the same tests and in a similar timeline as post-concussion subjects.
3031124|NCT02354443|Experimental|ProHema-CB|ProHema-CB represents Ex Vivo Modulated Human Cord Blood Cells. Each subject will receive one administration of ProHema-CB unit transplant.
3031125|NCT02354430|Active Comparator|Water-exercise|
3031126|NCT02354430|No Intervention|Control group|
3031127|NCT02354417|Experimental|ProHema-CB|"All subjects will receive treatment with ProHema-CB (ex-vivo modulated human cord blood cells) transplant.~ProHema-CB (the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 also referred to as FT1050) will be prepared and administered in one of two formulations, based upon subject weight:~For subjects > 35 kg, ProHema-CB will be administered as 150 mL product in a blood bag via gravity infusion. It will be infused at 10 mL to 15 mL per minute, for a total infusion time of 10 to 15 min.~For subject's ≤ 35 kg, ProHema-CB will be administered as a 50 mL product in a syringe via syringe pump.o It will be infused at 5 mL/kg per hour for a total infusion time of up to ~1 hour."
3031128|NCT02354404|Experimental|Group 1a: cAd3-EBOZ at 1x10(10) PU|Part 1: cAd3-EBOZ at 1x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
3031129|NCT02354404|Experimental|Group 1b: cAd3-EBOZ at 1x10(11) PU|Part 1: cAd3-EBOZ at 1x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
3031130|NCT02354404|Experimental|Group 1c: cAd3-EBO at 2x10(10) PU|Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
3031131|NCT02354404|Experimental|Group 1d: cAd3-EBO at 2x10(11) PU|Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
3031132|NCT02354404|Experimental|Group 2a:cAd3-EBO at 2x10(10) PU|Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
3031133|NCT02354404|Experimental|Group 2b: cAd3-EBO at 2x10(11) PU|Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
3031134|NCT02354391|Experimental|Ingenol mebutate and MAL PDT|Participants will recieve Ingenol mebutate 0.015% topical gel treatment applied day 2,3 and 4 to quadrant 1. Patients will recieve ingenol mebutate 0.015% applied on day 1 followed by methyl aminolevulate and photodyamnic therapy on day 5 to quadrant 2. Particpants will recieve methyl aminolevulate and photodynamic therapy on day 5 to quadrant 3, and quadrant 4 will act as the control, with no treatment.
3031135|NCT02354378||Children undergoing sedation with Dexmedetomidine|Children who will undergo sedation for MRI will be given a memory encoding task during dexmedetomidine bolus induction to measure the effects of sedation. The mere task of naming a picture will encode that picture into memory. When the anesthesia has worn off (at approximately 1 hour later), children will be given a memory recognition task to measure the amnesic effects of dexmedetomidine.
3031136|NCT02354378||Children not undergoing sedation|A control group of children of similar age scheduled for MRI will be recruited to perform memory recognition testing.
3031172|NCT02354105||CZP treatment|axSpA patients who have been newly prescribed Certolizumab Pegol (CZP).
3031137|NCT02354365||Normal lungs|Mechanically ventilated patients without pulmonary parenchymal disease or lower airway disease as measured by flow volume loops consistent with expiratory flow obstruction (e.g. seizures, apnea, upper airway obstruction).
3031138|NCT02354365||Acute Hypoxic Respiratory Failure|Mechanically ventilated patients with two consecutive Saturation to FiO2 (SF) ratio < 265 or PaO2 to FiO2 (PF) ratio < 300 (e.g. pneumonia, ARDS).
3031139|NCT02354365||Obstructive airway disease|Mechanically ventilated patients with flow volume loops consistent with expiratory flow obstruction (e.g. asthma, bronchiolitis).
3031140|NCT02354352|Active Comparator|Eplerenone|Eplerenone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Inspra. Eplerenone is a potassium-sparing diuretic.
3031141|NCT02354352|Active Comparator|Spironolactone|Spironolactone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Aldactone. Spironolactone is a potassium-sparing diuretic.
3031142|NCT02354339|Experimental|Irvingia gabonensis|Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
3031143|NCT02354339|Placebo Comparator|Placebo|Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
3031144|NCT02354326|Experimental|Diagnostic (VNC DECT)|Patients undergo CT scans with VNC DECT information
3031145|NCT02354326|Active Comparator|Diagnostic CT Scan|Patients undergo CT scans without VNC DECT information
3031146|NCT02354313|Experimental|Lenalidomide|lenalidomide 10-15 mg once daily on days 1-21, every 28 day, for two years
3031147|NCT02354313|No Intervention|Observation|no therapy is planned but only observation
3031148|NCT02354300||TCD Ultrasound|Transcranial doppler ultrasound monitoring during flow diverter placement.
3031149|NCT02354287||Patients having outpatient Colonoscopy.|Patients with Polyps ≤7mm that are deemed appropriate to be removed by cold forceps polypectomy with pre lift
3031150|NCT02354274|Active Comparator|Standard: Homogene dose plan|Treatment will be given over 33 treatments. The dose is 66 Gy.
3031151|NCT02354274|Experimental|Escalation: Inhomogene dose plan|"Radiation dose is increased to tumor and lymph nodes based on an inhomogeneous dose distribution determined by the most active ( FDG-PET criteria ) area of the node compared to a standard uniform dose distribution.~Treatment will be given over 33 treatments. The dose is as high as possible taking the tolerance of the normal tissue into consideration"
3031152|NCT02354261|Experimental|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-itraconazole daily.
3031153|NCT02354248|Experimental|Stroke patients|The patients will be submitted to a triple stimulation examination.
3031154|NCT02354248|Active Comparator|Control Subjects|This group of patients did not suffer from a stroke. They will also be submitted to a triple stimulation examination.
3031155|NCT02354235|Experimental|Canagliflozin + Teneligliptin|Patients receive Canagliflozin for 24 weeks in combination with Teneligliptin.
3031156|NCT02354235|Placebo Comparator|Placebo + Teneligliptin|Patients receive placebo for 24 weeks in combination with Teneligliptin.
3031157|NCT02354222|Experimental|Teneligliptin + Canagliflozin|Patients receive Teneligliptin for 24 weeks in combination with Canagliflozin.
3031158|NCT02354222|Placebo Comparator|Placebo + Canagliflozin|Patients receive placebo for 24 weeks in combination with Canagliflozin.
3031159|NCT02354209||HIV-1 patients receiving bPI ARV|"Non interventional study. Interventions will be clinically directed rather than by protocol.~The following procedures will be carried out:~Questionnaire on compliance and adherence~Clinic Visit~20ml blood sample to be taken for Virological Resistance Testing and Next Generation Sequencing (only if plasma viral load is detectable)"
3031160|NCT02354196||CCTA|Subjects who underwent a CCTA
3031161|NCT02354183|Experimental|Commitment|A 1-hour orientation session consisting of DBT commitment strategies plus psychoeducation. Therapists will also use commitment strategies to discuss goals related to self-harm. The psychoeducation will consist of information about DBT's biosocial theory and about why people self-harm. All participants will complete a DBT skills training group after their orientation.
3031162|NCT02354183|Active Comparator|Psychoeducation|A 1-hour orientation session consisting of psychoeducation only. The psychoeducation will consist of information about DBT's biosocial theory and about why people self-harm. All participants will complete a DBT skills training group after their orientation.
3031163|NCT02354170|Experimental|Cohort 1 (m300)|One (1) 300-mg mifepristone tablet, taken once daily for 4 weeks
3031164|NCT02354170|Experimental|Cohort 2 (m900)|Three (3) 300-mg mifepristone tablets (900-mg dose), taken once daily for 4 weeks
3031165|NCT02354170|Placebo Comparator|Cohort 3 (Placebo)|Placebo taken once daily for 4 weeks
3031166|NCT02354144|Experimental|Carrageenan-based gel|"The intervention to be administered is:~a commercially available gel that contains carrageenan.~water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the placebo gel.~also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water."
3031167|NCT02354144|Placebo Comparator|Control gel|"The intervention to be administered is:~a commercially available gel that does not contain carrageenan.~water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the carrageenan-containing gel.~also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water."
3031168|NCT02354131|Experimental|Niraparib monotherapy|Niraparib mono therapy until progression
3031169|NCT02354131|Experimental|Niraparib-bevacizumab combination|Niraparib-bevacizumab combination therapy until progression
3031170|NCT02354118|Active Comparator|Control Group|Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
3031173|NCT02354092|Sham Comparator|Sham Group|"This non-intervention group will receive the sham paracervical block. This intervention will include~Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement~Local anesthetic for tenaculum placement~Sham Paracervical Block done with capped spinal needle~osmotic dilators placed in the usual fashion~postprocedural assessment"
3031174|NCT02354092|Experimental|Paracervical Block Group|"This intervention group will receive the paracervical block. This intervention will include~Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement~Local anesthetic for tenaculum placement~18 ml 1% buffered lidocaine Paracervical Block~osmotic dilators placed in the usual fashion~postprocedural assessment"
3031175|NCT02354079|Other|genetic analysis|
3031176|NCT02354066|Experimental|Hallux valgus Surgery|Measurement of the Brake Response Time by Pat. undergoing hallux valgus surgery (first metatarsal osteotomy, Chevron, SCARF, Austin, etc.)
3031177|NCT02354066|Experimental|Hallux valgus and forefoot surgery|Measurement of the Brake Response Time by Pat. undergoing hallux valgus surgery (first metatarsal osteotomy; Chevron, Austin, SCARF, etc.) and additional forefoot surgery (PIP arthrodesis, second/third/etc. metatarsal osteotomy, etc.; Peg-in-Hole, WEIL-Osteotomy, etc.)
3031178|NCT02354066|Experimental|Control Run|Measurement of the Brake Response Time by Healthy Participants; control run; brake response time measurement with normal shoe and both foot orthoses
3031179|NCT02354053|Active Comparator|Current ART|Current ART + adherence support
3031180|NCT02354053|Experimental|Triumeq|Triumeq + adherence support
3031181|NCT02354040|Experimental|Talking Rx|Assigned to receive Health Literacy and Reminder Updates via the IT based intervention Talking Rx, in addition to Usual Care for patients in the intervention group. The physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
3031182|NCT02354040|No Intervention|Usual Care, Prescriptions and Counselling|Assigned to receive a standard prescription and Counselling only, there are no cointerventions in this group
3031183|NCT02354027|Experimental|SHR3824 25mg/metformin 1000mg|Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.
3031184|NCT02354014|Experimental|TMC207/Background Regimen (BR)|There will be 4 age based cohorts. Participants will be enrolled concurrently in Cohorts 1 and 2 followed by sequential enrollment of Cohorts 3 and 4. Cohort 1: greater than or equal to(>=) 12 to less than(<) 18 years: bedaquiline (TMC207) tablet orally as 400 mg, once daily(qd),for first 2 weeks,followed by TMC207, 200 mg 3 times per week (tiw) for 22 weeks; Cohort 2: >=5 to <12 years: TMC207 tablet given orally as 200 mg, qd, for first 2 weeks, followed by TMC207, 100 mg, tiw for 22 weeks. Cohort 3: >=2 to <5 years:Dose will depend upon review of safety and pharmacokinetic (pk) data from Cohort 1 and 2 by internal safety monitoring group(ISMG); Cohort 4: 0 months to <2 years:Dose will depend upon review of safety and pk data from Cohort 1, 2 and 3 by ISMG. TMC207 will be given in combination with Background Regimen of Multidrug Resistant Tuberculosis (MDR-TB) according to World Health Organization (WHO)/National Tuberculosis Program (NTP) guidelines/current standard of care.
3031185|NCT02354001|Experimental|Raloxifene Hydrochloride|120 mg per capsule (1 tablet daily)
3031186|NCT02354001|Placebo Comparator|placebo tablet|1 tablet daily for 12 weeks
3031187|NCT02353988|Experimental|bicalutamide|This is a multi-center, open-label, phase II study to evaluate the anti-tumor activity and safety of bicalutamide administered orally daily to patients with estrogen receptor (ER)-negative/ progesterone receptor (PgR)-negative/ androgen receptor (AR)-positive metastatic breast cancer. Eligible patients will receive bicalutamide at a dose of 150mg PO daily.
3031188|NCT02353988|Active Comparator|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable
3031189|NCT02353975|Experimental|SHR3824 10mg fasted to fed|SHR3824 tablet, fasting conditions day 1, visit 2, 7 days wash-out, SHR3824 tablet, high fat, high calorie breakfast day 1, visit 3.
3031190|NCT02353975|Experimental|SHR3824 10mg fed to fasted|SHR3824, high fat, high calorie breakfast day 1, visit 2, 7 days wash-out, SHR3824, fasting conditions day 1, visit 3.
3031191|NCT02353962|Experimental|Neglect Exergames|Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. 5 sessions per week, 30-45 minutes per training for 3 weeks, with an intensity individually adjusted by the treating therapist according to the progress of the participating patient.
3031192|NCT02353949|Experimental|Flutmetamol Group|PET-MR-Scan with 80-140 MBq Flutemetamol before observational period for diagnostic purpose
3031193|NCT02353936|Experimental|afatinib group|
3031194|NCT02353923|Experimental|OcuStem Supplementation|Twice daily supplementation with OcuStem. Subjects will take 2 capsules in the morning and 2 capsules at night for a total of 2800 mg/day of active ingredients.
3031195|NCT02353884||MCIp,MCIs|progressive MCI：those convert to AD in two years, stable MCI
3031196|NCT02353884||MCI，HC|mild cognitive impairment, healthy control
3031197|NCT02353871|Experimental|BTX-A-HAC NG|Clostridium Botulinum Toxin Type A (BTX-A-HAC NG) 50 Unit (U) solution, single dose (intramuscular injection). The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region. A total of 50 U was injected.
3031198|NCT02353871|Placebo Comparator|Placebo|Single dose (intramuscular injection). The total placebo volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region.
3031199|NCT02353858|Experimental|RtChx + Hyperthermia|Radiotherapy: 5 x 1,8 Gy/Week, cumulative dose 50,4 Gy (ICRU) Chemotherapy: 5-fluorouracil d1-5 and d29-d33 Deep regional hyperthermia: 2x/week
3031200|NCT02353845||aMCI|aMCI means a group of patients who do not qualify for a diagnosis of dementia but do display memory impairment beyond what is expected for their age and with regards to the educational history and with positive β-amyloid PET
3031201|NCT02353845||normal control|
3031399|NCT02352558|Experimental|Arm 6|Patients with multiple myeloma treated with BBI608 and bortezomib
3031202|NCT02353845||aMCIp|progressive aMCI：aMCI subjects who will convert to AD during the follow-up period
3031203|NCT02353845||aMCIs|stable aMCI：aMCI subjects who will not convert to AD during the follow-up period
3031204|NCT02353832|Experimental|Injectable Rectal Spacer|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)
3031205|NCT02353819|Experimental|Stereotactic Ablative Radiotherapy|Stereotactic Ablative Radiotherapy (SABR)
3031206|NCT02353806|Experimental|Pregnant women taking amlodipine|Women already taking amlodipine besylate 5 mg for treatment of chronic hypertension in pregnancy who plan to breastfeed postpartum will be assigned to the single experimental arm.
3031207|NCT02353793|Experimental|ReadyHeat® blanket|Patient warming with ReadyHeat® blanket
3031208|NCT02353793|Active Comparator|Cotton wool blanket|Patient warming with cotton wool blanket
3031209|NCT02353780|Active Comparator|Different TNF inhibitor|The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.
3031210|NCT02353780|Active Comparator|Abatacept|The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.
3031211|NCT02353780|Active Comparator|Tocilizumab|The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.
3031212|NCT02353767||Cases|Presence of metabolic syndrome according to the International Diabetes Foundation (IDF)
3031213|NCT02353767||Controls|"age ± 7 years from cases~duration of HIV-1 infection ± 3 years from cases~HIV-1 viral load matched to cases according to 3 thresholds: 50 - 500, 501 - 1000 or > 1000 copies/mL"
3031214|NCT02353754|Active Comparator|Standard of Care|Subjects in Group 1 (Standard of Care) will receive intrathecal morphine injection (e.g., Duramorph®) 0.2 mg in conjunction with the single-shot spinal anesthesia. No TAP block will be administered.
3031215|NCT02353754|Experimental|EXPAREL/TAP|Subjects in Group 2 will receive a bilateral TAP infiltration with a single 20 mL dose of EXPAREL 266 mg expanded in volume with 20 mL of normal saline for a total volume of 40 mL (20 mL infiltrated on each side of the abdomen).
3031216|NCT02353741|Experimental|EGFR-TKIs combined with radiotherapy|EGFR-TKIs combined with concurrent thoracic radiotherapy. Receive oral erlotinib 150mg per day with concurrent thoracic radiotherapy, within 2 weeks, pGTV54～60Gy/27～30f/5.5～6w.
3031217|NCT02353728|Experimental|All Patients|Nilotinib at a dose of 300 mg P.O. twice a day (BID) daily
3031218|NCT02353715||Enzalutamide|Subjects will be administered enzalutamide per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
3031219|NCT02353715||Abiraterone|Subjects will be administered abiraterone acetate per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
3031220|NCT02353715||Sipuleucel-T|Subjects will be administered sipuleucel-T per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
3031221|NCT02353702|Experimental|Infusion of Ropivacaine during 48 hours|"Evaluation of diaphragmatic function with Sniff test after 48h continuous parietal infiltration of Ropivacaine using parietal catheter at the following dose :~20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml)"
3031222|NCT02353702|Placebo Comparator|Infusion of placebo during 48 hours|"Evaluation of diaphragmatic function with Sniff test after 48h continuous parietal infiltration of placebo using parietal catheter at the following dose :~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour (NaCl 0.9 %)"
3031223|NCT02353689|Experimental|low FODMAP group|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
3031224|NCT02353689|Experimental|moderate FODMAP group|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
3031225|NCT02353689|Experimental|high FODMAP group|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
3031226|NCT02353676|Experimental|BUPIVACAINE GROUP|1.5 ml of 0.5% Bupivacaine solution to be injected into the operative site postoperatively.
3031227|NCT02353676|Placebo Comparator|PLACEBO GROUP|1.5 ml of saline solution to be injected into the opposite site postoperatively.
3031228|NCT02353663||All study participants|Schoolgoing children 5 to 16 years of age
3031229|NCT02353637|Active Comparator|Male High Protein, Restricted Carbo, Partial Meal Replacement|A high protein, restricted carbohydrates diet that utilizes partial meal replacements
3031230|NCT02353637|Active Comparator|Female High Protein, Restricted Carbo, Partial Meal Replaceme|A high protein, restricted carbohydrates diet that utilizes partial meal replacements
3031231|NCT02353611|Experimental|6% bleaching agent|One upper hemiarch will be bleached with 6% hydrogen peroxide with titanium oxide nanoparticles, activated by a led/laser hybrid light. Whitening compound will be mixed according to manufacturer's instructions and distributed uniformly over the buccal surface of the teeth of one upper hemiarch. In each bleaching session the gel will be applied twice for 12 minutes each and activated with continuous irradiance using the LED/laser light (Whitening Lase Plus-DMC Equipamentos, São Carlos, SP, Brazil). Three bleaching sessions will be completed with an interval of 7 days between them.
3031232|NCT02353611|Active Comparator|35% bleaching agent|Together with the experimental agent application, the other upper hemiarch will be bleached with 35% hydrogen peroxide whitening compound. The compound will be mixed according to manufacturer's instructions and distributed uniformly over the buccal surface of the teeth of the corresponding hemiarch. The gel will be applied twice for 12 minutes each and irradiated using the LED/laser light (Whitening Lase Plus-DMC Equipamentos, São Carlos, SP, Brazil). Three bleaching sessions will be completed with an interval of 7 days between them.
3031233|NCT02353598|Experimental|Double-blind treatment window: Crenezumab dose level 1|Participants will recieve crenezumab dose level 1 once every 4 weeks.
3031234|NCT02353598|Experimental|Double-blind treatment window: Crenezumab dose level 2|Participants will receive crenezumab dose level 2 once every 4 weeks.
3031235|NCT02353598|Experimental|Double-blind treatment window: Crenezumab dose level 3|Participants will receive crenezumab dose level 3 once every 4 weeks.
3031236|NCT02353598|Placebo Comparator|Double-blind treatment window: Placebo|Participants will receive placebo matched to crenezumab once every 4 weeks.
3058605|NCT02171013|Experimental|Dabigatran etexilate batch B|
3031237|NCT02353598|Experimental|Optional OLE window: Crenezumab|Participants will receive crenezumab dose levels 1 2, or 3 once in every 4 weeks.
3031238|NCT02353585||Intracranial hemorrhage|Intracranial hemorrhage occuring in patients on novel oral anticoagulants (NOAC) or vitamin-K antagonists
3031239|NCT02353585||Acute ischemic stroke|Acute ischemic stroke occuring in patients on novel oral anticoagulants (NOAC) or vitamin K antagonists (VKA)
3031240|NCT02353572|Experimental|Melphalan, Bortezomib, Autologous transplant|Patients receive melphalan IV continuously on days -5 to -2 and bortezomib IV over 3-5 seconds on days -4 and -1. Patients also receive dexamethasone IV on day -1 prior to the second dose of bortezomib. Beginning two days after completion of melphalan infusion, patients undergo autologous hematopoietic stem cell transplant. Eligible patients may undergo a second transplant 2-4 months after completion of the first transplant.
3031241|NCT02353559|Experimental|EASE|Patients assigned to the intervention arm will receive 8 - 12 psychotherapy sessions lasting 30 - 60 minutes each, delivered by a trained therapist at our center. Patients will receive specialized symptom control from a nurse/physician team in our Palliative Care Service, when indicated by routine symptom screening.
3031242|NCT02353559|No Intervention|Usual Care|Usual care
3031243|NCT02353546|Experimental|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
3031244|NCT02353546|No Intervention|Usual Care|
3031245|NCT02353533|Other|EMR|Standard EMR technique
3031246|NCT02353533|Experimental|FTRD|
3031247|NCT02353507|Active Comparator|Opticell Ag+|Absorbent, antibacterial, barrier dressing
3031248|NCT02353507|Active Comparator|Aquacel Ag+|Absorbent, antibacterial, barrier dressing
3031249|NCT02353481||Heart Failure|All patients in the audit that meets the eligibility criteria
3031250|NCT02353468|Experimental|Enzyme inhibitor, biological therapy, chemotherapy|"CONSOLIDATION: Patients receive VLD therapy comprising bortezomib IV on days 1, 4, 8, and 11, lenalidomide PO QD on days 1-14, and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Courses continue for 28 days and repeat every 3 months in the absence of disease progression or unacceptable toxicity.~In between courses of VLD, patients receive LD therapy comprising lenalidomide PO QD on days 1-21 and dexamethasone PO QD or IV every Monday (x3). Courses continue for 28 days.~MAINTENANCE: Starting in the third year of therapy, patients receive lenalidomide PO QD on days 1-14 and dexamethasone PO QD or IV every Monday (x2). Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
3031251|NCT02353455||healthy|"donors/patients without liver disease, with and without ongoing drug therapy including buffy coat samples of healthy blood / thrombocyte donors.~After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed . Buffy coats are obtained anonymously."
3031252|NCT02353455||prior to therapy|History will be obtained and blood sampling will be performed in patients in whom a drug therapy with a drug with DILI potential is planned.
3031253|NCT02353455||iDILI|Patients with clinical suspicion of idiosyncratic drug-induced liver injury. After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed.
3031254|NCT02353455||non DILI|Patients with other forms of liver injury. After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed.
3031255|NCT02353442|Placebo Comparator|Control group|"This group will perform during 4 weeks:~placebo ultrasound during 5min ;~scapular squeezing in the sitting position (3x10repetitions);~upper trapezius stretching (in sitting position, 3x30s and 30s of rest)."
3031256|NCT02353442|Active Comparator|Experimental group|"This group will perform during 4 weeks:~posterior shoulder mobilizations during 5min (mobilizations during 30s and 30s of rest);~external rotators strengthening in sidelying positions with load (3x10repetitions);~posterior capsule stretching (sleeper stretch in sidelying position, 3x30s and 30s of rest)."
3031257|NCT02353429|Experimental|Toremifene treatment|Patients will receive 60 mg daily of Toremifene and the dose will be escalated to 180 mg daily in case of progression
3031258|NCT02353416|Placebo Comparator|INRAM guidelines' diet|Intervention in this arm consists in some general dietary advice about healthy dietary components, serving size and frequency of servings following the Italian official guidelines.
3031259|NCT02353416|Active Comparator|Low Glycemic Index Mediterranean Diet|Intervention in this arm consists in a Low Glycemic Index Mediterranean Diet with indication about type of foods than can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
3031260|NCT02353403|Placebo Comparator|Sugar|Control group consuming a dairy dessert containing 35g of dextrose.
3031261|NCT02353403|Experimental|FOS|Group consuming a dairy dessert in which 30% of the dextrose was replaced by FOS.
3031262|NCT02353390|Active Comparator|Oral Water Hydration|Subjects will be given up to 15 minutes to drink up to 500 mL of water prior to the first IM vaccination.
3031263|NCT02353390|No Intervention|Usual Care|Subjects will receive usual care prior to the first IM vaccination. No water or food will be offered.
3031264|NCT02353364|Experimental|Group A|Transfer of 1 or 2 biopsied euploid embryo of high morphological grade based on NGS testing using CNV-Seq (PGS)
3031265|NCT02353364|No Intervention|Group B|Transfer of 1 or 2 non-biopsied embryo of high morphological grade (no PGS)
3031266|NCT02353338|Experimental|Group A: Surgical|Individuals in Group A will receive surgery to correct their radial fracture
3031267|NCT02353338|Active Comparator|Group B: Conservative Treatment|Individuals in Group B will be immobilized in a cast, as per usual standard of conservative treatment.
3031268|NCT02353325|Experimental|non-encapsulated FeSO4|Maize porridge with salt fortified with non-encapsulated FeSO4
3031269|NCT02353325|Experimental|encapsulated FeSO4, before cooking|Maize porridge with salt fortified with non-encapsulated FeSO4, added before cooking
3031270|NCT02353325|Experimental|encapsulated FeSO4, after cooking|Maize porridge with salt fortified with non-encapsulated FeSO4, added after cooking
3031271|NCT02353325|Experimental|non-encapsulated FeSO4 + ascorbic acid|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid
3031272|NCT02353325|Experimental|encapsulated FeSO4 + ascorbic acid, before cooking|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid, added before cooking
3031396|NCT02352558|Experimental|Arm 3|Patients with acute myeloid leukemia or myelo-dysplastic syndrome treated with BBI608
3031273|NCT02353325|Experimental|encapsulated FeSO4 + ascorbic acid, after cooking|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid, added after cooking
3031274|NCT02353312|Experimental|Initial Intervention Arm|Kuvan® supplementation in addition to standard care for heart failure for three months. At the end of three months, stop Kuvan®, patients will only receive Standard care for heart failure for another 3 months
3031275|NCT02353312|Active Comparator|Delayed Intervention Arm|Standard care for heart failure for three months. At the end of three months, Starting Kuvan® supplementation in addition to Standard care for heart failure for another 3 months
3031276|NCT02353299|Active Comparator|Silenor 6 mg (DXP-4H)|Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments
3031277|NCT02353299|Placebo Comparator|Placebo (PBO-4H)|placebo single nightime dose -4 hour post dose arousability and cognitive assessments
3031278|NCT02353299|Active Comparator|Zolpidem 10 mg (ZOL-1.5H)|zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments
3031279|NCT02353299|Placebo Comparator|Placebo (PBO-1.5H)|placebo single nightime dose -1.5 hour arousability and cognitive assessments
3031280|NCT02353286|Experimental|Post-cholecystecomy bile leak|Endoscopic insertion of biodegradable biliary stent
3031281|NCT02353286|Experimental|Benign biliary stricture|Endoscopic insertion of biodegradable biliary stent
3031282|NCT02353273|Experimental|WH-1 ointment|WH-1 ointment(1.25%),15g ointment per tube.
3031283|NCT02353260|Experimental|Ultrasound Hyperthermia+Chemotherapy|"Chemotherapy:~Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)~The treatments will be administrated in accord with the guideline for other types of cancer.~Ultrasound Hyperthermia: Ultrasound hyperthermia d1,3,5,7,9/21d for 2 cycles"
3031284|NCT02353260|Active Comparator|Chemotherapy|"Chemotherapy:~Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2cycles)~The treatments will be administrated in accord with the guideline for other types of cancer."
3031285|NCT02353247|Other|Norethindrone acetate (aygestin)|Norethindrone acetate (aygestin) will be used to manage bothersome bleeding. Patients will be prescribed aygestin 5 mg by mouth twice daily for one month, followed by aygestin 5 mg by mouth once daily for two months. Medication will then be discontinued. Patients will be evaluated in the office three months after medication initiation, and then again six months after medication initiation. If the patient is unable to take norethindrone acetate (aygestin) due to medical contraindications or cost, they will receive medroxyprogesterone acetate (provera) 10 mg once daily as alternate oral progesterone. Figure 1 below highlights the study
3031286|NCT02353234|Active Comparator|WHOLEGRAIN BREAD|Subjects feed with wholegrain bread, for which ferulic acid content has been quantified.
3031287|NCT02353234|Active Comparator|WHITE BREAD WITH ALEURONE - 4|Subjects feed with white bread with aleurone fraction in the same portion as wholegrain bread.
3031288|NCT02353234|Active Comparator|WHITE BREAD WITH ALEURONE - 8|Subjects feed with white bread with aleurone fraction, which contains the same quantity of ferulic acid as wholegrain bread.
3031289|NCT02353221||Subjects|Entry criteria include being at least 18 years old at screening visit, being able to understand the information given to them and to give written informed consent, willingness to comply with the requirements of the data collection, absence of a diagnose of autoimmune disease or inflammatory arthritis, and absence of a previous treatment with any disease modifying anti-rheumatic drug (DMARD). We will exclude patients that are pregnant or intend to become pregnant during the time of follow up.
3031290|NCT02353221||Controls|Healthy control subjects will be recruited based on similar criteria as study subjects. Our effort will be to include age and gender matched control subjects in the registry. We will be also aiming to match environmental characteristics (i.e. partners living in same location as registry subject or in a radius of 10 miles for at least one year previous to the date of evaluation) or genetic background (i.e. by asking the participation of first-degree relatives)
3031291|NCT02353208|Active Comparator|Sham Feeding of Bacon Bits|"In addition to the standard procedure, subjects will be asked to perform sham feeding on two occasions: 1) Immediately after having swallowed the capsule and 2) One hour after having swallowed the capsule.~Sham feeding will be performed as follows: The patients will be asked to chew 10 times on a piece of bacon over a period of 30 seconds, prior to spitting saliva and bacon into a container. This will be repeated 10 times at one minute intervals.~The patient will then complete the capsule study as per the standard procedure.~Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada."
3031292|NCT02353208|Placebo Comparator|Placebo|The control group will not chew bacon bits while undergoing capsule endoscopy.
3031293|NCT02353195|Experimental|Radio-frequency group|The equipment used, (INDIBA® activ 902, (448kHz)). The electricity was administered in the following manner: cream was applied to the site with the severe rest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient. Therapy was conducted for 12 minutes, two times per week over four weeks (eight sessions in total)
3031294|NCT02353195|Placebo Comparator|Placebo group|All patients were treated with the same device in a nonfunctional application (no energy source) and the therapy was conducted for 12 minutes, two times per week over four weeks (eight sessions in total).
3031295|NCT02353182|Experimental|Active open label single arm|"Dexmedetomidine- remifentanil- caudal based anaesthetic for lower abdominal/lower extremity surgery.~Dexmedetomidine (Precedex): loading dose: 1 mcg/kg over 10 minutes. Infusion: Start 1 mcg/kg/hr; titrate up or down within 50% of starting doses as needed~Remifentanil (Ultiva): loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed~Caudal- Bupivacaine (Marcaine) 0.175%-0.25% or Ropivacaine (Naropin) 0.2% with dose at discretion of anaesthetist"
3031296|NCT02353169|Experimental|Dexmedetomidine 0.25mcg/kg|0.25mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
3031297|NCT02353169|Experimental|Dexmedetomidine 0.5mcg/kg|0.5mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
3031397|NCT02352558|Experimental|Arm 4|Patients with chronic myeloid leukemia treated with BBI608
3058606|NCT02171000|Experimental|BIBR 1048|BIBR 1048 MS
3031298|NCT02353169|Experimental|Dexmedetomidine 0.75mcg/kg|0.75mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
3031299|NCT02353169|Sham Comparator|Saline bolus|10mL normal saline solution administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
3031300|NCT02353156|Experimental|Electronic bidet|Electronic bidet for 3min at early morning for 4 weeks after hemorrhoidectomy
3031301|NCT02353156|Active Comparator|Sitz bath|Wamr sitz bath for 3min at early morning for 4 weeks after hemorrhoidectomy
3031302|NCT02353143|Experimental|MEN1112|Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation
3031303|NCT02353130||Memantine-XR|Boys ages 8-12 with ASD treated with Memantine-XR daily for 8 weeks
3031304|NCT02353117|Active Comparator|Intervention|Behavioral intervention. The intervention will be multifaceted, tailored by formative research, and include: 1) opinion leaders, reminders, monitoring, and feedback; 2) point-of-care rapid tests and immediate treatment if the rapid test is positive; and 3) locally packaged treatment kits (benzathine penicillin 2.4 MIU, syringe and needle, instructions, and information on side-effects).
3031305|NCT02353117|No Intervention|Control|Prenatal care providers at control clinics will be invited to participate in a training workshop. They will be given refresher concepts on the prenatal care package and maternal and congenital syphilis and will be trained in syphilis case detection and management, using their standard and available screening methods. They will also be trained on how to document the screening and treatment process, using the same system as the intervention clinics. No other activities are planned in the control group; providers will be encouraged to disseminate and implement any strategy they consider useful to improve screening and treatment. Study personnel will ensure the availability of screening tests already in-use, as well as ensure the availability of benzathine penicillin at all control prenatal clinics.
3031306|NCT02353104|Experimental|Onion-Pumpkin Extract|Take two capsules, twice daily before breakfast and dinner
3031307|NCT02353091|Other|APD Group 1|APD Group 1 is comprised of 16 children diagnosed with APD and receives the device from the beginning of the study.
3031308|NCT02353091|Other|APD Group 2|APD Group 2 is comprised of 16 children diagnosed with APD and receives the device 3 months later than APD Group 1.
3031309|NCT02353078|Experimental|Sucralfate|This is a pilot study in which 6 patients with active EoE defined by consensus criteria (ref) who have undergone recent endoscopy will be administered sucralfate slurry 1 gram four times daily for four weeks following which repeat endoscopy with esophageal biopsies will be performed. Patients will be those who had not had medical treatment for EoE or those who have not responded to proton pump inhibitors.
3031310|NCT02353078|Experimental|Intraluminal Impedance|This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
3031311|NCT02353065|Active Comparator|Control|Assessment of adequacy of reduction by bedside x-ray during period of intravenous regional anaesthesia (Biers block)
3031312|NCT02353065|Experimental|Ultrasound|Assessment of adequacy of reduction by bedside ultrasound performed by the treating clinician during period of intravenous regional anaesthesia (Biers block)
3031313|NCT02353052||Treatment observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose postoperative Imatinib treatment are labeled treatment group.
3031314|NCT02353052||Control observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose no Imatinib treatment are labeled observation group.
3031315|NCT02353039|Experimental|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
3031316|NCT02353039|Experimental|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
3031317|NCT02353039|Experimental|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
3031318|NCT02353039|Placebo Comparator|Placebo|Administer placebo t.i.d for 2 weeks.
3031319|NCT02353026|Experimental|Intravenous Artesunate|Intravenous Artesunate administered on Day 1 and 8 every 3 weeks
3031320|NCT02353013|Active Comparator|Standard Protein Group|For infants in this group, the target protein-energy ratio (PER) will be ~3 g/100 kcal. This will be achieved by providing standard fortification by adding a commercially available human milk fortifier to human milk or by providing a preterm formula.
3031321|NCT02353013|Experimental|Enhanced Protein Group|For infants in this group, the target protein-energy ratio (PER) will be ~4 g/100 kcal. This will be achieved by providing standard fortification by adding a commercially available human milk fortifier to human milk or by providing a preterm formula. In addition, liquid protein will be added to provide protein supplementation and increase the PER.
3031322|NCT02353000|Experimental|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases:
3031323|NCT02353000|Other|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases:
3031324|NCT02352987|Experimental|Patients treated with 3 drugs|Neem plus propylene glycol plus salicylic acid: Neem extract, propylene glycol (40%) and salicylic acid (10%) once daily on palm for 12 weeks
3031325|NCT02352987|Active Comparator|Patients treated with 1 drug|Salicylic acid once daily on palm for 12 weeks
3031326|NCT02352974|Experimental|A|"GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals~Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days"
3031327|NCT02352948|Experimental|MEDI4736 (durvalumab) monotherapy in Sub-study A|MEDI4736 (durvalumab) by intravenous infusion. Sub-study A for patients with PD-L1 positive tumors.
3031328|NCT02352948|Active Comparator|Standard of Care in Sub-study A|Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study A for patients with PD-L1 positive tumors.
3031329|NCT02352948|Experimental|MEDI4736 (durvalumab) + tremelimumab in Sub-study B|MEDI4736 (durvalumab) by intravenous infusion and tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
3031330|NCT02352948|Active Comparator|Standard of Care in Sub-study B|Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study B for patients with PD-L1 negative tumors.
3031331|NCT02352948|Experimental|MEDI4736 (durvalumab) monotherapy in Sub-study B|MEDI4736 (durvalumab) by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
3031332|NCT02352948|Experimental|tremelimumab in Sub-study B|tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
3031333|NCT02352935|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
3031334|NCT02352922|Experimental|Liposomal Bupivacaine|extended-release bupivacaine (EXPAREL)
3031335|NCT02352922|Active Comparator|Bupivacaine HCl|short-acting bupivacaine
3031336|NCT02352909|Active Comparator|Control|Education will be given on how to modify running training to encourage improvement of symptoms.
3031337|NCT02352909|Experimental|Muscle recruitment|Subjects will receive an additional exercise program targeting non task-specific strengthening and motor control exercises of the lower limb.
3031338|NCT02352909|Experimental|Reduction of knee loading|Subjects will receive additional personalized advice on how to modify running gait in order to reduce mechanical loads at the knee (gait retraining).
3031339|NCT02352896|Experimental|EPI-743|EPI-743 administered at a dose of 15 mg/kg up to a total 200 mg three times daily
3031340|NCT02352883|Experimental|Arm A (MRI)|Patients undergo MRI prior to surgery. Patients undergo additional imaging and/or biopsies if indicated based on MRI.
3031341|NCT02352883|Experimental|Arm B (mastectomy)|Patients undergo a mastectomy. Patients do not register for Step 3.
3031342|NCT02352883|Experimental|Arm C (wide local excision)|Patients undergo wide local excision +/- re-excision. Patients may cross-over to Arm B if mastectomy is indicated. Tissue samples collected during surgery are used to calculate the DCIS score using genetic analysis testing. Patients may then proceed to Step 3.
3031343|NCT02352883|Experimental|Arm D (endocrine therapy)|Patients undergo endocrine therapy as directed.
3031344|NCT02352883|Experimental|Arm E (radiation therapy, endocrine therapy)|Patients undergo radiation therapy and endocrine therapy as directed.
3031345|NCT02352870|Experimental|Computerised CBT with therapist support|"Participants complete seven online cognitive behavioural therapy sessions weekly plus they receive three telephone support calls. The content of each of the sessions are summarised below:~Session 1: Psycho-education about end-stage renal failure Session 2: Generation of CBT hot cross bun model of psychological distress Session 3: Coping strategies for managing negative emotions, including: acceptance, relaxation, expression and tips for improving sleep quality.~Session 4: Identifying and challenging unhelpful thoughts Session 5: Goal setting and problem solving Session 6: Managing difficult social relationships Session 7: Progress recap and preparing for the future~In addition to completing the seven online sessions the intervention arm received three 30 minute telephone support calls at weeks two, four, and six to facilitate engagement and understanding of the contents of the website."
3031346|NCT02352870|Active Comparator|Computerised CBT without therapist support|"Participants complete seven online cognitive behavioural therapy sessions weekly but do not receive any telephone support calls. The content of each of the sessions are summarised below:~Session 1: Psycho-education about end-stage renal failure Session 2: Generation of CBT hot cross bun model of psychological distress Session 3: Coping strategies for managing negative emotions, including: acceptance, relaxation, expression and tips for improving sleep quality.~Session 4: Identifying and challenging unhelpful thoughts Session 5: Goal setting and problem solving Session 6: Managing difficult social relationships Session 7: Progress recap and preparing for the future"
3031347|NCT02352857|Placebo Comparator|Sugar|Control group consuming sponge cakes containing in total 24g of dextrose.
3031348|NCT02352857|Experimental|FOS|Group consuming sponge cakes in which 30% of the dextrose was replaced by FOS.
3031349|NCT02352844|Experimental|Arm 1 (everolimus)|Everolimus is an oral drug which will be administered on an outpatient basis at a dose of 10 mg daily on a 28-day cycle.
3031350|NCT02352831|Experimental|Phase I (tosedostat + capecitabine)|"Tosedostat by mouth daily Days 1-21 of each 21-day cycle~Capecitabine by mouth BID Days 1-14 of each 21-day cycle"
3031351|NCT02352831|Experimental|Phase II (tosedostat + capecitabine)|"Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle~Capecitabine by mouth BID Days 1-14 of each 21-day cycle"
3031352|NCT02352805||(1) veno-venous ECMO|ECMO - Patients being connected to veno-venous extracorporeal membrane oxygenation (ECMO)
3031353|NCT02352805||(2) veno-arterial ECLS|ECLS - Patients being connected to veno-arterial extracorporeal life support (ECLS)
3031354|NCT02352805||(3) LVAD (Heart Mate II)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Mate II)
3031355|NCT02352805||(4) LVAD (Heart Ware)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Ware)
3031356|NCT02352805||(5) LVAD (Impella)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Impella)
3031357|NCT02352805||(6) Dialysis system|Patients being connected to a dialysis system
3031358|NCT02352805||(7) LVAD (Heart Mate III)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Mate III)
3031359|NCT02352805||(8) HLM|HLM = Heart Lung Machine - patients undergoing coronary artery bypass grafting surgery and / or aortic valve replacement with cardiopulmonary bypass
3031360|NCT02352792|Active Comparator|Standard therapy|Standard radiochemotherapy (70 Gy, 5-fluorouracil 600 mg/m2 d1-5, mitomycin C d1+36 or cisplatinum 40 mg/m2 weekly for 5 weeks)
3031361|NCT02352792|Experimental|dose escalation|Standard plus 10% dose escalation to the hypoxic volume
3031362|NCT02352779|Experimental|Arm I (low-dose omega-3 fatty acid)|Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks.
3031363|NCT02352779|Experimental|Arm II (high-dose omega-3 fatty acid)|Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks.
3031364|NCT02352779|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO BID for 6 weeks.
3031398|NCT02352558|Experimental|Arm 5|Patients with multiple myeloma treated with BBI608 and dexamethasone
3058607|NCT02170987|Experimental|Dabigatran etexilate low|
3031365|NCT02352766||Routine FNA for thyroid nodules|Patients that undergo a clinically diagnostic thyroid FNA will be asked by their clinician, who is a study co-investigator, if they are interested in participating in the research study. A small part of FNA material will be collected for molecular analysis.
3031366|NCT02352753|Experimental|Denosumab|
3031367|NCT02352740|Experimental|Healthy subjects with 'hypertriglyceridemic waist'|"Subjects with overweight, elevated waist circumference and elevated fasting triglyceridemia.~Intervention : A form arginine and B form arginine"
3031368|NCT02352740|Experimental|Healthy subjects|"Control subjects, i.e. without overweight, elevated waist circumference and elevated fasting triglyceridemia.~Intervention : A form arginine and B form arginine"
3031369|NCT02352714|Active Comparator|Paracervical Nerve Block|Ten milliliters of 1% lidocaine paracervical anesthetic will be injected at three cervical locations: 1 mL at the tenaculum site (12 o'clock on a clock face) and 4.5 mL each at the 4 o'clock and 8 o'clock positions. A 3 minute waiting period will be used between the administration of the paracervical nerve block and the insertion of IUS to allow the paracervical block to take effect.
3031370|NCT02352714|Sham Comparator|Sham Paracervical Block|To perform the sham cervical block, the cervix will be touched with the blunt end of a Q-tip at the three locations described above for the paracervical block. The cervical mucosa will not be broken during the sham block. A 3 minute waiting period will again occur between administration of the sham block and IUS insertion to be consistent with the procedure used for the nerve block.
3031371|NCT02352701||Noltec®,ChongkundangAmoxicillin®,Cravit®|Noltec tab 10mg, Chongkundang Amoxicillin Cap 500mg 2caps and Cravit tab 500mg by oral, twice a day for 10 days
3031372|NCT02352688|Active Comparator|Enhanced Colorectal Geriatric Care|Multidisciplinary team involving in the elderly colorectal cancer patients' pre-, peri- and postoperative care.
3031373|NCT02352688|No Intervention|Standard Surgical Care|Standard care given to elderly patients undergoing colorectal cancer resection.
3031374|NCT02352675||Congenital Heart Disease|Infants with congenital heart disease (CHD) who are scheduled to undergo an elective cardiac catheterization lab procedure at Boston Children's Hospital
3031375|NCT02352675||Non Congenital Heart Disease|Infants who do not have congenital heart disease (No-CHD) and are scheduled to undergo a non-cardiac surgery (such as craniofacial surgery, neurosurgery, or orthopedic surgery) in the operating room at Boston Children's Hospital.
3031376|NCT02352662||Study Group|Three blood samples will be collected intra-operatively from each subject enrolled
3031377|NCT02352649|Experimental|Neovasculgen 1|Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 0,6 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.
3031378|NCT02352649|Experimental|Neovasculgen 2|Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 1,2 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.
3031379|NCT02352649|Placebo Comparator|water for injections|Instead of the gene therapy drug, 1 ml of aqueous vehicle (water for injections) will be administered by several intraneural injections.
3031380|NCT02352636|Active Comparator|Treatment arm 1|"Subjects will receive magnetotherapy (MAT). The magnetic pellets will contain an average of ~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm. The experimental object will be applied to the reactive region of each of the six selected acupoints as detected by an acupoint detector. The justifications for selecting these acupoints are described below. To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation prior to the application of MAT. Subjects will be asked to wear a pair of laser protective goggles to blind them during therapy administration."
3031381|NCT02352636|Active Comparator|Treatment arm 2|Subjects will receive laser auriculotherapy (LAT). A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use12, 26. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear. Laser protective goggles will be provided to the subjects and the researchers for eye protection. Similarly, a plaster without magnetic pellets that mimics MAT treatment will be applied on these six acupoints after LAT.
3031382|NCT02352636|Experimental|Treatment arm 3|Subjects will receive a combined approach using MAT and LAT. LAT will be administered prior to the application of MAT on the selected auricular points, which would be implemented similar to the procedures in treatment arm 1 and 2.
3031383|NCT02352636|Placebo Comparator|Placebo arm|"Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment."
3031384|NCT02352623||Cutaneous melanoma AJCC stage IB-III|Patients treated for cutaneous melanoma (AJCC stage IB-III) will fill out a questionnaire, undergo clinical examination and DXA scan
3031385|NCT02352610|Active Comparator|LRTI without a Biotenodesis Screw|Ligament Reconstruction Tendon Interposition without a Biotenodesis Screw
3031386|NCT02352610|Active Comparator|LRTI with Biotenodesis Screw|Ligament Reconstruction Tendon Interposition with Biotenodesis Screw
3031387|NCT02352597|Active Comparator|clomiphene citrate|only50 mg orally every 8 hours started from cycle day 3 for 5 days
3031388|NCT02352597|Active Comparator|estradiol valerate and CC|2mg estradiol valerate orally daily from cycle day 7 - 11 in addition to CC
3031389|NCT02352597|Active Comparator|Phytoestrogen and CC|20mg of cimifuga racemosaorally from day 1- 12) in addition to CC
3031390|NCT02352584|Experimental|GC3110A(Quadrivalent)|0.5ml, intramuscular, a single dosing
3031391|NCT02352584|Active Comparator|GC Flu (Trivalent)|0.5ml,intramuscular,a single dosing
3031392|NCT02352584|Active Comparator|GC3110A(Trivalent)|0.5ml,intramuscular,a single dosing
3031393|NCT02352571|Experimental|Single group assignment|GC1118 recombinant human anti-EGFR antibody
3031394|NCT02352558|Experimental|Arm 1|Patients with multiple myeloma treated with BBI608
3031395|NCT02352558|Experimental|Arm 2|Patients with lymphoma treated with BBI608
3031400|NCT02352558|Experimental|Arm 7|Patients with chronic myeloid leukemia treated with BBI608 and imatinib
3031401|NCT02352558|Experimental|Arm 8|Patients with chronic lymphocytic leukemia treated with BBI608
3031402|NCT02352558|Experimental|Arm 9|Patients with chronic lymphocytic leukemia treated with BBI608 and ibrutinib
3031403|NCT02352545|Experimental|Experimental: Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
3031404|NCT02352545|Placebo Comparator|Placebo Comparator|Patients in placebo treatment arm were given placebo tablets(main excipient lactose monohydrate,p.o., 10mg, q.d.). All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
3031405|NCT02352532|Experimental|Low Back Pain - Dry Needling|
3031406|NCT02352532|Sham Comparator|Low Back Pain - Sham|
3031407|NCT02352532|Active Comparator|Asymmptomatic - Dry Needling|
3031408|NCT02352519|Experimental|UGBRSB|Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.
3031409|NCT02352519|Active Comparator|Local infiltration|In those patients randomized to the LAI group, the surgeon will perform infiltration of 0.5 ml/kg of 0.25% bupivacaine (maximum, 10 ml) around the incision.
3031410|NCT02352506||AKI|Patients developing AKI during the ICU stay
3031411|NCT02352506||No AKI|Matched controls not developing AKI during the ICU stay
3031412|NCT02352493|Active Comparator|ALN-CC5|
3031413|NCT02352493|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3031414|NCT02352480|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment plus usual and customary care, which can include any advanced therapeutics.
3031415|NCT02352480|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week there after while receiving usual and customary care, but actual frequency of visits will be determined by the treating physician. Usual and customary care, which can include any advanced therapeutics.
3031416|NCT02352467|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
3031417|NCT02352467|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
3031418|NCT02352454|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
3031419|NCT02352454|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
3031420|NCT02352441|Experimental|Implementation Intentions|This group will receive training in Implementation Intentions during 3 sessions, 1 day/week, over 3 weeks. They will receive usual care through the standard program, 1 day/week during these 3 weeks.
3031421|NCT02352441|No Intervention|Usual Care|This group will participate in the usual group intervention provided to Service members experiencing executive dysfunction associated with mild traumatic brain injury, 2 days / week during 3 weeks.
3031422|NCT02352428|Experimental|Skin Cancer Screening Training|Recruited family physicians and dermatologists in Calgary, Canada, take part in a 5.5-hour face-to-face skin cancer screening training program. Screening for skin cancer will be conducted by trained physicians according to instructions they received in the training program.
3031423|NCT02352428|No Intervention|No Skin Cancer Screening Training|Recruited family physicians and dermatologists in Edmonton, Canada, WILL BE TRAINED AFTER THE SCREENING PHASE, i.e. during the screening phase non-trained physicians will carry out skin cancer screenings according to standard medical practice.
3031424|NCT02352402|Experimental|Ticagrelor|Ticagrelor 90mg twice daily for 1 year on top of ASA
3031425|NCT02352402|Placebo Comparator|Placebo|Placebo matching ticagrelor 90mg twice daily on top of ASA
3031426|NCT02352389||Influenza|"Children and young adults identified as having influenza infections by the St. Jude Children's Research Hospital diagnostic microbiology will be approached to participate in the study. Biological samples will be collected on Day 0 within 72 hours of the diagnosis of influenza, and at 7, 14, 21, and 28 days later.~Interventions: Symptom checklist, Blood sample, Nasal swab, Oropharyngeal swab, Stool sample."
3031427|NCT02352376|Other|Conventional ventilator|30 minutes of non-invasive ventilation was performed with conventional ventilator.The order of the procedures was determined by randomization.
3031428|NCT02352376|Other|Specific ventilator|30 minutes of non-invasive ventilation was performed with specific respirator. The order of the procedures was determined by randomization.
3031429|NCT02352363|Experimental|CVT-301|Capsules of Levodopa Inhalational Powder (LIP) used up to 5 times per day for OFF episodes, for up to 54 weeks duration.
3031430|NCT02352363|Other|Observational Cohort|Standard of care. Patients in both the CVT-301 treatment group and the observational cohort will be managed with their standard PD treatment throughout the study.
3031431|NCT02352350||Cardiac Arrest Patients|All adult patients with non traumatic cardiac arrest in Alachua County Florida will have blood lactate levels taken and neurological outcomes performed based on the Cerebral Performance Categories (CPC) Scale
3031463|NCT02352103|Active Comparator|Control arm|Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
3031432|NCT02352337|Active Comparator|FOLFIRINOX|Every two weeks (maximum of 12 cycles) : Oxaliplatin 85 mg / m2 Day1 in 2 hours - then Irinotecan 180 mg / m2 Day1 in 90 minutes - Folinic acid 400 mg / m2 Day1 in 2 h (during the irinotecan infusion) - 5-FU bolus 400 mg / m² Day1 followed by continuous 5-FU 2400 mg / m2 total over 46 hours
3031433|NCT02352337|Experimental|FOLFIRINOX + LV5FU2 in maintenance|"Folfirinox during 4 months followed by LV5FU2 maintenance until progression:~Folfirinox (as described in arm FOLFIRINOX) LV5FU2 : Folinic acid 400 mg/m² (200 mg/m² if Elvorine), in perfusion over 2 hours the 5FU 400 mg/m² in bolus over 10 mn followed by 5FU 2400 mg/m² in perfusion over 46 hours."
3031434|NCT02352337|Experimental|FIRGEM|"Alternance of 2 months of FOLFIRI.3 with 2 months of GEMCITABINE:~Folfiri.3: Irinotécan 90 mg/m² at day 1 in perfusion over 60 minutes in parralel of folinic acid Folinic acid 400 mg/m² (or 200 mg/m² Elvorine) at day 1 in perfusion over 2 hours 5FU continue 2000 mg/m² over 46 heures then irinotécan at 90 mg/m² (1h) at day 3 when 5U perfusion is over~Gemcitabine: 1000 mg/m² in perfusion over 30 mn at day 1,8,15,29,36 and 43 over (1 injection per week during 3 weeks followed with 7 days of rest )"
3031435|NCT02352324|Experimental|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
3031436|NCT02352311|Experimental|Arm 1 AVODART, CIALIS, DKF-313|In Period 1, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose. In Period 2, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose.
3031437|NCT02352311|Experimental|Arm 2 DKF-313, AVODART, CIALIS|In Period 1, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose. In Period 2, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose.
3031438|NCT02352298|Experimental|Dario Blood Glucose Monitoring System|Blood obtained via fingerstick and blood glucose level is tested on the Dario Blood Glucose Monitoring System
3031439|NCT02352298|Active Comparator|YSI STAT|Blood obtained via fingerstick and blood glucose level is tested on the YSI STAT for comparison to the results obtained with the Dario Blood Glucose Monitoring System
3031440|NCT02352285|Experimental|Tolvaptan|Tovaptan tablet 15mg, 30mg, 60mg, once a day, oral
3031441|NCT02352285|Placebo Comparator|placebo|placebo tablet 15mg, 30mg, 60mg, once a day, oral
3031442|NCT02352272|Experimental|Sleep extension|Subject spend 10 hours Time in bed per day during 6 nights. This period is follow by a total sleep deprivation intervention (i.e. 39 hours awaking) in laboratory.
3031443|NCT02352272|Sham Comparator|Habitual sleep|Subject respect their habitual Time in bed during 6 nights. This period is follow by a total sleep deprivation intervention (i.e. 39 hours awaking) in laboratory.
3031444|NCT02352246|Experimental|steady-state exercise (SSE)|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
3031445|NCT02352246|Other|high intensity intermittent exercise (HIIE)|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
3031446|NCT02352233||colonoscopy group|consecutive patients undergoing for colonoscopy for any formal indication. Patients were submitted to colonoscopy using RETROVIEW colonoscope
3031447|NCT02352207||identification of a pulmonary malformation in the fetus|pregnant women referred to a prenatal Center, because of the identification of a pulmonary malformation in the fetus
3031448|NCT02352194||Assessment|"One part of this study is to quantify physical capacity of patients with Multiple sclerosis.~Thirty patients will be enrolled in this study and performed assessments."
3031449|NCT02352194||Rehabilitation|A second part of this study is to quantify the benefit of a usual rehabilitation program in the day hospital. Thirty patients will be enrolled in this study and receive rehabilitation. They will be assessed before and after the rehabilitation program (physiotherapy and physical activity)
3031450|NCT02352181|Placebo Comparator|S group|S Group: will be transfused patients according to standard management based on conventional coagulation profile of the laboratory
3031451|NCT02352181|Experimental|R group|The R group will consist of patients transfused according to an algorithm based on the data of the coagulation ROTEM analysis.
3031452|NCT02352168|Active Comparator|Budesonide nasal spray|Budesonide nasal spray ,64mcg/putt,1 spray/nostril, 2 times/day,for 12 consecutive weeks.
3031453|NCT02352168|Placebo Comparator|Placebo|Placebo:nasal placebo spray,1spray/nostril, 2 times/day,for 12 consecutive weeks.
3031454|NCT02352155|Active Comparator|Second look endoscopy|Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
3031455|NCT02352155|Placebo Comparator|observation only|NO second look endoscopy (Observation)
3031456|NCT02352142|No Intervention|Standard Care|Mothers are given infant care instruction as part of standard care
3031457|NCT02352142|Experimental|Facilitated infant care|Family Nurture Intervention
3031458|NCT02352142|Other|Full Term EEG|Small group of healthy, Full-Term infants will receive two sleep EEGs (one in unit, and one 4 weeks post discharge) for healthy control comparison to preterm infants
3031459|NCT02352129|Experimental|Cardiomyopathy dilated patient|Cardiomyopathy dilated patients wil be evalueted by CMR using T1 mapping technique to evalueted the level myocardial fibrosis
3031460|NCT02352129|Active Comparator|healthy subjects|healthy subject wil be evaluated by CMR using T1 mapping technique to know the baseline of myocardial fibrosis in healthy subjects
3031461|NCT02352116|Experimental|Additional education|Subjects undergoing ambulatory surgery who receive standard of care management with additional face-to-face education in postoperative pain management.
3031462|NCT02352116|Active Comparator|No additional education|Subjects undergoing ambulatory surgery who receive standard of care management with no additional education in postoperative pain management.
3031464|NCT02352103|Experimental|Treatment arm|Retzius sparing radical prostatectomy da Vinci Surgical System
3031465|NCT02352090|Experimental|Synthetic estrogen + progestin|Ethinyl estradiol / dienogest
3031466|NCT02352090|Experimental|Natural estrogen + progestin|Estradiol valerate / dienogest
3031467|NCT02352090|Active Comparator|Progestin-Only|Dienogest
3031468|NCT02352077|Experimental|NeuroRegen Scaffold with BMMCs or MSCs transplantation|
3031469|NCT02352064|Experimental|PET-CT at day 150+/-15 days|Patient will have PET (18-FDG) following allogeneic stem cell transplantation
3031470|NCT02352051|Active Comparator|Atomoxetine group|The drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
3031471|NCT02352051|Active Comparator|Methylphenidate group|The drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg.
3031472|NCT02352038|Experimental|LLLT group|LLLT group: orthodontic treatment and low-level laser therapy
3031473|NCT02352038|Placebo Comparator|control group|Control group: orthodontic treatment and no laser treatment.
3031474|NCT02352025|Experimental|S-equol|After having a core needle biopsy of the breast confirming triple negative breast cancer, eligible women enrolled on the study will be treated with S-equol at a dose of 50 mg PO twice daily for 14 days.
3031475|NCT02352012|Experimental|Autologous blood group A|Autologous blood was perfused to the target pulmonary segment
3031476|NCT02352012|Experimental|Bronchial plug group B|Bronchial plug was placed to the target pulmonary segment
3031477|NCT02352012|No Intervention|control group|Control group was given to continuous negative pressure drainage
3031478|NCT02351999|Experimental|TSP Crosser Transseptal Access System|The TSP Crosser Transseptal Access System is a novel integrated system combining an extendable radiopaque loop wire to aid in localizing the fossa ovalis (FO); an innovative flexible needle to enable controlled selection of the FO puncture site; and a steerable sheath for enhanced maneuvering and orientation of catheters during LA navigation.
3031479|NCT02351986|Experimental|Subacromial Impingement Syndrome|Subjects between 18 to 45 years, with Subacromial Impingement Syndrome at least one week.
3031480|NCT02351986|No Intervention|Control|Healthy subjects between 18 to 45 years.
3031481|NCT02351973|Active Comparator|Hydrochlorthiazide|Hydrochlorothiazide (HCTZ) ATC class: C03AA03 Form: Tablet Dose range: Phase 1: 25mg (2 x 12.5mg tablet) Phase 2: 50mg (4 x 12.5mg tablet) Maximum allowed dose: 50mg Administration: oral
3031482|NCT02351973|Active Comparator|Amiloride|Amiloride ATC class: C03DB01 Form: Tablet Dose range: Phase 1: 10mg (2 x 5mg tablet) Phase 2: 20mg (4 x 5mg tablet) Maximum allowed dose: 20mg Administration: oral
3031483|NCT02351973|Active Comparator|Hydrochlorthiazide and Amiloride|Hydrochlorothiazide (HCTZ) + Amiloride Form: Tablets (separate tablet of each drug) Dose range: Phase 1: HCTZ 12.5mg (1 tablet) + Amiloride 5mg (1 tablet) Phase 2: HCTZ 25mg (2 x 12.5mg tablet) + Amiloride 10mg (2 x 5mg tablet) Maximum allowed dose: HCTZ 25mg/ Amiloride 10mg Administration: oral
3031484|NCT02351960|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, orally, once daily for up to 4 weeks to participants with non-erosive reflux disease (NERD).
3031485|NCT02351960|Experimental|Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules orally, once daily for up to 8 weeks to participants with erosive esophagitis (EE).
3031486|NCT02351947|Experimental|persons with chronic stroke|upper limb rehabilitation for chronic stroke
3031487|NCT02351947|No Intervention|Healthy, age matched control group|Healthy aged match control group undergoing MRI/EEG testing
3031488|NCT02351934|Experimental|Furosemide + Enhanced Recovery after Surgery (ERAS)|Furosemide 10 mg IV on post-operative day #1 and/or 2, plus ERAS, as described in other arm.
3031489|NCT02351934|Active Comparator|Enhanced Recovery after Surgery (ERAS)|ERAS included administration of celecoxib and gabapentin in the pre-operative setting, single-injection intrathecal analgesic administration immediately prior to induction of general anesthesia, post-operative administration of scheduled acetaminophen and nonsteroidal anti-inflammatory drug (NSAID) or tramadol, and discontinuation of IV fluids by 0800 on postoperative day (POD) 1. Intraoperative fluid administration was dependent on the individual anesthesia provider with no unified commitment to either zero balance or goal-directed fluid therapy. Fluid status was determined based on patient weight. Patients were weighed preoperatively and daily post-operatively using either a bed scale or a unit-based scale.
3031490|NCT02351921|Experimental|iTBS to primary motor cortex|Intermittent TBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS TMS coil will be placed over the motor hotspot for the representation of the flexor carpi radialis muscle.
3031491|NCT02351921|Experimental|iTBS to primary somatosensory cortex|Intermittent TBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS TMS coil will be placed over the primary somatosensory cortex located 2cm posterior to the motor hotspot for the representation of the flexor carpi radialis muscle.
3031492|NCT02351921|Sham Comparator|Sham iTBS to primary motor cortex|Sham iTBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS sham coil will be placed over the motor hotspot for the representation of the flexor carpi radialis muscle.
3031493|NCT02351908|Experimental|Arm 1|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat150mg/150mg/200mg/245mg) tablet 1 once daily for 48 weeks
3031494|NCT02351908|Experimental|Arm 2|Isentress® (Raltegravir 400 mg) 1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet once a day for 48 weeks
3031495|NCT02351908|Experimental|Arm 3|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir) 1 tablet once a day for 48 weeks
3031496|NCT02351895||Copper linens|One ward during each period (23 weeks each) used copper impregnated linen on the bed and as patient gowns. The second ward used regular linen on the bed and as patient gowns
3031497|NCT02351882|Active Comparator|Nabilone|Participants randomized into the nabilone arm will be prescribed nabilone for 6 weeks. After one-week placebo washout, they will be taking placebo for an additional 6 weeks.
3031498|NCT02351882|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be receiving placebo for 6 weeks. After one-week placebo washout, they will be prescribed nabilone for an additional 6 weeks.
3058608|NCT02170987|Experimental|Dabigatran etexilate high|
3031499|NCT02351869|Active Comparator|Nitrous oxide|N2O-condition participants will inhale an initial mixture of 10% N2O in oxygen (O2) for 5 minutes, followed by 25% N2O in O2 for 20 minutes. N2O-condition participants will also receive 5ml intravenous saline concomitantly with 10% N2O, and again with 25% N2O.
3031500|NCT02351869|Placebo Comparator|Midazolam|Inhaled room air plus intravenous midazolam bolus (total 2mg). Midazolam-condition participants will receive intravenous infusions of 0.5mg midazolam in 5ml saline (start of 1st inhalation epoch), followed by 1.5mg midazolam in 5ml saline (start of 2nd inhalation epoch).
3031501|NCT02351856|Experimental|ARRY-371797|
3031502|NCT02351843|Experimental|500 mA ECT|Right unilateral, ultra brief pulse ECT, with 500 mA current amplitude
3031503|NCT02351843|Active Comparator|800 mA ECT|Right unilateral, ultra brief pulse ECT, with 800 mA current amplitude
3031504|NCT02351817|Experimental|Baseline - Test A - Test B|"Three period investigation. First each subject tests baseline product, then Test A and finally Test B.~Baseline product: the subject's usual product~Test A: A newly developed 1-piece, open ostomy appliance for collecting feces~Test B: A newly developed 1-piece, open ostomy appliance for collecting feces"
3031505|NCT02351817|Experimental|Baseline - Test B - Test A|"First each subject tests baseline product, then Test B and finally Test A.~Baseline product: the subject's usual product~Test A: A newly developed 1-piece, open ostomy appliance for collecting feces~Test B: A newly developed 1-piece, open ostomy appliance for collecting feces"
3031506|NCT02351804|Experimental|Ropivacaine + dexamethasone|20 ml ropivacaine 0.5% + 0.5 ml dexamethasone 4 mg7ml
3031507|NCT02351804|Placebo Comparator|Ropivacaine + placebo|20 ml ropivacaine 0.5% + 0.5 ml isotonic saline ad
3031508|NCT02351791|Experimental|Patch 1, 3 and 5|"Patch 1, Patch 3 and Patch 5 applied on peristomal skin.~Measurements of skin at three locations of each patch: Center, Leakage pocket and Adhesive."
3031509|NCT02351791|Experimental|Patch 2, 4 and 6|"Patch 2, Patch 4 and Patch 6 applied on peristomal skin.~Measurements of skin at three locations of each patch: Center, Leakage pocket and Adhesive."
3031510|NCT02351765|Experimental|Acelarin & Cisplatin|"The maximum tolerated dose (MTD) of Acelarin in combination with 25mg/m2 Cisplatin will be determined.~The starting dose will be 625mg/m2 Acelarin which will be escalated to 725mg/m2 if the criteria for dose escalation is met (i.e. the proportion of dose limiting toxicities is acceptable as detailed in the protocol). Escalation will continue in accordance with the protocol up to a maximum of 925mg/m2. Only if the MTD is exceeded at the starting dose level (at least 2 of 3 participants or at least 2 of 6 participants have DLT at the first dose level) will there be a de-escalation to 500mg."
3031511|NCT02351752|Experimental|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate 0.1 Tid (eGFR 30-59), 0.2 Bid(eGFR >60)
3031512|NCT02351739|Other|Pembrolizumab|Arm 1: pembrolizumab monotherapy
3031513|NCT02351739|Other|ACP-196 in combination with pembrolizumab|Arm 2: ACP-196 in combination with pembrolizumab
3031514|NCT02351726|Experimental|Mitroflow DL|Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
3031515|NCT02351713|Experimental|Threshold based method|Exercise Week 1 Heart rate (HR) < first ventilatory threshold (VT1) 3 days 20 min/day Week 2 HR < VT1 4 days 25 min/day Week 3 HR < VT1 4 days 30 min/day Week 4 HR < VT1 5 days 30 min/day Week 5-6 HR ≥ VT1 to < second ventilatory threshold (VT2) 5 days 30 min/day Weeks 7-8 HR ≥ VT1 to < VT2 5 days 30 min/day Weeks 9-12 HR ≥ VT2 5 days 30 min/day
3031516|NCT02351713|Experimental|Relative percent method|Exercise Week 1 40-45% heart rate reserve 3 days 20 min/day Week 2 40-45% heart rate reserve 4 days 25 min/day Week 3 40-45% heart rate reserve 4 days 30 min/day Week 4 40-45% heart rate reserve 5 days 30 min/day Week 5-6 50-55% heart rate reserve 5 days 30 min/day Weeks 7-8 50-55% heart rate reserve 5 days 30min/day Weeks 9-12 60-65% heart rate reserve 5 days 30 min/day
3031517|NCT02351713|No Intervention|Control|Non-exercise control group
3031518|NCT02351700|Active Comparator|opioid-sparing group|Intravenous (IV) Caldolor (ibuprofen) (800mg every 8 hours) initiated during surgery and oral acetaminophen 1000mg every 6 hours initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.
3031519|NCT02351700|Placebo Comparator|standard treatment group|IV Caldolor placebo will be initiated during surgery and oral acetaminophen 1000mg every 6 hours will be initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.
3031520|NCT02351687|No Intervention|No Intervention|No specific intervention given after recovery from moderate acute malnutrition.
3031521|NCT02351687|Experimental|Package of interventions|Package of interventions given after recovery from moderate acute malnutrition -- includes lipid-nutrient supplement for 2 months, malaria chemoprophylaxis for 3 months during malaria season, an insecticide-treated bed net, a one-time albendazole treatment, and 14 days of zinc.
3031522|NCT02351674||Heart rate ≤70bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 1 will be defined as subjects' mean heart rate ≤70 BPM.
3031523|NCT02351674||Heart rate between 71 to 80bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 2 will be defined as subjects' mean heart rate between 71 to 80bpm.
3031524|NCT02351674||Heart rate between 81 to 90bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 1 will be defined as subjects' mean heart rate between 81 to 90bpm.
3031525|NCT02351674||Heart rate>90bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 4 will be defined as subjects' mean heart rate>90bpm
3031526|NCT02351661||medica/surgical|Medical or surgical patients from 18 hospitals
3031599|NCT02351115|Experimental|Staccato® Alprazolam, 1 mg|Single-dose Staccato® Alprazolam for Inhalation, 1 mg
3031527|NCT02351648|Experimental|Intervention'|"Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge~Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge~Intervention after discharge:~Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients"
3031528|NCT02351648|Active Comparator|Control'|Patients receive usual standard of care from the internal medicine team
3031529|NCT02351635||IBD|Adult subjects with inflammatory bowel disease, confirmed by endoscopy and histologic support. Fecal calprotectin Level.
3031530|NCT02351635||IBS|Adult subjects with Irritable Bowel Syndrome meeting the Rome III criteria. Fecal calprotectin Level.
3031531|NCT02351635||other GI disorders|Adult subjects with gastrointestinal disorders other than IBD or IBS. Fecal calprotectin Level.
3031532|NCT02351635||pediatric|Pediatric patients (2-21 y) diagnosed with IBD, IBS, or other gastrointestinal disorders. Fecal calprotectin Level.
3031533|NCT02351635||healthy controls|Normal adult subjects with no abdominal complaints. Fecal calprotectin Level.
3031534|NCT02351622|Experimental|caffeic acid tablet and dexamethasone|Oral administration of caffeic acid tablet 0.3g three times per day for 1 year. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
3031535|NCT02351622|Active Comparator|Placebo and dexamethasone|Oral administration of placebo tablet 0.3g three times per day for 1 year. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
3031536|NCT02351609|Experimental|Intervention|Patients in this arm will receive a low literacy smoking cessation educational brochure and a list of resources for smoking cessation. Patients will also receive navigation from a trained navigator Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 6-month period. Patients will receive financial incentives for biochemically confirmed smoking cessation.
3031537|NCT02351609|Active Comparator|Enhanced Traditional Care control|Patients receive information about smoking cessation resources and an educational brochure developed by the Massachusetts Department of Public Health.
3031538|NCT02351596|Active Comparator|Intervention Group 7-12 years|"Intervention consists of attending a Physiotherapy Core stability group programme for 8 sessions over 4 weeks. Each session lasts 60 minutes (mins).~Dosage: 60minsX 2 =120mins/week X 4 = 480 mins total dosage of intervention Participants also given a home exercise programme with a diary to record how long they practice for every day."
3031539|NCT02351596|Active Comparator|Control Group 7-12 years|Participants continue with usual care but do not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration, type and frequency of this intervention is recorded.
3031540|NCT02351596|Active Comparator|Clontarf Intervention Group 13-17 years|"Intervention consists of attending a Physiotherapy Core stability group programme for 8 sessions over 4 weeks. Each session lasts 60 minutes (mins).~Dosage: 60minsX 2 =120mins/week X 4 = 480 mins total dosage of intervention Participants also given a home exercise programme with a diary to record how long they practice for every day."
3031541|NCT02351596|Active Comparator|Clontarf Control Group 13-17 years|Participants continue with usual care but do not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration, type and frequency of this intervention is recorded.
3031542|NCT02351583||preclampsia|10 with diagnosis of preeclampsia will be examined with both NIRS and cytocam to obtain data
3031543|NCT02351583||normal pregnancy|10 with normal pregnancy will be examined with both NIRS and cytocam to obtain data
3031544|NCT02351557||Reference|Baseline cardiac index more than or equal to 2.1 liters per minute per square meter
3031545|NCT02351557||Low cardiac output|Baseline cardiac index less than 2.1 liters per minute per square meter
3031546|NCT02351544|Experimental|Botulinum toxin|Patients in this arm will receive botulinum toxin for migraine headaches
3031547|NCT02351544|Experimental|Surgery|Patients in this arm will receive surgery for migraine headaches
3031548|NCT02351531|Experimental|New Thickened Extensively Hydrolyzed formula|
3031549|NCT02351505|Experimental|Treatment (selinexor)|Patients receive selinexor PO twice weekly. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3031550|NCT02351492|Active Comparator|Cholecystectomy and intraoperative cholangiography|Patients with suspected bile duct obstruction intraoperative cholangiography (IOC) to investigate bile ducts.
3031551|NCT02351492|Active Comparator|Magnet resonance cholangio-pancreaticography|Patients get Magnet resonance cholangio-pancreaticography (MRCP) first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
3031552|NCT02351479|Other|Hula|Hula is an ancient, Native Hawaiian dance form of cultural expression and physical activity. Participants will attend one-hour hula classes twice a week for six months.
3031553|NCT02351466||Children with Type 1 Diabetes|Subjects with T1 diabetes will undergo a physical exam and blood test as well as structural and functional brain MRI, neurocognitive testing and wear a continuous glucose monitor every 3 months for 24 months.
3031554|NCT02351466||Healthy Controls|Subjects will undergo a physical exam and blood test as well as structural and functional brain MRI at baseline and after 24 months.
3031555|NCT02351440|Experimental|Duloxetine|duloxetine 60mg PO
3031556|NCT02351440|Placebo Comparator|Placebo|placebo
3031557|NCT02351427|Active Comparator|Bortezomib|"Bortezomib (subcutaneous) 1.3mg/m2 on day 1, 4 and 7~with~Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage"
3031600|NCT02351115|Experimental|Staccato® Alprazolam, 2 mg|Single-dose Staccato® Alprazolam for Inhalation, 2 mg
3031558|NCT02351427|Active Comparator|Steroid|Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage
3031559|NCT02351414||Primary Total Knee Arthroplasty|Single study group previously implanted with the EVOLUTION® TKA System with cruciate sacrificing (CS) inserts
3031560|NCT02351401|Experimental|Education with ultrasonography|Intervention includes education of self-assessment of synovitis using ultrasonography as a feedback training tool
3031561|NCT02351401|No Intervention|Standard Care|Normal standard care where patients are not taught how to self-assess for synovitis, without ultrasonography a training tool
3031562|NCT02351388|Active Comparator|Active stimulation|Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
3031563|NCT02351388|Sham Comparator|Sham stimulation|Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
3031564|NCT02351375|Experimental|high protein, low carbohydrate|a high-protein/low-carbohydrate diet (26,7E% protein, 38.2E% carbohydrate)
3031565|NCT02351375|Experimental|low protein, high carbohydrate|a low-protein/high-carbohydrate diet (7E% protein, 59.6E% carbohydrate)
3031566|NCT02351362|Experimental|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
3031567|NCT02351362|No Intervention|Control Group|Standard of care
3031568|NCT02351349|Experimental|Intervention|frail elderly patients with CKD receiving multidisciplinary intervention
3031569|NCT02351349|No Intervention|Standard care|Frail elderly patients with CKD receive standard of care
3031570|NCT02351336||threatened preterm labour|"Women who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) :~Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )~Cervical dilataion >1cm, &/or~Cervical effacement ≥ 80%"
3031571|NCT02351323|Experimental|Glutamine + Lifestyle change|Glutamine 30 grams/day X 12-14 weeks, Lifestyle change
3031572|NCT02351323|Placebo Comparator|No glutamine + Lifestyle change|Lifestyle change
3031573|NCT02351310|Active Comparator|Betamethasone|Betamethasone: 12 mg given intramuscularly (IM), 24 hours apart or if as in some hospitals occasionally occurs and betamethasone is unavailable - • 4 doses of Dexamethasone IM 6 mg, 12 hours apart
3031574|NCT02351310|Placebo Comparator|Normal Saline|Quantity Sufficient (QS) of Normal Saline (NS) given intramuscularly (IM), 24 hours apart or if hospital is using Dexamethasone in place of Betamethasone then administer NS x 4 doses 12 hours apart
3031575|NCT02351297|Experimental|Casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
3031576|NCT02351297|Experimental|Soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
3031577|NCT02351297|Placebo Comparator|Maltrodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
3031578|NCT02351271|Experimental|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
3031579|NCT02351271|Active Comparator|Manual capsulorhexis&lens fragmentation|The Conventional group acts as a control group with conventional capsulorhexis and ultrasound phacoemulsification
3031580|NCT02351258|No Intervention|Control Arm|Usual care for central line while patients are at home
3031581|NCT02351258|Experimental|Intervention|Use of 70% isopropyl alcohol embedded caps on central lines in addition to usual care of central line in the home setting
3031582|NCT02351245||lip hemangiomas|
3031583|NCT02351232|Experimental|Intervention|Liraglutide; daily subcutaneous injection; 1.8 mg; 6 months
3031584|NCT02351232|Placebo Comparator|Placebo|Placebo; daily subcutaneous injection; 1.8 mg; 6 months
3031585|NCT02351219|Experimental|FOLFOXIRI|
3031586|NCT02351206||The experimental group|Patients with intervertebral disc protrusion, extrusion, or migration at L4/5 randomly selected from a population pool of 665 patients with L-spine X-ray and L-spine MRIs taken within a week of the other test.
3031587|NCT02351206||The control group|Patients with normal or disc bulging readings at L4/5 randomly selected from a population pool of 665 patients with L-spine X-ray and L-spine MRIs taken within a week of the other test.
3031588|NCT02351193||Group I|poor responder females with age less than 35
3031589|NCT02351193||Group II|poor responder females with age more than 35
3031590|NCT02351180|Experimental|Inhaled beclomethasone|Inhaled beclomethasone 320 mcg twice daily for 180 days.
3031591|NCT02351180|Placebo Comparator|Placebo|Inhaled placebo twice daily for 180 days.
3031592|NCT02351167|Active Comparator|Combination NRT and Counseling|Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
3031593|NCT02351167|Active Comparator|Varenicline (Chantix) and Counseling|Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.
3031594|NCT02351167|Placebo Comparator|Placebo Medicine and Counseling|Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
3031595|NCT02351154|Other|Atrophic gastritis|gastric glands (crypts) with atrophic gastritis were measured using the Cellvizio Viewer software
3031596|NCT02351141|Other|Asthma Patients|All enrolled asthma patients will undergo hyperpolarized noble gas MRI with Helium-3 and/or Xenon-129, Pulmonary Function Tests, Quality of Life Questionnaires, dyspnea scales in two visits over three years.
3031597|NCT02351128|Experimental|Only one arm|All patients receive Lanreotide.
3031598|NCT02351115|Experimental|Staccato® Alprazolam, 0.5 mg|Single-dose Staccato® Alprazolam for Inhalation, 0.5 mg
3031601|NCT02351115|Placebo Comparator|Staccato® Placebo (a)|Single-dose inhaled Staccato® Placebo, Inhaler with no drug
3031602|NCT02351115|Placebo Comparator|Staccato® Placebo (b)|Single-dose inhaled Staccato® Placebo, Inhaler with no drug
3031603|NCT02351102|Active Comparator|Valacyclovir|Participants will receive Valacyclovir at a dose of 8g/d starting at time of proof of primary maternal CMV infection and until amniocentesis (minimum 21 weeks gestation)
3031604|NCT02351102|Placebo Comparator|Placebo|Participants will receive placebo pills (same daily amount as the intervention group) starting at time of proof of primary maternal CMV infection and until amniocentesis (minimum 21 weeks gestation)
3031605|NCT02351089|Placebo Comparator|Placebo|capsules containing corn starch
3031606|NCT02351089|Active Comparator|Probiotic low dose|capsules containing probiotic powder and corn starch
3031607|NCT02351089|Active Comparator|Probiotic high dose|capsules containing probiotic powder and corn starch
3031608|NCT02351063|Experimental|Daily BNP|Subjects will be asked to test their BNP at home every day for a period of 180 days using the AlereTM HeartCheck System (the Test System). In addition to BNP, weights and signs and symptoms of HF will be collected each day of testing. The HeartCheck data is transmitted via a secure wireless protocol to the HealthCOM health monitoring portal where it is available to the medical staff. The subject's's physician and medical staff will be required to evaluate the data and determine if a change in HF treatment is advisable. All changes of heart failure medications are at the discretion of the treating physician and medical staff of the institution.
3031609|NCT02351050|Experimental|Sonolysis|continual transcranial Doppler monitoring with maximal intensity during endovascular procedure
3031610|NCT02351050|Placebo Comparator|placebo|sham transcranial Doppler monitoring during endovascular procedure
3031611|NCT02351037|Experimental|Ibrutinib Monotherapy Cohort|Up to 33 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis.
3031612|NCT02351037|Experimental|Ibrutinib + LD-AraC Combination Cohort|Up to 25-28 additional response evaluable subjects (for a total of 34 subjects) will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
3031613|NCT02351037|Experimental|Ibrutinib+Azacitidine Combination Cohort|Up to 34 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75mg/m2 IV once daily Days 1-7 of a 28-day cycle (with an option to increase to 100mg/m2 after 2 cycles).
3031614|NCT02351024|Experimental|OXP005|
3031615|NCT02351024|Active Comparator|Naproxen|
3031616|NCT02351011|Experimental|Cohort 1|1 x 10^6 MSCs
3031617|NCT02351011|Experimental|Cohort 2|10 x 10^6 MSCs
3031618|NCT02351011|Experimental|Cohort 3|50 x 10^6 MSCs
3031619|NCT02350998|Experimental|OTO-201|6 mg OTO-201 administered trans-tympanostomy tube
3031620|NCT02350985|Active Comparator|Propranolol|Propranolol up to 160 mg/day
3031621|NCT02350985|Active Comparator|Venlafaxine|Venlafaxine up to 150 mg/day
3031622|NCT02350972|Experimental|Autologous cytokiines|Autologous cytokines obtained from patients' blood mononuclear cells injected in volumes of 0.1 ml
3031623|NCT02350959|Experimental|High dose statin|In high dose statin group, atorvastatin 40mg will be used
3031624|NCT02350959|Active Comparator|Moderate dose statin|in moderate dose statin group, atorvastatin 10mg will be used
3031625|NCT02350946|Experimental|Cross over Oxytocin and Placebo|fMRI measurement and blood examinations following 26 IU Oxytocin (Syntocinon) on day 1 and following placebo on day 14
3031626|NCT02350946|Experimental|Cross over Placebo and Oxytocin|fMRI measurement and blood examinations following placebo on day 1 and following 26 IU Oxytocin (Syntocinon) on day 14
3031627|NCT02350933|Other|0° rigid endoscope|Endoscopy of the trachea is performed using a 0° rigid endoscope
3031628|NCT02350920|Active Comparator|Acceptance and Committment Therapy (ACT)|This group will consist of patients who will receive ACT therapy.This intervention will run with 8-12 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
3031629|NCT02350920|No Intervention|Control|The control group will consist of patients who will receive no ACT therapy during the 26 week st udy period
3031630|NCT02350894||mTBI subjects|mTBI subjects with ongoing symptoms
3031631|NCT02350868|Experimental|Arm 1|Subjects will be treated with oral doses of MPT0E028 in consecutive, 28-day cycles, and will be evaluated regularly for safety. Subjects who tolerate the drug and who do not experience progressive disease may continue to receive MPT0E028 at the discretion of the principal Investigator for up to 6 cycles.
3031632|NCT02350855|Experimental|Intervention group|Patients in the intervention group were given dietary supplement (Improved Atta: 100 g) daily along with nutritional counseling and physical activity counseling for six months.
3031633|NCT02350855|Other|Control group|Patients in the control group were given nutritional and physical activity counseling for six months every fortnight.
3031634|NCT02350842|Experimental|Triple-site biventricular pacing|Triple-site biventricular pacing with individual optimization of the placement of the third lead by peri-operative echo guidance. Devices used will be the Sorin, locally approved and commercially available Paradym SonR Tri-V CRT-D.
3031635|NCT02350842|Active Comparator|Standard biventricular pacing|Standard biventricular pacing (1RV/1LV) through classical implantation procedure without peri-operative optimization. Devices used will be locally approved and commercially available Sorin implantable cardioverter defibrillators.
3031636|NCT02350829|Active Comparator|Cardiomyopathy|"Clinically established diagnosis of dilated, hypertrophic or arrhythmogenic right ventricular cardiomyopathy~Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers"
3031637|NCT02350829|Active Comparator|Congenital Heart Disease|"Diagnosis of Transposition of the great arteries after arterial switch operation, repaired Tetralogy of Fallot, patients after single ventricle palliation at the Fontan stage, native and repaired Aortic Coarctation Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan~Obtaining bloodwork for assessment of hematocrit and collagen biomarkers"
3031663|NCT02350660|Experimental|Peanut powder|peanut oral immunotherapy
3031664|NCT02350647|Experimental|HEALICOIL Regenesorb|Suture anchor for rotator cuff repair
3031638|NCT02350829|Active Comparator|Controls|Patients undergoing a non-cardiac MR investigation (musculoskeletal / abdomen / brain) without a history of cardiac disease Adding limited cardiac sequence to the clinical magnetic resonance scan including T1 mapping Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
3031639|NCT02350816|Active Comparator|HGT-1410 Q2W in Study HGT-SAN-093 randomized to HGT-1410 Q2W|"Patients in Group 1 will continue HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 50, with a cumulative treatment period of up to 42 months (168 weeks) . HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).~HGT-SAN-093 = NCT02060526"
3031640|NCT02350816|Active Comparator|HGT-1410 Q4W in Study HGT-SAN-093 randomized to HGT-1410 Q4W|Patients in Group 2 will continue HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 52, with a cumulative treatment period of up to 42 months (168 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
3031641|NCT02350816|Active Comparator|no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q2W|Patients in Group 3A will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
3031642|NCT02350816|Active Comparator|no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q4W|Patients in Group 3B will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
3031643|NCT02350803|Placebo Comparator|distraction osteogenesis|treatment of maxillary deficiency was done just by distraction osteogenesis and no mini plate was used after removal of distractor
3031644|NCT02350803|Active Comparator|distraction osteogenesis+ mini plate|treatment of maxillary deficiency was done just by distraction osteogenesis and after removal of distractor 4 mini plate L shaped was used after removal of distractor as an intervention
3031645|NCT02350790|Active Comparator|Robotic ablation|Half of the patients in the study will be randomized to robotic ablation of endometriosis with the argon beam coagulator (ABC).
3031646|NCT02350790|Active Comparator|Robotic Excision|Half of the patients in the study will be randomized to robotic excision of endometriosis.
3031647|NCT02350777|Experimental|active infection and/or organ compromise or GVHD.|This protocol includes two single-arm phase II trials to assess the efficacy and confirm the safety of administration of TCD stem cell boost or bone marrow (BM) HPC (M) boost from the original donor for patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
3031648|NCT02350777|Experimental|active infection, active or controlled GVHD &/or organ compro|This protocol includes two single-arm phase II trials to assess the efficacy and confirm the safety of administration of TCD stem cell boost or bone marrow (BM) HPC (M) boost from the original donor for patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
3031649|NCT02350764|Experimental|Nivolumab|Patients will begin treatment with nivolumab IV 3mg/kg and ipilimumab 1mg/kg. Treatment with nivolumab will continue every 2 weeks (+/- 3 days) thereafter and treatment with ipilimumab will continue every 6 weeks (+/- 3 days) thereafter. Treatment will continue until protocol-defined toxicity, confirmed progression of disease*, withdrawal of consent, or death.
3031650|NCT02350751|Experimental|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) supplied as 50 mg/mL solution for infusion. MEDI8852 is being evaluated for treatment of patients hospitalized with influenza A.
3031651|NCT02350751|Placebo Comparator|Placebo|Solution containing no active ingredients
3031652|NCT02350738|Experimental|MCET_Mock group|Period I: MCET for 8 weeks (3 sessions/ week); Washout for 4 weeks and cross-over; Period II: mock therapy for 8 weeks (3 sessions/week)
3031653|NCT02350738|Experimental|Mock_MCET group|Period I: mock therapy for 8 weeks (3 sessions/week); Washout for 4 weeks cross-over; Period II: MCET for 8 weeks (3 sessions/ week);
3031654|NCT02350725|Experimental|Group 1|Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours followed by Oral Furosemide tablets (80 mg) in second period.
3031655|NCT02350725|Experimental|Group 2|Oral Furosemide tablets (80 mg) followed by Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours in second period.
3031656|NCT02350712|Experimental|All Participants - Period 1|All participants receive patritumab with cetuximab plus platinum-based therapy (cisplatin or carboplatin) in Period 1 - Initial phase of the trial.
3031657|NCT02350712|Experimental|All Participants - Period 2|Participants deriving clinical benefit enter Period 2 - Extension phase, during which they continue to receive patritumab with cetuximab, but not platinum-based therapy.
3031658|NCT02350699||Control|Nautilus BrainPulse
3031659|NCT02350686|Experimental|capecitabine+oxaliplatin|XELOX every 3 weeks
3031660|NCT02350673|Experimental|Cergutuzumab+Atezolizumab (Part I)|Participants will receive escalated IV doses of cergutuzumab amunaleukin in combination with atezolizumab. This is a Part I dose escalation phase of the study. Cergutuzumab amunaleukin will be escalated from a starting dose of 6 milligrams (mg) and dosing schedules of every week (qw) and every 2 weeks (q2w) may be explored. Atezolizumab will be administered in fixed flat doses of either 840 mg q2w or 1200 mg every 3 weeks (q3w). Treatment will be continued until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent for a maximum treatment period of 24 months for both cergutuzumab amunaleukin and atezolizumab and may be modified if emerging data suggest longer treatment period is needed.
3031661|NCT02350673|Experimental|Cergutuzumab +Atezolizumab (Part II)|This is a Part II expansion phase of the study. Participants will receive cergutuzumab amunaleukin at maximum tolerated dose (MTD) (or recommended dose) identified during Part I in combination with atezolizumab. Treatment will be continued until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent for a maximum treatment period of 24 months for both cergutuzumab amunaleukin and atezolizumab and may be modified if emerging data suggest longer treatment period is needed.
3031662|NCT02350660|Experimental|Cow's milk for alpha-gal allergics|daily consumption of cow's milk
3031665|NCT02350647|Active Comparator|Twinfix Ultra HA|Suture anchor for rotator cuff repair
3031666|NCT02350634|Experimental|Autopsy Cohort|End-of-life subjects (life expectancy < 6 months) consenting to brain donation at autopsy. Subjects will receive a single IV bolus injection of 370 MBq(10 mCi) of 18F-AV-1451.
3031667|NCT02350621|Active Comparator|ACDF|Anterior Cervical Discectomy and Fusion
3031668|NCT02350621|Active Comparator|miPCF|minimal invasive Posterior Cervical Foraminotomy
3031669|NCT02350595|Experimental|Lean fish|Participants eat 750g of lean fish per week for 8 weeks.
3031670|NCT02350595|Experimental|Fatty fish|Participants eat 750g of fatty fish per week for 8 weeks.
3031671|NCT02350595|No Intervention|Control|Participants eat as normal, but avoid fish and seafood for 8 weeks.
3031672|NCT02350582|Experimental|Telerehabilitation|Resistence and endurance exercise adapted to individual requeriment using internet to monitor progression during chemotherapy treatment. Telerehabilitation eCUIDATE system
3031673|NCT02350582|No Intervention|Control group|usual care offered to patients during chemotherapy treatment
3031674|NCT02350569|Experimental|LDV/SOF|Participants with genotype 1 or 4 HCV who are undergoing liver transplant will receive one dose of LDV/SOF prior to the transplant and then will receive LDV/SOF once daily for 4 weeks following the transplant.
3031675|NCT02350556|Other|hemiplegic patients|Dynamic Avoidance Task
3031676|NCT02350556|Other|healthy volunteers|Dynamic Avoidance Task
3031677|NCT02350543|Active Comparator|Aspirin continuation|Continued use of Acetylsalicylic acid at prior dosage (75mg or 100mg tablet one-per-day).
3031678|NCT02350543|No Intervention|Aspirin discontinuation|Discontinuation of Acetylsalicylic acid ten days prior to surgery, and re-initiation two weeks after hospital discharge.
3031679|NCT02350530|Experimental|A (FOLFOXIRI + Bevacizumab)|FOLFOXIRI + Bevacizumab
3031680|NCT02350530|Active Comparator|B (FOLFOXIRI)|FOLFOXIRI
3031681|NCT02350517|Experimental|Paclitaxel+Nedaplatin+Endostar|Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14.
3031682|NCT02350504|Experimental|Full interactive instruction|Full interactive instruction- which will include an instructional booklet, a movie and a simulator's practice
3031683|NCT02350504|Placebo Comparator|Partial instruction|Partial instruction which included the booklet only.
3031684|NCT02350491||RA group|Pregnant women suffering from Rheumatoid Arthritis.
3031685|NCT02350491||SLE group|Pregnant women suffering from Systemic Lupus Erythematosus.
3031686|NCT02350491||healthy group|Healthy pregnant woman.
3031687|NCT02350478|Active Comparator|Linagliptin|The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
3031688|NCT02350478|Placebo Comparator|Placebo|The subjects will receive placebo.
3031689|NCT02350465|Experimental|Eccentric Exercise|Supervised strengthening exercise using eccentric muscle actions.
3031690|NCT02350465|Active Comparator|Concentric Exercise|Supervised strengthening exercise using concentric muscle actions.
3031691|NCT02350452|Experimental|Diode laser coagulation|Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
3031692|NCT02350452|Active Comparator|Bipolar coaugulation|Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
3031693|NCT02350439|Experimental|Adenosine intravenous infusion at 200μg/Kg/min|Fractional flow reserve assessment under Adenosine intravenous infusion at 200μg/Kg/min
3031694|NCT02350426|Experimental|Arm 1|As per randomization schedule, subjects will undergo two half body PET/CT scans (PET/CT1 and PET/CT2). During visit 1 subject will undergo PET/CT1 scan with 18F-FDG followed by PET/CT2 scan with 18F-GE-180 in visit 2. A sub-group of patients will participate in an additional dynamic PET/CT scan with 18F-GE-180 prior to their 18F-GE-180 PET/CT half body scan.
3031695|NCT02350426|Experimental|Arm 2|As per randomization schedule, , subjects will undergo two half body PET/CT scans (PET/CT1 and PET/CT2). During visit 1 subject will undergo PET/CT1 scan with 18F-GE-180 followed by PET/CT2 scan with 18F-FDG in visit 2. A sub-group of patients will participate in an additional dynamic PET/CT scan with 18F-GE-180 prior to their 18F-GE-180 PET/CT half body scan.
3031696|NCT02350413||Endometriosis|Women referred to five Obstetrics and Gynecological Department for the treatment of endometriosis
3031697|NCT02350400|Experimental|DEBIRI|For unilobar disease, two treatments will be planned, separated by four weeks. For bilobar disease, there will be four treatments planned, alternating between right and left lobe, separated by 2 weeks duration.
3031698|NCT02350387|Experimental|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
3031699|NCT02350387|Experimental|Low Intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
3031700|NCT02350374|Other|carbohydrate counting|patients must fill their logbook during 28 days
3031701|NCT02350361|Experimental|Endostar Arm|Gefitinib re-challenging, oral daily use Docetaxel 60mg/m2 and Cisplatin 70mg/m2, 21 days Recombinant human endostatin 15mg/day, day 1 - 14
3031702|NCT02350361|Active Comparator|Standard Arm|Gefitinib re-challenging, oral daily use Docetaxel 60mg/m2 and Cisplatin 70mg/m2, 21 days Placebo
3031703|NCT02350335|Active Comparator|NRT|"Active smokers with acute aneurysmal hemorrhage randomly assigned to transdermal nicotine replacement after securing of the aneurysm.~Patient management for all patients is according to the institutional treatment guidelines and independent of group assignment.~The dose is dependent on smoke consumption prior to the ictus. Nicorette 7 mg/day for smokers smoking 1-10 cigarettes /day Nicorette 14mg/day for smokers smoking 11-19 cigarettes/day Nicorette 21 mg/day for smokers smoking 20 or more cigarettes daily"
3031704|NCT02350335|No Intervention|no NRT|Active smokers with acute aneurysmal hemorrhage that were assigned to not receive transdermal nicotine replacement.
3031705|NCT02350335|No Intervention|non-smokers|Non-smokers with acute aneurysmal hemorrhage. Non-smokers do not receive transdermal nicotine replacement. This group is to be compared to the group of active smokers receiving transdermal nicotine replacement and to the group of active smokers not receiving transdermal nicotine replacement.
3031707|NCT02350322|Experimental|Schoolmeal without fish|Meat/cheese diet (non-seafood)
3031708|NCT02350322|Experimental|Supplement|Omega-3 capsules
3031709|NCT02350309|Experimental|E2006 5 mg|Participants will receive a single, oral tablet formulation dose of E2006 5 mg within 5 minutes before bedtime.
3031710|NCT02350309|Experimental|E2006 10 mg|Participants will receive a single, oral tablet formulation dose of E2006 10 mg within 5 minutes before bedtime.
3031711|NCT02350309|Placebo Comparator|E2006-matched Placebo|Participants will receive a single, oral tablet formulation dose of E2006-matched placebo within 5 minutes before bedtime.
3031712|NCT02350309|Active Comparator|Flurazepam 30 mg|Participants will receive a single, oral capsule formulation dose of flurazepam 30 mg within 5 minutes before bedtime.
3031713|NCT02350296|Experimental|KSL 40 mg|Ketoprofen lysine salt (KLS) immediate release tablets 40 mg, corresponding to 25 mg of ketoprofen free acid
3031714|NCT02350296|Active Comparator|OKi® 80 mg|OKi® 80 mg granules for oral solution (bipartite sachets: each half sachet containing 40 mg of KLS corresponding to 25 mg of ketoprofen free acid)
3031715|NCT02350283|Experimental|Solitaire Device|Interventional treatment with Solitaire. After the procedure, the patients will be admitted to intensive care unit. Standard medical management will be provided to these patients.
3031716|NCT02350283|No Intervention|Medical treatment|Standard medical treatment alone.
3031717|NCT02350270||cognitively healthy individuals (CHI)|CHI were participants without objective cognitive impairment
3031718|NCT02350270||mild cognitive impairment (MCI)|MCI was diagnosed if participants met the following criteria: presence of spontaneous cognitive complaints and objective cognitive impairment
3031719|NCT02350270||mild and moderate dementia|Diagnoses of dementia were assigned according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV TR, 2000; Association, 2000; 22) at consensus diagnostic case conferences
3031720|NCT02350257|Experimental|ICBT|Internet-based cognitive behavior therapy
3031721|NCT02350257|No Intervention|Supportive control|Control participants has weekly contact with a therapist and receives internet-based training in child directed play. Participants are informed that this training will not likely reduce anxiety.
3031722|NCT02350244|Experimental|Experimental group|Subjects of the experimental group will have to follow an intervention for one month, consisting in active breaks from computer work
3031723|NCT02350244|Other|Control group|Control group patients had no intervention
3031724|NCT02350231|Active Comparator|The progesterone vaginal pessary group|Where they will have progesterone vaginal pessary (Prontogest 400 mg) daily at bed time from 28 weeks of pregnancy till delivery in addition to tonic and calcium
3031725|NCT02350231|Placebo Comparator|Tonics group|Where they will receive only tonics and calcium from 28 weeks of pregnancy till delivery
3031726|NCT02350218|Experimental|Eglandin 720㎍|Eglandin® (Alprostadil) 720㎍
3031727|NCT02350218|Active Comparator|Eglandin 360㎍|Eglandin® (Alprostadil) 360㎍
3031728|NCT02350205|Experimental|Treatment (SASS)|All patients will receive both Self assembled skin substitute (SASS) and Split-thickness autograft (paired samples).
3031729|NCT02350205|Active Comparator|Control (split-thickness autograft)|All patients will receive both SASS and Split-thickness autograft (paired samples).
3031730|NCT02350192|Experimental|e-health educational intervention (eHEI)|Participants in the intervention group received usual care and additional individualized educational intervention administered by a trained nurse who was experienced in cardiac nursing. The exercise prescription had been set as walking exercise for 30 minutes per day for 5 days per week. The exercise dosage might be modified with physician's order to suit the individual's physical condition and agreed goals if necessary. The 30- minutes educational intervention was conducted in a private room of the clinic. The content covered general information related to coronary heart disease and benefit of performing exercise, the e-health educational intervention (eHEI) link demonstration and re-demonstration. In addition, one telephone follow-up was conducted at week 2 to facilitate the usage of the e-HEI link.
3031731|NCT02350192|No Intervention|Control group|Control group received standard care only. The control group also received standard usual care comprising the doctor follow up with medication. During an individualized educational session conducted by a trained research assistant , a briefing on healthy life style and an an additional educational leaflet about coronary heart disease which is customarily given to patient with cardiovascular risks was given to the patient. In the control group, no e-health educational intervention has been provided to the patients of the control group.
3031732|NCT02350179|Experimental|cases|Women assigned to the study group will receive 1 gr of Tranexamic acid injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.
3031733|NCT02350179|Placebo Comparator|control|The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
3031734|NCT02350166|Experimental|Laparoscopic group|Laparoscopic group, laparoscopic surgery or laparoscopic-assisted small-incision for resection of laparoscopic colorectal tumor combined with synchronously small-incision open resection of liver metastasis
3031735|NCT02350166|No Intervention|Conventional group|Conventional group, conventional laparotomy for simultaneously resection of both primary colorectal tumor and liver metastasis
3031736|NCT02350153||Patients with verified Cushing's Disease|
3031737|NCT02350140|Experimental|Text messaging from beginning|Half of the health facilities will be randomly allocated to receive the TextIT intervention during the first time period (six months), while the other half to continue with current standard care (first step)
3031738|NCT02350140|Active Comparator|Text messaging after 6 months of control|Half the facilities will receive standard of care for six months (first time period). After the first time period, the these facilities will then also receive the TextIT intervention (second step)
3031739|NCT02350127|Experimental|PLIE|PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
3031778|NCT02349802|Experimental|Arm 1|exenatide suspension - 9 mg / 0.85 mL
3031740|NCT02350127|Active Comparator|Usual Care Control|Study participants who are randomized to the Usual Care (UC) control group will continue to participate in usual activities at the adult day center, which include a combination of daily physical, mental and social activities.
3031741|NCT02350114|Experimental|Functional Capacity|6 Minute Walk Test
3031742|NCT02350088|Active Comparator|Fast-track Surgery|probiotics,oral,b.i.d.
3031743|NCT02350088|Active Comparator|Traditional Group|placebo,oral,b.i.d.
3031744|NCT02350075|Experimental|Short implants group|Patients receive short dental implants installation (6mm) without additional augmentation procedures.
3031745|NCT02350075|Other|Standard implants with OSFE group|Patients receive standard dental implants installation (10mm) combined with osteotome sinus floor elevation.
3031746|NCT02350049||Investigational|Cementless Medial Partial Knee
3031747|NCT02350049||Control|Cemented Medial Partial Knee
3031748|NCT02350036||preeclmapsia|women developed preeclampsia. ultrasound monitoring and uterine artery Doppler
3031749|NCT02350036||control|women with normal blood pressure all through pregnancy. ultrasound monitoring and uterine artery Doppler
3031750|NCT02350023|Active Comparator|Topical latanoprost|Topical latanoprost 0.005%
3031751|NCT02350023|Active Comparator|Topical betamethasone|Topical betamethasone 0.05%
3031752|NCT02349997||OSA group|"Of the 180 heart failure patients,20 OSA were enrolled. Clinical evaluations including NYHA class, electrocardiographic, echocardiographic, arterial blood gas analysis findings, baseline medication, and 6-minute walk test (6MWT) were recorded.~The fluid index, head and neck CT and pharyngeal resistance were tested at 20:00. Then a full night PSG and percutaneous PaCO2 were performed. The fluid index, head and neck CT and pharyngeal resistance were repeated at 6:00 after PSG.~The volume of fluid shift from legs to head and neck,inside diameter of the upper airway, and water content of neck soft tissue were calculated. The lung-to-finger circulation time and loop gain were measured."
3031753|NCT02349997||CSA group|"Of the 180 heart failure patients,20 CSA were enrolled. Clinical evaluations including NYHA class, electrocardiographic, echocardiographic, arterial blood gas analysis findings, baseline medication, and 6-minute walk test (6MWT) were recorded.~The fluid index, head and neck CT and pharyngeal resistance were tested at 20:00. Then a full night PSG and percutaneous PaCO2 were performed. The fluid index, head and neck CT and pharyngeal resistance were repeated at 6:00 after PSG.~The volume of fluid shift from legs to head and neck,inside diameter of the upper airway, and water content of neck soft tissue were calculated. The lung-to-finger circulation time and loop gain were measured."
3031754|NCT02349971|Experimental|All Patients|Patients will undergo a one-time procedure of MR-HIFU ablation of OO under sedation or anesthesia. Patients will be monitored for disease status and adverse events for at least 12 months following procedure.
3031755|NCT02349958|Other|Ovarian peritoneal|CDDP Cisplatin 75 mg/m2 @T0 Ovarian peritoneal fallopian tube Uterine
3031756|NCT02349958|Other|Appendix Psuedomyxoma|MMC Mitomycin 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0 Appendix Psuedomyxoma colorectal small bowel
3031757|NCT02349958|Other|Gastric and Pancreato-biliary|MMC Mitomycin + CDDP Cisplatin 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0
3031758|NCT02349958|Other|Mesothelioma and Sarcoma|CDDP Cisplatin + Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
3031759|NCT02349945|Experimental|Arm 1|FSHR A680G SNP homozygous for allele N treated with follitropin alpha
3031760|NCT02349945|Experimental|Arm 2|FSHR A680G SNP homozygous for allele S treated with follitropin alpha
3031761|NCT02349932||Healthy Adults|The following samples will be collected: fecal, blood, and saliva
3031762|NCT02349919|Experimental|Procaterol|Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
3031763|NCT02349919|Placebo Comparator|Placebo|Placebo twice daily for 4 weeks
3031764|NCT02349906|Experimental|Treosulfan|One Treosulfan dose per day (10, 12 or 14 g/m2/day, based on body surface area) administered i.v. on three consecutive days (-6, -5 and -4); given over 2 hours as part of background conditioning regimen prior to allogeneic stem cell transplantation.
3031765|NCT02349906|Active Comparator|Busulfan|Total daily Busilvex dose (3.2 to 4.8 mg/kg/day, based on body weight) according to authorised dosage for children and adolescents administered i.v. as part of the background conditioning regimen on four consecutive days (days -7, -6, -5 and -4); given in 1, 2, or 4 portions per day according to the respective hospital's standard.
3031766|NCT02349893|Experimental|RFA treatment|RFA treatment performed with CelonProSleep plus device
3031767|NCT02349880|Active Comparator|control|5 hour cognitive training
3031768|NCT02349880|Experimental|intervention|5 hour shared decision making training
3031769|NCT02349867|Experimental|Treatment (chemotherapy, chemoradiation)|Patients must receive neoadjuvant chemotherapy (multiple regimens are acceptable) prior to enrollment onto this clinical trial. Chemoradiation study treatment should start within 6 weeks of completing chemotherapy. Patients receive gemcitabine IV infusion over 30 minutes (200 mg/m2 weekly) x 6, concurrent administration of oral sorafenib and oral vorinostat (both per dose-escalation schema), and concurrent RT( 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy) administered at 1.8-Gy fractions to a total dose of 50.4 Gy over 5 ½ weeks (28 daily fractions). Correlative studies will be performed by collecting peripheral blood samples at several time-points for circulating tumor cells (CTC) enumeration and to evaluate CD95 density. Samples will be analyzed by negative-selection techniques (RosetteSep) or with ApoStream dielectrophoretic field-flow fractionation (DEPfff) enrichment device.
3031770|NCT02349854||Cases|patients with scalp itch and seborrheic dermatitis who will get biopsy
3031771|NCT02349854||Controls|patients without scalp itch and without seborrheic dermatitis who will get biopsy
3031772|NCT02349841|Experimental|Meropenem;amoxycillin/clavulanic acid|Meropenem 2g will be administered intravenously 8-hourly; plus amoxycillin/CA 500mg/125mg will be administered orally 8-hourly for 14 days
3031773|NCT02349841|Experimental|Faropenem; amoxycillin/CA|Faropenem 600mg will be administered orally 8-hourly; plus amoxycillin/CA 500mg/125mg will be administered orally 8-hourly for 14 days
3031774|NCT02349841|Active Comparator|Rifafour e-275|Rifafour e-275 will be administered orally once daily for 14 days as per South African National TB Treatment Guidelines
3031775|NCT02349828|Active Comparator|Zovirax|Adult dose - 400 mg twice daily generic name: Acyclovir
3031776|NCT02349828|No Intervention|No treatment|standard of care
3031777|NCT02349815||Group 1|Women prescribed JAYDESS in Sweden
3031779|NCT02349802|Experimental|Arm 2|exenatide suspension - 9 mg / 0.85 mL
3031780|NCT02349802|Experimental|Arm 3|exenatide suspension - 4.5 mg /1.1 mL
3031781|NCT02349802|Experimental|Arm 4|exenatide suspension - 9 mg / 1.1 mL
3031782|NCT02349802|Experimental|Arm 5|exenatide suspension - 9 mg / 1.5 mL
3031783|NCT02349776|Experimental|All patients for allograft transplant|For the testimonial part all patients who have received an allograft transplant in the last five years will be eligible for participation if they have capacity to consent and can speak English fluently.
3031784|NCT02349763|Active Comparator|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
3031785|NCT02349763|Experimental|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
3031786|NCT02349750|Active Comparator|endometrial scratch injury|Patients received 100 mg of oral clomiphene citrate for five days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of hMG and when more than two dominant follicles reached a diameter of 17 mm 5,000 IU of hCG was injected intramuscularly. Group S had ESI using No.8 neonatal feeding tube and after 24 to 36 hours, IUI was performed.
3031787|NCT02349750|No Intervention|Non endometrial scratch injury|Patients received 100 mg of oral clomiphene citrate for five days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of hMG and when more than two dominant follicles reached a diameter of 17 mm 5,000 IU of hCG was injected intramuscularly. Group C received IUI without ESI and after 24 to 36 hours, IUI was performed.
3031788|NCT02349737||Electromagnetic Interference|
3031789|NCT02349724|Other|Pancreatic cancer|Pancreatic cancer treated with Anti-CEA-CAR T.
3031790|NCT02349724|Other|Lung cancer|Lung cancer treated with T cells modified with Anti-CEA-CAR T.
3031791|NCT02349724|Other|Gastric cancer|Gastric cancer treated with T cells modified with Anti-CEA-CAR T.
3031792|NCT02349724|Other|Breast cancer|Breast cancer treated with T cells modified with Anti-CEA-CAR T.
3031793|NCT02349724|Other|Colorectal cancer|Colorectal cancer treated with T cells modified with Anti-CEA-CAR T.
3031794|NCT02349711|Placebo Comparator|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
3031795|NCT02349711|Experimental|Probiotic mixture|A commercially available probiotic mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
3031796|NCT02349698|Other|Acute Lymphoblastic Leukemia|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells targeting CD19.
3031797|NCT02349698|Other|Chronic Lymphcytic Leukemia|Chronic lymphocytic leukemia with chimeric antigen receptor modified T cells targeting CD19.
3031798|NCT02349698|Other|Non-Hodgkin Lymphoma|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells targeting CD19.
3031799|NCT02349685|Experimental|14 day bismuth based quadruple therapy (PBMT) group|Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
3031800|NCT02349685|Experimental|14 day Moxifloxacin containing triple therapy (MEA) group|PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.
3031801|NCT02349685|Active Comparator|14 day tailored therapy group|based on H. pylori culture and antimicrobial sensitivity, select the 2nd rescue regimen between 14 days of bismuth-based quadruple therapy or 14 days moxifloxacin-containing triple therapy according to antibiotics susceptibility.
3031802|NCT02349672||Healthy Control|The healthy control group will have 500-800uL (less than 1 mL) of blood collected. This sample will be obtained at the same time that the neonate is already having a standard blood screenings drawn at 24 and 48 hours of life.
3031803|NCT02349672||Clinical Control|The clinical control group will be healthy neonates that are being evaluated for jaundice, with multiple blood samples drawn between birth and 48 hours of life to monitor serum bilirubin. With these already scheduled lab draws, we will draw an additional 0.8-1 mL of blood.
3031804|NCT02349659|No Intervention|Conservative Medical Management|Continued medical management restricted to exclude interventional pain treatments
3031805|NCT02349659|Active Comparator|Axium Group|As the CMM group but also treated with Dorsal Root Ganglion stimulation using the Axium neurostimulator
3031806|NCT02349646||Treated subjects|All subjects recruited and treated with the Axium neurostimulator
3031807|NCT02349633|Experimental|Cohort 1|Cohort 1 will be initiated (current dose 200 mg)
3031808|NCT02349633|Experimental|Cohort 2A|Cohort 2A will evaluate PF-06747775 200 mg by mouth (PO) daily (QD) in combination with palbociclib continuous PO QD dosing in 21-day cycles. The starting dose (DL1) for palbociclib will be 100 mg PO daily. Dose finding will follow mTPI method with adjustments using DLT rate.
3031809|NCT02349633|Experimental|Cohort 2B|Cohort 2B will be initiated once the RP2D of the PF-06747775 and palbociclib combination is determined.
3031810|NCT02349633|Experimental|Cohort 3|Cohort 3 combination is PF-06747775 200 mg PO QD and avelumab 10 mg/kg IV Q2W in 28-day (4-week) cycles. Dose finding will follow the mTPI design. Once RP2D of PF-06747775 in combination with avelumab is determined, the Dose Expansion Phase will be opened.
3031811|NCT02349620|Active Comparator|A:partialy edutolus patients|In this group surface treated implant with PRF will be inserted.Immediately after the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequency analysis (RFA), using the smart peg type 1, then stability will be measured every 2 weeks up to 3 months .Bone height will be measured in mesial and distal side immediately after placement and in months 3 and 6 with Intra Oral Peri Apical xray (IOPA x-ray)
3031812|NCT02349620|Placebo Comparator|B: partialy edutolus patients|In this group implant with out PRF will be inserted.Immediately after the surgery the implant stability will be measured with the Osstell mentor to verify the resonance frequence analysis (RFA ), using the smartpeg type 1, then stability will be measured every 2 weeks up to 3 months. Bone height was measured in mesial and distal side immediately after placement and in months 3 and 6 with IOPA xray
3031813|NCT02349607|Experimental|PF-05089771 300 mg|
3031818|NCT02349594|Active Comparator|treatment order A|Participants in this arm first receive 'Omegaven 10%' and after crossing over the 'Intralipid 20%'
3031819|NCT02349594|Active Comparator|treament order B|Participants in this arm first receive 'Intralipid 20%' and after crossing over the 'Omegaven 10%'
3031820|NCT02349581|Experimental|Block|Patients with persistent pain after breast cancer surgery receive the ultrasound guided PECS block of 20mls 0.25% bupivacaine
3031821|NCT02349581|No Intervention|Sonoanatomy|16 patients awaiting surgery for breast cancer were scanned using ultrasound to determine the sonoanatomy of the PECS block
3031822|NCT02349568||High risk group|High risk group was defined when CBD stones was detected by ultrasound ( US ) / computed tomography ( CT ) or dilated duct with abnormal LFT.
3031823|NCT02349568||Intermediate risk group|Intermediate risk group was defined when US/CT showed normal bile duct with abnormal LFT or dilated duct with normal LFT.
3031824|NCT02349555|Experimental|Nutritional Supplement Blend|The nutritional supplement contains a proprietary blend consisting of 15 unique nutritional ingredients.
3031825|NCT02349542|Experimental|Liposomal bupivacaine|Patients will receive liposomal bupivacaine following simultaneous bilateral total knee arthroplasty.
3031826|NCT02349529|Experimental|Psychosocial group intervention|
3031827|NCT02349529|Other|Waiting List control|Participants in the waiting list control will continue in TAU but will then start the intervention once the first group of participants have completed the 3 month follow up in the psychosocial group intervention arm.
3031828|NCT02349516|Experimental|Squalamine Solution BID 0.2%|Squalamine Lactate Ophthalmic Solution 0.2% administered twice a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranibizumab as needed from week 24 through week 52
3031829|NCT02349516|Placebo Comparator|Vehicle Solution 0.2% BID|Vehicle Ophthalmic Solution 0.2% administered twice a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranbizumab as needed from week 24 through week 52
3031830|NCT02349516|Experimental|Squalamine Solution 0.2% QID|Squalamine Lactate Ophthalmic Solution 0.2% administered four times a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranibizumab as needed from week 24 through week 52
3031831|NCT02349516|Placebo Comparator|Vehicle Solution 0.2% QID|Vehicle Ophthalmic Solution 0.2% administered four times a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranbizumab as needed from week 24 through week 52
3031832|NCT02349503|Experimental|NBI-77860 Dose Group1|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours).
3031833|NCT02349503|Experimental|NBI-77860 Dose Group 2|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours). Dosing will not commence until all safety and PK results from the dose group 1 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
3031834|NCT02349503|Experimental|NBI-77860 Dose Group 3|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours). Dosing will not commence until all safety and PK results from the dose group 2 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
3031835|NCT02349490|Active Comparator|Group A first line therapy|In group A, Seraseal is applied as initial method for hemostasis. If successful, the bleeding site isthen observed for 5 minutes. If bleeding remains active or recurs the institutional standard of care for hemostasis is applied.
3031836|NCT02349490|Active Comparator|Group B rescue therapy|In group B, Seraseal is applied as rescue therapy after an initial failure of the institutional standard method. If Seraseal was successful, the bleeding site was then observed for 5 minutes. If the bleeding remains active or recurs after Seraseal, alternative methods of hemostasis would be applied.
3031837|NCT02349477|Experimental|Gabapentin|Gabapentin up to 1200 mg per day in 3 divided doses
3031838|NCT02349477|Placebo Comparator|placebo|matching placebo
3031839|NCT02349464|Active Comparator|Intervention|For infants receiving pediatric care at one of the seven intervention practices, mothers will receive the Specialized Preterm Infant/Mother Dyad Lactation Support which includes home equipment and pediatric clinic-lactation support to support lactation for four months post-hospital discharge.
3031840|NCT02349464|No Intervention|Control|For infants receiving pediatric care at one of the seven control practices, mothers will receive standard support.
3031841|NCT02349451|Active Comparator|Adalimumab|Double-blind adalimumab 40 mg administered every other week (EOW) for 12 weeks
3031842|NCT02349451|Placebo Comparator|Placebo|Double-blind placebo administered every week (EW) for 12 weeks
3031843|NCT02349451|Experimental|ABT-122 120 mg|Double-blind ABT-122 120 mg administered EW for 12 weeks
3031844|NCT02349451|Experimental|ABT-122 240 mg|Double-blind ABT-122 240 mg administered EW for 12 weeks
3031845|NCT02349438|Experimental|senofilcon A|The lenses will be worn for 2 hours in both eyes, and not dispensed
3031846|NCT02349438|Active Comparator|lotrafilcon A|The lenses will be worn for 2 hours in both eyes, and not dispensed
3031847|NCT02349425|Experimental|Gefapixant|Gefapixant 50 mg tablets administered by mouth twice daily for 16 days
3031848|NCT02349425|Placebo Comparator|Placebo to match gefapixant|Matching placebo tablets administered by mouth twice daily for 16 days
3031849|NCT02349412|Experimental|Arm 1|Patients receive early palliative care and standard oncology care. Patients and family caregivers will be asked to complete quality-of-life questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years.
3031850|NCT02349412|Experimental|Arm 2|Patients receive standard oncology care. Patient and family caregiver will be asked to complete self-report questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years. Palliative care visit only upon request from attending oncologist(s) or patient/family.
3031851|NCT02349399||Drug Utilisation / Cohort 1|New users of CPA/EE in 2011/2012 and in 2014
3031852|NCT02349386|Experimental|BHR-200 Low Dose|3 mg estradiol per 1 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
3031853|NCT02349386|Experimental|BHR-200 Mid Dose|6 mg estradiol per 2 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
3058609|NCT02170987|Placebo Comparator|Placebo to dabigatran etexilate|
3031854|NCT02349386|Experimental|BHR-200 High Dose|9 mg estradiol per 3 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
3031855|NCT02349386|Placebo Comparator|Placebo|1, 2 or 3 mL of Placebo gel containing 0 mg estradiol applied daily for up to 52 weeks.
3031856|NCT02349373|Active Comparator|Preconditioning running|An 8 week preconditioning period. The variables of interest are running distance and running intensity: running speed >80% VO2max (maximal oxygen uptake).
3031857|NCT02349373|Active Comparator|Follow-up period|"The Volume group progress 23% in total weekly running distance in the last adaptation week in the prior 4 week block.~The Intensity group progress 23% in weekly distance of running above 80% VO2 max (maximal oxygen uptake), based on the distance of running above 80% VO2max in the last adaptation week in the prior 4 week block."
3031858|NCT02349360|Active Comparator|Probiotic|L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks
3031859|NCT02349360|Placebo Comparator|Placebo|Encapsulated starch placebo administered for 8 weeks
3031860|NCT02349347|Experimental|Melphalan and lenograstim|
3031861|NCT02349334|Sham Comparator|Sham electrical stimulation|Sham electrical stimulation to forefoot by TENS
3031862|NCT02349334|Active Comparator|Percutaneous tibial nerve stimulation|Active PTNS via Urgent PC Neuromodulation device, Uroplasty
3031863|NCT02349321|Experimental|School Strengthening|Skhokho Supporting Success for Schools: (a) Full year Grade 8 Life Orientation Learner Workbook (following the national curriculum), Educator Guide, and LO Educator support workshops; (b) Educator workshops including values, positive discipline skills, adolescent development, and stress and coping; (c) Learner club workshops (Grade 8s-11s) including creating change for a safe and vibrant school community, human rights at school, communication and conflict resolution skills, and stress and coping.
3031864|NCT02349321|Experimental|School + Family Strengthening|"Skhokho Supporting Success for Schools: See description above.~Skhokho Supporting Success for Families: Participatory four-day workshop for parents/caregivers and their young adolescent children including parallel and joint dialogue sessions. This workshop aims to promote supportive, open relationships between parents/caregivers and their teens and includes communication, negotiation and conflict resolution skills; positive discipline skills; challenging traditional gender constructions; understanding the impact of child abuse; stress and coping."
3031865|NCT02349321|No Intervention|Arm 3: Control (Delayed Intervention)|"This group will continue with treatment as usual (i.e: school services, activities, and textbooks without specialised intervention). At the end of primary data collection, these schools will be eligible to receive the Schools Strengthening Intervention."
3031866|NCT02349308||CentrosFLO Long Term Hemodialysis Catheter|Schedule placement of catheter. Arterial tip of the catheter should be placed at or just above the junction of the right atrium and superior vena cava, with the arterial lumen on the left side of the catheter. The venous limb will extend into the right atrium. Catheter will be locked with the usual heparin lock solution for a newly placed catheter (at least 500 units per lumen). Fluoroscopic images will document tip position.
3031867|NCT02349295|Placebo Comparator|Placebo|Participants received placebo for ixekizumab(Ixe) as 2 subcutaneous (SC) injections followed by 1 SC injection every 2 Weeks (Q2W) given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders (IR) at Week 16 receive rescue therapy and re-randomized to either ixekizumab group, receiving a starting dose of 160 milligram (mg) at Week 16 given as 2 SC injections followed by 80 mg given as 1 injection according to ixekizumab regimen: Q2W or every 4 Weeks (Q4W) (with placebo (PBO) every other dose). All other participants continue placebo as 1 injection Q2W given on Weeks 16, 18, 20 and 22
3031868|NCT02349295|Experimental|Ixekizumab 80 mg Q4W|Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q4W given on Weeks 4, 8 and 12 alternating with placebo for ixekizumab injections Q4W given on Weeks 2, 6, 10 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q4W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16 and 20 alternating with placebo for ixekizumab injections Q4W given on Weeks 18 and 22
3031869|NCT02349295|Experimental|Ixekizumab 80 mg Q2W|Participants received a starting dose of 160 mg of ixekizumab given as 2 SC injections at Week 0 followed by 1 SC injection of 80 mg of ixekizumab Q2W given on Weeks 2, 4, 6, 8, 10, 12 and 14. Inadequate responders at Week 16 receive rescue therapy while continuing ixekizumab given as 1 injection of 80 mg Q2W given on Weeks 16, 18, 20 and 22. All other participants continue 80 mg given as 1 injection Q2W given on Weeks 16, 18, 20 and 22
3031870|NCT02349282|Experimental|Calcifediol 10 ug/day|Capsule with 10 ug/day Calcifediol taken together with breakfast for a total period of 24 weeks.
3031871|NCT02349282|Experimental|Vitamin D3 20 ug/day|Capsule with 20 ug/day Vitamin D3 taken together with breakfast for a total period of 24 weeks.
3031872|NCT02349282|Placebo Comparator|Placebo|Capsule without active ingredients, taken together with breakfast for a total period of 24 weeks.
3031873|NCT02349256||Diagnosed with Somatic Syndrome Disorder|Group of participants that are screened and meet criteria for diagnosis of Somatic Syndrome disorder will be asked if they wish to take part in a 1-1 qualitative interview with the researcher.
3031874|NCT02349243|Experimental|entacapone|An approach of 200mg entacapone at a time and 4 times a day(0.5 hour after every breakfast, lunch and supper and at 0.5 hours before bedtime) is adopted. Every participant is required to record his/her diet, exercise, and drug intake condition in a standard record card which is provided by the researchers.
3031875|NCT02349243|Placebo Comparator|placebo|Except for taking the placebo rather than the entacapone, any intervention in the placebo group is the same with that in the entacapone group.
3031876|NCT02349230|Experimental|Astym treatment|Astym treatment is a manual therapy intervention applied by certified therapists with specialized instruments
3031877|NCT02349230|Sham Comparator|Sham Astym|A sham Astym treatment applied with non-therapeutic pressure and
3031878|NCT02349230|No Intervention|Control|12 minutes of rest
3031910|NCT02348931|Active Comparator|Only device (Nasella)|No need for surgery; use of customized nasal brace (Nasella) for nose deformities is made to improve look (cosmetic reason).
3032054|NCT02347904|Experimental|Adjuvant S-1 and Oxaliplatin|Adjuvant treatment with s-1 and oxaliplatin after neoadjuvant chemoradiation and esophagectomy in patients with resectable esophageal cancer
3032217|NCT02346890|Experimental|AD1722 with Renvela|AZD1722 15 mg BID and Renvela 800 mg TID
3031879|NCT02349217|Experimental|Mindfulness Based Stress Reduction Intervention (MBRE)|"Participant and partner take part in an 8-week Mindfulness-Based Relationship Enhancement (MBRE) intervention course. MBRE course consists of meditation and yoga techniques and handouts.~Pain assessment administered at baseline and at follow up visit. Questionnaires completed at baseline and at follow up visit. Neurocognitive tests administered at baseline and at follow up visit. Cortisol testing performed after baseline visit and at follow up visit. Interviews conducted after follow up visit. These interviews are audio-taped and transcribed."
3031880|NCT02349217|Active Comparator|Standard of Care|"Participants receive self-help materials that have been previously developed by MD Anderson's Office of Public Education, the American Cancer Society, and the National Cancer Institute.~Pain assessment administered at baseline and at follow up visit. Questionnaires completed at baseline and at follow up visit. Neurocognitive tests administered at baseline and at follow up visit. Cortisol testing performed after baseline visit and at follow up visit. Interviews conducted after follow up visit. These interviews are audio-taped and transcribed."
3031881|NCT02349204|Experimental|Exposure to music|The participants in this groups will have to complete the tasks on the intraocular surgery simulator while listening to Mozart's sonata for 2 pianos in D-440
3031882|NCT02349204|No Intervention|No exposure|The participants in this groups will have to complete the tasks on the intraocular surgery simulator in silence
3031883|NCT02349191|Experimental|Interventional cohort|Omental transposition for mild Alzheimers Disease
3031884|NCT02349178|Experimental|Bridging Arm|Days 1-5 Receive 20 mg/m2 IV Clofarabine (CLOLAR) over 2 hours followed by 100 mg/m2 IV Etoposide (VP-16, Etopophos) over 2 hours followed by 300 mg/m2 IV Cyclophosphamide (Cytoxan, CTX) as a 30-60 minute infusion
3031885|NCT02349165|Active Comparator|epithelium off CXL|epithelium removal + 30 minute isotonic riboflavin eye drops (3 minute interval) + 30 minutes ultraviolet-A irradiation (riboflavin every 5 minutes)
3031886|NCT02349165|Experimental|Ricrolin TE CXL|Ricrolin-TE eye drops for 15 minutes (2 minute interval) and 15 minute Ricrolin TE pooled on the cornea using a silicone ring + 30 minutes ultraviolet-A irradiation (Ricrolin TE every 5 minutes).
3031887|NCT02349152|Experimental|Remifentanil group|Half of subjects enrolled will be randomized to the remifentanil group
3031888|NCT02349152|Active Comparator|Fentanyl group|Half of subjects enrolled will be randomized to the fentanyl group
3031889|NCT02349139|Experimental|ASN001: Escalating dose Part A|The dose of ASN001 will be based on the assigned study group. The initial dose level of ASN001 will be 50 mg daily. After a safety review, the dose may be escalated for the next group of subjects. Additional dose levels are 100 mg, 200 mg, 300 mg, and 400 mg.
3031890|NCT02349126|Experimental|Treatment Group|ARC-520 Injection
3031891|NCT02349113|Experimental|Estrogens|Estrogens treatment: Intervention with short course (3 weeks) of treatment with transdermal estrogen (0.1mg/d)
3031892|NCT02349100||Treated group|Patient group treated with Nellix Endoprosthesis.
3031893|NCT02349074|Experimental|Digestive endoscopy|Performed a systematic œsophago-gastro-duodenoscopy during Intensive Care Unit stay after out-of-hospital cardiac arrest
3031894|NCT02349061|Experimental|Ustekinumab plus Concomitant Medication|Participants will receive weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0 followed by ustekinumab 90 mg subcutaneously (SC) every 8 weeks (q8w) up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
3031895|NCT02349061|Experimental|Placebo followed by Ustekinumab plus Concomitant Medication|Participants will receive placebo intravenously at Week 0 followed by placebo subcutaneously at Weeks 8 and 16. At week 24 participants will receive ustekinumab SC q8w up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
3031896|NCT02349048|Experimental|Arm A|Chronic hepatitis C virus (HCV) genotype 1 infected participants with early stages of liver fibrosis, will receive Simeprevir (SMV) 150 milligram (mg), Daclatasvir (DCV) 60 mg and Sofosbuvir (SOF) 400 mg once daily for 6 weeks.
3031897|NCT02349048|Experimental|Arm B|Chronic HCV genotype 1 infected participants with cirrhosis, will receive SMV 150 mg, DCV 60 mg and SOF 400 mg once daily for 8 weeks.
3031898|NCT02349035|Experimental|TMR surgery to evaluate pattern recognition control|Perform Targeted Muscle Reinnervation (TMR) surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.
3031899|NCT02349022|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg.
3031900|NCT02349009|Placebo Comparator|placebo|C-82 Topical Gel, Placebo
3031901|NCT02349009|Active Comparator|Active|C-82 Topical Gel, 1%
3031902|NCT02348996|Other|Clinical assessment|Patients would have dry weight determined by clinical evaluation (blood pressure levels, peripheral edema, pulmonary auscultation and symptoms).
3031903|NCT02348996|Experimental|Bioimpedance|Patients would have dry weight determined according to volume status with a body composition monitor (BCM)
3031904|NCT02348983|Experimental|Interventional Arm|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
3031905|NCT02348970|Experimental|mandibular advancement devices ONIRIS®|The patients will use the mandibular advancement devices ONIRIS®
3031906|NCT02348970|Active Comparator|laboratory devices TALI|The patients will use the laboratory devices TALI
3031907|NCT02348944||15 healthy volunteers|Other: serum and urine sample
3031908|NCT02348931|Active Comparator|Surgery plus device (Nasella)|Person in need of surgery has cast for one week, then use of customized nasal brace for nose (Nasella) deformities during 8 weeks.
3031909|NCT02348931|Experimental|Surgery, no device thereafter|Person in need of surgery has cast for 1 week; thereafter no use of customized nasal brace (Nasella) .
3031911|NCT02348918|Experimental|Luminate 1.0mg group|Luminate 1.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
3031912|NCT02348918|Experimental|Luminate 2.0mg group|Luminate 2.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
3031913|NCT02348918|Experimental|Luminate 3.0mg group|Luminate 3.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
3031914|NCT02348918|Active Comparator|Avastin® group|Avastin 1.25 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Avastin injection at weeks 12, 16, or 20 for a total of at least 3 and up to 6 Avastin injections. Sham injections may be performed at weeks 12, 16, and 20 if prn Avastin is not required; sham laser treatment will be administered at baseline and at 16 weeks.
3031915|NCT02348918|Active Comparator|focal laser photocoagulation group|Focal laser photocoagulation performed at baseline (Day 0) with possible prn laser retreatment at week 16. Sham intravitreal injections will be performed at baseline (Day 0), 4 weeks, 8 weeks, 12 weeks, 16 weeks and 20 weeks.
3031916|NCT02348905|Experimental|ACTHAR Gel 40 units twice weekly|ACTHAR Gel at a dose of 40 units twice weekly sub cutaneous injections between Baseline and week 12.
3031917|NCT02348905|Experimental|ACTHAR Gel 80 units twice weekly|ACTHAR gel at a dose of 80 units twice weekly sub cutaneous injections between Baseline and week 12.
3031918|NCT02348892||With coordinator|Elderly patients, in complex situation, taken care by coordinator
3031919|NCT02348892||Without coordinator|Elderly patients, in complex situation, taken care by the classic plan
3031920|NCT02348879|Experimental|AMG 403|AMG 403 administered as subcutaneous and intravenous doses
3031921|NCT02348879|Placebo Comparator|Placebo|No active drug
3031922|NCT02348866|Active Comparator|Group 1|home laundered/home-donned
3031923|NCT02348866|Active Comparator|Group 2|Hospital laundered/home-donned
3031924|NCT02348866|Active Comparator|Group 3|Home laundered/hospital donned
3031925|NCT02348866|Active Comparator|Group 4|Hospital laundered/hospital donned
3031926|NCT02348853|Experimental|Healthy Weight For Living (HWL)|HWL is a behavioral intervention designed to effectively facilitate hunger suppression with several concurrent approaches. Hunger suppression is a core behavioral goal of the intervention, and strategies will be used to support that goal, for example increasing meal frequency and encouraging the use of highly satiating low-energy foods to reduce hunger acutely. A unique combination of healthy dietary goals will be recommended that support hunger suppression and/or maintenance of satiety: high total dietary fiber, moderately high protein, moderately low glycemic load (GL) and low energy density.
3031927|NCT02348853|Experimental|Current Best Practice (CBP)|This intervention is an adapted version of Group Lifestyle Balance which is a validated weight loss program for community groups and military populations that is an official adaptation of the gold standard Diabetes Prevention Program Lifestyle Balance intensive research intervention. It has both training programs for interventionists and program material available on the web and is also slightly modified from the Diabetes Prevention Program study to take into account changing national nutrition recommendations.
3031928|NCT02348840|Experimental|mHealth midwives|Midwives will receive access to mHealth technology immediately and use it for 12 months
3031929|NCT02348840|Active Comparator|mHealth midwives - control|Midwives will not have access to mHealth technology for the first six months, and then will receive the technology for the remaining six months.
3031930|NCT02348840|Active Comparator|Pregnant Women|Pregnant women may or may not receive mHealth technology, based on the collaborating midwife they are assigned.
3031931|NCT02348827|Experimental|Family psychoeducation|The intervention consists of group-based family psychoeducation-program aimed at the patients' relatives. Each group will consist of 5 participants and the patients will not be present at group sessions. The program consists of four weekly sessions each consisting of both short lectures on relevant topics as well as interactive séances designed to give participants problem-solving skills.
3031932|NCT02348827|Active Comparator|Social support group|Relatives in the social support group will attend the same number of sessions of the same duration, as the relatives in the intervention group (family psychoeducation). The psychiatric nurse who will be in charge of the social support group will not give any psychoeducational intervention.
3031933|NCT02348814||normal weight|BMI 20-25
3031934|NCT02348814||overweight|BMI 25-30
3031935|NCT02348814||obese|BMI 30-35
3031936|NCT02348814||morbidly obese|BMI > 35
3031937|NCT02348814||non-diabetic|HgbA1c (<5.7%) and blood glucose (65-99 mg/dL) within normal range as defined at UCLA Clinical Lab
3031938|NCT02348814||diabetic|HgbA1c (>6.5%) and blood glucose (>100 mg/dL) as defined at UCLA Clinical Lab
3031939|NCT02348814||non-cirrhotic|Normal liver function tests (AST/SGOT, ALT, SGPT, alkaline phosphatase, bilirubin) as defined at UCLA Clinical Lab
3031940|NCT02348814||dyslipidemic|Abnormal lipid profile (Total cholesterol >170 mg/dL, LDL >100 mg/dL, HDL >130 mg/dL, triglycerides >150 mg/dL) as defined at UCLA Clinical Lab
3031941|NCT02348801|Active Comparator|Healthy Lifestyle Group|Group diabetes educations sessions that focus on diet, exercise, and social support.
3031942|NCT02348801|Experimental|Weight Loss plus Exercise Group|Behavioral therapy for weight loss and exercise training
3031943|NCT02348788|Active Comparator|Artemether-lumefantrine + Primaquine|"1 tablet = 20mg artemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; >35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, >10-15kg = 1 tablet.~Primaquine = 7.5mg tablet. Dosing daily for 14 days from Day 0. Dose according to bodyweight; >35kg = 30mg, <35kg = 0.5mg/kg"
3032086|NCT02347696|Other|LGIMD|The subjects will follow a Low Glycemic Index Mediterranean Diet without doing any physical activity.
3031944|NCT02348788|Active Comparator|Chloroquine + Primaquine|"1 tablet contains 155mg chloroquine base. Adult dose (>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.~Child dose (>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours. Primaquine = 7.5mg tablet. Dosing daily for 14 days from Day 0. Dose according to bodyweight; >35kg = 30mg, 10-35kg = 0.5mg/kg"
3031945|NCT02348775|Experimental|Cysteine/glycine|Older HIV infected subjects will be studied before and after taking oral cysteine (as n-acetylcysteine) and glycine for 3 months
3031946|NCT02348762|Experimental|Cysteine/glycine|Older subjects will be studied before and after taking oral cysteine (as n-acetylcysteine) and glycine for 6 months
3031947|NCT02348749|Experimental|pts with primary or metastatic neuroendocrine tumors|For phase I, a single dose of 18F-MFBG will be injected intravenously in patients. For all patients, pharmacokinetics and bio distribution will be evaluated using non invasive PET scanning and blood assays at multiple time points post injection. In the expansion phase, a single dose of 18F-MFBG will be injected intravenously followed by a single time point imaging using PET MR scanner (PET/CT if scan cannot be performed on PET/MR for technical reasons). In expansion cohort, an additional 50 patients with NB will be imaged. Patients will receive a single dose of 18F-MFBG intravenously, followed by a whole body PET scan on PET/CT or PET/CT scanner at 60-90 minutes post injection. All patients will be imaged on PET/MR scanner unless technical reasons (claustrophobia, patient refusal, technical difficulty with PET MR) prevents imaging on PET/MR in which case, patients will be imaged on PET CT scanner.
3031948|NCT02348736|Experimental|SensaScope|Time for tracheal intubation with the SensaScope
3031949|NCT02348736|Experimental|McGrath Series 5|Time for tracheal intubation with the McGrath Series 5
3031950|NCT02348723|Experimental|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
3031951|NCT02348723|Active Comparator|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR) between 2.0 - 3.0
3031952|NCT02348710|Experimental|exercise outcome expectation workbook|Intervention arm participants will receive: 1) the ACS exercise and diet guidelines; and 2) an exercise outcome expectation workbook. The workbook contains self-directed activities to increase OE importance, certainty, and accessibility. The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many positive exercise outcomes breast cancer survivors may experience. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes.
3031953|NCT02348710|Active Comparator|diet workbook|Attention control participants will receive via mail 1) the ACS exercise and diet guidelines; and 2) a diet workbook. The diet workbook contains the same activities as the exercise outcome expectation workbook but is focused on diet instead of exercise.
3031954|NCT02348684||Radiation therapy groups|Risk groups based on dosimetric radiation parameters.
3031955|NCT02348658|Other|Fasted dosing followed by fed dosing|Dosing in the fasted state followed by fed dosing
3031956|NCT02348658|Other|Fed dosing followed by fasted dosing|Dosing in the fed state followed by fasted dosing
3031957|NCT02348645|Active Comparator|Decompression with fusion|Spinal decompression surgery with instrumented spinal fusion
3031958|NCT02348645|Active Comparator|Decompression alone|Midline-sparing spinal decompression alone
3031959|NCT02348632|Other|75 mg - 300 mg of JZP-110|Once Daily Dosing
3031960|NCT02348619|Active Comparator|75, 150, 300 mg of JZP-110|Once Daily Dosing
3031961|NCT02348619|Active Comparator|Placebo|Once Daily Dosing
3031962|NCT02348606|Active Comparator|37.5 mg of JZP-110|Once Daily Dosing
3031963|NCT02348606|Active Comparator|75 mg of JZP-110|Once Daily Dosing
3031964|NCT02348606|Active Comparator|150 mg of JZP-110|Once Daily Dosing
3031965|NCT02348606|Active Comparator|300 mg of JZP-110|Once Daily Dosing
3031966|NCT02348606|Active Comparator|Placebo|Once Daily Dosing
3031967|NCT02348593|Active Comparator|75 mg of JZP-110|Once Daily Dosing
3031968|NCT02348593|Active Comparator|150 mg JZP-110|Once Daily Dosing
3031969|NCT02348593|Active Comparator|300 mg of JZP-110|Once Daily Dosing
3031970|NCT02348593|Placebo Comparator|Placebo|Once Daily Dosing
3031971|NCT02348580|No Intervention|Treatment as usual|Schools in which regular curriculum is delivered and teachers do not receive any additional training in child centered methodologies.
3031972|NCT02348580|Experimental|Child centered teaching of life-skills|Training of teachers and weekly implementation of hour long sessions based on child centered teaching of life-skills education over the course of the school year in P6 and S3 classes as designed by Aflatoun Stichting Child Savings International and the Association of Microfinance Institutions in Rwanda (AMIR). The life-skills curriculum is known as Aflatoun's Child Social and Financial Education program. The training of teachers element of the intervention is known as Aflatoun Academy, which trains teachers in active learning, child centered methodologies as well as how to implement the life-skills curriculum of Aflatoun Child Social and Financial Education.
3031973|NCT02348567|Active Comparator|announced hospital surveys|Eleven hospitals will receive announced surveys (control group)
3031974|NCT02348567|Experimental|unannounced hospital surveys|12 hospitals will receive unannounced surveys (intervention group).
3031975|NCT02348554|Experimental|Controlled conditions|Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 1h30 They wore 3 research sensors that estimated energy expenditure: Fitmate, Armband and Actiheart. They also wore smartphones (in front pant pockets) that collected accelerometry data.
3031976|NCT02348554|Experimental|Free-living conditions|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimated energy expenditure: Armband and Actiheart. They also wore smartphones (in front pant pockets) that collected accelerometry data.
3031977|NCT02348541|Other|CollaGUARD|
3032017|NCT02348268|Experimental|Myofascial Release + Analgesic therapy|The intervention for this group consisted of analgesic treatment in accordance with the guidelines of the FREMAP Protocol for the treatment of mechanical NP and additionally, this group was treated with myofascial release therapy (for 15 minutes).
3032216|NCT02346890|Experimental|AZD1722 alone|15 mg BID
3031978|NCT02348528|Experimental|Lenalidomide and dexamethasone|"Cycle 1: 25 mg oral lenalidomide once daily on Days 1-21 every 28 Days and 40 mg oral dexamethasone on Days 8, 15, and 22. Cycle 2 and beyond: 25 oral lenalidomide once daily on Days 1-21 every 28 days and 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22.~The starting doses of Rd regimen will be the same last doses that the subjects received in Study CC-5013-MM-021, unless event(s) that require dose adjustments (dose modifications, reductions and interruptions) per protocol occurred prior to roll-over."
3031979|NCT02348515||Heart failure or coronary disease|This group will have small samples collected from the apex core (that would be routinely discarded at the time of the implantation procedure) by undergoing a left ventricular assist device implantation. In addition, a blood sample will be collected.
3031980|NCT02348515||Heart transplant patients|This group will have multiple samples collected including, excess myocardial biopsy samples that will not be utilized by pathology. In addition, a blood sample will be collected.
3031981|NCT02348515||Orthotopic Heart Transplant Patients|This group will have myocardial tissue samples collected from the diseased heart. In addition, a blood sample will be taken.
3031982|NCT02348515||Heart Surgery Patients|This groups will have samples collected from the left atrial appendages that are routinely removed to prevent thrombosis during atrial fibrillation surgery and a piece of the right atria will be cut in order to implant the cannula. In addition, a blood sample will be taken.
3031983|NCT02348489|Experimental|SGI-110 (guadecitabine)|Intervention: SGI-110 (guadecitabine)
3031984|NCT02348489|Active Comparator|Treatment Choice|Intervention: Choice of one: cytarabine, decitabine, or azacitidine
3031985|NCT02348476||Simbrinza™|Patients treated with Simbrinza™ (brinzolamide 1%/brimonidine 0.2%) as standard of care in clinical practice. No study drug is administered in this study.
3031986|NCT02348463||treatment of bacterial vaginosis|women with bacterial vaginosis will be offered treatment with clindamycin-2-phosphate
3031987|NCT02348450|Experimental|Irinotecan plus Cisplatin|first line: irinotecan 65mg/m2 d1,8. Cisplatin 30mg/m2，d1,8, 21days/cycle×6 cycles Second-line: etoposide alone OR etoposide plus cisplatin, dosage will be same as first line or on investigator's discretion.
3031988|NCT02348450|Experimental|Etoposide plus Cisplatin|first line: etoposide 60mg/m2 d1-5 Cisplatin 75mg/m2，d1(recommended), or administer three times with same total daily dose , 21days/cycle×6 cycles Second-line: irinotecan alone or irinotecan plus cisplatin, dosage is same as first line or on investigator's discretion.
3031989|NCT02348437|Experimental|Repair|Repair of the pronator quadratus muscle
3031990|NCT02348437|Active Comparator|Non-repair|Non-repair of the pronator quadratus muscle
3031991|NCT02348424|Experimental|Female solithromycin|14 females will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted) administered orally.
3031992|NCT02348424|Experimental|Male solithromycin|14 males will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted) administered orally.
3031993|NCT02348411|Experimental|ExAblate Treatment group|
3031994|NCT02348398|Experimental|Pazopanib + Topotecan|"Pazopanib 600 mg taken orally continuously while Topotecan 0.25 mg taken orally for 21 days continuously followed by 7 days off. A cycle will be defined as 28 days.~During follow up if disease gets worse, participant called by study staff every 3 months."
3031995|NCT02348385||Healthy Tobacco Smokers|There is only one arm to the study. All subjects will receive amphetamine
3031996|NCT02348385||Healthy Nonsmokers|There is only one arm to the study. All subjects will receive amphetamine
3031997|NCT02348372|Placebo Comparator|GSK1278863A Placebo|5, 25 and 100 mg matched
3031998|NCT02348372|Experimental|GSK1278863A 10mg|A round, biconvex, white film coated tablet
3031999|NCT02348372|Experimental|GSK1278863A 25mg|A round, biconvex, white film coated tablet
3032000|NCT02348372|Experimental|GSK1278863A 50mg|A round, biconvex, white film coated tablet
3032001|NCT02348372|Experimental|GSK1278863A 100mg|A round, biconvex, white film coated tablet
3032002|NCT02348359|Experimental|50 mg of X-82 plus ivt anti-VEGF prn|Subject will administer one 50 mg tablet of X-82 and one placebo tablet once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
3032003|NCT02348359|Experimental|100 mg of X-82 plus ivt anti-VEGF prn|Subject will administer two 50 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
3032004|NCT02348359|Experimental|200 mg of X-82 plus ivt anti-VEGF prn|Subject will administer two 100 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
3032005|NCT02348359|Placebo Comparator|Placebo plus ivt anti-VEGF prn|Subject will administer two placebo tablets once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
3032006|NCT02348333|Active Comparator|FYU-981|
3032007|NCT02348333|Placebo Comparator|Placebo|
3032008|NCT02348320|Experimental|Personalized polyepitope DNA vaccine|Participants will be treated by electroporation with 4 mg of a personalized polyepitope DNA vaccine at Day 1, Day 29 (+/1- 7 days), and Day 57 (+/- 7 days) with at least 21 days between injection days. Each DNA vaccination with be 4 mg vaccine administered intramuscularly using a TriGrid electroporation device.
3032009|NCT02348307|Active Comparator|FYU-981|
3032010|NCT02348307|Placebo Comparator|Placebo|
3032011|NCT02348294|Other|Healthy volunteers|Shear- force 19 newton and 3,9 kpa pressure for half an hour
3032012|NCT02348294|Other|Diabetes Mellitus type 2 without neuropathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
3032013|NCT02348294|Other|Diabetes Mellitus type 2 with neuropathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
3032014|NCT02348294|Other|Charcot Osteoarhtopathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
3032015|NCT02348281|Experimental|bicalutamide|150mg, po, qd, d1-28
3032016|NCT02348268|Active Comparator|Manual Therapy + Analgesic therapy|The intervention for this group consisted of analgesic treatment in accordance with the guidelines of the FREMAP Protocol for the treatment of mechanical NP and additionally this group was treated with manual therapy (for 15 minutes).
3032051|NCT02347956|Experimental|Reduced port group|
3032052|NCT02347930||Confirmed acute kidney injury|Confirmed acute kidney injury
3032053|NCT02347917|Experimental|BBI608 puls pemetrexed and cisplatin|
3032018|NCT02348255|Experimental|Treatment (bevacizumab, carmustine, NovoTTF-100A)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks beginning on day -7 for up to 13 doses and carmustine IV over 4 hours every 8 weeks beginning on day 1 for up to 3 doses. Patients also undergo NovoTTF-100A according to standard procedures starting one week before the first dose of carmustine.
3032019|NCT02348242|Experimental|Aqueous gel|In the same patient : one eye receives regular administration of aqueous gel (experimental treatment 1) and the other eye receives regular administration of artificial tears (active comparator)
3032020|NCT02348242|Experimental|Eyelid occlusion dressing|In the same patient : one eye is closed with an eyelid closure dressing (experimental treatment 2) and the other eye receives regular administration of artificial tears (active comparator)
3032021|NCT02348229|Experimental|ERAS group|ERAS protocols
3032022|NCT02348229|Other|conventional pathway group|using conventional pathway
3032023|NCT02348216|Experimental|Single Arm|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg
3032024|NCT02348203|Experimental|Arm I (aspirin, zileuton)|Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.
3032025|NCT02348203|Placebo Comparator|Arm II (double placebo)|Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.
3032026|NCT02348190|Active Comparator|Lipid/heparin|16 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) lipid/heparin co-infusion for 8 hours.
3032027|NCT02348190|Placebo Comparator|Control|16 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and without (n=16) lipid/heparin co-infusion for 8 hours.
3032028|NCT02348177|Experimental|TB/HIV co-infection|Superboosting lopinavir with ritonavir in 1:1 ratio during TB/HIV co-infection and treatment of HIV with lopinavir/ritonavir 4:1
3032029|NCT02348164|Experimental|Treatment 1|Volunteers receive pink grapefruit first followed by tangerines two weeks later
3032030|NCT02348164|Experimental|Treatment 2|Volunteers receive tangerines first followed by pink grapefruit two weeks later
3032031|NCT02348151|Experimental|Treadmill|The Shuttle is going to play on treadmill
3032032|NCT02348151|Active Comparator|Corridor|The Shuttle is going to play on corridor
3032033|NCT02348138|Experimental|Home-based isometric handgrip training|All participants that will be assigned to home-based isometric handgrip training (HBT) will train three times per week for a total of 12 weeks, will perform a bout of isometric handgrip exercise: four sets of 2-min isometric contractions (using alternate hands) at 30% of maximal voluntary contraction; however, the training will be performed without daily supervision. Therefore, the subjects will receive a logbook to record the exercise sessions. In addition, visits will be scheduled at weeks 1, 3, 6, 9 and 11 to provide feedback to individuals and discuss potential problems in conducting training.
3032034|NCT02348138|Experimental|Supervised isometric handgrip training|All participants that will be assigned to supervised isometric handgrip training (ST) will train three times per week for a total of 12 weeks, will perform a bout of isometric handgrip exercise: four sets of 2-min isometric contractions (using alternate hands) at 30% of maximal voluntary contraction with. The training will be performed with daily supervision.
3032035|NCT02348138|No Intervention|Control group|Subjects randomized to the control group (CG) will be encouraged to increase the level of physical activity and make healthy eating, without, however, receive specific recommendations
3032036|NCT02348125|Experimental|Mitochondrial Cocktail|"The precise content of the Mitochondrial Cocktail will be:~ubiquinol (liquid form, 150 mg/kg subject weight/day~carnitine, 50 mg/kg subject weight/day~alpha-lipoic acid, 100 mg/ day"
3032037|NCT02348112||Altis Sling|Subjects will have an Altis sling placed to treat stress urinary incontinence.
3032038|NCT02348112||Transobturator or Retropubic Sling|Subjects will have a transobturator or retropubic sling placed to treat stress urinary incontinence.
3032039|NCT02348073|Active Comparator|PS-OMEGA 3, capsules twice daily|Vayarin®, supplementation of n-3 PUFA: each capsule contains 8.5 mg of docosahexaenoic acid (DHA), 21.5 mg of eicosapentaenoic acid (EPA) and 75 mg of phosphatidylserine.
3032040|NCT02348073|Placebo Comparator|PLACEBO, capsules twice daily|The placebo will be made of cellulose and a small amount of fish powder to maintain the double-blind in odor and taste. The supplementation in n-3 PUFA in the placebo group may be considered as negligible. Placebo will be administered as indistinguishable capsules, identical to the active product.
3032041|NCT02348047|Active Comparator|Conventional ventilation|Conventional ventilation - manual mode
3032042|NCT02348047|Experimental|ASV|Intellivent ASV ( Adaptative Support Ventilation )Ventilation- automatic mode
3032043|NCT02348034|Experimental|Prevena Dressing|This group will receive prevena dressing after the elective colorectal surgery
3032044|NCT02348034|No Intervention|Conventional dressing|This group will receive conventional dressing after the elective colorectal surgery
3032045|NCT02348021|Other|Drug Coated Stent|All patients in the one arm will be treated by PCI with the Drug Coated Stent.
3032046|NCT02348008|Experimental|Arm A - Phase 1b Dose Escalation Cohort|"Cohort 1 will consist of 3-6 patients who will receive MK-3475 200mg and bevacizumab 10mg on day 1 of the 21-day cycle. The drugs are administered 15-30 minutes apart in separate intravenous infusions.~Cohort 2 will consist of 3-9 patients who will receive MK-3475 200mg and bevacizumab 15mg on day 1 of the 21-day cycle. The drugs are administered 15-30 minutes apart in separate intravenous infusions.~If none of the 3 subjects experience a dose limiting toxicity (DLT) during the first cycle of therapy, an additional 3 subjects will be enrolled at dose level 2. If all three subjects in dose level 2 complete the first cycle of therapy without DLT, 3 more subjects will be enrolled to ensure only 0-1 of 6 subjects have a DLT. There will be no further escalation beyond dose level 2."
3032047|NCT02348008|Other|Arm B - Phase II Investigational Treatment|The maximum safe dose of MK-3475 in combination bevacizumab (as determined in the phase 1b cohort) will be given on day 1 of each 21 day cycle.
3032048|NCT02347995|Placebo Comparator|Resistive Training|Participants will drink a placebo beverage after each resistance training session.
3032049|NCT02347995|Experimental|Resistive Training + Protein|Participants will drink 30 grams of whey protein after each resistance training session.
3032050|NCT02347969|Experimental|X34|Arm supplemented with X34
3032055|NCT02347891|Experimental|Belimumab + Standard of Care|"Patients in this arm will be given belimumab with a background of standard of care therapy during the randomized controlled treatment period.~Patients in this arm will continue to receive belimumab during the open label phase of the study (week 40 - week 64)"
3032056|NCT02347891|Active Comparator|Placebo + Standard of Care|"Patients in this arm will be given a placebo with a background of standard of care therapy during the randomized controlled treatment period.~Patients in this arm will receive belimumab during the open label phase of the study (week 40 - week 64)."
3032057|NCT02347878|Experimental|treatment arm|this treatment arm will received aprepitant 1 hour before lumbar puncture and intrathecal treatment.
3032058|NCT02347878|No Intervention|control arm|this arm will received nothing 1 hour before lumbar puncture
3032059|NCT02347865||wave 1|postmenopausal women with osteoporosis treated with Prolia
3032060|NCT02347865||wave 2|postmenopausal women with osteoporosis treated with Prolia
3032061|NCT02347852||Physical activity / Cohort 1|The non influenced and non triggered habitual physical activity of patients will be assessed by pedometer and physical activity questionnaire. The study population will consist of patients with metastatic CRC (mCRC) who are included in the NIS CORRELATE, have been previously treated with other approved regimens for metastatic disease and for whom a decision has been made by the physician to treat with regorafenib according to local health authority approved label prior to and independent of the inclusion into this observational study.
3032062|NCT02347839|Experimental|Intervention group|Gefitinib-surgery-gefitinib. Induction gefitinib therapy was given for 8 weeks. Patients' resectability was assessed after 8-week gefitinib. Adjuvant gefitinib was given within 3-6 weeks after surgery until progression or unacceptable toxic effects.
3032063|NCT02347813|Other|Delayed Intervention|After enrollement, subjects will be observed for 24 weeks for skin cancer tumors. Tumors will be appropriately treated as per standard of care. Then they will begin the pioglitazone regimen for 24 more weeks, during which time skin cancer tumors will be observed and appropriately treated as per standard of care.
3032064|NCT02347813|Other|Immediate Intervention|Subjects will begin the 24 week pioglitazone regimen immediately after enrollment, during which time skin cancer tumors will be observed and appropriately treated as per standard of care. After 24 weeks of drug, subjects will be observed for 24 weeks for skin cancer tumors. Tumors will be appropriately treated as per standard of care.
3032065|NCT02347787|Placebo Comparator|Usual clinician support|Prior to randomization, patients in this arm will already have set a chronic disease management goal with their primary care provider (who will have received training in collaborative goal-setting). After randomization, patients in the usual clinician support arm will receive usual care in accordance with guidelines at each site.
3032066|NCT02347787|Experimental|CHW support|Prior to randomization, patients in this arm will already have set a chronic disease management goal with their primary care provider (who will have received training in collaborative goal-setting). After randomization, patients in the CHW arm will receive the IMPaCT intervention.
3032067|NCT02347774|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg Twice Daily (BID) via e-Flow (R) Closed System (CS) nebulizer
3032068|NCT02347774|Experimental|SUN-101 25 mcg BID e-Flow (CS) nebulizer|SUN-101 25 mcg (BID) via e-Flow (R) Closed System (CS) nebulizer
3032069|NCT02347774|Placebo Comparator|Placebo BID Eflow (CS) nebulizer|Placebo (BID) via e-Flow (R) Closed System (CS) nebulizer
3032070|NCT02347761|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow (R) Closed System (CR) nebulizer
3032071|NCT02347761|Experimental|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow (R) Closed System (CR) nebulizer
3032072|NCT02347761|Placebo Comparator|Placebo BID eFlow (CS) nebulizer|Placebo twice daily (BID) eFlow (R) Closed System (CR) nebulizer
3032073|NCT02347748|Experimental|Group A - Reading pre-procedure script|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
3032074|NCT02347748|Experimental|Group B - Reading pre-extubation script|Patients will be read a pre-extubation script;
3032075|NCT02347748|Experimental|Group C - Reading 2 scripts|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area Patients will be read a pre-extubation script
3032076|NCT02347748|No Intervention|Group D|Patients will not be read any script
3032077|NCT02347735||Anastomotic leakage|Of the entire cohort, data collected from patients suffering from anastomotic leakage will be evaluated and compared to patients that did not develop anastomotic leakage. No interventions, only data collection.
3032078|NCT02347735||No anastomotic leakage|Of the entire cohort, data collected from patients suffering from anastomotic leakage will be evaluated and compared to patients that did not develop anastomotic leakage. No interventions, only data collection.
3032079|NCT02347722||Retrospective|Heart failure patients where the etiology of their heart failure has been diagnosed. This cohort will consist of 3 groups: 1) Ischemic cardiomyopathy, 2) dilated cardiomyopathy and 3) diastolic heart failure
3032080|NCT02347722||Prospective|This cohort will consist of symptomatic heart failure patients diagnosed within 2 years.
3032081|NCT02347722||Acute|Sub-study: This cohort will consist of newly diagnosed patients admitted with acute heart failure.
3032082|NCT02347709||Group 1/Diabetic Foot Ulcer|Group 1 will be recruited from the Wound Center, and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥5.9%), and a diabetic foot ulcer (defined as a break in the skin on the foot). Subjects in this group will complete a survey, undergo a Comprehensive Neuropathy Evaluation, and have a photograph and biopsy of their Diabetic Foot Ulcer in addition to the standard of care.
3032083|NCT02347709||Group 2/Diabetic Neuropathy|Group 2 will be recruited from the Neurology clinic and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥ 5.9%) and neuropathy. Subjects in this group will complete a survey and undergo a Comprehensive Neuropathy Evaluation in addition to the standard of care.
3032084|NCT02347709||Group 3/Type 2 Diabetes|Group 3 will be recruited from the Endocrinology clinic and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥ 5.9%) who currently do not have a diagnosis of neuropathy or a diabetic foot ulcer. Subjects in this group will complete a survey and undergo a Comprehensive Neuropathy Evaluation in addition to the standard of care.
3032085|NCT02347696|Other|Control|The subjects will follow a diet based on INRAN guidelines without doing any physical activity.
3032087|NCT02347696|Other|Endurance Activity (EA)|The subjects will follow a program of endurance (aerobic) activity (EA) without following a specific diet.
3032088|NCT02347696|Other|EA+Resistance Training (RT)|The subjects will follow a program of endurance activity (EA) and resistance training (RT) without following a specific diet.
3032089|NCT02347696|Other|LGIMD+EA|The subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) togheter with a program of endurance activity (EA).
3032090|NCT02347696|Other|LGIMD+EA/RT|The subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) togheter with a program of endurance activity (EA) and resistance training (RT).
3032091|NCT02347683||Benign pathology|We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days, 4, 6, and 12 weeks
3032092|NCT02347683||Malignant pathology|We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days ; 4, 6, and 12 weeks and 6 and 12 months
3032093|NCT02347670|Active Comparator|Group 1M- Community Site|"Participants randomized to Group 1-Main will attend follow-up visits at one of the four main community sites. A glaucoma specialist will perform the comprehensive eye examination and a ophthalmic technician will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.~Intervention: Efficacy-patient navigator to improve follow-up adherence"
3032094|NCT02347670|Active Comparator|Group 2- Office-Based|"Office-Based, Follow-Up Eye Care with Patient Navigation Protocol: Participants randomized to Group 2 will attend follow-up visits at the Wills Eye Hospital Glaucoma Research Center. A glaucoma specialist will perform the eye examination. Ophthalmic technicians will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.~Intervention: Efficacy-patient navigator to improve follow-up adherence"
3032095|NCT02347670|Active Comparator|Group 3- Office-Based|"Group 3- follow-up eye care at the Wills Eye Hospital. There will be no charge or co-pay for these visits. Those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire. These participants will receive a phone number to call and schedule their appointment and will receive a reminder phone call similar to the standard appointment-reminding procedure commonly used at the Wills Eye Hospital. Group 3 represents a realistic choice currently available for patients and thus will be used to compare with usual care and will have 2-3 visits over the one-year period depending on diagnosis.~Intervention: Office-Based Usual Care"
3032096|NCT02347670|Active Comparator|Group 1R- Community Site|"Participants randomized to Group 1-Randomized will attend follow-up visits at one of the four main community sites, these participants were randomized from the 40 community sites to the closest community location. A glaucoma specialist will perform the comprehensive eye examination. Ophthalmic technicians will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.~Intervention: Efficacy-patient navigator to improve follow-up adherence"
3032097|NCT02347657|Placebo Comparator|Placebo|Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA tablet administered orally in the evening up to Week 24.
3032098|NCT02347657|Experimental|VX-661/IVA|VX-661 100 mg plus IVA 150 mg FDC tablet administered orally in the morning and IVA 150 mg tablet administered orally in the evening up to Week 24.
3032099|NCT02347644|Experimental|Brief Motivational Interview|Given a brief motivational interview encouraging reduced use of alcohol and drugs.
3032100|NCT02347644|No Intervention|Youth Control Group|Given a brochure with all available organizations in the community for help with alcohol and drug problems.
3032101|NCT02347631|Experimental|Alcon DAILIES TOTAL1|Intervention: Soft Contact Lens - Daily Disposable Name - Alcon Dailies Total 1 Material - Delefilcon A Water Content - 33% Oxygen Permeability - 140 x10-11 (cm2/sec)(mL O2/mL mmHg) Oxygen Transmissibility - 156 x10-9 (cm/sec)(mL O2/mL mmHg) Base Curve - 8.5mm Manner of Wear - Daily Disposables Wearing Time - 2 months
3032102|NCT02347631|Active Comparator|ACUVUE TruEye|Intervention: Soft Contact Lens - Daily Disposable Name - Acuvue TruEye Material - Narafilcon A Water Content - 46% Oxygen Permeability - 100 x10-11 (cm2/sec)(mL O2/mL mmHg) Oxygen Transmissibility - 118 x10-9 (cm/sec)(mL O2/mL mmHg) Base Curve - 8.5mm & 9.0mm Manner of Wear - Daily Disposables Wearing Time - 2 months
3032103|NCT02347618|Experimental|Preoperative SBRT|This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
3032104|NCT02347605|Experimental|Nicotine lozenge 4 mg prior to cue exposure|Nicotine lozenge is used 15 minutes prior to smoking cue exposure
3032105|NCT02347605|Placebo Comparator|Placebo lozenge prior to cue exposure|Placebo lozenge is used 15 minutes prior to smoking cue exposure
3032106|NCT02347605|Other|Control condition: Lozenge after cue exposure|Lozenge is used immediately after smoking cue exposure
3032107|NCT02347592|Active Comparator|straight Tenckhoff|The straight Tenckhoff catheter (sT) is the most common used catheter for peritoneal dialysis (PD).
3032108|NCT02347592|Active Comparator|self-locating catheter|A new, more expensive, self-locating catheter (sLC) has been developed by Di Paolo.
3032109|NCT02347579||Patients with CRPS|Patients with Complex Regional Pain Syndrome, Type I
3032110|NCT02347579||Patients with CLBP|Patients with chronic low back pain
3032111|NCT02347579||Healthy controls|
3032112|NCT02347566|Experimental|Physical activity enhancing programme|Usual care + physical activity enhancing programme (PAEP) (Study group, [S]), which includes both pulmonary rehabilitation programme plus the PAEP using an activity monitor (DirectLife) with set targets of physical activity levels to stimulate and increase physical activity in daily life.
3032113|NCT02347566|Other|Control|Usual care (control, [C]) that includes only the pulmonary rehabilitation programme with the use of an activity monitor (DirectLife) in daily routine without any feedback or incentive to increase physical activity in daily life.
3032114|NCT02347540||PE|"Cases: women with a history of preeclampsia. Measurements will be performed in a postpartum interval from 0.5 years until 30 years after the first complicated pregnancy.~This group will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure."
3032115|NCT02347540||Control|Controls include women with a history of uncomplicated pregnancies. The controlgroup will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure.
3032116|NCT02347527|Experimental|Active Implicit Priming|Participants will complete active implicit priming, in which food images are implicitly primed (i.e., below conscious awareness) with images of positive or negative affect.
3032117|NCT02347527|Placebo Comparator|Control Implicit Priming|Participants will complete a control implicit priming intervention, which matches the active intervention, but with neutral stimuli as primes.
3032118|NCT02347514|Experimental|Diabetes Group Visit|"Subjects in this arm will be asked to attend one group visit at their health center each month for six months. The group visits will involve various staff and providers at the health center who will teach them how to take care of their diabetes. Subjects will be scheduled to attend the same group visit appointments as the other subjects, and health center staff will encourage the group to share their own experiences about living with diabetes with the rest of the group.~If subjects at the health center additionally implementing the text-messaging intervention consent to enroll in the study, their phone number will also be entered into a secure system that will allow the group visit healthcare team to send them text messages during the course of the six months they are in the program. These text messages are intended to offer the subjects additional support in taking care of their diabetes."
3032119|NCT02347514|No Intervention|Usual care|Patients in the control arm will be selected after the follow-up period is over for the intervention arm. They will receive the care they normally receive at their health center.
3032120|NCT02347501|Experimental|A|"Sitagliptin 100mg once daily orally or 50mg once daily for participants with moderate kidney disease for 24 weeks and narrowband ultraviolet-B (NBUVB) phototherapy.~NBUVB light therapy is continued until the participants' psoriasis clears (<1% body surface area involved)."
3032121|NCT02347501|No Intervention|B|"No additional treatment other than narrowband ultraviolet-B (NBUVB) phototherapy.~NBUVB light therapy is continued until the participants' psoriasis clears (<1% body surface area involved)."
3032122|NCT02347488|Experimental|ETT holder and bite guard|Participants will have endotracheal tubes secured with tape prior to having surgery, which is the current standard of care. Following the traction test and measurement of displacement, participants will have endotracheal tubes secured with a combined Haider ETT Tube Holder and Bite Guard.
3032123|NCT02347462|Experimental|BiPAP plus standard care|Bilevel Positive Airway Pressure (BiPAP) plus standard care according to the hospital's severe asthma protocol
3032124|NCT02347462|Active Comparator|Standard care alone|Standard care according to the hospital's severe asthma protocol
3032125|NCT02347449|Experimental|Early stage breast cancer|"Women with node positive (1-3 nodes), ER positive breast cancer who are receiving (or will receive) endocrine therapy, and who are candidates for chemotherapy.~Study subjects will have ONCOTYPE Dx assay performed on their breast tumors, and will complete study questionnaires."
3032126|NCT02347436||benign prostatic hypertrophy|patients who are diagnosed with lower urinary tract symptoms caused by prostatic hypertrophy, undergo transurethral resection of the prostate, and post-surgery 24-hr ambulatory blood pressure measurement.
3032127|NCT02347436||inguinal hernia or hydrocele|patients who are diagnosed with lower urinary tract symptoms caused by inguinal hernia or hydrocele, undergo surgical inguinal hernia repair or hydrocele repair, and post-surgery 24-hr ambulatory blood pressure measurement
3032128|NCT02347423|Experimental|1/3 IPV-Al SSI|3 vaccinations of 1/3 IPV-Al SSI given at 6, 10 and 14 weeks of age
3032129|NCT02347423|Experimental|1/5 IPV-Al SSI|3 vaccinations of 1/5 IPV-Al SSI given at 6, 10 and 14 weeks of age
3032130|NCT02347423|Experimental|1/10 IPV-Al SSI|3 vaccinations of 1/10 IPV-Al SSI given at 6, 10 and 14 weeks of age
3032131|NCT02347423|Active Comparator|IPV Vaccine SSI|3 vaccinations of IPV Vaccine SSI given at 6, 10 and 14 weeks of age, The comparator IPV Vaccine SSI contains: Type 1: 40DU, Type 2: 8 DU and Type 3: 32 DU.
3032132|NCT02347410|Other|SIFS Graft Containment Device|Investigational
3032133|NCT02347397|Experimental|SS Bipolar Head + SL-TWIN Stem|Subject will be implanted with the SS Bipolar Head & SL-TWIN Stem
3032134|NCT02347397|Active Comparator|Bipolar Head + SL-PLUS Stem|Subject will be implanted with the Bipolar Head & SL-PLUS Stem
3032135|NCT02347384|Experimental|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will be implanted with Delta PLUS Femoral Head & SL-TWIN Stem
3032136|NCT02347384|Active Comparator|BIOLOX forte ball head + SL-PLUS Stem|Subject will be implanted with BIOLOX forte ball head & SL-PLUS Stem
3032137|NCT02347358|Experimental|IV r-tPA with JRecanTM blood FR device|Dual IV r-tPA therapy and adjunctive treatment with JRecanTM blood flow recanalisation device
3032138|NCT02347358|Active Comparator|IV r-tPA|IV infusion of r-tPA
3032139|NCT02347345|Active Comparator|Active injection drug use (IDU)|In active IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
3032140|NCT02347345|Active Comparator|Former injection drug use (former IDU)|In former IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
3032141|NCT02347345|No Intervention|Healthy volunteers|HIV, HCV and HBV negative, never injected drugs, no recreational drugs for at least 2 years (does not include marijuana) and negative urine screen for opiates at the screening visit.
3032142|NCT02347332|Experimental|Vinflunine plus methotrexate|vinflunine IV 280 mg/m² Day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks
3032143|NCT02347332|Active Comparator|methotrexate|methotrexate IV 40 mg/m² Day 1, 8 and 15 every 3 weeks
3032144|NCT02347319|Experimental|Pennel|This group will treated with DDB 25mg/Garlic oil 50mg for 12 weeks.
3032145|NCT02347319|Active Comparator|Legalon|This group will treated with Silymarin 140mg for 12 weeks.
3032146|NCT02347319|Placebo Comparator|Placebo|This group will treated with Placebo for 12 weeks.
3032147|NCT02347306||cohort of patients with suspected coronary artery disease|a cohort of patients with suspected coronary artery disease going forward for conventional angiography and (2) whether CT-TCFA is associated with future adverse cardiovascular events.
3032148|NCT02347293|Experimental|+ ind. CHO|Test meals: intake of high levels of indigestible carbohydrates the evening prior to measurements of variables
3032149|NCT02347293|Experimental|- ind. CHO|Reference meal: scarce intake of indigestible carbohydrates the evening prior to measurements of variables
3032150|NCT02347280|Experimental|Loop ileostomy with colonic lavage|creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
3032151|NCT02347280|Active Comparator|Total abdominal colectomy with end ileostomy|Removal of entire colon with preservation of rectal stump and construction of end ileostomy
3032152|NCT02347267|Experimental|Caloric and non-caloric SSBS reduction|Sweetened beverages (SSBS) caloric and non-caloric were not permitted and allowed only plain water
3032153|NCT02347267|Active Comparator|Caloric SSBS reduction|Only plain water and non-caloric sweetened beverages (SSBS) were allowed
3032154|NCT02347267|No Intervention|All beverages|Beverages were not restricted
3032155|NCT02347254|Experimental|Transcranial ExAblate|Transcranial ExAblate MRgFUS
3032156|NCT02347241|No Intervention|Control period|Assessment of resuscitation quality and clinical outcomes prior to educational intervention
3032157|NCT02347241|Experimental|Educational intervention|Assessment of resuscitation quality and clinical outcomes after educational intervention consisting of debriefing and rolling refreshers.
3032158|NCT02347228|Experimental|OB318 capsule|
3032159|NCT02347215|Other|All patients|All patients undergo quality of life assessment at 2-3 time points and stress imaging at two time points
3032160|NCT02347202|Experimental|Online counseling via Zoom teleconferencing|Each participant will be assigned a random number which is linked to group assignment. The numbers will be assigned consecutively to participants as they enroll. All caregivers in the treatment group will receive 6 counseling sessions in 4 months, using teleconferencing. The first session will be an individual session. The caregiver will be asked to select family members to participate in the next 4 sessions. The 4 family sessions will be followed by another individual session with the spouse/partner caregiver. The counselor will send the primary caregiver an email to be forwarded to family members with instructions on how to access the TTDC training on using the teleconferencing technology. All caregivers in the control group will be able to call the counselor for resource information and support.
3032161|NCT02347202|Other|Telephone support as needed|All caregivers in the control group will be able to call the counselor for resource information and support as needed.
3032162|NCT02347189|Other|Melody TPV PB1016|
3032163|NCT02347176|Placebo Comparator|Placebo|Placebo matched to Tralokinumab will be administered subcutaneously to participants once every 2 Weeks (Q2W) for 12 weeks.
3032164|NCT02347176|Experimental|Tralokinumab Dose 1|Tralokinumab Dose 1 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
3032165|NCT02347176|Experimental|Tralokinumab Dose 2|Tralokinumab Dose 2 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
3032166|NCT02347176|Experimental|Tralokinumab Dose 3|Tralokinumab Dose 3 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
3032167|NCT02347163|Experimental|Zoledronate|Patients fulfilling the eligibility criteria will receive a pre-operative, single administration of zoledronate (4mg i.v.), 7 days before definitive breast surgery
3032168|NCT02347150||ICU LOS>24h|30-110 patients discharged from the ICU
3032169|NCT02347137|Active Comparator|Isolated Whey Protein|20 g isolated whey protein + 15 g non-essential amino acids
3032170|NCT02347137|Experimental|Micellar Whey Protein|20 g micellar whey protein + 15 g non-essential amino acids
3032171|NCT02347137|Experimental|Micellar Whey Protein + Citrulline|20 g micellar whey protein + 5 g citrulline
3032172|NCT02347124|Active Comparator|Usual Care Control|Standard tobacco quitline counseling program and materials + attention-matched text messaging.
3032173|NCT02347124|Experimental|Enhanced Intervention|Standard tobacco quitline counseling program and materials + multi-modal oral health promotion program .
3032174|NCT02347111|Experimental|flecainide 1st|flecainide x 6 months, then crossover to sotalol x 6 months
3032175|NCT02347111|Experimental|sotalol 1st|sotalol x 6 months, then crossover to flecainide x 6 months
3032176|NCT02347098|Experimental|intensive LDL-lowering therapy (ILLT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to LDL-apheresis and an oral daily dose of 40-80mg of Atorvastatin or equivalent.
3032177|NCT02347098|Active Comparator|standard statin monotherapy (SMT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to an oral daily dose of 40-80mg of Atorvastatin or equivalent without LDL-apheresis
3032178|NCT02347085|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
3032179|NCT02347085|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
3032180|NCT02347072|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
3032181|NCT02347072|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
3032182|NCT02347072|Active Comparator|Spiriva® Respimat® (Tiotropium Bromide)|Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
3032183|NCT02347059|Experimental|L-dopa|L-dopa will be administered as monotherapy. The dosage and the frequency of intakes are not pre-specified and will be individualized.
3032184|NCT02347059|Active Comparator|Dopamine agonist|Dopamine agonists (either pramipexole or ropirinole) will be administered as monotherapy. The dosage and the frequency of intakes are not pre-specified and will be individualized.
3032185|NCT02347046|Experimental|Moderately-decreased group|(eGFR: >=30mL/min/1.73m^2 and < 60mL/min/1.73m^2)
3032186|NCT02347046|Experimental|Slightly-decreased group|(eGFR: >=60mL/min/1.73m^2 and < 90mL/min/1.73m^2)
3032187|NCT02347046|Experimental|Normal group|(eGFR: >=90mL/min/1.73m^2)
3032188|NCT02347033|Active Comparator|Sertraline|The pharmacological arm of the trial is the Selective Serotonin Reuptake Inhibitor (SSRI) Sertraline, prescribed at a daily dose of between 25 and 150mg by the patient's general practitioner (GP). If the medication is well tolerated and associated with reported clinical improvement we are asking the patients in this arm to continue taking it for 12 months.
3032189|NCT02347033|Active Comparator|Cognitive Behavioural Therapy (CBT)|The psychological therapy arm of the trial is Cognitive Behavioural Therapy (CBT) delivered by high intensity psychological therapists from local IAPT services. They will provide 14 to 16 sessions of a manualised treatment developed specifically for use in GAD and will be trained in its delivery.
3032190|NCT02347020|Experimental|Normal Sleep/ Normal Meal|sleep 0000-0800 h, meals at 1, 5, 11, and 12.5 (snack) h after awakening
3032191|NCT02347020|Experimental|Normal Sleep/ Late Meal|Ns/Lm: sleep 0000-0800 h, meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening
3032192|NCT02347020|Experimental|Late Sleep/ Normal Meal|sleep 0330-1130 h, meals at 1, 5, 11, and 12.5 (snack) h after awakening
3032193|NCT02347020|Experimental|Late Sleep/ Late Meal|sleep 0330-1130 h, meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening
3032194|NCT02347007|Experimental|Almond|
3032195|NCT02347007|Active Comparator|Cereal Bar|
3032196|NCT02346994|Experimental|Melt test blend 3.2|
3032197|NCT02346994|Active Comparator|Corn Oil|
3032198|NCT02346981|Experimental|Intervention gruop|The intervention group was submitted to a resistance training program that consisted of eight exercises performed in two sets of 10 to 15 repetitions, three times per week.
3032199|NCT02346981|No Intervention|Control group|The control group performed a stretching training program for the major muscle groups, in sessions of 30 minutes, twice a week
3032200|NCT02346968||All study participants|Patients with end stage renal disease (ESRD) planned to undergo kidney transplantation.
3032201|NCT02346955|Experimental|Cohort A Monotherapy Dose Escalation|Participants will be enrolled in a staggered manner starting at a dose of 0.01 mg/kg of CM-24 (MK-6018) and continuing to 0.03, 0.1, 0.3, 1.0, 3.0, and 10 mg/kg to determine the recommended Phase 2 dose (RP2D). The dose will be escalated after a 6- to 8-week DLT window. Participants will be treated for 12 weeks during Cycle 1. Afterwards participants with clinical benefit and no dose-limiting toxicites (DLTs) are treated for up to 6 cycles.
3032202|NCT02346955|Experimental|Cohort B Combination Dose Escalation|Participants will be enrolled at the recommended phase 2 dose (RP2D) of CM-24 (MK-6018), determined by escalation studies, minus 1 dose level of MK-6018 in combination with a fixed dose of 200 mg pembrolizumab. Participants will be escalated to the RP2D of MK-6018 + 200 mg pembrolizumab. If the RP2D of MK-6018 + 200 mg pembrolizumab is not tolerated, the dose of MK-6018 will be de-escalated but will not fall below 1 mg/kg. Participants will be treated for 6 weeks during Cycle 1 and 2. Afterwards participants with clinical benefit and no DLTs are treated for up to 35 cycles.
3032203|NCT02346955|Experimental|Cohort C Monotherapy Expansion|Participants with advanced or recurrent cutaneous melanoma will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
3032204|NCT02346955|Experimental|Cohort D Monotherapy Expansion|Participants with advanced or recurrent colorectal cancer will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
3032205|NCT02346955|Experimental|Cohort E Monotherapy Expansion|Participants with advanced or recurrent gastric cancer will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
3032206|NCT02346955|Experimental|Cohort C1 Combination Expansion|Participants with advanced or recurrent cutaneous melanoma will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
3032207|NCT02346955|Experimental|Cohort D1 Combination Expansion|Participants with advanced or recurrent colorectal cancer will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
3032208|NCT02346955|Experimental|Cohort E1 Combination Expansion|Participants with advanced or recurrent gastric cancer will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
3032209|NCT02346955|Experimental|Cohort F Combination Expansion|Participants with advanced or recurrent non-small cell lung adenocarcinoma will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
3032210|NCT02346942||Patients who have no history of bDMARD therapy use|
3032211|NCT02346942||Patients who have a prior history of bDMARD therapy use|
3032212|NCT02346929|Experimental|ultrasound-guided hematoma block|Patients in this arm will receive a bed-side ultrasound guided hematoma block with analgesia (0.25% bupivacaine)
3032213|NCT02346929|No Intervention|traditional hematoma block|Patients in this arm will have the hematoma block of the distal radius fracture with no ultrasound for guidance with analgesia (0.25% bupivacaine)
3032214|NCT02346916|Other|Cardiac Catheterization Patients|"Subjects will undergo the cutaneous capsaicin test at the time of the study visit. A one inch ribbon of Capzasin-HP Cream (0.1%) will be applied to the skin on the forearm of the non-dominant arm. Subjects will be asked to assign a numerical score to the maximum intensity of any cutaneous discomfort experienced during the subsequent 30 minutes, from 0 (no discomfort) to 10 (the worst discomfort imaginable). The cream will then be removed by washing the affected arm with cold water. Efforts will then be made to examine the association between the pain score documented in response to the cutaneous capsaicin test with the pain score obtained during coronary balloon occlusion. This method should allow an individual's subjective sensitivity to the TRPV1-mediated noxious stimulus of myocardial ischemia to be compared with his/her sensitivity to the TRPV1-mediated noxious stimulus of cutaneous capsaicin in extra-cardiac tissues."
3032215|NCT02346903|Other|Cardiac Catheterization Patients|"Subjects will undergo the cutaneous capsaicin test. A one inch ribbon of Capzasin-HP Cream (0.1%) will be applied to the skin on the forearm of the non-dominant arm. Subjects will be asked to assign a numerical score to the maximum intensity of any cutaneous discomfort experienced during the subsequent 30 minutes, ranging from 0 (no discomfort) to 10 (the worst discomfort imaginable). The cream will then be removed by washing the affected arm with cold water. The patients will be asked follow-up questions concerning their experiences with chest pain in the past and their tolerance of spicy foods. Efforts will then be made to examine the association between the pain score documented in response to the cutaneous capsaicin test with the pain score obtained during coronary balloon occlusion."
3032218|NCT02346877|No Intervention|Standard of Care Cohort|The first 100 participants will be enrolled in the standard of care (control) cohort. These participants will receive treatment with Enbrel® (etanercept) in routine clinical practice and will complete a 52 week study period as per the investigator's standard of care.
3032219|NCT02346877|Other|Personalized Patient Counselling Cohort|Initiation of the personalized patient counselling cohort will begin after 75% of participants in the control cohort have been analyzed and shown not to have high persistence. Participants will receive Enbrel® (etanercept) therapy in routine clinical practice and personalized patient counselling based on the Information-Motivation-Strategy (IMS) model based on Beliefs about Medicines Questionnaire (BMQ) baseline results through a patient assistance program for patients on Enbrel (etanercept) therapy.
3032220|NCT02346864|Experimental|Three-stair-position group|The infants in the study group (n=72) received three-stair-position (TSP) intervention (head up 15°) for a week.
3032221|NCT02346864|Other|head elevated tilt position group|The control group(n=72)received head elevated tilt position (HETP) intervention (head up 15°) for a week．
3032222|NCT02346851|Experimental|triggered FES|
3032223|NCT02346851|Active Comparator|conventional FES|
3032224|NCT02346851|No Intervention|control group|
3032225|NCT02346838|Experimental|Inulin|Participants will receive 10 g of inulin powder each day for 6 weeks.
3032226|NCT02346838|Placebo Comparator|Placebo|Participants will receive 10 g of maltodextrin each day for 6 weeks.
3032227|NCT02346825|Experimental|Intensive Plus Cast|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
3032228|NCT02346825|Experimental|Intensive Plus Splint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
3032229|NCT02346825|Experimental|Intensive no Constraint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks but will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
3032230|NCT02346812|Experimental|Brassica|Brassica vegetables will be consumed daily as part of a controlled diet.
3032231|NCT02346812|Other|Control|Typical American diet will be consumed, without any Brassica vegetables.
3032232|NCT02346799|Experimental|Control|Participants in the control group will not receive any additional treatment, apart from receiving daily emails 15 minutes before the start of their self-reported workout window. This is to control for reminder effects that may be present in the other treatment conditions. Participants in this condition will also receive a lump payment upon completion of an exit survey at the end of the intervention to equalize overall compensation.
3032233|NCT02346799|Experimental|Flexible Incentive|Participants in the flexible incentive condition will be paid $3 or $7 for each workout they complete during the treatment period (with a limit of one incentivized workout per day, and twelve incentivized workouts during the four-week treatment period). These participants will receive daily emails 15 minutes before the start of their self-reported workout window, but they can work out anytime of the day and still receive their incentive payment.
3032234|NCT02346799|Experimental|Routine Incentive|Participants assigned to the routine incentive condition will receive the same treatment as those in the flexible incentive condition except that, in order to receive their incentive payment, they must begin their workout within their two-hour workout window. For instance, if an employee chooses a 2pm to 4pm workout window, she will receive a reminder to exercise at 1:45 pm and must swipe into the gym between 2pm and 4pm in order to receive the $3 or $7 incentive payment.
3032235|NCT02346799|Experimental|Social Routine Incentive|Participants assigned to this condition will have an identical experience to those in the routine incentive except that both partners who sign up for the study will be required to coordinate and select a common workout window. Thus, both partners will receive their daily reminders at the same time (and will be incentivized for working out at the same time). The incentive payment, however, will not be linked to whether or not a participant's partner completes a workout - only to the participant's own exercise decision.
3032236|NCT02346799|No Intervention|Holdout Control|If experimental enrollment exceeds target, exercise data will be collected for these additional participants, but they will receive no intervention of any kind.
3032237|NCT02346786|Experimental|Mineral Water|mineral water
3032238|NCT02346786|Active Comparator|Tap Water|usual water intake
3032239|NCT02346773|Active Comparator|ω-3 LC-PUFA group|The intervention product was a full fat (80%) margarine. The active intervention product contained 590 mg docosahexaenoic acid (DHA) and 650 mg eicosapentaenoic acid (EPA) per 10-g daily serving.
3032240|NCT02346773|Placebo Comparator|Placebo group|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
3032241|NCT02346760|Experimental|UB-621|Intervention drug: UB-621
3032242|NCT02346747|Active Comparator|Group A|Group A will receive 1.0 x 10e7 cells of gene transfected, irradiated, autologous tumor cells via intradermal injection once a month.
3032243|NCT02346747|Placebo Comparator|Group B|"Group B will receive freeze media (10% DMSO, 1% human serum albumin in Plasma-Lyte) via intradermal injection once a month."
3032244|NCT02346734|Active Comparator|MSHAT|The study participants will receive a clinical physical therapy evaluation and a physical therapy program to do at their own pace in the home and the intervention group will receive access to the MSHAT system via a website in which they will utilize each day. The study participants in the intervention group will login to the MSHAT system, go through a pre-exercise symptom diary to determine their eligibility to exercise, perform exercise while watching a video demonstration and report results real-time. The intervention group will also be able to send and receive messages via the MSHAT system. The time to complete the daily exercises will vary from patient to patient ranging for 10-30 minutes.
3032305|NCT02346266|Active Comparator|SMART|The intervention group of school-aged children will receive education on the F.A.S.T. (Face, Arm, Speech and Time) acronym, additional signs and symptoms of stroke and the need for immediate activation of Emergency Medical Services (EMS) by calling 911.
3032306|NCT02346266|No Intervention|Usual Care|This group will not receive stroke education.
3032245|NCT02346734|No Intervention|Control|The study participants randomized to group 2 will serve as the control. The study participants will receive a clinical physical therapy evaluation and a physical therapy program to do at their own pace in the home and will be given a paper diary to report their exercise completion. The control group will bring their paper diary showing their exercise completion results to their 3 month and 6 month follow-up visits.
3032246|NCT02346721|Experimental|SOF/VEL|SOF/VEL for 12 weeks
3032247|NCT02346708|Experimental|Real TMS|TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magstim Stimulator. Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodmann area 46) using a frameless stereotactic navigation system and the subject's magnetic resonance imaging (MRI) in Brainsight software. Stimuli will be delivered at 20 Hz at 90% resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. This dose and duration of repetitive TMS (rTMS) is based on physiological studies of healthy adults and treatment studies of cognition in PD and Alzheimer's disease.52, 123 Side of first stimulation (left vs right hemisphere) will be counterbalanced across subjects.
3032248|NCT02346708|Sham Comparator|Sham TMS|Sham stimulation will be delivered using a sham coil fitted with electrodes to mimic both the auditory and somatic sensation of real TMS.
3032249|NCT02346695||Hypertensives|Untreated consecutive patients with newly diagnosed essential hypertension
3032250|NCT02346695||Controls|Normotensive individuals
3032251|NCT02346682|Active Comparator|LDQS group|"Liver Depression and Qi Stagnation (LDQS)group,Liver Depression and Qi Stagnation Syndrome should include at least the following 5 symptoms and signs: emotional depression or sadness, pessimism, short breath, sigh, dysphoria，thin coating，stringy pulse Drugs use generic name :Venlafaxine; Dosage form:capsule Dosage, frequency and duration:Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks.~The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline and after 6-week venlafaxine administration."
3032252|NCT02346682|Active Comparator|DBHS group|"Deficiency of Both Heart and Spleen (DBHS) group,Deficiency of Both Heart and Spleen Syndrome should include at least following 6 symptoms and signs: emotional depression, thinking torpidity, tiredness, forgetfulness, insomnia, loose stool, sweating, pale tongue body, thin tongue coating, and thin and deep pulse Drugs use generic name :Venlafaxine; Dosage form:capsule Dosage, frequency and duration:Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks.~The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline and after 6-week ."
3032253|NCT02346682|No Intervention|the normal controls group|The normal controls group including the healthy volunteer None drug The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline .
3032254|NCT02346669|Active Comparator|FMT from a lean donor+ high fat diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:~at time 0~after 6 weeks Patient will start high fat low fiber diet 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
3032255|NCT02346669|Sham Comparator|FMT from a lean donor+ sham diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:~at time 0~after 6 weeks Patient will start sham diet (no change in fat/fiber consumption) 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
3032256|NCT02346669|Active Comparator|FMT from lean donor+ low fat diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:~at time 0~after 6 weeks Patient will start low fat high fiber diet 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
3032257|NCT02346656||Treated subjects|All subjects recruited and treated with the Axium neurostimulator
3032258|NCT02346643||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
3032259|NCT02346630|Active Comparator|Levodopa / Carbidopa + Armeo|Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
3032260|NCT02346630|Placebo Comparator|Placebo + Armeo|Placebo capsules daily for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
3032261|NCT02346617|Experimental|allogeneic HSCT|The present study will investigate in a single-center (Samsung Medical Center), open-label, single arm by direct infusions of donor-derived CMV-spefic IFN-γ positive T-cells for the treatment of refractory CMV infection in allogeneic hematopoietic stem cell transplant (HSCT) recipients.
3032262|NCT02346604||Mild COPD|Symptomatic smokers with mild COPD
3032263|NCT02346604||Healthy Control|Non-smokers, matched to mild COPD group for age (at least 50 years) and gender
3032264|NCT02346591|Experimental|Jauntly|Mobile app designed to take advantage of the known connections between positive emotions, stress reduction and stress resilience; goal was to lead users through research-proven positive emotion enhancing exercises and relevant educational materials. Intervention activities covered five well-being generating content areas: 1) promoting the experience and recognition of gratitude; 2) encouraging positive social relationships and feelings of social support; 3) improving stress resilience via mindfulness and other relaxation-focused activities; 4) focusing and capitalizing on individual strengths (as opposed to limitations and weaknesses); and 5) general positive mood inducing activities.
3032265|NCT02346591|Active Comparator|Online stress management information|The control participants were emailed links to vetted online information about stress and encouraged to visit the websites.
3032266|NCT02346578|Experimental|Enzalutamide|Enzalutamide 160 mg administered orally once a day as four 40-mg soft capsules
3032267|NCT02346578|Active Comparator|Flutamide|Flutamide 125 mg administered orally three times a day as one tablet after meal
3032268|NCT02346565|Other|Exercise ECG|Patients will undergo an exercise test using the standard Bruce protocol. Standard end points of exercise testing will include: fatigue, severe ischaemia (severe chest pain, >2mm ST depression on ECG), hypertension (systolic BP>220mmHg), hypotension, pre-syncope or arrhythmia.
3032269|NCT02346565|Other|Stress Echocardiography|"A two-dimensional echocardiogram will be performed in the lateral decubitus position. Digitized images of the left ventricle (LV) will be obtained in the parasternal long-axis, short-axis, and apical four-, two-, and three-chamber views.~In the case of exercise stress echo, images will be acquired at rest and immediately (within 90 seconds) after peak exercise.~In the case of dobutamine stress echo, images will be acquired at rest, at the end of stage one of dobutamine administration (10mcg/Kg/min) and at peak stress."
3032270|NCT02346552|Experimental|Group 1|Procedures will be performed with the AutoLpap system used for holding and controlling the movement of the laparoscope.
3032271|NCT02346552|No Intervention|Group 2|Procedures will be performed with the assistance of human camera holder.
3032272|NCT02346539|Experimental|Nicotine|"2mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time.~4mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time."
3032273|NCT02346539|Placebo Comparator|Placebo|Placebo comparator
3032274|NCT02346526|Experimental|Radium-223 dichloride|"After the screening procedures confirm that a patient is eligible to participate in the research study.~Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments. These treatments are designed to be entirely standard. Extra testing during and after that six month period will be added to standard testing and monitoring.~Blood Tests~CT scan and bone scan~FACBC PET/MRI in a subset of participants"
3032275|NCT02346513||A: Ceramic on Metal THA|"Subgroup A1: Consist of ceramic on metal THAs with short term follow-up (less than 2years)~Subgroup A2: Consist of ceramic on metal THAs with midterm follow-up (more than 2years)~Subgroup A3: Consist of bilateral ceramic on metal THAs"
3032276|NCT02346513||B: Non-Ceramic on Metal THA|Patients have THA with non COM bearing
3032277|NCT02346513||C: Healthy subjects|Patients without any implant or systemic disease, to served as controls
3032278|NCT02346500|Experimental|Transrectal ultrasound|TRUS and TRUS-Robot will be used during PVP
3032279|NCT02346487|Experimental|LPV/RTV pellets and AZT/3TC or ABC/3TC|Only 1 arm. No comparator
3032280|NCT02346461|Active Comparator|Cohot A|6 subjects on Cohort A will receive ManNAc 3,000 mg twice daily (6,000 mg/day) for 7 days and, if safe, continue on 6,000 mg twice daily (12,000 mg/day) for the remainder of the study.
3032281|NCT02346461|Active Comparator|Cohort B|6 subjects on Cohort B will receive ManNAc 6,000 mg twice daily (12,000 mg/day) for 90 days.
3032282|NCT02346448|Active Comparator|endoscopic sphincterotomy|performing endoscopic sphincterotomy of papilla of Vater during ERCP Device: standard sphincterotome
3032283|NCT02346448|Active Comparator|balloon dilatation for 3 minutes|Balloon dilatation of papilla of Vater for 3 minutes during ERCP using 10mm balloon Device: standard dilation balloon catheter (10mm size)
3032284|NCT02346448|Active Comparator|balloon dilatation for 6 minutes|Balloon dilatation of papilla of Vater for 6 minutes during ERCP using 10mm balloon Device: standard dilation balloon catheter (10 mm size)
3032285|NCT02346435||Active Surveillance|
3032286|NCT02346435||Immediate Intervention|May include patients undergoing open or minimally-invasive partial nephrectomy, radical nephrectomy or energy ablation.
3032287|NCT02346435||Crossover (Delayed Intervention)|Initially patients in active surveillance that meet progression criteria or elect to undergo delayed intervention.
3032288|NCT02346422|Experimental|MYDICAR|Single intracoronary infusion of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 2.5 x 10^13 DRP. Administered in MYDICAR Phase 1 and MYDICAR Phase 2.
3032289|NCT02346422|Placebo Comparator|Placebo|Single intracoronary infusion of placebo (Sodium Chloride Injection, USP) (Placebo Phase 2 only).
3032290|NCT02346409|Experimental|LFP-MEG recording with tACS of the cerebellum|To explore how cerebellar stimulation (using tACS) will alter oscillations and coupling along the CTC pathway, relating these changes in brain activity to clinical improvement.
3032291|NCT02346409|Active Comparator|tACS of the cerebellum vs VIM-DBS|To evaluate the differential effects of non invasive high-frequency stimulation tACS of the cerebellum, as compared to high-frequency stimulation of the thalamus (using DBS of the VIM).
3032292|NCT02346396|Experimental|Patients with neuropathic chronic pain|
3032293|NCT02346383|Active Comparator|program 1|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
3032294|NCT02346383|Active Comparator|program 2|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
3032295|NCT02346383|Active Comparator|program 3|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
3032296|NCT02346370|Experimental|PEGPH20 + Docetaxel|PEGPH20 (RP2D) intravenously once every 3 weeks + Docetaxel 75 mg/m2 intravenously once every 3 weeks
3032297|NCT02346357|Active Comparator|Obturator nerve block|Ultrasound-guided single-injection obturator nerve block with 20 mL ropivacaine 0.5%
3032298|NCT02346357|Placebo Comparator|Sham block|Placebo arm. Ultrasound-guided injection of 3-5 mL normal saline in the subcutaneous tissue in the same location as would for an obturator nerve block.
3032299|NCT02346331|Experimental|WHO intervention|This arm will be treated with the 2011 WHO sepsis recommendations for the first 6 hours of their hospitalization. The WHO recommendations involve fluid boluses guided by vital signs and physical exam, frequent patient monitoring, rapid and early administration of empiric antibiotics, oxygen delivery, correction of hypoglycemia, and correction of severe anemia.
3032300|NCT02346331|No Intervention|Standard care|This arm will be managed per standard care by the hospital clinicians.
3032301|NCT02346318|Experimental|KS injection arm|Radiation and chemotherapy and compound Kushen Injection
3032302|NCT02346318|No Intervention|Control arm|Radiation and chemotherapy
3032303|NCT02346292||1|Patients of both genders aged 40 years and older, smokers, with smoking history more than 10 pack-years, with severe and very severe COPD who were hospitalized with COPD exacerbation
3032304|NCT02346279||Persons in physical therapy treatment|Questionnaires (MSQPT, HAQUAMS, Transition Questionnaire for Patient and treating physiotherapist), physical tests (9HPT, 6MTWT, BBS, 6MWT), EDSS
3058610|NCT02170987|Active Comparator|Moxifloxacin|
3032307|NCT02346253|Experimental|Treatment (HDR brachytherapy, ADT and LHRH agonist therapy)|Patients undergo high-dose-rate brachytherapy over 2 fractions. Patients also receive ADT comprising bicalutamide PO QD. Patients may also receive LHRH agonist therapy comprising leuprolide acetate IM or SC, goserelin acetate SC, triptorelin pamoate IM, or degarelix SC for 4-6 months (intermediate-risk patients receiving ADT) or 6-36 months (high-risk patients) at the discretion of the treating physician.
3032308|NCT02346240|Experimental|CZP 200 mg|"Certolizumab Pegol (CZP) subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 will be re-randomized to receive either CZP 200 mg Q2W or CZP 400 mg every 4 weeks (Q4W; with Placebo administered on alternate dosing weeks to maintain the blind) or Placebo Q2W.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
3032309|NCT02346240|Experimental|CZP 400 mg|"Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W) through Week 14.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 will be re-randomized to CZP 200 mg Q2W or CZP 400 mg Q2W or Placebo Q2W.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
3032310|NCT02346240|Active Comparator|Etanercept|"Etanercept (ETN) subcutaneous (sc) injection 50 mg twice weekly through Week 12.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 will be re-randomized to either Certolizumab Pegol (loading dose of 400 mg at Weeks 16, 18, and 20 followed by 200 mg Q2W) or Placebo Q2W.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
3032311|NCT02346240|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 continue to receive blinded Placebo.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
3032312|NCT02346227|Active Comparator|AV2|Drug: application of topical spray on the cervix one time (2 puffs) topical application of 100µl AV2 antiviral spray( natural essential oil components in equal volumes diluted 50% in olive oil)
3032313|NCT02346227|Placebo Comparator|Placebo|Drug: application of topical spray on the cervix one time (2 puffs) topical spray of 100 µl on the cervix.
3032314|NCT02346214||Preterm and term neonates|A. Preterm and term neonates B. Singleton live births between 26 and 42 weeks gestation (determined by first of early-second trimester ultrasound dating) at three referral hospitals
3032315|NCT02346201|Active Comparator|Methylphenidate|Methylphenidate, target dose 20 mg per day (range 10-20 mg per day), in 5 mg over-capsulated tablets, and psychosocial intervention
3032316|NCT02346201|Placebo Comparator|Placebo|Matching over-encapsulated placebo and psychosocial intervention
3032317|NCT02346188|Experimental|Ferrous fumarate|Tablet formulated as ferrous fumarate, 30 mg. Given once daily for 6 months.
3032318|NCT02346188|Experimental|Zinc oxide|Tablet formulated as zinc oxide, 30 mg. Given once daily by mouth for 6 months.
3032319|NCT02346188|Experimental|Ferrous fumarate and zinc oxide|Tablet, formulated as ferrous fumarate 30 mg plus zinc oxide 30 mg. Given once daily by mouth for 6 months.
3032320|NCT02346188|Placebo Comparator|Placebo|Sugar tablet formulated to look like the experimental arms of the study. Given daily by mouth for 6 months.
3032321|NCT02346175|Experimental|Cohort1|5-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
3032322|NCT02346175|Experimental|Cohort2|10-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
3032323|NCT02346175|Experimental|Cohort3|20-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
3032324|NCT02346162|Experimental|Intervention|Weight management intervention
3032325|NCT02346162|Other|Usual Care Control|Usual Care for planning healthy pregnancy
3032326|NCT02346149|Other|Patient with imparied glucose tolerance|Bold-MRI before and after glucose injection
3032327|NCT02346149|Other|Healthy subjects|Bold-MRI before and after glucose injection
3032328|NCT02346136|Experimental|Tai Chi|This arm will receive a 6-month Tai Chi training intervention. Tai Chi training will include gentle dynamic stretching and strengthening, slow integrated movements, efficient posture, heightened body awareness and inner focus, active relaxation of body and mind, mindful diaphragmatic breathing, and healing imagery and intention. Participants will be asked to complete two formal group classes each week for at least 6 months, led by senior Tai Chi instructors. Additionally, participants will be given practice DVDs (and DVD players if necessary) and instructions for daily home practice a minimum of 20 minutes on 3 non-class days each week.
3032329|NCT02346136|Active Comparator|Educational Control|This arm will receive a 6-month educational control intervention. Participants will attend monthly educational group sessions within a common area of each housing facility. Sessions will be led by research personnel and include material from Patient Education Forms (PEFs) produced by the American Geriatric Society. Sessions will be semi-structured and contain approximately 30 minutes of lecture and 30 minutes of group discussion.
3032330|NCT02346123||Single group|Group which contains all the patients of the study.
3032331|NCT02346110|Active Comparator|Bupivacaine-adrenalin + sodium chloride|"Single shot saphenous block:~10 mL of 5 mg/mL bupivacaine with 5 μg/mL adrenalin = 50 mg bupivacain and 50 μg adrenalin~1 mL sodium chloride solution"
3032332|NCT02346110|Experimental|Bupivacaine-adrenaline + Dexamethasone|"Single shot saphenous block:~10 mL of 5 mg/mL bupivacaine with 5 μg/mL adrenalin = 50 mg bupivacain and 50 μg adrenalin~1 mL of 4 mg/mL dexamethasone = 4 mg dexamethasone"
3032333|NCT02346097|Experimental|Optimal electrical resynchronization|"Cardiac Resynchronization Therapy: LV lead implant according to electrical activation mapping of available epicardial veins to identify the latest electrical activated myocardial region. Post-implant interventricular (VV) electrical optimization for narrowing the paced QRS width. Post-implant standard pacemaker settings: Atrioventricular (AV) interval 100-130 ms and VV interval settings with simultaneous biventricular pacing.~Day 1 after implantation: ECG, AV-optimization guided by echocardiography, high-pitch cardiac CT to verify LV lead position.~Programming of the VV interval to obtain the narrowest QRS-width"
3032334|NCT02346097|Active Comparator|Routine CRT-strategy, imaging guided|"Cardiac Resynchronization Therapy: LV lead implant guided by echocardiography and Rb-PET towards the latest mechanically activated myocardial segment and separate from scar. Post-implant VV electrical optimization for narrowing the paced QRS width. Standard pacemaker settings for both groups: AV-interval 100-130 ms and VV-interval settings with simultaneous biventricular pacing.~Day 1 after implantation: ECG, AV-optimization guided by echocardiography, high-pitch cardiac CT to verify LV lead position.~Continue standard interventricular pacing interval settings with simultaneous pacing in both ventricular leads."
3032335|NCT02346084|Experimental|Female Participants - Arms 1A through 9A|"Female Participants 9 Arms (1A through 9A) 3 Product Sequences~Product Sequence 1 Rx1- MVC tablet PO Rx2- MVC 1% gel PR Rx3- MVC 1% gel PV~Product Sequence 2 Rx1- MVC 1% gel PR Rx2- MVC 1% gel PV Rx3- MVC tablet PO~Product Sequence 3 Rx1- MVC 1% gel PV Rx2- MVC tablet PO Rx3- MVC 1% gel PR~3 Biopsy Schedules D8- (~2-hr after the 8th dose) D9- (~24-hr after the 8th dose) D10- (~48-hr after the 8th dose)"
3032336|NCT02346084|Experimental|Male Participants - Arms 1B through 4B|"Male Participants 4 Arms (1B through 4B) 2 Product Sequences 2 biopsy schedules~Product Sequence 1 Rx1- MVC tablet PO Rx2- MVC 1% gel PR~Product Sequence 2 Rx1- MVC 1% gel PR Rx2- MVC tablet PO~Biopsy Schedule D8- (~2-hr after the 8th dose) D10- (~48-hr after the 8th dose)"
3032337|NCT02346071|Active Comparator|Enhanced Usual Care (EUC)|Clinical psychiatric and somatic assessment. Standard psychiatric consultation (SPC) given 2 weeks after randomization.
3032338|NCT02346071|Experimental|Acceptance and Commitment Therapy (ACT)|Clinical psychiatric and somatic assessment. Standard psychiatric consultation (SPC) given 2 weeks after randomization. ACT-based group therapy.
3032339|NCT02346058|Experimental|Esarin Gel|"Dosage form:One tube of Esarin Gel contains 20 gm of compound. Each gm contains:10 mg Heparinoid, 10 mg Escin, 50 mg Diethylamine Salicylate.~Dosage and frequency: Approx. 3-5 cm Gel was applied topically on skin.twice daily.~Duration: 28 days."
3032340|NCT02346045|Experimental|Renal sympathetic denervation|Renal sympathetic denervation procedure plus antihypertensive medication (doses and types of medication are maintained as previously prescribed)
3032341|NCT02346045|Sham Comparator|Medical therapy|renal angiogram plus antihypertensive medications (doses and types of medication are maintained as previously prescribed)
3032342|NCT02346032|Experimental|refametinib|refametinib medication
3032343|NCT02346019|Experimental|Surgical: Medial thighplasty|Perform a standard medial thighplasty with our without additional thigh liposuction on up to three obese transfemoral amputee subjects. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
3032344|NCT02346006|Experimental|Physical activity|Subject from schools with more physical activity.
3032345|NCT02345993|Active Comparator|Extra fine Formoterol/Beclomethasone|"Group receiving the drug additional to standard treatment standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline, 0, 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40 minutes"
3032346|NCT02345993|Placebo Comparator|Placebo|"Group receiving placebo additional to standard treatment consisting in:~Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ Placebo, 3 puffs administered via aerochamber at baseline (0), 20, 40 minutes"
3032347|NCT02345980|Active Comparator|Sildenafil|Patient in this arm will receive sildenafil citrate 50 mg tablet once daily after ureteral stent fixation.
3032348|NCT02345980|Placebo Comparator|Placebo|Patient in this arm will receive placebo daily after ureteral stent fixation.
3032349|NCT02345967|Experimental|Study Group|Device: Model 100 Sensor
3032350|NCT02345954|Experimental|Supracervical Hysterectomy and Sacropexy|Laparoscopic Supracervical Hysterectomy and Sacropexy
3032351|NCT02345954|Experimental|Hysteropexy|Laparoscopic Hysteropexy
3032352|NCT02345941|Experimental|Invervention|The intervention group will get tailored information on the Parent Action Report and the Parent Portal about child safety seats and booster seats.
3032353|NCT02345941|Active Comparator|Control|The control group will get tailored information in the Parent Action Report and the Parent Portal about smoke alarms.
3032354|NCT02345928|Experimental|Part 1: Dose 1|Drug CNTO7160 or Placebo administered IV infusion Dose 1.
3032355|NCT02345928|Experimental|Part 1: Dose 2|Drug CNTO7160 or Placebo administered IV infusion Dose 2.
3032356|NCT02345928|Experimental|Part 1: Dose 3|Drug CNTO7160 or Placebo administered IV infusion Dose 3.
3032357|NCT02345928|Experimental|Part 1: Dose 4|Drug CNTO7160 or Placebo administered IV infusion Dose 4.
3032358|NCT02345928|Experimental|Part 1: Dose 5|Drug CNTO7160 or Placebo administered IV infusion Dose 5.
3032359|NCT02345928|Experimental|Part 1: Dose 6|Drug CNTO7160 or Placebo administered IV infusion Dose 6.
3032360|NCT02345928|Experimental|Part 1: Dose 7|Drug CNTO7160 or Placebo administered IV infusion Dose 7.
3032361|NCT02345928|Experimental|Part 1: Dose 8|Drug CNTO7160 or Placebo administered IV infusion Dose 8.
3032362|NCT02345928|Experimental|Part 1: Dose 9|Drug CNTO7160 or Placebo administered IV infusion Dose 9.
3032363|NCT02345928|Experimental|Part 2 (Asthma): Dose 1|Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks).
3032364|NCT02345928|Experimental|Part 2 (Asthma): Dose 2|Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks).
3032365|NCT02345928|Experimental|Part 2 (Atopic Dermatitis): Dose 1|Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks).
3058611|NCT02170974|Experimental|BIBR 1048 MS polymorph II|
3032366|NCT02345928|Experimental|Part 2 (Atopic Dermatitis): Dose 2|Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks).
3032367|NCT02345915|Other|Young adult acute leukemia-survivor|
3032368|NCT02345902|Experimental|Haloperidol and non-pharmacologic|"Haloperidol 1.25mg PO q. d. during nine days~Non-pharmacologic measures:~A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)"
3032369|NCT02345902|Active Comparator|Placebo and non-pharmacologic|"Placebo 1.25 mg PO q.d during nine days.~Non-pharmacologic measures:~A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)"
3032370|NCT02345889|Active Comparator|FUSE® Colonoscopy|A FUSE® system with 3 HD (high-definition) monitors will be used to perform the colonoscopy
3032371|NCT02345889|Active Comparator|Colonoscopy with EndoCuff™|An EndoCuff™ distal attachment will be placed at the distal end of a standard colonoscope
3032372|NCT02345889|Active Comparator|Colonoscopy with EndoRings™|An EndoRings™ distal attachment will be placed at the distal end of a standard colonoscope
3032373|NCT02345889|Active Comparator|Standard Colonoscopy|A standard colonoscope will be used to complete the procedure
3032374|NCT02345876||Dyslexic children|Longitudinal follow-up without intervention
3032375|NCT02345876||Normal reading children|Longitudinal follow-up without intervention
3032376|NCT02345863|Experimental|Bendamustine + GA101 + Ibrutinib|"Bendamustine 70mg/m² i´v~GA101: 1000 mg iv~Ibrutinib: 420 mg po daily"
3032377|NCT02345850|Active Comparator|Tacrolimus/Methotrexate Control Arm|"Unmanipulated bone marrow graft with Tacrolimus/Methotrexate GVHD prophylaxis. Tacrolimus will be maintained at therapeutic doses for a minimum of 90 days. Methotrexate will be dosed at 5-15mg/m^2 for a maximum of 4 doses post-transplant.~Cyclosporine may be substituted for tacrolimus if the patient is intolerant of tacrolimus or per institutional practice."
3032378|NCT02345850|Experimental|CD34 Selection Arm|"Mobilized CD34-selected Peripheral Blood Stem Cell graft~Following screening and enrollment, the donor of patients randomized to the CD34-selection arm will receive mobilization therapy with once daily Granulocyte Colony Stimulating Factor (G-CSF). Mobilization will begin on Day -5 prior to the patient's transplant date.~Leukapheresis will be performed on a continuous flow cell separator according to institutional standards and will commence on the morning of the fifth day of G-CSF treatment. The anti-coagulant used for the procedure will be acid citrate dextrose (ACD).~Decisions concerning the need for further product collection will be based on the known or projected enriched CD34+ cell content of the previously collected products."
3032379|NCT02345850|Experimental|Post Transplant Cyclophosphamide|Unmanipulated Bone Marrow Graft with Cyclophosphamide
3032380|NCT02345837|Active Comparator|clomiphene and endometrial sampling|Couples who will undergo endometrial sampling in the luteal phase of the cycle preceding ovulation induction by clomiphene citrate.
3032381|NCT02345837|Active Comparator|clomiphene citrate|Couples who will undergo ovulation induction with clomiphene citrate.
3032382|NCT02345824|Experimental|Ribociclib (LEE011) Treatment|Patients will be treated with ribociclib (LEE011) (recommended phase 2 dose of 600 mg/day) for 8-21 days prior to surgery. For preliminary evaluation of efficacy and toxicity, patients with Rb-positive tumors will resume treatment with ribociclib at 14-28 days post-surgery on a schedule of 21 days on, 7 days off in a 28-day cycle. Patients will be treated until unacceptable toxicity is observed, or until disease progression as assessed by radiographic or clinical metrics.
3032383|NCT02345798|Active Comparator|Arm I (standard care)|Patients and caregivers receive standard care during routine clinic visits.
3032384|NCT02345798|Experimental|Arm II (video-assisted intervention)|Patients view Parts 1 and 2 of the video program, which focus on what to expect before surgery and after surgery in the hospital, on a tablet over approximately 8 minutes at a scheduled pre-operative visit. Patients then receive an educational handbook and discuss the video with a nurse. After surgery and before hospital discharge, patients view Part 3 of the video over approximately 6 minutes, which focuses on what to expect after going home.
3032385|NCT02345785||Group 1|pediatric patients who need urologic surgery and caudal block
3032386|NCT02345772|Experimental|Treatment Protocol|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery. Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
3032387|NCT02345759||Keto-diet group|Vegetarian very low protein regimen (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.
3032388|NCT02345759||Conventional LPD group|0.6 g/kg per day, including high biological value proteins
3032389|NCT02345746|Experimental|Hepatic Artery Infusion|Hepatic Arterial Infusion (HAI) with the drugs Oxaliplatin, Folinic Acid and 5 Fluorouracil
3032390|NCT02345733|Experimental|Ulcerative Colitis Diet|Patients will receive a structured novel diet termed the UCD for 6 weeks, and those in remission at week 6 will receive the step down diet for another 6 weeks.
3032391|NCT02345733|Experimental|Antibiotic Treatment|This antibiotic treatment will be given as an open label for patients who refuse diet therapy or for patients who show no improvement by week 3 , deteriorate by week 6, or patients who are not in full remission by week 6 will receive a 14 day course of antibiotics as previously described by Kato and colleagues.
3032392|NCT02345720|Experimental|etafilcon - PVP (multi-focal)|The investigational soft contact lenses will be worn in a daily wear modality for 30 days over the course of the study.
3032393|NCT02345707|Experimental|Part A|Subjects will receive reference cabotegravir 30 mg current formulation (Treatment A), Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) and Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) in one of six sequences ABC, ACB, BCA, BAC, CAB, CBA in three treatment periods under fasting condition
3032394|NCT02345707|Experimental|Part B|Subjects will receive reference Cabotegravir 30 mg current formulation (Treatment A), Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) and Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) in one of six sequences ADE, AED, DAE, DEA, EAD, EDA in three treatment periods under fasting condition
3032395|NCT02345694|Experimental|Effective CPAP|Continuous Positive Airway Pressure (RESMED S9™ Series), all the nights, during 8 weeks.
3032396|NCT02345694|Sham Comparator|Sub-therapeutic CPAP|Sub-therapeutic Continuous Positive Airway Pressure (RESMED S9™ Sham-Continuous Positive Airway Pressure System), validated placebo of Continuous Positive Airway Pressure, all the nights, during 8 weeks.
3032397|NCT02345681|Experimental|Test Furosemide|We will test our furosemide algorithm in one arm
3032398|NCT02345681|No Intervention|Classical Strategy|It's a classical strategy without diuretics
3032399|NCT02345668|Experimental|Transdiagnostic Internet-based Treatment|Intervention group that carries out the Emotion Regulation Protocol and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages)
3032400|NCT02345668|Experimental|Treatment as Usual|Intervention group that receives psychological and/or pharmacological treatment from a clinician of the mental health unit.
3032401|NCT02345655|Experimental|Urine Drug Testing|GPs of the intervention group will dedicate an average 5 minutes during the consult to perform OS-UDT. Patients will be asked to collect a urine sample at the GP's medical office. GP will read and communicate the results immediately to the patients. GPs will keep free of their management according to OS-UDT results.
3032402|NCT02345655|Other|No test|Patients will not have to performed the OS-UDT test
3032403|NCT02345642|Active Comparator|10 Healthy Patients without THA|The 10 test subjects of this study arm will be healthy volunteers of various ages that are willing to have the efficacy of pneumatic compression tested on them.
3032404|NCT02345642|Experimental|10 Patients with THA on Post-Op Day 2|The 10 test subjects of this study arm will be primary THR patients of Dr. Westrich that have undergone uncomplicated THR surgery in which they are allowed to be full weight bearing by or before post-op day 2.
3032405|NCT02345629|Experimental|Cordotomy Group|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours. Quantitative sensory testing on day prior to procedure, and on postoperative days number 1 and 7. Pain and symptom questionnaire completed at baseline, over the phone during the first week of study, and at each follow up visit/phone call. Participants undergo quantitative sensory testing on day prior to procedure, and on postoperative days number 1 and 7. Sensory testing to include sharpness and heat detection.
3032406|NCT02345629|Active Comparator|Comprehensive Medical Management Group|Participants receive best supportive care for 1 week. Depending on pain level after the first week, they may have a cordotomy at that time. Pain and symptom questionnaire completed at baseline, over the phone during the first week of study, and at each follow up visit/phone call.
3032407|NCT02345616|Experimental|Nitric oxyde|
3032408|NCT02345603|Experimental|Cryo-therapy|Cryo-therapy of renal arteries
3032409|NCT02345603|No Intervention|Control|No intervention in renal arteries
3032410|NCT02345590|Experimental|Eplerenone|25mg Eplerenone once daily for 12 months
3032411|NCT02345590|Placebo Comparator|Matching placebo|Matching placebo once daily for 12 months
3032412|NCT02345577|Active Comparator|Physiotherapeutical intervention|3 WBV-sessions per week for 3 consecutive months. Each session consists of 5 series with a duration of 60 sec with 60 sec rest-time with vibration of increasing frequency starting at 1Hz / Noise 4 going up to 6Hz / Noise 5 depending on patients' tolerability and with a fixed 3mm amplitude.
3032413|NCT02345577|Sham Comparator|Sham physiotherapeutical intervention|3 WBV-sessions per week for 3 consecutive months. Each session consists of 5 series with a duration of 60 sec with 60 sec rest-time at 1 Hz / Noise 1 and 3mm amplitude.
3032414|NCT02345564|Other|osteochondral lesions in knee/ankle|patients with traumatic and atraumatic osteochondral lesions in knee/ankle, implantation of MaioRegen fleece into osteochondral lesion
3032415|NCT02345551|Experimental|Exercise|The behaviour change intervention to promote an increase in moderate-vigorous physical activity (to meet the cancer prevention guidelines of 150 min/week) will be guided by the Health Action Process Approach (HAPA) model. This model aims to promote behaviour change through increasing self-efficacy for intention, planning and maintenance of physical activity. As a compliment to the behavioural counseling sessions, participants will be asked to track their physical activity using the FitBit, a wrist-worn activity monitor (www.fitbit.com) which monitors step counts, distance covered, and active minutes and also tracks sleep. The FitBit synchronizes wirelessly to the participants' computer and/or smartphones, thus minimizing the need for daily data entry tracking by participants.
3032416|NCT02345538||Women with Chronic Pelvic Pain|Use of perineometer to measure pelvic resting tone and contraction in women with chronic pelvic pain and determine if resting tone correlates with severity of pain.
3032417|NCT02345538||Women without Chronic Pelvic Pain|Use of perineometer to measure pelvic resting tone and contraction in women without chronic pelvic pain
3032418|NCT02345525|Active Comparator|mCIMT|2 hours intensive upper limb practice with shaping techniques supervised by an experienced physiotherapist + 2 hours ADLs at home (supervised by a caregiver) Patients are supposed to wear a mitt on the unaffected hand for 4 hours daily.
3032419|NCT02345525|Experimental|hCIMT|"2 hours intensive upper limb practice with shaping techniques + 2 hours ADLs supervised by a caregiver.~Patients are supposed to wear a mitt on the unaffected hand for 4 hours daily."
3032420|NCT02345512|Other|Lycra Splint|Wearing of Lycra splinting garment
3032421|NCT02345499|Experimental|Laparoscopic radical cystectomy|Surgery: Laparoscopic radical cystectomy with open urinary diversion
3032422|NCT02345499|Active Comparator|Open radical cystectomy|Surgery: Open radical cystectomy with open urinary diversion
3032423|NCT02345486|Active Comparator|0.9% sodium chloride|Participants in the '0.9% sodium chloride' arm will receive 0.9% sodium chloride ('normal saline') any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
3032424|NCT02345486|Active Comparator|Physiologically balanced fluid|Participants in the 'physiologically balanced fluid' arm will receive physiologically balanced fluid (Lactated ringers or Plasmalyte-A) any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
3032425|NCT02345473||Cystectomy patients|Arm of patients undergoing radical cystectomy for bladder cancer providing peripheral blood samples for detection of circulating cancer cells
3032426|NCT02345473||Healthy volunteers|Arm of healthy subjects not undergoing radical cystectomy providing peripheral blood samples for detection of circulating cancer cells
3032427|NCT02345460|Experimental|Treatment (FOLFIRINOX)|Patients receive FOLFIRINOX regimen comprising irinotecan hydrochloride IV over 90 minutes, oxaliplatin IV over 120 minutes, leucovorin calcium IV over 120 minutes, and fluorouracil IV over 1-2 minutes and then continuously over 46 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3032428|NCT02345447|Active Comparator|Herbal-based Medication|"Trade Name of active comparator: Otovowen® Substances: Aconitum napellus Dil. D6; Capsicum annuum Dil. D4; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum Dil. D6; Hydrastis canadensis Dil. D4; Iodum Dil. D4; Natrium tetraboracicum Dil. D4; Sambucus nigra; Sanguinaria canadensis.~Manufacturer: Weber & Weber, Inning/Ammersee Dose: Three times daily 7 drops Mode of Application: orally Duration of Treatment: at first signs of Upper respirtory tract infection until symptoms resolve (maximally 8 weeks of continuous application)."
3032429|NCT02345447|Placebo Comparator|Placebo|Placebo Substance: Aqueous ethanol solution non-distinguishable from verum. Manufacturer: Weber & Weber, Inning/Ammersee Dose: Three times daily 7 drops Mode of Application: orally Duration of Treatment: at first signs of URI until symptoms resolve (maximally 8 weeks of continuous application).
3032430|NCT02345434|No Intervention|No informative letter|This is the control arm and it involves no contact with the prescriber
3032431|NCT02345434|Experimental|Informative letter|This is the treatment arm; prescribers in this arm receive an informative letter (called a comparative billing report or peer activity report)
3032432|NCT02345421||At risk population|
3032433|NCT02345408|Experimental|CCX872-B|150 mg once or twice daily given orally for at least 12 weeks
3032434|NCT02345395|Experimental|Transpalpebral Approach|Aneurysm Clipping - Patients will be submitted to a Transpalpebral Approach to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital on the next day.
3032435|NCT02345395|Experimental|NanoPterional Approach|Aneurysm Clipping - Patients will be submitted to a Modified MiniPterional Approach (Nanopterional) to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital on the next day.
3032436|NCT02345395|Sham Comparator|Classical Pterional Craniotomy|Aneurysm Clipping - Patients will be submitted to a Classical Pterional Approach to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital 4-5 days after the procedure.
3032437|NCT02345382|Experimental|20 mg BAY1143572|Subjects received 20 milligram (mg) BAY1143572 tablet orally once daily from Cycle 1 Day 1 of each cycle.
3032438|NCT02345382|Experimental|40 mg BAY1143572|Subjects received 40 mg BAY1143572 tablet orally once daily from Cycle 1 Day 1 of each cycle.
3032439|NCT02345382|Experimental|80 mg BAY1143572|Subjects received BAY1143572 80 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
3032440|NCT02345382|Experimental|120 mg BAY1143572|Subjects received BAY1143572 120 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
3032441|NCT02345382|Experimental|160 mg BAY1143572|Subjects received BAY1143572 160 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
3032442|NCT02345382|Experimental|200 mg BAY1143572|Subjects received BAY1143572 200 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
3032443|NCT02345382|Experimental|240 mg BAY1143572|Subjects received BAY1143572 240 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
3032444|NCT02345369|Active Comparator|Locked Set Screw|In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw with locking of the set screw.
3032445|NCT02345369|Active Comparator|Unlocked Set Screw|In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw without locking of the set screw.
3032446|NCT02345356||Standard-of-Care|the standard clinical approach will be followed
3032447|NCT02345356||Genotype-guided|algorithmically guided personalized therapy of warfarin, using a pharmacogenetic model developed in Caribbean Hispanics
3032448|NCT02345343||Drug: Apixaban|Patients with VTE who are being given apixaban for the treatment and/or prevention of recurrence of DVT and PE at the sentinel site
3032449|NCT02345330|Experimental|Tavokinogene Telseplasmid (tavo) Electroporation (EP)|Participants received tavo intratumorally followed immediately by electroporation (EP) on Days 1, 8, and 15 in a 6-week cycle for up to 9 cycles.
3032450|NCT02345304|Experimental|Treatment 3|single dose of midazolam + BI drug
3032451|NCT02345304|Experimental|Treatment 4|single dose of probe drugs + BI drug
3032452|NCT02345304|Experimental|Treatment 5|single dose of digoxin + BI drug
3032453|NCT02345304|Experimental|Treatment 1|single doses of probe drugs
3032454|NCT02345304|Experimental|Treatment 2|single dose of digoxin
3032455|NCT02345291|Experimental|NRD135S.E1 A|A = 10 mg NRD135S.E1 once daily PO for 21 days
3032456|NCT02345291|Experimental|NRD135S.E1 B|B = 40 mg NRD135S.E1 once daily PO for 21 days
3032457|NCT02345291|Experimental|NRD135S.E1 C|C = 150 mg NRD135S.E1 once daily PO for 21 days
3032458|NCT02345291|Placebo Comparator|Placebo to match NRD135S.E1 D|D = Placebo once daily PO for 21 days
3032459|NCT02345278|Placebo Comparator|Placebo|once daily sublingual administration for 1 month
3032460|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 10,000 AU/mL|once daily sublingual administration for 1 month
3032461|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 25,000 AU/mL|once daily sublingual administration for 1 month
3032462|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 50,000 AU/mL|once daily sublingual administration for 1 month
3032463|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 100,000 AU/mL|once daily sublingual administration for 1 month
3032464|NCT02345265|Experimental|Treatment (olaparib and cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3032465|NCT02345252|Experimental|FTC/RPV/TAF|FTC/RPV/TAF FDC plus FTC/RPV/TDF placebo for at least 96 weeks. After the Week 96 visit is completed, participants will be given the option to receive open label FTC/RPV/TAF FDC for up to an additional 48 weeks. In countries where FTC/RPV/TAF FDC is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF FDC for oral once-daily use, and attend visits every 12 weeks until FTC/RPV/TAF FDC becomes commercially available, or until Gilead Sciences elects to discontinue the study, whichever occurs first.
3032466|NCT02345252|Active Comparator|FTC/RPV/TDF|FTC/RPV/TDF FDC plus FTC/RPV/TAF placebo for at least 96 weeks. After the Week 96 visit is completed, participants will be given the option to receive open label FTC/RPV/TAF FDC for up to an additional 48 weeks. In countries where FTC/RPV/TAF FDC is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF FDC for oral once-daily use, and attend visits every 12 weeks until FTC/RPV/TAF FDC becomes commercially available, or until Gilead Sciences elects to discontinue the study, whichever occurs first.
3032467|NCT02345239|Experimental|Pantoprazole|Pantoprazole
3032468|NCT02345226|Experimental|FTC/RPV/TAF|FTC/RPV/TAF plus EFV/FTC/TDF placebo for at least 96 weeks. After the Week 96 visit is completed, participants will be given the option to receive open label FTC/RPV/TAF FDC for up to an additional 48 weeks. In countries where FTC/RPV/TAF FDC is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF FDC for oral once-daily use, and attend visits every 12 weeks until FTC/RPV/TAF FDC becomes commercially available, or until Gilead Sciences elects to discontinue the study, whichever occurs first.
3032469|NCT02345226|Active Comparator|EFV/FTC/TDF|EFV/FTC/TDF plus FTC/RPV/TAF placebo for at least 96 weeks. After the Week 96 visit is completed, participants will be given the option to receive open label FTC/RPV/TAF FDC for up to an additional 48 weeks. In countries where FTC/RPV/TAF FDC is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF FDC for oral once-daily use, and attend visits every 12 weeks until FTC/RPV/TAF FDC becomes commercially available, or until Gilead Sciences elects to discontinue the study, whichever occurs first.
3032470|NCT02345213|Experimental|E2020|"Treatment period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, Weeks 7-12 E2020 10 mg.~Extension period: Weeks 1-6 E2020 10 mg, After Week 7 up to week 60 E2020 10 mg."
3032471|NCT02345213|Placebo Comparator|Placebo|"Treatment period: Weeks 1-12 placebo~Extension period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, After Week 7 up to week 60 E2020 10 mg."
3032472|NCT02345200|Active Comparator|Ataxia telangiectasia|26 patients with clinically and/or genetically diagnosed Ataxia telangiectasia will be examined with bioelectrical impedance analysis (BIA), muscle force measurement, calipometry and get a blood draw
3032473|NCT02345200|Active Comparator|Healthy subjects|26 age and sex matched subjects without any chronic disease or hormone displacement will be examined with bioelectrical impedance analysis (BIA), muscle force measurement, calipometry and get a blood draw
3032474|NCT02345187|Active Comparator|Treatment Arm|Entire content of a sachet of the beverage powder fortified with multiple micronutrients and bacopa monnieri extract will be emptied in a graduated drinking tumbler and reconstituted with 180 mL potable lukewarm water. Water will be added to the tumbler gradually with stirring to avoid lump formation. The reconstituted beverage will be administered to the participants orally twice daily for 17 weeks
3032475|NCT02345187|Placebo Comparator|Control arm|Entire content of a sachet of the non-fortified isocaloric beverage powder will be emptied in a graduated drinking tumbler and reconstituted with 180 mL potable lukewarm water. Water will be added to the tumbler gradually with stirring to avoid lump formation. The reconstituted beverage will be administered to the participants orally twice daily for 17 weeks
3032476|NCT02345174|Experimental|Imaging Phase + Continuation Phase|In Part 1 of the study, participants will receive a dose of 89Zr-GSK2849330 (Dose 1), with an activity of no more than 37 MegaBequerel (MBq) and a variable total dose of GSK2849330. PET scans will be acquired within 7 days. Two weeks after Dose 1 participants will receive second dose of 89Zr-GSK2849330 (Dose 2) and a variable total dose of GSK2849330. Participants will continue to receive unlabelled GSK2849330 (in Part 2) either at established dose level or as decided by medical monitor.
3032477|NCT02345161|Experimental|FF/UMEC/VI (100 mcg/62.5 mcg/25 mcg)|Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive FF/UMEC/VI (100mcg/62.5mcg/25mcg) via the ELLIPTA DPI and placebo via reservoir inhaler.
3032478|NCT02345161|Experimental|Budesonide/formoterol (400 mcg/12 mcg)|Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive Budesonide/formoterol (400mcg/12mcg) via reservoir inhaler and placebo via the ELLIPTA DPI.
3032479|NCT02345148|Experimental|Cohort 1|Elder participants will receive esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) by intranasal route using nasal spray pump at 0, 5 and 10 minutes on Day 1.
3032480|NCT02345148|Experimental|Cohort 2|Younger adults will receive esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) by intranasal route using nasal spray pump at 0, 5 and 10 minutes on Day 1.
3032481|NCT02345135|Active Comparator|Ataxia Telangiectasia|All A-T patients presented for 3 study visits. In all visits patients had a clinical examination, a blood collection and a lung function measurement. Furthermore symptom diaries were distributed and collected on these visits.
3032482|NCT02345135|Active Comparator|Healthy Control|All healthy controls presented for 3 study visits. In all visits patients had a clinical examination and a lung function measurement. Furthermore symptom diaries were distributed and collected on these visits.
3058612|NCT02170974|Active Comparator|BIBR 1048 MS polymorph I|
3032483|NCT02345122|Other|Enhanced Usual Care|This group will receive Enhanced Usual Care. The subject's Primary Care Provider will receive results of baseline, four, eight, and twelve month assessments examining the subject's symptoms of depression, anxiety, and other mental health problems, use of alcohol and illicit substances, physical pain, and quality of life . If the subjects primary care provider chooses, they can use this information to construct the subject's treatment plan.
3032484|NCT02345122|Experimental|Intervention: Mental Health Technician|The subject's Primary Care Provider will receive results of baseline, four, eight, and twelve month assessments examining the subject's symptoms of depression, anxiety, and other mental health problems, use of alcohol and illicit substances, physical pain, and quality of life and recommendations for treatment. Over a 3-12 months period, the Intervention group will receive a brief, telephone-based intervention by a Mental Health Technician that will focus on monitoring symptoms, treatment adherence, and providing psychoeducation.
3032485|NCT02345109|Experimental|Transtek DUT|Which measured by DUT: GBF-835-N2, GBF-835-N2 Plus, LS202-B1, Ls202-B1 Plus, LS206-E1, LS206-E1 Plus, GBF-1251-B1, and GBF-1251-B1 Plus.
3032486|NCT02345109|Experimental|Reference|Measured by Reference: TRANSTEK® Glass Body Fat Analyzer GBF-1251-B, Tanita® Body Composition Monitor BC-533.
3032487|NCT02345096|Active Comparator|Saccharomyces cerevisiae CNCM I-3856|In this arm, subjects will be asked to consume one capsule of Saccharomyces cerevisiae CNCM I-3856 per day.
3032488|NCT02345096|Placebo Comparator|placebo|In this arm, subjects will be asked to consume one capsule of placebo per day.
3032489|NCT02345070|Experimental|SAR156597 dose 1|subcutaneous injection once every week
3032490|NCT02345070|Experimental|SAR156597 dose 2|subcutaneous injection once every two weeks
3032491|NCT02345070|Placebo Comparator|placebo|subcutaneous injection once every week
3032492|NCT02345057|Experimental|CS-3150 0.625 mg|One CS-3150 0.625 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
3032493|NCT02345057|Experimental|CS-3150 1.25 mg|Two CS-3150 0.625 mg tablets administered orally, once daily after breakfast.
3032494|NCT02345057|Experimental|CS-3150 2.5 mg|One CS-3150 2.5 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
3032495|NCT02345057|Experimental|CS-3150 5.0 mg|Two CS-3150 2.5 mg tablets administered orally, once daily after breakfast
3032496|NCT02345057|Placebo Comparator|Placebo|Two placebo tablets to match CS-3150 tablet, administered orally, once daily after breakfast.
3032497|NCT02345044|Experimental|CS-3150 1.25 mg|One CS-3150 1.25 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
3032498|NCT02345044|Experimental|CS-3150 2.5 mg|Two CS-3150 1.25 mg tablets administered orally, once daily after breakfast.
3032499|NCT02345044|Experimental|CS-3150 5 mg|Two CS-3150 2.5 mg tablets administered orally, once daily after breakfast.
3032500|NCT02345044|Placebo Comparator|Placebo|Two placebo tablets to match CS-3150 tablet, administered orally, once daily after breakfast.
3032501|NCT02345044|Active Comparator|Eplerenone, 50-100 mg (Open Label)|One or two 50mg eplerenone tablet(s) administered orally, once daily after breakfast.
3032502|NCT02345031|Active Comparator|AUT00063 (600 mg capsules)|3 capsules of 200 mg of the investigational drug AUT00063, to take orally once daily with food for 4 weeks
3032503|NCT02345031|Placebo Comparator|(AUT00063 placebo capsules)|3 capsules of placebo, to take orally once daily with food for 4 weeks
3032504|NCT02345018||GSV with diameters >/= 12 mm|30 patients with primary insufficiency of the GSV with diameters >/= 12 mm, treated with mechano-chemical ablation (MOCA)
3032505|NCT02345018||Antero-lateral branches|30 patients with insufficient antero-lateral branches, treated with mechano-chemical ablation (MOCA)
3032506|NCT02345018||GSV below-knee|30 patients with below-knee GSV insufficiency, treated with mechano-chemical ablation (MOCA)
3032507|NCT02344992|Experimental|Biochaperone Insulin Lispro|
3032508|NCT02344992|Active Comparator|Humalog®|
3032509|NCT02344979||Group rHuTPO|Patients were treated with recombinant human thrombopoietin(rHuTPO)on d2,d4,d6,d9 of chemotherapy cycle.
3032510|NCT02344979||Group rHuIL-11|Patients were treated with recombinant human interleukin-11(rHuIL-11)on d9-d15 after chemotherapy.
3032511|NCT02344940|Experimental|toremifene|patients who will be treated with toremifene.
3032512|NCT02344940|Active Comparator|tamoxifen|patients who will be treated with tamoxifen.
3032513|NCT02344927|Active Comparator|Non-Clinically Assisted Hydration arm|"The interventions utilised within this trial are representative of standard clinical practice~Continuance of oral intake (if appropriate)~Regular (4 hourly) mouth care~Standard management of pain and other symptoms in the terminal phase."
3032514|NCT02344927|Active Comparator|Clinically Assisted Hydration arm|"The interventions utilised within this trial are representative of standard clinical practice~Continuance of oral intake (if appropriate)~Regular (4 hourly) mouth care~Clinically-assisted hydration~Standard management of pain and other symptoms in the terminal phase"
3032515|NCT02344914|Experimental|receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
3032516|NCT02344914|No Intervention|do not receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the control group.
3032517|NCT02344901||atrial fibrillation patients|>18 year old. Atrial fibrillation patients without mitral stenosis or any prosthesis.
3032518|NCT02344888|Active Comparator|Clomiphene citrate-Prednisolone group|Women will receive clomiphene citrate and prednisolone
3032519|NCT02344888|Active Comparator|Clomiphene citrate group|Women will receive clomiphene citrate alone
3032520|NCT02344875|Experimental|Male elder subjects|Male 65- Years
3032521|NCT02344875|Experimental|Male non-elder subjects|Male 20-35 Years
3032522|NCT02344875|Experimental|Female elder subjects|Female 65- Years
3032523|NCT02344875|Experimental|Female non-elder subjects|Female 20-35 Years
3032524|NCT02344862|Active Comparator|FYU-981 High dose|
3032525|NCT02344862|Active Comparator|FYU-981 Middle dose|
3032526|NCT02344862|Active Comparator|FYU-981 Low dose|
3032527|NCT02344862|Placebo Comparator|Placebo|
3032528|NCT02344849|Experimental|Mesenchymal stem cell|Patients will receive single intracavernous injection of MSC. Oral PDE5-inhibitor can take on demand.
3032529|NCT02344836|Active Comparator|Theory-based podcast|"Receive a 3-month weight loss intervention delivered via theory-based podcast (TBP) plus self-monitoring using a commercially-available calorie and weight tracking app (current most popular diet self-monitoring method).~Intervention: podcast + mobile diet app"
3032530|NCT02344836|Experimental|Theory-based podcast + Social POD|"Receive a 3-month weight loss intervention delivered via Theory-based Podcast (TBP) plus self-monitoring and social support/incentive points for participating with the Social POD app (TBP+Social POD).~Intervention: podcast + theory-based mobile diet app"
3032531|NCT02344823|Active Comparator|Vardenafil Phase A|HVPG (Hepatic Venous Pressure Measurement) at baseline and Response to Vardenafil 10mg per oral for 7 days at day 7 IIEF5 at baseline and day 7
3032532|NCT02344823|Placebo Comparator|Placebo Phase A|HVPG (Hepatic Venous Pressure Measurement) Measurement at baseline and Response to Placebo per oral for 7 days at day 7 IIEF 5 at baseline and day 7
3032533|NCT02344823|Active Comparator|Vardenfil Phase B|IIEF 5 (International Index of Erectile Function) at baseline and Response to Vardenafil 10mg per oral ad libidum in 28 days at day 28
3032534|NCT02344823|Placebo Comparator|Placebo Phase B|IIEF 5 (International Index of Erectile Function) at baseline and Response to Placebo per oral ad libidum in 28 days at day 28
3032535|NCT02344810|Experimental|Arm A (AMG 337, mFOLFOX6)|Patients receive c-Met inhibitor AMG 337 PO QD on days 1-28; and oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1 and 15.
3032536|NCT02344810|Active Comparator|Arm B (placebo, mFOLFOX6)|Patients receive placebo PO QD on days 1-28; and oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1 and 15.
3032537|NCT02344797|Active Comparator|Intervention|Remote ischemic preconditioning, 4 cycles of 5 minutes ischemia and 5 minutes reperfusion of the forearm before surgery.
3032538|NCT02344797|No Intervention|Control|
3032539|NCT02344758|Experimental|Celiac adult|Patient >16 years, initially diagnosed based on the detection of IgA anti-endomysial and anti-tissue transglutaminase antibodies in serum and confirmed by a small intestinal biopsy, on a GFD for >2 years
3032540|NCT02344758|Experimental|Celiac child|Patient <16 years, initially diagnosed based on the detection of IgA anti-endomysial and anti-tissue transglutaminase antibodies in serum and confirmed by a small intestinal biopsy, on a GFD for >2 years
3032541|NCT02344758|Active Comparator|Healthy adult|Healthy individual > 16 years. Exclusion criteria: the presence of family history of CD, digestive disease symptoms, known medical disease, use of prescription medications, and use of antibiotics and probiotics in the previous 2 months to the inclusion in the study.
3032542|NCT02344758|Active Comparator|Healthy child|Healthy individual < 16 years. Exclusion criteria: the presence of family history of CD, digestive disease symptoms, known medical disease, use of prescription medications, and use of antibiotics and probiotics in the previous 2 months to the inclusion in the study.
3032543|NCT02344745|Placebo Comparator|Control|Distilled water
3032544|NCT02344745|Experimental|Lavender|Lavandula angustifolia essential oil (Aura Cacia)
3032545|NCT02344732|Active Comparator|Standard Group|topical Maxitrol™ six-hourly and homatropine 2% six-hourly
3032546|NCT02344732|Experimental|Oxygen Group|standard medical treatment of topical Maxitrol™ six-hourly and homatropine 2% six-hourly, plus systemic oxygen via simple face mask at 10 litres/min for one hour, in 12-hourly sessions for 3 days
3032547|NCT02344719|Active Comparator|6 capsules Taurin per day|After baseline HVPG (Hepatic Venous Pressure Measurement)patients take 6x1g capsules of GMP produced Taurin per day, on day 28, after intake of the 6x1g Taurin capsules, HVPG measurement will be repeated.
3032548|NCT02344719|Placebo Comparator|6 capsuless placebo per day|After baseline HVPG measurement patients take 6x1g capsules of placebo per day, on day 28, after intake of the 6x1g placebo capsules, HVPG measurement will be repeated.
3032549|NCT02344706||Mini-EEG, NCSE|Unconscious patients due to seizures, of whom EEG is registered
3032550|NCT02344680||HIV-HBV co-infected|HIV-HBV co-infected patients receiving anti-retroviral therapy
3032551|NCT02344667|Experimental|Cyberknife|Cyberknife based SBRT 36.25 Gy in 5 fractions
3032552|NCT02344667|Experimental|Volume Modulated Arc Therapy|Volume Modulated Arc Therapy based SBRT 36.25 Gy in 5 fractions
3032553|NCT02344654|Experimental|Fluorescence cholangiography|After induction of anaesthesia 2.5-7.5 mg of indocyanine green (0.05 mg/kg) is injected intravenously. The operation field is routinely inspected in the fluorescence imaging mode before dissection of Calot´s triangle. During dissection, the fluorescence imaging mode is used when needed, before division of any tubular structure and after division of the cystic duct and artery.
3032554|NCT02344654|Active Comparator|X-ray cholangiography|The cholangiography is performed after dissection of the cystic duct by cannulation of the cystic duct with a catheter using either a Kumar- or Olsen grasper. A mobile X-ray C-arm system is used, and the monochrome X-ray image is shown on a separate screen. After satisfactory identification of the extra-hepatic biliary ducts, the intraoperative cholangiography is discontinued and the gallbladder is removed in a standardized manner.
3032555|NCT02344641|Experimental|Exenatide|exenatide group receive exenatide (5μg, subcutaneous injection, Bid）
3032556|NCT02344641|No Intervention|control group|control group do not receive exenatide
3032557|NCT02344628|Active Comparator|AZT30|Single dose of azithromycin at a dose of 30mg/kg - max 2 Grams
3032558|NCT02344628|Experimental|AZT20|Single dose of azithromycin at a dose of 20mg/kg - max 1 Grams
3032559|NCT02344615|Active Comparator|NS-guided infraclavicular block|NS-guided infraclavicular block is performed using 35 ml of 0.5% ropivacaine.
3032560|NCT02344615|Experimental|US-guided infraclavicular block|US-guided infraclavicular block is performed using 35 ml of 0.5% ropivacaine.
3032561|NCT02344602|Experimental|Febuxostat (trade name Uloric®)|Oral tablet, 80mg, OD, 8 weeks
3032562|NCT02344589|Experimental|ACB 10|ACB in right leg with 10ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
3032563|NCT02344589|Experimental|ACB 20|ACB in right leg with 20ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
3032564|NCT02344589|Experimental|ACB 30|ACB in right leg with 30ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
3032565|NCT02344589|Active Comparator|FNB|FNB in left leg with 20ml of lidocaine 10mg/ml on day 1. Unblinded arm, used for model control
3032566|NCT02344589|Placebo Comparator|Placebo|ACB in left leg with 30ml of isotonic saline on day 2. Unblinded arm used for model control
3032567|NCT02344576|No Intervention|Control: Usual Care|Patients and caregivers will receive the current usual education and consent process for DT LVAD at each hospital. This often means viewing consent forms and industry materials.
3032568|NCT02344576|Experimental|DT LVAD Decision Support Intervention|In the intervention phase of the study, patients and caregivers will receive the new decision support intervention, which consists primarily of decision aid materials about DT LVAD. The standard consent process will also still take place, but will be supplemented with additional decision support.
3032569|NCT02344563|Experimental|Meropem|0.5g/vial,one vial
3032570|NCT02344563|Active Comparator|Mepem|0.25g/vial ,two vials
3032571|NCT02344550|Experimental|Everolimus arm|Everolimus 10mg p.o. daily Letrozole 2.5 mg p.o. daily Leuprorelin (Leuprolide) 3.75mg SC every 4 weeks
3032572|NCT02344550|Active Comparator|Control arm|Letrozole 2.5 mg p.o. daily Leuprorelin (Leuprolide) 3.75mg SC every 4 weeks
3032573|NCT02344537|Experimental|Meditation Group Therapy|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
3032574|NCT02344537|No Intervention|Wait-List Controls|The wait-list group will not take part in study treatment (daily meditation or stretching) during the study wait of 8 weeks in order for us to compare change related to the study intervention to change associated with no active treatment ( treatment-as-usual). (After completing 8 weeks of no study treatment as part of the wait-list group, these patients will be offered the opportunity to receive 8 weeks of treatment.)
3032575|NCT02344524|Experimental|Small bore chest drain|Intercostal drainage for traumatic hemothorax and pneumothorax using small bore chest drain
3032576|NCT02344524|Active Comparator|Large bore chest drain|Intercostal drainage for traumatic hemothorax and pneumothorax using large bore chest drain
3032577|NCT02344511|Experimental|Dalbavancin|"Patients with Creatine Clearance (CrCl) greater than 30 mL/min and patients receiving regular hemodialysis or peritoneal dialysis will receive 15 mg/kg Intravenous (IV) dalbavancin over 30 (+/- 5) minutes on Day 1 and on Day 8, not to exceed 1500 mg per administration in children at least 12 years and not to exceed 1000 mg per administration in children less than 12 years of age.~• Patients with CrCl < 30 mL/min who are not receiving regular hemodialysis or peritoneal dialysis will receive 10 mg/kg IV dalbavancin over 30 (+/- 5) minutes on Day 1 and on Day 8, not to exceed 1000 mg per administration in children at least 12 years and not to exceed 750 mg per administration in children less than 12 years of age.~Additionally, subjects randomized to the dalbavancin group will receive an IV placebo infusion at times corresponding to comparator group dosage times for the first eight days."
3032578|NCT02344511|Active Comparator|4 Comparators|"cefazolin, oxacillin, nafcillin or vancomycin according to the commercial label~Patients with normal renal function will receive either vancomycin 15 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour) not to exceed a daily total dose of 4000 mg, with dose adjustment based on local standard of care to achieve serum trough concentrations of 10 μg/mL to 20 μg/mL; or cefazolin 25 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour); or nafcillin or oxacillin 50 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour)."
3032579|NCT02344498||Urban|HBV patients in Addis Abeba. Eligible patients treated with tenofovir disoproxil fumarate 245 mg OD.
3032580|NCT02344498||Rural|HBV patients in Harar. Eligible patients treated with tenofovir disoproxil fumarate 245 mg OD.
3032581|NCT02344485|Experimental|OMM treatment|Subject will receive osteopathic manipulative treatment protocol for constipation in Parkinson's disease once a week for 4 weeks, in addition to continuing with their routine care
3032582|NCT02344485|No Intervention|Control|Subjects will continue with their routine care. No OMM will be performed during this study period
3032583|NCT02344472|Experimental|Chemotherapy with docetaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus docetaxel
3032584|NCT02344472|Experimental|Chemotherapy with paclitaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus paclitaxel
3032585|NCT02344472|Experimental|Chemotherapy with vinorelbine|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus vinorelbine
3032586|NCT02344472|Experimental|Chemotherapy with capecitabine|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus capecitabine.
3032587|NCT02344472|Experimental|endocrine therapy with tamoxifen|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus endocrine therapy with tamoxifen
3032588|NCT02344472|Experimental|endocrine therapy with exemestane|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus exemestane
3032589|NCT02344472|Experimental|endocrine therapy with fulvestrant|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus fulvestrant
3032590|NCT02344472|Experimental|endocrine therapy with anastrozole|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus anastrozole
3032591|NCT02344472|Experimental|endocrine therapy with letrozole|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus letrozole
3032592|NCT02344459|Experimental|80mL double balloon catheter (Cook catheter®)|
3032593|NCT02344459|Active Comparator|30mL single Foley balloon catheter|
3032594|NCT02344446|Experimental|Skilled Therapy|Differential physical therapy treatment, based on assessment results, with follow-up visits for PT treatment 1 - 2 times per week until patient achieves at least 1 primary outcome. They will pragmatically design an individualized and progressive treatment plan, including manual therapy (manipulation and/or mobilization), neuromotor control strategies, and vestibular rehabilitation techniques, depending on the findings at assessment and patient response. Therapists can also tailor education regarding mental and physical rest according to specific parameters provided by the treating physician. Patients may also be prescribed a home exercise program and exercise education. The precise treatment strategies will be recorded.
3032595|NCT02344433|Experimental|VICKY|"Relational agent, virtual counselor for collecting family health history (VICKY: VIrtual Counselor for Knowing Your Family History)."
3032596|NCT02344433|Active Comparator|MFHP|Online family health history collection tool (MFHP: My Family Health Portrait).
3032597|NCT02344420|Other|Single Arm|As it is not a randomize trial there is only one study arm. Described interventions as echocariography, six minute walk test, Quality of Life test or self assessment score should be done in all patients.
3032598|NCT02344407|Experimental|2|ChAd3-EBO Z
3032599|NCT02344407|Experimental|3|VSVG-ZEBOV
3032600|NCT02344407|Placebo Comparator|1|Placebo (Saline)
3032601|NCT02344394|Other|Hybrid Ablation-cryoballoon alone|This group receives the hybrid surgical ablation (epicardial-endocardial ablation) with epicardial ablation and endocardial ablation consisting of pulmonary vein isolation with no further catheter ablation. This will be achieved using the nContact and Medtronic cryoballoon
3032602|NCT02344394|Other|Hybrid ablation-cryoballoon plus RF|This group receives the hybrid surgical ablation (epicardial-endocardial ablation) with epicardial ablation and endocardial ablation. Endocardial portion consists of pulmonary vein isolation using the cryoballoon with further catheter ablation, which may consist of ablation of complex fractionated electrograms and linear lesions. This will be achieved using the nContact and Medtronic Cryoballoon plus Thermocool Catheter.
3032603|NCT02344381|Experimental|Sucrose|Sucrose ingestion post-exercise
3032604|NCT02344381|Active Comparator|Glucose|Glucose ingestion post-exercise
3032605|NCT02344368|Experimental|0.2 ml sucrose|on 2 occasions within 1 week 0.2 ml sucrose 25% or 0.5 ml sucrose 25% will be given in randomized order to the same infant during blood sampling
3032606|NCT02344368|Experimental|0.5 ml sucrose|on 2 occasions within 1 week 0.2 ml sucrose 25% or 0.5 ml sucrose 25% will be given in randomized order to the same infant during blood sampling
3032607|NCT02344355|Experimental|ascorbate, radiation, temozolomide|"Concomitant therapy:~Radiation therapy, oral temozolomide, and pharmacological ascorbate (ascorbic acid) infusions~Adjuvant therapy:~Oral temozolomide and pharmacological ascorbate (ascorbic acid) infusions"
3032608|NCT02344342|Experimental|Health Buddy Web Management system|Patients randomized to the telemonitoring intervention will be assigned to use the Bosch Health Buddy Web management system.
3032609|NCT02344342|Experimental|Flexible Diuretic Regimen|Patients randomized into the Flexible Diuretic Regimen intervention will have a diuretic regimen specified by specific weight ranges.
3032610|NCT02344329|Active Comparator|Control|TCC-EZ and Standard Wound Care (Topical wound dressing) Two dressing and cast changes in week one followed by weekly applications until 12 weeks or closure which ever occurs first. Usual wound care would involve assessment, debridement, moist wound environment, and off-loading.
3032611|NCT02344329|Experimental|Intervention|TCC-EZ and Human Amnion Allograft One dressing and two cast changes in week one followed by dressing change every two to three weeks and weekly cast changes until 12 weeks or closure which ever occurs first. Usual wound care would involve assessment, debridement, moist wound environment, and off-loading.
3032612|NCT02344316|Active Comparator|Melatonin|Group randomized to melatonin 3 mg orally nightly
3032613|NCT02344316|Placebo Comparator|Placebo|Group randomized to placebo orally nightly
3032614|NCT02344303|Experimental|Part A|Fixed sequence, open label
3032615|NCT02344303|Experimental|Part B|4 way cross over, double blind
3032616|NCT02344290|Experimental|Pitavastatin|Participants will receive pitavastatin once a day for the entire time they are enrolled in the study.
3032617|NCT02344290|Placebo Comparator|Placebo|Participants will receive placebo for pitavastatin once a day for the entire time they are enrolled in the study.
3032618|NCT02344264|Other|RP|first blockade: ropivacaine 7,5mg/ml 8 ml second blockade: placebo: saline 8 ml
3032619|NCT02344264|Other|PR|first blockade: placebo: saline 8 ml second blockade: ropivacaine 7,5mg/ml 8 ml
3032620|NCT02344251|Other|Group 1|Adherence measured by MEMS Cap
3032621|NCT02344251|Other|Group 2|Adherence measured by ID-Cap technology.
3032622|NCT02344238|Other|Group 1|Compliance measured by self-report and riboflavin measurement.
3032623|NCT02344238|Other|Group 2|Compliance measured by self-report, riboflavin measurement, and data collected by the ID Cap.
3032624|NCT02344238|Other|Group 3|Compliance measured by self-report, riboflavin measurement, and data collected by the ID Cap. This arm will also receive prompts (reminder calls and/or text messages) to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
3032625|NCT02344225|Active Comparator|Caffeine+Saline IV+Saline drops|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose) plus placebo saline IV (1 ml/kg followed by 0.25 ml/kg) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Caffeine is the intervention
3032626|NCT02344225|Experimental|Caffeine+Ibp IV+Saline drops|Caffeine citrate as described in group 1, plus Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Ibuprofen is the intervention
3032627|NCT02344225|Experimental|Caffeine+Saline+Ketorolac drops|Caffeine citrate plus saline IV placebo as described in group 1, and Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days (n=40); Ketorolac is the intervention
3032628|NCT02344212|Experimental|ESENCIAL Para Vivir|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
3032629|NCT02344186|Experimental|Liraglutide|Liraglutide will be started first with 0.6 mg/d for 1 week, then increased to 1.2 mg/d from week 2 to week 12, followed by 1.8 mg/d from week 12 to week 24.
3032630|NCT02344186|Placebo Comparator|Placebo|Subjects will receive placebo for 12 weeks.
3032631|NCT02344134|Experimental|NBP607|cell culture-derived trivalent inactivated subunit influenza vaccine
3032632|NCT02344134|Active Comparator|Agrippal S1|egg-derived trivalent inactivated subunit influenza vaccine
3032633|NCT02344108|Experimental|Inspire® Upper Airway Simulation System|Subjects meeting inclusion criteria, including sleep study and drug induced sleep endoscopy criteria, will undergo surgical placement of a hypoglossal nerve simulator (Inspire® Upper Airway Simulation System Model 3028 IPG). The simulator will be activated one month after surgery and subjects will undergo repeat sleep study evaluation and device titration at one, two, six and twelve months after implantation. Subjects will be followed for one year to determine safety and efficacy of the device.
3032634|NCT02344095|Experimental|weekly paclitaxel with oncothermia|Paclitaxel group are treated with weekly paclitaxel and oncothermia for 4-cycles.
3032635|NCT02344095|Experimental|weekly cisplatin with oncothermia|Cisplatin group are treated with weekly cisplatin and oncothermia for 4-cycles.
3032636|NCT02344082|No Intervention|Standard of Care|The control arm will receive face-to-face pharmacy clinic visits per usual care.
3032637|NCT02344082|Active Comparator|Intervention Arm|The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
3032638|NCT02344069|Active Comparator|Fibrinogen|Immediate intravenous administration as a single dose of fibrinogen concentrate (Riastap®, CSL Behring), when haemostatic resuscitation is deemed necessary by the clinician.
3032639|NCT02344069|Placebo Comparator|Placebo|Saline 0.9%
3032640|NCT02344056|Experimental|having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
3032641|NCT02344056|Experimental|skipping lunch/having lunch|no lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
3032642|NCT02344043||Critical illness|This prospective cohort of critically ill patients will have brain tissue oxygen levels recorded for 24 hours after admission with near infrared spectroscopy.
3032643|NCT02344030|Experimental|standard blade|Standard Blade: tracheal intubation with standard blade
3032644|NCT02344030|Experimental|channeled blade|Channeled Blade: tracheal intubation with channeled blade
3032645|NCT02344017|Experimental|ODM-204 Phase I dose escalation|Dose escalation
3032646|NCT02344017|Experimental|ODM-204 Phase II dose expansion|
3032647|NCT02344004|No Intervention|Multi-drug regimen|Patients will receive their already prescribed anti-mycobacterial regimen (based on the 2007 ATS/IDSA Guidelines)
3032648|NCT02344004|Experimental|Multi-drug regimen + LAI|Subjects will receive LAI in addition to their already prescribed anti-mycobacterial regimen (based on the 2007 ATS/IDSA Guidelines)
3032649|NCT02343991|Experimental|Transcranial ExAblate|MR Guided Focused Ultrasound
3032650|NCT02343978|Experimental|KWA-0711 High dose|
3032651|NCT02343978|Experimental|KWA-0711 Low dose|
3032652|NCT02343965|Experimental|Touch-massage group|Patient receive 3 sessions of touch-massage (the duration of a session of touch massage is 15 minutes) ,once a week, for 3 weeks
3032653|NCT02343965|No Intervention|without touch-massage group|
3032654|NCT02343952|Experimental|Experimental Arm|Pembrolizumab
3032655|NCT02343939|Experimental|Entospletinib + daunorubicin + cytarabine (Group A)|"Dose Escalation: Entospletinib up to 400 mg for 14 days and then entospletinib up to 400 mg in combination with daunorubicin and cytarabine for up to two 14-day cycles.~Dose Expansion: Entospletinib 400 mg for 14 days and then entospletinib 400 mg in combination with daunorubicin and cytarabine for up to two 14-day cycles. Some participants will have the option to receive post-induction therapy with entospletinib 400 mg in combination with cytarabine/cytosine arabinoside (ARA-C). Participants may receive maintenance therapy with 28-day cycles of entospletinib 400 mg for up to twelve 28-day cycles, if the participant is not eligible for stem cell transplant."
3032656|NCT02343939|Experimental|Entospletinib + decitabine (Group B)|"Dose Escalation: Entospletinib 400 mg for 14 days and then entospletinib 400 mg in combination with decitabine for 10 days beginning on Day 1 of every 28-day cycle (at least 2 cycles of induction therapy but no more than 4 cycles). Participants who are intolerant of decitabine may switch to entospletinib monotherapy maintenance at any time after completing the first 2 cycles.~Dose Expansion: Entospletinib 400 mg for 14 days for the safety run-in participants or Entospletinib 400 mg for 5 days for the randomization participants. Then entospletinib 400 mg in combination with decitabine or azacitidine (at least 2 cycles of induction therapy but no more than 4 cycles). Some participants will have the option to receive maintenance therapy with entospletinib in combination with decitabine or azacitidine. Participants who are intolerant of decitabine or azacitidine may switch to entospletinib monotherapy maintenance at any time after completing the first 2 cycles."
3032657|NCT02343939|Experimental|Entospletinib (Group C)|"Dose Escalation: Entospletinib up to 800 mg for 28-day cycles until the participant meets criteria for study treatment discontinuation per the study protocol.~Dose Expansion: Entospletinib 400 mg for 28-day cycles until the participant meets criteria for study treatment discontinuation per the protocol."
3032658|NCT02343926|Experimental|Gemigliptin|GEMIGLIPTIN LS15-0444 administered once a day for 24 weeks as add-on therapy to metformin
3032659|NCT02343926|Active Comparator|Vildagliptin|Vildagliptin administered twice a day for 24 weeks as add-on therapy to metformin
3032660|NCT02343913|Experimental|PAC checklist|Pictorial checklist which illustrates these signs and symptoms
3032661|NCT02343887|Active Comparator|control group|"patients without taking into cognitive or psychological treatment for 6 months (period 1) and~if the situation improves in the neuropsychological assessment of M6 further with simple monitoring neuropsychological evaluation M12~or persistence or worsening of the disorder, the beginning of a cognitive remediation program for 6 months (period 2)."
3032662|NCT02343887|Experimental|group with cognitive rehabilitation,|"patients treated for 6 months Cognitive remediation (period 1), then~Stop if the situation improves in the evaluation and monitoring of M6 to M12 with neuropsychological assessment,~or persistence or worsening of the disorder, further cognitive remediation for 6 months (period 2)."
3032663|NCT02343887|Experimental|group with psychological support.|"patients treated with counseling for six months (period 1) and~Stop if the situation improves with neuropsychological assessment and monitoring to M12,~or if persistent or worsening unrest in the neuropsychological assessment of M6, the beginning of a cognitive remediation program for 6 months (period 2)."
3032664|NCT02343874||Alcohol consumption|"Patients over 17 years old with alcohol consumption registered in the electronic medical record (31st December 2012).~No intervention is going to be administered but exposure to alcohol will be analysed"
3032665|NCT02343861|Active Comparator|Tailored leaflet group|Participants (parents of children with atopic dermatitis) receive a tailored leaflet about the detailed amount of emollients as well as general information about use of emollients.
3032666|NCT02343861|Placebo Comparator|Control group|Participants (parents of children with atopic dermatitis) receive general information about use of emollients only.
3032667|NCT02343848|Experimental|treatment|smart bracelet.
3032668|NCT02343835|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
3032669|NCT02343822|Experimental|Multiple PRP Injection|2 PRP Injections 2 months apart
3032670|NCT02343822|Experimental|Single PRP Injection|1 PRP Injection and Saline Injection 2 months apart
3032671|NCT02343822|Active Comparator|Saline Injection|2 Saline Injections 2 months apart
3032672|NCT02343809|Experimental|Intervention Group|Actual Diacutaneous Fibrolysis and Protocolized Physiotherapy
3032673|NCT02343809|Sham Comparator|Placebo Group|Sham Diacutaneous Fibrolysis and Protocolized Physiotherapy
3032674|NCT02343809|Other|Control Group|Protocolized Physiotherapy
3032675|NCT02343796|Experimental|Fibre-reinforced composite|Fibreglass reinforced composite restoration-everStick as a medical device intervention will be applied on each subject by using either direct or indirect method. everStick (GC, Belgium) will be used as a fibre reinforcement material.
3032676|NCT02343783|Experimental|Healthy + Atopic Dermatitis + Allergic Asthmatic Participants|Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. Participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed for the use of induced skin blisters after allergic skin reaction (ASR).
3032677|NCT02343770|Experimental|idiopathic juvenile arthritis|blood sample
3032678|NCT02343770|Other|control|blood sample
3032679|NCT02343757|Other|PET/CT vs. PET/MRI|"Patients will be included if presenting with the clinical suspicious of AD, Mild Cognitive Impairment (MCI) or other cognitive impairment to be further determined.~Patients will undergo two doubles scans in two steps with a maximum of 2 week between both: the first step will be one day double scan with FDG imaged by PET-CT and PET-MRI; and the second step will be one day double scan with 18F-florbetapir imaged by PET-CT and PET-MRI at a different timepoints as shown in figure 1."
3032680|NCT02343744|Experimental|Guselkumab|"Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary."
3032681|NCT02343731|Experimental|Dog Introduction|Participants will receive a dog from the Humane Society of Southern Arizona's (HSSA) foster care program to live with them for three months.
3032682|NCT02343718|Experimental|Vinblastine and Temsirolimus|"Vinblastine starting dose:~Weight >12 kg 4mg/m^2 Weight ≤ 12 kg 0.13mg/kg IV push for 1 minute Days 1, 8, 15, 22, 29 and 36. Cycle length is 6 weeks up to 6 cycles.~Temsirolimus starting dose:~Weight >12 kg 15mg/m^2 Weight ≤ 12 kg 0.5 mg/kg IV for 1 hour on days 1, 8, 15, 22, 29 and 36. Cycle length is 6 weeks up to 6 cycles."
3032683|NCT02343705|Experimental|Latella Knee Implant System|
3032684|NCT02343692|Experimental|Radiofrequency abalation|"Intervention: Endoscopic Ultrasound (EUS) guided radiofrequency ablation (RFA) of cystic tumours of the pancreas~Device: An RFA generator (ERBE VIO 300D, Dolby medical products, Scotland)~Procedure: Delivery of sequential doses of electrical energy at 10W for a total of up to 4 minutes 30 seconds (3 x 90 second applications) to ablate the cystic lesion.~Ablation of cystic tumours of the pancreas"
3032685|NCT02343679|Experimental|Ceritinib for ALK + patients|all ALK + hematologic malignancies patients will receive ceritinib
3032686|NCT02343666|Experimental|Treatment (gene modified HPSC)|See Detailed Description.
3032687|NCT02343653|Active Comparator|Nutrition|Participants receive a controlled diet consisting of 1.2-1.5 g of protein/kg/day for 12 weeks according to guidelines for enteral nutrition and patients with cirrhosis. The group receives dietary guidance and protein supplements.
3032688|NCT02343653|Experimental|Nutrition and strength training|"Participants in this group receive same controlled diet consisting of 1.2-1.5 g of protein/kg/day for 12 weeks as the No intervention-group. Participants will also receive supervised strength training 3 x 60 min./week for 12 weeks. The group receives dietary guidance and protein supplements, which on training days should be consumed within 30 minutes after exercise."
3032689|NCT02343640||Baseball players|Members of the baseball team, both pitchers and fielders, who participate in repetitive baseball throwing and are exposed to damage of the ulnar collateral ligament in the arm that is used for throwing.
3032690|NCT02343627|Experimental|NVXT Solution|NVXT Solution once daily for 60 days
3032691|NCT02343627|Placebo Comparator|Vehicle of test product|Vehicle of test product, once daily for 60 days
3032692|NCT02343614|Experimental|ARM A|Patients undergoing treatment with oral celecoxib
3032693|NCT02343601|No Intervention|Control group|Control group using a hemodynamic standard protocol
3032694|NCT02343601|Other|Photoplethysmography group|Hemodynamic optimization using Photoplethysmography device (ClearSight, Edwards Lifesciences, Irvine, CA)
3032695|NCT02343588|Experimental|The Health Lifestyles Interventions|"Creating a supportive school, family and community environment;~Health lifestyles educational strategies;~Instruct and promote school physical education;~The monitoring and instruction of obesity related behaviors (focus group)"
3032696|NCT02343588|No Intervention|Receive no intervention|Usual practice
3032697|NCT02343575|Experimental|Valproic Acid|"Start:~VPA PO/NGT 500 mg BID~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS~Rescue at all stages: HAL IV 2-5 mg Q4hr PRN"
3032698|NCT02343575|Placebo Comparator|Placebo|"Placebo: PO/NGT BID~Rescue: HAL IV 2-5 mg Q4hr PRN"
3032699|NCT02343562|Active Comparator|Probiotics Group|Will receive Sachet-form probiotics
3032700|NCT02343562|Placebo Comparator|Placebo Group|Will receive off-the-shelf oral multivitamin
3032701|NCT02343549|Experimental|A|All Patients
3032702|NCT02343536|Experimental|Oral Azacitidine (CC-486) and R-CHOP|Will examine four escalating dose-levels of CC- 486 (100 mg, 150 mg, 200 mg and 300 mg).
3032703|NCT02343536|Active Comparator|R-CHOP|R-CHOP, (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) * rituximab, cyclophosphamide, doxorubicin, and vincristine are administered on Day 1; while prednisone is administered Days 1-5
3032704|NCT02343510||primary tubal cancer group|Paraffin blocks of cases of primary tubal cancer
3032705|NCT02343510||high grade serous ovarian cancer group|Paraffin blocks of cases of high grade serous ovarian cancer
3032706|NCT02343510||Low Grade Serous Ovarian Cancer|Paraffin blocks of cases of low grade serous ovarian cancer
3032707|NCT02343510||normal tubes group|Paraffin blocks of tubes of hysterectomies due to non-oncologic causes
3032708|NCT02343497|Experimental|Astaxanthin|Astaxanthin supplement from Phaffia rhodozyma, 6mg in lipid capsules, 2 caps per day, duration 12 weeks
3032709|NCT02343497|Placebo Comparator|Placebo|filling agent, in lipid capsules, 2 caps per day, duration 12 weeks
3032710|NCT02343484|Active Comparator|Gelified ethanol|Gelified ethanol (Discogel) is a sterile, implantable medical solution containing ethyl alcohol, cellulose derivative product and an opaque agent (tungsten). The implant is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. The implant causes migration of fluid (by hydrophilic and osmotic phenomena) from the periphery towards the center, causing disk reinforcement. Filling of the annulus fibrosus tears interrupts the outflow of inflammatory factors towards dorsal root ganglions, dura and posterior longitudinal ligament.
3032711|NCT02343484|Active Comparator|Gelified ethanol combined to pulsed radiofrequency|Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain.Intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
3032712|NCT02343471|Experimental|20 g whey protein|20 g whey protein dissolved in 200 milliliter (mL) water is consumed as a pre-meal 15 min prior to the main meal. Additionally, 200 mL water is consumed as a part of the main meal.
3032713|NCT02343471|Placebo Comparator|Water|200 milliliter (mL) water consumed as pre-meal 15 min prior to the main meal. 20 g whey protein dissolved in 200 mL water is consumed as a part of the main meal.
3032714|NCT02343458|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
3032715|NCT02343458|Experimental|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
3032716|NCT02343458|Experimental|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
3032717|NCT02343458|Placebo Comparator|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
3032718|NCT02343445|Experimental|P-1037 in Hypertonic Saline|P-1037 Solution for Inhalation, 85 μg BID (28.3 μg/mL) in hypertonic saline (4.2% saline) BID
3032719|NCT02343445|Experimental|P-1037 in Saline|P-1037 Solution for Inhalation, 85 μg BID (28.3 μg/mL) in 0.17% saline BID
3032720|NCT02343445|Placebo Comparator|Saline|Placebo (0.17% saline) BID
3032721|NCT02343445|Sham Comparator|Hypertonic Saline|Hypertonic saline (4.2% saline) BID
3032722|NCT02343432|Experimental|Epidural Volume 10mL|Epidural Volume 10mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 10mL Intervention: Drug: Bupivacaine 12.5mg
3032723|NCT02343432|Experimental|Epidural Volume 15mL|Epidural Volume 15mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 15 mL Intervention: Drug: Bupivacaine 12.5mg
3032724|NCT02343432|Experimental|Epidural Volume 20mL|Epidural Volume 20mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 20 mL Intervention: Drug: Bupivacaine 12.5mg
3032725|NCT02343419|Experimental|Bronchial challenge test|Patients will undergo Methacholine Challenge Test assessed by forced oscillation technique (FOT), plethysmography, interrupter technique and spirometry.
3032726|NCT02343406|Experimental|Arm 4 Pediatric sub-study|ABT-414 at a dose of 1.0 mg/kg for participants who are 6 to 17 years old (at the date of first ABT-414 dose), or 1.3 mg/kg for participants who are 0 to 5 years old administered via intravenous infusion every other week. Prophylactic steroid eye drops (temozolomide) will be administered as described for the adult participants. Investigator discretion to use ABT-414 as monotherapy or in combination with temozolomide. The use of TMZ in combination with ABT-414 for a pediatric patient must be reviewed by the EORTC/AbbVie medical monitor prior to the initiation of therapy.
3032727|NCT02343406|Experimental|Arm 2|ABT-414 administered every two weeks as monotherapy
3032728|NCT02343406|Active Comparator|Arm 3A|Lomustine: For patients relapsing during TMZ treatment, or within 16 weeks after first day of last TMZ cycle: Lomustine will be administered on day 1 of every 42 day cycle.
3032729|NCT02343406|Experimental|Arm 1|ABT-414 administered via intravenous infusion every two weeks in combination with Temozolomide
3032730|NCT02343406|Active Comparator|Arm 3B|Temozolomide re-challenge: For patients that relapse 16 weeks or more after the first day of last dose of TMZ cycle: TMZ will be administered on day 1-5 of every 28 day cycle
3032731|NCT02343393|Experimental|H-ISDN|Eligible patients randomised to treatment arm will be initiated on a starting dose of hydralazine 60mg and ISDN 30mg daily (20/10mg three times daily). After 7 days following the first dose, if the starting medication is well-tolerated, the patient is instructed to double the dose of study medication to the target maintenance dose of hydralazine 120mg and ISDN 60mg daily for 24 weeks
3032732|NCT02343393|No Intervention|Standard Medical Therapy|Current standard HF therapy include the use of beta-blockers, ACE inhibitors/ARBs and diuretics.
3032733|NCT02343380|Experimental|morning-first|calorimetric exam after a standard meal
3032734|NCT02343380|Experimental|evening-first|calorimetric exam after a standard meal
3032735|NCT02343367|Active Comparator|Standard Care|Brief patient-centered behavioral counseling using the Healthy Lifestyle Prescription, health education materials and a community resource guide. Follow-up visits scheduled at 1, 6, and 12 months. Parent receives weekly general health education cell phone text messages for 12 months
3032736|NCT02343367|Experimental|Pediatric Obesity Management|All elements of standard care plus a family-based face to face counseling session with a health educator, telephone counseling, mailed newsletters and regularly scheduled cell phone text messages with tips and motivational messages for healthy eating and PA, as well as information on community events and resources.
3032768|NCT02343146|No Intervention|Comparison|The comparison group will receive usual care with the diabetes team.
3032769|NCT02343133|Experimental|HemaMax|Single subcutaneous dose of HemaMax
3032770|NCT02343133|Placebo Comparator|Placebo|Single subcutaneous dose of Placebo
3032737|NCT02343354|Experimental|Nutrition/physical activity intervention|There will be five in-person group sessions (3 to 4 weeks appart) with on-site child care. Sessions will include preparation of a healthy meal (hands-on) and discussions of mindful eating, balanced meals, portion sizes, and preparing food at home, under a dietitian's supervision. Sessions will also include a one-hour physical activity information/practice session with a kinesiologist. Participants will track daily step counts with a pedometer and aim to eventually reach more than 10,000 steps/day. They will also receive instruction and demonstration from a kinesiologist of some simple resistance exercises they may perform at home. Between sessions, participants will receive advice and support through a study-specific website, telephone calls and phone applications.
3032738|NCT02343341|Experimental|Preschool Health Promotion Education Program|Children randomized to the intervention arm will receive an up to 5-month health promotion education program along with their parents/caregivers and teachers.
3032739|NCT02343341|Other|Control Arm|The control arm will receive the standard curriculum in their schools. The control arm will receive the health promotion education program for up to 5 months after the intervention arm has completed it
3032740|NCT02343328|Active Comparator|Fecal Microbiota Transplant Capsules|Fecal microbiota transplant capsules
3032741|NCT02343328|Placebo Comparator|Placebo Capsules|Placebo capsules made from a mixture of natural cocoa powder and gelatin
3032742|NCT02343315|Experimental|TENS|Participants will receive Active-TENS along with SMCE and UHEP. Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.
3032743|NCT02343315|Experimental|SMCE|Participants will receive SMCE and UHEP. Six sessions of supervised Motor control exercises will be provided over the period of two weeks.
3032744|NCT02343315|Active Comparator|UHEP|Unsupervised home exercise program will be prescribed with home exercise leaflet and education leaflet in the form of back book on first treatment session.
3032745|NCT02343302|Other|Soft Pancreatic Gland|This arm will be patients with glands felt to have a soft texture during surgery. This arm will receive either a suction drain or a gravity drain based on the note inside the sealed envelope.
3032746|NCT02343302|Other|Hard Pancreatic Gland|This arm will include patients felt to have a hard gland tecture at the time of surgery. This arm will receive either a suction drain or a gravity drain based on the note inside the sealed envelope.
3032747|NCT02343289|Experimental|Esketamine Regimen|All participants will first receive 28 milligram (mg) of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, followed by 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, followed by 84 mg of intranasal esketamine on Day 1 of Period 3 and then 500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4 and 84 mg of intranasal esketamine on Day 1 of Period 4. Each period will be separated by a washout period of up to 21 days in between.
3032748|NCT02343276|Placebo Comparator|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
3032749|NCT02343276|Experimental|Intervention|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
3032750|NCT02343263|No Intervention|Control|44 patients will be randomized to receive no topical treatment to their tonsillectomy (or adenotonsillectomy) wound bed as is the current standard of care at our institution. The wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis alone.
3032751|NCT02343263|Active Comparator|Fibrin Sealant Alone|44 patients will be randomized to receive application of topical fibrin sealant to their tonsillectomy (or adenotonsillectomy) wound bed to assess the pain reduction benefits of fibrin sealant alone. Prior to application of fibrin sealant, the wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis.
3032752|NCT02343263|Experimental|Bupivacaine-infused Fibrin Sealant|44 patients will be randomized to receive application of topical bupivacaine-infused fibrin sealant to their tonsillectomy (or adenotonsillectomy) wound bed to assess the pain reduction benefits of fibrin sealant alone. Prior to application of fibrin sealant, the wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis.
3032753|NCT02343250|Experimental|Cinidipine/Valsartan tablet|Cinidipine/Valsartan tablet
3032754|NCT02343250|Active Comparator|Cilnidipine+Valsartan|coadministration of cilinidipine and valsartan
3032755|NCT02343237|Experimental|Osteopathy +|75 patients will make 6 osteopathic sessions
3032756|NCT02343237|Active Comparator|Osteopathy -|75 patients will make 6 factitious osteopathic sessions
3032757|NCT02343224|Experimental|Pegylated interferon alpha-2b|Subjects will receive PEG-Intron based on their weight (1 mcg/kg/dose) once a week
3032758|NCT02343211|Experimental|immunoglobulin|
3032759|NCT02343198|Experimental|Stimulation|Custom-built research muscle stimulator. Muscle stimulator is set to provide a comfortable stimulation when applied to the soleus muscle using two 5x5cm electrodes.
3032760|NCT02343198|Placebo Comparator|Placebo-control|Custom-built research muscle stimulator. Muscle stimulator is set to provide sensory stimulation but will not cause an active muscle contraction. Stimulation is also delivered to the soleus muscle through two 5x5cm electrodes.
3032761|NCT02343185|Experimental|diaphragmatic treatment|Subjects in this arm receive different manual techniques for the low back pain and diaphragmatic treatment.
3032762|NCT02343185|Placebo Comparator|Placebo|Subjects in this arm receive different manual techniques for the low back pain and a sham diaphragmatic treatment.
3032763|NCT02343172|Experimental|HDM201+LEE011|
3032764|NCT02343159|Experimental|Arm 1: Standard MEMS Cap|A standard MEMS cap that records the time and date when the bottle is opened without a visual LCD reader. Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
3032765|NCT02343159|Experimental|Arm 2: Smart MEMS Cap|A smart MEMS cap with feedback (an LCD reader that allows the participant to monitor DMF bottle openings). Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
3032766|NCT02343159|Experimental|Arm 3: Smart MEMS Cap + Counseling|A smart MEMS cap with feedback (an LCD reader that allows the participant to monitor DMF bottle openings) and an adherence counseling intervention. Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
3032767|NCT02343146|Experimental|Type One Training (TOT)|The intervention group will receive the proposed intervention composed of peer parent consultants, telephone and in-person sessions with a trained interventionist, and SMS text messaging aimed at improving child glycemic control through improved nutrition and physical activity.
3032772|NCT02343107|Experimental|1|Subgroup of subjects who benefit of the e-coaching
3032773|NCT02343107|No Intervention|2|Subgroup of subjects who are asked to follow the conventional nutritional recommendations of the treatment of abdominal obesity and diabetes
3032774|NCT02343094|Experimental|PBA 7,5g/d|Treatment for 14 days
3032775|NCT02343094|Experimental|PBA 15g/d|Treatment for 14 days
3032776|NCT02343081|Active Comparator|Temodal|Temozolomide (Schering-Plough) 200 mg/m2, single oral dose.
3032777|NCT02343081|Experimental|Dralitem|Temozolomide (Monte Verde S.A.) 200 mg/m2, single oral dose
3032778|NCT02343055|Experimental|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
3032779|NCT02343055|Placebo Comparator|Usual Care|A Certified Respiratory Educator (CRE) will meet with subjects to obtain a detailed COPD history and do a breathing test. Subjects will receive COPD care as usually provided by their physician.
3032780|NCT02343042|Experimental|1: Selinexor, Low-dose Dexamethasone & Pomalidomide (SPd)|"Pomalidomide will be dosed at 4 mg daily for 21 days per cycle.~Cohort 1.1: Selinexor 80 mg with dexamethasone 40 mg once weekly.~Cohort 1.2: Selinexor 60 mg with dexamethasone 20 mg twice weekly; dexamethasone 40 mg weekly will also be given (without selinexor) on Days 22 & 24."
3032781|NCT02343042|Experimental|2: Selinexor, Low-dose Dexamethasone & Bortezomib (SVd)|"One cycle is either 21 or 35 days (depending on bortezomib dosing schedule).~Cohort 2.1: Selinexor 80 mg with dexamethasone 40 mg once weekly. Bortezomib 1.3 mg/m2 subcutaneous (SC) once weekly.~Cohort 2.2: Selinexor 60 mg with dexamethasone 20 mg twice weekly; dexamethasone 40 mg weekly will also be given on Days 29 and 31. Bortezomib 1.3 mg/m2 SC dosed once weekly."
3032782|NCT02343042|Experimental|3: Selinexor, Low-dose dexamethasone, & Lenalidomide (SRd)|"Lenalidomide at 25mg daily for 21 days per 28 day cycle.~Cohort 3.1: Selinexor 80mg with dexamethasone 40mg once weekly.~Cohort 3.2: Selinexor 60mg with dexamethasone 20mg twice weekly; dexamethasone 40mg weekly will also be given (without selinexor) on Days 22 and 24."
3032783|NCT02343042|Experimental|4:Selinexor,Low-dose dexamethasone,Pomalidomide,Velcade (SPVd)|"Cohort 4.1: Selinexor 100 mg with dexamethasone 40 mg once weekly. Pomalidomide at 4 mg daily for 21 days per 28 day cycle. Bortezomib 1.3 mg/m2 subcutaneous (SC) once weekly.~Cohort 4.2: Selinexor 60 mg with dexamethasone 20 mg twice weekly. Pomalidomide at 4 mg daily for 21 days per 28 day cycle. Bortezomib 1.3 mg/m2 subcutaneous (SC) once weekly.~Note: This arm is not open for enrollment at any institution in this study."
3032784|NCT02343042|Experimental|5: Selinexor, Low-dose dexamethasone, & Daratumumab (SDd)|"Daratumumab at 16 mg/kg IV every week for cycles 1 and 2; then every 2 weeks for cycles 3-6, then once a month for cycles 6 and beyond.~Cohort 5.1: Selinexor 100 mg once weekly, with dexamethasone or equivalent dose of other corticosteroid, given intravenously or by mouth, 40 mg weekly in single or divided doses.~Cohort 5.2: Selinexor 60 mg twice weekly with dexamethasone or equivalent dose of other corticosteroid, given intravenously or by mouth, 40 mg weekly in single or divided doses."
3032785|NCT02343042|Experimental|6: Selinexor, Low-dose Dexamethasone, & Carfilzomib (Skd)|Cohort 6.1: Selinexor 100 mg with dexamethasone 40 mg once weekly. Carfilzomib 56 mg/m2 IV once weekly per 28 day cycle.
3032786|NCT02343042|Experimental|7: Selinexor,Low-dose Dexamethasone,Lenalidomide (SRd) NDMM|Cohort 7.1 in Newly Diagnosed MM: Selinexor 60 mg with dexamethasone 40 mg once weekly. Lenalidomide at 25 mg daily for 21 days per 28 day cycle.
3032787|NCT02343029|Experimental|Intervention|Participants in the Intervention group exercise three times a week for 30 minutes on a bicycle ergometer (optibike med, ergoline GmbH, Bitz, Germany) in the integrated gym hall of one of the participating residencies. Training is individualised as respective performance is adapted to the power at the first ventilator threshold (assessed during cardiopulmonary exercise test).
3032788|NCT02343029|Active Comparator|Waiting Control|Participants of Waiting Control continue their regular physical activity behaviour for 12 weeks. They will start the same exercise intervention after a reassessment at week 12 for the next upcoming 12 weeks. (13-24)
3032789|NCT02343016||Near-InfraRed Spectroscopy (NIRS)|The NIRS Group will be monitored with the interventional system (NIRS) and with the standard one (ecodoppler)
3032790|NCT02343003|Experimental|Cooled radiofrequency|Cooled radiofrequency energy will be delivered to study subjects' knees to ablate culprit sensory nerves and reduce knee pain
3032791|NCT02343003|Active Comparator|Corticosteroid injection|Corticosteroid injections will be administered to study subjects' knees to reduce knee pain
3032792|NCT02342990|Experimental|Cluster B|After the first neuropsychological assessment (T1), children will start CogMed working memory training. Children will be retested (T2) about six or seven weeks later.
3032793|NCT02342990|Other|Cluster A|After the first neuropsychological assessment (T1), children will not start any training. Children will be retested (T2) about six or seven weeks later and will start CogMed working memory training. The group will be again retest (T3) after six or seven weeks after ended training.
3032794|NCT02342977|Placebo Comparator|Placebo|Patient will randomly receive a placebo
3032795|NCT02342977|Experimental|Experimental|Patients will randomly receive experimental drug (lacosamide).
3032796|NCT02342964|Other|MUCO-FIBRO|Measures of hepatic elasticity
3032797|NCT02342951|Other|LCI|Measure of lung clearance index
3032798|NCT02342938|Experimental|Patient|
3032799|NCT02342938|Experimental|Volunteers|
3032800|NCT02342925|Experimental|RG1662 plus metformin|
3032801|NCT02342925|Experimental|metformin alone|
3032802|NCT02342912|Experimental|Social Media Targeted Treatment|Participants randomly assigned to this treatment arm will receive weight loss materials via text messages, Facebook postings, on-line videos, and weekly reports. The topics relate to relate to behavioral and lifestyle changes associated with weight-loss (e.g., nutrition, exercise, social support, and self-monitoring). Calorie and physical activity targets also are set. Participants will receive a suggestion to track diet, physical activity, and weight.
3032868|NCT02342561|Experimental|Intervention knees (Drape side)|One knee of the patient is randomly selected to be drape with an Ioban 2 incision drape.
3032803|NCT02342912|Experimental|Social Media Tailored Treatment|Participants randomly assigned to this treatment arm receive all of the same weight loss materials (as well as weight, calorie, and physical activity targets) as the Targeted group above. Weekly reports will be more personalized to help participants track diet, physical activity, and weight. Additionally, participants will be asked to report on their weight, exercise and calorie goals, and receive feedback.
3032804|NCT02342912|Active Comparator|Social Media Contact Control|Participants randomly assigned to this treatment arm receive health information via text messages, Facebook postings, on-line videos, and weekly reports. Topics relate to having a healthy body weight through a healthy mind, body, and energy. Some topics include stress management, importance of sleep, and importance of accepting one's body. Participants will receive a suggestion to track stress, body image, and energy levels.
3032805|NCT02342899|Active Comparator|Control Goup|Inpatient initiation of noninvasive ventilation.
3032806|NCT02342899|Active Comparator|Intervention Group|Initiated on NIV during an elective outpatient clinic review during which an arterial blood gas measurement will be obtained to confirm the presence of chronic respiratory failure.
3032807|NCT02342886|Experimental|MDR-TB|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg for 26 weeks.
3032808|NCT02342886|Active Comparator|DS-TB (HRZE), HR|"26 consecutive weeks to DS-TB subjects only, as follows:~HRZE Weeks 1-8 with daily dose per the subjects weight~HR Weeks 9 - 26 with daily dose per the subjects weight~Daily dose per the subjects weight as follows: 30-39kg: 2 tablets; 40-54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets."
3032809|NCT02342886|Experimental|DS-TB PA-824 200mg 26 weeks|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once daily for 26 weeks
3032810|NCT02342886|Experimental|DS-TB PA-824 200mg 17 weeks|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once a day for 17 weeks
3032811|NCT02342886|Experimental|DS-TB PA-824 100mg 17 weeks|moxifloxacin 400 mg + PA-824 100 mg + pyrazinamide 1500 mg orally once daily for 17 weeks
3032812|NCT02342873|Active Comparator|NS-guided interscalene block|NS-guided interscalene block is performed using 20 ml of 0.75% ropivacaine.
3032813|NCT02342873|Experimental|US-guided interscalene block|US-guided interscalene block is performed using 20 ml of 0.75% ropivacaine.
3032814|NCT02342860|Experimental|WASH in Schools (WinS) programme|Schools in the intervention group will receive the UNICEF/Department of Foreign Affairs and Trade (DFAT)-supported WinS programme that includes a new water supply, 3 latrines (boys, girls, handicapped), and handwashing facilities. It will also include behavior change education.
3032815|NCT02342860|No Intervention|Control|Schools in the control group will receive no additional WinS programming.
3032816|NCT02342847||Pateints with metastatic pancreatic cancer|"Patients diagnosed with metastatic pancreatic cancer confirmed histologically or cytologically, who will be treated with chemotherapy as first-line treatment of metastatic pancreatic cancer.~This study is designed to observe patients treated in routine clinical practice, without the exclusion limitations of a clinical trial. The decision to treat patients will be performed prior to the decision to include the patient in the study.~The follow-up of patients will be performed according to standard clinical practice of each site"
3032817|NCT02342834|No Intervention|Control|"During the control study, each subject ingest 500 ml of water 30 minutes before a standard 75 g Oral Glucose Tolerance Test"
3032818|NCT02342834|Experimental|Small mixed protein and lipid meal|"During the preload study, each subject ingest a small mixed meal 30 minutes before a standard 75 g Oral Glucose Tolerance Test. The meal is composed by 50 g of parmesan cheese, one small size boiled egg and 300 ml of water (250 kcal, 23 g protein, 17 g fat and 2 g of carbohydrate)."
3032819|NCT02342808|Experimental|Structured center-based lifestyle intervention|The Structured center-based Lifestyle Intervention (C-LIFE) will include individualized plans for the DASH diet, weight management, and aerobic exercise.
3032820|NCT02342808|Experimental|Standard education and physician advice|The Medical Management with Standardized Education and Physician Advice (SEPA) will consist of encouragement to achieve an ideal body weight and engage in exercise as part of routine counseling in primary care, but no special program will be delivered to enhance the participants' ability to comply with these recommendations.
3032821|NCT02342795|Experimental|cigarette substitute|The QuitSmart cigarette substitute is a plastic tube that looks like a real cigarette and is designed to provide the same draw resistance as a smoker's usual cigarette. There is no drug delivery with this product. Two cigarette substitutes and a product manual are provided to participants following randomization and replacement products are provided throughout the intervention period (24 weeks).
3032822|NCT02342795|Experimental|e-cigarette (with 0 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 0 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
3032823|NCT02342795|Experimental|e-cigarette (with 8 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 8 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
3032824|NCT02342795|Experimental|e-cigarette (with 36 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 36 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
3032825|NCT02342782|Experimental|Treatment (yttrium Y 90 basiliximab, BEAM, AHCT)|Patients receive yttrium Y 90 basiliximab IV on days -21 and -14, carmustine IV over 1-2 hours on days -7 and -6, cytarabine IV BID on days -5 to -2, etoposide IV BID on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic stem cell transplant on day 0.
3032826|NCT02342769||Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
3032869|NCT02342561|No Intervention|Control knees (no-drape side)|The knee that is not drape is left uncovered during the intervention.
3032870|NCT02342548|Experimental|20 mg BID PF-02545920 non-titrated|Subjects who received 20 mg BID in completed study A8241021 will continue to receive 20 mg BID PF-02545920
3032827|NCT02342756|Experimental|Group 1: CMV - HFOV|"Patients in group 1 will start with conventional mechanical ventilation with different values of PEEP (A-PEEP so that PLEEO = 0 cmH2O, B- PEEP so that PLEIO = 15 cmH2O, C- PEEP so that PLEEO = 0 cmH2O) and then will be ventilated with high frequency oscillatory ventilation (D- mPaw so that PL = 0 cmH2O, E- mPaw so that PL = 15 cmH2O, F- mPaw so that PL = 0 cmH2O)~Intervention: Device: Targeting transpulmonary pressure to avoid VILI"
3032828|NCT02342756|Experimental|Group 2: HFOV - CMV|"Patients in group 2 will start with high frequency oscillatory ventilation (D- mPaw so that PL = 0 cmH2O, E- mPaw so that PL = 15 cmH2O, F- mPaw so that PL = 0 cmH2O) and then will be ventilated with conventional mechanical ventilation with different values of PEEP (A-PEEP so that PLEEO = 0 cmH2O, B- PEEP so that PLEIO = 15 cmH2O, C- PEEP so that PLEEO = 0 cmH2O).~Intervention: Device: Targeting transpulmonary pressure to avoid VILI"
3032829|NCT02342743|Experimental|Active|Daily trigeminal nerve stimulation session of 20 minutes with CEFALY
3032830|NCT02342730|Experimental|Weight Loss Referral|Patients are referred to a weight loss specialist for assistance with weight loss and medical chart reviews are performed at baseline and every 3 months for 24 months. Patients complete Quality-of-Life Assessment (EORTC- QLQ-C30 and EORTC-QLQ-EN24) at baseline, 12, and 24 months. Patients are also contacted at 90 days to determine whether they have initiated any weight loss interventions.
3032831|NCT02342717|Experimental|Reference|single dose BI 425809
3032832|NCT02342717|Experimental|Test|multiple doses of Itraconazole + single dose BI 425809
3032833|NCT02342704|Experimental|natalizumab|Open-label natalizumab 300 mg IV every 4 weeks (Q4W)
3032834|NCT02342704|Active Comparator|fingolimod|Open-label fingolimod 0.5 mg once daily orally
3032835|NCT02342691|Experimental|BLXA4-ME oral rinse|The topical oral rinse dosage form of BLXA4-ME (also known as ClinRinse-1) will consist of drug substance prepared at a concentration of 1.0 μM in an aqueous vehicle solution
3032836|NCT02342691|Placebo Comparator|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
3032837|NCT02342691|No Intervention|No Rinse Control|The no-rinse control group will use no oral rinse, in order to assess the effect of the rinsing action independent of the active ingredients
3032838|NCT02342678|Experimental|Yoga Therapy Group|Participants will take part in twice weekly group yoga classes focusing on selected Iyengar-based yoga techniques as well as practice study-specific yoga techniques at home for at least one hour per week for a total of 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing yoga exercises for at least an hour per week.
3032839|NCT02342678|Experimental|Physical Conditioning Group|Patricipants will take part in twice weekly group physical conditioning classes and practice stretching exercises at least one hour per week at home for 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing stretching exercises for at least an hour per week.
3032840|NCT02342665|Experimental|Copanlisib (BAY80-6946)|Dose escalation/safety evaluation cohort and objective tumor response (OR) expansion cohort
3032841|NCT02342652|Experimental|ASLAN003|Substance: ASLAN003 Administration route: Oral. Dosage form: Hard gelatine 50 mg capsules. Frequency: 100 mg (2 capsules) once daily for 14 consecutive days
3032842|NCT02342652|Placebo Comparator|Matched Placebo|Substance: Placebo Administration route: Oral Dosage form: Hard gelatine capsules Frequency: 2 capsules once daily for 14 consecutive days
3032843|NCT02342639|Experimental|Rifaximin|Participants will receive a 10-day course of Rifaximin.
3032844|NCT02342639|Placebo Comparator|Placebo|Participants will receive a 10-day course of placebo.
3032845|NCT02342626|No Intervention|Control|No use of the decision aid dashboard before, during or after the treatment decision time period.
3032846|NCT02342626|Experimental|Dashboard|Use of the decision aid dashboard before, during and after the treatment decision time period.
3032847|NCT02342613|Experimental|MILs treatment|Patients treated with the activated PTCy-MILs
3032848|NCT02342600|Experimental|Trametinib with Pazopanib|Participants will take pazopanib (800mg) and trametinib (2mg) by mouth daily for a 28 day cycle.
3032849|NCT02342587|Experimental|single arm|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
3032850|NCT02342574|Experimental|A active|Six subjects receiving F901318 1.5 mg/kg intravenously for eight days
3032851|NCT02342574|Placebo Comparator|A placebo|Two subjects receiving F901318 placebo intravenously for eight days
3032852|NCT02342574|Experimental|B active|Six subjects receiving F901318 3 mg/kg intravenously for eight days
3032853|NCT02342574|Placebo Comparator|B placebo|Two subjects receiving F901318 placebo intravenously for eight days
3032854|NCT02342574|Experimental|C active|Six subjects receiving F901318 4 mg/kg intravenously for eight days
3032855|NCT02342574|Placebo Comparator|C placebo|Two subjects receiving F901318 placebo intravenously for eight days
3032856|NCT02342574|Experimental|D1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
3032857|NCT02342574|Placebo Comparator|D1 placebo|Two subjects receiving F901318 placebo intravenously for one day
3032858|NCT02342574|Experimental|E1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
3032859|NCT02342574|Placebo Comparator|E1 placebo|Two subjects receiving F901318 placebo intravenously for one day
3032860|NCT02342574|Experimental|F1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
3032861|NCT02342574|Placebo Comparator|F1 placebo|Two subjects receiving F901318 placebo intravenously for one day
3032862|NCT02342574|Experimental|D2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
3032863|NCT02342574|Placebo Comparator|D2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
3032864|NCT02342574|Experimental|E2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
3032865|NCT02342574|Placebo Comparator|E2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
3032866|NCT02342574|Experimental|F2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
3032867|NCT02342574|Placebo Comparator|F2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
3058780|NCT02170012|Experimental|Cohort 1-PF-06743649 or placebo|
3032871|NCT02342548|Experimental|20mg BID PF-02545920 titrated|Subjects who received either Placebo or 5mg BID of PF-02545920 in completed study A8241021 will be titrated up to 20 mg with 5mg increment per week, over 4 weeks (5mg increment/wk)
3032872|NCT02342535|Other|Physical activity intervention|"Participants will attend bi weekly exercise classes for a total of 16 weeks, led by certified, and trained instructors.~The participant's children between the ages of 6 and 14 years will participate in the martial arts class with the mothers."
3032873|NCT02342522|Active Comparator|Remote ischemic conditioning|AutoRIC device will be placed on the upper arm and an active RIC protocol will be delivered (4x5 min cycles of inflation to 200mmHg and deflation) prior to PPCI.
3032874|NCT02342522|Sham Comparator|Sham control|Sham AutoRIC device will be placed on the upper arm and a sham RIC protocol will be delivered prior to PPCI.
3032875|NCT02342509|Experimental|Desflurane|Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
3032876|NCT02342509|Experimental|Sevoflurane|Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
3032877|NCT02342509|Active Comparator|Isoflurane|Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
3032878|NCT02342496|Placebo Comparator|Placebo|Powder consisting of maltodextrine, treated to resemble the Active product in appearance and taste.
3032879|NCT02342496|Active Comparator|Active, only probiotics|Powder consisting of freezedried bacteria at 10 billions cfu/daily dose and maltodextrine, treated to resemble the Active product in appearance and taste.
3032880|NCT02342496|Active Comparator|Active, blend of berries and probiotics|Powder consisting of freezedried berries , probiotics at 10 billions cfu/daily dose and maltodextrine.
3032881|NCT02342483|Active Comparator|1g|METHYLSULFONYLMETHANE
3032882|NCT02342483|Active Comparator|3g|METHYLSULFONYLMETHANE
3032883|NCT02342483|Active Comparator|6g|METHYLSULFONYLMETHANE
3032884|NCT02342470|Placebo Comparator|Placebo|Placebo Comparator / Bid
3032885|NCT02342470|Experimental|PMK-S005 1|Total 50mg, by mouth, bid
3032886|NCT02342470|Experimental|PMK-S005 2|Total 100mg, by mouth, bid
3032887|NCT02342470|Experimental|PMK-S005 3|Total 150mg, by mouth, bid
3032888|NCT02342457|Experimental|Child suspected of Hirschsprung disease|Children admitted for biopsy, so that Hirschsprungs desease may be ruled out or diagnosed, whom are planned for rectal biopsy, by clinical decision.
3032889|NCT02342444|Active Comparator|Enoxaparin Sodium Injection 30 mg BID|Subjects are randomized to receive 30 mg twice daily of enoxaparin.
3032890|NCT02342444|Active Comparator|Enoxaparin Sodium Injection 40 mg QD|Subjects are randomized to receive 40 mg once daily of enoxaparin.
3032891|NCT02342431|Active Comparator|Forced air compressible warming|Warming with a compressible forced air mattress
3032892|NCT02342431|Experimental|Forced air non-compressible|Warming with a non-compressible forced air mattress
3032893|NCT02342418|Active Comparator|Morbidly obese|The morbidly obese (BMI ≥ 40 kg/m2) arm will be recruited first. Each morbidly obese subject will be matched to a non-obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
3032894|NCT02342418|Active Comparator|Non-obese|Each non-obese subject will be matched to a morbidly obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
3032895|NCT02342405|Placebo Comparator|30% oxygen|Inhalation of 30% oxygen
3032896|NCT02342405|Experimental|80% oxygen|Inhalation of 80% oxygen
3032897|NCT02342392|Active Comparator|treatment group|intralesional ranibizumab injected
3032898|NCT02342392|No Intervention|control group|no intralesional ranibizumab injected.
3032899|NCT02342379|Experimental|Bevacizumab and TH-302|Patients will be treated with combination of bevacizumab and TH-302.
3032900|NCT02342366|Placebo Comparator|Placebo|Placebo
3032901|NCT02342366|Experimental|GHB|GHB, Gamma-Hydroxybutyrate, two doses (20 and 35 mg/kg p.o.)
3032902|NCT02342353|Experimental|Phase I (pacritinib and erlotinib)|"Pacritinib will be administered orally twice a day; dosing will depend on the dose level the patient is enrolled.~Erlotinib will be taken by mouth on an outpatient basis daily at a dose of 150 mg.~A 28-day interval is defined as a cycle"
3032903|NCT02342353|Experimental|Phase II (pacritinib and erlotinib)|"Pacritinib will be administered orally twice a day; the dose used will be the dose determined to be the MTD in phase I.~Erlotinib will be taken by mouth on an outpatient basis daily at a dose of 150 mg.~A 28-day interval is defined as a cycle"
3032904|NCT02342340|Active Comparator|Navy Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked navy beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
3032905|NCT02342340|Active Comparator|Red Kidney Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked red kidney beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
3032936|NCT02342171|No Intervention|standard care|The control arm will consist of historical controls having being treated with standard of care
3032937|NCT02342158|Experimental|Locally advanced /metastatic cancer|
3032938|NCT02342145|Active Comparator|group A|The patients were used cycloaporine A:2mg/kg combined with methotrexate 15mg/m2 +1d，10mg/m2 +3,+6,+11d,mycophenolate mofetil: 0.25g/d, -1d to 90d and basiliximab: 10mg each time, 0d and +4 d for prevention of graft-versus-host-disease.
3032906|NCT02342340|Active Comparator|Pinto Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked pinto beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
3032907|NCT02342340|Active Comparator|Black Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked navy beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
3032908|NCT02342340|Active Comparator|Lentils (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked lentils. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
3032909|NCT02342340|Placebo Comparator|White Rice (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked white rice. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
3032910|NCT02342327|Other|Continue smoking menthol cigarettes|Menthol cigarette smokers continue to smoke menthol cigarettes for a four week period before attempting to quit smoking
3032911|NCT02342327|Other|Switch to non-menthol cigarettes|Menthol cigarette smokers switch to non-menthol cigarettes for a four week period before attempting to quit smoking
3032912|NCT02342314|Experimental|LY3143753 (Part A)|Single subcutaneous (SC) injection of ascending doses of LY3143753 on Day 1
3032913|NCT02342314|Experimental|LY3185643 (Part B)|Single SC injection of ascending doses of LY3185643 on Day 1
3032914|NCT02342314|Placebo Comparator|Normal Saline|Single SC injection of normal saline on Day 1.
3032915|NCT02342301|Experimental|Standing Desk|Will use standing desk for 3 months
3032916|NCT02342301|Active Comparator|Traditional Desk|Will use traditional desk for 3 months
3032917|NCT02342288|Experimental|Head raised 10 degrees|Head raised 10 degrees from neutral position using Gardner Wells tongs
3032918|NCT02342288|Active Comparator|Head in neutral position|Head in neutral position
3032919|NCT02342275|Active Comparator|Propranolol|Propranolol
3032920|NCT02342275|Active Comparator|Atenolol|Atenolol
3032921|NCT02342262|Experimental|Probiotics|EcologicBarrier, 5x10E9 cfu/day
3032922|NCT02342262|Placebo Comparator|Placebo|carrier material of Ecologic Barrier, not containing bacterial strains
3032923|NCT02342249|Placebo Comparator|VX-787 Placebo BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of matching placebo of VX-787 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
3032924|NCT02342249|Active Comparator|VX-787 300 mg BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of VX-787 300 milligram (mg) tablet along with matching placebo of Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
3032925|NCT02342249|Active Comparator|VX-787 600 mg BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of VX-787 600 mg (2*300 mg tablets) along with matching placebo of Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
3032926|NCT02342249|Active Comparator|VX-787 600 mg BID + Oseltamivir 75 mg BID|Subjects will receive 10 doses of VX-787 600 mg tablets (2*300 mg tablets) along with 75 mg Oseltamivir capsule twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
3032927|NCT02342236|Other|cemented|Primary hip arthroplasty with bone cement use.
3032928|NCT02342236|Other|cementless|Primary hip arthroplasty without bone cement use.
3032929|NCT02342223|Experimental|Voluma|"Subjects will be screened for severity on their HIV facial lipoatrophy according to the Carruthers Lipoatrophy Severity Scale (CLSS), and will receive subcutaneous injections of Voluma in the affected facial areas with the 'smile and fill' technique (Jagdeo 2014) based on Carruthers scoring scale.~Subjects with Carruthers Score level 2 will receive total of 2-6 syringes of Voluma.~Subjects with Carruthers Score level 3 will receive total of 4-8 syringes of Voluma.~Subjects with Carruthers Score level 4 will receive total of 6-12 syringes of Voluma.~All subjects will receive one Voluma treatment at initial time = 0 and may be eligible for touchup treatment, if necessary, at 2 weeks post-initial treatment."
3032930|NCT02342210|Other|Group-A - Immediate Intervention|Immediate Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
3032931|NCT02342210|Other|Group-B - Delayed Intervention|3 month treatment as usual waitlist followed by Mindfulness Ambassador Council for Early Psychosis (MAC-EP).
3032932|NCT02342197|Active Comparator|Minidose long protocol|Half dose of GnRH agonist (Decapeptyl 0.05) was started in the midluteal phase and Gn's was started from the second day of the cycle.
3032933|NCT02342197|Active Comparator|Microdose flare protocol|Half the dose of GnRH agonist (Decapeptyl 0.05) was started on the second day of the cycle together with Gn's
3032934|NCT02342184|Experimental|GB-0998|
3032935|NCT02342171|Experimental|Convalescent Plasma|Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children <45kg
3032939|NCT02342145|Experimental|group B|The patients were used cyclosporine A 2mg/kg,methotrexate,15mg/m2 +1d，10mg/m2 +3,+6,+11d,mycophenolate mofetil: 0.25g/d, -1d to 90d for prevention of graft-versus-host-disease.
3032940|NCT02342132|Experimental|Respiratoy Therapy Devices|Non-Invasive Bipap Ventilator, Mechanical Insufflator-Exsufflator, and High Frequency Percussive Oscillator are the three respiratory therapy devices that all participants will be using in a random order, in three consecutive days, one device per day.
3032941|NCT02342119|Experimental|KTFT+TALK|Patients who are being evaluated for a kidney transplantation via Kidney Transplant Fast Track and who are receiving the Talking About Living Kidney Donation intervention
3032942|NCT02342119|Active Comparator|KTFT+No TALK|Patients who are being evaluated for a kidney transplantation via Kidney Transplant Fast Track and who are not receiving the Talking About Living Kidney Donation intervention
3032943|NCT02342106||Poor responders|In order to define the poor response in IVF, at least two of the following three features must be present: (i) advanced maternal age or any other risk factor for poor ovarian response; (ii) a previous poor ovarian response; and (iii) an abnormal ovarian reserve test . Two episodes of poor ovarian response after maximal stimulation are sufficient to define a patient as poor responder in the absence of advanced maternal age or abnormal ovarian reserve test. By definition, the term poor ovarian response refers to the ovarian response, and therefore, one stimulated cycle is considered essential for the diagnosis .
3032944|NCT02342106||Good responders|"Total number of antral follicles : 22-35 Normal (good) antral count, should have an excellent response to ovarian stimulation.Likely to respond well to low doses of FSH drugs.~Very low risk for IVF cycle cancellation. Some risk for ovarian overstimulation if a Lupron trigger is not used for final egg maturation injection.~Excellent pregnancy success rates."
3032945|NCT02342093|Active Comparator|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
3032946|NCT02342093|Active Comparator|20EE+DRSP|Combined oral contraceptive containing 20 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
3032947|NCT02342080|Experimental|Interventional group|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period. For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
3032948|NCT02342067|Experimental|Group 1 (Cenicriviroc, PGZ, CVC+PGZ)|Treatment A: CVC 150 mg QD for 10 days followed by 10-day washout Treatment B: PGZ 45 mg QD for 10 days Treatment C: co-administration of PGZ 45 mg QD + CVC 150 mg QD for 10 days
3032949|NCT02342067|Experimental|Group 2 (Pioglitazone, CVC, CVC+PGZ)|Treatment B: PGZ 45 mg QD for 10 days followed by 10-day washout Treatment A: CVC 150 mg QD for 10 days Treatment C: co-administration of CVC 150 mg QD + PGZ 45 mg QD for 10 days
3032950|NCT02342054|Experimental|MRI-TRUS fusion guided Single Frac HDR|Patients treated with a Single Fraction Real-Time High-Dose-Rate (HDR 19Gy)
3032951|NCT02342041|Placebo Comparator|Single ascending dose|Single dose of SUVN-G3031or placebo in healthy male subjects
3032952|NCT02342041|Placebo Comparator|Multiple ascending dose|Multiple doses of SUVN-G3031 or placebo in healthy male subjects
3032953|NCT02342028||OSA|"The study group enrolled patients with OSA, fulfilling the following requirements~20~60 years ago, female or males~Agree participate the study and sign informed consent~Has not received any treatment for OSA~No obvious comorbidities (including autoimmune diseases)~No history of sarcoidosis and tuberculosis~No use of steroid and immunosuppressant"
3032954|NCT02342028||Control|"The control group enrolled age-, gender- and BMI-matched individuals without OSA, fulfilling the following requirements~20~60 years ago, female or males~Agree participate the study and sign informed consent~No obvious comorbidities (including autoimmune diseases)~No history of sarcoidosis and tuberculosis~No use of steroid and immunosuppressant"
3032955|NCT02342015|Experimental|Atorvastatin|Atorvastatin 40 mg/day for three months
3032956|NCT02342002|Experimental|Mifepristone-misoprostol regimen|After a woman is determined eligible and signs the informed consent document, she will receive 200 mg mifepristone and advised to swallow the pill when they arrive at home. 24 hours after administration of the mifepristone, women will administer the four tablets of 200 mcg misoprostol sublingually.
3032957|NCT02342002|Placebo Comparator|Misoprostol alone regimen|After a woman is determined eligible and signs the informed consent document, she will receive a placebo (of same shape and size of mifepristone) and advised to swallow the pill when they arrive at home. 24 hours after administration of the mifepristone, women will administer the four tablets of 200 mcg misoprostol sublingually.
3032958|NCT02341989|Experimental|Bleomycin-Etoposide-Cisplatin|One course of adjuvant BEP.
3032959|NCT02341989|Active Comparator|Carboplatin|One course of adjuvant carboplatin AUC7
3032960|NCT02341976|Other|Vibratory platform exercises|Vibratory platform exercises: different positions on a vibratory platform in different frequencies
3032961|NCT02341963|Experimental|Oral Ketamine|Subjects will receive Oral Ketamine (1.0 mg/kg) ) presurgery and 3 days postsurgery (including surgery day).
3032962|NCT02341950|Experimental|SCI Hard|This arm plays the SCI HARD game
3032963|NCT02341950|No Intervention|Control|Plays an alternate, publicly available game
3032964|NCT02341924|Experimental|Portfolio of functional foods|"A portfolio of functional foods provided as packaged shelf-stable food products (Step One Treatment) which will include foods such as oatmeal, pancakes, cranberry bars, chocolate bars, smoothies, and a sprinkle offering which can be added to almost any food to enhance its nutritional impact.~All products are interchangeable in terms of their nutrients of interest and contain a minimum of 5 g of fibre, 1800 mg of omega-3 fatty acids, 1000 mg of phytosterols and 1800 µmol antioxidants per serving. Calorie counts range from 110-190 kcal per serving."
3032965|NCT02341924|Placebo Comparator|Control foods|Control products will be like-items drawn from the general grocery marketplace. Test and control products will be packaged and coded identically.
3032966|NCT02341911|Experimental|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin combination)
3032967|NCT02341911|Active Comparator|Gemcitabine,carboplatin|GC (gemcitabine and carboplatin combination)
3032968|NCT02341898|Experimental|Updated original programme|Educational programme for all nurses (90 min. single information session); training and structured support for nominated key nurses (one-day training workshop); provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives); supportive material (poster, mugs etc.)
3032969|NCT02341898|Experimental|Concise updated programme|Training and structured support for nominated key nurses (one-day training workshop); nurses' training will be carried out by key nurses as facultative option; key nurses receive an additional train-the-trainer module to apply the educational programme; provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives); supportive material (poster, mugs etc.)
3032970|NCT02341898|Active Comparator|Optimized usual care|Provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives) only
3032971|NCT02341885||One Group|This is an observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
3032972|NCT02341872|No Intervention|Control|The investigators won't do any application , the oral hygiene konwledge will be given only.
3032973|NCT02341872|Active Comparator|Fluoride + Calcium varnish|The investigators will do fluoride+ calcium varnish( Clinpro White Varnish) application on white spot lesions.
3032974|NCT02341872|Experimental|Polipeptide solution|The investigators will do polipeptide ( Curodont Repair) solution application on white spot lesions.
3032975|NCT02341872|Experimental|Fluoride + calcium + polipeptide|The investigators will do polipeptide ( Curodont Repair) solution and fluoride + calcium varnish (Clinpro White Varnish) application on white spot lesions.
3032976|NCT02341859|Active Comparator|stenfilcon A and delefilcon A|Participants randomized wear the stenfilcon A and the delefilcon A contralaterally.
3032977|NCT02341859|Active Comparator|stenfilcon A and narafilcon A|Participants randomized wear the stenfilcon A and the narafilcon A contralaterally
3032978|NCT02341846||Patients with cancer pain|Qualitative semi-structured interviews with patients who have experienced cancer pain
3032979|NCT02341846||Caregivers for those with cancer pain|Qualitative semi-structured interviews with caregivers who have cared for those who have experienced cancer pain.
3032980|NCT02341846||Healthcare professionals|Healthcare professionals whose role involves the management of cancer pain.
3032981|NCT02341833|Active Comparator|Sevoflurane|1 MAC of sevoflurane for 15 minutes before organs procurement.
3032982|NCT02341833|No Intervention|No intervention|No volatile anesthetics during organs procurement
3032983|NCT02341807|Experimental|Dose Group 1|Single, unilateral administration of a single low dose range of AAV2-hCHM.
3032984|NCT02341807|Experimental|Dose Group 2|Single, unilateral administration of a single high dose range of AAV2-hCHM.
3032985|NCT02341794|Experimental|Rosuvastatin|
3032986|NCT02341781||Relapsed,Progressed,Refractory or Intolerant to ibrutinib|MCL subjects who received lenalidomide after having relapsed or progressed on ibrutinib treatment or were refractory or intolerant to ibrutinib treatment
3032987|NCT02341742||Patients|follow up of patients (children and adolescent) with inflammatory bowel disease in looking for the relationship between the bone mineral density and physical activity.
3032988|NCT02341729|Other|starting with ticagrelor|"Patients, after CPR because of an ACS, will receive 2 crushed tablets of ticagrelor (180mg) through a gastric tube. After this dose twice a day 90mg is given for the duration of 1 year. The 1st blood sample is taken before administration. In total 10 blood samples are taken for determination of platelet aggregation and plasma concentrations.~When patients receive a semi-urgent CABG, ticagrelor has been interrupted for 3 days. Postoperative the patients get crushed tablets of ticagrelor, the 1st dose will be 90mg, and every 12h 90mg is given, for the duration of 1 year. The 1st blood sample is taken before the 1st dose. In total 9 blood samples are taken for determination of platelet aggregation and plasma concentrations."
3032989|NCT02341716|Active Comparator|Walk advice|All WA patients receive best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and are recommended outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The WA patients are unsupervised during the study period and are followed by a blinded observer at baseline, three, six and 12 months.
3032990|NCT02341716|Active Comparator|Hospital-based supervised exercise|All SET patients receive the same basic treatment as WA patients: best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and recommendation of outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The SET group in addition receives three times weekly during six months in-hospital muscle exercise therapy in a group supervised by a physiotherapist. After the six months of supervised exercise therapy, the SET patients are recommended to continue the same muscle exercise therapy at home, but without feedback, between seven and 12 months.
3032991|NCT02341716|Active Comparator|Home-based supervised exercise|All HET patients receive the same basic treatment as WA patients: best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and recommendation of outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The HET group patients in addition perform the same muscle exercise therapy three times weekly during six months as the SET patients, but in their homes, and are supervised and given feedback by phone calls every 14th day by a physiotherapist. After six months of supervised exercise therapy, the HET patients are recommended to continue the same muscle exercise therapy, but without feedback, between seven and 12 months.
3032992|NCT02341703|Active Comparator|letrozole-metformin group|"this group will receive letrozole 2.5 mg daily from day 3 of the cycle and for 5 days + metformin 500 mg three times daily from the first day of the cycle and continuous for three months unless pregnancy occurred. treatment will continue for 3 cycles unless pregnancy occurred.~for this group: transvaginal ultrasound will monitor follicular enlargement laboratory investigations in the form of day 3 FSH, LH, TSH and serum testosterone will be done day 12 E2 day 21 serum progesterone"
3033031|NCT02341586|Active Comparator|18 mg iron|This group will receive a daily oral iron supplement.
3033032|NCT02341586|Other|Control group|This group will receive nutrition education
3033200|NCT02340338|Experimental|Dose Group 1|Treatment: rTSST-1 Variant Candidate Vaccine 100 ng
3032993|NCT02341703|Active Comparator|letrozole-metformin-pioglitazone group|"this group will receive letrozole 2.5 mg daily from day 3 of the cycle and for 5 days + (metformin 850 mg + pioglitazone 15 mg) once daily from the first day of the cycle and for 10 days. treatment will continue for 3 cycles unless pregnancy occurred.~for this group: transvaginal ultrasound will monitor follicular enlargement laboratory investigations in the form of day 3 FSH, LH, TSH and serum testosterone will be done day 12 E2 day 21 serum progesterone"
3032994|NCT02341690|Active Comparator|Control|Standard rehabilitation with exercise
3032995|NCT02341690|Experimental|Intervention (Interval Walking Training)|"Interval Walking Training with the InterWalk app, 3 times per week, 60 min. per sessions for 52 weeks. The intervention period is divided into~a period that follows standard care in the municipality (from 8-14 weeks according to the municipality.~a period (from week 8-14 to week 52) the patients will do Interval Walking on their own.~After the intervention at the promotion centre (8-14 weeks), the intervention group will be divided into to groups - a Interval Walking group (IWT) and a Interval Walking group with support (IWTsupport).~IWTsupport: Patients in this group (after intervention at the promotion centre) will in addition to the IWT receive motivational support from week 8-14 to week 52 by the health professionals at the promotion centre."
3032996|NCT02341677|Experimental|Biopsy|Single Arm Study. Biopsy Intervention.
3032997|NCT02341651|Experimental|"Multicomponent combination"|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
3032998|NCT02341651|No Intervention|Usual Care|No active intervention
3032999|NCT02341638|Experimental|Part A Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
3033000|NCT02341638|Experimental|Part A Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
3033001|NCT02341638|Experimental|Part A Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
3033002|NCT02341638|Experimental|Part A Panel 4: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
3033003|NCT02341638|Experimental|Part A Panel 5: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
3033004|NCT02341638|Experimental|Part A Panel 6: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
3033005|NCT02341638|Experimental|Part A Panel 7: BMS-986141|Single dose by mouth as specified
3033006|NCT02341638|Experimental|Part A Panel 8: BMS-986141|Single dose by mouth as specified
3033007|NCT02341638|Experimental|Part B Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
3033008|NCT02341638|Experimental|Part B Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
3033009|NCT02341638|Experimental|Part B Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
3033010|NCT02341638|Experimental|Part C Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
3033011|NCT02341638|Experimental|Part C Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
3033012|NCT02341638|Experimental|Part C Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
3033013|NCT02341638|Experimental|Part D Panel 1: BMS-986141 and Aspirin|BMS-986141 and Aspirin by mouth as specified
3033014|NCT02341638|Placebo Comparator|Part D Panel 1: Placebo matching BMS-986141 and Aspirin|BMS-986141 placebo and Aspirin by mouth as specified
3033015|NCT02341638|Experimental|Part E Panel 1: BMS-986141 and Itraconazole|BMS-986141 and Itraconazole by mouth as specified
3033016|NCT02341625|Experimental|Part 1: Ascending dose of BMS-986148|BMS-986148 Intravenous injection at increasing doses on specific days until the maximum tolerated dose is reached. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer. Alternate dose and schedules may be explored.
3033017|NCT02341625|Experimental|Part 2: Expansion dose of BMS-986148|BMS-986148 Intravenous injection of Maximum tolerated dose (MTD) on specific days. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
3033018|NCT02341625|Experimental|Part 3A: Ascending dose of BMS-986148|Set dose of nivolumab and BMS-986148 intravenous injection at increasing doses on specific days until the maximum tolerated dose is reached. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
3033019|NCT02341625|Experimental|Part 3B: Expansion dose of BMS-986148|Set dose of nivolumab and BMS-986148 intravenous injection at or below maximum tolerated dose on specific days. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
3033020|NCT02341612|Experimental|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion (CWI) immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
3033021|NCT02341612|Experimental|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
3033022|NCT02341612|Experimental|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
3033023|NCT02341612|Experimental|whole body criotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
3033024|NCT02341612|Experimental|passive recovery|The control group was not exposed to treatment after the EIMD protocol.
3033025|NCT02341599|Experimental|Group A|Healthy subjects with normal renal function (Stage 1, eGFR ≥90 mL/min/1.73m2 )
3033026|NCT02341599|Experimental|Group B|Subjects with mild renal impairment (Stage 2, eGFR ≥60- <90 mL/min/1.73m2)
3033027|NCT02341599|Experimental|Group C|Subjects with moderate renal impairment (Stage 3, eGFR ≥30- <60 mL/min/1.73m2)
3033028|NCT02341599|Experimental|Group D|Subjects with severe renal impairment (Stage 4, eGFR <30 mL/min/1.73m2) not receiving dialysis
3033029|NCT02341599|Experimental|Group E|Subjects with ESRD receiving HD for at least three months preceding the initial dose in this study (Stage 5)
3033030|NCT02341586|Experimental|Lucky Iron Fish|This group will receive a Lucky Iron Fish to use during cooking.
3033033|NCT02341573|Experimental|chinese medicine group|Children of chinese medicine group will be treated with experienced chinese herbal formula based on different stages and different symptoms.Patients at the acute stage of asthma will be given Shegan mixture ,at the remission stage, will be treated with Huangqi Bushen mixture-based formulation with modification according to their symptoms,10-30 mL , 2 times a day, for 3 months.
3033034|NCT02341573|Active Comparator|western medicine group|Children of western medicine group will be treated with leukotriene receptor antagonist and a bronchial relaxant.Children at the acute stage of asthma will be treated with etinoline,twice a day for 7 days.At the remission stage, they will be given leukotriene receptor antagonist Singulair, once daily for 3 months.
3033035|NCT02341560|Active Comparator|single dose or multiple dose|QPI-1007 Injection - 1.5 mg
3033036|NCT02341560|Active Comparator|single or multiple dose|QPI-1007 Injection - 3.0 mg
3033037|NCT02341560|Sham Comparator|Sham|Sham injection procedure
3033038|NCT02341534|Other|BioMonitor arm|BioMonitor group (standard of care and implantation with investigational device)
3033039|NCT02341534|No Intervention|Control arm|Control group (standard of care)
3033040|NCT02341521|Experimental|OC000459 50 mg|OC000459 50 mg daily for 8 days
3033041|NCT02341508|Experimental|Lpathomab|0.5 mg/kg Lpathomab, 1.0 mg/kg Lpathomab, 3.0 mg/kg Lpathomab, 10 mg/kg Lpathomab, 20 mg/kg Lpathomab,
3033042|NCT02341508|Placebo Comparator|Placebo|Saline solution for intravenous infusion
3033043|NCT02341495|Experimental|Drug Treatment|Deferasirox (20mg/kg/day)on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Cholecalciferol(4,000 units/day), on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol, repeated every four weeks for 8 cycles given either subcutaneously or IV
3033044|NCT02341482|Experimental|PF-04958242 and itraconazole|PF-04958242 with and without itraconazole
3033045|NCT02341469|No Intervention|Standard-of-care|
3033046|NCT02341469|Experimental|integrated ediagnostic approach|
3033047|NCT02341456|Experimental|AZD1775|AZD1775 will be administered orally as a single dose on Day 1 Cycle 0. Following a 5±2 days washout period, AZD1775 (5 doses BID over 2.5 days) will be taken in combination with paclitaxel and carboplatin in each 21-day cycle for 6 cycles. Following 6 cycles of combination treatment, patients may continue on AZD1775 monotherapy (5 doses BID Day 1 to Day 2.5 in each 21-day cycle) at the investigator's discretion.
3033048|NCT02341456|Experimental|Paclitaxel|Commercially available paclitaxel will be administered at a dosage of 175 mg/m2 as a 3-hour IV infusion on Cycle Day 1 of a 21-day cycle for 6 cycles.
3033049|NCT02341456|Experimental|Carboplatin|Following the paclitaxel infusion, carboplatin will be administered at a dose of AUC 5 as an IV infusion on Cycle Day 1 of a 21-day cycle for 6 cycles. According to the Cancer Therapy Evaluation Program Information Letter Regarding the AUC Based Dosing of Carboplatin, the maximum carboplatin dose should not exceed the target AUC (mg*min/mL)*150 mL/min, but it may be less (Ivy et al 2010). For this study, the maximum dose of carboplatin cannot exceed a total dose of 750 mg.
3033050|NCT02341443|Experimental|Rigid|Surgery using mandibulo-maxillary fixation, implants providing rigid fixation on most anterior fracture and non-rigid fixation on the most posterior fracture.
3033051|NCT02341443|Active Comparator|Non-rigid|Surgery using mandibulo-maxillary fixation and implants providing non-rigid fixation on both fracture sides.
3033052|NCT02341417|Experimental|Cinacalcet|"Participants received cinacalcet daily for 24 weeks in this extension study. For participants who received standard of care (SOC) in parent study 20130356, the starting dose was 0.20 mg/kg/day. For participants who received SOC and cinacalcet in parent study 20130356 or 20110100 the starting dose was either the same as the last dose received in the parent study or 0.20 mg/kg/day if the last dose of cinacalcet in the parent study was received > 14 days before day 1 of this study.~Dose adjustments and withholding were based on weekly assessments of ionized calcium as well as plasma intact parathyroid hormone (iPTH) and corrected serum calcium levels assessed monthly."
3033053|NCT02341404|Experimental|Liproca Depot|A parenteral controlled release depot formulation of 2-hydroxyflutamide (2-HOF) is given as a single dose injection into the prostate gland within the lobe area where the tumour tissue is localized.
3033054|NCT02341391|Experimental|TissueGene-C(Low dose)|Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10^6 cells
3033055|NCT02341391|Experimental|TissueGene-C(Medium dose)|Single intra-articular injection to the damaged knee joint at doses of 1.0 x 10^7 cells
3033056|NCT02341391|Experimental|TissueGene-C(High dose)|Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10^7 cells
3033057|NCT02341378|Experimental|TissueGene-C (Low dose)|Single intra-articular injection to the damaged knee joint at a dose of 6.0 x 10^6 cells
3033058|NCT02341378|Experimental|TissueGene-C (High dose)|Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10^7 cells
3033059|NCT02341352|No Intervention|Control|Only behavioral education for Caregiver
3033060|NCT02341352|Experimental|fluoride varnish|fluoride varnish every 6 months
3033061|NCT02341352|Experimental|ImmunoglobulinY|anti-S.mutans Immunoglobulin yolk for everyday use
3033062|NCT02341352|Experimental|Probiotics|Probiotics use for 1 months
3033063|NCT02341339|Experimental|Fallopian Tube Co-culture|fallopian tube biopsy for co-culture of embryos
3033064|NCT02341326||Healthy nonsmokers|"n=20 for Aim 1 n=20 for Aim 2~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 2.To test the hypothesis that FGFR2 signaling is necessary for normal SAE BC stem cell function and suppression of FGFR2 caused by inhibitors and smoking associated factors (EGF and TGF- beta)leads an altered stem cell functional phenotype similar to SAE BC from COPD smokers with reduced capacity as characterized by Aim 1."
3033065|NCT02341326||Healthy smokers|"n=20- for Aim 1 n=20 for Aim 3~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 3.To assess the hypothesis that increasing FGFR2 signaling and suppressing smoking induced EGF receptors and TGF-beta pathways will restore the FGFR2 expression and normalize the capacity of SAE BC stem cells to generate and maintain normally differentiated SAE."
3033066|NCT02341326||COPD smokers|"n=20- for Aim 1 n=20 for Aim 3~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 3.To assess the hypothesis that increasing FGFR2 signaling and suppressing smoking induced EGF receptors and TGF-beta pathways will restore the FGFR2 expression and normalize the capacity of SAE BC stem cells to generate and maintain normally differentiated SAE."
3033067|NCT02341313||Newborns at risk of hypoglycaemia|Measurement of ketones
3033068|NCT02341300|Experimental|Cast-Iron Pot|The treatment arm will receive a 12 inch pre seasoned cast iron pot
3033069|NCT02341300|Placebo Comparator|Aluminum Pot|12 inch nonstick aluminum fry pan
3033070|NCT02341287|Active Comparator|Warming hydrogel glove|"Patients will wear a warming hydrogel glove in the second two week period. Also a actigraph to monitor sleep latency.~Warming hydrogel device"
3033071|NCT02341287|Placebo Comparator|Non thermal hydrogel glove|"Patients will wear a hydrogel glove in the second two week period. Also a actigraph to monitor sleep latency.~Non thermal hydrogel device"
3033072|NCT02341274|Active Comparator|Fresh Brand Name Tacrolimus (Prograf®)|Oral administration of 5 mg capsule of fresh brand name tacrolimus (Prograf®) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
3033073|NCT02341274|Active Comparator|Fresh Generic Tacrolimus|Oral administration of 5 mg capsule of fresh generic tacrolimus to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
3033074|NCT02341274|Active Comparator|Low Crystal Generic Tacrolimus|Oral administration of 5 mg capsule of 10-30% crystallized generic tacrolimus (Low Crystal) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
3033075|NCT02341274|Active Comparator|High Crystal Generic Tacrolimus|Oral administration of 5 mg capsule of 40-60% crystallized generic tacrolimus (High Crystal) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
3033076|NCT02341261|Experimental|Standard Care Counseling|Participants randomized to the control group will receive diet and exercise counseling at baseline and 9 months. Participants will wear an ActivePAL for 7 days at baseline, 9 months, and 18 months without stimulation.
3033077|NCT02341261|Experimental|Supervised Exercise and Counseling|"Participants randomized to the intervention will perform supervised aerobic, resistance and balance training twice weekly for 12 weeks, and weekly thereafter. Actigraphy-based counseling to reduce sedentary behavior will follow a similar taper. Daily text messages, tweets, emails, and social media posts at random times during waking hours will be used to provide reminders and motivational messages. Participants will have 11 separate 7-day continuous ActivePAL training session incorporating vibrostimulatory feedback spread across the treatment period."
3033078|NCT02341248||A) Newly diagnosed with Crohn's disease|"Children undergoing endoscopic investigations (colonoscopy) for colonic inflammation including Crohn's disease [children who are found not to have Crohn's disease will not participate further].~[Intervention - clinical, not research decision - Exclusive Enteral Nutrition for 8 weeks; usually 330ml 6 times per day] per day"
3033079|NCT02341248||B) Existing diagnosis of Crohn's disease|"Previously diagnosed patients with Crohn's disease due to start an 8 week standard course of treatment with EEN due to disease flare up.~[Intervention - clinical, not research decision - Exclusive Enteral Nutrition for 8 weeks; usually 330ml 6 times per day]"
3033080|NCT02341248||c) Healthy control group|Healthy children unrelated to Crohn's disease patients No intervention
3033081|NCT02341235|Experimental|Game intervention|Participants will receive narrative-based games on a mobile device and telephone counseling (weekly for the first 12 weeks, then once per month until 6 months)
3033082|NCT02341235|Active Comparator|Standard intervention|Participants will receive an electronic activity monitor with a mobile device and telephone counseling (weekly for the first 12 weeks, then once per month until 6 months)
3033083|NCT02341222|Experimental|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
3033084|NCT02341222|Active Comparator|PR (parietene) mesh device|A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
3033085|NCT02341209|Experimental|Doxycycline monohydrate|Doxycycline in either capsules or tablets will be administered at 400mg total per day. Patients will be treated for five months, or up to one year for those with a partial response at 5 months.
3033086|NCT02341196|Experimental|CEA + Polyester patch|225 Patients
3033087|NCT02341196|Experimental|CEA + Patch Polyurethane|225 Patients
3033201|NCT02340338|Experimental|Dose Group 2|Treatment: rTSST-1 Variant Candidate Vaccine 300 ng
3033088|NCT02341183|Active Comparator|A: Treatment order: tPAD treatment, then no treatment|Subjects will receive one overnight treatment with 7% hypertonic saline administered via the tPAD device. They will then have one overnight stay without treatment.
3033089|NCT02341183|Active Comparator|B: Treatment order: no treatment, then tPAD treatment|Subjects will have overnight stay w/o treatment, and one overnight treatment with 7% hypertonic saline administered via the tPAD device.
3033090|NCT02341170|Experimental|HS-PCI|Hippocampal-sparing prophylactic cranial irradiation (25 Gy in 10 fractions)
3033091|NCT02341170|No Intervention|Observation|Observation
3033092|NCT02341144|Active Comparator|Pre-op percutaneous rectus sheath block|ultrasound-guided, percutaneous rectus sheath block with ropivacaine by a qualified anesthesiologist
3033093|NCT02341144|Active Comparator|Intra-operative rectus sheath block|rectus sheath block with ropivacaine under direct visualization by the attending surgeon
3033094|NCT02341131|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Therapy -Frontal/Executive Program (Delahunty)- (Wykes & Reeder, 2005)
3033095|NCT02341131|Active Comparator|Psychoeducation|Symptom Management Module from the University of California. Liberman & Kopelowicz (1995)
3033096|NCT02341131|No Intervention|Healthy Controls|No intervention
3033097|NCT02341105|Active Comparator|Medical therapy|Amiodarone treatment. Amiodarone will be given at a loading dose of 400 mg per day for two week and then lowered to 200 mg daily for 6 months at which point the dose will be lowered to 1000 mg per week. The dose of amiodarone will then be lowered every six, as long as the patient has a satisfactory response. The minimum dose will be 700 mg per week.
3033098|NCT02341105|Active Comparator|Catheter ablation|A standard pulmonary vein isolation procedure will be done. Additional ablation will be permitted (roof and mitral lines/ CFAE )
3033099|NCT02341079|Active Comparator|Femoral Nerve Blockade|Femoral nerve block delivered via indwelling femoral nerve catheter
3033100|NCT02341079|Experimental|Bupivacaine Liposome Injection|Intraoperative intracapsular injection of bupivacaine liposome
3033101|NCT02341066||Rheumatoid Arthritis|Rheumatoid arthritis patients free of overt cardiovascular disease. Endothelial Dysfunction evaluation by EndoPAT
3033102|NCT02341053|Other|Load-measuring platform|"Load-sensing platform A load-sensing platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.~Intervention: Assisted Standing Treatment Program. Assisted standing treatment program will gradually increase their duration of standing by up to 75% after the baseline phase."
3033103|NCT02341027|Active Comparator|Levonorgestrel (LNG) implants immediately postpartum|LNG contraceptive implants provided within 5 days of delivery
3033104|NCT02341027|Active Comparator|Levonorgestrel (LNG) implants 6 weeks postpartum|LNG contraceptive implants provided 6-8 weeks postpartum
3033105|NCT02341014|Experimental|Carfilzomib, Romidepsin, Lenalidomide|All patients will be treated with romidepsin administered intravenously on days 1 and 8 of a 21-day cycle. Lenalidomide will be taken orally daily for days 1-14 of a 21-day cycle. The carfilzomib will be given weekly on days 1, and 8 of a 21-day cycle. Once a MTD is determined this dosing level will be used for the phase IIa portion. Cycles will be continued as above until the patient's wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs.
3033106|NCT02341001|No Intervention|Standard care|Patients are discharged from the bariatric service at 18 months after surgery.
3033107|NCT02341001|Experimental|Standard care with text message support|Patients are discharged from the bariatric service at 18 months after surgery but receive a daily text message for one year.
3033108|NCT02340988|Experimental|Oritavancin and Warfarin|Oritavancin 1200 mg Single-Dose IV Oritavancin Diphosphate given simultaneously with 25mg dose of Warfarin
3033109|NCT02340988|Experimental|Warfarin 24 hours post dose|25mg dose of Warfarin given 24 hours post 1200 mg Single-Dose IV Oritavancin Diphosphate.
3033110|NCT02340975|Experimental|MEDI4736 + tremelimumab (Arm A)|Second line subjects with metastatic or recurrent gastric or GEJ adenocarcinoma
3033111|NCT02340975|Experimental|MEDI4736 (Arm B)|Second line subjects with metastatic or recurrent Gastric or GEJ adenocarcinoma
3033112|NCT02340975|Experimental|Tremelimumab (Arm C)|Second line subjects with metastatic or recurrent Gastric or GEJ adenocarcinoma
3033113|NCT02340975|Experimental|MEDI4736 + tremelimumab (Arm D)|Third line subjects with metastatic or recurrent Gastric or GEJ adenocarcinoma
3033114|NCT02340975|Experimental|MEDI4736 + tremelimumab (Arm E)|Second or third line biomarker-selected subjects with metastatic or recurrent Gastric or GEJ adenocarcinoma
3033115|NCT02340962|Experimental|Group I|200 mg TG-2349 (2 capsules) + Interferon or Peg-interferon + Ribavirin
3033116|NCT02340962|Experimental|Group II|400 mg TG-2349 (4 capsules) + Interferon or Peg-interferon + Ribavirin
3033117|NCT02340949|Experimental|mFOLFOX6 + Aflibercept|"- mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².~- Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml.~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs."
3033118|NCT02340949|Active Comparator|mFOLFOX6|"- mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs."
3033119|NCT02340936|Experimental|LR-ESHAP (lenalidomide 5 mg)|Intervention: lenalidome 5mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 5 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
3033202|NCT02340338|Experimental|Dose Group 3|Treatment: rTSST-1 Variant Candidate Vaccine 1 µg
3033203|NCT02340338|Experimental|Dose Group 4|Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
3033120|NCT02340936|Experimental|LR-ESHAP (lenalidomide 10mg)|Intervention: lenalidome 10mg combined with R-ESHAP( 3 cycles of treatment every 21 days: lenalidomide 10 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
3033121|NCT02340936|Experimental|LR-ESHAP (lenalidomide 15mg)|Intervention: lenalidome 15mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 15 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
3033122|NCT02340936|Experimental|LR-ESHAP (lenalidomide 20mg)|Intervention: lenalidome 20mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 20 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
3033123|NCT02340923||Healthy Subjects|Healthy subjects aged 0-18 years old. Subjects cannot have a presence or past history of a neurological disorder or other disease that would be expected to substantially impact health.
3033124|NCT02340923||Duchenne Muscular Dystrophy Subjects|Male subjects aged 0-18 years old with genetic or histopathologic diagnosis of duchenne muscular dystrophy, or signs and symptoms of DMD and genetic or histopathologic diagnosis in a family member. Additionally, subjects cannot have the presence of a superimposed neuromuscular or other medical condition that substantially impacts the individual's health or ability to cooperate.
3033125|NCT02340910|Experimental|Short duration|Short Duration WBV consists of 8 45-sec bouts of 50Hz WBV followed by a 1-minute seated rest
3033126|NCT02340910|Experimental|Long duration|Long Duration WBV consists of 16 bouts 45-sec of 50Hz WBV followed by a 1-minute seated rest
3033127|NCT02340897||Nontuberculous lung disease|Patients with Nontuberculous Mycobacteria satisfying American Thoracic Society and British Thoracic Society guidelines
3033128|NCT02340897||pulmonary tuberculosis|Patients with culture confirmed tuberculosis
3033129|NCT02340897||bronchiectasis|Patients with bronchiectasis based on chest CT findings as well as symptoms
3033130|NCT02340884|Experimental|PRISM|Promoting Resilience In Stress Management Intervention (skills-based intervention designed to teach stress-management, goal-setting, cognitive reframing, and meaning-making skills)
3033131|NCT02340884|No Intervention|Control|Standard psychosocial supportive care
3033132|NCT02340871||Genetic Neurological Diseases|The group consists of patients with a neurological disease that are tested for finding the genetic basis of their disease.The neurological signs and symptoms include ataxia, intellectual disability, seizures, movement disorders, migrational disorders, macrocephaly, microcephaly and various other signs and symptoms. The group consists of patients from 1-year-old until 90 years who are having a neurological disease as stated above or who are the parents or siblings of the affected patients. Blood specimens will be taken from them and DNA will be extracted for next generation studies like whole exome sequence or whole genome sequence. This process is called genetic testing. The current proposal will assist in diagnosing children and families with a neurological disease for genetic counseling.
3033133|NCT02340858|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
3033134|NCT02340845|Active Comparator|Bromalian 10 mg/kg/day|The number of patients suffering from well-documented malignancies to be assigned to this group will be at least 30: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 500 mg/day, divided into two doses of 250 mg/dose and taken with meals.
3033135|NCT02340845|Active Comparator|Bromalian 50mg/kg/day|The number of patients suffering from well-documented malignancies with be at least 60: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 2400 mg/day, divided into two doses of 1200 mg/dose and taken with meals.
3033136|NCT02340819|Experimental|Arm 1|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
3033137|NCT02340806|Experimental|High rate bolus (CADD-Solis pump)|Labor analgesia will be maintained using timed-intermittent boluses of local anesthetic with PCEA using the CADD-Solis pump. The bolus rate will be 300 mL/h in the high-rate bolus group.
3033138|NCT02340806|Experimental|Low rate bolus (CADD-Solis pump)|Labor analgesia will be maintained using timed-intermittent boluses of local anesthetic with PCEA using the CADD-Solis pump. The bolus rate will be 100 mL/h in the low-rate bolus group.
3033139|NCT02340793|Experimental|Counterweight Plus Dietary Intervention|Weight management programme including total diet replacement with soups and shakes; approximately 800 calories/day
3033140|NCT02340780|Experimental|Buparlisib|100mg daily orally every 28 days
3033141|NCT02340767|No Intervention|No Device Practitioners|The practitioners will not receive any additional training.
3033142|NCT02340767|Experimental|Spectra Device Practitioners|The practitioners in the Spectra Device Arm will be trained to the device according to the manufacturers' usual care for training. The training will consist of viewing the manufacturer's instructions for the device. Training will also consist of practitioners familiarizing themselves with the device through unsupervised clinical use with patients.
3033143|NCT02340767|Experimental|DIAGNOdent Device Practitioners|The practitioners in the DIAGNOdent Device Arm will be trained to the device according to the manufacturers' usual care for training. The training will consist of viewing the manufacturer's instructions for the device. Training will also consist of practitioners familiarizing themselves with the device through unsupervised clinical use with patients.
3033144|NCT02340754|Experimental|Mindfulness-base Stress Reduction|Mindfulness-based stress reduction is a formalized, experiential, 8-week stress-management program. Participants attend weekly two-hour classes and a half-day retreat during which they learn mindfulness meditation, breath work, yoga postures, self-reflection and awareness.
3033170|NCT02340585|Experimental|Next Generation Neuroform Stent System|The Next Generation Stent System is a self-expanding, open cell, nitinol stent designed to provide support of the coil mass within the aneurysm and minimize stent deflection.
3033171|NCT02340572|Experimental|PRS-080#022-DP|hepcidin antagonist, single administration, ascending doses
3033145|NCT02340754|Active Comparator|MS Education Control|The MS Education Control program is matched to MBSR for time and attention yet has no overlap with intervention content. Each two-hour class uses a pamphlet published by the National MS Society to present information about a different MS topic such as Fatigue; Bowel and Bladder Problems; Diet; Spasticity; and Nutritional Supplementation: Vitamins, Minerals, and Herbs.
3033146|NCT02340741|Other|conventional prophylaxis of aeroembolism|"Procedure: cardiac surgery with opening of heart chambers.~Will be including 167 patients to undergo cardiac surgery. After the main operation phase all heart cavities are sealed, left vent drainage is stopped, ascending aorta is punctured and cardiac massage is performed, ventilation is started and the heart is filled with volume. Operating table is positioned in the Trendelenburg position, and aorta is opened. The amount of air in the cavities is evaluated by transesophageal echocardiography."
3033147|NCT02340741|Other|conventional prophylaxis plus CO2 insufflation|"Procedure: cardiac surgery with opening of heart chambers.~Will be including 167 patients to undergo cardiac surgery. After the main phase of the operation standard measures of aeroembolism prevention are carried out. The amount of air in the cavities is evaluated by transesophageal echocardiography."
3033148|NCT02340728|Experimental|ERCP with SEMS plus radiofrequency ablation|Endoscopic retrograde cholangiopancreatogram (ERCP) is performed under standard conditions with cannulation of the bile duct, and demonstration on a cholangiogram the location, diameter and length of the biliary stricture. The HabibTM EndoHBP probe (EMcision, London, United Kingdom) is advanced through the working channel of a side viewing endoscope over a 0.035in guidewire, and positioned across the occluded SEMS under fluoroscopy. 7-10W are usually delivered for 90 seconds with a standard high frequency generator, followed by a 1 minute resting period. Sequential applications of RFA are applied along the entire length of the stricture with an overlap of 1cm.
3033149|NCT02340728|Active Comparator|ERCP with SEMS alone (standard of care)|Endoscopic retrograde cholangiopancreatogram (ERCP) is performed under standard conditions with cannulation of the bile duct, and demonstration on a cholangiogram the location, diameter and length of the biliary stricture. The HabibTM EndoHBP probe (EMcision, London, United Kingdom) is advanced through the working channel of a side viewing endoscope over a 0.035in guidewire, and positioned across the occluded SEMS under fluoroscopy. 7-10W are usually delivered for 90 seconds with a standard high frequency generator, followed by a 1 minute resting period.
3033150|NCT02340715||MRI for treatment planning or follow up|MRI for treatment planning for radiation therapy or those who have completed treatment and are receiving follow up care.
3033151|NCT02340702||Patient with COPD and those without COPD|The participants of acute decompensated heart failure national registry would be stratified in to two group: those with COPD and those without COPD, to determine prognostic implication of COPD in participants with acute decompensated heart failure
3033152|NCT02340689||Genetic testing|Genetic Analysis
3033153|NCT02340676|Experimental|ECP plus IL-2|"Extracorporeal Photopheresis (ECP) standard-of-care~Daily subcutaneous (SC) interleukin-2 (IL-2) (Proleukin®) during predetermined weeks of treatment cycle"
3033154|NCT02340663|Experimental|SOVA bite splint|SOVA Bite splint: Over-the-counter, heat-and-mold bite splint. Investigators evaluate subject self-fabrication, and evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
3033155|NCT02340663|Active Comparator|Michigan Bite Splint|Michigan bite splint: Gold standard, custom acrylic bite splint made for subjects. Investigators evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
3033156|NCT02340650|Experimental|Bladder Cancer Patients|Subjects aged 18 years and older who have a suspicious bladder lesion or clinical presentation identified by a physician who recommends further evaluation with cystoscopy and bladder biopsy or who are undergoing cystoscopy as part of their routine clinical care.
3033157|NCT02340637|Experimental|Coping Kids|"A Program for Managing Anxiety and Depression (P.C Kendall et al., 2013) is a newly developed group intervention targeting children aged 8 to 13 years who experience difficulty with symptoms of anxiety, depression, or both. The program is designed as an indicated prevention intervention to reduce the symptom levels and reduce the likelihood of the development of an anxiety disorder and/or depression.~The youth-focused sessions are designed for implementation in school settings, and the program includes parent group meetings.~All groupleaders participate in a three days training, followed by supervision. Manuals and workbooks are provided by the project. In addition is the same presentation as in TAU offered to the schools."
3033158|NCT02340637|Active Comparator|TAU|The teachers and school-nurses in the control schools will conduct treatment as usual (TAU).The project offers a 2,5 hours presentation to the schools, providing general information about the research study, the prevalence of emotional disorders and how to handle emotional disorders in treatment as usual. No materials are provided by the project.
3033159|NCT02340624|No Intervention|Control group|No intervention(control group)
3033160|NCT02340624|Experimental|condition 2|Intervention:Smokefreemoms texting
3033161|NCT02340624|Experimental|condition 3|Intervention: Quitline referral
3033162|NCT02340624|Experimental|condition 4|Intervention:Smokefreemoms texting and quitline referral
3033163|NCT02340624|Experimental|condition 5|Intervention: Brief intervention
3033164|NCT02340624|Experimental|condition 6|Intervention:Smokefreemoms texting and Brief intervention
3033165|NCT02340624|Experimental|condition 7|Intervention: Quitline referral and Brief intervention
3033166|NCT02340624|Experimental|condition 8|Intervention:Smokefreemoms texting, Quitline referral and Brief intervention
3033167|NCT02340611|Experimental|Cediranib and Olaparib|Cediranib, 20 mg , orally, once a day, every day. Olaparib, 150 mg or 200 mg (depending on previous treatment dose), orally, once a day, every day.
3033168|NCT02340598|Experimental|cold vest|Participants are given a cold vest that the pre-cool in a freezer. They are encouraged to use it daily to activate metabolism through brown adipose tissue and shivering.
3033169|NCT02340598|No Intervention|control|No intervention, just recording of risk factors and basal metabolic rate.
3033172|NCT02340572|Placebo Comparator|PRS-080-Placebo#001|Comparotor treatment, single administration
3033204|NCT02340338|Experimental|Dose Group 5|Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
3033173|NCT02340559|Experimental|Meta-cognitive Training|"The metacognitive training program is comprised of eight modules targeting common cognitive errors in schizophrenia. The modules are : attributional distortions (module 1), a jumping to conclusions bias (module 2 and 7), a bias against disconfirmatory evidence (module 3), deficits in theory of mind (module 4 and 6), over-confidence in memory errors (module 5) and depressive cognitive patterns (module 8).~The treatment group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group."
3033174|NCT02340559|Active Comparator|Psychoeducational group|In the control group the modules worked were: 1. Healthy Habits, 2. Risk Behaviors, 3. Prevention of relapse, 4 and 5.Videoforum, 6. Resources of work and development of curriculum vitae 7. Leisure activities, and 8. Resources of the community. The psychoeducational group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group.
3033175|NCT02340533|Experimental|adenomyosis|females attending the gynecology outpatient clinic complaining of chronic pelvic congestion will get enrolled in the study. Two dimensional ultrasonography will be performed to asses the presence or absence of adenomyosis or any associated lesions. All the patients were then be subjected to office hysteroscopy and endo-myometrial biopsies will be taken. Histopathological examination of the samples will then be done. From these recruited patients, some will be indicated to perform hysterectomy. The final diagnosis will then be based on the histopathological examination of the specimen retrieved from hysterectomy. The accuracy of the ultrasound and the hysteroscopic endo-myometrial biopsy will then be compared and assessed.
3033176|NCT02340520|Experimental|thophylline and roflumilast|Theophylline for one week, followed by the addition of Roflumilast for a further one week.
3033177|NCT02340507|Experimental|High glycemic index|The subject will consume a high glycemic index glutinous rice for breakfast (75g available carbohydrates), and a high glycemic index white bread for snack (25g available carbohydrates). The lunch is a standardized, weighed portion buffet.
3033178|NCT02340507|Experimental|Low glycemic index|The subject will consume a low glycemic index parboiled basmati rice for breakfast (75g available carbohydrates), and a low glycemic index multigrain bread for snack (25g available carbohydrates). The lunch is a standardized, weighed portion buffet.
3033179|NCT02340494|No Intervention|Control group|Women without access to the website.
3033180|NCT02340494|Experimental|Intervention group|Women with access to the website.
3033181|NCT02340481|Experimental|Loperamide Hydrochloride + Simethicone|Participant will take 2 loperamide hydrochloride and simethicone chewable tablets + 2 loperamide hydrochloride placebo capsules orally, as their first dose, and subsequently 1 loperamide hydrochloride and simethicone chewable tablet + 1 loperamide hydrochloride placebo capsule orally, in the event of unformed stool (provided that no more than 4 tablets/capsules are taken within a 24-hour period) up to 48 hours.
3033182|NCT02340481|Active Comparator|Loperamide Hydrochloride|Participant will take 2 loperamide hydrochloride capsules + 2 loperamide hydrochloride and simethicone chewable placebo tablets orally, as their first dose, and subsequently 1 loperamide hydrochloride capsule + 1 loperamide hydrochloride and simethicone chewable placebo tablet orally, in the event of unformed stool (provided that no more than 4 capsules/tablets are taken within a 24-hour period) up to 48 hours.
3033183|NCT02340455|Experimental|Pregabalin_male|
3033184|NCT02340455|Experimental|Pregabalin_female|
3033185|NCT02340455|Active Comparator|Placebo_male|
3033186|NCT02340455|Active Comparator|Placebo_female|
3033187|NCT02340442||Low risk group|40 subjects: Healthy, pregnant women
3033188|NCT02340442||High risk group|"40 pregnant women:~20 Pregnant women with preeclampsia~20 Obese pregnant women"
3033189|NCT02340442||Healthy control subjects|40 subjects
3033190|NCT02340429|Experimental|video otoscopy|children under 18y admitted to the pediatric emergency room for any reason, will undergo video otoscopy
3033191|NCT02340429|No Intervention|standard otoscopy|children under 18y admitted to the pediatric emergency room for any reason, undergoing routine otoscopy
3033192|NCT02340403|Experimental|Oxaliplatin and neuropathic pain|The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).
3033193|NCT02340403|Other|Oxaliplatin without neuropathic pain|The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).
3033194|NCT02340390|Experimental|Hip implant1|The Biomet G7 Acetabular System is a modular acetabular system, offering two types of acetabular shells. The shells are available in either a solid shell design, with an apical plug, or a limited hole with an apical plug and optional screw holes. Components are available in numerous designs and sizes intended for both primary and/or revision applications.
3033195|NCT02340390|Experimental|Hip implant2|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
3033196|NCT02340364|Experimental|Education + PN Arm|208 patients randomized to self-care education+ Patient navigator-delivered self-care plan.
3033197|NCT02340364|Active Comparator|Educational Control Arm|- 208 patients randomized to self-care education alone.
3033198|NCT02340351|Active Comparator|Auricular acupuncture|Within this arm, patients were treated with auricular acupuncture according to the NADA protocol. Each setting involved not more than eight patients at a time and was performed in a sitting position. Each session lasted 30 minutes and took place twice a week over a period of 4 weeks.
3033199|NCT02340351|Active Comparator|Progressive muscle relaxation|Within this arm, patients were treated with who chose treatment with progressive muscle relaxation. Each setting involved not more than eight patients at a time and was performed in a sitting position. Each session lasted 30 minutes, took place twice a week over a period of 4 weeks.
3033205|NCT02340338|Experimental|Dose Group 6|Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
3033206|NCT02340338|Placebo Comparator|Dose Group 0|Control: Al(OH)3 Adjuvant
3033207|NCT02340325|Other|Acute Sensitivity Test to FS2 cream|Twenty (20) healthy volunteers will be assigned volunteer numbers and will have a testing areas identified by permanent marker on their backs. Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area once for 24 hours. The pouch order will be random, generated by the www.random.org list generator each application. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
3033208|NCT02340325|Other|Chronic Sensitivity Test to FS2 cream|Twenty (20) randomized healthy volunteers will be assigned numbers and will have a single testing area identified by permanent marker on either shoulder or upper back. Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30.
3033209|NCT02340299|Experimental|nHFOV|"Immediately after extubation, nHFOV is provided via binasal prongs. Ventilator settings: Frequency set at 10 Hz, I:E ratio 33:66, amplitude 20 cm H2O, Pmean 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.~The weaning process is left to the discretion of the attending physician. Maximum amplitude 30 cm H2O, minimum frequency 9 Hz, maximum Pmean 8 cm H2O.~For infants in the nHFOV-group who fail nHFOV (see definition below), but do not need immediate reintubation, a non-invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
3033210|NCT02340299|Active Comparator|nCPAP|"Immediately after extubation, nCPAP is provided via binasal prongs. Ventilator settings: CPAP level set at 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.~The weaning process is left to the discretion of the attending physician. Maximum CPAP level 8 cm H2O, maximum flow 8 l/min.~For infants in the nCPAP-group who fail nCPAP (see definition below), but do not need immediate reintubation, Rescue-nHFOV via binasal prongs may be provided. The decision to attempt Rescue-nHFOV and the ventilator settings used are at the discretion of the attending clinician."
3033211|NCT02340273|Experimental|Therapeutic ultrasound device|Patients receive treatment from the long duration therapeutic ultrasound device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
3033212|NCT02340273|Placebo Comparator|Placebo therapeutic ultrasound device|"Patients receive the sham long duration therapeutic ultrasound device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound."
3033213|NCT02340260|Other|High intensity interval training|High intensity interval training starts with warming up for 3 minutes at 70 % of maximum heart rate before treadmill training 10x1-minute intervals at 90 % of HRmax, with 75 seconds of active recovery at 70 % of HRmax between each interval. Exercise is completed with a three minute cool down. All training sessions are supervised by an exercise physiologist. Treadmill inclination and/or speed will be adjusted to make sure prescribed intensity is met throughout the intervention.
3033214|NCT02340260|Other|Sprint interval training|Sprint interval training starts with warming up for 3 minutes at 70 % of maximum heart rate before treadmill training 2x20 seconds of maximum intensity intervals, with 3 minutes and 20 seconds of active recovery at 70 % of HRmax between each interval, followed by 3 minutes cooling down at the same intensity. All training sessions are supervised by an exercise physiologist. Treadmill inclination and/or speed will be adjusted to make sure prescribed intensity is met throughout the intervention.
3033215|NCT02340247|Experimental|Placebo|150mL water
3033216|NCT02340247|Experimental|Ursodeoxycholic acid|Ursodeoxycholic acid (750mg) dissolved in 150mL water
3033217|NCT02340247|Experimental|Chenodeoxycholic acid|Chenodeoxycholic acid (1250mg) dissolved in 150mL water
3033218|NCT02340234|Experimental|Lebrikizumab 250 mg Single Dose + TCS Cream|Participants will receive lebrikizumab 250 milligrams (mg) SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
3033219|NCT02340234|Experimental|Lebrikizumab 125 mg Single Dose + TCS Cream|Participants will receive lebrikizumab 125 mg SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
3033220|NCT02340234|Experimental|Lebrikizumab 125 mg Q4W + TCS Cream|Participants will receive lebrikizumab 125 mg SC every 4 weeks (Q4W) for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
3033221|NCT02340234|Placebo Comparator|Placebo Q4W + TCS Cream|Participants will receive placebo Q4W for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
3033222|NCT02340221|Experimental|Taselisib + Fulvestrant|Participants will receive taselisib 4 milligrams (mg) orally (PO) once daily (QD) beginning at Cycle 1, Day 1 and fulvestrant 500 mg intramuscular (IM) injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle, until disease progression, unacceptable toxicity, or study termination by the Sponsor.
3033223|NCT02340221|Placebo Comparator|Placebo + Fulvestrant|Participants will receive placebo matching to taselisib PO QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle, until disease progression, unacceptable toxicity, or study termination by the Sponsor.
3033224|NCT02340208|Experimental|L-DOS47|Patient will be recruited into cohorts of L-DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort. The starting dose of L-DOS47 will be 0.12 μg/kg; further possible dose levels include 0.21, 0.33, 0.46, 0.59, 0.78, 1.04, 1.38, 1.84, 2.45, 3.26 and 4.33 μg/kg.
3033589|NCT02337543|Experimental|Active: NEO6860|NEO6860 suspension is the drug under evaluation
3033225|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group A)|8 patients with severe renal impairment and not on dialysis
3033226|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group B)|8 healthy subjects
3033227|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group C)|"Group C will not be tested, if severe renal impairment does not alter the pharmacokinetics to a clinically relevant extent, based on results from group A and B~8 patients with moderate renal impairment"
3033228|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group D)|"Group D will not be tested, if severe renal impairment does not alter the pharmacokinetics to a clinically relevant extent, based on results from group A and B~8 patients with mild renal impairment"
3033229|NCT02340182|Experimental|Antibiotics|"All volunteers will self-administer the following antibiotics for 7 consecutive days (concomitantly):~Vancomycin 250mg 3dd2;~Ciprofloxacin 500mg 2dd1;~Metronidazole 500mg 3dd1."
3033230|NCT02340169|Experimental|Topicort® Topical Spray, 0.25%|Topicort® (desoximetasone) Topical Spray, 0.25%, twice a day for 28 days
3033231|NCT02340156|Experimental|SGT-53 with Temozolomide|SGT-53, at 3.6 mg DNA/infusion, will be administered twice weekly in a 28 day cycle starting on Day 1 (cycle 1), Day 29 (cycle 2) and Day 57 (cycle 3). Temozolomide (TMZ) will be administered by mouth daily on days 9-13 of each cycle. Patients who are responding to treatment may receive three additional cycles of SGT-53/TMZ therapy or continue on TMZ alone at investigator's discretion. Surgical resection of recurrent or progressive tumor for tumor analysis is an optional procedure. In these individuals SGT-53, at 3.6 mg DNA/infusion, will be administered twice (on days -1 and -3) in the week prior to surgery. Surgical resection is Day 0. 14-21 days post operatively and having recovered from the effects of surgery, the patients will then start cyclical TMZ with SGT-53 as described above.
3033232|NCT02340143|Active Comparator|Control|Marketed partially hydrolyzed cow's milk protein infant formula
3033233|NCT02340143|Experimental|Investigational|Partially hydrolyzed cow's milk infant formula with a probiotic
3033234|NCT02340130|Experimental|DP/MG/14-1|DP/MG/14-1: Depigmented modified allergen extract of D. pteronyssinus 50% / Depigmented, glutaraldehyde-polymerised B. tropicalis 50% (200DPP/mL) The administration regimen will consist of a rush build-up régimen and a follow up period
3033235|NCT02340130|Experimental|DP/MG/14-2|DP/MG/14-2: Depigmented modified allergen extract of D. pteronyssinus 50% / Depigmented, glutaraldehyde-polymerised L.destructor 50% (200DPP/mL) The administration regimen will consist of a rush build-up régimen and a follow up period
3033236|NCT02340117|Experimental|SGT-53 with gemcitabine/nab-paclitaxel|A course of therapy will include 7 weeks of treatment. In week 1, SGT-53, at 2.4 mg DNA/infusion, will be administered on day 1 and day 5, 1000 mg/m² gemcitabine and 125 mg/m² nab-paclitaxel will be administered on day 3 of each week except week 4. If the combination is well-tolerated, starting at week 2, 3.6 mg DNA/infusion of SGT-53 will be administered bi-weekly on days 1 and 5 in weeks 2-3, weekly on day 3 in week 4, and weekly on day 1 in weeks 5-7. Patients who are responding to treatment may receive one additional course (7 weeks) of SGT-53/gemcitabine/nab-paclitaxel therapy at investigator discretion. If still responding to treatment, they may continue on gemcitabine/nab-paclitaxel alone at investigator discretion.
3033237|NCT02340104|Experimental|Baricitinib|Single oral dose of baricitinib and single intravenous (IV) infusion of [^13C4D3^15N]-baricitinib over 1.5 hours.
3033238|NCT02340091|Experimental|HA IDF plus|cross-linked HA filler with lidocaine
3033239|NCT02340091|Active Comparator|HA IDF|cross-linked HA filler without lidocaine
3033240|NCT02340078|Active Comparator|HA IDF II|cross-linked HA filler
3033241|NCT02340078|Experimental|HA IDF II plus|cross-linked HA filler with lidocaine
3033242|NCT02340065|Active Comparator|standard colonoscopy|total polyp/adenoma detection with standard colonoscopy, polyp/adenoma detection in the right colon with standard colonoscopy
3033243|NCT02340065|Active Comparator|Endocuff-assisted colonoscopy|total polyp/adenoma detection with Endocuff-assisted colonoscopy, polyp/adenoma detection in the right colon with Endocuff-assisted colonoscopy
3033244|NCT02340052||Frederiksberg Hospital|100 patients undergoing planned total hil arthroplasty
3033245|NCT02340052||Koege hospital|100 patients undergoing planned total hil arthroplasty
3033246|NCT02340052||Naestved Hospital|100 patients undergoing planned total hil arthroplasty
3033247|NCT02340052||Hilleroed Hospital|100 patients undergoing planned total hil arthroplasty
3033248|NCT02340052||Nykoebing Falster Hospital|100 patients undergoing planned total hil arthroplasty
3033249|NCT02340039|Experimental|Blackcurrant &Apple|600 mg blackcurrant anthocyanins + 600 mg apple polyphenols delivered in a low sugar fruit drink
3033250|NCT02340039|Experimental|Apple|1200 mg apple polyphenols delivered in a low sugar fruit drink
3033251|NCT02340039|Placebo Comparator|Control drink|No polyphenols delivered in a low sugar fruit drink
3033252|NCT02340026|Experimental|Conventional Therapy|"The conventional treatment group will receive traditional, therapist-directed pediatric physical therapy. Therapy will focus on early gait training strategies and encouragement of normal movement patterns for walking and other age-appropriate movements, with manual guidance or correction of atypical movements from the therapist. This group may use assistive devices, orthoses, and may receive static body weight support for gait training. Therapy activities will be performed in blocks of practice, with the specific activities and level of therapist assistance tailored to each child."
3033253|NCT02340026|Experimental|Dynamic Supported Mobility|Children will receive dynamic weight support during all DSM treatment time. The environment will be arranged to encourage active motor exploration, somewhat similar to a play gym for toddlers, to promote the motor variability, engagement, and error experiences that characterize the typical development of upright motor skills and walking. The floor area within 3 feet below either side of the overhead track for a distance of 20 feet (approximately 120 ft2 total) will be defined with colorful thin rubber interlocking mats and arranged with pediatric toys and activities, tailored to the child's interests and to encourage motor skills just beyond his/her current ability. The therapist will minimally assist the child as needed to perform the movements he/she initiates.
3033254|NCT02340013|Active Comparator|Medroxyprogesterone acetate|Medroxyprogesterone acetate 10mg per os x 10 days prior to starting clomiphene citrate 50mg once daily days 3 - 7 of bleeding after stopping medroxyprogesterone acetate
3033255|NCT02340013|No Intervention|Control|Women are assigned to start clomiphene citrate 50mg tabs x 5 days on an assigned day, without any vaginal bleeding
3033256|NCT02340000|Active Comparator|standard dose|amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days
3033257|NCT02340000|Experimental|high dose|Time Period I (November 18, 2014-January 5, 2016): extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets (by different manufacturer) twice a day for 7 days Time Period 2 (February 6, 2016-February 27, 2017): immediate-release amoxicillin/clavunate 875/125 mg plus standard immediate-release amoxicillin 875 mg twice a day for 7 days
3033258|NCT02339974|Experimental|Severe Tricuspid Regurgitation|
3033259|NCT02339948|Active Comparator|SBRT only|Patients assigned to this arm receive 8.0 Gy per fraction for 5 fractions for a total of 40 Gy
3033260|NCT02339948|Active Comparator|IMRT plus SBRT Boost|Patients assigned to this arm receive 1.8 Gy per fraction for 25 fractions over 5 weeks for a total of 45.0 Gy followed by an SBRT boost of 5.5 Gy per fraction for 4 fractions after IMRT for a total of 22.0 Gy
3033261|NCT02339935|Experimental|ABA Treatment Group|20 Children - 10 hospitalized at Vanderbilt Children's Hospital and 10 hospitalized at Vanderbilt Psychiatric hospital - will receive Brief Analogue Functional Analysis (Brief AFA) targeted to their most problematic behavior(s) while hospitalized
3033262|NCT02339935|Other|Control Group|20 Children - 10 hospitalized at Vanderbilt Children's Hospital and 10 hospitalized at Vanderbilt Psychiatric hospital - will receive all typical standard of care procedures while hospitalized, but will not receive Brief AFA
3033263|NCT02339922|Experimental|Treatment (ixazomib citrate, rituximab)|Patients receive ixazomib citrate PO once weekly every 4 weeks. Upon completion of 6 courses of ixazomib citrate therapy, patients also receive rituximab IV once weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3033264|NCT02339909|Active Comparator|Control|"The intervention for the Control group consists of the standard invitation letter from the Screening service. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
3033265|NCT02339909|Experimental|Fixed Incentive|"The intervention for the fixed incentive group consists of the standard invitation letter from the Screening service, with additional text offering a fixed financial incentive (£10) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
3033266|NCT02339909|Experimental|Probabilistic Incentive|"The intervention for the probabilistic incentive group consists of the standard invitation letter from the Screening service, with additional text offering a probabilistic financial incentive (entry into a lottery offering at least a 1 in 100 chance to win £1000) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
3033267|NCT02339896||WHO category 2|Children patient who have experienced WHO category II exposure will receive rabies vaccine (SPEEDA) 0.1 ml intradermal two site for 4 times
3033268|NCT02339896||WHO category 3|Children patient who have experienced WHO category II exposure will receive rabies vaccine (SPEEDA) 0.1 ml intradermal two site for 4 times with ERIG
3033269|NCT02339870|Experimental|Arm I (expressive disclosure)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about their emotions pertaining to managing and providing care for the cancer patient.
3033270|NCT02339870|Experimental|Arm II (benefit finding)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about any benefits that have arisen because of the cancer diagnosis.
3033271|NCT02339870|Sham Comparator|Arm III (control)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about an emotionally neutral topic.
3033272|NCT02339857||No-touch vein grafts to LAD|
3033273|NCT02339844|Active Comparator|antipsychotic treatment|individual doses of aripiprazole for all patients
3033274|NCT02339844|No Intervention|no treatment|no treatment for all healthy controls
3033275|NCT02339831|Active Comparator|active motion device|An active motion device (CAM) known as a CAMOPED was given after surgery. The device was used for 3 sessions of 20 minutes for 3 weeks.
3033276|NCT02339831|Active Comparator|CPM passive motion device|A continuous passive motion device (CPM) given after surgery. The device bends and moved the knee passively. It was used for 4 hours daily for 3 weeks.
3033277|NCT02339818||HCPs|HCPs involved in using Eliquis (apixaban)
3033278|NCT02339818||Patients|Patients taking Eliquis for any of the three currently approved indications
3033279|NCT02339805|Experimental|next generation sequencing|Determination of clonotypic evolution of the minimal residual disease by next generation sequencing.
3033280|NCT02339792|Other|Intervention|e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
3033281|NCT02339792|Other|Control|e-learning program of medical education, focused on teaching only geriatric pharmacological notions (GPNs)
3033282|NCT02339779|Experimental|Autologous fat transfer reconstruction|Breast reconstruction achieved by serial autologous fat transfer (AFT) procedures, accompanied by external tissue expansion of the breast.
3033283|NCT02339779|Active Comparator|Reconstruction with breast implants|Control group will receive implant-based reconstruction, in some cases preceded by the implantation of a tissue expander.
3033284|NCT02339766|Sham Comparator|Group 1|Group 1 will receive intrathecal morphine co-administered with the spinal anesthetic. After the completion of surgery, bilateral ultrasound guided Sham Block be done with 25 mL of saline per side.
3033285|NCT02339766|Active Comparator|Group 2|Group 2 will receive an equivalent volume of intrathecal saline co-administered with the spinal anesthetic. After surgery, bilateral ultrasound guided Quadratus Lumborum Block will be performed with 25 ml 0.5% Ropivacaine per side.
3033286|NCT02339766|Active Comparator|Group 3|Group 3 will receive will receive intrathecal morphine with the spinal anesthetic. After the completion of surgery, bilateral ultrasound guided Quadratus Lumborum Block will be performed with 25 ml 0.5% Ropivacaine per side.
3033393|NCT02338921|Active Comparator|Glimepirde, Metformin, Lobeglitazone|"Peroxisome proliferator-activated receptor gamma agonist~Lobeglitazone"
3033473|NCT02338362|Placebo Comparator|Saline placebo|10 participants will be asked to use a saline placebo metered-dose inhaler 1 puff twice-daily for 6 weeks.
3033287|NCT02339753|Experimental|Carboplatin-treatment arm|"Arm description : Carboplatin intravenous administration once daily for 3 to 4 days~Topotecan + Thiotepa + Carboplatin : carboplatin 500mg/m2/day, for 3 days~MEC for 2nd PBSCT : carboplatin 350 mg/m2/day, for 4 days~MEC for other solid tumor : carboplatin 400 mg/m2/day, for 4 days~MEC + MIBG Tx for 2nd PBSCT (neuroblastoma) : carboplatin 300 mg/m2/day, for 4 days"
3033288|NCT02339740|Experimental|Treatment (tretinoin, arsenic trioxide, chemotherapy)|See Detailed Description
3033289|NCT02339727|Active Comparator|Omega-6/omega-3=2/1 milk formula|Preterm infants will receive a formulas supplemented with Docosahexaenoic acid and Arachidonic acid with a relationship omega 6/omega 3 = 2/1.
3033290|NCT02339727|Active Comparator|Omega-6/omega-3=1/1 milk formula|preterm infants will receive other formulas with Docosahexaenoic acid and Arachidonic acid, but with a ratio of 1/1.
3033291|NCT02339714|Experimental|Acupuncture combined moxibustion|Acupuncture at Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14). Needle warming moxibustion at Dazhui(Du14). Patients will be treated once per day for 30 min, 3 times in a weeks for 4 weeks.
3033292|NCT02339714|Active Comparator|loratadine|Loratadine taken orally, 10mg/day in the morning
3033293|NCT02339701|Other|IMRT|Patients will receive 38 fractions of radiation, each fraction size will be 2Gy. The total dose will be 78Gy to PTV 1. Whereas the total dose will be 70Gy over 38 fractions to PTV 2. The treatment will be delivered 5 fractions per week consecutively except public holiday, and the total duration of treatment will be 7.5 to 8 weeks.
3033294|NCT02339701|Other|SBRT|Patients will receive 5 fractions of radiation; each fraction size will be 7.25Gy. The total dose will be 36.25 Gy to PTV1. Whereas the total dose will be 32.5Gy over 5 fractions to PTV2. The 5 treatments will be scheduled to be delivered twice aweek over approximately 15-17 days. A minimum of 72 hours and a maximum of 96 hoursshould separate each treatment. No more than 2 fractions will be delivered per week. The total duration of treatment will be no shorter than 15 days and no longer than 17 days.
3033295|NCT02339688|Other|convential MS rehabilitation|Investigation of the quality (psychometric properties) and clinical utility of several measures of mobility
3033296|NCT02339675|Other|convential MS rehabilitation|Investigate the quality (psychometric properties) and clinical utility of several measures of the upper limb function
3033297|NCT02339662|Active Comparator|gabapentin|900 mg per day total, 3 pills of 300mg.
3033298|NCT02339662|Active Comparator|amitriptyline|20 mg total, 1pill
3033299|NCT02339649|Other|Sepsis/septic Shock|"Men and women seen at the intensive care units of the Anesthesiology Department of the University Hospital Bonn aged 25-80; fulfill the criteria of sepsis and/or septic shock patients according to theThird International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3, Singer et al, 2016).~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
3033300|NCT02339649|Other|Postoperative ICU Patients|"Men and women seen at the intensive care units of the Anesthesiology Department of the University Hospital Bonn aged 25-80:~Admitted to the intensive care units of the Anesthesiological-Operative Intensive Care Unit of the University Hospital Bonn, which includes a surgical ICU, an anesthesiological ICU, and a cardio-surgical ICU~Duration of ICU stay must be a minimum of 24 hours.~Mini-Mental State Examination (MMSE) Score of 25 or above~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
3033301|NCT02339649|Other|Healthy Controls|"Healthy Controls will only be included in the study if they meet all of the following criteria: Written informed consent of the subject, Aged 25-80 years, Male or female.~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
3033302|NCT02339636||case group|100 patients with vulgaris psoriasi without arthritis
3033303|NCT02339636||control group|100 age-matched patients with other skin diseases without arthritis
3033304|NCT02339623||threatened preterm labour|"Women who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) :~Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )~Cervical dilataion >1cm, &/or~Cervical effacement ≥ 80%"
3033305|NCT02339610|Experimental|ATTUNE Primary, Cemented Total Knee Replacement|"Subjects will receive one of four available ATTUNE total knee implants:~(CR FB, CR RP, PS FB, PS RP)."
3033306|NCT02339597|Experimental|APAP Lab|standard Initiation of APAP therapy in sleep laboratory.
3033307|NCT02339597|Experimental|APAP Home|initiation of APAP therapy in homely environment with additional continuous telemetric support.
3033308|NCT02339584|Experimental|Brinz/Brim|Vehicle solution, 1 drop, followed by Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension, 1 drop, administered at least 5 minutes apart in the treated eye(s) twice daily (BID) for 3 months
3033309|NCT02339584|Active Comparator|Brinz+Brim|Brimonidine 2 mg/mL eye drops, solution, 1 drop, followed by Brinzolamide 10 mg/mL eye drops, suspension, 1 drop, administered at least 5 minutes apart in the treated eye(s) BID for 3 months
3033310|NCT02339571|Experimental|Arm I (nivolumab, ipilimumab, sargramostim)|"INDUCTION THERAPY: Patients receive nivolumab IV over 60 minutes on day 1, ipilimumab IV over 90 minutes on day 1, and sargramostim SC on days 1-14. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive nivolumab and sargramostim as in Induction therapy. Patients with PR, SC, or CR at 24 weeks may continue maintenance therapy for up to 2 years in the absence of disease progression or unacceptable toxicity."
3033311|NCT02339571|Experimental|Arm II (nivolumab, ipilimumab)|"INDUCTION THERAPY: Patients receive nivolumab and ipilimumab as in Arm I. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive nivolumab as in Induction therapy. Patients with PR, SD, or CR at 24 weeks may continue maintenance therapy for up to 2 years in the absence of disease progression or unacceptable toxicity."
3033312|NCT02339558|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over approximately 60 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3033313|NCT02339545|Other|Coronary Flow Reserve|Single arm study. All subjects will receive Coronary Flow Reserve measurements post-stenting using Volcano FloWire.
3033472|NCT02338362|Active Comparator|Fluticasone|10 participants will be asked to use fluticasone propionate 250 µg metered-dose inhaler 1 puff twice-daily for 6 weeks.
3033314|NCT02339532|Experimental|TOP2A amplified|"If TOP2A amplified: FEC x 3 then THP x 3 3 cycles of FEC 100 administered IV q3w~5-Fluorouracil (5-FU) 500 mg/m2~Epirubicin 100 mg/m2~Cyclophosphamide 500 mg/m2~Followed by 3 cycles of Trastuzumab-Pertuzumab-Docetaxel:~Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.~Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.~DOCETAXEL 75 mg/m2 IV escalading at 100 mg/m2 IV as tolerated q3w"
3033315|NCT02339532|Experimental|TOP2A not amplified|"If TOP2A not amplified: TCHP x 6 TCHP administered IV q3w for 6 cycles~Trastuzumab 8 mg/kg loading dose administered IV followed by 6 mg/kg IV q3w in subsequent cycles.~Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.~DOCETAXEL 75 mg/m2 IV q3w~CARBOPLATIN AUC 6 IV q3w~The Calvert formula will be used to calculate the dose of carboplatin:~Dose (mg) = target AUC (mg/mL x min) x [GFR mL/min + 25] Dose (mg) = 6 x [GFR mL/min + 25] NOTE: the Calvert formula gives the dose in mg, not mg/m². GFR, glomerular filtration rate The maximum dose of CARBOPLATIN must not exceed 900 mg."
3033316|NCT02339519|Active Comparator|group LMA supreme|Patients who received Laryngeal Mask Airway; LMA supreme
3033317|NCT02339519|Active Comparator|group LMA classic|Patients who received Laryngeal Mask Airway; LMA classic
3033318|NCT02339519|Active Comparator|group Fastrach|Patients who received Laryngeal Mask Airway; LMA fastrach
3033319|NCT02339506|Active Comparator|Cosyntropin|Subjects will receive cosyntropin infusion at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
3033320|NCT02339506|Placebo Comparator|Normal saline (Placebo)|Subjects will receive normal saline infusion for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
3033321|NCT02339493|Experimental|Alert Group|If the patient is randomized to the alert group, their ordering provider will receive a computer electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy.
3033322|NCT02339493|No Intervention|Control Group|If the patient is randomized to the control group, the computer program will not issue an on-screen electronic alert.
3033323|NCT02339480|No Intervention|Healthy volunteers|Healthy volunteers'hypothalamus picture of fMRI will compare with Obesity group' , no intervention and remaining unchanged lifestyle.
3033324|NCT02339480|Active Comparator|Obesity group|An intervention group of patients is put on a waiting list for massage therapy.Observing the Curative effect and hypothalamus picture of fMRI compare with healthy volunteers
3033325|NCT02339467|Experimental|GO-OUT program|An outdoor walking workshop with stations to learn various outdoor walking skills and information, followed by a supervised, group based outdoor walking program, twice a week for 60 minutes, for 3 months.
3033326|NCT02339467|Active Comparator|Task-oriented outdoor walking workshop|An outdoor walking workshop with stations to learn various outdoor walking skills and information.
3033327|NCT02339454|Active Comparator|Active treatment group|"Patients in this group receive actual shockwave therapy. Study treatment consists of 9 sessions, with 3 sessions per week 1, 5 and 9. 100 shocks are delivered per spot, 1200 shocks per session.~During 1st treatment week ESMR will be delivered 3 times (every other day) to basal segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).~During 2nd treatment week ESMR will be delivered 3 times (every other day) to middle segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).~During 3rd treatment week ESMR will be delivered 3 times (every other day) to apical segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions)."
3033328|NCT02339454|Placebo Comparator|Placebo group|This group of patients undergoes the same procedure as the treatment group; however shockwaves are not delivered to the heart.
3033329|NCT02339441||Methotrexate|Patients treated with Methotrexate at the entry of the study.
3033330|NCT02339441||Mycophenolate Mofetil|Patients treated with Mycophenolate Mofetil at the entry of the study.
3033331|NCT02339441||Cyclophosphamide|Patients treated with Cyclophosphamide at the entry of the study
3033332|NCT02339441||No Immunosuppressant|Patients without immunosuppressant treatment at the entry of the study
3033333|NCT02339428|Experimental|Diclophenac sodium 100mg p.o.|Patients will be given 100mg of diclophenac sodium two hours prior to colonoscopy.
3033334|NCT02339428|Placebo Comparator|Placebo|Patients will be given placebo tablets of same appearance as the intervention.
3033335|NCT02339415|Active Comparator|Treatment|Edoxaban 30mg daily
3033336|NCT02339415|Placebo Comparator|Placebo|Matching Placebo
3033337|NCT02339389||ventilation during labor analgesia|We are simply measuring ventilation changes that occur following labor analgesia.
3033338|NCT02339376|Experimental|Group 1|Low-frequency repetitive transcranial magnetic stimulation: 30-minute sessions of 1-Hz continuous stimulation at 95% resting motor threshold, with one session each day over 10 consecutive weekdays
3033339|NCT02339376|Experimental|Group 2|High-frequency repetitive transcranial magnetic stimulation: 30-minute sessions of 10-Hz continuous stimulation at 110% resting motor threshold, with one session each day over 10 consecutive weekdays
3033340|NCT02339376|Sham Comparator|Group 3|Sham repetitive transcranial magnetic stimulation: use of a specially fabricated coil that provides no magnetic stimulation but has a similar appearance and creates an auditory artifact that mimics TMS
3033341|NCT02339363|Experimental|Sitting Meditation|4 weeks (45-min sessions, 2x per week) of sitting meditation, based on MBSR. The sitting meditation condition consisted of three parts: (a) breathing techniques, (b) meditation, and (c) discussion. Participants in the sitting meditation group learned new types of sitting meditation each week. Participants in the sitting meditation group received a CD that consisted of audio meditations that they could follow along at home. The sitting meditation participants were encouraged to practice formal sitting meditation for 15 to 30 minutes every day and asked to record details of their practice on their daily home practice logs.
3033389|NCT02338947|Active Comparator|On-Pump Coronary-Artery Bypass Grafting|"Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass - CABG~Surgical access to the heart will be gained through a median sternotomy in all of the patients. On-pump surgery will be performed in normothermia, with the use of aortic cross-clamping and cold cardioplegic arrest. Patients will be heparinized with 500 IU/kg to achieve an activated clotting time >480 s. Heparin will be neutralized with 1 mg protamine sulfate per 5000 IU given. During the trial, there will be no changes in the 2 surgical techniques that followed a pre-established protocol."
3033584|NCT02337582|Other|Control|
3033342|NCT02339363|Experimental|Hatha Yoga|4 weeks(45-min sessions, 2x per week) of Hatha Yoga. The adolescent hatha yoga curriculum was used with permission from Shanti Generation Yoga © (2009) created by Abby Wills. The hatha yoga sessions consisted of three parts: (a) breathing techniques, (b) yoga poses, and (c) discussion. Participants in the hatha yoga group learned a series of new yoga poses each week, as well as reviewed old poses. During the first session, participants in the hatha yoga group received a DVD that contained five yoga lessons corresponding to the yoga poses being taught in the intervention. Participants were encouraged to practice the series of yoga poses at home for 15 to 30 minutes each day and record their home practice in their daily home practice logs.
3033343|NCT02339363|No Intervention|Waitlist Control|4-week waitlist control condition. Completed all study measures at same time points as experimental groups. Were randomly assigned to one of the two active treatment conditions after completing the waitlist period.
3033344|NCT02339350|No Intervention|Rapid early responder group|"RER Consolidation BM exam on day 63: M1, M2 -> IM M3 or residual CNS ds or Bx proven extramedullary ds - off protocol~RER Interim Maintenance #1~RER Delayed Intensification~RER Interim Maintenance #2~RER Maintenance (12 weeks=84 days)"
3033345|NCT02339350|Experimental|Slow early responder group|"Includes : SER, Testis(+), CNS 3, T-cell (non ETP), Initial PB WBC ≥ 100,000/μL~1. SER Consolidation~Intrathecal triple chemotherapy at d0, 7, 14, 21 2. SER Interim Maintenance #1~high dose methotrexate included~Intrathecal triple chemotherapy at d0, 28 3. SER Delayed Intensification #1~Intrathecal triple chemotherapy at d0, 28, 35 4. SER Interim Maintenance #2~high dose methotrexate included~Intrathecal triple chemotherapy at d0, 28 5. SER Delayed Intensification #2~Intrathecal triple chemotherapy at d0, 28, 35 6. SER Maintenance~Intrathecal triple chemotherapy at d0"
3033346|NCT02339337|Experimental|RGT group|For subjects who were randomized into the RGT group, the duration of Peg-IFN and RBV therapy was abbreviated to 24 weeks in subjects with HCV genotype 1, a pre-treatment low viral load (LVL, < 400000 IU/mL) and RVR (defined asHCV RNA <50 IU/mL at 4th week of therapy); the duration was 16 weeks in subjects with HCV genotype 2/3 and RVR.
3033347|NCT02339337|Active Comparator|GGT group|Subjects who were randomized into the GGT group received Peg-IFN and standard dose RBV (1200 mg/day) for 48 weeks in subjects infected with HCV genotype 1 or Peg-IFN and low dose RBV (800 mg/day) for 24 weeks in subjects infected with HCV genotype 2/3; the patients were then followed for 6 months.
3033348|NCT02339324|Experimental|This study has one arm that consists of 3 phases or steps.|"Induction phase (first 6 weeks): Pembrolizumab and High Dose IFNα-2b (HDI) Pembrolizumab I.V. every 3-4 weeks for 2 doses concurrently with HDI I.V. x 5 consecutive days every week for 4 weeks, followed by S.C. every other day 3x each week for 2 weeks.~Surgery phase (week 6-8).~Maintenance phase (following recovery from surgery): Pembrolizumab I.V. infusion every 3 weeks given concurrently with HDI S.C. QOD (e.g. M,W,F) TIW every week for 46 additional weeks"
3033349|NCT02339298|Active Comparator|Music group|music application
3033350|NCT02339298|Sham Comparator|Control group|only headphones
3033351|NCT02339285|Experimental|tACS (alpha)|10 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (alpha) device.
3033352|NCT02339285|Experimental|tACS (gamma)|40 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (gamma) device.
3033353|NCT02339285|Sham Comparator|Sham stimulation|Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation. Uses tACS (alpha) device.
3033354|NCT02339272||NOA|Infertile males with non obstructive azoospermia
3033355|NCT02339272||OA|Post-vasectomized patients with proven fertility before vasectomy
3033356|NCT02339259||Febrile patients|Febrile patients admitted to CMCH who have had malaria film and scrub typhus and murine typhus rapid test will be screened for enrolment.
3033357|NCT02339259||Healthy|Healthy subjects with no recent history of fever will be recruited to provide control samples for the blood and plasma assays.
3033358|NCT02339246|Active Comparator|Prograf vs Envarsus XR vs Astagraf XL|Prograft capsules Twice daily for 7 days, followed by Envarsus XR tablets once daily for 7 days followed by Astagraf XL capsules once daily for 7 days.
3033359|NCT02339246|Active Comparator|Prograf vs Astagraf XL vs Envarsus XR|Prograf capsules twice daily for 7 days followed by Astagraf XL capsules once daily for 7 days followed by Envarsus XR tablets once daily.
3033360|NCT02339233|Experimental|Epidural Stimulator|Eligible participants will be implanted with 16-electrode epidural array in the T11-S2 area of the spinal cord
3033361|NCT02339220|Experimental|Standard CI Therapy Group|This group will receive Constraint-Induced Movement Therapy (CIMT) with the Standard Transfer Package (sTP).
3033362|NCT02339220|Experimental|Enhanced CI Therapy Group|This group will receive CIMT with the enhanced Transfer Package (eTP).
3033363|NCT02339220|Active Comparator|Standard Fitness Training Group|This group will receive Lakeshore Enriched Fitness Training (LEFT) with the standard Transfer Package (sTP).
3033364|NCT02339220|Active Comparator|Enhanced Fitness Training Group|This group will receive LEFT with the enhanced Transfer Package (eTP)
3033365|NCT02339207|Placebo Comparator|Placebo|Placebo dosed once in human volunteers in increasing dosages or once daily for seven days in patients with chronic Hepatitis C in increasing dosages.
3033366|NCT02339207|Experimental|AL-335|AL-335 dosed once in human volunteers in increasing dosages or once daily for seven days in patients with chronic Hepatitis C in increasing dosages.
3033367|NCT02339194|Experimental|Simplified protocol|"The application of a simplified denture fabrication technique will be tested for patients presenting severely resorbed mandibular alveolar bones according to the following steps:~Obtainment of maxillary and mandibular casts by using irreversible hydrocolloid in stainless steel stock trays for record bases fabrication.~Adjustment of record bases according to vertical dimension and centric relation measurements, with no use of facebow transfer. Casts will be mounted in semi-adjustable articulator using standardized measures and artificial teeth will be selected.~Trial dentures will be evaluated for esthetics and maxillomandibular relationship.~Insertion of finished dentures."
3033390|NCT02338934|Experimental|Cinacalcet with Vitamin D arm|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal <2.4 mmol/L - Start Cinacalcet 25mg OD & Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if >2.54 mmol/L - Start Cinacalcet 25mg OD & Maintain active Vit D dose. Then they will go to maintenance phase.
3033368|NCT02339194|No Intervention|Traditional protocol|"The importance of a second impression for denture fabrication technique will be tested for patients presenting severely resorbed mandibular alveolar bones according to the following steps:~Maxillary and mandibular casts obtained by using irreversible hydrocolloid in stainless steel stock trays for maxillary record base and mandibular custom tray fabrication.~Mandibular second impression with border molding using compound and impression rubber in custom tray.~Record bases adjustments without facebow transfer. Casts will be mounted in semi-adjustable articulator using standardized measures and artificial teeth will be selected.~Trial dentures will be evaluated for esthetics and maxillomandibular relationship.~Finished dentures insertion."
3033369|NCT02339168|Experimental|enzalutamide and metformin hydrochloride|Patients receive enzalutamide PO QD and metformin hydrochloride PO BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3033370|NCT02339155|Experimental|Anthrax Vaccine Adsorbed|Subjects will be administered subcutaneous (SC) 0.5 mL AVA doses on Days 1, 15, and 29 (0, 2, and 4 weeks).
3033371|NCT02339155|Experimental|AVA + Raxibacumab|Subjects will be administered SC 0.5 mL AVA doses on Days 1, 15, and 29 (0, 2, and 4 weeks), with the first AVA dose administered immediately after completion of a single intravenous (IV) infusion 40 milligram (mg)/kilogram (kg) raxibacumab dose. Subjects will be premedicated with 25-50 mg of diphenhydramine up to 1 hour prior to the raxibacumab infusion to reduce the risk of infusion reactions.
3033372|NCT02339142|Experimental|Combined radiotherapy and iv corticosteroid|"Therapy: iv MP 500 mg iv weekly for 6 weeks, then 250 mg iv weekly for 6 weeks~+ External beam radiotherapy: 100 Rads to each orbit x 10 doses"
3033373|NCT02339142|Active Comparator|iv Corticosteroid|iv MP 500 mg iv weekly for 6 weeks, then 250 mg iv weekly for 6 week No Radiotherapy administered
3033374|NCT02339129|Experimental|SST-0225|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
3033375|NCT02339129|Placebo Comparator|Placebo|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
3033376|NCT02339116|Experimental|Folfoxiri/bev --> folfoxiri/bev|"FOLFOXIRI plus bev (to be repeated every 2 weeks for a maximum of 8 cycles):~Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Irinotecan 165 mg/sqm iv over 60 minutes, day 1 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 At the time of disease progression, patients will re-introduce FOLFOXIRI plus bev at the same doses and schedule previously tolerated, for a maximum of 8 cycles. If no progression occurs during FOLFOXIRI plus bev, patients will receive maintenance 5-FU/LV plus bev at the same dose used in the last cycle of the induction treatment."
3033377|NCT02339116|Active Comparator|folfox/bev-->folfiri/bev|"mFOLFOX-6 plus bev (to be repeated every 2 weeks for a maximum of 8 cycles) Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluoruracil 400 mg/sqm iv bolus, day 1 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1~At the time of disease progression patients will receive FOLFIRI plus bev (to be repeated every 2 weeks for a maximum of 8 cycles):~Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Irinotecan 180 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluoruracil 400 mg/sqm iv bolus, day 1 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion."
3033378|NCT02339103|No Intervention|Shivering only|Pt placed in sleeping bag and warmed by shivering only
3033379|NCT02339103|Experimental|Warmed IV fluids|1 Liter of 42 degree celsius normal saline
3033380|NCT02339103|Experimental|Warmed perfusion pads|Warmed perfusion pads placed to palms and soles to rewarm through arteriovenous anastomoses
3033381|NCT02339090|Experimental|somavaratan|somavaratan long acting recombinant human growth hormone administered subcutaneously twice-monthly
3033382|NCT02339090|Active Comparator|Daily rhGH|Daily recombinant growth hormone therapy administered subcutaneously every day
3033383|NCT02339064|Experimental|Apomorphine infusion|Continuous subcutaneous apomorphine infusion
3033384|NCT02339051|Experimental|One leg jumping|Study subjects will jump on one leg on repeated occasions (incremental daily repetitions) for a period of three months. The same leg will be used for jumping throughout the study. The other leg will serve as control.
3033385|NCT02339038|Other|Standard of Care|Standard of care treatment using Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination by mouth daily for 2, 3, or 6 months
3033386|NCT02338960|Experimental|Bremelanotide|Subjects will self-administer a fixed dose of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours.
3033387|NCT02338960|Placebo Comparator|Placebo Comparator|Subjects will self-administer a fixed dose of placebo subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours.
3033388|NCT02338947|Active Comparator|Off-Pump Coronary-Artery Bypass Grafting|"Coronary Artery Bypass Graft Surgery Without Cardiopulmonary Bypass - OPCAB~Surgical access to the heart will be gained through a median sternotomy in all of the patients. In order to reduce the risk of bleeding and transfusions an absorbable hemostat is used to sternal bone marrow and recovery of red blood cells in all patients. Off-pump surgery will be performed with the use of heart stabilizers. Patients will be heparinized with 250 IU/kg intravenously to achieve activated clotting time >200s. The proximal anastomosis will be performed according to protocol to be discussed with our advisor. The distal anastomosis will be constructed with the help of mechanical stabilizers and cardiac positioner. Intracoronary shunts will be used routinely."
3033391|NCT02338921|Active Comparator|Glimepirde, Metformin, Sitagliptin|"Dipeptidyl peptidase-4 (DPP4) inhibitor~Sitagliptin"
3033392|NCT02338921|Active Comparator|Glimepirde, Metformin, Dapagliflozin|"Sodium-glucose cotransporter 2 (SGLT2) inhibitors~Dapagliflozin"
3033585|NCT02337569|Experimental|NPC-02|Oral dose
3033394|NCT02338908|Experimental|Experimental group|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks. In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
3033395|NCT02338908|Active Comparator|Control group|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
3033396|NCT02338895||acutly oliguric patients with ultrasound|Patients with septic shock and acute oliguria that will undergo bedside ultrasonographic assessment of inferior vena caval diameter, respiratory variation and renal perfusion.
3033397|NCT02338882|Experimental|Bi flex M multifocal intraocular lens|Subjects implanted bilaterally with the Bi flex M multifocal intraocular lens
3033398|NCT02338882|Active Comparator|Bi flex 1.8 monofocal intraocular|Subjects implanted bilaterally with the Bi flex 1.8 monofocal intraocular lens
3033399|NCT02338869|Experimental|Dialogue-based psychosocial intervention|Participants receive six individual meetings with trained health care professional in additional to usual rehabilitation and care. Dialogues focus on individual psychosocial challenges and needs and provide emotional and informational support to encourage and facilitate coping.
3033400|NCT02338869|No Intervention|Usual care Control group|Participants receive usual rehabilitation and care.
3033401|NCT02338856|Experimental|MB12066 200mg|
3033402|NCT02338856|Placebo Comparator|Placebo|
3033403|NCT02338843|Experimental|LJPC-501 (angiotensin II)|Treatment arm
3033404|NCT02338843|Placebo Comparator|Placebo (0.9% sodium chloride solution)|Placebo arm
3033405|NCT02338830|Active Comparator|Progesterone group|Women received vaginal progesterone suppositories
3033406|NCT02338830|No Intervention|No treatment group|Women received no treatment
3033407|NCT02338817||GSD 1|These will be subjects with GSD I. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
3033408|NCT02338817||GSD 0, III, VI, or IX|These will be subjects with GSD 0, III, VI, or IX. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
3033409|NCT02338804|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line
3033410|NCT02338804|Experimental|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line and simultaneous injection of mix vaccine (MV).
3033411|NCT02338791|Experimental|Manual Mobilization|Grade I, II and III manual mobilizations in the inferior, posterior and distractive directions.
3033412|NCT02338778|Active Comparator|Control|Patients in this group will be receiving standard treatment according to National Comprehensive Cancer Network (NCCN) guide line
3033413|NCT02338778|Experimental|MV+control|Patients in this group will be receiving both standard treatment according to NCCN guide line and simultaneous injection of mix vaccine (MV)
3033414|NCT02338765|Experimental|Buddy|Physical activity plus having a buddy
3033415|NCT02338765|Active Comparator|Control|Physical activity only
3033416|NCT02338752|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line
3033417|NCT02338752|Active Comparator|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line and simultaneous injection of mix vaccine (MV).
3033418|NCT02338739|Active Comparator|REC; Outreach if Failure|
3033419|NCT02338739|Active Comparator|REC; SMS + Voucher if Failure|
3033420|NCT02338739|Active Comparator|REC; Navigator if Failure|
3033421|NCT02338739|Active Comparator|SMS; Outreach if Failure|
3033422|NCT02338739|Active Comparator|SMS; Outreach if Failure; Stop SMS if Success|
3033423|NCT02338739|Active Comparator|SMS; SMS+Voucher if Failure|
3033424|NCT02338739|Active Comparator|SMS; SMS+Voucher if Failure; Stop SMS if Success|
3033425|NCT02338739|Active Comparator|SMS; Navigator if Failure|
3033426|NCT02338739|Active Comparator|SMS; Navigator if Failure; Stop SMS if Success|
3033427|NCT02338739|Active Comparator|Voucher; Outreach if Failure|
3033428|NCT02338739|Active Comparator|Voucher; Outreach if Failure; Stop Voucher if Success|
3033429|NCT02338739|Active Comparator|Voucher; SMS+Voucher if Failure|
3033430|NCT02338739|Active Comparator|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|
3033431|NCT02338739|Active Comparator|Voucher; Navigator if Failure|
3033432|NCT02338739|Active Comparator|Voucher; Navigator if Failure; Stop Voucher if Success|
3033433|NCT02338713|Experimental|Noncarbonated Water + Calcichew D3|Noncarbonated water 200 milliliter (mL), orally, once daily on Days 1, 2 and 3 in period 1 (dummy treatment period) followed by Calcichew D3 500 milligram (mg)/1000 international units (IU) (Calcium 500 mg, chewable tablets and vitamin D3 1000 IU, chewable tablets), orally, once daily on Days 4, 5 and 6 in period 2 (study treatment period) of 6 days treatment period.
3033434|NCT02338700|Active Comparator|Control|Patients in this group will be receiving standard treatment according to National Comprehensive Cancer Network (NCCN) guide line
3033435|NCT02338700|Experimental|MV+control|Patients in this group will be receiving both standard treatment according to NCCN guide line and simultaneous injection of mix vaccine (MV)
3033436|NCT02338687|Active Comparator|Education|Educational sessions
3033437|NCT02338687|Experimental|Education plus supplement|Educational sessions and 500 mg calcium per day
3033438|NCT02338674|Experimental|normal ALT|chronic hepatitis B patients with normal ALT
3033439|NCT02338674|Active Comparator|elevated ALT|chronic hepatitis B patients with elevated ALT
3033440|NCT02338648|Experimental|SUN-131 1.5% TDS|Subjects will be randomly assigned to receive SUN-131 1.5% TDS for the affected eye. All patches will be worn for 16±4 hours each day for 21 days.
3033441|NCT02338648|Placebo Comparator|Placebo TDS|Placebo Patch for Blinding Purposes
3033586|NCT02337569|Placebo Comparator|Placebo|Oral dose
3033442|NCT02338635|Experimental|URSA group|Drug: Ursodeoxycholic acid Other Name: URSAⓇ (Daewoong Pharmaceutical Co., Ltd) Ursodeoxycholic acid (100 mg/tablet) 300 mg/day ( 100mg tid) for 6 months 3 times after meal
3033443|NCT02338635|Placebo Comparator|Placebo group|Placebo drug 1 tablet tid for 6 months
3033444|NCT02338622|Experimental|Schedule A: 4 days on, 3 days off|"300mg olaparib + intrapatient dose escalation of AZD5363 4 days on, 3 days off~Schema for dose escalation in schedule A (4-days-on, 3-days-off AZD5363)~-1. Olaparib: 200mg, AZD5363 240mg~Olaparib: 300mg, AZD5363 320mg~Olaparib: 300mg, AZD5363 400mg~Olaparib: 300mg, AZD5363 480mg"
3033445|NCT02338622|Experimental|Schedule B: 2 days on, 5 days off|"300mg olaparib + intrapatient dose escalation of AZD5363 2 days on, 5 days off~Schema for dose escalation in schedule B (2-days-on, 5-days-off AZD5363)~-1. Olaparib: 200mg, AZD5363 400mg~Olaparib: 300mg, AZD5363 480mg~Olaparib: 300mg, AZD5363 560mg~Olaparib: 300mg, AZD5363 640mg"
3033446|NCT02338609|Experimental|Everolimus|All patients will have been previously treated with everolimus as part of CRAD001M2301. Continued treatment with everolimus is allowed but not required for participation in this study. However, the physician may choose to place the patient on another treatment.
3033447|NCT02338609|Experimental|Physician Choice|
3033448|NCT02338596|Experimental|Conventional stem|total hip replacement operated with conventional stem (Profile; DePuy, Leeds, United Kingdom)
3033449|NCT02338596|Active Comparator|Ultra-Short stem|total hip replacement operated with ultra-short stem (Proxima; DePuy, Leeds, United Kingdom)
3033450|NCT02338570|Other|Everolimus|All patients will receive everolimus 10 mg orally per day. Treatment will continue until progression, unacceptable toxicity, patient refusal or medical decision
3033451|NCT02338557|Experimental|GROUP A|Subjects in Group A received MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects.
3033452|NCT02338557|Active Comparator|GROUP B|Group B received Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
3033453|NCT02338531|Experimental|Therapeutic regimen|oral administration of PF-03084014, 9 days at 150 mg q.d. (day 1 and 9) and 150 b.i.d. (day 2 till 8)
3033454|NCT02338518|Experimental|SEEOX group|A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, oxaliplatin 100 mg/m2, etoposide 80 mg/m2, and pharmorubicin 30 mg/m2 were administered from the celiac artery on day 1. 80 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
3033455|NCT02338518|Active Comparator|SOX group|A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, patients received intravenous oxaliplatin 130 mg/m2 on day 1, and 80 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
3033456|NCT02338505|Experimental|Telelap ALF-X in obese patients with gynecological disease|
3033457|NCT02338492|Experimental|Photodynamic Bone Stabilization System|Photodynamic Bone Stabilization System (PBSS) is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone
3033458|NCT02338466|Placebo Comparator|rt-PA|"Patients treated by thrombolysis with rt -PA within 4h30 of the onset of symptoms to a proximal middle cerebral artery occlusion visible on a MRI 1 are pre- included. A second MRI ( IRM2 ) is performed between 1 hour and 1.5 hours after administration of rt-PA in the usual way .~After the treatment by rt-PA, if there is no recanalization (TIMI score: 0,1, 2a), the patient is included. A patient included will be randomized either in the arm rt-PA treatment only or in the arm rt-PA + tenecteplase treatment. If he is included in the arm rt-PA only, he will not receive any other treatment for the study."
3033459|NCT02338466|Active Comparator|rt-PA + tenecteplase|"If patient is in the arm rt-PA + tenecteplase, he will receive tenecteplase (50UI/Kg) treatment. A third MRI will be performed at 24hour that will assess the recanalization status (TIMI), the final volume infarct and the hemorrhagic complications."
3033460|NCT02338453|Active Comparator|Attention Bias Modification Treatment|Participants will receive an attention bias modification protocol designed to divert attention away from socially-threatening stimuli via repeated trials of a dot-probe task.
3033461|NCT02338453|Placebo Comparator|placebo-control condition|Participants will receive an placebo control protocol using the same task and stimuli but not designed to change attention patterns
3033462|NCT02338440|Experimental|lipoprostaglandin E1 treatment arm|"lipoprostaglandin E1 1mcg/kg/day, continuous infusion~lipoprostaglandin E1 1.5mcg/kg/day, continuous infusion (for patients with elevating total bilirubin, hepatomegaly, right upper quadrant abdominal pain, unexplained weight gain)"
3033463|NCT02338427|Experimental|proteomic|
3033464|NCT02338414|Other|Romiplostim|Patients receiving romiplostim due to ITP
3033465|NCT02338401|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
3033466|NCT02338401|Placebo Comparator|Placebo Pill|Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.
3033467|NCT02338388|Active Comparator|Single-layer unlocked closure|
3033468|NCT02338388|Active Comparator|Single-layer locked closure|
3033469|NCT02338388|Active Comparator|Double-layer closure|The first layer was continuous and unlocked and a second, continuous non-locking imbricating layer was applied over the first suture.
3033470|NCT02338375|Experimental|Cartistem|For control group patients currently standard treatment of arthroscopic curettage and microfracture is performed, and for study group patients allogenic umbilical cord blood-derived mesenchymal stem cell product(Cartistem®) is added on the lesion after above mentioned procedure.
3033471|NCT02338375|Active Comparator|standard treatment|standard treatment of arthroscopic curettage and microfracture for osteochondral lesion of talus
3033587|NCT02337556|Experimental|Intervention Group|Peptamen Bariatric
3033474|NCT02338349|Experimental|Elacestrant|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of elacestrant.~Part B, Safety Expansion: Once the MTD has been identified and/or a RP2D has been selected, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary efficacy of the RP2D.~Part C, Tablet Introduction: A cohort of patients will be enrolled to evaluate the safety, tolerability, and PK of a tablet dosage form at 400 mg QD.~Part D, Dose Expansion: A cohort of patients will be enrolled to evaluate the safety, tolerability, PK and preliminary anti-tumor effect of elacestrant in tablet dosage form at 400 mg QD PO in a group of patients with a more homogeneous prior treatment history"
3033475|NCT02338336|Placebo Comparator|Placebo|Placebo
3033476|NCT02338336|Experimental|Nowarta110 3 drops|Nowarta110 3 drops administration
3033477|NCT02338336|Experimental|Nowarta110 6 drops|Nowarta110 6 drops administration
3033478|NCT02338336|Experimental|Nowarta110 10 drops|Nowarta110 10 drops administration
3033479|NCT02338323|Experimental|Febuxostat|take orally, 40mg per day, for 1 year
3033480|NCT02338323|Experimental|Benzbromarone|take orally, 50mg per day, for 1 year
3033481|NCT02338310|No Intervention|No Aromatase Inhibitor|No aromatase inhibitor given around the time of surgery
3033482|NCT02338310|Experimental|Aromatase Inhibitor|Aromatase Inhibitor given perioperatively for 4 weeks (two weeks before and two weeks after surgery) Choice of AI is according to centre policy and may be either anastrozole (1mg/day) or letrozole (2.5mg/day)
3033483|NCT02338297|Experimental|TACE+EGM|Occlude APS with EGM and perform TACE sequentially
3033484|NCT02338297|Active Comparator|TACE+PVA|Occlude APS with PVA and perform TACE sequentially
3033485|NCT02338271|Other|a single, open clinical trial|"a single-group, open, investigator-initiated clinical study~: autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) plus Tissuefill (hyaluronic acid derivatives) 1mL/syringe"
3033486|NCT02338258|Experimental|The Anti-rotational plate group|The method was used to control the rotational unstabilization at the fracture site
3033487|NCT02338258|Placebo Comparator|Exchanged Intramedullary nailing group|the method Provided the axial and rotational stability
3033488|NCT02338245|Experimental|Treatment Arm A|ASLAN001 + Capecitabine
3033489|NCT02338245|Active Comparator|Treatment Arm B|Lapatinib + Capecitabine
3033490|NCT02338232|Experimental|160 mg Telmisartan|60 patients will receive 160 of Telmisartan (2 80 mg tablets) for 101 days
3033491|NCT02338219|Active Comparator|vaginal delivery|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
3033492|NCT02338219|Active Comparator|elective cesarean section|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
3033493|NCT02338219|Active Comparator|urgent cesarean section|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
3033494|NCT02338206|Active Comparator|Long + Growth hormone|Patients in this group were given a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) starting on the day 21 of preceding cycle at a dose of 0.1 mg/day, subcutaneously along with Growth hormone (Norditropin, Novo nordisk) co-treatment daily in a dose of 2.5 mg S.C. till the day of hCG administration.. On the second day of menstruation, Human menopausal gonadotrophin HMG (75 IU, Merional, IBSA) was started, and this was associated with reduction of triptorelin dose to 0.05 mg/day. This reduced daily dose, in addition to HMG and growth hormone, were continued till the day of hCG administration.
3033495|NCT02338206|No Intervention|Long protocol only|Patients in this group were given a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) starting on the day 21 of preceding cycle at a dose of 0.1 mg/day, subcutaneously. On the second day of menstruation, Human menopausal gonadotrophin HMG (75 IU, Merional, IBSA) was started, and this was associated with reduction of triptorelin dose to 0.05 mg/day. This reduced daily dose, in addition to HMG, were continued till the day of hCG administration.
3033496|NCT02338193|Experimental|DAPA/MET XR|Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
3033497|NCT02338193|Active Comparator|Dapaglifloxin|Dapagliflozin- 10 mg once daily before first meal for 24 weeks
3033498|NCT02338193|Active Comparator|Metformin XR|Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
3033499|NCT02338180|No Intervention|Control group A|Children with no caries lesion on adjacent surfaces of second primary molar and first permanent molar
3033500|NCT02338180|Experimental|Group B Preventive sealant|Children with active caries lesion on distal surfaces of second primary molar and sound mesial surface of first permanent molar. In every children a split mouth design was applied, in one mesial surfaces of first molar randomize selected received a proximal preventive sealants, and the other remain as a control
3033501|NCT02338180|Experimental|Group C Therapeutic sealant|Children with active caries lesion on distal surfaces of second primary molar and active lesion on mesial surface of first permanent molar. In every children a split mouth design was applied, in one mesial surfaces of first molar randomize selected received proximal therapeutic sealant, and the other remain as a control
3033502|NCT02338141|Experimental|Portable colposcopy|Diagnostic evaluation with 8x magnification portable colposcopy after visual inspection with acetic acid
3033503|NCT02338141|Active Comparator|Conventional colposcopy|Diagnostic evaluation with standard 25x magnification conventional colposcopy after visual inspection with acetic acid
3033504|NCT02338115||Weekly paclitaxel treatment group|Breast cancer patients initiating paclitaxel 80mg/m2 weekly x 12 weeks for curative treatment will be followed prospectively for collection of samples and longitudinal neuropathy data.
3033505|NCT02338102|Experimental|Treatment Group|Subjects in this group will perform twice daily nasal irrigations. Nasal irrigations will be performed by using premeasured salt packets mixed with distilled water in NeilMed irrigation bottles. The subject will be instructed to lean forward over the sink, place the bottle up to the nostril, and hold their breath while gently squeezing the bottle. One bottle is used to irrigate both nostrils, using half the solution on each side.
3033506|NCT02338102|No Intervention|Control Group|Subjects randomized to this arm receive no intervention.
3033507|NCT02338089|No Intervention|Control (no oxytocin) pretreatment|Physiological saline solution (PSS). Every 15-minutes, the PSS will be flushed and fresh PSS will be added.
3033508|NCT02338089|Active Comparator|Continuous oxytocin (desensitizing) pretreatment|Continuous oxytocin 10-5M. This desensitizing treatment is based on previous experiments in our laboratory demonstrating this phenomenon (reference 25 of Internal Review). The desensitizing pretreatment mimics the clinical setting of labor augmentation. Every 15-minutes, the 10-5M oxytocin will be flushed and fresh 10-5M oxytocin will be added.
3033509|NCT02338089|Active Comparator|Pulsatile oxytocin pretreatment|15-minutes of 10-5M oxytocin, followed by PSS for 15-minutes, followed by 10-5M oxytocin, followed by 15-minutes PSS, and so-on, for a total duration of two-hours,
3033510|NCT02338076|Experimental|Interventional arm|petrolatum application under occlusion
3033511|NCT02338063|Experimental|1|Virtual Reality
3033512|NCT02338063|Experimental|2|Health Promotion
3033513|NCT02338050|Experimental|Moxetumomab Pasudotox|Moxetumomab pasudotox 32 mcg/kg/dose IV every other day for a total of 6 doses. Dexamethasone 2.5 mg/m2/dose (or corticosteroid equivalent) will be administered before and after each dose of moxetumomab pasudotox.
3033514|NCT02338037|Experimental|Treatment (eribulin mesylate)|Patients undergo tumor resection or biopsy and have microdialysis catheter placed on day 0. Beginning at least 24 hours later, patients receive eribulin mesylate IV over 2-5 minutes on day 1. Serial brain fluid samples are collected for approximately 72 hours and the microdialysis catheter is then removed. Beginning at least 2 weeks after tumor resection or biopsy, patients may continue to receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3033515|NCT02338024|Experimental|MARTAS intervention|Structured motivational sessions and further communication between linkage coordinators and HIV-positive patients focused on engagement in HIV medical care.
3033516|NCT02338024|No Intervention|Standard of care|
3033517|NCT02338011|Experimental|Gefitinib alone|Patients harboring an EGFR mutation with multiple BM from NSCLC will receive Gefitinib 250mg per day until progression of disease.
3033518|NCT02338011|Experimental|Gefitinib concurrent WBRT|Patients harboring an EGFR mutation with multiple BM from NSCLC will receive Gefitinib concurrent WBRT until progression of disease.Gefitinib was given 250mg per day. WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
3033519|NCT02337998|Experimental|Healthy men|each individual will serve as his own control by comparing baseline values to post intervention values
3033520|NCT02337985|Experimental|Treatment (R-EPOCH, rHIV7-shI-TAR-CCR5RZ-transduced HSPC)|"Patients receive prednisone PO BID on days 1-5; rituximab IV on day 1; etoposide IV over 96 hours, doxorubicin hydrochloride IV over 96 hours and vincristine sulfate IV over 96 hours on days 1-4; and cyclophosphamide IV over 30-60 minutes on day 5. Patients then receive filgrastim SC QD beginning on day 6 and continuing until absolute neutrophil count recovers. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic stem/progenitor cells IV on day 0 (48 hours after the final combination chemotherapy course.)"
3033521|NCT02337972|Experimental|Diabetic patients|Patients with Diabetes Mellitus and macular edema who were determined by their treating physician to require at least 3 serial injections with an anti-Vascular epithelial growth factor (VEGF). Prior to each injection a use of povidone-iodine 4% drops will be performed to clean the conjunctival sac
3033522|NCT02337959|Experimental|Predicate & Invest.-GOS|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
3033523|NCT02337959|Experimental|Predicate & Invest.-CsI|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
3033524|NCT02337959|Experimental|Predicate & Invest.-Cadavers GOS & CsI|Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using the both the GoS and the CsI investigational detectors.
3033525|NCT02337946|Experimental|Protocol Treatment [1] and Group A, Protocol treatment [2]|Protocol Treatment [1]mFOLFOX6 + panitumumab combination therapy [oxaliplatin (OXA): 85 mg/m2/day 1; levofolinate calcium (l-LV): 200 mg/m2/day 1; bolus 5-FU: 400 mg/m2/day 1; infusional 5-FU: 2400 mg/m2/day 1-3; panitumumab: 6 mg/kg] once every two weeks, 6 cycles Protocol Treatment [2] Group A mFOLFOX6 + panitumumab combination therapy, once every two weeks
3033526|NCT02337946|Active Comparator|Protocol Treatment [1] followed by Group B, Treatment [2]|Protocol Treatment [1] mFOLFOX6 + panitumumab combination therapy [oxaliplatin (OXA): 85 mg/m2/day 1; levofolinate calcium (l-LV): 200 mg/m2/day 1; bolus 5-FU: 400 mg/m2/day 1; infusional 5-FU: 2400 mg/m2/day 1-3; panitumumab: 6 mg/kg] once every two weeks, 6 cycles Protocol Treatment [2] Group B 5-FU/LV + panitumumab combination therapy [levofolinate calcium (l-LV): 200 mg/m2/day 1; bolus 5-FU: 400 mg/m2/day 1; infusional 5-FU: 2400 mg/m2/day 1-3; panitumumab: 6 mg/kg] once every two weeks
3033527|NCT02337933|Experimental|Ursolic acid|Ursolic acid capsules, 150 mg, once a day before breakfast during 12 weeks
3033528|NCT02337933|Placebo Comparator|Placebo|Calcined magnesia capsules, 150 mg, once a day before breakfast during 12 weeks
3033529|NCT02337907|Placebo Comparator|Placebo comparator|
3033530|NCT02337907|Experimental|BI 409306 dose 1|
3033531|NCT02337907|Experimental|BI 409306 dose 2|
3033532|NCT02337907|Experimental|BI 409306 dose 3|
3033533|NCT02337907|Active Comparator|Active Comparator Donepezil|
3033534|NCT02337907|Experimental|BI 409306 dose 4|
3033535|NCT02337894|Experimental|Essential amino acids plus arginine|Children randomized to the intervention group will receive a supplement containing essential amino acids plus arginine in the form of a drink which they will have to take for 8 weeks. Measurement of liver lipid content, hepatic apoptosis, plasma lipids, apolipoprotein B-100 levels, hepatic fatty oxidation, whole body insulin sensitivity, body composition and whole body protein turnover will be compared with the the placebo group, and before and after the intervention.
3033536|NCT02337894|Placebo Comparator|Control drink|The control drinks will be indistinguishable from the intervention drinks in taste and volume, but will contain placebo rather than essential amino acids plus arginine.
3033537|NCT02337881|Active Comparator|nifedipen and sildenafil|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours, at the same time sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
3033588|NCT02337556|Active Comparator|Control Group|Replete
3033538|NCT02337881|Active Comparator|nifedipen only|nifedipine alone in the same regimen and duration described before.
3033539|NCT02337868|Experimental|High Dose Expanded|15 subjects will receive 4 mcg of HydroVax-001 IM and 4 subjects will receive placebo IM on Days 1 and 29.
3033540|NCT02337868|Experimental|High Dose Sentinel|5 subjects will receive 4 mcg of HydroVax-001 IM and 1 subject will receive placebo IM on Days 1 and 29.
3033541|NCT02337868|Experimental|Low Dose Expanded|15 subjects will receive 1 mcg of HydroVax-001 IM and 4 subjects will receive placebo IM on Days 1 and 29.
3033542|NCT02337868|Experimental|Low Dose Sentinel|5 subjects will receive 1 mcg intramuscularly (IM) of HydroVax-001 and 1 subject will receive placebo IM on Days 1 and 29.
3033543|NCT02337855|Experimental|Group A|N=10 subjects will receive single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113
3033544|NCT02337855|Experimental|Group B|N=10 subjects will receive single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
3033545|NCT02337855|Placebo Comparator|Group C|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
3033546|NCT02337855|Experimental|Group D|N=10 subjects will receive single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113
3033547|NCT02337855|Experimental|Group E|N=10 subjects will receive single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
3033548|NCT02337855|Placebo Comparator|Group F|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
3033549|NCT02337855|Experimental|Group G|N=10 subjects will receive single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113
3033550|NCT02337855|Experimental|Group H|N=10 subjects will receive single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
3033551|NCT02337855|Placebo Comparator|Group I|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
3033552|NCT02337842|Experimental|Cohort 1|N= 9 subjects will receive single oral dose of GII.4 CIN-1 at 10^3 RT-PCR units and N=1 single oral dose Placebo.
3033553|NCT02337842|Experimental|Cohort 2|N=9 subjects will receive single oral dose of GII.4 CIN-1 either at 10^2 or 5x10^3 RT-PCR units and N=1 single oral dose of Placebo.
3033554|NCT02337842|Experimental|Cohort 4|N=36 subjects will receive single oral dose of GII.4 CIN-1 at either 5x10^4 or 5x10^3 or 10^3 or 10^2 or 10^4 or 5x10^2 or 5x10^1RT-PCR units , N=4 subjects receive a single oral dose of Placebo
3033555|NCT02337842|Experimental|Cohort 3|N=18 subjects will receive single oral dose of GII.4 CIN-1 at either 10^4, 10^3, 5x10^2 or 5x10^1 RT-PCR units and N=2 single oral dose of Placebo
3033556|NCT02337829|Experimental|A|to undergo superficial lymph node biopsies
3033557|NCT02337829|Experimental|B|to undergo bone marrow biopsies
3033558|NCT02337816|Other|Endometriosis|Patients will undergo laparoscopic surgery in order to treat endometriosis. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood, with the purpose to study metabolitis, will be collected before surgery.
3033559|NCT02337816|Other|Controls|Patients will undergo laparoscopic surgery in order to treat benign gynecological diseases. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood,with the purpose to study metabolitis, will be collected before surgery.
3033560|NCT02337803|Experimental|Strength Training Group|Participants will meet three times a week for one hour strength training sessions for twelve weeks.
3033561|NCT02337803|Active Comparator|Usual Care|Participants will be given access to the strength training program after the twelve week study ends.
3033562|NCT02337790||Cohort 1|Subjects will have a pacemaker, implanted cardioverter-defibrillator, or ventricular assist device.
3033563|NCT02337764|Experimental|TVP-1012 Group|TVP-1012 (1 mg/day) once daily orally, either before or after breakfast.
3033564|NCT02337751|Experimental|TVP-1012 1mg Group|TVP-1012 (1 mg/day) once daily, either before or after breakfast.
3033565|NCT02337738|Experimental|TVP-1012 1mg Group|TVP-1012 (1 mg/day) once daily orally, either before or after breakfast, concomitantly with levodopa tablet.
3033566|NCT02337738|Experimental|TVP-1012 0.5mg Group|TVP-1012 (0.5 mg/day) once daily orally, either before or after breakfast, concomitantly with levodopa tablet.
3033567|NCT02337738|Placebo Comparator|Placebo Group|One Placebo tablet once daily orally, either before or after breakfast, concomitantly with levodopa tablet.
3033568|NCT02337725|Experimental|TVP-1012 Group|TVP-1012 (1 mg/day) once daily orally, either before or after breakfast.
3033569|NCT02337725|Placebo Comparator|Placebo Group|Placebo once daily orally, before or after breakfast.
3033570|NCT02337712|Experimental|q.d. RT|q.d. RT (65 Gy in 26 fractions) to the chest and four cycles of etoposide and cisplatin
3033571|NCT02337712|Active Comparator|b.i.d.RT|b.i.d.RT (45Gy in 30 fractions) to the chest and four cycles of etoposide and cisplatin
3033572|NCT02337699||Treated Subjects|All subjects recruited into the main study treated with the Axium neurostimulator
3033573|NCT02337699||QST Group|A sub-set of the main study group who also consent to take part in the Quantitative Sensory Testing based feasibility study
3033574|NCT02337686|Experimental|Pembrolizumab|Pembrolizumab 200 mg, intravenously (IV) once every 3 weeks prior to surgery for two doses and then restarting 200 mg every 3 weeks following surgical resection. Cycles defined as every 42 days.
3033575|NCT02337660|Experimental|Healthy, lean|"15 healthy, lean subjects.~Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed."
3033576|NCT02337660|Experimental|Obese, otherwise healthy|"15 obese, otherwise healthy subjects~Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed."
3033577|NCT02337647|Other|DCDC app|Subjects will evaluate the DCDC app
3033578|NCT02337634|Placebo Comparator|Placebo|Matched dosage of milk thistle daily.
3033579|NCT02337634|Active Comparator|Milk Thistle|Capsule form, 150mg BID to 300mg BID
3033580|NCT02337621||pectus excavatum surgical candidates|Any person who is eligible to undergo the Nuss procedure for surgical correction of pectus excavatum
3033581|NCT02337608|Experimental|GLPG1205 100mg QD|GLPG1205 100mg daily dosing in the morning
3033582|NCT02337608|Placebo Comparator|Placebo|Placebo daily dosing in the morning
3033583|NCT02337582|Active Comparator|Intervention|
3033590|NCT02337543|Placebo Comparator|placebo|Placebo matching NEO6860 suspension formulation
3033591|NCT02337530|Active Comparator|Arm A|"Selumetinib: 75mg/ bid PO given on days 2-19 Pemetrexed: 500mg/m^2 & Cisplatin or Carboplatin*: AUC6: 75mg/m^2 given on day 1 Schedule = q 21 days~*Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
3033592|NCT02337530|Active Comparator|Arm B|"Selumetinib: 75mg/ bid PO given on days 1-21 (continuous) Pemetrexed: 500mg/m^2 & Cisplatin*: 75mg/m^2 or carboplatin AUC 6 given on day 1 Schedule = q 21 days~**Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
3033593|NCT02337530|Active Comparator|Arm C|"Selumetinib: NOT GIVEN Pemetrexed: 500mg/m^2 & Cisplatin*: 75mg/m^2 or carboplatin AUC6 given on day 1 Schedule = q 21 days~*Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
3033594|NCT02337517|Experimental|Supportive care (vismodegib)|Patients receive vismodegib PO daily, every other day, every three days, or twice weekly for 6-12 months in the absence of disease progression or unacceptable toxicity.
3033595|NCT02337504|No Intervention|clinic-based care|Will receive HIV care at the clinic from the nurses and clinical officer on their regular schedule
3033596|NCT02337504|Active Comparator|Community-based care|Will receive HIV care in their community from a community health worker every month as part of a group of 6-10 people
3033597|NCT02337491|Experimental|Cohort A Safety Lead-In: Pembrolizumab (DL 0) + Bevacizumab|"Pembrolizumab (Dose Level 0): 200 mg administered intravenously on days 1 and 22 of each 42 day cycle Bevacizumab: 10 mg/kg administered Intravenously on days 1, 15 and 29 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
3033598|NCT02337491|Experimental|Cohort A: Pembrolizumab + Bevacizumab|"Pembrolizumab: 200 mg administered intravenously on days 1 and 22 of each 42 day cycle Bevacizumab: 10 mg/kg administered Intravenously on days 1, 15 and 29 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
3033599|NCT02337491|Experimental|Cohort B: Pembrolizumab|"Pembrolizumab: 200 mg administered intravenously on days 1 and 22 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
3033600|NCT02337478|Experimental|Treatment (vincristine sulfate liposome)|Patients receive vincristine sulfate liposome via injection on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3033601|NCT02337465|Experimental|Diagnostic (KV-CBCT, ultrasound-guided radiation therapy)|Patients undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Patients also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.
3033602|NCT02337452||MDA Participant with Genetic Mutation|Participants complete a family history questionnaire online, which should take about 20 minutes to complete. Participants also taught how to use the Web-Based Family Outreach Registry. They will be given a secure log-in username and password for the web site.
3033603|NCT02337452||Relative of MDA Participant with Genetic Mutation|Participants complete a family history questionnaire online, which should take about 20 minutes to complete. Participants also taught how to use the Web-Based Family Outreach Registry. They will be given a secure log-in username and password for the web site.
3033604|NCT02337452||Non-MDA Participant with Genetic Mutation|Participants complete a family history questionnaire online, which should take about 20 minutes to complete. Participants also taught how to use the Web-Based Family Outreach Registry. They will be given a secure log-in username and password for the web site.
3033605|NCT02337439|Experimental|Sensory Information Processing Training|Computerized training designed to improve sensory processing
3033606|NCT02337439|Active Comparator|Active Control Training|Commercially available computer exercises that were not designed specifically to improve sensory information processing.
3033607|NCT02337426|Experimental|Treatment (dimethyl fumarate, temozolomide, radiation therapy)|"CONCOMITANT THERAPY: Between 21 days (3 weeks) and 42 days (6 weeks) following the last surgical procedure, patients receive temozolomide PO QD for 42-49 days and dimethyl fumarate PO BID or TID continuously. Patients also undergo radiation therapy 5 days a week over 6 weeks for a total of 30 fractions~MAINTENANCE THERAPY: Patients continue to receive dimethyl fumarate PO BID or TID continuously. Four weeks after completing concomitant temozolomide and radiation therapy, patients also receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity."
3033608|NCT02337413|Active Comparator|Urotherapy + Constipation Treatment|This group will be treated with standard behavioral urotherapy in addition to receiving active stool softening with PEG3350 and standard constipation instruction.
3033609|NCT02337413|Other|Urothearpy alone|This group will receive standard behavioral urotherapy alone
3033610|NCT02337400|Experimental|Smoking Reduction Program|"Cognitive behavioral smoking reduction program Smoke_less Duration: 5 weeks with 4 weekly sessions over 2,5 hours and two phone calls"
3033611|NCT02337400|Active Comparator|Counseling Interview|15 minute counseling interview
3033612|NCT02337400|No Intervention|Waiting Control Group|
3033613|NCT02337387|Experimental|Blosozumab Formulation A|Part A. Blosozumab administered as 2 subcutaneous (SC) injections in week 1 followed by once weekly (QW) injections SC in weeks 2 to 6, followed by six week follow-up period.
3033614|NCT02337387|Experimental|Blosozumab Formulation B|Part A. Blosozumab administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
3033615|NCT02337387|Placebo Comparator|Placebo|Part A. Placebo administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
3033616|NCT02337387|Experimental|Blosozumab (Part B)|Part B. Blosozumab formulation determined by Part A administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
3033617|NCT02337361|Experimental|e-SBI|Single session, Electronic SBI for risky alcohol use
3033618|NCT02337361|No Intervention|Control|Treatment as usual with only assessment
3033619|NCT02337348|Experimental|OCT guided coronary intervention|Coronary angiography and optical coherence tomography imaging
3033620|NCT02337348|Active Comparator|Conventional coronary intervention|Coronary angiography
3058781|NCT02170012|Experimental|Cohort 2-PF-06743649 or placebo|
3033621|NCT02337322|Active Comparator|ABC+3TC+DTG|Abacavir+lamivudine+Dolutegravir, QD, Single tablet Regimen
3033622|NCT02337322|Active Comparator|ABC+3TC+DRV/r|Abacavir+lamivudine+ritonavir-boosted darunavir, QD
3033623|NCT02337309|Other|SF1126|Patients will receive SF1126 IV over 90 minutes on Days 1 and 4 of each week during each cycle.
3033624|NCT02337296|Other|Phase 1 - Intervention|Five patients will be enrolled consecutively for the ADHERE intervention and be followed in order to refine the intervention as needed. This permits the investigation of the process of change at baseline, after the intervention, and across the phases.
3033625|NCT02337296|No Intervention|Phase 2 - Control Group|Following completion of Phase 1 and prior to initiation of enrollment in the intervention group, patients will be enrolled in the control group and will receive usual care.
3033626|NCT02337296|Experimental|Phase 2 - Intervention Group|Following enrollment of all control group patients, the intervention group will be recruited and enrolled and the ADHERE intervention will be conducted by the trained APRN interventionist at cancer center.
3033627|NCT02337283|Experimental|BI 425809 very low dose - part I|Part I only - very low dose tablet, oral administration with 240 ml water, over 14 days
3033628|NCT02337283|Placebo Comparator|Placebo - part I|Part I only - placebo tablet, oral administration with 240ml water, over 14 days
3033629|NCT02337283|Experimental|BI 425809 low dose - part I|Part I - low dose tablet, oral administration with 240 ml water, over 14 days
3033630|NCT02337283|Experimental|BI 425809 medium dose - part I|Part I only - medium dose tablet, oral administration with 240 ml water, over 14 days
3033631|NCT02337283|Experimental|BI 425809 high dose -part I|Part I only - high dose tablet, oral administration with 240 ml water, over 14 days
3033632|NCT02337283|Experimental|BI 425809 low dose - part II|Part II - one low dose tablet on day 1 of visit 2 and 2a
3033633|NCT02337283|Experimental|BI 425809 very high dose -part I|Part I only - very high dose tablet, oral administration with 240 ml water, over 14 days
3033634|NCT02337270|Experimental|Group 1 Aerosol|Receive 10^6 Ad5Ag85A by aerosol at day 0
3033635|NCT02337270|Experimental|Group 2 Aerosol|Receive 10^7 Ad5Ag85A by aerosol at day 0
3033636|NCT02337270|Experimental|Group 3 Aerosol|Receive 10^8 Ad5Ag85A be aerosol at day 0
3033637|NCT02337270|Experimental|Group 3 Intramuscular|Receive 10^8 Ad5Ag85A by intramuscular injection at day 0
3033638|NCT02337257|Active Comparator|cholecalciferol|Subjects will take 4000 IU per day for 30 days
3033639|NCT02337257|Placebo Comparator|Placebo|Subjects will take placebo everyday for 30 days
3033640|NCT02337231|Other|GG genotype|Healthy participants with genotype GG at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
3033641|NCT02337231|Other|GT genotype|Healthy participants with genotype GT at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
3033642|NCT02337231|Other|TT genotype|Healthy participants with genotype TT at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
3033643|NCT02337218|Active Comparator|SENSUS Pain Management System|Electrical stimulation device worn on the leg delivering a dose of 50 volts.
3033644|NCT02337218|Sham Comparator|SENSUS Pain Management System - Sham|Electrical stimulation device worn on the leg and programmed to deliver no stimulation.
3033645|NCT02337205|Experimental|KX2-391 Ointment|
3033646|NCT02337192|Experimental|Group 1|Negative control - Moutwash with 1,5mL of dimethyl sulfoxide at 5% (DMSO) in water solution - During 2 minutes.
3033647|NCT02337192|Experimental|Group 2|Mouthwash with Swish with Curcumin
3033648|NCT02337192|Experimental|Group 3|Moutwash with Swish with Curcumin + SDS
3033649|NCT02337192|Experimental|Group 4|Experiment use dental irradiation with blue light (LED) only.
3033650|NCT02337192|Experimental|Group 5|Antimicrobial Photodynamic Therapy (APDT) with blue light and Curcumin salt.
3033651|NCT02337192|Experimental|Group 6|Antimicrobial Photodynamic Therapy (APDT) with blue light, Curcumin salt and surfactant.
3033652|NCT02337192|Experimental|Group 7|Positive control - Use of mouthwash with Chlorhexidine only
3033653|NCT02337179|Experimental|Voluntary medical male circumcision|Eligible men will be circumcised according to protocol
3033654|NCT02337166|Active Comparator|Control|open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap
3033655|NCT02337166|Experimental|Test|open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap and application of a rhFGF-2/HA in the intrabony defect
3033656|NCT02337140|Experimental|Pacemaker|Patient who have been implanted with a pacemaker after TAVI
3033657|NCT02337140|Active Comparator|No Pacemaker|Patient who have not been implanted with a pacemaker after TAVI
3033658|NCT02337127|Active Comparator|Arm A|250 treatment-naïve CHB patients who received at least 3-year of oral antiviral agents will receive Lamivudine extending therapy for 5 years.
3033659|NCT02337127|No Intervention|Arm B|250 treatment-naïve CHB patients who received at least 3-year of oral antiviral agents will receive follow-up.
3033660|NCT02337114|Experimental|Intervention group|Treatment as Usual and Acceptance & Commitment Therapy
3033661|NCT02337114|Other|Comparison group|Treatment as Usual
3033662|NCT02337101|Active Comparator|Enhanced Usual Care (EUC)|Clinical psychiatric and neurological assessment. Information and advice.
3033663|NCT02337101|Experimental|EUC + Early intervention programme|Clinical psychiatric and neurological assessment. Information and advice. Individually targeted treatment programme.
3033664|NCT02337088|Active Comparator|30 seconds|For subjects in the 30 second arm, the umbilical cord will be clamped at 30 seconds after delivery.
3033665|NCT02337088|Experimental|60 seconds|For subjects in the 60 second arm, the umbilical cord will be clamped at 60 seconds after delivery.
3033666|NCT02337075|Experimental|Now Group - PATH Program|The Now Group will receive the PATH program. They will participate in a brief education session, use a wearable physical activity tracker, and physical activity mentoring by an Activity Mentors. In Month 1 and 2, participants will meet with their Activity Mentor once every 2 weeks to review their physical activity status, activity goals, and the health programs available at the Centre. In Month 3 and 4, they will continue to use physical activity tracker but will no longer have regular meetings with the Activity Mentor.
3033667|NCT02337075|Active Comparator|Later Group|The Later Group will receive the PATH program in Month 1-2. Intervention will be provided two months later (i.e., Month 3 and 4).
3033668|NCT02337062|Experimental|APD421 + standard anti-emetic|Single dose of IV APD421
3033669|NCT02337062|Placebo Comparator|Placebo + standard anti-emetic|Single dose of IV placebo
3033670|NCT02337049||Previously early onset preeclampsia|Women with a history of early onset preeclampsia 10 years ago
3033671|NCT02337049||Previously late onset preeclampsia|Women with a history of late onset preeclampsia 10 years ago
3033672|NCT02337049||Previously normotensive pregnancy|Women with a history of normotensive pregnancies 10 years ago
3033673|NCT02337036|Experimental|Arm 1: Pharmacokinetic and Pharmacogenetic|Liver Transplant Children treated with tacrolimus
3033674|NCT02337023||healthy subjects|
3033675|NCT02337023||patients with Kleine-Levin Syndrome|
3033676|NCT02337010|Active Comparator|Control|In the control group if the mean arterial pressure fall below 60 mm Hg and the central venous pressure (CVP) is low fluid bolus is administered if the central venous pressure is in normal range vasopressor is given.
3033677|NCT02337010|Experimental|CeVOX|In the ScvO2 group patients receive interventions in two options: if the ScvO2 fall below 75% or more than 3% or if the mean arterial pressure fall below 60 mm Hg. In the former case the mean arterial pressure in the latter the ScvO2 values determined if tha patient received fluid or vasopressor or both.
3033678|NCT02336997|Experimental|FAT-GRAFT|Fat graft transplantation
3033679|NCT02336997|Experimental|SVF-TRANSPLANTATION|Transplantation of resuspended SVF
3033680|NCT02336997|Placebo Comparator|CONTROL|Same volume saline injection
3033681|NCT02336984|Experimental|Combination Therapy|Combination Therapy: HER-2 pulsed DC1 vaccine with trastuzumab and pertuzumab.
3033682|NCT02336971|Experimental|CBCT for PTSD|"CBCT for PTSD is a time-limited, problem-focused treatment that aims to improve PTSD and relationship functioning. The study investigators have developed a 15-session treatment plan each session lasting 75-minutes.~The treatment is sequenced such that the rationale and psychoeducation provide the basis for the behavioral skills training designed to improve communication and relationship functioning, and to overcome behavioral and experiential avoidance. These skills are used in the final phase of the treatment that is focused on cognitive mechanisms contributing to PTSD and relationship dysfunction."
3033683|NCT02336971|Experimental|Prolonged Exposure|"PE for combat-related stress disorders [13-14] serves as the comparison treatment.~The therapy is usually conducted in 10-12 sessions, each lasting 90-minutes, with the majority of the sessions devoted to imaginal exposure to traumatic memories and homework assignments that include in vivo exposure assignments. In the present study, participants will complete 12 sessions of PE to equate the number of sessions with those of CBCT. Partners of individuals with PTSD are not typically incorporated into the treatment program and so for this study a revised version of PE [1-3] will be administered in which the partner is seen during the second session to discuss PTSD, other reactions to trauma and the treatment procedures."
3033684|NCT02336958|Active Comparator|ropivacaine|Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml ropivacaine 0.75%.
3033685|NCT02336958|Placebo Comparator|saline|Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml saline 0.9%.
3033686|NCT02336945||Type 2 diabetes|Subjects with type 2 diabetes who meet one of the therapy conditions
3033687|NCT02336919|Experimental|Txt2Prevent|The treatment group will receive all the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the Txt2Prevent text-messaging program. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living texts. There will be two streams, one for current/recent smokers and one for non-smokers. Texts will be sent out every 1-3 days for 60 days. All participants in the same stream will receive the same texts in the same order.
3033688|NCT02336919|No Intervention|Usual Care|The usual care group will receive all standard discharge treatment, instructions and information for patients with acute coronary syndrome, but no text-messaging program. Nurses typically go over important information with patients before they leave as well as give them printed materials.
3033689|NCT02336906|Active Comparator|Urotherapy + Constipation Treatment|This group will be treated with standard behavioral urotherapy in addition to receiving active stool softening with PEG3350 and standard constipation instruction.
3033690|NCT02336906|Other|Urotherapy alone|This group will receive standard behavioral urotherapy alone.
3033691|NCT02336893|No Intervention|Pre-intervention|Family members of patients admitted to the ICU from August to December 2013 that consented to participate in the satisfaction survey and had been in the ICU for 72 h.
3033692|NCT02336893|Experimental|Post-intervention|Family members of patients admitted to the ICU from March to August 2014 that consented to participate in the satisfaction survey and had been in the ICU for 72 h.
3033693|NCT02336880|Experimental|Intervention group|4 weeks guided internet-delivered cognitive behavioural therapy program. The program consists of psychoeducation, exposure to physical activity, and a breathing-based relaxation exercise
3033694|NCT02336880|No Intervention|Control group|Care as usual
3033695|NCT02336867|Experimental|Experimental group|closure clip (OTSC® Proctology Laboratory: OVESCO and French Distributor: Life Partners)
3033696|NCT02336867|Other|Control group|advancement flap technique
3033697|NCT02336854|Experimental|Tacrobell tab. 2mg|2mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
3033698|NCT02336854|Active Comparator|Prograf cap. 2mg|1mg/capsule, PO, 2 capsule once daily for Period I & II D1(crossover)
3033699|NCT02336841|Experimental|Intervention|Participants in this condition will receive the guided self-help intervention.
3033700|NCT02336841|Active Comparator|Control|Participants in this condition will not receive the guided self-help intervention. They will receive treatment as usual and weekly feedback on their eating disorder symptoms for a period of 6 weeks.
3033701|NCT02336828||MEWS alarm and mortality|Reach MEWS Alarm, Not reach MEWS Alarm, With 7 day mortality, Without 7 day mortality
3033702|NCT02336815|Experimental|Selinexor & Dexamethasone|Selinexor 80 mg (45 mg/m2 BSA) plus low-dose Dexamethasone (20 mg), both twice weekly by mouth
3033703|NCT02336802||Healthy Control Group|Volunteers that meet no diagnostic criteria for mental disorders.
3033704|NCT02336802||Panic Disorder Group|Volunteers that meet diagnostic criteria for Panic Disorder.
3033705|NCT02336802||Phobic Disorder Group|Volunteers that meet diagnostic criteria for a Phobic Disorder.
3033706|NCT02336802||PTSD group|Volunteers that meet diagnostic criteria for Post-Traumatic Stress Disorder
3033707|NCT02336789|Placebo Comparator|placebo|250 ml of normal saline (sham transplantation).
3033708|NCT02336789|Active Comparator|intervention|250 ml of diluted fecal material prepared from a screened donor
3033709|NCT02336776|Experimental|Functional electrical stimulation group|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20s time off, intensity as patient tolerance, total session time ranged from 20 to 34 minutes.
3033710|NCT02336776|No Intervention|Control group|The patients in this group were evaluated at baseline and reassessed after eight weeks of follow-up.
3033711|NCT02336763|Experimental|Treatment (external beam radiation therapy)|Patients undergo external beam radiation therapy daily over 20 minutes on Monday-Friday for up to 10 fractions over approximately 2 weeks.
3033712|NCT02336750|Experimental|treatment group|D1:Chemotherapy Dexamethasone:7.5mg D2-4 Aprepitant:125mg D1, 80mg D2-3 Mirtazapine:15mg D2-4
3033713|NCT02336750|Experimental|control group|D1:Chemotherapy Dexamethasone:7.5mg D2-4 Aprepitant:125mg D1, 80mg D2-3
3033714|NCT02336737|Experimental|SiennaXP injection|"Single injection of SiennaXP in addition to comparator single dose of radioisotope (Technetium Tc99m Sulfur Colloid) and single dose of isosulfan blue dye.~Lymph node localization using the SentiMag handheld intraoperative localization system in addition to localization with standard of care handheld gamma probe."
3033715|NCT02336724|Experimental|Famitinib|25 mg qd p.o.,28 days as one cycle,treatment discontinued when disease progression determined or intolerable toxicity or patients withdrawal of consent
3033716|NCT02336711|Experimental|Dose escalation|Dose escalation
3033717|NCT02336698|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
3033718|NCT02336698|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
3033719|NCT02336698|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
3033720|NCT02336685|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase in addition to opioids as standard of care.
3033721|NCT02336685|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase in addition to opioids as standard of care.
3033722|NCT02336685|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase in addition to opioids as standard of care.
3033723|NCT02336672|No Intervention|Group A Chemotherapy|Patients receiving chemotherapy alone. These patients start standard chemotherapy right after the oncologist's evaluation according to accepted Guidelines of the Italian Association of Medical Oncologists (AIOM). Restaging is performed 2, 4 and 6 months after chemotherapy onset, with MDCT scan and DW-MRI.
3033724|NCT02336672|Experimental|Group B Chemotherapy + HybridTherm|Patients receiving chemotherapy plus EUS-guided Cryothermal Ablation with HybridTherm probe. These patients are first treated by cryothermal ablation and one week after they start with chemotherapy. Cryothermal ablation can be performed up to three times, with interval of 4 +/- 1 weeks. Restaging is performed 2, 4 and 6 months after chemotherapy onset, with MDCT scan and DW-MRI.
3033725|NCT02336659|Placebo Comparator|Saline|Mixed meal test and ad libitum meal test duing infusion of saline
3033726|NCT02336659|Experimental|Exendin 9-39|Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min
3033727|NCT02336659|Experimental|DPP-4 Inhibition|Mixed meal test and ad libitum meal test during intake of sitagliptin 100 mg * 2
3033728|NCT02336659|Experimental|Exendin 9-39 / DPP 4-Inhibition|Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min and intake of sitagliptin 100 mg * 2
3033729|NCT02336646|Experimental|Low Dose Allogenic MSC|Low dose allogenic mesenchymal stem cells with IM injection
3033730|NCT02336646|Experimental|High Dose Allogenic MSC|High dose allogenic mesenchymal stem cells with IM injection
3033731|NCT02336646|Placebo Comparator|Placebo|normal saline with Intramuscular injection
3033732|NCT02336633|Experimental|1|Resveratrol (80mg/j = 4 capsules/day)
3033733|NCT02336633|Placebo Comparator|2|Placebo (4 capsules/day)
3033734|NCT02336620|Experimental|Ringer Acetate|Ringer acetate 10-20 ml/kg IV bolus when patient need fluid bolus
3033735|NCT02336620|Active Comparator|Normal saline|NSS 10-20 ml/kg IV bolus when patient need fluid bolus
3033736|NCT02336607|Experimental|Felodipine tablet (Plendil)|
3033737|NCT02336607|Active Comparator|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|
3033738|NCT02336607|Active Comparator|Felodipine tablets (Plendil)+Lisinopril (Zestril)|
3033739|NCT02336607|Active Comparator|Felodipine tablet (Plendil)+Hydrochlorothiazide|
3033740|NCT02336594|Experimental|Sequence ABCD|2.5 mg x 4 tablets qd (once daily) fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat.
3033741|NCT02336594|Experimental|Sequence BACD|10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat
3033742|NCT02336594|Experimental|Sequence ABDC|2.5 x 4 mg tablets qd fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat
3033743|NCT02336594|Experimental|Sequence BADC|10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat
3033744|NCT02336581|Experimental|Acceptance and Commitment Therapy (ACT)|ACT which includes individual and group sessions during hospitalization and follow-up phone contacts the first month following hospital discharge.
3033745|NCT02336581|Active Comparator|Enhanced Treatment as Usual (eTAU)|Enhanced treatment as usual (eTAU) which includes other individual and group sessions during hospitalization and follow-up phone contacts the first month following hospital discharge.
3033746|NCT02336568|Experimental|intervention|intervention: Oxytoine treatments - 20 PTSD patients
3033747|NCT02336568|Placebo Comparator|Placebo treatments|Other: Placebo treatments- 20 PTSD patients
3033748|NCT02336555|Experimental|MK-8291 → Placebo|In period 1 participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once on Day 28. Period 1 was followed by a minimum seven day washout, followed by period 2. In period 2 participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27; concluding with once daily on Day 28.
3033749|NCT02336555|Experimental|Placebo → MK-8291|In period 1 participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once on Day 28. Period 1 was followed by a minimum seven day washout, followed by period 2. In period 2 participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27; concluding with once daily on Day 28.
3033750|NCT02336542|Experimental|TB subjects|96 TB subjects are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.
3033751|NCT02336542|Active Comparator|non-TB subjects with lung disease|96 non-TB subjects with lung disease are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.
3033752|NCT02336529|Experimental|ICBN, active|Ultrasound guided injection of bupivacain, 10mL, 0.5% in proximity of the ICBN
3033753|NCT02336529|Placebo Comparator|ICBN, placebo|Ultrasound guided injection of NaCl, 10mL in proximity of the ICBN
3033754|NCT02336529|Experimental|Tenderpoint, active|Ultrasound guided injection of bupivacain, 20mL, 0.25% in the tenderpoint
3033755|NCT02336529|Placebo Comparator|Tenderpoint, placebo|Ultrasound guided injection of NaCl, 20mL in the tenderpoint
3033756|NCT02336516|Experimental|Azithromycin|ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ®
3033757|NCT02336516|Placebo Comparator|Glucose solution 10%|Glucose solution 10%
3033758|NCT02336503|Experimental|BBI-4000 Dose 1|Low concentration of BBI-4000
3033759|NCT02336503|Experimental|BBI-4000 Dose 2|Middle concentration of BBI-4000
3033760|NCT02336503|Experimental|BBI-4000 Dose 3|High concentration of BBI-4000
3033761|NCT02336503|Placebo Comparator|Vehicle|Vehicle (placebo)
3033762|NCT02336490|No Intervention|Usual Care|discharge medication prescriptions are printed or sent electronically to a patient's pharmacy of choice
3033763|NCT02336490|Active Comparator|Meds-in-Hand|discharge medication delivery service: discharge prescriptions are filled at the hospital pharmacy and delivered to patients before they leave the hospital
3033764|NCT02336477|Experimental|1|Mexiletine / Placebo
3033765|NCT02336477|Experimental|2|Placebo / Mexiletine
3033766|NCT02336451|Experimental|LDK378|LDK378 will be administered orally once daily at a dose of 750 mg (five 150 mg capsules) on a continuous dosing schedule. The treatment period will start on Cycle 1 Day 1.
3033767|NCT02336438|No Intervention|Baseline Phase (Control)|"iPro CGM device will be worn for next 5 days. The subjects will maintain a diet history and will be given a One Touch glucometer and strips to check their blood glucose at home four times a day for next five days and log this onto the System Patient Log (included).~Subjects will undergo MMTT, which includes consumption of a standard meal (Boost) and scheduled blood draws over 3 hours."
3033768|NCT02336438|Experimental|Treatment Phase (Glucomannan)|"iPro CGM device will be worn for next 5 days. The subjects will maintain a diet history and will be given a One Touch glucometer and strips to check their blood glucose at home four times a day for next five days and log this onto the System Patient Log (included).~Subjects will undergo MMTT, which includes consumption of a standard meal (Boost) + 5 grams of Glucomannan soluble fiber powder and scheduled blood draws over 3 hours.~For the next five days subjects will take the following amounts of Glucomannan soluble fiber (provided by the investigator) three times a day with meals."
3033769|NCT02336425|Experimental|QGE031 240 mg|QGE031 240 mg subcutaneous injection every 4 weeks
3033770|NCT02336425|Experimental|QGE031 72 mg|QGE031 72 mg subcutaneous injection every 4 weeks
3033771|NCT02336425|Experimental|QGE031 24 mg|QGE031 24 mg subcutaneous injection every 4 weeks
3033772|NCT02336425|Placebo Comparator|Placebo to QGE031|Placebo subcutaneous injection every 4 weeks
3033773|NCT02336412|Experimental|SMS reminder|Daily SMS medication reminder
3033774|NCT02336412|No Intervention|No SMS reminder|No daily SMS medication reminder
3033775|NCT02336386|Experimental|CDD Plus Bortezomib|Patients will receive Bortezomib (1.3mg/m2) Subcutaneous injection on Days 1, 4,8,11 and plus dexamethasone 20 mg/day PO on Days 1-4, 9-12,Cyclophosphamide 300mg/m2 D1-4, Liposome doxorubicin 40mg D4 of each 28-day cycle; Patients may continue to receive treatment until PD or unacceptable toxicity.
3033776|NCT02336386|Active Comparator|CDD|Dexamethasone 20 mg/day PO on Days 1-4, 9-12,Cyclophosphamide 300mg/m2 D1-4, doxorubicin Dexamethasone 40mg D4 of each 28-day cycle; Patients may continue to receive treatment until PD or unacceptable toxicity
3033777|NCT02336373|Experimental|Hydroxurea|Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria on at least 2 blood tests over eight weeks prior to dose increase.
3033778|NCT02336360|Experimental|Urine Analysis|Urine will be collected from subjects administered 18F-AV-1451 in an Avid-sponsored study to determine the amount of radioactivity excreted in urine.
3033779|NCT02336347|Experimental|Group 1 - Period 1|Twice daily dosing of AVP-786 orally for 8 days
3033780|NCT02336347|Active Comparator|Group 1 - Period 2|Twice daily dosing of AVP-923 orally for 8 days
3033781|NCT02336347|Active Comparator|Group 2 - Period 1|Twice daily dosing of AVP-923 orally for 8 days
3033782|NCT02336347|Experimental|Group 2 - Period 2|Twice daily dosing of AVP-786 orally for 8 days
3033783|NCT02336334|Experimental|With macular hole|"Inclusion of patients with macular holes and randomized allocation to sensor-types and information-types~Interventions:~Positioning measurement Patient feedback Usefulness of a sketch Closure rate of macular holes"
3033851|NCT02335827|Experimental|Group B|irreversible electroporation with voltage in level B for renal tumors
3058782|NCT02170012|Experimental|Cohort 3-PF-06743649 or placebo|
3033784|NCT02336334|Experimental|Without macular hole|"Inclusion of patients without macular holes and randomized allocation to sensor-types and information-types~Interventions:~Positioning measurement Patient feedback Usefulness of a sketch"
3033785|NCT02336321|Experimental|BNCI hand-exoskeleton|Hand motor function before, during and after application of the device
3033786|NCT02336308|Active Comparator|Ketamine|Ketamine 50mg/1mL will be diluted with 9mL of normal saline to create 50mg in the 10mL syringe. Administered twice via intravenous administration; the first dose 10 minutes prior to the dressing change and a second dose 20-30 minutes into the dressing change procedure. The study will provide study drug for up to five dressing change procedures (i.e. ten total doses).
3033787|NCT02336308|Placebo Comparator|Placebo|Placebo will be 10mL of normal saline in the syringe. Administered twice via intravenous administration; the first dose 10 minutes prior to the dressing change and a second dose 20-30 minutes into the dressing change procedure. The study will provide study drug for up to five dressing change procedures (i.e. ten total doses).
3033788|NCT02336295|Other|Food Frequency Questionnaires|Filling out a Food Frequency Questionnaires (FFQ)
3033789|NCT02336282|Active Comparator|tDCS on Day 1|"On day one, participants will be randomized to receive the transcranial Direct Current Stimulation (tDCS) intervention. On day two, participants receive sham intervention.~On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.~In the second phase of the trial, participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive assessment will be conducted pre- and post-intervention using remote assessment."
3033790|NCT02336282|Active Comparator|tDCS on Day 2|"On day one, participants will be randomized to receive sham intervention. On day two, participants receive the transcranial Direct Current Stimulation (tDCS) intervention.~On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.~The second phase of the trial will be conducted the same as for participants in the tDCS on Day 1 arm. Participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive testing will be conducted pre- and post-intervention using remote assessment."
3033791|NCT02336256|Experimental|TEP SILS|Procedures of hernia repair. Patients operated due to inguinal hernia using modified single incision laparoscopic surgery (SILS) methods.
3033792|NCT02336256|Active Comparator|Typical TEP|Procedures of hernia repair. Patients operated due to inguinal hernia using typical totally extra peritoneal.
3033793|NCT02336243|Experimental|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA) 200 mg capsules, 3 capsules by mouth every day, from early gestation until the end of pregnancy
3033794|NCT02336243|Placebo Comparator|Placebo|Placebo 200 mg capsules, 3 capsules by mouth every day, from early gestation until the end of pregnancy
3033795|NCT02336230|Experimental|Active Treatment|
3033796|NCT02336217|Experimental|Functioning App|These subjects have the complete algorithm functioning and communicated via the App.
3033797|NCT02336217|Placebo Comparator|Non-functioning App|These subjects receive routine instructions via the App but not the complete algorithm.
3033798|NCT02336191||LDLT Recipients|Patients subjected to living donor liver transplantation
3033799|NCT02336178|Experimental|Benefix|This is a single arm study. Subjects will be treated with Benefix by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.
3033800|NCT02336165|Experimental|Cohort A|Approximately 37 subjects with newly diagnosed unmethylated MGMT GBM will receive MEDI4736 every 2 weeks in combination with standard radiotherapy.
3033801|NCT02336165|Experimental|Cohort B|Approximately 30 bevacizumab-naïve subjects with recurrent GBM will receive MEDI4736 every 2 weeks as monotherapy.
3033802|NCT02336165|Experimental|Cohort C|Approximately 17 bevacizumab-refractory subjects with recurrent GBM will receive MEDI4736 every 2 weeks in combination with continued bevacizumab.
3033803|NCT02336165|Experimental|Cohort B2|Approximately 32 bevacizumab-naive subjects with recurrent GBM will receive MEDI4736 every 2 weeks in combination with bevacizumab (10 mg/kg).
3033804|NCT02336165|Experimental|Cohort B3|Approximately 32 bevacizumab-naive subjects with recurrent GBM will receive MEDI4736 every 2 weeks in combination with bevacizumab (3 mg/kg).
3033805|NCT02336152|Experimental|Body suit|The patients will receive a body suit at least 30 min before start of general anaesthesia, and will keep the suit on until warm and comfortable in the post-operative unit. The suit is supplied with multiple snap openings to allow for draping, washing and surgery.
3033806|NCT02336152|Active Comparator|Forced warm air|The patients will receive forced warm air on their lower body when placed on operating table, ready for surgery.
3033807|NCT02336139|Experimental|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose combination
3033808|NCT02336126|Experimental|Biopsychological intervention|
3033809|NCT02336113|No Intervention|Control group|Standard care during hospital stay, without pharmacist involved
3033810|NCT02336113|Experimental|Pharmacist intervention|A pharmacist is included in the multidisciplinary treatment team during the hospital stay
3033811|NCT02336100|Experimental|GERD patient|36 GERD patients without obviously abnormality were examined by FICE and then followed by pCLE to evaluate minimal change esophagitis
3033812|NCT02336100|Experimental|Control|18 control patients were were examined by FICE and then followed by pCLE to evaluate minimal change esophagitis
3033813|NCT02336087|Experimental|Treatment (gemcitabine, Abraxane, metformin, DS)|Patients receive gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15. Patients also receive metformin hydrochloride PO BID starting day -6 and dietary supplement PO BID starting day -3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3033814|NCT02336074|Active Comparator|Arm A|Combination Antiretroviral Therapy (cART) preferably including raltegravir prescribed at week 0 for the duration of the study up to post-randomisation week 18 (42 weeks in total)
3033849|NCT02335840|Experimental|Three doses of decaffeinated coffee|Ingestion of three doses of 150 ml of decaffeinated coffee (144 mg of caffeine) ingested 10, 20 and 30 minutes post-exercise (denominated DESC)
3033815|NCT02336074|Experimental|Arm B|Combination Antiretroviral Therapy (cART) preferably including raltegravir prescribed at week 0 for the duration of the study up to post-randomisation week 18 (42 weeks in total) Plus ChAdV63.HIVconsv prime (post-randomisation week 00) and MVA.HIVconsv boost (post randomisation week 08 day 1) vaccines; followed by a 28-day course of vorinostat (10 doses in total).
3033816|NCT02336061||male|It will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts.
3033817|NCT02336061||female|It will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts.
3033818|NCT02336048|Active Comparator|Placebo + Obinutuzumab + Chlorambucil|Participants will receive placebo and standard premedications on Days 1 and 2 of Cycle 1 (cycle length= 28 days) along with obinutuzumab and chlorambucil administered for 6 cycles.
3033819|NCT02336048|Experimental|Tocilizumab + Obinutuzumab + Chlorambucil|Participants will receive tocilizumab and standard premedications on Days 1 and 2 of Cycle 1 (cycle length= 28 days) along with obinutuzumab and chlorambucil administered for 6 cycles.
3033820|NCT02336035|No Intervention|Cast immobilization|"Cast immobilization for 5 weeks from primary injury/reduction. Thereafter active exercise within the range of pain.~Both groups will be followed after 3, 6 and 12 months, and after 2 and 5 years."
3033821|NCT02336035|Experimental|Operation|"Operation with a volar plate. Cast immobilization for 2 weeks after operation, thereafter active motion without weight for 4 weeks. 6 weeks after operation the patients are allowed active exercise within the range of pain.~Both groups will be followed after 3, 6 and 12 months, and after 2 and 5 years."
3033822|NCT02336009|Experimental|total wrist arthroplasty, Trimed|This is a pilot study where all patients will be operated with the Trimed total wrist arthroplasty.
3033823|NCT02335996|Active Comparator|patients with active hypercortisolism|
3033824|NCT02335996|Active Comparator|Patients in remission of their hypercortisolism after surgery|
3033825|NCT02335983|Experimental|Dose-evaluation: Part 1 - Cohort 1|Subjects will receive a dose level combination regimen of carfilzomib 56 mg/m2, lenalidomide 25 mg, and dexamethasone 40 mg
3033826|NCT02335983|Experimental|Dose-evaluation: Part 1 - Cohort 2|Subjects will receive a dose level combination regimen of carfilzomib 70 mg/m2, lenalidomide 25 mg, and dexamethasone 40 mg.
3033827|NCT02335983|Experimental|Dose-expansion: Part 2 - Arm 1|Newly diagnosed multiple myeloma subjects will receive the regimen selected by the Cohort Safety Review Committee (CSRC) in the Dose-evaluation component.
3033828|NCT02335983|Experimental|Dose-expansion: Part 2 - Arm 2|Relapsed multiple myeloma subjects will receive the regimen selected by the Cohort Safety Review Committee (CSRC) in the Dose-evaluation component.
3033829|NCT02335983|Experimental|Dose-evaluation: Part 1 - Cohort 4|Newly Diagnosed multiple myeloma subjects will receive a 2-step-up regimen of carfilzomib at 56 mg/m2 in Cycle 1 and then at 70 mg/m2 beginning with Cycle 2, lenalidomide 25 mg and dexamethasone 40 mg. (note: all subjects receive 20 mg/m2 carfilzomib on Cycle 1 Day 1)
3033830|NCT02335983|Experimental|Dose-expansion: Part 2 - Arm 3|Newly diagnosed multiple myeloma subjects will receive a combination regimen of carfilzomib 56 mg/m2, lenalidomide 25 mg and dexamethasone 40 mg
3033831|NCT02335970|Experimental|Training group|Training program: Daily exercises for 3 months
3033832|NCT02335970|No Intervention|Controls|Standard care
3033833|NCT02335957|Other|Intentional irradiation of lymph nodes|Patients will receive a total dose of 50 Gy in the whole breast and nodal areas(axillary I, II, III, and supraclavicular) with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
3033834|NCT02335957|Experimental|Incidental irradiation of lymph nodes|Patients will receive a total dose of 50 Gy in the whole breast, but not aimed at nodal areas, with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
3033835|NCT02335944|Experimental|INC280 plus EGF816|Recruitment in Phase I dose escalation part is completed. Recruitment in Phase II dose expansion is ongoing.
3033836|NCT02335931||Charcot foot|Patients with Charcot foot and diabetes mellitus 1 or 2
3033837|NCT02335931||No charcot foot|patients with diabetes mellitus type 1 or 2
3033838|NCT02335918|Experimental|Varlilumab and Nivolumab|
3033839|NCT02335905|Experimental|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour). The dose may vary with age.
3033840|NCT02335879|Experimental|Recombinant Human Follitropin|
3033841|NCT02335866|Experimental|Test groups.|This clinical study was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+PRF) or the control (CAF+SCTG) groups with the use of computer-generated randomization table after assessment of clinical parameters at baseline.
3033842|NCT02335866|Active Comparator|Control groups.|This clinical study was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+PRF) or the control (CAF+SCTG) groups with the use of computer-generated randomization table after assessment of clinical parameters at baseline.
3033843|NCT02335853||women with metabolic syndrome and overactive bladder|"women with urinary urgency+frequency+nocturia and current ATP III criteria define the metabolic syndrome as the presence of any three of the following five traits:~Abdominal obesity, defined as a waist circumference in men ≥88 cm~Serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides~Serum HDL cholesterol <40 mg/dL (1 mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C~Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure~Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose"
3033844|NCT02335853||women with overactive bladder|women with urinary urgency+frequency+nocturia
3033845|NCT02335853||healthy control group|women not overactive bladder and metabolic syndrome
3033846|NCT02335840|Experimental|One dose of coffee|Ingestion of one dose of 150 ml of coffee (144 mg of caffeine) ingested 10 minutes post-exercise (denominated CAF-1)
3033847|NCT02335840|Experimental|Two doses of coffee|Ingestion of two doses of 150 ml of coffee (144 mg of caffeine) ingested 10 and 20 minutes post-exercise (denominated CAF-2)
3033848|NCT02335840|Experimental|Three doses of coffee|Ingestion of three doses of 150 ml of coffee (144 mg of caffeine) ingested 10, 20 and 30minutes post-exercise (denominated CAF-3)
3033850|NCT02335827|Experimental|Group A|irreversible electroporation with voltage in level A for renal tumors
3033852|NCT02335827|Experimental|Group C|irreversible electroporation with voltage in level C for renal tumors
3033853|NCT02335814|Experimental|FLX925|
3033854|NCT02335788|Other|Single arm - EMBA PED|The EMBA Peripheral Embolization Device when indicated for arterial and venous embolization in the peripheral vasculature.
3033855|NCT02335749|Experimental|Fat Reduction|The treatments are designed to see if the fat, on the distal thigh, can be reduced.
3033856|NCT02335736|Active Comparator|Normal|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
3033857|NCT02335736|Active Comparator|Poor responders|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
3033858|NCT02335736|Active Comparator|Polycystic ovarian disease|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant(Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
3033859|NCT02335723|Active Comparator|Alteco LPS Adsorber|Hemoperfusion and Standard therapy
3033860|NCT02335723|Placebo Comparator|Placebo|Placebo and Standard therapy. The placebo comparator device differs from Alteco® LPS Adsorber only in that no peptide component (i.e. active component) has been attached to the matrix.
3033861|NCT02335710||Smith & Nephew Journey II BCS TKA|Subjects must be implanted with a Smith & Nephew Journey II bi-cruciate stabilizing (BCS) total knee arthroplasty (TKA) implanted by Dr. Harold Cates
3033862|NCT02335710||Normal knee|Subjects must have a healthy, functioning knee with no osteoarthritis or knee pathologies
3033863|NCT02335697|Other|Intervention|Attitude change towards female circumcision
3033864|NCT02335697|Other|No intervention|No intervention
3033865|NCT02335684|Experimental|CF-LVAD patients.|Patients are compared with themselves during submaximal exercise testing with baseline pump speed vs. submaximal exercise testing with increased pump speed.
3033866|NCT02335671|Experimental|Intra-operative Magnetic Resonance Imaging (MRI)|"Preoperative diagnostic MRI~Intra-operative MRI~Standard lumpectomy and sentinel node biopsy if indicated, or standard axillary dissection if clinically indicated~Specimen to Pathology and Mass Spectrometer (Analysis of Tissue Sample)"
3033867|NCT02335658|Experimental|DSP-5423P|Percutaneous
3033868|NCT02335645||Body Weight Supported Treadmill|Post surgical ACL patients who will complete standard ACL protocol with the addition of body weight supported treadmill use.
3033869|NCT02335632|Placebo Comparator|Placebo|For Probiotics, 7 days
3033870|NCT02335632|Active Comparator|Probiotics|Probiotics of 120 mg/day for 7days
3033871|NCT02335619|Active Comparator|Early Palliative Care|During their first oncology appointment, the intervention arm patients will self-report any symptoms related to their cancer or treatment to the study team; scores at or above a defined benchmark will be seen by Pain and Symptom Management/Palliative Care team members during or immediately after their oncology appointment. Patients will be asked to self-report symptoms once a month following recruitment, for 4 months.
3033872|NCT02335619|No Intervention|Standard Care|During their first oncology appointment, the control arm patients will self-report any symptoms related to their cancer or treatment to the study team; self-reports will be collected but not shared with the Pain and Symptom Management/Palliative Care team, and patients will continue with their oncology appointment as per standard procedure. Patients will be asked to self-report symptoms once a month following recruitment, for 4 months.
3033873|NCT02335606||Patients treating with Abatacept|Patients who are abatacept naive and are initiating abatacept treatment (either IV or SC) including those that are switching from another bDMARD, as well as, patients currently being treated with IV or SC abatacept some of which may have switched from IV abatacept to SC abatacept
3033874|NCT02335593|Experimental|Zinc group|Zinc Sulphate Hard Gel Capsules 110 mg once daily for three months plus Epoetin alfa 2000-4000 IU solution for injection andIron Hydroxide Saccharate Complex Solution for injection.
3033875|NCT02335593|Active Comparator|Placebo group|Corn starch filled Hard Gel capsules once daily plus 'Epoetin alfa 2000-4000 IU solution for injection and Iron Hydroxide Saccharate Complex Solution for injection.
3033876|NCT02335554|Experimental|MoodHacker|Participants in the treatment condition were emailed a link to the MoodHacker mobile-web app and instructed to use the program for the next six weeks. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline.
3033877|NCT02335554|Active Comparator|Alternative Care|Alternative care participants were emailed and encouraged to browse links to vetted online information about depression. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline and were given access to the MoodHacker program after the 10-week assessment
3033878|NCT02335528|Experimental|SimCoach intervention|"Participants randomized to the SimCoach intervention arm interacted with Bill Ford, a simulated human (avatar) enacted in the SimCoach program. This white male avatar representing himself as an Army veteran who spoke to participants in a conversational manner. Participants interacted with him using a chat interface, where they could type responses to him. Bill Ford asked participants a series of questions that corresponded to validated PTSD or depression screening questionnaires. SimCoach then provided personalized recommendations for a symptom if the user reported experiencing the symptom at one of the two highest frequencies on the response scale. These recommendations consisted of a behavioral recommendation with an accompanying link to a website or online article on the topic."
3033879|NCT02335528|No Intervention|Content Matched Control|Participants assigned to the Content Matched Control condition arm completed text-based versions of the PCL PTSD screening inventory and PHQ-9 depression screening inventory. These instruments used standard, validated language and did not use the modified conversational versions used in the SimCoach intervention condition. The same personalized recommendations provided to the SimCoach group were provided as conventional text and links. After receiving personalized recommendations, participants completed text versions of primary help-seeking, perceived barriers to seeking help, and secondary outcome (user experience) measures.
3033913|NCT02335242|Experimental|Sildenafil 20 mg tablets (Revatio)|Active Drug: Sildenafil tablets (Revatio)
3034910|NCT02328963|Active Comparator|mycophenolic acid|mycophenolic acid + standard dose of cyclosporin A
3033880|NCT02335528|No Intervention|No-Treatment Control|Participants randomized to the No-Treatment Control arm completed measures of the primary outcome (intentions to seek help) prior to being given a choice of SimCoach or the conventional screening administered in the other two arms of the study. After the help-seeking intention questionnaire was administered, participants were told that they would be asked some questions about any PTSD or depression symptoms that they might be having and were given the choice between chatting online with a virtual human or using an online form (options were presented in random order to prevent any influence of ordering on selection of the tool). After either interacting with SimCoach or filling out an online form, participants completed a questionnaire assessing user experience.
3033881|NCT02335515|Experimental|Soctec / Capsule|HS intakes one(1) Soctec Capsule after standardized breakfast
3033882|NCT02335502||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
3033883|NCT02335489||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
3033884|NCT02335450|Experimental|Single Arm|All five participants in the study will receive this intervention. The participants will be visited in their homes by a physical therapist once a week. The physical therapist will use a coaching technique called motivational interviewing to help the participant develop personal physical activity goals. The participant will discuss their physical activity challenges, and with the help of the physical therapist the participant will set up personal physical activity goals for the following week. The participant will be given a wristband physical activity monitor to wear during the day for four weeks to track their progress in meeting their activity goals.
3033885|NCT02335437||Acute EBV infection|
3033886|NCT02335437||Healthy controls|
3033887|NCT02335424|Experimental|Pembrolizumab|Participants receive pembrolizumab, 200 mg intravenous (IV) on Day 1 of each 3-week cycle for up to 24 months.
3033888|NCT02335411|Experimental|Cohort 1: Pembro monotherapy, previously treated|Participants receive pembrolizumab (Pembro) 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 24 months
3033889|NCT02335411|Experimental|Cohort 2: Pembro combination therapy, treatment naive|Participants receive pembrolizumab 200 mg IV Q3W for up to 24 months + cisplatin 80 mg/m^2 IV Q3W for up to 6 cycles + 5-FU 800 mg/m^2 IV on Days 1-5 every 3 weeks or (Japan only) capecitabine 1000 mg/m^2 orally, twice per day (BID) on Days 1-14 of each 3-week cycle
3033890|NCT02335411|Experimental|Cohort 3: Pembro monotherapy, treatment naive|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle (Q3W) for up to 24 months
3033891|NCT02335398|Experimental|methadone|single group
3033892|NCT02335385|Active Comparator|SIL-V|single incision laparoscopic varicocelectomy
3033893|NCT02335385|Active Comparator|CTL-V|conventional transperitoneal laparoscopic varicocelectomy
3033894|NCT02335372|Experimental|Multi-Modal Optical Imaging of Cervix|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes before application of 3-6% acetic acid. The clinician will identify all sites required for biopsy according to clinical impression, marking each location on the recorded unpolarized white light image. Topical application of 0.01% proflavine solution will then be applied for 1 minute, after which wide-field imaging in fluorescence mode will be performed. The clinician will then select up to 2 additional sites for biopsy based on the appearance of this wide-field fluorescence image, recording the location of each. The high-resolution microendoscope will then be used to acquire images at all sites selected for biopsy, followed by collection of biopsy specimens.
3033895|NCT02335359|Experimental|Tranexamic Acid|A 500 mg loading dose of tranexamic acid diluted in 100 ml of saline solution will be slowly administered intravenously to patients 20 minutes before surgery, followed by a continuos infusion of 250 mg/h of tranexamic acid from surgical incision until skin closure.
3033896|NCT02335359|Placebo Comparator|Placebo|Saline
3033897|NCT02335346|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. During tapering period, dose of 40 mg for one week and then 20 mg for the last week.
3033898|NCT02335307||Control|Patients will continue to receive their current pain management therapy. In addition, a pain assessment questionnaire will be administered at baseline and 3 months.
3033899|NCT02335307||Implementation|Patients will undergo CYP2D6 genotyping, with results entered into the medical record to assist the physician with prescribing pain medication. In addition, a pain assessment questionnaire will be administered at baseline and 3 months.
3033900|NCT02335307||Physician assessment|At the end of the study, a 20-item survey will be administered to physicians who treated patients enrolled in the study. The survey will assess whether having CYP2D6 genotype results is useful to inform prescribing decisions for pain medication from the physician's perspective.
3033901|NCT02335294|Experimental|TRV130|
3033902|NCT02335294|Active Comparator|Morphine|
3033903|NCT02335294|Placebo Comparator|Placebo|
3033904|NCT02335281|Experimental|Standardized FMT|The group include 20 patients. They will receive standardized FMT. The FMT was given to mid-gut by nose-jejunum nutrition tube. It was given only once.
3033905|NCT02335281|Active Comparator|Mesalazine|This group include 20 patients . The patients will receive traditional medicine of mesalazine treatment.
3033906|NCT02335268|Experimental|Group 1|"Stratification into group 1 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are +3~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
3033907|NCT02335268|Experimental|Group 2|"Stratification into group 2 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are -1 or -2~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
3033908|NCT02335268|Experimental|Group 3|"Stratification into group 3 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are -6~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
3033909|NCT02335255|Experimental|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% (Taro Pharmaceuticals Inc.)
3033910|NCT02335255|Active Comparator|Naftin® Gel 2%|Naftin® (Naftifine Hydrochloride) Gel 2% (Merz Pharmaceuticals, LLC)
3033911|NCT02335255|Placebo Comparator|Placebo Topical Gel|Placebo Topical Gel (Taro Pharmaceuticals Inc.)
3033912|NCT02335242|Placebo Comparator|Placebo tablets (resembling Revatio)|Placebo Drug: Placebo tablets (resembling Revatio)
3033914|NCT02335229||Treated Subjects|All eligible subjects recruited and treated with the Axium Neurostimulator
3033915|NCT02335216||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
3033916|NCT02335203|Experimental|Depot medroxyprogesterone acetate|Women randomized to receive one intramuscular injection of 400mg depot medroxyprogesterone acetate prior to hysterectomy.
3033917|NCT02335203|Placebo Comparator|Placebo injection|Women randomized to receive one intramuscular injection of 1mL normal saline prior to hysterectomy.
3033918|NCT02335190|Experimental|PSN block and RF ablation|Participants will first undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. On a separate visit, participants will then undergo ablation of the PSN at the lateral crest under ultrasound-guidance.
3033919|NCT02335177|Active Comparator|Interventionnal arm|Interventional arm : patients at home with technologies for autonomy and tailored physical activity program.
3033920|NCT02335177|No Intervention|Control arm|Control arm : patients with usual care home
3033921|NCT02335164|Experimental|HA 45ug|recombinant influenza hemagglutinin (H5) 45ug, i.m. injection, 2 doses
3033922|NCT02335164|Experimental|HA 45ug+Advax1|recombinant influenza hemagglutinin(H5) 45ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
3033923|NCT02335164|Experimental|HA 45ug+Advax2|recombinant influenza hemagglutinin (H5) 45ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
3033924|NCT02335164|Experimental|HA 15ug+Advax1|recombinant influenza hemagglutinin (H5) 15ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
3033925|NCT02335164|Experimental|HA 15ug+Advax2|recombinant influenza hemagglutinin (H5) 15ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
3033926|NCT02335164|Experimental|HA 5ug+Advax1|recombinant influenza hemagglutinin (H5) 5ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
3033927|NCT02335164|Experimental|HA 5ug+Advax2|recombinant influenza hemagglutinin (H5) 5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
3033928|NCT02335164|Experimental|HA 2.5ug+Advax2|recombinant influenza hemagglutinin (H5) 2.5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
3033929|NCT02335164|Experimental|HA 15ug|recombinant influenza hemagglutinin (H5) 15ug, i.m. injection, 2 doses
3033930|NCT02335151|Experimental|Desflurane|General anesthesia with Desflurane
3033931|NCT02335151|No Intervention|Propofol|General anesthesia with Propofol
3033932|NCT02335138|Placebo Comparator|Control Arm|Each participant will receive an at-home test kit and will be asked to test and return results to investigator.
3033933|NCT02335138|Active Comparator|Intervention Arm|Each participant will receive an at-home test kit and will be asked to take the test in conjunction with an online CHTC session.
3033934|NCT02335125|Experimental|Intervention|The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both TBI and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, medication, and psychotherapy elements.
3033935|NCT02335125|No Intervention|Usual Care|Only standard care practices will be administered to this arm.
3033936|NCT02335125|No Intervention|Provider Staff|Staff at a site who work on the protocol will also be consented into the study as participants in order to complete an organizational survey.
3033937|NCT02335125|No Intervention|Provider Care Manager|Individuals acting in the protocol as care managers will also be consented into the study as participants in order to complete an organizational survey, an assessment on understanding of PTSD screening and intervening, standardized patient interviews, and an exit interview.
3033938|NCT02335112|Experimental|Group A|irreversible electroporation with voltage in level A for Unresectable Head and Neck Neoplasms
3033939|NCT02335112|Experimental|Group B|irreversible electroporation with voltage in level B for Unresectable Head and Neck Neoplasms
3033940|NCT02335112|Experimental|Group C|irreversible electroporation with voltage in level C for Unresectable Head and Neck Neoplasms
3033941|NCT02335099|Active Comparator|ticagrelor|90 mg of ticagrelor to be given orally twice a day for 6 months
3033942|NCT02335099|Placebo Comparator|Placebo|Placebo drug to be given twice a day for 6 months
3033943|NCT02335086||Stable angina patients|"Patients with stable angina not responding to 2 anti-anginals presenting for coronary angiography with the possibility of proceeding to stent implantation at Ashford and St. Peter's Hospital.~Clinical and angiographic exclusion criteria as stated in the study protocol."
3033944|NCT02335086||NSTEMI patients|"Patients presenting to Ashford and St. Peter's Hospital with an non ST-elevation myocardial infarction defined by :~Detection of a rise and/or fall of cardiac biomarker values (troponin I) with at least one value above the 99th percentile upper reference limit at analysing laboratories at Ashford and St. Peter's Hospital along with at least one of the following:~Symptoms of ischaemia~Development of pathologic Q waves in the electrocardiogram (ECG)~New or presumed new significant ST-segment-T wave (ST-T) changes on ECG.~Identification of an intracoronary thrombus by angiography.~Imaging evidence of new loss of viable myocardium or a new regional wall motion abnormality."
3033945|NCT02335060|Experimental|Active N-acetylcysteine and Active Delta-9-THC|
3033946|NCT02335060|Placebo Comparator|Placebo and Active Delta-9-THC|
3033947|NCT02335060|Experimental|Active N-acetylcysteine and Placebo|
3033948|NCT02335060|Placebo Comparator|Placebo and Placebo|
3033949|NCT02335047|Other|lower back pain|
3033950|NCT02335034|Experimental|Study group|Intervention: study group will attend two days of classes (two months apart) with the seven professional teams, covering what is the disease arthritis, its causes and treatment options; what is disease, being ill, and the role of the patient in the treatment to obtain behavioral change; the importance of exercise in relieving symptoms, the importance of rest and proper ergonomics at home and at work; proper alimentation; the difference between labor work and regular physical activity as well as the importance of strength resistance and stretching exercises; and the importance of leisure. The second intervention verifies the acquired concepts.
3033951|NCT02335034|Experimental|Control Group|The control group will only make evaluations / consultations with all professional teams without classes for 2 years, then will attend the courses and will be followed by two more years.
3033952|NCT02335021|Experimental|Sucralose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucralose.
3033953|NCT02335021|Experimental|Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucrose.
3033954|NCT02335021|Experimental|Sucralose + maltodextrin|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + maltodextrin .
3033955|NCT02335021|Experimental|Sucralose + Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + sucrose.
3033956|NCT02335008|Experimental|Sucralose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucralose.
3033957|NCT02335008|Experimental|Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucrose.
3033958|NCT02334982|Experimental|Cohort 1: TAK-137 2 mg|TAK-137 2 mg, tablets, orally, once on Day 1.
3033959|NCT02334982|Experimental|Cohort 2: TAK-137 5 mg|TAK-137 5 mg, tablets, orally, once on Day 1.
3033960|NCT02334982|Experimental|Cohort 3: TAK-137 10 mg|TAK-137 10 mg, tablets, orally, once on Day 1.
3033961|NCT02334982|Experimental|Cohort 4: TAK-137 5 mg Food Effect|TAK-137 5 mg, tablets, orally, under fasted conditions, once on Day 1 of Period 1, followed by 14 days of follow-up, followed by TAK-137 5 mg, tablets, orally, under fed conditions, once on Day 1 of Period 2.
3033962|NCT02334982|Experimental|Cohort 5: TAK-137 0.5 mg|TAK-137 0.5 mg, tablets, orally, once on Day 1.
3033963|NCT02334982|Experimental|Cohort 6: TAK-137 20 mg|TAK-137 20 mg, tablets, orally, once on Day 1.
3033964|NCT02334982|Placebo Comparator|Cohorts 1-6: Placebo|TAK-137 placebo-matching tablets, orally, once on Day 1.
3033965|NCT02334969|Experimental|Experimental group|On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Naoxintong capsule, 2 times a day, three granule per time
3033966|NCT02334969|Active Comparator|Control group|On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Placebo capsule，which is identical with Naoxintong capsule in the appearance, shape, color and content, 2 times a day, three granule per time
3033967|NCT02334956|Experimental|Patient|Patient with addiction
3033968|NCT02334956|Experimental|Control|healthy subject
3033969|NCT02334943|Experimental|Treated HIV-1 infected patients|Treated HIV-1 infected patients for Blood test
3033970|NCT02334943|Experimental|No treated HIV-1 infected patients|No treated HIV-1 infected patients for Blood test
3033971|NCT02334943|Experimental|Healthy witness|Healthy witness for Blood test
3033972|NCT02334930||Patients|Patients who will have biopsy or surgery for Perivascular epithelioid cell tumor (PEComa) or vascular pediatric tumor (Rapidly Involuting Congenital Hemangioma (RICH), Non Involuting Congenital Hemangioma (NICH), hemangioma or pyogenic granuloma)
3033973|NCT02334917|Experimental|Absorbable suture closure|Patients will have half of their surgical wound closed using one kind of absorbable superficial sutures, and the other half with a different kind of absorbable superficial suture. Which half receives which suture will be randomly determined.
3033974|NCT02334904||Aripiprazole|Participants receiving treatment of only aripiprazole, as prescribed to them by their psychiatrists, for a minimum of at least 3 continuous months.
3033975|NCT02334904||Risperidone|Participants receiving treatment of only risperidone, as prescribed to them by their psychiatrists, for a minimum of at least 3 continuous months.
3033976|NCT02334904||Controls|Healthy participants who are not taking any antipsychotic medications.
3033977|NCT02334878|Experimental|Stem cells,Mesenchymal|Periurethral injection of autologous bone-marrow derived stem cells.
3033978|NCT02334878|Active Comparator|surgery (TVT)|Tension-free vaginal tape operation: a midurethral sling operation
3033979|NCT02334865|Experimental|Group A (vaccine and week-4 lenalidomide maintenance therapy)|Patients receive SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC every 2 weeks at weeks 0, 2, 4, and 6 for up to 4 doses and then receive a booster in week 12. Beginning in week 4, patients receive lenalidomide maintenance therapy PO QD in the absence of disease progression or unacceptable toxicity.
3033980|NCT02334865|Experimental|Group B (vaccine and week-0 lenalidomide maintenance therapy)|Patients receive SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC every 2 weeks at weeks 4, 6, 8, and 10 for up to 4 doses and then receive a booster in week 16. Beginning in week 0, patients receive lenalidomide maintenance therapy PO QD in the absence of disease progression or unacceptable toxicity.
3033981|NCT02334839||Preeclampsia|women with diagnosed preeclampsia
3033982|NCT02334839||gestational hypertension|women with diagnosed gestational hypertension without preeclampsia
3033983|NCT02334839||healthy|women without gestational hypertension or preeclampsia
3033984|NCT02334826|Active Comparator|PCI - BVS|percutaneous coronary intervention with the use of bioresorbable scaffolds (Absorb)
3033985|NCT02334826|Active Comparator|CABG|coronary artery bypass grafting
3033986|NCT02334813|Active Comparator|Arm A: daily prednisone|During the first week of treatment patients in both arms receive prednisone at 1 mg/kg/d. In arm A prednisone is continued at 1 mg/kg/d for a second week. If platelets increase to ≥50/nl, its dose is reduced to <25 mg/d by week 14 and <7.5 mg/d by week 20 according to a step-wise reduction scheme provided in the protocol. In patients without response after 2 weeks of treatment, the prednisone dose is increased to 2 mg/kg/d for another 2 weeks, then tapered as described above.
3033987|NCT02334813|Active Comparator|Arm B: pulsed dexamethasone|During the first week of treatment patients in both arms receive prednisone at 1 mg/kg/d. In arm B patients subsequently receive six 21-day courses of pulsed dexamethasone (0.6 mg/kg/d, days 1-4).
3033988|NCT02334800|Experimental|Healthy Volunteers|Cohort of Healthy Volunteers
3033989|NCT02334800|Experimental|Mild Hepatic Impairment|Cohort of mild hepatic impairment subjects meeting the criteria for Child-Pugh Class A
3033990|NCT02334800|Experimental|Moderate Hepatic Impairment|Cohort of moderate hepatic impairment subjects meeting the criteria for Child-Pugh Class B
3033991|NCT02334800|Experimental|Severe Hepatic Impairment|Cohort of severe hepatic impairment subjects meeting the criteria for Child-Pugh Class C
3034026|NCT02334592|Experimental|High Pressure sunbed|
3033992|NCT02334787|Experimental|0.3% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned0.3% OPA-15406 ointment assessed until 48 hours postdose.
3033993|NCT02334787|Experimental|1% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1% OPA-15406 ointment assessed until 48 hours postdose.
3033994|NCT02334787|Experimental|3% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3% OPA-15406 ointment assessed until 48 hours postdose.
3033995|NCT02334787|Placebo Comparator|Placebo in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned placebo ointment assessed until 48 hours postdose.
3033996|NCT02334787|Experimental|0.3% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
3033997|NCT02334787|Experimental|1% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
3033998|NCT02334787|Experimental|3% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
3033999|NCT02334787|Experimental|Placebo in the multiple administration period|In the multiple administration period, same subjects were treated with assigned OPA-15406 ointment placebo twice daily for 14 days and assessed until 48 hours post dose.
3034000|NCT02334774|Experimental|Participants receiving an Oral Swallowing Care Program|Participants following prolonged endotracheal intubation receiving a 14-day daily Oral Swallowing Care Program.
3034001|NCT02334748|Experimental|canakinumab|Patients will continue the same dose as their last dose administered in the study CACZ885G2301E1, CACZ885N2301 or CACZ885G2306. For all indications, the maximum canakinumab dose is 4 mg/kg or 300 mg for patients ≥ 40 kg. Ilaris® dosage may be adjusted (or interrupted) according to the clinical response and to investigators judgment.
3034002|NCT02334735|Experimental|DC Vaccine|"Study subjects receive KLH and NY-ESO-1 and Melan-A/MART-1 peptide-pulsed DCs:~DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) and KLH will be administered intracutaneous as a single vaccine product followed by a subcutaneous injection of Poly-ICLC (Hiltonol®)."
3034003|NCT02334735|Active Comparator|Montanide Vaccine|"Study subjects receive KLH and NY-ESO-1 and Melan-A/MART-1 peptides and Montanide® ISA-51 VG:~Vaccine consisting of NY-ESO-1 peptide, Melan-A/MART-1 peptide, and KLH with an oil phase containing Montanide ISA-51 VG adjuvant will be administered subcutaneously as a single vaccine product followed by a subcutaneous injection of Poly-ICLC (Hiltonol®)."
3034004|NCT02334722|Experimental|1 Week Levetiracetam extended release|Levetiracetam extended release 1000 mg taken by mouth, once daily, for one week.
3034005|NCT02334722|Active Comparator|6 Week Levetiracetam extended release|Levetiracetam extended release 1000 mg taken by mouth, once daily, for six weeks.
3034006|NCT02334709|Experimental|SBRT + fixed dose Tyrosine Kinase Inhibitor|Single arm phase I trial with 3 dose-escalation arms
3034007|NCT02334683|Experimental|Electrophysiologic guidance|Electrophysiologic guidance, using electrical stimulation
3034008|NCT02334683|Active Comparator|Ultrasound guidance|Ultrasound guidance,using sound waves through a wand directed towards the targeted muscles.
3034009|NCT02334670||CrAg(+) and CM(+)|Patients with symptoms of CNS disease will be treated according to Vietnam national guidelines for HIV/AIDS management.
3034010|NCT02334670||CrAg(+) and CM(-)|Patients with CrAg(+) and without CM symptoms will be treated with high-dose fluconazole. The initial dosage of fluconazole will be 900 mg taken each day for 2 weeks. This will be followed by fluconazole 450 mg orally each day for 8 weeks. Finally, maintenance treatment with fluconazole 200mg orally each (2 tablets of 100 mg procured especially for the study) day will continue until CD4 >200 cells/µL for at least 6 months.
3034011|NCT02334670||CrAg negative|Patients with CrAg negative results will be managed as other HIV positive patients according to the national guidelines
3034012|NCT02334657||non-aneurysmal subarachnoid hemorrhage|patients with non-aneurysmal subarachnoid hemorrhage, short-term outcome measured by modified Rankin Scale and long-term outcome by SF-36
3034013|NCT02334657||perimesencephalic SAH|subgroup of non-aneurysmal subarachnoid hemorrhage
3034014|NCT02334657||non-perimesencephalic (NPM) SAH|subgroup of non-aneurysmal subarachnoid hemorrhage
3034015|NCT02334657||subgroup of NPM-SAH with Fisher 3|patients with non-aneurysmal (non-perimesencephalic) SAH and a Fisher 3 bleeding pattern
3034016|NCT02334657||subgroup of NPM-SAH w/o Fisher 3|patients with non-aneurysmal (non-perimesencephalic) SAH and not a Fisher 3 bleeding pattern
3034017|NCT02334644|Experimental|1|Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)
3034018|NCT02334644|Placebo Comparator|2|Placebo
3034019|NCT02334631|Experimental|High volume simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
3034020|NCT02334631|Active Comparator|Standard volume simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
3034021|NCT02334605|Other|cold dry air|"Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%."
3034022|NCT02334605|Other|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
3034023|NCT02334605|Other|capsaisin nasal spray|one puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
3034024|NCT02334592|Experimental|Low Pressure 100W sunbed|
3034025|NCT02334592|Experimental|Low Pressure 160W sunbed|
3034028|NCT02334579|Experimental|CyberKnife Stereotactic Radiosurgery|This treatment concentrates large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. CyberKnife Stereotactic Radiosurgery is not investigational and is considered standard of care.
3034029|NCT02334566|Experimental|NET TX|Behavioral intervention for PTSD (NET/KIDNET) with 8-12 sessions administered on a weekly basis.
3034030|NCT02334566|Active Comparator|Delayed TX|Exact treatment procedure following a three-month wait.
3034031|NCT02334553|Active Comparator|S1226 (8%)|The drug S1226(8%), consists of Perflubron and 8% CO2 in a medical gas mixture. The dosage is 3ml delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer.
3034032|NCT02334553|Placebo Comparator|Placebo|The comparator is normal saline delivered as an aerosol with compressed medical air with a Circulaire nebulizer.
3034033|NCT02334540|Other|purses or a calorie/protein matched smoothie|
3034034|NCT02334527|Other|Palbociclib Single Arm trial|Palbociclib
3034035|NCT02334514||Adults with influenza|Patients diagnosed with influenza by PCR testing
3034036|NCT02334501|Experimental|Treatment A (Period 1) and Treatment B (Period 2)|Treatment A (240mg Neratinib x1) Treatment B (30mg Lansoprazole X 7 days + 240mg Neratinib x1)
3034037|NCT02334488|Active Comparator|Everolimus-Tacrolimus|"Tacrolimus (Prograf®) started at 0,1 mg/kg/day since Day0, then adapted to C0 concentration (4-7 ng/ml),~Everolimus (Certican®) started within 24h after reperfusion, to be adapted to C0 concentration (3-8 ng/ml)."
3034038|NCT02334488|Experimental|Everolimus-Mycophenolate sodium|"Everolimus (Certican®) started within 24h after reperfusion, to be adapted to C0 concentration (3-8 ng/ml),~Tacrolimus (Prograg®) started at 0,1 mg/kg/day from J0 then to be adapted to C0 concentration (4-7 ng/ml), then replacement by mycophenolate sodium (Myfortic®) at M3 (3 months visit) started at 1440 mg/day."
3034039|NCT02334475|Experimental|GROUP (P)|Ultrasound guided sacroiliac joint injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml) per course. Single injection per course is being given.
3034040|NCT02334475|Active Comparator|GROUP (S)|Ultrasound guided sacroiliac joint injection of 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml). Single injection per course is being given.
3034041|NCT02334462|Experimental|Group 1-U.S|Arm 1a (N=5) to receive 16 micrograms Pfs25M on D0, D28. Arm 1b (N=5) to receive 47 micrograms Pfs25M on D0, D28.
3034042|NCT02334462|Experimental|Group 2-U.S|Arm 2a (N=5) to receive 5 micrograms Pfs230D1M on D0, D28.Arm 2b (N=5) to receive 15 micrograms Pgs230D1M on D0, D28. Arm 2c (N=5) to receive 40 micrograms Pfs230D1M on D0, D28.
3034043|NCT02334462|Experimental|Group 3- U.S.|Arm 3a (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28. Arm 3b (N=5) to receive 47 micrograms Pfs25M and 40 micrograms Pfs230D1M on D0, D28.
3034044|NCT02334462|Experimental|Group 1- Mali|Arm A1 (N=5) to receive 16 micrograms Pfs25M on D0, D28 Arm A2 (N=50) to receive 47 micrograms Pfs25M and Normal Saline on D0, D28, D168, D530
3034045|NCT02334462|Experimental|Group 2- Mali|Arm B1 (N=5) to receive 15 micrograms Pfs230D1M on D0, D28 Pfs230D1M-EPA/Alhydrogel Arm B2 (N=50) to receive 40 micrograms Pfs230D1M and Normal Saline on D0, D28, D168, D530
3034046|NCT02334462|Experimental|Group 3- Mali|Arm C1 (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28Arm C2 (N=50) to receive 47 micrograms Pfs25M and 40 microgramsPfs230D1M on D0, D28, D168, D530
3034047|NCT02334462|Active Comparator|Group 4- Mali|Arm D1 (N=5) to receive TWINRIX on D0, D28Arm D2 (N=5) to receive TWINRIX and NormalSaline on D0, D28Arm D3 (N=50) to receive TWINRIX and NormalSaline on D0, D28, D168; to receive Menactra andNormal Saline on D530
3034048|NCT02334449|Experimental|Single dose study part|there will be 8 cohorts of healthy volunteers dosed with single doses of LML134 (8 planned dose levels) or with placebo and 2 potential additional cohorts (also dosed with single dose of LML134 or placebo)
3034049|NCT02334449|Experimental|Multiple dose study part|there will be 3 cohorts of healthy volunteers dosed with multiple doses of LML134 (3 planned dose levels) or placebo and one potential additional cohort (also dosed with multiple doses of LML134 or placebo)
3034050|NCT02334436|Experimental|Botulinum toxin, Type A|Botulinum toxin, Type A
3034051|NCT02334436|Placebo Comparator|Placebo|0.9% sterile, unpreserved saline
3034052|NCT02334423|Experimental|Botulinum toxin, Type A|Botulinum toxin, Type A
3034053|NCT02334423|Placebo Comparator|Placebo|0.9 % sterile, unpreserved saline
3034054|NCT02334410|No Intervention|Reference|
3034055|NCT02334410|Experimental|Whole body vibration (WBV)|Vibration therapy
3034056|NCT02334397|Active Comparator|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program. Specifically, Total Control is a comprehensive pelvic fitness and wellness program designed by board-certified female pelvic medicine and reconstructive surgery (FPMRS) practitioners as well as physical therapists that combines pelvic floor and core muscle strengthening. Subjects will participate in 1 standardized class per week during their second trimester for a total of 6 weeks. Women will also participate in a weekly educational session which will include keynote speakers who are experts in various aspects of the labor and delivery process. Women in this group will complete questionnaires and consent to use of their delivery outcomes. Women will also wear pedometers to track daily general activity.
3034057|NCT02334397|No Intervention|Control Group|This group will consist of eligible women who were not randomized to the fitness and education program. Participants will complete questionnaires and consent to use of their delivery outcomes. Women will also wear pedometers to track daily general activity.
3034058|NCT02334384|Experimental|Antimicrobial TheraGauze|Antimicrobial TheraGauze (i.e. tobramycin impregnated TheraGauze) will be used as a wound packing after incision and drainage of skin abscess (i.e. furunculosis). Antimicrobial TheraGauze will be administered once.
3034059|NCT02334384|Active Comparator|Standard wound packing|Standard wound packing will be the intervention in the active comparator. The ED physician will have the choice to use plain cotton wick or iodoform wick. Standard wound packing will be administered once.
3034060|NCT02334371|Other|MR-PET|Preoperative whole-body MR-PET with 18F-FDG
3034061|NCT02334345|Experimental|EVOSKIN|Patients are to apply Evoskin ( topical agent) in the half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.
3034092|NCT02334150|No Intervention|Control group|Women in the control group were not provided any analgesia during labor.
3034062|NCT02334345|Active Comparator|TRIXIERA|Patients are to apply Trixiera ( topical agent) in the other half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.
3034063|NCT02334332|Active Comparator|Cohort I (standard care)|Participants receive standard post-operative care.
3034064|NCT02334332|Experimental|Cohort II (educational brochure)|Participants receive a 2-page educational brochure after surgery and prior to discharge home.
3034065|NCT02334319|Experimental|Treatment (ganetespib, surgery)|Patients receive ganetespib IV over 1 hour twice weekly for 2 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery the day after the last dose of ganetespib.
3034066|NCT02334306|Experimental|AMG 557/MEDI5872|Fixed subcutaneous (SC) dose of AMG 557/MEDI5872 every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85). Beginning on Day 99, all subjects (n = 42) will receive a fixed SC dose of AMG 557/MEDI5872 every week (Days 99 to 113) and every 2 weeks (Days 127 to 183) for an additional 12 weeks.
3034067|NCT02334306|Placebo Comparator|Placebo|Fixed SC dose of placebo every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85). Beginning on Day 99, all subjects (n = 42) will receive a fixed SC dose of AMG 557/MEDI5872 every week (Days 99 to 113) and every 2 weeks (Days 127 to 183) for an additional 12 weeks.
3034068|NCT02334293|Other|Omegaven|
3034069|NCT02334280|Experimental|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
3034070|NCT02334280|No Intervention|Usual-Care Control|Usual-care consumers agreed to delay participation in In SHAPE for 12 months.
3034071|NCT02334267|Active Comparator|Group 1: GranuFlo|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of NaturaLyte for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
3034072|NCT02334267|Active Comparator|Group 2: NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of GranuFlo for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
3034073|NCT02334254|Experimental|Dual antithrombotic therapy (DAT)|Dual Antithrombotic Therapy (DAT) regimen of rivaroxaban 2.5mg/5mg b.i.d. plus ticagrelor 90mg b.i.d.
3034074|NCT02334254|Active Comparator|Triple antithrombotic therapy (TAT)|Triple antithrombotic therapy (TAT) regimen of aspirin 100mg q.d., clopidogrel 75mg q.d. plus warfarin (INR 1.8-2.5).
3034075|NCT02334241|Experimental|Sorbact®|The basic Sorbact® presentation is an antimicrobial, non-adhesive absorbent wound dressing. It consists of a highly absorbent hydropolymer matrix with an antimicrobial Sorbact® mesh (Sorbact® acetate fabric coated with dialkyl carbamoyl chloride - DACC) and is covered by a semipermeable polyurethane film.
3034076|NCT02334241|Active Comparator|Best local cares|Dressing requirements in this study have to be consistent with international guidelines.
3034077|NCT02334228|Experimental|In SHAPE Lifestyles|In SHAPE Lifestyle is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
3034078|NCT02334228|Active Comparator|Health Club Membership and Education|Fitness club membership with education in using the exercise equipment.
3034079|NCT02334215|Experimental|Methadone plus Patient Navigation|Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
3034080|NCT02334215|Experimental|Methadone|Participants will begin methadone during detention.
3034081|NCT02334215|Active Comparator|Enhanced Treatment as Usual|Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
3034082|NCT02334202|Active Comparator|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program for adolescent military dependents."
3034083|NCT02334202|Experimental|Interpersonal Psychotherapy-Weight Gain|IPT-WG is designed to decrease excessive weight gain among adolescents who are at risk for adult obesity. IPT-WG involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. The IPT-WG program has been adapted to be appropriate for military dependents.
3034084|NCT02334189|Experimental|Letter|Patients receive a letter containing information on alternative healthcare options for non-emergency health concerns.
3034085|NCT02334189|No Intervention|No letter|Patients receive no letter (this is the usual care).
3034086|NCT02334176|Active Comparator|single injection|Axillary plexus block performed with single injection dorsally to the artery
3034087|NCT02334176|Active Comparator|Double injection|Axillary plexus block performed with 2 injections: one over musculocutaneous nerve the second one dorsally to the artery
3034088|NCT02334163|Experimental|Nitazoxanide group|"12 patients will receive the following for 7 days:~Oral lactulose~500 mg nitazoxanide tablets twice daily"
3034089|NCT02334163|Active Comparator|Metronidazole group|"12 patients will receive the following for 7 days:~Oral lactulose~250 mg metronidazole tablets every 8 hours"
3034090|NCT02334163|Active Comparator|Rifaximine group|"12 patients will receive the following for 7 days:~Oral lactulose~Two 200 mg rifaximine tablets every 8 hours"
3034091|NCT02334150|Experimental|CSEA group|Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
3034093|NCT02334137||iPad app|This group will have unlimited access to educational iPad app while waiting for ophthalmology visits.
3034094|NCT02334137||Educator sessions|This group will have unlimited access to educational iPad app AND at least one appointment with a certified diabetes educator or registered dietitian while waiting for ophthalmology visits.
3034095|NCT02334137||Educator sessions + retinal photos|"This group will have same access as iPad app + education sessions and in addition will be able to briefly review their own retinal photos (compared to normal retina) with a resident ophthalmologist during timeline of pilot program."
3034096|NCT02334124|Experimental|Home|Patients will be treated at home through the Hospital-In-The-Home program with intravenous once daily ceftriaxone (50mg/kg once daily), administered by a nurse/doctor visiting once daily.
3034097|NCT02334124|Active Comparator|Ward|Patients will be admitted to hospital ward and treated with six hourly flucloxacillin (50mg/kg), administered by a ward nurse as per routine practice.
3034098|NCT02334111|No Intervention|(Control)|Patients will receive standard of care
3034099|NCT02334111|Experimental|(Intervention)|Patients will receive RESPECT-Plus intervention
3034100|NCT02334098|Experimental|Omega-3 supplemented drink|A 200 ml. drink product with 1.1 grams of omega-3 from Smartfish (Smartfish: Forsiden in Norway).
3034101|NCT02334098|Placebo Comparator|Placebo Drink|exactly the same fruit drink contained in the same packaging, but will contain no omega-3.
3034102|NCT02334098|No Intervention|treatment-as-usual controls|No drinks are taken.
3034103|NCT02334085||HOW study participants|
3034104|NCT02334072|Experimental|Classical|Laryngeal mask airway (LMA) is manufactured from medical grade silicone rubber and is reusable. It consists of 3 main components: An airway tube, inflatable mask and mask inflation line. The airway tube is slightly curved to match the oropharyngeal anatomy, semirigid to facilitate atraumatic insertion and semitransparent, so that condensation and regurgitated material is visible. The distal aperture of the airway tube opens into the lumen of an inflatable mask and is protected by two flexible vertical rubber bars, called mask aperture bars, to prevent the epiglottis from entering and obstructing the airway. The laryngeal mask classical application will be done following anesthesia induction.
3034105|NCT02334072|Experimental|I-Gel|I-Gel LMA is anatomically designed mask made of a gel-like thermoplastic elastomer. It has a drain tube for gastric aspiration. I-gel laryngeal mask application will be done following anesthesia induction.
3034106|NCT02334072|Experimental|Cobra|Cobra LMA consists of a translucent silicone airway tube with an inflatable cuff sited approximately two-thirds of the way to the tip, a 15-mm standard adapter and an expanded distal end with a smooth posterior surface. The cuff forms a seal in the upper pharynx and the distal end sits in the laryngopharynx. The distal grill is designed to sit over the laryngeal inlet.Cobra laryngeal mask application will be done following induction of anesthesia
3034107|NCT02334072|Experimental|Supreme|The Supreme LMA is a single-use polyvinyl chloride supraglottic device. High oropharyngeal leak pressures are important as they indicate airway protection, feasibility of positive pressure ventilation and likelihood of successful LMA placement.Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia.
3034108|NCT02334072|Experimental|Proseal|The ProSeal LMA is the most complex of the specialized laryngeal mask devices.The primary design goal was to construct a laryngeal mask with improved ventilatory characteristics that also offered protection against regurgitation and gastric insufflation. The principal new features are a modified cuff and a drain tube.Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia.
3034109|NCT02334059|Active Comparator|Ketamine|Ketamine: 0.5 mg/kg IV dose
3034110|NCT02334059|Active Comparator|Ketamine plus magnesium|Ketamine plus magnesium group: 0.5 mg/kg IV dose as well as Magnesium 2 grams IV
3034111|NCT02334059|Placebo Comparator|Placebo|Placebo (normal saline)
3034112|NCT02334046|Experimental|Elderly|Remifentanil was maintained at predetermined effect-site concentration during the emergence period in elderly patients.
3034113|NCT02334046|Active Comparator|Adult|Remifentanil was maintained at predetermined effect-site concentration during the emergence period in adult patients.
3034114|NCT02334020|Experimental|Training course|12 hour training course in Mental Health First-aid
3034115|NCT02334020|Other|Waiting list|Waiting list design, hence delayed offering of Mental Health First-aid
3034116|NCT02334007|Experimental|LMWH: Dalteparin|Consenting patients undergoing lung resection will receive standard postoperative thromboprophylaxis in hospital until the time of discharge. Subsequently, patients will be administered LMWH for duration of 30 days as outpatients.
3034117|NCT02334007|Placebo Comparator|Placebo|After undergoing lung resection these patients will research standard post-op TE prophylaxis and upon discharge will be administered a placebo injection of subcutaneous saline for 30 days duration.
3034118|NCT02333994|Experimental|GROUP A|EDUCATION PROGRAMME AND BALANCE TRAINING EXERCISES
3034119|NCT02333994|Active Comparator|GROUP B|BALANCE EXERCISES
3034120|NCT02333981|Experimental|Passive oral motor therapy group|All the subjects received passive treatment which included light touch, stroking, vibration, tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
3034121|NCT02333968|Experimental|Intervention group|Self-management support
3034122|NCT02333968|No Intervention|Control group|Care as usual
3034123|NCT02333955|Experimental|3 mg IV push|GCS-100
3034124|NCT02333942||Alzheimer's Disease|Nautilus NeuroWaveTM System'
3034125|NCT02333942||Mild Cognitive Impairment|Nautilus NeuroWaveTM System'
3034126|NCT02333942||Frontotemporal Lobar Degeneration|Nautilus NeuroWaveTM System'
3034127|NCT02333942||Age-Matched Controls|Nautilus NeuroWaveTM System'
3034128|NCT02333929||VTE prevention|Prophylaxis of VTE in patients undergoing knee or hip replacement surgery (10 mg OD): orthopaedic department of the hospital will be in charge of the sample collection.
3034195|NCT02333474|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line Version 2.2014.
3034129|NCT02333929||DVT/PE treatment|Treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and risk reduction of DVT and PE recurrence; (15 mg BID for 3 weeks then 20 mg OD): different departments of the hospital will be in charge of the sample collection (samples can come e.g., from emergency room, vascular lab or cancer unit).
3034130|NCT02333929||SPAF|Stroke prevention and reduction of systemic embolism in non-valvular patients with atrial fibrillation (SPAF) (20 mg OD): cardiology department of the hospital will be in charge of the sample collection.
3034131|NCT02333916|Experimental|Overfeeding + exercise pre/post training|"overfeeding + exercise pre-training: day1 energy balance; day2 and day3: energy intake equals 1.25 times day 2 and day 3 energy expenditure respectively, no exercise; day4: 3 cycling bouts to expend 0.25 times day3 energy expenditure + energy intake equals 1.25 times day4 energy expenditure - before training period.~fitness training: 10-week training period (3 times per week at a gym, 30-45 minutes cardio training and 15-30 minutes strength training).~overfeeding + exercise post-training: day1 energy balance; day2 and day3: energy intake equals 1.25 times day 2 and day 3 energy expenditure respectively, no exercise; day4: 3 cycling bouts to expend 0.25 times day3 energy expenditure + energy intake equals 1.25 times day4 energy expenditure - after training period."
3034132|NCT02333903|Experimental|Personalized Physical Activity|Patients will undergo a personalized physical activity program after sleeve gastrectomy.
3034133|NCT02333903|No Intervention|Regular Activity|Patients will have regular physical activity after sleeve gastrectomy.
3034134|NCT02333890|Experimental|Chloroquine|The daily oral dose per patient is 500 mg of chloroquine. Patients may be taking the drug for 2-6 weeks leading up to the date of the surgery. The last dose will be taken the evening before surgery.
3034135|NCT02333890|Placebo Comparator|Placebo|The daily oral dose per patient is 500 mg of placebo (lactose). Patients may be taking the drug for 2-6 weeks leading up to the date of the surgery. The last dose will be taken the evening before surgery.
3034136|NCT02333877|Experimental|Skinlink|applying Skinlink on simple laceration (length < 5cm)
3034137|NCT02333877|Other|Nylon|applying conventional suture using nylon on simple laceration (length < 5cm)
3034138|NCT02333864||PWD testing POGO® BGMS|All enrolled persons with diabetes
3034139|NCT02333851|Experimental|Premixed insulin|Mixtard 30:70 Novonordisk® twice daily, before breakfast and before dinner.
3034140|NCT02333851|Experimental|Basal-bolus|'Lantus® once daily and Apidra® before meals
3034141|NCT02333838|Experimental|Reduced toxicity conditioning regimen|"Reduced toxicity conditioning regimen (thiotepa, busulfan, fludarabine and ATG) followed by unrelated cord blood allogeneic stem cell transplant for high risk myeloïd malignancies.~The conditioning regimen will include:~IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6)~IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)~IV Busulfan (Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3)~IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)~In patient with co-morbidities and/or older than 60 years, conditioning could be reduced after consulting the coordinator of the study:~IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)~IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)~IV Busulfan (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)~IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)"
3034142|NCT02333825|Other|Surgical Intervention|The surgical intervention to be studied in this arm is medial patellofemoral ligament reconstruction surgery using hamstring tendon. The tendon used will generally consist of autograft semitendinosus. If the hamstrings have been previously harvested or injured (i.e. in the setting of anterior cruciate ligament reconstruction or proximal tibial surgery), or if the patient/his or her family prefers to minimize donor site morbidity, allograft may be used.
3034143|NCT02333825|Other|Conservative treatment|The intervention to be studied in this arm is a rehabilitation program directed by physical therapists. If patients in this arm are found to have a small loose body, a simple arthroscopy will be performed to remove the loose body, but no stabilization of the patellofemoral joint will be performed. The rehabilitation program will be compiled into a booklet and distributed for use by the physical therapist chosen by the patient.
3034144|NCT02333812||copd patients|Adult patients with COPD
3034145|NCT02333812||healthy smokers|Adult patients with smoking history and no clinical manifestation of COPD who will be recruited form the institute of pulmonary medicine and the otolaryngology outpatient clinic.
3034146|NCT02333812||Adult patients with lung disease unrelated to smoking|Adult patients with lung disease unrelated to smoking
3034147|NCT02333799|Experimental|Bedaquiline + PA-824 + Linezolid|bedaquiline 400 mg once daily for 2 weeks then 200mg 3 times per week plus PA-824 200mg once daily plus linezolid 1200mg once daily .
3034148|NCT02333786|Experimental|Infant|Radial artery or posterior tibial artery of patients younger than 1 year old are either cannulated with short-axis/out-of-plane or long-axis/in-plane US-guided arterial catheterization technique.
3034149|NCT02333786|Experimental|Preschool child|Radial artery or posterior tibial artery of patients older than 1 year old and younger than 5 years old are either cannulated with long-axis/in-plane or short-axis/out-of-plane US-guided arterial catheterization technique.
3034150|NCT02333773|Experimental|Group A|irreversible electroporation with voltage in level A for Unresectable Portal Venous Tumor Emboli
3034151|NCT02333773|Experimental|Group B|irreversible electroporation with voltage in level B for Unresectable Portal Venous Tumor Emboli
3034152|NCT02333773|Experimental|Group C|irreversible electroporation with voltage in level C for Unresectable Portal Venous Tumor Emboli
3034153|NCT02333747|Experimental|the TEAS group|Patients in the TEAS group received pre-operative TEAS for 30 min before the induction of anesthesia using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China) in the holding area. TEAS was applied to two pairs of acupoints: bilateral Hegu (LI4) and Neiguan (PC6).
3034154|NCT02333747|Sham Comparator|the sham group|In the sham group, the patients were connected to the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China), but electronic stimulation was not applied.
3034155|NCT02333734|Experimental|Type 2 diabetic subjects|Type 2 diabetic subjects physical training (interval training 3 times at week) in a period of 8 weeks.
3034156|NCT02333734|Experimental|Healthy subjects|Healthy subjects physical training (interval training 3 times at week) in a period of 8 weeks.
3034229|NCT02333279||Organ transplant recipients|Follow-ups in regular intervals following the organ transplant date.
3034230|NCT02333266||Candidemia|0
3034157|NCT02333721|Experimental|D2 Lymphadenectomy including No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
3034158|NCT02333721|Active Comparator|D2 lymphadenectomy excluding No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
3034159|NCT02333708||GCA group|
3034160|NCT02333708||Inflammatory syndrome (without GCA) group|
3034161|NCT02333708||Without inflammatory syndrome and without GCA group|
3034162|NCT02333695|Experimental|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
3034163|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 10 mcg, 1 capsule/day before breakfast, Duration: 6 months
3034164|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 15 mcg, 1 capsule/day before breakfast, Duration: 6 months
3034165|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 20 mcg, 1 capsule/day before breakfast, Duration: 6 months
3034166|NCT02333682|Active Comparator|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol), Dose: 20 mcg, 1 capsule/day before breakfast, Duration: 6 months
3034167|NCT02333669||Control group|The control blood samples, which were collected from healthy neonatal umbilical cord blood, were obtained from the maternity ward of 80 hospitals in Chongqing and nearby areas
3034168|NCT02333669||RDS group|Newborns with RDS were consecutively recruited for this study from the neonatal intensive care unit (NICU) at Daping Hospital, Third Military Medical University, Chongqing, China, a tertiary care facility
3034169|NCT02333656|No Intervention|Control group|Usual care. The participants enrolled in the control period will receive OA treatment as it is currently offered in primary health care services.
3034170|NCT02333656|Experimental|Intervention group|New OA model. Health professionals attend an interactive workshop, implementation of international recommendations for OA care, multidiciplinary collaboration
3034171|NCT02333643|Experimental|CLS003|Topical digoxin/furosemide
3034172|NCT02333643|Experimental|Digoxin topical formulation|
3034173|NCT02333643|Experimental|Furosemide topical formulation|
3034174|NCT02333643|Placebo Comparator|Vehicle topical formulation|
3034175|NCT02333630|Experimental|AsthmaCare intervention|Participants randomized to this arm will have the AsthmaCare app downloaded to their mobile device at time of study recruitment. They will have access to AsthmaCare indefinitely after enrollment.
3034176|NCT02333630|Active Comparator|Control group|Participants randomized to this arm will receive a link to a website containing asthma education videos and information. They will be able to access this link at their discretion.
3034177|NCT02333617|Experimental|Dry Needling and Exercise|Dry Needling to treat gluteus medius trigger points followed by hip and core exercises.
3034178|NCT02333617|Active Comparator|Soft Tissue Mobilization|Soft tissue mobilization to treat gluteus medius trigger points followed by hip and core exercises.
3034179|NCT02333617|Placebo Comparator|Placebo Control|Placebo to control for hands on time and attention from therapist followed by hip and core exercises.
3034180|NCT02333591|Active Comparator|GlucagonLikePeptide-1 (7-36)|"GLP-1 (7-36) is diluted in saline and human serum albumin. Plasma levels of GLP-1 (7-36) are rapidly raised and then maintained stable with 5,91 pmol/kg/min (0-2 min) reduced to 2,53 pmol/kg/min (2-4 min) reduced to 2,34 pmol/kg/min (4-6 min) reduced to 2,2 pmol/kg/min (6-8 min) reduced to 2,02 pmol/kg/min (8-10 min) and then maintained stable for 2½ hours with 1.5 pmol/kg/min.~A DPP-IV inhibitor - Januvia 100 mg is given the evening before and ½ an hour before the infusion is started."
3034181|NCT02333591|Active Comparator|GlucagonLikePeptide-1 (9-36)|GLP-1 (9-36) is diluted in saline and human serum albumin. Plasma levels of GLP-1 (9-36) are rapidly raised and then maintained stable with 5,91 pmol/kg/min (0-2 min) reduced to 2,53 pmol/kg/min (2-4 min) reduced to 2,34 pmol/kg/min (4-6 min) reduced to 2,2 pmol/kg/min (6-8 min) reduced to 2,02 pmol/kg/min (8-10 min) and then maintained stable for 2½ hours with 1.5 pmol/kg/min
3034182|NCT02333591|Placebo Comparator|NaCl|Saline is infused with a flow rate of 240 ml/h for 10 min and then reduced to 86 ml/h for 2½ hours.
3034183|NCT02333578|Experimental|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
3034184|NCT02333565|Experimental|Combinaison everolimus and octreotide|
3034185|NCT02333539|Experimental|Tailored feedback|Participants are provided a Tailored Feedback report based on data downloaded from their insulin pumps. Summaries are provided about insulin pump adherence behaviors and recommendations for improvement are made.
3034186|NCT02333539|Experimental|Problem Solving|Participants receive a problem-solving session based on data downloaded from their insulin pumps. An insulin pump adherence behavior that needs improvement is targeted; goals are set and solutions generated.
3034187|NCT02333539|No Intervention|Treatment as Usual|Standard of care as provided by the endocrinologist occurs.
3034188|NCT02333513|Experimental|case group|
3034189|NCT02333500|Experimental|olfactory workshop|Influence of sensory therapy on the rate of oxytocin
3034190|NCT02333500|Active Comparator|other workshop|Influence of other workshop on the rate of oxytocin
3034191|NCT02333500|Other|control group|Rate of oxytocin of the control group
3034192|NCT02333487|Experimental|Lu AF35700 (Groupe A)|Up to 3 PET scans, besides baseline scan, using [11C]-NNC 112 tracer to detect D1 receptor occupancy before and after multiple oral dosing of Lu AF35700
3034193|NCT02333487|Experimental|Lu AF35700 (Groupe B)|Up to 3 PET scans, besides baseline scan, using [11C]-Raclopride to detect D2 receptor occupancy before and after multiple oral dosing of Lu AF35700
3034194|NCT02333487|Experimental|Lu AF35700 (Groupe C)|Up to 3 PET scans, besides baseline scan, using [11C]- Lu AE60157 tracer to detect 5-HT6 receptor occupancy before and after multiple oral dosing of Lu AF35700
3034196|NCT02333474|Experimental|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line Version 2.2014 and simultaneous injection of mix vaccine (MV). MV will be given
3034197|NCT02333461|Placebo Comparator|Placebo|333 mg capsule comprised of silicified microcrystalline cellulose, magnesium stearate, modified cellulose gum, silicon dioxide, dextrose, corn starch, and caramel color. Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
3034198|NCT02333461|Experimental|Apple|333 mg capsule comprised of apple peel extract (115:1, standardized to 80% polyphenol and 5% phlorizin). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
3034199|NCT02333461|Experimental|Grape|333 mg capsule comprised of grape extract (8000:1, standardized to 75% total polyphenol, 50% oligomeric proanthocyanidin). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
3034200|NCT02333461|Experimental|Red Raspberry|333 mg capsule comprised of red raspberry leaf extract (4:1, standardized to 6% ellagic acid). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
3034201|NCT02333461|Experimental|Apricot/Nectarine|333 mg capsule comprised of apricot/nectarine extract (40:1, standardized to 50% polyphenol).
3034202|NCT02333448||patients with suspected invasive candidiasis|
3034203|NCT02333435|Experimental|Purified EPA group|3g per day of purified EPA, capsules, to be taken once a day, for 14 months.
3034204|NCT02333435|Experimental|Placebo group|3 g per day of high-oleic sunflower oil capsules, to be taken once a day, for 14 months.
3034205|NCT02333422|Experimental|NIRS Neurofeedback|NIRS Neurofeedback training of frontal and pre frontal lobes activation. The intervention consist of 24 NIRS neurofeedback sessions over 12 weeks, 2 sessions per week.
3034206|NCT02333409|Active Comparator|Electroacupuncture|A Hong Kong registered Chinese Medicine practitioner will give Electroacupuncture treatments. Patients will be treated in a comfortable prone position. Jiaji (Ex-B2) points form T8 to T12 bilaterally are chosen based on traditional Chinese medicine (TCM) theory and neurophysiologic basis of Jiaji points. After De Qi sensation is achieved, the handles of needles on homolateral T8-T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1 mA with a disperse-dense waveform. The needles remained for 30 min. The treatment was given twice weekly on week 1 and week 3.
3034207|NCT02333409|Sham Comparator|Sham|For placebo acupuncture, sham placebo acupuncture needles (DongBang AcuPrime Acupuncture Inc., South Korea) will be used. Its validity and credibility have been well demonstrated. The needles with blunt tips are quickly put onto the same points used in the electroacupuncture group without inserting into the skin. The needles on homolateral T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
3034208|NCT02333396|Experimental|PICU Supports|Participants will receive the PICU Supports intervention.
3034209|NCT02333396|Active Comparator|Educational Brochure|Participants will receive an educational brochure about the pediatric intensive care unit.
3034210|NCT02333383||Subjects with Ankylosing Spondylitis|Subjects who have been diagnosed with active ankylosing spondylitis according to the 1984 modified New York criteria.
3034211|NCT02333370|Experimental|LEE011 +Letrozole|LEE011 - 3 weeks on 1 week off Letrozole 2.5mg - Once daily
3034212|NCT02333370|Experimental|LEE011 + Tamoxifen|LEE011 - 3 weeks on 1 week off Tamoxifen 20mg - Once daily
3034213|NCT02333370|Experimental|LEE011 + Fulvestrant|LEE011 - 3 weeks on 1 week off Fulvestrant 500 mg - Dosed every 28 days (Day 1 for each cycle) with 1 additional dose on Day 15 of Cycle 1
3034214|NCT02333357|Experimental|Toolkit|Counselors randomized to the toolkit (TK) condition will receive a one to three hour standardized toolkit orientation that will include a description of the overall goal of the toolkit curriculum comprised of five modules, the purpose of each individual element of the toolkit, and an introduction to the toolkit teaching aids such as counselor guides, posters, and patient materials (hand-outs, sampling menus, worksheets, etc). TK counselor participants then conduct group treatment sessions using the toolkit materials with their patient participants.
3034215|NCT02333357|Active Comparator|Treatment as Usual|Counselors assigned to the Treatment as Usual (TAU) attention control condition complete a training that reviews the same five 12-step topics that are included in the toolkit, but they do not receive any toolkit materials. TAU counselor participants then conduct group treatment sessions on the 12-step topics without using toolkit materials.
3034216|NCT02333344|Experimental|Zoledronic acid 5mg|interventional group which receive yearly Zoledronic acid 5mg/100ml infusion treatment for two years
3034217|NCT02333344|No Intervention|blank|blank group
3034218|NCT02333331|Experimental|bimagrumab low dose|bimagrumab low dose infusion
3034219|NCT02333331|Experimental|bimagrumab moderate dose|bimagrumab moderate dose infusion
3034220|NCT02333331|Experimental|bimagrumab high dose|bimagrumab high dose infusion
3034221|NCT02333331|Placebo Comparator|Placebo|Placebo infusion
3034222|NCT02333318|Experimental|Single Dose_VVZ-149 injection|"Cohort A (50-64 years old), Cohort B (65-84 years old)~For 2.5, 5mg/kg~4-hr intravenous infusion of VVZ-149 injection~6 subjects will be administered within each age group. Total 24 subjects will participate."
3034223|NCT02333318|Experimental|Loading/Maintenance_VVZ-149 injection|"Cohort A (50-64 years old) This trial is conducted only in the Cohort A one week after the single IV infusion.~For Loading + Maintenace dose: 0.75 mg/kg+ 0.55 mg/kg/h, 1.5 mg/kg + 1.10 mg/kg/h~intravenous infusion~4 subjects will be randomly assigned within each dose group, respectively. Total 8 subjects will participate."
3034224|NCT02333318|Placebo Comparator|Loading/Maintenance_Placebo|"Cohort A (50-64 years old)~For Loading + Maintenace dose: 0.75 mg/kg+ 0.55 mg/kg/h, 1.5 mg/kg + 1.10 mg/kg/h~intravenous infusion~2 subjects will be randomly assigned within each dose group, respectively. Total 4 subjects will participate."
3034225|NCT02333305|Experimental|1|Coenzyme Q10 (CoQ10) - is a Dietary complement that contains Coenzyme Q10 (Ubidecarenone) well characterized nano particles.
3034226|NCT02333305|Placebo Comparator|2|Placebo of CoQ10 is a translucent nano-emulsion of well characterized nano particles. Lecithin (and) Alcohol (and) Glycerin (and) Aqua
3034227|NCT02333292||IFN|HCV-infected patients, pre-treated or treatment-naïve, who start a regimen containing pegylated interferon in combination with any DAA
3034228|NCT02333292||IFN-free|HCV-infected patients, pre-treated or treatment-naïve, who start a regimen containing one or more DAA
3034231|NCT02333253|Active Comparator|Delayed start protocol|First group received 300 U r FSH +150 U urinary GN from day 2 till day of HCG ,dose adjusted according to the response then 0.25 cetrotide S.c was added on when leading follicle reach >12 mm, HCG was given only if we have at least 3 mature follicles >14 mm and the leading one >17mm then OPU done after 36 hrs of HCG, oocytes were denuded and fertilized by ICSI to avoid low fertilization rate by conventional IVF,embryo transfer were done on day 3 when we have at least one embryo GI other wise cancelled ET, then cyclogest 800mg were given intravaginal for 14 days then quantitative BHCG done and considered positive if > 5miu/ML
3034232|NCT02333253|Active Comparator|conventional antagonist protocol|Second group were received cetrotide 0.25 mg s.c alone from day 2 to day 8then we initiate GN therapy by same initial GN dose (300FSH+150U urinary GN).same adjustment of dose were done and antagonist restarted when DF >12mm, till day of HCG, OPU done after 36 hrs of HCG, oocytes were denuded and fertilized by ICSI to avoid low fertilization rate by conventional IVF,embryo transfer were done on day 3 when we have at least one embryo GI other wise cancelled ET, then cyclogest 800mg were given intravaginal for 14 days then quantitative BHCG done and considered positive if > 5miu/ML
3034233|NCT02333240|No Intervention|Usual care|"Women randomised to usual care will have their blood pressure monitored by their community midwife, and will have their anti-hypertensive medication adjusted by their general practitioner. There will be no intervention in this group.~All women will be followed up at ten days, four and six weeks, then three and six months postpartum and have their blood pressure measured by one of the study team."
3034234|NCT02333240|Experimental|Self-management|Self-management of postnatal anti-hypertensive treatment. Women will be provided with, and taught to use, a validated home blood pressure monitor, and perform daily BP readings. When treatment is discontinued we will ask them to continue daily BP measurements for 1 week. Provided these are <140/90 mmHg they will be asked to check their BP weekly for the remainder of the trial period. The self-monitoring BP data will be collated centrally through the use of a smart phone app or SMS based system. This service will respond to participants regarding the level of their BP and what action is required. Women in the self-management group will have an individualised medication adjustment schedule developed by the research team in conjunction with the participant's obstetric team.
3034235|NCT02333227|No Intervention|Control|Cluster of sites not receiving xylitol gum. This is a cluster randomized trial, whereby 4 sites will not receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
3034236|NCT02333227|Experimental|Xylitol|Cluster of sites receiving xylitol gum.
3034237|NCT02333214|Experimental|Exergame + conventional physiotherapy|This group will be submitted to 30 minutes of conventional physiotherapy and 20 minutes of therapy using interactive games Xbox 360 Video Game and Entertainment Microsoft System with Kinect sensor, intervention twice a week for 12 weeks. Each game has three difficulty levels that can be used according to the performance of each participant. The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain.
3034238|NCT02333214|Active Comparator|Conventional physiotherapy|The control group will receive 50 minutes of conventional physiotherapy intervention twice a week for 12 weeks. The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain.
3034239|NCT02333188|Experimental|Treatment (FOLFIRABRAX)|Patients receive FOLFIRABRAX comprising paclitaxel albumin-stabilized nanoparticle formulation IV over 0.5 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 1.5 hours, and fluorouracil IV over 46 hours on days 1 and 15. Courses repeat every 4 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.
3034240|NCT02333175|Active Comparator|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
3034241|NCT02333175|No Intervention|Care as usual|Care as usual
3034242|NCT02333162|Experimental|Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes daily on days -7 to -3 and melphalan IV on day -2. Patients also undergo IMTMI BID for 2 to 5 days between days -7 to -3.~TRANSPLANT: Patients undergo allogeneic PBSCT or BMT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously over 24 hours or PO BID on days -2 to 180 with taper thereafter and mycophenolate mofetil IV every 8 hours or PO on days 0-28 (for matched donors) or days 0-40 (for alternative donors) with taper to day 60."
3034243|NCT02333149|Experimental|Melatonin|Dietary supplement: Melatonin 3 mg or 6 mg
3034244|NCT02333149|Placebo Comparator|Placebo|Drug: Placebo
3034245|NCT02333136||IVRS studied|subjects will be monitored for changes in hematocrit based on results of in vivo raman spectroscopy scatter
3034246|NCT02333123|Experimental|Aspirin|Aspirin 300mg capsule by mouth once a day for 24 weeks.
3034247|NCT02333123|Placebo Comparator|Placebo|Placebo capsule (for aspirin 300mg capsule) by mouth once a day for 24 weeks.
3034248|NCT02333110|Experimental|GRID radiation therapy|A single dose of 15-20Gys of spatially fractionated radiation therapy
3034249|NCT02333084|Experimental|Joint Health Product|natural dietary supplement
3034250|NCT02333084|Placebo Comparator|Placebo|vegetable oil placebo
3034251|NCT02333084|Active Comparator|Combination with Omega-3|combination with omega-3 fish oil
3034252|NCT02333071|Experimental|Bremelanotide|Subjects will self-administer a fixed dose of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours.
3034253|NCT02333071|Placebo Comparator|Placebo|Subjects will self-administer a fixed dose of placebo subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours.
3034283|NCT02332837|Experimental|Test to train informed consent|"Informed consent with images, text, auditory presentation and test to train feature where participants get feedback on comprehension responses throughout the consent and can change them~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
3034284|NCT02332824|Placebo Comparator|Placebo|"TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
3034254|NCT02333058|Experimental|Treosulfan|"Treosulfan dose per day is to be calculated by using BSA. One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.~Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.~Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2."
3034255|NCT02333045|Experimental|Truvada qd|Women will be assigned at random Truvada 1 tablet PO daily
3034256|NCT02333045|Experimental|Maraviroc 300 qd|Women will be assigned at random Maraviroc 300 mg PO daily
3034257|NCT02333032|Experimental|hemiplegic patient|
3034258|NCT02333019|Experimental|Let's Talk About Sex|Participants assigned to the treatment condition viewed a multimedia web site designed to help parents of pre-adolescent children, aged 10 to 14 years old, build skills to communicate effectively about parental values and issues relating to sexuality, sex and relationships, and preventing pregnancy and sexually transmitted infections.
3034259|NCT02333019|Active Comparator|Websites; preventing teen pregnancy|Participants assigned to the control condition were emailed urls for websites with information similar to the Let's Talk about Sex program. Parents were directed to the parents section of the National Campaign to Prevent Teen and Unplanned Pregnancy and children were directed to Nemours' KidsHealth website.
3034260|NCT02333006|Other|Traumatic brain injury questionnaires|Traumatic brain injury patients with anosognosia will answer to quetionnaires about Anosognosia compare to the answer of participant without neurological deficits
3034261|NCT02332993||Supplementation Group|15 Type 2 Diabetics receiving Negative Wound Pressure Therapy will receive the FPP supplementation to take 3 times a day for 12 weeks (3g/dose).
3034262|NCT02332993||Control Group|15 Type 2 Diabetics receiving Negative Wound Pressure Therapy will receive no supplementation for 12 weeks.
3034263|NCT02332980|Experimental|Treatment (pembrolizumab, idelalisib, or ibrutinib)|"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator. Patients with CLL or CLL with Richter's transformation experiencing stable disease without partial remission or progressive disease at 3 months of treatment with pembrolizumab proceed to the treatment continuation phase.~CONTINUATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive idelalisib PO BID on days 1-21 OR ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 12 or 24 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator."
3034264|NCT02332967|Active Comparator|Whey predominant starter formula|Whey predominant starter formula
3034265|NCT02332967|Experimental|Whey predominant starter formula + 40% palmitic acid|Whey predominant starter formula + 40% palmitic acid in sn-2 position
3034266|NCT02332967|Experimental|Whey predominant starter formula + 50% palmitic acid|Whey predominant starter formula + 50% palmitic acid in sn-2 position
3034267|NCT02332954|Other|vortioxetine naive|vortioxetine 10 mg 100 patients with Major Depressive Disorder who have not been treated with another antidepressant for the current MDE
3034268|NCT02332954|Other|Switch|vortioxetine 10 mg 100 patients with Major Depressive Disorder that require a switch from their current antidepressant due to inadequate response
3034269|NCT02332941|Experimental|Single Arm|This is a pilot study. It will be an interventional, prospective, observational, clinical study that seeks to evaluate the effect of intravitreal rituximab over a period of one month.
3034270|NCT02332928|Active Comparator|20 mg Melatonin|RT (as clinically indicated) + melatonin (Subjects will receive 20-mg oral melatonin the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
3034271|NCT02332928|Placebo Comparator|Placebo|RT (as clinically indicated) + placebo (Subjects will receive 20-mg oral placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
3034272|NCT02332915|Experimental|SPT - Intense First|Participants will receive intense application in the first phase of treatment, followed by the non intense application of treatment.
3034273|NCT02332915|Experimental|SPT - Traditional First|"Participants will receive non intense, traditional application of treatment in the first phase of treatment, followed by the intense application of treatment."
3034274|NCT02332902|Experimental|Intervention|This is a single arm intervention using Everolimus
3034275|NCT02332889|Experimental|Decitabine/Vaccine Therapy|Biological/Vaccine: Vaccine (autologous dendritic cells) and Drug: Decitabine and Hiltonol
3034276|NCT02332876|Experimental|Exercise Intervention|This arm will receive a 12-week individually tailored phone and email-based exercise program.
3034277|NCT02332876|Active Comparator|Wellness Waitlist Control|This arm will receive emails on the same schedule as the exercise arm, that cover a variety of health and wellness topics. At the end of the 12 weeks, participants will be able to start the exercise program.
3034278|NCT02332863|Active Comparator|Back-loaded needle|The patients will undergo Linear EUS and have fiducial marker placement via a traditional 22G back-loaded needle. CRFs will be used to record data for primary and secondary endpoints.
3034279|NCT02332863|Experimental|Preloaded Needle|The patients will undergo Linear EUS and have fiducial marker placement via a traditional 22G preloaded needle. CRFs will be used to record data for primary and secondary endpoints.
3034280|NCT02332850|Experimental|Treatment|SAR650984: 5 mg/kg or 10 mg/kg Day 1 and 15 of each 28-day cycle (escalating cohorts) Carfilzomib: standard dose (20-27 mg/m2)
3034281|NCT02332837|Experimental|Digital informed consent|"Traditional digitally signed text based informed consent~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
3034282|NCT02332837|Experimental|Multi-media informed consent|"Informed consent with images, text and auditory presentation~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
3034285|NCT02332824|Experimental|TAK-272 5 mg|"TAK-272 5 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
3034286|NCT02332824|Experimental|TAK-272 20 mg|"TAK-272 20 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
3034287|NCT02332824|Experimental|TAK-272 40 mg|"TAK-272 20 mg 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
3034288|NCT02332824|Experimental|TAK-272 80 mg|"TAK-272 20 mg 4 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
3034289|NCT02332824|Active Comparator|Candesartan cilexetil 8 mg|"TAK-272 placebo 4 tablets and Candesartan cilexetil 8 mg one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
3034290|NCT02332811|Experimental|CKD patients not on dialysis 800 mg|Sevelamer carbonate 800 mg in tabs 3 times per day with meals
3034291|NCT02332811|Experimental|CKD patients not on dialysis 2.4 g|Sevelamer carbonate 2.4 g powder carbonate per day
3034292|NCT02332811|Experimental|CKD patients on dialysis 800 mg|Sevelamer carbonate 800 mg in tabs 3 times per day with meals
3034293|NCT02332811|Experimental|CKD patients on dialysis 2.4 g|Sevelamer carbonate 2.4 g powder carbonate per day
3034294|NCT02332798|Experimental|Cohort 1- PF-04958242 or placebo|Subjects receiving PF-04958242 or placebo for the treatment phase of the study
3034295|NCT02332798|Experimental|Cohort 2- PF-04958242 or placebo|Subjects receiving PF-04958242 or placebo for the treatment phase of the study
3034296|NCT02332785||Composite Data Collection of Endoscopy of Serrated Polyps|Goal is to collect data from endoscopy reports & electronic medical record system to complete a descriptive analysis of the demographics, colonoscopy resection procedure, and outcome of resection - immediate and delayed complications, tumor recurrence, and cancer during follow-up 010/01/2014 - 12/31/2025.
3034297|NCT02332772||Data Collection Endoscopy of Colon Polyps|Data collected from endoscopy reports and electronic medical record system to complete a descriptive analysis of the 1) demographics, 2) colonoscopy resection procedure, and 3) outcome of resection - immediate and delayed complications, tumor recurrence, and cancer during follow-up 01/01/2014 - 12/31/2025.
3034298|NCT02332759|Experimental|Materna Device|The device will be inserted vaginally for one hour during active phase of labor to dilate the vaginal canal.
3034299|NCT02332746||Middle-aged women|Middle-aged women (35-64 years)
3034300|NCT02332733|Experimental|TV003 Vaccine|Participants will receive a single injection of TV003 at Days 0 and 180.
3034301|NCT02332733|Placebo Comparator|Placebo vaccine for TV003|Participants will receive a single injection of placebo for TV003 at Days 0 and 180.
3034302|NCT02332720|Experimental|A1: GT3 NC TN Grazoprevir+Uprifosbuvir+Elbasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (300 mg) + elbasvir (50 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
3034303|NCT02332720|Experimental|A2: GT3 NC TN Grazoprevir+Uprifosbuvir+Ruzasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (300 mg) + ruzasvir (60 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
3034304|NCT02332720|Experimental|A3: GT3 NC TN Grazoprevir+Uprifosbuvir+Elbasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (450 mg) + elbasvir (50 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
3034305|NCT02332720|Experimental|A4/B4: GT3 NC TN Grazoprevir+Uprifosbuvir+Ruzasvir (8 weeks)|Participants will be randomized to either Part A or Part B. In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (450 mg) + ruzasvir (60 mg) q.d. by mouth for 8 weeks. In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
3034306|NCT02332720|Experimental|B5: GT3 NC TN MK-3682B + RBV (8 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 8 weeks.
3034307|NCT02332720|Experimental|B6: GT3 NC TN MK-3682B (12 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
3034308|NCT02332720|Experimental|B7: GT3 NC TN MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
3034309|NCT02332720|Experimental|B8: GT3 NC TE MK-3682B (8 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks.
3058783|NCT02170012|Experimental|Cohort 4-PF-06743649 or placebo|
3034310|NCT02332720|Experimental|B9: GT3 NC TE MK-3682B + RBV (8 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 8 weeks.
3034311|NCT02332720|Experimental|B10: GT3 NC TE MK-3682B (12 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
3034312|NCT02332720|Experimental|B11: GT3 NC TE MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682 FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
3034313|NCT02332720|Experimental|B12: GT3 NC TE MK-3682B (16 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
3034314|NCT02332720|Experimental|B13: GT3 C TN MK-3682B (12 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
3034315|NCT02332720|Experimental|B14: GT3 C TN MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
3034316|NCT02332720|Experimental|B15: GT3 C TN MK-3682B (16 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
3034317|NCT02332720|Experimental|B16: GT3 C TE MK-3682B (12 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
3034318|NCT02332720|Experimental|B17: GT3 C TE MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
3034319|NCT02332720|Experimental|B18: GT3 C TE MK-3682B (16 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
3034320|NCT02332720|Experimental|B19: GT3 C TE MK-3682B + RBV (16 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 16 weeks.
3034321|NCT02332720|Experimental|B20: GT4 NC TN MK-3682B (8 weeks)|In Part B, HCV GT4-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks.
3034322|NCT02332720|Experimental|B21: GT5 NC TN MK-3682B (12 weeks)|In Part B, HCV GT5-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
3034323|NCT02332720|Experimental|B22: GT6 NC TN MK-3682B (12 weeks)|In Part B, HCV GT6-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
3034324|NCT02332707|Experimental|A1: GT1 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
3034325|NCT02332707|Experimental|A2: GT1 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
3034326|NCT02332707|Experimental|A3: GT2 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
3034327|NCT02332707|Experimental|A4: GT2 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
3034328|NCT02332707|Experimental|A5: GT1 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
3034329|NCT02332707|Experimental|A6: GT1 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks.
3034330|NCT02332707|Experimental|B7: GT2 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
3034331|NCT02332707|Experimental|A8: GT2 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks. In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
3034332|NCT02332707|Experimental|B9: GT1 NC GZR+UPR+RZR (12 weeks)|In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
3034333|NCT02332707|Experimental|B10: GT2 NC GZR+UPR+RZR (8 weeks) + RBV|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
3034334|NCT02332707|Experimental|B11: GT2 NC GZR+UPR+RZR (12 weeks)|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
3034335|NCT02332707|Experimental|B12: GT1 C GZR+UPR+RZR (8 weeks)|In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
3034336|NCT02332707|Experimental|B13: GT1 C GZR+UPR+RZR (12 weeks)|In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
3034337|NCT02332707|Experimental|B14: GT2 C GZR+UPR+RZR (12 weeks)|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
3034338|NCT02332707|Experimental|B15: GT2 C GZR+UPR+RZR (12 weeks) + RBV|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
3034373|NCT02332473|Active Comparator|Arm A|Ypeginterferon alfa-2b,sc. Qw. 48 weeks.
3034339|NCT02332707|Experimental|B16: GT2 C GZR+UPR+RZR (16 weeks)|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 16 weeks.
3034340|NCT02332707|Experimental|B6: GT1 NC GZR+UPR+RZR (8 weeks)|In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
3034341|NCT02332707|Experimental|B8: GT2 NC GZR+UPR+RZR (8 weeks)|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
3034342|NCT02332694|Experimental|High intensity whole-body infrared heating|The participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
3034343|NCT02332681||With insufficiency fracture|Patients with acute pain that sustained a knee insufficiency fracture
3034344|NCT02332681||Without insufficiency fracture|Patients with acute pain that did not sustained a knee insufficiency fracture
3034345|NCT02332668|Experimental|Melanoma|Participants aged 6 months to <18 years with melanoma receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), intravenously (IV) once every 3 weeks (Q3W).
3034346|NCT02332668|Experimental|Solid Tumors and Other Lymphomas|Participants aged 6 months to <18 years with solid tumors and other lymphomas receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W. Initial enrollment limited to programmed death-ligand 1 (PD-L1)-positive participants. PD-L1-negative participants may enroll if responses are observed.
3034347|NCT02332668|Experimental|rrcHL|Participants aged 3 years to <18 years with rrcHL receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
3034348|NCT02332668|Experimental|MSI-H|Participants aged 6 months to <18 years with microsatellite-instability-high (MSI-H) solid tumors receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
3034349|NCT02332655|Experimental|Cannabidiol|All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis. The drug will be taken for 48 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of epilepsy in patients with Sturge-Weber syndrome.
3034350|NCT02332629|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
3034351|NCT02332629|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
3034352|NCT02332616|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
3034353|NCT02332616|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
3034354|NCT02332603|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
3034355|NCT02332603|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
3034356|NCT02332590|Active Comparator|Adalimumab 40 mg|Adalimumab 40 mg subcutaneous (SC) injection in combination with placebo for sarilumab every 2 weeks (q2w) for 24 weeks during randomized treatment period. The dosing frequency of adalimumab may be adjusted to 40 mg every week (qw) dosing in case of participants with inadequate response (<20% improvement from baseline tender joint count [TJC] and swollen joint count [SJC] for 2 consecutive visits) at or after Week 16 until Week 23. Participants completed 24 weeks treatment period had the option to continue in open-label treatment period and received sarilumab 200 mg q2w until commercial availability of sarilumab in the country or maximum of 276 weeks.
3034357|NCT02332590|Experimental|Sarilumab 200 mg|Sarilumab 200 mg SC injection in combination with placebo for adalimumab q2w for 24 weeks during randomized treatment period. The dosing frequency of placebo for adalimumab may be adjusted to qw dosing in case of participants with inadequate response (<20% improvement from baseline TJC and SJC for 2 consecutive visits) at or after Week 16 until Week 23. Participants completed 24 weeks treatment period had the option to continue in open-label treatment period and received sarilumab 200 mg q2w until commercial availability of sarilumab in the country or maximum of 276 weeks.
3034358|NCT02332577|Experimental|Pristinamycin + Placebo|Pristinamycin: 500 mg tablet, 4 tablets x 2/day for 2 days then 2 tablets x 3/day for 5 to 7 days Amoxicillin Placebo: capsule, 2 capsules x 3 /day for 7 to 9 days.
3034359|NCT02332577|Active Comparator|Amoxicillin + Placebo|Amoxicillin: 500 mg capsule, 2 capsules x 3/day for 7 to 9 days Pristinamycin Placebo: tablet, 4 tablets x 2/day for 2 days then 2 tablets x 3/day for 5 to 7 days.
3034360|NCT02332564||Coronary Artery Disease|Patient with significant coronary artery disease
3034361|NCT02332564||no Coronary Artery Disease|Patient without significant coronary artery disease
3034362|NCT02332551|Experimental|NanoKnife IRE System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
3034363|NCT02332538|Active Comparator|Greenlight (532nm-laser) PVEP|532nm-laser photoselective vapo-enucleation of the prostate)
3034364|NCT02332538|Active Comparator|Holmium laser enucleation of prostate|Holmium-Yag laser enucleation of the prostate
3034365|NCT02332538|Active Comparator|Bipolar TURP|Bipolar transurethral resection of the prostate in saline
3034366|NCT02332525|Experimental|Intervention|20 elders (10 mild cognitive impairment, 10 cognitive normal elders) those who received oral vibrational stimulation
3034367|NCT02332512|Experimental|Apatinib|Apatinib tablet administered orally, 750 mg,once daily until progression
3034368|NCT02332512|Placebo Comparator|Placebo|Placebo tablet administered orally, once a day until progression
3034369|NCT02332499|Active Comparator|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3034370|NCT02332499|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3034371|NCT02332486|Active Comparator|Intervene|For Qingxuan Decoction there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China. Qingxuan Decoction is given two times after breakfast and dinner in 56 days.
3034372|NCT02332486|No Intervention|Blank|There is no intervention for people in the blank group.
3034374|NCT02332473|Experimental|Arm B|Ypeginterferon alfa-2b,sc. Qw. 48 weeks. Granulocyte-macrophage colony stimulating factor,sc.qd, the first three day of every 28 days, starting from interferon treatment week 13.
3034375|NCT02332460||Infliximab|Patients treated with Infliximab
3034376|NCT02332447|Experimental|NALOXONE|
3034377|NCT02332447|Placebo Comparator|PLACEBO|
3034378|NCT02332434|Experimental|sleeve gastrectomy|bariatric surgery procedure based exclusively on the gastric restriction (the sleeve gastrectomy).
3034379|NCT02332434|Experimental|gastric bypass|bariatric surgery procedure associating a malabsorption (the gastric bypass).
3034380|NCT02332421|Experimental|modified dentoalveolar distractor|Canine retraction will be accomplished using a modified dentoalveolar distractor
3034381|NCT02332421|No Intervention|conventional dentoalveolar distractor|Canine retraction will be accomplished using a conventional dentoalveolar distractor
3034382|NCT02332408|Experimental|Cybernetic microradiosurgery|Hypofractionated microradiosurgery using Cyber Knife to the vertebral hemangioma to the total dose of 25 Gy in 5.0 Gy per fraction, 2 or 3 days a week over the period of 2 weeks,
3034383|NCT02332408|Active Comparator|Conventional radiotherapy|Conventionally fractionated external beam conformal radiotherapy to the vertebral hemangioma to the total dose of 36 Gy in 2.0 Gy per fraction, 5 days a week over the period of 3,5 weeks,
3034384|NCT02332395||Emergency caesarean section|patients whose underwent emergency caesarean section operation
3034385|NCT02332395||Elective caesarean section|patients whose underwent elective caesarean section operation
3034386|NCT02332369|Experimental|Device|Polymethylmethacrylate Capsular Tension Ring introduced into the posterior chamber of the eye following cataract surgery before the implantation of an intraocular lens.
3034387|NCT02332356|Active Comparator|step up|Procedure: MREC patients receive therapeutic step up
3034388|NCT02332356|No Intervention|observation step up|
3034389|NCT02332356|Active Comparator|step down|Procedure: MREC patients receive therapeutic step down
3034390|NCT02332356|No Intervention|observation step down|
3034391|NCT02332330|Experimental|VEST|
3034392|NCT02332317|No Intervention|Control arm|150 patients will receive standard oncology treatment.
3034393|NCT02332317|Active Comparator|Intervention arm|150 patients will receive standard oncology treatment alongside a 12-week specialized palliative rehabilitation program
3034394|NCT02332304|Other|Preterm fetus|Patients with pregnancies between 26 and 36 6/7 weeks of pregnancy. Before the birth, a sample of amniotic fluid was taken and analyzed using optical density at 650nm. A value above 0.15 was considered an indication of fetal lung maturity.
3034395|NCT02332291|Active Comparator|Blinded Escitalopram / Open-Label Bupropion|8 weeks of blinded escitalopram, followed by 8 weeks of open-label bupropion xl for nonremitters
3034396|NCT02332291|Placebo Comparator|Blinded Placebo / Open-Label Bupropion|8 weeks of blinded placebo, followed by 8 weeks of open-label bupropion xl for nonremitters.
3034397|NCT02332278|Experimental|Early feeding|Early feeding (fluid diet), four hours after cesarean section.
3034398|NCT02332278|Active Comparator|Late feeding|Late feeding (fluid diet) 12 hours after cesarean section.
3034399|NCT02332265||Program Participant Study SAFE area, control area|"Participants from two types of areas of rural central Malawi: traditional authorities (TA) selected by CARE to receive the SAFE program (intervention group) and TAs receiving other unrelated CARE programming (controls).~Intervention TAs: 598 program participants (398 women, 200 men) were interviewed at baseline and 18- and 36-month follow-ups;~Control TAs: 301 control households were interviewed at baseline and 18- and 36-month follow-ups"
3034400|NCT02332265||Community Impact Study, non-SAFE participants|We conducted random surveys (n = 1002)--501 living in the intervention areas but not directly receiving the SAFE intervention and 501 living in the control areas not receiving the SAFE intervention with a 36-month assessment interval, prior to and after implementation of SAFE. Thus, we examined intervention outcomes both in direct SAFE program participants and their larger communities. We used multilevel modeling to examine mediators and moderators of the effects of SAFE on HIV outcomes at the individual and community levels and determine the ways in which changes in HIV outcomes feed back into economic outcomes and food security at later interviews.
3034401|NCT02332265||Qualitative SAFE program participant in-depth interview & FGD|We conducted a qualitative end-of-program evaluation consisting of in-depth interviews with 90 SAFE participants.
3034402|NCT02332252|Active Comparator|Scalpel|Skin incision performed with a scalpel during cesarean section.
3034403|NCT02332252|Experimental|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
3034404|NCT02332239|Experimental|iDOVE Intervention (ED+text)|"In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~Eight-week longitudinal tailored CBT-based text-message program"
3034405|NCT02332239|Placebo Comparator|Control (EUC)|"In-ED brief session, discussing home safety & nutrition~Eight-week longitudinal home safety & nutrition text-message program"
3034406|NCT02332226|Experimental|Representational approach|Four sessions with a nurse. For each session, the parent identifies an area where he/she needs more information. The nurse and the parent jointly survey the parent's knowledge of the area and discusses consequences of knowledge gaps or misunderstandings. Then, new information is introduced and benefits from the new information is discussed.
3034407|NCT02332226|No Intervention|Control|Standard care as per ward protocol.
3034408|NCT02332213||1. Colorectal cancer|Patients with histologically confirmed colorectal cancer (adenocarcinoma)
3034409|NCT02332213||2. Colorectal high-risk lesions|Patients without colorectal adenocarcinoma, but carrying high-risk adenomatous polyps being described by one of the following: 1) size≥1 cm; 2) high-grade dysplasia; 3) villous component. Prior to removal of the lesions.
3034410|NCT02332213||3. Colorectal low-risk adenoma|Patients without colorectal adenocarcinoma and without colorectal high-risk lesions as described under Group 2 criteria
3034411|NCT02332213||4. Group of control (colorectal)|Patients having undergone colonoscopy without an evidence for colorectal lesions fulfilling Group 1 or Group 2 or Group 3 criteria. Prior to removal of the lesions.
3034412|NCT02332213||5. Gastric cancer|Patients with histologically confirmed gastric cancer (adenocarcinoma)
3034834|NCT02329470|Experimental|No device, n=50|Withdrawal of device, CPAP, of obstructive sleep apnea treatment during 5 nights
3034413|NCT02332213||6. Gastric dysplasia|Patients without gastric adenocarcinoma but with histologically confirmed dysplasia (either high- or low-grade) of the stomach
3034414|NCT02332213||7. High-risk gastric lesions|Patients graded Stage III-IV according to OLGIM (Operative Link of Gastric Intestinal Metaplasia Assessment) staging system, but excluding those with dysplasia (Group 5)
3034415|NCT02332213||8. Normal and low-risk gastric lesions|Staged 0-III according to OLGIM. Dysplasia should be excluded
3034416|NCT02332213||9. Average risk population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer.
3034417|NCT02332200||Early referral to therapy|Patients with a confirmed diagnosis of spondylolysis or spondylolisthesis whose physicians median referral to physical therapy time is less than or equal to 10 weeks.
3034418|NCT02332200||Later referral to therapy|Patients with a confirmed diagnosis of spondylolysis or spondylolisthesis whose physicians median referral to physical therapy time is >10 weeks.
3034419|NCT02332187|Sham Comparator|Sham electrical stimulation|The intervention will consist of sham electrical stimulation using an All Stim stimulator of each quadriceps leg muscle for 30 minutes per day for a total of 7 days.
3034420|NCT02332187|Active Comparator|Active electrical stimulation|The intervention will consist of active electrical stimulation using an All Stim stimulator of each quadriceps leg muscle for 30 minutes per day for a total of 7 days.
3034421|NCT02332174|Experimental|200-mg group|Ten healthy subjects were administered a single oral dose of 200 mg rufinamide tablets in fasted and fed state at day 1 and then received repeated oral doses of rufinamide (200 mg) once daily for 6 days.
3034422|NCT02332174|Experimental|400-mg group|Ten healthy subjects were administered a single oral dose of 400 mg rufinamide tablets in fasted state.
3034423|NCT02332174|Experimental|800-mg group|Ten healthy subjects were administered a single oral dose of 800 mg rufinamide tablets in fasted state.
3034424|NCT02332174|Experimental|1200-mg group|Ten healthy subjects were administered a single oral dose of 1200 mg rufinamide tablets in fasted state.
3034425|NCT02332148|Experimental|3Vm1001|3VM1001 topical cream containing 10 mg/day of copper, for 30 days
3034426|NCT02332148|Placebo Comparator|Placebo|Placebo for 3VM1001, topical cream without 3VM1001
3034427|NCT02332135|Experimental|microwave ablation group|patients in ultrasonic ablation will be treated by ultrasound guided percutaneous parathyroid gland microwave ablation
3034428|NCT02332135|Active Comparator|control group|patients in control group will be treated by active vitamin D and other general treatments according to the suggestions in K/DOQI guidelines
3034429|NCT02332122||COPD patients with bronchiectasis|"All patients will receive standard therapy for AECOPD.~Additional for this study are:~Sputum induction, Skin prick test, Questionnaires"
3034430|NCT02332122||COPD patients without bronchiectasis|"All patients will receive standard therapy for AECOPD.~Additional for this study are:~Sputum induction, Skin prick test, Questionnaires"
3034431|NCT02332109||ODM 5-group|
3034432|NCT02332096||Patients with Atrial Fibrillation|We propose to enroll 100 patients with symptomatic paroxysmal or persistent AF without a known diagnosis of sleep apnea who are referred for an AF ablation procedure at BIDMC. All enrolled subjects will undergo pre-procedure screening sleep study using the Berlin questionnaire and home sleep study using an FDA approved home sleep testing device (HST).
3034433|NCT02332083|Experimental|Intervention group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (start with 3 up to 6 Hz, noise 4) T1 - intervention 4 weeks (SR-WBV (start with 3 up to 6Hz, noise 4 & Exergame) - T2
3034434|NCT02332083|Sham Comparator|Sham Comparator|T0 - intervention 4 weeks (SR-WBV 1 Hz, noise 1) - T1 - intervention 4 weeks (SR-WBV 1 Hz, noise 1 & Aktiv Tramp) - T2
3034435|NCT02332057|Active Comparator|Diclofenac plus lidocaine|Diclofenac(100 mg) is administered 1 hour before IUD insertion and lidocaine gel is placed on cervix three minutes before IUD insertion
3034436|NCT02332057|Placebo Comparator|Placebo|Placebo tablets is administered 1 hour before IUD insertion and placebo gel is placed on cervix three minutes before IUD insertion
3034437|NCT02332044|Experimental|Erdosteine 300mg|
3034438|NCT02332044|Experimental|Bepotastine besilate 10mg|
3034439|NCT02332044|Experimental|Erdosteine 300mg + Bepotastine besilate 10mg|
3034440|NCT02332031|Experimental|Sorafenib (Nexavar, BAY43-9006) & Levothyroxine|Sorafenib be administrated without and with levothyroxine orally
3034441|NCT02332018||Limb Torsion|adult patients, lower limb assessment retrospectively limb length and limb axis, torsion biplanar x-ray images
3034442|NCT02332018||Limb Length and Axis|adult patients, lower limb assessment prospectively limb length and limb axis biplanar x-ray images
3034443|NCT02332018||Spine|adult patients, spine assessment prospectively Cobb angles, plumbline biplanar x-ray images
3034444|NCT02332005|Active Comparator|Group 1 150 mg|150 mg diepalrestat choline administered as twice daily dosing morning and evening with an oral tablet of either 150 mg diepalrestat choline or placebo
3034445|NCT02332005|Active Comparator|Group 2 300 mg|300 mg diepalrestat choline administered as twice daily dosing morning and evening with an oral tablet of 150 mg diepalrestat choline
3034446|NCT02332005|Placebo Comparator|Group 3|Tablet administered twice daily morning and evening containing placebo
3034447|NCT02331992|Experimental|Positive airway pressure adherence program|Participants will be enrolled in the automated adherence program and will receive supportive messages while they use CPAP as prescribed by their healthcare provider. These messages are designed to aid the participant towards therapy adherence.
3034448|NCT02331979|Experimental|Stimulation of Non-Naive|Evaluate neuromodulation in 6 subjects with prior motor training.
3034449|NCT02331979|Experimental|Stimulation of Naive|Evaluate neuromodulation in 6 naive subjects.
3034450|NCT02331979|Experimental|Stimulation|Apply parameters discovered in Arm 1 and Arm 2 to evaluate neuromodulation in 12 naive subjects.
3034451|NCT02331953||delirium group|the patients with delirium after spine surgery
3034452|NCT02331953||no delirium group|the patients without delirium after spine surgery
3034453|NCT02331940|Active Comparator|Handihaler|Tiotropium was delivered by the HandiHaler® device, a single-dose dry powder inhaler
3034454|NCT02331940|Active Comparator|Respimat|Tiotropium was delivered via the Respimat® Soft Mist Inhaler,
3058784|NCT02170012|Experimental|Cohort 5-PF-06743649 or placebo|
3034455|NCT02331927|No Intervention|Randomized Part: Arm A|Conventional switch of chemotherapy together with the antiangiogenic treatment: Bevacizumab and mFOLFOX6 (continuation of same regimen until progressive disease (PD) according to RECIST v1.1, followed by switch to aflibercept and FOLFIRI after PD).
3034456|NCT02331927|Experimental|Ramdomized Part: Arm B|Early marker-driven switch of anti-angiogenic agent and maintenance of chemotherapy: Bevacizumab and mFOLFOX6 will be administered until change of the CAF-profile and at least stable disease according to RECIST v1.1. Change to Aflibercept and mFOLFOX6 (change of bevacizumab to aflibercept and continuation of mFOLFOX6) until PD according to RECIST v1.1, followed by change to FOLFIRI after PD).
3034457|NCT02331914||Gastro-intestinal stromal tumors|"A bio-databank consisting of TKI drug level and serum for analysis of mutations in circulating tumor DNA will be set up. This bio-databank will be used to study whether changes in the amount of the primary KIT mutation is an early predictor of treatment response and/of failure. Moreover, secondary TKI resistant mutations in circulating tumor DNA will be assessed.~To be able to assess those mutations, a tumor biopsy will be performed at the time of radiologic progressive disease. Vena puncture for blood collection will be performed at routine out patient visits."
3034458|NCT02331901||MTBI SYMP|Mild Traumatic Brain Injury subjects with symptoms
3034459|NCT02331901||MTBI NO SYMP|Mild Traumatic Brain Injury subjects without symptoms
3034460|NCT02331888|Experimental|Scalp electrode, fetal doppler and EUM|Once in labor, the parturient will be connected to the routine fetal doppler and EUM. When necessary according to clinical indications, the scalp electrode will be connected. Tracing will be recorded simultaneously from all three devices until delivery.
3034461|NCT02331875|Experimental|single arm|IPH2201 followed by standard surgery and standard postsurgical adjuvant therapy
3034462|NCT02331862|Experimental|UTI treated with Methylprednisolone|UTI treated with Methylprednisolone in addition to the effective antibiotics
3034463|NCT02331862|No Intervention|UTI not treated with Methylprednisolone|UTI treated with effective antibiotics only
3034464|NCT02331849|Other|Eosinophilic esophagitis|Patients with eosinophilic esophagitis after exclusion of GERD
3034465|NCT02331836|Active Comparator|Arc Endocuff (AEC 110, 120, 130, 140)|Endocuff-assisted colonoscopy Colonoscopy with the Endocuff attached at the distal tip of the scope
3034466|NCT02331836|Active Comparator|Cap|Cap-assisted colonoscopy Colonoscopy with the transparent Cap attached at the distal tip of the scope
3034467|NCT02331836|Active Comparator|Standard Colonoscope|Standard colonoscopy without any additional device
3034468|NCT02331823|Experimental|arm A: super-short retreatment regimen|A regimen of 5 drugs is to be administered. Isoniazid Aminosalicylate Tablets,0.3g tid po for 5 mon moxifloxacin tab, 0.4g qd po for 5 mon rifabutin capsule,0.3g qd po for 5 mon ethambutol tab, 0.75g qd po for 5 mon pyrazinamide tab, 0.5g tid po for 5 mon
3034469|NCT02331823|Active Comparator|arm B:standardized retreatment regimen|8-9 months of standardized regimen is to be administered. regimen 1.2SHREZ/6HRE streptomycin injectable,0.75g qd intramuscular for 2 mon isoniazid tab,0.3g qd po for 8 mon rifampicin capsule,0.45-0.6g po for 8 mon ethambutol tab, 0.75g qd po for 8 mon pyrazinamide tab, 0.5g tid po for 2 mon or regimen 2.3HREZ/6HRE isoniazid tab,0.3g qd po for 9 mon rifampicin capsule,0.45-0.6g po for 9 mon ethambutol tab, 0.75g qd po for 9 mon pyrazinamide tab, 0.5g tid po for 3 mon
3034470|NCT02331810|Experimental|SAR113244|Single subcutaneous dose of SAR113244
3034471|NCT02331810|Placebo Comparator|Placebo|Single subcutaneous dose of placebo
3034472|NCT02331797|Experimental|Endoscopic Technique|All patients are operated under the endoscope. The endoscope passed through external auditory canal (transcanal approach) to visualize tympanic remnant.
3034473|NCT02331797|Active Comparator|Microscopic Technique|All patients are operated under the microscope.A postauricular or transcanal approach is chose depend on ear canal size and size of perforation. When the ear canal is too small, the postauricular is used.
3034474|NCT02331784|Experimental|Computerized Plasticity-based Software|Computerized Plasticity-based software training requiring a total maximum of 50 treatment sessions, 4-5 times weekly, 40 minutes each session.
3034475|NCT02331784|Active Comparator|Commercially available video game|Commercially available video game training. Treatment is software based, will occur up to 50 times throughout study duration, 4-5 times per week, 40 minutes each session..
3034476|NCT02331771|Active Comparator|donepezil|Subjects will receive donepezil 5 mg before before they start ECT and continue the agent through the ECT procedures up to 4 weeks.
3034477|NCT02331771|Placebo Comparator|Placebo|Subjects will receive the placebo before they start ECT and continue the agent through the ECT procedures up to 4 weeks.
3034478|NCT02331758|Experimental|Lifestyle counseling|The investigators use several methods to educate patients of controllable factors like lifestyle counseling, and monitor the factors like BMI and other index until the statistics become normal.
3034479|NCT02331758|No Intervention|No treatment|Patients without any intervention and still have abnormal factors like BMI, etc.
3034480|NCT02331745|Experimental|Granulocyte colony-stimulating factor|"Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).~Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time"
3034481|NCT02331745|Active Comparator|standard treatment|Standard treatment alone
3034482|NCT02331732|Active Comparator|Control|Patients receive DOT as normal - involves patient going to polyclinic to be observed taking treatment every day
3034483|NCT02331732|Experimental|Treatment|Patients receive VOT - involves patient sending a video of themselves taking their treatment over M-health app which will be reviewed remotely by observers
3034484|NCT02331719||MiSPACE Eligible Cohort|This will be a prospective record review of patients where the MiSPACE technique is being/was used for the treatment of their ICH.
3034485|NCT02331719||Historical Cohort|This is a retrospective records review of patients who received either medical intervention or conventional surgical intervention for the treatment of their ICH.
3034486|NCT02331706|Experimental|Subject Recipients|
3034487|NCT02331706|Experimental|Subject Donors|
3034488|NCT02331693|Experimental|anti-EGFR CAR T|
3034489|NCT02331680|Experimental|OPC-41061 15mg/day|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 24 week.
3034490|NCT02331680|Experimental|OPC-41061 30mg/day|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 1 week and then OPC-41061 30 mg/day for 23 weeks
3034491|NCT02331680|Placebo Comparator|Placebo|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. Placebo will be administered for 24 week.
3034492|NCT02331667|Experimental|Seafood|Intervention with meals consisting of seafood (herring and mackrell).
3034493|NCT02331667|Experimental|Non-seafood|Intervention with meals constisting of non-seafood (meat).
3034494|NCT02331654|Experimental|Experimental Treatment|Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes: the anode will be placed on the thoracic spinal cord (over the spinal process of the tenth thoracic vertebra) and the cathode (reference) above the right shoulder. Stimulating electrodes will be thick (6 mm), rectangular pieces of saline-soaked synthetic sponge. The sDCS polarity (anodal) will refer to the electrode over the spinal cord.
3034495|NCT02331654|Placebo Comparator|Placebo treatment|For sham sDCS (placebo), electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s.
3034496|NCT02331641||Major hepatectomy (MH)|Patients who underwent MH for CLM instead of multiple minor hepatectomy (MMH)
3034497|NCT02331641||Multiple minor hepatectomy (MMH)|Patients who underwent MMH for CLM instead of MH
3034498|NCT02331628|No Intervention|Control|Usual care only will be provided during Baseline period and Follow-up period.
3034499|NCT02331628|Experimental|ESWT - Extracorporeal Shockwave Therapy|Participants will receive 4 applications of extracorporeal shockwave therapy to the affected hip and/or knee over a period of 8 weeks (one dose every 2 weeks).
3034500|NCT02331615|Experimental|Right|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: Right hemisphere anodal stimulation of the dorso lateral frontal area (F3), left hemisphere catodal stimulation of the dorso lateral frontal area (F4). Intensity of 1.5 mA (milliampere) for duration of 15 minutes. A total of 9 sessions: 4 sessions a week for 2 weeks.
3034501|NCT02331615|Experimental|left|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: left hemisphere anodal stimulation of the dorso lateral frontal area (F3), right hemisphere catodal stimulation of the dorso lateral frontal area (F4). Intensity of mA1.5 (milliampere) for duration of 15 minutes. A total of 9 sessions: 4 sessions a week for 2 weeks.
3034502|NCT02331615|Sham Comparator|sham|The stimulator will be turned on for only a very short duration of time (msec) no meaningful stimulation is believed to be administered in such a way.
3034503|NCT02331602|Active Comparator|rivaroxaban|Patients are assigned to receive rivaroxaban 15mg once daily for 12 months according to a computer-generated randomization sequence at the central registration center. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
3034504|NCT02331602|Active Comparator|dabigatran|Patients are assigned to receive dabigatran 150mg twice daily for 12 months according to a computer-generated randomization sequence at the central registration center. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
3034505|NCT02331589|Active Comparator|Korea Red Ginseng (KRG)|KRG capsule (3,000 mg/day) for 3 weeks
3034506|NCT02331589|Placebo Comparator|Placebo (for KRG)|placebo (for KRG) for 3 weeks
3034507|NCT02331576|Placebo Comparator|rocaine|continuous femoral nerve block with ropivacaine alone.
3034508|NCT02331576|Active Comparator|rocaine with fentanyl|continuous femoral nerve block with combination of ropivacaine and fentanyl.
3034509|NCT02331563|Experimental|0.5% bupivacaine|group 1 receiving TAP block with 0.25% bupivacaine 20 ml for each side of abdomen Bupivacaine is a local anaesthetic agent. transvers abdominis plane block with %0.5 Bustesin which is diluated with normal saline
3034510|NCT02331563|Active Comparator|dexmedetomidine added bupivacaine|group II receiving TAP block with 0.25% bupivacaine + 0.5 mcg/kg dexmedetomidine each side of abdomen
3034511|NCT02331550|Experimental|Expectant treatment|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions that were managed with observation and evaluation at 6 and 12 months after diagnosis.
3034512|NCT02331550|Experimental|Ablative treatment|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions that were managed with an ablative treatment and evaluated at 6 and 12 months after diagnosis.
3034513|NCT02331537|Experimental|Internet-based cognitive-behavior therapy|The experimental group will go through active internet-based treatment. The treatment is 10 weeks long and is based on the principles of exposure i.e. the participant is instructed to stay with the frightening thought until it is no longer associated with anxiety.
3034514|NCT02331537|No Intervention|Waitlist|Waitlist control that will get the internet-based treatment when the first group has finished (i.e. Week 10). There are no active treatment for these participants at all.
3034515|NCT02331524|No Intervention|Control/Usual Care|Usual care only
3034516|NCT02331524|Experimental|Activity Feedback and Encouragement|Weekly Feedback about daily activity using the FitBit Zip
3034517|NCT02331524|Experimental|Health Coaching/Home Exercise|Weekly contact from physical therapist to develop and progress home exercise program and by health coach for goal setting and support
3034518|NCT02331511|Placebo Comparator|placebo|No antiplatelet drug
3034519|NCT02331511|Active Comparator|Aspirin|Aspirin 80 mg daily
3034520|NCT02331511|Active Comparator|Clopidogrel|Clopidogrel 75mg daily
3034521|NCT02331498|Other|A Pazopanib|Open label study with one group
3034522|NCT02331485|Experimental|PICO + Acticoat group|Patients randomized to negative pressure group will received negative pressure dressing (Pico Wound Management System - manufacture by Smith & Nephew) associated with Acticoat Flex dressing which will be applied immediately after skin closure in a conventional way and left in place for 7 days. Negative pressure dressing will be changed once during 7 days period - after day 2 to 4. Wound complications within first 30 days of surgery will be recorded on clinical examination.
3034523|NCT02331485|Active Comparator|Standard Wound management|If a patient is randomized to standard wound treatment group - he/she will receive standard skin closure and standard Mepore dressing, which will be changed on a daily basis.
3034524|NCT02331472||Interstitial cystitis|
3034525|NCT02331472||Contral|
3060179|NCT02160314|Experimental|pessary|disposable, single-use pessary
3034526|NCT02331459|Experimental|Intervention group|"Multicomponent training intervention :~3 sessions a week of 45 minutes of resistance activity (24 weeks) 2 sessions a week of 45 minutes of strength training (24 weeks) 5 sessions a week of 15 minutes of proprioceptive training (24 weeks)"
3034527|NCT02331459|Placebo Comparator|Control group|Normal routine during 24 weeks.
3034528|NCT02331446|No Intervention|Control|The control group will be oriented to maintain their normal activity and habits and will not receive the intervention.
3034529|NCT02331446|Experimental|90 minutes per week|The group of 90 minutes per week will do three sessions of 30 minutes per week of concurrent training, which consists on 15 minutes of aerobic exercise and 15 minutes of strength training.
3034530|NCT02331446|Experimental|150 minutes per week|The group of 150 minutes will do three sessions of 50 minutes per week, which consists on 25 minutes of aerobic exercise and 25 minutes of strength training.
3034531|NCT02331446|Experimental|210 minutes per week|The group pf 210 minutes per week will do three sessions of 70 minutes per week, which consists on 35 minutes of aerobic exercise and 35 minutes of strength training.
3034532|NCT02331433|Experimental|Experimental: 1|
3034533|NCT02331433|Placebo Comparator|Placebo Comparator: 2|
3034534|NCT02331420|Experimental|Bariatric Surgery|Gastric bypass
3034535|NCT02331420|Active Comparator|Optimal Medical Therapy|planned visits, optimized hypoglycemic treatment, diet and lifestyle modification
3034536|NCT02331407|Experimental|Robot arm rehabilitation therapy|Arm training using the ReoGo robotic device, 3 times a week for 3 weeks.
3034537|NCT02331394|Experimental|Chinese herbs formula: Shu Yu Wan|All participants will be offered the choice of taking the CH formula in capsules or sachets in addition to standard care. This study will use the Shu Yu Wan formula which comprises 23 different herbs and is based on the best evidence in the literature of use of CH in lung cancer. The formula should be taken with meals 3 times a day (each dose is either 1 sachet or 4 capsules) for six-weeks.
3034538|NCT02331381|Experimental|MRI|Participants will have a custom immobilization device created for them for the purpose of the study. They will be scanned from one to four occasions during radiation treatment. If enrolled in the study prior to the first radiation treatment, the first imaging scan may be scheduled prior to the first radiation treatment, with subsequent scans during treatment separated by at least one day. Patients will be in the scanner for approximately 30 minutes to one hour, either prior to or following their standard of care radiotherapy treatment.
3034539|NCT02331368|Experimental|Anti-PD-1 (MK-3475)|"Standard Treatment:~High-dose Melphalan and autologous stem cell transplantation with post-transplant maintenance of Lenalidomide.~Study Treatment:~200 mg/day of MK-3475 administered every 3 weeks, starting day +14 post-transplant for a total of 9 doses."
3034540|NCT02331316|Experimental|Daily extra water intake 2L|"Timing of daily extra water intake~intervention-A: extra water intake: 8 8oz glasses of water a day (2L) - 2 first thing in the morning before breakfast, 2 before midday or midday meal, 2 before afternoon meal and 2 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
3034541|NCT02331316|Experimental|Daily extra water intake 1L|"Timing of daily extra water intake~Intervention-A: 4 8oz glasses of water a day (1L) - 1 first thing in the morning before breakfast, 1 before midday or midday meal, 1 before afternoon meal and 1 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
3034542|NCT02331316|Experimental|Daily extra water intake 500ml|"Timing of daily extra water intake~Intervention-A: 2 8oz glasses of water a day (500ml) - each half an hour before a meals.~Intervention-B: Drink extra water at anytime over 24 hours"
3034543|NCT02331316|Experimental|Daily extra water intake 120ml|"Timing of daily extra water intake~Intervention-A: 1/2 a glass of water on waking (120ml). If you forget to drink your water first thing, do not drink it later in the day, just skip this day and drink ½ a glass the next day on waking.~Intervention-B: Drink extra water at anytime over 24 hours"
3034544|NCT02331303||Group1|"This is a single-arm descriptive observational drug utilization study based on secondary data collection of patients treated with Xofigo in Sweden.~This study will include patients receiving treatment of Xofigo at certified nuclear medicine centers across Sweden during a two year period."
3034545|NCT02331290||All patients|20 newly diagnosed patients with small-cell lung cancer and adenocarcinoma of the lung stage III or IV
3034546|NCT02331277|Experimental|Multiple dose|Weekly dosing for four weeks
3034547|NCT02331277|Placebo Comparator|Placebo|Placebo
3034548|NCT02331264||MoM >7ppb|Patients with Metal on Metal hip implants and blood metal ions above the Medicines and Healthcare Products Regulatory Agency (MHRA) threshold of 7 parts per billion
3034549|NCT02331264||MoM <7ppb|Patients with Metal on Metal hip implants and blood metal ions below the MHRA threshold of 7 parts per billion
3034550|NCT02331264||Non MoM|Patients with non Metal bearing hip implants such as Ceramic on Ceramic or Plastic
3034551|NCT02331251|Experimental|Arm 1|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 on day 1 and day 8 every 21 days
3034552|NCT02331251|Experimental|Arm 2|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 900 mg/m2 on day 1 and 8 and docetaxel 75 mg/m2 on day 8 every 21 days
3034553|NCT02331251|Experimental|Arm 3|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2 on day 1 and day 8 every 21 days
3034554|NCT02331251|Experimental|Arm 4|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 and vinorelbine 25 mg/m2 on day 1 and day 8 every 21 days
3034555|NCT02331251|Experimental|Arm 5|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Irinotecan 300 mg/m2 on day 1 every 21 days
3034556|NCT02331251|Experimental|Arm 6|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Liposomal doxorubicin 30 mg/m2 on day 1 every 21 days
3034557|NCT02331238|No Intervention|Control School|"Control schools (where the coaches do not receive the Coaching Boys into Men training until following academic year ;wait list control)"
3034592|NCT02331017|Experimental|Bimodal users|"Bilateral-bimodal users with moderate-to-severe hearing loss who use hearing aids for at least 75% of their waking hours.~Administration of Speech perception tests and self-rating questionnaire"
3034593|NCT02331004|Active Comparator|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
3034558|NCT02331238|Experimental|Intervention School|"Intervention schools (where coaches receive the Coaching Boys into Men training at start of each sports season).~Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
3034559|NCT02331225||Systemic sclerosis, no pulmonary hypertension|This group will be systemic sclerosis patients without pulmonary hypertension
3034560|NCT02331225||Systemic sclerosis/pulmonary hypertension|This group will be systemic sclerosis patients with pulmonary hypertension
3034561|NCT02331225||Healthy controls|These will be healthy age- and sex-matched controls
3034562|NCT02331212||Ancillary-correlative (role of HAS2+ in CSCs)|Blood and bone marrow samples are collected and analyzed via flow cytometry and PCR. Cells are also transplanted into mice and studied.
3034563|NCT02331199|Experimental|preterm labour|200 women with preterm prelabour ruptured membranes or undergoing preterm CS
3034564|NCT02331186||obese women who underwent bariatric surgery|obese women who underwent bariatric surgery
3034565|NCT02331173||Main Study Group|All subjects enrolled in this study will be seen every 6 months following the screening visit. During the 3 main study visits, a series of tests will be performed to assess visual function. Some of these tests are part of routine care that patients would receive on an annual basis regardless of study participation. Other tests are being performed to determine if they are effective at monitoring disease progression in this population. For each of the 3 main study visits, testing may be spread over multiple days to ensure completion of all tests.
3034566|NCT02331173||Carbonic anhydrase inhibitor sub-study|Subjects with maculoschisis may be offered topical treatment with CAIs. These subjects will be asked to visit the study site at 1 month and 3 months after starting topical treatment. During these additional visits, subjects will undergo a dilated eye exam, BCVA, and SD-OCT imaging to assess efficacy of treatment (i.e. reduction of maculoschisis).
3034567|NCT02331160|Experimental|Rebozo|Intervention by Rebozo
3034568|NCT02331160|No Intervention|Control|Standard
3034569|NCT02331147|Sham Comparator|Standard of Care|Surgical debridement of DFU, The wound will be debrided and cleaned. Patient ulcers will be assessed and measured weekly in cm length by width. Application of collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice off loading
3034570|NCT02331147|Active Comparator|Human Dermis|"Application of Human Allogenic Dermis with Dressing Application, to be changed weekly. Patient would will be measured in cm length by width weekly Patient will practice Offloading.~If the ulcer has not closed completely, an additional piece of Human Dermis will be applied weekly at weeks 2-11 in a similar fashion"
3034571|NCT02331134|Other|Melanoma, head and neck|10 μg/kg/day of Filgrastim will be given subcutaneously for 4 days
3034572|NCT02331121|Active Comparator|Text-only Online Training|Text-only evidence-based training content on CPR, choking relief & first aid
3034573|NCT02331121|Experimental|Family First Aid Online Training|Interactive multimedia evidence-based training content on CPR, choking relief & first aid
3034574|NCT02331108|Active Comparator|sevoflurane in 100% oxygen, age <56|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age 18-55.
3034575|NCT02331108|Active Comparator|sevoflurane in 50% nitrous, age <56|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age 18-55.
3034576|NCT02331108|Active Comparator|propofol, age <56|The intervention will be the randomized selection of anesthetic induction technique to intravenous induction with 2.2 mg/kg propofol. Age 18-55.
3034577|NCT02331108|Active Comparator|propofol with phenylephrine, age <56|The intervention will be the randomized selection of anesthetic induction technique to intravenous induction 2.2 mg/kg propofol immediately preceded by 160 mcg intravenous phenylephrine. Age 18-55.
3034578|NCT02331108|Active Comparator|sevoflurane in 100% oxygen, age >55|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age >55.
3034579|NCT02331108|Active Comparator|sevoflurane in 50% nitrous, age >55|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age >55.
3034580|NCT02331095|Active Comparator|Warfarin|Patients will be treated with warfarin as standard anticoagulation, dose adjusted to goal INR (international normalized ratio) of 2-3
3034581|NCT02331095|Experimental|Atorvastatin + warfarin|In addition to warfarin as standard anticoagulation, patients will be given concurrent atorvastatin 40 mg daily for 3 months, starting from the time of enrollment
3034582|NCT02331082|Active Comparator|Control|Existing healthcare system
3034583|NCT02331082|Experimental|Health System Improvement|Structured Quality Improvement Chronic Care Model Integrated Electronic Medical Record Solar-powered electrical supply Performance-based financing
3034584|NCT02331069|Active Comparator|Dextrose 5% (D5W) Injection|Glucose injection in 5% concentration, administered weekly X 4 times in a volume of 12 ml or less.
3034585|NCT02331069|Active Comparator|Physical Therapy|Physical therapy for a month in the posterior deltoid region 3 times a week.
3034586|NCT02331056||thoracoscopic pulmonary lobectomy|to observe a fluid responsiveness in patients who receives scheduled thoracoscopic pulmonary lobectomy
3034587|NCT02331056||open pulmonary lobectomy(thoracotomy)|to observe a fluid responsiveness in patients who receives scheduled open pulmonary lobectomy(thoracotomy)
3034588|NCT02331043|Placebo Comparator|Placebo biscuit|Biscuit without plant stanol ester
3034589|NCT02331043|Experimental|Plant stanol ester biscuit|Biscuit with plant stanol esters
3034590|NCT02331030|Experimental|Combined (C)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.5% 20ml and Pecs II block with Ropivacaine 0.5% 10ml.
3034591|NCT02331030|Active Comparator|Supraclavicular (S)|Ultrasound-guided supraclavicular BPB with Ropivacaine 0.5% 20ml and sham block (grade 1)
3034909|NCT02328963|Experimental|Everolimus|Everolimus + reduced dose of cyclosporine A
3034594|NCT02331004|Placebo Comparator|Support to activities of daily living|Performing of general activities planned in the centres where the participants are included
3034595|NCT02330991|Experimental|Arm1 ,one-week on/one-week off regimen|One-week on/one-week off regimen is administered for 12 cycles of 28 days. Arm 1 receives temozolomide 150 mg/m2 daily during days 1 to 7 and 15 to 21 of each cycle.Treatment will continue until tumor progression, development of excessive toxicity, withdrawal of consent, or completion of 12 cycles.
3034596|NCT02330991|Experimental|Arm 2,continuous dose-intense regimen|Continuous dose-intense regimen is administered for 12 cycles of 28 days .Arm 2 receives temozolomide 50mg/m2 daily during days 1 to 28 of each cycle. Treatment will continue until tumor progression, development of excessive toxicity, withdrawal of consent, or completion of 12 cycles.
3034597|NCT02330978|Experimental|MSC transplantion|One group of glaucomatous patients will receive 10(6) autologous bone marrow-derived mesenchymal stem cells transplantation into their worst eyes, through an unique intravitreal injections, under anesthesia.
3034598|NCT02330965||Subjects Assigned to BAF312|Patients with secondary progressive multiple sclerosis (SPMS) randomized to receive BAF312 (siponimod). Refer to ClinicalTrials.gov record NCT01665144 for more information.
3034599|NCT02330965||Subjects Assigned to Placebo (Controls)|Patients with secondary progressive multiple sclerosis (SPMS) randomized to receive placebo. Refer to ClinicalTrials.gov record NCT01665144 for more information.
3034600|NCT02330952|Experimental|Prednisone|
3034601|NCT02330952|Placebo Comparator|Placebo|
3034602|NCT02330939|Active Comparator|Low fat- Low glycemic index|Participants consumed a meal with low glycemic index and poor in fat
3034603|NCT02330939|Experimental|MUFA- Low glycemic index|Participants consumed a meal with low glycemic index and rich in MUFA
3034604|NCT02330939|Experimental|SAFA- Low glycemic index|Participants consumed a meal with low glycemic index and rich in SAFA
3034605|NCT02330939|Active Comparator|Low fat- High glycemic index|Participants consumed a meal with high glycemic index and low in fat
3034606|NCT02330939|Experimental|MUFA- High glycemic index|Participants consumed a meal with high glycemic index and rich in MUFA
3034607|NCT02330939|Experimental|SAFA- High glycemic index|Participants consumed a meal with high glycemic index and rich in SAFA
3034608|NCT02330926|Experimental|multimodal intervention|standard care plus multimodal intervention consisting of nutritional supplements and advice, home-based self-assisted exercise program, and anti-inflammatory medication (ibuprofen)
3034609|NCT02330926|Active Comparator|standard care|standard palliative care
3034610|NCT02330913|Experimental|Intracorporeal esophagojejunostomy|Patient group with intracorporeal esophagojejunostomy with linear stapler
3034611|NCT02330900|No Intervention|Study group|Evaluation of interference
3034612|NCT02330887|Experimental|Intervention Cohort|We will use a cohort of 60 women from intervention village clusters for the group antenatal care intervention.
3034613|NCT02330887|Active Comparator|Control Cohort|We will use a cohort of 60 women from control village clusters as an active comparison.
3034614|NCT02330861|Other|Normal coronary artery|
3034615|NCT02330848|Active Comparator|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum.
3034616|NCT02330848|Active Comparator|Walnut Calorie Controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan. Participants will receive on-going instruction to preserve an isocaloric condition after the addition of walnuts. The study dietitian will customize dietary adjustments to make room for walnuts in the diet, while accommodating the priorities of each study participant. The general approach will emphasize general reduction in portion sizes; participants will also receive advice, based on baseline dietary intake analysis, of food eliminations that they might want to consider.
3034617|NCT02330835|Experimental|In the Driver's Seat|Treatment materials. In the Driver's Seat: A Roadmap to Managing Student Behavior on the Bus is a comprehensive multimedia program that guides transportation departments in creating and maintaining a safe, responsible, and positive environment on the school bus through effective student behavior management. The program includes three components: 1) In the Driver's Seat: Transportation Supervisor Program for transportation department administrative staff, 2)In the Driver's Seat: Group Lessons DVD for Drivers. The DVD-based curriculum is designed to be facilitated by a transportation supervisor or driver trainer in groups and 3)In the Driver's Seat: Bus Driver Program. This CD-ROM-based program for bus drivers.
3034618|NCT02330835|Active Comparator|School bus driver training videos|Control materials. Bus drivers in the control condition viewed two linear videos on study computers. In Session 1 of the intervention, Control drivers viewed School Bus Driving, Part 1, 2nd Edition, © 1991, AIMS Media, 23-minute linear video showing defensive driving techniques. In Session 2, Control drivers viewed Decide Smart, Arrive Safe, © 2005, Operation Lifesaver, Inc., a video about school bus safety at railroad crossings produced in conjunction with the National Association of State Directors of Pupil Transportation services. Supervisors in the control condition received no materials until completing the study (waitlisted).
3034619|NCT02330822|Experimental|Hyaluronic Acid Group|In this Group, Hyaluronic acid will be injected following extraction.
3034620|NCT02330822|No Intervention|Traditional Extraction Group|In this group, traditional extraction procedures will be followed.
3034621|NCT02330809|Experimental|Daily extra water intake 2L|"Timing of daily extra water intake intervention-A: extra water intake: 8 8oz glasses of water a day (2L) - 2 first thing in the morning before breakfast, 2 before midday or midday meal, 2 before afternoon meal and 2 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
3034622|NCT02330809|Experimental|Daily extra water intake 1L|"Timing of daily extra water intake Intervention-A: 4 8oz glasses of water a day (1L) - 1 first thing in the morning before breakfast, 1 before midday or midday meal, 1 before afternoon meal and 1 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
3034623|NCT02330809|Experimental|Daily extra water intake 500ml|"Timing of daily extra water intake Intervention-A: 2 8oz glasses of water a day (500ml) - each half an hour before a meals~Intervention-B: Drink extra water at anytime over 24 hours"
3034728|NCT02330133|Active Comparator|Online sexual health content|Online general text-based information about reproductive health issues and STD prevention strategies
3034624|NCT02330809|Experimental|Daily extra water intake 120ml|"Timing of daily extra water intake Intervention-A: 1/2 a glass of water on waking (120ml). If you forget to drink your water first thing, do not drink it later in the day, just skip this day and drink ½ a glass the next day on waking.~Intervention-B: Drink extra water at anytime over 24 hours"
3034625|NCT02330796|Experimental|Arm A|Bucillamine (900 mg total dose over 7 days)
3034626|NCT02330796|Experimental|Arm B|Bucillamine (1,800 mg total dose over 7 days)
3034627|NCT02330796|Active Comparator|Arm C|Colchicine (1.8 mg total dose in 2 doses taken 1 hour apart)
3034628|NCT02330783|Experimental|Bevacizumab plus Sorafenib|Bevacizumab 5mg/kg Q2w Sorafenib 400mg Bid
3034629|NCT02330783|Active Comparator|Sorafenib|Sorafenib 400mg Bid
3034630|NCT02330770|Active Comparator|Dual trigger group|Trigger with concomitant GnRHa and HCG (single low-dose) administration
3034631|NCT02330770|Active Comparator|Single low-dose HCG group|Trigger with GnRHa then HCG (single low-dose) administration in luteal phase
3034632|NCT02330770|Active Comparator|Multiple low-doses HCG group|Trigger with GnRHa then HCG (multiple low-doses) administration in luteal phase
3034633|NCT02330757|Active Comparator|HRT group|Women will be subjected to HRT using Estradiol valerate before FET
3034634|NCT02330757|Active Comparator|MOS group|Women will be subjected to MOS using sequential clomiphene citrate and gonadotropin before FET
3034635|NCT02330744|Experimental|Approach-positive AAT|Computerized AAT procedure designed to increase automatic approach responses for positive social cues.
3034636|NCT02330744|Placebo Comparator|Control AAT|Computerized AAT procedure in which there is no contingency between arm movement and positive social cues.
3034637|NCT02330731|Other|N-butyl-2-cyanoacrylate|injection sclerotherapy for gastric varices
3034638|NCT02330731|Other|iso-amyl-2-cyanoacrylate|injection sclerotherapy for gastric varices
3034639|NCT02330731|Other|72% chromated glycerin|injection sclerotherapy for gastric varices
3034640|NCT02330705|Active Comparator|Group A|IUI at time of HCG
3034641|NCT02330705|Active Comparator|Group B|IUI 12 hours after HCG
3034642|NCT02330705|Active Comparator|Group C|IUI 34-36 hours after HCG
3034643|NCT02330679|Other|Desvenlafaxine|2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine
3034644|NCT02330666|No Intervention|Comparison|Standard care
3034645|NCT02330666|Experimental|Intervention|Communication skills training Mission Possible: Parents & Kids Who Listen
3034646|NCT02330653|Experimental|Fecal Microbiota Transplant|Induction retention enema for the first week of treatment followed by 15 capsules of study treatment (the equivalent of 7.5 grams of human stool) will be (administered within 60 minutes of thawing once weekly for a total of 7 weeks) for a total of 8 weeks. After completing 8 weeks of blinded study treatment, study subjects on FMT who have shown improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks.
3034647|NCT02330653|Placebo Comparator|Placebo|Induction placebo enema for the first week of treatment followed by 15 capsules of study placebo (administered within 60 minutes of thawing once weekly for a total of 7 weeks) for a total of 8 weeks. After completing 8 weeks of blinded study placebo, study subjects on placebo who DO NOT demonstrate improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks.
3034648|NCT02330640|Experimental|ticagrelor|90mg Bid for 30days after first dose
3034649|NCT02330640|Active Comparator|clopidogrel|75mg Qd for 30days first dose
3034650|NCT02330640|Other|asprin|100mg Qd all patients will be given asprin 100mg Qd within 24hours after CABG
3034651|NCT02330627|Experimental|Positive Valence System Treatment|10 one-hour individual sessions comprised of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors.
3034652|NCT02330627|No Intervention|Delayed Treatment (Waitlist)|
3034653|NCT02330614||bleaching patients|Patients who agreed to be bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications , before and after this procedure was applied again the NEO-FFI personality test form, had 30 minutes to answer it.
3034654|NCT02330614||Control group|Patients who refused to be bleached were administered the personality test NEO-FFI, had 30 minutes to answer it.
3034655|NCT02330601|No Intervention|control group|The papilla orifice could be enlarged by asphincterotomeif necessary. The stones were retrieved by a basket or a retrieval balloon
3034656|NCT02330601|Other|EPLBD group|a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
3034657|NCT02330588|Experimental|Eat It! (Injunctive Feedback)|Parents are presented with two questions about portion size and sugar-sweetened beverages; answers are contrasted with injunctive feedback (i.e., Canadian guidelines).
3034658|NCT02330588|Experimental|Eat It! (Normative Feedback)|Parents are presented with two questions about portion size and sugar-sweetened beverages; answers are contrasted with normative feedback (i.e., referent data from Canadian children).
3034659|NCT02330588|Experimental|Move It! (Injunctive Feedback)|Parents are presented with two questions about screen time and moderate-to-vigorous physical activity (MVPA); answers are contrasted with injunctive feedback (i.e., Canadian guidelines).
3034660|NCT02330588|Experimental|Move It! (Normative Feedback)|Parents are presented with two questions about screen time and moderate-to-vigorous physical activity (MVPA); answers are contrasted with normative feedback (i.e., referent data from Canadian children).
3034661|NCT02330588|Placebo Comparator|eHealth Control|Parents randomly assigned to the control arm will include information on children's lifestyle behaviors only (no intervention questions).
3034662|NCT02330575|Active Comparator|Standard Care|Participants in this group will receive standard education on the importance of physical activity in the recovery from cancer and how to become more active. Participants assigned to this group will have the option to participate in the exercise program after the 16-week follow-up assessment.
3034729|NCT02330120|Experimental|propofol|Propofol infusion 0.5-2 mg/kg/h for sedation in mechanically ventilated patients
3034663|NCT02330575|Experimental|Supervised Community-based Exercise|Participants in this group will take part in an 8-week supervised exercise program at the YMCA. Following the 8-week intervention, participants will have the option to continue for an additional 8-weeks at the YMCA (fee for service) or follow an 8-week self-directed program.
3034664|NCT02330562|Experimental|Phase 1: MRZ + BEV; Phase 2: MRZ alone|"Part 1 (Phase 1): MRZ 10 minute IV infusion on Days 1, 8, and 15 plus BEV IV infusion on Days 1 and 15 of each 28-day cycle.~Part 2 (Phase 2): MRZ 10 minute IV infusion administered on Days 1, 8, and 15 of each 28-day cycle.~Part 3 (Phase 2): All subjects will receive IV MRZ infusion and IV BEV infusion.~MRZ will be administered as a 10-minute, IV infusion on Days 1, 8, and 15 of every 28-day cycle using intra-patient dose escalation. Starting dose will be 0.8 mg/m2.~Part 4 (Phase 1): All subjects will receive MRZ enterally by NG tube (reconstituted IV formulation) as a bolus on Days 1, 8 and 15 of the first 28-day cycle and BEV IV infusion on Day 15 of the first 28-day cycle. For subsequent 28-day treatment cycles, MRZ will be administered as an IV at the recommended dose and schedule determined in Part 1, with BEV IV on Days 1 and 15."
3034665|NCT02330549|Experimental|Cenicriviroc 150mg|CVC 150 mg, administered orally once daily and taken every morning with food for 24 weeks
3034666|NCT02330549|Placebo Comparator|Matching placebo|Matching placebo, administered orally once daily and taken every morning with food for 24 weeks
3034667|NCT02330536|Experimental|Flowrate A|insufflation of carbon dioxide at 8L/min
3034668|NCT02330536|Experimental|Flowrate B|insufflation of carbon dioxide at 16L/min
3034669|NCT02330523|Active Comparator|allograft + x-link collagen membrane|Demineralized freeze-dried allograft + x-linked collagen membrane will be used for guided bone regeneration of dehiscence buccal defects post extraction.
3034670|NCT02330523|Active Comparator|xenograft + non-x-link collagen|Xenograft + non-x-linked collagen membrane will be used for guided bone regeneration of dehiscence buccal defects post extraction.
3034671|NCT02330510||Alzheimer's Disease|Individuals with early Alzheimer's Disease (AD) or amnestic or multi-domain Mild Cognitive Impairment who have extensive Periventricular White Matter Hyperintensities
3034672|NCT02330510||Transient Ischemic Attack/Mild Subcortical Stroke|Individuals who have had a mild subcortical stroke or a Transient Ischemic Attack (TIA) with extensive Periventricular White Matter Hyperintensities in the absence of cortical infarcts
3034673|NCT02330497|Experimental|Radiofrequency|Procedure/Surgery Thermal Radiofrequency Ablation under endoscopic ultrasonography guidance of the pancreatic neuro endocrine tumor or mucinous cyst.
3034674|NCT02330484|Experimental|incentives to physicians|Give incentives to physicians according to patients' HbA1c improvement
3034675|NCT02330484|Experimental|incentives to patients|Give incentives to patients according to their HbA1c improvement
3034676|NCT02330484|Experimental|incentives to both physicians and patients|intervention mode: Give incentives to physicians and patients according to patients' HbA1c improvement
3034677|NCT02330484|No Intervention|Group with no incentives|
3034678|NCT02330471|Experimental|Spray|cervical coagulation using a superficial electrical coagulation mode, ie spray coagulation
3034679|NCT02330471|Active Comparator|Forced|cervical coagulation using a deep tissue electrical coagulation mode, ie forced coagulation
3034680|NCT02330445|Experimental|Part A|Up to 12 Part A recipients will have rheumatoid arthritis since this was an entry criterion for Study 104. All subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses followed by 5 monthly doses of PRTX-100. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 8 months. Subjects will be evaluated for adverse events, rheumatoid arthritis activity and the development of anti-PRTX-100 antibodies. The feasibility of different assessment methods of disease activity may be explored. Novel methods of joint evaluation will be explored. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
3034681|NCT02330445|Experimental|Part B|Five healthy subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses. All subjects will have a serum collection requiring approximately 600 mL of blood. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 3 months. Subjects will be evaluated for adverse events and the development of anti-PRTX-100 antibodies. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
3034682|NCT02330432|Experimental|Mycobacterium w group|Patients in the experimental arm (Mw) in addition to standard care will receive single daily dose of 0.3 mL of Mw (heat-inactivated Mw [0.5 × 10^9]; Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
3034683|NCT02330432|Active Comparator|Best standard care|Best standard care for sepsis
3034684|NCT02330419|Placebo Comparator|Placebo|Placebo 50mg, as needed
3034685|NCT02330419|Active Comparator|Naltrexone|Naltrexone 50mg, as needed
3034686|NCT02330406|Active Comparator|Anagliptin|Anagliptin 100 mg bid for 52 weeks. Can increase to 200 mg bid if needed.
3034687|NCT02330406|Active Comparator|Sitagliptin|Sitagliptin 50 mg qd for 52 weeks. Can increase to 100 mg qd if needed
3034688|NCT02330380||Methotrexate|Methotrexate will be dosed weekly. Methotrexate is given as a single, weekly dose and is will be started at 15mg after a first week test dose of 2.5 mg to minimize side effects and achieve efficacy. Weekly dosages will be 15mg.
3034689|NCT02330380||Ustekinumab|Ustekinumab is given as a subcutaneous injection of 45mg if the patient is <100Kg or 90mg if the patient is >100Kg at weeks 0, 4, 16, and every 12 weeks thereafter.
3034690|NCT02330380||Etanercept|Etanercept will be given in the first 3 months of treatment as 50 mg twice a week (3 or 4 days apart). After 3 months, a reduced dose of 50 mg will be given once per week.
3034691|NCT02330380||Adalimumab|Adalimumab will be given in a dose of 40 mg subcutaneously every other week.
3034692|NCT02330380||Acitretin|Acetretin will be prescribed as daily with 25mg if the patient is <80Kg or 35mg if the patient is >80Kg.
3034730|NCT02330120|Active Comparator|dexmedetomidine|dexmedetomidine infusion 0.2-0.7 mcg/kg/h for sedation in mechanically ventilated patients
3034758|NCT02329951||Sacroiliac joint injections|Patients will receive a single SI joint injection on the affected side(s) with 40 mg depomethylprednisolone and 2 ml of 0.5% bupivacaine.
3034759|NCT02329938|Active Comparator|Lichtenstein tension free reair|mesh repair of inguinal hernia
3034760|NCT02329938|Active Comparator|Desarda's repair|non-mesh repair of inguinal hernia
3034693|NCT02330380||UVB Excimer Laser|Dose determination will be determined by a physician per standard-of-care by performing a Sunburn Test/Minimal Erythemal Dose Test, or by visually evaluating the patient's skin type and thickness of psoriasis plaque. Initial laser dose will be 1-4X the MED depending on the thickness of the plaque. Escalation will be 25-50% increase in dose per treatment if there is no residual erythema, 25% increase per treatment if there is mild residual erythema, and 0% increase per treatment if there is moderate residual erythema. Investigators also have the option to skip a treatment, if there is above moderate erythema, or significant patient discomfort. Patients will receive treatment twice a week.
3034694|NCT02330380||Narrowband UVB|Narrowband UVB (311nm) will be used to treat patients 3X per week with 311nm of UVB light. Uninvolved areas of skin will be covered where possible to minimize excess sun exposure. Patients will be tested for their minimal erythemal dose (MED), after which, based upon Fitzpatrick Scale skin type, a patient will typically beginning with 1-2 minutes based on skin type and gradually increased by 10-15% per treatment dose as tolerated.
3034695|NCT02330367|Experimental|AC0010|Oral AC0010 monotherapy
3034696|NCT02330354|Experimental|Intervention group|Centers in this group will participate in the Healthy Me, Healthy We program.
3034697|NCT02330354|Other|Control Group|Centers in this group will participate in the Healthy Me, Healthy We program after follow-up measures are collected.
3034698|NCT02330341|Experimental|Artemisia Dracunculus|Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
3034699|NCT02330341|Placebo Comparator|Placebo|Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
3034700|NCT02330328|Experimental|No Telemetry Monitoring|The participants in this arm will be admitted to a bed without telemetry monitoring
3034701|NCT02330328|Active Comparator|Telemetry|The participants in this arm will be admitted to a bed with telemetry monitoring
3034702|NCT02330315|Experimental|Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
3034703|NCT02330315|Sham Comparator|Sham tDCS + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
3034704|NCT02330302|Active Comparator|Femoral nerve block|Procedure: Ultrasound-guided femoral nerve block Drug: Ropivacaine 0.5% 30mls
3034705|NCT02330302|Active Comparator|Fascia Iliaca block|Procedure: Ultrasound-guided suprainguinal approach to fascia iliaca block Drug: Ropivacaine 0.5% 30mls
3034706|NCT02330289|Experimental|Report card arm|The intervention arm will receive an email report card describing their lab use compared to their peers as well as a link to a website visually tracking the team's daily ordering of common lab tests compared to the peer teams.
3034707|NCT02330289|No Intervention|Control arm|Physicians in the control arm will not receive the email or website link.
3034708|NCT02330276|Experimental|10 mg (+)-epicatechin|4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
3034709|NCT02330276|Experimental|30 mg (+)-epicatechin|4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
3034710|NCT02330276|Experimental|100 mg (+)-epicatechin|4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
3034711|NCT02330263|Experimental|carbohydrate group|Randomly selected patients of the carbohydrate group are given 400ml of 12.8 g/100 ml carbohydrate beverage in the evening before their surgery and in the morning of the operation day (3 hours before their scheduled operation).
3034712|NCT02330263|No Intervention|control group|Patients in the control group consume no food or drink after midnight before surgery.
3034713|NCT02330250|Experimental|Pharmaceutical Care|The patients will receive guidance from a pharmacist based on the Dader Method for Pharmaceutical Care, in addition to the medical care habitually delivered by the hospital.
3034714|NCT02330250|Sham Comparator|Control|The control group will receive the medical care habitually provided by the hospital, and the follow-up by a non-pharmacist professional.
3034715|NCT02330237|Active Comparator|patients|natural gels
3034716|NCT02330237|Placebo Comparator|subjects|These patients will receive that placebo (vehicle) products.
3034717|NCT02330224|Experimental|Hypertension Management Intervention|Multifaceted hypertension management intervention
3034718|NCT02330224|No Intervention|Usual Care|Control group
3034719|NCT02330211|Experimental|Fecal Microbiota Transplant|Induction retention enema for the first week of treatment followed by 15 capsules of study treatment (the equivalent of 7.5 grams of human stool) will be (administered within 60 minutes of thawing once weekly for a total of 7 weeks) for a total of 8 weeks. After completing 8 weeks of blinded study treatment, study subjects on FMT who have shown improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks.
3034720|NCT02330211|Placebo Comparator|Placebo|Induction placebo enema for the first week of treatment followed by 15 capsules of study placebo (administered within 60 minutes of thawing once weekly for a total of 7 weeks) for a total of 8 weeks. After completing 8 weeks of blinded study placebo, study subjects on placebo who DO NOT demonstrate improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks.
3034721|NCT02330185|Experimental|spinal anesthesia for knee arthroscopy|The intervention is spinal anesthesia. Tenth rib line or Tuffier's line will be examined as application landmarks by ultrasonography for spinal anesthesia.
3034722|NCT02330172|Active Comparator|rocuronium 0.45 - neostigmine|"when anesthetic induction, inrocuronium 0.45 mg/kg will be administered for muscle relaxation.~When the end of operation, a injection of neostigmine or sugammadex will be administered."
3034723|NCT02330172|Active Comparator|rocuronium 0.9 - sugammadex|"When anesthetic induction, rocuronium 0.9 mg/kg will be injected to rocuronium 0.9 - sugammadex group for muscle relaxation.~When the end of operation,, a injection of neostigmine or sugammadex be administered."
3034724|NCT02330159||Novel Wound Healing Protocol|Subjects who have pilonidal disease that are being scheduled for surgical excision with our novel wound healing protocol. The disease can be actively infected or chronic.
3034725|NCT02330146|Experimental|RCT-01|Cultured, autologous hair follicle cells suspended in cryomedium
3034726|NCT02330146|Placebo Comparator|Placebo|cryomedium
3034727|NCT02330133|Experimental|Women's Reproductive Health|Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections
3034731|NCT02330107|Experimental|Treatment arm 1|"Subjects will receive MAT and placebo LA. The magnetic pellets will be applied to the six selected acupoints as detected by an acupoint finder. To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation before the application of MAT. Subjects will be asked to wear a pair of laser protective goggles to blind them during treatment."
3034732|NCT02330107|Experimental|Treatment arm 2|Subjects will receive a combined approach that includes the use of MAT and LA. A laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use (King et al., 1990; Round et al., 2013). This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear. Laser protective goggles will be provided to the subjects and the researchers for eye protection.
3034733|NCT02330107|Placebo Comparator|Treatment arm 3|"Subjects will serve as a placebo control and will receive LA at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plasters centred with a small portion of Junci Medulla (mimicking the MAT treatment)."
3034734|NCT02330094|Experimental|Gabapentin|Gabapentin capsules 100 mg TID, 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
3034735|NCT02330094|Placebo Comparator|Control|Placebo capsules 100 mg TID, 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
3034736|NCT02330081|Experimental|Mirasol|"Subject will be infused with two products at the same time:~radio-labeled platelets derived from subjects stored whole blood which has been treated with Mirasol.~radio-labeled platelets derived from subjects untreated fresh whole blood."
3034737|NCT02330068||Controls|Males and females ages 18-55 without Major Depressive Disorder, Bipolar I or Bipolar II who are not on an antidepressant and do not have a first degree relative with a diagnosis of Major Depressive Disorder and not currently taking citalopram.
3034738|NCT02330068||Cases|Male or female participants ages 18-55 with Major Depressive Disorder, Bipolar I or Bipolar II whom antidepressant treatment is deemed necessary will be given citalopram.
3034739|NCT02330055|Active Comparator|Forty-five degrees elevated upper body position|"If the patient is randomized in this study arm after enrollment, the investigators will elevate the patients upper body to 45 degree prior to sleeping. The patient will wear a pulseoximeter (WristOx Model 3150) during the night. The investigators will collect the SpO2 and pulse rate with this device and then quantify desaturation events.~The investigators will ask the patient to fill out a questionnaire, which includes the P-SAP score, the STOP-BANG score, the Epworth Sleepiness Scale and the self-reported pain."
3034740|NCT02330055|Placebo Comparator|Non-elevated upper body position|"If the patient is randomized in this study arm after enrollment, the investigators will flatten the patients upper body to a supine position prior to sleeping. The patient will wear a pulseoximeter (WristOx Model 3150) during the night. The investigators will collect the SpO2 and pulse rate with this device and then quantify desaturation events.~The investigators will ask the patient to fill out a questionnaire, which includes the P-SAP score, the STOP-BANG score, the Epworth Sleepiness Scale and the self-reported pain."
3034741|NCT02330042||Group A|"Patients with:~Type 1 or Type 2 diabetes mellitus~severe non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR)."
3034742|NCT02330042||Group B|"Patients with:~Type 1 or Type 2 diabetes mellitus~with or without mild to moderate NPDR"
3034743|NCT02330042||Group C (controls)|Patients without diabetes or evidence of any form of eye disease
3034744|NCT02330029|Active Comparator|TCM (Traditional Chinese medicine)|Formula for pain and diarrhea, Atractylodes (~10-15g), Paeonia Lactiflora (~15-30g), Tangerine Peel (~10g), Ledebouriella Root (~10g), Radix codonopsitis (~10-15g), Radix curcumae (~10g), Fingered citron (~10g), Tuckahoe (~15g), etc.
3034745|NCT02330029|Active Comparator|Pinaverium|
3034746|NCT02330029|Placebo Comparator|Placebo|Placebo is blindly given to patients
3034747|NCT02330016|Experimental|Voluma XC|Injections of Voluma will be accomplished using a serial puncture and fanning technique with the needle inserted to the periosteal plane as well as in the subcutaneous plane. The treatment area will include the medial and lateral chin as defined: lateral chin landmark is the depressor anguli oris.
3034748|NCT02330003|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
3034749|NCT02330003|Active Comparator|TIV PFS|Fluarix Prefilled Syringe
3034750|NCT02329990|Active Comparator|phosphorus|phosphorus ingestion (375mg) with each main meal ( breakfast, lunch, dinner)
3034751|NCT02329990|Placebo Comparator|placebo|ingestion of placebo tablets with each meal ( breakfast, lunch, dinner)
3034752|NCT02329977||Recurrent group|Patients with history of recurrent common bile duct stone after successfully ERCP stone remove.
3034753|NCT02329977||Control group|Patients without history of recurrent common bile duct stone after successfully ERCP stone remove.
3034754|NCT02329964|Experimental|R-S group|"Rocuronium-Sugammadex group~Induction of anesthesia : 1% propofol 1.5-2.5 mg/kg with fentanyl 1.5 mcg/kg~Muscle relaxant agent : Rocuronium 1mg/kg~After endotracheal intubation : normal saline(0.025 ml/kg)~Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery : Rocuronium 0.15mg/kg~Relaxant agent reversal. at the the end of surgery : sugammadex 2mg/kg"
3034755|NCT02329964|Active Comparator|S-C-N group|"Succinylcholine-Cisatracurium-Neostigmine group~Induction of anesthesia :1% propofol 1.5-2.5 mg/kg with fentanyl 1.5 mcg/kg~Muscle relaxant agent :Succinylcholine 1mg/kg~After endotracheal intubation : Cisatracurium 0.08mg/kg~Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery : Succinylcholine 10mg~Relaxant agent reversal at the appearance of second TOF twitch (T2) : Neostigmine 0.2mg/kg with atropine 10 mcg/kg (for preventing side effects of neostigmine)"
3034756|NCT02329951||Epidural steroid injections|Patients will receive a single interlaminar epidural steroid injection with 60 mg depomethylprednisolone, 1.5 ml of 0.25% bupivacaine and 1.5 ml of saline or a transforaminal epidural steroid injection with 60 mg depomethylprednisolone, 1.5 ml of 0.25% bupivacaine and 0.5 ml of saline.
3034757|NCT02329951||Facet interventions|Patients will receive diagnostic medial branch (facet joint nerve) blocks with 0.5 ml of 0.5% bupivacaine. If they experience a positive block (> 50% pain relief lasting more than 3 hours), they will then receive radiofrequency denervation.
3034761|NCT02329925|Experimental|Tongue Stabilizing Device Treatment|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
3034762|NCT02329912|Experimental|Patients after abdominal surgery|SmartPill application after abdominal surgery
3034763|NCT02329912|Sham Comparator|Patients after extraabdominal surgery|SmartPill after extraabdominal surgery
3034764|NCT02329899||Possible MBD|"Defined by:~a bleeding score >= 4 in adults;~a bleeding score >= 2 in children (for girls, up to menses);~a past medical history that include menorrhagia, haemorrhage from the umbilical stump, bleeding at circumcision, cephalhematoma at birth, hematuria, whatever the bleeding score is;~a past medical history suggestive of a MBD with no haemostatic challenge and a low bleeding score.~In this group, the second step of investigations will be performed."
3034765|NCT02329899||MBD unlikely|"Patients without criteria for possible MBD as listed above.~In this group, no further investigation will be performed if the first step is normal. The second step of investigations will be performed only in case of significant abnormalities in the first step of investigation."
3034766|NCT02329873|Experimental|Experimental group|Respiratory rehabilitation exercise training 2 times/day, 10-30 minutes per session for 4 days.
3034767|NCT02329873|No Intervention|Control group|Control group received usual care and health education.
3034768|NCT02329860|Experimental|Apatinib|750 mg orally (p.o.) every day (qd), 28 days as one cycle
3034769|NCT02329860|Placebo Comparator|Placebo|orally (p.o.) every day (qd), 28 days as one cycle
3034770|NCT02329847|Experimental|Cohort A1|Participants will receive ibrutinib 420 milligram (mg) capsule orally once daily and nivolumab intravenously as 3 milligram/kilogram (mg/kg) every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
3034771|NCT02329847|Experimental|Cohort A2|Participants will receive ibrutinib 560 mg capsule orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
3034772|NCT02329847|Experimental|Cohort B1|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
3034773|NCT02329847|Experimental|Cohort B2|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
3034774|NCT02329847|Experimental|Cohort B3|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
3034775|NCT02329847|Experimental|Cohort B4|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
3034776|NCT02329834|Experimental|Treatment Sequence 1|Furosemide Injection Solution for subcutaneous administration (80mg) over 5 hours followed by i.v. Furosemide Injection, USP (80 mg)by i.v. bolus in second period
3034777|NCT02329834|Experimental|Treatment Sequence 2|Furosemide Injection, USP (80 mg) by i.v. bolus, followed by Furosemide Injection Solution for subcutaneous administration (80mg) over 5 hours in second period.
3034778|NCT02329821||HCC group|patients with hepatocellular carcinoma
3034779|NCT02329821||donor group|patient for liver transplantation donation
3034780|NCT02329808||Mycophenolic acid|Patients treated for their regular patient care with mycophenolic acid.
3034781|NCT02329808||Cyclosporin|Patients treated for their regular patient care with cyclosporin.
3034782|NCT02329808||Tacrolimus|Patients treated for their regular patient care with tacrolimus.
3034783|NCT02329808||Sirolimus|Patients treated for their regular patient care with sirolimus.
3034784|NCT02329808||Everolimus|Patients treated for their regular patient care with everolimus.
3034785|NCT02329808||Voriconazole|Patients treated for their regular patient care with voriconazole.
3034786|NCT02329808||Posaconazole|Patients treated for their regular patient care with posaconazole.
3034787|NCT02329808||Itraconazole+metabolite|Patients treated for their regular patient care with itraconazole.
3034788|NCT02329808||Fluconazole|Patients treated for their regular patient care with fluconazole.
3034789|NCT02329795||Standard chemoradiotherapy|Group to receive 60 Gy radiotherapy in 30 fractions with concomitant and adjuvant temozolomide.
3034790|NCT02329782|Experimental|ARP intervention|Adherence counseling intervention
3034791|NCT02329782|No Intervention|usual care|no intervention, standard care practices regarding adherence support
3034792|NCT02329769|Experimental|PRO044 SC 6 mg/kg|Weekly subcutaneous (SC) dosing with 6 mg/kg
3034793|NCT02329769|Experimental|PRO044 IV 6 mg/kg|Weekly intravenous (IV) dosing with 6 mg/kg
3034794|NCT02329769|Experimental|PRO044 SC 9 mg/kg|Weekly intravenous (IV) dosing with 9 mg/kg
3034795|NCT02329756|Active Comparator|Treatment|Tranexamic acid (TXA) will be compared with matching placebo (sodium chloride 0.9%).
3034796|NCT02329756|Placebo Comparator|Control|Matching placebo (sodium chloride 0.9%) will be compared with treatment group
3034797|NCT02329743|Experimental|RX-10045 0.05% nanomicellar solution|topical eye drops
3034798|NCT02329743|Experimental|RX-10045 0.1% nanomicellar solution|topical eye drops
3034799|NCT02329743|Placebo Comparator|Vehicle|topical eye drops
3034800|NCT02329730|Experimental|the healthy subjects|The healthy subjects inject 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time .Right arm inject ESAT6-CFP10 and left arm inject tuberculin purified protein derivative. Two drugs must be use in the same subjects.
3034832|NCT02329496|Experimental|Lotus Valve and LOTUS Edge Valve System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System
3034833|NCT02329483||High responder infertile patients|Ovarian high responder patients who are being planned for low-dose step-up protocol ovulation induction and intrauterine insemination.
3034801|NCT02329730|Experimental|the first part of tuberculosis subjects|The first part kind of tuberculosis subjects inject 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time .Right arm inject ESAT6-CFP10 and left arm inject tuberculin purified protein derivative. Two drugs must be use in the same subjects.
3034802|NCT02329730|Experimental|the second part of tuberculosis subjects|The second part of tuberculosis subjects inject 1μg/ml ESAT6-CFP10 and placebo only one time , or 5μg/ml ESAT6-CFP10 and placebo only one time , or 10μg/ml ESAT6-CFP10 and placebo only one time , or 20μg/ml ESAT6-CFP10 and placebo only one time .Right arm inject ESAT6-CFP10 and left arm inject placebo. Two drugs must be use in the same subjects.
3034803|NCT02329717|Experimental|PBI 05204|PBI 05204 capsules dosed at 0.2255 mg/kg/day, continuous dosing
3034804|NCT02329704||Density Gradient processing|"Semen portion processed using Density Gradient (80/40 %) Spin on 1200 r.p.m./20min Wash on 1200 r.p.m./5min Rewash on 1200 r.p.m./5min~then evaluation to be done using : Diff-Quik staining for morphology evaluation Motility Evaluation for grade A and B Concentration (mil/ml) 24 H half life 48 H half life HBA Testing Bacterial contamination"
3034805|NCT02329704||Swimming down Processing|"Semen portion processed using swimming down (100 %) 30 min at room temperature processing for swim down Wash on 1200 r.p.m./5min Rewash on 1200 r.p.m./5min~then evaluation to be done using : Diff-Quik staining for morphology evaluation Motility Evaluation for grade A and B Concentration (mil/ml) 24 H half life 48 H half life HBA Testing Bacterial contamination"
3034806|NCT02329691||Changes in the WHO checklist|Specific changes in the WHO checklist will be performed after observational studies to enhance the WHO checklist at the specific institution
3034807|NCT02329678|Active Comparator|collagen membrane group and control group|GTR group: a bioresorbable collagen membrane (Healiguide, Advanced Biotech Products (P) Ltd., Encoll Corp., Fremont, CA, USA) was placed over the apicomarginal defect, covering 2-3mm of the healthy bone around all the margins after periodical surgery.
3034808|NCT02329678|Active Comparator|Control group|Control Group:No membrane was placed after periapical surgery.
3034809|NCT02329665|Experimental|NeedleWays™ System|A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
3034810|NCT02329652|Experimental|Intervention - implant neuroprosthesis|Receives implanted networked neuroprosthetic system for hand, arm, and trunk function. Undergoes functional training and assessment.
3034811|NCT02329639||case group|genetic interaction analysis of women with HER2 negative metastatic breast cancer performing a first-line chemotherapy with bevacizumab
3034812|NCT02329639||control group|genetic interaction analysis of women with HER2 negative metastatic breast cancer performing a first-line chemotherapy without bevacizumab
3034813|NCT02329626||Study population|"The study population consists of patients with paralysis, motor weakness or abnormal movements meeting DSM-IV criteria for motor conversion disorder consulting via the Emergency or Neurology department of participating centers.~Intervention: PET CT 18 FDG"
3034814|NCT02329613|Active Comparator|Standard evening meal|"Patients randomized to this arm will receive standard evening meals.~Intervention: Standard evening meals."
3034815|NCT02329613|Experimental|Improved evening meal|"Patients randomized to this arm will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.~Intervention: Improved evening meal"
3034816|NCT02329600|No Intervention|control subjects|10 systemically healthy control subjects taking no medication.
3034817|NCT02329600|Active Comparator|OLP and corticosteroid|15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month.
3034818|NCT02329600|Experimental|OLP and corticosteroid and green tea|15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with both topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month in addition to green tea tablets 200 mg (Green tea extract 5:1, El Obour For Modern Pharmaceutical Industries) as one tablet a day also for one month.
3034819|NCT02329587|Experimental|ERP plus tDCS|ERP plus anodal tDCS of right inferior frontal gyrus
3034820|NCT02329587|Active Comparator|ERP plus sham tDCS|ERP plus sham tDCS of right inferior frontal gyrus
3034821|NCT02329561|Active Comparator|Tramadol extended release and CP/T|Tramadol extended release: 200mg Single-dose, extended-release, once-daily, tablet; Current Perception and Tolerance (CP/T)
3034822|NCT02329561|Placebo Comparator|Placebo and CP/T|Single-dose, placebo identical in appearance to an extended release once-daily tablet; Current Perception and Tolerance (CP/T)
3034823|NCT02329548|Experimental|Alizarin Red|All participating patients will undergo the Alizarin Red intervention.
3034824|NCT02329535|Experimental|Treatment group|Treatment with 400 mg Micronized progesterone (Utrogestan) daily up to 6 weeks of geastation
3034825|NCT02329535|No Intervention|No treatment|No treatment. Regular follow up
3034826|NCT02329522||Stable COPD patients|Patients will be assessed using USCOM and spirometry. For those with FEV1 to FVC ratio smaller than 70%, they will be classified as COPD.
3034827|NCT02329522||AECOPD patients|Patients will be assessed using USCOM and spirometry. Spirometry will be assessed after 2 to 4 weeks post-hospital discharge.
3034828|NCT02329522||Patient Controls|Patients will be assessed using USCOM and spirometry. For those with COPD symptoms but FEV1 to FVC ratio greater than 70%, they will be classified as non-COPD.
3034829|NCT02329522||Healthy Controls|Healthy subjects, with no history of COPD or other significant chronic illness will be recruited as healthy controls. Subjects will be matched for age and gender with the patient groups. They will be assessed using USCOM.
3034830|NCT02329509|Active Comparator|one stage cleft palate surgery|Subjects submitted to one stage palate surgical repair after 9 months old and before 24 months old ,
3034831|NCT02329509|Active Comparator|two stage palate repair|Subjects submitted to two stage palate surgical repair (first soft palate repair between 6 and 12 months old and hard palate closure at 3 to 4 years old)
3034835|NCT02329470|No Intervention|Device, CPAP, n=50|Continues with device, CPAP, treatment for obstructive sleep apnea during the study frame
3034836|NCT02329457|Experimental|ID varicella zoster vaccine (VZVv) group|intradermal 0.2 mL Zostavax
3034837|NCT02329457|Active Comparator|SC VZVv group|subcutaneous 0.65 mL Zostavax
3034838|NCT02329457|Placebo Comparator|ID NS Group|intradermal 0.2 mL normal saline
3034839|NCT02329457|Placebo Comparator|SC NS Group|subcutaneous 0.65 mL normal saline
3034840|NCT02329457|Active Comparator|ID VZVv with imiquimod group|intradermal 0.2mL Zostavax with imiquimod pretreatment
3034841|NCT02329444|Experimental|Remote Ischemic Preconditioning|Patients treated with Remote Ischemic Preconditioning
3034842|NCT02329444|Active Comparator|Sham ischemic preconditioning|Patients treated with sham ischemic preconditioning
3034843|NCT02329431|Experimental|activation curriculum|Psycho-social curriculum teaching activation skills
3034844|NCT02329431|Active Comparator|support group|Parent-directed support group
3034845|NCT02329418|Experimental|Written document|Accompanying relatives with a written document when discussing withholding and withdrawing life-sustaining therapies . All other procedures are standard.
3034846|NCT02329418|Active Comparator|Standard|Discussing withholding and withdrawing life-sustaining therapies following standard procedure without written document
3034847|NCT02329405|Experimental|Rifampicin|Rifampicin 600 mg tablet once a day orally for a week.
3034848|NCT02329405|Placebo Comparator|Placebo|Placebo tablet once a day orally for a week.
3034849|NCT02329392||SPP|Patients undergoing cardiac surgery with perioperative monitoring of Skin Perfusion Pressure
3034850|NCT02329379|Experimental|Unigoiter, ATA (+), AUS (+) on Tx|The patients who have uninodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
3034851|NCT02329379|Active Comparator|Unigoiter, ATA (-), AUS (+) on Tx|The patients who have uninodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
3034852|NCT02329379|No Intervention|Unigoiter, ATA (+), AUS (+) without Tx|The patients who have uninodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
3034853|NCT02329379|No Intervention|Unigoiter, ATA (-), AUS (+) without Tx|The patients who have uninodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
3034854|NCT02329379|Experimental|Multigoiter, ATA (+), AUS (+) on Tx|The patients who have multinodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
3034855|NCT02329379|Active Comparator|Multigoiter, ATA (-), AUS (+) on Tx|The patients who have multinodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
3034856|NCT02329379|No Intervention|Multigoiter, ATA (+), AUS (+) without Tx|The patients who have multinodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
3034857|NCT02329379|No Intervention|Multigoiter, ATA (-), AUS (+) without Tx|The patients who have multinodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
3034858|NCT02329366||Diabetic Foot Ulcer Group|Subjects in this group will have tissue specimens collected from their Diabetic Foot Ulcer during Standard of Care debridement.
3034859|NCT02329366||Control Group|Skin tissue samples will be collected from subjects undergoing routine surgical procedures during which normal skin is removed
3034860|NCT02329353|Experimental|Smoker group|30 chronic periodontitis patients, having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks
3034861|NCT02329353|Experimental|Non-smoker|30 chronic periodontitis patients, not having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks
3034862|NCT02329340|Active Comparator|Am Academy of Pediatrics print materials|In-person session to read online version of American Academy of Pediatrics The Injury Prevention Program (TIPP sheets) childhood injury prevention print materials, followed by access to the TIPP sheets for 30 days.
3034863|NCT02329340|Experimental|Family Safety 1-2-3|In-person session to view video and text-based interactive web site on injury prevention information and strategies, followed by 8 emails delivered over a 30-day period inviting participant to view additional child safety videos.
3034864|NCT02329327|Experimental|Single Arm|
3034865|NCT02329301|Experimental|MDA with DHAp (Eurartesim)|All consenting community members eligible to receive DHAp will be provided age-appropriate treatment dose of DHAp regardless of the malaria rapid diagnostic test (RDT) result. Treatment will be administered in a house-to-house campaign.
3034866|NCT02329301|Experimental|Focal MDA with DHAp (Eurartesim)|All consenting household members eligible to receive DHAp and living in a household where anyone in the household tests positive with a malaria rapid diagnostic test (RDT) will receive the age-appropriate treatment dose of DHAp. If no one in the household tests RDT positive then no one in the household will receive DHAp. Treatment will be administered in a house-to-house campaign.
3060378|NCT02158780|Experimental|Scrotal Orchidopexy|Single incision
3034867|NCT02329301|No Intervention|Standard of Care (Control)|The standard of care arm will reflect no community-based treatment interventions but will have the standard of care offered by the Ministry of Health and Ministry of Community Development, Mother and Child Health which applies to all arms. This includes available mosquito net coverage, indoor residual spraying and passive case detection of individuals seeking treatment from a health provider at a clinic or health post.
3034868|NCT02329288|Active Comparator|Triamcinolone Acetonide|40mg/1ml
3034869|NCT02329288|Placebo Comparator|placebo|1ml
3034870|NCT02329275||Azoospermic men|
3034871|NCT02329275||Men with proven fertility|
3034872|NCT02329262|Experimental|Mentoring to be Active|Trained teen mentors will deliver the physical activity curriculum to high school students in a school setting. Physical activity will be measured with accelerometers.
3034873|NCT02329262|Active Comparator|Planning to be Active|High school teachers will deliver the physical activity curriculum (usual care) to high school students enrolled in health education courses. Physical activity will be measured with accelerometers.
3034874|NCT02329249|Experimental|Smokefree Partners: 21 Days to Freedom|Smoking cessation website program with live personal coach
3034875|NCT02329249|Other|Wait-list control|120-day wait-list and then provided access to the smoking cessation website
3034876|NCT02329236||children with constitutional growth delay|
3034877|NCT02329236||children with Familial short stature|
3034878|NCT02329223|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 12 week treatment period.
3034879|NCT02329223|Experimental|Omalizumab 150 mg|Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 12 week treatment period.
3034880|NCT02329223|Placebo Comparator|Placebo|Participants will receive placebo subcutaneously every 4 weeks during the 12 week treatment period.
3034881|NCT02329197|Experimental|Group A|women undergoing IVF treatment will be subjected for intrauterine injection of 10 IU of human chorionic gonadotropin (HCG) (diluted in 0.025ml of tissue culture), 10 minutes before embryo transfer procedure.
3034882|NCT02329197|No Intervention|Group B|women undergoing IVF treatment will embryo transfer procedure performed in the standard way without intrauterine injection of HCG.
3034883|NCT02329184|Experimental|MYK-461|
3034884|NCT02329171|Experimental|Imiquimod treatment arm|Patients in this group will be treated with imiquimod during 16 weeks. Colposcopy with diagnostic biopsies will be performed after 10 weeks. In case of progressive disease, the treatment will be ended and appropriate surgical excision will be performed. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies.
3034885|NCT02329171|Active Comparator|Standard treatment arm|Large loop excision of the transformation zone (LLETZ) will be performed in this group, as standard treatment.
3034886|NCT02329158||Arm: Exposed: Hydroxyethyl starch|Cardiac surgical patients exposed to 6% hydroxyethyl starch (130/0.4).
3034887|NCT02329158||Arm: Unexposed: Hydroxyethyl starch|Cardiac surgical patients not exposed to 6% hydroxyethyl starch (130/0.4).
3034888|NCT02329145|Experimental|Active treatment|Renal denervation
3034889|NCT02329145|No Intervention|Observational|
3034890|NCT02329119|Experimental|G1-SCZ|patients with schizophrenia as defined in DSM IV-TR
3034891|NCT02329119|Active Comparator|G2-TAB|patients with bipolar affective disorder (BD) type I as defined by the DSM IV-TR
3034892|NCT02329106|Experimental|NanoKnife LEDC System|Ablation with the NanoKnife Low Energy Direct Current (LEDC) System, alao called Irreversible electroporation (IRE), 90 pulses of 70 microseconds each in duration will be administered per electrode pair.
3034893|NCT02329093|Experimental|Bone Signal Changes|
3034894|NCT02329080|Experimental|MATRIX - R-ICE - Conditioning and ASCT|"MATRIX (courses 1,2,3): Rituximab 375 mg/m2 d0/Methotrexate 3.5 g/m2 d1/Cytarabine 2 g/m2 d2 & d3/Thiotepa 30 mg/m2 d4/Liposomial Cytarabine 50 mg* d5~R-ICE (courses 4,5,6):Rituximab 375 mg/m2 d1/Etoposide 100 mg/m2 d1,d2, d3/Ifosfamide 5 g/m2 d2/Carboplatin 5 AUC d2/Liposomial Cytarabine 50 mg* d4~*If liposomal cytarabine is not available, standard intrathecal chemotherapy with methotrexate 10 mg + cytarabine 40 mg + hydrocortisone 50 mg can be administered. Oral steroids are suggested for 2-3 days after intrathecal liposomial cytarabine delivery to prevent chemical or aseptic meningitis/ arachnoiditis.~Conditioning and ASCT: BCNU (carmustine)** 400 mg/m2 d-6/Thiotepa 5 mg/kg d-5 & d-4 ASCT: 5 x 106 CD34+cells/kg d0~**In case of BCNU unavailability, the recommended conditioning regimen (Phase IV) is: Thiotepa 5 mg/kg d-6 & d-5/Busulfan 3.2 mg/kg d-4,d -3,d-2/Clonazepam 2 mg/d d-4,d -3,d-2 ASCT: 5 x 106 CD34+cells/kg d0"
3034895|NCT02329067|Experimental|walnut-CH|Western type diet including walnuts (43g/day); Walnuts substitute carbohydrates
3034896|NCT02329067|Experimental|Walnut-SFA|Western type diet including walnuts (43g/day); Walnuts substitute saturated fatty acids
3034897|NCT02329067|Experimental|Walnut-LIB|Western type diet including walnuts (43g/day); no specific recommendation
3034898|NCT02329067|No Intervention|Control|Isocaloric western type diet w/o nuts, nut butters or nut oils of any kind
3034899|NCT02329054|Experimental|Favipiravir|Favipiravir (oral administration, 200 mg light yellow, round-shaped, coated divisible tablets that can be crushed and mixed with liquid)
3034900|NCT02329041|Experimental|McGrath Series 5|DLT intubation with McGrath Series 5 videolaryngoscope
3034901|NCT02329041|Active Comparator|Airtraq|DLT intubation with Airtraq videolaryngoscope
3034902|NCT02329028||Prehospital mini-EEG|Feasibility of prehospital EEG device in unconscious patients.
3034903|NCT02329015|Experimental|Health and Wellness program|Behavioral intervention
3034904|NCT02329015|Active Comparator|Physical Education Class|Behavioral intervention
3034905|NCT02328989|Experimental|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
3034906|NCT02328989|No Intervention|No pessary|No pessary will be placed in the vagina.
3034907|NCT02328976|Experimental|chronic migraineurs|functional Magnetic Resonance Imaging (fMRI) analysis to compare connectivity of hypothalamus
3034908|NCT02328976|Experimental|Episodic migraineurs|functional Magnetic Resonance Imaging (fMRI) analysis to compare connectivity of hypothalamus
3060379|NCT02158780|Other|Inguinal Orchidopexy|Double Incision (Standard)
3034911|NCT02328937|Active Comparator|etafilcon A/lotrafilcon B/comfilcon A|Subjects that were randomized to receive the etafilcon A lens 1st, the lotrafilcon B lens 2nd and the comfilcon A lens 3rd.
3034912|NCT02328937|Active Comparator|etafilcon A/comfilcon A/lotrafilcon B|Subjects that were randomized to receive the etafilcon A lens 1st, the comfilcon A lens 2nd and the lotrafilcon B lens 3rd.
3034913|NCT02328937|Active Comparator|comfilcon A/etafilcon A/lotrafilcon B|Subjects that were randomized to receive the comfilcon A lens 1st, the etafilcon A lens 2nd and the lotrafilcon B lens 3rd.
3034914|NCT02328937|Active Comparator|comfilcon A/lotrafilcon B/etafilcon A|Subjects that were randomized to receive the comfilcon A lens 1st, the lotrafilcon B lens 2nd and the etafilcon A lens 3rd.
3034915|NCT02328937|Active Comparator|lotrafilcon B/etafilcon A/comfilcon A|Subjects that were randomized to receive the lotrafilcon B lens 1st, the etafilcon A lens 2nd and the comfilcon A lens 3rd.
3034916|NCT02328937|Active Comparator|lotrafilcon B/comfilcon A/etafilcon A|Subjects that were randomized to receive the lotrafilcon B lens 1st, the comfilcon A lens 2nd and the etafilcon A lens 3rd.
3034917|NCT02328924|Other|LH value in fixed group|LH value predictive of IVF in 104 patients entered in fixed protocol
3034918|NCT02328924|Other|LH value in flexible group|LH value predictive of IVF in 109 patients entered in flexible protocols
3034919|NCT02328911|Experimental|Laser treatment|Twice-per-week laser treatment for 4 weeks and once-per-week laser treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
3034920|NCT02328911|Sham Comparator|Sham treatment|Twice-per-week sham treatment for 4 weeks and once-per-week sham treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
3034921|NCT02328898|Experimental|Cre8 stent|PCI with the Polymer Free Amphilimus Eluting Stent 'Cre8™'
3034922|NCT02328898|Active Comparator|Resolute Integrity Stent|Comparison of the Cre8 stent with the Permanent Polymer Zotarolimus Eluting Stent 'Resolute Integrity™'
3034923|NCT02328885|Experimental|Experimental|DLI of the 20 fraction of the UCBT
3034924|NCT02328872|Experimental|Intervention (HPV Arm)|"Molecular testing for HPV with partial genotyping for types 16/18, with referral of the HPV16/18-positive group for diagnostic evaluation, and secondary randomisation of women testing positive for other oncogenic HPV infection (not 16/18), to either image-read cytology screening or dual-stained (DS) cytology testing with p16/Ki67 - the HPV arm. Screening performed 5 yearly."
3034925|NCT02328872|Active Comparator|Control (LBC Arm)|"Image-read liquid based cytology (LBC) screening with reflex HPV triage testing for low grade smears, the LBC arm. Screening performed 2.5 yearly."
3034926|NCT02328859|Experimental|Virtual reality gait rehabilitation|Subjects will be trained using a custom treadmill with a virtual environment
3034927|NCT02328859|Active Comparator|Treadmill training gait rehabilitation|Subjects wil be trained using a standard treadmill without any visual display
3034928|NCT02328833|Experimental|Active Implementation of Guidelines|Primary Care Centers where the experimental strategies of guidelines implementation will be done
3034929|NCT02328833|No Intervention|No Active Implementation of Guidelines|Primary Care Centers where the experimental strategies of guidelines implementation not will be done
3034930|NCT02328820|Other|All patients|All lesions undergo simultaneous assessment with a combined pressure and flow sensor
3034931|NCT02328807|Experimental|Radio-Frequency Ablation (RFA)|Focal Prostate Radio-Frequency Ablation (RFA). Focal bipolar RFA followed by clinical follow-up visits at 6 weeks, 3 months and 6 months.
3034932|NCT02328794|Active Comparator|Control|Participants randomized to this arm will receive a standardized Vitality program aimed at promoting tobacco cessation. This program includes existing employee benefits for quitting and the use of text/email messages to encourage tobacco cessation. No incentives will be given to participants randomized to this arm. Free cessation aids will not be available to participants in this arm. They will receive compensation for completing study related activities (sample submissions).
3034933|NCT02328794|Experimental|E-cigarette free access|Participants randomized to this experimental arm will receive the standardized program including text/email messaging and will have access to free e-cigarettes only. These products can be ordered directly, free of charge, through the web-based interface. No incentives will be given to participants randomized to this arm. They will receive compensation for completing study related activities (sample submissions).
3034934|NCT02328794|Experimental|E-cigarette/NRT/Zyban/Chantix Choice|Participants randomized to this experimental arm will receive the standardized program including text/email messaging and will have access to free e-cigarettes, conventional Nicotine Replacement Therapy (NRT), Zyban, or Chantix. Each of these can be ordered directly, free of charge, through the web-based interface. No incentives will be given to participants randomized to this arm. They will receive compensation for completing study related activities (sample submissions).
3034935|NCT02328794|Experimental|Outcome Incentive arm|Participants randomized to this experimental arm will receive the standardized program and access to free e-cigarettes, NRT, Zyban, or Chantix. In addition, they will also be able to earn incentives across six months for testing negative for tobacco use (see Incentive payout, below). They will also receive compensation for completing study related activities (sample submissions).
3034936|NCT02328794|Experimental|Loss framing incentive arm|Participants randomized to this experimental arm will receive the standardized program and access to free e-cigarettes, NRT, Zyban, or Chantix. In addition they will also be able to earnincentives across six months through a pre-funded deposit or precommitment account. They will be notified that money has been placed into an account for them. At each time point they will lose a portion (see below) of this initial funding if they do not provide biochemical evidence of abstinence. They will also receive compensation for completing study related activities (sample submissions).
3034937|NCT02328781|Experimental|Experimental|Drug-eluting stent
3034938|NCT02328768|Experimental|Omegaven®|Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 8-24 hours every day until the patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
3034939|NCT02328755|Experimental|peg-IFN-α|"peg-IFN-α will be administered prior to HCT (Hematopoietic Cell Transplant) and at three subsequent time points post HCT. (Maximum of 4 doses) It will be administered by subcutaneous injection every 14 days beginning with dose level 1.~Dose Level -1 - 45mcg Dose Level 1 - 90mcg Dose Level 2 - 180 mcg"
3035150|NCT02327247|Active Comparator|Reference|Plendil® Extended release tablets 10 mg
3034940|NCT02328742||No intracavitary pathology|"During the first diagnostic hysteroscopy, patients in this group are found to not have an intracavitary pathology. (The first 20 such patients will be retained in this group.)~Intervention: Hysteroscopy + endometrial biopsy~Intervention: Telephone call"
3034941|NCT02328742||Synechia|"During the first diagnostic hysteroscopy, patients in this group are found to have synechia.~Intervention: Hysteroscopy + endometrial biopsy~Intervention: Resection + endometrial biopsy~Intervention: Follow-up hysteroscopy + endometrial biopsy~Intervention: Telephone call"
3034942|NCT02328742||Intracavitary pathology|"During the first diagnostic hysteroscopy, patients in this group are found to have an intracavitary pathology.~Intervention: Hysteroscopy + endometrial biopsy~Intervention: Resection + endometrial biopsy~Intervention: Follow-up hysteroscopy + endometrial biopsy~Intervention: Telephone call"
3034943|NCT02328729||Mandibular block with Epinephrine|Lidocaine 2% with 1:100,000 Epinephrine
3034944|NCT02328729||C-CLAD-IL with Epinephrine|Lidocaine 2% and 1:100,000 Epinephrine
3034945|NCT02328729||Infiltration with Epinephrine|Lidocaine 2% and 1:100,000 Epinephrine
3034946|NCT02328729||Mandibular block without Epinephrine|Mepivacain HCl 3% without Epinephrine
3034947|NCT02328729||Infiltration without Epinephrine|Mepivacain 3% without Epinephrine
3034948|NCT02328729||CCLAD-IL without Epinephrine|Mepivacain HCl 3% without Epinephrine
3034949|NCT02328716|Active Comparator|Comparator|Comparator
3034950|NCT02328716|Experimental|Experimental|Experimental
3034951|NCT02328703|Experimental|Reiki Therapy by a Reiki Master|The Reiki Master will take approximately 30 minutes to perform a hand placement sequence that will allow the direction of energy toward the site of pain.
3034952|NCT02328703|Placebo Comparator|Sham Reiki Therapy by a Clinician|The Clinician, who has not trained in Reiki, will mimic the same 30 minute hand placement protocol as the Reiki Master.
3034953|NCT02328690|Experimental|Music with BBT|Music embedded with special tones.
3034954|NCT02328690|Placebo Comparator|Music without BBT|Music not embedded with special tones.
3034955|NCT02328677||ColoCare FHCRC|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status June 2017: n= 389
3034956|NCT02328677||ColoCare Moffitt (affiliated cohort)|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status June 2017: n=508
3034957|NCT02328677||University Hospital Heidelberg|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status June 2017: n=590
3034958|NCT02328677||ColoCare Huntsman Cancer Institute|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status June 2017: n=96
3034959|NCT02328677||Cedars-Sinai Medical Center|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status June 2017: n=40
3034960|NCT02328677||University of Washington St. Louis|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status June 2017: n=4
3034961|NCT02328677||University of Tennessee|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status June 2017: n=20
3034962|NCT02328664|Other|Flexible sigmoidoscopy or colonoscopy|Subjects will undergo these investigation to take biopsies from the polypectomy scar.
3034963|NCT02328651|Experimental|Ribavirin treatment plus testing drug|
3034964|NCT02328651|Active Comparator|Ribavirin treatment|
3034965|NCT02328638|Active Comparator|Manual-based Behavioral Treatment|up to 16 weekly behavioral therapy sessions (intervention) following the CHANGE obesity manual, lasting approximately 45 minutes and nutritional therapy sessions, lasting approximately 30 to 60 minutes.
3034966|NCT02328638|Placebo Comparator|Parent Education Program|up to 16 weekly behavioral therapy sessions following the parent education program
3034967|NCT02328612|Experimental|First arm|250,000 cells/kg will be administered via intravenous infusion.
3034968|NCT02328612|Experimental|Second arm|1,000,000 cells/kg will be administered via intravenous infusion.
3034969|NCT02328612|Experimental|Third arm|4,000,000 cells/kg will be administered via intravenous infusion.
3034970|NCT02328612|Placebo Comparator|Fourth arm|Placebo (Ringer's lactate solution) volume according to subject's weight.
3034971|NCT02328599||Surgical|Prior Bariatric surgery
3034972|NCT02328599||Non-surgical|Medical / Lifestyle management
3034973|NCT02328586|Experimental|Group Acupuncture|Participants will then be invited to participate in an 8-week, group-based acupuncture treatment intervention delivered by a licensed acupuncturist. The group will meet weekly for 8 consecutive weeks, each session lasting about 75 minutes.
3034974|NCT02328573|Experimental|Communal singing|Participants in the study group will join the choir and participate in a weekly hour rehearsal for six months and will be assessed for aphasia, mood, and quality of life outcomes
3034975|NCT02328573|No Intervention|Control|The control group will not participate in the choir for the first six months. At the end of the six months study period, all participants will be evaluated again for changes in aphasia, language, mood and quality of life
3034976|NCT02328560||Paramedical ad consultation|Monitoring will be the same in the 2 groups; That paramedical consultation announcement is made in current practice.
3034977|NCT02328560||No paramedical ad consultation|Monitoring will be the same in the 2 groups
3034978|NCT02328547|Experimental|FMT capsules|Intervention: Fecal microbiota transplantation capsules containing extensively screened donor stool, prepared by OpenBiome, Medford, MA. 25 FMT capsules will be take on three consecutive days.
3034979|NCT02328547|Placebo Comparator|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug, prepared by OpenBiome, Medford, MA. 25 placebo capsules will be taken on three consecutive days.
3034980|NCT02328534||Density Gradient semen|"ICSI Cases processed using DG semen processing and evaluated by~Blastocyst Formation Rate Blastocyst Rate Pregnancy Rate"
3034981|NCT02328534||Swimming down semen|"ICSI Cases processed using SD semen processing and evaluated by~Blastocyst Formation Rate Blastocyst Rate Pregnancy Rate"
3034982|NCT02328521|Experimental|Nicorandil group|Drug: Nicorandil (Chugai Pharmaceutical Co, Japan). The first dose is given 8h before selective percutaneous coronary intervention, 10mg, oral. After the percutaneous coronary intervention, nicorandil is given for 30 days, 5mg each time, 3 times daily oral.
3034983|NCT02328521|Placebo Comparator|Control group|Drug: Nicorandil placebo (Sihuan Pharmaceutical Co, China). The first dose is given 8h before selective percutaneous coronary intervention, 2 tablets, oral. After the percutaneous coronary intervention, placebo is given for 30 days, 1 tablet each time, 3 times daily oral.
3034984|NCT02328508|Experimental|hyperbaric oxygen therapy|The experimental group received treatments in a hyperbaric chamber for 120-min per session, once per day, and five days per week for four consecutive weeks (20 treatment sessions).
3034985|NCT02328508|No Intervention|Control|The control group received only routine care.
3034986|NCT02328495|Active Comparator|Misoprostol|Misoprostol (400µg) is administered vaginally 12 hours before office hysteroscopy
3034987|NCT02328495|Active Comparator|bladder Filling|Uterine straightening by bladder filling before office hysteroscopy
3034988|NCT02328482|Experimental|Arm 1|Cabaletta 30 g for IV infusion administered every week over an additional 52 weeks
3034989|NCT02328482|No Intervention|Arm 2|no-treatment concurrent control; follow-up over 52 weeks
3034990|NCT02328469||unidentified aseptic meningitis|Patients with etiologically unidentified aseptic meningitis will be treated with symptomatic therapy and will be asked to complete a questionnaire.
3034991|NCT02328469||tick-borne encephalitis|Patient with aseptic meningitis in whom serological diagnosis of tick-borne encephalitis will be established. Patients will be treated with symptomatic therapy and will be asked to complete a questionnaire.
3034992|NCT02328469||Lyme neuroborreliosis|Patients with acute aseptic meningitis in whom Lyme neuroborreliosis will be proven or suspected according to microbiological criteria. Patients will be treated with antibiotic therapy (ceftriaxone or doxycycline) and will be asked to complete a questionnaire.
3034993|NCT02328469||healthy controls|Patients will be asked to refer a spouse to serve as a control . If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control.
3034994|NCT02328469||identified aseptic meningitis|Patients with microbiologically identified cause of acute aseptic meningitis/meningoencephalitis will receive symptomatic therapy. If the identified causative agent will be Herpes Simplex Virus or Varicella Zoster Virus, patients will be treated with acyclovir and will be asked to complete a questionnaire.
3034995|NCT02328456|Other|SMS and free eye drops group|the patient after trabeculectomy surgery in the SMS associated with free eye drops group will receive free eye drops and a SMS reminder message about the revisit time.
3034996|NCT02328456|No Intervention|the control group|the patient after trabeculectomy surgery in the control group won't get any free eye drop and reminder message before the appointment.
3034997|NCT02328443|Experimental|midazolam alone|midazolam administration alone
3034998|NCT02328443|Experimental|midazolam and itraconazole|Itraconazole 200 mg PO twice; midazolam iv single administration
3034999|NCT02328443|Experimental|midazolam and rifampicin|rifampicin 150 mg PO for 9 days administration, midazolam iv single administration
3035000|NCT02328417||Control|Consecutive radical cystectomies up to 94 patients in 13 participating hospitals in Madrid, Spain. These patients will be taken care of as it is done regularly in each of participating hospitals. All study variables will be prospectively collected in this group
3035001|NCT02328417||Active Treatment|"After recruiting cotrol group, another consecutive radical cystectomies up to 94 patients in 13 participating hospitals will be recruited and the following measures will be followed with them:~I.-PREOPERATIVE MEASURES: (eight measures according to Protocol) II.- INTRAOPERATIVE MEASURES: (six measures according to Protocol) III.- POSTOPERATIVE MEASURES: (eight measures according to Protocol)"
3035002|NCT02328404|Active Comparator|vitamin D3 (Biodal 50,000 IU)|50,000 IU Vitamin D3 tablet given orally once weekly for 3 months
3035003|NCT02328404|Placebo Comparator|placebo|Placebo tablet given orally once weekly for 3 months
3035004|NCT02328378|Active Comparator|Quadratus Lumborum block group (QL)|patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
3035005|NCT02328378|Placebo Comparator|Control Group|patients will receive a bilateral placebo block
3035006|NCT02328365|No Intervention|Standard|Patients screened positive for cardiopulmonary disease and having a medical (pulmonary and/or cardiology) visit preoperatively, but randomized to standard follow-up
3035007|NCT02328365|Experimental|Intervention|Patients screened positive for cardiopulmonary disease and having a medical (pulmonary and/or cardiology) visit preoperatively, but randomized to structured medical follow-up after operation
3035008|NCT02328352|Experimental|BP selfstanding felt|"laparotomy intervention with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.~V-Loc 180 (ref VLOCL0024, lot. A1D0899)"
3035009|NCT02328352|Active Comparator|PP mesh|"intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PP mesh was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia.~Other names: V-Loc 180 (ref VLOCL0024, lot. A1D0899) PR Parietene mesh Tyco (ref. PP3030, lot. SIK00587)"
3035010|NCT02328352|Experimental|BP intraperitoneal mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply for entering into the abdominal cavity. In five rabbits (BPR21-BPR25). A 2x2cm2 BP intraperitoneal mesh was then be inserted with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut.
3035011|NCT02328352|Active Comparator|control group|Five rabbits (R26-R30) will be used as control group.
3035012|NCT02328339|Experimental|Black tea|Approximately 400 mg total polyphenols in 240 ml hot water (loading dose; 2 hours before the start of measurements; t=0) and 130 mg total polyphenols in 120 ml hot water (maintenance dose just before start of the measurements; t=120 min)
3035151|NCT02327234|Experimental|Ibuprofen|400mg (2X200mg) ibuprofen single dose once
3035013|NCT02328339|Placebo Comparator|Placebo|Caramel colour, maltodextrin and tea flavour in 240 ml hot water (2 hours before the start of measurements; t=0) and 120 ml hot water (maintenance dose just before start of the measurements; t=120 min)
3035014|NCT02328326|Experimental|CO-IMPACT|patient and supporter (dyad) receive one coaching session on action planning, communicating with providers, navigation skills and support skills; preparation by phone before patients? primary care visits; after-visit summaries by mail; and biweekly automated phone calls to prompt action on new patient health concerns
3035015|NCT02328326|Active Comparator|PACT|patient and their health supporter (dyad) will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
3035016|NCT02328313|Experimental|Intervention Cohort|Breast cancer patients 65 and older undergoing chemotherapy and participating in a home-based physical activity intervention.
3035017|NCT02328300||FLT PET/MR|"All participants will have known brain lesion in the central nervous system (CNS) scheduled to have surgical biopsy of the lesion, identified by the UNC Brain Tumor Board and will have the clinical question of radiation necrosis vs. recurrence.~All participants will receive a FLT PET/MR scan."
3035018|NCT02328287|Experimental|ALLOB® Implantation|
3035019|NCT02328261|Experimental|Icotinib|Icotinib (125 mg tablet) is orally administered three times daily
3035020|NCT02328248|Experimental|Biological patch|Use biological patch (Biodesign Surgisis Tissue Graft from Cook Biotech Incorporated) to repair hiatal hernia laparoscopically
3035021|NCT02328248|Placebo Comparator|Plastic patch|Use plastic patch (Parietex Composite from Sofradim Production) to repair hiatal hernia laparoscopically
3035022|NCT02328235|Experimental|High Saturated Fat Diet|Subjects will receive a high fat diet for 5 day following a 2 week lead in diet. Measurements will be made pre-post high fat diet
3035023|NCT02328222|No Intervention|CONTROL GROUP|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
3035024|NCT02328222|Experimental|ESW group|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
3035025|NCT02328209|Experimental|ranibizumab|ranibizumab
3035026|NCT02328183|Experimental|Polymyxin B|Polymyxin B 1.5-2.5 mg/kg/day intravenous q 12 hrs duration 7-14 days
3035027|NCT02328170||EUROIMMUN Allergy|Immunoblot assay
3035028|NCT02328170||ImmunoCap|Fluoroallergosorbent test
3035029|NCT02328157|Experimental|Cataract with ERM and astigmatism|Eyes that have cataract and ERM with a preoperative corneal cylinder of more than 0.75 diopter.
3035030|NCT02328144|Active Comparator|Metronidazole|22 patients received oral metronidazole 500mg 3 times for day for 7 days
3035031|NCT02328144|Placebo Comparator|Placebo|22 patients received oral placebo 500mg 3 times for day for 7 days
3035032|NCT02328118|Experimental|Ranibizumab 0.5 mg|All subjects in this group will receive Ranibizumab (0.5mg/0.05ml) intravitreal injection.
3035033|NCT02328118|Experimental|Triamcinolone Acetonide 4mg|All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
3035034|NCT02328105|Experimental|Carboplatin + Abraxane|Carboplatin (AUC = 6; on Day 1) plus Abraxane (nab-paclitaxel; 100 mg/m^2; Days 1, 8, 15) for 6 21-day cycles. Treatment was discontinued if: disease progression, unacceptable toxicity, withdrawn consent, or completion of treatment
3035035|NCT02328092|Active Comparator|Real group|The real group received biphasic rSMS using a Magstim Super Rapid (Magstim, Whitland, UK) stimulator connected to a 120-mm outer diameter figure-of-8 air film cooling coil positioned in the midline over the sacral vertebrae (approximately 5 cm above the natal cleft, which approximates to the level of S2). Stimulation was delivered at 15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upward. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off.
3035036|NCT02328092|Sham Comparator|Sham Group|The control group received sham rSMS stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
3035037|NCT02328079|Active Comparator|First group|prednisolone 60 mg /day IM /IV for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days)
3035038|NCT02328079|Active Comparator|Second group|Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days)
3035039|NCT02328066|Experimental|NBI used by trained endoscopists|Assessment with NICE classification and NBI technology of colonic lesions (Paris classification type 0) greater than 1 cm found in a routine colonoscopy. This assessment was performed by previously trained endoscopists.
3035040|NCT02328053|Experimental|Collagen crosslinking group|patients not resolving to standard antifungal therapy were assigned to receive adjuvant collagen crosslinking with riboflavin and Ultraviolet-A along with topical medical therapy
3035041|NCT02328053|Active Comparator|standard medical therapy|patients were continued on topical antifungal therapy namely Natamycin eye drops and voriconazole eye drops
3035042|NCT02328040|Placebo Comparator|Part A|Placebo and Insulin monotherapy via CL
3035043|NCT02328040|Active Comparator|Part B|Sitagliptin and insulin/novolog via CL
3035044|NCT02328027|Experimental|99mTc-rhAnnexin V-128, i.v.|Patients will receive 2 administrations of the 99mTc-rhAnnexin V-128 medical imaging agent: one at Day 1 and the other at Day 42.
3035045|NCT02328014|Experimental|Dose Escalation|The ACP-196 dose will be fixed and the ACP 319 dose will be escalated in each cohort.
3035046|NCT02328014|Experimental|Expansion|Will commence once the safety and efficacy results from the dose escalation cohorts of the study indicate further evaluation of the combination is warranted.
3035047|NCT02328001|No Intervention|Pre-intervention phase/phase 1|No intervention will be applied in phase 1
3035048|NCT02328001|Other|Post-intervention phase/phase 2|Intervention will be applied in phase 2 i.e; Debriefing endoscopists of the procedure accessory costs and pathology specimen costs
3035152|NCT02327234|Placebo Comparator|Placebo|identical appearing lactose capsules single dose 2 capsules once
3035049|NCT02327988|Experimental|Cryotherapy|To the cryotherapy group a 1kg ice pack was strapped over the entire brachial biceps muscle and adjacent muscles of the arm under study using a bandage, and the application lasted 25 minute laser
3035050|NCT02327988|Experimental|Laser therapy|The laser therapy group received laser application to the muscle belly of the non-dominant upper limb brachial biceps at four different points.
3035051|NCT02327988|No Intervention|Control|The control group did not undergo any intervention and remained at rest for 25 minutes.
3035052|NCT02327975|Experimental|Training group|Participants in this group received twice-weekly non-consecutive sessions of physical exercise for 10 weeks. Each session lasted approximately 60-70 minutes. Exercise program consisted of strength training and aerobic exercise. Each session began with a warm low intensity (10 min), then the main part of the session (25 min) and aerobic training and recovery period (25-35 min) was performed. The equipment used during the procedure was the Thera-Band elastic band.
3035053|NCT02327975|Experimental|Mobile group|Intervention content was the same in both intervention arms; only the delivery mode differed. Participants in this group received two podcast (digital multimedia file available for download in a media player) per week for 10 weeks of the intervention, each podcast lasted about 5 min. Participants in this group received a weekly message with the aim of fostering motivation toward physical activity. Subjects in this group performed two sessions per week on non-consecutive days, the days could be chosen by the participants themselves.
3035054|NCT02327975|Other|Control group|No received intervention.
3035055|NCT02327962||Hemodialysis|Hemodynamic measurements with PWV
3035056|NCT02327962||Control|Hemodynamic measurements with PWV
3035057|NCT02327949|Experimental|WP group|WP group:treated with W-Shaped Angular Plate
3035058|NCT02327949|Active Comparator|RP group|RP group:treated with Reconstruction Plate
3035059|NCT02327936|Experimental|Fesoterodine 4mg|Fesoterodine 4 mg Po Die, dose could be increased to 8mg Po Die after 4 weeks, for a total of 8 weeks
3035060|NCT02327936|Active Comparator|Oxybutynin XL 10mg|Oxybutynin XL 10 mg Po Die, dose could be increased to 20 mg Po Die after 4 weeks, for a total of 8 weeks
3035061|NCT02327923|Active Comparator|Lidocaine|Intravenous bolus administration of lidocaine at the time of induction followed by infusion till the last suture.
3035062|NCT02327923|Active Comparator|Esmolol|Intravenous bolus administration of esmolol at the time of induction followed by infusion till the last suture.
3035063|NCT02327910|No Intervention|Conventional group|Conventional group:The patients of conventional group were extubated when standard criteria were met;
3035064|NCT02327910|Experimental|TOF group|TOF group: patients had a TOF ratio of greater than 0.90 as an additional extubation criterion;
3035065|NCT02327910|Experimental|TOF unit TcPCO2 group|Qualitative TOF and transcutaneous partial pressure of carbon dioxide monitoring(Unite group):the patients of U group were extubated when TOF ratio greater than 0.9 and TcPCO2 recovery to preoprative(±5mmHg)
3035066|NCT02327871|Experimental|Esophageal cooling|Specific treatment: The placement of the ECD will follow standard recommendations as per Instructions for Use. The ECD will be connected to the Gaymar console (Meditherm III, Gamida, France). In our institution, TH is performed in all patients resuscitated from an OHCA except those presenting exclusion criteria. TH can be initiated as soon as possible by administration of cold saline at 4°C if necessary followed by application of the available cooling device (blankets, endovascular methods, etc) aiming a target temperature of 32-34°C for 24 hours as recommended. 8-11,13 For all enrolled patient, the ECD will hereby replace the other cooling device usually used in our ICU.
3035067|NCT02327858|Experimental|Supportive text message group|Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months .
3035068|NCT02327858|No Intervention|No supportive text message group|Patients in the control group will only receive a text message once every two weeks thanking them for participating in the study. The aim of this will be to help increase the retention rate for the study.
3035069|NCT02327845||Affected|Affected with any of the diseases that are the focus of study by the CReATe Consortium, including ALS, ALS-FTD, HSP, PLS, PMA and MSP.
3035070|NCT02327845||Unaffected|Unaffected family members of enrolled affected individuals.
3035071|NCT02327832|Experimental|Autologous BMSCs|Infusion of cultured autologous bone marrow derived mesenchymal stem cells
3035072|NCT02327819|Active Comparator|BCAA supplement|Branched-chain amino acids supplement, 12 g/day
3035073|NCT02327819|Sham Comparator|non-BCAA protein supplement|non-BCAA protein supplement
3035074|NCT02327806|Other|10 minutes of pulsed electromagnetic field therapy|10 minutes of pulsed electromagnetic field therapy
3035075|NCT02327806|Other|20 minutes of pulsed electromagnetic field therapy|20 minutes of pulsed electromagnetic field therapy
3035076|NCT02327806|Other|30 minutes of pulsed electromagnetic field therapy|30 minutes of pulsed electromagnetic field therapy
3035077|NCT02327793|No Intervention|Mean Arterial Pressure <100 mmHg|Patients with mean arterial pressure <100 mmHg at the time of the perfusion weighted magnetic resonance imaging will not be treated. After 15 minutes of the baseline perfusion imaging a repeat perfusion weighted magnetic resonance imaging would be performed.
3035078|NCT02327793|Experimental|Mean Arterial Pressure 100-120 mmHg|Patients with mean arterial pressure between 100-120 mmHg at the time of the perfusion weighted magnetic resonance imaging will be treated with sublingual 0.3 mg nitroglycerin. A repeat blood pressure would be assessed at 5min, 10min, 15min and 20 min of nitroglycerin administration. After a sustained drop of blood pressure (>10% of the baseline reading) as defined by two reading 5minutes apart, a perfusion weighted magnetic resonance imaging will be performed.
3035079|NCT02327793|Experimental|Mean Arterial Pressure >120 mmHg|Patients with mean arterial pressure >120 mmHg at the time of the perfusion weighted magnetic resonance imaging will be treated with intravenous 10-20mg labetalol injection. A repeat blood pressure would be assessed at 5min, 10min, 15min and 20 min of labetalol injection. After a sustained drop in blood pressure (>10% of the baseline reading) as defined by two reading 5minutes apart, a perfusion weighted magnetic resonance imaging will be performed.
3035080|NCT02327780|Other|FODMAP diet|participants will be put on a low FODMAP diet.
3035112|NCT02327507||Toothpaste & Telephone Support|A tool kit with toothpaste and toothbrushes for the whole family along with oral hygiene instructions in both English and Spanish will be mailed to the homes of all OHP children and adolescents every three months. Half the populations will be assigned to also receive telephone support.
3035081|NCT02327767|Experimental|Resonating Arm Exerciser|The treatment group will participate in supervised Resonating Arm Exerciser (RAE) group sessions of 45 minutes, three times a week, for a total of eight sessions for three consecutive weeks. During each treatment session, the affected upper extremity will be used to push on the lever of the RAE in the sagittal plane. Upon pushing and pulling on the lever, the wheelchair moves a total of 20 cm from a neutral position, which indicated a repetition counted by a programed iphone.
3035082|NCT02327767|No Intervention|Physical Therapy|The control group will continue with existing physical therapy treatment of passive range of motion (PROM) and therapeutic exercise to their involved upper extremity by the physical therapist.
3035083|NCT02327754|Active Comparator|Active comparator|Topiroxostat, (Oral daily dosing for 28 weeks)
3035084|NCT02327754|Placebo Comparator|Placebo comparator|Placebo, (Oral daily dosing for 28 weeks)
3035085|NCT02327741|Experimental|plavix long term|taking plavix more than 12 months
3035086|NCT02327741|Active Comparator|plavix short term|taking plavix less than 12 months
3035087|NCT02327728|Experimental|medial lower eyelid waived|Botulinum toxin A 10U per eye subcutaneous injection at orbicularis oculi
3035088|NCT02327728|Active Comparator|full injection pattern|Botulinum toxin A 12.5U per eye subcutaneous injection at orbicularis oculi
3035089|NCT02327715|Experimental|Chinese naive pregnant HBsAg positive patients|single group patients were enrolled to receive emtricitabine(200mg one time per day) till 24 weeks after dilivery,patients and followed up for 24 weeks.
3035090|NCT02327702|Experimental|Chinese naive pregnant chronice hepatitis B|Chinese naive pregnant chronice hepatitis B were enrolled to take emtricitabine (200 mg one time per day) till 48 weeks after delivery.
3035091|NCT02327689|Experimental|compensated HBV related cirrhosis patients|Chinese naive compensated HBV related cirrhosis patients were treated with generic emtricitabine capsule(200 mg one time per day) plus adefovir dipivoxil(10 mg one time per day) for 96 weeks
3035092|NCT02327689|Experimental|decompensated HBV related cirrhosis patients|Chinese naive decompensated HBV related cirrhosis patients were treated with generic emtricitabine capsule(200 mg one time per day) plus adefovir dipivoxil(10 mg one time per day) for 96 weeks
3035093|NCT02327676|Experimental|naive child CHB group|200 patients take generic emtricitabine capsule(200 mg one time per day) for 48 weeks
3035094|NCT02327663|Experimental|HBeAg positive CHB group|1000 patients take generic emtricitabine capsule(200 mg one time per day) for 96 weeks,and for patients who have HBV DNA > 500 copies/ml, adefovir dipivoxil were combined
3035095|NCT02327663|Experimental|HBeAg negativie CHB group|1000 patients take generic emtricitabine capsule(200 mg one time per day) for 96 weeks,and for patients who have HBV DNA > 500 copies/ml, adefovir dipivoxil were combined
3035096|NCT02327650||RA and OA|Every 2 or 3 months, plain radiograph, blood and urinary tests, and MRI are performed in the painful joints of RA.
3035097|NCT02327637|No Intervention|Bedrest|"Bedrest is a standard recommendation for patients with PPROM. Subjects randomized to this arm of the study will undergo the following:~Receive recommendation for bedrest (standard of care).~Have maternal mood and muscle strength evaluated on enrollment and after delivery (observational study procedure).~Wear a pedometer to measure activity when out of bed (observational study procedure)."
3035098|NCT02327637|Experimental|Moderate Activity|"Subjects randomized to this arm of the study will undergo the following:~Receive recommendation to ambulate 150 feet, twice per day (interventional study procedure). Prior to each session of ambulation, an ultrasound will be performed to ensure adequate amniotic fluid volume and appropriate fetal position, and a fetal heart rate tracing will be obtained to ensure that there is reassuring fetal status (observational study procedure). During each session of ambulation, the fetal heart rate tracing will be monitored continuously (observational study procedure).~Have maternal mood and muscle strength evaluated on enrollment and after delivery (observational study procedure).~Wear a pedometer to measure activity when out of bed (observational study procedure)."
3035099|NCT02327624|Active Comparator|Clopidogrel|The standard antiplatelet treatment for patients is pretreatment with aspirin and clopidogrel. In this trial patients will be randomised in clopidogrel orTicagrelor of two doses
3035100|NCT02327624|Experimental|Ticagrelor 60|Ticagrelor 60 is a new dosage to be tried in this trial.
3035101|NCT02327624|Experimental|Ticagrelor 90|Ticagrelor 90 is used following clopidogrel as maintenance therapy with aspirin 75 mg daily and clopidogrel 75 mg daily following PCI for at least 1 month.
3035102|NCT02327611|Experimental|Custodiol|Renal perfusion with Custodiol (cold crystalloid solution enriched with histidine-tryptophan-ketoglutarate).
3035103|NCT02327611|Active Comparator|enriched Ringer's lactate solution|Renal perfusion with cold Ringer's lactate solution enriched with methylprednisolone 125 mg /L and mannitol 12.5 g /L.
3035104|NCT02327585|Experimental|Executive function training|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of executive function training weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
3035105|NCT02327559|Experimental|Mind in Labor (MIL)|Mind in Labor: Working with Pain in Childbirth (MIL) is a 16-hour mindfulness-based childbirth education course. It is an abbreviated weekend workshop form of the 9-week Mindfulness-Based Childbirth and Parenting (MBCP) education program, which is a tailored form of Mindfulness-Based Stress Reduction.
3035106|NCT02327559|Active Comparator|Treatment As Usual (TAU)|Treatment As Usual (TAU) refers to standard hospital- and community-based childbirth preparation courses (high quality childbirth education that excludes a mindfulness or mind/body stress reduction focus).
3035107|NCT02327546|Experimental|AKB-6548|AKB-6548
3035108|NCT02327546|Experimental|AKB-6548 plus Ferrous Sulfate|AKB-6548 plus ferrous sulfate
3035109|NCT02327533||Patients with Aggressive Periodontitis|The periodontal diagnosis of subjects with GAgP was established on the basis of clinical and radiographic criteria and was defined by the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions.(Lang et al., 1999)
3035110|NCT02327533||Controls|Control subjects had no radiographic evidence of bone loss or any sign of past and present periodontitis.
3035111|NCT02327520||Colitis with CDI|Patients who diagnosed with CDI will be analysed
3035113|NCT02327507||Toothpaste only|A tool kit with toothpaste and toothbrushes for the whole family along with oral hygiene instructions will be mailed every three months
3035114|NCT02327481|Experimental|3D Laparoscopic Surgery|3D Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
3035115|NCT02327481|Active Comparator|2D Laparoscopic Surgery|2D Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
3035116|NCT02327455|Experimental|Stress Dobutamine Echocardiographic 4DE Image System|Subjects will undergo their clinically indicated stress dobutamine echocardiographic studies using our standard clinical graded dobutamine stress imaging protcol, employing the iE33 4DE system.
3035117|NCT02327442||Volunteers|Healthy Volunteers undergo whole-body 68Ga-NOTA-NFB PET/CT scans 0, 0.5, 1.0, 2.0, and 3.0 hours after tracer injection. During the imaging period, 1 mL blood samples are obtained specifically at 1, 3, 5, 10, 30,60, 90, 120, 150, and 180 minutes after the injection, for time-activity curve calculations.
3035118|NCT02327442||Glioma Patients|Glioma Patients enrolled for the clinical study of diagnosing glioma are performed with both 68Ga-NOTA-NFB PET/CT and18F-FDG PET/CT scans before surgery.
3035119|NCT02327442||Breast Cancer Patients|68Ga-NOTA-NFB PET/CT and 18F-FDG PET/CT scans will undergo in patients with breast cancer before and after neoadjuvant chemotherapy.
3035120|NCT02327429|Experimental|A Chinese menu plan for type 2 diabetes|All participants will be in the intervention arm for this pilot study
3035121|NCT02327416|Active Comparator|1,conventional control group|Drug: Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks. Entecavir 0.5mg po daily or plus ADV （adefovir dipivoxil）10mg po daily.
3035122|NCT02327416|Experimental|2，combination and sequential group|Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
3035123|NCT02327416|Experimental|3, multitarget group|Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Granulocyte-macrophage colony stimulating factor is used for 48 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
3035124|NCT02327403|Active Comparator|B7-1 positivity on kidney allograft biopsy|Belatacept conversion
3035125|NCT02327403|Active Comparator|B7-1 negativity on kidney allograft biopsy|Belatacept conversion
3035126|NCT02327390|Experimental|X-ACT lymph node cell dose and schedule|"All patients will begin at dose level 1 and will be moved to higher dosing levels as long as the patient does not experience two or more dose limiting toxicities and maintains an acceptable performance status. A minimum of three patients will be enrolled per dose level and no patients will be enrolled on higher dose levels if dose limiting toxicities are encountered.~Dose level 1: 0.5 x 10^10 X-ACT cells. 2 infusions 4 weeks apart~Dose level 2: 1.0 x 10^10 X-ACT cells. 1 infusion~Dose level 3: 0.5 x 10^10 X-ACT cells. 4 infusions 4 weeks apart~Dose level 4: 1.0 x 10^10 X-ACT cells. 2 infusions 4 weeks apart~Dose level -1: 0.5 x 10^10 X-ACT cells. 1 infusion (if necessary)"
3035127|NCT02327377|Experimental|Online Cognitive Behavior Therapy|Online cognitive behavior therapy for coping with pain
3035128|NCT02327377|Active Comparator|Online Education|Educational information about pain
3035129|NCT02327351|Experimental|TCR alfa beta depletion|TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.
3035130|NCT02327338|Experimental|continuous low level heat for neck|30 subjects to use ThermaCare heat wraps on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where heat wraps are not used.
3035131|NCT02327338|Experimental|Ibuprofen and continuous low level heat|30 subjects to use 1200 mg per day Ibuprofen dosed in 3 dosages 4 hours apart on the same days as heat wraps were to be used. ThermaCare heat wraps to be used on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where heat wraps and ibuprofen are not used.
3035132|NCT02327338|No Intervention|control|15 subjects with no heat or ibuprofen just physical therapy 2 times per week.
3035133|NCT02327338|Sham Comparator|sham heat and sham ibuprofen|30 subjects to use 1200 mg per day Ibuprofen sham dosed in 3 dosages 4 hours apart on the same days as sham heat wraps were to be used. ThermaCare heat sham wraps to be used on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where sham heat wraps andsham ibuprofen are not used.
3035134|NCT02327325|Experimental|Physical Activity Only|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
3035135|NCT02327325|Experimental|Physical Activity + Cognitive Behavioral Therapy|12-week combined home-based physical activity and cognitive behavioral program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive physical activity program including stretching, strengthening and aerobic activity. Cognitive behavioral component includes training in multiple skills for managing pain.
3035136|NCT02327325|No Intervention|Wait List Control Group|Will receive the physical activity only or physical activity + cognitive behavioral therapy (based on participant choice) after completing all follow-up assessments.
3035137|NCT02327312|Experimental|Surgical|Implantation of two Trabecular Meshwork stents into the study eye
3035138|NCT02327312|Active Comparator|Laser|Laser Trabeculoplasty
3035139|NCT02327299|Experimental|FePP|Bouillon fortified with 4mg FePP
3035140|NCT02327299|Experimental|FePP + Stabilizer|Bouillon fortified with 4mg FePP + Stabilizer
3035141|NCT02327299|Experimental|FeSO4|Bouillon fortified with 4mg FeSO4
3035142|NCT02327299|Experimental|FeSO4 + Stabilizer|Bouillon fortified with 4mg FeSO4 + Stabilizer
3035143|NCT02327286|Experimental|Intervention|Promote and support healthy behaviors
3035144|NCT02327286|No Intervention|Control|Conventional care for women with prior GDM.
3035145|NCT02327273|Experimental|Part A SAD: BMS-963272 or Placebo|BMS-963272 or Placebo oral capsule on specific days
3035146|NCT02327273|Experimental|Part B MAD: BMS-963272 or Placebo|BMS-963272 or Placebo oral capsule on specific days
3035147|NCT02327260|Experimental|Video + MI for CR|This group receives the educational video and an MI session for CR participation.
3035148|NCT02327260|Experimental|MI for medication adherence|This group receives an MI session for taking prescribed cardioprotective medications,
3035149|NCT02327247|Experimental|Test|Felodipine Extended Release Tablets USP 10 mg
3035157|NCT02327208|Placebo Comparator|Control|3 Combat rations only per day. No additional experimental food items (those assigned to the active comparator groups will consume isoenergetic carbohydrate and protein-based food products).
3035158|NCT02327208|Active Comparator|Protein|Consume 4 whey protein-based snack-bars in addition to 3 combat rations each day during training.
3035159|NCT02327208|Active Comparator|Carbohydrate|Consume 4 carbohydrate-based snack-bars in addition to 3 combat rations each day during training.
3035160|NCT02327195|Experimental|Methylphenidate|Quillivant XR - Methylphenidate HCL Extended Release oral suspension - (after reconstruction with water - 5mg/mL) 20 mg (PO) given 2 hours prior to surgery
3035161|NCT02327195|Placebo Comparator|Placebo|20 mg Placebo (PO) given 2 hours prior to surgery
3035162|NCT02327182|Experimental|MT-4666 low dose|Low Dose, Tablet, Once Daily, For 52 Weeks
3035163|NCT02327182|Experimental|MT-4666 high dose|High Dose, Tablet, Once Daily, For 52 Weeks
3035164|NCT02327169|Experimental|MLN2480 + MLN0128|"Dose Escalation Phase: MLN2480 100 milligram (mg), tablets, orally, once on protocol specified days of a 28-day Cycle for up to 12 Cycles, and MLN0128 2 mg, capsules, orally, once on protocol specified days of a 28-day Cycle for up to 12 Cycles. The doses of MLN2480 and MLN0128 may be increased during this phase based on tolerability during each 28-day cycle.~Dose Expansion Phase: MLN2480 at a previously deemed maximum tolerated dose, tablets, orally, once, on protocol specified days of a 28-day Cycle for up to 12 Cycles, and MLN0128 capsules, orally, once on protocol specified days of a 28-day Cycle for up to 12 Cycles."
3035165|NCT02327169|Experimental|MLN2480 + Alisertib|"Dose Escalation Phase: MLN2480 100 mg, tablets, orally, once on protocol specified days of a 28-day Cycle for up to 12 Cycles, and alisertib 30 mg, tablets, orally, twice daily (BID) on protocol specified days of a 28-day Cycle for up to 12 Cycles. The doses of MLN2480 and alisertib may be increased during this phase based on tolerability during each 28-day cycle.~Dose Expansion Phase: MLN2480 at a previously deemed maximum tolerated dose, tablets, orally, once, on protocol specified days of a 28-day Cycle for up to 12 Cycles, and alisertib, tablets, orally, BID on protocol specified days of a 28-day Cycle for up to 12 Cycles."
3035166|NCT02327169|Experimental|MLN2480 + Paclitaxel|"Dose Escalation Phase: MLN2480 100 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 Cycles, and paclitaxel 80 milligram per square meter (mg/m^2), intravenous (IV) infusion, once weekly (QW) for 3 weeks in each 28-day Cycle for up to 12 Cycles. The dose of MLN2480 may be increased during this phase based on tolerability during each 28-day cycle. Any changes in paclitaxel dose will be based on the standard of care.~Dose Expansion Phase: MLN2480 at a previously deemed maximum tolerated dose, tablets, orally, once, on protocol specified days of a 28-day Cycle for up to 12 Cycles, and paclitaxel dose based on standard of care, intravenous infusion, QW for 3 weeks in each 28-day Cycle for up to 12 Cycles."
3035167|NCT02327169|Experimental|MLN2480 + Cetuximab|"Dose Escalation Phase: MLN2480 400 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 Cycles, and cetuximab will be administered intravenously at a loading dose of 400 mg/m^2 (Cycle 1 Day 1), then at 250 mg/m^2 QW on Days 8, 15, and 22 of Cycle 1 and Days 1, 8, 15, and 22 in each additional 28-day cycle for up to 12 Cycles. The dose of MLN2480 may be increased during this phase based on tolerability during each 28-day cycle. Any changes in cetuximab dose will be based on the standard of care.~Dose Expansion Phase: MLN2480 at a previously deemed maximum tolerated dose, tablets, orally, once, on protocol specified days of a 28-day Cycle for up to 12 Cycles, and cetuximab dose based on standard of care, intravenous infusion, QW in each 28-day Cycle for up to 12 Cycles."
3035168|NCT02327169|Experimental|ML2480 + Irinotecan|"Dose Escalation Phase: MLN2480 400 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 Cycles, and irinotecan 180 mg/m^2, intravenous infusion over 90 minutes, every other week (Q2W) for 2 weeks in each 28-day Cycle for up to 12 Cycles. The dose of MLN2480 may be increased during this phase based on tolerability during each 28-day cycle. Any changes in irinotecan dose will be based on the standard of care.~Dose Expansion Phase: MLN2480 at a previously deemed maximum tolerated dose, tablets, orally, once, on protocol specified days of a 28-day Cycle for up to 12 Cycles, and irinotecan dose based on standard of care, intravenous infusion, Q2W in each 28-day Cycle for up to 12 Cycles."
3035169|NCT02327156|No Intervention|group L|receive 4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU diluted with 1mL normal saline
3035170|NCT02327156|Active Comparator|group LD|4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU and dexmedetomidine 20 μg diluted with 1mL normal saline
3035171|NCT02327143|Experimental|200 mg LY2835219|200 mg LY2835219 administered orally on day 1.
3035172|NCT02327143|Experimental|0.4 mg ¹³C₈-LY2835219|0.4 mg ¹³C₈-LY2835219 given intravenously (IV) for 15 minutes, starting approximately 6 hours after the oral dose.
3035173|NCT02327130|Experimental|Exhaled Breath|Exhaled breath samples will be collected 6 times per day and blood samples will be collected once per day for 7 days. Subjects will be followed for an additional 3 days. We will use the Isomark Canary™ to determine the BDV of breath samples collected during this study. Analysis results of these samples will be combined with data that is abstracted from the subjects' medical records.
3035174|NCT02327117|Experimental|Tranexamic acid|
3035175|NCT02327117|Placebo Comparator|Normal Saline|
3035176|NCT02327104|Experimental|Mindfulness Based Relapse Prevention|The Experimental Group (EG) will undergo eight sessions of MBRP after Brazilian Ministry of Health Protocol (BMHP) for Tobacco dependence treatment. MBRP Program: the first three sessions: focus on practicing mindful awareness and integrating mindfulness practices into daily life (body scan, sitting meditation, walking meditation); The next three sessions: emphasize acceptance of present experience and application of mindfulness practices to relapse prevention; The final two sessions: expand to include issues of self-care, support network, and lifestyle balance.
3035177|NCT02327104|Other|Brazilian Ministry of Health Protocol|The Control Group (CG) is undergo the protocol of the Brazilian Ministry of Health Protocol (BMHP): clinical evaluation, four sessions of cognitive-behavioral approach and Nicotine Replacement Therapy and/or Bupropion as needed, as the Experimental Group. And during the eight sessions of MBRP (EG) both groups (EG and CG) are subjected to eight maintenance sessions of BMHP.
3035178|NCT02327091|Placebo Comparator|white rice flour capsule|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo for 12 weeks
3035179|NCT02327091|Active Comparator|alfacalcidol|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
3035180|NCT02327078|Experimental|(Phase 1, Part 1) : Nivolumab + Epacadostat|
3035182|NCT02327078|Experimental|(Phase 1, Part 2): Nivolumab + Epacadostat + Chemotherapy|
3035183|NCT02327065|Active Comparator|EUS-FNA Group|FNA,Fine needle aspiration
3035184|NCT02327065|Active Comparator|EUS-FNB Group|FNB,Fine needle biopsy
3035185|NCT02327052||Chagas disease|The study comprised 58 subjects with Chagas disease, confirmed by two positive serologic tests.
3035186|NCT02327039|Experimental|Dapagliflozin|Dapagliflozin 10 mg tablet once daily for 12 weeks
3035187|NCT02327039|Placebo Comparator|Placebo|Placebo 10 mg tablet once daily for 12 weeks
3035188|NCT02327026|Experimental|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative
3035189|NCT02327026|Active Comparator|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management.
3035190|NCT02327013|Experimental|vortioxetine 10 mg tablet|"In Stage 1, patients will receive vortioxetine 10mg/day for 6 weeks.~In Stage 2, patients who received vortioxetine 10mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
3035191|NCT02327013|Experimental|vortioxetine 20 mg tablet|"In Stage 1, patients will receive vortioxetine 20mg/day for 6 weeks.~In Stage 2, patients who received vortioxetine 20mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
3035192|NCT02327013|Placebo Comparator|Placebo tablet|"In Stage 1, the patients will receive placebo for 6 weeks.~In Stage 2, placebo responders will continue on placebo for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
3035193|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day, after meal)
3035194|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 300mg|GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day, after meal)
3035195|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 450mg|GLA5PR GLARS-NF1 tablet 450mg/day(Pregabalin 150mg 1 tablet and Pregabalin 300mg 1 tablet, 1 times a day, after meal)
3035196|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 600mg|GLA5PR GLARS-NF1 tablet 600mg/day(Pregabalin 300mg, 2 tablets 1 times a day, after meal)
3035197|NCT02326987|Experimental|GLA5PR GLARS-NF1 tab.150mg(fasted)|GLA5PR GLARS-NF1 tab. 150mg/day(Pregabalin 150mg once a day)
3035198|NCT02326987|Experimental|GLA5PR GLARS-NF1 tab.150mg(after high fat meal)|GLA5PR GLARS-NF1 tab. 150mg/day(Pregabalin 150mg once a day)
3035199|NCT02326987|Active Comparator|Lyrica Capsule 75mg(after high fat meal)|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
3035200|NCT02326974|Experimental|T-DM1 and Pertuzumab|T-DM1 via IV every 3 weeks for 6 doses and Pertuzumab loading dose via IV on Cycle 1 Day 1 followed by maintenance dose via IV every 3 weeks for 6 doses. Excision of tumor/mastectomy of biopsy residual tumor
3035201|NCT02326961|Experimental|Celution ADRCs; Low Dose|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 20,000,000 ADRCs per single intraarticular administration
3035202|NCT02326961|Experimental|Celution ADRCs; High Dose|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs per single intraarticular administration
3035203|NCT02326961|Placebo Comparator|Placebo|Sterile Lactated Ringers Solution (5mL) mixed with ≤ 0.20 ml of the study subject's own freshly drawn blood.
3035204|NCT02326948||Gallbladder cancer case group|Gallbladder cancer case group was defined as newly diagnosed gallbladder cancer diagnosed as GBC at the Department of Internal Medicine in Cheju Halla General Hospital, Jeju, Korea from 2009 to 2013.
3035205|NCT02326948||Age and sex matched control group|Age and sex matched control group was determined as age-sex matched subjects selected from the participants of Health Promotion Center in the same institute from 2009 to 2012.
3035206|NCT02326935|Experimental|Adipose derived mesenchymal cells|"Intervention: Autologous adipose derived mesenechymal stem cells, 150 million cells deployed via two (2) treatments via intravenous injection~Other Names:~ADSC, mesenchymal cells, stromal cells"
3035207|NCT02326922|Experimental|Metraplant-E First prototype|Metraplant-E (first prototype) levonorgestrel-releasing intrauterine device
3035208|NCT02326922|Experimental|Metraplant-E second prototype|Metraplant-E (second prototype) levonorgestrel-releasing intrauterine device
3035209|NCT02326909|Experimental|optical coherence tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
3035210|NCT02326883|Experimental|Care Management|The Care Management intervention will last up to a year and includes routine outreach to assess ongoing risk of suicide attempt, and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
3035211|NCT02326883|Experimental|Skills Training|The Skills Training intervention will last up to a year and uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
3035212|NCT02326883|Active Comparator|Usual Care|Those assigned to the Usual Care group will not be approached or contacted.
3035213|NCT02326870|Experimental|The AutoLap system|Use of the AutoLap system for controlling the laparoscope during the procedure
3035214|NCT02326844|Experimental|Ovarian Cancer Patients|Ovarian cancer patients with germline breast cancer mutation (gBRCAm) who have progressed on prior poly (ADP-ribose) polymerase inhibitor (PARPi) therapy
3035215|NCT02326818|Experimental|4 Stim-US|Patientes randomized to first E-stim then US guidance
3035216|NCT02326818|Experimental|3 US-Stim|Patients randomized to first US then E-stim guidance
3035217|NCT02326818|Experimental|1 US-Stim|Patients randomized to US guidance first
3035218|NCT02326818|Experimental|2 Stim-US|Patients randomized to E-stim first
3035219|NCT02326805|Experimental|Arm I (rilimogene-galvacirepvec)|Patients receive rilimogene-galvacirepvec SC at baseline and on days 14, 28, 56, 84, 112, and 140.
3035220|NCT02326805|Placebo Comparator|Arm II (placebo)|Patients receive placebo SC at baseline and on days 14, 28, 56, 84, 112, and 140.
3035221|NCT02326792|Experimental|G1-Three sets of exercise|G1 group - the participants will perform three sets of 15-20 repetitions of the trunk extensor exercise on a roman chair machine with the hips at 45 degrees relative to horizontal; performing trunk flexion-extension cycles for a total of 4 seconds (2 s concentric and 2 s eccentric contraction). The relative load for initial training will be placed at 20% back maximal voluntary contraction (MVC) and will be progressive during the training. The time session of training will be of 10 weeks.
3035222|NCT02326792|Experimental|G2-One set of exercise|G2 group - the participants will perform only one set of 15-20 repetitions of the trunk extensor exercise on a roman chair machine with the hips at 45 degrees relative to horizontal; performing trunk flexion-extension cycles for a total of 4 seconds (2 s concentric and 2 s eccentric contraction). The relative load for initial training will be placed at 20% back maximal voluntary contraction (MVC) and will be progressive during the training. The time session of training will be of 10 weeks.
3035223|NCT02326792|No Intervention|G3-Control|G3 group - the participants will be the control group, which not participating of exercise program in any time during the study.
3035224|NCT02326779|Experimental|Experimental Arm|Experimental Arm: acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
3035225|NCT02326779|No Intervention|Comparator Arm|Non-aspirin use arm as comparator
3035226|NCT02326766|Experimental|KRG|5g Korea red ginseng (KRG)
3035227|NCT02326766|Placebo Comparator|Placebo|5 g placebo (corn starch)
3035228|NCT02326753|Experimental|No. 7 oral airway|
3035229|NCT02326753|Experimental|No. 8 oral airway|
3035230|NCT02326753|Active Comparator|No. 9 oral airway|
3035231|NCT02326740|Experimental|gevokizumab|Solution for subcutaneous injection (Part 1, Group B)
3035232|NCT02326740|Placebo Comparator|Placebo|Solution for subcutaneous injection (Part 1, Group A)
3035233|NCT02326740|Experimental|gevokizumab open-label|Solution for subcutaneous injection (Part 2, Open-label)
3035234|NCT02326727|Active Comparator|General Anesthesia|Patients receiving general anesthesia with Fentanyl,Propofol, Isoflurane and Nitrous Oxide only during colonic cancer surgery
3035235|NCT02326727|Active Comparator|Combined anesthesia|Patients receiving general anesthesia and epidural analgesia with Ropivacaine during colonic cancer surgery
3035236|NCT02326714|Experimental|Auricular acupressure|The magnetic beads will be taped to the seven pressing points: Hunger point, Ovary, Uterus, Endocrine point, liver, kidney and spleen.
3035237|NCT02326714|Placebo Comparator|Placebo auricular acupressure|The magnetic beads will be taped to the three pressing points:Tonsil, eye and elbow.
3035238|NCT02326688|Experimental|stroke patients|"Kinematic measurement of the amount of trunk displacement during a grasping task~Two separated measurements are recorded with a 6-hours interval~A third measurement provided by a second examinator is conducted"
3035239|NCT02326688|Experimental|control patients|"Kinematic measurement of the amount of trunk displacement during a grasping task~Two separated measurements are recorded with a 6-hours interval~A third measurement provided by a second examinator is conducted"
3035240|NCT02326675|Active Comparator|Cryotherapy Group (Group A)|Subjects in the intervention group will receive both standard oral care and cryotherapy. During the 30 minute cryotherapy periods, subjects will eat ice chips, and/or consume very cold or frozen foods. Cryotherapy will begin 15 minutes prior to the start time of each etoposide infusion. After 30 minutes of cryotherapy, subjects will begin the saline rinses. The subject should perform 3 saline rinses over 15 minutes. After 15 minutes of saline rinses, the 30-minute cryotherapy / 15-minute saline rinse cycles will be repeated until 30 min after completion of etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
3035241|NCT02326675|Active Comparator|Standard Oral Care Group (Group B)|Subjects in the control group will receive standard oral care only. At the beginning of each etoposide infusion, the subject will begin the saline rinses. The subject will perform 3 saline rinses over 15 minutes followed by 30 minutes of rest (no rinses). The 15-minute saline rinse / 30-minute rest cycles will be repeated until 30 minutes after the completion of the etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
3035242|NCT02326662|Experimental|Paraplegics Acute|Acute [1-6 mo.] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
3035243|NCT02326662|Experimental|Paraplegics Sub-chronic|Sub-chronic [6-12 mo.] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
3035244|NCT02326662|Experimental|Paraplegics Chronic|"Chronic [1- 5 years]) patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.~Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix."
3035245|NCT02326662|Experimental|Tetraplegics Acute|Acute [1-6 mo.] patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
3035246|NCT02326662|Experimental|Tetraplegics Sub-chronic|"sub-chronic [6-12 mo.] patients (tetraplegics) with complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.~Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix."
3035330|NCT02326051|Active Comparator|Later Enoxaparin initiation|Women will start Enoxaparin therapy after sonographic confirmation of fetal cardiac pulsation
3035331|NCT02326038|Experimental|Ritalin|Methylphenidate, capsule, 20 mg, single oral administration
3035247|NCT02326662|Experimental|Tetraplegics Chronic|Chronic [1- 5 years]) patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells Intervention: Autologous Stem Cell Transplantation & Biomatrix
3035248|NCT02326649||CHD patients undergoing cardiac MRI without sedation|
3035249|NCT02326623|Experimental|iPad distraction|The intervention will be the use of an iPad that will include a selection of child-appropriate games. We will select popular, age-appropriate items to include on the iPad, chosen based on the most current online consumer ratings. Children and parents will be able to select their choice of distraction and can change their selection as desired during the course of the procedure. These choices will be recorded for study purposes.
3035250|NCT02326623|Other|standard care|The control group will receive standard care, which generally includes the use of topical anesthetic cream.
3035251|NCT02326610|Active Comparator|hGH, ZOMACTON® (somatropin)|For infants in the treatment group receiving ZOMACTON® (somatropin) growth hormone by injection
3035252|NCT02326610|No Intervention|No human growth hormone|No growth hormone is given.
3035253|NCT02326597|Active Comparator|Standard Practice|Standard care teaching and discussion. This group will crossover to be offered the opportunity to visit the Decision Aid website after the final study visits/surveys and data collection of the intervention group (standard practice plus decision aid).
3035254|NCT02326597|Experimental|Standard Practice plus Decision Aid|Standard care teaching and discussion in addition to web-based decision aid tool access
3035255|NCT02326584|Experimental|Induction with SGN-CD33A|7+3 (Standard dose cytarabine for induction and daunorubicin) + SGN-CD33A
3035256|NCT02326584|Experimental|Consolidation with SGN-CD33A|High dose cytarabine for consolidation + SGN-CD33A (28-day cycles)
3035257|NCT02326584|Experimental|SGN-CD33A Maintenance|SGN-CD33A Monotherapy (42-day cycles)
3035258|NCT02326584|Experimental|Induction and Consolidation with SGN-CD33A|7+3 (standard dose cytarabine for induction and daunorubicin) + SGN-CD33A and High dose cytarabine for consolidation + SGN-CD33A
3035259|NCT02326571||spontaneous intracerebral hemorrhage|
3035260|NCT02326558|Experimental|microwave enucleation|zero ischemia laparoscopic microwave ablation-assisted enucleation of the tumor
3035261|NCT02326558|Active Comparator|laparoscopic partial nephrectomy|conventional laparoscopic partial nephrectomy with clamping of the renal artery
3035262|NCT02326545|Experimental|MindLight|MindLight is the video game being tested for effectiveness to reduce child anxiety
3035263|NCT02326545|Active Comparator|Online CBT|Online CBT program for children
3035264|NCT02326532|Experimental|PRO data utilized|PRO data derived from the patient-completed MDHAQ/RAPID3 questionnaire will be collected from this arm and provided to the treating physicians.
3035265|NCT02326532|Sham Comparator|PRO data not utilized|PRO data derived from the patient-completed MDHAQ/RAPID3 questionnaire will be collected from this arm but will not be provided to the treating physicians.
3035266|NCT02326519|Other|Intracardiac electrode catheter|All patient in the study will have same data collected during the procedure using the Steerable intracardiac electrode catheter.
3035267|NCT02326506|Experimental|Pump speed variation|VA-ELS pump speed variations
3035268|NCT02326493|Experimental|CRT implantation|Patients who have a class I indication for cardiac resynchronization therapy according to current international guidelines
3035269|NCT02326480||Syndromic obesity|Identification of genetic causes of obesity
3035270|NCT02326480||Familial obesity|Identification of genetic causes of obesity
3035271|NCT02326480||Isolated obesity|Identification of genetic causes of obesity
3035272|NCT02326467|Experimental|Chlorhexidine gluconate bath|All subjects will receive a bath twice a week with 2% CHG bathing cloths. The baths will be followed by blood sampling for CHG levels prior to initiation of baths and every Friday for the duration of study participation. The study team will monitor the infant's skin for evidence of untoward lesions prior to the first bath and every 12 hours during the course of the study. CHG blood levels will be monitored for associated adverse events and accumulation.
3035273|NCT02326454|Active Comparator|Talaporfin sodium/Light dose 100 J/cm|Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
3035274|NCT02326454|Active Comparator|Talaporfin sodium/Light dose 200 J/cm|Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours
3035275|NCT02326454|Placebo Comparator|Saline/Light dose 100 J/cm|0.9% Sodium Chloride is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
3035276|NCT02326454|Placebo Comparator|Saline/Light dose 200 J/cm|0.9% Sodium Chloride is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours.
3035277|NCT02326441|Experimental|KX2-361|
3035278|NCT02326428|Experimental|Thrombectomy|Thrombectomy arm consists of patients undergoing thrombectomy according to accepted critera in the judgement of investigator. Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reasons.
3035279|NCT02326428|Active Comparator|Control|Control arm patients are treated with standard stroke care including IVT but do not receive Thrombectomy. Control arm consists of patients fulfilling criteria for thrombectomy according to accepted critera in the judgement of investigator. Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reason.
3035280|NCT02326415|Active Comparator|"Clinical Pathway With Fast-Track"|All the clinical performances that the health personal have to do about the patient with uncomplicated acute appendicitis is already established in a care maps since the patient comes to hospital until the discharge.
3035281|NCT02326415|Active Comparator|Postoperative Usual Protocol|The postoperative time and the clinical cares in patients with uncomplicated acute appendicitis, are defined by responsability sugery as he thinks he should be according to the literature.
3035282|NCT02326389|Experimental|Exercise and Cognitive Remediation|The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down. The experimental group will participate in the exercise intervention as well as cognitive remediation.
3060446|NCT02158299|Active Comparator|Drainaging,reexamine|
3035283|NCT02326389|Active Comparator|Cognitive Remediation Only|Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
3035284|NCT02326376||CAPS patients|CAPS patients treated with anakinra, using the Kineret graduated syringe
3035285|NCT02326363|Experimental|Mindfulness Based Relapse Prevention (MBRP):|The Introductory session provides an orientation to the intervention, basic mindfulness techniques and general description of group sessions. Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of mindfulness meditation (MM) practices such as breath meditation, urge surfing, walking or movement meditation.
3035286|NCT02326363|Active Comparator|Twelve-Step Facilitation Intervention (TSF)|"The Introductory session covers the 12-Step view of addiction and therapy overview. The manual, originally developed for individual sessions, has been adapted for group delivery (Brown et al., 2002). The eight selected sessions include four topics chosen by the manual developers as core topics and four elective topics. The intervention involves helping participants understand and incorporate core principles of 12-Step approaches while encouraging active participation in 12-Step meetings and related activities. The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment."
3035287|NCT02326350|Experimental|Aspirin 75mg|Aspirin 75mg enterally once daily for a maximum of 14 days
3035288|NCT02326350|Placebo Comparator|Placebo|Lactose powder placebo enterally once daily for a maximum of 14 days
3035289|NCT02326337|Active Comparator|Topical Wound Oxygen Device|"Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with Advanced Moist Wound Therapy (AMWT) dressings.~Other Names:~Topical Wound Oxygen Therapy~TWO2"
3035290|NCT02326337|Placebo Comparator|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
3035291|NCT02326311|Active Comparator|Fixed INTERIM TKI|"Intervention: fixed intermittent administration (one month ON/one month OFF) of TKIs (imatinib, nilotinib, dasatinib)"
3035292|NCT02326311|Experimental|Progressive INTERIM TKI|"Intervention: progressive intermittent administration (one month ON/one month OFF for the 1st year; one month ON/two months OFF for the 2nd year; one month ON/three months OFF for the 3rd year) (imatinib, nilotinib, dasatinib)"
3035293|NCT02326298|Experimental|CZP 200 mg|"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~Treatment received from Week 16-48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study."
3035294|NCT02326298|Experimental|CZP 400 mg|"CZP 400 mg every two weeks (Q2W) through Week 14.~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W."
3035295|NCT02326298|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.~PASI75 responders at Week 16 continue to receive Placebo.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W."
3035296|NCT02326285|Experimental|Treatment phase|Enrolled patients will be treated with 250mg/day Gefitinib for 11 days (day -12 until day -1) followed by 3 cycles (length 21 days) of chemotherapy with docetaxel (75mg/m2 d1) and cisplatin (50 mg/m2 d1+2) combined with intercalated gefitinib (250mg/day, d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
3035332|NCT02326038|Placebo Comparator|Placebo|Placebo, capsule, single oral administration
3035333|NCT02326025|Experimental|Olaratumab (Part A)|Olaratumab administered intravenously (IV) on Day 10 of Cycle 1 and Days 1 and 8 of Cycles 2 through 8. Participants may continue to receive olaratumab after Cycle 8, until discontinuation criteria are met.
3035334|NCT02326025|Experimental|Olaratumab + Doxorubicin (Part A)|On Cycle 1, Day 1 doxorubicin will be administered via IV infusion. On Cycle 1, Day 10, olaratumab administered via IV infusion. For Cycles 2 to 8, olaratumab administered on Days 1 and 8 of each 21-day cycle, via IV infusion. On Day 1 of Cycles 2 to 8, doxorubicin will be administered via IV infusion immediately following the completion of the olaratumab infusion.
3035297|NCT02326272|Experimental|CZP 200 mg|"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~Treatment received from Week 16-48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study."
3035298|NCT02326272|Experimental|CZP 400 mg|"CZP 400 mg every two weeks (Q2W) through Week 14.~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W."
3035299|NCT02326272|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.~PASI75 responders at Week 16 continue to receive Placebo.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W."
3035300|NCT02326246|Experimental|men with low-risk PC|men newly diagnosed with low-risk prostate cancer and put in an active surveillance (AS) program. Eight weeks post TRUS-guided biopsies they are scanned with a multi-parametric magnetic resonans imaging (mMRI). If the scans shows a PIRADS 4 or 5 lesion, MRI-guided biopsies are performed. Otherwise the patients will continue in the AS program as usual. The mMRI will in these cases be repeated after 1 year.
3035301|NCT02326233|Experimental|Pen of SB5|Pen of SB5, single-dose of 40 mg via subcutaneous injection (study drug)
3035302|NCT02326233|Active Comparator|PFS of SB5|PFS of SB5, single-dose of 40 mg via subcutaneous injection (reference drug)
3035303|NCT02326220|Experimental|Alirocumab|Alirocumab subcutaneous (SC) dose regimen
3035304|NCT02326220|Placebo Comparator|Placebo|Placebo matching alirocumab subcutaneous (SC) dose regimen
3035305|NCT02326207|Experimental|Weekly ventilator circuit change|Ventilator circuit change every 7 days until extubation
3035306|NCT02326207|Active Comparator|No routine ventilator circuit change|No routine ventilator circuit change until soiling or malfunction or extubation
3035307|NCT02326194|Placebo Comparator|Placebo group (one shot)|one dose
3035308|NCT02326194|Placebo Comparator|Placebo group (two shots)|two doses, with one dose to each arm at a same time.
3035309|NCT02326194|Experimental|Low dose vaccine group|one dose, low dose Ebola Zaire vaccine (Ad5-EBOV)
3035310|NCT02326194|Experimental|High dose vaccine group|two doses, high dose, with one dose to each arm at a same time
3035311|NCT02326181|No Intervention|control group|without inspiratory and expiratory pressure threshold training
3035312|NCT02326181|Experimental|inspiratory pressure training group|The patients will perform daily in 2 sessions of 30 minutes, using a pressure threshold trainer.
3035313|NCT02326181|Experimental|mixed training group|The patients will perform daily in 2 sessions of 30 minutes, using a pressure threshold trainer.
3035314|NCT02326168|Experimental|non-muscle invasive bladder cancer|"Every patient meeting eligibility criteria will receive a standard WHO adult potency Bacillus Calmette-Guerin (BCG) immunization (1cc/50mg live mycobacilli) in the right or left deltoid. Following a 19 - 31day wait period after BCG vaccination patients will then receive standard strength BCG intravesical therapy returning once a week for 6 consecutive weeks. Cystoscopy will be performed at 3 and 6 months.~Interventions: BCG immunization in deltoid and BCG intravesical therapy once a week for 6 weeks."
3035315|NCT02326155||Remsima™|Patients who are taking Remsima™ for the treatment
3035316|NCT02326142|Experimental|OBE001|
3035317|NCT02326142|Placebo Comparator|Placebo|
3035318|NCT02326129||Obese with Type 2 Diabetes|Obese adolescents with Type 2 Diabetes
3035319|NCT02326129||Obese without Type 2 Diabetes|Obese adolescents without Type 2 Diabetes
3035320|NCT02326129||Normal weight|Normal weight adolescents
3035321|NCT02326116|Experimental|Group 1|Trachael Traction Exercises
3035322|NCT02326116|Placebo Comparator|Group 2|Trachael Massage
3035323|NCT02326103|Active Comparator|Ciprofloxacin|Oral administration of Ciprofloxacin 500mg twice daily
3035324|NCT02326103|Placebo Comparator|Placebo|Oral administration of Placebo pill twice daily
3035325|NCT02326090|Active Comparator|cis-UCA ophthalmic solution 1.0%|One drop in each eye
3035326|NCT02326090|Active Comparator|cis-UCA ophthalmic solution 2.5%|One drop in each eye
3035327|NCT02326090|Placebo Comparator|Placebo ophthalmic solution|One drop in each eye
3035328|NCT02326077||Intervention group|"Clinical evaluation in active labor: Leopold manoeuvres, vaginal digital examination.~Transabdominal and transperineal ultrasound evaluations of the mechanism of labor: fetal head position, progression and rotation.~Investigation by questionnaire regarding the psychological impact of labor monitoring assisted by sonoraphy."
3035329|NCT02326051|Active Comparator|Early Enoxaparin initiation|Women will start Enoxaparin therapy once positive pregnancy test is established
3035460|NCT02325258|No Intervention|No telephone call|control arm: no intervention
3035335|NCT02326025|Experimental|Olaratumab (Part B)|Olaratumab administered intravenously (IV) on Day 10 of Cycle 1 and Days 1 and 8 of Cycles 2 through 8. Participants may continue to receive olaratumab after Cycle 8, until discontinuation criteria are met.
3035336|NCT02326025|Experimental|Olaratumab + Doxorubicin (Part B)|On Cycle 1, Day 1 doxorubicin will be administered via IV infusion. On Cycle 1, Day 10, olaratumab administered via IV infusion. For Cycles 2 to 8, olaratumab administered on Days 1 and 8 of each 21-day cycle, via IV infusion. On Day 1 of Cycles 2 to 8, doxorubicin will be administered via IV infusion immediately following the completion of the olaratumab infusion.
3035337|NCT02326012|Experimental|Emotion Regulation Individual Therapy for Adolescents|
3035338|NCT02325999|Experimental|ESD and LRLD|The experimental group accept Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection.
3035339|NCT02325999|No Intervention|Endoscopic Submucosal Dissection (ESD)|The group accept Endoscopic Submucosal Dissection only.
3035340|NCT02325986|Experimental|Weekly PF with radiation|4 cycles of weekly cisplatin and fluorouracil (cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3, repeated weekly for 4 weeks) concurrently with Intensity-modulated radiation therapy (60Gy/28fr).
3035341|NCT02325973|Other|IMR evaluation|Assessment of IMR index in coronaries through PressureWire Certus guidewire
3035342|NCT02325960|Active Comparator|exenatide|5 μg BID for the first 4 weeks of treatment and 10 μg thereafter
3035343|NCT02325960|Active Comparator|Insulin glargine|≥8 IU QD, and titrate based on a dosing algorithm targeting FPG <6.1 mmol/L. Titration is only allowed in first 4 weeks.
3035344|NCT02325947|Experimental|Study group|Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes
3035345|NCT02325947|Sham Comparator|Placebo group|Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
3035346|NCT02325934|Active Comparator|Reference|Stribild Standardized breakfast followed by a single dose of STB (whole tablet).
3035347|NCT02325934|Experimental|Intervention I|Stribild, crushed Standardized breakfast followed by a single dose of crushed and suspended STB.
3035348|NCT02325934|Experimental|Intervention II|Stribild, crushed 350 mL of drip feed (type) followed by a single dose of crushed and suspended STB.
3035349|NCT02325921||(Partial) nephrectomy|Patients >18 years of age scheduled for undergoing (partial) tumor nephrectomy.
3035350|NCT02325908||Hemodialysis patients|Dialysis patients will have their estimated dry weight measured with calf segmental bioimpedance. Based on these measurements, their dry weight will be adjusted and the amount of fluid removed during subsequent dialysis treatments will be increased by 200-300mL. The additional fluid removal will occur during 3 consecutive hemodialysis sessions. In addition, these subjects will also use VStim during these treatments. to prevent common intradialytic symptoms by promoting vascular refilling.
3035351|NCT02325908||Healthy Controls|No Intervention was administered. Both groups had their hydration status measured with segmental bioimpedance The group of healthy subjects was studied in order to obtain a range of values for normal hydration status.
3035352|NCT02325895|No Intervention|Control (0 g Dried plum/day)|Participants only received 400IU of vitamin D and 500mg of calcium daily for 6 months.
3035353|NCT02325895|Experimental|50 g Dried plum/day|Participants received 400IU of vitamin D and 500mg of calcium and 50g of dried plum daily for 6 months.
3035354|NCT02325895|Experimental|100 g Dried plum/day|Participants received 400IU of vitamin D and 500mg of calcium and 100g of dried plum daily for 6 months.
3035355|NCT02325882|Active Comparator|Conventional fentanyl-based epidural PCA|
3035356|NCT02325882|Experimental|dexmedetomidine to fentanyl-based intravenous PCA|
3035357|NCT02325882|Active Comparator|Conventional fentanyl-based intravenous PCA|
3035358|NCT02325869|Experimental|Bell Balloon Catheter|The Bell Balloon Catheter is designed to help the physician capture some of this material that may have broken off.
3035359|NCT02325856|Active Comparator|Study group|Dry weight determined by performing Bioimpedance Spectroscopy (intervention is the performance of this tool)
3035360|NCT02325856|Placebo Comparator|Control group|Dry weight determined by clinical symptoms
3035361|NCT02325843|Active Comparator|human bone marrow MSC|human bone marrow MSC: 0.5ml （about 1 × 107 cells）subconjunctival injection every two weeks ,adiministered for 4 weeks,and combined with Amniotic Membrane Transplantation
3035362|NCT02325843|Placebo Comparator|fake subconjunctival injection|fake subconjunctival injection :0.5ml subconjunctival injection every two weeks ,adiministered for 4 weeks,and combined with Amniotic Membrane Transplantation
3035363|NCT02325830|Experimental|Treatment Group|Implantation of the CARILLON Mitral Contour System
3035364|NCT02325830|No Intervention|Control Group|Optimized stable medical therapy
3035365|NCT02325817|Experimental|Drug-eluting balloon|Treat the side branch of bifurcation lesion with drug-eluting balloon
3035366|NCT02325817|Active Comparator|Uncoated balloon|Treat the side branch of bifurcation lesion with uncoated balloon
3035367|NCT02325804|Active Comparator|Conventional lifestyle counseling|Randomized, open label study to assess effect of 8 weeks of Conventional lifestyle counseling (low calorie diet and exercise) on body composition, physical fitness, and metabolic parameters
3035368|NCT02325804|Active Comparator|Unconventional lifestyle counseling|"Randomized, open label study to assess effect of 8 weeks of unconventional lifestyle counseling (low calorie metabolic stairs diet and circuit-based exercise) on body composition, physical fitness, and metabolic parameters"
3035369|NCT02325791|Experimental|Open-Label Treatment|Participants were assigned to the REGN2222 open label treatment cohort
3035370|NCT02325791|Experimental|Double-Blind Treatment|Participants were assigned to REGN2222 or placebo
3035371|NCT02325778|Experimental|CTI First|CTI ablation prior to left atrial ablation
3035372|NCT02325778|Experimental|CTI second|CTI ablation after left atrial ablation
3035373|NCT02325765||category of RACHS-2 for cardiac surgery|ASD & VSD repair; VSD repair; Tetralogy repair; Tetralogy repair
3035374|NCT02325765||category of RACHS-3 for cardiac surgery|DORV repair with or without RV obstruction; AVSD (complete or transitional) repair with or without valve replacement; Coarctation & VSD repair
3035461|NCT02325245|Experimental|Metformin|Metformin tablet 500 mg three times a day for 16 weeks.
3035462|NCT02325245|Placebo Comparator|Placebo|Placebo tablet three times a day for 16 weeks.
3062781|NCT02142946||Chronic UVL|Chronic unilateral vestibular loss patients
3035375|NCT02325752|No Intervention|Control|Patients in the control group received usual care by the hospital. There was no contact between the patients in the control group and the study team throughout the 3 months interval. A scheduled telephone call was made at the end of 3 months when they were invited to participate in a telephone survey.
3035376|NCT02325752|Active Comparator|Intervention|Intervention
3035377|NCT02325739|Experimental|FGF401 single agent|Approximately 168 patients enrolled
3035378|NCT02325739|Experimental|FGF401 in combination with PDR001|Approximately 70 patients enrolled
3035379|NCT02325726||Renal Resistive Index/Nephrocheck test|Patients undergoing elective cardiac surgery with extracorporeal circulation and who are at risk to develop postoperative Acute Kidney Injury.
3035380|NCT02325713|Experimental|Sequence A-B-C1-D1|
3035381|NCT02325713|Experimental|Sequence A-B-C1-D2|
3035382|NCT02325713|Experimental|Sequence A-B-C2-D1|
3035383|NCT02325713|Experimental|Sequence A-B-C2-D2|
3035384|NCT02325713|Experimental|Sequence A-B-D1-C1|
3035385|NCT02325713|Experimental|Sequence A-B-D2-C1|
3035386|NCT02325713|Experimental|Sequence A-B-D1-C2|
3035387|NCT02325713|Experimental|Sequence A-B-D2-C2|
3035388|NCT02325713|Experimental|Sequence B-A-C1-D1|
3035389|NCT02325713|Experimental|Sequence B-A-C1-D2|
3035390|NCT02325713|Experimental|Sequence B-A-C2-D1|
3035391|NCT02325713|Experimental|Sequence B-A-C2-D2|
3035392|NCT02325713|Experimental|Sequence B-A-D1-C1|
3035393|NCT02325713|Experimental|Sequence B-A-D2-C1|
3035394|NCT02325713|Experimental|Sequence B-A-D1-C2|
3035395|NCT02325713|Experimental|Sequence B-A-D2-C2|
3035396|NCT02325700||Open aortic repair|145 patients with open aortic repair for abdominal aortic aneurysmal disease (n=139) or abdominal aortic occlusive disease (n=89)
3035397|NCT02325700||Laparoscopic aortic repair|83 patients with Laparoscopic aortic repair for abdominal aortic aneurysmal disease (n=30) or abdominal aortic occlusive disease (n=53)
3035398|NCT02325687|Experimental|Treated OSA (CPAP-compliant)|"Treated OSA patients will have previously been diagnosed with OSA, and are currently CPAP-compliant. CPAP compliance is defined by daily use of a CPAP machine for at least 4 hours. We will determine if patients are CPAP-compliant by looking at their medical records and pre-operative assessments, as well as directly verifying compliance with the patient.~Intervention: Lumbar Puncture (Standard-of-Care)"
3035399|NCT02325687|Experimental|Untreated OSA (non-CPAP-compliant)|"Patients in the untreated OSA group will have previously been diagnosed with OSA, but for some reason do not use a CPAP machine every night. We will determine if patients are CPAP-compliant by looking at their medical records and pre-operative assessments, as well as directly verifying compliance with the patient.~Intervention: Lumbar Puncture (Standard-of-Care)"
3035400|NCT02325687|Experimental|Control (No suspicion of OSA)|"Patients in the control group will not have previously been diagnosed with OSA, and are currently not at high risk. We will determine overall risk for OSA using the STOP-BANG questionnaire. Patients with a STOP-BANG score <3 are considered to have minimal risk for OSA and will be included in the control group.~Intervention: Lumbar Puncture (Standard-of-Care)"
3035401|NCT02325674||Metreleptin|Generalised lipodystrophy patients treated with Metreleptin
3035402|NCT02325661|Other|cognitive interviewing|individual cognitive interviewing, 30 minutes per patient
3035403|NCT02325648||HIPEC cytoreductive surgery|
3035404|NCT02325635|Experimental|Training of Endoscopist|A series of 1 hour classes with ongoing monitoring and feedback to endoscopist only.
3035405|NCT02325635|No Intervention|Deferred Training of Endoscopist|No intervention during the data collection period. Training will be deferred to end of study.
3035406|NCT02325596||control|Patients with only nasal septum deviation
3035407|NCT02325596||CRS sNP|Chronic Rhinosinusitis patients without nasal polyps
3035408|NCT02325596||atopic CRS wNP|Chronic Rhinosinusitis patients with allergic constitution and nasal polyps
3035409|NCT02325596||non-atopic CRS wNP|Chronic Rhinosinusitis patients with nasal polyps but not allergic constitution
3035410|NCT02325583|Experimental|Intraoral 30% Glucose in Newborns|0.5-1 mL 30% glucose solution was administered orally and the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added. After 2 consecutive oral glucose administration the newborns who did not keep motionless or sleep and had motion artefacts sedated with midazolam. The routine blood glucose level measurement was also performed in ICU.
3035411|NCT02325570|Experimental|KLOX BioPhotonic OraLum Gel + SRP|Split-mouth design:the half-mouth randomly selected will be treated with KLOX BioPhotonic OraLum gel (with a LED curing lamp) as an adjunct to SRP.
3035412|NCT02325570|Other|Scaling and Root Planing (SRP)|The second half-mouth will be treated with SRP alone.
3035413|NCT02325557|Experimental|Part A|Patients will receive ADXS31-142 monotherapy. Dosing will start at 1 x 10^9 cfu IV and escalate to 1 x 10^10 if appropriate.
3035414|NCT02325557|Experimental|Part B/Expansion|Patients will receive ADXS31-142 and pembrolizumab (MK-3475) in combination. Dosing of ADXS31-142 will start at one dose level less that appropriate in Part A in combination with 200 mg of pembrolizumab. Dosing of ADXS31-142 will be escalated if appropriate
3035415|NCT02325544|Experimental|CBT+SMC|12 sessions of Cognitive Behavioural Therapy adapted for DS (plus one booster session) plus standardised medical care
3035416|NCT02325544|Active Comparator|SMC|Standardised medical care provide by neurologist and/or psychiatrist
3035417|NCT02325531|Other|Low support|"Low support (toolkit only), includes the following:~EHR-based tools, built by OCHIN, activated during Year 1 TOOLKIT, paper and electronic form, includes documents to help support ALL implementation, and~BASIC WEBINAR, Annual, 1-hour, topics such as:~Talking to Clinicians About ALL, Using The Monthly Feedback Report and Integrating the Toolkit into Workflows"
3035418|NCT02325531|Other|Medium support|"Medium support (toolkit, staff training), includes the following:~Same as above (EHR-based tools, built by OCHIN, activated during Year 1 TOOLKIT, paper and electronic form, includes documents to help support ALL implementation) Plus STAFF TRAINING (2-day meeting in Portland, Oregon, Led by Implementation Specialists (IS), How to use the toolkit and how to train others to use it, Content guided by previous research, baseline survey results, study team and the S-N advisory group Plus ADAPTIVE WEBINARS, Quarterly 1-hr webinars, Content from basic webinars, tailored to topics requested by study clinics. Forum for group discussion and best practice sharing. Open any interested clinics in Arm 2 & 3."
3035419|NCT02325531|Other|High support|"High support (toolkit, training, on-site facilitation), includes the following:~Same as above (EHR-based tools, built by OCHIN, activated during Year 1 TOOLKIT, paper and electronic form, includes documents to help support ALL implementation, STAFF TRAINING, and ADAPTIVE WEBINARS Plus PRACTICE FACILITATION: Site visits with support as needed, Staff presentations, Coaching on tools (how to present to clinic staff and how to use in the clinic workflow), Tailored problem-solving support to address identified barriers, Clinical questions fielded by RN practice facilitator and site clinician champion."
3035420|NCT02325518|Experimental|BRI/TIM|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.
3035421|NCT02325518|Active Comparator|DOR/TIM|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.
3035422|NCT02325505||Tuberous sclerosis complex|All patients with TSC, LAM or AML followed at Hospital das Clínicas, University of São Paulo Medical School will be included in the proposed study. Patients of all ages will participate in the study.
3035423|NCT02325492|Experimental|Aramchol 400 mg|• One tablet of Aramchol 400 mg and one tablet of Placebo
3035424|NCT02325492|Experimental|Aramchol 600 mg|• One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
3035425|NCT02325492|Placebo Comparator|Placebo|• Two tablet of Aramchol matching placebo.
3035426|NCT02325479|Experimental|Group A|After scheduled oocyte pick up, a mock embryo transfer will be done using labotec catheter (Labotec, Gottingen Germany), and an injection of Enaoxaprin sodium (LMWH) (Clexane® Sanofi S.A Paris, France) will be given intrauterine in group A patients, 500 IU of LMWH which is 5mg, in 0.05 ml.
3035427|NCT02325479|Placebo Comparator|Group B|The control arm (group B) will be injected intrauterine with similar volume of tissue culture media (G.2 plus ref. 10132, Vitrolife)
3035428|NCT02325466|Placebo Comparator|Aspirin/Ticagrelor placebo|aspirin 81 mg daily and ticagrelor placebo twice daily
3035429|NCT02325466|Active Comparator|Aspirin/Ticagrelor|aspirin 81 mg daily and ticagrelor 90 mg twice daily
3035430|NCT02325466|Active Comparator|Aspirin Placebo/Ticagrelor|aspirin placebo daily and ticagrelor 90 mg twice daily
3035431|NCT02325453||Robotic Surgery|Patients underwent gastric surgery through the use of a robotic system.
3035432|NCT02325453||Laparoscopic Surgery|Patients underwent gastric surgery with laparoscopic procedures.
3035433|NCT02325453||Open Surgery|Patients underwent gastric surgery with open approach.
3035434|NCT02325440|Experimental|Natalizumab - Washout - Fingolimod|One experimental arm: Patients receive one final dose of natalizumab 300mg followed by an 8-week washout Phase and subsequent 32-week treatment Phase with fingolimod 0.5mg o.i.d.
3035435|NCT02325427|Experimental|real tDCS|Subjects will receive tDCS stimulation at the intensity of 1 mA and last for 20 minutes. The anode will be placed over the affected primary motor cortex (M1) of cortical representation of the hand, while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
3035436|NCT02325427|Sham Comparator|sham tDCS|Subjects will receive sham tDCS stimulation. The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
3035437|NCT02325427|No Intervention|no stimulation|Subjects will not received any intervention.
3035438|NCT02325414|Experimental|Zol/Zol|Intravenous infusion of zoledronic acid (zol) 5 mg at baseline and at 12 months.
3035439|NCT02325414|Experimental|Zol/Placebo|Intravenous infusion of zoledronic acid (zol) 5 mg at baseline. Intravenous infusion of placebo at 12 months.
3035440|NCT02325414|Experimental|Placebo/Zol|Intravenous infusion of placebo at baseline. Intravenous infusion of zoledronic acid (zol) 5 mg at 12 months.
3035441|NCT02325414|Sham Comparator|Placebo/Placebo|Intravenous infusion of placebo at baseline and at 12 months.
3035442|NCT02325401|Experimental|Metformin with Chemoradiation|Metformin administered orally daily to start one week prior to Cisplatin and Radiation Therapy. Metformin dose is escalating.
3035443|NCT02325388|Experimental|Treatment group with ForeSite PT™ system|Inpatients assigned to the treatment group with the ForeSite PT™ system will have its LCD monitor turned on (i.e., real-time images of interface pressure will be displayed on the monitor) during their enrolment in the trial.
3035444|NCT02325388|No Intervention|Control group|Inpatients assigned to the control group will have the ForeSite PT™ system's LCD monitor turned off and hidden (i.e., real-time images of interface pressure will not be displayed on the monitor). As the ForeSite PT™ system will continue to record interface pressure with the display turned off, this enables patients enrolled in the control group to undergo silent monitoring.
3035445|NCT02325375||ALS newly diagnosed|
3035446|NCT02325375||ALS treated|
3035447|NCT02325375||controls|
3035448|NCT02325362|Experimental|Miglustat then placebo|10 patients will received Miglustat then the placebo
3035449|NCT02325362|Experimental|Placebo then Miglustat|10 patients will received Placebo then Miglustat
3035450|NCT02325349|Experimental|radiopharmaceutical|PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
3035451|NCT02325336|Experimental|bar-code-assisted administration|during administration rounds, nurses will use the BCMA system to help preventing administration errors
3035452|NCT02325336|No Intervention|control|during administration rounds, nurses will administer drugs as usual
3035453|NCT02325310|Experimental|Breastfeeding women|70 breastfeeding women meeting all the inclusion criteria and none of the exclusion criteria will be immunized with MMR vaccine in postpartum (before the exit of the maternity)
3035454|NCT02325297|Experimental|Letter of condolence|Letter of condolence 15 days after the death of the relative.
3035455|NCT02325297|No Intervention|No letter of condolence|No letter of condolence
3035456|NCT02325284||Healthy adults|
3035457|NCT02325271||Control group|Subjects with normal glucose tolerance
3035458|NCT02325271||Diabetes group|Patients with type 2 diabetes
3035459|NCT02325258|Experimental|Telephone call|Telephone call to physicians in charge of patients who have just had blood cultures drawn. Diagnostic and therapeutic recommendations to physicians in charge.
3035463|NCT02325232|Experimental|Enteroscopy|Capsule endoscopy, double balloon enteroscopy sequential use
3035464|NCT02325219|Experimental|Group 1|Participants will receive subcutaneous injection of CNTO 1959 50 milligram (mg) and placebo 100 mg at Week 0, 4 and then every 8 weeks thereafter.
3035465|NCT02325219|Experimental|Group 2|Participants will receive subcutaneous injection of CNTO 1959 100 milligram (mg) and placebo 50 mg at Week 0, 4 and then every 8 weeks thereafter.
3035466|NCT02325219|Experimental|Group 3|Participants will receive subcutaneous injection of placebo 50 mg and 100 mg at Weeks 0, 4 and 12. At Week 16, participants will be randomized in sub-group 3a to receive either CNTO1959 50 mg and placebo 100 mg at Week 16, 20 and then every 8 weeks thereafter or sub-group 3b to receive CNTO 1959 100 mg and placebo 50 mg at Week 16, 20 and then every 8 weeks thereafter.
3035467|NCT02325206|Experimental|dapafliflozin|one administration of 10mg dapagliflozin as tablet
3035468|NCT02325206|Placebo Comparator|placebo|one administration as tablet identical to the experimental drug
3035469|NCT02325180|Experimental|DHA-PQ|One tablet of dihydroartemisinin-piperaquine consists of 40 mg of dihydroartemisinin and 320 mg of piperaquine. DHA-PQ is administered once daily for 3 days (at enrolment, hour 24 and you 48). Dosing should be given based on body weight. Daily dose for dihydroartemisinin is 2.25 mg/kg (total 6.75 mg/kg) and for piperaquine is 18 mg/kg (total 54 mg/kg).
3035470|NCT02325180|Active Comparator|AL|Half a tablet of artemether-lumefantrine consists of 20 mg of artemether and 120 mg of lumefantrine is given per 5 kg body weight. AL is administered as 6-dose regimens given twice daily for 3 days (at enrolment, hour 8, hour 24, hour 36, hour 48 and hour 60).
3035471|NCT02325167|Experimental|EBT|
3035472|NCT02325167|Experimental|Treatment-as-usual|
3035473|NCT02325154||THA Patients|Patients undergoing unilateral total hip arthroplasty
3035474|NCT02325141|Active Comparator|LSG|patients undergoing laparoscopic sleeve gastrectomy without BTX-A injection into the pyloric sphincter
3035475|NCT02325141|Active Comparator|BTX-LSG|patients undergoing laparoscopic sleeve gastrectomy with BTX-A injection into the pyloric sphincter
3035476|NCT02325128|Experimental|Post-Exposure Nap|Sleep-enhancement of extinction memory: At the end of the third and fourth of 5 exposure therapy sessions, all participants deliver a speech designed to elicit significant social anxiety. Following this speech, this arm will be given a 2-hour sleep opportunity with polysomnographic (PSG) monitoring.
3035477|NCT02325128|Active Comparator|Post-Exposure Wake|At the end of the third and fourth of 5 exposure therapy sessions, all participants deliver a speech designed to elicit significant social anxiety. Following this speech, this arm will be instrumented for PSG but, instead of napping, will undergo 2 hours of quiet wakefulness. Therefore, this arm will not undergo sleep-enhancement of extinction memory.
3035478|NCT02325115||students (STUD)|The STUD population was a convenient sample of 75 first year students (51 females and 24 males); with 45 from a School of Business Management and 30 from a medical university.
3035479|NCT02325115||working adults (WORK)|The WORK population was also a convenient sample of 113 (63 females and 256 males) working adults including 217 soldiers from Paris Fire Brigade, 93 nurses and 9 individuals from a research laboratory.
3035480|NCT02325115||remitted schizophrenia (PRS)|The PRS population was comprised of 121 remitted schizophrenia patients (39 females and 82 males) who were all clients of the rehabilitation centre for psychotic disorders (Le Vinatier hospital),
3035481|NCT02325089|Experimental|Mandibular advancement device|Mandibular advancement device titrated to reduce or eliminate snoring and sleep apnea
3035482|NCT02325089|Placebo Comparator|Placebo|Oral appliance identical to the mandibular advancement device without mandibular advancement
3035483|NCT02325076|Experimental|Spirodoc|One time during examination at the outpatient unit
3035484|NCT02325063|Experimental|PRP-L Group|"Patients randomized to this group will be treated with an injection of Leukocyte and Platelet Rich Plasma (PRP-L).~Intervention: PRP-L Injection"
3035485|NCT02325063|Active Comparator|Botox Group|"Patients randomized to this group will be treated with an injection of Type A Botulinum Toxin (Xeomin®, MERZ).~Intervention: Botox injection"
3035486|NCT02325063|Active Comparator|Corticoid Group|"Patients randomized to this group will be treated with an injection of Corticoids.~Intervention: Corticoid injection"
3035487|NCT02325050|Experimental|Group 1|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
3035488|NCT02325050|Experimental|Group 2|Participants will receive MVA-BN-Filo/Ad26.ZEBOV (Day 1 /Day 29) or placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
3035489|NCT02325050|Experimental|Group 3|Participants will receive MVA-BN-Filo /Ad26.ZEBOV/ (Day 1/Day 57) or placebo (Day 1/Day 57). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
3035490|NCT02325050|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
3035491|NCT02325050|Experimental|Group 5|Participants will receive MVA-BN-Filo (Day 1 and Day 15) or placebo (Day 1 and Day 15). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
3035492|NCT02325050|Experimental|Group 6|Participants will receive Ad26.ZEBOV (Day 1 and Day 15) or placebo (Day 1 and Day 15). Participants will receive MVA-BN-Filo (1*10^8 TCID50) on Day 360.
3035493|NCT02325050|Experimental|Group 7|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1/Day 15) or Placebo (Day 1/Day 15). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
3035494|NCT02325050|Experimental|Group 8|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1 /Day 29) or Placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (1x10^11 vp) on Day 360.
3035495|NCT02325050|Experimental|Group 9|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 8) or Placebo (Day 1/Day 8).
3035496|NCT02325050|Experimental|Group 10|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15).
3035497|NCT02325037|Experimental|GLPG1837 single dose|Single oral dose of GLPG1837 suspension - ascending doses
3035498|NCT02325037|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension
3035499|NCT02325037|Experimental|GLPG1837 muliple doses|Multiple oral doses of GLPG1837 suspension - ascending doses
3035500|NCT02325037|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
3062782|NCT02142946||Phobic|Phobic vertigo patients
3035501|NCT02325024|Experimental|Renally Impaired Subjects|"Treatment group consists of subjects with severe renal impairment or ESRD and in accordance with the following criteria;~Clinically significantly abnormal creatinine and creatinine clearance (CLcr <30 mL/min) and not requiring dialysis.~Onset of renal impairment must have been documented at least 3 months prior to study start."
3035502|NCT02325024|Experimental|Matched subjects with Normal Renal Function|Group consists of healthy subjects (as determined by medical history, physical examination, biochemistry, hematology, urinalysis, hepatitis B and C, and HIV testing) who demonstrate normal renal function (CLcr > 80 mL/min) and are individually matched to renally impaired subjects with respect to age (within the decile or five years, whichever is less), gender, and Body Mass Index (BMI) (+/- 10% BMI).
3035503|NCT02325011|Experimental|Treatment Sequence 1|"During each of the four Inpatient Periods (Visit 2 to Visit 5 inclusive), healthy subjects with a history of cannabis use will either receive a single dose of Sativex® alone (Treatment A) or a single-dose of Sativex coadministered with the interaction drug, fluconazole (Treatment B) on a repeated, cross-over basis.~Subjects will be randomly assigned to one of two treatment sequences. Treatment sequence 1 is as follows;~Visit 2 (Treatment A)~Visit 3 (Treatment B)~Visit 4 (Treatment A)~Visit 5 (Treatment B)~The crossover treatments will be separated by a washout period of at least 10 days, but no more than 12 days, between each Sativex® dose."
3035504|NCT02325011|Experimental|Treatment Sequence 2|"During each of the four Inpatient Periods (Visit 2 to Visit 5 inclusive), healthy subjects with a history of cannabis use will either receive a single dose of Sativex® alone (Treatment A) or a single-dose of Sativex coadministered with the interaction drug, fluconazole (Treatment B) on a repeated, cross-over basis.~Subjects will be randomly assigned to one of two treatment sequences. Treatment sequence 2 is as follows;~Visit 2 (Treatment B)~Visit 3 (Treatment A)~Visit 4 (Treatment B)~Visit 5 (Treatment A)~The crossover treatments will be separated by a washout period of at least 10 days, but no more than 12 days, between each Sativex® dose."
3035505|NCT02324998|Experimental|Group A|Olaparib Monotherapy
3035506|NCT02324998|Experimental|Group B|Olaparib in combination with degarelix
3035507|NCT02324985|Active Comparator|Active Arm|S-Ibuprofen Topical Gel 5%
3035508|NCT02324985|Placebo Comparator|Placebo Arm|Vehicle Topical Gel
3035509|NCT02324972|Experimental|AQX-1125|1 x AQX-1125 Capsule daily
3035510|NCT02324972|Placebo Comparator|Placebo|1 x placebo capsule daily
3035511|NCT02324959|Active Comparator|Acupuncture|Needling of affected meridian groups in line with Traditional Chinese Medicine procedures (Baihui and Shenting).
3035512|NCT02324959|Active Comparator|Computer-based|Computer-based attention training (RehaCom).
3035513|NCT02324959|Experimental|ACoTrain|A combination of computer-based attention training with acupuncture.
3035514|NCT02324946||Study Group|Mass Screening
3035515|NCT02324933|Experimental|Fentanyl Challenge Dosing|"In the operating room a fentanyl infusion will be started at 2 mcg/kg/min. The time from start of the infusion to respiratory depression(rate < 5 breaths/minute) will be used to calculate the effect-site concentration (Ce).Using the pharmacodynamic model calculated by the Stanpump PCA software, the infusion will continue intraoperatively to achieve a fentanyl Ce of 30%. In the Post Anesthesia Care Unit (PACU), the rate would be changed with the following parameters:~50% of the hourly dose is given as a basal infusion~The remainder of the hourly dose is ordered as a demand dose q 15 minutes. Post-operatively, the basal rate is adjusted according to the average demand dose use. In patients using < 1 demand dose per hour, the basal rate is decreased by 20%. In patients using > 3 demand doses per hour, the basal rate is increased by 20%. Patients whose pain cannot be managed by this protocol will be removed from the study and pain management will revert to the primary service."
3035516|NCT02324933|Active Comparator|Standard of Care (Control)|"Patients in the best practice arm would receive pre-operative sedation in the operating room comparable to the dose normally given in the Ambulatory Surgery Unit as a simulated fentanyl challenge. Best practice (control) patients will be followed by the Pain & Palliative Care team in order to make adjustments in pain management as required by the patients."
3035517|NCT02324920|Experimental|DDD+CLS|The pacemaker will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON.
3035518|NCT02324920|Placebo Comparator|ODO|The pacemaker will be programmed in ODO mode.
3035519|NCT02324907||Tibiotalocalcaneal arthrodesis with DynaNail|Procedure/Surgery: Tibiotalocalcaneal arthrodesis with a novel dynamic compression intramedullary nail
3035520|NCT02324894|Other|MRI screening|Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
3035521|NCT02324881|Experimental|Health Services Research (PMSA)|"Patients/caregivers are instructed to download the PMSA and are demonstrated how to properly use the application. Beginning on the first day of radiation therapy (day 1), patients are instructed to use the PMSA for the duration of their radiation therapy (up to day 50). The patient will fill out a satisfaction questionnaire at the completion of their treatment (Questionnaire administration). The timing of use may change depending on the availability of the app. The use of the app is classified as the telephone-based intervention per NCI."
3035522|NCT02324868|Experimental|Shower patch IV catheter protection|Newly developed waterproof catheter dressing may be used for bathing activities
3035523|NCT02324868|Other|Conventional IV catheter protection|No specific dressing will be provided to the patient to protect the catheter entry site during bathing activities.
3035524|NCT02324855|No Intervention|Usual care|Subjects will receive the usual medical care in accordance with Spanish non cystic fibrosis bronchiectasis guidelines. In addition they will receive educational sessions about their disease and their pharmacology treatment.
3035525|NCT02324855|Experimental|Chest physiotherapy plus usual care|Subjects will introduce chest physiotherapy as part of their daily treatment
3035526|NCT02324842|Active Comparator|Canagliflozin|canagliflozin (film-coated tablet), 100 mg/day, increased to 300 mg/day after week two if tolerated without side effects
3035527|NCT02324842|Active Comparator|liraglutide|liraglutide, 1.2 mg/day, increased to 1.8 mg/day after week two if tolerated without side effects
3035528|NCT02324842|Active Comparator|canagliflozin plus liraglutide|canagliflozin, 100 mg/day, plus liraglutide, 1.2 mg/day, increased to 300 mg/day and 1.8 mg/day, respectively at week two, if tolerated without side effects
3035529|NCT02324829||Total joint replacement|Patients who has undergone lower body total joint replacement surgery.
3035530|NCT02324816|Experimental|Fat Reduction|
3035531|NCT02324803|Experimental|pazopanib once daily|Patients received continuous treatment of 800 mg pazopanib once daily until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Dose reductions by 400 mg to a lowest dose of 200 mg daily were allowed on the basis of tolerability and according to protocol-defined guidelines.
3035532|NCT02324790|Experimental|Treatment|Treated with iNAP® Sleep Therapy System on the treatment PSG night.
3035533|NCT02324777|Experimental|CanniMed™ DPF-I Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation (DPF) with a potency specification similar to CanniMed™ 22·1 product, of 21.9% w/w total THC and 0.8% w/w total CBD is vapourized and inhaled by study subjects.
3035534|NCT02324777|Experimental|CanniMed™ DPF-II Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification the same as the CanniMed™ 15·5 product, of 15.0% w/w total THC and 5.0% w/w total CBD is vapourized and inhaled by study subjects.
3035535|NCT02324777|Experimental|CanniMed™ DPF-III Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification the same as CanniMed™ 9·9 product, of 9.0% w/w total THC and 9.5% w/w total CBD is vapourized and inhaled by study subjects.
3035536|NCT02324777|Experimental|CanniMed™ DPF-IV Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification similar to CanniMed™ 4·10 product, of 3.8% w/w total THC and 10.0% w/w total CBD is vapourized and inhaled by study subjects.
3035537|NCT02324777|Experimental|CanniMed™ DPF-V Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification similar to CanniMed™ 1·13 product profile of 0.6% w/w total THC and 13.0% w/w total CBD is vapourized and inhaled by study subjects.
3035538|NCT02324777|Placebo Comparator|CanniMed™ DPF-P Volcano® Vapourization|"Using the Volcano® Medic, a dose of 100 mg of ethanol extracted DPF-V, reducing the potency profile to <0.3% w/w total THC and <0.3% w/w total CBD (comparable to the threshold levels described for industrial hemp, as per the Canadian Industrial Hemp Regulations (SOR/98-156), is vapourized and inhaled by study subjects."
3035539|NCT02324764|Experimental|Glidesheath Slender|The transradial procedure will be performed using the glidesheath slender (studied sheath)
3035540|NCT02324764|Active Comparator|Standard sheath|The transradial procedure will be performed using the standard 6- French radial sheath (comparator sheath)
3035541|NCT02324751|Experimental|Vi-TCV|Single intramuscular injection
3035542|NCT02324751|Active Comparator|Vi-PS Vaccine|Single intramuscular injection
3035543|NCT02324751|Other|Control (Men ACWY)|Single intramuscular injection
3035544|NCT02324738|Experimental|Healthy Volunteer|All subjects will receive Mefloquine and Dihydroartemisinin-piperaquine, wash out then will receive Mefloquine
3035545|NCT02324725|Experimental|Naltrexone Intervention|Eligible participants receive up to three monthly injections of 380 mg of naltrexone contained in dissolvable polymer microspheres and administered by deep intramuscular injection and slowly released over a period of approximately 4 weeks.
3035546|NCT02324712|Active Comparator|Acupuncture|Acupuncture treatment for TMD
3035547|NCT02324712|Sham Comparator|Sham Acupuncture|Acupuncture treatment for TMD using the non-penetrating Park Sham Acupuncture Device
3035548|NCT02324699|Experimental|Prednisone co-inductive therapy|Prednisone 40 mg/day starting at week 0 for 2 weeks, tapered by 10 mg weekly to achieve 0 mg by end of week 5
3035549|NCT02324699|Placebo Comparator|Placebo|Identical placebo taper
3035550|NCT02324686|Other|Vitamin K1|Vitamin K1 400 mcg orally three times a week on dialysis days for four months
3035551|NCT02324673|Experimental|Low Dose Cannabidiol Oral Solution [10 mg/kg/day]|Low Dose [10 milligrams/kilogram/day (mg/kg/day)] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 5 mg/kg in the morning on Day 1 followed by total dose of 10 mg/kg/day (5 mg/kg in the morning and 5 mg/kg in the evening) on Days 4 to 10.
3035552|NCT02324673|Experimental|Mid Dose Cannabidiol Oral Solution [20 mg/kg/day]|Mid Dose [20 mg/kg/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 10 mg/kg in the morning on Day 1 followed by total dose of 20 mg/kg/day (10 mg/kg in the morning and 10 mg/kg in the evening) on Days 4 to 10.
3035553|NCT02324673|Experimental|High Dose Cannabidiol Oral Solution [40 mg/kg/day]|High Dose [40 mg/kg/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 20 mg/kg in the morning on Day 1 followed by total dose of 40 mg/kg/day (20 mg/kg in the morning and 20 mg/kg in the evening) on Days 4 to 10.
3035554|NCT02324660|Other|screening test|all consecutive patients admitted to our hospital for ACS and current/former smokers will be screened according our protocol with PEF and RHSQ. Patients will be blinded to result of both tests. Indipendently to results, all included patients will receive spirometry (50-70 days after inclusion) to assess the presence or not of COPD (primary outcome).
3035555|NCT02324634|Experimental|ES intervention|Electrical stimulation (ES) twice a day, 5 days a week, for 3 months
3035556|NCT02324634|No Intervention|Control|Usual care only
3035557|NCT02324621|Experimental|Treatment (oral ONC201)|Patients receive oral ONC201 PO on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3035558|NCT02324608|Experimental|Treatment (cetuximab)|Patients receive cetuximab IV over 60-120 minutes once weekly for 8 weeks.
3035559|NCT02324595|Experimental|Laparoscopic Interval Debulking Surgery|Patients affected by advanced epithelial ovarian cancer already submitted to neoadjuvant chemotherapy with evidence of complete/partial response
3035560|NCT02324582|Experimental|Intravenous MK-3475/ Intravesical BCG|3 subjects will be treated at a dose of 100 mg MK-3475 at 100 mg every 3 weeks (Q3W) intravenously (IV) for 6 doses and 1 vial intravesicular BCG suspended in 50 ml preservative-free saline once per week of 6 weekly doses 12 subjects will be treated at a dose of 200 mg MK-3475 at 100 mg every 3 weeks (Q3W) intravenously (IV) for 6 doses and 1 vial intravesicular BCG suspended in 50 ml preservative-free saline once per week of 6 weekly doses
3035561|NCT02324569|Experimental|Treatment Group I|One tablet of SYR-472 100 mg orally or one placebo tablet orally once weekly before breakfast
3035562|NCT02324569|Experimental|Treatment Group II|One tablet of SYR-472 100 mg orally once weekly before breakfast
3035599|NCT02324335|Placebo Comparator|Placebo Comparator Oral Rinse|Water for Injection
3035563|NCT02324556||Laparoscopic total mesorectal excision|Patients operated with laparoscopic total mesorectal surgery for rectal cancer
3035564|NCT02324556||transanal total mesorectal excision|Patients operated with a combined transanal and laparosocopic total mesorectal surgery for rectal cancer
3035565|NCT02324543|Experimental|untreated metastatic pancreatic adenoca|
3035566|NCT02324530|Experimental|Lung tumors|Patients with > 1 cm tumor motion simulated using 4DCT with and without CPAP
3035567|NCT02324530|Experimental|Left sided Breast cancer|Patients with heart abutting chest wall will be simulated using 4DCT with and without CPAP
3035568|NCT02324530|Experimental|Abdominal tumors|Patient with liver metastases for SBRT or pancreatic tumors will be simulated using 4DCT with and without CPAP
3035569|NCT02324517||Hemophilia|Patients with Hemophilia A OR B
3035570|NCT02324517||inhibitor patients|Hemophilia or FXI def with inhibitors
3035571|NCT02324517||anticoagulants|patients under therapy with various anticoagulant drugs
3035572|NCT02324517||thrombocytopenia|patients with ITP, chronic thrombocytopenia, chemotherapy induced thrombocytopenia
3035573|NCT02324517||platelet function disorders|Glanzmann, Bernard Soulier, antiplatelet therapy
3035574|NCT02324517||Fibrinogen disordsers|hyperfibrinogenemia, hypofibrinogenemia, dysfibrinogenemia
3035575|NCT02324517||acquired hemophilia|patients with autoimmune Ab's to FVIII
3035576|NCT02324517||RBD|FXIII DEF, FV+FVIII DEF, FVII DEF, FV DEF
3035577|NCT02324517||THROMBOLYTICS|Patients treated by thrombolytic agents
3035578|NCT02324517||Hypercoag|thrombophilias, thrombosis- inc under therapy, acquired high thrombotic risk (eg: cancer)
3035579|NCT02324504|Experimental|Placement with C3 Wave Tip System|Subjects will have their central catheters placed with the addition of the FDA approved C3 Wave ECG-Based PICC Tip Confirmation System to the standard institution protocol. The system will assist with location of the catheter tip in real-time, during the procedure.
3035580|NCT02324491|Experimental|ZGN-440 Injectable Suspension (1.2mg)|ZGN-440 for Injectable Suspension
3035581|NCT02324491|Experimental|ZGN-440 Injectable Suspension (1.8mg)|ZGN-440 for Injectable Suspension
3035582|NCT02324491|Placebo Comparator|Placebo|ZGN-440 Placebo for Injectable Suspension
3035583|NCT02324465|Active Comparator|King Vision Video Laryngoscope|The patient would be randomized to intubation via use of the King Vision VL then Glidescope VL
3035584|NCT02324465|Active Comparator|Glidescope Video Laryngoscope|The patient would be randomized to intubation via use of the Glidescope VL then King Vision VL
3035585|NCT02324452|Experimental|heterozygous carrier of DPYD variant|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be heterozygous for one of these SNPs
3035586|NCT02324452|Experimental|wild type for DPYD|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be wild type for these SNPs
3035587|NCT02324439|Experimental|Omega Nutrition cold-milled flaxseeds|All subjects will receive a 20g daily dose of cold-milled flaxseeds for 24 months.
3035588|NCT02324426|Experimental|Reduced Glutathione|The study medication is packaged in sterile 1 ml pre-filled syringes, each containing 200 mg/ ml of reduced glutathione (GSH), which will be delivered intranasally.
3035589|NCT02324413|Active Comparator|clonidine|Clonidine intravenous 1 or 2 micrograms / kg
3035590|NCT02324413|Placebo Comparator|Placebo|
3035591|NCT02324400|Active Comparator|Treatment|
3035592|NCT02324400|Sham Comparator|Control|
3035593|NCT02324387|Experimental|Molecular Breast Imaging (MBI) + Tc99m sestamibi|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled chemotherapy treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
3035594|NCT02324374|Experimental|Endocytoscopy During Colonoscopy|Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.
3035595|NCT02324361|Experimental|Facebook group|"The intervention consists of evidence-based information on healthy family routines and parenting strategies adapted for Facebook posts on a private study Facebook group.~Participating parents/guardians will have access to all features of the secret study Facebook group (e.g., create and view postings, comment and like existing posts and view user names of other members of the group (existing study participants and staff) for the duration of the study.~All index children will be provided with a Physical Activity Monitor to wear during waking hours for the duration of the study."
3035596|NCT02324361|Experimental|Text messaging|"The intervention consists of evidence-based information on healthy family routines and parenting strategies adapted for 140-character text messages.~The automated text-messaging algorithm consists of the delivery of two types of text messages: 1-way messages, in which participating parents/guardians will receive a piece of education or motivation on the dimension topic that they're being coached on and 2-way messages, in which participants are able to respond to an educational message containing a number response prompt that will provide them with personalized feedback regarding a dimension they are being coached on.~All index children will be provided with a Physical Activity Monitor to wear during waking hours for the duration of the study."
3035597|NCT02324348|Placebo Comparator|Immediate coronary stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, stent implantation is done on the initial procedure in immediate coronary stenting group
3035598|NCT02324348|Active Comparator|Deferred coronary stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, only TIMI Ⅲ flow achievement is done on the initial procedure and stent implantation is deferred after 5-7 days admission in the deferred coronary stenting group.
3035600|NCT02324335|Active Comparator|Active Compator Oral Rinse|Brilacidin 3 mg/mL in Water for Injection
3035601|NCT02324322|Experimental|Exoskeleton training|"To examine the effectiveness of robotic exoskeleton-assisted over ground walking (5 hrs. p/wk, 100 sessions, 20 wks = 100 hrs) to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI. Combined with our current training protocol where people step 1500-2000/session we predict that the 2,000 lower extremity muscle contractions will be sufficient in our proposed exoskeletal study.~MRI's will be performed to accurately assess muscle CSA of each lower limb to determine individual's muscle thigh and shank volume.~Muscle Biopsies for the quadricep muscle will be performed to determine changes in BMD and bone structure due to intensive exoskeleton assisted walking."
3035602|NCT02324309|Experimental|BIOD-531 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
3035603|NCT02324309|Active Comparator|Humalog Mix 75/25 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
3035604|NCT02324309|Active Comparator|Humulin R U-500 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
3035605|NCT02324309|Experimental|BIOD-531 post-meal|Subcutaneous injections of 1.2 U/kg 20 minutes after the start of a standardized breakfast and 0.8 U/kg 20 minutes after the start of a standardized dinner.
3035606|NCT02324283|Active Comparator|Desflurane|Desflurane group: this group of patients receives desflurane as the main anesthetic agent in addition to remifentanil infusion at 0.1~0.3 mcg/kg/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
3035607|NCT02324283|Active Comparator|Propofol|Propofol group: this group of patients receives propofol as the main anesthetic agent in addition to remifentanil infusion at the rate of 0.1~0.3 mcg./g/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
3035608|NCT02324270|Active Comparator|Diclofenac epolamine|Flector® (Diclofenac Epolamine Topical Patch 1.3%) (Pfizer)
3035609|NCT02324270|Experimental|generic diclofenac epolamine patch|Generic Diclofenac Epolamine Topical Patch 1.3% (Watson Laboratories, Inc.)
3035610|NCT02324270|Placebo Comparator|Placebo|Placebo patch of the test product (Watson Laboratories, Inc.); Identical in appearance and formulated as the test product, omitting the active ingredient, diclofenac epolamine
3035611|NCT02324257|Experimental|Part I: RO6958688|Participants will receive single dose of RO6958688 starting from a dose of 0.05, 0.15, 0.45, 1.3, and 2.5 mg in Part I of the study.
3035612|NCT02324257|Experimental|Part II: RO6958688 With/Without Obinutuzumab Pretreatment|Participants will receive MTD (or lower dose) of RO6958688 with or without obinutuzumab pretreatment in Part II of the study and different dosing schedules will be assessed.
3035613|NCT02324244||immunocompetent patients underwent heart surgery|
3035614|NCT02324231|Other|39.0°C temperature limit defining fever|Temperature limit defining fever, for definition of fever in neutropenia (FN), is single temperature >=39.0°C measured in the ear by infrared tympanic thermometry. If clinically indicated, the treating physician is allowed to make the diagnosis of FN at lower temperatures.
3035615|NCT02324231|Other|38.5°C temperature limit defining fever|Temperature limit defining fever, for definition of fever in neutropenia (FN), is single temperature >=38.5°C measured in the ear by infrared tympanic thermometry. If clinically indicated, the treating physician is allowed to make the diagnosis of FN at lower temperatures.
3035616|NCT02324218||Diabetes mellitus Group|All the subjects with diabetes mellitus diagnosed with hepatitis B, reported in the CPRD database of UK, from the Year 2000 to 2012.
3035617|NCT02324218||Non-Diabetes mellitus Group|All the subjects with hepatitis B who are diagnosed negative diabetes mellitus, reported in the CPRD database of UK, from the Year 2000 to 2012.
3035618|NCT02324205|Active Comparator|FFDM|Subjects will undergo 2D breast imaging with full-field digital mammography (FFDM) device
3035619|NCT02324205|Experimental|DBT|Subjects will undergo 3D breast imaging with digital breast tomosynthesis (DBT) device
3035620|NCT02324192|Other|Normal ultrasonography|Patients with normal ultrasonography findings
3035621|NCT02324192|Other|Inflammatory ultrasonography|Patients with inflammatory ultrasonography findings
3035622|NCT02324179||HIV positive|people with HIV diagnosis
3035623|NCT02324179||Control (HIV negative)|people without HIV
3035624|NCT02324166|Active Comparator|Cefazolin|For the control group, cefazolin will be drawn into a 1 mL syringe and 0.5 mL will be injected with a 30-gauge needle into the subconjunctival space. This will be performed at the end of the retinal surgery.
3035625|NCT02324166|Active Comparator|Cefazolin + Lidocaine|For the comparator group, the cefazolin and 0.2 mL lidocaine 2% will be mixed together in the same 1 mL syringe and 0.5 mL of the mixed solution injected with a 30-gauge needle into the subconjunctival space. This will be performed at the end of the retinal surgery surgery.
3035626|NCT02324153|Experimental|Treatment|Ramelteon 8 mg oral dose Riboflavin 100 mg (preoperative first dose only)
3035627|NCT02324153|Placebo Comparator|Placebo|Capsule Shells filled with microcrystalline cellulose Riboflavin 100 mg (preoperative first dose only - if received as an outpatient)
3035628|NCT02324140||Minimized extracorporeal circulation|Patients with severe aortic valve stenosis undergoing surgical aortic valve replacement using the minimized extracorporeal circulation (MECC, group 1)
3035629|NCT02324140||Conventional extracorporeal circulation|Patients with severe aortic valve stenosis undergoing surgical aortic valve replacement using the conventional extracorporeal circulation (CECC, group 2)
3035630|NCT02324140||Transcatheter aortic valve implantation, transfemoral access|Patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation using the transfemoral access route
3035631|NCT02324140||Transcatheter aortic valve implantation, transapical access|Patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation using the transapical access route
3035632|NCT02324127|Experimental|liver cancer|Detect plasma Hsp90α concentration of liver cancer patients
3035633|NCT02324114|Experimental|Rectal cancer|Detect plasma Hsp90α concentration of patients,
3035685|NCT02323685|Experimental|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
3035634|NCT02324101|Experimental|Breast cancer|Detect plasma Hsp90α concentration of breast cancer patients
3035635|NCT02324088|Active Comparator|Arm A|4 cycles of high-dose EC (E150 mg/m² and C 4000 mg/m² every 3 weeks) then mastectomy with axillary lymph node dissection and radiotherapy
3035636|NCT02324088|Experimental|Arm B|4 cycles of high-dose EC (E150 mg/m² and C 4000 mg/m² every 3 weeks) then mastectomy with axillary lymph node dissection and radiotherapy followed by 4 cycles of D-5FU (D 85 mg/m², day 1 and 5FU 2500 mg/m²/day continuous infusion, days 1-5 every 3 weeks)
3035637|NCT02324075|Experimental|Behavior change|Behavior change messaging with facilitating hardware
3035638|NCT02324075|No Intervention|Control Arm|Standard habits and practices
3035639|NCT02324062||Pathogenic group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.~Patients identified with a mutation in a gene not commonly tested for prior to the advent of multiplex panel testing. This excludes BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MYH unless a patient tested positive for one of these 9 genes but did not meet clinical criteria for the underlying syndrome (n = 124). These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
3035640|NCT02324062||VUS group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.~Patients identified with a variant of unknown significance of any gene of any nonBRCA (BRCA1 and BRCA2) or non-Lynch syndrome gene (MLH1, MSH2, MSH6, PMS2 and EPCAM).~Target accrual is 100. These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
3035641|NCT02324062||Negative Group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.~Patients who test negative for all the genes tested. Target goal is 50 for Stanford (100 for the study). These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
3035642|NCT02324062||No follow-up intervention group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.~All other participants who do not meet any of the above criteria or fall into one of these groups after the target goal is met for that group."
3035643|NCT02324049|Experimental|SBC-103|"Part A (Initial therapy): Participants received SBC-103, 0.3, 1.0, or 3.0 mg/kg QOW for 24 weeks, followed by a ≥ 4-week treatment break. Participants enrolled in the lowest dosage first.~Part B: Participants were escalated to the next highest dose that was considered safe (1.0 or 3.0 mg/kg QOW) for ≥ 8 weeks. Participants who received doses of 0.3 mg/kg in Part A were considered for a second dose escalation to 3.0 mg/kg at any time during Part B provided that they tolerated at least 2 doses of 1.0 mg/kg in Part B. Participants who received and tolerated at least 4 doses of SBC-103 QOW at 3.0 mg/kg were considered for participation in Part C.~Part C: Participants received SBC-103 5.0 or 10.0 mg/kg administered IV QOW. Dosing in Part C began at the 5.0 mg/kg dose level. The decision to begin dosing the first participant at 10.0 mg/kg was based on the review of safety data at 5.0 mg/kg."
3035644|NCT02324036|Experimental|Coached Care+EMPATHy;|EMPATHy Toolkit: Patient coaching with computer assisted preference assessment
3035645|NCT02324036|Active Comparator|Routine Coached Care|Patient coaching only
3035646|NCT02324023|Experimental|Endoscopic ultrasound and pathology|Endoscopic ultrasound and contrast enhanced endoscopic ultrasound for staging and perfusion (preoperatively) compared to pathological stage and vessel density in the pathological specimen (postoperatively).
3035647|NCT02324010|Experimental|Sitaglipltin (100mg)|Active drug (sitagliptin)
3035648|NCT02324010|Placebo Comparator|Placebo (sugar pill)|Inactive drug (placebo)
3035649|NCT02323984||Hypoactive Delirium - Delirious|Hypoactive delirious patients presenting with lethargy and sedation and are slow to respond to questions and demonstrate little spontaneous movement. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
3035650|NCT02323984||Hyperactive Delirium - Delirious|Hyperactive delirious patients presenting with restlessness, agitation, hyper vigilance, and occaionally hallucinations. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
3035651|NCT02323984||No Delirium - Nondelirious|Patients not presenting any symptoms of hypoactive or hyperactive postoperative delirium. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
3035652|NCT02323958|Experimental|Acupoint stimulation|Electrical stimulation is given through electrodes attached to acupoints
3035653|NCT02323958|Placebo Comparator|Non-acupoint stimulation|Electrical stimulation is given through electrodes attached to non-acupoints
3035654|NCT02323958|Sham Comparator|Control stimulation|Electrode attached but no stimulation is given
3035655|NCT02323945|Active Comparator|AIH/Walk|Subjects with chronic, motor-incomplete SCI receive acute intermittent hypoxia (AIH) with walking practice, then AIH with strength practice and compare their efficacy on enhancing strength and/or walking performance.
3035656|NCT02323945|Active Comparator|AIH/Strength|Subjects with chronic, motor-incomplete SCI receive AIH with strength practice, then AIH with walking practice and compare their efficacy on enhancing strength and/or walking performance.
3035657|NCT02323932|Active Comparator|Bilateral Cochlear implant users|The perception of intonation will be assessed through the use of 2 tests. In the first test, listeners will have to identify statements and yes/no questions that will be presented by male and female talkers in the background of four- talkers-babble noise comprised of two females and two males. In the second test, listeners will be presented with gradual changes in the fundamental frequency of a sentence. They will be required to identify the sentence with each of the changes as a statement or a question. Each of the 2 tests will be presented in three listening conditions: each of the CI alone and bilateral (CI/CI) conditions.
3035683|NCT02323698|Active Comparator|Caffeine/AIH|Subjects with chronic, motor-incomplete SCI receive Caffeine and AIH
3035684|NCT02323698|Active Comparator|Placebo/AIH|Subjects with chronic, motor-incomplete SCI receive Placebo and AIH
3035658|NCT02323932|Active Comparator|Bimodal Cochlear implant users|The perception of intonation will be assessed through the use of 2 tests. In the first test, listeners will have to identify statements and yes/no questions that will be presented by male and female talkers in the background of four- talkers-babble noise comprised of two females and two males. In the second test, listeners will be presented with gradual changes in the fundamental frequency of a sentence. They will be required to identify the sentence with each of the changes as a statement or a question. Each of the 2 tests will be presented in three listening conditions: CI alone, HA alone and bimodal (CI/HA) conditions.
3035659|NCT02323919|Active Comparator|SystemCHANGE|consists of self-efficacy enhancement and relapse prevention strategies, but is primarily anchored in a set of behavior change strategies based on System Improvement techniques.
3035660|NCT02323919|Active Comparator|CHANGE+|is based on several cognitive-behavioral theoretical frameworks: Social Problem-solving Model, Self-efficacy theory, Expectancy-value theory and Relapse Prevention theory.
3035661|NCT02323919|Placebo Comparator|Usual Care|Usual Care
3035662|NCT02323906|Experimental|CC-122 + Fixed-dose Sorafenib|"A dose escalation and expansion clinical study of CC-122 in combination with sorafenib in subjects with unresectable HCC who have received no prior systemic therapy for HCC.~The dose escalation part of the study will explore several dose levels of CC-122 in combination with sorafenib, followed by an expansion part."
3035663|NCT02323893|Experimental|18F-FAraG|A single dose intravenous injection of 18F-FAraG followed by PET scanning.
3035664|NCT02323880|Experimental|Treatment (selinexor)|Patients receive selinexor PO twice weekly (days 1, 3, 8, 10, 15, and 17). Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3035665|NCT02323867|Experimental|Alpha Beta Total Body Irradiation - TBI first|"Alpha Beta Total Body Irradiation - TBI first Day Treatment~8 TBI~7 TBI~6 TBI~5 Thiotepa & ATG~4 Thiotepa & ATG~3 Cyclophosphamide & ATG~2 Cyclophosphamide~1 Rest 0 Transplant with alpha beta T cell depleted stem cells"
3035666|NCT02323867|Experimental|Alpha Beta Total Body Irradiation - TBI last|"Alpha Beta Total Body Irradiation - TBI last Day Treatment~7 Thiotepa~6 Thiotepa~5 Cyclophosphamide & ATG~4 Cyclophosphamide & ATG~3 TBI & & ATG~2 TBI~1 TBI 0 Transplant with alpha beta T cell depleted stem cells"
3035667|NCT02323867|Experimental|Alpha Beta Non-irradiation regimen|"Alpha Beta Non-irradiation regimen Day Treatment~9 Busulfan~8 Busulfan~7 Busulfan~6 Busulfan~5 Thiotepa & ATG~4 Thiotepa & ATG~3 Cyclophosphamide & ATG~2 Cyclophosphamide~1 0 Transplant with alpha beta T cell depleted stem cells"
3035668|NCT02323854|Other|Ablation and Surgical Resection|Ablation of lung tumor; followed by surgical resection of the ablation zone.
3035669|NCT02323841|Experimental|conservative treatment in cervix cancer|we performed conservative treatment cervix cancer patients with IB FIGO stage without pelvic involvement
3035670|NCT02323828|Experimental|Investigational product|"The investigational products are RS starch cookies (40 g resistant starch) from high amylose maize starch.~Nine young healthy volunteers (males and females) consumed RS rich cookies (40 g RS) in two separate occasions."
3035671|NCT02323828|Placebo Comparator|Placebo|The placebo products are common wheat-maize cookies (2 g RS). Nine young healthy volunteers (males and females) consumed placebo in two separate occasions.
3035672|NCT02323815|Active Comparator|Control|Behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly meetings for children 6-23 months of age
3035673|NCT02323815|Experimental|PROMIS intervention|"Behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly meetings for children 6-23 months of age~Caregivers with children 6-23 months of age that attend Counselling meetings will be provided with a monthly dose of SQ-LNS (20g/day)"
3035674|NCT02323802|Experimental|educational group intervention|"The group educational food intervention: it provides the delivery of information leaflet and inclusion in groups on a weekly basis for the first 3 meetings, and then, there are other 2 meetings on the third and sixth month by the AMI.~The meetings will cover education to self-nutrition, physical activity and learning techniques for stimulus control and management of high-risk situations."
3035675|NCT02323802|Active Comparator|prescriptive diet|An objectives food scheme elaborated for each patients will provide the reduction in caloric intake (equivalent to 500-600 calories in deficit if compared to the estimated daily requirement, based on the RDAs) and a reduced intake of lipids, which does not exceed 30% of total calories introduced, with a contribution of saturated fat no more than 7-9% .
3035676|NCT02323789|Experimental|Intervention arm|10 patients with RDEB will be selected to receive the intervention - mesenchymal stromal cells.
3035677|NCT02323763||Bipolar I or II Disorder|30 currently depressed patients with DSM-IV bipolar I and II disorder who are currently or previously suicidal will receive fMRI.
3035678|NCT02323737|Active Comparator|Irinotecan and cisplatin|The IP regimen consisted of at most 6 cycles of irinotecan 65 mg/m2 of body-surface area on days 1, 8 and cisplatin 75mg/m2 of body-surface area on day 1.
3035679|NCT02323737|Active Comparator|Etoposide and Cisplatin|The EP regimen consisted of at most 6 cycles of etoposide 100 mg/m2 of body-surface area from day 1 to 3 and cisplatin 75mg/m2 of body-surface area on day 1.
3035680|NCT02323724||Selected Papillary carcinoma|Cases with histological diagnosis of papillary carcinoma (CP) and previous cytological diagnosis in groups III, IV and V Bethesda, collected between October 1989 and July 2014 in Corporació Parc Taulí.
3035681|NCT02323711|No Intervention|Control|This group would be receiving the standard of care. The subject would receive the standard dressing applied by a member of the surgical team in the standard fashion as follows: The closed incision will be covered first with a primary dressing consisting of a nonadherent, composite dressing (Telfa), which is covered with a secondary dressing consisting of an Army Battle Dressing (ABD), before removal of the sterile surgical drapes. This dressing is then held in place with an adhesive fabric tape, currently Mefix tape, which is typically applied by the surgical scrub tech.
3035682|NCT02323711|Experimental|2-octyl cyanoacrylate|This group would receive the experimental treatment. If allocated to coverage with glue, no dressing is placed. After closure of the incision with suture or staples, the incision is patted dry under sterile conditions. The incision is then covered longitudinally by a member of the surgical team with a thick layer of skin glue dispensed from 1 tube of surgical skin glue (2-octyl cyanoacrylate, currently using brand: Derma+Flex QS). The glue is then allowed to dry before the sterile surgical drapes are removed.
3035686|NCT02323672||oral premalignant patients|15 patients suffering from oral premalignant lesions as lichen planus, actinic keratosis, leukoplakia and erythroplakia.
3035687|NCT02323672||oral malignant patients|15 patients suffering from oral malignant lesions
3035688|NCT02323672||control subjects|15 individuals age, gender and periodontal status matched with oral premalignant and malignant patients and not suffering from any oral mucosal lesions or periodontal disease.
3035689|NCT02323659|Active Comparator|Methotrexate arm|Patients assigned to receive methotrexate
3035690|NCT02323659|Active Comparator|Interferon Alfa-2b|Patients assigned to receive Interferon alfa 2b
3035691|NCT02323646|Placebo Comparator|Placebo|
3035692|NCT02323646|Experimental|6 mg Proellex® (Telapristone Acetate)|6 mg Proellex® (Telapristone Acetate) vaginal suppository
3035693|NCT02323646|Experimental|12 mg Proellex® (Telapristone Acetate)|12 mg Proellex® (Telapristone Acetate) vaginal suppository
3035694|NCT02323633|Active Comparator|tPCS group|Arm in which random noise oscillating frequencies will be produced for the duration of 20 minutes.
3035695|NCT02323633|Sham Comparator|Sham group|Arm in which no random noise oscillating frequencies will be produced for the duration of 20 minutes
3035696|NCT02323620|No Intervention|Standard care|Optimal standard care after myocardial infarction.
3035697|NCT02323620|Experimental|Intracoronary infusion of BM-MC|Bone marrow-derived progenitor autologous cells aspiration and intracoronary infusion of the cells.
3035698|NCT02323607|Experimental|Cohort A (pacritinib, cytarabine, daunorubicin hydrochloride)|INDUCTION: Patients receive pacritinib PO on days 1-21, cytarabine IV every 24 hours on days 5-11, and daunorubicin hydrochloride IV every 24 hours on days 5-7. Treatment repeats every 28 days for 1-2 courses in the absence of disease progression or unacceptable toxicity.
3035699|NCT02323607|Experimental|Cohort B (pacritinib, decitabine)|"INDUCTION: Patients receive pacritinib PO on days 1-21 and decitabine IV every 24 hours on days 5-14. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients achieving CR will proceed with transplant evaluation (if appropriate). Transplant-ineligible patients will receive maintenance courses of pacritinib PO on days 1-21 and decitabine IV over 1 hour daily on days 1-5. Maintenance courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3035700|NCT02323594|Experimental|Group 1: Daclatasvir|Single oral dose of Daclatasvir (DCV) tablet and single oral dose of DCV pediatric chewable tablet
3035701|NCT02323594|Experimental|Group 2: Daclatasvir|Single oral dose of Daclatasvir (DCV) pediatric chewable tablet and single oral dose of DCV pediatric chewable tablet
3035702|NCT02323594|Experimental|Group 3: Asunaprevir|Single oral dose of Asunaprevir (ASV) tablet, single oral dose of ASV pediatric chewable tablet and single oral dose of ASV pediatric chewable tablets
3035703|NCT02323594|Experimental|Group 4: Daclatasvir|Single oral dose of Daclatasvir (DCV) tablet and single oral dose of DCV tablets
3035704|NCT02323581|Experimental|Interventional|"Either the TAAA device or the Physician-Specified TAAA Device will be implanted.~The TAAA Device is a standard configuration branched stent graft with a combination of two branches for the mesenteric arteries and two fenestrations for the renal arteries.~The Physician-Specified TAAA Devices are designed on a per patient basis and may include a combination of up to 4 fenestrations and branches for mesenteric and renal arteries. An additional 5th branch or fenestration may be included if there is a large accessory renal artery. Branches will be used for downward-oriented mesenteric and renal arteries and fenestrations for renal arteries that project laterally or upwards."
3035705|NCT02323568|Other|Gynecological consulation|
3035706|NCT02323555|Experimental|Paramedic telephone consultation|"Establishment of a paramedic telephone consultation to the doctor to record the virtual early prescription or non-injectable cancer treatment before the arrival of the patient (Feasibility Process Optima), without changing the current practice of prescribing and dispensing of these treatments on the day of the coming of the patient."
3035707|NCT02323542|Experimental|High-SDS biscuit|Biscuit with high Slowly Digestible Starch content
3035708|NCT02323542|Active Comparator|Low-SDS cereal product|Cereal product with low Slowly Digestible Starch content
3035709|NCT02323529|Experimental|Nitisinone treatment group|All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks.
3035710|NCT02323516|Experimental|Acetylsalicylic acid + loperamide|Acetylsalicylic acid + loperamide
3035711|NCT02323516|Active Comparator|diosmectite + loperamide|Acetylsalicylic acid + loperamide
3035712|NCT02323490|Experimental|with microfractures|Standardized meniscal repair with bone marrow stimulation techniques (microfractures)
3035713|NCT02323490|Placebo Comparator|without microfractures|Standardized meniscal repair without augmentation
3035714|NCT02323477|Experimental|Allogeneic umbilical cord MSC group|Allogeneic human umbilical cord MSCs will be transplanted to 39 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF<%45)
3035715|NCT02323477|Active Comparator|Autologous bone marrow-derived MNC group|Autologous bone marrow-derived MNCs will be transplanted to 20 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF<%45)
3035716|NCT02323477|No Intervention|Control group|20 male patients (age 30-80) undergoing CABG in chronic ischemic cardiomyopathy (EF<%45) whom will not received any further transplantation
3035717|NCT02323464||1. Before surgery|240 patients scheduled for surgery of colorectal cancer
3035718|NCT02323464||2. Before and after open surgery|35 patients scheduled for open surgery of colorectal cancer.
3035719|NCT02323464||3. before and after robot or laparoscopic surgery|25 patients scheduled for laparoscopic or robot surgery of colorectal cancer.
3035720|NCT02323451|Experimental|Medical Chitosan|Medical Chitosan, 2ml/vial (12mg/ml), intra-articular injection with a volume less than 2ml every two weeks, a total of 3 times
3035721|NCT02323451|Active Comparator|Sodium Hyaluronate Injection|Sodium Hyaluronate Injection, 2ml/vial (10mg/ml), intra-articular injection with a volume less than 2ml every one weeks, a total of 5 times.
3035722|NCT02323438|Active Comparator|Usual Brand (UB) Cigarettes|Usual Brand Cigarette
3035723|NCT02323438|Experimental|Electronic Cigarette #1|VUSE® (original flavor, 29 mg nicotine)
3035724|NCT02323438|Experimental|Electronic Cigarette #2|VUSE® (menthol flavor, 26 mg nicotine)
3035725|NCT02323438|Experimental|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
3035726|NCT02323425|Experimental|Remote Ischemic Postconditioning|remote ischemic postconditioning（RIPC） treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation twice a day for the total of 180 consecutive days.
3035727|NCT02323425|No Intervention|Control|Patients in control group will receive foundation treatment. Foundation treatment: including blood vessel expansion、free radical elimination etc during acute phase and aspirin (100-300 mg/d), and atorvastatin (20 mg/d) till the end of the study (180 consecutive days).
3035728|NCT02323412|Experimental|Amoxicillin|Amoxicillin (Amoksicillintrihydrat) tablets 750 mg 1x3 for 100 days (oral intake). The tablets will be encapsulated in Capsugel DB-caps AAel Swedish orange.
3035729|NCT02323412|Placebo Comparator|Placebo|Placebo capsules for 100 days of daily (1x3), oral intake. The placebo tablets will also be encapsulated in Capsugel DB-caps AAel Swedish orange.
3035730|NCT02323399|Experimental|Phenylephrine|Phenylephrine Hydrochloride Injection, USP (United States Pharmacopeia) 10 mg/mL label claim
3035731|NCT02323386|Experimental|ATTUNE knee system|The patients will undergo primary Total Knee Arthroplasty (ATTUNE knee system)
3035732|NCT02323373|Experimental|Topical group|Intervention: Tranexamic Acid - topical. Topical administration of a solution of 1.5 g of tranexamic acid (50 mg/ml, Transamin, Zydus Nikkho) diluted in 50 ml of saline (at 0.9%), sprayed over the operated area, covering it for 5 minutes, before the tourniquet release.
3035733|NCT02323373|Active Comparator|Intravenous group|Intervention: Tranexamic Acid - intravenous Intravenous injection of 20 mg/kg of tranexamic acid, diluted in 100 ml of saline at 0.9%, administered with anesthesia in 10 minutes.
3035734|NCT02323373|Placebo Comparator|Placebo|Intervention: intravenous injection of 100 ml of saline solution also administered with anesthesia in 10 minutes.
3035735|NCT02323360|Experimental|Stereotactic body radiation therapy|HCC after incomplete TAE or TACE treated by SBRT
3035736|NCT02323360|Active Comparator|TACE/TAE|HCC after incomplete TAE or TACE treated by a new cycle of TAE or TACE
3035737|NCT02323334|Experimental|LY3202626 Part A|Single doses of LY3202626 given orally in capsule form administered up to once in each of 4 periods in a crossover fashion. Some participants may also receive multiple doses of 200 mg of Itraconazole orally in 1 period.
3035738|NCT02323334|Experimental|LY3202626 Part B Low dose|Single oral dose of LY3202626 in capsule form. Dose determined by Part A.
3035739|NCT02323334|Experimental|LY3202626 Part B Mid dose|Single oral dose of LY3202626 in capsule form. Dose determined by Part A.
3035740|NCT02323334|Experimental|LY3202626 Part B High Dose|Single oral dose of LY3202626 in capsule form. Dose determined by Part A.
3035741|NCT02323334|Experimental|LY3202626 Part C Low dose|Multiple oral doses of LY3202626 in capsule form. Drug is given once daily, for 14 days. Dose determined by Part B.
3035742|NCT02323334|Experimental|LY3202626 Part C Mid dose|Multiple oral doses of LY3202626 in capsule form. Drug is given once daily for 14 days. Dose determined by Part B.
3035743|NCT02323334|Experimental|LY3202626 Part C High dose|Multiple oral doses of LY3202626 in capsule form. Drug is given once daily for 14 days. Dose determined by Part B.
3035744|NCT02323334|Experimental|LY3202626 Part D|Multiple oral doses of LY3202626 in capsule form. Drug is given once daily for 14 days. Dose determined by Part B.
3035745|NCT02323334|Placebo Comparator|Placebo Part A|Single oral dose of placebo given in capsule form.
3035746|NCT02323334|Placebo Comparator|Placebo Part B|Single oral dose of placebo given in capsule form.
3035747|NCT02323334|Placebo Comparator|Placebo Part C|Multiple oral doses of placebo given in capsule form. Placebo is given once daily for 14 days.
3035748|NCT02323321|Experimental|OCS Preservation|OCS Preservation and Assessment
3035749|NCT02323308||vaccination|Anti-HBV vaccine injection
3035750|NCT02323295|Experimental|Non Surgical-Radiation Only|Non-surgical candidates receive 72 up to 77.l4 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma
3035751|NCT02323295|Experimental|Malignant Tumor Surgery And Radiation|The standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor. After approximately 6 weeks of recovery, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease). If the wound is not healed or there is another medical reason to delay adjuvant radiation, then radiation may begin later.
3035752|NCT02323282|Other|ropivacine|
3035753|NCT02323269||Treatment naive to dimethyl fumarate|Participants who are prescribed dimethyl fumarate as their initial therapy will receive 120 mg tablet administered orally twice a day for 7 days, then switch to maintenance dose of 240 mg tablet twice daily.
3035754|NCT02323269||Switch to dimethyl fumarate|Participants who are prescribed dimethyl fumarate after suboptimal response to IFN or GA will receive 120 mg tablet administered orally twice a day for 7 days, then switch to maintenance dose of 240 mg tablet twice daily.
3035755|NCT02323256|Experimental|newly cochlear implanted adult patients|longitudinal group
3035756|NCT02323256|Experimental|newly cochlear implanted children|longitudinal group
3035757|NCT02323256|Active Comparator|cochlear implanted adult patients (CI>1 year)|transversal group
3035758|NCT02323256|Active Comparator|normal hearing adult subjects|transversal group
3035759|NCT02323243|Experimental|Allium BUS|Temporary urethral stent
3035760|NCT02323230|Experimental|DPX-Survivac + low dose cyclophosphamide|
3035761|NCT02323217|Experimental|Healthy Volunteers|
3035762|NCT02323204|Experimental|Psychological First Aid|Link for Injured Kids, a form of psychological first aid
3035763|NCT02323204|Active Comparator|Trauma Education|"Educational materials, So you've been in an accident provided to parents."
3035764|NCT02323191|Experimental|Part 1 (Dose-finding): Emactuzumab + Atezolizumab|Participants will receive escalating doses of emactuzumab along with atezolizumab every 3 weeks (q3w).
3035765|NCT02323191|Experimental|Part 2 (Expansion): Emactuzumab + Atezolizumab|Participants will receive emactuzumab at or below the MTDs for the combination treatments that are determined during Part 1 along with atezolizumab.
3035766|NCT02323178|Experimental|eltrombopag|
3035767|NCT02323165||Burns and Wound Care|Blood samples will be taken to detect and identify a molecular detection of bacteria in the bloodstream. In addition, data will be collected from the standard of care blood samples and compared.
3035768|NCT02323152|Experimental|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
3035769|NCT02323152|Active Comparator|Control group|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment.
3035770|NCT02323139|Experimental|Combination of azacitidine and LDE255|Combination of azacitidine at maximum tolerated dose and LDE255 at dose escalation, the starting dose will be 400 mg
3035771|NCT02323126|Experimental|Nivolumab and EGF816|Arm 1 (EGF816 + nivolumab) is currently closed to new enrollment.
3035772|NCT02323126|Experimental|Nivolumab and INC280|Arm 2 (INC280 + nivolumab) is open and enrolling as planned.
3035773|NCT02323113|Experimental|Phase 1b: TAK-659|TAK-659 tablets taken orally, once daily or twice daily on Days 1-28 in a 28 day cycle, for up to 12 cycles or until disease progression. Dosage of TAK-659 may increase in 20 mg increments using a 3 + 3 dose escalation design to determine a MTD and/or RP2D.
3035774|NCT02323113|Experimental|Phase 2: TAK-659|TAK-659, tablets taken orally, once daily or twice daily on Days 1-28 in a 28 day cycle, for up to 12 cycles or until disease progression. Dosage for this phase will be determined from results of Phase 1b MTD/RP2D.
3035775|NCT02323100|Active Comparator|Ravicti low dose|Low dose Ravicti® oral liquid at 6ml (6.6 gm) by mouth or gastrostomy tube at 8 am, 5.5 ml (6.05gm) at 4pm and midnight for 7 days.
3035776|NCT02323100|Active Comparator|Ravicti high dose|Ravicti® oral liquid at 9ml (9.9 gm)at 8 am and 8.25ml (9.08 gm) at 4pm and midnight for 7 days.
3035777|NCT02323100|Placebo Comparator|Placebo|Matching placebo taken at 8am, 4pm and midnight for 7 days.
3035778|NCT02323087|Active Comparator|Culture and susceptibility testing|Urine culture and sensitivity testing will be performed using the FLEXICULT™ SSI-Urinary Kit
3035779|NCT02323087|Active Comparator|Culture|Point of care culture will be performed using ID FlexicultTM
3035780|NCT02323074|Experimental|fBCI-robot|focalized BCI-robot hand training
3035781|NCT02323074|Experimental|gBCI-robot|generalized BCI-robot hand training
3035782|NCT02323074|Sham Comparator|sham-BCI|Sham BCI
3035783|NCT02323061|Experimental|BCI-robot (I)|EEG guided training based on ipsilesional EEG signals; Training for 20 sessions
3035784|NCT02323061|Experimental|BCI-robot (IC)|EEG guided training based on both ipsilesional and contralesional EEG signals; Training for 20 sessions
3035785|NCT02323061|Placebo Comparator|robot|Training for 20 sessions
3035786|NCT02323048|Experimental|Paired, high reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
3035787|NCT02323048|Experimental|Paired, low reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
3035788|NCT02323048|Experimental|Paired no reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
3035789|NCT02323048|Experimental|Unpaired, high reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
3035790|NCT02323048|Experimental|Unpaired, low reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
3035791|NCT02323035|Experimental|Headgear|Investigative Headgear with CPAP Mask.
3035792|NCT02323022|Experimental|IAC regimen|Patients in this arm will receive an IAC induction therapy
3035793|NCT02323022|Active Comparator|High-dose IA regimen|Patients in this arm will receive an IA induction therapy, in which the idarubicin dose should be 10mg/msq/d
3035794|NCT02323022|Active Comparator|Intermediate-dose IA regimen|Patients in this arm will receive an IA induction therapy, in which the idarubicin dose should be 12mg/msq/d
3035795|NCT02323009|Active Comparator|Esophageal balloon Arm|Patients in this arm were randomly assigned to have their PEEP adjusted to maintain a positive transpulmonary pressure (0 to 10 cm H20).
3035796|NCT02323009|Active Comparator|Cstat Arm|Patients in this arm had their PEEP adjusted to achieve the best static effective compliance (CStat).
3035797|NCT02323009|No Intervention|Historic Controls|These were historic controls with similar patient characteristics weaned by traditional methods in the 2-year period prior to the start of the study.
3035798|NCT02322996||open label|After the surgery and the onset of moderate-severe pain, QST and PROMIS questionnaires will be repeated. Throughout these procedures, patients will rate their pain perception using a numeric rating scale. Approximately 2-3 hours after surgery at the onset of moderate pain, the rescue analgesic (toradol) will be administered via intramuscular injection. Again, QST and PROMIS protocols will be repeated after the drug is given and when patients report pain relief. A standard naproxen dose of 500 mg will be given to patients upon leaving the clinic and they will be instructed to take one pill orally each day before returning for evaluation after 48 hours.
3035799|NCT02322983|Experimental|Cerebral Palsy Subjects|Use of conscious sedation with nitrous oxide in the control of stress during dental treatment in individuals with Cerebral Palsy
3035800|NCT02322970||Intracranial Pressure monitoring|Invasive Intracranial Pressure monitoring will be compared to non invasive intracranial monitoring ( through use of transcranial Doppler ).
3035801|NCT02322957|Experimental|Treatment Regimen A|FV-100 400mg OD as a single dose fasted (>/= 8 hours)
3035802|NCT02322957|Experimental|Treatment Regimen B|FV-100 400 mg OD as a single dose with ritonavir 200mg OD as a single fasted dose (>/= 8 hours)
3035803|NCT02322944|Experimental|Intervention group|The intervention group will take the treatment quality improvement strategies and tools into implementation.
3035804|NCT02322944|No Intervention|Control group|The control group will maintain the routine practice pattern.
3035805|NCT02322944|Experimental|Process optimization group|The process optimization group's clinical pathways and team building will be re-organized for the purpose of quality improvement, and develop individualized treatment strategies and process.
3035806|NCT02322931|Experimental|Imaging interventions|Eligible patients who consent to participate in this study will undergo a combination of 4 different imaging interventions (based on the group they're in, as described in the protocol), intra-operatively, in addition to their standard LDR brachytherapy treatment.
3035807|NCT02322918||Participants admitted to BCPP|Blood or saliva samples will be collected from participants for whole genomic/transcriptomic sequencing
3035808|NCT02322905|Experimental|Emotion Regulation Therapy|8 sessions of Emotion Regulation Therapy.
3035809|NCT02322905|No Intervention|Usual Medical Care|No planned psychotherapy.
3035810|NCT02322892|Placebo Comparator|Control Arm|50 mL normal saline solution
3035811|NCT02322892|Experimental|Thiamine|200 mg thiamine in 50 mL normal saline solution
3035812|NCT02322879|Experimental|Acetaminophen first, then Acetaminophen + Propylene Glycol|"Subjects in this arm will receive 4 grams of solid acetaminophen formulation for two weeks, followed by a two week wash out period.~Then, subjects will receive 4 grams of solid acetaminophen formulation in addition to 70 mg/kg/day of liquid propylene glycol for two weeks.~The total study time is 6 weeks."
3035813|NCT02322879|Experimental|Acetaminophen + Propylene Glycol first, then Acetaminophen|"Subjects in this arm will receive 4 grams of solid acetaminophen formulation in addition to 70 mg/kg/day of liquid propylene glycol for two weeks, followed by a two week wash out period.~Then, subjects will receive 4 grams of solid acetaminophen formulation for two weeks.~The total study time is 6 weeks."
3035814|NCT02322866|Experimental|Sarecycline|Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
3035815|NCT02322866|Placebo Comparator|Placebo|Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.
3035816|NCT02322853|Active Comparator|TAMOXIFEN|"Tamoxifen will be administered daily orally~Patients will receive study medication until disease progression or unacceptable toxicity"
3035817|NCT02322853|Experimental|TAMOXIFEN + LY2228820|"Tamoxifen will be administered daily orally LY2228820 dimesylate (Ralimetinib) will be administered orally~Patients will receive study medication until disease progression or unacceptable toxicity"
3035818|NCT02322827||single tablet regimen|Subjects whose most recent antiretroviral therapy consist of a single tablet regimen
3035819|NCT02322827||multiple tablet regimen|Subjects whose most recent antiretroviral therapy consist of multi tablet regimen
3035820|NCT02322814|Experimental|Cohort I: Cobimetinib, Paclitaxel|Participants will receive a combination of cobimetinib plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
3035821|NCT02322814|Placebo Comparator|Cohort I: Placebo, Paclitaxel|Participants will receive a combination of cobimetinib placebo plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
3035822|NCT02322814|Experimental|Cohort II:Cobimetinib,Paclitaxel,Atezolizumab|Participants will receive cobimetinib plus paclitaxel plus atezolizumab in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
3035823|NCT02322814|Experimental|Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab|Participants will receive cobimetinib plus nab-paclitaxel plus atezolizumab until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
3035824|NCT02322801||Cohort|
3035825|NCT02322788|Active Comparator|Bricanyl Turbuhaler M2, Active|Terbutaline sulphate powder for inhalation, 0.5 mg terbutaline per inhalation
3035826|NCT02322788|Active Comparator|Bricanyl Turbuhaler M3, Active|Terbutaline sulphate powder for inhalation, 0.4 mg terbutaline per inhalation
3035827|NCT02322788|Placebo Comparator|Turbuhaler M2, Placebo|Placebo powder for inhalation
3035828|NCT02322788|Placebo Comparator|Turbuhaler M3, Placebo|Placebo powder for inhalation
3035829|NCT02322775|Experimental|Arm A|Benralizumab administered subcutaneously every 4 weeks
3035830|NCT02322775|Experimental|Arm B|Placebo administered subcutaneously every 4 weeks
3035831|NCT02322762||One single cohort.|One single cohort of patients with type 2 diabetes mellitus initiating their second line anti-diabetic therapy after first line anti-diabetic therapy.
3035832|NCT02322749|Experimental|Treatment A|AZD6244 blue reference capsules (3 x 25 mg) administered orally
3035833|NCT02322749|Experimental|Treatment B|AZD6244 blue capsules (3 x 25 mg) Variant 1 (free base variant) administered orally
3035834|NCT02322749|Experimental|Treatment C|AZD6244 blue capsules (3 x 25 mg) Variant 2 (vitamin E polyethylene glycol succinate [TPGS] variant) administered orally
3035835|NCT02322736||WT RAS mCRC|Wild Type RAS metastatic colorectal cancer patients
3035836|NCT02322723||Moderately to severely active RA patients|Moderately to severely active RA patients aged 18 years or older, both male and female
3035837|NCT02322710|Active Comparator|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
3035838|NCT02322710|Active Comparator|Urgotul|Sterile, hydrocolloid dressing, that consists of a polyester fabric coated with hydrocolloid particles and vaseline
3035839|NCT02322697|Experimental|Carnitine group|Intravenous administration of L-carnitine 1000mg after each hemodialysis session (three times a week) for one year.
3035840|NCT02322697|No Intervention|control group|No intervention
3035841|NCT02322684|Active Comparator|Group Q|Blind endotracheal intubation will be performed through the air-Q
3035842|NCT02322684|Active Comparator|Group B|Blind endotracheal intubation will be performed through the air-Q with bougie assisted
3035843|NCT02322671|Experimental|Sequence ABC|Subjects will be administered a single oral dose of treatment A, B and C in the sequence ABC, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
3035879|NCT02322463||Jewish children (controls)|Jewish patients who were admitted to the pediatric ED due to a limb fracture between 01 January 2011 and 31 October 2014, who were treated with Oxycodone
3035844|NCT02322671|Experimental|Sequence ACB|Subjects will be administered a single oral dose of treatment A, B and C in the sequence ACB, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
3035845|NCT02322671|Experimental|Sequence BAC|Subjects will be administered a single oral dose of treatment A, B and C in the sequence BAC, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
3035846|NCT02322671|Experimental|Sequence BCA|Subjects will be administered a single oral dose of treatment A, B and C in the sequence BCA, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
3035847|NCT02322671|Experimental|Sequence CAB|Subjects will be administered a single oral dose of treatment A, B and C in the sequence CAB, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
3035848|NCT02322671|Experimental|Sequence CBA|Subjects will be administered a single oral dose of treatment A, B and C in the sequence CBA, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
3035849|NCT02322658|Experimental|Eszopiclone Tablets|Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited
3035850|NCT02322658|Active Comparator|Lunesta|Lunesta Tablets 3 mg of Sepracor Inc.
3035851|NCT02322645|Experimental|Eszopiclone Tablets|Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited
3035852|NCT02322645|Active Comparator|Lunesta|Lunesta Tablets 3 mg of Sepracor Inc.
3035853|NCT02322632|Experimental|Paricalcitol Capsules, 4 mcg|Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
3035854|NCT02322632|Experimental|Zemplar Capsules, 4 mcg|Zemplar Capsules, 4 mcg of Abott Laboratories USA
3035855|NCT02322619|Experimental|Moxifloxacin Tablets 400 mg|Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
3035856|NCT02322619|Active Comparator|Avelox Tablets 400 mg|Avelox® Tablets 400 mg of Bayer Healthcare Pharmaceuticals Inc.
3035857|NCT02322606|Other|Cohort 1: TAK-137 5 mg, TAK-137 placebo|Single-dose administration in a fasting state
3035858|NCT02322606|Other|Cohort 2: TAK-137 10 mg, TAK-137 placebo tablet|Single-dose administration in a fasting state
3035859|NCT02322606|Other|Cohort 3: TAK-137 20 mg or TAK-137 2 mg + TAK-137 placebo|Single-dose administration in a fasting state
3035860|NCT02322606|Other|Cohort 4: TAK-137 5mg, TAK-137 placebo|Once daily for 7 days in a fasting state
3035861|NCT02322606|Other|Cohort 5: TAK-137 10 mg, TAK-137 placebo|Once daily for 7 days in a fasting state
3035862|NCT02322606|Other|Cohort 6: TAK-137 15 mg, TAK-137 placebo|Once daily for 7 days in a fasting state
3035863|NCT02322593|Experimental|TAS-118/Oxaliplatin|TAS-118 plus Oxaliplatin
3035864|NCT02322593|Active Comparator|S-1/Cisplatin|S-1 plus Cisplatin
3035865|NCT02322580||Psoriasis patients who receive Enbrel® therapy|
3035866|NCT02322567||LV diastolic dysfunction|
3035867|NCT02322567||No LV diastolic dysfunction|
3035868|NCT02322554||wounds treated with CTPs|All cellular and tissue based products currently reimbursed in the hospital based outpatient department, administered at intervals as determined in the course of clinical practice
3035869|NCT02322541|Experimental|Time Course|Measurement of garlic metabolites over 24 hours following garlic intervention.
3035870|NCT02322528|Other|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to both eyes to induce an inflammatory mediated response.
3035871|NCT02322515|Experimental|Intervention Taping|The experimental group will use a rigid patellar taping (G1, n = 22) for the correction of lateralization of the patella and stabilization of the knee. The lateral stabilization will be made with self-adhesive taping positioned in the lateral border of the patella and tensioned in relation to the medial portion of the femur condyle, which allows an edge of the medial board patella and a stretching of lateral structures of the knee. All procedure will follow the recommendation from McConnell studies with regard to the patellar femoral syndrome.
3035872|NCT02322515|Placebo Comparator|Placebo Taping|The placebo group will use a rigid patellar taping (G2, n = 22), but without no correction of lateralization of the patella and/or stabilization of the knee. The taping will be placed incorrectly such as in the vertical position of knee and without any tension or traction around structures and patella.
3035873|NCT02322502|Experimental|desflurane|Suprane® Dose: 0.8 MAC / 4-5 vol. % Mode of administration: inhalation with laryngeal mask One application
3035874|NCT02322502|Active Comparator|sevoflurane|"Sevoflurane:~Dose: 0.8 MAC / 1.2-1.4 vol.% Mode of administration: inhalation with laryngeal mask One application"
3035875|NCT02322502|Active Comparator|propofol|Propofol Dose: 5-7 mg kg-1 h-1 to maintain a BIS index value between 40 and 60 Mode of administration: intravenous One application
3035876|NCT02322489|Sham Comparator|Sham microcurrent therapy|The participant is lying on an examination table for one hour; several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but it lasts only for 5 seconds.
3035877|NCT02322489|Experimental|Microcurrent Group|The participant is lying on an examination table for one hour; several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started.
3035878|NCT02322463||Arab children (case subjects)|Arab patients who were admitted to the pediatric ED due to a limb fracture between 01 January 2011 and 31 October 2014, who were treated with Oxycodone
3035978|NCT02321709|Experimental|SAR113244 cohort 1|Two administrations of dosage 1 SAR113244 or placebo subcutaneous dose (Q4 weeks)
3035880|NCT02322450|Experimental|A: P1-QGC001 - Washout-placebo - P2-placebo|The first period (P1) will correspond either to QGC001 or placebo, the second period (P2) will correspond either to QGC001 or placebo.
3035881|NCT02322450|Experimental|B: P1-placebo - Washout-placebo - P2-QGC001|The first period (P1) will correspond either to QGC001 or placebo, the second period (P2) will correspond either to QGC001 or placebo.
3035882|NCT02322437|Experimental|Home treatment|Patients in need of acute psychiatric inpatient care are treated at their houses by mobile treatment teams instead of treatment at mental hospitals whenever home treatment is possible and appropriate.
3035883|NCT02322437|Active Comparator|Treatment as usual|Patients in need of acute psychiatric inpatient care are treated at a mental hospital.
3035884|NCT02322424||Patients who undergo pancreaticoduodenectomy|
3035885|NCT02322411|Active Comparator|Compensatory|This group will receive standard swallowing intervention, which is identified by the SLP as appropriate to treat the patient's dysphagia and is common clinical practice. Their therapy may include: 1) modifying their foods and fluids; 2) changing their posture when they eat or drink; or 3) having them eat more slowly or in a quiet environment to make swallowing easier and safer. These compensatory approaches will ensure safety while swallowing foods and fluids. Range of motion, vocal exercises, and other oromotor exercises, such as the Shaker Exercise, as well as any other potential strengthening regimens for swallowing or speech will be delayed until subjects have completed participation.
3035886|NCT02322411|Experimental|I-PRO + compensatory|The Device-Facilitated Isometric Progressive Resistance Oropharyngeal (D-F I-PRO) intervention will be completed using the SwallowSTRONG® device. Tongue press exercises consist of pressing the tongue against the sensors located along the hard palate. Isometric exercises will focus on the anterior and posterior sensor. Subjects will take the SwallowStrong® device home with them and will complete 20 repetitions of the exercise (10 repetitions at the front sensor; 10 repetitions at the back sensor), three times per day on three days per week for twelve weeks.
3035887|NCT02322398||Group A|Patients who had been stimulated with a starting dose of 150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio.
3035888|NCT02322398||Group B|Patients who had been stimulated with a starting dose of 150-300 IU/d hMG.
3035889|NCT02322372|Active Comparator|Group F|Ultrasound-guided femoral blockade with 15 mL of bupivacaine 0.5% diluted in 15 mL saline was performed in supine position. Then the patient was turned to lateral decubitus position with the operated extremity on dependant position and intrathecal injection of heavy bupivacaine 1 mL (5 mg) was administered from L3-L4 intervertebral space at a rate of 1 mL/20 second.
3035890|NCT02322372|Active Comparator|Group S|The patient was turned to lateral decubitus position with the operated extremity on dependant position and intrathecal injection of heavy bupivacaine 2 mL (10 mg) was administered from L3-L4 intervertebral space at a rate of 1 mL/20 second.
3035891|NCT02322346|Placebo Comparator|Group S|Preincisional bilateral peritonsillar infiltration of a total of 6 mL of saline
3035892|NCT02322346|Active Comparator|Group LL|Preincisional bilateral peritonsillar infiltration of levobupivacaine 0.25% (3 mL to each tonsil).
3035893|NCT02322346|Active Comparator|Group HL|Preincisional bilateral peritonsillar infiltration of levobupivacaine 0.5% (3 mL to each tonsil).
3035894|NCT02322333|Active Comparator|MLD10|Subjects randomized to MLD10 will be dispensed a 28 day supply of magnesium L-lactate dehydrate for daily treatment. A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window. Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day. Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
3035895|NCT02322333|Placebo Comparator|Placebo|Subjects randomized to placebo will be dispensed a 28 day supply of matching placebo for daily treatment. A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window. Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day. Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
3035896|NCT02322320|Active Comparator|Tandem Auto Transplant|Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance
3035897|NCT02322320|Active Comparator|RVD Consolidation|Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance
3035898|NCT02322320|Active Comparator|Lenalidomide Maintenance|Initial autologous transplant followed by lenalidomide maintenance
3035899|NCT02322307|Experimental|HealthPROMISE users|These are patients who will receive HealthPROMISE application. Patients will be asked to track their quality of life and quality of care using standardized metrics. A combination of different questionnaires (i.e. Short IBD Questionnaire), symptom updates, and IBD quality indicators will be the collected during this study through the HealthPROMISE application.
3035900|NCT02322307|Placebo Comparator|Control Group|After entering baseline questionnaire, control patients get a link to download education application along with PIN. Once patients install app on their devices and use the PIN, the patient is considered to be enrolled in the trial from intention to treat perspective. This control app allows access to patient education content only. There is not any direct feedback on Quality of Life, quality of care and resource utilization.
3035901|NCT02322294|Experimental|Glucodia™|
3035902|NCT02322294|Placebo Comparator|Placebo|
3035903|NCT02322281|Experimental|Rociletinib Monotherapy (500 mg BID)|Daily oral rociletinib at 500 mg BID with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Treatment with rociletinib is continuous and each cycle will comprise of 21 days.
3035904|NCT02322281|Experimental|Rociletinib Monotherapy (625 mg BID)|Daily oral rociletinib at 625 mg BID with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Treatment with rociletinib is continuous and each cycle will comprise of 21 days.
3035938|NCT02322021|Experimental|MCI/Prodromal Cohort: Low Dose|A low dose of elenbecestat (E2609) will be assessed. After 6 or more months of treatment with a low dose of elenbecestat (E609), participants with at least 3 months of treatment remaining will be re-assigned to receive a high dose of elenbecestat (E2609) for the remainder of the double-blind treatment period. Eligible participants will receive a high dose of open-label elenbecestat (E2609) during the Open-Label Extension (OLE) Phase.
3062783|NCT02142933|Other|rectal swab and vagino-perineal swab|single-arm
3035905|NCT02322281|Active Comparator|Pemetrexed or gemcitabine or paclitaxel or docetaxel|"Pemetrexed~500 mg/m2 pemetrexed given intravenously on Day 1 of each 21-day cycle.~Gemcitabine~1250 mg/m2 gemcitabine given intravenously on Day 1 and 8 of each 21-day cycle.~Docetaxel~75 mg/m2 docetaxel (60 mg/m2 for patients residing in East-Asian territories) given intravenously on Day 1 of each 21-day cycle.~or 35 mg/m2 docetaxel given intravenously on a weekly basis as part of a continuous 21-day cycle; i.e. dosing will be on Days 1, 8, and 15 of each 21-day cycle.~Paclitaxel~80 mg/m2 paclitaxel given intravenously on a weekly basis as part of a continuous 21-day cycle; i.e. dosing will be on Days 1, 8, and 15 of each 21-day cycle."
3035906|NCT02322268|Experimental|Diabetic Cosmos caudatus treated group|Subjects in this arm will receive Cosmos caudatus for 8 weeks.
3035907|NCT02322268|No Intervention|Diabetic control group|Subject in this group will not receive Cosmos caudatus. However, they will be educated for the same calorie intake and lifestyle intervention as in Cosmos caudatus treated group.
3035908|NCT02322255||All Subjects|All subjects enrolled in the study.
3035909|NCT02322242|Active Comparator|Perineural Dexamethasone|ISB performed with local anesthetic (ropivacaine 0.5%) and perinerual dexamethasone (4mg)
3035910|NCT02322242|Other|Systemic Dexamethasone|ISB with local anesthetic alone (ropivacaine 0.5%) alone and intravenous dexamethasone (4mg)
3035911|NCT02322229|Experimental|Ocriplasmin|Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal (IVT) injection
3035912|NCT02322216|Experimental|PATADAY|Olopatadine hydrochloride ophthalmic solution 0.2% in the morning and olopatadine 0.2% vehicle in the evening, 1 drop in each eye for 14 days
3035913|NCT02322216|Active Comparator|PATANOL|Olopatadine hydrochloride ophthalmic solution 0.1%, 1 drop in each eye in the morning and evening, for 14 days
3035914|NCT02322203|Experimental|1|Niacin - 500 mg/day for 1 week, then 1000 mg/day for 1 week, then 2000 mg/day for 14 weeks.
3035915|NCT02322190|No Intervention|1|Investigator chosen second line therapy
3035916|NCT02322190|Experimental|2|Second line therapy in addition to ECP
3035917|NCT02322138|Experimental|Experimental 1 Infant Formula|Milk-based infant formula without prebiotics
3035918|NCT02322138|Experimental|Experimental 2 Infant Formula|Milk-based infant formula with prebiotics
3035919|NCT02322138|Other|Human Milk-Fed Reference Group|Breast fed infants
3035920|NCT02322125|Experimental|ReWalk training|ReWalk exoskeleton training: 1.5 hr/day, 4 days/week, for 12-14 weeks (approximately 50 training sessions). Participants will progress through the following: sit-to-stand, stand-to-sit, standing balance and weight shift, walking on smooth ground, stopping, turning while walking, walking on rough ground, ascending and descending slopes, ascending and descending steps and curbs.
3035921|NCT02322112|Placebo Comparator|Microcrystalline Cellulose (Control)|Microcrystalline cellulose will be used as a placebo control, as it is known to be an insoluble, non-viscous fiber that is essentially not fermented by the human gut microbiota. However, it is important to note that cellulose does have fermentation potential within the gastrointestinal tract and may be associated with improved health benefits; indicating a role as an active comparator.
3035922|NCT02322112|Experimental|Acacia Gum|Acacia gum is composed largely of arabinogalactan, and is considered to be a relatively non-viscous, soluble fiber this is highly fermented by the gut microbiota and well tolerated.
3035923|NCT02322112|Experimental|Resistant Starch Type 4|Cross-linked phosphorylated resistant starch (type IV) is generally insoluble and with low viscosity; yet it tends to have physiologic properties similar to soluble fibers, such as fermentability.
3035924|NCT02322099|Active Comparator|Alendronate|Alendronate 70 mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada®
3035925|NCT02322099|Placebo Comparator|Placebo|Placebo to alendronate 70mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada®
3035926|NCT02322086|Experimental|PH-10|Active treatment
3035927|NCT02322073||Lean healthy controls|Healthy controls with BMI 18.5-24.9 Laparoscopic surgery eg cholecystectomy, fundoplication or Heller myotomy and fundoplication or laparoscopic hernia repair.
3035928|NCT02322073||Obese healthy|Obese healthy BMI 35-55 Laparoscopic Roux-en-Y gastric bypass
3035929|NCT02322073||Obese kidney disease|Obese kidney disease BMI 35-55 Laparoscopic Roux-en-Y gastric bypass
3035930|NCT02322073||Obese liver disease|Obese liver disease BMI 35-55 Laparoscopic Roux-en-Y gastric bypass
3035931|NCT02322060||Primary ovarian insufficiency|"Primary ovarian insufficiency (POI; also known as premature ovarian failure/dysfunction/insufficiency or premature menopause) is characterised by amenorrhoea, sex hormone (oestrogen, progesterone and testosterone) deficiency and elevated gonadotrophins levels in a woman aged more than two standard deviations below the mean age of menopause estimated for her reference population. POI is defined as a disorder in ovarian function in any woman before the age of 40 years, irrespective of the cause.~In our study, we mainly recruit POI patients who also desire to have a baby of their own."
3035932|NCT02322047|Experimental|Prazosin and Naltrexone|Prazosin and Naltrexone
3035933|NCT02322047|Active Comparator|Prazosin and Placebo|Prazosin and (Nal)Placebo
3035934|NCT02322047|Active Comparator|Naltrexone and Placebo|Naltrexone and (Praz)Placebo
3035935|NCT02322047|Placebo Comparator|Placebo and Placebo|(Praz)Placebo and (Nal)Placebo
3035936|NCT02322034|Experimental|Interval Training|Hospital outpatient-based regimen (3 times/week for 24 weeks) exercise program will be performed by cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
3035937|NCT02322034|No Intervention|Controls|CHF patients allocated to the control group (no intervention) will undergo biochemical and hormonal sampling, Doppler-echocardiography, cardiopulmonary exercise stress testing at study enrollment and at 24-week follow-up.
3035975|NCT02321748|Other|Montelukast|10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
3035976|NCT02321748|Other|ASP2151|10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
3035977|NCT02321735|Other|Long-Term Ovarian Cancer survivors|Genomic, immunologic and psychosocial characterization of Long-Term survivors of ovarian cancer. This will involve a Quality of Life Questionaire.
3035939|NCT02322021|Experimental|MCI/Prodromal Cohort: Middle Dose|A middle dose of elenbecestat (E2609) will be assessed. After 6 or more months of treatment with a middle dose of elenbecestat (E2609), participants with at least 3 months of treatment remaining will be re-assigned to receive a high dose of elenbecestat (E2609) for the remainder of the double-blind treatment period. Eligible participants will receive a high dose of open-label elenbecestat (E2609) during the OLE Phase.
3035940|NCT02322021|Experimental|MCI/Prodromal Cohort: High Dose|A high dose of elenbecestat will be assessed during the double-blind treatment period and during the OLE Phase for participants meeting OLE eligibility criteria.
3035941|NCT02322021|Placebo Comparator|MCI/Prodromal Cohort: Placebo|During the double-blind portion of the study, two matching placebo tablets will be administered daily. During the OLE Phase, participants will receive the high dose as a single tablet.
3035942|NCT02322021|Experimental|Mild to Moderate AD Cohort: Low Dose|A low dose of elenbecestat (E2609) will be assessed. After 6 or more months of treatment with a low dose of elenbecestat (E2609), participants with at least 3 months of treatment remaining will be re-assigned to receive a high dose of elenbecestat (E2609) for the remainder of the double-blind treatment period. Eligible participants will receive a high dose of open-label elenbecestat (E2609) during the OLE Phase.
3035943|NCT02322021|Experimental|Mild to Moderate AD cohort: Middle Dose|A middle dose of elenbecestat (E2609) will be assessed. After 6 or more months of treatment with a middle dose of elenbecestat (E2609), participants with at least 3 months of treatment remaining will be re-assigned to receive a high dose of elenbecestat (E2609) for the remainder of the double-blind treatment period. Eligible participants will receive a high dose of open-label elenbecestat (E2609) during the OLE Phase.
3035944|NCT02322021|Experimental|Mild to Moderate AD Cohort: High Dose|A high dose of elenbecestat will be assessed during the double-blind treatment period and during the OLE Phase for participants meeting OLE eligibility criteria.
3035945|NCT02322021|Placebo Comparator|Mild to Moderate AD Cohort: Placebo|During the double-blind portion of the study, two matching placebo tablets will be administered daily. During the OLE Phase, participants will receive the high dose as a single tablet.
3035946|NCT02321982|No Intervention|Separate-day preoperative consultation|Patients referred for Mohs surgery for non-melanoma skin cancer will have a preoperative consultation in advance of the day of the procedure.
3035947|NCT02321982|Experimental|Same-day preoperative consultation|Patients referred for Mohs surgery for non-melanoma skin cancer will have a preoperative consultation on the day same day as the procedure.
3035948|NCT02321969|No Intervention|Control|Without green tea extract (GTE) supplementation
3035949|NCT02321969|Experimental|GTE group|GTE supplementation for 12 months after polypectomy for colorectal adenomatous polyps
3035950|NCT02321956|Experimental|Ultrasound|Using ultrasound measurement of the subglottic area to choose endotracheal tube size
3035951|NCT02321956|No Intervention|Formula|Using Cole's formula to choose endotracheal tube size
3035952|NCT02321943||Follow-Up Group|"An earlier investigated cohort with first episode psychosis patients from two Norwegian counties. Being between 18 - 65 years old and being consecutive in- or outpatient referred to first adequate treatment for a DSM-IV diagnosis of schizophrenia, bipolar disorder, or other psychosis."
3035953|NCT02321930|Other|tofacitinib 5mg po bid|Open label with tofacitinib 5mg po bid
3035954|NCT02321917|Active Comparator|Rheoparin coating|MECC system with rheoparin coating
3035955|NCT02321917|No Intervention|No rheoparin coating|MECC system without rheoparin coating
3035956|NCT02321904||Diabetic cases|Children with Type 1 Diabetes 8 to 18 years old followed at the Alberta Children's Hospital Diabetes Clinic with duration of diabetes for at least 5 years will undergo Corneal Confocal Microscopy, Nerve Conduction Studies, Quantitative sensory testing, Neuropathy Symptom Scoring and Clinical nerve examinations.
3035957|NCT02321904||Normal controls|Healthy children aged 8 to 18 years will undergo Corneal Confocal Microscopy, Nerve Conduction Studies, Quantitative sensory testing, Neuropathy Symptom Scoring and Clinical nerve examinations.
3035958|NCT02321891|Experimental|Treatment 1|NeuroConn DC Stimulator Plus, tDCS treatment protocol no 1
3035959|NCT02321891|Experimental|Treatment 2|NeuroConn DC Stimulator Plus, tDCS treatment protocol no 2
3035960|NCT02321878||Liraglutide|
3035961|NCT02321865|Experimental|NPC-02|
3035962|NCT02321852|Experimental|Verum/Placebo|This group will start with triflusal and after washout will receive placebo
3035963|NCT02321852|Experimental|Placebo/Verum|This group will start with placebo and will receive triflusal after washout.
3035964|NCT02321839|Experimental|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
3035965|NCT02321826|Experimental|Music|Listening to music for 45 minutes at bedtime
3035966|NCT02321826|Active Comparator|Audiobook|Listening to audiobook for 45 minutes at bedtime
3035967|NCT02321826|No Intervention|Control|No intervention control group
3035968|NCT02321813|Experimental|intervention group|In the quality of life pathway results of the quality of life (QoL) measure are transferred to a QoL-profile. Three experts with various professional background use the individual patient`s QoL-profile and clinical and sociodemographic information in order to generate a QoL-report including therapy recommendation which is sent to the coordinating practitioner. Specific therapeutic options for the treatment of diseased QoL have been identified: pain therapy, psychotherapy, social support, nutrition counseling, stoma care, physiotherapy, fitness. To provide continuous medical education, quality circles for each therapy option haven been founded. Coordinating practitioners receive a list with addresses of all quality circle members.
3035969|NCT02321813|Placebo Comparator|control group|In control group QoL is also measured but the coordinating practitioner neither receives a QoL-profile nor a QoL-report.
3035970|NCT02321800|Experimental|S-649266|
3035971|NCT02321800|Active Comparator|Imipenem/cilastatin|
3035972|NCT02321787|No Intervention|Traditional Methods of Assessment|The caudal block will be done using traditional means of assessment, not confirmed by ultrasound.
3035973|NCT02321787|Experimental|Ultrasound for Confirmation|The caudal block will be performed utilizing ultrasound as an additional method of assessment for successful block (in addition to all traditional means of assessment).
3035974|NCT02321761|Experimental|study group|"Dosage (mg) Day days 0-14 no drug will be given days 15-21 dosage is 100 mg days 22-28 dosage is 200mg days 29-42 dosage is 400mg days 43-56 dosage is 200mg~days 57-70 no drug will be given"
3035979|NCT02321709|Experimental|SAR113244 cohort 2|Two administrations of dosage 2 SAR113244 or placebo subcutaneous dose (Q4 weeks)
3035980|NCT02321709|Experimental|SAR113244 cohort 3|Two administrations of dosage 3 SAR113244 or placebo subcutaneous dose (Q4 weeks)
3035981|NCT02321696|Experimental|Acupuncture and eccentric exercise|Treatment will be performed according to traditional Chinese methods (STRICTA: Standards for reporting interventions in controlled trials of acupunc-ture). Therapists will select points frequently recommended for the treatment of LE. As local point, LI11 and LI10 over the muscular origin of the lateral extensor group of the forearm will be used, and LU5 in the cubical region. LI4 and TE5 will be regional points for pain therapy in the upper limb, GB34 will be used as a distal point for treatment of tendinosis in general, and ST36 for treatment of pain. Needles will be inserted down to the musculature and obtaining De Qi sensation and will remain in situ for 20 min. All patients will receive four treatment sessions; this may be extended to eight depending on patient's pain report and the therapists' clinical evaluation. Maximum treatment period is 4 weeks. Patients will also be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward.
3035982|NCT02321696|Experimental|Physiotherapy and eccentric exercise|"Manual techniques as gliding mobilization of elbow, therapists are spezialised in manual therapy. At least four treatment sessions will be performed, but depending on the patient's perceived intensity of pain and the therapists' clinical evaluation, a maximum of eight treatment session can be given. All treatment session will be performed during a period of maximum 4 weeks.~In addition, patients will be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward."
3035983|NCT02321696|Active Comparator|Watchful waiting and eccentric exercise|Patients will be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward.
3035984|NCT02321683|Experimental|Bonemaster|Cement-less femoral stems with electrochemical deposition of hydroxyapatite
3035985|NCT02321683|Active Comparator|Hydroxyapatite|Cement-less femoral stems with plasmasprayed hydroxyapatite
3035986|NCT02321670|Active Comparator|End-to-end|Excision of the stricture and end-to-end anastomosis of the urethra.
3035987|NCT02321670|Active Comparator|Graft|Incision of the stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided.
3035988|NCT02321657|Experimental|iPad app containing art, music and games|On entry to the anaesthetic room, children will be given an iPad (the intervention) with art, music and games to distract them. A nurse will help them engage with the iPad whilst the anaesthetists complete the anaesthetic. Once the child falls asleep, the iPad will be removed. This process is anticipated to last between 3 and 30 minutes depending on the time taken to anaesthetise the child.
3035989|NCT02321657|Active Comparator|Toys, books and games|On entry to the anaesthetic room, children will be given toys or games to distract them. A nurse will help them play whilst the anaesthetists complete the anaesthetic. Once the child falls asleep, the games will be removed. This process is anticipated to last between 3 and 30 minutes depending on the time taken to anaesthetise the child.
3035990|NCT02321644|Experimental|CC-90001|"Part 1: All subjects will receive the following doses of CC-90001 in the fixed sequence below:~Treatment A: 60 mg CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days Treatment B: 160 mg CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days Treatment C: 400 mg of CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days"
3035991|NCT02321644|Experimental|CC-90001 2 X 100mg fasted|Treatment D: 2 x 100 mg CC-90001 as Active-Ingredient-in-Capsule, single oral dose administered under fasted conditions.
3035992|NCT02321644|Experimental|CC-90001 1 X 200mg fasted|Treatment E: 1 x 200 mg CC-90001 [formulated tablet(s)] single oral dose administered under fasted conditions
3035993|NCT02321644|Experimental|CC-90001 1 X 200mg fed|Treatment F: 1 x 200 mg CC-90001 [formulated tablet(s)] single oral dose administered under fed conditions (standard high fat breakfast).
3035994|NCT02321631|Experimental|EPA-enriched supplement|EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
3035995|NCT02321631|Placebo Comparator|standard formula supplement|The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
3035996|NCT02321618|Experimental|BP measurement & pharmacy|BP measurements performed by barber, role model poster exposure in barbershop, and BP medication management visits with study pharmacist
3035997|NCT02321618|Other|BP educational materials|Exposure to hypertension educational materials in barbershop
3035998|NCT02321605|Experimental|BPS exercise|Intervention group which requires people to envision themselves in a future in which all has gone in the best possible way.
3035999|NCT02321605|Placebo Comparator|Daily Activities|Control group which consists of thinking and writing about all the activities and situations that had taken place during the last 24 h.
3036000|NCT02321592|Active Comparator|Arm A|"AFM13 is administered three times a week (e.g. monday-wednesday-friday) for 8 consecutive weeks.~Arm A ist closed."
3036001|NCT02321592|Active Comparator|Arm B|"AFM13 is administered three times a week (e.g. monday-wednesday-friday) for 2 consecutive weeks followed by a weekly appication 6 consecutive weeks.~Arm B is closed."
3036002|NCT02321592|Active Comparator|Arm C|AFM13 is administered for five consecutive days a week as continuous infusion for 8 consecutive weeks
3036003|NCT02321579|Placebo Comparator|Negative control|Dextrins
3036004|NCT02321579|Experimental|Supplement 1|50 mg/d vitamin B-6
3036005|NCT02321579|Experimental|Supplement 2|500 mg/d Glutathione
3036006|NCT02321579|Experimental|Supplement 3|50 mg/d vitamin B-6 plus 500 mg/d Glutathione
3036007|NCT02321566|Experimental|Treatment Arm|A craniotomy will be performed for the placement of an epidural motor cortex stimulation lead in the context of subjects with chronic facial, upper extremity, and throat pain. If the stimulation is successful during a trial period with externalized lead cabling, the system cabling will be internalized and connected to an internal implantable pulse generator to power and control the system for the duration of the trial.
3036008|NCT02321553|Experimental|Brown Rice|Eat 100g of brown rice cake (3 packets) per day for 5 weeks
3036009|NCT02321553|Experimental|White Rice|Eat 100g of white rice cake (3 packets) per day for 5 weeks
3036062|NCT02321111|Active Comparator|D5W (5% Dextrose in water) + Intralipid|IV Administration of 5% Dextrose in water /D5W (vehicle) 12 mg plus Intralipid infusion at a rate of 30 ml/hour
3036010|NCT02321540|Experimental|Ibrutinib|"Participants in Part 1 receive dose level of Ibrutinib depending on study joined. First group of participants receive lowest dose level of Ibrutinib. Each new group receives a higher dose of Ibrutinib than the group before it, if no intolerable side effects were seen. This continues until highest tolerable dose of Ibrutinib is found.~Participants in Part 2 receive Ibrutinib at highest dose that was tolerated in Part 1 or 840 mg daily.~Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle."
3036011|NCT02321527|Experimental|Perflutren Protein-Type A Microspheres Injectable Suspension|Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™). Ultrasound images and videos of tumor and lymph nodes in underarm area taken. Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery. Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
3036012|NCT02321514|Experimental|Tendyne Mitral Valve System|Transcatheter mitral valve replacement
3036013|NCT02321501|Experimental|Dose Escalation of Ceritinib (LDK378) + Everolimus|"First group of participants receive the lowest dose level of Ceritinib (LDK 378) and Everolimus. Each new group receives either higher dose of Ceritinib (LDK 378) or a higher dose of everolimus than the group before it, if no intolerable side effects were seen. This continues until highest tolerable dose of Ceritinib (LDK 378) and Everolimus is found.~Dose Escalation Phase Starting Dose of Ceritinib (LDK378): 450 mg by mouth once a day in a 28 day cycle.~Dose Escalation Phase Starting Dose of Everolimus: 5 mg by mouth once a day in a 28 day cycle."
3036014|NCT02321501|Experimental|Dose Expansion of Ceritinib (LDK378) + Everolimus|"Non small cell lung cancer participants (NSCLC) with anaplastic lymphoma kinase (ALK+) expression on IHC treated with combination of Ceritinib (LDK378) and Everolimus at maximum tolerated dose (MTD) from Dose Escalation Phase.~Dose Expansion Phase Starting Dose of Ceritinib (LDK378): MTD from Dose Escalation Phase.~Dose Expansion Phase Starting Dose of Everolimus: MTD from Dose Escalation Phase."
3036015|NCT02321501|Experimental|Dose Expansion of Ceritinib (LDK378) - NSCLC + ALK+|Non small cell lung cancer (NSCLC) participants with anaplastic lymphoma kinase (ALK+) expression on IHC receive single agent Ceritinib (LDK378) at 750 mg by mouth once a day for a 28 day cycle.
3036016|NCT02321501|Experimental|Ceritinib (LDK378) + Everolimus - Progression|Dose Expansion Phase participants with non small cell lung cancer (NSCLC), with anaplastic lymphoma kinase (ALK+) expression on IHC who have progressed, treated with Ceritinib (LDK378) and Everolimus at MTD from Dose Escalation Phase.
3036017|NCT02321475||Psycho-emotional symptoms, added to cognitive disorders|Patients of middle age and younger with psycho-emotional symptoms, added to cognitive disorders.
3036018|NCT02321462|Experimental|Eziclen|
3036019|NCT02321462|Active Comparator|Fortrans®|
3036020|NCT02321436|Active Comparator|Treatment group|Dysport® 500U intramuscular injection
3036021|NCT02321436|Placebo Comparator|Placebo Group|Placebo intramuscular injection
3036022|NCT02321410|Other|Imaging of carotid plaque|Patient undergo contrast enhanced ultrasound of the carotid plaque and dynamic contrast-enhanced carotid plaque MRI
3036023|NCT02321397|Experimental|OXN PR HST|Prolonged release oxycodone/naloxone higher strength tablets
3036024|NCT02321397|Active Comparator|OXN PR LST|Prolonged release oxycodone/naloxone lower strength tablets
3036025|NCT02321384|Experimental|A: SAD Cohorts - RO6889678/Matching Placebo|Healthy participants will be enrolled into 1 of 6 planned SAD cohorts to receive single dose of RO6889678/matching placebo in fasted state as per anticipated dose escalation sequence (30 milligrams [mg], 100 mg, 300 mg, 600 mg, 1000 mg and 1500 mg). Cohort 1 will be split in 2 groups: 2 participants will be dosed 1 day (1 on RO6889678 and 1 on matching placebo) and 3 participants (2 on RO6889678 and 1 on matching placebo) will be dosed at least 24 hours afterward following satisfactory safety assessment for first 2 participants. Cohort 2 & beyond will include 8 healthy participants with 6 participants randomly assigned to RO6889678 & 2 randomly assigned to placebo. Participants who will tolerate fasted dose and agree to continue in food-effect SAD cohort, will receive single dose (dose level, either 300 mg or 600 mg, decided based on PK and safety data of first 2 SAD cohorts) of RO6889678/matching placebo with US FDA recommended high-fat and high-calorie breakfast on Day 16.
3036026|NCT02321384|Experimental|B: MAD Cohorts - RO6889678/Matching Placebo|Healthy participants will be enrolled into 1 of 4 planned MAD cohorts to receive RO6889678 or matching placebo (at a dose that will be decided as per the safety, tolerability and PK data from SAD 4 cohort) twice daily (BID) for 14 days except for Day 14, where only one dose in the morning will be given. Each of the MAD cohorts will include 8 healthy participants with 6 participants randomly assigned to RO6889678 and 2 participants randomly assigned to placebo. All participants enrolled to the MAD cohorts will receive an oral microdose of midazolam (100 micrograms [mcg]) before (Day -1) and after (Day 14) the repeat treatment with RO6889678 or matching placebo.
3036027|NCT02321384|Experimental|C:RTV-Boosted SAD & MAD Cohorts-RO6889678/Matching Placebo+RTV|Healthy participants will be enrolled in up to 3 SAD cohorts (2 compulsory and 1 optional) and up to 3 MAD cohorts (1 compulsory and 2 optional) to receive RO6889678 in combination with RTV in fed state. Participants of the first 2 RTV-boosted SAD cohorts will receive 100 mg RO6889678 + 100 mg RTV and 300 mg RO6889678 + 100 mg RTV respectively. Based on the PK and safety evaluation of the first 2 RTV-boosted SAD cohorts, another SAD cohort may be enrolled to receive a different dose of RO6889678 in combination with RTV. MAD RTV-boosted cohort will start based on the safety, tolerability and PK data of the RTV-boosted SAD cohorts. All participants enrolled to the RTV-boosted MAD cohorts will receive RO6889678 or placebo together with RTV on BID schedule for 14 days, and additionally an oral microdose of midazolam (100 mcg) before (Day -1) and after (Day 14) the treatment.
3036028|NCT02321371|Experimental|Lactulose + Rifaximin|Continuation of Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route.
3036029|NCT02321371|Active Comparator|Lactulose therapy|
3036030|NCT02321358|Experimental|Two-time implementation intention|Group will receive physical activity materials along with the implementation intention intervention and a booster again six weeks following.
3036031|NCT02321358|Active Comparator|One-time implementation intention|Group will receive physical activity materials along with the implementation intention intervention.
3036032|NCT02321358|Sham Comparator|Sham Comparator Group|Group will receive Canada's Food Guide which contains a small amount of physical activity information.
3036033|NCT02321345|Experimental|Palliative Care Support|Palliative care meetings will address the following issues: 1) values and meaning of life 2) greatest hopes and fears 3) communication preferences 4) proxy readiness to make decisions, and patient preferences, if the patient were to become seriously ill, and 5) symptom management strategies.
3036034|NCT02321332|Active Comparator|B-ETS|Bilateral simultaneous endoscopic thoracic sympathectomy: bilateral simultaneous T2-T3 ganglionectomy.
3036035|NCT02321332|Active Comparator|S-ETS|unilateral sequential endoscopic thoracic sympathectomy: unilateral T2-T3 ganglionectomy of the dominant side followed by T2-T3 ganglionectomy of the other side after 2 months interval
3036036|NCT02321319|Experimental|Hydromorphone HCl ER Tablets|Hydromorphone HCl ER Tablets 4 mg, 8 mg, 12 mg, or 16 mg
3036037|NCT02321306|Experimental|LUM001|LUM001 administered orally once each day.
3036038|NCT02321293|Experimental|1|"CurcuVIVA™ (NPN 80027414) at a single dose of 80 mg PO daily without any dose escalation to be taken in conjunction with an EGFR-TKI therapy.~CurcuVIVA™ is given in capsule forms. Unit strength of CurcuVIVA™ is equal to Turmeric Extract 25:1 348 mg (containing 80mg Longvida® Optimized Curcumin)~Tyrosine Kinase Inhibitors:~Gefitinib is a targeted therapy, given in a capsule form once daily. The daily dose is 250 mg .~Erlotinib is a targeted therapy, given in a capsule form once daily. The daily dose is 150 mg .~Study intervention is 8 weeks, following which the patients will continue taking their EGFR-TKI without curcumin until progression. The side effects of curcumin will be followed for another 8 weeks from the date of stopping curcumin."
3036039|NCT02321280|Experimental|Single arm single dose of denosumab|Open label = Single dose administration of single dose Denosumab 120 mg subcutaneously
3036040|NCT02321267|Other|Macular disease with adequate treatments|Macular diseases can be treated with most appropriate treatment, including pegaptanib, ranibizumab, afibercept, visudyne, or vitrectomy.
3036041|NCT02321254|Experimental|The RehaARM-Robot|Receive 45 min of robot-assisted therapy for the shoulder and 1 hour of daily standard rehabilitation therapy.
3036042|NCT02321241||Group 1|According to the recommendations of the Summary of Products Characteristics (SmPC) Administration by intravitreal injection
3036043|NCT02321228|Experimental|Salpingectomy with delayed oophorectomy|Female BRCA mutation carriers can opt for early salpingectomy upon completion of childbearing, followed by second stage oophorectomy delayed for five years beyond current guideline ages for risk-reducing salpingo-oophorectomy (i.e. age 40-45 for BRCA1 mutation carriers and 45-50 for BRCA mutation carriers).
3036044|NCT02321228|Active Comparator|Risk-reducing salpingo-oophorectomy|Female BRCA mutation carriers can opt for standard risk-reducing salpingo-oophorectomy at current guideline ages (age 35-40 for BRCA1 mutation carriers and age 40-45 for BRCA2 mutation carriers).
3036045|NCT02321215|No Intervention|Control|Usual care: This group will receive usual care from their physician without any special focus on education. At the end of the study period, patients that were assigned to the control group will receive the booklet at home and be offered two education sessions by phone or in-person if the patient is willing to return to the hospital.
3036046|NCT02321215|Active Comparator|Education Intervention|Introductory disease education: This group will attend two one-on-one education sessions. The educational content will be standardized and a checklist will be used to ensure that all topics are addressed. The sessions will focus on enhancing self-efficacy in areas that are thought to be important to individuals who recently had an AECOPD.
3036047|NCT02321202|Active Comparator|Control group|For postoperative parenteral nutrition, only Structolipid applied for 5 consecutive days.
3036048|NCT02321202|Experimental|Trial group|For postoperative parenteral nutrition, Omega-3 Fatty Acid-Based Parenteral Nutrition (20% Structolipid and 10% Omegaven) were applied for 5 consecutive days.
3036049|NCT02321189|Placebo Comparator|LONGEVINEX|The Effect of LONGEVINEX on Choroidal Thickness
3036050|NCT02321189|Placebo Comparator|placebo|The Effect of placebo on Choroidal Thickness
3036051|NCT02321176|Experimental|pharmacokinetics,trans-resveratrol|tissues from the eyes of the surgery of patients who received 1 Longevinex containing 100 mg of trans resveratrol active ingredient brand capsule for three days
3036052|NCT02321163|Experimental|NMES new paradigm|For the NMES new paradigm, A portable electrical stimulator will be used to produce simultaneous stimulation to both the quadriceps and calf muscles. The stimulator delivers a biphasic, asymmetrical square wave at a pulse width of 250 μs and duty cycle 5:10 sec with 2 Hz frequencies of stimulation. To disperse current intensity and enhance the comfort of the stimulation, large rectangular electrodes (80 × 100 mm) will be positioned at the best motor points of the quadriceps and calf muscles. The electrodes will be secured by tight short and sock at the respective positions. The stimulation intensity will be set to just visible muscle contractions. Stimuli will be applied twice a day for 3 h (with a 2 h rest between treatments), 5 days a week for 8 weeks.
3036053|NCT02321163|Active Comparator|NMES conventional|For NMES conventional, the experimental protocol will be the conventional electrical stimulation protocol i.e frequency: 50 Hz; intensity: maximum intensity tolerated by the subject; duration: 30 min.
3036054|NCT02321163|Sham Comparator|Placebo|For placebo, electrodes will be applied and all conditions will be similar to those in the NMES group, except that the amplitude will be set to 0 mA so that no muscle stimulation occurs.
3036055|NCT02321150|Active Comparator|Sutures|After pterygium removal the conjunctival graft to cover bare sclera will be secured with interrupted 8.0 polyglactin sutures.
3036056|NCT02321150|Experimental|Cautery|After pterygium removal the conjunctival graft to cover bare sclera will be secured with bipolar electrocautery, power set at 25 until whitening of tissue observed.
3036057|NCT02321137|Active Comparator|BioAVR with surgical closure of LAA|Aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease including surgical closure of left atrial appendage
3036058|NCT02321137|Placebo Comparator|BioAVR alone|Aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
3036059|NCT02321124|Active Comparator|intervention|we will apply connective tissue manipulation and life style advice.
3036060|NCT02321124|Other|control group|We will apply only life style advice.
3036061|NCT02321111|Active Comparator|D5W (5% Dextrose in water) + Saline|IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours plus Saline infusion at a rate of 30 mL/hour
3036063|NCT02321111|Active Comparator|Eritoran + Intralipid|IV administration of Eritoran 12 mg every 12 hours plus Intralipid infusion at a rate of 30 ml/hour
3036064|NCT02321098|Experimental|Loceryl Nail Lacquer + Cosmetic varnish|First treatment period: Once weekly application of Loceryl Nail Lacquer and that of Cosmetic varnish for 12 weeks
3036065|NCT02321098|Active Comparator|Loceryl Nail Lacquer|First treatment period: Once weekly application of Loceryl Nail Lacquer for 12 weeks
3036066|NCT02321098|Experimental|Loceryl Nail Lacquer follow up period|Follow up period: Once weekly application of Loceryl Nail Lacquer for 15 additional months
3036067|NCT02321085|Active Comparator|Sinus Rhythm Control group|"Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~Cardioversion after 1 month~Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~If AF recur, RFCA"
3036068|NCT02321085|Active Comparator|Pulse Rate Control Group|"No AAD, just anticoagulation~HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)~Without the treatment about antiarrhythmia and rhythm control, diffraction of rate control, the subject will be drop out for study."
3036069|NCT02321072|Active Comparator|High-normal PaO2|In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a PaO2 of 120 mmHg (16 kPa), range 105-135 mmHg (14-18 kPa).
3036070|NCT02321072|Active Comparator|Low-normal PaO2|In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a target PaO2 of 75 mmHg (10 kPa), range 60-90 mmHg (8-18 kPa).
3036071|NCT02321059||No incisional hernia group|Healthy volunteers with an intact abdominal wall.
3036072|NCT02321059||Incisional hernia group|Patients with a ventral incisional hernia.
3036073|NCT02321033|Experimental|low glycemic index|palatinose in soft drinks
3036074|NCT02321033|Experimental|high glycemic index|sucrose plus maltodextrin in soft drinks
3036075|NCT02320994||stroke patients|post-rehabilitation stroke patients
3036076|NCT02320981||EGD with Biopsy|Pediatric patients scheduled for standard of care EGD with biopsy also received measurement of mucosal impedance
3036077|NCT02320968|Experimental|Patients with nocturnal extraesophageal reflux|This is a non-randomized study to evaluate the effectiveness of the MedclineTM Sleep Assist Device on patients who experience nocturnal extraesophageal reflux. All patients will receive the device. Participants will serve as their own controls while undergoing 96-hour pH monitoring. Participants will follow their regular sleep position patterns on Days 1 and 2 of the study and will use the sleep assist device on Days 3 and 4. pH data and patient report of symptoms will be evaluated during the initial 96 hours of the study to capture physiologic results. All participants will use the sleep assist device for the remainder of the study to determine if a reduction in overall reflux symptom index (RSI) is achieved.
3036078|NCT02320955||Reimplantation of cryoconserved bone flap|All patients who receive reimplantation of a cryoconserved autologous bone flap
3036079|NCT02320942|Experimental|Exercise Intervention|At discharge from the inpatient unit, participants will receive a practical introduction by an exercise specialist and enrolled in the 12-week exercise intervention
3036080|NCT02320929|Experimental|Intraoperative irrigation only|The infected tendon sheath is irrigated intraoperatively, the catheter is removed, and small rubber srains are left in small incisions.
3036081|NCT02320929|Active Comparator|Intra- and postoperative irrigation|The infected tendon sheath is irrigated intraoperatively, the catheter is kept in place, the irrigation is continued postoperatively 3 times a day for 3 days.
3036082|NCT02320916|Active Comparator|23Gauge|Arterial blood puncture will be performed using a 23Gauge needle
3036083|NCT02320916|Active Comparator|25Gauge|Arterial blood puncture will be performed using a 25Gauge needle
3036084|NCT02320903|Experimental|Use of VillageWhere App Prototype|In this single-arm study design, all enrolled caregivers and teens will use the VillageWhere App Prototype that has been developed for this study. They are requested to use it as often as they would like throughout the duration of the trial. The app is designed to be used several times throughout each day.
3036085|NCT02320890|Experimental|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 3 days a week for 12 weeks (total of 36 applications)
3036086|NCT02320890|Sham Comparator|sham-Yband (YDT-201N)|sham-tDCS application 3 days a week for 12 weeks (total of 36 applications)
3036087|NCT02320877|Experimental|Mandibular Advancement Device|Mandibular advancement Devices are worn intra-orally at night in order to advance the mandible and to reduce the collapsibility of the upper airway.
3036088|NCT02320864||Non-surgical group|Adults who have knee osteoarthritis, but do not elect to have a total knee replacement surgery.
3036089|NCT02320864||Surgical group|Adults who have knee osteoarthritis and elect to have total knee replacement surgery.
3036090|NCT02320851|Experimental|SVD-tailored Integrative Psychotherapy (IPT)|IPT is a short-term psychotherapy aiming to ameliorate both physical and psychosocial distress. It emanates from a multidirectional and dynamic relationship among body, mind, and environment irrespective of causality. In a multi-component approach, other elements are integrated into it, such as cognitive-behavioral and psychodynamic techniques, psychoeducation and body-oriented techniques. The IPT intervention tailored to SVD will be delivered for 16 weeks in a manualised setting with one group session per week (à 90 minutes) and one additional booster session three months after the end of the therapy. The group psychotherapy is on a 6-8:1 basis and will be conducted by a psychotherapist trained on the basis of the manual and under regular clinical supervision.
3036091|NCT02320851|Active Comparator|Self-help group (SHG)|The experimental condition will be compared to moderated self-help groups without the implementation of additional therapeutic interventions. Those can be classified as low-level non-placebo control. Treatment will consist of 16 weekly moderated SHG sessions (one weekly session à 90 minutes) and one additional booster-session at three months after the end of the control intervention to be delivered on a 6-8:1 basis by a trained SHG moderator under clinical supervision.
3036092|NCT02320838|Experimental|5 KHz|"Transcutaneous application of 5 KHz current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
3036093|NCT02320838|Experimental|TENS|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are frequency 110 Hz and pulse width 200 microseconds"
3036167|NCT02320344|Experimental|Partners in Care|
3036168|NCT02320331|Experimental|PILI Lifestyle Program|
3036094|NCT02320838|Sham Comparator|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
3036095|NCT02320825|Experimental|single-fraction SRS (24 Gy)|single-fraction (24Gy) SRS within eight weeks of having undergone spinal decompression surgery.
3036096|NCT02320825|Experimental|high-dose hypofractionated SRS (27 Gy in 3 fractions)|hypofractionated (3 fractions of 9Gy, total dose of 27Gy) SRS within eight weeks of having undergone spinal decompression surgery.
3036097|NCT02320812|Experimental|Treated subjects|human retinal progenitor cells
3036098|NCT02320799|Active Comparator|treatment as usual|Usual Clinic psychosocial treatment
3036099|NCT02320799|Experimental|interpersonal psychotherapy|Interpersonal Psychotherapy is an evidence-based structured, brief psychotherapy which focuses on improving relationships in order to improve mood and reduce anxiety.
3036100|NCT02320786|Experimental|CoPILOT|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 12 hours total training time (one hour, four times per week for three weeks).
3036101|NCT02320786|No Intervention|Standard of Care|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair, consisting of 12 hour protocols in a standard power wheelchair (one hour, four times per week for three weeks).
3036102|NCT02320773||1. OAB patients taking Betmiga®|OAB patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment
3036103|NCT02320760|Experimental|Physical activity on prescription|
3036104|NCT02320760|No Intervention|Ordinary care|
3036105|NCT02320747|Experimental|Tai Chi Group|Experienced instructor at teaching tai chi delivered in a group setting in the community lasted approximately 40 minutes. Participants in the program served as an active control group that matched to the program and delivered.The class comprised mainly seated exercises including stretching, low-level strength, and low-level cardiovascular exercise. Participants walked (warm-up and cool-down) for 7 min in class, remaining seated or standing with arm support the rest of the time.
3036106|NCT02320747|No Intervention|Control Group|
3036107|NCT02320734|Active Comparator|deep neuromuscular relaxation|continuous infusion of rocuronium 0.6 mg/kg/hr (group 1). On demand bolus rocuronium can be given if demanded by anesthesiologist or surgeon
3036108|NCT02320734|No Intervention|on demand neuromuscular relaxation|continuous infusion of NaCl 0.9% 0.06 ml/kg/hr (group 2) On demand bolus of Rocuronium will be given when demanded by anesthesiologist or surgeon.
3036109|NCT02320721|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine, 300 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
3036110|NCT02320721|Active Comparator|Lantus|Lantus (Insulin glargine, 100 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
3036111|NCT02320708|Experimental|Test Acetaminophen (ACE) (1000 mg) and placebo|
3036112|NCT02320708|Active Comparator|Commerical ACE (1000 mg) and placebo|
3036113|NCT02320708|Active Comparator|Commerical Ibuprofen (IBU) (400 mg) and placebo|
3036114|NCT02320708|Placebo Comparator|Placebo|
3036115|NCT02320695|Placebo Comparator|Saline|0.9% Sodium Chloride Saline Solution (0.3 cc)
3036116|NCT02320695|Placebo Comparator|Isopropyl Alcohol|70% Isopropyl Alcohol (0.3 cc)
3036117|NCT02320695|Experimental|Pain Relieving Cream|Neosporin® Plus Pain Relieving Cream formula with pH balance technology (0.3 cc)
3036118|NCT02320695|Experimental|Antibiotic/Pain Relieving Ointment|Neosporin® Complete First Aid Antibiotic/Pain Relieving Ointment (0.3 cc)
3036119|NCT02320695|Experimental|Original Ointment|Neosporin® Original Ointment (0.3 cc)
3036120|NCT02320695|Experimental|Pain Relief Ointment|Neosporin® Plus Pain relief Ointment (0.3 cc)
3036121|NCT02320682|Active Comparator|Exeter femur component and Delta TT acetabular component|
3036122|NCT02320682|Active Comparator|SP-CL femur component and Delta TT acetabular component|
3036123|NCT02320682|Active Comparator|SP-CL femoral component and Delta PF acetabular component|
3036124|NCT02320682|Active Comparator|Exeter femoral component and Delta PF acetabular component|
3036125|NCT02320669|Experimental|Triostat|Active Medication - Synthetic Thyroid Hormone
3036126|NCT02320669|Placebo Comparator|Placebo|Placebo Control
3036127|NCT02320656|Experimental|Acute leukemia/myelodysplastic or myeloproliferative disease|
3036128|NCT02320643|Experimental|Seratom® PA mesh|Partially absorbable mesh
3036129|NCT02320630|Experimental|A|Maintenance treatment group
3036130|NCT02320630|Experimental|B|Combination treatment group
3036131|NCT02320630|Experimental|C|Single drug group
3036132|NCT02320617|Experimental|DW-MRI group|To evaluate the efficacy of chemoradiotherapy in lung cancer patients by DW-MRI when compared with conventional imaging modalities(CT, ultrasound et al.)
3036133|NCT02320604|Experimental|Obese Subjects 1mg/kg|8 obese subjects will receive 1mg/kg Ambisome i.v. infused over 45 minutes
3036134|NCT02320604|Experimental|Obese Subjects 2mg/kg|8 obese subjects will receive 2mg/kg Ambisome i.v. infused over 90 minutes
3036135|NCT02320591|Experimental|Treatment group|Practices assigned to the treatment group received per member per month care management fees for each Medicare beneficiary attributed to their practice. They also received quarterly feedback reports on their patients' average Medicare expenditures and use of hospital and emergency room services. Practices also had access to regional learning faculties for technical assistance with transformation activities and to share lessons across practices.
3036136|NCT02320591|No Intervention|Comparison group|Within each of the 7 regions, this group is comprised of practices that were matched to the treatment practices on a wide range of baseline characteristics of the practices (including their service utilization patterns) and their patients. Comparison practices were selected from a pool of practices including those that applied to participate but were not selected, and practices serving nearby external comparison areas.
3036302|NCT02319512|Sham Comparator|Control|Controls received standard care and sips of glucose, in total 3.6g/day in a 12-ml mixture per day, the same amount of glucose per day as the treatment group received via the chewing gum
3036137|NCT02320578|Experimental|3D Laparoscopy|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with 3D Laparoscopic technology.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition 3D telescope. Two additional 5 mm ports are placed under direct visualization. One more 5- mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
3036138|NCT02320578|Active Comparator|Standard Laparoscopy|Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with standard laparoscopy technology. A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope. Two additional 5 mm ports are placed under direct visualization. One more 5 mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system.
3036139|NCT02320565|Experimental|3D Laparoscopy|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with 3D Laparoscopic technology.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition 3D telescope. Two additional 5 mm ports are placed under direct visualization. One more 5- mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system"
3036140|NCT02320565|Active Comparator|Standard Laparoscopy|Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with standard laparoscopy technology. A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope. Two additional 5 mm ports are placed under direct visualization. One more 5 mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system.
3036141|NCT02320552||PD patients|Patients receiving peritoneal dialysis. No intervention
3036142|NCT02320552||HD patients|Patients receiving hemodialysis. No intervention
3036143|NCT02320539||SAH with DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
3036144|NCT02320539||SAH without DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
3036145|NCT02320539||SAH good grade|SAH without external ventricular drainage
3036146|NCT02320539||Healthy controls|Blood sample in healthy donors registered in the National Donor Registry.
3036147|NCT02320526|Experimental|Control|Control intervention: Subjects will continue their life unaltered during the 14 days intervention period
3036148|NCT02320526|Experimental|Continuous walking|Training intervention: Subjects will perform continuous walking for one hour per day at every weekday during the 14 days intervention period
3036149|NCT02320526|Experimental|Interval Walking|Training intervention: Subjects will perform interval walking for one hour per day at every weekday during the 14 days intervention period. Interval walking will be performed as repeated cycles of three minutes of slow and hree minutes of fast walking during the entire training session
3036150|NCT02320513||Control Group|Subjects will wear the activity monitoring device to track their activity between dialysis treatments, however, the feedback from the device will not be shared with them.
3036151|NCT02320513||Feedback Group|The feedback from the activity monitoring device will be shared with subjects at each visit.
3036152|NCT02320500|Active Comparator|standard physiotherapy|Standard of care physiotherapy for knee osteoarthritis (OA) patients who have been diagnosed with knee OA and may be candidates for total knee replacement (TKA)
3036153|NCT02320500|Experimental|Myofascial-specific therapy|Patient undergo myofascial pain-specific therapy which includes trigger point injections at the same time points as the comparator (1 session every 2 weeks for 8 weeks)
3036154|NCT02320487|Experimental|Obinutuzumab + Bendamustine (BG)|Participants received obinutuzumab + bendamustine (BG) induction therapy in 28-day cycles for 6 cycles.
3036155|NCT02320474|Experimental|Aflibercept|
3036156|NCT02320448|Experimental|PIPAC|"PIPAC with cisplatin (7.5mg/m2 in 150 ml saline) and doxorubicin (1.5mg/m2 in 50 ml saline) in patients with peritoneal metastases (PM) from any origin besides colorectal/appendiceal cancers in whom oxaliplatin (92mg/m2 in 150 ml dextrose) will be used.~The aerosolised chemotherapy will be nebulized at a flow of 0.5ml/min at a maximum pressure of 200 PSI during a standard laparoscopy with an intraabdominal pressure of 12mmHg. The CO2 will be evacuated 30 minutes after administration of chemotherapy and the patient is closed similar to a standard laparoscopy."
3036157|NCT02320435|Experimental|Extension Study|Open-label
3036158|NCT02320422|Experimental|Behavioral Telehealth|
3036159|NCT02320409|Experimental|Sufatinib ,after general diet|First cycle, single oral Sufatinib after general diet intake; Second cycle, Sufatinib before general diet intake.
3036160|NCT02320409|Experimental|Sufatinib, before general diet|First cycle, single oral Sufatinib before general diet intake;Second cycle,single oral Sufatinib after general diet intake
3036161|NCT02320396|Experimental|Desloratadine|After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded desloratadine (one 5 mg tablet) orally (PO) once daily (QD) in the morning for 2 weeks during the Treatment Period.
3036162|NCT02320396|Placebo Comparator|Placebo|After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded placebo (one tablet) PO QD in the morning for 2 weeks during the Treatment Period.
3036163|NCT02320383|Experimental|B + GA101|"Induction:~Bendamustine + GA101; a maximum of 6 cycles of BG will be administered; each cycle with a duration of 28 days~Maintenance:~GA101 i.v. 1000 mg (flat dose): every 84 days starting on final restaging continued until progression or to a maximum of 2 years"
3036164|NCT02320370|Experimental|Treatment 1|NeuroConn DC Stimulator Plus tDCS treatment protocol no 1
3036165|NCT02320370|Experimental|Treatment 2|NeuroConn DC Stimulator Plus tDCS treatment protocol no 1
3036166|NCT02320357|Experimental|Clopidogrel|
3036169|NCT02320318|Experimental|Ibodutant 10 mg|Oral tablet once daily for 12 weeks of treatment. At week 13, patients in the ibodutant 10 mg arm will be re-randomised in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.
3036170|NCT02320318|Placebo Comparator|Placebo|Oral tablet once daily for 12 weeks of treatment. At week 13, patients in the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant 10 mg for additional 4 weeks of treatment.
3036171|NCT02320305|Experimental|Arm I (MART-1 antigen and TLR4 antagonist GLA-SE)|Patients receive MART-1 antigen and TLR4 antagonist GLA-SE IM on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3036172|NCT02320305|Experimental|Arm II (MART-1 antigen)|Patients receive MART-1 antigen IM on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3036173|NCT02320292|Active Comparator|Arm A (rituximab)|Patients receive rituximab IV on days 1, 8, 15, and 22.
3036174|NCT02320292|Experimental|Arm B (rituximab, yttrium Y-90 ibritumomab tiuxetan)|Patients receive rituximab IV on days 1 and 8 and yttrium Y-90 ibritumomab tiuxetan over 10 minutes on day 8.
3036175|NCT02320279||Women in labor|Pregnant women, women in labor, and women who are admitted to labor and delivery for scheduled c-sections will form the eligible population for recruitment into our study.
3036176|NCT02320266||Parkinson's Disease|Patients diagnosed with Parkinson's Disease undergoing DBS surgery.
3036177|NCT02320266||Control|Age matched controls without Parkinson's Disease and no history of mental illness.
3036178|NCT02320266||Essential Tremor|Patients diagnosed with Essential Tremor undergoing DBS surgery.
3036179|NCT02320266||Dystonia|Patients diagnosed with Dystonia undergoing DBS surgery.
3036180|NCT02320266||Obsessive-Compulsive disorder|Patients diagnosed with Obsessive-Compulsive disorder undergoing DBS surgery.
3036181|NCT02320253|Active Comparator|Medical Nutrition Therapy (MNT)|Participants in this arm will meet with a dietitian at their respective Health Center, not with a study dietitian. The participant and dietitian will decide how frequently to meet and create an individualized treatment plan. The participant's health insurance will be billed for these dietitian visit(s) and the participant is responsible for any copay(s) or deductible(s) associated with the visit(s).
3036182|NCT02320253|Experimental|In Person Group (IP)|Participants enrolled to the IP arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
3036183|NCT02320253|Experimental|Telephone Conference Call Group (TCC)|Participants enrolled in the TCC arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led, over-the-phone, by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
3036184|NCT02320240||SNRI Exposure Group|Patients who received a new prescription for an SNRI (duloxetine, venlafaxine, or desvenlafaxine at any dosage) with no prescriptions for either SNRI or SSRI in the prior year.
3036185|NCT02320240||SSRI Exposure Group|Patients who received a new prescription for an SSRI (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, or sertraline at any dosage) with no prescriptions for either SSRI or SNRI in the prior year.
3036186|NCT02320227|Experimental|Miami w/o frag Personal lubricant|Healthy subjects use Miami w/o frag Personal lubricant at least 4 times per week for 2 weeks
3036187|NCT02320214|Experimental|Miami w/ frag Personal lubricant|Healthy subjects use Novel lubricant Miami w/ frag Personal lubricant at least 4 times per week for 2 weeks.
3036188|NCT02320201|Experimental|Electrical stimulation|Transcutaneous Electrical Nerve Stimulator (TENS) will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects. Subjects will be required to keep a daily voiding diary for one week before treatment to establish a control, during the treatment week and for one week after treatment. Subjects will also be asked to complete a validated questionnaire prior to treatment, during treatment week and one week after treatment. The primary outcomes of this study are improvement in objective measures of frequency as indicated by voiding diary and subjective symptom improvement based on questionnaire comparison.
3036189|NCT02320188|Experimental|Eccentric exercise|Thirty sessions of Eccentric training in twelve weeks. Average of two sessions per week without spacing higher than eight days between two sessions.
3036190|NCT02320188|Experimental|Concentric exercise|Thirty sessions of Concentric training in twelve weeks. Average of three sessions per week without spacing higher than eight days between two sessions.
3036191|NCT02320188|No Intervention|No training (control)|Usual activities. No further training during the observation period
3036192|NCT02320175|No Intervention|Pre-intervention Arm|This group is the pre-intervention group of physicians, residents, nurses and patients and families that will be interviewed and surveyed before applying the intervention (standard practices). Data on patient safety will be gathered as well
3036193|NCT02320175|Experimental|Post-intervention Arm|This arm is the post-intervention group of physicians, residents, nurses and patients and families that will be interviewed and surveyed after applying the intervention - the Communication Bundle to Improve Patient Safety and Experience. Data on patient safety will be gathered as well
3036194|NCT02320162|Experimental|Experiential learning|Oral health education using experiential learning (EL)
3036195|NCT02320162|Placebo Comparator|Traditional lecturing|Oral health education using traditional lecturing (TL)
3036196|NCT02320149|Experimental|Sarecycline|Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
3036197|NCT02320149|Placebo Comparator|Placebo|Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.
3036198|NCT02320136||epilepsy|epilepsy patients
3036199|NCT02320136||tumor with epilepsy|tumor patients with epileptic seizures
3036200|NCT02320136||tumor without epilepsy|tumor patients without epileptic seizures
3036201|NCT02320123|Experimental|Patients|Patients will be invited to view the DVD explaining end-of-life care options.
3036303|NCT02319499|Experimental|Zinc Alone|Zinc Sulphate (10 mg Zn/day)
3036202|NCT02320097|Other|Foot pressure measurement|"The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.~The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions."
3036203|NCT02320084||HT-1 patients on Orfadin treatment|HT-1 patients on Orfadin (nitisinone) treatment
3036204|NCT02320071||Patients with incisional hernia|Patients with one or more incisional hernias, combined horizontal fascial defect 3-8 cm, planned for laparoscopic mesh repair. Patients are examined before and one and three months postoperative in regard to abdominal wall function, pain, discomfort, hernia-related quality of life and physical activity level.
3036205|NCT02320058|Experimental|Nivolumab and Ipilimumab|"Induction Phase: Nivolumab + Ipilimumab infusion intravenously~Maintenance Phase: Nivolumab infusion intravenously"
3036206|NCT02320045|Experimental|Group 1: Normal|Normal Subjects estimated creatinine clearance (eGFR) ≥90 mL/min/1.73 m2
3036207|NCT02320045|Experimental|Group 2: Mild Renal Dysfunction|Subjects with Mild Renal Dysfunction estimated creatinine clearance (eGFR) 60-89 mL/min/1.73 m2
3036208|NCT02320045|Experimental|Goup 3: Moderate Renal Dysfunction|Subjects with Moderate Renal Dysfunction estimated creatinine clearance (eGFR) 45-59 mL/min/1.73 m2
3036209|NCT02320045|Experimental|Group 4: Moderate Renal Dysfunction|Subjects with Moderate Renal Dysfunction estimated creatinine clearance (eGFR) >30-44 mL/min/1.73 m2
3036210|NCT02320032|Experimental|Aripiprazole Lauroxil - A|Intramuscular (IM) injection Dose and Dosing Sequence A
3036211|NCT02320032|Experimental|Aripiprazole Lauroxil - B|Intramuscular (IM) injection Dose and Dosing Sequence B
3036212|NCT02320032|Experimental|Aripiprazole Lauroxil - C|Intramuscular (IM) injection Dose and Dosing Sequence C
3036213|NCT02320032|Experimental|Aripiprazole Lauroxil - D|Intramuscular (IM) injection Dose and Dosing Sequence D
3036214|NCT02320019|Placebo Comparator|Placebo group|Placebo
3036215|NCT02320019|Experimental|Group A|YH14618 A mg/disc
3036216|NCT02320019|Experimental|Group B|YH14618 B mg/disc
3036217|NCT02320019|Experimental|Group C|YH14618 C mg/disc
3036218|NCT02320019|Experimental|Group D|YH14618 D mg/disc
3036219|NCT02320006|Active Comparator|True acupuncture plus hydrotubation|The treatment group will receive true acupuncture and hydrotubation,Hydrotubation (80,000 U gentamicin , 400U chymotrypsin , 5mg dexamethasone , 50ml 0.9% saline) will be performedwithin 3 7 days after the menstruation[12].We use a manometer to measure the pressure and record the number on a card, then calculate the gap of the first and last time,it continues 3 menstrual cycles. The points (points used for every participant of treatment group) include bilateral RN4、CV6、CV3、EX-CA1、ST36、SP6,All the needles will be keep in positions for 30 min.Acupuncture will be performed three times per week,for a total of 36 sessions (12 wk)
3036220|NCT02320006|Sham Comparator|control acupuncture plus hydrotubation|The control group will receive control acupuncture and hydrotubation.Hydrotubation (80,000 U gentamicin , 400U chymotrypsin , 5mg dexamethasone , 50ml 0.9% saline) will be performed within 3 7 days after the menstruation[12].We use a manometer to measure the pressure and record the number on a card, then calculate the gap of the first and last time,it continues 3 menstrual cycles.Two needles will be inserted in each arm, one in each shoulder and one in each upper arm at nonacupuncture pointsAll the needles will be keep in positions for 30 min. Acupuncture will be performed three times per week,for a total of 36 sessions (12 wk).
3036221|NCT02319993|Experimental|TIAN WANG BU XIN DAN|"Drug:TIAN WANG BU XIN DAN CONCENRATED GRANULES CHUANG SONG ZONG"
3036222|NCT02319993|Experimental|Suan Tzao Ren Tang|"Drug:Suan Tzao Ren Tang Granula Subtilae CHUANG SONG ZONG"
3036223|NCT02319993|Placebo Comparator|Placebo|Drug:1/10 TIAN WANG BU XIN DAN
3036224|NCT02319980|Active Comparator|Surgical intervention|All participants in this group will be assigned to receive extracranial-intracranial arterial bypass surgery.
3036225|NCT02319980|No Intervention|Conservative management(medical management)|All participants in this group will be assigned to receive conservative management or medical management which involves drug therapy as considered appropriate for medical symptoms by the treating investigator.
3036226|NCT02319967|No Intervention|Usual Care|Inhaler technique education and distribution of spacers to all participants.
3036227|NCT02319967|Experimental|CAPE|Inhaler technique education and distribution of spacers to all participants. Structured patient-centered ED discharge template (CAPE) to be completed by ED coordinator.
3036228|NCT02319967|Experimental|CAPE + Home|"Inhaler technique education and distribution of spacers to all participants. Structured patient-centered ED discharge template (CAPE) to be completed by ED coordinator.~Community-health worker-led home visits."
3036229|NCT02319954|Active Comparator|Compression|Each patient will be randomized to receive compression of their nose on either the left or right for 5 continuous minutes after performing a lateral rhinotomy.
3036230|NCT02319954|No Intervention|No compression|Each patient will serve as their own control with the other side not receiving any compression after a lateral rhinotomy.
3036231|NCT02319941|Experimental|Low dose ticagrelor|60mg bid
3036232|NCT02319941|Active Comparator|standard dose ticagrelor|90mg bid
3036233|NCT02319941|Active Comparator|standard dose clopidogrel|75mg qd
3036234|NCT02319928|Active Comparator|Short-term surveillance|Short-term surveillance. Colonoscopy at 5+10 years in low-risk adenomas or 3+5 years in high-risk adenomas.
3036235|NCT02319928|Experimental|Long-term surveillance|Long-term surveillance. Colonoscopy at 10 years in low-risk adenomas or 5 years in high-risk adenomas.
3036236|NCT02319915|Experimental|Tranexamic acid|Study of the pharmacokinetic profile of the plasmatic resorption of tranexamic acid after an intra-articular injection.
3036237|NCT02319915|Active Comparator|Tranexamic acid + adrenalin|Study of the pharmacokinetic profile of the plasmatic resorption of tranexamic acid after an intra-articular injection of tranexamic acid with adrenalin 1/200 000.
3036238|NCT02319902|Placebo Comparator|Standard cold carbon dioxide gas|Standard cold carbon dioxide gas
3036239|NCT02319902|Active Comparator|Heated humidified carbon dioxide gas|Heated humidified carbon dioxide gas
3036304|NCT02319499|Experimental|Iron and Zinc|Ferrous Sulphate and Zinc Sulphate (10 mg/day of each zinc and iron)
3036345|NCT02319213|Experimental|Group L|Intraocular pressure measurement with 9 mmHg insufflation
3036240|NCT02319889|Experimental|Treatment (SBRT, carboplatin, Abraxane)|Patients undergo Stereotactic Body Radiotherapy every other day for up to 14 days for a total of 5 fractions. After a break period of about 30 days, patients will then start chemotherapy. Patients will receive carboplatin IV over 30-40 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3036241|NCT02319876||Severe sepsis|Patients with severe sepsis
3036242|NCT02319876||SIRS patient|Patients after elective surgeries presented with SIRS but without sepsis
3036243|NCT02319876||Volunteer|Volunteers
3036244|NCT02319863|Active Comparator|conventional resection|Perform hepatectomy with conventional method for HCC patients.
3036245|NCT02319863|Experimental|new method|The new technique of rapid ligating the corresponding inflow and outflow vessels without hills dissection before parenchyma transection during hepatectomy.
3036246|NCT02319850||Reference Group|18 - 29 years of age; apparently healthy younger participants; 1:1 male and female recruitment ratio (Exposure include DXA scanning).
3036247|NCT02319850||Comparison Group|55 - 75 years of age; apparently healthy older participants; 1:1 male and female recruitment ratio (Exposure include DXA scanning).
3036248|NCT02319837|Experimental|Enzalutamide plus leuprolide|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with leuprolide administered as as a single intramuscular or subcutaneous injection once every 12 weeks
3036249|NCT02319837|Experimental|Enzalutamide monotherapy|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily
3036250|NCT02319837|Active Comparator|Placebo plus leuprolide|Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with leuprolide administered as a single intramuscular or subcutaneous injection once every 12 weeks
3036251|NCT02319824|Experimental|Treatment (radiation and NY-ESO-1-specific T cells)|Patients undergo palliative radiation therapy at the discretion of the treating radiation oncologist. Patients then receive NY-ESO-1-specific T cells IV over 60 minutes 2-3 days after completion of radiation therapy.
3036252|NCT02319811||Cryopreserved meniscus transplant|Intervention: Lateral or medial cryopreserved meniscus transplant implanted into appropriately indicated patients.
3036253|NCT02319798|Active Comparator|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital as usual.
3036254|NCT02319798|Experimental|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
3036255|NCT02319785|Experimental|RAT-NMES|The combined treatment of robot-assisted therapy and neuromuscular electrical stimulation.
3036256|NCT02319785|Experimental|RAT-MT|The combined treatment of robot-assisted therapy and mirror therapy.
3036257|NCT02319785|Active Comparator|Mirror therapy|Patients practice motion in a mirror box, and look into mirror while practicing.
3036258|NCT02319785|Experimental|Unilateral RAT|Unilateral robot-assisted therapy provided by InMotion Isokinetic Testing and Evaluation System.
3036259|NCT02319785|Active Comparator|Bilateral RAT|Bilateral robot-assisted therapy provided by Bi-Manu-Track.
3036260|NCT02319785|Active Comparator|Conventional rehabilitation|Conventional rehabilitation provided by therapist.
3036261|NCT02319772|Experimental|BCX4430|BCX4430 administered as an IM injection
3036262|NCT02319772|Placebo Comparator|Placebo|Matched placebo administered as an IM injection
3036263|NCT02319759|Experimental|Guselkumab|Participants will receive guselkumab 100 milligram (mg) subcutaneous injection (injected under the skin by way of a needle) at Weeks 0, 4, 12, 20, 28, 36, and 44, and placebo for guselkumab at Week 24 to maintain the blind. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
3036264|NCT02319759|Experimental|Placebo|Participants will receive placebo for guselkumab at Weeks 0, 4, 12, and 20, and guselkumab 100 mg subcutaneous injection at Weeks 24, 28, 36, and 44. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
3036265|NCT02319746|Experimental|Experimental group|The subjects of experimental group will receive a cognitive-behavioral treatment program specific for reduce cannabis use composed of 16 weekly sessions (one hour in duration), in addition to regular psychiatric review and pharmacological treatment. The group will consist of 6-8 subjects.
3036266|NCT02319746|Active Comparator|Control group|The control group will receive standard care for psychotic episodes which includes pharmacological treatment and psychoeducation, following the same format as the experimental group. 16 weekly sessions of psychoeducation (one hour in duration) will be conducted, in addition to regular psychiatric review and pharmacological treatment. Like the experimental group the group will consist of 6-8 subjects.
3036267|NCT02319733|Experimental|Bioresorbable vascular scaffold|Implantation of Bioresorbable vascular scaffold in vulnerable plaques
3036268|NCT02319720|Experimental|BMA/Cultured Bone Marrow Cells|The subjects in this arm will have fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken. Part of the aspirate will be cultured. Up to three applications of cultured cells will be applied to the wound following the bone marrow biopsy. A single treatment cycle will consist of one application of a freshly obtained bone marrow aspirate and up to three applications of cultured cells derived from that aspirate. If the wound has not healed, up to three additional treatment cycles may be performed. Each bone marrow biopsy will be followed by direct application of fresh bone marrow to the wound and up to three applications of cultured cells (prepared from the most recent bone marrow biopsy).
3036269|NCT02319720|Experimental|Cultured Bone Marrow Cells|In this group, the bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound. Up to three applications of cultured cells will be applied to the wound following the bone marrow biopsy. A single treatment cycle will consist of up to three applications of cultured cells derived from a single bone marrow aspiration. If the wound has not healed, up to three additional treatment cycles may be performed. Each bone marrow biopsy will be followed by up to three applications of cultured cells (prepared from the most recent bone marrow biopsy).
3036270|NCT02319720|Experimental|Bone Marrow Aspirate|The subjects in this group will have fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken. A single treatment cycle will consist of one application of a freshly obtained bone marrow aspirate. If the wound has not healed, up to three additional bone marrow biopsies may be performed. If the wound heals at any point during this protocol, no additional bone marrow biopsy procedures will be performed and no additional cells will be applied.
3036271|NCT02319720|Active Comparator|Control|In this arm, subjects will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressing and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
3036272|NCT02319707|Experimental|Intramuscular treatment:IV|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.
3036273|NCT02319707|Experimental|Combined treatment:IV+IM|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor.
3036274|NCT02319707|Active Comparator|The control group|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department).
3036275|NCT02319681|Experimental|Simple Reminiscence (SR) caregiver|Subjects are caregivers for a persons with EAD and will be administered SR intervention and an attention control treatment four times
3036276|NCT02319681|Experimental|Simple Reminiscence (SR) EAD|Subjects are persons with EAD and will be administered SR intervention and an attention control treatment four times
3036277|NCT02319668|Experimental|Test product|Mouthwash containing 0.2% w/v Chlorhexidine digluconate
3036278|NCT02319668|Placebo Comparator|Control|Sodium fluoride toothpaste (Aquafresh Mild & Minty)
3036279|NCT02319655|Active Comparator|Air tamponade|Air is injected after vitrectomy/membrane peeling
3036280|NCT02319655|Active Comparator|Balanced salt solution filling|Balances salt solution is injected after vitrectomy/membrane peeling
3036281|NCT02319642|Experimental|Certolizumab Pegol (CZP)|"Those subjects from either treatment group in RA0044 (NCT02151851) who fail to achieve an ACR20 response in RA0044 (NCT02151851) at Week 12, which is confirmed at Week 14. These subjects are withdrawn from RA0044 (NCT02151851) at Week 16 of that study, and that assessment will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 400 mg sc at Weeks 0, 2, and 4 followed by CZP 200 mg sc Q2W.~Subjects from either treatment group in RA0044 (NCT02151851) who completed RA0044 (NCT02151851) through Week 24. The Week 24 assessment in RA0044 (NCT02151851) will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 200 mg sc Q2W."
3036282|NCT02319629|Experimental|URSODIOL - URSODEOXYCHOLIC ACID|300 mg twice a day
3036283|NCT02319629|Placebo Comparator|placebo|placebo twice a day
3036284|NCT02319616|Experimental|Clobetasol 0.05% ointment|All patients will have one arm assigned to receive the experimental treatment (topical clobetasol 0.05% ointment) applied daily for a period of fourteen days.
3036285|NCT02319616|Placebo Comparator|Placebo|All patients will have one arm assigned to receive the placebo treatment (topical petrolatum ointment) applied daily for a period of fourteen days.
3036286|NCT02319603|Active Comparator|Low dose WenXin keli|"Low dose group (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.~Oral ,1 bag each time, 3 times a day, 4 weeks for 1 course of treatment."
3036287|NCT02319603|Experimental|High dose WenXin keli|"High dose group(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.~Oral ,1 bag each time, 3 times a day, 4 weeks for 1 course of treatment."
3036288|NCT02319590||heart failure, no CAD, QRS < 150ms|no CAD, QRS < 150ms
3036289|NCT02319590||heart failure, CAD QRS < 150ms|CAD, QRS < 150ms
3036290|NCT02319590||heart failure, CAD > 150ms|CAD, QRS > 150ms
3036291|NCT02319590||heart failure, no CAD, > 150ms|no CAD, QRS > 150ms
3036292|NCT02319577|Experimental|Gefitinib plus oral vinorelbine|"Arm A (21-days cycles until progressive disease or unacceptable toxicity):~Oral vinorelbine 60 mg/mq on days 1,8 Gefitinib 250 mg daily from day 9 to day 21"
3036293|NCT02319577|Active Comparator|Gefitinib alone|"Arm B (21-days cycles until progressive disease or unacceptable toxicity):~Gefitinib 250 mg daily from day 1 to day 21"
3036294|NCT02319564|Active Comparator|beclomethasone|"beclomethasone dipropionate 250mcg per puff per puff (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
3036295|NCT02319564|Active Comparator|beclomethasone and salbutamol|"beclomethasone diprionate 250mcg and salbutamol 100mcg per puff (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
3036296|NCT02319564|Placebo Comparator|Placebo|"placebo (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
3036297|NCT02319538|No Intervention|Non-surgical treatment only|Control arm. This arm receives standard medical hormone treatment (Thyroxine substitution) only and no surgical intervention.
3036298|NCT02319538|Active Comparator|Total thyroidectomy performed|Surgical arm.The approach for total thyroidectomy will be a complete removal of all visible, and immunological active thyroid tissue with a high accuracy, with a special focus on three sites; 1) The angle where the recurrent laryngeal nerve enters the cricothyroid membrane, 2) The pyramidal lobe and 3) The hilus where the superior vessels are entering the field. Standard Thyroxine supplementation maintained as in the control group.
3036299|NCT02319525|Experimental|Computerized patient decision-aid|A computerized decision-aid showing benefits and harms of medications in words patients prefer
3036300|NCT02319525|Active Comparator|Usual care (lupus pamphlet)|A handout/pamphlet from a non-profit organization on lupus and lupus medications (American College of Rheumatology [ACR])
3036301|NCT02319512|Experimental|Chewing gum|Chewing gum was administered every fourth hour (08.00-12.00, 12.00-16.00 and 16.00-20.00). During each four-hour period, patients chewed two pieces of gum for 30 minutes each. Chewing gum was used during the whole hospital stay.
3036305|NCT02319499|Experimental|Iron, Zinc and Vitamin A|Ferrous Sulphate, Zinc Sulphate and Vitamin A (10 mg/day of each zinc and iron, plus 1,000 IU vitamin A/day)
3036306|NCT02319499|Placebo Comparator|Placebo|No minerals/vitamin
3036307|NCT02319486|Experimental|CEV with/without carboplatin|CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months) together with/without 20mg/2ml carboplatin periocular injection
3036308|NCT02319460||Retrospective|Retrospective cohort of adults hospitalized for major bleeding during 2008 to 2013 who receive plasma for urgent reversal of acquired coagulation factor deficiency induced by oral VKA therapy
3036309|NCT02319460||Prospective|Prospective parallel cohort of adults hospitalized for major bleeding during 2014 to 2020 who either receive Kcentra® or plasma for urgent reversal of acquired coagulation factor deficiency induced by oral VKA therapy
3036310|NCT02319447|No Intervention|Usual Care|After randomization, these study participants will receive the Usual Care received by all listed kidney transplant candidates at our center.
3036311|NCT02319447|Experimental|Additional education|These study participants will be invited to attend a 60-90 minute educational seminar, entitled Destination: Transplant, delivered in a group setting. They will also receive monthly mailings for 9 months and a follow-up phone call from a transplant educator.
3036312|NCT02319421|Experimental|Primary Subjects|"Physicians and nurse practitioners caring for patients in the Pediatric Intensive Care Unit (PICU). An alarm reduction script will be used to help facilitate discussion of alarm data during weekday morning team huddles."
3036313|NCT02319408|No Intervention|No radiation|Lobectomy for lung cancer without preoperative radiation
3036314|NCT02319408|Experimental|Preoperative radiation|Lobectomy for lung cancer with preoperative radiation
3036315|NCT02319395||cases|Presence of ICD in PD patients (cases) is defined as a score ≥ 2 at 1 hyperdopaminegic item, or 2 scores ≥ 2 at 1 hyperdopaminergic item of the scale for assessment of behavior and mood in PD (ECMP).
3036316|NCT02319395||controls|Absence of ICD in PD patients (controls) is defined as a score ≤ 1 at all hyperdopaminergic items of ECMP and no more than 2 items of a score = 1.
3036317|NCT02319382|Experimental|2 markers: 18F-DPA-714 and 11C-PE2I|PET with the tracer [18F]DPA-714 and second PET with the tracer [11C]-PE2I. [18F]DPA-714 is a new marker. It allows the macroscopic visualization of active microglia in the brain. [11C]-PE2I allow measures dopaminergic neuronal loss.
3036318|NCT02319369|Experimental|Part 1, Milademetan Alone|Participants receive milademetan alone with different dose schedules
3036319|NCT02319369|Experimental|Part 1A, Milademetan with AZA|Participants receive milademetan in combination with AZA, with different dose schedules
3036320|NCT02319369|Experimental|Part 2, Cohort 1|Participants with refractory or relapsed AML receive the recommended dose for Part 2 of milademetan or milademetan with AZA
3036321|NCT02319369|Experimental|Part 2, Cohort 2|Participants with newly diagnosed AML unfit for intensive chemotherapy receive the recommended dose for Part 2 of milademetan or milademetan with AZA
3036322|NCT02319369|Experimental|Part 2, Cohort 3|Participants with high-risk MDS receive the recommended dose for Part 2 of milademetan or milademetan with AZA
3036323|NCT02319356|Active Comparator|Beetroot juice (BRJ)|beetroot juice
3036324|NCT02319356|Placebo Comparator|Placebo (PL)|placebo juice
3036325|NCT02319343|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
3036326|NCT02319343|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride.
3036327|NCT02319330|Experimental|Phone counseling intervention|Treatment as usual (TAU) plus a nurse-delivered mobile phone counseling intervention delivered at weeks 1 to 12, 14, and 16 post-randomization.
3036328|NCT02319330|Active Comparator|Treatment as Usual|Routine HIV clinic-based counseling
3036329|NCT02319317|Experimental|Risky driving prevention|Web-based behavioral intervention to promote teen driver attention to the roadway, addressing mobile technology and passengers.
3036330|NCT02319317|Experimental|Control group|Web-based behavioral intervention for healthy lifestyles.
3036331|NCT02319304|Other|Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX|"Part I:~FOLFOX: combination of drugs administered in a specific sequence as perscribed below.~Oxaliplatin: 85 mg/m2 intravenously (IV) over 2 hours~Leucovorin: 200 mg/m2 IV bolus over 2 hours~5-FU: 400 mg/m2 IV bolus over 5-15 minutes, then 2,400 mg/m2 continuous IV infusion over 46-48 hours~Part II:~Low dose fractionated radiation therapy (LDFRT) Intensity-modulated, bone marrow sparing, whole pelvic radiation therapy 40 cGy fractions twice per day delivered at least 4-6 hours apart on the first 2 days of each chemotherapy cycle for a total of 6 cycles"
3036332|NCT02319291||Participants|P.F.C. Sigma PS150 RP Total Knee System
3036333|NCT02319278|Active Comparator|Myocarditis|
3036334|NCT02319278|Active Comparator|Cardiac sarcoid|
3036335|NCT02319278|Active Comparator|Cardiac Transplant|
3036336|NCT02319278|Placebo Comparator|Healthy Volunteers|
3036337|NCT02319265|Experimental|Melatonin|Melatonin at a dose of either 50mg (50ml) or 100mg (100ml) to be decided after an initial PK study to be given at intervals to be decided after PK data is available, for 72h. Oral liquid via nasogastric tube.
3036338|NCT02319265|Placebo Comparator|Placebo|Placebo at a dose of either 50ml or 100ml (to be decided after an initial PK study) to be given at intervals to be decided after PK data, is available for 72h. Oral liquid via nasogastric tube.
3036339|NCT02319252|Active Comparator|Gastric tube|A gastric tube is used
3036340|NCT02319252|Active Comparator|Jejunal tube|A jejunal tube is used
3036341|NCT02319239|Active Comparator|Conventional fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
3036342|NCT02319239|Experimental|hypofractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months.
3036343|NCT02319239|Experimental|Stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months.
3036344|NCT02319213|No Intervention|Group C|The control group (Group C) was not subjected to laparoscopic intervention
3036346|NCT02319213|Experimental|Group M|Intraocular pressure measurement with 12 mmHg insufflation
3036347|NCT02319213|Experimental|Group H|Intraocular pressure measurement with 15 mmHg insufflation
3036348|NCT02319200|Experimental|Metformin|"1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)~Metformin daily during 36 months"
3036349|NCT02319200|Placebo Comparator|placebo tablet|2 tablets at morning and 2 tablets at afternoon 4 tablets per day
3036350|NCT02319187|Active Comparator|Arm A|S1
3036351|NCT02319187|Experimental|Arm B|S1 and irinotecan
3036352|NCT02319174||Sphygmo|All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device.
3036353|NCT02319161||Group I|Group I: the patients with systolic blood pressure above to 150 mmHg following tourniquet inflation and in which bolus dose of calcium channel blocker 10 mg was administered by intravenous route.
3036354|NCT02319161||Group II|Group II: the patients with systolic blood pressure above to 150 mmHg following tourniquet inflation and in which bolus dose of beta blocker 0.5mg/kg was administered by intravenous route
3036355|NCT02319148|Experimental|Treatment B|Treatment B subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of itraconazole (200 mg once daily).
3036356|NCT02319148|Experimental|Treatment C|Treatment C subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of diltiazem (240 mg once daily).
3036357|NCT02319148|Experimental|Treatment D|Treatment D subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of verapamil (240 mg once daily).
3036358|NCT02319135|Active Comparator|fludarabine cytarabine|"Priming with daily administration of subcutaneous G-CSF (lenograstim or filgrastim 5 mcg /kg / day, days -1, 1 and 2) (not given if hyperleukocytosis> 25 x 109/l), followed by:~Oral fludarabine (40 mg/m2/day, days 1 to 5) and subcutaneous cytarabine (75mg/m2/day, days 1 to 5) (FLUGA scheme) (fludarabine and cytarabine only days 1 to 4 if age ≥75 years), OR~Fludarabine (25 mg/m2/day) and cytarabine (75 mg/m2/day infusion of 6 hours) on their intravenous formulations if the patient is hospitalized (patients with hyperleukocytosis or other unfavourable conditions).~Treatment cycles every 28 days"
3036359|NCT02319135|Experimental|Azacitidine|Subcutaneous Azacitidine 75 mg/m2/day, days 1 to 7. Treatment cycles every 28 days.
3036360|NCT02319122|Other|Progressive Resistance Training|"The key for the PRT is the timely progression of load, based on the child's individual level of strength, which ensures progressive overload.~Every training session will consist of a warm up, progressive resistance exercises and a cool down period. During warm up and cool down periods.These exercises will be the same for both training groups.~The strength training exercises have been chosen to strengthen the main lower extremity muscle groups which are important for the gait: sit-to-stand, lateral step-ups, the half knee rise, heel-rises and bridging.~All these exercises are performed loaded according to the individual level. Three sets of 8 to 10 repetitions of each exercise will be practiced on 3 non-consecutive days with moderate velocity."
3036361|NCT02319122|Other|High Intensity Interval Training|The High Intensity Circuit Training is a sub form of High Intensity Interval Training. The key feature is the very little rest between the exercises which causes a consistent elevation of the participant's heart rate and a short duration of the whole exercise session. Every training session consists of a warm-up, a circuit of 5 exercises (the same as these in the PRT group) and a cool-down period. The children will be asked to train 3 times a week on non-consecutive days and to perform 3 sets. Exercise workload is controlled by determination of time intervals (30 seconds). The children will be instructed to perform as many repetitions as possible during the exercise interval and to keep the rest between the exercises short (it must not exceed 30 seconds).
3036362|NCT02319096|Experimental|Patients with stress incontinence|Patients who present to urogynaecology clinic with proven stress urinary incontinence who will be offered Whole body vibration therapy.
3036363|NCT02319083||Coronary artery bypass surgery|Patients undergoing coronary artery bypass surgery.
3036364|NCT02319070||Cohort 1|Adult patients with severe Hemophilia A.(25 patients on Secondary Prophylaxis treatment)
3036365|NCT02319070||Cohort 2|Adult patients with severe Hemophilia A.(50 patients on On Demand treatment)
3036366|NCT02319057|Experimental|Panel 1|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
3036367|NCT02319057|Experimental|Panel 2|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
3036368|NCT02319057|Experimental|Panel 3|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
3036369|NCT02319057|Experimental|Panel 4|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
3036370|NCT02319057|Experimental|Panel 5|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
3036371|NCT02319057|Experimental|Panel 6|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
3036372|NCT02319044|Experimental|MEDI4736|MEDI4736 monotherapy
3036373|NCT02319044|Experimental|Tremelimumab|Tremelimumab monotherapy
3036374|NCT02319044|Experimental|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
3036375|NCT02319031|Active Comparator|Arm1: Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks)|Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
3036376|NCT02319031|Active Comparator|Arm2 : Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)|Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
3036405|NCT02318836|Active Comparator|Mild Hepatic Impairment|(Child-Pugh score 5-6)
3036406|NCT02318836|Active Comparator|Moderate Hepatic Impairment|(Child-Pugh score 7-9)
3036407|NCT02318836|Active Comparator|Severe Hepatic Impairment|(Child-Pugh score 10-15)
3036377|NCT02319018|Experimental|Treatment (alisertib, mFOLFOX)|Patients receive alisertib PO BID on days 1-3 and mFOLFOX regimen comprising oxaliplatin IV over 2 hours on day 2, leucovorin calcium IV over 2 hours on day 2, and fluorouracil IV continuously over 46 hours on days 2-4. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3036378|NCT02319005|Active Comparator|Revusiran (ALN-TTRSC)|administered by subcutaneous (SC) injection
3036379|NCT02319005|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|administered by subcutaneous (SC) injection
3036380|NCT02318992|Active Comparator|Fecal Microbiota_Fresh|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500mL (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was used within 2 hours of preparation (Fresh).
3036381|NCT02318992|Active Comparator|Fecal Microbiota_Frozen|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500mL (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was kept at -80C freezer labeled with ID and expiration date which was 6 months after preparation day (Frozen).
3036382|NCT02318992|Active Comparator|Fecal Microbiota_Lyophilized|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500mL (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was starting lyophilization process within 30 minutes after completion of stool filtration (Lyophilized). Lyophilized microbiota products were kept at 4C and were used within 6 months after preparation day.
3036383|NCT02318979|Experimental|Running|Participants will run on an instrumented treadmill at one speed using three different prostheses.
3036384|NCT02318979|Experimental|Sprinting|Participants will run on an instrumented treadmill at a range of speeds from a jogging speed up to top speed.
3036385|NCT02318966|Active Comparator|Glycosade|Participants will be randomised to receive the medical food Glycosade as a starch load with a maximum dose of 100g. Glycosade to be taken as one dose.
3036386|NCT02318966|Placebo Comparator|Uncooked corn starch|Participants will be randomised to receive uncooked corn starch as a starch load with a maximum dose of 100g. Uncooked corn starch to be taken as one dose.
3036387|NCT02318953|Experimental|Mobile app follow-up care|"The mobile app follow-up group will have no planned in-person follow-up at one- and four weeks postoperative. However, these visits will be replaced with surgical site examination via submitted photos, visual analog scale (VAS) to assess pain, and the quality of recovery-9 (QoR9) questionnaire monitoring. All of this information is submitted via the mobile application (QoC Health Inc. Toronto). Patient will use daily monitoring for two weeks and then weekly monitoring for four weeks. The surgeon will use a wireless interface to access that data and monitor the patient's condition (not in real time). Physicians will summarize the clinical findings recorded by the mobile app at one week and four weeks postoperative using the prototypical SOAP note."
3036388|NCT02318953|Active Comparator|Conventional, in-person follow-up care|Patients in the conventional, in-person follow-up group will have a planned clinic follow-up at one- and 4-weeks postoperative. This is the follow-up schedule currently used by both surgeons. At these scheduled follow-ups, patients will be asked to complete the VAS to assess pain and the QoR9 questionnaire.
3036389|NCT02318940|Other|Landmark method|"installation of Central venous catheter In this arm the catheter will be installed under the usual method guided by anatomical landmarks.~access will be through the femoral vein only"
3036390|NCT02318940|Active Comparator|Ultrasound method|installation of Central venous catheter This arm of the catheter is installed using real-time ultrasound. Access will be through the femoral vein only
3036391|NCT02318927|Experimental|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
3036392|NCT02318914|Experimental|gevokizumab|Solution for subcutaneous injection
3036393|NCT02318901|Experimental|Arm 1|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. Intravenous (i.v.) trastuzumab 6 mg/kg on day 1 every 21 days.
3036394|NCT02318901|Experimental|Arm 2|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. ado-trastuzumab emtansine 3.6 mg/kg on day 1 every 21 days.
3036395|NCT02318901|Experimental|Arm 3|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. cetuximab 400 mg/m2 on cycle 1 day 1, then i.v. cetuximab 250 mg/m2 on day 8. Each subsequent cycle will be i.v. cetuximab 250 mg/m2 on days 1 and 8 every 21 days.
3036396|NCT02318888|Experimental|Surgery and Icodextrin|Icodextrin 4% instilled every 30 minutes during surgery and 1000 ml instilled before closure of abdomen
3036397|NCT02318888|Active Comparator|Surgery|No instillations during surgery
3036398|NCT02318875|Experimental|Kritech group|Subjects take 1 Kritech capsule per day (dose of 300mg)
3036399|NCT02318875|Placebo Comparator|Placebo group|Subjects take 1 placebo capsule per day
3036400|NCT02318862|Other|GERD|Those who have abnormal pH and abnormal esophageal mucosa and those who have abnormal pH and normal esophageal mucosa and are scheduled for standard of care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
3036401|NCT02318862|Other|non-GERD|Those who have normal pH and normal esophageal mucosa and are scheduled for standard of care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
3036402|NCT02318849|Experimental|Web intervention|Online intervention that uses information, engaging contests, and advocacy drives to encourage college students to become designated organ donor on driver's license
3036403|NCT02318849|No Intervention|Control|No intervention provided
3036404|NCT02318836|Active Comparator|Normal Hepatic function|
3036408|NCT02318823|Other|Beer (alcoholic) followed by placebo (non-alcoholic)|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has two treatment conditions in the same subject.
3036409|NCT02318823|Other|Placebo (non-acoholic beer) followed by Beer (alcoholic)|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has two treatment conditions in the same subject.
3036410|NCT02318810|Active Comparator|Rocuronium 0.3 mg/kg|Patients receive rocuronium 0.3 mg/kg
3036411|NCT02318810|Active Comparator|Rocuronium 0.6 mg/kg|Patients receive rocuronium 0.6 mg/kg
3036412|NCT02318810|Active Comparator|Rocuronium 0.9 mg/kg|Patients receive rocuronium 0.9 mg/kg
3036413|NCT02318810|Placebo Comparator|Placebo|Patients receive saline
3036414|NCT02318797|Active Comparator|Patient Self-Directed Care|See intervention description
3036415|NCT02318797|Active Comparator|Provider-Supported Integrated Care|See intervention description
3036416|NCT02318784|Experimental|Carfilzomib|"Carfilzomib will be administered as intravenous (IV) infusion over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of each 28-day cycle.~Cycle 1: First two doses of Carfilzomib 20 mg/m2 IV; subsequent doses at 56 mg/m2 IV~Cycle 2 onwards: Carfilzomib 56 mg/m2 IV"
3036417|NCT02318771|Experimental|A1: RT (1 fraction, 8 Gy) + MK-3475|Patients undergo RT on day 1 per standard of care and then undergo biopsy 3-10 days later. Beginning 0-7 days after biopsy, patients receive MK-3475 IV over 30 minutes on day 1. Courses of MK-3475 repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3036418|NCT02318771|Experimental|A2: RT (5 fractions, 4 Gy) + MK-3475|Patients undergo RT on days 1-5 and then undergo biopsy 3-10 days later. Beginning 0-7 days after biopsy, patients receive MK-3475 as in Arm A1.
3036419|NCT02318771|Experimental|B1: MK-3475 + RT (1 fraction, 8 Gy) + MK-3475|Patients receive one dose of MK-3475 IV over 30 minutes on day 1 and then undergo 1 fraction of RT. Patients then receive MK-3475 IV over 30 minutes in the absence of disease progression or unacceptable toxicity.
3036420|NCT02318771|Experimental|B2: MK-3475 + RT (5 fractions, 4 Gy) + MK-3475|Patients receive MK-3475 as in Arm B1 and undergo 5 fractions of RT.
3036421|NCT02318758|Active Comparator|Comparison 1|UT-15C 1 mg alone
3036422|NCT02318758|Active Comparator|Comparison 2|UT-15C 1 mg plus ethanol (simultaneously)
3036423|NCT02318758|Active Comparator|Comparison 3|UT-15C 1 mg administered 1 hour before ethanol
3036424|NCT02318758|Active Comparator|Comparison 4|UT-15C 1 mg administered 1 hour after ethanol
3036425|NCT02318745|Experimental|Culturally Informed Family Treatment for Adolescents|CIFTA focuses on improving parenting practices, parent-adolescent attachment, adolescent ability to meet developmental challenges, increasing family support and decreasing family conflict/negativity, increasing knowledge of drug effects and triggers to use. Parents are taught general parenting and how to help a son or daughter with depression, conduct problems, and/or ADHD. Psycho-educational modules complement the family therapy and culturally relevant information is infused throughout the treatment. In family therapy sessions family members practice the skills and psycho-educational material they have learned. Treatment last approximately 4 months and includes approximately 6 session per month. Session may be family therapy sessions, individual sessions, or psycho-educational modules.
3036426|NCT02318745|Active Comparator|Individual Treatment As Usual|The active comparison condition reflects the typical individually-oriented services that behavior problem youth receive in the community. It was designed to isolate the effects of the CIFTA family interventions. A community agency helped us to standardize the individually-oriented services that were normally provided and a therapist trained by that agency was hired to work on the study to provide continuity to the services. The adolescent individual sessions addressed depression, ADHD, and/or conduct disorder through Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, and assertiveness training. The ITAU therapists were expected to hold 6 sessions per month with the youth.
3036427|NCT02318732|Experimental|Group 1|APPS intervention will be implemented in Group 1 communities prior to implementation in Group 2 communities.
3036428|NCT02318732|Active Comparator|Group 2|APPS intervention will be implemented in Group 2 communities following implementation in Group 1 communities.
3036429|NCT02318719|Placebo Comparator|Placebo|Placebo (14-weeks)
3036430|NCT02318719|Experimental|DS-5565 15 mg Group|DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
3036431|NCT02318719|Experimental|DS-5565 20 mg Group|DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
3036432|NCT02318719|Experimental|DS-5565 30 mg Group|DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
3036433|NCT02318706|Placebo Comparator|placebo|placebo group (14 weeks)
3036434|NCT02318706|Experimental|DS-5565 15mg|DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
3036435|NCT02318706|Experimental|DS-5565 20 mg group|DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
3036436|NCT02318706|Experimental|DS-5565 30 mg group|DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
3036437|NCT02318693|Experimental|Sitagliptin 50 mg|Sitagliptin 50 mg administered orally once daily before breakfast for 14 days.
3036438|NCT02318693|Active Comparator|Glibenclamide 2.50 mg TDD|Glibenclamide 1.25 mg administered orally twice daily (2.5 mg TDD) for 14 days. TDD = Total daily dose.
3036439|NCT02318680|Experimental|Intervention|Review of follow home visits after discharge from Nykøbing Falster Hospital
3036440|NCT02318680|No Intervention|Control|Standard health care and discharge services
3036441|NCT02318667|Experimental|Golimumab treatment|Golimumab 200 mg initially administered by subcutaneous (SC) injection at Week 0, followed by 100 mg at Week 2 and then 50 mg or 100 mg every 4 weeks (per prescribing information) up to 16 weeks.
3036442|NCT02318654|Active Comparator|Ice Pack|
3036443|NCT02318654|Active Comparator|Topical EMLA cream|
3036444|NCT02318615|Experimental|Immediate Axillary Plasty|Immediate Axillary Plasty ：After axillary lymph node dissection, a pedicled flap named Partial Latissimus Dorsi Muscle Flap is filled in the cavity of axilla, and fixed around the axillary vessels.
3036474|NCT02318381|No Intervention|Control|Patients with suprascapular neuropathy and rotator cuff tear treated arthroscopically without release of the superior transverse scapular ligament.
3036445|NCT02318615|No Intervention|Education|Education：After surgery, education on the prevention of lymphedema. In patients suffering with upper limb lymphedema during follow-up, any treatment except axillary or breast reconstruction can be used.
3036446|NCT02318602|Experimental|Infants|"Participants 1 to<2 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant. The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose, milligrams per kilograms per day (mg/kg/day), will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
3036447|NCT02318602|Experimental|Children|"Participants 2 to <12 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose (mg/kg/day) will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
3036448|NCT02318602|Experimental|Adolescents|"Participants 12 to <17 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant. The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose (mg/kg/day) will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
3036449|NCT02318576|No Intervention|Control|This group will do nothing for the 12 week program.
3036450|NCT02318576|Experimental|Cognitive Trained Group|This group will train three time a week for one hour on the given computerized cognitive training website for the 12 week program.
3036451|NCT02318563|Experimental|Cannabidiol Oral Solution|Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
3036452|NCT02318563|Placebo Comparator|Placebo Solution|Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
3036453|NCT02318537|Experimental|Cannabidiol Oral Solution|Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
3036454|NCT02318537|Placebo Comparator|Placebo Solution|Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
3036455|NCT02318511|Experimental|ReNu amniotic allograft|Knee injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
3036456|NCT02318511|Placebo Comparator|Saline|Knee injection with saline. Injectable saline will be used as the placebo control.
3036457|NCT02318511|Active Comparator|HA injection|Knee injection with HA. HA will be used as a viscosupplementation injection consisting of cross linked HA.
3036458|NCT02318498|Active Comparator|Prospective MINCA patients|Patients with MINCA prospectively investigated with an early CMR with latest technique
3036459|NCT02318498|Placebo Comparator|Historical MINCA patients|Patients with MINCA investigated earlier with a late CMR (median 12 days)
3036460|NCT02318485|Experimental|Transplant|A limbal epithelial stem cell graft will be transplanted onto the limbal stem cell deficient eye after it has been debrided of fibrovascular pannus
3036461|NCT02318472|Experimental|Early mobilization|Functional mobilization initiated directly post-operative with a weight-bearing VACOped orthosis with adjustable range of motion of the ankle
3036462|NCT02318472|Active Comparator|Immobilization|Treatment as usual using plaster cast immobilization
3036463|NCT02318459|Experimental|high intensity interval training-HIIT|HIIT 4 times a week, 30 minutes duration
3036464|NCT02318459|Active Comparator|Traditionnal rehabilitation|Traditionnal group rehabilitation 3 times a week, 1 hour duration.
3036465|NCT02318446|Placebo Comparator|Control group|Will receive Oral saccharine tablet daily for 1month along with their existing antiepileptic therapy
3036466|NCT02318446|Experimental|Test group|Will receive Oral Folic acid 1mg tablet daily for 1month along with their existing antiepileptic therapy
3036467|NCT02318433|Experimental|Dexamethasone|Subjects receive dexamethasone (4 mg) injection within the radiocarpal joint either in clinic or in the OR.
3036468|NCT02318433|Placebo Comparator|Saline|Subjects receive sterile saline (4 mg) injection within the radiocarpal joint either in clinic or in the OR.
3036469|NCT02318420|Experimental|Women in labour|"All women in labour during the study period (4 months baseline and the 9th-12th month of the intervention) will be included for this pre- vs. post-study of the PartoMa intervention.~The following subgroups will be studied in-depth:~All stillbirths~All maternal deaths~All women with severe hypertensive disorders~A randomized selected group of women delivering a the study site, approximately 300-600 each year."
3036470|NCT02318420|Experimental|Health care providers|All health care providers (physicians and nurse-midwives) working at the Department of Obstetrics during the study period will be invited to participate in knowledge tests of obstetric care and qualitative participant observations as well as in-depth interviews regarding quality of care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.
3036471|NCT02318407|Experimental|AMG 403|AMG 403 administered as subcutaneous doses
3036472|NCT02318407|Placebo Comparator|Placebo|No active drug
3036473|NCT02318394|Experimental|Monotherapy Arm|MEDI0562 monotherapy
3036475|NCT02318381|Other|Ligament Release|"Patients with suprascapular neuropathy and rotator cuff tear treated arthroscopically with release of the suprascapular nerve.~Arthroscopic dissection of the superior transverse scapular ligament"
3036476|NCT02318368|Experimental|Ficlatuzumab plus erlotinib|150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with 20 mg/kg Ficlatuzumab administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
3036477|NCT02318368|Active Comparator|Placebo plus erlotinib|150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with Placebo administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
3036478|NCT02318355|No Intervention|Control|Control group that receives no intravenous fluid after blood donation
3036479|NCT02318355|Experimental|Lactated Ringers|Experimental group that receives two liters lactated ringers after blood donation.
3036480|NCT02318355|Experimental|Normal Saline|Experimental group that receives two liters normal saline after blood donation.
3036481|NCT02318342|Experimental|Pre-existing bioprosthetic aortic valve|Patients with a history of surgical or transcatheter valve replacement with bioprosthetic valves undergo cardiac contrast CT imaging and transthoracic echocardiography to evaluate structural and functional integrity of the aortic valves. Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
3036482|NCT02318329|Experimental|Part 1A: FPA144 Dose Escalation Solid Tumors|IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined.
3036483|NCT02318329|Experimental|Part 1B: FPA144 Dose Escalation Gastric Cancer|IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined.
3036484|NCT02318329|Experimental|Part 2: FPA144 Dose Expansion Gastric or Other Solid Tumors|"Part 2: FPA144 Dose Expansion Gastric, Bladder or Other Advanced Solid Tumors~The study is not currently enrolling patients. Cohorts with Advanced Solid Tumors, Gastric Cancer and Bladder Cancer are closed. IV infusion; once MTD and/or RD has been determined in Part 1, one expansion cohort of approximately 30 Bladder Cancer patients will be enrolled."
3036485|NCT02318316||EBC level|Exhaled breath condensate level of allogeneic stem cell transplantation patients
3036486|NCT02318303|Placebo Comparator|GSP 301 Placebo NS|
3036487|NCT02318303|Experimental|GSP 301-1 NS (QD)|
3036488|NCT02318303|Experimental|GSP 301-2 NS (BID)|
3036489|NCT02318303|Active Comparator|Olopatadine HCl-1 NS (QD)|
3036490|NCT02318303|Active Comparator|Olopatadine HCl-2 NS (BID)|
3036491|NCT02318303|Active Comparator|Mometasone Furoate-1 NS (QD)|
3036492|NCT02318303|Active Comparator|Mometasone Furoate-2 NS (BID)|
3036493|NCT02318290||Critically ill patients|Mechanically ventilated critically ill patients receiveing opiates for more than 96 hours will be prospectively followed for the emergence of withdrawal symptoms upon weaning of opiates
3036494|NCT02318277|Experimental|MEDI4736 + INCB024360|MEDI4736 at selected dose levels every 2 weeks + INCB024360 25 mg BID as starting dose, followed by dose escalations until MTD or PAD is identified
3036495|NCT02318264|Experimental|Distal to Proximal Tape|Quadriceps muscle taped (Using Kinesio Tape) starting distal by knee and ending proximal by hip.
3036496|NCT02318264|Experimental|Proximal to Distal Tape|Quadriceps muscle taped (Using Kinesio Tape) starting proximal by hip and ending distal by knee.
3036497|NCT02318251|Experimental|Involuntary muscle contractions|Standard physiotherapy program (focus on involuntary reflexive pelvic floor muscle contractions)
3036498|NCT02318251|Active Comparator|Voluntary muscle contractions|Physiotherapy program (focus on voluntary pelvic floor muscle contractions)
3036499|NCT02318238|Active Comparator|6 minute walking test|walking during 6 minutes
3036500|NCT02318238|Experimental|6 minute step test|stepping during 6 minutes
3036501|NCT02318238|Experimental|4 meter gait speed|walking as fast as possible on 4 meters
3036502|NCT02318225|Active Comparator|Misoprostol|Misoprostol (400µg) is administered vaginally 12 hours before office hysteroscopy
3036503|NCT02318225|Placebo Comparator|Placebo|Placebo is administered vaginally 12 hours before office hysteroscopy
3036504|NCT02318199||Agitation group|Patient is evaluated by the sedation-agitation scale (SAS) during the anesthesia recovery after intracranial surgery under general anesthesia. SAS equals to 5-7 during the first 12 hours after surgery.
3036505|NCT02318199||Non-agitation group|Patient is evaluated by the sedation-agitation scale (SAS) during the anesthesia recovery after intracranial surgery under general anesthesia. SAS equals to 1-4 during the first 12 hours after surgery.
3036506|NCT02318186||0 months - 1 year|
3036507|NCT02318186||11-16 years|
3036508|NCT02318186||7-11 years|
3036509|NCT02318186||4-6 years|
3036510|NCT02318186||1-3 years|
3036511|NCT02318147|Experimental|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor，At the same time give patients the traditional treatment of SAP
3036512|NCT02318147|Other|The traditional treatment|The traditional treatment of SAP according to the associated guidelines
3036513|NCT02318134|Experimental|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor，At the same time give patients the traditional treatment of SAP
3036514|NCT02318134|Other|The traditional treatment|The traditional treatment of SAP according to the associated guidelines
3036515|NCT02318121|Active Comparator|Amniotomy first|Will be done with sterile gloves after insurance that is the baby's head fits in the pelvis ( 3\5 or less of fetal head felt by first pelvic grip ) and by vaginal examination the head at station zero . The membranes are then punctured using an a hook during uterine contractions.
3036516|NCT02318121|Active Comparator|Oxytocin first|The starting dose will be the low dose rate equal or less than 4 m unit\minute (4 drops\minute doubled every 15 minutes up to 40 drops \minute) as intravenous drip on dextrose ,Ringer's lactate or saline solution.
3036517|NCT02318121|Active Comparator|Amniotomy and oxytocin|Amniotomy will be done (as explained above) and oxytocin (the same regimen mentioned above) at the same time.
3063281|NCT02139839|Experimental|Lactobacillus capsules first|
3036518|NCT02318108|Experimental|Intervention|Mentored organizational change and feedback.
3036519|NCT02318108|Other|Education only|Education and feedback.
3036520|NCT02318095|Other|Chemotherapy/radiation/surgery|This is a single arm prospective study. All eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel, followed by hypofractionated radiation therapy followed by surgical resection. Subjects may receive adjuvant chemotherapy post surgical resection at the clinical discretion of the medical oncologist.
3036521|NCT02318082|Experimental|Interleukin-2 (IL-2)|Interleukin-2: Each participant will receive daily subcutaneous IL-2 for self-administration per cycle. Each participant will start at Dose Level A. In the abscence of DLTs or severe non-DLT adverse events, participants will have daily SC IL-2 dose-escalated at Week 2 (to dose level B) and at Week 4 (to Dose Level C), and continue on their maximum tolerated dose (MTD) IL-2 for 4 weeks total.
3036522|NCT02318069|Active Comparator|TBE vaccine at 0+30 days|This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later
3036523|NCT02318069|Active Comparator|TBE vaccine at 0+7+21 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later
3036524|NCT02318069|Active Comparator|TBE vaccine at 0+30+90 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later
3036525|NCT02318069|Active Comparator|younger participants|This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later
3036526|NCT02318069|Active Comparator|double dose of vaccine|This group of 50 participants will be given two doses of TBE vaccine 0.5 ml FSME immune at the first day of the study and an additional dose at day 30 as well as one year later
3036527|NCT02318056|Experimental|Aquacel® Ag Burn Glove|Application of Aquacel® Ag Burn Glove burn dressing
3036528|NCT02318056|Active Comparator|Mepilex® Transfer Ag|Application of Mepilex® Transfer Ag burn dressing
3036529|NCT02318056|Active Comparator|Xeroform®/Bacitracin®|Application of Xeroform® burn dressing and Bacitracin® topical antibiotic
3036530|NCT02318043|Active Comparator|AMP-BPT|Methods of AMP-BPT, by applying dosimeters, resembled that reported previously [see references 21-25]. Briefly, dilutions were delivered via nebulizers (output: 160 μl/min) using automated APS pro system (JAEGER, Hochburg, Germany). Inhalation challenge with normal saline served as control step. Challenge steps were proceeded if FEV1 fall <15% and restored to <10% within 1 minute. Subsequent inhalation challenges were performed at 1-minute intervals, and ceased when FEV1 fell by ≥20%. Salbutamol was administered via spacer (Volumatic, Allen & Hanbury's, UK). Spirometry was reexamined at minutes 3, 5, 10 and thereafter, to ensure safety, before discharge.
3036531|NCT02318043|Active Comparator|His-BPT|Methods of His-BPT, by applying dosimeters, resembled that reported previously [see references 21-25]. Briefly, dilutions were delivered via nebulizers (output: 160 μl/min) using automated APS pro system (JAEGER, Hochburg, Germany). Inhalation challenge with normal saline served as control step. Challenge steps were proceeded if FEV1 fall <15% and restored to <10% within 1 minute. Subsequent inhalation challenges were performed at 1-minute intervals, and ceased when FEV1 fell by ≥20%. Salbutamol was administered via spacer (Volumatic, Allen & Hanbury's, UK). Spirometry was reexamined at minutes 3, 5, 10 and thereafter, to ensure safety, before discharge.
3036532|NCT02318030||Solid organ transplant|
3036533|NCT02318030||Hematopoietic Stem Cell Transplant|
3036534|NCT02318017|Active Comparator|Methylphenidate|Methylphenidate 0.5mg/kg - once
3036535|NCT02318017|Placebo Comparator|Placebo|Placebo - once
3036536|NCT02318004|Experimental|Home monitoring|Home monitoring via the EarlySense non-invasive nocturnal monitoring system. Movement, heart rate and respiratory rates will be monitored while subject is in his bed. The trends of monitored values will be daily reported to a central repository. No intervention will be attempted and care will be coordinated by the family physician and treating cardiologist as usual.
3036537|NCT02317991|Experimental|nab-paclitaxel and ramucirumab|"All patients will receive 125 mg/m^2 of nab-Paclitaxel intravenously (IV) on Days 1, 8, and 15 of a 28-day cycle (weekly for 3 weeks, with 1 week of rest).~Patients will receive ramucirumab 8mg/kg IV in combination with nab-paclitaxel on Days 1 and 15 of the 28-day cycle."
3036538|NCT02317978||Subfertility without polycystic ovarian syndrome|The records of all women with infertility who had IVF/ICSI without polycystic ovarian syndrome (PCO) will be reviewed
3036539|NCT02317965||Pregnant Women|"Pregnant women who are scheduled to undergo an amniocentesis or chorionic villus sampling (CVS) procedure~Intervention: Single Maternal blood draw of 20mL"
3036540|NCT02317952|Experimental|New Extensively Hydrolyzed Formula|Administered in context of oral food challenge and then for 16 weeks.
3036541|NCT02317952|Active Comparator|Comparator Formula|Administered in context of oral food challenge and then for 16 weeks.
3036542|NCT02317939|Experimental|online instruction at followup visits|patients in this group will be subjected to view video instructions online prior to performing the follow-up joint scoring at home
3036543|NCT02317939|Active Comparator|standard baseline instruction|after the initial training patients in this group will not be subjected to any subsequent instructions prior to performing the follow-up joint scoring at home
3036544|NCT02317926|Active Comparator|Levothyroxine Plus Liothyronine Group|Levothyroxine Plus Liothyronine Group
3036545|NCT02317926|Active Comparator|Levothyroxine Group|Levothyroxine Group
3036546|NCT02317926|Active Comparator|Desiccated Thyroid Extract Group|Desiccated Thyroid Extract Group
3036547|NCT02317900|Experimental|TV005 and rDEN2∆30-7169|Participants will receive one injection of TV005 at study entry (Day 0). On Day 180, participants will receive one injection of rDEN2∆30-7169.
3036548|NCT02317900|Placebo Comparator|Placebo and rDEN2∆30-7169|Participants will receive one injection of placebo at study entry (Day 0). On Day 180, participants will receive one injection of rDEN2∆30-7169.
3036549|NCT02317887|Experimental|Group 1|Low
3036550|NCT02317887|Experimental|Group 2|Medium
3036551|NCT02317887|Experimental|Group 3|High
3036653|NCT02317172|Experimental|Gel-based artificial saliva|Continuous oral intake of edible gel-based artificial saliva (30-50 ml/day) for four weeks
3036552|NCT02317874|Experimental|Schedule A (7-day talazoparib, paclitaxel, carboplatin)|"Patients receive talazoparib PO QD on days 1-7, paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.~At any time after 4-6 courses of treatment, patients may continue combination study therapy with talazoparib, carboplatin, and paclitaxel, talazoparib and carboplatin, talazoparib alone (continuous dosing), or observation without therapy at the discretion of the treating physician."
3036553|NCT02317874|Experimental|Schedule B (3-day talazoparib, paclitaxel, carboplatin)|"Patients receive talazoparib PO QD on days 1-3, paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.~At any time after 4-6 courses of treatment, patients may continue combination study therapy with talazoparib, carboplatin, and paclitaxel, talazoparib and carboplatin, talazoparib alone (continuous dosing), or observation without therapy at the discretion of the treating physician."
3036554|NCT02317861|Experimental|Cohort 1|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
3036555|NCT02317861|Experimental|Cohort 2|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
3036556|NCT02317861|Experimental|Cohort 3|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.
3036557|NCT02317861|Experimental|Cohort 4|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.
3036558|NCT02317861|Experimental|Cohort 5|RDEA3170 2.5mg, RDEA3170 5mg, RDEA3170 10mg, RDEA3170 15mg
3036559|NCT02317861|Experimental|Cohort 6|The half of patients randomized to this cohort will be dosed in the order of Benzbromarone 50 mg, Febuxostat 10mg+RDEA3170 2.5 mg, then Febuxostat 20mg+RDEA3170 5 mg. The other half will be dosed in the order of Febuxostat 10mg+RDEA3170 2.5 mg, Febuxostat 20mg+RDEA3170 5 mg, then Benzbromarone 50mg.
3036560|NCT02317848|Other|patients with acute heart failure|polygraphy, echocardiography, ECG during hospitalisation for acute heart failure
3036561|NCT02317835|Other|Study in healthy volunteers|Skin foot temperature measurement by DFUPS device
3036562|NCT02317809|Experimental|First Liquid Pergoveris, Then Freeze-dried Pergoveris|
3036563|NCT02317809|Experimental|First Freeze-dried Pergoveris, Then Liquid Pergoveris|
3036564|NCT02317796|Placebo Comparator|Placebo|
3036565|NCT02317796|Active Comparator|100 mg q.d.|
3036566|NCT02317796|Active Comparator|100 mg b.i.d.|
3036567|NCT02317796|Active Comparator|200 mg q.d.|
3036568|NCT02317796|Active Comparator|200 mg b.i.d.|
3036569|NCT02317783|Experimental|FDG-PET, [18F]Flutemetamol Scanning|
3036570|NCT02317770|Active Comparator|Lidocaine Spray|20 puffs of 10% Lidocaine spray
3036571|NCT02317770|Active Comparator|Nebulized Lidocaine|2.5 mL of 10% Lidocaine
3036572|NCT02317757||cancer patients receiving chemotherapy|Patients who are older than 70 years old receiving chemotherapy
3036573|NCT02317744|Experimental|Naltrexone/ Bupropion combination|50 mg naltrexone and 300 mg bupropion per day for 3 months
3036574|NCT02317744|Placebo Comparator|Pill placebo|Daily placebo medication for 3 months
3036575|NCT02317731|No Intervention|Routine|Subjects will ingest the bowel preparation from a cup
3036576|NCT02317731|Experimental|Straw|Subjects will ingest the bowel preparation with a straw
3036577|NCT02317718||Normal vitamin D levels group|MORE THAN 20 NG/ML VITAMIN D LEVELS
3036578|NCT02317718||Deficient Vitamin D GROUP|LESS THAN 20 NG/ML LEVELS
3036579|NCT02317692|Active Comparator|Standard ADHD parent training|8 sessions of evidence-based parent training plus school intervention
3036580|NCT02317692|Experimental|Culturally-modified ADHD parent training|8 sessions of culturally-modified parent training plus school intervention
3036581|NCT02317679|Experimental|Bosentan and laser|Patients with PWS resistant to PDL treatment will be included. A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject). The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
3036582|NCT02317666|Experimental|Medication Review|Structured 5-step multidisciplinary medication review (STRIP method) performed by the pharmacist in collaboration with the general practitioner.
3036583|NCT02317666|No Intervention|Delayed Medication Review|Patients in the control group will not undergo a medication review during the study period (delayed medication review).
3036584|NCT02317653||Overweight/Obese|Archive blood, archive breast milk, and clinical assessment data from 15 participants who were considered overweight or obese at enrollment in the Expecting Success study conducted at Pennington Biomedical Research Center (NCT01610752) will be used to represent the overweight and obese sample for study investigations.
3036585|NCT02317653||Normal Weight|Up to 20 pregnant women who were considered normal weight (18.5 ≤ BMI ≤ 24.9 kg/m2) prior to pregnancy will be enrolled in the study.
3036654|NCT02317159|Experimental|imatinib，Capsule|400mg imatinib qd
3036655|NCT02317146|Experimental|Six Hours Postpartum|The woman received magnesium sulfate for 6 hours after delivery as prophylaxis to eclampsia.
3036656|NCT02317146|Active Comparator|Twenty-four hours Postpartum|The woman received magnesium sulfate for 24 hours after delivery as prophylaxis to eclampsia.
3036657|NCT02317133||HSP: acute episode|"Patients in this group are going through an acute episode of Henoch Schönlein Purpura.~Intervention: Blood samples Intervention: Stool samples"
3036586|NCT02317640|Active Comparator|Stand Training Alone|Standing training will be prescribed 3 days/week (1.5 hours/sessions) for 60 sessions. All individuals randomized to stand training will train with BWST with manual assistance and will undergo a stand evaluation. During the evaluation the participants will be placed on the treadmill in an upright position and suspended in a harness by an overhead cable (i.e. BWST). A trainer will be positioned to assist the participant while standing and to provide manual assistance if needed. The amount of BWS and level of assistance given for each body segment will be recorded. The BWS level at which the participant can independently support good standing posture will also be recorded. Standing time while on treadmill and overground will be recorded daily as part of the training sessions.
3036587|NCT02317640|Experimental|ST with placebo or testosterone|Stand Training as described above with Placebo or testosterone Gel applied by a pump. After a baseline testing period, TRT will begin in the treatment groups by application of a daily dose of 40.5 mg of testosterone or placebo gel. The gel is to be applied to the upper arms and shoulders and is absorbed and eliminated over the course of a day. To ensure proper dosing serum T concentration will be assessed at screening, baseline, 2 weeks, 1 month and 3 month time points. As such, follow-up with the participant will be necessary to determine the correct replacement dose of TRT, and adjustment of dose if needed, (i.e. 40.5 mg up to 81 mg of gel). If serum T levels are not within normal range at the 2 week time point, the dose will be increased in increments of 20.25 mg up to 81 mg.
3036588|NCT02317640|Experimental|ST with Placebo or Testosterone and ES|"Stand Training described above with Placebo or testosterone gel applied by a pump. Electrical stimulation will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points (both legs) on the following muscles: gluteus maximus (GL), rectus femoris (RF), biceps femoris (BF), gastrocnemei (GC), and anterior tibialis (TA) of both legs. Two electrodes will be used for each muscle. One RT300 portable stimulator (Restorative Therapies, Inc., Baltimore, MD) will be used to induce the electrical stimulation with 10 sets of electrodes for stimulation."
3036589|NCT02317640|Experimental|ST with ES|Stand Training as described above in Stand Training alone and Electrical Stimulation as described above in ST with Placebo or Testosterone and ES.
3036590|NCT02317627|Experimental|Cohort 1|KD025 will be orally administered to subjects at 400 mg once daily for 12 weeks
3036591|NCT02317627|Experimental|Cohort 2|KD025 will be orally administered to subjects at 200mg twice daily for 12 weeks
3036592|NCT02317627|Experimental|Cohort 3|KD025 will be orally administered to subjects at 400mg twice daily for 12 weeks
3036593|NCT02317614|Experimental|SteadyRx|This group will be assessed at monthly intervals. They will receive their usual care at their regular providers. In addition, they will be given Smartphones loaded with the SteadyRx intervention.
3036594|NCT02317614|No Intervention|Usual Care|This group will be assessed at monthly intervals. They will receive their usual care at their regular providers. They will not receive a Smartphone or the SteadyRx adherence intervention.
3036595|NCT02317601|Active Comparator|Methylprednisolone sodium succinate|125 mg iv, as single dose, preoperative.
3036596|NCT02317601|Placebo Comparator|physiological saline|5 mL of Sodium-Chloride 9 mg/ml, Fresenius Kabi
3036597|NCT02317588|Active Comparator|Flax Oil|Flax oil 4 grams of ALA per day for 28 days (4 weeks).
3036598|NCT02317588|Active Comparator|Fish Oil|Fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day for 28 days (4 weeks).
3036599|NCT02317575|Experimental|Part A:LY900014 (A)|Formulation A. Single dose of LY900014 administered subcutaneously (SC) in one of five periods.
3036600|NCT02317575|Experimental|Part A:Insulin Lispro|Reference formulation. Single dose of insulin lispro administered SC in one of five periods.
3036601|NCT02317575|Experimental|Part A:LY900014 (B)|Formulation B. Single dose of LY900014 administered SC in one of five periods.
3036602|NCT02317575|Experimental|Part A:LY900014 (C)|Formulation C. Single dose of LY900014 administered SC in one of five periods.
3036603|NCT02317575|Experimental|Part A:LY900014 (D)|Formulation D. Single dose of LY900014 administered SC in one of five periods.
3036604|NCT02317575|Experimental|Part B:LY900014|Formulation selected from Part A. Single dose of LY900014 administered SC in one of four periods.
3036605|NCT02317562|Experimental|I10E Arm|
3036606|NCT02317549|Experimental|Tranexemic Acid|Daily a total of 700 mL of LB1148 solution containing 7.5 g of tranexemic acid will be administered orally or via NG/OG/NJ/ND/PEG tube
3036607|NCT02317549|Placebo Comparator|Placebo|Daily a total of 700 mL of Placebo solution will be administered orally or via NG/OG/NJ/ND/PEG tube
3036608|NCT02317536|Experimental|Carnipure Product 1|Carnitine-based product 1, subjects will take one dose once daily for 56 days.
3036609|NCT02317536|Experimental|Carnipure Product 2|Carnitine-based product 2, subjects will take one dose once daily for 56 days.
3036610|NCT02317536|Placebo Comparator|Placebo|Placebo, subjects will take one dose once daily for 56 days.
3036611|NCT02317523|Experimental|Behavioral Activation|Behavioral Activation (BA) emphasize self-monitoring as an aid for increasing one's engagement in self-reinforcing activities while simultaneously reducing negative avoidant coping responses. The intervention consists of 6 total face-to-face sessions lasting 60 minutes each.
3036612|NCT02317523|Active Comparator|Information and Support|Information and Support (IS) consists of providing education on Alzheimer's disease, coping with specific stresses prevalent in caregiving, and community-based services available for caregivers. Caregivers choose information most relevant to their current circumstances, and can discuss this with their counselor during the sessions. In addition, the IS condition encompasses elements of supportive therapy including empathy and active listening. The intervention consists of 6 total face-to-face sessions lasting 60 minutes each.
3036613|NCT02317510|Active Comparator|group 1|Laparoscopic cholecystectomy in General Anesthesia
3036614|NCT02317510|Active Comparator|group 2|Laparoscopic cholecystectomy in combined anesthesia (Spino epidural).
3036615|NCT02317497|Experimental|Moderate sedation (M)|1. Moderate sedation defined by target RASS of >= -3. The intervention (M) is sedation by use of any sedative and/or analgesic medication(s) left at the discretion of the treating physicians targeted at a RASS of >= -3 (patient responds to verbal stimulus) from randomization for the next 72h. RASS will be assessed once every 8 h (at he beginning of each shift) and measures undertaken to achieve the target level. If safety-limits are violated, sedation may have to be deepened below the target level for 8h and re-assessed at the beginning of the next shift with the aim to approach the target level of the intervention group again.
3036616|NCT02317497|Active Comparator|Deep sedation (D)|2. Deep sedation defined by target RASS of < -3. The control (D) is sedation by use of any sedative and/or analgesic medication(s) left at the discretion of the treating physicians targeted at a RASS of < -3 (patient does not respond to verbal stimulus) from randomization for the next 72h. RASS will be assessed once every 8 h (at he beginning of each shift) and measures undertaken to achieve the target level. If safety-limits are violated, sedation may have to be reduced above the target level for 8h and re-assessed at the beginning of the next shift with the aim to approach the target level of the control group again.
3036617|NCT02317484||Ipragliflozin (SGLT2 inhibitor)|
3036618|NCT02317471|Experimental|gp96 group|autologous gp96 vaccination + basal treatment for gastric cancer
3036619|NCT02317471|Other|control group|Oxaliplatin+S-1
3036620|NCT02317458|Experimental|Active arm|One arm with standard of care and C3BS-CQR-1 injection (treatment group) using intramyocardial catheter injection.
3036621|NCT02317458|Sham Comparator|Control arm|One arm with standard of care undergoing a sham procedure (control group)using intramyocardial catheter injection. .
3036622|NCT02317432|Experimental|CBT + InVEST exercise|10 sessions of individual CBT plus 36 sessions of InVEST group exercise, provided over a 12-week intervention period.
3036623|NCT02317432|Active Comparator|Enhanced Usual Care|Usual care, as accessed through the community-based organization, plus written material from the NIH on depression, anxiety, and physical health for elders.
3036624|NCT02317419|Experimental|Part A MAD Phase RO6927005 Monotherapy|RO6927005 given as a single agent in participants with tumors known to be mesothelin expressing and with mesothelin-positive tumors. MAD = multiple ascending dose.
3036625|NCT02317419|Experimental|Part A Extension Phase Group 1|RO6927005 given as a single agent in participants with mesothelin-positive refractory/recurrent solid tumors, other than malignant pleural mesothelioma (MPM) and pancreatic ductal adenocarcinoma (PDA)
3036626|NCT02317419|Experimental|Part A Extension Phase Group 2|RO6927005 given as a single agent in participants with mesothelin-positive metastatic and/or advanced PDA
3036627|NCT02317419|Experimental|Part B MAD Phase|RO6927005 with gemcitabine/nab-paclitaxel in participants with mesothelin-positive metastatic and/or advanced PDA
3036628|NCT02317419|Experimental|Part B Extension Phase|RO6927005 with gemcitabine/nab-paclitaxel in participants with PDA
3036629|NCT02317406|Active Comparator|Probiotics|Biostime probiotics sachet children's formula, 1.5g/d/sachet, administrated during the consumption of the first feeding-bottle of the day. Duration: 4 weeks
3036630|NCT02317406|Placebo Comparator|Probiotics simulation|Biostime probiotics sachet children's formula（placebo）, 1.5g/d/sachet, administrated during the consumption of the first feeding-bottle of the day. Duration: 4 weeks
3036631|NCT02317393|Other|K5-RGD PET + FDG|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy, with a maximal delay from end of chemotherapy of 2 months. Delay between FDG and 18F-K5-RGD PET scans will not exceed 2 weeks.
3036632|NCT02317341|Experimental|1|Single intravenous dose given over 40 minutes
3036633|NCT02317341|Active Comparator|2|Single intravenous dose goven over 40 minutes
3036634|NCT02317315||Preterm labor group|Patients who are admitted for evaluation of preterm labor.
3036635|NCT02317302|Experimental|FDG-PET/CT or FDG-PET/MR|"Standard of care FDG-PET/CT or FDG-PET/MR at baseline~FDG-PET/CT or FDG-PET/MR after the 2nd but before the 3rd brachytherapy treatment~Standard of care 3 month post treatment FDG-PET/CT or FDG-PET/MR~We will perform the research-related FDG-PET on the PET/MR rather than the PET/CT if the patient is safe to undergo MR and agrees to undergo MR.~The standard of care imaging may be performed on the PET/CT scanner or the PET/MR scanner."
3036636|NCT02317289|Experimental|Detection of freezing|freezing parkinsonian patients
3036637|NCT02317276|Experimental|Treatment|Topical Triamcinolone 0.1% ointment will be provided for twice daily application, during treatment periods.
3036638|NCT02317263|Active Comparator|Testosterone gel|Apply gel once a day for 96 weeks
3036639|NCT02317263|Placebo Comparator|Placebo gel|Apply gel once a day for 96 weeks
3036640|NCT02317250|Experimental|prompt amyloid imaging, delayed FDG-PET|Subject's managing physicians will be given the results of amyloid imaging scans immediately. FDG-PET results will be released two years after scanning.
3036641|NCT02317250|Experimental|prompt FDG-PET, delayed amyloid imaging|Subject's managing physicians will be given the results of FDG-PET scans immediately. Amyloid imaging results will be released two years after scanning.
3036642|NCT02317250|Experimental|prompt FDG-PET, prompt amyloid imaging|Both FDG-PET and amyloid imaging scan results will be made immediately available to the managing physician.
3036643|NCT02317250|Active Comparator|delayed FDG-PET, delayed amyloid imaging|Neither FDG-PET nor amyloid imaging scan results will be released to the managing physician for 2 years.
3036644|NCT02317237|No Intervention|General Anesthesia|The patients, who will receive general anesthesia during intervention
3036645|NCT02317237|Experimental|Local Anesthesia|The patients, who will receive local anesthesia/conscious sedation during intervention
3036646|NCT02317224|Experimental|"3-Hole subxiphorid and subcostal approach"|The patient were in the supine position with legs apart at about 45°, made a 2.0 cm incision below xiphoid process as the observation hole. Then made two 0.5cm operation holes along bilateral rib arch at midclavicular line, two trocars were inserted into the two holes under the guidance of B-ultrasound.After that, carbon dioxide was pumped into the anterior mediastinum, the pressure was maintained at 8 mmH2O, ultrasound scalpel and a grasping forceps were inserted through the operating ports respectively. Retrosternal space including bilateral lower poles of thymus, internal mammary arteries and phrenic nerves were exposed by both blunt and sharp dissection. Then ultrasound scalpel were used to separate the thymus and its surrounding fat tissue, cut off thymic veins by ultrasound scalpel.For patients with myasthenia gravis, bilateral mediastinal pleurae and the affected adipose tissues had been thoroughly removed.
3036647|NCT02317224|Experimental|Trans sternal approach|
3036648|NCT02317224|Experimental|VATS approach|
3036649|NCT02317211|Placebo Comparator|control|placebo 320 mg daily for twelve weeks
3036650|NCT02317211|Experimental|anthocyanins treatment|anthocyanin supplement 320mg daily for twelve weeks
3036651|NCT02317198|Experimental|Intervention|Clopidogrel
3036652|NCT02317198|Active Comparator|Control|Ticagrelor/Prasugrel
3036686|NCT02316925|Experimental|Glutathione supplement|500 mg/day Setria glutathione supplement
3036658|NCT02317133||HSP: remission|"Patients in this group have had Henoch Schönlein Purpura in the past but currently have no symptoms.~Intervention: Blood samples Intervention: Stool samples"
3036659|NCT02317133||Control group|"Control patients recruited from elective surgery candidates at the participating hospitals.~Intervention: Blood samples Intervention: Stool samples"
3036660|NCT02317107||Concussion|Individuals who report to the Division of Sports Medicine at Boston Children's Hospital will be identified for inclusion in the study if they receive a diagnosis of concussion, defined as a complex pathophysiological process affecting the brain, induced by biomechanical forces. If they agree to participate, they will be placed in the concussion group and assessed at each visit to the clinic. No intervention will be administered.
3036661|NCT02317107||Control|Individuals who report to the Division of Sports Medicine at Boston Children's Hospital will be identified for inclusion in the study if they come to the clinic for an injury unrelated to brain function or a lower extremity function (which may affect normal gait patterns). If they agree to participate, they will be placed in the control group and assessed at each visit to the clinic. No intervention will be administered.
3036662|NCT02317094|Other|Control|Participants receive care as usual (various DMARDs, different from patient to patient).
3036663|NCT02317094|Experimental|Blood-flow restricted tranining|Participants will receive care as usual (various DMARDs, different from patient to patient) + 12 wks of low-intensity blood-flow restricted training twice per week.
3036664|NCT02317081|Experimental|Axetis Inert Coronary Stents|Axetis Inert Coronary Stents for de novo coronary lesion
3036665|NCT02317068|Experimental|High Atrial Base Rate Pacing|The base rate of pacemaker will be determined 75-100 beats/minute in condition that during first step of follow-up, his/her atrial pacing will be more than 80% of atrial high rate/automatic mode switch
3036666|NCT02317068|Active Comparator|Device Default|The base rate of pacemaker will be determined 60 beats/minute
3036667|NCT02317055|Other|Patient|Imaging
3036668|NCT02317055|Other|healthy subject|Imaging
3036669|NCT02317042|Other|Phase I: Intellgent Volume Assured Pressure Support (iVAPS)|"iVAPS is a type of respiratory support ventilation. It is used to treat people with respiratory insufficiency, respiratory failure or hypoventilation. It is commercially available. iVAPS is the predicate therapy for the Experimental therapy: Automatic Expiratory Positive Airway Pressure (AutoEPAP) iVAPS.~iVAPS delivers two air pressures (one for inspiration and a second for expiration) and provides a back-up breathing rate. Collectively, this optimises ventilation and ensures a target alveolar ventilation is achieved."
3036670|NCT02317042|Experimental|Phase I: AutoEPAP iVAPS|AutoEPAP iVAPS is a proposed new type of respiratory support ventilation. It is used to treat people with respiratory insufficiency, respiratory failure or hypoventilation, AND introduces the treatment of upper airway obstruction (i.e. sleep apnea). It is being developed by AutoEPAP iVAPS delivers two air pressures (one for inspiration and a second for expiration) and provides a back-up breathing rate. It is similar to iVAPS, but it introduces an auto-adjusting expiratory pressure to treat airway obstruction.
3036671|NCT02317042|Other|Phase II: Spontaneous Timed (ST) mode|"ST mode is another type of respiratory support ventilation, and is, historically, the commonly used ventilation therapy. It is used to treat people with respiratory insufficiency, respiratory failure or hypoventilation. It is commercially available.~ST mode delivers two air pressures (one for inspiration and a second for expiration) and provides a back-up breathing rate. Collectively, this optimises ventilation using pressure ventilation."
3036672|NCT02317042|Experimental|Phase II: AutoEPAP iVAPS|AutoEPAP iVAPS is a proposed new type of respiratory support ventilation. It is used to treat people with respiratory insufficiency, respiratory failure or hypoventilation, AND introduces the treatment of upper airway obstruction (i.e. sleep apnea). It is being developed by AutoEPAP iVAPS delivers two air pressures (one for inspiration and a second for expiration) and provides a back-up breathing rate. It is similar to iVAPS, but it introduces an auto-adjusting expiratory pressure to treat airway obstruction.
3036673|NCT02317029|Experimental|"1 (Standard: Oxygen / LIFEPAK 20)"|"Intervention: Cardioversion with a biphasic truncated exponential waveform~Intervention: Hyperoxia during cardioversion"
3036674|NCT02317029|Active Comparator|2 (room air / LIFEPAK 20)|"Intervention: Cardioversion with a biphasic truncated exponential waveform~Intervention: Normoxia during cardioversion"
3036675|NCT02317029|Active Comparator|3 (Oxygen / Schiller Defigard 5000)|"Intervention: Cardioversion with a pulsed biphasic waveform~Intervention: Hyperoxia during cardioversion"
3036676|NCT02317029|Active Comparator|4 (Room air / Schiller Defigard 5000)|"Intervention: Cardioversion with a pulsed biphasic waveform~Intervention: Normoxia during cardioversion"
3036677|NCT02317016|Experimental|AZD9291 and rosuvastatin|Sequential treatments of rosuvastatin alone followed by AZD9291 alone, followed by rosuvastatin + AZD9291.
3036678|NCT02317003|Experimental|Intervention PPIL|Intervention delivered by the family doctor and based on structured information delivery according to cognitive and behavioural theories, a personalised written physical activity prescription in number of steps per day, a pedometer, and a pedometer logbook similar to diabetes logbooks.
3036679|NCT02317003|Active Comparator|Control OR|Oral recommendation of physical exercise delivered by the family doctor.
3036680|NCT02316990||patients ≥18 ,Neurosurgical departments and whose GCS≤10[4]|"The subject population that will be included in the NIS are the consecutive discharged patients ≥18 years old who were hospitalized to Neurosurgical departments and whose GCS≤10[4] within 24 hours of lesion/admission.(GCS: Glasgow Coma Scale NIS: Non-Interventional Study~)"
3036681|NCT02316964|Experimental|Treatment (decitabine, allogeneic NK cells, aldesleukin)|Patients receive decitabine IV over 60 minutes on days -4 to 0 and undergo infusion of allogeneic NK cells on day 0. Beginning 1 hour after infusion allogeneic NK cells, patients also receive aldesleukin SC every other day for 6 doses.
3036682|NCT02316951||single-arm study group|Study participants will be adult patients recovering from orthopedic surgery. The study group will wear a small motion detection device and a regular Webcam will be placed near the wall facing the bed in each patient's hospital room.
3036683|NCT02316938|Experimental|Everolimus|Treatment not given as part of this substudy, it is given as part of the core CRAD001A2433 study.
3036684|NCT02316938|Active Comparator|MPA and standard CNI|Treatment not given as part of this substudy, it is given as part of the core CRAD001A2433 study.
3036685|NCT02316925|Placebo Comparator|Crystalline Cellulose|looks like and is given in the same way as the experimental treatment but contains no active ingredient
3036687|NCT02316912|Active Comparator|Single dose level 1 active|Six subjects ATX2417 I mg tablet once.
3036688|NCT02316912|Active Comparator|Single dose level 2 active|Six subjects ATX2417 2x1 mg tablet once.
3036689|NCT02316912|Active Comparator|Single dose level 3 active|Six subjects ATX2417 5 mg tablet once.
3036690|NCT02316912|Active Comparator|Single dose level 4 active|Six subjects ATX2417 4x5 mg tablets once.
3036691|NCT02316912|Active Comparator|Single dose level 5 active|Six subjects ATX2417 to be determined.
3036692|NCT02316912|Active Comparator|Multiple dose level 1 active|Six subjects ATX2417 dose to be determined once daily for 8 days.
3036693|NCT02316912|Active Comparator|Multiple dose level 2 active|Six subjects ATX2417 dose to be determined once daily for 8 days.
3036694|NCT02316912|Placebo Comparator|Single dose level 1 placebo|Two subjects one placebo tablet once.
3036695|NCT02316912|Placebo Comparator|Single dose level 2 placebo|Two subjects one placebo tablet x2 once.
3036696|NCT02316912|Placebo Comparator|Single dose level 3 placebo|Two subjects one placebo tablet once.
3036697|NCT02316912|Placebo Comparator|Single dose level 4 placebo|Two subjects two placebo tablets once.
3036698|NCT02316912|Placebo Comparator|Single dose level 5 placebo|Two subjects four placebo tablets once.
3036699|NCT02316912|Placebo Comparator|Multiple dose level 1 placebo|Two subjects matching placebo(s) once daily for 8 days
3036700|NCT02316912|Placebo Comparator|Multiple dose level 2 placebo|Two subjects matching placebo(s) once daily for 8 days.
3036701|NCT02316912|Active Comparator|Single dose level 6 active|Six subjects ATX2417 to be determined.
3036702|NCT02316912|Active Comparator|Single dose level 7 active|Six subjects ATX2417 to be determined.
3036703|NCT02316912|Placebo Comparator|Single dose level 6 placebo|Six subjects placeboto be determined.
3036704|NCT02316912|Placebo Comparator|Single dose level 7 placebo|Six subjects placebo to be determined.
3036705|NCT02316899|Experimental|ASP0456 (Period I)|Up to 12 weeks
3036706|NCT02316899|Placebo Comparator|Placebo (Period I)|Up to 12 weeks
3036707|NCT02316899|Experimental|ASP0456 (Period II)|From 12 weeks to 52 weeks
3036708|NCT02316886|Experimental|Coronary intervention|Bioresorbable Vascular Scaffold or Everolimus Eluting stent (EES) +Optimal Medical Treatment
3036709|NCT02316886|Active Comparator|Optimal Medical Treatment|Optimal Medical Treatment
3036710|NCT02316873|Experimental|Music training|twice a week one hour for 30 weeks, music training
3036711|NCT02316873|Active Comparator|Visual arts|twice a week one hour for 30 weeks, visual arts training
3036712|NCT02316860|Other|History of reflex syncope|Passive tilt test in athletes with a history of reflex syncope
3036713|NCT02316860|Other|No history of reflex syncope|Passive tilt test in athletes without history of reflex syncope
3036714|NCT02316847|Experimental|diazepam nasal spray (Adults)|One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
3036715|NCT02316847|Experimental|Diazepam Nasal Spray (Adolescents)|One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
3036716|NCT02316834|Experimental|BMN 673|Starting the day of laparoscopic surgery, participants treated with BMN 673 for at least 7 days prior to tumor reductive surgery. BMN 673 treatment discontinued at time of tumor reductive surgery. BMN 673 given at a dose of 1 mg by mouth once daily. Participants instructed to take the BMN 673 until the day before surgery. Maximum duration of therapy is 28 days.
3036717|NCT02316821|Experimental|bardoxolone methyl|bardoxolone methyl capsules, dosage To Be Determined, once daily for 16 weeks
3036718|NCT02316821|Placebo Comparator|Placebo|Placebo capsules, once daily for 16 weeks
3036719|NCT02316808|Placebo Comparator|Placebo smoothie|
3036720|NCT02316808|Experimental|Plant stanol ester smoothie|
3036721|NCT02316795|Experimental|SLN biopsy with ICG injection|"During the SLN biopsy, the patient will undergo injection of ICG around the breast tumor or melanoma per standard techniques. 1.6 mL of 500 micro-molar ICG will be injected periareolarly (for breast cancer) or peri-tumorly (for melanoma). This will be performed after standard of care technetium-colloid injection. Patients will then undergo the standard SLN biopsy procedure.~After gamma-probe identification of the SLN, the surgeon will put on the goggle system to attempt to identify the SLN using fluorescence guidance. After this is performed, the goggle system will be removed and the SLN biopsy will be completed per standard techniques. Findings with the goggles will be recorded but will not change how the SLN biopsy is performed."
3036722|NCT02316782||Non-blinded IVUS assessment|The non-blinded arm will use the angiogram and IVUS grayscale and VH-IVUS to guide the procedure.
3036723|NCT02316782||Blinded IVUS assessment|After routine coronary angiogram, the physicians in the blinded arm of the study will only use the angiogram to guide the DES stenting procedure;
3036724|NCT02316769|Active Comparator|King Vision Video Laryngoscope|Patient intubated with the King Vision Video Laryngoscope
3036725|NCT02316769|Active Comparator|McGrath MAC Video Laryngoscope|Patient intubated with the McGrath MAC Video Laryngoscope
3036726|NCT02316756|Experimental|Single Ascending Doses Cohort 1|subjects receive 3 active doses and one placebo
3036727|NCT02316756|Experimental|Single Ascending Doses Cohort 2|subjects receive 3 doses and one placebo
3036728|NCT02316756|Experimental|Cohort 3|optional cohort
3036729|NCT02316743|Experimental|Levothyroxine|Levothyroxine supplementation
3036730|NCT02316730|Experimental|Sanchi-Tongshu Capsule (Enteric coated pellets)|Sanchi-Tongshu Capsule (Enteric coated pellets) is developed by pharmaceutical factory of Chengdu Huasun Group Inc., 0.35g/capsule, containing 100mg of panaxatriol saponins (PTS).
3036731|NCT02316730|Active Comparator|Sanchi-Tongshu Capsule|Sanchi-Tongshu Capsule is developed by pharmaceutical factory of Chengdu Huasun Group Inc., 0.2g/capsule, containing 100mg of panaxatriol saponins (PTS).
3036732|NCT02316717|Experimental|Treatment Arm A|IMM-124E, 600 mg three times daily, orally plus matching placebo
3036733|NCT02316717|Experimental|Treatment Arm B|IMM-124E, 1200 mg three times daily, orally
3036734|NCT02316717|Placebo Comparator|Treatment Arm C|Matching placebo, three times daily, orally
3036735|NCT02316704|Active Comparator|OsseoTi™ G7 large|OsseoTi™ G7 acetabular cup and an E1™ liner holding largest possible femoral head (36mm-44mm)
3036736|NCT02316704|Active Comparator|OsseoTi™ G7 32|OsseoTi™ G7 acetabular cup and an E1™ insert holding a 32mm femoral head
3036737|NCT02316704|Active Comparator|conventional PPS coated G7 large|conventional PPS coated G7 acetabular cup and an E1™ insert holding largest possible femoral head (36mm-44mm)
3036738|NCT02316704|Active Comparator|conventional PPS coated G7 32|conventional PPS coated G7 acetabular cup and an E1™ insert holding a 32mm femoral head
3036739|NCT02316691||Thyroid Eye Disease|Blood samples will be drawn from subjects diagnosed with Thyroid Eye Disease. This study is observational. No interventions will be given as part of this study.
3036740|NCT02316678||anti-TNF - no intervention|Patients who are new users of anti-TNF therapy
3036741|NCT02316678||Corticosteroids - no intervention|Patients initiating corticosteroids
3036742|NCT02316665|Experimental|continuous positive airway pressure|Patients will receive continuous positive airway pressure during three months
3036743|NCT02316665|Sham Comparator|Sham-continuous positive airway pressure|Patients will receive sham-continuous positive airway pressure during 3 months
3036744|NCT02316652|No Intervention|Healthy sites|Healthy sites with no inflammation; observational only
3036745|NCT02316652|Placebo Comparator|Scaling and root planing sites|Inflamed pocket receiving mechanical instrumentation
3036746|NCT02316652|Active Comparator|Scaling and root planing with solution|Inflamed pocket receiving mechanical instrumentation with sodium hypochlorite solution
3036747|NCT02316639|Experimental|Neuromuscular Training - No Exercise|Subjects will participate in 5 weeks of neuromuscular training followed by 5 weeks of no exercise intervention
3036748|NCT02316639|Experimental|No Exercise - Neuromuscular Training|No exercises will be administered for 5 weeks, followed by 5 weeks of neuromuscular Training.
3036749|NCT02316626|Experimental|Subcutaneous progesterone|Luteal phase support cycles will involve once-daily administration of 25 mg of SC P from the day after insemination for 14 days.
3036750|NCT02316626|Active Comparator|Vaginal Progesterone|Luteal phase support cycles will involve once-daily administration of 90 mg vaginal gel from the day after insemination for 14 days.
3036751|NCT02316613||All Participants|Participants with histologically confirmed, refractory/relapsed cluster of differentiation-20 (CD20) positive follicular non-Hodgkin's lymphoma (grade IIII), whatever the first-line treatment was (chemotherapy and/or immunotherapy and/or radio-immunoconjugate and/or radiochemotherapy), and eligible for salvage treatment were observed for approximately 6 years. All participants received at least one cycle of rituximab (MabThera) during maintenance therapy or observation period.
3036752|NCT02316600|No Intervention|Control|30 frail volunteers of the control group in the second phase won't be equipped with the smart insole.
3036753|NCT02316600|Experimental|Intervention|30 frail volunteers of the intervention group in the second phase will be equipped with the smart insole for 3 months, to encourage the frail elderly person's physical activity and to monitor key parameters of frailty
3036754|NCT02316574|Experimental|Cognitive Behavioral Coping Skills|Cognitive Behavioral Coping Skills Therapy is an individual psychotherapy for alcohol use disorders that has been previously shown to reduce drinking. The focus of this treatment is the teaching of coping skills for managing alcohol craving and negative emotions as a way to reduce drinking behavior.
3036755|NCT02316561|Experimental|Single dose ablative radiotherapy|Eligible patients for single dose ablative radiotherapy according to inclusion and exclusion criteria
3036756|NCT02316548|No Intervention|No Radiation Therapy|Patients do not receive radiation therapy (RT).
3036757|NCT02316548|Experimental|Intensity-modulated radiation therapy (IMRT)|Postoperative adjuvant intensity-modulated radiation therapy (IMRT).
3036758|NCT02316535|Active Comparator|standard-dose|capecitabine, oral administration, 1,250 mg/m2 twice daily on days 1-14, and repeated on day 22; 8 circles in total.
3036759|NCT02316535|Experimental|reduced-dose|capecitabine, oral administration, 1,000 mg/m2 twice daily on days 1-14, and repeated on day 22; 8 circles in total.
3036760|NCT02316522||Group I: T2D nephropathy|Individuals with type 2 diabetes and nephropathy
3036761|NCT02316522||Group II: T2D and no nephropathy|Individuals with type 2 diabetes and no nephropathy
3036762|NCT02316522||Group III: Control, non-diabetic|Non-diabetic individuals with normal kidney function
3036763|NCT02316522||Group IV: Controls, non-diabetic|Non-diabetic individuals with hypertensive nephropathy
3036764|NCT02316509|Experimental|Part I: Dose Escalation - GDC-0927|Participants will receive GDC-0927 orally as a single dose on Day -7. Continuous daily dosing will commence on Day 1. Depending on safety and tolerability, participants will be assigned sequentially to escalating doses of GDC-0927 with use of a standard 3 + 3 design. The starting dose will be 600 milligrams per day (mg/day), followed by dose escalation in 400 milligrams (mg) increments.
3036765|NCT02316509|Experimental|Part II: Dose Expansion - GDC-0927|Participants in the expansion cohorts will receive GDC-0927 at MTD/RP2D starting from Day 1 of Cycle 1 (cycle length: 28 days) up to disease progression, unacceptable toxicity, participant withdrawal of consent or study termination.
3036766|NCT02316496|Experimental|open label , single arm|cetuximab - irinotecan until progression or unacceptable toxicity
3036767|NCT02316483||Group I: T2D and Charcot foot|Individuals with confirmed diagnosis of type 2 diabetes, using the American Diabetes Association guidelines and confirmed diagnosis of Charcot foot, based on clinical and radiological evidence of Charcot foot.
3036768|NCT02316483||Group II: T2D neuropathy, no charcot|Individuals with type 2 diabetes and presence of neuropathy but the absence of Charcot foot.
3036769|NCT02316483||Group III: Control, non-diabetic|Individuals without history of type 2 diabetes.
3036770|NCT02316470|Active Comparator|VLA84 75 mcg (microgram) w/o Alum|VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
3036771|NCT02316470|Active Comparator|VLA84 200 mcg w/o Alum|VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
3036772|NCT02316470|Active Comparator|VLA84 200 mcg with Alum|VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
3036773|NCT02316470|Placebo Comparator|Placebo|Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
3063419|NCT02138890|Experimental|APS injection|Autologous Protein Solution
3036774|NCT02316457|Experimental|ARM1 IVAC_W_bre1_uID|• Patients enrolled in ARM1 will receive a treatment with four RNAs. This includes two to three variant RNAs selected from the IVAC®WAREHOUSE plus p53 RNA. The selection process of RNAs from the warehouse is based on RT-PCR-based profiling of RNA extracted from patient tumour sample specimens, pre-defined cut-offs and algorithms to select the three relevant RNAs for a given patient.
3036775|NCT02316457|Experimental|ARM2 IVAC_W_bre1_uID/IVAC_M_uID|ARM2 will first receive the IVAC®WAREHOUSE treatment as described above followed by the personalized IVAC® MUTANOME immunotherapy. The mutation selection process constitutes a multi-step process including identification of somatic mutations by NGS, mutation confirmation and prioritization, selection, and on demand manufacturing.
3036776|NCT02316444|Other|HAART exposed|Participants in both arms will receive the Hepatitis B vaccine as summarized in the study description
3036777|NCT02316444|Other|HAART naive|Participants in both arms will receive the Hepatitis B vaccine as summarized in the study description
3036778|NCT02316418|Experimental|Hairstetics™ anchoring system|Prosthetic hair implantation using the Hairstetics™ anchoring system, followed by attachment of hair extensions.
3036779|NCT02316405|Experimental|Test Group|5 weeks of arm and leg cycling, 3 times per week for 30 minute of total exercise per session
3036780|NCT02316392||Post transplant subjects|Hyperpolarized Helium-3 MRI. Subjects who have had or are scheduled to have a lung transplant
3036781|NCT02316379|Experimental|Hyperpolarized 129 Xenon|Administration of up to 1 liter doses of Hyperpolarized Xenon gas during MRI to optimize acquisition of images for adults vs. proton MR imaging. These scans, utilizing volunteers for calibration, may be utilized through this study to optimize the scan details.
3036782|NCT02316366|Experimental|Warm fluid|Patients in this arm of the study receive intravenous saline warmed to 37.5 degrees Celsius by Astoflo Plus fluid warmer
3036783|NCT02316366|No Intervention|Room temperature Fluid|Patients receive intravenous saline at room temperature (22-24 degrees Celsius)
3036784|NCT02316353|Experimental|C1-INH - low-volume dose|A low-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
3036785|NCT02316353|Experimental|C1-INH - medium-volume dose|A medium-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
3036786|NCT02316340|Experimental|Study Arm - VOR with HCQ|Patients will be given vorinostat 400 mg daily and hydroxychloroquine 600 mg daily in 4 week cycles.
3036787|NCT02316340|Active Comparator|Control Arm - Regorafenib|Patients will be given oral RGF 160 mg daily for 3 weeks in 4 week cycles.
3036788|NCT02316327|Experimental|gemcitabine, cisplatin and bevacizumab|"Bevacizumab will be given by I.V infusion at the dose of 7.5 mg/kg on days 1 every 21 days~Cisplatin 80 mg/m2 I.V on day 1~Gemcitabine 1250 mg/m2 I.V on day 1 & 8~Treatment cycles will be repeated every three weeks up to 6 cycles~Bevacizumab monotherapy as maintenance allowed in non-progressive tumors"
3036789|NCT02316314||Individuals diagnosed with FRDA|Individuals diagnosed with FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies
3036790|NCT02316314||Healthy controls|Individuals without FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies
3036791|NCT02316301|Experimental|Long interval misoprostol|A small envelope including two labeled plastic bags (A & B) (each bag containing either 2 misoprostol tablets(400µg) or 2 identically appearing placebo tablets) will be packaged in sequentially numbered sealed envelopes. In long interval misoprostol group, bag (A) contains misoprostol tablets and bag (B) contains placebo tablets. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
3036792|NCT02316301|Active Comparator|Short interval misoprostol|A small envelope including two labeled plastic bags (A& B) (each bag containing either 2 misoprostol tablets(400µg) or 2 identically appearing placebo tablets) will be packaged in sequentially numbered sealed envelopes. In short interval misoprostol group, bag (A) contains placebo tablets and bag (B) contains misoprostol tablets. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
3036793|NCT02316288|Experimental|Therapy|Mindfulness and Acceptance Therapy
3036794|NCT02316288|Active Comparator|Education|Health Education
3036795|NCT02316275|Active Comparator|Standard post-operative activity restriction|As a traditional method, patients will be restricted from activity for six weeks after sling surgery.
3036796|NCT02316275|Experimental|No post-operative activity restrictions|Patients are to resume regular activity immediately after mid-urethral sling surgery.
3036797|NCT02316262|Experimental|TR|All subjects enrolled in this study will undergo pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). Gentle traction will be applied to the nerve while excising the neuroma (traction neurectomy) allowing the nerve to retract more proximally.Targeted muscle reinnervation involves transfer of residual nerves to otherwise redundant target muscles. Native motor innervation of the target muscle is cut, and the residual nerves—after excision of end-neuromas—are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle.
3036798|NCT02316249|Active Comparator|Gellhorn Pessary|Patients who are fitted with a Gellhorn pessary for reduction of pelvic organ prolapse. Patients will then be randomized based on pessary to either Estradiol vaginal cream or Placebo vaginal cream. Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
3036799|NCT02316249|Active Comparator|Ring with Support Pessary|Patients who are fitted with a Ring with Support Pessary for reduction of pelvic organ prolapse. Patients will then be randomized based on pessary to either Estradiol vaginal cream or Placebo vaginal cream. Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
3036800|NCT02316236|Experimental|dexmedetomidine loading dose|dexmedetomidine is given at load dose
3036801|NCT02316236|Experimental|dexmedetomidine sustaining dose|dexmedetomidine is given at sustaining dose
3036802|NCT02316223|Experimental|Clinic-based care coordination|The ACC and CHW programs for asthma CC/SMS will have the same objectives and provide the same general services at the office/clinic. The ACC and CHW programs were developed from existing, successfully operating programs at the participating sites, and in the East Harlem and South Bronx communities.
3036803|NCT02316223|Active Comparator|Home-based care coordination|The ACC and CHW programs for asthma CC/SMS will have the same objectives and provide the same general services at participant's home. The ACC and CHW programs were developed from existing, successfully operating programs at the participating sites, and in the East Harlem and South Bronx communities.
3036804|NCT02316223|No Intervention|Usual care|Clinician-centric strategy and EMR-based clinician decision support
3036805|NCT02316210|Experimental|Digitimer stimulation|
3036806|NCT02316197|Experimental|MSC2490484A|Initial starting dose at 100 mg (oral administration), once daily, subsequent doses and treatment regimens will be determined by the SMC (once or twice daily). MSC2490484A will be administered in continuous 21-day cycles in dose escalation or dose expansion cohorts, as long as they do not experience unacceptable toxicity or disease progression.
3036807|NCT02316184|Placebo Comparator|Brief Advice|Participants in this arm will receive brief advice about alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
3036808|NCT02316184|Active Comparator|MI|Participants in this arm will receive a talking intervention designed to explore their interest in reducing/eliminating alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
3036809|NCT02316171|Experimental|CAVATAK|CAVATAK will be administered by intravesical instillation up to a total dose of 3 x 10⁸ TCID50
3036810|NCT02316171|Other|Mitomycin C|Mitomycin C will be administered at 10 mg by intravesical instillation on day 1.
3036811|NCT02316158|Experimental|Webb-based support and education|It contains of two parts 1) evidence based information (about mental diseases, early signs, coping strategies, what you can do for your relative or close friend, what you can do for yourself, addresses to networks and web sites, relevant juridical issues, etc), 2) FAQ, where you directly can find answers to common questions.
3036812|NCT02316158|Active Comparator|Available support in society|Available support in society for young persons presented in a brochure
3036813|NCT02316145|Other|'Habilitation (Internet-based support)|Before the individual started with the internet-based support and coaching (IBSC), a meeting with the coach was compulsory to discuss what specific issues they were going to work with during the period of IBSC. The IBSC was offered at fixed times twice a week during an eight-week period. Two meetings between the individual and the coach were included. Between chat sessions the individuals and the coaches could get in touch using the programme's e-mail. The content of the support and coaching was individualised based on each individual's requirement. Once a fortnight a meeting was held with the head of the project and coaches. Issues regarding ongoing support and coaching were addressed.
3036814|NCT02316132|Active Comparator|Stress|Injection of corticotropin releasing factor
3036815|NCT02316132|Placebo Comparator|Control|Injection of 0.9% saline 10 ml
3036816|NCT02316119||Control group|Post-ACS patients without history of IS/TIA previously to the acute coronary and taking aspirin
3036817|NCT02316119||Case group|Post ACS patients with history of IS/TIA previously to the acute coronary event and taking aspirin
3036818|NCT02316106|Experimental|Arm A (Long Intense)|
3036819|NCT02316106|Experimental|Arm B (Intermediate)|
3036820|NCT02316106|Experimental|Arm C (Short Intense)|
3036821|NCT02316093||obese-chronic periodontitis patients|
3036822|NCT02316093||obese-gingivitis patients|
3036823|NCT02316093||obese-periodontally healthy controls|
3036824|NCT02316093||normal weight-chronic periodontitis patients|
3036825|NCT02316093||normal weight-gingivitis patients|
3036826|NCT02316093||normal weight-periodontally healthy controls|
3036827|NCT02316080|Experimental|Desensitizing therapy|14 groups (7 treated with in-office dental bleaching and 7 treated with home-use dental bleaching) . There will be 7 different types of dessensitizing agents that will be used together with the dental bleaching treatment
3036828|NCT02316080|Experimental|Dental Bleaching|2 groups of dental bleaching treatment - 16% carbamide peroxide and 35% peroxide
3036829|NCT02316067|Experimental|Rehabilitation|Eight weeks of rehabilitation (CHORDATA® Method)
3036830|NCT02316067|No Intervention|Control|Participants maintained their daily-life activities routine during the same eight weeks period and were tested before and after this control period.
3036831|NCT02316054||diabetes and MPHI|myocardial perfusion heterogeneity imaging
3036832|NCT02316041|Experimental|Small incision lenticule extraction|Small incision lenticule extraction (SMILE) is a form of corneal laser refractive surgery performed using a femtosecond laser
3036833|NCT02316028|Experimental|decitabine|"administration of decitabine by hepatic arterial infusion~Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.~Proposed dose levels:~10 mg/m2 per course~15 mg/m2 per course~20 mg/m2 per course"
3036834|NCT02316015|Experimental|Intervention group|Children in the intervention group will receive a protein-energy enriched milk (Infatrini®, or in the case of children on a partial or fully hydrolized milk Infatrini Peptisorb®). The volume of milk offered will be the same quantity as they usually drink at home (within the limits of 120-170 ml/kg/day). The intervention will be carried out during the first 7 days of hospitalisation, or until the day of discharge (if hospitalized for less than 7 days).
3036835|NCT02316015|No Intervention|Control group|Children in the control group will receive their regular milk. The volume of milk offered will be the same quantity as they usually drink at home (within the limits of 120-170 ml/kg/day).
3036836|NCT02315989|Other|safety|proton therapy
3036837|NCT02315976|Experimental|Propatyl nitrate|Patients treated with propatyl nitrate 10mg thrice daily
3036838|NCT02315963|No Intervention|No intervention group|Patients in stroke rehabilitation receiving standard therapy
3036839|NCT02315963|Active Comparator|Intervention group|Patients in stroke rehabilitation receiving standard therapy plus performance feedback
3036840|NCT02315950|Other|Arm 1|Botulinum toxin and cineMRI-UDS
3036841|NCT02315924|Experimental|coronary and cerebral stenosis|
3036842|NCT02315924|Active Comparator|coronary or cerebral stenosis|
3036843|NCT02315911|No Intervention|expectancy for mild-moderate OSA|6 months expectancy
3036844|NCT02315911|Experimental|ATE for mild-moderate OSA|adeno-tonsillectomy
3036845|NCT02315911|Experimental|ATE for severe OSA|adeno-tonsillectomy
3036846|NCT02315911|Experimental|APP for severe OSA|adeno-pharyngoplasty
3036847|NCT02315898|Experimental|Treatment-inhaled tPA|All patients with plastic bronchitis enrolled into the study will receive inhaled tPA.
3036848|NCT02315872|Experimental|ACTH|The study drug (ACTH 40 units) will be given subcutaneously twice weekly for 2 weeks. If the patient tolerates this dosage regimen, the dose will be increased to 80 units twice weekly. If the 80 unit dosage is not tolerated, the dosage will be reduced to 40 units twice weekly for the remainder of the 24 week participation. The weekly doses will be given 3 days apart, for example, on every Monday and Thursday or every Tuesday and Friday.
3036849|NCT02315872|Placebo Comparator|Placebo|Placebo will be given subcutaneously twice weekly for 28 weeks.
3036850|NCT02315859||All patients|All patients
3036851|NCT02315833|Experimental|Acetium|Patient will administer Acetium capsules (100mg l-cysteine) twice a day for three months
3036852|NCT02315833|Placebo Comparator|Placebo|Patient will administer placebo capsules twice a day for three months
3036853|NCT02315820|Experimental|Induction of Labor (IOL)|Group I, Induction of Labor group (IOL). Women will be admitted for induction at 38-40+3 weeks when estimated fetal weight 3800-4500 gram.
3036854|NCT02315820|No Intervention|Expectant|Group II. Will be expectantly managed until 40+6 weeks, or an induction indication will appear.
3036855|NCT02315807|Experimental|dlPFC|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in dorsolateral prefrontal cortex
3036856|NCT02315807|Experimental|CON|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in cingulo-opercular network
3036857|NCT02315807|Active Comparator|M1|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in motor primary cortex
3036858|NCT02315794|Experimental|SPI®ART|in test group after a three month healing period a zirconia abutment was connected to the implant to realize the prosthetic restoration
3036859|NCT02315794|Active Comparator|SPI®EASY|in control group a three month healing period a titanium abutment was connected to the implant for the prosthetic restoration
3036860|NCT02315781|Active Comparator|Active tDCS|active tDCS will be used on half of the study participants
3036861|NCT02315781|Sham Comparator|Sham tDCS|Sham tDCS will be used on half of the study participants
3036862|NCT02315768|Experimental|GA101+ibrutinib|"Ibrutinib 420 mg (140 mg capsules 3 times) orally once daily for up to 6 cycles.~GA101 (Obinutuzumab) by Intravenous infusion for up to 6 cycles (28 day cycles) as follows:~Cycle 1, Day 1,100 mg GA101 obinutuzumab will be administered.~Cycle 1, Day 2, 900 mg of GA101 obinutuzumab will be administered.~Cycle 1, Days 8 and 15,1,000 mg of GA101 obinutuzumab will be administered.~Cycles 2-6, Day 1, 1,000 mg of GA101 obinutuzumab will be administered."
3036863|NCT02315755||Study cohort|Metastatic renal cell carcinoma patients under 3rd line targeted therapy following 1st line interferon alpha and 2nd line TKI. All patients will be ≥ 18 years old and have signed the informed consent document.
3036864|NCT02315742|Experimental|Let's Move Program|Patients will take part in a 12-week exercise program.
3036865|NCT02315716|Experimental|Consolidation with 4 cycles of CarCyDex|Patients responding to induction treatment will receive 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone (CarCyDex) treatment followed by 18 months of maintenance carfilzomib
3036866|NCT02315716|Active Comparator|ASCT|Patients responding to induction treatment will receive a melphalan conditioned autologous stem cell transplant followed by 18 months of maintenance carfilzomib
3036867|NCT02315703|Experimental|Group 1|Participants will receive adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV) vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + HIV type 1 Clade C glycoprotein 140 drug product (gp140 DP) vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
3036868|NCT02315703|Experimental|Group 2|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + gp140 DP vaccine containing 50 mcg of total protein mixed with adjuvant at Week 24 and 48.
3036869|NCT02315703|Experimental|Group 3|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + placebo injection at Week 24 and 48.
3036870|NCT02315703|Experimental|Group 4|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by modified Vaccinia Ankara (MVA)-Mosaic vaccine + gp140 DP vaccine containing 250 mcg of total protein mixed with adjuvant at Week 24 and 48.
3036871|NCT02315703|Experimental|Group 5|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by MVA-Mosaic vaccine + gp140 DP vaccine containing 50 mcg of total protein mixed with adjuvant at Week 24 and 48.
3036872|NCT02315703|Experimental|Group 6|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by MVA-Mosaic vaccine + placebo injection at Week 24 and 48.
3036873|NCT02315703|Experimental|Group 7|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by gp140 DP vaccine containing 250 mcg of total protein mixed with adjuvant + placebo injection at Week 24 and 48.
3036874|NCT02315703|Placebo Comparator|Group 8|Participants will receive 1 placebo injection at Week 0 and 12; followed by 2 placebo injections at Week 24 and 48.
3036875|NCT02315690|Active Comparator|Reactive case detection (RACD)|Individuals in RACD Target Areas will be tested by RDT (rapid diagnostic test) and if positive, taken to the nearest health facility for treatment with artemether-lumefantrine per national policy.
3036876|NCT02315690|Experimental|Reactive focal mass drug administration (fMDA)|In the fMDA arm, all individuals in the Target Area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
3036877|NCT02315677|Active Comparator|Nasal intubation-Standard RAE ETT|This arm will receive nasal intubation with the standard RAE endotracheal tube with bevel facing left.
3036878|NCT02315677|Active Comparator|Nasal intubation-Parker Flex-Tip ETT|This arm will receive nasal intubation with the Parker Flex-tip ETT with bevel facing posteriorly.
3036914|NCT02315417|Placebo Comparator|Placebo|Solution for subcutaneous injection (Part 1, Group A)
3036879|NCT02315664|Experimental|Immediate Intervention Group|Education session, Fitbit Flex, and remote coaching by a PT: These three components of the intervention will be delivered to the participants in Month 1 and 2. At the end of the education session, the PT will help participants set personal activity goals. In Month 1 and 2, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will keep the Fitbit and continue to use it with access to a PT via email as needed. In addition, they will receive a monthly e-newsletter about arthritis research that is not related to physical activity.
3036880|NCT02315664|Experimental|Delayed Intervention Group|Same intervention with a 2 month delay: The Delayed Intervention Group (control group) will receive the same monthly e-newsletter in Months 1-2. The full intervention will be initiated in Month 3 with a brief education session, use of Fitbit Flex, and counseling by a physiotherapist. In Month 4, they will continue the intervention without the PT phone calls. Participants will keep the Fitbit for Month 5-6, and have email access to PT as needed.
3036881|NCT02315651|Experimental|Coenzyme Q10|30 children aged 6-12 will consume daily a snack containing 60 mg of CoQ10 for 8 weeks.
3036882|NCT02315651|Placebo Comparator|Placebo|30 children aged 6-12 years will consume an identical snack without CoQ10 for 8 weeks
3036883|NCT02315638||Dosed subjects|There is no intervention. This is a observational study monitoring subjects that were dosed with TT-034 in the Tacere B2801001 study,
3036884|NCT02315625|Experimental|1/ Arm 1|Sunitinib
3036885|NCT02315625|Experimental|2/ Arm 2|Everolimus
3036886|NCT02315612|Experimental|1|Dose escalation of CD22-CAR
3036887|NCT02315612|Experimental|Arm 2|Dose expansion of CD22-CAR
3036888|NCT02315599||1|subjects who have participated in POB gene therapy clinical trials
3036889|NCT02315573|Experimental|Lidocaine with epinephrine|"Wrist block anesthesia with Lidocaine 1% with epinephrine; 10cc.~Group 1 will receive the same treatment as group 2, except that the wide-awake carpal tunnel release surgery will be performed under Lidocaine anesthesia instead of Bupivacaine anesthesia."
3036890|NCT02315573|Experimental|Bupivacaine with epinephrine|"Wrist block anesthesia with Bupivacaine 0.25% with epinephrine; 10cc.~Group 2 will receive the same treatment as group 1, except that the wide-awake carpal tunnel release surgery will be performed under Bupivacaine anesthesia instead of Lidocaine anesthesia."
3036891|NCT02315560|Experimental|Tibial Nerve Stimulation|The subject/parents will be instructed to record a night-time voiding log specifying the number of incontinent episodes per night. This log is included in the Institutional Review Board application. Subjects/parents will fill out the log for a two week period prior to foot stimulation to determine a baseline average of nocturnal enuresis episodes, during the two week foot stimulation period to measure any acute effect on nocturnal enuresis episodes and finally during the two weeks after stimulation to evaluate any post-stimulation residual benefit
3036892|NCT02315547|Other|Antibiotics|Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline [16]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
3036893|NCT02315534|Experimental|Arm A|Patients for whom surgery is recommended as part of treatment for recurrent Glioblastoma.
3036894|NCT02315534|Experimental|Arm B|Patients for whom surgery is not recommended as part of the treatment for recurrent Glioblastoma.
3036895|NCT02315521||Group 1|Fetuses with LUTO before 18 weeks
3036896|NCT02315521||Group 2|Fetuses with LUTO between 18 and 30 weeks
3036897|NCT02315521||Group 3|Fetuses with LUTO between 30 and 34 weeks
3036898|NCT02315521||Group 4|Fetuses with LUTO after 34 weeks
3036899|NCT02315508|Experimental|AUT00063|4 capsules of 200 mg of the new medicine, AUT00063, to take orally with food for 4 weeks.
3036900|NCT02315508|Placebo Comparator|Placebo|4 capsules of placebo, to take orally with food for 4 weeks.
3036901|NCT02315495|Experimental|5 mg saxagliptin + 100 mg acarbose|"Acute dosing:~5 mg saxagliptin is given with water, 60 min before a test meal 100 mg acarbose is given with a test meal"
3036902|NCT02315495|Experimental|5 mg saxagliptin|"Acute dosing:~5 mg saxagliptin is given 60 min before a test meal,"
3036903|NCT02315495|Experimental|100 mg acarbose|"Acute dosing:~100 mg acarbose is given with a test meal"
3036904|NCT02315495|No Intervention|control|
3036905|NCT02315482|Experimental|Group A|after induction of general anesthesia (i) a pneumoperitoneum is induced then (ii) patient is placed in steep trendelenburg position at 25 degrees head down
3036906|NCT02315482|Experimental|Group B|after induction of general anesthesia (i) the patient is placed in steep trendelenburg position at 25 degrees head down then (ii) a pneumoperitoneum is induced
3036907|NCT02315469||Observational (geriatric assessment)|At time of consent and within 14 days of surgery, patients complete a pre-operative geriatric assessment that evaluates functional status, comorbid medical conditions, psychological state, social support, and nutritional status. Post-operative complications are also collected for 6 weeks after surgery or until the date patients initiate or restart chemotherapy whichever is first.
3036908|NCT02315456|Other|Capsule centration|Capsulorhexis made with capsule centration
3036909|NCT02315456|Other|Pupil centration|Capsulorhexis made with pupil centration
3036910|NCT02315443|Experimental|NA-1|2.60 mg/kg of NA-1 administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.
3036911|NCT02315443|Placebo Comparator|Placebo|Placebo administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.
3036912|NCT02315430|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3036913|NCT02315417|Experimental|gevokizumab|Solution for subcutaneous injection (Part 1, Group B)
3036915|NCT02315417|Experimental|gevokizumab open-label|Solution for subcutaneous injection (Part 2, Open-label)
3036916|NCT02315404|Placebo Comparator|No cap|enteroscopy performed without a cap
3036917|NCT02315404|Active Comparator|Enteroscopy with a cap|Enteroscopy performed with a CAP fitted to the end of the scope
3036918|NCT02315391|Experimental|20g isolated whey protein + 30g carb, 8,5g fat, 15g glycine|20g isolated whey protein + 30g carb, 8,5g fat, 15g glycine
3036919|NCT02315391|Experimental|20g micellar whey protein + 30g carb, 8.5g fat, 15g glycine|20g micellar whey protein + 30g carb, 8.5g fat, 15g glycine
3036920|NCT02315391|Experimental|20g micellar whey protein + 30g carb, 8.5g fat, 5g citrulline|20g micellar whey protein + 30g carb, 8.5g fat, 5g citrulline
3036921|NCT02315378|Other|ARTAT|A one-session intervention targeting at-risk individuals (those continuing to experience peritraumatic panic following a trauma) and designed to reduce peritraumatic anxiety and enhance self-efficacy.
3036922|NCT02315378|Other|TAU|Treatment as Usual
3036923|NCT02315352|Experimental|Period 1 and 2|A-B or B-A where A: L-PZQ ODT (MSC 2499550A) put on tongue; B: Rac-PZQ ODT (MSC1028703A) put on the tongue
3036924|NCT02315352|Experimental|Period 3, 4 and 5|C-D-E; C-E-D; D-E-C; D-C-E; E-C-D; E-D-C where C: L-PZQ ODT (MSC 2499550A) dispersed in water; D: Rac-PZQ ODT (MSC1028703A) dispersed in water; E: Cesol® 150 mg crushed in water
3036925|NCT02315326|Experimental|Ibrutinib|This is an open-label, non-randomized, single center, dose escalation, phase I/II study to establish the maximum-tolerated dose (MTD) of ibrutinib as a single agent in patients with refractory/recurrent PCNSL or refractory/recurrent SCNSL (Arm A). The defined MTD will then be used in an expansion cohort to further assess toxicity and clinical activity(Arm B). Arm C will investigate the MTD of ibrutinib in combination with HD-MTX and to determine the safety and tolerability of the ibrutinib/HD-MTX combination regimen in PCNSL and SCNSL patients. To minimize drug-drug interaction between HD-MTX and Ibrutinib, Ibrutinib will not be administered concurrently with HD-MTX.
3036926|NCT02315313||group1|RHR≤60bpm
3036927|NCT02315313||group2|RHR 61-70bpm
3036928|NCT02315313||group3|RHR 71-80bpm
3036929|NCT02315313||group4|RHR >80bpm
3036930|NCT02315300|Experimental|Study Tretament|Long term ECG measurement is performed with the 12-lead ECG system medilog® DARWIN FD12 from Schillermed to detect different ECG parameter. The continuous glucose monitoring (CGM) system G4 from Dexcom use a tiny sensor inserted under the skin to check glucose levels in tissue fluid. The sensor stays in place for 7 days in parallel to the ECG measurement. A transmitter sends information about glucose levels via radio waves from the sensor to a pagerlike wireless monitor.
3036931|NCT02315287|Active Comparator|Metformin, Sitagliptin, Pioglitazone|Thiazolidinedione
3036932|NCT02315287|Active Comparator|Metformin, Sitagliptin, Lobeglitazone|Thiazolidinedione
3036933|NCT02315274|Experimental|Single arm, remote contact.|Between visit remote contact.
3036934|NCT02315235|Active Comparator|control|The operator inject normal saline(control) to thirty site of the other side leg of active comparator. The volume of one site injection is 0.5 ml. The depth of needle injection would be 1.5cm.
3036935|NCT02315235|Active Comparator|stem cell (mononuclear cell)|The stem cell (mononuclear cell) is injected to thirty site of one side leg in operating room after general anesthesia. The volume of one site injection is 0.5 to 1.0 ml. The depth of needle injection would be 1.5cm.
3036936|NCT02315222|Active Comparator|Test|Dietary Supplementation
3036937|NCT02315222|Placebo Comparator|Control|Placebo Supplementation
3036938|NCT02315196|Experimental|Treatment (doxil, carboplatin, surgery, paclitaxel)|"NEOADJUVANT: Patients receive pegylated liposomal doxorubicin hydrochloride* IV over 90 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.~ADJUVANT: Patients undergo definitive surgery at the discretion of the treating physician. Patients then receive paclitaxel IV over 60 minutes once weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.~*NOTE: If there is a shortage of pegylated liposomal doxorubicin hydrochloride, patients receive epirubicin hydrochloride IV over 15-20 minutes on day 1."
3036939|NCT02315170|Experimental|intraocular injection guide|novel intraocular injection guide is a long, tubular structure consisting of a non-moldable material with a single internal opening. There is a 2x2 square hole located at the bottom of the device where the needle exits the guide and enters the eye
3036940|NCT02315170|Active Comparator|standard lid speculum|Standard wire eyelid speculum
3036941|NCT02315157|Experimental|Bendamustine 200 mg/m2|Patients receive bendamustine hydrochloride IV over 60-180 minutes on days 1 and 2 (total dose 400 mg/m2).
3036942|NCT02315157|Experimental|Bendamustine 250 mg/m2|Patients receive bendamustine hydrochloride IV over 60-180 minutes on days 1 and 2 (total dose 500 mg/m2).
3036943|NCT02315144|Experimental|TV48108 - Healthy Volunteers|Stage 1 is a randomized, placebo-controlled, double-blind, single-dose study. Healthy subjects will be randomized to receive a single inhaled dose of TV48108 120 µg
3036944|NCT02315144|Placebo Comparator|Placebo - Healthy Volunteers|Placebo
3036945|NCT02315144|Experimental|TV48108 15 µg COPD|Stage 2 consists of a 2-period open-label study with an ipratropium bromide reference to evaluate the single administration of 3 ascending doses of inhaled TV48108 in COPD patients.
3036946|NCT02315144|Experimental|TV48108 60 µg COPD|Stage 2
3036947|NCT02315144|Experimental|TV48108 120 µg COPD|Stage 2 .
3036948|NCT02315131|Experimental|TV46017- Healthy Volunteers|Stage 1 includes a single-dose treatment period
3036949|NCT02315131|Placebo Comparator|Placebo - Healthy Volunteers|Some healthy subjects will be randomized to receive placebo.
3036950|NCT02315131|Experimental|TV46017 15 μg- COPD|Stage 2 includes two 24 hour treatment periods with approximately 7 days of washout in between each treatment period; and open label ipratropium bromide pressurized metered-dose inhaler hydrofluoroalkane (HFA) will be administered
3036951|NCT02315131|Experimental|TV46017 60 μg- COPD|Stage 2
3036952|NCT02315131|Experimental|TV46017 120 μg- COPD|Stage 2
3036953|NCT02315131|Experimental|TV46017 240 μg- COPD|Stage 2
3037023|NCT02314728|Active Comparator|Oxytocin Alone|Those randomized to the oxytocin arm will receive infusion of oxytocin, which will then be titrated per hospital protocol or until adequate contractions.
3037024|NCT02314715||Knee Osteoarthritis|Participants with diagnosed knee osteoarthritis
3036954|NCT02315118|Experimental|T-cell therapy + Rituximab + IL-2|"Patients will undergo apheresis procedure and T cell expansion will be done in the laboratory. All patients will receive Rituximab on day -2 and IL-2 three times per week for one week starting on day -1 (dose 1 of 3). IL-2 dosing will be continued 3 times per week for one week (3 doses total).~On Day 0, T cell modification in the laboratory and T cell infusion in the patient will be done.~A disease status evaluation will be conducted approximately 4 weeks post-T cell infusion."
3036955|NCT02315105|Experimental|Morbid Obese patients|This purpose of this study is to find out more about the safety and effectiveness of the Laparoscopic Greater Curvature Plication (LGCP) for Morbid Obese Patients with related problems such as diabetes, hypertension, high cholesterol, mild obstructive sleep apnea and joint problems.
3036956|NCT02315092||Diabetic foot ulcers|Patients who present with diabetic foot ulcers will undergo fluorescence imaging.
3036957|NCT02315079||Eye inflammation|This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
3036958|NCT02315079||Without eye inflammation|This group will have a regular eye exam with the collection of tears.
3036959|NCT02315066|Experimental|PF-04518600|OX40 agonist
3036960|NCT02315066|Experimental|PF-04518600 plus PF-05082566|OX40 (CD134) agonist plus 4-1BB (CD137) agonist
3036961|NCT02315053|Other|Low dose FDG PET/CT 5x|Stage II/III NSCLC will undergo a Low dose FDG PET/CT 5x during treatment (CCRT).
3036962|NCT02315040|Active Comparator|IUI|standard intrauterine insemination method
3036963|NCT02315040|Experimental|EVIE|Slow release insemination method (SRI)
3036964|NCT02315027|Experimental|autologous mesenchymal stem cells|Administration of autologous mesenchymal stem cells
3036965|NCT02315014|Experimental|whey protein|whey protein micelles
3036966|NCT02315014|Placebo Comparator|placebo|calorie-free placebo
3036967|NCT02315001|Active Comparator|Liraglutide|"Week 1 Run-In Phase = 0.6 mg (0.1 ml) Liraglutide once daily via subcutaneous injection~Week 2 Low-Dose Phase = 1.2 mg (0.2 ml) Liraglutide once daily via subcutaneous injection~Week 3 High-Dose Phase = 1.8 mg (0.3 ml) Liraglutide once daily via subcutaneous injection"
3036968|NCT02315001|Placebo Comparator|Saline Placebo|"Week 1 Run-In Phase = 0.1 ml normal saline once daily via subcutaneous injection~Week 2 Low-Dose Phase = 0.2 ml normal saline once daily via subcutaneous injection~Week 3 High-Dose Phase = 0.3 ml normal saline once daily via subcutaneous injection"
3036969|NCT02314988|Active Comparator|Intervention|Subjects will receive tranexamic acid on the surgical wound.
3036970|NCT02314988|Placebo Comparator|Placebo control|Subjects will receive placebo (saline solution) on the surgical wound.
3036971|NCT02314975|Experimental|AcceleDent vibrational device|Fixed appliances with supplementary vibrational force
3036972|NCT02314975|Sham Comparator|Sham AcceleDent device|Fixed appliances with supplementary sham device
3036973|NCT02314975|Active Comparator|Fixed appliance only|Fixed appliances only
3036974|NCT02314949||intestinal transplantation|all performed intestinal transplants underwent the same Leuven intestinal transplant protocol
3036975|NCT02314936|Experimental|Litesse powder containing 12 g polydextrose|12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
3036976|NCT02314936|Experimental|Litesse powder containing 8 g polydextrose|8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
3036977|NCT02314936|Experimental|Litesse powder containing 4 g polydextrose|4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
3036978|NCT02314936|Placebo Comparator|Placebo|Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
3036979|NCT02314923|Experimental|3x10^3 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of BPSC-1001 3x10^3 pfu in the deltoid on Day 0.
3036980|NCT02314923|Experimental|3x10^4 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of BPSC-1001 3x10^4 pfu in the deltoid on Day 0.
3036981|NCT02314923|Experimental|3x10^5 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of BPSC-1001 3x10^5 pfu in the deltoid on Day 0.
3036982|NCT02314923|Experimental|3x10^6 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of BPSC-1001 3x10^6 pfu in the deltoid on Day 0.
3036983|NCT02314923|Experimental|9x10^6 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of BPSC-1001 9x10^6 pfu in the deltoid on Day 0.
3036984|NCT02314923|Experimental|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of BPSC-1001 2x10^7 pfu in the deltoid on Day 0.
3036985|NCT02314923|Experimental|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of BPSC-1001 1x10^8 pfu in the deltoid on Day 0.
3036986|NCT02314923|Placebo Comparator|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0.
3036987|NCT02314910||Failed implant|There is only one group, being the group of patients of which the oral implant needed to be removed for clinical reasons.
3036988|NCT02314897|Experimental|LV pacing|Left ventricular pacing lead implanted via coronary sinus
3036989|NCT02314897|Active Comparator|RV pacing|Conventional right ventricular pacing lead.
3036990|NCT02314884|Experimental|Cafusertib Hydrochloride|Cafusertib Hydrochloride d1q3w
3036991|NCT02314871|Active Comparator|Epidural|Patients will receive perioperative epidural analgesia. Drugs: bupivacaine 1.25 mg/ml and sufentanil 0.5 mcg/ml Form and frequency: continuous infusion Dosage: 4 - 14 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
3036992|NCT02314871|Active Comparator|Piritramide|Patients will receive postoperative analgesia with piritramide. Drugs: piritramide 1.0 mg/ml Form and frequency: continuous infusion Dosage: 0 - 4 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
3036993|NCT02314871|Active Comparator|Morphine|Patients will receive postoperative analgesia with morphine. Drugs: morphine 1.0 mg/ml Form and frequency: continuous infusion Dosage: 0 - 4 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
3037025|NCT02314715||Controls|Participants without knee osteoarthritis
3037026|NCT02314702||Revision Total Hip Arthroplasty|Single study group previously implanted with a PROFEMUR® L Revision Femoral Stem
3063420|NCT02138890|Placebo Comparator|Placebo|Placebo
3036994|NCT02314858|Experimental|Brief Personalized Video (BPV)|Our BPV intervention focuses on augmenting risk perception and reducing optimistic bias by showing the patient a dramatic video of his/her own apnea (which shows them struggle to breathe), as well as by explaining the physiological processes involved in an apneic event. Specific apneic events are highlighted and associated decreases in blood oxygen levels are demonstrated via oxygen saturation recording superimposed on the video. This group will receive educational information about OSA, its consequences and the need for treatment.
3036995|NCT02314858|Active Comparator|Non-Personalized Video (NPV)|NPV will include a video of someone having apnea, but it will not be personalized. This group will receive educational information about OSA, its consequences and the need for treatment.
3036996|NCT02314858|Placebo Comparator|Treatment As Usual (TAU)|The TAU group will receive no special treatment from study interventionist team and will not view a video.
3036997|NCT02314845|Experimental|Optimal PEEP|"Patients submitted to general anesthesia and abdominal laparoscopic surgery (number=10) or open surgery (number=10) will be submitted to a recruitment maneuver followed by a PEEP titration procedure using Electrical Impedance Tomography (EIT). Patients will be mechanically ventilated during intraoperative period using Optimal PEEP determined by Electrical Impedance and FIO2 of 0.5."
3036998|NCT02314845|Other|Low PEEP|"Patients submitted to general anesthesia and abdominal laparoscopic surgery (number=10) or open surgery (number=10) will be submitted to a recruitment maneuver followed by a PEEP titration procedure EIT. In this arm, the ventilator will be set with a PEEP=4 cmH2O (Low PEEP) and FIO2 of 0.5 during intraoperative period."
3036999|NCT02314832|Active Comparator|Continuous femoral nerve block|patients receiving continuous femoral nerve block for analgesia after total knee arthroplasty
3037000|NCT02314832|Active Comparator|adductor canal block|adductor canal block group will receive adductor canal block for analgesia after TKA
3037001|NCT02314819|Active Comparator|treatment arm|treatment arm- subjects will receive Fruquintinib 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
3037002|NCT02314819|Placebo Comparator|control arm|control arm- subjects will receive Fruquintinib placebo 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
3037003|NCT02314806|Experimental|Irrigation with Gentamicin solution|The surgical bed is irrigated with a gentamicin solution
3037004|NCT02314806|Experimental|Irrigation with Clindamycin solution|The surgical bed is irrigated with a clindamycin solution
3037005|NCT02314806|Placebo Comparator|Irrigation with Normal saline|The surgical bed is irrigated with normal saline
3037006|NCT02314793|Experimental|Part 1: Single Ascending Dose ASP2205 (Fasting)|Young male and female subjects will receive single doses of ASP2205 in a dose escalation format.
3037007|NCT02314793|Placebo Comparator|Part 1: Single Ascending Dose Placebo (Fasting)|Young male and female subjects will receive single doses of matching placebo in a dose escalation format.
3037008|NCT02314793|Experimental|Part 1: Single Ascending Dose ASP2205 (Fed)|Young male and female subjects will receive a single dose of ASP2205
3037009|NCT02314793|Experimental|Part 2: Multiple Ascending Dose ASP2205, Young females|Young female subjects will receive multiple dosing of ASP2205 for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
3037010|NCT02314793|Placebo Comparator|Part 2: Multiple Ascending Dose Placebo, Young females|Young female subjects will receive matching placebo for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
3037011|NCT02314793|Experimental|Part 2: Multiple Ascending Dose ASP2205, Elderly females|Elderly female subjects will receive multiple dosing of ASP2205 for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
3037012|NCT02314793|Placebo Comparator|Part 2: Multiple Ascending Dose Placebo, Elderly females|Elderly female subjects will receive matching placebo for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
3037013|NCT02314780|Placebo Comparator|Placebo|Placebo 24h prior surgery
3037014|NCT02314780|Active Comparator|Treatment cohort A|heme arginate 1mg/kg 24h prior surgery
3037015|NCT02314780|Active Comparator|Treatment cohort B|heme arginate 3mg/kg 24h prior surgery
3037016|NCT02314767|Active Comparator|Interpersonal Psychotherapy|Interpersonal Psychotherapy treatment for MDD patients was implemented with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression. Intervention:Interpersonal psychotherapy as ADD-on method. Outcome was compared with patients in treatment as usual group.
3037017|NCT02314767|Active Comparator|Psychoeducational Group Therapy|Psychoeducational Group Therapy arm for MDD patients with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression. Intervention: Psychoeducational Group Treatment as ADD-on method.
3037018|NCT02314767|No Intervention|Treatment as Usual|Treatment as usual ( consisting of supportive psychodynamic-oriented treatment) with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression
3037019|NCT02314754|Experimental|71-77 days gestational age|Women whose pregnancies are estimated to have a gestational age of 71-77 days.
3037020|NCT02314754|No Intervention|64-70 days gestational age|Women whose pregnancies are estimated to have a gestational age of 64-70 days.( Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range).
3037021|NCT02314741|Experimental|POEM Treatment Arm|Patients treated with the POEM (per-oral endoscopic myotomy) procedure.
3037022|NCT02314728|Active Comparator|Misoprostol|Those randomized to the prostaglandin arm will receive PGE1 (misoprostol) in a dose of 25mcg placed vaginally every 4 hours as per hospital protocol.
3037138|NCT02313883|Placebo Comparator|SRP and Placebo|Scaling and root planing followed by placebo drug administration
3037027|NCT02314689|Experimental|IV citrulline|IV citrulline 20 mg/kg bolus with dose escalation of 10 mg/kg to target citrulline concentration of 100 µmol/L with a maximum dose of 60 mg/kg.
3037028|NCT02314676|Experimental|PEG-somatropin|
3037029|NCT02314663|Experimental|Intervention group|"COMBINED STRATEGY (a + b + c). Participants in the intervention group will be supplied with: a) printed matter; b) mobile-telephone text messages; and, c) self-report cards.~This group receive routine recommendations from their GPs, in accordance with current European clinical practice guidelines on the management of hypercholesterolaemia and cardiovascular risk"
3037030|NCT02314663|No Intervention|Control group|This group receive routine recommendations from their GPs, in accordance with current European clinical practice guidelines on the management of hypercholesterolaemia and cardiovascular risk
3037031|NCT02314650|Experimental|Transcutaneous acupoint stimulation|Electrical stimulation was given through electrodes attached to skin at Ximen and Shenmen acupoint during anesthesia
3037032|NCT02314650|Placebo Comparator|Non-acupoint stimulation|Electrical stimulation was given through electrodes attached to skin at shoulder (non-acupoint) during anesthesia
3037033|NCT02314650|Sham Comparator|Control|patients were with electrodes attached but no stimulation was given
3037034|NCT02314637|Experimental|Teneligliptin|Teneligliptin for 52 weeks
3037035|NCT02314637|Experimental|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
3037036|NCT02314624|Experimental|PracticeGround|Clinicians have access to PracticeGround's dynamic progress monitoring, clinical decision support, rich visual displays of client outcomes, online training modules in ESTs, just-in-time training for guided real-time assistance in delivering ESTs, educational videos, and a client portal
3037037|NCT02314624|Active Comparator|Care-as-Usual|Usual care without access to PracticeGround.
3037038|NCT02314611||PROFEMUR® Gladiator HA Coated Stem|Single study group previously implanted with a primary PROFEMUR® Gladiator HA Coated Modular Femoral Stem (HA = Hydroxyapatite)
3037039|NCT02314598||No treatment|
3037040|NCT02314585|Other|Education|In the second phase, participants will partake in an instructional class relating to gait, balance, and falls.
3037041|NCT02314585|Other|Exercise|In the second phase,participants will partake in an exercise course relating to gait, balance, and falls.
3037042|NCT02314572|Other|Single-arm|
3037043|NCT02314559|Experimental|Propofol (manual titration)|
3037044|NCT02314559|Active Comparator|Propofol (target controlled infusion)|
3037045|NCT02314546|Placebo Comparator|Saline placebo|saline placebo
3037046|NCT02314546|Active Comparator|Nasal Midazolam only|Nasal Midazolam only - Patients received 0.2 mg/kg of intranasal midazolam
3037047|NCT02314546|Active Comparator|Midazolam and Xylocaine|Midazolam Plus Xylocaine - Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam
3037048|NCT02314533|Experimental|fenofibrate|Fenofibrate 200mg capsule will be administered orally with breakfast once daily according to the Chinese prescription information of Lipanthyl, while previous type and dose of statin will be administered in the evening.
3037049|NCT02314520|Active Comparator|PICC|Patients randomly assigned to receive a peripherally inserted central catheter and they will be monitored for either having a complication or no complication.
3037050|NCT02314520|Active Comparator|CVC|Patients randomly assigned to receive a centrally inserted central catheter and they will be monitored for either having a complication or no complication.
3037051|NCT02314507|Experimental|Gua sha|Paritcipants in this group will receive a single treatment of Gua sha conducted by a well-trained nurse or Chinese practitioner
3037052|NCT02314507|Active Comparator|Hot Pack Therapy|Participants in this group will receive a single treatment of Hot Pack conducted by a well-trained nurse or Physiotherapist
3037053|NCT02314494||Infants at risk|Infants identified as at risk of obesity using the ProAsk intervention
3037054|NCT02314494||Infants not at risk|Infants identified as not at risk of obesity using the ProAsk intervention.
3037055|NCT02314481|Experimental|No actionable mutation - MPDL3280A|MPDL3280A 1200mg - 3 weekly for 16 cycles
3037056|NCT02314481|Experimental|BRAF V600 - vemurafenib|Vemurafenib 960mg twice daily until PD
3037057|NCT02314481|Experimental|ALK/RET gene rearrangement - alectinib|Alectinib 600mg twice daily until PD
3037058|NCT02314481|Experimental|HER2 amplification - T-DM1|Trastuzumab emtansine (T-DM1) 3.6mg/kg - 3 weekly until PD
3037059|NCT02314468|Active Comparator|negative pressure wound therapy (NPWT)|negative pressure wound therapy (NPWT)
3037060|NCT02314468|Active Comparator|Glycerol Preserved Allografts (GPA)|Glycerol Preserved Allografts (GPA)
3037061|NCT02314455|Experimental|D-xylose, water, honey|"25 grams of D-xylose~10 cc of water~2 teaspoons of honey"
3037062|NCT02314442|Active Comparator|ALN-PCSSC|
3037063|NCT02314442|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3037064|NCT02314429|Experimental|Vaginal Ring|A vaginal ring that slowly releases lactic acid (racemic mixture) into the vaginal environment, will be inserted in healthy volunteering women and left in place for 7 days.
3037065|NCT02314416|Active Comparator|Standard Treatment|Patients in the Control Arm will receive collagen matrix for wound coverage and standard wound care that will include chemical/surgical debridement (using a topical paste to clean the wound or removing bad tissue using a scalpel or scissors) and dressing care. In addition, they may also have imaging studies (such as x-ray, CAT scan, ultrasound) performed if determined to be necessary by the physician.
3037066|NCT02314416|Experimental|Amniotic Stem Cells and Collagen Matrix|Patients will receive amniotic stem cells(NuCel) embedded in collagen matrix for wound coverage, and standard wound care that will include chemical/surgical debridement (using a topical paste to clean the wound or removing bad tissue using a scalpel or scissors) and dressing care. In addition, they may also have imaging studies (such as x-ray, CAT scan, ultrasound) performed if determined to be necessary by the physician.
3037139|NCT02313883|Experimental|SRP and 0.3% PerioSept(r)|Scaling and root planing followed by 0.3% PerioSept(r) drug administration
3037140|NCT02313883|Experimental|SRP and 1 % PerioSept(r)|Scaling and root planing followed by 1% PerioSept(r) drug administration
3037141|NCT02313883|Experimental|SRP and 3% PerioSept(r)|Scaling and root planing followed by 3% PerioSept(r) drug administration
3037142|NCT02313870|Experimental|A|Superpotent topical steroids/methotrexate
3037067|NCT02314403|Experimental|Combined Bone Marrow and Kidney Transplantation|Recipients will receive a conditioning regimen that starts with Rituximab on day -7 (and days -2, 5, 12), Whole Body Irradiation 1.5 Gy x2 on study days -6 and -5, followed by ATG on Days -2, -1, 0. Belatacept 10mg/kg on Days 0, 3, 10, 17, 24, 38, 52. Thymic irradiation (7 Gy) will be given on study day -1, and combined renal and bone marrow transplant will be done on study day 0. Prednisone will be started at 2 mg/kg on day 4 and tapered off by day 20. Tacrolimus will be administered on study days -1 through 60, and then tapered if weaning criteria are met.
3037068|NCT02314390|Experimental|G-MBCT|Group-Mindfulness-Based Cognitive Therapy
3037069|NCT02314390|Experimental|I-MBCT|Individual-Mindfulness-Based Cognitive Therapy
3037070|NCT02314377|Experimental|AVM treatment with Bevacizumab|Bevacizumab infusion dose of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
3037071|NCT02314364|Experimental|SBRT with protons or photons|"Dosage determined by treating physician~If there is more than one active site of cancer, additional site(s) will be treated with stereotactic treatment courses. The total duration of SBRT courses (from the first day of any SBRT course to the last day of any SBRT course) will not exceed 4 months."
3037072|NCT02314351|Active Comparator|Intravenous metoclopramide|Intravenous metoclopramide, 10 mg (2 mL) in 98 mL 0.9% normal saline solution (total 100 mL)
3037073|NCT02314351|Placebo Comparator|Placebo|0.9% normal saline solution (total 100 mL)
3037074|NCT02314338|Experimental|Pulmonary rehabilitation|Multi-disciplinary pulmonary rehabilitation
3037075|NCT02314325|Active Comparator|Standard prophylaxis|Advate [Antihemophilic Factor(Recombinant)] 20-40 IU/kg 5-7 infusions per 14days
3037076|NCT02314325|Experimental|Pharmacokinetic tailored prophylaxis|Advate [Antihemophilic Factor(Recombinant)] dose determined by individual patient pharmacokinetics and infusions administerd on alternate days
3037077|NCT02314312|Experimental|A: investigation arm|De novo kidney transplantation form ECD/AKI donor with Everolimus + low dose cyclosporinA + prednisolone as immunosuppressive regimen
3037078|NCT02314312|Other|B: control arm|De novo kidney transplantation form ECD/AKI donor with standard immunosuppressive regimen
3037079|NCT02314299|Experimental|Low Dose Regimen|MTP-131 (Low Dose) sterile topical ophthalmic solution twice a day into the study eye
3037080|NCT02314299|Experimental|High Dose Regimen|MTP-131 (High Dose) sterile topical ophthalmic solution twice a day into the study eye
3037081|NCT02314286|Placebo Comparator|control|"After signing an informed consent form and filling a demographic and medical questionnaire, a randomization 1:1 will be carried. 50 women will be in the control arm. the group will be treated according to ACOG guidelines (Appendix). After the delivery, a small placenta sample will be collected.~Control group will be treated with placebo."
3037082|NCT02314286|Experimental|treatment|50 women will be in the treatment arm. the group will be treated according to ACOG guidelines (Appendix). After the delivery, a small placenta sample will be collected. In addition, following randomization experimental group will be treated with Rosuvastatin 40mg that will be administrated orally with or without food. Treatment will be carried within the first hour following delivery. Another dose will be given 24 hours after first administration. Control group will be treated with placebo.
3037083|NCT02314273|Experimental|rhIL-11 group|patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80,000/mL
3037084|NCT02314273|No Intervention|control group|control group
3037085|NCT02314260||Labour Induction|80 primigravidas undergoing bishop score calculation, trans-vaginal ultrasound assessment of cervical length &, Modified bishop score calculation, then induction of labour at our hospital.
3037086|NCT02314247|Experimental|Selinexor|60 mg dose (equivalent to ~35 mg/m²)
3037087|NCT02314234||Control group|did not receive muscle relaxant during anesthesia
3037088|NCT02314234||Sugammadex group|received single dose of rocuronium for anesthesia and sugammadex at skin incision
3037089|NCT02314221|Experimental|Exoskeletal-Assisted Walking (WALK)|WALK first for 12 weeks (36 sessions)
3037090|NCT02314221|No Intervention|Usual Activities (UA)|Usual activities first for 12 weeks
3037091|NCT02314208|Active Comparator|Xenbilox|Xenbilox (chenodeoxycholic acid) 1000mg capsule by mouth every day for 2 months
3037092|NCT02314208|Active Comparator|Resveratrol|Resveratrol 80mg capsule by mouth every day for 2 months
3037093|NCT02314208|Active Comparator|Tahor|Tahor (atorvastatin) 40mg tablet by mouth every day for 2 months
3037094|NCT02314195|Active Comparator|Standard treatment + music therapy|Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy. Music therapy encompassing 12 half-hour sessions of therapist-supervised receptive music therapy scheduled over four weeks
3037095|NCT02314195|Active Comparator|Standard treatment only|Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy.
3037096|NCT02314182|Experimental|A Primary tumor resection + chemotherapy|PT resection + systemic chemotherapy +/- target therapy
3037097|NCT02314182|Other|B Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab|Chemotherapy (+/- target therapy)
3037098|NCT02314169|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over approximately 60 minutes once every two weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3037099|NCT02314156|Experimental|Arm I (transdermal telapristone acetate)|Patients receive telapristone acetate transdermally and placebo PO QD for 4 weeks.
3037100|NCT02314156|Active Comparator|Arm II (oral telapristone acetate)|Patients receive placebo transdermally and telapristone acetate PO QD for 4 weeks.
3037101|NCT02314143|Experimental|Arm A|Dabrafenib 150 milligrams (mg) twice a day (BID) continuously during eight weeks followed by the combination of trametinib 2 mg once daily with dabrafenib 150 mg BID until disease progression, death or unacceptable toxicity.
3037102|NCT02314143|Experimental|Arm B|Trametinib 2 mg/day continuously during eight weeks followed by the combination of trametinib 2 mg once daily with dabrafenib 150 mg BID until disease progression, death or unacceptable toxicity.
3037103|NCT02314143|Experimental|Arm C|Trametinib 2 mg/day plus dabrafenib 150 mg BID continuously until disease progression, death or unacceptable toxicity.
3037143|NCT02313870|Other|B|Superpotent topical steroids (clobetasol propionate)
3037198|NCT02313467|Sham Comparator|Control|Topical application of sham control per every other day around acne lesions in the face
3037237|NCT02313155|Experimental|TAK-850 0.5 mL (subcutaneous)|Single subcutaneous injection of TAK-850
3037104|NCT02314130|Experimental|Dietary therapy Standardized diet|The study was constituted by sixty-six patients, thirty-three in each group. Patients on not industrialized enteral diet (standardized diet group) entered at random in the study and were matched by gender, age, socioeconomic status and medical diagnosis to patients using commercial diet (commercial group). The evaluation consisted of anthropometric measures of weight, height, arm circumference, triceps skin fold and biochemical índices at baseline and at the end of the intervention.
3037105|NCT02314130|No Intervention|Dietary therapy Commercial diet group|The study was constituted by sixty-six patients, thirty-three in each group. Patients on not industrialized enteral diet (standardized diet group) entered at random in the study and were matched by gender, age, socioeconomic status and medical diagnosis to patients using commercial diet (commercial group). The evaluation consisted of anthropometric measures of weight, height, arm circumference, triceps skin fold and biochemical índices at baseline and at the end of the intervention.
3037106|NCT02314117|Experimental|Ramucirumab + Cisplatin + Capecitabine|8 milligrams/kilogram (mg/kg) ramucirumab given intravenously (IV) on days 1 and 8 in combination with 80 mg/square meter (m^2) cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m^2/day fluorouracil (5-FU) IV on days 1 to 5 of each 21-day cycle.
3037107|NCT02314117|Active Comparator|Placebo + Cisplatin + Capecitabine|Placebo for blinding given IV on days 1 and 8 in combination with 80 mg/m^2 cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m^2/day 5-FU IV on days 1 to 5 of each 21-day cycle.
3037108|NCT02314104|Active Comparator|Treatment TAP, placebo local injection|Treatment TAP block was 30 mL 0.5% ropivacaine bilaterally. Placebo local injection was 2 mL of 0.9% normal saline at each port site.
3037109|NCT02314104|Active Comparator|Placebo TAP, treatment local injection|Placebo TAP was 30 mL of 0.9% normal saline bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.
3037110|NCT02314104|Active Comparator|Treatment TAP, treatment local injection|Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.
3037111|NCT02314091|Experimental|Onlay|Onlay mesh repair group
3037112|NCT02314091|Experimental|sublay|Sublay mesh repair group
3037113|NCT02314065|Experimental|Conventional CBT|Cognitive Behavioural Therapy delivered in a conventional manner
3037114|NCT02314065|Experimental|Internet-delivered CBT|Cognitive Behavioural Therapy delivered via the Internet
3037115|NCT02314052|Experimental|DCR-MYC|Patient groups (cohorts) will receive a single dose level of DCR-MYC; the dose level of DCR-MYC will be increased in subsequent cohorts
3037116|NCT02314026|Experimental|Suspected NASH|13C-Octanoate, 13C-Methacetin
3037117|NCT02314013|Active Comparator|Cephalosporin + Metronidazole|intravenous antibiotics injection (3rd generation cephalosporin + metronidazole) and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
3037118|NCT02314013|No Intervention|No antibiotic|bowel rest and then, discharge until tolerable soft diet.
3037119|NCT02314000|Experimental|SCS at sub-perception amplitude|BSC Precision™ SCS System programmed at sub‐perception amplitude.
3037120|NCT02314000|Active Comparator|SCS at supra-perception amplitude|BSC Precision™ SCS System programmed at supra‐perception amplitude.
3037121|NCT02313987||A-Usual care- Standard care for NOCAD|"Subjects with non obstructive CAD (20-70% luminal diameter stenosis) and normal Endothelial function as defined by EndoScore.~These subjects will receive the standard care usually provided in each facility for patients with NOCAD"
3037122|NCT02313987||B1-Usual Care-Standard care for NOCAD|"Subjects with non obstructive CAD (20-70% luminal diameter stenosis ) and abnormal Endothelial function as defined by EndoScore.~These subjects will receive the standard care usually provided in each facility for patients with NOCAD. (Same care as Group A)"
3037123|NCT02313987||B2- Endothelial function guid care|"Subjects with non obstructive CAD and abnormal Endothelial function as defined by EndoScore.~These subjects will receive the an Endothelial Function-guided Therapy."
3037124|NCT02313961|Experimental|RIC patients|Subjects submitted to remote ischaemic conditioning (RIC)
3037125|NCT02313961|No Intervention|No RIC patients|Subjects not submitted to remote ischaemic conditioning (RIC)
3037126|NCT02313935|Experimental|LLM|LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
3037127|NCT02313935|Experimental|PTC|Physical training only. Participants use the FitForAll exergaming computer platform as the physical training component (PTC).
3037128|NCT02313935|Experimental|CTC|Cognitive training only. Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
3037129|NCT02313935|No Intervention|Passive|Passive Control Participants do not receive an intervention serving as passive controls
3037130|NCT02313935|Active Comparator|Active|Active Control Participants receive an alternative cognitive training scheme; software was built on purpose by the AUTH team. The software is called VideoGrade and uses YouTube documentaries.
3037131|NCT02313922|Experimental|etanercept combined with methotrexate|patients treated with etanercept combined with methotrexate
3037132|NCT02313922|Experimental|etanercept as monotherapy|patients treated with etanercept combined with placebo
3037133|NCT02313909|Experimental|Rivaroxaban|Rivaroxaban 15 mg orally once daily
3037134|NCT02313909|Active Comparator|Aspirin|Aspirin 100 mg orally once daily
3037135|NCT02313896|No Intervention|Standard of Care|Patients recieve standard care. On discharge they receive an information packet about cirrhosis and hepatic encephalopathy. They will continue to follow with their doctor as usual.
3037136|NCT02313896|Experimental|Phone calls|On discharge, patients will receive an information package about cirrhosis and hepatic encephalopathy. In addition to regular visits with the doctor, they will receive phone calls from one of our research providers who will be a nurse practitioner, doctor, or physician assistant. In the first 2 weeks after discharge, they will receive phone calls every other day. For the following 10 weeks, they will receive phone calls once a week.
3037137|NCT02313883|Placebo Comparator|SRP only|Scaling and root planing only
3037144|NCT02313857|Experimental|Viralym-C|"Partially HLA-matched Viralym-C cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-C/m2 as a single infusion.~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
3037145|NCT02313844|Experimental|Viralym-B|"Partially HLA-matched Viralym-B cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-B/m2 as a single infusion.~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
3037146|NCT02313831|Experimental|Exercise training|Patients of this group will be submitted to an interval training
3037147|NCT02313818|Experimental|CPT-C|Cognitive Processing Therapy-Cognitive Only (CPT-C) conducted twice weekly for 4-24 sessions based on good end state functioning.
3037148|NCT02313805|Experimental|With checklist|Students will simulate insulin initiation with the aid of a checklist
3037149|NCT02313805|No Intervention|Without checklist|Students will simulate insulin initiation without the aid of a checklist
3037150|NCT02313792|Active Comparator|Palifermin|The patients belong to this arm will be given palifermin, keratinocyte growth factor, in addition to the conventional supportive care for oral mucositis. Palifermin will be given at a dose of 60 mcg/kg for 3 days before commencement of the preparative regimen and for 3 days after stem cell infusion
3037151|NCT02313792|Placebo Comparator|Normal saline|The patients belong to this arm will be given normal saline as placebo plus conventional supportive care for oral mucositis. Normal saline will be given at the same volume and schedule with the study drug.
3037152|NCT02313779|Placebo Comparator|Neutral|Reading passage about brain function which is masked as a news article.
3037153|NCT02313779|Experimental|Lovingkindness Meditation (LKM)|Lovingkindness guided meditation experienced in the laboratory and 6 additional LKM meditations taken home on the iPod.
3037154|NCT02313779|Placebo Comparator|Mindfulness Meditation|Mindfulness guided meditation experienced in the laboratory and 6 additional Mindfulness meditations taken home on the iPod.
3037155|NCT02313779|Experimental|Positivity|Reading passage about prioritizing positive emotions which is masked as a news article.
3037156|NCT02313766|No Intervention|spontaneous breathing (SB)|"preoxygenation through a face mask firmly applied and connected to the anaesthesia machine delivering a fresh gas flow of 12 l min-1. The inspired O2 concentration was set at 100%.~End of preoxygenation FEO2=90%"
3037157|NCT02313766|Experimental|positive pressure ventilation (PPV)|"PPV : positive pressure ventilation : preoxygenation with noninvasive positive inspiratory pressure ventilation (12 cmH2O) without PEEP.~Preoxygenation through a face mask firmly applied and connected to the anaesthesia machine - non invasive inspiratory ventilation mode - inspiratory trigger sensitivity was set at -2 l min-1, the adjustable pressure limiting valve was opened, and maximal airway pressure was limited at 18 cmH2O - PEEP=0 cmH2O End of preoxygenation FEO2=90%"
3037158|NCT02313766|Experimental|PPV + PEEP|"PEEP : PPV + PEEP : preoxygenation with noninvasive positive inspiratory pressure ventilation (12 cmH2O) with PEEP at 6 cmH2O.~Preoxygenation through a face mask firmly applied and connected to the anaesthesia machine - non invasive inspiratory ventilation mode - inspiratory trigger sensitivity was set at -2 l min-1, the adjustable pressure limiting valve was opened, and maximal airway pressure was limited at 18 cmH2O - PEEP=6 cmH2O End of preoxygenation FEO2=90%"
3037159|NCT02313753|Active Comparator|SAFE|Safety Assessment and Follow-up Evaluation Protocol
3037160|NCT02313753|Experimental|CLASP|Coping Long Term with Active Suicide Program Protocol
3037161|NCT02313740||Healthy adults group|Healthy adults aged 18 to 59 years Butantan Fragmented Inactivated Trivalent Influenza Vaccine
3037162|NCT02313740||Elderly group|Elderly aged over than 60 years completed Butantan Fragmented Inactivated Trivalent Influenza Vaccine
3037163|NCT02313727|Active Comparator|pamidronate|pamidronate
3037164|NCT02313727|Placebo Comparator|placebo|placebo
3037165|NCT02313714|Experimental|Neuromuscular stimulation|The patients will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.
3037166|NCT02313714|Placebo Comparator|Sham Group|The patients will receive very low electric muscular stimulation with a no biological or clinical effects
3037167|NCT02313701|No Intervention|Vaginal hysterectomy counseling|Standard verbal counseling to consent for vaginal hysterectomy in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
3037168|NCT02313701|Experimental|Vaginal hysterectomy visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for vaginal hysterectomy. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
3037169|NCT02313701|No Intervention|Robotic sacrocolpopexy counseling|Standard verbal counseling to consent for robotic sacrocolpopexy in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
3037196|NCT02313480|Experimental|massage group|Received massage, exercise, manual therapy and advice over the 30 minute intervention period, in conjunction with an exercise program to perform at home.
3037197|NCT02313467|Active Comparator|1.5% Butenyl ALA|Topical application of 1.5% Butenyl ALA per every other day around acne lesions in the face
3037170|NCT02313701|Experimental|Robotic sacrocolpopexy visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for robotic sacrocolpopexy. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
3037171|NCT02313701|No Intervention|Sub-urethral sling counseling|Standard verbal counseling to consent for sub-urethral sling in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
3037172|NCT02313701|Experimental|Sub-urethral sling visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for sub-urethral sling. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
3037173|NCT02313688|Experimental|Group A|Group A: Patients in the Group A will underwent D2 total gastrectomy and with 3±0.5 cm lengthen proximal resection margin. Intraoperative frozen section will routinely performed to secure the tumor free resection margin.
3037174|NCT02313688|Experimental|Group B|Patients in the Group B will underwent D2 total gastrectomy and with 5±0.5 cm lengthen proximal resection margin. Intraoperative frozen section will routinely performed to secure the tumor free resection margin.
3037175|NCT02313675|Experimental|IV tylenol|One time intra-operative IV acetaminophen administration
3037176|NCT02313675|Experimental|IV toradol|One time intra-operative IV ketorolac thromethamine administration
3037177|NCT02313675|Experimental|IV tylenol/toradol combination|One time intra-operative IV combination of acetaminophen/ketorolac administration
3037178|NCT02313675|Placebo Comparator|saline|One time intra-operative 50ml IV normal saline administration
3037179|NCT02313623||Patient Scheduled for Prostate Fusion Biopsies|For subjects with scheduled fusion biopsies, we propose a research plan to acquire additional biopsy cores for research purposes without impacting clinical protocol. After acquiring clinically-necessary biopsies, we propose taking an additional research biopsy to establish a matched-pair of clinical and research samples.
3037180|NCT02313610|Experimental|Qinbudan|the patient will receive 2HRZES/6HRE follow guidelines of the implementation of China tuberculosis control program （2HRZES/6HRE means： Intensive phase: isoniazid（H）, rifampicin（R）, pyrazinamide（Z）, ethambutol（E）, streptomycin（S）, once, for two months（2）；Consolidation: isoniazid（H）, rifampicin（R）, ethambutol（E）, once, for six months（6）.） Intervention: Qinbudan table, table, 4, thrice a day, 8 months
3037181|NCT02313610|Placebo Comparator|Control Qinbudan Placebo|the patient will receive 2HRZES/6HRE follow guidelines of the implementation of China tuberculosis control program（2HRZES/6HRE means： Intensive phase: isoniazid（H）, rifampicin（R）, pyrazinamide（Z）, ethambutol（E）, streptomycin（S）, once, for two months（2）；Consolidation: isoniazid（H）, rifampicin（R）, ethambutol（E）, once, for six months（6）.） Intervention: Qinbudan Placebo, table, 4, thrice a day, 8 months
3037182|NCT02313597|Placebo Comparator|SETON|Seton placement is a method of treatment for complex fistulas in which seton placement method is used.
3037183|NCT02313597|Experimental|VAAFT|Video assisted anal fistula treatment
3037184|NCT02313584|Active Comparator|Short Group|The patients taking dabigatran for 1 month after the radiofrequent catheter ablation for paroxysmal atrial fibrillation.
3037185|NCT02313584|Placebo Comparator|Conventional Group|The patients taking dabigatran for 2 months after the radiofrequent catheter ablation for paroxysmal atrial fibrillation.
3037186|NCT02313558|Experimental|Dentifrice Containing Ilex Rotunda Thunb|use the dentifrice containing Ilex Rotunda Thunb to brush teeth twice daily for 12 weeks
3037187|NCT02313558|Placebo Comparator|control dentifrice|use the control dentifrice to brush teeth twice daily for 12 weeks
3037188|NCT02313545|Experimental|Experimental - IZN-6NVS Cream|Eligible women of 3 groups will be assigned to receive IZN-6NVS (IP) - 2.5 g of cream/day for the first 14 days, followed by 3 applications per week for the next 4 weeks.
3037189|NCT02313519|Placebo Comparator|Placebo|Capsules of powdered glucose polymer given one capsule every 12 hours for 15 days
3037190|NCT02313519|Active Comparator|Probiotics|Capsules containing Lactobacillus acidophilus LA-5 [1.75x10^9 cfu], Lactobacillus plantarum [0.5x10^9 cfu], Bifidobacterium lactis BB-12 [1.75x10^9cfu], and Saccharomyces boulardii [1.5x10^9] per capsule. One capsule is given every 12 hours for 15 days
3037191|NCT02313506|Active Comparator|Immediate Intervention Group|Education session, Fitbit Flex, and remote coaching by a PT. These three components of the intervention will be delivered to the participants in Month 1. At the end of the education session, the PT will help participants set personal activity goals. In Month 1, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute weekly phone calls and progressively modify their activities. In Month 2, they will continue using the Fitbit and have access to a PT via email as needed, but no weekly phone calls.
3037192|NCT02313506|Placebo Comparator|Delayed Intervention Group|Same intervention with a 1 month delay: The full intervention will be initiated in Month 2 with a brief education session, use of Fitbit Flex, and counselling by a physiotherapist. The trial will conclude at the end of Month 2.
3037193|NCT02313493|Experimental|Baby Triple P parent training group|The 8- session program delivered in four group sessions before birth and four telephone sessions after birth is developed for parents at the transition to parenthood or with a baby (up to 12 months of age).
3037194|NCT02313493|No Intervention|Care as usual control group|
3037195|NCT02313480|Active Comparator|non-massage group|received exercise, manual therapy and advice over the 30 minute intervention period, in conjunction with an exercise program to perform at home.
3037199|NCT02313441|Active Comparator|RIPC (Remote Ischemic Pre-Conditioning)|Patients used RIPC had a blood pressure cuff placed around their upper arm at < 2 hours before the PCI procedure. The blood pressure cuff was inflated to for 5 minutes, followed by 5 minutes of deflation. This procedure was repeated 3 times
3037200|NCT02313441|Placebo Comparator|Control|Control participants did not experience this procedure of transient upper-limb ischemia.
3037201|NCT02313428|Experimental|Ohio Department of Medicaid|Medicaid patients who have a chronic wound, will be randomized to either receive standard treatment plus Topical Oxygen Therapy (Topical Oxygen Chamber for Extremities) or only their standard of care treatment
3037202|NCT02313428|Experimental|Medicare and Dual Medicare/Medicaid|Medicare and Dual Medicare/Medicaid patients who have a chronic wound, will be randomized to either receive standard treatment plus Topical Oxygen Therapy (Topical Oxygen Chamber for Extremities) or only their standard of care treatment
3037203|NCT02313415|Experimental|UC-MSCs therapy|transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by recurrent intrauterine adhesions
3037204|NCT02313402|Experimental|EOL (Eye On Line)|training program allowing a gradual acquisition of the eye-writing
3037205|NCT02313389|Experimental|maintenance chemotherapy|"Clinical examination and MRI will be performed every 3 months for 2 years and then every 6 months until tumor progression.~Neurocognitive tests will be performed at randomization and annually. Quality of life questionnaires at randomisation and every 3 months"
3037206|NCT02313389|No Intervention|observation|"Clinical examination and MRI will be performed every 3 months for 2 years and then every 6 months until tumor progression.~Neurocognitive tests will be performed at randomization and annually. Quality of life questionnaires at randomisation and every 3 months"
3037207|NCT02313376|Experimental|GAP3KO|
3037208|NCT02313363|Experimental|PSDCS|using the patient-centered smartphone-based diabetes care system (PSDCS) for 12 weeks
3037209|NCT02313350|Experimental|Chemonucleolysis with Discogel|Discogel® is a class III medical device (CE0459 mark on 28/09/2007) constituted by a radiopaque jellified ethanol. Discogel® is provided in a kit containing a 2 ml solution for injection with two disposable 1ml syringes. Discogel® chemonucleolysis for herniated disc-related sciatica is performed under local anesthesia. A volume of 0.9 ml of Discogel® is finally slowly injected during 10 to 15 minutes
3037210|NCT02313350|Active Comparator|Open discectomy|surgery : The comparator is open surgical discectomy. The procedure will be performed under general anesthesia. It will consist in removing the disc herniation after exposition and examination of the nerve root
3037211|NCT02313337|Experimental|Oral administration|-Oral administration of a mixture at preoperative 30 minutes : ketamine 3 mg/kg, midazolam 0.5 mg/kg and atropine 0.02 mg/kg, plus 50% glucose solution to 0.5ml /kg.
3037212|NCT02313337|Experimental|Intramuscular injection|-At preoperative 30 minutes intramuscular injection of atropine 0.02 mg/kg, 5 minutes before entering the operation room, intramuscular injection of ketamine 5 mg/kg.
3037213|NCT02313337|Experimental|Rectal perfusion|-At preoperative 30 minutes rectal infusion of midazolam 0.5mg/kg
3037214|NCT02313337|Experimental|Dripping nose|-At preoperative 30 minutes dripping nose of Imidazole valium 0.2 mg/kg
3037215|NCT02313324|Experimental|ESWT group|The patients were randomly assigned to the extracorporeal shock wave therapy (ESWT) group.
3037216|NCT02313324|Active Comparator|SWD combined IFC group|The patients were randomly assigned to the SIT group. The patients received combined therapy with shortwave diathermy (SWD) and interferential current (IFC) performed by the same physiotherapist at each treatment session.
3037217|NCT02313298|Experimental|Stereotactic Body Radiotherapy|An extreme hypofractionated regimen of 36.25Gy in 5 fractions over 10-11 days
3037218|NCT02313285||GZ402668|Patient who received GZ402668 in prior study (TDU13475 or TDU14981)
3037219|NCT02313285||Placebo|Patient who received placebo in prior study (TDU13475 or TDU14981)
3037220|NCT02313272|Experimental|HFSRT with Pembrolizumab and Bevacizumab|Hypofractionated Stereotactic Irradiation (HFSRT). Pembrolizumab intravenous (IV) infusion every 3 weeks. Bevacizumab administered intravenously every 2 weeks.
3037221|NCT02313259||AMD controls|15 patients with early to intermediate AMD (grade 2-8) were enrolled using the Age-Related Eye Disease Study (AREDS) severity scale for AMD.
3037222|NCT02313259||Age-matched controls|15 drivers without ocular disease.
3037223|NCT02313259||Young controls|15 drivers without ocular disease. Between 18 and 25 years old.
3037224|NCT02313259||Glaucoma patients|15 patients having a Humphrey visual field mean deviation between -10 and -12 (better eye).
3037225|NCT02313246|Experimental|Group Cognitive Behaviour Therapy|Patients will complete an 11-session group cognitive behaviour therapy for IBS that will be led by two clinicians, one of whom will be a registered clinical psychologist, at the Digestive Diseases Clinic at McMaster University Medical Centre. The group cognitive behaviour therapy will include weekly 2-hour sessions for 11 weeks. Sessions will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
3037226|NCT02313233|Experimental|Umooze|Tablet oral dosage. Astragalus radix Extracts 480 mg+ Soy extracts 20 mg
3037227|NCT02313233|Placebo Comparator|Placebo|Cornstarch.
3037228|NCT02313220|Experimental|Dapagliflozin and exenatide|Dapagliflozin 10 mg film-coated tablet once daily and exenatide 2 mg once weekly injection combined treatment for 24 weeks
3037229|NCT02313220|Placebo Comparator|Placebo|Placebo film-coated tablet once daily and placebo once weekly injection combined treatment for 24 weeks
3037230|NCT02313207|Active Comparator|FODMAP diet|FODMAP diet for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.
3037231|NCT02313207|Active Comparator|Specific bread diet|Specific bread diet eliminating wheat and yeast for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.
3037232|NCT02313194|Experimental|Stimulation|Determine if epidural stimulation can improve motor function.
3037233|NCT02313181|Experimental|Early Limited Formula|10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
3037234|NCT02313181|Other|Standard Care|Continue exclusive breastfeeding unless otherwise instructed by a health care provider
3037235|NCT02313168||1|preoperative FRONT score
3037238|NCT02313155|Experimental|TAK-850 0.5 mL (Intramuscular)|Single intramuscular injection of TAK-850
3037239|NCT02313142|Experimental|Subjects|
3037240|NCT02313129||Rheumatoid Arthritis|This group will complete questionnaires related to prior pregnancies, intentions and goals for childbearing, fertility history and detailed menstrual history. They will also have a physical exam and blood tests.
3037241|NCT02313129||Healthy Controls|This group will complete questionnaires related to prior pregnancies, intentions and goals for childbearing, fertility history detailed menstrual history, and blood tests.
3037242|NCT02313103|Other|Lofexidine HCl|End Stage Renal Disease (ESRD) subjects will be dosed with 400 micrograms of lofexidine HCl with 240 mL water after their hemodialysis session.
3037243|NCT02313103|Other|Matched Control|normal renal function subjects (enrolled to match each End Stage Renal Disease subject) will be dosed with 400 micrograms of lofexidine HCl with 240 mL water at the same clock time as ESRD subjects.
3037244|NCT02313090|Experimental|Welltang|patients using Welltang
3037245|NCT02313090|No Intervention|usual standard care|patients under usual standard of diabetic care
3037246|NCT02313077|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
3037247|NCT02313077|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
3037248|NCT02313077|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
3037249|NCT02313077|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
3037250|NCT02313077|Experimental|Group 5|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 15).
3037251|NCT02313064|Active Comparator|CXA-10|single dose of CXA-10 oral formulation
3037252|NCT02313064|Placebo Comparator|CXA-10 placebo|single oral doses of CXA-10 placebo
3037253|NCT02313051|Experimental|Everolimus arm|Everolimus+letrozole
3037254|NCT02313051|Active Comparator|Controll arm|letrozole alone, and when progress, followed by everolimus
3037255|NCT02313025|Experimental|Speech sound intervention|This group receives a speech sound and phonemic awareness intervention for four months.
3037256|NCT02313025|Active Comparator|World-project|This group receives the WORLD intervention for four months.
3037257|NCT02313012|Experimental|Dose Level 1 CC-90003|CC-90003 by mouth (PO) daily on days 1 -21 of every 28 day cycle; Cycle 1, Days 1 to 28 will constitute the dose limiting toxicity (DLT) assessment period for purposes of non-tolerated dose (NTD) and Maximum Tolerated Dose determination.
3037258|NCT02312999|Experimental|Volulyte|A baseline crystalloid infusion (plasmalyte®) will be set by the attending physician at 3 cc/kg/hr (standard patient care) for each of the randomized groups. The patient will receive fluid management via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to standardize the way fluids are administered intra-operatively and eliminate variation between clinical providers. The liquid perfused will be bolus amounts of volulyte.
3037259|NCT02312999|Active Comparator|Plasma-Lyte|A baseline crystalloid infusion (plasmalyte®) will be set by the attending physician at 3 cc/kg/hr (standard patient care) for each of the randomized groups. The patient will receive fluid management via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to standardize the way fluids are administered intra-operatively and eliminate variation between clinical providers. The liquid perfused will be bolus amounts of plasma-lyte.
3037260|NCT02312986|Experimental|Fecal microbiota transplantation|Subjects will receive 150mL of fecal microbiota product via enema.
3037261|NCT02312973|Experimental|Arm 1|Single oral dose of 75 mg molidustat (fasted) in subjects on hemodialysis (at start of hemodialysis and on a hemodialysis free day,respectively)
3037262|NCT02312973|Experimental|Arm 2|Single oral dose of 75 mg molidustat (fasted) in subjects on peritoneal dialysis (after start of peritoneal dialysis intervall and, optionally, after the start of a peritoneal dialysis-free intervall,respectively)
3037263|NCT02312973|Experimental|Arm 3|Single oral dose of 75 mg molidustat (fasted) in healthy subjects
3037264|NCT02312960|Other|Arm 1|The subjects previously enrolled in a selected radium-223 dichloride feeder trial, their treating health care professional, or caregiver will be contacted in 6-month intervals for follow up and query.
3037265|NCT02312947|Active Comparator|coblation|coblation adenoidectomy
3037266|NCT02312947|Active Comparator|cold dissection|cold dissection adenoidectomy
3037267|NCT02312934|Experimental|Transdermal Nicotine|"Nicotine will be delivered by a transdermal patch delivery system for topical application. Each patch will contain approximately 1.75mg nicotine/cm2, and releases 7, and 14mg of nicotine, respectively, over 24 hours. Patches will be applied for 16 hours per day. Participants will be titrated over the course of the 6-week treatment period in order to avoid initial side effects as follows:~Week 1: ½ 7 mg patch per day, Week 2: 7 mg patch per day, Weeks 3-4: ¾ 14 mg patch per day, Weeks 5-6: 14 mg per day, Weeks 7-8: Treatment withdrawal"
3037268|NCT02312934|Placebo Comparator|Placebo|"Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.~Week 1: ½ 7 mg patch per day, Week 2: 7 mg patch per day, Weeks 3-4: ¾ 14 mg patch per day, Weeks 5-6: 14 mg per day, Weeks 7-8: Treatment withdrawal"
3037269|NCT02312921||PREDICT|"Delivery system changes where a team of dental providers (dentists, dental hygienists, case managers, community outreach workers and others) within Advantage Dental Services, LLC provide evidence-based screening, risk assessment and primary and secondary preventive care in non-conventional community settings (WIC, Head Start and similar settings) and seamless, timely and appropriate evidence-based care in dental clinics.~Payment plan model based on global budgeting and Alternative Quality Contract (pay-for-performance) for dental providers within Advantage Dental Services, LLC (Advantage) with the goal of incentivizing implementation of delivery system changes aimed at reducing disparities in dental care utilization and oral health for low-income mothers and children.."
3037270|NCT02312921||Control|Usual care
3037271|NCT02312908|Experimental|Clonazepam|Clonazepam 0.5 mg 1 Tablet by mouth, 1/day before sleeping for 4 weeks
3037272|NCT02312908|Placebo Comparator|Placebo|Placebo 1 Tablet by mouth, 1/day before sleeping for 4 weeks
3037452|NCT02311699|No Intervention|Control Group|Community members in the control villages will receive a short informational session on violence reduction.
3037273|NCT02312895|Experimental|Dry Needling|A total of 30 subjects will be randomized to this experimental arm. If randomized to this arm, subjects will receive dry needling, patient education, and a home exercise program.
3037274|NCT02312895|Experimental|Manual Therapy|A total of 30 subjects will be randomized to this experimental arm. If randomized to this arm, subjects will receive manual therapy, patient education, and a home exercise program.
3037275|NCT02312882|Experimental|Tofacitinib|Participants will receive tofacitinib for 3 months.
3037276|NCT02312856|Experimental|PulseRider aneurysm|Endovascular treatment of intracranial aneurysms
3037277|NCT02312843|Active Comparator|High-Intensity Program-aerobic exercises|This exercise program will consist of walking or running on a treadmill or elliptical trainer, or spinning on a stationary bicycle. The goal of the program will be for participants to exercise at a moderate to high level of intensity, defined as 70-80% (American College of Sports Medicine guidelines) of heart rate reserve (HRR), for 45-60 minutes 4 days per week. At the start of each training session and following a 5-minute warm-up, subjects will exercise at 50% HRR (0.5[HRmax-HRrest] +HRrest) and intensity will gradually be increased to the individualized target heart rate training zone. Exercise facilitators will use a pre-specified computerized program. This program provides guidelines for the individualized progression of exercise based on age and resting heart rate. Subjects will wear a digital heart rate monitoring device for the duration of the training session to ensure they are exercising safely at the specified level of intensity.
3037278|NCT02312843|Placebo Comparator|Low-intensity Program-Stretching|The low-intensity activity program will consist of an individualized and organized series of stretching and balance activities for the whole body, specifically designed for older adults. Consistent with the high-intensity protocol, subjects will complete the prescribed 45-60 minute stretching routine 4 days per week at the exercise facility. All stretching routines will include warm-up and cool-down activities, and will be within each subject's range of motion. Each stretch will be held for 20-30 s and repeated 5-10 times. Subjects will wear a digital heart rate monitoring device to ensure they are stretching safely and at an intensity below 35% HRR. The activity log completed during each stretching session will include HR, stretching duration, and mean HR during stretching. Subjects will also have the option to participate in structured pre-approved (by the exercise facilitator) stretching classes at the exercise facility when available.
3037279|NCT02312817|No Intervention|Group 1|Individuals randomized to Group 1 will receive usual medical care and will not be directly contacted at any point of the trial. Study data and outcomes will be abstracted from the EMR.
3037280|NCT02312817|Experimental|Group 2|Individuals randomized to Group 2 will receive mailed outreach invitation.
3037281|NCT02312817|Experimental|Group 3|Individuals randomized to Group 3 will receive mailed outreach invitation and patient navigation.
3037282|NCT02312804|Experimental|Dose Escalation|To determine the MTD/RP2D of BGJ398 when combined with carboplatin and paclitaxel in subjects with locally advanced for metastatic solid tumors.
3037283|NCT02312804|Experimental|Expansion Cervical Cancer|To assess the anti-tumor effect of BGJ398 when combined with carboplatin and paclitaxel in cervix cancer.
3037284|NCT02312791||Palliative Patients|Inpatients evaluated for palliative radiation therapy.
3037285|NCT02312778|Experimental|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation is delivered to the subjects in the side lying position. The more restricted lumbar segment (mobility restriction) will be the target region for the manipulative procedure.
3037286|NCT02312778|No Intervention|Sham Manipulation|Control Group who receives a simulated manipulation.
3037287|NCT02312765|Experimental|Open-label Pilot|Study participants will receive a tablet computer with the AirCare system.
3037288|NCT02312752|Other|Intra-epidermal stimulation|"A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds."
3037289|NCT02312739|Active Comparator|Vicodin, Lorazepam and Oxygen|"Patients in this group will receive the Standard Oral Pain Medications consisting of Vicodin and Lorazepam, as well as intramuscular ketorolac at least 30 minutes prior to the procedure. Oxygen via scented mask will also given.~All participants randomized to this group will undergo in-office transcervical sterilization (Essure® procedure ) using standard technique."
3037290|NCT02312739|Experimental|Placebo pills and Nitrous Oxide|"Patients in this group will receive two placebo pills, as well as intramuscular ketorolac at least 30 minutes prior to the procedure. Nitrous oxide will be administered during the procedure via scented mask.~All participants randomized to this group will undergo in-office transcervical sterilization (Essure® procedure ) using standard technique."
3037291|NCT02312726||Epidural group|Participants who elect to have an epidural anesthesia during labor, delivery and postplacental IUD insertion
3037292|NCT02312726||Non Epidural group|Participants who elect not to have epidural anesthesia during labor, delivery and postplacental IUD insertion
3037293|NCT02312713|Active Comparator|Standard Physical Therapy|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
3037294|NCT02312713|Experimental|Internet Based Exercise Training|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
3037295|NCT02312713|No Intervention|Wait list control|no intervention
3037296|NCT02312700|Experimental|Interactive empowerment (IEm) group|Intervention: Patients fill in the questionnaire online and their profile (obtained from their answers) is immediately sent to the physician
3037297|NCT02312700|Sham Comparator|Control|Intervention: Patients fill in the questionnaire online, but their profile (obtained from their answers) is not sent to the physician
3037298|NCT02312687|Experimental|All Subjects|Subjects will receive sub-cutaneous injections of KRN23 every 4 weeks. Starting doses will be based on the subject's last dose in study KRN23-INT-001 or KRN23-INT-002. Doses may be titrated to achieve the target peak serum phosphorus range.
3037299|NCT02312674|Experimental|Intervention|Patient group which takes daily an adjusted amount of oral nutritional supplements through an intervention period of three months
3037300|NCT02312674|No Intervention|Control|Patients group which takes no oral nutritional supplements
3037301|NCT02312661|Experimental|Carboplatin / paclitaxel /metformin|Three-weekly cycles of carboplatin/paclitaxel chemotherapy in combination with metformin treatment
3037302|NCT02312648|Active Comparator|Early mobilization Group|Patients will perform deep breaths (3 sets of 10 repetitions), once a day, for 30 minutes until 7th postoperative day. Non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.Early mobilization protocol consist of upper and lower (cycle ergometer) limb exercises, chair transfer, deambulation for 10 to 20 minutes, step exercise (six times).
3037303|NCT02312648|Other|Control Group - Respiratory exercise|Respiratory exercises with patient sitting in bed with a high headboard 45, the same breathing exercises will be held
3037304|NCT02312635|Experimental|Cogmed + D-cycloserine|Partifcipants will receive 6 weeks of cogmed working memory training M-F for 45 min each day. Participants in this arm will also take drug Monday, Wednesday, Friday throughout 6 weeks.
3037305|NCT02312635|Placebo Comparator|Cogmed + Placebo|Participants will receive 6 weeks of cogmed training M-F and also take a placebo pill Monday, Wednesday, Friday throughout 6 week period.
3037306|NCT02312622|Experimental|Treatment (pegylated irinotecan NKTR 102)|Patients receive pegylated irinotecan NKTR 102 IV over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
3037307|NCT02312609|Experimental|Test|Minocycline hydrochloride extended release tablets 135 mg
3037308|NCT02312609|Active Comparator|Reference|Solodyn Extended Release Tablets 135 mg
3037309|NCT02312596|Experimental|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix
3037310|NCT02312596|Active Comparator|Usual and customary practice|Usual and customary practice
3037311|NCT02312583|Sham Comparator|Psychoeducational online information|Psychoeducational online information. During 7 weeks as a complement to the usual treatment.
3037312|NCT02312583|Experimental|iFightDepression online programme.|iFightDepression online programme. During 7 weeks as a complement to the usual treatment.
3037313|NCT02312570|Experimental|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
3037314|NCT02312570|Other|Usual and Customary Practice|Usual and customary practice for non-healing pressure wounds
3037315|NCT02312557|Experimental|Treatment (pembrolizumab)|"INITIAL TREATMENT PHASE: Patients who are progressing on enzalutamide will receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily.~MONITORING PHASE: After completion of the initial treatment phase, patients continue to receive standard of care enzalutamide PO daily for the duration of the trial.~RETREATMENT PHASE: Patients with disease response or stability after the initial treatment phase will receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for an additional 4 courses in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily for the duration of the trial."
3037316|NCT02312544|Active Comparator|OTX-TP treatment|OTX-TP (sustained release travoprost, 0.36 mg) to be used in this trial with placebo drops administered separately
3037317|NCT02312544|Active Comparator|Timolol control|Timolol Maleate Ophthalmic Solution, 0.5% dosed twice daily (BID) in the presence of a placebo vehicle punctum plug (PV).
3037318|NCT02312531|Experimental|HBIG group|Mothers in HBIG group received 'Hepatitis B immunoglobulin' (HBIG 200 IU, S20023028, Hualan Biological Engineering Inc.) injection at gestational weeks 20, 24, 28, 32, 34, 36, 38, 39, and 40.
3037319|NCT02312531|No Intervention|Control group|Mothers in control group had no HBIG injection during pregnancy.
3037320|NCT02312518|Experimental|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
3037321|NCT02312518|Other|Usual and Customary Practice|usual and customary practice
3037322|NCT02312505|Other|COPFX|cardiac output by PulsioFlex® Monitoring system (COPFX)
3037323|NCT02312492|Experimental|18:1 diet|Oleic Diet - volunteers will consume oleic enriched food for a period of 5 weeks.
3037324|NCT02312492|Experimental|16:0 diet|Palmitic diet - Volunteers will consume palmitic enriched food for a period of 5 weeks.
3037325|NCT02312492|Experimental|18:0|Stearic Diet - Volunteers will receive Stearic enriched food for a period of 5 weeks.
3037326|NCT02312479|Experimental|Nyxoah SAT therapy|
3037327|NCT02312466||School aged children|
3037328|NCT02312466||Pregnant women|
3037329|NCT02312466||Women of reproductive age|
3037330|NCT02312453|Experimental|Posterior approach|All patients were given a single shot ultrasound-guided posterior parasagittal in-plane approach infraclavicular brachial plexus block under aseptic technique. The blocks were performed using a 21G, 100 mm insulated short bevel needle (Stimuplex A, B Braun, Melsungen, Germany) without nerve stimulation. A 25-ml local anaesthetic admixture [Lignocaine 2% (100mg) plus Ropivacaine 0.75% (150mg)] was administered. We used an ultrasound machine (Sonosite M-Turbo; Sonosite®, Bothell, WA, USA) with HFL38x/ 13-6 MHz linear transducer probe.
3037331|NCT02312440|Placebo Comparator|Group1|60 Milliliters（ml）Normal saline (0.9% sodium chloride) will be applied by soaking the hip cavity for at least 3 minutes before wound closure and then sucked away.
3037332|NCT02312440|Experimental|Group2|two-dose intravenous tranexamic acid will be applied as follow: 10mg/kg of Tranexamic Acid in 100 Milliliters（ml) normal saline (0.9% sodium chloride),the first dose 15' prior to skin incision and the second dose at 180' after the first dosage.
3037333|NCT02312440|Experimental|Group 3|3g Tranexamic Acid diluted to 60 Milliliters（ml） with normal saline (0.9% sodium chloride) will be applied by soaking the hip cavity for at least 3 minutes before wound closure and then sucked away.
3037334|NCT02312427|Experimental|Outpatient arm|After baseline data collection, DPP-4 inhibitor will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
3037335|NCT02312427|Experimental|Hospitalization arm 1|After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
3037336|NCT02312427|Experimental|Hospitalization arm 2|After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
3037337|NCT02312414|No Intervention|IVIR|Patients given IV iron (Sodium ferric gluconate, [125 mg/100 ml] from week 1 to week 4
3037338|NCT02312414|Experimental|IVIR Carnitine|Patients given Carnitine (20mg/kg, IV) perior to IV iron (Sodium ferric gluconate, [125 mg/100 ml] from week 4 to week 8.
3037339|NCT02312401|Experimental|Multiparametric MRI|Patients undergo baseline standard (clinical) MP-MRI prior to therapy (ADT or RT). After completion of radiotherapy, follow-up MRIs will be obtained using the same 3T Philips MRI unit at approximately 3, 6, 12, 18 & 24 (+/- 4 weeks) months after radiotherapy. A standard post-tx biopsy will be performed at 24 months (+/- 4 weeks) after therapy which will serve to define the local control status after therapy. Local control based on this biopsy will be interpreted as negative or adenoca with severe tx effect; a positive biopsy will be a specimen which demonstrates adenocarcinoma that can be classified with a Gleason score as we have previously reported.
3037340|NCT02312388|Experimental|Catheter-over-the-needle technique|to use the 22G angiocatheter for central venous catheterization
3037341|NCT02312388|Experimental|Thin-wall needle technique|to use the sharp hollow 23G needle for central venous catheterization
3037342|NCT02312375|Experimental|Fimasartan|Expreimental drug is fimasartan.
3037343|NCT02312375|Active Comparator|Amlodipine|Active comparator is amlodipine.
3037344|NCT02312362|Experimental|Combined sclerotomy ab interno and phaco|Combined sclerotomy ab interno and phacoemulsification with IOL implantation
3037345|NCT02312362|Active Comparator|Phacoemulsification with IOL implantation|Phacoemulsification with IOL implantation
3037346|NCT02312336|Placebo Comparator|Cohort A|Cohort A - Room temperature coronary perfusate
3037347|NCT02312336|Active Comparator|Cohort B|Cohort B - Cooled coronary perfusate
3037348|NCT02312323|Experimental|Definitive 65 HPT|
3037349|NCT02312323|Active Comparator|Definitive 65|
3037350|NCT02312310|Placebo Comparator|F 0 mg|daily consumption of capsules containing 0 mg cocoa flavanol for 12 weeks
3037351|NCT02312310|Active Comparator|F 225 mg|daily consumption of capsules containing 225 mg cocoa flavanol for 12 weeks
3037352|NCT02312310|Active Comparator|F 400 mg|daily consumption of capsules containing 400 mg cocoa flavanol for 12 weeks
3037353|NCT02312310|Active Comparator|F 650 mg|daily consumption of capsules containing 650 mg cocoa flavanol for 12 weeks
3037354|NCT02312297|Experimental|Test|Minocycline hydrochloride extended release tablets 135 mg
3037355|NCT02312297|Active Comparator|Reference|Solodyn Extended Release Tablets 135 mg
3037356|NCT02312284||Radiotherapy/Chemoradiotherapy|Pre- or postoperative or palliative radiotherapy/chemoradiotherapy based on 5-fluorouracil or Capecitabine +/-Oxaliplatin
3037357|NCT02312284||Surgery|Transabdominal resection or transanal excision
3037358|NCT02312284||Chemotherapy|Pre- or postoperative chemotherapy including 5-fluorouracil/leucovorin with oxaliplatin, Capecitabine, etc
3037359|NCT02312271||enterally fed adults|adult subjects with established enteral access receiving standard tube feeding formula
3037360|NCT02312258|Experimental|Ixazomib|Ixazomib 3 mg, capsule, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib 3 or 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26. Participants experiencing adverse events (AEs) attributed to study drug during any cycle may continue in the study but may have doses of study drug held or reduced by at least 1 dose level. Reduced doses are: 3 mg, 2.3 mg, 1.5 mg and discontinuation of study drug.
3037361|NCT02312258|Placebo Comparator|Placebo|Ixazomib placebo-matching 3 mg capsule, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib placebo-matching 3 or 4 mg capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26. Participants experiencing adverse events (AEs) attributed to study drug during any cycle may continue in the study, but may have doses of study drug held or reduced by at least 1 dose level. Reduced doses are: 3 mg, 2.3 mg, 1.5 mg and discontinuation of study drug.
3037362|NCT02312245|Experimental|Arm A (Avatar-directed paclitaxel)|Patients receive paclitaxel IV over 1-96 hours on days 1, 8, and 15. Patients may also receive bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
3037363|NCT02312245|Experimental|Arm B (Avatar-directed gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3037364|NCT02312245|Experimental|Arm C (Avatar-directed liposomal doxorubicin)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1. Patients may also receive bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3037365|NCT02312245|Experimental|Arm D (Avatar-directed topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5 every 21 days or days 1, 8, and 15 every 28 days. Patients may also receive bevacizumab IV over 90 minutes on day 1 every 21 days or days 1 and 15 every 28 days. Courses repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
3037366|NCT02312232|Experimental|Levodopa formulation A|Levodopa formulation A together with ODM-104 100 mg and carbidopa
3037367|NCT02312232|Experimental|levodopa formulation B|levodopa formulation B together with ODM-104 100 mg and carbidopa
3037368|NCT02312232|Experimental|levodopa formulation C|levodopa formulation C together with ODM-104 100 mg and carbidopa
3037369|NCT02312232|Active Comparator|Sinemet IR 100/25 mg|Sinemet IR 100/25 mg together with ODM-104 100 mg
3037370|NCT02312232|Active Comparator|Half Sinemet CR 100/25 mg|Half Sinemet CR 100/25 mg together with ODM-104 100 mg
3037521|NCT02311127|Active Comparator|StatLock|Adhesive securement
3037371|NCT02312219||Low Dose Methotrexate|Subjects will take 1 mg folic acid once daily plus 5 mg methotrexate (MTX) . If clinically stable at the week 1 visit, the dose of MTX will be increased to 10 mg once weekly through week 12. For subjects who remain clinically stable on 10 mg MTX or placebo through the week 12 visit, the dose of MTX will be increased to 15 mg once weekly through week 24. If the subject does not meet the criteria for dose escalation at the week 1 or 12 study visit, then the subject will remain on his/her current dose until the next study visit at which time he/she will be re-evaluated for dose escalation.
3037372|NCT02312219||Placebo|Subjects will take 1 mg folic acid once daily plus placebo once weekly. If clinically stable at weeks 1 and 12, the number of placebo tablets will be increased in a manner matching those on the MTX.
3037373|NCT02312206|Experimental|NEOD001|24 mg/kg (maximum dose of 2500 mg) of NEOD001 administered once every 28 days.
3037374|NCT02312206|Placebo Comparator|Placebo|Placebo will be administered as a 250 mL bag of normal saline once every 28 days.
3037375|NCT02312193||Case|Hypertensive subjects
3037376|NCT02312193||Control|Normotensive subjects
3037377|NCT02312180|Experimental|Cohort 1|low dose group of 2 mg/kg Plasminogen (Human) Intravenous
3037378|NCT02312180|Experimental|Cohort 2|mid-dose group of 6 mg/kg Plasminogen (Human) Intravenous
3037379|NCT02312167|Experimental|confocal laser endomicroscopy|confocal laser endomicroscopy : 10 to 15 minutes endomicroscopy procedure to obtain real time microscopical images of healthy and malignant tissue of the targeted organs
3037380|NCT02312154|Experimental|treated side (Restylane vital)|"We injected staabilized hyaluronic acid (HA)-based gel of nonanimal origin on the left side of face.~(We performed split face study)"
3037381|NCT02312154|No Intervention|untreated side (control)|We did nothing on the right side of face and we compared the results on same participants
3037382|NCT02312128|Active Comparator|Early Mobilisation|"receives a removable plastic cast for one week and is allowed to move the wrist directly postoperative.~Interventions:~Range of Motion measurement (ROM),~Grip strength measurement,~VAS Score according to the visual analogue scale ().~Questionnaire: PRWE Score, DASH Score and Mayo Wrist Score.~X- Rays in two planes.~Follow-up: 6., 9., 12. postoperative week, a half and one year after surgery"
3037383|NCT02312128|Active Comparator|Cast Group|"receives a non removable cast for 5 weeks~Interventions:~Range of Motion measurement (ROM),~Grip strength measurement,~VAS Score according to the visual analogue scale ().~Questionnaire: PRWE Score, DASH Score and Mayo Wrist Score.~X- Rays in two planes.~Follow-up: 6., 9., 12. postoperative week, a half and one year after surgery"
3037384|NCT02312115|Active Comparator|Furosemide|Patients assigned to the furosemide infusion group will receive furosemide infusions, as outlined in figure 2. This has been adapted from Ostermann et al. (2007) and the SPARK study protocol (Bagshaw et al. 2010). Furosemide will be prepared in bags that contain 1000 mg of furosemide per 250 mL of saline reaching a concentration of 4 mg/mL. All medication and placebo bags will have no identifiers that show what type of drug is being administered, for blinding purposes. Medication and placebo bags will have randomly generated study identifier numbers. The protocol in figure 2 will be followed to achieve a total urine output of 1mL/kg/h. The furosemide infusion rate will not exceed 4mg/min IV as this is the maximum set by the manufacturer.
3037385|NCT02312115|Placebo Comparator|Saline|All patients assigned to the saline group will receive saline that is equal in volume as compared to the treatment group. The amount of saline given to the patients in the placebo arm is so small that its effect on these patients is negligible. All other aspects of care for the enrolled patient will be managed per primary team and any consultants.
3037386|NCT02312102|Experimental|Velcade and Lenalidomide|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Each treatment cycle lasts 28 days (4 weeks). The first two cycles are called the induction cycles. If the participant respond to treatment during the first two cycles, they can continue on to the maintenance cycles.~During the induction and maintenance cycles, patients receive up to the MTD of lenalidomide on days 1-21 days only. During days 22-28 (4th week) there is a rest period.~Bortezomib: During the induction cycles, the medication will be given on days 2, 5, 9, and 12 followed by a 17-day rest period. During the maintenance cycles, bortezomib will be given on days 2, and 5 followed by 23-day rest period."
3037387|NCT02312089|Active Comparator|GnRHa group|Luteal phase SC administration of a single dose (0.2 mg) of GnRHa (Triptorelin)
3037388|NCT02312089|No Intervention|Control group|No GnRHa administration in luteal phase
3037389|NCT02312076|Active Comparator|GnRHa group|Luteal phase SC administration of a single dose (0.2 mg) of GnRHa (Triptorelin)
3037390|NCT02312076|No Intervention|Control group|No GnRHa administration in luteal phase
3037391|NCT02312063|Experimental|Sitagliptin|Sitagliptin 50 mg a day for 16 weeks
3037392|NCT02312063|Active Comparator|Glimepiride|Glimepiride 0.5 mg a day for 16 weeks
3037393|NCT02312050|Experimental|GCS-100 1 mg|Dose level 1 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
3037394|NCT02312050|Experimental|GCS-100 3 mg|Dose level 2 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
3037395|NCT02312050|Experimental|GCS-100 9 mg|Dose level 3 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
3037396|NCT02312050|Placebo Comparator|Normal Saline Solution 0.9%|Placebo - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
3037397|NCT02312024||Patients with severe sepsis/septic shock|Use of CytoSorb adsorber in patients with severe sepsis/septic shock
3037398|NCT02312024||Cardiac surgery with CPB: preemptive use|Use of CytoSorb adsorber in patients with cardiac surgery with CPB: preemptive use
3037399|NCT02312024||Cardiac surgery with CPB: postop. use|Use of CytoSorb adsorber in patients with cardiac surgery with CPB: postoperative use
3037400|NCT02312024||Patients with other indications|Use of CytoSorb adsorber in patients with other indications
3037401|NCT02312011|Experimental|IONIS-DMPKRx|"IONIS DMPKRx is administered subcutaneously over the course of 6 weeks for dose levels 1, 2, 3, 4, and 5.~IONIS DMPKRx is administered subcutaneously over the course of 12 weeks for dose levels 4 or 5."
3037402|NCT02312011|Placebo Comparator|Placebo|A placebo is administered subcutaneously over the course of 6 weeks. A placebo is administered subcutaneously over the course of 12 weeks.
3063861|NCT02136030|Active Comparator|Amphotericin B|
3037403|NCT02311998|Experimental|Bosutinib + Inotuzumab Ozogamicin|"Phase I Dose Escalation - Starting dose of Bosutinib at 300 mg by mouth once daily.~Inotuzumab Ozogamicin given by vein on a weekly schedule 0.8 mg/m2 by vein day 1, 0.5 mg/m2 day 8, and 0.5 mg/m2 day 15. A minimum of 6 days should be maintained between subsequent doses.~Study cycle is 28 days.~Phase II Dose Expansion - Starting dose of Bosutinib is maximum tolerated dose from Phase I Dose Escalation.~Dose of Inotuzumab Ozogamicin is same as Phase I Dose Escalation: 0.8 mg/m2 by vein Day 1, 0.5 mg/m2 Day 8, and 0.5 mg/m2 Day 15.~After end of treatment visit, participants called 1 time about every 12 weeks for up to 1 year, and asked about any anti-cancer therapy they may have started. This call will last about 5 minutes."
3037404|NCT02311985|Active Comparator|Coagulogram-based protocol|Arm based on standard coagulation tests protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.
3037405|NCT02311985|Experimental|Thromboelastometry-based protocol|Arm based on rotational thromboelastometry (ROTEM(R)) protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.
3037406|NCT02311985|Experimental|Restrictive strategy|Arm based on a restrictive protocol strategy based on INR/PT and platelets count. The possible components to be used include fresh frozen plasma and/or platelets (random or aphaeresis).
3037407|NCT02311972|Active Comparator|Control - Standard of Care|Infants in the standard of care group will receive no study interventions other than study recorded axillary temperatures on admission, and at 1, 4, 8 and 24 hours. Infants will receive standard delivery room stabilization and NICU stabilization. Infants in the control group will receive a feeding tube as standard of care, and the standard issue feeding tube used in the Intensive Care Nursery does not have the capability to record or display esophageal temperatures. Nurses will record an axillary temperature upon admission to the NICU, and at 1, 4, 8 and 24 hours of age for each infant in both groups on a data sheet at the bedside. These data will be entered into a RedCap data base created for the study.
3037408|NCT02311972|Active Comparator|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|The nurse will insert an InnerSense temperature sensor/feeding tube per normal standards as soon after birth as possible, during delivery room stabilization. Nurses will record an axillary temperature upon admission to the NICU, and at 1, 4, 8 and 24 hours of age. The InnerSense tube will be attached to the infant's bedside monitor to continuously display esophageal temperatures. The tube will stay in place until the infant is 24 hours of age. Central body temperature will be displayed continuously for care-providers in the delivery room, through transport from the birthing center to the NICU and through stabilization. Infants will have a thermistor placed on the abdominal skin with standard skin tape once admitted in the NICU. This thermistor will be attached to a Squirrel SQ2010 (Grant Instruments) temperature monitor/data logger to collect abdominal temperatures every minute for the first 24 hours of life. All temperatures entered into the study database.
3037409|NCT02311959|Experimental|Invasive or in situ breast carcinoma.|
3037410|NCT02311946|Experimental|Cohort 1|Cohort 1 will receive a 125 mg round yellow palbociclib tablet containing succinic acid
3037411|NCT02311946|Experimental|Cohort 2|Cohort 2 will receive a 125 mg oval yellow palbociclib spray-dried dispersion tablet containing HMPC E3
3037412|NCT02311946|Experimental|Cohort 3|Cohort 3 will receive a 125 mg oval yellow palbociclib spray-dried dispersion tablet with HMPC E3 and succinic acid.
3037413|NCT02311946|Experimental|Cohort 4|Cohort 4 will receive a 125 mg oval white/yellow palbociclib bilayer tablet with tartaric and succinic acid.
3037414|NCT02311946|Experimental|Cohort 5|Cohort 5 will receive a 125 mg oval yellow palbociclib fluid bed granulation tablet with succinic acid.
3037415|NCT02311946|Experimental|Cohort 6|Cohort 6 will receive a 125 mg palbociclib oral solution
3037416|NCT02311933|Experimental|Arm I (z-endoxifen hydrochloride)|Patients receive z-endoxifen hydrochloride PO on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3037417|NCT02311933|Experimental|Arm II (tamoxifen citrate)|Patients receive tamoxifen citrate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression and bone metastases may cross over to Arm I and receive z-endoxifen hydrochloride starting no later than 28 days after documentation of disease progression.
3037418|NCT02311920|Experimental|Arm I (temozolomide and ipilimumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 90 minutes once every 4 weeks for 4 courses and then beginning 3 months after course 4 once every 3 months for 4 courses in the absence unacceptable toxicity.
3037419|NCT02311920|Experimental|Arm II (temozolomide and nivolumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 60 minutes once every 2 weeks for 16 weeks and then once every 2 weeks for 48 weeks in the absence unacceptable toxicity.
3037420|NCT02311920|Experimental|Arm III (temozolomide, nivolumab, ipilimumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 90 minutes once every 4 weeks for 4 courses and nivolumab IV over 60 minutes once every 2 weeks for 64 weeks in the absence unacceptable toxicity.
3037421|NCT02311907|Experimental|Arm I (glutathione, carboplatin)|Patients receive glutathione intravenously (IV) over 15 minutes, paclitaxel* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
3037422|NCT02311907|Placebo Comparator|Arm II (placebo, paclitaxel)|Patients receive placebo IV over 15 minutes, paclitaxel* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
3037423|NCT02311894|Experimental|Somatropin|Children will receive daily SC injections of somatropin at a dose of up to 0.043 milligrams per kilogram per day (mg/kg/day) for 1 year.
3037424|NCT02311881|Experimental|Paracetamol 2000 mg twice daily (BID)|Participants will be instructed to take two active paracetamol 1000 mg SR tablets twice daily (with 10-12 hours between adjacent doses) and two placebo to match paracetamol 665 mg SR tablets thrice daily (with 6-8 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
3037425|NCT02311881|Active Comparator|Paracetamol 1330 mg thrice daily (TID)|Participants will be instructed to take two active paracetamol 665 mg SR tablets orally thrice daily (with 6-8 hours between adjacent doses) and two placebo to match paracetamol 1000 mg SR tablets orally twice daily (with 10-12 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
3037426|NCT02311881|Placebo Comparator|Placebo|Participants will be instructed to take two placebo to match paracetamol 1000 mg SR tablets twice daily (with 10-12 hours between adjacent doses) and two placebo to match paracetamol 665 mg SR tablets thrice daily (with 6-8 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
3037427|NCT02311868|Experimental|SYNBIOTIC|Patients of this group assumed Probinul-Neutro® po 5g three times a day for 30 day
3037428|NCT02311868|Placebo Comparator|Placebo|patients of this group received 5g of placebo 3 times a day for 30 days
3037429|NCT02311855|Other|Influenza vaccination|all patients are vaccinated per protocol
3037430|NCT02311829|Experimental|Telephone follow-up device (DST)|"An external independent clinical psychologist is responsible for calling regular the patient included in DST-arm.~Telephone follow-up device(DST) consists of telephone calls at 15 day, 2 month and then every 2 months until 12 months. The clinical psychologist is designed to inform the patient about its pathology, promote acceptance of diagnosis, support the patient in his approach to care encouraging psychiatric observation. The device does not replace psychiatric counseling recommended."
3037431|NCT02311829|No Intervention|Group control ; usual care|"- Usual care: After diagnosis of PNES: orientation psychiatric care or CMP liberal and meeting biannually with the neurologist~- For patients in both groups: in addition, quotation questionnaires of quality of life and evaluation by a neuropsychologist biannual for 24 months after the appointment with the neurologist."
3037432|NCT02311816||Infection|"Based on the microbiological results and clinical picture patients were grouped post hoc into infection and no infection groups by two independent experts (intensivist, infectologist) who were blinded for procalcitonin."
3037433|NCT02311816||No infection|"Based on the microbiological results and clinical picture patients were grouped post hoc into infection and no infection groups by two independent experts (intensivist, infectologist) who were blinded for procalcitonin."
3037434|NCT02311803|Experimental|Preservation of Denonvilliers Fascia|Preservation of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery for male mid-low rectal cancer patients
3037435|NCT02311803|Active Comparator|Excision of Denonvilliers Fascia|Excision of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery for male mid-low rectal cancer patients
3037436|NCT02311790|Experimental|Trans-C16:1 supplement|Volunteers will take trans-C16:1 supplement for 3 weeks
3037437|NCT02311790|Experimental|Cis-C16:1 supplement|Volunteers will take cis-C16:1 supplement for 3 weeks
3037438|NCT02311777|Active Comparator|Pregabalin-ketamine|Pregabalin and ketamine will be given preoperative period
3037439|NCT02311777|Placebo Comparator|Placebo|Placebo will be given preoperative period
3037440|NCT02311764|Experimental|Carboplatin|Carboplatin will be administered weekly
3037441|NCT02311751|Active Comparator|Active rTMS|"Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 25 simulation trains of 30 stimuli each (i.e., 750 stimuli) and an intertrain interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right dorsolateral prefrontal cortex (DLPFC). The order of bilateral stimulation (i.e. right then left or left than right) will be held constant for all 20 treatments.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
3037442|NCT02311751|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
3037443|NCT02311738|Experimental|High intensity training group|"HIE will consist of the following:~10 minute warm up at 70% of maximal heart rate.~4 minute exercise intervals at 90-95% of maximal heart rate.~4 minute interval bouts repeated 4 times.~Between each bouts there will be a 3 minute active recovery at 70% of maximal heart rate~After all four bouts are completed; 5 minute cool-down at 70% of maximal heart rate."
3037444|NCT02311738|Experimental|Moderate intensity training group|"MIE will consist of the following:~10 minute warm up at 50% of maximal heart rate.~35 minutes exercise at 70% of maximal heart rate.~4 minute cool-down at 50% of maximal heart rate."
3037445|NCT02311725|Experimental|aTAU + sTVi|"Antidepressant Treatment as Usual (aTAU): All participants will receive antidepressant treatment as usual provided by their primary care doctor during the study.~Storytelling Video Intervention (sTVi): We will develop a series of 4 videos, each episode approximately 30 minutes long, which will illustrate the key principles of Acceptance and Commitment Therapy.~In addition, we will develop an accompanying personal journal for participants that includes a brief self-help guide which encourages participants to write about what they learned in the videos and how they will take similar steps in their own lives to cope with depression."
3037446|NCT02311725|Active Comparator|aTAU + Attention Control Videos|"Antidepressant Treatment as Usual (aTAU): All participants will receive antidepressant treatment as usual provided by their primary care doctor during the study.~Attention Control Videos: Control participants will view videos about general mental health and well-being. Specifically, we plan to give participants 4 30-minute videos on topics including nutrition, stress reduction, movement and recreation, and becoming an educated patient. The series comes with an accompanying course guidebook. We will provide videos on the same schedule as sTVi."
3037447|NCT02311712|Active Comparator|Capsule sponge|Capsule sponge cytology examination coupled with H&E staining analysed for the presence of atypia and p53 immunohistochemistry
3037448|NCT02311712|No Intervention|Control|No intervention
3037449|NCT02311699|Experimental|Women Only|Groups of women will receive the behavioral intervention to reduce IPV and HIV. Sessions will be led by female facilitators.
3037450|NCT02311699|Experimental|Men Only|Groups of men will receive the behavioral intervention to reduce IPV and HIV. Sessions will be led by male facilitators.
3037451|NCT02311699|Experimental|Couples|Couples will receive the behavioural intervention to reduce IPV and HIV. Sessions will be led by a male and a female facilitator.
3037453|NCT02311686|Experimental|10 g ethanol|Subjects will be required to drink a dilution of 31 mL of vodka in 369 mL of lemon-flavored water in 15 minutes.
3037454|NCT02311686|Experimental|20 g ethanol|Subjects will be required to drink a dilution of 63 mL of vodka in 337 mL of lemon-flavored water in 15 minutes.
3037455|NCT02311686|Experimental|40 g ethanol|Subjects will be required to drink a dilution of 125 mL of vodka in 275 mL of lemon-flavored water in 15 minutes.
3037456|NCT02311686|Experimental|60 g ethanol|Subjects will be required to drink a dilution of 188 mL of vodka in 212 mL of lemon-flavored water in 15 minutes.
3037457|NCT02311686|Experimental|80 g ethanol|Subjects will be required to drink a dilution of 250 mL of vodka in 150 mL of lemon-flavored water in 15 minutes.
3037458|NCT02311673|Active Comparator|RM-493 Once Daily Dose 1|Dose 1 once daily in the morning
3037459|NCT02311673|Active Comparator|RM-493 Once Daily Dose 2|Dose 2 once daily in the morning
3037460|NCT02311673|Placebo Comparator|Placebo|Placebo in the morning
3037461|NCT02311660|Experimental|vagus nerve stimulation|Patients will have an implanted vagus nerve stimulation device.
3037462|NCT02311647||Post Tamoxifen exposure group|Breast cancer patients receiving or formerly received Tamoxifen for at least 1 year.
3037463|NCT02311647||Control group|Breast cancer patients who did not receive endocrine treatment
3037464|NCT02311634|Experimental|Electrical pudendal nerve stimulation|At a frequency of 2.0 Hz and a moderate intensity (25~35 mA); 60 minutes three times a week for a total of three weeks
3037465|NCT02311634|Active Comparator|Transvaginal ES|At a current intensity of < 60 mA (in 5% increments from 0 mA to the intensity that is sensed without obvious discomfort) and frequencies of 12.5 to 30 Hz, 45 min three times a week for a total of four weeks.
3037466|NCT02311621|Experimental|A: 2nd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
3037467|NCT02311621|Experimental|B: 3rd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
3037468|NCT02311621|Experimental|C: Long Spacer 2nd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
3037469|NCT02311608||High Dose Somatostatin/Octreotide|continuous IV infusion of 500μg/h of Somatostatin or continuous IV infusion of 50μg/h of Octreotide when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
3037470|NCT02311608||Terlipressin as salvage|an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
3037471|NCT02311608||Terlipr+usual dose somato/Octreo|an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h together with continuous IV infusion of 250μg/h of Somatostatin or continuous IV infusion of 25μg/h of Octreotide when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
3037472|NCT02311608||Control:Usual Dose Somato/Octreo|Hemostasis achieved by continuous IV infusion of 250μg/h of Somatostatin or continuous IV infusion of 25μg/h of Octreotide
3037473|NCT02311608||Control: Initial Terlipressin|Hemostasis achieved by an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h
3037474|NCT02311595|Experimental|reduced port|gastric cancer patients go through reduced port laparoscopic distal gastrectomy with D2 lymph node dissection
3037475|NCT02311582|Experimental|Phase I: MK-3475 + MLA|-In the phase I portion of this study, MK-3475 will be given every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.
3037476|NCT02311582|Experimental|Phase II: MK-3475 Only (Arm B)|"In the phase II portion of this study, MK-3475 will be given every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no debulking)~The phase II dose was determined during the Phase I portion of the study. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will be performed"
3037477|NCT02311582|Experimental|Phase II: MK-3475 + MLA (Arm A)|"In the phase II portion of this study, MK-3475 will be given every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no debulking).~The phase II dose will be determined during the phase I portion of this study and is 200 mg. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~--For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will be performed during MSA~MLA will take place at least 3 weeks but not more than 6 weeks after surgical resection/debulking or if no surgical resection/debulking will start on day 1"
3037478|NCT02311569|Experimental|Arm Mirabegron|Mirabegron treatment of at least 24 weeks with an initial dose of 25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
3037522|NCT02311114||Telehomecare patients|Observational fieldwork, in depth interviews and surveys up to 4 times will be conducted.
3037479|NCT02311556|Experimental|DSC-PMR|DSC-PMR (dynamic susceptibility-weighted contrast- enhanced perfusion magnetic resonance imaging) at baseline (screening or time of radiosurgery) and after radiosurgery
3037480|NCT02311543|No Intervention|Arm A: no TachoSil®|After axillary lymph node dissection no surgical sealing patch (TachoSil®) is applied.
3037481|NCT02311543|Active Comparator|Arm B: TachoSil®|After axillary lymph node dissection, 3 large TachoSil® patches in the dissected axilla are positioned to cover as much of the axillary walls as possible.
3037482|NCT02311530|Experimental|Test|Felodipine Extended Release Tablets USP 10 mg
3037483|NCT02311530|Active Comparator|Reference|Plendil® Extended release tablets 10 mg
3037484|NCT02311517|Experimental|ropivacaine group|45 patients will be randomly allocated into ropivacaine group with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia.
3037485|NCT02311517|Placebo Comparator|saline group|40 patients are randomly allocated into saline group with 0.4 ml/kg saline after induction of anesthesia.
3037486|NCT02311504||DiabCheck ophta OCTplus|persons with diabetes undergoing OCT examination
3037487|NCT02311491|Experimental|Ceramic Coated Orthodontic Archwire|Ceramic coated orthodontic archwires will be evaluated in a limited clinical study at the university of North Carolina to test their efficacy in early and intermediate stages of tooth straightening in orthodontic patients.
3037488|NCT02311491|No Intervention|Control|The patients will receive the ordinary archwires. There is no intervention to the standard treatment.
3037489|NCT02311478|Experimental|T380A Copper IUD|All participants will receive a T380A copper intrauterine device when enrolled. They can continue using the device for as long as they wish. The study will be completed when 6 months of prospective bleeding data has been collected.
3037490|NCT02311465|Experimental|Palliative Care + Standard of Care|Consenting patients will be approached by a research nurse to complete quality of life questionnaires (baseline measures) either in the oncology clinics or infusion clinics. Patients assigned to early palliative care will meet with a member of the palliative care team after enrollment and completion of the initial questionnaires to receive and review patient-oriented materials detailing palliative care services. Patients will then receive a comprehensive initial consult with a palliative care provider (a trained physician, nurse or nurse practitioner). Additional consults with the palliative care service will be scheduled approximately every 6 weeks for the duration of the study period (one year) at the discretion of the patient and palliative care provider.
3037491|NCT02311465|No Intervention|Standard of Care|Patients will receive standard care from their oncologist. An assessment of health related quality of life will be conducted at regular oncology clinic visits at baseline and 3,6,9,and 12 months.
3037492|NCT02311452||Acute Osteomyelitis|
3037493|NCT02311452||Complicated Pneumonia|
3037494|NCT02311452||Complicated Appendicitis|
3037495|NCT02311439|Experimental|FOLFIRINOX + CRT|FOLFIRINOX regimen, consisted of oxaliplatin, irinotecan, leucovorin and fluorouracil (5-FU), for 4 cycles, followed by consolidation radiotherapy concurrent with capecitabine 625mg/m2 BID in non-progressed cases, in treating patients with locally advanced cancer pancreas.
3037496|NCT02311426||Norway|500 consecutive patients with stroke from the stroke units at the University Hospital of North Norway located in the cities Narvik, Harstad and Tromsø.
3037497|NCT02311426||Denmark|500 consecutive patients from the stroke unit at Århus Hospital in Denmark.
3037498|NCT02311413|Experimental|Cat-PAD|Subjects will be treated with four monthly doses of Cat-PAD, a peptide immunotherapy product consisting of Fel d 1 synthetic peptide immunoregulatory epitopes (SPIRE).
3037499|NCT02311413|Placebo Comparator|Placebo|Subjects will be treated with 4 monthly doses of Placebo.
3037500|NCT02311361|Experimental|3/B1 (was removed with Amendment A)|Tremelimumab + 8 Gy in 1 fraction
3037501|NCT02311361|Experimental|1/A1|Durvalumab + 8Gy in 1 fraction
3037502|NCT02311361|Experimental|2/A2|Durvalumab +5 Gy in 5 fractions
3037503|NCT02311361|Experimental|4/B2 (was removed with Amendment A)|Tremelimumab + 5 Gy in 5 fractions
3037504|NCT02311361|Experimental|5/C1|Durvalumab +Tremelimumab + 8 Gy in 1 fraction
3037505|NCT02311361|Experimental|6/C2|Durvalumab +Tremelimumab +5 Gy in 5 fractions
3037506|NCT02311335||1|Dyslipidemia patients
3037507|NCT02311309||control|Patients with either transfusion with pre ordered packed red blood cells or hemoglobin concentration > 8 g/dL.
3037508|NCT02311309||unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or hemoglobin concentration < 8 g/dL.
3037509|NCT02311231|Experimental|bivalirudin|bivalirudin as intravenous bolus of 0,75 mg per kilogram followed by an infusion of 1,75 mg per kilogram per hour
3037510|NCT02311231|Active Comparator|heparin|unfractionated Heparin 5 000 IU/ml as intravenous bolus according to local practice
3037511|NCT02311218|Active Comparator|Test group with L. reuteri|Subjects in the test group take one Lactobacillus reuteri DSM 17938 and PTA 5289 containing lozenge in the morning and one in the evening.
3037512|NCT02311218|Placebo Comparator|Placebo group without L. reuteri|Subjects in the placebo group take one placebo lozenges with same look, taste and smell as the test lozenge but lacking the Lactobacillii the morning and one in the evening.
3037513|NCT02311205|Experimental|TACE+sorafenib|Concurrent Conventional Transarterial Chemoembolization (TACE) and Sorafenib
3037514|NCT02311192|Experimental|Ultrasonography B-scan|Patients of uveitis who are included in the study will be imaged using ultrasound B-scan
3037515|NCT02311179|Active Comparator|Prosthesis, BoneMaster-Exceed cup|Prosthesis, BoneMaster-Exceed cup: A hemispheric joint cup of the type Exceed cup (Biomet) characterized by a porous surface of titanium plasma spray. The surface is coated with hydroxyapatite deposited electrochemically (BoneMaster)
3037516|NCT02311179|Active Comparator|Prosthesis Exceed cup without HA|Prosthesis Exceed cup without HA: A hemispheric joint cup of the type Exceed cup (Biomet) characterized by a porous surface of titanium plasma spray
3037517|NCT02311153|Active Comparator|Endotracheal intubation|Endotracheal intubation for airway management and ventilation during sinonasal surgical procedure
3037518|NCT02311153|Experimental|Laryngeal mask airway|Laryngeal mask for airway management and ventilation during sinonasal surgical procedure
3037519|NCT02311140||Cystic Fibrosis patients with G551D mutation|
3037520|NCT02311127|Experimental|SecurAcath|Subcutaneous securement
3037523|NCT02311114||Health care providers|In-Depth interviews, observational fieldwork and one time survey will be conducted.
3037524|NCT02311114||Telehomecare administrators|In depth interviews will be conducted
3037525|NCT02311114||Telehomecare technicians|In-depth interviews, observational fieldwork will be conducted.
3037526|NCT02311101|Experimental|Therapy Group MMC 10/BCG Half|"Intravesical Mitomycin C and intravesical BCG~First intravesical mitomycin C (10 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (half dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The first 3 participants received 10mg of MMC and half dose of BCG. The dose was assigned in order of enrollment."
3037527|NCT02311101|Experimental|Therapy Group MMC 10/BCG Full|First intravesical mitomycin C (10 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The following 3 participants received 10mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
3037528|NCT02311101|Experimental|Therapy Group MMC 20/BCG Full|First intravesical mitomycin C (20 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The next 3 participants enrolled received 20mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
3037529|NCT02311101|Experimental|Therapy Group MMC 40/BCG Full|First intravesical mitomycin C (40 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The last 3 participants received 40mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
3037530|NCT02311088|Experimental|Caffeine|Caffeine capsules. 200 mg twice daily orally for 7-10 days.
3037531|NCT02311088|Placebo Comparator|Placebo|Matching placebo capsules twice daily orally for 7-10 days.
3037532|NCT02311075|Experimental|Patient comparative approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples.
3037533|NCT02311075|Experimental|Control subjects comparative approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples.
3037534|NCT02311075|Experimental|Healthy volunteers metabolic approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples during hyperglycemia or hyperinsulinemia.
3037535|NCT02311062|Experimental|Eccentric hamstring exercises|Three workouts per week on non-consecutive days for 6 weeks. 1)Assisted Nordic Curl: Kneeling on the ground with ankles fixed by a partner, participant lowering the trunk to the ground by eccentrically contracting the hamstrings. 2) Eccentric single stiff-legged dead lift: From standing position with the arm crossing over the chest, participant lowering the body toward the ground by flexing the hip joint without bending the support leg knee and raising the other leg until form an straight line with the trunk4 3) Eccentric double stiff-legged dead lift: From standing position with the arm crossing over the chest, participant lowering the body toward the ground by flexing the hip joint without bending the knees until the body parallel with the floor.
3037536|NCT02311062|Experimental|Unistable exercises|Trained 3 times per week on non-consecutive days for 6 weeks for a total of 18 training sessions. UNS training consisted in the following three exercises: 1) One leg squat: Standing on the floor on one leg only and squat down until knee flexed to 900 and press back up with just that single leg. 2) One leg Squat on Bosu® balance Trainer: Standing on the Bosu® balance Trainer on one leg only and squat down until supported leg knee flexes to 900 and press back up with just that single leg. 3) Forward lunges on a Bosu® balance Trainer: position the forward leg on the Bosu® balance Trainer and squatting with the forward leg.
3037537|NCT02311062|Active Comparator|Control|Participants did not undergo any resistance training and continued with their regular soccer training.
3037538|NCT02311049|Experimental|Arm 1|16 fractions à rato of 4 fractions a week over 4 weeks
3037539|NCT02311049|Experimental|Arm 2|25 fractions à rato of 5 fractions a week over 5 weeks
3037540|NCT02311036|Other|Comorbidity_Comprehensive Rehabilitation|Charlson Comorbidity Index contains 19 categories of comorbidity and predicts the ten-year mortality for a patient who may have a range of co-morbid conditions Each condition is assigned with a score of 1,2,3 or 6 depending on the risk of dying associated with this condition. For a physician, it is helpful in knowing how aggressively to treat a condition. Higher scores indicating greater comorbidity (patients with a score > 5 have essentially a 100% risk of dying at one year).
3037541|NCT02311036|Other|MRS_Comprehensive Rehabilitation|The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.
3037542|NCT02311036|Other|MMSE_Comprehensive Rehabilitation|The mini mental state examination (MMSE) is the most commonly used instrument for screening cognitive function. This examination is not suitable for making a diagnosis but can be used to indicate the presence of cognitive impairment, such as in a person with suspected dementia or following a head injury. The examination has been validated in a number of populations. Scores of 25-30 out of 30 are considered normal; the National Institute for Health and Care Excellence (NICE) classifies 21-24 as mild, 10-20 as moderate and <10 as severe impairment. The MMSE may not be an appropriate assessment if the patient has learning, linguistic/communication or other disabilities (eg, sensory impairments).
3037610|NCT02310555|Active Comparator|Gastric bypass|classic Gastric bypass
3037611|NCT02310555|Active Comparator|Modified gastric bypass.|Modified gastric bypass. Resection body and fundus gastric
3037543|NCT02311036|Other|BSRS_Comprehensive Rehabilitation|Brief Symptom Rating Scale is a rating scale which a clinician or researcher may use to measure psychiatric symptoms such as depression, anxiety, hallucinations and unusual behavior. Each symptom is rated 1-7 and depending on the version between a total of 18-24 symptoms are scored. The scale is the one of the oldest, widely used scales to measure psychotic symptoms and was first published in 1962.
3037544|NCT02311023|Experimental|Intermittent fasting|Patients consume their normal diet for 5 days in the week. On 2 days they only consume 500 Cals if female and 600 Cals if male.
3037545|NCT02311010|No Intervention|CYP 3 A 5 *3/*3 control group|CYP 3 A 5 *3/*3 control group will receive 0,20 mg/kg of Advagraf®
3037546|NCT02311010|Active Comparator|CYP 3 A 5 *3/*3|CYP 3 A 5 *3/*3 will receive 0,25 mg/kg of Advagraf®
3037547|NCT02311010|Active Comparator|CYP 3 A 5 *1/*3|CYP 3 A 5 *1/*3 will receive 0,30 mg/kg of Advagraf®
3037548|NCT02311010|Active Comparator|CYP 3 A 5 *1/*1|CYP 3 A 5 *1/*1 will receive 0,35 mg/kg of Advagraf®
3037549|NCT02310997|Experimental|Fludarabine + Cyclophosphamide + TBI|"Patients aged 2-45 years (excluding AML, JMML and MDS patients aged <16 years) will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:~Fludarabine 25mg/m^2/day day -8 to -6 (total 75mg/m^2) Cyclophosphamide 60mg/kg day -7 and -6 (total 120mg/kg) Total body irradiation 13 - 14.4Gy in 6-8 fractions"
3037550|NCT02310997|Experimental|Busulfan + Cyclophosphamide + Melphalan|"Patients aged < 2 years and AML, JMML and MDS patients <16 years will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:~Busulfan 3.2mg/kg/day in 2 or 4 doses per day, days -9 to -6 (total 12.8mg/kg). Cyclophosphamide 60mg/kg days -4 and -3 (total 120mg/kg) Melphalan 140mg/m^2 day -2"
3037551|NCT02310971|Experimental|Biologic/Vaccine|Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
3037552|NCT02310958||Children with inguinal hernia|Laparoscopic surgical hernia repair in children aged between 1 day and 16 years
3037553|NCT02310945||Knee osteoarthritis|People with moderate/severe symptomatic knee osteoarthritis referred for physiotherapy
3037554|NCT02310932|Experimental|Healthy Living Intervention|The Healthy Living Intervention group will participate in an intervention designed to improve depression, anxiety, diabetes and CVD outcomes. This will be achieved through a 12 month intervention which consists of participation in healthy living groups and integrated collaborative clinic care at their Primary Health Clinic (PHC).
3037555|NCT02310932|Placebo Comparator|Enhanced Standard Care Model|"Patients in control groups will receive an enhanced standard care model, which includes providing referrals for mental health needs."
3037556|NCT02310919|Experimental|Low dose hCG plus FSH co-trigger|On the day of ovulation trigger the patient will receive hCG 1,500 IU SQ plus FSH 450 IU SQ
3037557|NCT02310919|Active Comparator|Standard dose of hCG alone|On the day of ovulation trigger the patient will receive standard dose of hCG (10,000 or 5,000 IU SQ)
3037558|NCT02310906|Experimental|Part 1: SRP-4053|Patients will receive SRP-4053 intravenous (IV) infusions, weekly, at escalating dose levels as follows: Weeks 1-2, 4 mg/kg/week; Weeks 3-4, 10 mg/kg/week; Weeks 5-6, 20 mg/kg/week; Weeks 7-12, 30 mg/kg/week. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
3037559|NCT02310906|Placebo Comparator|Part 1: Placebo|Patients will receive SRP-4053 placebo-matching IV infusions, weekly, for 12 weeks. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
3037560|NCT02310906|Experimental|Part 2: SRP-4053|All eligible patients from Part 1, as well as new patients, will receive SRP-4053 30 mg/kg/week IV infusions, weekly, for up to 168 weeks.
3037561|NCT02310906|No Intervention|Part 2: Untreated Group|Patients with DMD who have a genotypically confirmed deletion of exon(s) not amenable to treatment by exon 53 skipping, but who otherwise meet the same eligibility criteria as treated patients newly recruited to Part 2, will undergo the same study assessments as treated Patients (except for pharmacokinetic [PK] sampling and muscle biopsies), but at a reduced schedule through Week 144.
3037562|NCT02310893|Active Comparator|Contingency Management only|Participants assigned to this arm will receive payments for attending regular HIV medical appointments at the clinic and filling prescribed HIV medications at the pharmacy
3037563|NCT02310893|Active Comparator|Peer Navigation only|Participants in this arm will be assigned a peer navigator to assist them in accessing and remaining in HIV care
3037564|NCT02310893|Experimental|Combined Contingency Management and Peer Navigation|Participants in this arm will be assigned a peer navigator to assist them in accessing and remaining in HIV care and will be eligible to receive incentives for attending HIV care visits/refilling prescriptions.
3037565|NCT02310893|No Intervention|Usual care|Participants in this arm will receive the care that they would usually get in their clinic in the absence of this study.
3037566|NCT02310880||Low vision (virtual street training)|Low vision subjects trained in virtual streets and observed in real streets
3037567|NCT02310880||Low vision (real street training)|Low vision subjects trained in real streets and observed in real streets
3037568|NCT02310867|Experimental|Hand transplant with Belatacept|
3037569|NCT02310854|Active Comparator|ACL Reconstruction|Primary reconstructive surgery of ACL with hamstring autograft (All-inside, Arthrex, Napels, Florida, USA)
3037570|NCT02310854|Experimental|ACL Repair|Primary augmented suture of ACL using Dynamic Intraligament Stabilization (DIS; Mathys Medical Bettlach, Switzerland)
3037571|NCT02310841|Experimental|unilateral transfemoral amputees|
3037572|NCT02310828|Experimental|Acetium|Patient will administer Acetium capsules (100mg l-cysteine) twice a day for one month
3037573|NCT02310828|Placebo Comparator|Placebo|Patient will administer placebo capsules twice a day for one month
3037574|NCT02310802|Experimental|OBE001 dose 1|
3037575|NCT02310802|Experimental|OBE001 dose 2|
3037576|NCT02310802|Experimental|OBE001 dose 3|
3037577|NCT02310802|Placebo Comparator|Placebo|
3037612|NCT02310555|Active Comparator|Slevee Gastrectomy|Slevee Gastrectomy
3037613|NCT02310542|Experimental|MARS-SPAD|Patients will receive first the MARS albumin dialysis system and then, in a second time, the SPAD albumin dialysis system.
3037957|NCT02308163|Active Comparator|Reference drug group|Etanercept will administered
3037578|NCT02310789|Experimental|Ivacaftor|Participants will receive ivacaftor orally for 3 days, followed by 35 days off drug. Participants will repeat this cycle then receive ivacaftor for 3 additional days. For sweat testing, participants will receive β-adrenergic cocktail to stimulated sweating, at both 1% stimulation strength and full stimulation strength. Each participant will also receive pilocarpine nitrate 5% administered by Macroduct sweat stimulator device. Sweat stimulation testing will be done on- and off-ivacaftor.
3037579|NCT02310776|Other|Automated & Handheld breast US exams|"Automated breast ultrasound exam: 3D supine automated breast ultrasound scanner.~Handheld breast ultrasound exam: High-resolution handheld breast ultrasound."
3037580|NCT02310763|Experimental|PF-06252616|3 dose levels (5mg/kg, 20mg/kg and 40 mg/kg) of IV infused PF-06252616 will be investigated within each subject
3037581|NCT02310763|Placebo Comparator|Placebo|Matching Placebo
3037582|NCT02310750|Experimental|PF-06700841 Oral Solution/Suspension|
3037583|NCT02310750|Experimental|PF-06700841 Tablet|
3037584|NCT02310750|Placebo Comparator|Placebo|Oral placebo comparator for the healthy subject single and multiple ascending dose periods, and the psoriasis multiple dose period. No placebo used for the bioavailability investigation.
3037585|NCT02310737|Active Comparator|sharp incision|the patients who were included as the control group (Group 1) with sharp fascia incision
3037586|NCT02310737|Active Comparator|blunt incision|the patients who were included as the another group (Group 2) with blunt fascia incision
3037587|NCT02310724||TODAY cohort|All subjects randomized to the TODAY clinical trial are eligible to participate in T2P2. The study performs long-term observation only and administers no treatment, care, or management.
3037588|NCT02310698||Breast Cancer Screening Patients|"Women presenting for screening full field digital mammography (FFDM) and WBUS on the same day or within 30 days of one another.~o These women will be offered CEDM instead of the FFDM.~Women that are scheduled for CEDM alone.~o These women will be offered WBUS in addition to the CEDM.~Women scheduled for both CEDM and WBUS on the same day or within 30 days of one another."
3037589|NCT02310685|Active Comparator|Intervention|Active Comparator: Intervention The primary focus is CVD risk factors. Subjects will be shown how to update Cardiovascular Age or Cardiometabolic Age on website. Pharmacists will give overview of comprehensive ehealth wellness program. Subjects will complete additional health assessments which include questionnaires considered gold standard. Pharmacists will explain that participants have access to ehealth coaching based educational modules with information relevant to a better understanding of cardiovascular risk factors. The ehealth coaching modules are guides to help understand risk factors and importance of making lifestyle changes. As information alone is often insufficient to promote change, participants will have access to online physical activity challenges.
3037590|NCT02310685|No Intervention|No Intervention|Individuals randomized to the non active intervention group will have access to modified version of ehealth website. The pharmacist will show participants how to update Cardiovascular Age or Cardiometabolic Age on website. They will have access to health assessments but not ehealth coaching educational modules or challenges. They will have online support tools including public domain education material on exercise, healthy eating, understanding and managing blood pressure, diabetes and smoking cessation. Participants will return to the pharmacist for follow-up visits at 3, 6 months and one year. The pharmacist will update their cardiovascular risk profile with current information At the first follow up visit and at 1 year participants will be asked to have blood lipids reassessed.
3037591|NCT02310672|Experimental|Macitentan|All patients take open-label macitentan 10mg o.d.
3037592|NCT02310659||lower calcificant score group|patients with coronary artery calcificant score <400
3037593|NCT02310659||higher calcificant score group|patients with coronary artery calcificant score ≥400
3037594|NCT02310646|Active Comparator|Treatment group 1|Day 1 to 7: LEO 90100 aerosol foam Day 8 to 14: Daivobet® gel
3037595|NCT02310646|Active Comparator|Treatment group 2|Day 1 to 7: Daivobet® gel Day 8 to 14: LEO 90100 aerosol foam
3037596|NCT02310633|Active Comparator|Memory Strategy Training|This arm involves intervention that teaches participants to use active encoding strategies to learn and remember new information.
3037597|NCT02310633|Active Comparator|Errorless Learning|This arm involves intervention that enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase.
3037598|NCT02310633|Active Comparator|Retrieval Practice|This arm involves intervention that enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue.
3037599|NCT02310620|Experimental|Cognitive Training|
3037600|NCT02310594||Ancillary-Correlative (blood banking)|Samples of blood are collected before, during, and within two weeks after radiation therapy and then stored for analysis of anti-tumor immunity.
3037601|NCT02310581|Experimental|Buprenorphine 0.5 mg TID|Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) and placebo-matching buprenorphine sublingual spray once daily (QD) for two days.
3037602|NCT02310581|Experimental|Buprenorphine 1.0 mg BID|Participants received buprenorphine 1.0 mg sublingual spray twice daily (BID) and placebo-matching buprenorphine sublingual spray BID for two days.
3037603|NCT02310581|Experimental|Buprenorphine 1.0 mg TID|Participants received buprenorphine 1.0 mg sublingual spray TID and placebo-matching buprenorphine sublingual spray QD for two days.
3037604|NCT02310581|Placebo Comparator|Placebo|Participants received placebo-matching buprenorphine sublingual spray four times daily for two days.
3037605|NCT02310568|Experimental|PF 06372865 2.5 mg BID then placebo.|PF 06372865 2.5 mg tablet 2 times daily for 4 weeks (Stage 1), followed by placebo 2 times daily for 4 weeks (Stage 2).
3037606|NCT02310568|Experimental|PF 06372865 7.5 mg BID then placebo.|PF 06372865 2.5 mg tablet 2 times daily for one week, then PF 06372865 7.5 mg tablet 2 times daily for 3 weeks (Stage 1), followed by placebo (2 times daily) for 4 weeks (Stage 2).
3037607|NCT02310568|Experimental|Placebo then PF 06372865 2.5 mg BID.|Placebo 2 times daily for 4 weeks (Stage 1), followed by PF 06372865 2.5 mg tablet 2 times daily for 4 weeks
3037608|NCT02310568|Experimental|Placebo then PF 06372865 7.5 mg BID.|Placebo 2 times daily for 4 weeks (Stage 1), followed by PF 06372865 2.5 mg tablet 2 times daily for one week, then PF 06372865 7.5 mg tablet 2 times daily for 3 weeks (Stage 2).
3037609|NCT02310568|Placebo Comparator|Placebo followed by placebo.|Placebo 2 times daily for 4 weeks (Stage 1) followed by Placebo 2 times daily for 4 weeks (Stage 2).
3037614|NCT02310542|Experimental|SPAD-MARS|Patients will receive first the SPAD albumin dialysis system and then, in a second time, the MARS albumin dialysis system.
3037615|NCT02310529|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group). IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected. Intervention will be delivered by trained clinical psychologists.
3037616|NCT02310529|No Intervention|Treatment as usual|Patients including in this group will be taking only treatment as usual (in Pakistan it means that participants attending in outpatients' clinic at regular intervals and may or may not be taking prescribed medication).
3037617|NCT02310516|Experimental|Patient with preoperative device|patients undergoing brain awake surgery with adequate explanations which are provided preoperatively. Preoperative device corresponds to a pre/ perioperative coaching involving the provision of a comprehensive information support on the awake surgery (short video and information brochure) and an interview with an operating room nurse
3037618|NCT02310516|Active Comparator|Patient with standard procedure|patients undergoing brain awake surgery with standard procedure (without adequate explanations)
3037619|NCT02310503||Mohs surgery|Patients treated using Mohs surgery. Other exposures considered include patient characteristics, preoperative care and technical variants.
3037620|NCT02310490|Active Comparator|Right Side DermaVeil, Left Side Sculptra|DermaVeil right with left side Sculptra left side
3037621|NCT02310490|Active Comparator|Left Side DermaVeil, Right Side Sculptra|DermaVeil left with left side Sculptra right side
3037622|NCT02310464|Experimental|Dose escalation|Each subject will be given a total of 10 doses of OBI-833/OBI-821 subcutaneously at weeks 1,2,3,4,6,8,12,16,20,and 24 (Visits 1,2,3,4,5,6,7,8,9 and 10, respectively). Post treatment, subjects will be continually evaluated for safety and immune response every 4 weeks until the end of study, which is 12 weeks after the last dose, i.e., week 36. Subsequently, subjects will be followed for survival every 8 weeks up to 12 months after the end of study.
3037623|NCT02310464|Experimental|Cohort expansion phase|Each subject will be given OBI-833/OBI-821 at Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, and every 8 weeks thereafter (Visits 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and every 8 weeks thereafter) until disease progression. For the subjects discontinued treatment because of disease progression, subjects will be continually evaluated for safety and immune response every 8 weeks until the end of the study, which is 24 weeks after the last dose.
3037624|NCT02310451|Experimental|metastatic melanoma|Patients affected by advanced melanoma not resectable (stage IIIc) or metastatic (stage IV)
3037625|NCT02310438|Experimental|Early intervention music therapy|"music therapy:~6 stroke patients with hemiparesis begin music therapy treatment in their home as soon as they have completed statutory NHS community rehabilitation."
3037626|NCT02310438|Active Comparator|Delayed intervention music therapy|"music therapy:~6 stroke patients with hemiparesis begin music therapy treatment in their home 9 weeks after they have been randomised into the wait list group."
3037627|NCT02310425|Active Comparator|The study group|The study group received S. boulardii supplementation, 50 mg/kg twice daily, compared to no intervention in the control group.
3037628|NCT02310425|Placebo Comparator|The control group|A prospective, Placebo Comparator,randomized case-controlled trial was conducted in infants with a gestational age of 30 to 37 weeks and a birth weight between 1500 to 2500 g.
3037629|NCT02310412|Experimental|Amicus platelet components|The two stages of this pilot study consist of the following: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT treatment, storage for 7 days, collection of fresh platelets, radiolabeling, infusion of fresh and stored INTERCEPT treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). In Stage 1, apheresis platelets will be collected using the Amicus separator and stored for 7 days in 35% Plasma and 65% InterSol
3037630|NCT02310412|Experimental|Trima platelet components|The two stages of this pilot study consist of the following: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT treatment, storage for 7 days, collection of fresh platelets, radiolabeling, infusion of fresh and stored INTERCEPT treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). In Stage 2, apheresis platelets will be collected using the Trima separator and stored for 7 days in 100% plasma.
3037631|NCT02310399|Experimental|Pre-lingual Deafness|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in prelingiustically deaf children ages 18 months - 5 years
3037632|NCT02310399|Experimental|Post-Lingual Deafness|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in postlinguistically deaf children < 21 years of age
3037633|NCT02310386|Active Comparator|activated BEMER-device|Activated BEMER electromagnetic field therapy (BEMER, Innomed International, AG, Lichtenstein).
3037634|NCT02310386|Sham Comparator|inactivated BEMER-device|Inactivated BEMER electromagnetic field therapy (BEMER, Innomed International, AG, Lichtenstein).
3037635|NCT02310373|Experimental|Nicotine free hookah (herbal/steam stones) smoking|Healthy habitual Hookah smokers will undergo microneurography, myocardial contrast echocardiogram or venous occlusion plethysmography before and after nicotine free hookah smoking.
3037636|NCT02310360||Healthy volunteers|
3037637|NCT02310347|Experimental|Marinol|"generic name: dronabinol~dosage: 0.1 mg/kg~frequency: 2 times a single dose~duration: acute adminstration"
3037638|NCT02310347|Placebo Comparator|Placebo|Empty hard gelatin capsules
3037639|NCT02310334|Experimental|Unguided Pacing Strategy|Each participant will stay in the calorimeter (~24 hrs) on 2 different occasions. During the first visit, the participant will partake in an unguided exercise session.
3037640|NCT02310334|Experimental|Guided Pacing Strategy|Each participant will stay in the calorimeter (~24 hrs) on 2 different occasions. During the second visit, the participant will partake in a guided exercise session.
3037679|NCT02310022|Experimental|Drug Omega 3|4g (4 capsules) once a day, administered with food Other name MAT9001
3037680|NCT02310022|Active Comparator|Drug Omega 3 Comparator|4g (4 capsules) once a day, administered with food Other name Omega 3 Active Comparator
3037641|NCT02310321|Experimental|A2215 Dose Evaluation Part|In the dose-evaluation part, subjects will receive ASP2215 at assigned single dose for determination of MTD and/or RED. Treatment of AML in this study is composed of 3 periods of therapy: remission induction, consolidation, and maintenance. The decision of whether or not to proceed to the next dose will be made based on the occurrence of DLT during Cycle 1 of the induction period.
3037642|NCT02310321|Experimental|A2215 Dose Expansion Part|In the expansion part, subjects will receive ASP2215 at RED that has been determined in the dose-evaluation part, and the safety will be assessed based on the onset of DLTs during Cycle 1 of the induction and consolidation periods.
3037643|NCT02310308|Active Comparator|xylitol chewing gum|Intervention chewing gum administration Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
3037644|NCT02310308|Experimental|Xylitol-magnolia chewing gum|Intervention chewing gum administration Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
3037645|NCT02310308|Placebo Comparator|Control chewing gum|Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
3037646|NCT02310295|Active Comparator|IVB-Laser|Intravitreal Bevacizumab combined with focal laser therapy
3037647|NCT02310295|Active Comparator|IVTA-Laser|Intravitreal Triamcinolone combined with focal laser therapy
3037648|NCT02310295|Active Comparator|Laser|focal laser therapy
3037649|NCT02310282||Telemedicine|In-hospital telemedicine by a stroke expert aiming to assess stroke severity using the Unassisted TeleStroke Scale.
3037650|NCT02310269||Pasireotide|
3037651|NCT02310256|No Intervention|Usual care|
3037652|NCT02310256|Active Comparator|Five Plus|Exercise training
3037653|NCT02310243|Experimental|Palbociclib|"Phase1b: 125 mg palbociclib once daily for 21 days followed by 7 days of rest; this regimen will be chosen for the first dose to be evaluated.~phase IIa: single-agent palbociclib using the tolerable dose defined in the phase Ib part of the study is administered once daily for 21 days followed by 7 days of rest."
3037654|NCT02310230|Other|Blinded Group|Data from the ExSpiron Respiratory Variation Monitor (minute ventilation, tidal volume, and respiratory rate) will not be displayed. The anesthesia provider will care for the patient in the usual manner.
3037655|NCT02310230|Experimental|Monitor Group|The ExSpiron Respiratory Variation Monitor will display continuous real-time measurements of minute ventilation, tidal volume, and respiratory rate, and the anesthesia provider will be instructed to utilize this information in the care of the patient as they deem appropriate.
3037656|NCT02310217||1|Hypertensive
3037657|NCT02310217||2|Normotensive
3037658|NCT02310204|Experimental|multidisciplinary education program|individual and group education sessions over a 6-month period
3037659|NCT02310204|Active Comparator|Standard psoriasis care alone|Standard psoriasis care alone
3037660|NCT02310191||Stenting|Carotid stenting
3037661|NCT02310178|Other|Group/Cohort|all of the current bariatric surgeries are allowed in this prospective cohort study
3037662|NCT02310165|Other|Z-tract Insertion Technique|For this technique, the skin is pulled 2 cm downward before the paracentesis needle is inserted and advanced.
3037663|NCT02310165|Other|Coaxial Insertion Technique|For this technique, the needle is directly inserted to minimize the distance between he cutaneous tissue and ascites
3037664|NCT02310152|Active Comparator|Active Treatment: CBT|Cognitive Behavioral Therapy
3037665|NCT02310152|Experimental|Experimental Treatment: SPACE|Parent-Based Treatment of Childhood and Adolescent Anxiety Disorders
3037666|NCT02310139||Failed/Difficult Colonoscopy|Patients referred for colonoscopy because of previously failed attempt at complete caecal intubation.
3037667|NCT02310126|Active Comparator|etafilcon A(sphere)/etafilcon A(multi-focal)|Subjects were randomized to one of two lens wear sequences. subjects randomized to this sequence received etafilcon A (sphere) contact lens first and then the etafilcon A (multi-focal) contact lens second.
3037668|NCT02310126|Active Comparator|etafilcon A(multi-focal)/etafilcon A(sphere)|Subjects were randomized to one of two lens wear sequences. subjects randomized to this sequence received etafilcon A (multi-focal) contact lens first and then the etafilcon A (sphere) contact lens second.
3037669|NCT02310113||Hematologic outpatients|Chronic anaemic outpatients who are planed to get transfusion RBC
3037670|NCT02310100|Experimental|TactiCath Quartz|TactiCath Quartz treatment
3037671|NCT02310087|Active Comparator|astaxanthin with vitamin E|The participants in the study group will be given perorally four tablets of 4 mg astaxanthin with 10 mg vitamin E (Astasan, Sensilab, Slovenia) daily, taken in single daily dose. The total daily dose will be 16 mg astaxanthin with 40 mg vitamin E. The product will be taken for three months continuously.
3037672|NCT02310087|Placebo Comparator|placebo|The participants in the control group will be given perorally four tablets of placebo daily taken in single daily dose. The placebo tablets are of the same size and colour as the study tablets and were produced by manufacturer of Astasan, Sensilab, Slovenia. The placebo will be taken for three months continuously.
3037673|NCT02310074|Experimental|Pulsatile Gonadotropin Releasing Hormone|Pulsatile Gonadotropin Releasing Hormone: subjects in the GnRH group initiated a regimen of pulsatile GnRH administered subcutaneously via a portable infusion pump for 18 months.
3037674|NCT02310074|Active Comparator|combination gonadotropin therapy|combined human chorionic gonadotropin (hCG)/urinary Follicle-Stimulating Hormone (uFSH) therapy:HCG treatment was maintained alone for 6 months and then uFSH was added for the next 12 months
3037675|NCT02310061|Placebo Comparator|Control arm|Standard protocol of fluid management in hemodialysis
3037676|NCT02310061|Experimental|Active arm|Extra-vascular lung water measurements by ultrasound (LW-US)
3037677|NCT02310048|Experimental|MT-1303-FormA|MT-1303, Capsule Formulation A
3037678|NCT02310048|Experimental|MT-1303-FormB|MT-1303, Capsule Formulation B
3037681|NCT02310009|Experimental|Control (CON)|Placebo will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.
3037682|NCT02310009|Experimental|Anakinra (AN)|100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.
3037683|NCT02310009|Experimental|Exercise (EX)|1 hour of cycling exercise will be performed at 75% VO2max, the day prior to the repeated measurement of beta-cell function.
3037684|NCT02310009|Experimental|Anakinra + Exercise (ANEX)|100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus followed by 1 hour of cycling exercise at 75% VO2max, the day prior to the repeated measurement of beta-cell function.
3037685|NCT02309996|Experimental|Supervisor Training Program|All supervisors from work units randomized to the intervention will receive a supervisor training program, the Supervisor/Manager Accommodation Recognition & Training (SMART) Program. This training program is modeled on a program developed by Shaw and colleagues of the Liberty Mutual Research Institute for Safety (LMRIS). The aim of the training program is to prevent/reduce work disability by improving supervisor communication, response to workplace injury, and problem solving mechanisms. The training program is designed to be administered by two facilitators to groups of 10 to 12 supervisors, during one 4-hour session or two 2-hour sessions. The training program delivery mode includes PowerPoint presentation with supplementary audio or video segments, case studies, and group discussion.
3037686|NCT02309996|No Intervention|No Supervisor Training Program|All supervisors from work units randomized to the control group will not receive the supervisor training program.
3037687|NCT02309983|Active Comparator|Electrical Stimulation Alone Group|Group 1 will receive 1hr of electrical stimulation while lying down followed by 15 min of overground training. Electrical stimulation will be applied through leads and self-adhesive electrodes over muscles of both legs. Two electrodes will be used for each muscle. Electrical stimulation will be induced by using the EMPI, Inc., St. Paul, MN [Respond Select Neuromuscular Stimulation]. There will be 60 sessions/3x week for 20 weeks.
3037688|NCT02309983|Placebo Comparator|Stand Retraining Alone with BWS|Group 2 will receive standing retraining with BWS alone on a treadmill without functional electrical stimulation. Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. The duration of stand retraining sessions will be up to 1 hour or determined by subject's fatigue. There will be 60 sessions/3x week for 20 weeks.
3037689|NCT02309983|Experimental|Stand Retraining and ES Group|Group 3 will receive standing retraining with BWS with electrical stimulation, followed by 15 min of overground training. Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. Electrical stimulation will start while participant is seated and before he/she is brought up to full standing. There will be 60 sessions/3x week for 20 weeks.
3037690|NCT02309970||Conservative|patient will get treatment with Antiplatelets or Anticoagulant depending on their clinical status/etiology
3037691|NCT02309970||IV tPA|patient will receive intravenous thrombolysis treatment
3037692|NCT02309970||Endovascular treatment|patient who will receive endovascular treatment
3037693|NCT02309957||BioMatrix CRD|All patients will receive BioMatrix CRD to repair an articular cartilage lesion or osteochondral defect.
3037694|NCT02309944|Active Comparator|Standard Wound Closure|Standard surgical closure of the fascia and skin.
3037695|NCT02309944|Experimental|Negative Pressure Wound Therapy|Standard surgical closure as used by the standard of care group plus placement of the Prevena™ Incision Management System over the closed incision.
3037696|NCT02309931|Active Comparator|Isoperistaltic anastomosis|Patients with right colon cancer who undergo a right laparoscopic hemicolectomy and a isoperistaltic side-to-side ileocecal anastomosis
3037697|NCT02309931|Active Comparator|Antiperistaltic anastomosis|Patients with right colon cancer who undergo a right laparoscopic hemicolectomy and a antiperistaltic side-to-side ileocecal anastomosis
3037698|NCT02309918|Other|LDV/SOF FDC|Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
3037699|NCT02309905||Control group before telemedicine|Inmates of prisons not having telemedicine before implementation of telemedicine in prisons having telemedicine
3037700|NCT02309905||Control group after telemedicine|Inmates of prisons not having telemedicine after implementation of telemedicine in prisons having telemedicine
3037701|NCT02309905||Exposed group, before telemedicine|Inmates of prisons having telemedicine before implementation of telemedicine
3037702|NCT02309905||Exposed group, after telemedicine|Inmates of prisons having telemedicine after implementation of telemedicine
3037703|NCT02309892|Experimental|Pemetrexed and Carboplatin plus L-DOS47|Patients will be recruited into cohorts of L DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort. The starting dose of L DOS47 will be 0.59 µg/kg; further possible dose levels that may be assessed are 0.78, 1.04, 1.38 and 1.84 µg/kg. The standard of care doses of pemetrexed [500 mg/m2] and carboplatin [AUC6], respectively, to be administered in combination with L-DOS47, will remain constant across cohorts.
3037704|NCT02309879|Active Comparator|Remifentanil group|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
3037705|NCT02309879|Active Comparator|Lidocaine group|Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
3037706|NCT02309879|Active Comparator|Magnesium group|Patients in lidocaine group received an intravenous bolus injection of 50 mg/kg magnesium sulphate followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
3037707|NCT02309879|Active Comparator|Magnesium and Lidocaine group|Patients received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
3037708|NCT02309866||Genetic Testing|All participants determined eligible for the study will be placed into genetic testing arm.
3037709|NCT02309853|Experimental|Visual and tactile scanning training|20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space combined with trunk rotation
3037710|NCT02309853|Active Comparator|Unimodal visual scanning training|20 sessions of 30 minutes with traditional uni-modal visual scanning training
3037711|NCT02309840|No Intervention|control|Students received standard meals in a standard cafeteria environment
3037712|NCT02309840|Experimental|Chef|Students were exposed to chef-enhanced meals
3037713|NCT02309840|Experimental|choice architecture|"Students were exposed to modifications to the physical environment in the cafeteria to nudge students towards healthier choices"
3037714|NCT02309840|Experimental|Chef and choice architecture|"Students were exposed to both chef-enhanced meals and modifications to the physical environment in the cafeteria to nudge students towards healthier choices"
3037715|NCT02309827|Experimental|Cohort 1: PF-06651600 or Placebo|Single ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3037716|NCT02309827|Experimental|Cohort 2: PF-06651600 or Placebo|Single ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3037717|NCT02309827|Experimental|Cohort 3: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3037718|NCT02309827|Experimental|Cohort 4: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3037719|NCT02309827|Experimental|Cohort 5: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3037720|NCT02309827|Experimental|Cohort 6: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3037721|NCT02309827|Experimental|Cohort 7: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3037722|NCT02309827|Experimental|Cohort 8: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3037723|NCT02309827|Experimental|Cohort 9: PF-06651600 or Placebo|Multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3037724|NCT02309814|Experimental|eyelid motion sensor device|all volunteers will wear the monitor eyelid sensor device (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance.
3037725|NCT02309801|Experimental|Daidzin and alcohol|"Daidzin 80 mg, single dose, oral administration (4 capsules of Super-Absorbable Soy Isoflavones®).~Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml."
3037726|NCT02309801|Active Comparator|Alcohol|Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml.
3037727|NCT02309788||RT|Resectable HCC patients adjuvant RT for PVT or NM
3037728|NCT02309788||No RT|Resectable HCC patients adjuvant other treatment for PVT or NM
3037729|NCT02309775|Active Comparator|Auriculotherapy Group|The placement, points according to Souza (1997), will be: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. The point descriptions are: Shen Men, is located in the vertex of the angle formed by the lower root and the upper root of the antihelix; the Sympathetic is situated in the middle of the lower root below the Helix membrane (located at the lower end of the Lobe); the Kidney point is situated in cymba concha, near its junction with the lower root of the antihelix, in the same line as the Shen Men point; the Subcortex is situated on upward curve towards the apex of the antitragus, on the upper edge of the concha; the Adrenal is located at the apex of the tragus, on its projection towards the concha cava; the Cerebral point is situated above the edge of the antitragus. As sessions will held twice a week for a total of 10 sessions.
3037730|NCT02309775|Placebo Comparator|Placebo Grup|The point stimulated will be the Trachea, which is one millimeter in the direction of the auditory meatus. This point does not cause risk to the research participant. As sessions will held twice a week for a total of 10 sessions.
3037731|NCT02309762|Experimental|FB825|6 cohorts of subjects are planned to be dosed by IV injection, with single- ascending doses ranging from 0.003 - 10 mg/kg
3037732|NCT02309762|Placebo Comparator|Placebo|Placebo
3037733|NCT02309749||Naive cohort|
3037734|NCT02309723|Experimental|Positive beta amyloid findings|Beta amyloid imaging results indicated a positive finding.
3037735|NCT02309723|Experimental|Negative beta amyloid findings|Beta amyloid imaging results indicated a negative finding.
3037736|NCT02309723|No Intervention|No beta amyloid information|
3037737|NCT02309710|Experimental|ShangRing|ShangRing administered to men seeking medical male circumcision
3037738|NCT02309697||Full Term|Children born at full term on or after Jan 1, 2011
3037739|NCT02309697||PreTerm|Children born preterm on or after Jan 1, 2011
3037740|NCT02309684||Study Population|Study population are subjects at least 18 years old and of any ethnic background with a full thickness diabetic foot ulcer or venous leg ulcer, where the ulcer has been diagnosed/present for greater than 4 weeks duration.
3037741|NCT02309671|Experimental|FE 999049 6 µg|
3037742|NCT02309671|Experimental|FE 999049 9 µg|
3037743|NCT02309671|Experimental|FE 999049 12 µg|
3037744|NCT02309671|Active Comparator|FOLLISTIM 150 IU|follitropin beta
3037745|NCT02309658|Experimental|Interventional|Treatment consisted of gemcitabine at a dose of 1000 mg/m2, followed by cisplatin 35 mg/m2 administered on day 1 and 8, for two cycles. After that, weekly cisplatin 40mg/m2 is administered concomitant with radiotherapy (45-55Gy) in 1,8-2,0 daily fractions and a 10Gy boost when there was parametrial involvement. Low-dose rate brachytherapy, in 4 fractions of 7Gy, in a total of 28Gy will complete the protocol.
3037746|NCT02309645|Experimental|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
3037747|NCT02309645|Other|Sutures Only|Subjects randomized to control will receive additional dural repair sutures as deemed necessary by the surgeon to attempt to achieve a watertight closure.
3037748|NCT02309632|Active Comparator|Pathway 1|Individuals at high risk of pancreatic cancer who will participate in Pancreatic Cancer Screening Pathway 1
3037749|NCT02309632|Active Comparator|Pathway2|Individuals at high risk of pancreatic cancer who will participate in Pancreatic Cancer Screening Pathway 2
3037750|NCT02309619|Experimental|trans-substernal group|Patients who undergo esophagectomy with the gastric tube lifting to the neck through trans-substernal path.
3037751|NCT02309619|Experimental|trans-esophageal bed group|Patients who undergo esophagectomy with the gastric tube lifting to the neck through trans-esophageal bed path.
3037752|NCT02309606||Migraine without aura|Migraine patients suffering from migraine 0-4 days per month.
3037753|NCT02309606||Healthy controls|Healthy controls with no history of migraine or other primary headaches.
3037754|NCT02309606||Chronic migraine|Migraine patients with chronic migraine
3037755|NCT02309593||PROFEMUR® Xm Femoral Stems|Single study group either previously implanted or will be implanted with the following combination of components: PROFEMUR® Xm Femoral Stems, DYNASTY® Porous Coated Acetabular Shells, DYNASTY® A-Class® Cross Linked Polyethylene Liners, and TRANSCEND®/LINEAGE® Ceramic Femoral Heads.
3037756|NCT02309580|Experimental|Ibrutinib|This will be a standard dose-escalation study to determine the MTD of ibrutinib in relapsed/refractory PTCL or CTCL. At each dose 6 patients with TCL (PTCL or CTCL) will be enrolled. The first 6 patients will be enrolled at dose level 1. Dose escalation to the next dose level will proceed after DLT assessment of all 6 patients at the end of cycle 1 (28-days).
3037757|NCT02309554|Active Comparator|SILCS Diaphragm alone|Participants will complete a post-coital test cycle with SILCS diaphragm alone.
3037758|NCT02309554|Active Comparator|SILCS Diaphragm with 3% Nonoxynol-9 Gel|Participants will complete a post-coital test cycle with SILCS diaphragm used with 3% nonoxynol-9 gel.
3037759|NCT02309554|Experimental|SILCS Diarphragm with ContraGel|Participants will complete a post-coital test cycle with SILCS diaphragm used with ContraGel.
3037760|NCT02309541|Experimental|Firmware N|New feedback canceller algorithm
3037761|NCT02309541|Active Comparator|Firmware R|Current feedback canceller algorithm (reference)
3037762|NCT02309515|Experimental|Arm I (lenalidomide, pneumococcal 13-valent conjugate vaccine)|Patients receive lenalidomide PO QD on days 1-42 and pneumococcal 13-valent conjugate vaccine IM on day 15.
3037763|NCT02309515|Active Comparator|Arm II (pneumococcal 13-valent conjugate vaccine)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 15.
3037764|NCT02309502|Experimental|Green Pascal|Single-session Barely Visible Pascal 532nm 3,000 burns 20ms
3037765|NCT02309502|Experimental|Yellow Pascal|Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management:70%
3037766|NCT02309502|No Intervention|Observation|Observation
3037767|NCT02309489|Experimental|Intervention|"Receive standard maternity care~Woman and partner attend one extra couple counselling session during pregnancy (A)~Partner attends one group education session for men (B)~Partner participates in pre-discharge consultation (C)"
3037768|NCT02309489|No Intervention|Control|"Receive standard maternity care~No active encouragement of partner involvement, no extra sessions offered"
3037769|NCT02309476|Experimental|PASCAL Laser, Green Laser 0.75|"Barely Visible Pascal laser grid using 532nm green wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
3037770|NCT02309476|Experimental|PASCAL Laser, Green Laser 1 burn|"Barely Visible Pascal laser grid using 532nm green wavelength, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
3037771|NCT02309476|Experimental|PASCAL Laser, 70% Yellow Laser 0.75|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
3037772|NCT02309476|Experimental|PASCAL Laser, 70% Yellow Laser 1|"Pascal EM at 70% 577nm yellow, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
3037773|NCT02309476|Experimental|PASCAL Laser, 40% Yellow Laser 0.75|"Pascal EM at 40% 577nm yellow, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 40% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
3037774|NCT02309476|Experimental|PASCAL Laser, 40% Yellow Laser 1|"Pascal EM at 40% 577nm yellow laser grid, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 40% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
3037775|NCT02309450|Experimental|Asunaprevir, Daclatasvir and BMS - 791325|
3037776|NCT02309437|Experimental|Mild group|Use oxycodone when pain is mild level. Start from 10 mg every 12 hours and titrate for appropriate dose.
3037777|NCT02309437|Active Comparator|Moderate group|Use oxycodone when pain is moderate or severe level. Start from 10 mg every 12 hours and titrate for appropriate dose.
3037778|NCT02309424|Active Comparator|Vinegar|0,50mmol vinegar (6% acetic acid)
3037779|NCT02309424|Placebo Comparator|Placebo|50 ml water
3037780|NCT02309411|Experimental|Rivaroxaban|Age and body weight-adjusted twice daily dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily
3037781|NCT02309385|Experimental|8% DSP-Visulex|8% dexamethasone sodium phosphate - Visulex (DSP- Visulex) and placebo eye drops in the affected eye.
3037782|NCT02309385|Experimental|15% DSP-Visulex|15% dexamethasone sodium phosphate - Visulex (DSP- Visulex) and placebo eye drops in the affected eye.
3037783|NCT02309385|Active Comparator|Pred Forte|Prednisolone acetate (1%) eye drops and vehicle - Visulex in the affected eye.
3037784|NCT02309372|Experimental|Cognitive Behavioral Therapy (CBT)|Those assigned to the CBT arm will undergo therapy with the Beating the Blues (BtB) computerized intervention.
3037785|NCT02309372|No Intervention|Usual Care|No specific depression care will be provided through this study for those assigned to this arm. However, the participant's caregiver may choose to provide depression treatment outside of this trial.
3037786|NCT02309359|Placebo Comparator|Group 1: Placebo|Placebo, at week 0 and every 2 weeks thereafter up to and including week 22
3037787|NCT02309359|Experimental|Group 2: ALX-0061 Dose A + Placebo|"ALX-0061 Dose A at week 0 and every 4 weeks thereafter up to and including Week 20.~Placebo at week 0 and every 2 weeks thereafter up to and including week 22."
3037788|NCT02309359|Experimental|Group 3: ALX-0061 Dose B + Placebo|"ALX-0061 Dose B at week 0 and every 4 weeks thereafter up to and including Week 20.~Placebo at week 0 and every 2 weeks thereafter up to and including week 22."
3037789|NCT02309359|Experimental|Group 4: ALX-0061 Dose B + Placebo|"ALX-0061 Dose B at Week 0 and every 2 weeks thereafter up to and including Week 22.~Placebo at week 0 and every 2 weeks thereafter up to and including week 22."
3037790|NCT02309359|Experimental|Group 5: ALX-0061 Dose C|ALX-0061 Dose C at Week 0 and every 2 weeks thereafter up to and including Week 22.
3037791|NCT02309346|Experimental|clindamycin once a day|Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day until clinical improvement
3037792|NCT02309346|Active Comparator|clindamycin thrice a day|Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
3037793|NCT02309320|Experimental|ALX-0171|Inhalation of ALX-0171 during 3 consecutive days
3037794|NCT02309320|Placebo Comparator|Placebo|Inhalation of Placebo during 3 consecutive days
3037795|NCT02309307|Experimental|Arm 1 Tissue Repair Device|Tissue Repair Device
3037796|NCT02309294|Experimental|Healthy Subject|Occlusive patches applied each day for 14 days for each intervention (Experimental: Novel lubricant Miami w/ fragrance, Experimental: Novel lubricant Miami no fragrance, KY Liquid lubricant, Astroglide Gel lubricant, Wet Platinum lubricant).
3037797|NCT02309281|Other|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
3037798|NCT02309255||coronary heart disease patients|
3037799|NCT02309242|No Intervention|Neuropsychological assessment, MRI|This is a cross-sectional mono-center study examining survivors who were exposed to chemotherapy for bone or soft tissue sarcomas in childhood. Survivors of bone or soft tissue sarcomas will be examined with neuropsychological tests, questionnaires and advanced MR imaging (Neuropsychological assessment, MRI). Results will be compared to a healthy control group matched for age and sex.
3037800|NCT02309229||Cystic fibrosis patients|patients with cystic fibrosis
3037801|NCT02309203|Experimental|Flow Re-Direction Endoluminal Device|Flow Re-Direction Endoluminal Device (FRED Device)
3037802|NCT02309190||transpulmonary pressures|Esophageal balloon to measure transpulmonary pressures. PEEP adjustment as per transpulmonary pressures.
3037803|NCT02309177|Experimental|nab-Paclitaxel and Nivolumab in Pancreatic Cancer|nab-paclitaxel 125 mg/m2 on Days 1, 8 and 15, and nivolumab on Days 1 and 15 of each 28 day cycle.
3037804|NCT02309177|Experimental|nab-Paclitaxel, Gemcitabine and Nivolumab in Pancreatic Cancer|nab-paclitaxel 125 mg/m2 on Days 1, 8 and 15, gemcitabine 1000 mg/m2 on Days 1, 8 and 15, and nivolumab on Days 1 and 15 of each 28-day cycle.
3037805|NCT02309177|Experimental|nab-Paclitaxel, carboplatin and nivolumab Cycle 1 in NSCLC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 (Cycles 1 to 4 only) of each 21 day cycle; nivolumab on Day 15 of each 21 day cycle starting in Cycle 1.
3037806|NCT02309177|Experimental|nab-Paclitaxel, carboplatin and nivolumab Cycle 3 in NSCLC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 (Cycles 1 to 4 only) of each 21 day cycle; nivolumab on Day 15 of each 21 day cycle starting in Cycle 3.
3037807|NCT02309177|Experimental|nab-Paclitaxel 100 mg/m2 and Nivolumab in MBC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 of each 28 day cycle, plus nivolumab on Days 1 and 15 starting in Cycle 3.
3037808|NCT02309177|Experimental|nab-Paclitaxel 260 mg/m2 and Nivolumab in MBC|nab-paclitaxel 260 mg/m2 on Days 1 of each 21 day cycle, plus nivolumab on Days 15 starting in Cycle 3.
3037809|NCT02309164|Active Comparator|Acupuncture|acupuncture
3037810|NCT02309164|Sham Comparator|orientation group|medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
3037811|NCT02309151|Experimental|Acute coronary angiography|Acute coronary angiography for out of hospital cardiac arrest patients with no STEMI signs in ECG
3037812|NCT02309151|Other|Routine care ICU|Routine care at ICU for out of hospital cardiac arrest patients with with no signs of ST elevation in ECG.
3037813|NCT02309151|Other|Routine care STEMI|Routine care with acute coronary angiography for STEMI patients.
3037814|NCT02309138|Active Comparator|3 hour 100 gm OGTT (CC Criteria)|Gestational diabetes screening with fasting 3 hour 100 gm. Receive a fasting 3 hour 100 gram oral glucose tolerance test and are diagnosed based on the Carpenter Coustan Criteria: a 50 gm Glucose tolerance test of >130 + fasting 3 hour 100 gram oral glucose tolerance test with two or more values greater than the following diagnostic threshold: Fasting 95, 1-hour 180, 2-hour 155, or 3 hour 140 mg/dL . A positive criteria will be diagnostic for gestational diabetes.
3037815|NCT02309138|Active Comparator|2 hr 75 gm OGTT (IADPSG Criteria)|Gestational diabetes screening with fasting 2 hour 75g. Receive a fasting 2 hour 75 gm oral glucose tolerance test and diagnosed based on the IADPSG which is if one or more values exceed the following diagnostic threshold: Fasting 92, 1-hour 180, or 2-hour 153 mg/dL.
3037816|NCT02309125|Experimental|implant A|will include implants with immediate progressive loading using gingival formers of different sizes
3037817|NCT02309125|Other|implant B|The implants will remain submerged from surgery time till loading time 2 month.(submerged healing)
3037818|NCT02309112|Experimental|Yoga Group A: Minimum Exposure|The minimum-exposure yoga package, this intervention included 45-minutes of contact time with a trained yoga professional. In Week 1, this session included a 30-minute introductory session focussing on pranayama (breathing techniques), as well as a brief introduction to available community-based and online yoga to encourage a safe home-based practice (15-minutes). Financial subsidy, compensation or special promotion of any particular yoga was not provided. Participants were invited to stay for a social discussion following the yoga class.
3037952|NCT02308176|Experimental|intervention group|health advice and app installation in patient's mobile
3037819|NCT02309112|Experimental|Yoga Group B: Medium Exposure|The medium-exposure yoga package, this intervention included the components of Group A, with an additional 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were then invited to stay and ask questions following the yoga class. A pre-paid online yoga membership to http://www.myyogaonline.com was offered for the duration of the study (Weeks 1 to 4). In addition to this, one 120-minute workshop to further develop yoga pranayama, dhyana and asana training was administered by an expert instructor during Week 2 or 3.
3037820|NCT02309112|Experimental|Yoga Group C: Maximum Exposure|The maximum-dose yoga package, this intervention includes the components of Group A, with the same 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were invited to stay and ask questions following the yoga class. As in Group B, a pre-paid online yoga membership to http://www.myyogaonline.com was also provided for the duration of the study (Weeks 1 to 4). Participants were then invited to attend three 60-minute yoga group classes led by an expert yoga instructor per week (Weeks 1 to 4). These yoga sessions were held in a clinical setting in proximity to their treatment location and delivered at no cost to the patient.
3037821|NCT02309099|Experimental|Cochlear Implant|Cochlear implantation of the affected ear
3037822|NCT02309086|Experimental|Single arm|Autologous dendritic cells transduced with Ad encoding NS3
3037823|NCT02309073||women with a regular indication for ART|In the present proposal we are aiming to include all normo-ovulatory women with a regular indication for ART.
3037824|NCT02309060|Experimental|Storytelling Video Intervention (sTVi)|"We will develop a series of 4 videos, each episode approximately 30 minutes long, which will illustrate the key principles of Acceptance and Commitment Therapy.~We will add a short, non-narrative, epilogue at the end of each of the 4 episodes that summarizes key messages and provides information on identifying signs of depression and suggestions for efficacious treatments.~In addition, we will develop an accompanying personal journal for participants that includes a brief self-help guide which encourages participants to write about what they learned in the videos and how they will take similar steps in their own lives to cope with depression."
3037825|NCT02309047||WHO anovulation|WHO I, II. III anovulation. See inclusion criteria
3037826|NCT02309034|Experimental|Jump exercise|rebound exercises.
3037827|NCT02309034|Experimental|Aquatic exercise|Hydrogimnastic.
3037828|NCT02309034|Active Comparator|Nutritional guidance|Nutritional counseling classes.
3037829|NCT02309021|Other|Sport Group|Participants randomised to the exercise condition will receive 12 weeks of physical exercise training. Once they have been assigned to this group, they will be informed about the training programme and its content. Training will be carried out in groups (two groups of ten or four groups of five, depending on scheduling, sport preferences, available materials) to ensure that individual attention can be paid to each participant.
3037830|NCT02309021|Other|Control Group|The control group will not receive any exercise training. In order to control, as far as possible, for the potentially therapeutic effects of extra contact time with investigators, and the potentially motivational elements of participation in an intervention, the C group will have equal contact time with an investigator and participate in a leisure program without physical activity component. This time will be filled with group mealtimes, games, films, painting, handcrafts, stretching or relaxation exercises.
3037831|NCT02309008|Placebo Comparator|placebo|vehicle cream, dermal administration, multiple dosing
3037832|NCT02309008|Experimental|drug|PAC-14028 cream, dermal administration, multiple dosing, dose escalation
3037833|NCT02308995|Experimental|Cystectomy using barbed sutures|Endometrioma bed is sutured with barbed sutures
3037834|NCT02308995|Active Comparator|Cystectomy using conventional sutures|Endometrioma bed is sutured with conventional sutures
3037835|NCT02308982|Active Comparator|Intravenous immunoglobulin|Intravenous immunoglobulin: 1g/kg per day for 2 consecutive days
3037836|NCT02308982|Placebo Comparator|Placebo|Equivalent volume to 1g/kg of IVIG per day for 2 consecutive days
3037837|NCT02308969|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.
3037838|NCT02308956|Experimental|Integrated mental health in primary care|Participants in the new intervention arm will receive a task sharing model of locally-delivered mental health care integrated into primary healthcare. General health workers (health officers, nurses and community-based health extension workers) will be given brief training using the WHO's mental health Gap Action Programme and ongoing supervision in order to deliver mental health care to people with severe mental disorders.
3037839|NCT02308956|Active Comparator|Psychiatric nurse-led specialist care|Participants in the active control arm will receive an established model of centralised, specialist mental health care delivered by psychiatric nurses at an out-patient clinic within Butajira general hospital and supported by outreach from project workers.
3037840|NCT02308930|Experimental|Vitamins + DHA supplement|2 x 400 mg capsules per day orally for 6 months, each capsule providing 154μg Vitamin A, 2.36μg Vitamin D, 0.4mg Vitamin E and 375mg algal oil (containing 150mg DHA).
3037841|NCT02308930|Other|Vitamins supplement|2 x 400 mg capsules per day orally for 6 months, each capsule providing 154μg Vitamin A, 2.36μg Vitamin D, 0.4mg Vitamin E and 375mg corn oil (free of omega-3 fatty acids).
3037842|NCT02308904|Other|Laboratory Studies for Pituitary-Gonadal Function|"Females: We expect to enroll approximately 15 females ages 12 years and older.~Males: We expect to enroll approximately 15 males ages 12 years and older."
3037843|NCT02308904|Other|Data on iron burden and chelation history|"Retrospective data, as listed in this section, will be obtained from chart review and results of relevant clinical data.~Iron burden data~Assay for non-transferrin bound iron (NTBI)~Chelation data~Oxidant stress~History or presence of hypogonadism"
3037844|NCT02308904|Other|Pituitary MRI|MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland.
3037845|NCT02308891|Experimental|vigorous hydration arm|"Patients will be randomly allocated to vigorous hydration arm. Patients in the vigorous hydration arm will receive fluids via infusion by the following protocol.~Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP~Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.~At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour"
3037953|NCT02308176|Placebo Comparator|control group|health advice
3037846|NCT02308891|Active Comparator|standard hydration arm|"Patients will be randomly allocated to standard hydration arm. Patients in the standard hydration arm will receive fluids via infusion by the following protocol.~- Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP."
3037847|NCT02308878|No Intervention|Treatment-as-usual|This group consists of treatment-as-usual for opioid dependence syndrome.
3037848|NCT02308878|Experimental|Mobile health cognitive stimulation|Cognitive stimulation using mobile technology with m-Health applications.
3037849|NCT02308865|No Intervention|Control arm|Patient supported by the onco respiratory service for the treatment of their disease by chemotherapy and for the treatment of complications.
3037850|NCT02308865|Experimental|intervention arm|Multi disciplinary palliative care monthly consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a chaplain in addition to standard onco-pneumologic care.
3037851|NCT02308852|Active Comparator|real tDCS|"Patients will receive non-invasive and painless brain stimulation over the brain areas involved in cognitive aptitudes.~tDCS will be applied during 20 minutes while patients will perform motor bimanual tasks"
3037852|NCT02308852|Placebo Comparator|Sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
3037853|NCT02308826|Experimental|Turtle Program|The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
3037854|NCT02308826|Active Comparator|Cool Little Kids|A 6-week parent psychoeducation group administered over an 8-week period.
3037855|NCT02308813|Experimental|Braking and functionality with hip osteoarthritis|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with hip osteoarthritis
3037856|NCT02308813|Experimental|Braking and functionality with hip arthroplasty|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with total hip arthroplasty
3037857|NCT02308800|Active Comparator|Quantum™ Therapy/NPWT with Prontosan|Quantum™ Negative Pressure Wound Therapy with Prontosan irrigant.
3037858|NCT02308800|Active Comparator|Quantum™ Therapy|Quantum™ Negative Pressure Wound Therapy without irrigant.
3037859|NCT02308761|Experimental|RO6870810|Participants with RR-AML and HMA-refractory MDS will receive RO6870810, as per schedule described in intervention description.
3037860|NCT02308748|Active Comparator|Dofetilide|Dofetilide alone arm
3037861|NCT02308748|Active Comparator|Dofetilide + Mexiletine|Dofetilide combined with mexiletine
3037862|NCT02308748|Active Comparator|Dofetilide + Lidocaine|Dofetilide combined with lidocaine
3037863|NCT02308748|Active Comparator|Moxifloxacin + Diltiazem|Moxifloxacin with and without diltiazem.
3037864|NCT02308748|Placebo Comparator|Placebo|Placebo (#2 gelcap and intravenous saline)
3037865|NCT02308735||Control|Pregnant women without either gestational or pre-gestational diabetes mellitus (and their offspring).
3037866|NCT02308735||A1 IDM|Pregnant women with abnormal glucose tolerance test but normal fasting serum glucose levels (and their offspring).
3037867|NCT02308735||A2 IDM|Pregnant women with abnormal glucose tolerance test and fasting hyperglycemia (and their offspring).
3037868|NCT02308735||PGDM - IDM|Pregnant women with diabetes mellitus diagnosed prior to current pregnancy (and their offspring).
3037869|NCT02308722|Experimental|5-fraction stereotactic body radiation therapy|See intervention
3037870|NCT02308709|Experimental|Ventilation image-guided radiotherapy|Patients will receive 4D CT ventilation image-guided personalized radiotherapy treatment that selectively avoids irradiating highly-functional lung regions
3037871|NCT02308696|Experimental|Peer-to-peer support (non-randomized)|225 older adults that are currently receiving peer-to-peer support
3037872|NCT02308696|Active Comparator|Standard Services (non-randomized)|225 older adults will continue receiving standard community services
3037873|NCT02308683|Experimental|hsCRP, Hgba1c|Pre treatment hsCRP and hgba1c will be initially measured After 12 weeks supplementation of Moringa oleifera, post treatment hsCRP and Hgba1c will be measured
3037874|NCT02308670||RRMS changing from 20mg to 40mg GA|Relapsing-remitting Multiple Sclerosis patients who are switching from 20mg of glatiramer acetate (GA) to 40mg. The investigator is not influencing this clinical decision, just measuring its impact using MRI metrics.
3037875|NCT02308644|Experimental|Bevacizumab|Group 1 - 21 eyes treated with intravitreal bevacizumab injection (1.25mg) at the weeks 0, 6,12 and 18 plus standard metabolic control with glycated hemoglobin measured at baseline, week 12 and 18. All patients were followed by expert (endocrinologist)
3037876|NCT02308644|Sham Comparator|Sham|Group 2 - 20 eyes treated with sham injection at weeks 0 and 6; and intravitreal bevacizumab injection(1.25mg) in the weeks 12 and 18 plus standard metabolic control with glycated hemoglobin measured at baseline, week 12 and 18. All patients were followed by expert (endocrinologist)
3037877|NCT02308631|Experimental|Colostomy with colopexy by endoscopy|Colostomy with colopexy by endoscopy. 5 porks underwent endoscopic assisted colostomy with percutaneous colopexy. Animals were evaluated in post-operative days 1, 2, 5 and 7 Procedure/Surgery: ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY
3037878|NCT02308618|Experimental|Traditional Immobilization|45 days of plaster cast immobilization After the immobilization period, subjects received instructions on how to perform a home-based exercise program
3037879|NCT02308618|Experimental|Early mobilization|Six weeks of physical therapy program
3037880|NCT02308618|No Intervention|Control|Subjects had no history of lower limb injury, and were matched in age and anthropometric measurements to subjects that performed physical rehabilitation and to subjects that remained immobilized.
3037881|NCT02308605||Suspected stroke patients and subset|"Blood samples taken on admission and at 24 hours, MRI scan between 24 and 48 hours~Subset: Blood samples repeated once per hour for six hours"
3037882|NCT02308605||Control participants (relatives)|To donate blood on two occasions, 24 hours apart, to draw comparison with stroke patients
3037883|NCT02308605||Feeding control participants|To donate a baseline blood sample, eat a simple purine rich meal (meat sandwich), then donate 4 more blood samples at 10, 30, 60 and 120 minutes following the meal
3037884|NCT02308592|Placebo Comparator|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
3037885|NCT02308592|Active Comparator|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
3037886|NCT02308579||Multiple Sclerosis|Patients diagnosed with Multiple Sclerosis (MS), identified in the CTEVD trial
3037887|NCT02308579||Clinically Isolated Syndrome|Patients diagnosed with Clinically Isolated Syndrome (CIS), identified in the CTEVD trial.
3037888|NCT02308579||Other Neurological Disorders|Patients diagnosed with Other Neurological Disorders (OND), identified in the CTEVD trial. ONDs fall into one of four categories: Neurodegenerative, Vascular, Autoimmune, and Neuromuscular; and the following disorders: Acute Disseminated Encephalomyelitis (ADEM); Antiphospholipid Antibody (syndrome; APLA); Atypical, short-lasting neurodegenerative disease; Autoimmune disease not otherwise specified (NOS); Cerebellum Syndrome; Charcot-Marie Tooth Disease; Chiari Malformation; Chronic Fatigue Syndrome; Central Nervous System Vasculitis; Demyelinating Disease; Epilepsy; Headaches; Idiopathic Chronic Neuropathy; Migraines; Mitochondrial Disease; Myelopathy; Neurofibromatosis; Neuropathy; Optic Neuritis; Parasthesia related to Transient Ischemic Attacks (TIA); Parkinson's Disease; Restless legs syndrome; Seizures; Spinal Cerebellum Disease; Spinal Disc Degeneration; Syringomyelia; and Vertigo
3037889|NCT02308579||Healthy Controls|Individuals who are healthy (i.e., free from neurological conditions; HC) , identified in the CTEVD trial.
3037890|NCT02308566|Active Comparator|Conventional Extracorporeal Circulation Technique|Conventional Extracorporeal Circulation Technique
3037891|NCT02308566|Experimental|Minimized Extracorporeal Circulation Technique|Minimized Extracorporeal Circulation Technique
3037892|NCT02308553|Experimental|Nintedanib + Paclitaxel|Nintedanib (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses
3037893|NCT02308553|Placebo Comparator|Nintedanib-Placebo + Paclitaxel|Placebo (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses
3037894|NCT02308540|Experimental|Adult SIILPCV10|Single dose of SIILPCV10 on day 0
3037895|NCT02308540|Active Comparator|Adult Pneumovax 23|Single dose of Pneumovax 23 on day 0
3037896|NCT02308540|Experimental|Toddler SIILPCV10|Single dose of SIILPCV10 on day 0
3037897|NCT02308540|Active Comparator|Toddler Prevenar 13|Single dose of Prevenar 13 on day 0
3037898|NCT02308540|Experimental|Infants SIIL PCV10|A three-dose series of SIILPCV10 on day 0, day 28, and day 56
3037899|NCT02308540|Active Comparator|Infants Prevenar 13|A three-dose series of Prevenar 13 on day 0, day 28, and day 56
3037900|NCT02308527|Active Comparator|Temozolomide|Temozolomide Days 1-5 every 4 weeks
3037901|NCT02308527|Experimental|Bevacizumab + Temozolomide|Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 every 4 weeks
3037902|NCT02308527|Experimental|Irinotecan + Temozolomide|Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
3037903|NCT02308527|Experimental|Bevacizumab + Irinotecan + Temozolomide|Bevacizumab Day 1 + Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
3037904|NCT02308527|Experimental|Temozolomide + Topotecan|Temozolomide Days 1-5+ Topotecan Days 1-5 every 4 weeks
3037905|NCT02308527|Experimental|Bevacizumab + Temozolomide + Topotecan|Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
3037906|NCT02308514|Active Comparator|conservative care|this group of patients will receive the conservative care: myofascial point release and radial head mobilisation
3037907|NCT02308514|Experimental|cryostimulation|this group of patients will receive the conservative care :myofascial point release and radial haed mobilisation and the cryostimulation (30-40 second of cold air application (-70 celsius degree) in order to lower skin temperature around the lateral epicondyle at 4 celsius degree.
3037908|NCT02308501|Active Comparator|Lastacaft ®|One drop Lastacaft® in right eye and one drop Tears Naturale® in left eye once on Day 1 and once on Day 2
3037909|NCT02308501|Placebo Comparator|Tears Naturale ®|One drop Tears Naturale® in right eye and one drop Lastacaft® in left eye once on Day 1 and once on Day 2
3037910|NCT02308488|Other|Radiation|The treatment will consist of 15 fractions, with one fraction daily for five days a week, for 3 consecutive weeks. Whole breast/chest wall, level 1- III (includes Cohort A) and SCV nodes IMRT at 2.7 Gy x 15 fractions
3037911|NCT02308475|Experimental|Myocardial Stress CT Perfusion|"Dynamic volume CT myocardial perfusion using the experimental scanner (Force, Siemens), applying the dynamic shuttle mode will be used to rapidly cover the entire cardiac anatomy during infusion of a contrast medium bolus for monitoring bolus passage through the left ventricular myocardium."
3037912|NCT02308462|Experimental|CHIMPs intervention|Family-Intervention
3037913|NCT02308462|No Intervention|Control|"The long-term effectiveness of the CHIMPs intervention under conditions of practice will be examined in comparison to a control condition receiving the usual after care (Treatment as usual = TAU); this testing of effectiveness will be performed in due consideration of the health economic aspects.~The treatment as usual implies that families of the control Group receive the Treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every Family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system."
3037914|NCT02308449|Placebo Comparator|Iron-deficient, given placebo|Iron-deficient participants given an infusion of sodium chloride at conclusion of baseline experimental visit
3037915|NCT02308449|Active Comparator|Iron-deficient, given iron|Iron-deficient participants given an infusion of ferric carboxymaltose at conclusion of baseline experimental visit
3037916|NCT02308449|Placebo Comparator|Iron-replete, given placebo|Iron-replete participants given an infusion of sodium chloride at conclusion of baseline experimental visit
3037917|NCT02308449|Active Comparator|Iron-replete, given iron|Iron-deficient participants given an infusion of ferric carboxymaltose at conclusion of baseline experimental visit
3037918|NCT02308436|Experimental|Candida Mouthwash with Curolox™ Peptide|Repeated applications 2.5 ml or 5 ml twice daily
3037919|NCT02308410||Tourniquet group|This group received a pneumatic tourniquet during total knee arthroplasty.
3037920|NCT02308410||Non-tourniquet group|This group received no tourniquet during total knee arthroplasty.
3037921|NCT02308397|Experimental|Group 1|Begins with Normal gluten containing bread
3037922|NCT02308397|Experimental|Group 2|Begins with Bread with reduced gliadins content
3037923|NCT02308397|Experimental|Group 3|Begins with Bread with reduced ATIs content
3037924|NCT02308397|Experimental|Group 4|Begins with Bread with reduced overall protein content
3037925|NCT02308384|No Intervention|Before intervention|GPs in this group have not yet received intervention.
3037926|NCT02308384|Experimental|After intervention|GPs in this group have received the intervention.
3037927|NCT02308371|Experimental|Prospective|Patients in this arm will have fluid given based on standard clinical data (blood pressure, heart rate, lactate level, urine output) in addition to information provided by automated pulse pressure variation (PPV). PPV will be followed for first 48 hours after recruitment to the study. Fluid (normal saline, albumin 5%, hetastarch per the clinician preference) will be given in 5cc/kg increments for PPV> 13 (in addition to standard clinical data) until PPV < 13.
3037928|NCT02308371|No Intervention|Retrospective|Patients in this arm were previously admitted to the PICU and were given fluid based on standard clinical data. PPV was not used to guide therapy in this group of patients.
3037929|NCT02308358||Allograft Transplantation|Subjects with femoral condyle osteochondral defects ≥10mm, as determined by MRI or diagnostic knee arthroscopy, will be recruited for allograft transplantation.
3037930|NCT02308358||Microfracture Treatment|Subjects with femoral condyle osteochondral defects <10mm, as determined by MRI or diagnostic knee arthroscopy, will be recruited for microfracture treatment.
3037931|NCT02308345|Experimental|Video summary|Participants in this arm will be given online access to a 5-minute video summary of their pre-chemotherapy visit, recorded by their physician.
3037932|NCT02308332|Active Comparator|Intervention|patients switching from Atripla to Eviplera
3037933|NCT02308332|No Intervention|Control|patients remaining on Atripla
3037934|NCT02308319|Active Comparator|PROMPT|Prompt therapy with Tenofovir disoproxil fumarate (Viread(R)) 300mg p.o
3037935|NCT02308319|Other|Watchful monitoring|Wait and treat with Tenofovir disoproxil fumarate (Viread(R)) when active liver disease is present [defined as HBV DNA >2,000 IU/ml and abnormal ALT (>40 IU/ml)]
3037936|NCT02308306||Opioid analgesics|Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
3037937|NCT02308293|Experimental|High intensity exercise|Subjects will preform a high intensity training exercise (3* 30 seconds all out sprint on a cycle ergometer) to raise plasma lactate levels
3037938|NCT02308293|Sham Comparator|Lay down comfortably|As a control conditions, subjects wil lay down comfortably and rest
3037939|NCT02308280|Experimental|Bortezomib post-transplantation|"Non myeloablative allogeneic transplantation followed by Bortezomib for 1 year after a Bortezomib-based induction and autologous stem cell transplantation.~Bortezomib: 1,3 mg/m2 subcutaneously every 2 weeks for 26 injections."
3037940|NCT02308267||Cystic fibrosis|Cystic fibrosis patients More than 18 years old DF508/DF508 mutation colonized or not with Pseudomonas aeruginosa
3037941|NCT02308267||Controls|Controls patients More than 18 years old Without CF Smokers or nonsmokers
3037942|NCT02308254|Active Comparator|Lixisenatide|Lixisenatide: 10 mcg, one subcutaneous injection dose
3037943|NCT02308254|Placebo Comparator|Placebo|Matching placebo: one subcutaneous injection dose
3037944|NCT02308241|Experimental|Ribavirin|Study subjects will self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day). All patients will complete pill diaries to document administration of study drug. Cycle length is 28 days with continuous dosing. Clinic visits for safety assessments and routine laboratory studies will occur weekly in Cycle 1, in weeks 1 and 3 of Cycle 2, and on Week 1 of subsequent cycles. Cross sectional imaging (CT or MRI) is obtained at baseline and q2 cycles and at End-of Treatment (EOT). Response assessments will follow RECIST 1.1 criteria.
3037945|NCT02308228|Experimental|Metformin|Participants will be randomized to receive Metformin (1700 mg/day) for a period of 16 weeks; 2 weeks of Metformin only followed by 14 weeks of continued Metformin use in combination with progressive resistance training.
3037946|NCT02308228|Placebo Comparator|Placebo, Sugar Pill|Participants will be randomized to receive placebo sugar pills (1700 mg/day) for a period of 16 weeks; 2 weeks of placebo only followed by 14 weeks of continued placebo use in combination with progressive resistance training. Placebos will be almost identical to the Metformin medication.
3037947|NCT02308202|Active Comparator|doxazosin|Subjects will be randomized to receive either doxazosin XL or placebo. Participants will receive doses of study medication as over-encapsulated doxazosin XL or placebo dosed once in the morning. Study medication will be initiated as one capsule of doxazosin XL 4 mg or placebo given in the morning. The dose will be titrated up to 16 mg/d doxazosin XL or placebo as follows: Days 1-4: 4mg, Days 5-8: 8mg, Day 9-12: 12 mg, Days 13-16: 16 mg.
3037948|NCT02308202|Active Comparator|perindopril|Subjects will be randomized to receive either perindopril 16mg or placebo for 8 days. Participants will receive doses of study medication as over-encapsulated perindopril or placebo dosed once in the morning.
3037949|NCT02308202|Placebo Comparator|placebo|Subjects will be randomized to receive either doxazosin XL or placebo. Participants will receive placebo for doxazosin XL for 16 days and placebo for perindopril for 8 days.
3037950|NCT02308189|Active Comparator|Exercise|Low load resistance exercise training
3037951|NCT02308189|Experimental|Exercise with blood flow restriction|Low load resistance exercise training with blood flow restriction
3037958|NCT02308137|Experimental|Domperidone|Treatment: Oral domperidone four times daily Target dose: 40mg per day Duration: 1 year
3037959|NCT02308124|Experimental|Midodrine|Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.
3037960|NCT02308124|Experimental|Pyridostigmine|Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.
3037961|NCT02308124|Experimental|Midodrine + Pyridostigmine|Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.
3037962|NCT02308111|Experimental|Obeticholic Acid (OCA) 5 mg to 10 mg|Obeticholic Acid (OCA) 5 mg for a minimum 3 months and then titrating up to a maximum 10 mg for the remainder of the trial (based on tolerability and Child Pugh Score).
3037963|NCT02308111|Placebo Comparator|Placebo|
3037964|NCT02308098|Experimental|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh
3037965|NCT02308098|Experimental|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh
3037966|NCT02308098|Experimental|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh
3037967|NCT02308098|Experimental|Symbicort Turbuhaler 320/9 ug/inhalation 1 inh|Symbicort Turbuhaler 320/9 ug/inhalation 1 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh
3037968|NCT02308085|Experimental|Endocrine therapy interruption|Endocrine therapy interruption after having completed between ≥ 18 months and ≤ 30 months.
3037969|NCT02308072|Experimental|Olaparib + Cisplatin + IMRT|"Olaparib: 50, 100, 150 or 200 mg twice a day for between 3-5 sequential days, depending on cohort allocation, in combination with Cisplatin: 35 mg/m^2 on day 1, and IMRT: 2 Gy radiotherapy given on days 1-5~Treatment will start on day 1 of every week. Patients will receive up to 7 weeks of combination chemotherapy and radiotherapy treatment."
3037970|NCT02308059||Patients with diabetes mellitus|Group I; the patients with diabetes mellitus who had peripheral neuropathy as diagnosed.
3037971|NCT02308059||Control|Group II; healthy volunteers
3037972|NCT02308046|Active Comparator|Terconazole vaginal gel|One applicator full at bedtime
3037973|NCT02308046|Placebo Comparator|Gel vehicle|One applicator full at bedtime
3037974|NCT02308033|Active Comparator|Metronidazole vaginal gel|One applicator full at bedtime
3037975|NCT02308033|Placebo Comparator|Gel vehicle|One applicator full at bedtime
3037976|NCT02308020|Experimental|Part A: HER2+ Breast Cancer|"Participants with HR+, HER2+ breast cancer.~200 milligrams (mg) abemaciclib given orally once every 12 hours on days 1-21 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."
3037977|NCT02308020|Experimental|Part B: HER2- Breast Cancer|"Participants with HR+, HER2- breast cancer.~200 mg abemaciclib given orally once every 12 hours on days 1-21 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."
3037978|NCT02308020|Experimental|Part C: Surgical Resection|"Participants with HR+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated.~200 mg abemaciclib given orally once every 12 hours for 5-14 days prior to surgical resection. Dosing may resume following wound healing on a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."
3037979|NCT02308020|Experimental|Part D: NSCLC|"Participants with NSCLC.~200 milligrams mg (150 mg for participants receiving concurrent gemcitabine or pemetrexed) abemaciclib given orally once every 12 hours on days 1-21 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."
3037980|NCT02308020|Experimental|Part E: Melanoma|"Participants with melanoma.~200 milligrams mg abemaciclib given orally once every 12 hours on days 1-21 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."
3037981|NCT02308020|Experimental|Part F: HR+ Breast Cancer, NSCLC, or Melanoma|"Participants with HR+ breast cancer, NSCLC, or melanoma and leptomeningeal metastases.~200 milligrams mg abemaciclib given orally once every 12 hours on days 1-21 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."
3037982|NCT02308007|Active Comparator|Terconazole vaginal gel|One applicator full at bedtime
3037983|NCT02308007|Active Comparator|Metronidazole vaginal gel|One applicator full at bedtime
3037984|NCT02308007|Active Comparator|Terconazole/metronidazole vaginal gel|One applicator full at bedtime
3037985|NCT02307994|Experimental|75IU uFSH|75IU uFSH (Livzon Pharm Group Inc., China) being injected into severe oligospermia patients or azoospermia patients every 3 days for 6 months
3037986|NCT02307981||Visual field defect with vision teacher|Patients With occipital ischemic stroke and Visual Field defect that live in a geographical region where training With vision teacher is an available service (vision Teachers are a Limited Resource in Norway)
3037987|NCT02307981||Visual field defect without vision teacher|Patients With occipital ischemic stroke and a Visual Field defect, who live in a geographical area where training With vision teacher is not an available service.
3037988|NCT02307968||inner thigh insulin injection|inject insulin at inner thigh site is the intervention arm. So we inject insulin at this site to see if this site is suitable for insulin injection.
3037989|NCT02307968||outer thigh insulin injection|outer thigh site for insulin therapy is the usual site
3037990|NCT02307955|Experimental|firefly|participants treated with firefly device
3037991|NCT02307955|Other|Control|Standard of care
3037992|NCT02307942|Experimental|SURGERY|Patient will be operated for a gastric banding disposal
3037993|NCT02307942|No Intervention|STANDARD|Standard of care for obesity
3037994|NCT02307929||Chronic Disease Management|Aging population with the need of Chronic Disease Management
3037995|NCT02307916|Experimental|FGF-2|FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
3037996|NCT02307916|Placebo Comparator|Placebo|Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
3037997|NCT02307903||End-stage renal failure (ESRF)|end-stage renal failure (ESRF)
3038050|NCT02307513|Experimental|Apremilast (CC-10004)|Patients randomized to this arm will receive 30 mg Apremilast (CC-10004) tablets twice daily by mouth for 64 weeks.
3037998|NCT02307890||Liver transplantation group|Participants will include all deceased adult liver transplant donors (>16 years of age) whose livers are being utilised for transplantation in the Scottish Liver Transplant Unit in the Royal Infirmary of Edinburgh. Exclusion criteria will include paediatric liver transplant donors (<16 years of age).
3037999|NCT02307877||Fingolimod|Subjects currently taking Fingolimod for a minimum of 2 years
3038000|NCT02307877||glatiramer acetate|Subjects currently taking glatiramer acetate for a minimum of 2 years
3038001|NCT02307864|Experimental|Treatment Sequence 1|Participants will receive treatment A (2*50 milligram [mg] tramadol hydrochloride [HCl] immediate release [IR] tablet + 1 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 2*50 mg tramadol HCl IR tablet + 1 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4); treatment B (3*50 mg tramadol HCl IR tablet every 6 hours on Days 1, 2, and 3, along with single dose of 3*50 mg tramadol HCl IR tablet + 1 moxifloxacin placebo on Day 4); treatment C (3 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 3 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4); and treatment D (3 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 3 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4) in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
3038002|NCT02307864|Experimental|Treatment Sequence 2|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
3038003|NCT02307864|Experimental|Treatment Sequence 3|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
3038004|NCT02307864|Experimental|Treatment Sequence 4|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
3038005|NCT02307851|Experimental|Group A|Quadrivalent VLP vaccine, low dose, intramuscular injection (0.5mL)
3038006|NCT02307851|Experimental|Group B|Quadrivalent VLP vaccine, high dose, intramuscular injection (0.5mL)
3038007|NCT02307851|Experimental|Group C|Quadrivalent VLP vaccine, medium dose, intramuscular injection (0.5mL)
3038008|NCT02307851|Active Comparator|Group D|Comparator TIV, intramuscular injection (0.5mL)
3038009|NCT02307838|Other|Phase 2 CFTY720D2201 (NCT02307838) participants|CFTY720D2201E2 participants did not receive any protocol specified treatment. The original D2201 study sites, who agreed to participate in this study, were required to locate their participants who were randomized in D2201 and asked them to return for a 10 year assessment, regardless of current treatment status.
3038010|NCT02307825|Active Comparator|Azithromycin|Patients will receive the active study drug, azithromycin, as well as sinus irrigations with budesonide.
3038011|NCT02307825|Placebo Comparator|Placebo|Patients will receive a placebo as well as sinus irrigations with budesonide.
3038012|NCT02307786||Beta-Thalassemiall -Transplantation|
3038013|NCT02307786||Beta-Thalassemia Supportive Care|
3038014|NCT02307773||Case Group|Treated with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope before intubation with conventional pharyngeal anesthesia
3038015|NCT02307773||Control Group|Treated with conventional pharyngeal anesthesia without further treatment.
3038016|NCT02307760|Active Comparator|Study Human Milk Fortifier A|Acidified processing method.
3038017|NCT02307760|Experimental|Study Human Milk Fortifier B|Non-acidified processing method.
3038018|NCT02307747|Experimental|trauma patients|Blood samples will be collected every 4 hours during 24 h, between day 2 and day 4 after inclusion
3038019|NCT02307734|Experimental|Quit Smoking for a Healthy Family|The experimental/intervention study arm focuses on providing smoking cessation education and support through 2 LHW outreach small group educational sessions (4-5 weeks apart) and 2 individual follow-up telephone calls to smoker and family participants separately.
3038020|NCT02307734|Active Comparator|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
3038021|NCT02307721|Experimental|intranasal naloxone|8 mg/ml naloxone 0,1 mL IN as one puff in one nostril in supine position
3038022|NCT02307721|Active Comparator|Intramuscular naloxone|0,4 mg/ml Naloxone B Braun 2 ML in deltoid muscle
3038023|NCT02307708|Experimental|8° incline shoe|"The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.~During the walk we will have:~In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).~In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction)."
3038024|NCT02307708|Active Comparator|kinesitherapy|The patient performs its home therapy and consults his physiotherapist once a week according to the protocol Stanish
3038025|NCT02307695|Experimental|insulin+Saxagliptin|Patients who have diagnosed type 1 diabetes are assigned to receive Saxagliptin tablets 5 mg and insulin for 24-week.
3038026|NCT02307695|Active Comparator|insulin|Patients who have diagnosed type 1 diabetes only use insulin.
3038027|NCT02307682|Experimental|RTH258 Dose A|RTH258 solution for IVT injection, single injection at Day 0, Week 4, and Week 8, then as specified in the protocol up to Week 92
3038028|NCT02307682|Experimental|RTH258 Dose B|RTH258 solution for IVT injection, single injection at Day 0, Week 4, and Week 8, then as specified in the protocol up to Week 92
3038029|NCT02307682|Active Comparator|Aflibercept|Aflibercept solution for IVT injection, single injection at Day 0, Week 4, and Week 8, then as specified in the protocol up to Week 92
3038051|NCT02307500|Experimental|Regorafenib|Regorafenib 160 mg (40 mg tablets), po, every day for 3 weeks of every 4 week cycle
3038052|NCT02307487|Experimental|Cohort A2|120 mg MMC in 90ml gel
3038053|NCT02307487|Experimental|Cohort B2|140 mg MMC in 90ml gel
3038054|NCT02307487|Experimental|Cohort C2|160 mg MMC in 90ml gel
3038055|NCT02307487|Experimental|Cohort A|120 mg MMC in 60ml gel
3038030|NCT02307669|Placebo Comparator|Routine inhaler adherence care|"Normal Care group This management is based on the recommendations of the BTS/SIGN group (http://www.brit-thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines/sign101%20Jan%202012.pdf)~The core features of the usual care group are:~The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.~Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.~Written action plans for managing asthma, based on changes in PEFR and symptoms will be given.~In follow up, medication changes in response to the above will be directed by these, as suggested by Guidelines"
3038031|NCT02307669|Active Comparator|INCA feedback|"The patient's treatment goal is established and used as the focus of the conversation.~Data from the INCA device including (1) time of use, (2) handling proficiency and (3) inhalation flow rates are discussed, with three graphs as shown in the appendix and derived as discussed. These are aimed to enhance the value of the inhaler.~Data from the hand held PEFR and AQLQ are correlated with the adherence so that these can be used to account for improvements or declines in these measures.~In follow up, medication changes in response to the above(adherence, PEFR, ACT and exacerbations) will be made"
3038032|NCT02307656|Other|Atazanavir and Cobicistat|"Stage 1:Taste evaluation using Active Pharmaceutical Ingredient (API)~Stage 2:Taste Optimization using API (flavours and sweeteners)~Stage 3:Prototypes of the API - containing clinical trial materials"
3038033|NCT02307643|Experimental|Part 1|MT-1303 Low dose+Corticosteroid
3038034|NCT02307643|Experimental|Part 2-A|MT-1303 High dose+Corticosteroid
3038035|NCT02307643|Experimental|Part 2-B|MT-1303 Low dose+Corticosteroid+Immunosuppressant
3038036|NCT02307630|Experimental|PET Imaging using 124I-Humanized 3F8|124I-hu3F8 at a dose of 3mCi/m2 (with a maximum dose of 5mCi) will be injected IV. 124I-hu3F8 PET/CT scans will be performed at approximately 2-4 hours, 18-26hours, 48-72 hours and 96-144 hours after injection of 124I-hu3F8. A low dose CT scan will be obtained with each PET scans. PET/CT scan images will be analyzed to determine biodistribution of 124I-hu3F8 and to determine dosimetry to organs and sites of disease. Comparison of tumor targeting and tumor dosimetry will be made between the two cohorts of patients: (a) NB and (b) other solid tumors. Blood will be drawn where feasible at multiple time points: approximately 0h, 0.5h, 1h, 2h, 4-8h, 24h, 48h, 96h and 120h-144h after injection of 124I-hu3F8 and radioactivity measured to determine pharmacokinetics of 124I-hu3F8.
3038037|NCT02307617||Group 2|Adolescent participants who plan to start selective serotonin reuptake inhibitor (SSRI) treatment for their depression. Data will be collected prior to the start of the medication and again 6 weeks after the start of the medication.
3038038|NCT02307617||Medication Responders|Adolescent participants who have responded to SSRI treatment for their depression.
3038039|NCT02307617||Medication Non-Responders|Adolescent participants with depression that has not responded to SSRI treatment.
3038040|NCT02307617||Healthy Controls|Adolescent participants who have no current or past mental health diagnoses.
3038041|NCT02307604||Brain cancer|Patients with diagnosis of brain cancer at any stage
3038042|NCT02307591|Active Comparator|Best Supportive Care|Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is >7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
3038043|NCT02307591|Experimental|Best Supportive Care + Amiodarone|"This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .~During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).~Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.~Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.~Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).~Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:~Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)~Children < 29 kg: 5 mg/kg 3 times a day"
3038044|NCT02307565|Experimental|Midodrine|Arm 1 last 30 days. Subject will either be given midodrine or placebo to take during Arm 1.
3038045|NCT02307565|Placebo Comparator|Placebo|Arm 2 is followed by a 14 day washout period. Arm 2 last 30 days. Subject will be given a drug (placebo or midodrine) to take during Arm 2.
3038046|NCT02307552|Experimental|All patients|All patients in the study will receive a scan of their prostate with the novel UreScan machine. All scans will be evaluated in their accuracy of detecting cancer loci within the prostate as compared to histopathological reviews of the prostate post robotic prostatectomy.
3038047|NCT02307539|Experimental|Supportive care (PCPI intervention)|"Patients receive a handbook titled Supporting You During Cancer Treatment with educational material on QOL issues. Patients undergo 2 education sessions on handbook material in-person or by telephone, with session 1 focusing on physical and social well-being issues and session 2 focusing on psychological and spiritual well-being issues. At the beginning of each session, patients select 3 priority topics from a list, and content is tailored to patient needs."
3038048|NCT02307526|Experimental|Spinal Cord Injury|After being transferred onto a tilt table, subject with complete SCI will lie in a rested, supine position in which the study drug, pyridostigmine bromide (60 mg) will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
3038049|NCT02307513|Experimental|Placebo + Apremilast|Patients randomized to this arm will receive placebo tablets by mouth twice daily for the first twelve weeks followed by 52 weeks of 30 mg apremilast tablets twice daily by mouth
3038056|NCT02307487|Experimental|Cohort B|140 mg MMC in 60ml gel
3038058|NCT02307474|Experimental|Treatment (Stereotactic Radiosurgery, pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO daily for up to 60 days. Patients then continue to receive pazopanib hydrochloride PO daily and undergo stereotactic radiosurgery (SBRT) every other day over days 60-65.
3038059|NCT02307461|Experimental|Part 1 Cohort 1|IPI-145 test formulation (capsule) high single dose and IPI-145 reference formulation (capsule) high single dose
3038060|NCT02307461|Experimental|Part 1 Cohort 2|IPI-145 test formulation (capsule) low single dose and IPI-145 reference formulation (capsule) low single dose
3038061|NCT02307461|Experimental|Part 2 Cohort 3|IPI-145 test formulation (capsule) high single dose administered under fasted and fed conditions
3038062|NCT02307448|Active Comparator|PRP Group|Patients will receive weekly PRP treatments
3038063|NCT02307448|Placebo Comparator|Standard of Care|Patients will receive weekly standard of care.
3038064|NCT02307435|Experimental|implantation group|implantation group will receive MSC and HA-CaSo4
3038065|NCT02307422||Case|Diabetic patients undergoing coronary angiography (both sexes), who are age 18-90, and admitted in the Department of Cardiology in the University General Hospital of Ioannina and Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. Presence epicardial vessel stenosis (>50%), and multi-vessel disease will be recorded. Excluded: previous history of revascularization procedure or moderate to severe stenosis. Patient samples will be evaluated for quantitative levels of the biomarkers Lp(a) and OXPL/apoB. IL-1 Genotypes, and other SNPs associated with CAD will be assessed in this group and related to levels of Lp(a) and oxidized phospolipids. No interventions other than the post-hoc DNA testing will be performed.
3038066|NCT02307422||Control|Non-diabeticpatients undergoing coronary angiography (both sexes), who are age 18-90, and admitted in the Department of Cardiology in the University General Hospital of Ioannina and Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. Presence epicardial vessel stenosis (>50%), and multi-vessel disease will be recorded. Excluded: previous history of revascularization procedure or moderate to severe stenosis. Patient samples will be evaluated for quantitative levels of the biomarkers Lp(a) and OXPL/apoB. IL-1 Genotypes, and other SNPs associated with CAD will be assessed in this group and related to levels of Lp(a) and oxidized phospolipids. No interventions other than the post-hoc DNA testing will be performed.
3038067|NCT02307409||Decompensated Chronic Liver Disease|Decompensated Chronic Liver Disease patients will be enrol
3038068|NCT02307409||Healthy Controls|Healthy Controls will be enrol
3038069|NCT02307396|Experimental|Intervention|"Intervention group: guided discontinuation or dose-reduction of the current antipsychotic medication. The antipsychotic drug used before study start will be discontinued gradually under medical surveillance. The process of discontinuation depends on the physicians judgement und should be guided be the participants needs and clinical status. This approach was already used before in another study (gradual discontinuation, Wunderink et al., 2007). We assume that the dose can be reduced by approximately 1/6 of the starting dose every two weeks. If long acting antipsychotics are applied, there is no need for a gradual discontinuation due to their long half life."
3038070|NCT02307396|Active Comparator|Control|The participants receive the same antipsychotic drugs, they have received before the start of the study, without changing the dose or the application form. Study medication is, with exception of Clozapin, every oral or depot neuroleptic drug approved for the treatment of schizophrenia in Germany.
3038071|NCT02307383|Experimental|Lactitol and Lactobacillus|"Lactitol monohydrated 10g (Emportal®), 1 sachet dissolved in water, three times a day for 21 days.~Lactobacillus acidophilus, 1 x 109 UFC and Lactobacillus Biphidus 1 x 109 UFC, (Infloran Berna), 2 tablets by mouth, three times a day for 21 days."
3038072|NCT02307370|Experimental|Turbo-Elite Atherectomy|
3038073|NCT02307357|Experimental|newcomball players|active newcomball women players will perform physical fitness tests
3038074|NCT02307357|Experimental|control|not physically active women will perform physical fitness tests
3038075|NCT02307344|Active Comparator|Nigella Sativa Supplement|Fifty patients suffering from Nonalcoholic Steatohepatitis or Liver Steatosis will ingest capsules containing 2 grams of Nigella Sativa divided into 1 grams twice a day.
3038076|NCT02307344|Active Comparator|Patients receiving a placebo tablet|Twenty patients suffering from Nonalcoholic Steatohepatitis or Liver Steatosis will ingest placebo capsules twice a day, that look like the capsules of those receiving the Nigella Sativa.
3038077|NCT02307331|Other|Optivac and E1|Sirius stem used with Optivac mixed cement - Exceed Cup - E1 PE
3038078|NCT02307331|Other|Optivac and Arcom|Sirius stem used with Optivac mixed cement - Exceed Cup - Arcom PE
3038079|NCT02307331|Other|Optipac and E1|Sirius stem used with Optipac mixed cement - Exceed Cup - E1 PE
3038080|NCT02307331|Other|Optipac and Arcom|Sirius stem used with Optipac mixed cement - Exceed Cup - Arcom PE
3038081|NCT02307318|Other|SoftSeal Hemostatic Pad|This is a single arm study. All patients received the SoftSeal hemostatic pad for compression following elective or urgent coronary angiogram.
3038082|NCT02307305|Experimental|Duloxetin group|"Phase I (preemptive): 2 hour before surgery (30mg for 1 day)~Phase II (titration): POD#1~6 (30mg for another 6 days)~Phase III (maintenance): POD#7~13(60mg for 7 days)~Phase IV (tapering-1): POD#14~20 (30mg for 7 days)~Phase V (tapering-2): POD#21~27 (30mg another every day for 7 days)~plus routine pain control (celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone)"
3038083|NCT02307305|Active Comparator|routine pain control group|"Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)~Other name of drugs: celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone"
3038084|NCT02307279|Experimental|Gelesis100|Gelesis100 twice daily
3038085|NCT02307279|Placebo Comparator|Placebo|Matching placebo twice daily
3038086|NCT02307266|Experimental|Standard of care + supplementary education|Subjects will receive supplementary patient educational material in addition to standard-of-care instructions.
3038087|NCT02307266|Experimental|Standard of care|Subjects will receive standard-of-care instructions only.
3038088|NCT02307266|Experimental|Standard of care + additional visits|Subjects will receive standard-of-care instructions, and two additional clinical visits.
3038089|NCT02307253|Experimental|patients with solid lesions|Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)
3038090|NCT02307240|Experimental|CUDC-907 - five days on/two days off|60 mg/day CUDC-907, oral administration, five days on/two days off until disease progression or other discontinuation criteria are met.
3038091|NCT02307227|Experimental|Locally advanced HER2+ breast cancer pts|"HER2 positive (defined as 3+ at Herceptest or FISH/CISH positive):~treatment with Trastuzumab 4mg/kg first time, then 2 mg/kg weekly with concomitant paclitaxel 80 mg/mq weekly (one cycle corresponding to 4 weeks) for 12 weeks (3 cycles). Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 6 cycles), then surgical excision"
3038092|NCT02307227|Experimental|Locally advanced HER2- breast cancer pts|"HER2 negative:~treatment with Epirubicin 90 mg/mq and docetaxel 75 mg/mq every 3 weeks for 4 cycles. Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 8 cycles), then surgical excision."
3038093|NCT02307214|Other|Coronary X syndrome|BaroReflex Sensitivity, endothelial function measurement
3038094|NCT02307214|Other|Tako-tsubo cardiomyopathy|BaroReflex Sensitivity, endothelial function measurement
3038095|NCT02307214|Other|Healty Volunteers|BaroReflex Sensitivity, endothelial function measurement
3038096|NCT02307201|Experimental|Postpartum Magnesium sulfate|The patient will receive magnesium sulfate as usual for 24 hours postpartum
3038097|NCT02307201|No Intervention|No postpartum treatment|The patient did not receive postpartum magnesium sulfate or other anticonvulsant during 24 hours postpartum
3038098|NCT02307188|Experimental|Basket Catheter|The Constellation Full Contact Mapping Catheter (multipolar catheter) to be utilized for collection of atrial electrograms.
3038099|NCT02307175||Cyclotec|The first 10 consecutively enrolled patients will have thyroid and whole body scan with CycloTec
3038100|NCT02307175||generator produced Tc99m-pertechnetate|20 subsequent case-matched controls will have thyroid and whole body scan with conventional Tc99m-pertechnetate
3038101|NCT02307162|Placebo Comparator|Dummy solution|Nebulised suspension to be administered as either a single dose (Part A) or 11 doses over 6 days (Parts B anc C)
3038102|NCT02307162|Experimental|RPL554 suspension|"Nebulised suspension to be administered as either a single dose (Part A) or 11 doses over 6 days (Parts B anc C).~Starting dose in Part A to be 1.5mg/mL with planned up to 2 fold increments. Doses in Part B will be selected from Part A. Doses in Part C to be selected from Part B"
3038103|NCT02307149|Experimental|CAVATAK and ipilimumab|CAVATAK intratumoral injection up to a total dose of 3 x 10⁸ TCID50 and ipilimumab intravenously at the recommended dose of 3 mg/kg
3038104|NCT02307123||HEMS treated patients|Patients whose airways were secured by the HEMS physician.
3038105|NCT02307110|Other|1 arm study|cross-sectional observation
3038106|NCT02307097|Experimental|CBB|
3038107|NCT02307097|Experimental|CBT|
3038108|NCT02307097|Active Comparator|WAIT|
3038109|NCT02307084|Experimental|Pre-operative ultrasound imaging|Subjects that are randomly allocated to this group will have ultrasound imaging assessment of the long saphenous vein in both legs. This will allow assessment of the suitability of the long saphenous vein and marking of the distribution prior to heart bypass surgery to allow targeted harvesting of a bypass conduit.
3038110|NCT02307084|No Intervention|Current protocol|This group will not undergo pre-operative ultrasound imaging of the long saphenous vein in accordance with current Trust protocols.
3038111|NCT02307071|Experimental|Cefaly Kit Arnold|Occipital transcranial stimulation is implemented in occipital region at 16 mA of intensity, for 20 minutes, everyday for 3 months, in 20 chronic migraine patients.
3038112|NCT02307058|Active Comparator|LEAD RT|LEAD: Lattice Extreme Ablative Dose, a form of Stereotactic Lattice radiotherapy; International Prostate Symptom Score, Memorial Anxiety Scale for Prostate Cancer patients, and Expanded Prostate Cancer Index Composite-Short Form 12 (EPIC SF-12) questionnaires
3038113|NCT02307058|Active Comparator|HEIGHT RT|HEIGHT: Hypofractionated Extended Image-Guided Highly Targeted, a form of Moderate Hypofractionation; International Prostate Symptom Score, Memorial Anxiety Scale for Prostate Cancer patients, and Expanded Prostate Cancer Index Composite-Short Form 12 (EPIC SF-12) questionnaires.
3038114|NCT02307045|Active Comparator|varenicline|Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po
3038115|NCT02307045|Active Comparator|nicotine|Nicotine replacement therapy with transdermal patches and/or chewing gums
3038116|NCT02307019|Experimental|Program on specific prevention of health|The caregivers will be randomly assigned to an experimental group, to receive the program on specific prevention of health. The workshop will be performed twice a month, two hours a day, during a 4-week period.
3038117|NCT02307019|Active Comparator|Program on general prevention of health|Control group will receive an intervention by mean of a general health program to manage the common situations when a caregiver is caring for a patient with dependency. The workshop will be performed two a month, two hours a day, during a 4-week period.
3038118|NCT02307006|Experimental|Ceftaroline|Experimental comparator for surgical peri-operative prophylaxis for procedures at increased risk if MRSA infection
3038119|NCT02307006|Active Comparator|Cefazolin / Vancomycin|Standard of care comparator for surgical peri-operative prophylaxis for procedures at increased risk if MRSA infection
3038120|NCT02306993||Healthy volunteers without SCT|Includes Healthy African American female volunteer between the ages of 18 and 45 years without sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
3038121|NCT02306993||Healthy volunteers with SCT|Includes Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
3038122|NCT02306993||Volunteers with SCD|Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell disease. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell disease affects bone.
3038123|NCT02306980|Experimental|Colostrum|Colostrum administration
3038124|NCT02306980|No Intervention|Control|Routine care
3038125|NCT02306967|Active Comparator|Standard Resection|Oral resection will be guided by usual practice. This involves identifying the tumour with white light and then marking surgical margins and resection the primary cancer.
3038363|NCT02305329|Experimental|Group 1 BIA 9-1067 25 mg|Period 1 - 5x5 mg OPC Period 2 - 1x25 mg OPC
3038126|NCT02306967|Experimental|FV Guided Resection|The oral resection will be guided by fluorescent visualization (FV).
3038127|NCT02306954|Active Comparator|High Dose IL-2|"Patients will receive IL-2 at 600,000 international units per kg IVB every 8 hours for 14 planned doses with an additional cycle 14 days after the first. Responding patients with regressing disease are eligible for up to 6 IL-2 cycles.~Patients assigned to the IL-2 arm who have disease progression after the first two IL-2 cycles have the option to receive SBRT followed by 2 additional cycles of IL-2."
3038128|NCT02306954|Experimental|High Dose IL-2 and SBRT|Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before IL-2 starts (the following Monday). Patients will receive IL-2 at 600,000 international units per kg IVB every 8 hours for14 planned doses with an additional cycle 14 days after the first. Responding patients with regressing disease are eligible for up to 6 IL-2 cycles.
3038129|NCT02306941|Experimental|Internet-delivered CBT|10 sessions of ICBT during 10 weeks for the adolescents. 5 session of parent training during 10 weeks for parents. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
3038130|NCT02306928||Piperacillin pharmacokinetics|Patients with suspected septic shock who are treated with piperacillin/tazobactam.
3038131|NCT02306915|Experimental|lipegfilgrastim 30|
3038132|NCT02306915|Experimental|lipegfilgrastim 60|
3038133|NCT02306915|Experimental|lipegfilgrastim 100|
3038134|NCT02306902|Experimental|Test|Fenofibrate Capsules, USP 130 mg
3038135|NCT02306902|Active Comparator|Reference|ANTARA® (fenofibrate) Capsules 130 mg
3038136|NCT02306889|Experimental|Test|Fenofibrate Capsules, USP 130 mg
3038137|NCT02306889|Active Comparator|Reference|ANTARA® (fenofibrate) Capsules 130 mg
3038138|NCT02306876|Experimental|PF-06412562 3mg|PF-06412562 3mg BID
3038139|NCT02306876|Placebo Comparator|Placebo|Placebo BID
3038140|NCT02306876|Experimental|PF-06412562 15mg|PF-06412562 15mg BID
3038141|NCT02306863|Experimental|whole-body vibration|40 Hz Whole-body vibration applied via physioaccoustic method for 12 weeks, 3 times a week
3038142|NCT02306863|Sham Comparator|sham treatment|simulated whole-body vibration applied 3 times a week for 12 weeks
3038143|NCT02306850|Experimental|Pembrolizumab|Open-label non-randomized trial. All subjects will receive active drug (pembrolizumab).
3038144|NCT02306837|Experimental|Consolidation chemo|Patients recieved 3 cycles of consolidation chemotherapy post-auto-HSCT: mini-Bu-Cy-E regimen
3038145|NCT02306811|Experimental|Vatelizumab Dose 1|Vatelizumab dose 1 every 4 weeks (Q4W) for 96 weeks
3038146|NCT02306811|Experimental|Vatelizumab Dose 2|Vatelizumab dose 2 every 4 weeks (Q4W) for 96 weeks
3038147|NCT02306811|Experimental|Vatelizumab Dose 3|Vatelizumab dose 3 every 4 weeks (Q4W) for 96 weeks
3038148|NCT02306811|Experimental|Vatelizumab Dose 4|Vatelizumab dose 4 every 4 weeks (Q4W) for 96 weeks
3038149|NCT02306798|Experimental|Formulation D|TP05
3038150|NCT02306785|Experimental|Formulation D|TP05 Coating D
3038151|NCT02306785|Experimental|Formulation E|TP05 Coating E
3038152|NCT02306785|Experimental|Formulation H|TP05 Coating H
3038153|NCT02306772|Experimental|Formulation A|TP05 Coating A
3038154|NCT02306772|Experimental|Formulation B|TP05 Coating B
3038155|NCT02306759|Experimental|Treatment|Ketamine 0.3mg/kg intravenous piggyback (IVPB) in 50ml NS over 15 minutes Morphine 0.1mg/kg intravenous push (IVP) PRN at designated intervals
3038156|NCT02306759|Placebo Comparator|Placebo|Normal saline 50ml intravenous piggyback (IVPB) over 15 minutes Morphine 0.1mg/kg intravenous push (IVP) PRN at designated intervals
3038157|NCT02306746|Experimental|TARGET protocol EN 1.5 kcal/mL|Enteral (EN) feed 1.5 kcal/mL. The goal rate for administration of TARGET protocol EN is 1ml/kg/hr. To calculate the goal rate, weight is based on ideal body weight.
3038158|NCT02306746|Active Comparator|TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL The goal rate for administration of TARGET protocol EN is 1ml/kg/hr. To calculate the goal rate, weight is based on ideal body weight.
3038159|NCT02306733|Active Comparator|Ergometrine|100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv)
3038160|NCT02306733|Active Comparator|Oxytocin|100 women with atonic PPH will receive oxytocin 10 IU (Syntocinon® Novartis, Switzerland) slowly intravenous.
3038161|NCT02306707||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Stomach Lesions will be included in this cohort.
3038162|NCT02306694|Experimental|Open label|Everyone receives Advate (antihemophilic factor) on Day 1 and 3.
3038163|NCT02306681||SAQ-Self-Assessment Questionnaire|
3038164|NCT02306668||Ocular surface discomfort|There are no interventions with this observational study
3038165|NCT02306642||Premature Acute Kidney Injury in NICU|This group of babies born less than 1500 grams will have experienced acute kidney injury based on the modified KDIGO guidelines for acute kidney injury.
3038166|NCT02306642||Premature No Acute Kidney Injury in NICU|This group of babies born less than 1500 grams will have not experienced acute kidney injury in the NICU.
3038167|NCT02306642||Term No Acute Kidney Injury|This group of babies born at term will have not experienced any acute kidney injury.
3038168|NCT02306629|Experimental|Epratuzumab dose 1 sc|This group of Caucasian and Japanese subjects will receive one single dose 1 of epratuzumab subcutaneous
3038169|NCT02306629|Experimental|Epratuzumab dose 2 sc|This group of Caucasian and Japanese subjects will receive one single dose 2 of epratuzumab subcutaneous
3038170|NCT02306629|Experimental|Epratuzumab dose 3 sc|This group of Caucasian subjects will receive one single dose 3 of epratuzumab subcutaneous
3038171|NCT02306629|Active Comparator|Epratuzumab dose 2 iv|This group of Caucasian and Japanese subjects will receive one single dose 2 of epratuzumab as an intra venous infusion
3038172|NCT02306603||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Duodenal and Ampullary Lesions will be included in this cohort.
3038173|NCT02306590|Experimental|Study Intervention|High caloric fatty diet for drinking (100% lipids, 4.5 kcal/ml) 405 kcal/90 ml/day in addition to daily food intake and standard of care; corresponding to an additional intake of 45 g fat per day
3038226|NCT02306265|Active Comparator|FFDM|Subjects will undergo 2D breast imaging with full-field digital mammography (FFDM) device
3038174|NCT02306590|Placebo Comparator|Placebo|Placebo drinking solution 8 kcal/90ml/day in addition to daily food intake and standard of care
3038175|NCT02306577||Vancouver|HIV infected people who are current of recent illicit drug users and receive Stribild for their HIV treatment at Vancouver Infectious Diseases Centre and Regina General Hospital.
3038176|NCT02306564|Experimental|Group A|Group A will include patients at risk of OHSS receiving Cabergoline 0.5mg daily for 8 days (Dostinex®, Pfizer Australia Pty Ltd ) from the day of oocyte pick up for prevention of hyperstimulation
3038177|NCT02306564|No Intervention|Group B|Group B will include patients AT RISK of ovarian hyperstimulation syndrome (OHSS) not receiving Cabergoline.
3038178|NCT02306564|No Intervention|Group C|Group C will serve as a control group and will include age & BMI matched patients NOT AT RISK of OHSS, and not receiving cabergoline.
3038179|NCT02306551||Psychotic Disorder|Biological and psycho-social risk and resilience factors
3038180|NCT02306551||Bipolar Disorder|Biological and psycho-social risk and resilience factors
3038181|NCT02306551||Depressive Disorder|Biological and psycho-social risk and resilience factors
3038182|NCT02306551||Non-psychiatric Control|Biological and psycho-social risk and resilience factors
3038183|NCT02306525||Ptt. with Femoracetabular Impingement|Enrollment anticipated: 60 Arthroscopic surgery of the hip joint
3038184|NCT02306525||Healthy volunteers|Enrollment anticipated: 30
3038185|NCT02306512|Active Comparator|Standard vs. IF MART-1|"Samples removed with MMS within the first 3 mm margin from the tumor will be the first section. They will be processed as a conventional H&E frozen section and section stained with IHC MART-1. Samples removed with MMS within 3-6 mm from tumor margin will be the second section. They will be processed with fluorescent MART-1 antibodies. Based on the pre-defined characteristics MMS surgeon will evaluate each MART-1 immunofluorescent section as no evident melanoma or possible melanoma or present melanoma. Dermatopathologist will secondarily review each section scoring them in the same manner. If standard H&E, IHC, or immunofluorescence is recorded as present melanoma or possible melanoma a third section from 6-9mm will have the same procedure described before."
3038186|NCT02306512|Active Comparator|IF MART-1 versus IF cocktail|In the second arm of the study, assuming that immunofluorescence with MART-1 proves to be superior or at least equivocal to regular MART-1 IHC, the same method will be applied, but the control sections will be stained with fluorescent MART-1 antibodies and compared to a section stained with a cocktail of fluorescent melanocytic antibodies.
3038187|NCT02306499|Experimental|ICSI WITH CRYOPRESERVED SPERM FROM NOA WITH VARICOCELE|ICSI cases using cryopreserved testicular sperm from infertile azoospermic men, with proven diagnosis of varicocele (clinical & sonographic), which will be used for ICSI in an ART program
3038188|NCT02306499|Experimental|ICSI WITH CRYOPRESERVED SPERM FROM NOA WITH NO VARICOCELE|ICSI cases using cryopreserved testicular sperms from infertile azoospermic men due to etiologies other than varicocele
3038189|NCT02306486|Placebo Comparator|z250 resin composite|(n=31) Treated with distilled water (placebo) and restored with a methacrylate resin-based-composite (Z250, 3M ESPE, shade: A3)
3038190|NCT02306486|Active Comparator|z250 resin composite + oxalic acid|(n=31) treated with 0.5% oxalic acid (Desenssiv, SSWhite)(intervention)// and restored with a methacrylate resin-based-composite (Z250, 3M ESPE, shade: A3)
3038191|NCT02306486|Placebo Comparator|p 90 resin composite|(n=31) Treated with distilled water (placebo) and restored with a silorane resin-based-composite.
3038192|NCT02306486|Active Comparator|p 90 resin composite + oxalic acid|(n=31) treated with 0,5% oxalic acid (Desenssiv SSWhite)(Intervention)/ and restored with a silorane resin-based-composite (Filtek Silorane p90, £M ESPE, shade:)
3038193|NCT02306473|Experimental|Asthma|Subjects with asthma will be exposed to inhaled mannitol according to FDA approved protocols.
3038194|NCT02306473|Experimental|Controls|Healthy control subjects will be exposed to inhaled mannitol according to FDA approved protocols.
3038195|NCT02306460||left atrial catheter ablation|
3038196|NCT02306460||left atrial appendix closure|
3038197|NCT02306460||paroxysmal atrial fibrillation control group|
3038198|NCT02306460||persistent atrial fibrillation control group|
3038199|NCT02306447|Experimental|rPMS and rTMS|"rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.~rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.~For stimulation we use MagPro X100 (Medtronic, Denmark)."
3038200|NCT02306434|Active Comparator|Therapy by iCBT|Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.
3038201|NCT02306434|Other|Standard care-Counselling|Counselling for childbirth fear is given by the antenatal care midwife and by specially trained midwives working in collaboration with obstetricians at approximately 3-5 face to face counselling sessions. Often a visit to the delivery unit is included in the program and a care plan for the coming birth.
3038222|NCT02306291|Experimental|Arm B (Phase II Arm A)|GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
3038223|NCT02306291|Experimental|Arm C (Phase II Arm B)|GMI-1271 in combination with cytarabine and idarubicin (7+3 regimen) in newly diagnosed subjects 60 years and older
3038224|NCT02306278|Placebo Comparator|vitamin capsules|vitamin capsules orally at the night before operation and 2 hours before surgery,respectively
3038225|NCT02306278|Experimental|gabapentin|gabapentin 600mg orally at the night before operation and 2 hours before surgery,respectively
3038202|NCT02306421|Active Comparator|RPH with the simplified Milligan-Morgan|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation. The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer, anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids. Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
3038203|NCT02306421|Active Comparator|PPH with the simplified Milligan-Morgan|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position.Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
3038204|NCT02306421|Active Comparator|R P H|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation.The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer , anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids , making hemorrhoidal lump shrink, thus eliminating bleeding and prolapse symptoms of hemorrhoid.It is suitable for internal hemorrhoids in every period and internal hemorrhoids part of mixed hemorrhoid.
3038205|NCT02306421|Active Comparator|P P H|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids-PPH.In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position
3038206|NCT02306421|Active Comparator|Milligan-Morgan|Milligan-Morgan surgery ,created in 1937 by Milligan etc,whose essence is to excise hemorrhoids of increasing prolapse in anatomy has good curative effect, low recurrence.It is currently the most common clinical surgery.
3038207|NCT02306395|Experimental|Endometrial local injury|Endometrial local injury is carried in the first 3-5 days after menstrual period at the same time of hysteroscopy.
3038208|NCT02306395|No Intervention|The blank group|Any processing does not carry on the endometrium in the first 3-5 days after menstrual period except hysteroscopy.
3038209|NCT02306382|Experimental|ultrasonography, abscess|The experimental group will be treated after examination with 3D ultrasonography. Follow up after two months and one year.
3038210|NCT02306382|Other|Control group with clincial inscision|The control group will have drainage of their perianal abscess in the OR without ultrasound. Follow-up after two months and one year.
3038211|NCT02306369|No Intervention|Treatment as usual|A wait-list control.
3038212|NCT02306369|Experimental|Internetdelivered exposure-based CBT|10 sessions of ICBT during 10 weeks for the adolescents. 5 session of parent training during 10 weeks for parents. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
3038213|NCT02306356|Experimental|Interventional|Behavioral: Internet-delivered Cognitive Behavior Therapy
3038214|NCT02306343|Experimental|Test (with the InsuPad device)|"In the Meal Tolerance Test protocol - After overnight fast followed by a pre-study stabilization period, the InsuPad device was placed on the abdomen of the subject. The InsuPad device was activated and insulin bolus (0.2 units/kg body weight) was injected right before study start. The injection was given to the subject's abdomen through the injection window of the InsuPad device. Immediately afterwards the subject was asked to drink a standardized liquid meal within 10 minutes. Blood glucose measurements were taken from a peripheral venous line at a pre-determined time points. Total follow up time was 5 hours post meal.~In the daily life setting - Up to 12 months with the device (test). Subjects were asked to perform at least 3 blood glucose measurements during the day."
3038215|NCT02306343|No Intervention|Control (without the InsuPad device)|"In the Meal Tolerance Test protocol - After overnight fast followed by a pre-study stabilization period, insulin bolus (0.2 units/kg body weight) was injected to the abdomen right before study start. Immediately afterwards the subject was asked to drink a standardized liquid meal within 10 minutes. Blood glucose measurements were taken from a peripheral venous line at a pre-determined time points. Total follow up time was 5 hours post meal.~In the daily life setting - Up to 12 months without the device (control). Subjects were asked to perform at least 3 blood glucose measurements during the day."
3038216|NCT02306330|Experimental|Malditof|Specimens of patients (diagnostic aspirates from normally sterile sites: cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies) in Malditof arm will be performed by Malditof instrument to identify the pathogens. It takes 20 minutes for Malditof to identify the pathogens. Then patients will be treated based on these results.
3038217|NCT02306330|Active Comparator|Routine clinical microbiology|Specimens of patients (diagnostic aspirates from normally sterile sites: cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies) in routine clinical microbiology arm will be conducted by the routine clinical microbiologies and followed the treatment process of the hospital.
3038218|NCT02306317|Active Comparator|Control by nursing.|FiO2 adjusted manually by nursing staff. Intervention: Other. Standard procedure
3038219|NCT02306317|Experimental|Control by parents.|FiO2 adjusted manually by parents. Intervention. Other. Experimental procedure
3038220|NCT02306304|Other|Israeli Arab men|Single arm study. The arm includes all enrolled patients screened by duplex ultra sound for abdominal aortic aneurysms.
3038221|NCT02306291|Experimental|Arm A (Phase I)|GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
3038287|NCT02305888|Experimental|LEO 43204, 0.1% once daily for 3 days|
3038227|NCT02306265|Experimental|DBT|Subjects will undergo 3D breast imaging with digital breast tomosynthesis (DBT) device
3038228|NCT02306252|Experimental|CARE Intervention|This group will be contacted to make an appointment for outpatient Occupational and Physical therapy. The therapist will determine the type, frequency and length of treatment. Follow up phone calls will be made to ensure appointments are made, kept and rescheduled as needed.
3038229|NCT02306252|No Intervention|CARE Control|Patients randomized to this arm will receive contact information and a brochure outlining the services available within the supportive care program. The study coordinator will provide the information based on their results and assist the patient with contacting the program if desired.
3038230|NCT02306239|Active Comparator|norepinephrine|patients received norepinephrine
3038231|NCT02306239|Experimental|terlipressin|patients received terlipressin
3038232|NCT02306213|Experimental|Hydroxyethylstarch 6% 130/0.4|These patients have received Hydroxyethylstarch 6% 130/0.4 intraoperatively or postoperatively in addition to standard volume therapy.
3038233|NCT02306213|Active Comparator|No Hydroxyethylstarch 6% 130/0.4|These patients have not received Hydroxyethylstarch 6% 130/0.4 at any time point. Only standard volume therapy has been used.
3038234|NCT02306200||Aortic Disease|Patients with a diagnosis of any form of Aortic Disease
3038235|NCT02306200||Controls|Patients without a diagnosis of Aortic Disease
3038236|NCT02306187|Experimental|Non-Alfacaocidol|Ahead of Eldecalcitol treatment, this group has not taken Alfacaocidol before. Eldecalcitol: the commercial name is Edirol We prescribe Edirol 0.5 or 0.75ug per day into each patient.
3038237|NCT02306187|Experimental|Alfacalcidol|Ahead of Eldecalcitol treatment, this group has taken Alfacaocidol before. Eldecalcitol: the commercial name is Edirol We prescribe Edirol 0.5 or 0.75ug per day into each patient.
3038238|NCT02306174|Experimental|Cognitive Rehabilitation and Exposure-based Class for Compulsi|
3038239|NCT02306161|Experimental|Regimen A (VDC/IE)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV over 1 minute on day 1; doxorubicin hydrochloride IV over 1-15 minutes on days 1 and 2; and cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 5, and 9; and ifosfamide IV over 1 hour on days 1 to 5 and etoposide IV over 1-2 hours on days 1 to 5 of weeks 3, 7, and 11.~LOCAL CONTROL THERAPY: Between weeks 13-18, patients undergo surgery and/or radiation therapy.~CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1, 7, 9, and 13; doxorubicin hydrochloride IV over 1-15 minutes on days 1 and 2 of weeks 1 and 7; cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 7, 9, and 13; ifosfamide IV over 1 hour on days 1 to 5 of weeks 3, 5, 11, and 15; and etoposide IV over 1-2 hours on days 1 to 5 of weeks 3, 5, 11, and 15.~METASTATIC SITE IRRADIATION: Patients with lung metastases undergo definitive SBRT or EBRT over 5 days."
3038240|NCT02306161|Experimental|Regimen B (VDC/IE + ganitumab)|"INDUCTION THERAPY: Patients receive Induction therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11.~LOCAL CONTROL THERAPY: Between weeks 13-18, patients undergo surgery and/or radiation therapy.~CONSOLIDATION THERAPY: Patients receive Consolidation therapy as in Regimen A and ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 7, 9, 11, 13, and 15.~METASTATIC SITE IRRADIATION: Patients with lung metastases undergo definitive SBRT or EBRT over 5 days.~MAINTENANCE THERAPY: Patients receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 in weeks 1, 4, 7, 10, 13, 16, 19, and 22."
3038241|NCT02306148|Placebo Comparator|Control Group|Group will practice 15 seconds isometric lower limb stretching protocol and must continue practicing running as usual.
3038242|NCT02306148|Experimental|Foot and ankle strengthening|Group will be trained during 2 months by a physiotherapist for foot and ankle strengthening and must continue to exercise at home with a training software supervision. Must continue practicing running as usual.
3038243|NCT02306122|Experimental|Default patient default doctor|Patient nonadherence information sent to physician; Pharmacist calls patient unless physician cancels call
3038244|NCT02306122|Experimental|Information patient default doctor|Patient nonadherence information sent to physician
3038245|NCT02306122|No Intervention|Control patient default doctor|Control - no intervention
3038246|NCT02306122|Experimental|Choice patient choice doctor|Patient nonadherence information sent to physician; Pharmacist calls patient if physician requests call
3038247|NCT02306122|Experimental|Information patient choice doctor|Patient nonadherence information sent to physician
3038248|NCT02306122|No Intervention|Control patient choice doctor|Control - no intervention
3038249|NCT02306122|Experimental|Information patient information doctor|Patient nonadherence information sent to physician
3038250|NCT02306122|No Intervention|Control patient information doctor|Control - no intervention
3038251|NCT02306122|Experimental|Default patient default doctor status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician; Pharmacist calls patient unless physician cancels call
3038252|NCT02306122|Experimental|Information patient default doc status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician
3038253|NCT02306122|Experimental|Choice patient choice doc status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician; Pharmacist calls patient if physician requests call
3038254|NCT02306122|Experimental|Information patient choice doc status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician
3038255|NCT02306122|Experimental|Information patient info doc status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician
3038256|NCT02306109|Active Comparator|Standard motor rehabilitation treatment|
3038257|NCT02306109|Experimental|Intensive motor rehabilitation treatment|
3038258|NCT02306083|Placebo Comparator|Administration of the Placebo|Placebo three times a day.
3038259|NCT02306083|Placebo Comparator|Administration of the glucosamine sulfate|glucosamine sulfate 1500 mg three times a day
3038260|NCT02306070|Experimental|Metformin + lifestyle modification|Metformin + lifestyle modification pre, during and post HCV antiviral therapy
3038261|NCT02306070|Placebo Comparator|No Metformin + Lifestyle modification|No metformin + lifestyle modification pre, during and post HCV antiviral therapy.
3038262|NCT02306057||Pre BCPC|Children undergoing catheterization before Bidirectional CavoPulmonary Connection (BCPC) procedure
3038263|NCT02306057||BCPC surgery|Children undergoing surgical BCPC procedure
3038264|NCT02306057||Pre TCPC|Children undergoing catheterization before Total CavoPulmonary Connection (TCPC )procedure
3038265|NCT02306057||TCPC surgery|Children undergoing surgical TCPC procedure
3038266|NCT02306031|Placebo Comparator|placebo (ARTIFICIAL TEAR)|control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations.
3038267|NCT02306031|Active Comparator|diclofenac sodium drop|case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.. Theses drops continued up to 6 weeks with the same dose after operations.
3038268|NCT02306018||EV1000™/volumeView™|
3038269|NCT02306005||Type 1 diabetic patients|Newly diagnosed diabetes type 1 admitted to the Department of Internal Medicine and Diabetology. Measurement of lipid profile and lipoproteins before and after administration of insulin. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years.
3038270|NCT02305992|Experimental|Axillary Block with 0.5% Ropivicaine|Patients will receive an axillary block using an ultrasound-guided technique. After skin infiltration with 1 mL of 2% lidocaine, a 22-gauge insulated needle is advanced in-plane from the cephalic aspect of the transducer toward the posterior aspect of the axillary artery. Prior to injection, the syringe is aspirated to confirm extra-vascular placement of the needle. 20 mL solution of 0.5% ropivicaine is then injected slowly, with syringe aspiration after every 5 mL injection to confirm extravascular placement.
3038271|NCT02305992|Experimental|Stellate Ganglion Block with 0.2% Ropivicaine|Patients will receive stellate ganglion block and local anesthetic using an ultrasound-guided technique.After skin infiltration with 1 mL of 2% lidocaine, a 22-gauge insulated needle is advanced in-plane from the lateral position toward the anterior aspect of longus colli muscle just posterior to the internal jugular vein. Prior to injection, the syringe is aspirated to confirm extra-vascular placement of the needle. 10 mL of 0.2% ropivicaine is then injected slowly, with syringe aspiration after every 5 mL injection to confirm extravascular placement.
3038272|NCT02305992|Active Comparator|Local anesthetic infiltration with 0.25% Bupivicaine|Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
3038273|NCT02305979||Treatment with Loratadine|Treatment with Loratadine
3038274|NCT02305966|Active Comparator|pressfit humerus & non-lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented). Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is -pressfit humerus & non-lateralized glenoid.
3038275|NCT02305966|Active Comparator|pressfit humerus & lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented). Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is - pressfit humerus & lateralized glenoid.
3038276|NCT02305966|Active Comparator|cemented humerus & non-lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented).Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component. Therefore, 4 randomization groups will be created and one of them is cemented humerus & non-lateralized glenoid
3038277|NCT02305966|Active Comparator|cemented humerus & lateralized glenoid.|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented).Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is cemented humerus & lateralized glenoid.
3038278|NCT02305953||Frozen serum|The cohort consists of original subjects from the Inno-6025 Trial who previously consented to measuring protein in the blood involved in skin inflammation.
3038279|NCT02305940|Active Comparator|Doxycycline|Doxycycline: oral dose of 100 mg once daily, for a total duration of 52 weeks.
3038280|NCT02305940|Placebo Comparator|Placebo|Placebo: an oral dose of one capsule once daily, for a total duration of 52 weeks.
3038281|NCT02305927|Experimental|Vitamin D3 (cholecalciferol)|
3038282|NCT02305927|Placebo Comparator|Placebo|
3038283|NCT02305914||follow-up visit|Patients who come for follow-up visit will fill in the questionnaire and undergo regular laboratory examination such as liver function test and CRP,faecal elastase-1 as well as CT scanning.Additionally,blood sample of every patient will be collected and sent to the Lab for storage and further experimented.
3038284|NCT02305901|Experimental|Repaglinide + Bupropion + BI 187004|repaglinide tablets and bupropion tablets with and without concomitant administration of BI 187004
3038285|NCT02305888|Experimental|LEO 43204, 0.018% once daily for 3 days|
3038286|NCT02305888|Experimental|LEO 43204, 0.037% once daily for 3 days|
3038288|NCT02305875|Experimental|MCN scoring|Scoring of the mcn nerve's position in the axillary sheat using MRI
3038289|NCT02305862|Experimental|low dose group (5mg)|low dose Rosuvastatin
3038290|NCT02305862|Experimental|high dose group (20mg)|high dose Rosuvastatin
3038291|NCT02305849|Experimental|ASP015K low dose group|oral
3038292|NCT02305849|Experimental|ASP015K high dose group|oral
3038293|NCT02305849|Placebo Comparator|Placebo group|oral
3038294|NCT02305836|Experimental|Electroacupuncture combined with donepezil|Every session will last for 30 minuets and will be given every other day. There are 36 sessions for each participant in all (3 session per week, 12 weeks).
3038295|NCT02305836|Active Comparator|donepezil|Donepezil will be given once daily before bed-time for the first 4-6 weeks. Based on the treatment effect, the dosage may be increased to 10 mg once daily before bed-time for the next 6-8 weeks. Donepezil will be taken for continuous 24 weeks. The full course of treatment is 36 weeks.
3038296|NCT02305823|Active Comparator|Aripiprazole|Oral, dose range 5-30 mg/day, once or twice a day, during study duration
3038297|NCT02305823|Active Comparator|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
3038298|NCT02305823|Active Comparator|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
3038299|NCT02305810|Experimental|Single arm receiving everolimus|single treatment arm receiving everolimus 10 mg daily
3038300|NCT02305797|Experimental|EDG004|EDG004
3038301|NCT02305797|Placebo Comparator|Placebo|Placebo
3038302|NCT02305771|Other|Healthy volunteers|"20 healthy volunteers will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Electroencephalography~MRI"
3038303|NCT02305758|Placebo Comparator|Group 2|Placebo plus FOLFIRI with or without bevacizumab.
3038304|NCT02305758|Experimental|Group 1|Veliparib plus modified FOLFIRI with or without bevacizumab.
3038305|NCT02305745||Preeclampsia- observational|45 women with preeclampsia
3038306|NCT02305745||No preeclampsia- observational|10 women without preeclampsia
3038307|NCT02305719||Epidural anesthesia|Patients receiving thoracic epidural anesthesia for thoracoscopic surgery. Standard regimen with 8-20 ml Ropivacaine 0,5% in the epidural catheter. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered.
3038308|NCT02305719||Serratus-anterior-plane-Block|"Patients receiving (ultrasound-guided) Serratus-anterior-plane-Block for thoracoscopic surgery.~Standard regimen up to 20 ml Ropivacaine 0,5%, were installed. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered."
3038309|NCT02305719||Local infiltration|Patients receiving local infiltration with up to 20 ml Ropivacaine 0,5% for thoracoscopic surgery (at the site of thoracoscopy)
3038310|NCT02305706|Experimental|Right|patients will be positioned on the right-lateral position at the start of colonoscopy
3038311|NCT02305706|Active Comparator|Left|patients will be positioned on the left-lateral position at the start of colonoscopy
3038312|NCT02305693|Active Comparator|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding
3038313|NCT02305693|Active Comparator|Ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary.
3038314|NCT02305667|Placebo Comparator|Macintosh|Double lumen tube intubation using Macintosh laryngoscope
3038315|NCT02305667|Active Comparator|Glidescope®|Double lumen tube intubation using Glidescope® videolaryngoscope
3038316|NCT02305667|Active Comparator|Airtraq®|Double lumen tube intubation using Airtraq® videolaryngoscope
3038317|NCT02305667|Active Comparator|King Vision™|Double lumen tube intubation using King Vision™ videolaryngoscope
3038318|NCT02305654|Active Comparator|Arm A - Standard Surgery (ILND)|"Part of randomisation 1.~The total treatment duration (Inguinal Lymph Node Dissection (ILND)) is estimated to be over 1 day for those patients allocated to Arm A - standard surgery."
3038319|NCT02305654|Experimental|Arm B - neoadjuvant chemotherapy|"Part of randomisation 1.~Patients will receive up to 4 cycles of Paclitaxel, Ifosfamide, and Cisplatin (TIP).~Administration on an outpatient basis:~Paclitaxel 175 mg/m2, day 1, Ifosfamide 900 mg/m2, days 2-5, Cisplatin 15 mg/m2, days 1-5~Administration on an inpatient basis:~Paclitaxel 175 mg/m2, day 1, Ifosfamide 1200 mg/m2, days 1-3, Cisplatin 25 mg/m2, days 1-3"
3038320|NCT02305654|Experimental|Arm C - neoadjuvant chemoradiotherapy|"Part of randomisation 1.~Radiotherapy dose is 45Gy in 25 fractions over 5 weeks using 6-10 MV photons to all regions.~Concurrent cisplatin 40mg/m2 will be given weekly, subject to GFR>45mls/min."
3038321|NCT02305654|Experimental|Arm P - prophylactic PLND|"Part of randomisation 2.~Prophylactic pelvic lymph node dissection (PLND) - The total treatment duration is estimated to be over 1 day.~Patients who have NOT received neoadjuvant chemoradiotherapy will receive adjuvant chemoradiotherapy:~Cisplatin 40mg/m2 will be given weekly, subject to GFR>45mls/min.~Groin: One or both groins may be boosted up to 54Gy in 25 fractions. An IMRT boost of up to 57 Gy can be given to recurrent or residual macroscopic tumour~Pelvis: the dose is limited to 45Gy unless IMRT is available. An IMRT boost of up to 54Gy in 25 fractions is applied to:~Any macroscopic tumour or pathological lymph nodes~Electively to external iliac nodes in patient with high disease burden~Patients who have had neoadjuvant chemoradiotherapy will have prophylactic PLND alone."
3038322|NCT02305654|No Intervention|Arm Q - Surveillance no prophylactic PLND|"no prophylactic PLND Part of randomisation 2.~For patients who have NOT received neoadjuvant chemoradiotherapy:~Groin: One or both groins may be boosted up to 54Gy in 25 fractions. An IMRT boost of up to 57 Gy can be given to recurrent or residual macroscopic tumour~Pelvis: the dose is limited to 45Gy unless IMRT is available. An IMRT boost of up to 54Gy in 25 fractions is applied to:~Any macroscopic tumour or pathological lymph nodes Electively to external iliac nodes in patient with high disease burden"
3038323|NCT02305641||Cohort|Method of continuous surveillance per standard of care
3038324|NCT02305628||Cohort|Method of continuous surveillance per standard of care
3038359|NCT02305368||Oncogramme|Taking a fragment of colon tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
3038360|NCT02305355|Experimental|Omega-3-acids ethylesters 90 4g, any statin|
3038361|NCT02305355|Active Comparator|any statin|
3038325|NCT02305615||Participants with CRC|This is an observational study; thus, no intervention or treatment is required by the protocol. During the study, the treatment will be determined according to the treating physician decision. Eligible participants will be observed for safety and efficacy of continued bevacizumab plus fluoropyrimidine-based doublet chemotherapy treatment in routine clinical practice for 1 year.
3038326|NCT02305602|Experimental|Post Myocardial Infarction|VentriGel will be injected via a MyoStar catheter after NOGA mapping in the 60 day to 3 year window since the first STEMI myocardial infarction
3038327|NCT02305563|Experimental|Ulocuplumab + low dose Cytarabine|Ulocuplumab + low dose Cytarabine (LDAC) Phase 1 (escalation cohort) - closed for enrollment
3038328|NCT02305563|Experimental|Ulocuplumab Dose A + low dose Cytarabine|Ulocuplumab Dose A + low dose Cytarabine Phase 2 (expansion cohort)
3038329|NCT02305563|Experimental|Ulocuplumab Dose B + low dose Cytarabine|Ulocuplumab Dose B + low dose Cytarabine Phase 2 (expansion cohort)
3038330|NCT02305563|Other|low dose Cytarabine only|Low Dose Cytarabine only Phase 2 (expansion cohort)
3038331|NCT02305550|Experimental|electrical synthesis nitric oxide|Participants will breath 20 minutes of electrical pulsed plasma discharge synthesis of nitric oxide at 25 parts per million
3038332|NCT02305537|Experimental|Treatment (Cognitive-Behavioral Therapy)|Participants in the McLean Anxiety Mastery Program
3038333|NCT02305537|No Intervention|Waitlist|Participants on the waitlist for the McLean Anxiety Mastery Program
3038334|NCT02305524|Experimental|ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3038335|NCT02305524|Experimental|ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
3038336|NCT02305511|Experimental|Peripheral venous catheterization|Peripheral venous catheterization during pediatric resuscitation
3038337|NCT02305511|Experimental|intraosseous access|Intraosseus access using intraosseous access devices during resuscitation
3038338|NCT02305498|Experimental|Vigorous yoga practice|Supervised vigorous yoga practice, 60 minutes/session, 3 sessions/wk for 12 weeks, followed by 12 weeks of home practice.
3038339|NCT02305498|Active Comparator|Restorative (gentle) yoga practice|Supervised restorative (gentle) yoga practice, 60 minutes/session, 3 sessions/wk for 12 weeks, followed by 12 weeks of home practice.
3038340|NCT02305485|Experimental|NeoVas|"The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA- based polymer scaffold and contains the antiproliferative drug sirolimus.~Intervention: Device: NeoVas BCS"
3038341|NCT02305485|Active Comparator|XIENCE PRIME|XIENCE PRIME Everolimus Eluting Coronary Stent System is a balloon expandable metallic platform stent manufactured from a flexible cobalt chromium alloy with a multicellular design and coated with a thin nonadhesive, durable, biocompatible acrylic, and fluorinated everolimus-releasing copolymer. Intervention: Device: XIENCE PRIME EECSS
3038342|NCT02305472|Experimental|NeoVas BCS|The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA-based polymer scaffold and contains the antiproliferative drug sirolimus.
3038343|NCT02305459||Patients treated with Radioembolisation|"All Patients treated with Radioembolisation with yttrium-90 loaded SIR-Spheres microspheres are asked to be enrolled. In no way will participation in the registry influence the way in which the patient is treated or will it influence the quality of the treatment.~In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient."
3038344|NCT02305446|Experimental|rMenB+OMV NZ|Subjects who received two doses of rMenB+OMV NZ according to a 0, 2-month schedule
3038345|NCT02305433|Experimental|Physiotherapy for frail elderly|Individually tailored, long-term home-based physiotherapy twice a week for 12 months. The duration of one session is 60 minutes.
3038346|NCT02305433|Experimental|Physiotherapy for operated hip fracture|Individually tailored, long-term home-based physiotherapy twice a week for 12 months. The duration of one session is 60 minutes.
3038347|NCT02305433|No Intervention|Usual care for frail elderly|Usual care follows the standard care procedures in the South Karelia Social and Health Care District in health care and in assisted home living.
3038348|NCT02305433|No Intervention|Usual care for operated hip fracture|Usual care follows the standard care procedures in the South Karelia Social and Health Care District in health care and in assisted home living.
3038349|NCT02305420|Experimental|EmbryoGen/BlastGen|"EmbryoGen and BlasGen media containing GM-CSF 2ng/ml will be used in the experimental arm~The intervention is to use EmbryoGen/BlastGen"
3038350|NCT02305420|Active Comparator|Control|Standard Cook sequential media
3038351|NCT02305407|Experimental|surgical revascularization|Patients will be assigned to either surgical or conservative treatment depending on their clinical symptoms and radiological assessment.
3038352|NCT02305407|Experimental|conservative treatment|Normal conservative treatment without surgical intervention.
3038353|NCT02305394|Experimental|PK group (ketamine and propofol)|propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.When patients become unconscious, succinylcholine 1 mg/kg (a muscle relaxant) will be administered intravenously. After 1 minute of succinylcholine infused, ECT will be performed with bitemporal electrode placement using a stimulus dose of 1.0-millisecond pulse width, 60-Hz frequency, 6.0-second stimulus duration, and 0.8-A maximal stimulus intensity.
3038354|NCT02305394|Active Comparator|P group (propofol group)|propofol 1.5 mg/kg and normal saline [weight(kg)×0.3÷10]ml will be administered to participants separately by intravenous infusion.When patients become unconscious, succinylcholine 1 mg/kg (a muscle relaxant) will be administered intravenously. After 1 minute of succinylcholine infused, ECT will be performed with bitemporal electrode placement using a stimulus dose of 1.0-millisecond pulse width, 60-Hz frequency, 6.0-second stimulus duration, and 0.8-A maximal stimulus intensity.
3038355|NCT02305381|Experimental|Semaglutide 0.5 mg/Week|
3038356|NCT02305381|Experimental|Semaglutide 1.0 mg/Week|
3038357|NCT02305381|Placebo Comparator|Semaglutide Placebo 0.5 mg/Week|
3038358|NCT02305381|Placebo Comparator|Semaglutide Placebo 1.0 mg/Week|
3038362|NCT02305342||Urinary Tract Infections (UTIs)|Uncomplicated UTIs
3038364|NCT02305329|Experimental|Group 2 BIA 9-1067 25 mg|Period 1 - 1x25 mg OPC Period 2 - 5x5 mg OPC
3038365|NCT02305329|Experimental|Group 1 BIA 9-1067 50 mg|Period 1 - 2x25 mg OPC Period 2 - 1x50 mg OPC
3038366|NCT02305329|Experimental|Group 2 BIA 9-1067 50 mg|Period 1 - 1x50 mg OPC Period 2 - 2x25 mg OPC
3038367|NCT02305316|Experimental|BIA 9-1067 non-micronized - micronized|Each subject was orally administered with 50 mg OPC non-micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC micronized
3038368|NCT02305316|Experimental|BIA 9-1067 micronized - non-micronized|Each subject was orally administered 50 mg OPC micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC non-micronized
3038369|NCT02305303|Experimental|Diary|Use of diary
3038370|NCT02305303|No Intervention|Without Diary|
3038371|NCT02305290||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Upper Gastrointestinal Lesions will be included in this cohort.
3038372|NCT02305277|Experimental|BIA 9-1067 5 mg Sequence 1|"volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
3038373|NCT02305277|Experimental|BIA 9-1067 25 mg Sequence 1|"volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
3038374|NCT02305277|Experimental|BIA 9-1067 50 mg Sequence 1|"volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
3038375|NCT02305277|Experimental|BIA 9-1067 5 mg Sequence 2|"volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
3038376|NCT02305277|Experimental|BIA 9-1067 25 mg Sequence 2|"volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
3038377|NCT02305277|Experimental|BIA 9-1067 50 mg Sequence 2|"volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
3038378|NCT02305264|Experimental|PET -18F-DPA-714 and 18F-FDG|"18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mCi(185MBq), will be injected via an arm intravenous catheter."
3038379|NCT02305238|Experimental|2 Weeks adjustment|Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals with the criteria of Treat and Extend regimen. In the case the study eye of a participant met the criteria, the length of treatment interval was to be extended or shortened by 2 weeks from the last interval, respectively. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
3038380|NCT02305238|Experimental|4 Weeks adjustment|Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals. In the case the study eye of a participant met the criteria of the shortening, the length of the treatment interval was to be shortened by 2 weeks. But when the last treatment interval for a participant was extended by 4 weeks from the second last interval, the treatment interval was shortened by 4 weeks. In the case the study eye of a participant met the criteria of the extension, the length of the treatment interval was to be extended by 4 weeks. But when a participant had a history of receiving treatment with interval shortened by 4 weeks during this study, the length of the extension was 2 weeks. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
3038381|NCT02305225|Experimental|SDSR|first total then partial Sleep deprivation
3038382|NCT02305225|Experimental|SRSD|first partial then total Sleep deprivation
3038383|NCT02305212|Experimental|Cogmed|Cogmed is a cognitive rehabilitation protocol designed to improve working memory. The Cogmed sessions are on a computer at home for 30-40 min per day, 5 days per week for 5 weeks.
3038384|NCT02305212|No Intervention|Wait list|
3038385|NCT02305199|Active Comparator|Hartmanns' solution|"All the participants went on a fast at midnight and 1 L of 5% dextrose fluid containing 10 units of regular insulin (RI) and 40 mEq of potassium was administered intravenously.~On participant's arrival to the operation room, fluid from the ward was immediately removed and replaced it with 1 L of unknown fluid completely sealed in black bag. Neither the participant nor the researcher were aware of the type of the fluid.~After the fluid change, general anesthesia was induced. Intraoperative blood glucose was checked every one hours and 20% dextrose was injected if the number was below 100 and RI was injected if the number was checked over 200."
3038386|NCT02305199|Active Comparator|Normal saline|"All the participants went on a fast at midnight and 1 L of 5% dextrose fluid containing 10 units of RI and 40 mEq of potassium was administered intravenously.~On participant's arrival to the operation room, fluid from the ward was immediately removed and replaced it with 1 L of unknown fluid completely sealed in black bag. Neither the participant nor the researcher were aware of the type of the fluid.~After the fluid change, general anesthesia was induced. Intraoperative blood glucose was checked every one hours and 20% dextrose was injected if the number was below 100 and RI was injected if the number was checked over 200"
3038387|NCT02305186|Experimental|Neodjuvant CRT + Pembrolizumab|Standard neoadjuvant chemoradiation treatment (CRT) with pembrolizumab
3038388|NCT02305186|Active Comparator|Neoadjuvant CRT|Standard neoadjuvant chemoradiation treatment (CRT) alone
3038389|NCT02305173|Active Comparator|dexamethasone group|patients receive one single dose of intravenous dexamethasone 8 mg.
3038390|NCT02305173|Placebo Comparator|placebo group|patients receive one single dose of intravenous placebo.
3038391|NCT02305160|Experimental|Butantan|The new pulmonary surfactant produced by Butantan Institute. Butantan Surfactant: 100 mg/kg, IT, maximum of 3 doses.
3038392|NCT02305160|Active Comparator|Control|The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
3038393|NCT02305147||Patients with an idiopathic Parkinson Disease,|Patients with recent onset of Parkinson Disease: N=200
3038394|NCT02305147||Subjects at risk of PD|"Subjects at risk to develop Parkinson Disease:~subjects with idiopathic Rem-sleep behavior disorder (iRBD): N=50~subjects related to a patient with genetically confirmed Parkinson Disease: N=30"
3038395|NCT02305147||Controls|Healthy controls: N=50
3038429|NCT02304887||Selective estrogen receptor modulator|
3038430|NCT02304887||Teriparatide|
3038396|NCT02305147||Patients with Parkinson Disease with genetic mutation|Patients with Parkinson Disease with a genetic mutation in parkin, LRRK2, SNCA or GBA (N=30)
3038397|NCT02305134|Active Comparator|Tipepidine Hibenzate|Tipepidine is taken orally at 30 mg/day (10 mg after breakfast, 10 mg after supper, and 10 mg before bedtime), for 4 weeks.
3038398|NCT02305134|Placebo Comparator|Placebo|Placebo is taken orally after breakfast, after supper, and before for 4 weeks.
3038399|NCT02305108|Experimental|fascial manipolation and standard|
3038400|NCT02305108|Active Comparator|standard treatment|
3038401|NCT02305095||GNB3 TT|All subjects with the GNB3 TT genotype for the polymorphism at position 825 (T/C). They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).
3038402|NCT02305095||GNB3 C|All subjects with at least one copy of the GNB3 C allele which includes both subjects homozygous for the 825C allele (GNB3 CC genotype) and subjects who are heterozygous (GNB3 TC genotype).They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).
3038403|NCT02305082||Fast-track group|Patients treated according to the enhanced recovery pathway. This group is examined prospectively.
3038404|NCT02305082||Control group|Patients treated according to the historic recovery pathway. This group is examined retrospectively.
3038405|NCT02305069|Placebo Comparator|Placebo|"Placebo tablet taken once daily for 12 weeks.~For study visits performed pre- and post 12-week placebo treatment for the assessment of muscle protein synthesis and leg protein breakdown, the following substances are administered as part of the analytical technique: insulin, octreotide, glucose, mixed amino acids, [2H5]phenylalanine and [1-13C]leucine. The doses administered change as the analytical technique is conducted and for clarity are described in detail in the protocol."
3038406|NCT02305069|Experimental|Pioglitazone|"30mg pioglitazone encapsulated and taken once daily for 12 weeks.~For study visits performed pre- and post 12-week pioglitazone treatment for the assessment of muscle protein synthesis and leg protein breakdown, the following substances are administered as part of the analytical technique: insulin, octreotide, glucose, mixed amino acids, [2H5]phenylalanine and [1-13C]leucine. The doses administered change as the analytical technique is conducted and for clarity are described in detail in the protocol."
3038407|NCT02305056|Experimental|C13 N15 Valine|Intervention C13 N15 Valine
3038408|NCT02305030|Experimental|BIA 9-1067 / Warfarin|BIA 9-1067 capsules of 25 mg or 50 mg Warfarin capsules of 5 mg
3038409|NCT02305017|Experimental|Period 1 OPC + Paracetamol; Period 2 OPC|Period 1 BIA 9-1067 (Opicapone, OPC) + Paracetamol; Period 2 BIA 9-1067 (Opicapone, OPC)
3038410|NCT02305017|Experimental|Period 1 OPC; Period 2 OPC+ Paracetamol|Period 1 BIA 9-1067 (Opicapone, OPC) Period 2 BIA 9-1067 (Opicapone, OPC) + Paracetamol;
3038411|NCT02304991|Experimental|Peanut (liquid peanut extract) SLIT|After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to peanut SLIT therapy will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
3038412|NCT02304991|Placebo Comparator|Placebo Glycerin SLIT|After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to placebo glycerin SLIT will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
3038413|NCT02304978|Experimental|Group CRC|patient with a colorectal cancer
3038414|NCT02304978|Experimental|Group control|Control - volunteers
3038415|NCT02304965|Experimental|Daily physical activity|Eligible subjects will be included in the feasibility study to conduct an individualized and structured training program with defined walking and cycling on a bicycle ergometer for 2 months.
3038416|NCT02304952|Active Comparator|Eccentric exercise|Conservative treatment with eccentric exercise as self-training
3038417|NCT02304952|Active Comparator|Radiofrequency microtenotomy|A minimally invasive surgery (Topaz) and eccentric exercise as postoperative treatment
3038418|NCT02304939|Active Comparator|Quick change|"For this changeover : When the syringe of norepinephrine stops (pre alarm), start the second syringe pumps at the same speed of the first, wait for a first drop at the end of the tubing.~Close the first syringe, disconnect it and connect the second syringe, open the valve on and stop the first syringe."
3038419|NCT02304939|Experimental|Double Pumping|"For this changeover : When the syringe of norepinephrine stops (pre alarm), start the second syringe pumps, open the second syringe while leaving the first syringe open. Wait until the blood pressure rises 5 mmHg (SBP, DBP or MAP).~Once the blood pressure increased or 2 minutes from the start of the relay if no increase in blood pressure is observed, close the first syringe."
3038420|NCT02304939|Experimental|Smart infusion pump|For this automatic changeover : When the syringe of norepinephrine stops (pre alarm), oversee the progress of the automatic relay.
3038421|NCT02304926|Experimental|Simvastatin|Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
3038422|NCT02304926|Experimental|Ezetimibe|Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
3038423|NCT02304913|Experimental|Hypoglossal acupuncture|Following acupuncture points will be engraved: Jinjin (EX-HN12) and Yuye (EX-HN13).
3038424|NCT02304913|Sham Comparator|Sham acupuncture|The sham acupuncture will also carried out twice, each time after the CTX cycle. But the needle will be applied 1-1,5 cun beside the real acupuncture points in the palate using the dull side of the needle.
3038425|NCT02304913|Active Comparator|Dietary recommendations|This group adheres to specific dietary recommendations for dysgeusia of the German Cancer Society.
3038426|NCT02304900|Experimental|Group 1 : white implant|Randomization will determine the color of the implant to be used for each patient for interventions in both eyes, white or yellow to know.
3038427|NCT02304900|Experimental|Group 2 : yellow implant|Randomization will determine the color of the implant to be used for each patient for interventions in both eyes, white or yellow to know.
3038428|NCT02304887||Bisphosphonate|
3038432|NCT02304874|Other|Phlebotomy|Phlebotomies will be performed every 14 days at the Clinical Investigation Unit (CIU) until the value of ferritin level is below 50 µg/mL and/or the value of hemoglobin level is below 12 g/dL.
3038433|NCT02304861|Active Comparator|Viscoat group|Patients operated using Viscoat OVD
3038434|NCT02304861|Active Comparator|Visthesia group|Patients operated using Visthesia OVD
3038435|NCT02304848|Experimental|DBS (Deep Brain Stimulation)|DBS ( Deep Brain Stimulation) ( both high and low frequency deep brain stimulation will be applied to the subthalamic nucleus)
3038436|NCT02304822|Active Comparator|Multiple-dose of ciprofloxacin prophylaxis|Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally
3038437|NCT02304822|Experimental|Single-dose of ciprofloxacin prophylaxis|Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only
3038438|NCT02304822|Experimental|Zero-dose of ciprofloxacin prophylaxis|Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
3038439|NCT02304809|Experimental|VEMURAFENIB|"all eligible patients entering the study will receive oral Vemurafenib as monotherapy.~Vemurafenib ZELBORAF 240 mg tablets Per OS 960 mg twice daily, to a total daily dose of 1,920 mg Cycles are defined in 28-day periods Disease response will be assessed every 8 weeks Safety will be assessed continuously~Treatment will be pursed until disease progression, unacceptable toxicity, intercurrent conditions that preclude continuation of treatment, or patient refusal."
3038440|NCT02304796|Experimental|Unified CBT|Group psychotherapy according to the principles of the Cognitive-Behavioral Unified Protocol for Trans-diagnostic Treatment of Emotional Disorders (Barlow et al., 2011).
3038441|NCT02304796|Experimental|Combined CBT-DMT|Group psychotherapy combining cognitive-behavioral principles and techniques with dance/movement therapy techniques.
3038442|NCT02304783|Active Comparator|Oral Piroxicam|Piroxicam : 20 mg per pill; one pill per day for five days
3038443|NCT02304783|Placebo Comparator|Placebo|Placebo: one pill per day for five days
3038444|NCT02304770|Experimental|cervical persistent high risk HPV infection|Aminolaevulinic acid photodynamic therapy for the treatment of patients with cervical persistent high risk HPV infection
3038445|NCT02304770|Experimental|CIN 1 with high risk HPV infection|Aminolaevulinic acid photodynamic therapy for the treatment of patients with CIN 1 and high risk HPV infection
3038446|NCT02304770|Experimental|CIN 2/3|Aminolaevulinic acid photodynamic therapy for the treatment of patients with CIN 2/3
3038447|NCT02304757|Experimental|low dose 99Tc-MDP|Patients with slightly decreased BMD (T or Z-score in lumbar spine or neck region of femur > -2.0 SD by dual energy X-ray) taking suppressive doses of L-T4 to treatment divided into 2 groups of 99Tc-MDP (Technetium [99Tc] methylenediphosphonate) and calcium alone.99Tc-MDP group:10mg Intravenous drip every 1week for ten weeks, every 2weeks for 22 weeks, every 1 month for 4 months.
3038448|NCT02304757|Active Comparator|Caltrate|600mg caltrate containing vitamin D everyday for 12 months.
3038449|NCT02304757|Experimental|high dose 99Tc-MDP|148 patients with obviously decreased BMD (T or Z-score in lumbar spine or neck region of femur≤-2.0 SD) taking suppressive doses of L-T4 divided into 2 groups of 99Tc-MDP and or fosamax. 99Tc-MDP group:15mg 99Tc-MDP Intravenous drip every 1week for ten weeks, every 2weeks for 22 weeks, every 1 month for 4 months (99Tc-MDP) for 12 months.
3038450|NCT02304757|Active Comparator|fosamax|70mg po every week for 12 months.
3038451|NCT02304731|Experimental|Exercise and Pollution Groups|Physical Exercise performed in a clean environment and in a polluted environment.
3038452|NCT02304718|Experimental|exercise intervention group|Pregnant women randomised to the exercise intervention group will complete three supervised, exercise sessions each week, exercise sessions completed on alternate days, and lasts until they give birth by using a stational bike. And also they will have regular prenatal care.
3038453|NCT02304718|No Intervention|control group|Pregnant women randomised to the control group only have regular prenatal care.
3038454|NCT02304705|Placebo Comparator|Placebo|Placebo three times per day, orally
3038455|NCT02304705|Active Comparator|Sildenafil|Sildenafil 20 mg three times per day, orally
3038456|NCT02304692|Sham Comparator|Oticon Medical Machined Abutment|A non surface modified abutment is used
3038457|NCT02304692|Experimental|Oticon Medical Modified Abutment|A surface modified abutment is used
3038458|NCT02304679|Experimental|LIESWT arm|"Patients randomized to this arm will have two sequences of Low-Intensity Extracorporeal Shock Wave Therapy (LIESWT).~Interventions: Pre-inclusion questionnaires; 1 month of PDE5i treatment; PDE5i follow-up questionnaires; Inclusion questionnaires; 4 weekly LIESWT (Wave 1) with the RENOVA device; Follow-up questionnaires 1 month after Wave 1; Follow-up questionnaires 3 months after Wave 1; 8 bi-weekly LIESWT (Wave 2) with the RENOVA device; Follow-up questionnaires 1 month after Wave 2; Questionnaires via postal mail; Final follow-up questionnaires 12 months after Wave 2."
3038459|NCT02304679|Placebo Comparator|Sham arm|"Patients randomized to this arm will have one sequence of sham Low-Intensity Extracorporeal Shock Wave Therapy and then three months later one sequence of Low-Intensity Extracorporeal Shock Wave Therapy.~Interventions: Pre-inclusion questionnaires; 1 month of PDE5i treatment; PDE5i follow-up questionnaires; Inclusion questionnaires; 4 weekly sham LIESWT (Wave 1) with the RENOVA device; Follow-up questionnaires 1 month after Wave 1; Follow-up questionnaires 3 months after Wave 1; 8 bi-weekly LIESWT (Wave 2) with the RENOVA device; Follow-up questionnaires 1 month after Wave 2; Questionnaires via postal mail; Final follow-up questionnaires 12 months after Wave 2."
3038460|NCT02304666|Experimental|Crohn disease's Patients|Patients with Crohn disease or presenting an ulcerative colitis
3038461|NCT02304666|Other|Control patient|Patients with programmed colonoscopy screening for familial colon cancer history, polyps or for irritbale bowel syndrome
3038462|NCT02304640||Early-stage breast cancer patients|
3038463|NCT02304640||Healthy control|
3038464|NCT02304627|Experimental|Eating meal immediately after dosing|
3038465|NCT02304627|Experimental|Eating meal 30 min after dosing|
3038466|NCT02304627|Experimental|Eating meal 1 hour after dosing|
3038467|NCT02304627|Experimental|Eating meal 6 hour after dosing|
3038468|NCT02304614||Group 1|Patients who have undergone Breast conserving Therapy
3038469|NCT02304601||Comorbid symptoms|
3038470|NCT02304601||No comorbid symptoms|
3038471|NCT02304588|Experimental|Mesenchymal stem cells|Maximal amount of MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight).
3038472|NCT02304575||Testicular cancer survivors|Patients treated for testicular cancer, will receive questionnaires and hormonal function measurement.
3038473|NCT02304575||Surgery for benign testicular problems|Patients treated for benign testicular conditions, will receive questionnaires and hormonal function measurement.
3038474|NCT02304575||Healthy males|Healthy volunteers, will receive questionnaires and hormonal function measurement.
3038475|NCT02304562|Experimental|UCB Mesenchymal Stem Cells|UCB Mesenchymal Stem Cells treatment of patients with skin injury
3038476|NCT02304549||patients with BPH undergoing TUV-P|patients with Benign Prostatic Hyperplasia undergoing TUV-P
3038477|NCT02304536|Active Comparator|FSH|will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day.
3038478|NCT02304536|Active Comparator|Ovarian drilling|70 women will have laparoscopic ovarian drilling in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
3038479|NCT02304523|Experimental|Test 1|"CDFR0612 Solution 150mL will be mixed with water of 350ml to prepare a bowel cleansing preparation solution 500mL. Take it within 30min. After then, take additional water 500ml within 30min.~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
3038480|NCT02304523|Experimental|Test 2|"CDFR0613 Solution 150mL will be mixed with water of 350ml to prepare a bowel cleansing preparation solution 500mL. Take it within 30min. After then, take additional water 500ml within 30min.~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
3038481|NCT02304523|Active Comparator|Comparator|"Coolprep Powder A and B will be mixed with water to prepare a mixture of a bowel cleansing preparation solution 500mL. Repeat it twice. Take these of IL (2 * 500mL) within 1 hour. After then, take additional 500ml water.~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
3038482|NCT02304510||females|females aged between 18 and 50 years old living in Beijing
3038483|NCT02304497||DM-CTRL|Diabetes mellitus patients with periodontally healthy Platelet Rich Fibrin obtained
3038484|NCT02304497||DM-CP|Diabetes mellitus patients with chronic periodontitis Platelet Rich Fibrin obtained
3038485|NCT02304497||CP|Chronic periodontitis patients with systemically healthy Platelet Rich Fibrin obtained
3038486|NCT02304497||CTRL|Periodontally and systemically healthy subject Platelet Rich Fibrin obtained
3038487|NCT02304484|Experimental|Evolocumab|single arm all subjects receive Evolocumab
3038488|NCT02304471||Control|healthy subjects
3038489|NCT02304471||CKD|chronic kidney disease
3038490|NCT02304471||ESRD|end-stage renal disease
3038491|NCT02304458|Experimental|Treatment (nivolumab, ipilimumab)|See Detailed Description
3038492|NCT02304445|Active Comparator|Transarterial Chemoembolization (TACE)|Subjects will randomized receive one TACE treatment then receive observation or up to 3 additional TACE treatments as clinically indicated.
3038493|NCT02304445|Experimental|TACE+Stereotactic Body Radiotherapy|Subjects will receive one TACE treatment then receive 1-5 Stereotactic Body Radiotherapy treatments.
3038494|NCT02304432|Experimental|Open label DCS|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule for 8 weeks.
3038495|NCT02304432|Experimental|DCS or placebo|Randomized to DCS or placebo. Participants underwent double-blind placebo-controlled exposures to DCS for 6 weeks or placebo for 6 weeks. One participant received exposure to DCS for 6 weeks and then received placebo dosing for 6 weeks. The other participant received exposure to placebo dosing for 6 weeks and then DCS for 6 weeks.
3038496|NCT02304432|Experimental|Second open label DCS|Both participants received second open label exposures to D-cycloserine (seromycin), 50 mg/d capsule for 24 weeks.
3038497|NCT02304419|Experimental|Galunisertib|150 milligrams galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
3038498|NCT02304393|Experimental|Part IA: Selicrelumab (IV) + Atezolizumab|Selicrelumab at a dose of 16 milligrams (mg) will be administered intravenously (IV) on Day 1 of Cycle 1 (first cycle in this group was of 42 days, and subsequent 21-day cycles); and atezolizumab 1200 mg will be administered IV after 6 weeks on Day 1 of Cycle 2, followed by every 3 weeks during Part IA until disease progression, death, loss of follow-up, or withdrawal of consent.
3038499|NCT02304393|Experimental|Part IA: Selicrelumab(SC) + Atezolizumab|Selicrelumab at a starting dose of 1 mg will be administered subcutaneously (SC) on Day 1 of Cycle 1 (21-day cycle) which will follow escalation in sequential cohorts; and atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 2, and followed by every 3 weeks during Part IA as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
3038500|NCT02304393|Experimental|Part IB: Selicrelumab + Atezolizumab|Selicrelumab will be administered at a starting dose of 1 mg SC or at 50 percent (%) of the SC MTD (but not more than 4 mg) IV on Day 2 of Cycle 1 (21-day cycle) which will follow escalation in sequential cohorts; and atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 1, and followed by every 3 weeks during Part IB as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
3038501|NCT02304393|Experimental|Part II: Selicrelumab + Atezolizumab|Atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 1, and followed by every 3 weeks; and Selicrelumab will be administered at the dose defined in Part IB (not exceeding 80 mg SC [unless IV administration in Part IB demonstrates better benefit/risk ratio]) on Day 2 (1 day after atezolizumab administration) of every second cycle from Cycles 1 to 7, and every fourth cycle thereafter during Part II as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
3038502|NCT02304367|Experimental|KRN23 0.3 mg/kg|KRN23 starting dose 0.3 mg/kg administered subcutaneously (SC) every 4 weeks (Q4W). Doses may be titrated up to a maximum of 2.0 mg/kg every 2 weeks (Q2W).
3038503|NCT02304354|Experimental|Rituximab|two intravenous infusions of 1000 mg with a two-week interval between them
3038504|NCT02304341||intermediate units|Children admitted to the paediatric inpatient unit in 7 regional hospitals French
3038505|NCT02304328||No clinical signs of brain herniation syndrome|Poor grade (WFNS IV and V) SAH patients without clinical signs of brain herniation syndrome
3038506|NCT02304328||Clinical signs of brain herniation syndrome|Poor grade (WFNS IV and V) SAH patients with clinical signs of brain herniation syndrome
3038507|NCT02304315|Experimental|GC1102 50,000 IU|Anhepatic phase: 50,000 IU intravenous during surgery, Post-transplantation(1st week): 50,000 IU intravenous every day, Post-transplantation(2nd-4th weeks): 50,000 IU intravenous every weeks, Post-transplantation(8th weeks and till 24 weeks): 50,000 IU intravenous every 4 weeks.
3038508|NCT02304315|Experimental|GC1102 80,000 IU|Anhepatic phase: 80,000 IU intravenous during surgery, Post-transplantation(1st week): 80,000 IU intravenous every day, Post-transplantation(2nd-4th weeks): 80,000 IU intravenous every weeks, Post-transplantation(8th weeks and till 24 weeks): 80,000 IU intravenous every 4 weeks.
3038509|NCT02304302|Placebo Comparator|Placebo|Identically-looking placebo pills to memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
3038510|NCT02304302|Experimental|Memantine|Memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
3038511|NCT02304289|Experimental|Oral Artesunate|The first patient will receive 200 mg Artesunate once-daily for 14 days. If no dose-limiting toxicity (DLT) is observed after 14 days, the next patient will start at a daily dose of 300 mg Artesunate. If no DLT is observed after 14 days, a cohort of 3 patients will receive 400 mg once-daily for 14 days. For each subsequent cohort of 3 patients 200 mg will be added to the dose, until the maximum tolerated dose (MTD) is determined.
3038512|NCT02304276|Active Comparator|1 (Explanted valves)|"10 subjects who are due to undergo repeat aortic valve replacement surgery~Investigations:~Baseline 18F-Fluoride PET-CT scan~Retrieval of explanted bioprosthetic aortic valve at time of surgery for analysis"
3038513|NCT02304276|Experimental|2 (AVR)|"70 subjects with surgical bioprosthetic AVR, to include 10 subjects who have had a valve replacement < 1 month; 20 at 2 years; 20 at 5 years and 20 at >10 years.~Investigations:~Baseline 18F-Fluoride PET-CT scan~Repeat CT calcium score of aortic valve at 2 years~Annual clinical follow-up for 5 years (history, examination, blood tests, ECG and echocardiogram)"
3038514|NCT02304276|Experimental|3 (TAVI)|"50 subjects who have undergone TAVI with the COREVALVE and 50 subjects with the SAPIEN valve. In each group this will include 10 subjects who have had TAVI < 1 month; 20 at 2 years and 20 at 5 years.~Investigations:~Baseline 18F-Fluoride PET-CT scan~Repeat CT calcium score of aortic valve at 2 years~Annual clinical follow-up for 5 years (history, examination, blood tests, ECG and echocardiogram)"
3038515|NCT02304263||Younger (18-35 years old)|iohexol
3038516|NCT02304263||Older (>60 years old)|iohexol
3038517|NCT02304250|Active Comparator|Group D|Group D: dexamethasone group
3038518|NCT02304250|Placebo Comparator|Group S|Group S: saline group
3038519|NCT02304237|Experimental|Vaginal progesterone|Vaginal progesterone(Utrogestan)200mg/day, during 14~21 weeks.
3038520|NCT02304237|Active Comparator|Intramuscular progesterone|Intramuscular progesterone(Progesterone Depot Jenapharm Injection)250mg/week, during 14~21 weeks.
3038521|NCT02304224|No Intervention|Control|the patients with sepsis admitted in the intensive care unit aren't applied with eye masks at night
3038522|NCT02304224|Experimental|Eye masks|the patients with sepsis in the intensive care unit are applied with eye masks at night in the duration of admission
3038523|NCT02304211|Experimental|Intra-Arterial Microdose Insulin|Healthy volunteers will receive microdose insulin intra-arterially into the radial artery.
3038524|NCT02304211|Active Comparator|Systemic Insulin|Healthy volunteers will receive full-dose insulin intra-venously.
3038525|NCT02304198|Experimental|Udenafil|Udenafil 50mg tablet by mouth, every 12 hours for 1-year(48-weeks)
3038526|NCT02304185|Experimental|gp140, 50 mcg|
3038527|NCT02304185|Experimental|gp140, 50 mcg + Adjuvant|
3038528|NCT02304185|Placebo Comparator|Placebo 1|
3038529|NCT02304185|Experimental|gp140, 250 mcg|
3038530|NCT02304185|Experimental|gp140, 250 mcg + Adjuvant|
3038531|NCT02304185|Placebo Comparator|Placebo 2|
3038532|NCT02304172|Active Comparator|Thunderbeat (Group A)|Patients submitted to thyroidectomy with the use of the Thunderbeat device.
3038533|NCT02304172|Active Comparator|Harmonic (Group B)|Patients submitted to thyroidectomy with the use of the Harmonic scalpel device
3038534|NCT02304159|Experimental|Group A - 16 weeks|Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 16 weeks
3038535|NCT02304159|Active Comparator|Group B - 24 weeks|Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 24 weeks
3038536|NCT02304146||High ligation and stripping (surgery)|6-10 years post classical stripping of the great saphenous vein.
3038537|NCT02304146||Foam sclerotherapy|6-10 years post post ultrasound guided foam sclerotherapy of the great saphenous vein.
3038538|NCT02304133|Active Comparator|Intervention|participating in a four-hour course in abdominal POC US
3038539|NCT02304133|Placebo Comparator|Control|no training
3038540|NCT02304120|Experimental|Sensorimotor|"The experimental group will receive added PPT to the conventional physiotherapy. PPT will be applied by means of a neuro-orthopaedic medical device (Posturomed®, see section 3.2). The Posturomed allows adaptive oscillation in the horizontal plane. Therapy instructions advise seven stages of difficulty. In all stages the patient is asked to provoke oscillation by stepping on site. After three steps, the patient must stand still on one leg for 2 seconds before he or she repeats the steps. Difficulty is increased by a) decreasing the damping through release of the breaks and b) through added juggling of a ball during the motor task (dual-task and divided attention). The next stage is reached once stabilisation in the previous stage is secured."
3038693|NCT02302989|No Intervention|Observation|No treatment. Observation only
3038541|NCT02304120|Active Comparator|Low-intensity activity|Added to conventional therapy, as administered to all participants, the control group will do added treadmill walking. The control intervention will consist of 10 minutes of walking at comfortable pace. The patient will be instructed in treadmill functions and asked to set the speed between 2 and 4 km/h. The speed should be adjusted to the level where the patient would still be able to talk comfortably.
3038542|NCT02304107|Active Comparator|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9 mm the dose will be increased by 37.5 IU every 7 days.
3038543|NCT02304107|Active Comparator|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
3038544|NCT02304094|Experimental|manipulation|Those in the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique. They will be asked to return once each week for a further five weeks. At each visit the VAS and PTM measurements shall be repeated, as will the manual manipulation. They shall also be asked to return for a review in the sixth week.
3038545|NCT02304094|Active Comparator|Steroid|Those randomised to the steroid group shall receive a single injection of 1 mL methylprednisolone [40 mg] and 1 mL 2% lignocaine. They shall then be asked to return for review in six weeks. A second injection may be offered at this point if clinically indicated.
3038546|NCT02304081|Active Comparator|Saxagliptin|Metformin and Dapagliflozin background therapy
3038547|NCT02304081|Placebo Comparator|Placebo|Metformin and Dapagliflozin background therapy
3038548|NCT02304068|Other|Intra-vitreal injection|
3038549|NCT02304055|Active Comparator|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
3038550|NCT02304055|Active Comparator|Oxytocin|100 women with atonic PPH will receive oxytocin 5IU slowly iv.
3038551|NCT02304042|Active Comparator|Carbetocin|125 women will receive carbetocin after delivery of the anterior shoulder. The drug will be diluted in 10ml saline and will be given by the slowly intravenously after delivery of the anterior shoulder
3038552|NCT02304042|Active Comparator|Oxytocin|125 women will receive carbetocin oxytocin after delivery of the anterior shoulder. The drug will be diluted in 10ml saline and will be given by the slowly intravenously after delivery of the anterior shoulder
3038553|NCT02304029|Experimental|assessment of a innovative MRI|Sodium MRI will be performed at CEMEREM, CHU Timone, the only site with this technique, with a Siemens Verio 3T MRI using a dedicated coil and a sequence already developed locally, in 90 patients with partial drug -resistant epilepsy
3038554|NCT02304016|Experimental|Pelvic floor physical therapy|
3038555|NCT02304016|No Intervention|Observatoin|
3038556|NCT02304003|Experimental|Structured Physiotherapy regimen|Heavy-slow resistance training of rotator cuff . Scapular exercises. Manual mobilisation of glenohumeral joint . Stretching. Low Level Laser therapy
3038557|NCT02304003|Other|Standard care|Standard care offered in primary care while waiting for surgery , this may be but are not limited to : Wait and see, Drugs ( NSAIDS ), Corticosteroid injections, physiotherapy or other conservative treatment options.
3038558|NCT02303964|Active Comparator|Type A Thawed Plasma|"Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive 2 units of thawed Type A plasma in the pre-hospital setting administered by EMS first responders.~An exception from informed consent under 21CFR 50.24 is required since enrollment will occur (for the majority of subjects) before consent can be obtained."
3038559|NCT02303964|Placebo Comparator|Normal saline|Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive normal saline in the pre-hospital setting administered by EMS first responders. Normal saline is standard of care
3038560|NCT02303951|Experimental|Vemurafenib + cobimetinib|Vemurafenib 960 mg bid orally + cobimetinib 60 mg 21/7 orally (vemurafenib: daily intake; cobimetinib: 3 weeks on drug, 1 week off)
3038561|NCT02303938|Experimental|physical exercise|Patients will exercise three times per week for 6 months home-based exercise intervention. Session duration will vary between 20 minutes and 45 minutes.
3038562|NCT02303938|No Intervention|Active control group|Patients in the active control group will be advised to walk regularly based on brochures from 30minutenbewegen.nl
3038563|NCT02303925|Experimental|coils|
3038564|NCT02303912|Other|Open label dose escalation|"Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days.~Dose escalation will be done using 3+3 dose escalation design"
3038565|NCT02303899|Experimental|Gemcitabine & Imatinib mesylate|Gemcitabine 1000 mg/m2, i.v., days 3 and 10 of a 21-days schedule; Imatinib mesylate 400 mg/die orally on days 1-5 and 8-12 of a 21-days schedule.
3038566|NCT02303886|Active Comparator|A Methylene blue 10 mg/ml 2mg/kg|ten patients that recieved MB1 methylene blue 2 mg/kg infusion under 60 min
3038567|NCT02303886|Placebo Comparator|B Methylene blue 10 mg/ml 0.02 mg/kg|Same patients received MB2 Methylene blue 0.02 mg/kg infusion under 60 min
3038568|NCT02303873|Experimental|an open label, prospective, self-controlled study|Children or adolescents under the age of 18 years old with minor trauma fracture were recruited from 30 provinces of China. The diagnosis of OI was made by endocrinology department of Peking Union Medical College Hospital(PUMCH).
3038569|NCT02303860|Experimental|Panel 1|Adaptive design: Each subject will receive MR A or MR B formulation of ORM-12741 or a combination of these once or twice daily for one week either combined with IR formulation or not.
3038570|NCT02303860|Experimental|Panel 2|Adaptive design: Each subject will receive MR A or MR B formulation of ORM-12741 or a combination of these once or twice daily for one week either combined with IR formulation or not.
3038571|NCT02303847|Active Comparator|Active Drug|ketamine 16 mg in flavored syrup by mouth twice daily for 1 week, then ketaming 32 mg in flavored syrup by mouth twice daily for 1 week
3038572|NCT02303847|Placebo Comparator|Placebo|Flavored syrup (without ketamine) by mouth twice daily for 2 weeks
3038573|NCT02303834|No Intervention|Control|The control group will not be fitted with CPAP.
3038574|NCT02303834|Experimental|CPAP group|The group will wear a CPAP device throughout the night. The mask fits comfortably over the nose and delivers a steady stream of air under slight pressure (auto-set).
3039368|NCT02298231|Experimental|Group 3|Mystic Isle (MI) Dual Task Training
3038575|NCT02303821|Experimental|Dose Escalation 1|"Subjects will receive carfilzomib in combination with induction chemotherapy, comprising either an R3 backbone of dexamethasone, mitoxantrone, PEG asparaginase, and vincristine (Dose Escalation 1) or a VXLD backbone of vincristine, dexamethasone, PEG asparaginase, and daunorubicin (Dose Escalation 2).~Subjects participating in the Dose Escalation 1 (R3) portion of the study will have a 1 week carfilzomib single agent Lead in Window prior to the Induction Cycle. Subjects in both dose escalation portions of the study will receive a 4 week cycle of induction chemotherapy and have the option to receive a 4 week cycle of consolidation chemotherapy (Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if stable disease or better response is achieved at the end of the Induction Cycle."
3038576|NCT02303808|No Intervention|USUAL CARE|Patients will perform the inhalation of the 7% hypertonic saline (following the gold standard recomendation) during 15 minutes. Right after, patients will perform independently their usual session of autogenic drainage during 30 minutes.
3038577|NCT02303808|Active Comparator|INHALATION WITH PEP DEVICE|Patients will perform the inhalation of the 7% hypertonic saline (following the gold standard recomendation) combined with a PEP device (Acapella Duet) during 15 minutes. Right after, patients will perform independently their usual session of autogenic drainage during 30 minutes.
3038578|NCT02303795|Active Comparator|Rivaroxaban 20mg|Oral Rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
3038579|NCT02303795|Active Comparator|Warfarin|Warfarin Warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.
3038580|NCT02303782|Experimental|OTX015 + azacitidine|
3038581|NCT02303782|Experimental|Azacitidine|
3038582|NCT02303769|Active Comparator|Tamsulosin HCL 0.2mg|Harnal-D tablet (Tamsulosin HCL 0.2mg)
3038583|NCT02303769|Experimental|Tamsulosin HCL 0.4mg|GL2702 GLARS-NF1 tablet (Tamsulosin HCL 0.4mg)
3038584|NCT02303756|Experimental|Pillcam® COLON Capsule|Detection of neoplastic lesions in colon and rectum compared to colonoscopy
3038585|NCT02303743|Active Comparator|Smart Phone Application (SPA) Group|Patients assigned to SPA group were instructed on how to free-download the application onto their smartphone. Each patient enters the date and time of his colonoscopy and timed alerts appeared on the phone to alert the patient of the next step in bowel preparation. In addition to the alerts, the app assists in bowel preparation by explaining the procedure, providing tips, examples of low fiber diet, and displaying pictures of preparation quality and educational video to explain how to prepare the purgative solution.Finally, the patient can obtain a checklist to confirm all steps.
3038586|NCT02303743|Active Comparator|Control Group|Written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution
3038587|NCT02303730|Experimental|Exenatide|Exenatide 5 ug twice daily 1 hour before meal subcutaneously for 4 weeks, then add to 10 ug twice daily 1 hour before meal subcutaneously for another 20 weeks
3038588|NCT02303730|Active Comparator|Insulin glargine|Insulin glargine subcutaneously, once daily, for 24 weeks
3038589|NCT02303717|Active Comparator|Xience|Percutaneous coronary intervention utilising a cobalt chromium everolimus eluting stent with durable polymer (Xience) plus oral dual antiplatelet therapy (DAPT) for 12 months. DAPT will be aspirin 75-100mg daily plus either clopidogrel 75mg daily or prasugrel 5-10mg daily or ticagrelor 90mg twice daily.
3038590|NCT02303717|Experimental|Synergy|Percutaneous coronary intervention utilising a platinum chromium everolimus eluting stent with bioresorbable polymer (Synergy) plus oral dual antiplatelet therapy (DAPT) for 4 months. DAPT will be aspirin 75-100mg daily plus either clopidogrel 75mg daily or prasugrel 5-10mg daily or ticagrelor 90mg twice daily.
3038591|NCT02303704|Active Comparator|multiport antegrade cardioplegia|Patients who received multiport antegrade cardioplegia and continuous controlled warm blood perfusion through vein grafts.
3038592|NCT02303704|Active Comparator|Aortic root antegrade cardioplegia|Patients who underwent routine conventional CABG with antegrade aortic root cardioplegia without warm blood perfusion
3038593|NCT02303691|Experimental|Computerized Attention Bias Modification|
3038594|NCT02303691|Sham Comparator|Computerized Neutral Training|
3038595|NCT02303678|Experimental|D2C7-IT|Recurrent malignant glioma patients will receive D2C7-IT, delivered intratumorally by CED following confirmatory diagnostic biopsy.
3038596|NCT02303665|No Intervention|The control group|No Intervention
3038597|NCT02303665|Experimental|The dual therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy.
3038598|NCT02303665|Experimental|The triple therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM.
3038599|NCT02303639|Experimental|Radiofrequency catheter ablation|Radiofrequency catheter ablation using open-irrigated ablation catheter and 3D electroanatomical mapping
3038600|NCT02303639|Active Comparator|Antiarrhythmic drug therapy|Amiodarone (or sotalol) tablet by mouth for the duration of the study
3038601|NCT02303626|Experimental|BCX4161 300 mg three times daily|Three BCX4161 capsules (100 mg) and two placebo capsules to be taken three times daily by mouth
3038602|NCT02303626|Experimental|BCX4161 500 mg three times daily|Five BCX4161 capsules (100 mg) to be taken three times daily by mouth
3038603|NCT02303626|Placebo Comparator|Placebo three times daily|Five placebo capsules to be taken three times daily by mouth
3038604|NCT02303600|Experimental|biomarker treatment arm|Patients in biomarker guided positive treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . Patients in biomarker guided negative treatment arm were given placebo tablets (main excipient lactose monohydrate).
3038605|NCT02303600|Active Comparator|standard treatment arm|Patients in standard treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
3038606|NCT02303587|Experimental|low dose group|methylprednisolone 2mg-4mg/Kg
3038607|NCT02303587|Experimental|high dose group|methylprednisolone 10mg/Kg
3038608|NCT02303574|Experimental|AZD7986, single and mulltiple doses|In Part 1 up to 8 cohorts with single doses starting with 5 mg AZD7986 as oral solution. In Part 2 up to 5 cohorts with multiple doses of AZD7986 as oral solution
3038609|NCT02303574|Placebo Comparator|Placebo, single and multiple doses|In Part 1 up to 8 cohorts and in Part 2 up to 5 cohorts with matching placebo to AZD7986 as oral solution
3038610|NCT02303561|Experimental|CHAMP|Families assigned to this arm will receive tailored asthma education and behavioral skills focused on improving asthma and weight management.
3038611|NCT02303561|Active Comparator|Health education|Families assigned to this arm will receive tailored asthma education and general health education on a variety of topics.
3038612|NCT02303548|Experimental|1 (Sodium bicarbonate)|Sodium bicarbonate 50cc (50mEq) intravenous injection over 2 min
3038613|NCT02303548|Placebo Comparator|2 (Normal saline)|Normal saline 50cc intravenous injection over 2 min
3038614|NCT02303535||Congenital|"All patients with congential and acquired heart disease treated by cardiac surgery and therapeutic cardiac catheterisations procedures .~For acquired heart disease, the audit covers all arrhythmias & cardiomyopathies in patients less than 16 years old only.~For congenital heart disease, the audit collects data on both children and adult patients."
3038615|NCT02303522||All subjects|All subjects will be included in a unique cohort
3038616|NCT02303509|Experimental|UCB5857 Part 1|Part 1: Subjects assigned to UCB5857 or placebo single dose.
3038617|NCT02303509|Experimental|UCB5857 Part 2|Part 2: Subjects assigned to UCB5857 or placebo multiple doses.
3038618|NCT02303496|Experimental|PRP Cream Application|Application of Cream Containing Platelet Rich Plasma and Oleaginous Base
3038619|NCT02303496|Active Comparator|SW Cream Application - Placebo|Application of Cream Containing Sterile Water and Oleaginous Base
3038620|NCT02303483|Placebo Comparator|Placebo|lime tablets
3038621|NCT02303483|Experimental|Nicotinamide riboside (NR, Vit B3)|NIAGEN (ChromaDex) 1 g x 2 orally per day
3038622|NCT02303470|Experimental|Vigorous Exercise|High-intensity interval training for 15 minutes daily, 5 days per week for 8 weeks
3038623|NCT02303470|Experimental|Moderate Exercise|Brisk walking for 30 minutes daily, 5 days per week for 8 weeks
3038624|NCT02303457|Experimental|CO2 laser surgery|CO2 Laser surgery for T1N0 Glottic Squamous Cell Carcinoma With Anterior Commissure Involved. All patients, under general anesthesia, underwent endoscopic excision of the lesion using a carbon dioxide (CO2) laser (Sharplan 100) coupled with a microscope (Zeiss) set to an output power of between 5 and 12 W in superpulse mode. The lesion's resection was accomplished in a radical fashion, with a free margin of 2 mm. For lesions which involved the anterior commissure, the excision plane always uncovered the cartilage.
3038625|NCT02303457|Other|Open surgery|"Open Surgery for T1N0 Glottic Squamous Cell Carcinoma With Anterior Commissure Involved.~open surgery :Frontolateral Vertical Partial Laryngectomy or laryngofissure with cordectomy was accomplished in a radical fashion, with a free margin of 2 mm."
3038626|NCT02303444||MKI patients|Asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to initiate MKIs at study entry. For patients on sorafenib, treatment start and stop dates will be collected along with any adverse events observed.
3038627|NCT02303444||non-MKI patients|Asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to not initiate MKIs at study entry. For patients on sorafenib, treatment start and stop dates will be collected along with any adverse events observed.
3038628|NCT02303431|Experimental|Cohort 1a|12 to < 18 years of age: edoxaban low dose group
3038629|NCT02303431|Experimental|Cohort 1b|12 to < 18 years of age: edoxaban high dose group
3038630|NCT02303431|Experimental|Cohort 2a|6 to < 12 years of age: edoxaban low dose group
3038631|NCT02303431|Experimental|Cohort 2b|6 to < 12 years of age: edoxaban high dose group
3038632|NCT02303431|Experimental|Cohort 3a|2 to < 6 years of age: edoxaban low dose group
3038633|NCT02303431|Experimental|Cohort 3b|2 to < 6 years of age: edoxaban high dose group
3038634|NCT02303431|Experimental|Cohort 4a|6 months to <2 years of age: edoxaban low dose group
3038635|NCT02303431|Experimental|Cohort 4b|6 months to <2 years of age: edoxaban high dose group
3038636|NCT02303431|Experimental|Cohort 5a|0 to 6 months of age: edoxaban low dose group
3038637|NCT02303431|Experimental|Cohort 5b|0 to 6 months: edoxaban high dose group
3038638|NCT02303418|Active Comparator|Carbetocin|100 µgm of Carbetocin will be diluted in 10ml saline and will be given by the anesthesist slowly intravenously after delivery of the baby. The uterine tone and amount of bleeding will be noted and the need for further uterotonic agents will be determined 2 minutes after giving the drug.
3038639|NCT02303418|Active Comparator|Oxytocin|5 mg of oxytocin will be diluted in 10ml saline and will be given by the anesthesist slowly intravenously after delivery of the baby. The uterine tone and amount of bleeding will be noted and the need for further uterotonic agents will be determined 2 minutes after giving the drug.
3038640|NCT02303405|Experimental|Hydroxychloroquine|Treatment with hydroxychloroquine 400 mg (2 x 200 mg tablets) po once daily x 4 months
3038641|NCT02303405|Active Comparator|Pioglitazone|Treatment with pioglitazone 45 mg po (1 tablet) once daily x 4 months
3038642|NCT02303392|Experimental|Treatment (selinexor, ibrutinib)|Patients receive ibrutinib PO on days 8-28 of course 1 and on days 1-28 on subsequent courses and selinexor PO BID weekly on day 1 or bi-weekly on days 1 and 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3038643|NCT02303379|Active Comparator|Continuous Endurance training|Endurance training with constant work load 31min at 65-75% maximal heart rate (HRmax)
3038644|NCT02303379|Experimental|Pyramid Training|One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
3038645|NCT02303379|Experimental|High-intensity intervall training|HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
3038646|NCT02303366|Experimental|SABR + MK-3475|SABR treatment (20Gy in 1 fraction) to at least one metastases (to a maximum of 5 metastases) followed by 8 cycles of 3 weekly treatment with MK-3475 (200mg IV per dose).
3038647|NCT02303353||Cancer patients|Patients suffering from a carcinoma (either breast, ovarian, lung, colon, stomach, pancreas, rectum or plasmacytoma)
3038648|NCT02303340||Study Group|Any patient who enrolled and signed informed consent will be sent to bone mineral density DEXA Scan, and for blood testing for PTH, Phosphor, Calcium ,Vitamin D and Creatinine levels. Density measurements will be done in specific sites on the CBCT's of the jaws.
3038649|NCT02303327|Other|ADT+EBRT+ HDR brachytherapy boost|Standard fractionation radiotherapy: 46 Gy in 23 fractions (EBRT) and a 15-Gy HDRB boost in conjunction with 28 months of androgen deprivation therapy (ADT).
3038650|NCT02303327|Active Comparator|ADT+Hypofractionated Dose Escalation RT|Hypofractionated dose escalation radiotherapy: 68 Gy in 25 fractions in conjunction with 28 months of androgen deprivation therapy (ADT).
3038651|NCT02303314|Other|Drug: Trigonella Foenum-graecum|in this group patients use Trigonella Foenum-graecum seed extract twice daily.
3038652|NCT02303314|Other|Drug: Placebo|in this group patients use placebo twice daily.
3038653|NCT02303301|Active Comparator|Probiotics|Patients gurgle twice a day with a suspension of two probiotic strains of bacteria- Contains also a filling material - maltodextrin
3038654|NCT02303301|Placebo Comparator|Control|Patients gurgle twice a day with a suspension of the filling material - maltodextrin
3038655|NCT02303275|Other|Lifestyle Change|Lifestyle Change
3038656|NCT02303262|Experimental|Mocetinostat and gemcitabine|
3038657|NCT02303249|Experimental|Intervention|Review of discharges and cross-sectoral video conferencing immediately after discharge
3038658|NCT02303249|No Intervention|Control|Standard health care services
3038659|NCT02303223|Other|Propofol|Single intravenous bolus dose of Propofol 2.5mg/kg for induction of anesthesia
3038660|NCT02303210|Other|hearing aid NaidaUP|Within subject design: compare frequency lowering one with frequency lowering two.
3038661|NCT02303210|Other|hearing aid NaidaSP|Within subject design: compare frequency lowering one with frequency lowering two.
3038662|NCT02303197|Experimental|ChiNing decoction|60ml ChiNing decoction by mouth，three times a day for 46 days.
3038663|NCT02303197|No Intervention|rhEGF spray|The rhEGF spray spray on the oral mucosal surface irradiated area, 3 times a day for 46 days.
3038664|NCT02303184|Experimental|suprachoroidal CLS-TA + IVT aflibercept|Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA following a 2 mg intravitreal injection of aflibercept
3038665|NCT02303184|Active Comparator|suprachoroidal sham + IVT aflibercept|Single unilateral, suprachoroidal sham procedure following a 2 mg intravitreal injection of aflibercept
3038666|NCT02303171|Active Comparator|Enoxaparin group|Women will be subjected to anticoagulant therapy by Enoxaparin throughout pregnancy
3038667|NCT02303171|Active Comparator|Warfarin group|Women will be subjected to anticoagulant therapy by Enoxaparin in the first trimester then Warfarin after the first trimester
3038668|NCT02303145||Breast cancer survivor Group|Breast Cancer Survivor Group includes: women between the ages of 18 to 69 who have received a stage I-III diagnosis of breast cancer in the past and completed primary treatment and finished with treatment for at least 6 months; currently employed working part-time or full-time at the time of assessment. Participants working between 1 to 34 hours a week will be considered part-time employees.
3038669|NCT02303145||Control Group|Control Group includes: women between the ages of 18 to 60 who are healthy with no diagnosis of cancer, currently employed working part-time or full-time at the time of assessment. Participants working between 1 to 34 hours a week will be considered part-time employees.
3038670|NCT02303132|Other|Active MC|Patients with active MC will be included
3038671|NCT02303132|Other|MC in remission|Patients with MC in remission will be included
3038672|NCT02303132|Other|Controls|Patients without MC will be included
3038673|NCT02303119|Active Comparator|Am A : Rituximab IV|4 infusions of intravenous rituximab (375mg/m²) at Day 1, Day 8, Day 15 and D22
3038674|NCT02303119|Experimental|Arm B: Rituximab SC|1 infusion of intravenous rituximab (375mg/m²) at Day 1, and 7 administrations of sub-cutaneous rituximab (1400mg) at Day 8, Day15, Day 22, Month 3, Month 5, Month 7 and Month 9.
3038675|NCT02303106|Active Comparator|lamotrigine|lamotrigine alone
3038676|NCT02303106|Experimental|Lamotrigine + paracetamol|Lamotrigine + paracetamol
3038677|NCT02303093||Octagam|Patient receiving Octagam 5% or 10% IVIG
3038678|NCT02303093||Panzyga|Patient receiving panzyga
3038679|NCT02303080|Placebo Comparator|Control (WPM 0)|400 mL beverage with 85.0% maltodextrine, 15.0% fat and 0% of whey protein micelles Product given once after 1 hour of monitoring for baseline
3038680|NCT02303080|Active Comparator|WPM 30|400 mL beverage with 43.7% of maltodextrine, 15.2 % fat and 41.1% (30 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
3038681|NCT02303080|Active Comparator|WPM 50|400 mL beverage with 16.3% of maltodextrine, 15.2 % fat and 68.5% (50 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
3038682|NCT02303080|Active Comparator|MC 50|400 mL beverage with 16.7% of maltodextrine, 15.0 % fat and 68.2% (50 g) of whey protein micelles 50 g of micellar casein Product given once after 1 hour of monitoring for baseline
3038683|NCT02303054|Experimental|Bipolar Radiofrequency Focal Ablation|Men identified as having suspicious regions on an Prostatic multi-parametric MRI (mpMRI) of the prostate will be considered for enrollment. If followed by a positive MRI-US targeted biopsy of the prostate, men who be offered enrollment into the study. All men enrolled in the study will undergo bipolar radiofrequency ablation. Efficacy will be assessed through MRI-US biopsy after focal bipolar RFA.
3038684|NCT02303041|Experimental|BCC Smoothened inhibitor-naive|Participants with locally advanced or metastatic basal cell carcinoma (BCC) and naive to treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
3038685|NCT02303041|Experimental|BCC refractory or relapsed after Smoothened inhibitor|Participants with locally advanced or metastatic basal cell carcinoma (BCC) that is refractory or relapsed after treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
3038686|NCT02303028|Experimental|Topotecan and Pazopanib|Low dose Topotecan will be given metronomically at the dose level assigned at study entry, in combination with a fixed dose of Pazopanib
3038687|NCT02303015||Danish germ cell cancer patients|Danish patients with germ cell cancer diagnosed from 1984 to 2007.
3038688|NCT02303002|Experimental|Dose A|Dose A: Botulinum Toxin Type A
3038689|NCT02303002|Experimental|Dose B|Dose B: Botulinum Toxin Type A
3038690|NCT02303002|Experimental|Dose C|Dose C: Botulinum Toxin Type A
3038691|NCT02303002|Active Comparator|Dose D|Dose D: Botulinum Toxin Type A
3038694|NCT02302989|Active Comparator|Quarterly Ranibizumab 0.5|Quarterly intravitreal injection of 0.5mg Ranibizumab Intervention: Drug: Ranibizumab 0.5mg
3038695|NCT02302976|Experimental|acute pre-treatment with exenatide|This arm plans to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide vs. placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. We propose to study 24 subjects in a within-subject (two-day, randomized, placebo-controlled) human laboratory study of self-regulated cocaine administration. We hypothesize that acute treatment with exenatide will reduce cocaine-induced euphoria and self-regulated cocaine administration as compared to placebo
3038696|NCT02302976|Experimental|sub-chronic (5 day) treatment with exenatide|This arm plans to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug. Upon completion of arm 1, subjects may opt to be randomized to five days of treatment with either exenatide or placebo, followed by a one-day human laboratory study of self-regulated cocaine administration. We hypothesize that subjects treated with exenatide (up to N=12) will demonstrate decreased self-regulated cocaine administration as compared to subjects treated with placebo (up to N=12).
3038697|NCT02302976|Placebo Comparator|acute pre-treatment with placebo|This arm plans to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide vs. placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. We propose to study 24 subjects in a within-subject (two-day, randomized, placebo-controlled) human laboratory study of self-regulated cocaine administration. We hypothesize that acute treatment with exenatide will reduce cocaine-induced euphoria and self-regulated cocaine administration as compared to placebo
3038698|NCT02302976|Placebo Comparator|sub-chronic (5 day) treatment with placebo|This arm plans to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug. Upon completion of arm 1, subjects may opt to be randomized to five days of treatment with either exenatide or placebo, followed by a one-day human laboratory study of self-regulated cocaine administration. We hypothesize that subjects treated with exenatide (up to N=12) will demonstrate decreased self-regulated cocaine administration as compared to subjects treated with placebo (up to N=12).
3038699|NCT02302963|Experimental|AP System (DiAs or inControl) with USS Virginia|Subject will complete an 8-hour inpatient assessment of hypoglycemia counterregulation. Subject will then proceed through 7 weeks of training and use of the AP System with USS Virginia and study pump. The inpatient testing will be repeated after wearing the AP System at home.
3038700|NCT02302963|Placebo Comparator|Sensor-Augmented Pump Therapy|Subject will complete an 8-hour inpatient assessment of hypoglycemia counterregulation. Subject will then wear a continuous glucose monitor and their own insulin pump at home for 5 weeks. The inpatient testing will be repeated at the completion of the 5 weeks at home.
3038701|NCT02302950||women that picked up raltegravir 2013|minority women that picked up raltegravir at Thomas street Health Center 2013
3038702|NCT02302937|Active Comparator|group A: Standard TEP|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
3038703|NCT02302937|Active Comparator|Group B: LESS Port|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port (12 to 15 mm transumbilical).
3038704|NCT02302911||Early intensive behavioral intervention|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving early intensive behavioral Intervention at one of the participating centres.
3038705|NCT02302911||Early intensive eclectic intervention|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving early intensive eclectic Intervention at the participating centre.
3038706|NCT02302911||Control group|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving treatment as usual or no treatment at all.
3038707|NCT02302898||Wt maintenance|Eating Behavior Evaluation Measurement of Functional gastric volume Measurement of gastric pouch and GJ sizes
3038708|NCT02302898||Wt Regain|Eating Behavior Evaluation Measurement of Functional gastric volume Measurement of gastric pouch and GJ sizes
3038709|NCT02302872|Experimental|ARTO system|
3038710|NCT02302859|Experimental|Standard Treatment (ST)|"Participants supplied with a 8-week supply of nicotine patches, a smart phone and brief advice to quit smoking. Participants also receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone, and again at 3 months after intervention.~Participants complete saliva cotinine test 3 months after intervention."
3038711|NCT02302859|Experimental|Automated Treatment (AT)|"Participants supplied with a 8-week supply of nicotine patches and a smart phone. Participants also receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone, and again at 3 months.~Participants complete saliva cotinine test 3 months after intervention."
3038712|NCT02302846|Experimental|Ixazomib|Participants receive 4 mg oral dose of Ixazomib on Days 1, 8 and 15 of each 28-day cycle.
3038713|NCT02302833|Experimental|Cabozantinib|Participants take Cabozantinib by mouth at a dose of 60 mg once daily. Questionnaire completion regarding symptoms completed at baseline, 4 days before starting Cabozantinib, and weekly while taking the drug.
3038714|NCT02302820|Active Comparator|Make Your Wishes Known|"A Decision Aid that uses interactions, videos, vignettes.~A formatted Advance Directive; saved data that may be revisited to produce a revised Advance Directive"
3038715|NCT02302820|Active Comparator|Mayo Clinic-Advance Health Care Planning|"Not an online decision aid~Written instructions, worksheets, and Advance Directive to complete"
3038716|NCT02302820|Active Comparator|Mydirectives.com|"Online decision aid that uses interactions, videos, and vignettes.~An electronically stored Advance Directive that may be printed."
3038797|NCT02302300|Experimental|Manufacturer STELLAR 150|5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
3038717|NCT02302820|Active Comparator|Prepare|"An online decision aid that uses interactions, videos and vignettes.~A printed summary useful for transposing values and treatment wishes into an Advance Directive; a list of action steps."
3038718|NCT02302807|Experimental|Arm A: Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants will receive atezolizumab as long as they continue to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
3038719|NCT02302807|Active Comparator|Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)|Participants randomized to the chemotherapy arm will receive vinflunine, paclitaxel, or docetaxel per the investigator's choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.
3038720|NCT02302794|Active Comparator|open surgery|Conventional procedure
3038721|NCT02302794|Experimental|laparoscopic surgery|Minimum invasive procedure
3038722|NCT02302781||Subfertile couples|Couples referred to one of the four participating hospitals with any type of subfertility for work up and/ or treatment will be screened for inclusion. Couples have not visited only other clinic yet.
3038723|NCT02302768|Placebo Comparator|Placebo|Patients randomized to receive same pharmaceutical form (capsule) used for the two Semet groups, with the same excipients but the active drug.
3038724|NCT02302768|Active Comparator|80-Semet|Patients randomized to receive selenomethionine at 80 mcg per day.
3038725|NCT02302768|Active Comparator|160-Semet|Patients randomized to receive selenomethionine at 160 mcg per day.
3038726|NCT02302755|Experimental|Screening/ Active Treatment Arm|"Screening Period: This includes diagnosis confirmation, consent, required tests and vaccinations.~Treatment Period: All patients will be enrolled through the University of Iowa. This study will follow a patient-specific TP10 dose-escalation scheme during the Induction Period and subsequent dose adjustments based on complement levels during the Maintenance Period"
3038727|NCT02302742||Triple Negative Breast Cancer patients|No intervention
3038728|NCT02302742||Germline HBOC Mutation Carriers|No intervention
3038729|NCT02302729|Experimental|Micronutrients No responsive feeding|Micronutrient powder and no responsive feeding
3038730|NCT02302729|Placebo Comparator|Placebo and Responsive Feeding|Placebo (vitamin B2) and Responsive Feeding
3038731|NCT02302729|Experimental|Micronutrients and Responsive caregiving|Micronutrients and Responsive feeding intervention
3038732|NCT02302729|Placebo Comparator|Placebo and No responsive caregiving|Placebo and No responsive caregiving
3038733|NCT02302716|Experimental|LY2963016|Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or neutral protamine hagedorn (NPH) QD will begin the study at their current dose SC. Participants will self titrate LY2963016 based on fasting blood glucose (FBG). Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will continue oral antihyperglycemic medication (OAM).
3038734|NCT02302716|Active Comparator|LANTUS®|Insulin naive participants started on 10 U LANTUS® given SC QD for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or NPH QD will be started at the same dose SC. Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will self titrate LANTUS® based on FBG. Participants will continue OAM.
3038735|NCT02302703|Active Comparator|the low FODMAP diet|
3038736|NCT02302703|Active Comparator|Gluten free diet|
3038737|NCT02302664|Active Comparator|PRP Injection|Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
3038738|NCT02302664|Sham Comparator|Imitation Injection|Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
3038739|NCT02302651|Other|Osteoid Osteoma|MR guided High Intensity focused ultrasound
3038740|NCT02302638|Active Comparator|Sage 1-step|"Embryo culture in different single-step media:~Half of each patient's oocytes will be randomly allocated to be cultured in Sage 1-step medium for up to six days following oocyte retrieval."
3038741|NCT02302638|Active Comparator|CSCM|"Embryo culture in different single-step media:~Half of each patient's oocytes will be randomly allocated to be cultured in CSC medium for up to six days following oocyte retrieval."
3038742|NCT02302625|Experimental|Cognitive behavior therapy|Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
3038743|NCT02302612|Experimental|CREATE Wellness|Patients allocated to the intervention arm will receive three group sessions with between visit contacts designed to increase activation and engagement with their care plans. They will also continue to be enrolled in the KP PHASE disease management program.
3038744|NCT02302612|Active Comparator|Usual Care Control|Patients allocated to the control arm will continue to receive usual care, including disease management within the KP PHASE program.
3038745|NCT02302599|Experimental|Umbilical cord mesenchymal stem cells|Patients receive Umbilical cord mesenchymal stem cells in the absence of disease progression or unacceptable toxicity
3038746|NCT02302599|Experimental|Controlled suspension liquid|Patients receive Controlled suspension liquid
3038798|NCT02302300|No Intervention|Control Group|Standard preparation
3039429|NCT02297854|Active Comparator|Valcyte|Valcyte® 450 mg tablets of Genentech USA Inc., San Francisco
3038747|NCT02302586|Active Comparator|Patient Controlled Analgesia (IV PCA)|Postoperative intravenous (IV) morphine PCA is being used for acute pain control: Basal infusion: 0.3 mg/kg/h Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
3038748|NCT02302586|Active Comparator|Thoracic Paravertebral Block (TPVB)|Preoperative thoracic paravertebral block (TPVB) at 4 levels from T4 to T8 is being performed and total of 20 mL Bupivacaine 0.5% is deposited (5 mL per level by using landmark technique)
3038749|NCT02302573|Experimental|placenta accreta|contast-enhanced ultrasound with sonovue
3038750|NCT02302560||Patients with elective hip surgery|Patients with elective hip surgery (implementation or replacement of hip joint endoprotheses).
3038751|NCT02302547|Active Comparator|triple therapy|Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor) + third agent (boosted protease inhibitor or unboosted protease inhibitor or integrase inhibitor or celsentri or non-nucleoside reverse transcriptase inhibitor).
3038752|NCT02302547|Experimental|dual therapy|"Truvada®245mg:oral administration Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor)"
3038753|NCT02302534|Experimental|patients|"2 groups with MRI :~- 8 right thoracic AIS participants (Cobb angle between 20 and 40°)"
3038754|NCT02302534|Experimental|controls subjects|- 8 healthy controls (no clinical scoliosis)
3038755|NCT02302521||Healthy Younger Adults|Age: 20-30. Gender: male or female. No neurological conditions.
3038756|NCT02302521||Healthy Older Adults|Age: 50-70. Gender: male or female. No neurological conditions.
3038757|NCT02302521||Parkinson's disease|Gender: male or female. Tremor dominant Parkinson's disease.
3038758|NCT02302521||Healthy Children|Age: 4-8. Gender:male or female. No neurological conditions.
3038759|NCT02302508|Experimental|T2D patients with A1C ≤7.0|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
3038760|NCT02302508|Experimental|T2D patients with A1C>7.5|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
3038761|NCT02302508|Experimental|Insulino-treated|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
3038762|NCT02302508|Active Comparator|Non-diabetic healthy subjects|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
3038763|NCT02302495|Other|Carfilzomib weekly+Melphalan+Prednisone|one arm, two steps and two parts.In the first step of the study: 5 cohorts of 6 patients with Carfilzomib weekly administrated at different dose regimen will be opened one after the other to determine Maximum tolerated dose of Carfilzomib based on definition of Dose-limiting toxicities.In the second step of the study:expanded Cohort, 50 patients received Carfilzomib at the MTD. In Part 1. Induction.Nine 5 weeks cycles of weekly CMP are plannedCarfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route . Patients will start the first cycle day 1 with 20mg/m². In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.Part 2. Maintenance.Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year.
3038764|NCT02302482|Experimental|Functional autonomy level collection|Collection of the Functional autonomy level every 6 - 12 months by phone
3038765|NCT02302469|Other|revlimid|a dose-escalation of revlimid
3038766|NCT02302456|Experimental|TXA|Intravenous administration of 1g of tranexamic acid within 2 minutes after birth and prophylactic oxytocin administration
3038767|NCT02302456|Placebo Comparator|Placebo|Intravenous administration of placebo within 2 minutes after birth and prophylactic oxytocin administration
3038768|NCT02302443|Experimental|Cohort 1|Very low dose of HM12470 (single dose, subcutaneous injection)
3038769|NCT02302443|Experimental|Cohort 2|Low dose of HM12470 (single dose, subcutaneous injection)
3038770|NCT02302443|Experimental|Cohort 3|Intermediate dose of HM12470 (single dose, subcutaneous injection)
3038771|NCT02302443|Experimental|Cohort 4|High dose of HM12470 (single dose, subcutaneous injection)
3038772|NCT02302443|Experimental|Cohort 5|Active comparator and a selected dose of HM12470 (single dose, subcutaneous injection)
3038773|NCT02302443|Experimental|Cohort 6|Active comparator and a selected dose of HM12470 (single dose, subcutaneous injection)
3038774|NCT02302430|Experimental|Treatment|Treatment group will receive either 20IU or 40IU intranasal oxytocin
3038775|NCT02302430|Placebo Comparator|Placebo|Placebo group will receive a saline nasal spray
3038776|NCT02302417|Other|All Subjects|Approximately 1000 subjects with clinical diagnoses of asthma and/or COPD or clinical presentations suggestive of either or both will be included. Subjects will undergo spirometry assessments and also will be asked a series of questions by a qualified health care practitioner using a questionnaire containing 41 questions concerning their respiratory condition.
3038777|NCT02302404|Experimental|Cohort 1: GSK2982772 Single Ascending Dose (Part A) (0.1-10mg)|Eight subjects will be randomized equally (1:1:1:1) to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2982772 + 1 placebo dose). The subjects will fast overnight from Day -1 to Day 1 of the treatment period. Two of the 8 subjects will be randomized to the dosing on Day 1 as sentinel dosing. Assuming adequate safety in the judgment of the Principal Investigator (e.g., vital signs, ECGs, and adverse events) through approximately 24 hours; the remaining 6 subjects may be randomized to dosing on the following day. Subjects will receive single planned doses of GSK2982772 as 0.1, 0.5, 2.5, and 10mg. A sequential design will be used including approximately weekly dose escalations while allowing for a sufficient washout period. The proposed doses may be adjusted based on emerging safety and PK
3038829|NCT02302079|Active Comparator|Placebo + ranibizumab intravitreal (IVT) injections|Placebo will be given orally once daily and ranibizumab injections 3 times with 1 month intervals
3038830|NCT02302066|Experimental|Group 1 (TDV 2-Dose)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Days 1 and 91. Takeda's tetravalent dengue placebo, 0.5 mL, subcutaneous injection on Day 365.
3039050|NCT02300454|Placebo Comparator|Balloon|Non-compliant balloon dilatation before use of SeQuent® Please drug coated balloon (DCB)
3038778|NCT02302404|Experimental|Cohort 2: GSK2982772 Single Ascending Dose (Part A) (40-240mg)|Eight subjects will be randomized equally to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having 4 dose periods (3 active dose of GSK2982772 +1 placebo dose). The subjects will fast overnight from Day -1 to Day 1 of the treatment period. Two of the 8 subjects will be randomized to the dosing on Day 1 as sentinel dosing. Assuming adequate safety in the judgment of the Principal Investigator (e.g., vital signs, ECGs, and adverse events) through 24 hours; the remaining 6 subjects may be randomized to dosing on the following day. Subjects will receive single planned doses of GSK2982772 as 40, 100, 180, and 240 mg. A sequential design with weekly dose escalations and sufficient washout period will be used. The proposed doses may be adjusted based on emerging safety and PK. After the completion of the fasted treatment periods, subjects will receive a high fat meal within 30 minutes of dosing with GSK2982772 during a final treatment period.
3038779|NCT02302404|Experimental|Cohort 3: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in the Part A data
3038780|NCT02302404|Experimental|Cohort 4: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in Part A or any preceding repeat dose cohorts in Part B
3038781|NCT02302404|Experimental|Cohort 5: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in the Part A or any preceding repeat dose cohorts in Part B.
3038782|NCT02302404|Experimental|Cohort 6: GSK2982772 Single Ascending Dose (Part A)|This additional cohort in Part A of the study will only be conducted to allow for evaluation of additional dose levels or repeated evaluation of a dose level already studied. Doses will be selected based on the safety, tolerability, and PK data from Part A and/or previous Part B cohorts. Eight subjects will be randomized equally (1:1:1:1) to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2982772 + 1 placebo dose). The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B.
3038783|NCT02302404|Experimental|Cohort 7: GSK2982772 Repeat Dose (Part B)|This additional cohort in Part B of the study will only be conducted to allow for evaluation of additional dose levels or repeated evaluation of a dose level already studied Doses will be selected based on the safety, tolerability, and PK data from Part A and/or previous Part B cohorts. Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B.
3038784|NCT02302391||Midazolam/fentanyl: PK analysis|Pediatric intensive care patients under analgosedation with midazolam and fentanyl.
3038785|NCT02302378|Active Comparator|Taylor's approach|This arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
3038786|NCT02302378|Active Comparator|Lumbar approach|This arm will have the procedure of spinal anesthetic performed via a paramedian 'Lumbar approach' at interspace L3-L4. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
3038787|NCT02302352|Active Comparator|Probiotic|Oral probiotic 1g, once/day, containing: Lactobacillus paracasei, 10x9 CFU; Lactobacillus rhamnosus,10x9 CFU; Lactobacillus acidophillus, 10x9 CFU; Bifidobacterium lactis 10x9 CFU per sachet
3038788|NCT02302352|Placebo Comparator|Placebo|Maltodextrin 1g per sachet, once/day
3038789|NCT02302339|Experimental|Glembatumumab vedotin|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle.
3038790|NCT02302339|Experimental|Glembatumumab vedotin and varlilumab|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. Varlilumab administered as an intravenous infusion on Day 1 of cycles 1, 2, 4, 6, 8 and 10.
3038791|NCT02302339|Experimental|Glembatumumab vedotin and PD-1 targeted checkpoint inhibitor|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. Nivolumab OR pembrolizumab administered according to institutional standard of care.
3038792|NCT02302339|Experimental|Glembatumumab vedotin and CDX-301|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. CDX-301 is injected once a day for five days before cycles 1 and 2.
3038793|NCT02302326|Experimental|Metformin|PCOS women began treatment with ER 500 mg metformin per day, and the dose was increased to 1000 mg after 2 weeks, and to 1700 mg/d after a further 2 weeks, and was maintained at this dose for a total of 12 weeks.
3038794|NCT02302326|Experimental|Myo-inositol + folic acid|PCOS women received a dietary supplement (Ovusitol® : 4 g myo-inositol plus 400 micrograms of folic acid) for 12 weeks
3038795|NCT02302326|No Intervention|Healthy women|Healthy untreated women adjusted for age and body mass index
3038796|NCT02302313|Other|painful stimuli|"No drug and no placebo will be used in this study. The study participants will only rate their pain on a numerical scale (EN) following cutaneous painful stimulation (6 for each phase) of variable intensity, delivered by a CO2 laser. ANI (Analgesia Nociception Index) will be raised simultaneously by the ANI monitor. This sequence will be performed on subjects at rest and in a state of hypnosis by the technique of remembering a pleasant memory and the ideo-sensory technique of protective glove."
3039151|NCT02299830|Experimental|cryotherapy|give the cases whose central airway stricture were caused by soft neoplasm tissues cryotherapy
3038799|NCT02302287|Experimental|Group A|"Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;~Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day~Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day~Mediterranean diet and ketoacids for 6 months"
3038800|NCT02302287|Experimental|Group B|"Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;~Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day;~Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day~Mediterranean diet and ketoacids for 6 months"
3038801|NCT02302287|Other|Group control|Free diet: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day
3038802|NCT02302274|Other|flecainide infusion test|Patients with suspect Brugada Syndrome will be asked to undergo flecainide infusion (2 mg/Kg up to 150 mg maximum dose) over 10 minutes and their ECG will be continuously monitored. The objective of the study is to investigate if they show conversion from type 2 or type 3 ECG to a diagnostic type 1 ECG.
3038803|NCT02302261||Status Asthmaticus|Any patient presenting to the ED with status asthmaticus.
3038804|NCT02302248|Experimental|Crowdsourced Reappraisal|Participants received the web-based crowdsourcing reappraisal intervention.
3038805|NCT02302248|Active Comparator|Expressive Writing|Participants received the web-based expressive writing intervention.
3038806|NCT02302235|Active Comparator|Ketogenic Diet|Treatment will consist of ketogenic diet. KGD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. Diet will be started at the time of initiation of radiation treatment.
3038807|NCT02302235|Other|Standardized diet|The subjects will be taken standard diet in a 1:1 ratio.
3038808|NCT02302222|Active Comparator|Standard of Care|dry sterile dressing/gauze and steristrips
3038809|NCT02302222|Experimental|Customizable|Customizable Dressing with ActiV.A.C. Therapy Unit
3038810|NCT02302209|Experimental|Oxytocin|40 IU Oxytocin Intranasal
3038811|NCT02302209|Placebo Comparator|Placebo|Saline Nasal Spray
3038812|NCT02302196||Autologous Fat Grafting of the breast|Approximately 100 women who have had a lumpectomy and qualify, will be offered Autologous Fat Grafting (AFG) procedure. Patients will be assessed 3 months post grafting for safety and efficacy by Breast-Q survey, mammography BIRADS scoring and physical assessment. The AFG may be repeated x 2 at a 3-6 month interval if deemed necessary by the treating surgeon, then reassessed again 3 months later in the same way. Repeat mammogram will be done 1 year post AFG.
3038813|NCT02302196||Control arm standard treatment|Retrospective chart review will be done in 100 women who have undergone standard treatment for breast contour defect after lumpectomy.The control group will be measured by compiling BIRADS scores as well as frequency of subsequent surgical intervention (as necessitated by increased BIRADS scores or by new physical findings on exam) over a 5 year period post lumpectomy.
3038814|NCT02302183|Experimental|Experimental: device FreeO.|Automatic adjustment of oxygen
3038815|NCT02302183|Active Comparator|Manual oxygenation|Manual adjustment of oxygen
3038816|NCT02302170|Experimental|H. pylori vaccine in children|H. pylori vaccine (15mg/dose) in children between 6-15 years of age
3038817|NCT02302170|Placebo Comparator|placebo in children|placebo (0mg/dose) in children between 6-15 years of age
3038818|NCT02302157|Experimental|AST-OPC1|Open label, dose escalation, cross-sequential cohort of subjects who receive an injection or two injections of AST-OPC1 at a single time-point
3038819|NCT02302144|Experimental|Early Multi-Ex-PD|Immediately following enrollment, subjects will participate in a group balance and strengthening program (Multi-Ex-PD) 2x/week for 90 minutes over 3 months within the Center for Neurorehabilitation at Sargent College. Each of the exercises consists of a progression which ranges from less challenging to more challenging. The program will be individualized to the subject to appropriately match their abilities. Each subject will be progressed to a more challenging exercise once specific criteria are met. Resistance for the strengthening exercises will be applied using weighted vests.
3038820|NCT02302144|Experimental|Late Multi-Ex-PD|Three months after enrollment, subjects will participate in a group balance and strengthening program (Multi-Ex-PD) 2x/week for 90 minutes over 3 months within the Center for Neurorehabilitation at Sargent College. Each of the exercises consists of a progression which ranges from less challenging to more challenging. The program will be individualized to the subject to appropriately match their abilities. Each subject will be progressed to a more challenging exercise once specific criteria are met. Resistance for the strengthening exercises will be applied using weighted vests.
3038821|NCT02302131||pulmonary valve replacement|SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection
3038822|NCT02302118||Surgical approach|Group A: Esophagogastrectomy Group B: Extended gastrectomy
3038823|NCT02302105|Active Comparator|Prostate Only|66-68 Gray (Gy) in 25 fractions will be prescribed for the prostate PTV
3038824|NCT02302105|Experimental|Whole Pelvis|66-68 Gray (Gy) in 25 fractions will be prescribed for the prostate PTV and 50 Gy in 25 fractions to nodal region .
3038825|NCT02302092|Experimental|Flomoxef|Flomoxef, 2g, injection, intravenously, twice daily (every 12 hours), for up to 12 days.
3038826|NCT02302092|Active Comparator|Cefepime|Cefepime, 1g, injection, intravenously, twice daily (every 12 hours) for up to 14 days.
3038827|NCT02302079|Experimental|ASP8232 + sham intravitreal (IVT) injections|ASP8232 will be given orally once daily and sham injections 3 times with 1 month intervals
3038828|NCT02302079|Experimental|ASP8232 + ranibizumab intravitreal (IVT) injections|ASP8232 will be given orally once daily and ranibizumab injections 3 times with 1 month intervals
3038831|NCT02302066|Experimental|Group 2 (TDV 1-Dose)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Day 1. Takeda's tetravalent dengue placebo, 0.5 mL, subcutaneous injection on Days 91 and 365.
3038832|NCT02302066|Experimental|Group 3 (TDV 1-Dose + Booster)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Days 1 and 365. Takeda's tetravalent dengue placebo, 0.5 mL, subcutaneous injection on Day 91.
3038833|NCT02302066|Placebo Comparator|Group 4 (Placebo Control)|Takeda's tetravalent dengue placebo, 0.5 mL, subcutaneous injection on Days 1, 91 and 365.
3038834|NCT02302053|Active Comparator|New Viviscal Professional Supplement|New Viviscal Professional Strength Supplements. One tablet taken by mouth in the morning and one tablet in the evening with food for 180 days.
3038835|NCT02302053|Placebo Comparator|Placebo Tablet|Placebo tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 180 days.
3038836|NCT02302040|Experimental|AIM2ACT|AIM2ACT uses existing mHealth technology developed by the study team to elucidate tailored intervention targets for each family. AIM2ACT then facilitates collaborative caregiver/adolescent asthma management by automatically guiding dyads through a structured process that includes the supportive behavioral management strategies of goal setting, contingency management, and problem solving communication. Skills-training videos for adolescents and caregivers provide guidance on how to complete each collaborative asthma management component.
3038837|NCT02302040|Active Comparator|Self-Guided|Participants in the self-guided control condition will be given general information on supportive behavioral management techniques they can use to target improvement in asthma self-management behaviors. The control condition will serve as an attention control and is designed to optimize recruitment and sustain interest while concurrently having a minimal impact on asthma management.
3038838|NCT02302027|Experimental|platinium IRC9LXO2AWQ|Normobaric oxygen therapy with high flow concentrator to treat headaches attacks, 30 minutes of oxygene inhalation with mask, 9l/minute, no frequency limitation
3038839|NCT02302014|Experimental|Palliative Care Intervention|Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
3038840|NCT02302014|No Intervention|Usual Care|Usual Care
3038841|NCT02302001|Experimental|Primary Breast Augmentation|
3038842|NCT02301988|Experimental|Ipatasertib + Paclitaxel|Participants will receive ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses).
3038843|NCT02301988|Placebo Comparator|Placebo + Paclitaxel|Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses).
3038844|NCT02301975|Experimental|Fluticasone Furoate/Vilanterol 100/25 mcg|FF/VI 100/25 mcg by inhalation OD (PM) via ELLIPTA plus placebo by inhalation BD (AM and PM) via ACCUHALER/DISKUS for 24 weeks.
3038845|NCT02301975|Experimental|Fluticasone Propionate/Salmeterol 250/50 mcg|FP/Salmeterol 250/50 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
3038846|NCT02301975|Experimental|Fluticasone Propionate 250 mcg|FP 250 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
3038847|NCT02301962|Experimental|Panitumumab arm|Subjects will receive panitumumab 6 mg/kg intravenously as monotherapy every 14 days until disease progression, intolerability, withdrawal of consent, or death.
3038848|NCT02301949|Active Comparator|Thalidomide Retreatment Group|
3038849|NCT02301949|Placebo Comparator|Placebo Group|
3038850|NCT02301936|Experimental|LDV/SOF 12 weeks|Treatment-naive or treatment-experienced participants without cirrhosis will receive LDV/SOF for 12 weeks.
3038851|NCT02301936|Experimental|LDV/SOF 24 weeks|Treatment-experienced participants with cirrhosis will receive LDV/SOF for 24 weeks.
3038852|NCT02301923||CPAP compliant (C)|Patients confirmed with obstructive sleep apnea and succeeded to pursue treatment with CPAP
3038853|NCT02301923||CPAP noncompliant (NC)|Patients confirmed with obstructive sleep apnea but did not succeed to pursue treatment with CPAP
3038854|NCT02301910|Experimental|Recombinant staphylokinase|Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
3038855|NCT02301910|Active Comparator|Tenecteplase|"50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)~55 to <60 30 mg 6 ml~60 to <70 35 mg 7 ml~70 to <80 40 mg 8 ml~80 to <90 45 mg 9 ml~90 50 mg 10 ml"
3038856|NCT02301897|Placebo Comparator|Placebo|sugar pill manufactured to mimic Proellex capsule
3038857|NCT02301897|Experimental|6 mg Telapristone Acetate|
3038858|NCT02301897|Experimental|12 mg Telapristone Acetate|
3038859|NCT02301884|Experimental|Allergen extract|"Causal allergen such as D. farinae (30 AU/ml), D. pteronyssinus (30 AU/ml), cat hair (10 AU/ml), dog hair/dander (1:1/10 w/v), or combination of those.~Allergen extract, HollisterStier, New Orleans, USA. Intralymphatic injection in volume of 0.1 ml, three times with 4-week interval. Concentration was increased, decreased, or unchanged at 2nd or 3rd injection according to local or systemic reaction after previous injection"
3038860|NCT02301871|Active Comparator|Conventional group|The treatment was given for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
3038949|NCT02301208|Experimental|Low dose nedaplatin arm|concurrent chemotherapy: nedaplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
3063944|NCT02135471|Experimental|acellular dermal matrix graft|
3038861|NCT02301871|Experimental|DNF Group|"DNF training along with conventional treatment. In this programme, emphasis was placed on first attaining the correct craniocervical flexion action, with minimal activity of the superficial cervical flexor muscles. The craniocervical flexion action involves a specific craniocervical movement (nodding - yes movement) of head such that it remains in contact with the supporting surface. Once the correct action had been achieved, participants were instructed in the use of the sphygmomanometer to guide the training of the CCF muscle contraction at the various incremental levels of pressure (22 to 30 mmHg, progressively inner range positions)."
3038862|NCT02301871|Experimental|MET Group|MET in additional to conventional treatment. MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
3038863|NCT02301858|Other|Study arm|Genome analysis of tissue samples.
3038864|NCT02301845|Experimental|Suspended Diatoms|Suspended diatom shells (10 mg/ 10 ml of saline) will be instilled in the oral cavity of the study subject every 12 hours for the first three study days. The total amount of amorphous silica administered will be 20 mg/day, which is the average daily intake of amorphous silica in normal human diet (0.3 mg/kg body weight/day)
3038865|NCT02301819|Active Comparator|Invasive|Immediate veno-arterial extracorporeal membrane oxygenation (ECMO)
3038866|NCT02301819|Active Comparator|Conservative|Early conservative therapy according to standard practice
3038867|NCT02301806|Experimental|Sitagliptin|sitagliptin 50 mg tablet by mouth 12 weeks
3038868|NCT02301806|Active Comparator|Glimepiride|glimepiride 1 mg tablet by mouth 12 weeks
3038869|NCT02301793|Experimental|Contemporary Education Format|"Nurses in this arm received education about venous thromboembolism (VTE) in a web-based contemporary interactive format.~Intervention: Nurse education in contemporary format"
3038870|NCT02301793|Active Comparator|Traditional Education Format|"Nurses in this arm received education about venous thromboembolism (VTE) in a web-based traditional linear PowerPoint format with voice over.~Intervention: Nurse education in traditional format"
3038871|NCT02301780|Placebo Comparator|Control Group|Placebo
3038872|NCT02301780|Active Comparator|Intervention Group|Aspirin
3038873|NCT02301767||women that are diagnosed with breast cancer|To complete the study women need to have undergone their scheduled contrast-enhanced MRI, completed the study questionnaire, and provided written consent to release MRIs/mammograms. Although attempts will be made to obtain written consent from all women, the questionnaire data captured from the women who only provide verbal consent may be used in analysis. Optional saliva samples will also be collected for future use.
3038874|NCT02301767||women at high risk of breast cancer|To complete the study women need to have undergone their scheduled contrast-enhanced MRI, completed the study questionnaire, and provided written consent to release MRIs/mammograms. Although attempts will be made to obtain written consent from all women, the questionnaire data captured from the women who only provide verbal consent may be used in analysis. Optional saliva samples will also be collected for future use.
3038875|NCT02301754|Experimental|INVAC-1|"INVAC-1 at escalating doses of 100, 400 and 800 µg will be given as a single agent by intradermal injection (Q 4 weeks x 3 cycles), always combined with electroporation.~Each patient will receive 3 cycles, unless motivated treatment interruption."
3038876|NCT02301741|Experimental|Game Condition|Participants in the GAME condition will complete laboratory sessions on five consecutive days. Session 1 (baseline) and Session 5 (post-test) will be used to assess lumbar spine motion and expectations of pain and harm during standardized reaching tasks. In sessions 2 through 4 they will play the virtual dodge ball game.
3038877|NCT02301741|No Intervention|Control Condition|Participants in the CONTROL condition will complete baseline and post-test standardized reaching tasks, but will not play the game in the intervening three days.
3038878|NCT02301715|Active Comparator|Oxytocin|24 IU Oxytocin, 3 puffs per nostril, each with 4 IU OXT, intranasal application 45 min prior to the experiment
3038879|NCT02301715|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril, 45 min prior to the experiment
3038880|NCT02301702|Experimental|Tdap Vaccine|Combination Tetnus Toxoid, Reduced Diptheria Toxoid and Acellular Pertusis (Tdap)
3038881|NCT02301702|Active Comparator|Td Vaccine|Tetanus toxoid and reduced diphtheria toxoid vaccine (Td)
3038882|NCT02301689||Heart Failure patients|
3038883|NCT02301676|Active Comparator|General anesthesia & Control|"After the surgery, the patients are discharged from the hospital, investigators will check the postoperative cognitive function 4 times: 1weak, 3months, 6months, 1 year later using the intervention Korean version of telephone interview for cognitive status (TICS). The test will be administered to spouse simultaneously by telephone."
3038884|NCT02301676|Active Comparator|Sevoflurane & Propofol & Dexmedetomidine|The anesthetic methods are divided into the following 3 kinds: Sevoflurane, Propofol, Dexmedetomidine. These anesthetic drugs are used in general anesthesia generally.
3038885|NCT02301663|Experimental|Women w/microvascular disease|10 women with microvascular disease
3038886|NCT02301663|Experimental|Normal controls|10 age-matched women with no evidence of microvascular disease
3038887|NCT02301663|Experimental|calibration|10 healthy individuals who will help to synchronize our imaging and stress testing maneuvers.
3038888|NCT02301650||group A|The one year old children born in Beijing Ditan hospital and whose mothers had taken Lamivudine in late pregnancy
3038889|NCT02301650||group B|The one year old children born in Beijing Ditan hospital and whose mothers had taken Telbivudine in late pregnancy
3038890|NCT02301650||group C|The one year old children born in Beijing Ditan hospital and whose mothers had taken Tenofovir in late pregnancy
3038891|NCT02301650||group D|The one year old children born in Beijing Ditan hospital and whose mothers untreated in late pregnancy
3038892|NCT02301624|Experimental|Eculizumab|See interventions
3038893|NCT02301611|Experimental|Treatment|autologous TLPLDC (active vaccine)
3038894|NCT02301611|Placebo Comparator|Placebo|unloaded YCWP + autologous DC (control)
3038895|NCT02301598|Experimental|FS-ALK|Femtosecond laser-assisted maximum thickness anterior lamellar keratoplasty (FS-ALK) was performed for 11 eyes of 11 patients with advanced keratoconus and 2 eyes of 2 patients with superficial corneal scattering.
3038896|NCT02301585|Experimental|Passive Leg Raising|Before decision on fluid administration a passive leg raising test is performed. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
3038897|NCT02301585|Active Comparator|Standard of care|Patients are treated according to Surviving Sepsis Guidelines. Fluid is administered according to the choice of the clinician.
3038898|NCT02301572||Aggressive onset MS|Two or more relapses in the preceding year and 2 or more gadolinium enhancing lesions on brain MRI scan or a significant T 2 lesion burden or One relapse if it results in sustained EDSS of 3.0 along with 2 or more gadolinium enhancing lesions or significant T2 lesion burden ( T2 lesion burden being determined by factoring the number of lesions, the size of the lesions and lesion location)
3038899|NCT02301559|Experimental|Pilates Group|Pilates Group, Pilates exercises, 20 sessions, lasting 40 minutes each, 3 times per week. Soil and ball exercises, with emphasis on the pelvic region. The program began with the work of breathing and postural correction, with warm-up exercises or preparatory, followed by the framework of classical movements of the method.
3038900|NCT02301546|Experimental|experimental cognitive training|Participants will use experimental computerized cognitive training exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks.
3038901|NCT02301546|Active Comparator|control cognitive exercises|Participants will use control computerized cognitive activities, 1 hour per day, 3 - 5 days per week, for 13 weeks.
3038902|NCT02301533|Experimental|Shikamana Intervention|The Shikamana Intervention consists of provider support (modified Next Step Counseling) and peer support (trained peer navigator) to promote adherence to antiretroviral therapy
3038903|NCT02301533|Other|Standard Care|The standard care arm will receive adherence counseling per standard Kenyan Ministry of Health guidelines, along with the recommendation to disclose to a family member or friend in order to obtain support
3038904|NCT02301507|Experimental|SMS (texting) Arm|texts received
3038905|NCT02301494|Experimental|Fluocinonide (Vanos) cream 0.1%|Fluocinonide (Vanos) cream 0.1% will be applied as currently approved by the FDA for treatment of corticosteroid responsive disorders of the skin. Treatment will continue for 4 months with a follow up at 6 and 12 months.
3038906|NCT02301494|Experimental|3.75% Imiquimod (Zyclara) Cream|3.75% Imiquimod (Zyclara) Cream will be used as currently labeled by the FDA for treatment of actinic keratoses. Treatment will continue for 4 months with follow up at 6 and 12 months.
3038907|NCT02301481|Experimental|Neoadjuvant Chemoradiotherapy (NCRT)|NCRT arm receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (45.1Gy and 40.04Gy in 22 fractions) concurrently with oral S-1(40mg/m2, orally twice daily every weekday) followed by surgery and four to six cycles of SOX at the same dosage with NCT arm.
3038908|NCT02301481|Active Comparator|Neoadjuvant Chemotherapy (NCT)|NCT arm consists of neoadjuvant three cycles of SOX(S-1: 40~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle followed by radical surgery and another postoperative three cycles of SOX.
3038909|NCT02301468|Experimental|Dry needling|Dry needling (experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained
3038910|NCT02301468|Experimental|Ischemic compression|Ischemic compression (experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
3038911|NCT02301455|No Intervention|Control, Not hypertensive|Participants who after 3 weeks do not have high blood pressure or are not responsive to text messages.
3038912|NCT02301455|Experimental|Text messages, hypertensive|Participants who after 3 weeks have high blood pressure and are responsive to text messages, who are then randomized to receive text messages.
3038913|NCT02301455|No Intervention|No text messages, hypertensive|Participants who after 3 weeks have high blood pressure and are responsive to text messages, who are then randomized to not receive text messages.
3038914|NCT02301442|Experimental|Exercise + behaviour change intervention|This arm of the trial includes assessments at weeks 0, 12, 24 and 36. A 10-week exercise + behaviour change intervention will be delivered by physiotherapists between weeks 1 and 11.
3038915|NCT02301442|Active Comparator|Exercise + control education|This arm of the trial includes assessments at weeks 0, 12, 24 and 36. A 10-week exercise + control education intervention will be delivered by physiotherapists between weeks 1 and 11.
3038916|NCT02301429|Experimental|Model 20105|Receiving the model 20105 Lead
3038917|NCT02301416|Experimental|Phentermine/topiramate|All subjects enrolled in the study will be placed on the study medication.
3038918|NCT02301403|Active Comparator|Modern Usual Care|Participants assigned to the M-UC will receive 8 weeks of nicotine patch, a single brief, in-person counseling session, a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), and will be signed up for either the QUITNOW app or the Web Coach (both provided by Alere Wellbeing, the vendor that provides the WTQL services).
3038919|NCT02301403|Experimental|Abstinence-Optimized Cessation Treatment|There are 5 intervention components to include in the AOCT package: 1) Preparation Nicotine Mini-Lozenges; 2) 26-week postquit Combination NRT (nicotine patch + nicotine mini-lozenges); 3) Intensive In-Person Cessation Counseling; 4) Extended Maintenance Counseling Calls; and 5) Automated Adherence Calls.
3038920|NCT02301390|Active Comparator|Amiodarone only|The control group will receive amiodarone only.
3038921|NCT02301390|Experimental|Amiodarone + Catheter Ablation|The experimental group will receive amiodarone plus catheter VT ablation.
3038950|NCT02301208|Experimental|High dose nedaplatin arm|concurrent chemotherapy: nedaplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
3039049|NCT02300454|Active Comparator|Non-slip element balloon (NSE)|Lacrosse® NSE dilatation before use of SeQuent® Please drug coated balloon (DCB)
3038922|NCT02301377|Active Comparator|Intervention Group|Participants will receive a Spiro PD personal spirometer that will allow them to measure their lung function at home and provide medication reminders. Participants will be instructed to use the device to check their lung function once a week. They will also be asked to use the medication reminder feature of their device daily. Participants in this group will receive a telephone call once a week from the research team to review lung function results and answer questions. All participants need to fill out a quality of life questionnaire at the time of enrollment and at the end of the study. Participants will be asked to sign a release form so their pharmacies can be contacted for prescription refill data to monitor adherence over the course of the study. All participants will be asked to come to their quarterly clinic visits with their pediatric pulmonologist where their height, weight, body mass index, lung function and frequency of hospitalizations will be assessed.
3038923|NCT02301377|No Intervention|Control|Participants will be asked to fill out a quality of life questionnaire at the time of enrollment and at the end of the study. All participants will be asked to come to their quarterly clinic visits with their pediatric pulmonologist where their height, weight, body mass index, lung function and frequency of hospitalizations will be assessed. All participants will be asked to sign a release form so their pharmacies can be contacted for prescription refill data to monitor adherence over the course of the study.
3038924|NCT02301364|Experimental|Buparlisib (BKM120)|This is an open-label, phase II trial of the pan-PI3K inhibitor buparlisib (BKM120) for patients with recurrent or refractory primary central nervous lymphoma (PCNSL) and recurrent or refractory secondary central nervous lymphoma (SCNSL).
3038925|NCT02301351|Other|Graphic Warning Label|Days 5-50: Participants will receive cigarette packs as per the study randomization schema (e.g. three15-day periods of red, gold, and plain packs; order counterbalanced within subject) with FDA-approved graphic warning labels.
3038926|NCT02301351|Other|Text Warning Label|Days 5-50: Participants will receive cigarette packs as per the study randomization schema (e.g. three15-day periods of red, gold, and plain packs; order counterbalanced within subject) with standard text warning labels.
3038927|NCT02301338||Usual Care|"The patient will get instructions on: - Follow-up appointment date/time with your surgeon - Proper diet - Medications - Communicating concerning symptoms with the surgeon~The patient will answer questions on:~Social support~Quality of life"
3038928|NCT02301338||Phone Calls|"In addition to what the usual care group gets, the patient will also receive weekly phone calls by a geriatrics RN following hospital discharge.~The patient will answer questions on:~Social support~Quality of life"
3038929|NCT02301325|Other|0.03 mg Nicotine Cigarette|Participants will be assigned to smoke 0.03 mg nicotine Spectrum cigarettes
3038930|NCT02301325|Other|0.03 mg Nicotine Cigarette and NRT|Participants will be assigned to smoke 0.03 mg nicotine Spectrum cigarettes and use nicotine replacement patches.
3038931|NCT02301325|Other|0.80 mg Nicotine Cigarette|Participants will be assigned to smoke 0.80 mg nicotine Spectrum cigarettes.
3038932|NCT02301325|Other|0.80 mg Nicotine Cigarette and NRT|Participants will be assigned to smoke 0.80 mg nicotine Spectrum cigarettes and use nicotine replacement patches.
3038933|NCT02301312|Experimental|POSS-PCU graft|POSS-PCU vascular graft will be used to create vascular access for dialysis.
3038934|NCT02301299|Other|Community-based Stroke Awareness Program|Neighborhoods in the south side of Chicago surrounding 2 primary stroke center hospitals will be targeted for a community-partnered stroke awareness and action educational campaign. To assess the effectiveness of this intervention, the investigators will monitor early hospital arrival and EMS use for stroke over a 60-month period at the 2 primary stroke center hospitals using an interrupted time-series analysis.
3038935|NCT02301286|Experimental|Aspirin|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
3038936|NCT02301286|Placebo Comparator|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
3038937|NCT02301273|Active Comparator|Usual Physiotherapy|Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
3038938|NCT02301273|Experimental|Enhanced Physiotherapy|Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
3038939|NCT02301260|Experimental|Speed of Processing Training (SPT)|SPT will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
3038940|NCT02301260|Placebo Comparator|Placebo control group|Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 sessions)
3038941|NCT02301247|Experimental|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
3038942|NCT02301247|Placebo Comparator|Placebo|The placebo group will receive placebo control memory exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
3038943|NCT02301234|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib 100 mg orally (by mouth) twice daily for up to 16 weeks.
3038944|NCT02301234|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
3038945|NCT02301234|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
3038946|NCT02301221|Experimental|Fecal microbiota transplantation (FMT)|Patients included will receive standard FMT, and then will be followed up for 24 weeks.
3038947|NCT02301208|Active Comparator|Low dose cisplatin arm|concurrent chemotherapy: cisplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
3038948|NCT02301208|Active Comparator|High dose cisplatin arm|concurrent chemotherapy: cisplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
3038951|NCT02301195|Experimental|Therapeutic Horseback Riding|Ten-weekly one-hour manualized small group Therapeutic Horseback Riding intervention led by certified THR instructor.THR intervention taught riding and horsemanship skills.
3038952|NCT02301195|Active Comparator|Barn Activity Intervention|Ten-weekly one-hour manualized small group Barn Activity Intervention led by THR instructor, teaching horsemanship skills without horses present.
3038953|NCT02301182|Active Comparator|ADM X3-MoP Cup|THA: ADM dual-mobility hydroxyapatite coated cups with X3TM HXLPE liners on 28mm BIOLOX® delta femoral heads (Stryker) with femoral stems being 2nd generation Accolade stems of the taper lock type, proximal circumferential coated with a 50µm plasma-spray PureFix HA coating to aid the mechanical engagement in bone coating (Stryker)
3038954|NCT02301182|Active Comparator|CoC Cup|THA: CoC BIOLOX® delta-delta large-head single-mobility cementless fiber-mesh titanium coated acetabular system from Zimmer (Zimmer TrilogyIT cup/CLS spotorno stem) with a grit-blasted osteophilic titanium alloy CLS® Spotorno femoral stems (Zimmer) that has a three-dimensional wedge shape and sharpened ribs in the proximal region
3038955|NCT02301169|Active Comparator|T4P1001|
3038956|NCT02301169|Sham Comparator|Placebo|
3038957|NCT02301156|Experimental|Ublituximab + ibrutinib|"Ublituximab: IV infusion dose Days 1, 8 and 15 followed by maintenance infusions~Ibrutinib: Fixed oral daily dose"
3038958|NCT02301156|Active Comparator|Ibrutinib|- Ibrutinib: Fixed oral daily dose
3038959|NCT02301143|Experimental|nab-Paclitaxel plus Gemcitabine|"nab-Paclitaxel 125 mg/m2 intravenous (IV) infusion over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle Subjects who complete 6 cycles of nab-paclitaxel and gemcitabine without disease progression or unacceptable toxicities, the Investigator will then determine the best option for the subject.~Continuation of nab-paclitaxel and gemcitabine therapy to disease progression or unacceptable toxicity OR~Chemoradiation therapy consisting of the concurrent use of capecitabine or gemcitabine with radiation according to institutional practice OR~Surgical intervention"
3038960|NCT02301130|Experimental|mogamulizumab + MEDI4736 (Durvalumab)|"During Parts 1 and 2, mogamulizumab and MEDI4736 (Durvalumab) are administered at appropriate intervals.~Part 1 (Dose Escalation Phase)~- During Cohort 1A to 4A, increased doses of mogamulizumab and MEDI4736 (Durvalumab) are administered.~Part 2 (Cohort Expansion Phase)~Patients will be treated with maximum tolerated dose established in the Dose Escalation Phase for each combination."
3038961|NCT02301130|Experimental|mogamulizumab + tremelimumab|"During Parts 1 and 2, mogamulizumab and tremelimumab are administered at appropriate intervals.~Part 1 (Dose Escalation Phase)~- During Cohort 1B to 4B, increased doses of mogamulizumab and tremelimumab are administered.~Part 2 (Cohort Expansion Phase)~Patients will be treated with maximum tolerated dose established in the Dose Escalation Phase for each combination."
3038962|NCT02301117|Experimental|Mild Renal Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
3038963|NCT02301117|Experimental|Moderate Renal Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
3038964|NCT02301117|Experimental|Severe Renal Impairment|"35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.~The dose level of severe cohort will be determined based on the Interim Assessment of mild and moderate cohorts"
3038965|NCT02301117|Experimental|Normal Renal Function|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
3038966|NCT02301104|Experimental|Mild Hepatic Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
3038967|NCT02301104|Experimental|Moderate Hepatic Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
3038968|NCT02301104|Experimental|Severe Hepatic Impairment|"35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.~The dose level of severe cohort, if enrolled, will be determined based on the Interim Assessment of mild and moderate cohorts."
3038969|NCT02301104|Experimental|Normal Hepatic Function|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
3038970|NCT02301091|Experimental|TACE-RFA|2 times TACE first, RFA for residual viable tumors and PVTT within 1 month.
3038971|NCT02301091|Active Comparator|TACE alone|repeated TACE and 1 to 2 months interval between two sessions of TACE.
3038972|NCT02301078||Percutaneous Needle Aponeurotomy|Patients who choose to undergo percutaneous needle aponeurotomy (PNA) for primary treatment of Dupuytren's disease
3038973|NCT02301078||Xiaflex|Patients who choose to receive Collagenase clostridium histolyticum injection (drug name Xiaflex) for primary treatment of Dupuytren's disease.
3038974|NCT02301065||Stem Cell Donors|Allogeneic hematopoietic stem cell transplant (HSCT) donors. Blood samples for phenotypes research will be collected once from donors, prior to apheresis for collection of donor stem cells.
3038975|NCT02301065||Stem Cell Recipients|Allogeneic hematopoietic stem cell transplant (HSCT) recipients. Blood samples will be drawn prior to transplantation and every two weeks, up to day 100 post-transplantation.
3038976|NCT02301052|Placebo Comparator|placebo|placebo topical cream 2 cc twice daily for 3 weeks
3038977|NCT02301052|Active Comparator|Anti-hemorrhoid topical cream drug|Anti hemorrhoid topical cream as a standard drug 2 cc twice daily for 3 week
3038978|NCT02301052|Active Comparator|Leek topical cream|Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks
3038979|NCT02301039|Experimental|Soft tissue sarcoma|Patients with the following types of soft tissue sarcoma: leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH, MPNST and synovial sarcoma). Pembrolizumab will be administered at 200 mg intravenously every 3 weeks
3038980|NCT02301039|Experimental|Bone sarcoma|Patients with the following types of bone sarcoma: Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal]. Pembrolizumab will be administered at 200 mg intravenously every 3 weeks
3038981|NCT02301013|Experimental|Urinary incontience surgery|Patients who is between 25 to 70 years old and positive stress test and have TVT or TOT operations with diagnoses of stress urinary incontinence and mixed urinary incontinence .
3038982|NCT02301000|Experimental|Intestinal microbiota therapy|The patients allocated to this group will receive 60 ml of the anaerobically cultivated human intestinal microbiota through a rectal catheter.
3038983|NCT02301000|Active Comparator|Metronidazole|The patients allocated to this group will receive metronidazole 400 mg t.i.d. for 10 days
3038984|NCT02300987|Active Comparator|LEE011|
3038985|NCT02300987|Placebo Comparator|Placebo Arm|
3038986|NCT02300961|Experimental|Cognitive rehabilitation arm|Cognitive rehabilitation program
3038987|NCT02300948|Experimental|PregVit-Folic 5®-5 mg folic acid|Prenatal multivitamin-mineral supplement called PregVit-folic 5® contains 5 mg of folic acid. All other vitamin and mineral doses are identical between the 2 supplements, except for folic acid. Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation.
3038988|NCT02300948|Active Comparator|PregVit®-1.1 mg folic acid|Prenatal multivitamin-mineral supplement called PregVit® contains 1.1 mg of folic acid. All other vitamin and mineral doses are identical between the 2 supplements, except for folic acid. Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation.
3038989|NCT02300935|Experimental|trametinib and nab-paclitaxel|Trametinib will be dosed at 1mg, 1.5mg, and 2mg orally (PO) daily based on Phase I data of this drug as a single agent. All patients entering this study will receive intravenous (IV) nab-paclitaxel on Day 1, 8, and 15. Dose levels will be assigned to each patient, and dose escalation decisions will be based on the evaluation of safety data from the prior cohort.
3038990|NCT02300922|Experimental|several cohorts|"All patients will receive 3 injections of TF2 (the first: 14 mg/m², the second and the third:75 mg/m²). One day after each injection of TF2, the patient will receive a radiolabelled peptide (IMP-288) with Yttrium for therapeutic injectionThe First cohort will receive 555 MBq/m2 X 2 of 90-Y-IMP-288.:~All patient will receive 180 MBq of 111-In-IMP-288 for dosimetry analysis"
3038991|NCT02300909|Experimental|dHACM|Lumbar Decompression Surgery or Microdiscectomy Surgery with Application of Dehydrated Human Amnion/Chorion Membrane (dHACM)
3038992|NCT02300909|Other|Surgery without dHACM|Control Group - Lumbar Decompression Surgery or Microdiscectomy Surgery without application of dHACM
3038993|NCT02300896|Experimental|Intervention|Group-based exercise training during hospitalization Procedure: Exercise training. Individual program training 5 days a week during hospitalization
3038994|NCT02300896|No Intervention|Control|Usual care including rehabilitation when necessary
3038995|NCT02300883||no treatment|no treatment
3038996|NCT02300870||Heart Transplant Rejection|Patients presenting with acute cellular rejection
3038997|NCT02300870||Heart Transplant Control|Patients presenting for routine office visit
3038998|NCT02300857|Active Comparator|Low carbohydrate diet|
3038999|NCT02300857|Active Comparator|Moderate carbohydrate diet|
3039000|NCT02300857|Active Comparator|High carbohydrate diet|
3039001|NCT02300844|Experimental|NNC0174-0833 10 mg/mL|
3039002|NCT02300844|Placebo Comparator|Placebo|
3039003|NCT02300831||NSCLC|The eligible patient population of this study will comprise of advanced 2nd line NSCLC patients who are screened for two randomised clinical trials (RCTs) sponsored by AstraZeneca (AZ): SELECT-1 and SELECT-2 trials, but who do not meet eligibility criteria for those trials
3039004|NCT02300818|Active Comparator|Pulsed Electromagnetic Field Therapy|"Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.~PEMF has also proved to be beneficial in vision acuity of patients with low vision. In 50 per cent of the cases, values improved. Patients with vision acuity of 0.2 diopters showed improvement from 46 before treatment to 75 after treatment.~Different studies on varied diseases have proved that Pulsed Electromagnetic Field Therapy (PEMF) treatment is a safe, non-invasive and effective option for curing ocular conditions."
3039005|NCT02300818|Active Comparator|Seawater eyedrops|instantly soothes and clears the eye irritation caused by pollution, pollen, smoke, etc. It is a very practical system for eye daily hygiene · enables efficient therapeutic help in basic eye conditions such as: · · internal and external stye blepharitis and keratoconjunctivitis · · Conjuntiviti Episcleritis and scleritis
3039006|NCT02300792|Active Comparator|honey|Each patient in the honey group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
3039007|NCT02300792|Placebo Comparator|molasses|Each patient in the molasses (placebo) group (group 1) took molasses in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
3039008|NCT02300779|Experimental|Low-residue diet|Subjects will follow a low-residue diet for 4 days. Their usual treatment for diabetes will be adjusted to the degree of glycemic control.
3039009|NCT02300779|Active Comparator|Usual care|Subjects will follow a low-residue diet for 3 days (from 4 to 2 days before the procedure) and a liquid diet on the following day (the one before the procedure). No changes in their treatment for diabetes will be made
3039010|NCT02300766||Posterior fossa tumor patients|Children (0-18 years) with a tumour in the posterior fossa (cerebellum/4th ventricle/brainstem ) requiring surgery or open biopsy at one of the participating centres.
3039011|NCT02300740|Experimental|low dose|500 mg nicotinamide riboside oral
3039012|NCT02300740|Experimental|high dose|1000 mg nicotinamide riboside oral
3039013|NCT02300727|Active Comparator|Mouthwash-standard pharmacy preparation|"Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine."
3039014|NCT02300727|Experimental|Curcumin|Curcumin (BCM-95) administered by ingested mouth rinse three times per day. Subjects will be in this arm at the previously determine maximum tolerated dose (MTD).
3039048|NCT02300467|Experimental|NOV120401 (CKD-516 Tablet)|5 to 45 mg/day PO for 5 consecutive days and 2 days off
3063945|NCT02135471|Experimental|enamel matrix derivative|
3039015|NCT02300727|Other|Curcumin-MTD|"Curcumin (BCM-95) administered by ingested mouth rinse. A total of 12-15 subjects will be in this arm to determine maximum tolerated dose (MTD).~There will be 3 participant at each of 4 does levels (0.33g, 1g, 2g, 3g) per rinse, three times daily for 4-6 weeks. (additional 3 subjects if a dose-limiting toxicity occurs)"
3039016|NCT02300714|Active Comparator|AP group|oblique view approach during transforaminal epidural block
3039017|NCT02300714|Active Comparator|OB group|oblique view approach during transforaminal epidural block
3039018|NCT02300701|Experimental|Xolair/Omalizumab|
3039019|NCT02300701|Placebo Comparator|Placebo|
3039020|NCT02300688|Experimental|Arm 1|Period 1 (Treatment A) - Wash out - Period 2 (Treatment B)
3039021|NCT02300688|Experimental|Arm 2|Period 1 (Treatment B) - Wash out - Period 2 (Treatment A)
3039022|NCT02300675|No Intervention|control arm|Patients follow the classic support prescription of hormonotherapy
3039023|NCT02300675|Experimental|therapeutic education program|Patients follow the 4 sessions of PEP hormonotherapy. The therapeutic education prgram is led by a trained educational team, inside a prevention center : Hygée centre.
3039024|NCT02300662|Experimental|Cycle Ergometer|Conventional physiotherapy and cycle ergometer 20 minutes, at 20 cycles per minute, once per day for as long as they remain on invasive mechanical ventilation
3039025|NCT02300662|Sham Comparator|Conventional Physiotherapy|Upper and lower extremity functional diagonals from the proprioceptive neuromuscular facilitation method and manual bronchial hygiene exercises.
3039026|NCT02300649|Experimental|Dexmedetomidine group|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
3039027|NCT02300649|Placebo Comparator|Control group|Saline will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
3039028|NCT02300636|Experimental|Training: open kinetic|"Co-contraction training in open kinetic chain position~8 weeks, 3 days in a week"
3039029|NCT02300636|Experimental|Training: closed kinetic|"Co-contraction training in closed kinetic chain position~8 weeks, 3 days in a week"
3039030|NCT02300636|Active Comparator|Training: Standard ACL rehabilitation|"Standard ACL rehabilitation~8 weeks, 3 days in a week"
3039031|NCT02300623|Active Comparator|Control|Antiretroviral therapy alone
3039032|NCT02300623|Experimental|Treatment|Antiretroviral therapy plus Interleukin-2'
3039033|NCT02300610|Experimental|Dose Escalation and Dose Expansion|Dose Escalation: Begin with Level 1 dose of enzalutamide (orally), with standard doses of cisplatin and gemcitabine via intravenous (IV). Dose Expansion: Enzalutamide at recommended dose level with standard doses of cisplatin and gemcitabine.
3039034|NCT02300597|Experimental|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
3039035|NCT02300597|No Intervention|Treatment as usual (TAU)|A comparison group matched for age, gender and neuropsychiatric diagnosis is offered treatment as usual and is assessed at the same time points as the intervention group.
3039036|NCT02300584|Experimental|Prototype Program|The Savvy Caregiver (Savvy) - program delivered on an iPad (a tablet computer with an internet connection) extends over a six week period. Caregivers are asked to view brief daily videos (8-12 minutes) on the iPad. Once each week, a group of caregivers joins in a videoconference (an hour) with one or two trained leaders to review material from the week and to learn new material.
3039037|NCT02300584|Experimental|Field Program|The Savvy Caregiver (Savvy) - program delivered on an iPad (a tablet computer with an internet connection) extends over a six week period. Caregivers are asked to view brief daily videos (8-12 minutes) on the iPad. Based on the feedback from the prototype program, the videos may vary. Once each week, a group of caregivers joins in a videoconference (an hour) with one or two trained leaders to review material from the week and to learn new material.
3039038|NCT02300558|Experimental|Eleclazine (Single-blind treatment phase)|Eleclazine and/or eleclazine placebo up to Week 24
3039039|NCT02300558|Experimental|Open-label Extension Phase|Eligible participants will continue to receive open-label eleclazine until this drug is commercially available for the treatment of patients with LQT3, or until Gilead terminates development of eleclazine for the treatment of patients with LQT3, or the investigator deems it no longer in the participant's best interest.
3039040|NCT02300545|Experimental|Pazopanib|Pazopanib will be started at a dose of 200 mg BID for four days, then escalated to a dose of 400 mg BID for four days, then escalated once more to a dose of 800 mg QD for the duration of participation (or until dose reduction, if necessary). Pazopanib should be taken orally without food at least one hour before or two hours after a meal. One cycle of pazopanib is 28 days.
3039041|NCT02300532||Cohort 1|Patients with diagnosed malignant glioma treated by surgery, implanted Gliadel wafers 7.7mg
3039042|NCT02300519||Volunteers|Blood sampling : 1 blood punction of 36.5 ml for each volunteer
3039043|NCT02300506||Cohort 1|Patients with diagnosed malignant glioma treated by surgery, implanted Gliadel wafers 7.7mg, and enrolled in study GLI01S.
3039044|NCT02300493|Experimental|Experimental|weigh themselves daily
3039045|NCT02300493|Active Comparator|Control|Weigh themselves every six months
3039046|NCT02300480|Experimental|CTB group|Participants in this group will receive a single injection for calot's triangle block combined with PCIA post-operatively. CTB will be conducted by bile duct needle and 1.0% 10 ml ropivacaine will be injection in calot's triangle when before surgical dissection.Participants in this group will also receive PCIA after surgery,the regimens of PCIA are included tramadol 800 mg, flurbiprofenaxetil 100 mg with normal saline added up to a volume of 80 ml in total.
3039047|NCT02300480|Active Comparator|PCIA group|Participants in this group will receive PCIA post-operatively (tramadol 800 mg and flurbiprofen axetil 100mg with normal saline added up to a volume of 80ml in total ) .The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
3039962|NCT02294071|Experimental|acetaminophen|acetaminophen 15mg/kg (max 975mg)
3039051|NCT02300428||1-year cohort|"Patients with at least 1 prescription of any oral iron preparation in the last 2 years and who have at least 1 year of follow up data post-prescription.~It is anticipated that ca. 123,000 patients in CPRD fulfil this criteria."
3039052|NCT02300428||10-year cohort|"All pre-menopausal women (18-45 years old) with at least 1 prescription of one ferrous iron salt (i.e. sulphate, fumarate and gluconate) since January 2000.~It is anticipated that ca. 299,000 patients in CPRD fulfil this criteria."
3039053|NCT02300415||patient with sepsis|Patients admitted to the emergency department and with criteria of sepsis.
3039054|NCT02300389|Experimental|Hypofractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
3039055|NCT02300389|Active Comparator|Conventional Fractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
3039056|NCT02300376|Experimental|Calcium edetate de sodium versus inulin|The designing a Bayesian model of the plasma clearance of Calcium edetate de sodium is compared to the renal clearance of Inulin.
3039057|NCT02300363|Experimental|Treatment A|10 mg oral rosuvastatin administration
3039058|NCT02300363|Experimental|Treatment B|400 mg oral LX4211 qd administration
3039059|NCT02300363|Experimental|Treatment C|10 mg oral rosuvastatin administration + 400 mg oral LX4211 qd administration
3039060|NCT02300350|Experimental|Treatment A|0.5 mg single-dose oral digoxin administration
3039061|NCT02300350|Experimental|Treatment B|400 mg oral LX4211 qd administration
3039062|NCT02300350|Experimental|Treatment C|0.5 mg single-dose oral digoxin administration + 400 mg oral LX4211 qd administration
3039063|NCT02300337|Experimental|Reduce Cuff Pressure|Cuff Pressure difference between inspiration and expiration is measured.
3039064|NCT02300324|Experimental|Standard v Beneforte v Beneforte Extra|This is a randomized, double-blinded, three-phase crossover trial investigating the bioavailability of SF following consumption of three types of broccoli + stilton soup containing different concentrations of glucoraphanin. The three types of soup are standard broccoli and stilton soup, beneforte broccoli and stilton soup, and beneforte extra broccoli and stilton soup.
3039065|NCT02300311|Experimental|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
3039066|NCT02300311|Placebo Comparator|placebo|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
3039067|NCT02300298|Experimental|Nintedanib plus Docetaxel|patients to receive backbone chemotherapy and nintedanib
3039068|NCT02300285|Experimental|CGM Protocol|Subjects will receive continuous glucose monitoring and caregivers will be able to view continuous glucose measurements.
3039069|NCT02300285|Placebo Comparator|Standard of Care|Subjects will receive continuous glucose monitoring but caregivers will not be able to view continuous glucose measurements.
3039070|NCT02300272||Typically healthy older adults|Adults 65 years and older with only common late-life medical conditions who will complete a screening that includes a Polysomnograph and assessment that includes Actiwatch.
3039071|NCT02300259|Experimental|LY2623091 (Group 1)|LY2623091 administered orally once on Day 1 of Period 1.
3039072|NCT02300259|Experimental|Itraconazole + LY2623091 (Group 1)|200 mg itraconazole administered orally twice daily on Day 1 of Period 2 and once daily on Days 2 - 20 of Period 2. Single oral dose of LY2623091 coadministered on Day 6 of Period 2.
3039073|NCT02300259|Experimental|Simvastatin (Group 2)|20 mg simvastatin administered orally once daily on Day 1.
3039074|NCT02300259|Experimental|LY2623091 + Simvastatin (Group 2)|LY2623091 administered orally once daily on Days 3 - 13. Single oral dose of 20 mg simvastatin coadministered on Day 12.
3039075|NCT02300259|Experimental|Tadalafil (Group 3)|5 mg tadalafil administered on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
3039076|NCT02300259|Experimental|Tadalafil + LY2623091 (Group 3)|LY2623091 administered orally once daily on Day 1 up to Day 15 of Period 2. 5 mg tadalafil co-administered once daily on Day 10 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
3039077|NCT02300259|Experimental|LY2623091 (Group 4)|LY2623091 administered orally once on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
3039078|NCT02300259|Experimental|Diltiazem + LY2623091 (Group 4)|240 mg diltiazem administered once daily on Days 1 to 13 of Period 2. Single oral dose of LY2623091 coadministered on Day 4 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
3039079|NCT02300246|Experimental|Test Group|Alveolar socket post-extraction covered with PRF
3039080|NCT02300246|No Intervention|Control Group|Only clot (spontaneous healing)
3039081|NCT02300233|Active Comparator|volanesorsen|
3039082|NCT02300233|Placebo Comparator|Placebo|
3039083|NCT02300220|Active Comparator|Ciprofloxacin|500 mg, twice daily for 1 week (oral).
3039084|NCT02300220|Placebo Comparator|Placebo|one capsule, twice daily for 1 week.
3039085|NCT02300207|No Intervention|Control group|Subjects were in a resting, flat, head-down position -6° from the horizontal. The entire bed rest period was composed of the 4-day head-down bed rest and 2-day period of data collection (before and after the bed rest period). During all of these periods, there was intensive care monitoring. All dining, washing, urination, and defecation were carried out in the bedridden state. Changing position around the body axis was permitted. Dietary intake was 2300-2500 kcal/day, and water intake was 1.0-1.5 L/day. Urine samples (24 h) were collected every day throughout the study. Body weight, heart rate (HR), and blood pressure (BP) were measured in the morning before breakfast.
3039152|NCT02299830|Experimental|argon plasma coagulation|give the cases whose central airway stricture were caused by hard neoplasm tissues argon plasma coagulation
3039086|NCT02300207|Experimental|Electroacupuncture group|During the bed rest phase, subjects in the Electroacupuncture(EA) groups received 30 min of EA treatment, while subjects in the Con group did not receive any treatment.EA was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms. The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
3039087|NCT02300194|Active Comparator|Topic Morphine|Use of topic morphine for treatment of procedure associated pain
3039088|NCT02300194|Placebo Comparator|Placebo|Use of topic hydrogel (placebo) for treatment of procedure associated pain
3039089|NCT02300181|Placebo Comparator|Placebo (flour)|5 placebo capsules for each test (4.88 kcal/5 cap)
3039090|NCT02300181|Experimental|Bacillus subtilis var natto DC-15|5 experimental capsules for each test (4.96 kcal/5 cap) Extract powder of the flour fermented with Bacillus subtilis var natto DC-15
3039091|NCT02300155|Experimental|PregVit®|Women will be randomized to the '35 mg' group, who will start supplementation with PregVit® (low iron content, small size)
3039092|NCT02300155|Active Comparator|Orifer F®|Women will be randomized to the '60 mg' group, who will start supplementation with Orifer F® (high iron content, small size).
3039093|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M 25μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
3039094|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 50μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
3039095|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 75μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
3039096|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 25μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
3039097|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 50μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
3039098|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 75μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
3039099|NCT02300129|Experimental|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:~Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design)~Period 2 (cross-over design):~Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks"
3039100|NCT02300129|Experimental|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:~Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks."
3039101|NCT02300129|Experimental|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:~Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks."
3039102|NCT02300129|Experimental|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:~Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks."
3039103|NCT02300103|Experimental|SOF/VEL+RBV|Participants will receive SOF/VEL fixed dose combination (FDC) and RBV for 24 weeks.
3039104|NCT02300090||Intervention group|This group of patients (n=250) will receive the digital service (smart phone application and bluetooth inhaler device) in addition to current best care from their healthcare professional.
3039105|NCT02300090||Control group|This group of patients (n=250) will receive current best care alone. Control patients will not have access to the digital service.
3039106|NCT02300077|Active Comparator|Control|Control (Intra-operative administration of opioids, other than methadone)
3039107|NCT02300077|Active Comparator|Treatment|methadone
3039108|NCT02300064|Experimental|Healthy volunteers|Healthy volunteers will undergo one or more exercise interventions: knee-extensor exercise test; exercise test with restricting/releasing blood flow; exercise test with variable oxygen concentration and MRI; or exercise test with oral antioxidant or placebo cocktail.
3039109|NCT02300064|Experimental|COPD patients|Patients with Chronic Obstructive Pulmonary Disease (COPD) will undergo one or more exercise interventions: knee-extensor exercise test; exercise test with restricting/releasing blood flow; exercise test with variable oxygen concentration and MRI; or exercise test with oral antioxidant or placebo cocktail.
3039110|NCT02300051|Experimental|STPGP and RPGT|16 weekly sessions of 90 minutes of Short-Term Psychodynamic Group Psychotherapy (STPGP) followed by 8 weekly sessions of 90 minutes of Relapse Prevention Group Therapy (RPGT)
3039111|NCT02300051|Active Comparator|TAU|Treatment as usual (TAU) will be introduced through psychiatric follow up, in which the three first visits will occur at intervals of 30 days and the followings will occur with an interval of 60 days. The medication protocol includes serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day) or mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).
3039963|NCT02294071|Experimental|ibuprofen|ibuprofen 10mg/kg (max 600mg)
3039112|NCT02300051|Experimental|STPGP and RPGT + TAU|Participants undergo both interventions: 1) 16 weekly sessions of 90 minutes of Short-Term Psychodynamic Group Psychotherapy (STPGP) followed by 8 weekly sessions of 90 minutes of Relapse Prevention Group Therapy (RPGT); 2)Treatment as usual (TAU) will be introduced through psychiatric follow up, in which the three first visits will occur at intervals of 30 days and the followings will occur with an interval of 60 days. The medication protocol includes serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day) or mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).
3039113|NCT02300038|Active Comparator|Lidocaine (Xylocaine) 0.5%|Injection of 1ml after mixing Lidocaine 10 mg/ml 1 ml +1 ml NaCl was administrated perineuromally
3039114|NCT02300038|Placebo Comparator|Lidocaine (Xylocaine) 10 mg/ml 0.01%|Injection of 1 ml from 10 mg/ml 1 ml lidocaine Xylocaine +10 ml Nacl was adminsitrated perineuromally
3039115|NCT02300025|Experimental|Cohort 1: Normal function|
3039116|NCT02300025|Experimental|Cohort 2: Mild Hepatic Impairment|
3039117|NCT02300025|Experimental|Cohort 3: Moderate Hepatic Impairment|
3039118|NCT02300025|Experimental|Cohort 4: Severe Hepatic Impairment|
3039119|NCT02300012|No Intervention|Operation - No PBI|Patients requiring operation - baseline PBI data not seen by surgeon
3039120|NCT02300012|Experimental|Operation - PBI available|Patients requiring operation - baseline PBI data seen by surgeon pre-operatively
3039121|NCT02300012|No Intervention|Non-operation|Patients with ACL rupture not requiring operation
3039122|NCT02300012|No Intervention|Control|Healthy age matched volunteers - No operation
3039123|NCT02299999|Experimental|Substudy 1: targeted agent|Arm A1 / Targeted Arm : targeted maintenance from a list of 8 targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, bicalutamide tablet per os 150 od, continuous dosing, olaparib tablet per os 300 mg bd, continuous dosing
3039124|NCT02299999|Active Comparator|Substudy 1: standard maintenance therapy|Arm B1/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicine or Epirubicine or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycine C, Eribuline
3039125|NCT02299999|Experimental|Substudy 2: Immunotherapy|Arm A2/ Immunotherapy arm: maintenance with MEDI4736 for patient without actionable genomic alterations or non eligible to Targeted substudy 1, MEDI4736 Intra-venous 10 mg/kg, Q2W
3039126|NCT02299999|Active Comparator|Substudy 2: standard maintenance therapy|Arm B2/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicine or Epirubicine or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycine C, Eribuline
3039127|NCT02299986||Single arm Ultrasound measurement|Ultrasound measurement
3039128|NCT02299973|Placebo Comparator|Placebo group (FMT with own stool)|Fecal microbiota transplantation with patient's own stool
3039129|NCT02299973|Experimental|Treatment group (FMT with donor stool)|Fecal microbiota transplantation with healthy donor stool
3039130|NCT02299960||HFpEF|patients with heart failure with preserved ejection fraction
3039131|NCT02299960||HFrEF|patients with heart failure with reduced ejection fraction
3039132|NCT02299960||AH|patients with hypertension
3039133|NCT02299960||Nephropathy|patients with diabetic nephropathy
3039134|NCT02299947|Experimental|Haemocomplettan P|Study patients that receive Haemocomplettan P
3039135|NCT02299947|Placebo Comparator|NaCl 0.9%|Study patients that receive NaCl 0.9%
3039136|NCT02299934|Other|Subjects who fulfill the criteria for living liver donation|Subjects who fulfill the criteria for living liver donation and are evaluated for the procedure with Computerized Tomography (CT) and Magnetic Resonance Imaging (MRI).
3039137|NCT02299921||Adult ICU patients with respiratory problem|Adult medical ICU patients admitted to the University of Colorado Hospital for a primary respiratory problem, and who are expected to require ICU care ≥48 hrs.
3039138|NCT02299921||Intubated Adult ICU patients with respiratory failure|A subset of subjects, adult medical ICU patients with respiratory failure (due to underlying lung pathology) and who require endotracheal intubation and mechanical ventilation.
3039139|NCT02299908|Experimental|TAP block with Bupivacaine at 0.25%|Intervention: Injection of local anesthetics in the transverses abdominal plane
3039140|NCT02299908|Placebo Comparator|Placebo saline solution|Placebo: Injection of saline solution in the transverses abdominal plane
3039141|NCT02299882|Experimental|Vancomycin|Patient will receive Vancomycin powder to the incision just before skin closure
3039142|NCT02299882|No Intervention|no vancomycin|Patient will be randomized to either vancomycin powder or no vancomycin powder. This arm the patient will not have the powder placed in the incision before skin closure.
3039143|NCT02299869|Other|Group 1 - Verde (Competitor-control) vs. Green (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
3039144|NCT02299869|Other|Group 2 - Cinza (Competitor-control) vs. Grey (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
3039145|NCT02299869|Other|Group 3 - Esmeralda (Competitor-control) vs. Jade (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
3039146|NCT02299869|Other|Group 4 - Azul (Competitor-control) vs. Blue (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
3039147|NCT02299856||Myocarditis|Patients with strong clinical evidence for acute myocarditis (recent infection, elevated troponin and white blood cell count).
3039148|NCT02299856||Healthy Controls|Healthy volunteers without any signs of cardiac disease.
3039149|NCT02299843|Active Comparator|ALPPS|Using ALPPS for the the treatment of hepatocellular carcinoma.
3039150|NCT02299843|Experimental|RALPPS|Using radiofrequency ablation instead of in-situ split of liver in ALPPS stage I（RALPPS）.Habib 4X was used in RFA.
3039153|NCT02299830|Experimental|stent|give the cases whose central airway stricture were caused by neoplasm compression stent placement
3039154|NCT02299830|Experimental|snare|give the cases whose central airway stricture were caused by polypoid neoplasm tissues snare
3039155|NCT02299817|Active Comparator|Denosumab|Patients will receive a dose of 60 mg denosumab (1 ml solution) for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months.
3039156|NCT02299817|Placebo Comparator|Placebo|Patients will receive a dose of placebo (1 ml solution) for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months.
3039157|NCT02299804|Experimental|High dose arm|Have included the Levophencynonate Hydrochloric 1.5mg bid.
3039158|NCT02299804|Experimental|Low dose arm|Have included the Levophencynonate Hydrochloric 1.0mg bid.
3039159|NCT02299804|Placebo Comparator|Placebo arm|Have no any active component
3039160|NCT02299791|Active Comparator|Early Intervention|6 study clinics received the ALL intervention starting 6/1/11
3039161|NCT02299791|Active Comparator|Late implementation|5 study clinics received the ALL intervention starting 6/1/12
3039162|NCT02299778|Experimental|1mg of 13C6-p-aminobenzoic acid|
3039163|NCT02299765|Experimental|Arm A|"Four cycles gemcitabine(d1,8 ) + carboplatin (d1) + gefitinib (15-25), gefitinib 250mg/d from d15 of last cycle until disease progression.~Gemcitabine=1000mg/m2;Carboplatin 5×AUC ; One cycle is 28 days"
3039164|NCT02299765|Active Comparator|Arm B|Gefitinib 250mg/d until disease progression
3039165|NCT02299752|Experimental|Catheterization|Blood vessel Catheterization during resuscitation with single and double - gloving system. Catheterization was performed using simulation mannikin
3039166|NCT02299726|Experimental|Active|spironolactone
3039167|NCT02299726|Placebo Comparator|Placebo|matching placebo to active study drug
3039168|NCT02299713|Sham Comparator|placebo/sham acupuncture|There are different types of controls used in acupuncture trials. We used the control described as sham and by some as minimal acupuncture. This group had the same schedule as the electro-acupuncture group. Sham acupuncture was administered, with the same duration and frequency and by the same specialist who performed the non-sham acupuncture. Retractable needles were placed into small adhesive cylinders, so that the needles were supported but did not perforate the skin. The acupuncturist placed the needles at the same points as the non-sham group and used the same pairs of electrodes to simulate the electrical connection.
3039169|NCT02299713|Active Comparator|Electroacupuncture|The electro-acupuncture device was a biphasic pulse generator. It was used with maximum tolerable intensity of current and a frequency of 3 Hz. The points were selected according to the Traditional Chinese Medicine meridian theory to treat knee pain. The points selected were local points St 34, St 35, St 36,Liv 8, Sp 10. One distal point St 44.A total of six needles were inserted into each leg by the acupuncturist (the out come measures were not specifically targeted to whether the patient had one or both knees involved). All patients belonging to this group experienced a De Qi sensation, which is a tingling and numbness sensation upon needling of specific points.
3039170|NCT02299700||Autism Spectrum Disorder (ASD) Participants (6-9 years)|Participants with ASD aged 6 to 9 years will be observed for the usability of the Janssen Autism Knowledge Engine (JAKE) personal healthcare record (pHR) and biosensors in stage 1 and stage 2 (at laboratory sites).
3039171|NCT02299700||ASD Participants (13-17 years)|Participants with ASD aged 13 to 17 years will be observed for the usability of the JAKE pHR and biosensors in stage 1 and stage 2 (at laboratory sites).
3039172|NCT02299700||ASD Participants (3 or greater than 3 years)|Participants with ASD aged 3 or greater than 3 years will be observed for the usability of the JAKE pHR and biosensors in stage 2 (at clinical sites).
3039173|NCT02299687|Experimental|CYP2C19 EM|CYP2C19 EM
3039174|NCT02299687|Experimental|CYP2C19 IM|CYP2C19 IM
3039175|NCT02299687|Experimental|CYP2C19 PM|CYP2C19 PM
3039176|NCT02299674||Persons with unilateral transfemoral amputation|
3039177|NCT02299661|Experimental|7.5mg DS-1093a|DS-1093a, single oral dose of 7.5 mg
3039178|NCT02299661|Experimental|25mg DS-1093a|DS-1093a, single oral dose of 25 mg
3039179|NCT02299661|Experimental|50mg DS-1093a|DS-1093a, single oral dose of 50 mg
3039180|NCT02299648|Other|Single arm|molecular profiling, patient derived cells
3039181|NCT02299635|Experimental|PF-03084014|PF-03084014 will be administered orally, continuously, twice daily at 150 mg, but the dose can be reduced to 100 mg or 80 mg.
3039182|NCT02299609|Active Comparator|Beam Receiver|Philips HD11 XE® 30 min qid x 4 days
3039183|NCT02299609|Sham Comparator|Beam Non-Receiver|Philips HD11 XE® (ultrasound turned-off) 30 min qid x 4 days
3039184|NCT02299596|Experimental|Pre and postoperative exercise|"The intervention is prehabilitation preoperatively and physical training postoperatively. During the hospital stay both groups will be treated in the same manner.~Preoperative intervention:~One half hour of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Inspiratory muscle training. Thirty breaths x two twice daily. Postoperative intervention is mainly the same as preoperatively."
3039185|NCT02299596|No Intervention|Control|Standard treatment with one exception, patients will fill in a physical activity diary
3039186|NCT02299583|Experimental|Preventive intervention|In this arm HCPs will conduct a trauma-informed early intervention with children and families after exposure to potentially traumatic events (PTE).
3039187|NCT02299583|No Intervention|Control group|There will be no intervention in this arm. The outcome will show the efficiency of usual care.
3039188|NCT02299570|Active Comparator|Group A|Two enemas of RBX2660 administered 7 days apart
3039189|NCT02299570|Placebo Comparator|Group B|Two enemas of placebo administered 7 days apart
3039190|NCT02299570|Active Comparator|Group C|1 enema of RBX2660 and 1 enema of placebo administered 7 days apart
3039191|NCT02299557|Experimental|Treatment|Intra-anal Oxymetazoline gel once daily
3039192|NCT02299557|Placebo Comparator|Placebo|Intra-anal Placebo gel once daily
3039221|NCT02299375|Experimental|Placebo|Subjects with COPD will receive placebo orally, twice daily, approximately 12 hours apart and within 30 minutes after meals with a full glass of water for the duration of the treatment period in addition to standard of care, stratified according to whether a center collects sputum or not and current use of ICS. Salbutamol MDI will be provided as a rescue medication.
3039193|NCT02299544|Experimental|OAB|"Patients with overactive bladder (OAB) with or without urge incontinence.~Two patient populations will be enrolled in the study:~Patients with no previous treatment with percutaneous tibial nerve stimulation (PTNS) [de novo patient group] and Patients with a documented success on PTNS therapy [prior-PTNS group]. Documented success on PTNS is defined by a ≥50% reduction in urinary frequency, and/or ≥50% fewer incontinence episodes, or a return to normal voiding frequency [<8 voids/day], based on retrospective diary review.~All patients will be treated with BlueWind Medical System."
3039194|NCT02299531|Experimental|Low Energy Density, Small Portions|Low meal energy density and small portion sizes
3039195|NCT02299531|Experimental|Low Energy Density, Medium Portions|Low meal energy density and medium portion sizes
3039196|NCT02299531|Experimental|Low Energy Density, Large Portions|Low meal energy density and large portion sizes
3039197|NCT02299531|Experimental|High Energy Density, Small Portions|High meal energy density and small portion sizes
3039198|NCT02299531|Experimental|High Energy Density, Medium Portions|High meal energy density and medium portion sizes
3039199|NCT02299531|Experimental|High Energy Density, Large Portions|High meal energy density and large portion sizes
3039200|NCT02299518|Experimental|Cohort A (mitoxantrone, etoposide, cytarabine, selinexor)|Patients receive mitoxantrone hydrochloride IV, etoposide IV, and cytarabine IV QD on days 1-6 and selinexor PO on days 1, 3, 8, 10, 15, and 17. Treatment continues for 1 course (28 days). Further treatment is based on disease response. Patients achieving CR/CRi are evaluated for stem cell transplant; patients who do not proceed to transplant may receive selinexor as monotherapy in the absence of disease progression or unacceptable toxicity.
3039201|NCT02299518|Experimental|Cohort B (etoposide, selinexor)|Patients receive etoposide PO QD on days 1-5 and selinexor PO on days 1, 3, 8, 10, 15, and 17. Treatment may repeat every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving response after 4 courses discontinue treatment; patients achieving response may receive up to 4 courses of maintenance therapy every 8 weeks. Patients may then continue selinexor as monotherapy at the discretion of the principal investigator.
3039202|NCT02299505|Experimental|ceritinib 450 mg with a low-fat meal|
3039203|NCT02299505|Experimental|ceritinib 600 mg with a low-fat meal|
3039204|NCT02299505|Active Comparator|ceritinib 750 mg on an empty stomach|
3039205|NCT02299492|Experimental|Person-Centered Care Planning|Arm will receive provider level training in Person Centered Care Planning
3039206|NCT02299492|No Intervention|Treatment as Usual|Arm will receive treatment as usual in community mental health clinic
3039207|NCT02299479|Experimental|Intervention|Volunteers will wear a Dexcom G4 Platinum CGM device as well as an activity monitor. Data will be uploaded to study investigators on a regular basis, and recommendations will be made to adjust insulin dosing based upon analysis of these data.
3039208|NCT02299453|Experimental|Experimental|Participants receive 9 sessions of telephone-administered PT and have access to standard community-based services. As part of the 9 sessions, participants discuss the extent to which interpersonal issues such as bereavements, role transitions, interpersonal disputes, and relationship difficulties may be related to their depression.
3039209|NCT02299453|No Intervention|Standard of Care|Participants receive no active intervention but do have access to standard community-based services, such as individual therapy, support groups, 12-step programs, and other social serves.
3039210|NCT02299440|Experimental|Ketamine|"Patients randomized to this group will be treated via Ketamine infusion.~Intervention: Baseline evaluation Intervention: 1st perfusion of ketamine Intervention: Follow-up between perfusions Intervention: 2nd perfusion of ketamine Intervention: Follow-up after perfusions"
3039211|NCT02299440|Placebo Comparator|Placebo/Control|"Patients randomized to this group will be treated via saline solution infusion.~Intervention: Baseline evaluation Intervention: 1st perfusion of saline Intervention: Follow-up between perfusions Intervention: 2nd perfusion of saline Intervention: Follow-up after perfusions"
3039212|NCT02299427|Experimental|dog safety|2 weeks of regular use of website on child dog safety developed for this research
3039213|NCT02299427|Active Comparator|transportation safety|2 weeks of regular use of publicly-available website on child transportation safety
3039214|NCT02299414|Experimental|Anti-hypertensive therapy|Labetalol or Nifedipine ER will be used as first-line to achieve target BP <140/90; if necessary Nifedipine ER or Labetalol will be second-line antihypertensive.
3039215|NCT02299414|Active Comparator|No anti-hypertensive therapy (or low dose)|Antihypertensive therapy given only if BP becomes severe (defined as BP ≥160/105). The lowest dose of anti-hypertensive needed to keep blood pressure below this threshold will be given (1st-line - Labetalol or Nifedipine ER and 2nd-line - Labetalol or Nifedipine ER).
3039216|NCT02299401|Experimental|Buccal|Women randomized to receive three 800 mcg doses of misoprostol taken buccally in three hour intervals. All women receive a semi-quantitative pregnancy test for at-home follow up.
3039217|NCT02299401|Experimental|Sublingual|Women randomized to receive three 800 mcg doses of misoprostol taken sublingually in three hour intervals. All women receive a semi-quantitative pregnancy test for at-home follow up.
3039218|NCT02299388|Active Comparator|Liraglutide|All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
3039219|NCT02299388|Placebo Comparator|Placebo|All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
3039220|NCT02299375|Experimental|Losmapimod 15 mg|Subjects with COPD will receive losmapimod 15 mg tablets orally, twice daily, approximately 12 hours apart and within 30 minutes after meals with a full glass of water for the duration of the treatment period in addition to standard of care, stratified according to whether a center collects sputum or not and current use of inhaled corticosteroid (ICS). Salbutamol metered dose inhaler (MDI) will be provided as a rescue medication.
3039222|NCT02299349|Experimental|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
3039223|NCT02299349|Active Comparator|concentrated multi drug injection|concentrated multi drug periarticular injection
3039224|NCT02299336|Other|PRN (pro re nata)|2 mg intravitreal aflibercept (Eylea) PRN, focal laser administered based on pre-specified criteria, 104 weeks
3039225|NCT02299310|Experimental|Valsartan|Valsartan 80mg/tablet, 1 tablet once daily (crossover)
3039226|NCT02299310|Active Comparator|Perindopril|Perindopril 4mg/tablet, 1 tablet once daily (crossover)
3039227|NCT02299297|Experimental|Tofacitinib|Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.
3039228|NCT02299284|Experimental|Hand-Arm Bimanual Intensive Therapy (HABIT)|HABIT, bimanual training, bilateral training, restraint therapy, PT, OT, rehab
3039229|NCT02299284|Experimental|Intensive Functional Lower-Limb Training|lower-limb function, strength training, balance, PT, OT, rehab
3039230|NCT02299271|Active Comparator|ropivacaine block|Ropivacaine 0.375% as a one-time 60 milliliter injection.
3039231|NCT02299271|Placebo Comparator|saline block|Sodium chloride 0.9% as a one-time 60 milliliter injection.
3039232|NCT02299258|Active Comparator|Tailored stents MTN-WE-20/100-A|The distal portion of the GOO tailored stents was semi-spherical, with a length of 20 mm, and a diameter of 28 mm. The middle segment had a diameter of 20 mm. The overall length of the stents was 100 mm. Both the middle part and the bottom of the proximal cup segment, and a part of the proximal funnel segment, were covered by a polyethylene membrane.
3039233|NCT02299258|Experimental|Standard stents MTN-CG-s-20/100|Standard uncovered stents were used in the control group. The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
3039234|NCT02299245|Experimental|randomised to rosuvastatin (20mg/d)|randomised to rosuvastatin (20mg/d)
3039235|NCT02299245|Active Comparator|randomised to rosuvastatin (10mg/d)|randomised to rosuvastatin (10mg/d)
3039236|NCT02299232|Active Comparator|dexmedetomidine 3mcg/kg|dexmedetomidine 3 mcg/kg intranasal 50 minutes before MRI
3039237|NCT02299232|Active Comparator|dexmedetomidine 4mcg/kg|dexmedetomidine 4 mcg/kg intranasal 50 minutes before MRI
3039238|NCT02299219|Experimental|Taking Charge Experimental Group|
3039239|NCT02299219|Active Comparator|Control Group|
3039240|NCT02299206|Experimental|CeraVe Baby Diaper Rash Cream|Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
3039241|NCT02299206|Experimental|Desitin Maximum Strength Original Paste|Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
3039242|NCT02299193|Experimental|Cognitive Behavioral Therapy|online sessions on how behaviors and thoughts that can affect sleep.
3039243|NCT02299193|Sham Comparator|Healthy Sleep Habits|online sessions about healthy sleep practices
3039244|NCT02299180|No Intervention|Control arm|The control arm patients will not take part in ACP discussions and documentation, but will continue to receive usual care.
3039245|NCT02299180|Experimental|Intervention (ACP) arm|The patient and his/her family members will be referred to an ACP facilitator and will undergo ACP as an ongoing process, integrated with patient's care, from the facilitator, in coordination with a coordinator/nurse, and treating physician. The ACP facilitator will be certified in providing ACP and will possess sufficient knowledge of the risks, benefits, and harms of treatments and procedures available to the patient. The ACP facilitator will be supported by the physician with the specialized knowledge of treatment options, especially with regards to prognosis. Family members will be encouraged to be present during the ACP discussion so that the whole family unit will be able to explore goals, values and beliefs towards the patient's medical care.
3039246|NCT02299167|Experimental|Saddle block|The dose of bupivacaine given to each patient was determined by the response of the previously tested patient using a modified Dixon's up-and-down method
3039247|NCT02299154|Experimental|Patient with memory disorders|psychological questionnaires
3039248|NCT02299154|Experimental|Accompanier|psychological questionnaires
3039249|NCT02299141|Experimental|Nintedanib|-Nintedanib will be administered orally at a dose of 200 mg twice daily during each 28 day cycle
3039250|NCT02299128|Sham Comparator|Minimally Therapeutic Treatment|Non-differential, prescriptive protocol of physical therapy treatment with minimal to no therapeutic benefit.
3039251|NCT02299128|Experimental|Skilled Treatment|Differential treatment based on the results from the assessment. Physical Therapy treatment in this arm will be pragmatically designed and modified by the treating therapist. Treatments will include manual therapy to the cervical spine, neuromotor retraining (position sense and movement sense), habituation and adaptation exercises.
3039252|NCT02299115|Experimental|Prednisolone|Single center, prospective, observational, open trial using high-dose oral prednisolone as first-line treatment for newly diagnosed Infantile Spasms (non-Tuberous Sclerosis)
3039253|NCT02299115|Active Comparator|Vigabatrin|Retrospective controls composed of our cohort of non-Tuberous Sclerosis Infantile Spasms patients from January 2010- September 2013 who received Vigabatrin as first-line treatment.
3039254|NCT02299102|Other|Jamshidi Manual Standard Device|The Jamshidi manual standard device will be randomized for use on the right or left iliac crest
3039255|NCT02299102|Other|OnControl Powered Ported Device|The OnControl power ported device will be used on the opposite iliac crest
3039256|NCT02299089|Experimental|CAM2029 10 mg (NET)|CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
3039257|NCT02299089|Experimental|CAM2029 20 mg (NET)|CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly
3039258|NCT02299089|Experimental|CAM2029 10 mg (Acromegaly)|CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
3039259|NCT02299089|Experimental|CAM2029 20 mg (Acromegaly)|CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly
3039260|NCT02299076|Other|Usual care with minimal incentives|Participants in this arm receive usual care from the Pro-Change smoking cessation program, and receive compensation for enrolling and completing a survey at the end of the study.
3039453|NCT02297659|Active Comparator|Crystalloid resuscitation|Patients to receive normal saline resuscitation at a rate of 30cc/hr.
3039261|NCT02299076|Active Comparator|Usual care with BE incentives|Participants in this arm receive usual care from the Pro-Change smoking cessation program, the chance to win money based on their behavior (behavioral economics incentives), and receive compensation for enrolling and completing a survey at the end of the study.
3039262|NCT02299063|Placebo Comparator|Placebo (0.9% Saline)|0.9% Saline: bolus dose of 0.125mL/kg infused over 10 minutes, followed by a continuous infusion (CI) dose at 0.15mL/kg/hr for the duration of surgery.
3039263|NCT02299063|Experimental|Dexmedetomidine|Dexmedetomidine: bolus dose of 0.5 mcg/kg infused over 10 minutes, followed by a continuous infusion (CI) dose at 0.6 mcg/kg/hr for the duration of surgery.
3039264|NCT02299050|Other|Cycloset|"Drug - Cycloset Cycloset 2.4 -3.2 mg/day~Other Names:~Bromocriptine Mesylate Quick Release"
3039265|NCT02299024|No Intervention|Control|Patients in this arm are discharged from the Northwestern Emergency Department with standard communication about their prescribed opioid pain medication from their care providers. They are called for a follow up survey 4-7 days after their visit.
3039266|NCT02299024|Experimental|Dual Modality Educational Intervention|"Patients in this arm are discharged from the ED with an additional information sheet about their prescribed opioid pain medication, via the intervention titled Additional Opioid Information. The sheet is read aloud to them by a research assistant. They are called 4-7 days later for a follow up survey."
3039267|NCT02299011|Experimental|Orsiro drug eluting stent|Orsiro drug eluting stent
3039268|NCT02299011|Active Comparator|Biomatrix drug eluting stent|Biomatrix drug eluting stent
3039269|NCT02298998||Intervention|The intervention group refers to surveillance based on the EAU guidelines.
3039270|NCT02298998||Control|The control group refers to surveillance based on the AUA guidelines.
3039271|NCT02298985|Active Comparator|curcumin|curcumin 3 g/day for 6 months
3039272|NCT02298985|Placebo Comparator|placebo|curcumin 3 g/day for 6 months
3039273|NCT02298972|No Intervention|Comparison group|The comparison group will receive standard care.
3039274|NCT02298972|Active Comparator|Intervention group|After completion of the comparison group, new patients starting chemotherapy treatment will be offered this study. Study participants will receive the nurse support and selfmanagement intervention.
3039275|NCT02298959|Experimental|Treatment (pembrolizumab and ziv-aflibercept)|Patients receive pembrolizumab IV over approximately 30 minutes and ziv-aflibercept IV over 1-2 hours on day 1. Courses repeat every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
3039276|NCT02298946|Experimental|DL 1|CTX 200mg/m2 IV on day 0, SBRT 8Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then q14 days
3039277|NCT02298946|Experimental|DL 2|CTX 200mg/m2 IV on day 0, SBRT 8Gy x 3 day ondays -2, -1, 0, AMP-224 10mg/kg on day 1 then q14 days
3039278|NCT02298933|Experimental|1|1200 mg IV infusion over 30-40 min
3039279|NCT02298920|Experimental|Single Group|Open Label ADME Study
3039280|NCT02298881||Dry eye group|People with dry eye symptoms
3039281|NCT02298881||Non-dry eye group|People with no dry eye symptoms
3039282|NCT02298868|Experimental|Treatment|All patients will be administered a standing dose of Baclofen initially at 5 mg three times a day for the first week and then increased to 10 mg three times a day for the next 3 weeks with a tapering dose the final week, a total of 5 weeks of therapy.
3039283|NCT02298855|No Intervention|Conventional follow-up|Treatment as usual will involve: one post treatment appointment then 3 monthly appointments with a Dr. At appointments: medical history; investigations to monitor disease progression including CA125 tumour marker blood test if this were raised at diagnosis. A physical examination may be performed.
3039284|NCT02298855|Experimental|Individualised follow-up|Follow-up is delivered by a nurse and frequency and type (telephone or face-to-face) is negotiated to suit their individual situation. Assessment by holistic guide. The intervention is informed by a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to help patients manage symptoms and psychological discomfort.
3039285|NCT02298842|Active Comparator|Platelets Stored in Plasma|Platelets stored in Plasma
3039286|NCT02298842|Experimental|Test Platelets Stored in InterSol|Platelets stored in InterSol
3039287|NCT02298829||No Treatment|Subjects who received AA4500 in a 12-month double blind placebo-controlled study (AUX CC 803 or AUX-CC-804) or in a 9-month open label study (AUX-CC-802 or AUX-CC-806) sponsored by Auxilium Pharmaceuticals, Inc.
3039288|NCT02298816||new B-Cell Hematologic Malignancy diagnosis|All adult patients who are newly diagnosed at Aurora Health Care with the following B-Cell Hematologic Malignancies: Monoclonal gammopathy of undetermined significance (MGUS), Smoldering multiple myeloma (SMM), Multiple myeloma (MM), Waldenstroms Macroglobulinemia (WM), Monoclonal B-cell lymphocytosis (MBL), Chronic lymphocytic leukemia (CLL), or B-Cell Non-Hodgkin lymphoma (NHL).
3039289|NCT02298803|Other|Holter and Glucose monitoring|In this study the interventions will be the simultaneous monitoring of glucose and QT interval via a subcutaneous continuous glucose monitor and a Hoter monitor, respectively.
3039290|NCT02298790|Experimental|Early Meals|Meals are eaten early in the wake episode
3039291|NCT02298790|Experimental|Late Meals|Meals are eaten late in the wake episode
3039292|NCT02298777||Scleroderma (SSc) patients (beginners and established forms).|"Patients with the ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001)~Biological samples (skin, urine and blood):~1st point at patient's inclusion visit~2nd point (optional) at SSc patient's visceral complication (assessed during 3 years)"
3039293|NCT02298777||Undifferentiated Connective Tissue Disease (UCDT) patients|"Patients with criteria proposed by Mosca et al. (1998)~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
3039294|NCT02298777||Raynaud disease patients|"Patients with primary and isolated Raynaud disease~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
3039295|NCT02298777||Vascular disease patients|"Patients with vascular disease (type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke)~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
3039296|NCT02298777||Healthy control subjects|"Healthy subjects (no sign of connective tissue disease, no Raynaud, no vascular disease)~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
3039862|NCT02294682|Experimental|GSK2140944 3000 mg|Subjects will receive single oral dose of GSK2140944 3000 mg.
3039297|NCT02298764|Active Comparator|standard + 10 psychotherapeutic sessions|- standard back pain treatment plus 10 psychotherapeutic sessions, that will include the shock-trauma method 'Somatic Experiencing'.
3039298|NCT02298764|Active Comparator|Standard back pain treatment|Standard back pain treatment
3039299|NCT02298751|Experimental|CET via smartphone|Cue Exposure Treatment
3039300|NCT02298751|Experimental|CET via group sessions|Cue Exposure Treatment
3039301|NCT02298751|No Intervention|Aftercare as usual|
3039302|NCT02298738||New onset Atrial fibrillation|New-onset AF was defined as patients with hypertension and atrial fibrillation which was identified for the first time by an electrocardiogram or ambulatory holter monitoring.
3039303|NCT02298738||control|Hypertensive patients without atrial fibrillation.
3039304|NCT02298725|Experimental|DGA Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans. All foods and beverages will be provided to enrolled subjects during the intervention period.
3039305|NCT02298725|Experimental|NHANES Diet Plan|"A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet plan will be closely aligned with the NHANES What We Eat In America report. All foods and beverages will be provided to enrolled subjects during the intervention period."
3039306|NCT02298712||Observation|Patients with Hurler disease or high-grade suspicion for Hurler disease
3039307|NCT02298699||Observation|Patients with Sly disease or high-grade suspicion for Sly disease
3039308|NCT02298686||Observation|Patients with Sanfilippo Type A-B-C-D disease or high-grade suspicion for Sanfilippo Type A-B-C-D disease
3039309|NCT02298673||Observation|Patients with Mucolipidosis Disorder type I,II,III or IV or high-grade suspicion for Mucolipidosis Disorder type I,II,III or IV
3039310|NCT02298660|Experimental|BOTOX|BOTOX® Total dose OR units/kg (per patient): 200U Number of cycles:1 cycle Treatments will be conducted according to established protocol, 200 units with intravesical injections under cystoscopic guided injections into 20 points. One month later, urodynamics with continuous arterial blood pressure and electrocardiogram measurements will be repeated, as well as 24 hour blood pressure monitoring. AD- HR QoL and I-QoL questionnaires will be administered to evaluate the effect of Botox on AD-QoL and bladder-related QoL.
3039311|NCT02298647||Observation|Patients with GM1/GM2-Gangliosidosis or high-grade suspicion for GM1/GM2-Gangliosidosis
3039312|NCT02298634||Observation|Patients with a diagnosis of Farber disease based upon biochemical and/or genetic criteria or profound suspicion for Farber disease
3039313|NCT02298621|Experimental|pomegranate juice|pomegranate juice: 500 ml
3039314|NCT02298621|Placebo Comparator|placebo|sugar + aroma+ color: 500ml
3039315|NCT02298608|Experimental|Irreversible Electroporation|Percutaneous, CT guided, Irreversible Electroporation of renal mass
3039316|NCT02298595|Experimental|1: Low risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then observation.
3039317|NCT02298595|Experimental|2: Intermediate risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then Intensity Modulated Radiation Therapy (IMRT).
3039318|NCT02298595|Experimental|3: High risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then Intensity Modulated Radiation Therapy (IMRT) + cisplatin.
3039319|NCT02298582|Experimental|Intranasal fentanyl|
3039320|NCT02298569|No Intervention|Phase 1 (before multi-pronged program)|400 low-risk mothers having given birth without any complication to a healthy newborn are to be recruited in the 5 maternity wards of a French perinatal network consecutively, whatever the duration of their hospital stay
3039321|NCT02298569|Experimental|Phase 2 (after multi-pronged program)|400 low-risk mothers having given birth without any complication to a healthy newborn are to be recruited in the 5 maternity wards of the same French perinatal network 3 months after the intervention (introduction of the multi-pronged program) consecutively, whatever the duration of their hospital stay
3039322|NCT02298556||Hypertensive patients|Hypertensive patients with elevated heart rate and type 2 diabetes mellitus
3039323|NCT02298543||coronary spasm|
3039324|NCT02298530|Experimental|Combination of caffeine and theanine|250 mg caffeine + 200 mg theanine
3039325|NCT02298530|Placebo Comparator|Caffeine|250 mg caffeine
3039326|NCT02298517|No Intervention|Control|Individuals will be treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
3039327|NCT02298517|Experimental|Incentive spirometry to flow|Was determined for this study that the flow of inspired air will be sufficient to raise up to three spheres. In addition to direct them to do explosive, fast and deep, lifting the ball explosively breaths. Every fifteen inspirations volunteers will be invited to rest for intervals of 30-60 seconds and repeat six times. The use of incentive spirometry was adapted from the recommendations of the American Association for Respiratory Care (1991).
3039328|NCT02298517|Experimental|incentive spirometry to volume|Use of this incentive spirometry will be done as follows: the participants will be instructed to inhale deeply through the mouthpiece, to total lung capacity, starting from functional residual capacity. Will be performed 6 sets of 15 breaths each (deep, slow and sustained) intervals with 30-60 seconds between each series.
3039329|NCT02298517|Experimental|inspiratory load equipment-Threshold|This group will use the device Threshold™. Where adjustment is considered 40% of PNSN achieved by the patient evaluation. The volunteer will be instructed to remain in a supine position with 45 ° fowler comfortably with arms and shoulders relaxed and perform an inspiration with enough force to overcome the linear load of the device, then make a normal expiration. This study was determined to carry six sets of 15 repetitions. The rest will be about one to two minutes in each intervention.
3039363|NCT02298257|Experimental|Treatment (BV + combination chemotherapy)|Patients receive doxorubicin hydrochloride given IV , vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3039330|NCT02298517|Experimental|inspiratory load equipment-Power breathe|To exercise inspiratory muscle in this group will be used device Power breathe ® K2 have the same resistance setting, allowing us to tailor your level of inspiratory muscles. Such adjustment will be made considering 40% of PNSN achieved by the patient in the assessment sniff. For its implementation, the patient will be lying with a tilt of the head of the litter at 45 °, the patient will be asked to inspire to overcome the resistance of the linear unit and after performing a normal expiration. This group will also be achieved 6 series with 15 repetitions each, with an interval of one to two minutes between sets.
3039331|NCT02298504|Experimental|Indirect pulp cap|IDP will be performed for this group
3039332|NCT02298504|Experimental|MTA pulpotomy|MTA pulpotomy will be performed for this group
3039333|NCT02298504|Experimental|Biodentin pulpotomy|Biodentin pulpotomy will be performed for this group
3039334|NCT02298491|Experimental|H.P. Acthar Gel|
3039335|NCT02298478|Experimental|Group without support by the therapist|"Intervention group that do the NO-FEAR Airlines program and does not receive support by the therapist."
3039336|NCT02298478|Experimental|Group with support by the therapist|"Intervention group that do the NO-FEAR Airlines program and receives support by the therapist (a brief weekly five-minutes call)."
3039337|NCT02298478|Other|Waiting list control group|"Control group that could access the NO-FEAR Airlines program after waiting for 6 weeks.~After that time, those participants still interested were randomly assigned to one of two intervention conditions (with or without support by the therapist)."
3039338|NCT02298465|Active Comparator|Prone ESWL|ESWL for distal ureteric stone is performed in the traditional prone position
3039339|NCT02298465|Experimental|Supine ESWL|ESWL for distal ureteric stone is performed in the supine position, with the shockwave generator head placed at a 30 degree angle to the vertical at the patient's gluteal muscles. Thus, the shockwaves will travel via the greater and lesser sciatic foramina to reach the stone
3039340|NCT02298452|Other|Hearing aid|172 subjects with a mild hearing loss. 140 subjects with a moderate hearing loss. 70 subjects with a severe/ profound hearing loss.
3039341|NCT02298426|Experimental|health management and product|"We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.~Meanwhile, we use dietary supplement products of SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS® to help balance the constitution of participants."
3039342|NCT02298426|Experimental|general management and product|"We provide general information about health. Information is provided through telephones and materials.~Meanwhile, we use dietary supplement products of SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS® to help balance the constitution of participants."
3039343|NCT02298426|Experimental|health management and placebo|"We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.~Meanwhile, we use placebo to replace the dietary supplement products."
3039344|NCT02298426|Placebo Comparator|general management and placebo|"We provide general information about health. Information is provided through telephones and materials.~Meanwhile, we use placebo to replace the dietary supplement products."
3039345|NCT02298400|Active Comparator|Acuvue®Oasys® Lenses(senofilcon A)|Acuvue® Oasys® Lenses (senofilcon A) contact lenses
3039346|NCT02298400|Active Comparator|Bausch + Lomb PureVision (balafilcon A)|30-Day Bausch + Lomb PureVision (balafilcon A) contact lenses
3039347|NCT02298400|Active Comparator|Clariti® 1-Day (Somofilcon A)|Clariti® 1-Day (Somofilcon A) contact lenses
3039348|NCT02298387|Experimental|OMP-305B83|The dose levels of OMP-305B83 will be 0.5, 1.0, 2.5, 5 and 10 mg/kg administered IV once every 3 weeks.
3039349|NCT02298374|Experimental|Homecare reablement|Receives comprehensive assessment and individualized follow-up according to a plan with short and longterm goals.
3039350|NCT02298374|Active Comparator|Usual care|Receives normal care
3039351|NCT02298361||Intervention patients|Community Health Centers that implemented health insurance outreach IT tools: active patients on whom tools were used
3039352|NCT02298361||Within-clinic comparison patients|Community Health Centers that implemented health insurance outreach IT tools: active patients on whom tools were not used
3039353|NCT02298361||Control clinic comparison patients|Matched Community Health Centers that did not implement health insurance outreach IT tools: active patients
3039354|NCT02298348|Other|Sorafenib and Cyclophosphamide/Topotecan|Sorafenib and Cyclophosphamide/Topotecan with growth factor support.
3039355|NCT02298335|Experimental|prednisone|First,full-dose induction period, then protracted tapering period.
3039356|NCT02298322|No Intervention|Fat Reduction|Other Names: Cryolipolysis; Lipolysis
3039357|NCT02298309|No Intervention|Usual Care|Patients in the usual care arm will be screened for tuberculosis (TB) on a mobile unit and referred for treatment according to the current standard of care in South Africa
3039358|NCT02298309|Active Comparator|Test-and-Treat Intervention|Patients in the intervention arm will partake in a Test-and-Treat TB strategy involving mobile GeneXpert MTB/RIF testing, facilitated TB treatment initiation, SMS reminders for clinic visits, and cashless incentives.
3039359|NCT02298296||No treatment|
3039360|NCT02298283|Experimental|study treatment|"induction = BEACOPP-escalated (bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine, and prednisone) : 2 cycles every 3 weeks~radiotherapy = involved field radiotherapy (IFRT) will be given 3 to 4 weeks after the last day of second BEACOPP at 30 Grays (+boost 6 Grays to area with residual lesion) in 3 weeks~Consolidation = brentuximab vedotin treatment will start 4 weeks after the last day of IFRT and up to 6 weeks. The dose of study treatment is 1.8 mg/kg"
3039361|NCT02298270|Experimental|Relaxation Response Resiliency Program|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
3039362|NCT02298270|Placebo Comparator|Health Education|Participants will receive and 8-week general stress and health education program, with none of the active relaxation and resiliency-based components being tested in the experimental condition.
3039364|NCT02298244|Active Comparator|PV isolation + GP Ablation|
3039365|NCT02298244|Active Comparator|PV isolation + GP ablation + Pulmonary GP ablation|
3039366|NCT02298231|Experimental|Group 1|Standard of Care Balance (SCB) Treatment
3039369|NCT02298218|Experimental|Meloxicam|The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
3039370|NCT02298218|No Intervention|No intervention|During 6 months, without meloxicam, the maintenance will be decided by the comparison of liver stiffness score comparing the intervention group.
3039371|NCT02298205|Other|Provider-based adjustment|Primary care provider will adjust the dose of asthma controller medication based on asthma control at each encounter
3039372|NCT02298205|Active Comparator|Symptom-based adjustment|The dose of asthma controller medication is adjusted based on the symptoms
3039373|NCT02298192|Experimental|Once weekly titration|
3039374|NCT02298192|Experimental|Twice weekly titration|
3039375|NCT02298179|Experimental|RSV F 45 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with no adjuvant.
3039376|NCT02298179|Experimental|RSV F 45 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with aluminum hydroxide adjuvant.
3039377|NCT02298179|Experimental|RSV F 45 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with MF59 adjuvant.
3039378|NCT02298179|Placebo Comparator|Placebo 1 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 1.
3039379|NCT02298179|Experimental|RSV F 90 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with no adjuvant.
3039380|NCT02298179|Experimental|RSV F 90 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with aluminum hydroxide adjuvant.
3039381|NCT02298179|Experimental|RSV F 90 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with MF59 adjuvant.
3039382|NCT02298179|Placebo Comparator|Placebo 2 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 2.
3039383|NCT02298179|Experimental|RSV F 135 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with no adjuvant.
3039384|NCT02298179|Experimental|RSV F 135 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with aluminum hydroxide adjuvant.
3039385|NCT02298179|Experimental|RSV F 135 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with MF59 adjuvant.
3039386|NCT02298179|Placebo Comparator|Placebo 3 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 3.
3039387|NCT02298166|Placebo Comparator|Standard arm|chemotherapy (MC) in combination with placebo
3039388|NCT02298166|Experimental|Experimental arm|chemotherapy (MC) in combination with crenolanib
3039389|NCT02298153|Experimental|atezolizumab (MPDL3280A) + epacadostat (INCB024360)|atezolizumab (MPDL3280A) 1200 mg given every 3 weeks + epacadostat (INCB024360) 25 mg BID as starting dose, followed by dose escalations until MTD or PAD is identified
3039390|NCT02298140|Experimental|SMS reminders|This arm will receive automated mobile phone text message reminders for health workers in outpatient departments of public and private health facilities on issues related to care of malaria patients and suspected patients.
3039391|NCT02298127|Experimental|Shenmen, mouth, lung & stomach|Participants in this group will receive 4 weekly treatment sessions of auricular acupressure via the shenmen, mouth, lung and stomach.
3039392|NCT02298127|Experimental|Subcortex,endocrine&sympathetic systems|Participants in this group will receive 4 weekly treatment sessions of auricular acupressure via the subcortex, endocrine and sympathetic systems.
3039393|NCT02298127|Sham Comparator|Elbow, shoulder & knee|Participants in this group will receive 4 weekly treatment sessions of sham-controlled acupressure on the elbow, shoulder and knee acupoints on the auricle that is non-specific to smoking cessation.
3039394|NCT02298114|Experimental|neuromuscular electrical stimulation|Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine. The electrodes will be placed over the motor points of the following muscles: pectoral muscles (fibres of the pectoralis major muscle) and rectus abdominis muscles (bilaterally) The first training session will have a duration of 30 minutes , which will then be extended by 1 minute for every 2 days of administration. The intensity will be increased until muscle contraction is visible or palpable or, intensity will be adjusted according to tolerance associated conventional physiotherapy. Neuromuscular electrical stimulation will be applied held until extubation end conventional respiratory and motor physiotherapy until discharge from the ICU.
3039454|NCT02297659|Active Comparator|Hypertonic saline resuscitation|Patients to receive 3% hypertonic saline resuscitation at a rate of 30cc/hr.
3039455|NCT02297646|Experimental|Carbohydrates|50 grams of carbohydrates 4 times a week for each training session
3039395|NCT02298114|Sham Comparator|Conventional physiotherapy|Conventional physiotherapy will be administered by professionals from the physiotherapy department twice a day, for 30 minutes. The protocol will include upper and lower extremity functional diagonals from the proprioceptive neuromuscular facilitation method (two series of 10 repetitions for each bilateral diagonal), manual bronchial hygiene exercises, such as thoracic vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary. Associated will receive placebo electrical stimulation, in this case the procedure is the same, but intensity is set to a sensory level, not high enough to provoke either visible or palpable muscle contractions.
3039396|NCT02298101|Active Comparator|Aeroneb Solo Adapter|Subjects inhaled radiolabelled aerosol via the Aeroneb Solo Adapter
3039397|NCT02298101|Active Comparator|Standard Jet Nebulizer|Subjects inhaled radiolabelled aerosol via a standard jet nebulizer, the Opti-Mist Plus Nebulizer
3039398|NCT02298088|Active Comparator|Ticagrelor 180 mg|Patients assigned to Ticagrelor will receive oral Ticagrelor, 180 mg as early as possible after the index event and not >24 h post event followed by 90 mg twice daily for 12 months.
3039399|NCT02298088|Active Comparator|Clopidogrel|"Patients will take the 300 mg clopidogrel as early as possible after the index event and not > 24h post event, followed by 75mg/day for 12 months.~For patients with > 75 years the recommended load dose is 75 mg instead 300 mg."
3039400|NCT02298062|Experimental|Infliximab|For one group of patients with resistance to intravenous immunoglobulin in Kawasaki disease , we will give them infliximab (5mg/kg) once.
3039401|NCT02298062|Active Comparator|IVIG|For the other group of patients with resistance to intravenous immunoglobulin in Kawasaki disease , we will give them IVIG (2g/kg) once.
3039402|NCT02298049|Other|Scanning|"Repeated measures:~Satiation scan + Pre-meal scan~All participants undertook both scans"
3039403|NCT02298036|Experimental|Remote Therapy Offered|Participants randomised to this arm receive 6-10 sessions of remote CBT
3039404|NCT02298036|No Intervention|Treatment as Usual|Participants do not receive remote therapy and remain in usual care
3039405|NCT02298023|Experimental|allogenic adipose stem cell treatment|Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.
3039406|NCT02298023|Placebo Comparator|Placebo Comparator (Fibrin glue) group|Normal saline 0.5cc + Fibrin glue 0.5cc + range of motion exercise
3039407|NCT02298023|No Intervention|Exercise comparator group|Normal saline 0.5cc + Normal saline 0.5cc + range of motion exercise
3039408|NCT02298010||Adjuvant chemotherapy group|Research subjects who were enrolled in CLASSIC trial and underwent adjuvant chemotherapy.
3039409|NCT02298010||Only surgery group|Research subjects who were enrolled in CLASSIC trial and did not undergo adjuvant chemotherapy
3039410|NCT02297997|Experimental|1.5mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 1.5mg will be taken daily for two weeks.
3039411|NCT02297997|Experimental|3mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 3mg will be taken daily for two weeks.
3039412|NCT02297997|Experimental|4.5mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 4.5mg will be taken daily for two weeks.
3039413|NCT02297997|Experimental|6mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 6mg will be taken daily for two weeks.
3039414|NCT02297997|Placebo Comparator|Control|Placebo will be taken daily for two weeks.
3039415|NCT02297984||Acute ischemic stroke|Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study.
3039416|NCT02297945|Experimental|Metyrapone|Metyrapone will be administered orally in an open-label fashion. Two possible initiation doses will be used depending on the severity of hypercortisolism, dose will then be adjusted (up or down-titrated) during the first month on an individual basis according to clinical tolerance and cortisol levels achieved.
3039417|NCT02297932|Experimental|Strength training|The intervention will consist of a Home-based Resistant Training Intervention. Participants randomized to the home-based progressive resistance training (PRT) condition and will be provided with a training manual, an exercise log book, and resistance training equipment. The training manual will consist of a detailed description of the exercises to be performed and how to progress over 4-months. The exercise logbook will allow participants to provide a detailed recording of each training session. Home-based PRT equipment will consist of elastic bands (Thera-Band®, Hygenic Corporation, Akron, OH) and weighted vests.
3039418|NCT02297932|Active Comparator|Stretching|Individuals in the comparator group will participate in a four month home-based stretching program developed by the National Multiple Sclerosis Society (NMSS). They will be provided text-based materials and asked to provide a weekly log book. In efforts to equate the attention received, individuals will come to KF at the same frequency as those receiving the PRT intervention and will also engage in the same number of sessions to assess their adherence to the program.
3039419|NCT02297919|Experimental|web based intervention|Web based intervention: Students will have access to the educational content through the learning management system on the web site (genc-e-saglik) created for this project.
3039420|NCT02297919|Active Comparator|classic preprepared lesson|Training at the control group,lectures will be presented on the basis of the classic preprepared lesson by educator and at the end of the training, will be answered student's questions.
3039421|NCT02297906|Experimental|Intranasal ketorolac|Ketorolac 0.5 mg/kg, maximum single dose = 30 mg. Administered once by intranasal route using a mucosal atomization device.
3039422|NCT02297906|Active Comparator|Intravenous ketorolac|Ketorolac 0.5 mg/kg, maximum single dose = 30 mg. Administered once by intravenous route.
3039423|NCT02297893|Experimental|Dexterity training program (HOMEDEXT)|This program is a a high intensity training program adapted from a previously published arm ability training program
3039424|NCT02297893|Active Comparator|Theraband training program|7 different Theraband exercises. Total duration is 30 minutes, trained 5 times a week over a period of 4 weeks
3039425|NCT02297880|Experimental|Beverage containing low calorie sweeteners|Beverage containing low calorie sweeteners (flavour)
3039426|NCT02297880|Active Comparator|Still water|Still water (no flavour)
3039427|NCT02297867|Experimental|ADSCs|One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
3039428|NCT02297854|Experimental|Valganciclovir Hydrochloride Tablets 450 mg|Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddys Laboratories Limited
3039456|NCT02297646|Placebo Comparator|Control|no carbohydrate intake
3039430|NCT02297841|Experimental|Human Repeat Insult Patch Test|Approximately 0.2ml of each intervention (Experimental: Novel lubricant Miami Fragrance, Experimental: Novel lubricant Miami no Fragrance, KY Liquid lubricant, Astroglide Gel lubricant) was applied to an occlusive patch and applied to participant's back.
3039431|NCT02297828|Experimental|Boussignac CPAP|"Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).~Arterial blood samples to measure PaO2 and PaO2/FiO2 ratio are collected before surgery and at 1, 2 and 24 hours after extubation. Spirometry is performed at the same intervals measuring FEV1 and FVC."
3039432|NCT02297828|Active Comparator|Ventury face mask|"Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).~Arterial blood samples to measure PaO2 and PaO2/FiO2 ratio are collected before surgery and at 1, 2 and 24 hours after extubation. Spirometry is performed at the same intervals measuring FEV1 and FVC."
3039433|NCT02297815||Children treated for an ARTI|Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed antibiotics.
3039434|NCT02297789|Experimental|Headgear 1|Full Face Mask with Headgear 1
3039435|NCT02297789|Experimental|Headgear 2|Full Face Mask with Headgear 2
3039436|NCT02297776||CPC score 1 to 2|The patients with CPC score 1 to 2 judged half a year after cardiac arrest
3039437|NCT02297776||CPC scores 3 to 5|The patients with CPC score 3 to 5 judged half a year after cardiac arrest
3039438|NCT02297763|Active Comparator|quetiapine|quetiapine 12.5mg (bwt <50kg ) or 25mg (bwt>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.
3039439|NCT02297763|Placebo Comparator|placebo|The placebo is made of 100mg of corn starch which is melted in 10cc water.
3039440|NCT02297750|Active Comparator|single wire technique|single wire technique in patients undergoing ERCP with biliary cannulation
3039441|NCT02297750|Active Comparator|Double wire technique|double-wire technique in patients undergoing ERCP with biliary cannulation
3039442|NCT02297737|Experimental|Tai Chi|A manual consisting of 8 movements learned over a period of 12 weeks will be used to teach participants in the Tai Chi condition. Classes will include around 5-6 subjects, each class lasting one hour, including a 10-minute warm-up and cool-down, and meet twice per week. Patients will be told to practice Tai Chi three times/week at home. After 12 weeks of training patients will be told to practice at home five times/week for 8 more weeks, until the 8-week follow-up visit. Subjects will be asked to rate their perceived exertion/work intensity during each session using the Borg's perceived exertion scale and asked to increase the size of their movements to reach 12-13 (moderate difficulty), which consistently matches with 65-70% of HR max.
3039443|NCT02297737|Active Comparator|Health Education|Participants in the Health Education condition will also meet for one hour, twice per week for 12 weeks for a total of 24 hours. Sessions will be highly structured and will emphasize key concepts in the presentations. Medical and allied health experts will provide twelve didactic videotaped presentations on a series of health-related themes and a group leader will be present to answer questions. Themes will include: Epidemiology of Cardiovascular Disease, Patient/Physician Communication, Medication Adherence, Nutrition and Exercise, The Nature and Structure of Sleep, and Navigating the Health Care System.
3039444|NCT02297724||all subjects|For all subjects, administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan. Data collection will start about 10 min before the administration of oxygen, and last throughout the oxygen exposure, then continue for about 10 min after oxygen exposure for each subject.
3039445|NCT02297711|Experimental|Total ExtraPeritoneal|Total ExtraPeritoneal (TEP) technique in general anesthesiacanal from behind
3039446|NCT02297711|Active Comparator|Open minimal suture repair|Open minimal repair (OMR) technique in local or spinal anesthesia
3039447|NCT02297698|Experimental|Trastuzumab + NeuVax|Patients randomized to this arm will receive vaccinations of nelipepimut-S (1000 μg) and GM-CSF (250 μg) (NeuVax vaccine) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumbab to overlap with the PVS. Upon completion of the primary vaccination series (PVS), booster inoculations (same dose and route) will be administered every six months x 4. The first booster inoculation will occur 6 months ± 2 weeks after the completion of the PVS, with subsequent boosters timed every six months + 2 weeks. Boosters will therefore occur at the following time points after completion of the PVS: 6 months ± 2 weeks, 12 months ± 2 weeks, 18 months ± 2 weeks and 24 months ± 2 weeks.
3039448|NCT02297698|Active Comparator|Trastuzumab + GM-CSF|Patients randomized to this arm will receive inoculations of GM-CSF (250 μg) administered in an identical manner to those receiving nelipepimut-S/GM-CSF (NeuVax). Patients will be blinded as to whether they are receiving nelipepimut-S/GM-CSF or GM-CSF alone. Upon completion of the primary vaccination series (PVS), booster inoculations (same dose and route) will be administered every six months x 4. The first booster inoculation will occur 6 months ± 2 weeks after the completion of the PVS, with subsequent boosters timed every six months + 2 weeks. Boosters will therefore occur at the following time points after completion of the PVS: 6 months ± 2 weeks, 12 months ± 2 weeks, 18 months ± 2 weeks and 24 months ± 2 weeks.
3039449|NCT02297685|Sham Comparator|Sham Transcutaneous nerve stimulation|The group with sham TENS did not receive any current. Four surface electrodes (5×5 cm Prim-Trode®, Spain) were symmetrically placed over the L1 and L5 transverse processes with respect to the spine. The patients were informed that they may or may not feel any sensation at the application site of the electrodes.
3039450|NCT02297685|Experimental|Transcutaneous nerve stimulation|The group with TENS received current at a frequency of 80 Hz and with a pulse width of 150 μs with two channels, for 30 minutes over a period of 4 weeks, including a total of 12 sessions.
3039451|NCT02297685|Experimental|Interferential currents|The group with IC received a base frequency of 4000 Hz with AMF = 65 Hz, sweep = 95 Hz and slope of 1/1 in tetrapolar mode, for 30 minutes over a period of 4 weeks, including a total of 12 sessions.
3039452|NCT02297672|Experimental|Breast seed implant|Stranded palladium seed interstitial radioactive seed implant to seroma with margin with 3 dimensional ultrasound and CT guidance
3039457|NCT02297633||Stability in patients with COPD|Those patients diagnosed COPD according to the GOLD guideline and without acute exacerbation within one month.
3039458|NCT02297633||AECOPD|the diagnosis of an exacerbation relies exclusively on the clinical presentation of the patient complaining of an acute change of symptoms (baseline dyspnea, cough, and/or sputum production) that is beyond normal day-to-day variation.
3039459|NCT02297633||Healthy persons without smoking|The healthy people who do not smoke
3039460|NCT02297633||Healthy persons with smoking|Healthy persons who smoke
3039461|NCT02297620||Suglat group|
3039462|NCT02297607|Experimental|Tube Feeding|Study subjects will continue to receive tube feedings (for at least 50% of caloric need) for 1-month post-operatively.
3039463|NCT02297607|No Intervention|Standard of Care|Tube feeding to continue in the hospital until the patient is taking adequate nutrition by mouth at post-op day #8, or upon discharge,
3039464|NCT02297594|Experimental|AK0529|Generic name: AK0529 Dosage Form: capsule
3039465|NCT02297594|Placebo Comparator|Placebo|Sugar placebo
3039466|NCT02297581||GFC: Geriatric Fracture Center|"Patient treatment in a geriatric fracture center~A GFC is defined as follows:~General geriatrician or ortho-geriatrician available in trauma/orthopaedic department~Geriatrician sees the patient prior to surgery (except if the patient is admitted over night or during weekends)~Local medical guidelines, consented by orthopedic surgeons and geriatrician~Pre-defined order set for assessing laboratory values~Pre-defined patient pathway to guarantee a fast track in the emergency room~Daily communication among involved specialists~Postoperative phase up to discharge from orthopaedic / trauma department (i.e. Discharge 1):~Daily patient visit by geriatrician~Daily patient visit by orthopedic surgeon in combination with nurse~Daily therapy by physiotherapists, except for weekends~Access to social workers, if required"
3039467|NCT02297581||UCC: Usual Care Center|"Patient treatment in an usual care center~A UCC is defined as follows:~No geriatrician available in trauma/orthopaedic department~No pre-operative visit by a geriatrician as a standard~No pre-defined medical guidelines for geriatric fracture patients~Postoperative phase up to discharge from orthopaedic / trauma department (i.e. Discharge 1):~No daily patient visits by a geriatrician as a standard"
3039468|NCT02297568|Active Comparator|Calciferol,1800 IU/d supplement|The lactating mothers and their breastfed infants with maternal 25 Hydroxy-vitamin D (25OHD) levels of 10-30 ng/ml in third trimester were randomly assigned to 1,800 IU/d .
3039469|NCT02297568|Placebo Comparator|Placebo|The lactating mothers and their breastfed infants with maternal 25 Hydroxy-vitamin D (25OHD) levels of 10-30 ng/ml in third trimester were randomly assigned to receive placebo.
3039470|NCT02297555|No Intervention|Conventional medical therapy|Conventional medical therapy is defined as the use of the latest lifestyle guidelines to optimize weight loss and glycaemic management, frequent home monitoring/titration strategies, use of latest approved drug therapy for treatment of hyperglycaemia and restoration of pancreatic B cell function, also for dyslipidemia and hypertension in addition to regular follow-up visits to a medical doctor from a multidisciplinary team
3039471|NCT02297555|Experimental|ENDOBARRIER®|The interventional therapy will be the device ENDOBARRIER® over conventional medical therapy
3039472|NCT02297542|Active Comparator|Flu Vaccine SD|Fluzone Standard Dose Influenza Vaccine
3039473|NCT02297542|Active Comparator|Flu Vaccine HD|Fluzone High Dose Influenza Vaccine
3039474|NCT02297516|Experimental|Azzalure/Dysport as single treatment|Azzalure/Dysport as single treatment at initial treatment
3039475|NCT02297516|Experimental|Filler as single treatment|Filler as single treatment at initial treatment
3039476|NCT02297503|Experimental|Azzalure alone as single treatment|Azzalure alone as single treatment at initial treatment
3039477|NCT02297503|Experimental|Filler alone as single treatment|Filler alone as single treatment at initial treatment
3039478|NCT02297490|Placebo Comparator|Placebo|Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
3039479|NCT02297490|Experimental|Allergovit 6-grasses immunotherapy|Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.
3039480|NCT02297477|Active Comparator|atovaquone-proguanil (AP)|A standard fixed-dose 3 day regimen of Atovaquone-proguanil (AP) for treatment of uncomplicated P. falciparum malaria.
3039481|NCT02297477|Active Comparator|artesunate-atovaquone-proguanil (ASAP)|A standard fixed-dose 3 day regimen of Atovaquone-proguanil (AP) plus 3 days of artesunate (200mg per day) for treatment of uncomplicated P. falciparum malaria.
3039482|NCT02297464|Experimental|Eggs - 2 per day for breakfast|Participants will consume 2 eggs per day for breakfast for 4 weeks of the study.
3039483|NCT02297464|Experimental|Oatmeal - 1 packet per day for breakfast|Participants will consume 1 packet of oatmeal per day for breakfast for 4 weeks of the study.
3039484|NCT02297451|No Intervention|Brachial artery inflow|Elbow fistula created with brachial artery as inflow (ie. either brachiocephalic or brachiobasilic fistulas)
3039485|NCT02297451|Active Comparator|Proximal radial/ulnar artery as inflow|Elbow fistula created with either proximal radial or ulnar artery as inflow
3039486|NCT02297438|Experimental|Palbociclib + Letrozole|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously)
3039487|NCT02297438|Active Comparator|Placebo + Letrozole|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
3039488|NCT02297425|Experimental|Single agent - study drug|The study will evaluate single-agent PF-06459988
3039489|NCT02297412|Experimental|Arm I (minocycline hydrochloride)|Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3039490|NCT02297412|Placebo Comparator|Arm II (placebo)|Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3039491|NCT02297399|Experimental|PEG-ascorbate 2L|Subjects will take 2 liters of a polyethylene glycol 3500 (sodium sulphate, sodium chloride, postassium chloride), ascorbic acid and sodium ascorbate solution.
3039789|NCT02295202|Experimental|CPAP|CPAP: Continuous Positive Airway Pressure - Device used for treating OSA during sleep.
3039492|NCT02297399|Active Comparator|PEG 4L|Subjects will take 4 liters of a polyethylene glycol 4000 (sodium sulphate, sodium chloride, postassium chloride and sodium bicarbonate) solution.
3039493|NCT02297386|Experimental|[18F] DIHYDRO-TESTOSTERONE PET|"The diagnostic intervention of this study is the use of FDHT PET in localized prostate cancer. Patients will undergo a 30 minute dynamic scan of the pelvis followed by a whole body scan of approximately 30-minutes duration. The dynamic scan will be optional, but strongly encouraged. PET scanning will preferably be done on the GE Discovery STE PET/CT scanner or the equivalent generation of scanner. The PET scans are routinely quantitative, that is corrected for attenuation and scatter and adjusted for system sensitivity and providing parametric images in terms of standardized uptake values (SUV) (= μCi found/gm tissue / μCi injected/gm body mass)."
3039494|NCT02297360|Active Comparator|Viviscal Extra-Strength Supplement|Viviscal Extra-strength tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 90 days.
3039495|NCT02297360|Placebo Comparator|Placebo Tablet|Placebo tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 90 days.
3039496|NCT02297334|Active Comparator|With CytoSorb device|Patients randomised to this arm are treated with the CytoSorb device during bypass.
3039497|NCT02297334|No Intervention|Withouot device|Patients randomised to this arm are treated without the CytoSorb device during bypass.
3039498|NCT02297321|Experimental|DeScribe patch|Comparison of the number of passes achieved using the Describe patch plus laser compared to laser along
3039499|NCT02297308||SoloPath Sheath|The study focuses on subjects that underwent TAVI with a SoloPath Sheath used for femoral vascualar access
3039500|NCT02297295|Experimental|Physiotherapy|Comparing the patients to themselves (spontaneus evolution) before intervention.
3039501|NCT02297282|Experimental|Behavioural Activation|Originally a component of Cognitive Therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. Behavioural Activation involves the use of activities to improve life situations or depressed mood.
3039502|NCT02297282|No Intervention|Wait List (Control Group)|The Control group (waitlist) will receive treatment as usual while they are waiting to start the BA intervention at the end of the Intervention Group Therapy time (28 sessions over an 18 week period). In addition to usual care, the control group will be assessed by clinical staff that offers treatment as usual for mood symptoms and quality of life measures during the waiting time.
3039503|NCT02297269||group laparoscopic surgery|Participants undergo laparoscopic gastrointestinal malignancy surgery will be included in this group. The pressure of pneumoperitoneum maintain in 10-12mmHg.
3039504|NCT02297269||group open surgery|Participants undergo open gastrointestinal malignancy surgery will be included in this group.
3039505|NCT02297256|Active Comparator|BMAC & Allograft|Subjects will be treated with bone marrow aspirate concentrate (BMAC) and allograft during posterior lumbar/lumbosacral spinal fusion. During lumbar spine surgery, 12 teaspoons of bone marrow will be taken (aspirated) from one side of hip bone. This may be repeated on the other side of hip bone for a total of 12, 24, or 36 teaspoons of bone marrow total taken from your hip bone depending on the decision made by the surgeon. The bone marrow will then be concentrated with a machine for 15 minutes to a final volume of 2, 4, or 6 teaspoons of BMAC. BMAC will be combined with packed allograft bone chips using another machine to produce two or three constructed bone logs. The bone logs will be laid along the backside of the spine and between each vertebral body.
3039506|NCT02297256|Active Comparator|Iliac Crest Bone Graft|Subjects who are in the Iliac Crest Bone Graft arm will be treated with Iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion. During lumbar spine surgery, the surgeon will make an incision to expose the iliac crest (hip bone), and cutting out the segments of the bone that will be needed, based on the decision of the surgeon. The bone chips will be laid along the backside of the spine and also between each vertebral body where the bone will fuse into place. When the bone becomes solid/fused, there is no movement in the fused spine.
3039507|NCT02297243|Experimental|Sinopsys Lacrimal Stent|The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
3039508|NCT02297230|Experimental|Arm 1 Capecitabine and RT|Her-2/neu negative patients will be given Capecitabine (xeloda, 750mg/m2 twice daily orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
3039509|NCT02297230|Experimental|Arm 2 Paclitaxel/Trastuzumab and RT|Trastuzumab (Herceptin®) will begin on day 1 of radiation therapy and be administered weekly to Her-2/neu Positive patients. The first dose will be 4mg/kg given IV over 90 minutes. Weekly doses will be 2 mg/kg/week IV over 30 minutes.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
3039510|NCT02297230|Experimental|Arm 3: Paclitaxel and RT|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour to Her-2/neu negative patients. Treatment will be initiated during the first week of radiation therapy and should be administered on a Monday/Thursday or Tuesday/Friday schedule.
3039511|NCT02297230|Experimental|Arm 4: Paclitaxel/Trastuzumab and RT|Trastuzumab (Herceptin®) tx will be administered weekly, together with one of the 2 weekly doses of Paclitaxel to Her-2/neu Positive patients. The 1st dose will be 4mg/kg given IV over 90 minutes. Weekly doses will b given at a dose of 2 17mg/kg/week IV over 30 minutes. The Tx with Trastuzumab will continue weekly after the completion of the radiation tx until surgery & thereafter as per std of care up to 1 yr post surgery.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Tx will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.
3039512|NCT02297217|Experimental|Chemotherapy with Concurrent Radiation|Carboplatin and paclitaxel will be administered intravenously on Days 1 and 8 while radiation therapy is administered
3039513|NCT02297204|Experimental|aflibercept|"2mg, as needed, intravitreal administration. All subjects will be treated with intravitreal (IVT) aflibercept injections as needed in the presence of clinically relevant diabetic macular edema (CR-DME). If CR-DME is not present the subject will not receive an IVT aflibercept injection and will be observed.~If a subject has recurrent CR-DME they will receive an IVT aflibercept 2.0 mg injection and interval between visits will be reduced to 4 weeks.~At week 12 through end of study, all subjects will be evaluated for focal laser treatment."
3039790|NCT02295202|Placebo Comparator|Placebo|Nasal Strips
3039863|NCT02294669|Experimental|Turris Facet Fuser|
3039514|NCT02297191|Experimental|Thoracolumbar Interfascial Plane Block|"All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle, evaluate for spread of local anesthesia and to minimize the risk of Ropivicaine being injected intravascularly.~a. Ultrasound images will be saved using the nomenclature TLIP Anat"
3039515|NCT02297178||Cystoscopy Alone|Patients who received cystoscopy only for treatment of OAB and voiding dysfunction.
3039516|NCT02297178||Cystoscopy & Urethral Dilatation|Patients who received urethral dilatation and cystoscopy for treatment of OAB and voiding dysfunction.
3039517|NCT02297165|Experimental|Program|olfactory stimulation program
3039518|NCT02297165|No Intervention|Control|normal follow-up
3039519|NCT02297152|Other|FLIP HOLE|The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation
3039520|NCT02297139|Experimental|Dasatinib|This is a continuation roll-over study for patients receiving benefit from prior dasatinib protocols. All subjects will receive dasatinib as per previous protocol
3039521|NCT02297126|No Intervention|Control Arm|4,000 patients receiving a new prescription for targeted medication(s) randomized into the control arm receive standard care (no intervention affecting drug selection, dosage, dosage form, frequency and duration of therapy). Healthcare costs and adverse events data collected and analyzed for 12 months from time of entry into study. List of targeted medications: codeine, amitriptyline, aripiprazole, atazanavir, atomoxetine, azathioprine, citalopram, clopidogrel, cyclophosphamide, doxepin, efavirenz, escitalopram, esomeprazole, fluconazole, simvastatin, fluorouracil, phenytoin, quetiapine, glyburide, lansoprazole, mercaptopurine, methadone, methotrexate, nortriptyline, omeprazole, pantoprazole, rasburicase, tacrolimus, thioguanine, tramadol, venlafaxine, voriconazole and warfarin
3039522|NCT02297126|Experimental|Pharmacogenetic Intervention Arm|2,000 patients receiving new prescription for targeted medication(s) identified in the control arm will be randomized to the intervention arm, consented and a tests will be performed from a blood sample. The treating physicians will be provided with the pharmacogenetic information and will determine if intervention is appropriate. Physician may elect to stay the course of therapy or alter drug selection, dosage, dosage form, frequency or duration of therapy based on the pharmacogenetic test results and input from clinical pharmacology consultations (if requested). Patients in the intervention arm will have their overall healthcare costs and clinical outcomes (specifically adverse events) followed and analyzed for a 1 year period from the time that they are entered into the study
3039523|NCT02297113|Active Comparator|conventional endotracheal intubation|Patients assigned to this group will be intubated using conventional Macintosh blade in adequate size.
3039524|NCT02297113|Active Comparator|C-MAC|Patients assigned to this group will be intubated using C-MAC videolaryngoscope in adequate size.
3039525|NCT02297100|Experimental|Botox upper aspect trigone|Subjects in the experimental cohort will receive a one time dose of 100 units of Onabotulinumtoxin A diluted in 10 mL of preservative free normal saline and injected in 1.0 mL boluses in a set pattern across the upper aspect of the trigone of the urinary bladder.
3039526|NCT02297100|Active Comparator|botox periphery of trigone|Each group will receive a total of 100 units of botox spread out among 10 separate injections. Subjects in the control group will have 10 injections made about the periphery of the trigone. The control cohort will receive a one time dose of Onabotulinumtoxin A using the same dilution and number of boluses, but boluses will be administered at random sites on the posterior bladder wall (excluding the trigone).
3039527|NCT02297087|Other|Pilot|Obtain the necessary tumor biopsies to yield sufficient DNA and RNA for Genome-Wide Sequencing (GWS).
3039528|NCT02297074|Experimental|Ordinary White Bread|Ordinary white bread bread is characterised by a white crumb with regular soft alveoli and a slightly soft thin crust.
3039529|NCT02297074|Experimental|Precooked-Frozen White Bread|Precooked-Frozen white bread is characterized by white crumb with regular soft alveoli and bright crusty crust
3039530|NCT02297074|Experimental|Candeal-flour White Bread|Candeal-flour white bread has a thick crust of between one and two millimetres, which is smooth and crisp, golden to light brown in colour and which tastes of toasted cereal. The crumb of the bread is white and its texture is smooth, spongy and consistent, with little regular alveolus and with an intense cereal aroma with a pleasant and slightly sweet taste
3039531|NCT02297074|Experimental|Alfacar White Bread|Alfacar white bread is made according to its protected designation of origin and protected geographical indication (D.O. Alfacar, Granada, Spain). The bread has a creamy white, flexible and soft crumb, with many randomly scattered holes. The crust is medium-thick to thick, golden, slightly shiny and quite smooth
3039532|NCT02297074|Experimental|Organic Wholemeal Bread|The Organic wholemeal bread only includes organic whole grain flours as the unique difference compared with the Ordinary bread. The resulting dark brown bread is characterized by compact crumb free of alveoli and hard thin crust
3039533|NCT02297074|Active Comparator|Glucose|Glucose is used to calculate glycemic index, glycemic load and insulinemic index
3039534|NCT02297061||TEG group|200 consecutive hip fracture patients, Thrombelastography is performed on admission.
3039535|NCT02297048|Experimental|RU 486 (mifepristone)|Subjects will receive 400 mg once a day of RU486
3039536|NCT02297048|Placebo Comparator|Placebo|Subjects will receive placebo once a day
3039537|NCT02297035|Experimental|PPA patients|Experimental (Patients responding to current diagnostic criteria for Primary Progressive Aphasia (PPA) patients) : Behavioural testing, Brain imaging (MRI, PET), Genetic screening (APOE, Progranulin)
3039538|NCT02297035|Experimental|healthy controls|Healthy controls : Behavioural testing, Brain imaging (MRI, PET).
3039539|NCT02297022|Experimental|Deep Brain Stimulation|Patients with Prader-Willi syndrome to receive DBS.
3039540|NCT02297009||Volunteers|30 volunteers, half men and half women Buccal swab
3039541|NCT02296996|Experimental|Dabrafenib + trametinib|Single arm study with dabrafenib + trametinib combination therapy
3039542|NCT02296983|Experimental|Low dose arm|The low dose cohort will receive an intramuscular (deltoid) injection of 3x106 pfu of VSV-ZEBOV vaccine.
3039543|NCT02296983|Experimental|Full dose arm|The full dose cohort will receive an intramuscular (deltoid) injection1x107 pfu of VSV-ZEBOV vaccine.
3039544|NCT02296957|Experimental|Intervention|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
3039545|NCT02296957|No Intervention|Control|Usual Care
3039546|NCT02296944||Children aged under 7 years old when tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
3039547|NCT02296944||Children aged 7 to 10 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
3039548|NCT02296944||Children aged 11 to 14 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
3039549|NCT02296944||Children aged over 14 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
3039550|NCT02296931|Active Comparator|Healthy Adults|Phase 1 will be an initial validation of the clinical performance of the device delivering only standard IV saline to 10 stable women.
3039551|NCT02296931|Experimental|Pre-eclamptic pregnant women|In Phase 2, the device will deliver MgSO4 to up to 40 women presenting with symptoms of pre-eclampsia.
3039552|NCT02296918|Experimental|Double combo with acalabutinib in RR|For Relapse Refractory subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles.
3039553|NCT02296918|Experimental|Double combo with acalabutinib in TN|For previously untreated subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles.
3039554|NCT02296918|Experimental|Triplet combo with acalabutinib in RR|For Relapse Refractory subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with rituximab starting at Cycle 2 for 6 cycles. Venetoclax, starting at Cycle 3 taken up to 12 cycles
3039555|NCT02296918|Experimental|Triplet combo with acalabutinib in TN|For previously untreated subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles. Venetoclax, starting at Cycle 3 taken up to 12 cycles
3039556|NCT02296905|Experimental|Group I|Subjects with mild hepatic impairment
3039557|NCT02296905|Experimental|Group II|Subjects with moderate hepatic impairment
3039558|NCT02296905|Experimental|Group III|Subjects with severe hepatic impairment
3039559|NCT02296905|Experimental|Group IV|Subjects with normal hepatic function
3039560|NCT02296892|Experimental|Remimazolam|Remimazolam iv 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.
3039561|NCT02296892|Placebo Comparator|Placebo|Placebo iv for sedation induction and maintenance.
3039562|NCT02296892|Active Comparator|Midazolam|Midazolam iv 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance. *1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill.
3039563|NCT02296879|Experimental|SAIT301|"For Stage 1, subjects will be sequentially assigned to 1 of approximately 8 cohorts comprised of 3 to 6 subjects each. SAIT301 will be administered according to a modified Fibonacci sequence and following a 3 + 3 design.~For Stage 2, the MTD or (RP2D) determined in the Stage 1 will be administered to additional subjects with selected diagnoses, 15 subjects per selected diagnosis. After completion of Stage 1 the SRC may elect to increase the interval between doses (i.e., increase cycle length to 28 days) based on the emerging PK data from the lower SAIT301 dose levels."
3039564|NCT02296853|Experimental|TAF - Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single dose of TAF.
3039565|NCT02296853|Active Comparator|TAF - Normal Hepatic Function|Participants with normal hepatic function will receive a single dose of TAF.
3039566|NCT02296840|Experimental|Ibuprofen|After undergoing adenotonsillectomy, patients who are randomized into the test intervention arm will receive ibuprofen (10mg/kg/day every 6-8 hours) after surgery.
3039567|NCT02296840|Active Comparator|Hydrocodone-acetaminophen (Control)|After undergoing adenotonsillectomy, patients who are randomized into the control intervention will receive hydrocodone-acetaminophen (0.15mg/kg/day every 4-6 hours).
3039568|NCT02296814|Active Comparator|Sinusitis Hevert SL Tablet|two weeks treatment
3039569|NCT02296814|Placebo Comparator|Placebo for Sinusitis Hevert SL Tablet|two weeks treatment
3039570|NCT02296801|Active Comparator|A: letrozole|letrozole 2.5 mg tablet orally daily for 14 weeks
3039571|NCT02296801|Experimental|B: letrozole then letrozole + palbociclib|letrozole 2.5 mg orally daily plus beginning 2 weeks after starting letrozole, palbociclib 125 mg capsule orally daily for 1 week then 1 week off, then a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of letrozole therapy
3039572|NCT02296801|Experimental|C: palbociclib then letrozole + palbociclib|palbociclib 125 mg capsule orally daily (for a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of palbociclib) plus beginning 2 weeks after starting palbociclib, letrozole 2.5 mg tablet orally daily for a total of 12 weeks from start of letrozole therapy
3039573|NCT02296801|Experimental|D: letrozole + palbociclib|letrozole 2.5 mg tablet orally daily for a total of 14 weeks plus palbociclib 125 mg capsule orally daily for a 3 weeks on and 1 week off cycle, for a total of 14 weeks from start of therapy
3039574|NCT02296788|No Intervention|No Exercise Control|Healthy Living Control Group
3039575|NCT02296788|Experimental|Aerobic Exercise Group|8 kcal/kg of body weight/week (KKW) (~900 kcal/wk)
3039576|NCT02296788|Experimental|Aerobic Exercise Group 2|20 KKW (~2250 kcal/wk)
3039577|NCT02296775|Experimental|DRL_RI|
3039578|NCT02296775|Active Comparator|Rituxan|
3039579|NCT02296775|Active Comparator|MabThera|
3039580|NCT02296762|Experimental|Sirolimus tablets 2 mg|Sirolimus tablets 2 mg of Dr. Reddys Laboratories Limited
3039581|NCT02296762|Active Comparator|Rapamune|Rapamune® 2 mg tablets of Wyeth Laboratories, Philadelphia
3039582|NCT02296749|Experimental|Sirolimus tablets 2 mg|Sirolimus tablets 2 mg of Dr. Reddys Laboratories Limited
3039583|NCT02296749|Active Comparator|Rapamune|Rapamune® 2 mg tablets of Wyeth Laboratories, Philadelphia
3039584|NCT02296736||Pancreatic malignancy|All patients who have undergone surgery for presumed pancreatic malignancy in Derriford Hospital between Jan 2006 and Jan 14 and had a Computerised tomography (CT) scan.
3039832|NCT02294903|Experimental|ProRAFT|Procedure/Surgery: Coiled Bipolar Radiofrequency Ablation
3039585|NCT02296723|Experimental|Valganciclovir Hydrochloride Tablets 450 mg|Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddys Laboratories Limited
3039586|NCT02296723|Active Comparator|Valcyte|Valcyte® 450 mg tablets of Genentech USA Inc., Sanfrancisco
3039587|NCT02296710|Experimental|Echocardiographic and sleep apnea test|Echocardiographic Evaluation of systolic and diastolic function of both ventricles and evaluation of apnea-hypopnea index and type of apnea
3039588|NCT02296697|Active Comparator|Low-level laser therapy AlGaInP|AlGaInP 660 nm laser and dose of 6 J / cm 2 with point application on the edges of the lesion and sweep up application in the center.
3039589|NCT02296697|Active Comparator|High-frequency therapy with O3 formation|High frequency generator, spherical electrode. Direct spark technique will be used, in which the electrode is positioned millimeters away from the skin of the patient, causing the formation of sparks, with increasing intensity up to 80 to 100% for ozone formation.
3039590|NCT02296697|Placebo Comparator|Wound dressing with saline solution|Wound dressing with hygiene of the pressure ulcer with warm saline and after applying the bandage will be held will be held.
3039591|NCT02296684|Experimental|Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475|"MK-3475 will be given intravenously once approximately 2-3 weeks prior to standard of care surgery.~Adjuvant therapy will be dictated by surgical pathology and occurs after standard of care surgery and will consist of:~risk-based intensity modulated radiation therapy consisting of 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions)once-daily fraction size (total of 30 fractions)~optional image-guided radiation therapy~risk-based cisplatin administered intravenously on Days 1, 22, and 43 of treatment course~MK-3475 will be given intravenously once every 3 weeks for a maximum of 6 doses if participant is considered high-risk based on 's surgical pathology from standard of care surgery shows high risk features (positive margins or extracapsular extension). These doses of MK-3475 will be given after surgery and after all acute toxicities of post-operative standard of care chemotherapy and radiation have resolved to grade 1 or less."
3039592|NCT02296684|Experimental|Cohort 2: Neoadjuvant MK-3475|-MK-3475 will be given once intravenously and then given again 21 days after dose 1 (14-24 days before standard of care surgery
3039593|NCT02296671|Experimental|PEMOX|"Pemetrexed will be given intravenously (IV) on an outpatient basis on Day 1 of each 14-day cycle over 10 minutes. Oxaliplatin will be given (IV) on an outpatient basis on Day 1 of each 14-day cycle at a dose over 120 minutes. Drugs may be given in either order.~-Oxaliplatin will be administered on Day 2 for Cycle 1 only. **"
3039594|NCT02296671|Experimental|FOLFOX|"The modified FOLFOX-6 regimen is the following drugs given every 14 days:~Oxaliplatin on Day 1 of each cycle~Leucovorin over 120 minutes on Day 1 of each cycle~5-FU bolus and continuous infusion over 46 hours beginning on Day 1 of each cycle~Oxaliplatin will be administered on Day 2 for Cycle 1 only and the 5-FU infusion will be interrupted at 20 hours so that the FLT-PET scan can be performed (only for FLT-PET scan eligible patients)."
3039595|NCT02296658|Experimental|S-1 based chemoradiotherapy|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with intensity-modulated radiotherapy in a standard manner.
3039596|NCT02296645|Experimental|ZuraPrep|Isopropyl alcohol (IPA) (70%)
3039597|NCT02296645|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
3039598|NCT02296619|Experimental|TAP Block|Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
3039599|NCT02296619|Sham Comparator|Control|A sham band-aid will be applied to the abdomen of subjects who are randomized to the no intervention group.
3039600|NCT02296580|Experimental|Nativis Voyager RFE Therapy|Subjects will be treated with Nativis Voyager therapy until tumor progression.
3039601|NCT02296567|Active Comparator|Group 1 Lucentis 4 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
3039602|NCT02296567|Active Comparator|Group 2 Avastin 4 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
3039603|NCT02296567|Active Comparator|Group 3 Eylea 4 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
3039604|NCT02296567|Active Comparator|Group 4 Lucentis 6 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
3039605|NCT02296567|Active Comparator|Group 5 Avastin 6 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
3039606|NCT02296567|Active Comparator|Group 6 Eylea 6 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
3039607|NCT02296567|Active Comparator|Group 7 Lucentis 8 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
3039608|NCT02296567|Active Comparator|Group 8 Avastin 8 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
3039609|NCT02296567|Active Comparator|Group 9 Eylea 8 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
3039610|NCT02296567|Active Comparator|Group 10 Control Group no treatment|Blood samples will be collected from patients who are not receiving anti-VEGF treatment.
3039611|NCT02296554|Experimental|SLAP Repair|Patient will receive SLAP repair for their SLAP tear.
3039612|NCT02296554|Experimental|Biceps Tenodesis Repair|Patient will receive biceps tenodesis repair for their SLAP tear.
3039613|NCT02296541|Experimental|Group 1: DNA Nat-B env and MVA-CMDR|Participants will receive a single injection of DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
3039614|NCT02296541|Placebo Comparator|Group 1: Placebo vaccines for DNA Nat-B env and MVA-CMDR|Participants will receive a single injection of placebo for DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
3039615|NCT02296541|Experimental|Group 2: DNA CON-S env and MVA-CMDR|Participants will receive a single injection of DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
3039616|NCT02296541|Placebo Comparator|Group 2: Placebo vaccines for DNA CON-S env and MVA-CMDR|Participants will receive a single injection of placebo for DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
3064570|NCT02131077|Placebo Comparator|Placebo|Saline injection
3039617|NCT02296541|Experimental|Group 3: DNA Mosaic env and MVA-CMDR|Participants will receive a single injection of DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
3039618|NCT02296541|Placebo Comparator|Group 3: Placebo vaccines for DNA Mosaic env and MVA-CMDR|Participants will receive a single injection of placebo for DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
3039619|NCT02296528|Other|Swallowing Expansion Device|Titanium swallowing expansion device
3039620|NCT02296502||Autism Spectrum Disorder|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD.
3039621|NCT02296502||Non-Autism Spectrum Disorder|All children and adolescents seen for autism diagnostic evaluations at the study sties who do not meet diagnostic criteria for ASD.
3039622|NCT02296489||Healthy volunteers|
3039623|NCT02296489||Asthma patients|
3039624|NCT02296476|Experimental|MK-8628 80 mg|Participants received 80 mg of oral MK-8628 administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
3039625|NCT02296476|Experimental|MK-8628 120 mg|Participants received 120 mg of oral MK-8628 administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
3039626|NCT02296476|Experimental|MK-8628 160 mg|Participants received 160 mg of oral MK-8628 administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
3039627|NCT02296463|Experimental|Treatment Group A|Day 0: RSV F Vaccine with adjuvant, Day 28: RSV F Vaccine with adjuvant
3039628|NCT02296463|Experimental|Treatment Group B|Day 0: RSV F Vaccine with adjuvant, Day 28: Hepatitis A Vaccine
3039629|NCT02296463|Experimental|Treatment Group C|Day 0: RSV F Vaccine, Day 28: RSV F Vaccine
3039630|NCT02296463|Experimental|Treatment Group D|Day 0: RSV F Vaccine, Day 28: Hepatitis A Vaccine
3039631|NCT02296463|Placebo Comparator|Treatment Group E|Day 0: Placebo, Day 28: Hepatitis A Vaccine
3039632|NCT02296450||Quality of Life (QoL) Assessment|Patients involved in this study will have a wide range of dermatologic conditions for which they will be assessed and managed by the treating physician. An appropriate QoL instrument will be administered at the initial visit, and if applicable, at subsequent follow-up visit(s). Treatment of the dermatologic condition will be at physician's discretion based on the patient's presenting symptoms and is not an intervention itself within this study.
3039633|NCT02296437|Experimental|tDCS + CT|
3039634|NCT02296424|Experimental|Canakinumab Dose Reduction|All patients will receive canakinumab 4mg/kg (300 mg max) every 4 weeks in Part I of the study. Patients eligible for Part II of the study will be randomized to one of two treatment arms. This is Treatment Arm 1 in Part II of the study: Canakinumab will be administered at a reduced dose (2 mg/kg every 4 weeks). If the patient continues to maintain inactive disease for 24 additional weeks, canakinumab will be administered at 1mg/kg every 4 weeks. If the patient continues to maintain inactive disease for another 24 additional weeks, canakinumab treatment will be discontinued.
3039635|NCT02296424|Experimental|Canakinumab Dose Interval Prolongation|All patients will receive canakinumab 4mg/kg (300 mg max) every 4 weeks in Part I of the study. Patients eligible for Part II of the study will be randomized to one of two treatment arms. This is Treatment Arm 2 in Part II of the study: Canakinumab dose interval will be prolonged to a regimen of 4mg/kg every 8 weeks. If the patient continues to be stable with inactive disease for 24 additional weeks, canakinumab dose interval is prolonged to a regimen of 4mg/kg every 12 weeks. If the patient is clinically stable with inactive disease for another 24 additional weeks, canakinumab treatment will be discontinued.
3039636|NCT02296411|Experimental|CHF 5259 12.5 µg|CHF 5259 12.5 µg: 2 inhalations bid (50µg daily dose)
3039637|NCT02296411|Placebo Comparator|CHF 5259 placebo|CHF 5259 placebo: 2 inhalations bid
3039638|NCT02296398||Romidepsin therapy|Patients who received romidepsin per standard of care practice or included in other clinical trials (when receiving romidepsin therapy).
3039639|NCT02296385|Experimental|Supplementation|Supplementation
3039640|NCT02296372|Other|SOFA <7|"Critically ill patients with a Sequential Organ Failure Assessment (SOFA) score < 7 at first day of measurement.~Intervention: Measuring continuous glucose monitoring."
3039641|NCT02296372|Other|SOFA >7|"Critically ill patients with a Sequential Organ Failure Assessment (SOFA) score > 7 at first day of measurement.~Intervention: Measuring continuous glucose monitoring."
3039642|NCT02296359||Asthma Discordant Monozygotic Twins|This is a group where one of the monozygotic twins has asthma and the other is non-asthmatic. Influenza Vaccination will be performed for both cohorts.
3039643|NCT02296359||Non-Asthma Concordant Monozygotic Twins|This is a group where both of the monozygotic twins are non-asthmatic. Influenza Vaccination will be performed for both cohorts.
3039644|NCT02296346|Active Comparator|Corticosteriod arm|Patients will receive 1 gram of IV SoluMedrol over 1 hour, once every month for 12 months.
3039645|NCT02296346|Experimental|Extracorporeal Photopheresis|"Patient will receive an Extracorporeal Photopheresis treatment at a set frequency over the course of 1 year. The treatment takes about 2-3 hours per session to complete. The treatment schedule is as follows:~ECP will be administered according to the following schedule:~Study Arm: Weeks 1-8: 3 times per week Weeks 9-16: Twice per week Weeks 17-36: Treatment on two consecutive days every 2 weeks (or optionally, one treatment per week) Weeks 37-43: Once every 2 weeks Weeks 44-52: Once every 4 Weeks"
3039646|NCT02296333|Active Comparator|ondansetron|ondansetron iv, 8 mg, skin closure time
3039647|NCT02296333|Placebo Comparator|isotonic|isotonic 2ml, once, skin closure time
3039648|NCT02296320|Active Comparator|MEDI4893 high dose|
3039649|NCT02296320|Placebo Comparator|Placebo|
3039650|NCT02296307||DOvEE Participants|"All symptomatic women who are eligible for participation in the DOvEE trial receive the same interventions:~Blood test: CA-125 biomarker at day 1 and week 6. Second Test: Transvaginal Ultrasound at day 1. Follow-up Phone Call: Confirms continuing health 6 months after last visit."
3039651|NCT02296294|Active Comparator|Fluid Therapy|"Intravenous isotonic fluid therapy of Elo-mel® (Fresenius Kabi Austria) at a rate of 0,50ml/kg/min for one hour.~Body Composition Monitoring every 10 minutes for 6hours."
3039652|NCT02296294|Placebo Comparator|Zero Therapy|Body Composition Monitoring every 10 minutes for 6hours. No intravenous fluid therapy
3039653|NCT02296281|Experimental|treatment group|
3039861|NCT02294682|Experimental|GSK2140944 1500 mg|Subjects will receive single oral dose of GSK2140944 1500 mg.
3039654|NCT02296268||Pre-Clinic Stroke Group|In- or out-patients with diagnosis of ischemic or hemorrhagic stroke who have been referred to the NSRC prior to the establishment of the Clinic and are willing/able to provide written informed consent and have no contraindications to exercise testing. Utilization of aerobic exercise will be monitored during their physiotherapy sessions (Aim 3).
3039655|NCT02296268||Post-Clinic Stroke Group|In- or out-patients with diagnosis of ischemic or hemorrhagic stroke who have been referred to the NSRC after the establishment of the Clinic and are willing/able to provide written informed consent and have no contraindications to exercise testing. Each patient will undergo an assessment in the Aerobics Clinic and will receive a prescription for aerobic training based on the assessment findings. Utilization of aerobic exercise will be monitored during their physiotherapy sessions (Aim 3).
3039656|NCT02296268||Stroke Rehabilitation Physiotherapists|Physiotherapists whose current practice involves working full-time or part-time on in- or out-patient stroke service at the NSRC. Their self-efficacy regarding the clinical utilization of aerobic exercise post-stroke will be conducted prior to, and after, implementation of the Aerobics Clinic.
3039657|NCT02296255|No Intervention|no HPV vaccine|No delivery of HPV vaccine
3039658|NCT02296255|Experimental|HPV vaccine (Cervarix®, GlaxoSmithKline)|Delivery of HPV vaccine (Cervarix®, GlaxoSmithKline) at 0, 1, 6 months
3039659|NCT02296242|Experimental|BVD-523|
3039660|NCT02296229|Experimental|Treatment (SBRT)|Patients undergo SBRT daily or every other day for a total of 5 fraction not exceeding 14 consecutive days. Patients may also receive androgen deprivation therapy for up to 9 months at the discretion of the treating physician.
3039661|NCT02296216|Active Comparator|Exposed patients|Exposed patients have been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion
3039662|NCT02296216|Placebo Comparator|Unexposed patients|Unexposed patients have not been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion
3039663|NCT02296203|Experimental|cetuximab and irinotecan|
3039664|NCT02296190|Experimental|Etripamil|1 dose of Etripamil via 4 intranasal applications at time 0 (140 mg, 105 mg, 70 mg, or 35 mg)
3039665|NCT02296190|Placebo Comparator|Placebo|1 dose of water and disodium ethylenediaminetetraacetic acid solution via 4 intranasal applications at time 0
3039666|NCT02296177|No Intervention|Control|The control group will receive the standard practice of care related to mammography phone call reminders. If a clinic currently conducts reminders, they will receive that standard call. If no reminders are done, then they will not receive a call during the control period.
3039667|NCT02296177|Active Comparator|Intervention|The intervention group will receive a reminder call about their upcoming appointment that assesses their intent to attend the appointment and counsels them through barriers to attendance. The call is conducted by a trained patient navigator using an adapted NCI RTIP to increase mammography appointment adherence.
3039668|NCT02296164||MF-CTCL Patients receiving Valchlor|Patients will undergo clinical assessments and receive standard medical care, as determined by the patients' physician, in the real world setting. With the exception of protocol-required patient completed questionnaires for symptoms and Quality Of Life.
3039669|NCT02296151|Placebo Comparator|Group A|Four iliotibial band stretches; to be completed 3 days per week.
3039670|NCT02296151|Active Comparator|Group B|Four conventional hip exercises (Hip abductor, gluteus medius strengthening); to be completed 3 days per week.
3039671|NCT02296151|Experimental|Group C|Four conventional hip exercises progressed during the 8-weeks, totalling 16 exercises over the 8-week period (Hip abductor, gluteus medius strengthening). Exercises to be completed 3 days per week.
3039672|NCT02296138|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
3039673|NCT02296138|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
3039674|NCT02296125|Experimental|AZD9291+ placebo|AZD9291 (80 mg or 40 mg orally, once daily) plus placebo Erlotinib (150mg or 100mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
3039675|NCT02296125|Active Comparator|Standard of Care + placebo AZD9291|"Erlotinib (150 mg or 100 mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily) plus placebo AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomisation schedule.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
3039676|NCT02296112|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3039677|NCT02296099|Experimental|Liposomal Bupivacaine|The placement of the retropublic sling will be placed in routine fashion under general anesthesia. If randomized to liposomal bupivacaine, the standard 20 milliliter (ml) vial (266mg dose) will be diluted with 10ml of preservative-free, sterile normal saline (0.9%) for injection to a reconstituted volume of 30ml. At the completion of the procedure, and at least 20 minutes after the injection of 30ml lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have the 30ml dilutional volume injected. 10ml will be injected into the vaginal epithelium in the mid-urethral area and 10ml will be injected into each of the trocar paths through the suprapubic incisions bilaterally. An aspiration and moving needle technique will be employed.
3039678|NCT02296099|Placebo Comparator|Saline Placebo|The placement of the retropublic sling will be placed in routine fashion under general anesthesia. At the completion of the procedure, and at least 20 minutes after the injection of 30ml lidocaine with epinephrine (routine for the surgical procedure), those subjects in the saline placebo arm will receive 30ml normal saline injected. 10ml will be injected into the vaginal epithelium in the mid-urethral area and 10ml will be injected into each of the trocar paths through the suprapubic incisions bilaterally. An aspiration and moving needle technique will be employed.
3039679|NCT02296086||Group I|"Study sites in which patients perform early mobilization as per local standard of care, which is as follows:~2 days (at the latest) after surgery: Transfer from the bed to a sitting chair for the first time~4 (± 2) days after surgery: Stand up and put both feet on the ground for the first time (walking aids allowed)~5 (± 2) days after surgery: Walking (at least partial weight bearing, walking aids allowed)~The patients are instructed by the investigator at the hospital about a standardized mobilization program to be followed at home"
3065637|NCT02123875|Other|Control arm|Routine hospital based physiotherapy
3039680|NCT02296086||Group II|Study sites in which patients start walking (i.e. partial weight bearing, walking aids allowed) more than 7 days after surgery as per local standard of care
3039681|NCT02296073|Experimental|Midazolam|midazolam 3～5μg/kg•min for maintenance of sedation.
3039682|NCT02296073|Experimental|Dexmedetomidine1|Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
3039683|NCT02296073|Experimental|Dexmedetomidine2|Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
3039684|NCT02296073|Experimental|Dexmedetomiding3|Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
3039685|NCT02296060|Experimental|6 minutes walking test|
3039686|NCT02296047|Experimental|Group A|The medication order: subjects inhaled placebo,ipratropium bromide 80μg, salbutamol 400μg in sequence.
3039687|NCT02296047|Experimental|Group B|The medication order: subjects inhaled placebo, salbutamol 400μg, ipratropium 80μg in sequence.
3039688|NCT02296021|Experimental|berberine quadruple therapy|Berberine 500 mg, esomeprazole 20 mg,amoxicillin 1000 mg, and clarithromycin 500 mg by mouth, twice daily for 14 days.
3039689|NCT02296021|Active Comparator|bismuth quadruple therapy|Bismuth 220 mg, esomeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
3039690|NCT02296008|Other|surgery for Hirschsprung's disease|children after surgery for Hirschsprung's disease will undergo 3D high resolution anorectal manometry procedure
3039691|NCT02296008|Other|surgery for anorectal malformation|children after surgery for anorectal malformation will undergo 3D high resolution anorectal manometry procedure
3039692|NCT02296008|Other|surgery for other disorders|children after surgery for other disorders will undergo 3D high resolution anorectal manometry procedure
3039693|NCT02295995|Experimental|Physical Activity|Participants randomized to this arm will be enrolled in a 12-week physical activity program.
3039694|NCT02295995|No Intervention|Usual Care Wait-List|Participants randomized to this arm will continue to receive usual care services for PTSD through the VHA for 12 weeks after which time they will be offered the physical activity program for 12 weeks.
3039695|NCT02295982|Placebo Comparator|Laparoscopic nephrectomy|Patient with renal cell carcenoma will undergo laparoscopic nephrectomy within standarized technique
3039696|NCT02295982|Active Comparator|Hand assisted laparoscopic nephrectomy|Patient with renal cell carcenoma will undergo hand assisted laparoscopic nephrectomy
3039697|NCT02295956|Experimental|Home Based Exercise and Nutrition Program|Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete. Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Exercise instructional booklet given to all participants describing all exercises. Participants to walk 20-30 minutes at least 3 times a week. Nutrition program discussed with participants. Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.
3039698|NCT02295943|Other|Positioning measuring device|The supine time during the first postoperative day is measured
3039699|NCT02295930|Experimental|folfoxiri+cetuximab+surgery+cetuximab|"Induction FOLFOXIRI plus cetuximab will consist of:~CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by~IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~l-LV 200 mg/sqm IV over 2-h, day 1 followed by~5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
3039700|NCT02295930|Experimental|folfoxiri+cetuximab+surgery+bevacizumab|"Induction FOLFOXIRI plus cetuximab will consist of:~CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by~IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~l-LV 200 mg/sqm IV over 2-h, day 1 followed by~5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
3039701|NCT02295891|Experimental|MiraDry ® treatment|"MiraDry ® is the trademarked name of a non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface.~Each participant will be scheduled two MiraDry ® treatment appointments approximately three months apart."
3039702|NCT02295878|Active Comparator|Treatment|400mg capsule containing seaweed extract (treatment)
3039703|NCT02295878|Placebo Comparator|Placebo|400mg capsule containing maltodextrin (placebo)
3039704|NCT02295865|Experimental|JNJ-38518168 60 mg|Participants will receive two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, together with one 30 mg matching placebo tablet and one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
3039705|NCT02295865|Experimental|JNJ-38518168 30 mg|Participants will receive one tablet of JNJ-38518168, 30 mg, together with two 30 mg matching placebo tablets and one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
3039706|NCT02295865|Experimental|JNJ-38518168 3 mg|Participants will receive one tablet of JNJ-38518168, 3 mg, together with three 30 mg matching placebo tablets, orally, once daily, for 12 Weeks.
3039707|NCT02295865|Experimental|Placebo|Participants will receive three tablets of JNJ-38518168, 30 mg matching placebo, together with one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
3039708|NCT02295852|Experimental|Group A: LOW-SODIUM LOW LIPID CALCIUM RICH DIET|Experimental Group A: patients will change their diet in a diet similar for total daily calories, sodium and macronutrients but enriched in calcium (1200 mg/daily) and will be followed up to 1 year with an intermediate control after the first 3 months;
3039709|NCT02295852|Active Comparator|Group B: LOW-SODIUM LOW LIPID DIET|Experimental Group B: patients will continue the low-lipid, low-sodium diet up to 1 year with an intermediate control after the first 3 months.
3039710|NCT02295839|No Intervention|Usual care|
3039711|NCT02295839|Experimental|Sleep Hygiene and Relaxation Education|
3040696|NCT02289287|Active Comparator|Standard Care|Participants will receive Standard Care only
3039712|NCT02295826|Experimental|Dabigatran therapy|150 mg BID for 30 days (dose modification - reduced to 110mg BID in patients >80 years of age and/or an eGFR of 30-50 ml/min)
3039713|NCT02295826|Active Comparator|Acetylsalicylic Acid thereapy|325 mg loading dose then 81 mg/day for 30 days
3039714|NCT02295813|Experimental|FBF001|"FBF001 must be administered by intravenous route during 1 hour. The dose must be calculated according to the body weight of the subject and diluted in sodium chloride 0.9%.~FBF001 is administered once during 1 day or once per day during 5 days."
3039715|NCT02295813|Placebo Comparator|Placebo|The placebo must be administered by intravenous route during 1 hour. It administered once during 1 day or once per day during 5 days.
3039716|NCT02295800||Mothers|HIV Infected mothers
3039717|NCT02295800||Infants|HIV exposed infants
3039718|NCT02295800||Healthcare workers|Facility based healthcare workers
3039719|NCT02295787|Experimental|Ketamine|Intranasal Ketamine 50mg administered six times over three weeks.
3039720|NCT02295787|Placebo Comparator|Placebo|Intranasal saline solution administered six times over three weeks.
3039721|NCT02295774|Placebo Comparator|Group A|Biopsy samples collected during standard white light colonoscopy.
3039722|NCT02295774|Active Comparator|Group B|Subjects who have had samples collected during a Group A colonoscopy, who require a second colonoscopy within 2 weeks. Prior to this second colonoscopy the subjects take Methylene Blue MMX tablets. Biopsies collected are compared to their previous group A colonoscopy for histone gamma H2AX activity.
3039723|NCT02295761|Active Comparator|Lifestyle counseling|12-weeks
3039724|NCT02295761|Active Comparator|Lifestyle counseling + activity watch|12-weeks
3039725|NCT02295748|Experimental|Deflazacort|0.9 mg/kg oral deflazacort (between 2 to 12 x 6mg tablets based on body weight) will be administered daily.
3039726|NCT02295735|Experimental|Mepilex® Border|If a patient is assigned to the intervention group the dressings Mepilex® Border Sacrum and Mepilex® Border Heel will be applied onto the respective intact skin areas in addition to standard pressure ulcer prevention
3039727|NCT02295735|No Intervention|Control|Standard pressure ulcer prevention according to hospital standard
3039728|NCT02295722|Experimental|Gemcitabine/Melphalan Condition + ASCT|"Day -1 -~IV gemcitabine 1.5-2.5 g/m2 (depending on dose level assigned) administered as a loading bolus of 75 mg/m2, followed by a continuous infusion of 10 mg/m2/min.~immediately following gemcitabine - IV melphalan 200 mg/m2 over 5 minutes.~Day 0~•Stem cell infusion~Patients will be assigned a dose level using the continual reassessment method based on the toxicity data available at the time of their enrollment. The dosing will start at 1.5 g/m2 and will increase by 0.5 mg/m2 at each level to a maximum of 2.5 g/m2. Dose-limiting toxicity is defined as grade 3 mucositis or skin toxicity lasting more than 3 days before downgrading, or any grade 4 non-hematological toxicity."
3039729|NCT02295709|Experimental|USNR steroid injection|the patient who are treated with steroid (dexamethasone) injection through selected cervical spinal nerve block approach guided by ultrasound and C arm.
3039730|NCT02295709|Experimental|UCTF steroid injection|the patients who are treated with steroid (dexamethasone) injection through cervical transforaminal approach guided by ultrasound and C arm.
3039731|NCT02295709|Experimental|XCTF steroid injection|the patients who are treated with steroid (dexamethasone) injection through cervical transforaminal approach guided only by C arm.
3039732|NCT02295696|Experimental|Intervention group|Intervention arm : EMMA consultations
3039733|NCT02295696|No Intervention|Control group|Control arm: Usual care/consultations
3039734|NCT02295670|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
3039735|NCT02295670|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3039736|NCT02295657|Experimental|ETI intubation|endotracheal intubation in manikin
3039737|NCT02295644|Experimental|A: 0.4 Watts/Sq cm 50% Duty cycle|0.4 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 (MegaHertz) MHz, 5 minutes
3039738|NCT02295644|Experimental|B: 0.4 Watts/Sq cm 100% Duty cycle|0.4 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
3039739|NCT02295644|Experimental|C: 0.8 Watts/Sq cm 50% Duty cycle|0.8 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
3039740|NCT02295644|Experimental|D: 0.8 Watts/Sq cm 100% Duty cycle|0.8 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
3039741|NCT02295631|Experimental|ETI during immobilized spine (oral intubation)|intubation with immobilized cervical spine endotracheal intubation with immobilized cervical spine
3039742|NCT02295631|Experimental|ETI during immobilized spine (nasal intubation)|intubation with immobilized cervical spine endotracheal intubation with immobilized cervical spine
3039743|NCT02295618|Experimental|ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3039744|NCT02295618|Experimental|ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
3039745|NCT02295605|Experimental|Land-based exercises|Land-based muscle strengthening exercises protocol
3039746|NCT02295605|Experimental|Water-based exercises|Water-based muscle strengthening exercises protocol
3039747|NCT02295592|Experimental|group A( TSTstarr+ group)|"TSTstarr+ is a kind of modified STARR（stapled transanal rectal resection ） operation, compared to the traditional STARR operation, it does not need two staplers but with a larger diameter stapler,  + means better . Patients in group A with severe prolapsed hemorrhoids will undergo TSTstarr+ operation ."
3039748|NCT02295592|Active Comparator|group B ( PPH group)|PPH is short fo procedure for prolapsed hemorrhoids .Patients in group B with severe prolapsed hemorrhoids will undergo PPH operation.
3039749|NCT02295566|Active Comparator|Nitric Oxide Group|Inhaled Nitric Oxide delivered via nasal canulae at 10ppm for 8 hours a night for 7 nights.
3039750|NCT02295566|Placebo Comparator|Control Group|Air/oxygen mix (according to clinical need) delivered via nasal canulae for 8 hours a night for 7 nights.
3039751|NCT02295553|Experimental|Ketamine 0 mg/kg|Ketamine dose will be 0 mg/kg. Propofol dose for the first patient will be 4 mg/kg. Doses for the subsequent patients will increase or decrease by 1.6 mg/kg using the Dixon Up and Down method.
3039752|NCT02295553|Experimental|Ketamine 0.25 mg/kg|Ketamine dose will be 0.25 mg/kg. Propofol dose for the first patient will be 3 mg/kg. Doses for the subsequent patients will increase or decrease by 1.2 mg/kg using the Dixon Up and Down method.
3039753|NCT02295553|Experimental|Ketamine 0.5 mg/kg|Ketamine dose will be 0.5 mg/kg. Propofol dose for the first patient will be 2.5 mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
3039754|NCT02295553|Experimental|Ketamine 1.0 mg/kg|Ketamine dose will be 1.0 mg/kg. Propofol dose for the first patient will be 2 mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.
3039755|NCT02295540|Experimental|Treatment (hypofractionated IMRT, surgery)|Patients undergo hypofractionated IMRT every other day for up to 5 treatments. Patients then undergo surgery 7-14 days after the last radiation treatment.
3039756|NCT02295527|Experimental|Home-based physical exercise|Participants randomized to the Intervention Group (IG) will be submitted to a physical exercise program involving a progressive and challenging balance training and a neuromuscular and functional training of the lower limbs, conducted at home by physiotherapists, once a week, lasting about one hour, in the first, second and third month after randomization and will be oriented to perform exercises, twice a week, through a booklet. Visits to follow up exercises progression will be conducted once a month, from de fourth to the sixth month and each two months until the end of the follow up at the 12th month, summing up 18 sessions. Participants will receive monthly phone calls to increase exercise adherence.
3039757|NCT02295527|Other|Control Group Usual Care|This group will receive usual care and the booklet regarding bone health information.
3039758|NCT02295514|Experimental|PTP1B dosage|PTP1B dosage during sepsis
3039759|NCT02295501|Experimental|EBOV convalescent donors|EBOV convalescent donors for passive immune therapy in subjects with acute EVD
3039760|NCT02295488|Experimental|Desensitization|Blood intake for biological sampling during validated desensitization protocol (Alyostall®)
3039761|NCT02295475|Experimental|Apixaban|Subjects will receive apixaban 5 mg tablets taken twice daily for the duration of the study.
3039762|NCT02295475|Active Comparator|Warfarin|Subjects will receive warfarin for the duration of the study. The dose and how frequently warfarin is taken depends on the results of the patient's INR blood test(s). The target INR range for this study is 2-3.
3039763|NCT02295462|Experimental|Person-centered Care|Medication Review + Person-centered Care
3039764|NCT02295462|Active Comparator|Optimised Treatment|Medication Review
3039765|NCT02295449|Experimental|1|
3039766|NCT02295436|Experimental|1-mg group|Twelve healthy young subjects were administered a single oral dose of 1 mg minodronic acid tablets at day 1 and then received repeated oral doses of minodronic acid (1 mg) once daily for 7 days (day 3 to day 9).
3039767|NCT02295436|Experimental|2-mg group|Twelve healthy young subjects were administered a single oral dose of 2 mg minodronic acid tablets.
3039768|NCT02295436|Experimental|4-mg group|Twelve healthy young subjects were administered a single oral dose of 4 mg minodronic acid tablets under fasting state at period 1.After a washout period of 8 days, they received the same dosage under fed conditions (administrated 30 minutes before high-fat breakfast).
3039769|NCT02295436|Experimental|1-mg elderly group|Twelve healthy elderly subjects were administered a single oral dose of 1 mg minodronic acid tablets.
3039770|NCT02295410||Engaged in Home-Based CPT|Home-Based Telemental Health-Patients undergoing Home-Based CPT for PTSD
3039771|NCT02295410||Comparison|Treatment as Usual (TAU) Patients NOT receiving regular CPT or other evidence-based therapy for PTSD.
3039772|NCT02295397|Experimental|food provocation|open and placebo-controlled food challenges
3039773|NCT02295384||Audit Group|"Patients attending HHMP in Darlinghurst, Sydney, New South Wales with documented HIV-1 infection from 1st January 2005 to 31st July 2014, who were considered linked to care (Attendance during the study period for at least 2 visits >3 months and <12 months apart with measured laboratory virological or immunological markers (either on-site or at a co-management site))."
3039774|NCT02295371||Patients with an incident|Patients undergoing a safety incident while being treated with drugs
3039775|NCT02295345|Experimental|CBT for Insomnia|Participants attend 5 weekly sessions of Cognitive Behavioural Therapy for Insomnia for pregnant women, administered by licensed clinical psychologist.
3039776|NCT02295332|Experimental|Cohort A|
3039777|NCT02295332|Experimental|Cohort B|
3039778|NCT02295319|Experimental|Individual discharge|Discharge based on the patients individual needs and conditions. The discharge focus on information, communication, follow-up plans and collaboration, as well as the patients understanding and accept of the discharge plan. In addition, it includes a telephone interview 2 days after discharge to home.
3039779|NCT02295319|No Intervention|Control|Usual discharge procedures
3039780|NCT02295293|Experimental|Rhus|500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
3039781|NCT02295293|Placebo Comparator|Placebo|Placebo capsule: 1 capsule twice daily for 6 weeks
3039782|NCT02295280|Active Comparator|Metoclopramide IV & Diphenhydramine IV|Intravenous (IV) access will be obtained and administration of 10mg Metoclopramide IV and 25mg Diphenhydramine IV Group A
3039783|NCT02295280|Active Comparator|Codeine|Group B (control group) will receive standard treatment consisting of a codeine 30mg tablet.
3039784|NCT02295267|Experimental|walnut allergy provocation|inclusion of walnut allergic patients, food provocation with walnut
3039785|NCT02295254||Research group|The study contain only one group: travelers who intended to travel to tropical destinations. The participants will give a feces sample before and after the travel.
3039786|NCT02295228||Adults undergoing total hip arthroplasty|No intervention will be administered, this is an observational trial. The study population includes adults 50+ who are undergoing elective total hip arthroplasty for osteoarthritis.
3039787|NCT02295215|No Intervention|Sedentary Group|The patients will not do exercise training
3039788|NCT02295215|Experimental|Trained Group|The patients will do exercise training for sixteen weeks.
3039791|NCT02295189|Active Comparator|Visual analogue scale|visual analogue scale versus triamcinolone acetonide visual analogue scale versus ketorolac tromethamine
3039792|NCT02295189|Active Comparator|Treatment|visual analogue scale versus triamcinolone acetonide visual analogue scale versus ketorolac tromethamine
3039793|NCT02295176|Experimental|Armolipid Plus|Armolipid Plus: 1 tablet daily in the evening after dinner for 24 weeks.
3039794|NCT02295176|Placebo Comparator|Placebo|1 tablet matching Armolipid Plus daily in the evening after dinner for 24 weeks
3039795|NCT02295163|Sham Comparator|Sham procedure|injection of NACL 0,9% in the stellate ganglion
3039796|NCT02295163|Experimental|Stellate ganglion block|injection of Bupivacaine 0,5% in the stellate ganglion
3039797|NCT02295150|Experimental|Nadroparin|patients above 140 kg will receive a dose of 2850 IU nadroparine pre-operatively, anti-Xa factor will be determined 3 days after nadroparin use. After surgery patients receive 5700 IU nadroparin (our standard treatment). Three days after surgery and 4 weeks after surgery anti-Xa factor will be measured again.
3039798|NCT02295137|Experimental|pre-procedure image guidance|
3039799|NCT02295124|Active Comparator|Oxycodone|Patients will be prescribed oxycodone 10mg (5mg if > age 65) every 2 hours as needed for post-operative pain management in addition to tylenol 1000mg every 6 hours and celecoxib 200mg every 12 hours.
3039800|NCT02295124|Active Comparator|Hydromorphone|Patients will be prescribed hydromorphone 2mg (1mg if > age 65) every 2 hours as needed in addition to tylenol 1000mg every 6 hours and celecoxib 200mg every 12 hours.
3039801|NCT02295111|Active Comparator|EA treatment and TCM health consult|Participants randomized to the EA treatment will receive 2 EA +TCM health consult once a week x 4 weeks (8 total)
3039802|NCT02295111|Experimental|TCM health consult|Participants randomized to TCM health consult will receive 2 TCM health consult once a week x 4 weeks ( 8 total)
3039803|NCT02295111|Active Comparator|Usual care|Participants randomized to usual care will continue with their usual care
3039804|NCT02295098|Active Comparator|Thoracic epidural catheter|Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
3039805|NCT02295098|Active Comparator|Paracostal catheter|Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
3039806|NCT02295072|No Intervention|Control group|2 Usual Physical Education sessions/week
3039807|NCT02295072|Experimental|Intervention Group|A 5-months physical exercise-based program (3-5 Physical Education after school sessions/week + 2 Usual Physical Education sessions/week)
3039808|NCT02295059|Experimental|Omega 3 fatty acids - high dose|~5 g EPA+DHA in 5 capsules per day
3039809|NCT02295059|Experimental|Omega 3 fatty acids - low dose|~0.9 g EPA+DHA + fatty acids based on the typical American diet in 5 capsules per day
3039810|NCT02295046|Experimental|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg of Dr. Reddys Laboratories Limited
3039811|NCT02295046|Active Comparator|Caduet|Caduet® 10/80 mg tablets of Pfizer, Ireland
3039812|NCT02295033|Experimental|Boost irradiation|
3039813|NCT02295033|No Intervention|No boost irradiation|
3039814|NCT02295020|Active Comparator|Standard Treatment Only|Group A will receive standard treatment only such as NSAIDs and injections
3039815|NCT02295020|Experimental|Standard Treatment plus Bioskin Ten-7|Group B will receive standard treatment such as NSAIDs and injections and the Bioskin Ten-7 knee brace.
3039816|NCT02295007|Other|text message|all families will receive text messages to which they can respond to report symptoms
3039817|NCT02294994|Experimental|half dose tirofiban|Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.075 µg per kilogram per minute for 24 to 36 hours.UFH heparin was administered as a bolus of 100 U/kg before PCI.
3039818|NCT02294994|Active Comparator|recommended-dose Tirofiban|Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours. UFH heparin was administered as a bolus of 100 U/kg before PCI.
3039819|NCT02294994|Placebo Comparator|none tirofiban|Tirofiban was not administered ,UFH heparin was administered as a bolus of 100 U/kg before PCI.
3039820|NCT02294981|Active Comparator|Conventional Dosing|Patients psoriasis to be treated with Excimer laser phototherapy based on conventional dosing guidelines. These guidelines determine the starting dose based on plaque thickness and the skin type of the patient.
3039821|NCT02294981|Experimental|Plaque based dosing|Patients psoriasis to be treated with Excimer laser phototherapy based on psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
3039822|NCT02294968|Experimental|Family Startup|Family Startup plus usual pre- and postnatal care
3039823|NCT02294968|No Intervention|Control|Usual pre- and postnatal care
3039824|NCT02294955|Active Comparator|Catheterablation|Pulmonary vein isolation with Cryo-energy using a Arctic Front™ Cardiac CryoAblation Catheter or an irrigated radiofrequency ablation catheter, with an optional roof line.
3039825|NCT02294955|Active Comparator|Antiarrhythmic drug Class IC or III.|Serial testing of oral antiarrhythmic drugs; amiodarone 600 mg once daily 7-10 days, then 100-200 mg once daily; sotalol: 80-160 mg twice daily; flecainide 100 to 150 mg twice daily or entire dose as slow-release formula once daily; propafenone 300 mg twice daily; disopyramide 250-375mg twice daily, or dronedarone 400 mg twice Daily.
3039826|NCT02294942|Experimental|RANCAD 500mg|RANCAD 1 tab (500 mg) + Placebo 1 tab, twice daily.
3039827|NCT02294942|Experimental|RANCAD 1000mg|RANCAD 2 tabs (500 mg), twice daily
3039828|NCT02294942|Active Comparator|Placebo|2 tabs, twice daily
3039829|NCT02294929|Other|Atrial fibrillation ablation|Cryoballoon ablation for pulmonary vein isolation
3039830|NCT02294916|Experimental|Child ETI withoutchest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
3039831|NCT02294916|Experimental|Child ETI with chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3039833|NCT02294890||Fibrosis diathesis|"all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis.~This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis."
3039834|NCT02294890||No fibrosis diathesis|"all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis.~This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis."
3039835|NCT02294864|Experimental|Pulsed Radiofrequency|Pulsed Radiofrequency This group will receive one dose of intra-articular PRF in the affected knee using previous literature standards. This includes standard blood pressure monitoring, sterile preparation, and needle insertion of the PRF probe directed at the site of maximal pain. The RFG-3C Plus radiofrequency generator will be activated at 42C, pulse width 10ms, and 2Hz frequency for 15 min.
3039836|NCT02294864|Active Comparator|Physical Therapy|This group will receive standard of care outpatient physical therapy weekly for 3-4 weeks with therapist instructions to reduce knee pain.
3039837|NCT02294851|Experimental|Single Ascending dose cohorts|Single ascending dose escalation, safety, tolerability, PK, PD and immunogenicity study of BMS-986168 administered by an intravenous infusion in healthy subjects.
3039838|NCT02294851|Placebo Comparator|Placebo|BMS-986168 Placebo
3039839|NCT02294838|Experimental|MRI with parotid gland stimulation|All participants will have MRI imaging of the parotid gland with IV Gadovist pre and post parotid stimulation with lemon juice. 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered. Approximately three minutes after scan commencement, the salivary glands will be stimulated by orally administering a small portion (≈5 ml) of Citric acid.
3039840|NCT02294812|Active Comparator|Control, cognitive training|Participants in the control arm will receive cognitive training for cognitive abilities not affected by age-related hearing loss.
3039841|NCT02294812|Experimental|Experimental, cognitive training|Participants in the experimental arm will receive cognitive training for cognitive abilities affected by age-related hearing loss.
3039842|NCT02294812|Active Comparator|Active Control, crossword training|Participants in this group will undergo crossword puzzle training. The purpose of this group is control for any effects that may be due to engaging in cognitive training.
3039843|NCT02294799|Other|Intervention Group|TMD diagnosed sujects that will receive the mobilization treatment
3039844|NCT02294799|Placebo Comparator|Placebo Group|TMD diagnosed sujects that will receive the placebo treatment
3039845|NCT02294786|Experimental|Octreotide treatment|Subjects randomised to receive Octreotide will be administered with Octreotide (Sandostatin LAR™) 40mg 7 days before the start of treatment with Lapatinib and Capecitabine and again 28 days later. All subjects will receive treatment with Lapatinib 1250milligram (mg) once daily and Capecitabine 1000 milligram/square meter (mg/m^2) twice daily until disease progression. Lapatinib will be given every day; Capecitabine will be given in 3 week cycles of two weeks treatment followed by one week off treatment. SANDOSTATIN™ is a trademark of Novartis.
3039846|NCT02294786|Experimental|No Octreotide treatment|Subjects randomised to receive no octreotide, treatment with Lapatinib and Capecitabine will be initiated immediately following enrolment. All subjects will receive treatment with Lapatinib 1250mg once daily and Capecitabine 1000mg/m^2 twice daily until disease progression. Lapatinib will be given every day; Capecitabine will be given in 3 week cycles of two weeks treatment followed by one week off treatment
3039847|NCT02294773|Active Comparator|Day Of|This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day the home ovulation predictor kit first turns positive.
3039848|NCT02294773|Active Comparator|Day After|This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day after the home ovulation predictor kit first turns positive.
3039849|NCT02294760|Active Comparator|Subsensory, OFF, subsensory|The stimulator is set subsensory for the first 4 weeks (90% of sensory threshold), then turned OFF for the next 4 weeks and finally set subsensory for the last 4 weeks.
3039850|NCT02294760|Active Comparator|Subsensory, subsensory, OFF|The stimulator is set subsensory for the first 4 weeks (90% of sensory threshold), then set subsensory for another 4 weeks and finally turned OFF for the last 4 weeks.
3039851|NCT02294747|Active Comparator|SHS without TSP|Patients with AO 31 A2 trochanteric fractures operated with sliding hip screw without trochanteric stabilization plate.
3039852|NCT02294747|Active Comparator|SHS with TSP|Patients with AO 31 A2 trochanteric fractures operated with sliding hip screw with trochanteric stabilization plate.
3039853|NCT02294734|Experimental|GSK2269557 repeat dose|Participants will receive 2 inhalation of GSK2269557 dry powder once daily via DISKUS™ 'device' (DISKUS is a trademark of the GSK group of companies)
3039854|NCT02294734|Placebo Comparator|Matching placebo repeat dose|Participants will receive 2 inhalation matching placebo dry powder once daily via DISKUS 'device'
3039855|NCT02294721|Experimental|Without feedback|Participants compress the chest of the manikin without CPR feedback device
3039856|NCT02294721|Experimental|With feedback|Participants compress the chest of the manikin with CPR feedback device.
3039857|NCT02294708|Experimental|supine|postoperative postures: patients in this arm are assigned to adopt supine position for 24 hours after the surgery
3039858|NCT02294708|Experimental|temporal lateral|postoperative postures: patients in this arm are assigned to adopt temporal lateral position for 24 hours after the surgery
3039859|NCT02294695||Appropriate empiric antibiotic therapy|"Based on the microbiological results patients were grouped post hoc into appropriate and inappropriate groups by two independent experts (intensivist, infectologist) who were blinded for PCT."
3039860|NCT02294695||Inappropriate empiric antibiotic therapy|"Based on the microbiological results patients were grouped post hoc into appropriate and inappropriate groups by two independent experts (intensivist, infectologist) who were blinded for PCT."
3039864|NCT02294656|Experimental|RANIBIZUMAB|Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
3039865|NCT02294656|Active Comparator|TRIAMCINOLONE ACETONIDE|Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
3039866|NCT02294643|Active Comparator|aspirin, clopidogrel & sarpogrelate|the triple anti-platelet treatment group will receive aspirin 100mg, clopidogrel 75mg and sarpogrelate (Anplag®, Yuhan Corporation, Seoul, South Korea) 100mg twice daily
3039867|NCT02294643|Placebo Comparator|aspirin, clopidogrel & placebo|the dual anti-platelet group will receive aspirin 100mg and clopidogrel 75mg daily plus placebo twice daily
3039868|NCT02294630|Active Comparator|Surfactant Dose - 100|Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.
3039869|NCT02294630|Active Comparator|Surfactant Dose - 200|Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.
3039870|NCT02294617|Active Comparator|Nicotrol Inhaler|Subjects will use the Nicotine Inhaler for 3 days.
3039871|NCT02294617|Active Comparator|Electronic Cigarette|Subject will use the electronic cigarette for 3 days.
3039872|NCT02294604|Experimental|Group R|Waterless surgical hand rub formulation containing 61% ethyl alcochol, 1% chlorhexidine and moisturizers
3039873|NCT02294604|Active Comparator|Group I|Traditional scrub formation with 10 % povidone-iodine
3039874|NCT02294604|Active Comparator|Group C|Traditional scrub formation with 4% chlorhexidine
3039875|NCT02294591|Active Comparator|NAC group|Receiving N-acetylcysteine as add-on treatment
3039876|NCT02294591|Placebo Comparator|Placebo group|Receiving placebo as add-on treatment
3039877|NCT02294578||Lung Cancer|Patients with biopsy proven lung cancer
3039878|NCT02294578||Controls|Patients with lung lesions suspicious for the presence of cancer and with cancer excluded after further diagnostic study
3039879|NCT02294565|Other|VST-1001 & 99mTc-labeled sulfur colloid|"VST-1001 (with medical devices) and 99mTc-labeled sulfur colloid are used together during a SLNB procedure in a single subject. Both drugs are evaluated for lymphatic mapping and localization of lymph nodes. The current standard of care for lymphatic mapping and lymph node localization during a SLNB procedure is a combined-modality technique that employs both a radiotracer (99mTc-labeled sulfur colloid is the radiotracer used in this study) and a vital blue dye (a patient receives both drugs). In this study, the vital blue dye is replaced with VST-1001 and companion medical devices.~VST-1001 is excited by a medical device (blue-light LED illuminator) to fluoresce; the surgeon is wearing blue-light filtering eyewear to improve visualization of the relevant tissue structures."
3039880|NCT02294552|Experimental|Matched bone marrow graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv
3039881|NCT02294552|Experimental|Matched peripheral blood stem cells graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
3039882|NCT02294552|Experimental|Mismatched peripheral blood stem cells or bone marrow graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
3039883|NCT02294539|Experimental|Losartan 50mg/amlodipine 5mg|Once daily, 1T, PO medication
3039884|NCT02294539|Experimental|Losartan 100mg/amlodipine 5mg|Once daily, 1T, PO medication
3039885|NCT02294539|Active Comparator|Losartan50 mg/Hydrochlorothiazide12.5 mg|Once daily, 1T, PO medication
3039886|NCT02294539|Active Comparator|Losartan100 mg/Hydrochlorothiazide25 mg|Once daily, 1T, PO medication
3039887|NCT02294526|Experimental|Sardine diet|Subjects follow general dietary recommendations for diabetes including a fixed amount of sardine in daily meals (100g per day, 5 days a week) as part of their usual diet.
3039888|NCT02294526|No Intervention|Control diet|Subjects only follow general dietary recommendations for diabetes.
3039889|NCT02294513||AD_HI|This group will consist of participants with Alzheimer's disease who receive treatment (Standard audiologic rehabilitation (incl. HI)) immediately and are followed over a three-month intervention period.
3039890|NCT02294513||NC_HI|This group will consist of participants with normal cognition (i.e., no diagnosis of Alzheimer's disease) who receive treatment (Standard audiologic rehabilitation (incl. HI)) immediately and are followed over a three-month intervention period.
3039891|NCT02294487||Subjects|Individuals over 50 who are going to get the seasonal flu vaccine, pneumococcal, HIB, and/or meningococcal vaccination and either have multiple myeloma or do not have multiple myeloma.
3039892|NCT02294474|Experimental|SAR342434|SAR342434 100 Unit/mL (U/mL) before meals intake on top of once daily (QD) Insulin Glargine, up to Week 26.
3039893|NCT02294474|Active Comparator|Humalog|Humalog 100 U/mL before meals intake on top of QD Insulin Glargine, up to Week 26.
3039894|NCT02294461|Experimental|Enzalutamide|Participants received 160 mg of enzalutamide orally once a day until Prostate-Specific Antigen (PSA) progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
3039895|NCT02294461|Experimental|Placebo|Participants received matching placebo orally once a day until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
3039896|NCT02294448|Experimental|cohort 1|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China） in low dosage(3.75mg)
3039897|NCT02294448|Experimental|cohort 2|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China) in medial dosage(7.5mg)
3039898|NCT02294448|Experimental|cohort 3|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China）in high dosage(15mg)
3039899|NCT02294435|Experimental|Primary Study Arm|The TAAA Debranching Stent Graft System is comprised of two investigational devices including the thoracic bifurcation and the visceral manifold and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
3039900|NCT02294435|Experimental|Expanded Selection Arm|The expanded selection arm is for subjects not eligible for open repair or other endovascular options due to comorbidities or anatomical limitations and do not meet inclusion in the primary study arm.
3039901|NCT02294422|Experimental|2. LOR and aneroid manometer group|after inflating the endotracheal tube (ETT) cuff using a loss of resistance syringe (BD Epillor LOR), the LOR syringe is left attached to the pilot balloon and and any excess pressure will be passively released until the plunger stops drawing back.
3039902|NCT02294422|Placebo Comparator|1. PBP and aneroid manometer group|The anaesthesia care provider shall inflate the ETT cuff via the pilot balloon with small volumes of air as he/she 'feels ' for the pressures in the pilot balloon to a pressure he/she thinks is just enough. An aneroid manometer (VBM, Germany. Accurate in the range 0-120 cmH2O +-2 cmH2O) shall then be attached by the investigator and measurement of the pressure taken.
3039903|NCT02294409|Experimental|Cognitive-behavioral therapy (CBT)|Manualized group cognitive-behavioral therapy for social anxiety in first episode psychosis
3039904|NCT02294409|Active Comparator|Computer assisted Cognitive Remediation therapy (CACRT)|Group computer assisted cognitive remediation therapy
3039905|NCT02294396|Experimental|Solifenacin add-on group|Patients will receive orally 1 mirabegron 50 mg tablet once daily after breakfast + 1 solifenacin 5 mg tablet (may be increased to 2 tablets) once daily after breakfast.
3039906|NCT02294396|Experimental|Propiverine add-on group|Patients will receive orally 1 mirabegron 50 mg tablet once daily after breakfast + 1 propiverine 20 mg tablet once daily after breakfast (may be increased to 1 propiverine 20 mg tablet twice daily after breakfast and after dinner).
3039907|NCT02294396|Experimental|Imidafenacin add-on group|Patients will receive orally 1 mirabegron 50 mg tablet once daily after breakfast + 1 imidafenacin 0.1 mg tablet (may be increased to 2 tablets) twice daily after breakfast and after dinner.
3039908|NCT02294396|Experimental|Tolterodine add-on group|Patients will receive orally 1 mirabegron 50 mg tablet once daily after breakfast + 1 tolterodine 4 mg capsule once daily after breakfast (dose increase of tolterodine is not permitted).
3039909|NCT02294383||Pre/post surgery pelvic floor assessment|
3039910|NCT02294383||Conservative treatmen monitoring|
3039911|NCT02294383||Pelvic floor muscle contrictions|
3039912|NCT02294383||Imaging reproducibility|
3039913|NCT02294370||subjects at the early stages of diabetes|Subjects at the early stages of diabetes, individuals with impaired glucose tolerance (IGT, 2h plasma glucose during oral glucose tolerance test >7.8-11.1 mmol/l (n=50) or with type 2 diabetes (fasting plasma glucose > 7.0 mmol/l and/or 2h plasma glucose > 11.1 mmol/l on two occasions, or both criteria fulfilled in same oral glucose tolerance test while not pregnant, n=50) with short duration (<3 years)
3039914|NCT02294357|Experimental|Carfilzomib + Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration.
3039915|NCT02294357|Experimental|Carfilzomib + Prednisone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Prednisone (IV or PO) will be given prior to each carfilzomib administration.
3039916|NCT02294357|Experimental|Carfilzomib + Methylprednisolone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Methylprednisolone(IV or PO) will be given prior to each carfilzomib administration.
3039917|NCT02294357|Experimental|Carfilzomib+Lenalidomide+Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration. Lenalidomide will be given at the same dose and schedule as patient was receiving previously.
3039918|NCT02294357|Experimental|Carfilzomib+Pomalidomide+Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration. Pomalidomide will be given PO at 4mg daily on days 1-21 of a 28-day cycle
3039919|NCT02294344|Experimental|DFPP&CTX|double filtration plasmapheresis(DFPP) combined with intravenous cyclophosphamide (IV-CTX) pulse therapy in addition(DFPP&CTX)
3039920|NCT02294344|Active Comparator|cyclophosphamide|cyclophosphamide(CTX) pulse therapy
3039921|NCT02294331||Attain Performa™ LV Leads|Patients who meet all Inclusion criteria and no Exclusion criteria and are implanted with an Attain Performa™ LV lead.
3039922|NCT02294318|Active Comparator|Motivational Interviewing (MI)|Participants will engage in a 30-minute Motivational Interviewing session with the study counselor to discuss participant's drug and alcohol use, its implications for their health, and the possibility of drug and alcohol use reduction. This counseling session is intended to help people reduce their drug and alcohol use if they wish. In the counseling session, participants describe the pros and cons of their drug and alcohol use and whether it might be important to quit using drugs and drinking alcohol. Open discussion of the pros (what they like about drug use and drinking) and cons (what they don't like) can help people think about reducing drug and alcohol use in a more complete way than they might have before. This arm will be compared to the HealthCall+Motivational Interviewing arm.
3039956|NCT02294123|Experimental|Healthy (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
3039957|NCT02294110||diabetes mellitus|spinal anesthesia
3039958|NCT02294097|No Intervention|Non-biopsy|Population in this arm will be adjusted immunosuppressive drug only from the result of tough level.
3039959|NCT02294097|Experimental|Protocol biopsy|Population in this arm will be adjusted immunosuppressive drug upon both pathological findings and the result of tough level.
3039923|NCT02294318|Experimental|HealthCall+Motivational Interviewing|The HealthCall+Motivational Interviewing arm will investigate whether the addition of HealthCall, a smartphone application designed to keep track of the participant's drug and alcohol use and other health-related behaviors through short daily use, will help participants reduce their substance use more than Motivational Interviewing alone. Participants will receive the same 30-minute Motivational Interviewing session as described in the MI arm. After the session, participants will be introduced to HealthCall and will be asked to use the app daily over the next 30 days. Each use lasts 2-3 minutes and can be done anywhere on the phone in the U.S. The purpose of daily HealthCall use is to help participants keep track of their drug and alcohol use.
3039924|NCT02294305|Experimental|Vortioxetine|Vortioxetine 10 to 20 mg PO QD for 12 weeks.
3039925|NCT02294305|Placebo Comparator|Placebo|Placebo PO QD for 12 weeks.
3039926|NCT02294292|Experimental|Carvedilol + Ivabradine|"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.~if carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"
3039927|NCT02294292|Active Comparator|Endoscopic Variceal Ligation (EVL)|
3039928|NCT02294279|Experimental|Active|4 weeks of corticosteroid treatment with QVAR (100mcg), 400 mcg daily; two puffs twice daily
3039929|NCT02294279|No Intervention|Placebo|Blinded placebo inhaler
3039930|NCT02294266|Experimental|Mephedrone and alcohol|"Mephedrone 200 mg, single dose, oral administration~Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration"
3039931|NCT02294266|Active Comparator|Mephedrone|"Mephedrone 200 mg, single dose, oral administration~Lemon-flavoured water (350 ml), single dose, oral administration"
3039932|NCT02294266|Active Comparator|Alcohol|"Lactose 200 mg, single dose, oral administration~Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration"
3039933|NCT02294266|Placebo Comparator|Placebo|"Lactose 200 mg, single dose, oral administration~Lemon-flavoured water (350 ml), single dose, oral administration"
3039934|NCT02294253|Experimental|Buprenorphine/naloxone stabilization|Participants who have initially failed outpatient induction onto XR-NTX will receive buprenorphine/naloxone (BUP) on a weekly basis that they will take daily,
3039935|NCT02294240|Experimental|Arm One|Energy dense biscuits will be provided throughout pregnancy after enrolment
3039936|NCT02294240|Placebo Comparator|Arm Two|Wheat Flour,oil, iron and folic acid will be provided fortnightly throughout pregnancy after enrolment
3039937|NCT02294227|Experimental|Secukinumab 150 mg s.c. with loading|Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
3039938|NCT02294227|Experimental|Secukinumab 150 mg s.c. without loading|Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at Baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
3039939|NCT02294227|Placebo Comparator|Placebo|Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
3039940|NCT02294214|Placebo Comparator|Placebo|Placebo Repellent product with no active ingredient
3039941|NCT02294214|Active Comparator|Intervention|Spatial Repellent product with active ingredient
3039942|NCT02294201|Placebo Comparator|Placebo|Placebo Repellent product with no active ingredient
3039943|NCT02294201|Active Comparator|Intervention|Spatial Repellent product with active ingredient
3039944|NCT02294188|Placebo Comparator|Placebo|Spatial Repellent product without active ingredient (SHIELD)
3039945|NCT02294188|Active Comparator|Intervention|Spatial Repellent product with active ingredient (SHIELD)
3039946|NCT02294175|Active Comparator|Larval Debridement Therapy|Larval debridement therapy intervention (Biobags) filled with sterile green bottle fly maggots (larvae) placed in open, chronic lower extremity or diabetic foot ulcer once every 4 days for total of 2 applications over the 8 day study period.
3039947|NCT02294175|Active Comparator|Sharp Debridement Therapy|Bedside sharp debridement therapy as a comparator performed by wound care clinician once every 7 days in a chronic lower extremity or diabetic foot ulcer for a total of 2 sharp debridements over the 8 day study period.
3039948|NCT02294162|Experimental|0.5 mg/kg body weight Ketamin|Patients allocated to this arm will receive an iv dose of 0.5 mg/kg body weight ketamine.
3039949|NCT02294162|Placebo Comparator|5 ml normal saline as placebo|Patients allocated to this arm will receive an iv dose of 5ml saline as placebo.
3039950|NCT02294149|Placebo Comparator|Placebo|A ineffective placebo drug with the same taste, route of administration and physical appearance as the study drug (omega 3/Vit D 3) that has received approval by health Canada.
3039951|NCT02294149|Experimental|Omega 3 FA/Vitamin D3 sublingual|patients will be allocated randomly to receive Sub-lingual Omega 3 FA and Vitamin D3 supplements for 6 months, twice daily ,1/2 tea spoon with instructions to keep it under the tongue for 45 sec.
3039952|NCT02294136|Experimental|Prep-C|Four session nurse administered behavioral intervention.
3039953|NCT02294136|Active Comparator|Educational Control|Attention Control
3039954|NCT02294123|Experimental|Diabetes (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
3039955|NCT02294123|Experimental|Overweight (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
3039960|NCT02294084|Experimental|Sitagliptin|Subjects will receive Sitagliptin in a dosage of 100 mg/day p.o. for 12 weeks. The dosage corresponds to 1 gift/day.
3039961|NCT02294084|Placebo Comparator|Placebo|Subjects will receive placebo for 12 weeks. Placebo will be given in 1 gift/day
3039964|NCT02294071|Experimental|combination|acetaminophen 15mg/kg (max 975mg) and ibuprofen 10mg/kg (max 600mg)
3039965|NCT02294058|Experimental|0.5 mg RPC1063 oral capsule|0.5 mg RPC1063 oral capsule daily, matching weekly IM placebo
3039966|NCT02294058|Experimental|1 mg RPC1063 capsule|1 mg RPC1063 capsule daily, + weekly IM placebo injection
3039967|NCT02294058|Active Comparator|Beta interferon IM injection weekly|Beta interferon IM injection weekly, + daily oral placebo
3039968|NCT02294032||Kidney Transplant|Patients who are about to undergo a kidney transplant and are on immunosuppressive agents.
3039969|NCT02294019|Experimental|Ibuprofen caplet arm|
3039970|NCT02294006|Experimental|everolimus+octreotide LAR+metformin|
3039971|NCT02293993|Experimental|Cohort1|SGI-110 36mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
3039972|NCT02293993|Experimental|Cohort2|SGI-110 60mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
3039973|NCT02293993|Experimental|Cohort3|SGI-110 90mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
3039974|NCT02293993|Experimental|Cohort4|SGI-110 60mg/m2 will be administered subcutaneously once daily for 10 days (Day 1 to Day 5 and Day 8 to Day 12 with dosing, Day 6 and 7 with non-dosing), followed by a 16-day non-dosing period (Day 13 to Day 28).
3039975|NCT02293980|Experimental|Part 1: PT2385 Tablets|PART 1: Multiple Dose/Dose-Escalation
3039976|NCT02293980|Experimental|Part 2: PT2385 Tablets and nivolumab|PART 2: PT2385 Tablets in combination with nivolumab
3039977|NCT02293980|Experimental|Part 3: PT2385 and cabozantinib tablets|PART 3: PT2385 Tablets in combination with cabozantinib tablets
3039978|NCT02293967|Experimental|MT-1303|[14C] MT-1303 after a single oral dose
3039979|NCT02293954|Experimental|Diagnostic (copper Cu 64 anti-CEA monoclonal antibody M5A PET)|Patients receive copper Cu 64 anti-CEA monoclonal antibody M5A IV on day 0 and then undergo PET on day 1 and day 2.
3039980|NCT02293941|Experimental|JKB-122 5mg|
3039981|NCT02293941|Experimental|JKB-122 15 mg|
3039982|NCT02293941|Experimental|JKB-122 35 mg|
3039983|NCT02293941|Placebo Comparator|placebo|
3039984|NCT02293928||Elective hybrid coronary revascularization|All patients are treated with non-enteric coated aspirin 75 mg once daily prior to study participation. Aspirin treatment is discontinued 8-10 days prior to surgery and resumed 6-9 hours after surgery. Left internal mammary grafting of the left descendent coronary artery is performed off-pump through an inferior J-hemisternotomy (JOPCAB). All patients receive an oral loading dose of aspirin 300 mg 6-9 hours after surgery followed by daily maintenance doses of 75 mg aspirin. An oral loading dose of clopidogrel 300 mg 12 hours prior to PCI is followed by daily maintenance doses of 75 mg for 12 months. Patients are followed for 1 year.
3039985|NCT02293915|Experimental|sodium oligo-mannurarate 900mg|
3039986|NCT02293915|Placebo Comparator|Placebo|
3039987|NCT02293902|Experimental|Sarilumab 150 mg/150 mg|Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either tender joint count [TJC] or swollen joint count [SJC], or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
3039988|NCT02293902|Experimental|Sarilumab 200 mg/200 mg|Sarilumab 200 mg SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
3039989|NCT02293902|Placebo Comparator|Placebo/Sarilumab 150 mg|Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 150 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
3039990|NCT02293902|Placebo Comparator|Placebo/Sarilumab 200 mg|Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 200 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
3039991|NCT02293889|Experimental|Vitamin D|Vitamin D3 2000IU/daily 3 months
3039992|NCT02293889|Experimental|Physical Activity|PA intervention People with Osteoarthritis Walking Programme
3039993|NCT02293889|Experimental|Vitamin D and Physical Activity|Vitamin D3 2000IU/daily 3 months PA intervention People with Osteoarthritis Walking Programme
3039994|NCT02293889|Placebo Comparator|Placebo|Placebo capsule: edible oil
3039995|NCT02293876|Sham Comparator|Eye drop|Eye drop LACRIBELL® - two drops each eye, three times a day, after eye cleansing.
3039996|NCT02293876|Sham Comparator|Ocular gel|Ocular gel LIPOSIC® applied three times a day at the lower palpebra from medium line to the lateral border.
3039997|NCT02293876|Sham Comparator|Glad wrap|Occlusion of the orbital area with a Glad wrap, turning the area into a moisture chamber.
3039998|NCT02293876|No Intervention|Control group|Ocular cleansing three times a day.
3039999|NCT02293863|Experimental|A: MHAA4549A 3600 mg + Oseltamivir|Participants will receive a single low IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
3040117|NCT02293096|Other|Clinical Factors|Subjects compared on the outcome of metoprolol effectiveness for SBP based upon clinical factor prediction alone.
3040000|NCT02293863|Experimental|B: MHAA4549A 8400 mg + Oseltamivir|Participants will receive a single high IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
3040001|NCT02293863|Placebo Comparator|C: Placebo + Oseltamivir|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1 and standard oseltamivir therapy (75 or 150 mg BID) for minimum of 5 days.
3040002|NCT02293850|Experimental|single intra-tumoral injection|OBP-301 ; Cohort 1: 1x10 10 viral particle (VP)/ tumor Cohort 2: 1x10 11 viral particle (VP)/ tumor Cohort 3: 1x10 12 viral particle (VP)/ tumor
3040003|NCT02293837|Experimental|Tocilizumab (TCZ)|Subjects will receive intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥30 kg) or 10.0 mg/kg (body weight <30kg) tocilizumab every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management.
3040004|NCT02293837|Placebo Comparator|Tocilizumab Placebo Group|Subjects will receive IV infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) placebo every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management.
3040005|NCT02293824||Premature infants|Premature infants <29 weeks birth gestational age receiving caffeine per standard of care for the prevention or treatment of apnea of prematurity.
3040006|NCT02293811|Other|biopsy|"We will use colonic biopsies performed in the gastroenterology after obtaining consent from the patient and the agreement of the committee for the protection of persons. 5 biopsy will be performed for all patients except those with colon cancer for xhich we realize only 3 colonic biopsy (1 in healthy area and 2 in cancerous area )~To obtain statistically significant results we will establish the following six study groups, as far as possible matched for age and sex:~healthy patients;~patients with colonic Crohn disease in acute phase;~patients with colonic Crohn disease in chronic phase;~patients with ulcerative colitis in acute phase;~patients with ulcerative colitis in chronic phase;~patients with colon cancer"
3040007|NCT02293798|Experimental|SERI|Subjects receiving SERI for mastopexy
3040008|NCT02293772|Active Comparator|Hypoxic ambulatory|Ambulatory in normobaric hypoxia
3040009|NCT02293772|Experimental|Hypoxic Bedrest|Bedrest in normobaric hypoxia
3040010|NCT02293772|Active Comparator|Normoxic bedrest|Bedrest in normobaric normoxia
3040011|NCT02293759|Active Comparator|HoLEP|Holmium laser enucleation of the prostate
3040012|NCT02293759|Active Comparator|Greenlight laser PVP|Phtoselective vaporization of the prostate
3040013|NCT02293746|Other|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System.
3040014|NCT02293733||Patients NSCLC EGFR mutated|This is an observational study, there is no intervention.
3040015|NCT02293720|Experimental|EndoBarrier Device|Subjects who participated in the control arm of study #09-1 who are not treatment failures and have completed 12 months of the study. These subjects will have the EndoBarrier device implanted for 12 months.
3040016|NCT02293707|Experimental|GX301 Regimen A (8 administrations)|Administration time frame: Day 1 to Day 63.
3040017|NCT02293707|Experimental|GX301 Regimen B (4 administrations)|Administration time frame: Day 1 to Day 63.
3040018|NCT02293707|Experimental|GX301 Regimen C (2 administrations)|Administration time frame: Day 1 to Day 63.
3040019|NCT02293694|Active Comparator|self-injection|Women randomized to this arm will be trained to self-inject Sayana Press at home every three months
3040020|NCT02293694|Active Comparator|provider injection|Women randomized to this arm will received Sayana press from a family planning provider every three months.
3040021|NCT02293681||Cohort 1: Infliximab and/or NSAIDs and DMRADs|Participants receiving intravenous infusion of infliximab with or without non-steroidal anti-inflammatory drugs (NSAIDs: aspirin, ibuprofen and naproxen) and Disease-modifying anti-rheumatic drugs (DMRADs: methotrexate (MTX), sulfasalazine, and thalidomide) will be observed.
3040022|NCT02293681||Cohort 2: NSAIDs and DMARDs|Participants receiving NSAIDs (aspirin, ibuprofen and naproxen) and DMARDs (MTX, sulfasalazine, and thalidomide) will be observed.
3040023|NCT02293668|Active Comparator|Combined 450|Recombinant FSH 225IU/day and human menopausal gonadotropin (hMG) 225IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
3040024|NCT02293668|Active Comparator|Combined 300|Recombinant FSH 150IU/day and human menopausal gonadotropin (hMG) 150IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
3040025|NCT02293668|Active Comparator|Letrozole and hMG|Letrozole (Femara; Novartis, East Hanover, NJ) at a dose of 5 mg/day and human menopausal gonadotropin (hMG) 150IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
3040026|NCT02293655|Placebo Comparator|MPH Discontinuation|"Double-blind (DB) placebo-controlled 4-week methylphenidate (MPH) titration trial. Pts will receive 3 active dosages of MPH (children <25kg: 18mg, 27mg, 36mg; children >25kg: 18mg, 36mg, 54mg for) as well as 1 random week of placebo, given qAM. Pts will begin on the lowest dose (or a randomized placebo week) and proceed through all dose conditions in an incremental fashion.~DB 4-week MPH maintenance phase. The clinician, parent, and teacher ratings of behavior and side effects from the titration trial weeks will be graphed. Two doctors will blindly review the graphs and judge which week was the optimal dose week. Pts will then receive their optimal dose of MPH (qAM) for 4 weeks.~DB 4-week MPH Discontinuation Phase. Pts in this arm will receive placebo (qAM)."
3040055|NCT02293499|Active Comparator|Adult Led Asthma Self-Management|The adult led asthma self-management will take place within 2 weeks of the peer-led camp to minimize the history effect. Two healthcare professionals will attend peer-leader training sessions to become familiar with the program content, then lead instructional activities. As in PLASMA, adult leaders will base their instruction on the program manual to ensure comparable program content. Adult leaders will adopt mainly a didactic format and skill demonstration.
3040056|NCT02293486|No Intervention|Control|Arm that followed all the protocols with the exception of the pomegranate juice intake.
3040027|NCT02293655|Active Comparator|Sustained MPH|"Double-blind (DB) placebo-controlled 4-week methylphenidate (MPH) titration trial. Pts will receive 3 active dosages of MPH (children <25kg: 18mg, 27mg, 36mg; children >25kg: 18mg, 36mg, 54mg for) as well as 1 random week of placebo, given qAM. Pts will begin on the lowest dose (or a randomized placebo week) and proceed through all dose conditions in an incremental fashion.~DB 4-week MPH maintenance phase. The clinician, parent, and teacher ratings of behavior and side effects from the titration trial weeks will be graphed. Two doctors will blindly review the graphs and judge which week was the optimal dose week. Pts will then receive their optimal dose of MPH (qAM) for 4 weeks.~DB 4-week MPH Discontinuation Phase. Pts in this arm will continue their optimal MPH dose (qAM)."
3040028|NCT02293629|Placebo Comparator|A1: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
3040029|NCT02293629|Placebo Comparator|A2: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
3040030|NCT02293629|Placebo Comparator|A3: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
3040031|NCT02293629|Active Comparator|B1: BMS-986147 or Placebo matching BMS-986147|Daily oral dose as specified
3040032|NCT02293629|Active Comparator|B2: BMS-986147 or Placebo matching BMS-986147|Daily oral dose as specified
3040033|NCT02293616|Experimental|Nitrate Rich|A nitrate rich beetroot juice supplement (Beet It Shot®, James White Drinks, UK) high in nitrates will be provided to the subjects. Subject's diet will be supplemented once daily while hospitalized up to 14 days with one 70 ml bottle containing 300 mg of dietary nitrate.
3040034|NCT02293616|Placebo Comparator|Nitrate Depleted|This group will consume a beetroot juice supplement (Beet It Shot®, James White Drinks, UK) that has had the nitrate removed from the beverage by the manufacturer. Patient's diet will be supplemented once daily with one 70 ml bottle while hospitalized up to 14 days.
3040035|NCT02293603|Experimental|Allogeneic Cardiosphere-Derived Cells|"The Phase I study consists of a Phase Ia portion and a Phase Ib portion. The Phase Ia portion (N=14 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=28 subjects) consists of a double-blind, randomized, placebo-controlled study design.~The Phase Ia portion is an open-label, dose escalation of Allogeneic Cardiosphere-Derived Cells (CDCs)."
3040036|NCT02293603|Placebo Comparator|Placebo|The placebo study arm only applies to the Phase Ib portion of the study design. The Phase Ia portion (N=14 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=28 subjects) consists of a double-blind, randomized, placebo-controlled study design.
3040037|NCT02293590|Experimental|intensive, adapted treatment strategy|"Experimental: intensive, adapted treatment strategy Certolizumab pegol (CZP, Cimzia (R)): 200mg every 2 weeks after loading d 400mg at Weeks 0, 2 and 4~DMARD:~Patients without sufficient treatment response will be taken to the next step according to the therapeutic algorithm or next drug, for example: 15=>25mg Metoject (R)/week => Leflunomide Gebro (R)20mg/d => Salazopyrine EN(R) 2000mg/d~Glucocorticoids:~At Week, 0 patients will be initiated on Spiricort (R) 20mg/d and tapered every 5 days~Joint injections:~Starting at Week 0 up to 5 joint injections may be conducted into synovitic joints at every visit of the study.~The maximum cumulative Lederlon (R) dose is 100mg/visit. Joints are to be infiltrated with the following doses of triamcinolone and lidocaine"
3040038|NCT02293590|Active Comparator|fixed-dosed program|"Intervention:~Certolizumab pegol (Cimzia (R), CZP) CZP of 400mg at Weeks 0, 2 and 4, followed by 200mg injections from Week 6, every 2 weeks until Week 24.~DMARD:~Patients are to continue to receive their stable weekly dose of DMARD as noted at study entry for the duration of the study (24 weeks)~Glucocorticoids:~Prednisolone (Spiricort (R)) daily dose of ≤ 10 mg~Joint injections:"
3040039|NCT02293564|Experimental|gevokizumab|
3040040|NCT02293551|Experimental|Part A: Lispro (A)|Formulation A: Single dose of lispro administered subcutaneously (SC) in one of five periods.
3040041|NCT02293551|Experimental|Part A: Lispro (B)|Formulation B: Single dose of lispro administered SC in one of five periods.
3040042|NCT02293551|Experimental|Part A: Lispro (C)|Formulation C: Single dose of lispro administered SC in one of five periods.
3040043|NCT02293551|Experimental|Part A: Lispro (D)|Formulation D: Single dose of lispro administered SC in one of five periods.
3040044|NCT02293551|Experimental|Part A: Lispro (Reference)|Reference formulation: Single dose of lispro administered SC in one of five periods.
3040045|NCT02293551|Experimental|Part B: Lispro|Formulation selected from Part A. Single dose of lispro administered SC in one of four periods.
3040046|NCT02293538|Experimental|FID 114657|FID 114657 eye drops (10 ml), 1-2 drops instilled in each eye 10 minutes prior to inserting a new pair of habitual contact lenses and after removing them, daily for 2 weeks.
3040047|NCT02293538|Active Comparator|Saline Control|Saline control eye drops (15 ml), 1-2 drops instilled in each eye 10 minutes prior to inserting a new pair of habitual contact lenses and after removing them, daily for 2 weeks.
3040048|NCT02293525|Active Comparator|Ropivacaine|Continuous 0.2% Ropivacaine infusion until catheter removal (typically 36 hours)
3040049|NCT02293525|Placebo Comparator|Saline|Continuous saline infusion until catheter removal (typically 36 hours)
3040050|NCT02293512|Experimental|Coping Effectiveness Training (CET)|A 3-session intervention to facilitate coping strategies among individuals with tinnitus.
3040051|NCT02293512|Active Comparator|Cognitive-behavioral therapy (CBT)|A 3-session intervention to reduce negative affectivity triggered by tinnitus.
3040052|NCT02293512|Active Comparator|Acceptance and Commitment Therapy|A 3-session intervention to decrease resistance to tinnitus and increase committed action based on values, despite having tinnitus.
3040053|NCT02293512|No Intervention|Wait-list control group|No intervention. This is a 'usual care' group.
3040054|NCT02293499|Active Comparator|Peer Led Asthma Self-Management|Peer-led asthma self-management for adolescents : PLASMA will be implemented in small groups at a camp setting where paired peer-leaders will facilitate learning activities.Paired peer leaders will share and coordinate the responsibilities of facilitating group activities. Training content includes: Day 1: Asthma basics and prevention; Day 2: Asthma monitoring and management; Day 3: Communication/ psychosocial issue management/leadership training/hands-on practice in simulated peer-led group settings (role-play)
3040057|NCT02293486|Experimental|Pomegranate Juice|Arm that followed all the protocols and the pomegranate juice intake.
3040058|NCT02293486|Experimental|Pomegranate Juice Dilution|Arm that followed all the protocols and the pomegranate juice dilution (1:1) intake.
3040059|NCT02293473|Experimental|Protocol Group|"Using multimodal monitoring to optimise the patients' haemodynamic status, namely, the use of LiDCO Rapid, BIS-Bispectral Index Monitor and INVOS-Cerebral Oxygenation Monitor monitors to assess and fine tune the patient, as described in the study protocol in detail."
3040060|NCT02293473|Active Comparator|Control Group|Using current standard of care
3040061|NCT02293460|Experimental|I10E Arm|
3040062|NCT02293447|No Intervention|Control|The control group will undergo uterine artery embolization according to regular protocol, without the administration of lidocaine.
3040063|NCT02293447|Experimental|Lidocaine per-embolization|This group will receive 10mL of 1% lidocaine in both uterine artery during the embolization; the lidocaine will be mixed with the embolization particles.
3040064|NCT02293447|Experimental|Lidocaine post-embolization|10mL of 1% lidocaine will be injected in both uterine arteries after embolization endpoint is achieved.
3040065|NCT02293434||All Children (1 month to 18 years)|All children (1 month to 18 years) admitted to all PICUs in France during three one-week periods (February, June, October) in the course of a year
3040066|NCT02293421|Other|STOP BANG|STOP BANG screening questionnaire and a snore question
3040067|NCT02293408||Component 1|Assessment of current clinical and neurocognitive status and retrospective chart review
3040068|NCT02293408||Component 2|Prospective cross-sectional and longitudinal follow-up ( for up to 3 years), non-interventional
3040069|NCT02293395|Active Comparator|Stratum 1/ASA|Acetylsalicylic acid (ASA) 100 milligram (mg) enteric-coated tablet once daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
3040070|NCT02293395|Experimental|Stratum 1/Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
3040071|NCT02293395|Active Comparator|Stratum 2/ASA|ASA 100 mg enteric-coated tablet once daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
3040072|NCT02293395|Experimental|Stratum 2/Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
3040073|NCT02293369|Active Comparator|Cuff closure via vaginal route|For vaginal cuff closure both in laparoscopic approach and vaginal route, we will use the same horizontal method, which can be described as closing the vagina anterior to posterior by leaving a horizontal scar. The repair will start at one end of the vaginal cuff, taking care to incorporate the uterosacral ligament into the initial bite and will continue toward the surgeon until the other uterosacral ligament will be incorporated into the repair, using a continuous 0-Vicryl suture in the vaginal route.
3040074|NCT02293369|Active Comparator|Cuff closure via laparoscopic route|For vaginal cuff closure both in laparoscopic approach and vaginal route, we will use the same horizontal method, which can be described as closing the vagina anterior to posterior by leaving a horizontal scar. In the laparoscopic approach, needles will be introduced through the umbilical trocar and removed through the peripheral trocars and intracorporeal knots will be utilized.
3040075|NCT02293356|Experimental|Nimotuzumab Injection|200mg,Once a week，Intravenous infusion over 60 minutes
3040076|NCT02293343||control group|healthy subjects
3040077|NCT02293343||IgE positive|patients with high IgE level in serum
3040078|NCT02293343||IBS patients|patients with afflictions, but no high IgE level and suspicion on histamine intolerance
3040079|NCT02293330|Experimental|C group|continuous infusion of levobupivacaine
3040080|NCT02293330|Experimental|B group|Intermittent bolus infusion of levobupivacaine
3040081|NCT02293317|Experimental|M-001 0.5mg & TIV|M-001 (0.5mg) administered intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
3040082|NCT02293317|Experimental|M-001 1.0mg & TIV|M-001 (1.0mg) administered intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
3040083|NCT02293317|Placebo Comparator|Placebo & TIV|0.3ml Saline administered Intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
3040084|NCT02293304|Experimental|Self-etch approach|Application of universal adhesive as self-etch mode
3040085|NCT02293304|Experimental|Etch-and-rinse approach|Application of universal adhesive as etch-and-rinse mode
3040086|NCT02293291|Active Comparator|Lithium Water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in reducing violence based on previous research."
3040087|NCT02293291|Placebo Comparator|MIneral water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in reducing violence based on previous research."
3040088|NCT02293278|Experimental|Physical Activity Intervention|"The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention.~During the 6 month intervention, Preschoolers Activity Trial staff will visit the day care facilities to conduct baseline, 3 month, and 6 month measurements."
3040116|NCT02293096|Experimental|CYP2D6 Phenotyping|Subjects compared on the outcome of metoprolol effectiveness for SBP decline stratified by CYP2D6 phenotype.
3040697|NCT02289274|Experimental|NVP-1203|NVP-1203
3040089|NCT02293278|No Intervention|Control Group|"Day cares randomly assigned to the control group will continue with their existing programming. Day care providers will receive the PA intervention upon completion of their involvement in the 6 month trial, including: 2 three hour educational workshops, Healthy Opportunities for Preschoolers manual and program outlining the ideal implementation of activities from the manual.~During the 6 month intervention, Preschoolers Activity Trial staff will visit the day care facilities to conduct baseline, 3 month, and 6 month measurements."
3040090|NCT02293265|Other|Non-drug interventional group|All enrolled participants will provide a blood sample, spirometry , and feedback on their severe asthma symptoms via questionnaires, and health related quality of life and burden of illness through response to self-administered questionnaires. No investigational product will be administered to participants.
3040091|NCT02293252|Experimental|Interventional group|Remote patient monitoring system (Motiva)
3040092|NCT02293252|No Intervention|Control group|Best medical treatment according to the guidelines of the European Society of Cardiology (ESC)
3040093|NCT02293239|No Intervention|Control Group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
3040094|NCT02293239|Experimental|WB-EMS group|"physical exercise group regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
3040095|NCT02293226|Experimental|Child ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3040096|NCT02293226|Experimental|Infant ETI with chest compressions|endotracheal intubation (ETI) during infant mannikin resuscitation with uninterrupted chest compressions
3040097|NCT02293213|Active Comparator|Counseling only|All participants who receive EMR referral to CTIS because they are taking class D or X medications AND are randomized to counseling only will receive: CTIS Counseling, Baseline Questionnaire, 3 Month Follow up Questionnaire, and 6 Month Follow up Questionnaire.
3040098|NCT02293213|Experimental|Counseling + Contraception Appointment|All participants who receive EMR referral to CTIS because they are taking class D or X medications AND are randomized to counseling + Contraception Appointment will receive: CTIS Counseling, Baseline Questionnaire, Contraception Provision Appointment, 3 Month Follow up Questionnaire, and 6 Month Follow up Questionnaire.
3040099|NCT02293200|Experimental|Traditional learning|chest compression group learning without CPR feedback device. After a month of quality control of chest compressions is made also without the device.
3040100|NCT02293200|Experimental|Experimental learning|Training is done using TrueCPR feedback device. After a month of quality control of chest compressions is made without the device. To do this will be indicated on the impact of the use of feedback devices for improving the effectiveness of training in CPR.
3040101|NCT02293187|Active Comparator|vitamin D3|Vitamin D3, 800 IU will be given initially; after 4 months if D level < 70 nmol/L, increase dose to 1600 IU for remainder of study.
3040102|NCT02293187|Placebo Comparator|Placebo|Placebo, microcrystalline cellulose
3040103|NCT02293174||Normal Healthy Eyes|Willing and able subjects with normal and healthy eyes
3040104|NCT02293161|Experimental|Cohort A GSK2618960|Subjects will receive GSK2618960 0.6 milligram per kilogram (mg/kg)
3040105|NCT02293161|Placebo Comparator|Cohort A Placebo|Subjects will receive Sodium Chloride Intravenous as placebo
3040106|NCT02293161|Experimental|Cohort B GSK2618960|Subjects will receive GSK2618960,planned dose being 2mg/kg. However, actual dose level for Cohort B may be adjusted based on the emerging data on safety, tolerability, PK and RO from Cohort A. The maximum dose will not exceed 2.4 mg/kg (i.e. a 4-fold dose escalation from 0.6 mg/kg)
3040107|NCT02293161|Placebo Comparator|Cohort B Placebo|Subjects will receive Sodium Chloride Intravenous as placebo
3040108|NCT02293148|Experimental|GSK1278863 (Part A)|All subjects will receive a single, oral 500 mg dose of GSK1278863 on Day 1 administered as 5 x 100 mg tablets of GSK1278863. Additional doses/cohorts may be added depending upon the emerging safety, tolerability, pharmacokinetic and/or pharmacodynamics findings at the 500 mg dose level in Part A
3040109|NCT02293148|Experimental|GSK1278863 (75 mg/500 mg)/Moxifloxacin 400 mg/Placebo (Part B)|Subjects will be assigned to one of four treatment sequences (A-1 x Moxifloxacin placebo tablet, 3 x 25 mg tablets of GSK1278863, 2 x GSK1278863 matched placebo; B-1 x Moxifloxacin placebo tablet, 5 x 100 mg tablets of GSK1278863; C-1 x Moxifloxacin placebo tablet, 5 x GSK1278863 matched placebo tablets; D-1 x 400 mg Moxifloxacin tablet, 5 x GSK1278863 matched placebo tablets) (ABDC, BCAD, CDBA, DACB) in accordance with the randomization schedule
3040110|NCT02293135|Experimental|Group 1|Verum Stendo session on V1 and Phantom Stendo session on V2
3040111|NCT02293135|Experimental|Group 2|Phantom Stendo session on V1 and Verum Stendo session on V2
3040112|NCT02293122||Observational|Observational group exposure to three test devices and one comparative device. The test Konan Non-con Robo Pachy F&A Specular Microscope.
3040113|NCT02293109|Experimental|Treatment (carfilzomib and hyper-CVAD)|Patients receive carfilzomib IV over 30 minutes on days 0, 1, 7, and 8. Patients also receive hyper-CVAD comprising cyclophosphamide IV over 2 hours every 12 hours for 6 doses beginning on day 1, vincristine sulfate IV on days 4 and 11, doxorubicin hydrochloride IV over 2-24 hours on day 4, and dexamethasone PO on days 1-4 and 11-14 (courses 1 and 3) and methotrexate IV over 24 hours on day 1, cytarabine IV over 2 hours every 12 hours for 4 doses starting on day 2, leucovorin calcium IV or PO every 6 hours beginning 36 hours after the start of methotrexate infusion, and methylprednisolone IV every 12 hours for 6 doses beginning on day 1 (courses 2 and 4). Patients with CD20 positive disease also receive rituximab twice daily on days 1 and 11 of courses 1 and 3 and days 1 and 8 of courses 2 and 4. Treatment repeats every 3-4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
3040114|NCT02293096|Other|Metoprolol succinate|The parent study will integrate covariates to predict metoprolol effectiveness for SBP decline of 10%. All patients will receive metoprolol and groups the following covariates will be used to predict metoprolol effectiveness: clinical variables (Age, sex, race/ethnicity, co-medications, and BMI) CYP2D6 genotype, CYP2D6 phenotype, and metabolomic factors.
3040115|NCT02293096|Experimental|Genotyping|Subjects compared on the outcome of metoprolol effectiveness for SBP decline stratified by CYP2D6 genotype.
3065818|NCT02122718|Placebo Comparator|Placebo|
3040118|NCT02293083|Experimental|Lidocaine|Group L received trigger point injection with a 3.2 ml of a 1:1 mixture of 1% lidocaine and 0.9% normal saline
3040119|NCT02293083|Experimental|Hyaluronidase|Group H received trigger point injection with the same volume of solution supplemented with hyaluronidase (H-LASE®, 1500 iu, L&H Pharm., Seoul, Korea) 600 iu/ml
3040120|NCT02293070|Experimental|Repeat Cardiac MRI Post Cryoablation|All subjects in this study receive a follow up delayed enhanced cardiac MRI 2-6 weeks after they undergo a cryoablation procedure.
3040121|NCT02293057|Active Comparator|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 90 minutes long and include required and optional activities.
3040122|NCT02293057|Placebo Comparator|Girl Health Group (Attention Control)|The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
3040123|NCT02293044|Experimental|Crest® Sensi-Stop™ Strips|Self Applied
3040124|NCT02293031|Experimental|"Gene-activated matrix Nucleostim"|"Implantation of gene-activated matrix Nucleostim into the bone defects or sites of bone atrophy"
3040125|NCT02293018|Experimental|0.75% (w/w) MTC896 Gel once daily|Subjects will apply topically daily 0.75% (w/w) MTC896 Gel
3040126|NCT02293018|Experimental|0.75% (w/w) MTC896 Gel twice daily|Subjects will apply topically twice daily 0.75% (w/w) MTC896 Gel
3040127|NCT02293018|Experimental|1.5% (w/w) MTC896 Gel once daily|Subjects will apply topically daily 1.5% (w/w) MTC896 Gel
3040128|NCT02293005|Experimental|Alisertib|Alisertib administered by mouth at 50 mg twice a day for 7 days in each treatment cycle, followed by a 14-day, treatment-free period.
3040129|NCT02292992|Experimental|Nasal pillow CPAP|Nasal pillow CPAP
3040130|NCT02292979|Active Comparator|ABVD|Patients in standard arm receive Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine on Day 1 and D14 of each 4-week-cycle during 4 cycles
3040131|NCT02292979|Experimental|AVD+BV|Patients in experimental arm receive Doxorubicin, Vinblastine, Dacarbazine and Brentuximab vedotin on Day 1 and D14 of each 4-week-cycle during 4 cycles
3040132|NCT02292966|Experimental|Hepatitis C treatment|12 weeks of DCV/ASV/BCV therapy.
3040133|NCT02292927||Pre-intervention|Patients treated as standard before intervention
3040134|NCT02292927||Post-intervention|Patients after the institution of a physical, psychological and social training programme
3040135|NCT02292914|Experimental|Robot-Assisted Surgery|patients undergoing robot assisted surgery for the treatment of cancer
3040136|NCT02292914|Active Comparator|Conventional Surgery|patients undergoing conventional surgery for the treatment of cancer
3040137|NCT02292901|Active Comparator|Macintosh laryngoscope|Tracheal intubation will be performed using a Macintosh laryngoscope
3040138|NCT02292901|Experimental|McGrath Mac videolaryngoscope|Tracheal intubation will be performed using a McGrath Mac videolaryngoscope
3040139|NCT02292888|Active Comparator|patients with LVEF >40%|Correlation between hemodynamic variable : SV and echocardiographic variable : Doppler VTI will be compared before and after Passive Leg Raising (PLR) test.
3040140|NCT02292888|Active Comparator|patients with LVEF < or equal to 40%|Correlation between hemodynamic variable : SV and echocardiographic variable : Doppler VTI will be compared before and after Passive Leg Raising (PLR) test.
3040141|NCT02292875||TG002 Subjects|Subjects previously randomised in study TG002
3040142|NCT02292862||MG Main Group|lymph node and blood sampling
3040143|NCT02292849|Experimental|Peer to Peer|These individuals will receive a standard mental health referral to a community agency and in addition meet with a trained peer coach for 12 weekly meetings.
3040144|NCT02292849|Active Comparator|Referral|These individuals will receive a standard mental health referral to a community agency.
3040145|NCT02292836||rosacea patients|Questionnaire testing on routine dermatologist patient population
3040146|NCT02292836||non-rosacea patients|Questionnaire testing on routine dermatologist patient population
3040147|NCT02292810|Experimental|Inspiratory muscle exercise|Patients will exercise the inspiratory muscle using a load of 60% of maximum inspiratory mouth pressure (MIP 60%).
3040148|NCT02292810|Placebo Comparator|Inspiratory muscle exercise placebo|Patients will exercise the inspiratory muscle using a load of 2% of maximum inspiratory mouth pressure (MIP 2%).
3040149|NCT02292784|Placebo Comparator|Placebo|All infants and children exposed to placebo during their mother's participation in a Phase III SPTL treatment study for SPTL
3040150|NCT02292784|Experimental|Retosiban|All infants and children born to women who received at least 1 dose of retosiban in SPTL treatment study treatment group
3040151|NCT02292784|Active Comparator|Atosiban|All infants and children born to women who received at least 1 dose of atosiban in SPTL treatment study treatment group
3040152|NCT02292784|Active Comparator|All comparator|This group will include the pooling of placebo and atosiban into a group called all comparators
3040153|NCT02292771|Experimental|Retosiban + Atosiban Placebo|Participants will receive retosiban 6 milligrams (mg) intravenous (IV) loading dose over 5 minutes, followed by a 6mg/hour continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, investigators will administer another 6mg IV loading dose and increase the infusion rate to 12 mg/hour for the remainder of the 48-hour treatment period. Participants will also receive placebo infusion matched for the atosiban loading (bolus) dose and continuous infusion to ensure blinding.
3040154|NCT02292771|Active Comparator|Atosiban + Retosiban Placebo|Participants will receive atosiban in 3 successive stages: an initial bolus dose (6.75 mg) over 1 minute, immediately followed by a continuous infusion at 18 mg/hour for 3 hours, followed by a 6 mg/hour infusion for the remainder of the 48-hour treatment period. Participants will also receive placebo infusion matched for retosiban loading (bolus) dose and continuous infusion to ensure blinding.
3040155|NCT02292758|Experimental|Arm I (cetuximab, bevacizumab, irinotecan)|Patients receive cetuximab IV over 90-120 minutes, bevacizumab IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3040193|NCT02292524|Experimental|Arm IV: Sauce|Commercially-available tomato food product: men in this group consumed Prego® spaghetti sauce (5-7 oz./day).
3040156|NCT02292758|Active Comparator|Arm II (cetuximab, placebo, irinotecan)|Patients receive cetuximab IV over 90-120 minutes, placebo IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3040157|NCT02292745|Experimental|Stereotactic radiotherapy|Standard of care FOLFIRINOX treatment followed by stereotactic radiotherapy
3040158|NCT02292732|Experimental|Trametinib/ ORTHO-NOVUM® tablet|Subjects in treatment period 1will take one active tablet from the ORTHO-NOVUM® tablet 1/35 dial-pack once daily at approximately the same time each day for 21 days (Days 1 through 21), followed by one placebo tablet once daily at approximately the same time each day for 7 days (Days 22 through 28). In addition, subjects will take trametinib 2 mg (1 tablet) once daily at approximately the same time each day for a total of 17 days (Days 12 through 28). Subjects in treatment period 2 will take one active tablet from the ORTHO-NOVUM® tablet 1/35 dial-pack once daily at approximately the same time each day for 11 days (Days 1 through 11). In addition, subjects will take trametinib 2 mg (1 tablet) once daily at approximately the same time each day for 11 days (Days 1 through 11).
3040159|NCT02292719|Experimental|Arm A (genotype [GT]3, noncirrhotic)|Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) and sofosbuvir (SOF) 400 mg QD for 12 weeks.
3040160|NCT02292719|Experimental|Arm B (GT3, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided twice daily [BID]) for 12 weeks.
3040161|NCT02292719|Experimental|Arm C (GT2, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight- based 1,000 mg or 1,200 mg daily divided BID) for 8 weeks.
3040162|NCT02292719|Experimental|Arm D (GT2, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 6 weeks.
3040163|NCT02292719|Experimental|Arm E (GT3, cirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 12 weeks.
3040164|NCT02292719|Experimental|Arm F (GT3, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD and SOF (400 mg QD) for 12 weeks.
3040165|NCT02292693|Experimental|intubation with immobilized cervical spine|endotracheal intubation with immobilized cervical spine
3040166|NCT02292680||NICU Tooth Study Cohort|All study subjects will have been cared for in the Mount Sinai NICU and have had the same hospital environment exposure.
3040167|NCT02292667|Experimental|TAP BLOCK|"Patients included in the ETAP group will receive the combination of a bilateral ultrasound-guided Transversus Abdominis Plane (TAP) block and a multimodal intravenous analgesia protocol for the postoperative pain management after the surgical open repair of an aortic abdominal aneurysm.~The TAP block consists in 2 ultrasound-guided injections of Ropivacaine 0.375% on each side of the abdominal wall between the internal oblique and transversus abdominis muscles: 1 subcostal injection and 1 supra-iliac injection (i.e 10 ml of Ropivacaine 0.375% by injection).~The multimodal intravenous analgesia protocol consists in the association of intravenous infusion of 1 g of Acetaminophen every 6 h and intravenous patient-controlled analgesia (PCA) with Chlorhydrate of Morphine 1 mg/ml."
3040168|NCT02292667|Active Comparator|CONTROL|"Patients included in the CONTROL group will receive a multimodal intravenous analgesia protocol alone for the postoperative pain management after the surgical open repair of an aortic abdominal aneurysm.~The multimodal intravenous analgesia protocol consists in the association of intravenous infusion of 1 g of Acetaminophen every 6 h and intravenous patient-controlled analgesia (PCA) with Chlorhydrate of Morphine 1 mg/ml."
3040169|NCT02292654|Experimental|GZ402665|Olipudase alfa, dose (up to 3.0 mg/kg body weight) once every 2 weeks for 64 weeks
3040170|NCT02292641|Other|Patients with advanced or recurrent rectal cancer|Provide these patients with a compartmentalized radiology report which will provide surgeons with data on optimal exenterative surgery
3040171|NCT02292628|Experimental|Mesenchymal stem cells|Autologous mesenchymal stem cells from the adipose tissue in an unique intralesional infusion with a dose of 40 million cells.
3040172|NCT02292628|Placebo Comparator|Ringer lactate solution|Ringer lactate solution
3040173|NCT02292615||cervical cancer|Group 1: Patients with newly diagnosed gynecologic cancers (including cervical, endometrial, and ovarian cancers).
3040174|NCT02292615||endometrial cancer|Group 2: Patients with suspicious recurrent gynecologic cancers (including cervical, endometrial, and ovarian cancers).
3040175|NCT02292615||ovarian cancer|Group 3: Patients with ovarian cancer who had debulking surgery and are going to receive adjuvant chemotherapy.
3040176|NCT02292602|Experimental|Family-Based Weight Control Intervention|Families will receive the FBWC
3040177|NCT02292602|No Intervention|Control|Families will continue with standard of care at WIC
3040178|NCT02292589|Experimental|Frontal Stimulation|Left dorsolateral prefrontal cortex stimulation
3040179|NCT02292589|Experimental|Temporal Stimulation|Left temporal cortex stimulation
3040180|NCT02292589|Experimental|Sham Stimulation|Sham stimulation
3040181|NCT02292576|Experimental|Acute dose/Chronic dose|Acute dose/Chronic dose.
3040182|NCT02292576|Experimental|Chronic dose/Acute dose|Chronic dose/Acute dose.
3040183|NCT02292563|Experimental|endoscopist only|Single inspection by endoscopist during colonoscopy
3040184|NCT02292563|Experimental|nurse participation|Dual inspection by both an endoscopist and an experienced nurse during colonoscopy
3040185|NCT02292550|Experimental|Group A|Patients naive to treatment with any ALK inhibitor
3040186|NCT02292550|Experimental|Group B|Patients who have progressed after treatment with an ALK inhibitor other than ceritinib
3040187|NCT02292550|Experimental|Group C|Patients who have progressed after treatment with ceritinib
3040188|NCT02292537|Experimental|Nusinersen|Nusinersen 12 mg solution via intrathecal (IT) injection on Days 1, 29, 85 and 274.
3040189|NCT02292537|Sham Comparator|Sham procedure|Sham comparator on Days 1, 29, 85 and 274.
3040190|NCT02292524|No Intervention|Arm I: Control|Men in this group consumed a tomato free diet for the duration of the study (less than or equal to 5 mg lycopene/day) and, thus, did not consume a tomato intervention product.
3040191|NCT02292524|Experimental|Arm II: Juice|Commercially-available tomato food product: men in this group consumed V8® juice (11-16.5 fl. oz./day).
3040192|NCT02292524|Experimental|Arm III: Soup|Commercially-available tomato food product: men in this group consumed Campbell's® Tomato Soup (2-2 ¾ cups/day).
3040401|NCT02291055|Experimental|Arm B|Medi4736, IV Infusion vs. ADXS11-001 & Medi4736, IV Infusion
3040194|NCT02292511|Experimental|Square-Stepping Exercise Intervention|Participants in this group will attend a square-stepping exercise intervention 60 minutes on two days a week at a community location.
3040195|NCT02292511|No Intervention|Usual-care wait-list control|This group will receive standard care and be invited to partake in the intervention after all assessments have been completed.
3040196|NCT02292498|Experimental|FLIR ONE thermal camera|Thermal camera (FLIR ONE)
3040197|NCT02292485||Physicians - Texas Academy of Family Physicians|Physicians attending Texas Academy of Family Physicians event asked to fill out an anonymous survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
3040198|NCT02292472|Experimental|Medytoxin®|Botulinum toxin type A
3040199|NCT02292472|Placebo Comparator|Normal Saline|Normal Saline
3040200|NCT02292459|Experimental|PEG 3350|Participants will receive a 17 g oral dose of 1 sachet of PEG 3350 mixed in 120 to 240 mL of water, once a day, for 7 days.
3040201|NCT02292459|Active Comparator|PEG 4000|Participants will receive a 10 to 20 g oral dose of 1 to 2 sachets of PEG 4000 mixed in 120 to 140 mL of water, once a day, for 7 days.
3040202|NCT02292446|Experimental|Ruxolitinib|All patients will receive ruxolitinib
3040203|NCT02292433|Experimental|PF-04937319|PF-04937319 Split dose
3040204|NCT02292433|Placebo Comparator|Placebo|Placebo split dose
3040205|NCT02292407|Experimental|LigaSure Precise instrument|ALND with use of LigaSure Precise instrument, closure of dead space, omission of a postoperative drain.
3040206|NCT02292394|Experimental|Multicomponent Cognitive Behavioral Telephone Intervention|In this study, we will apply a telephone intervention that is a modified version of a brief prevention intervention for depressed caregivers that previously was applied in person in a group format during five 90-minute sessions (Vazquez et al., 2014). During the intervention, participants will be trained in various behavioral and cognitive abilities such as increasing pleasant activities, self-reinforcement, relaxation techniques, assertive communication, strategies to increase social contacts and social skills, and strategies to increase positive thoughts and decrease depressive ones.
3040207|NCT02292394|Experimental|Telephone Intervention Pleasant Activities|This intervention is also a modified version of a protocol described by Vazquez et al. (2014). However, in this case, we will specifically focus on the behavioral activation components of the multicomponent cognitive-behavioral telephone intervention. This intervention will also be structured in groups and administered by phone in five 90-minute sessions.
3040208|NCT02292394|No Intervention|Usual care|Individuals assigned to this group will receive no intervention or material, but they will have unrestricted access to any routine medical or psychological care that they might want to seek to treat depressive symptoms. The use of such treatments will be recorded.
3040209|NCT02292381||Glaucoma Patients|Patients with primary open angle glaucoma
3040210|NCT02292381||Healthy controls|age- and sex matched controls
3040211|NCT02292368|Experimental|Acupuncture - One Type|"Participants recruited between weeks 3-5 of radiotherapy. Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.~At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.~Participants also have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes."
3040212|NCT02292368|Experimental|Acupuncture - Different Type|"Participants recruited between weeks 3-5 of radiotherapy. Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.~At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.~Participants also have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes."
3040213|NCT02292355|Experimental|Pilates|Intervention group will undergo Pilates sessions in addition to conventional treatment with occlusal splint
3040214|NCT02292355|No Intervention|Occlusal splint|Control group who receive conventional treatment with occlusal splint
3040215|NCT02292342|Active Comparator|0.1 mg/ kg BW pure (-)-epicatechin|0.1 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
3040216|NCT02292342|Active Comparator|0.5 mg/ kg BW pure (-)-epicatechin|0.5 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
3040217|NCT02292342|Active Comparator|1.0 mg/ kg BW pure (-)-epicatechin|1.0 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
3040218|NCT02292342|Placebo Comparator|0.0 mg/ kg BW pure (-)-epicatechin|Water only (3 ml/kg BW)
3040219|NCT02292329|Active Comparator|150g of acai fruit|150g of acai fruit in fruit smoothie form
3040220|NCT02292329|Placebo Comparator|Placebo control|The control will be a smoothie-like drink matched for major macro- and micro-nutrients
3040221|NCT02292316|Experimental|Fall with fracture|Fall with fracture in the last 6 months; Interventions : behavioral, biological and other; Behavioral intervention includes gait and cognitive assessments Blood sample Osteodensitometry
3040222|NCT02292316|Sham Comparator|controls|Fall without fracture in the last 12 months; Interventions : behavioral, biological and other; Behavioral intervention includes gait and cognitive assessments Blood sample Osteodensitometry
3040223|NCT02292303|Experimental|zinc-enriched yeast|zinc-enriched yeast capsules
3040224|NCT02292303|Active Comparator|zinc oxide|zinc oxide capsules
3040225|NCT02292303|Active Comparator|zinc gluconate|zinc gluconate capsules
3040226|NCT02292290|Active Comparator|Monotherapy 2|addition of Sulfonylurea or Pioglitazone to Metformin
3040698|NCT02289274|Active Comparator|Eperisone SR tab. + and Airtal tab.|Eperisone HCl and aceclofenac
3040227|NCT02292290|Experimental|Dual Therapy 1|Swap Liraglutide for sulfonylurea or pioglitazone taken as second line therapy (Metformin) first line)
3040228|NCT02292290|Active Comparator|Dual therapy 2|Maintain sulfonylurea or pioglitazone as second line therapy (Metformin first line)
3040229|NCT02292290|Experimental|Monotherapy|Addition of Liraglutide to Metformin
3040230|NCT02292277||NSTEMI patients|Subjects eligible for the study will be ticagrelor naïve patients with NSTEMI presenting at the emergency room. Upon arrival to the emergency room written informed consent will be obtained before the patients receive their 180 mg loading dose of ticagrelor, as prescribed by the responsible physician.
3040231|NCT02292277||SCAD controls|Patients with stable coronary artery disease (SCAD) planned for elective angiography. If PCI is to be performed and if the responsible physician decides to administrate a loading dose of 180 mg ticagrelor, written informed consent will be obtained before loading dose and blood sampling.
3040232|NCT02292264||Surgical treatment of ventral hernia|Adult patients who underwent a ventral hernia Repair at Zealand University hospital
3040233|NCT02292251|Active Comparator|Device-assisted therapy|30 hours of therapy with the ArmeoPower device, a commercially available device for arm rehabilitation
3040234|NCT02292251|Active Comparator|Therapy-based occupational therapy|30 hours of conventional occupational therapy that emphasizes task-oriented training.
3040235|NCT02292238|Experimental|Benfotiamine|The patients in this arm will be treated with benfotiamine
3040236|NCT02292238|Placebo Comparator|Placebo|The patients in this arm will be treated with placebo
3040237|NCT02292225|Experimental|IPI-145 in Combination with Obinutuzumab|
3040238|NCT02292212|Experimental|Single arm|The dialyzer will be changed from conventional one to ViE-21 for 36 sessions for all the enrolled subjects.
3040239|NCT02292199|Experimental|TENS High Frequency 100 Hz|TENS was applied for thirty minutes, with the frequency defined according to randomization. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
3040240|NCT02292199|Active Comparator|TENS Low Frequency 4 Hz|TENS was applied for thirty minutes, with the frequency defined according to randomization. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
3040241|NCT02292199|Placebo Comparator|TENS Placebo|The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
3040242|NCT02292186|Experimental|Revusiran (ALN-TTRSC)|
3040243|NCT02292173|Experimental|Trametinib plus Sorafenib|"Dose Escalation Followed by Dose Expansion.~Trametinib: Daily (To start on day 8 during cycle 1 and on day 1 from cycle 2 onwards), according to dose level upon entry.~Sorafenib: Twice daily, according to dose level upon entry.~Each cycle is repeated every 28 days."
3040244|NCT02292134|Experimental|earplug and sleep mask|
3040245|NCT02292134|No Intervention|control|
3040246|NCT02292121|Experimental|obese group|40 obese subjects undergoing gastric bypass explored at baseline and 30 explored post-surgery at 6 months
3040247|NCT02292121|Active Comparator|non-obese control group (T1)|30 non-obese control subjects investigated for bio-clinical measures, IPT, zonulin, and LPS
3040248|NCT02292121|No Intervention|non obese control group undergoing a surgery (T2)|40 non-obese candidates to a surgery that gives access to surgical jejunal samples to measure the expression of tight junctions proteins
3040249|NCT02292108|Experimental|Hypnosis and dietetic counselling|Patient will benefit of usual dietetic counselling and experimental hypnosis
3040250|NCT02292108|Other|dietetic counselling|Patient will only benefit of usual dietetic counselling
3040251|NCT02292095|Experimental|TAPB group|Participants in this group will receive transverse abdominis plane block combined with patient controlled intravenous analgesia.Transverse abdominis plane block will be guided by ultrasound and 0.75% 20 ml ropivacaine will be injected with the sonographic view at the end of the surgery.Participants in this group will also receive patient controlled intravenous analgesia after surgery,the regimens of patient controlled intravenous analgesia are included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total
3040252|NCT02292095|Active Comparator|PCIA group|Participants in this group will only receive patient controlled intravenous analgesia after surgery.The formula of the PCIA included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
3040253|NCT02292082|Active Comparator|Peri-Articular Injections only|"Intra-Operatively~Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)~Surgeon will perform the periarticular injections:~First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc~Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine~Intravenous sedation with midazolam and propofol."
3040254|NCT02292082|Experimental|Peri-Articular Injections and Adductor Canal Block|"Intra-Operatively~Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)~Adductor canal block technique:~Supine position, after IV sedation~Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches~Femoral artery will be identified in the adductor canal deep to the Sartorius muscle~15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone~Local anesthetic will be delivered periarterial between 12 and 6 o'clock~Intravenous sedation with midazolam and propofol.~First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc~Second superficial injection prior to closure. 20 ml 0.25% bupivacaine"
3040255|NCT02292069|Experimental|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg of Dr. Reddys Laboratories Limited
3040256|NCT02292069|Active Comparator|Caduet|Caduet® 10/80 mg tablets of Pfizer, Ireland
3040257|NCT02292056|Experimental|Counseling Group|Participation in the study will be completed in a single session and will involve a pre-counseling questionnaire, followed by a pre-counseling quiz, individualized counseling session, post-counseling quiz and post-counseling questionnaire.
3040258|NCT02292043||idiopathic dilated cardiomyopathy group|idiopathic dilated cardiomyopathy group treated with HTEA
3040259|NCT02292043||post-myocardial infarction group|post-myocardial infarction group treated with TEA
3040260|NCT02292030||cardioversion+HTEA|Heart failure patients accompanied by atrial fibrillation receive the treatment of cardioversion+HTEA.
3040261|NCT02292030||only cardioversion|Heart failure patients accompanied by atrial fibrillation receive the treatment of cardioversion, but not with HTEA.
3040262|NCT02292017|Experimental|Embolization of intracranial aneurysm|Embolization with Target Coils
3040263|NCT02292004|Experimental|ACL repair with MIACH scaffold|Patients will undergo ACL repair surgery using the newly developed MIACH scaffold
3040264|NCT02292004|Active Comparator|Standard ACL reconstruction|Patients will undergo a standard ACL reconstruction surgery
3040265|NCT02291991|Experimental|Group A|"Drug : GX-E2 - Intravenously injection once day at dose 8 ug/kg Drug : Placebo~(1 subject : GX-E2, 1 subject : Placebo)~Subjects in group A will be injected drug, So we observe safety. After three days, Subject in group B will be injected drug."
3040266|NCT02291991|Experimental|Group B|Drug : GX-E2 - Intravenously injection once day at dose 8 ug/kg Drug : Placebo (7 subjects : GX-E2, 1 subject : Placebo)
3040267|NCT02291978|Experimental|ExAblate 2100 Treatment|The ExAblate 2100 system will be used in the MRgHIFU treatment of lower back pain arising from facet joint arthritis.
3040268|NCT02291952|Experimental|Experimental|During Forced Desynchrony sleep and wake will occur at different circadian phases, while meals are restricted to the biological day.
3040269|NCT02291952|Other|Control|During Forced Desynchrony sleep and wake, as well as meals, will occur at different circadian phases.
3040270|NCT02291939||Parotidectomy|Patients with an indication for surgical intervention for a parotidectomy.
3040271|NCT02291926|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
3040272|NCT02291913|Experimental|everolimus|Everolimus will be administered at a dose of 10 mg PO daily combined with any one of the following anti-estrogen therapies on which the patient most recently progressed (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy). Anti-estrogen therapy will be administered at the US Food and Drug Administration (FDA) prescribed doses.
3040273|NCT02291900|Active Comparator|medial femoral condyle|Patients in this arm receive core decompression followed by free vascularized medial femoral condyle graft
3040274|NCT02291900|Active Comparator|core decompression|Patients in this arm receive core decompression followed by osseous autograft from the iliac crest
3040275|NCT02291887||Neovascular ARMD Patients|Patients with Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab but Resistant to Aflibercept Treatment
3040276|NCT02291874|Experimental|Ipragliflozin group|Ipragliflozin treatment
3040277|NCT02291861|Placebo Comparator|Placebo|Placebo tablets taken twice daily for 12 weeks.
3040278|NCT02291861|Experimental|SD-809 12 mg/day|SD-809 tablets 6 mg taken twice a day (BID) for 12 weeks.
3040279|NCT02291861|Experimental|SD-809 24 mg/day|SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 12 mg BID. The total daily dose of 24 mg was maintained for an additional 8 weeks.
3040280|NCT02291861|Experimental|SD-809 36 mg/day|SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 18 mg BID. The total daily dose of 36 mg was maintained for an additional 8 weeks.
3040281|NCT02291848|Experimental|Group A|Patients receiving TAA-specific CTLs as therapy for Myeloma
3040282|NCT02291848|Experimental|Group B|Patients receiving TAA-Specific CTLs as adjunctive therapy following autologous or syngeneic transplant for myeloma
3040283|NCT02291809|Experimental|REMUNE|Remune vaccine consists of a suspension of killed HIV-1 virus particles that have been emulsified with Incomplete Freund's Adjuvant (IFA, a mixture of mannide mono-oleate and a highly purified mineral oil). Each dose is given by IM injection and contains 10 μg of p24 antigen in approximately 100 μg of total protein.
3040284|NCT02291809|Placebo Comparator|REMUNE Low Dose|Remune low dose vaccine consists of a suspension of killed HIV-1 virus particles that have been emulsified with Incomplete Freund's Adjuvant (IFA, a mixture of mannide mono-oleate and a highly purified mineral oil). Each dose is given by IM injection and contains 2.5 μg of p24 antigen in approximately 25 μg of total protein.
3040285|NCT02291796|Experimental|Bezafibrate group|Patients with acute coronary syndrome with ST elevation and fibrinogen receiving a dose of 400 mg every 24 hours of Bezafibrate in addition to conventional anti-ischemic treatment
3040286|NCT02291796|No Intervention|Control group|Patients with acute coronary syndrome with ST elevation and hyperfibrinogenemia who received only conventional anti-ischemic treatment
3040287|NCT02291783|Experimental|HTL0009936|HTL0009936 single and multiple ascending oral doses.
3040288|NCT02291783|Placebo Comparator|HTL0009936 Placebo|HTL0009936 matching placebo
3040289|NCT02291770|Active Comparator|Mesenchymal stem cells (MSC)|"Patients with newly diagnosed cGvHD receive primary treatment plus MSC:~MSC+prednisone+cyclosporine;~MSC+prednisone+tacrolimus;~MSC+prednisone+mycophenolate mofetil."
3040290|NCT02291770|Placebo Comparator|Placebo|"Patients with newly diagnosed cGvHD receive primary treatment:~Placebo+prednisone+cyclosporine;~Placebo+prednisone+tacrolimus;~Placebo+prednisone+mycophenolate mofetil."
3040291|NCT02291757|Active Comparator|NEM brand eggshell membrane|Subjects will be given enough treatment capsules or placebo capsules for 30-days after initial assessment, covering both the 7- and 30-day follow-up visits.
3040292|NCT02291757|Placebo Comparator|Placebo|Subjects will be given enough treatment capsules or placebo capsules for 30-days after initial assessment, covering both the 7- and 30-day follow-up visits. At the 30-day evaluation, patients in the placebo group will cross over to the treatment group for the remainder of the study and all patients will be given a 60-day supply of treatment capsules covering the 90-day follow-up visit.
3040293|NCT02291744|Experimental|XELOX plus surgery|Eight cycles of XELOX chemotherapy plus surgery:Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle. After 4 cycles, the patients are randomized to surgery group. Then the rest four cycles are administrated.
3040294|NCT02291744|Active Comparator|XELOX|Eight cycles of XELOX chemotherapy: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
3040734|NCT02289027|Placebo Comparator|Not deployed volunteers - Group 5|
3040295|NCT02291731|Experimental|Continuous use of autologous serum|with continuous use of topical autologous serum for an additional 2 weeks after total re-epithelialization.
3040296|NCT02291718|Active Comparator|Isovue 300 75mL|Isovue 300 75mL injected 120 kVp 250 mAs
3040297|NCT02291718|Active Comparator|Isovue 370 75mL|Isovue 370 75mL injected 100 kVp 240 mAs
3040298|NCT02291718|Active Comparator|Isovue 370 60mL|Isovue 370 60mL injected 100 kVp 240 mAs
3040299|NCT02291705|Experimental|rectus sheath block|rectus sheath block
3040300|NCT02291705|Active Comparator|tramadol|tramadol control group
3040301|NCT02291692|Active Comparator|Paravertebral blockade|Paravertebral blockade
3040302|NCT02291692|No Intervention|Paracetamol|The patients was given 15 mg/kg of paracetamol.
3040303|NCT02291679|Experimental|72 μg linaclotide|72 μg oral linaclotide, once daily for 12 weeks
3040304|NCT02291679|Experimental|145 μg linaclotide|145 μg oral linaclotide, once daily for 12 weeks
3040305|NCT02291679|Placebo Comparator|Placebo|matching placebo, once daily for 12 weeks
3040306|NCT02291666|Experimental|T2D patients with A1C ≤7.0|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
3040307|NCT02291666|Experimental|T2D patients with A1C>7.0|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
3040308|NCT02291666|Active Comparator|Non T2D subjects|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
3040309|NCT02291653|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
3040310|NCT02291653|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3040311|NCT02291640|Experimental|Child ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3040312|NCT02291640|Experimental|Child ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
3040313|NCT02291627|Experimental|intubation with immobilized cervical spine|endotracheal intubation with immobilized cervical spine
3040314|NCT02291614|Experimental|AMG 211|comparison of different dosages of drug
3040315|NCT02291601|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
3040316|NCT02291601|Placebo Comparator|Vehicle Cloth|Excipients on cloth
3040317|NCT02291601|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
3040318|NCT02291588|Experimental|AMG 811|AMG 811 administered as subcutaneous and intravenous doses
3040319|NCT02291588|Placebo Comparator|Placebo|No active drug
3040320|NCT02291575|Experimental|Training|Of the 304 participants in the study, half will be randomized into the treatment arm in which they will receive training from the Liver Foundation.The objective of the Liver Foundation's training program will be capacity building through information in health sciences, training in referral techniques during emergencies, and maternal and child health care priorities in rural areas. The training will be in the form of two three-hour classes per week and will continue for nine months, with three mid-term exams administered every three. During this time, the evaluation team will only collect the rosters of the attendees of the training classes and conduct sporadic random visits to the sessions to gain a better sense of the training methods and attendance rates.
3040321|NCT02291575|Active Comparator|Control|Half of the sample will be randomized into the control group, for whom there will be no training. They will be phased into training the following year. For the current year, the control group will experience no difference in their routine, aside from some (infrequent) opportunities to participate in other public health activities as provided by the Liver Foundation to any provider involved in their various programs.
3040322|NCT02291562|Experimental|Tetrahydrocannabinol|10 mg of Tetrahydrocannabinol as capsule (once)
3040323|NCT02291562|Experimental|Cannabidiol|600 mg Cannabidiol capsule (once)
3040324|NCT02291562|Placebo Comparator|placebo|placebo capsule (once)
3040325|NCT02291549|Experimental|Treatment|"In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses~Mometasone furoate nasal spray (200mcg) once daily"
3040326|NCT02291549|Sham Comparator|Control|"In-office bilateral sham procedure~Mometasone furoate nasal spray (200mcg) once daily"
3040327|NCT02291536|Experimental|tetrahydrocannabinol|oral administration of 10mg of tetrahydrocannabinol, once
3040328|NCT02291536|Experimental|cannabidiol|oral administration of cannabidiol, 600mg, once
3040329|NCT02291536|Placebo Comparator|placebo|oral administration of placebo, once
3040330|NCT02291523|Sham Comparator|Patient Stool Transplant|Arm 1 will get FMT (Fecal Microbial Transplant) placebo and high dose 5-ASA (Pentasa). The FMT is done through colonoscopy.
3040331|NCT02291523|Active Comparator|Donor Stool Transplant|Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool and high dose 5-ASA (Pentasa). The FMT is done through colonoscopy.
3040332|NCT02291510|Experimental|500 mg Met DR BID|Two doses of 500 mg metformin delayed-release
3040333|NCT02291510|Experimental|1000 mg Met DR BID|Two doses of 1000 mg metformin delayed-release
3040334|NCT02291510|Active Comparator|1000 mg Met IR BID|Two doses of 1000 mg metformin immediate-release
3040335|NCT02291510|Active Comparator|2000 mg Met XR QD|Single dose of 2000 mg metformin extended-release
3040336|NCT02291484|Experimental|Comprehensive cardiac CT|"Tiered cardiac CT protocol:~CT calcium scan~CT angiography (if calcium scan positive or high pre-test probability)~CT perfusion (if >50% stenosis on CTA, or cannot be ruled out)"
3040337|NCT02291484|No Intervention|Standard care|Standard diagnostic management of suspected CAD, using stress testing
3040338|NCT02291471|Experimental|T0001|
3040339|NCT02291458|Experimental|L-arginine|Subjects will receive 9 gram of L-arginine per day in three gifts (3dd 3 gram) during 6 weeks.
3040340|NCT02291458|Placebo Comparator|Placebo|Subjects will receive 9 gram of placebo per day in three gifts (3 dd 3 gram) during 6 weeks.
3040341|NCT02291445|Experimental|Tempocol-ColoPulse®|Tempocol-ColoPulse® is a colon-targeted-delivery peppermint oil capsule that will deliver peppermint oil in the (ileo-) colonic region specifically.
3040342|NCT02291445|Active Comparator|Tempocol®|Tempocol® is an enteric-coated peppermint oil capsule that delivers peppermint oil in the upper small intestine.
3040343|NCT02291432|Experimental|AMDC-USR|Cell treatment
3040344|NCT02291419|Experimental|ticagrelor|ticagrelor 90mg bid
3040345|NCT02291419|Active Comparator|aspirin|Patients in the aspirin arm will receive aspirin 81 mg daily orally
3040346|NCT02291406|Active Comparator|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
3040347|NCT02291406|Active Comparator|Abdominal hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
3040348|NCT02291393|Other|Patient|Patients with previously confirmed Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
3040349|NCT02291393|Other|Healthy volunteers|Aged and gender matched healthy controls.
3040350|NCT02291380|Active Comparator|Botulinum Toxin Type A for Injection|Botulinum Toxin Type A is a specific formulation of a locally injected muscle relaxant whose active ingredient is botulinum toxin type A produced by clostridium botulinum A strain Hall. Excipients contain sucrose, dextran and gelatin.
3040351|NCT02291380|Placebo Comparator|Placebo|The placebo does not include botulinum toxin A ,but includes sucrose, dextran and gelatin.
3040352|NCT02291367|Experimental|Duloxetine Delayed-Release Capsules, 60 mg|
3040353|NCT02291367|Active Comparator|Cymbalta|Cymbalta® 60 mg capsule of Eli Lilly and Company
3040354|NCT02291354|Placebo Comparator|FMT + Placebo|Patients allocated to control group will receive standard FMT, followed by placebo for 12 weeks.
3040355|NCT02291354|Experimental|FMT + Pectin|Patients allocated to experiment group will receive standard FMT, followed by 24g pectin each day for 12 weeks.
3040356|NCT02291341|Experimental|Duloxetine Delayed-Release Capsules, 60 mg|Duloxetine Delayed-Release Capsules, 60 mg of Dr. Reddys Laboratories Limited
3040357|NCT02291341|Active Comparator|Cymbalta|Cymbalta® 60 mg capsule of Eli Lilly and Company
3040358|NCT02291328|Experimental|High Brassica|Participants will be asked to consume 3x 84g portions of frozen broccoli, 3x 84g portions of frozen cauliflower, and 3x 300g portions of frozen broccoli and sweet potato soups a week for a total of 2 weeks.
3040359|NCT02291328|Experimental|Low Brassica|Participants will be asked to consume 1x 84g portion of either frozen broccoli or frozen cauliflower in week one, and the remaining 84g portion of Brassica in week two.
3040360|NCT02291315||Test meal ingestion|On the morning of the absorption study, fasted women received 2 mg of 42Ca intravenously (in 5 ml of isotonic saline) over 5 minutes before being randomly assigned to receive either the milk or cassia meal first for breakfast and the milk or cassia meal second for lunch. The milk meal consisted of approximately 100 mg of fresh ultrahigh temperature (UHT) milk to which 2 mg of 44Ca was added and allowed to equilibrate for 12 h prior to ingestion and the cassia meal consisted of 142 g of cooked cassia to which 1 mg of 43Ca was extrinsically added.
3040361|NCT02291302|Active Comparator|Environmental Intervention|Active Classroom air purifiers and school integrated pest management environmental intervention
3040362|NCT02291302|Placebo Comparator|Sham and Control|Sham air purifiers and no school integrated pest management environmental intervention
3040363|NCT02291302|Placebo Comparator|Active Air Purifier and Control|Active air purifiers and no school integrated pest management environmental intervention
3040364|NCT02291302|Sham Comparator|Sham and Inegrated Pest|Sham air purifiers and active school integrated pest management
3040365|NCT02291289|Experimental|Induction Treatment Phase|All patients will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab
3040366|NCT02291289|Experimental|Cohort 1 (Maintenance Phase[MP]):5-FU/LV,cetuximab,vemurafenib|Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.
3040367|NCT02291289|Experimental|Cohort 2 (MP):5-FU/LV or capecitabine,bevacizumab,atezolizumab|Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.
3040368|NCT02291289|Experimental|Cohort 3 (MP): capecitabine,trastuzumab,pertuzumab|Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.
3040369|NCT02291289|Experimental|Cohort 4 (MP): Experimental arm Cobimetinib,atezolizumab|Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.
3040524|NCT02290262|Experimental|Comprehensive phase one rehabilitation|Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education plus usual care.
3040370|NCT02291289|Active Comparator|Control (MP): 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
3040371|NCT02291289|Experimental|BRAFmut Early Progression (EP): 5-FU/LV,cetuximab,vemurafenib|Participants with MSS, will receive will receive 1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 mg vemurafenib BID by mouth.
3040372|NCT02291289|Experimental|BRAFmut EP: 5-FU/LV or capecitabine,bevacizumab,atezolizumab|Participants with MSI-H will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.
3040373|NCT02291276||Female cancer patients with ascites|Primary epithelial ovarian female cancer patients with ascites (> 500 ml ascites in the preoperative sonographic examination)
3040374|NCT02291276||Female cancer patients aged > 70 years|"Primary epithelial ovarian female cancer patients aged > 70 years with at least one of the following secondary diagnoses:~Status Post stent placement due to coronary heart disease respectively Status Post-myocardial infarction~existing arterial Hypertension for more than 5 years~chronic heart failure (New York Heart Association (NYHA) class II-III)~peripheral arterial disease"
3040375|NCT02291263|Active Comparator|Arm A|Group A will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group A participants will also receive inactivated polio vaccine (IPV) at 6 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
3040376|NCT02291263|Active Comparator|Arm B|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group B participants will also receive inactivated polio vaccine (IPV) at 14 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
3040377|NCT02291263|Active Comparator|Arm C|Group C will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group C participants will also receive inactivated polio vaccine (IPV) at 6 and 14 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
3040378|NCT02291250|Experimental|Sugar matched water with polycal OGTT|"Control: sugar matched (matched to currant sugar content) water with polycal~Blackcurrants (200grams) with polycal~Blackcurrants (200grams) with glucose~Greencurrants (200grams) with polycal Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load.~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
3040379|NCT02291250|Experimental|Blackcurrants with polycal OGTT|"Blackcurrants (200grams) with polycal~Blackcurrants (200grams) with glucose~Greencurrants ( 200grams) with polycal~Control: sugar matched (matched to currant sugar content) water with polycal~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above.~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
3040380|NCT02291250|Experimental|Blackcurrants with glucose OGTT|"Blackcurrants (200grams) with glucose~Greencurrants (200grams) with polycal~Control: sugar matched (matched to currant sugar content) water with polycal~Blackcurrants (200grams) with polycal~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
3040381|NCT02291250|Experimental|Greencurrants with polycal OGTT|"Greencurrants (200grams) with polycal~Control: sugar matched (matched to currant sugar content) water with polycal~Blackcurrants (200grams) with polycal~Blackcurrants (200grams) with glucose~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above.~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments."
3040382|NCT02291237|Experimental|Eleclazine|Eleclazine 30 mg single loading dose followed by 3 mg daily maintenance dose up until Week 12, then 6 mg daily maintenance dose from Week 12 at least Week 24, followed by eleclazine 6 mg in an open-label extension period.
3040383|NCT02291237|Experimental|Placebo|Placebo to match eleclazine until at least Week 24, followed by active eleclazine 6 mg in an open-label extension period.
3040384|NCT02291224|Other|Control|The control arm receives the clinic standard of care counseling. This includes individual clinical care and counseling consistent with protocols at the Grady Health System Teen Services Clinic, with study visits at enrollment, 6 months, and 12 months, during which any medical care or counseling included in the clinic standard of care will be provided. All control group members will see a provider on the day of enrollment. Control arm participants will get phone calls from clinic staff to update their contact information and remind them of upcoming appointments at 3 weeks and 5 months after both the enrollment visit and the 6 month visit. Participants may visit the clinic at any time and will be encouraged to come into the clinic for any concerns. If they have an interim visit during the study period, they will receive the clinic standard of care.
3040525|NCT02290262|No Intervention|Usual care|The control group will receive usual care alone.
3040526|NCT02290249|Active Comparator|normal airway|İntubation with glidescope or airtraq in normal airway
3040385|NCT02291224|Experimental|Intervention|"Enrollment~Interactive multimedia platform focused on DP strategies.~Intervention arm counseling by a health care provider to select DP strategy.~Intervention arm counseling and skill-building by a nurse educator (NE) on correct, consistent use of DP strategy.~Booster counseling by an NE via phone at 3 weeks and 5 months after both the enrollment visit and the 6 month visit.~6 month visit~Abbreviated version of the interactive multimedia platform on DP strategies and adherence.~Intervention arm counseling by an NE to reinforce skills for correct, consistent use of DP strategy.~Interim visits: Participants may visit the clinic at any time. If intervention group members visit the clinic for STI treatment or to switch birth control method, providers and/or NEs will follow structured counseling guides. If they have an interim visit for another reason, they will receive the clinic standard of care."
3040386|NCT02291211|Experimental|S-1 plus cisplatin HIPEC|8 cycles of hyperthermic intraperitoneal chemotherapy (cisplatin) and S-1(oral) were performed after palliative operation gastric cancer of stage IV limited peritoneal metastasis. HIPEC was conducted in d1 and d3: Normal saline 2000ml-5000ml, Cisplatin 60mg/m^2, 43°C, 60min. every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks.Subjects should be given maximum 8 cycles, or progression/intolerance.
3040387|NCT02291172|Experimental|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry. The comprehensive communication intervention: (a) teaches foundational social communicative behaviors, (b) related skills that predict long term language outcomes, (c) a range of communicative functions, (d) spoken language skills, (e) provides children with an immediate mode of communication, (f) incorporates instructional methods, contexts, and partners that increase both the critical skills for spoken language and social use of language. Because parents are essential partners for young children with ASD who are learning to communicate, we (g) include parents
3040388|NCT02291172|No Intervention|Business as Usual Control Group|All children, regardless of group assignment will participate in all assessments. Children randomized to the control group will not receive intervention, but will complete all other research procedures. Other treatments that all children receive in the community will be recorded with bi-monthly surveys.
3040389|NCT02291159|Experimental|Intervention-DNHS technique|Dry needling of Myofascial Trigger Points
3040390|NCT02291159|Sham Comparator|Control-Sham Dry Needling|Sham Dry Needling of Myofascial Trigger Points
3040391|NCT02291146|Experimental|LA Sprouts intervention|"The intervention classes will be taught during a 90-minute session once a week for 12 weeks. Participants will receive a 45-minute gardening lesson, taught by a Master Gardener (supervised by Dr. Gatto). This lesson will include learning how to plant, maintain and harvest various fruits and vegetables. Supplementing the gardening lesson, a USC nutrition educator, with help from various graduate students (supervised by PI Dr. Davis), will lead a 45-minute cooking activity and nutrition education lesson. Every participant will participate in the cooking activity and sample the food. The program will include lessons on growing crops that have cultural significance to Latino youth such as nopales, beans, corn and squash (the latter three crops are commonly referred to as the three sisters)."
3040392|NCT02291146|No Intervention|control|Approximately 200 students in the second region who are enrolled in LA's Best will serve as control participants. After the 12-week intervention is conducted and all post-testing measures are collected on controls, a vegetable/fruit garden will be built at both control schools and the LA Sprouts program will be taught to all 3rd, 4th and 5th graders in LAs Best and their parents at the control school as a delayed intervention.
3040393|NCT02291120|Active Comparator|MTA|ProRoot® MTA is a root canal repair material that is a unique improvement over other materials used for root canal repair. Made up of fine hydrophilic particles that set in the presence of water, ProRoot® MTA seals off all pathways between the root canal system and surrounding tissues, significantly reducing bacterial migration. Its excellent compatibility with the dentinal wall allows for a predictable clinical healing response.
3040394|NCT02291120|Experimental|MedCem Portland Cement (PC)|MedCem PC is an excellent capping material for cariology on permanent teeth (direct and indirect capping) and in milk tooth endodontics (milk tooth amputation). Is characterized by excellent colour stability and neutrality and does not contain any additional ingredients
3040395|NCT02291107|Experimental|Experimental group|Participants received 25 sessions of robotically driven gait orthosis training on the Lokomat. Training occurred approximately 5 days/ week for 5 weeks, and each training session on the Lokomat lasted 30 minutes. All sessions were supervised by a trained research therapist. All participants started with 40% body weight-support and an initial treadmill speed of 1.5 km/h. Body weight-support was used primarily to facilitate an increase in walking speed; therefore, progression of training across subsequent sessions was standardized by preferentially increasing speed and then unloading body weight-support. Speed was increased to a range of 2.2 to 2.5 km/h before body weight-support was decreased. There was an active attempt to enhance the level of training at each session. After every Lokomat session, participants performed also 60 minutes of physiotherapy including general exercise program and a conventional gait training
3040396|NCT02291107|Active Comparator|Control group|Participants received 25 sessions of conventional physiotherapy. Training occurred approximately 5 days/week for 5 weeks, and each training session lasted 1 hour and half. Patients allocated to the Control Group performed the same conventional physiotherapy training of the other group: a general exercise program and a conventional gait training. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and static/dynamic balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation concept, training in walking on different surfaces with or without appropriate walking aids, exercises for the restoration of a correct gait pattern, implementation of residual compensatory strategies and progressive increase of walking resistance
3040397|NCT02291094|Active Comparator|Lidocaine group|Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
3040398|NCT02291094|Active Comparator|Remifentanil group|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
3040399|NCT02291068|Other|psychotherapy treatment|3 months long (12 sessions) dynamic psychotherapy.
3040400|NCT02291055|Experimental|Arm A|ADXS11-001& Medi4736, IV Infusion
3040402|NCT02291042|Experimental|Suppository|Patients will receive a single antispasmodic muscarinic suppository after induction of anesthesia but before insertion of urological scope for surgery. The suppository is composed of Belladonna (16.2 mg) and Opium (30 mg) in a water soluble base manufactured as Belladonna and Opium Supprettes.
3040403|NCT02291042|No Intervention|Control|Patients will be provided with routine care.
3040404|NCT02291029|Experimental|CFZ533 active- Cohort 2|multiple doses of CFZ533 intravenous infusion
3040405|NCT02291029|Placebo Comparator|CFZ533 placebo- Cohort 2|multiple doses of placebo intravenous infusion
3040406|NCT02291029|Experimental|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
3040407|NCT02291029|Placebo Comparator|CFZ533 placebo - Cohort 1|multiple doses of placebo s.c. injection
3040408|NCT02291029|Experimental|CFZ533 Treatment Arm 1 - Cohort 3|multiple doses of CFZ533 s.c. injection
3040409|NCT02291029|Experimental|CFZ533 Treatment Arm 2 - Cohort 3|Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
3040410|NCT02291016|Active Comparator|Group A|Group A will receive formoterol via a DPI and placebo via a nebulizer at treatment visit #1. At treatment visit #2, Group A will receive formoterol via a nebulizer and placebo via a DPI.
3040411|NCT02291016|Active Comparator|Group B|Group B will receive formoterol via a nebulizer and placebo via a DPI at treatment visit #1. At treatment visit #2, Group B will receive formoterol via a DPI and placebo via a nebulizer.
3040412|NCT02291003||Healthy controls|Healthy controls -observational, no intervention administered.
3040413|NCT02290990|Experimental|Multiple Sclerosis patients|Patients with MS
3040414|NCT02290990|Experimental|Insomnia patients|Patients with insomnia
3040415|NCT02290990|Experimental|Health professionists|Health professionists as healthy volunteers
3040416|NCT02290990|Active Comparator|Waiting list MS|pw MS filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated
3040417|NCT02290990|Active Comparator|Waiting list arm Insomnia|pw INS Insomnia Subject filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated
3040418|NCT02290990|Active Comparator|Waiting list arm Health professionists|Health professionist filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated.
3040419|NCT02290977|Experimental|Scheduled TACE-RT|RT will be delivered at two weeks after TACE for HCC combined PVTT.
3040420|NCT02290964|No Intervention|Control group|After general anesthesia is applied, surgery is performed. Whenever transfusion is indicated, the patients will received allogenic blood transfusion
3040421|NCT02290964|Active Comparator|ANH group|After general anesthesia is applied, blood from patients in this group were withdrawn. the volume of blood withdrawn was determined based on Gross equation. The blood obtained was then stored in the operating room at temperature between 23 - 25 Celsius degree, and given back to the patient whenever transfusion is indicated.
3040422|NCT02290951|Experimental|Experimental cohorts N|Experimental cohorts N (participants with CD20+NHL) will receive multiple dose levels of REGN1979
3040423|NCT02290951|Experimental|Experimental cohorts C|Experimental cohorts C (participants with CLL) will receive multiple dose levels of REGN1979
3040424|NCT02290938|Active Comparator|Community Wellness Gatherings|All youth will attend a CWG, which is a monthly gathering focused on making healthy choices and learning about Native American culture
3040425|NCT02290938|Experimental|MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
3040426|NCT02290925|Experimental|Kothala Himbutu biscuit|A biscuit containing Kothala Himbutu (Salacia reticulata) extract. This biscuit is available in the supermarkets. Four biscuits twice a day for 3 months.
3040427|NCT02290925|Placebo Comparator|placebo biscuit|An identical biscuit without the herbal extract from Kothala Himbutu (Salacia reticulate)
3040428|NCT02290912|Experimental|Treatment|Health education program; informational website, experiential classes in various help domains, custom smart phone application, and wearable technology
3040429|NCT02290912|No Intervention|Control|No intervention
3040430|NCT02290886|Placebo Comparator|Placebo|Intravenous administration of placebo
3040431|NCT02290886|Experimental|1 million of MSC|Intravenous administration of 1 million of MSC/ kg
3040432|NCT02290886|Experimental|2 million of MSC|Intravenous administration of 2 million of MSC/ kg
3040433|NCT02290886|Experimental|4 million of MSC|Intravenous administration of 4 million of MSC/ kg
3040434|NCT02290873|Experimental|Remimazolam|Remimazolam iv 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.
3040435|NCT02290873|Placebo Comparator|Placebo|Placebo iv for sedation induction and maintenance
3040436|NCT02290873|Active Comparator|Midazolam|"Midazolam iv 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.~*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill"
3040437|NCT02290860|Other|Intervention|Type 2 diabetes diagnosis test.
3040438|NCT02290847|Active Comparator|In-Home Therapy|Cognitive Processing Therapy (CPT-C) will be delivered to participants face to face in their homes by a certified therapist.
3040439|NCT02290847|Active Comparator|In-Office Therapy|Cognitive Processing Therapy (CPT-C) will be delivered to participants face to face in a mental health clinic office setting by a certified therapist.
3040440|NCT02290847|Active Comparator|Telebehavioral Health|Cognitive Processing Therapy (CPT-C) will be delivered to participants over the internet using video conferencing software by a certified therapist.
3040441|NCT02290834|Active Comparator|ARM 1|"Breast cancer patients treated with chemotherapy~Cognitive, functional and subjective assessments (Pre and Post Treatment)~Imaging (Pre and Post Treatment)~Magnetic Resonance Imaging (MRI) Scan~Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
3040442|NCT02290834|Active Comparator|ARM 2|"Non-treated breast cancer patient control~Cognitive, functional and subjective assessments (Post enrollment and 6-14 months later~Imaging (Post Enrollment and at 8-14 months later)~Magnetic Resonance Imaging (MRI) Scan~Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
3040527|NCT02290249|Active Comparator|tongue edema|intubation with glidescope or airtraq in tongue edema simulation
3040809|NCT02288481|Experimental|Cohort 2 25 mg TBA-354|
3040443|NCT02290834|Active Comparator|ARM 3|"Healthy control subjects~Cognitive, functional and subjective assessments (Post enrollment and 6-14 months later~Imaging (Post Enrollment and at 8-14 months later)~Magnetic Resonance Imaging (MRI) Scan~Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
3040444|NCT02290821|Experimental|diclofenac sodium gel 1%|diclofenac sodium gel 1%
3040445|NCT02290821|Placebo Comparator|Placebo|Placebo
3040446|NCT02290808|Experimental|Theory-based group|The theory-based intervention group will receive strategies based on the Theory of Planned Behaviour to help increase physical activity among couples. Parents will receive materials on how to work together.
3040447|NCT02290808|No Intervention|Information group|The information group will serve as the control group and will receive informational materials on the benefits of physical activity.
3040448|NCT02290795||healthy subjects|Healthy subjects (not diagnosed with any eye disease affecting the vitreous or optic nerve head).
3040449|NCT02290795||Glaucoma patients|Glaucoma patients visiting the glaucoma consultation.
3040450|NCT02290795||Patients scheduled for trabeculectomy|Glaucoma patients scheduled for filtering surgery (=trabeculectomy)
3040451|NCT02290795||Vitreomacular traction patients|Patients with symptomative vitreomacular adhesion scheduled for treatment with Ocriplasmin
3040452|NCT02290782|Experimental|Intraoperative radiotherapy (IORT)|"IORT (20Gy) as intervention will be given during breast conserving surgery. If risk factors (Tumor > 3.5 cm, lobular cancer, resection margin < 2 mm*, L1, pN+ mulitfocal/multicentric, EIC, negative hormone receptors) are present, external beam radiotherapy will be added.~* In case of positive margins (<2 mm resection margin) a re-resection should be done"
3040453|NCT02290769|Experimental|Short guide wire rapid exchange|Use of short guide wire rapid exchange to guide the cannulation during primary ERCP
3040454|NCT02290769|Active Comparator|Long guide wire|Use of long wire to guide the cannulation during primary ERCP
3040455|NCT02290756|Active Comparator|Parenting program and toolkit|The intervention arm of the study will have the low cost evidence based toolkit delivered to the the pregnant women for the duration of their pregnancy and the parenting program delivered to the newborn for 12 months.
3040456|NCT02290756|Other|Control- toolkit|The control arm of the study will only have the low cost evidence based toolkit delivered to the the pregnant women for the duration of their pregnancy.
3040457|NCT02290743|Experimental|Kinesio tape|Kinesio tape on quadriceps femoris
3040458|NCT02290743|No Intervention|Control|No intervention
3040459|NCT02290730|Experimental|Kinesio tape|Kinesio tape on lower trapezius
3040460|NCT02290730|No Intervention|Control|No intervention
3040461|NCT02290717|Experimental|Laser+fluticason+UVB|The treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser). 5 days after laser therapy topical steroids (fluticasone cream) 4 times a week will be applied on the treatment site until the end of the study.
3040462|NCT02290717|Experimental|Laser+UVB|In one session the treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser).
3040463|NCT02290717|Active Comparator|UVB|As control site, 1 similar depigmented lesion will be used. This site will receive the same NB-UVB treatment as sites 1 and 2.
3040464|NCT02290704||controls|People without eye disease
3040465|NCT02290704||GO patients|patients with Graves' ophthalmopathy
3040466|NCT02290691|Experimental|Needle- Free|Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.
3040467|NCT02290691|Active Comparator|Needle and Syringe|Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.
3040468|NCT02290678|Experimental|Intervention|Participate in a two day Adventure-based Programming retreat and team building exercises.
3040469|NCT02290665|Experimental|Thermosensitive gel formulation|Thermosensitive gel rectal formulation or saline (control) enema with crossover to the other.
3040470|NCT02290665|Experimental|Saline enema|Thermosensitive gel rectal formulation or saline (control) enema with crossover to the other.
3040471|NCT02290652||Prospective|Prospective - Factors affecting sexual function pre-THR
3040472|NCT02290652||Retrospective|Retrospective- Factors affecting sexual function post-THR
3040473|NCT02290639|Experimental|Immediate Treatment|Four 30-minute sessions of Brief Cognitive Behavioral treatment starting immediately upon randomization.
3040474|NCT02290639|Active Comparator|Minimal Contact followed by treatment|6-week Minimal Contact period consisting of weekly phone calls starting immediately upon randomization. Experimental treatment will be provided to all subjects upon completion of Minimal Contact period.
3040475|NCT02290626|Experimental|Elemental diet|"Study 1: Elemental diet (300 kcal/300 ml) containing a contrast medium (5 ml) is administered within 15 min using the PEG.~Study 2: Elemental diet (200 kcal/200 mL) labeled with 100 mg [13C]sodium acetate is administered within 15 min using the PEG."
3040476|NCT02290626|Active Comparator|Semi-solid diet|"Study 1: Semi-solid diet (300 kcal/300 ml) containing a contrast medium (5 ml) is administered within 15 min using the PEG.~Study 2: Semi-solid diet (200 kcal/200 mL) labeled with 100 mg [13C]sodium acetate is administered within 15 min using the PEG."
3040477|NCT02290613|Experimental|Ambrisentan Verum|Study medication will be ambrisentan 10 mg (starting with 5 mg in the beginning of the study and then up-titrated to 10 mg/die).
3040478|NCT02290613|Placebo Comparator|Placebo|Placebo tablet
3040479|NCT02290600||type 1 diabetes|type 1 diabetes with continuous glucose monitor (CGM)
3040480|NCT02290587|Experimental|Patient|MS diagnosis according to McDonald criteria (Polman et al., 2005). Relapsing-remitting MS (RRMS) according to Lublin et al. (1996);
3040481|NCT02290587|Experimental|Control|healthy subject
3040482|NCT02290574|Experimental|Thermo-radio-chemotherapy arm|
3040483|NCT02290548|Experimental|high flow nasal cannula|High flow nasal cannula immediately use after extubation
3040484|NCT02290548|Placebo Comparator|stanrd oxygen therapy|Oxygen cannula or mask after extubation
3040485|NCT02290535||Patients|Children and Teenager of 5-18 years with obstructive pulmonary disease (asthma, cystic fibrosis, immotile-cilia-syndrome, obstructive bronchitis, obstructive pneumonia).
3040486|NCT02290535||Probands|Children and Teenager of 5-18 years without known obstructive pulmonary diseases
3040487|NCT02290522|Experimental|tumor biopsy|Tumor biopsy for targeted treatment according to molecular profile
3040488|NCT02290509|Experimental|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
3040489|NCT02290509|Active Comparator|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
3040490|NCT02290496|Experimental|CBT for Insomnia (CBT-I)|Cognitive behavior therapy to improve sleep and depression.
3040491|NCT02290496|Placebo Comparator|Sleep Hygiene (SH)|Attention control placebo comprising sleep hygiene therapy
3040492|NCT02290470|Experimental|olanzapine Days 1-3|"Olanzapine + Chemotherapy + Antiemetic treatment~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as the following anti-nausea/vomiting drugs:~Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone (16 mg intravenously on the day of chemotherapy), plus~Olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3 post chemotherapy)"
3040493|NCT02290470|Experimental|olanzapine+Dexamethasone d 1-3|"Olanzapine + Chemotherapy + Antiemetic treatment~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as the following anti-nausea/vomiting drugs:~Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone (16 mg intravenously on the day of chemotherapy and 4 mg orally days 2, 3 post chemotherapy), plus~Olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3 post chemotherapy)"
3040494|NCT02290470|Active Comparator|dexamethasone days 1-3|"Dexamethasone + Chemotherapy + Antiemetic treatment~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as usual anti-nausea/vomiting drugs:~Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone 16 mg intravenously on the day of chemotherapy (day 1), plus~Dexamethasone 8 mg orally on days 2 and 3 post chemotherapy"
3040495|NCT02290457|Experimental|CSTS|core strength training performed on stable surfaces
3040496|NCT02290457|Experimental|CSTU|core strength training performed on unstable surfaces
3040497|NCT02290444|Experimental|Cognitively Relapsing Patients|For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days.
3040498|NCT02290444|No Intervention|Stable Multiple Sclerosis Patients|Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state.
3040499|NCT02290431|Experimental|LBH589 + bortezomib + dexamethasone|LBH589 will be administered in combination with bortezomib and dexamethasone 2 weeks on/1 week off.
3040500|NCT02290418|Active Comparator|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass and routine care.
3040501|NCT02290418|Active Comparator|Omega-Loop Gastric Bypass|Laparoscopic Omega-Loop Gastric Bypass and routine care.
3040502|NCT02290405||Primary Insomnia (PI)|PI sufferers enrolled will meet Research Diagnostic Criteria for insomnia disorder, score > 14 on the Insomnia Severity Index, report insomnia for > 3 months, have sleep difficulties > 3 nights per week, score < 3 on the Epworth Sleepiness Scale (ESS), score > 40 on the Hyperarousal Scale10 and report an inability to nap in the daytime.
3040503|NCT02290405||Normal Sleepers (NS)|The normal sleepers enrolled will report general satisfaction with sleep and no sleep/wake complaints, score < 10 on the ESS, score < 35 on the Hyperarousal Scale10, and deny a practice of routine daytime napping.
3040504|NCT02290379|Experimental|TNX-201 35 mg|Drug: TNX-201 35 mg
3040505|NCT02290379|Experimental|TNX-201 70 mg|Drug: TNX-201 70 mg
3040506|NCT02290379|Experimental|TNX-201 140 mg|Drug: TNX-201 140 mg
3040507|NCT02290379|Active Comparator|Racemic isometheptene 70 mg|Comparator: Racemic Isometheptene 70 mg
3040508|NCT02290379|Placebo Comparator|Placebo|Drug: Placebo
3040509|NCT02290366|Experimental|Focal Therapy|
3040510|NCT02290353|Experimental|Adult (Stroke) group|This includes early intervention and late intervention sub-groups. Intervention: FEATHERS Device
3040511|NCT02290353|Experimental|Teenagers (Cerebral Palsy) group|This includes early intervention and late intervention sub-groups. Intervention: FEATHERS Device
3040512|NCT02290340|Experimental|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life.
3040513|NCT02290340|Placebo Comparator|Placebo|Solution containing no active ingredients
3040514|NCT02290327|Placebo Comparator|Placebo|50 ml of 0.9% Normal Saline Intravenously once daily
3040515|NCT02290327|Active Comparator|Pantoprazole|Pantoprazole 40 mg in 50 ml 0.9% Normal Saline Intravenously once daily
3040516|NCT02290314|Other|minimally invasive MID-line Lumbar Fusion (MIDLF)|MIDLF surgery involves a minimally invasive midline laminectomy posterior approach to the lumbar spine. An incision that is smaller than the standard incision is made in the midline of the low back directly over the spinal levels. Afterward the pressure on the compressed nerves is released, and the disc between the affected vertebrae is completely removed. A metal cage filled with bone graft is placed as described in the PLIF procedure.
3040517|NCT02290314|Other|posterior lumbar interbody fusion (PLIF)|PLIF surgery involves a standard incision in the midline of the low back directly over the involved spinal levels. Afterward the pressure on the compressed nerves is released, and the disc between the affected vertebrae is completely removed. A metal cage filled with bone graft is placed in between the vertebral bodies where the disc usually lies. This will allow bone fusion (healing) to occur from one vertebral body to the other.
3040518|NCT02290301||Type 2 Diabetes Mellitus|
3040519|NCT02290288|Active Comparator|SSF|1. vaginal surgery arm (SSF)
3040520|NCT02290288|Active Comparator|LSC|laparoscopic surgery arm (LSC)
3040521|NCT02290275|Placebo Comparator|Placebo|The subjects in this arm will receive 20 grams of a placebo (maltodextrin) for 1 week and then 5 grams of placebo (maltodextrin) for 11 weeks in addition to their regular diets.
3040522|NCT02290275|Experimental|Creatine|The subjects in this arm will receive 20 grams of creatine for 1 week and then 5 grams of creatine for 11 weeks in addition to their regular diets.
3040523|NCT02290275|Experimental|Walking Exercise|The subjects in this arm will receive a walking exercise program on a motorized treadmill where they will walk for 30 minutes at 3.1 mph, 3 days per week for 12 weeks.
3040528|NCT02290249|Active Comparator|face-to-face|intubation with glidescope or airtraq in face-to-face intubation
3040529|NCT02290223|Experimental|Patient Activation Group Intervention|The experimental procedure is a behavioral based treatment model, structured in the form of four group sessions, one meeting per week plus usual care which is is determined by patients' individual providers, according to practice guidelines related to specific conditions.
3040530|NCT02290223|No Intervention|Usual Care|Usual care is determined by patients' individual providers, according to practice guidelines related to specific conditions.
3040531|NCT02290210|Placebo Comparator|Placebo|Placebo x 2weeks
3040532|NCT02290210|Placebo Comparator|URC102 0.25mg|0.25mg URC102 x 2weeks
3040533|NCT02290210|Experimental|URC102 0.5mg|0.5mg URC102 x 2weeks
3040534|NCT02290210|Placebo Comparator|URC102 1.0mg|1.0mg URC102 x 2weeks
3040535|NCT02290210|Placebo Comparator|URC102 2.0mg|2.0mg URC102 x 2weeks
3040536|NCT02290197|Experimental|Hinged External Fixator|Hinged external fixator allows early and aggressive joint mobility in the sagittal plane only. Flexion and extension are permitted, but rotational movements, translations in the anterior-posterior plane, lateral (varus) and medial (valgus) openings are not allowed. Thus protective stability is ensured for ligament reconstruction procedures. Simultaneously we allow immediate joint mobilization, reducing the risk of arthrofibrosis, joint stiffness and postoperative ligament laxity.
3040537|NCT02290197|Active Comparator|Cast Immobilization|In these patients we used cast postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
3040538|NCT02290184|Experimental|Start with PilAm Go4Health Program|In the first 3 months this groups will start with the PilAm Go4Health Weight-loss Program lifestyle intervention. After 3 months this group will transition to a 3-month maintenance phase where they will continue to maintain the physical activity and healthy eating behaviors learned in the PilAm Go4Health Weight-loss Program lifestyle intervention and will complete the study for a total of 6 months.
3040539|NCT02290184|Active Comparator|Start with pedometer only|In the first 3 months this groups will start with a pedometer only. After 3 months, this group will transition to receive the PilAm Go4Health Weight-loss Program lifestyle intervention for the next 3 month and will complete the study for a total of 6 months
3040540|NCT02290171|Active Comparator|Intervention group|The intervention groups start the intervention 6 months ahead of the control group.
3040541|NCT02290171|No Intervention|Delayed intervention group|The control groups will start intervention with 6 months delay
3040542|NCT02290158|Active Comparator|Orthodontic finishing|Patients receiving a complete orthodontic finishing protocol according to the ABO-OGS
3040543|NCT02290158|No Intervention|No orthodontic finishing|Patients receiving orthodontic treatment without the finishing protocol according to the ABO-OGS
3040544|NCT02290145|Experimental|TPF group|TPF induction chemotherapy followed with surgery and post-operative radiotherapy docetaxel 75mg/m2 cisplatin 75 mg/m2 5-Fu 750 mg/m2/day
3040545|NCT02290145|Other|surgery group|surgery with post-operative radiotherapy
3040546|NCT02290132||highly aggressive T cell tumors|The study is to research the outcome of Rabbit Anti－human Thymocyte Globulin (ATG)based myeloablative conditioning regimen after allo-HSCT in patients with highly aggressive T-cell tumors.
3040547|NCT02290119|Sham Comparator|Control - Without the use of Verasense|Total Knee Replacement without the use of intraoperative sensors
3040548|NCT02290119|Active Comparator|Sensor-assisted TKR (Verasense)|Total Knee Replacement with the use of intraoperative sensors
3040549|NCT02290106|Experimental|Pitavastatin|pitavastatin 4mg daily by mouth for 6 months
3040550|NCT02290106|Placebo Comparator|Placebo|Identical placebo 4mg by mouth daily for 6 months
3040551|NCT02290093|Active Comparator|Standard full-volume PEG|
3040552|NCT02290093|Experimental|Split-dose full-volume PEG|
3040553|NCT02290093|Experimental|Split-dose low-volume PEG|
3040554|NCT02290080|Experimental|Oxygen|"For patients randomized to oxygen therapy:~6 L/min of oxygen delivered by oxymask® started immediately after inclusion of the ambulance service or in the emergency department given continuously for 6-12 hours (at least 6 hours)~all patients receive standard acute coronary syndrome treatment including reperfusion strategies"
3040555|NCT02290080|No Intervention|No oxygen|"For patients randomized to withholding oxygen treatment~no oxygen is administered at any time as long as the oxygen saturation is ≥90% on pulse oximeter (repetitive checks are performed)~all patients receive standard acute coronary syndrome treatment including reperfusion strategies~observation duration 12 hours"
3040556|NCT02290067|Active Comparator|Omnitest 3|Blood glucose monitoring system
3040557|NCT02290067|Experimental|Omnitest 5|Blood glucose monitoring system
3040558|NCT02290067|Experimental|Omnitest 5D|Blood glucose monitoring system
3040559|NCT02290054|Sham Comparator|Control|A thoracic epidural catheter is inserted first. Then total intra-venous anesthesia is performed. Implementation of adhesive pads on the ears is performed while the patient is sleeping but before thoracic incision.
3040560|NCT02290054|Experimental|Treated|"A thoracic epidural catheter is inserted first. Then total intra-venous anesthesia is performed. Auriculotherapy is performed while the patient is sleeping but before thoracic incision.~Auriculotherapy uses semi-permanent needles and implementation of adhesive pads to mask the needles."
3040561|NCT02290041|Experimental|Mesenchymal stem cells|Intravenous infusion of 4 doses of allogenic adult mesenchymal stem cells from adipose tissue
3040562|NCT02290041|Placebo Comparator|Placebo|Intravenous infusion of 4 doses of Placebo
3040563|NCT02290028|Other|Sentus QP left ventricular lead|Implantation of Sentus QP left ventricular lead Pacing threshold test at PHD and 3-month follow-up
3040564|NCT02290015|Experimental|true acupuncture|12 sessions of ACP treatment were performed twice a week. Before ACP was performed, patients were examined based on the diagnostic pattern of TCM. Then, the appropriate acupoints for treatment were selected according to the tinnitus-related syndrome. The experimental group was treated with true ACP (stimulating selected meridian points), and the control group was treated with sham-ACP (stimulating false meridian points). The patients were blinded to the identity of their treatment group. Disposable stainless steel ACP needles (0.25 x 30 mm, Dong Bang Acupuncture, Korea) were used in both groups. Needles were inserted manually at each meridian point, and the retention time was twenty minutes.
3040688|NCT02289352|Active Comparator|Mirvaso gel|Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA)
3040565|NCT02290015|Sham Comparator|sham acupuncture|The control group was treated with sham-ACP (stimulating false meridian points). Disposable stainless steel ACP needles (0.25 x 30 mm, Dong Bang Acupuncture, Korea) were used. Needles were inserted manually at each false meridian point, and the retention time was twenty minutes.
3040566|NCT02290002|Active Comparator|group A|In group A, (Calcium Dobesilate group), 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given from at day of HCG injection and for 21 days.
3040567|NCT02290002|Active Comparator|group B|In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
3040568|NCT02289989|Active Comparator|Standard: Hydrocortisone 1% ointment|Intervention: hydrocortisone 1% ointment will be applied to one patient's forearm
3040569|NCT02289989|Experimental|Experimental: oregano extract cream|Intervention: Oregano extract cream for mild to moderate atopic dermatitis will be applied to the other patient's forearm
3040570|NCT02289976|Active Comparator|femoral condyle|Core decompression of the talar avascular necrosis followed by free microvascular femoral condyle grafting
3040571|NCT02289976|Active Comparator|core decompression|Core decompression and nonvascularized autograft from the iliac crest
3040572|NCT02289963|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
3040573|NCT02289963|Placebo Comparator|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg SC injection Q2W added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
3040574|NCT02289950|Experimental|Farletuzumab|All subjects will receive a loading dose for the first 2 weeks of 10 mg/kg farletuzumab, followed by 5 mg/kg weekly farletuzumab administered intravenously (IV)
3040575|NCT02289950|Placebo Comparator|Placebo|All subjects will receive placebo weekly, administered intravenously (IV).
3040576|NCT02289937|Experimental|Ropivacaine|8 ml of ropivacaine 7,5 mg/ml will be injected around nervus cutaneous femoral lateralis. Ultrasound-guided.
3040577|NCT02289937|Placebo Comparator|Placebo|8 ml of isotonic saline will be injected around nervus cutaneous femoral lateralis. Ultrasound-guided
3040578|NCT02289924||Cohort 1|According to the recommendations of the Summary of Product Characteristics (SmPC) in Italy
3040579|NCT02289911|Active Comparator|Class|Traditional learning form
3040580|NCT02289911|Active Comparator|Web|Didactic training using internet
3040581|NCT02289898|Experimental|Abraxane® and gemcitabine plus placebo|Abraxane® and gemcitabine plus placebo (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression
3040582|NCT02289898|Experimental|Abraxane® and gemcitabine plus demcizumab plus placebo|Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression
3040583|NCT02289898|Experimental|Abraxane® and gemcitabine plus demcizumab|Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus demcizumab (3 cycles) and then Abraxane® and gemcitabine until disease progression
3040584|NCT02289885|Experimental|normal model patient|Images of the ultrasound window were captured to disk and later evaluated by an expert in emergency medicine. In this study, the FAST examination was measured to the perihepatic space (also called Morison's pouch or the hepatorenal recess), perisplenic space, pericardium, and the pelvis.
3040585|NCT02289885|Experimental|ascites positive model patient|Images of the ultrasound window were captured to disk and later evaluated by an expert in emergency medicine. In this study, the FAST examination was measured to the perihepatic space (also called Morison's pouch or the hepatorenal recess), perisplenic space, pericardium, and the pelvis.
3040586|NCT02289872|Experimental|Scenario A|The control scenario, where neither chest compression nor cervical stabilization was applied during intubation.
3040587|NCT02289872|Experimental|Scenario B|The chest compression scenario, where continuous chest compression was applied using chest compression system LUCAS-2 (Physio-Control, Redmond, WA, USA). Chest compression was provided at a rate of 100 min-1 to a depth of 5-6 cm during all intubation procedures.
3040588|NCT02289872|Experimental|Scenario C|The chest compression with cervical stabilization scenario, where both chest compression using Lucas-2 and cervical stabilization were applied. A correctly fitting standard cervical immobilization collar (StifNeck Select, Laerdal, Stavanger, Norway) was applied to the manikin's neck to prevent movement of the cervical spine.
3040589|NCT02289859|Active Comparator|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
3040590|NCT02289859|Active Comparator|Wound Closure without Undermining|One side of the wound will remain un-undermined.
3040591|NCT02289846|Placebo Comparator|Placebo BID|Placebo once in the morning and once in the evening.
3040592|NCT02289846|Experimental|IW-9179 QD AM + Placebo QD PM|IW-9179 once in the morning and placebo once in the evening.
3040593|NCT02289846|Experimental|Placebo QD AM + IW-9179 QD PM|Placebo once in the morning and IW-9179 once in the evening.
3040594|NCT02289846|Experimental|IW-9179 BID|IW-9179 once in the morning and once in the evening
3040595|NCT02289833|Experimental|Cohort IHC2+|Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.
3040596|NCT02289833|Experimental|Cohort IHC3+|Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.
3040597|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1|Participants will receive a single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.
3040689|NCT02289352|Placebo Comparator|Placebo|Topical gel base only (Watson Laboratories Inc., USA)
3040690|NCT02289339||TAVI patients|all patients undergoing transcatheter aortic valve prostheses implantation
3040598|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2|Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
3040599|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 5 mcg GLA), Cohort 3|Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
3040600|NCT02289820|Experimental|MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4|Participants will receive a single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.
3040601|NCT02289820|Active Comparator|Inactivated Influenza Vaccine (IIV)|Participants will receive a single dose of IIV by intramuscular injection in contralateral arms on Day 1.
3040602|NCT02289807|Experimental|RT group|intensity modulated-radiotherapy (IMRT) alone Patients receive intensity modulated-radiotherapy (IMRT) alone
3040603|NCT02289807|Active Comparator|CCRT group|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles
3040604|NCT02289794|Active Comparator|E.coli bioconjugate vaccine|E.coli bioconjugate vaccine in saline buffer
3040605|NCT02289794|Placebo Comparator|Placebo|Saline buffer
3040606|NCT02289781||Zirconia posterior crowns|Monolithic zirconia crowns which are polished and non-glazed
3040607|NCT02289781||Metal-Ceramic posterior crowns|Metal-supported glass-ceramic veneered crowns which are polished and non-glazed
3040608|NCT02289768|Experimental|5-fluorouracil/salicylic acid|Actikerall® solution (5-fluorouracil 0.5%, salicylic acid 10.0%) applied to the affected area once-daily for 12 weeks
3040609|NCT02289768|Placebo Comparator|Vehicle|Vehicle solution applied to the affected area once-daily for 12 weeks
3040610|NCT02289755|Experimental|ALLN-177|"Recurrent Calcium Oxalate Stone Formers with Hyperoxaluria Subjects with Enteric or Idiopathic hyperoxaluria~Dosing: 5 capsules of ALLN-177 orally (p.o.) up to 3 times daily (TID) with meals for 4 consecutive days."
3040611|NCT02289742|Other|Arm1: Presbyopes|Nelfilcon A contact lenses (multifocal and sphere) worn as randomized in a crossover design during Periods 1 and 2, with nelfilcon A sphere contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 12 hours.
3040612|NCT02289742|Other|Arm2: Astigmats|Nelfilcon A contact lenses (toric and sphere) worn as randomized in a crossover design during Periods 1 and 2, with nelfilcon A sphere contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 12 hours.
3040613|NCT02289729||Duodopa patients|Naive patients to Duodopa
3040614|NCT02289716|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase.
3040615|NCT02289716|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase.
3040616|NCT02289716|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase.
3040617|NCT02289703|Experimental|Group A|Participants with end-stage renal disease (ESRD), will receive a single 15-milligram (mg) oral dose of rivaroxaban in Treatment Period 1 on Day 1, administered 2 hours before the start of a 4-hour hemodialysis session followed 7 to 14 days later by Treatment Period 2 wherein a single 15-mg oral dose of rivaroxaban will be given 3 hours after the completion of a 4-hour hemodialysis session on Day 1.
3040618|NCT02289703|Experimental|Group B|Healthy control participants matching to 'Group A' participants, will receive a single 15-mg oral dose of rivaroxaban on Day 1.
3040619|NCT02289690|Experimental|Veliparib and carboplatin and etoposide|Veliparib in combination with carboplatin/etoposide followed by veliparib monotherapy
3040620|NCT02289690|Experimental|Veliparib and carboplatin and etoposide and placebo|Veliparib in combination with carboplatin/etoposide followed by placebo monotherapy
3040621|NCT02289690|Placebo Comparator|Placebo and Carboplatin and etoposide|Placebo in combination with carboplatin/etoposide followed by placebo monotherapy
3040622|NCT02289677|Experimental|Intubation during chest compression|Intubation during mannequin chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control, Redmond, WA, USA).
3040623|NCT02289664|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
3040624|NCT02289664|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3040625|NCT02289651|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
3040626|NCT02289651|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3040627|NCT02289638|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
3040628|NCT02289638|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3040629|NCT02289625|Active Comparator|Attentional performance in OSA|To investigate the attentional performance and muscle sympathetic nerve activity (MSNA) response during Color Word Stroop Test (CWST) in patients with obstructive sleep apnea (OSA) before and after intervention with exercise training.Individuals with no other comorbidities (age=52±1 years, body mass index=29±0.4) were divided in control (n=15) and untreated OSA (n=20) defined by polysomnography.
3040691|NCT02289313|Experimental|Youth Healthy Living Program|Youth attending the Rochester Alternative Learning Center (ALC) will be enrolled in a youth healthy living program at the ALC.
3040630|NCT02289625|Active Comparator|metaboreflex in OSA|"To investigate the metaboreflex control of MSNA before and after intervention with exercise training in patients with obstructive sleep apnea.~Methods: Thirty-five patients underwent conventional polysomnography. The MSNA was assessed by microneurography technique. Beat to beat blood pressure was measured during 4 minutes at rest, 3 minutes of isometric exercise at 30% maximal voluntary contraction, followed by 2 minutes of occlusion of the circulation in previously exercised muscle. The metaboreflex sensitivity was calculated during the first and second minutes of circulatory occlusion when metaboreceptors are evaluated independently of central command and muscle mechanoreceptors."
3040631|NCT02289612|Placebo Comparator|Tapioca Starch - Low-Fibre|Tapoica starch pudding without added fibre
3040632|NCT02289612|Placebo Comparator|High Maltose Corn Syrup - Low-Fibre|High maltose corn syrup pudding without added fibre
3040633|NCT02289612|Placebo Comparator|Trutol Glucose Beverage (#1)|Trutol Glucose Beverage containing 50 g of glucose without added fibre. Consumed at first treatment study visit.
3040634|NCT02289612|Placebo Comparator|Trutol Glucose Beverage (#2)|Trutol Glucose Beverage containing 50 g of glucose without added fibre. Consumed at final treatment study visit.
3040635|NCT02289612|Active Comparator|Yellow Mustard Gum Fibre - Tapioca Starch|Yellow mustard gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
3040636|NCT02289612|Active Comparator|Yellow Mustard Gum Fibre - High Maltose Corn Syrup|Yellow mustard gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
3040637|NCT02289612|Active Comparator|Soluble Flaxseed Gum Fibre - Tapioca Starch|Soluble flaxseed gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
3040638|NCT02289612|Active Comparator|Soluble Flaxseed Gum Fibre - High Maltose Corn Syrup|Soluble flaxseed gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
3040639|NCT02289612|Active Comparator|Fenugreek Gum Fibre - Tapioca Starch|Fenugreek gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
3040640|NCT02289612|Active Comparator|Fenugreek Gum Fibre - High Maltose Corn Syrup|Fenugreek gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
3040641|NCT02289599|Experimental|Part A: 1 mg E2307 (young cohort)|E2307 (1 x 1 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
3040642|NCT02289599|Experimental|Part A: 3 mg E2307 (young cohort)|E2307 (3 x 1 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
3040643|NCT02289599|Experimental|Part A: 10 mg E2307 (young cohort)|E2307 (1 x 10 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
3040644|NCT02289599|Experimental|Part A: 30 mg E2307 (young cohort)|E2307 (3 x 10 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
3040645|NCT02289599|Experimental|Part A: 100 mg E2307 (young cohort)|E2307 (1 x 100 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
3040646|NCT02289599|Experimental|Part A: 200 mg E2307 (young cohort)|E2307 (2 x 100 mg E2307 capsules) or placebo (2 x 1 E2307 matching placebo capsules)
3040647|NCT02289599|Experimental|Part A: 300 mg E2307 (young cohort)|E2307 (3 x 100 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
3040648|NCT02289599|Experimental|Part B: Elderly cohort|One dose level below MTD from Part A
3040649|NCT02289586|Active Comparator|hypoxemia, central airway stenosis.|"Inclusion Criteria:~(a)patients with central airway stenosis need interventional bronchoscopy (b) partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio less than 300;~Exclusion Criteria:~(a) facial deformity sufficient to preclude mask fitting; (b) upper gastrointestinal bleeding; (c) upper airway obstruction; (d) acute coronary syndromes; (e) tracheostomy or endotracheal intubation(ETI) before admission; (f) need for urgent ETI due to cardiac or respiratory arrest."
3040650|NCT02289586|Experimental|hypoxemia, central airway stenosis|"Inclusion Criteria:~(a)patients with central airway stenosis need interventional bronchoscopy (b) partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio less than 300;~Exclusion Criteria:~(a) facial deformity sufficient to preclude mask fitting; (b) upper gastrointestinal bleeding; (c) upper airway obstruction; (d) acute coronary syndromes; (e) tracheostomy or endotracheal intubation(ETI) before admission; (f) need for urgent ETI due to cardiac or respiratory arrest."
3040651|NCT02289573|Experimental|neurally adjusted ventilatory assist|
3040652|NCT02289573|Sham Comparator|pressure support ventilation|
3040653|NCT02289560|Experimental|Transcranial ExAblate|Transcranial ExAblate
3040654|NCT02289547|No Intervention|Group A|observational arm
3040655|NCT02289547|Experimental|Group B|arm of capecitabine maintenance treatment
3040656|NCT02289521|Active Comparator|Anodal Transcranial Direct Current Stim.|"Transcranial Direct Current Stimulation~Anodal (A-tDCS): Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20 min. To decrease current-induced injuries, at the beginning the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out)."
3040657|NCT02289521|Sham Comparator|Sham Transcranial Direct Current Stim.|"Transcranial Direct Current Stimulation~Sham: The parameters mimics the A-tDCS (electrode placement, fade-in and current intensity), except the stimulation duration: the current will reach 1.5mA in 30 sec (fade-in) and lasts only for 30 sec (to give the initial sensation of stimulation).~After the stimulation, language performance and EEG will be recorded. Order of interventions (anodal - sham) will be randomised across subjects."
3040658|NCT02289508||acute decompensated heart failure|Patients who fulfill Framingham criteria will be classified as acute decompensated heart failure (adHF). For this study we define this as an acute change in symptoms and signs within the previous 24 hours. When symptoms gradually deteriorate between one day and one month, it is described as gradual decompensated heart failure (gdHF). Some patients may have both.
3040659|NCT02289508||compensated heart failure|compensated heart failure (cHF) is defined as the existence of heart failure in the absence of any acute exacerbation but which may either include typical chronic symptoms and signs or may be asymptomatic but with evidence of cardiac dysfunction i.e. a reduced ejection fraction.
3040692|NCT02289300|Experimental|DCB-BO1202|
3040693|NCT02289300|Experimental|DCB-BO1202+Placebo|
3040694|NCT02289300|Placebo Comparator|Placebo|
3040695|NCT02289287|Experimental|Self-Management group-intervention|Participants will receive Self-Management group-intervention + Standard Care
3040660|NCT02289508||non-heart failure patients|Non-heart failure patients (nHFp) are a patient control group with suspected heart failure but who after further assessment are found not to meet the criteria. Such patients may subsequently be found to have COPD, anaemia, over transfusion. As the purpose of this study is to assess the potential value of USCOM parameters in the assessment of patients with possible heart failure in the clinical setting, it is important to include patients without heart failure.
3040661|NCT02289508||healthy controls|Healthy controls are subjects with not acute or chronic illness.
3040662|NCT02289495|Experimental|GSK2838232 without RTV|Subjects will receive 20 mg of GSK2838232/ placebo (3:1) in cohort 1 and 50 mg of GSK2838232/ placebo (3:1) in cohort 2, administered QD for 8 days. There will be a minimum period of 7 days between successive cohorts to establish safety and PK for dose escalation; enrollment into a cohort will commence following review of interim PK and safety data from at least 4 subjects in the preceding cohort
3040663|NCT02289495|Experimental|GSK2838232 with RTV|Subjects will receive 10 mg of GSK2838232/ placebo (3:1) in cohort 3, 20 mg of GSK2838232/ placebo (3:1) in cohort 4 and 50 mg of GSK2838232/ placebo (3:1) in cohort 5, co administered with RTV 100 mg, QD for 11 days. There will be a minimum period of 7 days between successive cohorts to establish safety and PK for dose escalation; enrollment into a cohort will commence following review of interim PK and safety data from at least 4 subjects in the preceding cohort
3040664|NCT02289482|Experimental|GSK2838232 Part A: Single Dose Escalation|During Part A, subjects will receive GSK2838232/ placebo (3:1) in 4-period (period 1: GSK2838232 200mg, period 2: GSK2838232 500mg), single dose escalation design. Subjects randomized to placebo will receive placebo in all four periods. Following completion of Period 2 PK assessments at 96hr post-dose, subjects will begin daily dosing of RTV 100mg (period 3: GSK2838232 20 mg + RTV 100 mg, period 4: GSK2838232 50 mg + RTV 100 mg) for a total of 26 days.
3040665|NCT02289482|Experimental|GSK2838232 Part B: Single Dose, 3-Period Crossover, Relative B|During Part B, subjects will receive GSK2838232/ placebo, in an open-label, unbalanced, 3-period, cross-over design; subjects will be randomized (1:1) to each sequence. The relative bioavailability of single 100 mg doses of powder in a bottle (PIB) Active Pharmaceutical Ingredient (API) of GSK2838232 versus PIB Spray-Dried Dispersion (SDD) will be assessed (Period 1: SDD GSK2838232 100 mg vs GSK2838232 API 100 mg; period 2: GSK2838232 API 100 mg Vs SDD GSK2838232 100 mg ). A single dose of GSK2838232 will be co-administered on the 10th day of RTV dosing (period 3:GSK2838232 10 mg + RTV 100 mg); RTV dosing will continue for an additional 4 days (total of 14 days).
3040666|NCT02289469|Experimental|PictureRx|PictureRx medication history platform
3040667|NCT02289469|No Intervention|Usual care|Usual medication history process
3040668|NCT02289456|Experimental|nab-Paclitaxel|"nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle~• Carboplatin AUC = 5 mg*min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion."
3040669|NCT02289443||Simplified|Complete denture fabricated by simple way than the textbook traditional method.
3040670|NCT02289443||Traditional|Complete denture fabricated by textbook discribed traditional method.
3040671|NCT02289430|Experimental|Crestor+Ezetrol|rosuvastatin+ezetimibe
3040672|NCT02289430|Active Comparator|Ezetrol|ezetimibe
3040673|NCT02289430|Active Comparator|Crestor|rosuvastatin
3040674|NCT02289417|Experimental|Apremilast 30 mg PO BID|"Apremilast 30 mg by mouth (PO) twice a day (BID) for 12 weeks .~After 12 weeks:~Subjects who achieve at least a 20% decrease from baseline in the TMS will continue to receive apremilast 30 mg BID for an additional 40 weeks. (Wk 52)~Subjects who do not achieve at least a 20% decrease from baseline in the TMS will receive apremilast 40 mg BID for an additional 40 weeks (Wk 52).~After 52 weeks, subjects who are eligible for the Extension Phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)"
3040675|NCT02289417|Experimental|Apremilast 40 mg PO BID|"Apremilast 40 mg by mouth (PO) twice a day (BID) for 12 weeks.~After 12 weeks, subjects assigned to the 40 mg BID dose of apremilast at baseline will continue to receive apremilast 40 mg BID for an additional 40 weeks (Wk 52).~After 52 weeks, subjects who are eligible for the Extension Phase will continue to receive apremilast 40 mg BID for an additional 52 weeks (Wk 104)"
3040676|NCT02289417|Placebo Comparator|Placebo BID|"Identically matching placebo by mouth (PO) twice a day (BID) for 12 weeks. After 12 weeks all subjects randomized to placebo at baseline will be re-randomized to receive apremilast 30 mg or 40 mg BID for an additional 40 weeks (Wk 52).~After Wk 52, subjects who are eligible for the Extension Phase will continue to to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)"
3040677|NCT02289404|Experimental|NVP-1203(Fed)|fed
3040678|NCT02289404|Active Comparator|NVP-1203(Fasting)|fasting
3040679|NCT02289391|Placebo Comparator|non-asthma group|"Non-asthma history~Infusion of normal saline(1μg/kg) at 10 minutes before anesthesia induction.~Infusion of normal saline at 0.4μg•kg-1•h-1during anesthesia maintenance.~Stop infusion of normal saline at 10 minutes before the end of surgery."
3040680|NCT02289391|Experimental|Dexmedetomidine A|"With a history of asthma~Infusion of dexmedetomidine(1μg/kg) at 10 minutes before anesthesia induction.~Infusion of dexmedetomidine at 0.4μg•kg-1•h-1during anesthesia maintenance.~Stop infusion of dexmedetomidine at 10 minutes before the end of surgery."
3040681|NCT02289391|Experimental|Dexmedetomidine B|"With a history of asthma~Infusion of dexmedetomidine(1μg/kg) at 10 minutes before anesthesia induction.~Infusion of dexmedetomidine at 0.7μg•kg-1•h-1during anesthesia maintenance.~Stop infusion of dexmedetomidine at 10 minutes before the end of surgery."
3040682|NCT02289391|Placebo Comparator|Control group|"With a history of asthma~Infusion of normal saline(1μg/kg) at 10 minutes before anesthesia induction.~Infusion of normal saline at 0.4μg•kg-1•h-1during anesthesia maintenance.~Stop infusion of normal saline at 10 minutes before the end of surgery."
3040683|NCT02289378|Experimental|Docetaxel, Oxaliplatin and 5-Fu|Docetaxel 50mg/m2 Oxaliplatin 85mg/m2 5-Fu 2800mg/m2 Repeated every two weeks
3040684|NCT02289365|Placebo Comparator|Group I|Totally 3000 mg of PEG-400 per day. 3 capsules of 500 mg PEG-400 per time, twice a day.
3040685|NCT02289365|Experimental|Group II|Totally 2000 mg of JBM-TC4 per day. 2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400 per time, twice a day.
3040686|NCT02289365|Experimental|Group III|Totally 3000 mg of JBM-TC4 per day. 3 capsules of 500 mg JBM-TC4 per time, twice a day.
3040687|NCT02289352|Experimental|brimonidine 0.33% gel|Brimonidine Topical Gel, 0.33%, 30 gram fill (Watson Laboratories, Inc., USA)
3040699|NCT02289261|Active Comparator|Control|Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
3040700|NCT02289261|Active Comparator|Morphine plus dexmedetomidine|Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
3040701|NCT02289248|Experimental|Ketamine/CBT Group|Subjects will undergo 2 week course of 4 intravenous infusions of ketamine (given twice weekly for two weeks) in combination with twice weekly cognitive behavioral therapy for a total of 8 weeks.
3040702|NCT02289235|Experimental|Ginger|Ginger powder capsule 500 mg daily for 3 months
3040703|NCT02289235|Placebo Comparator|Placebo|Placebo powder 1 capsule daily for 3 months
3040704|NCT02289222|Experimental|Pomalidomide, Dexamethasone & MK-3475|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days and dexamethasone is given at 40 mg orally weekly. MK3475 will be given as an intravenous infusion at 200 mg every 2 weeks (days 1 and 14).
3040705|NCT02289209|Experimental|Reirradiation + MK-3475|Reirradiation 1.2 Gy BID for 5 days a week for 5 weeks with MK-3475 (Keytruda, pembrolizumab) 200mg intravenous every 3 weeks until 3 months post completion of reirradiation.
3040706|NCT02289196|Experimental|Vx-006: 0,5mg|Six injections of Vx-006 at 0,5 mg + Montanide ISA51™ will be administrated every 3 weeks
3040707|NCT02289196|Experimental|Vx-006: 1mg|Six injections of Vx-006 at 1 mg + Montanide ISA51™ will be administrated every 3 weeks
3040708|NCT02289196|Experimental|Vx-006: 5mg|Six injections of Vx-006 at 5 mg + Montanide ISA51™ will be administrated every 3 weeks
3040709|NCT02289196|Experimental|Vx-006: 10mg|Six injections of Vx-006 at 10 mg + Montanide ISA51™ will be administrated every 3 weeks
3040710|NCT02289183|Experimental|Totally laparoscopic distal gastrectomy|The totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy will be performed for the treatment of patients with distal gastric cancer assigned to this group.
3040711|NCT02289183|Active Comparator|Laparoscopy-assisted distal gastrectomy|The laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis will be performed for the treatment of patients with distal gastric cancer assigned to this group.
3040712|NCT02289170|Experimental|Heating and cooling combination therapy|The patients in this group received heating and cooling combination therapy by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. Doctor press 8 acupuncture points which is treated in LBP patients and select the most painful 2 acupuncture points. Device's probe is attached to the acupuncture points in 15 minutes. Probe's temperature is changed 5 cycles from maximum 45℃ to minimum 15℃.
3040713|NCT02289170|Sham Comparator|Sham heating and cooling therapy|The patients in this group received sham heating and cooling combination therapy in same conditions of treatment group except the temperature. Before the treatment begin, caregiver measure the patient's skin temperature. Then probe's temperature is changed 5 cycles from 1℃ over the skin temperature to 1℃ under the skin temperature.
3040714|NCT02289157|Experimental|Negative Pressure Wound Therapy|After standard cesarean section completed patients will have Prevena negative pressure wound therapy system placed.
3040715|NCT02289157|No Intervention|Standard dressing|After standard cesarean section completed patients will have standard dressing placed.
3040716|NCT02289144|Experimental|Ceritinib|
3040717|NCT02289131|Experimental|Frequency of Once a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours)
3040718|NCT02289131|Experimental|Frequency of Twice a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 1:00 pm (+/- 1.5 hours)
3040719|NCT02289131|Experimental|Frequency of Three Times a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 1:00 pm (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 6:00 pm (+/- 1.5 hours)
3040720|NCT02289118|Experimental|Diagnostic Imaging|[18F]T807 imaging tracer.
3040721|NCT02289105|Experimental|Mandatory active choice|The mandatory active choice group will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
3040722|NCT02289105|No Intervention|Control|Participants in the control group will be presented an AD form only and will be encouraged to complete, and submit the form without having to declare the choice of completing or declining the AD.
3040723|NCT02289092|Experimental|Family Check-Up Intervention|Prior to the feedback session, trained clinicians will observe family interactions by reviewing the video-taped observations and questionnaires filled out by parents. Therapists then use this data to inform the intervention process and provide feedback to parents based on norms for this age period. Feedback sessions will include a discussion of goal attainment and plans to achieve goals, with specific attention to the parent's role in supporting positive behavior. Options for obtaining goals are based on the literature about empirically supported interventions for this age group and include (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
3040724|NCT02289092|No Intervention|Control|Control families will receive services as usual that are being provided to the families within their school
3040725|NCT02289079|Experimental|liposomal bupivacaine TAP|these patients receive a subcostal TAP with liposomal bupivacaine
3040726|NCT02289079|Active Comparator|bupivacaine TAP|These patients receive a subcostal TAP with bupivacaine
3040727|NCT02289053||Positive Family History|"Eligible participants with a family history of colorectal cancer or polyps will be grouped into the subjects group."
3040728|NCT02289053||Average Risk Patients|"Eligible participants without a family history of colorectal cancer or polyps will be grouped into the control group."
3040729|NCT02289040||Children undergoing cardiac surgery|Paediatric patients (<17 years with a body weight >2000g) undergoing cardiac surgery for congenital heart disease with extracorporeal circulation
3040730|NCT02289027|Experimental|Deployed volunteers - Group 1|Low dose cAd3-EBOZ (2.5x10e10 vp)
3040731|NCT02289027|Experimental|Deployed volunteers - Group 2|High dose cAd3-EBOZ (5x10e10 vp)
3040732|NCT02289027|Experimental|Not deployed volunteers - Group 3|Low dose cAd3-EBOZ (2.5x10e10 vp)
3040733|NCT02289027|Experimental|Not deployed volunteers - Group 4|High dose cAd3-EBOZ (5x10e10 vp)
3040735|NCT02289014|No Intervention|Wait-list control group|Wait-list control group
3040736|NCT02289014|Experimental|Active treatment group|online stress Management program
3040737|NCT02289001|Experimental|Education on SBAR worksheet|Training in the use of the SBAR worksheet created to structure information exchange between healthcare professionals
3040738|NCT02289001|No Intervention|No education on SBAR worksheet|The control group will participate in the simulation without any prior training in teamwork skills beyond those included in the undergraduate nursing degree curriculum, which the intervention group also received.
3040739|NCT02288988|Other|GERD patients with Short Esophagus|Patients with True Short Esophagus diagnosed intra-operatively: The length of the intra-abdominal portion of the esophagus < 2.5 cm measured intra-operatively using a combined endoscopic-laparoscopic method. Minimally invasive antireflux surgery was performed (Collis gastroplasty + Nissen fundoplication).
3040740|NCT02288975||CytoSorb|Patients with septic shock will get routine ICU care supported by CytoSorb® treatment.
3040741|NCT02288975||Control|Patients with septic shock will get routine ICU care.
3040742|NCT02288962|Experimental|cabergoline|"Target dose for cabergoline is 2 mg/week.The medication is administered in the evening to minimize side effects. If intolerable side effects occur despite this, it may be necessary to treat with a lower dose than 2 mg per week.~Treatment scheme: 0.5 mg x 1 per week the first 2 weeks, then 0.5 mg x 2 per week the next 2 weeks, then 1 + 0.5 mg per week the next 2 weeks, then 1 mg x 2 per week (target dose) for the rest of the study"
3040743|NCT02288962|No Intervention|observation|visits and controls as usual
3040744|NCT02288949||Validation cohort|Stratification of patients admitted into a network of Spanish ICUs.
3040745|NCT02288949||Confirmation Cohort|Stratification of patients admitted into a network of Chinese ICUs.
3040746|NCT02288936|Experimental|Enzalutamide|Enzalutamide 160 mg/day
3040747|NCT02288923|Active Comparator|Femoral nerve block|Femoral nerve block with 20ml 0.375% Levobupivacaine
3040748|NCT02288923|Active Comparator|Local Infiltration Analgesia|Local infiltration of knee joint using 40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve).
3040749|NCT02288897|Experimental|PV-10|Subjects will receive intralesional PV-10 to all Study Lesions on study Day 1. PV-10 should be re-administered at 28-day intervals until complete response, disease progression or study termination occurs.
3040750|NCT02288897|Active Comparator|Chemotherapy or Oncolytic Viral Therapy|Subjects will receive (a) dacarbazine (intravenously at 850 m/m2) or temozolomide (orally at 200 mg/m2 daily for 5 consecutive days), administered at consecutive 28-day intervals, or (b) intralesional talimogene laherparepvec administered on an initial 21 interval followed by consecutive 14 day intervals, until complete response, disease progression or study termination occurs.
3040751|NCT02288884|Active Comparator|Silver containing dressing|Subjects will have a silver containing dressing (Acticoat PostOp) applied at the time of elective cesarean section.
3040752|NCT02288884|Placebo Comparator|Standard dressing|Subjects will have a standard dressing (OpSite PostOp) applied at the time of elective cesarean section.
3040753|NCT02288871|Other|"Sutureless valve"|"Patients who underwent aortic valve replacement with a sutureless aortic valve.~An echocardiogram and a cardiac CT-scan will be conducted."
3040754|NCT02288871|Other|"Sewed-in valve"|"Patients who underwent aortic valve replacement with a sewed-in aortic valve. An echocardiogram and a cardiac CT-scan will be conducted."
3040755|NCT02288858|Active Comparator|Test product|Viviscal Oral Supplement Tablets (as 512mg coated red-brown tablets in unbranded blister packs)
3040756|NCT02288858|Placebo Comparator|Placebo|Placebo Tablets (as 512 coated red-brown tablets in unbranded blister packs)
3040757|NCT02288845|Experimental|ITI-007|ITI-007 formulated capsule will be administered orally once daily for up to 14 days in up to 14 subjects.
3040758|NCT02288832|Experimental|Innovative strategy (group A):|these women will undergo routine screening for bacterial vaginosis by analysis of their self-collected vaginal samples with this innovative technique; if the test is found to be positive, an appropriate treatment will be prescribed. The POC (point-of-care) test will be considered positive if: A. vaginae is detected at a threshold > 105.copies per ml and/or G. vaginalis > 105 copies per ml. The women with vaginosis will be screened monthly for recurrences through 28 weeks, and recurrence will be treated.
3040759|NCT02288832|Other|Standard strategy (group B):|This group will be followed according to the usual practices of the physicians seeing them.
3040760|NCT02288819|Experimental|Loop diuretic downtitration|Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
3040761|NCT02288780||Control|BPH patients with normal diastolic function
3040762|NCT02288780||Diastolic dysfunction|BPH patients with preoperative diastolic dysfunction
3040763|NCT02288767|Active Comparator|Control group|For the traditional method group, crystalloid and colloid (maximum 50 ml/kg) are provided through the traditional method of assessing the blood pressure, heart rate and urine volume.
3040764|NCT02288767|Experimental|SVV group|The method of fluid administration to be employed (traditional or SVV via a FloTrac/ EV1000™ monitor) is determined based on the group. Fluid administration is performed in accordance with the group; in general, about 10 ml/kg/h is administered although it may vary for each patient depending on the preoperative fasting, fluid loss during surgery (evaporation, emanation, urination, surgical area, etc.), and blood loss. Crystalloid is administered in the SVV-monitored group with a target below SVV 12%, and a 200-300 ml of colloid (maximum 50 ml/kg) is loaded when SVV is above 12%. If the patient shows hypertension even when SVV is below 12%, a vasoconstrictor should be administered intermittently or consistently.
3040765|NCT02288754||Stage II or III curative surgery (closed to accrual)|Patients with stage II or III solid tumors undergoing curative intend surgery enrolled before surgery.
3040766|NCT02288754||Stage II or III neoadjuvant therapy cohort (closed to accrual)|Patients with stage II or III solid tumors undergoing neoadjuvant therapy followed by curative intend surgery enrolled before neoadjuvant therapy.
3040767|NCT02288754||Metastatic disease|Patients with advanced, recurrent and/or metastatic disease requiring systemic therapy with chemotherapy, targeted therapy, immunotherapy or a combination of any before initiation of any therapy or a new line of therapy following documentation of disease progression on prior therapy.
3040768|NCT02288741|Experimental|A1: Induction chemotherapy|Anthracycline/dexamethasone-based induction chemotherapy Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
3040769|NCT02288741|Active Comparator|A2: No induction chemotherapy|Dexamethasone for control of symptoms Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
3040770|NCT02288741|Other|B: Observation|Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
3040771|NCT02288728|Experimental|Group B (double-track anastomosis)|Patients in the Group B will received the double-track anastomosis with proximal gastrectomy.
3040772|NCT02288728|Other|Group A (Gastric tube anastomosis)|Patients in the Group A (Gastric tube anastomosis) will take the gastric tube anastomosis with proximal gastrectomy.
3040773|NCT02288715||SAE|patient who develop encephalopathy in the progress of sepsis
3040774|NCT02288715||non-SAE|patient who do not develop encephalopathy in the progress of sepsis
3040775|NCT02288702||Normal|This is the group with no neurological problems or syndrome
3040776|NCT02288702||Down syndrome|This is the group with Down syndrome
3040777|NCT02288676||Cancer Case Group|Participants must have suspected or confirmed upper genital tract cancer (uterine, tubal and ovarian) and must be scheduled to undergo surgery for tumor removal.
3040778|NCT02288676||Control Group|Participants must not be under investigation for any pre-cancerous or cancerous lesions of the genital tract, and must be scheduled for a hysterectomy, bilateral salpingectomy with/without bilateral oopherectomy for presumed benign condition.
3040779|NCT02288663|Other|Freage group|only one group in this trial. All the participants will follow all the listed interventions.
3040780|NCT02288650|Experimental|Liberal group|Early refeeding
3040781|NCT02288650|Sham Comparator|Control group|Refeeding in the day case ward (usual practice)
3040782|NCT02288637|Experimental|Conventional Olyset LLIN|High coverage (>80% access) of conventional Olyset LLIN The arm is the standard of care from the National Malaria Control Program
3040783|NCT02288637|Experimental|Olyset Plus LLIN|High coverage (>80% access) of Olyset Plus LLIN
3040784|NCT02288637|Experimental|Conventional Olyset LLIN and IRS|High coverage (>80% access) of conventional Olyset LLIN and high coverage IRS (>80% of the household sprayed) with pirimiphos methyl CS
3040785|NCT02288637|Experimental|Olyset Plus LLIN and IRS|High coverage (>80% access) of Olyset Plus LLIN and high coverage Indoor Residual Spraying (>80% of the household sprayed) with pirimiphos methyl CS
3040786|NCT02288624|Placebo Comparator|Control|Water control (240 ml)
3040787|NCT02288624|Experimental|Orange Juice|Orange juice, 240 ml. Commercial orange juice
3040788|NCT02288624|Experimental|Whole orange|Whole orange, 240 ml. Whole orange, blended to include all edible orange material.
3040789|NCT02288624|Experimental|processed orange juice|Processed orange juice, 240 ml. Experimental orange juice processing
3040790|NCT02288611|Placebo Comparator|Maltodextrin/Dextrose mix|"Twenty-two healthy human individuals were randomly assigned to consume a control (maltodextrin-dextrose, 40.2g) at one of the arms period. Each arm was 21 days in duration, separated by a 14 days washout period.~P.S. placebo is called control in this study, where the bioactive comparator is a fruit."
3040791|NCT02288611|Active Comparator|Date fruit - Ajwa variety|Twenty-two healthy human individuals were randomly assigned to consume date fruits (approx. 50g) at one of the arms period. Each arm was 21 days in duration, separated by a 14 days washout period.
3040792|NCT02288598|Experimental|Anodal TDCS|Participants will receive anodal TDCS over the left inferior frontal cortex. TDCS will be delivered at 1milliampere (mA) intensity for 20 minutes during speech fluency training (5 consecutive days).
3040793|NCT02288598|Sham Comparator|Sham TDCS|Participants will receive sham TDCS over the left inferior frontal cortex. Sham stimulation will involve 30 seconds stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
3040794|NCT02288585|Active Comparator|Plant sterols|Plant sterols
3040795|NCT02288585|Placebo Comparator|Placebo product|Placebo product
3040796|NCT02288572|Active Comparator|Lactobacillus plantarum PCS 26|Dosage: 1.000.000.000 Colony Forming Units (CFU) per day in powdery form for 3 months Vehicle: 70 % glucose, 15 % powder milk, 15 % whey
3040797|NCT02288572|Placebo Comparator|Placebo|Only vehicle components in powdery form for 3 months Vehicle: 70 % glucose, 15 % powder milk, 15 % whey
3040798|NCT02288559|Experimental|Lampalizumab: Open-label Safety Run-In|Participants will receive 10 milligrams (mg) lampalizumab intravitreally Q2W during the safety run-in period.
3040799|NCT02288559|Experimental|Q2W Lampalizumab: Randomized Treatment|Participants will receive 10 mg dose of lampalizumab intravitreally Q2W during the 24-week treatment period.
3040800|NCT02288559|Experimental|Q4W Lampalizumab: Randomized Treatment|Participants will receive 10 mg dose of lampalizumab intravitreally Q4W during the 24-week treatment period.
3040801|NCT02288559|Sham Comparator|Sham: Randomized Treatment|Participants randomized to control arms will receive sham injections, that mimics intravitreal injection of lampalizumab.
3040802|NCT02288546||Vegans|Vegans' data are compared with those of sex-and age-matched non vegetarians
3040803|NCT02288546||Non-vegans|Non-vegans are age and sex-matched controls
3040804|NCT02288533|Experimental|real-tDCS|Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).
3040805|NCT02288507|Experimental|sorafenib & Yttrium-90 radioembolization|Sorafenib dose de-escalation starting at 400mg PO BID starting on Day1 Yttrium-90 radioemoblization on Day 14
3040806|NCT02288494||hypoalbuminemia|The primary purpose was to describe the acid base balance of ICU patients with severe hypoalbuminemia using Stewart's approach for acid base disorders, before and after an human albumin perfusion
3040807|NCT02288481|Experimental|Cohort 1 10 mg TBA-354|
3040808|NCT02288481|Placebo Comparator|Cohort 1 placebo|Placebo Suspension
3040819|NCT02288468|Experimental|STN|"Deep Brain Stimulation of Nucleus subthalamicus with Vercise™ Deep Brain Stimulation System.~The STN will be typically reached with the most distal contacts of the DBS electrode (8 contact). Imaging studies (postop helical CT and re-fusion to planning MRI data) will allow for the identification of contacts located in the STN. We expect the STN to be typically covered by contacts 1-4 of the Vercise™ DBS lead. Typically, only the most superficial contacts (3,4) will be activated after a monopolar review of each contact. In this monopolar review the therapeutic widths of each contact will be tested for its effectiveness in tremor reduction, reduction of rigidity and bradykinesia. Typical settings will be: Frequency 130-180 Hz, pulse width 60-90 us, Amplitude 1-7 mA."
3040820|NCT02288468|Experimental|Vim/DRT|"Deep Brain Stimulation of Ventral intermediate nucleus with Vercise™ Deep Brain Stimulation System.~The thalamic target (Vim/DRT) will be typically reached with the proximal contacts. Imaging studies (postop helical CT and re-fusion to planning MRI data) will allow for the identification of contacts located the thalamic target. We expect the thalamic target to be typically covered by contacts 5-8 of the Vercise™ DBS lead. We will perform a monopolar review of each contact. In this monopolar review the therapeutic widths of each contact will be tested for its effectiveness in tremor reduction and the occurrence of side effects (typically capsular e.g. facial contraction). Typical settings will be: Frequency 130-180 Hz, pulse width 60-90 us, Amplitude 1-7 mA."
3040821|NCT02288468|Experimental|STN+Vim/DRT|"Combined Deep Brain Stimulation of Nucleus subthalamicus and Ventral intermediate nucleus with Vercise™ Deep Brain Stimulation System.~STN+Vim/DRT stimulation is essentially a combination of the previously described procedure."
3040822|NCT02288455|Experimental|RELIEF II - GTU AUS|Prospective, non-randomized multi-center study testing the safety and efficacy of the GTU Artificial Urinary Sphincter device in males with stress urinary incontinence.
3040823|NCT02288442|No Intervention|control|
3040824|NCT02288442|Experimental|exercise|exercise intervention during 8 weeks
3040825|NCT02288429||Colistin|"Patients ≥ 18 years old receiving intravenous colistimethate sodium for the treatment of infection~Have cystic fibrosis and/or are critically ill (admitted to a critical care unit)"
3040826|NCT02288416|Active Comparator|Group I (standard of care)|Patients receive standard of care following LCS consisting of routine visits and telephone contact with the LCS program nurse practitioner and coordinator.
3040827|NCT02288416|Experimental|Group II (video-based intervention)|Patients undergo a video-based intervention prior to undergoing LCS. Patients watch a 5-minute video that focuses on preparing patients for LCS by providing information on the following: program team and contact information; reason to be screened; screening eligibility; how screening is performed; what to expect on the day of screening; what to expect after screening; what to expect if result is positive; what to expect if result is negative; and risks of screening. Patients also receive an educational handbook. Patients with positive scans (a Lung-RADS 3 or 4) receive additional brochure and nursing support within 1 week after notification of scan results.
3040828|NCT02288403|Experimental|Aerobic interval training|"Interval exercise at an intensity between 90-95% of maximum heart rate (15x30 s), with recoveries at an equivalent speed to 50-55 % of maximal oxygen consumption at baseline (14x60 s).~24 training sessions, 3x weekly (on alternate days)."
3040829|NCT02288403|Active Comparator|Continuous training|"40 minutes of continuous exercise at an intensity between 65-75% of maximum heart rate.~24 training sessions, 3x weekly (on alternate days)."
3040830|NCT02288390|Active Comparator|Miswak (Sewak)|Miswak (sewak) oral care applied 4 hourly for oral care in mechanically ventilated patients.
3040831|NCT02288390|Active Comparator|Chlorhexidine/ toothbrush|Chlorhexidine 0.12 % plus toothbrushing oral care applied 4 hourly for oral care in mechanically ventilated patients.
3040832|NCT02288377|Experimental|lanreotide|In this arm, patients will receive lanreotide 120 mg every 28 days until disease progression
3040833|NCT02288377|Placebo Comparator|placebo|In this arm, patients will receive placebo every 28 days until disease progression
3040834|NCT02288364|Active Comparator|1% Lidocaine|1% Lidocaine alone.
3040835|NCT02288364|Active Comparator|1% Lidocaine plus sodium bicarbonate|1% Lidocaine plus 8.4% sodium bicarbonate
3040836|NCT02288351|Other|RYGB with mucosal abnormality on EGD|Subjects with Type 2 Diabetes undergoing a Roux-en-Y Gastric Bypass with a diagnosis of gastritis, esophagitis, ulcer, or other mucosal abnormality discovered at routine preoperative upper endoscopy, requiring follow-up endoscopy in the post-operative period.
3040837|NCT02288338|Experimental|1(Lipitor®>Ezetrol®>Lipitor®, Ezetrol®)|"Three treatment~atorvastatin calcium 40mg will be administration to healthy volunteers during 7days~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days"
3040838|NCT02288338|Experimental|2(Ezetrol®>Lipitor®, Ezetrol®>Lipitor®)|"Three treatment~ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days"
3040839|NCT02288338|Experimental|3(Lipitor®, Ezetrol®>Lipitor®>Ezetrol®)|"Three treatment~atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days"
3040840|NCT02288338|Experimental|4(Lipitor®>Lipitor®, Ezetrol®>Ezetrol®)|"atorvastatin calcium 40mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days"
3040841|NCT02288338|Experimental|5(Ezetrol®>Lipitor®>Lipitor®, Ezetrol®)|"ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days"
3040880|NCT02288130|No Intervention|Control|No pre-treatment prior to laparoscopic myomectomy
3040943|NCT02287714|Experimental|Instep with Gastrocnemius Recession|Patient will receive an instep plantar fascial release as well as a gastrocnemius recession.
3040944|NCT02287701|Experimental|PET/MRI|Patient receives MRI
3040842|NCT02288338|Experimental|6(Lipitor®, Ezetrol®>Ezetrol®>Lipitor®)|"atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days"
3040843|NCT02288325|Experimental|Levomilnacipran ER|40mg, 80mg or 120mg levomilnacipran ER (Extended Release)
3040844|NCT02288325|Placebo Comparator|Placebo|Dose-matched placebo
3040845|NCT02288312|Experimental|BIA 2-093 800 mg fasting|Tablets 800 mg. Administration:Oral.
3040846|NCT02288312|Experimental|BIA 2-093 800 mg fed|Tablets 800 mg. Administration:Oral.
3040847|NCT02288312|Experimental|BIA 2-093 400 mg|Tablets 2 x 400 mg. Administration:Oral.
3040848|NCT02288299|Experimental|non invasive mechanical ventilation|Patients suffering from neuromuscular disease with NIV indication and cough inefficiency
3040849|NCT02288286|Experimental|2.5IU/ml in humans aged 10-20 years old|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 10-20 years old on days 0,3,7,14,28
3040850|NCT02288286|Experimental|2.5IU/ml in humans aged 21-50|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 21-50 years old on days 0,3,7,14,28
3040851|NCT02288286|Experimental|2.5IU/ml in humans aged 51-60|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 51-60 years old on days 0,3,7,14,28
3040852|NCT02288286|Placebo Comparator|2.5IU/ml in humans(from 10-20 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 10-20 years old on days 0,3,7,14,28
3040853|NCT02288286|Placebo Comparator|2.5IU/ml in humans(from 21-50 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 21-50 years old on days 0,3,7,14,28
3040854|NCT02288286|Placebo Comparator|2.5IU/ml in humans(from 51-60 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 51-60 years old on days 0,3,7,14,28
3040855|NCT02288273|Experimental|Bydureon|Once weekly injected exenatide
3040856|NCT02288273|Placebo Comparator|Placebo|Placebo comparator
3040857|NCT02288260||Part A|PATIENTS RECEIVED THE STANDARD MEDICAL CARE AS DETERMINED BY THE TREATING CARDIOLOGIST
3040858|NCT02288260||Part B|Patients on ticagrelor at the time of discharge from hospital
3040859|NCT02288247|Experimental|Enzalutamide with docetaxel + prednisolone|Continued treatment with enzalutamide after adding docetaxel and prednisolone
3040860|NCT02288247|Placebo Comparator|Placebo with docetaxel + prednisolone|Treatment with placebo after adding docetaxel and prednisolone
3040861|NCT02288234||Patients receiving Vibativ|
3040862|NCT02288221|Experimental|With non pharmacological therapeutic|Installation of ICT at patient's home
3040863|NCT02288221|Active Comparator|Without non pharmacological therapeutic|No change at patient's home
3040864|NCT02288208|Experimental|Antiviral Therapy & Birinapant|Antiviral therapy (tenofovir 300 mg or entecavir 0.5 mg) taken once daily by mouth, and birinapant administered as a 30 minute IV infusion once weekly for four weeks.
3040865|NCT02288208|Placebo Comparator|Antiviral Therapy & Placebo|Antiviral therapy (tenofovir 300 mg or entecavir 0.5 mg) taken once daily by mouth, and placebo (for birinapant) administered as a 30 minute infusion once weekly for four weeks.
3040866|NCT02288195|Experimental|Chemotherapy|Patients receive neoadjuvant chemotherapy comprising oxaliplatin 130mg/m² ivdrip over 2 hours on day 1,capecitabine 2000 mg/m² on days 1-14, treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.Patients without disease progression undergo low-anterior resection (LAR) with total mesorectal excision (TME) and 4 cycles of XELOX ( oxaliplatin 130mg/m² day 1，capecitabine 2000mg/m² days 1-14, repeated every 21 days). Patients with disease progression undergo chemoradiation as in group chemoradiotherapy before proceeding to LAR with TME.
3040867|NCT02288195|Experimental|Chemoradiotherapy|Patients receive capecitabine 825 mg/m² twice daily concurrently with radiation therapy for 5 days per week. Patients also undergo intensity-modulated radiation therapy 5 days a week for approximately 5.5 weeks. Patients then undergo LAR with TME and 4 cycles of XELOX ( oxaliplatin 130mg/m² day 1，capecitabine 2000mg/m² days 1-14, repeated every 21 days) .
3040868|NCT02288182|Experimental|Straumann VivOss|Straumann® VivOss™Straumann® VivOss™, is a synthetic bone graft substitute in granulated form. It consists of > 90% TCP (Tri-Calcium-Phosphate -Ca3(PO4)2) and < 10% Hydroxyapatite (Ca10(PO4)6 (OH)2). The granules have a size of 250-1000 μm.
3040869|NCT02288182|Active Comparator|Geistlich Bio-Oss|The control device is Geistlich Bio-Oss® spongiosa granules (Geistlich Pharma AG, Wolhusen, Switzerland), 0.25-1 mm in diameter. It's a natural bone mineral of bovine origin. It shall be used according to the instructions of the manufacturer.
3040870|NCT02288169|Experimental|COPE|The experimental group will receive usual care plus the COPE intervention. This group will receive 3 individual intervention sessions. During the first intervention visit at the cancer center, the COPE group will be taught the COPE intervention in a session focusing on the patient's self-identified most bothersome symptom. Role modeling and additional instruction will be provided via video, and patients will receive the Home Care Guide for Cancer and a copy of the video to take home. Three subsequent visits with the patient during regularly scheduled clinic visits will reinforce the principles of COPE and the use of the Home Care Guide, and will help patients apply this approach to managing other symptoms. In addition they will get 2 phone calls encouraging them to apply COPE.
3040871|NCT02288169|Sham Comparator|Support|The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls, matched for time with COPE participants.
3040872|NCT02288169|No Intervention|Control|The control group will receive usual care and no additional attention from our interventionists.
3040873|NCT02288156|Active Comparator|0,1mM|
3040874|NCT02288156|Experimental|0,01mM|
3040875|NCT02288156|Experimental|0.001mM|
3040876|NCT02288156|Placebo Comparator|Placebo|
3040877|NCT02288143|Experimental|COOL-COS|All women will receive the intervention: Letrozole, Clomiphene, and low-dose hMG for the controlled ovarian stimulation.
3040878|NCT02288130|Active Comparator|GnRHa and placebo tablets|11.25 mg Leuproreline injections at the onset of pretreatment with placebo tablets (once daily)
3040879|NCT02288130|Active Comparator|Ulipristal|Three months of Ulipristal 5 mg once daily combined with a single saline injection at the onset of pretreatment (produced as placebo of Leuproreline)
3040881|NCT02288104|Other|needle based confocal endomicroscopy|The patient, scheduled for a standard liver or kidney percutaneous biopsy or ablation will undergo a needle-based confocal laser endomicroscopy procedure during the procedure. The objectives of this study are to demonstrate the technical feasibility and safety of doing endomicroscopic imaging during interventional radiology procedure and determine whether it is technically feasible to obtain images from Cellvizio during an interventional radiology procedure.
3040882|NCT02288091|Experimental|Open-label|Subjects will receive oral inosine daily.
3040883|NCT02288078|Active Comparator|Treatment group|"Treatment with regorafenib (160 mg/day, oral administration, 3 weeks on therapy followed by 1 week off therapy), test drug capsule (dexamethasone 2 mg) and proton pump inhibitors (PPIs) will be started within 14 days of enrollment. The protocol treatment period is 4 weeks.~Follow-up treatment for the underlying disease after the 4-week protocol treatment is not specified. The physician in charge will decide whether or not to continue treatment with regorafenib. For the prevention of fatigue/malaise, dexamethasone 2 mg can be used.~General condition, blood pressure, Patient Reported Outcome, clinical findings, hematology/blood chemistry, coagulation and fibrinolysis system, urinalysis, medicatiob check, adverse event, thyroid function test, brain MRI, Contrast-enhanced torso CT"
3040884|NCT02288078|Placebo Comparator|Placebo group|"Treatment with regorafenib (160 mg/day, oral administration, 3 weeks on therapy followed by 1 week off therapy), placebo capsule (lactose) and proton pump inhibitors (PPIs) will be started within 14 days of enrollment. The protocol treatment period is 4 weeks.~Follow-up treatment for the underlying disease after the 4-week protocol treatment is not specified. The physician in charge will decide whether or not to continue treatment with regorafenib. For the prevention of fatigue/malaise, dexamethasone 2 mg can be used.~General condition, blood pressure, Patient Reported Outcome, clinical findings, hematology/blood chemistry, coagulation and fibrinolysis system, urinalysis, medication check, adverse event, thyroid function test, brain MRI, Contrast-enhanced torso CT"
3040885|NCT02288065||responders|amelioration of dyspnea radiological amelioration after sterile talc pleurodesis
3040886|NCT02288065||failed intervention|unchanged symptoms and radiology after sterile talc pleurodesis
3040887|NCT02288052|Experimental|Writing program|The program will train participants in maintaining writing amplitude, writing speed, writing fluently and automatization of writing.
3040888|NCT02288052|Placebo Comparator|Stretch & Relaxation program|The program will learn participants to alleviate tension in the upper limbs and will consist of exercises performed while lying down or sitting.
3040889|NCT02288039|Experimental|Social Identity Goal-Based Intervention|Participants will receive collaborative goal-setting
3040890|NCT02288039|No Intervention|Standard Care|Participants will receive usual standard treatment
3040891|NCT02288026||Arm I|Patients undergo lobectomy
3040892|NCT02288026||Arm II|Patients undergo a wedge resection or anatomical segmentectomy
3040893|NCT02288013|Other|Stratafix Tissue control device|Closure of Uterine incision at C section
3040894|NCT02288013|Other|Vicryl suture|Closure of uterine incision at C section
3040895|NCT02288000|Active Comparator|Memantine|Memantine will be administered OS as of 10 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
3040896|NCT02288000|Placebo Comparator|Placebo|The placebo will be presented as tablet comparable to Ebixa
3040897|NCT02287987|Active Comparator|Clamp|Laparoscopic robot-assisted partial nephrectomy with clamping the renal pedicle during the resection of the tumor
3040898|NCT02287987|Experimental|Off clamp|Laparoscopic robot-assisted partial nephrectomy without clamping the renal pedicle during the resection of the tumor
3040899|NCT02287974|Experimental|Autologous mononuclear stem cell from the bone marrow|Autologous mononuclear stem cell from the bone marrow in an unique infusion of 150-250 millions of cells
3040900|NCT02287974|Experimental|Autologous endothelial stem cell from the bone marrow|Autologous endothelial progenitor CD133 stem cell from the bone marrow in an unique infusion of 2 - 7 millions of CD133 cells
3040901|NCT02287974|Experimental|Autologous mesenchymal stem cells from the adiposite tissue|Autologous mesenchymal stem cells from the adipose tissue in an unique infusion of 0.5 millions of cells
3040902|NCT02287974|Active Comparator|Current medication for the disease|Current medication for the disease
3040903|NCT02287961|Other|Subjects|"Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits~High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits~Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy~High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3)"
3040904|NCT02287948||MS subjects group|Multiple sclerosis subjects wiht mild-moderate gait disability with EDSS score not higher than 5.5
3040905|NCT02287948||Healthy subjects group|Healthy subjects age-matched with multiple sclerosis subjects.
3040906|NCT02287935|Active Comparator|Limberg flap|Patients were divided into two groups, group 1 were treated with Limberg flap technique
3040907|NCT02287935|Active Comparator|Karydakis procedure|Patients were divided into two groups, group 2 were treated with Karydakis procedure
3040908|NCT02287922|Experimental|ALX-0061 dose A + Placebo|"Dose A of ALX-0061: every 4 weeks from Week 0 through Week 12~Placebo: every 2 weeks from Week 0 through Week 12"
3040909|NCT02287922|Experimental|ALX-0061 dose B + Placebo|"Dose B of ALX-0061: every 2 weeks from Week 0 through Week 12~Placebo: every 2 weeks from Week 0 through Week 12"
3040910|NCT02287922|Experimental|ALX-0061 dose C|- Dose C of ALX-0061: every 2 weeks from Week 0 through Week 12
3040911|NCT02287922|Active Comparator|Tocilizumab|- Open-label TCZ according to the TCZ dosing regimen approved per region
3040912|NCT02287909|Experimental|A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
3040941|NCT02287727|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3065819|NCT02122705||VPIA remifentanil|VPIA remifentanil labour analgesia
3040913|NCT02287909|Experimental|B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
3040914|NCT02287909|Experimental|C) clopidogrel 75mg MD 24 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
3040915|NCT02287909|Active Comparator|D) continue ticagrelor MD 90mg twice daily|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
3040916|NCT02287896|Experimental|Roledumab Open-label|"- Planned antenatal prophylaxis: A single dose of 300 µg IM/IV of Roledumab at 28 or 29 weeks of gestation.~- Antenatal prophylaxis following sensitising events: One or more dose(s) of 300μg IM/IV anti-RhD antibodies (Rhophylac or Roledumab) based on the Kleihauer-test as soon as possible and no later than 72 hours after event occurrence.~- Postnatal prophylaxis: Roledumab should be administered to the mother as soon as possible within 72 hours of delivery of an RhD positive infant.~The postnatal dose must still be given even when antenatal prophylaxis has been administered.~Before Roledumab 300μg IM/IV postnatal administration, a Kleihauer-Betke test will be performed on maternal blood sample taken no earlier than 30 min after delivery in order to determine the volume of foetomaternal haemorrhage (FMH)."
3040917|NCT02287883||Patients at high PAE clinic|"Patients with diabetes or cardiovascular disease receiving care within two Accountable Care Organizations (ACOs) at clinics with high implementation of patient activation and engagement activities.~Observational: Patient Activation and Engagement (PAE)"
3040918|NCT02287883||Patients at low PAE clinic|"Patients with diabetes or cardiovascular disease receiving care within two Accountable Care Organizations (ACOs) at clinics with low implementation of patient activation and engagement activities.~Observational: Patient Activation and Engagement (PAE)"
3040919|NCT02287870|Experimental|Chloroprocaine Group|Epidural anesthesia with 3% chloroprocaine.
3040920|NCT02287870|Active Comparator|Lidocaine Group|Epidural anesthesia with 2% lidocaine.
3040921|NCT02287857|Experimental|Domestic Tenofovir Disoproxil Fumarate Tablets|
3040922|NCT02287857|Active Comparator|Tenofovir Disoproxil Fumarate Tablets of Gilead|
3040923|NCT02287844|Experimental|XOS group|Subjects consumed 6.64 g of a XOS-enriched compound derived from wheat arabinoxylans (5 g of XOS) everyday for 4 weeks.
3040924|NCT02287844|Experimental|INU-XOS group|Subjects consumed 6.64 g of a mixture containing inulin-type fructans, XOS and maltodextrins (3 g of inulin and 1 g of XOS) everyday for 4 weeks.
3040925|NCT02287844|Active Comparator|Placebo|Subjects consumed 6.64 g of wheat maltodextrins everyday for 4 weeks.
3040926|NCT02287831|Experimental|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
3040927|NCT02287818|Placebo Comparator|Placebo|Placebo plus Febuxostat
3040928|NCT02287818|Experimental|AC-201|AC-201 CR tablet plus Febuxostat
3040929|NCT02287805||quantitative survey 1|parents of 300 patients with craniosynostosis diagnostic
3040930|NCT02287805||qualitative survey|"parents of 12 newly diagnosed patients, they will be seen 3 times (after the diagnosis, 3 months after surgery, 1 year after surgery~12 patients aged over 15 years, operated more than 10 years before"
3040931|NCT02287805||quantitative survey 2|"100 parents of patients 1 year after surgery~100 parents of patients, 5 years after the operation~100 patients aged over 15 years and operated over 10 years ago"
3040932|NCT02287792|Experimental|18-FDG PET/CT scan|All patients will undergo a whole body PET/CT scan
3040933|NCT02287779|Experimental|SHP626|9/12 subjects -1x daily dose of 20mg for 12 days 9/12 subjects-1x daily dose of 40mg for 12 days 9/12 subjects-1x daily dose of 80mg for 12 days 9/12 subjects-1x daily dose of 120mg for 12 days or dose lower than 80mg for 12 days 9/12 subjects-1x daily dose of 160mg for 12 days or dose lower than 80mg for 12 days 9/12 subjects-2x daily dose of SHP626 (dose TBD) for 12 days 9/12 subjects-2x daily dose of SHP626 (dose TBD; lower or higher than cohort 6) for 12 days 9/12 subjects-1x or 2x daily dose of SHP626 in an escalating titration (doses TBD). Initial 3 days of SHP626 followed by an increased dose of SHP626 for 3 days and finally a further increase in dose of SHP626 for 6 days 9/12 subjects will take a 1x or 2x daily dose of SHP626 in escalating titration (doses TBD; lower or higher dose than cohort 8). Initial 3 days of SHP626 followed by an increased dose of SHP626 for 3 days and finally a further increase in dose of SHP626 for 6 days
3040934|NCT02287779|Placebo Comparator|Placebo|Three subjects per cohort will take a matched placebo
3040935|NCT02287766||Control|Men and women ages 21-85 lacking any medical diagnosis (as defined in the protocol) of one or more of the following cancer, coronary artery disease or heart attack, renal failure or dialysis, hepatitis, Multiple Sclerosis, or any autoimmune disorder.
3040936|NCT02287766||Metabolic Syndrome Diagnosis Group|Men and women ages 21-85 with at least of at least three of the following (as defined in the protocol) : Elevated waist circumference, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, elevated fasting glucose.
3040937|NCT02287753|Experimental|Vascular occlusion test (VOT)|Pediatric patients aged under 8 years old are enrolled in this study. VOT is performed in 3 times : after induction of anesthesia, during cardiopulmonary bypass (CPB) for main surgical procedure and after weaning from CPB. The relationship between postoperative outcome variables and the dynamic parameters from VOT, such as desaturation and reoxygenation rate, and reactive hyperemic area, will be evaluated.
3040938|NCT02287740|Experimental|Tai Ji Quan: Moving for Better Balance|This protocol involves training 2 times a week for 6 months.
3040939|NCT02287740|Active Comparator|Multimodal Exercise|This protocol involves training 2 times a week for 6 months.
3040940|NCT02287740|Sham Comparator|Stretching|This protocol involves participation of 2 times a week for 6 months.
3040942|NCT02287714|Active Comparator|Instep without Gastrocnemius Recession|Patient will receive an instep plantar fascial release but not a gastrocnemius recession.
3040945|NCT02287688||Exposure group|Children 2-23 months of age who receive at least one dose of MenACWY-CRM vaccine at a Kaiser Permanente Southern California (KPSC) facility while enrolled as a KPSC health plan member.
3040946|NCT02287675|Active Comparator|Lymphoseek|Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma and guiding sentinel lymph node biopsy using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.
3040947|NCT02287675|Active Comparator|Sulfur Colloid|"Technetium Tc 99m Sulfur Colloid Injection is a radioactive diagnostic agent indicated for use as follows:~In adults, to assist in the:~localization of lymph nodes draining a primary tumor in patients with~breast cancer or malignant melanoma when used with a hand-held gamma counter.~evaluation of peritoneovenous (LeVeen) shunt patency in adults."
3040948|NCT02287662|Experimental|Vancouver 3M Clinical Pathway|The Vancouver 3M Clinical Pathway utilizes objective anatomical and functional screening criteria as well as strict peri-procedural guidelines to determine if next day discharge home is appropriate.
3040949|NCT02287649|Other|patients with rituximab treatment|blood sample intake
3040950|NCT02287636|Experimental|Diagnostic (fludeoxyglucose F 18 PET/CT and PET/MRI)|Patients undergo fludeoxyglucose F 18 PET/CT followed by PET/MRI.
3040951|NCT02287623|Experimental|liposomal bupivacaine TAP|Patients will receive a TAP block with liposomal bupivacaine
3040952|NCT02287623|Active Comparator|bupivacaine TAP|Patients will receive a TAP block with bupivacaine
3040953|NCT02287597||Cohort|
3040954|NCT02287584|Placebo Comparator|DSP-5423P Placebo|Percutaneous
3040955|NCT02287584|Experimental|DSP-5423P 40mg|Percutaneous
3040956|NCT02287584|Experimental|DSP-5423P 80mg|Percutaneous
3040957|NCT02287571|Active Comparator|Skin traction|Prior to hip fracture surgery, affected limb was wrapped with a special elastic bandage and pulled from the sole of the foot with a weight of 5-10% of total body weight of the patient (min 2.3 kg, max 4.5 kg).
3040958|NCT02287571|Experimental|Position splint|Prior to hip fracture surgery, position splint was applied to the affected limb in order to keep the extremity in the proper positon without any weight lifting.
3040959|NCT02287558|Experimental|Pomalidomide|Pomalidomide will be supplied as 1.0 mg, 2.0 mg, 3.0 mg and 4.0 mg capsules for oral administration. The principal investigator will determine whether intrapatient dose escalation is indicated based on the response of the patient's bleeding during the first 30 days of therapy. If dose escalation is indicated, pomalidomide will be increased by 1 mg/month at the investigator's discretion to a maximal dose of 5 mg/day.
3040960|NCT02287545||Glaucoma, primary|Glaucoma patients undergoing trabeculectomy
3040961|NCT02287532|Experimental|DIABEO software alone|Patient will have an introductory training session in the use of DIABEO by the investigating physician an will return for an on site consultation at 6 mounths (optional), 12 mounths and 24 mounths
3040962|NCT02287532|Experimental|DIABEO+paramedical telemonitoring|"Patient will have an on site introductory training session in the use of DIABEO, by his/her telemedicine nurse from his/her region. The nurse will then follow up the patient according to a delegated tasks protocol written by the investigating physician with the nurse. Patient will be asked to return to see the investigator at 6 mounths (optional), 12 mounths and 24 mounths"
3040963|NCT02287532|No Intervention|Usual Follow up|Patient will continue his/her usual follow up and return to see the investigator at 6 mounths (optional) and at the one year end of follow up for the study
3040964|NCT02287519|Experimental|Support Group|"One group educational session will include information on resources, self-help strategies, and relaxation techniques.~One telephone coaching session after the group session Or~Pilot webinar format of the educational session"
3040965|NCT02287506|Experimental|ODS from enrolment|Optimised Diagnostic Strategy used from enrolment to study
3040966|NCT02287506|No Intervention|ODS at end of study|ODS fed back at the end of the participants involvement with the study
3040967|NCT02287493||Meropenem|Adult ICU patients receiving meropenem during SLED will be analyzed for meropenem pharmacokinetics.
3040968|NCT02287493||Ceftazidim|Adult ICU patients receiving ceftazidim during SLED will be analyzed for ceftazidim pharmacokinetics.
3040969|NCT02287480|Experimental|VSV-ZEBOV lower dose|"One intramuscular (deltoid) injection of a lower dose (10^7 plaque-forming units) of VSV-ZEBOV.~Study amendment (01.2015) : One intramuscular (deltoid) injection of a markedly lower dose (3x 10^5 plaque-forming units) of VSV-ZEBOV"
3040970|NCT02287480|Experimental|VSV-ZEBOV higher dose|"One intramuscular (deltoid) injection of a higher dose (5 x 10^7 pfu) of VSV-ZEBOV.~Study amendment (01.2015) : interrupted"
3040971|NCT02287480|Placebo Comparator|Placebo|One intramuscular (deltoid) injection of normal saline (0.5 ml)
3040972|NCT02287467|Experimental|Arm A: IVIG and standard of care (SOC) treatment|Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
3040973|NCT02287467|Placebo Comparator|Arm B: Placebo for IVIG and SOC treatment|Participants will receive a single infusion of placebo for IVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
3040974|NCT02287454|Experimental|Cognitive remediation program: REHACOP|Cognitive rehabilitation program (REHACOP) including intervention in: attention, memory, processing speed, language, executive functioning and social cognition during 3 months, 3 times per week
3040975|NCT02287454|No Intervention|Control group|No intervention was administered.
3040976|NCT02287441|Placebo Comparator|Raw Group|Vegetables Prepared Raw (raw)
3040977|NCT02287441|Experimental|Tomato Group|Tomato Products (tomato)
3040978|NCT02287428|Experimental|Cohort 1: Standard RT Followed by NeoVax|"After the screening procedures confirm participant eligible to participate in the research study (must be registered to within 6 weeks of resection):~~ 6 weeks of standard radiation therapy (RT) followed by an RT-recovery period.~During that time, participant NeoAntigen Vaccine-Preparation is created (process takes ~ 12 weeks)~After participant recovers from RT and vaccine is created, participant will re-screen to confirm participant is eligible to receive study vaccinations. Once registered, participant will proceed to receive study vaccinations:~- NeoAntigen Vaccine: NeoVax will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases (~ 7 months total: 5 priming followed by 2 boost vaccine administrations)"
3040979|NCT02287428|Experimental|Cohort !a: Pembrolizumab + RT Followed by NeoVax|"Concurrent Treatment ~ 10 weeks:~Standard Radiotherapy (RT) over 6 weeks (60Gy)~Pembrolizumab once every 3 weeks Adjuvant Stage: Up to 24 months~Pembrolizumab once every 3 weeks~NeoVax to begin as soon as available after RT and administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o Day 1 of NeoVax does not have to coincide with Pembrolizumab dosing"
3040980|NCT02287428|Experimental|Cohort 1b: Pembrolizumab + RT w/ TMZ Followed by NeoVax|"Concurrent Treatment ~ 10 weeks:~Standard RT (60Gy) + concurrent daily temozolomide (TMZ) over 6 weeks~Pembrolizumab once every 3 weeks Adjuvant Treatment): Up to 24 months~TMZ Cycles: to begin 4 weeks after RT for 6-12 cycles (TMZ on Days 1-5 of every 28 day cycle)~Pembrolizumab once every 3 weeks~NeoVax to begin as soon as available after RT and administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o Day 1 of NeoVax does not have to coincide with any adjuvant cycle counting, and actually cannot coincide with a dose of TMZ (see section 5.6 for more detail)"
3040981|NCT02287415|Experimental|Group 1|Phase A: Warfarin Phase B: Warfarin + BIA 2-093 (ESL) Phase C: Warfarin
3040982|NCT02287402|Experimental|AO-128 0.6 mg|One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.
3040983|NCT02287389|Experimental|balloon dilation|give the cases balloon dilation as the intervention
3040984|NCT02287389|Experimental|balloon dilation plus cryotherapy|give the cases balloon dilation plus cryotherapy as the intervention
3040985|NCT02287389|Experimental|BD plus spiculiform electrosurgery|give the cases balloon dilation plus spiculiform electrosurgery as the intervention
3040986|NCT02287389|Experimental|BD plus mitomycin C|give the cases Balloon dilation plus mitomycin C as the intervention
3040987|NCT02287376|Experimental|Diclofenac Potassium|Diclofenac Potassium for Oral Solution 50 mg
3040988|NCT02287363||TPP group|TPP patients(between episodes of paralysis), the inclusion criteria consisted of a certain history of acute limb muscle weakness, hypokalemia and decreased TSH with elevated free FT4, FT3. Subjects who suffered from hyperthyroid myopathy with long term muscle weakness, family periodic paralysis, renal tubular acidosis, hyperaldosteronism, hemiplegia, paraplegia, or any history of other metabolic or traumatic muscular disease were excluded.
3040989|NCT02287363||hyperthyroidism group|Control group, we included subjects with evidence of aberrant thyroid function (decreased TSH, elevated FT4, FT3) without paralysis. Graves' disease(GD) was preferred which required information concerning either increased thyrotrophin receptor antibody(TRAb) level, ophthalmopathy or diffusively enlarged goiter. Individuals with pure thyroid associated ophthalmopathy, history of thyroidectomy due to malignancy or adenoma as well as subacute thyroiditis and pituitary hyperthyroidism were excluded.
3040990|NCT02287350|Experimental|diclofenac potassium oral solution|5 mg/mL, liquid form, weight-based dosing, every 6 hours, for up to 4 days.
3040991|NCT02287337|Experimental|Manipulation|Patients will receive cervical manipulation on 2 visits and then a further 3 visits of therapeutic exercises
3040992|NCT02287337|Other|Exercise|Patients will receive 5 visits of therapeutic exercises
3040993|NCT02287324|Active Comparator|Manipulation|High velocity low amplitude thrust joint manipulation to the cervical spine
3040994|NCT02287324|Placebo Comparator|Manual Contact|Manual contact to suboccipital region of the cervical spine for 5 minutes
3040995|NCT02287311|Experimental|Group A: MABEL CTLs|"Patients with 1st or subsequent relapse.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
3040996|NCT02287311|Experimental|Group B: MABEL CTLs|"Patients with persistent active disease despite therapy.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
3040997|NCT02287311|Experimental|Group C: MABEL CTLs|"Patients with active disease if immunosuppressive chemotherapy is contraindicated.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
3040998|NCT02287298||2006 TO 2010 PATIENTS|PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY
3040999|NCT02287298||CURRENT PATIENTS|PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY AND ADDITION OF 20 MG OF ORAL ZEAXANTHIN
3041000|NCT02287285|Experimental|Exendin9|Longitudinal study of insulin secretion and sensitivity in patients with type 2 diabetes before and after gastric bypass surgery.
3041001|NCT02287272|Active Comparator|Treatment period R|single inhaled dose of CHF 5993 pMDI (BDP/FF/GB fixed dose combination)
3041002|NCT02287272|Active Comparator|Treatment period T|Cimetidine plus CHF5993 pMDI: repeated doses of oral cimetidine for 6 days plus a single inhaled dose of CHF 5993 pMDI (BDP/FF/GB fixed dose combination)
3041003|NCT02287259|Experimental|Olanzapine|PO start with 2.5mg daily once for 7days, since then flexible dose.
3041004|NCT02287259|Active Comparator|Lithium|PO start with 400mg daily twice for 7days, since then flexible dose.
3041005|NCT02287246|Experimental|Extended-Release liposomal bupivacaine|20mL Extended-release liposomal bupivacaine injected into the posterior vaginal wall following surgery
3041006|NCT02287246|Active Comparator|Placebo (normal saline)|20mL normal saline injected into the posterior vaginal wall following surgery
3041007|NCT02287233|Experimental|Venetoclax + low-dose cytarabine|Treatment Naive Acute Myelogenous Leukemia
3041008|NCT02287220||Newborn Infants|0-12 months old Male or female Any ethnicity
3041009|NCT02287207|Active Comparator|Anodal tDCS|20 minutes, 1.0 mA unilateral-anodal motor cortex (M1) tDCS stimulation
3041010|NCT02287207|Sham Comparator|Sham tDCS|20 minutes, sham tDCS stimulation
3041011|NCT02287194||SpyGlass Direct Visualization System|Any patient who has undergone SpyGlass Choledochoscopy procedures for diagnosis and/or treatment of biliary tract diseases.
3041051|NCT02286882|Experimental|Cohort 2: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3041937|NCT02281006|Experimental|Treated ear|Trans-tympanic injection of a sodium thiosulfate gel
3041012|NCT02287181|Active Comparator|remifentanil effect site concentration 0ng/ml|remifentanil run as an infusion using the minto TCI model, at an effect site concentration of 0 nano grams per millilitre, commenced from start of proposal infusion to point at which patient is anaesthetised and not responding to painful stimuli.
3041013|NCT02287181|Active Comparator|remifentanil effect site concentration 3ng/ml|remifentanil run as an infusion using the minto TCI model, at an effect site concentration of 3 nano grams per millilitre, commenced from start of proposal infusion to point at which patient is anaesthetised and not responding to painful stimuli.
3041014|NCT02287168|Experimental|dissemination of cancer cells|conversion of negative result of pre-gastrectomy peritoneal washing cytology to positive cytology after gastrectomy
3041015|NCT02287168|Experimental|elimination of cancer cells|elimination of peritoneal cancer cells occurred before (pre-gastrectomy peritoneal washing cytology) or after gastrectomy (post-gastrectomy peritoneal washing cytology) by intra operative peritoneal lavage ('post-lavage peritoneal washing cytology)
3041016|NCT02287155|Experimental|occupation based health promotion|"The description of the health promotion intervention is provided in the detailed description of the study. It's a single arm study."
3041017|NCT02287142|Active Comparator|Interscalene|Single-shot Interscalene Nerve Block with ropivacaine 0.5%
3041018|NCT02287142|Active Comparator|Supraclavicular|Single-shot Supraclavicular Nerve Block with ropivacaine 0.5%
3041019|NCT02287142|Active Comparator|Suprascapular|Single-shot Suprascapular Nerve Block with ropivacaine 0.5%
3041020|NCT02287129|Experimental|Non-Responder|Oxaliplatin Epirubicin Capecitabine 5-FU Carboplatin Paclitaxel Radiation Biopsy
3041021|NCT02287129|Active Comparator|Responder|Oxaliplatin Epirubicin Capecitabine 5-FU Biopsy
3041022|NCT02287116|No Intervention|nasal mask and nasal prongs|
3041023|NCT02287103|Experimental|Skipping Breakfast (NoB)|The patients in No B will omit the breakfast and will continue the overnight fast until lunch. Will eat only lunch and dinner. In YesB will eat all three meals
3041024|NCT02287103|Active Comparator|Eating Breakfast (YesB):|The patients in YesB will eat all three mealswill consume three meals: breakfast, lunch and dinner
3041025|NCT02287077|No Intervention|Immediate cord clamping|At birth, neonate will be held at the level of placenta and umbilical cord will be clamped immediately (standard of care for depressed neonates).
3041026|NCT02287077|Experimental|Umbilical cord milking|At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
3041027|NCT02287064|Experimental|Intravenous Immune Globulin (IVIG)|
3041028|NCT02287051||colonoscopy population|
3041029|NCT02287038||ATX Phase I|Group one will receive Atomoxetine during the first phase of the study followed by a second phase of a placebo. During this time you and all of the researchers will be blind to which medication you are receiving to ensure that all of the treatment results are accurate.
3041030|NCT02287038||ATX Phase II|Group two will receive the placebo during the first phase of the study followed by receiving Atomoxetine during the second phase. During this time you and all of the researchers will be blind to which medication you are receiving to ensure that all of the treatment results are accurate.
3041031|NCT02287025|Experimental|SMART|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
3041032|NCT02287025|Active Comparator|Standard of Care|Investigators were supported with standard prescribing information.
3041033|NCT02287012||Pre-Plerixafor era|The first era (Pre-Plerixafor era) will be defined as a two year period immediately preceding commercialization of plerixafor in Europe, (e.g., June 1, 2007 through June 1, 2009).
3041034|NCT02287012||Plerixafor era|The second era (Plerixafor era) will be defined as July 1, 2010 through July 1, 2012).
3041035|NCT02286999|Experimental|B.infantis|Infants in the experimental arm will have two doses of the probiotic Bifidobacterium longum subsp. infantis (B. infantis) on Day 7 and Day 14 of life.
3041036|NCT02286999|Placebo Comparator|Placebo|Infants in the experimental arm will have two doses of placebo (powdered maltodextrin) on Day 7 and Day 14 of life.
3041037|NCT02286986|Other|Cannabidiol|open label administration
3041038|NCT02286973|Active Comparator|Only Intravenous Group|Only Intravenous Injection During Operation, 10mg/kr
3041039|NCT02286973|Active Comparator|Intravenous + Topical 1g Group|"Intravenous Injection During Operation, 10mg/kr~After Capsule Closure, Tranexamic acid Topical Injection 1g"
3041040|NCT02286973|Active Comparator|Intravenous + Topical 2g Group|"Intravenous Injection During Operation, 10mg/kr~After Capsule Closure, Tranexamic acid Topical Injection 2g"
3041041|NCT02286973|Active Comparator|No Intravenous, Only Topical 2g Group|Only Topical Injection 2g
3041042|NCT02286960|Active Comparator|Steroid|Prednizone pills. 4 day course 2 x 20mg per day.
3041043|NCT02286960|Placebo Comparator|Placebo|Lactose Pills. 4 day course 2 x 20mg per day.
3041044|NCT02286947|Experimental|Eteplirsen 30 mg/kg|Participants will receive eteplirsen 30 mg/kg/week intravenous (IV) infusions, weekly, for up to 96 weeks.
3041045|NCT02286934|Experimental|Carvedilol|"Day 1 to 3 : Carvedilol 12.5 mg qd~Day 4 to 8 : Carvedilol 25 mg qd~Day 9 to 11 : Carvedilol 12.5 mg qd~Isoproterenol Sensitivity Test~Day 0, 1.5h post-dose Injection of isoproterenol 4 times (0.25, 0.5, 1, 2 ug/mL), time interval of 10 minutes.~Day 1, 8, 1.5h post-dose Injection of isoproterenol 4 times (5, 10, 20, 40 ug/mL), time interval of 10 minutes.~Measure change of heart rates after 1, 2, 3 minutes post injection of isoproterenol."
3041046|NCT02286921|Experimental|Arm A|Patients on BAT (Arm A) will receive testosterone cypionate or testosterone enanthate administered as an intramuscular injection. A dose of 400 mg of either agent will be injected intramuscularly (IM) every 28 days.
3041047|NCT02286921|Experimental|Arm B|Patients randomized to enzalutamide (Arm B) will be prescribed enzalutamide 40 mg tablets and instructed to take 4 tablets per day orally for 28 days/cycle.
3041048|NCT02286895|Active Comparator|Group A|Group A will receive measles vaccine, yellow fever vaccine, and meningitis conjugate vaccine.
3041049|NCT02286895|Experimental|Group B|Group B will receive measles vaccine, yellow fever vaccine, and meningitis conjugate vaccine plus one oral dose of pentavalent rotavirus vaccine (PRV).
3041050|NCT02286882|Experimental|Cohort 1: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3041403|NCT02284698||Study Group|Study Group will have the field workers and active health education with referral mechanism
3041052|NCT02286882|Experimental|Cohort 3: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3041053|NCT02286882|Experimental|Cohort 4: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3041054|NCT02286882|Experimental|Cohort 5: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3041055|NCT02286882|Experimental|Cohort 6: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3041056|NCT02286882|Experimental|Cohort 7: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3041057|NCT02286882|Experimental|Cohort 8: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3041058|NCT02286882|Experimental|Cohort 9: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3041059|NCT02286869|Experimental|Pressure Controlled Ventilation|"INTERVENTION: respiratory trial in pressure controlled mode: (i) the inspiratory pressure is set up to obtain the same tidal volume than baseline, (ii) the imposed respiratory rate is the same respiratory rate than baseline.~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline.~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
3041060|NCT02286869|Experimental|Pressure Support Ventilation|"INTERVENTION: respiratory trial in pressure support mode: (i) the inspiratory pressure is set up to obtain the same tidal volume than baseline, (ii) the inspiratory trigger is a flow-trigger with medium sensitivity.~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline. In this ventilatory mode the respiratory rate is not imposed because is driven by the patient's respiratory effort.~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
3041061|NCT02286869|Experimental|Neurally Adjusted Ventilatory Assist|"INTERVENTION: respiratory trial in Neurally Adjusted Ventilatory Assist (NAVA) mode: (i) NAVA-level (gain) is set up to obtain the same tidal volume than baseline, (ii) the inspiratory trigger is a neural trigger set at 0.5 microVolt.~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline. In this ventilatory mode the respiratory rate is not imposed because is driven by the patient's respiratory effort.~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
3041062|NCT02286856|Other|control group|Usual care followed bij diet intervention after 6 months
3041063|NCT02286856|Active Comparator|intervention group|diet intervention
3041064|NCT02286843|Experimental|HER2-targeted PET/CT|Pts with confirmed HER2- breast cancer will then undergo HER2-targeted PET/CT. 89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. 89Zr-pertuzumab is a novel radiotracer which may allow for specific visualization of HER2+ lesions. PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions, rather than evaluation of only single lesions by biopsy. Avid lesions will be considered suspicious for HER2+ malignancy. Pts with at least one 89Zr-trastuzumab or 89Zr-pertuzumab avid lesion will be biopsied to confirm HER2+ pathology. From these 50 pts, we will determine the proportion of HER2- primary breast cancer pts that express HER2+ malignancy imagable by HER2-targeted PET/CT. Pts recruited to the protocol, but then drop out prior to HER2-targeted PET/CT due HER2+ disease being identified on retesting of the patient's archived tissue samples, will be replaced with newly recruited pts.
3041065|NCT02286830|Active Comparator|zoledronic acid|treatment with zoledronic acid for 4 years
3041066|NCT02286830|Placebo Comparator|no treatment|treatment with zoledronic acid withheld after two years
3041067|NCT02286817|Experimental|Single arm of 30 subjects|Subjects will be administered single dose of NFC-1 to assess safety, tolerability, and pharmacokinetics, then proceed to continuous, daily administration of NFC-1 for 4 weeks to assess safety, tolerability, and impact on ADHD severity.
3041068|NCT02286804|Experimental|Ultherapy treatment|Subjects receiving Ultherapy treatment to up to 4 spider veins
3041069|NCT02286791|Experimental|Mindful Awareness Program|18 sessions of mindful awareness program teaching the elderly mindful awareness practice techniques
3041070|NCT02286791|Active Comparator|Health Education Program|18 sessions of health education program focusing on healthy living topics
3041071|NCT02286778|Active Comparator|Acetogenins|Dietary Supplement: Acetogenins BID for 12 months
3041072|NCT02286778|Placebo Comparator|Placebo|Dietary Supplement: No Acetogenins BID for 12 months
3041073|NCT02286778|No Intervention|Control|Control subjects will not receive the Acetogenins or the placebo. They will be evaluated every other month to monitor disease progress.
3041074|NCT02286765|Active Comparator|Group A|Subjects receiving Ulthera System treatment in a 3 x 4 grid, 12 treatment squares, 60 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy
3041075|NCT02286765|Active Comparator|Group B|Subjects receiving Ulthera System treatment in a 3 x 4 grid, 12 treatment squares, 40 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy
3041076|NCT02286752|Active Comparator|neostigmine|
3041077|NCT02286752|Active Comparator|sugammadex|
3041078|NCT02286739|Sham Comparator|Group A TKA without VERASENSE|will consist of 250 consecutive patients who will undergo primary PCL-retaining or - sacrificing TKA without the use of VERASENSE to guide rotational alignment and balance.
3041079|NCT02286739|Active Comparator|Group B TKA with VERASENSE|will consist of 250 consecutive patients who will undergo primary PCL-retaining or - sacrificing TKA with the use of VERASENSE to guide rotational alignment and balance.
3041080|NCT02286726|Experimental|CPX-351 - Lower Dose Group|"Induction: CPX-351 50 units/m2 administered by vein on Days 1, 3, and 5. If AML persists induction may be repeated administering same dose intravenously on Days 1 and 3. No more than two induction courses are to be given.~Consolidation: Participants achieving complete remission are eligible to receive consolidation treatment with CPX-351. A course of consolidation treatment consists of 2 doses of CPX-351 (Days 1 and 3). Up to 4 cycles of consolidation may be administered."
3041216|NCT02285868||Hip and lower extremity injuries|Pre- and post-treatment outcomes of care as measured by the Lower Extremity Functional Scale via physical therapy
3041217|NCT02285868||Neck injuries|Pre- and post-treatment outcomes of care as measured by the Neck Disability Index Questionnaire via physical therapy
3041081|NCT02286726|Experimental|CPX-351 - Higher Dose Group|"Induction: CPX-351 75 units/m2 administered by vein on Days 1, 3, and 5. If AML persists induction may be repeated administering same dose intravenously on Days 1 and 3. No more than two induction courses are to be given.~Consolidation: Participants achieving complete remission are eligible to receive consolidation treatment with CPX-351. A course of consolidation treatment consists of 2 doses of CPX-351 (Days 1 and 3). Up to 4 cycles of consolidation may be administered."
3041082|NCT02286726|Experimental|CPX-351 - Maximum Tolerated Dose Level Group|If safety is demonstrated for both of the sub-MTD dose levels, and escalation deemed feasible above 75 units/m2, then CPX-351 100 units/m2 administered.
3041083|NCT02286713|Active Comparator|Patient Decision Aid|Decision Aid study materials including video mailed to participant with 1-week, 3-month, and 6-month Follow-up Assessments
3041084|NCT02286713|Active Comparator|Standard Educational Information|Study materials including education booklet mailed to participant with 1-week, 3-month, and 6-month Follow-up Assessments
3041085|NCT02286700|Active Comparator|Desonide Group|Group randomly receiving desonide cream as the treatment cream for 3 weeks. Fifteen (15) gram tubes are dispensed at the beginning of each week and will be applied twice daily, by the subject, during the 3 week treatment phase.
3041086|NCT02286700|Experimental|Amino Acid Group|Group randomly receiving amino acid moisturizing cream as the treatment cream for 3 weeks. Fifteen (15) gram tubes are dispensed at the beginning of each week and will be applied twice daily, by the subject, during the 3 week treatment phase.
3041087|NCT02286687|Experimental|Mutation of BRCA1 or BRCA 2|"Participants have mutation of BRCA1 or BRCA 2.~Participants receive Talazoparib tosylate at 1 mg by mouth daily. Study staff calls participant after completion of the treatment."
3041088|NCT02286687|Experimental|Deletion of BRCA1 or BRCA2|"Participants have deletion of BRCA1 or BRCA2.~Participants receive Talazoparib tosylate at 1 mg by mouth daily. Study staff calls participant after completion of the treatment."
3041089|NCT02286687|Experimental|Mutation/Deletion ATM,PALB2,MER11,RAD50,NBS1|"Participants have mutation or deletion in ATM, PALB2, MER11, ARID1A, RAD50, NBS1, ATR; amplification of EMSY or Fanconi Anemia Genes.~Participants receive Talazoparib tosylate at 1 mg by mouth daily. Study staff calls participant after completion of the treatment."
3041090|NCT02286687|Experimental|Mutation/Deletion in PTEN or PTEN Loss by IHC|"Participants have mutation or deletion in PTEN, or PTEN Loss.~Participants receive Talazoparib tosylate at 1 mg by mouth daily. Study staff calls participant after completion of the treatment."
3041091|NCT02286687|Experimental|Myriad HRD Assay LOH ≥ 42 Homologous Recombination Defects|"Participants have Myriad HRD assay LOH ≥ 42 homologous recombination defects.~Participants receive Talazoparib tosylate at 1 mg by mouth daily. Study staff calls participant after completion of the treatment."
3041092|NCT02286687|Experimental|Germline Mutation of BRCA 1/ BRCA 2(not breast/ovarian ca)|"Participants have Germline mutations of BRCA 1 or BRCA 2 (not breast or ovarian cancer)~Participants receive Talazoparib tosylate at 1 mg by mouth daily. Study staff calls participant after completion of the treatment."
3041093|NCT02286674|Experimental|Tablet for watching movie|The study group will receive standard of care in addition to a tablet to watch movies and/or TV
3041094|NCT02286674|No Intervention|Standard of care - no tablet|The control group will receive standard of care only.
3041095|NCT02286661|Active Comparator|Short Arm Cast|Short arm cast below the elbow
3041096|NCT02286661|Active Comparator|Long Arm Cast|Long arm cast above the elbow
3041097|NCT02286648|Experimental|Mineral Trioxide Aggregate|pulpotomy with MTA
3041098|NCT02286648|Active Comparator|Formocresol|pulpotomy with FC
3041099|NCT02286635|Experimental|Cohort A Deflazacort and Rifampin|Subjects will recieve one 18 mg dose of deflazacort on Day 1, Period 1 and Day 10, Period 2; cohort A. Subjects will receive once daily dosing of rifampin on Day 1, Period 2 through Day 10, Period 2.
3041100|NCT02286635|Experimental|Cohort B Deflazacort and Clarithromycin|Subjects will recieve one 18 mg dose of deflazacort on Day 1, Period 1 and Day 4, period 2; cohort B. Subjects will receive twice daily dosing of clarithromycin on Day 1, Period 2 through Day 4, Period 2.
3041101|NCT02286622|Experimental|Renal Impairment|Eight (8) subjects with ESRD on HD will receive one 18 mg dose of deflazacort.
3041102|NCT02286622|Experimental|Healthy Volunteers|Eight (8) healthy subjects with estimated creatinine clearance (CLcr) ≥ 90 mL/min. Subjects will be matched for age [± 15 years], BMI [± 15 %], and gender [1:1] to the subjects in the ESRD cohort. Subjects will receive one 18 mg dose of deflazacort.
3041103|NCT02286609|Experimental|Hepatic Impairment|Eight (8) subjects with moderate hepatic insufficiency (a score of 7 to 9, on the Child-Pugh scale) will receive one 18 mg dose of deflazacort
3041104|NCT02286609|Experimental|Healthy Volunteer|Eight (8) healthy subjects. Subjects will be matched for age [± 15 years], BMI [± 15 %], and gender [1:1] to the subjects in the moderate hepatic impaired cohort; will receive 18 mg dose of deflazacort
3041105|NCT02286596||heparin-induced extracorporeal LDL precipitation|Lipid apheresis treatment for 3 hours
3041106|NCT02286596||dextran sulfate adsorption|Lipid apheresis treatment for 3 hours
3041107|NCT02286583|No Intervention|Microwave Thermography RTM-01-RES|Microwave thermography with sensitive probe that can detect skin and up to 8 cm microwave radiation deep tissues
3041108|NCT02286570|Active Comparator|face-to-face intubation of Glidescope|patients were intubated using glidescope by face-to-face approach
3041109|NCT02286570|Active Comparator|face-to-face intubation with Airtraq|patients were intubated using the Airtraq by face-to-face approach
3041110|NCT02286570|Active Comparator|face-to-face intubation with fastrach|patients were intubated using the Fastrach by face-to-face approach
3041111|NCT02286557|Experimental|Arm I|Arm 1 will undergo four weeks of treatment with MP extended-release (20 mg/day in the morning). Following the four weeks of treatment, all assessments performed at baseline will be repeated. To minimize practice effects, alternate versions of the neuropsychological tests will be used wherever available. A 7-day washout period will follow in which no medication will be administered. Following the washout period, Arm 1 will undergo four weeks of placebo. This will be followed by a final assessment consisting of measures of fatigue, cognitive functioning, and physical disability.
3041243|NCT02285751|Active Comparator|prasugrel 10mg|patients treated with 10mg prasugrel daily
3041404|NCT02284698||Control Group|Control group will not have field workers and active health education. They will follow routine health care
3041112|NCT02286557|Experimental|Arm II|Arm 2 will undergo four weeks of placebo (in the morning). Following the four weeks of placebo, all assessments performed at baseline will be repeated. To minimize practice effects, alternate versions of the neuropsychological tests will be used wherever available. A 7-day washout period will follow in which no medication will be administered. Following the washout period, Arm 2 will undergo four weeks of treatment with MP extended-release (20mg/day). This will be followed by a final assessment consisting of measures of fatigue, sleep quality, cognitive functioning, and physical disability.
3041113|NCT02286544|Active Comparator|Salmonella typhi vaccine|0.5 mL Salmonella typhi vaccine
3041114|NCT02286544|Experimental|Salmonella typhi vaccine + oxygen|0.5 mL Salmonella typhi vaccine + 6l/min oxygen
3041115|NCT02286544|Experimental|S. typhi vaccine + oxygen + Atorvastatin|0.5 mL Salmonella typhi vaccine + 6l/min oxygen + 80mg Atorvastatin
3041116|NCT02286531|Experimental|FET imaging|FET Imaging. Patient 0.1 mCi / kg (maximum 185 MBq) of FET with 'O-(2[18F]FLUOROETHYL)-L-TYROSINE' will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
3041117|NCT02286518|Experimental|Cohort 1A: TAK-114 10 mg|Orally, once only.
3041118|NCT02286518|Experimental|Cohort 1B: TAK-114 10 mg|Orally, once
3041119|NCT02286518|Experimental|Cohort 2A: TAK-114 20 mg|Orally, once
3041120|NCT02286518|Experimental|Cohort 2B: TAK-114 20 mg|Orally, once
3041121|NCT02286518|Experimental|Cohort 3A: TAK-114 50 mg|Orally, once
3041122|NCT02286518|Experimental|Cohort 3B: TAK-114 50 mg|Orally, once
3041123|NCT02286518|Experimental|Cohort 4a: TAK-114 20 mg|Period 1: Single-dose administration in a fasting state Period 2: Single-dose administration 30 minutes after breakfast
3041124|NCT02286518|Experimental|Cohort 4b: TAK-114 20 mg|Period 1: Single-dose administration 30 minutes after breakfast Period 2: Single-dose administration in a fasting state
3041125|NCT02286518|Experimental|Cohort 5A: TAK-114 20 mg|Orally, Twice daily, 10 days
3041126|NCT02286518|Experimental|Cohort 5B: TAK-114 20 mg|Orally, Twice daily, 10 days
3041127|NCT02286518|Experimental|Cohort 6A: TAK-114 50 mg|Orally, Twice daily, 10 days
3041128|NCT02286518|Experimental|Cohort 6B: TAK-114 50 mg|Orally, Twice daily, 10 days
3041129|NCT02286518|Placebo Comparator|Cohort 1A, 2A, 3A: TAK-114 placebo|Cohort 1A, 2A, 3A: Orally, once
3041130|NCT02286518|Placebo Comparator|Cohort 5A: TAK-114 placebo|Cohort 5A: Orally, Twice daily, 10 days
3041131|NCT02286518|Placebo Comparator|Cohort 6A: TAK-114 placebo|Cohort 6A: Orally, Twice daily, 10 days
3041132|NCT02286505|Experimental|Brain Morphometry|Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.
3041133|NCT02286505|Other|Standard radiological assessment.|Standard neuroradiological report of the structural MRI only.
3041134|NCT02286479|Active Comparator|Incision and Drainage|In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.
3041135|NCT02286479|Experimental|Loop drainage|In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
3041136|NCT02286466|Active Comparator|Health Education Program|The presence and usage of Health Education Program.
3041137|NCT02286466|Experimental|CBT Mobile Application|The presence and usage of a CBT Mobile Application.
3041138|NCT02286453|Experimental|1|Benjakul
3041139|NCT02286453|Active Comparator|2|diclofenac
3041140|NCT02286440|Experimental|GeneSight guided treatment|GeneSight guided group will have their research psychiatrist make treatment recommendations based on test results
3041141|NCT02286440|Active Comparator|Treatment as usual group|Treatment as usual group will have treatment recommendations based on clinical judgment
3041142|NCT02286427|Active Comparator|Standard Dressing|J0 to J42 : once a week, primary dressing with Mepitel®
3041143|NCT02286427|Experimental|Amniotic Membrane|J0 to J42: once a week, Mepitel® and amniotic membrane (one or several depending on the graft size, so that the ulcer was completely covered with MAH). The last amniotic membrane is left in place.
3041144|NCT02286414||Exposed group|Patients recieving direct oral anticoagulants (DOA)
3041145|NCT02286414||Non-exposed group|Patients recieving vitamine K antagonists (VKA)
3041146|NCT02286388|Experimental|Partial excavation|patients receiving after excavation (in case of absence of pulp exposure after excavation necessitating endodontic treatment) antibacterial adhesive or non-antibacterial adhesive
3041147|NCT02286388|Active Comparator|Complete excavation|patients receiving after excavation (in case of absence of pulp exposure after excavation necessitating endodontic treatment) antibacterial adhesive or non-antibacterial adhesive
3041148|NCT02286388|Experimental|Antibacterial dental adhesive|patients with prior partial or complete caries removal (excepted patients with a pulp exposure after excavation necessitating endodontic treatment)
3041149|NCT02286388|Active Comparator|Conventional dental adhesive|patients with prior partial or complete caries removal (excepted patients with a pulp exposure after excavation necessitating endodontic treatment)
3041150|NCT02286375|Experimental|Intervention group|Interventions include providing comprehensive assessment from Omaha system, giving information regarding the self-care management, assisting and coordinating self-regulating skills and abilities, and providing social support from health-social care team to community-dwelling older adults for three months
3041151|NCT02286375|Placebo Comparator|customary care group|Customary care includes receiving community services from the community center in the district, providing monthly social call by a reserch assistant for three months
3041152|NCT02286362||Cohort|
3041153|NCT02286349|Experimental|Real rTMS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 5 blocks of real stimulation intensity of 10 Hz, each block containing 15 series of repetitive transcranial magnetic stimulation with 1 second duration and presenting interval of 10 seconds between sets + 20 minutes of neuropsychological reassessment (on average).
3041309|NCT02285309||Cardiac surgery|
3041310|NCT02285296|No Intervention|control arm|usual care
3041154|NCT02286349|Sham Comparator|Sham rTMS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 5 stimulation sham blocks, each block containing 15 series of repetitive transcranial magnetic stimulation with 1 second duration and presenting interval of 10 seconds between sets + 20 minutes of neuropsychological reassessment (on average)
3041155|NCT02286349|Experimental|Real tDCS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 10 minutes of real anodal transcranial direct current stimulation with intensity of 1 mA + 20 minutes of neuropsychological reassessment (on average).
3041156|NCT02286349|Sham Comparator|Sham tDCS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 10 minutes of sham transcranial direct current stimulation + 20 minutes of neuropsychological reassessment (on average)
3041157|NCT02286336|Experimental|middle aged group|brachial plexus block with ropivacaine 40ml, MEC90 for USG-SCB
3041158|NCT02286336|Active Comparator|young group|brachial plexus block with ropivacaine 40ml, MEC90 for USG-SCB
3041159|NCT02286323|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
3041160|NCT02286323|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3041161|NCT02286310|Experimental|Group A|Kinetic Chain Exercises
3041162|NCT02286310|Active Comparator|Group B|Traditional Exercises
3041163|NCT02286297|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
3041164|NCT02286297|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3041165|NCT02286284|Experimental|Apheresis arm|Apheresis for extracorporal removal of sFlt-1
3041166|NCT02286258|Experimental|Inuline - Calcium EDTA|Calcium EDTA clearance for GFR measurement is compared to inuline clearance in healthy volunteers and CKD patients (stage 1 to 4).
3041167|NCT02286258|Experimental|Inuline - Gd-DOTA|Gd-DOTA clearance for GFR measurement is compared to inuline clearance in healthy volunteers and CKD patients (stage 1 to 4).
3041168|NCT02286245|Experimental|1: focused Telephonic Medical Advice|The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board. Patients are invited to recall in case of worsening or onset of new symptoms and to get an appointment with their general practitioner during working hours.
3041169|NCT02286245|Active Comparator|2: Usual practice|The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
3041170|NCT02286232|Experimental|Stretching exercise|A series of 12 standardized, weekly stretching exercise classes will be held at the Wilton Family YMCA, designed for people with chronic low back pain unaccustomed to stretching. Participants will be asked to practice the identical routine of that week's stretching exercise class on off days and will be given handouts and CD's to assist in this.
3041171|NCT02286232|Active Comparator|Self-care book|The Back Pain Helpbook (Moore JE, Lorig K, Von Korff M, Gonzalez VM, Laurent DD. The Back Pain Helpbook. Reading, MA: Perseus Books; 1999)provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
3041172|NCT02286219|Experimental|FS102|Dose escalation of either weekly or Q3W of FS102
3041173|NCT02286206|Experimental|Clozapine bid|"Participants have been taking clozapine once daily and have reached steady-state prior to the start of this study.~Intervention: Days 1-14"
3041174|NCT02286193||Patients presenting to Community Resource Specialist (CRS)|Primary care patients who are referred or self-refer to the CRS for education and linkage to community resources that can help support health goals
3041175|NCT02286167|Other|Single arm diet|Intermittent, modified Atkins diet
3041176|NCT02286154|Experimental|Hydroxyurea|"All enrolled participants will receive hydroxyurea, but upon enrollment, participants will be identified as part of the New Cohort or Old Cohort New Cohort participants include those who are not receiving hydroxyurea therapy upon study entry. Old Cohort participants include those who are already receiving hydroxyurea therapy upon study entry. New Cohort participants will have starting dose predicted using PK/PD data and Old Cohort participants will continue dosing per clinical guidelines."
3041177|NCT02286141||Intervention|Patients receiving care at primary care clinics randomized to receive the supplemental training on stratified care for back pain through the use of the StartBack Tool will be considered to be a part of the intervention group. Randomization is done at the clinic level and not at the individual patient level.
3041178|NCT02286141||Control|Patients receiving care at primary care clinics randomized to receive the standard Group Health training on the updated Guidelines for Back Pain Care will be considered to be a part of the control group. Randomization is done at the clinic level and not at the individual patient level.
3041179|NCT02286128||Non-diabetic controls|Age-matched non-diabetic subjects
3041180|NCT02286128||Type 2 diabetes|Type 2 diabetes with metformin monotherapy failure
3041181|NCT02286115|Experimental|Life-Stress Interview|The Life-Stress Interview is an experiential assessment technique
3041182|NCT02286115|No Intervention|Wait-list Control|Wait-list Control
3041183|NCT02286102|Experimental|OrthoPAT|Patients in the experimental group will receive OrthoPAT drains, which will be used to collect and retransfuse postoperative blood loss. Drains will be removed after 48 hours.
3041184|NCT02286102|Active Comparator|Constavac|Patients identified as active comparator will receive standard Constavac drains, which will be removed after 48 hours.
3041185|NCT02286089|Experimental|OpRegen|Up to 12 legally blind subjects with best corrected visual acuity of 20/200 or less in first three cohorts and 12 subjects with best corrected visual acuity of 20/64 and 20/250 in fourth cohort
3041484|NCT02284178|Sham Comparator|Usual Care Oral Suction|Oropharyngeal suction with suction swab
3041186|NCT02286063|Active Comparator|ambulatory oxygen cylinders|Subjects randomised to have the intervention of portable oxygen for the first two weeks. Only patients with stable symptoms at the end of the 'run in' period and reproducible 6-minute walk distance on the 6MWT during the baseline visit, as a marker of clinical stability of the disease will be randomized. They will be a portable oxygen cylinder during 2 weeks when they realize activities.
3041187|NCT02286063|No Intervention|no oxygen cylinders|Subjects randomised to be on air for the first two weeks of the treatment period.
3041188|NCT02286050|Experimental|CF Nursing Intervention|
3041189|NCT02286011|Experimental|MNC (Mononuclear cells)|"All patients included in the clinical trial will receive an intramuscular infusion of autologous mononuclear cells (MNC) of Bone Marrow (BM) in TA muscle of one of the lower limb (experimental group). The lower limb on the CMN infuse autologous BM will be determined randomly.~The average dose is 550 millions of cells (100-1200 million) diluted in 2 ml. saline"
3041190|NCT02286011|Placebo Comparator|Saline|All patients included in the clinical trial will receive an intramuscular infusion of 2 mL of saline (placebo) in the TA muscle of the contralateral limb (group control).
3041191|NCT02285998|Experimental|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
3041192|NCT02285998|Active Comparator|Inactivated Influenza Vaccine|Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
3041193|NCT02285985|Experimental|Saxagliptin|Saxagliptin (trade-name ONGLYZA™) is used along with diet and exercise to lower blood sugar levels in patients with Type II diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Saxagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amount of insulin produced by the body after meals when blood sugar is high As the blood sugar returns towards normal, the medication effect on insulin is decreased.
3041194|NCT02285985|Placebo Comparator|Placebo|Sugar pill
3041195|NCT02285972|Placebo Comparator|saline|
3041196|NCT02285972|Active Comparator|dexketoprofen|
3041197|NCT02285972|Active Comparator|tenoxicam|
3041198|NCT02285959|Experimental|Intra Arterial Bevacizumab|Repeated Intra Arterial bevacizumab injections at 15 mg/kg every 3 weeks
3041199|NCT02285933|Experimental|VRT|sitting balance exercises delivered via virtual reality training
3041200|NCT02285933|Active Comparator|control|virtual reality training requiring limited arm movements and no challenge to sitting balance
3041201|NCT02285920|Active Comparator|Spironolactone 12.5 mg|Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
3041202|NCT02285920|Active Comparator|Spironolactone 25 mg|Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
3041203|NCT02285920|Active Comparator|Spironolactone 50 mg|Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
3041204|NCT02285920|Placebo Comparator|Placebo|Participants will be treated with placebo for 36 weeks.
3041205|NCT02285907|Experimental|Macronutrient and Fiber Matched BEEF|The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
3041206|NCT02285907|Experimental|Macronutrient and Fiber Matched SOY|The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
3041207|NCT02285907|Experimental|Serving Size Matched BEEF|The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
3041208|NCT02285907|Experimental|Serving Size Matched SOY|The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
3041209|NCT02285894|Experimental|Inspiratory hold|Mechanical inspiratory pressure held for 10 seconds at a time.
3041210|NCT02285881|Experimental|shared decision making|In the intervention practices the SDM process is used. In the SDM proces the patient and GP use a decision aid to discuss the pros and cons of two evidence based treatment possibilities, according to the Dutch College of General Practitioners (NHG) versus the ADDITION guideline, and the patients' preferences for either of these treatments. Together they choose one of these treatments, and set the five treatment targets (blood pressure, cholesterol, HbA1c, smoking status and weight) in order of priority. Subsequent treatment will take place according to the priorities of these OPTIMAL treatment targets. The priorities will be evaluated every 12 months.
3041211|NCT02285881|No Intervention|control group|Patients in the control practices will receive treatment-as-before, which means that the patients will not be offered the structured SDM process. So the GP will treat the former ADDITION patients as they were used during the period that followed after the ADDITION study (2009), either according to the national guidelines or to the ADDITION intensive treatment algorithm.
3041212|NCT02285868||Arm, Shoulder and Hand injuries|Pre- and post-treatment outcomes of care as measured by the DASH (Disabilities of the Arm, Shoulder and Hand) via physical therapy
3041213|NCT02285868||Lumbar spine injuries|Pre- and post-treatment outcomes of care as measured by the Modified Oswestry (lumbar spine) via physical therapy
3041214|NCT02285868||Knee injuries|Pre- and post-treatment outcomes of care as measured by the Knee Outcome Survey via physical therapy
3041215|NCT02285868||Foot and ankle injuries|Pre- and post-treatment outcomes of care as measured by the Foot & Ankle Ability Measure via physical therapy
3041938|NCT02281006|No Intervention|Control ear|No intervention
3041218|NCT02285855|Experimental|Stereotactic body Radiotherapy (SBRT) + Metformin|Participants randomized to Metformin treatment receive Metformin for 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Metformin administered at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week. SBRTdelivered per standard of care practice.
3041219|NCT02285855|Placebo Comparator|Stereotactic Body Radiotherapy (SBRT) + Placebo|Participants randomized to placebo treatment 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day. SBRT delivered per standard of care practice.
3041220|NCT02285842||Primary Hip Resurfacings|Single study group previously implanted with CONSERVE® Press-Fit Femoral Components
3041221|NCT02285829||T4/T1=0.1-0.25|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium, 0.5 µg/kg/min for Cisatracurium ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.1-0.25, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
3041222|NCT02285829||T4/T1=0.25-0.50|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.25-0.50, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
3041223|NCT02285829||T4/T1=0.50-0.75|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.50-0.75, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
3041224|NCT02285829||T4/T1=0.75-0.90|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.75-0.90, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
3041225|NCT02285816|Experimental|Arm A (MG1MA3 virus alone)|The starting dose of MG1MA3 will be 1 x 10^10 pfu administered by IV on day 1 and day 4.MG1MA3 dose will be escalated as per protocol.
3041226|NCT02285816|Experimental|Arm B- AdMA3 (vaccine prime) alone|Six patients will receive prime AdMA3 vaccine at a dose of 1x10^10 pfu administered IM on day (-14). No dose escalation is planned.
3041227|NCT02285816|Experimental|Arm C- AdMA3 plus MG1MA3 (prime + boost)|Prime AdMA3 vaccine will be administered as a single dose of 1x10^10 pfu IM at day (-14) followed by dose escalation of MG1MA3 boost, IV administered on days 1 & 4 at a starting dose of 1 log below the recommended phase II dose (RP2D), as determined in Arm A of this study. MG1MA3 dose will be escalated as defined in protocol.
3041228|NCT02285803|Active Comparator|TRT and real tDCS|
3041229|NCT02285803|Sham Comparator|TRT and sham tDCS|
3041230|NCT02285790|Experimental|RCM-OSS procedure|The Vivascope 1500 will be used (CE certified, Lucid Technologies, Henrietta, NY, USA). Reflectance confocal microscopy (RCM) imaging will be performed for intended use only and interpreted on the Vivascope workstation by two investigators independently at both study locations. The investigators will be blinded to the results of the reference standard. After RCM imaging subjects will receive OSS surgical excision according to subtype. Clinically suspected primary BCCs that are not confirmed by RCM will also receive surgical treatment with a margin of 3mm.
3041231|NCT02285790|Active Comparator|Standard of care procedure|Clinical suspected primary BCCs, of all subtypes, will be diagnosed by conventional 3mm punch biopsy of the most elevated part of the lesion. Punch biopsies will be performed under local anesthetics using 1% xylocaine/adrenaline. HE stained sections of the punch biopsies will be evaluated by an experienced board certified pathologist. Subjects will receive surgical excision according to subtype within 6 weeks after punch biopsy has been performed. Clinically suspected new primary BCCs that are not confirmed by punch biopsy will also receive surgical treatment with a margin of 3mm.
3041232|NCT02285777|Experimental|MenABCWY Group|Subjects who received 2 doses of MenABCWY vaccine in the parent study and a 3rd dose of MenABCWY vaccine in the current study.
3041233|NCT02285777|Active Comparator|MenACWY Group|Subjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study and 1 dose of placebo in the current study.
3041234|NCT02285764|Experimental|Nutritional Supplement|One 237 ml oral supplement consumed two times a day; Not commercially available.
3041235|NCT02285764|Other|Standard of Care|As determined by the study site
3041236|NCT02285751|Experimental|200mg acetylsalicylic acid per os|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 200mg acetylsalicylic acid per os"
3041237|NCT02285751|Experimental|100mg acetylsalicylic acid intravenous|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 100mg acetylsalicylic acid intravenously."
3041238|NCT02285751|Experimental|81 mg chewable acetylsalicylic acid|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 81mg chewable acetylsalicylic acid"
3041239|NCT02285751|Active Comparator|75mg clopidogrel|"control group for patients with high on treatment platelet reactivity to clopidogrel patients continue with standard treatment 75mg clopidogrel/day"
3041240|NCT02285751|Experimental|60mg prasugrel|"Loading dose of prasugrel for patients who remain tested with high on treatment platelet reactivity in spite of having received an additional loading dose of 600mg clopidogrel"
3041241|NCT02285751|Experimental|600mg clopidogrel|"additional loading dose for 24 patients tested with high on treatment platelet reactivity to clopidogrel"
3041242|NCT02285751|Experimental|180mg ticagrelor|"Loading dose of ticagrelor for patients who remain tested with high on treatment platelet reactivity in spite of having received an additional loading dose of 600mg clopidogrel Loading dose of ticagrelor for patients who remain tested with high on treatment platelet reactivity after being treated with 10mg prasugrel daily"
3065820|NCT02122692|Experimental|Lu AE58054 30 mg + itraconazole 200 mg|
3041244|NCT02285738|Active Comparator|Aspirin+Asprin/Simvastatin+Observation|Aspirin 81mg/day for 4 weeks followed by 2-week washout, followed by 4 weeks of Aspirin 81mg/day with daily dose of Simvastatin with a 2-week washout period, ending with 4 weeks of observation
3041245|NCT02285738|Experimental|Aspirin+Observation+Asprin/Simvastatin|Aspirin 81mg/day for 4 weeks followed by 2-week washout, followed by 4 weeks of observation with 2-week washout, ending with Aspirin 81mg/day with daily dose of Simvastatin
3041246|NCT02285738|Experimental|Aspirin/Simvastatin+Observation+Asprin|Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, followed by 4 weeks of observation with 2-week washout, ending with Aspirin 81mg/day
3041247|NCT02285738|Experimental|Aspirin/Simvastatin+Asprin+Observation|Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, followed by 4 weeks of Aspirin 81mg/day and a 2-week washout, ending with observation for 4 weeks.
3041248|NCT02285738|Experimental|Observation+Aspirin/Simvastatin+Asprin|Observation for 4 weeks with 2-week washout, followed by Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, ending with Aspirin 81mg/day for 4 weeks.
3041249|NCT02285738|Experimental|Observation+Aspirin+Asprin/Simvastatin|Observation for 4 weeks with 2-week washout, followed by Aspirin 81mg/day for 4 weeks followed by 2-week washout, ending with Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin.
3041250|NCT02285725|Experimental|Augmented Microdrilling Surgery|
3041251|NCT02285712|No Intervention|Classical method of peripheral venous catheterization|Classical method will be applied only on arm and forearm.
3041252|NCT02285712|Experimental|Ultrasound guided peripheral venous catheterization|Nurse will use a vascular ultrasound system to orient the catheter toward the peripheral vein. Ultrasound method will be applied only on arm and forearm.
3041253|NCT02285699|Other|SSRI treatment|The intervention only applies to Phase II of the proposed study. Individuals in the OCD group will be offered 12-weeks of standard SSRI treatment ti determine whether 12-weeks of treatment results in a change of the gut microbiota/inflammatory markers.
3041254|NCT02285673|Experimental|Umbilical Cord Mesenchymal Stem Cell|
3041255|NCT02285660|Other|Routine CT scan plus 4D PET-CT scan|
3041256|NCT02285660|Other|Routine CT scan|
3041257|NCT02285647|Experimental|Rolapitant - Oral|Investigational Product: Rolapitant Dose: 200 mg (4 x 50mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
3041258|NCT02285647|Experimental|Rolapitant - IV|Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
3041259|NCT02285634|Experimental|Oxymetazoline 0.05%|Oxymetazoline 0.05%
3041260|NCT02285634|Experimental|Phenylephrine 0.25%|Phenylephrine 0.25%
3041261|NCT02285634|Experimental|Lidocaine 1% plus epinephrine 1:100,000|Lidocaine 1% plus epinephrine 1:100,000
3041262|NCT02285634|Placebo Comparator|Bacteriostatic 0.9% NaCL|Bacteriostatic 0.9% NaCL
3041263|NCT02285621|Experimental|Optimized brace|Test group: Patient will receive optimized brace (3D computer assisted design of the brace)
3041264|NCT02285621|Active Comparator|Standard brace|Control goup: Patient will receive the Boston Thoracolumbosacral orthosis (TLSO) (conventional design method)
3041265|NCT02285608|Experimental|PIMM/SAM|Partnership in Medication Management (PIMM): The nurse and the attending physician will meet with the patient and ask how s/he administers medication at home (i.e., blister pack). Initial education session: the nurse will teach the patient about his/her medications, dosage, purpose, when and how to take them. Nurse and patient will establish reminders to take his/her medication. Following the education session, patients will be required to notify the nurse when it is time to take their medications, where their medications are, dosage, purpose and side effects. Self-Administered Medication (SAM): Patients will transition to SAM once the clinical team feels that no further medication changes are required. SAM is also the model that the participants will follow after discharge.
3041266|NCT02285608|No Intervention|Standard Prescribing Practice(SPP)|Standard prescribing practice (SPP): medication administration will proceed as standard practice. Patients will not receive a personalized medication training. The nurse will administer the patient's medications. However, patients are encouraged to ask any questions regarding his/her medications.Patients will not be provided with any tool to help them to remember when to take their medications. The nurse will record the patient's knowledge regarding his/her medications.
3041267|NCT02285595|Other|Sonendo GentleWave™ System|The Sonendo GentleWave System is intended to prepare, clean, and irrigate 1st and 2nd molar teeth indicated for root canal therapy.
3041268|NCT02285556|No Intervention|general information|use cross-sectional study to collect 1000 ATS abuse or dependence patients' general information and 5 ml blood,get their blood plasma and DNA sample in order to explore the possible addict mechanism.
3041269|NCT02285556|No Intervention|ATS diagnosis and evaluation for abusers|Use cohort study design to establish ATS abuse induced craving experiment.Do the initial and follow-up assessment from start smoking to stop smoking after 4 weeks, 12 weeks, 26 weeks, 52 weeks and 26 weeks of returning to the community . Thus compare with normal group to explore the possible psychological abuse mechanism.
3041270|NCT02285556|Active Comparator|psychological training intervention|The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
3041271|NCT02285556|Active Comparator|brain stimulation intervention|Use randomized, prospective pseudo stimulus controlled clinical trial design, evaluation of repetitive transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
3041272|NCT02285556|No Intervention|ATS diagnosis and evaluation for normal people|Do the same initial and follow-up assessment as ATS abusers who stop smoking after 4 weeks, 12 weeks, 26 weeks, 52 weeks and 26 weeks of returning to the community .
3041273|NCT02285556|Active Comparator|physical and neurological rehabilitation|The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .
3041487|NCT02284139|Active Comparator|Arm EGF ointment 1ppm|Arm EGF ointment 1ppm will be treated with EGF ointment of 1 ppm concentration
3041274|NCT02285556|Placebo Comparator|fake brain stimulation intervention|fake transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
3041275|NCT02285543|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed with surgery and radiotherapy/chemoradiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
3041276|NCT02285543|Other|Control group|The patients in the control group received the radical surgery and radiotherapy/chemoradiotherapy.
3041277|NCT02285530|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.~docetaxel:75mg/m2 cisplatin:75 mg/m2 5-Fu:750 mg/m2/day"
3041278|NCT02285530|Other|surgery group|Radical resection of the primary lesion and full neck,radiotherapy was arranged 4 to 6 weeks after surgery
3041279|NCT02285517|Active Comparator|modified Meek technique|Intervention: modified Meek skin grafting technique. Patients with third degree of burns without infected wounds are included and the modified Meek results are studied , measured and compared to other group which is operated lesions by mesh technique
3041280|NCT02285517|Active Comparator|mesh technique|Intervention: mesh skin grafting technique. patients with third degree of burns without infected wounds are included and the mesh skin grafting technique results are studied , measured and compared to other group which is operated lesions by modified Meek skin grafting technique
3041281|NCT02285504|Experimental|SAGE-547|
3041282|NCT02285491|Experimental|bupivacaine group|This is the group of patients that will receive 10ml of bupivacaine 0.5% injection in both angles of the rectus sheath incision
3041283|NCT02285491|Placebo Comparator|saline group|This group will receive saline injections as placebo into both angles of the rectus sheath incision
3041284|NCT02285491|Experimental|bupivacaine and saline group|This group will receive saline injection in one angle and 10ml of bupivacaine 0.5% injection in the opposite angle.
3041285|NCT02285465|Experimental|ASP3700 multiple ascending dose cohort|
3041286|NCT02285465|Placebo Comparator|Placebo cohort|
3041287|NCT02285452|Active Comparator|Thorax wrap with ginger flour (Zingiberis Rhizoma plv.)|Thorax wrap with ginger flour, duration max. 20 minutes
3041288|NCT02285452|Active Comparator|Thorax wrap with mustard flour (Sinapis nigrea semen)|Thorax wrap with mustard flour, duration max 20 minutes
3041289|NCT02285452|Placebo Comparator|Thorax wrap with warm water (placebo)|Thorax wrap with warm water (placebo), duration: 20 minutes
3041290|NCT02285439|Experimental|Phase 1|Patients with non-hematologic malignancies that are recurrent, progressive, or refractory after standard up-front therapy receiving MEK162 will define the MTD, DLT, and toxicity profile.
3041291|NCT02285439|Experimental|Phase 2|Children with recurrent tumors signaling through the Ras/Raf pathway will be treated in 3 strata to define the activity of MEK162. S1: Children with LGG characterized by a BRAF truncated fusion (KIAA1549 and similar translocations). S2: Children with NF1 and LGG. S 3: Children with tumors involving the Ras/Raf pathway not included in strata 1 or 2.
3041292|NCT02285439|Experimental|Target Validation|Patients eligible for phase 2 (any stratum) for whom tumor biopsy or resection is clinically indicated may be enrolled on the target validation arm. Patients will receive MEK162 for 7 to 21 days prior to their surgery. Tumor sample will be analyzed for drug concentration and target inhibition.
3041293|NCT02285426||suspected lungcancer|"Patients will undergo a bronchoscopy with the Pentax EB1990i HD-bronchoscope investigating the entire bronchial tree. The HD+ bronchoscopy needs to be performed in a standardized way using 3 different imaging modes:~HD+bronchoscopy~HD+bronchoscopy + i-Scan 1~HD+bronchoscopy + i-Scan 2"
3041294|NCT02285413|Experimental|DC vaccination|mature DC injected intradermally and intravenously loaded with mRNA encoding tumor-associated antigens gp100 and tyrosinase
3041295|NCT02285413|Experimental|DC vaccination with cisplatinum|mature DC injected intradermally and intravenously loaded with mRNA encoding tumor-associated antigens gp100 and tyrosinase. each DC vaccine will be preceded by cisplatin infusion: 50 mg/m2, 1-2h before DC injection.
3041296|NCT02285400|Experimental|Moderate COPD patients|Patients are connected to the noninvasive ventilator and incremental CPAP level is performed.
3041297|NCT02285400|Experimental|Severe COPD patients|Patients are connected to the noninvasive ventilator and incremental CPAP level is performed.
3041298|NCT02285387|Experimental|Rhythm control group|"Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~Cardioversion after 1 month~Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~If AF recur, RFCA"
3041299|NCT02285387|Active Comparator|Rate control group|"No AAD, just anticoagulation~HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)~Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study."
3041300|NCT02285374|Experimental|Arm 1|Truvada (tenofovir 245mg/emtricitabine 200mg) or Kivexa (abacavir 600mg/lamivudine 300mg) one tablet once daily plus Dolutegravir 50mg (one tablet) once daily
3041301|NCT02285374|Experimental|Arm 2|Atripla (efavirenz 600mg, emtricitabine 200mg, tenofovir 245mg) one tablet once daily, or Truvada (tenofovir 245mg/emtricitabine 200mg) or Kivexa (abacavir 600mg/lamivudine 300mg) one tablet once daily plus efavirenz 600mg one tablet once daily for 4 weeks. At week 4, efavirenz is switched to Dolutegravir 50mg (one tablet) once daily
3041302|NCT02285361||GIOTRIF|
3041303|NCT02285348|Other|Ataxia Telangiectasia|20 patients with clinically and/or genetically diagnosed Ataxia telangiectasia will get a lumbar puncture
3041304|NCT02285348|Other|Healthy Control|20 patients without inflammation, infection or any other pathology of the CNS, in that a lumbar puncture is indicated for either diagnostic or therapeutic reason (i.e. for the exclusion of a meningitis, subarachnoid hemorrhage or in therapeutic liquor drain in idiopathic intracranial hypertension)
3041305|NCT02285335|Experimental|Low group|GINST15 3g/day
3041306|NCT02285335|Experimental|High group|GINST15 6g/day
3041307|NCT02285322||BP control reached|Patients diagnosed with high blood pressure who lowered their blood pressure measurements during follow-up to <140/90mmHg if aged less than 60 years old, and <150/90mmHg for those of ≥60 years
3041308|NCT02285322||BP control not reached|Patients diagnosed with high blood pressure who did not lower their blood pressure measurement during follow-up (measurements were ≥140/90mmHg for individuals aged less than 60 years old, and ≥150/90mmHg for those of ≥60 years)
3041311|NCT02285296|Experimental|personalized support program|"interview of the primary caregivers to identify their needs and expectations, the implementation of a personalized support program, including telephone follow-up"
3041312|NCT02285283|Placebo Comparator|Placebo|2 capsules by mouth twice a day for 24 weeks
3041313|NCT02285283|Active Comparator|Itraconazole|Two 100mg capsules by mouth twice a day for 24 weeks
3041314|NCT02285270|Other|Single group assignment|Diagnostic test/procedure - FDG PET/CT
3041315|NCT02285244|Experimental|Treatment (sotrastaurin acetate)|Patients receive sotrastaurin acetate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3041316|NCT02285231|Experimental|TEST|Arginyl-fructose Supplementation
3041317|NCT02285231|Experimental|Placebo|Placebo Supplementation
3041318|NCT02285218||1) Normal control|metabolically healthy with no obesity
3041319|NCT02285218||2) dyslipidemia|high triglyceride levels or LDL-C levels
3041320|NCT02285218||3) type 2 diabetes|defined in 'inclusion criteria'
3041321|NCT02285218||4) non-alcoholic fatty liver disease|defined in 'inclusion criteria'
3041322|NCT02285205|Experimental|Lobeglitazone|
3041323|NCT02285192|Experimental|intracervical 18F-FDG injection during a dynamic PET/CT|The first 20 eligible patients will be consented to undergo intracervical 18F-FDG injection during a dynamic PET/CT scan. Study enrollment will occur in the clinic during the visit in which they are consented for surgery. Recruited patients will undergo 18F-FDG-guided PET imaging on the day of their scheduled staging surgery. The experimental PET/CT is anticipated to take 2 hours. The second stage of accrual will replace PET/CT with PET/MRI imaging. In every other aspect, patients will receive standard peri- and postoperative care.
3041324|NCT02285179|Experimental|tamoxifen and GDC-0032|20 mg tamoxifen QD and 4 MG GDC-0032 QOD
3041325|NCT02285179|Placebo Comparator|tamoxifen and placebo|20 mg tamoxifen QD and placebo QOD
3041326|NCT02285166||Oral administration of 2 g of omega-3-acid ethyl esters|Oral administration of 2 g of omega-3-acid ethyl esters once daily or twice daily immediately after meals
3041327|NCT02285166||Standard antihyperlipidemic therapy|Standard antihyperlipidemic therapy other than omega-3 fatty acid ethyl esters (Lotriga) administration.
3041328|NCT02285153|Experimental|Acetylsalicylic acid lysinate|100mg Acetylsalicylic Acid
3041329|NCT02285153|Placebo Comparator|0.9% sodium-chloride solution|0.9% sodium-chloride solution
3041330|NCT02285140|Experimental|Cefazolin monotherapy, short course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered
3041331|NCT02285140|Experimental|Cefazolin monotherapy, long course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose).
3041332|NCT02285140|Experimental|Combination therapy, short course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered. In addition, one dose of vancomycin 60-90min pre-op will be administered.
3041333|NCT02285140|Experimental|Combination therapy, long course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose). In addition, one dose of vancomycin 60-90min pre-op will be administered followed by 3 post-op doses every 12 hours (last dose 36 hours after first dose)
3041334|NCT02285127|Active Comparator|Short nail implant|used to treat pertrochanteric fractures
3041335|NCT02285127|Active Comparator|Long nail implant|used to treat pertrochanteric fractures
3041336|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 1)|Participants between 12 to < 18 years of age will switch their current 2-NRTI containing regimen to F/TAF while continuing on their 3rd ARV agent for 48 weeks.
3041337|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 1, Part A)|Participants between 6 to < 12 years of age must be on a boosted protease inhibitor (PI) as their 3rd ARV agent and will switch their current 2-NRTI regimen to F/TAF while continuing on their boosted PI for 48 weeks.
3041338|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 2, Part A)|Participants between 2 to < 12 years of age must be on a boosted protease inhibitor (PI) or other protocol specified 3rd ARV agent and will switch their current 2-NRTI containing regimen to F/TAF while continuing their 3rd ARV agent for 48 weeks.
3041339|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 3, Part A)|Participants between 2 to < 6 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
3041340|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 4, Part A)|Participants between 1 month to < 2 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
3041341|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 1, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
3041342|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 2, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
3041343|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 3, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
3041344|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 4, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
3041400|NCT02284724|Other|Sham|The plastic tube containing the mono-filament needle will be pressed into the skin over the lumbar multifidus muscle at both sides of L4/5 segment - without insertion through the skin
3042219|NCT02279082|Experimental|DFN-02|DFN-02 to be taken during migraine attack
3041345|NCT02285101|Experimental|Cohort 1|PEG-BCT-100 at 0.5 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 0.5 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 0.5 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 0.5 mg/kg until disease progression at the discretion of the investigator.
3041346|NCT02285101|Experimental|Cohort 2|PEG-BCT-100 at 1.0 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 1.0 mg/kg on days 22 (week4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 1.0 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 1.0 mg/kg until disease progression at the discretion of the investigator.
3041347|NCT02285101|Experimental|Cohort 3|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 1.7 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 1.7 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 1.7 mg/kg until disease progression at the discretion of the investigator.
3041348|NCT02285101|Experimental|Cohort 4|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 2.7 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 2.7 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 2.7 mg/kg until disease progression at the discretion of the investigator.
3041349|NCT02285101|Experimental|Cohort 5|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 4.0 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 4.0 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 4.0 mg/kg until disease progression at the discretion of the investigator.
3041350|NCT02285101|Experimental|Cohort 6|PEG-BCT-100 at a dose to be determined administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT-100 will be administered at at a dose to be determined on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at at a dose to be determined. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at at a dose to be determined until disease progression at the discretion of the investigator.
3041351|NCT02285088|Experimental|GBT440|Subjects randomized 6:2 to receive daily oral dosing of GBT440 or placebo for 1 day (single dose) and up to 118 days (multiple dose)
3041352|NCT02285088|Placebo Comparator|Placebo|Subjects randomized 6:2 to receive daily oral dosing of GBT440 or placebo for 1 day (single dose) and up to 118 days (multiple dose)
3041353|NCT02285075|Other|temocillin PK/PD in haemodialysis|Pharmacokinetic study measuring total and free temocillin concentrations in patients treated with haemodialysis receiving 1 gram temocillin for a 1 day interval, 2 gram temocillin for a two day interval and 3 gram temocillin for a 3 day interval to the next dialysis session
3041354|NCT02285062|Experimental|R2-CHOP|lenalidomide plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
3041355|NCT02285062|Active Comparator|R-CHOP|placebo plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
3041356|NCT02285049||Urticaria Control Test|"Evaluation by UAS28, PatGA-LS, PhyGA-LS~Fill the UCT and DLQI questionnaire"
3041357|NCT02285036|Experimental|A newly PPV23|The treatment pneumococcal vaccine was developed by Yunnan Walvax Biotech Co., Ltd (Walvax) China, is a sterile, liquid vaccine for intramuscular or subcutaneous injection. It consists of a mixture of highly purified capsular polysaccharides from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae, including the six serotypes that most frequently cause invasive drug-resistant pneumococcal infections among children and adults in China. The dose of vaccine is an individual with a 0.5ml dose contains 23 kinds of pneumococcal polysaccharide serotypes each 25μg, and does not contain any preservatives. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
3041358|NCT02285036|Active Comparator|PNEUMOVAX 23|PNEUMOVAX 23 is an established US-licensed vaccine and manufactured by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
3041359|NCT02285023||CU-Q2oL|"Evaluation by the Urticaria Activity Score (UAS7)~Fill the DLQI and CU-Q2oL questionnaire"
3041360|NCT02285010|Placebo Comparator|Placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery.
3041361|NCT02285010|Active Comparator|Pregabalin|Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.
3041362|NCT02284997|Experimental|Treatment|Participants will be instructed to use a warming MGDRx® EyeBag for minimum of 10 minutes, twice a day
3041363|NCT02284997|No Intervention|Control|No treatment
3041364|NCT02284984|Experimental|Rituximab with belimumab|Rituximab 1000mg on day 0 and day 14 Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks.
3041365|NCT02284971|Experimental|Arm A: CDX1127 & SBRT Concurrent|"SBRT will be administered to the primary tumor and/or site of metastatic disease over a period of 5 days (Days 1-5) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 1, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
3041401|NCT02284711|Active Comparator|Bipolar|Coagulation during salpingectomy using conventional bipolar electric energy
3041366|NCT02284971|Experimental|Arm B: CDX1127 & SBRT Sequential; CDX1127 upfront|"SBRT will be administered to the primary tumor and/or sites of metastatic disease over a period of 5 days (Days 22-26) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 1, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
3041367|NCT02284971|Experimental|Arm C: CDX1127 & SBRT Sequential; SBRT upfront|"SBRT will be administered to the primary tumor and/or sites of metastatic disease over a period of 5 days (Days 1-5) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 22, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
3041368|NCT02284958|Active Comparator|Standard/Control group|Each participant will receive a one-off individualized educational session regarding the management of chronic low back pain with a Physical Therapist: includes a physical examination, standardized advice & provision of the 'Back Book'.
3041369|NCT02284958|Experimental|Walking group|Each participant will receive a one-off educational session as per standard/control group followed by a 12 week graded, individually tailored, pedometer driven walking programme given by a Physical Therapist. Participants will be monitored each week and provided with encouragement and advice to increase the number of steps taken each day.
3041370|NCT02284945|Experimental|Posterior percutaneous instrumentations|
3041371|NCT02284945|Other|Traditional open surgery with pedicle screw fixation|
3041372|NCT02284932||COPD patients|Group : COPD patients No specific intervention for this study
3041373|NCT02284932||Healthy controls|Group : healthy volunteers No specific intervention for this study
3041374|NCT02284919|Experimental|ISO-1 PET/CT|All subjects will receive an [18F]ISO-1 PET/CT scan
3041375|NCT02284906|Experimental|Pioglitazone 0.8 mg|Pioglitazone 0.8 mg, tablets, orally, once, daily, for minimum of 2 years.
3041376|NCT02284906|Placebo Comparator|Placebo|Pioglitazone placebo-matching tablets, orally, once, daily, for minimum of 2 years.
3041377|NCT02284893|Experimental|A1:Saxagliptin / Placebo + Dapagliflozin / Placebo|Saxagliptin 5 mg and matching placebo 0 mg (once daily) plus Dapagliflozin 10 mg and matching placebo 0 mg (once daily)
3041378|NCT02284893|Experimental|A2: Sitagliptin / placebo|Sitagliptin 100 mg and matching placebo 0 mg (once daily)
3041379|NCT02284880|Experimental|Group 1 BIA 2-093|Subjects randomly received on period 1 and 2, either a single 400 mg tablet of ESL (MF - marketed formulation), or a single 400 mg tablet of ESL (TBM - o-be-marketed);
3041380|NCT02284880|Experimental|Group 2 BIA 2-093|Subjects randomly received on period 1 and 2, either a single 800 mg tablet of ESL (MF - marketed formulation), or a single 800 mg dose of ESL (TBM - o-be-marketed).
3041381|NCT02284867||Preterm labor|Patients who has threatened preterm labor and will receive tocolysis and these patients will either not respond to tocolysis and delivered preterm or will respond to tocolysis and will deliver at term .
3041382|NCT02284867||Term labor|Patient delivered vaginally at term with no history of having tocolysis for preterm labor at the current pregnancy .
3041383|NCT02284854|Experimental|Group A|Day 1 to Day 8 - BIA 2-093 800 mg Day 9 to Day 14 - BIA 2-093 800 mg + CBZ 200 mg Day 15 to Day 22 - BIA 2-093 800 mg + CBZ 400 mg Day 23 to Day 35 - BIA 2-093 800 mg + CBZ 400 mg twice-daily
3041384|NCT02284854|Experimental|Group B|Day 1 to Day 8 - CBZ 200 mg Day 9 to Day 14 - CBZ 400 mg Day 15 to Day 29 - CBZ 400 mg twice-daily Day 30 to Day 35 - BIA 2-093 800 mg + CBZ 400 mg twice-daily
3041385|NCT02284841|Experimental|Hilotherm cooling face mask|Use of Hilotherm cooling face mask post-operatively following surgical wisdom tooth removal to evaluate the incidence of pain and swelling
3041386|NCT02284841|No Intervention|No Hilotherm|No intervention following surgical wisdom tooth removal (same patient), therefore the patient is their own control.
3041387|NCT02284828|Experimental|Group 1 BIA 2-093|A single dose of oral ESL 900 mg was followed by consecutive 7-day periods of: Placebo, ESL 800 mg, and ESL 1200 mg.
3041388|NCT02284815|Active Comparator|Glutenfree diet|Self-chosen glutenfree diet
3041389|NCT02284815|Placebo Comparator|Normal diet|Those not following the glutenfree diet
3041390|NCT02284802|Experimental|Confocal endomicroscopy|Pts will be submitted to confocal endomicroscopy examination of the area of interest during endoscopy. A presumptive diagnosis will be made. This diagnosis will be compared to the definitive histologic diagnosis provided by endoscopic biopsies of the area of interest.
3041391|NCT02284789|Other|CAJAS evaluation|
3041392|NCT02284776|No Intervention|Témoin|No treatment.
3041393|NCT02284776|Experimental|Action|People in hydrotherapeutic cure are following a program of Therapeutic Education. This program includes dietary advice, physical activities, behavior advice in order to change the lifestyle of the obese people.
3041394|NCT02284763|Experimental|Change of EtCO2|Changes of rSO2 after adjustment of EtCO2 between 27-45 mmHg
3041395|NCT02284750|Experimental|Two-stenting technique|Percutaneous coronary intervention with DK crush, or culotte technique
3041396|NCT02284750|Active Comparator|Provisional stenting technique|Percutaneous coronary intervention with Provisional stenting technique. Stenting of the side branch was required if TIMI flow was <3, or ≥ type B dissection after kissing balloon inflation.
3041397|NCT02284737|Experimental|PADN + sildenafil|Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
3041398|NCT02284737|Sham Comparator|sham PADN + sildenafil|The radiofrequency ablation catheter placed, no ablations.
3041399|NCT02284724|Experimental|Needling|Insertion of solid mono-filament needle into lumbar multifidus muscle at both sides of L4/5 segment
3041402|NCT02284711|Active Comparator|Ultrasound|Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
3041405|NCT02284685|Experimental|A (opt-out, loss, social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, loss, social norming).
3041406|NCT02284685|Experimental|B (opt-out, gain, social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, gain, social norming).
3041407|NCT02284685|Experimental|C (opt-out, loss, no social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, loss, no social norming).
3041408|NCT02284685|Experimental|D (opt-out, gain, no social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, gain, no social norming).
3041409|NCT02284685|Experimental|E (opt-in, loss, social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, loss, social norming).
3041410|NCT02284685|Experimental|F (opt-in, gain, social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, gain, social norming).
3041411|NCT02284685|Experimental|G (opt-in, loss, no social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, loss, no social norming).
3041412|NCT02284685|Experimental|H (opt-in, gain, no social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, gain, no social norming).
3041413|NCT02284672|Placebo Comparator|control|"After preoxygenation for 3 minutes, normal saline would be injected to patient for 10 minute. First, 1% lidocaine 3 ml were given for reducing injection pain of propofol and the settled amount of propofol was injected during 15 seconds.~After 90 seconds, other anesthesiologist who did'nt know the injected drug tried to insert LMA."
3041414|NCT02284672|Experimental|dexmedetomidine|"After preoxygenation for 3 minutes, dexmedetomidine would be injected to patient for 10 minute. First, 1% lidocaine 3 ml were given for reducing injection pain of propofol and the settled amount of propofol was injected during 15 seconds.~After 90 seconds, other anesthesiologist who did'nt know the injected drug tried to insert LMA."
3041415|NCT02284659|Sham Comparator|FES-sham|Functional Electro Stimulation (FES-sham)
3041416|NCT02284659|Active Comparator|Intervention (FES)|functional electro stimulation
3041417|NCT02284646|Experimental|Personalized physical training|9-week personalized physical training program (ergometric bicycle)
3041418|NCT02284646|No Intervention|Information about physical activity|2 sessions of information on physical activity
3041419|NCT02284620|Experimental|CFNB group|Particiants in this group will receive a single injection for femoral nerve block intra-operatively combined continuous femoral nerve block post-operatively. This technique will be guided by ultrasound and nerve stimulator.The regimen is a loading dose of 0.8% ropivacaine 30 ml intra-operatively and 0.15% ropivacaine 300ml in the form of continuous femoral nerve block post-operatively.
3041420|NCT02284620|Active Comparator|LWI group|Particiants in this group will receive a peri-articular injection of suspension (48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone) combined with intravenous patient controlled analgesia post-operatively (tramadol 800 mg and flurbiprofenaxetil 100 mg with saline added up to a volume of 80 ml )
3041421|NCT02284607|Experimental|MHAA4549A higher dose|
3041422|NCT02284607|Experimental|MHAA4549A lower dose|
3041423|NCT02284607|Placebo Comparator|Placebo|
3041424|NCT02284594|Experimental|text message|Receipt of series of text messages regarding influenza vaccination
3041425|NCT02284594|No Intervention|usual care|
3041693|NCT02282761|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as formulated capsules once daily for 28 days
3041426|NCT02284581||Retrospective cohort|All consecutive metastatic breast cancers patients treated in the participating sites with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from Feb 2014 retrospectively back until 2000.
3041427|NCT02284581||Prospective cohort|All new consecutive metastatic breast cancers patients will be treated in the participating sites with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from March 2014 to December 2016.
3041428|NCT02284568|Experimental|laquinimod 0.6 mg|once daily oral dose.
3041429|NCT02284568|Experimental|laquinimod 1.5 mg|"once daily oral dose~NOTE- As of January 2016, this arm has been discontinued."
3041430|NCT02284568|Placebo Comparator|Placebo|once daily oral dose
3041431|NCT02284555|Experimental|Mupirocin 2% nasal Ointment|Mupirocin (Bactroban 2% nasal ointment) will be administered twice daily for 5 days in accordance with the Summary of Product Characteristics (SmPC).
3041432|NCT02284542||Patients with successful trial implant|Patients who have had a successful SCS trial and are indicated for permanent implantation will be approached to participate in this study prior to permanent implantation. Patients will be recruited and enrolled by physicians at any one of the involved sites. Each Investigator will only use one method (awake or non-awake) according to his/her typical practice. Patients will receive treatment from their enrolling physician.
3041433|NCT02284529|Experimental|Orectalip® (Oxaliplatin)|High-risk Stage-Ⅱ Colorectal Cancer treatment with Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1 to execute 8~12 cycles
3041434|NCT02284516|Experimental|Lifitegrast|
3041435|NCT02284516|Placebo Comparator|Placebo|
3041436|NCT02284503|Experimental|40mg Rosuvastatin group|The subjects in this group will receive Rosuvastatin 40mg within 12±2h before PCI, follow 20mg post PCI for 30days.
3041437|NCT02284503|Experimental|20mg Rosuvastatin group|The subjects in this group will receive Rosuvastatin 20mg within 12±2h before PCI, follow 20mg post PCI for 30days.
3041438|NCT02284503|Experimental|no statin group|The subjects in this group will not receive Rosuvastatin before PCI, follow 10mg post PCI for 30days.
3041439|NCT02284490|Experimental|Treatment Arm|Pemetrexed 900 mg/m² every 21 days until disease progression.
3041440|NCT02284477|Experimental|non- PVC containing packing materials|Participants will be provided food for lunch and dinner with 360mL apple juice which was stored in glass bottle for 24 hours in 4 ℃. After 1 week, participant will cross over to other intervention.
3041441|NCT02284477|Experimental|PVC containing packing materials|Participants will be provided food for lunch and dinner with 360mL apple juice which was stored in PVC blood bag for 24 hours in 4 ℃. After 1 week, participant will cross over to other intervention.
3041442|NCT02284477|No Intervention|Only lunch and dinner|Participant received food for lunch and dinner After 1 week, participant get over to each experimental arms.
3041443|NCT02284464|Active Comparator|Steroids, tacrolimus and mycophenolate|Normal treatment arm
3041444|NCT02284464|Experimental|Tacrolimus and mycophenolate|Normal treatment for first 90 days, then steroid withdrawal carrying on with the other drugs
3041445|NCT02284451|Active Comparator|English HIGH Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
3041446|NCT02284451|Active Comparator|English LOW Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
3041447|NCT02284451|Active Comparator|Spanish HIGH Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
3041448|NCT02284451|Active Comparator|Spanish LOW Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
3041449|NCT02284438|Other|Biofilm formation on ETT|Three different endotracheal tubes uses on intubated mechanical ventilated patients will after extubation be examined regarding biofilm, structure and presence of microbes on the ETTs The different tubes will be used during consecutive time periods The study does not include any interventions concerning the treatment of these critically ill patients
3041450|NCT02284425|Experimental|Part A|Participants in Part A will consist of 4 sequential ascending dose cohorts. Each cohort will receive 1 of 4 ascending dose levels of study drug (REGN1193) or placebo.
3041451|NCT02284425|Experimental|Part B|Participants in Part B will consist of a single cohort and will receive three doses of study drug (REGN1193) or placebo.
3041452|NCT02284412|Active Comparator|neostigmine|Neostigmine will be dosed as 60 μg/kg, and glycopyrrolate 12 μg/kg (commercially available 5:1 co-formulation), as a single iv bolus administered over 10sec, for reversal of rocuronium-induced moderate neuromuscular blockade.
3041453|NCT02284412|Experimental|Sugammadex|Sugammadex will be dosed 15 mg/kg, as a single iv bolus administered over 10sec, for reversal of rocuronium-induced moderate neuromuscular blockade.
3041454|NCT02284412|Placebo Comparator|Water for injection|Water will be dosed arbitrarily as a 1 mL single iv bolus administered over 10sec.
3041455|NCT02284399||IDTFK Group Post NIPT - (January 2012-June 2014)|Pregnant women who present to participating centers between January 2012-June 2014, after the release of non-invasive prenatal testing (NIPT), who are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
3041456|NCT02284399||IDTFK Group pre-NIPT (January 2010-July 2010)|A control group of pregnant women, prior to the release of non-invasive prenatal testing (NIPT), who present to participating centers between January 2010-June 2010 and are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
3041457|NCT02284386|Experimental|Bupivacaine SNB + EXPAREL Infiltration|Spinal block with bupivacaine HCl 7.5 mg/mL. Local infiltration of EXPAREL 266 mg.
3041485|NCT02284152|Experimental|Typical versus Infant-Led feeding|This is a within-subject study; all infants and mothers will be exposed to both conditions (typical feeding versus infant-led feeding conditions). Order of presentation will be counterbalanced across infant/mother dyads.
3041486|NCT02284139|Placebo Comparator|Placebo|Placebo ointment dose not contain EGF.
3041458|NCT02284373|Other|Randomization Arm 1:|70 subjects with venous ulcers will receive pneumatic compression with the Flexitouch® for the duration of one month in addition to routine care of venous ulcers and lymphedema. A pre- and post-PCD treatment CIVIQ-2 quality of life questionnaire will be administered to the subjects. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded
3041459|NCT02284373|Other|Randomization Arm 2:|70 subjects with venous ulcers will receive routine care of venous ulcers and lymphedema. A quality of life questionnaire will be administered at enrollment and again after one month. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded.
3041460|NCT02284373|Other|Observational Arm 3|50 subjects with lymphedema will ALL receive PCD treatment. A pre-and post- PCD treatment CIVIQ-2 QOL questionnaire will be administered to all subjects at enrollment and again after one month of treatment.
3041461|NCT02284360|Experimental|Group A: Low dose|"Each volunteer in group A will receive both Verum and Placebo.~The Verum lyophilized APOSEC™ is derived from 12.5*10^6 cells/ml irradiated lyophilized PBMC. The lyophilizate will be resuspended in 0.9% 200 µL NaCl and finally formulated in 800 µL Nugel.~As Placebo a cell-free control lyophilisate resuspended in 0.9% 200 µL NaCl and finally formulated with 800 µL Nugel is used. The location of application on the inner upper arm (proximal or distal) of Verum and Placebo will be randomized."
3041462|NCT02284360|Experimental|Group B: High dose|"Each volunteer in group B will receive both Verum and Placebo.~The Verum lyophilized APOSEC™ is derived from 25*10^6 cells/ml irradiated lyophilized PBMC. The lyophilizate will be resuspended in 0.9% 200 µL NaCl and finally formulated in 800 µL Nugel.~As Placebo a cell-free control lyophilisate resuspended in 0.9% 200 µL NaCl and finally formulated with 800 µL Nugel is used. The location of application on the inner upper arm (proximal or distal) of Verum and Placebo will be randomized."
3041463|NCT02284347|Experimental|NuVent™|Revision patients treated with NuVent™
3041464|NCT02284334||Low GI-High GI|"Two study visits are separate by around one month.~For this arm, test meal (Visit 1): low-glycemic index; test meal (Visit 2): high-glycemic index"
3041465|NCT02284334||High GI-Low GI|"Two study visits are separate by around one month.~For this arm, test meal (Visit 1): high-glycemic index; test meal (Visit 2): low-glycemic index"
3041466|NCT02284308|Active Comparator|Concurrent RCHT|"Etoposide (day 1, 2 and 3) and cisplatin (day 1) every 3 weeks, 3 cycles)~Etoposide (day 1, 2 and 3) and carboplatin (every 3 weeks, 3 cycles)~Cisplatin (daily)~Pemetrexed/Alimta and cisplatin (day 1 every 3 weeks, 3 cycles)~Pemetrexed/Alimta and carboplatin (day 1 every 3 weeks, 3 cycles)~Radiation schedule:~Radiotherapy in both arms is delivered to a minimal total tumour dose (TTD) of 66 Gy (biologically equivalent dose (EQD2), corrected for overall treatment time), unless restricted by one of the normal tissue constraints (see below). In the latter case, the mininimal TTD (EQD2 corrected for overall treatment time) is 60 Gy. Possible RT schedules include 33*2 Gy (once daily), 24*2.75 Gy (once daily) or RT according to an individualized prescribed maximal tolerated dose protocol (once or twice daily). The maximal allowed TTD (EQD2) is 86 Gy, corrected for overall treatment time. The overall treatment time should be no more than 47 days."
3041467|NCT02284308|Active Comparator|Sequential RCHT|"Pemetrexed/Alimta and cisplatin day 1 every 3 weeks, 3 cycles,~Pemetrexed/Alimta and carboplatin (every 3 weeks, 3 cycles),~Gemcitabine (day 1 and 8) and cisplatin (day 1) every 3 weeks, 3 cycles)~Gemcitabine (day 1 and 8) and carboplatin, (day 1 every 3 weeks, 3 cycles)~Radtiation schedule:~Radiotherapy in both treatment arms is delivered to a minimum total tumour dose (TTD) of 66 Gy (biologically equivalent dose (EQD2), corrected for overall treatment time), unless restricted by one of the normal tissue constraints (see below). In the latter case, the minimum TTD (EQD2 corrected for overall treatment time) is 60 Gy. Possible RT schedules include 33*2 Gy (once daily), 24*2.75 Gy (once daily) or RT according to an individualized prescribed maximal tolerated dose protocol (once or twice daily). The maximal allowed TTD (EQD2) is 86 Gy, corrected for overall treatment time. The overall treatment time should be no more than 47 days."
3041468|NCT02284295||occupational COPD|"Consists of 2 subgroups~COPD patients with history of exposure to respirable silica dust~COPD patients with history of exposure to aromatic hydrocarbons"
3041469|NCT02284295||smokers with COPD and healthy control|"patients with COPD, history of tobacco smoke and no history of occupational exposure~healthy subjects"
3041470|NCT02284282|Active Comparator|Spinal injection|Patients receive spinal injection Bupivacaine/Morphine
3041471|NCT02284282|Placebo Comparator|Subcutaneum injection|Placebo subcutaneum injections
3041472|NCT02284256|Experimental|Fibrocaps|"Human fibrinogen and thrombin powder. Single application during surgery~Other Names:~Raplixa~PRO-0601~Fibrin sealant~Device: Gelatin sponge. Single application during surgery~Other Name: Spongostan"
3041473|NCT02284256|Active Comparator|TachoSil|Human fibrinogen and thrombin powder. Single application during surgery
3041474|NCT02284243|Experimental|DEX-IN 50mcg|DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
3041475|NCT02284243|Placebo Comparator|IN Placebo|IN Placebo every 6 hours for 48 hours.
3041476|NCT02284230|Active Comparator|Liraglutide treatment|Subcutaneous, once daily injection of liraglutide, individually dosed up to 1.8 mg/day.
3041477|NCT02284230|Placebo Comparator|Placebo treatment|Subcutaneous, once daily injection of placebo, individually dosed up to 1.8 mg/day.
3041478|NCT02284217|Experimental|Patients with invasive ICP monitor (EVD)|Hospitalized patients who have already been implanted with an invasive ICP monitor. Eligible patients will be enrolled into the study and HS-1000 headset portion of the device will be placed in their ears.
3041479|NCT02284204|Active Comparator|Midazolam and Ketamine|In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). This combination of drugs were administered fifteen minutes before the start of treatment sessions.
3041480|NCT02284204|Experimental|Midazolam, Ketamine and Sevoflurane|In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). After fifteen minutes of this drug administration, the investigators start to provide sevoflurane, through a nasal hood, in an initial concentration of 0.1%, with 0.1% increment every 30 seconds, until a final expired concentration between 0.3 and 0.4%.
3041481|NCT02284191|Active Comparator|CT Coronary Angiogram|CT Coronary Angiogram plus standard care
3041482|NCT02284191|No Intervention|Standard Care|Standard care only
3041483|NCT02284178|Experimental|Enhanced oral suction|Deep oropharyngeal suction with catheter
3041488|NCT02284139|Active Comparator|Arm EGF ointment 20ppm|Arm EGF ointment 20ppm will be treated with EGF ointment of 20 ppm concentration
3041489|NCT02284126|Experimental|Topical Vancomycin|Treatment group, receive 2 g topical vancomycin hydrochloride (1 g applied as powder, 1 g mixed with sterile solution and applied as paste) at the time of closure, in addition to the standard of care for wound prophylaxis
3041490|NCT02284126|No Intervention|Standard of Care|Control group, receive standard of care only
3041491|NCT02284113|Experimental|Treatment|Treatment with focused cold therapy.
3041492|NCT02284113|Sham Comparator|Sham|Sham treatment with focused cold therapy device
3041493|NCT02284100|Experimental|animal assisted therapy group|the dog was present during post-operative awakening (2 hours after surgery)
3041494|NCT02284100|No Intervention|standard group|children had standard post-operative medical care
3041495|NCT02284087||V_PAS|Visuomotor paired associative stimulation protocol
3041496|NCT02284087||Sham V_PAS|Placebo group of Visuomotor paired associative stimulation protocol
3041497|NCT02284087||CER_PAS|cerebellar-motor associative stimulation protocol
3041498|NCT02284087||Sham CER_PAS|Placebo group of cerebellar-motor associative stimulation protocol
3041499|NCT02284074|Experimental|Nasal LPS spray|"This is a 5-way crossover, randomised, placebo-controlled study.~Arms consists of the following nasal challenges:~placebo, 1, 10, 30 and 100µg LPS."
3041500|NCT02284061|Experimental|experimental|Immediate Program : the child follows the physical activity program for a period of 18 months, as soon as his medical condition permits.
3041501|NCT02284061|Other|Control|Delayed Program: the child does not participate to the program during the first 6 months, and he joins the delayed program late after 6 months.
3041502|NCT02284048|Placebo Comparator|control|nitrate,beta blocker
3041503|NCT02284048|Active Comparator|ticagrelor|ticagrelor 90mg qd
3041504|NCT02284035|Experimental|Group 1 Raltegravir / 3TC (MK0518B|Raltegravir / 3TC (MK0518B ) (50 patients)
3041505|NCT02284035|Active Comparator|Group 2 standard combination therapy|"NNRTI-Based Regimen:~• EFV/TDF/FTC~PI-Based Regimens:~ATV/r + TDF/FTC or DRV/r + TDF/FTC~INSTI-Based Regimens:~DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC~NNRTI-Based Regimens:~EFV plus ABC/3TC or RPV/TDF/FTC~PI-Based Regimen:~ATV/r plus ABC/3TC~PI-Based Regimens:~DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC~INSTI-Based Regimen:~RAL plus ABC/3TC~And other ART regimens"
3041506|NCT02284022||Brain Computer Interface|Patients will test the brain computer interface system
3041507|NCT02284009|Experimental|Albiglutide|Approximately 51 subjects will be assigned to albiglutide 30 mg weekly (with treatment-masked increase to 50 mg weekly at Week 6) + background insulin. The starting dose of albiglutide will be 30 mg once weekly and will be increased at Week 6 to 50 mg, once weekly, if the 30-mg weekly dose is tolerated.
3041508|NCT02284009|Experimental|Placebo|Approximately 17 subjects will be assigned to albiglutide matching placebo + background insulin
3041509|NCT02283996|Experimental|Physical Therapy with Steroid Injection|Patients will undergo regular physical therapy as defined by the standard of care at Massachusetts General Hospital for Adhesive Capsulitis (Frozen Shoulder). If they are in the inflammatory phase of the condition, they will receive 40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine.
3041510|NCT02283996|Experimental|Watchful Waiting with Steroid Injection|Patients will undergo no therapeutic intervention outside of steroid injection. If they are in the inflammatory phase of the condition, they will receive 40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine.
3041511|NCT02283983|Active Comparator|Standard cryoprotection|Proposal helmet without mittens and booties
3041512|NCT02283983|Experimental|Cryoprotection with mittens and booties|Standard cryoprotection with mittens and booties
3041513|NCT02283970||BAV and aortic regurgitation|BAV Diagnosis, Aortic Regurgitation with surgical indication (according to current clinical guidelines or best clinical practice), normal ascending aorta
3041514|NCT02283970||BAV and Ascending aorta dilatation|BAV diagnosis, no or trivial Aortic Regurgitation, ascending aorta dilatation with surgical indication (according to current clinical guidelines or best clinical practice)
3041515|NCT02283970||BAV, aortic regurgitation and dilatation|BAV diagnosis, Aortic Regurgitation and ascending aorta dilatation with surgical indication (according to current clinical guidelines or best clinical practice).
3041516|NCT02283970||BAV with aortic stenosis in pts>60yrs|BAV diagnosis, Aortic stenosis with surgical indication (according to current clinical guidelines or best clinical practice). Normal ascending aorta
3041517|NCT02283957|Experimental|2 mL injection of 200 µg of CNTX-4975|Single dose, 2 mL
3041518|NCT02283957|Experimental|2 mL injection of 600 µg of CNTX-4975|Single dose, 2 mL
3041519|NCT02283957|Placebo Comparator|2 mL injection of placebo|Single dose, 2 mL
3041520|NCT02283957|Experimental|2 mL injection of 25 µg of CNTX-4975|Single dose, 2 mL
3041521|NCT02283944|Experimental|TMS electrochemotherapy|Combined TMS (transcranial magnetic stimulation) and Temozolomide chemotherapy.
3041522|NCT02283931|Active Comparator|One handed uterine displacement|Uterine displacement using one hand
3041523|NCT02283931|Active Comparator|two handed uterine displacement|Uterine displacement using two hands
3041524|NCT02283931|Active Comparator|30 degrees uterine displacement|Uterine displacement using a 30 degrees wedge
3041525|NCT02283918||Participants with education less than bachelor's degree|Participants are further divided into three sub-groups based on their age group Group 1: Participants aged between 25 to 34 years Group 2: Participants aged between 35 to 44 years Group 3: Participants aged between 45 to 58 years
3041526|NCT02283918||Participants with bachelor's degree or equivalent|Participants are further divided into three sub-groups based on their age group Group 1: Participants aged between 25 to 34 years Group 2: Participants aged between 35 to 44 years Group 3: Participants aged between 45 to 58 years
3041527|NCT02283905|Other|Amphotericin-B and Voriconazole|Treatment with a 24 hour continuous infusion of amphotericin B deoxycholate at 1.0 mg/kg/day for a total dose of at least 1 g (i.e. ~ 14 days); and then the patient is stepped down to voriconazole 6 mg/kg i.v. q12h for 2 doses, then 4 mg/kg q12h either i.v. or orally as appropriate. The oral dose will be rounded for convenience to either the 200 mg or 400 mg tablet twice daily.
3041586|NCT02283489|Experimental|Chemotherapy|Paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
3041528|NCT02283892|Experimental|Checklist|2 checklists available for consultation by the attending physician: (1) dyspnea evaluation checklist and (2) cough evaluation checklist. The checklists are available on computers and mobile devices (smartphone, PDA or tablet computer).
3041529|NCT02283892|Active Comparator|Conventional assessment|Evaluation of patients reporting dyspnea or cough made by the attending physician, without the use of the checklists for dyspnea or cough evaluation.
3041530|NCT02283879|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
3041531|NCT02283866|Experimental|Administering desflurane according to the patient's BIS value|The anesthesiologist administers the volatile anesthetic desflurane to set the patient's BIS value at 50 during balanced anesthesia, and titrate the remifentanil dose to set the patient's systolic arterial blood pressure between 100-140mmHg.
3041532|NCT02283866|Experimental|Administering desflurane at 1 MAC|The anesthesiologist administers the volatile anesthetic desflurane at 1 MAC during balanced anesthesia, and titrate the remifentanil dose to set the patient's systolic arterial blood pressure between 100-140mmHg.
3041533|NCT02283853|Experimental|BG00012|Participants will receive 120 mg capsule(s) taken orally.
3041534|NCT02283853|Active Comparator|IFN β-1a (Avonex)|Participants will receive the recommended dose of 30 μg (weekly)
3041535|NCT02283840|Experimental|Cohort A1:BIA 2-093 400 mg|"One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (Clinical Trial Formulation, CTF)"
3041536|NCT02283840|Experimental|Cohort A2:BIA 2-093 400 mg|One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (To-Be-Marketed Formulation, TBM)
3041537|NCT02283840|Experimental|Cohort B1:BIA 2-093 600 mg|"One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (Clinical Trial Formulation, CTF)"
3041538|NCT02283840|Experimental|Cohort B2:BIA 2-093 600 mg|One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (To-Be-Marketed Formulation, TBM)
3041539|NCT02283840|Experimental|Cohort C1:BIA 2-093 800 mg|"One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (Clinical Trial Formulation, CTF)"
3041540|NCT02283840|Experimental|Cohort C2:BIA 2-093 800 mg|One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (To-Be-Marketed Formulation, TBM)
3041541|NCT02283827|Experimental|Group A BIA 2-093 + Phenytoin (PHT)|Day 1 to 2: Pre-treatment 1: 600 mg ESL Day 3 to 8: Treatment 1: 1200 mg ESL Day 9 to 10: Treatment 1 + Pre-treatment 2: 1200 mg ESL+ 100 mg PHT Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + 300 mg PHT
3041542|NCT02283827|Experimental|Group B BIA 2-093 + Phenytoin (PHT)|Day 1 to 2: Pre-treatment 2: 100 mg PHT Day 3 to 8: Treatment 2: 300 mg PHT Day 9 to 10: Treatment 2 + Pre-treatment 1: 300 mg PHT + 600 mg ESL Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + 300 mg PHT
3041543|NCT02283814|Experimental|Group A BIA 2-093 + Topamax|"Group A~Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;~Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg for two consecutive days~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg (morning) + 100mg (evening) for two consecutive days~Treatment 4: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200 mg for fifteen consecutive days"
3041544|NCT02283814|Experimental|Group B BIA 2-093 + Topamax|"Pre-treatment: 100 mg once daily dose of TPM administered for two consecutive days;~Pre-treatment 2: 100 mg twice daily dose of TPM administered for two consecutive days;~Treatment: 200 mg once daily dose of TPM administered for four consecutive days;~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 600 mg and TPM 200 mg for two consecutive days~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200mg for seventeen consecutive days"
3041545|NCT02283801|Experimental|Group A|"Group A~Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;~Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 50 mg for two consecutive days~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 150 mg for seventeen consecutive days"
3041546|NCT02283801|Experimental|Group B|"Group B~Pre-treatment: 50 mg once daily dose of lamotrige (LMT) administered for two consecutive days;~Treatment: 150 mg once daily dose of lamotrige (LMT) administered for six consecutive days;~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1600 mg and lamotrigine 150 mg for two consecutive days~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 150 mg for seventeen consecutive days"
3041547|NCT02283788|Experimental|Treatment Sequence ABCD|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
3041548|NCT02283788|Experimental|Treatment Sequence BDAC|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
3041549|NCT02283788|Experimental|Treatment Sequence CADB|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
3041550|NCT02283788|Experimental|Treatment Sequence DCBA|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
3041551|NCT02283775|Experimental|PomdeSAR|"Part A: Isatuximab (escalating dose) on Day 1, 8, 15, and 22, then Day 1 and 15 + pomalidomide 4 mg on Day 1 to 21 + dexamethasone 40 mg (20 mg in patients of 75 years or older) on Day 1, 8, 15, 22 in 28-day cycles up to disease progression~Part B: Isatuximab 10 mg/kg on Day 1, 8, 15, and 22, then Day 1 and 15 + pomalidomide 4 mg on Day 1 to 21 + dexamethasone 40 mg (20 mg in patients of 75 years or older) on Day 1, 8, 15, 22 in 28-day cycles up to disease progression"
3041552|NCT02283762|Experimental|Riociguat|Increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5mg TID and maintenance period of 42 weeks
3041553|NCT02283762|Placebo Comparator|Placebo|Sham-titration
3041728|NCT02282488|No Intervention|Group Breastfeeding|Breastfeeding
3041554|NCT02283749|Experimental|Xofigo|Xofigo, 50 kBq/kg body weight, will be administered in the nuclear medicine department as a bolus intravenous (IV) injection (up to 1 minute) at intervals of every 4 weeks for up to 6 cycles.
3041555|NCT02283736|Experimental|Periodontal treatment, Probitic|Periodontal treatment (scaling and root planning) and one tablet containing Lactobacillus rhamnosus SP1 per day during 3 months.
3041556|NCT02283736|Placebo Comparator|Periodontal treatment, talc powder tab|Periodontal treatment (scaling and root planning) and one tablet containing talc powder per day during 3 months
3041557|NCT02283723|Experimental|Patient Group 1|This patient group will begin receiving the Health TAPESTRY intervention from time zero.
3041558|NCT02283723|Active Comparator|Patient Group 2|Using a step-wedge approach, this patient group will receive the intervention after a six month waiting period where they will be used as a comparable group. In the first six months, they will receive usual care.
3041559|NCT02283710|Experimental|Pentoxifylline + lifestyle modification|Pentoxifylline for 6 months plus obtaining ideal body weight by calorie restriction diet and programmed physical activity.
3041560|NCT02283710|Experimental|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity.
3041561|NCT02283697|Experimental|Dietary Counseling|Apart from standard care, an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the DASH (Dietary Approach to Stop Hypertension) diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.
3041562|NCT02283697|Other|Control: Standard Care|A standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
3041563|NCT02283684|Active Comparator|Greenlight laser PVP|Greenlight (532-nm) laser Photoselective vaporization of the prostate using (XPS) 180W system
3041564|NCT02283684|Active Comparator|Bipolar PKVP|Plasma Kinetic vaporization of the prostate using bipolar system
3041565|NCT02283671|Experimental|Tolerogenic dendritic cells|"Somatic-cell therapy medicines: tolerogenic dendritic cells loaded with myelin peptides.~Patients will receive intravenous administration every two weeks (week 0 , 2 and 4 ) representing a total of three administrations per patient.~The dose escalation will occur as expected in the absence of limiting toxicity in the previous dosage level."
3041566|NCT02283658|Experimental|Treatment (everolimus and letrozole)|Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3041567|NCT02283645|Experimental|Minoxidil|3% Minoxidil lotion is applied twice daily to the chest.
3041568|NCT02283645|Placebo Comparator|Placebo|Placebo lotion is applied twice daily to the chest.
3041569|NCT02283632|Experimental|Jejunal Diversion|all subjects who receive jejunal diversion surgery
3041570|NCT02283619||Patients with LBBB being evaluated for ACS|Patients who present to the emergency department with left bundle branch block on the electrocardiogram, who are being evaluated for acute coronary syndrome, and who qualify based on the inclusion/exclusion criteria listed in the detailed description.
3041571|NCT02283580|Experimental|Single limb resistance training|"Low load, high-repetitive resistance training.~single limb at a time (e.g., one arm or one leg)~elastic bands"
3041572|NCT02283580|Active Comparator|Two limb resistance training|"Low load, high-repetitive resistance training.~two limbs at a time (e.g., both arms or both legs)~elastic bands"
3041573|NCT02283554|Placebo Comparator|ARM1- open flap debridement (OFD)|open flap debridement done for 30 subjects. After debridement, Metformin or PRF was not added into the intrabony defect.
3041574|NCT02283554|Experimental|ARM2- open flap debridement plus PRF(Platelet rich fibrin)|"After open flap debridement, PRF( Platelet rich fibrin) was added into the intrabony defect.~No. of subjects= 30"
3041575|NCT02283554|Experimental|ARM3- open flap debridement plus 1%Metformin|After open flap debridement, 1% metformin was added into the intrabony defect No. of subjects= 30
3041576|NCT02283554|Experimental|ARM4- open flap debridement plus PRF plus metformin|"After open flap debridement, PRF and 1% metformin was added into the intrabony defect.~No. of subject- 30"
3041577|NCT02283541|Experimental|ASTM|Participants in Automatic self-transcending meditation (ASTM) arm will complete a 12 week meditation training program in addition to their existing treatment plan. This involves participating in 120-minute sessions on each of four consecutive days of the first week. Participants will individually be given a mantra on day one, and then be instructed in use of the mantra according to specific criteria over the four session program. This will be followed by weekly 60-minute follow up sessions for the 11 subsequent weeks. In addition, participants will be asked to practice ASTM at home for 20 minutes twice daily over the study period. Assessments of depression severity will be completed at specific times over the 12 week training period: at Weeks 0, 4, 8 and 12.
3041578|NCT02283541|No Intervention|TAU|Participants in TAU arm will continue with their existing treatment schedule as usual. Assessments of depression severity will be completed at specific times over the 12 week training period: at Weeks 0, 4, 8 and 12. However, no assessments will be done or information collected on the TAU arm from week 12 onwards. After week 12, TAU arm participants will be offered the opportunity to learn ASTM and attend follow up meditation.
3041579|NCT02283528|Experimental|Hybrid|Placement of Hybrid arch bars for open or closed reduction of mandible fractures
3041580|NCT02283528|Active Comparator|Erich|Placement of Erich archbars for open or closed reduction of mandible fractures
3041581|NCT02283515|Active Comparator|group I - Rosuvastatin, 1.2 mg|Rosuvastatin- locally placed in intrabony defect sites.
3041582|NCT02283515|Placebo Comparator|group II - placebo|placebo-placed locally in intrabony defects.
3041583|NCT02283502|Experimental|Intervention: MRgHIFU, Surgery|Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
3041584|NCT02283489|Experimental|Combination therapy A|Recombinant human endostatin adenovirus (EDS01), 5.0 × 1011 VP intratumorally on days 0 and 7; paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
3041585|NCT02283489|Experimental|Combination therapy B|Recombinant human endostatin adenovirus (EDS01), 1.0 × 1012 VP intratumorally on days 0 and 7; paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
3067641|NCT02110420|Experimental|CC-90001 10mg (Multiple Doses)|
3041587|NCT02283476|Experimental|Endostar continuous intravenous infusion|Endostar continuous intravenous infusion in combination with Gemcitabine and Cisplatin
3041588|NCT02283476|Active Comparator|Endostar routine intravenous infusion|Endostar routine intravenous infusion in combination with Gemcitabine and Cisplatin
3041589|NCT02283463|Active Comparator|Standard Cervical Tenaculum|Single tooth tenaculum, pierces the tissue of the cervix to allow provider to stabilize and place traction on the cervical cal/uterus
3041590|NCT02283463|Experimental|Bioceptive Cervical Retraction Device|Suction based method for stabilizing the cervix and uterus. Achieves suction 360 degrees around cervical os creating a portal through which instruments can be passed into the cervical canal and uterus. Provider can still place traction on uterus with this device just as with tenaculum.
3041591|NCT02283450||the experimental group|The patients in experimental group received the relevant tests and inspections before the beginning of experiment，signed the informed consent. Then we get the venous blood centrifugalization and cryopreservation. The patients take the medicine qiliqiangxin three times per day，four tablets at a time. Afrer a month，we evaluated the symptoms，the function of heart，blood pressure，heart rate and keep blood specimens. Three and six month later，electrocardiogram and echocardiography were taken and the determination of the NT - proBNP was done.
3041592|NCT02283450||the placebo group|The placebo group was followed up in the same way.
3041593|NCT02283437|Experimental|Problem-solving Based Bibliotherapy|The Problem-solving Based Bibliotherapy Program using a self-help manual based on problem-solving therapy defined by D'Zurilla and Nezu (2007) to be 'a self-directed cognitive-behavioral process by which a person attempts to identify/discover effective/adaptive solutions for specific problems encountered in everyday living'(p.11).
3041594|NCT02283437|Active Comparator|Psychoeducation Group Program|The psychoeducation group program will be guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) and McFarlane et al.'s (2003) psychoeducation programs for schizophrenia.
3041595|NCT02283437|No Intervention|Routine Outpatient Service|Participants in the control group (and 2 treatment groups) will receive routine psychiatric outpatient and family services.
3041596|NCT02283424|Active Comparator|chemotherapy|Carboplatin,350mg/m2,1/3weeks Docetaxel,75mg/m2,1/3weeks
3041597|NCT02283424|Experimental|Icotinib|Icotinib, 125mg,3/D,2years
3041598|NCT02283411|Other|Diabetes Mellitus, Type 1 and Type 2|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
3041599|NCT02283398|Experimental|with RIPC|RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated
3041600|NCT02283398|Sham Comparator|without RIPC|the cuff will be placed around the left arm without being inflated
3041601|NCT02283385|Experimental|PROTECT Intervention|Participants will receive a brief psychotherapy that builds on Problem Solving Therapy (PST)
3041602|NCT02283372|Experimental|nab-Paclitaxel + Gemcitabine + IMRT|"Prior to initiation of chemoradiation, patients will undergo 1 full cycle of gemcitabine and nab-paclitaxel on Days 1, 8, and 15 of a 28-day cycle.~Both gemcitabine and nab-paclitaxel will be given intravenously on an outpatient basis during the one-month lead-in period and during Weeks 1 and 2 (and, if enrolled to Dose Level or 2, Weeks 4 and 5) of radiotherapy. There may be up to 21 days between the last dose of lead-in chemotherapy (given on Day 15) and initiation of chemoradiation (inclusive of the week following Day 15, the fourth week of the lead-in cycle (an off-week), and an additional week following that).~Intensity modulated radiation (IMRT) - the prescribed dose will range from 40-67.5 Gy over 15 to 25 fractions."
3041603|NCT02283359|Experimental|Selinexor in Combination with Irinotecan|"The first study drug is called selinexor (KPT-330). This drug is taken by mouth on days 1, 3, 8 and 10 of each cycle. The starting dose of selinexor will be dependent on the cohort in which the patient is enrolled into. Level -1: 25 mg/m^2; Level 1: 40 mg/m^2; Level 2: 50 mg/m^2; Level 3: 65 mg/m^2.~The second drug is called irinotecan. This drug is given as intravenous (IV) infusion on days 1 and 8 of each cycle. Participants will receive the standard recommended dose: 125 mg/m^2."
3041604|NCT02283346|Experimental|HDR Brachytherapy + EBRT|HDR brachytherapy + hypofractionated EBRT
3041605|NCT02283333|Experimental|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy are delivered in 7 weekly sessions to the participant.
3041606|NCT02283333|Active Comparator|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling are delivered in 7 weekly sessions to the participant.
3041607|NCT02283320|Experimental|BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)|
3041608|NCT02283307|Experimental|Reduced contrast DECT scan|Reduced Contrast Dual Energy CT
3041609|NCT02283294|Experimental|Apixaban|Apixaban twice a day for 180 days with drug initiation day 0-3 (TIA), day 3-5(small stroke) or day 7- 9 (medium stroke) respectively
3041610|NCT02283294|Active Comparator|Warfarin|standard of care warfarin starting at day 7±5 (TIA) or day 14 ±5 (small to medium ischemic stroke).
3041611|NCT02283281|Experimental|Nabiximols high dose|"Single-dose, before anesthetic induction:~21.6 mg tetrahydrocannabinol + 20 mg cannabidiol, oromucosal spray.~Dummy 50 ml vial containing 0.9% sodium chloride solution, intravenous.~Prefilled dummy 2ml syringe containing 0.9% sodium chloride solution, intravenous."
3041612|NCT02283281|Experimental|Nabixomols low dose|"Single-dose, before anesthetic induction:~10.8 mg tetrahydrocannabinol + 10 mg cannabidiol, oromucosal spray.~Dummy 50 ml vial containing 0.9% sodium chloride solution, intravenous.~Prefilled dummy 2ml syringe containing 0.9% sodium chloride solution, intravenous."
3041613|NCT02283281|Active Comparator|Active placebo|"Single-dose, before anesthetic induction:~Dummy oromucosal spray containing alcohol vehicle without nabiximols.~Prefilled 50 ml vial containing 1 g acetaminophen, intravenous.~Prefilled 2 ml syringe containing 2 mg midazolam, intravenous."
3041614|NCT02283281|Placebo Comparator|Control|"Single-dose, before anesthetic induction:~Dummy oromucosal spray containing alcohol vehicle without nabiximols.~Dummy 50 ml vial containing 0.9% sodium chloride solution, intravenous.~Prefilled dummy 2ml syringe containing 0.9% sodium chloride solution, intravenous."
3041615|NCT02283268|Experimental|Recombinant von Willebrand Factor (rVWF)|Surgery participants treated with Recombinant von Willebrand Factor (rVWF)
3041616|NCT02283255|Active Comparator|Physical Activity 1|Aerobic Training: Aerobic training and muscle strength exercise for upper and lower limbs, 3 times a week for 4 months.
3042220|NCT02279069|Active Comparator|4-point canne|Stroke patients walk with 4-point canne
3041617|NCT02283255|Active Comparator|Physical Activity 2|Respiratory Training: muscle training using POWERbreathe device, 7 times a week, 3 series of 30 repetitions per day, for 4 months.
3041618|NCT02283255|Active Comparator|Physical Activity 3|Aerobic and Respiratory Training: Aerobic training and muscle strength exercise for upper and lower limbs, 3 times a week for 4 months and respiratory muscle training using POWERbreathe device, 7 times a week, 3 series of 30 repetitions per day, for 4 months.
3041619|NCT02283255|No Intervention|Physical Activity 4|No Physical Activity: Control group (usual care)
3041620|NCT02283242|Experimental|Galantamine|"8 mg of Galantamine for 4 weeks~16 mg Galantamine for 8 weeks"
3041621|NCT02283242|Placebo Comparator|Placebo|"8 mg of placebo for 4 weeks~16 mg placebo for 8 weeks"
3041622|NCT02283229|Active Comparator|Active|Newborns with preventive caring advices
3041623|NCT02283229|Placebo Comparator|Surveillance|Newborns with normal caring advices
3041624|NCT02283216|Experimental|Acoustic, Body, Cortical|Acoustic corresponds to noise sound stimulation. Body corresponds to body electrical stimulation. Cortical corresponds to transcranial magnetic stimulation. Acoustic is presented together with body and cortical stimulation. Different body locations and timing among acoustic, body, and cortical stimulation are presented across testing sessions.
3041625|NCT02283203|Active Comparator|APOTEL max|Active drug; water for injection at a volume of 100ml with added 1g of paracetamol and inactive ingredients (ΑPOTEL max®), infused within 15 minutes. Available in 100ml bags.
3041626|NCT02283203|Placebo Comparator|Placebo|Placebo; water for injection at a volume of 100ml with added inactive ingredients, infused within 15 minutes. Available in 100ml bags.
3041627|NCT02283190|Experimental|Ewwinase|Six doses of Erwinase given three times weekly (Monday-Wednesday-Friday) for two weeks. Possible dose levels used are 20.000 IU/m2/day, 25,000IU/m2/day, and 30,000IU/m2/day.
3041628|NCT02283177|Experimental|Cohort A|Patients will be given cytarabine and daunorubicin during induction therapy plus crenolanib at 100 mg TID.
3041629|NCT02283177|Experimental|Cohort B|Patients will be given cytarabine and idarubicin during induction therapy plus crenolanib at 100 mg TID.
3041630|NCT02283164|Experimental|Treatment|Hazardous materials online education and study feedback
3041631|NCT02283164|Active Comparator|Control then treatment|Hazardous materials online education and study feedback
3041632|NCT02283151|Other|energy-restricted diet|The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d). Supplementation of multivitamins and minerals was provided per day.
3041633|NCT02283151|Experimental|diet nutrition bar|The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake < 20g/d). Carbohydrate-rich foods, such as white rice, steamed bread and tubers, were substituted with fish, poultry and plant oil. All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar (106 Kcal: 2.8 g carbohydrate, 11.2 g protein and 5.6 g fat; Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (<200 kcal), and 50 g protein from meat (i.e., beef, lean pork, skinned chicken, fish) at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
3041634|NCT02283099|Experimental|rVSVΔ-ZEBOV-GP (BPSC1001)|Subjects will be allocated to three cohorts of 10 subjects each receiving one single vaccine injection administered as an i.m. injection.
3041635|NCT02283086|No Intervention|Control|
3041636|NCT02283086|Experimental|Intervention|The intervention consisted of quarterly performance feedback reports sent via e-mail.
3041637|NCT02283073||Idiopathic Parkinson's disease|Patient with clinical diagnosis of Idiopathic Parkinson's Disease according to Queen Square Brain Bank Criteria up to one year prior to enrollment in study.
3041638|NCT02283073||Differential Diagnosis Group|MSA, PSP, CBD, Lewy body dementia, Essential Tremor, and Healthy Controls
3041639|NCT02283060|Experimental|Stribild switch arm|Patient to be taken off Atripla and switched to Stribild (co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) -one tablet taken daily with food
3041640|NCT02283060|Active Comparator|Atripla control arm|Patient to continue taking Atripla (co-formulated efavirenz/emtricitabine/ tenofovir disoproxil fumarate) - one tablet taken daily at bedtime on an empty stomach
3041641|NCT02283047|Active Comparator|CONTROL GROUP-DIET|Hypocaloric diet intervention with no supervised exercise intervention
3041642|NCT02283047|Experimental|DIET & MODERATE CONTINUOUS TRAINING|Intervention with hypocaloric diet and supervised moderate continuous exercise training (60-80%HRpeak). High volume training (45 minutes in progression from 20 min)
3041643|NCT02283047|Experimental|DIET & HIGH VOLUME HIIT|Intervention with hypocaloric diet and supervised high intensity interval training (85-95%HRpeak). High volume training (45 minutes in progression from 20 min)
3041644|NCT02283047|Experimental|DIET & LOW VOLUME HIIT|Intervention with hypocaloric diet and supervised high intensity interval training (85-95%HRpeak). Low volume training (20 min)
3041645|NCT02283034|Experimental|With feedback|Participants compress the chest of the manikin with CPR feedback device.
3041646|NCT02283034|Experimental|Without feedback|Participants compress the chest of the manikin without CPR feedback device
3041647|NCT02283021||NSCLC Patients|Sample biopsies from normal and cancerous lung tissue.
3041648|NCT02283021||Patients without NSCLC|Sample biopsies from normal lung tissue.Control group.
3041649|NCT02283008|No Intervention|Standard care|This arm will receive standard care which involves informal education on how to use metered dose inhalers
3041650|NCT02283008|Active Comparator|Structured education|This arm will receive structured education on the use of inhalers. At 6 weeks post education inhaler technique will be re-assessed. Participants who fail to achieve a set level of competence may be chosen for semi structured interview.
3041651|NCT02282995||•FDR-Relatives of FD patients|"Relatives of FD patients. Patients may bring at most two FDRs to participate in this study.~Up to 20 ml of fasting blood sample will be collected~Serology test of Hp status will be performed for healthy volunteers and all FDRs"
3041652|NCT02282995||•FDC-Healthy control|"Healthy control. Controls who are self-referred to this study will be recruited.~Up to 20 ml of fasting blood sample will be collected~Fasting glucose test will be performed for FD patients~Serology test of Hp status will be performed for healthy volunteers and all FDRs"
3041653|NCT02282995||•FD-Patients with FD|"Patients with FD. Patients referred for OGD in Endoscopy Center, Prince of Wales Hospital, with symptoms suggestive of FGID will be invited to participate in this study.~Up to 20 ml of fasting blood sample will be collected~Fasting glucose test will be performed for FD patients"
3041654|NCT02282995||•FDCR-Relatives of healthy controls|"Relatives of healthy controls. Each participating control is required to bring at least one and up to two FDRs to participate in this study.~Up to 20 ml of fasting blood sample will be collected~Serology test of Hp status will be performed for healthy volunteers and all FDRs"
3041655|NCT02282982||Infants at high-risk of serious RSV illness|Infants who received immunoprophylaxis during the RSV season
3041656|NCT02282969||Lung Cancer Screening Decision Aids|Participants are asked to look over education materials about lung cancer screening, and interviewed. Some participants will look at a video patient decision aid, with an interview and questionnaire completion. Some participants complete lung cancer screening knowledge questionnaire at first visit, and then again in one month.
3041657|NCT02282956|Experimental|study group|single shot, posterior tibial nerve block with 5 ml of Ropivacaine 0,75% before surgery postoperative PCA pump with morphine and droperidol (DHBP®) for the next 24 hours.
3041658|NCT02282956|Other|controll Group|After surgery: standard analgesic treatment by PCA (patient controlled analgesia) pumps with morphine and Droperidol (DHBP®) for the next 24 hours.
3041659|NCT02282943|Active Comparator|Laser|vapourisation/excision of endometriosis using CO2 laser
3041660|NCT02282943|Experimental|Harmonic scalpel|excision of endometriosis using Harmonic scalpel
3041661|NCT02282930|Experimental|ACTH Gel|Injected does of 80 units subcutaneously twice weekly for 6 months.
3041662|NCT02282917|Experimental|AR-42 Administration|AR-42 will be administered three times per week beginning 3 weeks prior to surgery.
3041663|NCT02282904|Experimental|CGD Recipient|CGD patients that will undergo haplo transplantation with post-transplant cyclophosphamide as described
3041664|NCT02282891|Active Comparator|Propofol|Induction of general Anesthesia using propofol 2mg/kg
3041665|NCT02282891|Experimental|Propofol/Ketamine (ketofol)|Induction of general anesthesia using a mixture of 1.5mg/kg:0.75mg/kg Propofol/ketamine
3041666|NCT02282878|Experimental|High/Low Sodium Diet|All MS patients will receive 2 weeks of controlled high sodium diet followed by a 1 week washout and 2 weeks of low sodium diet.
3041667|NCT02282878|Active Comparator|High/Low Sodium Diet Control|Age matched controls will receive two weeks of controlled high sodium diet followed by a 1 week washout and 2 weeks of low sodium diet.
3041668|NCT02282865||Visual analogue scale (VAS) >5|The degree of surgery-related anxiety assessment using VAS
3041669|NCT02282865||Visual analogue scale (VAS) ≤5|The degree of surgery-related anxiety assessment using VAS
3041670|NCT02282852|Experimental|Wireless Capsule Endoscopy|Wireless capsule endoscopy is the investigation modality of choice for suspected diseases of the small bowel. A small pill-sized capsule contianing a camera is swallowed by the patient. The procedure is safe and non-invasive. Normally, the pill camera travels through the gut an exits the bowel via natural means. In a small number of cases the capsule is maintained. If the capsule is still in the stomach, mobilisation is encouraged followed by an intramuscular pro-kinetic injection if this fails.
3041671|NCT02282852|Active Comparator|Magnetically steerable capsule endoscopy|A handheld magnet (manufactured by Intromedic Ltd.) has been developed to allow some control of the pill camera (that contains a small amount of magnetic material) in the upper GI tract. We propose that this could be used, alongside positional changes, to expedite capsule transit through the stomach thus improving completion rates and avoiding the risks of unnecessary medication.
3041672|NCT02282839|Active Comparator|Study group|Oral glutamine 10 g TID (total 30 g/day) one week before radiotherapy till the end of radiotherapy
3041673|NCT02282839|Placebo Comparator|Control group|Placebo (Same ingredients without glutamine) one week before radiotherapy till the end of radiotherapy
3041674|NCT02282826|Experimental|Dose 1 IV|GZ402668 dose 1 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
3041675|NCT02282826|Experimental|Dose 2 IV|GZ402668 dose 2 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
3041676|NCT02282826|Experimental|Dose 3 IV|GZ402668 dose 3 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
3041677|NCT02282826|Experimental|Dose 3 SC|GZ402668 dose 3 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
3041678|NCT02282826|Experimental|Dose 4 SC|GZ402668 dose 4 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
3041679|NCT02282826|Experimental|Dose 5 SC|GZ402668 dose 5 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
3041680|NCT02282826|Placebo Comparator|Placebo SC|placebo subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
3041681|NCT02282826|Placebo Comparator|Placebo IV|placebo intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
3041682|NCT02282813|Experimental|CTAP101 Capsules alone|CTAP101 Capsules 30 or 60 mcg daily for up to 26 weeks
3041683|NCT02282813|Experimental|CTAP101 Capsules +calcitriol|CTAP101 Capsules 60 mcg +calcitriol daily for 14 weeks
3041684|NCT02282813|Experimental|CTAP101 Capsules +doxercalciferol|CTAP101 Capsules 60 mcg +doxercalciferol daily for 14 weeks
3041685|NCT02282813|Experimental|CTAP101 Capsules +paricalcitol|CTAP101 Capsules 60 mcg +paricalcitol daily for 14 weeks
3041686|NCT02282800||Case group|Case group include patients with generalized AgP were the tissue samples taken to analyse the number of vitamin D receptor present.
3041687|NCT02282800||Control group|Ethnically matched, systemically and periodontally healthy individuals were included in control group were also gingival tissue taken for analysis of number of receptors present in nucleus and cytoplasm
3041688|NCT02282787|Experimental|5 micron dex arm|
3041689|NCT02282787|Experimental|10 micron dex arm|
3041690|NCT02282774|Experimental|SB|receive subtenon block of 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture
3041691|NCT02282774|Sham Comparator|C|receive subtenon block of 4mL saline
3041692|NCT02282761|Experimental|40 mg ITI-007|40 mg ITI-007 administered orally as formulated capsules once daily for 28 days
3041694|NCT02282761|Placebo Comparator|Placebo|Placebo administered orally as formulated capsules once daily for 28 days
3041695|NCT02282722|Active Comparator|Usual informed consent|Study participant will receive usual, standard-of-care informed consent for chemotherapy materials.
3041696|NCT02282722|Experimental|Investigational informed consent|Study participant will receive investigational informed consent for chemotherapy materials that were developed by the study team.
3041697|NCT02282709|Experimental|Daclatasvir and asunaprevir|daclatasvir 60 mg once daily asunaprevir 100 mg BID
3041698|NCT02282696|Experimental|cancer patients|Questionnaire, focus group participation
3041699|NCT02282683|Experimental|Prednisone|Prednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months.
3041700|NCT02282683|No Intervention|Control|Maximum tolerated guideline-directed medical therapy
3041701|NCT02282670|Experimental|DA-5204|DA-5204 administered two times daily for two weeks
3041702|NCT02282670|Active Comparator|Stillen tab.|Stillen tab. administered three times daily for two weeks
3041703|NCT02282657|Experimental|One single arm|Procedure: Baseline ventilator settings will be established per the EXPRESS protocol: VT = 6 mL/kg (ideal body weight); inspiratory flow will be set at 50-70 L/min resulting in an end-inspiratory pause of 0.2-0.5 sec, I:E ratio 1:1 to 1:3, PEEP set so that the plateau pressure (Pplat), measured during the end-inspiratory pause of 0.2 to 0.5 s, will be within the following limits: 28 cm H2O ≤ Pplat ≤ 30 cm H2O; Set RR to 20-35 to maintain approximately the same minute ventilation as before study initiation. Baseline ventilator settings will be maintained for a 2-hour run-in time (time to setup ECCO2R devices). Use heated humidifiers for gas humidification and minimize instrumental dead space. ECCO2R will be initiated during the 2-hour run-in time. Neuromuscular blocking agents (NMBA) will be used. EtCO2 will be monitored. RR will be kept what it was at Baseline. Sweep gas flow will be adapted. Ventilation will be adapted. Respiratory rate will be adapted.
3041704|NCT02282644|Experimental|CellSearch|
3041705|NCT02282631|Experimental|Intervention group school|School where the incentive scheme will be run.
3041706|NCT02282631|No Intervention|Control group school|School with no intervention; ongoing advice on active school travel.
3041707|NCT02282618||heart failure with HTEA|Heart failure patients are treated with the world-wide accepted medicine, plus HTEA for 4 weeks.
3041708|NCT02282618||heart failure with medicine|Heart failure patients are treated with the world-wide accepted medicine.
3041709|NCT02282605|Experimental|XF-73 2.0 mg/g nasal gel|0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris, twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.6mg XF-73 per naris/1.2mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
3041710|NCT02282605|Experimental|XF-73 0.5 mg/g nasal gel|0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.15mg XF-73 per naris/0.3mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
3041711|NCT02282605|Placebo Comparator|Placebo nasal gel|0.3mL nasal gel will be applied to each naris twice daily for two days. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
3041712|NCT02282592||Cases|newly diagnosed (within 6 months) breast cancer patients, before adjuvant or neoadjuvant treatment.
3041713|NCT02282592||Controls|patients without any malignant disease, matched for age an menopausal status with cases.
3041714|NCT02282579||Patient with metastatic renal cell carcinoma treated|Patient with metastatic renal cell carcinoma treated with Pazopanib
3041715|NCT02282566|Placebo Comparator|Protein-nutrition beverage - Placebo|: 8 oz protein-nutrition beverage 1
3041716|NCT02282566|Experimental|Protein-nutrition beverage - Beverage 2|8 oz protein-nutrition beverage 2
3041717|NCT02282566|Experimental|Protein-nutrition beverage - Beverage 3|8 oz protein-nutrition beverage 3
3041718|NCT02282566|Experimental|Protein-nutrition beverage - Beverage 4|8 oz protein-nutrition beverage 4
3041719|NCT02282553|Experimental|Magnetically steerable pill camera|Capsule endoscopy uses a swallowable pill camera which passes through the GI tract by the action of peristalsis. The procedure utilizes a battery powered wireless capsule to transmit images of the gastrointestinal tract as it passes through the small intestine. The images are later downloaded to a computer and reviewed by a trained physician. Magnetically steerable gastric capsule endoscopy uses a pill camera containing a small amount of magnetic material, that can be manoeuvred in the gut and intestine by the physician using a handheld magnet. This technique will be compared to conventional gastroscopy which uses a flexible endoscope. Both techniques will be used to diagnose upper gastrointestinal pathology in patients with recurrent/refractory iron deficient anemia.
3041720|NCT02282540|Experimental|Iodixanol to the Eustachian tube|Iodixanol contrast medium diluted with NaCl to 20% into the tympanostomy tube while the patient lies on his / her back with the head slightly turned to the opposite side. After 10 minutes the CT examination will be conducted using 200 mA and 120 kV.
3041721|NCT02282527|Other|Treatment Sequence 1|Subjects were treated first with Liquid Alpha₁-PI and then treated with Prolastin-C
3041722|NCT02282527|Other|Treatment Sequence 2|Subjects were treated first with Prolastin-C and then treated with Liquid Alpha₁-PI
3041723|NCT02282514|Experimental|Hematopoietic Stem Cell Transplantation|The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused intravenously before each dose of rATG. Autologous hematopoietic stem cells will be infused intravenously on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.
3041724|NCT02282501|Active Comparator|intermittent feeding|Bolus infusion - The total daily feeding period was also 4-6 times a day.
3041725|NCT02282501|Active Comparator|continuous feeding|Continuous infusion - The daily desired amount was offered continuously for 20 hours a day.
3041726|NCT02282488|Experimental|Group 1: Low protein formula|Low protein formula
3041727|NCT02282488|Experimental|Group 2: high protein formula|High protein formula
3041729|NCT02282475||Cohort study of pregnant women|"Participants will complete the following at 12-16 weeks gestation and again at 32-36 weeks gestation:~Fasting glucose, insulin and insulin sensitivity testing;~Blood tests for cholesterol and fatty acids, liver function, inflammation, and markers of metabolism;~Measurements of body fat using air displacement technology and MRI;~Ultrasound to measure placental blood flow, visceral fat thickness (12-16 weeks only) and to estimate fetal weight (32-36 weeks only);~24 hour diet recalls~Questionaires regarding activity level"
3041730|NCT02282475||Case-control study Gestational Diabetes|"Participants diagnosed with gestational diabetes (cases) and without gestational diabetes (controls) will complete the following at 32-36 weeks gestation:~Fasting glucose, insulin and insulin sensitivity testing;~Blood tests for cholesterol and fatty acids, liver function, inflammation, and markers of metabolism;~Measurements of body fat by using air displacement technology and MRI;~Ultrasound to measure placental blood flow and to estimate fetal weight;~24 hour diet recalls~Questionaires regarding activity level"
3041731|NCT02282462|Experimental|Reg pressure, Active suction (Dig)|Regulated pleural pressure with active suction
3041732|NCT02282462|Experimental|Reg pressure, Passive drainage (Dig)|Regulated pleural pressure with passive drainage
3041733|NCT02282462|Experimental|Unreg pressure, Active suction (Trad)|Unregulated pleural pressure with active suction
3041734|NCT02282462|Experimental|Unreg pressure, Passive drainage (Trad)|Unregulated pleural pressure with passive drainage
3041735|NCT02282449|Experimental|Power Injectable Port|The subjects randomized to this group will receive the newer, power injectable port.
3041736|NCT02282449|Active Comparator|Non-Power Injectable Port|The subjects randomized to this group will receive the older, non-power injectable port.
3041737|NCT02282436||COPD exacerbation|No specific intervention for this study
3041738|NCT02282423|Experimental|Lean Controls|"Lean controls will have BMI of 25 or less, gender specific normal body fat, and not be taking any medication that affects glucose metabolism.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
3041739|NCT02282423|Experimental|Obese, Non-diabetic|"Obese nondiabetics will have a BMI between 30-50 and not be taking any medication that affects glucose metabolism.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
3041740|NCT02282423|Experimental|Diabetic|"Diabetic patients will have a BMI between 30-50. We will recruit patients with mild or newly diagnosed type 2 diabetes who are treated with diet, sulfonylureas, or other drugs working through enhanced insulin secretion. Patients taking metformin or TZDs will not be recruited due to the effects of those drugs on insulin action.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
3041741|NCT02282423|Experimental|Non-diabetic|"Patients will be nondiabetic, although we will include patients with impaired glucose tolerance. Patients will meet criteria for treatment with fibrates to lower plasma triglyceride concentrations (triglyceride>300 mg/dl for nondiabetics, 250 mg/dl for patients with impaired glucose tolerance). We will aim at recruiting equal numbers of men and women. All participants will be between the ages of 30 and 59. Patients will have a BMI of 25-50 and not be taking any other medication that affects glucose metabolism. All participants will be sedentary (not reporting more than 10 minutes per day of light to vigorous leisure time physical activity.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
3041742|NCT02282410|Experimental|ADVATE standard prophylaxis|This study is a prospective, open-label, interventional, multicenter study in a total of 15 PTPs with hemophilia A (FVIII≤2 %).The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year. Subjects must be prescribed ADVATE by the treating physician. Data will be collected over a period of 2 years from the time of study enrollment. Study visits are to coincide with routinely rescheduled and emergency visits. Available data from these visits shall be transcribed onto the case report forms (CRFs).
3041743|NCT02282397|No Intervention|Phase 1: SMBG|Type 1 or Type 2 diabetes mellitus subjects using SMBG testing and usual care for diabetes management. No intervention to be administered
3041744|NCT02282397|Other|Phase 1: CGM|Type 1 or Type 2 diabetes mellitus subjects using RT-CGM and SMBG testing for diabetes management. RT-CGM (Continuous Glucose Monitoring) is the intervention.
3041745|NCT02282397|No Intervention|Phase 2: CGM/MDI|Type 1 Diabetes Mellitus subjects using RT-CGM and injections for diabetes management.
3041746|NCT02282397|No Intervention|Phase 2: CGM/CSII|Type 1 Diabetes Mellitus subjects using RT-CGM and CSII for diabetes management.
3041747|NCT02282384|Experimental|oseltamivir|75 mg oseltamivir orally twice daily for 5 days within 72 hours of symptom onset
3041748|NCT02282384|Placebo Comparator|Placebo|75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir
3041749|NCT02282371|Experimental|Cetuximab + BYL719 + IMRT|Cetuximab loading dose, 400 mg/m2 intravenously (IV). IMRT, 1 fraction/day, up to total of approximately 70 Gy, over approximately 33 treatment days Cetuximab 250 mg/m2 weekly IV X 7 weeks Daily BYL719, according to dose escalation scheme followup clinic visits every 3 months for 2 years,every 6 months for the next 3 years, and annually thereafter.
3041750|NCT02282358|Experimental|Mocetinostat|Patients who harbor mutations for CREBBP and/or EP300 will be started on mocetinostat 70 mg orally three times per week on a 28 day schedule in cycle 1. The dose will be escalated in cycle 2 to 90 mg orally three times per week on a 28 day schedule if there are no grade 3 or higher drug related toxicities. Therapy will continue until disease progression, intolerable toxicities or death.
3041751|NCT02282345|Experimental|Talazoparib|"Talazoparib administered by mouth at 1 mg per day for a total of 6 cycles before participants proceed to the standard of care therapy of the treating physician's choice.~Each cycle will consist of 28 days.~Expansion Cohort:~After receiving study drug for up to 6 cycles, participants have surgery to remove the tumor as part of the standard of care for the disease."
3041752|NCT02282332|Experimental|Patiens Discharged on Ticagrelor|Patients to be discharged on ticagrlore regiment of 90mg twice a day for 6 months.
3041753|NCT02282319|Experimental|A chloro|spinal chloroprocaine 40 mg
3041754|NCT02282319|Experimental|B chloro+ spin dexdor|Spinal chloroprocaine 40 mg spinal dexmedetomidine 0.5 mcg
3041755|NCT02282319|Experimental|C chloro + IV dexdor|Spinal chloroprocaine 40 mg IV dexmedetomidine 0.5 mcg/kg
3041795|NCT02281994|Placebo Comparator|Control/no PEMF|control/placebo device does not emit Pulsed Electromagnetic Field (PEMF)
3041756|NCT02282306|Other|TTIP-PRO|"Patients who have experienced an OOD in the past 8 months will be eligible to receive TTIP-PRO. A letter about the study will be sent to those patients. Interested patients will call the UC Health staff working on this study. The intervention entails administering the Personal Opioid-Overdose Risk Survey and the Opioid Overdose and Treatment Awareness Survey to the patient. The TTIP-PRO computer program uses the information to generate the Personal Feedback Report, which is used by the Peer Interventionist to provide the intervention. The TTIP-PRO computer program also creates the Personal Risk Factors Report which is mailed to the participant with some other helpful information."
3041757|NCT02282293|Active Comparator|Daily TS + Monthly DP pregancy / infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.~Infants will be given DP (half strength tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines."
3041758|NCT02282293|Placebo Comparator|TS + DP Placebo pregancy/infancy|"Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.~Infants will be given DP placebo (tablets once a day for 3 consecutive days) every four weeks from 2 months to 24 months of age. Infants will be given TS daily starting at 6 weeks of life using weight-based guidelines."
3041759|NCT02282280||Study Group|All patients included in the study
3041760|NCT02282267|Experimental|Gefitinib|Patients with EGFR mutation in plasma detected by droplet digital PCR could receive Gefitinib 250mg every day until disease progression.
3041761|NCT02282254|Active Comparator|Single-hormone closed-loop strategy|
3041762|NCT02282254|Active Comparator|Dual-hormone closed-loop strategy|
3041763|NCT02282241|Placebo Comparator|Placebo|Patients given once daily placebo (cellulose) orally in the evening, for 14 days.
3041764|NCT02282241|Experimental|Melatonin|Patients given once daily melatonin 1.5mg orally in the evening, for 14 days.
3041765|NCT02282215|Experimental|CLT-008 low dose with G-CSF|Dose escalation
3041766|NCT02282215|Experimental|CLT-008 high dose with G-CSF|Dose escalation
3041767|NCT02282215|Experimental|CLT-008 with G-CSF|Randomized
3041768|NCT02282215|Active Comparator|G-CSF|Randomized
3041769|NCT02282202|Other|Off/on for 3 weeks followed by on/off for 3 weeks|Subjects are randomized to either Oscillating Positive Expiratory Pressure device (Aerobika ®) or no device for three weeks, then crossover for the following three weeks.
3041770|NCT02282189|Other|Off/on for 4 weeks followed by on/off for 4 weeks|Subjects are randomized to either Oscillating Positive Expiratory Pressure device or no device for four weeks, then crossover for the following four weeks.
3041771|NCT02282176|Experimental|Azithromycin|10mg/kg azithromycin IV daily (administered over a period of at least one 1 hour) for a period of 10 days.
3041772|NCT02282176|Placebo Comparator|Placebo|Placebo IV daily (administered over a period of at least one 1 hour) for a period of 10 days.
3041773|NCT02282163|Experimental|Lumason|"All patients will be administered, Lumason sulphur hexafluoride lipid-type A microspheres an ultrasound contrast agent as a single 0.03 mL/kg bolus injection during echocardiography."
3041774|NCT02282150|Other|Conventional vs modified hydrocortisone;|5 weeks of conventional hydrocortisone followed by 16 weeks of modified-release hydrocortisone (Plenadren)
3041775|NCT02282137|Experimental|68Ga-PSMA|Evaluation of concordance and discordance between the results of 68Ga-PSMA PET/CT and other available conventional imaging modalities (such as CT, MRI, FDG, NaF scan), histology or follow up.
3041776|NCT02282124|Experimental|Intervention|"The intensity of the intervention follows a defined algorithm during the first eight months after renal transplantation. Behaviours are classified in three groups:~Group 1: Patients with optimal behaviour in all three behaviours.~Group 2: Patients with slight deviation (defined) from optimal behaviour in one or more behaviours.~Group 3: Patients with larger deviation (defined) from optimal behaviour in one or more behaviours.~All patients (group 1-3) will receive an assessment, education and a monthly reassessment.~Patients from group 2 und 3 will receive additionally behavioral education and peer involvement. Patients from group 3 will receive additionally a consilium of specialized healthcare professionals such as a nutritionist, physiotherapist, or psychologist."
3041777|NCT02282124|Other|Control|
3041778|NCT02282111|Active Comparator|EUS-CNB|Endoscopic ultrasound-core needle biopsy technique
3041779|NCT02282111|Active Comparator|EUS-SINK|Endoscopic ultrasound- single incision needle knife technique
3041780|NCT02282098|Experimental|Active Colchicine|The intervention group will receive colchicine 0.6 mg twice daily orally for 3 months
3041781|NCT02282098|Placebo Comparator|Placebo Colchicine|The control group will receive colchicine placebo 0.6mg twice daily orally for 3 months.
3041782|NCT02282085|Experimental|Aripiprazole Once-Monthly|Switch to 400 mg aripiprazole once-monthly injection
3041783|NCT02282085|Active Comparator|Standard of Care|Continue current SOC oral antipsychotic medication
3041784|NCT02282072|Active Comparator|Deep Brain Stimulation|Stimulator is ON
3041785|NCT02282072|Sham Comparator|Placebo|Stimulator is OFF
3041786|NCT02282059||sunitinib group|patients with progressive, unresectable, advanced or metastatic well-differentiated pNET
3041787|NCT02282046||non-diabetic group|patients without diagnosed type 2 diabetes, having an HbA1c level below 6.0%
3041788|NCT02282046||type 2 diabetes group|patients diagnosed with type 2 diabetes of over 1 year duration.
3041789|NCT02282033|Experimental|Treatment|"This is an unblinded, treatment only study in which each patient serves as his or her own control.~All patients who meet entry criteria will undergo implantation of the Moderato System. During the first month the pacemaker Performance will be evaluated and an additional 3 month period of treatment for studying the Moderato-HTN therapy effect."
3041790|NCT02282020|Experimental|1/OLAPARIB|olaparib 300mg oral tablets; twice daily
3041791|NCT02282020|Active Comparator|2/CHEMOTHERAPY|Physician's choice single agent chemotherapy
3041792|NCT02282007|No Intervention|No Intervention:Control group|
3041793|NCT02282007|Experimental|Individual NPMP to the participants|This arm will receive NPMP for 6 months, individually adjusted to their problems.
3041794|NCT02281994|Active Comparator|Active PEMF|Active device emits Pulsed Electromagnetic Field (PEMF)
3041796|NCT02281981|Experimental|Curcumin supplement|200 mg, curcuminoids, 7d of supplementation in capsular form
3041797|NCT02281981|Placebo Comparator|Placebo|sucrose, capsular
3041798|NCT02281968|Experimental|NSAID cohort|Patients who have had surgical management of ankle fracture will be given a standing regimen (scheduled doses) of 500 mg naproxen twice a day and will have received one intraoperative dose of ketorolac. Patients will have a prescription for opioids for breakthrough pain.
3041799|NCT02281968|Placebo Comparator|Placebo cohort|Patients who have had surgical management of ankle fracture will be given a standing regimen (scheduled doses) of placebo twice a day and will have received one intraoperative dose of saline solution. Patients will have a prescription for opioids for pain.
3041800|NCT02281955|Experimental|De-escalated Radiation and Chemotherapy|Patients will receive Intensity Modulated Radiotherapy Treatments (IMRT), 60 Gy at 2 Gy/fx. The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 total doses. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history. Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
3041801|NCT02281942|Experimental|Yoga|Sequential movements in coordination to the breath cycle followed by seated and supine postures to release muscle tension.
3041802|NCT02281942|Placebo Comparator|Education|A series of 30-minute recordings focused on different aspects of healthy living (e.g. diet, stress).
3041803|NCT02281929|Active Comparator|amoxicillin+ prednisolone|Oral antibiotherapy during 30 days using amoxicillin+clavulanic acid at a daily dose of 3 gram (amoxicillin) and 375 mg (clavulanic acid) in three daily doses of 1g/125mg. Oral corticotherapy during 30 days with prednisolone at 40 mg/j in a single daily dose in the morning.
3041804|NCT02281929|Placebo Comparator|Placebo + prednisolone|Oral placebo of amoxicillin- clavulanic acid in three daily doses during 30 days Oral corticotherapy during 30 days with prednisolone at 40 mg/j in a single daily dose in the morning.
3041805|NCT02281916|Experimental|P28GST treatment|P28GST as a parasite enzyme
3041806|NCT02281903|Experimental|Chest compression of manikins chest|Compression of pediatric manikins chest according European Resuscitation Council 2010 guidelines for cardiopulmonary resuscitation.
3041807|NCT02281890||Proven sepsis|Children included in the INIS trial in whom pathogenic organisms (i.e. bacteria or fungi) were cultured from blood and/or cerebrospinal fluid during the sepsis period at the time of study inclusion
3041808|NCT02281890||Clinical sepsis|Children included in the INIS trial in whom no pathogenic organisms (i.e. bacteria or fungi) were cultured from blood or cerebrospinal fluid during the sepsis period at the time of study inclusion
3041809|NCT02281877|Experimental|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) 48 hours after TKA, 5x/week, 2x/day, for 45 minutes/session.~Standard Rehabilitation Protocol"
3041810|NCT02281877|Active Comparator|Control|Standard Rehabilitation Protocol
3041811|NCT02281864|Other|Control Group: Quitline|Quitline referral. If the family is randomized to the control group, the research team will give the parent a brochure for the QuitLine
3041812|NCT02281864|Experimental|Intervention Group|Smoking Cessation Intervention Bundle. The Investigator has developed an intervention that bundles the best evidence for tobacco dependence treatment, including the USPHS guidelines, and evidence from parent-specific interventions, to create a sustainable, transferrable intervention specific to using the inpatient stay to help parents quit smoking and reduce their children's exposure. The intervention bundle includes screening for exposure, assessing readiness to quit, providing at least one brief motivational interviewing session in the hospital, dispensing nicotine replacement therapy if appropriate, providing a smoking cessation/reduction starter kit and arranging for follow up after the child is discharged.
3041813|NCT02281851||Supplemented|The group consists of well-trained cyclists who habitually consume vitamin/antioxidant supplements for a period longer than 6 months
3041814|NCT02281851||Non-supplemented|The group consists of well-trained cyclists who do not consume vitamin/antioxidant supplements
3041815|NCT02281838|Experimental|Target systolic BP <140mmHg|Systolic blood pressure will be reduced to <140 mmHg within 1 hour of randomization.
3041816|NCT02281838|Active Comparator|Target systolic BP <180mmHg|Systolic blood pressure will be reduced, to <180 mmHg within 1 hour of randomization.
3041817|NCT02281825||Control|Adolescents without any psychiatric disorder
3041818|NCT02281825||Study|Adolescents with psychiatric disorder of the following: Attention-Deficit and Hyperactivity Disorder, Conduct, Oppositional defiant Disorder, Anxiety, Depression, Disruptive Mood Dysregulation Disorder
3041819|NCT02281812|Experimental|RFA group|A percutaneous (utlrasound-guided) radiofrequency ablation (RFA) of the tumor will be performed by the radiologist under general anesthesia. Immediately after, excision of the tumor with appropriate margin will be accomplished.
3041820|NCT02281812|No Intervention|Control group|Normal excision of the tumor according to the protocol
3041821|NCT02281799|Experimental|Open label|"10 patients diagnosed with IBD, treated previously with thiopurines and ceased treatment due to suspected thiopurine-induced pancreatitis.~Patients will be commenced on an alternative thiopurine to that used initially,. The medications will be commenced at standard dose (ie Azathioprine 2.5mg/kg/day, 6-MP 1.5mg/kg/day)."
3041822|NCT02281786|Experimental|Cohort 1|8 volunteers (6 active, 2 placebo)
3041823|NCT02281786|Experimental|Cohort 2|8 volunteers (6 active, 2 placebo)
3041824|NCT02281786|Experimental|Cohort 3|8 volunteers (6 active, 2 placebo)
3041825|NCT02281786|Experimental|Cohort 4|8 volunteers (6 active, 2 placebo)
3041826|NCT02281786|Experimental|Cohort 5|8 volunteers (6 active, 2 placebo)
3041827|NCT02281786|Experimental|Cohort 6|8 volunteers (6 active, 2 placebo)
3041828|NCT02281773|Experimental|dose 1|
3041829|NCT02281773|Experimental|dose 2|
3041830|NCT02281773|Experimental|dose 3|
3041831|NCT02281773|Experimental|dose 4|
3041832|NCT02281773|Placebo Comparator|placebo|
3041833|NCT02281760|Experimental|1-ECD|All subjects enrolled in this trial will receive combination therapy of dabrafenib and trametinib for up to 12 months.
3041834|NCT02281760|Experimental|2-ECD|All subjects enrolled in this trial will receive combination therapy of dabrafenib and trametinib for up to 12 months.
3041835|NCT02281721||Single Group; Surpass Flow Diverter(s)|Individuals using the Surpass Flow Diverter(s)
3041836|NCT02281708|No Intervention|low risk|low risk; observation
3041837|NCT02281708|No Intervention|high risk; observation group|high risk: observation
3041838|NCT02281708|Experimental|high risk; adjuvant chemotherapy group|high risk. vinorelbine plus cisplatin
3041839|NCT02281695|Active Comparator|Arm A|"Patients that are mechanically ventilated for less than 24 hours until the weaning process can be started.~At the beginning of the weaning process the PEEP will be adjusted at a value equal with the PEEP during BiPAP (Group 1) and Pmean during BiPAP (Group 2) During controlled mechanical ventilation all patients will be for 5 minutes with FiO2 - 100% ventilated. The PaO2/FiO2 after 5 minutes ventilation with 100% oxygen will be compared with the PaO2/FiO2 during ventilation with 30% oxygen."
3041840|NCT02281695|Active Comparator|Arm B|Patients that are mechanically ventilated for more than 24 hours until the weaning process can be started. At the beginning of the weaning process the PEEP will be adjusted at a value equal with the PEEP during BiPAP (Group 1) and Pmean during BiPAP (Group 2) During controlled mechanical ventilation all patients will be for 5 minutes with FiO2 - 100% ventilated. The PaO2/FiO2 after 5 minutes ventilation with 100% oxygen will be compared with the PaO2/FiO2 during ventilation with 30% oxygen.
3041841|NCT02281682|Active Comparator|Imiquimod|three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
3041842|NCT02281682|Active Comparator|5-Fluorouracil|during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
3041843|NCT02281682|Active Comparator|Ingenol mebutate 0.015%|during 3 (consecutive) days once daily. Prior to treatment: curettage
3041844|NCT02281682|Active Comparator|MAL-PDT|methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
3041845|NCT02281669||Research group|The study group includes all CL cases for whom the treating physician decides to treat by IL Pentostam. The patients will return to follow up and additional treatment every 3 weeks until full recovery [as our current policy].
3041846|NCT02281656|Experimental|Reverse End-to-side|"Surgery: a reverse end-to-side AIN to ulnar nerve transfer whereby the motor branch of the ulnar is left intact and the end of the AIN nerve is coapted to the side of the ulnar motor fascicle(5,6). The advantage of this technique is it preserves the continuity of the ulnar motor branch for axons if they do eventually reinnervate the intrinsic muscles while augmenting or babysitting these muscles during the time period until this occurs."
3041847|NCT02281656|Active Comparator|Surgery:standard care|Surgery: the anterior interosseous (AIN) to motor branch of the ulnar nerve transfer has been established as an effective means to reinnervate ulnar innervated intrinsic hand muscles (without loss of function from using the AIN) when nerve injury is too proximal for recovering axons to reach the hand by 18 months. . The procedure (surgery) is presently the standard of care
3041848|NCT02281643|Experimental|Early doxycycline administered|Early doxycycline administered - volunteers will be treated immediately with 200mg daily doxycycline for 6 weeks
3041849|NCT02281643|Active Comparator|Delayed doxycycline administered|Delayed doxycycline administered-volunteers will be treated six months after the early group has received treatment with 200mg daily doxycycline for 6 weeks
3041850|NCT02281630|Experimental|KWA-0711 High dose|
3041851|NCT02281630|Experimental|KWA-0711 Low dose|
3041852|NCT02281630|Placebo Comparator|Placebo|
3041853|NCT02281604||0.2/1.2 microliter filter|Use of 0.2/1.2 microliter filters for intravenous drug administration
3041854|NCT02281604||5 mircroliter filter|Use of 5 microliter filters for intravenous drug administration
3041855|NCT02281591|Experimental|eslicarbazepine acetate|900mg of eslicarbazepine acetate (ESL, BIA 2-093)
3041856|NCT02281591|Active Comparator|S-licarbazepine R-licarbazepine|450 mg of S-licarbazepine plus 450 mg of R-licarbazepine
3041857|NCT02281591|Active Comparator|S-licarbazepine|450 mg of S-licarbazepine
3041858|NCT02281591|Active Comparator|R-licarbazepine|450 mg of Rlicarbazepine
3041859|NCT02281578|Experimental|Combination prevention|Community-based, combination HIV prevention intervention package
3041860|NCT02281578|Active Comparator|Standard of care|Locally run standard of care HIV prevention, treatment and care services
3041861|NCT02281552|Experimental|tofacitinib modified release tablet|
3041862|NCT02281552|Active Comparator|tofacitinib immediate release tablet|
3041863|NCT02281539|Experimental|Treatment using myoelectric signals|Virtual- and augmented reality, are controlled by the patient's phantom limb using muscle (myoelectric) signals from the stump. The patient learns to reactivate areas in the brain related to motor control of the missing limb. The medical device is non-invasive and based on surface electromyography
3041864|NCT02281526|Other|Subjects with moderate hepatic impairment|This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
3041865|NCT02281526|Other|subjects - healthy controls|This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
3041866|NCT02281513|Other|ANTLER Pilot Cohort|Pilot study participants will be provided the smartphone application, fitbit activity monitor, and coaching sessions.
3041867|NCT02281500|Experimental|Single|Human Plasma-Derived Fibrinogen Concentrate Grifols (FIB Grifols)
3041868|NCT02281487|Active Comparator|Hysterectomy|standard hysterectomy
3041869|NCT02281487|Experimental|Hysterectomy plus tubectomy|Hysterectomy plus tubectomy
3041870|NCT02281474|Active Comparator|150mg dosing|This arm will take 150mg of Nilotinib by mouth daily for the 6 month drug period to establish a safe and efficacious dose.
3041871|NCT02281474|Active Comparator|300mg dosing|This arm will take 300mg of Nilotinib by mouth daily for the 6 month drug period to establish a safe and efficacious dose.
3041872|NCT02281461|Experimental|Early ifants|Intervention Male circumcision using a non-surgical device
3041873|NCT02281461|Experimental|Cildren|Intervention Male circumcision using a non-surgical device
3041874|NCT02281448|Other|Treatment sequence A|oral once daily dose of 1200 mg of BIA 2-093 plus single-dose of a contraceptive for 15 days followed by washout and 3 days of oral single-dose contraceptive
3042221|NCT02279069|Experimental|4-roll canne|Stroke patients walk with 4-roll canne
3041875|NCT02281448|Other|Treatment sequence B|oral single-dose of a contraceptive for 3 days after pre-treatment with an oral once daily dose of 1200 mg of BIA 2-093 plus single-dose of a contraceptive for 15 days
3041876|NCT02281435|Experimental|PrePex with Incision|Adult male circumcision by the PrePex™ device using foreskin incision
3041877|NCT02281422|Other|Group 1 normal renal function|normal renal function (creatinine clearance > 80 mL/min)
3041878|NCT02281422|Other|Group 2 mild renal impairment|mild renal impairment (creatinine clearance 50-80 mL/min)
3041879|NCT02281422|Other|Group 3 moderate renal impairment|moderate renal impairment (creatinine clearance 30-50 mL/min)
3041880|NCT02281422|Other|Group 4 severe renal impairment|severe renal impairment (creatinine clearance <30 mL/min)
3041881|NCT02281422|Other|Group 5 end stage renal disease|end stage renal disease, requiring haemodialysis (ESRD)
3041882|NCT02281409|Experimental|Mogamulizumab (KW-0761)|Patients will be enrolled to receive a weekly intravenous (IV) dose of KW-0761 ranging from 0.5 mg/kg to 10.0 mg/kg as feasible starting on Day 1 for 4 weeks. In the absence of toxicity or progression of disease, patients may continue receiving KW-0761 for up to 12 months. Subsequent treatment courses will consist of an infusion every other week. Following end of treatment or treatment completion date, a 24-week short term follow-up (STFU) period of observation will begin. Phase II of the study will enroll a total of 48 subjects, 16 patients in 3 tumor-specific expansion cohorts each treated at the RP2D (MTD, or highest dose tested in Phase I part of trial).
3041883|NCT02281396|Experimental|2.5IU/ml in humans aged 10-20 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml in 20 humans aged 10-20 years old on day 0,3,7,14,28
3041884|NCT02281396|Experimental|2.5IU/ml in humans aged 21-60 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml in 20 humans aged 21-60 years old on day 0,3,7,14,28
3041885|NCT02281396|Active Comparator|2.5IU/ml in humans(from 10-20 years old)|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml in 20 humans aged 10-20 years old on day 0,3,7,14,28
3041886|NCT02281396|Active Comparator|2.5IU/ml in humans(from 21-60 years old)|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml in 20 humans aged 21-60 years old on day 0,3,7,14,28
3041887|NCT02281383|Experimental|Bacillus Calmette-Guérin (BCG)|Patients will be treated with an induction course (6 intravesical instillations) of BCG followed by a second induction course (6 intravesical instillations), with a recovery period between the 2 treatment courses.
3041888|NCT02281370|Experimental|SEQUENCE D0, D1, D2|Participants will receive treatment D0 in treatment period 1, D1 in treatment period 2 and D2 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 milligram (mg), D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
3041889|NCT02281370|Experimental|SEQUENCE D1, D0, D2|Participants will receive treatment D1 in treatment period 1, D0 in treatment period 2 and D2 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 mg, D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
3041890|NCT02281370|Experimental|SEQUENCE D1, D2, D0|Participants will receive treatment D1 in treatment period 1, D2 in treatment period 2 and D0 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 mg, D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
3041891|NCT02281357|Experimental|Tralokinumab|Tralokinumab subcutaneous injection
3041892|NCT02281357|Placebo Comparator|Placebo|Placebo subcutaneous injection
3041893|NCT02281344|Experimental|Cohort 1|Cohort 1 will receive a single, dose of 20mg MMV390048.
3041894|NCT02281344|Experimental|Cohort 2|Cohort 2 will receive a single dose of MMV390048. Depending on the data obtained from the 20mg cohort, the dose in Cohort 2 may be adjusted but will not exceed the maximum tolerated dose (or highest achieved dose based on a pre-defined exposure cap) as determined in an ongoing single ascending dose study.
3041895|NCT02281344|Experimental|Cohort 3|Cohort 3 will receive a single dose of MMV390048. Depending on the data obtained from the first two cohorts, there may be a 3rd cohort, with the investigated dose of MMV390048 to be determined by the Sponsor and Principal Investigator (PI) and endorsed by the Safety Review Team.
3041896|NCT02281331|Active Comparator|Supplement|Each day, participants in this group will receive a supplement that provides a total of protein, creatine monohydrate, calcium, vitamin D and carbohydrate. This supplement will be provided to participants in beverage format, twice daily.
3041897|NCT02281331|Placebo Comparator|Placebo|The placebo will provide participants with maltodextrin (carbohydrate) and sucrose.
3041898|NCT02281318|Experimental|Mepolizumab SC|Participants will receive Mepolizumab 100 mg subcutaneously (SC) into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
3041899|NCT02281318|Placebo Comparator|Placebo SC|Participants will receive placebo (0.9% sodium chloride) subcutaneously into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
3041900|NCT02281305|Experimental|Colchicine Active treatment group|Drug: Colchicine 2 mg loading dose; 0.5 mg bid for 5 days
3041901|NCT02281305|Placebo Comparator|Control group|Drug: Placebo
3041902|NCT02281292|Experimental|LKA651 (Part 1)|LKA651 ophthalmic solution in 1 of 5 concentrations, administered as a single IVT injection in the study eye
3041903|NCT02281292|Placebo Comparator|Sham injection (Part 1)|Sham injection in the study eye
3041904|NCT02281292|Experimental|LKA651 and Lucentis (Part 2)|LKA651 ophthalmic solution in 1 of 3 concentrations, administered as a single IVT injection in the study eye, followed by ranibizumab ophthalmic solution, 0.5 mg injection in the same eye 30 minutes later
3041905|NCT02281292|Placebo Comparator|Sham injection and Lucentis (Part 2)|Sham injection in the study eye, followed by ranibizumab ophthalmic solution, 0.5 mg injection in the same eye 30 minutes later
3041906|NCT02281279|Experimental|Treatment (rituximab, romidepsin, lenalidomide)|Patients receive rituximab IV over 90 minutes on day 1; romidepsin IV over 4 hours on either day 1, days 1 and 8, or days 1, 8, and 15; and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3041933|NCT02281032|No Intervention|No interRAI Palliative Care|"15 control nursing homes:~- Caregivers of control nursing homes do not receive the intervention and provide care as usual"
3041907|NCT02281266|Experimental|treatment (T)|"The patients of treatment arm will be administered subcutaneously Thymalfasin at dose of 1.6mg twice a week for 12 months after curative resection, followed by 12 months observation.~Nucleoside analog plan to give to HBV DNA positive patients."
3041908|NCT02281266|Other|control (C)|"The patients of control arm will be followed up for 2 years periodically after curative resection, without the investigational product (Thymalfasin) therapy.~Nucleoside analog plan to give to HBV DNA positive patients."
3041909|NCT02281253|Experimental|With metabolic syndrome|Before dietary therapy was initiated, in order to stabilise dietary patterns prior to intervention, patients were submitted to a 4-weeks run-in period of a caloric restriction of 500 Kcal to their usual diet. After this adaptation period, two intervention groups were evaluated: a calorie-restricted diet plus bread-enriched product that received 15.08 g of dietary fibre (9.49 g of insoluble fibre and 5.59 g of soluble fibre) plus 2325 mg of L-carnitine/day in 130 g of bread (enriched group) and a calorie-restricted diet plus placebo bread group whose diet included 130 g/day of not-enriched bread (placebo group).
3041910|NCT02281253|Experimental|Without metabolic syndrome|Before dietary therapy was initiated, in order to stabilise dietary patterns prior to intervention, patients were submitted to a 4-weeks run-in period of a caloric restriction of 500 Kcal to their usual diet. After this adaptation period, two intervention groups were evaluated: a calorie-restricted diet plus bread-enriched product that received 15.08 g of dietary fibre (9.49 g of insoluble fibre and 5.59 g of soluble fibre) plus 2325 mg of L-carnitine/day in 130 g of bread (enriched group) and a calorie-restricted diet plus placebo bread group whose diet included 130 g/day of not-enriched bread (placebo group).
3041911|NCT02281240||With hemostatic complications|The hemostatic and antithrombotic (thrombopoietin, interleukin-11, heparin) measures during HSCT.
3041912|NCT02281227|Active Comparator|compression group|skin compression with an indicator for determination of needle entry point
3041913|NCT02281227|Active Comparator|non-compression group|non skin compression with an indicator for determination of needle entry point
3041914|NCT02281214|Experimental|blood sample, biopsy|
3041915|NCT02281201|Experimental|BE1116|Single intravenous (I.V.) infusion, dosage depending on baseline INR and body weight
3041916|NCT02281175|No Intervention|No contact intervention|Informative document that proposes a 12-week self-withdrawal grid
3041917|NCT02281175|Active Comparator|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
3041918|NCT02281175|Experimental|psychosocial intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal + psychosocial intervention (PASSE-65+ program: 12 sessions over 16 weeks)
3041919|NCT02281162||Weight Gain|No intervention. Will evaluate vitamin D levels and other biomarkers affecting weight with venous blood draw.
3041920|NCT02281162||No Weight Gain|No intervention. Will evaluate vitamin D levels and other biomarkers affecting weight with venous blood draw.
3041921|NCT02281136|Experimental|ALA|20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment
3041922|NCT02281123||Patient suspected of being infected by chikungunya|Patient (>= 45 ans) suspect d'infection par le virus du chikungunya et présentant des symptomes depuis moins de 10 jours
3041923|NCT02281110||iFR/FFR assessment|Patients enrolled into this prospective registry will be derived from Stable Coronary Artery disease or Acute Coronary Syndrome (ACS) population undergoing cardiac catheterization. Patients with ACS may be evaluated by functional assessment in the non-culprit stenosis during the index PCI revascularization or in a staged procedure. The registry will enroll patients in whom physiological assessment (iFR/FFR) is particularly helpful in identifying haemodynamically significant stenosis: MVD patients defined by patients with lesions > 40% and <100% in 2 or more vessels.
3041924|NCT02281097|Active Comparator|Vagal Stimulation First|"Vagal stimulation to improve upright heart rate modulation and symptoms is given on first tilt study day.~Placebo stimulation with ineffective low amplitude and frequency (sham intervention) is given on second tilt study."
3041925|NCT02281097|Placebo Comparator|Placebo First|"Placebo stimulation with ineffective low amplitude and frequency (sham intervention) is given on first tilt study day.~Vagal stimulation to improve upright heart rate modulation and symptoms is given on second tilt study day."
3041926|NCT02281084|Experimental|Monotherapy|Dispense CC-486 (Oral azacitidine) alone to subjects divided in 2 Cohorts of Stable versus Progressive disease
3041927|NCT02281071|Experimental|laterally moved coronally advanced flap microsurgical|For the test group (LMCAF-M), the surgical procedures were performed with the aid of a galilean loupe, under 2.5x magnification vision, microsurgical instruments and microsurgical suture material .
3041928|NCT02281071|Active Comparator|laterally moved coronally advanced flap macrosurgical|For the control group (LMCAF), LMCAF was performed with conventional instruments (detaylı) and materials (stur). Loupe magnification, microsurgical instruments and suture material were not used in the control group.
3041929|NCT02281058|Experimental|intervention group|Ten subjects recruited to self-administer abatacept 125mg injected subcutaneously weekly for 24 weeks to determine the impact it has on their vitiligo skin lesions.
3041930|NCT02281045|Experimental|EVODIAL dialyzer and Selectbag citrate|Intervention for anticoagulation during dialysis: Combination of Heparin-coated AN69ST membrane (EVODIAL, Gambro-Hospal, Meyzieu, France) and citrate-containing dialysate (Selectbag citrate, Gambro, Lund, Sweden).
3041931|NCT02281045|Active Comparator|Regional citrate anticoagulation|Regional citrate anticoagulation, using a hypertonic sterile solution of trisodium citrate dihydrate (1.035 Mol/L, Baxter, Lessines, Belgium), infused into the afferent blood line. Citrate will be infused at a rate of 62.1 mM/h (60 mL/h). The anticoagulant effect of citrate will be neutralized using calcium containing dialysate (Ca 1.50 mmol/L). Dialysate sodium content will be set at 135 mEQ/L, and bicarbonate will be reduced to 25 mEq/L.
3041932|NCT02281032|Other|interRAI Palliative Care|"15 experimental nursing homes:~Caregivers of 15 participating nursing homes receive a training about the interRAI PC and the BelRAI webapplication~Caregivers of 15 experimental nursing homes fill out the interRAI PC multidisciplinary every three months during one year for all nursing home residents with palliative care needs. Based on the results (Client Assessment Protocols and Scales) of the interRAI PC instrument, care plans are being evaluated, adapted and designed."
3041934|NCT02281019||Indeterminate strictures or undefined filling defects|
3041935|NCT02281019||Biliary stone cases|
3041939|NCT02280993|Experimental|DHAP-BV|Brentuximab Vedotin with DHAP chemotherapy follow by Autologous Peripheral Blood Stem Cell Transplantation
3041940|NCT02280980|Experimental|Combined rehabilitation protocol|The usual rehabilitation protocol in the physiotherapy department is supplemented with a three weeks home protocol of oculomotor and gaze stability exercises.
3041941|NCT02280980|No Intervention|Usual rehabilitation protocol|The usual rehabilitation protocol in the physiotherapy department for patients after stroke.
3041942|NCT02280967|Experimental|Education about HPV by school nurse|The educational intervention consists of education about HPV and a special designed leaflet and self-reported questionnaires. The educational intervention is included in the regular health interview with the school nurse (scheduled for about one hour) and includes information about HPV; facts about the virus, transmission, what it can cause and prevention (i.e. safe sex with condom use and HPV vaccination), facts about HPV vaccine and the importance of attending future cervical cancer screening controls. Students complete questionnaires before the health interview at baseline and after three months. A follow-up with parts of the boys will be performed with qualitative interviews. Participants (n=40)
3041943|NCT02280967|No Intervention|Control group 1|Students allocated to control group 1 receives standard treatment, the regular health interview with the school nurse. Students complete questionnaires before the health interview at baseline and after three months (n=400).
3041944|NCT02280954|Experimental|ICG injection group|This group will receive a single dose of ICG, infused over 40 minutes. During surgery, they will be imaged with a camera and an imaging probe the investigators have developed.
3041945|NCT02280941|Experimental|Single photon emission computed tomography|Myocardial blood flow (MBF) measurement will be analyzed using attenuation and scatter corrected dynamic single photon emission computed tomography (SPECT) imaging data. The data will be compared to MBF obtained from positron emission tomography (PET) imaging.
3041946|NCT02280928|Experimental|Single-task motor training group|The participants will receive only balance training which will progress from stance activities, to stance activities plus hand manipulation, then gait activities, and finally gait activities plus hand manipulation.
3041947|NCT02280928|Experimental|Single-task cognitive training group|The participants will receive cognitive training that will involve executive function, attention, and working memory.
3041948|NCT02280928|Experimental|Dual-task motor-cognitive training group|The participants assigned to the dual-task motor-cognitive training group will receive the same exercises as single-task motor training while simultaneously performing secondary tasks as those in the single-task cognitive training group.
3041949|NCT02280928|Experimental|Dual-task cognitive-cognitive training group|The participants in the dual-task cognitive-cognitive trainings group will receive two cognitive tasks at the same time.
3041950|NCT02280915|Experimental|Fortified savoury food product 1|Savoury food product fortified with iron
3041951|NCT02280915|Experimental|Fortified savoury food product 2|Savoury food product fortified with iron
3041952|NCT02280915|Experimental|Fortified savoury food product 3|Savoury food product fortified with iron
3041953|NCT02280915|Experimental|Fortified savoury food product 4|Savoury food product fortified with iron
3041954|NCT02280902||Patient with immunologic and inflammatory diseases|Patient treated with corticosteroids, immunosuppressive drugs or biotherapy for immunologic and inflammatory diseases
3041955|NCT02280876|Active Comparator|1 - Andrographis paniculata p/st extract|1 - Andrographis paniculata extract. Active comparator, consists of 15 adult patients with active Recurrent Remitting Multiple Sclerosis, randomly assigned, taking the active test product (Andrographis paniculata p/st extract, oral lozenges, one BID, for 12 months), in addition to base medication (Interferon).
3041956|NCT02280876|Placebo Comparator|2 - Excipients|2 - Excipients. Placebo comparator, consists of 15 adult patients with active Recurrent Remitting Multiple Sclerosis, randomly assigned, taking the placebo formulation (Only the excipients of the active test product, in oral lozenges of same shape, one BID, for 12 months), in addition to base medication (Interferon).
3041957|NCT02280863|Experimental|Adult Cohort|Medtronic Hybrid Closed-Loop System will be used by adults for five days in open-loop (sensor augmented pump) and five days in closed-loop. The first 8 Adults use the Android Platform.
3041958|NCT02280863|Experimental|Adolescent Cohort|Medtronic Hybrid Closed-Loop System will be used by adolescents for four days in open-loop (sensor augmented pump) and four days in closed-loop.
3041959|NCT02280850|Experimental|Guanxin Shutong Capsule|3 capsules once, tid, Oral Duration: 4 weeks
3041960|NCT02280850|Placebo Comparator|Placebo Capsule|"Placebo capsule and Guanxin Shutong Capsule the same appearance are made by SHAANXI BUCHANG PHARMACEUTICAL CO.,LTD.~3 capsules once, tid, Oral Duration: 4 weeks"
3041961|NCT02280837||Patients with suspected or diagnosed coronary artery disease|
3041962|NCT02280824|Experimental|A|Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access
3041963|NCT02280811|Experimental|T Cell Receptor Immunotherapy|patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin
3041964|NCT02280798||pilot study|"A total of 5 volunteers from our egg donation program were included in the study with 4 endometrial biopsies for each one after 4 diferente protocols~Endometrial biopsy after Stimulated cycle~Endometrial biopsy after Natural Cycle~Endometrial biopsy after Natural modified cycle: the biopsy is taken seven days after the hCG~Endometrial biopsy after Hormone Replacement Therapy Cycle"
3041965|NCT02280785|Experimental|Brentuximab vedotin|"Brentuximab vedotin administered in 250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.~In the absence of infusion toxicities, the infusion rate for all patients must be calculated in order to achieve a 30-minute (approximate) infusion period.~Brentuximab Vedotin is dosed at 1.8mg/kg (capped at 100kg of body weight). Dosing is based on patients' weight according to the institutional standard; however, doses will be adjusted for patients who experience a ≥ 10% change in weight from baseline. Actual weight will be used except for patients weighing greater than 100 kg; dose will be calculated based on 100 kg for these individuals. The dose will be rounded to the nearest whole number of milligrams."
3041966|NCT02280772|Experimental|Glucomannan|Glucomannan orally, 3g/day (in three divided doses), for 12 weeks
3041967|NCT02280772|Placebo Comparator|Maltodextrin|Maltodextrin orally, 3g/day (in three divided doses), for 12 weeks
3042281|NCT02278614|Experimental|T2347|T2347: fixed combination Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops
3041968|NCT02280759|Active Comparator|Gelatin Tannate|"Gelatin Tannate:~4 times 250 mg/daily for 5 days for children under 3. years old or 4 times 500mg/daily for 5 days for children older then 3. years and under 5 years."
3041969|NCT02280759|Placebo Comparator|Placebo|Placebo consists of an identical formulation, except active substance.
3041970|NCT02280746|Experimental|A - gluten challenge group|Gluten challenge group - recommended daily intake of at least one normal meal containing gluten such as bread, pita, pasta, biscuits.
3041971|NCT02280746|No Intervention|B - gluten-free diet|Continuation of GFD.
3041972|NCT02280720|Active Comparator|CoCr-BAS|Stenting using Optimax™ cobalt-chromium alloy platform with a titanium-nitride-oxide coating
3041973|NCT02280720|Active Comparator|PtCr-EES|Stenting using PROMUS Element™ Plus durable polymer everolimus-eluting stent built on a platinum-chromium platform.
3041974|NCT02280707|Experimental|Intervention|
3041975|NCT02280707|No Intervention|Control|
3041976|NCT02280694|Experimental|capecitabine, cyclophosphamide, methotrexate, celecoxib|"The Investigational Product: Route and Dosage Form Ambulatory/oral, continuous but not uniform, DAILY treatment~Tab. CYCLOPHOSPHAMIDE 50mg, 1X1/day ONLY days 1-5 / week; At evening only (at the end of meal)~Tab. CAPECITABINE 500mg, fixed dose of 1500mg/day (1000mg at morning + 500mg at evening) ONLY on days 1-5 / week; At morning AND at evening (at the end of meals)~Tab. METHOTREXATE 2.5mg, 1x2/day ONLY on days 6-7/week; At morning AND evening (one hour before meal)~Tab. CELECOXIB 200 mg, 1x2/day EVERY day (at the end of meal)"
3041977|NCT02280681||Couples with ovarian failure|Heterosexual couples confronted with infertility due to ovarian failure between the age of 18 and 44 years old treated in the K.U.Leuven and
3041978|NCT02280681||Clinicians|Clinicians who indicated an interest in reproductive medicine in their membership of the Belgian Society for Reproductive Medicine (BSRM).
3041979|NCT02280668|Active Comparator|Control Group|Will perform the eccentric muscle damage exercise and will not perform any icing interventions post damage. These participants will be the control group.
3041980|NCT02280668|Experimental|Icing Protocol 1|Will perform the eccentric muscle damage exercise and will begin the icing intervention immediately after the muscle damage. The icing protocol will be icing the elbow flexor muscles for 10 minutes with a cold pack followed by 10 minutes with no icing and another 10 minutes of elbow flexor muscle icing. The participants will perform this protocol every day at approximately the same time for the duration of the study.
3041981|NCT02280668|Experimental|Icing Protocol 2|Will perform the eccentric muscle damage exercise and will begin the icing intervention 6 hours post muscle damage. The icing protocol will be icing the elbow flexor muscles for 10 minutes with a cold pack followed by 10 minutes with no icing and another 10 minutes of elbow flexor muscle icing. The participants will perform this protocol every day at approximately the same time for the duration of the study.
3041982|NCT02280655|Active Comparator|Storage-aged red blood cells (saRBCs)|Subjects with cardiovascular disease (CVD) received a transfusion with older stored red blood cells (RBCs) units. The units had been stored for greater than 21 days.
3041983|NCT02280655|Active Comparator|Fresh red blood cells (RBCs)|Subjects with cardiovascular disease (CVD) received a transfusion with fresh red blood cells (RBCs) units. The units had been stored for less than 14 days.
3041984|NCT02280642||Both doses on time|An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2.
3041985|NCT02280642||Dose 2 delayed|A delayed dose 2 was defined as > 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2.
3041986|NCT02280642||Dose 3 delayed|An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and a delayed dose 3 was defined as >180 days after dose 2.
3041987|NCT02280642||Both doses delayed|A delayed dose 2 was defined as > 90 days after dose 1 and a delayed dose 3 was defined as >180 days after dose 2.
3041988|NCT02280629|Experimental|LT-02|LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
3041989|NCT02280629|Placebo Comparator|Placebo|LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
3041990|NCT02280629|Active Comparator|Mesalamine|LT-02 PLACEBO twice daily AND 500mg mesalamine PLACEBO three-times daily
3041991|NCT02280616|Experimental|Low dose budesonide tablet|
3041992|NCT02280616|Experimental|High dose budesonide tablet|
3041993|NCT02280616|Experimental|High dose budesonide suspension|
3041994|NCT02280616|Placebo Comparator|Placebo|
3041995|NCT02280603|Experimental|DA-4001C|DA-4001C is administered
3041996|NCT02280603|Active Comparator|5% minoxidil|5% minoxidil is administered
3041997|NCT02280590|Experimental|Cresnon®|Rosuvastatin 10mg, tablet, q.d.
3041998|NCT02280590|Active Comparator|Crestor®|Rosuvastatin 10mg, tablet, q.d.
3041999|NCT02280564|No Intervention|Control|Standard diabetes care
3042000|NCT02280564|Experimental|Health coaching with technology support|Behavioral strategies including problem solving skills building, family communication counseling, technology support, motivational interviewing support.
3042001|NCT02280551||Adolescents|1927 Grade 7 high school students
3042002|NCT02280551||Parent|A parent of each of the 1927 Grade 7 high school students
3042003|NCT02280538|Experimental|Intra-Articular Hyaluronic Acid|"hylan G-F 20 (high molecular weight hyaluronic acid):~intra-articular administration~6 mL~administered every 6 months~for 2 years"
3042004|NCT02280538|Placebo Comparator|Placebo|"Saline solution:~intra-articular administration~6 mL~administered every 6 months~for 2 years"
3042005|NCT02280525|Experimental|Lymphodepleting Chemotherapy Option #1|"Preferred regimen for CLL and low grade lymphoma~Lenalidomide 2.5 mg by mouth once a day on Days -2 through Day +14. Fludarabine 25 mg/m2 by vein over 1 hour on Days -5 to -3. Cyclophosphamide 200 mg/m2 by vein over 3 hours on Days -5 to -3. Rituximab 375 mg/m2 by vein over 3-6 hours on Day -5 for participants with B-cell cancer.~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10^7 NK cells/kg given by vein on Day 0.~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
3042091|NCT02279901|Experimental|Telemedicine Both Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. In addition, patients are provided both Emmi education programs and IVR follow-up as previously outlined. These patients are also scheduled for a 3 month follow-up.
3042092|NCT02279888||CardioMEMS HF System Group|Patients implanted with a CardioMEMS HF System.
3042006|NCT02280525|Experimental|Lymphodepleting Chemotherapy Option #2|"For all malignancies if able to tolerate higher dose cyclophosphamide per the discretion of the treating physician~Lenalidomide 2.5 mg by mouth once a day on Days -2 through Day +14. Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2. Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4.~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10^7 NK cells/kg given by vein on Day 0.~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
3042007|NCT02280525|Experimental|Lymphodepleting Chemotherapy Option #3|"For myeloid malignancies~Lenalidomide 2.5 mg by mouth once a day on Days -2 to Day +14. Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2. Cytarabine 2 mg/m2 by vein on Days -6 to -2.~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10^7 NK cells/kg given by vein on Day 0.~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
3042008|NCT02280512||elderly with fractures|patients more than 65 years old accepting surgeries for lower extremities fracture
3042009|NCT02280486|Active Comparator|Saxagliptin|The treatment of saxagliptin will be initiated and maintained at 5mg every morning until the completion of the test.Meanwhile,subjects will be instructed to take stable doses of metformin (1500mg/d) through the whole trial.
3042010|NCT02280486|Active Comparator|Glimepiride|Glimepiride will be initially treated with 1 mg every morning to a dose of 6 mg/day.a.m. Every 4-week the subjects will be evaluated whether reach the target fasting plasma glucose (assayed by finger-stick ≦6.1 mmol/l ). If the fasting blood glucose not achieved the target at the maximum dose, maintain the maximum dose(6mg/d) until the completion of the test.Meanwhile,subjects will be instructed to take stable doses of metformin (1500mg/d) through the whole trial.
3042011|NCT02280473|Experimental|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
3042012|NCT02280473|Active Comparator|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
3042013|NCT02280460||VA ECMO|Patients who are placed on VA ECMO.
3042014|NCT02280460||VV ECMO|Patients who are placed on VV ECMO.
3042015|NCT02280447|Experimental|1/3 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/3 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL suspension for injection for intramuscular use"
3042016|NCT02280447|Experimental|1/5 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/5 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL suspension for injection for intramuscular use"
3042017|NCT02280447|Experimental|1/10 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/10 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL suspension for injection for intramuscular use"
3042018|NCT02280447|Active Comparator|IPV SSI|"Non-adjuvated full dose IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL solution for injection for intramuscular use"
3042019|NCT02280434|Active Comparator|CBP-307|Participants will receive a single dose or once daily dose of CBP-307 for 28 days.
3042020|NCT02280434|Placebo Comparator|Placebo|Participants will receive a single dose or once daily dose of matching placebo for 28 days.
3042021|NCT02280421|Other|ASP2151 400mg|ASP2151 400mg + 100mg ciclosporin
3042022|NCT02280421|Other|ASP2151 1200mg|ASP2151 1200mg + 100mg ciclosporin
3042023|NCT02280408|Experimental|3x10^6 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of BPSC-1001 3x10^6 pfu in the deltoid on Day 0 and Day 28.
3042024|NCT02280408|Experimental|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of BPSC-1001 2x10^7 pfu in the deltoid on Day 0 and Day 28.
3042025|NCT02280408|Experimental|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of BPSC-1001 1x10^8 pfu in the deltoid on Day 0 and Day 28.
3042026|NCT02280408|Placebo Comparator|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0 and Day 28.
3042027|NCT02280395|Experimental|RUT058-60|
3042028|NCT02280395|Placebo Comparator|Sterile Saline for Irrigation|
3042029|NCT02280382|Other|Femmeze®|Femmeze® will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
3042030|NCT02280369||automated abdominal binder|automated abdominal binder with waist and thigh accelerometers, and ActivPAL
3042031|NCT02280356|Experimental|radiation therapy in combination with brachytherapy|Patients will undergo low dose rate (LDR) prostate brachytherapy using Pd-103 followed approximately 4 weeks later with hypofractionated image-guided external beam radiation therapy (25Gy in 5 fractions; 5Gy x 5 fractions every other day) to the prostate & seminal vesicles. Both brachytherapy as well as external beam will be performed according to our current standards of practice using the same equipment, techniques, & treatment planning procedures. Pts will be followed post-treatment at 1, 3, 6 (+/- 4 weeks) & every 6 months (+/- 4 weeks) thereafter until 36 months. During the post-treatment followup, pts will be evaluated for urinary, bowel/rectal & sexual toxicity. Baseline measures of these domains will be obtained prior to treatment at the time of enrollment. Serum PSA levels will be drawn on the same schedule as clinical followup. Post-treatment prostate biopsies will be obtained once between 24-36 months post-treatment to evaluate pathologic response to therapy
3042032|NCT02280330|Active Comparator|MNP group|The MNP group will receive 60 sachets of MNP in a period of 6 months or 10 sachets per month equivalent to 3-4 sachets in a week.
3042033|NCT02280330|Placebo Comparator|Placebo group|The placebo group will receive 60 sachets of placebo (with same characteristics) as the MNP or 10 sachets per month equivalent to 3-4 sachets in a week.
3042034|NCT02280317|Experimental|VAL201: Laboratory & Clinical Assessment|VAL201-001 Sub-cutaneous injection.
3042035|NCT02280304|Experimental|Inner Resources for Veterans meditation therapy|Participants will complete meditation therapy
3042036|NCT02280304|Active Comparator|PTSD and mTBI education|Participants will learn about symptoms and triggers of PTSD and mTBI
3042093|NCT02279875|Experimental|Linezolid 300 mg once per day|Half of a 600mg (scored) tablet
3042094|NCT02279875|Experimental|Linezolid 300 mg twice per day|Half of a 600mg (scored) tablet
3042095|NCT02279875|Experimental|Linezolid 600 mg once per day (A)|600mg (scored) tablet
3042096|NCT02279875|Experimental|Linezolid 600 mg once per day (B)|600mg (scored) tablet
3042037|NCT02280291|Active Comparator|GA/sedation with a SS block|"Intervention-GA/sedation with a Single Shot, peripheral nerve block. The standard single shot block will 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20 cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.~After placement of the regional block, general anesthesia/sedation will be administered and maintained at the discretion of the anesthesiologist. Induction of anesthesia will involve IV propofol (2mg/kg) and fentanyl (1-2mcg/kg). Anesthetic maintenance will involve inhalational agents, IV agents, air, and oxygen. Fentanyl will be the only intraoperative analgesic used and will be dosed as determined by the anesthesiologist."
3042038|NCT02280291|Experimental|GA/sedation with continuous infusion|"Intervention-GA/sedation with continuous, peripheral nerve block. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine + 20 cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5cc. Once the injection is complete, an indwelling catheter will be placed with its tip location confirmed and then secured at the skin.~Neuromuscular blockade will be used at the discretion of the anesthesiologist and will be reversed appropriately. Anesthetic maintenance will involve inhalational agents, IV agents, air, and oxygen. Fentanyl will be the only intraoperative analgesic used and will be dosed as determined by the anesthesiologist."
3042039|NCT02280278|Experimental|CIK group|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy will receive 8 cycles of CIK therapy in this group.
3042040|NCT02280278|Active Comparator|Control group|Stage III Colon Cancer patients will only receive radical operation and adjuvant chemotherapy.
3042041|NCT02280265|Experimental|ADVATE|The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight every 48 ± 6 hours) with Recombinant Human Coagulation Factor VIII for injection(ADVATE) for 1 year. Subjects must be prescribed ADVATE by the treating physician. Data will be collected over a period of 2 years from the time of study enrollment. Study visits are to coincide with routinely rescheduled and emergency visits. Available data from these visits shall be transcribed onto the case report forms (CRFs).
3042042|NCT02280252|Experimental|Concurrent Paclitaxel and RT|"Patients will be administered pre-operatively over 12 weeks either:~Paclitaxel, 30mg/m^2 twice per week, intravenously over 1 hour on a Monday/Thursday or Tuesday/Friday schedule~Abraxane, 30mg/m^2 twice per week, intravenously administered over 30 minutes, on a Monday/Thursday or Tuesday/Friday schedule~Patients will concurrently receive 6 weeks of radiation therapy, weeks 2-7:~Patients will receive a total dose to the breast, axilla and supraclavicular area of 45 Gy at 1.8 Gy/fraction, +14 Gy to the area of the original palpable tumor at 2 Gy/fraction (32 fractions)"
3042043|NCT02280239|Placebo Comparator|Control Group|This group consists of stable but febrile ICU patients (temp >38.3°C). Participants in this group will receive a one-time dose of placebo via the enteral route (via the gut), after which vital signs (including continuous measures of core temperature, heart rate, and blood pressure) will be monitored for 4 hours.
3042044|NCT02280239|Experimental|Acetaminophen Group|This group consists of stable but febrile ICU patients (temp >38.3°C). Participants in this group will receive a one-time does of acetaminophen 650mg via the enteral route (via the gut), after which vital signs (including continuous measures of core temperature, heart rate, and blood pressure) will be monitored for 4 hours.
3042045|NCT02280226|Experimental|Deliberate Apnea Group|Subjects undergo maximum apnea.
3042046|NCT02280213|Experimental|Intubation without chest compression|Endotracheal intubation of infant mannikin using different laryngoscope blades (MAC, MIL, PHIL, WIS) during resuscitation without chest compressions.
3042047|NCT02280213|Experimental|Intubation with chest compression|Endotracheal intubation of infant mannikin using different laryngoscope blades (MAC, MIL, PHIL, WIS) with uninterrupted chest compressions. Chest compressions with the two thumb-encircling hands technique were performed by the same Basic Life Support (BLS) instructor at a rate of 100 compressions per minute and at a depth of about 1.5 inches according to the European Resuscitation Council guidelines of 2010 year.
3042048|NCT02280200|Experimental|AFO to improve outcomes|open label, non-interventional design (all patients who volunteer for trial receive AFO)
3042049|NCT02280187||Spine Fusion with InductOs|Patient had spinal fusion surgery with InductOs between 1st January 2011 and 31st December 2012
3042050|NCT02280174|Experimental|Drug: linagliptin|linagliptin 5 mg/d for 12 weeks
3042051|NCT02280174|No Intervention|Drug: standard treatment|sulfonylurea treatment for 12 weeks
3042052|NCT02280161||Ancillary-Correlative (germ-line mutation analysis)|Patients undergo collection of blood and saliva samples 1-3 times at the discretion of the investigator for germ-line mutation analysis.
3042053|NCT02280148|Experimental|Endoscopy of Intravenous Anesthesia|20-70 year-old volunteers who hold legitimate licenses were recruited to have gastroscopy or colonoscopy under intravenous anesthesia with propofol
3042054|NCT02280135|Experimental|Intravitreal injection of Autologous bone marrow Stem Cell|"Patients included in the trial will receive a pars plana intravitreal injection of autologous mononuclear cells (MNC) of bone marrow (BM) in one eye (experimental group A or group). The eye in which autologous BM MNCs were injected will be determined randomly.~The average dose will be 30 million of cells (5-60 million) diluted in 0.1 ml. of saline."
3042055|NCT02280135|Placebo Comparator|Subconjunctival injection of saline|Patients included in the trial will receive a subconjunctival injection of 0.1 ml of saline (SF) (placebo) in the fellow eye (group B or control group). In this way the patient will receive an injection in the control eye but avoid the risks of intraocular injection.
3042056|NCT02280122||gen. mod. to sev. chronic periodontitis|"Sites with probing pocket depths (PPD) ≥ 3.5 mm~Attachment loss (PAL-V) ≥ 3 mm > 30% of sites~no Intervention provided"
3042057|NCT02280122||periodontally healthy|"PPD ≤ 3 mm~PAL-V ≤ 2 mm at < 30% of sites~BOP < 20%~No radiographically detectable bone loss: distance cemento-enamel junction to provided~no Intervention but aMMP-8 test"
3042058|NCT02280109|Active Comparator|Tenofovir Gel|Women will receive a single dose of tenofovir gel (1%;equivalent to 40 mg in 4ml's of gel) to determine the pharmacokinetics of tenofovir in the blood, cervical tissue, and cervicovaginal fluid.
3042059|NCT02280109|Active Comparator|Tenofovir Film|Women will receive a single dose of tenofovir film (1.3%;40 mg) to determine the pharmacokinetics of tenofovir in the blood, cervical tissue, and cervicovaginal fluid.
3042097|NCT02279875|Experimental|Linezolid 600 mg twice per day|600mg (scored) tablet
3042060|NCT02280096|Active Comparator|4-aminopyridine treatment|4-aminopyridine is given as gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as the excipient. Each patient will take two capsules every 6 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study. After 22 weeks of treatment and 2 weeks of wash-out period, this group of patients will start placebo branch.
3042061|NCT02280096|Placebo Comparator|Placebo|Patients randomized to the placebo sequence will receive placebo for 20 weeks after the run-in period. They will be blinded to the fact that they are taking placebo, and capsules will be identical in appearance to the intervention capsules. Then, after a 2 weeks wash-out period, they will receive 4-aminopyridine in the same way as it was described previously.
3042062|NCT02280083|Experimental|Botulinum Toxin Type A for Injection|"HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)"
3042063|NCT02280083|Placebo Comparator|placebo|excipient
3042064|NCT02280070|Active Comparator|SOX (S-1 + L-OHP)|"S-1 (80 mg/m2, p.o.) (day1-14）, L-OHP (130 mg/m2)(day 1): repeated every 3 weeks until 4 courses or meet discontinuation criteria.~Medical history and physical examination, BW and height, performance status, laboratory test, creatinine clearance, biomarker, contrasting CT, adverse event, HBs antigen and HCV antibody, endoscopy, HBs antibody and HBc antibody"
3042065|NCT02280070|Active Comparator|mFOLFOX6|"L-OHP (85 mg/m2) and l-LV (200 mg/m2) by IV infusion drip for 2hr at day 1. 5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards (day 1-2: repeated every 2 weeks until 6 courses or meet discontinuation criteria.~Medical history and physical examination, BW and height, performance status, laboratory test, creatinine clearance, biomarker, contrasting CT, adverse event, HBs antigen and HCV antibody, endoscopy, HBs antibody and HBc antibody"
3042066|NCT02280057|Active Comparator|Metformin|Metformin 850 mg x 2 in six months
3042067|NCT02280057|Placebo Comparator|Placebo|Placebo 2 tablets daily for six months
3042068|NCT02280044|Experimental|rifaximin|Subjects receiving rifaximin prophylaxis will be challenged with C. jejuni
3042069|NCT02280044|Placebo Comparator|placebo|Subjects receiving placebo will be challenged with C. jejuni
3042070|NCT02280031|Active Comparator|Experimental|Acetylsalicylic Acid 80mg administered daily at bedtime
3042071|NCT02280031|Placebo Comparator|Control|Identical placebo administered daily at bedtime
3042072|NCT02280018|Experimental|JNJ-49122944, 5 milligram (mg)|Single dose of 5 mg JNJ-49122944, administered as a 22.2 milliliter (mL) intravenous (IV) infusion over 45 minutes in the morning following an overnight fast.
3042073|NCT02280018|Placebo Comparator|Placebo|Placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes in the morning following an overnight fast.
3042074|NCT02280005|Experimental|WAK Treatment|Use of experimental device.
3042075|NCT02279992|Experimental|Vardenafil + Carboplatin|Vardenafil (Levitra®) 20 mg oral administered 1 hour prior to start of craniotomy + Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy
3042076|NCT02279992|Active Comparator|Carboplatin Alone|Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy
3042077|NCT02279979|Experimental|Treatment Arm|All enrolled patients will be treated with the HeartMate PHP device
3042078|NCT02279966|Experimental|Vortioxetine 10 mg|daily, encapsulated, orally
3042079|NCT02279966|Other|Paroxetine 20 mg (active reference)|daily, encapsulated, orally
3042080|NCT02279966|Placebo Comparator|Placebo|capsules, orally
3042081|NCT02279953|Experimental|Vortioxetine 10-20 mg|daily, encapsulated, orally
3042082|NCT02279953|Experimental|Vortioxetine 10-20 mg + SSRI|daily, encapsulated, orally
3042083|NCT02279953|Experimental|SSRI|licensed doses, encapsulated, orally
3042084|NCT02279927|Experimental|Low energy high frequency|Ureteroscopy with laser settings of low energy & high frequency with aim of stone dusting
3042085|NCT02279927|Active Comparator|High energy low frequency|Ureteroscopy with laser settings of low energy high frequency with aim of stone fragmentation and basket extraction of fragments
3042086|NCT02279914|Experimental|400 mcg|receives 400 mcg of misoprostol 3 hours prior to the procedure
3042087|NCT02279914|Experimental|600 mcg|receives 600 mcg of misoprostol 90 minutes prior to the procedure
3042088|NCT02279901|No Intervention|Traditional|Patients will attend a 1 hour OSA Class where OSA education is provided and home sleep testing is set up. These patients return the next day for individual appointments where study is scored and test results are discussed with patient. If study is consistent with OSA based on AHI4% at least 5/hour, patients undergo a 1 week autoCPAP trial. During this week, wireless remote monitoring is performed and troubleshooting is provided via telephone if problems with CPAP use are identified. The autoCPAP is returned during an individual visit, and CPAP is ordered for long-term use based on trial results and patient feedback. Patients are scheduled a 3 month follow-up appointment but are also instructed to call their sleep center case manager prior to that visit if there are problems with CPAP use.
3042089|NCT02279901|Experimental|Telemedicine Education Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. In addition, patients are emailed a link to view the Emmi OSA program within 2 weeks prior to their initial OSA class. If the patient tests positive for OSA and agrees to an autoCPAP trial, the patient is emailed a link to view the Emmi CPAP program. These patients are also scheduled for a 3 month follow-up visit to check CPAP usage.
3042090|NCT02279901|Experimental|Telemedicine IVR Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. Additionally, if CPAP is ordered for long-term therapy, the patient is enrolled into an IVR protocol that automatically analyzes the patient's CPAP use. If specific provider-defined thresholds are met, the platform will automatically deliver feedback messages to the patient (phone call, text messaging, or email) with the intention of encouraging better CPAP use. Patients are instructed to contact the sleep center for any issues with their therapy. This platform also includes a method for patients to track their own usage online. Automated messaging mechanism will be active for 3 months after CPAP is ordered, after which the messaging will stop. These patients are also scheduled for a 3 month follow-up visit.
3042098|NCT02279875|Experimental|Linezolid 1200 mg once per day|Two 600mg (scored) tablets
3067642|NCT02110420|Experimental|CC-90001 30mg (Multiple Doses)|
3042099|NCT02279875|Experimental|Linezolid 1200 mg 3 times per week|Linezolid 1200 mg administered as a single oral dose three times per week (1200 mg: Day 1, 3, 5, 8, 10, and 12)
3042100|NCT02279875|Active Comparator|HRZE once per day|"Treatment will be administered orally once daily for 14 days per the~Subject's weight as follows:~30‐37 kg: 2 tablets;~38‐54 kg: 3 tablets;~55‐70 kg: 4 tablets;~71 kg and over: 5 tablets."
3042101|NCT02279862|Experimental|Arm 1: Ipilimumab 3 mg/kg|Ipilimumab 3 mg/kg injection intravenously every 3 weeks for 4 doses in Induction phase. Subjects that are eligible to receive Ipilimumab in the Maintenance phase will be dosed every 12 weeks for a maximum of 3 years since the first induction dose
3042102|NCT02279862|Experimental|Arm 2: Ipilimumab 10 mg/kg|Ipilimumab 10 mg/kg injection intravenously every 3 weeks for 4 doses in Induction phase. Subjects that are eligible to receive Ipilimumab in the Maintenance phase will be dosed every 12 weeks for a maximum of 3 years since the first induction dose
3042103|NCT02279849|Experimental|Communications|﻿These 6 stores received the communications intervention. Communications materials were developed for each program phase; 1) Healthier Drinks, 2) Healthier Essentials, and 3) Healthier Snacks. Each phase's materials included posters, recipe cards, educational handouts, shelf talkers, price tags, door signs, educational displays, and promotional giveaways (i.e., drink tumblers, re-usable shopping bags) to encourage healthy food purchasing and consumption. Stores receiving the communications intervention also received either a small refrigerator or freezer to help provide the environmental supports needed to stock perishable fruits and vegetables.
3042104|NCT02279849|No Intervention|Control|These 6 stores received no intervention.
3042105|NCT02279849|Experimental|Pricing|These 6 stores received a pricing intervention. 10-30% with discounts for specific foods contingent on price elasticity of demand, initial wholesale price, and projected store-level sales. Items were given the minimum discount needed to increase store supply and consumer demand. For example, brand name frozen vegetables were discounted 30% at the wholesaler, in order to provide the storeowner with enough incentive to stock the item. The % discount passed from the storeowner to the consumer was ultimately a decision made by the storeowner, but was suggested to be at least 50% in order to increase consumer demand. Discounts were automatically applied at wholesaler registers to stores receiving the pricing intervention.
3042106|NCT02279849|Experimental|Combined (Communications & Pricing)|These 6 stores received communications materials as well as pricing incentives as intervention (see Communications & Pricing Arms Descriptions).
3042107|NCT02279836|Other|Single arm post-marketing Study|SC20 Colonoscope and Colonoscopy System For Colonoscopy
3042108|NCT02279823|Experimental|CB-03-01 solution|Topical solution applied twice daily for 26 weeks
3042109|NCT02279823|Active Comparator|Minoxidil Solution 5%|Topical solution applied twice daily for 26 weeks
3042110|NCT02279823|Placebo Comparator|Placebo solution|Topical solution applied twice daily for 26 weeks
3042111|NCT02279810||Medical students, medical staff|Survey about Knowledge, Attitude and Practice About Organ Transplantation
3042112|NCT02279784|Experimental|Freeway|angioplasty with Freeway drug-eluting balloon
3042113|NCT02279784|Experimental|Lutonix|angioplasty with Lutonix drug-eluting balloon
3042114|NCT02279771|Active Comparator|transanal anastomotic reinforcement|Low anterior resection with TME plus anastomotic transanal reinforcement without protective ileostomy/colostomy (transanal anastomotic reinforced arm:TAR-LAR)
3042115|NCT02279771|Active Comparator|protective ileostomy group|Standard low anterior resection with TME plus protective ileostomy/colostomy (S-LAR)
3042116|NCT02279758|Experimental|METFORMIN|850mg of metformin every 12 hours.
3042117|NCT02279745|Experimental|APD811|
3042118|NCT02279732|Experimental|Arm 1: Carboplatin + Paclitaxel + Ipilimumab|"Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by modified WHO (mWHO)~Carboplatin Area Under the Curve (AUC6) IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Ipilimumab 10 mg/kg IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO"
3042119|NCT02279732|Experimental|Arm 2: Carboplatin + Paclitaxel + Placebo|"Carboplatin AUC6 IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Placebo IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO"
3042120|NCT02279719|Experimental|BBI608 and Sorafenib|
3042121|NCT02279719|Experimental|BBI503 and Sorafenib|
3042122|NCT02279719|Active Comparator|Sorafenib|
3042123|NCT02279693|Other|CBCT|cone beam computed tomography (CBCT) repositioning
3042124|NCT02279693|Other|fiducial markers|kV imaging of fiducial marker repositioning
3042125|NCT02279680|Other|Patients|Adults between 18 and 30 years old right handing Patients with ASD
3042126|NCT02279680|Other|Healthy volunteers|Adults between 18 and 30 years old Right handing Healthy
3042127|NCT02279667|Experimental|Group A|"st period - 16 mL oral suspension 50 mg/mL~nd period - Four 200 mg tablets~rd period - One 800 mg tablet"
3042128|NCT02279667|Experimental|Group B|"st period - One 800 mg tablet~nd period - 16 mL oral suspension 50 mg/mL~rd period - Four 200 mg tablets"
3042129|NCT02279667|Experimental|Group C|"st period - Four 200 mg tablets~nd period - One 800 mg tablet~rd period - 16 mL oral suspension 50 mg/mL"
3042130|NCT02279654||Lenalidomide Population|Patients with transfusion-dependent, low- or intermediate (int)-1risk MDS and isolated del (5q) who receive at least 1 dose of lenalidomide after 15th June 2007 and have been followed up for on the registry for 3 years or until death/consent withdrawal
3042131|NCT02279654||Background Population|All MDS patients who have been diagnosed on 15th June 2007 or later, have never been exposed to lenalidomide and have been followed up on the registry for 3 years or until death/consent withdrawal
3042132|NCT02279641|Experimental|Sequence A|RDEA3170 qd (once daily), RDEA3170 + allopurinol qd, allopurinol qd
3042133|NCT02279641|Experimental|Sequence B|allopurinol qd, RDEA3170 + allopurinol qd, RDEA3170 qd
3042172|NCT02279407|Experimental|Omega-3 carboxylic acids 4g/day+Dapagliflozin 10mg/day|
3042173|NCT02279381|Experimental|Intervention group A|"Essential Neonatal Care~Kangaroo mother Care~Application of 4% Chlorhexidine~Education and counseling for mothers and care providers"
3042134|NCT02279628|Experimental|Continuous wound infiltration alone|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 1 ml sodium chloride 0.9% (without morphine). Patient will then receive a continuous wound infiltration of ropivacaine 0.2% 8 ml/H via a preperitoneal catheter.
3042135|NCT02279628|Active Comparator|Intrathecal moprhine alone|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 0.1mg morphine. Patient will then receive a continuous wound infiltration of sodium chloride 0.9% 8 ml/H via a preperitoneal catheter.
3042136|NCT02279628|Experimental|Intrathecal morphine&wound infiltration|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 0.1mg morphine. Patient will then receive a continuous wound infiltration of ropivacaine 0.2% 8 ml/H via a preperitoneal catheter.
3042137|NCT02279615|Active Comparator|Treatment Group|(Mirabegron + Tamsulosin)
3042138|NCT02279615|Placebo Comparator|Control Group|(Placebo + Tamsulosin)
3042139|NCT02279602|Experimental|Single Arm|Subjects will receive fosbretabulin at the same dose and frequency as in study OX4218s
3042140|NCT02279589|Active Comparator|Group A|"Description :~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,5 then Pneumo 23® 0,1~Route : Intramuscular vaccination schedule : M0, M2, M12"
3042141|NCT02279589|Active Comparator|Group B|"Description 15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,1 then Pneumo 23® 0,1~Route : Intramuscular vaccination schedule : M0, M2, M12"
3042142|NCT02279589|Active Comparator|Group C|"Description :~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,1 then Pneumo 23® 0,5~Route : Intramuscular vaccination schedule : M0, M2, M12"
3042143|NCT02279589|Active Comparator|Group D|"Description:~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,5 then Pneumo 23® 0,5~Route : Intramuscular vaccination schedule : M0, M2, M12"
3042144|NCT02279576|Experimental|Pazopanib plus weekly paclitaxel|Pazopanib 800mg /day continuously administered plus paclitaxel 65 mg/m2 in weekly administration, 3 administrations (D1, D8 and D15) every 4 weeks period.
3042145|NCT02279563|Experimental|Azelastine HCl and Fluticasone Propionate Nasal Spray|"The investigational product was administered via nasal inhalation with one spray in each nostril twice daily.~Batch Number KL1981, Expiry Date Mar 2015."
3042146|NCT02279563|Active Comparator|Dymista™ Nasal Spray|"The reference product was administered via nasal inhalation with one spray in each nostril twice daily.~Batch Number G30349, Expiry Date Mar 2015."
3042147|NCT02279563|Placebo Comparator|Placebo Nasal Spray|"The placebo was administered via nasal inhalation with one spray in each nostril twice daily.~Batch Number KL0781, Expiry Date Mar 2015."
3042148|NCT02279550||hip fracture|aged >65 with hip fracture
3042149|NCT02279537||Cohort 1|According to the recommendations of the Summary of Product Characteristics (SmPC)
3042150|NCT02279524|Experimental|Aramchol 600mg|One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
3042151|NCT02279524|Experimental|Aramchol 400mg|One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.
3042152|NCT02279524|Placebo Comparator|Placebo|Two tablet of Aramchol matching placebo.
3042153|NCT02279511|Experimental|24 hours infusion of ATP|
3042154|NCT02279511|Experimental|6 hours infusion of ATP|
3042155|NCT02279511|Placebo Comparator|24 hours infusion of placebo|
3042156|NCT02279511|Placebo Comparator|6 hours infusion of placebo|
3042157|NCT02279498|Experimental|Liprotamase|Individually-optimized dose to be administered orally
3042158|NCT02279498|Active Comparator|porcine (pig) PERT|Individually-optimized dose to be administered orally
3042159|NCT02279485|Experimental|Perampanel - Group 1|"Treatment A: Single oral dose of a 12-mg perampanel tablet under fasted condition.~Treatment B: Single 12 mg dose of perampanel oral suspension under fasted condition.~Subjects will be randomized on Study Day 1 for Treatment Period 1 to Treatment A or Treatment B. On Study Day 43 the subject will then receive the alternate Treatment for Treatment Period 2."
3042160|NCT02279485|Experimental|Perampanel - Group 2|"Treatment C: Single oral dose of a 12-mg perampanel tablet co-administered with high fat meal.~Treatment D: Single 12 mg dose of perampanel oral suspension co-administered with high fat meal.~Subjects will be randomized on Study Day 1 for Treatment Period 1 to Treatment C or Treatment D. On Study Day 43 the subject will then receive the alternate Treatment for Treatment Period 2."
3042161|NCT02279472|Other|laser peripheral iridotomy|Laser peripheral iridotomy (LPI) is widely regarded as the first-line intervention for either acute or chronic types of angle-closure glaucoma in early stage ,which relieves pupil block and thus flattening the iris contour and widening the drainage angle,performd by Nd.YAG LASER
3042162|NCT02279459||Patient|Patients head and neck CT scans performed as standard of care done prior to radiation treatment and approximately 12 weeks following treatment, will be acquired in the dual-energy computed tomography (DECT) mode. Participants will have one additional scan, also in the DECT mode, 2 to 3 weeks after the start of their radiation treatment.
3042163|NCT02279446||20/20ND group|This group will have 20/20 visual acuity both in distant and near.
3042164|NCT02279446||20/20D group|This group will have 20/20 distant visual acuity and variable near visual acuity.
3042165|NCT02279446||20/20N group|This group will have 20/20 near visual acuity and variable distant visual acuity.
3042166|NCT02279446||s20/20ND group|This group will have variable near and distant visual acuity (both less than 20/20)
3042167|NCT02279433|Experimental|DS-6051b|DS-6051b is orally administered as 50 mg and 200 mg capsules once daily on Days 1 to 21 of a 21-day cycle. Dose escalation in Part 1 will continue until tentative Recommended Part 2 Dose (RP2D) is determined. In Part 2 participants will receive the RP2D.
3042168|NCT02279420|Other|Essential Study Sham Cross-over|Device: g-Cath EZ™ Suture Anchor Delivery Catheter This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
3042169|NCT02279407|Placebo Comparator|placebo|
3042170|NCT02279407|Experimental|Omega-3 carboxylic acids 4g / day|
3042171|NCT02279407|Experimental|Dapagliflozin, 10mg / day|
3042174|NCT02279381|Experimental|Intervention group B|"Essential Neonatal Care~Application of 4% Chlorhexidine~Education and counseling for mothers and care providers"
3042175|NCT02279381|Active Comparator|Control group|"Essential Neonatal Care~Education and counseling for mothers and care providers"
3042176|NCT02279368|Experimental|Intervention Group|Nurses delivered the supportive intervention along with family counselling from last term of pregnancy through three months and then were followed till the first birthday of the child.
3042177|NCT02279368|No Intervention|Control Group|Control group families were followed in usual care.
3042178|NCT02279355||pressure ulcer group|Patient who developing pressure ulcer categorized as stage more than II after surgery
3042179|NCT02279355||Control group|Patients has identical values on the matching factors such as age, sex and surgical procedures of control group
3042180|NCT02279342|No Intervention|Non febuxostat treatment group|No febuxostat treatment
3042181|NCT02279342|Experimental|Febuxostat treatment group|once daily after breakfast
3042182|NCT02279329|Other|COPD and Bronchiectasis Patients|All enrolled COPD and Bronchiectasis patients will undergo Pulmonary Function Tests, Hyperpolarized Helium MRI, chest CT, 6-Minute Walk Test, and complete questionnaires at two visits over 2-3 years.
3042183|NCT02279316|Experimental|Jaques-Dalcroze eurhythmics|Jaques-Dalcroze eurhythmics (60min/wk) + 800 IU Vitamin D3
3042184|NCT02279316|Experimental|Home exercise program|Home exercise strength program (3x30min/wk) + 800 IU vitamin D
3042185|NCT02279316|Other|Vitamin D only|800 IU Vi-De 3
3042186|NCT02279303|Experimental|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
3042187|NCT02279303|Active Comparator|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
3042188|NCT02279290|Experimental|Healthy Mind Intervention (HMI)|This intervention will focus on teaching individuals a way to manage acute and chronic stressors more effectively.
3042189|NCT02279290|Active Comparator|Healthy Body Intervention (HBI)|This intervention will focus on important health-related topics.
3042190|NCT02279277|No Intervention|No physical therapy|No prescribed, supervised physical therapy prior to total knee replacement
3042191|NCT02279277|Active Comparator|Physical Therapy|Prescribed, supervised physical therapy prior to total knee replacement
3042192|NCT02279251|Active Comparator|Brief CBT (VÅG)|This is a brief five session CBT group intervention developed at Uni Research. The intervention include self-help material (Psychological First Aid) for the adolescents to use at home between sessions.
3042193|NCT02279251|Active Comparator|Established CBT program (CHILLED)|An established, 10 session CBT group program (school version) developed by researchers at Macquarie University, Australia. The intervention has previously not been evaluated with Norwegian adolescents.
3042194|NCT02279251|No Intervention|Waitlist|Waiting period is ten weeks, then participants are randomized to one of the two active interventions
3042195|NCT02279225|Placebo Comparator|placebo (P)|Intervention without radiation
3042196|NCT02279225|Experimental|phototherapy (FT)|Intervention only with phototherapy radiation
3042197|NCT02279225|Experimental|phototherapy+Physical activity (FT+A)|Intervention associated
3042198|NCT02279225|Experimental|Physical activity (A)|Intervention with physical activity: the gold standard of treatment in fibromyalgia
3042199|NCT02279199||Control|Normative data from standardized assessment
3042200|NCT02279199||Hemophilia|Persons aged 4-21 with any severity of hemophilia A or B
3042201|NCT02279186|Active Comparator|group A|receiving tranexamic acid
3042202|NCT02279186|No Intervention|group B|does not receive tranexamic acid
3042203|NCT02279173|Experimental|Romiplostim|Romiplostim subcutaneous weekly injection
3042204|NCT02279160|Experimental|APD811|Multiple dose titration to maximum tolerated dose.
3042205|NCT02279160|Placebo Comparator|Placebo|Multiple dose titration to maximum tolerated dose.
3042206|NCT02279147|Experimental|raceanisodamine & neostigmine|Patients receive immediately raceanisodamine（10mg）by intramuscular injection after operation.Then the patients will be receive 50mg raceanisodamine and 0.15mg neostigmine within 24hs by slow injection into vein for three consecutive days.
3042207|NCT02279147|No Intervention|blank|Patients do not receive special treatment after operation.
3042208|NCT02279134|No Intervention|Surgery alone|No adjuvant treatment after radical resection is developed in this arm
3042209|NCT02279134|Experimental|Adjuvant Chemoradiation|Adjuvant chemoradiation after radical resection is developed in this arm
3042210|NCT02279134|Active Comparator|Adjuvant Radiation|Adjuvant radiation after radical resection is developed in this arm
3042211|NCT02279121|Experimental|TauroLock|solution of taurolidine-citrate
3042212|NCT02279121|Other|Control|saline solution
3042213|NCT02279108|Experimental|double detection Indocyanine + isotope|intradermal injection of 2.5 milligrams of indocyanine green and 20 MBq of technetium 99 before breast surgery
3042214|NCT02279108|Active Comparator|isotope detection alone|intradermal injection of 20 MBq of technetium 99 before breast surgery
3042215|NCT02279095|Experimental|Palovarotene dose level 1 (completed)|Subjects received weight-adjusted doses of palovarotene equivalent to 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days for an eligible flare-up (Part A).
3042216|NCT02279095|Experimental|Palovarotene dose level 2|Subjects with at least 90% skeletal maturity received 5 mg palovarotene once daily for up to 24 months; and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
3042217|NCT02279095|Experimental|Palovarotene dose level 3|Subjects with less than 90% skeletal maturity received weight-adjusted doses of 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
3042218|NCT02279095|Experimental|Palovarotene dose level 4|All subjects will receive 5 mg palovarotene once daily for up to 36 months; and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part C). Doses are adjusted for weight in skeletally immature subjects
3042222|NCT02279056|Experimental|Self-help book|A self-help book for insomnia (written in Norwegian). Earlier proven to be effective among insomnia patients (without OSA co-morbidity).
3042223|NCT02279056|Placebo Comparator|Sleep hygiene advice|A sheet of paper with sleep hygiene advice.
3042224|NCT02279043|Experimental|Intervention|IUC users and non-IUC user participants randomized to the intervention arm will take part in small intervention groups in an online community called Birth Control Connect for twelve days. There will be up to 35 intervention groups with 9 members each. Non-IUC users in these groups will receive the intervention of interaction with IUC users in the context of the online community. About 50% of participants in intervention groups will be current IUC users, and 50% will not be current IUC users. We will measure the attitudes and behaviors of those who do not have IUC before and after the intervention, considering social exposure to IUC users as a possible predictor of changes in knowledge, attitude and behavior.
3042225|NCT02279043|Placebo Comparator|Control|Participants randomized to the control arm will take part in Birth Control Connect control groups identical to those in the intervention arm, except no participants in the control arm will be current IUC users. Therefore, participants in the control arm will not have social exposure to IUC users. We will measure these participants' attitudes and behavior related to IUC use before and after the twelve-day study period, and compare results to those of participants in the intervention arm. There will be up to 35 control groups of 9 members each.
3042226|NCT02279017|Other|Weight Loss|We will send the study participate a daily text message for 2 months to their phone at 8 A.M. and a weekly text message for 6 months asking them to report their weight through a 2-question online survey. After that, a monthly text message for 18 months asking them to report their weight.
3042227|NCT02279004||Newly Diagnosed Patients|Newly diagnosed patients with advanced NSCLC or melanoma with complete or planned tissue genotyping.
3042228|NCT02279004||Acquired Resistance Patients|NSCLC patients with a known EGFR mutation or other targetable mutation and acquired resistance to initial kinase inhibitor therapy.
3042229|NCT02279004||Known Genotype Patients|NSCLC patients with a known genomic alteration detectable by ddPCR-based plasma genotyping and planned to start a new line of therapy.
3042230|NCT02279004||Advanced NSCLC|Advanced NSCLC patients with a biopsy planned for tissue genotyping.
3042231|NCT02278991||Lutonix Drug Coated Balloon|Paclitaxel coated balloon catheter
3042232|NCT02278978|Experimental|FGFR3 mutated|BIBF 1120 in patients with advanced FGFR3 mutated
3042233|NCT02278978|Experimental|FGFR3 overexpressed|BIBF 1120 in patients with advanced FGFR3 overexpressed
3042234|NCT02278978|Experimental|FGFR3 wild type|BIBF 1120 in patients with advanced FGFR3 wild type
3042235|NCT02278965|Experimental|Main Arm|Open Label- Metformin and Omega-3 fatty acids for 12 months post baseline data collection.
3042236|NCT02278939|Experimental|Fit and Trim group|This groups will start with the Filipinos Fit and Trim Weight Loss Program mobile phone based (smartphone) intervention with social networking for 3 months, a pedometer/accelerometer, access to a study private Facebook virtual social networking group, and and 4 in-person intervention session with individually tailored goals for physical activity, diet, and weight. At 3months, the Fit and Trim group will transition to a maintenance phase for 3 months, receive one in-person session for maintenance support (at 4.5 months) and complete the study at month 6.
3042237|NCT02278939|Active Comparator|Pedometer only group|This group will start with the pedometer/accelerometer only to monitor/ track their physical activity step-counts for the initial 3 months. In addition, subjects will receive an educational materials on Hepatitis B and Tuberculosis. At 3 months the pedometer only group will transition to receive the Filipinos Fit and Trim Weight Loss Program intervention (as previously described) for the next 3 months and complete the study at month 6.
3042238|NCT02278926||Patients ultrasound lypo-hypertrophy identification|Type 1 diabetes patients with visible lypo-hypertrphy attended in outpatient clinic
3042239|NCT02278926||Control group|Type 1 diabetes patients with visible lypo-hypertrphy attended in outpatient clinic
3042240|NCT02278913|Experimental|Basal Bolus (Glargine and Glulisine)|Basal bolus: with Insulin analogs (glargine and glulisine), 50% of total daily dose as glargine given before breakfast and 50% as glulisine insulin given in three equally divided doses before each meal.
3042241|NCT02278913|Active Comparator|Human Insulin|Human insulin: NPH and regular insulin: 2/3 of total daily dose as NPH and 1/3 as regular insulin. NPH insulin dose given as 2/3 in the morning before breakfast and 1/3 before dinner. Regular insulin given in three equally divided doses before each meal
3042242|NCT02278900|Experimental|Communication aids|Patients in the intervention group will receive the QPL at home in advance of the consultation along with information about the clinic.The consultations will be recorded in both the control and intervention group. The recording will be done on the computer, and the patients in the intervention group will be given the recording immediately after the consultation on a memory stick.
3042243|NCT02278900|No Intervention|Control group|No intervention.
3042244|NCT02278887|Active Comparator|Ipilimumab|4 cycles of ipilimumab treatment, the standard treatment
3042245|NCT02278887|Experimental|TIL treatment|non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2
3042246|NCT02278874||Multiple gestation high risk pregnancies|women pregnant with twins or triplets at high risk for aneuploidy
3042247|NCT02278861|Active Comparator|Oral isotretinoin 10mg/day|Oral isotretinoin 10mg/day for 6 months The dose could be reduced if there were any significant laboratory alterations or clinical adverse events, along with sunscreen FPS 60 every 3 hours during the day.
3042248|NCT02278861|Active Comparator|Tretinoin 0,05% cream|"An every other night application of tretinoin 0,05% cream in the face and forearms for 6 months, along with sunscreen FPS 60 every 3 hours during the day.~If there were any clinical adverse events the drug could be reduced to twice a week."
3042249|NCT02278848|Experimental|Diagnosis of ICAH|"One arm: patients with chronic adult hydrocephalus.~All patients have: Computerised gait analysis, Ultrasound measurement of cerebral pulsatility, MRI flow, Urinary incontinence scale"
3042250|NCT02278835|Other|level1|Patients classified in level 1 were randomized in the breathing exercises group or incentive spirometry group
3042251|NCT02278835|Other|level2|Patients classified in level 2 were randomized in the Intermittent Positive Pressure Breathing group or Continuous Positive Airway Pressure group
3042321|NCT02278302|Experimental|Aggrenox®|treatment alone or in combination with Ethanol
3042252|NCT02278822|Experimental|Low dose oral liposomal glutathione|Intervention: low dose oral liposomal glutathione supplementation. 500 mg oral liposomal glutathione each day for 4 weeks.
3042253|NCT02278822|Experimental|High dose oral liposomal glutathione|Intervention: high dose oral liposomal glutathione supplementation. 1000 mg oral liposomal glutathione each day for 4 weeks.
3042254|NCT02278809|No Intervention|waitlist control group|The waitlist control group parents received the online videos when the intervention period was over.
3042255|NCT02278809|Experimental|intervention group|
3042256|NCT02278796|Experimental|BeEAM|Chemotherapy regimen consisting of bendamustine intravenously on days −7 and −6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day −5 to day−2; etoposide, 200 mg/m2 intravenously daily from day −5 to day −2; and melphalan, 140 mg/m2 intravenously on day −1 before reinfusion of autologous stem cells
3042257|NCT02278796|Active Comparator|BEAM|Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day −5 to day−2; etoposide, 200 mg/m2 intravenously daily from day −5 to day −2; and melphalan, 140 mg/m2 intravenously on day −1 before reinfusion of autologous stem cells
3042258|NCT02278783|Experimental|Regorafenib Treatment arm, all patients|
3042259|NCT02278757|Placebo Comparator|Low protein diet (LPD)|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
3042260|NCT02278757|Experimental|High protein diet (HPD)|HPD received a diet with higher protein content (1.34gr/kg body weight). HPD and LPD diets had equal amount of calories, were equivalent in the type of carbohydrate, and had a caloric restriction of 500 calories less than the resting metabolic rate (RMR). Meal replacements (drinks and bars), and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
3042261|NCT02278744|Experimental|single-fraction radiosurgery|
3042262|NCT02278731|No Intervention|Control Group|The elderly in Control Group suffered no intervention and continued with their daily activities.
3042263|NCT02278731|Active Comparator|Pilates Group|Pilates group (PG), which underwent one-month (three times per week) training program with the Pilates method. This protocol consisted of Pilates exercises on the ground.Stretches were performed on upper trunk and lower limbs before the exercises. Subsequently, exercises that included the range of motion and strength of the upper limbs, trunk and lower limbs were performed, always associated with breathing and contraction of transversus abdominis muscles, in different positions, increasing repetitions and resistance in the weeks of the study, using the Swiss ball, thera-band and the magic circle.
3042264|NCT02278731|Active Comparator|PNF Group|PNF group that underwent one-month (three times per week) training program using the propriocptive neuromuscular facilitation method.The selected PNF diagonal patterns were chosen with all the basic procedures to the facilitation and according to three specific principles of PNF: rhythmic initiation, sustain and relax and reversal of antagonists. During the first week, one set of ten repetitions for each diagonal was performed; in the second week, two sets of ten repetitions and in the third and fourth weeks, three sets of ten repetitions were performed.
3042265|NCT02278718|Experimental|NexoBrid Gel|NexoBrid Gel is applied to the burn wound at a dose of 2g or 5g NexoBrid sterile powder mixed with 20g or 50g sterile Gel Vehicle per 180cm^2 of TBSA for four hours.
3042266|NCT02278718|Active Comparator|Standard of Care|Non surgical and Surgical Debridement
3042267|NCT02278705||Weight-status improved|"Cases, termed, weight-status improved, are defined as children whose BMI percent relative to their age/sex-specific BMI at the 95th percentile decreases from one visit to the next; and from one well-child visit to the next well-child (or primary-care visit approximately 9-18 months later)."
3042268|NCT02278705||Weight-status unchanged/worse|Controls are defined as children whose BMI percent relative to their age/sex-specific BMI at the 95th percentile remains unchanged or increases from one visit to the next; and from one well-child visit to the next well-child (or primary-care visit approximately 9-18 months later).
3042269|NCT02278692|Active Comparator|Vitamin K|Vitamin K (phylloquinone) 10 mg orally three times a week after dialysis for 12 weeks
3042270|NCT02278692|Placebo Comparator|Placebo|Identical appearing placebo orally three times a week after dialysis for 12 weeks
3042271|NCT02278679||Anesthitized patient|First, it will be validated on 120 anesthetized patients undergoing prostate surgery comparing responses on the digital rectal exam clinical tool (DiRECT) from both expert and novice clinicians, with surgical pathology reports.
3042272|NCT02278679||Standardized patients|During a standardized patient exercise focusing on digital rectal exam in the University of Virginia School of Medicine curriculum, 160 second-year medical students will be given the DiRECT to document their examination. An attending physician will also attend the standardized patient exercise and document their examination for comparison with the medical students.
3042273|NCT02278679||Clinic patient|The third phase includes 8 residents and up to10 attendings in the Urology clinic, who will independently complete the DiRECT documenting their DRE in the course of usual care.
3042274|NCT02278666||upper mini-sternotomy|aortic valve replacement surgery via upper J or T sternotomy (ministernotomy)
3042275|NCT02278666||right mini thoracotomy|aortic valve replacement/repair surgery via right mini thoracotomy
3042276|NCT02278666||conventional sternotomy|aortic valve replacement surgery via conventional full sternotomy
3042277|NCT02278653||Study group|The population will consist of patients, aged 18 years or older, with locally advanced rectal cancer who after chemoradiation have a clinical complete response (ycT0N0) or very good response (ycT1-2N0).
3042278|NCT02278640|Other|Harmonic ACE®+7 Shears|Single Arm study using Harmonic ACE for dissection and transection in Hysterectomy
3042279|NCT02278627|Experimental|manual lymphatic drainage|We wish to complete the physiotherapist's support with manual lymphatic drainage (MLD) using a specific method based on pressure of finger splayed (PFS)
3042280|NCT02278627|No Intervention|Usual treatment|
3042282|NCT02278614|Active Comparator|Xalacom|Xalacom®: Latanoprost 0.005% + Timolol 0.5% preserved eye drops
3042283|NCT02278601|Experimental|VAMB variable automated|variable frequency automated mandatory bolus (VAMB) up-down frequency of 5mls ropivacaine/fentanyl solution in bolus with epidural delivery system
3042284|NCT02278601|Experimental|CIPCEA|computer integrated patient controlled epidural analgesia (CIPCEA) up-down variable basal infusion of ropivacaine/fentanyl solution with epidural delivery system
3042285|NCT02278601|Active Comparator|patient controlled epidural analgesia|patient controlled epidural analgesia (PCEA) with fixed basal infusion of ropivacaine/fentanyl solution with epidural delivery system
3042286|NCT02278588||PD-R|Parkinson's disease receiving rasagiline
3042287|NCT02278588||PD-NMAO|Parkinson's disease not receiving any MAO-B inhibitors
3042288|NCT02278588||HC|Healthy Controls
3042289|NCT02278575|Other|Consisting of treatment with Atenativ|During two weeks antithrombin concentrate(Atenativ) will be administered in order to maintain normal levels of antithrombin
3042290|NCT02278562|Active Comparator|anakinra|100 mg of Anakinra in syringes administered subcutaneously 3 times a week for 3 months and lactose (placebo) in capsules administered orally 1 capsule per day for 3 months
3042291|NCT02278562|Active Comparator|actos|Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and 30 mg of Actos in capsules administered orally 1 capsule per day for 3 months
3042292|NCT02278562|Placebo Comparator|placebo 1 and 2|Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and lactose (placebo) in capsules administered orally 1 capsule per day for 3 months
3042293|NCT02278549||Asymptomatic|Individuals between 30 and 50 years old that have had no episode of low back pain in the last two years requiring medical attention
3042294|NCT02278549||Patients with Low Back Pain|Individuals between 30 and 50 years old that present with non-specific low back pain for more than 3 months
3042295|NCT02278536||Multiple high risk gestation pregnancies|women pregnant with twins or triplets at high risk for aneuploidy
3042296|NCT02278536||Multiple low risk gestation pregnancies|women pregnant with twins or triplets at low risk for aneuploidy
3042297|NCT02278523|Experimental|Inspiratory muscle training group|COPD patient use Inspiratory muscle trainer (Threshold IMT®)
3042298|NCT02278523|Active Comparator|control group|normal volunteers use Inspiratory muscle trainer(Threshold IMT®)
3042299|NCT02278510|Experimental|Direct infusion of topotecan|The experimental Cleveland Multiport Catheter will be used to inject a chemotherapy, topotecan, and a contrast agent, gadolinium DTPA, into the high grade brain tumors of study participants
3042300|NCT02278497|Other|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
3042301|NCT02278484|Other|Balloon Sinus Dilation|
3042302|NCT02278471|No Intervention|Usual Care|Subjects in this arm will not receive any investigational medications. They will remain on the same care that they are use to receiving.
3042303|NCT02278471|Experimental|Polypill|"The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.~Polypill will be taken once daily."
3042304|NCT02278458|Experimental|icotinib plus gemcitabine|"Three dose of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.~Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks."
3042305|NCT02278445|Experimental|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
3042306|NCT02278419|Experimental|Group A1|Participants without cirrhosis will receive simeprevir 150 milligram (mg) capsule along with sofosbuvir 400 mg tablet, orally, once daily for 8 weeks.
3042307|NCT02278419|Experimental|Group A2|Participants without cirrhosis will receive simeprevir 150 mg capsule along with sofosbuvir 400 mg tablet, orally, once daily for 12 weeks.
3042308|NCT02278419|Experimental|Group B|Participants with cirrhosis will receive simeprevir 150 mg capsule along with sofosbuvir 400 mg tablet, orally, once daily for 12 weeks.
3042309|NCT02278406|Experimental|Parkinson's patients with DBS|Patients with Parkinson's Disease who are at least 3-months post subthalamic deep brain stimulator surgery
3042310|NCT02278393|Active Comparator|1-Fermented Dairy Product with Phytosterols (test)|one arm active = 3 bottles of test product/day with 1,6g of phytosterols each
3042311|NCT02278393|Placebo Comparator|2-Fermented dairy Product with No Phytosterols (control)|one arm control product= 3 bottles test productl/day with no Phytosterols
3042312|NCT02278380|Other|Arm 1|"To compare the Glycemic Index value of seven test foods:~Low GI standard Breakfast Medium GI standard Breakfast Nutritional pregnant milk supplement Nutritional product for diabetics Pregnant and lactation women milk powder Nutritional drinks for diabetics Test product"
3042313|NCT02278367|Experimental|18F-AV-1451 PET Scans|Subjects will receive a single IV bolus injection of 370 MBq (10 mCi) of 18F-AV-1451. With prior sponsor approval, subjects in longitudinal companion studies may receive up to two injections of 18F-AV-1451 within a 12 month period.
3042314|NCT02278354|Experimental|Active Professional Fighters|Active professional fighters (with and without cognitive impairment) will receive a single intravenous (IV) bolus injection of 370 megabecquerel (MBq) (10 millicurie [mCi]) of 18F-AV-1451.
3042315|NCT02278354|Experimental|Retired Professional Fighters|Retired professional fighters (with and without cognitive impairment) will receive a single IV bolus injection of 370 MBq (10mCi) of 18F-AV-1451.
3042316|NCT02278341|Experimental|roxadustat treatment|Dose adjustments are allowed during the study.
3042317|NCT02278341|Active Comparator|ESA (Erythropoiesis Stimulating Agent) treatment|Treatment administered can be epoetin alfa or darbepoetin alfa. Dose adjustments are allowed during the study.
3042318|NCT02278328|Active Comparator|STX209|Subjects will receive a single dose of STX209 starting at 15 mg, increasing to 30 mg. Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets.
3042319|NCT02278328|Placebo Comparator|Placebo|participants will receive a single randomly administered dose of placebo. Subjects will receive placebo via oral disintegrating tablets.
3042320|NCT02278315|Experimental|Single|I-131-CLR1404 with or without concurrent dexamethasone
3042322|NCT02278302|Placebo Comparator|Placebo|treatment alone or in combination with Ethanol
3042323|NCT02278289|Active Comparator|ultrasound therapy group|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
3042324|NCT02278289|Active Comparator|paraffin therapy group|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
3042325|NCT02278276|Placebo Comparator|0 mg SG1002|Capsules containing 400 mg of placebo will be provided to subjects. Subjects will take two tablets twice each day.
3042326|NCT02278276|Active Comparator|1600 mg SG1002|Capsules containing 400 mg of sodium polysulthionate (SG1002) will be provided to subjects. Subjects will take two tablets twice each day, providing subjects with 1600 mg SG1002 daily.
3042327|NCT02278263|Placebo Comparator|Control|Application of 20ml of normal saline (NaCl 0.9%) topically after implantation of prosthesis and left to sit for two minutes, excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
3042328|NCT02278263|Experimental|Topical|Application of 1.5g in 20ml tranexamic acid topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
3042329|NCT02278263|Experimental|Systemic|Application of 20ml of normal saline topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; Application of tranexamic acid intravenously (1.5g/15ml) at the same time prior to release of tourniquet
3042330|NCT02278250|Experimental|Part A: M4344 BIW|Dose escalation of M4344 administered BIW as a single agent.
3042331|NCT02278250|Experimental|Part A2: M4344 BID or once daily|Dose escalation of M4344 administered BID or once daily as a single agent.
3042332|NCT02278250|Experimental|Part B1: M4344 + Carboplatin|Dose escalation of M4344 in combination with carboplatin.
3042333|NCT02278250|Experimental|Part B2: M4344 + Gemcitabine|Dose escalation of M4344 in combination with gemcitabine.
3042334|NCT02278250|Experimental|Part B3: M4344 + Cisplatin|Dose escalation of M4344 in combination with cisplatin.
3042335|NCT02278250|Experimental|Part C: M4344 + Carboplatin or Cisplatin|An expanded cohort study to confirm the effect of M4344 in combination with carboplatin or cisplatin in participants with advanced serous ovarian cancer who have received prior therapy with carboplatin.
3042336|NCT02278237|Experimental|VME Group|
3042337|NCT02278224|Experimental|Rumination Focused CBT|11 sessions of manualised group based Rumination Focused CBT for depression. 3 hours sessions are administered once during 11 weeks in groups of approximately 8 patients and two therapist.
3042338|NCT02278224|Active Comparator|Cognitive Behavioral Therapy|11 sessions of manualised group based CBT for depression. 3 hours sessions are administered once during 11 weeks in groups of approximately 8 patients and two therapist.
3042339|NCT02278211||Study Cohort|Patients hospitalised with myocardial infarction and angiographically proven multivessel coronary artery disease
3042340|NCT02278198|Experimental|Differentiated Thyroid Cancer|"All patients will receive one extra imaging scan with I-123 in addition to their routine care as described above. This research portion of their care will be similar to the scan that they undergo for the I-123 planning scan that is already a part of their routine care. The research study, which will be performed in the middle of the patient's normal standard of care treatment, will take 4 days.~On days 1 and 2, all patients will receive a intramuscular injection of rhTSH (Thyrogen).~On day 3, all patients will be given 3 mCi of I-123 in the form of a pill to take by mouth.~On day 4, all patients will receive a I-123 Whole Body Imaging Scan and a thyroid camera scan of the neck and thigh."
3042341|NCT02278185|Experimental|Arm I (enzalutamide)|Patients receive enzalutamide PO QD for 12 months in the absence of disease progression or unacceptable toxicity.
3042342|NCT02278185|Active Comparator|Arm II (ADT)|Patients receive standard of care ADT comprising one of the following at the discretion of the treating physician: leuprolide acetate, goserelin acetate, histrelin acetate, triptorelin, or degarelix SC or IM for 12 months in the absence of disease progression or unacceptable toxicity. Patients may also choose to undergo surgical castration as an alternative form of ADT.
3042343|NCT02278172|Active Comparator|Vitamin D3 3000IU (75μg)|Treatment solution delivered via oral spray once daily for 12-weeks
3042344|NCT02278172|Placebo Comparator|Placebo|Placebo solution delivered via oral spray once daily for 12-weeks
3042345|NCT02278159||Peritoneal dialysis only|Patient on PD modality 90 days after renal replacement therapy initiation and not transferred to HHD
3042346|NCT02278159||Home hemodialysis only|Patient on HHD 90 days after renal replacement therapy initiation and not transferred to PD
3042347|NCT02278159||PD and HHD|Patient on PD 90 days after RRT initiation and transferred to HHD less than 90 days after PD failure
3042348|NCT02278159||HHD and PD|Patient on HHD after RRT initiation and transferred to PD less than 90 days after HHD failure
3042349|NCT02278146|Experimental|1) Stress urinary incontinence|Stress urinary incontinence. Diagnosed with urinary stress incontinence and treated with the ParaPatch System
3042350|NCT02278146|Experimental|2) Overactive bladder|Overactive bladder. Diagnosed with overactive bladder syndrome and treated with the ParaPatch System
3042351|NCT02278133|Experimental|WNT974, LGX818 and cetuximab combo|Phase l: Dose Escalation phase; Phase ll: SIngle group assessing the triple combination of WNT974, LGX818 and cetuximab
3042352|NCT02278120|Experimental|LEE011 + NSAI/tamoxifen + goserelin|LEE011 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
3042353|NCT02278120|Placebo Comparator|LEE011 placebo+NSAI/tamoxifen+goserelin|LEE011 Placebo 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
3042354|NCT02278107|Experimental|Tidal Assist Ventilator System|Lightweight, portable, positive pressure ventilator system with proprietary nasal interface. Ventilator is powered by compressed oxygen delivered by cylinder, concentrator, or wall source.
3042510|NCT02276976||cerebral white matter lesions|patients with MRI confirmed cerebral white matter lesions
3042355|NCT02278107|Active Comparator|Nasal Cannula Oxygen|Nasal Cannula Oxygen Standard nasal cannula oxygen at 2-5 liters per minute (LPM) based on patient requirement. Oxygen sources includes cylinder, concentrator, or wall source.
3042356|NCT02278094|Experimental|Experimental group|Subjects will be in random cluster assign to walking exercise (WE), Threshold Inspiratory Muscle Trainer (TIMT) and Tongue Muscle Trainer (TMT) treatment groups.
3042357|NCT02278094|Active Comparator|Control group|Up to 95% of OSAS cases are treated with continuous positive airway pressure (CPAP), CPAP treatment group will be the control group.
3042358|NCT02278081|Experimental|treatment group|The treatment group will receive 30 mg lansoprazole (prevacid) one capsule per day for three months and mometasone furonate (nasonex) one puff in each nostril per day for three months.
3042359|NCT02278081|Placebo Comparator|placebo group|The placebo group will receive one capsule per day of prevacid placebo for three months and mometasone furonate (nasonex) one puff in each nostril per day for three months.
3042360|NCT02278068|Experimental|Metabolic Neuromodulation System (MNS)|Hepatic sympathetic denervation therapy to aid in glycemic control
3042361|NCT02278055|Experimental|Radium-223|Radium Ra 223 dichloride will be administered as a bolus intravenous (IV) injection (up to 1 minute) at intervals of every 4 weeks for up to 6 cycles. The dosage of Radium Ra 223 dichloride after implementation of the new 2015 NIST standard is 55kBq/kg body weight.
3042362|NCT02278042|Active Comparator|9% Fuctose|Milk Sweetened with fructose in an amount that the added fructose contributes 9% of the calories required for weight maintenance.
3042363|NCT02278042|Active Comparator|18% Sucrose|Milk Sweetened with sucrose in an amount that the added sucrose contributes 18% of the calories required for weight maintenance.
3042364|NCT02278042|Active Comparator|18% High fructose corn syrup|Milk Sweetened with High fructose corn syrup (HFCS) in an amount that the added HFCS contributes 18% of the calories required for weight maintenance.
3042365|NCT02278042|Active Comparator|9% Glucose|Milk Sweetened with glucose in an amount that the added glucose contributes 9% of the calories required for weight maintenance.
3042366|NCT02278042|Active Comparator|Unsweetened Milk|Unsweetened milk consumed in amount the contributes 18% of the calories required for weight maintenance.
3042367|NCT02278029||Concussed|those subjects with a concussion
3042368|NCT02278029||Controls|those subjects without a concussion
3042369|NCT02278003|Experimental|children going under sedation with propofol|"Children who will undergo sedation as part of their clinical management and give them a memory encoding task during propofol infusion to measure the effects of sedation. The mere task of naming a picture will encode that picture into memory. When the anesthesia has worn off (at approximately 1 hour later), children will be given a memory recognition task to measure the amnesic effects of propofol.~measure the amnesic effects of propofol."
3042370|NCT02278003|Active Comparator|children not going under sedation|A control group of children of similar age and undergoing similar minor therapeutic procedures will be recruited to perform memory.
3042371|NCT02277990|Active Comparator|TYRX envelope|The Medtronic TYRX Absorbable Antibacterial Envelope is an absorbable sterile prosthesis designed to hold a pacemaker pulse generator or defibrillator to create a stable environment when implanted in the body. The purpose of the absorbable coating is to act as a carrier for the antimicrobial agents.
3042372|NCT02277990|No Intervention|Control|No TYRX envelope, bare CIED
3042373|NCT02277977|Experimental|Contrast enhanced ultrasound|Contrast enhanced ultrasound during septic shock
3042374|NCT02277964||RRMS with treatment change|"All patients with treatment change from natalizumab 300mg iv monthly to fingolimod 0.5mg orally/daily.~16 patients were switched with an interval of 8 weeks until october 2013. After an interims analysis the interval has been changed to 4 weeks (after october 2013)."
3042375|NCT02277951||Participants|The Bonfils Intubation Fibrescope the Video Rigid Flexing Laryngoscope the C-MAC® S Video Laryngoscope the Macintosh Laryngoscope
3042376|NCT02277938|Experimental|Amantadine|
3042377|NCT02277925|Experimental|Gore-Tex permanent suture|polytetrafluoroethylene, Gore-Tex permanent suture
3042378|NCT02277925|Experimental|PDS delayed absorbable suture|2-0 polydioxanone, PDS delayed absorbable monofilament suture
3042379|NCT02277912|Experimental|Transcranial Magnetic Stimulation I|Intervention: Repetitive navigated Transcranial Magnetic Stimulation of the motor cortex
3042380|NCT02277912|Experimental|Transcranial Magnetic Stimulation II|Intervention: Repetitive navigated Transcranial Magnetic Stimulation of the secondary somatosensory cortex
3042381|NCT02277912|Sham Comparator|Sham Stimulation|Intervention: Repetitive sham Transcranial Magnetic Stimulation with SHAM block of the motor cortex
3042382|NCT02277899||Overweight school-age children|"Overweight 6-12 year-old children. Weight status will be measured and parents complete surveys at baseline and one year later. Pediatricians will complete surveys at baseline, and after index visit. Visits will be directly video-recorded.~The impact of pediatrician clinical practices and communication strategies on child's weight status will be evaluated at one year. Clinical practices (such as risk-factor screening) that occur during the 1-year interval between well-child visits also will be assessed. Specific clinical practice elements and communication strategies that will be examined include:~Communication regarding child's high weight status~Counseling regarding cardiovascular risk factor screening and assessment~Behavioral counseling~Interval follow-up to readdress weight, and~Patient-centeredness, scored as the ratio of patient to doctor-centered communication regarding weight topics."
3042383|NCT02277886|Experimental|Alginos plus Nexium|sodium alginate 20ml (50mg/ml) once at bed time, and esomeprazole (40mg/tablet) 1 tablet once before breakfast, 4 weeks
3042384|NCT02277886|Active Comparator|Nexium alone|esomeprazole (40mg/tablet) 1 tablet once before breakfast, 4 weeks
3042385|NCT02277873||No Treatment|Defined population (pregnant women) compared on a environmental moon luminosity influence
3042386|NCT02277860|Experimental|Exercise|Aerobic and strength training using the Wii Fit Plus for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
3042387|NCT02277847|Experimental|IDA 8mg/M2|IDA 8mg/M2 per day, D1-3. iv injection in 10 minutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
3042511|NCT02276976||healthy volunteers|healthy volunteers 1:1 matched by age,sex and education years
3042388|NCT02277847|Active Comparator|IDA 10mg/M2|IDA 10mg/M2 per day, D1-3. iv. injection in 10mimutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
3042389|NCT02277834||pancreatic adenocarcinoma|15 patients receiving Endoscopic Retrograde Cholangiopancreatography with suspected pancreatic adenocarcinoma (localized or metastatic).
3042390|NCT02277834||chronic pancreatitis|15 patients with a history of chronic pancreatitis that are having Endoscopic Retrograde Cholangiopancreatography .
3042391|NCT02277834||non-pancreatic, non-neoplastic disorders|15 patients undergoing an Endoscopic Retrograde Cholangiopancreatography for non-pancreatic, non-neoplastic indications.
3042392|NCT02277821|Experimental|Stendo pulsating suit System|One 20 minutes Stendo pulsating suit session will be applied to the patient.
3042393|NCT02277808|Active Comparator|Respirgard II|Determination of pulmonary deposition
3042394|NCT02277808|Active Comparator|Isoneb|Determination of pulmonary deposition
3042395|NCT02277795|Experimental|AccuCirc|"The AccuCirc procedure is performed according to manufacturer instructions: http://www.clinicalinnovations.com/site_files/files/AccuCirc_IFUs.pdf~Before the surgery, the mother (and father, if available) will be counseled on benefits and risks of EIMC in their language of choice (English, Kiswahili, DhoLuo). At least one parent/guardian will provide documented informed consent using IRB-approved Consent Form. Providers will record demographic and locator information and EIMC eligibility criteria. If the infant is eligible for EIMC, the provider will perform the procedure and document the outcome of the surgery on a post-operative form. Information recorded will include: amount and type of anesthesia provided, intra-operative adverse event and outcome, and procedure start and end time."
3042396|NCT02277782|Active Comparator|No Hydromorphone|1.7 mg bupivacaine + 17 mcg fentanyl + 0.05 ml of 0.9% normal saline.
3042397|NCT02277782|Experimental|Hydromorphone|1.7 mg bupivacaine + 17 mcg fentanyl + 50 mcg preservative-free hydromorphone (0.05 ml)
3042398|NCT02277769|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
3042399|NCT02277769|Experimental|Dupilumab 300 mg every 2 weeks (q2w)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a placebo alternating with single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
3042400|NCT02277769|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
3042401|NCT02277756|Experimental|high functioning Autism|Thermal stimulation with test thermode Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms with high functioning Autism
3042402|NCT02277756|Placebo Comparator|witness|Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms with a witness
3042403|NCT02277743|Experimental|Placebo|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
3042404|NCT02277743|Experimental|Dupilumab 300 mg once weekly (qw)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
3042405|NCT02277743|Experimental|Dupilumab 300 mg every 2 weeks (q2w)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a placebo alternating with single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
3042406|NCT02277730|Experimental|vasopressor delivery automated system|vasopressor delivery automated system administering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique
3042407|NCT02277730|Active Comparator|manual vasopressor delivery|manual bolus delivering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique
3042408|NCT02277717|Experimental|SYD985 (trastuzumab vc-seco-DUBA)|HER2-targeting Antibody-Drug Conjugate
3042409|NCT02277704|Placebo Comparator|Treatment A|"2 x placebo tablet (placebo) to be taken sublingually once daily at bedtime."
3042410|NCT02277704|Active Comparator|Treatment B|"1 x TNX-102 SL 2.8mg tablet (TNX-102 SL) and 1 x placebo tablet (placebo) to be taken sublingually once daily at bedtime."
3042411|NCT02277704|Active Comparator|Treatment C|"2 x TNX-102 SL 2.8mg tablets (TNX-102 SL) to be taken sublingually once daily at bedtime."
3042412|NCT02277691|Experimental|TAK-536TCH|"For 4 weeks during the run-in period, one tablet of TAK-536CCB (as TAK-536/AML, 20 mg/5 mg, respectively) orally, once daily, before or after breakfast.~For 48 weeks during 52 weeks of the treatment period, one tablet of TAK-536TCH (as TAK-536/AML/HCTZ, 20 mg/5 mg/12.5 mg, respectively) orally, once daily, before or after breakfast. For the remaining 4 weeks of the treatment period, one tablet each of TAK-536CCB and HCTZ 12.5 mg orally, once daily, before or after breakfast."
3042413|NCT02277678|Experimental|Oxycodone|Epidural oxycodone 3mg single dose as opioid administration
3042414|NCT02277678|Active Comparator|Morphine|Epidural morphine 3mg single dose as opioid administration
3042415|NCT02277665|Active Comparator|CUD Treatment Only|12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD
3042416|NCT02277665|Experimental|CUD and Tobacco Treatment|12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD, and behavioral counseling and nicotine replacement therapy (NRT) for tobacco
3042417|NCT02277652|Experimental|Scenario 1: Uninterrupted chest compressions|Endotracheal intubation (ETI) during pediatric manikin with uninterrupted chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control, USA).
3042418|NCT02277652|Experimental|Scenario 2: Neutral position|ETI performed in neutral mannikin head position
3042419|NCT02277652|Experimental|Scenario 3: Sniffing position|ETI performed in sniffing mannikin head position
3042420|NCT02277652|Experimental|Scenario 4: Pharyngeal swelling|ETI performed during mannikin pharyngeal swelling scenario
3042421|NCT02277652|Experimental|Scenario 5: Swollen tongue|ETI performed during mannikin swollen tongue scenario
3042422|NCT02277652|Experimental|Scenario 6: Immobilized cervical spine|ETI performed during mannikin immobilized cervical spine scenario
3042423|NCT02277639|Experimental|Bone Marrow Failure Syndrome|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells. Reduced intensity conditioning will include Busulfan, Fludarbine, Cyclophosphamide followed by stem cell infusion.
3042424|NCT02277639|Experimental|Immunodeficiency / Dysregulation|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells. Reduced intensity conditioning will include Busulfan, Fludarbine, Cyclophosphamide followed by stem cell infusion.
3042425|NCT02277626|Experimental|Randomized Crossover to ElectroFlo|Experimental: ElectroFlo 5000, then VEST Patients are randomized to a sequence of ElectroFlo 5000 on one visit and during the second visit, they cross-over to the Vest system.
3042426|NCT02277626|Experimental|Randomized Crossover to Vest|Experimental: VEST, then ElectroFlo 5000 Patients are randomized to a sequence of Vest system on one visit and during the second visit, they cross-over to the ElectroFlo 5000.
3042427|NCT02277613|Experimental|AMI MultiStem cells|AMI MultiStem cells is a cell therapy medicinal product originating from adherent stem cells taken from the bone marrow of a non-related donor and expanded ex vivo.
3042428|NCT02277613|Sham Comparator|Sham|Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
3042429|NCT02277600|Experimental|Cohort 1, Treatment A, B|"Treatment A:~BMS-663068 orally twice daily (BID) on Days 1 through 4~Treatment B:~BMS-663068 orally BID plus DRV/COBI orally once daily (QD) on Days 5 through 14"
3042430|NCT02277600|Experimental|Cohort 2, Treatment C, D|"Treatment C:~BMS-663068 orally BID on Days 1 through 4~Treatment D:~BMS-663068 orally BID plus COBI QD on Days 5 through 14"
3042431|NCT02277587|Experimental|Plenadren|Plenadren (modified release hydrocortison) 20-25 or 30 mg oral tablets will be administered once-daily at 8.00 AM in the fasting state The dose is kept the same as patients had before entering the trial.
3042432|NCT02277587|Active Comparator|Conventional glucocorticoid therapy|"Hydrocortisone (dose range 10 to 30) mg will be continued as before entering the study. Cortisone Acetate (dose 25 to 37.5 mg) will be continued as before entering the study. The morning dose will be administered in the fasting state.~The total daily dose and timing is not changed during the study period."
3042433|NCT02277587|No Intervention|Healthy volunteers|Healthy volunteers will be enrolled as control group
3042434|NCT02277574|Experimental|Crossover Group 1|Subjects assigned to this arm will receive 1 of 3 escalating doses of AMP-110 once a week for 4 weeks followed by 4 weekly doses of placebo
3042435|NCT02277574|Experimental|Crossover Group 2|Subjects assigned to this arm will receive 4 weekly doses of placebo followed by 1 of 3 escalating doses of AMP-110 once a week for 4 week
3042436|NCT02277561|Experimental|Diagnostic (VB-DTI, MRI)|Patients undergoing WBRT for a total of 10 fractions also undergo VB-DTI MRI at baseline, 1 week after WBRT initiation, and 7-11 days after completion of WBRT. Patients undergoing SRS without WBRT also undergo VB-DTI MRI at baseline and 7-11 days after completion of SRS.
3042437|NCT02277548|Experimental|Lyrica at 300 mg per day|
3042438|NCT02277535|Experimental|E-mail intervention|"ICU clinicians caring for patients who have not yet been initiated on nutrition 48 hours after ICU admission will receive a reminder email.~ICU clinicians caring for patients who accumulate a caloric deficit greater than 4000 calories or 150 g protein deficit will receive a feedback email"
3042439|NCT02277535|No Intervention|No E-mail intervention|Nutrition status of patients will be assessed but no reminder or feedback emails will be sent
3042440|NCT02277522|Experimental|RNA autologous T cells (anti CD19 CAR T cells)|
3042441|NCT02277509|Experimental|Chinese DPP|Our Chinese DPP intervention includes: 1) skills development core adapted from the DPP core curriculum, 2) stress reduction counseling and activities, 3) physical activity sessions, 4) self-monitoring tools for diet and physical activity, 5) barriers assessment linked to tool box, and 6) post-core support intervention.
3042442|NCT02277509|Active Comparator|Minimal Intervention Control|The minimal control intervention will consist of providing patients with publically available materials on diabetes prevention, which are produced in Chinese.
3042443|NCT02277496|Experimental|HC toolkit intervention students|HC students will receiveeExperimental wellness education via a toolkit approach to address the 2010 Dietary Guidelines for reducing obesity in youth. The specific recommendations include: 1) reducing intake of sugary beverages, 2) increasing intake of fruits and vegetables, 3) increasing frequency of eating breakfast, 4) decreasing fast and junk food choices, 5) increasing physical activity to 1 hour/day, and 6) decreasing screen time to 2 hours per day.
3042444|NCT02277496|No Intervention|Comparison Schools|During the 2014-2015 school year, control schools were utilized to compare outcomes.
3042445|NCT02277483|Active Comparator|active treatment|LAIS® Mites Sublingual tablets + rescue medication
3042446|NCT02277483|No Intervention|control|Rescue medication
3042447|NCT02277470||Golimumab|Patients who are eligible for golimumab therapy.
3042448|NCT02277457|Experimental|EGFR Mutation|Patients with an identified EGFR mutation will receive PET (Positron Emission Tomography) - Adaptive RT (Radiation Therapy) plus concurrent Erlotinib followed by 1 year total of Erlotinib Treatment.
3042449|NCT02277457|Experimental|ALK Rearrangement|Patients with an identified EGFR mutation will receive PET (Positron Emission Tomography) - Adaptive RT (Radiation Therapy) plus concurrent Crizotinib followed by 1 year total ofCrizotinib Treatment.
3042450|NCT02277444|Experimental|Golimumab + Methotrexate|Participants will receive 80 milligram per meter square (mg/m^2) as an intravenous (IV) infusion at Weeks 0, 4, and every 8 weeks thereafter up to Week 244, along with commercial methotrexate (MTX) weekly through Week 28 at the same Body Surface Area (BSA)-based dosage (10 to 30 mg/m^2 per week for participants with BSA less than [<] 1.67 meter square (m^2), or minimum of 15 mg/week for participants with BSA greater than or equal to [>=] 1.67 m^2) as at the time of study entry.
3042451|NCT02277431|Experimental|Probiotic dietary supplement|"Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am & pm) offering a total daily serving of:~Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units [CFU])~Bifidobacterium bifidum Malyoth super strain (40 billion CFU)~Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)"
3042565|NCT02276586|Active Comparator|Group 1|Horizontal Tooth preparation
3042566|NCT02276586|Experimental|Group 2|Vertical tooth preparation
3042452|NCT02277431|Placebo Comparator|Placebo|The placebo capsules utilized in this study will be indistinguishable from the probiotic dietary supplement capsules as they will be identical in appearance, odor, weight, and taste. Furthermore, the same sunflower oil matrix will be in both the probiotic dietary supplement and placebo. The only difference between the dietary supplement and placebo capsules will be the probiotic bacteria.
3042453|NCT02277418|Experimental|Child ETI withoutchest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
3042454|NCT02277418|Experimental|Child ETI with chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3042455|NCT02277418|Experimental|Infant ETI with chest compressions|endotracheal intubation (ETI) during infant mannikin resuscitation with uninterrupted chest compressions.
3042456|NCT02277418|Experimental|Infant ETI without chest compressions|Endotracheal intubation of infant mannikin during resuscitation without chest compressions.
3042457|NCT02277405|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
3042458|NCT02277405|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3042459|NCT02277366||Fluorescence/Narrow Band Bronchoscopy|All patients in the group are examined by Fluorescence Bronchoscopy and Narrow Band Bronchoscopy to make a early detection of lung cancer.
3042460|NCT02277366||Routine Bronchoscopy|All patients in this group are examined by routine bronchoscopy to make a early detection of lung cancer.
3042461|NCT02277353||All enrolled patients|This study enrolls patients undergoing elective spine surgery in prone position and all enrolled subjects may receive fluid loading with hemodynamic monitoring by Flotrac/Vigileo and NICOM, but the investigator does not assign specific interventions to the subjects of the study because this is a prospective observational study.
3042462|NCT02277340|Experimental|EAPA for Pilonidal Disease|The abbrevition EAPA is used to describe the study. The cohort of pilonidal disease patients treated who do not have an acute abscess or other problems like hydradenitis suppurativa, has been treated by endoscopy assisted fulguration of the inner surface and additional crystallized phenol application for further clean up of the remaining tissue as well as preventing bacterial growth.
3042463|NCT02277327|Experimental|Intervention|"Subjects randomized to the intervention group will participate in a bundled intervention that includes action planning and care transitions (for those hospitalized during the study period)"
3042464|NCT02277327|Placebo Comparator|Routine Care|"Subjects randomized to the routine care group will continue to receive their usual care from the Pediatric Medical Home Program at UCLA"
3042465|NCT02277314|Other|Low Cost Treatment for Cataracts|Low cost, manual small incision cataract surgery performed in an educational environment. All costs covered by subjects.
3042466|NCT02277301|Experimental|Mellow Babies|Mellow Babies is a group day programme, run one day a week over 14 weeks with a joint focus on maternal wellbeing and the parentinfant interaction: transport and crèche facilities are provided.The focus is to: (a) explicitly enhance close mother-infant attunement, using a combination of baby-massage, interaction coaching and infant focussed speech; and (b) offer mothers support for their own distress. Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
3042467|NCT02277301|No Intervention|Care as Usual|Routine care received by mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
3042468|NCT02277288|No Intervention|Emptied bladder arm|No instillation of fluid into bladder.
3042469|NCT02277288|Experimental|Filled bladder arm|Instilled bladder with fluid.
3042470|NCT02277275|Placebo Comparator|Standard protein diet with placebo|Subjects will be provided with standard protein diet for four months and corn starch pills(Placebo) for 6 months
3042471|NCT02277275|Experimental|Standard protein diet with BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months, standard protein diet will be provided for four months
3042472|NCT02277275|Placebo Comparator|High protein diet with placebo|Subjects will be provided with high protein diet for four months and corn starch pills(Placebo) for 6 months
3042473|NCT02277262|Experimental|Treatment arm|Patients randomized to this arm will be operated for the primary disease and at the end of the intervention the laparotomy will be closed reinforcing the suture with a swine dermis biological prosthesis positioned sublay
3042474|NCT02277262|Active Comparator|Control arm|Patients randomized to this arm will be operated for the primary disease and at the end of the intervention the laparotomy will be closed by emi-continuous monofilament sutures with an intermediate-reabsorbable-time suture
3042475|NCT02277249|Other|Transvaginal digoxin|Transvaginal administration of digoxin for inducing fetal death prior to second-trimester abortion
3042476|NCT02277249|Other|Transabdominal digoxin|Transabdominal administration of digoxin for inducing fetal death prior to second-trimester abortion
3042477|NCT02277236||Younger Veterans|Male Veterans, 45-64.9 years of age. (Exposures include DXA scanning and CT imaging.)
3042478|NCT02277236||Young-Old Veterans|Male Veterans, 65-84.9 years of age. (Exposures include DXA scanning and CT imaging.)
3042479|NCT02277223|Experimental|Interventional|In addition to induction therapy, patients will receive oral capsules of curcumin (Bara Herbs Inc): Weight<20kg: 1 gram, twice daily, 20-30 kg: 1.5 grams twice daily, weight>30kg: 2 grams twice daily. For Maintenance, in addition to oral 5-ASA maintenance treatment, responding patients will receive oral capsules of curcumin (Bara Herbs Inc): Weight<30kg: 500 milligram, twice daily, weight>30kg: 1 gram twice daily
3042480|NCT02277223|Placebo Comparator|Control|In addition to induction and maintenance therapy, patients will receive matched oral placebo capsules for induction and maintenance (Bara Herbs Inc), twice daily.
3042481|NCT02277210|Placebo Comparator|Non-flushing group|Aspiration alone for all follicular larger than 10mm on both sides. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
3042482|NCT02277210|Active Comparator|Flushing group|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
3042483|NCT02277197|Experimental|Ficlatuzumab and Cetuximab|"Ficlatuzumab will be administered as an IV infusion over 30-60 minutes, once every 2 weeks. Ficlatuzumab will be administered 30-60 minutes after the completion of the cetuximab infusion.~Cetuximab will be administered as an IV infusion once every 2 weeks. The first dose will be administered over 120 minutes (± 15 minutes). Subsequent doses may be infused over 60 minutes (± 15 minutes). The starting dose of cetuximab (dose tier 1) will be 500 mg/m2. Cetuximab will be administered prior to ficlatuzumab."
3042484|NCT02277184|Experimental|Ficlatuzumab, Cisplatin and IMRT|"Ficlatuzumab will be administered as an IV infusion over 30-60 minutes, once every two weeks beginning the week prior to cisplatin-IMRT (week -1), for a total of 4 doses.~Cisplatin will be administered as an IV infusion over 60 minutes on Monday, Tuesday, or Wednesday of each treatment week beginning concurrent with IMRT during week 1 of study treatment (and one week following the first dose of ficlatuzumab) for a total of 7 doses.~IMRT: Treatment will be delivered once daily, 5 fractions per week, 35 - 37 fractions, no weekends or holidays over 7 - 8 weeks. All targets will be treated sequentially."
3042485|NCT02277171|Experimental|Nitric oxide impregnated catheter|
3042486|NCT02277158|Experimental|Chemoradiotherapy|There are four dose levels and one arm only. Level 1: S-1, 50 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 2: S-1, 65 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 3: S-1, 80 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 4: S-1, 90 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks
3042487|NCT02277145|Experimental|treatment group|Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade umbilical cord mesenchymal stem cells (MSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions
3042488|NCT02277132|Active Comparator|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery
3042489|NCT02277132|Placebo Comparator|Placebo|Placebo tablets three times daily orally from randomization until delivery
3042490|NCT02277119|Experimental|Normal Eyes|Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
3042491|NCT02277119|Experimental|Glaucomatous Eyes|Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
3042492|NCT02277119|Experimental|Eyes with Retinal Diseases|Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
3042493|NCT02277106|Experimental|SAGE-547|Intravenous
3042494|NCT02277106|Placebo Comparator|Placebo|Intravenous sterile saline
3042495|NCT02277093|Experimental|Pacritinib|"Pacritinib is an oral drug which will be taken on an outpatient basis daily on a 28-day cycle at a dose of 200 mg twice a day (BID)~Pacritinib should be take at approximately the same times every day with a glass of water, with or without food"
3042496|NCT02277080||Opioid group|These patients should have been treated only with one opioid (morphine, oxycodone, fentanyl, methadone, hydromorphone, tapentadol or tramadol) for more than one month
3042497|NCT02277080||Control group|Chronic non-cancer pain patients not treated with analgesics
3042498|NCT02277067|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
3042499|NCT02277067|Active Comparator|Misoprostol|Misoprostol ( Misotac, Sigma, Egypt) is a stable, synthetic form of prostaglandin E1 analogue. Patients wil be given 600 microgram of misotac immediately postoperative.
3042500|NCT02277054|Experimental|Collagen-MPC cornea substitute|Collagen-phosphorylcholine (collagen-MPC) cornea substitute transplantation using anterior lamellar keratoplasty technique.
3042501|NCT02277041|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
3042502|NCT02277041|Active Comparator|Misoprostol|Misoprostol ( Misotac, Sigma, Egypt) is a stable, synthetic form of prostaglandin E1 analogue. Patients wil be given 600 microgram of misotac immediately postoperative.
3042503|NCT02277028|Experimental|Bilateral Priming|"Bilateral priming a priming technique which is non-invasive and free of side effects. The technique described in this study uses bilateral, symmetrical, rhythmic movement bilateral priming and its purpose is to ready the motor cortex for functional limb training. A rocker is used so that the less affected limb can drive the affected one in symmetrical wrist flexion and extension. The priming (15 minutes) will be following by task specific training (45 minutes). Subjects will then have a break (betw. 30-60 minutes) and then repeat the above. Total priming for one day is 30 minutes. Total task specific training for one day is 90 minutes"
3042504|NCT02277028|Active Comparator|Health Education|The group with no priming will receive stroke related health education via a website from the American Heart Association (15 minutes). They will use their affected hand (as they are able) This will be followed by 45 minutes of the same task specific arm training protocol described in the bilateral priming group. This group will follow the same schedule as above. The health education (15 minutes) will be following by task specific training (45 minutes). Subjects will then have a break (betw. 30-60 minutes) and then repeat the above. Total time on health education website for one day is 30 minutes. Total task specific training for one day is 90 minutes
3042505|NCT02277015|Experimental|ETI without chest compressions|Endotracheal intubation during pediatric resuscitation without chest compressions.
3042506|NCT02277015|Experimental|ETI with chest compressions|Endotracheal intubation during pediatric resuscitation with chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control).
3042507|NCT02277002|Placebo Comparator|Placebo|Participants are exposed to unfiltered cabin air
3042508|NCT02277002|Active Comparator|Cabin Air Filter|Participants are exposed to filtered cabin air
3042509|NCT02276989|Experimental|Compliance Intervention|Subjects will receive acetazolamide, quinine and riboflavin as experimental compliance markers and will serve as their own controls.
3042653|NCT02275962|Experimental|K-877|K-877
3042512|NCT02276963|Experimental|Ublituximab Plus Glucocorticoids|Ublituximab 450 mg intravenously once on day 1, plus glucocorticoids 1000 mg intravenously daily on days 1-5
3042513|NCT02276937|Placebo Comparator|Placebo (0 ciu/limb)|Placebo control
3042514|NCT02276937|Active Comparator|DVC1-0101 low dose (1x10^9 ciu/limb)|Low dose cohort
3042515|NCT02276937|Active Comparator|DVC1-0101 high dose (5x10^9 ciu/limb)|High dose cohort
3042516|NCT02276924|Experimental|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will follow a laser confocal microscopy procedure.
3042517|NCT02276911|Active Comparator|Intravenous (IV) ibuprofen|800mg IV ibuprofen before incision, followed by four total scheduled doses of IV ibuprofen every six hours for 24 hours, in addition to whatever narcotic or other pain control regimens prescribed by the treating physician to control postoperative pain.
3042518|NCT02276911|Placebo Comparator|Intravenous (IV) normal saline|800mg normal saline before incision, followed by four total scheduled doses of IV ibuprofen every six hours for 24 hours, in addition to whatever narcotic or other pain control regimens prescribed by the treating physician to control postoperative pain.
3042519|NCT02276898|Active Comparator|Hypertonic Saline|The treatment intervention is 1 inhalation of 7% hypertonic saline (4ml)
3042520|NCT02276898|Placebo Comparator|Isotonic Saline|The placebo intervention is 1 inhalation of 0.9% isotonic saline
3042521|NCT02276885|Experimental|PBI Radiotherapy 6 Gy|Prone partial breast irradiation of 6 Gy x 5 over 5 days, on five consecutive days
3042522|NCT02276885|Experimental|PBI Radiotherapy 8 Gy|Prone partial breast irradiation of 8 Gy x 3 over 5 days, every other day
3042523|NCT02276872|Experimental|Cohort 1: Parenteral Remodulin to oral treprostinil transition|Subjects will transition in the hospital from Remodulin to oral treprostinil within 5 days of the start of the transition. A cross titration will occur so that doses of parenteral Remodulin will be decreased as oral treprostinil is increased. Oral treprostinil will be dosed three times daily (TID; every 6-8 hours) or four times daily (QID; every 4-6 hours) at the discretion of the investigator. Once subjects have been transitioned from Remodulin, the dose of oral treprostinil will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.
3042524|NCT02276872|Experimental|Cohort 2: Inhaled prostacylin to oral treprostinil transition|A cross titration will occur so that doses of inhaled prostacyclin will be decreased as oral treprostinil is increased. Oral treprostinil will be dosed three times daily (TID; every 6-8 hours) or four times daily (QID; every 4-6 hours). Oral treprostinil will be initiated at 0.125 mg TID or QID and dose escalations may occur in either 0.125 mg or 0.25 mg increments every 24 hours, as tolerated.
3042525|NCT02276872|Experimental|Cohort 3: Oral treprostinil added to background PAH therapy|Oral treprostinil will be dosed three times daily (TID; every 6-8 hours) or four times daily (QID; every 4-6 hours). Oral treprostinil will be initiated at 0.125 mg TID or QID and dose escalations may occur in either 0.125 mg or 0.25 mg increments every 24 hours, as tolerated.
3042526|NCT02276859|Experimental|Normal/ Dual-wave|"On the first study day, pre-breakfast insulin was given as a normal bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a dual-wave bolus before the same high-protein meal.~The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
3042527|NCT02276859|Experimental|Dual-wave/Normal|"On the first study day, pre-breakfast insulin was given as a dual-wave bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a normal bolus before the same high-protein meal.~The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
3042528|NCT02276833|Experimental|Single patient group with qualifying OA|intra-articular space injection of SVF Single patient group with pre-operative and post-operative assessments
3042529|NCT02276820|Experimental|Viralym-A|"Partially HLA-matched Viralym-A cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-A/m2 as a single infusion.~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
3042530|NCT02276807|Experimental|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques. Emphasis is placed upon understanding the individuals values and increasing the number of pleasurable activities aligned with the individuals values.
3042531|NCT02276807|Active Comparator|Usual Care|This is the usual care condition, where participants often times will be provided with brief treatment in primary care that can take many forms.
3042532|NCT02276794|Experimental|Thrust manipulation (TM)|"The patients allocated to the TM group will receive TM aimed at the L4-L5 intervertebral segments. All the patients will be positioned in a standardized position (right side-lying) and will receive a rotational TM technique. The treating therapist will have up to two attempts to perform the TM in each patient.~There is no need for cavitation in order to consider the TM successful; the occurence of cavitation, however, will be recorded.~A single treatment will be provided."
3042533|NCT02276794|Experimental|Non-thrust manipulation (NTM)|"The patients allocated to the NTM group will receive TM aimed at the L4-L5 intervertebral segments. All the patients will be positioned in a standardized position (right side-lying) and will receive 30 oscilations of a grade III rotational NTM.~A single treatment will be provided"
3042534|NCT02276781||PAD Participants|PAD participants from among consecutive patients with PAD identified from Chicago area non-invasive vascular laboratories
3042535|NCT02276768|Experimental|GIC-1001 mid-dose|GIC-1001 , 375 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
3042536|NCT02276768|Experimental|GIC-1001 high-dose|GIC-1001 , 500 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
3042537|NCT02276768|Active Comparator|GIC-1002 mid-dose|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg) 345 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
3042654|NCT02275962|Experimental|K-877 with Rifampin|K-877 with Rifampin
3042538|NCT02276768|Active Comparator|GIC-1002 high-dose|GIC-1002 460 mg (equimolar to GIC-1001 500 mg) 460 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
3042539|NCT02276768|Placebo Comparator|Placebo matching GIC-1001 and GIC-1002|"Placebo matching GIC-1001 doses Placebo matching GIC-1002 doses~Placebo, TID during 3 consecutive days, + a 10 th dose in the morning of day 4 (colonoscopy day)"
3042540|NCT02276755|Active Comparator|Intervention: 1|Dietary Supplement: cholecalciferol (vitamin D)
3042541|NCT02276755|Placebo Comparator|Placebo Comparator: 2|Dietary Supplement: Placebo
3042542|NCT02276742|No Intervention|Usual Care (UC)|Participants randomized to UC will receive baseline advice about the value of losing weight, becoming more physically active, and limiting intake of sodium and inorganic phosphates followed by 12 mos of UC. We have elected not to use a control group in which we provide equivalent attention to both study arms. Behaviors are difficult to change and there is no reason to believe that simply giving participants attention would create behavioral changes sufficient to result in weight loss, reduce sodium excretion, or reduce serum phosphorus. Numerous weight loss studies, including Look AHEAD, have used attention control groups that did not demonstrate weight loss.
3042543|NCT02276742|Active Comparator|Social Cognitive Theory (SCT)|Participants will be exposed to a group behavioral intervention that is based on SCT, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Mastery experiences will include emphasizing past successes; setting incremental, easily achievable goals; identifying modifiable barriers to healthy behavior; receiving positive feedback on goal achievement; and practicing problem solving skills around barriers to adherence.
3042544|NCT02276742|Active Comparator|Monitoring|Participants will be taught how to use a lifestyle self-monitoring program to reduce information processing requirements, make readily available the information required to make good self-management decisions, deliver automated, real-time feedback about achievement of behavioral goals, and permit individualized guidance from an interventionist who uses the MyNetDiary® electronic log to provide targeted education and advice. The Monitoring intervention reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling
3042545|NCT02276742|Active Comparator|Combined|Participants randomized to COMBINED will receive all aspects of the SCT and MONITORING intervention conditions. Social Cognitive Theory based behavioral intervention in complex patients is strengthened when technology is used to manage information complexity, and weakened in its absence. The Monitoring intervention reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling
3042546|NCT02276729|Experimental|Mirror Box Treatment Group|Participants in the intervention group will be required to perform two 20 minute sessions of Mirror Box Therapy, five days/week for the duration of their in-patient stay carried out under the direction of members of the OT stroke team as well as receiving their standard OT treatment for upper limb rehabilitation for the duration of their in-patient stay, which is 3-5 sessions per week of approximately 45 minutes duration. This classic rehabilitation treatment is based upon neurodevelopmental theory using the Bobath approach of postural control and repetitive task training.
3042547|NCT02276729|No Intervention|Conventional Therapy Control Group|Participants in the control group shall receive their standard OT treatment for upper limb rehabilitation for the duration of their in-patient stay, which is 3-5 sessions per week of approximately 45 minutes duration. This classic rehabilitation treatment is based upon neurodevelopmental theory using the Bobath approach of postural control and repetitive task training.
3042548|NCT02276716|Experimental|Phosphatidylserine|"Phosphatidylserine titration from 300, 600 and 800 mg/day~duration: 6 months"
3042549|NCT02276690|Experimental|Dosage of hepcidin|In order to assess iron deficiency, patients randomized in this arm will have dosage of hepcidin by mass spectrometry
3042550|NCT02276690|Active Comparator|Usual biomarker dosage|In order to assess iron deficiency, patients randomized in this arm will have usual biomarker dosages (ferritin and transferrin saturation)
3042551|NCT02276677|Experimental|Oxytocin|Oxytocin 24 IU x 1
3042552|NCT02276677|Placebo Comparator|Placebo|Placebo 24 IU x 1
3042553|NCT02276664|No Intervention|Study 1 - Focus Groups|Using focus group methodology, investigators will identify and explore new content topics for inclusion in smoking cessation booklets and gather feedback about the existing Stop Smoking for Good booklets regarding tone and message design. Results will be used to modify and adapt the existing cessation intervention.
3042554|NCT02276664|Experimental|Study 2 - Self-Help Intervention (SHI)|The SHI arm will receive the intervention developed in Study I.
3042555|NCT02276664|Active Comparator|Study 2 - Usual Care (UC)|The UC arm will receive the existing Clearing the Air smoking-cessation manual.
3042556|NCT02276638||18-28 years old Non-pathologic|Device: Nidek CEM-530 Device: Konan Specular Microscope CELLCHEK XL
3042557|NCT02276638||29-9- years old Non-pathologic|Device: Nidek CEM-530 Device: Konan Specular Microscope CELLCHEK XL
3042558|NCT02276638||29-80 years old pathological|Device: Nidek CEM-530 Device: Konan Specular Microscope CELLCHEK XL
3042559|NCT02276625|Experimental|A - ID|Intradermal administration. 20% dose in a single visit.
3042560|NCT02276625|Experimental|B - ID|Intradermal administration. 40% dose in a single visit.
3042561|NCT02276625|Experimental|C - ID|Intradermal administration. 60% dose in a single visit.
3042562|NCT02276625|Active Comparator|D - IM|1x IM
3042563|NCT02276612|Experimental|E/C/F/TAF|"Treatment-experienced participants will receive open-label E/C/F/TAF for up to 48 weeks.~After completion of 48 weeks of treatment, all eligible participants will be given the option to participate in an open-label extension phase to receive E/C/F/TAF until a) the participant turns 18 years old and E/C/F/TAF is commercially available for use in adults in the country the participant is enrolled, or b) E/C/F/TAF becomes commercially available for use in the participant's current age group in the country the participant is enrolled, or c) E/C/F/TAF becomes accessible to participants through an access program, or d) Gilead Sciences elects to terminate development of E/C/F/TAF in the applicable country."
3042564|NCT02276599||Cardiac catheterization|Patients with a diagnosis of atrial septal defect who are having a cardiac catheterization.
3042567|NCT02276573|Experimental|Oral lichen planus disease|buccal cavity sample
3042568|NCT02276560|Experimental|Neoadjuvant Cisplatin,nab-paclitaxel|Neoadjuvant cisplatin (75 mg/m2) D1 and nab-paclitaxel (125 mg/m2) D1, 8, 15, repeat each 28D cycle x 3 and then surgery per standard of care
3042569|NCT02276560|Experimental|Adjuvant Cisplatin,nab-paclitaxel|Adjuvant cisplatin (75mg/m2) D1, nab-paclitaxel (125 mg/m2)for D1, 8, 15 repeat each 28D x 2
3042570|NCT02276560|Other|Cisplatin+pemetrexed or gemcitabine|Adjuvant cisplatin (75mg/m2) D1, pemetrexed (500mgm2) D1 or; cisplatin (75 mg/m2),Gemcitabine (1000mg/m2) D1, 8 repeat each 21D cycle x 4
3042571|NCT02276547|Experimental|Treatment|Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system
3042572|NCT02276534|Experimental|Theatre|The participants will receive 10 sessions of peer-mediated, theatre-based intervention.
3042573|NCT02276534|Experimental|No Intervention then Theatre|The participants will not receive the treatment for a period of time.
3042574|NCT02276521||Zero dose group|Participants that did not received any HPV vaccine previously.
3042575|NCT02276521||One dose group|Participants that received one dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
3042576|NCT02276521||Two dose group|Participants that received two dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
3042577|NCT02276521||Three dose group|Participants that received three dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
3042578|NCT02276508|Experimental|Probiotic|Participants will take the E. coli Nissle 1917 as an orally administered medication first while in clinic to be observed for 30 minutes for any hypersensitivity reaction. The dose of Nissle 1917 will be 100mg capsule (2.5-25x109 organism) once daily for a total of 4 days. Participants will then increase the dose to 2 capsules (200mg) once daily for the remaining 26 days of the study period.
3042579|NCT02276495|Experimental|ACB Control + Local Infiltration|ACB Control - 20 ml saline injection for ACB + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
3042580|NCT02276495|Experimental|ACB Study + Local infiltration|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
3042581|NCT02276495|Experimental|ACB Study Only|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block
3042582|NCT02276482|Experimental|Tedizolid Phosphate|IV and/or oral 200 mg once per day for 6 days
3042583|NCT02276482|Active Comparator|Antibiotic comparator drug|IV and/or oral antibiotic comparator drug for 10 days
3042584|NCT02276469|Experimental|peer support|peer support is delivered on individual basis for half a year, the frequency depends on the patients requirement, but at least 3 sessions has to occur
3042585|NCT02276469|No Intervention|usual care|usual care was delivered to the patients
3042586|NCT02276456|Experimental|early follow-up|Follow-up within 7 days after discharge from hospital after having an MI. This will be the early-follow-up or experimental arm.
3042587|NCT02276456|No Intervention|standard follow-up|Follow-up appointment within 14-18 days after discharge from hospital after having an MI
3042588|NCT02276443|Experimental|Receives Results From Molecular Testing|"Biopsy for biomarker and molecular testing performed at baseline. Participant receives standard-of-care chemotherapy for 4 cycles. A cycle of treatment may be given once every 2 or 3 weeks depending upon doctor's decision. After cycle 4, participant receives the molecular testing results. This will guide physician and participant's decision with additional standard chemotherapy treatments or a clinical trial.~Diagnostic imaging performed at baseline prior to therapy, then after 2 cycles of anthracycline-based chemotherapy (+/- 1 week) and after 4 cycles of anthracycline-based chemotherapy (+/- 1 week)."
3042589|NCT02276430||Cases|Patients who developed cardiovascular disease after testicular cancer treatment
3042590|NCT02276430||Subcohort members|A random selection out of the total cohort of testicular cancer patients per participating hospital
3042591|NCT02276417||Sepsis|Blood Collection. Urine collection. Bioimpedance analysis. Quality-of-life questionnaires, physical function tests and cognitive function tests.
3042592|NCT02276417||Healthy Controls|Blood Collection.
3042593|NCT02276404|Experimental|relaxation training|Each participant of the experimental group 1 receives 2 one-hour sessions of guided relaxation training prior to surgery.
3042594|NCT02276404|Experimental|acupuncture|Each participant of the experimental group 2 receives 3 acupuncture treatments with a semi-standardized acupoint scheme: once a week over 2 weeks and the day before surgery.
3042595|NCT02276404|Experimental|relaxation training and acupuncture|Each patient of the experimental group 3 receives 3 acupuncture treatments with a semi-standardized acupoint scheme and 2 one-hour sessions of guided relaxation training prior to surgery.
3042596|NCT02276404|No Intervention|usual care|Patients receive usual senological treatment
3042597|NCT02276391|Experimental|Telmisartan/HCTZ fixed-dose combination|
3042598|NCT02276391|Active Comparator|Telmisartan|
3042599|NCT02276378|Experimental|Telmisartan low / HCTZ fixed-dose combination, fed|
3042600|NCT02276378|Experimental|Telmisartan high / HCTZ fixed-dose combination, fed|
3042601|NCT02276378|Active Comparator|Telmisartan low /HCTZ fixed-dose combination, fasted|
3042602|NCT02276378|Active Comparator|Telmisartan high /HCTZ fixed-dose combination, fasted|
3042603|NCT02276365|Experimental|Sequence ABC|"Treatment A: 50 mg BI 10773 once daily from day 1 to 5~Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7~Treatment C: 45 mg pioglitazone once daily from day 1 to 7 after 7 days wash-out"
3042604|NCT02276365|Experimental|Sequence CAB|"Treatment C: 45 mg pioglitazone once daily from day 1 to 7~Treatment A: 50 mg BI 10773 once daily from day 1 to 5 after 7 days wash-out~Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7"
3042605|NCT02276352|Experimental|Meloxicam low dose - one tablet|
3042606|NCT02276352|Experimental|Meloxicam high dose - two tablets|
3042607|NCT02276352|Active Comparator|Meloxicam high dose - one tablet|
3042608|NCT02276339|Experimental|Single arm ankle exercise intervention|Chronic Ankle Instability Group assessed pre and post a 6 week eccentric - concentric exercise intervention
3042609|NCT02276326|Experimental|VSL#3 sachets|VSL#3 is a mix of lactic acid bacteria and bifidobacteria (original De Simone's formulation)
3067643|NCT02110420|Experimental|CC-90001 60mg (Multiple Doses)|
3042610|NCT02276300|Experimental|HER2-Peptid-Vakzine, Cyclophosphamide|Her2-peptide vaccination, Sargramostim, Imiquimod, Cyclophosphamide
3042611|NCT02276274|Experimental|Fasted dosing followed by fed dosing|Oral administration
3042612|NCT02276274|Experimental|Fed dosing followed by fasted dosing|Oral administration
3042613|NCT02276261|Experimental|Vertical|Vaginal cuff closure performed in a vertical manner.
3042614|NCT02276261|Active Comparator|Horizontal|Vaginal cuff closure performed in a horizontal manner.
3042615|NCT02276248|Experimental|radiotherapy+chemotherapy|Radiotherapy technique: Intensity-modulated radiation therapy total dose: 50 to 56 grays per fraction: 2 grays GDP chemotherapy: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
3042616|NCT02276235|Experimental|catgut embedding group|Catgut will be embedding in acupoints as below. Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26) Frequency: one time per week Duration: 6 weeks
3042617|NCT02276235|Sham Comparator|sham catgut embedding group|"The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. All the procedure will be performed as in catgut embedding group.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)~The other procedure were the same as catgut embedding group Frequency: one time per week Duration: 6 weeks"
3042618|NCT02276222|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
3042619|NCT02276222|Active Comparator|Spiriva 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
3042620|NCT02276209|Experimental|Dasotraline 4 mg|Dasotraline 4 mg once daily
3042621|NCT02276209|Experimental|Dasotraline 6 mg|Dasotraline 6 mg once daily
3042622|NCT02276209|Placebo Comparator|Placebo|Placebo once daily
3042623|NCT02276196|Experimental|Lixisenatide|Lixisenatide will be administered subcutaneously, once daily for 8 weeks
3042624|NCT02276196|Active Comparator|Insulin glulisine|Insulin glulisine will be administered subcutaneously, once daily for 8 weeks
3042625|NCT02276183|Experimental|Arm1, Nutrition intervention, test formula and activity|
3042626|NCT02276170||Aminophylline per standard of care|
3042627|NCT02276157||Direct peroral cholangioscopy|Patients with bile duct disease that is eligible to direct peroral cholangioscopy
3042628|NCT02276131|Experimental|Usability testing|Patients will participate in summative human factors testing of the Vigilant Diabetes Management Application in a controlled environment and during home use testing. Clinicians will participate in summative human factors testing in a controlled environment.
3042629|NCT02276118|Experimental|e.motion PS Pro group|the patients who receives total knee arthroplasty with the e.motion PS pro prosthesis
3042630|NCT02276118|Active Comparator|Genesis II group|the patients who receives total knee arthroplasty with the Genesis II prosthesis
3042631|NCT02276092||intervention|exposure to antimicrobial stewardship intervention
3042632|NCT02276092||control|usual care with no exposure to antimicrobial stewardship
3042633|NCT02276079|Experimental|mTBI Aerobic Exercise Group|Participants are two-three weeks post-mild traumatic brain injury are randomized to receive a daily aerobic exercise intervention lasting 1-week.
3042634|NCT02276079|Experimental|mTBI Non-Aerobic Exercise Group|Participants are two-three weeks post-mild traumatic brain injury are randomized to receive a daily non-aerobic exercise intervention lasting 1-week.
3042635|NCT02276079|No Intervention|Non-injured Reference Group|Non-injured, healthy participants will serve as a reference group for functional outcome measures.
3042636|NCT02276066|Active Comparator|Inhospital group at day 14|This group of sepsis participants will remain hospitalized after day 14. A normal saline dilution of Iohexol 0.5-1 ml will be given IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year. In addition to or as an option would be to have a timed urine collection to determine clearance of urea and creatinine can be performed instead of the saline dilution of Iohexol 0.5-1 ml and/or an estimated of GFR using serum creatinine and cystatin C measurement using calculations from blood samples.
3042637|NCT02276066|Other|Released from hosptial prior to day 14|This group of sepsis participants will be released from the hospital prior to day 14. A normal saline dilution of Iohexol 0.5-1 ml will be given IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year. In addition to or as an option would be to have a timed urine collection to determine clearance of urea and creatinine can be performed instead of the saline dilution of Iohexol 0.5-1 ml and/or an estimated of GFR using serum creatinine and cystatin C measurement using calculations from blood samples.
3042638|NCT02276053||BTRE patients|Patients with brain tumor-related epilepsy (BTRE) routinely treated with lacosamide as add on to one or two baseline anti-epileptic drugs.
3042639|NCT02276040||Exparel|Participants will receive Exparel (periarticular bupivicaine and liposomal bupivicaine).
3042640|NCT02276027|Experimental|BYL719|20 NSCLC patients. Patient's tumor must have molecular alteration of the PIK3CA gene.
3042641|NCT02276027|Experimental|INC280|20 NSCLC patients. Patient's tumor must have molecular alteration of the c-MET gene.
3042642|NCT02276027|Experimental|LDK378|25 NSCLC patients.Patient's tumor must have ALK or ROS1 gene rearrangement.
3042643|NCT02276027|Experimental|MEK162|20 NSCLC patients. Patient's tumor must have KRAS, NRAS or BRAF mutation.
3042644|NCT02276014|Other|Supplement A|Beta-carotene 7mg formulation A
3042645|NCT02276014|Other|Supplement B|Beta-carotene 7mg formulation B
3042646|NCT02276014|Other|Supplement C|Beta-carotene 7mg formulation C
3042647|NCT02276001|Experimental|K-877|K-877
3042648|NCT02276001|Experimental|K-877 with Cyclosporine|K-877 with Cyclosporine
3042649|NCT02275988|Experimental|K-877|K-877
3042650|NCT02275988|Experimental|K-877 with Clarithromycin|K-877 with Clarithromycin
3042651|NCT02275975|Experimental|K-877|K-877
3042652|NCT02275975|Experimental|K-877 with Fluconazole|K-877 with Fluconazole
3042655|NCT02275949|Experimental|Study group|acupuncture, electroacupuncture and intradermal acupuncture are done at every session.
3042656|NCT02275949|Sham Comparator|Control group|Mock transcutaneous electrical nerve stimulation(mock TENS) and sham intradermal acupuncture are carried out.
3042657|NCT02275936|Experimental|Group 1 - 50 mg|Every 12 hour oral dosing of N91115 for 28 days
3042658|NCT02275936|Experimental|Group 2 - 100 mg|Every 12 hour oral dosing of N91115 for 28 days
3042659|NCT02275936|Experimental|Group 3 - 200 mg|Every 12 hour oral dosing of N91115 for 28 days
3042660|NCT02275936|Placebo Comparator|Group 4 - Placebo|Every 12 hour oral dosing of placebo comparator for 28 days
3042661|NCT02275923|Experimental|Diagnostic|'Reveal LINQ™ Insertable Cardiac Monitor' will be used to measure changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions.
3042662|NCT02275910|Experimental|E7090 Arm|Oral, starting dose 1 mg once a day, dose escalation in part 1. Cycle 0 is for 7 days. For Cycle 1 and onward, each cycle is 28 days long. The Cycle 0 is set up for PK analysis of a single dose of E7090. In the following Cycle 1, subjects will be administered E7090 QD, and the PK and safety will be assessed for 28 days. One or two doses may be selected from part 1 for Part 2. E7090 will be administered continuously once a daily. Subjects can continue treatment unless they meet discontinuation criteria.
3042663|NCT02275897|Experimental|Slow Speed|Slow group patients will receive spinal injection over 60 seconds. Vital signs monitored every minute after injection. Hypotension is treated with IV Phenylephrine or Ephedrine.
3042664|NCT02275897|Experimental|Fast Speed|Fast group patients will receive spinal injection over 15 seconds. Vital signs monitored every minute after injection. Hypotension is treated with IV Phenylephrine or Ephedrine.
3042665|NCT02275884|Active Comparator|Dark chocolate (85% cocoa)|Patients will initially receive 50 grams of dark chocolate (85% cocoa) b.i.d. for one week. Patients will then cross over to intake of 50 grams of white chocolate (0% cocoa) b.i.d. for another week.
3042666|NCT02275884|Sham Comparator|White chocolate (0% cocoa)|Patients will initially receive 50 grams of white chocolate (0% cocoa) b.i.d. for one week. Patients will then cross over to intake of 50 grams of dark chocolate (85% cocoa) b.i.d. for another week.
3042667|NCT02275871|Experimental|MRI and CESM|High risk patients will get standard of care screening MRI and study CESM on the same day.
3042668|NCT02275858|Experimental|Stiffening wire first|This arm will use the stiffening wire first followed by the placebo wire
3042669|NCT02275858|Placebo Comparator|Placebo wire first|This arm will use the placebo wire first followed by the stiffening wire
3042670|NCT02275845|Experimental|intervention|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg. All the subjects are receiving a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
3042671|NCT02275845|Active Comparator|control diet|a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
3042672|NCT02275832|Experimental|Minoxidil|3% Minoxidil lotion is applied twice daily to the beard.
3042673|NCT02275832|Placebo Comparator|Placebo|Placebo is applied twice daily to beard.
3042674|NCT02275819||control|Will not receive intervention with exercise
3042675|NCT02275819||Intervention group|2 groups will receive 2 different types of exercise
3042676|NCT02275806|Other|All enrolled patients|"Induction Chemotherapy Cycle 1 - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 1 and 8~Concurrent Chemotherapy Cycles 2-4 - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 22 and 29, days 43 and 50, and days 64 and 71 along with radiation therapy of 60-70 Gy in 2 GY fractions on days 22 -71."
3042677|NCT02275793||high PH and normal PVR|Group I, diastolic heart failure with high PH and normal PVR
3042678|NCT02275793||high PH and high PVR|Group II, diastolic heart failure with high PH and High PVR
3042679|NCT02275793||normal PH and normal PVR|Group III, no heart failure, normal PH and normal PVR
3042680|NCT02275780|Experimental|Doravirine 100 mg|Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
3042681|NCT02275780|Active Comparator|Darunavir 800 mg and Ritonavir 100 mg|Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
3042682|NCT02275767|Experimental|Combination 50% cortical/50% cancellous FDBA|Ridge preservation with Combination 50% cortical/50% cancellous freeze-dried bone allograft (FDBA)
3042683|NCT02275767|Active Comparator|100% cortical FDBA|Ridge preservation with 100% cortical freeze-dried bone allograft (FDBA)
3042684|NCT02275767|Active Comparator|100% cancellous FDBA|Ridge preservation with 100% cortical freeze-dried bone allograft (FDBA)
3042685|NCT02275754|Experimental|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
3042686|NCT02275754|Active Comparator|PN only|Patient Navigation ONLY. Participants assigned to this group will be assisted by the patient navigator with their health-related needs. Navigation will occur ONLY on contact with navigators initiated by the study participants.
3042721|NCT02275468|Experimental|Fu-zheng-qu-zhuo oral liquid Group|Patients of FZQZ Group received Fu-zheng-qu-zhuo (FZQZ) oral liquid 20ml every time, and three times a day combined with integrated therapy. The integrated therapy was same to Control Group.
3042722|NCT02275455|Experimental|Participants with autism|
3042687|NCT02275728|Experimental|Pelvic Floor Muscle Training(PFMT)|The conducted training by two groups, consisting of phasic contractions (3 sets of 10 repetitions of maximal contraction for two seconds to double or triple rest), endurance (two sets of six repetitions of sustained contractions of 6-10 seconds with the same rest time) and training effort, requesting the anticipated contraction of the abdominal pelvic floor coughing effort. We used the same protocol in the supine position, sitting and standing, as evolution of the patient. Both were treated 2 times per week, 20 minutes, totaling 8 sessions.
3042688|NCT02275728|Active Comparator|EMG Biofeedback treatment|In this group, the same protocol of the TMAP will be held, however, emg biofeedback is used during training for 20 minutes, 2 times a week, 8 sessions.
3042689|NCT02275728|No Intervention|no treatment|In this group, will be held only the initial assessment, you will not receive treatment for a month and will be reevaluated after being serviced this period.
3042690|NCT02275715|Experimental|Parent Training Program (PT-F)|Treatment group
3042691|NCT02275715|No Intervention|Waitlist|Control group in which parents randomized to this group will be offered the PT-F at the end of the 20 week study period to address their child's feeding issues.
3042692|NCT02275702|Placebo Comparator|Group 1|saline solution IV, bolus
3042693|NCT02275702|Active Comparator|Group 2|0,1mg/kg systemic dose of dexamethasone, bolus
3042694|NCT02275689|Active Comparator|Arthrocopic acromioplasty|Surgical intervention with arthroscopic acromioplasty, bursectomy and subacromial decompression
3042695|NCT02275689|Active Comparator|Radiofrequency microtenotomy|Surgical intervention With arthroscopic radiofrequency microtenotomy
3042696|NCT02275689|No Intervention|Physical therapy|Muscle strength training, home trainings programme
3042697|NCT02275676||Inflammatory bowel disease|Patients with active and inactive inflammatory bowel disease
3042698|NCT02275663|Experimental|Azacytidine plus FLAG|"Azacytidine 75 mg/m2 = mg IV in 100 ml Normal Saline (NS) over 30 minutes on days -5 t0 -1~G-CSF 5 mcg/kg subcut on days 0 to + 6~Fludarabine 30mg/m² in 100ml NS IV daily over 30min., on Days +1 to +5~Cytarabine 2gm/m² = 500ml NS IV daily over 4h, on Days +1 to +5 Start 4h after completion of fludarabine infusion."
3042699|NCT02275650|Experimental|nbUVB|2 SED dose of nbUVB will be given every other week for this intervention group.
3042700|NCT02275650|No Intervention|control|No nbUVB illumination will be given for the control group.
3042701|NCT02275611|Active Comparator|Intranasal oxytocin spray (Syntocinon Spray)|TID inpatient; BID outpatient for 12 wks
3042702|NCT02275611|Placebo Comparator|Intranasal Placebo Spray|TID inpatient; BID outpatient for 12 wks
3042703|NCT02275598|Experimental|BV-ABVD|Treatment will consist of two three-weekly doses of Brentuximab vedotin, followed by standard treatment, ABVD (3 o 6 cycles q4w).
3042704|NCT02275585||Cirrhosis|Patients with cirrhosis will be followed looking about the event of portal vein thrombosis
3042705|NCT02275572|Experimental|Pharmacist Intervention|Primary care pharmacist apply the GP-GP algorithm to each drug with the support of STOPP criteria, Beers and / or recommendations CatSalut. The pharmacist submit to doctor his findings and reach a consensus and decide which recommendations will be presented to patient.
3042706|NCT02275572|No Intervention|Control|Usual procedure.
3042707|NCT02275559|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
3042708|NCT02275559|Active Comparator|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
3042709|NCT02275546|Experimental|Applicator→No Applicator (manual)|Treatment period 1: Participants will use applicator to insert vaginal ring. Treatment period 2: Participants will manually insert vaginal ring using fingers only.
3042710|NCT02275546|Experimental|No applicator (manual)→Applicator|Treatment period 1: Participants will manually insert vaginal ring using fingers only. Treatment period 2: Participants will use applicator to insert vaginal ring.
3042711|NCT02275533|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes once every 2 weeks. Treatment repeats every 2 weeks for 46 courses in the absence of disease progression or unacceptable toxicity.
3042712|NCT02275533|Active Comparator|Arm II (observation)|Patients undergo standard of care clinical observation for up to 2 years. Upon disease relapse, patients may cross-over to Arm I.
3042713|NCT02275520|Other|IO access|Performed intraosseus access device during simulated cardiopulmonary resuscitation
3042714|NCT02275507||Women Undergoing Scheduled Cesarean Delivery|We will be recruiting women who are scheduled for an elective repeat or primary cesarean delivery.
3042715|NCT02275494||shortening group|Shortening group where the operated leg was more than 5mm shorter compared with the contralateral side
3042716|NCT02275494||Restoration group|the restoration control group where the operated leg was within 5mm shortening and 9mm lengthening compared with the contralateral side
3042717|NCT02275494||Lengthening group|The lengthening group where the operated leg became more than 9mm longer compared with the contralateral side.
3042718|NCT02275481|Experimental|BROVANA|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
3042719|NCT02275481|Active Comparator|SPIRIVA|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
3042720|NCT02275468|Placebo Comparator|Control Group|Patients of Control Group received FZQZ-Placebo 20ml every time, and three times a day combined with integrated therapy.The integrated therapy was as follows: (1)low-protein dietary with sufficient calorie supply.(2) Anti-hypertensive agents to achieve a systolic blood pressure of less than 140 mm Hg and a diastolic blood pressure of less than 90 mmHg.(3)Anti-hyperlipidemic agentsas necessary to achieve low-density lipoprotein cholesterol（LDL-CH）less than 2.6mmol/L and triglycerides less than1.7mmol/L.（4）Patients with Diabetes Mellitus received insulin or oral hypoglycemic agents to achieve HbA1c 6.5～8.0%. (5)Received Sodium Bicarbonate as necessary to achieve serum HCO3-≥22mmol/L.(6) Received ferrous succinate, folic acid, and erythropoietin to achieve HB 90~110g/L.
3042723|NCT02275455|Experimental|Aged-matched controls|
3042724|NCT02275429|Other|Runners|Each year, about 1,200 runners residing on Reunion Island take the start of the Madmen's Diagonal ultramarathon. Among those, 500 runners will be selected at random and will receive a letter informing them of the study and requesting their participation. Those who accept are to contact the study team. Among those volunteers, 100 runners will be selected randomly and included in the study. They will undergo a blood test the day before the race starts (day 0, when they retrieve their race number), upon completion of the race, and upon days 7 and 28.
3042725|NCT02275416|Experimental|Ipilimumab & UV1 vaccine & GM-CSF|Ipilimumab (3 mg/kg) every 3rd week for a total of 4 doses. GM-CSF (75 μg) followed by UV1 vaccine (300 μg) will be injected intradermally in the lower abdomen before and between treatments of ipilimumab and thereafter every 4th week up to 28 weeks, and thereafter at week 36 and 48.
3042726|NCT02275403|Experimental|Arm A: Standard care plus acupuncture|Medication taken to manage the symptom burden of CIPN plus acupuncture
3042727|NCT02275403|Active Comparator|Arm B: Standard care alone|Medication taken to manage the symptom burden of CIPN
3042728|NCT02275390|Experimental|Nurse-led Psycho-education Program|The Nurse-led Psychoeducation Program is comprised of eight 2-hour sessions held at every two weeks (i.e., over four months). The program consists of five themes: (a) orientation and engaging and understanding of mental health/illness, its related behaviors and community support resources; (b) working collaboratively and empowering and minimizing resistance and challenges using motivational interviewing approach; (c) effective interpersonal and communication skills; (d) strategies in coping with mental illness, sleep hygiene and allaying anxiety; and (e) self-review and evaluation and establishing a realistic plan for future.
3042729|NCT02275390|Active Comparator|Usual Psychiatric Outpatient Care|Routine psychiatric outpatient care provided by two psychiatric outpatient clinics under study
3042730|NCT02275377|Experimental|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 8 weeks.
3042731|NCT02275377|Placebo Comparator|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance.
3042732|NCT02275377|No Intervention|Normotensive|The normotensive control group (healthy) will go through the same initial evaluation without performing inspiratory muscle training.
3042733|NCT02275364|Experimental|Test nasal strip|Marketed Nasal Strip to be applied for up to two hours, and during the third scanning session for approximately 20 minutes.
3042734|NCT02275364|Placebo Comparator|Placebo nasal strip|Placebo nasal strip to be applied for up to two hours in either of the first two scans only.
3042735|NCT02275351|Experimental|Active Arm 1|Topical SM04554 0.15% solution, applied once a day for 90 days
3042736|NCT02275351|Experimental|Active Arm 2|Topical SM04554 0.25% solution, applied once a day for 90 days
3042737|NCT02275351|Placebo Comparator|Vehicle Arm|Topical vehicle solution, applied once a day for 90 days
3042738|NCT02275338|Experimental|Lanreotide Autogel|120mg administered via deep subcutaneous injection at Day 0 and Day 28.
3042739|NCT02275325|Experimental|Preoperative rehabilitation|Patients that have a preoperative vestibular rehabilitation before vestibular schwannoma surgery in addition to the usual postoperative vestibular rehabilitation
3042740|NCT02275325|No Intervention|Usual|Group of patients that solely have a postoperative vestibular rehabilitation after vestibular schwannoma surgery
3042741|NCT02275299|Experimental|Iguratimod and MTX combination|Drug:Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid) Drug:MTX 2.5 mg/tablet, taken orally once a week, 4 tablets/week
3042742|NCT02275299|Active Comparator|Leflunomide and MTX combination|Drug: Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid) Drug: Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week
3042743|NCT02275286|Experimental|Trabectedin+Radiotherapy|Trabectedin 1.3 or 1.5mg/m2 and radiotherapy 30Gy or 45Gy.
3042744|NCT02275273||Patients with adnexal masses|Every patient that are at least 18 years old with a planned pelvic magnetic resonance imagery and an adnexectomy within the institution.
3042745|NCT02275260|Experimental|All patients|All patients undergo cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI), Transesophageal (or Intracardial) Echocardiography and paperbased neurocognitive testing
3042746|NCT02275247|Experimental|Intervention 'Stellate Ganglion Block'|Experimental patients will receive a stellate ganglion block with 0.25% ropivacaine 6-8mL on the right side at the level of the sixth cervical vertebrae (C6) before surgery.Then the catheter will be attached to a single use patient-controlled analgesia pump containing 0.2% ropivacaine 150 mL, which will be infused at 2 mL/h.
3042747|NCT02275247|No Intervention|without 'Stellate Ganglion Block'|In the control group, every thing will be conducted as a matter of routine without intervention.
3042748|NCT02275234||Retrospective|Patients who survived cardiac arrest >3 months prior to the start of the study and a close family/friend,will be invited to attend an outpatient clinic
3042749|NCT02275234||Prospective- psychological intervention|In patients who survived cardiac arrest and a close family/friend,will be invited to attend an outpatient clinic
3042750|NCT02275221||Hepatitis B and C|Hepatitis B and C
3042751|NCT02275182|Experimental|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
3042752|NCT02275182|Placebo Comparator|Controlled|0.5μg/kg Saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
3042753|NCT02275169|Experimental|Treated|Urofollitropin 150 IU ampoules three times a week for three months
3042754|NCT02275169|Placebo Comparator|Controls|Placebo ampoules three times a week for three months
3042755|NCT02275156|Experimental|Evolocumab|Participants received a single 140 mg dose of evolocumab subcutaneously on Day 1.
3042756|NCT02275143||CT TAP scan|Suitable patients will be identified after consultant radiologists have approved a request for cancer routine CT TAP scan.
3042757|NCT02275130|Experimental|Calcium Hydroxyapatite|30 patients with glottic insufficiency treated operatively with augmentation of vocal cords with injection technique
3042758|NCT02275117|Experimental|ALD403 Dose Level 1|ALD403 Dose Level 1 (IV)
3042759|NCT02275117|Experimental|ALD403 Dose Level 2|ALD403 Dose Level 2 (IV)
3042760|NCT02275117|Experimental|ALD403 Dose Level 3|ALD403 Dose Level 3 (IV)
3042761|NCT02275117|Experimental|ALD403 Dose Level 4|ALD403 Dose Level 4 (IV)
3042762|NCT02275117|Placebo Comparator|Placebo|Placebo (IV)
3042763|NCT02275104||Ventricular arrhythmias|
3042764|NCT02275104||Persistent atrial fibrillation|
3042765|NCT02275091||Diabetes|Children with diabetes type 1 , 12-21 years old
3042766|NCT02275091||Healthy|Healthy children 12-21 years old
3042767|NCT02275078|Other|Interventional|The program consists of 3 components: 1) COPD self-management using an Action Plan; 2) Telesystem-Phone self-assessment/reporting system; and 3) Nurse case manager support.
3042768|NCT02275065|Experimental|Cohort 1|GS-9883 1 × 25 mg tablet (or placebo to match) for 10 days.
3042769|NCT02275065|Experimental|Cohort 2|GS-9883 1 × 100 mg (or placebo to match) for 10 days.
3042770|NCT02275065|Experimental|Cohort 3|GS-9883 5 mg or 10 mg (1 × 5 or 2 × 5 mg tablet) (or placebo to match) for 10 days.
3042771|NCT02275065|Experimental|Cohort 4|GS-9883 50 mg or 75 mg (2 × 25 or 3 × 25 mg tablet) (or placebo to match) for 10 days.
3042772|NCT02275052|Experimental|UMEC/VI 62.5/25mcg|Participants will self-administer blinded UMEC/VI (62.5 mcg/25 mcg) each morning (once daily) as one inhalation from the double-blind DPI in one of the 2 treatment periods of 12 weeks. The treatment periods will be separated by a wash out period of 12-17 days.
3042773|NCT02275052|Experimental|Placebo|Participants will self-administer blinded placebo each morning (once daily) as one inhalation from the double-blind DPI in one of the 2 treatment periods of 12 weeks. The treatment periods will be separated by a wash out period of 12-17 days
3042774|NCT02275039|Experimental|Treatment (MVA-p53 vaccine and gemcitabine hydrochloride)|Patients receive modified vaccinia virus ankara vaccine expressing p53 SC on day 15 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then continue to receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 every 21 days in the absence of disease progression or unacceptable toxicity.
3042775|NCT02275026|Experimental|Functional magnetic resonance imaging|Magnetic resonance images will be acquired on a 3 Tesla scanner (Skyra, Siemens, Erlangen, Germany) with a 20 channel receiver coil.
3042776|NCT02275013||Early|Levosimendan administration within first hour of post-operative ICU admission
3042777|NCT02275013||Late|Levosimendan administration within 24 hours of post-operative ICU admission but after first hour
3042778|NCT02275000|Experimental|Intervention|5 Day physiotherapy programme at the National Hospital for Neurology and Neurosurgery, Queen Square, London UK.
3042779|NCT02275000|Active Comparator|Treatment as usual|Participants are referred to their local neuro-physiotherapy service and if appropriate placed on a waiting list for inpatient rehabilitation.
3042780|NCT02274987|Experimental|Treatment|The treatment plan for each patient is individualized and different depending on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
3042781|NCT02274974|Active Comparator|lidocaine|20 ml of 2% lidocaine.
3042782|NCT02274974|Experimental|lidocaine and epinephrine.|20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000. I.e.: by adding 1/4 from ampoule of adrenaline 1mg./1ml to bottle of lidocaine Hydrochloric acid (HCL) 2% 50 ml(20mg/ml).
3042783|NCT02274961|Experimental|S-pantoprazole 10mg|S-pantoprazole 10mg Tablet once daily for 4 weeks
3042784|NCT02274961|Placebo Comparator|Placebo|Placebo tablet for the test drug
3042785|NCT02274948|Active Comparator|Metformin|8-10.99 year old children received metformin. Initially children given 250mg of metformin daily for a week and increased to 250mg twice daily for a week and then to 500 mg twice daily there after. 11-16 year old children received 500mg of metformin daily initially for one week which increased to 500mg twice daily for a week and then to 1g twice daily. The medication was continued for 12 months.
3042786|NCT02274948|Placebo Comparator|Placebo|"A placebo tablet which is physically similar to metformin tablets will be given in a similar manner as described above.~Metformin and placebo is manufactured by the State Pharmaceutical Manufacturing Corporation (SPMC)"
3042787|NCT02274935|Experimental|Gait and balance exercise|Traditional exercises focusing on gait and balance
3042788|NCT02274935|Experimental|Cognitive training and physical exercise|Gait and balance exercises done in combination with cognitive training (i.e. counting backwards by 7s from 98)
3042789|NCT02274909|No Intervention|control group|The subjects received no intervention and continued with their daily activities.
3042790|NCT02274909|Active Comparator|Pilates group|The exercise protocol of Pilates method consisted of muscle stretching of the upper limbs, trunk and lower limbs before the exercises. Then, exercises involving range of motion and strength of upper limbs, trunk and lower limbs were performed, always associated with breathing in different positions and with increasing repetitions and resistance along the weeks of training.
3042791|NCT02274909|Active Comparator|PNF group|The exercises from the PNF method were performed with stretching, associated to hold-relax technique, for upper and lower limbs. Then, subjects carried out exercises with the upper limbs, in a bilaterally symmetrical pattern, and with the lower limbs, in the asymmetric bilateral pattern. Additionally, scapular and pelvic girdle exercises were done with symmetrical and reciprocal combination.
3042792|NCT02274896|Experimental|PD catheter group|All patients will receive the Bayston PD catheter
3042793|NCT02274883|Experimental|Enriched Protein Fractions|This group is given Infant formula with enriched protein fractions.
3042794|NCT02274883|Active Comparator|Protein Fractions|This group is given Infant formula with protein fractions.
3042795|NCT02274870|Experimental|Liposome Bupivacaine,|Liposome Bupivacaine 266mg, Knee Infiltration
3042796|NCT02274870|Active Comparator|Bupivacaine HCl|Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
3042797|NCT02274857|Active Comparator|Standard PVI Ablation|Standard catheter ablation including pulmonary vein isolation (PVI) procedure for the treatment of persistent AF.
3042798|NCT02274857|Experimental|FIRM-guided Procedure and PVI|FIRM-guided procedure followed by standard catheter ablation including PVI.
3042989|NCT02273570|Experimental|Optimal CKD-MBD control|Optimal CKD-MBD control: in this group the PTH target is150-300 pg/ml to be achieved with a therapeutic algorithm
3042799|NCT02274844|Experimental|Peer Coaching|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching.
3042800|NCT02274844|No Intervention|Usual Care|At enrollment, the investigators will provide an educational DVD on general health and wellness topics including vaccination, cancer screening, osteoporosis and other topics not related to diabetes care. There will be no peer storytelling on these DVDs.
3042801|NCT02274831|Experimental|Email Group|Includes receiving standard of care discharge instructions plus an email after being discharged home from the emergency department, reinforcing their discharge instructions. Included in the email is their physician's name and recommended timing of follow-up visit.
3042802|NCT02274831|No Intervention|Standard of Care|Includes standard of care discharge instructions after being discharged from the emergency department. This included receiving paper copies of their discharge instructions.
3042803|NCT02274818|No Intervention|Standard Duty Hour Schedule|IM programs randomized to the currently mandated duty 16 hour standards (maximum work duration of 16 hours for interns and 28 hours for PGY2-3); this schedule may involve night float.
3042804|NCT02274818|Experimental|Flexible Duty Hour Schedule|"IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:~No more than 80 hours of work per week (when averaged over 4 weeks)~1 day off in 7 (when averaged over 4 weeks)~In-house call no more frequently than every 3rd night (when averaged over 4 weeks)"
3042805|NCT02274805||Adults presenting for surgery in the neck area|
3042806|NCT02274792|Experimental|Etanercept|Participants received etanercept 50 mg subcutaneously twice a week (BIW) for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
3042807|NCT02274779|Experimental|Hight dose IMRT, ELIGARD|"PTV1 PTV5 to 66 Gy in 30 fractions of 2.2 Gy~PTV Pelvis: 54 Gy in 30 fractions of 1.8 Gy~PTV Loge 60 Gy in 30 fractions of 2 Gy 6 Gy A complement of 3 in two additional fractions Gy may be delivered across the lodge PTV.~PTV Relapse Lodge: In addition to treating the PTV Lodge, additional radiation of 6 Gy in 3 fractions of 2 Gy may be made to bring the total dose of 72 Gy in 36 fractions of 2 Gy."
3042808|NCT02274766|Experimental|ADS-5102 (amantadine HCl extended release)|ADS-5102 (amantadine HCl extended release)
3042809|NCT02274766|Placebo Comparator|Placebo|Placebo
3042810|NCT02274740|Experimental|lixisenatide|"Lixisenatide injection should be performed in the morning, within 1 hour (ie, 0-60 minutes), prior to breakfast (or standardized meal).~Lixisenatide is to be started with once daily injections of 10 μg per day for 2 weeks then to be continued by the maintenance dose (8 weeks) of 20 μg/d up to the end of the treatment period."
3042811|NCT02274740|No Intervention|metformin|Greater than or equal than 1.5 g/day as background therapy for 10 weeks
3042812|NCT02274714||Case (with IBD)|Women aged 18-48 years with regular menstrual cycles AND with an established diagnosis of CD or UC involving the small bowel, colon or both
3042813|NCT02274714||Control (without IBD)|Women aged 18-48 years with regular menstrual cycles and without a diagnosis of CD will qualify for the study
3042814|NCT02274701|Experimental|Holistic Needs Assessment|Participants (patients) complete a self-reported paper assessment that asks them to indicate whether they have any emotional, practical, financial and/or clinical concerns. The patient then takes this completed assessment into their consultation. It is then given to the clinician where it informs a discussion based on the patient's needs and concerns as identified by them. A care plan is then written based on this assessment.
3042815|NCT02274701|No Intervention|Control|The control group entails standard care - routine consultation between the patient and clinician.
3042816|NCT02274688|No Intervention|Enhanced Usual Care - Nurse Notification of Patient Concerns|Randomized and will be blindly assessed.
3042817|NCT02274688|Experimental|Patient-centered care transition|"Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.~Randomized and will be blindly assessed."
3042818|NCT02274675|Experimental|Robot group|Receive 0.5 hour of robot-assisted therapy for wrist and forearm and 1.5 hours of daily standard rehabilitation therapy
3042819|NCT02274649|Experimental|Intervention|Intervention group receiving one-to-one peer mentoring
3042820|NCT02274649|Active Comparator|Control|Control group receiving general peer support
3042821|NCT02274636|No Intervention|Data collection|This first phase will involve having you report to the research coordinator through email the presence or absence of several symptoms associated with GERD that can occur during sleep. Phase 1 will occur over 14 days (and nights).
3042822|NCT02274636|Active Comparator|Intervention|In the second phase of the study, each subject will be given either a gel containing xylitol or discs containing xylitol to use for 14 days (the duration of the second phase of the study). If given the gel, a small amount (specified in the directions) is to be applied to the mouth lining just before bed. If given the discs, one will be placed on the gums beside a molar in each cheek each night just before bed (specified in the directions). Each subject will be asked to continue to provide daily email communication with the research coordinator detailing symptoms suggesting reflux experienced the prior night during product use as was provided during phase 1 of the study.
3042823|NCT02274623|Experimental|CTAP101 Capsules|CTAP101 Capsules daily
3042824|NCT02274610|Experimental|Group A|Period 1: Docetaxel-PNP / Washout: 3 weeks / Period 2: Taxotere
3042825|NCT02274610|Experimental|Group B|Period 1: Taxotere / Washout: 3 weeks / Period 2: Docetaxel-PNP
3042826|NCT02274597||Environmental impact on epitympanic temperature measurment|volunteers exposed to different environmental factors to simulate field settings
3042827|NCT02274584|Experimental|CAR T cells|Autologous 4th generation anti-CD30 CAR T cells
3042828|NCT02274571|Experimental|Drug|TSEC (Duavee™, combination of CE and BZA)
3042829|NCT02274571|Placebo Comparator|Placebo|Non active comparator
3042830|NCT02274558|Experimental|NBI-98854 40 mg|NBI-98854 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
3042859|NCT02274324|Active Comparator|PD patients- Diet B first|Patients treated with Duodopa at least three months and are stable on medical therapy. The intervention cosists of Dietary Change. Patients that will be randomized to this group will start diet B and then crossover to diet C.
3042831|NCT02274558|Experimental|NBI-98854 80 mg|Subjects randomized to the NBI-98854 80 mg dose will receive NBI-98854 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by NBI-98854 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning between 7:00am - 10:00am for 5 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
3042832|NCT02274558|Experimental|Placebo|Placebo administered as two (2) placebo capsules, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and be randomized to either a 40 mg or 80 mg dose. Subjects re-randomized to receive NBI-98854 80 mg will receive 40 mg for the first week.
3042833|NCT02274545|Experimental|H7N9 live attenuated vaccine & inactivated subvirion H7N9 vac.|Participants will receive one dose of the H7N9 vaccine at Days 0 and 28. They will receive one dose of the inactivated subvirion H7N9 vaccine on Day 98.
3042834|NCT02274532|Experimental|Patient|Testing will include self-report questionnaires, assessments of activities of daily living (ADL) by an occupational therapist, and biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks. Motion will be recorded using sensors that are attached to the arm and SoftHand. During each session, videos will be obtained of the subjects performing tasks. The experimental data collections are organized into 5 Sessions, which will take place over the course of 1 week, scheduled by the subject's availability, with the option with patients for a 1-week period of take-home testing and associated pre- and post-assessments.
3042835|NCT02274532|Other|Control|Testing will include self-report questionnaires, assessments of activities of daily living (ADL) by an occupational therapist, and biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks. Motion will be recorded using sensors that are attached to the arm and SoftHand. During each session, videos will be obtained of the subjects performing tasks. The experimental data collections are organized into 4 Sessions, which will take place over the course of 1 week, scheduled by the subject's availability. Control subjects will participate in two sessions, including a pre- and post-training assessments.
3042836|NCT02274519|Experimental|Tai Chi|Group randomized to participate in Tai Chi intervention
3042837|NCT02274519|Active Comparator|Educational|Group randomized to participate in educational intervention
3042838|NCT02274506|Experimental|T-Cell Administration|"Cyclophosphamide 60 mg/kg by vein for 2 consecutive days, followed by Fludarabine at 25 mg/m2/day by vein for 5 consecutive days. Fludarabine dose calculated per adjusted ideal body weight.~T-cell product divided into 2 portions. Up to 25% of the genetically modified cells given on first day, with plan to infuse up to 75% of the remaining T-cell dose no sooner than 24 hours after completion of first portion. Second portion should not be given later than 72 hours after first portion. First group of 3 participants receive lowest dose of T-cells. Each new group receive a higher dose of T-cells than the group before it, if no intolerable side effects were seen. Up to 6 dose levels of T-cells will be tested."
3042839|NCT02274493|Experimental|Robotic Harvest of the LD Muscles|Surgical harvesting of the Latissimus Dorsi (LD) Muscles using da Vinci® robotic surgical system in participants undergoing LD muscle flap harvest procedures in conjunction with breast, scalp, upper extremity and lower extremity reconstructive surgery procedures.
3042840|NCT02274480||Breast cancer patients with cardiotoxicity|Each patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete.
3042841|NCT02274480||Breast cancer patients without cardiotoxicity|Each patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete.
3042842|NCT02274467|Active Comparator|Uniport catheter|19 gauge uniport epidural catheter
3042843|NCT02274467|Active Comparator|Multiport catheter|19 gauge multiorifice epidural catheter
3042844|NCT02274454|Active Comparator|1.25mM Calcium-NO oxytocin pretreatment|
3042845|NCT02274454|Active Comparator|2.5mM Calcium-NO oxytocin pretreatment|
3042846|NCT02274454|Active Comparator|5.0mM Calcium-NO oxytocin pretreatment|
3042847|NCT02274454|Active Comparator|1.25mM Calcium-WITH oxytocin pretreatment|
3042848|NCT02274454|Active Comparator|2.5mM Calcium-WITH oxytocin pretreatment|
3042849|NCT02274454|Active Comparator|5.0mM Calcium-WITH oxytocin pretreatment|
3042850|NCT02274428|Other|pneumostem group|single arm, pneumostem treated infants
3042851|NCT02274415|Experimental|PCV vaccine following by the PSV vaccine|Group 1: patients will receive a first boost with 13-valent pneumococcal conjugate vaccine (PCV) (one dose at W0) and then one administration of the PSV vaccines (one dose at W4).
3042852|NCT02274415|Active Comparator|vaccine Pneumo 23|Group 2: patients will receive a single administration of 23-valent pneumococcal polysaccharide vaccine (PSV) (one dose at W4)
3042853|NCT02274402||adults with glucocorticoids|Adults receiving Prednisone
3042854|NCT02274389||Bedaquiline Patient Registry (BPR)|
3042855|NCT02274376||Cohort|
3042856|NCT02274363||Brazilian Participants with Chronic Plaque-type Psoriasis|Brazilian participants with plaque psoriasis followed up at teaching and non-teaching specialized dermatology centers will be included in this study.
3042857|NCT02274350||radiation therapy|Patients treated with either external beam radiation therapy or brachie therapy for localized prostate cancer
3042858|NCT02274337|Experimental|AC0010|patients receiving avitinib treatment Qd, at different dose stages
3042951|NCT02273856||Relapsed/refractory patients with CLL|
3042860|NCT02274324|Active Comparator|PD patients- Diet C first|Patients treated with Duodopa at least three months and are stable on medical therapy. The intervention cosists of Dietary Change. Patients that will be randomized to this group will start diet C and then crossover to diet B.
3042861|NCT02274311|Experimental|Clomiphene citrate|Patients receiving clomiphene citrate
3042862|NCT02274298|Active Comparator|CKD feedback and tools|Physicians in these clinics/clusters will receive feedback on their performance for screening and managing CKD quality indicators as well as EMR tools to aid in their performance
3042863|NCT02274298|No Intervention|No Intervention|Physicians in these clinics/clusters will not receive CKD feedback or tools
3042864|NCT02274285|Experimental|Group A (SP0204)|Participants will receive DTaP-IPV/Hib vaccine administered subcutaneously
3042865|NCT02274285|Active Comparator|Group B (control)|Participants will be given a co-administration of DTaP-IPV vaccine and Hib vaccine subcutaneously
3042866|NCT02274285|Experimental|Group C|Participants will receive DTaP-IPV/Hib vaccine administered intramuscularly
3042867|NCT02274272|Placebo Comparator|Placebo Capsules|
3042868|NCT02274272|Experimental|ADR-1|Lactobacillus reuteri GMNL-89
3042869|NCT02274272|Experimental|GMNL-263|Lactobacillus reuteri GMNL-263
3042870|NCT02274259|Active Comparator|Aflibercept|Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
3042871|NCT02274259|Active Comparator|Ranibizumab|Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
3042872|NCT02274246|Experimental|Gadobutrol|Gadobutrol in Healthy volunteers
3042873|NCT02274233|Experimental|1.5 mg/kg|1.5 mg/kg SP-420 once daily for 14 days
3042874|NCT02274233|Experimental|3 mg/kg|3 mg/kg SP-420 once daily for 14 days
3042875|NCT02274233|Experimental|6 mg/kg|6 mg/kg SP-420 once daily for 14 days
3042876|NCT02274233|Experimental|12 mg/kg|12 mg/kg SP-420 once daily for 14 days
3042877|NCT02274233|Experimental|24 mg/kg|24 mg/kg SP-420 once daily for 28 days
3042878|NCT02274233|Experimental|9 mg/kg|9 mg/kg SP-420 twice daily for 28 days
3042879|NCT02274220|Experimental|Rapid Advancement of Feeds|Postoperative feeds are initiated on first postoperative day and rapidly advanced over 27 hours.
3042880|NCT02274220|Experimental|Average feeding protocol|Postoperative feeds are initiated on first postoperative day and advanced in using a standardized protocol that best-reflects current feeding practice. Maximum feeding volume is reached at 60 hours.
3042881|NCT02274220|No Intervention|Feeds not affected|Postoperative feeds for patients not eligible for randomization are initiated by the treating clinical team and increased as per clinical team's preference.
3042882|NCT02274207|Experimental|silver dressing|Frequency and duration : 1 change/1day or according to statue of patient Dosage : 1 ea
3042883|NCT02274207|Active Comparator|non-silver dressing|Frequency and duration : 1 change/1day or according to statue of patient Dosage : 1 ea
3042884|NCT02274194|Active Comparator|Nasal CPAP during titration|Group nasal mask: use of CPAP for one night whit wash out of two weeks
3042885|NCT02274194|Experimental|Oronasal CPAP during titration|Group oronasal mask: use of CPAP for one night with wash out of two weeks.
3042886|NCT02274181|Experimental|25 mg (approximately equivalent to [(~]) 500 nanocurie|A single 25 mg (approximately equivalent to [(~]) 500 nanocurie [nCi]) dose of [14C]Androxal
3042887|NCT02274168|Other|Conventional RF catheter ablation|Conventional RF ablation will be performed without using ICD-EG information
3042888|NCT02274168|Other|Investigational RF Catheter Ablation using ICD-EG information|RF Catheter Ablation will be performed using ICD-EG information
3042889|NCT02274155|Experimental|Group 1|Anti-OX40 antibody administration 3 weeks prior to surgical resection
3042890|NCT02274155|Experimental|Group 2|Anti-OX40 antibody administration 2 weeks prior to surgical resection
3042891|NCT02274155|Experimental|Group 3|Anti-OX40 antibody administration 1 week prior to surgical resection
3042892|NCT02274142|Active Comparator|ART with Encapsulated material|Restorations performed with encapsulated glass ionomer cement (EQUIA - GC Corp). Capsules with glass ionomer will be activated and applied after caries removal in primary molars.
3042893|NCT02274142|Experimental|ART with Powder-liquid material|Restorations will be performed with powder-liquid glass ionomer cement (Fuji IX - GC Corp) after caries removal in primary molars.
3042894|NCT02274129|Experimental|Use of Healing cap II|Single arm study using a new healing cap as intervention
3042895|NCT02274116|Active Comparator|Intermittent Hypoxia (AIH)|"Subjects with chronic, motor-incomplete SCI will breath mild bouts of low oxygen.~Intervention: AIH - Intermittent Hypoxia - hypoxia air mixture Dosage: 9% oxygen Frequency: 1.5 minutes bouts with 1.0 minute intervals Duration: 38 minutes"
3042896|NCT02274116|Sham Comparator|Intermittent Room Air (SHAM)|"Subjects with chronic, motor-incomplete SCI will breath mild bouts of room air.~Intervention: SHAM - Intermittent Room Air - room air mixture Dosage: 21% oxygen Frequency: 1.5 minutes bouts with 1.0 minute intervals Duration: 38 minutes"
3042897|NCT02274103|Active Comparator|Clinic|BFST delivered to youth with poorly controlled diabetes and their families in the clinic, face-to-face.
3042898|NCT02274103|Active Comparator|Skype|BFST delivered to youth with poorly controlled diabetes and their families using Skype.
3042899|NCT02274090|Placebo Comparator|Placebo Group|Placebo gel without the active ingredient. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.
3042900|NCT02274090|Active Comparator|1% Metformin|1% Metformin gel. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.
3042901|NCT02274077|Active Comparator|EXPAREL|Bilateral, one time injections using 30ml of EXPAREL ((bupivacaine liposome injectable suspension) 1.3% ( 13.3mg/ml)) into the transverse abdominal plane at the time of abdominal component separation. A total of 60cc used with a Bupivacaine concentration of 0.44%.
3042902|NCT02274077|Placebo Comparator|Normal Saline|Bilateral, one time injections of 30ml normal saline into the transverse abdominal plane at the time of abdominal component separation.
3042903|NCT02274064|Experimental|Intervention|Donors randomly assigned to this group will receive a motivational interview and implementation intention intervention telephone call.
3042904|NCT02274064|No Intervention|Control|Donors randomly assigned to this group will receive a standard donor recruitment telephone call.
3042905|NCT02274051|Experimental|Kinetin|"Kinetin titration phase to 30mg/kg dose or individual max dose taken once daily.~Patients will then proceed to steady state long-term phase at maximum individual dose of kinetin over a 3 year period."
3042906|NCT02274038|Experimental|All patients will be enrolled in a single arm of the study|All patients enrolled in the study will receive three 18F-thymidine (FLT) PET/CT scans at the following timepoints: before therapy, on the day of starting pemetrexed therapy (within 24 hours of starting pemetrexed) and at 2-4 weeks of starting pemetrexed therapy.
3042907|NCT02274012|Experimental|Afatinib and weekly Paclitaxel|In addition to the standard chemotherapy, afatinib 40 mg orally once daily will be administered starting on the first day of paclitaxel. Translational studies to assess circulating tumor cells at the start of therapy and then at several later time points, including at the time of progression. These studies will assess the correlation of circulating tumor cell numbers with radiographic response and pilot studies will also be conducted to assess HER2 expression, HER2 genomic amplification, HER2 pathway activation and secondary genetic changes in the HER2 coding sequence as well as other pathway components.
3042908|NCT02273999|No Intervention|Control Group (no device)|No devices were delivered after third molar tooth extraction
3042909|NCT02273999|Placebo Comparator|Placebo group (Inactivated device)|Inactivated devices were delivered after third molar tooth extraction
3042910|NCT02273999|Experimental|Test (activated device)|Activated devices were delivered after third molar tooth extraction
3042911|NCT02273986|Experimental|Digoxin|Digoxin
3042912|NCT02273986|Experimental|Digoxin with K-877|Digoxin with K-877
3042913|NCT02273973|Placebo Comparator|Letrozole + Placebo|Participants will receive 2.5 mg letrozole tablets orally QD along with placebo on a 5-days-on/2-days-off schedule for a total of 16 weeks.
3042914|NCT02273973|Experimental|Letrozole + Taselisib|Participants will receive 2.5 milligrams (mg) letrozole tablets orally once daily (QD) along with taselisib tablets at 4 mg (two 2 mg tablets) orally on a 5 days-on/2 days-off schedule for a total of 16 weeks.
3042915|NCT02273960|Experimental|Arm A: BMS-986004|BMS-986004 solution intravenously as specified
3042916|NCT02273960|Experimental|Arm B: BMS-986004|BMS-986004 solution intravenously as specified
3042917|NCT02273960|Experimental|Arm C: BMS-986004|BMS-986004 solution intravenously as specified
3042918|NCT02273960|Experimental|Arm D: BMS-986004|BMS-986004 solution intravenously as specified
3042919|NCT02273947|Experimental|Arm 1 (ABDC): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
3042920|NCT02273947|Experimental|Arm 2 (BCAD): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
3042921|NCT02273947|Experimental|Arm 3 (CDBA): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
3042922|NCT02273947|Experimental|Arm 4 (DACB): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
3042923|NCT02273947|Experimental|Arm 5 (EFHG): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
3042924|NCT02273947|Experimental|Arm 6 (FGEH): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
3042925|NCT02273947|Experimental|Arm 7 (GHFE): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
3042926|NCT02273947|Experimental|Arm 8 (HEGF): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
3042927|NCT02273947|Experimental|Arm 9 (IJK): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3042928|NCT02273947|Experimental|Arm 10 (JKI): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3042929|NCT02273947|Experimental|Arm 11 (KIJ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3042930|NCT02273947|Experimental|Arm 12 (IKJ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3042931|NCT02273947|Experimental|Arm 13 (JIK): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3042932|NCT02273947|Experimental|Arm 14 (KJI): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3042933|NCT02273947|Experimental|Arm 15 (LMN): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3042934|NCT02273947|Experimental|Arm 16 (OPQ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3042935|NCT02273947|Experimental|Arm 17 (PQO): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3042936|NCT02273947|Experimental|Arm 18 (QOP): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3042937|NCT02273947|Experimental|Arm 19 (OQP): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3042938|NCT02273947|Experimental|Arm 20 (POQ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3042939|NCT02273947|Experimental|Arm 21 (QPO): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3042940|NCT02273934|Experimental|Reablement|Reablement is an intensive, multidisciplinary, client-centered, home-based type of rehabilitation, where ordinary activities of daily living are used for rehabilitative purposes. It is a rehabilitation alternative that may be offered to adults, and there is no lower age limit. An occupational therapist and physical therapist, or nurse, constitutes the key personal, while home helpers, assistants and others with lower education, are the ones who work rehabilitative with the person on a daily basis focusing on self-help.
3042941|NCT02273934|Active Comparator|Standard treatment|This arm consists of the standard treatment home-dwelling elderly persons receive when applying for home-based help. Some elderly may receive home-based nursing or home help services assisting them in daily activities, while others may receive occupational therapy or physical therapy measures for rehabilitative purposes.
3042942|NCT02273921|No Intervention|EEG|A non-invasive EEG recording
3042943|NCT02273908||Pregabalin|Patients will be treated for 8 weeks with pregabalin in primary care: no intervention
3042944|NCT02273908||Usual care|Patients will be treated for 8 weeks with other analgesics in usual care: no intervention
3042945|NCT02273895|Active Comparator|Control|Scopolamine
3042946|NCT02273895|Active Comparator|MCI|Scopolamine
3042947|NCT02273895|Active Comparator|AD|Scopolamine
3042948|NCT02273882||Preterm Infants 29-35 Weeks Gestation <12 months of age|Preterm Infants 29-35 Weeks Gestation <12 months of age
3042949|NCT02273856||Treatment naïve patients with CLL|
3042950|NCT02273856||Treatment naïve patients with iNHL|
3042953|NCT02273843|Experimental|High-dose vitamin D|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU
3042954|NCT02273843|Active Comparator|Conventional-dose vitamin D|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
3042955|NCT02273830|Active Comparator|oxygen adjusted|oxygen adjusted to get SpO2> 90% during the walking test
3042956|NCT02273830|Placebo Comparator|control group|oxygen at 3L/min
3042957|NCT02273817|Experimental|Ciclesonide Nasal Spray (Apotex, Inc.)|"Ciclesonide nasal spray~Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide.~Strength: 50 μg per actuation.~Batch/Lot number (Expiry date): JM6697 (May 2012)~Manufacturer: Apotex, Inc."
3042958|NCT02273817|Active Comparator|Omnaris™ nasal spray|"Omnaris™ Nasal Spray,~Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide~Strength: 50 μg per actuation~Batch/Lot number (Expiry date): 131657 (03/2012)~Manufacturer: Sepracor, Inc."
3042959|NCT02273817|Placebo Comparator|Placebo|"Placebo~Dosage form: Contain the aqueous medium of each metered-dose pump spray formulation unit minus the active ingredient, ciclesonide.~Batch/Lot number (Expiry date): JR3808 (Nov 2012)~Manufacturer: Apotex, Inc."
3042960|NCT02273804|Experimental|topiramate|pill
3042961|NCT02273804|Placebo Comparator|placebo|Sugar pill
3042962|NCT02273791|Active Comparator|HRT group|Women will be subjected to HRT using Estradiol valerate before FET
3042963|NCT02273791|Active Comparator|MOS group|Women will be subjected to MOS using sequential clomiphene citrate and gonadotropin before FET
3042964|NCT02273778|Other|Routine radiotherapy treatment plus MRI scan and PET-CT scan|
3042965|NCT02273778|Other|Routine radiotherapy treatment|
3042966|NCT02273765|Active Comparator|Raltegravir|Tenofovir 300mg QD + lamivudine 300mg QD + raltegravir 400mg BID
3042967|NCT02273765|Experimental|Efavirenz|Tenofovir 300mg QD + lamivudine 300mg QD + efavirenz 600mg QD
3042968|NCT02273752|Experimental|Supportive care (real-time pharmacokinetic TDM of everolimus)|Patients receive everolimus PO daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo real-time pharmacokinetic TDM on days 4, 8, and 15 of course 1. Dosing adjustments of everolimus will be performed on day 8, if necessary. If the everolimus dose is adjusted, patients will continue to undergo real-time pharmacokinetic TDM weekly until goal concentrations are achieved on 2 consecutive measures. Patients whose everolimus dose is not adjusted undergo real-time pharmacokinetic TDM on day 1 of courses 2-6.
3042969|NCT02273739|Experimental|AG-221|
3042970|NCT02273726|Experimental|Roxadustat (FG-4592)|Roxadustat will be dosed orally three times a week.
3042971|NCT02273726|Active Comparator|Epoetin Alfa|Epoetin alfa will be dosed intravenously three times a week.
3042972|NCT02273713|Experimental|Nab-Paclitaxel|Nab-Paclitaxel added to first line treatment with Oxaliplatin and Capecitabine
3042973|NCT02273700||the Study Population|"The study population consists of patients in the cardiology department at the Nîmes University Hospital with non-valvular atrial fibrillation and who are candidates for treatment with a direct oral anticoagulant: Rivaroxaban (Xarelto®). Patients will be selected according to criteria designed to result in a homogeneous population (associated anticoagulants, etc., see below). For this study, patients must not have had a direct oral anti-Xa (activated Factor 10) in the 6 months preceding enrollment.~Intervention: Rivaroxaban"
3042974|NCT02273687|Experimental|Prognostic study population|"The study population consists of patients treated for acute respiratory distress in the emergency department at the Nîmes University Hospital. See inclusion and exclusion criteria.~Intervention: Diaphragmatic ultrasound"
3042975|NCT02273674|Experimental|Left rTMS 5 Hz|This group receive transcranial magnetic stimulation at 5 Hz of frequency over left dorsolateral prefrontal cortex. Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
3042976|NCT02273674|Experimental|Right r TMS 1 Hz|This group receive transcranial magnetic stimulation at 1 Hz of frequency over right dorsolateral prefrontal cortex. Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
3042977|NCT02273661|Placebo Comparator|Control|An aerosol of isotonic saline x 1/ week will be administered during 6 months
3042978|NCT02273661|Experimental|Ambisome|An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
3042979|NCT02273648||Orsiro|"Subjects requiring coronary revascularization with Drug Eluting Stents (DES) as well as Subjects presenting with~Diabetes (all types) at least 300 subjects should be included and analyzed in this segment~Small vessels (≤2.75 mm) approx. 150 subjects~Chronic total occlusion (CTO) approx. 50 subjects~Acute Myocardial Infarction (incl. STEMI and NSTEMI) approx. 100 subjects~Multivessels approx. 250 subjects~In stent restenosis approx. 100 subjects~Different type of DAPT interruption : <3 months, between 3 and 6 months, after 6 months approx. 300 subjects subjects who stopped <3 months"
3042980|NCT02273635|Experimental|andrographolides|Coated tablets containing 140 mg andrographolides twice a day orally administered for a period of 24 months.
3042981|NCT02273635|Placebo Comparator|sugar tablets|Coated tablets containing 140 mgs excipients twice a day orally administered for a period of 24 months.
3042982|NCT02273622|Experimental|hydroxytyrosol 5 mg|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
3042983|NCT02273622|Experimental|hydroxytyrosol 20 mg|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
3042984|NCT02273622|Placebo Comparator|placebo|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
3042985|NCT02273596|Experimental|WTX101|WTX101 Dosage Form: Enteric Coated Tablet WTX101 Dose: 15 - 60 mg, individualized dosing, WTX101 Frequency: QOD, QD or BID, individualized dosing WTX101 Duration: 76 weeks
3042986|NCT02273583|Experimental|Maintenance therapy|73 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX) following 31 weeks of MAP.
3042987|NCT02273583|No Intervention|Control|31 weeks of MAP.
3042988|NCT02273570|Active Comparator|control|Control group: standard care. The iPTH target in this group is 300-540 pg/ml
3042991|NCT02273557|Experimental|Asasantin ER (new formulation III - medium)|
3042992|NCT02273557|Experimental|Asasantin ER (new formulation II - high)|
3042993|NCT02273557|Active Comparator|Asasantin ER (present commercial formulation)|
3042994|NCT02273544|Experimental|Asasantin ER (new formulation - low)|
3042995|NCT02273544|Experimental|Asasantin ER (new formulation - medium)|
3042996|NCT02273544|Experimental|Asasantin ER (new formulation- high)|
3042997|NCT02273544|Active Comparator|Asasantin ER - commercial formulation|
3042998|NCT02273531|Experimental|Asasantin ER, new formulation|
3042999|NCT02273531|Active Comparator|Asasantin ER, present commercial formulation|
3043000|NCT02273518|Experimental|Asasantin ER, new formulation I|
3043001|NCT02273518|Experimental|Asasantin ER, new formulation II|
3043002|NCT02273518|Active Comparator|Asasantin ER, present commercial formulation|
3043003|NCT02273505|Experimental|Asasantin (ER)|
3043004|NCT02273505|Active Comparator|Combination of Persantin and ASA|
3043005|NCT02273492|Experimental|Asasantin ER after a standardized breakfast|
3043006|NCT02273492|Active Comparator|Asasantin ER at fasted state|
3043007|NCT02273479|Experimental|Asasantin®|
3043008|NCT02273479|Placebo Comparator|Placebo|
3043009|NCT02273466|Active Comparator|Desipramine alone|
3043010|NCT02273466|Experimental|Desipramine with Crobenetine|
3043011|NCT02273453|Experimental|Songha® Night|
3043012|NCT02273453|Active Comparator|Placebo + Oxazepam|
3043013|NCT02273453|Placebo Comparator|Placebo|
3043014|NCT02273440|Experimental|BIIL 284 BS with theophylline|
3043015|NCT02273440|Placebo Comparator|Placebo with theophylline|
3043016|NCT02273427|Active Comparator|BIIL 284 BS fasted|
3043017|NCT02273427|Experimental|BIIL 284 BS with high fat meal|
3043018|NCT02273427|Experimental|BIIL 284 BS with low fat meal|
3043019|NCT02273414|Experimental|BIIL 284 BS - rising dose|
3043020|NCT02273414|Placebo Comparator|Placebo|
3043021|NCT02273401|Experimental|BI 11054 CL|
3043022|NCT02273401|Placebo Comparator|Placebo|
3043023|NCT02273388|Experimental|Volasertib|
3043024|NCT02273375|Experimental|MEDI4736|MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier.
3043025|NCT02273375|Placebo Comparator|Placebo|PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier
3043026|NCT02273362|Experimental|Prevention (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD for 7 days (depending on the date of surgery, treatment range may be 5-14 days).
3043027|NCT02273349|Experimental|Treatment|Patients with Alpha-1-Antitrypsin deficiency treated with endoscopic lung volume reduction using Lung Volume Reduction Coils (PneumRx Inc.)
3043028|NCT02273336||Ancillary-Correlative (comprehensive genomic analysis)|Tissue and blood samples are analyzed via next generation sequencing and whole exome sequencing.
3043029|NCT02273323|Experimental|Tea|Black tea
3043030|NCT02273323|Placebo Comparator|Placebo|Placebo
3043031|NCT02273310|Experimental|Families Taking Control|Families participate in a 1 day Problem-Solving Skills training for disease management intervention
3043032|NCT02273310|No Intervention|Delayed Intervention Control|Families are given the opportunity to complete the Problem-solving Skills training for disease management intervention after assessment time 2.
3043033|NCT02273297||Pregnant women and their offspring|Ethnically diverse pregnant women and their offspring
3043034|NCT02273284|Experimental|Buzzy|Participants will use the Buzzy, a small vibration device during their Botulinum toxin treatments. The Buzzy will be held over the injection site for 30 sec prior to the injection, then will be moved more rostral during the actual injection. The Buzzy will be applied in the same fashion to each targeted muscle.
3043035|NCT02273284|No Intervention|control - no Buzzy|Participants in the control group will receive their regular Botulinum toxin treatment without the use of the Buzzy
3043036|NCT02273271|Experimental|Imaging arm|18F-FLT-PET/CT and DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 4 cycles of chemotherapy
3043037|NCT02273258|Experimental|Test (T)|SAR342434: single dose injection
3043038|NCT02273258|Active Comparator|Reference 1 (R1)|US-approved Humalog®: single dose injection
3043039|NCT02273258|Active Comparator|Reference 2 (R2)|EU-approved Humalog®: single dose injection
3043040|NCT02273245||thoracic aortgram CTs|A retrospective cohort assessment of thoracic aortogram CTs of male and female adult (age>18) patients presenting with symptoms of AAS.
3043041|NCT02273232|Active Comparator|Supervised Exercise Group|All PVD patients will get the standard advice regarding exercises but this group will have a constructed exercise program under supervision of Dr. Micheál Newell who is qualified Sports and Exercise Scientist with a Doctorate degree in Integrated Biology. This include six minute walk test, Chair Stand Test and symptoms free distance.
3043042|NCT02273232|Active Comparator|RIPC and supervised Exercise Group|This group will have structured intermitting periods of induced remote ischaemic preconditioning using standard blood pressure cuffs. The cuff will be applied for 5 minutes alternatively with 5 minutes rest to the total of 4 cycles, which needs 40 minutes per day. The RIPC group will receive an exercise program identical to the first group. The total number of days for each participant will be 28 days.
3043043|NCT02273232|Active Comparator|RIPC with Standard Care Group|The patients in this group will receive standard care advice regarding exercise in addition to RIPC as in the 2nd group.
3043044|NCT02273232|Sham Comparator|Control Group (Standard Care)|This group will get the standard advice regarding exercise for PVD patients and all the information available in Out patients clinic settings.
3043045|NCT02273219|Experimental|AEB071 and BYL719|AEB071, oral, 100-400 mg twice daily BYL719, oral, 200-350 mg daily
3043046|NCT02273206|Active Comparator|Preventive Care Management for Cancer Screening|The Care Manager will focus on cancer screening, providing education, patient navigation, and motivational support to overcome screening barriers and form favorable attitudes towards screening.
3043264|NCT02271867|Active Comparator|Levobupivacaine 0,5% with epinephrine|Levobupivacaine 0,5% with 1/200000 epinephrine 15 ml once
3043047|NCT02273206|Experimental|Preventive Care Management for Deprssion and Cancer Screening|"The Care Manager will provide depression care management and motivational support (supportive counseling) and act as a critical link between primary care, mental health care provider, and the patients, helping to develop and implement a treatment plan.~In addition, the Care Manager will work with participants on cancer screening, providing education, patient navigation, and motivational support to overcome screening barriers and form favorable attitudes towards screening."
3043048|NCT02273193||Pregnant Women|Pregnant Women in the first trimester (<13 weeks) of pregnancy and the second trimester of pregnancy.
3043049|NCT02273180|Experimental|SAR342434|SAR342434 before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
3043050|NCT02273180|Active Comparator|Humalog|Humalog before meals intake on top of QD Insulin Glargine, up to Week 52.
3043051|NCT02273167|Experimental|NER1006, 2-Day Split-Dosing|NER1006: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
3043052|NCT02273167|Experimental|NER1006,1-Day Morning Split-Dosing|NER1006: 1-Day Morning Split-Dosing Regimen (to commence in the morning of the day of colonoscopy).
3043053|NCT02273167|Active Comparator|MOVIPREP, 2-Day Split-Dosing|MOVIPREP®: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
3043054|NCT02273154|Experimental|paroxetine and buspirone group|receive paroxetine (20-60mg/d) and buspirone(30mg/d)
3043055|NCT02273154|Active Comparator|paroxetine group|receive paroxetine (20-60mg/d)
3043056|NCT02273141|Experimental|NER1006, Day Before-Only Dosing|NER1006 1-Day Day Before-Only Split-Dosing Regimen (to commence on the evening of the day before colonoscopy).
3043057|NCT02273141|Active Comparator|SP+MS, Day Before-Only Dosing|SP+MS 1-Day Day Before-Only Split-Dosing Regimen (to commence on the morning of the day before colonoscopy).
3043058|NCT02273128||CTR Gene in Osteoporosis and Periodontitis|Patients aged between 35 - 60 yrs with Osteoporosis (BMD>-2.5) and Chronic Periodontitis (>3mm Pocket Probing Depth)
3043059|NCT02273115|Active Comparator|Nulliparous - Foley only|Nulliparous women randomized to receive Foley only treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. No additional ripening agents or oxytocin will be administered while the Foley is in place. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol after Foley removal.
3043060|NCT02273115|Active Comparator|Nulliparous - Foley and oxytocin|Nulliparous women randomized to receive Foley and oxytocin treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol immediately after Foley placement.
3043061|NCT02273115|Active Comparator|Multi(primi)parous - Foley only|Multiparous and primiparous women randomized to receive Foley only treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. No additional ripening agents or oxytocin will be administered while the Foley is in place. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol after Foley removal.
3043062|NCT02273115|Active Comparator|Multi(primi)parous - Foley and oxytocin|Multiparous and primiparous women randomized to receive Foley and oxytocin treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol immediately after Foley placement.
3043063|NCT02273102|Experimental|TCP Dose Level 1|20mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
3043064|NCT02273102|Experimental|TCP Dose Level 2|40mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
3043065|NCT02273102|Experimental|TCP Dose Level 3|60mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
3043066|NCT02273089||OSA w/o EDS|Males with moderate to severe obstructive sleep apnea without excessive daytime sleepiness will be proposed nocturnal CPAP (ResMed S9 AutoSet) for three months
3043067|NCT02273089||OSA w EDS|Males with moderate to severe obstructive sleep apnea with excessive daytime sleepiness will be proposed nocturnal CPAP (ResMed S9 AutoSet) for three months
3043068|NCT02273063|Experimental|TMS Prescription|5Hz delivered over L DLPFC. Intensity: 120% of Motor Threshold, 5 Sec Train, 14 Sec Inter-Train Interval, Frequency: 5Hz, Total Pulses: 3000
3043069|NCT02273050|Experimental|Saxagliptin 5 mg + Metformin (500 mg with titration)|Saxagliptin 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
3043070|NCT02273050|Active Comparator|Saxagliptin 5 mg + Placebo|Saxagliptin 5 mg once daily and Placebo 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
3043071|NCT02273050|Active Comparator|Metformin (500 mg with titration) + Placebo|Placebo 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
3067644|NCT02110420|Experimental|CC-90001 120mg (Multiple Doses)|
3043072|NCT02273037|Placebo Comparator|Pinard horn|Pinard horn (current practice) used to monitor the fetal heart rate in labour in this arm of the study.
3043073|NCT02273037|Experimental|Fetal heart rate Doppler|Doppler used to monitor the fetal heart rate in labour in this arm of the study.
3043074|NCT02273024|Experimental|Exercise|Individuals will participate in weekly supervised and unsupervised exercise sessions prior to HSCT, during hospitalization and till 100 days from HSCT. Exercise will consist of endurance and resistance exercise 3-5 days a week.
3043075|NCT02273024|No Intervention|Usual Care|Usual care will have continue with standard of care treatment without any specific exercise instruction or guidance other than what is provided by the patient education team at the cancer centre.
3043076|NCT02273011||single shot spinal anesthesia|single shot spinal anesthesia for caesarean section was executed for anesthesia, oral analgesic medication was applicated for postoperative analgesia.
3043077|NCT02273011||combuned spinal epidural anesthesia|combined spinal epidural anesthesia for caesarean section was executed for anesthesia, epidural and oral analgesic medication was applicated for postoperative analgesia.
3043078|NCT02272998|Experimental|Treatment (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3043079|NCT02272985|Other|CBF change during hemodialysis|[15O]H2O PET-CT scan and NIRS (Invos)
3043080|NCT02272972||Retrospective group|One x-ray image per patient is assessed by the surgeon. The surgeon undergoes an educational intervention (video/poster) and applies the achieved knowledge during the second assessment of the same image. The intervention is not administered to patients, only to an image.
3043081|NCT02272972||Prosp.group (Application of knowledge)|No direct intervention at the patient. The surgeon applies the achieved knowledge during the performance of the fluoroscopy in the operating room. This image is assessed.
3043082|NCT02272959|Experimental|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral stimuli.
3043083|NCT02272959|Placebo Comparator|Placebo Group|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns using only neutral stimuli.
3043084|NCT02272946|Other|Safety Arm|In Stage 1: all 10 subjects will receive 150 mg Canakinumab subcutaneous injection. This will be a preliminary safety study (before Stage II).
3043085|NCT02272946|Experimental|Canakinumab|In Stage II: About 67 subjects will receive 150mg Canakinumab subcutaneous injection.
3043086|NCT02272946|Placebo Comparator|Placebo|In Stage II: About 33 subjects will receive 150mg placebo subcutaneous injection
3043087|NCT02272933|Experimental|Wireless Body-Worn Sensors|Elderly patients will wear sensors (Smart Slippers and a belt-clip sensor) as they go about their daily life in a geriatric care center.
3043088|NCT02272920|Experimental|Renal denervation|"One procedure will be performed using one of the CE-marked devices for renal denervation: Medtronic Symplicity Flex, Medtronic Symplicity Spyral or St Jude EnligHTN.~Renal denervation is performed within seven days after PCI in patients with acute myocardial infarction and hypertension."
3043089|NCT02272920|No Intervention|Control: Standard of care|Standard-of-care follow-up after ACS. Including nurse and physician out-patient visits.
3043090|NCT02272907|Experimental|Non-buttressed, non-imbricated oversewing|Along the staple line, the surgical attending will oversew the length of the staple line using a 2-0 Vicryl suture in a continuous fashion.
3043091|NCT02272907|Experimental|Non-buttressed, imbricated suture line|Along the staple line, the surgical attending will oversew the staple line using a 2-0 Vicryl suture in a continuous, imbricating fashion.
3043092|NCT02272907|Experimental|Buttressed stapling|"The specimen will be stapled utilizing the same stapling device, with Seamguard applied as a buttress. We will use the standard methodology to apply Seamguard as illustrated in the company's Instructions for Use."
3043093|NCT02272907|Active Comparator|No reinforcement|Data will be collected on staple lines without any reinforcement as a baseline for leak pressure.
3043094|NCT02272894||Group A|D2 Radical Gastrectomy Adding Dissection of the Superior Mesenteric Vein Lymph Node
3043095|NCT02272894||Group B|D2 Radical Gastrectomy
3043096|NCT02272881|Experimental|immediate surgical intervention|immediate surgical reconstruction of the pressure ulcer via flap closure or comparable procedure
3043097|NCT02272881|Other|wound care|conservative wound management directed by certified wound care experts
3043098|NCT02272868|Experimental|Fecal microbiome transplant|Pretransplant(Rifaximin 400mg tid x 10 days + omeprazole 20 mg night before transplant and day of transplant + miralax 17g tid x 2 days) + Fecal Microbial Transplant
3043099|NCT02272868|Placebo Comparator|Normal saline|Pretransplant(Rifaximin 400mg tid x 10 days + omeprazole 20 mg night before transplant and day of transplant + miralax 17g tid x 2 days) + Normal saline
3043100|NCT02272855|Experimental|HF10 plus ipilimumab|
3043101|NCT02272842|Experimental|Vitamin B12|A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)
3043102|NCT02272842|Placebo Comparator|Placebo|A paste containing no vitamin administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)
3043103|NCT02272829|Active Comparator|Active|Participants in this arm will receive the study intervention (sessions with the BHC and the PCP).
3043104|NCT02272829|Placebo Comparator|Health Education|Participants in this arm will receive study sessions about various health topics.
3043105|NCT02272816|Experimental|Carboplatin AUC-10|"Carboplatin will be administered as a day case and doses will be calculated using the Calvert formula as below:~Dose (mg) = (GFR + 25) x 10~Treatment will be repeated every 3 weeks for 3 or 4 cycles depending on the metabolic response after cycle 1 (assessed by PET-CT scan). Patients who display complete response after cycle 1 will have 3 cycles in total. Those who display partial response will have 4 cycles in total. Patients who display no response after cycle 1 but do display a response after cycle 2 will have 4 cycles in total. Those who display no response after cycle 2 will be withdrawn."
3043131|NCT02272647|Experimental|IM E2 - Oral Plac - Ghrelin|Day 1: IM Estradiol (2.5 mg) Day 10: IM Estradiol (5.0 mg) and Oral Placebo 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Medroxyprogesterone (5 mg - for 10 days)
3067645|NCT02110420|Experimental|CC-90001 240mg (Multiple Doses)|
3043106|NCT02272803|Experimental|Arm A: Lenalidomide + Dexamethasone + Elotuzumab (BMS-901608)|"Drug: Lenalidomide~Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug~Drug: Dexamethasone~Tablets, Oral 28 mg and Intravenous (IV) 8 mg, once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Tablets, Oral, 40 mg, once daily, on Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Biological: Elotuzumab (BMS-901608)~Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug"
3043107|NCT02272803|Active Comparator|Arm B: Lenalidomide + Dexamethasone|"Drug: Lenalidomide~Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug~Drug: Dexamethasone~Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
3043108|NCT02272790|Experimental|Arm A (AZD1775 + gemcitabine)|AZD1775 (175 mg PO) will be taken on Days 1-2, 8-9, and 15-16. Gemcitabine 800 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
3043109|NCT02272790|Experimental|Arm B (AZD1775 + paclitaxel)|Five doses of AZD1775 (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days weekly (Days 1-3, 8-10, and 15-17). Weekly paclitaxel 80 mg/m² IV will be administered according to institutional standards on Day 1, 8, and 15 of each 28 day cycle.
3043110|NCT02272790|Experimental|Arm C/C2 (AZD1775 + carboplatin)|"Arm C: Five doses of AZD1775 (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days (Days 1-3). Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21-Day cycle.~Arm C2: Five doses of AZD1775 (225 mg PO BID) 2.5 days per dosing week (QW), on Weeks 1 (D1-3), 2 (D8-10) and 3 (D15-17), or on Weeks 1 (D1-3) and 2 (D8-10) ( 2 weeks on followed by 1 week off.) Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21 day cycle."
3043111|NCT02272790|Experimental|Arm D (AZD1775 + PLD)|Five doses of AZD1775 (175 mg or 225 mg) will be taken in approximate 12 hour intervals over 2.5 days (Days 1, 2, and 3) of each 28-day cycle. PLD will administered IV on Day 1 of each cycle.
3043112|NCT02272777|Active Comparator|Imatinib|Eligible patients from imatinib arm in core study CAMN107ECN02 will be enrolled into imatinib arm in this study.
3043113|NCT02272777|Experimental|Nilotinib|Eligibel patients from nilotinib arm in core study CAMN107ECN02 will be enrolled into imatinib arm in this study.
3043114|NCT02272764|Other|Itraconazole|Itraconazole or placebo
3043115|NCT02272764|Experimental|ALKS 5461|ALKS 5461 or placebo Sublingual tablet
3043116|NCT02272751|Experimental|Exercise Intervention|"Subjects allocated to the Exercise arm will aim to undertake a personal prescribed home exercise programme for half an hour three times a week.~Exercises will be progressed at 6 weeks as subjects progress. All exercise sessions will be documented in the logbooks provided.~Outcome measures will be assessed at baseline, mid-way (6 weeks) and at the end of intervention (12 weeks)."
3043117|NCT02272751|Experimental|Relaxation Intervention|"Subjects allocated to the Relaxation arm will aim to undertake a guided relaxation programme on a CD for half an hour three times a week.~All relaxation sessions will be documented in the logbooks provided. Outcome measures will be assessed at baseline, mid-way (6 weeks) and at the end of intervention (12 weeks)."
3043118|NCT02272738|Experimental|Gemcitabine, Nab-Paclitaxel|"A conformal phase I study using 3 plus 3 method.~Chemoradiotherapy while Gemcitabine, Nab-Paclitaxel are administered.~Both Gemcitabine and Nab-Paclitaxel are an interventional agents in this arm.~Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.~Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.~Radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions."
3043119|NCT02272725|Placebo Comparator|Placebo|tasteless and inert tablets
3043120|NCT02272725|Active Comparator|Ibuprofen|Each tablet containing 400mg of ibuprofen
3043121|NCT02272712|Experimental|Cognitive Behavioural Therapy|A 6-week online cognitive-behavioural treatment for insomnia. Each week focuses on a different topic consistent with the cognitive-behavioural theory of insomnia.
3043122|NCT02272712|No Intervention|Control Condition|The online attention matched control arm will provide education about sleep without any focus on the active ingredients that constitute the intervention group.
3043123|NCT02272699|Experimental|Nimotuzumab with Chemotherapy|"Patients will receive neoadjuvant chemotherapy of paclitaxel and cisplatin with concurrent nimotuzumab.~Paclitaxel 175mg per square metre on day 1 and cisplatin 30mg per square metre on day 1 and day 2 every 3 weeks for 2 cycles. Nimotuzumab 200mg per week for 6 weeks.~After neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
3043124|NCT02272699|Experimental|Nimotuzumab with radiotherapy|"Patients will receive neoadjuvant radiotherapy with concurrent nimotuzumab. Intensity-modulated radiation therapy(IMRT) of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.~After neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
3043125|NCT02272699|Active Comparator|Surgery alone|Patients in this group will be given esophagectomy without any neoadjuvant treatment. Adjuvant radiotherapy is permit for patients with positive lymph nodes metastasis.
3043126|NCT02272686|Experimental|Ibrutinib|Ibrutinib started at a daily dose of 560 mg by mouth daily for up to 3 years.
3043127|NCT02272660|Experimental|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision.
3043128|NCT02272660|Placebo Comparator|Normal saline injection|The control group received 2 mL normal saline injection at the same time point.
3043129|NCT02272647|Experimental|IM Plac - Oral Plac - Ghrelin|Day 1: IM Saline Placebo (0.25 ml) Day 10: IM Saline Placebo (0.5 ml) and Oral Placebo 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
3043130|NCT02272647|Experimental|IM Plac - Oral Prog - Ghrelin|Day 1: IM Saline Placebo (0.25 ml) Day 10: IM Saline Placebo (0.5 ml) and Oral Micronized Progesterone 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
3067646|NCT02110420|Experimental|Placebo|
3043132|NCT02272647|Experimental|IM E2 - Oral Prog - Ghrelin|Day 1: IM Estradiol (2.5 mg) Day 10: IM Estradiol (5.0 mg) and Oral Micronized Progesterone 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
3043133|NCT02272634|Experimental|YPL-001 low dose|Active arm including patients who receive the YPL-001 low dose
3043134|NCT02272634|Experimental|YPL-001 high dose|Active arm including patients who receive the YPL-001 high dose
3043135|NCT02272634|Placebo Comparator|placebo|Control arm including patients who receive the placebo drug
3043136|NCT02272621|Experimental|Partial upper hemisternotomy aortic valve replacement|Partial upper hemisternotomy AVR will be performed according to current standard of care practices.
3043137|NCT02272621|Experimental|Full sternotomy aortic valve replacement|Full sternotomy AVR through a standard median sternotomy will be performed according to current standard of care practices.
3043138|NCT02272608||control|patients WHO do not have sleep apnea
3043139|NCT02272608||mild OSAS|mild apnea patients (AHI: 5-15)
3043140|NCT02272608||moderate OSAS|moderate apnea patients (AHI: 16-30)
3043141|NCT02272608||severe OSAS|severe OSAS patients (AHI: more than 30)
3043142|NCT02272595||Arm A - Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
3043143|NCT02272595||Arm B - Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
3043144|NCT02272582|Experimental|SOMVC001 Vascular Conduit Solution|Each patient will serve as his/her own control because each patient will have two graft segments with one segment immersed in SOMVC001 and the other in heparin dosed saline (Standard solution). Patients will be randomized using a simple random sample allocation scheme. At the time of randomization, patients will be assigned an allocation number. Each randomized patient will be implanted with two SVGs, alternating Target Region A (Circumflex or Diagonal) and Target Region B (Right Coronary System or Diagonal) and alternating (proximal vs. distal) segments of the harvested SV. A randomization schedule will be developed to ensure appropriate randomization allocation of the harvested vein segment being grafted to the targeted regions.
3043145|NCT02272582|Active Comparator|Standard of Care Heparin-dosed saline|Each patient will serve as his/her own control because each patient will have two graft segments with one segment immersed in SOMVC001 and the other in heparin dosed saline (Standard solution). Patients will be randomized using a simple random sample allocation scheme. At the time of randomization, patients will be assigned an allocation number. Each randomized patient will be implanted with two SVGs, alternating Target Region A (Circumflex or Diagonal) and Target Region B (Right Coronary System or Diagonal) and alternating (proximal vs. distal) segments of the harvested SV. A randomization schedule will be developed to ensure appropriate randomization allocation of the harvested vein segment being grafted to the targeted regions.
3043146|NCT02272569|Experimental|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant by an ab-externa technique with connection from the anterior chamber to the suprachoroidal space
3043147|NCT02272556|Active Comparator|Subjects with Type 2 Diabetes|Type 2 DM subjects with HbA1C > 7.5% treated with metformin, sulfonylurea, insulin or combination
3043148|NCT02272556|Active Comparator|Non-Diabetic Obese|Age-matched, non-diabetic obese (BMI > 30 kg/m^3) individuals
3043149|NCT02272556|Active Comparator|Lean, healthy control subjects|Age-matched, lean, healthy control subjects (BMI < 25 kkg/m^3)
3043150|NCT02272543|Active Comparator|Fish surimi peptide powder|Fish surimi peptide powder
3043151|NCT02272543|Placebo Comparator|Placebo|Placebo
3043152|NCT02272530||Healthy|100 healthy volunteers in age of 20-75 years
3043153|NCT02272530||Patients|100 patients with stable coronary artery disease and accordingly endothelial dysfunction
3043154|NCT02272517|Active Comparator|Escitalopram 10-20 mg|Encapsulated tablets once daily for 8 weeks
3043155|NCT02272517|Experimental|Vortioxetine 10-20 mg|Encapsulated tablets once daily for 8 weeks
3043156|NCT02272504||Standard of care arm|Chronic liver disease patients who are under going standard of care surveillance for the development of HCC as defined by AASLD guidelines.
3043157|NCT02272504||Biomarker Arm|Chronic liver disease patients who are under going standard of care surveillance for the development of HCC as defined by AASLD guidelines plus the addition of biomarker assays (AFP, AFP-L3 and DCP) every 6 months.
3043158|NCT02272491|Experimental|ZrO2|"Straumann CARES Variobase Abutment RN~Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)"
3043159|NCT02272491|Active Comparator|PFM crown|Straumann Gold Abutment RN Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
3043160|NCT02272478|Active Comparator|Arm A|"Patients not known adverse karyotype~Randomise between~Daunorubicin 60mg/m2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 10 inclusive (20 doses) Mylotarg (GO) 3mg/m2 on day 1 of DA chemotherapy~Versus~CPX-351 100 units/m2 on days 1, 3 and 5"
3043161|NCT02272478|Active Comparator|Arm B|"Patients with known adverse karyotype~5 cycles of Vosaroxin and Decitabine therapy"
3043162|NCT02272478|Active Comparator|Arm C|"Prior to Course 2 - Patients receving DA plus GO in course 1 and MRD positive PC1~Randomise between~Daunorubicin 50mg/2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v.push on days 1 - 8 inclusive (16 doses)~Versus~Daunorubicin 50mg/m2 daily by i.v. infusion on days 1, 3 and 5 Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 8 inclusive Cladribine 5mg/m2 daily on days 1 - 5 inclusive~Versus Patients aged 60-69 Fludarabine 30mg/m2 daily on i.v. on days 2 - 6 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 6 inclusive~Patients aged 70+ Fludarabine 25mg/m2 daily i.v. on days 2 - 5 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 5 inclusive Idarubicin 5mg/m2 i.v. daily on days 3, 4 and 5 (3 doses)~And Randomisation to receive AC220 or not"
3043163|NCT02272478|Active Comparator|Arm D|"Prior to Course 2 - Patients that received DA plus GO in course 1 and MRD negative PC1~Randomisation to receive AC220 or not"
3043164|NCT02272478|Active Comparator|Arm E|"Prior to Course 2 for patients receiving CPX in course 1 and MRD positive PC1~Randomisation between~CPX-351 100 units/m2 on days 1, and 3 (CPX 200) versus CPX-351 100 units/m2 on days 1, 3 and 5 (CPX 300)"
3043165|NCT02272478|Active Comparator|Arm F|"Prior to Course 3 - Patients that received DA plus GO in course 1 and MRD negative PC1~Randomise between Daunorubicin 50 mg/m2 daily by i.v. infusion on days 1 and 3 (2 doses) Cytosine Arabinoside 100 mg/m2 12-hourly by i.v. push on days 1 - 5 inclusive (10 doses)~versus~Intermediate dose Cytarabine (IDAC) schedule Cytosine Arabinoside 1g/m2 daily by 4 hour infusion on days 1- 5 inclusive (5 doses)"
3043166|NCT02272465||Received blood products during transport|There is no intervention as this is an observational study. The first group will be the patients that received blood products during the helicopter transport from the scene of the injury per standard of care guidelines at the participating institutions.
3043167|NCT02272465||Received crystalloid during transport|There is no study intervention. The second group will be the patients that did not receive blood products during the helicopter transport because blood products are not available or part of the standard of care during flight.
3043168|NCT02272439||Unexplained (male)|Men of couples with a diagnosis of Unexplained infertility (n=15)
3043169|NCT02272439||Unexplained (female)|Women of couples with a diagnosis of Unexplained infertility (n=15)
3043170|NCT02272439||male factor (male)|Men of couples with a diagnosis of male factor infertility (n=15)
3043171|NCT02272439||male factor (female/control)|Women of couples with a diagnosis of male factor infertility (n=15)
3043172|NCT02272439||PCOS (female)|Women of couples with a diagnosis of Polycystic Ovarian Syndrome-related infertility (n=15)
3043173|NCT02272439||PCOS (male/control)|Men of couples with a diagnosis of Polycystic Ovarian Syndrome-related infertility (n=15)
3043174|NCT02272439||healthy volunteer (male/control)|Men with a history of no reproductive dysfunction and proven fertility (n=15)
3043175|NCT02272439||healthy volunteer (female/control)|Women with a history of no reproductive dysfunction and proven fertility (n=15)
3043176|NCT02272426|Experimental|CARET + CTI|Combined Aerobic and Resistance Exercise Training (CARET) plus Cognitive Training Intervention (CTI)
3043177|NCT02272426|Sham Comparator|Sham CARET + Sham CTI|Control group Sham Combined Aerobic and Resistance Exercise Training (CARET) plus Sham Cognitive Training Intervention (CTI)
3043178|NCT02272413|Experimental|BI 695502|
3043179|NCT02272413|Active Comparator|Avastin|
3043180|NCT02272400|Experimental|IGRT of prone partial breast|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy.
3043181|NCT02272387|Active Comparator|Vitamin D3 (cholecalciferol) treatment|50,000 IU vitamin D3 (cholecalciferol) tablet weekly x 8 weeks plus prenatal vitamin (400 IU vitamin D)
3043182|NCT02272387|Placebo Comparator|Vitamin D placebo|Placebo tablet (appearance same as active vitamin D) plus prenatal vitamin (400IU vitamin D)
3043183|NCT02272374|Experimental|e-AVF group|120 elderly with end stage renal disease will undergo AVF creation.
3043184|NCT02272374|Experimental|e-TCC group|120 elderly with end stage renal disease will undergo TCC placement.
3043185|NCT02272374|Experimental|e-AVG group|60 elderly with end stage renal disease will undergo AVG creation.
3043186|NCT02272374|Experimental|ve-AVF group|80 very elderly with end stage renal disease will undergo AVF creation.
3043187|NCT02272374|Experimental|ve-TCC group|80 very elderly with end stage renal disease will undergo TCC placement.
3043188|NCT02272374|Experimental|ve-AVG group|40 very elderly with end stage renal disease will undergo AVG creation.
3043189|NCT02272361|Other|laparoscopic sacrocolpopexy|laparoscopic sacrocolpopexy
3043190|NCT02272361|Other|vaginal mesh surgery|vaginal mesh surgery
3043191|NCT02272348|Experimental|Education to functional insulin therapy immediately|Immediately after inclusion, patients will follow a functional insulin therapy training course during 2.5 days.
3043192|NCT02272348|Other|No education to functional insulin therapy immediately|After inclusion in the study, patients go on usual diabetes management. At the end of study, they will receive education to functional insulin therapy.
3043193|NCT02272335|Experimental|CB Stress Management|The Cognitive-Behavioral Stress Management (CBSM) intervention arm is a closed, structured group intervention that offers 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the Cancer Wellness and Education (CW) condition as well. i.e. Group Sessions
3043194|NCT02272335|Active Comparator|Cancer Wellness (CW)|Enhanced Breast Cancer Wellness and Education (CW). The CW condition consists of 10 weekly sessions that are roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain (e.g., National Cancer Institute, Susan G. Komen Foundation, American Cancer Society).i.e. Group Sessions
3043195|NCT02272309|Experimental|Healthy volunteers|Healthy volunteers
3043196|NCT02272309|Experimental|Patients with LUTS|Patients with LUTS
3043197|NCT02272309|Experimental|Patients with LUTS and treatment|Patients with LUTS and treatment
3043198|NCT02272296|Active Comparator|Jet Injector_main study|Administration of insulin or placebo injection in main study
3043199|NCT02272296|Placebo Comparator|conventional pen, NovoPen IV|Administration of insulin or placebo injection in main study
3043200|NCT02272296|Active Comparator|jet injector_sub study|Administration of insulin or placebo injection in sub study
3043201|NCT02272283|Active Comparator|Angio-guided PCI|"Patients allocated to angio-guided PCI are having Percutaneous Coronary Intervention (PCI) with stent implantation guided by routine angiography alone.~Documentary (comparator) intravascular imaging with Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS) is performed. The PCI-operator is blinded to the image aquisitions, and the analysis is performed offline later."
3043227|NCT02272062|Experimental|Preferences Provided|Subjects will complete a shared decision-making tool and express preferences regarding treatment for coronary artery disease, and these preferences WILL be shared with the treating clinicians.
3043228|NCT02272049|Experimental|Hyperpolarized 129 Xenon|Administration of up to 1 liter doses of Hyperpolarized Xenon gas during MRI (less for children) to optimize acquisition of images for children and adults vs. proton MR imaging
3068475|NCT02104817|Experimental|EPANOVA|Epanova + statin, once daily
3043202|NCT02272283|Experimental|OCT-guided PCI|"After obtaining an angiographic optimal result, patients allocated to OCT-guided PCI have guiding Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS) performed. Online image interpretation is performed by a dedicated OCT-analyst and the PCI-operator. If the OCT reveals; 1) under expansion of the stent with a minimal stent area (MSA) <90% of the distal/proximal reference vessel lumen area and/or; 2) significant acute incomplete stent apposition (defined as more than or equal to 3 stent struts detached >140 microns from the underlying vessel wall), and/or; 3) edge dissection(s) causing significant reduction in minimal lumen area(s) (MLA <4 mm2) and/or, 4) significant residual stenosis (MLA <4 mm2) at the proximal and/or distal reference segment(s), additional intervention is encouraged. The degree of optimization based upon OCT findings is left to the judgement of the PCI-operator."
3043203|NCT02272270|Experimental|Treatment with Study Agent Combination|"Radiation Therapy 2.0GyX30fx, 5 days per week for a total of 60 Gy Temozolomide 75mg/m2 daily throughout radiation Minocycline begins one week prior to chemoradiation, and continues twice a day throughout radiation Arm -2:100mg PO BID Arm -1:150mgPO BID Arm 0: 200mg PO BID Arm 1: 400mg PO BID Arm 1a: 300mg PO BID~Followed by 28 day break followed by~Temozolomide 150-200mg/m2 on days 1-5 out of 28 for up to12 cycles~Minocycline taken twice a day throughout each 28 day cycle for up to 12 cycles:~Arm -2:100mg PO BID Arm -1:150mgPO BID Arm 0: 200mg PO BID Arm 1: 400mg PO BID Arm 1a: 300mg PO BID"
3043204|NCT02272257|Experimental|Early Direct Access Physical Therapy|All care will be administered by one or more physical therapists employed by Temple University. This arm will be early, direct access, physical therapy (immediately evaluation following contacting the front desk administrator or reporting a work injury). Intervention will include interventions matched to their stratified risk category incorporating biopsychosocially oriented education, therapeutic exercise, and manual therapy tailored to the patient's needs.
3043205|NCT02272257|Active Comparator|Physician management|All usual care by physician will be administered by one or more employee health physicians employed by Temple University. Recommendations may or may not include referral to physical therapy.
3043206|NCT02272244|Active Comparator|Standard|SI Group participants will be mailed a set of standard materials. The materials will include a letter from the participant's primary care practice encouraging selection and performance of either (1) colonoscopy screening, or (2) stool blood test (SBT) screening. Accompanying the letter will be instructions for arranging a colonoscopy appointment and instructions for completing an enclosed immunochemical SBT kit. Print materials and contacts will be provided, in both English and Spanish, after the baseline survey. At 45 days following random assignment that encourages screening.
3043207|NCT02272244|Experimental|Decision Support & Navigation|DSNI Group will be mailed print materials, including a letter from the practice on CRC screening, an informational booklet, and instructions for arranging a colonoscopy appointment and for completing an enclosed immunochemical SBT kit. All materials will be provided in both English and Spanish. Within 7 days after this mailing, participants will receive a telephone call from a trained bilingual study navigator. Following the call, the navigator will enter the participant's screening plan into the participant's electronic medical record, send the participant a letter describing the screening plan, and send the participant's primary care provider a copy of that same letter. At 45 days following random assignment, research staff will send participants a reminder letter encouraging the participant's preferred test. At 6 months after randomization, the navigator will send the provider and their office manager a participant CRC screening status report.
3043208|NCT02272218|Other|LAGB|There is only one arm for this study, since this study involves a single cohort receiving the same intervention, laparoscopic gastric banding (LAGB) surgery.
3043209|NCT02272192|Experimental|Play-based 15 hr/week|Children receive 15 hours a week of 1:1 intervention at home plus parent coaching using a play and routines based intervention based on techniques from the Early Start Denver Model
3043210|NCT02272192|Experimental|Play-based 25 hr/week|Children receive 25 hours a week of 1:1 intervention at home plus parent coaching using a play and routines based intervention based on techniques from the Early Start Denver Model
3043211|NCT02272192|Experimental|Discrete Trial Teaching 15 hr/week|"Children receive 15 hours per week of 1:1 intervention at home plus parent training using discrete trial teaching and following the Manual A Work in Progress"
3043212|NCT02272192|Experimental|Discrete Trial Teaching 25 hr/week|"Children receive 25 hours per week of 1:1 intervention at home plus parent training using discrete trial teaching and following the Manual A Work in Progress"
3043213|NCT02272179|Experimental|ASAP Treatment and Brite|Participants in the experimental arm received the ASAP treatment, during their transition from inpatient to outpatient care, as well as the Brite app for distress tolerance/emotion regulation and safety planning.
3043214|NCT02272179|Active Comparator|Treatment as Usual|Participants in this grouping were studied as they proceed from inpatient to outpatient care, per usual treatment protocols at each site. Participants completed paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
3043215|NCT02272166|Active Comparator|propofol|Hypnotic used in this arm is exclusively intra-venous propofol.
3043216|NCT02272166|Active Comparator|sevoflurane|Hypnotic used in this arm is exclusively inhaled sevoflurane.
3043217|NCT02272153|Active Comparator|Egg refined grain|Eggs with white toast
3043218|NCT02272153|Active Comparator|Egg whole grain|Eggs with whole grain toast
3043219|NCT02272153|Active Comparator|Cereal Refined grain|rice cereal with white toast
3043220|NCT02272127|Experimental|intercalated treatment|Patients will receive 4 cycles treatment: chemotherapy(day 1) plus intercalated icotinib(day 8-21) every 3 weeks, and then oral icotinib continuously for 2 years or until disease progression or unacceptable toxic effects
3043221|NCT02272101|Experimental|Vitamin D|Vitamin D 4,000 I.U. orally
3043222|NCT02272101|Placebo Comparator|Placebo|Placebo orally
3043223|NCT02272088|Experimental|physical activity-moderate|participants will be walking during 60 minutes in a moderate pace
3043224|NCT02272088|Experimental|intense physical activity|participants will be running during 60 minutes in na intense pace.
3043225|NCT02272075|No Intervention|mobile colposcope|
3043226|NCT02272062|No Intervention|Preferences Not Provided|Subjects will complete a shared decision-making tool and express preferences regarding treatment for coronary artery disease, but these preferences will NOT be shared with the treating clinicians.
3043263|NCT02271867|Active Comparator|Levobupivacaine 0,5%|Levobupivacaine 0,5% 15 ml once
3043229|NCT02272036|Active Comparator|SMS receiving|Study participants of the SMS group receive in total 14 short messages (SMS) containing time adjusted information on colonoscopy preparation starting 4 days before colonoscopy appointment on their mobile phones.
3043230|NCT02272036|Active Comparator|Non-SMS receiving|Study participants of the Non-SMS-Group do not receive any SMS before colonoscopy. Preparation is done according to regular written information given to the patient.
3043231|NCT02272023|Experimental|9 sessions of Intensive Motivational Interviewing|Experimental condition will consist of 9 1-hour intensive motivational interviewing sessions.
3043232|NCT02272023|Active Comparator|1 Standard Motivational Interview plus 8 nutrition classes|The standard MI intervention will consist of a commonly used, single session of MI (50 minutes) plus 8 hours of nutrition education to achieve time and attention equivalence of study conditions.
3043233|NCT02272010|Experimental|Experimental diet|Altered n-6 and n-3 fatty acid intake.
3043234|NCT02272010|Active Comparator|Comparator Diet|Diet standardized to usual n-6 and n-3 intake.
3043235|NCT02271997|Active Comparator|Ferrous fumarate|40 patients receive ferrous fumarate 3 times a day 200mg
3043236|NCT02271997|Active Comparator|Ferrous gluconate|40 patients receive ferrous gluconate 2 times a day 695 mg
3043237|NCT02271997|Active Comparator|Iron(III)carboxymaltose|40 patients receive a single intravenous shot of ferinject
3043238|NCT02271984|Experimental|Treatment A: MSC2499550A|MSC2499550A: 20 milligram per kilogram (mg/kg) under fed condition
3043239|NCT02271984|Experimental|Treatment B: Cysticide|Cysticide® 40 mg/kg under fed condition
3043240|NCT02271984|Experimental|Treatment C: MSC2499550A|C1:MSC2499550A :10 mg/kg under fed condition C2:MSC2499550A : 30 mg/kg under fed condition
3043241|NCT02271984|Experimental|Treatment D: MSC2499550A|MSC2499550A 20 mg/kg under fasting condition
3043242|NCT02271984|Experimental|Treatment E: MSC2499550A|MSC2499550A: 20 mg/kg directly disintegrated in mouth under fed condition
3043243|NCT02271971|Experimental|Vitamin D3 supplementation|Subjects in the experimental arm will receive a daily 5.000 IU vitamin D3 capsule during 6 weeks.
3043244|NCT02271971|Placebo Comparator|Placebo|Subjects in the placebo arm will receive a daily placebo capsule during 6 weeks.
3043245|NCT02271958|Experimental|Group 1|Oral administration of 2,5 mg of mifepristone daily for 6 months
3043246|NCT02271958|Experimental|Group 2|Oral administration of 5 mg of mifepristone daily for 6 months
3043247|NCT02271958|Experimental|Group 3|Oral administration of 10 mg of mifepristone daily for 6 months
3043248|NCT02271958|Experimental|Group 4|Oral administration of mifepristone placebo daily for 3 months
3043249|NCT02271945|Experimental|MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
3043250|NCT02271945|Experimental|MEDI-551 12 mg/kg and MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
3043251|NCT02271932||Surgery|Surgical management with appendectomy consists of hospital admission with initiation of intravenous antibiotics and urgent appendectomy .
3043252|NCT02271932||Non-operative|Non-operative management consists of hospital admission for observation with a minimum of 24 hours of intravenous antibiotics and a minimum of 12 hours nil per os (NPO). With clinical improvement, patients are switched to oral antibiotics and discharged home with a prescription for oral antibiotics to complete a total antibiotic course of 7 days (including the duration of intravenous antibiotics).
3043253|NCT02271919|Experimental|Varenicline Group (VAR)|"Phase I Weeks 1 - 6: Participant receives Varenicline tablets, Placebo patches, and Placebo lozenges. Varenicline dosing follows recommended dosing schedule (i.e., 0.5 mg/day Varenicline for days 1-3; 0.5 mg twice a day for days 4-7; and 1 mg twice a day thereafter). Placebo patch placed to upper arm on Days 9 - 11, then starting on Day 12, one patch placed in the morning and one in the evening. Placebo lozenges may be used as needed.~Phase II Weeks 7 - 12: If participant has quit smoking, they will stay on current treatment regimen. If participant is still smoking, they will be randomized to one of three other treatment groups."
3043254|NCT02271919|Experimental|Nicotine Patch + Nicotine Lozenge Group (NPL)|"Phase I Weeks 1 - 6: Participants receive Placebo tablets, Nicotine patches, and Nicotine lozenges. Participants take 1 Placebo tablet each morning starting on Day 9 - 11, then starting on Day 12, participant takes 1 in the morning and 1 at night. Nicotine 21 mg patch applied to upper arm starting on Day 12. Nicotine 2 mg lozenges may be used as needed.~Phase II Weeks 7 - 12: If participant has quit smoking, they will stay on current treatment regimen. If participant is still smoking, they will be randomized to one of three other treatment groups."
3043255|NCT02271919|Active Comparator|Group 3 - Tablets, Patches, Lozenges Previously Assigned|Participants remain on tablets, patches, and lozenges that they were previously assigned to but take extra placebo tablet with evening dose, and place 1 extra placebo patch every day.
3043256|NCT02271919|Active Comparator|Group 4 - Switch to Different Active Therapy|Participants switched to opposite active therapy. Participants to take extra placebo tablet in evening and place extra placebo patch every day.
3043257|NCT02271919|Active Comparator|Group 5 - Extra Tablet + Patch|Participants receive extra dose of same tablet they were assigned to at start of study. Participants apply 1 extra patch previously assigned to, and continue using the lozenge they had been on.
3043258|NCT02271906|Experimental|BIBW 2992|BIBW 2992 40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
3043259|NCT02271893|Experimental|Dextromethorphan|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
3043260|NCT02271893|Placebo Comparator|placebo|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
3043261|NCT02271880|Active Comparator|Medication as usual|Medication as typically prescribed by physician.
3043262|NCT02271880|Active Comparator|Medication as usual + STAR|Medication as typically prescribed with the addition of the psychosocial intervention to improve medication adherence
3043265|NCT02271867|Active Comparator|Ropivacaine 0,75%|Ropivacaine 0,75% 15 ml once
3043266|NCT02271854|Experimental|diclofenac sodium gel 1%|diclofenac sodium gel 1% applied four times daily
3043267|NCT02271854|Placebo Comparator|Placebo|Placebo gel applied four times daily
3043268|NCT02271841||Before introduction of PVI|Physicians' practices
3043269|NCT02271841||After introduction of PVI|Physicians' practices
3043270|NCT02271828|Active Comparator|Sentinel lymph node procedure|Sentinel lymph node procedure according to the Dutch breast cancer guideline
3043271|NCT02271828|No Intervention|No sentinel lymph node procedure|No sentinel lymph node procedure
3043272|NCT02271815||Oral Hygiene|Oral Hygiene
3043273|NCT02271802|Experimental|Butyrate|Enema containing sodium butyrate
3043274|NCT02271802|Placebo Comparator|Placebo|Enema containing NaCl
3043275|NCT02271776|Active Comparator|Galactooligosaccharide|5g 3x per day for 12 weeks
3043276|NCT02271776|Placebo Comparator|maltodextrin|3x per day for 12 weeks (isocaloric to intervention)
3043277|NCT02271763|Active Comparator|Palpating neck|Subjects will have their neck palpated by an anesthesiologist to locate their cricothyroid membrane
3043278|NCT02271763|Experimental|Ultrasound neck|Subjects will have their neck scanned with ultrasound by an anesthesiologist to locate their cricothyroid membrane
3043279|NCT02271750||Dementia|
3043280|NCT02271750||controls|
3043281|NCT02271737|Experimental|Experimental|Improve infection control in health centers; improve home hygiene; improve newborn danger signs recognition by the HC staff, VHSG, and mothers; and improve care coordination between community and health facilities. The above improvements will be through the training of health center staff and VHSG; HC staff and VHSG provide health education to mothers at the health centers and at home respectively; and provide supportive supervision to both HC and VHSG. VHSG will conduct three home visits to the mothers/newborns on the first 24 hours, the 3rd day, and the 7th day after delivery.
3043282|NCT02271737|No Intervention|No Intervention|We do not make any interventions.
3043283|NCT02271724||CIDP/MMN newly diagnosed (drug naive)|"Patients, who are suspected to suffer from CIDP or MMN, will undergo a lumbar puncture as a part of the diagnostic procedure. We expect to include 5-10 patients.~Lumbar puncture Blood sample"
3043284|NCT02271724||CIDP/MMN treated|"All patients with established CIDP in maintenance treatment with SCIG or IVIG are recruited from local registries at the outpatient clinic at Department of Neurology, Aarhus University Hospital.~We expect that 10-15 patients with CIDP and MMN treated with SCIG or IVIG eligible for inclusion. Furthermore, we expect to include 10 CIDP and MMN patients in maintenance therapy from the outpatient clinics at Department of Neurology, Odense University Hospital and Department of Neurology, Aalborg University Hospital."
3043285|NCT02271724||Other peripheral neuropathies|Patients who are diagnosed with other causes of peripheral neuropathies than CIDP. We expect to include 20 patients
3043286|NCT02271724||Syptomatic controls|Controls include patients with unspecified neurological symptoms or diseases who will undergo a lumbar puncture at the Department of Neurology at Aarhus University Hospital as part of their diagnostic work up irrespective of this study plus healthy controls. We expected to include 40-50 symptomatic controls
3043287|NCT02271711|Experimental|Natural Killer (NK) Cell Infusions|Patient receives 3 cycles of Natural Killer (NK) cell infusions. Each cycle 4 weeks duration. During the first 3 weeks (Day 1-7 weekly) NK cells infused at Day 1, 3 and 5 (+/- 2 days). The 4th week will be a rest week. Follow-up visit will be 30 days from last infusion (cycle 3). Starting dose level of NK-cell number per infusion is 10^6/m^2. Infusions given through ommaya reservoir catheter.
3043288|NCT02271698|Active Comparator|Dexamethasone 6mg|Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
3043289|NCT02271698|Active Comparator|Dexamethasone 12mg|Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
3043290|NCT02271698|Active Comparator|Dexamethasone 24mg|Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
3043291|NCT02271698|Placebo Comparator|Placebo|Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
3043292|NCT02271685|Experimental|Overestimate Parkinson's|People are told that overestimates on the sound estimation task are associated with being healthy and having a low risk of Parkinson's disease, whereas those who are accurate are more likely to develop the disease later in life.
3043293|NCT02271685|Experimental|Overestimate Alzheimers|People are told that overestimates on the sound estimation task are associated with being healthy and having a low risk of Alzheimers disease, whereas those who are accurate are more likely to develop the disease later in life.
3043294|NCT02271685|Experimental|Underestimate Parkinson's|People are told that underestimates on the sound estimation task are associated with being healthy and having a low risk of Parkinson's disease, whereas those who are accurate are more likely to develop the disease later in life.
3043295|NCT02271685|Experimental|Underestimate Alzheimers|People are told that underestimates on the sound estimation task are associated with being healthy and having a low risk of Alzheimers disease, whereas those who are accurate are more likely to develop the disease later in life.
3043296|NCT02271672|Experimental|XP1000 RF group|Subjects in the XP1000 RF group will be treated with the XP1000 RF device.
3043297|NCT02271672|Sham Comparator|Sham group|Subjects in the Sham group will be treated with the sham XP1000 RF device.
3043298|NCT02271659|Experimental|Brachytherapy boost|Brachytherapy boost with external beam radiotherapy. External beam radiotherapy of 46 Gy delivered to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds (110Gy) or high dose rate (14Gy) with iridium-192) only to the prostate. Each center will choose the appropriate brachytherapy technique
3043393|NCT02271061|Sham Comparator|Control tape|Apply tape in same technique without tension.
3043422|NCT02270840||CRT-D|Patients currently implanted with a single or dual chamber pacemaker or ICD will be upgraded to CRT.
3043299|NCT02271659|Active Comparator|Exclusive external beam irradiation|Exclusive external beam radiotherapy. External beam radiotherapy of 46 Gy delivered to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
3043300|NCT02271646|Experimental|0.5% marcaine 20ml|3 levels ultrasound guided thoracic paravertebral blocks at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
3043301|NCT02271633|Active Comparator|Sodium nitrate|Dietary supplement: 800 mg of nitrate in sodium nitrate added with water to get a 140 mL solution (BASF, Ludwigshafen, Germany)
3043302|NCT02271633|Active Comparator|Beetroot juice|Dietary supplement: 800 mg of nitrate in concentrated beetroot juice (Beet-IT)
3043303|NCT02271633|Active Comparator|Spinach|Dietary supplement: 800 mg of nitrate in a spinach based beverage
3043304|NCT02271633|Active Comparator|Rocket salad|Dietary supplement: 800 mg of nitrate in a rocket salad based beverage
3043305|NCT02271620|Other|nonallergic rhinitis|nonallergic rhinitis nasal allergen provocation test
3043306|NCT02271607|Experimental|moxibustion|A series of moxibustion sessions within four weeks from the baseline followed by observation period of four weeks.
3043307|NCT02271607|No Intervention|waiting|Waiting period of four weeks followed by moxibustion therapy sessions on the same way with moxibustion group.
3043308|NCT02271594|Active Comparator|Intensive Training|The intervention consists of instructing patients in whom lipohypertrophy (LH) is detected and who are currently injecting into it to move injections to non-LH areas; reducing insulin doses initially by 10-20% to avoid hypoglycaemia and then titrating to target control; instructing these patients to correctly rotate sites (leaving 1 cm between injection punctures and allowing used sites to heal for 2-4 weeks before injecting in them again); instructing these patients to forego needle reuse; and instructing these patients to switch to 4 mmx32G needles. A battery of tools (described below) will be used to deliver and reinforce this training, including frequent contact by phone or other electronic means after the initial training.
3043309|NCT02271594|No Intervention|Standard Care|Standard care means affording the patients randomized to the control arm the customary education and follow-up usually given at the centre. This would include appraising them of the presence of LH (if they were not previously aware) and stating that injections should not be given into that area. The training approach, tools and intensive follow-up given the Intervention arm patients will not be given to the Controls. Additionally, at their return visit (3 and 6 months), Control patients will be asked if they did indeed change their injection habits (e.g. stopped injecting into LH) since entering the study. Those who did and those who did not will be analysed separately to see if there is a difference in outcomes and both groups will be compared to the Intervention arm patients.
3043310|NCT02271568||Obese patients|15 Obese patients (BMI>30) having one of comorbidity (type 2 diabetes, dyslipidemia, or hypertension) and morbid obese patients (BMI>35) accepted for bariatric surgery.
3043311|NCT02271568||Control patients|15 matched controls receiving Intensive medical therapy
3043312|NCT02271555|Active Comparator|sevoflurane-remifentanil (Group SR)|Sevoflurane will be initiated, at 8% for anesthesia induction until loss of consciousness will achieve, at which point it will be discontinued. After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
3043313|NCT02271555|Placebo Comparator|sevoflurane-saline (Group SS)|Sevoflurane will be initiated, at 8% for anesthesia induction until loss of consciousness will achieve, at which point it will be discontinued. Placebo is 0.9% saline. After the loss of consciousness saline will be administered to Group sevoflurane-saline in the form of intravenous bolus.
3043314|NCT02271542|Experimental|between 1-10 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
3043315|NCT02271542|Experimental|under 60 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
3043316|NCT02271542|Experimental|upper 60 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
3043317|NCT02271529|Experimental|Drug Eluting Stent|Zilver® Paclitaxel(PTX)® Drug-Eluting Peripheral Stent
3043318|NCT02271516|Experimental|188Re-BMEDA-liposome|"Stage I:~188Re-BMEDA-liposomes, 14±1.4 mCi, single dose~Stage II:~188Re-BMEDA-liposomes, dose-escalation, single dose Dose Level Dose of 188Re-BMEDA-liposome (mCi/kg)~0.42±0.04 mCi/kg~0.63±0.06 mCi/kg~0.84±0.08 mCi/kg~1.05±0.11 mCi/kg~1.26±0.13 mCi/kg~1.47±0.15 mCi/kg"
3043319|NCT02271503|Other|Sequence 1|Subject received a single dose of IPX203 180 mg and/or IPX203 270mg in Period 1, a single dose of CD-LD IR in Period 2, and a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 3.
3043320|NCT02271503|Other|Sequence 2|Subject received a single dose of a single dose of CD-LD IR in Period 1, a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 2, and a single dose of IPX203 180 mg and/or IPX203 270mg in Period 3.
3043321|NCT02271503|Other|Sequence 3|Subject received a single dose of a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 1, a single dose of IPX203 180 mg and/or IPX203 270mg in Period 2, and a single dose of CD-LD IR in Period 3.
3043322|NCT02271490|Active Comparator|micoinjection according to classical protocole|incubation of sperm in incubation medium
3043323|NCT02271490|Experimental|incubation in follicular fluid|incubation of sperm in follicular fluid prior to microinjection
3043324|NCT02271477|No Intervention|Wild-Type|The setting is standard spinal anesthesia and corresponds to our first arm of the study, used as the control sample and statistical reference. During the induction phase, the patient is fitted with non-invasive blood pressure monitoring, three-lead ECG, pulse-oximetry and peripheral intravenous device. Data and vital signs are recorded and an infusion of crystalloid (NaCl 0.9% or Ringer's acetate) is given during the procedure until the beginning of the operation. Total amount of fluid is also recorded before and after the spinal anesthesia.
3043575|NCT02269735|Experimental|Part I: MK-2640 (Panel A)|Part I: Lowest dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
3043325|NCT02271477|Experimental|Echocardiography|In addition to the current clinical standard, a Trans-Thoracic Echocardiography is performed before spinal anesthesia, with the aim of assessing the patient's volume status; the exam is performed to assess size and collapsing of the Inferior Vena Cava during breathing cycle. According to different pre-established parameters13, the patient is defined as fluid-responsive or unresponsive. If the patient is not responsive, investigators proceed to spinal anesthesia; otherwise they proceed to administration of crystalloid bolus (500 ml of NaCl 0.9% or Hartmann's solution). The patient may receive another bolus so as to reach a non-responsive pattern for echocardiographic evaluation.
3043326|NCT02271464|Experimental|Maintenance:BEVACIZUMAB|Induction: FOLFOXIRI; Manteinance: Bevacizumab
3043327|NCT02271464|Experimental|Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE|Induction: FOLFOXIRI; Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE(Metronomic Chemotherapy)
3043328|NCT02271451|Experimental|Q collar|subjects wearing the q collar
3043329|NCT02271451|No Intervention|Control|subjects not wearing the Q collar
3043330|NCT02271438|Experimental|Part 1: Ibrutinib 840 milligram (mg)|Participants will receive ibrutinib 840 mg (6*140 mg capsules) + 6 placebo capsules on Day 1 of Part 1, Period 1.
3043331|NCT02271438|Experimental|Part 1: Ibrutinib 1680 mg|Participants will receive ibrutinib 1680 mg (12*140 mg capsules) on Day 1 of Part 1, Period 2.
3043332|NCT02271438|Experimental|Part 2: Treatment A|Participants will receive ibrutinib, 1680 mg (12*140 mg capsules) + 1 moxifloxacin-matching placebo capsule Day 1of Part 2.
3043333|NCT02271438|Experimental|Part 2: Treatment B|Participants will receive ibrutinib, 840 mg (6*140 mg capsules) + 6 ibrutinib-matching placebo capsules + 1 moxifloxacin-matching placebo capsule.
3043334|NCT02271438|Experimental|Part 2: Treatment C|Participants will receive placebo (12 ibrutinib-matching placebo capsules + 1 moxifloxacin-matching placebo capsule) Day 1 of Part 2.
3043335|NCT02271438|Experimental|Part 2: Treatment D|Participants will receive moxifloxacin 400 mg (1 capsule) + 12 ibrutinib-matching placebo capsules Day 1 of Part 2.
3043336|NCT02271425|Experimental|Evacetrapib: Tablet|A single oral dose of evacetrapib tablet
3043337|NCT02271425|Experimental|Evacetrapib: Intravenous|A single intravenous (IV) dose of evacetrapib administered over a 4 hour infusion.
3043338|NCT02271412|Experimental|LY03005|LY03005 40, 80, 120, or 160 mg
3043339|NCT02271412|Placebo Comparator|Placebo|Placebo at 40, 80, 120, or 160 mg
3043340|NCT02271399|Active Comparator|acetylsalicylic acid|aspirin 300mg tablet by mouth, every 24 hours for postoperatively 10 days
3043341|NCT02271399|Experimental|rivaroxaban|xarelto 10mg tablet by mouth, every 24 hours for postoperatively 10 days
3043342|NCT02271386|Experimental|Intervention|Clinicians in the intervention arm will receive the three-part intervention (Supporting Practice for ADHD, or SPA) which includes: education about ADHD management and communication training, collaborative consultation, and performance feedback, for the first 8 months of the study.
3043343|NCT02271386|Other|Control|Clinicians in the control arm will receive no intervention for the first 8 months of the study, then will receive the full SPA intervention for the last 8 months of the study.
3043344|NCT02271373|Experimental|intervention group|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
3043345|NCT02271373|No Intervention|control group|The control school did not have any interventions.
3043346|NCT02271360|Active Comparator|group A|In group A, (Calcium Dobesilate group), 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given from at day of HCG injection and for 21 days.
3043347|NCT02271360|Active Comparator|group B|while in group B (Cabergoline group), 1 tab/day Cabergoline(Dostinex)( 0.5 mg) will be givenat day of HCG injection and for 8 days .
3043348|NCT02271347|Experimental|CMX001|CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
3043349|NCT02271334|Experimental|Treatment T1|One inhalation of 110 mcg A006 DPI. Total 110 mcg
3043350|NCT02271334|Experimental|Treatment T2|One inhalation of 220 mcg A006 DPI. Total 220 mcg.
3043351|NCT02271334|Active Comparator|Treatment R1|One inhalation of 90 mcg Proventil® MDI. Total 90 mcg.
3043352|NCT02271334|Active Comparator|Treatment R2|Two inhalations of 90 mcg Proventil® MDI. Total 180 mcg
3043353|NCT02271321|No Intervention|control group|The control group will receive usual care
3043354|NCT02271321|Experimental|experimental group|The experimental group will receive 20 minute white noise of the ocean and the sound of running water at 16:00 to 17:00 for four weeks periods.
3043355|NCT02271308|No Intervention|Control group|Residents in control group will receive regular activity in nursing homes.
3043356|NCT02271308|Experimental|Experimental group|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
3043357|NCT02271295|Experimental|Enoxaparine|69 Child Pugh B7-C10, cirrhotic patients receiving anticoagulation treatment (daily subcutaneous injection of enoxaparin 4000UI/day) during 24 months
3043358|NCT02271295|No Intervention|Control|69 Child Pugh B7-C10, cirrhotic patients not receiving anticoagulation treatment
3043359|NCT02271282|Experimental|Oral Toremifene/Oral Placebo|"Oral toremifene will be given once on Day 1 and continue daily x10 days. A single combined IV injection of growth hormone releasing hormone (GHRH)/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit.~After at least 3 weeks, subjects will return to receive oral placebo on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit."
3043360|NCT02271282|Experimental|Oral Placebo/Oral Toremifene|"Oral placebo will be given once on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit.~After at least 3 weeks, subjects will return to receive oral toremifene on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit."
3043421|NCT02270853|Other|sleep apnea screening with ApneaLinkTM|This is the only group in the present study. Patients with bronchial carcinoma (or reasonable suspicion) perform sleep screening with ApneaLinkTM at home or during the hospitalization.
3043361|NCT02271269|No Intervention|Usual Care (UC)|"Patients receiving Usual Care for Glaucoma comprising:~Education on effective glaucoma treatment~Routine check-ups with an ophthalmologist and prescription of glaucoma eye drops~Glaucoma counselling [Can be recommended by ophthalmologist for non-adherent patients] covering:~Glaucoma risk factors and symptoms~Management and treatment~Medications and optimal dosage windows~Risks of medication non-adherence~Formulation of a dosing schedule that compliments each patient's lifestyle"
3043362|NCT02271269|Experimental|Value Pricing (VP)|Patient receiving Usual Care for Glaucoma and given the opportunity to receive Value Pricing Subsidies.
3043363|NCT02271256|Experimental|Functional intimate apparel|A tailor-made functional intimate apparel will be provided to patient to wear it 8 hours daily. Monitoring and observation will be provided during the 12-18 months wearing period. Clinical, radiography, self-report and follow-up after completion of the study
3043364|NCT02271243||Subject with suspected MBI|
3043365|NCT02271243||Subjects without suspected MBI|
3043366|NCT02271230|Experimental|Vitamin D and fish oil|2000 IU per day and 1 g per day of fish oil
3043367|NCT02271230|Placebo Comparator|Vitamin D alone|2000 IU Vitamin D and fish oil placebo
3043368|NCT02271230|Experimental|Fish oil (EPA/DHA) alone|1 g per day of fish oil and vitamin D placebo
3043369|NCT02271230|Placebo Comparator|Fish oil and vitamin D placebo|Placebo for both vitamin D and fish oil
3043370|NCT02271217|Placebo Comparator|Placebo|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
3043371|NCT02271217|Active Comparator|dalfampridine-ER 7.5 mg|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
3043372|NCT02271217|Active Comparator|dalfampridine-ER 10mg|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
3043373|NCT02271191|Active Comparator|Nicardipine and Remifentanil|intravenous nicardipine and remifentanil during deliberate hypotension
3043374|NCT02271191|Placebo Comparator|Remifentanil|intravenous remifentanil during deliberate hypotension
3043375|NCT02271178|Experimental|Combined capsule|Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
3043376|NCT02271178|Other|Conventional treatment|Usual therapy
3043377|NCT02271165|Active Comparator|IVIg naive|Patients naïve to IVIg who have active disease responding to corticosteroids or are corticosteroid-dependent, will be also included. Before these patients enter the study, they will receive 3 monthly infusions of IVIg starting with the standard dose of 2gram/kg/month and followed with monthly maintenance of 1 or 2gram/kg according to their response.
3043378|NCT02271165|Active Comparator|non-IVIg naive|Participants already on IVIg will be observed for 12 weeks under their existing IVIg regimen and will undergo measurements of their muscle strength, skin changes, assessments of their daily activities and quality of life (QoL) every 4 weeks at scheduled visits for monthly maintenance IVIg infusions (weeks 0,4,8,12).
3043379|NCT02271152|Experimental|FAST ablation + PVI|FAST mapping and ablation will be performed in addition to PVI
3043380|NCT02271152|Active Comparator|PVI|Pulnonary vein isolation will be performed
3043381|NCT02271126|Experimental|TEG|TEG-driven anticoagulation group: Anticoagulation will be monitored by TEG. Target will be a range of R parameter at Kaolin activated-TEG (R K-TEG) is 16 - 24 seconds; frequency of TEG assays may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol. When TEG value falls well below the desired range an heparin bolus will be administered, when is too high infusion will be stopped for either 30 or 60 minutes.
3043382|NCT02271126|Active Comparator|APTT|APTT-driven anticoagulation group: anticoagulation will be monitored by aPTT. aPTT ratio target is 1.5 - 2.0 as for actual clinical practice; frequency of aPTT measurements may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol. When aPTT value falls well below the desired range an heparin bolus will be administered. When too high, infusion will be stopped for either 30 or 60 minutes.
3043383|NCT02271113|Experimental|GMI-1271|IV GMI-1271
3043384|NCT02271113|Placebo Comparator|Placebo|IV Placebo
3043385|NCT02271113|Active Comparator|Enoxaparin Sodium (Lovenox®)|SC Lovenox®
3043386|NCT02271100|Placebo Comparator|palpation guidance|placement of spinal or combined spinal epidural needle using palpation to guide entry position
3043387|NCT02271100|Active Comparator|ultrasound guidance|placement of spinal or combined spinal epidural using ultrasound to guide entry position
3043388|NCT02271074|No Intervention|Standard of Care|The role of this arm is to provide a baseline measure that can be used to assess the effectiveness of the combination interventions in improving the proportion of individuals entering care within 3 months. Participants in this arm only receive standard post-test counselling after they are issued with a positive HIV result. They are counselled on possible emotional resources, and given information on how to reduce risk of HIV transmission, ongoing positive living, nutrition and healthy lifestyles. These clients are given referral letters and referred to health facilities of their choice that offer HIV care/treatment. They are then followed up at the designated study time points to ascertain entry into care.
3043389|NCT02271074|Experimental|Point of care CD4 testing|Participants in this arm will receive point of care (POC) cluster differentiation 4 (CD4) testing using the PIMA™ CD4 test system.
3043390|NCT02271074|Experimental|Care facilitation|Participants receive a combination of POC CD4 testing and care facilitation.
3043391|NCT02271074|Experimental|Transport support|Participants receive a combination of POC CD4 testing and transport support.
3043392|NCT02271061|Experimental|Kinesio Tape|Taping method will be performed in supine position .The taping technique will be started at tibial tuberosity to medial and lateral epicondyles of the femur. The tape will be cut in I shape with 30 cm. The back paper of tape will be removed from the center of tape and both end of the back paper will be placed at each end of tape. Center of the tape will be placed on the tibial tuberosity with no tension. Participants' knee will be bend approximately 20 - 30 degrees. The tape will be pulled at 1/3 of each end with 75% of available tension along the medial and lateral collateral ligaments and the tibia will be pushed to the back. The end of the tape will be placed with no tension toward the medial and lateral aspects of the thigh .
3043394|NCT02271048|Experimental|Group I|"The raters in this group one firstly review ultrasound images numbered from one to 50 using LCD monitor of ultrasound machine and after mandatory rests of 20 minutes, review the remaining ultrasound examinations numbered from 51 to 100 using iPhone display with CubeView at their first visit.(Remote ultrasonography interpretation using the smartphone)~They visited twice with an interval of four weeks and reviewed the ultrasound images using revered devices at each session."
3043395|NCT02271048|Experimental|Group II|"The raters in this group II firstly review the ultrasound images numbered from one to 50 using iPhone with CubeView (Remote ultrasonography interpretation using the smartphone) and 51 to 100 with the LCD monitor.~They visited twice with an interval of four weeks and reviewed the ultrasound images using revered devices at each session."
3043396|NCT02271035|Active Comparator|Deflux|In each patient, Deflux will be injected into one of the ureteral orifices using the the HIT technique.
3043397|NCT02271035|Active Comparator|Vantris|Vantris will be injected into the other ureteral orifice using the same technique and the same amount of implant.
3043398|NCT02271022||Cohort 1|"Patients (≥18 years of age) with a working diagnosis of NSTEMI and treatment with an OAP agent (ticagrelor, clopidogrel, or prasugrel) either in the ED, or in any case within the timeframe that emergency physicians consider to be upstream-within the first 72 hours of care and at least 4 hours before diagnostic angiography. In addition, only those patients who undergo a diagnostic coronary angiography within 72 hours of ED arrival will be eligible for UPSTREAM."
3043399|NCT02271009|Placebo Comparator|Placebo without Al(OH)3|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:~First three SC injections at weekly intervals.~Fourth SC injection two weeks after the third injection.~Fifth SC injection four weeks after the fourth injection."
3043400|NCT02271009|Active Comparator|AllerT (10 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:~First three SC injections at weekly intervals.~Fourth SC injection two weeks after the third injection.~Fifth SC injection four weeks after the fourth injection."
3043401|NCT02271009|Active Comparator|AllerT (25 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:~First three SC injections at weekly intervals.~Fourth SC injection two weeks after the third injection.~Fifth SC injection four weeks after the fourth injection."
3043402|NCT02271009|Active Comparator|AllerT (50 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:~First three SC injections at weekly intervals.~Fourth SC injection two weeks after the third injection.~Fifth SC injection four weeks after the fourth injection."
3043403|NCT02270996||NO Antimicrobial Stewardship Program|Prospective cohort of children who undergo appendectomy for acute appendicitis (perforated and non-perforated) BEFORE the implementation of the Antimicrobial Stewardship Program.
3043404|NCT02270996||WITH Antimicrobial Stewardship Program|Prospective cohort of children who undergo appendectomy for acute appendicitis (perforated and non-perforated) WITH the implementation of the Antimicrobial Stewardship Program.
3043405|NCT02270983|Experimental|Linaclotide 145 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
3043406|NCT02270983|Experimental|Linaclotide 290 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
3043407|NCT02270983|Experimental|Placebo|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
3043408|NCT02270970|Active Comparator|Responders to Belimumab|This Arm is defined as patients who complete 6 months of belimumab without and meet the primary endpoint
3043409|NCT02270970|Active Comparator|Non Responders to Belimumab|This Arm is defined as patients who complete 6 months of study and do not meet the primary endpoint
3043410|NCT02270957|Active Comparator|Abatacept|Patients receive Abatacept 125 mg subcutaneously weekly for six months. An optional continuation up until 12 months is allowed. Background immune suppressants are withdrawn at the beginning of the study and the option of depomedrol up to 320 mg total (in divided doses) is allowed at any time up through the visit 2 months after study medication is started. After this additional rescue is allowed with any standard of care treatment and/or open label abatacept (since patients are blinded) but this additional rescue will define non-response in the primary endpoint at six months.
3043411|NCT02270957|Placebo Comparator|Placebo|Patients receive Abatacept 125 mg subcutaneously weekly for six months. An optional continuation up until 12 months is allowed. Background immune suppressants are withdrawn at the beginning of the study and the option of depomedrol up to 320 mg total (in divided doses) is allowed at any time up through the visit 2 months after study medication is started. After this additional rescue is allowed with any standard of care treatment and/or open label abatacept (since patients are blinded) but this additional rescue will define non-response in the primary endpoint at six months.
3043412|NCT02270944|Experimental|Liquid GBS trivalent vaccine|Healthy non-pregnant women aged 18-40 years that received a single dose of liquid GBS trivalent vaccine
3043413|NCT02270944|Active Comparator|Lyophilized GBS trivalent vaccine|Healthy non-pregnant women aged 18-40 years that received a single dose of lyophilized GBS trivalent vaccine
3043414|NCT02270918|Active Comparator|Apixaban with Kcentra|Oral apixaban will be administered to steady state in healthy volunteers followed by a single infusion of prothrombin complex concentrate Kcentra at 25 units/Kg
3043415|NCT02270918|Placebo Comparator|Apixaban with placebo|Oral apixaban will be administered to steady state in healthy volunteers followed by a single infusion of saline
3043416|NCT02270905|Experimental|dCELL® Meniscus|
3043417|NCT02270892|Active Comparator|Group A|Left side Ulthera treatment
3043418|NCT02270892|Active Comparator|Group B|Right side Ulthera treatment
3043419|NCT02270879||Main group|Patients having performed bilateral consecutive cataract surgery between 1st October 2012 and 24th April 2014 in a single ophthalmological center (Centro Hospitalar Baixo Vouga, Portugal).
3043420|NCT02270866|Experimental|TNM(trademark) - thermoneuromodulation|TNM (thermoneuromodulation device). A standardized active thermal neuromodulation waveform will be used for all patients. The device is noninvasive and does not use electrical stimulation.
3043423|NCT02270840||Only ICD|"In the ICD arm, choosing single or dual chamber device is based upon the investigator's discretion.~Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only)."
3043424|NCT02270814|Experimental|CACTUX: nab-paclitaxel, cisplatin (or carboplatin), cetuximab|"Up to 6 cycles of CACTUX may be given. The CACTUX regimen consists of:~nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle followed by~cisplatin given intravenously over 60 minutes on an outpatient basis OR carboplatin AUC5 given intravenously over 30 minutes on an outpatient basis on Day 1 of each 21-day cycle followed by~cetuximab given intravenously on an outpatient basis of Days 1, 8, and 15 of each 21-day cycle~Cisplatin is preferred but carboplatin may be given if the patient has a prior intolerance to cisplatin or at the discretion of the treating physician.~After the completion of 6 cycles of CACTUX, maintenance therapy will be given and consists of:~nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1 and 8 of each 21-day cycle~cetuximab given intravenously on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle"
3043425|NCT02270801|Experimental|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
3043426|NCT02270788|Experimental|Study Participants|"All participants who consent and are enrolled on the study.~Interventions: Crenolanib, sorafenib, triple intrathecal chemotherapy (methotrexate, hydrocortisone and cytarabine with leucovorin)."
3043427|NCT02270775||Fibromyalgia Patients|"The central Sensitization questionnaire will be filled in by each patients included.~After One week, patients will filled it the questionnaire again to study the reliability."
3043428|NCT02270775||Ankle sprain Patients|The central Sensitization questionnaire will be filled in by each patients included.
3043429|NCT02270775||Healthy Volunteers|"The central Sensitization questionnaire will be filled in by each volunteer included.~After One week, volunteers will filled it the questionnaire again to study the reliability."
3043430|NCT02270762|Experimental|1) Rest in bed|First evaluation of EIT with patient in bed at 30º of head inclination during 5 minutes.
3043431|NCT02270762|Experimental|2) Passive Verticalization|Second evaluation of EIT with patient in tilt table at 60º of verticalization during 10 minutes.
3043432|NCT02270762|Experimental|3) Rest in bed|Last evaluation of EIT with patient in bed at 30º of head inclination during 20 minutes.
3043433|NCT02270749|Active Comparator|hydroxocobalamin injection|25 patients receive the standard treatment of a vitamin B12 deficiency: hydroxocobalamin injection
3043434|NCT02270749|Active Comparator|FitForMe vitamin B12 tablets|25 patients receive a daily dose vitamine B12 tablets
3043435|NCT02270736|Experimental|IncobotulinumtoxinA (Xeomin)|"Main and extension period: subjects to receive on average 2 units incobotulinumtoxinA per kg body weight per treatment cycle (subjects with a body weight ≥ 30 kg to receive a fixed total dose of 75 U per cycle).~Mode of administration: Four injections at the beginning of each treatment cycle (parotid and submandibular glands, bilateral)"
3043436|NCT02270736|Placebo Comparator|Placebo|"For subjects aged 6-17 years only.~Main period (1 treatment cycle): Subjects to receive placebo injection.~Extension period (3 treatment cycles): Subjects to receive on average 2 Units IncobotulinumtoxinA per kg body weight per treatment cycle (subjects with a body weight ≥ 30 kg to receive a fixed total dose of 75 U per cycle).~Mode of administration: Four injections at the beginning of each treatment cycle (parotid and submandibular glands, bilateral)"
3043437|NCT02270723|Active Comparator|"Human Albumin  Behring"|Infusion of 5% Human Albumine, maximal 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
3043438|NCT02270723|Placebo Comparator|Lactated Ringer|Infusion of Lactated Ringer solution 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
3043439|NCT02270710||Healthy Subjects|Overall in good health Provide informed consent Male and females, age 18 years and older Nonsmokers
3043440|NCT02270710||SLE Subjects|Enrolled by Hospital for Special Surgery Diagnosed with Systemic Lupus Erythematosus
3043441|NCT02270697||Regular Diagnosis|Difficult in regular diagnosis specimens, assistance with array.
3043442|NCT02270684|Experimental|Device|Participants in this arm will receive the StepRite device. They will have a remote visit with their Physical Therapist in place of one in-person visit per week during the outpatient phase of their treatment
3043443|NCT02270684|No Intervention|Usual and customary care|Participants in this arm will undergo usual care and will not be issued with the StepRite device
3043444|NCT02270671|Placebo Comparator|Placebo|The placebo protocol consists of 160 trials (120 angry-neutral face pair and 40 neutral-neutral face pair presentations). In this condition, angry-face location, probe location and actor are fully counterbalanced in presentation. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
3043445|NCT02270671|Experimental|Intervention|The attention bias modification training (ABMT) protocol consists of 160 trials (120 angry-neutral face pair presentations and 40 neutral-neutral face pair presentations). In the ABM condition, the target-probe appears at the neutral-face locations in all angry-neutral trials. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
3043446|NCT02270658|Experimental|Continuous positive airway pressure|Continuous positive airway pressure therapy (CPAP)
3043447|NCT02270658|Placebo Comparator|Nasal strips|Nasal strips applied to the outside surface of the nose with adhesive.
3043448|NCT02270645|Experimental|Treatment: 595/1064 multiplex laser|"Subjects in the treatment arm will receive 3 treatments using the 595/1064 multiplex laser spaced by a four week interval (+/- 3 days), administered in an outpatient clinic setting. If a subject in the treatment arm has multiple BCCs satisfying inclusion criteria, all BCCs will be treated.~Four weeks (+/- 3 days) after the last treatment (Day 84) both treatment and control patients will be assessed for final clinical appearance, measurement, and evaluation of the lesion by a dermatologist.~Subjects will also undergo deep excisional biopsy encompassing the entire lesion to determine residual tumor cell presence. If histologic examination of the tissue reveals residual BCC, then the subject will receive standard of treatment."
3043449|NCT02270645|No Intervention|Control|"Subjects in the control arm will receive 3 regular study visits spaced 4 weeks (+/- 3 days) apart. If a subject in the control arm has multiple BCCs satisfying inclusion criteria, all BCCs will not be treated.~Four weeks (+/- 3 days) after the last (Day 84) both treatment and control patients will be assessed for final clinical appearance, measurement, and evaluation of the lesion by a dermatologist.~Subjects will also undergo deep excisional biopsy encompassing the entire lesion to determine residual tumor cell presence. If histologic examination of the tissue reveals residual BCC, then the subject will receive standard of treatment."
3043450|NCT02270632|Placebo Comparator|Arm 1|Placebo
3043451|NCT02270632|Experimental|Arm 2|F8IL10, 30 μg/kg
3043452|NCT02270632|Experimental|Arm 3|F8IL10, 160 μg/kg
3043453|NCT02270619|Placebo Comparator|Uninterrupted sleep & placebo|Uninterrupted sleep followed by placebo
3043454|NCT02270619|Experimental|Uninterrupted sleep & endotoxin|Uninterrupted sleep followed by endotoxin 0.8 ng/kg of body weight IV bolus
3043455|NCT02270619|Experimental|Partial sleep deprivation & placebo|Partial sleep deprivation followed by placebo
3043456|NCT02270619|Experimental|Partial sleep deprivation & endotoxin|Partial sleep deprivation followed by endotoxin 0.8 ng/kg of body weight IV bolus
3043457|NCT02270606|Experimental|Treatment(IMRT,fluorouracil,chemotherapy,surgery)|"CHEMORADIATION:Patients undergo Intensity Modulated Radiation Therapy (IMRT) once a day over 5 days for total of 5 fractions and concurrently receive fluorouracil IV continuously over 96 hours.~PREOPERATIVE CHEMOTHERAPY:Within 2 weeks of completing chemoradiation, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV as a push followed by IV continuously over 46 hours on day 1.Treatment repeats every 14 days for 4 courses in absence of disease progression or unacceptable toxicity.~SURGERY:Within 4-8 weeks of completing preoperative chemotherapy, patients undergo total mesorectal excision as therapeutic conventional surgery.~POSTOPERATIVE CHEMOTHERAPY:Within 4-8 weeks after surgery, patients receive oxaliplatin, leucovorin calcium, and fluorouracil(preoperative chemotherapy).Treatment repeats every 14 days for 6 courses in absence of disease progression or unacceptable toxicity."
3043458|NCT02270593||Placenta previa|first; maternal serum, fetal membranes (placenta) and maternal myometrial samples will be investigated for ADAMTS, Proteoglycans and oxidative/antioxidative enzyme status levels in patients with placental invasion anomalies Placenta Previa totalis by ELISA, western blot, immunohystochemistry and PCR (polymerase chain reaction).
3043459|NCT02270580|Experimental|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
3043460|NCT02270580|Active Comparator|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
3043461|NCT02270554|Experimental|Reinforced staple|Endo GIA Reinforced Reload with Tri-Staple technology
3043462|NCT02270541|No Intervention|Control|Standard pre-hospital emergency care by the Paramedic Intervention Team, in accordance with their standing operating procedures.
3043463|NCT02270541|Experimental|Telemedicine|In-ambulance teleconsultation by a stroke expert aiming to support the Paramedic Intervention Team by focusing on patient identification, obtaining homeostasis (optimal control of blood pressure, blood oxygenation, temperature, heart rate and rhythm, glycemia), assessment of the patient's neurological status, stroke diagnosis, hospital notification, and patient selection for specific stroke treatment.
3043464|NCT02270528|Experimental|HIT1|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt, prior to the WCST, this group will perform a warm-up and the high intensity interval exercise. The second attempt, prior to the WCST, this group will perform a warm-up and 5-minute stationary period. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
3043465|NCT02270528|Experimental|HIT2|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt, prior to the WCST, this group will perform a warm-up and a 5-minute stationary period. The second attempt, prior to the WCST, this group will perform a warm-up and the high intensity interval exercise. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
3043466|NCT02270528|Other|CON|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt and second attempt, prior to the WCST, this group will participate in a 15-minute stationary period. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
3043467|NCT02270515|Experimental|PCMH-KD dialysis care|Dialysis care team is expanded to include a primary care doctor, nurse coordinator, community health worker, and pharmacist. Enrolled patients are observed for an initial baseline period receiving care under the usual dialysis care model called the 'usual dialysis care phase'.
3043468|NCT02270502||Adult patients on the SICU|Adult patients on the surgical intensive care unit (SICU), within 72 hours of admission to the SICU and until SICU discharge. Ultrasound Philips CX50, Frailty Index questionnaire and muscle strength tests.
3043469|NCT02270489|Experimental|AFFITOPE® PD01A + Adjuvant|"4 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
3043470|NCT02270489|Experimental|AFFITOPE® PD03A + Adjuvant|"4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
3043471|NCT02270489|Placebo Comparator|Adjuvant without active component|"4 injections of Placebo once every 4 weeks~1 administration 36 weeks after first injection"
3043472|NCT02270476||Early diagnosed (ED)|Children diagnosed with CF in the first 4 months of life.
3043473|NCT02270476||Late diagnosed (LD)|Children diagnosed with CF after the first 4 months of life.
3043474|NCT02270463|Experimental|SL-401|
3043475|NCT02270450|Experimental|Arm I (randomized to surgery)|Patients undergo therapeutic conventional surgery (abdominal) as defined by the treating physician.
3043476|NCT02270450|Experimental|Arm II (randomized to non-surgical management)|Patients are offered gastrointestinal complications management/prevention (non-surgical management) as determined by the treating physician.
3043477|NCT02270450|Experimental|Arm III (no randomization, surgery)|Patients undergo therapeutic conventional surgery (abdominal) as defined by the treating physician as in Arm I.
3043576|NCT02269735|Experimental|Part I: MK-2640 (Panel B)|Part I: Low dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
3043478|NCT02270450|Experimental|Arm IV (no randomization, non-surgical management)|Patients are offered gastrointestinal complications management/prevention (non-surgical management) as determined by the treating physician as in Arm II.
3043479|NCT02270437|Experimental|cocktail analgesia|The local infiltration mixture of ropivacaine, fentanyl, adrenaline is used intra-articularly during operation. The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
3043480|NCT02270437|No Intervention|no cocktail injection|The patients in the no cocktail injection group received PCIA morphine postoperatively.
3043481|NCT02270424|Experimental|Conventional medicine+ placebo TCM|Patients in this group will be given conventional medicine, Salmeterol / fluticasone based on the classes of medications recommended by 2011 GOLD and Chinese Treatment Guidelines for COPD, and three placebo TCM treatment, which are which are placebo Bufeijianpi granule, placebo Bufeiyishen granule and placebo Yiqizishen granule corresponding to the three traditional Chinese syndromes in sequence, which are syndrome of deficiency of pulmono-splenic qi, syndrome of insufficiency of qi of the lung and kidney, syndrome of insufficiency of qi and yin of the lung and kidney.
3043482|NCT02270424|Experimental|conventional medicine+ TCM|Patients in this group will receive Salmeterol / fluticasone based on the classes of medications recommended by 2011 GOLD and Chinese Treatment Guidelines for COPD, and three types of TCM treatment, which are Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule. A herbal extract twice daily for 52 weeks for lower dosage. The three granules are corresponding to the three traditional Chinese syndromes in sequence, which are syndrome of deficiency of pulmono-splenic qi, syndrome of insufficiency of qi of the lung and kidney, syndrome of insufficiency of qi and yin of the lung and kidney.
3043483|NCT02270411||Healthy Subjects|
3043484|NCT02270411||Atopic Dermatitis|Patient has a history of atopic dermatitis for at least 6 months.
3043485|NCT02270411||Acne Rosacea|Patient has a history of acne rosacea for at least 6 months.
3043486|NCT02270411||Acne Vulgaris|Patient has a history of acne vulgaris for at least 6 months.
3043487|NCT02270398|Experimental|Dual-task training group|Participants in this group will receive dual-task balance and gait training for half hour and relaxation exercise for another half hour in each session. There will be 3 sessions per week for 8 weeks.
3043488|NCT02270398|Active Comparator|Single-task training group|This group of subjects will participate in single-task gait and balance activities for half hour and single-task cognitive training in sitting position for another half hour in each session. There will be 3 sessions per week for 8 weeks.
3043489|NCT02270398|Active Comparator|Flexibility and strength training group|The subjects in this group will engage in flexibility exercises and upper limb strengthening exercises for one hour in each session. There will be 3 sessions per week for 8 weeks.
3043490|NCT02270385|Experimental|Experimental group|The experimental group will be implemented a 16-week PU prevention programme. The PU prevention programme includes an intensive training on knowledge and skills ono PU prevention and also a PU prevention protocol. The purpose of the programme is to equip care staff with PU knowledge and skills and to guide especially health workers and personal care workers in PU prevention.
3043491|NCT02270385|Other|control group|The control group will be provided with the usual PU prevention care
3043492|NCT02270372|Experimental|Drug Combination|The drug combination of ONT-10 and varilumab
3043493|NCT02270359|Other|MI without obstructive CAD|MI without obstructive CAD, with OCT and CMR imaging
3043494|NCT02270346|Active Comparator|Treatment group|Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device.
3043495|NCT02270346|Sham Comparator|Control group|Sham: Control group received sham inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device .
3043496|NCT02270333|Active Comparator|Treatment group|Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device .
3043497|NCT02270333|Sham Comparator|Control group|Sham: Control group received sham inspiratory muscle training using POWERbreathe Classic threshold loading device .
3043498|NCT02270320|No Intervention|Control|Control group will receive a telephone consultation once every two weeks for 12 weeks.
3043499|NCT02270320|Active Comparator|Physical activity|Experimental group will receive a 60-minute 24 forms Yang-style Tai Chi Chuan exercise program, three times per week for 12 weeks.
3043500|NCT02270307|Experimental|MSC+CY|Cyclophosphamide 50 mg/kg/day at +3, +4 day once daily after BMT Mesenchymal stromal cells 1*10^6/kg at day of recovery
3043501|NCT02270294|Experimental|Thai traditional massage|
3043502|NCT02270294|Sham Comparator|No massage|
3043503|NCT02270281|Experimental|Dexmedetomidine|Drug: Dexmedetomidine CIF 0.3 and 0.6 mcg/kg/h Goal of sedation: Richmonad agitation-sedation scale 0 to -2 Other Name: Precedex
3043504|NCT02270268|Experimental|pectin|a kind of soluble dietary fiber
3043505|NCT02270268|Placebo Comparator|Placebo|maltodextrin
3043506|NCT02270255|Sham Comparator|Control group|Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.
3043507|NCT02270255|Experimental|Sup Hypogastric Nerve block group|Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.
3043508|NCT02270242|Active Comparator|Aspirin + Ticagrelor|enteric coated aspirin 81mg daily p.o. for 12 months and ticagrelor 90mg tablet bid for 15 months
3043509|NCT02270242|Placebo Comparator|Placebo + Ticagrelor|placebo pill daily p.o. for 12 months - match for enteric coated aspirin 81mg and ticagrelor 90mg tablet bid for 15 months
3043510|NCT02270229||Healthcare providers|
3043511|NCT02270229||PD patients|
3043512|NCT02270229||Primary caregivers of the PD patients|
3043513|NCT02270229||Laboratory personnel|
3043514|NCT02270216|Active Comparator|elderly with isolated systolic hypertension|over 60 years of age with essential isolated systolic hypertension (stage I-II base on recommendation of JNC-VII) for the hypertension group. Good communication, independent physical activity. The healthy subject should be non-smokers, free of any signs or symptoms of disease as revealed by medical history
3043708|NCT02268942|Experimental|HeartWare HVAD via Thoracotomy|HeartWare HVAD implanted via thoracotomy
3043515|NCT02270216|Active Comparator|healthy elderly|over 60 years of age with normal blood pressure in the healthy group. Good communication, independent physical activity. The healthy subject should be non-smokers, free of any signs or symptoms of disease as revealed by medical history
3043516|NCT02270190|Other|tenesmus patients|Percutaneous Tibial Nerve Stimulation (PTNS) will be applied to all patients in the study
3043517|NCT02270177|No Intervention|Regular consultation|Regular headache consultations
3043518|NCT02270177|Other|Videoconsultation|Headache consultations through telemedicine technology
3043519|NCT02270164|Experimental|Artichoke Leaf Extract|Pycrinil® 100 mg/flaxseed oil 380 mg liquid filled hard plant based capsules (Licaps®) twice daily with food
3043520|NCT02270164|Placebo Comparator|Placebo|Placebo/flaxseed oil 380 mg liquid filled hard plant based capsules (Licaps®) twice daily with food
3043521|NCT02270151|Active Comparator|MyDiagnostick|Everyone aged 65 years or over, who visits the GP practice will be screened for AF with the MyDiagnostick. When the device indicates a positive result, the single lead ECG will be assessed to confirm/reject the diagnosis. Every new case of diagnosed AF will be evaluated for further treatment by the general practitioner.
3043522|NCT02270151|No Intervention|Control|Control arm will perform care as usual with selective screening by feeling the pulse.
3043523|NCT02270138|Experimental|Movement-to-music|Three movement-to-music video programs will be used by the participants. First and second videos last about 10 minutes including two songs and their movement preparation. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
3043524|NCT02270138|No Intervention|No movement-to-music|Another group will not receive movement-to-music video during intervention. However, their physical activity will be objectively measured as well.
3043525|NCT02270125||Adult patients with chronic rhino sinusitis|Group of adult patients indicated for mucotomy due to chronic hypertrophic rhinosinusitis, with or without polyposis
3043526|NCT02270125||Stillborn children|Control group of stillborn children whose nasal mucosa was not exposed to airborne particles
3043527|NCT02270112||Paroxysmal Af|No Intervention is planned. All patients receive a 5 Minute ECG and have their pulse recordes by an iPhone.
3043528|NCT02270099||Subjects with suspected HSV Lesions|
3043529|NCT02270086||Sarcoma patient|Patient diagnosed with soft tissue sarcoma and receiving preoperative radiotherapy.
3043530|NCT02270073|Experimental|TAU + mindfulness intervention|"In the first five minutes of each of 25 therapy sessions (duration: about 25 weeks), both patient and therapist perform together the brief intervention with mindfulness elements. Participants sit upright in their chairs in a comfortable position at a distance about one meter from the audio recorder. The text is standardized and spoken by Dr. Thomas Heidenreich. During the exercise, participants are instructed to observe their breathing and body sensations. After completion of the mindfulness intervention, the regular therapy session begins.~Intervention: Cognitive behavior therapy of trainee therapists"
3043531|NCT02270073|Active Comparator|TAU + progressive muscle relaxation|"In the first five minutes of each of 25 therapy sessions (duration: about 25 weeks), both patient and therapist perform together a short version of progressive muscle relaxation (PMR). Both patient and therapist sit upright in their chairs in a comfortable position at a distance about one meter from the audio recorder. The PMR text is standardized and spoken by Dr. Thomas Heidenreich. Wording is as similar as possible to the mindfulness interventions.During the exercise, participants are instructed to tense and relax arms, face, body and legs. After completion of PMR, the regular therapy session begins.~Intervention: Cognitive behavior therapy of trainee therapists"
3043532|NCT02270073|Other|Treatment as usual|"No specific intervention is conducted at the beginning of therapy sessions. Standard cognitive behavior therapy treatment, based on the individualized case conception of the trainee therapist, is conducted during the whole treatment sessions.~Intervention: Cognitive behavior therapy of trainee therapists"
3043533|NCT02270060|Experimental|Music Therapy Group|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
3043534|NCT02270060|Active Comparator|Music Listening Group|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
3043535|NCT02270060|No Intervention|Control Group|Patient receives standard care and waits in treatment room/bay for twenty minutes.
3043536|NCT02270047|Active Comparator|A|Orange nectar with NAXUS fibre, 5g/100mL
3043537|NCT02270047|Placebo Comparator|B|Orange nectar
3043538|NCT02270034|Experimental|Cohort crizotinib|Combination of crizotinib with temozolomide and radiotherapy following Stupp regime
3043539|NCT02270021|Experimental|Mobile Application (APP)|Mobile phone application for providers.
3043540|NCT02270021|Experimental|Patient-Centered Approach (PCA) + APP|Patient educational tool; plus the Mobile phone application for providers.
3043541|NCT02270021|No Intervention|Comparison Group|Clinics in this group are those NOT randomized - receiving no intervention. These clinics will be chosen at random for comparison using Family PACT claims data.
3043542|NCT02270008|Active Comparator|Pelvic floor training|The intervention group will undergo an in-person standardized training session by a trained nurse practitioner. The intervention is the pelvic floor training session. They will then be asked to continue muscle training at home at regular intervals and asked to log their exercises on a standardized exercise diary that is provided to them.
3043543|NCT02270008|No Intervention|Literature-only group|The literature-only group will receive a pamphlet with instructions for pelvic floor muscle exercises; however, no in-person training will be administered.
3043544|NCT02269995||E7040|
3043545|NCT02269982||men with mCRPC prior to enzalutamide/abiraterone|
3043546|NCT02269969|Experimental|Once daily aminoglycoside|Once daily dosing of Tobramycin
3043547|NCT02269956|Active Comparator|Intervention|The 2 NH's not used in the focus groups will receive the intervention, a 12-week feasibility study. At baseline, weeks 6 and 12, dementia feeding skills knowledge and self-efficacy tests will be administered, meal observations of nursing staff assisting PWD with meals will be video recorded for 3 meals over 2 days at baseline and again at week 6 and 12, and a medical record review will be conducted. After baseline data is collected, the training program will be delivered in 5 weekly modules with group coaching sessions completed the same week.
3043709|NCT02268929|Other|Control Group|Patients treated by usual customary medical practice (Usual Care)
3043548|NCT02269956|No Intervention|Focus Groups|Year 1 focus groups will aim to identify how nursing staff feel about usual interventions for feeding behaviors of PWD and staff responses when a PWD displays difficult eating behaviors. Year 2 focus groups will evaluate the revised dementia feeding skills training program, the coaching interventions, and case scenarios, and indicate how realistic and compatible the intervention is with their work environment.
3043549|NCT02269943|Experimental|CC-486|CC-486 will be administered orally every day on Days 1-14 of a 21 day cycle at a dose of 300 mg. The first 6 participants of Asian-Pacific ethnicity will receive a starting dose of 200 mg. If there are no safety concerns, the 300 mg dose will be administered to all subsequent participants of Asian-Pacific ethnicity.
3043550|NCT02269930|Experimental|Group 1|Treatment Sequence 1: Single subcutaneous (SC) dose of BIIB017 on Day 1; and SC doses of Rebif on Days 29, 32, 34, 36, 39, and 41 Treatment Sequence 2: SC doses of Rebif on Days 1, 4, 6, 8, 11, and 13; and a single SC dose of BIIB017 on Day 29
3043551|NCT02269930|Experimental|Group 2|Treatment Sequence 1: SC doses of Rebif on Days 1, 4, 6, 8, 11, and 13; and a single SC dose of BIIB017 on Day 29 Treatment Sequence 2: Single subcutaneous (SC) dose of BIIB017 on Day 1; and SC doses of Rebif on Days 29, 32, 34, 36, 39, and 41
3043552|NCT02269917|Experimental|Experimental Treatment Regimen|Participants will receive a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily, up to Week 48. After Week 48, all participants will continue to receive the D/C/F/TAF tablet in a 48 week extension phase (up to Week 96).
3043553|NCT02269917|Active Comparator|Current Treatment Regimen|Participants will receive a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) up to Week 52. After Week 52, all participants will receive the D/C/F/TAF tablet in a 44 week extension phase (up to Week 96).
3043554|NCT02269904|Active Comparator|Fluorouracil Implants and Xelox regimes|"Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.~Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished."
3043555|NCT02269904|Active Comparator|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
3043556|NCT02269891|Experimental|Nu Femme|Two capsules (500mg total) taken once daily in the morning after breakfast for 24 weeks
3043557|NCT02269891|Placebo Comparator|Placebo|Two capsules taken once daily in the morning after breakfast for 24 weeks
3043558|NCT02269878||people with MPM with Thymine/Thymine,Thymine/cytosine genotype|according to Single nucleotide polymorphism analysis of rs 763110, people have one of the following genotypes, Thymine/Thymine,Thymine/Cytosine,Cytosine/Cytosine. we will assign Thymine/Thymine, Thymine/Cytosine to group one and Cytosine/Cytosine to group two. for rs 1800682 people will have one of the following genotypes Adenine/Adenine, Adenine/Guanine or Guanine/Guanine.
3043559|NCT02269878||people with MPM, Cytosine/Cytosine genotype|according to Single nucleotide polymorphism analysis of rs 763110, people have one of the following genotypes, Thymine/Thymine,Thymine/Cytosine,Cytosine/Cytosine. we will assign Thymine/Thymine, Thymine/Cytosine to group one and Cytosine/Cytosine to group two. for rs 1800682 people will have one of the following genotypes Adenine/Adenine, Adenine/Guanine or Guanine/Guanine.
3043560|NCT02269852|Experimental|trivalent seasonal influenza vaccine|"Northern hemisphere 2013-2014 trivalent seasonal influenza vaccine~60 infants: two-dose regimen with a 28-day interval;~60 adults: single-dose regimen;~60 seniors: single-dose regimen;"
3043561|NCT02269839|Active Comparator|theta-burst rTMS|Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
3043562|NCT02269839|Sham Comparator|Control arm|The control (sham) stimulation will consist of stimulating with the rTMS coil held at right angles to the participants' head. This will result in no active stimulation of brain tissue but would feel similar to the patient. Each treatment session will therefore last approximately 20 minutes.
3043563|NCT02269826|Experimental|Vagisan® Moisturising Cream|non-hormonal vaginal cream for the treatment of vulvovaginal dryness
3043564|NCT02269826|Active Comparator|Gynomunal® vaginal gel|non-hormonal gel
3043565|NCT02269813||ET/GOOD|Endocrine therapy only.
3043566|NCT02269813||CT/POOR|Chemoendocrine therapy according to national guidelines.
3043567|NCT02269800|Experimental|Benzalkonium chloride solution|Tid, for 7 days.
3043568|NCT02269800|Active Comparator|Normal saline|Tid, for 7 days.
3043569|NCT02269787|Experimental|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one 15-minute telephone call per week for 12 weeks.
3043570|NCT02269787|No Intervention|Usual Care|Patients in the usual care condition will receive the care they would receive in the absence of a research project.
3043571|NCT02269774|Other|Pulmonary vein isolation|Intra-thoracic pressure swings induced by breathing manoeuvres during standard catheter-ablation procedure. Catheter-based electrical mapping and pressure in the left atrium and pulmonary veins during standard catheter-ablation procedure. Only patients with an apnea-hypopnea index > 5/h and documented premature atrial beats during the Mueller manoeuvre will be eligible for the catheter-based electrical mapping. Follow-up after 1 year for atrial fibrillation recurrence.
3043572|NCT02269774|No Intervention|No intevention|Intra-thoracic pressure swings induced by breathing manoeuvres during ECG-monitoring. Only patients with an apnea-hypopnea index < 5/h and no premature atrial beats during the Mueller manoeuvre will be assigned to the no intervention arm.
3043573|NCT02269748|Experimental|Root coverage with Tunnel (TT)|The tunnel technique with subepithelial connective tissue graft (TT+SeCTG) will be utilized to cover the denude root surface
3043574|NCT02269748|Active Comparator|Coronally advanced flap (CAF+SeCTG)|The Coronally advanced flap with subepithelial connective tissue graft (CAF+SeCTG) will be utilized to cover the denude root surface
3068476|NCT02104817|Active Comparator|Corn oil|Corn oil + Statin
3043577|NCT02269735|Experimental|Part I: MK-2640 (Panel C)|Part I: Medium-low dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
3043578|NCT02269735|Experimental|Part I: MK-2640 (Panel D)|Part I: Medium dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
3043579|NCT02269735|Experimental|Part I: MK-2640 (Panel E)|Part I: Medium-high dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
3043580|NCT02269735|Experimental|Part I: MK-2640 (Panel F)|Part I: High dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
3043581|NCT02269735|Experimental|Part I: MK-2640 (Panel G)|Part 1: Highest dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
3043582|NCT02269735|Experimental|Part II: MK-2640 followed by RHI|Part II: MK-2640 infusion and dextrose infusion for 9 hours during Period 1 of Part II followed by a 7-day wash-out period followed by RHI infusion and dextrose infusion for 9 hours during Period 2 of Part II. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part II.
3043583|NCT02269735|Experimental|Part II: RHI followed by MK-2640|Part II: RHI infusion and dextrose infusion for 9 hours during Period 1 of Part II followed by a 7-day wash-out period followed by MK-2640 infusion and dextrose infusion for 9 hours during Period 2 of Part II. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part II.
3043584|NCT02269735|Experimental|Part III: MK-2640 followed by RHI|Part III: MK-2640 infusion and dextrose infusion for 7 hours during Period 1 of Part III followed by a 7-day wash-out period followed by RHI infusion and dextrose infusion for 7 hours during Period 2 of Part III. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part III.
3043585|NCT02269735|Experimental|Part III: RHI followed by MK-2640|Part III: RHI infusion and dextrose infusion for 7 hours during Period 1 of Part III followed by a 7-day wash-out period followed by MK-2640 infusion and dextrose infusion for 7 hours during Period 2 of Part III. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part III.
3043586|NCT02269722|Experimental|Short Clamp time|Radial clamp applied at full pressure for 20 minutes. At the end of 20 minutes, the clamp will be loosened ¼ turn every 5 minutes over 20 minutes and then removed.
3043587|NCT02269722|Experimental|Long Clamp Time|Radial clamp applied at full pressure for 60 minutes. At the end of 60 minutes, the clamp is to be loosened and removed under the same instruction as those patients in arm one.
3043588|NCT02269709|Experimental|ARFI Ultrasound|This study uses ultrasound scanning with acoustic radiation force impulse shear wave velocity imaging to measure pediatric liver fibrosis. Patients will be children who have had the Fontan operation. This is a non-invasive scan that uses sound waves to create images.
3043589|NCT02269696|Experimental|Metoprolol|Metoprolol infusion
3043590|NCT02269696|Placebo Comparator|Normal saline|Equal volume of saline.
3043591|NCT02269683|Experimental|Robot-assisted|Distal pancreatectomy via robot-assisted minimally-invasive approach
3043592|NCT02269683|Active Comparator|Laparoscopic|Distal pancreatectomy via a conventional laparoscopic approach
3043593|NCT02269670|Experimental|Treatment (everolimus, hormone therapy)|Patients receive everolimus PO daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant IM or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO QID; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.
3043594|NCT02269657||Subject Cohort|Two bi-planar full spinal X-rays will be taken using the EOS® imaging system with subjects standing in two different positions. The first x-ray will be taken while the subject's hands and forearms in front of them on the wall vertically. A second image will be taken while the subject's knuckles loosely placed on ipsi-lateral clavicles. A pressure mat will record the magnitude of pressure under the subjects' feet during each set of images. A third set of pressure mat recordings will be obtained while the subject is in a natural standing position with both arms hanging on either side (no x-ray images will be taking in this position).
3043595|NCT02269644|Experimental|Dalbavancin|Dalbavancin randomized subjects will receive one dose of dalbavancin 1500 mg IV over 30 minutes on Day 1 plus azithromycin 500 mg IV on Day 1. Dalbavancin dose will be adjusted for subjects with significant renal insufficiency who are not receiving regular hemodialysis. All patients in the dalbavancin group will receive placebo linezolid infusions or tablets to maintain the blinding. Dalbavancin dose will be adjusted for subjects with significant renal insufficiency who are not receiving regular hemodialysis
3043596|NCT02269644|Active Comparator|Linezolid|Linezolid randomized subjects will receive linezolid 600 mg every 12 hours for a minimum of 10 days, and a maximum of 14 days. All patients will receive at least one IV dose of linezolid initially plus azithromycin 500 mg IV only on Day 1. Subjects then may then be switched to oral linezolid at the discretion of the investigator, if clinical improvement in the signs and symptoms of pneumonia is observed, to complete the 10-14 day course of therapy,. No dose adjustment is required for renal insufficiency.
3043597|NCT02269644|Other|Linezold Placebo IV and Oral Capsules|Dalbavancin randomized subjects after the 1st dose on Day 1 will receive placebo linezolid every 12 hours for a minimum of 10 days and a maximum of 14 days. Dalbavancin randomized subjects may be switched to oral linezolid placebo therapy to complete the 10-14 day course of therapy.
3043598|NCT02269644|Other|Azithromycin|Dalbavancin and linezolid randomized subjects on Day 1, 1st dose will also receive 500 mg of IV azithromycin
3043599|NCT02269631|Experimental|Legume diet group|Meals will include approximately 1 ½ cups of cooked legumes, such as pinto, baked and navy beans as part of your 2 daily main dishes (lunch and dinner) and additional foods and snacks, preferably from the recommended healthy foods list. The smartpill will be administered at the end of the study.
3043600|NCT02269631|Active Comparator|Control diet group|Meals will be healthy, typical American foods (without legumes) for 2 daily main dishes and additional foods and snacks, preferably from the recommended healthy foods list.The smartpill will be administered at the end of the study.
3043601|NCT02269618|Active Comparator|Control group (Group A)|The patients will be followed in the usual care manner by GPs and by routine specialist visits, if needed
3043645|NCT02269384|Active Comparator|History of Significant Injury|Experimental Noxious Stimulus, Memory of Experimental Noxious Stimulus, Memory of Prior Significant Injury, Mental Challenge Test
3043602|NCT02269618|Other|Intervention group (Group B)|"Group B (Home-based intervention): the patients will be followed at home for 4 months by nurse and therapist and will perform an individual rehabilitative program. The interventions will be:~Home-based telehealth program~Home-based rehabilitation"
3043603|NCT02269605|Placebo Comparator|Group 1|Patients receiving placebo (sodium chloride) at single dose
3043604|NCT02269605|Active Comparator|Group 2|Patients receiving Bryostatin 1 (10ug/m2) at single dose
3043605|NCT02269605|Active Comparator|Group 3|Patients receiving Bryostatin 1 (20ug/m2) at single dose
3043606|NCT02269592||Specimen Collection|Patients' tumor tissue including bone marrow, blood, buccal swab or mouthwash, lymph node, urine or other specimens will be collected from patients who consent to the protocol
3043607|NCT02269579|Experimental|CPX-351|Study Drug CPX-351 will be given intravenously at 100u/m2 on days 1, 3 and 5 by approximately 90 minute infusion.
3043608|NCT02269566|Active Comparator|Allergen extract|0.1 ml of allergen extracts
3043609|NCT02269566|Placebo Comparator|Placebo|Normal saline, 0.1 ml
3043610|NCT02269553|Active Comparator|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. They are constructed from methacrylate polymers - the same material as has been used in hearing aids. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the individuals' ear canals when the jaw is in the open position and permit full passage of sound into each ear. The device is FDA cleared under a 510(k) with an indication of reducing TMD pain.
3043611|NCT02269553|Active Comparator|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch. Each patient assigned to the occlusal splint treatment group may wear either maxillary or mandibular splints or both, as prescribed by the subject's dentist, during the study. All occlusal splints used in the study will be custom fit to each patient using standard dental processes. All occlusal splints used in the study will be manufactured by Paul O'Neill Dental Lab, Yucaipa , CA, USA using clear ADA approved orthodontic acrylic
3043612|NCT02269540|Experimental|Sertraline and n-acetylcysteine|Sertraline and n-acetylcysteine for seven weeks of treatment
3043613|NCT02269540|Experimental|Citalopram and n-acetylcysteine|Citalopram and n-acetylcysteine for seven weeks of treatment
3043614|NCT02269540|Experimental|Existing medication treatment & NAC|Existing depression medication treatment and n-acetylcysteine for seven weeks of treatment
3043615|NCT02269527|Other|Live music|1-hour live music 5 days/week
3043616|NCT02269514|Active Comparator|Own Brand Cigarette|Own Brand Cigarette
3043617|NCT02269514|Experimental|Electronic Cigarette #1|VUSE® (original flavor, 14mg nicotine)
3043618|NCT02269514|Experimental|Electronic Cigarette #2|VUSE® (original flavor, 29mg nicotine)
3043619|NCT02269514|Experimental|Electronic Cigarette #3|VUSE® (original flavor, 36mg nicotine)
3043620|NCT02269514|Active Comparator|Leading U.S. Nicotine Gum|Leading U.S. Nicotine Gum
3043621|NCT02269501|Experimental|Exercise treatment|Exercise treatment
3043622|NCT02269501|No Intervention|No treatment|No treatment
3043623|NCT02269488|Experimental|MEDI3250|MEDI3250 Nasal spray
3043624|NCT02269475|Experimental|MEDI3250|MEDI3250 Nasal Spray
3043625|NCT02269475|Placebo Comparator|Placebo|Placebo Nasal spray
3043626|NCT02269462||Pregnant women - efavirenz|Pregnant women taking 600 mg efavirenz daily as part of combination antiretroviral therapy for PMTCT and for their own health
3043627|NCT02269462||Nursing mothers - efavirenz|Nursing mothers taking 600 mg efavirenz daily as part of combination antiretroviral therapy for PMTCT and for their own health and their breastfed babies
3043628|NCT02269462||Pregnant women - nevirapine|Pregnant women taking 200 mg nevirapine twice daily as part of combination antiretroviral therapy for PMTCT and for their own health
3043629|NCT02269462||Nursing mothers - nevirapine|Nursing mothers taking 200 mg nevirapine twice daily as part of combination antiretroviral therapy for PMTCT and for their own health and their breastfed babies
3043630|NCT02269449|Experimental|6Fr Glidesheath Slender sheath|TRI will be performed using a new 6Fr sheath (Glidesheath slender: GSS).
3043631|NCT02269449|Active Comparator|5Fr contemporary sheath|TRI will be performed using a contemporary safety of 5Fr sheath.
3043632|NCT02269449|Experimental|Hemostasis with TR band|Hemostasis is achieved by randomization of using TR band (TERUMO) Patent hemostasis.
3043633|NCT02269449|Active Comparator|Any hemostasis procedure|Hemostasis is achieved by randomization of any hemostasis of each hospital's routine procedure.
3043634|NCT02269436|Experimental|sNN0029 infusion solution|
3043635|NCT02269423|Experimental|3x10^6 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of BPSC-1001 3x10^6 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
3043636|NCT02269423|Experimental|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of BPSC-1001 2x10^7 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
3043637|NCT02269423|Experimental|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of BPSC-1001 1x10^8 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
3043638|NCT02269423|Placebo Comparator|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in each deltoid on Day 0.
3043639|NCT02269410|Active Comparator|GBP-SPS|GBP Standard PRO-S (0.8g protein/kg ideal body weigh/day)
3043640|NCT02269410|Experimental|GBP-HPS|GBP High PRO-S (1.2g protein/ kg ideal body weight/ day)
3043641|NCT02269410|Active Comparator|VSG-SPS|VSG Standard PRO-S (0.8g protein/kg ideal body weigh/ day)
3043642|NCT02269410|Experimental|VSG-HPS|VSG High PRO-S (1.2g protein/ kg ideal body weight/ day)
3043643|NCT02269397||Individuals with suspected epilepsy|The study will enroll individuals who are attending their first visit at the University of Pennsylvania for suspected epilepsy.
3043644|NCT02269384|Sham Comparator|No History of Significant Injury|Experimental Noxious Stimulus, Memory of Experimental Noxious Stimulus, Memory of Prior Significant Injury, Mental Challenge Test
3043705|NCT02268968|No Intervention|Control|No topical lidocaine will be used prior to application of nasal CPAP
3043646|NCT02269371|Experimental|Group 1|Group 1: Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.
3043647|NCT02269371|Sham Comparator|Group 2|Group 2: Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
3043648|NCT02269358|Experimental|Addition of methotrexate|Addition SC methotrexate at 15 mg/m2, not to exceed 25 mg/m2 . Patients in remission after 4 weeks will reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
3043649|NCT02269345|Experimental|Battlefield Acupuncture|BFA at points cingulate gyrus, thalamus, omega 2, shen-men, point zero
3043650|NCT02269345|Placebo Comparator|Standard Treatment|Standard Treatment alone
3043651|NCT02269332||Screening Colonoscopy|Referred for a screening colonoscopy or polyp surveillance or had one in the last 2 weeks
3043652|NCT02269319|Experimental|MRX-I|MRX-I tablets 800 mg given twice a day for 10 days
3043653|NCT02269319|Active Comparator|Linezolid|Linezolid 600 mg given twice a day for 10 days
3043654|NCT02269306|Experimental|clomiphen citrate(cc)|Initial CC doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles.
3043655|NCT02269293|Experimental|Regimen 1|Paclitaxel 175 mg/m^2 IV, Day 1 (administered over approximately 3 hours) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor (to be taken orally once daily on days 1, 4, 8, 11, 15, and 18 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
3043656|NCT02269293|Experimental|Regimen 2|Paclitaxel 80 mg/m^2 IV, Days 1, 8, 15 (administered over approximately 1 hour) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor orally (to be taken orally once daily on days 1, 4, 8, 11, 15, and 18 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
3043657|NCT02269293|Experimental|Regimen 3|Paclitaxel 80 mg/m^2 IV, Days 1, 8, 15 (administered over approximately 1 hour) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor orally (to be taken orally once weekly on days 1, 8, and 15 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
3043658|NCT02269293|Experimental|Regimen 4|Paclitaxel and carboplatin will be delivered intravenously (IV) on day 1 of each cycle. Selinexor will be taken orally once a week on days 1, 8 and 15 of each chemotherapy cycle.
3043659|NCT02269280|Experimental|Azacitidine (AZA) - Days 1 - 3|Azacitidine (AZA) Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.
3043660|NCT02269280|Experimental|Azacitidine (AZA) - Days 1 - 5|Azacitidine (AZA) 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
3043661|NCT02269280|Experimental|Decitabine (DAC)|Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
3043662|NCT02269280|Other|Best Supportive Care (BSC)|Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.
3043663|NCT02269267|Other|Discontinuation of TKI medication|Patients with CML patients who are on imatinib, dasatinib, nilotinib, or bosutinib and have had deep molecular response defined as BCR-ABL < 0.01%, (> MR4 i.e. > 4 log reduction) for at least 2 years will stop their TKI.
3043664|NCT02269254|Experimental|Persona PS|Total Knee Replacement with Persona PS Knee Prosthesis by Zimmer
3043665|NCT02269254|Active Comparator|NexGen PS|Total Knee Replacement with NexGen PS Knee Prosthesis by Zimmer
3043666|NCT02269241|Experimental|LF111 (drospirenone)|single treatment arm receives LF111
3043667|NCT02269228|Experimental|Asasantin ER|Administered once daily (days 1 to 7), followed by twice daily administration (days 8 to 14)
3043668|NCT02269228|Experimental|Asasantin ER, administered twice daily from day 1 to day 14|
3043669|NCT02269228|Placebo Comparator|Placebo|
3043670|NCT02269215|Experimental|BIII 890 CL single rising dose|
3043671|NCT02269215|Placebo Comparator|Placebo|
3043672|NCT02269202|Experimental|Midazolam and crobenetine|
3043673|NCT02269202|Placebo Comparator|Midazolam and placebo|
3043674|NCT02269189|Experimental|BIIL 284 BS, high dose in adult patients|
3043675|NCT02269189|Experimental|BIIL 284 BS, low dose in pediatric patients|
3043676|NCT02269189|Placebo Comparator|Placebo|
3043677|NCT02269176|Experimental|Telmisartan|Low dose of telmisartan, uptitrated to high dose in case no sufficient effect is observered
3043678|NCT02269176|Active Comparator|Losartan|Low dose of losartan, uptitrated to high dose in case no sufficient effect is observered
3043679|NCT02269163|Experimental|Group 1 - Adults|Cohort 1 (adult) will enroll approximately 5 subjects aged ≥ 17-80 years to obtain 5 evaluable subjects. The first IMP infusion of Immune Globulin (Human) Intravenous, in the first five subjects will be staggered at 2-week intervals.
3043680|NCT02269163|Experimental|Group 2 - Adults|After the 5 subject of Cohort 1 have been fully evaluated, Cohort 2 will enroll approximately 10 subjects to obtain 10 evaluable subjects who will receive Immune Globulin (Human) Intravenous.
3043681|NCT02269163|Experimental|Group 3 - Adults and Children|Cohort 3 will include adult and children that may start with Commercial Immune Globulin Intravenous, as per Investigator until Cohort 1 and 2 have been evaluated and then Cohort 3 will start receiving IMP, Immune Globulin (Human) Intravenous.
3043682|NCT02269150|Experimental|Fecal microbiota transplantation with pre-transplant feces|Prior to transplant hospitalization, store feces for testing and possible future use. Patients undergo fecal microbiota transplantation with the subject's stored pre-transplantation feces. The post-engraftment Bacteroidetes testing, randomization, and fecal microbiota transplantation procedure should all be performed within a 28-day window, beginning on the first day of engraftment. In the event that engraftment occurs prior to day +7, the 28-day window will start on day +7. Subjects from both arms will be followed for one year after transplantation for development of CDI, which will be treated by their BMT clinicians per the standards of care at MSKCC. Subjects from both arms will also be assessed for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially, if feasible, until one year post randomization and analyzed for microbial diversity and composition.
3043706|NCT02268955|Placebo Comparator|Control Group|Saline-only control group
3043707|NCT02268955|Active Comparator|IV Ibuprofen|Patients receiving intravenous ibuprofen therapy
3069429|NCT02098395|Placebo Comparator|Liraglutide placebo 0.3 ml + insulin|
3043683|NCT02269150|Active Comparator|No FMT, routine management|Subjects from both arms will be followed for one year after randomization for development of CDI, which will be treated by their primary BMT clinician per the standards of care at MSKCC. Subjects from both arms will also be assessed by their BMT clinicians for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially if feasible until one year post randomization and analyzed for microbial diversity and composition.
3043684|NCT02269124|No Intervention|Conventional measures arm|In arm 1, the child will utilize conventional measures for management of unilateral hearing loss, such as FM system and preferential seating in the classroom. While two basic types of FM systems exist, personal and sound field, subjects in our study will utilize a personal FM system, worn at the ear-level. This will increase the likelihood that the child will receive amplification in all classes, and will help to standardize this intervention. The HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm via Redcap. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals.
3043685|NCT02269124|Experimental|Conventional measures + hearing aid arm|In the second arm, the child will use the conventional measures described above in addition to a digital behind-the-ear hearing aid with a standard ear hook and custom ear mold on the affected ear. The hearing instrument will be customized by a Massachusetts Eye and Ear Infirmary (MEEI) audiologist. The subject will be instructed wear the hearing aid both at home and at school. In both arms, the FM system will be used in school only. As in the first arm, the HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals.
3043686|NCT02269111|Experimental|Diagnostic (hybrid MRI)|Patients undergo hybrid 3 Tesla MRI examination that includes standard MRI sequences, DW-MRI, CEST, and combined DCE-MRI/DSC-MRI at baseline.
3043687|NCT02269098|Experimental|Intervention|"Diabetes survival skills self-management education; plus diabetes medication management using medication algorithm by diabetes educator supervised by endocrinologist, plus health system naviagation.~Metformin, sulfonylureas and basal insulin were included in the algorithm. Survival skills DSME included: BG meter instruction if the patient did not already have a meter or confirmation of self-BG monitoring technique if they did; instructions on how to self-inject insulin if prescribed; and information on BG targets, signs and treatment of hypoglycemia and hyperglycemia, basic nutrition information and when to call the doctor or go to the ED."
3043688|NCT02269098|No Intervention|Control|Usual ED care was provided to controls. Hyperglycemia was treated with rapid acting insulin and with IV hydration, if indicated. DM medications were added and/or doses were adjusted at the discretion of the ED physician and prescriptions provided. Insulin, however, was not prescribed as a new medication due to staff concerns regarding post-discharge hypoglycemia and lack of certainty of timely medical follow-up. Follow-up with primary care was recommended.
3043689|NCT02269085|Experimental|Ibrutinib + Carfilzomib|"Phase I: Ibrutinib administered by mouth daily at 420 or 560 mg on Days 1 - 28 of a 28-day cycle. Carfilzomib administered by vein 20/27 mg/m^2, 20/36 mg/m^2, 20/45 mg/m^2 or 20/56 mg/m^2 on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle for Cycles 1- 12 and on Days 1, 2, 15 and 16 for Cycle 13 and higher.~Phase II: Once the MTD has been established 5 additional patients treated at the MTD to a maximum of 35 patients with MCL.~Study staff calls participant after end-of-dosing visit every 6 months for 5 years."
3043690|NCT02269072|Active Comparator|Testosterone|Testosterone cream applied daily
3043691|NCT02269072|Placebo Comparator|Placebo|Identical placebo cream applied daily
3043692|NCT02269059|Experimental|GT1 Participants|Participants take MK-7680 capsules by mouth once daily (QD) for 7 days. The starting dose will be 200 mg and the dose will be adjusted in successive panels of participants based on analysis of results of the previous panel.
3043693|NCT02269059|Experimental|GT3 Participants|Participants take MK-7680 capsules by mouth QD for 7 days. The starting dose will be 200 mg and the dose will be adjusted in successive panels of participants based on analysis of results of the previous panel.
3043694|NCT02269046|Experimental|Acupuncture and moxibustion|"therapeutic lifestyle change~Group I:Juque (RN14), Tianshu (ST25, bilateral), Fenglong (ST40, bilateral), Zusanli (ST 36, bilateral), Sanyinjiao (SP6, bilateral)~Group II: Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)~Group I and II will change alternatively every other week .~Once per day five days per week."
3043695|NCT02269046|Active Comparator|Simvastatin|"therapeutic lifestyle change~simvastatin~oral administration with 10mg per day~seven days per week for 12 weeks."
3043696|NCT02269046|Other|waiting list|- therapeutic lifestyle change
3043697|NCT02269033|Experimental|Patient Navigated Latinas|Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
3043698|NCT02269033|Active Comparator|Non Navigated Latinas|A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged > 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
3043699|NCT02269020|Experimental|3 patients cancer of the epi larynx|"3 patients with squamous cell carcinoma of the epi-larynx~Intervention: Neck Dissection"
3043700|NCT02269007|Experimental|0.5ml influenza vaccine|0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
3043701|NCT02268994|Experimental|KRX-0502 (ferric citrate)|1 g of KRX-0502 (ferric citrate) containing approximately 210 mg of ferric iron
3043702|NCT02268994|Placebo Comparator|Placebo|Matching Placebo
3043703|NCT02268981|Experimental|Oxymizer® compared to CNC|"From 7am to 7pm oxygen saturation is measured by a pulse oximeter. One day with conventional nasal cannula, one day with Oxymizer®, one day with Oxymizer® and reduced Oxygen flow (-1l/min). The order of these days is randomized in 6 groups.~The intervention will be performed on consecutive days and twice during study period."
3043704|NCT02268968|Experimental|Lidocaine|Intervention: Topical lidocaine gel 2% (0.3 ml/kg) will be applied once only to the nostrils and nasal CPAP prong 5 minutes prior to the application of nasal CPAP
3043710|NCT02268929|Other|Intervention Group|"Patients treated with Integrated Personalized Diabetes Management"
3043711|NCT02268916|Experimental|Intervention|OT-led counseling based on home activity pattern
3043712|NCT02268916|Placebo Comparator|Wait-listed|Usual activity during the study. At the end of the study, will receive OT-led counseling
3043713|NCT02268903|Active Comparator|Diuretics|
3043714|NCT02268903|Placebo Comparator|Placebo|
3043715|NCT02268890|Experimental|Bortezomib|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
3043716|NCT02268877|Experimental|Emergency Medicine Physician Ultrasound|Patients will receive an ultrasound performed by a credentialed emergency medicine attending or resident. The ultrasound will be transabdominal, transvaginal, or both. The intervention is the personnel who performs the ultrasound.
3043717|NCT02268877|Active Comparator|Radiology Tech Ultrasound|Patients will receive an ultrasound performed by a credentialed radiology department technician. The ultrasound will be transabdominal, transvaginal, or both. This is standard-of-care.
3043718|NCT02268864|Experimental|Simeprevir + Daclatasvir|Participants who have Hepatitis C virus (HCV) genotype 1b infection with advanced fibrosis or compensated cirrhosis (METAVIR F3/F4) will receive simeprevir 150 milligram (mg) capsule and daclatasvir 60 mg tablet orally once daily for 12 or 24 weeks.
3043719|NCT02268851|Experimental|CLL|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Each Cycle = 28 days~TGR-1202 (oral): Starting on Day 1 administered daily.~Ibrutinib (oral): Starting on Day 1 administered daily."
3043720|NCT02268851|Experimental|MCL|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Each Cycle = 28 days~TGR-1202 (oral): Starting on Day 1 administered daily.~Ibrutinib (oral): Starting on Day 1 administered daily."
3043721|NCT02268838|Experimental|50 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 1, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
3043722|NCT02268838|Experimental|100 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 2, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
3043723|NCT02268838|Experimental|200 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 4, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
3043724|NCT02268838|Experimental|400 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 8, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
3043725|NCT02268838|Experimental|200 mg E6007 fed condition|E6007 50mg or E6007 matching placebo x 4, orally once daily in the morning under fed condition. Drug administration on 1 day (Day 1).
3043726|NCT02268825|Experimental|MK-3475 treatment arm, all patients|
3043727|NCT02268812||Prialt|"No drug will be provided by the sponsor. Treatment decisions will be made by physicians independent of participation in the registry.~IT analgesia may consist of Prialt or any other drug used in IT therapy, including those used off-label as part of local clinical practice."
3043728|NCT02268799||DC Cardioversion|Patients undergoing DC cardioversion
3043729|NCT02268786|Experimental|Group A|Intent to transfer single euploid embryo based on NGS testing (VeriSeq™ PGS) of biopsied blastocysts
3043730|NCT02268786|No Intervention|Group B|Intent to transfer single embryo based on morphological assessment according to the Gardner scoring system (no PGS)
3043731|NCT02268773|Experimental|Acetylsalicylic acid low dose with Asasantin®|
3043732|NCT02268773|Active Comparator|Acetylsalicylic acid high dose|
3043733|NCT02268760|Experimental|BILN 2061 ZW single rising doses|
3043734|NCT02268760|Placebo Comparator|Placebo|
3043735|NCT02268760|Experimental|BILN 2061 ZW fixed dose fed|
3043736|NCT02268760|Active Comparator|BILN 2061 ZW fixed dose fasted|
3043737|NCT02268747|Experimental|Dacomitinib|"Patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade <2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).~If the highest skin toxicity will be grade >2, then the patient will interrupt the treatment following the criteria for dose reduction."
3043738|NCT02268734||Sporadic Medullary Thyroid Cancer|Patients with diagnosis of locally relapsed and or metastatic sporadic MTC surgically treated (total thyroidectomy)
3043739|NCT02268721|No Intervention|Controle Group|Patients in the control group are undergoing the same measurements and records before discharge, and at six and twelve weeks, as the intervention group. The control group receives no special treatment or care after discharge.
3043740|NCT02268721|Other|App for food delivery|"Intervention: Tablet Computer~Patients in the intervention group receives a tablet upon discharge from the hospital. The tablet contains an app, which the patients in the intervention group can use for ordering meals for delivery from the kitchen at the hospital three times a week. The app also ask the patients to register their own dietary intake, and give them feedback on their daily energy and protein intake.~Baseline measurements and records are taken at prior to discharge from the hospital, and after six and twelve weeks."
3043741|NCT02268708||COPD|"Patients:~>18 years old COPD: FEV/FEV1<80% in respiratory evaluation who have un oncological pulmonary resection in Cochin Hospital Paris France"
3043742|NCT02268695|Active Comparator|EXTREME: Cisplatin, 5-FU and Cetuximab|"Chemotherapy: 6 cycles (every 3 weeks) of Cisplatin (100 mg/m² iv on Day1), 5FU (4000 mg/m² total dose starting on day 1 and during 96h in continuous infusion), and Cetuximab (loading dose of 400 mg/m² iv on Day1, then 250 mg/m² iv weekly).~If cisplatin is not tolerated and/or when the total cumulative dose of cisplatin (including prior administration) reaches 600 mg/m², cisplatin has to be replaced by carboplatin, AUC 5 (but not exceeding 750 mg), except in the case of bleeding tumor.~Cetuximab maintenance : cetuximab continuation (250 mg/m² iv weekly) will begin only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until PD or unacceptable toxicity."
3043871|NCT02267759|Active Comparator|Macintosh|Nasotracheal intubation was performed with Macintosh direct laryngoscopy
3043743|NCT02268695|Experimental|TPEx: Cisplatin, Docetaxel and Cetuximab|"Chemotherapy: 4 cycles (every 3 weeks) of Cisplatin (75 mg/m² iv on Day1), Docetaxel (75 mg/m² iv on Day1), and Cetuximab (loading dose of 400 mg/m² iv on Day1, then 250 mg/m² iv weekly).~If Cisplatin is not tolerated, cisplatin is replaced by carboplatin, AUC 5 (but not exceeding 750 mg), except in the case of bleeding tumor.~Primary prophylactic administration of GCSF must be administered systematically after each cycle of chemotherapy.~Cetuximab maintenance : cetuximab continuation (500 mg/m² iv every two weeks) will begin only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until PD or unacceptable toxicity."
3043744|NCT02268682|No Intervention|Standard of Care (Control)|Patients randomized to the standard of care condition will not receive any educational materials from our program and will only participate in the survey portion of the investigation. Dialysis providers will be asked to continue their current practices throughout the study period without change. While Control patients will be free to ask additional questions or solicit more information from their dialysis educators at any point during the study period, no additional educational interventions will be added to what is currently being done.
3043745|NCT02268682|Experimental|Patient-Guided|Over an 8-month period, patients in the Patient-Guided intervention condition will receive four educational modules and twelve transplant education postcards in the mail. Modules will be mailed once every other month and consist of an introductory letter, a transplant video, and printed resources. Transplant education postcard will be mailed every two weeks following the mailing of each module, for a total of three postcards over the course of 6-weeks.
3043746|NCT02268682|Experimental|Educator-Guided|Patients in the Educator-Guided intervention condition will receive the same intervention components as those in the Patient-Guided condition; however, the key difference in this condition is that Educator-Guided patients will also receive telephonic support from an experienced clinical social worker in the role of a Transplant Educator to maximally facilitate learning. Telephonic meetings with the Transplant Educator will occur after the mailing of each study module, for a total of four calls, each lasting 20-minutes, totaling 1 hour and 20 minutes. Finally, Patient-Guided and Educator-Guided patients will have the option of enrolling in an educational text messaging service designed to supplement the ET education they are receiving in the mail.
3043747|NCT02268669|Active Comparator|Primary angioplasty|Patients assigned to this treatment will undergo cardiac catheterization within the time recommended by current guidelines. Double antiagregation will be used, vascular access wil be obtained and bivalirudin will be used as anticoagulation; all following current guidelines recommendations
3043748|NCT02268669|Active Comparator|Post-thrombolysis angioplasty|Patients will receive tenecteplase, enoxaparin, and double antiagreagation with clopidogrel or aspirin as recommended guidelines. Criteria of no reperfusion after fibrinolysis is defined as absence of ST-segment lowering >50%, 90 minutes after fibrinolysis. If not reperfusion is achieved recue angiplasty will be performed inmmediately if reperfusion is achieved cardiac catheterization will be performed the mornig following the day of randomization
3043749|NCT02268656|Other|concentration in male|after infusion of dexmedetomidine dexmedetomidine 0.5 mcg/kgfor 2 min, infusion of propofol as using target controlled infusion pump. Effect site concentration would be changed as the response to i-gel insertion as up and down method in male
3043750|NCT02268656|Other|concentraion in female|after infusion of dexmedetomidine dexmedetomidine 0.5 mcg/kgfor 2 min, infusion of propofol as using target controlled infusion pump. Effect site concentration would be changed as the response to i-gel insertion as up and down method in female
3043751|NCT02268643||group 1|ultrasound plus clinical breast examination
3043752|NCT02268630||Group A|Patients treated with Warfarin for VTE
3043753|NCT02268630||Grup B|Patients treated with Rivaroxaban for VTE
3043754|NCT02268617|Experimental|Treadmill Walking|All subjects will walk on treadmill for a total of 20 minutes.
3043755|NCT02268604|Experimental|BIIB 722 CL|
3043756|NCT02268604|Placebo Comparator|Placebo|
3043757|NCT02268591|Active Comparator|Transcranial Stimulator|We will apply oscillating current at a slow frequency of 0.5-1.5 Hz during early sleep, which is rich in slow waves [ie non-REM sleep]. The peak intensity of stimulation which allows for optimal phase entrainment will be determined in pilot studies. However, peak stimulation intensities will not exceed 2 mA (as discussed above). The current will be applied over the left and right prefrontal cortex (F3, F4), corresponding to the predominant region of slow oscillations, during the onset of deep sleep to the first REM episode (early non-REM-rich sleep).
3043758|NCT02268591|No Intervention|Sham Stimulation|The EEG and stimulation electrodes will be placed as in the stimulation sessions, but stimulation will not be administered.
3043759|NCT02268578|Active Comparator|Transcranial Direct Current Stimulation|Subjects will receive a total of 5 sessions on consecutive days. During each session, 2 mA of tDCS will be applied for 20 minutes over the left DLPFC (active or sham). The electrodes will have the size of 35cm2 each. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes and delivered b y a specially developed, battery driven, constant current stimulator with a maximum output of 2mA.
3043760|NCT02268578|Sham Comparator|Sham TDCS|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied for only 30 seconds - this is a reliable method of sham stimulation as sensations arising from tDCS treatment occur only at the beginning of application as also demonstrated by a randomized study (Gandiga et al. 2006).
3043761|NCT02268565|Placebo Comparator|Insomnia symptom induction/placebo|Daily intake of pill at bedtime over 2-week period prior to and during the 5-day in-hospital stay
3043762|NCT02268565|Experimental|Insomnia symptom induction/aspirin|Daily intake of pill at bedtime over 2-week period prior to and during the 5-day in-hospital stay
3043763|NCT02268552|Experimental|branaplam|branaplam Treatment
3043764|NCT02268539|Active Comparator|Ablation at 20 watt / 30 seconds|Participants randomised to 20 watt ablation for 30 seconds
3043765|NCT02268539|Active Comparator|Ablation at 20 watt /45 seconds|20 watt ablation for 45 seconds
3043766|NCT02268539|Active Comparator|Ablation at 25 watt / 30 seconds|25 watt ablation for 30 seconds
3043767|NCT02268539|Active Comparator|iAblation at 25 watt / 45 seconds|25 watt ablation for 45 seconds
3043768|NCT02268526|Experimental|Cohort 1: CSJ148|Cohort 1: CSJ148 IV q 4weeks
3043769|NCT02268526|Experimental|Cohort 2: CSJ148|Cohort 2: CSJ148 IV q 4weeks
3043770|NCT02268526|Placebo Comparator|Cohort 2: Placebo|Cohort 2: Placebo IV q 4weeks
3043771|NCT02268513||MASALA study|"Mediators of Atherosclerosis in South Asians Living in America (MASALA) study participants will be invited to participate in this ancillary study.~Objective of MASALA study:~The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study is investigating the prevalence, correlates, and outcomes associated with subclinical CVD in a population-based sample of South Asian men and women age 40-79 years at 2 US clinical field centers."
3043772|NCT02268500|Active Comparator|Standard dose influenza vaccine|Standard dose (45ug) influenza vaccine will be administered intramuscularly
3043773|NCT02268500|Active Comparator|High dose influenza vaccine|High dose (180ug) influenza vaccine will be administered intramuscularly
3043774|NCT02268487|Experimental|Sertraline|Patients using Sertraline with any dose will be evaluated about Early Improvement
3043775|NCT02268474|Experimental|532nm KTP Laser|Cutera® Excel V
3043776|NCT02268474|Active Comparator|595nm Pulse Dye Laser|Candela/Syneron Vbeam
3043777|NCT02268461|Active Comparator|rTMS|repetitive Transcranial Magnetic Stimulation (rTMS)
3043778|NCT02268461|Sham Comparator|Sham rTMS|Sham repetitive Transcranial Magnetic Stimulation (Sham rTMS)
3043779|NCT02268448|Experimental|Clonidine|Clonidine will be given orally as a starting dose of 0.1 mg daily. The drug will be administered orally by the subject at bedtime daily for four weeks.
3043780|NCT02268448|Experimental|Naltrexone|Naltrexone will be given to each subject at an oral dose of 50 mg daily. Subjects will self-administer the drug at bedtime.
3043781|NCT02268435|Experimental|Dovitinib plus Imatinib|Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
3043782|NCT02268422|Experimental|7 day patch|Buprenorphine transdermal system (BTDS) 2nd generation
3043783|NCT02268422|Active Comparator|7 Day Patch|1st Generation BTDS: Butrans
3043784|NCT02268409|Experimental|ACE-536 0.8 mg/kg once every 3 weeks SC|ACE-536 0.8 mg/kg once every 3 weeks by SC injection
3043785|NCT02268396|Experimental|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler (GFF MDI), PT003
3043786|NCT02268383|Experimental|ACE-536|ACE-536 1.0 mg/kg once every 3 weeks by subcutaneous injection.
3043787|NCT02268370|Other|Dasatinib|"This research is being done because dasatinib has been shown to achieve a deep molecular response in patients as compared to imatinib.~Patients in this study will continue to take their own supply of imatinib for three months to ensure they have achieved a stable response to the drug. Once this has been confirmed, imatinib will be stopped and the patients in this study will then be monitored to see if their CML relapses. This period can last up to 2.5 years.~If the participant has a relapse, they will be started on dasatinib and will continue to receive dasatinib for up to 2 years.~If after one year they achieve a response, they will continue on dasatinib for one more year. If the participant maintains this response, they will have the option of discontinuing dasatinib."
3043788|NCT02268357|Experimental|Propranolol|capsules PROPRANOLOL (study medication); 80 mg 1 hour preoperative; 40 mg directly postoperative
3043789|NCT02268357|Placebo Comparator|Placebo|capsules MICROCRYSTALLINE CELLULOSE (study medication); 80 mg 1 hour preoperative; 40 mg directly postoperative
3043790|NCT02268344|Active Comparator|Grass SD9 Stimulator|Brief intraoperative electrical stimulation of the spinal accessory nerve (ESSAN) continuously at 20 Hz, 10-15V for 60 minutes immediately following neck dissection.
3043791|NCT02268344|No Intervention|No Stimulation|No stimulation will be performed in this group, and patients will simply have the neck dissection as planned. No sham stimulation is required, as all outcome measures are performed by individuals not present in the operating room, and therefore, blinded to the treatment arm.
3043792|NCT02268331|Experimental|Active Surveillance|"For 60 consecutive pediatric visits, patients will be asked to complete a PRE & POST form to capture adverse events (AEs) that occur up to 1 week after treatment. The PRE-treatment form will be completed prior to the start of the visit. The POST-treatment form will be completed after the treatment visit and mailed directly to the investigative team.~The providers will collect data on the treatment provided on the same 60 pediatric patients. The treatment provided is at the discretion of the doctors. If a moderate, serious, or severe AE occurs, the provider will complete the AE form with detailed information about potential risk factors and patient outcomes."
3043793|NCT02268331|Active Comparator|Passive Surveillance|"All doctors allocated to this arm will be provided with a username and password with an established chiropractic passive surveillance reporting and learning online system (CPiRLS) in the UK. If a patient safety incident occurs in their office or an adverse event (AE), the provider will complete a report on the CPiRLS website. The providers can record events that occur during the time period of 60 pediatric visits.~Treatment provided during these treatments is at the doctor's discretion."
3043794|NCT02268318|Experimental|1-Fermented Dairy Product with Phytosterols (test)|one arm active = 1 bottle of dairy product/day with 1,6g of phytosterols
3043795|NCT02268318|Placebo Comparator|2-Fermented dairy Product with No Phytosterols (control)|one arm control product= 1 bottle of dairy product/day with no Phytosterols
3043796|NCT02268305|Experimental|MSM 1000mg twice a day (6000 mgs)|Group 1 will take by mouth three 1000 mg capsules twice a day (6000 mgs) of MSM plus standard of care naproxen
3043797|NCT02268305|Placebo Comparator|Placebo capsules twice a day|Group 2 will take by mouth three placebo capsules twice a day plus standard of care naproxen
3043798|NCT02268292|Experimental|Bicycle Exercise|Bicycle Exercise for 12 weeks
3043799|NCT02268279|Experimental|solithromycin|oral dosing (capsules and powder for suspension) by weight once per day intravenous dosing by weight once per day
3043800|NCT02268266|Other|Single-arm study|Early mobilization of patients after stroke or spinal cord injury. Monitoring of vital parameters during mobilization of healthy subjects
3043801|NCT02268240|Experimental|Experimental|Stepped Care
3043802|NCT02268240|No Intervention|Control|Usual Care
3043803|NCT02268214|Experimental|Arm A: Dapagliflozin|Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
3043804|NCT02268214|Experimental|Arm B: Dapagliflozin|Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
3043805|NCT02268214|Placebo Comparator|Arm C: Placebo for Dapagliflozin|Placebo tablet orally, once daily for 52 weeks
3043806|NCT02268201|Experimental|ADV group|
3043807|NCT02268201|Experimental|PRG group|
3043872|NCT02267746|Active Comparator|Fabior™(tazarotene)|Reference listed drug: Fabior™ 0.1% foam (Stiefel)
3043808|NCT02268188|Experimental|Supportive Care (Harvesting Health program)|Participants undergo a series of 10 education and training sessions over 1 hour every 2 weeks, comprising education on current research, evidence-based health guidelines, application techniques, reference materials specific to extended-stage cancer survivors, and recommendations and personal health goals for survivorship.
3043809|NCT02268175|Experimental|ARM 1|"Participants will be randomized in a 2:1 ratio to neoadjuvant treatment (ARM 1) or (ARM 2).~Participants will receive the assigned study treatment per cycle~Enzalutamide- Once daily at prespecified dose, orally~Abiraterone Acetate- Once daily at prespecified dose, orally~Prednisone-Once daily at prespecified dose, orally~Leuprolide Acetate-Intermuscular injection at prespecified dose and duration"
3043810|NCT02268175|Experimental|ARM 2|"Participants will be randomized in a 2:1 ratio to neoadjuvant treatment (ARM 1) or (ARM 2).~Participants will receive the assigned study treatment per cycle.~Enzalutamide- once daily at prespecified dose, orally~Leuprolide Acetate- Intermuscular injection at prespecified dose and duration"
3043811|NCT02268162|No Intervention|Routine Bronchoscopy|Participants in the group will receive routine bronchoscopy.
3043812|NCT02268162|Experimental|Routine Bronchoscopy with a guiding equipment|Participants in the group will receive routine bronchoscopy combined with a guiding equipment. These guiding equipments include virtual bronchoscopic navigation(VBN), endobronchial ultrasonography with a guide sheath(EBUS-GS) and fluoroscopy.
3043813|NCT02268162|Experimental|Routine Bronchoscopy with two or more guiding equipments|Participants in the group will receive routine bronchoscopy combined with two or more guiding equipments. These guiding equipments include virtual bronchoscopic navigation(VBN), endobronchial ultrasonography with a guide sheath(EBUS-GS) and fluoroscopy.
3043814|NCT02268149|Experimental|BIIL 284 BS + Prednisone|BIIL 284 BS 9 days; prednisone 2 single doses
3043815|NCT02268149|Placebo Comparator|Placebo|
3043816|NCT02268136|Experimental|BIII 890 CL|single increasing doses
3043817|NCT02268136|Placebo Comparator|Placebo|
3043818|NCT02268110|Experimental|Supervised exercise therapy|Participants will receive 12 sessions with a physiotherapist where they will receive instructions on body mechanics, and be given a progressive abdominal exercise program
3043819|NCT02268110|Experimental|Abdominal binding|Participants will be fitted for an abdominal binder and asked to wear it for a period of 12 weeks.
3043820|NCT02268110|Experimental|Exercise therapy and Abdominal Binding|Participants will attend 12 sessions with a physiotherapist, and receive an abdominal binder
3043821|NCT02268110|No Intervention|Control|Participants will not receive an intervention during the study period
3043822|NCT02268097|Experimental|Freehand|Patellar resurfacing with freehand technique:Using freehand technique for patella preparation during total knee arthroplasty.
3043823|NCT02268097|Active Comparator|Resection guide|Patellar resurfacing with resection guide technique: Using patellar resection guide technique for patella preparation during total knee arthroplasty.
3043824|NCT02268084|Sham Comparator|Sham|
3043825|NCT02268084|Experimental|Experimental|
3043826|NCT02268071|Experimental|Hypertensive patients|Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence
3043827|NCT02268058|Active Comparator|tx 1: acetaminophen and education|"Patient took routinely acetaminophen every 4 hours when awake for a 72 hour period and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency department."
3043828|NCT02268058|Active Comparator|Tx 2: ibuprofen and education|"Patient took routinely ibuprofen every 6 hours when awake for a 72 hour period and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency department."
3043829|NCT02268058|Active Comparator|Tx 3: ibuprofen/acetaminophen/education|"Patient took routinely ibuprofen (Q6H) and acetaminophen (Q4H) for when awake for 72 hours post concussion and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency Department."
3043830|NCT02268058|No Intervention|Tx 4: no routine meds and education|"Patient was advised to manage headaches as they typically would. There was no instruction given for the routine administration of either ibuprofen or acetaminophen.~The Patient and family received standard education in the ER department and diarized their headaches and medications they took for a one week period."
3043831|NCT02268045|Experimental|RTXM83|"Active Ingredient: Rituximab (Biosimilar)~Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed."
3043832|NCT02268045|Active Comparator|MabThera|"Active Ingredient: Rituximab~MabThera will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed."
3043833|NCT02268032|Experimental|Vaginal ring 1 (VRD)|20 women using DHEA (VRD)
3043834|NCT02268032|Experimental|Vaginal ring 2 (VRaA)|20 women using another androgenic agent (VRaA)
3043835|NCT02268032|Experimental|Vaginal ring 3 (VR2A)|20 women using fixed combination of 2 androgenic agents (VR2A)
3043836|NCT02268019|Experimental|Hypospadiasis repair|
3043837|NCT02268006|Other|IMRT-SIB|
3043838|NCT02267993|Experimental|Arm A|At the first chemotherapy cycle (treatment cycle), patients receive recombinant human thrombopoietin treatment. At the second chemotherapy cycle (control cycle), recombinant human thrombopoietin therapy is not given.
3043839|NCT02267993|Experimental|Arm B|At the first chemotherapy cycle (control cycle), recombinant human thrombopoietin therapy is not given; at the second chemotherapy cycle (treatment cycle), patients receive recombinant human thrombopoietin treatment.
3043840|NCT02267980|Active Comparator|Group SK|Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Following loss of consciousness ketamine was administered to Group SK (n=29) in the form of a 0.5mg/kg iv bolus. Patients in Group SS (n=30) received saline in the same manner.
3043873|NCT02267746|Experimental|Tazarotene|Tazarotene 0/1% foam (Actavis)
3043841|NCT02267980|Placebo Comparator|Group SS|Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Patients in Group SS (n=30) received saline in the same manner.
3043842|NCT02267967|Experimental|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
3043843|NCT02267954|Experimental|50% Prices/50% Calories|"The participant is exposed to the baseline menu, but the prices are edited to be at 50% of the actual price (e.g., a $1 coffee is listed as costing $.50) and the calorie labels are edited to be at 50% of the actual content (e.g., a 500 calorie Large Fries is listed as having 250 calories). In addition, the baseline mistakes are still included.~This is the Menu edited intervention."
3043844|NCT02267941||case|Diagnosis of aortic dissection was based on history and physical examination, and confirmed by imaging, visualization at surgery, and/or postmortem examination. According to the Stanford classification system, type A aortic dissection was defined as any dissection that involves the ascending aorta and type B as any that does not. Acute stage was confined to initial 14 days after symptom onset. Simple aortic aneurysm and pseudoaneurysm were excluded. Surgical and endovascular treatments were the main interventions and performed in the case group.
3043845|NCT02267941||control|As the control group, 2760 patients without AD were obtained from the hospitalized patients in the same period. Types of disease in the control group included congenital heart disease (632), coronary heart disease (467), adult valve disease (375), pulmonary artery hypertension (292), appendicitis (234), pneumonia (197), fracture (189), intestinal polyps (167), gallstone (156), esophagus cancer (51). Patients in the control group were derived from Department of Cardiovascular Surgery, Department of General Surgery, Department of Thoracic Surgery, and Department of Respiration, respectively.
3043846|NCT02267928|Experimental|Check/Experience|Participants are asked to check the symptoms that they have experienced in the last 6 weeks.
3043847|NCT02267928|Experimental|Un-check/Experience|Participants are asked to un-check the symptoms that they have experienced in the last 6 weeks.
3043848|NCT02267928|Experimental|Check/Not Experienced|Participants are asked to check the symptoms that they have NOT experienced in the last 6 weeks.
3043849|NCT02267928|Experimental|Un-check/Not Experienced|Participants are asked to un-check the symptoms that they have NOT experienced in the last 6 weeks.
3043850|NCT02267915|Experimental|subcutaneous rituximab|MabThera 1400 mg solution for subcutaneous injection
3043851|NCT02267902|Experimental|Part 1|Single oral therapeutic dose of 5mg DA-1229 as a tablet + An IV dose of 20㎍ [14C]-DA-1229
3043852|NCT02267902|Experimental|Part 2|Single oral therapeutic dose of 5mg [14C]-DA-1229
3043853|NCT02267889|Experimental|Image guided GP ablation|Use of cardiac nuclear imaging data to guide GP ablation procedures.
3043854|NCT02267863|Experimental|Dose escalation and expansion|APTO-253 HCl will be given in ascending doses in patients with acute leukemia, myelodysplastic syndrome, lymphoma or multiple myeloma until the maximum administered dose or appropriate dose is reached. Enrollment of approximately up to 15 patients with acute leukemia or myelodysplastic syndrome and 15 patients with lymphoma or multiple myeloma is anticipated in the dose escalation portion, followed by up to 30 patients enrolled in the expansion cohort at the recommended dose in two specific indications selected from the dose escalation experience.
3043855|NCT02267850|Experimental|OrthoPulse™|Subjects assigned to this group receive fixed orthodontic appliance treatment in conjunction with receiving daily OrthoPulse™ treatments.
3043856|NCT02267850|Sham Comparator|Sham-Control OrthoPulse™|Subjects assigned to this group receive fixed orthodontic appliance treatment in conjunction with carrying out daily non-functional OrthoPulse™ treatments (untreated control).
3043857|NCT02267837|Experimental|OrthoPulse™|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment in conjunction with receiving daily OrthoPulse™ treatments.
3043858|NCT02267837|No Intervention|Control|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment only, and no OrthoPulse™ treatments.
3043859|NCT02267824|Experimental|Extraoral OrthoPulse® PBM|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment in conjunction with receiving daily extraoral OrthoPulse® photobiomudulation (PBM) treatments.
3043860|NCT02267824|Other|Orthodontic Treatment (Control)|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment, only.
3043861|NCT02267811|Experimental|OrthoPulse™|Subjects assigned to this group receive orthodontic treatment in conjunction with receiving daily OrthoPulse™ treatments.
3043862|NCT02267811|Experimental|Crossover: OrthoPulse™ and no OrthoPulse™|Subjects assigned to this group receive orthodontic treatment in conjunction with a period of time receiving daily OrthoPulse™ treatments and no OrthoPulse™ therapy.
3043863|NCT02267798|Experimental|arm training combined with FES|"Arm training protocol Training sessions will last for 60 minutes and will focus on repetitive tasks that incorporate multidirectional reaching actions. In this robot-assisted therapy a robot manipulator applies forces to the paretic arm during goal-directed movements.~Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists of a battery powered programmable stimulator and a forearm-wrist-hand orthosis containing 5 electrodes positioned to provide reliable activation of muscles. The intensity of stimulation will be set to a level that provided comfortable and consistent activation of the extensor and flexor muscles to achieve whole hand opening and functional grasping."
3043864|NCT02267798|Active Comparator|conventional therapy|The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence, Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques based on neuro-developmental treatment.
3043865|NCT02267785|Experimental|Skill-Based Exercise|Participants assigned to this arm will complete the Skill-Based Exercise Intervention
3043866|NCT02267785|Experimental|Aerobic Exercise|Participants assigned to this arm will complete the Aerobic Exercise Intervention
3043867|NCT02267785|Experimental|Social Contact Group|Participants assigned to this arm will complete the Social Contact Intervention
3043868|NCT02267772|Experimental|IV Acetaminophen|IV acetaminophen for pain control
3043869|NCT02267772|Active Comparator|IV morphine|IV morphine for pain control
3043870|NCT02267759|Experimental|McGrath|Nasotracheal intubation was performed with McGrath videolaryngoscopy
3043874|NCT02267746|Placebo Comparator|Vehicle foam|Foam vehicle of the test product (Actavis)
3043875|NCT02267733|Experimental|Early Disease|Patients not requiring anti-tumor therapy
3043876|NCT02267733|Experimental|Disease Requiring Anti-tumor therapy|Patients that have disease requiring anti-tumor therapy at any time
3043877|NCT02267720|Active Comparator|Ketac Molar|Occlusal-proximal ART restorations - Ketac Molar
3043878|NCT02267720|Experimental|Vitro Molar|Occlusal-proximal ART restorations - Vitro Molar
3043879|NCT02267707|Experimental|Cohort 1 - Bilirubin level > 1.5 x ULN to 3 x ULN|4 dose levels may be given in this arm as follows: nab-paclitaxel 75 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 100 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 1000 mg/m2
3043880|NCT02267707|Experimental|Cohort 2 - Bilirubin level > 3 x ULN to 5 x ULN|6 dose levels may be given in this arm as follows: nab-paclitaxel 75 mg/m2 nab-paclitaxel 75 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 100 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 1000 mg/m2
3043881|NCT02267694|Other|Black raspberry powder|Black raspberry powder 25 grams once daily for 4 weeks. If tolerated, will increase to 25 grams twice a day for another 20 weeks. Total length of active treatment 24 weeks.
3043882|NCT02267681|Experimental|Group A|The patients in Group A will be given 100 mcg/kg/min propofol infusion and 10 mcg/kg loading dose of alfentanil and 5 mcg/kg additional bolus of alfentanil whenever FPS (Faces Pain Scale) is greater than 3 or the patients can not tolerate the procedure.
3043883|NCT02267681|Experimental|Group F|The patients in Group F will be given 100 mcg/kg/min propofol infusion and 1 mcg/kg loading dose of fentanyl and 5 mcg/kg additional bolus of fentanyl whenever FPS (Faces Pain Scale) is greater than 3 or the patients can not tolerate the procedure.
3043884|NCT02267681|Active Comparator|Group P|Group P is designated as the control group and the patients will be given 100mcg/kg/min infusion and sedation will be achieved via 1 mg/kg propofol loading dose and 0.5 mg/kg propofol additional bolus will be given whenever the patients can not tolerate the procedure or FPS is greater than 3.
3043885|NCT02267668|Experimental|STEP arm|"The Baseline Evaluation Session will include formal neuropsychological evaluation, postural stability evaluation, and an education session (education about mTBI, mTBI recovery, and expected outcomes from mTBI).~Intervention includes exercise tolerance evaluations, 3 times per week exercise by physical therapist. Self report of symptoms and exertion."
3043886|NCT02267668|Active Comparator|Control|"The Baseline Evaluation Session will include formal neuropsychological evaluation, posturalstability evaluation, and an education session (education about mTBI, mTBI recovery, and expected outcomes from mTBI).~Control protocol includes instructions for stretching, instructions for restricting physically demanding activity during first 3 weeks of study; instructions for light, self-guided daily exercise in last 3 weeks of study. Self report of symptoms and exertion."
3043887|NCT02267655|Active Comparator|inhaled Nitric Oxide 30 mcg/kg IBW/hr|30 mcg/kg IBW/hr of inhaled Nitric Oxide Part 1
3043888|NCT02267655|Active Comparator|inhaled nitric oxide 75 mcg/kg IBW/hr|Part 2: 75mcg/Kg IBW/hr
3043889|NCT02267655|Active Comparator|inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr|Part 3a: Dose tritration 5, 10 and 15 mcg/Kg IBW/hr Part 3b: continuing on dose determined by PI in 3a for 4 weeks
3043890|NCT02267655|Placebo Comparator|Placebo|Placebo for 75 mcg/kg IBW/hr
3043891|NCT02267642|Experimental|AbGn-168H|Seven (7) intravenous doses of AbGn-168H on D1 (Week 0), Day 8 (Week 1), Day 15 (Week 2), Day D29 (Week 4), D43 (Week 6), Day 57 (Week 8) and Day 71 (Week 10)
3043892|NCT02267629|Experimental|Experimental:Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13) infusion followed by assessments daily for a week, and weekly for a week.
3043893|NCT02267616|Experimental|Continued Use Implant Group|Woman randomly assigned to the continued use of their Etonogestrel Implant will continue to use their Etonogestrel Implant for contraception past FDA-approved duration of 36 months.
3043894|NCT02267616|Active Comparator|New Implant Group|Woman randomly assigned to the new Etonogestrel Implant will have their existing Etonogestrel Implant removed and a new implant placed.
3043895|NCT02267616|No Intervention|Observational Continued Use Group|Women who refuse randomization will have an option of continuing to use their existing Etonogestrel Implant beyond the FDA-approved duration (36 months).
3043896|NCT02267603|Experimental|Treatment (pembrolizumab)|"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression* or unacceptable toxicity.~* NOTE: Patients with confirmed disease progression may continue to receive treatment if they are otherwise clinically stable until there is an increase in tumor burden of 25% or more following initial confirmation of progression. Under exceptional circumstances, and with protocol P.I. and CITN P.I. approval, patients may receive treatment beyond 2 years."
3043897|NCT02267590||MCL: 80-100 samples from 60- 70 patients|Mantle Cell lymphoma patients
3043898|NCT02267590||CLL: 15-20 samples from 10-15 patients|Chronic lymphocytic leukaemia patients
3043899|NCT02267577||Adults Volunteers|Men and women over the age of 18
3043900|NCT02267564|Experimental|MPFLR without tibial tubercle transfer|Patients with patellar instability undergo MPFL reconstruction without tibial tubercle transfer.
3043901|NCT02267564|Active Comparator|MPFLR with tibial tubercle transfer|Patients with patellar instability undergo MPFL reconstruction with tibial tubercle transfer.
3043902|NCT02267551|Other|Mimic dV-Trainer|
3043903|NCT02267551|Other|daVinci Skills Simulator|
3043904|NCT02267538|Experimental|Dex group|The intervention drug (dexmedetomidine hydrochloride for injection) will be administered during a period from before anesthesia induction until the end of mechanical ventilation after surgery.
3043905|NCT02267538|Placebo Comparator|Placebo group|The placebo drug (normal saline, i.e., 0.9% sodium chloride for injection) will be administered in the same way and rate for a same duration as that in the Dex group.
3043906|NCT02267525|Experimental|Velusetrag 5mg|Velusetrag 5mg capsules QD (once daily) x 12 weeks
3043907|NCT02267525|Experimental|Velusetrag 15mg|Velusetrag 15mg capsules QD x 12 weeks
3043908|NCT02267525|Experimental|Velusetrag 30mg|Velusetrag 30mg capsules QD x 12 weeks
3043909|NCT02267525|Placebo Comparator|Placebo|Placebo capsules QD x 12 weeks
3043910|NCT02267512|Experimental|ATG-F single dosing group|Intravenous (IV)
3043911|NCT02267512|Experimental|ATG-F continuous dosing group|Intravenous (IV)
3043912|NCT02267499|Experimental|LLM training|Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
3043913|NCT02267499|No Intervention|Passive Control|Participants do not receive an intervention serving as passive controls
3043914|NCT02267486||Alzheimer Dementia (AD)|Patients with dementia caused by Alzheimer's disease
3043915|NCT02267486||Non-dementia|Patients with cognitive concern without dementia
3043916|NCT02267460|Active Comparator|AA4500 with investigator modeling and vacuum therapy|AA4500 with investigator modeling and home use of the ErecAid® Esteem® Manual Vacuum Therapy System.
3043917|NCT02267460|Active Comparator|AA4500 without investigator modeling/with vacuum therapy|AA4500 without investigator modeling but with home use of the ErecAid® Esteem® Manual Vacuum Therapy System.
3043918|NCT02267447||Derivation cohort|Eligible respondents to the combined 2001, 2003 and 2005 Canadian Community Health Surveys, conducted by Statistics Canada.
3043919|NCT02267447||Validation cohort|Eligible respondents to the 2007 and 2009 Canadian Community Health Surveys.
3043920|NCT02267434|Experimental|Low dose AFFITOPE® PD03A + Adjuvant|"4 injections of 15µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
3043921|NCT02267434|Experimental|High dose AFFITOPE® PD03A + Adjuvant|"4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
3043922|NCT02267434|Placebo Comparator|Adjuvant without active component|"4 injections of Placebo once every 4 weeks~1 administration 36 weeks after first injection"
3043923|NCT02267421|Experimental|Home based aerobic exercise|Home based aerobic exercise on cycle ergometer. Three times per week, 30-60 minutes per session.
3043924|NCT02267421|No Intervention|Usual Care group|These patients will continue with their normal activities of daily living and will not be provided with equipment or coaching for home based exercise during the study period .
3043925|NCT02267408|Experimental|Fearon algorithm dosing|Warfarin adjustment using the Fearon algorithm
3043926|NCT02267408|Active Comparator|Standard dosing|Warfarin adjustment using standard dosing
3043927|NCT02267395||(No-PRMSDs)|Group 1 : No Playing Related Musculoskeletal Injury
3043928|NCT02267395||(Yes-PRMSDs)|Group 2: Playing Related Musculoskeletal Injury
3043929|NCT02267382|Experimental|Active Arm 1|Low dose 12-week: Loading doses of VT-1161 150mg once daily for 7 days, then VT-1161 150mg once weekly for 11 weeks, followed by placebo once weekly for 12 weeks
3043930|NCT02267382|Experimental|Active Arm 2|Low dose 24-week: Loading doses of VT-1161 150mg once daily for 7 days, then VT-1161 150mg once weekly for 23 weeks
3043931|NCT02267382|Experimental|Active Arm 3|High dose 12-week: Loading doses of VT-1161 300mg once daily for 7 days, then VT-1161 300mg once weekly for 11 weeks, followed by placebo once weekly for 12 weeks
3043932|NCT02267382|Experimental|Active Arm 4|High dose 24-week: Loading doses of VT-1161 300mg once daily for 7 days, then VT-1161 300mg once weekly for 23 weeks
3043933|NCT02267382|Placebo Comparator|Control Arm|Placebo 24 weeks
3043934|NCT02267369|Active Comparator|Basic fitness program|The control condition provides study participants with online tools for enrolling in offline fitness workshops offered by the university's recreation department and recording their progress in the program. All fitness workshops are pre-programmed in an online calendar. Upon clicking a workshop, participants can read a detailed description and register for it directly on the calendar. The registration then triggers a confirmation email sent to the participant immediately and a reminder email 12 hours before the workshop starts. In addition, an online tracking tool is built that participants can use to keep a daily journal of their health activities and fitness status.
3043935|NCT02267369|Experimental|Media-assisted fitness program|"The media condition evaluates the effects of informational and motivational messages on physical activity by supplementing the basic program tools with promotional media, including: high arousal videos encouraging physical activity, real-time email notifications about upcoming fitness workshops, and informational graphics with exercise tips and motivational messages. In the media condition, participants receive two videos on the website and one informational graphic that encourage physical activity on a weekly basis."
3043936|NCT02267369|Experimental|Social network-assisted fitness program|"The social condition, by contrast, omits the media content. Instead, the basic program is supplemented with a network of four to six anonymous health peers, composed of other participants of the program. Within the program website, each participant is able to see their peers' basic profile information, as well as information about their peers' progress in the program, and real-time notifications about their peers' completion of program activities. These networks do not provide any added incentives or additional content to promote physical activity, nor can participants directly communicate with, or message their peers through the website."
3043937|NCT02267356|Experimental|Arm 1 Active|Low dose 12-week: Loading doses of VT-1161 300mg once daily for 2 weeks, then 300mg once weekly for 10 weeks, followed by placebo for 12 weeks
3043938|NCT02267356|Experimental|Active Arm 2|High dose 12-week: Loading doses of VT-1161 600mg once daily for 2 weeks, then 600mg once weekly for 10 weeks, followed by placebo for 12 weeks
3043939|NCT02267356|Experimental|Active Arm 3|Low dose 24-week: Loading doses of VT-1161 300mg once daily for 2 weeks, then 300mg once weekly for 22 weeks
3043940|NCT02267356|Experimental|Active Arm 4|High dose 24-week: Loading doses of VT-1161 600mg once daily for 2 weeks, then 600mg once weekly for 22 weeks
3043941|NCT02267356|Placebo Comparator|Control Arm|Placebo tablets corresponding to VT-1161 dosed for 24 weeks
3043942|NCT02267343|Experimental|ONO-4538 Arm|ONO-4538 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3043943|NCT02267343|Placebo Comparator|Placebo Arm|Placebo intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3043944|NCT02267330||Standard of care, Exposure recording|Patient will undergo fracture surgery as per standard of care, and will have radiation exposure recording.
3043974|NCT02267096|Experimental|Telephone Counseling (TC)|The TC arm will receive the list of minimal treatment interventions plus 3-6 sessions of stepped-care, proactive, telephone counseling.
3069430|NCT02098395|Placebo Comparator|Liraglutide placebo 0.2 ml + insulin|
3043945|NCT02267317|Active Comparator|Lean with normal glucose tolerance (NGT)|"Lean NGT; (20 Completers) Lean = BMI less than 26 kg/m2. NGT = Normal Glucose Tolerance.~Infusion protocol: Administer eritoran for injection 12 milligrams IV every 12 hours for 72 hours (6 doses) to inhibit TLR4 or placebo~In the first infusion visit; each subject will receive either the Eritoran 12 mg IV every 12 hours or the vehicle (D5W) 12 mg IV every 12 hours.~In the second infusion visit; each subject will receive one of the remaining infusion pairings that have been randomized to them"
3043946|NCT02267317|Active Comparator|Obese with NGT|"Obese with NGT; (20 Completers) Obese = BMI 30-37 kg/m2. NGT = Normal Glucose Tolerance.~Infusion protocol;~In the first infusion visit; each subject will receive either the Eritoran 12 mg IV every 12 hours or the vehicle (D5W) 12 mg IV every 12 hours.~In the second infusion visit; each subject will receive one of the remaining infusion pairings that have been randomized to them"
3043947|NCT02267317|Active Comparator|Obese with T2 DM|"Obese with T2 DM; (20 completers) Obese = BMI 30-37 kg/m2. T2DM = Type 2 Diabetes Mellitus.~Infusion protocol;~In the first infusion visit; each subject will receive either the Eritoran 12 mg IV every 12 hours or the vehicle (D5W) 12 mg IV every 12 hours.~In the second infusion visit; each subject will receive one of the remaining infusion pairings that have been randomized to them"
3043948|NCT02267291|Experimental|All patients|Ventilatory support to alter intrathoracic pressure
3043949|NCT02267278|Experimental|Ruxolitinib + Pracinostat|"Ruxolitinib starting dose 15 mg orally twice/day in 28-day cycle (dose assigned based on platelet count, if low platelet count gradual up-titration from a starting dose of 5 mg) - given alone for first 3 months, then Pracinostat added at starting dose 60 mg orally once/day for 3 alternating days every 3 weeks starting Day 1 of Cycle 4.~Dose of Ruxolitinib may be increased or decreased prior to initiation of Pracinostat. Quality of Life Questionnaire."
3043950|NCT02267265|Experimental|Treatment intervention|The treatment group will complete a demographics questionnaire and the knowledge survey before the intervention. Participants will then view the 10 minute TMW-Newborn Intervention video around the time of the newborn hearing screening. Participants whose newborn does not pass the hearing screen will view an additional 3 minute video detailing the importance of following up for an outpatient re-screening. The participant will complete the knowledge survey again before discharge, and after approximately four to six weeks.
3043951|NCT02267265|Active Comparator|Control intervention|The control group will complete a demographics questionnaire and knowledge survey. Participants will subsequently view the 10-minute Safe Sleep for your Baby (SIDS) educational video. It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome. This will be around the time of the newborn hearing screening. Participants will complete the knowledge survey again before discharge, and after approximately four to six weeks.
3043952|NCT02267239|Active Comparator|Essential Oils, immersion|Professional oral cleaning Plaster cast IDODS Immersion the disk with the biofilm in the essential oils antiseptic solution
3043953|NCT02267239|Active Comparator|Chlorhexidine, immersion|Professional oral cleaning Plaster cast IDODS Immersion the disk with the biofilm in the chlorhexidine antiseptic solution
3043954|NCT02267239|Other|baseline|Professional oral cleaning Plaster cast IDODS Disk in basal conditions.
3043955|NCT02267239|Active Comparator|Essential Oils, mouthwash|Professional oral cleaning Plaster cast IDODS Active mouthwash with the essential oils antiseptic solution
3043956|NCT02267239|Active Comparator|Chlorhexidine, mouthwash|Professional oral cleaning Plaster cast IDODS Active mouthwash with the chlorhexidine antiseptic solution
3043957|NCT02267226|Experimental|Octafibrin|
3043958|NCT02267213|Experimental|Lipotecan|Administer 40mg of Lipotecan at D1, D8, D15 of each cycles.
3043959|NCT02267200||reversible PAH group|reversible PAH was defined as sPAP decreasing to 40 mmHg after follow-up more than 6 months through echocardiography.
3043960|NCT02267200||irreversible PAH group|irreversible PAH was defined as 6 months after surgery through echocardiography ，the sPAP remaining 40 mmHg or up
3043961|NCT02267187|Experimental|Fat Graftting|For the purpose of this study the fat grafting procedure is a research procedure. It is very important to note that this research procedure is not an experimental procedure. Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is known as a filler providing an accurate means to restoring facial soft tissue structure.
3043962|NCT02267174|Other|Standardized OR to ICU handoff|A standardized handoff process for conducting OR to ICU handoffs will be implemented in two intensive care units without a standard process.
3043963|NCT02267161|Experimental|neuropsycological tests|Psychometric scales for infants at 3 years of age
3043964|NCT02267135|Experimental|Secukinumab|Eligible patients will receive secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 20 inclusive
3043965|NCT02267135|Placebo Comparator|Placebo|Eligible patients will receive placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8. Prior to taking the Week 12 dose, the patient will be assessed for response to treatment using the Psoriasis Scalp Severity Index (PSSI). If the subject is a responder, the subject will continue on placebo dosing weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20. Subjects who are not responders will be switched to treatment with secukinumab 300 mg and will dose once weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20.
3043966|NCT02267122|Experimental|ionic silver-containing dressing|After placing the staples, a ionic silver-containing dressing was placed covering the wound.
3043967|NCT02267122|Experimental|Mupirocin ointment application|After placing the staples, a Mupirocin ointment application was placed covering the wound.
3043968|NCT02267122|No Intervention|Conventional dressing|After placing the staples, a conventional dressing, without application of any special gauze or ointment, was placed covering the wound
3043969|NCT02267109|Experimental|2.5 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 2.5 x 10(10):
3043970|NCT02267109|Experimental|5 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 5 x 10(10):
3043971|NCT02267109|Experimental|1.0 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 1.0 x 10(10):
3043972|NCT02267109|Experimental|1.0 x 10(11) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 1.0 x 10(11):
3043973|NCT02267109|Experimental|Booster-MVA-BN® Filo or saline placebo|MVA-BN® Filo or saline placebo
3043975|NCT02267096|Active Comparator|Minimal Treatment|The minimal treatment intervention includes a list of print, online, national telephone quitline phone number, and in-person cessation resources that is sent to participants.
3043976|NCT02267083|Experimental|GPX-150|GPX-150 for Injection, 265 mg/m2, every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity, or subject withdrawal.
3043977|NCT02267070|Experimental|Cognitive Training and Exercise|24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. Aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations. All members receive individual case management and supportive psychotherapy, and family psychoeducation.
3043978|NCT02267070|Active Comparator|Cognitive Training|24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations. All members receive individual case management and supportive psychotherapy, and family psychoeducation.
3043979|NCT02267057|Active Comparator|Paracetamol or buprenorphine treatment|Paracetamol tablets 1 g three times daily or Buprenorphine transdermal system 5 micrograms/hour every 7 days, may be titrated up to 10 micrograms/hour every 7 days if clinically appropriate.
3043980|NCT02267057|Placebo Comparator|Paracetamol placebo or buprenorphine placebo|Paracetamol placebo tablet three times daily or buprenorphine transdermal system placebo every 7 days.
3043981|NCT02267044|Active Comparator|Ropivacaine Single Shot Block|Single Shot Interscalene block patients will receive a single shot of 30ml of 0.5% Ropivacaine prior to surgery
3043982|NCT02267044|Active Comparator|Ropivacaine Continuous block|Continuous Interscalene block patients will receive a shot of up to 30ml of 0.5% Ropivacaine and then a catheter is placed. The catheter is secured with Dermabond and Tegaderm. Once surgery is complete, the catheter is connected to a pain ball system which holds 400ml of 0.2% Ropivacaine local anesthetic. The rate is locked in at 8ml/hr. Catheter is pulled once the pain ball is empty.
3043983|NCT02267031|Active Comparator|normoxia and normocapnia|Normoxia PaO2 of 70-140 mm Hg Normocapnia PaCO2 of 35-48 mmHg
3043984|NCT02267031|Active Comparator|hyperoxia and normocapnia|Hyperoxia 150-300 mm Hg Normocapnia PaCO2 of 35-48 mmHg
3043985|NCT02267031|Active Comparator|normoxia and hypocapnia|Normoxia PaO2 of 70-140 mm Hg Hypocapnia PaCO2 of 25-35 mmHg
3043986|NCT02267031|Active Comparator|hyperoxia-hypocapnia|Hyperoxia 150-300 mm Hg Hypocapnia PaCO2 of 25-35 mmHg
3043987|NCT02267018|Active Comparator|nCPAP|Nasal continuous positive airway pressure is a frequently used modality for non-invasive respiratory support in preterm infants.
3043988|NCT02267018|Active Comparator|NIHFV|Non-invasive high-frequency ventilation is a relatively new modality that is being utilized to support preterm infants and prevent the need for invasive ventilation, but this particular modality is has not been well studied to date.
3043989|NCT02267005|Experimental|Treatment|patients on this arm will be treated with creapure supplements
3043990|NCT02267005|Placebo Comparator|Placebo|patients on this arm will be given a placebo glucose tablet supplement
3043991|NCT02266992|Experimental|Fluenz Tetra|Live attenuated influenza vaccine- Fluenz tetra. Intra-nasal administration of 0.2ml (0.1ml in each nostril).
3043992|NCT02266966|Experimental|F2695|Single dose - 2 capsules / Day on Day 1 and Day 8
3043993|NCT02266966|Placebo Comparator|placebo|Single dose - 2 capsules / Day on Day 1 and Day 8
3043994|NCT02266953|Experimental|Use of communication tool about diet|The children and parents in the intervention group are visiting consultations at the child health centre where the public health nurses use a communication tool about diet in order to promote dialogue about themes concerning food and feeding practices. This intervention is carried out at consultations when the child is 10-, 12- and 15-18 months old.
3043995|NCT02266953|Active Comparator|Treatment as usual|The children and parents in the control group are visiting consultations at the child health centre where the public health nurses will conduct the consultations as usual and without use of the actual communication tool about diet. The consultations are carried out when the child is 10-, 12- and 15-18 months old.
3043996|NCT02266940|Experimental|200mg DS-1971a oral suspension fasted|200 mg DS 1971a given as oral suspension in fasted condition
3043997|NCT02266940|Experimental|200 mg DS-1971a tablet fasted|single 200 mg DS 1971a oral tablet in fasted condition
3043998|NCT02266940|Experimental|200 mg DS-1971a tablet fed|single 200 mg DS 1971a oral tablet given in fed condition
3043999|NCT02266927|Active Comparator|Flovent® HFA 440µg|Flovent® HFA (fluticasone propionate) Inhalation Aerosol 440 µg
3044000|NCT02266927|Experimental|OPTINOSE™ FLUTICASONE 400µg intranasal|OPTINOSE™ FLUTICASONE, single dose of 400 µg intranasally
3044001|NCT02266914|Experimental|Arm 1|Patients who have received a cardiac transplant at The Ohio State University Ross Heart Hospital will undergo Magnetic Resonance Elastography (MRE) (using a Magnetic Resonance Elastography driver) within 24-48 hours of standard of care biopsy. Results of both will be compared to determine if MRE can successfully predict cardiac transplant rejection.
3044002|NCT02266901||Cases (endoscopic drainage)|Septic patients presenting post-bariatric collections related to leaks not adequately drained by percutaneous drain, for whom endoscopic drainage of the collections was performed by transluminal or percutaneous route.
3044003|NCT02266888|Experimental|Rituximab Induction|Rituximab (Rituxan®) Induction Therapy Plus Standard of Care Immunosuppression (thymoglobulin induction, tacrolimus or equivalent, MMF or equivalent, and steroids)
3044004|NCT02266888|Placebo Comparator|Placebo Induction|Placebo Induction Therapy Plus Standard of Care Immunosuppression (Thymoglobulin® induction, tacrolimus or equivalent, MMF or equivalent, and steroids)
3044056|NCT02266563||Mild Cognitive Impairment (MCI) Group|MCI Subjects will have MMSE scores between 24-30 (inclusive), a CDR of 0.5, have no depression, no history of TBI, and no dementia.
3044005|NCT02266875|Experimental|Hypertonic Saline|"Patients will receive nebulized hypertonic (3%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use).~Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale."
3044006|NCT02266875|Active Comparator|Standard Saline|"Patients will receive standard saline (0.9%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use).~Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale."
3044007|NCT02266862||Study Group|The purpose of this study is to evaluate the location within the renal artery of maximal angular displacement before and after fenestrated endovascular aortic repair (FEVAR) using CT with end-inspiration and end-expiration CT images before and after repair.
3044008|NCT02266849|Active Comparator|Loperamide|Patients will take the drug for three days. Day 1 - uploading with the drug Day 2 - collecting output when necessary Day 3 - radiopaque marker and collection of output every two hours
3044009|NCT02266849|Placebo Comparator|Placebo|Patients will take the drug for three days. Day 1 - uploading with the drug Day 2 - collecting output when necessary Day 3 - radiopaque marker and collection of output every two hours
3044010|NCT02266836|Experimental|MyndMove|The MyndMove system is a neuromodulation device that delivers short electrical pulses to stimulate muscle contractions and enhance motor recovery following Stroke or Spinal Cord Injury. MyndMove delivers therapeutic stimulation sequences called protocols, which are coded therapeutic algorithms which assist muscle movement allowing the brain and central nervous system to be retrained restoring voluntary reaching and grasping functions lost following neurological injury. The MyndMove system comprises the hardware device, stimulation electrodes and cables, hand and foot switches, and integrated software.
3044011|NCT02266823|Active Comparator|Intervention: Lifestyle A.|"Lifestyle A will receive an iPad loaded with a self-monitoring program used to support vigilance, reduce the information processing requirements, make readily available the information required to make good self-management decisions, provide real-time feedback, and permit targeted counseling in the context within which lifestyle behaviors occur.~Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling."
3044012|NCT02266823|Other|Intervention: Lifestyle B.|"Participants randomized to this group will receive 6 months of routine care followed by a delayed intervention. Lifestyle B will employ the same diet and physical activity prescription as Lifestyle A as described above.~Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling."
3044013|NCT02266810|Experimental|PROPEL Mini Sinus Implant|Propel Mini placed in frontal sinus opening following ESS
3044014|NCT02266810|Active Comparator|Sinus Surgery alone: cohort 1|Sinus Surgery only: cohort 1: ESS with standard post-operative care.
3044015|NCT02266810|Experimental|PROPEL Nova Sinus Implant|Propel Nova placed in frontal sinus opening following ESS
3044016|NCT02266810|Active Comparator|Sinus Surgery alone: cohort 2|Sinus Surgery only: cohort 2: ESS with standard post-operative care.
3044017|NCT02266797|Active Comparator|Dexamethasone|Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
3044018|NCT02266797|Placebo Comparator|Saline|Subject will receive doses of intravenous physiological saline solution.
3044019|NCT02266784|Experimental|Contingency Management (CM)|ADHD (N=20) & CTRL (N=20). Participants will earn compensation, based upon smoking abstinence via a Contingency Management (CM) system. This level of compensation will increase by the same amount each visit based upon abstinence. In addition, escalating bonus payments will be available for evidence of continued abstinence. The first 10 visits will be daily weekdays. The following 9 visits will be over three weeks. The final 3 treatment visits will occur weekly. The 2nd & 3rd type visits CM payments will be based upon monitoring participants' cotinine levels. A missed visit or elevated CO level will lead to 1) no CM payment for that day; 2) resetting the contingencies such that the next CO sample that is below the criterion will result in payment equal to the first day. If there is a lapse, participants' contingencies will be reinstated at their previous highest level post 3 abstinent days. Also follow-up visits at 3 and 6 months.
3044020|NCT02266784|Other|Treatment as Usual|ADHD (N=20). Transdermal nicotine skin patches (i.e. Habitrol) will be used along with supportive counseling in the treatment as usual groups. Visit schedules will coincide with the visit schedules for the CM groups (daily visits for 1st 2 weeks, 3X weekly visits for weeks 3-5, 1x weekly visit for weeks 6-8). A standard regimen of nicotine replacement with which the study team has experience will be used: four weeks of 21 mg/d beginning on the QD, two weeks of 14 mg/d and two weeks of 7 mg/d. Also follow-up visits at 3 and 6 months.
3044021|NCT02266771|Active Comparator|NPWT with Instillation|Negative Pressure Wound Therapy with Instillation.
3044022|NCT02266771|Placebo Comparator|NPWT without Instillation|Negative Pressure Wound Therapy without Instillation
3044023|NCT02266758|Other|GDM Screening Method 1|GDM Screening Methods
3044024|NCT02266758|Other|GDM Screening Method 2|GDM Screening Methods
3044025|NCT02266745|Experimental|PT-112 injection|PT-112 Injection, administered by intravenous infusion
3044026|NCT02266732|Other|Interscalene block|
3044027|NCT02266732|Other|Femoral block|
3044028|NCT02266719|Experimental|CMD arm|Patients enrolled in this arm will receive the custom made device to treat their condition.
3044029|NCT02266706|Experimental|Group 1: 12 to less than 18 years old|Includes ages 12 years up to, but not including, 18 years. Six participants to receive a fixed dose of ceftolozane/tazobactam (comprising 1000 mg ceftolozane and 500 mg tazobactam) as a 60 minute infusion.
3044057|NCT02266563||Healthy Control Group|Healthy control subjects will have no self or informant-reported problems with cognition, no depression, no history of TBI, and no dementia.
3044058|NCT02266537|Experimental|Tamsulosin|
3044030|NCT02266706|Experimental|Group 2: 7 to less than 12 years old|Includes ages 7 years up to, but not including, 12 years. Six participants to receive a dose of ceftolozane/tazobactam (comprising 18 mg/kg of ceftolozane and 9 mg/kg of tazobactam) as a 60 minute infusion.
3044031|NCT02266706|Experimental|Group 3: 2 to less than 7 years old|Includes ages 2 years up to, but not including, 7 years. Six participants to receive a dose of ceftolozane/tazobactam (comprising 18 mg/kg of ceftolozane and 9 mg/kg of tazobactam) as a 60 minute infusion.
3044032|NCT02266706|Experimental|Group 4: 3 months to less than 2 years|Includes ages 3 months up to, but not including, 2 years. Six participants to receive a dose of ceftolozane/tazobactam (comprising 18 mg/kg of ceftolozane and 9 mg/kg of tazobactam) as a 60 minute infusion.
3044033|NCT02266706|Experimental|Group 5: less than 3 months; greater than 32 weeks gestation|Includes ages birth (7 days postnatal) up to, but not including, 3 months and greater than 32 weeks gestation. Six participants to receive a dose of ceftolozane/tazobactam (comprising 12 mg/kg of ceftolozane and 6 mg/kg of tazobactam) as a 60 minute infusion.
3044034|NCT02266706|Experimental|Group 6: less than 3 months and 32 weeks gestation or less|Includes ages birth (7 days postnatal) up to, but not including, 3 months and less than or equal to 32 weeks gestation. Six participants to receive a dose of ceftolozane/tazobactam (comprising 12 mg/kg of ceftolozane and 6 mg/kg of tazobactam) as a 60 minute infusion.
3044035|NCT02266693|Experimental|ICBT Group|The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
3044036|NCT02266693|No Intervention|Waitlist Group|Upon completion of the 8-week study wait-list period (i.e. their study participation), the opportunity to participate in iCBT, outside the study framework will be provided.
3044037|NCT02266680|Experimental|Yoga Treatment Group|BFY will be taught by a trained yoga instructor. Group sessions will be offered twice a week for 60 minutes each (i.e., a total of 2 hours per week), for 8 weeks.
3044038|NCT02266680|No Intervention|Waitlist Group|Waitlisted participants will receive BFY at the next available group after their waitlist period is completed
3044039|NCT02266667|Experimental|Progressive scoliosis|Children with progressive scoliosis
3044040|NCT02266667|Experimental|Neuromuscular scoliosis|Children with neuromuscular scoliosis
3044041|NCT02266654|Experimental|Prehospital-directed therapy arm|Patients who are hypotensive or whose lactate is ≥ 2.5, prehospital providers will provide a notification to the receiving hospital (Hospital Notification), establish an IV, and provide 1 liter normal saline (NS) bolus of IV fluids. An additional 1 liter normal saline bolus will be given for systolic blood pressure less than 100. Patients who have a history of end-stage renal disease or congestive heart failure would receive only 20 milliliters/kilogram of fluid. If the patient remains hypotensive, Emergency Medical Services will continue providing fluids as is standard of care.
3044042|NCT02266654|Experimental|Control Arm|Prehospital providers will obtain a point of care lactate, establish an IV, and provide IV fluids as judged necessary.
3044043|NCT02266641|Active Comparator|healthy pregnant women|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
3044044|NCT02266641|Experimental|healthy pregnant women's lineal relative with cancer|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
3044045|NCT02266641|Experimental|pregnant women or lineal relative with overweight/obesity|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
3044046|NCT02266641|No Intervention|healthy pregnant women's lineal relative with diabetes|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
3044047|NCT02266628|Experimental|Treatmetn Group A|RSV-F vaccine (0.5mL Injection)
3044048|NCT02266628|Placebo Comparator|Treatment Group B|Saline Placebo (0.5mL Injection)
3044049|NCT02266615||Genetic research in 5 areas.|Cardiogenetics; Intellectual Disability, Multiple Congenital Abnormalities and Rare Diseases; Oncogenetics; Dermatogenetics; Reproductive Genetics.
3044050|NCT02266602|Other|Treatment|Patients treated with intraoperative radiation therapy at the time of partial mastectomy.
3044051|NCT02266589|Experimental|Hydrocortisone|little doses of hydrocortisone
3044052|NCT02266589|No Intervention|Placebo|Placebo
3044053|NCT02266576|Placebo Comparator|Standard DPP|The Standard Diabetes Prevention Program (DPP) delivered by the Indian Health Center is the Group Lifestyle Balance DPP, which has previously been tailored for the urban American Indian/Alaskan Natives (AIAN). The Standard DPP consists of 16 group classes, 4 visits with a lifestyle coach, and individual meetings with a registered dietician and fitness coordinator. The intervention will occur over the course of 20 weeks.
3044054|NCT02266576|Experimental|Enhanced DPP|The Enhanced Diabetes Prevention Program (DPP) will include all components of the Standard DPP [16 group classes, 4 visits with a lifestyle coach, and individual meetings with a registered dietician and fitness coordinator] delivered by the Indian Health Center and additional components to address psychosocial issues. The Enhanced DPP components include 4 visits with a mental health counselor, active referrals to mental health services, and traditional healing workshops, such as the use of talking circles to address specific psychosocial issues that are a result of historical trauma, stress, and grief. The intervention will occur over the course of 20 weeks.
3044055|NCT02266563||Traumatic Brain Injury (TBI) Group|TBI subjects will have a history of one or more concussions and have a memory complaint and objective decline that is considered to be worse than others of the same age (in the absence of an acute medical event). Severity classifications of the subjects selected for past history of TBI will be based upon established criteria used in TBI research (i.e., traumatically induced physiologic disruption of brain function as indicated by at least one of the following: any period of loss of consciousness, any loss of memory for events immediately before or after the accident, any alteration in mental state at the time of the accident, focal neurologic deficits that may or may not be transient). TBI cases will be those with mTBI (single or multiple concussion). Most recent injury must have occurred at least 1 year prior to study enrollment.
3044059|NCT02266537|Experimental|Alfuzosin|
3044060|NCT02266537|Experimental|Doxazosin|
3044066|NCT02266511|Experimental|Sequence 1|Flomax®, Nishine facility followed by Flomax®, Norman II facility
3044067|NCT02266511|Experimental|Sequence 2|Flomax®, Norman II facility followed by Flomax®, Nishine facility
3044068|NCT02266498|Experimental|BIBB 515 BS after a standard breakfast|
3044069|NCT02266498|Active Comparator|BIBB 515 BS|
3044070|NCT02266485|Experimental|BIBB 515 BS|
3044071|NCT02266485|Active Comparator|Pravastatin|
3044072|NCT02266485|Placebo Comparator|Placebo|
3044073|NCT02266472|Experimental|Fixed dose combination|Single dose empagliflozin/metformin
3044074|NCT02266472|Active Comparator|Single tablets combination|single doses empagliflozin and metformin
3044075|NCT02266446|Experimental|Attention & Interpretation Modification|The final product will be web-delivered, so it may be completed at the clinic or home. Treatment will consist of 8, 30-minute, twice-weekly sessions designed to: a) decrease attention bias to threat and b) extinguish threat interpretations/reinforce benign interpretations of ambiguity. Attention bias will be modified via a dot probe task that increases attentional control by directing attention away from threat faces via probe location. Patients will complete 256 trials per session. Interpretation bias will be modified via a word-sentence association task which provides positive feedback when participants endorse benign interpretations of ambiguous sentences and negative feedback for threat interpretations. Participants will complete 150 training trials per session
3044076|NCT02266433|Active Comparator|Arm Receiving Dexamethasone Injection|"Dexamethasone will be administered as a peritendinous soft tissue injection of 1 mL of dexamethasone sodium phosphate (4mg/mL) and 0.5 mL (5mg) of 1% lidocaine.~Dexamethasone will be administered as a peritendinous soft tissue injection of 1 mL of dexamethasone sodium phosphate (4mg/mL) and 0.5 mL (5mg) of 1% lidocaine~Patients will be followed at the initial office visit, 4-weeks, 8-weeks, 12-weeks, and 6 months post injection to determine clinical response. A second injection can be given only once if the patient desires due to no clinical response at the 4 or 8-week follow-up."
3044077|NCT02266433|Experimental|Arm Receiving Ketorolac Injection|"Ketorolac will be administered as a peritendinous soft tissue injection of 1 mL of ketorolac (30mg/mL) and 0.5 mL (5mg) of 1% lidocaine.~Patients will be followed at the initial office visit, 4-weeks, 8-weeks, 12-weeks, and 6 months post injection to determine clinical response. A second injection can be given only once if the patient desires due to no clinical response at the 4 or 8-week follow-up."
3044078|NCT02266420|Other|TNBC pT1a/b with size < or = 10 mm|Patients with pN0 triple negative breast tumor with size < or = 10 mm (pT1a/b) Study intervention = blood samples collected at initial visit
3044079|NCT02266420|Other|TNBC pT1c T2 with size <or = 30 mm|Patients with pN0 triple negative breast tumor with size < or = 30 mm (pT1c T2) Study intervention = blood samples collected at initial visit
3044080|NCT02266407|Active Comparator|ASEPTIC Revision TKA & Aquamantys System|Single-stage revision TKA cases performed for aseptic failure requiring an extended osteotomy for component removal and intra-operative blood management (bipolar sealing) with the Aquamantys® System. These will be compared to in-house matched historic control using patients presenting with ASEPTIC failed primary TKA and revised without use of the Aquamantys® System.
3044081|NCT02266407|Active Comparator|SEPTIC Revision TKA & Aquamantys System|Single-stage revision TKA cases performed for septic failure requiring an extended osteotomy for component removal and intra-operative blood management (bipolar sealing) with the Aquamantys® System. These will be compared to in-house matched historic control using patients presenting with SEPTIC failed primary TKA revised without use of the Aquamantys® System.
3044082|NCT02266394|Active Comparator|Mesenchymal stem cell delivery|To determine hemodynamic and immunologic changes associated with intra-renal delivery of adipose-derived MSC into human subjects with advanced RVD.
3044083|NCT02266394|Active Comparator|Mesenchymal stem cell delivery with stent placement|To test adjunctive delivery of MSC to individuals with advanced RVD undergoing renal artery stenting.
3044084|NCT02266381|Other|US-guided group|Patients in US-guided group undergo MPCNL using only US-guided renal access.
3044085|NCT02266381|Other|Fluoroscopy-guided group|Patients in Fluoroscopy-guided group undergo MPCNL using only fluoroscopy-guided renal access.
3044086|NCT02266381|Other|Combined-guided group|Patients in Combined-guided group undergo MPCNL using US combined with fluoroscopy-guided renal access.
3044087|NCT02266368|No Intervention|Control group|This arm will include patients with non-coated stents
3044088|NCT02266368|Active Comparator|Antimicrobeal group|This arm will include patients with antimicrobeal coated stents
3044089|NCT02266355|Experimental|OmalizumabTreatment Group|Omalizumab (Xolair) 300 mg SQ every 2 weeks
3044090|NCT02266329|Active Comparator|prazosin|Subjects will be gradually titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
3044091|NCT02266329|Placebo Comparator|placebo|Subjects will be gradually titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
3044092|NCT02266316|Experimental|Mask|Using mask that warms air at the mouth by utilising body heat
3044093|NCT02266316|No Intervention|No mask|Not using any mask that warms air at the mouth by utilising body heat
3044094|NCT02266303|Experimental|With checklist|Doctors will initiate insulin with the aid of a checklist
3044095|NCT02266303|No Intervention|Without checklist|Doctors will initiate insulin without the use of the checklist
3044096|NCT02266290|Experimental|Kinesio-Tape group|In this study, Sport tex® kinesiotape over lateral ankle (6cm*2.5m) is used.
3044097|NCT02266290|Placebo Comparator|Placebo Tape Group|In the placebo group, Pretape Cramer® (100% cotton, 1.25cm*10m) was used. With patient in the same position described above, horizontal strips were placed covering the sural region with no defined direction.
3044098|NCT02266277|Active Comparator|Arm 1: E-portal message with IVR call|Patients identified as e-portal users will receive an e-portal message with IVR call
3044099|NCT02266277|Active Comparator|Arm 2: E-portal message with no IVR call|Patients identified as e-portal users will receive an e-portal message only
3044100|NCT02266277|Active Comparator|Arm 3: No e-portal message with IVR call|Patients identified as e-portal users will receive an IVR call only
3044101|NCT02266277|No Intervention|Arm 4: No E-portal message with no IVR call|Patients identified as e-portal users will receive neither an e-portal message nor an IVR call
3044102|NCT02266277|Active Comparator|Arm 5: IVR call|Patients identified as non e-portal users will receive an IVR call only
3044103|NCT02266277|No Intervention|Arm 6: No IVR call|Patients identified as non e-portal users will not receive any outreach
3044104|NCT02266264|Experimental|100 milligrams of hydrocortisone|100 milligrams per day of hydrocortisone is the starting dosage.
3044105|NCT02266264|Active Comparator|200 milligrams of hydrocortisone|200 milligrams per day of hydrocortisone is the starting dosage.
3044106|NCT02266251||Surgical AVR|No interventions will be administered. Retrospective data analysis will be completed to compare health outcomes among patients with a similar baseline health satus who are eligible for both procedures (operative transcatheter AVR patients enrolled in the Transcatheter Valve Therapies (TVT) Registry (Nov 2011-Dec 2013) and surgical AVR patients with STS perioperative risk of mortality whose index procedure is included in the STS Adult Cardiac Surgical DAtabase (ACSD) (Jan 2011-Dec 2013).
3044107|NCT02266251||Transcatheter AVR|No interventions will be administered. Retrospective data analysis will be completed to compare health outcomes among patients with a similar baseline health satus who are eligible for both procedures (operative transcatheter AVR patients enrolled in the TVT Registry (Nov 2011-Dec 2013) and surgical AVR patients with STS perioperative risk of mortality whose index procedure is included in the STS ACSD (Jan 2011-Dec 2013).
3044108|NCT02266238|Experimental|Group 1|DSA guided percutaneous balloon dilatation to expand the stenosis of arteriovenous fistula
3044109|NCT02266238|Experimental|Group 2|Ultrasound guided percutaneous balloon dilatation to expand the stenosis of arteriovenous fistula
3044110|NCT02266238|Experimental|Group 3|Surgical reconstruction of the stenosis to reconstruction the lumen of arteriovenous fistula
3044111|NCT02266225|Experimental|Lifestyle-integrated functional exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
3044112|NCT02266212|Active Comparator|Smoke|Fagerstrom test for nicotine dependence
3044113|NCT02266212|Active Comparator|Pain|pain during post-operation Day1 to Day4
3044114|NCT02266212|Active Comparator|Morphine|Morphine consumption during post-operation Day1 to Day4
3044115|NCT02266199||conservative patients|in-patients on pneumology, cardiology, neurology, gastroenterology, endocrinology
3044116|NCT02266199||operative patients|inpatient on Traumatology, Plastic Surgery, Cardiothoracic Surgery, Gynecology, Abdominal Surgery
3044117|NCT02266186|Experimental|Internet CBT|Intervention:Internet-based cognitive behavioural therapy.
3044118|NCT02266186|Active Comparator|Traditional CBT|Intervention:Traditional CBT given by a therapist following given modules.
3044119|NCT02266186|No Intervention|Care as usual|Childbirth preparation according to local routine
3044120|NCT02266173||Pertuzumab|Participants for whom the treating physician has decided to administer pertuzumab according to standard of care and in line with the current summary of product characteristics (SmPC)/local labeling, will be observed.
3044121|NCT02266160|Experimental|1|"71 tinnitus patients treated with 2 gram EMLA 5% cream a day for 4 days, 4 hours a day.~we will compare the questionnaires results before and after 4 days of treatment to see whether EMLA cream changes the degree of suffer from tinnitus"
3044122|NCT02266160|Sham Comparator|2|71 tinnitus patients using cetomacrogol cream (lotion cream, does not contain any drug) for 4 days. these patients will fulfill the questionnaires as the investigational group.
3044123|NCT02266147|Experimental|SD-101 in combination with low-dose radiation|"PART 1~Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1~COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 2: 2 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 3: 4 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 4: 8 mg/mL at Days 1, 8, 15, 22, and 29~PART 2~Cycle 1: Required~Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1~COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 2: 8 mg/mL at Days 1, 8, 15, 22, and 29~Cycle 2: Optional~Radiation: 2 fractions of 2 Gy over 2 days at Days 180 and 181~COHORT 1: 1 mg/mL at Days 181, 188, 195, 202, and 209~COHORT 2: 8 mg/mL at Days 181, 188, 195, 202, and 209"
3044124|NCT02266134|Experimental|Standardized Implementation|Sites randomized to the standardized condition will be expected to use the Patient Health Questionnaire prior to each session with a depressed client and they will work as a team to maximize fidelity. Sites in this arm will receive the standard implementation of measurement based care intervention.
3044125|NCT02266134|Experimental|Tailored Implementation|Sites randomized to the tailored condition will develop a site-specific protocol for use of the Patient Health Questionnaire and they will work as a team to maximize the fit of measurement based care to this clinic. Sites in this arm will receive the tailored implementation of measurement based care intervention.
3044126|NCT02266121|Active Comparator|real tDCS|"Patients will receive non-invasive and painless brain stimulation over the rain areas involved in cognitive aptitudes.~tDCS will be applied during 20 minutes while patients will perform attentional, working memory and executive tasks"
3044127|NCT02266121|Placebo Comparator|Sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
3044128|NCT02266108|Experimental|ESTIMA intervention|This group is randomized to receive the ESTIMA intervention and will be followed for 12 months for follow-up.
3044129|NCT02266108|Other|Wait-list control|This group will receive standard of care (education as well as referrals to testing and treatment). After 12 months of follow-up, this group will receive the ESTIMA intervention.
3044130|NCT02266095|Active Comparator|Oval-8 Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee). Oval-8 splints are not commonly used for treatment of thumb CMC arthritis.~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
3044172|NCT02265822|Active Comparator|midazolam|0.5 mg/kg (max 20 mg) oral midazolam premedication will be administered approximately 40 min before the induction of general anaesthesia with propofol. The melatonin will be prepared in a fixed volume of 5 ml adding 5% dextrose in a syringe without needle.
3044460|NCT02264119|Active Comparator|Lefradafiban tablet without Pantoprazole|
3044131|NCT02266095|Active Comparator|Tee Pee Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee).~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
3044132|NCT02266095|Active Comparator|Forearm Based Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee).~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
3044133|NCT02266069|Other|Research cluster 1: Antwerp|The first Dutch-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from October 2014.
3044134|NCT02266069|Other|Research cluster 2: Mons|The first French-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from November 2014.
3044135|NCT02266069|Other|Research cluster 3: Brussels|The only bilingual Dutch/French-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from December 2014.
3044136|NCT02266069|Other|Research cluster 4: Limburg|The second Dutch-speaking research cluster in a stepped wedge cluster design. Family doctors will implement the Care Pathway for Primary Palliative Care and will recruit eligible patients from April 2015.
3044137|NCT02266069|Other|Research cluster 5: ?|A second French-speaking research cluster in a stepped wedge cluster design. Family doctors will implement the Care Pathway for Primary Palliative Care and will recruit eligible patients from October 2015.
3044138|NCT02266056|Experimental|Deep neuromuscular relaxation|
3044139|NCT02266056|Active Comparator|Moderate neuromuscular relaxation|
3044140|NCT02266030|Experimental|Cilostazol|Cilostazol 100-200 mg qd
3044141|NCT02266030|Active Comparator|Aspirin|Asprin 100mg qd for active comparator
3044142|NCT02266017|Experimental|Mobile Pain Coping Skills Training|Coping Skills Training for pain will be delivered to participants using video-conferencing via a tablet computer.
3044143|NCT02266017|Active Comparator|In person Pain Coping Skills Training|Participants will be provided with an in-person pain coping skills training intervention
3044144|NCT02266004|Experimental|tDCS+ LT|transcranial direct current stimulation(tDCS) plus locomotor training (LT)
3044145|NCT02266004|Placebo Comparator|sham-tDCS+LT|sham transcranial direct current stimulation(tDCS) plus locomotor training (LT)
3044146|NCT02265978|Experimental|CopeSmart|
3044147|NCT02265978|No Intervention|Control|
3044148|NCT02265965|Experimental|Intravenous Nitroglycerin|Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
3044149|NCT02265965|No Intervention|Intravenous Saline|Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
3044150|NCT02265952|Experimental|Open-Label|Open-label REGN1500
3044151|NCT02265939|Placebo Comparator|0% NPO-13|Placebo
3044152|NCT02265939|Active Comparator|0.2% NPO-13|Low dose
3044153|NCT02265939|Active Comparator|0.4% NPO-13|Medium dose
3044154|NCT02265939|Active Comparator|0.8% NPO-13|High dose
3044155|NCT02265926|Experimental|N95|Intervention: N95 mask material
3044156|NCT02265913|Experimental|Test Product|acyclovir cream
3044157|NCT02265913|Active Comparator|Reference Product|acyclovir cream
3044158|NCT02265913|Placebo Comparator|Placebo Product|Placebo cream
3044159|NCT02265900|Active Comparator|Exercise 1|One type of exercise
3044160|NCT02265900|Placebo Comparator|Exercise 2|A different type of exercise
3044161|NCT02265874|Active Comparator|Treatment|Habitrol Nicotine patch - 7,14,21 mg patches Qd
3044162|NCT02265874|Placebo Comparator|Control|Placebo patch
3044163|NCT02265861|Experimental|Group 1|typical PCOS
3044164|NCT02265861|Experimental|Group 2|PCOS without PCO
3044165|NCT02265861|Experimental|Group 3|PCOS without HA
3044166|NCT02265861|Experimental|Group 4|Control
3044167|NCT02265848|Active Comparator|Treatment group A|Subjects assigned to treatment group A will begin the 7 week study with high frequency stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the low frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
3044168|NCT02265848|Active Comparator|Treatment group B|Subjects assigned to treatment group B will begin the 7 week study with low frequency stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the high frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
3044169|NCT02265835||Cases of anastomotic airway complication|Cases of anastomotic airway complication
3044170|NCT02265835||Patients with normal anastomotic healing|Patients with normal anastomotic healing
3044171|NCT02265822|Experimental|melatonin|0.5 mg/kg (max 20 mg) oral melatonin premedication will be administered approximately 40 min before the induction of general anaesthesia with propofol. The melatonin will be prepared in a fixed volume of 5 ml adding water in a syringe without needle.
3044267|NCT02265315|Sham Comparator|LSVT +sham TMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS)
3044173|NCT02265809|Experimental|Aldesleukin|Aldesleukin will be administered subcutaneously at varying doses and frequencies for a period of up to 98 days from first administration depending on the treatment assignment. The maximum dose allowed is 0.6 X 10^6 IU/m2.
3044174|NCT02265796|Active Comparator|Ranolazine|"Ranolazine 500 mg tablets~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
3044175|NCT02265796|Placebo Comparator|Sugar pill|"Sugar pill that looks like the drug ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
3044176|NCT02265783|Other|Nellcor USB Pulse Oximeter Monitor Interface Cable Sensor Test|
3044177|NCT02265770|Experimental|Stratum 1 arm A|Conformal radiotherapy followed by 16 weeks of VEC + CDDP.
3044178|NCT02265770|Active Comparator|Stratum 1 arm B|Conformal radiotherapy.
3044179|NCT02265770|Experimental|Stratum 2 arm A|VEC + HD-MTX followed by conformal radiotherapy +/- boost
3044180|NCT02265770|Active Comparator|Stratum 2 arm B|VEC followed by conformal radiotherapy +/- boost
3044181|NCT02265770|Experimental|Stratum 3 arm A|Chemotherapy + Valproate.
3044182|NCT02265770|Active Comparator|Stratum 3 arm B|Chemotherapy
3044183|NCT02265757|Experimental|No Cognitive Rehabilitation|Will receive a 10 day intervention program (over 2 weeks) consisting of Computer Brain Fitness Training, Support Group, Wellness Education and Physical Exercise.
3044184|NCT02265757|Experimental|No Computer Brain Fitness Training|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Support Group, Wellness Education and Physical Exercise
3044185|NCT02265757|Experimental|No Support Group|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Wellness Education and Physical Exercise
3044186|NCT02265757|Experimental|No Wellness Education|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Support Group, and Physical Exercise
3044187|NCT02265757|Experimental|No Physical Exercise|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Support Group, and Wellness Education
3044188|NCT02265744|Experimental|Experimental:Arm A: BMS-931699|12.5mg subcutaneous (SC) injection Weekly dosing
3044189|NCT02265744|Experimental|Experimental:Arm B: BMS-931699|12.5mg SC injection Every other Week dosing
3044190|NCT02265744|Experimental|Experimental:Arm C: BMS-931699|5mg SC injection Every other Week dosing
3044191|NCT02265744|Experimental|Experimental:Arm D: BMS-931699|1.25mg SC injection Every other Week dosing
3044192|NCT02265744|Placebo Comparator|Placebo Comparator: Arm E: Placebo matching BMS-931699|0mg SC injection Weekly dosing
3044193|NCT02265731|Experimental|Arm A (Phase 1)|Step-up doses of venetoclax to the designated cohort dose administered in participants with relapsed or refractory (R/R) Non-Hodgkin lymphoma (NHL) or multiple myeloma (MM)
3044194|NCT02265731|Experimental|Arm B (Phase 1)|Step-up doses of venetoclax to the designated dose administered in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
3044195|NCT02265731|Experimental|Arm C (Phase 1)|Step-up doses of venetoclax to the designated dose with the addition of azacitidine administered in participants with acute myeloid leukemia (AML)
3044196|NCT02265731|Experimental|Arm D (Phase 2)|Step-up doses of venetoclax to the designated dose with the addition of rituximab in participants with R/R CLL
3044197|NCT02265718|Active Comparator|(Amyloid Negative)|
3044198|NCT02265718|Active Comparator|Amyloid Positive|
3044199|NCT02265705|Experimental|Baricitinib|"4 milligrams (mg) baricitinib administered orally once a day for 52 weeks. Participants with renal impairment will receive 2 mg baricitinib orally once a day for 52 weeks.~Participants will continue to take background methotrexate (MTX) therapy throughout study. Other background therapies, including non-steroidal anti-inflammatory drugs (NSAIDs) and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline."
3044200|NCT02265705|Placebo Comparator|Placebo|"Placebo administered orally once a day through week 24. At week 24, participants will be given 2 mg (participants with renal impairment) or 4 mg baricitinib orally once a day through Week 52.~Participants will continue to take background MTX therapy throughout study. Other background therapies, including NSAIDs and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline."
3044201|NCT02265679|Experimental|BIIL 284 BS, low dose in pediatric patients|
3044202|NCT02265679|Experimental|BIIL 284 BS, medium dose in pediatric patients|
3044203|NCT02265679|Experimental|BIIL 284 BS, high dose in pediatric patients|
3044204|NCT02265679|Experimental|BIIL 284 BS, low dose in adult patients|
3044205|NCT02265679|Experimental|BIIL 284 BS, medium dose in adult patients|
3044206|NCT02265679|Experimental|BIIL 284 BS, high dose in adult patients|
3044207|NCT02265679|Placebo Comparator|Placebo|
3044208|NCT02265666|Experimental|BIIL 284 BS Tablet FF|
3044209|NCT02265666|Active Comparator|BIIL 284 BS tablet C|
3044210|NCT02265653|Experimental|BIIL 284 BS tablet C|
3044211|NCT02265653|Experimental|BIIL 284 BS tablet D|
3044212|NCT02265653|Active Comparator|BIIL 284 BS WIF tablet|
3044213|NCT02265640|Experimental|BIIL 284 BS boli - fasted|
3044214|NCT02265640|Experimental|BIIL 284 BS boli - fed|
3044215|NCT02265640|Active Comparator|BIIL 284 BS tablet C - fasted|
3044216|NCT02265640|Active Comparator|BIIL 284 BS tablet C - fed|
3044217|NCT02265627|Experimental|BIIL 284 BS, normal hepatic function|
3044218|NCT02265627|Experimental|BIIL 284 BS, mild hepatic impairment|
3044219|NCT02265627|Experimental|BIIL 284 BS, moderate hepatic impairment|
3044220|NCT02265614|Experimental|PGS|blastocyst biopsy and chromosomal analysis
3044221|NCT02265614|No Intervention|control|regular IVF
3044222|NCT02265601|Experimental|computer-based decision aid|"Making Your Wishes Known: Planning Your Medical Future- Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team."
3044223|NCT02265601|Active Comparator|standard care|paper/pencil living will form
3044224|NCT02265588|No Intervention|Care as usual|Care as usual means receiving their regular medical care. This consists of the regular follow up visits at the gastroenterologist every 3 months.
3044225|NCT02265588|Experimental|Cognitive Behavioral Therapy|The intervention group receives regular medical care (care as usual) AND a cognitive behavioral therapy program called PASCET-PI. The therapy sessions will be performed by trained psychologist.
3044226|NCT02265575|Experimental|hyaluronic acid|Rehydration using hyaluronidase-assisted subcutaneous infusion
3044227|NCT02265562|Experimental|Misoprostol|60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally
3044228|NCT02265562|Placebo Comparator|Placebo|60 minutes before the surgery 2 tablets of placebo tablets inserted rectally
3044229|NCT02265536|Experimental|LY3022855 - 1.25 mg/kg Dose A|1.25 milligram per kilogram (mg/kg) LY3022855 administered intravenously (IV), once every two weeks. Treatment is 6 week cycle. Participants may receive multiple cycles if they are deriving clinical benefit.
3044230|NCT02265536|Experimental|LY3022855 - Dose B|LY3022855 administered IV. Participants may receive multiple cycles if they are deriving clinical benefit.
3044231|NCT02265536|Experimental|LY3022855 - Dose C|LY3022855 administered IV. Participants may receive multiple cycles if they are deriving clinical benefit.
3044232|NCT02265536|Experimental|LY3022855 - Dose D|LY3022855 administered IV. Participants may receive multiple cycles if they are deriving clinical benefit.
3044233|NCT02265523|No Intervention|Standard Post-op Exercise Group|The standard post-operative exercises are already currently recommended to patients. Briefly, they include deep breathing and coughing, ankle pumping, buttock contractions, and static quadriceps strengthening. These are performed on a daily basis , 2-3 times per day, 30 repetitions.
3044234|NCT02265523|Experimental|Viscus Group|The Viscus (intervention) group will complete the standard post-operative exercises and will also have access to a Viscus V1.5 cycle ergometer 24 hours per day in their recovery room to use at their leisure.
3044235|NCT02265510|Experimental|Phase 1a: INCB052793 Monotherapy|
3044236|NCT02265510|Experimental|Phase 1b: INCB052793 Combination Therapy|
3044237|NCT02265510|Experimental|Phase 2: INCB052793 and itacitinib Combination Therapy|
3044238|NCT02265497||Hodgkin's or non-Hodgkin lymphoma|All patients with diagnoses of Hodgkin's or non-Hodgkin lymphoma with available with available clinical, histopathology and treatment data.
3044239|NCT02265484|Experimental|Lactulose + Rifaximin + Bromocriptine|
3044240|NCT02265484|Active Comparator|Lactulose+Rifaximin+Placebo|
3044241|NCT02265471||university hospital|university hospital
3044242|NCT02265471||large or small public hospitals|large or small public hospitals
3044243|NCT02265471||private HCFs|private HCFs
3044244|NCT02265471||referral centers for cancer|referral centers for cancer
3044245|NCT02265471||chirurgical facilities, clinic|chirurgical facilities, clinic
3044246|NCT02265471||mixed group|local hospitals, long term care and post-op and rehabilitation facilities, and nursing homes
3044247|NCT02265458|Experimental|Musical intervention and sensory isolation|30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
3044248|NCT02265458|Active Comparator|Sensory isolation|Sensory isolation
3044249|NCT02265458|No Intervention|Standard of care|Standard of care
3044250|NCT02265445|Active Comparator|Maintaining carbapenem therapy|Intravenous therapy, Maintaining carbapenem therapy
3044251|NCT02265445|Active Comparator|Deescalation therapy|Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE. Deescalation therapy
3044252|NCT02265432|Experimental|Mobile technology intervention|"General physical activity educational materials~Wearable activity tracking devices to enable the intervention participants to self-monitor their physical activity behavior and receive real-time feedback~Access to an online map of Singapore providing location based information about leisure time physical activity opportunities~Personalized text messages which include, educational information, tailored theory-based motivational messages, as well as compliance enhancing reminders"
3044253|NCT02265432|Other|Control|1.General physical activity educational materials
3044254|NCT02265419|Experimental|Cytosorb group|Extracorporeal treatment with the Cytosorb adsorber for 24 hours after heart surgical operation.
3044255|NCT02265406|Experimental|Ceftriaxone|
3044256|NCT02265406|Placebo Comparator|Sodium Chloride|
3044257|NCT02265393|Active Comparator|OTO-104|12 mg OTO-104 (dexamethasone)
3044258|NCT02265393|Placebo Comparator|Placebo|OTO-104 vehicle
3044259|NCT02265380|Experimental|Treatment with OptiVein|The patient will have an IV catheter placed with the use of OptiVein device.
3044260|NCT02265380|Active Comparator|Treatment with Vasofix Certo|The patient will have an IV catheter placed with the use of Vasofix Certo device.
3044261|NCT02265367|Experimental|Levomilnacipran|In this three week period, baseline measures are obtained during the first week, levomilnacipran will be started during the second week and effects on smoking behavior will be assessed during the third week
3044262|NCT02265367|Placebo Comparator|Placebo|In this three week period, baseline measures are obtained during the first week, placebo will be started during the second week and effects on smoking behavior will be assessed during the third week
3044263|NCT02265354|Experimental|Collective-Intelligence computer tailored health communication|Smokers will have access to all Decide2quit.org website functions and will receive 4 tailored emails per week based on a collective intelligence recommender systems algorithm for up to 6 months
3044264|NCT02265354|Active Comparator|Rule-based computer tailored health communication|Smokers will have access to all Decide2quit.org website functions and will receive 4 tailored emails per week based on a rule-based algorithm for up to 6 months
3044265|NCT02265341|Experimental|Treatment (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3044266|NCT02265328|Experimental|Bovine colostrum + prednisolone|"Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.~Oral prednisolone 40mg/day × 4 weeks and tapered to <40mg/day for next 4 weeks. If Lilli score > 0.45 after 7 days, then GC would be stopped and patients will be counselled for liver transplantation.~Oral Bovine colostrum (200 ml (20 gram) TDS × 2 months."
3044450|NCT02264158|Active Comparator|Lacidipine low|
3044268|NCT02265315|Active Comparator|LSVT +left rTMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS) applied to left side of head
3044269|NCT02265315|Active Comparator|LSVT + right rTMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS) applied to right side of brain
3044270|NCT02265302|Experimental|BIIL 284 BS oral solution|
3044271|NCT02265302|Experimental|BIIL 284 BS WIF tablets|
3044272|NCT02265302|Placebo Comparator|Placebo|
3044273|NCT02265289|Experimental|Lefradafiban with clopidogrel|"All patients received the same treatment:~Lefradafiban only (day 1-4)~Lefradafiban in combination with Clopidogrel (day 5-8)~Clopidogrel only (day 9-12)"
3044274|NCT02265276|Active Comparator|Saroglitazar Group|Tab Saroglitazar 4 mg oral daily fixed dose for 24 weeks
3044275|NCT02265276|Placebo Comparator|Pioglitazone Group|Tab Pioglitazone 30 mg daily fixed dose for 24 weeks
3044276|NCT02265263||Surgical patients - 3 Tesla MRI|"A study group of at maximum n= 1200 is collected for measuring 3 Tesla MRI at two timepoints (Baseline and 90 days) in Berlin/Utrecht. They include surgical procedures within body cavity e.g. abdomen or thorax from departments of general surgery, urology, gynecology or thoracic surgery; orthopaedic operations (hip-, knee-, endoprosthesis or spine (including neurosurgical spine operations)); cardiac surgery and operation of extracranial/intracranial head and neck~Data collection from study center Utrecht ist within one year after initial hospital stay. Data collection from study center Berlin is within five years after initial hospital stay."
3044277|NCT02265263||Patients ASA II/III - 3 Tesla MRI|"A control group of at a maximum 300 ASA II/III- patients is collected for measuring the learning experience during the cognitive testings. They are matched on age, education, and gender to the study patients. The 300 ASA II/III- patients should receive additionally MRI-scan (3 Tesla) at baseline, after 3 months and after 1 year in Utrecht, after 3 months, after 1, 2 and 5 years in Berlin.~Data collection from study center Utrecht ist within one year after initial hospital stay. Data collection from study center Berlin is within five years after initial hospital stay."
3044278|NCT02265263||Volunteers ASA I/II - 3 Tesla MRI|To analyze scanner variability we additionally measure 20 subjects (Age ≥ 65 years) from Berlin in the MRI scanner (3-Tesla) in Utrecht und vice versa 20 subjects (Age ≥ 65 years) from Utrecht in the MRI scanner (3-Tesla) in Berlin.
3044279|NCT02265263||Surgical patients - 7 Tesla MRI|A study group (n= 80 ) is collected for measuring 7 Tesla MRI at two timepoints (Baseline and 90 days) in Berlin.
3044280|NCT02265263||Patients ASA II/III - 7 Tesla MRI|A matched control group of (n=80, patients ASA II and III) is collected for measuring 7 Tesla MRI at two timepoints (Baseline and 90 days) in Berlin.
3044281|NCT02265250||Asymptomatic, CACS <300|"5 asymptomatic subjects with low CVD risk, defined as recent coronary artery calcium score (CACS) <300~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers)"
3044282|NCT02265250||Asymptomatic, CACS ≥300|"5 asymptomatic subjects with increased CVD risk, defined as a recent coronary artery calcium score (CACS) ≥300~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
3044283|NCT02265250||Stable angina|"5 subjects with stable angina and evidence of coronary atherosclerosis based on a recent invasive or CT coronary angiogram~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
3044284|NCT02265250||Recent acute MI|"5 subjects with a recent acute myocardial infarction (within 1 month) and evidence of coronary atherosclerosis based on invasive or CT coronary angiogram~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
3044285|NCT02265237|Experimental|Arm A|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 12 weeks for genotype 4 treatment-naïve or treatment-experienced with IFN/RBV.
3044286|NCT02265237|Experimental|Arm B|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 16 weeks for genotype 4 treatment-naive or treatment-experienced with IFN/RBV.
3044287|NCT02265237|Experimental|Arm C|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 24 weeks for genotype 4 treatment-naive and treatment-experienced with IFN/RBV.
3044288|NCT02265237|Experimental|Arm D|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 24 weeks for genotype 4 SOF/pegIFN/RBV or SOF/RBV treatment-experienced.
3044289|NCT02265224|Experimental|NAC 600 mg uncoated tablet|single dose of one tablet
3044290|NCT02265224|Active Comparator|NAC 600 mg coated tablet|single dose of one tablet
3044291|NCT02265211|Experimental|Self-Help App|Smartphone app designed to teach cognitive defusion.
3044292|NCT02265198||PC Group|patients with Pulmonary Contusion on chest computed tomography (CT)
3044293|NCT02265198||Control Group 1|Uninjured patients undergoing elective surgical procedures that will require intubation and mechanical ventilation
3044294|NCT02265198||Control Group 2|Trauma patients without chest injury who are mechanically ventilated
3044295|NCT02265198||MICU group|Patients in the Medical ICU who are mechanically ventilated with acute respiratory failure
3044296|NCT02265185||ED Patients|Children aged 2-10 visiting the Emergency Department.
3044297|NCT02265172|Experimental|Physiotherapy screening|"Screening consisted of a 60-min appointment including assessment, diagnosis and management. The patients received advice regarding ergonomics, exercises and/or treatment when needed. Management options were;~Referral for orthopaedic surgeon consultation.~Referral back to the patient's General Practitioner.~Referral for further investigation.~Referral to the physiotherapy or the occupational therapy clinic."
3044298|NCT02265172|Active Comparator|Standard practice (orthopaedic surgeon)|"Appointment was 15 min, including assessment, diagnosis and management. The patients received advice, prescriptions or injections when needed. Management options were;~Referral for orthopaedic intervention.~Referral back to the patient's General Practitioner.~Referral for further investigation.~Referral to the physiotherapy or the occupational therapy clinic."
3044299|NCT02265159|Other|Focal Therapy Using High Intensity Focused Ultrasound|
3044451|NCT02264158|Experimental|Telmisartan+Lacidipine|
3044452|NCT02264158|Placebo Comparator|Placebo|
3044300|NCT02265120|Experimental|primary care providers by region|A questionnaire will be given to a randomized sample of primary care providers who care for patients in the 194 federally designated regions of Primary Care provider shortage within California will be studied.
3044301|NCT02265107|Experimental|cardiac rehabilitation|We invited all consecutive patients submitted to CABG alone at Cardiologic Hospital Doctor Pedro Bertoni of the Associação de Caridade Santa Casa do Rio Grande in the period of October, 2011 until October, 2012, who resided in the city of the Rio Grande (RS/Brazil), to participate of the exercise training (ET). All patients were evaluated by cardiologist, and were ranked in Functional Classification of New York Heart Association (NYHA) such class I and II. Initially, twenty-four patients accepted and start to participate of ET, but only nine patients completed the program until the end.
3044302|NCT02265094|Experimental|Patients|Electroencephalography and neuropsychological tests in children with autism
3044303|NCT02265094|Experimental|Control|Electroencephalography and neuropsychological tests in children without autism
3044304|NCT02265081|Active Comparator|nulliparous women|internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
3044305|NCT02265081|Experimental|parous women|those who had vaginal delivery in the past; internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
3044306|NCT02265081|Experimental|parous women - VBAC|those with previous LSCS and no vaginal births; internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
3044307|NCT02265055|Active Comparator|transfer early cleavage embryos (EC)|transfer early cleavage embryos
3044308|NCT02265055|Active Comparator|transfer non early cleavage embryo (NEC)|transfer non early cleavage embryos
3044309|NCT02265042|Experimental|electrical stimulation|electrical Stimulation using the Stimulette device
3044310|NCT02265029|Active Comparator|Immediate spa treatment|Spa treatment during 18 days soon after randomization : the most adapted to the concerned pathology and common to all of spa resorts (whirpool bath with automatic air and water massage cycles, massaging shower,...)
3044311|NCT02265029|Sham Comparator|Late SPA treatment|Spa treatment during 18 days soon after 6 months visit : the most adapted to the concerned pathology and common to all of spa resorts (whirpool bath with automatic air and water massage cycles, massaging shower,...)
3044312|NCT02265016||Patients with CAD|Patients with stable coronary artery disease
3044313|NCT02265016||Patients with ACS|Patients with acute coronar syndrome, instable Angina pectoris and low-risk NSTEMI
3044314|NCT02265016||healthy control group|healthy control group without clinical apparent arteriosclerosis
3044315|NCT02265003||Healthy young age|Healthy subjects in age of 18-35 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
3044316|NCT02265003||Healthy middle age|Healthy subjects in age of 35-45 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
3044317|NCT02265003||Healthy old|Healthy subjects in age of >70 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
3044318|NCT02265003||Patients|Patients with atherosclerosis
3044319|NCT02264990|Experimental|Veliparib/Carboplatin/Paclitaxel|veliparib on Days -2 to 5 (7days) and carboplatin and paclitaxel on Day 1 of a 21 day cycle
3044320|NCT02264990|Active Comparator|Investigator's choice of platinum doublet|Either carboplatin and paclitaxel, cisplatin and pemetrexed, or carboplatin and pemetrexed on Day 1 of a 21 day cycle.
3044321|NCT02264977|Experimental|Branched TAG® Device|Treatment with the GORE® TAG® Thoracic Branch Endoprosthesis
3044322|NCT02264964|Experimental|internal jugular vein catheterization|900 patients will be received temporary central vena catheterization in right internal jugular vein with non-cuff GamCath® catheter.They will undergo AVF creation.
3044323|NCT02264964|Experimental|femoral vein catheterization|500 patients will be received temporary central vena catheterization in femoral vein with non-cuff GamCath® catheter, which are unsuitable for right internal jugular vein catheterization.They will undergo AVF creation.
3044324|NCT02264951|Active Comparator|A meal containing carrot and tributyrin|A meal containing 200 g grated carrot and 0.0216 mol tributyrin; blood test taken from 0 - 2 hours postprandial
3044325|NCT02264951|Active Comparator|A meal containing carrot and C8-diet oil|A meal containing 200 g grated carrot and 0.0216 mol of C8-diet oil; blood test taken from 0 - 2 hours postprandial
3044326|NCT02264951|Active Comparator|A meal containing carrot and olive oil|A meal containing 200 g grated carrot and 0.0216 mol of olive oil; blood test taken from 0 - 2 hours postprandial
3044327|NCT02264951|Placebo Comparator|A meal containing carrot|A meal containing 200 g grated carrot; blood test taken from 0 - 2 hours postprandial
3044328|NCT02264938|No Intervention|Observation|Patients with AREDS category 2 and 3 AMD are observed during 1 year
3044329|NCT02264938|Active Comparator|Antioxidant|Patients with AREDS category 2 and 3 AMD are enrolled to take daily oral supplementation with lutein (12mg) + zeaxanthin (2mg) + astaxanthin (8mg) + omega-3 fatty acids (docosahexaenoic acid [DHA] 540mg + eicosapentaenoic acid [EPA] 360mg) + vitamin C (40mg) + vitamin E (20mg) + zinc (16mg) + copper (2mg) during 1 year.
3044330|NCT02264925|Experimental|Deep Brain Stimulation|All of included patients will receive a standard deep brain stimulation of the thalamus in order to reduce their essential tremor
3044331|NCT02264912||stent-PCI patients|Consecutive patients, who underwent intracoronary stent implantation, have been included regardless of whether percutaneous coronary intervention (PCI) was performed on urgent or elective basis.
3044332|NCT02264899|Experimental|Alzheimer's disease and related disorders|
3044333|NCT02264886|Experimental|Arm 1: Stereotactic body radiation therapy|"Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.~All patients will undergo MRI simulation in positioning appropriate for the specific treatment site. When medically feasible and applicable, patients will be simulated with IV and small bowel contrast (for non-thorax cases)."
3044334|NCT02264873|Other|Decitabine|This is a 3+3 design of dose escalation
3044335|NCT02264860|Other|Nutritional Supplements Zinc and SAMe|All men subjects will be started on 30 mg/day and women will be started on 25mg of elemental zinc plus 1600 mg/day of SAMe.
3044453|NCT02264145|Experimental|Ethanolic Solution From HFA134a-MDI - low|
3044454|NCT02264145|Experimental|Ethanolic Solution From HFA134a-MDI - medium|
3044336|NCT02264847|Active Comparator|Clomiphene citrate plus hCG|Women will receive clomiphene citrate from day 2 to day 6 of the cycle with a starting dose of 100 mg daily. If no response could be observed, the daily dose of clomiphene citrate in subsequent cycles will be increased by 50 mg until a response will be obtained or a maximum daily dose 200 mg of clomiphene citrate will be used. Once a follicle will reach more than 18 mm in size . Women will receive 5,000 IU human chorionic gonadotrophin trigger in the morning between 9 and 10 a.m. and the couple will be advised to have intercourse the following night, about 36 hours later.
3044337|NCT02264847|Active Comparator|Clomiphene Citrate alone|Women will receive clomiphene citrate from day 2 to day 6 of the cycle with a starting dose of 100 mg daily. If no response will be observed, the daily dose of clomiphene citrate in subsequent cycles will be increased by 50 mg until a response will be obtained or a maximum daily dose 200 mg of clomiphene citrate will be used. Once a follicle will reach more than 18 mm in size , the women will be advised to have intercourse frequently over the next few days.
3044338|NCT02264834|Active Comparator|Control group|Lumbar epidural analgesia during the labour and end up after delivery Levobupivacaine 0.1% + Sufentanil 0.2 µg/mL
3044339|NCT02264834|Experimental|Ambulatory group|Lumbar epidural analgesia during the labour and end up after delivery Levobupivacaine 0.07% + Sufentanil 0.3 µg/mL
3044340|NCT02264821|Experimental|ropivacaine infiltration|ropivacaine 2 mg/ml bolus 15 ml continuous 10 ml/h wound infusion and intrathecal saline
3044341|NCT02264821|Experimental|rachi morphine|100 µg intrathecal morphine and saline infiltration
3044342|NCT02264821|Placebo Comparator|placebo|intrathecal saline and saline infiltration
3044343|NCT02264808||Developmental outcomes|A developmental assessment (Bayley-III) of children 18-20 months who already enrolled in Florida Neonatal Neurologic Network. As part of this previous study, these children were born with Hypoxic Ischemic Encephalopathy (HIE) and underwent therapeutic cooling after birth.
3044344|NCT02264795|Placebo Comparator|Placebo|Intraperitoneal instillation of normal saline.
3044345|NCT02264795|Active Comparator|Lidocaine|Intraperitoneal instillation lidocaine 2% (400mg) with epinephrine 5mcg/ml.
3044346|NCT02264782|Experimental|Group I (PreView)|Patients complete PreView, the Video Doctor plus Provider Alert, over 45 minutes on an iPad in the waiting room before a doctor visit.
3044347|NCT02264782|Active Comparator|Group II (educational video)|Patients watch a video about healthy lifestyles including information about exercise and healthy eating over 45 minutes on an iPad in the waiting room before a doctor visit.
3044348|NCT02264769|Active Comparator|Carbetocin 20mcg|Patient is given carbetocin 20 mcg intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
3044349|NCT02264769|Active Comparator|Carbetocin 100mcg|Patient is given carbetocin 100 mcg intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
3044350|NCT02264756||Ward CAP|Adult immune-competent patients admitted to ward with clinical diagnosis of community-acquired pneumonia will be potentially exposed to ASP review
3044351|NCT02264743|Experimental|Femoston Conti 0.5mg/2.5mg|"Ultra low dose, film-coated 17β-estradiol (as hemihydrate) 0.5mg & dydrogesterone 2.5 mg~Once a day~The duration is six months.~Drug intervention: Estradiol&DydrogesteronevsOestradiol&Norethisterone acetate"
3044352|NCT02264743|Active Comparator|EVOREL® CONTI transdermal patches|"EVOREL CONTI is a transdermal self adhesive patch which is 0.1 mm in thickness and each patch releases 50mcg of oestradiol and 170mcg of norethisterone acetate over 24 hours .~The Evorel Conti patch is cut in half and applied to the lower part of the body for 3.5 days (delivering approx 25mcg of oestradiol over 24 hours ) this is replaced every 3.5 days .~The duration is six months.~Drug intervention: Estradiol&DydrogesteronevsOestradiol&Norethisterone acetate"
3044353|NCT02264730|Experimental|Clot Foam|Application of Clotfoam
3044354|NCT02264717|Active Comparator|Cardiac MRi|A minimum of 150 patients will be randomized to Cardiac MRI followed by conventional angiography CCA-FFR, after detection of obstructive anatomic coronary artery stenoses on coronary Computed Tomography Angiography (cCTA)
3044355|NCT02264717|Active Comparator|SPECT|A minimum 150 patients will be randomized to SPECT followed by conventional angiography CCA-FFR, after detection of obstructive anatomic coronary artery stenoses on coronary Computed Tomography Angiography (cCTA).
3044356|NCT02264704|Experimental|High intensity exercise|High intensity exercise Participants will exercise at high intensity (70% VO2 peak) intermittently (30 seconds on, 30 seconds off) for 15 minutes, twice weekly for 15 weeks.
3044357|NCT02264704|Experimental|Moderate intensity exercise|Participants exercise at moderate intensity (35% VO2 peak) continuously for 15 minutes, twice weekly for 15 weeks.
3044358|NCT02264704|No Intervention|Usual Care|Participants receive usual medical care.
3044359|NCT02264691||Normal (healthy volunteers)|No Research Intervention. Clinically indicated interventions only.
3044360|NCT02264691||Mild Asthmatics|No Research Intervention. Clinically indicated interventions only.
3044361|NCT02264691||Mild to Moderate Asthmatics|No Research Intervention. Clinically indicated interventions only.
3044362|NCT02264691||Severe Asthmatics|No Research Intervention. Clinically indicated interventions only.
3044363|NCT02264678|Experimental|Module 1 Part A|Module 1 Part A: ascending doses of AZD6738 in combination with carboplatin AUC5 will be administered to patients to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD).
3044364|NCT02264678|Experimental|Module 1 Part B|Module 1 Part B: patients with advanced lung adenocarcinoma with low expression of ATM will receive AZD6738 and carboplatin, at the dose, frequency and schedule recommended from Module 1 Part A.
3044365|NCT02264678|Experimental|Module 2 Part A1|Module 2 Part A1: ascending doses of AZD6738 will be administered alone to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD) to take into Module 2 Part A2.
3044366|NCT02264678|Experimental|Module 2 Part A2|Module 2 Part A2: ascending doses of AZD6738 will be administered in combination with olaparib to patients to define the dose, frequency and schedule of AZD6738 and olaparib to take into Module 2 Part B.
3044367|NCT02264678|Experimental|Module 2 Part B1|Module 2 Part B1: Patients with second line 'ATM deficient' gastric adenocarcinoma including GEJ adenocarcinoma will receive AZD6738 with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
3044455|NCT02264145|Experimental|Ethanolic Solution From HFA134a-MDI - high|
3044456|NCT02264145|Experimental|Ethanolic Solution From Respimat®|
3044368|NCT02264678|Experimental|Module 2 Part B2|Module 2 part B2: Patients with second line 'ATM proficient' gastric adenocarcinoma including GEJ adenocarcinoma will receive AZD6738 with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
3044369|NCT02264678|Experimental|Module 2 Part B3|Module 2 Part B3: Patient with second or third line breast cancer with BRCA mutations (somatic or germline), excluding HER2 positive breast cancer will receive AZD6738 with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
3044370|NCT02264678|Experimental|Module 2 Part B4|Module Part B4: Patients with second or third line triple negative breast cancer with no known BRCA mutations. This expansion will be enriched for patients with disease harbouring a HRR-related gene mutation (HRRm) will receive AZD6738 with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
3044371|NCT02264678|Experimental|Module 3 Part A|Module 3 Part A: cohort escalation of AZD6738 in combination with MEDI4736 in HNSCC or NSCLC patients to define the dose, frequency and schedule of AZD6738 and MEDI4736 to take into Module 3 Part B.
3044372|NCT02264678|Experimental|Module 3 Part B|Module 3 Part B: cohort expansions of AZD6738 in combination with MEDI4736 in HNSCC or NSCLC patients at dose, frequency and schedule from Module 3 Part A.
3044373|NCT02264665||Sunitinib|
3044374|NCT02264665||Afinitor|
3044375|NCT02264665||other treatment (chémotherapy, SSA..)|
3044376|NCT02264652|Experimental|HD Transcranial Direct Stimulation|Genuine cathodal HD-tDCS approximately 2mA will be delivered through High-Definition electrodes that will be arranged on the skull according to a 4x1-ring configuration with the central cathodal electrode placed over the identified target and surrounding return electrodes forming approximately a 5-cm radius ring.
3044377|NCT02264639|Experimental|Cohort 1|First Dose 25mg, Repeated Dose 5 mg/day
3044378|NCT02264639|Experimental|Cohort 2|First Dose 50 mg, Repeated Dose 30 mg/day
3044379|NCT02264639|Experimental|Cohort 3|Repeated Dose 180 mg/day
3044380|NCT02264639|Experimental|Cohort 4|Repeated Dose 270 mg/day
3044381|NCT02264626|Experimental|acutely ill patients|administration of remifentanil at the infusion rate by 0.025 μg kg-1 min-1 to a maximum of 0.10 μg kg-1 min-1.
3044382|NCT02264613|Experimental|Dose Regimen A (DR-A)|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days
3044383|NCT02264613|Experimental|Dose Regimen B (DR-B)|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 4, 8 and 11 every 21 days
3044384|NCT02264587|Experimental|mosapride|mosapride 5mg by mouth, 30 minutes before meals, every times one day for 14days
3044385|NCT02264587|Active Comparator|domperidone|domperidone 10mg by mouth, 30 minutes before meals, every times one day for 14days
3044386|NCT02264574|Experimental|A|Oral ibrutinib 420 mg daily (3 capsules) continuously (until evidence of progressive disease or no longer tolerated by the patient) in combination with obinutuzumab 1000 mg intravenously over 6 cycles: Days 1+2 (100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of Cycle 1 followed by Day 1 only on Cycles 2-6..
3044387|NCT02264574|Experimental|B|Treatment will be 6 cycles. Chlorambucil will be administered orally at a dose of 0.5 mg/kg body weight, on Days 1 and 15 of each cycle. Obinutuzumab will be administered intravenously at a dose of 1000 mg, over 6 cycles: given on Days 1+2 (100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of Cycle 1 and on Day 1 only on Cycles 2-6. Treatment will be administered up to a maximum of 6 cycles or until disease progression or unacceptable toxicity, whichever occurs first.
3044388|NCT02264561|Placebo Comparator|Placebo|Mannitol administered at visit 1 and at visit 2
3044389|NCT02264561|Active Comparator|caffeine|caffeine administered at visit 1 and at visit 2
3044390|NCT02264548|Experimental|Arm 1|Radiation: Radio-Ablation
3044391|NCT02264535|Experimental|0.1mg/ml Ginkgolides Meglumine Injection|Injection, 0.1mg/ml.
3044392|NCT02264535|Experimental|1mg/ml Ginkgolides Meglumine Injection|Injection, 1mg/ml.
3044393|NCT02264535|Experimental|5mg/ml Ginkgolides Meglumine Injection|Injection, 5mg/ml.
3044394|NCT02264522|Experimental|Single Arm|"All patients will be enrolled in the same intervention arm. Interventions are implemented based in 1-4 event levels on the device. Interventions include: Place dialysis chair into position 3, Decrease dialysate temperature, Decrease ultrafiltration rate by 25%, and Decrease ultrafiltration rate by 50%."
3044395|NCT02264509||Arterial insufficiency and HIV|Of a cohort of 206 HIV patients will be randomly selected 206 for Ankle-brachial index to identify wich suffer symptomatic or asymptomatic arterial insufficiency
3044396|NCT02264496|No Intervention|Control|Standard pre-operative care
3044397|NCT02264496|Experimental|Exercise|A 2-4 week low volume, moderate intensity, supervised, one to one, individualised exercise programme. `
3044398|NCT02264483||COPD exacerbation|"No intervention.~The subjects will be divided in 2 subgroups according to the image study:~COPD exacerbation with pneumonia~COPD exacerbation without pneumonia"
3044399|NCT02264483||COPD stable patients|
3044400|NCT02264470||Patients with clinical stroke|All patients with stroke, 18 years or older, are asked for participation.
3044401|NCT02264457|Other|First eye closed loop haptic|subjects implanted with the Closed loop haptic during first eye surgery and the plate haptics toric intraocular lens during second eye surgery
3044402|NCT02264457|Other|First eye plate haptic|subjects implanted with the plate haptic toric during first eye surgery and the closed loop haptic toric intraocular lens during second eye surgery
3044403|NCT02264444|Experimental|Cholecystectomy visualization|All patients will undergo a standard single site cholecystectomy and will have their operation recorded and scored for visualization.
3044404|NCT02264418|Experimental|ODM 203|Oral capsules given once daily dosage 50-800mg
3044405|NCT02264418|Experimental|ODM-203|Oral tablets given once daily 200-1600mg
3044406|NCT02264405||NISSC|Autologous HSCT
3044407|NCT02264392|Active Comparator|Ultrasound Guided|Ultrasound Guided Incision and Drainage- Patients will undergo ultrasound guided drainage of the abscess using bedside ultrasound
3044408|NCT02264392|Active Comparator|Blind I&D|Blind Incision and Drainage- Patients will undergo drainage of the abscess using physical exam.
3044409|NCT02264379||normal fractionated irradiation|
3044410|NCT02264379||hypo fractionated irradiation|
3044457|NCT02264132|Experimental|Pramipexole ER tablet versus Pramipexole IR tablet|
3044458|NCT02264132|Experimental|Pramipexole IR tablet versus Pramipexole ER tablet|
3044411|NCT02264366|Experimental|At Risk Group: ACCELERATION program|"This At Risk Group will include ;People at risk of cancer referred from UHN partners and community practices. Also included in this group are; First Nations population of BC, Asians and South Asian populations from Greater Vancouver and the working population of the City of Richmond employees. At the Montreal site users of the YMCA with risk factors for, or family history of, cancer and other chronic diseases will be targeted. And finally, in Nova Scotia the At Risk Group will be identified as being at risk of cancer and other chronic diseases referred from community practices and from the workplace population of the Capital District Health Authority (CDHA).~Intervention: Motivational Communication for Health Behavior management"
3044412|NCT02264366|Experimental|Friends & Family -ACCELERATION Program|This group includes family and friends of cancer survivors and family and friends of cardiac & COPD rehab patients. The intervention includes Motivational Communication for Health Behavior management
3044413|NCT02264353|Experimental|Donepezil|Sleep data with Donepezil given
3044414|NCT02264353|Placebo Comparator|Placebo|Sleep data with Placebo given
3044415|NCT02264340|Active Comparator|Control|Relaxation technique
3044416|NCT02264340|Experimental|Experimental|Combined treatment
3044417|NCT02264327|Experimental|MI Training + SIM|"Service Providers in all group will receive a free two-day Motivational Interviewing training. Service Providers in this group will also receive access and a brief introduction to the Motivational Interviewing Simulator (SIM). Sim is designed to help Service Providers practice, learn, maintain, and implement MI skills.~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
3044418|NCT02264327|Active Comparator|MI Training + MI eBook|"Service Providers in all group will receive a free two-day Motivational Interviewing training. Service Providers in this group will also receive a Motivational Interviewing eBook designed to help Service Providers learn, maintain, and implement MI skills.~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
3044419|NCT02264327|Active Comparator|MI Training Only|"Service Providers in this group will only receive a free two-day Motivational Interviewing training.~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
3044420|NCT02264314|Experimental|Intervention|This group received an audiological rehabilitation program with a tele-educative intervention boost
3044421|NCT02264314|Placebo Comparator|Control|This group received no intervention
3044422|NCT02264301|Active Comparator|Puerarin injection 400 mg|Patients under the treatment of Puerarin injection 400 mg,daily,for 24 weeks
3044423|NCT02264301|Experimental|Qingkailing injection 40 ml|Patients under the treatment of Qingkailing injection 40 ml,daily,for 24 weeks
3044424|NCT02264288|Experimental|3 x 10^6 cells|Human Placenta Derived cells (PDA-002) administered intramuscularly (IM) on Study Days 1 and 8
3044425|NCT02264288|Experimental|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
3044426|NCT02264288|Experimental|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
3044427|NCT02264288|Placebo Comparator|Placebo|Identically matching placebo administered IM on Study Days 1 and 8
3044428|NCT02264275|Experimental|Aerobic Exercise Training|An 8-week Nintendo Wii at-home dancing exergame Intervention
3044429|NCT02264262|Experimental|Sympathetic nerve activity|Healthy volunteers will undergo microneurography, and non invasive sympathetic nerve activity by EKG analysis at baseline and in response to stress.
3044430|NCT02264249||Split dose colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - split dose - ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)
3044431|NCT02264249||Evening before colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - Evening before (4L, 2L or miralax bowel preparation)
3044432|NCT02264249||Same day prep colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - Same day prep (4L volume or 2L volume or Miralax bowel preparation)
3044433|NCT02264236|Experimental|P10s-PADRE vaccine|Subjects will be immunized by administration of either three or four doses of P10s-PADRE vaccine over a six-week period at a dose level of 500 micrograms (µg) per injection depending on the slandered of care therapy they receive for their lung cancer.
3044434|NCT02264223|Active Comparator|Capsule (aglycone)|"single bolus 40mg isoflavone formulation of fermented extract in freeze-dried capsule.~Fermented red clover isoflavones in aglycone form"
3044435|NCT02264223|Active Comparator|Tablet (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract in freeze-dried tablet.~Fermented red clover isoflavones in aglycone form"
3044436|NCT02264223|Active Comparator|Yoghurt (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract mixed with yoghurt~Fermented red clover isoflavones in aglycone form"
3044437|NCT02264223|Active Comparator|Liquid extract (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract in liquid~Fermented red clover isoflavones in aglycone form"
3044438|NCT02264223|Active Comparator|Tablet unfermented (glycoside)|"single bolus 40mg isoflavone aglycone equivalent tablet formulation of unfermented red clover isoflavones~Unfermented glycosides (as aglycone equivalents)"
3044439|NCT02264210|Experimental|Intervention group|Icotinib 125 mg three times daily (375 mg per day) orally for 12 months.
3044440|NCT02264210|No Intervention|Observation group|Observation.
3044441|NCT02264197|Experimental|BIBX 245 CL - fed|after a light breakfast with 40 g fat
3044442|NCT02264197|Active Comparator|BIBX 245 CL - fasted|
3044443|NCT02264184|Experimental|Tamsulosin + Paroxetine|"Tamsulosin: q.d on day 1~Paroxetine: higher dose q.d. on days -7 to 2 q.d., lower dose on days -10 to -8 and 3 to 5"
3044444|NCT02264184|Active Comparator|Tamsulosin|Tamsulosin: q.d on day 1
3044445|NCT02264171|Experimental|Ketoconazole + Tamsulosin HCl|Ketoconazole given once daily in the morning on days -3 to 2 Tamsulosin HCl given at day 1
3044446|NCT02264171|Active Comparator|Tamsulosin HCl|Tamsulosin HCl given at day 1
3044447|NCT02264158|Experimental|Telmisartan high|
3044448|NCT02264158|Experimental|Telmisartan low|
3044449|NCT02264158|Active Comparator|Lacidipine high|
3044461|NCT02264119|Experimental|Lefradafiban double chamber sachet with Pantoprazole|
3044462|NCT02264119|Active Comparator|Lefradafiban double chamber sachet without Pantoprazole|
3044463|NCT02264106|Experimental|Lefradafiban tablet with pantoprazole|
3044464|NCT02264106|Active Comparator|Lefradafiban tablet|
3044465|NCT02264106|Experimental|Lefradafiban double chamber sachet with pantoprazole|
3044466|NCT02264106|Active Comparator|Lefradafiban double chamber sachet|
3044467|NCT02264093|Experimental|Talsaclidine with Propranol|
3044468|NCT02264093|Active Comparator|Propranolol|
3044469|NCT02264093|Active Comparator|Talsaclidine|
3044470|NCT02264080|Experimental|WAL2014|
3044471|NCT02264080|Placebo Comparator|Placebo|
3044472|NCT02264067|Experimental|Talsaclidine|single rising doses
3044473|NCT02264067|Placebo Comparator|Placebo|
3044474|NCT02264054|Experimental|[14C]talsaclidine, oral|single dose of 20 mg oral solution
3044475|NCT02264054|Active Comparator|[14C]talsaclidine, iv|single dose of 20 mg intravenous (iv) infusion
3044476|NCT02264041|Experimental|Cilobradine, low dose plus itraconazole|Pre-study
3044477|NCT02264041|Active Comparator|Cilobradine, low dose|Pre-study
3044478|NCT02264041|Experimental|Cilobradine, high dose plus itraconazole|main study
3044479|NCT02264041|Active Comparator|Cilobradine, high dose|main study
3044480|NCT02264028|Active Comparator|[14C]-DK-AH 269 CL intravenous|
3044481|NCT02264028|Experimental|[14C]-DK-AH 269 CL oral|
3044482|NCT02264015|Experimental|Cilobradine low|
3044483|NCT02264015|Placebo Comparator|Placebo|
3044484|NCT02264015|Active Comparator|Moxifloxacin|
3044485|NCT02264015|Experimental|Cilobradine high|
3044486|NCT02264002|Experimental|Cilobradine low dose 1|
3044487|NCT02264002|Experimental|Cilobradine low dose 2|
3044488|NCT02264002|Experimental|Cilobradine medium dose|
3044489|NCT02264002|Experimental|Cilobradine high dose 1|
3044490|NCT02264002|Experimental|Cilobradine high dose 2|
3044491|NCT02264002|Active Comparator|Metoprolol succinate|1 tablet on day 1, day 2 followed by two tablets from day 3 to day 14
3044492|NCT02264002|Placebo Comparator|Placebo|
3044493|NCT02263989|Experimental|Telmisartan film coated tablet|
3044494|NCT02263989|Active Comparator|Telmisartan conventional tablet|
3044495|NCT02263976|Experimental|BEA 2180 BR|single rising doses
3044496|NCT02263976|Placebo Comparator|Placebo|
3044497|NCT02263976|Experimental|Sub-Study|
3044498|NCT02263963|Experimental|TAP Block Experal|Patient who randomized to this arm, will be blinded, TAP block will be performed under ultrasound guidance, where 20-30 ml of Exparel will be injected in transversus abdominis plane, bilaterally.
3044499|NCT02263963|No Intervention|No TAP Block|
3044500|NCT02263950|Experimental|LON002|(Artemether sublingual spray)
3044501|NCT02263937|Active Comparator|Bilateral Nucleus Basalis Meynert DBS|6 week period of active NBM DBS
3044502|NCT02263937|Sham Comparator|Sham Nucleus Basalis Meynert DBS|6 week period of Sham DBS
3044503|NCT02263924|Experimental|Experimental: Tocotrienol|Mixed tocotrienol 200mg twice a day for 6 months
3044504|NCT02263924|Placebo Comparator|Placebo (for tocotrienol)|Placebo capsules, 1 capsule twice a day for 6 months
3044505|NCT02263911|Experimental|Baricitinib Test Treatment 1 (T1)|Single oral dose of 2 × 4 milligram (mg) baricitinib commercial formulation tablet fasted on Day 1 in one of five periods.
3044506|NCT02263911|Experimental|Baricitinib Reference Treatment 1 (R1)|Single oral dose of 1 × 8 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods.
3044507|NCT02263911|Experimental|Baricitinib Test Treatment 2 (T2)|Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet fasted on Day 1 in one of five periods.
3044508|NCT02263911|Experimental|Baricitinib Reference Treatment 2 (R2)|Single oral dose of 1 × 4 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods.
3044509|NCT02263911|Experimental|Baricitinib Test Treatment 2 with Meal (T2F)|Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet after food intake on Day 1 in one of five periods.
3044510|NCT02263898|Experimental|Treatment (LGX818, MEK162)|Patients receive LGX818 PO QD and MEK162 PO BID continuously for 8 weeks followed by intermittent dosing in subsequent cycles (3 weeks off therapy, 5 weeks on therapy). Cycles repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
3044511|NCT02263885|Experimental|ExAblate Transcranial System|Transcranial ExAblate MRgFUS
3044512|NCT02263872|Experimental|Minocycline|Minocycline 200mg perday
3044513|NCT02263872|Placebo Comparator|comparison group with placebo|Placebo provide
3044514|NCT02263859|Experimental|Treatment|The Treatment Group will be implanted with the aura6000 System and have therapy turned ON at the Month 1 follow-up visit.
3044515|NCT02263859|Other|Control|The Control Group will be implanted with the aura6000 System and receive treatment as-usual, (i.e. any non-PAP, non-surgical OSA treatment including oral appliances and positional devices being used prior to enrollment in the study) until 14 days (washout period) prior to the Month 4 visit. At the Month 4 + 1 day follow-up visit, subjects in the Control Group will have therapy turned ON for the duration of the study.
3044516|NCT02263846||Postmenopausal group|Patients at the age ≥ 60 years with more than one year of menopause, or patients having undergone bilateral oophorectomy.
3044517|NCT02263846||Premenopausal group|Patients with regular menses during recent 3 months and having never received luteinizing hormone-releasing hormone analogue therapy.
3044518|NCT02263833||Overall Participants|Participants not previously on erythropoietin-stimulating agent (ESA) therapy and participants on ESA therapy who were switched to Mircera
3044519|NCT02263807|Experimental|MPFL group|Arthroscopy and MPFL reconstruction
3044520|NCT02263807|Active Comparator|Control|Arhroscopy and rehabilitation
3044561|NCT02263495|Active Comparator|Paclitaxel & Gemcitabine(PG)|Paclitaxel 175mg/m2 IV , Day1,every 3weeks Gemcitabine 1250mg/m2 IV ,Day1& Day8 every 3weeks
3044562|NCT02263495|Experimental|Eribulin & Gemcitabine(EG)|Eribulin 1.0 mg/m2, 2-5min iv ,Day1& Day8 every 3weeks Gemcitabine 1,000 mg/m2 ,Day1& Day8 every 3weeks
3044716|NCT02262572|Experimental|Telmisartan /HCTZ - compression tablet (DC)|
3044521|NCT02263794|Experimental|Image guided bronchial thermoplasty|At pre-treatment Visit 3, imaging data will be acquired to generate a patient-specific bronchial thermoplasty treatment plan which will include 15-20 target airways, prioritized in order of importance and grouped by lobe, to be targeted during a single session BT treatment procedure. Airways demonstrating dynamic or static bronchoconstriction will be targeted for BT treatment based on their spacial proximity to ventilation defects.
3044522|NCT02263794|Active Comparator|Conventional bronchial thermoplasty|Patients in this group will undergo conventional 3 stage bronchial thermoplasty (during 3 separate bronchoscopies).
3044523|NCT02263781|Experimental|Control Blood|Patients on routine postinfectious control, blood draw
3044524|NCT02263781|Experimental|Primary PREPL deficiency Blood|Patients with primary PREPL deficiency, blood draw
3044525|NCT02263781|Experimental|Prader Willi syndrome Blood|Patients with Prader-Willi syndrome, blood draw
3044526|NCT02263781|Experimental|Primary PREPL deficiency like Blood|Patients with symptoms overlapping with primary PREPL deficiency (like hypotonia, growth hormone deficiency, obesity), blood draw
3044527|NCT02263781|Experimental|Control muscle|Patients without hypotonia, growth hormone deficiency, obesity, undergoing elective surgery, muscle biopsy from the surgical site and blood draw
3044528|NCT02263781|Experimental|Prader-Willli syndrome muscle|Patients with Prader-Willi syndrome undergoing elective anesthesia or surgery, muscle biopsy (from surgical site if applicable) and blood draw
3044529|NCT02263768|Other|Group 1 - Recall Interval of 12 months|"Oral clinical conditions:~Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
3044530|NCT02263768|Other|Group 2 - Recall Interval of 18 months|"Oral clinical conditions:~Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
3044531|NCT02263755||chronic hepatitis B subjects|Subjects who have been diagnosed with chronic hepatitis B.
3044532|NCT02263742|Experimental|Peer whole health|Peer whole health intervention will be compared to the treatment as usual at Wellness Center to assess healthcare choice and outcomes
3044533|NCT02263742|Active Comparator|EBPs at Wellness Center|EBPs at Wellness Center will be the active comparative to measure healthcare choice and outcomes with the peer whole health intervention
3044534|NCT02263729|Active Comparator|losartan|Subjects will taken 50mg of losartan per day for 4 weeks
3044535|NCT02263729|Placebo Comparator|placebo|Subjects will be given placebo to replicate appearance of losartan pills. Placebo pill will be taken once per day.
3044536|NCT02263716||Accelerometer|Utilize accelerometers to measure activity in a diverse population of patients with medical or surgical critical illness.
3044537|NCT02263703|Experimental|HPV vaccine|Quadrivalent HPV vaccine
3044538|NCT02263690|Active Comparator|Group Drops|"proparacaine 0.5% drops (Group Drops)~Patients from group Drops received a drop of proparacaine 0.5% before receiving a drop of povidone iodine 5%.~Patients from Group Drops received a second drop of proparacaine 0.5%, 5 minutes after the drop of povidone iodine 5%."
3044539|NCT02263690|Active Comparator|Group SC|"proparacaine 0.5% drops plus subconjunctival lidocaine (Group SC)~Patients from group SC received a drop of proparacaine 0.5% before receiving a drop of povidone iodine 5%.~For the patients from Group SC, a subconjunctival bleb of anesthesia was created by injecting 0.4 ml of lidocaine 1% into the subconjunctival space, posteriorly to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-ml syringe."
3044540|NCT02263690|Active Comparator|Group Gel|"Lidocaine gel 2% on the eye (Group Gel)~Patients from Group Gel received 1 mL of 2% lidocaine gel on the eye before receiving the drop of povidone iodine 5%.~For the patients from Group Gel, 1 mL of 2% lidocaine gel was applied on the eye before receiving the drop of povidone iodine 5%."
3044541|NCT02263677|Experimental|Sitagliptin|60 day supply of 100mg Sitagliptin
3044542|NCT02263651|Active Comparator|Closure with conventional technique with drainage|The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.
3044543|NCT02263651|Experimental|Quilting suture without drainage|In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (<2cm) are placed from the skin flaps to the underlying muscle.
3044544|NCT02263638|Experimental|Anakinra|One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time by a nurse during a five day period
3044545|NCT02263612||Danish Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
3044546|NCT02263599||Conservatively treated ventral hernias|
3044547|NCT02263599||Surgically treated ventral hernias|
3044548|NCT02263573|Experimental|PEP'C-R|Subjects will benefit from one preliminary session and 18 sessions of PEP'C-R, (2 sessions per week for 9.5 weeks).
3044549|NCT02263573|Active Comparator|Control group|Subjects do not participate in the program PEP'C-R and continue their usual activities at home for 9.5 weeks.
3044550|NCT02263560||Post-stroke patients|Patients who experienced stroke and who already recover gait abilities.
3044551|NCT02263560||Control population|Participants matching the criterion (age and gender) of the patients' group.
3044552|NCT02263547|Other|teriflunomide elimination with colestipol|
3044553|NCT02263534|Experimental|minisling|patients in this arm will undergo single incision minisling
3044554|NCT02263534|Sham Comparator|tension free vaginal tape|patients in this arm will undergo tension free vaginal tape
3044555|NCT02263521||physicians|Nationally-representative sample of physicians in all specialties who have direct or indirect patient care responsibilities
3044556|NCT02263521||resident physicians|Nationally-representative of resident physicians in all specialties
3044557|NCT02263521||medical students|Nationally-representative sample of 4th year medical students in all US allopathic medical schools.
3044558|NCT02263508|Experimental|Phase 1b;|Phase 1b: talimogene laherparepvec and pembrolizumab (MK-3475)
3044559|NCT02263508|Experimental|Phase 3 Arm 1;|Phase 3 Arm 1: talimogene laherparepvec and pembrolizumab (MK-3475)
3044560|NCT02263508|Experimental|Phase 3 Arm 2;|Phase 3 Arm 2: placebo and pembrolizumab (MK-3475)
3044702|NCT02262650|Active Comparator|Clopidogrel alone|
3044563|NCT02263482|Other|Control group|patients awaiting for evaluation to cardiac rehabilitation or transplantation
3044564|NCT02263482|Experimental|moderate-intensity group|Patients will be submitted to a 8-weeks training program, with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) and peripheral muscle trained with upper and lower exercises (50% of the 1-maximum repetition test).
3044565|NCT02263482|Active Comparator|low-intensity group|Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) and peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 Kg each).
3044566|NCT02263469|Experimental|Replenine®-VF|
3044567|NCT02263456|Active Comparator|Current Factor IX|
3044568|NCT02263456|Experimental|Replenine®-VF|
3044569|NCT02263443|Experimental|Soap sus enema (S.S.E.)|Patients in S.S.E. group will receive bowel preparation by soap suds enema until clear at night before surgery.
3044570|NCT02263443|Experimental|sodium chloride enema|Patients in unison enema group will receive Unison enema 100 ml per rectal at night before surgery.
3044571|NCT02263443|Placebo Comparator|no enema|Patients will receive none of bowel preparation. NPO after midnight
3044572|NCT02263430|Experimental|Deep Brain Stimulation|Stimulation is on.
3044573|NCT02263430|Sham Comparator|Placebo|Stimulation is off.
3044574|NCT02263417|Active Comparator|Deep Brain Stimulation|Stimulation is on
3044575|NCT02263417|Sham Comparator|Placebo|Stimulation is off
3044576|NCT02263404|Experimental|Deep Brain Stimulation|DBS Implant and stimulation Intervention: Device: Deep Brain Stimulation
3044577|NCT02263391|Experimental|Opt-in testing|"Common barriers to HIV screening testing will be removed as much as possible (i.e., providing rapid testing, results shortly available, testing on-site, confidentiality). The research assistant will say: There is voluntary HIV testing available to all study participants if you wish to do it. It is free, private, it is only a finger stick, and you will learn your HIV results in just minutes. Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group."
3044578|NCT02263391|Experimental|Opt-out testing|"Participants will be informed that a routine health test bundle is available on a voluntary basis to study participants, and the participant may elect to decline all or any individual part of the testing. The assistant will say: We are offering a voluntary panel of routine health screening test today for study participants. It includes blood sugar, cholesterol, and HIV. We recommend all of them for everyone, but you can choose to decline any or all of them. This is free, private, it is only a finger stick, and you will learn your results for all the tests in just minutes. Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group."
3044579|NCT02263378|Experimental|supplement|
3044580|NCT02263378|Placebo Comparator|not intervention|
3044581|NCT02263365|No Intervention|Control|
3044582|NCT02263365|Experimental|Therapeutic|Patients randomized to this arm will be administered 4mg tid (three times daily) of loperamide from the day of discharge onwards. A total of duration of 14 days of medication will be administered
3044583|NCT02263352|Experimental|Lycored soft gels , Scaling and Rootplaning.|Systemic Lycored soft gels,(Jagsonpal Pharma) was given orally 8mgms/day for 2 months and Scaling and rootplaning (otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus) which was performed at baseline
3044584|NCT02263352|Experimental|Scaling and Rootplaning only.|Scaling and rootplaning(otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus) which was performed at baseline.
3044585|NCT02263339|Experimental|Aerobic Exercise|
3044586|NCT02263339|Active Comparator|Stretching Program|
3044587|NCT02263339|Active Comparator|Aerobic Exercise, Healthy Subjects|
3044588|NCT02263326|Experimental|dolutegravir plus lamivudine|dolutegravir 50 mg plus lamivudine 300 mg once daily
3044589|NCT02263326|Active Comparator|Continue current ART regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
3044590|NCT02263313||EGO-COMBO group|Previously enrolled into EGO-COMBO Pilot study and with combo stent
3044591|NCT02263300||Supine- Supine|Group A (supine-supine) will first practice fiberoptic intubation with the iLarynx oriented in the supine position. Learning curves, global rating scale and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the supine, then Upright position. At the end of one week,the same medical student will then perform the intubation with the mannequin in both positions.
3044592|NCT02263300||Upright-upright|Group B (upright-upright) will first practice fiberoptic intubation with the iLarynx oriented in the upright position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the upright then supine position.At the end of one week, the same medical student will then perform the intubation with the mannequin in both positions.
3044593|NCT02263300||Supine -upright|Group C( supine -upright) will first practice fiberoptic intubation with the iLarynx oriented in the supine position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the upright then supine position. At the end of one week, The same medical student will then perform the intubation with the mannequin in both positions.
3044594|NCT02263300||Upright - supine|Group D( upright - supine) will first practice fiberoptic intubation with the iLarynx oriented in the upright position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the upright,then supine position. At the end of one week, the same medical student will then perform the intubation with the mannequin in both positions.
3044595|NCT02263287|Other|Alzheimer disease (AD)|Patients with AD according to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria Intervention: LeSCoD scale
3044703|NCT02262637||Hypertensive patients - Cardiologists|
3044596|NCT02263287|Other|Dementia with Lewy Bodies (DLB)|Patients with probable DLB according to McKeith criteria. Intervention: LeSCoD scale
3044597|NCT02263287|Other|Probable AD and possible DLB|Patients with clinical criteria for possible or probable AD and possible DLB Intervention: LeSCoD scale
3044598|NCT02263274|Experimental|Direct Cortical Measurement|Consented subjects will also have transcranial electrodes applied at four extracranial sites, below the sterile dressing and distant from the surgical skull defect. The four electrodes will be placed in uniform positions based on the standard 10-10 electrode system, at the temples bilaterally (positions F9 and F10) and at the occiput bilaterally (positions PO9 and PO10). Subjects will be stimulated according to a predetermined set of parameters which fall well within empirically and computationally determined safety thresholds, as discussed above. The entire stimulation protocol is described in detail in section 5, and is anticipated to last no longer than 30 minutes.
3044599|NCT02263261|Other|Flex HD Pliable Perforated HADM|Single Arm
3044600|NCT02263248|Experimental|venlafaxine XR plus buprenorphine|Drug Intervention: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks.
3044601|NCT02263248|Placebo Comparator|venlafaxine XR plus placebo|Drug Intervention: venlafaxine XR plus placebo Dosage varies . Subject remains on antidepressant throughout the 32 weeks study. Will be randomized to buprenorphine or placebo for up to 16 weeks
3044602|NCT02263235|Experimental|Group 1|60 patients (20 probable AD, 20 Parkinson Disease (PK), 20 neurological disease without cognitive degradation)
3044603|NCT02263235|Experimental|Group 2A|20 patients (patients with brain trauma, acute hydrocephaly), with temporary derivation of the CSF
3044604|NCT02263235|Experimental|Group 2B|30 patients (15 probable AD, 15 neurological disease without cognitive degradation)
3044605|NCT02263222|Experimental|MDT-10013|Subjects will receive MDT-10013.
3044606|NCT02263209|Experimental|Bioguard Group|Randomised study to either Bioguard or control stock
3044607|NCT02263209|Active Comparator|Control Group|Randomised study to either Bioguard or control stock
3044608|NCT02263196|Experimental|alcohol and povidone iodine|the efficacy of combination of alcohol and povidone iodine on inflammation related to vascular access
3044609|NCT02263196|Experimental|combination of alcohol and betadin|the efficacy of combination of alcohol and povidone iodine on infection related to vascular access
3044610|NCT02263183|Active Comparator|red palm olein(labelled A)|red palm olein (labelled A)
3044611|NCT02263183|Placebo Comparator|palm olein(labelled B)(control)|palm olein(labelled B)(control)
3044612|NCT02263170||All study participants|Healthy (m/f), normal weighted
3044613|NCT02263157||BSI group with thrombocytopenia|BSI patients with thrombocytopenia
3044614|NCT02263157||Non-BSI group with thrombocytopenia|Non-BSI patients with thrombocytopenia
3044615|NCT02263157||BSI group without thrombocytopenia|BSI patients without thrombocytopenia
3044616|NCT02263157||Non-BSI group without thrombocytopenia|Non-BSI patients without thrombocytopenia
3044617|NCT02263144||histologically-verified <10mm polyps|histologically-verified <10mm polyps, analyzed by virtual chromo-endoscopy using FICE Fujifilm Technology
3044618|NCT02263131|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
3044619|NCT02263131|Active Comparator|TIV PFS|VAXIGRIP Prefilled Syringe INJ.
3044620|NCT02263118|Experimental|Uni-directional SMS|Participants in this group received breastfeeding promoting messages based on the MAMA (http://www.mobilemamaalliance.org/) breastfeeding database. Individuals could only receive text messages.
3044621|NCT02263118|Experimental|Virtual communities|Participants were made part of virtual communities in which could exchange about infant's health as groups, via SMS, following the SHM Foundation's (http://www.shmfoundation.org/) m-health methodology.
3044622|NCT02263118|Experimental|Hybrid setup|Participants were made part of virtual communities in which they could exchange about infant's health as groups, via SMS. Additionally, a health professional was included in the virtual community.
3044623|NCT02263118|Experimental|Control group|Individuals were given a feature phone (simple mobile phone)
3044624|NCT02263105|Experimental|CDDP plus Temozolomide|"Patients were treated with CDDP and TMZ. CDDP was administered iv from Day 1 to 3 with everyday dose of 30mg. TMZ was orally administered from Day 1 to 7 and Day 15 to 21, with everyday dose of 125mg/m2 (Level 2). The period of one chemotherapy cycle is 28 days. TMZ dose levels were listed in Table 1.~Table 1 TMZ dose levels Dose levels Daily TMZ dose( mg/m2/d ) TMZ dose per cycle(mg/m2)~150 2100~125 1750~100 1400~75 1050"
3044625|NCT02263092|Experimental|15 minutes of physical exercise|the subjects will do physical exercise on a treadmill with 64 to 74% of maxHR
3044626|NCT02263092|Experimental|10 minutes of physical exercise|- the subjects will do physical exercise on a treadmill with 77 to 95% of maxHR.
3044627|NCT02263092|Experimental|30 minutes of physical exercise|- the subjects will do physical exercise on a treadmill with 57 to 63% of maxHR.
3044628|NCT02263092|Experimental|Rest/control|the subjects will be on 15 or 30 minutes seat without move the legs.
3044629|NCT02263092|Experimental|Anodal tDCS + physical exercise 1|the subjects will be undergo to anodal tDCS + physical exercise 1
3044630|NCT02263092|Experimental|Anodal tDCS + physical exercise 2|the subjects will be undergo to anodal tDCS + physical exercise 2
3044631|NCT02263092|Experimental|Cathodal tDCS + physical exercise 1|the subjects will be undergo to cathodal tDCS + physical exercise 1
3044632|NCT02263092|Experimental|Cathodal tDCS + physical exercise 2|- the subjects will be undergo to cathodal tDCS + physical exercise 2
3044633|NCT02263092|Experimental|Sham tDCS + physical exercise 1|the subjects will be undergo to sham tDCS + physical exercise 1
3044634|NCT02263092|Experimental|Sham tDCS + physical exercise 2|the subjects will be undergo to sham tDCS + physical exercise 2
3044635|NCT02263079|Experimental|Peg-IFN-Alfa-2A + Lamivudine or Entecavir|Participants will receive lamivudine or entecavir alone for 8 weeks followed by peg-IFN-alfa-2A in combination with lamivudine or entecavir for 48 weeks.
3044636|NCT02263079|No Intervention|Untreated Control Participants|Untreated control participants will be observed up to 80 weeks.
3044637|NCT02263066||Group 1|Chinese hemophilia A pediatric patients with medical records who had accepted regular prophylaxis, totally/partially with rFⅧ between Nov. 1st 2007 and May 31st 2013
3044638|NCT02263053|Active Comparator|Posterior Mobilization|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower lateral incisors and canines. Applies a force previous distraction grade III and performs oscillating for 1 minute.
3044639|NCT02263053|Active Comparator|Caudal Mobilization|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower molars of patients. Apply simultaneous flow and force the previous direction, and performs the degree of oscillation III for 1 minute.
3044640|NCT02263040|Experimental|High Dose Fluzone|Fluzone High-Dose® Licensed for use in the USA in persons ≥ 65 years of age as a single dose of 0.5mL containing 60μg HA per virus strain
3044641|NCT02263040|Active Comparator|Fluzone (standard dose)|Fluzone ® Licensed for the prevention of influenza as a single dose of 0.5mL containing 15μg HA per virus strain for adults
3044642|NCT02263027|Experimental|Vaccine, then placebo|1 injection of trivalent inactivated influenza vaccine, 0.5mL/dose, as approved for use in Canada for season of enrolment followed by 1 injection of normal saline placebo, 0.5mL/dose, 28 days later
3044643|NCT02263027|Experimental|Placebo, then vaccine|1 injection of normal saline placebo, 0.5mL/dose followed by 1 injection of trivalent inactivated influenza vaccine, 0.5mL/dose, as approved for use in Canada for season of enrolment, 28 days later
3044644|NCT02263014||Contralateral Prophylactic Mastectomy (CPM) Group|Group of women who decide to have contralateral prophylactic mastectomy (CPM) along with scheduled mastectomy. Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, 12, and 18 months after the surgery is completed.
3044645|NCT02263014||No Contralateral Prophylactic Mastectomy (CPM) Group|Group of women who decide not to have contralateral prophylactic mastectomy (CPM) performed during scheduled mastectomy. Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, 12, and 18 months after single mastectomy surgery is completed.
3044646|NCT02263001|Experimental|Auricular Acupuncture Plus Usual Care|Auricular acupuncture therapy for treatment of musculoskeletal pain, plus usual care therapy consisting of over-the-counter and prescribed pharmacotherapy.
3044647|NCT02263001|Active Comparator|Usual Care Only|Usual care therapy for treatment of musculoskeletal pain. Usual care therapy consists of over-the-counter and prescribed pharmacotherapy.
3044648|NCT02262988|Experimental|Autologous cells and knee arthroplasty|Regenerative cells recovered from the patient's infrapatellar fat pad will be processed using the Transpose RTTM system (InGeneron, Inc., Houston, TX, USA). The processed cells are injected into the knee as adjuvant treatment for total knee arthroplasty (TKA).
3044649|NCT02262988|Placebo Comparator|Control|Standard total knee arthroplasty (no fat cells harvested).
3044650|NCT02262975||donepezil (Aricept)|
3044651|NCT02262962|No Intervention|Usual Well-Child Care|No change in Well-Child Visits.
3044652|NCT02262962|Experimental|Redesigned Well-Child Care|The Redesigned Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and text messaging services (HealthyTxt).
3044653|NCT02262949|Experimental|LifeStent Vascular Stent|This is a single arm study and all subjects receive PTA and implantation of one Life Stent Vascular Stent.
3044654|NCT02262936|Active Comparator|Desmopressin|Patients randomized to receive Desmopressin will be given 0.1mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 0.2mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.
3044655|NCT02262936|Active Comparator|Fesoterodine|Patients randomized to receive Fesoterodine will be given 4mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 8mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.
3044656|NCT02262923|No Intervention|Control|"Poor responders will be defined as women who have undergone a previous IVF cycle with fewer than 4 oocytes retrieved and at least one of the following two criteria: (1) advanced age (≥40 years) or any other risk factor for poor ovarian response and (2) abnormal ovarian reserve testing (antral follicle count (AFC) < 5-7 or anti-mullerian hormone (AMH) level < 3.6-7.9 pmol/L). Poor responders who will be undergoing a repeat IVF cycle will be recruited for the study with informed consent.~In the control arm, patients will undergo the same ovarian stimulation protocol as the previous IVF cycle in which they experienced a poor response. Starting 3 weeks prior to the first day of stimulation until the time of ovulation trigger (approximately 5 weeks overall), these patients will receive an oral placebo three times daily."
3044657|NCT02262923|Experimental|Experimental|"Poor responders will be defined as women who have undergone a previous IVF cycle with fewer than 4 oocytes retrieved and at least one of the following two criteria: (1) advanced age (≥40 years) or any other risk factor for poor ovarian response and (2) abnormal ovarian reserve testing (antral follicle count (AFC) < 5-7 or anti-mullerian hormone (AMH) level < 3.6-7.9 pmol/L). Poor responders who will be undergoing a repeat IVF cycle will be recruited for the study with informed consent.~In the experimental arm, patients will undergo the same ovarian stimulation protocol as the previous IVF cycle in which they experienced a poor response. Starting 3 weeks prior to the first day of stimulation until the time of ovulation trigger (approximately 5 weeks in total), these patients will receive oral metoclopramide 5mg three times daily.."
3044658|NCT02262910|Experimental|ES414|Cohorts 1-3 of the dose escalation stage of the study (Stage 1) will test weekly doses of 0.2 mcg/kg to 2 mcg/kg. Cohorts 4-9 of the dose escalation stage of the study (Stage 1) will test continuous infusion at flat doses of 25 mcg to 300 mcg per day delivered continuously over 24 hours. The maximum tolerated dose from Stage 1 of the study will be further examined in Stage 2. Patients in cohorts 1-3 will receive ES414 weekly via intravenous (IV) infusion during the first three 28-day cycles and then on Day 1 and 15 of each subsequent cycle until disease progression, intolerable toxicity occurs, or the patient withdraws consent. Patients in cohorts 4-9 will receive ES414 as a continuous IV infusion for 6 months until disease progression, intolerable toxicity occurs, or the patient withdraws consent.
3044659|NCT02262897|Experimental|Nab-paclitaxel single agent|Nab-paclitaxel single agent, either in 130mg/m2 weekly regimen, d1,8,15 every 4 weeks or in 230mg/m2 d1 every 3 weeks
3044660|NCT02262884|Active Comparator|AIS @ 12mmHg pressure|SurgiQuest AirSeal Insufflation System (AIS) set at 12mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephrectomy.
3044704|NCT02262637||Hypertensive patients - Nephrologists|
3044661|NCT02262884|Active Comparator|AIS @ 15mmHg pressure|SurgiQuest AirSeal insufflation System (AIS) set at 15 mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephrectomy.
3044662|NCT02262884|Active Comparator|CIS @ 15mmHg pressure|Conventional Insufflation System (CIS) set at 15mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephectomy.
3044663|NCT02262871|Experimental|CF patients HFN|CF patients who meet the eligibility criteria will be randomized to receive HFN and then crossover to other device.
3044664|NCT02262871|Experimental|CF patients NIV|CF patients who meet the eligibility criteria will be randomized to receive NIV and then crossover to other device.
3044665|NCT02262858|Experimental|Telmisartan and HCTZ (fix dose combination)|
3044666|NCT02262858|Active Comparator|Telmisartan and HCTZ (monocomponent)|
3044667|NCT02262845||Group A: PEP Risk|In subjects deemed at high risk for acute pancreatitis post-endoscopic retrograde cholangiopancreatography (ERCP)
3044668|NCT02262845||Group B: Impaired Pancreatic Duct Drainage|In subjects with a pancreatic duct stricture and/or pancreatic duct stones and/or pancreatic duct sludge or debris, possibly, but not exclusively before or after ESWL or before pancreatic surgery
3044669|NCT02262845||Group C: Pancreatic Duct Leak|In subjects with a pancreatic duct leak
3044670|NCT02262845||Group D: Post Pancreatic Surgery|In subjects at risk of pancreatic duct leak or strictures after resection of a pancreatic lesion close to the main pancreatic duct or at the level of the pancreatico-jejunostomy after pancreatico-duodenectomy
3044671|NCT02262845||Group E: Other|In subjects with other indications
3044672|NCT02262793|Experimental|telmisartan and ASA/ER-DP (concomitant)|
3044673|NCT02262793|Active Comparator|ASA/ER-DP alone|
3044674|NCT02262793|Experimental|telmisartan and ASA/ER-DP (consecutively)|
3044675|NCT02262793|Active Comparator|telmisartan|
3044676|NCT02262780|Experimental|Single low dose Telmisartan with HCTZ|
3044677|NCT02262780|Experimental|Single high dose Telmisartan with HCTZ|
3044678|NCT02262780|Experimental|Multiple high dose Telmisartan with HCTZ|
3044679|NCT02262767|Experimental|Single Ascending Doses Cohort 1|Single doses, given by oral solution, starting at 0.75 mg up to a possible maximum of 3.0 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator while 6 are given active dose. The subjects will be given concomitant trimethobenzamide hydrochloride for the 3 weeks that the subject is in the CRU. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by one week.
3044680|NCT02262767|Experimental|Single Ascending Doses Cohort 2|Single doses, given by oral solution, starting at 4.5 mg up to a possible maximum of 9.0 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator while 6 are given active dose. The subjects will be given concomitant trimethobenzamide hydrochloride for the 3 weeks that the subject is in the CRU. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by one week.
3044681|NCT02262754|Experimental|PF-06372865|Daily BID dosing for 4 weeks
3044682|NCT02262754|Placebo Comparator|Placebo|Daily BID dosing for 4 weeks
3044683|NCT02262754|Active Comparator|Naproxen|Daily BID dosing for 4 weeks
3044684|NCT02262741|Experimental|MEDI4736 + tremelimumab|
3044685|NCT02262728|Experimental|Panel 1|Participants with Child-Pugh score <7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) will receive simeprevir (150 milligram [mg] capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.
3044686|NCT02262728|Experimental|Panel 2|Participants with Child-Pugh score 7 to 9 (extremes included) will receive simeprevir (150 mg capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.
3044687|NCT02262715|Experimental|Part 1|Participants will receive in random order Treatment A (VX-787, 600 mg tablet 2 times a day on Day 1 to 4, followed by VX 787, 600 mg tablet on Day 5); Treatment B (Oseltamivir, 75 mg capsule 2 times a day on Day 1 to 4, followed by oseltamivir 75 mg capsule in the morning on Day 5) or Treatment C (VX-787, 600 mg tablet, 2 times a day orally + oseltamivir, 75 mg capsule, 2 times a day on Day 1 to 4, followed by a single dose of VX-787, 600 mg + oseltamivir, 75 mg capsule on Day 5). Each participant will receive all three treatments (Treatment A, B and C) in a random sequence.
3044688|NCT02262715|Experimental|Part 2 VX-787|Participants will receive VX-787, 600 mg, tablet 2 times a day, orally on Day 1 to Day 9, followed by single dose of VX-787, 600 mg on Day 10.
3044689|NCT02262715|Experimental|Part 2 Placebo|Participants will receive placebo matching to VX-787, 2 times a day, orally on Day 1 to Day 9, followed by single dose of matching placebo on Day 10.
3044690|NCT02262702||Extended Release Paracetamol|Participants prescribed with extended release paracetamol tablet containing 665 mg paracetamol.
3044691|NCT02262702||Standard Paracetamol|Participants prescribed with standard paracetamol tablet containing 500 mg paracetamol.
3044692|NCT02262689|Experimental|GSK2256294 15 mg|Randomised subjects will be instructed to take three capsules of GSK2256294 15 mg, each morning for 7 days. Subjects will undergo echocardiography under normoxic and hypoxic conditions on Day 1 pre-dose and on Day 7 post-dose.
3044693|NCT02262689|Placebo Comparator|Placebo|Randomised subjects will be instructed to take three capsules of matching placebo, each morning for 7 days. Subjects will undergo echocardiography under normoxic and hypoxic conditions on Day 1 pre-dose and on Day 7 post-dose.
3044694|NCT02262676||Rivaroxaban|Patients with Atrial fibrillation treated with Rivaroxaban
3044695|NCT02262663|Experimental|Vilaprisan [0.5mg]|0.5 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
3044696|NCT02262663|Experimental|Vilaprisan [1mg]|1 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
3044697|NCT02262663|Experimental|Vilaprisan [2mg]|2 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
3044698|NCT02262663|Experimental|Vilaprisan [4mg]|4 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
3044699|NCT02262650|Active Comparator|Telmisartan alone|
3044700|NCT02262650|Experimental|Telmisartan + Clopidogrel (concomitantly)|
3044701|NCT02262650|Experimental|Telmisartan + Clopidogrel (consecutively)|
3044717|NCT02262572|Experimental|Telmisartan /HCTZ - dry granulation tablet (DG)|
3044718|NCT02262572|Active Comparator|Telmisartan /HCTZ - present commercial formulation|
3044719|NCT02262559|Experimental|BIBR 277 tablet|
3044720|NCT02262559|Active Comparator|BIBR 277 capsule|
3044721|NCT02262546|Experimental|Pramipexole|
3044722|NCT02262546|Active Comparator|Moxifloxacin|
3044723|NCT02262546|Placebo Comparator|Pramipexole Placebo|
3044724|NCT02262546|Placebo Comparator|Moxifloxacin Placebo|
3044725|NCT02262533|Experimental|Treatment A: Apixaban|Apixaban tablet by mouth on specified day
3044726|NCT02262533|Experimental|Treatment B: Atenolol|Atenolol tablet by mouth on specified day
3044727|NCT02262533|Experimental|Treatment C: Apixaban and Atenolol|Apixaban and Atenolol tablets by mouth on specified day
3044728|NCT02262520|Experimental|Treatment A: Digoxin|Digoxin tablet by mouth on specified days
3044729|NCT02262520|Experimental|Treatment B: Apixaban and Digoxin|Apixaban and Digoxin tablets by mouth on specified days
3044730|NCT02262507|Experimental|Device wearing|All subjects who meet the study criteria and volunteer to participate will be included in the study.
3044731|NCT02262494|Other|Suspected first episode of DVT|"The study population consists of patients presenting with suspected first episode of DVT at the Nîmes University Hospital.~Intervention: portable venous compression ultrasonography Intervention: venous compress ultrasonography Intervention: Doppler ultrasound of the lower limbs"
3044732|NCT02262481|Active Comparator|Dydrogesterone|tocolytic + corticosteroids + Dydrogesterone 10 mg/tablet prepare in capsule, 1 cap oral every 12 hours, starting form enrollment until gestational age 37 weeks
3044733|NCT02262481|Placebo Comparator|Placebo|tocolytic + corticosteroids + Placebo prepare in capsule, 1 cap oral every 12 hours, starting form enrollment until gestational age 37 weeks
3044734|NCT02262468||MOM total hip replacements|all patients with MOM 36mm hip replacements
3044735|NCT02262455|Experimental|STM 434|
3044736|NCT02262455|Experimental|STM 434 and Liposomal Doxorubicin|
3044737|NCT02262442|Experimental|Working channel|Patients will receive local anaesthetics via the working channel of the bronchoscope.
3044738|NCT02262442|Experimental|Enk Fiberoptic Atomizer|Patients will receive the local anaesthetics for the flexible bronchoscopy via the nebulizer Enk Fiberoptic Atomizer.
3044739|NCT02262429||ONS QIP|Two (2) hospitals will administer the new rapid, comprehensive oral nutritional supplementation (ONS) QIP.
3044740|NCT02262429||ONS Standard Feeding|"Two (2) hospitals will use their current standard ONS feeding protocol."
3044741|NCT02262416|Placebo Comparator|controls|Normal saline of equivalent volume
3044742|NCT02262416|Active Comparator|case|0.5mg Leuprolide acetate injection
3044743|NCT02262403|Experimental|Hookworm infected|The amount, phenotype and function of Treg will be explored at several time points. Cultures with environmental antigen will be subsequently performed.
3044744|NCT02262403|Active Comparator|Non infected (hookworms) healthy subjects|All the tests done in the experimental hookworm infected group will be also done in the comparator non infected group.
3044745|NCT02262390|Active Comparator|Standard of Care|Partner notification slip is given to the pregnant female participant on the day she receives her syphilis test results to give to their sexual partner encouraging them to come to the STI clinic and be screened for syphilis. The partner notification slip will have a code number, but no identifiable features (no names).
3044746|NCT02262390|Active Comparator|SMS reminders and notification slip for partner screening|Participants will receive weekly SMS reminders to encourage their partners to attend the STI clinic for syphilis testing for up to 8 weeks after initial positive syphilis test for the participant. The participant ID number will be written on both the notification paper which partners should bring in with them and on the SMS reminders.
3044747|NCT02262390|Active Comparator|Phone call reminders and notification slip for partner scree|Participants will receive weekly phone call reminders to encourage their partners to attend the STI clinic for syphilis testing for up to 8 weeks after initial positive syphilis test for the participant. The participant ID number will be written on both the notification paper which partners should bring in with them and be given to the participant when the nurse calls.
3044748|NCT02262377|Experimental|Integrative Medicine Group Visits|9-week integrative medicine group visit that meets 1 time per week for 2.5 hours followed by a 3 month Web based curriculum and final group meeting
3044749|NCT02262377|No Intervention|Standard of Care|primary care visits, which include medications and advice
3044750|NCT02262364|Experimental|NStride APS|Subjects will receive an intra-articular injection of APS.
3044751|NCT02262351|Experimental|Screening|"Subjects will undergo three screening methods for atrial fibrillation:~30 Second Pulse Check Watch BP Home A HeartCheck Hand-held ECG device"
3044752|NCT02262338|Experimental|Treated subjects|AGT-182 solution for infusion will be administered intravenously at doses of 1.0 mg/kg or 3.0 mg/kg weekly for 8-13 weeks.
3044753|NCT02262325|Experimental|Treatment (hypofractionated radiation boost, chemoradiation)|Patients undergo hypofractionated radiation boost over 2 fractions (at least 40 hours apart) during week 1. Beginning week 2, patients receive cisplatin IV on days 8, 15, 36, and 43; and etoposide IV over 60 minutes on days 8-12 and 36-40. Patients also undergo standard 3-D conformal radiation therapy QD 5 days a week for a total of 30 fractions. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
3044754|NCT02262312||Patients with myelodysplastic syndrome|Patients with myelodysplastic syndrome among these include also patients with chronic myelomonocytic leukemia with myelodysplasia, patients with acute myeloid leukemia progressed from myelodysplastic syndrome and patients with myelodysplastic/myeloproliferative neoplasm, unclassifiable
3044755|NCT02262299|Placebo Comparator|Placebo|Receive placebo tablets
3044756|NCT02262299|Active Comparator|Pirfenidone|Upon enrollment, subjects will be randomized to either the treatment group (Pirfenidone) or to the placebo group (1:1 ratio). The trial medication will be administered as 267-mg oral capsules and titrated to a maintenance dose of 2403 mg/d (3 capsules TID, for a total of 9 capsules/day).
3044757|NCT02262286||Brain Injury|Brain Injury
3044758|NCT02262286||Control|Healthy, or Head Trauma, or Orthopedic Trauma, or Poly-Trauma
3044759|NCT02262273||Serous ovarian cancer:|Women with platinum-sensitive recurrent serous ovarian cancer
3044985|NCT02260921|Sham Comparator|Sham|Sham Treatment
3044760|NCT02262260|Experimental|Ranibizumab labeled regime arm|Ranibizumab (Anti VEGF) 0.5mg treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month
3044761|NCT02262260|Experimental|Ranibizumab wait and Extend regime arm|Ranibizumab (Anti VEGF) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
3044762|NCT02262247||Transoral Visualization & Access|Subjects ≥ 22 yrs requiring transoral procedures
3044763|NCT02262234|Experimental|Education Program Type 1|
3044764|NCT02262234|Experimental|Education Program Type 2|
3044765|NCT02262221|No Intervention|ARM A (Non intensive Follow up)|Follow up consisting of outpatient visits according to the schedule foreseen for single head and neck subsite. At each follow up visit patients will report all new symptoms and they will receive physical and fiberoptic endoscopic head and neck examination. Laboratory tests will be performed once a year. Quality of life questionnaires will be administered to patients every other visit for the first 2 years and then at each visit. A socio-economic questionnaire will be also administered at each visit. Locoregional imaging will be performed within 6 months after radiotherapy end and recommended only at the occurrence of new signs or symptoms. Patients will be contacted by a phone call between visits in order to monitor patient's reported symptoms potentially related to disease recurrence.
3044766|NCT02262221|Other|ARM B (Intensive Follow up)|Intervention foreseen is scheduled radiologic evaluations (CT or MRI scan) and PET scan if patients ≥ 50 years old and with a smoking history ≥ 20 pack year. Follow up outpatient visits will be performed similarly to ARM A, including physical and fiberoptic endoscopic head and neck evaluation and laboratory tests and questionnaires. Locoregional imaging will be requested for all the patients 2 times/year in the first 2 years and 1 time/year in the third and fourth year; PET scan will be requested yearly in the first 3 years. In the first year after RT end, MRI or CT scan will be performed at screening and at sixth month after enrollment, while PET scan will be performed six months after enrollment only in patients ≥50 years and with a smoking history of ≥20 pack/years.
3044767|NCT02262208|Other|Patients with type 2 diabetes|
3044768|NCT02262208|Other|Healthy|
3044769|NCT02262195||Carboxyhemoglobin|Induced carboxyhemoglobin levels up tp 15 percent.
3044770|NCT02262195||Methemoglobin|Induced methemoglobin levels up to 15 percent.
3044771|NCT02262182|Experimental|KP group|PEP delivery by EzPAP® device with manual chest physiotherapy .
3044772|NCT02262182|Placebo Comparator|KM group|Manual chest physiotherapy only;
3044773|NCT02262169|Active Comparator|Treatment I|2 Omeprazole capsules 20 mg once daily and 1 placebo caplet of DLBS2411, twice daily
3044774|NCT02262169|Experimental|Treatment II|1 DLBS2411 caplet 250 mg twice daily and 2 placebo capsules of Omeprazole once daily
3044775|NCT02262156|Experimental|Cognitive behavioral Therapy|"CBT program to be used in group modality that focused on managing symptoms of depression in patients with epilepsy.~12 CBT sessions, consisting of one weekly 90-minute session for 12 consecutive weeks."
3044776|NCT02262156|Active Comparator|Selective serotonin euptake inhibitor|Patients will receive a SSRI (sertraline or citalopram) for 12 weeks. Dose will be adjusted every 4 weeks according to medical criteria.
3044777|NCT02262143|Experimental|Experimental|Rosuvastatin 10 mg, Fenofibrate 160 mg
3044778|NCT02262143|Active Comparator|Comparator|Rosuvastatin 10 mg
3044779|NCT02262130|Experimental|Omalizumab|Omalizumab 300 mg W0, W4 and W8
3044780|NCT02262117|Placebo Comparator|standard care|No specific treatment (standard care)
3044781|NCT02262117|Experimental|specific treatment|As a deregulation has been diagnosed by immune analysis, a personalization of the medical care for this IVF/ICSI attempt will be dispensed Personalization of treatment should follow a step-to step decision tree.
3044782|NCT02262104|Experimental|Intensive exercise|Intensive strengthening and balance exercises 1 hour twice a week 12 weeks. Lead by physiotherapists.
3044783|NCT02262104|Placebo Comparator|Control|Control group activities: Social activities one hour twice a week. Light physical activities, reading, conversation, games. Lead by occupational therapist or nursing staff
3044784|NCT02262091|Placebo Comparator|Placebo group|
3044785|NCT02262091|Experimental|Food fibers|
3044786|NCT02262078|Placebo Comparator|Placebo (Saline)|Participants receive normal saline, administered by inhalation over 10-15 minutes, using a nebulizer
3044787|NCT02262078|Experimental|Sodium Nitrite|Participants receive Sodium Nitrite inhalation solution, administered by inhalation over 10-15 minutes, using a nebulizer
3044788|NCT02262065||Patients|Patients with suspected arthroplasty intolerance
3044789|NCT02262065||Controls|Patients with well tolerated arthroplasties
3044790|NCT02262052|Other|Phase 4 cohort study|MRDTI
3044791|NCT02262039|Active Comparator|Conventional Pressure|Conventional Insufflation with 15mmHg target pressure
3044792|NCT02262039|Experimental|Low Pressure (VTI)|Valveless recirculating insufflation (VTI) with 10mmHg target pressure
3044793|NCT02262026|Experimental|FHP; 125mg AZD0530, then 50mg AZD0530, then placebo|Family History positive for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test
3044794|NCT02262026|Experimental|FHP; 125mg AZD0530, then placebo, then 50mg AZD0530|Family History positive for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test
3044795|NCT02262026|Experimental|FHP; 50mg AZD0530, then 125mg AZD0530, then placebo|Family History positive for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test
3069431|NCT02098395|Placebo Comparator|Liraglutide placebo 0.1 ml + insulin|
3044796|NCT02262026|Experimental|FHP; 50mg AZD0530, then placebo, then 125mg AZD0530|Family History positive for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test
3044797|NCT02262026|Experimental|FHP; placebo, then 50mg AZD0530, then 125mg AZD0530|Family History positive for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test
3044798|NCT02262026|Experimental|FHP; placebo, then 125mg AZD0530,then 50mg AZD0530|Family History positive for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test
3044799|NCT02262026|Active Comparator|FHN; 125mg AZD0530, then 50mg AZD0530, then placebo|Family History negative for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test
3044800|NCT02262026|Active Comparator|FHN; 125mg AZD0530, then placebo, then 50mg AZD0530|Family History negative for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test
3044801|NCT02262026|Active Comparator|FHN; 50mg AZD0530, then 125mg AZD0530, then placebo|Family History negative for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test
3044802|NCT02262026|Active Comparator|FHN; 50mg AZD0530, then placebo, then 125mg AZD0530|Family History negative for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test
3044803|NCT02262026|Active Comparator|FHN; placebo, then 50mg AZD0530, then 125mg AZD0530|Family History negative for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test
3044804|NCT02262026|Active Comparator|FHN; placebo, then 125mg AZD0530, then 50mg AZD0530|Family History negative for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test
3044805|NCT02262013|Active Comparator|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
3044806|NCT02262013|Experimental|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program.
3044807|NCT02262000|Experimental|A - 7.5 Gy x 10 daily fractions|Radiotherapy: 7.5 Gy x 10 daily fractions delivered with VMAT or regular IMRT at West Virginia University.
3044808|NCT02262000|Experimental|B - 12 Gy x 5 daily fractions|Radiotherapy: Optional schedule of 12 Gy x 5 daily fractions can may also be used ONLY in situations where dose constraints for organs at risk can be EASILY met while optimal PTV coverage is achieved
3044809|NCT02261987|Active Comparator|Autogenic drainage (AD)|Patients will perform the autogenic drainage technique following the Chevallier and Agostini recommendations.
3044810|NCT02261987|Active Comparator|Resistive inspiratory manoeuvre (RIM)|Patients will perform the repetitive inspiratory manoeuvers by breathing through a fixed resistance (Power Breathe device, model KH1) . Each session will comprise to cycles of 5 inspiratory breaths (60% of maximal inspiratory pressure). Patients will be stay in both lateral decubitus position (15 min per side).
3044811|NCT02261987|Active Comparator|Resistive inspiratory manoeuvre+autogenic drainage|First, patients will perform the resistive inspiratory manoeuvre during 10 minutes (5 min per side). Right after, patients will perform the autogenic drainage during 20 minutes.The instructions will be similar to described previously.
3044812|NCT02261974|Active Comparator|Active Viveve Treatment|Intervention in the active arm will be with the Viveve System using 90 Joules/cm2 active treatment with radiofrequency energy in the vaginal introitus
3044813|NCT02261974|Placebo Comparator|Sham Viveve Treatment|Intervention in the sham arm will be with the Viveve System using ≤1 Joule/cm2 sham treatment with radiofrequency energy in the vaginal introitus
3044814|NCT02261961|Experimental|Nutritional Supplement|Subjects in the supplement group will consume orange-flavored Muscle Armor according to the manufacturer's directions: one serving (approximately 30g, i.e. one scoop provided with the product by its manufacturer), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
3044815|NCT02261961|Placebo Comparator|Placebo|Subjects in the placebo group will consume orange-flavored Kool-Aid (Kraft Foods) according to the manufacturer's directions: one serving (approximately 13g, i.e. one scoop provided with the product by the pharmacy), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
3044816|NCT02261948|Active Comparator|Levosimendan|Levosimendan must be diluted before the administration (500 ml of glucose). The intravenous infusion may be administered either by the peripheral or central. The dose and duration of therapy should be decided according to the patient's clinical condition and response to the drug. Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min. A low infusion bolus (6 mcg / kg) is recommended for patients who have a concomitant intravenous treatment with vasodilators or inotropic. The patient's response should be evaluated during the infusion bolus or within 30 to 60 minutes and a dose adjustment based on clinical response.
3044817|NCT02261948|Placebo Comparator|Placebo|Placebo must be diluted before the administration (500 ml of glucose). The intravenous infusion may' be administered either by the peripheral or central. The dose and duration of therapy should be decided according to the patient's clinical condition and response to the drug. Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min. A low infusion bolus (6 mcg / kg) is recommended for patients who have a concomitant intravenous treatment with vasodilators or inotropic. The patient's response should be evaluated during the infusion bolus or within 30 to 60 minutes and a dose adjustment based on clinical response.
3044818|NCT02261935|Active Comparator|Existing Home Care Nursing Practice|Home care nurses provide care based on existing home care practice
3044819|NCT02261935|Experimental|Practice Support Tool Intervention|"The practice support tool intervention will be the routine use of the Carer Support Needs Assessment Tool (CSNAT) in the practice of home care nurses (once every 4 weeks with each family caregiver) to document, monitor and address family caregiver support needs.~Update - December 22, 2016 - In some home care offices only, a study nurse will meet with family caregivers who are in the intervention group to deliver the CSNAT intervention. Information arising from the CSNAT about family caregivers' support needs will be communicated by the study nurse to the home care nurse, and incorporated by the home care nurse into the home care plan for the patient and patient's family."
3044820|NCT02261922|Experimental|ticagrelor|ticagrelor treatment
3044821|NCT02261922|Active Comparator|prasugrel|prasugrel treatment
3044822|NCT02261909||normal creatinine|pts receiving an iv-contrast enhanced CT with normal baseline renal function
3044823|NCT02261909||elevated creatinine|pts receiving an iv-contrast enhanced CT with abnormal baseline renal function
3044824|NCT02261896|Experimental|Placebo|1 intravenous dose followed by 1 oral dose each 12 hours (complete 3 days)
3044825|NCT02261896|Active Comparator|Antibiotic|Ciprofloxacin 400 mg intravenous one dose followed by ciprofloxacin 500 mg oral each 12 hours (complete 3 days)
3044826|NCT02261883|Active Comparator|IV Remodulin|IV Remodulin will be initiated at 1 ng/kg/min. The dose will be increased in up to 2 ng/kg/min increments every 2 hrs until the OI is <10 (in the absence of dose-limiting side effects).
3044827|NCT02261883|Placebo Comparator|Placebo|Placebo will be initiated at 1 ng/kg/min. The dose will be increased in up to 2 ng/kg/min increments every 2 hrs until the OI is <10 (in the absence of dose-limiting side effects).
3044828|NCT02261870|Experimental|ALL_patients|MRI T2 quantification : heart transplant patients will have 4-6 MRI exams for T2 quantification during their first year after transplantation.
3044829|NCT02261857|Experimental|Intervention Arm|Intervention: Subjects will undergo assessment and a personalized CPAP mask device will be manufactured using patient-specific computer-aided design and 3D printing. The subject will use the personalized CPAP mask for 1 month of consistent use and post-intervention data will be collected for compare to historical control (see other arm)
3044830|NCT02261857|No Intervention|Historical Control Arm|Pre-interventional baseline data on subject OSA, CPAP compliance, and quality of life (QoL) measures will be collected to serve as historical controls.
3044831|NCT02261844|Experimental|resveratrol|Resveratrol 1 g daily for 10 days
3044832|NCT02261844|Placebo Comparator|Placebo|Placebo 1 pill daily for 10 days
3044833|NCT02261831|Experimental|obese patients|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
3044834|NCT02261831|Experimental|Diabetic patients|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
3044835|NCT02261831|Experimental|Patients free of obesity and diabetes|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
3044836|NCT02261831|Experimental|patients free type 2 diabetes.|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
3044837|NCT02261818|Other|Meetings with peer mentors|Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.
3044838|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase Ib Dose Level 1|Ganetespib 100 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
3044839|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase Ib Dose Level 2|Ganetespib 150 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
3044840|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase II Expansion|Ganetespib 150 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
3044841|NCT02261792|Active Comparator|A : 24 hours bed rest|24 hours bed rest
3044842|NCT02261792|Experimental|B : 24 hours Trendelenburg position|24 hours Trendelenburg position
3044843|NCT02261779|Experimental|Tretinoin & Tranylcypromine|Tretinoin started with 45mg/m2 on day 7 for one year, administered orally as soft capsules, Tranylcypromine started with 10mg/d up to a maximum dose of 60mg/d for on year, administered orally as tablets
3044844|NCT02261753|Active Comparator|A: Classical ketogenic diet|The KD is a high fat, low carbohydrate, low protein diet designed to mimic the effects of fasting on the body. It will be administered by calculation as per local standardised classical KD protocol with utilisation of long chain fat in a ratio of 2:1 to 4:1 carbohydrate and protein.
3044845|NCT02261753|No Intervention|B: No pretreatment|Following the decision to proceed to surgery, if randomised to this arm a date will be given for surgery as per routine clinical practice. No KD pre-treatment will be undertaken.
3044846|NCT02261740|Experimental|Yoga Therapy Group|Participants will attend twice-weekly group yoga classes and be instructed to practice yoga at home one additional hour a week, using a written manual.
3044847|NCT02261727|Placebo Comparator|Placebo|Placebo theophylline, one tablet twice daily, and Placebo prednisone, one tablet once daily
3044848|NCT02261727|Active Comparator|Low-dose theophylline arm|Theophylline 100 mg twice daily
3044849|NCT02261727|Active Comparator|Theophylline and Prednisone arm|Theophylline 100 mg twice daily plus prednisone 5 mg once daily
3044850|NCT02261714|Experimental|TG01/GM-CSF and Gemcitabine|
3044851|NCT02261701|Experimental|Early mobilization|Intervention is early mobilization, four weeks immobilization postsurgery with collar´n cuff only.
3044852|NCT02261701|Other|Post surgery shoulder lock|Post surgery shoulder lock with abduction cushion 3 weeks and after this period collar´n cuff 3 weeks
3044853|NCT02261688|Other|Subjects in study|All subjects in study are in a cross-over study with 3 interventions sequentially (low salt diet, low salt diet + IV normal saline, liberal salt diet)
3044854|NCT02261675|No Intervention|control group|children undergoing selective lower abdominal surgery received saline before induction
3044855|NCT02261675|Experimental|D1 group|children undergoing selective lower abdominal surgery received a bolus dose of 0.5 µg/kg dexmedetomidine followed by a continuous infusion of 0.5 µg/kg /h before induction
3044856|NCT02261675|Experimental|D2 group|children undergoing selective lower abdominal surgery received a bolus dose of 1.0µg/kg dexmedetomidine followed by a continuous infusion of 1.0 µg/kg /h before induction
3044857|NCT02261662|Experimental|Ribavirin and Betamethasone|"A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.~It will be used along with Topical steroids; Betamethasone"
3044858|NCT02261662|Experimental|Betamethasone alone|Topical steroids alone will be used; Betamethasone.
3044859|NCT02261649||Cerebellar Tumor Surgically Removed|"Quantitative Sensory Testing and Neuroimaging~Medoc Advanced Medical Systems PATHWAY Model ATS (Contact thermal stimulator)~Cold water bath~MRI scanner~Questionnaires"
3044860|NCT02261649||Healthy Volunteer|"Quantitative Sensory Testing and Neuroimaging~Medoc Advanced Medical Systems PATHWAY Model ATS (Contact thermal stimulator)~Cold water bath~MRI scanner~Questionnaires"
3044861|NCT02261636||Pentasa|Treatment according to standard clinical practice.
3044862|NCT02261623||Palliation|Palliative treatment of biliary strictures produced by malignant neoplasms, no intended surgery
3044863|NCT02261623||Curative intent surgery|Palliative treatment of biliary strictures produced by malignant neoplasms, prior to curative intent surgery, with or without neoadjuvant therapy
3044864|NCT02261623||Benign biliary strictures|Treatment of benign biliary strictures
3044865|NCT02261623||Other indication|Other indication
3044866|NCT02261610|Experimental|clinical group|In the first group of patients, the use of antibiotics will be guided by clinical (clinical group).
3044867|NCT02261610|Other|PCT group|In the second group, the use of antibiotics will be guided by the algorithm (PCT group).
3044868|NCT02261597|Experimental|Physiological challenge|Testing reactivity of stress-related systems to repeated exposure to the cold pressor test (hand immersion into ice-cold water)
3044869|NCT02261584|Experimental|Microwave Thermal Coagulation|MW ablation performed either laparoscopically or percutaneously is a safe, effective, and minimally invasive technique for the management of hypersplenism in patients with liver cirrhosis. It may significantly increase platelet count and white blood cell (WBC) count and improve hepatic blood supply with fewer complications. Ablating more than 40% of the splenic parenchyma may yield better long term results. This method may provide a new and promising minimally invasive alternative for treating hypersplenism.
3044870|NCT02261584|Experimental|Partial Splenic Embolization Catheter|Partial splenic embolization (PSE), which was first performed by Spigos et al in 1979, has been considered first-line therapy for hypersplenism in many institutions, and has been proposed as an effective alternative to splenectomy for improving peripheral blood cell counts. However, PSE is associated with many complications, including intermittent fever, abdominal pain, nausea, vomiting, post-embolization syndrome, splenic abscess, splenic rupture, pneumonia, refractory ascites, pleural effusion and gastrointestinal bleeding. To ensure a sustained and long-term increase in platelet and leucocytic counts, the splenic infarction rate needs to be greater than 50% (8). Thus, severe complications can ensue.
3044871|NCT02261571|Experimental|Moxibustion|A series of moxibustion sessions within six weeks from baseline with adjuvant chemotherapy.
3044872|NCT02261571|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no moxibustion treatments throughout the 6 weeks while receiving adjuvant chemotherapy
3044873|NCT02261558|Experimental|Clinical Improvisation Instrumental Music Therapy|Clinical Music Therapy session, 20 minutes. Focus on instrumental improvisation
3044874|NCT02261558|Experimental|Clinical Vocal Improvisation|Clinical Music Therapy session, 20 minutes. Focus on vocal improvisation
3044875|NCT02261558|No Intervention|Control Group|Participants enrolled in control group will complete the same study design, without having a clinical music improvisation
3044876|NCT02261545|Active Comparator|n-3 Fatty Acid Supplemetation|patients with Type II Diabetes who receive 3 cap omega3, 3 times a day, for 10 weeks.
3044877|NCT02261545|Placebo Comparator|Placebo|patients with Type II Diabetes who receive 3 cap of placebo/ for 10 weeks.
3044878|NCT02261532|Experimental|TAS-102|
3044879|NCT02261519|Experimental|NaBen®|NaBen® is a oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.
3044880|NCT02261519|Placebo Comparator|Placebo|The control treatment is placebo.
3044881|NCT02261506|Active Comparator|7 days|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
3044882|NCT02261506|Active Comparator|14 days|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
3044883|NCT02261493|Experimental|OnabotulinumtoxinA Dose A|OnabotulinumtoxinA Dose A injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
3044884|NCT02261493|Experimental|OnabotulinumtoxinA Dose B|OnabotulinumtoxinA Dose B injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
3044885|NCT02261493|Placebo Comparator|Placebo followed by OnabotulinumtoxinA Dose A|Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria, the subject will receive up to 2 treatments with onabotulinumtoxinA Dose A into the protocol-specified areas.
3044886|NCT02261480||Group A: Documented Prior History|"Pediatric and adult participants with sickle cell disease (SCD) with a documented prior history of parvovirus B19 infection (aplastic crisis).~Group A participants will have blood draw and nasopharyngeal wash on day 1 only. Nasopharyngeal wash will be optional for Group A."
3044887|NCT02261480||Group B: No Prior History|"Pediatric and adult participants with SCD who have never had a documented parvovirus B19 infection (aplastic crisis).~Group B participants will have blood draw and nasopharyngeal wash on day 1 only. Nasopharyngeal wash will be optional for Group B."
3044888|NCT02261480||Group C: Suspected and/or Confirmed|"Sickle cell disease patients with suspected and/or confirmed acute parvovirus B19 infection, the latter defined as febrile illness with anemia without adequate compensatory reticulocytosis.~Group C participants will have blood draw and nasopharyngeal wash on day 1, day 7±4 days, day 30±7 days, and day 120±14 days."
3044889|NCT02261467|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
3044890|NCT02261467|Placebo Comparator|Placebo followed by OnabotulinumtoxinA in Period 2|Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria in Period 2, the subject will receive up to 2 open-label treatments with onabotulinumtoxinA into the protocol-specified areas.
3045182|NCT02259803|Experimental|Telmisartan/amlodipine fixed-dose combination|
3044891|NCT02261454|No Intervention|No gum chewing|Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.
3044892|NCT02261454|Active Comparator|Gum chewing|"Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.~Intervention: 1 piece of sugarless gum to be chewed three times daily for 1 hour each."
3044893|NCT02261441||Group 1|Subjects irrespective of the presence of risk factors or cardiovascular disease throughout Spain will be included. This is an observational and non-interventional study
3044894|NCT02261428|Experimental|Catheter Tiemann|We tested the ability of Tiemman catheter to access trachea and aspirate bronchial secretions, measuring number of attempts and time required for the intervention
3044895|NCT02261428|Active Comparator|Suction catheter|We tested the ability of suction catheter to access trachea and aspirate bronchial secretions, measuring number of attempts and time required for the intervention
3044896|NCT02261415|Experimental|Tranexamic acid (TXA)|1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
3044897|NCT02261415|Placebo Comparator|Normal saline (0.9% sodium chloride)|1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
3044898|NCT02261402|Experimental|Medisinstart|Patients in this arm will receive the service; Medisinstart
3044899|NCT02261402|No Intervention|Current Practice|Patients in this arm will receive the current pharmacy practice of advice and guidance with their new medicine. This involves dispensing the medicine and briefly providing information regarding its use and potential side-effects.
3044900|NCT02261389|No Intervention|Arm A, usual follow-up practice|Imaging studies and serum markers (CEA, CA 15.3, others) performed according to local practice
3044901|NCT02261389|Experimental|Arm B, tumor markers assessment|Serum CEA and CA 15.3 performed every 3 months. No imaging studies allowed in asymptomatic patients: imaging studies (18 FDG-PET) performed only in case of critical increase of CEA and /or CA 15.3 serum levels (+100% for CEA and +75% for CA15.3), even if in the normal range.
3044902|NCT02261376|Experimental|Caucasian men, aged 18-55 years|
3044903|NCT02261376|Experimental|Caucasian men, aged 65 years or older|
3044904|NCT02261376|Experimental|Japanese men, aged 18-55 years|
3044905|NCT02261376|Experimental|Caucasian women, aged 18-55 years|
3044906|NCT02261363||Ecig group 1|
3044907|NCT02261363||Ecig group 2|
3044908|NCT02261350|Experimental|Food Fortification|Food Fortification
3044909|NCT02261350|Experimental|Oral Nutritional Supplements|Oral Nutritional Supplements - Fortisip Compact
3044910|NCT02261350|No Intervention|Usual Care|
3044911|NCT02261311||Quality of Life, tissue collection|All participants will complete the GAD-7 and Cancer Locus of Control Scale - Course of Illness Subscale questionnaires and additional tissue will be collected at the time of the diagnostic biopsy.
3044912|NCT02261298|Experimental|ONO-4538 1mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 1mg/kg, 3 times once every 2 weeks in each 6-week cycle
3044913|NCT02261298|Experimental|ONO-4538 3mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 3mg/kg, 3 times once every 2 weeks in each 6-week cycle
3044914|NCT02261298|Experimental|ONO-4538 10mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 10mg/kg, 3 times once every 2 weeks in each 6-week cycle
3044915|NCT02261285|Experimental|ONO-4538 1mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 1mg/kg, single dose
3044916|NCT02261285|Experimental|ONO-4538 3mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 3mg/kg, single dose
3044917|NCT02261285|Experimental|ONO-4538 10mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 10mg/kg, single dose
3044918|NCT02261272|Experimental|CBT for insomnia|Cognitive-behavioral therapy for insomnia
3044919|NCT02261272|Active Comparator|Sleep Hygiene|Psychoeducational intervention based on standard sleep hygiene advices
3044920|NCT02261259|Experimental|Immediate treatment|This arm receives osteopathic manipulative treatment shortly after enrollment
3044921|NCT02261259|Experimental|Delayed treatment|This arm receives osteopathic manipulative treatment approximately 4 weeks after enrollment
3044922|NCT02261259|No Intervention|Healthy control (no neck pain)|In this arm, healthy controls are tested at baseline.
3044923|NCT02261246|Experimental|Immediate treatment|This arm receives spinal manipulation treatment shortly after enrollment
3044924|NCT02261246|Experimental|Delayed treatment|This arm receives spinal manipulation treatment approximately 4 weeks after enrollment
3044925|NCT02261246|No Intervention|Healthy control (no low back pain)|In this arm, healthy controls are tested at baseline.
3044926|NCT02261233|Experimental|Immediate treatment|This arm receives osteopathic manipulative treatment shortly after enrollment
3044927|NCT02261233|Experimental|Delayed treatment|This arm receives osteopathic manipulative treatment approximately 4 weeks after enrollment
3044928|NCT02261220|Experimental|MEDI4736 + Tremelimumab|Subjects with multiple tumor types.
3044929|NCT02261207|Experimental|Axitinib|Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
3044930|NCT02261194|Experimental|Self-Care Tools|The tool binder includes 3 core tools and 4 supplemental tools. The tools that will be provided include a variety of self-care approaches to manage depression including audio-visual, internet, and paper-based tools that might appeal to individuals with different learning styles. The 3 core tools consist of the Antidepressant Skills Workbook, a Mood Monitoring Tool, and a DVD on depression.
3044931|NCT02261194|No Intervention|Delayed Self-Care Tools|This group will receive the self-care tools at the conclusion of the study.
3044986|NCT02260908|Active Comparator|Early initiation of thromboprophylaxis|Early initiation of thromboprophylaxis with Enoxaparin between 36-48 hours post-injury until day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting on post-injury day 6.
3044987|NCT02260908|Placebo Comparator|Late initiation of thromboprophylaxis|Initiation of placebo (normal saline) 36-48 hours post-injury until day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting on post-injury day 6.
3044988|NCT02260895|No Intervention|Control|Standard 2-hour 75-gram oral glucose tolerance test
3044932|NCT02261181|Experimental|XONRID|"Patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients.~Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines. The use of other topical medications for the treatment of dermatitis will be not permitted during the study."
3044933|NCT02261168|Other|Standardized living protocol|Subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws, MRS measurements and indirect calorimetry.
3044934|NCT02261155|Other|Hypnosis|hypnotic induction followed by relaxation and pleasant imagery
3044935|NCT02261142|Experimental|Multifocal TENS|Multifocal TENS given in the garment Mollii® (Elektrodress) 1 hour every second day together with individualized training exercises. The steering unit counts down 60 minutes visible for the patient
3044936|NCT02261142|Sham Comparator|Sham treatment|Use of the garment Mollii® (Elektrodress) but without the electrical stimulation combined with the individualized training exercises. The steering unit counts down 60 minutes visible for the patient
3044937|NCT02261129|Experimental|Telmisartan, film-coated tablet|one tablet of telmisartan
3044938|NCT02261129|Active Comparator|Telmisartan, conventional tablet|Two tablets of telmisartan
3044939|NCT02261116|Experimental|Telmisartan|
3044940|NCT02261116|Active Comparator|Candesartan|
3044941|NCT02261116|Placebo Comparator|Placebo|
3044942|NCT02261103|Active Comparator|Pramipexole IR, fasted|Pramipexole immediate release (IR) tablets
3044943|NCT02261103|Experimental|Pramipexole ER, fasted|Pramipexole extended release (ER) tablets
3044944|NCT02261103|Experimental|Pramipexole ER, fed|Pramipexole extended release tablets with a high-fat meal 30 min before drug administration
3044945|NCT02261090|Experimental|Formulation B|Slow release (SR) tablet
3044946|NCT02261090|Experimental|Formulation C|SR tablet
3044947|NCT02261090|Experimental|Formulation D|SR tablet
3044948|NCT02261090|Experimental|Formulation E|SR tablet
3044949|NCT02261090|Experimental|Formulation F|SR tablet
3044950|NCT02261090|Experimental|Formulation G|SR tablet
3044951|NCT02261090|Experimental|Formulation H|SR tablet
3044952|NCT02261090|Active Comparator|immediate release (IR) formulation|
3044953|NCT02261077|Experimental|Buscopan, single rising doses|
3044954|NCT02261077|Experimental|Buscopan, multiple rising doses|
3044955|NCT02261077|Placebo Comparator|Placebo|
3044956|NCT02261064|Experimental|Telmisartan/Amlodipine low dose, fed|Telmisartan low dose/Amlodipine fixed-dose combination
3044957|NCT02261064|Active Comparator|Telmisartan/Amlodipine low dose, fasted|Telmisartan low dose/Amlodipine fixed-dose combination
3044958|NCT02261064|Experimental|Telmisartan/Amlodipine high dose, fed|Telmisartan high dose/Amlodipine fixed-dose combination
3044959|NCT02261064|Active Comparator|Telmisartan/Amlodipine high dose, fasted|Telmisartan high dose/Amlodipine fixed-dose combination
3044960|NCT02261051||Non-concurrent control group|"A group of advanced cancer patients who received care at our Center before implementation of the LCCM model. They will receive current standard of care.~This current study is to collect data on the control group only. After system redesign, we will open an intervention arm study to collect data after implementation of the new care model (about 18-24 months from start of control phase)."
3044961|NCT02261038|Other|Kanekasu radiographs|No drugs or devices are used in this study. Commonly available radiological techniques such as radiographs and CT are used. All patients undergo a CT of the knee and a special radiograph (Kanekasu technique).
3044962|NCT02261025|Experimental|Aspirin group|Aspirin 75-100mg,per day，oral
3044963|NCT02261025|No Intervention|non-aspirin group|No interventions
3044964|NCT02261012||30 healthy probands|group without the condition of interest
3044965|NCT02261012||30 CRPS patients|group with condition of interest
3044966|NCT02261012||30 CTS patients|group with a different type of pain on the upper limbs
3044967|NCT02260999||healthy|> 18 years old sufficient language knowledge
3044968|NCT02260999||chronic pain patients|
3044969|NCT02260999||patients with injury at the upper etxremity|
3044970|NCT02260986|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection weekly (qw) from Week 1 to Week 51.
3044971|NCT02260986|Experimental|Dupilumab 300 mg q2w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 51. During weeks in which Dupilumab was not administered, participants received placebo.
3044972|NCT02260986|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 51.
3044973|NCT02260973|Active Comparator|Omega-3|re esterified TG omega-3
3044974|NCT02260973|Placebo Comparator|Safflower Oil|vegetable oil
3044975|NCT02260960|Experimental|Omega-3|Reesterified Triglyceride form omega 3
3044976|NCT02260960|Placebo Comparator|Placebo|safflower oil
3044977|NCT02260947|Experimental|1|
3044978|NCT02260947|Experimental|2|
3044979|NCT02260947|Active Comparator|3|
3044980|NCT02260947|Active Comparator|4|
3044981|NCT02260947|Placebo Comparator|5|
3044982|NCT02260934|Active Comparator|Rituximab/Cyclophosphamide (RC)|Prednisone taper to 10 mg/day by week 12 and continue prednisone 10 mg/day to week 96.
3044983|NCT02260934|Experimental|Rituximab/Cyclophosphamide/Belimumab (RCB)|"Belimumab (10 mg/kg IV) at weeks 4, 6, 8, and every 4 weeks to week 48.~Prednisone taper to 10 mg/day by week 12, and continue prednisone 10 mg/day to week 96."
3044984|NCT02260921|Experimental|Treatment|iovera Treatment
3044989|NCT02260895|Experimental|Almond Pre-test snack|1/2 ounce (14 g) almond snack 30 minutes prior to a 2-hour 75-gram oral glucose tolerance test
3044990|NCT02260882|Experimental|Revaccination Group|0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who received an initial vaccination at least 5 years prior
3044991|NCT02260882|Experimental|Primary Vaccination Group|0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who have never received PNEUMOVAX™ 23 vaccination
3044992|NCT02260869|Active Comparator|Cooled radiofrequency ablation|Patient is placed in supine position on a fluoroscopic table with a pillow under the popliteal fossa. An anterio-posterior fluoroscopic view of the tibio-femoral joint is obtained. Skin and subcutaneous tissues are anesthetized and a 17 g introducer needle is advanced percutaneously towards the junction of shaft with epicondyle until bone contact is made. The needle is then laterally displaced away from the bone. This process is performed at the superior medial and superior lateral aspects of the femur, and the inferior medial aspect of the tibia. The fluoroscope is placed in lateral view to guide the needle depth to be at the medial third of the femur or tibia. A cooled radiofrequency probe from a Pain Management Radiofrequency kit is advanced through the introducer. Following sensory and motor stimulation, cooled genicular nerve radiofrequency ablation is carried out at 60 Celsius for 150 seconds.
3044993|NCT02260869|Active Comparator|Monopolar radiofrequency ablation|Patient is placed in supine position on a fluoroscopic table with a pillow under the popliteal fossa. An anterio-posterior fluoroscopic view of the tibio-femoral joint is obtained. Skin and subcutaneous tissues are anesthetized and a 16 g introducer needle is advanced percutaneously towards the junction of shaft with epicondyle until bone contact is made. The needle is then laterally displaced away from the bone. This process is performed at the superior medial and superior lateral aspects of the femur, and the inferior medial aspect of the tibia. The fluoroscope is placed in lateral view to guide the needle depth to be at the medial third of the femur or tibia. A conventional radiofrequency probe from a Pain Management Radiofrequency kit is advanced through the introducer. Following sensory and motor stimulation, genicular nerve radiofrequency ablation will be carried out at 80 Celsius for 90 seconds.
3044994|NCT02260856|Active Comparator|Percutaneous Drill Epiphysiodesis|A 5 mm incision will be made centered over the physis both medially and laterally. A 4.5 mm drill will be passed repeatedly across the physis in a divergent manner. Curettes will then be used to further remove and disrupt the growth plate. Fluoroscopy will be used throughout to ensure proper passage of the drill and curettes. Omnipaque dye will then be inserted to confirm ablation of the physis.
3044995|NCT02260856|Experimental|Percutaneous Screw Epiphysiodesis|In the distal femur, guide wires will be placed in an antegrade fashion, with an 8 mm skin incision proximal to the physis both medially and laterally. The guide wire will be placed with the medial wire crossing the physis at the junction of the middle and medial third of the physis. The lateral guide wire will cross the physis at the junction of the lateral and middle third of the physis. The wires will extend into the epiphysis, but will not enter the joint. The guide wires will be over drilled with a 5 mm drill, and 7.3 mm fully threaded cannulated screws will be placed across the growth plate. For tibias, screw placement will be retrograde, with 8 mm incisions made medially and laterally distal to the physis, with guide wires aiming proximally.
3044996|NCT02260843|No Intervention|Control|Subjects in this group do not received any intervention.
3044997|NCT02260843|Active Comparator|Tai Chi Intervention|Subjects in this groups will receive three tai chi lessons in a weeks while each session last for 1 hour throughout the 12 weeks experimental period
3044998|NCT02260843|Placebo Comparator|Generic Fitness Intervention|Subjects in this groups will receive three fitness lessons in a weeks while each session last for 1 hour throughout the 12 weeks experimental period
3044999|NCT02260830|Experimental|Treatment Period A|1 reference treatment (2 mg Lu AF11167 immediate release hard capsule) + 5 different test prototype formulations of Lu AF11167
3045000|NCT02260830|Experimental|Treatment Period B|Food interaction and multiple dosing of Lu AF11167
3045001|NCT02260817|Experimental|11C-choline for Staging of Recurrent Prostate Cancer|"The key objective of this study is to provide expanded access to this drug product as currently defined under the reference listed drug as an investigational drug in geographical service areas where 11C-choline injection is not available.~Patients entered into the study will undergo a 11C-choline PET CT scan and MRI scan. The 11C-choline PET CT and MRI images will be evaluated for evidence of metastatic prostate cancer. Patient data obtained in this arm of the study will not be further analyzed beyond that need for clinical diagnosis."
3045002|NCT02260817|Experimental|11C-choline Comparison Study of CT and MR Modalities|"11C-choline injection is approved for use in conjunction with both CT and MR imaging modalities. This arm will attempt to determine which modality is most efficacious and under which conditions.~Patients entered into the study will undergo imaging using GE's Trimodality Imaging System that combines PET, CT, and MR techniques to provide PET/CT and PET/MR fused images"
3045003|NCT02260804|Experimental|CT-P10|CT-P10, intervention 375mg/m2, intravenous, 4 cycles in induction period and additional 12 cycles in maintenance period
3045004|NCT02260804|Active Comparator|Rituxan|Rituxan, 375mg/m2 intravenous, 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
3045005|NCT02260791|Experimental|FKB327|Patients will receive FKB327 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
3045006|NCT02260791|Active Comparator|Humira®|Patients will receive Humira® 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
3045007|NCT02260778|Experimental|Phase I Intervention|The learning collaborative as designed will be delivered to this arm during phase I, which will last a period of approximately 9 months. After the 9 months, there will be passive follow-up of this arm to see if outcomes following the first 9 months are sustained.
3045008|NCT02260778|No Intervention|Phase II Intervention|This arm will serve as a control for the Phase I intervention arm during the first 9 months of the study for primary analysis. After the first 9 months, the Phase II intervention arm will receive the learning collaborative during the following 9 months.
3045009|NCT02260765|Active Comparator|HCP dTMS|this arm will receive dTMS treatment
3045010|NCT02260765|No Intervention|HCP TAU|this arm will continue with the same drugs that they are using usually, which mean treatment as usual
3045011|NCT02260752||Medical|Patients who receive medical therapy only for treatment of their uterine fibroids
3045012|NCT02260752||Procedure|Patients who have a hysterectomy, myomectomy, uterine arterial embolization, endometrial ablation, radiofrequency ablation, or magnetic resonance guided focused ultrasound to treat their UF.
3045013|NCT02260739|Other|chronic myelomonocytic leukemia|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
3045014|NCT02260739|Other|essential thrombocytemia|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
3045015|NCT02260739|Other|myelofibrosis|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
3045016|NCT02260726|Experimental|Surgical group|Subjects already scheduled to undergo surgical correction of a symptomatic cam-type hip impingement deformity. Subjects will undergo magnetic resonance imaging (MRI) and ultrasound investigation prior to surgery.
3045017|NCT02260726|Other|Control|Asymptomatic subjects with normal hip morphometry, as determined by MRI. Subjects will undergo magnetic resonance imaging (MRI) and ultrasound imaging.
3045018|NCT02260713|No Intervention|Control|control subjects with acute complete spinal cord injury who would not receive any bone marrow transplantation.
3045019|NCT02260713|Experimental|Transplantation via intrathecal route|Subjects with acute complete spinal cord injury who receive autologous bone marrow cell transplantation via lumber puncture
3045020|NCT02260713|Experimental|Transplantation via intralesional route|Subjects with acute complete spinal cord injury who receive autologous bone marrow cell transplantation via durotomy and injection at the lesional site .
3045021|NCT02260700|Experimental|Sequence 1 (ABC)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 1; followed by Treatment B (single oral dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
3045022|NCT02260700|Experimental|Sequence 2 (ACB)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 1; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 2; followed by Treatment B (single oral dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
3045023|NCT02260700|Experimental|Sequence 3 (BAC)|Participants will receive Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 1; followed by Treatment A (single oral dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
3045024|NCT02260700|Experimental|Sequence 4 (BCA)|Participants will receive Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 1; followed byTreatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 2; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
3045025|NCT02260700|Experimental|Sequence 5 (CAB)|Participants will receive Treatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 1; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 2; followed by Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
3045026|NCT02260700|Experimental|Sequence 6 (CBA)|Participants will receive Treatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 1; followed by Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 2; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
3045027|NCT02260687||Group 1|Decision of treatment is made by attending investigator according to the Japanese Package Insert
3045028|NCT02260674|Experimental|Treatment Group 1|Participants will self-administer JNJ-54861911, two tablets of 5 milligram (mg) each for a total of 10 mg, orally, once daily, from Day 1 until Month 6.
3045029|NCT02260674|Experimental|Treatment Group 2|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6.
3045030|NCT02260674|Placebo Comparator|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6.
3045031|NCT02260661|Experimental|Part A|AZD8835 single agent dose escalation
3045032|NCT02260661|Experimental|Part B|Following the single agent dose escalation (Part A), additional patients with mutations in the PIK3CA gene will be enrolled to a single agent dose expansion phase at the MTD or recommended phase II dose (RP2D) at the selected dose schedule (as appropriate) to explore further the safety, tolerability, pharmacokinetics and biological activity at the selected dose (Part B). Part B will include patients with ER+/HER2 negative breast cancer whose tumours have a mutation of the PIK3CA gene and patients with any solid tumours which have a mutation of the PIK3CA gene.
3045033|NCT02260661|Experimental|Part C|AZD8835 in combination with fulvestrant dose escalation
3045034|NCT02260661|Experimental|Part D|Following the combination dose escalation segment of the study (Part C), additional postmenopausal patients with ER+/HER negative breast cancer and mutations of the PIK3CA gene will be enrolled to a AZD8835 and fulvestrant combination dose expansion phase at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) (as appropriate) to explore further the safety, tolerability, pharmacokinetics and biological activity at the selected dose (Part D).
3045035|NCT02260648|Experimental|Evacetrapib|130 milligrams (mg) evacetrapib and 10 mg atorvastatin administered orally once a day for 12 weeks.
3045036|NCT02260648|Active Comparator|Ezetimibe|10 mg ezetimibe and 10 mg atorvastatin administered orally once a day for 12 weeks as a reference arm.
3045037|NCT02260648|Placebo Comparator|Placebo|Placebo and 10 mg atorvastatin administered orally once a day for 12 weeks.
3045038|NCT02260635|Experimental|Evacetrapib|130 milligrams (mg) evacetrapib given orally once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given orally once a day for 40 weeks) after week 12.
3045039|NCT02260635|Placebo Comparator|Placebo|Placebo given orally once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given orally once a day for 40 weeks) after week 12.
3045040|NCT02260622|Active Comparator|clopidogrel plus aspirin|Clopidogrel 75 mg daily X 90 days plus ASA 81 mg daily
3045041|NCT02260622|Experimental|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg BID X 90 days plus ASA 81 mg daily
3045042|NCT02260609|Other|Open-Label|Grafix®: Cryopreserved Placental Membrane
3045043|NCT02260596||Cohort Population|Pediatric SOT/HSCT recipients
3045044|NCT02260583|Experimental|extracorporeal CO2 removal device|"the patients will be enroll to start a one shot session of extracorporeal CO2 removal. The patient will be connected to the device via a double lumen catheter inserted in the femoral vein An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used. Blood flow is driven by a roller nonocclusive pump (0-450 mL/min) through a polypropylene oxygenator ; priming volume, 100 mL; contact surface area, 1.35 m2; maximum blood flow rate, 7 L/min) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 L/min. Exiting the oxygenator, blood is driven to a hemofilter."
3045045|NCT02260570|Experimental|Functional MRI Arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
3045046|NCT02260557|Experimental|Selexipag|Selexipag is initiated at 200 µg twice daily (b.i.d.) and up-titrated every 3 days in 200 μg b.i.d. increments up to the maximum tolerated dose (MTD) for each individual patient but not above 1600 µg during the 3-week titration phase. This is followed by a 5-week maintenance phase, during which patients continue the treatment at their individual MTD.
3045047|NCT02260557|Experimental|Placebo|Placebo matching selexipag tablets is administered according to the same schedule as selexipag
3045048|NCT02260544|Experimental|Test Product - T|"doxorubicin hydrochloride liposome ( Dr. Reddy's Lab )~Use the test drug (doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Dr.Reddy's Laboratories Ltd., India) ; then use the reference drug ( doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Sun Pharma ) after at least 4-weeks."
3045049|NCT02260544|Active Comparator|Reference Product - R|"doxorubicin hydrochloride liposome ( Sun Pharma )~Use the reference drug (doxorubicin Hydrochloride Liposome Injection 20mg/10mL i.e. 2mg/mL; from Sun Pharma ) ; then use the test drug ( doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Dr.Reddy's Laboratories Ltd., India) after at least 4 weeks."
3045050|NCT02260531|Experimental|ARM 1|"HER2-positive~Cabozantinib- orally administered daily per treatment cycle~Trastuzumab- IV administered once per cycle~MRI- Baseline, Cycle 2 Day 1, and every 2 cycles~Magnetic Resonance Angiography (MRA ), Baseline, Cycle 2 Day 1,"
3045051|NCT02260531|Experimental|ARM 2|"Hormone receptor-positive (ER+ and/or PR+)~Cabozantinib- orally administered daily per treatment cycle~MRI- Baseline, Cycle 2 Day 1, and every 2 cycles~Magnetic Resonance Angiography (MRA ), Baseline, Cycle 2 Day 1,"
3045052|NCT02260531|Experimental|ARM 3|"Triple negative (ER-, PR-, HER2-)~Cabozantinib- orally administered daily per treatment cycle~MRI- Baseline, Cycle 2 Day 1, and every 2 cycles~Magnetic Resonance Angiography (MRA ), Baseline, Cycle 2 Day 1,"
3045053|NCT02260518|Experimental|Lifestyle Intervention|The intervention will focus on women gaining the recommended amount of weight, increasing physical activity to 150 minutes per week, and meeting healthy eating guidelines.
3045054|NCT02260518|Other|Standard Care|Women in the standard care group will attend their regularly scheduled obstetric (OB) visits with their prenatal care providers and will receive monthly mailings and matched number of podcasts.
3045055|NCT02260505|Experimental|Imatinib maintenance|Maintenance of Imatinib at the last dose routinely taken by the patient in the 3 years period prior to randomization (either 300 or 400 mg/day). Increase dose up to 800 mg/day if relapse according to RECIST 1.1 criteria. Any relapse/progressive disease at 800 mg/day will lead to Imatinib permanent discontinuation and study discontinuation. In case of toxicity, Imatinib dose will be interrupted or adjusted in accordance with Imatinib Specific Product Characteristics (SPC).
3045056|NCT02260505|No Intervention|Imatinib Interruption|Treatment corresponding to standard practice : interruption of Imatinib from the day of randomization. Reintroduction of Imatinib at 400 mg/day after first relapse according to RECIST 1.1 criteria; Then increase dose to 800 mg/day after 2d relapse. Any relapse/progressive disease at 800 mg/day will lead to Imatinib permanent discontinuation and study discontinuation. In case of toxicity, Imatinib dose will be interrupted or adjusted in accordance with Imatinib SPC.
3045057|NCT02260492|Experimental|OT329 Solis|OT329 Solis (twice daily inhalation throughout the study)
3045058|NCT02260492|Active Comparator|Advair Diskus|Advair Diskus (twice daily inhalation throughout the study)
3045059|NCT02260492|Placebo Comparator|Placebo|Placebo (twice daily inhalation throughout the study)
3045060|NCT02260479|Active Comparator|Preheated chlorhexidine|Preheated skin disinfection with 36ᵒC Chlorhexidine 5mg/ml in 70% alcohol.
3045061|NCT02260479|No Intervention|Room temperature chorhexidine|Room temperature skin disinfection with 20ᵒC Chlorhexidine 5mg/ml in 70% alcohol.
3045062|NCT02260466|Other|elderly patients with Aortic steNosis valvular replacement|
3045063|NCT02260453|Active Comparator|A - Coronary angiography|All the patients receive preoperative coronary angiography followed, if needed, by percutaneous intervention (PCI) or bypass (CABG)
3045064|NCT02260453|Active Comparator|B - standard cardiac workup|Standard cardiac workup
3045065|NCT02260440|Experimental|Pembrolizumab and Azacitidine Arm|"9 cycles~Pembrolizumab will be given at 200 mg every 21 days.~Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days."
3045066|NCT02260427|Experimental|the i-gel group|After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
3045067|NCT02260427|Active Comparator|the Air-Q sp group|After induction of general anesthesia, the air-Q sp will be inserted according to randomly allocated group.
3045068|NCT02260414|Experimental|Patients with multiple myeloma|Patient with multiple myeloma indication with de novo standard treatment thalidomide or lenalidomide or erythropoietin treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
3045069|NCT02260414|Active Comparator|Patients with agressive lymphoma|Patient hospitalized for aggressive lymphoma treated with chemotherapy treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
3045070|NCT02260414|Active Comparator|Patients with acute medical condition|Patient older than 40 years and hospitalized at least three days for an acute medical pathology type of acute respiratory or cardiac treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
3045071|NCT02260401|Experimental|Individualized report|Each patient in this group will receive an individualized report with their own outcome data (pain and function) during the first year of the LESS trial. They will receive these reports at 18 months.
3045072|NCT02260401|No Intervention|Individualized Reports after 24 months|Patients in this group will receive the individualized report, but will not receive it until after the conclusion of the study at 24 months. They will serve as the control group.
3045073|NCT02260388|Experimental|Nortriptyline|Nortriptyline - 25 mg daily for 1 week at bedtime, then 50 mg daily at bedtime for 1 week, then 75 mg daily at bedtime for the remainder of the study.
3045074|NCT02260388|Experimental|Duloxetine|Duloxetine - 20 mg daily for 1 week, then 40 mg daily for 1 week, then 60 mg daily for the remainder of the study.
3045075|NCT02260388|Experimental|Pregabalin|Pregabalin - 100 mg at bedtime for 1 week, then 100 mg 2 times per day for 1 week, then 100 mg 3 times per day for the remainder of the study.
3045076|NCT02260388|Experimental|Mexiletine|Mexiletine - 200 mg at bedtime for 1 week, then 200 mg 2 times per day for 1 week, then 200 mg 3 times per day for the remainder of the study.
3045077|NCT02260375|Experimental|Mesenchymal Stromal Cells (MSC)|A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party MSC (from healthy donors) will be performed in patients assigned to the MSC procedure in addition to the liver transplantation.
3045078|NCT02260375|No Intervention|No treatment.|
3045079|NCT02260362||HTAP of Congenital Heart Disease|
3045080|NCT02260349|Experimental|patient with Indocyanine green infusion|Infusion of Indocyanine Green 0,25 mg/Kg 24h before prostatic surgery
3045081|NCT02260336|Experimental|Panax Notoginseng Powder 1g|Panax Notoginseng Powder 1g, daily
3045082|NCT02260336|Experimental|Panax Notoginseng Powder 5g|Panax Notoginseng Powder 5g,daily
3045083|NCT02260336|Experimental|Panax Notoginseng Powder 10g|Panax Notoginseng Powder 10g,daily
3045084|NCT02260336|Experimental|Panax Notoginseng Powder 15g|Panax Notoginseng Powder 15g,daily
3045085|NCT02260336|Active Comparator|Celecoxib Capsule 400 mg daily|Celecoxib Capsule 400 mg daily
3045086|NCT02260323|Experimental|patient-tailored anti-arthritis herbs|patient use tailored anti-arthritis herbs
3045087|NCT02260323|Active Comparator|patient-tailored DMARDs|Patients use tailored DMARDs
3045088|NCT02260310|Experimental|Weizhong and Huantiao|Patients with Ankylosing Spondylitis use the Acupuncture Protocol Involving in Weizhong (BL4) and Huantiao (GB30) Points
3045089|NCT02260310|Active Comparator|A-shi point|Patients with Ankylosing Spondylitis use the Acupuncture Protocol Involving in A-shi points, without including Weizhong (BL4) and Huantiao (GB30) Points
3045090|NCT02260284|Experimental|Yaotong points acupuncture|patients under the treatment of Yaotong ponts penetration mode
3045091|NCT02260284|Active Comparator|standardized acupuncture|patients under the treatment of standardized acupuncture
3045092|NCT02260284|Other|the usual care|In the usual care group, participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS)).
3045093|NCT02260271||Database Entry/Biospecimen Collection|Medical information of infants born with HIE entered into RedCap database. In addition, Blood, urine, buccal samples will be collected.
3045094|NCT02260258|Experimental|Rocuronium|"Patients will receive a bolus dose of 1 mg/kg, then a continuous I.V. infusion as per standard intensive care unit practice.~Of note, protocol allows for use of cistatracurium in place of rocuronium for either reasons of drug-shortage or clinical conditions (if institutional preferences for dose adjustment in liver or renal insufficiency arise)."
3045095|NCT02260258|Placebo Comparator|Usual Care|Patients will receive 100 mL of normal saline over 5-10 minutes at the beginning of the study in addition to usual care.
3045096|NCT02260245|Other|Team training|All participating affiliates will undergo team training using the TeamSTEPPS model
3045097|NCT02260232|Experimental|exercise intervention|Components of the program included supervised moderate to high intensity cardiorespiratory exercise, resistance training, and flexibility.
3045098|NCT02260232|No Intervention|control|
3045099|NCT02260219|Active Comparator|S2|Surgically Implant an Ahmed Glaucoma Drainage Device Model S2 in Neovascular Glaucoma Patients and evaluate the IOP evolution, complications and need for medication to control IOP
3045100|NCT02260219|Active Comparator|M4|Surgically Implant an Ahmed Glaucoma Drainage Device Model M4 in Neovascular Glaucoma Patients and evaluate the IOP evolution, complications and need for medication to control IOP
3045101|NCT02260206|Experimental|Colchicine|Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
3045102|NCT02260206|No Intervention|No intervention|No intervention
3045103|NCT02260193|Experimental|AKB-6548, starting dose 1|
3045104|NCT02260193|Experimental|AKB-6548, starting dose 2|
3045105|NCT02260193|Experimental|AKB-6548, starting dose 3|
3045106|NCT02260180|Active Comparator|A-101 40%|A-101 40% Topical Solution
3045107|NCT02260180|Active Comparator|A-101 32.5%|A-101 32.5% Topical Solution
3045108|NCT02260180|Placebo Comparator|A-101 Vehicle Topical Solution|A-101 0% Topical Solution (vehicle)
3045109|NCT02260167|Experimental|Treatment with MIND|
3045110|NCT02260154||Post-cholecystectomy gastrointestinal spasms|Adult subjects suffering from post-cholecystectomy gastrointestinal spasms not requiring surgical treatment prescribed Duspatalin® 200 mg twice a day
3045111|NCT02260141|Experimental|Treatment with d-ribose|Treatment with ribose 5 gm TID
3045179|NCT02259829|Active Comparator|Telmisartan and Amlodipine monocomponents|
3045180|NCT02259816|Active Comparator|Telmisartan|
3045181|NCT02259816|Experimental|Telmisartan and amlodipine|
3045112|NCT02260128|Experimental|Gum chewing|"This intervention group will receive chewing gum four times daily following surgery. Each of which they are encouraged to chew for 30 minutes.~Gum chewing is terminated when one of the primary end points occurs."
3045113|NCT02260128|No Intervention|Control group|This group will receive the normal postoperative treatment. Occurence of primary end points are registrered.
3045114|NCT02260115|Experimental|LABS™|hydrogel sprayed laparoscopically over all pelvic areas of surgical trauma
3045115|NCT02260115|Sham Comparator|Surgical Control|Laproscopic Surgery Only
3045116|NCT02260102|Active Comparator|urinary tract infections|Children requiring antibiotic treatment for urinary tract infections. Intervention: blood sampling for assay of temocillin
3045117|NCT02260102|Active Comparator|cholangitis|"Cirrhotic children requiring antibiotic treatment due to suspicion of cholangitis.~Intervention: blood sampling for assay of temocillin"
3045118|NCT02260102|Active Comparator|hepatic transplant|Children requiring antibiotic prophylaxis following a hepatic transplant. Intervention: blood sampling for assay of temocillin
3045119|NCT02260089|Experimental|Low dose of telmisartan|4 week placebo run-in phase followed by 6 weeks of treatment with low dose of telmisartan
3045120|NCT02260089|Experimental|High dose of telmisartan|After 6 weeks of treatment with low dose of telmisartan, titration to high dose of telmisartan if blood pressure level is higher than 140/90 mm Hg
3045121|NCT02260076|Experimental|PEG 400|multiple rising doses
3045122|NCT02260076|Placebo Comparator|Placebo|
3045123|NCT02260063|Experimental|Epinastine syrup|
3045124|NCT02260063|Active Comparator|Epinastine tablets|
3045125|NCT02260050|Experimental|WAL 801 CL new formulation|
3045126|NCT02260050|Active Comparator|WAL 801 CL conventional formulation|
3045127|NCT02260037|Experimental|Epinastine nasal|single rising doses
3045128|NCT02260037|Placebo Comparator|Placebo|
3045129|NCT02260024|Active Comparator|Pramipexole IR|
3045130|NCT02260024|Experimental|Pramipexole SR C2 in the fasted state|
3045131|NCT02260024|Experimental|Pramipexole SR C2A in the fasted state|
3045132|NCT02260024|Experimental|Pramipexole SR C2B in the fasted state|
3045133|NCT02260024|Experimental|Pramipexole SR C in the fasted state|
3045134|NCT02260024|Experimental|Pramipexole SR C2 in the fed state|
3045135|NCT02260011|Experimental|Ipratropium bromide HFA-134a low|
3045136|NCT02260011|Experimental|Ipratropium bromide HFA-134a high|
3045137|NCT02260011|Active Comparator|Atrovent® CFC low|
3045138|NCT02260011|Active Comparator|Atrovent® CFC high|
3045139|NCT02260011|Placebo Comparator|Placebo|
3045140|NCT02259998|Experimental|Persantin® new formulation|
3045141|NCT02259998|Active Comparator|Persantin® commercial formulation|
3045142|NCT02259985|Experimental|Itasetron tablet fed|
3045143|NCT02259985|Active Comparator|Itasetron tablet fasted|
3045144|NCT02259985|Active Comparator|Itasetron infusion fasted|
3045145|NCT02259972|Experimental|BI 113823 solution|single rising doses, dose group 5 twice (fed and fasted)
3045146|NCT02259972|Experimental|BI 113823 tablet|dose group 5 only
3045147|NCT02259972|Placebo Comparator|Placebo|
3045148|NCT02259959|Experimental|BI 1744 CL in combination with Tiotropium|
3045149|NCT02259959|Placebo Comparator|Placebo|
3045150|NCT02259946|Experimental|BI 1744 CL - single rising dose + Tiotropium|Single rising dose of BI 1744 CL (conjointly with Tiotropium bromide)
3045151|NCT02259946|Placebo Comparator|Placebo|
3045152|NCT02259933|Experimental|KUC 7483 CL|increasing repeated oral doses
3045153|NCT02259933|Placebo Comparator|Placebo|
3045154|NCT02259920|Active Comparator|Treatment A|KUC 4783 CL, immediate release tablets
3045155|NCT02259920|Experimental|Treatment B|KUC 4783 CL delivered as a particulate formulation to the distal small bowel
3045156|NCT02259920|Experimental|Treatment C|KUC 4783 CL delivered as a particulate formulation to the ascending colon
3045157|NCT02259920|Experimental|Treatment D|KUC 4783 CL delivered as a solution formulation to the ascending colon
3045158|NCT02259920|Experimental|Treatment E|KUC 4783 CL delivered as a solution formulation to the descending colon
3045159|NCT02259907|Experimental|KUC 7483 CL|single rising doses
3045160|NCT02259907|Experimental|KUC 7483 CL, fed|dosing after high fat meal
3045161|NCT02259907|Placebo Comparator|Placebo|
3045162|NCT02259894|Experimental|BIRT 2584|single rising doses
3045163|NCT02259894|Placebo Comparator|Placebo|
3045164|NCT02259881|Experimental|Low dose of BIBT 986 CL|
3045165|NCT02259881|Experimental|Medium dose of BIBT 986 CL|
3045166|NCT02259881|Experimental|High dose of BIBT 986 CL|
3045167|NCT02259881|Placebo Comparator|Placebo|
3045168|NCT02259868|Experimental|Group A|randomized sequence of current low dose formulation (3 tablets) and high dose (1 tablet) BILR 355 BS 1B formulation, separated by 14-day washout
3045169|NCT02259868|Experimental|Group B|randomized sequence of BILR 355 BS (JM) + SDS formulation low dose (2 tablets) ,BILR 355 BS (HM) + SDS formulation low dose (2 tablets), BILR 355 BS high dose 1B formulation (4 low dose tablets), separated by 14-day washout
3045170|NCT02259868|Experimental|Group C|randomized sequence of BILR 355 BS (JM) + SDS formulation high dose (4 tablets) , BILR 355 BS (JM) + SDS formulation mid dose (3 tablets), BILR 355 BS (HM) + SDS formulation high dose (4 tablets), separated by 14-day washout
3045171|NCT02259868|Experimental|Group D|randomized sequence of BILR 355 BS Suspension high dose, BILR 355 BS Suspension low dose, current low dose BILR 355 BS 1B formulation (3 tablets) separated by 14-day washout
3045172|NCT02259855|Experimental|Mild hepatic insufficiency|
3045173|NCT02259855|Experimental|Moderate hepatic insufficiency|
3045174|NCT02259855|Experimental|Healthy subjects|
3045175|NCT02259842|Experimental|BI 34021 FU2 solution|single rising doses, dose groups 3 and 5 double-dosing (fed and fasted)
3045176|NCT02259842|Experimental|BI 34021 FU2 tablet|dose group 4 only
3045177|NCT02259842|Placebo Comparator|Placebo|
3045178|NCT02259829|Experimental|Telmisartan/Amlodipine fixed dose combination|
3045183|NCT02259803|Active Comparator|Telmisartan and amlodipine mono-components|
3045184|NCT02259790|Experimental|Telmisartan/amlodipine fixed-dose combination|
3045185|NCT02259790|Active Comparator|Telmisartan tablet and amlodipine tablet|
3045186|NCT02259777|Experimental|Telmisartan/Amlodipine, fed|
3045187|NCT02259777|Active Comparator|Telmisartan/Amlodipine, fasted|
3045188|NCT02259764|Experimental|KUC 7483 CL - single rising dose|"Treatment 1: KUC 7483 CL - low dose~Treatment 2: KUC 7483 CL - medium dose~Treatment 3: KUC 7483 CL - high dose~In treatment 3 the same subjects as in treatment 2 received drug immediately after the ingestion of a standardized high fat meal"
3045189|NCT02259764|Placebo Comparator|Placebo|
3045190|NCT02259751|Experimental|KUC 7483 CL|
3045191|NCT02259751|Placebo Comparator|Placebo|
3045192|NCT02259738|Experimental|Human urinary kallidinogenase and Shuxuening injection|Human urinary kallidinogenase 0.15PNA and Shuxuening injection 20mg, every day for 7 days.
3045193|NCT02259725|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3045194|NCT02259712|Active Comparator|Pelviperineal physiotherapy|"The treatment duration is 2 days per week during 8 weks (two months). The aproximate duration of the season is 45 minutes. The protocol consists in:~Anatomical and physiological explanation of the pelvic girdle (perineal organs bony, ligaments and muscular structures of the entire abdominal and pelvic cavity).~Hygienic and behavioral advises preventing pelvic floor dysfunctions.~Awareness of the pelvic floor muscles.~Strengthening the pelvic floor muscles and the entire abdominal pelvic cavity. Use of electrostimulation and biofeedback in different positions if deemed necessary.~Treatment the abdominal-pelvic cavity pain if it requires."
3045195|NCT02259712|Experimental|Hiporessive and Pelviperineal PT|The treatment duration is 2 days per week, 8 weeks (two months). The session is about 45 minutes. All women are instructed on hygienic and behavioral advises preventing pelvic floor dysfunctions. They are teach basic anatomy and physiology to understand the importance of these advises and anatomical and physiological explanation of the pelvic girdle. The participants are also treated by doing Hipopressive exercises and by specific physicaltherapy for the strengthening the pelvic floor muscles.
3045196|NCT02259712|Experimental|Hipopressive exercises|The treatment is done 2 times per week for 8 weeks (2 months). The session duration is about 45 minutes. All participants are instructed on hygienic and behavioral advises preventing pelvic floor dysfunctions. They are teach basic anatomy and physiology to understand the importance of these advises and anatomical and physiological explanation of the pelvic girdle (perineal organs bony, ligaments and muscular structures of the entire abdominal and pelvic cavity). The participants are also treated by doing Hipopressive exercises in standing, sitting, and supine fours.
3045197|NCT02259699|Experimental|Decision Aid (PCOA)|PCOA will be designed to accomplish 2 objectives: 1) it will educate patients and allow them to assimilate information about the differences in outcomes and survival between IP and IV therapies; and 2) it will help patients make the difficult trade-offs between these two treatment options.
3045198|NCT02259699|No Intervention|UC (Standard care)|Standard pamphlets will be given to patients to educate them about IV and IV/IP therapies.
3045199|NCT02259686|Experimental|Protocol 1. Apelin 1mg doses|5 Healthy volunteers
3045200|NCT02259686|Experimental|Protocol 2. Apelin 5mg doses|5 Healthy volunteers
3045201|NCT02259686|Experimental|Protocol 3. Apelin 10mg single dose|5 Healthy volunteers
3045202|NCT02259673|Experimental|Fun exercise|effect of fun physical exercise on sarcopenia
3045203|NCT02259673|Experimental|fun exercise|effect of fun physical exercise on interest in exercise
3045204|NCT02259660|Active Comparator|Active Group|Subjects in this arm will train their respiratory muscles at home. The training protocol will use progressively higher pressure threshold training valves to provide respiratory muscle strength training at a pressure threshold greater than 70% maximum inspiratory (MIP) and expiratory (MEP) pressures. The total daily training time should be 20 to 30 minutes in duration.
3045205|NCT02259660|Placebo Comparator|Sham Training|The intervention in the sham training arm will be identical in every way to that of the active arm with the exception of the trainer that is provided. Subjects in the sham training arm will have inspiratory and expiratory muscle strength trainers which have had the pressure threshold spring removed and are therefore unable to provide a load to the muscles being trained.
3045206|NCT02259647|Experimental|Sorafenib +intravenous infusion ofVit K1|Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month
3045207|NCT02259647|Active Comparator|Sorafenib+Placebo|Sorafenib 400 mg twice daily + Intravenousinfusion of placebo daily for 6 days, followed by oral placebo twice daily till 3month
3045208|NCT02259634|Experimental|Patient Navigation|Intensive Patient Navigation with Motivational Interviewing and Health Education for 8 months 18 month follow-up
3045209|NCT02259634|No Intervention|Treatment as Usual|Case Management and Medical Care as provided by the Coming Home Program at Mount Sinai St. Luke's Institute of Advanced Medicine, Morningside Clinic
3045210|NCT02259621|Experimental|Nivolumab & Ipilimumab|"Ipilimumab adminstration: Day -42~Nivolumab administration:~Three doses of nivolumab will be administered to enrolled patients on Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days."
3045211|NCT02259621|Experimental|Nivolumab|"Nivolumab administration:~Three doses of nivolumab will be administered to enrolled patients on Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days."
3045212|NCT02259608|Experimental|BCG vaccine SSI|Healthy volunteers are vaccinated with yBCG. Blood will be drawn before and at several timepoints after vaccination. Cytokine production before vaccination will be used as reference to compare later timepoints with.
3045213|NCT02259595|Experimental|HPN-07 500 mg / Placebo|Single dose of 500mg HPN-07 plus placebo in oral capsules.
3045214|NCT02259595|Experimental|HPN-07 1000 mg / Placebo|Single dose of 1,000mg HPN-07 plus placebo in oral capsules
3045215|NCT02259595|Experimental|HPN-07 1500 mg / Placebo|Single dose of 1,500mg HPN-07 plus placebo in oral capsules
3045216|NCT02259595|Experimental|HPN-07 MTD plus NAC 1200mg|Single dose of maximum tolerated dose of HPN-07 plus 1,200 mg NAC in oral capsules. Dose selection will be determined from safety data of previous cohorts by Data Assessment Committee (DAC).
3045217|NCT02259582|Placebo Comparator|Arm 1 Pem, carbo, placebo x 4 cycles|Pemetrexed (500 mg/m2),carboplatin (area under the concentration-time curve of 6 mg/mL x min) once every 21 days X 4 cycles, pemetrexed maintenance and placebo starting at Day 84
3045218|NCT02259582|Active Comparator|Arm 2 Pem, carbo x 4 cycles, one course of dem|Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, one course of demcizumab 5mg/kg, maintenance pemetrexed + placebo starting on Day 84
3045219|NCT02259582|Active Comparator|Arm 3 pem, carbo, dem x 4 cycles, dem retreatment|Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, maintenance pemetrexed starting on Day 84. 2 courses of demcizumab 5 mg/kg
3045220|NCT02259569|Experimental|PCV group|After insertion of I-gel, mechanical ventilation of the lungs was commenced. Mechanical ventilator was set to obtain a tidal volume of 8ml/kg in pressure-controlled mode.
3045221|NCT02259569|Active Comparator|VCV group|After insertion of I-gel, mechanical ventilation of the lungs was commenced. Mechanical ventilator was set to obtain a tidal volume of 8ml/kg in volume-controlled mode.
3045222|NCT02259556|Experimental|anti-CD30 CAR T cells|Patients receive CART30 cell infusions with an escalation dose.
3045223|NCT02259543|No Intervention|G0|Root decontamination performed by scaling and root planing followed by rinsing with saline solution during the treatment of recession defects by subepithelial connective tissue graft (SCTG). Control group.
3045224|NCT02259543|Active Comparator|G90|Root conditioning with citric acid+tetracycline solution (1:1) for 90 seconds after scaling and root planing, followed by rinsing with saline solution for root decontamination during the treatment of recession defects by subepithelial connective tissue graft (SCTG).
3045225|NCT02259543|Active Comparator|G180|Root conditioning with citric acid+tetracycline solution (1:1) for 180 seconds after scaling and root planing, followed by rinsing with saline solution for root decontamination during the treatment of recession defects by subepithelial connective tissue graft (SCTG).
3045226|NCT02259530|Experimental|Integrated Psychotherapeutic Intervention|Integrated treatment of khat use disorder and PTSD
3045227|NCT02259517|Experimental|Guanfacine|Participants will be administered extended-release guanfacine, which is in tablet form, and will be instructed to take the medication once daily for 6 weeks. The daily dose will range between 1 and 4 mg.
3045228|NCT02259517|Experimental|Lisdexamfetamine|Participants will be administered lisdexamfetamine, which is in tablet form, and will be instructed to take the medication daily for 6 weeks. The daily dose will range between 30 and 70mg.
3045229|NCT02259491|Experimental|Manuka Honey Dressing|Patient receive manuka honey dressings on skin graft and free flap donor sites
3045230|NCT02259491|No Intervention|Tegaderm and xeroform gauze|Patient receive standard wound care on skin graft and free flap donor sites which includes a tegaderm over the STSG site and xeroform gauze covered with dry gauze, kerlex and a cast for the STSG recipient site
3045231|NCT02259465|Active Comparator|Oligofructose|Participants will be asked to follow the low FODMAP diet for a week, supplementing the diet with oligofructose, 7grams twice daily
3045232|NCT02259465|Placebo Comparator|Maltodextrin|Participants will be asked to follow the low FODMAP diet for a week, supplementing the diet with maltodextrin, 7grams twice daily
3045233|NCT02259426|Active Comparator|Dihydroartemisínin-piperaquine (Artekin)|Dihydroartemisínin-piperaquine combination alone
3045234|NCT02259426|Experimental|Dihydroartemisinin-piperaquine, Primaquine|Dihydroartemisinin-piperaquine with single-dose 0.25mg/kg Primaquine
3045235|NCT02259413|Experimental|Exercise Rehabilitation|"Participants will receive baseline exercise counseling as described in the Standard Care group. In addition, participants will participate in a 12-week exercise rehabilitation program incorporating the 3 following components:~Self-management education/resistance exercise program class once per week during the first 4 weeks of the rehabilitation intervention. Participants will subsequently receive resistance training material to allow for home exercise for the remaining 8 weeks of the intervention.~Intradialytic aerobic exercise on a cycle ergometer 3 times weekly for 12 weeks at their usual hemodialysis sessions.~Four additional standardized information sessions will be completed in one-to-one format during each participant's hemodialysis treatment."
3045236|NCT02259413|No Intervention|Standard Care|Participants will receive one exercise counseling session as part of their baseline assessment as per the intervention group. Study participants in the control group will not undergo any other exercise counseling or formal exercise intervention, but will not be prohibited from participating in exercise outside of the study protocol.
3045237|NCT02259400|Active Comparator|NSIPPV group|The NSIPPV is a conventional modality of mechanical ventilation delivered by the nasal ventilator device Giulia (Ginevri, Rome, Italy), that in noninvasive modality detects the inspiratory effort by means of a pneumotachograph, equipped with a fixed orifice (2 mm in diameter for LBW infants), positioned proximally to the nasal interface. Short bi-nasal prongs (NIV set, Ginevri, Rome, Italy), with different size according to infants'weight, will be used as interface.
3045238|NCT02259400|Active Comparator|BiPAP group|The BiPAP is a modality of noninvasive respiratory support that provides two alternate different levels of CPAP in which the babies can breath spontaneously. The BiPAP will be delivered by the Infant Flow-driver device (Infant Flow System, Vyasis Corp,Yorba Linda, California (CA),USA) and bi-nasal prongs as interface (Vyasis Corp,Yorba Linda, CA,USA) with different size according to infants' weight.
3045239|NCT02259387||Cases|Children with migraines will be placed into this group.
3045240|NCT02259387||Controls|Children without migraines or headaches will be placed into this group.
3045241|NCT02259374|Active Comparator|TAP BLOCK 0.2% ROPIVACAINE|"Patients randomised into this group will receive bilateral TAP block (single shot) with 0.2% ropivacaine after hysterectomy.~Intervention: TAP block Dose: 20 ml 0.2% ropivacaine"
3045242|NCT02259374|Active Comparator|TAP BLOCK 0.4% ROPIVACAINE|"Patients randomised into this group will receive bilateral TAP block (single shot) with 0.4% ropivacaine after hysterectomy.~Intervention: TAP block Dose: 20 ml 0.4% ropivacaine"
3045243|NCT02259361|Active Comparator|Experimental|Intervention: Sustained-release oral dalfampridine, one 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) for 14 consecutive days.
3045244|NCT02259361|Placebo Comparator|Placebo|Placebo, one 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) for 14 consecutive days.
3045319|NCT02258880|Placebo Comparator|Placebo|Placebo: Matching Placebo daily for 28 days
3045245|NCT02259348|Experimental|Participants|Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level.
3045246|NCT02259335|Experimental|patients under invasive ventilation|those patients failing a T-piece trial beacuse of a PaCO2 rise>20% of baseline and/or a rapid shallow-breathing index >100 will be reconnected to the ventilator Two hours later they will repeat a T-piece trial after connection to the CO2 removal device
3045247|NCT02259322|Active Comparator|Standard-of-Care|Standard-of-care is the continuation of any treatment or recommendations participants receive from his/her bariatric surgeon/team.
3045248|NCT02259322|Experimental|Behavioral Weight Loss Treatment|Guided self-help Behavioral Weight Loss Treatment
3045249|NCT02259322|Experimental|Cognitive Behavioral Therapy|Guided self-help Cognitive Behavioral Therapy
3045250|NCT02259309|Experimental|Misoprostol administration - buccal then vaginal|Vaginal or buccal administration
3045251|NCT02259309|Experimental|Misoprostol administration - vaginal then buccal|Vaginal or buccal administration
3045252|NCT02259296|Experimental|Lower eGFR for AVF creation|
3045253|NCT02259296|Active Comparator|Higher eGFR for AVF creation|
3045254|NCT02259283|Experimental|Achalasia|Patients (age 18-75 years old) with diagnosis of achalasia, without megaesophagus or colonic esophagus, will undergo POEM with the hybrid knife.
3045255|NCT02259270||ASTRA-1|"All patients discharged from the participating hospitals between July 2012 and July 2013.~Determination of long term use of AST before, during and after hospitalisation based on dispensing data, no record review."
3045256|NCT02259270||ASTRA-2|Random selected subset of patients in ASTRA-1 with startup of AST in the hospital and AST at discharge. Record review for appropriateness of indication of startup of AST.
3045257|NCT02259244|Experimental|Mediterranean diet+physical activity|Mediterranean diet based on 1573 kcal/day with the goal of consumption of 30 ml/day of olive oil, 56g/week of nuts, 3-4 servings/week of fish, 3 servings/day of fruits, 2-3 servings/day of vegetables, 3 servings/week legumes and white meat instead of red meat
3045258|NCT02259244|Active Comparator|Hypolipemic reduction diet+physical activity|Hypolipemic reduction diet based on 1287 kcal/day with the goal of consumption of 3 servings/day of fruits, 2-3 servings/day of vegetables, 3 servings/week legumes and white meat instead of red meat, non-fat or low-fat dairy products
3045259|NCT02259231|Experimental|Omaveloxolone 5 mg & ipilimumab|Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
3045260|NCT02259231|Experimental|Omaveloxolone 10 mg & ipilimumab|Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
3045261|NCT02259231|Experimental|Omaveloxolone 5 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
3045262|NCT02259231|Experimental|Omaveloxolone 10 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
3045263|NCT02259231|Experimental|Omaveloxolone 20 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
3045264|NCT02259231|Experimental|Omaveloxolone 100 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
3045265|NCT02259231|Experimental|Omaveloxolone Dose5 TBD & nivolumab|Omaveloxolone (RTA 408) capsules, Dose5 TBD taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
3045266|NCT02259231|Experimental|Omaveloxolone Dose6 TBD & nivolumab|Omaveloxolone (RTA 408) capsules, Dose6 TBD taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
3045267|NCT02259218||Ancillary-Correlative|Prospectively collected blood, urine, and tissue samples are analyzed for potential predictive biomarkers via metabolomic and other molecular profiling.
3045268|NCT02259205|Experimental|Enriched Yogurt|150 g yogurt enriched with approximately 0.5 g bioactive lipids extract from olive oil mill provided daily for 8 weeks
3045269|NCT02259205|Placebo Comparator|Plain Yogurt|150 g not enriched yogurt provided daily for 8 weeks
3045270|NCT02259205|No Intervention|Control|No yogurt consumption
3045271|NCT02259192|Experimental|Open-label|Cochlear Implant
3045272|NCT02259179|Active Comparator|Fed Group|Reference and test product naltrexone SR/bupropion SR combination trilayer tablets tested in the fed state.
3045273|NCT02259179|Active Comparator|Fasted group|Reference and test product naltrexone SR/bupropion SR combination trilayer tablets tested in the fasted state.
3045274|NCT02259166|Experimental|EHFP+|Group receiving the intervention EHFP+, in addition to MNPs distribution for 2 months and malaria diagnosis and treatment for children enrolled, at baseline and after 12 months
3045275|NCT02259166|No Intervention|Control|MNPs distribution for 2 months and malaria diagnosis and treatment for children enrolled, at baseline and after 12 months
3045276|NCT02259153|Active Comparator|Lean red meat diet|Participants were given 350 g per day of lean red meat to incorporate to their usual diet for ten days.
3045277|NCT02259153|Active Comparator|Fat red meat diet|Participants were given 350 g per day of fat red meat to incorporate to their usual diet for ten days.
3045278|NCT02259140|Active Comparator|Proximal Femoral Resection Arthroplasty|A 10-12 cm direct lateral incision will be made distally from the greater trochanter. The abductors of the hip are detached with sharp dissection. A capsulotomy is performed. The femur is exposed in a supra-periosteal manner (2 cm distal to the lesser trochanter) at the level of the ischium; transverse osteotomy will then be performed. The joint capsule will be sutured to itself. The iliopsoas tendon and the abductor tendons are attached to the capsule. The quadriceps will be brought around the proximal femoral stump and sutured to medial tissues.
3045320|NCT02258867|Placebo Comparator|Placebo|
3045321|NCT02258867|Experimental|Gevokizumab|
3045322|NCT02258854|Experimental|Dose 2 gevokizumab|
3070647|NCT02089880|Experimental|C-brace then stance control orthosis|
3045279|NCT02259140|Experimental|Subtrochanteric Valgus Osteotomy|A 10-12 cm direct lateral incision will be made distally from the greater trochanter. The medial half of the abductors may be incised off the greater trochanter for repair. The femoral head is resected at the base of the neck. The ligamentum teres is incised off the head and preserved. A lateral closing wedge osteotomy is performed below the lesser trochanter. 3.5 or 4.5 5 hole locking/non-locking surgeon-contoured plate ( 45⁰) will be used to stabilize the osteotomy. Femoral torsion will be corrected. The psoas tendon will attach the ligamentum teres to the lesser trochanter. The anterior and posterior capsule is sutured together creating interposition tissue. If the ligamentum teres was sutured to the lesser trochanter, the capsule will not close, but will be covered by the psoas tendon.
3045280|NCT02259127|Active Comparator|SOC arm|SOC for ODYSSEY A is defined as a PI or non nucleoside transcriptase inhibitors + 2 or 3 nucleoside transcriptase inhibitor SOC for ODYSSEY B is defined as a PI or non nucleoside transcriptase inhibitor+ 2 nucleoside transcriptase inhibitors
3045281|NCT02259127|Experimental|DTG arm|DTG + 2 nucleoside transcriptase inhibitors
3045282|NCT02259114|Experimental|Continuous Dosing Regimen|Participants receive OTX105/MK-8628 capsules once daily in a fasted state in the morning on Days 1-21 of each 21-day cycle. Starting dose for dose escalation is 80 mg.
3045283|NCT02259114|Experimental|Days 1-7 Dosing Regimen|Participants receive OTX105/MK-8628 capsules once daily in a fasted state in the morning on Days 1-7 of each 21-day cycle. Starting dose for dose escalation is 100 mg.
3045284|NCT02259101|Experimental|CBT-I Treatment Condition|The CBT-I treatment condition will be delivered in a one-hour per week group format (10 participants) occurring over the course of six-weeks. Four total CBT-I groups occurring over the course of two years will be implemented, with at total of 40 participants enrolled for the CBT-I condition.
3045285|NCT02259101|Active Comparator|SH Comparison Condition|The SH comparison condition will also be delivered in a one-hour per week group format (10 participants) occurring over the course of six-weeks. Four total SH groups over the course of two years will be conducted, with a total of 40 participants enrolled for the SH condition.
3045286|NCT02259088|Experimental|ranibizumab 0.5 mg|intravitreal ranibizumab injection
3045287|NCT02259088|Active Comparator|laser photocoagulation|Laser photocoagulation
3045288|NCT02259075|Experimental|Botulinum Toxin|The patients will be injected with 25 IU of Botulinum Toxin Type A towards both the right and left sphenopalatine ganglion, a total of 50 IU.
3045289|NCT02259062|Active Comparator|Music listening|
3045290|NCT02259062|Experimental|Music listening with brief mindfulness|
3045291|NCT02259062|Placebo Comparator|Audio book intervention|
3045292|NCT02259049|Active Comparator|L-Tyrosine|We will administer 1,000 mg of L-tyrosine BID for 24 hours and record BP and HR.
3045293|NCT02259049|Placebo Comparator|Sugar Pill|We will administer a sugar pill BID for 24 hours and record BP and HR.
3045294|NCT02259036|Other|SmartCAT Enhanced Treatment|Cognitive Behavioral Therapy enhanced with an ecological momentary treatment enhancement smartphone app called SmartCAT.
3045295|NCT02259023|Experimental|Liquid: Sugar sweetened beverage consumption|Consumption of sugar-sweetened beverages
3045296|NCT02259023|Experimental|Solid: Grain based desserts and candy consumption|Consumption of grain based desserts and/or candy
3045297|NCT02259010|Experimental|Part A: Alisertib 30 mg + Itraconazole|Alisertib 30 mg, tablets, orally, on Day 1 and Day 10 plus itraconazole, 200 mg, oral solution, once daily on Days 5 to 13.
3045298|NCT02259010|Experimental|Part B: Alisertib 50 mg|Alisertib 50 mg, tablets, orally, twice daily, for 7 days in 21 day cycles until disease progression or unacceptable toxicity.
3045299|NCT02258997||HbSS|Subjects are homozygous for the sickle hemoglobin mutation (HbS).
3045300|NCT02258997||HbS-beta thalassemia|Subjects are heterozygous for the HbS mutation and beta thalassemia
3045301|NCT02258984|Other|Open physician access to Venus 1000 CVP data|
3045302|NCT02258984|Other|No open physician access to Venus 1000 CVP data|
3045303|NCT02258971|Experimental|BEA 2180 BR oral|
3045304|NCT02258971|Active Comparator|BEA 2180 BR infusion|
3045305|NCT02258945||Continuous Subcutaneous Insulin Infusion|This group will consist of patients with Type 1 diabetes using continuous subcutaneous insulin infusion therapy.
3045306|NCT02258945||Multiple Daily Injections|This group will consist of patients with Type 1 diabetes using multiple daily injection therapy.
3045307|NCT02258932||Continuous subcutaneous insulin infusion|This group will consist of patients with Type 1 diabetes commencing continuous subcutaneous insulin infusion therapy.
3045308|NCT02258919|Experimental|Decompressive craniectomy and best medical treatment|Decompressive craniectomy and best medical treatment
3045309|NCT02258919|Active Comparator|Best medical treatment|Best medical treatment
3045310|NCT02258906|Experimental|Ulinastatin group|Patients in the ulinastatin group are given ulinastatin during operation.
3045311|NCT02258906|Placebo Comparator|control group|Patients in the control group receive the same volume of normal saline during operation.
3045312|NCT02258893|Experimental|NO2 Scrubber, then HEPA filter, then Control|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of NO2 Scrubber, then HEPA filter, then Control.
3045313|NCT02258893|Experimental|NO2 Scrubber, then Control, then HEPA filter|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of NO2 Scrubber, then Control, then HEPA filter
3045314|NCT02258893|Experimental|HEPA filter, then NO2 scrubber, then Control|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of HEPA filter, then NO2 scrubber, then Control
3045315|NCT02258893|Experimental|HEPA filter, then Control, then NO2 scrubber|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of HEPA filter, then Control, then NO2 scrubber
3045316|NCT02258893|Experimental|Control, then HEPA filter, then NO2 scrubber|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of Control, then HEPA filter, then NO2 scrubber
3045317|NCT02258893|Experimental|Control, then NO2 scrubber, then HEPA filter|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of Control, then NO2 scrubber, then HEPA filter
3045318|NCT02258880|Experimental|SUN13837|Drug: SUN13837 daily for 28 days.
3045323|NCT02258841|Experimental|Personalized online Safety Decision Aid|Setting priorities for safety; Danger Assessment; Personalized Action Plan
3045324|NCT02258841|Active Comparator|General Online Risk/Safety Information|General Risk and Safety Information; Basic Emergency Safety Plan
3045325|NCT02258828|Experimental|Memantine|Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
3045326|NCT02258828|Placebo Comparator|Placebo|Patient received matched placebo
3045327|NCT02258815|Experimental|ch14.18|"A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.~Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year."
3045328|NCT02258802|Experimental|Psychoeducational intervention|Participants will be receiving a cooking lesson in their community every 2 weeks for 1 year.
3045329|NCT02258802|No Intervention|Usual food practices|These are participants from the communities where the intervention is active but are not attending the cooking lessons.
3045330|NCT02258789|Experimental|intervention - control|15 hours ( 3 times a week in 5 weeks) intense visio spatial scanning training Virtual Reality-method
3045331|NCT02258776|Active Comparator|Pomegranate Extract|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of pomegranate extract on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
3045332|NCT02258776|Active Comparator|Pomegranate Juice|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of pomegranate juice on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
3045333|NCT02258776|Placebo Comparator|Placebo|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of placebo on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
3045334|NCT02258763|Experimental|Amoxicillin-Potassium Clavulanate|Patient will be on amoxicillin-clavulanate 22.5mg/kg/dose bd for 10 days
3045335|NCT02258763|Active Comparator|Placebo|Patient will be on amoxicillin-clavulanate 22.5mg/kg/bd for 3 days followed by another 7 days of placebo medication given at the same dose and frequency
3045336|NCT02258750|Experimental|Polydextrose|Tomato soup enriched with added polydextrose
3045337|NCT02258750|Placebo Comparator|Control|Tomato soup without added polydextrose
3045338|NCT02258737|Experimental|transitional case management|
3045339|NCT02258737|Active Comparator|standard care|
3045340|NCT02258711|Experimental|SIMPLe 2.0 plus Treatment as Usual (TAU)|Psychoeducative and self-monitoring smart-phone application plus treatment as usual which includes pharmacological and psychological treatment.
3045341|NCT02258711|No Intervention|Treatment as usual (TAU)|Treatment as usual which includes pharmacological and psychological treatment.
3045342|NCT02258698||Elective on-pump cardiac surgery|Observation of perioperative Insulin resistance in patients undergoing elective on-pump cardiac surgery (CABG and/or valve repair)
3045343|NCT02258685||Cohort A1|ART-treated HIV-infected individuals with lipodystrophy
3045344|NCT02258685||Cohort A2|ART-treated HIV-infected individuals without lipodystrophy
3045345|NCT02258685||Cohort A3|HIV-1 infected individuals naïve to ART
3045346|NCT02258685||Cohort A4|HIV-1 seronegative individuals who are at a high risk for infection
3045347|NCT02258685||Cohort B1|A subset of subjects from Cohort A: ART-treated HIV-infected individuals with HIV-associated dysbiosis
3045348|NCT02258685||Cohort B2|A subset of subjects from Cohort A: ART-treated HIV-infected individuals without HIV-associated dysbiosis
3045349|NCT02258672|Experimental|Prehabilitation program|Participants will be physically trained before undergoing surgery
3045350|NCT02258672|No Intervention|Control|Patients will follow the normal course of care provided by the hospital
3045351|NCT02258659|Experimental|Group A (radiation therapy alone)|Patients undergo radiation therapy once daily for weeks.
3045352|NCT02258659|Experimental|Group B (combination chemotherapy, low-dose radiation therapy)|Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive low-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity.
3045353|NCT02258659|Experimental|Group C (combination chemotherapy, high-dose radiation)|"Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive standard-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.*~*NOTE: At the discretion of the PI, patients may receive cisplatin IV over 1-3 hours every 3 weeks during radiation therapy instead of paclitaxel and undergo daily radiation therapy."
3045354|NCT02258646|Experimental|Telerehabilitation|Exercise training at home, telemonitoring, and education/self-management
3045355|NCT02258646|Experimental|Unsupervised exercise training at home|Unsupervised exercise training at home
3045356|NCT02258646|No Intervention|Usual care|Usual care
3045357|NCT02258633|Experimental|Intervener Brief Intervention (IBI)|Subjects and parents will complete a Brief Motivational Interview (BMI) incorporating personalized feedback, discussion of choices and changes, and therapist led intervention message relating behavioral change and future goals.
3045358|NCT02258633|No Intervention|Enhanced Usual Care|Subjects and parents will receive standard trauma care, plus complete brief questionnaires and receive general safety information.
3045359|NCT02258620|Experimental|dinitrate isosorbide (intra venous)|dinitrate isosorbide by continuous intra venous injection (1 à 5 mg/h)
3045360|NCT02258620|Experimental|dinitrate isosorbide (intra arterial)|dinitrate isosorbide 5 mg by direct administration intra arterial
3046237|NCT02253082|Placebo Comparator|Standard fresh frozen plasma|replacement to bleeding
3045361|NCT02258620|Experimental|nitroglycerine (transdermic)|nitroglycerine dermal patch15 mg/24h soit 67,2 mg/21 cm2
3045362|NCT02258607|Experimental|MMB dose escalation|Participants will receive MMB plus trametinib. MMB dose will increase to find the MTD.
3045363|NCT02258607|Experimental|Trametinib dose escalation|Participants will receive MMB plus trametinib. Trametinib dose will increase to find the MTD.
3045364|NCT02258607|Experimental|MMB+trametinib|Expansion Phase: participants will receive MMB plus trametinib for the duration of the study.
3045365|NCT02258594|No Intervention|Baseline - Usual Care|"Usual Care on two Medical Intensive Care Units units~Usual Care on four Oncology units"
3045366|NCT02258594|Experimental|Post-Implementation - Intervention Units|"PROSPECT Intervention (Web-Based Patient Centered Toolkit (PCTK) + The Patient-SatisfActive® Model) on two MICU units~PROSPECT Intervention (Web-Based Patient Centered Toolkit (PCTK) + The Patient-SatisfActive® Model) on two Oncology units"
3045367|NCT02258594|No Intervention|Post-Implementation - Usual Care|Usual Care on two Oncology Units
3045368|NCT02258568|Experimental|Smoking abstinence counseling|Telephone motivational counseling sessions supporting smoking abstinence
3045369|NCT02258568|No Intervention|Control|Do not receive telephone motivational counseling sessions supporting smoking abstinence
3045370|NCT02258555|Experimental|GS-9901|Participants will receive one of 6 escalating doses of GS-9901 once daily until unacceptable toxicity, substantial noncompliance, disease progression, pregnancy, initiation of another anti-cancer or experimental therapy, or other protocol-specified reasons for GS-9901 discontinuation.
3045371|NCT02258542|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
3045372|NCT02258542|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
3045373|NCT02258529|Experimental|Idelalisib + rituximab|Idelalisib + rituximab for up to 104 weeks
3045374|NCT02258516|Experimental|behavioral intervention|"Patient education for self-management called CHIME 3-M will be delivered"
3045375|NCT02258516|Active Comparator|control|attention control arm received phone calls to discuss non-heart failure related health topics
3045376|NCT02258503||numerical scale|Evaluation of the pain of elderly patient admitted in the emergency department by numerical scale and then taken care according to the usual practice of the emergency department.
3045377|NCT02258503||algoplus scale|Evaluation of the pain of elderly patient admitted in the emergency department by numerical scale and by Algoplus® scale then taken care according to the usual practice of the emergency department.
3045378|NCT02258477|Active Comparator|Sequence 1 (D-B-A-C)|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
3045379|NCT02258477|Active Comparator|Sequence 2 (A-D-C-B)|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
3045380|NCT02258477|Active Comparator|Sequence 3 (C-A-B-D)|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
3045381|NCT02258477|Active Comparator|Sequence 4 (B-C-D-A)|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
3045382|NCT02258464|Experimental|Radium-223 dichloride + hormonal therapy|Up to 6 cycles of radium-223 dichloride 50kBq/kg body weight (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) (Randomized) + Hormonal therapy background treatment to be prescribed by Principal Investigator
3045383|NCT02258464|Placebo Comparator|Placebo + hormonal therapy|Up to 6 cycles of saline injection (placebo) (Randomized) + Hormonal therapy background treatment to be prescribed by Principal Investigator
3045384|NCT02258451|Experimental|Radium-223 dichloride + exemestane/everolimus|Up to 6 cycles of radium-223 dichloride 50kBq/kg body weight (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) (randomized) + All patients will receive exemestane and everolimus
3045385|NCT02258451|Placebo Comparator|Placebo + exemestane/everolimus|Up to 6 cycles of saline injection (placebo) (randomized) + All patients will receive exemestane and everolimus
3045386|NCT02258438|Experimental|Uninterrupted sitting|Patient will refrain from any structured activity and reduce any daily life activity. The patient will spend 24 hours in the calorimeter room. During the 24 hours the patient will remain sedentary for the 24 hours but will be able to watch TV, computer work or read.
3045387|NCT02258438|Experimental|Sitting + 1 bout of activity|The patient will be asked to perform the 45 minutes of moderate-exercise intervention in the morning once per day for two days in their daily life. This bout of exercise will be supervised by study staff on one of the treadmills On day 3 the patient will report at the Clinical and Translational Research Center (CTRC) of the University Hospital of Colorado and will spend 24hr in the room calorimeter. During the day, you will be asked to sit quietly in a chair, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity walking on a treadmill.
3045388|NCT02258438|Experimental|Sitting + microbursts of activity|The patient will be asked to refrain from any structured exercise running, swimming, lifting weights, yoga, dancing, etc.) for two days but to walk for the 5 minute intervention each hour between 1000 and 1800. On day 3, The patient will report at the CTRC of the University Hospital of Colorado and will spend 24hr in the room calorimeter. During the day, the patient will be asked to rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5 min moderate-intensity walking on a treadmill, which represents a total of 45 min.
3045389|NCT02258425|Experimental|FEM-CARE|Six specialized nurse case managed and health education sessions and coach-facilitated mentoring
3045390|NCT02258425|Active Comparator|Health Promotion|One brief basic health education session and coach-facilitated mentoring
3045391|NCT02258412|Active Comparator|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day.
3045392|NCT02258412|Active Comparator|hand antiseptic with CHG and alcohol|Hand antiseptic is applied by dispensing 1 pump into hands, spreading over the hands up to the wrist, and rubbing until dry. Hand antiseptic will be used twice approximately 15-30 minutes apart on one day.
3045393|NCT02258399|Active Comparator|Breakfast Rest|
3045394|NCT02258399|Active Comparator|Breakfast Exercise|
3045395|NCT02258399|Experimental|Fasted Exercise|
3045396|NCT02258373|Experimental|CGM Only|"Participants will be instructed to check the blood glucose with the standard study BGM for calibration of the CGM and for specific circumstances that are specified in the protocol. This group will make management decisions based on the CGM glucose value without a BGM confirmation measurement as long as the participant is confident that the CGM glucose value is not erroneous.~In addition, participants will be instructed to make a BGM measurement on the blinded study BGM before going to bed, whenever an insulin bolus is given and when treating or attempting to prevent hypoglycemia and a standard BGM measurement has not been made. The participant may be asked to make post-prandial blinded BGM measurements at selected times."
3045397|NCT02258373|Active Comparator|CGM+BGM|Participants will be instructed to perform BGM measurements for sensor calibration according to Dexcom specifications and measure the blood glucose whenever a diabetes management decision is made. A BGM measurement is to be made on the study BGM before going to bed, whenever an insulin bolus is given and when treating or attempting to prevent hypoglycemia. Additional BGM measurements can be made on the study BGM at any time that the participant desires.
3045398|NCT02258360|Active Comparator|24 hours hypothermia|Therapeutic hypothermia for 24 hours after reaching target temperature
3045399|NCT02258360|Experimental|48 hours hypothermia|Therapeutic hypothermia for 48 hours after reaching target temperature
3045400|NCT02258347|Experimental|Single arm|
3045401|NCT02258334|Experimental|Fluzone® Quadrivalent vaccine Group 1|Adults 18 to < 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® Quadrivalent vaccine
3045402|NCT02258334|Experimental|Fluzone® Intradermal vaccine Group 2|Adults 18 to < 65 years of age randomly assigned to receive an intradermal injection of Fluzone® Intradermal vaccine
3045403|NCT02258334|Experimental|Fluzone® Quadrivalent vaccine Group 3|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® Quadrivalent vaccine
3045404|NCT02258334|Experimental|Fluzone® High-Dose vaccine Group 4|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® High-Dose vaccine
3045405|NCT02258321|Experimental|PPI-668 tablet followed by capsule|On day 1, one 200 mg PPI-668 tablet will be administered. On day 6, two 100 mg PI-668 capsules will be administered.
3045406|NCT02258321|Experimental|PPI-668 capsule followed by tablet|On day 1, two 100 mg PI-668 capsules will be administered. On day 6, one 200 mg PPI-668 tablet will be administered.
3045407|NCT02258308|Experimental|CHW intervention|"The CHW intervention is in-home education and support by a community health worker (CHW). At the first home visit, the CHW assesses the participant's knowledge and skills related to asthma self-management, current status of the child's asthma, and resources and support for asthma self-management using a baseline questionnaire. The CHW will inspect the home environment using an Environmental Home Checklist to identify environmental triggers that can cause asthma symptoms and affect asthma control. The CHW makes up to three follow-up visits and two telephone visits during the year the participant is in the study. Participants receive resources to help them control asthma: vacuum cleaner, dust covers for a pillow and mattress and a green cleaning kit with cleaning supplies."
3045408|NCT02258308|No Intervention|control|The control group receives standard asthma care, as provided by a primary health care provider. When the intervention period is over, the control group receives one visit with a CHW and the resources provided to the intervention group participants.
3045409|NCT02258295|Experimental|Intragel|Intragel (IBSA) has an average size of 800-1200 kDaltons. Intragel will give given with a concentration of 16mg/2cc. Each injection (2cc) injection will be given at baseline, then 2 weeks and 4 weeks from the baseline.
3045410|NCT02258295|Active Comparator|Saline|Saline injections will be given similar to the active hyaluronic injections. Each injection (2cc) will be given at baseline, then 2 weeks and 4 weeks from the baseline.
3045411|NCT02258282|Experimental|Etanercept|Patients under the treatment of 50 mg Etanercept
3045412|NCT02258282|Sham Comparator|Control|Patients under the treatment of traditional DMARDs
3045413|NCT02258269|Experimental|SQ|Patients with rheumatoid arthritis exercise square dance
3045414|NCT02258269|Sham Comparator|Control|Patients with rheumatoid arthritis listen to accompany music of square dance at home
3045415|NCT02258256||Sphygmo|All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device
3045416|NCT02258230|Active Comparator|2D mode LSC|2D mode of the 3D Laparoscopic Video System for the Laprascopic Sacral Colpopexy (LSC) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
3045417|NCT02258230|Active Comparator|3D mode LSC|3D mode of the 3D Laparoscopic Video System for the Laprascopic Sacral Colpopexy (LSC) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
3045418|NCT02258230|Active Comparator|2D mode PVR|2D mode of the 3D Laparoscopic Video System for the Paravaginal Repair (PVR) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
3045419|NCT02258230|Active Comparator|3D mode PVR|3D mode of the 3D Laparoscopic Video System for the Paravaginal Repair (PVR) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
3045420|NCT02258217|Experimental|Single arm|Acthar 80 units subcutaneously for five consecutive days.
3045421|NCT02258204|Placebo Comparator|tPA-placebo|"tPA infusion : 0.9 mg/kg (90 mg maximum), 10% of the total dose is administered as an initial IV bolus dose over 1 minute and the remainder of the dose is infused over 60 minutes.~Saline infusion : 0.15 mL/kg IV bolus (maximum 15 mL) followed by an IV infusion of 0.15 mL/kg over 60 minutes (maximum 15 mL)."
3045422|NCT02258204|Experimental|tPA-ketamine|"tPA infusion : 0.9 mg/kg (90 mg maximum), 10% of the total dose is administered as an initial IV bolus dose over 1 minute and the remainder of the dose is infused over 60 minutes.~Ketamine infusion : 0.15 mg/kg IV bolus (maximum 15 mg) followed by an IV infusion of 0.15 mg/kg over 60 minutes (maximum 15 mg)."
3045423|NCT02258191|Active Comparator|NIV treatment with telemonitoring|telemonitoring is used to manage NIV treatment
3045424|NCT02258191|Sham Comparator|NIV treatment with sham telemonitoring|sham telemonitoring (data not used for NIV management)
3045425|NCT02258178||1, Flucelvax|Flucelvax exposure in pregnancy
3045426|NCT02258165||Advanced ovarian cancer|gated PET/CT imaging
3045427|NCT02258152|Placebo Comparator|Placebo|
3045428|NCT02258152|Experimental|SYN120|
3070648|NCT02089880|Experimental|Stance control orthosis then C-brace|
3045429|NCT02258126|Active Comparator|Control group|healthy lifestyle education including healthy lifestyle education, supportive therapy and behavioral advice for both children and parents to improve nutrition and physical activity
3045430|NCT02258126|Experimental|Exercise group|multidisciplinary intervention program including healthy lifestyle education, supportive therapy and behavioral advice for for both children and parents to improve nutrition and physical activity and supervised exercise.
3045431|NCT02258113|Other|LEA numbers, Pelli-Robson, Octopus|Comparable generally used method for measuring visual acuity, contrast sensitivity and visual field.
3045432|NCT02258100||Paper|Patients receiving care documented via paper anesthesia record.
3045433|NCT02258100||AIMS|Patients receiving care documented via electronic anesthesia record.
3045434|NCT02258087|Active Comparator|LDRPBT|Patients with low and selected intermediate risk prostate cancer are treated with Prostate LDR brachytherapy as monotherapy. 145 Gy is prescribed to the prostate. I-125 radioactive sources are used. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time dose optimization is applied.
3045435|NCT02258087|Experimental|HDRPBT|Patients with low and selected intermediate risk prostate cancer are treated with prostate HDR brachytherapy as monotherapy. The prescribed dose is 1x19 Gy to the whole prostate. Ir-192 radioactive source is used. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time dose optimization is applied.
3045436|NCT02258074|Experimental|Lanthanum carbonate + nicotinamide|One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
3045437|NCT02258074|Placebo Comparator|Lanthanum carbonate + nicotinamide placebo|Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months. One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months.
3045438|NCT02258074|Active Comparator|Lanthanum carbonate placebo and nicotinamide|One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
3045439|NCT02258074|Placebo Comparator|Lanthanum carbonate placebo and nicotinamide placebo|One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
3045440|NCT02258061|Experimental|DDD-80 pacing|To investigate the impact of basal pacing rates of 80-bpm (DDD-80) in CRT patients on: (i) autonomic nerve function; assessed by micro-neurography, and N-terminal pro-brain natriuretic peptide (NT-proBNP) and (ii) peak oxygen consumption (pVO2) and (iii) self-perceived quality of life (QoL).
3045441|NCT02258061|Sham Comparator|DDD-60 pacing|To investigate the impact of basal pacing rates of 60-bpm (DDD-60) in CRT patients on: (i) autonomic nerve function; assessed by micro-neurography, and N-terminal pro-brain natriuretic peptide (NT-proBNP) and (ii) peak oxygen consumption (pVO2) self-perceived quality of life (QoL).
3045442|NCT02258048||Patients with cirrhosis|
3045443|NCT02258035||DBP/Gc1f-1f genotype|Human volunteers homozygous for the 1f-1f (fast) genotype of DBP.
3045444|NCT02258035||DBP/Gc1s-1s genotype|Human volunteers homozygous for the 1s-1s (slow) genotype of DBP.
3045445|NCT02258035||DBP/Gc 2-2 genotype|Human volunteers homozygous for the 2-2 genotype of DBP.
3045446|NCT02258022|Experimental|Exhaled Breath|Exhaled breath samples will be collected 6 times per day and blood samples will be collected once per day for 7 days. Subjects will be followed for an additional 3 days. We will use the Isomark Canary™ to determine the breath delta value of breath samples collected during this study. Analysis results of these samples will be combined with data that is abstracted from the subjects' medical records.
3045447|NCT02258009|Experimental|Group 1|Monthly intravitreal injections of 0.5 mg ranibizumab
3045448|NCT02258009|Experimental|Group 2|Three monthly intravitreal injections of 2 mg aflibercept followed by three monthly intravitreal injections of 0.5 mg ranibizumab
3045449|NCT02257996|Experimental|Interventional Group|Online Systematic Brief Psychodynamic Psychotherapy
3045450|NCT02257996|No Intervention|Control Group|Waiting list
3045451|NCT02257983|Active Comparator|EPI-743|EPI-743 400 mg P.O. TID
3045452|NCT02257983|Placebo Comparator|Placebo|Sesame Oil, NF in sealed gelatin capsules to match the test product
3045453|NCT02257970|Experimental|oral anti-inflammatory drug|anti-inflammatory oral drug, 1 capsule, three times/day, for 4 months
3045454|NCT02257970|Placebo Comparator|Placebo|Placebo, 1 capsule, three times/day, for 4 months
3045455|NCT02257957|Experimental|Platelet -Rich Plasma (PRP)|15 patients with diagnosis of severe dry eye will receive PRP injection at day 0, 30,60 and 90
3045456|NCT02257957|Active Comparator|Standard Care|15 patients with diagnosis of severe dry eye will receive standard of care treatment and will be revised at day 0, 30,60,90
3045457|NCT02257944|Experimental|Motivational Interviewing|Receive brief hospital-based intervention
3045458|NCT02257944|Other|Treatment as Usual|Treatment as Usual
3045459|NCT02257931||HSCT recipient|Allogeneic or autologous HSCT recipients, of all ages, for any indications. From this group we take those with a gram-negative bacteremia within 6 months after HSCT.
3045460|NCT02257918|Experimental|Group 1|N = 70 subjects receive single oral dose , 2000 mg of AZD0914
3045461|NCT02257918|Experimental|Group 2|N =70 subjects receive single oral dose , 3000 mg of AZD0914
3045462|NCT02257918|Active Comparator|Group 3|N = 40 subjects receive single intramuscular dose, 500 mg of ceftriaxone
3045463|NCT02257905||AL Amyloidosis patients who received allo HSCT|
3045464|NCT02257853|No Intervention|Control Group|No Intervention Group
3045465|NCT02257853|Experimental|Intervention|Receives stress reduction intervention introduction with daily practice
3045466|NCT02257827|Experimental|IMRT- Hypofractionated schedule 70 Gy/25 fx|The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.By the linear-quadratic formula, considering an α/β ratio of 1.5 Gy for prostate cancer, 70 Gy/25 fractions is equivalent to 86 Gy in 43 fractions of 2 Gy. All patients were simulated on CT simulator.
3045512|NCT02257567|Experimental|Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
3045513|NCT02257567|Experimental|Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
3045467|NCT02257827|Active Comparator|3DCRT-Hypofractionated schedule 70 Gy/25 fx|The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy. By the linear-quadratic formula, considering an α/β ratio of 1.5 Gy for prostate cancer, 70 Gy/25 fractions is equivalent to 86 Gy in 43 fractions of 2 Gy. All patients were simulated on CT simulator.
3045468|NCT02257814|No Intervention|Control Group|Control group
3045469|NCT02257814|Experimental|Incredible Years|incredible years intervention
3045470|NCT02257814|Experimental|Preschool PATHS|Preschool PATHS (Promoting Alternative Thinking Strategies)
3045471|NCT02257814|Experimental|Tools of the Mind|Tools of the Mind
3045472|NCT02257801|Experimental|Nutritional beverage fortified with 6mg lutein/day|
3045473|NCT02257801|Experimental|Nutritional beverage fortified with 12mg lutein/day|
3045474|NCT02257801|Placebo Comparator|Nutritional beverage fortified with 0mg lutein/day|
3045475|NCT02257788|Active Comparator|Treatment Arm 1|PRO 140: one SC dose, 350 mg (day 1), followed by two single SC doses, 350 mg each (days 8 and 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
3045476|NCT02257788|Active Comparator|Treatment Arm 2|PRO 140: one SC loading dose, 700 mg (day 1), followed by two single SC doses, 350 mg each (days 8 and 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
3045477|NCT02257788|Active Comparator|Treatment Arm 3|PRO 140: one SC loading dose, 700 mg (day 1), followed by one single SC dose 350 mg (day 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
3045478|NCT02257788|Active Comparator|Treatment Arm 4|PRO 140: one SC dose, 700 mg (day 1) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
3045479|NCT02257762|Experimental|Lipid-based nutrient supplement (LNS)|LNS added to borbor, eaten over 6 months, age 6-12 months to age 11-17 months
3045480|NCT02257762|Active Comparator|Corn-soy blend ++ (CSB++)|CSB++ porridge, eaten over 6 months, age 6-12 months to age 11-17 months
3045481|NCT02257762|Active Comparator|Sprinkles|Sprinkles added to borbor, eaten over 6 months, age 6-12 months to age 11-17 months
3045482|NCT02257762|No Intervention|Control|Plain borbor and thereafter family foods, eaten over 6 months, age 6-12 months to age 11-17 months
3045483|NCT02257749|Experimental|Active Rehabilitation|Active Rehabilitation Intervention and Comprehensive Education Intervention (Standard Care)
3045484|NCT02257749|Active Comparator|Comprehensive Education Intervention|Comprehensive Education Intervention (Standard Care) only
3045485|NCT02257736|Experimental|Group 1: AAP and apalutamide|Participants will receive 240 milligram (mg) tablet of apalutamide and 1000 mg (four 250 mg tablets) of abiraterone acetate (AA) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily, until disease progression, unacceptable toxicity, or end of treatment, whichever occurs first.
3045486|NCT02257736|Placebo Comparator|Group 2: AAP and Placebo|Participants will receive matching Placebo of apalutamide and 1000 mg (four 250 mg tablets) of abiraterone acetate (AA)once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily until disease progression, unacceptable toxicity, or end of treatment, whichever occurs first.
3045487|NCT02257710||Orsiro|All subjects requiring coronary revascularization with Drug Eluting Stents (DES)
3045488|NCT02257697|Experimental|Mizoribine (MZR)|Oral administration, daily dose of 150mg (50mg/tablet, t.i.d) All study subjects will receive standard steroid therapies during the study.
3045489|NCT02257697|Active Comparator|Cyclophosphamide (CTX)|"Intravenous injection with between 0.5 to 1.0 g/m2 body surface area each time (the maximum dose is 1.0 g/day each time).~All study subjects will receive standard steroid therapies during the study."
3045490|NCT02257684|Experimental|Pegcrisantaspase|
3045491|NCT02257671|Active Comparator|Oral contraceptive|oral dose of ethinylestradiol 0.03 mg + levonorgestrel 0.15 mg per day during 11 weeks
3045492|NCT02257671|Placebo Comparator|Placebo|Oral placebo capsule daily during 11 weeks
3045493|NCT02257658|Experimental|Doxycycline|Subjects in the doxycycyline arm will receive Doxycycline, oral, 100 mg, once daily for 36 weeks.
3045494|NCT02257658|Active Comparator|Incentive|Subjects in the incentive arm will receive escalating payments for remaining STI free at Weeks 12, 24 and 36.
3045495|NCT02257645||Euforvac-Hib vaccine|
3045496|NCT02257632|Experimental|Group 1|Monthly intravitreal injections of 0.5 mg ranibizumab
3045497|NCT02257632|Experimental|Group 2|Three monthly intravitreal injections of 2 mg aflibercept followed by three monthly intravitreal injections of 0.5 mg ranibizumab
3045498|NCT02257619|Experimental|Itacitinib plus docetaxel|
3045499|NCT02257606|No Intervention|Control group (persons with MS)|no training
3045500|NCT02257606|Experimental|Experimental group (persons with MS)|Robot-assisted training
3045501|NCT02257593|Experimental|10 % Protein|10% Dietary protein energy
3045502|NCT02257593|Experimental|15% Protein|15% Dietary protein energy
3045503|NCT02257593|Experimental|25% Protein|25% Dietary protein energy
3045504|NCT02257580|Experimental|E-Aminocaproic acid (EACA)|An EACA loading dose of 100 mg/kg with a max of 4-5 grams will be given up to 1 hour prior to incision. During the case, an EACA infusion of 33 mg/kg/hr (max of 1 gram/hr) will be maintained. The use of EACA will be terminated at the end of the case.
3045505|NCT02257580|Placebo Comparator|Placebo|Equivalent volume of normal saline prepared by the pharmacy.
3045506|NCT02257567|Experimental|Arm A (Phase II Randomization): Polatuzumab+BR in FL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
3045507|NCT02257567|Active Comparator|Arm B (Phase II Randomization): BR in FL|Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with FL.
3045508|NCT02257567|Experimental|Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
3045509|NCT02257567|Active Comparator|Arm D (Phase II Randomization): BR in DLBCL|Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with DLBCL.
3045510|NCT02257567|Experimental|Arm E (Phase II Expansion): Polatuzumab+BG in FL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
3045511|NCT02257567|Experimental|Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
3045514|NCT02257567|Experimental|Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
3045515|NCT02257567|Experimental|Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
3045516|NCT02257567|Experimental|Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL|In this New Formulation (NF) cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
3045517|NCT02257541|Experimental|BGJ398 With Imatinib Mesylate|BGJ398 With Imatinib Mesylate In the phase Ib portion of the study, patients will receive imatinib at 400 mg once daily and BGJ398 at the standard 3+3 escalation doses for 21 days on, 7 days off (treatment schedule A).Using treatment schedule A, if dose level 1 to -2 is identified as the MTD and concern exists regarding therapeutic activity of BGJ398 at this dose level, expansions with higher dose levels (1 to 3) may be considered at the MSKCC PI's discretion, with modification of the treatment schedule. In this setting BGJ398 will be administered daily for one week followed by 3 weeks off and imatinib will be taken daily throughout the 4 week cycle period (treatment schedule B). In the phase II portion of the study, patients will receive imatinib at 400 mg once daily (standard of care first line imatinib dose) and BGJ398 at the RP2D and treatment schedule identified in the phase Ib portion of the study. One cycle is 28 days.
3045518|NCT02257528|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over approximately 60 minutes every 2 weeks for a maximum of 46 doses over 92 weeks in the absence of disease progression or unacceptable toxicity.
3045519|NCT02257502|Experimental|aflibercept|intravitreal injection of aflibercept (EYLEA)
3045520|NCT02257489|Experimental|50 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (50 mg) and 2 subjects to receive placebo, single injection, intramuscularly
3045521|NCT02257489|Experimental|100 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (100 mg) and 2 subjects to receive placebo, single injection, intramuscularly
3045522|NCT02257489|Experimental|200 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (200 mg) and 2 subjects to receive placebo, single injection, intramuscularly
3045523|NCT02257489|Experimental|100 mg multiple dose|8 subjects in total; 6 subjects to received ACE-083 (100 mg) and 2 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
3045524|NCT02257489|Experimental|200 mg multiple dose|8 subjects in total; 6 subjects to received ACE-083 (200 mg) and 2 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
3045525|NCT02257489|Experimental|100 mg (multiple dose)|9 subjects in total; 6 subjects to received ACE-083 (100 mg) and 3 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
3045526|NCT02257489|Experimental|150 mg multiple dose|9 subjects in total; 6 subjects to received ACE-083 (150 mg) and 3 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
3045527|NCT02257476|Experimental|Carfilzomib|Patients will receive single agent carfilzomib on a weekly dosing schedule (days 1, 8, 15) in a 21 day cycle. The initial dose will be 20 mg/m² for cycle 1, day 1. Dose escalation will proceed in a standard 3+3 fashion with the requirement that dose escalation to the next level can only proceed if 0 of 3 or ≤ 1 of 6 patients experience a dose limiting toxicity (DLT). Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses.
3045528|NCT02257463|Active Comparator|Study group (group A)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations peripheral muscles exercise training: (upper limb and lower limb strength and endurance training) inspiratory muscle training: (at intensity that progressively increased from 30% to 60% of patients' maximal inspiratory pressure)"
3045529|NCT02257463|Active Comparator|control positive group (group B)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations peripheral muscles exercise training: (upper limb and lower limb strength and endurance training)"
3045530|NCT02257463|Active Comparator|control negative group (group C)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations"
3045531|NCT02257437|Experimental|LNS + borbor|Lipid-based nutrient supplement (LNS) added to borbor
3045532|NCT02257437|Active Comparator|Corn-soy blend ++ (CSB++)|CSB++ porridge
3045533|NCT02257437|Active Comparator|Sprinkles|Sprinkles added to borbor
3045534|NCT02257437|Active Comparator|LNS snack|LNS eaten as snack
3045535|NCT02257424|Other|Phase 1/2|
3045536|NCT02257411|Active Comparator|Ear-sized based and weight based formula|the sizes of the PLMA determined with the ear-based compared with the sizes according to the manufacturer's weight-based formula
3045537|NCT02257398|Experimental|Sequence ABDC|Subjects will be administered treatments in Sequence ABDC where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
3045538|NCT02257398|Experimental|Sequence BCAD|Subjects will be administered treatments in Sequence BCAD where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
3045539|NCT02257398|Experimental|Sequence CDBA|Subjects will be administered treatments in Sequence CDBA where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
3046520|NCT02251158|Experimental|TPV/r with food|Tipranavir/Ritonavir paediatric/oral solution
3045540|NCT02257398|Experimental|Sequence DACB|Subjects will be administered treatments in Sequence DACB where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
3045541|NCT02257385|Experimental|UMEC/VI arm|Participants will be instructed to self-administer one dose each morning of UMEC/VI Inhalation Powder 62.5/25 mcg once daily via ELLIPTA DPI, placebo once daily via HANDIHALER inhaler and placebo once daily via BREEZHALER inhaler
3045542|NCT02257385|Placebo Comparator|Tiotropium + Indacaterol arm|Participants will be instructed to self-administer one dose each morning of Tiotropium bromide 18 mcg once daily via HANDIHALER inhaler, Indacaterol 150 mcg once daily via BREEZHALER inhaler and placebo once daily via ELLIPTA DPI
3045543|NCT02257372|Experimental|UMEC (62.5 mcg)|Participants will self-administer blinded UMEC (62.5 mcg) each morning (once daily) as one inhalation from the double-blind DPI over a treatment period of 12 weeks. Participants will receive open labeled ICS/LABA medication through out duration of the treatment period as background treatment.
3045544|NCT02257372|Experimental|Placebo|Participants will self-administer blinded placebo each morning (once daily) as one inhalation from the double-blind DPI over a treatment period of 12 weeks. Participants will receive open labeled ICS/LABA medication through out duration of the treatment period as background treatment
3045545|NCT02257359|Experimental|Epelsiban Cohort 1|Subjects will receive 300 mg of epelsiban administered orally twice (every 12 hr) on Day 1 (total daily dose of 600 mg)
3045546|NCT02257359|Experimental|Epelsiban Cohort 2|Epelsiban dose for Cohort 2 will be determined based on data from Cohort 1, but will not exceed a total daily dose of 900 mg, administered orally in divided doses (450 mg every 12 hrs or 300 mg every 8 hrs).
3045547|NCT02257359|Experimental|Additional Cohorts TBD (to be decided)|Subjects will be enrolled if determined necessary, based on data collected in Epelsiban Cohort 1 and Cohort 2
3045548|NCT02257346|Active Comparator|Lidocaine|Intravenous lidocaine 1.5 mg/Kg bolus dose and 2mg/Kg/hr infusion
3045549|NCT02257346|Placebo Comparator|Normal Saline|Intravenous normal saline infusion
3045550|NCT02257320|Other|Feasibility|Assessing EMG activity with Bruxoff(TM) device
3045551|NCT02257294|Placebo Comparator|Control Arm|two placebo vials
3045552|NCT02257294|Active Comparator|Arm A|Alteplase 10mg and placebo vial
3045553|NCT02257294|Active Comparator|Arm B|Alteplase 10mg and alteplase 10mg
3045554|NCT02257281|Experimental|Active Therapeutic Ultrasound|The three inflammatory forearm spots on the same side induce by the experimentally skin model(1%, 0.5%, 0% SLS) treat with active therapeutic ultrasound .
3045555|NCT02257281|Placebo Comparator|Non-active Therapeutic Ultrasound|The contralateral three inflammatory forearm spots induce by the experimentally skin model(1%, 0.5%, 0% SLS) treat with non-active therapeutic ultrasound .
3045556|NCT02257268|Experimental|Change behavior group|Change behavior group = Group of change behavior including physical activity and healthy habits promotion.
3045557|NCT02257268|No Intervention|Control group|Control group = Group that will not receive the VAMOS program as intervention.
3045558|NCT02257255|Active Comparator|Pfannenstiel cesarean section|Women in 36 to 40 weeks of pregnancy undergoing first cesarean section by Pfannenstiel technique. Pain assessment on postoperative hours 6, 12 and 24.
3045559|NCT02257255|Experimental|Misgav-Ladach cesarean section|Women in 36 to 40 weeks of pregnancy undergoing first cesarean section by minimally invasive technique. Pain assessment on postoperative hours 6, 12 and 24.
3045560|NCT02257242|Experimental|Dose-escalation cohort|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
3045561|NCT02257229||Surgical|Corrective Surgery only
3045562|NCT02257229||Non-Surgical|Correction with casting, braces, Physical therapy, other non-surgical methods
3045563|NCT02257229||Non-surgical + surgical|Correction with casting, braces, Physical therapy, other non-surgical methods subsequently followed by Corrective Surgery
3045564|NCT02257216|Active Comparator|Sequence 1: Treatment/Treatment|Treatment/Treatment- consists of Vayarin® for 8 weeks followed by 8 weeks of additional treatment with Vayarin®
3045565|NCT02257216|Active Comparator|Sequence 2: Placebo/Treatment|Placebo/Treatment- consists of Placebo for 8 weeks followed by 8 weeks of treatment with Vayarin®
3045566|NCT02257216|Placebo Comparator|Sequence 3: Placebo/Placebo|Placebo/Placebo- consists of Placebo for 8 weeks followed by 8 weeks of additional treatment with Placebo
3045567|NCT02257203|Experimental|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
3045568|NCT02257203|Active Comparator|Reading Education|Parents will receive an educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
3045569|NCT02257190|Experimental|Control (Con)|No exercise intervention.
3045570|NCT02257190|Experimental|Interval Walking - 3 min intervals (IW3)|One hour of classical interval walking exercise (repeated cycles of 3 min of fast and 3 min of slow walking.
3045571|NCT02257190|Experimental|Interval Walking - 1 min intervals (IW1)|One hour of fast alternating interval walking exercise (repeated cycles of 3 min of fast and 3 min of slow walking
3045572|NCT02257177|Placebo Comparator|HV placebo arm|placebo
3045573|NCT02257177|Active Comparator|HV treatment arm|inhaled TD139 single dose escalation
3045574|NCT02257177|Placebo Comparator|IPF patient placebo arm|placebo
3045575|NCT02257177|Active Comparator|IPF patient treatment arm|Inhaled TD139 od 2 weeks
3045576|NCT02257164|Active Comparator|femoral nerve block|20 ml injection of 2 mg/ml ropivacaine in femoral nerve
3045577|NCT02257164|Experimental|obturator nerve block and intraarticular injection|10 ml injection of 2 mg/ml ropivacaine in obturator nerve intraarticular injection : 10 ml of chlorhydrate ropivacaine (2 mg/ml) and 10ml of magnesium sulfate
3045704|NCT02256423|Active Comparator|REFERENCE 1: Nurofen® 200 mg tablet|Single group 3-way crossover study
3045578|NCT02257151|Experimental|Group 1: BMS-986142 or placebo|BMS-986142 or placebo Single dose oral Solution or spray dried dispersion as specified
3045579|NCT02257151|Experimental|Group 2: BMS-986142 or placebo|BMS-986142 or placebo Multiple dose oral Solution as specified
3045580|NCT02257138|Experimental|Ruxolitinib + Decitabine|"Phase I starting dose of Ruxolitinib: 10 mg by mouth twice a day for a 28 day cycle.~Phase I and II: Decitabine 20 mg/m^2 by vein on Days 1 - 5 of each 28 day cycle.~Phase II starting dose of Ruxolitinib: Maximum tolerated dose from Phase I."
3045581|NCT02257125|Experimental|high incentive|game version including visual effects and monetary rewards
3045582|NCT02257125|Active Comparator|low incentive|game version without visual effects or monetary rewards
3045583|NCT02257112|Experimental|Multistage low-energy stimulation|Multistage low-energy electrical pulses as described in Janardhan AH et al. JACC 2014 Jan7-14:63(1):40-8 will be delivered to a patient in atrial fibrillation. The responses to these stimuli will be recorded.
3045584|NCT02257073|Experimental|CBT|Cognitive-behavioral treatment
3045585|NCT02257073|Sham Comparator|WLT|Waiting in list
3045586|NCT02257060|Experimental|Endocardial Ablation|
3045587|NCT02257047|Experimental|RYR|Patients under the treatment of red yeast rice
3045588|NCT02257047|Sham Comparator|Control|Patients under the treatment of tea
3045589|NCT02257034|Experimental|Taichi|patients exercise with Tai chi
3045590|NCT02257034|Sham Comparator|Control|patients under exercise of dance
3045591|NCT02257021|Experimental|Tipranavir and high dose of ritonavir plus BILR 355 BS|
3045592|NCT02257021|Experimental|BILR 355 BS with low dose of ritonavir|
3045593|NCT02257008|Experimental|Single rising dose of BILR 355 BS with grapefruit juice|
3045594|NCT02257008|Experimental|Single rising dose of BILR 355 BS with nelfinavir|
3045595|NCT02257008|Experimental|Single dose of BILR 355 BS with atazanavir|
3045596|NCT02257008|Experimental|Single dose of BILR 355 BS with atazanavir, ritonavir|
3045597|NCT02256995||Pregnant Women (>22 weeks gestation)|Biomarkers tracked over 3 antenatal care visits via standard of care (dipstick, manually/visually assessed) and via uChek (automated assessment via computer application)
3045598|NCT02256982|Experimental|Resectable Disease|"Consent and Registration~3 cycles of gemcitabine + cisplatin~Evaluate for surgery* (weeks 10-15)~-- Patients who are eligible for surgery at restaging will receive surgery; patients not eligible for surgery at restaging will receive radiation therapy.~Proceed to surgery~Additional care as recommended; may include additional cycles of GEM + CDDP on a 21 day cycle and/or post-op radiation as recommended by treating medical oncologist and radiation oncologist"
3045599|NCT02256982|Experimental|Unresectable Disease|"Consent and Registration~3 cycles of gemcitabine + cisplatin~Evaluate for surgery* (weeks 10-15)~Patients who are eligible for surgery at restaging will receive surgery; patients not eligible for surgery at restaging will receive radiation therapy.~Proceed to radiation therapy with protons or photons, determined by available resources~Additional cycles of GEM + CDDP on a 21 day cycle as recommended by treating medical oncologist"
3045600|NCT02256969|Other|Meibomian Gland Probing plus lubricant|"Meibomian Gland Probing: Stainless steel probes were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were probed with a 1-mm probe followed by a 2-mm probe for all glands.~Lubricant: GenTeal PM Night-Time Ointment (Alcon), a sterile ophthalmic lubricant that is commonly used to relieve symptoms in patients with dry eye disease, was applied topically to both eyes for 4 weeks with the following regimen: twice daily for 2 weeks and then once daily for 2 weeks."
3045601|NCT02256969|Other|Sham Meibomian Gland Probing plus lubricant|"Sham Meibomian Gland Probing: The patient's the lid margin was touched with the probes without actual probing occurring.~Lubricant: GenTeal PM Night-Time Ointment, ophthalmic lubricant used to relieve symptoms in patients with dry eye disease, was applied topically to both eyes for 4 weeks: twice daily for 2 weeks and then once daily for 2 weeks."
3045602|NCT02256969|Active Comparator|Meibomian Gland Probing plus Blephamide|"Meibomian Gland Probing: Stainless steel probes were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were probed with a 1-mm probe followed by a 2-mm probe for all glands.~Blephamide: is a combination of an antibiotic and an anti-inflammatory agent commonly used to treat various ocular conditions. Blephamide was applied topically to both eyes for 4 weeks with a regimen of: twice daily for 2 weeks and then once daily for 2 weeks."
3045603|NCT02256956|Active Comparator|Amitriptyline first, Placebo second|Amitriptyline first, Placebo second
3045604|NCT02256956|Active Comparator|Placebo first, Amitriptyline second|Placebo first, Amitriptyline second
3045605|NCT02256943|Active Comparator|Amitriptyline first, Placebo second|Amitriptyline first, Placebo second
3045606|NCT02256943|Active Comparator|Placebo first, Amitriptyline second|Placebo first, Amitriptyline second
3045607|NCT02256930|Experimental|M518101|M518101 will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
3045608|NCT02256930|Placebo Comparator|M518101 Vehicle|M518101 Vehicle will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
3045609|NCT02256930|Active Comparator|Sodium lauryl sulfate|The sodium lauryl sulfate will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
3045610|NCT02256930|Sham Comparator|Saline|The saline will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
3045611|NCT02256917|Experimental|Human-cl rhFVIII|
3045612|NCT02256904|Experimental|Anatomical|67 subjects will be randomized to receive an Anatomical TKA with the My knee instruments and a GMK sphere device.
3045613|NCT02256904|Active Comparator|Mechanical|67 subjects will be randomized to receive a Mechanical TKA with the My knee instruments and the GMK sphere device.
3045614|NCT02256891|Experimental|Double Row|Double Row
3045615|NCT02256891|Experimental|Double Row with PRFM|Double Row with PRFM
3045616|NCT02256878|Experimental|BIRT 2584 XX + Amitriptyline|"BIRT 2584 XX:~Days 1 and 2: twice daily (bid) Days 3 to 21: once daily (qd)~Amitriptyline:~Single dose on day -8, day 1, and day 15"
3045617|NCT02256865|Placebo Comparator|Placebo and Drug Group 2|Placebo pills and gel is used in place. Placebo for Ketoconazole is taken 4 times a day Placebo for Hydrocortisone is taken 3 times a day Placebo for testosterone gel is applied once a day.
3045618|NCT02256865|Active Comparator|Drug and Placebo Group 1|Ketoconazole is taken 4 times a day Hydrocortisone is taken 3 times a day Testosterone gel is applied once a day
3045619|NCT02256852|Experimental|QBKPN SSI|Individualized maintenance dose administered subcutaneously for 12 weeks
3045620|NCT02256839||non TB infection|Group tested with CST_001
3045621|NCT02256839||low exposure risk|Group tested with CST_001
3045622|NCT02256826|Experimental|Group A|
3045623|NCT02256826|Experimental|Group B|
3045624|NCT02256813|Experimental|BIRT 2584 XX + PK-cocktail|
3045625|NCT02256800|Experimental|UGT1A1 genotyping (6,6)|The investigators will escalate the dosage of irinotecan from 180mg/m2 to 260 mg/m2
3045626|NCT02256800|Experimental|UGTA1T1 genotyping (6,7)|The investigators will escalate the dosage of irinotecan from 180mg/m2 to 240 mg/m2
3045627|NCT02256800|Experimental|UGTA1T1 genotyping (7,7)|The investigators will escalate the dosage of irinotecan from 120mg/m2 to 180 mg/m2
3045628|NCT02256800|Experimental|UGT1A1 non-genotyping|The investigators will maintain the dosage of irinotecan by 180mg/m2
3045629|NCT02256787|Experimental|BILB 1941 ZW - single rising dose|Single rising dose part
3045630|NCT02256787|Placebo Comparator|Placebo|Single rising dose part
3045631|NCT02256787|Experimental|BILB 1941 ZW - tablet - fasted|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
3045632|NCT02256787|Experimental|BILB 1941 ZW - solution|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
3045633|NCT02256787|Experimental|BILB 1941 ZW - tablet - fed|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
3045634|NCT02256774|Experimental|Combivir® plus BILR 355/Ritonavir|
3045635|NCT02256774|Experimental|BILR 355/Ritonavir|
3045636|NCT02256761|Experimental|BIRT 2584 XX - single dose|"Part 1 - bioavailability/food effect~two single doses, 30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served"
3045637|NCT02256761|Placebo Comparator|Placebo|Part 2
3045638|NCT02256761|Experimental|BIRT 2584 XX - multiple escalating dose|Part 2 - multiple escalating dose, 14 days and 28 days
3045639|NCT02256748|Experimental|BIRT 2584 XX + Midazolam|"BIRT 2584 XX: Multiple doses for 12 days (bid on days 1 and 2, qd from days 3 to 12)~Midazolam: Administration on days -2, 1, 3, and 12"
3045640|NCT02256735|Experimental|Treatment A|
3045641|NCT02256735|Experimental|Treatment B|
3045642|NCT02256735|Experimental|Treatment C|
3045643|NCT02256735|Experimental|Treatment D|
3045644|NCT02256735|Placebo Comparator|Placebo|
3045645|NCT02256735|Active Comparator|Moxifloxacin|
3045646|NCT02256722|Experimental|Treatment A|
3045647|NCT02256722|Experimental|Treatment B|
3045648|NCT02256722|Experimental|Treatment C|
3045649|NCT02256722|Experimental|Treatment D|
3045650|NCT02256722|Active Comparator|Treatment E|
3045651|NCT02256709|Experimental|single rising dose BIBP 5371 CL|
3045652|NCT02256709|Experimental|BIBP 5371 CL tablet high dose|to be compared with same daily dose level from single rising dose arm
3045653|NCT02256709|Experimental|BIBP 5371 CL tablet low dose|to be compared with same daily dose level from single rising dose arm
3045654|NCT02256709|Placebo Comparator|Placebo drinking solution|
3045655|NCT02256709|Experimental|BIBP 5371 CL drinking solution|
3045656|NCT02256709|Experimental|BIBP 5371 CL tablet high dose with food|
3045657|NCT02256709|Experimental|BIBP 5371 CL tablet low dose with food|
3045658|NCT02256709|Placebo Comparator|Placebo tablet|
3045659|NCT02256696|Experimental|Arm 1|PA-824 200 mg once daily (QD),Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
3045660|NCT02256696|Experimental|Arm 2|PA-824 200 mg once daily,Rifabutin 300 mg once daily , Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifabutin 300 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
3045661|NCT02256696|Active Comparator|Arm 3|Rifampin 600 mg once daily, Ethambutol 15mg/kg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
3045662|NCT02256683|Experimental|Dabigatran|Dabigatran etexilate (Pradaxa®) 150 mg capsule by mouth twice daly for 3 up to 6 weeks depending on treatment response
3045663|NCT02256683|Active Comparator|Phenprocoumon|Phenprocoumon (Marcumar®) 3 mg capsule by mouth according to INR (2-3) for 3 up to 6 weeks depending on treatment response
3045664|NCT02256670|Experimental|Text Message Application Intervention|The study intervention will include a mobile phone two-way text message application. Each prompt described below will generate either a yes (Y)/no (N) or ABCDE(F) response from patients. Each response will generate further prompts resulting in either notification for providers to call patients or relevant phone numbers for patients to call for assistance.
3045665|NCT02256657|Experimental|Step 1: Toolkit Implemented in Month 4|Quality Improvement Toolkit
3045666|NCT02256657|Experimental|Step 2: Toolkit Implemented in Month 8|Quality Improvement Toolkit
3045667|NCT02256657|Experimental|Step 3: Toolkit Implemented in Month 12|Quality Improvement Toolkit
3045668|NCT02256657|Experimental|Step 4: Toolkit Implemented in Month 16|Quality Improvement Toolkit
3045669|NCT02256657|Experimental|Step 5: Toolkit Implemented in Month 20|Quality Improvement Toolkit
3045670|NCT02256644||Million Veteran Program (MVP) participants|Veterans who are currently enrolled in the Million Veteran Program.
3045671|NCT02256631|Experimental|Dose Group 1|Infants in Dose Group 1 will receive a single VRC01 20 mg/kg injection less than 72 hours after birth.
3045672|NCT02256631|Experimental|Dose Group 2|Infants in Dose Group 2 will receive a single VRC01 40 mg/kg injection less than 72 hours after birth.
3045673|NCT02256631|Experimental|Dose Group 3|Infants in Dose Group 3 will receive a VRC01 40 mg/kg injection less than 5 days after birth. They will then receive a VRC01 20 mg/kg injection monthly for at least 6 months and no more than 18 months while breastfeeding.
3045674|NCT02256631|Experimental|Dose Group 4|Infants in Cohort 1 will receive a single VRC01LS injection less than 72 hours after birth. Dose is based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. Infants in Cohort 2 will receive an initial VRC01LS injection less than 5 days after birth, with dose based on weight. A second dose of 100 mg VRC01LS will be administered at Week 12 if an infant is still breastfeeding.
3045675|NCT02256618|Experimental|Cell therapy|Infants who are born at the study sites, have moderate to severe encephalopathy, and have cord blood available for infusion
3045676|NCT02256605||Insufficient Group|D-3 Chewable Wafer - 14,000 IU/wafer weekly Vitamin D-3 Caps - 2,000 IU/Cap daily Vitamin D-3 Liquid - 5,000 IU/ml (0.4) ml daily
3045677|NCT02256605||Deficient Group|D-3 Chewable Wafer - 50,000 IU/wafer weekly Vitamin D-3 Liquid - 5,000 IU/ml daily
3045678|NCT02256592|Experimental|Fecal microbiota transplant (FMT)|Donor fecal suspension will be delivered during colonoscopy to HIV+ individuals.
3045679|NCT02256566|Experimental|emotional memory training exercise|study training exercise - Emotional Faces Memory Task (EFMT)
3045680|NCT02256566|Active Comparator|memory training exercise|an active control exercise (CT)
3045681|NCT02256553|Experimental|MK-3641+ MK-7243|Participants receive one MK-7243 tablet, SL QD in the evening for 14 days during Period I; one MK-3641 tablet, SL QD in the morning and one MK-7243 tablet, SL QD in the evening for 14 days during Period II; and one MK-3641 tablet, SL QD, and one MK-7243 tablet, SL QD, within 5 minutes of each other for 14 days during Period III.
3045682|NCT02256540|Placebo Comparator|Placebo patch - placebo tablets|Postmenopausal women will be given a placebo patch to wear two days prior to exercise visit and a placebo tablet to take the morning of the exercise visit.
3045683|NCT02256540|Experimental|Placebo patch - Resveratrol tablets|Postmenopausal women will be given a placebo patch to wear for two days prior to the exercise visit and a resveratrol tablet (dosed at 250mg) to take the morning of the exercise visit.
3045684|NCT02256540|Active Comparator|Climara patch - placebo tablets|Postmenopausal women will be given a transdermal estrogen patch to wear (0.05mg/day) for two days prior to the exercise visit and a placebo tablet to take the morning of the exercise visit.
3045685|NCT02256527||Promus Premier|observational data
3045686|NCT02256514|Experimental|Daily oral dose of hepcortespenlisimut-L|Hepcortespenlisimut-L (V5) (850 mg pill) to be administered once per day for the duration of study
3045687|NCT02256501|Experimental|Mono Nunlear Cell (MNC)|The patients with idiopathic dilated cardiomyopathy who underwent intracoronary injection of autologous bone marrow-derived mononuclear cells .
3045688|NCT02256501|No Intervention|Control|The patients with cardiomyopathy that are under observe during the study.
3045689|NCT02256488|Experimental|TIVc-Lot A|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot A
3045690|NCT02256488|Experimental|TIVc-Lot B|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot B
3045691|NCT02256488|Experimental|TIVc-Lot C|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot C
3045692|NCT02256488|Active Comparator|TIVf|Subjects 18 to ≤ 49 years of age who received one vaccination of Control vaccine TIVf
3045693|NCT02256475|Experimental|Adolescents Dose Group 1|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days.
3045694|NCT02256475|Experimental|Adolescents Dose Group 2|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 1 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
3045695|NCT02256475|Experimental|Adolescents Dose Group 3|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
3045696|NCT02256475|Experimental|Children Dose Group 1|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 1 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
3045697|NCT02256475|Experimental|Children Dose Group 2|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the children dose group 1 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
3045698|NCT02256475|Experimental|Children Dose Group 3|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the children dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
3045699|NCT02256462|Experimental|Interventional|Adalimumab levels and antibodies will be obtained with every laboratory examination (every 2 months, except for the first 2 visits). Dose or interval adjustment will be performed as followed:when trough levels results taken prior to ADA injection are above 5 µg/ml no change in dosing is required. Detectable levels below 5 µg/ml will result in interval decrease to every week. If levels are still below 5 µg/ml dose will be increased to 40 mg (in patients receiving less than 40 mg). Undetectable levels below 0.3µg/ml will be followed by antibodies (ATAs) measurement. If ATAs are persistently above 8 µg/ml the patient will discontinue the study. If ATAs are below 8 µg/ml ADA intervals will be decreased to every week.
3045700|NCT02256462|No Intervention|Clinical|"Adalimumab levels and antibodies will be requested based on physician judgment when there are signs of loss of response (LOR). Dose and interval adjustment will be performed according to clinical measures: Following physician decision trough levels and ATAs will be collected and further adjustment may be considered according to results. Interval adjustment will be performed as described for the interventional arm.~LOR is defined as PCDAI equal or higher than 10 or CRP higher than 0.5 mg/dl (5mg/l) and/or Fecal calprotectin higher than 50 mcg/gr (If lower than 50 at randomization)."
3045701|NCT02256449||BVS patients|Use of bioresorbable coronary device, according to the indications of use, in daily clinical practice, in patients undergoing PCI in de novo coronary artery lesions.
3045702|NCT02256436|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W)
3045703|NCT02256436|Active Comparator|Active Comparator|Participants receive paclitaxel 175 mg/m^2 IV or docetaxel 75 mg/m^2 IV or vinflunine 320 mg/m^2 IV, on Day 1 Q3W
3045705|NCT02256423|Active Comparator|REFERENCE 2: Ibuprofen 200 mg soft gel capsule|Single group 3-way crossover study
3045706|NCT02256423|Experimental|ibuprofen 200 mg soft gel capsule|single group, 3-way cross
3045707|NCT02256410|Experimental|Stimulation|Patients will undergo 6 sessions, each including 20 minutes of stimulation. These are given after the Nervomatrix device determines the peak pain regions for each patient, and selects to stimulate the top 10 regions with least skin resistance. The frequency of stimulation is 8Hz, at an intensity matched for each patient's tolerance, without inflicting any pain. The location of the stimulations will change in accordance to the changes in the peak pain regions, reflecting changes in tissue physiology possibly linked to clinical improvements.
3045708|NCT02256410|Sham Comparator|sham stimulation|Patients will undergo 6 sessions, each including 20 minutesof sham stimulation (no stimulation). These are given after the Nervomatrix device determines the peak pain regions for each patient, and selects to stimulate the top 10 regions with least skin resistance.
3045709|NCT02256397|Active Comparator|Standard comprehensive care|Standard comprehensive care at High Risk Children's Clinic
3045710|NCT02256397|Experimental|Enhanced comprehensive care|"standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:~If between 2 and 5 years old--> will receive Home-centered comprehensive care with the propeller~5 and above--> will receive home-centered comprehensive care with propeller and PIKO"
3045711|NCT02256384|Experimental|Respiratory Acoustic Monitoring|All participants will wear the respiratory acoustic monitoring device.
3045712|NCT02256371|Experimental|Hypnotic analgesia|"Hypnosis sessions:~Hypnosis will consist of 45 minutes hypnosis session with a trained hypnotherapist"
3045713|NCT02256371|Experimental|Relaxation|"Relaxation group:~Relaxation will be conducted in 45 minutes sessions with a trained psychotherapist."
3045714|NCT02256371|No Intervention|Routine care|The patients will receive their usual pain treatments throughout the study
3045715|NCT02256358|Active Comparator|Midazolam|Intravenous 0.1 mg/kg midazolam was administered to the patients as premedication drug before entering operating room.
3045716|NCT02256358|Experimental|Ketamine|Intravenous 1 mg/kg ketamine was administered to the patients as premedication drug before entering operating room.
3045717|NCT02256345|Active Comparator|KNO3 active comparator|KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated
3045718|NCT02256345|Placebo Comparator|KCl placebo comparator|KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated
3045719|NCT02256332|Active Comparator|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
3045720|NCT02256332|Active Comparator|High dose plant based ingredient|Reference food with high dose of plant based ingredient
3045721|NCT02256332|Placebo Comparator|Reference food format|Reference food without plant-based ingredient
3045722|NCT02256319|Experimental|Dexmedetomidine recording|Recording registered through the deep brain stimulation electrodes with dexmedetomidine at 0.2 μg/kg/h.
3045723|NCT02256319|Active Comparator|Propofol recording|Recording registered through the deep brain stimulation electrodes with propofol at plasmatic levels of 0.5, 1, 1.5, 2, 2.5 μg/mL.
3045724|NCT02256319|No Intervention|Basal recording|Recording registered through the deep brain stimulation electrodes with no sedation .
3045725|NCT02256306|Experimental|Young Donor Plasma|Subjects will receive 1 unit of plasma, once weekly for 4 weeks.
3045726|NCT02256293|Experimental|Group Therapy|Diabetes self-management group based on Acceptance and Commitment Therapy (ACT).
3045727|NCT02256280|Experimental|S Group|Sugammadex 2 or 4 mg/kg iv once at the end of surgery
3045728|NCT02256280|Active Comparator|N Group|Neostigmine 0.05 or 0.07 mg/kg (+ atropine 0.02 mg/kg) iv once at the end of surgery
3045729|NCT02256267|Experimental|LY2835219|Single oral dose of LY2835219
3045730|NCT02256267|Experimental|LY2835219 + Rifampin|Single oral dose of LY2835219 with rifampin orally, once daily for 14 days
3045731|NCT02256254|Active Comparator|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
3045732|NCT02256254|Placebo Comparator|Placebo|2 placebo capsules every evening for 14 days
3045733|NCT02256241||The role of RING ubiquitin ligases in osteogenic progenitors|Bone marrow (BM) will be collected from healthy patients undergoing orthopedic surgery. BM will be collected from disposable tissue that is removed during the normal sequence of the surgery.
3045734|NCT02256241||The role of RING ubiquitin ligases in musculoskeletal cancer|Collection of connective tissue from patients with tumors of musculoskeletal origin - a part of the resected tumor specimens.
3045735|NCT02256228|Active Comparator|Group R|Ropivacaine is instillated through one multi-hole catheter wich would be inserted percutaneously in all patients and tunnelled about 1-2 cm lateral to the abdominal incision and the tip of the catheter placed in the intra-peritoneal cavity. The catheter would not be ligated and fixed in situ intra-peritoneally. Twenty ml of Ropivacaine would be injected subcutaneously along both sides of the incision prior to skin closure. Additionally, 20 ml of Ropivacaine (1mg/mL) would be injected every hour by an automatic pump via the intra-peritoneal catheter into the abdomen.
3045736|NCT02256228|Placebo Comparator|Group P|Saline is instillated through one multi-hole catheter wich would be inserted percutaneously in all patients and tunnelled about 1-2 cm lateral to the abdominal incision and the tip of the catheter placed in the intra-peritoneal cavity. The catheter would not be ligated and fixed in situ intra-peritoneally. Twenty ml of Saline would be injected subcutaneously along both sides of the incision prior to skin closure. Additionally, 20 ml of Saline would be injected every hour by an automatic pump via the intra-peritoneal catheter into the abdomen.
3045737|NCT02256215|Experimental|Vitamin D|• All patients will have their serum vitamin D levels measured at the baseline visit. Those assigned to the treatment arm (group A) will receive either 50,000 international units of vitamin D3 by mouth once or more per week for six to eight weeks, then 800 to 1000 (or more) international units of vitamin D3 daily thereafter, this is according to the recommendations of the Endocrine Society clinical practice guideline 2011. Group B patients will receive placebo supplements identical in appearance to the vitamin D supplements.
3045738|NCT02256215|Placebo Comparator|Placebo|
3045739|NCT02256189|Active Comparator|Sitagliptin|Hypoglycemia clamp with sitagliptin
3045740|NCT02256189|Placebo Comparator|Placebo|Hypoglycemia clamp with placebo
3045741|NCT02256150|Experimental|Mizoribine (MZR)|Oral administration, daily dose of 150mg (50mg/tablet, t.i.d) All study subjects will receive standard steroid therapies during the study.
3045742|NCT02256150|Active Comparator|Cyclophosphamide (CTX)|"Intravenous injection with between 0.5 to 1.0 g/m2 body surface area each time (the maximum dose is 1.0 g/day each time).~All study subjects will receive standard steroid therapies during the study."
3045743|NCT02256137||Childhood Cancer Survivors|This study will evaluate 1493 members of the St. Jude Lifetime Cohort Study (SJLIFE) who have completed a baseline functional assessment six or less years ago when 18-45 years of age.
3045744|NCT02256124|Experimental|Lamotrigine|"Lamotrigine during 28 consecutive weeks:~8 weeks dose-increase phase: from 25mg once daily to 100mg twice daily~18 weeks target-dose phase: 100mg twice daily~2 weeks decline-phase: 100mg once daily."
3045745|NCT02256124|Placebo Comparator|Placebo|Placebo tablets during 28 consecutive weeks, with identical appearance to lamotrigine tablets, mimicking the lamotrigine dosing schedule.
3045746|NCT02256111|Experimental|ENZ+ADT+Usual care|The usual care arm will receive treatment with enzalutamide with androgen deprivation therapy, with no supervised exercise training.
3045747|NCT02256111|Experimental|ENZ+ADT+Exercise|The ENZ+ADT+Exercise arm will receive treatment with enzalutamide plus androgen deprivation therapy along with supervised exercise training.
3045748|NCT02256098|Experimental|ATTUNE™|Total Knee Replacement Surgery with ATTUNE™ Knee Prosthesis by DePuy
3045749|NCT02256098|Active Comparator|PFC Sigma|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
3045750|NCT02256085|Sham Comparator|Sham rTMS|"Daily rTMS with Sham coil~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with Sham (placebo) coil"
3045751|NCT02256085|Experimental|Active rTMS|"Daily rTMS with Active coil~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil"
3045752|NCT02256085|Experimental|Open Active rTMS|"Open Label Daily rTMS with Active coil~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil"
3045753|NCT02256072|Experimental|Plan Your Lifespan Website|Participants in the intervention arm will navigate the Plan Your Lifespan website, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. The Plan Your Lifespan tool is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
3045754|NCT02256072|Other|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. Our attention control group will control for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention website.
3045755|NCT02256059||Plate osteosynthesis|Patients with fracture of the lateral clavicle and indication for surgical treatment
3045756|NCT02256046|Experimental|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
3045757|NCT02256033|Experimental|Istradefylline|One 40-mg tablet of istradefylline administered on Day 1.
3045758|NCT02256020|Other|Original lifestyle|Original lifestyle, watching TV 50 minutes, three times a week for 6 months.
3045759|NCT02256020|Experimental|Wheel-chair music aerobic exercise|Wheel-chair music aerobic exercise with 3 times of 50-minute session (10 minutes warm up, 30 minutes exercise and 10 minutes cool down) a week for 6 months.
3045760|NCT02256007|Active Comparator|Standardized Assessments|"Standardized Assessments (paper and pencil tests) to be given to each participant. The standardized assessments will be completed in paper and pencil format. These tests include:~Line Bisection Test~Patient Reported Outcomes~Trial Making A and B~Usability Questionnaire"
3045761|NCT02256007|Experimental|Videogame Assessments|"Videogame assessments will be performed by each participant using videogames. The videogame assessments will be performed using videogames on a tabletop platform with touchscreen which includes:~Line Crossing~Patient Reported Outcomes~Trial Making A & B-Asteroid Adventure Game~Usability Questionnaire"
3045762|NCT02255994|Experimental|UGYTEX|Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)
3045763|NCT02255994|Active Comparator|No MESH|Patients in this arm had subvesical plication without reinforcement.
3045764|NCT02255981|Experimental|Acupuncture effects in macular damage|Traditional Chinese Medicine (TCM). All cases in this group receive treatment with acupuncture. The protocol is the same for all by treat and extend program.
3045765|NCT02255981|No Intervention|Medical treatment in macular damage|Conventional macular damage cases treated by current protocols Intravitreal injections of anti VEGF drugs will be taken for comparison. .
3045766|NCT02255968|Experimental|EDP-788|Multiple doses with dose escalation to continue in successive cohorts
3045767|NCT02255968|Placebo Comparator|Placebo|Multiple doses with dose escalation to continue in successive cohorts
3045768|NCT02255955|Experimental|550 mg naproxen sodium and 30mg codeine|Preoperatively patients received oral naproxen sodium codeine, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
3045769|NCT02255955|Active Comparator|300 mg paracetamol and 30 mg codeine|Preoperatively patients received oral paracetamol codeine, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
3045770|NCT02255955|Placebo Comparator|Placebo|Preoperatively patients received oral placebo tablet, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
3045771|NCT02255942|Experimental|Iron fortified rice|Administration of iron fortified rice to all subjects; subjects will act as their own controls and each subject will receive all foreseen treatments/interventions.
3045772|NCT02255929|Experimental|Gamma Knife Radiosurgery|Gamma Knife treatment is conducted in one day and takes approximately 70 to 90 minutes.
3045773|NCT02255916|No Intervention|Controll|No sound-bed intervention
3045775|NCT02255903||Group 1(Control Group):|ultrasound and Doppler examination: of 100 pregnant females with gestational age 37-40 weeks.
3045776|NCT02255903||Group 2 (post date Group)|ultrasound and Doppler examination:will be done for 100 pregnant females with gestational age 41 weeks or more
3045777|NCT02255877|Active Comparator|Zip Surgical Skin Closure|Subjects randomized to receive one knee (left or right) closed with ZipSurgical Skin Closure and the other knee closed with standard staples
3045778|NCT02255877|Active Comparator|Steel Staples|Subjects randomized to receive one knee (left or right) closed with Staples and the other knee closed with ZipSurgical Skin Closure
3045779|NCT02255864|Experimental|Coronary Scaffold Implantation|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
3045780|NCT02255851||Treatment Group|TAVR + SENTINEL (Cerebral Protection System)
3045781|NCT02255838|Experimental|Bronchoscope disposable, aScope III|the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
3045782|NCT02255838|Active Comparator|Bronchoscope reusable Storz 8402 2x|the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
3045783|NCT02255825|Active Comparator|Control Group|Amniocentesis will be performed, Whole Genome Sequencing will not be performed, and psychosocial assessment will be performed.
3045784|NCT02255825|Experimental|Intervention Group|Amniocentesis will be performed, Whole Genome Sequencing will be performed if the karyotype is normal, and psychosocial assessment will be performed.
3045785|NCT02255812|Placebo Comparator|200 mL tap water|Single intragastric instillation of 200 mL tap water via nasogastric tube
3045786|NCT02255812|Active Comparator|2 g citric acid|Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube
3045787|NCT02255812|Active Comparator|2 g salt|Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube
3045788|NCT02255812|Active Comparator|0.017 g quinine|Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube
3045789|NCT02255812|Active Comparator|1 g monosodium glutamate|Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube
3045790|NCT02255812|Active Comparator|25 g glucose|Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube
3045791|NCT02255799|Active Comparator|Donepezil|Donepezil 5 mg capsules daily for 14 days. Donepezil 10 mg capsules daily for 56 days.
3045792|NCT02255799|Placebo Comparator|Placebo|Placebo capsules once daily for 70 days.
3045793|NCT02255786|Experimental|ACT Parent Group|Participants will complete a total of five Acceptance and Commitment Therapy - Parent Group Sessions First four are held weekly, last session held one month from 4th session.
3045794|NCT02255786|No Intervention|Treatment as Usual|Treatment as usual-Control
3045795|NCT02255773|Other|High-Fatigue Head and Neck (HNC) Cancer Survivors|Participants undergo assessment with three validated computerized tasks designed to measure the neurobehavioral domains of interest: the Effort Expenditure for Rewards Task (EEfRT), an associative learning task, and a set-switch task. Participants complete questionnaires assessing mood, somatic symptoms, and sleep quality, including the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), the Checklist Individual Strength (CIS), and others. A 10-mL blood sample drawn for assessment of inflammatory markers and COMT and DAT1 genotype.
3045796|NCT02255773|Other|Low-Fatigue Head and Neck (HNC) Cancer Survivors|Participants undergo assessment with three validated computerized tasks designed to measure the neurobehavioral domains of interest: the Effort Expenditure for Rewards Task (EEfRT), an associative learning task, and a set-switch task. Participants complete questionnaires assessing mood, somatic symptoms, and sleep quality, including the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), the Checklist Individual Strength (CIS), and others. A 10-mL blood sample drawn for assessment of inflammatory markers and COMT and DAT1 genotype.
3045797|NCT02255760|Experimental|MEDI3902 - Dose 1|Participants will receive a single intravenous (IV) dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
3045798|NCT02255760|Experimental|MEDI3902 - Dose 2|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
3045799|NCT02255760|Experimental|MEDI3902 - Dose 3|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
3045800|NCT02255760|Experimental|MEDI3902 - Dose 4|Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
3045801|NCT02255760|Placebo Comparator|Placebo|Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
3045802|NCT02255747|Active Comparator|anal dilatation|
3045803|NCT02255747|Active Comparator|Oral Lactulose|
3045804|NCT02255734|Active Comparator|Zovirax|
3045805|NCT02255734|Experimental|Virless|
3045806|NCT02255721|Experimental|SHIP Intervention|SHIP is a health behavior change intervention to give parents the knowledge, motivation, and skills necessary to set goals, problem-solve, and improve their child's sleep.
3045807|NCT02255721|Active Comparator|SHIP Control Arm|The active control arm uses the same strategies as the SHIP intervention arm, but for child health topics unrelated to sleep or outcome measures.
3045808|NCT02255708|Other|Healthy group.|Group formed by healthy patients.
3045809|NCT02255708|Other|Group with demyelinating polyneuropathy|Group formed by patients with demyelinating polyneuropathy.
3045810|NCT02255695|No Intervention|Control group|Control group
3045811|NCT02255695|Experimental|School-based exercise program|School-based exercise program
3073601|NCT02070289|Experimental|Group 1 or 2: Cohort 5|
3045812|NCT02255682|Placebo Comparator|Simvastatin and Q10-placebo|Simvastatin 40 mg orally administered daily and Q10-placebo for 8 weeks
3045813|NCT02255682|Active Comparator|Simvastatin and Q10|Simvastatin 40 mg orally administered daily for 8 weeks in combination with Q10 supplementation of 400 mg/daily
3045814|NCT02255669|Active Comparator|partially covered SEMS|Deployment of Partially covered biliary self expandable metal stent
3045815|NCT02255669|Active Comparator|fully covered SEMS|Deployment of Fully covered biliary self expandable metal stent
3045816|NCT02255656|Experimental|GZ402673 alemtuzumab|Intravenous infusion for 3 consecutive days, at the study investigators' discretion; and at least 12 months after the prior treatment course
3045817|NCT02255643|Experimental|-10% of effective PMT|Patients are set to a voltage 10% less than their original PMT at start of study, Changes in PMT settings
3045818|NCT02255643|Active Comparator|former setting (+/- 0% of PMT)|Patients are set to their original PMT at start of study, Changes in PMT settings
3045819|NCT02255643|Experimental|+10% of effective PMT|Patients are set to a voltage 10% more than their original PMT at start of study, Changes in PMT settings
3045820|NCT02255630|Experimental|Salbutamol inhalation|Study participants will be exposed to 1600ug salbutamol 30min prior to exercise
3045821|NCT02255630|Experimental|Placebo inhalation|Study participants will be exposed to 1600ug salbutamol 30min prior to exercise
3045822|NCT02255617|Experimental|Fecal Microbiota Transplant|Single arm open label FMT administered at Week 0 by colonoscopy and at Weeks 1-4 by enema
3045823|NCT02255604|Active Comparator|intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.~Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015."
3045824|NCT02255604|Placebo Comparator|3 intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.~Patients receive 3 injection in total. 3 injection in the spring 2014 with one month interval. In in the spring 2015 patients will have a placebo injection."
3045825|NCT02255604|Sham Comparator|no intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of isotone saline.~Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015. All injections are with isotone saline as placebo control."
3045826|NCT02255591|Experimental|Shamrock|Use of the Shamrock technique to place a lumbar plexus block with injection of 20 mL 2% Lidocaine-adrenaline added gadolinium.
3045827|NCT02255591|Active Comparator|Lumbar Ultrasound Trident|Use of the Lumbar Ultrasound Trident technique to place a lumbar plexus block with injection of 20 mL 2% lidocaine-adrenaline added gadolinium.
3045828|NCT02255578|Other|IVF treatment|Fertility, as determined by egg quality parameters, as well as metabolic parameters, will be assessed following Endobarrier treatment in PCOS during IVF treatment.
3045829|NCT02255578|Other|clomiphene citrate treatment|Ovulation rate in response to clomiphen citrate after Endobarrier treatment in PCOS.
3045830|NCT02255565|Experimental|Very Low Dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a very low dose level for 6 weeks.
3045831|NCT02255565|Experimental|Low Dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a low dose level for 6 weeks.
3045832|NCT02255565|Experimental|Moderate dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a moderate dose level for 6 weeks.
3045833|NCT02255552|Experimental|Treated Group|Approximately 80 patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with genetic deletions amenable to treatment by exon 51 skipping will receive 30 mg/kg of eteplirsen weekly for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
3045834|NCT02255552|No Intervention|Untreated Group|Approximately 30 DMD patients not amenable to exon 51 skipping will not receive eteplirsen.
3045835|NCT02255526||Healthy Volunteers|Healthy volunteers between the ages of 18 and 80 will wear BodyGuardian remote monitoring system to help validate respiration and activity levels.
3045836|NCT02255526||Heart Failure|Heart failure patients between the ages of 18 and 80 will wear BodyGuardian remote monitoring system to help validate respiration and activity levels.
3045837|NCT02255513|Experimental|HLD200 (methylphenidate)|Generic name: Methylphenidate hydrochloride (MPH) Dosage form: Capsules (20,40,60,80,100 mg) Frequency: Once per day during the evening Duration: 7 weeks
3045838|NCT02255513|Placebo Comparator|Placebo|Placebo capsules will be filled with microcrystalline cellulose (MCC) beads in place of MPH containing beads found in the HLD200 capsules
3045839|NCT02255500|Experimental|Bupivacaine FNB + EXPAREL Infiltration|FNB with bupivacaine HCl 0.5% with epinephrine 1:200,000 within 2 hours of the surgical procedure. Infiltration of EXPAREL 266 mg just prior to wound closure.
3045840|NCT02255487|Experimental|IrriSept System|IrriSept device used for surgical irrigation in subjects with abdominal trauma or acute surgical abdomen
3045841|NCT02255487|Active Comparator|Standard of Care (SoC) only|Institution will provide routine Standard of Care (SoC) surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
3045842|NCT02255474|Active Comparator|Biofinity|Soft spherical contact lens
3045843|NCT02255474|Experimental|Biofinity Multifocal D +1.50 add|"The Biofinity Multifocal D with a +1.50 add is a soft bifocal contact lens that has a medium reading power"
3045844|NCT02255474|Experimental|Biofinity Multifocal D +2.50 add|"The Biofinity Multifocal D with a +2.50 add is a soft bifocal contact lens that has a strong reading power"
3045845|NCT02255461|Experimental|Treatment (palbociclib isethionate)|Patients receive palbociclib isethionate PO QD on days 1-21. Treatment repeats every 4 weeks for 26 courses in the absence of disease progression or unacceptable toxicity.
3045846|NCT02255448|Other|SV1, SV2|SV1 intervention: stroke volume using transthoracic echo SV2 intervention: stroke volume measured using the esCCO device.
3045847|NCT02255435|Experimental|Omaveloxolone Capsules 2.5 and 5 mg|omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally one daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
3045848|NCT02255435|Experimental|Omaveloxolone Capsules 10 mg|omaveloxolone (RTA 408) Capsules, 10 mg taken orally once daily for 12 weeks
3045849|NCT02255435|Placebo Comparator|Placebo Capsules|Placebo capsules taken orally once daily for 12 weeks
3045850|NCT02255435|Experimental|Omaveloxolone Capsules 20 mg|omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks
3045851|NCT02255435|Experimental|Omaveloxolone Capsules 40 mg|omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks
3045852|NCT02255435|Experimental|Omaveloxolone Capsules 80 mg|omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks
3045853|NCT02255435|Experimental|Omaveloxolone Capsules 160 mg|omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks
3045854|NCT02255435|Experimental|Omaveloxolone Capsules 300 mg|omaveloxolone (RTA 408) Capsules, 300 mg taken orally once daily for 12 weeks
3045855|NCT02255435|Experimental|Omaveloxolone Capsules 150 mg|omaveloxolone (RTA 408) Capsules, 150 mg taken orally once daily for 24 weeks
3045856|NCT02255422|Experimental|omaveloxolone Capsules 2.5 mg and 5 mg|omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally once daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
3045857|NCT02255422|Experimental|omaveloxolone Capsules 10 mg|omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 12 weeks
3045858|NCT02255422|Placebo Comparator|Placebo Capsules|Placebo capsules taken orally once daily for 12 weeks
3045859|NCT02255422|Experimental|omaveloxolone Capsules 20 mg|omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks.
3045860|NCT02255422|Experimental|omaveloxolone Capsules TBD mg|omaveloxolone (RTA 408) Capsules, TBD mg taken orally once daily for 12 weeks.
3045861|NCT02255422|Experimental|omaveloxolone Capsules 40 mg|omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks.
3045862|NCT02255422|Experimental|omaveloxone Capsules 80 mg|omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks.
3045863|NCT02255422|Experimental|omaveloxone Capsules 160 mg|omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks.
3045864|NCT02255409|Experimental|aQIV|Adjuvanted Quadrivalent Subunit Influenza
3045865|NCT02255409|Active Comparator|QIV|Non-Adjuvanted Quadrivalent Subunit Influenza
3045866|NCT02255383|Other|PERSONA TKA|Primary total knee arthroplasty subjects that receive the Zimmer Persona Total Knee System
3045867|NCT02255370|Experimental|CURCUMIN|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
3045868|NCT02255370|Placebo Comparator|PLACEBO|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
3045869|NCT02255357|Placebo Comparator|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
3045870|NCT02255357|Active Comparator|Intranasal Syntocinon|Intranasal Oxytocin 24 IU per day.
3045871|NCT02255344||ST-Elevation Myocardial Infarction|Consecutive patients of any gender between 18 and 90 years old, diagnosed with ST-Elevation Myocardial Infarction according to international diagnostic criteria - ACC / AHA / ESC, attended in representative hospitals of tertiary and secondary care in the IMSS will be studied
3045872|NCT02255344||Non ST Segment Elevation|Consecutive patients of any gender between 18 and 90 years old, diagnosed with Non ST Segment Elevation (NSTEMI/ Unstable angina) according to international diagnostic criteria - ACC / AHA / ESC, attended in representative hospitals of tertiary and secondary care in the IMSS will be studied
3045873|NCT02255331||Retrieval Analysis|"You qualify for this arm of the study if you:~Have a metal-on-metal total hip replacement , or~Have a modular design metal-on-polyethylene total hip replacement, or~Have a hip resurfacing implant, or~Have a total hip replacement with a ceramic component undergoing revision for any reason, including recurrent dislocation, or~Have a metal-on-polyethylene total hip replacement and have repeated dislocation, or~Have a metal-on-polyethylene total hip replacement greater than 1 year old, or~Have an infected total hip replacement~You do not qualify for this arm of the study if you:~1. Have occupational exposure to cobalt or chromium"
3045874|NCT02255331||Longitudinal Evaluation|"You qualify for this arm of the study if you:~Have a hip resurfacing implant, or~Have a modular design metal-on-polyethylene total hip replacement, or~Have a traditional metal-on-poly total hip replacement, or~Have a total hip replacement with a ceramic component.~Are asymptomatic at 1 years post-operative~You do not qualify for this arm of the study if you:~1. Have occupational exposure to cobalt or chromium"
3045875|NCT02255318|Experimental|Taurolock|Patients received Taurolock lock for 3 months administration.
3045876|NCT02255318|Placebo Comparator|Placebo|Patients received placebo lock (physiological serum) for 3 months administration.
3045877|NCT02255305|Experimental|FMT Group (Intervention Arm)|Patients randomized to the FMT group will have antimicrobials targeting C. difficile discontinued at least 6 hours prior to undergoing an FMT via retention enema. A second FMT via retention enema will be administered at 24 hours if diarrhea persists.
3045878|NCT02255305|Active Comparator|Antimicrobial Group (Control Arm)|Patients randomized to the antimicrobial group will be treated with antibiotics targeting C. difficile according to the Society for Healthcare Epidemiology of America (SHEA) Clinical Practice Guidelines for CDI. FMT will be offered to this group after 90 days if they experience relapsing CDI.
3045879|NCT02255292|Experimental|cannabidiol (CBD)|Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status < or = 2 and aged 18 years old and more will be included in the current study.
3045880|NCT02255279|Experimental|aTIV|aTIV is a trivalent influenza virus vaccine, adjuvanted with MF59C.
3045881|NCT02255279|Active Comparator|TIV|TIV is trivalent influenza vaccine licensed in Mexico.
3045882|NCT02255266||A|
3045883|NCT02255253|Experimental|Telmisartan|capsule,40mg per day,2 months
3045884|NCT02255253|Experimental|Hydrochlorothiazide|tablet, 25mg per day, 2 months
3045885|NCT02255240|Experimental|Physical activity intervention|This arm will receive the physical activity intervention, which consists of three individual meetings, weekly brief counseling phone calls for 6 weeks, and provision of a video game console with three active video games.
3073602|NCT02070289|Experimental|Group 1 or 2: Cohort 6|
3045886|NCT02255227|Active Comparator|1 dose Prevenar13 and 1 dose PSV23|one dose of the polysaccharide vaccine, Prevenar 13 at M0 and one dose of polysaccharide vaccine, Pneumo 23 at M4
3045887|NCT02255227|Experimental|2 doses Prevenar13 and 1 dose PSV23|one dose of the polysaccharide vaccine, Prevenar 13 at M0, one dose of the polysaccharide vaccine, Prevenar 13, at M2 and one dose of polysaccharide vaccine, Pneumo 23 at M4
3045888|NCT02255214||Surgical Patient|These are the results from the blood samples taken from the study participants.
3045889|NCT02255201|Active Comparator|Beverage A|Single dose, Pre-Workout Master Performance Blend Dose 1
3045890|NCT02255201|Active Comparator|Beverage B|Single dose, Pre-Workout Master Performance Blend Dose 2
3045891|NCT02255201|Active Comparator|Beverage C|Single dose, Pre-Workout Performance Energy Blend
3045892|NCT02255201|Active Comparator|Beverage D|Single dose, Pre-Workout Energy Blend
3045893|NCT02255201|Placebo Comparator|Beverage E|Single dose, Pre-Workout Placebo
3045894|NCT02255188||Graft type - PCL|PCL - polycaprolactone
3045895|NCT02255188||Graft type - PCL/ gelatin|polycaprolactone/ gelatin/poorly permeable layer;
3045896|NCT02255188||Graft type - PLGA/PCL/gelatin|PLGA/PCL/gelatin - polylactide-co-glycolide / polycaprolactone / gelatin/poorly permeable layer
3045897|NCT02255188||Graft type - nylon 6|
3045898|NCT02255175|Experimental|Perimenopausal women, depressed|Participants will receive transdermal estradiol (100μg/day) for 3 weeks. Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
3045899|NCT02255175|Active Comparator|Perimenopausal women, non-depressed|Participants will receive transdermal estradiol (100μg/day) for 3 weeks. Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
3045900|NCT02255162|Experimental|Lenalidomide|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Participants will receive the following:~Cytarabine-intravenous, fixed dosage, given 5 times during cycle~HLA-mismatched stem-cell microtransplantation~Lenalidomide-administered daily per cycle"
3045901|NCT02255149|Experimental|Bone/Mesh|Allograft and Titanium mesh will be used to grow jaw bone vertically.
3045902|NCT02255136|Experimental|Individualized homeopathic medicines|Psorinum, Tuberculinum, Medorrhinum, Calcarea carbonica, Natrum sulphuricum etc. as indicated; Rescue medicines, e.g. Aralea racemosa, Arsenicum album, Histamine hydrochloride, House dust, Ipecacuanha, Antimonium tartaricum, Grindelia robusta etc. as indicated; 5 ml dose of indicated homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; administered twice daily for 1 year
3045903|NCT02255136|Placebo Comparator|Intervention placebo|5 ml dose made up of single drop of rectified spirit in 5 ml distilled water, identical in appearance of homeopathic medicine, to be administered twice daily for 1 year
3045904|NCT02255110|Experimental|TH-302 and doxorubicin|
3045905|NCT02255097|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 24 months
3045906|NCT02255084|Experimental|Group 1|"Group 1 remove self sample kit at gp consulting room or perform pap smear :~Study coordinators send mail inviting women to remove a kit for vaginal self-sampling at their general practitioner s consulting room.~Either a pap smear is perform or, at home, women perform vaginal self sampling. Then women send it to a central laboratory for HPV test (Human papillomaVirus)."
3045907|NCT02255084|Experimental|Group 2|"Group 2 perform self sample at home or pap smear :~Kit for vaginal self-sampling sent at women home. Women perform vaginal self sampling. Then women send it to a central laboratory for HPV test (Human papillomaVirus)."
3045908|NCT02255071|Experimental|Acupressure|Patients will band a acupressure wristband over Neiguan (P6 point) and acupressure for seven days.
3045909|NCT02255071|Sham Comparator|Sham-Acupressure|Patients will band a sham wristband over wrist but no acupressure for seven days.
3045910|NCT02255045|Experimental|Dose 1 of vaginal ring|2.4 g of meloxicam in a vaginal ring
3045911|NCT02255045|Experimental|Dose 2 of vaginal ring|3.0 g of meloxicam in a vaginal ring
3045912|NCT02255045|Active Comparator|oral non-steroidal anti-inflammatory drug|Potassium diclofenac
3045913|NCT02255045|Placebo Comparator|vaginal ring or oral pill|Placebo vaginal ring or placebo oral pill
3045914|NCT02255032|Experimental|4 mg CLS-TA|Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
3045915|NCT02255032|Experimental|0.8 mg CLS-TA|Single unilateral, suprachoroidal injection of 8 mg/mL (0.8 mg in 100 µL) of CLS-TA
3045916|NCT02255019||IBD, CD, UC|All patients should either have a known IBD diagnose or suspect of having IBD.
3045917|NCT02255006|Experimental|active acupuncture|The participants in this group receive real acupuncture treatment at first. Afterwards crossover study is scheduled to be performed.
3045918|NCT02255006|Sham Comparator|Sham acupuncture|The participants in this group receive sham acupuncture treatment at first. afterwards crossover study is scheduled to be performed
3045919|NCT02255006|Experimental|Euglycon|Glibenclamide (Euglucon, Roche Pharma) is administered 3 hours before FMD measurement.
3045920|NCT02255006|Experimental|Celebrex|Celebrex(celecoxib, pfizer) 200mg twice daily is administered for 5 days before FMD measurement.
3045921|NCT02254993|Experimental|Arm 1- Part A|One 30-minute C16G2 tray gel application (3.2 mg/mL) over the course of five days
3045922|NCT02254993|Experimental|Arm 2 - Part A|One 4-hour C16G2 tray gel application (3.2 mg/mL) over the course of five days
3045923|NCT02254993|Experimental|Arm 3- Part A|A single 4-hour C16G2 tray gel application (3.2 mg/mL)
3045924|NCT02254993|Experimental|Arm 4- Part A|One 4-hour C16G2 tray gel application (1.6 mg/mL) over the course of five days
3045925|NCT02254993|Experimental|Arm 5- Part A|One 30-minute C16G2 tray gel application (1.6 mg/mL) over the course of five days
3045926|NCT02254993|Experimental|Arm 6- Part A|One 5-minute C16G2 tray gel application (3.2 mg/mL) over the course of five days
3045927|NCT02254993|Experimental|Arm 1 - Part B|Four manual brush gel applications on Day 0 followed by twice daily manual brush gel applications (Days 1 through 6); total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
3046203|NCT02253290||Neuromuscular disease|Children and adolescents with Neuromuscular disease children according to neuromuscular convention UZL
3045928|NCT02254993|Experimental|Arm 2 - Part B|Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
3045929|NCT02254993|Experimental|Arm 3a or 3b or 3c - Part B|"Based on the microbiology review, one of 3 study arms will be conducted:~Arm 3a: Four manual brush gel applications on Day 0 followed by twice daily manual brush applications (Days 1 through 6); total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL~Arm 3b: Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL~Arm 3c: Three daily manual brush and/or tray gel applications for 7 days, lower C16G2 concentration of 1.6 mg/mL"
3045930|NCT02254993|Experimental|Arm 4a or 4b - Part B|"Based on the microbiology review, one of 2 study arms will be conducted:~Arm 4a: Four manual brush gel applications on Day 0 followed by twice daily manual brush applications (Days 1 through 6); total of 7-day study drug administration, C16G2 concentration of 1.6 mg/mL and lower gel volume~Arm 4b: Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL and lower gel volume"
3045931|NCT02254993|Experimental|Arm 5 - Part B|Arm 5: Three manual brush gel applications followed by one tray gel application on Day 0, 3.2 mg/mL C16G2 gel concentration.
3045932|NCT02254980|Experimental|Vitamin-E group|Vitamin-E diffused polyethylene
3045933|NCT02254980|Active Comparator|Control group|Standard polyethylene
3045934|NCT02254967|Experimental|Fidaxomicin Extended Pulsed Regimen (EPFX)|Participants receive 200 mg fidaxomicin from day 1 to day 5 twice daily, followed by a 1-day gap (day 6) before starting alternate day dosing of 1 tablet of fidaxomicin 200 mg once daily from day 7 to day 25.
3045935|NCT02254967|Experimental|Vancomycin|Participants receive 125 mg vancomycin from day 1 to day 10, 4 times daily.
3045936|NCT02254954|Experimental|Macitentan in combination with RT & TMZ|Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
3045937|NCT02254941||Active comparator: Chemotherapy|Metastatic colon cancer and first line treatment with conventional chemotherapy without monoclonal antibody.
3045938|NCT02254941||Experimental: Chemotherapy plus mAb|Metastatic colon cancer and first line treatment with conventional chemotherapy plus monoclonal antibody
3045939|NCT02254928|Other|Group 1|First stimulation cycle with corifollitropin alfa (experimental) Second stimulation cycle with rFSH and HMG (active comparator)
3045940|NCT02254928|Other|Group 2|First stimulation cycle with rFSH and HMG (active comparator) Second stimulation cycle with corifollitropin alfa (experimental)
3045941|NCT02254915|Experimental|Synergo + MMC|Synergo radiofrequency (RF)-Induced hyperthermia-chemotherapy (SHTC) with mitomycin C (RITE) intravesical therapy as first-line adjuvant treatment for intermediate and high-risk NMIBC,
3045942|NCT02254915|Active Comparator|Bacillus Calmette-Guérin|Intravesical BCG therapy as first-line adjuvant treatment for intermediate and high-risk NMIBC,
3045943|NCT02254902|Experimental|Physical Activity|Participants in the Physical Activity intervention arm of the study receive culturally-modified, materials through participation in 12 weekly 1-.5-hour sessions focused on increasing daily step counts and bouts of moderate intensity physical activity. The group sessions include participation in different forms of physical activity as well as group discussions on the barriers and opportunities for increasing physical activity in daily life.
3045944|NCT02254902|No Intervention|Wait List Control|Participants in the Wait List Control will be offered the program after a 3-month wait period. While waiting for the program, participants are offered to attend monthly sessions on various wellness and prevention topics.
3045945|NCT02254889|Active Comparator|pre-ESD group|All subjects were randomly assigned to treatment with intravenous proton pump inhibitor (PPI) before ESD.
3045946|NCT02254889|Placebo Comparator|post-ESD group|All subjects were randomly assigned to treatment with intravenous proton pump inhibitor (PPI) after ESD.
3045947|NCT02254876|Active Comparator|Standard physical therapy program|Standard physical therapy program is delivered for four rehabilitation sessions for a period of about 45 minutes each.
3045948|NCT02254876|Experimental|NeuroMuscular Taping (NMT)|"NeuroMuscular Taping is delivered in addiction to the Standard Treatment for four rehabilitation sessions. The sessions were spaced apart about five days to ensure the optimum adhesion of the NMT."
3045949|NCT02254863|Experimental|Intrathecal administration of DUOC-01|Administration of DUOC-01, given intrathecally, between day 26 and 28 post unrelated cord blood transplant
3045950|NCT02254850|Experimental|Mesoglycan|"The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml and inactive ingredients: sodium chloride, chlorocresol, water for injections.~Nextly the patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg and Inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.~Patients also performed Flow Mediated Dilation (FMD)."
3045951|NCT02254850|Placebo Comparator|Placebo|"The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.~Nextly the patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.~Patients also performed Flow Mediated Dilation (FMD)."
3045952|NCT02254837|Experimental|Zilver PTX|
3045953|NCT02254824|Active Comparator|Normal-dose statin|Lifestyle modification with Normal-dose statin
3045954|NCT02254824|Active Comparator|Lifestyle modification + Xuezhikang|Lifestyle changes with Xuezhikang
3045955|NCT02254824|Active Comparator|Lifestyle modification|Lifestyle modification
3045956|NCT02254811|Experimental|Delivery via capsule|Fecal microbiota transplant is delivered by oral capsules
3045957|NCT02254811|Experimental|Delivery via colonoscopy|Fecal microbiota transplant delivered by colonoscopy
3045958|NCT02254798||Transplanted patients|No intervention Prospective registration of patients receiving an allogeneic hematopoietic stem cell transplant
3045959|NCT02254785|Experimental|Cabazitaxel|
3045961|NCT02254772|Experimental|Treatment|Patients receive TLR9 agonist SD-101 via intratumoral injections; ipilimumab via intratumoral injection; and undergo radiation therapy on days 1 and 2.
3045962|NCT02254759|Other|IV Midazolam Alone|A single 1 milligram (mg) dose of IV Midazolam on Day 1.
3045963|NCT02254759|Other|Oral Midazolam Alone|A single 5 mg oral dose of midazolam on Day 2.
3045964|NCT02254759|Experimental|RO5186582 Alone|RO5186582 240 mg oral tablet twice daily (BID) for 14 days from Days 3 to 16.
3045965|NCT02254759|Experimental|RO5186582 Plus IV Midazolam|RO5186582 240 mg BID oral tablet in combination with a single 1 mg IV dose of midazolam on Day 17.
3045966|NCT02254759|Experimental|RO5186582 Plus Oral Midazolam|RO5186582 240 mg BID in combination with a single 5 mg oral dose of midazolam on Day 18.
3045967|NCT02254746|Experimental|Phase I (dose escalation)/ Phase II|"Phase I~Prostate tumor: starting dose 9 Gy per fraction in 5 fractions (total 45 Gy) and subsequent dose escalation up to 10 Gy.~Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions (no dose escalation). Total 36.25 Gy.~Phase II~Additional patients will be treated at either the maximum tolerated dose (MTD) or at the highest dose level as determined by the investigators from the Phase I portion of the study."
3045968|NCT02254733|Experimental|ACT + CBSST|Implementing Cognitive Behavioral Social Skills Training in an Assertive Community Treatment model
3045969|NCT02254733|Active Comparator|ACT only|Assertive Community Treatment only
3045970|NCT02254720|Experimental|BEA 2180 BR IV|Rising doses
3045971|NCT02254720|Placebo Comparator|Placebo|
3045972|NCT02254720|Experimental|BEA 2180 BR inhalation|
3045973|NCT02254707|Experimental|BILB 1941 ZW|Escalating Doses
3045974|NCT02254707|Placebo Comparator|Placebo|
3045975|NCT02254694|Experimental|high heeled shoes|see detailed description
3045976|NCT02254681|Experimental|Treatment|Four three-week treatment cycles. Gemcitabine (1000 gm/m^2) and cisplatin (25 mg/m^2) administered on days one and eight of each cycle. Whole liver and portal lymph node basin low dose radiotherapy on days one, two, eight, and nine of each cycle.
3045977|NCT02254668|Experimental|Everolimus (Certican®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®). No protocol with Mycophenolate mofetil (CellCept®). Daily dosage administered depending on blood concentration (control interval 6-12 months)
3045978|NCT02254668|Active Comparator|Mycophenolate mofetil (CellCept®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®). No protocol with Everolimus (Certican®). Daily dosage administered depending on blood concentration (control interval 6-12 months)
3045979|NCT02254655|Experimental|Puerarin injection 400 mg|Patients were administrated with 400 mg intravenously infused puerarin injection once a day. Puerarin injection was prepared in 250 mL 0.9% sodium chloride injection before the use. The treatment course consisted of 2 weeks followed by a 15-day interval for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
3045980|NCT02254655|Sham Comparator|Control|Patients receive routine anti-rheumatic care only. Patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
3045981|NCT02254642|Experimental|Ischemic preconditioning arm|Patients will have the ischemic preconditioning protocol 1 hour before the aortic clamping.
3045982|NCT02254642|Other|Control patients|Usual surgery assigned to control patients
3045983|NCT02254629|Experimental|laxative-probiotic sequential|laxative：2000 ml. Probiotic：2 tablets/ times, 3 times / day for the first 2 weeks，immediately after colonoscopy
3045984|NCT02254629|Active Comparator|probiotic|Probiotic：2 tablets/ times, 3 times / day for the first 2 weeks.
3045985|NCT02254629|Active Comparator|Laxative followed by Probiotic 2 weeks later|laxative：2000 ml. Probiotic：2 tablets/ times, 3 times / day for the last 2 weeks with two weeks interval after colonoscopy.
3045986|NCT02254616|Experimental|Mirror therapy with tDCS|
3045987|NCT02254616|Sham Comparator|Mirror therapy with sham-tDCS|
3045988|NCT02254616|Active Comparator|Mirror Therapy|
3045989|NCT02254616|Active Comparator|Control Intervention|
3045990|NCT02254603|Other|Acupuncture controls|Acupuncture group will receive 30-minutes treatment three times a week for 3 months.
3045991|NCT02254603|Experimental|acupuncture and yoga exercise|Subject will receive a combination of acupuncture and yoga exercise three times a week for 3 months.
3045992|NCT02254590|Experimental|IEDL|Endoscopic decompression of spinal stenosis
3045993|NCT02254577|Experimental|Endometrin® plus Progesterone in Oil (PIO)|Subjects in all arms will undergo the standard monitoring appointments and therapies involved in a frozen embryo transfer cycle. Patients randomized to the Endometrin® plus PIO arm will take progesterone as 2 100mg tablets of Endometrin® inserted vaginally twice daily. In addition, on the first day of Endometrin® therapy, patients randomized to this arm will take a 50mg intramuscular injection (1mL) of PIO and will repeat this injection every third day. Patients in this arm will undergo Frozen Embryo Transfer on the fifth day of Endometrin® therapy.
3045994|NCT02254577|Active Comparator|Progesterone in Oil (PIO) Alone|Subjects in all arms will undergo the standard monitoring appointments and therapies involved in a frozen embryo transfer cycle. Patients randomized to the PIO Only arm will take progesterone as a daily 50mg intramuscular injection (1mL) of PIO and will undergo Frozen Embryo Transfer on the sixth day of taking this medication.
3045995|NCT02254564||Positive Scrapings|Skin scrapings that are positive for scabies
3045996|NCT02254564||Negative Controls|collect negative controls from patients in whom tinea (superficial fungal infection) was clinically suspected. Samples from patients with demodex folliculitis (a mite that is commonly found in oil glands on the face) are also intended to be used as negative controls as well.
3046030|NCT02254369|Placebo Comparator|Cohort 4- placebo|single dose, 1.4 mg/kg subjects will receive matching placebo under fasting then under fed conditions separated by a washout of 14 (+/- 1) days after the first dose.
3046031|NCT02254369|Placebo Comparator|Cohort 5- placebo|single dose, 4.2 mg/kg matching placebo
3046032|NCT02254356|Experimental|Zilver|
3045997|NCT02254551|Experimental|LDE225 Plus Bortezomib|"Lead-In Portion: The lead-in portion of this study will investigate the safety and tolerability, and determine the MTD of LDE225, in combination with bortezomib in this patient population.~Expansion Portion: Eligible patients will receive LDE225 orally once daily for 21 days with the dose-level determined in the lead-in portion of the study. Eligible patients will also receive a standard regimen of bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of each 21 day cycle.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
3045998|NCT02254538|Experimental|BILR 355 BS|escalating doses
3045999|NCT02254538|Placebo Comparator|Placebo|
3046000|NCT02254525|Experimental|800 mg intravenous ibuprofen|Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours, infused over 15 minutes.
3046001|NCT02254525|Placebo Comparator|200 ml of saline solution|Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours, infused over 15 min.
3046002|NCT02254486|Experimental|NER1006, 2-Day Split-Dosing|NER1006:2-Day Split-Dosing Regimen (to commence in the evening of the day before the colonoscopy)
3046003|NCT02254486|Active Comparator|Trisulfate Solution, 2-Day Split-Dosing|Trisulfate Solution 2-Day Split-Dosing Regimen (to commence in the evening of the day before the colonoscopy)
3046004|NCT02254473|Experimental|Wedge Insert|Patients will receive a wedge insert
3046005|NCT02254473|Placebo Comparator|Flat insert|Patients will receive a flat insert
3046006|NCT02254460|Experimental|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
3046007|NCT02254460|Placebo Comparator|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
3046008|NCT02254447|Experimental|Sequence ABC|Subjects in this arm will receive single dose of treatment A in period 1, treatment B in period 2 and treatment C in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
3046009|NCT02254447|Experimental|Sequence ACB|Subjects in this arm will receive single dose of treatment A in period 1, treatment C in period 2 and treatment B in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
3046010|NCT02254447|Experimental|Sequence BAC|Subjects in this arm will receive single dose of treatment B in period 1, treatment A in period 2 and treatment C in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
3046011|NCT02254447|Experimental|Sequence BCA|Subjects in this arm will receive single dose of treatment B in period 1, treatment C in period 2 and treatment A in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
3046012|NCT02254447|Experimental|Sequence CAB|Subjects in this arm will receive single dose of treatment C in period 1, treatment A in period 2 and treatment B in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
3046013|NCT02254447|Experimental|Sequence CBA|Subjects in this arm will receive single dose of treatment C in period 1, treatment B in period 2 and treatment A in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
3046014|NCT02254434|Experimental|Eltrombopag 50 mg|Each volunteer will receive orally, single dose of tablet eltrombopag 50 mg under fasting conditions
3046015|NCT02254421|Experimental|Presatovir|Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
3046016|NCT02254421|Placebo Comparator|Placebo|Participants will receive placebo to match presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
3046017|NCT02254408|Experimental|Presatovir|Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
3046018|NCT02254408|Placebo Comparator|Placebo|Participants will receive placebo on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
3046019|NCT02254395|Experimental|Deep Brain Stimulation|Stimulation is on.
3046020|NCT02254395|Sham Comparator|Placebo|Sham Stimulation: Stimulation is off.
3046021|NCT02254382|Experimental|Adaptive servo ventilation (ASV)|This group will receive ventilation therapy (AutoSet CS, ASV device)
3046022|NCT02254369|Experimental|Cohort 1- GC021109|single dose, 0.0014 mg/kg GC021109
3046023|NCT02254369|Experimental|Cohort 2- GC021109|single dose, 0.014 mg/kg GC021109
3046024|NCT02254369|Experimental|Cohort 3-GC021109|single dose, 0.14 mg/kg GC021109
3046025|NCT02254369|Experimental|Cohort 4- GC021109|single dose, 1.4 mg/kg GC021109 subjects will receive GC021109 under fasting then under fed conditions separated by a washout of 14 (± 1) days after the first dose.
3046026|NCT02254369|Experimental|Cohort 5- GC021109|single dose, 4.2 mg/kg GC021109
3046027|NCT02254369|Placebo Comparator|Cohort 1- placebo|single dose, 0.0014 mg/kg matching placebo
3046028|NCT02254369|Placebo Comparator|Cohort 2- placebo|single dose, 0.014 mg/kg matching placebo
3046029|NCT02254369|Placebo Comparator|Cohort 3- placebo|single dose, 0.14 mg/kg matching placebo
3046236|NCT02253082|Active Comparator|OctaplasLG®|replacement to bleeding
3046033|NCT02254343|Experimental|proximal robot-assisted therapy|treatment programs will target to shoulder and elbow portions of upper extremity via the InMotion2 robotic system
3046034|NCT02254343|Experimental|distal robot-assisted therapy|the InMotion3 robot system will be used to execute treatment programs focus on wrist movements. It includes three degrees of freedom to allow wrist flexion/extension, abduction/adduction, and pronation/supination.
3046035|NCT02254343|Active Comparator|individualized intensive therapy|individualized occupational therapy which is dose-match to robot-assisted therapy, based on task-oriented principle.
3046036|NCT02254317|Placebo Comparator|0 mg placebo|Not containing GSE (Placebo)
3046037|NCT02254317|Active Comparator|300 mg GSE|Containing 300 mg of GSE
3046038|NCT02254317|Active Comparator|600 mg GSE|Containing 600 mg of GSE
3046039|NCT02254317|Active Comparator|900 mg GSE|Containing 900 mg of GSE
3046040|NCT02254304|Experimental|Rebif in Relapsing Multiple Sclerosis (RMS) Subjects|
3046041|NCT02254304|Experimental|Rebif in Clinically Isolated Syndromes (CIS) Subjects|
3046042|NCT02254291|Experimental|Semaglutide 0.5 mg|
3046043|NCT02254291|Experimental|Semaglutide 1.0 mg|
3046044|NCT02254291|Active Comparator|Sitagliptin 100 mg|
3046045|NCT02254278|Experimental|Arm I (IMRT, cisplatin)|Patients undergo IMRT QD five days a week for 6 weeks to a total dose of 60 Gy and receive cisplatin IV over 30-60 minutes weekly during radiation therapy for 6 doses in the absence of disease progression or unacceptable toxicity.
3046046|NCT02254278|Experimental|Arm II (IMRT)|Patients undergo IMRT five days a week for 5 weeks to a total dose of 60 Gy in the absence of disease progression or unacceptable toxicity.
3046047|NCT02254265|Experimental|OTX-101 0.05%|OTX-101 0.05% ophthalmic solution 1 drop in both eyes BID for 84 days
3046048|NCT02254265|Experimental|OTX-101 0.09%|OTX-101 0.09% ophthalmic solution 1 drop in both eyes BID for 84 days
3046049|NCT02254265|Placebo Comparator|Vehicle|Vehicle of OTX-101 ophthalmic solution 1 drop in both eyes BID for 84 days
3046050|NCT02254252|Active Comparator|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
3046051|NCT02254252|Active Comparator|Nicorandil|nicorandil (10mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
3046052|NCT02254239|Experimental|Treatment (everolimus, brentuximab vedotin)|"Patients receive brentuximab vedotin IV over 30 minutes on day 1 and everolimus PO QD or QOD on days 1-21. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity. Patients then receive brentuximab vedotin IV over 30 minutes on day 1 and everolimus PO QD or every other day on days 1-84 for 1 course.~MAINTENANCE THERAPY: Beginning on course 17, patients receive everolimus PO QD, QOD, twice weekly, or thrice weekly on days 1-84. Courses repeat every 84 days in the absence of disease progression and unacceptable toxicity."
3046053|NCT02254226|Experimental|Salmeterol MDI low|
3046054|NCT02254226|Active Comparator|Salmeterol MDI high|
3046055|NCT02254226|Experimental|Salmeterol Diskus low|
3046056|NCT02254226|Experimental|Salmeterol Diskus high|
3046057|NCT02254200|Experimental|Fatmax group|Group who performed a continuous training program at the intensity eliciting the maximal fat oxidation
3046058|NCT02254200|Experimental|HIIT group|Group who performed a continuous training program with high intensity interval
3046059|NCT02254187|Experimental|Salmeterol capsule via Handihaler - low|
3046060|NCT02254187|Experimental|Salmeterol capsule via Handihaler - high|
3046061|NCT02254187|Active Comparator|Salmeterol via Serevent® Diskus®|
3046062|NCT02254174|Experimental|Tiotropium/Salmeterol|
3046063|NCT02254174|Active Comparator|Serevent® Diskus®|
3046064|NCT02254174|Active Comparator|Spiriva®|
3046065|NCT02254174|Active Comparator|Spiriva® and Serevent® Diskus®|
3046066|NCT02254161|Experimental|BI 1181181 healthy young|Medium doses as tablets q.d. for 10 days
3046067|NCT02254161|Experimental|BI 1181181 healthy elderly|Medium doses as tablets q.d. for 10 days
3046068|NCT02254161|Placebo Comparator|Matching placebo in healthy young|Matching placebo for 10 days
3046069|NCT02254161|Placebo Comparator|Matching placebo in healthy elderly|Matching placebo for 10 days
3046070|NCT02254148|Experimental|Treatment|single dose of CYP 450 substrates and a P-gp substrate + multiple doses of BI 187004
3046071|NCT02254135|Experimental|BEA 2180 BR solution - rising dose|
3046072|NCT02254135|Placebo Comparator|Placebo|
3046073|NCT02254122|Experimental|BEA 2180 BR|
3046074|NCT02254122|Placebo Comparator|Placebo|
3046075|NCT02254109|Experimental|BEA 2180 BR - rising dose|
3046076|NCT02254109|Placebo Comparator|Placebo|
3046077|NCT02254096|Experimental|BIRT 1696 BS|single escalating dose phase
3046078|NCT02254096|Experimental|BIRT 1696 BS + GFJ|single dose grapefruit effect arm
3046079|NCT02254096|Experimental|BIRT 1696 BS + HFM|single dose food effect arm
3046080|NCT02254096|Placebo Comparator|Placebo|
3046081|NCT02254083|Experimental|BIBT 986 BS - low|
3046082|NCT02254083|Experimental|BIBT 986 BS - high|
3046083|NCT02254083|Placebo Comparator|Placebo|
3046084|NCT02254070|Experimental|BIBT 986 BS|
3046085|NCT02254057|Experimental|BIBT 986 BS - single rising dose|
3046086|NCT02254057|Placebo Comparator|Placebo|
3046087|NCT02254044|Experimental|bivatuzumab mertansine|dose escalation
3046088|NCT02254031|Experimental|bivatuzumab mertansine|dose escalation
3046089|NCT02254018|Experimental|bivatuzumab mertansine|single dose escalation
3046090|NCT02254005|Experimental|single dose escalation|
3046091|NCT02253992|Experimental|Dose Escalation and Cohort expansion: Urelumab + Nivolumab|"Nivolumab followed by Urelumab~Nivolumab every 2 weeks up to 12 cycles and Urelumab every 4 weeks up to 6 cycles"
3046092|NCT02253979|Placebo Comparator|standard double lumen tube|Intervention: Standard double lumen tube
3046093|NCT02253979|Experimental|VivaSight double lumen tube|Intervention: VivaSight double lumen tube
3046094|NCT02253966|Active Comparator|Methylprednisoloneacetate|"Administration of:~1 ml methylprednisoloneacetate 40 mg/ml 5 ml lidocaine 20 mg/ml 4 ml sodium chloride 9 mg/ml as a single intraarticular injection 7 days prior to surgery."
3046095|NCT02253966|Placebo Comparator|Sodium chloride|"Administration of:~5 ml lidocaine 20 mg/ml 5 ml sodium chloride 9 mg/ml as a singe intraarticular injection 7 days prior to surgery."
3046096|NCT02253953|Experimental|D1|
3046097|NCT02253953|Experimental|D2|
3046098|NCT02253953|Experimental|D3|
3046099|NCT02253953|Experimental|D4|
3046100|NCT02253953|Experimental|D5|
3046101|NCT02253953|Experimental|D6|
3046102|NCT02253953|Experimental|D7|
3046103|NCT02253953|Experimental|D8|
3046104|NCT02253953|Experimental|D10|
3046105|NCT02253953|Placebo Comparator|Placebo|for D3 - D10
3046106|NCT02253940|Experimental|Dose Group 1 - low dose|Treatment sequences ABC / CAB / BCA
3046107|NCT02253940|Experimental|Dose Group 2 - high dose|Treatment sequences DE / ED
3046108|NCT02253927|Experimental|BILR 355 (dose escalation) + Ritonavir|escalating dose groups, for food effect evaluation lowest dose group (D1) with high fat meal breakfast after wash-out period
3046109|NCT02253914|Experimental|BILR 355 BS, solution|escalating doses
3046110|NCT02253914|Experimental|BILR 355 BS, tablet|escalating doses
3046111|NCT02253914|Placebo Comparator|Placebo|
3046112|NCT02253901|Experimental|TRUVADA with BILR 355 BS and ritonavir|
3046113|NCT02253901|Active Comparator|BILR 355 BS in combination with ritonavir|
3046114|NCT02253888|Experimental|TPV/r - Room condition|
3046115|NCT02253888|Experimental|TPV/r - Refrigerated conditions|
3046116|NCT02253875|Experimental|TPV + RTV + Omeprazole|
3046117|NCT02253862|Experimental|Sequential treatment|
3046118|NCT02253849|Experimental|CBZ - TPB/r+CBZ|"Days 1-14: carbamazepine (CBZ) twice daily~Days 15-22: CBZ twice daily plus TPV/r twice daily"
3046119|NCT02253836|Experimental|TAZ/RTV - TPV/RTV - TPV/RTV+TAZ|"Days 1-9: single dose TAZ/RTV~Days 16-23: morning and evening dose TPV/RTV~Days 24-32: TPV/RTV + TAZ"
3046120|NCT02253823|Experimental|TPV+RTV - low dose|
3046121|NCT02253823|Experimental|TPV+RTV - high dose|
3046122|NCT02253810|Experimental|Tranexamic Acid|Patients randomized to this arm will receive standard dosing of tranexamic acid intraoperatively.
3046123|NCT02253810|Placebo Comparator|Placebo|Patients randomized to this arm will receive normal saline solution, instead of tranexamic acid, intraoperatively.
3046124|NCT02253797|Experimental|TPV/r followed by 14C-radiolabeled TPV|Tipranavir/Ritonavir dosed to steady state followed by single-dose 14C-radiolabeled tipranavir co-administered with Tipranavir/Ritonavir
3046125|NCT02253784|Active Comparator|Group I (ISB-P)|Four nerve blocks with perineural injection of dexamethasone 0.1 mg/kg and bupivacaine 0.5% - 45 ml
3046126|NCT02253784|Active Comparator|Group II (ISB-S)|Four nerve blocks with systemic injection of dexamethasone 0.1 mg/kg and bupivacaine 0.5% - 45 ml
3046127|NCT02253784|Active Comparator|Group III (ISB-C)|Four nerve blocks without dexamethasone
3046128|NCT02253771|Experimental|shockwave therapy|shockwave therapy
3046129|NCT02253771|Placebo Comparator|Placebo treatment|sham shockwave therapy by an identically looking device without any function
3046130|NCT02253758|Experimental|Sedation|Volunteers will be sedated to Ramsay score 4-5 with propofol, and data will be recorded during arousal
3046131|NCT02253745|Experimental|Placebo:V81444|Placebo followed by a 7 day washout then V81444
3046132|NCT02253745|Experimental|V81444:placebo|V81444 followed by a 7 day washout then Placebo
3046133|NCT02253732|Experimental|'3 months exercise intervention program'|all participants will be subjected to 3 months supervised exercise intervention programme
3046134|NCT02253719||HIV positive women|500 HIV women will be recruited from the hospital's current patient base as well as the community
3046135|NCT02253719||HIV negative women|500 HIV women will be recruited from the hospital's current patient base as well as the community
3046136|NCT02253706|Active Comparator|Low flow nasal oxygen supplementation|Low flow nasal oxygen supplementation as per routine standard of care(control arm)
3046137|NCT02253706|Experimental|High flow nasal oxygen supplementation|High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35
3046138|NCT02253693||Patients with haemophilia|Adult patients with haemophilia A presenting joint disease.
3046139|NCT02253680|No Intervention|Routine care|Wool and crepe bandage for 24 hours post-operatively
3046140|NCT02253680|Experimental|Compression bandage|Actico, inelastic, short-stretch compression bandage worn 24 hours post-operatively
3046141|NCT02253667|Experimental|HFONC|Patient will use HFONC with FiO2 enough to achieve SpO2>90%. If needed, morphine is titrated to reduce a patient's dyspnoea score by at least one point on the Borg scale and to achieve at least level 5 or less. Initial dose: 10 mg, repeated every 4h until the desired reduction in dyspnoea is obtained. In the case of refractory dyspnoea, the dose is increased by 50%.
3046142|NCT02253667|Other|Conventional oxygen|Patient will use venturi or reservoir mask with FiO2 enough to achieve SpO2>90%. If needed, morphine is titrated to reduce a patient's dyspnoea score by at least one point on the Borg scale and to achieve at least level 5 or less. Initial dose: 10 mg, repeated every 4h until the desired reduction in dyspnoea is obtained. In the case of refractory dyspnoea, the dose is increased by 50%.
3046143|NCT02253654|Experimental|Epoetin alfa Alternative Titration|Participants received epoetin alfa administered intravenously three times a week during hemodialysis for up to 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose changes may have occurred every 2 weeks according to the alternative dosing algorithm, where smaller, frequent dose adjustments were permitted based on six hemoglobin categories.
3046167|NCT02253511|Experimental|Cidan capsule|Patients who undergone operation and TACE were administered 1.35 g cidan capsules (Weida Pharmaceutical Co., Ltd., Beijing, China) three times a day for 3 months.
3046168|NCT02253511|No Intervention|Control group|Patients were only accepted operation and TACE.
3046144|NCT02253654|Active Comparator|Epoetin alfa USPI Titration|Participants received epoetin alfa administered intravenously three times a week during hemodialysis for 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose decreases were permitted every 2 weeks and beginning at week 5 dose increases could only occur ≥ 4 weeks from the last dose increase, according to the United States package insert (USPI) dosing algorithm which includes four categories of hemoglobin levels.
3046145|NCT02253641|Active Comparator|Standard Weight Loss Intervention|"Participants will take part in a 14 session weight loss/healthy lifestyle intervention. Sessions will be 2 hours in length and will occur weekly for month 1 then bi-weekly for months 2 - 6. The core lifestyle curriculum content for both groups will come from the previously IRB-approved Weight Wise intervention developed by Samuel-Hodge et al. (Samuel-Hodge, Carmen D., et al. Randomized Trial of a Behavioral Weight Loss Intervention for Low?income Women: The Weight Wise Program. Obesity 17.10 (2009): 1891-1899). The only modifications to the content (other than some general formatting) will be the combining of sessions 3 and 4 and sessions 6 and 7. These changes will allow us to fit the original 16-session curriculum into the 14-session format of our intervention."
3046146|NCT02253641|Experimental|Stress-Focused Weight Loss Intervention|Participants will take part in a 14 session weight loss/healthy lifestyle intervention. Sessions will be 2 hours in length and will occur weekly for month 1 then bi-weekly for months 2 - 6. The core lifestyle curriculum content for both groups will come from the previously IRB-approved Weight Wise intervention developed by Samuel-Hodge et al.. The participants in this arm will receive all of the content that the comparison group receives (just moderately condensed to allow time for additional components) plus a stress-reduction intervention woven into each of the sessions. The stress-reduction content aims to reduce stress by helping participants: (1) identifying and reducing exposure (to the degree possible) of current stressors, (2) change their perceptions of current stressors and (3) use healthier stress-coping techniques (e.g. yoga, meditation, etc.)
3046147|NCT02253628|Experimental|Trial 1|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
3046148|NCT02253628|Experimental|Trial 2|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
3046149|NCT02253628|Experimental|Trial 3|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
3046150|NCT02253628|Experimental|Trial 4|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
3046151|NCT02253615|Active Comparator|Machine resistance training (MRT)|The machine resistance training will consist of four exercises for lower limbs and four exercises for upper limbs which will be alternately performed with a one-minute interval between them during familiarization and training periods. Lower limb exercises will consist of: hip extension and abduction, and knee flexion and extension. Upper limb exercises will consist of: bench press, rowing, triceps and high pulley exercise.
3046152|NCT02253615|Experimental|Elastic resistance training (ERT)|The elastic resistance training will consist of four exercises for lower limbs and four exercises for upper limbs which will be alternately performed with a one-minute interval between them during familiarization and training periods. Lower limb exercises will consist of: hip extension and abduction, and knee flexion and extension. Upper limb exercises will consist of: bench press, rowing, triceps and high pulley exercise.
3046153|NCT02253602|Experimental|Ferumoxytol Dose optimization|"We will assess three different dose levels of Ferumoxytol (4 mg/kg, 6 mg/kg, 8 mg/kg).~Images will be acquired at baseline (before Ferumoxytol administration), during injection of Ferumoxytol and 24, 48 and 72 hours after Ferumoxytol administration to identify the optimal moment of scanning.To assess whether USPIOs are sufficiently cleared within 12 weeks from lymph nodes, the MRI scans will be repeated in all six volunteers at 12 weeks after Ferumoxytol administration. Thus, volunteers will undergo an MRI scan for five times. Ferumoxytol is administered only once"
3046154|NCT02253602|Experimental|Before Surgery|Twenty patients will be measured directly before surgery. Patients will be measured at baseline, during injection of Ferumoxytol and 24, 48 or 72 hours after Ferumoxytol administration, depending on the results of the dose optimization study. MR parameters will be correlated with pathology data.
3046155|NCT02253602|Experimental|Before Neoadjucant therapy|Ten patients will be measured before start of neoadjuvant chemoradiation. Patients will be measured at baseline, during injection of Ferumoxytol and 24, 48 or 72 hours after Ferumoxytol administration, based on the dose optimization study. MR parameters will be correlated with pathology data.
3046156|NCT02253589|No Intervention|Waiting list|Participants will assessment only during study, same intervention after posttest
3046157|NCT02253589|Experimental|Intervention|Participants assigned to this arm will receive the modified ASSIST-linked Brief Intervention
3046158|NCT02253576|Experimental|inhaled 7% hypertonic saline|Three consecutive 4ml doses of 7% NaCl solution with salbutamol(0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) nebulized over a 1-hour period
3046159|NCT02253576|Active Comparator|inhaled nebulized normal saline|Three consecutive 4ml doses of 0.9 NaCl solution added to salbutamol(0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) nebulized over a 1-hour period
3046160|NCT02253563|Experimental|Resistance Training|Group performing resistance training.
3046161|NCT02253563|Experimental|Balance Training|Group performing balance training.
3046162|NCT02253550|Experimental|Cirrhosis|Patients with confirmed presence of cirrhosis will received 12 weeks of treatment with Sofosbuvir and Simeprevir
3046163|NCT02253550|Experimental|Non-Cirrhotic|Patients with confirmed absence of cirrhosis will received 8 weeks of treatment with Sofosbuvir and Simeprevir
3046164|NCT02253537||Symptomatic|Patients with bacteriologically confirmed and untreated TB disease tested with CST001 assay.
3046165|NCT02253524|Active Comparator|Dimenhydrinate|50 mg Dimenhydrinate with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
3046166|NCT02253524|Active Comparator|Metoclopramide|10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
3046169|NCT02253498|Experimental|Deep Brain Stimulation|Deep Brain Stimulation is on
3046171|NCT02253485||telbivudine treated entire pregnancy|mothers in this group were treated with antiviral therapy during entire pregnancy for hepatitis, and their infants receive standard immunoprophylaxis for preventing MTCT of HBV.
3046172|NCT02253485||telbivudine treated in late pregnancy|mothers with high serum HBV DNA load were treated with antiviral therapy in late pregnancy, and their infants receive standard immunoprophylaxis for preventing MTCT of HBV.
3046173|NCT02253485||HBV DNA positive control|infants in this group born to mother with high serum HBV DNA load and receive standard immunoprophylaxis or additional HBIG injection at 1 month after birth for preventing MTCT of HBV.
3046174|NCT02253485||HBV DNA negative control|infants in this group born to a HBsAg positive and serum HBV DNA negative mothers and receive standard immunoprophylaxis for preventing MTCT of HBV
3046175|NCT02253472|Experimental|Deep Brain Stimulation|Stimulation is on.
3046176|NCT02253472|Sham Comparator|Placebo|Stimulation is off.
3046177|NCT02253459|Experimental|UTD1 Injection plus capecitabine|"UTD1 Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle; Capecitabine: 2000 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
3046178|NCT02253459|Active Comparator|capecitabine|"Capecitabine: 2500 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
3046179|NCT02253446|Experimental|Piroksikam|20 mg of piroxicam (feldene ampoule -Pfizer-France) intramuscularly (IM) was given 200 patients,
3046180|NCT02253446|Experimental|Diclofenac Sodium|Second Group: Diclofenac sodium 75mg (Miyadren drug-ampoule -Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
3046181|NCT02253433|No Intervention|Enhanced in-clinic care|This arm will receive enhanced in-clinic care that includes a standard clinical appointment as well as information from a detailed exposure history, asthma education, assessment for allergies, and a customized asthma self-management plan developed using motivational interviewing.
3046182|NCT02253433|Experimental|Enhanced in-clinic care and intervention|This arm receives enhanced in-clinic care, as well as a customized home-based environmental exposure assessment and multicomponent exposure reduction and asthma control intervention (five home visits over approximately 12 months).
3046183|NCT02253420|Experimental|Copanlisib with and without concomitant Itraconazole (Arm A)|"To evaluate the effect of Itraconazole on the pharmacokinetics of Copanlisib (BAY80-6946) and safety in patients with advanced solid tumor. Cycle 1 of the study will be conducted in 2 parts: Part 1 and part 2:~Part 1 of Cycle 1: 6 patients will be enrolled and will receive 12 mg of copanlisib on Day 1 and Day 15. Itraconazole 200 mg will be administered twice a day on Day 12 and then once daily from Days 13 to 21.~Part 2 of Cycle 1: 20 patients will be enrolled and receive copanlisib doses of either 12 mg, 30 mg or 60 mg on Days 1 and 15 with the same dose administered on both days. Copanlisib dose for Part 2 will be based on safety and copanlisib pharmacokinetics in Part 1. Itraconazole 200 mg will be administered twice a day on Day 12 and then once daily from Days 13 to 21.~Cycle 2 and subsequent cycles: All patients will receive copanlisib doses of 60 mg on Days 1, 8 and 15."
3046184|NCT02253420|Experimental|Copanlisib with and without concomitant Rifampin (Arm B)|"To evaluate the effect of Rifampin on the pharmacokinetics of Copanlisib (BAY 80-6946) and safety in patients with advanced solid tumor or non-Hodgkin's lymphoma in Cycle 1. Approximately 30 subjects will receive 60mg of copanlisib on Cycle 1 Day 1 and Cycle 1 Day 15. Rifampin will be administered once a day from Cycle 1 Day 10 to Day 21. Holter monitoring will be performed on Cycle 1 Day -1 and Cycle 1 Day 1 to evaluate the effect of copanlisib on the QT/QTc assessment.~Cycle 2 and subsequent cycles, all patients will receive copanlisib dose of 60 mg on Days 1, 8 and 15. Holter monitoring will be performed on Cycle 3 Day 1 and Cycle 6 Day 1."
3046185|NCT02253407|Experimental|Disposable syringe jet injector|Subjects in this arm will be given a single subcutaneous 0.5 mL dose of Serum Institute of India Ltd.'s MMR vaccine (Brand name: Tresivac) via Disposable Syringe Jet Injector (Brand Name:Stratis) of Pharmajet Inc.
3046186|NCT02253407|Active Comparator|Needle-Syringe|Subjects in this arm will be given a single subcutaneous 0.5 mL dose of Serum Institute of India Ltd.'s MMR vaccine (Brand name: Tresivac) via conventional needle and Syringe
3046187|NCT02253394|Active Comparator|AMB + Spiro, Cardiopulmonary fitness|Ambrisentan 5 or 10 mg every day (QD) Spironolactone 50 mg QD
3046188|NCT02253394|Placebo Comparator|Placebo Cardiopulmonary fitness|Placebo mimics spironolactone 50 mg and will be taken QD
3046189|NCT02253381|Active Comparator|Right lateral decubitus position|Right lateral decubitus position during spinal anesthesia
3046190|NCT02253381|Active Comparator|Left lateral decubitus position|Left lateral decubitus position during spinal anesthesia
3046191|NCT02253368|Other|Sleep Arm 1|Sleep Arm 1
3046192|NCT02253368|Other|Sleep Arm 2|Sleep Arm 2
3046193|NCT02253355|Experimental|Deep Brain Stimulation|Stimulation is on
3046194|NCT02253355|Sham Comparator|Placebo|Stimulation is off
3046195|NCT02253342|Experimental|WCK 2349|Subjects will receive oral doses of WCK 2349 administered twice-daily for five days starting on Day 1
3046196|NCT02253329|Active Comparator|Treatment during the day|Neuromuscular electrical stimulation after a protein bolus, performed during the day
3046197|NCT02253329|Active Comparator|Treatment prior to sleep|Protein ingestion directly after one-legged NMES, directly prior to sleep
3046198|NCT02253316|Experimental|Consolidation: Ixazomib, Lenalidomide, & Dexamethasone|Consolidation therapy will begin between Day 80 and Day 120 following ASCT and will consist of four 28-day cycles of IRD (ixazomib, lenalidomide, & dexamethasone). Barring dose modifications for toxicity, 4 mg of ixazomib and 40 mg of dexamethasone will be administered on Days 1, 8, and 15, and 55 mg of lenalidomide will be administered on daily on Days 1-21.
3046199|NCT02253316|Experimental|Maintenance Arm 1: Ixazomib|Ixazomib will be administered on Days 1, 8, and 15 of a 28-day cycle at a starting dose of 4 mg until patient progresses or experiences an unacceptable toxcity.
3046200|NCT02253316|Experimental|Maintenance Arm 2: Lenalidomide|Lenalidomide will be administered daily continuously for a 28-day cycle at a starting dose of 10 mg. If lenalidomide is tolerated well (i.e. no dose modification required) during the first three cycles, lenalidomide dose will be increased to 15 mg daily and will continue until patient progresses or experiences an unacceptable toxicity.
3046201|NCT02253303|Experimental|Midline incision|The extraction-site incision in laparoscopic colectomy is middline
3046202|NCT02253303|Active Comparator|off-midline incision|The extraction-site incision in laparoscopic colectomy is off-middline
3046204|NCT02253277|Experimental|Nilotinib and Ruxolitinib|The study includes two strata, which are to be treated in parallel. The first stratum consists of CML-patients in CP, which have been on nilotinib treatment before entering the study. These patients did not optimally respond to the previous treatment. The second stratum consists of patients with CML in AP or BC and patients with relapsed/refractory Ph+ ALL and Ph+ ALL patients with MRD, with or without previous nilotinib treatment. Patients will be treated with 300mg nilotinib BID during the escalation phase (12 months) with increasing doses of ruxolitinib. The dose expansion phase (12 months) will begin following the determination of the MTD of the combination and the decision to explore the cohort for confirmation of RPIID. In this phase, safety and tolerability of the MTD and/or potential RPIID will be further evaluated, with the purpose of establishing that this dose is suitable for use in this patient group.
3046205|NCT02253264|Experimental|Intrathecal rituximab|25 mg of rituximab will be administered intrathecally by direct infusion over 10 minutes at two time points, two weeks apart.
3046206|NCT02253251||Family Registry|For individuals identified with the KRAS-variant. Patients will be prospectively followed to determine the impact of lifestyle on disease risk.
3046207|NCT02253251||KRAS-variant BRCA negative Breast Cancer|Women with breast cancer who are BRCA negative will be tested for the KRAS-variant, to determine the associations as well as the prevalence.
3046208|NCT02253251||Double primary breast cancer|Women with multiple primary breast cancer will be tested for the KRAS-variant and compared between those with this mutation and those without.
3046209|NCT02253251||Autoimmunity|We have shown that the KRAS-variant and other members of this genetic class of mutations associate with altered immunity, leading to immunosuppression as well as autoimmunity.
3046210|NCT02253238|Other|Standard of Care Group|Surveys administered in person or by telephone interview and are audio-recorded.
3046211|NCT02253238|Experimental|CYCORE Group + Standard of Care|"Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer).~Surveys administered in person or by telephone interview and are audio-recorded."
3046212|NCT02253225||Bipolar Disorder|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 patients with bipolar disorder (BPAD).
3046213|NCT02253225||Major Depressive Disorder|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 patients with major depression (MDD).
3046214|NCT02253225||Healthy Control|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 normal, healthy volunteers.
3046215|NCT02253212|Experimental|SonoCloud + carboplatin|SonoCloud : dose escalation Carboplatin : 6 cycles - individual dose determination according to renal function and AUC
3046216|NCT02253199|Active Comparator|1-6 months (Group 1)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
3046217|NCT02253199|Active Comparator|7-12 months (Group 2)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
3046218|NCT02253199|Active Comparator|13-24 months (Group 3)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
3046219|NCT02253199|Active Comparator|25-36 months (Group 4)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
3046220|NCT02253186|Experimental|Group I|Patients wear, for 90 days, the experimental Auto-Adjustable MOBIDERM® Armsleeve during night-time and a usual custom-made compressive armsleeve during Day-time.
3046221|NCT02253186|No Intervention|Group II|Patients wear, for 30 days, only a usual custom-made compressive armsleeve during Day-time and no garment during night-time. Then, for the next 60 days, patients wear the experimental Auto-Adjustable MOBIDERM® Armsleeve during night-time and a usual custom-made compressive armsleeve during Day-time.
3046222|NCT02253173|Experimental|Estradiol 4mcg Vaginal Softgel Capsule|Estradiol 4mcg Vaginal Softgel Capsule
3046223|NCT02253173|Experimental|Estradiol 10mcg Vaginal Softgel Capsule|Estradiol 10mcg Vaginal Softgel Capsule
3046224|NCT02253173|Experimental|Estradiol 25mcg Vaginal Softgel Capsule|Estradiol 25mcg Vaginal Softgel Capsule
3046225|NCT02253173|Placebo Comparator|Placebo Vaginal Softgel Capsule|Placebo Vaginal Softgel Capsule
3046226|NCT02253160|Experimental|Spectra Optia CMNC first, then COBE Spectra MNC|Spectra Optia CMNC collection procedure followed by COBE Spectra MNC collection procedure.
3046227|NCT02253160|Experimental|COBE Spectra MNC first, then Spectra Optia CMNC|COBE Spectra MNC collection procedure followed by Spectra Optia CMNC collection procedure.
3046228|NCT02253147|Experimental|Left side TEOSYAL® RHA Ultra Deep, Right side Perlane-L®|Split-face injection of TEOSYAL® RHA Ultra Deep into the left Naso Labial Folds (NLFs) and Perlane-L® into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
3046229|NCT02253147|Experimental|Left side Perlane-L®, Right side TEOSYAL® RHA Ultra Deep|Split-face injection of Perlane-L® into the left Naso Labial Folds (NLFs) and TEOSYAL® RHA Ultra Deep into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
3046230|NCT02253121|Experimental|Dapagliflozin + sliding scale insulin.|Treatment with dapagliflozin 10mg once daily orally. Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days). In case of persistent glucose levels > 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.
3046231|NCT02253121|Placebo Comparator|Placebo + sliding scale insulin|Treatment with placebo once daily orally. Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days). In case of persistent glucose levels > 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.
3046232|NCT02253108|Experimental|SYNERGY drug eluting stent|Everolimus eluting bioresorbable polymer stent
3046233|NCT02253108|Experimental|Biomatrix NeoFlex drug eluting stent|Biolimus eluting bioresorbable polymer stent
3046234|NCT02253095|Experimental|Multiple Intervention Arm|single dose albendazole, two weeks of zinc, 24 weeks of multiple micronutrients
3046235|NCT02253095|Placebo Comparator|Placebo|three placebos
3046238|NCT02253069|Experimental|PHMB-based antiseptic|Applying Prontosan antiseptic solution to tie-over dressings
3046239|NCT02253069|Placebo Comparator|Control|Applying water to tie-over dressings
3046240|NCT02253056|Experimental|Fasting|Intermittent fasting over 8 weeks (one day per week)
3046241|NCT02253056|Active Comparator|Healthy diet|Regular healthy diet according to current German (DGE) guidelines for healthy nutrition.
3046242|NCT02253043|Experimental|Deep Brain Stimulation|DBS Implant and stimulation
3046243|NCT02253030||Newly-diagnosed, untreated wet AMD|This group will be adults newly diagnosed with wet AMD who have not undergone any treatment for the condition. Their data will be gathered only once, prior to treatment.
3046244|NCT02253030||"Wet AMD undergoing as-needed treatment"|This group will be adults undergoing treatment as-needed for wet AMD. They will be followed monthly over the course of 1 year.
3046245|NCT02253030||High-risk eyes|This group will be adults with wet AMD in one eye and findings of dry AMD in the other. The eye with dry AMD will be followed every 6 months for 3 years.
3046246|NCT02253030||"Wet AMD undergoing a treat and extend strategy"|"This group will be adults with wet AMD undergoing treatment under the treat and extend strategy. (The treat and extend strategy increases the intervals between treatments as long as the macula remains dry.) They will be followed over the course of 1 year with extra imaging before extending follow-up intervals."
3046247|NCT02253017||Children operated on for cataract|
3046248|NCT02253004|Experimental|Active|Cilostazol 200 mg single dose
3046249|NCT02253004|Placebo Comparator|Placebo|Placebo capsule
3046250|NCT02252991|Other|Arm A with physical activity during the treatment|In the arm A, patients will realise physical activity during the treatment. Blood samples will be realised. Questionnaries will be given to the patients.
3046251|NCT02252991|Other|Arm B with physical activity after the treatment|In the arm B, the physical activity will be realised after treatment. Blood samples will be realised. Questionnaries will be given to the patients.
3046252|NCT02252978|Experimental|Arm I (ciprofloxacin)|Patients receive ciprofloxacin PO BID for 2 weeks.
3046253|NCT02252978|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 2 weeks.
3046254|NCT02252965|Active Comparator|Metformin IR|
3046255|NCT02252965|Experimental|Metformin XR|
3046256|NCT02252952|Experimental|Sugar Sweetened Beverages|Any beverage from a range of caffeine free, sugar sweetened drinks. One serving =12oz. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
3046257|NCT02252952|Experimental|Diet Beverage|Any beverage from a range of caffeine free drinks sweetened with non-caloric sweetener. One serving =12oz. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
3046258|NCT02252952|Active Comparator|Water|12 oz of water. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
3046259|NCT02252939|Experimental|Patients with Trapeziometacarpal (TMC) Arthrosis|Patients presenting to the Orthopaedic Hand Service not seeking care for TMC Arthrosis
3046260|NCT02252926|Active Comparator|Bupivacaine lozenge|The patients can take up to eight 25 mg bupivacaine lozenges (max. every second hour in the awake hours) a day for seven days. The patients can use concomitant systemic pain treatment (e.g. morphine).
3046261|NCT02252926|Other|Standard treatment|The patients will be treated with the currently used standard pain treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin). The anesthetics are being administered at the physician's discretion.
3046262|NCT02252913|Experimental|Volitinib+docetaxel|"Dose escalation stage: oral administration, Volitinib 600mg/800 QD + docetaxel 75mg/m2.~If the dose of docetaxel 75mg/m2 is not tolerable, docetaxel dose will be reduced to 60mg/m2 while keep volitinib at 600mg QD as the initial dose. Volitinib dose escalation will be re-started and end at the dose of 800mg QD.~Dose expansion Stage:Volitinib with docetaxel. Use the prefer dose from escalation stage"
3046263|NCT02252900|Experimental|cerebral MRI during follow-up of IE|All patients will undergo the diagnostic test specific to the study (Magnetic resonance imaging)
3046264|NCT02252887|Experimental|Gemcitabine, Trastuzumab, and Pertuzuma|The regimen will consist of gemcitabine at 1000mg/m^2 IV weekly days 1 + 8 q 3 weeks + trastuzumab every 3 weeks (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose followed by 420 mg every 3 weeks), all given intravenously (IV). Trastuzumab may be given IV weekly (4 mg/kg loading dose followed by 2 mg/kg weekly) in lieu of the every 3 week schedule. A loading dose of trastuzumab will not be required for patients who have received it < 6 weeks prior to Cycle 1 Day 1.
3046265|NCT02252874|Placebo Comparator|Control Group|Receive leisure activities (e.g. reading, web-surfing, playing chess/ Mahjong) Twenty hours (2-3 sessions per week, 1.5 hours per session)
3046266|NCT02252874|Active Comparator|Intervention Group 1|Receive slow motion Nintendo Wii video games Twenty hours ( 2-3 sessions per week, 1.5 hours per session)
3046267|NCT02252874|Active Comparator|Intervention Group 2|Receive fast motion Nintendo Wii video games (e.g. shooting game) Twenty hours ( 2-3 sessions per week, 1.5 hours per session)
3046268|NCT02252861||Left Atrial Appendage Closure|Patients with atrial fibrillation and counter-indication to anticoagulant therapy referred for percutaneous Left Atrial Appendage Closure in routine care
3046269|NCT02252848|Experimental|Clonidine Safety|Mechanically ventilated patients receive clonidine for pain and sedation
3046270|NCT02252848|Experimental|Clonidine PK|Characterize population PK/PD of clonidine
3046271|NCT02252835|Experimental|Arhalofenate with febuxostat (PK cohort)|
3046272|NCT02252835|Experimental|Arhalofenate with febuxostat (non-PK cohort)|
3046273|NCT02252822|Experimental|The Overcoming Bulimia Online Programme|This treatment incorporates a combination of cognitive-behavioral, motivational and education strategies. The program will be presented in 8 collaborative, multi-media, web based CBT sessions for BN.
3046274|NCT02252809|Active Comparator|adalimumab|adalimumab 40 mg by subcutaneous way 7 days before endotoxin inhalation
3046275|NCT02252809|Active Comparator|methylprednisolone|methylprednisolone 20 mg daily , 7 days before endotoxin inhalation
3046276|NCT02252809|No Intervention|control|no intervention, 7 days before endotoxin inhalation
3046277|NCT02252796|Experimental|Sub-group 1|HySBst to be delivered during week 1 with Chemo-radiation to be delivered weeks 2-7
3073708|NCT02069405|No Intervention|Control Group - Normal standard of care|
3046278|NCT02252796|Experimental|Sub-group 2|Chemo-radiation to be delivered weeks 1-6 and HySBst to be delivered week 7
3046279|NCT02252783|Experimental|BFPET|BFPET will be administered as a single intravenous injection of up to 2 mCi (74 MBq) at rest and a single intravenous injection of up to 8mCi (296 MBq) following a stress protocol. Total amount not to exceed 10mCi (370 MBq).
3046280|NCT02252770|Active Comparator|Nitric oxide supplement arm|During this arm, subjects will receive a lozenge with nitric oxide supplement
3046281|NCT02252770|Placebo Comparator|Placebo Arm|During this arm, subjects will receive placebo
3046282|NCT02252731|Experimental|warfarin and FG-4592|Single dose of warfarin and Multiple doses of FG-4592 in combination with a single dose of warfarin
3046283|NCT02252718||Children 1-18 months of age|Children aged between 1 month and 18 months admitted to the Department of Pediatrics The Medical University of Warsaw
3046284|NCT02252705||Incident patients|Patients with less than three months from diagnosis to start of the Registry or those who have been diagnosed during the recruitment period.
3046285|NCT02252705||Prevalent patients|Patients who have been diagnosed with more than three months from diagnosis to start of the Registry.
3046286|NCT02252692|Active Comparator|Enalapril|Renitec® 2 x 5 mg tablets administered at once, to be entirely swallowed with 240 ml water
3046287|NCT02252692|Experimental|Enalapril ODMT|10 x 1mg of Enalapril ODMT, swallowed entirely with 240ml of water
3046288|NCT02252692|Experimental|Enalapril ODMT dispersed|10 x 1mg of Enalapril ODMT, dispersed on tongue
3046289|NCT02252679||Osteoporosis|Postmenopausal women, men > age 50 years, or other patients with well-established causes of secondary osteoporosis (incl. glucocorticoid-induced osteoporosis, transplantation-related osteoporosis, disuse osteoporosis, etc.) N=20 treated with antiresorptive drugs N=10 treated with osteoanabolic drugs (e.g. teriparatide, Forsteo)
3046290|NCT02252679||Calcium malabsorption|N=10 Patients with clinically obvious potential causes of calcium malabsorption (incl. severe vitamin D-deficiency, Scopinaro or other bariatric surgery, exocrine pancreatic insufficiency/steatorrhea, cystic fibrosis, inflammatory bowel disease, celiac disease, anorexia nervosa/eating disorders, malnutrition, etc.), with or without bone pains, muscle weakness and other typical osteomalacia symptoms. Confirmed by 24h urine collection showing calciuria <100 mg/24h.
3046291|NCT02252679||Various disorders|Exploratory, heterogeneous group of calcium-related disorders (incl.hypercalcemia, hypocalcemia, primary/secondary/tertiary hyperparathyroidism, hypoparathyroidism, vitamin D deficiency, X-linked/autosomal dominant hypophosphatemic rickets, familial hypocalciuric hypocalcemia,etc.) N=20
3046292|NCT02252679||Normal control subjects|N=40 Men and women ≤ 40 years recruited from the population
3046293|NCT02252666|Experimental|Neuromodulation Rehabilitation|Balance, posture and gait activities; therapeutic exercise for isolated muscle control; transfer training; and relaxation training using neurostimulation modulation. 2-week in lab intervention training, training at home and periodic return for follow-up testing and instruction on the next phase of the intervention.
3046294|NCT02252653||Familial Amyloidotic Cardiomyopathy (FAC)|
3046295|NCT02252640|Active Comparator|Group 1|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 8: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
3046296|NCT02252640|Active Comparator|Group 2|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 8: RTS,S/AS01B (10mcg of RTS,S and 1/5 of the standard dose of AS01), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
3046297|NCT02252640|Active Comparator|Group 3|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & ChAd63 ME-TRAP (5 x 10^10 vp), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 8: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
3046298|NCT02252640|Active Comparator|Group 4|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & ChAd63 ME-TRAP (5 x 10^10 vp), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 8: RTS,S/AS01B (10mcg of RTS,S and 1/5 of the standard dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
3046299|NCT02252640|No Intervention|Group 5|Week 11: Controlled Human Malaria Infection
3046300|NCT02252640|No Intervention|Group 6|Week 31-39: Controlled Human Malaria Infection
3046301|NCT02252627||Group 1|Healthy volunteers
3046302|NCT02252614|Active Comparator|Naproxen sodium codein|Preoperative Naproxen sodium codein administered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
3046303|NCT02252614|Experimental|Paracetamol codein|Preoperative paracetamol codein administrered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
3046304|NCT02252614|Placebo Comparator|Placebo tablet|Preoperative placebo tablet administered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
3046305|NCT02252601|Experimental|Well patients aged 11 and over|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
3046306|NCT02252601|Experimental|Acute exacerbation aged 11 and over|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity at the beginning of a course of IV antibiotics and at their convalescent clinic visit.
3046307|NCT02252601|Experimental|Children with CF aged 5-10 years|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
3046308|NCT02252601|Active Comparator|Healthy Control Children age 5-10 years.|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
3046309|NCT02252588|Experimental|Chlorhexidine|Oral Rinse
3046310|NCT02252588|Placebo Comparator|Placebo|Oral Rinse
3075007|NCT02060851|Experimental|group 2|intravenous iton but no EPO
3046311|NCT02252575|Experimental|Electromagnetic field|Exposure to the elctromagnetic field of an electric motor
3046312|NCT02252562|No Intervention|Standard practice|Usual intraoperative hand hygiene (standard wall mounted devices and machine and/or cart based dispensers)
3046313|NCT02252562|Experimental|Personal hand hygiene device|Intraoperative use of personalized body worn alcohol dispensers incorporating a novel wireless tracking system [(SAGE Products Inc., Cary, Il),
3046314|NCT02252549|Active Comparator|A|SPIES+WLI assisted TURB
3046315|NCT02252549|Active Comparator|B|WLI assisted TURB
3046316|NCT02252536|Placebo Comparator|Sugar Pill|Matching placebo, sugar pill
3046317|NCT02252536|Active Comparator|Gabapentin Enacarbil|600 mg Gabapentin Enacarbil (Horizant)
3046318|NCT02252523|Experimental|DEXMEDETOMIDINE|
3046319|NCT02252497|Active Comparator|Tranexamic acid|"1g Intra Venous just before surgery~Then infusion of 1g of Exacyl over eight hours."
3046320|NCT02252497|Placebo Comparator|Physiologic serum|"1g Intra Venous, just before surgery~Then infusion of 1g of physiologic serum over eight hours."
3046321|NCT02252484|Experimental|Weight loss intervention Group|Participants will receive tailor weight loss program. Participants will complete 8-weeks of the weight loss intervention prior to having their prostatectomy (weight loss phase). Program includes individual weight coaching, tailored diet and exercise plan, weight coaching and tracking of daily activities. Sessions will be held weekly during the weight loss phase. The groups will be facilitated by a registered dietitian with genitourinary (GU) oncology experience.
3046322|NCT02252484|Active Comparator|Comparison Group|All patients who are unwilling or not ready to engage in a weight loss program will be offered entry into the comparison group arm.
3046323|NCT02252471|Experimental|Choices-Teen Intervention|A three session intervention with two counseling sessions with a master's level therapist and a counseling session with a physician. The counseling with the master's level therapist utilizes a motivational interviewing approach to encourage changes in alcohol use, contraceptive use, smoking and HIV risk behaviors. This part of the intervention (a) provides norms-based-but personalized-feedback; (b) encourages participating in the smoking cessation program; (c) increases motivation to change each of the target behaviors; (d) decreases temptation to engage in risk behaviors; (e) increases confidence to avoid risk behaviors; and (f) develops a personalized, tailored change plan. The physician session provides individualized contraception and HIV risk reduction counseling.
3046324|NCT02252458|Experimental|Fentanyl high dose|Fentanyl 10mcg/kg of bodyweight
3046325|NCT02252458|Active Comparator|Fentanyl low dose|Fentanyl 1mcg/kg of bodyweight
3046326|NCT02252445|Active Comparator|Propofol|Propofol will be administered as the anesthetic maintenance agent.
3046327|NCT02252445|Experimental|Sevoflurane|Sevoflurane will be administered as the anesthetic maintenance agent.
3046328|NCT02252432|Active Comparator|Ketamine|A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min))
3046329|NCT02252432|Active Comparator|Methadone|Will receive a single dose of IV methadone (0.2 mg/kg) preinduction
3046330|NCT02252432|Experimental|Ketamine + methadone|Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
3046331|NCT02252419|Active Comparator|Dexamethasone|Dexamethasone will be administered 30 minutes before the anesthetic induction.
3046332|NCT02252419|Experimental|Dexamethasone+ Paracetamol (DP)|Dexamethasone will be administered 30 minutes before the anesthetic induction. Paracetamol will be administered at the end of the surgery.
3046333|NCT02252406|Experimental|Ranolazine|Ranolazine 500 mg up to 1000 mg daily for 24 weeks
3046334|NCT02252406|Placebo Comparator|Placebo|Matching placebo tablets daily for 24 weeks
3046335|NCT02252393|Experimental|Arm I (RARC with IUD)|Patients undergo RARC with IUD.
3046336|NCT02252393|Experimental|Arm II (RARC with EUD)|Patients undergo RARC with EUD.
3046337|NCT02252380|Experimental|Transcranial ExAblate System|Transcranial ExAblate System (MRgFUS)
3046338|NCT02252367|Experimental|Tadalafil|43 male subjects affected by BPH (benign prostatic hyperplasia) planned for simple prostatectomy will be randomized to tadalafil 5 mg - 1 film-coated tablet orally once daily for 12 weeks.
3046339|NCT02252367|Placebo Comparator|Placebo|43 male subjects affected by BPH (benign prostatic hyperplasia) planned for simple prostatectomy will be randomized to placebo.
3046340|NCT02252354|Experimental|Part 1: [14C]-TAK-385|[14C]-TAK-385 80 mg, solution, orally, once on Day 1.
3046341|NCT02252354|Experimental|Part 2: TAK-385 + [14C]-TAK-385 IV|TAK-385 80 mg, tablets, orally, and [14C]-TAK-385 80 μg, infusion, intravenous once on Day 1.
3046342|NCT02252341|Placebo Comparator|placebo|"Dietary Supplement: N-Acetyl-Cysteine Phase 4 Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized, Efficacy Study~Primary Outcome Measure:~Hamilton Depression Rating Scale [Time Frame: baseline, 1, 2, 3 months] [Designated as safety issue: Yes]~Secondary Outcome Measures:~Carbon Oxide exhalation [Time Frame: basal, 1, 2, 3 months] [Designated as safety issue: Yes]~Other Pre-specified Outcome Measures:~Biological outcome measures [Time Frame: baseline and 3 months] [Designated as safety issue: Yes] inflammatory and oxidative stress biomarkers N-Acetyl-cysteine 1800 mg / day will be taken for 12 weeks versus placebo 12 weeks."
3046343|NCT02252341|Placebo Comparator|N-Acetyl-Cysteine|"Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized, Efficacy Study~Official Title: Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder~Primary Outcome Measure:~Hamilton Depression Rating Scale [Time Frame: baseline] [Designated as safety issue: Yes]~Secondary Outcome Measures:~Carbon Oxide exhalation [Time Frame: basal, 1, 2, 3 months] [Designated as safety issue: Yes]~Other Pre-specified Outcome Measures:~Biological outcome measures [Time Frame: baseline and 3 months] [Designated as safety issue: Yes] inflammatory and oxidative stress biomarkers~Placebo will be taken for 12 weeks."
3046344|NCT02252328|Experimental|Simvastatine|Group of patients receiving simvastatin 80mg once daily in addition to standard care
3046345|NCT02252328|Placebo Comparator|Placebo|Group of patients receiving placebo once daily in addition to standard care
3046346|NCT02252315|Active Comparator|Written Education|
3046347|NCT02252315|Active Comparator|Verbal Education|
3046521|NCT02251158|Experimental|TPV/r|Tipranavir/Ritonavir paediatric/oral solution
3046348|NCT02252302|Active Comparator|Resting in diesel exhaust following salbutamol inhalation|Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of 400ug of salbutamol.
3046349|NCT02252302|Placebo Comparator|Resting in diesel exhaust following placebo inhalation|Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of a placebo.
3046350|NCT02252302|Active Comparator|Cycling in diesel exhaust following salbutamol inhalation|Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of 400ug of salbutamol.
3046351|NCT02252302|Placebo Comparator|Cycling in diesel exhaust following placebo inhalation|Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of a placebo
3046352|NCT02252302|Sham Comparator|Resting in filtered air following salbutamol inhalation|Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of 400ug of salbutamol.
3046353|NCT02252302|Placebo Comparator|Resting in filtered air following placebo inhalation|Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of a placebo.
3046354|NCT02252302|Sham Comparator|Cycling in filtered air following salbutamol inhalation|Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of 400ug of salbutamol.
3046355|NCT02252302|Placebo Comparator|Cycling in filtered air following placebo inhalation|Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of a placebo
3046356|NCT02252289||Problematic severe asthmatics|"Approximately 75 Children aged 5 to 17 years with problematic severe asthma (PSA). Two groups of PSA children will be recruited: those who have already been assessed as part of the Difficult Asthma protocol and classified as DA (difficult asthma)/ STRA (severe therapy resistant asthma) (training set) and those newly referred to the protocol (validation set).~Previous enrolment or new referral to the Royal Brompton Hospital Difficult Asthma Protocol."
3046357|NCT02252289||Control group of moderate asthmatics|A control group of 30 children aged 5 to 17 years with mild to moderate asthma.
3046358|NCT02252276|Experimental|Experimental|performed the same exercises and manual therapy during 4 weeks
3046359|NCT02252276|Active Comparator|Control|performed proprioceptive and strengthening exercises during 4 weeks
3046360|NCT02252263|Experimental|Arm 1: Elotuzumab + Lirilumab|Elotuzumab weekly for 8 wks and every 2 wks thereafter + Lirilumab every 4 wks Intravenous solution for Up to 2 yrs, depending on response
3046361|NCT02252263|Experimental|Arm 2: Elotuzumab + Urelumab|Elotuzumab weekly for 8 wks and every 2 wks thereafter + Urelumab every 4 wks Intravenous solution for Up to 26 weeks, depending on response
3046362|NCT02252250|Active Comparator|conventional laparoscopic|conventional laparoscopic total mesentery excision surgery for rectal cancer.
3046363|NCT02252250|Experimental|Transanal hybrid-laparoscopic|Transanal hybrid-laparoscopic total mesentery excision surgery for rectal cancer.
3046364|NCT02252237||Children with glucocorticoids|Children receiving Prednisone or Prednisolone or Methylprednisolone Pharmacokinetic
3046365|NCT02252224||T2DM patients treated with Forxiga|Korean patients who are at least 18 years old, diagnosed with type2 diabetes and treated with Forxiga according to the approved lable
3046366|NCT02252211|Experimental|Zr-DS-8895a, DS-8895a|
3046367|NCT02252198||Investigational|• Participants will be asked to provide a total of three sputum samples over Days 1 and 2. The intent is for all samples to be collected before the subject starts any form of TB treatment. The first specimen (S1) should be 2 ml or greater in volume, and the second and third specimens (S2 and S3) should each be 1 ml or greater in volume. On Day 1, each participant will be asked to submit one spot sputum (S1) after enrollment and a second spot sputum after at least 2 hours (S2). Participants will be instructed to come back the following day (Day 2) and provide a third spot sputum (S3). In the event that a participant fails to return on Day 2, S3 may be collected a maximum of 7 days after enrollment, provided that no TB treatment has been initiated.
3046368|NCT02252185|Experimental|China made spine fusion system|patents in this arm will be implanted with Johnson&Johnson Medical Suzhou made Spine Fusion System.
3046369|NCT02252185|Active Comparator|Imported spine fusion system|patents in this arm will be implanted with Imported EXPEDIUM screws and OPAL cage .
3046370|NCT02252172|Experimental|Daratumumab + Lenalidomide + Dexamethasone (DRd)|Participants will receive Daratumumab 16 milligram per kilogram (mg/kg) by intravenous infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years). Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, until disease progression or unacceptable toxicity, and Dexamethasone 40 mg orally or intravenously once a week until disease progression or unacceptable toxicity, whichever comes first.
3046371|NCT02252172|Active Comparator|Lenalidomide and Dexamethasone (Rd)|Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, until the disease progression or unacceptable toxicity and Dexamethasone 40 mg orally or intravenously once a week until disease progression or unacceptable toxicity, or end of study (maximum up to 7 years).
3046372|NCT02252159||Cohort A|"Patients with clinically overt PV (and not exhibiting any of the characteristics listed for Cohort B), managed with:~Watchful waiting (with or without aspirin)*, or~Phlebotomy (PHL) alone (with or without aspirin)* - or~HU alone (without concomitant PHL, with or without aspirin).~(*Unless patient has a history of intolerance or clinical resistance/ refractoriness to hydroxyurea [HU] (as assessed by the treating physician) - in which case, s/he belongs to Cohort B)"
3046373|NCT02252159||Cohort B|"Patients with clinically overt PV, with one or more of the following disease characteristics:~Treatment with HU and PHL in combination or~Treatment with any agent other than HU or aspirin (e.g., recombinant interferon (IFN) or pegylated IFN preparations, busulfan, anagrelide) or~A history of thrombosis (venous or arterial) or~A history of intolerance or clinical resistance/ refractoriness to HU (as assessed by the treating physician) or~Presence of documented splenomegaly (clinically assessed by palpation) or~Presence of one or more of the following uncontrolled symptoms related to PV despite therapy (Symptoms deemed uncontrolled as per physician's judgment)~Tiredness~Difficulty sleeping~Itching~Muscle aches and/or bone pain~Night sweats~Sweats while awake~Other"
3046374|NCT02252146|Experimental|IMO-8400|IMO-8400 0.3 mg/kg twice weekly, 0.6 mg/kg twice weekly, or 1.2 mg/kg twice weekly
3046375|NCT02252133|Other|DT1, then 1DAVTE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product worn bilaterally for 7 days on a daily wear, daily disposable basis.
3046376|NCT02252133|Other|1DAVTE, then DT1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product worn bilaterally for 7 days on a daily wear, daily disposable basis.
3046377|NCT02252120|Active Comparator|Supreme|Supreme LMA
3046378|NCT02252120|Active Comparator|Laryngeal Tube|Laryngeal tube LTSII
3046379|NCT02252107|Experimental|Decitabine|Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.
3046380|NCT02252094|Active Comparator|Conventional lung protective ventilation|Lung protective ventilation (6ml/kg predicted body weight). All other interventions per intensive care unit standardised ARDS management protocol
3046381|NCT02252094|Experimental|Ultra-protective ventilation|Ultra-protective ventilation (</= 3ml/kg predicted body weight) targeting plateau pressure of </= 25 cmH2O, supported by Prismalung. All other intervention per intensive care unit standardised ARDS management protocol
3046382|NCT02252081|Active Comparator|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR > 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =< 45 ml/min
3046383|NCT02252081|Placebo Comparator|Placebo|placebo pill(s) orally per day for 16 weeks
3046384|NCT02252068|Other|I-CBT feasibility pilot|Open trial of I-CBT
3046385|NCT02252068|Experimental|I-CBT vs IDC|Randomized control trial of I-CBT vs ICD
3046386|NCT02252055|Experimental|ATDC Treatment|"ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation.~Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus, as detailed below :~Prednidolone :~D 0: 500 mg IV~D 1: 125 mg IV~D 2 to 14: 20.0 mg/d~Wk 3 to 4: 15.0 mg/d~Wk 5 to 8: 10.0 mg/d~Wk 9 to 12: 5.0 mg/d~Wk 13 to 14: 2.5 mg/d~Wk 15 to End:Cessation~MMF (or biologic equiv.):~D -7 to -2: 500 mg/d (250mg 2x/d)~D -1 to 14: 2000 mg/d~Wk 3 to 36: 1000 mg/d~Wk 37 to 40: 750 mg/d~Wk 41 to 44: 500 mg/d~Wk 45 to 48: 250 mg/d~Wk 49 to End:Cessation Note : MMF tapering will only happen if the 36-week protocol biopsy shows no signs of subclinical rejection and there is evidence of declining renal function or if the clinician has any other concern about MMF dose reduction.~Tacrolimus :~≤ 48 h pre-Tx to D 14: 3-12 ng/ml~Wk 3 to 12: 3-10 ng/ml~Wk 13 to 36: 3-8 ng/ml~Wk 37 to End: 3-6 ng/ml"
3046387|NCT02252042|Experimental|Pembroliziumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
3046388|NCT02252042|Active Comparator|Active Comparator|Participants receive methotrexate 40 mg/m^2 IV (may be escalated to 60 mg/m^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle; or docetaxel 75 mg/m^2 IV on Day 1 of each 3- week cycle; or cetuximab 400 mg/m^2 IV loading dose on Day 1 and 250 mg/m^2 IV on Days 8 and 15 of Cycle 1, followed by cetuximab 250 mg/m^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
3046389|NCT02252016|Experimental|Immediate Treatment|Participants will take grazoprevir 100 mg + elbasvir 50 mg once daily during the 12-week treatment period and then will be monitored for safety during a 24-week follow-up period.
3046390|NCT02252016|Placebo Comparator|Deferred Treatment|Participants will take placebo tablets once daily during the 12-week treatment period and will then be monitored for safety during a 4-week follow-up period. Participants will then begin open-label treatment with grazoprevir 100 mg + elbasvir 50 mg for a 12-week treatment period and will then be monitored for safety during a 24-week follow-up period.
3046391|NCT02252003|Experimental|Pain scales testing|
3046392|NCT02251990|Experimental|Immediate Treatment Group (ITG): Grazoprevir/Elbasvir|Participants receive a grazoprevir/elbasvir FDC tablet once daily (q.d.) by mouth during a 12-week Active Treatment period (Week 1 to Week 12) and are followed-up for 24 weeks to Week 36.
3046393|NCT02251990|Placebo Comparator|Deferred Treatment Group (DTG): Placebo > Grazoprevir/Elbasvir|Participants receive a placebo tablet q.d. by mouth for 12 weeks (placebo treatment period). After a 4-week Follow-Up period, participants receive open-label grazoprevir/elbasvir FDC during a 12-week Active Treatment period (Week 16 to Week 28). Participants are then followed-up for 24 weeks to Week 52.
3046394|NCT02251977|Experimental|Adjuvant Chemotherapy plus GM1|Patients will receive mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) or XELOX (capecitabine and oxaliplatin) for adjuvant chemotherapy. While GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
3046395|NCT02251977|Placebo Comparator|Adjuvant Chemotherapy plus placebo|Patients will receive mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) or XELOX (capecitabine and oxaliplatin) for adjuvant chemotherapy. While placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4).
3046396|NCT02251964|Other|rituximab|single arm study with Zr-89-rituximab immuno PET/CT
3046397|NCT02251951|Experimental|nab-Paclitaxel|Abraxane
3046398|NCT02251938|Experimental|DE-109 Sirolimus|Medium dose of DE-109
3046399|NCT02251925|Experimental|Natural cycle|In natural cycle without hCG, daily monitoring of urinary LH is started from day eight of the cycle and frozen-thawed embryo transfer is planned 3-5 days after detection of LH surge, observing mature follicles in ultrasound and endometrial thickness over 7mm for cleavage embryos.
3046400|NCT02251925|Experimental|Natural cycle + hCG for ovulation induction|In natural cycle with hCG, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000IU hCG is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage.
3046401|NCT02251925|Experimental|Hormonally controlled cycle with GnRH-a|In this group , injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.
3046522|NCT02251158|Active Comparator|TPV/r capsules|
3046523|NCT02251145|Experimental|tipranavir/ritonavir low dose|
3046524|NCT02251145|Experimental|tipranavir/ritonavir high dose|
3046525|NCT02251132|Experimental|TPV/RTV Low 1|
3046402|NCT02251925|Experimental|Hormonally controlled cycle without GnRH-a|In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
3046403|NCT02251912|Experimental|Active|Intranasal oxytocin doses 2-3 times/day for 12 weeks
3046404|NCT02251912|Placebo Comparator|Control|Intranasal placebo doses 2-3 times/day for 12 weeks
3046405|NCT02251899|Experimental|Disease-Management intervention|Behavioral: Disease-Management intervention The participants in the intervention group receive a nurse-managed disease-management intervention that is regularly delivered by telephone or, when necessary, in person
3046406|NCT02251899|No Intervention|No Intervention: Control arm|Control group not receiving any in
3046407|NCT02251886|Active Comparator|Moxibustion in primiparae|Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in primiparae
3046408|NCT02251886|Active Comparator|Moxibustion in multiparae|Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in multiparae
3046409|NCT02251886|No Intervention|Control primiparae|No intervention. Routine control schedule for primiparae with midwife
3046410|NCT02251886|No Intervention|Control multiparae|No intervention. Routine control schedule for multiparae with midwife
3046411|NCT02251873|Experimental|TPV + RTV (low dose)+ ddI|
3046412|NCT02251873|Experimental|TPV+ RTV (high dose)+ ddI|
3046413|NCT02251860||Participants with Rheumatoid Arthritis|Participants with active rheumatoid arthritis who are prescribed tocilizumab treatment according to the marketing authorization by their physician will be followed under routine conditions over an observation period of up to 2 years if baseline and disease characteristics data are available.
3046414|NCT02251847|Active Comparator|R5|Rosuvastatin 5mg
3046415|NCT02251847|Active Comparator|R10|Rosuvastatin 10mg
3046416|NCT02251847|Active Comparator|R20|Rosuvastatin 20mg
3046417|NCT02251847|Experimental|R5/E10|Rosuvastatin 5mg/ezetimibe 10mg
3046418|NCT02251847|Experimental|R10/E10|Rosuvastatin 10mg/ezetimibe 10mg
3046419|NCT02251847|Experimental|R20/E10|Rosuvastatin 20mg/ezetimibe 10mg
3046420|NCT02251834|Experimental|Community Health Worker|Community Health Worker (CHW) home visits, coaching phone calls, group sessions .
3046421|NCT02251834|Other|Usual Care|usual care and health education brochures every 4 months.
3046422|NCT02251821|Experimental|Treatment (JAK inhibitor, transplant)|Patients receive a JAK inhibitor (ruxolitinib, momelotinib, or pacritinib) and undergo myeloablative or reduced-intensity conditioning followed by transplant and GVHD prophylaxis; see detailed description.
3046423|NCT02251795|Experimental|Tipranavir/Ritonavir|500 mg Tipranavir / 200 mg Ritonavir 10 days BID
3046424|NCT02251795|Active Comparator|Darunavir/Ritonavir|600 mg Darunavir /100 mg Ritonavir 10 days BID
3046425|NCT02251795|Active Comparator|Ritonavir|100 mg Ritonavir 10 days BID
3046426|NCT02251782||Epi proColon Group|Subjects assigned to the Epi proColon Group will be offered the Epi proColon test for colorectal cancer screening.
3046427|NCT02251782||FIT Group|Subjects in the FIT Group will be offered a fecal immunochemical test (FIT test) for colorectal cancer screening.
3046428|NCT02251782||Usual Care Group|For the purpose of comparison to usual care, participating health systems will build an anonymized group of patients meeting study eligibility criteria, who do not participate in the study. This group will serve as a passive control and their CRC screening activity will be monitored via Medical Record.
3046429|NCT02251769|Experimental|Sequential administration|
3046430|NCT02251756|Experimental|Actinica, 0.8 mg/cm2, 1application|Actinica, 0.8 mg/cm2, 1application over one day of sun exposure
3046431|NCT02251756|Experimental|Actinica, 0.8 mg/cm2, 2 applications|Actinica, 0.8 mg/cm2, 2 applications over one day of sun exposure
3046432|NCT02251756|Experimental|Actinica, 2 mg/cm2, 1 application|Actinica, 2 mg/cm2, 1 application over one day of sun exposure
3046433|NCT02251756|Experimental|Actinica, 2 mg/cm2, 2 applications|Actinica, 2 mg/cm2, 1 application over one day of sun exposure
3046434|NCT02251743|Experimental|Neurofeedback treatment|The intended treatment is downtraining of theta power and uptraining of beta power for 38 treatments of active NF.
3046435|NCT02251743|Placebo Comparator|Sham neurofeedback treatment|"Participants assigned to sham and their trainers will be fed EEG data from pre-recorded files (recorded during live clinical NF) rather than from the participant's live signal. In order to prevent unblinding of experienced NF trainers/technicians, artifacts from the participant's EMG and EOG are blended into the pre-recorded EEG so that the trainer controlling the feedback cannot differentiate between live and simulated data. To insure trainer/technician blindness, the pre-recorded EEG will be 38 consecutive EEGs from the same age-matched clinical case so that EEGs of the sham group will also show training progress over successive sessions, like real NF."
3046436|NCT02251730|Experimental|Refer for smoking cessation|Refer for smoking cessation
3046437|NCT02251717|Experimental|LDV/SOF 12 wk|Participants will receive LDV/SOF FDC for 12 weeks.
3046438|NCT02251717|Experimental|LDV/SOF 24 wk|Participants will receive LDV/SOF FDC for 24 weeks.
3046439|NCT02251704|Other|Study Group|Subjects 6 months to <10 years of age enrolled in HDSS catchment areas at the sites participating in the EPI-MAL-002 and EPI-MAL-003 studies of the candidate malaria vaccine RTS,S/AS01E in sub-Saharan Africa.
3046440|NCT02251691|Experimental|Advagraf|Take Advagraf once daily
3046441|NCT02251691|Active Comparator|Prograf|Take tacrolimus twice daily
3046442|NCT02251678|Experimental|Elimune capsules|Elimune capsules 2 capsules BID (four total capsules per day)
3046443|NCT02251665||Acute ischemic stroke, acute ICH, TIA|Consecutive patients with acute ischemic stroke, intracerebral hemorrhage, and transient ischemic attack who are emergently managed in the stroke care unit or stroke units in the National Cerebral and Cardiovascular Center
3046444|NCT02251652|Active Comparator|Combination Therapy|Cryotherapy followed by Ingenol Mebutate Gel
3046445|NCT02251652|Active Comparator|Cryotherapy Alone|Cryotherapy only
3046526|NCT02251132|Experimental|TPV/RTV Low 2|
3046527|NCT02251132|Experimental|TPV/RTV Low 3|
3046528|NCT02251132|Experimental|TPV/RTV Medium 1|
3046529|NCT02251132|Experimental|TPV/RTV Medium 2|
3046530|NCT02251132|Experimental|TPV/RTV High 1|
3046446|NCT02251639|Experimental|Oral Imaging and Cytology|Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors. Oral cavity inspected using a standard white light headlamp. Oral cavity then examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device. Exfoliative cells for cytology from an abnormal area (if present) and from a contralateral normal appearing area obtained using a brush.
3046447|NCT02251626|Experimental|Coenzyme Q10 (ubiquinol)|Coenzyme Q10 (ubiquinol) group will be given 1,800 mg coenzyme Q10 (ubiquinol) per day
3046448|NCT02251626|Placebo Comparator|Placebo for CoQ10 (ubiquinol)|Placebo group will be given placebo only
3046449|NCT02251613|Experimental|Olopatadine (right or left, randomized)|Olopatadine HCl ophthalmic solution, 0.1%, 1 drop in the right or left eye as randomized
3046450|NCT02251613|Active Comparator|Epinastine (fellow eye)|Epinastine HCl ophthalmic solution, 0.05%, 1 drop in the in the fellow eye
3046451|NCT02251600|Experimental|Deflazacort|This is an open label and single period study , dosed with 0.9mg/kg Deflazacort.
3046452|NCT02251587|Active Comparator|Standard Weight Management Program|Participants will be given information on diet and exercise. Participants will attend meetings to discuss barriers to exercise and nutrition and ways to solve these problems. Participants will be given healthy snack ideas and planning tools.
3046453|NCT02251587|Experimental|$ensible Weigh Program|Participants will be given information on diet and exercise with an emphasis on food security. Participants will be provided with additional information on community resources such as those for food, transportation, and safe places to exercise. A weekly cooking demonstration will be provided using inexpensive ingredients and common food pantry items.
3046454|NCT02251574|Experimental|Low Calorie Diet|Participants will take part in an experimental weight management program involving a low calorie diet (LCD), about 1200-1500 calories per day.
3046455|NCT02251574|Experimental|Very Low Calorie Diet|Participants will take part in an experimental weight management program involving a low calorie diet (LCD), about 520-800 calories per day.
3046456|NCT02251574|Active Comparator|Standard Care|Participants will receive normal care.
3046457|NCT02251561|Experimental|FID 109182|Senofilcon A contact lens pre-soaked in FID 109182 worn in the right or left eye as randomized for 2 hours
3046458|NCT02251561|Active Comparator|Opti-Free Plus|Senofilcon A contact lens pre-soaked in Opti-Free Plus worn in the fellow eye for 2 hours
3046459|NCT02251548|Experimental|Ibrutinib|"- Ibrutinib-~Oral, daily during each cycle~fludarabine-administered at standard dosing for up to 6 cycles~cyclophosphamide-administered at standard dosing for up to 6 cycles~rituximab-administered at standard dosing for up to 6 cycles"
3046460|NCT02251535|Experimental|test group 1|Retrospective test group 1 (n=10, ATTUNE® Knee System, rotating platform, cruciate retaining) with intraoperative high level rollback
3046461|NCT02251535|Experimental|test group 2|Retrospective test group 2 (n=10, ATTUNE® Knee System, rotating platform, cruciate retaining)with intraoperative low level rollback
3046462|NCT02251535|Experimental|control group|Control group (n=10, PFC® SIGMA® Knee System, rotatinq platform, cruciate retaininq)
3046463|NCT02251522||ConforMIS iTotal Knee Replacement System|Patients who have had an iTotal knee replacement at least 6 months prior to testing
3046464|NCT02251522||Off-the-Shelf Knee Replacement System|Patients who have had an off-the-shelf knee replacement at least 6 months prior to testing
3046465|NCT02251509|Experimental|Carvedilol|carvedilol BID for 2 weeks
3046466|NCT02251509|Experimental|Metoprolol tartrate|Metoprolol tartrate BID for 2 weeks
3046467|NCT02251496|Active Comparator|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
3046468|NCT02251496|Active Comparator|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
3046469|NCT02251483|Other|SBI|Group 1: SBI (N=30) - one packet daily
3046470|NCT02251483|Placebo Comparator|Placebo|Group 2: Placebo (N=30) - one packet daily
3046471|NCT02251470|Experimental|HBE Wii (EG)|Participants receive an introduction of using the Nintendo Wii by an individual mentoring for over 6 weeks (a total of 6 sessions á 60 minutes). During the following 6 weeks the participants perform the balance exercise program (wii-fit balances games) at home (instruction: min. 3 times a week for each 30 minutes).
3046472|NCT02251470|Active Comparator|HBE Control (CG)|Participants receive an introduction for conventional/traditional balance exercise by an individual mentoring for over 6 weeks (a total of 6 sessions á 60 minutes). During the following 6 weeks the participants perform the balance exercise program (exercises in standing and walking) at home (instruction: min. 3 times a week for each 30 minutes).
3046473|NCT02251457|Experimental|ranolazine|ranolazine 500mg, twice daily for two weeks; 1000mg twice daily for 2 weeks
3046474|NCT02251444|Experimental|outpatient rehabilitation program|whole-body resistance training, psychological interventions, sessions for information related to ergonomics and healthy alimentation
3046475|NCT02251444|Active Comparator|physical therapy|prescribed physical therapy
3046476|NCT02251431|Experimental|Exenatide-extended release|Exenatide-extended release (BYDUREON™) 2 mg subcutaneously once per week x 38 weeks
3046477|NCT02251431|Placebo Comparator|Placebo|Matching placebo subcutaneously once per week x 38 weeks
3046478|NCT02251418|Experimental|Extracorporeal shockwave therapy|6 times extracorporeal shockwave therapy in 3 weeks. This arm also receives standard care treatment.
3046479|NCT02251418|No Intervention|Control|Standard care treatment
3046480|NCT02251405|Placebo Comparator|One big bag, no stainless container|No stainless container
3046481|NCT02251405|Active Comparator|One big bag with two stainless containers|Two stainless containers
3046482|NCT02251392|Experimental|Chamomila recutita Gel|Experimental Group 1 - patients will apply the gel since the begging of radiodermatitis, three times a day. The dose is being determined in a Phase II study that is being conducted. Topical application of gel is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
3046483|NCT02251392|Experimental|Chamomila recutita Infuse 2,5%|Experimental Group 2 - patients will apply the infuse since the begging of radiodermatitis, three times a day. The dose of 2,5% was determined before in a Phase II study. Radiodermatitis grade and intensity is going to be evaluated. Topical application of the infuse is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
3046484|NCT02251392|Active Comparator|Urea cream based|Control Group - usual care to treat radiodermatitis, patients will apply the infuse since the begging of radiodermatitis, three times a day. Radiodermatitis grade and intensity is going to be evaluated. Topical application of urea is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
3046485|NCT02251379|Experimental|ECS + Medication Group|"The Environmental Control Strategy (Home Environmental Intervention) plus inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)"
3046486|NCT02251379|Active Comparator|Medication Group Alone|inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)
3046487|NCT02251366|No Intervention|SOC Examination Based Cohort|Participants in this arm will receive standard of care (SOC) retinal examinations at each study visit.
3046488|NCT02251366|Active Comparator|Physician-Guided Diagnostic|Participants in this arm of the study will only receive the physical standard-of-care retinal examination at the 4-month and -month office visits, unless requested by the Physician-Investigator or study participant. At each standard study visit, the physician will use diagnostic imaging to determine if the participant will receive the anti-VEGF injection.
3046489|NCT02251353||lung and/or hepatic metastasis|intervention to metastasis (resection and/or radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), cyberKnife stereotactic radio surgery) vs no intervention (only systemic treatment)
3046490|NCT02251340|Experimental|Intervention|Families in the intervention group will receive an Eczema Care Plan
3046491|NCT02251340|No Intervention|Control|Families in the control group will not receive an Eczema Care Plan
3046492|NCT02251327||Case detection group|Suspected or confirmed new pulmonary tuberculosis cases who have received anti-tuberculosis drugs for less than 3 (three) days and provide up to two expectorated sputum specimens. One investigational Xpert DST test and one Xpert MTB/RIF test were performed directly on the same sputum specimen; in addition, one smear microscopy test, one mycobacterial liquid culture, and one solid culture were performed after digestion and decontamination of sputum.
3046493|NCT02251327||Drug resistance risk group|Confirmed pulmonary tuberculosis cases with documented rifampin resistance, who have received anti-tuberculosis drugs for 31 days or less and/or history of prior tuberculosis PLUS ongoing signs and/or cases with symptoms of pulmonary tuberculosis PLUS suspected drug resistance and provide up to two expectorated sputum specimens. One investigational Xpert DST test and one Xpert MTB/RIF test were performed directly on the same sputum specimen; in addition, one smear microscopy test, one mycobacterial liquid culture, and one solid culture were performed after digestion and decontamination of sputum.
3046494|NCT02251301|Active Comparator|Macronutrient isoenergetic control|Participants will also engage in twelve weeks of high intensity interval training with consumption of one serving (250 mL) of macro nutrient matched isoenergetic control (whey/casein protein and dextrose/lactose) consumed immediately and 1 h after each training session
3046495|NCT02251301|Experimental|Skim Milk|Participants will also engage in twelve weeks of High intensity interval training with consumption of one serving (250 mL) of fat-free fluid milk immediately and 1 h after each training session
3046496|NCT02251301|Placebo Comparator|Placebo|Participants will also engage in twelve weeks of high intensity interval training with consumption of one serving (250 mL) of placebo (water) consumed immediately and 1 h after each training session.
3046497|NCT02251288|Experimental|Group 1|12 patients receive Intramuscular (IM) A/H7N9 15 mcg on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of Intranasal (IN) sprayer 10^7 FFU H7 N9 pLAIV on Day 29
3046498|NCT02251288|Experimental|Group 2|12 patients receive A/H7N9 15 mcg IM on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of IN sprayer10^7 FFU H7 N9 pLAIV on Day 85
3046499|NCT02251288|Experimental|Group 3|12 patients receive S A/H7N9 15 mcg IM on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of IN sprayer 10^7 FFU H7 N9 pLAIV on Day 169
3046500|NCT02251288|Experimental|Group 4|8 patients receive A/H7N9 15 mcg IM on Day 1, 8 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1
3046501|NCT02251288|Experimental|Group 5|12 patients receive A/H7N9 15 mcg plus MF59 adjuvant on Day 1 and Day 29
3046502|NCT02251275|Experimental|Tolvaptan (OPC-41061)|
3046503|NCT02251262|Experimental|Whole-body 18FDG-PET-CT scan|18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
3046504|NCT02251249|Experimental|STEMI Group|
3046505|NCT02251249|Other|Stable patient Group|Patient referred for angioplasty for angina or non-ST-segment elevation myocardial infarction (NSTEMI)
3046506|NCT02251236|Other|Track A|Track A is for participants already taking Stribild or Genvoya at the time of study entry. Participants taking Stribild at the time of study entry will switch to Genvoya before the second PK.
3046507|NCT02251236|Other|Track B|Track B is for participants who are not taking ART at the time of study entry. Participants will start Stribild at entry and switch to Genvoya before the second PK.
3046508|NCT02251223|Experimental|TPV/r low dose|
3046509|NCT02251223|Experimental|TPV/r medium dose|
3046510|NCT02251223|Experimental|TPV/r high dose|
3046511|NCT02251210|Experimental|BIIL 284 BS low dose|
3046512|NCT02251210|Experimental|BIIL 284 BS medium dose|
3046513|NCT02251210|Experimental|BIIL 284 BS high dose|
3046514|NCT02251210|Placebo Comparator|Placebo|
3046515|NCT02251197|Experimental|BIII 890 CL|escalating doses
3046516|NCT02251197|Placebo Comparator|Placebo|
3046517|NCT02251184|Experimental|Aggrenox|extended release
3046518|NCT02251184|Active Comparator|dipyridamole+aspirin|immediate release
3046519|NCT02251171|Experimental|TPV/RTV - Rifabutin|"Day 1: single dose Rifabutin~Days 8-20: morning and evening doses of Tipranavir/Ritonavir~Day 15: single dose Rifabutin"
3046531|NCT02251132|Experimental|TPV/RTV High 2|
3046533|NCT02251119|Experimental|TPV|"Administration of LOP on days 1, 9 and 22~Administration of TPV on days 4-9~Administration of TPV/RTV on days 12-22"
3046534|NCT02251119|Experimental|RTV|"Administration of LOP on days 1, 9 and 22~Administration of RTV on days 4-9~Administration of TPV/RTV on days 12-22"
3046535|NCT02251106|No Intervention|-LBP/-Brace|Subjects in this arm did not have back pain nor did they wear brace (asymptomatic controls). Subjects had their spine function measured before and after a two week period.
3046536|NCT02251106|Active Comparator|-LBP/+Brace|Intervention = Lumbar corset (Quickdraw, Aspen Medical Products) Subjects in this arm did not have back pain but wore a brace for a two week period (asymptomatic intervention). Subjects had their spine function measured before and after a two week period.
3046537|NCT02251106|Experimental|+LBP/+Brace|Intervention = Lumbar corset (Quickdraw, Aspen Medical Products) Subjects in this arm had back pain and wore a brace for a two week period (symptomatic intervention). Subjects had their spine function measured before and after a two week period.
3046538|NCT02251093|Experimental|Lcr Regenerans|
3046539|NCT02251093|Placebo Comparator|Placebo|
3046540|NCT02251080||Internet-based Survey|Assessments completed over the 2-month study will include: disease severity as measured by DSM-V classification and by several validated measures including the ADHD Rating Scale IV with adult prompts, and Clinical Global Impressions, severity and improvement scales; adherence measures (MEMS® and pill counts); validated medication satisfaction measure (the Treatment Satisfaction Questionnaire for Medication); and quality of life measured using the validated WHO Quality of Life Brief measure (WHOQOL-BREF); and responses to a weekly Internet-based questionnaire of adherence and disease severity.
3046541|NCT02251080||Standard-of-Care|Assessments completed over the 2-month study will include: disease severity as measured by DSM-V classification and by several validated measures including the ADHD Rating Scale IV with adult prompts, and Clinical Global Impressions, severity and improvement scales; adherence measures (MEMS® and pill counts); validated medication satisfaction measure (the Treatment Satisfaction Questionnaire for Medication); and quality of life measured using the validated WHO Quality of Life Brief measure (WHOQOL-BREF);
3046542|NCT02251067|Active Comparator|VPI-2690B low dose|6 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
3046543|NCT02251067|Active Comparator|VPI-2690B medium dose|18 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
3046544|NCT02251067|Placebo Comparator|Placebo|6 or 18 mg Placebo, administered subcutaneously every 2 weeks for 48 weeks
3046545|NCT02251067|Active Comparator|VPI-2690B high dose|48 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
3046546|NCT02251054|Experimental|Avatar group|"Intervention group viewed two avatar coaches: a generic avatar coach (GAC) and a self-avatar, peer mentor (SAP)."
3046547|NCT02251054|Active Comparator|No Avatar group|The control group version (voice only) observed the identical program, including introductions, question asking, narration of animations, delivery of key points, and summary of each section with identical pre-recorded voices without the avatars.
3046548|NCT02251041|Active Comparator|cases|the group receives a combination of drugs
3046549|NCT02251041|Placebo Comparator|controles|the group do not receive a combination of drugs, but a placebo (sodium chloride solution)
3046550|NCT02251028|Active Comparator|Group A|Group A receives value-based cognitive behavior therapy after randomization.
3046551|NCT02251028|Active Comparator|Group B|Group B receives value-based cognitive behavior therapy after 3 months.
3046552|NCT02251015|Active Comparator|therapeutic exercises|13 as control group - The control group got only orientation related to therapeutic exercises.The orientation for therapeutic exercises seek to correctly position the jaw in the resting position. Maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
3046553|NCT02251015|Experimental|occlusal plate group|36 getting occlusal splints - the splinted group was subjects that used occlusal plate under the occlusal stability criteria. The patients also received therapeutic exercises too. The plate group arm, the patients used the occlusal splints for all night plus 4 hours during the day and they made therapeutic exercises 15 repetitions 3 times a day.
3046554|NCT02251002||Control|no history of TBI or neurologic disorder
3046555|NCT02251002||mTBI|documented past mild to moderate TBI
3046556|NCT02250989||Hyperinsulinemia/Euglycaemia|In this group study, a condition of Hyperinsulinemia/Euglycaemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
3046557|NCT02250989||Hyperinsulinemia/Hyperglycemia|In this group study, a condition of Hyperinsulinemia/Hyperglycemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
3046558|NCT02250989||Hypoinsulinemia/Hyperglycemia group|In this group study, a condition of Hypoinsulinemia/Hyperglycemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
3046559|NCT02250976|Experimental|Livasupril Cap.160/2mg|"Fenofibrate pellet ( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg~once a day"
3046560|NCT02250976|Active Comparator|Lipilfen cap.160mg, Livaro tab. 2mg|"Lipilfen cap.160mg : Micronized fenofibrate 160mg , Livaro tab. 2mg : Pitavastatin ca 2mg~Coadministariton of Lipilfen cap.160mg and Livaro tab. 2mg, once a day"
3046561|NCT02250963||DSE|Patients, who underwent Dobutamine Stress Echocardiography (DSE)
3046562|NCT02250963||CTCA|Computed tomography coronary angiography is going to perform with a 64-slice system (Brilliance 64, Philips Healthcare, Best, the Netherlands).
3046563|NCT02250950|Experimental|MI and SDT Exercise Group|Intervention Condition: Participated in 12 weekly meetings led by MI- and SDT-trained exercise instructor.
3046564|NCT02250950|Sham Comparator|Non-MI and SDT Exercise Group|Control Condition: Participated in 12 weekly meetings led by an exercise instructor who was not trained in MI and SDT.
3046590|NCT02250742|Experimental|low back pain group|Dry needling to the lumbar multifidus muscles using a deep insertion technique with 4 needles (2 on each side of the spine) will be utielized. The needles will be left in situ for 10 minutes.
3046979|NCT02248038|Experimental|laparoscopic surgery|Minimum invasive procedure
3046565|NCT02250937|Experimental|Arm 1 - Busulfan, Cladribine, Fludarabine|"Arm 1 - Busulfan 80 mg/m2 (PK Studies) on Day -13 and Day -12.~Fludarabine 10 mg/m2 on Days -6 through -3.~Cladribine 10 mg/m2 administered after Fludarabine on Days -6 through -3.~Busulfan administered after Cladribine at dose calculated to achieve a total (including first two doses) systemic exposure of 20,000 ± 12% µMol-min based on pharmacokinetic studies on Days -6 to -3.~Stem cell transplant on Day 0.~G-CSF 5 mcg/kg/day subcutaneously on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 x 109/L for 3 consecutive days.~Methotrexate 5 mg/m2 on Days +1, +3, +6, and +11 post bone marrow transplant.~Cyclophosphamide 50 mg/kg on Day +3 and Day +4 post bone marrow transplant."
3046566|NCT02250937|Experimental|Arm 2 - Busulfan, Cladribine, Fludarabine|"Arm 2 - Busulfan 80 mg/m2 (PK Studies) on Day - 20 and Day -13.~Fludarabine 10 mg/m2 on Days -6 through -3.~Cladribine 10 mg/m2 administered after Fludarabine on Days -6 through -3 by controlled-rate infusion pump.~Busulfan administered after Cladribine at dose calculated to achieve a total (including first two doses) systemic exposure of 20,000 ± 12% µMol-min based on pharmacokinetic studies on Days -6 to -3.~Stem cell transplant on Day 0.~G-CSF 5 mcg/kg/day subcutaneously on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 x 109/L for 3 consecutive days.~Methotrexate 5 mg/m2 on Days +1, +3, +6, and +11 post bone marrow transplant.~Cyclophosphamide 50 mg/kg on Day +3 and Day +4 post bone marrow transplant."
3046567|NCT02250924|Placebo Comparator|Placebo|Subjects will wear a silicone bracelet for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
3046568|NCT02250924|Sham Comparator|Sugar-less Gum|Subjects will chew one stick of sugar-less gum for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
3046569|NCT02250924|Experimental|Caffeinated Gum|Subjects will chew one stick of caffeinated gum (100mg caffeine per stick) for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
3046570|NCT02250911|Experimental|This web-based CCC Workshop|The Care for the Cancer Caregivers (CCC) workshop is composed of six webcasts. The Introductory Webcast is based upon Sessions 1 and 2 of Meaning-Centered Psychotherapy for Cancer Caregivers (MCP-C) and provides participants with an introduction to the CCC Workshop, an overview of the different meaning-centered modules (i.e., legacy, choice, creativity, and connectedness), and a discussion about identity and how caregivers' identities have or have not changed since taking on this role.
3046571|NCT02250911|Active Comparator|Waitlist Control|"Participants randomized to the waitlist control arm will be offered what is considered usual care at the ACS: the provision of the ACS Telephone Hotline number (1-800- 227-2345) and direction to the ACS website (www.cancer.org) where participants can find many resources for caregivers, including links to the ACS Caregiver ToolKit. They will complete assessments at time points that correspond with the completion of assessments in the CCC Workshop arm: after consent as soon as they are able (T1), about 2 months (± 4 weeks) after T1 (T2), and about 2-3 months after T2 (T3). Upon completion of all study assessments the waitlist control arm participants will be offered the opportunity to complete the CCC Workshop."
3046572|NCT02250898|Experimental|Experimental/Myofascial|The intervention group will receive Myofascial Massage Therapy specific to breast/chest/shoulder of the affected side(s). These massages will include a variety of techniques specifically aimed at reducing pain, inflammation, and tissue sensitivity while also increasing mobility by breaking up scar tissue and thick fibrosis. The intervention massages will include the following specific techniques: skin glide, j stroking, vertical stroking, strumming, fascial stretch, circular friction, deep fascial restriction release, arm pull, side latissimus dorsi stretch, twisting, moist heat application, cold therapy, and lymphatic drainage. These massages will be twice a week at 30 minutes per massage for a period of 2 months after study enrollment.
3046573|NCT02250898|Active Comparator|Control/Global Relaxation|The control group will receive a general full body massage referred to as a Global Relaxation massage. The massage technique used here will be relaxation massage, avoiding the breast/chest/arm area. This includes light kneading and stroking in order to restore a sense of well- being. The relaxation massage will also be twice a week at 30 minutes per massage for a period of 2 months, avoiding the area of the affected shoulder/shoulders. In this way they are still being seen and touched by a massage therapist, without receiving the intervention treatment.
3046574|NCT02250885|Experimental|Selinexor (KPT-330)|Selinexor will be taken orally at a starting dose of 50mg/m2 twice weekly on weeks 1, 2, and 3 of each 4 week cycle.
3046575|NCT02250872|Active Comparator|Experimental: Gemigliptin and Cisplatin|Gemigliptin 100mg daily in two divided doses for 8 days starting from one day before cisplatin-treatment
3046576|NCT02250872|Placebo Comparator|Control arm|Placebo 100mg daily in two divided doses for 8 days starting from one day before cisplatin-treatment
3046577|NCT02250859|Experimental|FMX101 Minocycline 4% foam|FMX101, 4% applied to the face, upper chest, upper back and shoulders for sixsteen consecutive days in subjects either with acne or with normal skin
3046578|NCT02250846|Experimental|arm a|EGFR exon 19 mutation with EGFR-TKI
3046579|NCT02250846|Experimental|arm b|EGFR exon 21 mutation with EGFR-TKI
3046580|NCT02250833|Experimental|CKD-828(Fixed Dose Combination)|FDC tablet consisting of Telmisartan 80mg/S-Amlodipine 5mg
3046581|NCT02250833|Active Comparator|Combination Therapy|Coadministration of Telmisartan 80mg and S-amlodipine 5mg
3046582|NCT02250820|Experimental|Nasal Dexmedetomidine and oral placebo|If the patient is assigned to the dexmedetomidine arm, they will receive dexmedetomidine through the nose. In order to keep the assignment blinded, the patient will also receive an oral placebo.
3046583|NCT02250820|Experimental|Nasal placebo and oral pentobarbital|If the patient is assigned to the pentobarbital arm, they will receive pentobarbital through the mouth. In order to keep the assignment blinded, the patient will also receive an nasal placebo.
3046584|NCT02250807|Experimental|Simeprevir and Sofosbuvir|Subjects will receive oral capsule of Simeprevir 150 milligram (mg) along with oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
3046585|NCT02250794|Active Comparator|insulin glargine and insulin lispro|insulin glargine 0.3 units per kg and insulin lispro 0.1 units per kg with each meal
3046586|NCT02250794|Experimental|metformin and sitagliptin|metformin 750 mg PO twice daily and sitagliptin 100 mg PO once daily
3046587|NCT02250781|Experimental|Treatment (Oral ONC201)|Patients receive Oral ONC201 PO on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3046588|NCT02250768|Experimental|GM-CSF|Injected oocytes were cultured in GM-CSF supplemented media until day of transfer
3046589|NCT02250755|Experimental|MRI T1 T2 sequences|comparison of perfusion sequences T1 T2 in patients with brain metastase cancer
3046591|NCT02250742|Active Comparator|healthy group|Dry needling to the lumbar multifidus muscles using a deep insertion technique with 4 needles (2 on each side of the spine) will be utilized. The needles will be left in situ for 10 minutes.
3046592|NCT02250729|Experimental|cases with NMBA anaphylaxis|Patients who experienced NMBA anaphylaxis during anesthesia
3046593|NCT02250729|Other|controls|Patients who underwent anesthesia with NMBA injection but did not experience anaphylaxis
3046594|NCT02250716|Experimental|Arm 1|Immediate treatment with Cryotherapy and 12 month cytology and histology follow-up
3046595|NCT02250716|No Intervention|Arm 2|12 month cytology and histology follow-up
3046596|NCT02250703|Active Comparator|Midazolam|In M group, patients will be given oral midazolam 0.5mg/kg upto maximum dose of 15mg (5mg/ml parenteral preparation) mixed with flavored syrup as premedication
3046597|NCT02250703|Experimental|Dexmedetomidine|In D group, patients will be given intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg prepared from 100mcg/ml parenteral preparation (Hospira R) . The drug will be administered using a intranasal mucosal administration device (LMA MAD NasalTM).
3046598|NCT02250690|Experimental|experimental group - tDCS|The tDCS intervention occur at 10 sessions of intervention where electrodes are connected to head specifically in supplementary motor area placed at 2 cm in front of vertex. The clinical stimulator (NeuroConn, Germany) provided the direct current using two silicon-sponge electrodes with a surface area of 35 cm2 (5 × 7cm) embedded in a saline-soaked solution. Immediately after 13 minutes of tDCS application, patient was submitted to gait training three times a week during 4 weeks with visuals cues. The patients were asked to walk along at a 7 meters rubber carpet to at different speed, forward and backward gait, side walk during thirty minutes with three intervals of two minutes. The patient may be at on state of drug administration and the training is applied by another physiotherapist.
3046599|NCT02250690|Sham Comparator|Control group (tDCS sham)|The sham character is ensured by the stimulation time, once the device is programmed to turn off 30 seconds after the beginning of stimulation. The current is switched in ascending ramp mode for 10 seconds until 2 mili ampere and a descending ramp similar also for 10 seconds will be used until the end of stimulation. The sham stimulation is commonly perceived by the patient as the actual treatment and all procedures for the application of the technique should be similar to those adopted for the active stimulation. Immediately after tDCS stimulation, the gait training consisting of a protocol based on sensory cues for 30 minutes is administered three times a week for four weeks. Sham stimulation will be held for 30 seconds in order to mimic the perceived lowering effect of ramp current.
3046600|NCT02250677||Patients with myalgia|Patients with myalgia as a side effect to treatment with Simvastatin (minimum 20 mg daily)
3046601|NCT02250677||Patients without myalgia|Patients treated with Simvastatin (minimum 20 mg daily) without any side effects to the treatment
3046602|NCT02250677||Control group|Patients with elevated serum cholesterol not treated with cholesterol lowering drugs
3046603|NCT02250664|Experimental|0.8 mg nicotine|0.8 mg nicotine very low nicotine content cigarettes
3046604|NCT02250664|Experimental|0.12 mg nicotine|0.12 mg nicotine very low nicotine content cigarettes
3046605|NCT02250664|Experimental|0.03 mg nicotine|0.03 mg nicotine very low nicotine content cigarettes
3046606|NCT02250651|Experimental|Bimatoprost SR Dose A|Study Eye: bimatoprost sustained-release (SR) Dose A administered on Day 1, Week 16, and Week 32; timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1, Week 16, and Week 32; timolol administered once in the morning and once in the evening for up to 20 months.
3046607|NCT02250651|Experimental|Bimatoprost SR Dose B|Study Eye: bimatoprost SR Dose B administered on Day 1, Week 16, and Week 32; timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1, Week 16, and Week 32; timolol administered once in the morning and once in the evening for up to 20 months.
3046608|NCT02250651|Sham Comparator|Sham|Both Eyes: sham administered on Day 1, Week 16, and Week 32; timolol administered once in the morning and once in the evening for up to 20 months.
3046609|NCT02250612|Experimental|SYL040012 (bamosiran) eye drops Dose A|1 drop in each eye once daily for 28 consecutive days
3046610|NCT02250612|Experimental|SYL040012 (bamosiran) eye drops Dose B|1 drop in each eye once daily for 28 consecutive days
3046611|NCT02250612|Experimental|SYL040012 (bamosiran) eye drops Dose C|1 drop in each eye once daily for 28 consecutive days
3046612|NCT02250612|Experimental|SYL040012 (bamosiran) eye drops Dose D|1 drop in each eye once daily for 28 consecutive days
3046613|NCT02250612|Active Comparator|Timolol maleate 0.5% ophthalmic solution|1 drop in each eye twice daily for 28 consecutive days
3046614|NCT02250599|Active Comparator|carboplatin and paclitaxel|carboplatin and paclitaxel :paclitaxel 175 mg/m2 IV and carboplatin AUC 6 IV on Day 1 of each 3-week cycle
3046615|NCT02250599|Experimental|AVASTIN and carboplatin and paclitaxel|AVASTIN and carboplatin and paclitaxel: Bevacizumab(AVASTIN) 7.5 mg/kg intravenously (IV) infusion on Day 1 of each 3-week cycle; paclitaxel 175 mg/m2 IV and carboplatin AUC 6 IV on Day 1 of each 3-week cycle
3046616|NCT02250586|Experimental|CBT-CSO|"The CBT-CSO program will be based on concepts from cognitive-behavioral therapy and motivational interviewing, and is specifically developed for use with CSOs of treatment refusing problem gamblers. The program resembles the community reinforcement and family training approach that has been successfully used with CSOs of substance abusers.~The program will be given as guided self-help with guidance given via email and telephone. There are 8 modules, which all contain homework exercises and about 5-10 pages of text."
3046617|NCT02250586|No Intervention|Wait-list|The participants allocated to the control condition will be put on a waiting list and offered the CBT-CSO program after 10 weeks. The CSOs will receive information about available treatment options—in their area and web-based—for the problem gambler.
3046618|NCT02250573|Experimental|Replenine®-VF|
3046619|NCT02250560|Experimental|Replenine®-VF|
3046620|NCT02250534|Experimental|0.8 mg nicotine|0.8 mg nicotine very low nicotine content cigarettes
3046621|NCT02250534|Experimental|0.12 mg nicotine|0.12 mg nicotine very low nicotine content cigarettes
3046622|NCT02250534|Experimental|0.03 mg nicotine|0.03 mg nicotine very low nicotine content cigarettes
3046623|NCT02250521|Experimental|McGrath Mac intubations|All 100 patients will be intubated using the McGRATH® MAC video laryngoscope
3046624|NCT02250508|Experimental|Optivate®|
3046626|NCT02250495|Experimental|Sympara Therapeutic System|All subjects will wear for the Sympara device for 30 days
3046627|NCT02250482|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
3046628|NCT02250469|Active Comparator|Axium SCS System|Implantation with the Axium Neurostimulator
3046629|NCT02250469|Active Comparator|Medtronic SCS System|Implantation with the Medtronic Prime Advanced Dorsal Column Stimulation System
3046630|NCT02250456||Turner syndrome patients and vascular abnormalities|
3046631|NCT02250443|Experimental|BYM338|BYM338 Group
3046632|NCT02250430|Experimental|Topical SB204|Topical application of SB204 2% and 4% twice daily for 2 days and once on Day 3
3046633|NCT02250417|Experimental|Wave Surface, Then Non Wave Surface|Subjects sleep first for a whole night in the sleep laboratory with the Wave sleep surface. They then return to the sleep laboratory and sleep without the Wave sleep surface.
3046634|NCT02250417|Experimental|Non Wave Surface, Then Wave Surface|Subjects sleep first for a whole night in the sleep laboratory without the Wave sleep surface. They then return to the sleep laboratory and sleep with the Wave sleep surface.
3046635|NCT02250404||Ancillary-Correlative (molecular profile)|Previously collected tissue samples are analyzed via RNA sequencing and DNA methylation at baseline. Patients also undergo collection of tissue samples for analysis at relapse.
3046636|NCT02250391|Experimental|NPB-06|1,500 unit, 5 days continuous-infusion
3046637|NCT02250391|Placebo Comparator|Placebo|0 unit, 5 days continuous-infusion
3046638|NCT02250378|Experimental|Treatment (stereotactic radiosurgery, wedge resection)|Patients undergo stereotactic radiosurgery every other day for 3 or 5 fractions (depending on the size tumor and proximity to the chest wall). Within 4-6 weeks after completion of stereotactic radiosurgery, patients undergo wedge resection.
3046639|NCT02250365|Experimental|Continuous, suprasensory ESS|
3046640|NCT02250365|Active Comparator|Intermittent, suprasensory ESS|
3046641|NCT02250352||Cohort I (newly diagnosed, surgery before systemic therapy)|Patients undergo baseline and, if applicable, follow-up core needle biopsies of breast cancer in the breast, regional nodes, and distant metastases. Patients who experience a recurrence or progression after therapy undergo additional core biopsies at the time of recurrence. Clinical and blood specimens will also be gathered.
3046642|NCT02250352||Cohort II (newly diagnosed, systemic therapy before surgery)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients also undergo biopsies at a specific time point following the initiation of standard systemic therapy.
3046643|NCT02250352||Cohort III (patients with suspicious breast mass)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients who have BIRADS 4b, 4c, and 5 lesions may undergo up to 6 additional 6 core biopsies.
3046644|NCT02250352||Cohort IV (breast cancer recurrence or progression)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients may also undergo 1-3 extra core biopsies.
3046645|NCT02250339||LAKU family program|Time-limited (12 or 24 months) intervention program for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). LAKU family program (12 month program) includes 35 family-based meetings. Families are also given an opportunity to attend two separate family weekends. In addition to this, parent group format may include 10 meetings at maximum. A 24-month-program will include 15 additional family-based meetings.
3046646|NCT02250339||Etä-LAKU family program|Time-limited (18 or 24 months) intervention program for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). Etä-LAKU family program (18 months) includes 35 family-based meetings and two separate family weekends. A 24-month-program will include 10 additional family-based meetings.
3046647|NCT02250339||Family therapy|Time-limited (12 or 24 months) family therapeutic intervention for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). Family therapy intervention includes 15 (1-year program) or 30 (2-year program) family meetings.
3046648|NCT02250326|Experimental|Combination arm: nab-paclitaxel and CC-486|Subjects in the combination arm will receive nab-paclitaxel 100 mg^/m2 intravenous (IV) infusion over 30 minutes on Days 8 and 15 and CC-486 200 mg orally daily (QD) on Days 1 to14 of each 21-day treatment cycle
3046649|NCT02250326|Experimental|Monotherapy arm: nab-paclitaxel IV infusion|Subjects in the monotherapy arm will receive nab-Paclitaxel 100 mg/m^2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day treatment cycle
3046650|NCT02250326|Experimental|Nab-paclitaxel and Durvalumab combination|subjects in the nab-Paclitaxel/durvalumab combination arm will receive nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and durvalumab 1125 mg IV infusion over approximately 1 hour on Day 15 of each 21-day treatment cycle
3046651|NCT02250313||Case|All patients will have the tissue from their previous negative biopsy tested with the assay. Cases are defined as those subjects who receive the ConfirmMDx assay results.
3046652|NCT02250313||Control|All patients will have the tissue from their previous negative biopsy tested with the assay. Controls are defined as subjects who will be blinded to the ConfirmMDx assay results.
3046653|NCT02250300|Experimental|MLN9708 Phase II matched sibling|Phase II Patients will be enrolled in two independent cohorts of matched sibling and matched unrelated donor transplants. Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 starting on day +60 to +90 post allogeneic HCT.
3046654|NCT02250300|Experimental|MLN9708 Phase II matched unrelated|Phase II Patients will be enrolled in two independent cohorts of matched sibling and matched unrelated donor transplants. Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 starting on day +60 to +90 post allogeneic HCT.
3046655|NCT02250300|Experimental|MLN9708 Phase I|Phase I Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 orally based on a dose escalation schema NOTE: It was determined that the maximum tolerated dose is 4 mg. Phase I is closed.
3046656|NCT02250274|Other|LAIV 2014-15|Will receive LAIV this year. Includes 5-8 year olds and approximately half of the 9-17 year olds. Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, all ages.
3046657|NCT02250274|Other|IIV 2014-15|Will receive IIV this year. Includes only 9-17 year olds (unless shortages of LAIV encountered). Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, only 9-17 year olds.
3046658|NCT02250261|Experimental|KÄPY group|Workplaces, which are supported to promote employees' active travel to and from work.
3046659|NCT02250261|No Intervention|Comparison group|Workplaces, which are not supported to promote employees' active travel to and from work during the study but will be supported to do so after the study
3046660|NCT02250248|Active Comparator|AttraX Putty|Patient will be treated with AttraX Putty intraoperatively.
3046661|NCT02250248|Active Comparator|Iliac Crest Bone Graft (ICBG)|Patients will be treated with ICBG harvested during surgery.
3046662|NCT02250235|Experimental|Self-affirmation|In the self-affirmation arm, the patients completed a 10 item questionnaire about their past acts of kindness (self-affirmation) prior to reading the health risk information.
3046663|NCT02250235|No Intervention|Control|Control patients completed 10 matched control questions with no self-affirming properties, prior to reading the health risk information.
3046664|NCT02250222|Experimental|Part 1: LGD-6972 15 mg|15 mg LGD-6972 administered once daily (QD) for 14 days.
3046665|NCT02250222|Placebo Comparator|Part 1: Placebo (Captisol ®)|Placebo administered once daily (QD) for 14 days.
3046666|NCT02250222|Experimental|Part 2: LGD-6972 5 mg|5 mg LGD-6972 administered orally QD for 14 days.
3046667|NCT02250222|Experimental|Part 2: LGD-6972 10 mg|10 mg LGD-6972 administered orally QD for 14 days.
3046668|NCT02250222|Experimental|Part 2: LGD-6972 15 mg|15 mg LGD-6972 administered orally QD for 14 days.
3046669|NCT02250222|Placebo Comparator|Part 2: Placebo (Captisol ®)|Placebo administered orally QD for 14 days.
3046670|NCT02250209|Experimental|Trastuzumab,Capecitabine,Oxaliplatin|"Patients receive eight 3-week cycles of oral capecitabine (800-1000 mg/m2 twice daily on days 1-14 of each cycle) ,intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) plus intravenous Trastuzumab (440mg on day 0 of each cycle).~Number of cycle:capecitabine and oxaliplatin --8 cycles; Trastuzumab--14-16 cycles."
3046671|NCT02250196|Active Comparator|PEG-Asc|group 1 (PEG-Asc, N=100) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
3046672|NCT02250196|Active Comparator|SPMC 2|group 2 (SPMC 2, N=100) received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
3046673|NCT02250183|Other|Medihoney & Santyl|Each patient will receive both interventions simultaneously, but on non-contiguous parts of the body that each consist of partial thickness burn injuries of similar depth. For example, if a patient presents with bilateral second-degree burns to the lower extremities, one leg will be treated with MEDIHONEY® GEL with Active leptospermum honey dressing, while the other leg will be treated with SANTYL® ointment dressing. MEDIHONEY® is the target treatment for this study, while SANTYL® is standard care.
3046674|NCT02250170|Experimental|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on & 3 days-off (21 days=1cycle)
3046675|NCT02250157|Experimental|Part 1|"Part 1 of this study is a 3+3 design to define the MTD of Oratecan in up to 60 evaluable subjects. It will be conducted in 2 parts; 1A will test the oral liquid formulation and 1B will test the oral tablet formulation of irinotecan."
3046676|NCT02250157|Experimental|Part 2|Part 2 will enroll an additional 10 subjects at the Part 1 MTD to further characterize the safety, tolerability, pharmacokinetics, and activity of Oratecan at that dose.
3046677|NCT02250144|Experimental|Morpho-specific foot orthoses|"Morpho-specific thermo-molded foot orthoses are designed according to the patient's morphotype.~Orthoses are custom-molded from different materials such as BIOFLUX resin, Covercuir MF, EVA300/60, EVA400/70, PE255/55, ABSORB Dur and CAPITON PU."
3046678|NCT02250144|Placebo Comparator|Placebo foot orthoses|The placebo foot orthoses will be made with the same principle of molding and with the same materials as for the experimental group. The only difference is that they involve no active corrective insert element : they will be made without morphotype correction.
3046679|NCT02250131|No Intervention|Control|Routine cardiopulmonary bypass technique. Flow adjusted on BSA and temperature
3046680|NCT02250131|Active Comparator|Goal Directed Perfusion|Perfusion targeted at oxygen delivery
3046681|NCT02250118|Experimental|Bevacizumab|Intrapleural use: range 0.5 - 5 mg/kg
3046682|NCT02250105|Active Comparator|ARI-3037MO|ARI-3037MO 3g bid orally for 12 weeks
3046683|NCT02250105|Placebo Comparator|Placebo|Matching placebo 3g bid orally for 12 weeks
3046684|NCT02250092|Active Comparator|tDCS/CIMT|Intervention Group will receive 20 minutes of 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT.
3046685|NCT02250092|Placebo Comparator|tDCS sham/CIMT|Placebo Group will receive 20 minutes of sham 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT.
3046686|NCT02250079|Experimental|Polyethilene body bag group|The intervention group infants were provided the same care as control infants, but were dressed with the polyethylene body bag immediately after birth. The bag had an upper opening for the head and a seal at the bottom. The intervention group infants remained in the plastic bag for the first 10 minutes after birth. The same process was done in surgery room in case of cesarean. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process were done in surgery room in case of cesarean
3046687|NCT02250079|Active Comparator|Conventional group|): Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
3046688|NCT02250066|Other|Study group 1|Received high monounsaturated fat diet
3046689|NCT02250066|Other|Study group 2|Received high carbohydrate diet
3046690|NCT02250066|No Intervention|Control Group|Control group was encouraged to follow the Food Guide Pyramid
3046691|NCT02250040|Active Comparator|Control group|Conventional physiotherapy for stroke.
3046692|NCT02250040|Experimental|Target group|Techniques based on patients' functional level were added.
3046693|NCT02250027|Experimental|experimental A (0.6g/day)|HL301 0.6g/day: 2 capsules at once, 3 times a day, for 7 days
3046694|NCT02250027|Experimental|experimental B (1.2g/day)|HL301 1.2g/day: 2 capsules at once, 3 times a day, for 7 days
3046695|NCT02250027|Experimental|experimental C (1.8g/day)|HL301 1.8g/day: 2 capsules at once, 3 times a day, for 7 days
3046696|NCT02250027|Placebo Comparator|Placebo|placebo: 2 capsules at once, 3 times a day, for 7 days
3046697|NCT02250014|Experimental|Arm I (cryotherapy, sargramostim)|Patients undergo cryotherapy on day 0 and receive sargramostim subcutaneously on days 1, 3, 5, 8, 10, and 12.
3046698|NCT02250014|Active Comparator|Arm II (cryotherapy, standard of care)|Patients undergo cryotherapy on day 0.
3046699|NCT02250001||Treatment with DCV/ASV|Patients who are beginning to receive the treatment with DCV/ASV under the approved indications, dosage, and administration will be included in this study
3046700|NCT02249988|Experimental|Group 1 - ABX203 therapeutic Hepatitis B vaccine treatment arm|ABX203 therapeutic vaccine in addition to NUCs background therapy
3046701|NCT02249988|No Intervention|Group 2 - Control arm|NUCs background therapy only
3046702|NCT02249975|Experimental|C2 CryoBalloon Focal Ablation System|Cryoballoon ablation will be performed on patients with Barrett's Esophagus.
3046703|NCT02249962||Overall cohort: HIV+ women on Option B+ and their infants|Women (n=8000) visiting an antenatal clinic for care who will be followed prospectively for Malawi standard treatment outcomes and pregnancy outcomes as patients on Option B+
3046704|NCT02249962||Sub-cohort A: first HIV diagnosis|Women (n=300) who present to the antenatal care clinic and are diagnosed for the first time with HIV. These women will be started on Option B+ as anti-retroviral treatment, per Malawi Ministry of Health standard of care.
3046705|NCT02249962||Sub-cohort B: subsequent pregnancies failing 1st line ART|Women (n=150) who have failed first-line treatment (TDF/3TC/EFV) based on HIV RNA levels and CD4 count. These women will be switched to second-line treatment (AZT/3TC/ATZ/r) per Malawi Ministry of Health standard of care.
3046706|NCT02249962||Sub-cohort C: subsequent pregnancies who default from 1st line|Women (n=150) who are HIV+ and have a subsequent pregnancy who have not been adherent to first-line (Option B+: TDF/3TC/EFV). These women will be re-initiated on first-line treatment for 3 months, then evaluated to assess whether continuation on first-line treatment is sufficient, or if they need to be switched to second-line treatment (AZT/3TC/ATZ/r) per Malawi Ministry of Health standard of care.
3046707|NCT02249949|Experimental|efatutazone dihydrochloride|Patients receive efatutazone dihydrochloride PO BID continuously. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3046708|NCT02249936|Experimental|AZD1722 HCl Capsule|15 mg bid AZD1722 HCl and 20 mg bid Omeprazole
3046709|NCT02249936|Experimental|AZD1722 HCl Tablet|15 mg bid AZD1722 HCl and 20 mg bid Omeprazole
3046710|NCT02249936|Experimental|AZD1722 Free-base Tablet|15 mg bid AZD1722 and 20 mg bid Omeprazole
3046711|NCT02249923||Pulmonary Arterial Hypertension|
3046712|NCT02249910|Experimental|Semaglutide|
3046713|NCT02249897|Placebo Comparator|PLACEBO|AFTER COMPLETING THE INITIAL EVALUATION (ANTHROPOMETRY, SERUM BIOCHEMISTRY AND CML LEVELS, FUNDUS, MUTIFOCAL ELECTRORETINOGRAM AND OPTIC NERVE CONDUCTION VELOCITY) PATIENTS WILL RECEIVE ORAL PLACEBO CAPSULES 4 PER EACH MEAL/DAY DURING 12 WEEKS
3046714|NCT02249897|Active Comparator|CHOLESTIRAMINE|AFTER COMPLETING THE CONTROL PERIOD (PLACEBO CAPSULES) PATIENTS WILL BE REASSESSED, AND THEN TREATED WITH ORAL CHOLESTYRAMINE 6 G/DAY (500 MG CAPSULES -> 4 CAPSULES PER EACH MEAL/DAY) DURING 12 WEEKS AND E SAME INITIAL EVALUATION WILL BE REPEATED
3046715|NCT02249884|Experimental|Urea Dose A|Topical application of the urea cream in concentration A. The product should be applied on the skin three times daily over 3 weeks.
3046716|NCT02249884|Experimental|Urea Dose B|Topical application of the urea cream in concentration B. The product should be applied on the skin three times daily over 3 weeks.
3046717|NCT02249884|Experimental|Urea Dose C|Topical application of the urea cream in concentration C. The product should be applied on the skin three times daily over 3 weeks.
3046718|NCT02249884|Experimental|Chamomile Dose A|Topical application of chamomile recutita gel in concentration A. The product should be applied on the skin three times daily over 3 weeks.
3046719|NCT02249884|Experimental|Chamomile Dose B|Topical application of chamomile recutita gel in concentration B. The product should be applied on the skin three times daily over 3 weeks.
3046720|NCT02249884|Experimental|Chamomile Dose C|Topical application of chamomile recutita gel in concentration C. The product should be applied on the skin three times daily over 3 weeks.
3046721|NCT02249871|Experimental|Semaglutide|
3046722|NCT02249871|Experimental|Semaglutide + Omeprazole|
3046723|NCT02249858||Control Group: Cranial Vault Protocol Group|Cranial vault protocol group will receive cranial vault hold.
3046724|NCT02249858||Experimental Group: HVLA Protocol Group|HVLA protocol group will receive cervical HVLA to the key somatic dysfunction C2-C7 segment.
3046725|NCT02249845||dehydration scales|children aged 1 - 36 months for CDS scale; 1 month - 5 years old for WHO scale and Gorelick scale
3046726|NCT02249832|Experimental|Robotic lower extremity therapy|Anklebot therapy
3046727|NCT02249819|Experimental|anodal tDCS, then sham tDCS|Participants received 1 single 20 min session of anodal tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of sham tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
3046728|NCT02249819|Experimental|sham tDCS, then anodal tDCS|Participants received 1 single 20 min session of sham tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of anodal tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
3046729|NCT02249806||PH target therapy|Patients receiving PH target therapy
3046730|NCT02249793||Study group|Healthy volunteers
3046731|NCT02249780|Experimental|New treatment|In patients with at least one well perfused parathyroid gland on ICG parathyroid angiography, no postoperative parathyroid dosage and supplementation will be done. Calcium and parathormone dosage will be done 10 days after surgery.
3046769|NCT02249520|Other|PET-MR imaging on Biograph mMR scanner|Research PET-MR imaging on Biograph mMR scanner will be conducted immediately following administration of FDG for clinically approved scan. No additional radioisotope will be administered for the research scan.
3046732|NCT02249780|Active Comparator|Standart treatment|In those patients in whom at least on of the four parathyroid glands is well perused, postoperative parathyroid function test and parathyroid supplementation will be done. Calcium and parathormone dosage will be done at 24 hours and 10 days after surgery. Prophylactic supplementation of calcium and Vitamin D will be given.
3046733|NCT02249767|Active Comparator|Generic Tretinoin|Treatment of acne once daily over 12 weeks
3046734|NCT02249767|Active Comparator|Brand Tretinoin|Treatment of Acne once daily over 12 weeks
3046735|NCT02249767|Placebo Comparator|Placebo Vehicle|Treatment of acne once daily over 12 weeks
3046736|NCT02249754|Active Comparator|Routine health education|Routine health education alone
3046737|NCT02249754|Experimental|Nutrition education package|Nutrition education package and routine health education
3046738|NCT02249741|Experimental|Patients with osteoporosis|Treated with Ibandronic acid as per protocol
3046739|NCT02249728|Experimental|Absolute Bioavailability|IV PBT2 microtracer and oral PBT2 single dose
3046740|NCT02249728|Experimental|Radiolabelled AME|oral 14C PBT2
3046741|NCT02249715|Experimental|rDTMS|
3046742|NCT02249702|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 will be administered via a central venous catheter as a 24-hour infusion on day 1 of 21-days treatment cycles. Trabectedin treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician.
3046743|NCT02249702|Active Comparator|gemcitabine + docetaxel|Gemcitabine 900 mg/m2 will be administered via a central venous catheter on days one and eight over 90 min, followed by docetaxel 75 mg/m2 on day eight iv over 1 h. Gemcitabine+docetaxel treatment is planned for six cycles, unless there is evidence of disease progression, unacceptable toxicity or patient's intolerance or unwillingness to continue treatment, or medical decision by the responsible physician. Patients with continued response after six cycles can receive two additional cycles of combination therapy or continue with Gemcitabine alone.
3046744|NCT02249689|Experimental|Definitive 65|
3046745|NCT02249689|Active Comparator|Definitive 74|
3046746|NCT02249676|Experimental|Autologous mesenchymal stem cells group|"Generated clinical-grade MSC 10 mg chlorpheniramine Po.;100 mg hydrocortisone iv.;10 mg metoclopramide im.;30 min before administration of the cells .~MSC a day-case 2·0×106 cells/kg i.v. 15min Infused normal saline 500 Ml over 4 h i.v."
3046747|NCT02249676|Placebo Comparator|Control group|Patients with progressive and refractory NMO treated with regular methods
3046748|NCT02249663|Experimental|Investigational Test Product|Azelastine hydrochloride and Fluticasone propionate Nasal Spray, 137/50 mcg
3046749|NCT02249663|Active Comparator|Reference Listed Drug|Dymista™ (azelastine hydrochloride/fluticasone propionate) Nasal Spray, 137/50 mcg
3046750|NCT02249663|Placebo Comparator|Placebo|Placebo Nasal Spray
3046751|NCT02249650|Experimental|TSB-9-W1 cohort|TSB-9-W1 200 mg/day (Cohort 1) TSB-9-W1 400 mg/day (Cohort 2) TSB-9-W1 600 mg/day (Cohort 3) TSB-9-W1 800 mg/day (Cohort 4) TSB-9-W1 1000 mg/day (Cohort 5)
3046752|NCT02249637||Inguinal Orchidopexy|Patients with diagnosed palpable low inguinal cryptorchidism underwent inguinal approach as originally described by Schuller and Bevan.
3046753|NCT02249637||Novel Technique (Circumcision incision)|Patients with diagnosed palpable low inguinal cryptorchidism underwent novel technique- circumcision incision orchidopexy.
3046754|NCT02249624||Survivors of TTTS|Infants who have survived TTTS to hospital discharge, have an MRI at term, and return for nursery follow-up clinic.
3046755|NCT02249611|Experimental|MT and life counseling|To improve physical activity, body composition, physiological parameters and quality of life by using MT (mobile physical activity promotion tool) and lifestyle counseling in diet control, increased physical activity, less smoking and drinking, deal with pressure, and regular health examination will be conducted for 3 months in intervention periods.
3046756|NCT02249611|Active Comparator|Standard care|Lifestyle counseling in diet control, increased physical activity, less smoking and drinking, deal with pressure, and regular health examination based on the booklet of metabolic syndrome prevention which is edited by Health Promotion Administration, Ministry of Health and Welfare in Taiwan only once in this period (3 months).
3046757|NCT02249598|Experimental|Univeristy of Sheffield|lactamica
3046758|NCT02249598|Placebo Comparator|Hallam University|Phosphate Buffered Saline (PBS)
3046759|NCT02249585|Experimental|CS|Patients who receive laparoscopic colon surgery under Trendelenberg position with conventional neuromuscular blockade and standard abdominal pressure.
3046760|NCT02249585|Experimental|DS|Patients who receive laparoscopic colon surgery under Trendelenberg position with deep neuromuscular blockade and standard abdominal pressure.
3046761|NCT02249585|Experimental|DL|Patients who receive laparoscopic colon surgery under Trendelenberg position with deep neuromuscular blockade and low abdominal pressure.
3046762|NCT02249572|Experimental|gamma knife radiosurgery|Single fraction gamma knife radiosurgery given at 12 Gy to tumor periphery for vestibular schwannoma
3046763|NCT02249572|No Intervention|Expectation|No active treatment given for vestibular schwannoma
3046764|NCT02249559||GK subthalamotomy|Evaluate the safety and efficacy of unilateral GK subthalamotomy for PD in patients deemed poor candidates for DBS.
3046765|NCT02249546|Experimental|Acetylcysteine + PPI-amoxicillin-clarithromycin|N-acetylcysteine 600mg bid Dexlansoprazole 60mg qd Amoxicillin 1000mg bid Clarithromycin 500mg bid All for 14 days
3046766|NCT02249546|Active Comparator|PPI-amoxicillin-clarithromycin|Dexlansoprazole 60mg qd Amoxicillin 1000mg bid Clarithromycin 500mg bid All for 14 days
3046767|NCT02249533|Experimental|Spot Light and High School RIO|"A total of 200 youth football teams (100 high school and 100 middle school-aged teams) will be enrolled. Potential participating teams, all high schools eligible to report football data to High School RIO™ as well as all Pop Warner and Middle School sponsored football teams that have a valid e-mail contact, will be e-mailed a letter inviting them to participate (Appendix 3).~Intervention: Certified Athletic Trainers will be given access to report football injuries via High School RIO and will report potential concussions using the Spot Light Concussion app."
3046768|NCT02249533|No Intervention|Control|Control: Certified Athletic Trainers will be given access to report football injuries via High School RIO.
3046770|NCT02249520|Other|MR-only imaging on Biograph mMR scanner|Participants will undergo research MR-only imaging on Biograph mMR scanner.
3077021|NCT02047292|Active Comparator|THA40|THA Corail DeltaMotion40
3046771|NCT02249520|Other|MR imaging on the Siemens Vida 3T MR scanner|Participants will undergo research MR imaging on the Siemens MR scanner
3046772|NCT02249507|No Intervention|Control|sited rest for 45 minutes
3046773|NCT02249507|Experimental|higher intensity aerobic exercise|45 minutes of aerobic exercise at 75%HRmax
3046774|NCT02249507|Experimental|lower intensity aerobic exercise|45 minutes of aerobic exercise at 50%HRmax
3046775|NCT02249494|Experimental|Smartphone (mobile app) & telehealth|Participants will install and use a mobile application designed to provide nutritional recommendations for hypertensive patients. These recommendations will be based on the DASH diet guidelines appropriate to patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol. The call service will be offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can use this call center when they have questions about diagnosis and management of their patients.
3046776|NCT02249494|Placebo Comparator|nutritional counseling & telehealth|Physicians who are enrolled for this group will continue performing routine nutritional counseling in their clinical practice. The call service will be offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can use this call service when they have questions about diagnosis and management of their patients.
3046777|NCT02249481|Active Comparator|Group F|Femoral nerve catheter delivering 0.0625% L- Bupivacaine: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
3046778|NCT02249481|Experimental|Group A|Adductor canal catheter delivering 0.0625% L- Bupivacaine: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
3046779|NCT02249468||Mild and Moderate Alzheimer's Disease|
3046780|NCT02249468||Cognitively intact healthy people|
3046781|NCT02249455|Experimental|Acapella|Acapella is given to the patients twice daily for 20 min.
3046782|NCT02249455|Experimental|ELTGOL|Expiration with open glottis in lateral position is done twice daily for 20 min
3046783|NCT02249455|Active Comparator|conventional physiotherapy|Conventional physiotherapy like breathing exercise, active coughing, chest mobilisation was encouraged twice daily for 20 min.
3046784|NCT02249442|Experimental|Scheme A, mild hepatic subjects|multi-dose
3046785|NCT02249442|Experimental|Scheme B, moderate hepatic subjects|single dose
3046786|NCT02249429|Experimental|PQR309|
3046787|NCT02249416|Experimental|TPV/RTV low + ZDV|
3046788|NCT02249416|Experimental|TPV/RTV high + ZDV|
3046789|NCT02249403|Experimental|Talsaclidine, 6 mg tid|
3046790|NCT02249403|Experimental|Talsaclidine, 12 mg tid|
3046791|NCT02249403|Experimental|Talsaclidine, 24 mg tid|
3046792|NCT02249403|Experimental|Talsaclidine, 36 mg tid|
3046793|NCT02249403|Experimental|Talsaclidine, 36 mg bid|
3046794|NCT02249403|Placebo Comparator|Placebo|
3046795|NCT02249390||Anyone|Any individual may complete this survey
3046796|NCT02249377|Experimental|Platelets-Rich-Plasma Group|Patients will be asked to stop taking any type of anti-inflammatory medication from 7 days before the procedure to 2 weeks after and fasting for 3 hours before the procedure. At the moment of the procedure, the radiology team will draw 60ml of venous blood from the patient, the blood will be processed with different components of the PRP kit and centrifuged in the SmartPrep PRP machine, to obtain the PRP. The patient is then scanned prone using a linear 14 or 9 megahertz (MHz) transducer. A 20 Gauge spinal needle is usually employed for purposes of aspiration. Sterile saline will be used to confirm needle placement in the cyst in lieu of lidocaine and then inject the PRP by the radiologist.
3046797|NCT02249377|Active Comparator|Corticosteroid group:|Patients will be asked to stop taking any kind of anti-inflammatory medication from 7 days before the procedure to 2 weeks after but fasting in this group won't be required. An ultrasound guided aspiration and triamcinolone (40 mg) diluted with lidocaine without epinephrine and ropivacaine will be used to anesthetize the tissues down to the cyst (including within the cyst for steroid injections). A compression bandage will be placed locally for 7 days. Investigators will monitor any side effect from the injection and treat the patients per standard care - this can include prescription of analgesics.
3046798|NCT02249364|Active Comparator|Control|Standard care without hypnosis session followed by closed-loop administration of propofol for anesthesia induction
3046799|NCT02249364|Experimental|Hypnosis|Hypnosis session followed by closed-loop administration of propofol for anesthesia induction
3046800|NCT02249351|Experimental|Talsaclidine|
3046801|NCT02249351|Placebo Comparator|Placebo|
3046802|NCT02249338|Experimental|BIIL 284 BS|
3046803|NCT02249338|Placebo Comparator|Placebo|
3046804|NCT02249325|Experimental|Probiotic dietary supplement|Florajen3 oral probiotic (>7.5 x10^9 L. acidophilus, >6.0 x10^9 .B. lactis, and >1.5 x10^9 B .longum) taken daily beginning at 28 weeks gestation.
3046805|NCT02249325|No Intervention|Placebo|Women in the comparison group did not take a placebo.
3046806|NCT02249312|Experimental|BIIIL|
3046807|NCT02249312|Placebo Comparator|Placebo|
3046808|NCT02249299|Active Comparator|Sativex Oromucosal Spray|Participants will titrate onto Sativex during the first two weeks of the study, carried out according to a standardised dosing schedule. After 2 weeks the clinician and participant will decide on the optimal dose for the remainder of the 4 week trial
3046809|NCT02249299|Placebo Comparator|Placebo|Participants will titrate onto the placebo during the first two weeks of the study, carried out according to a standardised dosing schedule. After 2 weeks the clinician and participant will decide on the optimal dose for the remainder of the 4 week trial
3046810|NCT02249286|Experimental|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production.
3046812|NCT02249260|Experimental|Behavioral|Group-based high intensity interval training and lifestyle counseling
3046813|NCT02249247|Experimental|Low dose of BIIL 284 BS|
3046814|NCT02249247|Experimental|Medium dose of BIIL 284 BS|
3046815|NCT02249247|Experimental|High dose of BIIL 284 BS|
3046816|NCT02249247|Placebo Comparator|Placebo|
3046817|NCT02249234|Experimental|Botox|Botox 200 units reconstituted in 10ml of normal saline for a one-time injection
3046818|NCT02249234|Placebo Comparator|Saline|Saline 10ml of normal saline for a one-time injection
3046819|NCT02249221|Experimental|Quadrivalent cell-culture based influenza vaccin|Day 1: GC3106, 0.5ml, intramuscular, a single dosing
3046820|NCT02249221|Active Comparator|Trivalent influenza vaccine|Day 1: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing
3046821|NCT02249208|Active Comparator|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery.
3046822|NCT02249208|Experimental|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery.
3046823|NCT02249208|Experimental|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery.
3046824|NCT02249182|Experimental|PK Lead-in Phase, Cohort 1|During screening, participants will receive placebo to match LDV/SOF FDC to assess ability to swallow. After screening, participants between 12 to < 18 years of age weighing ≥ 45 kg will receive LDV/SOF FDC 90 mg/400 mg for 10 days (or LDV/SOF FDC 4 x 22.5 mg/100 mg based on swallowability assessment during screening).
3046825|NCT02249182|Experimental|PK Lead-in Phase, Cohort 2|During screening, participants will receive placebo to match LDV/SOF FDC to assess ability to swallow. After screening, participants between 6 to < 12 years of age weighing ≥ 17 kg and < 45 kg will receive LDV/SOF FDC 2 x 22.5 mg/100 mg for 10 days.
3046826|NCT02249182|Experimental|PK Lead-in Phase, Cohort 3|Participants between 3 to < 6 years of age weighing ≥ 17 kg will receive 45 mg/ 200 mg (4 x 11.25 mg/ 50 mg packets) LDV/SOF FDC and those weighing < 17 kg will receive 33.75 mg/ 150 mg (3 x 11.25 mg/ 50 mg packets) LDV/SOF FDC for 10 days.
3046827|NCT02249182|Experimental|Treatment Phase, Group 1|"Participants not rolling over from the PK Lead-in Phase will receive placebo to match LDV/SOF FDC to assess ability to swallow during screening. Participants between 12 to < 18 years of age will receive LDV/SOF FDC 90 mg/400 mg (or LDV/SOF FDC 4 x 22.5 mg/100 mg based on swallowability assessment during screening).~HCV Genotype 1, 4, 5, or 6 (United Kingdom/ United States/Australia/New Zealand): Treatment naive with or without cirrhosis and treatment-experienced without cirrhosis will receive LDV/SOF FDC for 12 weeks. Treatment-experienced with cirrhosis will receive LDV/SOF FDC for 24 weeks.~HCV Genotype 4, 5, or 6 (United States/Australia/New Zealand): Treatment-naïve or treatment-experienced participants with or without cirrhosis: LDV/SOF FDC for 12 weeks~HCV Genotype 3 (United Kingdom): Treatment-experienced with or without cirrhosis participants will receive LDV/SOF FDC + RBV for 24 weeks."
3046828|NCT02249182|Experimental|Treatment Phase, Group 2|"Participants not rolling over from the PK Lead-in Phase will receive placebo to match LDV/SOF FDC to assess ability to swallow during screening. Participants between 3 to < 12 years of age will receive LDV/SOF FDC (age-appropriate dose and formulation pending PK and safety results from Cohort 2 in PK lead-in phase).~HCV Genotype 1, 4, 5, or 6 (United Kingdom/ United States/Australia/New Zealand): Treatment naive with or without cirrhosis and treatment-experienced without cirrhosis will receive LDV/SOF FDC for 12 weeks. Treatment-experienced with cirrhosis will receive LDV/SOF FDC for 24 weeks.~HCV Genotype 4, 5, or 6 (United States/Australia/New Zealand): Treatment-naïve or treatment-experienced participants with or without cirrhosis: LDV/SOF FDC for 12 weeks~HCV Genotype 3 (United Kingdom): Treatment-experienced with or without cirrhosis participants will receive LDV/SOF FDC + RBV for 24 weeks."
3046829|NCT02249169||IBS-C|Patients with a clinical diagnosis of constipation-predominant irritable bowel syndrome
3046830|NCT02249169||IBS-D|Patients with a clinical diagnosis of diarrhea-predominant irritable bowel syndrome
3046831|NCT02249169||Healthy subjects|Subjects without a clinical diagnosis of IBS-C or IBS-D
3046832|NCT02249169||Healthy Controls|Subject without a clinical diagnosis of IBS-C or IBS-D and who is either a first-degree relative of an IBS participant or is not genetically related but resides with the IBS participant
3046833|NCT02249156||Financial incentive group|Employees of employers who have introduced the Rewards program. Currently there are two employers who have introduced the Rewards program, but there might be others that introduce it in the coming months. All intervention (and control) employers are customers of Castlight and use their price transparency product.
3046834|NCT02249156||Control population|Large employers who have not introduced the Rewards program, but work with Castlight and use their transparency product. It will be ideal if the control population looks similar to the intervention population in key characteristics - age, level of illness, industry of the employer (for example, manufacturing), pre-intervention spending, and geographic distribution. If possible, across a pool of potential control employers, we will identify control employers that look the most similar across these characteristics in the pre-intervention period. Another possible strategy we might use is to weight the individuals in the control population in our analyses by how similar they appear to those in the intervention population.
3046835|NCT02249143|Active Comparator|CPAP and room air|Stable premature infants on CPAP and room air will be randomized to stay on CPAP for an additional two weeks.
3046836|NCT02249143|No Intervention|Room air|Premature stable infants on CPAP and room air will be randomized to transition to room air alone.
3046837|NCT02249130|Experimental|Treatment of HIV- infected patients|14 days treatment with tipranavir, ritonavir, then 46 weeks of triple- treatment with delavirdine, zidovudine and lamivudine (stavudine for patients intolerant of zidovudine)
3046838|NCT02249117|Experimental|BIWH 3|single escalating dose
3046839|NCT02249117|Placebo Comparator|Placebo|
3046840|NCT02249104|Experimental|Acne treatment|"Adapalene/benzoyl peroxide gel, 0.1%/2.5%, once daily~Cetaphil Acne Regimen:~Cetaphil® DermaControl™ Moisturizer SPF 30, once daily and additionally 15 minutes prior to participation in outdoor sports if more than 2 hours elapsed since morning application~Cetaphil® DermaControl™ Foam Wash, at least twice daily"
3047328|NCT02245750|Experimental|Hysteroscopy|hysteroscopy will be done prior to the ICSI cycle
3046841|NCT02249091|Experimental|Selinexor in combination with cytarabine and idarubicin|"All enrolled patients will be treated with cytarabine at a dose of 100 mg/m² continuous infusion (day 1-7) and idarubicin at a dose of 10 mg/m² iv (day 1,3,5) every 4 weeks and selinexor for up to 2 induction cycles. If a second cycles is applied idarubicin is only given on day 1 and 3.~Selinexor will be administered at a dose of 40 mg/m² twice weekly orally starting on day 2 (total of 8 doses per induction cycle)."
3046842|NCT02249078|Experimental|Cohort 1|100 mg subcutaneous once every 2 weeks with initial double dose (200 mg total)
3046843|NCT02249078|Experimental|Cohort 2|200 mg subcutaneous once every 2 weeks with initial double dose (400 mg total)
3046844|NCT02249078|Experimental|Cohort 3|400 mg subcutaneous once every 2 weeks with initial double dose (800 mg total)
3046845|NCT02249078|Experimental|Cohort 4|10 mg/kg IV at Day 1, Day 8, Day 15, and every 2 weeks thereafter
3046846|NCT02249078|Placebo Comparator|Placebo|Placebo 2-mL vial solution for injection
3046847|NCT02249065|Experimental|Mirvaso Gel|Brimonidine topical gel, 0.33%
3046848|NCT02249052|Active Comparator|AA4500|single injection of 0.58 mg study drug
3046849|NCT02249052|Placebo Comparator|Placebo|single injection of placebo
3046850|NCT02249039|Experimental|intermittent IV CLON|Mechanically ventilated infants and children receive intravenous intermittentClonidine
3046851|NCT02249026|Experimental|BZDs + opiate exposure treated with BPN|In-utero opiate and BZD exposed neonates + Buprenorphine sub-lingual administered in dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed.
3046852|NCT02249026|Active Comparator|Opiates exposure treated with BPN|In-utero opiate exposed neonates + Buprenorphine sub-lingual administered in dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed.
3046853|NCT02249013|Experimental|HIPEC|Neoadjuvant Chemotherapy (NACT) followed by Cytoreductive Surgery (CRS) under a Fast-track recovery strategy plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and thus, Adjuvant Chemotherapy
3046854|NCT02249000|Experimental|BIOVALVE prosthesis|Transcatheter Aortic Valve Replacement (TAVR)
3046855|NCT02248987||Clozapine|stable patients treated with clozapine
3046856|NCT02248987||Other antipsychotics|stable patients treated with risperidone or paliperidone or olanzapine
3046857|NCT02248987||Healthy volunteer|healthy controls
3046858|NCT02248974|Active Comparator|LVAD Decision Aid|Decision aid presented to subjects was developed from patient and clinician feedback to increase patient knowledge on the risks, benefits, misconceptions or mispredictions regarding LVADs to help patients make an informed decision on accepting or declining LVAD placement.
3046859|NCT02248974|No Intervention|No LVAD Decision Aid|The standard education processis institution-specific and unstandardized. The education consists of viewing education pamphlets that are created by device manufacturers. The traditional informed consent process may also include viewing and manipulating the actual device and meeting a patient with a device already implanted. Additionally, the LVAD coordinator describes the device and answers any questions LVAD candidates have.
3046860|NCT02248961|Experimental|Kanarb (Fimasartan)|88 subjects will receive Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, tablets 60/120 mg for 12 weeks
3046861|NCT02248961|Active Comparator|Cozaar® (Losartan)|88 subjects will receive Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablets 50/100 mg for 12 weeks
3046862|NCT02248948|Placebo Comparator|Medium Chain Triglycerides Supplement|Medium Chain Triglycerides Oil with 5 micrograms of Vitamin D and 6 mg of Vitamin E in 4 ml.
3046863|NCT02248948|Experimental|Omega-3 Fatty Acids Supplement|The Omega-3 Fatty Acid supplement provides 540 mg of eicosapentaenoic acid (EPA), 340 mg of docosahexaenoic acid (DHA), 60 mg of gamma linolenic acid (GLA/Omega-6), 5 micrograms of Vitamin D and 6 mg of Vitamin E in 4 ml.
3046864|NCT02248935||Repair with Alyte or Restorelle Y-Mesh|Women who underwent their index robotic-assisted laparoscopic sacrocolpopexy at Morristown Medical Center or Overlook Medical Center using either the Alyte Y-mesh or Restorelle Y-smartmesh between 1/2007 and 8/2011.
3046865|NCT02248922|Experimental|Inhaled Tobramycin|300mg nebulized Tobramycin twice a day (BID) 28days on / 28 days off or equivalent dry powder Tobramycin
3046866|NCT02248909||Patients with COPD risk factors|Group of subjects with COPD risk factors. This group will include patients aged ≥40 years, with smoking history of ≥10 pack years and long-active (not less than 3 consequent months) respiratory complaints
3046867|NCT02248909||Patients previously diagnosed with COPD|Group of patients who according to the medical records have already been diagnosed with COPD
3046868|NCT02248896||Hypertensive patients|Hypertensive patients or patients treated with antihypertensive drugs with linked GPRD and hospital episodes statistics database (HES) data
3046869|NCT02248883|Experimental|low TPV/RTV|
3046870|NCT02248883|Experimental|high TPV/RTV|
3046871|NCT02248883|Experimental|Placebo/RTV|
3046872|NCT02248870|Placebo Comparator|Saline|Bupivacaine with adrenaline with 2 ml. of Saline added
3046873|NCT02248870|Experimental|Dexamethasone|Bupivacaine with adrenaline with 2 ml. of Dexamethasone added
3046874|NCT02248857|No Intervention|Usual Care|Employ the current standard of care. No intervention.
3046875|NCT02248857|Experimental|UMS strategy|"Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.~Prescription instructions will be adapted to UMS to establish four standard time intervals for prescribing and dispensing of medicine. UMS instructions also use simplified text and numeric characters instead of words to detail dose.~Single-page, plain language medication information sheets with content from a patient's perspective and following health literacy best practices.~A list of their current medications each corresponding to a set of instructions and a checkbox for morning, noon, evening, and bedtime medicine to help patients visually depict when to take their medicines."
3046876|NCT02248857|Experimental|UMS strategy + SMS texting reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
3046877|NCT02248844||Botulinum Toxin Type A|Subjects who receive botulinum toxin Type A injected into crow's feet line areas per clinical practice.
3078258|NCT02038673|Experimental|Dose escalation part 2.0 mg QD|Oral
3046878|NCT02248831|Experimental|Doppler ultrasound|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
3046879|NCT02248818|Experimental|AZD8108|Subjects will participate in 1 of 7 groups and receive single or multiple doses of AZD8108 or matching placebo. In each group 6 subjects will receive AZD8108
3046880|NCT02248818|Placebo Comparator|Placebo to match AZD8108|Subjects will participate in 1 of 7 groups and receive single or multiple doses of AZD8108 or matching placebo. In each group 2 subjects will receive matching placebo
3046881|NCT02248805|Experimental|Does Escalation Arm A|MGD007 treatment once weekly
3046882|NCT02248805|Experimental|Dose Escalation Arm B|MGD007 treatment once every 3 weeks
3046883|NCT02248805|Experimental|Dose Expansion Arm C|MGD007 once every 3 weeks for K-ras wild-type and mutant metastatic CRC
3046884|NCT02248805|Experimental|Dose Expansion Arms|MGD007 2, 3, 6, or 12 doses/cycle
3046885|NCT02248792|Experimental|Group A|Methotrexate 10mg orally once weekly
3046886|NCT02248792|Active Comparator|Group B|Methotrexate 25mg orally once weekly
3046887|NCT02248779||treated < 20 years prior to study enrollment|"The following information will be gathered:~A. Height, weight, waist circumference, blood pressure B. Oral glucose tolerance testing (OGTT) where in participants will ingest a standard oral glucose load (75 grams) in liquid formulation after an overnight fast. Blood samples for glucose and insulin concentrations will be taken at 0, 30, 60, 90, and 120 minutes post-glucose load.~C. Glutamic acid decarboxylase (GAD), islet cell (ICA-512), and insulin autoantibody (IAA) titers as well as serum adiponectin and hemoglobin A1c.~All enrolled patients will have a discussion with an LTFU doctor regarding the results of testing. Counseling and referral to a specialist will be provided if indicated."
3046888|NCT02248779||treated ≥ 20 years prior to study enrollment|"The following information will be gathered:~A. Height, weight, waist circumference, blood pressure B. Oral glucose tolerance testing (OGTT) where in participants will ingest a standard oral glucose load (75 grams) in liquid formulation after an overnight fast. Blood samples for glucose and insulin concentrations will be taken at 0, 30, 60, 90, and 120 minutes post-glucose load.~C. Glutamic acid decarboxylase (GAD), islet cell (ICA-512), and insulin autoantibody (IAA) titers as well as serum adiponectin and hemoglobin A1c.~All enrolled patients will have a discussion with an LTFU doctor regarding the results of testing. Counseling and referral to a specialist will be provided if indicated."
3046889|NCT02248766|Other|enfilcon A|All participants are habitual wearers of enfilcon A lens who are refitted with somofilcon A lens
3046890|NCT02248753|Active Comparator|Standard Care|Pharmacological cardioversion and/or electrical cardioversion
3046891|NCT02248753|Experimental|Wait-and-see Approach|Rate control drugs only (metoprolol, verapamil or digoxin)
3046892|NCT02248740|Active Comparator|Radiofrequency Ablation|"Device: ClosureFast radiofrequency catheter (VNUS Medical Technologies Inc, San Jose, CA).~Patients will have the intervention, ablation of the incompetent small saphenous vein, using this device."
3046893|NCT02248740|Active Comparator|Laser Ablation|"Device: EVLT 980nm diode laser system (Angiodynamics, Queensbury, NY).~Patients will have the intervention, ablation of the incompetent small saphenous vein, using this device."
3046894|NCT02248727|Other|enfilcon A|All participants are habitual wearers of enfilcon A lens and who are refitted with somofilcon A lens
3046895|NCT02248714|Experimental|Study arm|Use Glucerna SR as a meal replacement at breakfast meal in the study group, meanwhile patients receive diabetes diet management (Each subject will be individually instructed by a dedicating dietitian how to implement the daily diabetes diet before starting the study.)
3046896|NCT02248714|No Intervention|Control arm|Patients only receive diabetes diet management according to the instruction of dedicating dietitian on how to implement the daily diabetes diet.
3046897|NCT02248701|Experimental|testosterone enanthate, finasteride|Testosterone enanthate via i.m. injection (125 mg/week) and finasteride orally (5 mg/day)
3046898|NCT02248701|Placebo Comparator|placebo treatment|Placebo via i.m. injection (once weekly) and placebo pill orally (daily)
3046899|NCT02248688|Other|Embolic Agent - BeadBlock|Left Gastric Artery Embolization - Embolic Agent - BeadBlock 300 - 500 Micron will be used as the embolic agent to embolize left gastric artery.
3046900|NCT02248675|Experimental|CBT-I + TAU|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions as an adjunctive treatment to treatment as usual (TAU).
3046901|NCT02248675|Active Comparator|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
3046902|NCT02248662||BCS with radiation therapy|Women diagnosed with DCIS who receive breast conserving surgery (BCS) followed by radiation therapy.
3046903|NCT02248662||BCS without radiation therapy|Women diagnosed with DCIS who receive breast conserving surgery (BCS) not followed by radiation therapy.
3046904|NCT02248649|Experimental|Arm 1|Structured exercise
3046905|NCT02248649|Active Comparator|Arm 2|Health education
3046906|NCT02248636|Experimental|Real discontinuation|This group is tapered off their previous cholinesterase inhibitor medication.
3046907|NCT02248636|Sham Comparator|Sham discontinuation|This group receives their previous cholinesterase inhibitor medication, but in in placebo form.
3046908|NCT02248610||Rivaroxaban|All participants will be treated with rivaroxaban.
3046909|NCT02248597|Experimental|Treatment (stem cell transplant with GVHD prophylaxis)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV QD on days -6 to -2. Patients receiving myeloablative conditioning receive busulfan IV every 6 hours for 16 doses on days -7 to -4 and patients receiving reduced intensity conditioning receive busulfan IV every 6 hours for 8 doses on days -5 to -4. Patients also receive cyclophosphamide IV QD on days -3 and -2~TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide QD on days 3 and 4, tacrolimus on days 5-180, and mycophenolate mofetil on days 5-35. Allogeneic hematopoietic stem cell transplantation"
3046910|NCT02248584|Experimental|Vitamin E, C and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
3046911|NCT02248584|Placebo Comparator|Placebo|Capsule containing only lactose
3046912|NCT02248571|Experimental|Arm A|"Bevacizumab plus Capecitabine (1st treatment phase) followed by Everolimus plus Exemestane (2nd treatment phase)~Dosing (treatment cycle: 21days):~Capecitabine: 1000 mg/m2 orally applied twice daily as combined 150 mg and 500 mg tablets on days 1 to 14 of each 21-day cycle, followed by a seven day rest period (i.e. off-treatment) --- Bevacizumab: 15 mg/kg intravenously applied once every three weeks (i.e. 5 mg/kg/wk dose equivalent)~Everolimus: 10 mg/day orally applied tablet --- Exemestane: 25 mg/day orally applied tablet~Patient questionaires to assess patient reported outcome and patients' preference will be completed at four specific time points during study treatment (two timepoints in each treatment phase)"
3046913|NCT02248571|Experimental|Arm B|"Everolimus plus Exemestane (1st treatment phase) followed by Bevacizumab plus Capecitabine (2nd treatment phase)~Dosing (treatment cycle: 21days):~Everolimus: 10 mg/day orally applied tablet --- Exemestane: 25 mg/day orally applied tablet~Capecitabine: 1000 mg/m2 orally applied twice daily as combined 150 mg and 500 mg tablets on days 1 to 14 of each 21-day cycle, followed by a seven day rest period (i.e. off-treatment) --- Bevacizumab: 15 mg/kg intravenously applied once every three weeks (i.e. 5 mg/kg/wk dose equivalent)~Patient questionaires to assess patient reported outcome and patients' preference will be completed at four specific time points during study treatment (two timepoints in each treatment phase)"
3046914|NCT02248558|Active Comparator|Conventional video|This arm will receive a one-minute conventional video promoting HIV test uptake.
3046915|NCT02248558|Experimental|Crowdsourced video|This arm will receive a one-minute crowdsourced video promoting HIV test uptake.
3046916|NCT02248545||Non-celiac Wheat Sensitivity Patients|Consecutive adult patients with irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
3046917|NCT02248545||Celiac Disease Patients|Celiac disease adult patients, sex- and age-matched, diagnosed according to standard criteria, during the same study period, chosen at random and enrolled as first control group.
3046918|NCT02248545||Irritable Bowel Syndrome Patients|"Irritable Bowel Syndrome adult patients, sex- and age-matched, diagnosed according to Rome II criteria, and unrelated to NCWS or other food intolerance, during the same study period, chosen at random and enrolled as second control group."
3046919|NCT02248532|Active Comparator|Group A|Repetitive stem cell administration
3046920|NCT02248532|Active Comparator|Group B|Single stem cell administration
3046921|NCT02248519|Active Comparator|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
3046922|NCT02248519|Experimental|Laparoscopic Gastrectomy|Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy.
3046923|NCT02248506|Other|Clotrimazole|Clotrimazole 500 mg
3046924|NCT02248493|Experimental|paracetamol and ketoprofen|"paracetamol 20 mg/kg (1% 2 ml/kg) IV at the end of surgery 6 and 20 hours thereafter.~ketoprofen 1.5 mg/kg IV at the end of surgery 8 and 16 hours thereafter. tramadol 2 mg/kg IV on patient request up til 4 mg/kg or PCA morphine during 24 hours postoperatively."
3046925|NCT02248493|Placebo Comparator|placebo and ketoprofen|"0.9% sodium chloride (2 ml/kg) IV at the end of surgery 6 and 20 hours thereafter.~ketoprofen 1.5 mg/kg IV at the end of surgery 8 and 16 hours thereafter. tramadol 2 mg/kg IV on patient request up til 4 mg/kg or PCA morphine during 24 hours postoperatively."
3046926|NCT02248480|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for three days and 20 mg for four days.
3046927|NCT02248480|Placebo Comparator|Placebo|Placebo administered orally once a day for 15 weeks.
3046928|NCT02248467||eugonadal|50 eugonadal subjects
3046929|NCT02248467||untreated hypogonadal|25 asymptomatic hypogonadal subjects
3046930|NCT02248467||treated hypogonadal|25 symptomatic hypogonadal subjects treated - In the present study, we decided to monitor only sexual symptoms of androgen deficiency due to the fact that testosterone replacement therapy (TRT) should be expected to improve them in the time span until surgery. These patients will be treated with TRT as per clinical practice.
3046931|NCT02248454|Experimental|Insulin bolus dose/type|Lispro insulin, dose calculated by modeling analysis
3046932|NCT02248441|Experimental|Daily RIC|Daily ischemic conditioning treatment
3046933|NCT02248428|Experimental|BiCTd regimen|"Induction and consolidation therapy: BiCTd regimen for 8 cycles. Patients received Clarithromycin 500 mg orally on days 1-28,thalidomide 100-200mg orally on days d1-28, dexamethasone 40mg orally on days on 1,8,15,22, and cyclophosphamide 300mg/m^2 intravenously on day 1-3. Cycles were repeated every 28 days.~Maintenance therapy:CP regimen (cyclophosphamide 200 mg orally on days 1-14 and prednisone 30mg twice daily orally on days 1-7,repeated every 28 days) until disease progression.~If efficacy <PR after 4 cycles of induction or disease progression at anytime，patients will be quitted."
3046934|NCT02248428|Active Comparator|CTd regimen|"Induction and consolidation therapy: CTd regimen for 8 cycles. Patients received thalidomide 100-200mg orally on days d1-28, dexamethasone 40 mg orally on days on 1,8,15,22, and cyclophosphamide 300 mg/m^2 intravenously on day 1-3. Cycles were repeated every 28 days.~Maintenance therapy:CP regimen (cyclophosphamide 200 mg orally on days 1-14 and prednisone 30mg twice daily orally on days 1-7,28 Days per Cycle) until disease progression.~If efficacy <PR after 4 cycles of induction or disease progression at anytime，patients will be quitted.~If no further reduction in the serum and urine M protein in the next cycle，patients may cross over to BiCTd regimen."
3046935|NCT02248415|Experimental|No pump group|Blood cardioplegia administration without roller pump
3046936|NCT02248415|Other|Pump group|Blood cardioplegia administration with roller pump
3046937|NCT02248402|Experimental|Vax-DC/MM|
3046938|NCT02248389|Experimental|Ablation arm|Each person in study will receive ablation of their renal tumor followed by standard partial nephrectomy.
3046939|NCT02248376|Experimental|Gel +|Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
3046940|NCT02248376|No Intervention|Gel -|Patients aged of more than 18 years-old coming for a natural miscarriage who will not have the non-stick gel application at the end of the scraping surgery.
3046941|NCT02248350|Experimental|Exercise Group|8-weeks of supervised and home based exercise intervention, 3 times a week, 50-minutes a session for a total of 150/minutes a week
3046942|NCT02248350|Active Comparator|Stretching Control group|Informational booklet containing stretching exercises (20-minutes a day)
3046943|NCT02248337|Active Comparator|4 Liter PEG|Colon preparation for colonoscopy: PEG 4 Liter before endoscopy
3046944|NCT02248337|Experimental|2 Liter PEG plus bisacodil|Colon preparation for colonoscopy: PEG 2 L before endoscopy
3046945|NCT02248311||Patients/Control Group|Observational
3046946|NCT02248311||Patients/Group Control|Observational
3046947|NCT02248298|Experimental|2h-AFL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
3046948|NCT02248298|Active Comparator|3hr-AFL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
3046949|NCT02248298|Active Comparator|3hr-MAL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
3046950|NCT02248285|Experimental|Intervention|FilmArray™ GI Panel testing will be standard of care and provided at no cost. Additional testing may be ordered at the discretion of the clinician.
3046951|NCT02248285|No Intervention|Pre-intervention|Testing will be at the discretion of the clinician using standard laboratory tests, and specimens will be collected as appropriate for these methods.
3046952|NCT02248272|Experimental|Polycystic Ovary Syndrome|40 women with PCOS followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (40% carbohydrates, 25% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
3046953|NCT02248272|Experimental|Impaired Glucose Tolerance|35 individuals with Impaired Glucose Tolerance (IGT) followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (45% carbohydrates, 20% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
3046954|NCT02248272|Experimental|Type 2 Diabetes|12 individuals diagnosed with type 2 diabetes followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (45% carbohydrates, 20% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
3046955|NCT02248259|Experimental|Reference treatment|Single oral dose of BI 409306
3046956|NCT02248259|Experimental|Test treatment|Single oral dose of BI 409306 and Administration of Itraconazole
3046957|NCT02248246|Other|Colectomy with Harmonic ACE®+7 Shears|Laparoscopic colectomy with Harmonic ACE®+7 Shears for dissection and vessel transection
3046958|NCT02248233|Experimental|Saline + citicoline|The control group will receive physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days. Patients will receive additional drugs to treat dehydration, prevent infection and upper gastrointestinal bleeding, and maintain water and electrolyte balance. Patients with complications will receive symptomatic treatment.
3046959|NCT02248233|Experimental|Nimodipine|"The treatment group will receive 10 mg of nimodipine in 500 ml of physiological saline via intravenous drip, at a rate of 1-2 drops per minute initially, increasing gradually until systolic pressure decreases by 10 mmHg. Maximum drip speed is 10 drops/minute, administered once a day for 7 consecutive days. The nimodipine must be kept in the dark. Blood pressure and heart rate will be monitored throughout the administration period.~Patients in control group will receive additional drugs to treat dehydration, prevent infection and upper gastrointestinal bleeding, and maintain water and electrolyte balance. Patients with complications will receive symptomatic treatment."
3046960|NCT02248220||Parkinson's disease patients|
3046961|NCT02248207||Parkinson Disease patients|
3046962|NCT02248194|Experimental|"Group 1Tactile electrosurgical ablation"|Endometrial ablation will be done by Tactile electrosurgical ablation probe.
3046963|NCT02248194|Active Comparator|"Group 2 Hysteroscopic endometrial ablation"|Hysteroscopic endometrial ablation will be done by trans-cervical resection of endometrium.
3046964|NCT02248181||Idiopathic PD patients|
3046965|NCT02248168||Idiopathic Parkinson's disease patients|
3046966|NCT02248155||RLS patients|
3046967|NCT02248142||RLS patients|
3046968|NCT02248129||Hypertensive patients|
3046969|NCT02248116|Experimental|Alzheimer|
3046970|NCT02248103|Experimental|periosteal pedicle graft|autogenous marginal periosteal pedicle graft harvested by partial thickness periodontal flap.
3046971|NCT02248103|Active Comparator|Bioresorbable collagen membrane|Equine Achilles tendon collagen barrier membrane
3046972|NCT02248090|Experimental|AZD9496|AZD9496 dose escalation and expansion(s)
3046973|NCT02248077|Active Comparator|AutoloGel|AutoloGel consists of platelet-rich plasma (PRP) gel produced from the patient's own peripheral blood and pharmaceutical additives including calcium chloride, thrombin and ascorbic acid. The AutoloGel product is obtained by processing the patient's own blood using the AutoloGel System. After the final AutoloGel formulation is produced it is used immediately for patient's specific ulcer care.
3046974|NCT02248077|Other|Usual and Customary Care (UCC)|Standard of care
3046975|NCT02248064|No Intervention|Fixed flow oxygen|The 6MWT will done on the patients usual fixed flow ambulatory oxygen in this arm.
3046976|NCT02248064|Experimental|Auto-titrating arm|The 6MWT will done using the auto-titrating oxygen system in this arm of the study
3046977|NCT02248051|Experimental|CXA-10|
3046978|NCT02248038|Active Comparator|open surgery|Conventional procedure
3046980|NCT02248012|Experimental|Everolimus/temozolomide|Everolimus 10 mg daily, temozolomide 150 mg/m2 for 7 days every 2 weeks.
3046981|NCT02247973|Experimental|Mesenchymal stem cells|Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with severe aplastic anemia.
3046982|NCT02247960|Active Comparator|Ciprofloxacin|Antibiotic
3046983|NCT02247960|No Intervention|No Antibiotic|No Antibiotic
3046984|NCT02247947||dead|Patients dead until day 20 (primary outcome measure)
3046985|NCT02247947||survivors|patients alive after day 20 (primary outcome measure)
3046986|NCT02247934||Concept elicitation interviews (Step I)|Approximately 20 participants will be included.
3046987|NCT02247934||Cognitive interviews (Step II)|Approximately 30 participants will be included.
3046988|NCT02247921|Experimental|Rehabilitation|nurse-led caregiver-delivered rehabilitation
3046989|NCT02247921|No Intervention|Usual care|The patients in the control arm will receive conventional care in terms of access to rehabilitation in hospital, timeliness of discharge and follow-up, without any explicit provision of caregiver training or accelerated discharge.
3046990|NCT02247908|Experimental|Graphic Warning|Graphic warnings that include text and an image depicting a health effect of smoking will be applied on labels that cover the top half of the front and back of participants' cigarette packs each week for 4 weeks. Within the graphic warning condition, participants will be assigned to receive 1 of 4 warnings for 4 weeks. The text for these warnings was selected from the 2009 Family Smoking Prevention and Tobacco Control Act and the images were proposed by the FDA.
3046991|NCT02247908|Active Comparator|Surgeon General's Warning|Labels with Surgeon General's Warning text will be applied to the side of participants' cigarette packs each week for 4 weeks, on top of the Surgeon General's Warning printed by the manufacturer.
3046992|NCT02247895|Sham Comparator|Sham Treatment|Sham stimulation twice daily
3046993|NCT02247895|Active Comparator|Active Treatment|The active treatment group will receive neuromuscular electrical stimulation to both quadriceps muscle for 30 minutes twice daily for a total of 14 treatments.
3046994|NCT02247882|Experimental|Patient Education|Health Education.
3046995|NCT02247882|Active Comparator|Aquatic Physical Therapy|Protocol of aquatic physical therapy exercises.
3046996|NCT02247869|Experimental|dose dense ABVD|1 arm for all patients (dose dense ABVD on day 1 and 8 every 21 days)
3046997|NCT02247856|Active Comparator|Control Group|Noninvasive ventilation+ jet nebulizer
3046998|NCT02247856|Experimental|Experimental Group|Noninvasive ventilation+ Vibrating Mesh Nebulizer (VMN)
3046999|NCT02247843|Experimental|βAS3-FB vector transduced BM CD34+ cells|This is a single arm study without randomization. All subjects will receive the intervention of BetaAS3 lentiviral vector-modified autologous bone marrow stem cell transplant.
3047000|NCT02247830|Experimental|1 Chamomilla recutita gel|Experimental Group 01: usual care + topical application of the gel recutita chamomile. Such intervention will be characterized by topical application of the gel C. recutita, concomitantly to the initiation of radiotherapy, should be applied on the irradiated three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
3047001|NCT02247830|Experimental|2 Urea cream|Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the area irradiated three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
3047002|NCT02247830|No Intervention|Control Group (Usual Care)|The usual care consists of nursing consultation with instructional material (Manual guidelines) that is already done systematically in service. This query is made with all patients starting radiotherapy. Here, guidelines are provided about skin care and hydration, using topical moisturizing soap solution over the bath. Such information is contained in the manual that is provided to the patient during the consultation.
3047003|NCT02247817|Experimental|HYBRID|Hybrid transvenous/epicardial implantation of a CRT-(D) device.
3047004|NCT02247804|Experimental|Bimatoprost SR Dose A|Study Eye: bimatoprost sustained-release (SR) Dose A administered on Day 1, Week 16, and Week 32; timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1, Week 16, and Week 32; timolol administered once in the morning and once in the evening for up to 20 months.
3047005|NCT02247804|Experimental|Bimatoprost SR Dose B|Study Eye: bimatoprost SR Dose B administered on Day 1, Week 16, and Week 32; timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1, Week 16, and Week 32; timolol administered once in the morning and once in the evening for up to 20 months.
3047006|NCT02247804|Sham Comparator|Sham|Both Eyes: sham administered on Day 1, Week 16, and Week 32; timolol administered once in the morning and once in the evening for up to 20 months.
3047007|NCT02247791|Active Comparator|Cemented femoral stem|Patient undergoing total hip arthroplasty surgery
3047008|NCT02247791|Active Comparator|Uncemented femoral stem|Patients undergoing total hip arthroplasty
3047009|NCT02247778|Active Comparator|conventional plate osteosynthesis|Standard procedure
3047010|NCT02247778|Active Comparator|mini-incision-type osteosynthesis|mini-incision
3047011|NCT02247765|Experimental|Arterial Line|CO-Oximetry value obtained as a comparator. Obtained during motion conditions.
3047012|NCT02247765|Experimental|Motion|The subject has to perform motions during the procedure. This is to verify that device is able to read through motion.
3047013|NCT02247752|Other|Inactive carriers|
3047014|NCT02247739|Experimental|rhC1INH twice weekly|rhC1INH administered twice weekly
3047015|NCT02247739|Experimental|rhC1INH once weekly|rhC1INH administered once weekly
3047016|NCT02247739|Placebo Comparator|Placebo (Saline) twice weekly|Placebo (Saline) administered twice weekly
3047017|NCT02247726|Placebo Comparator|Treatment Group A|Saline Placebo (0.5mL injection)
3047018|NCT02247726|Experimental|Treatment Group B|RSV F vaccine with adjuvant (0.5mL injection)
3047019|NCT02247713||Retrospective cohort|Participating centers will retrospectively provide demographic, tumor, treatment and follow-up details on at least 25 consecutive patients with stage III NSCLC previously treated with curative intent chemoradiotherapy (concurrent or sequential) in the period between 2010 and 2013.
3047020|NCT02247713||Prospective cohort|Participating centers will provide prospective data on patients with stage III NSCLC treated with curative intent concurrent chemoradiotherapy. Centers will be asked to include at least 25 consecutive cases following the training intervention and the successful local implementation of PET/CT for RTP in NSCLC.
3047021|NCT02247700||Mechanical Ventilation|Infants and Children requiring mechanical ventilation
3047022|NCT02247687|Other|Counseling arm|Counseling without antiretroviral treatment modification
3047023|NCT02247687|Active Comparator|Switch arm for protease inhibitor|Switch arm for protease inhibitor : intervention is the switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling.
3047024|NCT02247687|Active Comparator|Addition of Isentress® (raltegravir)|"Drug: Addition of Isentress® (raltegravir) arm~• Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling"
3047025|NCT02247674|Placebo Comparator|Education & training consultation|Education and training consultations were provided for subjects in control group during study period.
3047026|NCT02247674|Experimental|Bilateral movement training|Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
3047027|NCT02247661||Direct lateral approach|Total or hemiarthroplasty operated with direct-lateral approach.
3047028|NCT02247661||Postero-lateral approach|Total or hemiarthroplasty operated with postero-lateral approach.
3047029|NCT02247648|Experimental|treatment|treatment: tramadol group
3047030|NCT02247648|Placebo Comparator|control|control: placebo group
3047031|NCT02247635|No Intervention|Conventional medical treatment|Based on the clinical guidelines of the Ministry of Health, medical treatment was provided and consisted in counseling for chronic diseases such as obesity, hyperglycemia, hypertension, dyslipidemia
3047032|NCT02247635|Active Comparator|Healthy lifestyle and adherence|1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake <30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.
3047033|NCT02247622||Healthy control|
3047034|NCT02247622||IBD|patients with inflammatory bowel disease, study group
3047035|NCT02247622||PSC|patients with primary sclerosing cholangitis, study group
3047036|NCT02247609|Experimental|CAR T cells|Autologous 4th generation anti-CD19-CAR T cells
3047037|NCT02247596|Placebo Comparator|Placebo|Sugar pill 1g tds for 2 weeks
3047038|NCT02247596|Experimental|Resveratrol|Trans-resveratrol extract from Polygonum Cuspidatum 1g three times a day for 2 weeks
3047039|NCT02247583||mRCC patients|Patients with metastatic renal cell carcinoma
3047040|NCT02247570|Experimental|Vestibular Rehabilitation|Vestibular Rehabilitation
3047041|NCT02247557|Experimental|Group A: Liposome encapsulated BoNT-A|Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
3047042|NCT02247557|Experimental|Group B: BoNT-A 200 U in Normal saline|BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation
3047043|NCT02247557|Placebo Comparator|Group C: Normal saline|Normal saline (N/S) 50ml in single intravesical instillation
3047044|NCT02247544|Experimental|Trabectedin|"Trabectedin will be administered intravenously at a dose of 1.5 mg/m2 or 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour infusion once every 3 weeks (cycle day 1).~Since trabectedin has no cumulative toxicities, treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician. In the subgroup of patients amenable to surgery, treatment will be reasonably continued until the best dimensional response."
3047045|NCT02247531|Experimental|Lampalizumab: Every 4 Weeks (Q4W)|Lampalizumab 10-milligram (mg) injections administered intravitreally during the 2-year treatment period.
3047046|NCT02247531|Experimental|Lampalizumab: Every 6 Weeks (Q6W)|Lampalizumab 10-mg injections administered intravitreally during the 2-year treatment period.
3047047|NCT02247531|Sham Comparator|Sham|Sham injections will be administered during the 2-year treatment period.
3047048|NCT02247518|Other|Group1: Treatment A + Treatment B, PO|Treatment A : Tadarafil 5mg*1t/day for 5days, Treatment B : Tadarafil 5mg*1t/day and Tamsulosin 0.2mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
3047049|NCT02247518|Other|Group2: Treatment B + Treatment A, PO|Treatment A : Tamsulosin 0.2mg*1t for 5days, Treatment B : Tamsulosin 0.2mg*1t/day and Tadalafil 5mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
3047050|NCT02247505|Other|Group1: Treatment A + Treatment B, PO|Treatment A : Tamsulosin 0.2mg*1t for 5days, Treatment B : Tamsulosin 0.2mg*1t/day and Tadalafil 5mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
3047051|NCT02247505|Other|Group2: Treatment B + Treatment A, PO|Treatment A : Tamsulosin 0.2mg*1t for 5days, Treatment B : Tamsulosin 0.2mg*1t/day and Tadalafil 5mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
3047052|NCT02247492||Orsiro|
3047053|NCT02247479|Experimental|Lampalizumab Once in Every Weeks (Q4W)|Participants will receive 10 milligrams (mg) dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
3047054|NCT02247479|Experimental|Lampalizumab Once in Every 6 Weeks (Q6W)|Participants will receive 10 mg dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
3047055|NCT02247479|Sham Comparator|Sham Comparator|Participants will receive sham comparator Q4W or Q6W for 96 weeks.
3047056|NCT02247466|Active Comparator|Group A - Saline, assesment, rocuronium and assesment|Intervention after intubation and placement of trocars without NMB. Bolus of saline (placebo) 6mL (TOF 100%) the surgeon assesses the surgical workspace with pneumoperitoneum 12 mmHg. After administration of rocuronium 0.6 mg/kg when TOF=0 the surgical workspace is assessed again
3047092|NCT02247297||Pregnant Women|Healthy pregnant women and women with preeclampsia, HELLP syndrom, amniotic infection syndrome, or preterm premature rupture of membranes
3078259|NCT02038673|Experimental|Dose escalation part 2.0 mg BID|Oral
3047057|NCT02247466|Active Comparator|Group B - Rocuronium, assesment, sugammadex and assesment|Intervention after intubation and placement of trocars without NMB. Bolus of rocuronium 0.6 mg/kg when TOF=0 the surgeon assesses the surgical workspace with pneumoperitoneum 12 mmHg. Three minutes after administration of sugammadex (TOF 100%) the surgical workspace is assessed again
3047058|NCT02247453|Experimental|Screening|Healthy heavy smokers aged 50-75 years
3047059|NCT02247440||PegINF-ribavirin|"Peg-interferon + ribavirin under HIV physician supervision Peg-interferon alpha 2-b initial dosing is 1.5 micrograms/kg (subcutaneous injection) once a week~Ribavirin initial dosing in the morning and in the evening:~For genotypes 2, 3: ribavirin 400 mg (i.e. 800 mg daily).~For genotypes 1, 4, 5 and 6:~800 mg/day, if bodyweight <65 kg,~1000 mg/day, if bodyweight between 66-80 kg,~1200 mg/day, if bodyweight between 81-105 kg,~1400 mg/day, if bodyweight >105 kg.~Duration: 48 weeks"
3047060|NCT02247427|Experimental|Off-pace group|Deactivated device group
3047061|NCT02247427|No Intervention|On-Pace group|Ongoing device activity group
3047062|NCT02247414|Experimental|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for one year irrespective of the occurrence of portal vein thrombus.
3047063|NCT02247414|Active Comparator|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for one year.
3047064|NCT02247401|Active Comparator|Arm A|ABT-450/r/ABT-267 (paritaprevir/ritonavir/ombitasvir; 2 direct acting antiviral agent [DAA]) plus Ribavirin (RBV) for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants without cirrhosis.
3047065|NCT02247401|Active Comparator|Arm B|ABT-450/r/ABT-267 plus RBV for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
3047066|NCT02247401|Active Comparator|Arm C|ABT-450/r/ABT-267 plus RBV for 24 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
3047067|NCT02247388|Experimental|AB-CASI|Automated Bilingual Computerized Alcohol Screening and Brief Negotiated Interview(BNI) Intervention
3047068|NCT02247388|No Intervention|Standard Care|Standard Care
3047069|NCT02247375|Experimental|Low dose of BIIL 284 BS|
3047070|NCT02247375|Experimental|High dose of BIIL 284 BS|
3047071|NCT02247375|Placebo Comparator|Placebo|
3047072|NCT02247362|Experimental|Vaccine Dose Group 12 mcg|VAX2012Q, 12 mcg dose
3047073|NCT02247362|Experimental|Vaccine Dose Group 20 mcg|VAX2012Q, 20 mcg dose
3047074|NCT02247362|Experimental|Vaccine Dose Group 16 mcg|VAX2012Q; 16 mcg dose
3047075|NCT02247362|Placebo Comparator|Vaccine Diluent|Vaccine Diluent, F147, as placebo control
3047076|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose -1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
3047077|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
3047078|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 2|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
3047079|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 3|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
3047080|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 4|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
3047081|NCT02247349|Experimental|Dose Expansion (Monotherapy)- Cohort A (Refractory)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
3047082|NCT02247349|Experimental|Dose Expansion (Monotherapy) Cohort B (Refractory)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
3047083|NCT02247349|Experimental|Dose Expansion (Monotherapy) Cohort C (Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
3047084|NCT02247349|Experimental|Dose Expansion (Monotherapy) Cohort D (Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
3047085|NCT02247349|Experimental|Dose Escalation (Combination) Dose 1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
3047086|NCT02247349|Experimental|Dose Escalation (Combination) Dose 2|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
3047087|NCT02247349|Experimental|Dose Expansion (Combination)- (Refractory and Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
3047088|NCT02247336|Experimental|Immediate|Patients will complete MeTree at enrollment
3047089|NCT02247336|Active Comparator|Delayed|Patients will complete MeTree 12 months following enrollment
3047090|NCT02247323||premenopausal women|premenopausal women with complex ovarian mass moderate for malignancy by risk of malignancy index score and low CA125.
3047091|NCT02247310||Cohort 1|Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome and be on treatment with Betaferon using the BETACONNECT auto-injector device.
3047331|NCT02245737|Placebo Comparator|Placebo|Placebo given orally once daily for 104 weeks.
3047093|NCT02247284|Experimental|group 1|patient with a diagnosis of primary open angle glaucoma will undergo 'RNFL and BMO-MRW SD-OCT' measurements with Heidelberg Spectralis SD-OCT old protocoll and Glaucoma Premium Module (new) protocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
3047094|NCT02247271|Other|Diabetes health coach support|The intervention is that subjects will receive coach support once a week for 30 minutes for six months. Support is provided by a Diabetes Coach who uses self-management support strategies to assist subjects to achieve their personal health goals.
3047095|NCT02247258|Active Comparator|Systematic azathioprine group|Patients randomized to the systematic azathioprine group received 2.0-2.5 mg/kg azathioprine within 14 days from surgery and throughout 102 weeks.
3047096|NCT02247258|Active Comparator|Endoscopy-driven azathioprine group|Patients randomized to the endoscopy-driven azathioprine group received no Crohn's disease specific treatment for 26 weeks postoperatively. A first ileocolonoscopy was performed at week 26. In case of endoscopic recurrence (Rutgeerts' score i2 or higher), azathioprine was introduced at a dose of 2.0-2.5 mg/kg until week 102. If not, an ileocolonoscopy was repeated at week 52, and azathioprine started in case of endoscopic recurrence. If no endoscopic recurrence was observed, no Crohn's disease-specific treatment was given until week 102.
3047097|NCT02247245|Placebo Comparator|Placebo|Subjects are given a placebo capsule (double-blinded) to take 90 minutes prior to the cardiopulmonary exercise test.
3047098|NCT02247245|Active Comparator|Ivabradine|Subjects are given an ivabradine capsule (double-blinded) to take 90 minutes prior to the cardiopulmonary exercise test.
3047099|NCT02247245|Experimental|Atrial fibrillation|Subjects are (double blind) randomised to either a low base pacing rate (30) or a standard base rate (60), with rate adaptive algortithms switched on.
3047100|NCT02247232|Placebo Comparator|Placebo|
3047101|NCT02247232|Experimental|Z-100|
3047102|NCT02247219|Experimental|Intervention|'Counselling and education individually and in groups'
3047103|NCT02247219|Other|Waiting list control|The waiting list group waits 6 months after assessment and allocation and is reassessed after 6 and 12 months. Both groups are reassessed after 24 months, and the second part of the study is a one group longitudinal cohort study.
3047104|NCT02247206|Experimental|Behavior Therapy for Tics (CBIT)|The child 1) learns to become more aware of any sensations, or urges that may trigger tics, and 2) learn some other behavior (competing response) to do every time he/she feels the urge to tic. The child's parent is trained to provide prompts and praise for use of the competing response. The parent and family also receive psychoeducation about tics, and learn ways to reduce the impact of environmental stimuli on tic severity. The child learns relaxation techniques to reduce stress and make it easier for him/her to resist his or her tics. Prior to treatment sessions, the parent and child spend about 10 minutes discussing with the therapist any problematic issues he/she is having. At the end of treatment sessions the child is assigned some tasks to practice prior to the next session.
3047105|NCT02247206|No Intervention|Waitlist-control Group|Participants in the waitlist-control group, do not receive behavior therapy for tics or any other treatment during the 10-week acute treatment period. Instead they child are placed on a waitlist to receive videoconference-delivered treatment following the end of the study period.
3047106|NCT02247193|Experimental|Botulinum Toxin|Injection of botulinum toxin into cleft lip at time of surgical repair.
3047107|NCT02247193|Placebo Comparator|Saline|Injection of normal saline into cleft lip at time of surgical repair.
3047108|NCT02247180|Experimental|Cognitive Rehabilitation|cognitive rehabilitation for 12 weeks
3047109|NCT02247180|Active Comparator|Cognitive Training|standardized cognitive training in the domesticity
3047110|NCT02247167|Experimental|adenotonsillectomy (AT)|Children with SDB studied before and after before adenotonsillectomy.
3047111|NCT02247154|Experimental|Vigam® Liquid|
3047112|NCT02247141|Experimental|Subgam®|
3047113|NCT02247128|Active Comparator|Aspirin + Clopicogrel (Cohort A)|Cohort A: patients will receive clopidogrel (75mg quaque die (qD), 3 months) on top of low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patient in Cohort A doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI.
3047114|NCT02247128|Active Comparator|Aspirin monotherapy (Cohort A)|Cohort A: patients will receive low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patients doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.
3047115|NCT02247128|Active Comparator|OAC + Clopicogrel (Cohort B)|Cohort B: patients will receive clopidogrel (75mg qD, 3 months) on top of OAC (according to its indication). The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. aspirin) at least 5 days prior to the TAVI procedure.
3047116|NCT02247128|Active Comparator|OAC monotherapy (Cohort B)|Cohort B: patients will receive OAC according to its indication. It is recommended to continue the OAC therapy peri-procedural (International Normalized Ratio aimed at 2.0). It is recommended to omit antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.
3047117|NCT02247102|Experimental|Isomaltulose|Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)
3047118|NCT02247102|Active Comparator|Sucrose|Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)
3047119|NCT02247076|Placebo Comparator|Grazing|"Participants will eat meals spread over the course of the day (grazing)."
3047120|NCT02247076|Experimental|Time-restricted feeding (early eating)|Participants will eat meals only in the early part of the day (early lunch and very early dinner).
3047121|NCT02247063|Sham Comparator|Placebo|The subjects in the placebo arm will participate in 5 daily M1 High-Definition Transcranial Direct Current Stimulation (HD-tDCS) sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Current will be applied only for 30 seconds - this is a reliable method of sham stimulation (Gandiga et al., 2006) as sensations arising from tDCS treatment occur only at the beginning of application.
3047194|NCT02246673|Experimental|RDEA3170 15 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
3047122|NCT02247063|Experimental|Experimental|The subjects in the experimental arm will participate in 5 daily sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Then 2mA of transcranial direct current stimulation will be applied for 20 minutes.
3047123|NCT02247050|Experimental|Commitment invitation at time 1|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the first clinic will remain in the control period (no intervention) for 2 months and then cross over to the intervention period for 6 months."
3047124|NCT02247050|Experimental|Commitment invitation at time 2|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the second clinic will remain in the control period (no intervention) for 3 months and then cross over to the intervention period for 5 months."
3047125|NCT02247050|Experimental|Commitment invitation at time 3|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the third clinic will remain in the control period (no intervention) for 4 months and then cross over to the intervention period for 4 months."
3047126|NCT02247050|Experimental|Commitment invitation at time 4|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the fourth clinic will remain in the control period (no intervention) for 5 months and then cross over to the intervention period for 3 months."
3047127|NCT02247050|Experimental|Commitment invitation at time 5|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the fifth clinic will remain in the control period (no intervention) for 6 months and then cross over to the intervention period for 2 months."
3047128|NCT02247050|Experimental|Commitment invitation at time 6|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the sixth clinic will remain in the control period (no intervention) for 7 months and then cross over to the intervention period for 1 month."
3047129|NCT02247037||Triple Negative Breast Cancers|All women eligible for this protocol will fall into this group. These women will have histologically confirmed triple negative breast cancer and be eligible for neoadjuvant chemotherapy or have evidence of metastatic disease.
3047130|NCT02247011|Other|fracture group|Fracture group included participants with new fractures during the 5 year follow-up visit. Fracture consists of non-vertebral fracture and vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
3047131|NCT02247011|Other|non-fracture group|Fracture group included participants without new fractures during the 5 year follow-up visit. Fracture consists of vertebral fracture and non-vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
3047132|NCT02246998|Experimental|STB+iohexol|Participants will receive STB+iohexol for 24 weeks.
3047133|NCT02246998|Experimental|RTV+ATV+TVD+iohexol|Participants will receive RTV+ATV+TVD+iohexol for 24 weeks.
3047134|NCT02246998|Experimental|ATR+iohexol|Participants will receive ATR+iohexol for 24 weeks.
3047135|NCT02246998|Experimental|RTV+ATV+ABC/3TC+iohexol|Participants will receive RTV+ATV+ABC/3TC+iohexol for 24 weeks.
3047136|NCT02246985|Experimental|Plain bread with plain mayonnaise|Control meal. The bread and mayonnaise in this meal does not have vegetable powders incorporated into them, hence this meal does not contain carotenoids
3047137|NCT02246985|Experimental|Vegetable bread only|A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread will be standardised to contain a known amount of carotenoids
3047138|NCT02246985|Experimental|Vegetable bread with plain mayonnaise|A vegetable powder (carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread will be standardised to contain a known amount of carotenoids.
3047139|NCT02246985|Experimental|Plain bread with vegetable mayonnaise|Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.
3047140|NCT02246972|Experimental|VRET Immediate treatment|Participants will be randomized to receive Virtual Reality Exposure Therapy (VRET) immediately
3047141|NCT02246972|Active Comparator|Waitlist|6 weeks standard of care, then Virtual Reality Exposure Therapy (VRET) treatment.
3047142|NCT02246959|No Intervention|Control Arm|Arm 1 will be the Control arm, in which participants receive electronic pill bottles for their statin medication but are not enrolled in the sweepstakes.
3047143|NCT02246959|Experimental|Process Arm|Arm 2 will be a Process incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication.
3047144|NCT02246959|Experimental|Outcome Arm|Arm 3 will be an Outcome incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group may receive incentives if they lower their LDL.
3047145|NCT02246959|Experimental|Process Plus Outcome Arm|Arm 4 will be a process plus outcome incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication and receive additional incentives for lowering their LDL cholesterol.
3047146|NCT02246946|Experimental|Positive Airway Pressure group|The patients allocated to this group will undergo bronchial hygiene treatments administered with a high-frequency oscillator for 5 sets of 10 repetitions, lung expansion exercises using flow oriented incentive spirometry for 5 sets of 20 repetitions and walking for 100 meters (i.e., the same treatment that will be administered to the Conventional Chest Physiotherapy group). Additionally, this group will receive positive airway pressure breathing with 15 mmHg by a device via a rubber facial mask for 30 minutes in a sitting position.
3047147|NCT02246946|Active Comparator|Conventional Chest Physiotherapy group|"In the sitting position, the patients allocated to this group will undergo bronchial hygiene treatments administered with a high-frequency oscillator for 5 sets of 10 repetitions, lung expansion exercises using flow oriented incentive spirometry for 5 sets of 20 repetitions and positive airway pressure breathing with 4 mmHg via a rubber facial mask for 5 minutes in a sitting position. These patients will also walk for 100 meters.~The use of positive pressure breathing with 4 mmHg has no therapeutic value, but will help keep the blinding of assessors by the presence of the equipment in the room and mark the patient's skin."
3047148|NCT02246946|Placebo Comparator|Control group|"The patients allocated to this group will receive positive airway pressure breathing with 4 mmHg (without therapeutic value) via a rubber facial mask for 30 minutes in a sitting position.~The use of positive pressure breathing with 4 mmHg has no therapeutic value, but will help keep the blinding of assessors by the presence of the complete kit of equipment in the room."
3047149|NCT02246933|Experimental|PUFA Diet|
3047150|NCT02246933|Placebo Comparator|Control Diet|
3047151|NCT02246920|Experimental|Investigational Test Product|Fluticasone propionate Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days
3047152|NCT02246920|Active Comparator|Reference Listed Drug|Flonase® (fluticasone propionate) Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days
3047153|NCT02246920|Placebo Comparator|Placebo|Saline Placebo Nasal Spray; 4 total sprays/day for 14 days
3047154|NCT02246907|No Intervention|Control Group|The control group will receive standard of care which includes recreational therapy and standard encouragement.
3047155|NCT02246907|Other|Exercise|Participants in this arm will receive standard of care plus exercise for the duration of their inpatient stay for induction chemotherapy.
3047156|NCT02246894|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
3047157|NCT02246881|Active Comparator|Current Factor VIII|Optivate® (Human Coagulation Factor VIII)
3047158|NCT02246881|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
3047159|NCT02246868|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
3047160|NCT02246855|Experimental|Vigam® Liquid infused at up to 3mL/min|Gammaplex® (Human Normal Immunoglobulin)
3047161|NCT02246855|Experimental|Gammaplex® infused at up to 3mL/min|Gammaplex® (Human Normal Immunoglobulin)
3047162|NCT02246855|Experimental|Gammaplex® infused at up to 6mL/min|Gammaplex® (Human Normal Immunoglobulin)
3047163|NCT02246842|Experimental|D-Gam®|D-Gam® (human anti-D immunoglobulin)
3047164|NCT02246842|Active Comparator|Rhophylac®|Human Anti-D Immunoglobulin
3047165|NCT02246829|Other|Aflibercept 2mg Intravitreal injection|2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
3047166|NCT02246816|Experimental|All Subjects|Assigned to receive open-label 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
3047167|NCT02246803|Active Comparator|CABG+pulmonary vein isolation|CABG+pulmonary vein isolation procedure
3047168|NCT02246803|Active Comparator|Isolated CABG|Isolated CABG procedure
3047169|NCT02246790|Active Comparator|Biatrial radiofrequency ablation and CABG|Biatrial radiofrequency ablation during CABG
3047170|NCT02246790|Active Comparator|Left atrial radiofrequency ablation and CABG|Left atrial radiofrequency ablation during CABG
3047171|NCT02246777|Experimental|Ex-PRESS|Ex-PRESS® Glaucoma Filtration Device, Model P50PL, implanted in the anterior chamber of the study eye during glaucoma surgery intended for the lifetime of the patient
3047172|NCT02246764|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) and 1 drop placebo in the morning (AM) in both eyes (OU)
3047173|NCT02246764|Experimental|AR-13324 Ophthalmic Solution 0.02% BID|1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
3047174|NCT02246764|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop Timolol maleate twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
3047175|NCT02246751|Experimental|Single subject design case series|Targeted Training for trunk control, 5-6 days a week for 9 months, minimum of 20 minutes per day.
3047176|NCT02246738||Cohort1|
3047177|NCT02246738||Cohort 2|
3047178|NCT02246738||Cohort 3|
3047179|NCT02246738||Cohort 4|
3047180|NCT02246738||Cohort 5|
3047181|NCT02246738||Cohort 6|
3047182|NCT02246738||Cohort 7|
3047183|NCT02246738||Cohort 8|
3047184|NCT02246738||Cohort 9|
3047185|NCT02246725||Contact with palliative care unit versus contact when needed.|
3047186|NCT02246712|Active Comparator|Control group|Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for the single nucleotide polymorphism (SNP) 516G>T in CYP2B6 gene (CYP2B6 genotype).
3047187|NCT02246712|Experimental|T2DM group|"Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for SNP 516G>T in CYP2B6 gene (CYP2B6 genotype).~The diagnosis of type 2 DM was performed according to the American Diabetes Association (2010)."
3047188|NCT02246712|Experimental|T1DM group|"Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for SNP 516G>T in CYP2B6 gene (CYP2B6 genotype).~The diagnosis of type 1 DM was performed according to the American Diabetes Association (2010)."
3047189|NCT02246699|Experimental|KiOnutrime®-Cs|The product is presented as a capsule containing chitosan as ingredient supporting the activity.
3047190|NCT02246699|Placebo Comparator|Placebo|Placebo is presented as a capsule containing inactive ingredients.
3047191|NCT02246686|Experimental|STW5-II|Half of study population, assigned randomly
3047192|NCT02246686|Placebo Comparator|Placebo|Half of study population, assigned randomly
3047193|NCT02246673|Experimental|RDEA3170 10 mg|Once daily (qd) with febuxostat 40mg (qd) for 7 days, and with febuxostat 80 mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
3047332|NCT02245724|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
3047195|NCT02246673|Experimental|RDEA3170 5 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
3047196|NCT02246673|Experimental|RDEA3170 2.5 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
3047197|NCT02246660|Active Comparator|Resveratrol - 500 mg/day|The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
3047198|NCT02246660|Active Comparator|Resveratrol - 125 mg/day|The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
3047199|NCT02246660|Placebo Comparator|Placebo|Placebo will be taken orally for 6 months.
3047200|NCT02246647||Healthy volunteers|Ingestion of saccharides (mannitol (regular, 12C) 100 mg, lactulose 1 g and (non-radioactive) 13C labeled mannitol, 100 mg and sucralose, 50 mg) in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy
3047201|NCT02246647||IBS-C|Ingestion of saccharides (mannitol (regular, 12C) 100 mg, lactulose 1 g and (non-radioactive) 13C labeled mannitol, 100 mg and sucralose, 50 mg) in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy
3047202|NCT02246634|Experimental|Diffusion Weighted MRI scan|Patients in the study will get a DW-MRI of the liver in addition to their standard treatment imaging prior to their surgery.
3047203|NCT02246621|Experimental|Abemaciclib + NSAI|150 milligrams (mg) Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
3047204|NCT02246621|Placebo Comparator|Placebo + NSAI|Placebo orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
3047205|NCT02246608|Active Comparator|Routine NPWT plus foam wound product|Prior to applying and activating the Negative Pressure Wound Treatment (NPWT) pump, foam wound product will be applied.
3047206|NCT02246608|Active Comparator|Routine NPWT plus Oasis wound product|Prior to applying and activating the Negative Pressure Wound Treatment (NPWT) pump, Oasis wound product will be applied.
3047207|NCT02246595|Active Comparator|CaCP29|dose escalating i.v. administration of CaCP29 (verum)
3047208|NCT02246595|Placebo Comparator|Placebo|dose escalation mimicing i.v. placebo treatment:
3047209|NCT02246582|Other|Group A|Subjects underwent FST at 30 mins, 50 hrs and 146 hrs from Enlite 3 Sensors connected to GST3C, GST4C Transmitter, and GSR
3047210|NCT02246582|Other|Group B|Subjects underwent FST at 14 hrs, 62 hrs and 158 hrs from Enlite 3 Sensors connected to GST3C, GST4C Transmitter, and GSR
3047211|NCT02246556|Active Comparator|Patching therapy|Patching treatment followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
3047212|NCT02246556|Active Comparator|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) therapy followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
3047213|NCT02246556|Experimental|Dichoptic therapy|Dichoptic virtual reality video game treatment using Diplopia (TM) software developed for the Oculus Rift (R) game system.
3047214|NCT02246543|Placebo Comparator|Treatment 1 - Control|Water, Toast & Egg (Yolk only) + 0.1g 13C Octanoic Acid
3047215|NCT02246543|Active Comparator|Treatment 2 - HPL|High Protein Smoothie (Liquid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
3047216|NCT02246543|Active Comparator|Treatment 3 - LPL|Low Protein Smoothie (Liquid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
3047217|NCT02246543|Active Comparator|Treatment 4 - HPS|High Protein Milk Jelly (Solid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
3047218|NCT02246543|Active Comparator|Treatment 5 - LPS|Low Protein Milk Jelly (Solid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
3047219|NCT02246530|Active Comparator|PRP injection into PTRCT|Treatment - PRP injection
3047220|NCT02246530|Active Comparator|Subacromial steroid bursal injection|Current standard of care for treatment of resistant partial thickness rotator cuff tears
3047221|NCT02246517|Experimental|N2O&Oxygen|70% N2O & 30% Oxygen by Aspiration for 5 min
3047222|NCT02246517|Placebo Comparator|Oxygen|100% Oxygen by Aspiration for 5 min
3047223|NCT02246504|Experimental|HIFU treatment|use of HIFU treatment in patients with non-malignant thyroid nodules
3047224|NCT02246491|Other|iPSCs without gene correction|This is not a clinical trial and there is no immediate benefit to the participants. At this time, iPSCs and their derived products are not suitable for administration to patients. However, they are useful for basic and preclinical studies of the disease, such as mechanistic studies of ATM function or screening for small molecules with therapeutic value. As regenerative medicine continues to advance, iPSCs and their products may ultimately be used for clinical studies aimed at replacing damaged tissues in A-T patients.
3047225|NCT02246491|Other|iPSCs with gene correction|This is not a clinical trial and there is no immediate benefit to the participants. At this time, iPSCs and their derived products are not suitable for administration to patients. However, they are useful for basic and preclinical studies of the disease, such as mechanistic studies of ATM function or screening for small molecules with therapeutic value. As regenerative medicine continues to advance, iPSCs and their products may ultimately be used for clinical studies aimed at replacing damaged tissues in A-T patients.
3047226|NCT02246478|Placebo Comparator|Placebo|
3047227|NCT02246478|Active Comparator|TAS-205 low dose|
3047228|NCT02246478|Active Comparator|TAS-205 middle dose|
3047229|NCT02246478|Active Comparator|TAS-205 high dose|
3047230|NCT02246465|Experimental|RXI-109|RXI-109 dosed at the site of the revised hypertrophic scar
3047231|NCT02246439|Experimental|RHB-102|RHB-102, Bimodal Release Ondasetron Tablets
3047232|NCT02246439|Placebo Comparator|Placebo|Placebo
3047233|NCT02246426|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 40 treatment sessions, 3-5 times weekly, 45-60 minutes per session.
3047234|NCT02246426|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 40 treatment sessions, 3-5 times weekly, 45-60 minutes per session.
3047329|NCT02245737|Experimental|Lanabecestat 20 mg|Lanabecestat 20 milligrams (mg) given orally once daily for 104 weeks.
3047333|NCT02245711|Experimental|Stem Cell|
3047235|NCT02246413|Experimental|RAINBOW Intervention Program|An integrated intervention program for helping to improve mood and weight in adults who may be at risk for diabetes and heart disease.
3047236|NCT02246413|No Intervention|Usual Care|Usual Care.
3047237|NCT02246400|Active Comparator|Delayed Intervention|Usual care for first three months. Initiation of the eCMP after the 3-month time point.
3047238|NCT02246400|Experimental|Immediate Intervention|Initiation of the eCMP immediately upon completion of baseline data collection and randomization
3047239|NCT02246387||Manchester Operation|Manchester Operation: Native tissue repair
3047240|NCT02246374|Experimental|ExAblate Treated Arm|ExAblate Transcranial System subthalamotomy for motor symptoms of Parkinson's Disease.
3047241|NCT02246374|Sham Comparator|ExAblate Sham Treated Arm|ExAblate Transcranial System sham subthalamotomy for motor symptoms of Parkinson's Disease. Sham subjects completing the 4 Month visit may be offered the actual ExAblate subthalamotomy.
3047242|NCT02246361|No Intervention|Phase 1 (without PIL)|No particular intervention during consultation for the patient
3047243|NCT02246361|Experimental|Phase 2|Patient Information Leaflet is given to the patient during the consultation
3047244|NCT02246348|Experimental|Doppler ultrasound|
3047245|NCT02246335|Active Comparator|Control group|Hemiarthroplasty
3047246|NCT02246335|Active Comparator|Treatment group|Total hip arthroplasty
3047247|NCT02246322|Experimental|25G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
3047248|NCT02246322|Experimental|22G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
3047249|NCT02246309|Experimental|Embryoscope Time Lapse System|All embryos from patients randomized to this arm will be cultured in the Embryoscope culture system from the time of insemination until the time of transfer on day 3. All staff interaction with the embryos or with maintenance or supervision of the system will be timed.
3047250|NCT02246309|Active Comparator|Standard Embryo Culture|All embryos from patients randomized to this arm will be cultured in the standard embryo culture system from the time of insemination until the time of transfer on day 3. All staff interaction with the embryos or with maintenance or supervision of the system will be timed.
3047251|NCT02246296|Active Comparator|Standard F75 Milk|F75 with 63% of total energy from carbohydrates, including 10% of energy from lactose (standard F75).
3047252|NCT02246296|Experimental|Modified F75 Milk|F75 milk with 43% of total energy from carbohydrates, without any lactose, and providing the same amount of energy as standard F75 by increased lipid in the form of medium chain triglycerides.
3047253|NCT02246270|Experimental|Intravesical heparin|Recurrent UTI subject receives intravesical heparin once every week for 6 weeks
3047254|NCT02246270|Active Comparator|Placebo|Recurrent UTI subject receives intravesical saline once every week for 6 weeks
3047255|NCT02246257|Other|Intervention|"In the intervention group all patients will receive statins according to national guidelines. Stepwise introduction of pharmacological therapy targeting 1) hyperlipidaemia, 2) hypertension, 3) hyperglycaemia and 4) microalbuminuria and behaviour modification will be controlled by the project team in an outpatient rheumatology department.~Hyperlipidaemia: LDL > 2.5 is treated with 40 mg Simvastatin; Hypertension: BT > 140/90 mmHg treated with 100 mg OD Losartan; Diabetes: DM BT > 130/80 mmHg treated with 100 mg OD Losartan; Microalbuminuria: Urinary albumin creatinin ratio > 30 mg treated with 100 mg OD Losartan; Hyperglycaemia: HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks Metformin"
3047256|NCT02246257|Other|Control|"In the control group patients will be refered to general practice for pharmacological therapy according to national guidelines targeting 1) hyperlipidaemia, 2) hypertension, 3) hyperglycaemia and 4) microalbuminuria.~Hyperlipidaemia: LDL > 2.5 is treated with 40 mg Simvastatin; Hypertension: BT > 140/90 mmHg treated with 100 mg OD Losartan; Diabetes: DM BT > 130/80 mmHg treated with 100 mg OD Losartan; Microalbuminuria: Urinary albumin creatinin ratio > 30 mg treated with 100 mg OD Losartan; Hyperglycaemia: HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks Metformin"
3047257|NCT02246244|Experimental|Escitalopram|10 mg once per day
3047258|NCT02246244|Placebo Comparator|Placebo|
3047259|NCT02246231|Experimental|NF2 who has an auditory implant|
3047260|NCT02246218|Experimental|RAVICTI|RAVICTI Oral Liquid should be administered just prior to breastfeeding or intake of formula or food. The recommended dosing regimen is 3-6 times per day depending on feeding schedule and at the discretion of the Investigator.
3047261|NCT02246205|Experimental|DPC DN|Roux-en Y reconstruction after pancreaticoduodenectomy
3047262|NCT02246205|Active Comparator|DPC UN|Child reconstruction after pancreaticoduodenectomy
3047263|NCT02246192|Experimental|control group|sinus pilonidal excision and standard cares
3047264|NCT02246192|Experimental|PRGF group|sinus pilonidal excision+ PRGF
3047265|NCT02246179|Experimental|1: AFXL + AHES|This test region will be pretreated with a fractional carbon dioxide laser (ablative fractional laser; AFXL) with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse at t0 in a subject blinded fashion. Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region at t1.Ten minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam.
3047266|NCT02246179|Experimental|2: AFXL + EMLA|This test region will be pretreated with a fractional carbon dioxide laser (ablative fractional laser; AFXL) with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse at t0 in a subject blinded fashion. Eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) will be applied at this test region at t1.Ten minutes after EMLA cream application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam.
3047300|NCT02245958||BOTOX®|Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
3047301|NCT02245958||Xeomin®|Retrospective chart review of doses of Xeomin® (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
3047330|NCT02245737|Experimental|Lanabecestat 50 mg|Lanabecestat 50 mg given orally once daily for 104 weeks.
3047267|NCT02246179|Sham Comparator|3: Sham AFXL + AHES|"A pass with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse will be given at the area right adjacent to this test region (sham AFXL) at t0 in a subject blinded fashion. Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will then be applied at this test region on the intact skin at t1. Ten minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam."
3047268|NCT02246179|Sham Comparator|4: Sham AFXL + EMLA|"A pass with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse will be given at the area right adjacent to this test region (sham AFXL) at t0 in a subject blinded fashion. Eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) will then be applied at this test region on the intact skin at t1. Ten minutes after EMLA cream application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam."
3047269|NCT02246166|Experimental|Test tablet|Tablet containing Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets (II) (Paracetamol 500mg, pseudoephedrine 30mg, chlorpheniramine 2mg and dextromethorphan 15mg).
3047270|NCT02246166|Placebo Comparator|Placebo|Matching placebo tablet
3047271|NCT02246153|Experimental|Laparoscopic gastrectomy|Laparoscopy-assisted distal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
3047272|NCT02246153|Active Comparator|Open gastrectomy|Open distal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
3047273|NCT02246140|Experimental|Cannabis users|Cerebral MRI and MRA
3047274|NCT02246140|Active Comparator|healthy volunteers|Cerebral MRI and MRA
3047275|NCT02246127|Active Comparator|Sequence A, drug: everolimus first|Everolimus (10mg/daily, oral) followed by STZ-5FU (injection/infusion; Moertel or Uppsala regime).
3047276|NCT02246127|Experimental|Sequence B, drug: STZ - 5FU first|STZ-5FU (injection/infusion; Moertel or Uppsala regime) followed by Everolimus (10 mg/ daily, oral)
3047277|NCT02246114|Experimental|no CO monitor|Not given a piCO+ Smokerlyzer® monitor, will receive daily text messages.
3047278|NCT02246114|Experimental|CO monitor|Given a piCO+ Smokerlyzer® monitor, will receive daily text messages, will receive feedback about the relative level of carbon monoxide.
3047279|NCT02246101||WTC responders|WTC responders who were enrolled in the WTC-CHEST program.
3047280|NCT02246088|Experimental|MT + NE|A manual therapy (MT) intervention combined with neuroscience education (NE)
3047281|NCT02246088|Active Comparator|MT + E|Manual therapy (MT) intervention plus an educational program based on a traditional patho-anatomical or biomedical model (E)
3047282|NCT02246075|Experimental|EVP-6124, low dose|Low dose, Tablet, Once Daily, Day 1 through Day 168
3047283|NCT02246075|Experimental|EVP-6124, high dose|High dose, Tablet, Once Daily, Day 1 through Day 168
3047284|NCT02246075|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 168
3047285|NCT02246062|No Intervention|Control group|in which the relative receive only conventional verbal information one day before the procedure at ward.
3047286|NCT02246062|Active Comparator|info group|in which the relative, in addition to conventional verbal information, received a leaflet containing information about the anesthetic procedure one day before the surgery at ward.
3047287|NCT02246062|Active Comparator|smartphone group|in which the relative received only conventional verbal information one day before the procedure and the child received smartphone application immediately before entering the operating room
3047288|NCT02246062|Active Comparator|smartphone and info group|in which the relative, in addition to conventional verbal information, received a leaflet containing information about the anesthetic procedure one day before the surgery and the child received smartphone application immediately before entering the operating room.
3047289|NCT02246049|Experimental|FOLFOXIRI plus bevacizumab|"Induction therapy is followed by the maintenance therapy.~[Induction treatment:FOLFOXIRI plus bevacizumab] Administered for a maximum of 12 cycles. BV: 5mg/kg (d.i.v.) L-OHP: 85 mg/sq.m (d.i.v.) CPT-11:165mg/sq.m (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~[Maintenance treatment:5-FU / I-LV plus bevacizumab] BV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks."
3047290|NCT02246036|Experimental|APD probe|Placement of a duodenal probe during 24 hours.
3047291|NCT02246023|Active Comparator|Fractionated propofol administration|"Flexible bronchoscopy in moderate sedation with fractionated propofol administrations: Patients receive an initial 20 mg of propofol, followed by a carefully titrated dose of10-20 mg propofol based on the clinical response.~Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy"
3047292|NCT02246023|Experimental|Propofol-TCI|"Flexible bronchoscopy in moderate sedation with TCI propofol perfusor:~Flexible bronchoscopy is started after reaching the initial targeted effect-site concentration (Ce) of 2.5 μg/mL using the Schnider pharmacokinetic model described elsewhere. Thereafter, Ce is adjusted by increments of 0.2 μg/mL depending on the clinical effect, in order to maintain the required level of sedation.~Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy The propofol-TCI perfusor is an active infusion system for fluid management. In the study, the Perfusor® Space of B. Braun AG, Melsungen is used exclusively."
3047293|NCT02246010|Experimental|Lactose-free milk|Lactose- free milk formula (Similac LF®) and anti-diarrheic diet for 7 days.
3047294|NCT02246010|No Intervention|Regular infant milk|Regular infant milk formula and anti-diarrheic diet for 7 days.
3047295|NCT02245997|Experimental|patients with high-risk neuroblastoma|Patients undergo external beam radiation therapy using IMRT or proton beam RT twice daily for 5-6 weekdays (10-12 treatments).
3047296|NCT02245984|Experimental|paper based nursing process|for two weeks, students in paper based nursing group will be implemented paper nursing process for patients.
3047297|NCT02245984|Experimental|electronic nursing process|for two weeks students in this group will be implemented electronic nursing process for patients.
3047298|NCT02245971|Active Comparator|Whole precutting group|
3047299|NCT02245971|Active Comparator|Partial precutting group|
3047302|NCT02245945|Experimental|TFV 1% gel|"Participants will be instructed to use TFV 1% vaginal gel according to the BAT 24 regimen (2 gel doses) at least twice per week, regardless of sexual frequency.~The BAT24 dosing regimen when used with sex is defined as one dose of gel within 12 hours before sex and a second dose of gel as soon as possible within 12 hours after sex and no more than two doses in a 24 hour period. Participants who do engage in sexual intercourse should use the BAT24 regimen with each sex act.~If used without sex, the BAT24 dosing regimen is defined as 2 doses of gel administered 2-24 hours apart, with no more than two doses in a 24 hour period."
3047303|NCT02245945|Placebo Comparator|hydroxyethylcellulose (HEC) placebo gel|"Participants will be instructed to use HEC placebo gel according to the BAT 24 regimen (2 gel doses) at least twice per week, regardless of sexual frequency.~The BAT24 dosing regimen when used with sex is defined as one dose of gel within 12 hours before sex and a second dose of gel as soon as possible within 12 hours after sex and no more than two doses in a 24 hour period. Participants who do engage in sexual intercourse should use the BAT24 regimen with each sex act.~If used without sex, the BAT24 dosing regimen is defined as 2 doses of gel administered 2-24 hours apart, with no more than two doses in a 24 hour period."
3047304|NCT02245932|Experimental|Resveratrol supplementation|150 mg of resveratrol for 4 weeks (split over two doses of 75 mg/day)
3047305|NCT02245932|Placebo Comparator|Placebo supplementation|Placebo for 4 weeks (split over two doses per day)
3047306|NCT02245919|Experimental|Back on Track intervention|A biopsychosocial primary care intervention based on multidisciplinary pain rehabilitation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
3047307|NCT02245906|Placebo Comparator|Control drink|300 ml control drink containing equal amount of total fiber and pectine as Brazilian fruit drink, acute study / one time administration
3047308|NCT02245906|Experimental|Brazilian fruit peel|300 ml test drink containing Brazilian fruit peel flour, acute study / one time administration
3047309|NCT02245906|Placebo Comparator|Negative control drink|300 ml control drink without containing amount of total fiber and pectine as Brazilian fruit drink, acute study / one time administration
3047310|NCT02245893|Active Comparator|Screw|"In the SCREW Group (standard surgery technique), surgical treatment will be by closed reduction utilizing intraoperative fluoroscopy to visualize the reduction and percutaneous syndesmosis screw insertion. Intraoperative fluoroscopic stress and non-stress views will be obtained as per standard of care.~'open reduction internal fixation (ORIF)"
3047311|NCT02245893|Active Comparator|Anatomic repair technique (ART)|"In the ART group (study group) surgical treatment will be by open reduction and internal fixation. In order to stabilize the syndesmosis, direct visual anatomic alignment will be conducted and a syndesmotic screw inserted. In addition, fixation of the anterior ligament will be performed with use of a 2.7 to 4.0 mm suture anchor. Repair of the intact portion of the ligament will be made using a modified Mason -Allen repair. Intraoperative fluoroscopic stress and non-stress views will be obtained as per standard of care.~'open reduction internal fixation (ORIF)"
3047312|NCT02245880|Active Comparator|Glidescope videolaryngoscope|cervical collar was applied to 47 patients then facemask ventilations were recoded intubated with Glidescope and insertion time: handling of the device till the good glottic visualisation intubation time: handling of the device till the capnography appears mucosal damage: bloodstain on the device after removal heart rate preinduction heart rate postinduction heart rate postinsertion heart rate postintubation mean arterial pressure preinduction mean arterial pressure postinduction mean arterial pressure postinsertion mean arterial pressure postintubation wrere recorded. postoperative minor complications were recorded.
3047313|NCT02245880|Active Comparator|Intubating laryngeal mask airway|cervical collar was applied to 47 patients then facemask ventilations through the collar were recorded and intubated with ILMA insertion time: handling of the device till the good glottic visualisation appears intubation time: handling of the device till the capnography appears mucosal damage: bloodstain on the device heart rate preinduction heart rate postinduction heart rate posinsertion heart rate postintubation mean arterial pressure preinduction mean arterial pressure postinduction mean arterial pressure postinsertion mean arterial pressure postintubation
3047314|NCT02245867|Experimental|Phase Ia|"Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:~A 1-patient cohort will be infused with 0.5 mg/m2 of Ch 11-1F4 and, if tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. All individuals will be evaluated prior to treatment, after infusion weekly for four weeks, as well as at 8 weeks."
3047315|NCT02245867|Experimental|Phase Ib|"Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:~Subjects will receive four weekly infusions of the monoclonal anti-body at Dose Level 1 (0.5 mg/m2). If tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. When the highest tolerated dose is reached without toxicity in 2 patients, an additional 4 patients will be enrolled and infused at that dose. Escalation or de-escalation will continue until we have determined the highest dose level at which less than 2 patients experience toxicity. All individuals will be evaluated prior to each course of treatment, as well as at weeks 5, 8, and 12."
3047316|NCT02245854|Experimental|Colonic polyps|Exacto™
3047317|NCT02245841|Experimental|H.P Acthar Gel|80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
3047318|NCT02245828|Placebo Comparator|Placebo|Placebo comparator
3047319|NCT02245828|Experimental|QCC374|Single and multiple ascending doses of QCC374
3047320|NCT02245815|Experimental|use probiotics Boucardii|group A will be administered the lactobacillus boucardii probiotic (1x109 colonies forming units (UFC) per day for 3 weeks).
3047321|NCT02245815|Experimental|use probiotics Multi-species|Group B will be administered multi-species probiotic (1x109 colonies forming units (UFC) per day for 3 weeks).
3047322|NCT02245802||Low risk group|CU Prediction model < 3
3047323|NCT02245802||High risk group|CU Prediction model >=3
3047324|NCT02245789|Active Comparator|Macintosh laryngoscope|Tracheal intubation will be performed using a Macintosh laryngoscope. All patients will received propofol and remifentanil anesthesia.
3047325|NCT02245789|Experimental|McGrath Mac videolaryngoscope|Tracheal intubation will be performed using a McGrath Mac videolaryngoscope. All patients will received propofol and remifentanil anesthesia.
3047326|NCT02245776|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
3047327|NCT02245750|No Intervention|Routine Invistigations|ICSI with long luteal phase protocol
3047334|NCT02245698|Experimental|Stem Cell|Bone marrow mononuclear cells
3047335|NCT02245672|Experimental|MGR001|MGR001 administered two times per day by inhalation throughout the study
3047336|NCT02245672|Active Comparator|Advair Diskus|Advair Diskus administered two times per day by inhalation throughout the study
3047337|NCT02245672|Placebo Comparator|Placebo|Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study
3047338|NCT02245659|Experimental|CPAP|
3047339|NCT02245659|Other|Nasal dilator strip|Control
3047340|NCT02245646||Control group|No indication for stapedotomy
3047341|NCT02245646||Distortion positive|Subjects after stapedotomy perceiving sound distortions
3047342|NCT02245646||Distortion negative|Subjects after stapedotomy not perceiving sound distortions.
3047343|NCT02245633||vitamin D levels deficient|Diabetic hemodialysis patients with vitamin D levels deficient
3047344|NCT02245633||vitamin D levels sufficient|Diabetic hemodialysis patients with vitamin D levels sufficient
3047345|NCT02245620|Experimental|MTP-131 (Bendavia™)|
3047346|NCT02245620|Placebo Comparator|Placebo|
3047347|NCT02245607|Experimental|Compensatory Cognitive Training|Compensatory Cognitive Training
3047348|NCT02245607|Active Comparator|Recreational Therapy|Recreational Therapy
3047349|NCT02245594||Gl motility and sleep pattern|
3047350|NCT02245581|Active Comparator|SVV-guided fluid management|SVV : Stoke volume variation
3047351|NCT02245581|Active Comparator|CVP-guided fluid management|CVP : Central venous pressure
3047352|NCT02245568|Experimental|TRx0237|
3047353|NCT02245555||Patients with benign prostatic hyperplasia|
3047354|NCT02245542||BPH patients|
3047355|NCT02245529||Patients with benign prostatic hyperplasia (BPH)|
3047356|NCT02245516|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% Ophthalmic Suspension dosed QID for 4 weeks in subjects with Retinal Vein Occlusion or Diabetic Macular Edema
3047357|NCT02245516|Active Comparator|KPI-121 1.0% Ophthalmic Suspension|KPI-121 1.0% Ophthalmic Suspension dosed QID for 4 weeks in subjects with Retinal Vein Occlusion or Diabetic Macular Edema
3047358|NCT02245503||Benign prostatic hyperplasia|Patients with symptomatic BPH to whom ALNA was prescribed
3047359|NCT02245490|Experimental|Tamsulosin|
3047360|NCT02245490|Placebo Comparator|Placebo|
3047361|NCT02245477||Obstetric Ultrasoud|Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
3047362|NCT02245477||Serum Vascular Endothelial Growth Factor|Serum VEGF concentration will be determined by Enzyme Linked immunosorbant assay using Quantitative Human VEGF Immunoassay kit (cat. No. DVEOO) manufactured by R & D Systems, Inc , (Minneapolis, MN, USA).
3047363|NCT02245464||Patients with essential hypertension|
3047364|NCT02245451|Experimental|TPV/r with methadone|
3047365|NCT02245438|Experimental|TPV/RTV low dose|
3047366|NCT02245438|Experimental|TPV/RTV high dose|
3047367|NCT02245425|Active Comparator|Supine Thoracic Spine Manipulation|Supine (lying face-up on the treatment table) thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2)
3047368|NCT02245425|Active Comparator|Prone Thoracic Spine Manipulation|Prone (lying face down on the treatment table) thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2).
3047369|NCT02245412|Experimental|ALXN1007 10mg/kg once a week|
3047370|NCT02245412|Experimental|ALXN1007 20mg/kg once a week|
3047371|NCT02245412|Experimental|ALXN1007 20mg/kg twice a week|
3047372|NCT02245399|Experimental|A canola oil enriched mediterranean diet|Participants will be advised to consume, a low-carbohydrate diet (26-32% of calories), high in vegetable protein (28-32%) and fat (41-45%) with canola as the major component (10%). Carbohydrate sources will feature viscous fiber-containing foods (including psyllium cereal, oats and barley) and low-starch vegetables (emphasizing okra and eggplant) for the relatively limited amount of carbohydrate.
3047373|NCT02245399|Active Comparator|A high wheat fiber diet|Participant will be advised to consume a high carbohydrate diet (58% carbohydrate, 16% protein and 25% fat) emphasizing whole wheat/whole grain cereals and increased high fiber alternatives, with fruits and vegetables.
3047374|NCT02245386||Group 1|(40 women after normal vaginal delivery) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
3047375|NCT02245386||Group 2|(40 women after urgent cesarean section) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
3047376|NCT02245386||Group 3|(40 women after elective cesarean section) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
3047377|NCT02245373||Antidepressants|Naturalistic assignment: Patients whose physician decides to indicate antidepressants.
3047378|NCT02245373||Active Monitoring|Naturalistic assignment: Patients whose physician considers starting an Active Monitoring intervention.
3047379|NCT02245360|Experimental|Grass tablet 75,000 SQ-T|Grass tablet 75,000 Standardized Quality units Tablet (SQ-T)
3047380|NCT02245360|Placebo Comparator|Placebo|Placebo
3047381|NCT02245347||Patients with expected MDR TB|
3047382|NCT02245334|Experimental|Povidone-iodine|povidone iodine pill
3047383|NCT02245334|No Intervention|no intervention|no intervention
3047384|NCT02245321|Placebo Comparator|Letter Group- No information|Receive a thank you letter after each blood donation.
3047385|NCT02245321|Experimental|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
3047386|NCT02245321|Placebo Comparator|Ferrous gluconate- 0 mg|Receive pills to take daily that contain no iron (a placebo or inert pill).
3047387|NCT02245321|Experimental|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
3047388|NCT02245321|Experimental|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
3047389|NCT02245308|Experimental|ART|Participants assigned to this treatment arm will receive a tele-health intervention that combines guideline-based cognitive-behavioral counseling for smoking cessation, a tele-medicine clinic for access to smoking cessation aids, and an intensive behavioral therapy for smoking cessation called mobile contingency management.
3047390|NCT02245308|Active Comparator|Control Group|Participants assigned to this active control arm will be referred to VA Specialty Smoking Cessation Clinic for standard-of-care treatment, which may include group counseling, individual counseling, self-help materials, and smoking cessation aids.
3047391|NCT02245295||EBUS-TBNA|EBUS-TBNA for enlarged mediastinal/hilar lymph nodes
3047392|NCT02245269|Experimental|TPV/r + Atorvastatin followed by TPV/r + antacid|Day 1: first dose of ATV Day 8: single dose of TPV/r Day 13: single dose of TPV/r, followed by a single dose of Maalox Days 14-21: morning and evening doses of TPV/r on Day 20: second dose of ATV
3047393|NCT02245256|Placebo Comparator|Normal saline|same infusion rate as experimental group (dexmedetomidine)
3047394|NCT02245256|Experimental|dexmedetomidine|0.1mcg/kg/hr of dexmedetomidine infusion started after induction of anesthesia for liver transplantation and continued until 48 hours after surgery.
3047395|NCT02245243|Experimental|Delafloxacin|Single Dose 300 mg IV
3047396|NCT02245230|Active Comparator|Intact Study Day|Subjects will receive saline infusion for 60 minutes followed by five ascending doses of Angiotensin (1-7) ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
3047397|NCT02245230|Experimental|Autonomic Blockade Study Day|Autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min. Blood pressure will be restored to pre-trimethaphan levels with intravenous phenylephrine infusion at individually titrated doses, starting with 0.1 ug/kg/min. Angiotensin (1-7) will then be infused in five ascending doses ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
3047398|NCT02245217|Experimental|PET/CT Imaging arm|
3047399|NCT02245204|Experimental|Chlorgenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
3047400|NCT02245191|Experimental|Ephedrine Group|Patients who will receive ephedrine after spinal anesthesia
3047401|NCT02245191|Experimental|Phenylephrine Group|Patients who will receive Phenylephrine after spinal anesthesia
3047402|NCT02245191|Experimental|Metaraminol|Patients who will receive Metaraminol after spinal anesthesia
3047403|NCT02245178||Obervational - CARDIA participants|CARDIA study participants will undergo lung function testing and have existing thoracic CT scans analyzed for lung structure.
3047404|NCT02245165|Experimental|Nitric oxide synthase (NOS) inhibition|After a control period of 4 hours, intervention with L-NMMA (10 mg/kg IV) is done and recording continued for 4 hours.
3047405|NCT02245165|Sham Comparator|Saline|After a control period of 4 hours, intervention with saline is done and recording continued for 4 hours.
3047406|NCT02245152|Experimental|PROMIS intervention|"Small group behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly well-baby visits for children 0-17 months of age~Caregivers with children 0-17 months of age that attend the well-baby visit will be provided with a monthly dose of LNS (20g/day)"
3047407|NCT02245152|Active Comparator|control|Monthly well-baby visits as prescribed by national policy This arm is the basic comparison arm. Caregivers are invited to frequent the health center once a month for well-baby visits. During these visits necessary vaccinations are administered, child growth and nutrition status is evaluated and preventive counseling on child nutrition and health is provided in large groups of caregivers.
3047408|NCT02245126|Experimental|Lignocaine-bupivacaine lower dosage mix|"Men who received the 3-3-4 local anaesthetic mix( 3 cc of lignocaine 2% , 3cc of bupivacaine 0.5% and 4cc of water for injection)~3-3-4 mix was administered"
3047409|NCT02245126|Active Comparator|Lignocaine-bupivacaine higher dosage mix|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
3047410|NCT02245113|Experimental|Test Fat P|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
3047411|NCT02245113|Experimental|Test Fat Q|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
3047412|NCT02245113|Experimental|Test Fat R|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
3047413|NCT02245100||Predictive value of circulating DNA|Patients undergo blood sample collection within 1 month before surgery, radiation therapy, or chemotherapy; within 1 week after surgical resection (for patients having upfront surgery); within 1 month before beginning of post-operative radiation therapy (for patients having upfront surgery); during the second week of radiation therapy, during the last week of radiation therapy; and at 1 and 3 months after radiation therapy and then every 3 months for up to 18 months. Patients also undergo saliva sample collection within 1 month before surgery, radiation therapy, chemoradiation therapy, or system chemotherapy and tissue collection at the time of surgery (if upfront surgery is indicated). Blood, saliva, and tissue samples are analyzed for tumor mutations via next generation sequencing.
3047414|NCT02245087|Experimental|Atorvastatin|Atorvastatin(Lipitor) in addition to the usual guideline based care
3047415|NCT02245087|No Intervention|Guideline based care|Current guidelines for lipid-management in healthy middle aged men and women only.
3047416|NCT02245074|Other|Acute exacerbation|Cell profiles Analysis after sputum induction in infants with Acute exacerbation
3047417|NCT02245074|Other|Uncontrolled asthma|Cell profiles Analysis after sputum induction in infants with Uncontrolled asthma
3047418|NCT02245074|Other|controlled asthma|Cell profiles Analysis after sputum induction in infants controlled asthma
3047419|NCT02245061|Experimental|paired pulses cortical electrical stimulation|
3047420|NCT02245048||Stress Echocardiography (SE)|Subjects will undergo CIMT measurements.
3047421|NCT02245035||Low dairy intake|1 serving/day or less of dairy food characterized at enrollment using 24 hr dietary recall
3047422|NCT02245035||Moderate Dairy Intake|1-2 servings/day of dairy food characterized at enrollment using 24 hr dietary recall
3047423|NCT02245035||Recommended Dairy Intake|Greater than 3 servings/day of dairy food characterized at enrollment using 24 hr dietary recall
3047424|NCT02245022|Experimental|Dolutegravir 50mg od|30 patients who will receive dolutegravir 50mg once daily plus the same NRTI backbone as the active comparator group (lamivudine and tenofovir)
3047425|NCT02245022|Active Comparator|Standard of Care|Patients randomised to receive antiretroviral therapy as per Uganda national guidelines (Efavirenz 600mg od based plus Tenofovir 300mg od and Lamivudine 300mg od)
3047426|NCT02245009||Pacemaker patients|Patients with pacemaker, presenting for cardioversion.
3047427|NCT02245009||ICD patients|Patients with ICD, presenting for cardioversion.
3047428|NCT02245009||CRT patients|Patients with CRT device, presenting for cardioversion.
3047429|NCT02244996|Experimental|Lycium Barbarum|Daily Lycium Barbarum dosage: 10g of granules for 12 months
3047430|NCT02244996|Placebo Comparator|Placebo|Placebo
3047431|NCT02244983||EFAB 65|Patients presenting to the emergency department with falls, above 65 years of age. Patients History will be taken as well as a blood sample
3047432|NCT02244970|Experimental|Mindfulness|Subjects are scheduled to receive a 7-week group mindfulness-based intervention (MBI) program.
3047433|NCT02244970|Active Comparator|Psychoeducation|Subjects will receive 7 weeks of group-based psychoeducation as an active comparison group parallel to the mindfulness group.
3047434|NCT02244957|Active Comparator|Bi-level positive airway pressure (BPAP)|Bi-level positive airway pressure (BPAP)
3047435|NCT02244957|Active Comparator|Nocturnal oxygen|Nocturnal oxygen
3047436|NCT02244944|Experimental|EZ-URSO Combination Therapy|Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.
3047437|NCT02244931|Experimental|Phase 1: Performance evaluation on ergometer|"The 3 devices are experimented in random order to compare them on performance using an ergometer wheelchair:~Servomatic™ assisting device~E.Motion© assisting device~Standard manual Wheelchair"
3047438|NCT02244931|Experimental|Phase 2: Comparison of maneuverability|"The 3 devices are experimented in random order to compare them on maneuverability:~Servomatic™ assisting device~E.Motion© assisting device~Standard manual Wheelchair"
3047439|NCT02244931|Experimental|Phase 3: Comparison of the autonomy|"The 3 devices are experimented in random order to compare them on the autonomy they afford to patients:~Servomatic™ assisting device~E.Motion© assisting device~Standard manual Wheelchair"
3047440|NCT02244918|Active Comparator|Counseling|Participants will go to smoking cessation counseling over 12 weeks. They will be asked to participated in 5 total counseling sessions.
3047441|NCT02244918|Experimental|Counseling Plus Nicotine Replacement Therapy|Participants will go to smoking cessation counseling over 12 weeks. They will be asked to participated in 5 total counseling sessions. In addition to counseling, participants in this group will also take 12 weeks of a nicotine replacement therapy (like the patch, gum or lozenge) of their choice.
3047442|NCT02244905|Experimental|Positive Deviance Intervention Arm|Three hospital wards received Positive Deviance intervention.
3047443|NCT02244905|Other|Control Arm|Three hospital wards randomized to control arm received the Standard-of-Care Infection Control approach.
3047444|NCT02244879|Placebo Comparator|placebo|In this arm, 64 patients will receive a tablet of placebo once/day for 6 months
3047445|NCT02244879|Experimental|resveratrol 40|In this arm, 64 patients will receive a tablet of 40mg resveratrol once/day for 6 months
3047446|NCT02244879|Experimental|resveratrol 500|In this arm, 64 patients will receive a tablet of 500 mg resveratrol once/day for 6 months
3047447|NCT02244866|Active Comparator|Pergoveris (FSH and LH)|150 IU of recombinant FSH and 75 IU of recombinant LH (Pergoveris) daily subcutaneous injection
3047448|NCT02244866|Active Comparator|Follitropin alpha (FSH)|150 IU of recombinant FSH (follitropin alpha or Gonal-F) daily subcutaneous injection
3047449|NCT02244840|Experimental|Electronic bidet and sitz bath|Electronic bidet for 3 minutes and sitz bath for 3 minutes, at another day, for each subject
3047450|NCT02244827|Experimental|WCK 2349|Each subject will receive a single oral dose of WCK 2349 1000 mg (i.e., 2 tablets of 400 mg and 1 tablet of 200 mg) with 240 mL water on Day 1 in the morning. Study drug will be administered after a fast of at least 8 hours.
3047451|NCT02244814|Experimental|Choosing Healthy Options in Carbohydrate Energy|60% carbohydrate/25% fat/15% protein diet
3047452|NCT02244814|Active Comparator|Low Carbohydrate/Conventional|40% carbohydrate/45% fat/15% protein
3047453|NCT02244801|Other|Cohort 1|"3 subjects treated with a target dose of 300 million darTreg with the possibility of expanding to 5 patients if safety signals should require additional patients be observed at the 300 million dose.~The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients."
3047454|NCT02244801|Other|Cohort 2|"The second cohort will comprise a minimum of 3 and up to 5 subjects treated at a target dose of 900 million darTreg, depending on how many patients were required to be treated in lower dose group.~The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients."
3047455|NCT02244762|Experimental|Mild Renal Impairment|20 mg HC-ER
3047456|NCT02244762|Experimental|Moderate Renal Impairment|20 mg HC-ER
3047457|NCT02244762|Experimental|Severe Renal Impairment|20 mg HC-ER
3047458|NCT02244749||skin specimen|skin specimen
3047459|NCT02244736||Controls|Subjects with no family history of diabetes mellitus and normal OGTT
3047460|NCT02244736||Relatives|First-degree relatives of patients with diabetes mellitus and normal OGTT
3047461|NCT02244736||Diabetics|Subjects with abnormal OGTT
3047462|NCT02244723||Patients with suspected VAP|"Only one group is studied : mechanically-ventilated patients with suspected VAP in ICUs.~For each patient a lung ultrasound examination will be performed."
3047463|NCT02244710|Experimental|Ticagrelor|180mg initial dose next day 90mg BID
3047464|NCT02244710|Active Comparator|Clopidogrel|600mg po initial dose and 75mg qd starting next day
3047465|NCT02244697||Experimental: laryngeal ultrasound stridor|Children aged 0-16 years referred for an awake nasolaryngoscopy for stridor or dysphonia at the pediatric Otolaryngology unit at the Tel Aviv Sourasky Medical Centre.
3047466|NCT02244697||Other: laryngeal ultrasound -control|Infants matched for age referred for ANL for reasons other than stridor will undergo US of the larynx.
3047467|NCT02244684||Pregnant women|
3047468|NCT02244671|Experimental|fat, PRP, botulinum toxin|Fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin
3047469|NCT02244658|Experimental|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7~14 consecutive days
3047470|NCT02244658|No Intervention|control|no thrombopoietic agents
3047471|NCT02244645|Other|Passive modality control group|Passive modality control group will receive regular 40-minutes rehabilitation twice a week for 3 months.
3047472|NCT02244645|Experimental|Yoga treatment group|Yoga treatment group will receive regular 60-minutes yoga classes twice a week for 4 months.
3047473|NCT02244632|Experimental|Modufolin / Nordic FLV|Modufolin in combination with 5-Fluorouracil only.
3047474|NCT02244632|Experimental|Modufolin / Nordic FLOX|Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to Nordic FLOX regime
3047475|NCT02244632|Experimental|Modufolin / Nordic FLIRI|Modufolin in combination with 5-Fluorouracil and Irinotecan.
3047476|NCT02244632|Experimental|MOFOX|Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to mFOLFOX-6 regime
3047477|NCT02244632|Experimental|MOFOX / Bevacizumab|Modufolin in combination with 5-Fluorouracil, Oxaliplatin and Bevacizumab
3047478|NCT02244632|Experimental|MOFIRI|Modufolin in combination with 5-Fluorouracil and Irinotecan
3047479|NCT02244619|Active Comparator|Oral acetaminophen|Subjects receive 2 capsules each containing Tylenol 500 mg caplets. The test article administration will be initiated 60 minutes (± 15 minutes) prior to the scheduled surgery start time.
3047480|NCT02244619|Active Comparator|IV acetaminophen|Subjects receive Ofirmev 1000 mg in 100 ml Normal Saline IV infusion. The test article will be given perioperatively at the discretion of the attending anesthesiologist.
3047481|NCT02244606|Experimental|SCY-078 500 mg|A single loading dose of SCY-078 1000-mg orally on the first day, followed by SCY-078 500-mg orally once-daily on subsequent days.
3047482|NCT02244606|Experimental|SCY-078 750 mg|A single loading dose of SCY-078 1250-mg orally on the first day, followed by SCY-078 750-mg orally once-daily on subsequent days.
3047483|NCT02244606|Active Comparator|Standard-of-care|Oral fluconazole 400 mg daily (with a loading dose of 800 mg on the first day) or IV micafungin 100 mg daily.
3047484|NCT02244593|No Intervention|Mammography screening only|"This group will receive their standard of care mammogram only. Participants in this arm will not receive the FAST MRI.~Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram."
3047485|NCT02244593|Experimental|FAST MRI and mammogram screening|Patients in this group will receive Breast MRI and annual mammography. Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram. The intervention is the addition of the FAST Breast MRI.
3047486|NCT02244580|Experimental|MammaTyper™|MammaTyper™ kit will be used tio assess tumor material of patients enrolled into the FinHer trial.
3047487|NCT02244567|Active Comparator|Metformin|Cidophage 850 mg twice daily for three months will be given to the patientwith PCOS.
3047488|NCT02244567|Active Comparator|Serum under-carboxylated osteocalcin|Serum uc-oc will be measured before and after 3 months of treatment with cidophage.
3047489|NCT02244567|Active Comparator|Placebo|Other group of patients with high serum UC-OC will be given a placebo.
3047490|NCT02244554|Experimental|enLighten Laser Picosecond Pulse|Picosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
3047491|NCT02244554|Experimental|enLighten Laser Nanosecond Pulse|Nanosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
3047492|NCT02244541|Experimental|Anavex2-73 oral then the Anavex2-73 intravenous formulation|Participants first receive Anavex2-73 hard gelatin capsule each morning with a light breakfast for 11 days. After a washout period of 11 days they then receive the Anavex2-73 intravenous formulation each morning with a light breakfast for 11 days.
3047493|NCT02244541|Experimental|Anavex2-73 intravenous then the Anavex2-73 oral formulation|Participants first receive Anavex2-73 intravenous formulation each morning with a light breakfast for 11 days. After a washout period of 11 days then they receive the Anavex2-73 hard gelatin capsule each morning with a light breakfast for 11 days.
3047494|NCT02244541|Experimental|Anavex2-73 30 mg oral formulation|Participants will receive the 30 mg Anavex2-73 hard gelatin capsule orally once daily for 52 weeks.
3047495|NCT02244541|Experimental|Anavex2-73 50 mg oral formulation|Participants will receive the 50 mg Anavex2-73 hard gelatin capsule orally once daily for 52 weeks.
3047496|NCT02244528|Experimental|Treatment|sildenafil treatment
3047497|NCT02244515|Placebo Comparator|Group C|Five minutes prior to the commencement of the surgical procedure, Group D participants were administered 10 ml NaCI 0.9%.
3047498|NCT02244515|Experimental|Group D|Five minutes prior to the commencement of the surgical procedure, Group D participants were administered dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
3047499|NCT02244502|Experimental|TTFields in combination with weekly paclitaxel|Patients will be treated continuously with the NovoTTF-100L(O) device, in addition to weekly paclitaxel.
3047500|NCT02244489|Experimental|MMB+capecitabine|Participants will receive MMB+capecitabine at varying dose levels to determine the MTD for MMB and capecitabine.
3047501|NCT02244489|Experimental|MMB+capecitabine+oxaliplatin|Upon reaching the MTD for MMB and capecitabine or if no MTD is reached, participants will receive MMB+capecitabine at the MTD plus oxaliplatin at varying dose levels to determine the MTD of combination capecitabine, MMB, and oxaliplatin.
3047502|NCT02244463|Experimental|MLN0128|Treatment will be administered on an outpatient basis. MLN0128 at fixed dose will be administered orally, daily for treatment cycle. The participant will be requested to maintain a medication diary of medication. The medication diary will be returned to clinic staff at the end of each cycle. Treatment with MLN0128 will continue until progression or withdrawal of consent.
3047503|NCT02244450|Experimental|Screened patients|SCID screening: more drops of blood are placed on a second Guthrie card when current screening (72 hours of life ) is performed after parents' information and consent. The card drawn for the protocol will follow the usual network except that the test for quantifying TRECs will be realized to determine the presence of SCID.
3047504|NCT02244450|No Intervention|Control group|SCID children diagnosed without screening by pediatricians local referents DIP
3047505|NCT02244437|Active Comparator|Ibuprofen|Ibuprofen has been shown to prevent AMS from previous studies.
3047506|NCT02244437|Experimental|Acetaminophen|Acetaminophen has not been tested yet in AMS prevention.
3047507|NCT02244424|Experimental|Tools for Teen Moms Intervention Group|Tools for Teen Moms intervention group will receive daily challenges focusing on: 1) Maternal-Infant Feeding Interaction; and 2) Feeding Practices Challenges. The challenges will cycle through a pre-determined schedule where they are automatically updated each day at midnight. Participants will have a 24-hour period to complete each challenge. The intervention will provide a new daily challenge over six weeks, a time frame selected to provide participants with enough opportunities to form the habit of visiting the website daily. Participants will continue to receive usual MIHP care during the intervention.
3047508|NCT02244424|No Intervention|MIHP standard care|MIHP care consists of voluntary home visits: one week postpartum, at six weeks, and six months, and on-going as needed provided by a RN, licensed social worker, RD, infant mental health specialist and/or paraprofessional. Content includes a flexible plan of care with visits based on identified domains for both the mother and the infant.
3047509|NCT02244411|Experimental|Intervention group|Participants will be assigned an individual diet & physical activity counselor through Healthways at Hopkins. This counselor will stay with the participant for the 24 months. The primary communication with the counselor will be via website & email. Participants will be encouraged to consume a low-calorie, low-salt diet with 7-12 daily servings of fruits, vegetables & low-fat dairy products. Calorie goals are based upon weight at study entry & whether or not the weight loss goal has been met. Participants will gradually build to ≥ 180 minutes of moderate to vigorous physical activity per week, using the activity of their own choosing & gradually adding bouts of ≥ 10 minutes in length. Monitoring & Counselor Contacts: the first 3 months, the participants are encouraged to log into the web hub on a daily basis to record weight, food intake, & physical activity. Participants who decline or drop out of the intervention program will remain on-study doing home visits & questionnaires.
3047510|NCT02244411|Active Comparator|control group|Participants will receive general information brochures on healthy living and weight loss but will not have access to the Healthways at Hopkins website or counselors.
3047511|NCT02244398|Experimental|FP and HTC services|VHTs in the intervention arm provide both family planning and HTC services between May 2012 and September 2013, then return to providing family planning only at the end of the project. Services are made available to all adults in VHTs' communities. HIV testing is done using the national rapid testing algorithm. Clients who test positive for HIV are referred to a health center for care and treatment and receive disclosure support and information on peer support groups.
3047512|NCT02244398|Active Comparator|FP services|VHTs in the control arm only provide family planning services.
3047513|NCT02244385||Observation|No intervention
3047514|NCT02244372|Experimental|Cordyceps sinensis mycelium culture extract 0.76 g|Cordyceps sinensis mycelium culture extract 0.76 g
3047515|NCT02244372|Experimental|Cordyceps sinensis mycelium culture extract 1.15 g|Cordyceps sinensis mycelium culture extract 1.15 g
3047516|NCT02244372|Placebo Comparator|Placebo|Placebo
3047517|NCT02244359|Experimental|Training|Online tutorial, decision aid and interactive workshop
3047518|NCT02244359|Other|Usual care|Usual care
3047519|NCT02244346||Benign prostatic hyperplasia patients|
3047520|NCT02244333||Patients with symptomatic BPS|
3047521|NCT02244320||functional BPH|patients with functional BPH who switched from phytotherapy to ALNA®
3047522|NCT02244307||Patients with BPH treated with alpha-andrenergic blockade|
3047523|NCT02244294|Experimental|FLOMAX®|
3047524|NCT02244294|Placebo Comparator|Placebo|
3047525|NCT02244281|Experimental|FLOMAX®|
3047526|NCT02244281|Placebo Comparator|Placebo|
3047527|NCT02244268||Patient with symptomatic of benign prostatic hyperplasia|
3047528|NCT02244255|Experimental|FLOMAX®|
3047529|NCT02244255|Active Comparator|HYTRIN®|
3047530|NCT02244242|Experimental|Tamsulosin hydrochloride|modified release capsules
3047531|NCT02244229|Experimental|Tamsulosin|
3047532|NCT02244229|Active Comparator|Finasteride|
3047533|NCT02244216||Chronic Obstructive Respiratory Tract Disease|
3047534|NCT02244203|Experimental|Single rising doses of BI 60732|
3047535|NCT02244203|Placebo Comparator|Placebo|
3047536|NCT02244190|Experimental|new Tipranavir + Ritonavir|
3047537|NCT02244190|Active Comparator|current Tipranavir + Ritonavir|
3047538|NCT02244177||normotension group|Until 11,March, 2015, 31 cases are collected.
3047539|NCT02244177||hypertension group without treatment|Until 11,March, 2015, 60 cases are collected.
3047540|NCT02244177||hypertension group with antihypertensive treatment|"(ACEI, beta-blocker, Ca blocker, Diuretics) prior to the surgery.~Until 11,March, 2015, 59 cases are collected."
3047541|NCT02244164|Active Comparator|Sulfonylurea|Patient will received metformine with sulfonylurea
3047542|NCT02244164|Active Comparator|Incretinomimectics|Patients will received metformin with sulfonylurea with GLP-1 analogue
3047543|NCT02244164|Active Comparator|DPP-4 inhibitors|Patients will received metformin with DPP-4 inhibitors
3047544|NCT02244151|Experimental|DECAPEPTYL® diario|Group 1: DECAPEPTYL® diario,OPU 24 hours after GnRHa administration.
3047545|NCT02244151|Experimental|Decapeptyl® diaro|Group 2:Decapeptyl® diario OPU 30 hours after GnRHa administration.
3047546|NCT02244151|Experimental|Decapeptyl® diario.|Group 3: Decapeptyl® diario, OPU 40 hours after GnRHa administration.
3047547|NCT02244151|Active Comparator|Decapeptyl® daily|Group 4: Decapeptyl® daily OPU 36 hrs after GnRH administration
3047548|NCT02244138||Adolescent CDSS|Implementation clinic site for CDDS
3047549|NCT02244125|Other|Previous IFM/DFCI 2009 arm A|"Patients previously randomized into IFM/DFCI 2009 trial arm A (or if transplantation was not done) will receive:~The treatment phase:~4 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~The consolidation phase:~Melphalan 200mg/m2 followed by ASCT (Autologous Stem Cell Transplantation)~2 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~The maintenance phase: Until progression or discontinuation for any other reason~Pomalidomide and Dexamethasone"
3078260|NCT02038673|Experimental|Dose escalation part 4.0 mg BID|Oral
3047550|NCT02244125|Other|Previous transplantation IFM/DFCI 2009 arm B|"Patients previously randomized into IFM/DFCI 2009 trial arm B (RVD plus Transplant) will receive:~The treatment phase:~4 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~The consolidation phase:~5 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~The maintenance phase: Until progression or discontinuation for any oher reason~Pomalidomide and Dexamethasone"
3047551|NCT02244112|Experimental|Part I: Food Effect/QTc|"Subjects will receive a single dose of oprozomib 270 mg in 1 of 3 fasting/fed conditions:~Diet A: Fasted conditions~Diet B: A low-fat breakfast. A low-fat breakfast is defined as having a total caloric value of less than 400 calories, with less than 20% from fat~Diet C: A high-fat breakfast. A high-fat breakfast is defined as having a total caloric value of 800 to 1000 calories, with approximately 50% from fat"
3047552|NCT02244112|Experimental|Part II: Drug-Drug Interaction (DDI)|"Period 1: Midazolam 2 mg single oral dose on one day between Day -7 and -4~Period 2: Midazolam 2 mg single oral dose 1 hour following oprozomib dose on Day 1 of Cycle 1 and Day 2 of Cycle 2. Oprozomib 300 mg dose on Days 1, 2, 8 and 9 of Cycles 1 and Cycle 2"
3047553|NCT02244112|Experimental|Extension|After subjects complete the Food Effect/QTc or DDI part, subjects may participate in the extension part of the study, where oprozomib treatment will be continued on Days 1, 2, 8, and 9 of each 14-day cycle. During this part of the study, it is recommended that oprozomib be taken with food.
3047554|NCT02244099|Experimental|Controlled Substance|Consenting physicians who care for patients who have been prescribed a controlled substance, carisoprodol, or tramadol at least 3 times in the last 6 months in Martha Morehouse General Internal Medicine Resident Continuity Clinic.
3047555|NCT02244086|No Intervention|bupivacaine 0.125%|administrate bupivacaine at 0.125% during initiation of effective labor work
3047556|NCT02244086|Experimental|bupivacaine 0.25%|Administrate bupivacaine at 0.25% during initiation of effective labor work One of the researchers selected from a randomized list containing pages in both groups with numbers ranging from 0001 to 0110 with 55 pages for each group and these selected folios prepared in sterile form and start the day in the morning, the amount of 10 10 ml syringes with foil for each mixture. The remaining samples were discarded if 10 analgesics are not achieved during the day, and the day new preparations were made.
3047557|NCT02244073|Experimental|Individualized blood glucose target|Maintain blood glucose in individualized target based on glycated hemoglobin level (A1c); Blood glucose level is maintained bellow 1.59 × A1c - 1.59 (mmol/l).
3047558|NCT02244073|Active Comparator|Conventional blood glucose target|Maintain blood glucose bellow 10 mmol/l.
3047559|NCT02244060|Experimental|Direct comparison|The Direct comparison against vignette (DCV) questionnaire asks subjects to estimate their own vision against vignette situations.Priming effect from vignette is designed in the arm of DCV.
3047560|NCT02244060|No Intervention|Indirect comparison|The Indirect comparison against vignette (ICV) questionnaire asks self-assessed vision and single evaluation of vignettes.
3047561|NCT02244047|Active Comparator|Bifidobacterium breve|Bifidobacterium breve BR03 and B632 powder containing 10/9 CFU daily dosage in a period of 3 months
3047562|NCT02244047|Active Comparator|Placebo|Placebo in the same powder packages as Bifidobacterium breve
3047563|NCT02244034||1250 patients who had cardiac surgery wit|
3047564|NCT02244021|Experimental|BRENTUXIMAB VEDOTIN|1 arm for all patients
3047565|NCT02244008|Experimental|joint mobilization|Anteroposterior mobilization of the talus (Maitland mobilization grade III)
3047566|NCT02244008|Placebo Comparator|manual contact|
3047567|NCT02243995|Experimental|Physical training|
3047568|NCT02243982|Experimental|[F18]-FDDNP|2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl)amino]-2-naphthyl}-ethylidene)malononitrile. Radiopharmaceutical tracer
3047569|NCT02243969|Experimental|flaxseed oil (rich in α-linolenic acid )|
3047570|NCT02243969|Placebo Comparator|high oleic sunflower oil|
3047571|NCT02243956|Experimental|Flavanol rich food product|A portion of a common flavanol rich food product is consumed daily for 4 weeks
3047572|NCT02243956|Placebo Comparator|Non-flavanol food product|A portion of a product similar to the experimental Product, but instead contains low amounts of flavanol, is consumed Daily for 4 weeks as a control.
3047573|NCT02243943|Experimental|Sugammadex|Subjects in this arm will be reversed with sugammadex 2-4 mg/kg
3047574|NCT02243943|Active Comparator|neostigmine|subjects in this arm will be reversed with neostigmine 1.0-2.5 mg and atropine 0.5-1.0mg
3047575|NCT02243930|Experimental|Cap|Sigmoidoscopy with cap
3047576|NCT02243930|No Intervention|No cap|Sigmoidoscopy without cap
3047577|NCT02243917|Experimental|Dose Escalation Stage - CB-5083|CB-5083 will be orally administered daily, 4 days on and 3 days off, for 28 day cycles; subjects who have completed at least one cycle may optionally participate in a food effect week, wherein CB-5083 will be orally administered once daily, on days 1 and 4, and thereafter return to the original dosing schedule
3047578|NCT02243917|Experimental|Dose Expansion Stage - CB-5083|CB-5083 will be orally administered daily, 4 days on and 3 days off, for 28 day cycles
3047579|NCT02243917|Experimental|Food Effect Stage - CB-5083|CB-5083 will be orally administered once daily, on days 1 and 4 of week 1, cycle 1, and orally administered daily, 4 days on and 3 days off, for the remaining 3 weeks of cycle 1; for subsequent 28 day cycles, CB-5083 will be orally administered daily, 4 days on and 3 days off
3047580|NCT02243904||Lead exposure|
3047581|NCT02243891|Active Comparator|Control|Atrial fibrillation ablation only
3047582|NCT02243891|Experimental|ROX Coupler|Atrial fibrillation ablation with concurrent ROX Coupler insertion
3047583|NCT02243878|Experimental|Arm A (treatment)|"Participants will receive Stereotactic radiotherapy, a 16 Gy dose of radiation, delivered to the macula.~Participants will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met."
3047584|NCT02243878|Sham Comparator|Arm B (control)|"Participants will receive a sham treatment.~Participants will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met."
3047585|NCT02243865|Experimental|Chordate System S200 + CT100 (active treatment)|
3047586|NCT02243865|Placebo Comparator|Chordate System S200 + CT100 (placebo treatment)|
3047614|NCT02243683|Experimental|Cohort B|Single ascending oral administrations of AX-024.HCl (hydrochloride) and matching placebo
3047587|NCT02243852||Growth Hormone Deficiency (n=16)|16 asymptomatic GHD patients (who have confirmed GHD but who remain without GH replacement) will be compared with 16 healthy controls. Participants will be asked to undertake a single fasting blood sample and an MRI scan (whole body MRI and proton- and phosphorus-MR spectroscopy) to determine VAT, SAT and liver fat and muscle mitochondrial function. FGF21, body composition and mitochondrial function will be assessed in each of cohort to determine the correlation of FGF21 levels with VAT, SAT and liver fat.
3047588|NCT02243852||Healthy Controls (n=16)|16 healthy controls will be compared with 16 asymptomatic GHD patients (who have confirmed GHD but who remain without GH replacement). Participants will be asked to undertake a single fasting blood sample and an MRI scan (whole body MRI and proton- and phosphorus-MR spectroscopy) to determine VAT, SAT and liver fat and muscle mitochondrial function. FGF21, body composition and mitochondrial function will be measured in all cohorts to determine the correlation of FGF21 levels with VAT, SAT and liver fat.
3047589|NCT02243852||Growth Hormone Replacement Therapy (n=16)|"GHD patients, who are eligible for GH replacement therapy as part of their routine clinical care, according to the National Institute for Clinical Excellence (NICE) recommendations, based on the biochemical deficiency and the appropriate AGHDA questionnaire score (AGHDA score>11) will be recruited. These patients attend the Joint Endocrine clinic at University Hospital Aintree, Liverpool, and those who are about to commence growth hormone replacement will be asked to participate in this observational study.~Anthropometric, biochemical including measurement of FGF21 and MR evaluation will be carried out in patients who are to be treated with GH as part of their routine clinical care immediately prior to GH therapy and after six months of replacement treatment. The type of GH and dose of treatment will be at the discretion of the treating physician. Standard doses will be used and patients will remain under the care of the supervising"
3047590|NCT02243839|Active Comparator|Thrombolytic therapy|In the first arm, thrombolytic therapy (TT) is performed to the patients with obstructive prosthetic valve thrombosis. The TT regimen depends on the functional status of the patient. In patients with NYHA class III-IV dyspnea low dose, relatively faster TT regimen (25 mg tPA/6 hours) is performed. In patients with NYHA class I-II dyspnea TT with low dose and ultra-slow infusion of tPA (25 mg tPA/25 hours) is performed. During TT, patients are followed up with transesophageal echocardiography in every 24 hours.
3047591|NCT02243839|Active Comparator|Surgery|In the second arm, redo valve surgery is performed for obstructive valve thrombosis. Intraoperative and postoperative results are recorded
3047592|NCT02243826|Experimental|N20|One group will inhale N2O for the 5 minutes before the puncture and during the rest of the procedure.
3047593|NCT02243826|Other|compressed air|The second group will inhale compressed air during the same period of time
3047594|NCT02243813|Experimental|Delayed Participation|Participants will begin the psilocybin intervention 6 months after study enrollment.
3047595|NCT02243813|Experimental|Immediate Participation|Participants will begin psilocybin intervention immediately after study enrollment.
3047596|NCT02243800|Experimental|cholecalciferol|One group will receive the study treatment: cholecalciferol One group will receive placebo
3047597|NCT02243800|Placebo Comparator|placebo|One group will receive the study treatment: cholecalciferol One group will receive placebo
3047598|NCT02243787|Experimental|COVA322|single i.v. infusion
3047599|NCT02243787|Placebo Comparator|Placebo|single i.v. infusion
3047600|NCT02243774|No Intervention|No letter|Individuals randomized to the control group who will not receive any of the four letters
3047601|NCT02243774|Experimental|Core letter signed by Surgeon General|Individuals randomized to receive only a core letter signed by the Surgeon General
3047602|NCT02243774|Experimental|Core letter signed by Director of the National Vaccine Program|Individuals randomized to receive only a core letter signed by the Director of the National Vaccine Program
3047603|NCT02243774|Experimental|Core letter signed by Surgeon General + implementation prompt|Individuals randomized to receive a core letter signed by the Surgeon General with an implementation intention prompt added in an appended P.S. tag region below the signature line
3047604|NCT02243774|Experimental|Core letter signed by SG + enhanced implementation prompt|Individuals randomized to receive a core letter signed by the Surgeon General (SG) with an enhanced implementation intention prompt added in an appended P.S. tag region below the signature line
3047605|NCT02243761|Experimental|DBT Based Skills Groups for Families|Family members of youth with concurrent disorder participate in a 12-week DBT based skills group led by therapists and/or peer facilitators.
3047606|NCT02243748|Active Comparator|Phase I (usual care)|Participants receive usual care. This phase will aid in identifying usual care patterns in each site and provide an audit of system utilization as well as finalization of the educational materials for Phase II.
3047607|NCT02243748|Experimental|Phase II (individualized palliative care)|Participants receive individualized palliative care comprised of tailored educational sessions designed for each patient and FCG that have been modified based on patterns observed in Phase I. The first patient teaching session will cover physical and psychological areas and the second will cover social and spiritual areas. These sessions will be completed within 2 weeks of accrual. A third teaching session is held with the FCG alone to give the FCG the opportunity to discuss their perspectives and focus on their needs. Patients will be asked to identify topics they want included and which if any should be omitted which provides for tailoring of the content to the patient's needs and preferences.
3047608|NCT02243735|Active Comparator|Ferrous fumarate|Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery
3047609|NCT02243735|Active Comparator|ferric(III)carboxymaltose|Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
3047610|NCT02243722||Larynx pharynx and Esophagus Ca with VCP|The cases of laryngopharyngeal and esophageal cancer with endoscopic characters of vocal fold motion impairment (paralysis or fixation)
3047611|NCT02243709|Active Comparator|Mifepristone|mifepristone 600-mg/day for a week, in a stress-induced condition triggered by a single dose of 32.4-mg of yohimbine
3047612|NCT02243709|Placebo Comparator|Sugar pill|matching placebo/day for a week, in a stress-induced condition triggered by a single dose of 32.4-mg of yohimbine
3047613|NCT02243683|Experimental|Cohort A|Single ascending oral administrations of AX-024.HCl (hydrochloride) and matching placebo
3047615|NCT02243670|Experimental|AiCure monitoring and intervention|Participants will use the AiCure app to monitor ingestion of all prescribed doses of Zubsolv®.
3047616|NCT02243657|Placebo Comparator|1: Placebo dose level|
3047617|NCT02243657|Experimental|2: ASP3652 lowest dose level twice daily|
3047618|NCT02243657|Experimental|3:ASP3652 low dose level twice daily|
3047619|NCT02243657|Experimental|4: ASP3652 medium dose level twice daily|
3047620|NCT02243657|Experimental|5: ASP3652 high dose level twice daily|
3047621|NCT02243657|Experimental|6: ASP3652 highest dose level once daily|
3047622|NCT02243644|Active Comparator|Group A|7 days of albendazole 15 mg/kg/day
3047623|NCT02243644|Active Comparator|Group B|28 days of albendazole 15 mg/kg/day
3047624|NCT02243631|Experimental|Probenecid|These patients will receive 5 days of probenecid.
3047625|NCT02243631|No Intervention|No intervention|These patients will receive no intervention.
3047626|NCT02243618|Active Comparator|Rebamipide group|
3047627|NCT02243618|Active Comparator|Polaprezinc group|
3047628|NCT02243605|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3047629|NCT02243592||Ancillary-Correlative (molecular profiling)|Previously collected tissue samples are analyzed via whole exome sequencing and/or targeted NGS assay deep sequencing. Cases for which sufficient nucleic acid amounts are available will undergo additional analyses including whole genome sequencing, mRNA-sequencing, miRNA sequencing, promoter methylation analysis, and SNP analysis.
3047630|NCT02243579|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years (6 months for patients achieving CR) in the absence of disease progression or unacceptable toxicity.
3047631|NCT02243566||Essential hypertension|
3047632|NCT02243553|Experimental|Treatment A|tipranavir (TPV) capsule + ritonavir (RTV) capsule + cocktail + digoxin oral
3047633|NCT02243553|Experimental|Treatment B|TPV capsule + RTV capsule + cocktail + digoxin injection
3047634|NCT02243553|Experimental|Treatment C|TPV solution + RTV capsule + cocktail + digoxin oral
3047635|NCT02243553|Experimental|Treatment D|TPV solution + RTV capsule + cocktail + digoxin injection
3047636|NCT02243527|Experimental|Inspiratory Muscle Training|
3047637|NCT02243527|Sham Comparator|Sham-Control Inspiratory Muscle Training|Inspiratory muscle training at a low intensity meant to elicit no physiological changes.
3047638|NCT02243514||Resistant hypertension|
3047639|NCT02243514||Essential hypertension|
3047640|NCT02243514||Chronic heart failure|
3047641|NCT02243514||Control|
3047642|NCT02243501|Experimental|Intervention Group|The Intervention Group receives access to the BNBD intervention, and can access alternative resources while enrolled in the study. The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
3047643|NCT02243501|No Intervention|Usual Care Group|The Usual Care Group will receive no treatment until after the 8 month follow-up assessment. The Usual Care Group can access alternative resources and additional programs and services while enrolled in the study.
3047644|NCT02243488|Experimental|12 month menstrual hygiene programme|This is the first group to receive the intervention. They will receive the intervention after baseline and be followed up for the following 12 months.
3047645|NCT02243488|Experimental|6 month menstrual hygiene programme|This is the second group to receive the intervention. They will act as a control group for the first 6 months then receive intervention at 6 months.
3047646|NCT02243462|Other|No pre-op warming|No pre-warming in bay before surgery.
3047647|NCT02243462|Active Comparator|Pre-op forced air warming|A forced air warmer device (WarmTouch Convective Warming System) will be used to pre-warm patients in holding bay before surgery
3047648|NCT02243449|Active Comparator|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
3047649|NCT02243449|Experimental|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
3047650|NCT02243436|Experimental|BV-ESHAP|"- 3 cycles every 21 days:~Brentuximab Vedotin, on day 1 (BV will be administered at three different doses 0.9mg/kg, 1.2mg/kg, 1.8mg/kg)~Etoposide 40 mg/m2/day, on days 1 to 4~Soludomerin (methylprednisolone) 250 mg/day, on days 1 to 4~Cisplatin 25 mg/m2/day, on days 1 to 4~Ara C (cytarabine) 2 g/m2, on day 5~- A fourth dose of BV will be given 21 days after the third BV dose during the evaluation of response before the transplant.~- Autologous peripheral blood stem cell transplant~- A fifth dose of BV (1.8mg/kg) will be given on between day 28 and 35 post-transplant, followed by two additional doses (1.8mg/kg) every 3 weeks, to complete a total of 7 BV infusions."
3047651|NCT02243423|Experimental|SUPINE group|The surgical table will remain horizontal after intrathecal (spinal) anesthesia injection for cesarean section. Choosing to position the patient supine is the intervention.
3047652|NCT02243423|Active Comparator|TILT group|The surgical table will be turned to 15° of left lateral tilt after patients are laid supine after spinal anesthesia injection. The tilted group is the control group.
3047653|NCT02243384|Experimental|Laparoscopic Hepatectomy|Laparoscopic Hepatectomy
3047654|NCT02243384|Active Comparator|Radiofrequency Ablation|Radiofrequency Ablation
3047655|NCT02243371|Experimental|CY/ GVAX/ CRS-207/ nivolumab|
3047656|NCT02243371|Experimental|CY/ GVAX/ CRS-207|
3047657|NCT02243345||Delayed|Time from surfacing to recompression >=48 hours
3047658|NCT02243345||Early|Time from surfacing to recompression <48 hours
3047659|NCT02243332|Experimental|Device (rehabilitation assistance)|Device: KneeStim mobile rehabilitation assistance device
3047660|NCT02243319|Experimental|Group 1|"A → B → C~A: HGP1201 for 9 days B: HGP0904 for 9 days C: HGP1201+ HGP0904 for 9 days"
3047661|NCT02243319|Experimental|Group 2|C → A → B
3047662|NCT02243319|Experimental|Group 3|B → C → A
3047663|NCT02243319|Experimental|Group 4|C → B → A
3047664|NCT02243319|Experimental|Group 5|B → A → C
3047665|NCT02243319|Experimental|Group 6|A → C → B
3047666|NCT02243306|Experimental|Cohort 1|Subjects on continuous ambulatory peritoneal dialysis (CAPD) will receive 5 mg of GSK1278863 orally, once daily for 14 days.
3047667|NCT02243306|Experimental|Cohort 2|Subjects on automated peritoneal dialysis (APD) will receive 5 mg of GSK1278863 orally, once daily for 14 days
3047668|NCT02243293|Experimental|Arm A|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 2 (GT2) -infected treatment naïve and treatment experienced participants without cirrhosis.
3047669|NCT02243293|Experimental|Arm B|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
3047670|NCT02243293|Experimental|Arm C|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided twice daily (BID) for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
3047671|NCT02243293|Experimental|Arm D|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 3 (GT3) -infected treatment naïve and treatment experienced participants without cirrhosis.
3047672|NCT02243293|Experimental|Arm E|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
3047673|NCT02243293|Experimental|Arm F|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided BID for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
3047674|NCT02243293|Experimental|Arm G|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
3047675|NCT02243293|Experimental|Arm H|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
3047676|NCT02243293|Experimental|Arm I|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
3047677|NCT02243293|Experimental|Arm J|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
3047678|NCT02243293|Experimental|Arm K|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
3047679|NCT02243293|Experimental|Arm L|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
3047680|NCT02243293|Experimental|Arm M|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
3047681|NCT02243293|Experimental|Arm N|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD and ribavirin (RBV) (800 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
3047682|NCT02243293|Experimental|Arm O|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis and for 16 weeks in HCV GT3 -infected treatment-experienced participants with compensated cirrhosis.
3047683|NCT02243293|Experimental|Arm P|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and RBV (800 mg) QD for 12 weeks in HCV GT3-infected treatment naïve and treatment-experienced participants with compensated cirrhosis.
3047684|NCT02243293|Experimental|Arm Q1|ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment naïve participants with cirrhosis.
3047685|NCT02243293|Experimental|Arm Q2|ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
3047686|NCT02243293|Experimental|Arm R1|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
3047687|NCT02243293|Experimental|Arm R2|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants with cirrhosis.
3047688|NCT02243293|Experimental|Arm S1|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT2 infected treatment naïve and treatment experienced participants without cirrhosis.
3047689|NCT02243293|Experimental|Arm S2|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT4-6 infected treatment naïve and treatment experienced participants without cirrhosis.
3047690|NCT02243280|Experimental|Arm A|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 1-infected participants without cirrhosis
3047691|NCT02243280|Experimental|Arm B|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 1- infected participants without cirrhosis
3047692|NCT02243280|Experimental|Arm C|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 8 weeks in HCV genotype 1-infected participants without cirrhosis (never opened - Sponsor decision)
3047693|NCT02243280|Experimental|Arm D|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 8 weeks in HCV genotype 1-infected participants without cirrhosis (never opened - Sponsor decision)
3047694|NCT02243280|Experimental|Arm E|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD + ribavirin (RBV) 800 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
3047695|NCT02243280|Experimental|Arm F|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 1- infected participants with compensated cirrhosis
3047696|NCT02243280|Experimental|Arm G|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD + ribavirin (RBV) 800 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
3047697|NCT02243280|Experimental|Arm H|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
3047698|NCT02243280|Experimental|Arm I|ABT-493 300 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 4-, 5-, and 6-infected participants without cirrhosis
3047699|NCT02243280|Experimental|Arm J|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 4-, 5-, and 6-infected participants without cirrhosis (never opened - Sponsor decision)
3047700|NCT02243280|Experimental|Arm K|ABT-493 300 mg once daily (QD) + ABT-530 120 mg QD for 8 weeks in HCV genotype 1- infected participants without cirrhosis
3047701|NCT02243254|Placebo Comparator|high dose remifentanil without ibuprofen|remifentanil target-controlled infusion effect-site concentration 4 ng/ml normal saline before surgical incision
3047702|NCT02243254|Placebo Comparator|low dose remifentanil without ibuprofen|remifentanil target-controlled infusion effect-site concentration 1 ng/ml normal saline before surgical incision
3047703|NCT02243254|Active Comparator|high dose remifentanil with ibuprofen|remifentanil target-controlled infusion effect-site concentration 4 ng/ml Intravenous ibuprofen 800 mg before surgical incision
3047704|NCT02243254|Active Comparator|low dose remifentanil with ibuprofen|remifentanil target-controlled infusion effect-site concentration 1 ng/ml Intravenous ibuprofen 800 mg before surgical incision
3047705|NCT02243241|Experimental|HYD|
3047706|NCT02243241|Other|Moxifloxacin|Moxifloxacin is the positive control.
3047707|NCT02243241|Placebo Comparator|Placebo|Placebo for HYD and placebo for moxifloxacin
3047708|NCT02243228|Experimental|GM-CSF, nebulizer|After the patients were randomly divided into two groups, they will be treated by GM-CSF (using nebulizer, 150ug bid) every other week for 6 months.
3047709|NCT02243215|Experimental|Offsite training|Access to a portable trainer for laparoscopic skills
3047710|NCT02243215|No Intervention|Onsite training|Will be able practice on-site at Center of Clinical Education and at their local hospital.
3047711|NCT02243202|Experimental|Canagliflozin + Phentermine|300 mg capsule of Canagliflozin along with 15 mg capsule of Phentermine, taken once daily, orally for 26 weeks.
3047712|NCT02243202|Experimental|Canagliflozin + Placebo (Phentermine)|300 mg capsule of Canagliflozin along with matching placebo to Phentermine, taken once daily, orally for 26 weeks.
3047713|NCT02243202|Experimental|Phentermine + Placebo (Canagliflozin)|15 mg capsule of Phentermine along with matching placebo to Canagliflozin, taken once daily, orally for 26 weeks.
3047714|NCT02243202|Placebo Comparator|Placebo|Matching placebo to Canagliflozin and Phentermine, taken once daily, orally for 26 weeks.
3047715|NCT02243189|Experimental|JNJ-43260295 (Healthy Participants)|Participants will receive a single nasal dose of JNJ-43260295, 6400 microgram, equally spread over the two nostrils.
3047716|NCT02243189|Placebo Comparator|Placebo (Healthy Participants)|Participants will receive a single nasal dose of placebo matching to JNJ-43260295.
3047717|NCT02243189|Experimental|JNJ-43260295 (Asthmatic Participants)|Participants will participate in 3 consecutive treatment periods (Periods 1, 2, and 3). In Period 1, each participant will receive a single nasal dose of JNJ-43260295 without prior nasal allergen challenge. In Period 2, each participant will receive a single nasal dose of JNJ-43260295, preceded by a nasal allergen challenge approximately 15 hours prior to the dosing. In Period 3, each participant will receive single nasal allergen challenge without JNJ-43260295. There will be a washout period of at least 21 days between 3 consecutive treatment periods.
3047718|NCT02243176|Experimental|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocated to this arm.
3047719|NCT02243176|Active Comparator|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocalted to this arm.
3047720|NCT02243163|Experimental|Yoga exercise|Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
3047721|NCT02243150|Experimental|Cohort 1|6mg/m2 of G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion
3047722|NCT02243150|Experimental|Cohort 2|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 1; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
3047723|NCT02243150|Experimental|Cohort 3|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 2; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
3047724|NCT02243150|Experimental|Cohort 4|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 3; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
3047725|NCT02243150|Experimental|Cohort 5|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 4; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion. Subjects from this cohort may be selected to participate in the Whole Blood Ex-Vivo Stimulation group.
3047726|NCT02243150|Experimental|Cohort 6|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 5; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion. Subjects from this cohort may be selected to participate in the Whole Blood Ex-Vivo Stimulation group.
3047755|NCT02242916||Patients with recurrent HN tumors|Patients with recurrent Head and Neck tumors
3047756|NCT02242903|Experimental|LY3079514|Single dose of LY3079514 administered intravenous (IV) or subcutaneous (SC) during a single occasion
3078261|NCT02038673|Experimental|Dose escalation part 6.0 mg BID|Oral
3047727|NCT02243150|Experimental|Cohort 7 - Bone Marrow Cohort|All subjects in this cohort will receive active drug, G1T28-1. Dose of G1T28-1 will be determined based on the safety and PK data from previous cohorts. G1T28-1 will be administered in 50mL of 5% dextrose by IV infusion. Subjects in this cohort will be selected for the Ex-Vivo Stimulation group and will have a one time bone marrow aspirate at one of the following time points: pre dose, 12 or 24 hours post dose.
3047728|NCT02243137|Active Comparator|prasugrel and acetylsalicylic|single dose of prasugrel 60 mg orally and 300 mg acetylsalicylic acid orally
3047729|NCT02243137|Experimental|lysine acetylsalicylate and prasugrel|single dose of prasugrel 60 mg oral and lysine acetylsalicylate 450 mg intravenous
3047730|NCT02243124|Active Comparator|Group 1|cenersen IV infusion 0.3 mg/kg/day (0.1 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no Hematologic Improvement (HI) is observed.
3047731|NCT02243124|Active Comparator|Group 2|cenersen IV infusion 0.6 mg/kg/day (0.2 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
3047732|NCT02243124|Active Comparator|Group 3|cenersen IV infusion 1.2 mg/kg/day (0.4 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
3047733|NCT02243111|Experimental|Doppler ultrasound|Recording Doppler signals from the lungs
3047734|NCT02243098|Experimental|Semaglutide|
3047735|NCT02243085||photoselective vaporization|
3047736|NCT02243072|Experimental|Fit Familes plus Standard Medical Care|Participants will receive the intervention Fit Families plus Standard Medical Care which is an adaptation of Multisystemic Therapy for Type 1 Diabetes delivered by Community Health Workers (CHWs) in addition to standard medical care.
3047737|NCT02243072|No Intervention|Standard Medical Care|Standard medical care is provided at Children's Hospital of Michigan consistent with the standards for the care of children with T1D outlined by the American Diabetes Association.
3047738|NCT02243059|Experimental|GDF-MRI|"In this pilot study, all included patients will undergo conventional MRI with contrast enhancement (gadofosveset trisodium) and diffusion weighted MRI.~Ablavar™ solution contains 244 mg/mL (0.25 mmol/mL) gadofosveset trisodium. 0.03 mmol/kg of gadofosveset will be administered by manual injection as a single intravenous bolus injection over a period of time up to 30 seconds followed by a 25-30 ml saline flush. In practice, this comes down to the maximum of one vial for one patient (one vial contains 10 ml solution, which contains a total of 2.50 mmol of gadofosveset trisodium equivalent to 2.27 g of gadofosveset)."
3047739|NCT02243046|Placebo Comparator|Control toothpaste|1450 ppm Fluoride toothpaste
3047740|NCT02243046|Experimental|Experimental toothpaste|1450 ppm sodium fluoride toothpaste with a zinc base
3047741|NCT02243046|Active Comparator|Active comparator|1450 ppm sodium fluoride/triclosan toothpaste
3047742|NCT02243033||Visualase|MR-guided laser focal therapy
3047743|NCT02243020|Experimental|VNS + Rehabilitation (1)|This group receives vagus nerve stimulation during rehabilitation.
3047744|NCT02243020|Active Comparator|VNS + Rehabilitation (2) - Comparator|This group receives rehabilitation and VNS, but the VNS is different than given in the other group. It may not be as effective as the other group's settings. Both groups receive the same amount of rehabilitation.
3047745|NCT02243007|Experimental|Folfirinox-ARM A|"Upon registration patients will be randomized to Arm A (FOLFIRINOX) or Arm B (Gemcitabine/nab-Paclitaxel~Treatment will be administered on an outpatient basis and will include intravenous administration of the FOLFIRINOX regimen on predetermined days.~After completion of FOLFIRINOX all patients without progressive disease will proceed with radiation therapy with the standard dose of capecitabine.~Between 2 and 4 weeks after radiation is complete, patients will proceed for surgical resection of pancreatic cancer"
3047746|NCT02243007|Experimental|Gemcitabine/nab-Paclitaxel- Arm B|"Treatment will be administered on an outpatient basis. Upon registration patients will be randomized to Arm A (FOLFIRINOX) or Arm B (Gemcitabine/nab-Paclitaxel).~Intravenous administration of the Gemcitabine/Nab-paclitaxel regimen on predetermined days of each 28 day treatment cycle (unless a delay is mandated by toxicity criteria). A cycle of Gemcitabine/Nab-paclitaxel will constitute a 28 day treatment period.~After Gemcitabine/Nab-paclitaxel, all patients without progressive disease will proceed to radiation therapy with the standard dose of capecitabine~Between 2 and 4 weeks after radiation is complete, patients will proceed for surgical resection of pancreatic cancer"
3047747|NCT02242994|Experimental|Dynavox Maestro and Experimental App|Receives both Experimental App and Dynavox Maestro to communicate. Each participant will receive both devices. Order of device received is randomly assigned.
3047748|NCT02242981|Experimental|LY2623091|Single oral dose of LY2623091
3047749|NCT02242955|Active Comparator|"AD = as-usual diazepam"|Diazepam treatment duration will not exceed 10 days (commonly recommended duration for alcohol detoxification).
3047750|NCT02242955|Experimental|"PD = prolonged diazepam"|Diazepam will be slowly tapered to be stopped at day 30
3047751|NCT02242942|Experimental|Obinutuzumab + Chlorambucil|Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.
3047752|NCT02242942|Experimental|Obinutuzumab + Venetoclax|Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.
3047753|NCT02242929|Active Comparator|Standard surgical excision|"Standard surgical elliptical excision including a 3-mm clinically tumour-free margin according to the current local hospital arrangements."
3047754|NCT02242929|Experimental|Imiquimod 5% cream with prior curettage|Tumours will be partially debulked under local anaesthesia by removing all tumour tissue until normal dermis remains with a blunt curette. After curettage patients will receive an instruction sheet to apply imiquimod 5% cream once daily, 5 days a week, during 6 weeks, starting one week after the curettage procedure. Patients will be instructed to apply a thin layer to the tumour including 5-10mm of the surrounding skin at least 1 hour before going to bed at night. The lesion will not be covered (unless needed because of weeping or bleeding). Participants will be asked to wash their hands after applying the cream, and to wipe the cream off after 8 hours (in the morning).
3047757|NCT02242903|Placebo Comparator|Placebo|Single dose of placebo matching LY3079514 administered IV infusion or SC injection during a single occasion.
3047758|NCT02242890|Other|Contraception Information Packet|Everyone in the study will receive the intervention, which is an information packet designed to facilitate conversations among peers about intrauterine contraception.
3047759|NCT02242877||Isolated systolic hypertension|
3047760|NCT02242877||Systolic and diastolic hypertension|
3047761|NCT02242864||Patients with hypertension and diabetes mellitus|
3047762|NCT02242851||Hypertensive patients|
3047763|NCT02242838||Hypertensive patients|
3047764|NCT02242825||Patients with hypertension and diabetes mellitus|
3047765|NCT02242812|Experimental|Telmisartan|MICARDIS®
3047766|NCT02242812|Active Comparator|Metoprolol succinate|BELOC ZOK®
3047767|NCT02242799|Experimental|Study A Sequence 1|Artemether-lumefantrine combination alone for 3 days with PK sampling at steady state, then 21 day washout period followed by Dolutegravir 50mg od dosing to steady state (7 days) with PK sampling then a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, with PK sampling at steady state.
3047768|NCT02242799|Experimental|Study A Sequence 2|Dolutegravir 50mg od given for 7 days with PK sampling at steady state, followed immediately by a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, again with PK sampling at steady state. Following a 21 day washout period, the subject will then receive Artemether-lumefantrine combination alone for 3 days, with PK sampling at steady state.
3047769|NCT02242799|Experimental|Study B Sequence 1|Administration of artesunate-amodiaquine for 3 days with PK sampling at steady state
3047770|NCT02242799|Experimental|Study B Sequence 2|Dolutegravir alone for 7 days with PK sampling at steady state, followed immediately by administration of both artesunate-amodiaquine and dolutegravir together for a further 3 days with PK sampling at steady state
3047771|NCT02242786|Experimental|EBRT|
3047772|NCT02242773|Experimental|Active Surveillance|"Multi-parametric MRI and MRI-guided biopsy active surveillance of subjects with prostate cancer, including the following quality of life questionnaires:~Expanded Prostate Cancer Index Composite SF12 Questionnaire (EPIC-SF12);~Memory Anxiety Scale for Prostate Cancer patients (MAX-PC);~Food Frequency Questionnaire (FFQ)"
3047773|NCT02242760|Experimental|SB204 2% Twice daily|Twice daily SB204 2%
3047774|NCT02242760|Experimental|SB204 4% daily|Once daily SB204 4%
3047775|NCT02242760|Placebo Comparator|Vehicle Gel Daily|Vehicle Gel Daily
3047776|NCT02242760|Placebo Comparator|Vehicle Gel Twice Daily|Twice daily Vehicle Gel
3047777|NCT02242760|Experimental|SB204 4% Twice Daily|Twice daily SB204 4%
3047778|NCT02242747|Other|ingenol mebutate|Patients assigned to ingenol mebutate gel received an application a day for three consecutive days in a pre-determined area
3047779|NCT02242747|Other|5% 5-FU|Patients assigned to 5% 5-FU received two applications a day for four weeks in a pre-determined area
3047780|NCT02242734|Experimental|Mild Hepatic Impairment|20 mg HC-ER
3047781|NCT02242734|Experimental|Moderate Hepatic Impairment|20 mg HC-ER
3047782|NCT02242734|Experimental|No Hepatic Impairment|20 mg HC-ER
3047783|NCT02242721||Intensive care unit patients needing renal replacement therapy|Male and female patients in the intensive care unit (ICU), needing renal replacement therapy due to renal dysfunction and are treated with antiinfective drugs.
3047784|NCT02242708|No Intervention|Normal breathing|The control group will do normal breathing.
3047785|NCT02242708|Experimental|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
3047786|NCT02242695|Experimental|Fluomizin vaginal tablets|Fluomizin vaginal tablets containing 10mg dequalinium chloride once daily for 6 days and one placebo vaginal tablet on day 7
3047787|NCT02242695|Active Comparator|Canesten vaginal tablets|Canesten vaginal tablets containing 100mg clotrimazole once daily for 7 days
3047788|NCT02242682|No Intervention|Control|This group of subjects will not be exposed to a video during their time in the ED waiting room
3047789|NCT02242682|Experimental|Child passenger safety video|This group of subjects will be exposed to a video during their time in the ED waiting room
3047790|NCT02242669||AIM 1|200 current DBSA participants.
3047791|NCT02242669||AIM 2|60 new DBSA attendees with mood disorders who have attended their first meeting in the past month.
3047792|NCT02242669||AIM 3|100 matched control group individuals with mood disorders with no current or prior exposure to DBSA.
3047793|NCT02242656|Experimental|Group 1|Assigned to receive Treatment A (Period 1), Treatment B (Period 2), Treatment C (Period 3)
3047794|NCT02242656|Experimental|Group 2|Assigned to receive Treatment B (Period 1), Treatment A (Period 2), Treatment C (Period 3)
3047795|NCT02242643|Experimental|FluLaval™ Quadrivalent Group|"Subjects in this group received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of FluLaval™ Quadrivalent vaccine.~The vaccine was administered intramuscularly into the anterolateral region of the thigh (subjects below 12 months of age) or in the deltoid muscle of the non-dominant arm (subjects ≥12 months of age)."
3047796|NCT02242643|Active Comparator|Fluzone® Quadrivalent Group|"Subjects in this group received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluzone® Quadrivalent vaccine.~The vaccine was administered intramuscularly into the anterolateral region of the thigh (subjects below 12 months of age) or in the deltoid muscle of the non-dominant arm (subjects ≥12 months of age)."
3047797|NCT02242630|Active Comparator|Methylprednisolone, 20 mg|Methylprednisolone, 20 mg, will be injected
3047798|NCT02242630|Active Comparator|Methylprednisolone, 40 mg|Methylprednisolone, 40 mg, will be injected
3047799|NCT02242630|Active Comparator|Triamcinolone, 20 mg|Triamcinolone, 20 mg, will be injected
3047800|NCT02242630|Active Comparator|Triamcinolone, 40 mg|Triamcinolone, 40 mg, will be injected
3047801|NCT02242617|Active Comparator|MAS-PAP|Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep; followed by positive airway pressure (PAP)
3047802|NCT02242617|Active Comparator|PAP-MAS|Positive airway pressure (PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open; followed by mandibular advancement splints (MAS)
3047803|NCT02242604||Not treatment|Patients with the age of 70 years or above, that have a serum sodium of below 130 mmol/L on admission. All patients will be routinely evaluated at admission with a standardized multidimensional geriatric assessment (MGA) consisting of a battery of validated assays.
3047804|NCT02242591|Active Comparator|ACB_active/placebo|"Patients will receive the first ACB with a active drug, 30 ml bolus Ropivacaine 7,5 mg/ml at T0. First outcome measurement are made one hour after the first ACB, prior to their second ACB. At T60 (60 minutes after T0), patients will receive their second ACB with the placebo drug, 30 ml bolus Saline and outcome measures performed again at T120(120 minutes after T0).~The measurements for baseline and outcome will be made in following order:~VAS pain score at rest - VAS pain score during active flexion of the knee - Muscle strength - TUG test - Highest VAS pain score during TUG test"
3047805|NCT02242591|Placebo Comparator|ACB_placebo/active|"Patients will receive the first ACB with placebo, 30 ml isotonic saline at T0. First outcome measurement are made one hour after the first ACB, prior to their second ACB. At T60(60 minutes after T0), patients will receive their second ACB with the ropivacaine 7,5 mg/ml 30 ml and outcome measures performed again at T120(120 minutes after T0).~The measurements for baseline and outcome will be made in following order:~VAS pain score at rest - VAS pain score during active flexion of the knee - Muscle strength - TUG test - Highest VAS pain score during TUG test"
3047806|NCT02242578|Experimental|Active|Active rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
3047807|NCT02242578|Experimental|Placebo|Sham rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
3047808|NCT02242565|Other|Control: all-sizes of ShangRing|All-sizes of ShangRings will be available.
3047809|NCT02242565|Active Comparator|Reduced-sizes|7 adult sizes of ShangRings will be available
3047810|NCT02242539|Experimental|Height measurement poster|
3047811|NCT02242539|Experimental|Community-based monitoring|
3047812|NCT02242539|No Intervention|Control|
3047813|NCT02242526|Active Comparator|Parietex™ Composite Hiatal Mesh, North Haven, CT|Synthetic prosthetic mesh Parietex™ Composite Hiatal (PCO 2H) Mesh (Covidien, North Haven, CT) designed for hiatal hernia repair.
3047814|NCT02242526|Active Comparator|Biodesign™ Surgisis® Graft, Cook Medical, Bloomington|Biologic mesh Biodesign™ Surgisis® Graft Reinforcement in Hiatal, Cook Medical, Bloomington, IN which will be placed for repair of hiatal hernia
3047815|NCT02242513|Active Comparator|pulsed mode radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury. One dose of PRF was given in tibial nerve behine the medial ankle in intervention group.
3047816|NCT02242513|Placebo Comparator|Xylocaine|2 c.c xylocaine was given in tibial nerve behind the medial ankle in control group.
3047817|NCT02242500|Experimental|Coronally advanced flap + Mucograft|coronally advanced flap associated with a porcine collagen matrix graft as a subepithelial graft
3047818|NCT02242500|Other|Coronally advanced flap|Coronally advanced flap procedure alone
3047819|NCT02242487|Experimental|CVT-301 Low Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 12 months duration
3047820|NCT02242487|Experimental|CVT-301 High Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 12 months duration
3047821|NCT02242474|Active Comparator|Anti-TNF suspended perioperatively|Patients randomized to Group B will have their anti-TNFα therapy interrupted before surgery. Different authors suggested that anti-TNFα therapies should be suspended between two and five half-lives prior to surgery. In the current trial, anti-TNFα will be suspended three half-lives (± seven days) prior to surgery. All other medications used in the treatment of the disease (methotrexate, hydroxychloroquine, corticosteroid, etc.) will be documented and continued in the perioperative period. Non-steroidal anti-inflammatory drugs (NSAID) will be suspended seven days prior to surgery and will be restarted postoperatively. Anti-TNFα will be restarted once wound healing is completed.
3047822|NCT02242474|Experimental|Anti-TNFα continued perioperatively|Patients randomized to Group A will continue their anti-TNFα treatment unaltered during the whole perioperative period. Surgery will be performed without consideration in regards to the timing of the treatment. The time elapsed between the last anti-TNFα administration and the surgery will nonetheless be documented.
3047823|NCT02242461|Placebo Comparator|Rhodiola placebo capsules|starch
3047824|NCT02242461|Experimental|Rhodiola Crenulata|Rhodiola Crenulata
3047825|NCT02242435|Experimental|Ampion 4ml|4 mL intra-articular injection of Ampion
3047826|NCT02242435|Placebo Comparator|Placebo Solution|4 mL placebo intra-articular injection
3047827|NCT02242422||transobturator tape|
3047828|NCT02242409|Experimental|Gemcitabine/abraxane|Gemcitabine and Abraxane
3047829|NCT02242396||Hypertensive patients|
3047830|NCT02242383||Essential hypertension|
3047831|NCT02242370|Experimental|Telmisartan low dose|
3047832|NCT02242370|Experimental|Telmisartan high dose|
3047833|NCT02242357||Patients with hypertension|
3047834|NCT02242344|Experimental|telmisartan - low dose|
3047835|NCT02242344|Experimental|telmisartan - high dose|
3047836|NCT02242344|Placebo Comparator|Placebo|
3047837|NCT02242331||essential hypertension patients|
3047838|NCT02242318|Experimental|Telmisartan|low dose for two weeks, then up titration to high dose, once daily
3047839|NCT02242318|Active Comparator|Valsartan|low dose for two weeks, then up titration to high dose, once daily
3047840|NCT02242318|Placebo Comparator|Placebo|
3047841|NCT02242305|Experimental|Hyoscine Butylbromide - Tablet|
3047842|NCT02242305|Active Comparator|Hyoscine Butylbromide - Capsule|
3047843|NCT02242292|Experimental|Hyoscine butylbromide|"5 tablets taken in a 24-hour period/each episode:~for up to 7 episodes, or~over a period of up to 6 weeks"
3047844|NCT02242292|Placebo Comparator|Placebo|
3047845|NCT02242279|Experimental|BEA 2180 - low dose|
3047846|NCT02242279|Experimental|BEA 2180 - medium dose|
3047847|NCT02242279|Experimental|BEA 2180 - high dose|
3047848|NCT02242279|Active Comparator|Tiotropium|
3047849|NCT02242279|Placebo Comparator|Placebo|
3047850|NCT02242266|Experimental|Tiotropium low dose|oral inhalation via the blue HandiHaler®
3047851|NCT02242266|Experimental|Tiotropium medium dose|oral inhalation via the blue HandiHaler®
3047852|NCT02242266|Active Comparator|Spiriva® HandiHaler® high dose|oral inhalation via the grey HandiHaler®
3047853|NCT02242266|Placebo Comparator|Placebo|
3047854|NCT02242253|Experimental|Tiotropium+salmeterol QD|free combination of tiotropium and salmeterol
3047855|NCT02242253|Active Comparator|Tiotropium+salmeterol BID|free combination of tiotropium and salmeterol
3047856|NCT02242253|Active Comparator|Tiotropium QD|
3047857|NCT02242253|Active Comparator|Salmeterol BID|
3047858|NCT02242240|Experimental|Tiotropium with single dose of formoterol|
3047859|NCT02242240|Experimental|Tiotropium with double dose of formoterol|
3047860|NCT02242240|Experimental|Tiotropium with Placebo|
3047861|NCT02242227|Experimental|Salmeterol xinafoate|25 μg Salmeterol inhalation powder administered via HandiHaler®
3047862|NCT02242227|Active Comparator|Serevent® Diskus®|50 μg Salmeterol (dry powder inhaler) administered via Diskus®
3047863|NCT02242227|Placebo Comparator|Placebo|
3047864|NCT02242214||Misoprostol 200 µg VDS|At the discretion of the investigator in accordance with their usual practice and consistent with the Dutch prescribing information.
3047865|NCT02242201|Active Comparator|PNB Bupivacaine|Bupivacaine 0.5% with 1:200,000 epinephrine 30 ml bolus preoperatively followed by an infusion of bupivacaine 0.2% on post anesthesia care unit (PACU) arrival.
3047866|NCT02242201|Active Comparator|PAI Ropivacaine|Patients 50 to 74.9 kg: ropivacaine 200 mg, epinephrine 100 ug, ketorolac 30 mg. Patients 75 to 99.9 kg: ropivacaine 300 mg, epinephrine 200 ug, ketorolac 30 mg. Patients 100 to 125 kg: ropivacaine 400 mg, epinephrine 300 ug, ketorolac 30mg.
3047867|NCT02242201|Active Comparator|PAI liposomal bupivacaine|Liposomal bupivacaine 255 mg, ketorolac 30 mg, bupivacaine 125 mg, epinephrine 125 ug.
3047868|NCT02242188|Experimental|Iron|"Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
3047869|NCT02242188|Placebo Comparator|Placebo|"Maltodextrin prepared in sachets. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
3047870|NCT02242175|Other|normal group|
3047871|NCT02242175|Other|irritable bowel syndrome group|
3047872|NCT02242162||neuromuscular diseases|
3047873|NCT02242149|Placebo Comparator|Placebo|All subjects will be given placebo identically matched with regard to shape, color and taste. They will be given one tablet/day for 2 weeks and then two tablets/day for the duration of sudy.
3047874|NCT02242149|Experimental|Diacerein|All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
3047875|NCT02242136|Experimental|FORNET|During FORNET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress and committed violence. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for the client's emotions, cognitions, physiological reactions, and sensory informations during traumatic and aggressive events to link them to an autobiographical context, namely time and place. In total the individuals receive 8 sessions of FORNET, every session lasting between 1,5 and 2 hrs depending on the needs of the participant.
3047876|NCT02242136|No Intervention|Waiting list|
3047877|NCT02242123||Study group|Symptomatic patients, with weakly positive serum anti-tTG and evidence of mild intestinal histology damage (grade 1-2) at first evaluation.
3047878|NCT02242123||Control group|Symptomatic patients, with weakly positive serum anti-tTG and evidence of intestinal villous atrophy (intestinal histology damage grade 3) at first evaluation.
3047879|NCT02242110|Experimental|Nightmare Treatment|The nightmare treatment, Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder (ERRT-Bipolar Disorder), is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
3047880|NCT02242097|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib orally PO QD on days 1-28. Courses repeat every 28 days for up to 4 years in the absence of disease progression, unacceptable toxicity, or patient preference.
3047881|NCT02242084|Experimental|Alteplase treatment|All subject who enter the trial will receive treatment with Alteplase along with questionnaire.
3047882|NCT02242071|Experimental|Stem Cell|bone marrow mononuclear cell transplantation
3047883|NCT02242058||High frequency pain group|39 pediatric or adult patients with high pain frequency (greater than or equal to 3 ER visits and/or hospitalizations for pain per year over the last two years)
3047884|NCT02242058||Low Pain Frequency group|39 pediatric or adult patients with low pain frequency (less than or equal to 1 severe pain episode for the last two years)
3047885|NCT02242058||Healthy control group|39 pediatric or adult relatives of sickle cell disease patients, who do not have the sickle cell trait of SCD.
3047886|NCT02242058||Pain Crisis group|30 patients with sickle cell disease with severe phenotype (HbSS, HbSβ0 thalassemia, HbSOArab)
3047887|NCT02242058||Pain Service group|10 patients without sickle cell disease admitted to the pain service.
3047888|NCT02242045|Experimental|Idelalisib|- Idelalisib cohort: Idelalisib 150 mg in participants with iNHL or CLL
3047889|NCT02242032|Experimental|P-321|P-321 Ophthalmic Solution
3047890|NCT02242032|Placebo Comparator|P-321 Ophthalmic Solution Placebo|P-321 Ophthalmic Solution Placebo
3047891|NCT02242019|Experimental|Erchonia LUNULA|The Erchonia LUNULA emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
3047892|NCT02242006||piperacillin/tazobactam|Serial serum sampling of patients receiving piperacillin/tazobactam and SLED simultaneously
3047893|NCT02242006||meropenem|Serial serum sampling of patients receiving meropenem and SLED simultaneously
3047894|NCT02242006||vancomycin|Serial serum sampling of patients receiving vancomycin and SLED simultaneously
3047895|NCT02241993||Type 1 diabetic|
3047896|NCT02241980||Medicare Part D patients|Survey
3047897|NCT02241980||Physician Providers|Survey
3047898|NCT02241967|Experimental|tDCS Full Dose|4 active treatments
3047899|NCT02241967|Experimental|tDCS Half Dose|2 active treatments
3047900|NCT02241967|Experimental|tDCS Minimal dose|1 active treatment
3047901|NCT02241967|Sham Comparator|Sham tDCS|no active treatments
3047902|NCT02241954||Expansion Thoracoplasty|The rib prosthesis is lengthened periodically to correct the concavity of the deformity, expanding the volume of the hypoplastic thorax and improving associated spinal deformity. This device has been FDA approved by a Humanitarian Device Exemption and is described as a Vertical Expandable Prosthetic Titanium Rib (VEPTR). An updated version of the VEPTR, the VEPTR II, may be used instead depending on the physician's preference and the patient's anatomy. The VEPTR II device has greater size range and modularity of implants than the original VEPTR.
3047903|NCT02241941|Experimental|Daptomycin|
3047904|NCT02241928|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
3047905|NCT02241915|Active Comparator|Microbial Sealant|Integuseal (Kimberly Clark)
3047906|NCT02241915|Sham Comparator|Control|No microbial sealant
3047907|NCT02241902||No pyuria|
3047908|NCT02241902||Persistent pyuria|
3047909|NCT02241889|Active Comparator|Standard Insulin Pump Therapy|Subjects will undergo 21 hour study with exercise using Insulin pump therapy and managing their blood glucose as they normally would.
3047910|NCT02241889|Experimental|Closed-loop without adjustment|Subjects will undergo 21 study using the Closed-loop Artificial Pancreas Controller to manage blood sugar. Exercise will not be annouced to the controller and no adjustments to insulin and glucagon delivery will be made.
3047911|NCT02241889|Experimental|Closed-loop with adjustment|Subjects will undergo 21 hour study using the Closed-loop Artificial Pancreas Controller to manage blood sugar. Exercise will be annouced to the controller and adjustments to insulin and glucagon delivery will be made.
3047912|NCT02241876|Placebo Comparator|Placebo|The patients will be treated with placebo as follows: 15 mL (0 mg of drug), once a day, during 7 days in each cycle (2 days before chemotherapy with cisplatin, on the day of chemotherapy and more 4 days after chemotherapy).
3047913|NCT02241876|Experimental|N-Acetylcysteine|The patients will be treated with n-acetylcysteine as follows: 15 mL (600mg of drug), once a day, during 7 days in each cycle (2 days before chemotherapy with cisplatin, on the day of chemotherapy and more 4 days after chemotherapy).
3047914|NCT02241863|Experimental|Multifaceted intervention|Patients, their caregivers and family members will received the educational and motivational interventions
3047915|NCT02241863|Active Comparator|Active Comparator|Usual Care The usual care group received routine counseling performed by the psychiatrist and nurses.
3047916|NCT02241850|Other|High intensity training|9 weeks of supervised training
3047917|NCT02241824|Active Comparator|Elastic abdominal binder|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen after an intervention of an elastic abdominal binder.
3047918|NCT02241824|No Intervention|No brace|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen with no brace (control).
3047919|NCT02241824|Experimental|In-elastic lumbar brace|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen after an intervention of an in-elastic lumbar brace.
3047920|NCT02241811|Placebo Comparator|Control|After wound dressing we applied hydrogel without any active ingredient everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
3047921|NCT02241811|Experimental|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
3047922|NCT02241798|Experimental|Pre-oxygenation first|"st, 3rd, 5th, etc seizure: continuous 'pre-oxygenation' up to 4L O2 nasal prongs, as tolerated~nd, 4th, 6th, etc seizure: Standard practice (O2 only in post-ictal period)."
3047923|NCT02241798|Experimental|Standard practice first|"st, 3rd, 5th, etc seizure: Standard practice (O2 only in post-ictal period).~nd, 4th, 6th, etc seizure: continuous 'pre-oxygenation' up to 4L O2 nasal prongs, as tolerated"
3047924|NCT02241785|Experimental|natalizumab|natalizumab 300 mg intravenously (IV) every 4 weeks
3047925|NCT02241772|Experimental|10mg TA-8995|10mg TA-8995 once daily
3047926|NCT02241772|Experimental|2.5mg TA-8995|2.5mg TA-8995 once daily
3047927|NCT02241772|Placebo Comparator|Placebo to TA-8995|Placebo to TA-8995 once daily.
3047928|NCT02241759|Experimental|TA-8995|Single oral dose of 150mg TA-8995
3047929|NCT02241759|Experimental|Placebo|Single oral dose of placebo to TA-8995
3047930|NCT02241759|Active Comparator|Moxifloxacin|Single open-label oral dose of 400mg moxifloxacin
3047931|NCT02241746||malnutrition|
3047932|NCT02241733|Active Comparator|exercise|Patients will exercise for 12 weeks and then participate in an adherence program
3047933|NCT02241733|Experimental|exercise plus breathing retraining|Patients will exercise plus breathing retraining for 12 weeks and then participate in an adherence program
3047934|NCT02241720|Experimental|Regorafenib treatment|
3047935|NCT02241694||survey|
3047936|NCT02241681|Other|Peptamen 1.5|500 mL of Peptamen 1.5
3047937|NCT02241668|Experimental|FLT PET Scan + 3'-Deoxy-3'-18f-Fluorothymidine|After a magnetic resonance imaging (MRI) scan of brain performed, an FLT PET scan using 3'-Deoxy-3'-18f-Fluorothymidine solution performed. After solution is injected into a vein, the PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. The entire procedure should last about 60-70 minutes.
3047938|NCT02241655|Experimental|EEG guided protocol|Participants will have a pragmatic EEG-guided anesthetic protocol during their surgery. Practitioners will modify administration of anesthesia in an attempt to limit the occurrence of EEG burst suppression or persistent suppression.
3047939|NCT02241655|No Intervention|Control Arm|Participants will have the standard anesthetic protocol.
3047940|NCT02241642|Experimental|Treatment|VIVASURE CLOSURE DEVICE™
3047941|NCT02241629|Experimental|levo phencynonate hydrochloride 1mg|levo phencynonate hydrochloride tablet 1mg
3047942|NCT02241629|Placebo Comparator|placebo|Placebo
3047943|NCT02241629|Experimental|levo phencynonate hydrochloride 2mg|levo phencynonate hydrochloride 2mg
3047944|NCT02241616|Experimental|Entecavir+Fuzheng Huayu+TCM Granule|Tablet with Entecavir+ Tablet with Fuzheng Huayu+ Granule with TCM
3047945|NCT02241603|Experimental|Weight loss|Obese Veterans will aim to lose 5-10% body weight
3047946|NCT02241603|No Intervention|Baseline comparator|Obese Veterans similar to Aim 1 in BMI, age, gender but not insulin sensitivity will not undergo weight loss
3047947|NCT02241590|Placebo Comparator|Entecavir + Placebo|Tablet with Entrcavir+ Tablet with starch
3047948|NCT02241590|Experimental|Entecavir + Fuzheng Huayu Tablet|Tablet with Entrcavir+ Tablet with Fuzheng Huayu
3047949|NCT02241577|Experimental|Surgical treatment|Surgical access for scaling and disinfection of dental implant
3047950|NCT02241577|Experimental|Non-surgical treatment|Non-surgical subgingival scaling and disinfection of dental implant
3047951|NCT02241564||Malignancy post transplantation|
3047952|NCT02241551|Experimental|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
3047953|NCT02241551|Experimental|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
3047954|NCT02241538|Experimental|Pilates 1|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 6 sessions of treatment over a period of 6 weeks (1 session/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
3047955|NCT02241538|Experimental|Pilates 2|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 12 sessions of treatment over a period of 6 weeks (2 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
3047956|NCT02241538|Experimental|Pilates 3|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
3047957|NCT02241538|Active Comparator|Control|Patients will receive an educational booklet containing information about the anatomy of the spine and pelvis and the low back pain and recommendations regarding posture and movements involved in activities of daily living. The participants in this group will not receive additional exercise.
3047958|NCT02241525||Prospective|Twenty patients will be enrolled and scanned with the RESEARCH procedures
3047959|NCT02241525||Retrospective|Patients with matching age and BMI will be selected from existing patients with a CLINICAL STANDARD of Care CTPA scan.
3047960|NCT02241512|Experimental|Ibuprofen|Single dose IV Ibuprofen at a dose of 10mg/kg (max: 800mg).
3047961|NCT02241512|Placebo Comparator|Placebo|Single dose IV normal saline
3047962|NCT02241499|Experimental|Radiotherapy and chemotherapy (oxaliplatin and fluorouracil).|Radiotherapy (5 x 4 Gy) will be given. After completion of radiotherapy, 4 cycles of chemotherapy will be administered, cycle length 14 days. Each patient will receive oxaliplatin as infusion at a dose of 85 mg/m2, followed by a bolus injection of fluorouracil at a dose of 400 mg/m2, and a long time infusion (44 hours) of fluorouracil at a dose of 2 400 mg/m2.
3047963|NCT02241486|Experimental|Sublingual Fentanyl Spray|Examine the efficacy and safety of sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement) in patients with burn injury.
3047964|NCT02241473|Experimental|CH training group|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single‐blind fashion.
3047965|NCT02241473|Active Comparator|CN training group|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) condition in a single‐blind fashion.
3047966|NCT02241460|Active Comparator|Promescent Lidocaine Spray|Double-Blind Treatment Period: 3 cycles (3 weeks each); 1 week wash-out between each cycle Open-Label Treatment Period: 4 cycles (1 week each); no wash-out
3047967|NCT02241460|Placebo Comparator|Placebo|Double-Blind Treatment Period: 3 cycles (3 weeks each); 1 week wash-out between each cycle Open-Label Treatment Period: 4 cycles (1 week each); no wash-out
3047968|NCT02241447|No Intervention|Observation|the nurse identifies cases with severe AS at the hub AND the satellite and collects their data. Baseline data for each patient will be collected and a follow-up will be done after three months for each patient to determine his/her outcome and the treatment that was decided on
3047969|NCT02241447|Other|Early information|in this arm, the physician referring a patient for echocardiography will be notified of a finding of severe aortic stenosis: the nurse brings cases with severe AS to the attention of the referring physician within a week (via phone, e-mail or letter) to make them aware of the diagnosis.
3047970|NCT02241434|Experimental|Stem Cell|bone marrow mononuclear cell transplantation
3047971|NCT02241421|Placebo Comparator|Placebo|No intervention: Placebo 3x2 capsules per day during 7 consecutive days.
3047972|NCT02241421|Experimental|Treatment Antibiotics: Amoxicillin|Experimental: Amoxicillin (broad spectrum antibiotics) 1500 mg/day (3x2 capsules of 250 mg) during 7 consecutive days.
3047973|NCT02241421|Experimental|Treatment Antibiotics: Vancomycin|Experimental: Vancomycin (small spectrum antibiotics) 1500mg/day (3x2 capsules of 250 mg) during 7 consecutive days
3047974|NCT02241395|Experimental|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
3047975|NCT02241382|Active Comparator|External Electrocardioversion|"Cardioversion with an external cardioverter-defibrillator with a step-up energy protocol (100, 150, 200, 360 J biphasic) in antero-posterior orientation, maintaining a > 8 cm distance between shock electrodes and device and complying with a cool-down phase of 2 minute between shocks, if more than one shock is required."
3047976|NCT02241382|Experimental|Internal Electrocardioversion|Cardioversion via the implanted ICD with a maximum energy synchronized shock (41 J, with a RV -> SVC+can shock orientation in pts with SVC leads). After 1 ineffective internal shock, the patient will be counted as internal CV failure and cardioverted externally, following the same protocol as the external CV group.
3047977|NCT02241369|Experimental|Cohort I|3 mg of INO-3106 (D0); 6 mg of INO-3106 (Wk3); 6 mg of INO-3106 + 1 mg of INO-9012 (Wk6); 6 mg of INO-3106 + 1 mg of INO-9012 (Wk9);
3047978|NCT02241369|Experimental|Cohort II|6 mg of INO-3106 in combination with 1 mg of INO-9012, or at the MTD determined above at D0, Wk3, Wk6, Wk9
3047979|NCT02241356|Active Comparator|single vision glasses|single vision glasses
3047980|NCT02241356|Experimental|bifocals|bifocal glasses
3047981|NCT02241343|Other|Trial cohort|Measurements taken before and after venous occlusion applied
3047982|NCT02241330|Placebo Comparator|Control|Control wheat used for meal, level of zinc is usual
3047983|NCT02241330|Active Comparator|fortification|Fortification Wheat is fortified before testmeal administration. Zinc level is comparable to WHO recommendation
3047984|NCT02241330|Active Comparator|Biofortified|Biofortification Biofortified wheat is used for testmeal administration. Zinc concentration is around 30% higher than control
3047985|NCT02241304||Elective surgery with muscle relaxation|ASA I-II-III patients. Fentanyl (2-3 ug/kg) - Propofol (2 mg/kg) induction, sevoflurane anesthesia, type and dose of muscle relaxant up to the decision of attending anesthetist. Neuromuscular stimulation with TetraGraph (30mA current intensity, 0.2 msce pulse duration, 20 sec intervals)
3047986|NCT02241291||All patients|Patients undergoing PCI at Bern University Hospital
3047987|NCT02241278|Placebo Comparator|Control|In the operating room, the anesthesiologist administered 50 mL of 0.9% saline intravenously to patients in the control group 30 minutes before surgical incision.
3047988|NCT02241278|Experimental|Ketamine|In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision. (a single dose).
3047989|NCT02241265|Experimental|Thermoplasty|Patients that have undergone thermoplasty
3047990|NCT02241252|Other|iPhone ECG QT recording|iPhone ECG
3047991|NCT02241239||participants|healthy adults without stroke and coronary heart disease
3047992|NCT02241226|Experimental|Perfect health course|Perfect health course at the Chopra Center for Wellbeing
3047993|NCT02241226|No Intervention|Resort group|Resort group at the La Costa resort
3047994|NCT02241213|Active Comparator|Active Transcranial Magnetic Stimulation TMS- r|Application of single stimulation pulses and regularly repeated ones, the frequency may be divided into high frequency EMT (> 1 Hz), low frequency (<1 Hz) This classification is based on physiological effects (stimulation or inhibition neuronal respectively). In this particular case, we will use low frequency <1 Hz with repetitive pulses.
3047995|NCT02241213|Placebo Comparator|Placebo Transcranial Magnetic Stimulation|Placebo coil that will simulate the sound of the pulses.
3047996|NCT02241200|Experimental|IV Administration|The iv solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
3047997|NCT02241200|Experimental|SC Administration|The sc solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
3047998|NCT02241187|Experimental|PEGPH20 And Cetuximab|5 participants will undergo DW- & DCE-MRI for sequence parameter optimization. The 1st stage of the study, patients (n = 5) will have the option to undergo (DW-) & (DCE)-MRI for repeatability investigation & T1 mapping. Optional DW- & DCE-MRI will be repeated 2 to 5 days later, followed shortly by administration of 1 intravenous dose of cetuximab at 250 mg/m2/60 min. Pancreatic tumor resection will be performed 1 to 2 days later.Blood samples will be drawn at various time points. The resected tumor specimen will be studied. If deemed safe, we will proceed to the second stage of the study. Patients (n = 5) will have the option to undergo DW- & DCE-MRI. 1 to 3 days later, patients will receive 1 IV dose of PEGPH20 at 3 μg/kg/10 min. Optional DW- & DCE-MRI will be repeated 1 to 2 days after PEGPH20 administration, followed on that day by administration of 1 IV dose of cetuximab at 250 mg/m2/60 min. Pancreatic tumor resection will be performed 1 to 2 days later.
3047999|NCT02241174|Experimental|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water.
3048000|NCT02241174|Placebo Comparator|Placebo|100ml distilled water will be used as a placebo and will be stored on amber bottles identical with the treatment group
3048001|NCT02241161|Active Comparator|plantaricin a - rejuvenating cream|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
3048002|NCT02241161|Active Comparator|plantaricin a - rejuvenating serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
3048003|NCT02241161|Active Comparator|plantaricin a - antioxidant serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
3048004|NCT02241161|Active Comparator|plantaricin a (rejuvenating cream +rejuvenating serum)|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
3048005|NCT02241161|Active Comparator|plantaricin a (rejuvenating cream + antioxidant serum)|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
3048006|NCT02241148|Active Comparator|Acetaminophen 500mg|The control group will receive treatment with acetaminophen 500mg and physical therapy rehabilitation
3048007|NCT02241148|Experimental|Kinesio taping|The experimental treatment group will receive acetaminophen 500mg and physical therapy rehabilitation, plus the application of the technique NUCAP Medical Upper Knee Spider ® Kinesio taping
3048008|NCT02241135|Experimental|80 µg CV7201 mRNA short|Vaccination by injection on days 0, 7, 28.
3048009|NCT02241135|Experimental|160µg CV7201 mRNA short|Vaccination by injection on days 0, 7, 28.
3048010|NCT02241135|Experimental|80 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
3048011|NCT02241135|Experimental|160 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
3048012|NCT02241135|Experimental|320 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
3048013|NCT02241135|Experimental|640 µg CV7201 mRNA long|Vaccination by injection on days 0, 28.
3048014|NCT02241135|Experimental|200 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
3048015|NCT02241135|Experimental|400 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
3048016|NCT02241122|Experimental|MRI guided prostate biopsy|prostate biopsy after MR-imaging
3048256|NCT02239627|Experimental|Clonidine|Epidural clonidine injection
3048017|NCT02241109|Other|All patients|Compare patients with high calcification propensity do have faster valve-stenosis progression
3048018|NCT02241096|Experimental|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
3048019|NCT02241083|Active Comparator|dopamine group|vasopressor dosage individually titred according to the mean arterial pressure
3048020|NCT02241083|Active Comparator|norepinephrine group|vasopressor dosage individually titred according to the mean arterial pressure
3048021|NCT02241083|Active Comparator|control group|no medication
3048022|NCT02241070|Experimental|mindulness-based intervention|Mindulness-based intervention was eight weeks of mindfulness training with forty-five minutes of homework practice every day during the training course. A leader and a professional facilitator led the group. The leader was a long-term mindfulness and vipassana meditation trainer who had practiced both types of meditation for more than two decades and had completed mindfulness trainer education; the professional facilitator was a mindfulness practitioner and a psychiatrist. The group met weekly for two hours in-session at the workplace.
3048023|NCT02241070|No Intervention|waiting-list control|passive control group
3048024|NCT02241057|Experimental|Temperature|Evaluate the temperature profile of the air activated 3-cell patch during 8 hours of wear
3048025|NCT02241057|Experimental|Adhesion|Evaluate the adhesion with and without the presence of a temperature probe
3048026|NCT02241044|Active Comparator|the Combined group|The Combined group patients received Argon plasma coagulation therapy, PSD-60/Endoplasma (Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period.
3048027|NCT02241044|Placebo Comparator|the Injection group|Injection group patients underwent distilled water alone at index endoscopy. Then patients were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period.
3048028|NCT02241031|Experimental|MPs|MPs will be intravenously infused within 48 hours after chemotherapy. During the study period, patients can receive platelet infusion but can not receive platelet stimulating factors.
3048029|NCT02241031|Active Comparator|Non-MPs|Patients can receive platelet infusion but can not receive platelet stimulating factors.
3048030|NCT02241018|Experimental|Mesenchymal stem cells|MSCs will be given at a median dose of 1×10^6 cells/kg once weekly for 4 dose (as 1 cycle) or until CR. The response should be evaluated at 3 and 4 weeks. If symptoms of aGVHD progress at 3 weeks or the patients have NR at 4 weeks, these patients will switch to other therapy. If patients achieved PR at 4 weeks, another cycle will be given. Besides, CD25 monoclonal antibody (20mg/kg) will be administered at day 1,4,8,15, 21 and calcineurin inhibitors will also be used.
3048031|NCT02241018|Experimental|CD25 Mc Ab & calcineurin inhibitors|CD25 monoclonal antibody (20mg/kg, day 1,4,8,15,21) will be administered combined with calcineurin inhibitors. The response should be evaluated at 3 and 4 weeks. If symptoms of aGVHD progress at 3 weeks or the patients have NR at 4 weeks, these patients will switch to other therapy. If patients achieved PR at 4 weeks, another cycle will be given.
3048032|NCT02241005|Active Comparator|Theraworx™|Participants are randomized to use the Theraworx™ bath wipes.
3048033|NCT02241005|Active Comparator|Standard|Participants are randomized to use standard bath wipes.
3048034|NCT02240992|Experimental|MSCs&PBSC|PBSC will be intravenously infused at a dose of 2×10^8/kg. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week or until complete response(CR) . If the patients do not achieve CR or partial remission (PR) within 4 weeks, they will swithed to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given.
3048035|NCT02240992|Experimental|MSCs|MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week or until CR. If the patients have no response (NR) within 4 weeks, they will switch to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given.
3048036|NCT02240979||Adults able to undergo cardiac MRI exam|Adults able to undergo cardiac MRI
3048037|NCT02240953|Active Comparator|Warfarin|In the first arm only warfarin is given with a target INR level of 2.5-4 to the patients with prosthetic heart valve thrombosis
3048038|NCT02240953|Active Comparator|Warfarin + ASA 100 mg + PPI|In the second arm 100 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
3048039|NCT02240953|Active Comparator|Warfarin + ASA 300 mg + PPI|In the third arm 300 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
3048040|NCT02240953|Active Comparator|Observational Warfarin|This arm is an observational group of patients who do not have prosthetic heart valve thrombosis. These patients also are followed under only warfarin therapy with INR level of 2.5-4.
3048041|NCT02240940|Experimental|Parachute Implant|Appropriate patients meeting inclusion / exclusion will be implanted with the Parachute device after screening with transthoracic echocardiography (TTE) and cardiac CT or MRI.
3048042|NCT02240927|Active Comparator|Enoxaparine|During first trimester, warfarin is stopped and enoxaparine is started in 1mg/kg dose twice a day. Dose is adjusted according to Anti Factor Xa levels (between 0.7-1.2). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
3048043|NCT02240927|Active Comparator|Enoxaparine and 2.5 mg warfarin|If the patient's therapeutic warfarin dose is more than 5 mg before pregnancy, warfarin dose is decreased to 2.5 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1.0). Full dose warfarin is continued after first trimester and dose is regulated according to INR (between 2.5-4)
3048044|NCT02240927|Active Comparator|Enoxaparine and 4 mg warfarin|If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
3048045|NCT02240927|Active Comparator|Warfarin|If the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy and the dose is adjusted according to INR level (between 2.5-4).
3048046|NCT02240914||Vascular USG and IVUS imaging diagnosis|
3048047|NCT02240901|Experimental|Laryngeal mask airway|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
3048048|NCT02240901|Experimental|Endotracheal intubation group（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
3048049|NCT02240888|Active Comparator|vaccinated patients|patients with different inflammatory rheumatic disease immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
3048050|NCT02240888|Active Comparator|vaccinated controls|healthy controls immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
3048051|NCT02240888|Active Comparator|seasonal influenza vaccine|patients with different inflammatory rheumatic diseases immunized with 0,5 mg seasonal influenza vaccine i.m.
3048052|NCT02240888|Active Comparator|non-vaccinated controls|healthy controls immunized with 0,5 mg seasonal influenza vaccine i.m.
3048053|NCT02240875|Experimental|Group 1|Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly
3048054|NCT02240875|Experimental|Group 1b|Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo
3048055|NCT02240875|Experimental|Group 1c|Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo
3048056|NCT02240875|Experimental|Group 2|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly
3048057|NCT02240875|Experimental|Group 2b|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo
3048058|NCT02240875|Experimental|Group 2c|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo
3048059|NCT02240875|Experimental|Group 3|Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly
3048060|NCT02240875|Experimental|Group 3b|Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo
3048061|NCT02240875|Experimental|Group 3c|Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo
3048062|NCT02240875|Experimental|Group 4|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 2.2 x 10^8 TCID50s MVA-BN® Filo at day 7
3048063|NCT02240875|Experimental|Group 5|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 2.2 x 10^8 TCID50s MVA-BN® Filo at day 14
3048064|NCT02240875|Experimental|Group 6|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 4.4 x 10^7 TCID50s MVA-BN® Filo at day 7
3048065|NCT02240875|Experimental|Group 7|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 4.4 x 10^7 TCID50s MVA-BN® Filo at day 14
3048066|NCT02240862||Carotid Artery Disease|Patients undergoing carotid artery stenting for high grade carotid artery stenosis with or without neurologic symptoms and with or without a high risk for carotid endarterectomy.
3048067|NCT02240849|Experimental|Functional pillow|cervical pillow, designed functionally to decrease neck pain and help to ensure the right support of the cervical curve, was applied to patients' posterior neck area.
3048068|NCT02240849|Placebo Comparator|General pillow|Applicants Randomly allocated to this group were issued by placebo-general pillow. There is not any specific intervention for their neck discomfort except for that.
3048069|NCT02240836|Experimental|Intervention. Exercise|The intervention starts 3-4 weeks after surgical treatment. The exercise program is performed in parallel with standard breast cancer treatment, and take place in supervised exercise groups by experienced physiotherapists. The duration of the intervention exercise program is 12 months, and the participants will attend the exercise groups for training 60 minutes twice a week. Additionally, they will exercise at home for at least 120 minutes a week, aiming to perform a total of 240 minutes of exercise per week
3048070|NCT02240836|No Intervention|Control group|Control group, standard treatment regimen
3048071|NCT02240823|Experimental|adipose derived stem cells|
3048072|NCT02240810||Promus PREMIER Everolimus-Eluting Platinum Chromium CSS|
3048073|NCT02240797||Anorexia Nervosa - Recovered (AN-REC)|Anorexia Nervosa - Recovered (AN-REC)
3048074|NCT02240797||Healthy Control (HC)|Healthy Control (HC)
3048075|NCT02240784||Acute Hepatic Porphyria|
3048076|NCT02240771|Active Comparator|Transarterial chemotherapy|Doxorubicin 50mg, Cisplatin 100mg
3048077|NCT02240771|Placebo Comparator|Oral chemotherapy|Thalidomide---50-300mg once a day Capecitabine---- 500-1500mg once a day
3048078|NCT02240758|Experimental|surgical removal of the tumors+stereotaxic biopsy|
3048079|NCT02240745||All patients|Patients with a suspicion of coronary heart disease
3048080|NCT02240732||Total knee replacement patients|"Patients who are due to have a total knee replacement will be studied to look for the presence of Emboli.~Observational with imaging."
3048081|NCT02240719|Experimental|Everolimus + Bendamustine|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2 and everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3048082|NCT02240706|Active Comparator|Arm B|Best Supportive Care Alone
3048083|NCT02240706|Experimental|Arm A|BI 836858 plus Best Supportive Care
3048084|NCT02240693|Experimental|BI 409306 dose 1|
3048085|NCT02240693|Experimental|BI 409306 dose 2|
3048086|NCT02240693|Experimental|BI 409306 dose 3|
3048087|NCT02240693|Experimental|BI 409306 dose 4|
3048088|NCT02240693|Placebo Comparator|Placebo|
3048089|NCT02240680|Experimental|linagliptin 5 mg|patient to receive a tablet of linagliptin 5 mg each day
3048090|NCT02240680|Placebo Comparator|placebo|patient to receive a tablet of placebo matching linagliptin 5 mg
3048091|NCT02240667||A|
3048092|NCT02240667||B|
3048093|NCT02240654||Dabigatran etexilate|
3048094|NCT02240641||hypertension treatment strategies|
3048095|NCT02240628|Active Comparator|Propofol-Lidocaine mixture|All patients from both groups will receive a Synera Patch. Patients in this group will receive Propofol mixed with Lidocaine. Pain will be evaluated during the Propofol injection by both a blinded observer and a blinded anesthesia member.
3048096|NCT02240628|Placebo Comparator|Propofol -Saline mixture|All patients from both groups will receive a Synera Patch. Patienst in this group will receive Propofol mixed with Saline. Pain will be evaluated on Propofol injection by both a blinded observer and a blinded anesthesia member.
3048097|NCT02240615|Experimental|Sinopsys Lacrimal Stent|All enrolled patients will receive a Sinopsys Lacrimal Stent inserted from the caruncle to the ethmoid sinus. Discharge instructions will include administration of sterile saline and ophthalmic drops as well as assessments for device patency.
3048098|NCT02240602|Experimental|Oxycodone, 1.00 mg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 1.00 mg with lock out time of 10 min without basal infusion.
3048099|NCT02240602|Experimental|Oxycodone, 0.03 mg/kg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 0.03 mg/kg with lock out time of 10 min without basal infusion.
3048100|NCT02240602|Experimental|Oxycodone, 0.02 mg/kg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 0.02 mg/kg with lock out time of 10 min without basal infusion.
3048101|NCT02240589|Experimental|Memantine|24 weeks of memantine with accelerated titration, beginning within 48 hours of injury.
3048102|NCT02240589|Placebo Comparator|Placebo|24 weeks of placebo matched to memantine formulation, beginning within 48 hours of injury.
3048103|NCT02240563|Experimental|Low-level laser therapy|This group of patients was treated with a continuous wave diode laser device (830 nanometer, infrared) with a beam area of 0.002827 cm2 using the punctual method on the continuous emission mode at an output power of 50 milliwatts and a fluence of 707 Joules/cm2 six years before.
3048104|NCT02240563|Placebo Comparator|Non laser ordinary red light|This group of patients was treated using the same method and equipment, except that a non laser ordinary red light, an output power of 0.1 Watt and a fluence of 1.41 Joules/cm2 and an irradiance value of 0.0002827 Watts/cm2 (the placebo), indistinguishable from the laser beam, was used. Therefore, the patients were blinded to which treatment they received.
3048105|NCT02240550|Active Comparator|ProFlor Hernia Repair System|A 3-D hernia mesh
3048106|NCT02240550|Active Comparator|Lichtenstein Hernia Repair|Using flat polypropylene mesh
3048107|NCT02240537|Experimental|Open Label Treatment Arm|BB-MPI-03 peptides plus montanide plus sargramostim
3048108|NCT02240524|Experimental|D2 lymphadenectomy and HIPEC and Systemic chemotherapy|"Intraoperative and postoperative hyperthermic intraperitoneal chemotherapy (twice HIPEC) were performed after radical gastrectomy with D2 lymphadenectomy, followed by 8 cycles of systemic chemotherapy.~HIPEC was conducted within 48 h after surgery: Normal saline 3000ml-4000ml, Paclitaxel 75mg/m^2, 43°C, 60min.~Systemic chemotherapy (XELOX):~Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance."
3048109|NCT02240524|Placebo Comparator|D2 lymphadenectomy+Systemic chemotherapy|"8 cycles of systemic chemotherapy were performed after radical gastrectomy with D2 lymphadenectomy.~Systemic chemotherapy (XELOX):~Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance."
3048110|NCT02240511|Active Comparator|Resistance Exercise|"Resistance Exercise (RE) therapy was divided in four parts: stretching: arms, hands, wrists, legs, knees and ankles, each one for 10 - 20 seconds with resting intervals of 5 seconds (4 series), warming and flexion: the same muscle groups, making small circles forward and backward for 5 - 10 seconds with resting intervals of 5 seconds (4 series), resistance exercises: flexion, contractions and twisting of the same muscle groups worked in the two previous sections. In this part resistance was increased with the aid of dumbbells (500 g - 1500 g), barbells and bands, and patients performed the same exercises with 15 - 20 repetitions with resting intervals of 10 seconds. (4 series), relaxation: involved the same exercises as stretching to rest all muscle groups worked."
3048111|NCT02240511|Experimental|RE and BCAA Supplementation|"RE: Resistance Exercise Resistance Exercise therapy was the same as in the Active Comparator~Branched Chain Aminoacids Amino 2000 BCAA (PRONAT® laboratory) supplementation group received 180 packets of 5 grams (g)and ingested 10 g/day (5 g after breakfast and 5 g before RE)"
3048112|NCT02240498|Experimental|MB-PDT, 5 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 5 minutes.
3048113|NCT02240498|Experimental|MB-PDT, 10 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 10 minutes.
3048114|NCT02240498|Experimental|MB-PDT, 15 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 15 minutes.
3048115|NCT02240498|Experimental|MB-PDT, 20 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 20 minutes.
3048116|NCT02240498|Experimental|MB-PDT, 25 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 25 minutes.
3048117|NCT02240498|Experimental|MB-PDT, 30 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 30 minutes.
3048118|NCT02240485|Experimental|Behavioral Couple Therapy|"Already described in the Intervention Description section"
3048119|NCT02240485|Active Comparator|Usual individual/group treatment|Well described in the Intervention section
3048120|NCT02240472|No Intervention|Axillary clearance|Patients in this arm will be treated by completion axillary clearance after a sentinel node biopsy showing 1-2 nodes with macrometastasis
3048121|NCT02240472|Experimental|No axillary clearance|Patients in this arm will not undergo further axillary surgery after a sentinel node biopsy showing 1-2 nodes with macrometastasis
3048122|NCT02240459|Experimental|Fesoterodine 4mg daily|fesoterodine 4mg oral
3048123|NCT02240459|Experimental|Fesoterodine 8mg|Fesoterodine 8mg in form of 2, 4mg tablets
3048124|NCT02240459|Active Comparator|oxybutynin|oxybutynin immediate release, encapsulated 2, 5mg capsules daily
3048125|NCT02240459|Placebo Comparator|placebo capsule|placebo capsule, 2 per day
3048126|NCT02240446|Experimental|Active tDCS|Active tDCS
3048127|NCT02240446|Placebo Comparator|Sham tDCS|Sham tDCS
3048487|NCT02237976|Active Comparator|Routine practice|No specific intervention
3048128|NCT02240433|Experimental|LY2157299 + Sorafenib|LY2157299 will be administered orally twice daily for 14 days, followed by 14 days with no study drug per 28-day cycle. Sorafenib will be administered orally twice daily for 28 days, in each cycle.
3048129|NCT02240420|Active Comparator|Life Style counseling (Star-Mama)|Star-Mama intervention group will receive during 6 months weekly phone calls with queries and narratives about health habits. The participant's answers will be sent to a health coach who will follow up with the participant, and develop a plan with the participant to address her needs.
3048130|NCT02240420|No Intervention|Educational Resource Support|Participants in the control group of the study will receive a set of educational materials with information about their health and the health of their babies.
3048131|NCT02240407|Experimental|rAAV9-DES-hGAA vector|Each subject will receive Rituxan and Rapamycin prior to the initial exposure to the study agent in one leg and the subsequent exposure of the same vector to the contralateral leg after four months. Diphenhydramine and acetaminophen will be provided before each Rituxan dose. Immune Globulin will be administered to each subject every other month after first exposure to Rituxan and as clinical necessary. Lidocaine will be administered through percutaneous infiltration before injection of the study agent. Side of administration will be randomized at first Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase injection.
3048132|NCT02240407|Sham Comparator|Excipient|Each subject will receive Rituxan and Rapamycin prior to the initial exposure to the study agent in one leg and the subsequent exposure of the same vector to the contralateral leg after four months. Diphenhydramine and acetaminophen will be provided before each Rituxan dose. Immune Globulin will be administered to each subject every other month after first exposure to Rituxan and as clinical necessary. Lidocaine will be administered through percutaneous infiltration before injection of the study agent. Side of administration will be randomized at first saline injection.
3048133|NCT02240381|Experimental|Diagnostic (OGTT, euglycemic hyperinsulinemic clamp)|Patients undergo OGTT and a standard 2-step euglycemic hyperinsulinemic clamp procedure prior to HCT. Patients then undergo repeat OGTT and a 2-step euglycemic hyperinsulinemic clamp procedure once after HCT between days 90-100.
3048134|NCT02240368||Group 1|Children age between 1 month to 12 months
3048135|NCT02240368||Group 2|Children age between 13 months and 36 months
3048136|NCT02240368||Group 3|Children age between 37 months to 144 months
3048137|NCT02240355|Experimental|Part 1|Up to 2 cohorts of patients, within each cohort patients will receive either RO6885247 or placebo once daily for 12 weeks
3048138|NCT02240355|Experimental|Part 2|1 cohort of patients, within each cohort patients will receive either RO6885247 or placebo once daily for 12 weeks
3048139|NCT02240355|Experimental|Part 3|1 cohort of patients, within each cohort patients will receive RO6885247 once daily for 12 weeks or 20 weeks
3048140|NCT02240342|Experimental|Poor ovarian reserve women|
3048141|NCT02240329|Other|Individuals with TBI|Individuals who have sustained a traumatic brain injury during the previous five years. Will have the following tests performed: Neuropsychological Testing and Measures of TBI severity; Cough and respiratory measures (including Maximum Respiratory Pressures); and Capsaicin cough sensitivity testing.
3048142|NCT02240316||Follicular NHL Cohort|
3048143|NCT02240316||DLBCL Cohort|
3048144|NCT02240303||Chronic Pain Group|Participants that experience chronic pain will have the following procedures performed: A sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin; Pressure sense will be produced by a device that will be pressed against the skin for several seconds; Pinprick pressure will be applied to determine if the pain can be rated; a Physical Performance test will be performed; and an magnetic resonance imaging (MRI) will be done. In addition, blood sample, blood pressure, heart rate, and skin temperature will be taken during the procedures.
3048145|NCT02240303||No Chronic Pain Group|Participants that do not experience chronic pain will have the following procedures performed: A sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin; Pressure sense will be produced by a device that will be pressed against the skin for several seconds; Pinprick pressure will be applied to determine if the pain can be rated; a Physical Performance test will be performed; and an magnetic resonance imaging (MRI) will be done. In addition, blood sample, blood pressure, heart rate, and skin temperature will be taken during the procedures.
3048146|NCT02240290|Experimental|tozadenant|A single dose of 240 mg tozadenant (four 60 mg tablets) and a 74 kBq (2 μCi) 14C-labeled tozadenant capsule will be administered with 240 mL of water.
3048147|NCT02240264|Active Comparator|Krill oil capsules|"Capsules containing krill oil rich in omega-3 fatty acid's.~Dietary supplements (krill oil) are provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.~Addendum 25-4-2016: In the Original protocol a dose adjustment after 3 months according to Omega-3 Index was to be executed. As no participant achieved the target Omega-3 Index the dosage was adjusted to 800mg DHA + EPA per day for all participants. The also led to the decision to increase the starting dosage of cohort II to 800mg DHA+ EPA."
3048148|NCT02240264|Placebo Comparator|Placebo|Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
3048149|NCT02240251||Patients undergoing IVC filter removal using the excimer laser|Laser Assisted IVC Filter Removal
3048150|NCT02240238|Experimental|NC-6004 and Gemcitabine|
3048151|NCT02240212|Experimental|Part 1: Dose-escalation (weekly paclitaxel)|The dose escalation will be started from Cohort A (afuresertib combined with weekly paclitaxel regimen at 80 mg/m^2 d1, 8,15, q4w). The starting dose in Cohort A will be 125 mg afuresertib QD to indentify MTD
3048152|NCT02240212|Experimental|Part 1: Dose-escalation (3 weeks Paclitaxel)|Once its MTD is identified, and then the study will move to dosing Cohort B (afuresertib combined with 3 weekly paclitaxel regimen at 175 mg/m^2 d1, q3w. Cohort B (afuresertib combined with 3 weekly paclitaxel regimen at 175 mg/m^2 d1, q3w). The starting daily dose of Cohort B will be 25 mg less than the MTD dose from Cohort A for afuresertib. If it is tolerated, then the dose escalation schedule will be followed in Cohort B until the MTD in this Cohort is reached. If the starting dose is not tolerated, then dose de-escalation will be explored until the MTD in this Cohort is reached. Once two dimensions of the MTD are achieved, then the optimal regimen for paclitaxel and MTD for afuresertib combined with paclitaxel based on the toxicity profile will be identified
3048153|NCT02240212|Experimental|Part 2: Experimental Cohort|The optimal regimen for paclitaxel and MTD for afuresertib combined with paclitaxel based on the toxicity profile will be administered
3048154|NCT02240199|Experimental|Pregabalin/Lidocaine|Perioperative Pregabalin, Intraoperative Intravenous Lidocaine Infusion
3048155|NCT02240199|Active Comparator|Pregabalin Placebo/Lidocaine|Perioperative Pregabalin Placebo, Intraoperative Intravenous Lidocaine Infusion
3048156|NCT02240199|Active Comparator|Pregabalin/Lidocaine Placebo|Perioperative Pregabalin, Intraoperative Intravenous Lidocaine Placebo Infusion
3048157|NCT02240199|Placebo Comparator|Pregabalin Placebo/Lidocaine Placebo|Perioperative Pregabalin Placebo, Intraoperative Intravenous Lidocaine Placebo Infusion
3048158|NCT02240186|Experimental|Prosthetic knee joints|Each subject will be tested using their current Non-Microprocessor Knee (NMPK) , fit and tested with a Microprocessor Knee (MPK), and then tested again with their NMPK, e.g. A-B-A design.
3048159|NCT02240173|Experimental|Jobelyn + Haloperidol|Combination of the conventional drugs and Jobelyn
3048160|NCT02240173|Active Comparator|Haloperidol + Placebo|Combination of the conventional drug + Placebo
3048161|NCT02240160|Experimental|Sativex: acidic oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with Coca-Cola (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
3048162|NCT02240160|Experimental|Sativex: neutral oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with tap water (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
3048163|NCT02240160|Experimental|Sativex: alkaline oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with milk of magnesia (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
3048164|NCT02240147|Experimental|home-based exercise training|
3048165|NCT02240147|No Intervention|Control group|
3048166|NCT02240134|Experimental|Education Intervention (Tx1)|The education components for this intervention are based on recent observations and recommendations from tribal, local, state and federal agencies. The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
3048167|NCT02240134|Active Comparator|Air Filtration Unit Treatment (Tx2)|"Within each randomly assigned home, a 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove."
3048168|NCT02240134|Sham Comparator|Placebo Intervention (Tx3)|"Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
3048169|NCT02240121|Active Comparator|Rifaximin DR|Rifaximin delayed release (DR) oral tablets 800 mg BID administered continuously without dose adjustment for 52 weeks.
3048170|NCT02240121|Placebo Comparator|Placebo|Matching placebo BID administered continuously without dose adjustment for 52 weeks.
3048171|NCT02240108|Active Comparator|Rifaximin DR|Rifaximin delayed release (DR) oral tablets 800 mg BID administered continuously without dose adjustment for 52 weeks.
3048172|NCT02240108|Placebo Comparator|Placebo|Matching placebo BID administered continuously without dose adjustment for 52 weeks.
3048173|NCT02240095|Experimental|Interventions: A + B + C|"See Interventions Description. In this arm, students will be offered all 3 online interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention B - Online Evidence Retrieval Coach~Intervention C - Online Audit and Feedback"
3048174|NCT02240095|Experimental|Interventions A + B|"See Interventions Description. In this arm, students will be offered the 2 following interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention B - Online Evidence Retrieval Coach"
3048175|NCT02240095|Experimental|Interventions A + C|"In this arm, students will be offered the 2 following online interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention C - Online Audit and Feedback"
3048176|NCT02240095|Experimental|Interventions B + C|"See Interventions Description. In this arm, students will be offered the 2 following online interventions combined:~Intervention B - Online Evidence Retrieval Coach~Intervention C - Online Audit and Feedback"
3048177|NCT02240095|Experimental|Intervention A alone|"See Interventions Description. In this arm, students will be offered only the following intervention:~* Intervention A - Online Clinical Questions Recorder"
3048178|NCT02240095|Experimental|Intervention B alone|"See Interventions Description. In this arm, students will be offered only the following intervention:~* Intervention B - Online Evidence Retrieval Coach"
3048179|NCT02240095|Experimental|Intervention C alone|"See Interventions Description. In this arm, students will be offered only the following intervention:~* Intervention C - Online Audit and Feedback"
3048180|NCT02240095|No Intervention|No intervention|In this arm, students will be offered none of the 3 online interventions, but will just be using the usual features of the search engine available to all users.
3048181|NCT02240082|Experimental|Web-based COPing with Shiftwork Program|Participants in this condition will use the web-based COPing with Shiftwork web-based program for three months
3048182|NCT02240082|No Intervention|Wait List Control|Participants in the wait list control group will not receive any intervention during the study period, but will have access to any program offered by the police department.
3048183|NCT02240069|Experimental|Education (Tx1)|Education on best burn practices
3048184|NCT02240069|Active Comparator|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove."
3048185|NCT02240069|Sham Comparator|Placebo Intervention (Tx3)|"A 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
3048186|NCT02240056||TTC|postmenopausal women with acute Takotsubo cardiomyopathy (TTC), diagnosis by coronary angiography within 24 hours of symptom onset
3048187|NCT02240056||NSTEMI / STEMI|postmenopausal women with acute ST elevation myocardial infarction (NSTEMI / STEMI), diagnosis by coronary angiography within 24 hours of symptom onset
3048188|NCT02240043|Other|growth hormone secretion|The elderly had common morbidities peculiar to their age, such as systemic arterial hypertension, diabetes mellitus, Parkinson's disease, initial stages of senile dementia, and osteoporosis.
3048189|NCT02240030|Experimental|CVT-301 Low Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
3048190|NCT02240030|Experimental|CVT-301 High Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
3048191|NCT02240030|Placebo Comparator|Placebo|Capsules of inhalation-grade lactose used up to 5 times/day for OFF episodes for 3 months duration.
3048192|NCT02240017|Active Comparator|Carboplatin/Gemcitabine|
3048193|NCT02240017|Experimental|Fractionated Cisplatin/Gemcitabine|
3048194|NCT02239991|No Intervention|Historical control|Group of patients that had their coagulopathy secondary to the liver transplant treated based on conventional laboratory tests. Before the implementation of thromboelastometry.
3048195|NCT02239991|Experimental|Intervention|Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
3048196|NCT02239978||Parkinsons disease|Individuals with Parkinsons disease
3048197|NCT02239978||Control|Age-matched healthy adults
3048198|NCT02239965||Anaesthesia personnel|Anaesthesiologists and nurse anaesthetists
3048199|NCT02239952|Experimental|sunitinib|
3048200|NCT02239952|Experimental|vandetanib|
3048201|NCT02239952|Experimental|Erlotinib|
3048202|NCT02239939|Experimental|Vest + Diet|All participants will undergo a 22 week dietary weight loss. In addition, participants will be asked to wear a weighted vest for >10 hours a day. Weight in the vest is adjusted to match weight lost during the intervention.
3048203|NCT02239939|Active Comparator|No Vest + Diet|All participants will undergo a 22 week dietary weight loss intervention. Participants in this group will be asked not to change their daily habits other than adherence to the diet protocol.
3048204|NCT02239926|Active Comparator|Ranolazine|tablet, 1000 mg twice daily for four weeks
3048205|NCT02239926|Placebo Comparator|Placebo|Placebo
3048206|NCT02239913|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and phentermine during placebo maintenance. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
3048207|NCT02239913|Experimental|Topiramate Dose 1|Subjects will be maintained on the low topiramate dose. Subjects will be maintained on placebo and phentermine during maintenance on the low dose of topiramate. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
3048208|NCT02239913|Experimental|Topiramate Dose 2|Subjects will be maintained on the high topiramate dose. Subjects will be maintained on placebo and phentermine during maintenance on the high dose of topiramate. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
3048209|NCT02239900|Experimental|Group 1 Liver: Concurrent (early) Ipilimumab and SBRT|Participants with at least 1 liver metastasis - Treatment Group 1: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses. SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 1 - 4 of Cycle 1.
3048210|NCT02239900|Experimental|Group 2 Liver: Sequential (late) Ipilimumab and SBRT|Participants with at least 1 liver metastasis - Treatment Group 2: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4. Each cycle is 21 days. SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 29 - 33 of each 21 day cycle.
3048211|NCT02239900|Experimental|Group 3 Lung: Concurrent (early) Ipilimumab and SBRT|Participants with at least 1 lung metastasis - Treatment Group 3: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses. SBRT 50 Gy in 4 fractions to 1 - 4 lung lesion(s) on Days 1 - 4 of Cycle 1.
3048212|NCT02239900|Experimental|Group 4 Lung: Sequential (late) Ipilimumab and SBRT|Participants with at least 1 lung metastasis - Treatment Group 4: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4. Each cycle is 21 days. SBRT 50 Gy in 4 fractions to 1 - 4 lung lesion(s) on Days 29 - 33 of each 21 day cycle.
3048213|NCT02239900|Experimental|Group 5 Liver/Lung Metastasis: (late) Ipilimumab and SBRT|Participants with 1 liver or lung metastasis - Treatment Group 5: Ipilimumab 3 mg/kg by vein on Day 1 of Cycle 1. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 2 - 4. Each cycle is 21 days. SBRT 60 Gy in 10 fractions to 1 - 4 lung, liver, or adrenal lesion (s) on Days 1 - 5 and Days 9 - 12 of Cycle 1.
3048214|NCT02239900|Experimental|Thyroid Expansion Cohort|"Participants enrolled in this arm treated to a total dose of 50 Gy in 4 fractions, 60 Gy in 10 fractions, or 20 Gy in 5 fractions with stereotactic radiotherapy to a liver or lung lesion. The choice of radiation dose will be at the discretion of the treating radiation oncologist.~Participants receive Ipilimumab every 21 days for a total of 4 doses."
3048215|NCT02239887||WaveCrest LAA occlusion device|Left Atrial Occlusion
3048216|NCT02239874|Placebo Comparator|Vitamin D placebo and fish oil placebo|vitamin D placebo + fish oil placebo
3048217|NCT02239874|Active Comparator|Fish oil and vitamin D placebo|Vitamin D placebo and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
3048218|NCT02239874|Active Comparator|Vitamin D and fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
3048219|NCT02239874|Active Comparator|Vitamin D and fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
3048220|NCT02239861|Experimental|TAA-Specific CTLs|"Four different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. The first two patients on each dose level will be staggered by 4 weeks (which starts when the first infusion is given, Day 0). No subjects between the ages of 2-18 will be enrolled to a dose level on this protocol, until an adult has been enrolled to and treated on that dose level on one of the protocols being conducted under this same IND. Each patient will receive 2 injections at the same dose,14 days apart, according to the following dosing schedules: The expected volume of infusion will be 1 to 10 cc.~Dose Level One:~Day 0: 5 x 10^6 cells/m^2 Day 14: 5 x 10^6 cells/m^2~Dose Level Two:~Day 0: 1 x 10^7 cells/m^2 Day 14: 1 x 10^7 cells/m^2~Dose Level Three:~Day 0: 2 x 10^7 cells/m^2 Day 14: 2 x 10^7 cells/m^2~Dose Level Four:~Day 0: 4 x 10^7 cells/m^2 Day 14: 4 x 10^7 cells/m^2"
3048221|NCT02239835|Experimental|TPV low dose + RTV low dose|
3048222|NCT02239835|Experimental|TPV high dose + RTV low dose|
3048223|NCT02239835|Active Comparator|SQV + RTV high dose|
3048224|NCT02239822|Active Comparator|Active Stimulation|Patients assigned to active stimulation arm will receive electrical stimulation during the study.
3048225|NCT02239822|Placebo Comparator|Placebo Stimulation|Patients assigned to the placebo arm did not receive stimulation electrical stimulation for 24 weeks. After this period the participants randomized to sham stimulation will be moved to the active stimulation and will be followed until study completion.
3048226|NCT02239809|Active Comparator|Active Stimulation|Patients assigned to active stimulation arm will receive electrical stimulation during the study.
3048227|NCT02239809|Placebo Comparator|Placebo Stimulation|Patients assigned to the placebo arm did not receive stimulation electrical stimulation for 24 weeks. After this period the participants randomized to sham stimulation will be moved to the active stimulation and will be followed until study completion.
3048228|NCT02239796|Experimental|TPTNS|"12 stimulation sessions of 30 minutes duration, delivered twice weekly over a 6 week period using a NeuroTrac continence stimulator.~Two surface electrodes are applied to the non-hemiparetic ankle, where appropriate, or the right ankle where no hemiparesis exists. The electrical stimulator is pre-programmed to safely deliver 30 minutes of continuous stimulation with a pulse frequency of 10 hertz and pulse width 200µs22. The intensity of the current will depend on the stroke survivor's perception threshold and individual comfort and is self-adjusted at each session, but will normally range between 15 and 40 milliamps."
3048229|NCT02239796|Sham Comparator|Sham TPTNS|"The sham stimulation group will self- or carer-deliver a similar programme of twelve, 30 minute sessions twice weekly for 6 weeks NeuroTrac continence stimulator.~The surface electrodes will be positioned on the lateral malleolar area of the ankle, not the medial aspect, to avoid the posterior tibial nerve.~The stimulation intensity will be increased until sensation is reported, then turned down to 4mA for the 30 minute session, ensuring that despite avoiding the posterior tibial nerve, there is no therapeutic stimulation provided."
3048230|NCT02239783||Total Hip Arthroplasty|Single group previously implanted with the following combination of components: PROFEMUR® TL modular femoral stem, MicroPort Orthopedics acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.
3048231|NCT02239770|Placebo Comparator|0 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one placebo nicotine film.
3048232|NCT02239770|Experimental|2 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one 2 mg nicotine film.
3048233|NCT02239770|Experimental|4 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one 4 mg nicotine film.
3048234|NCT02239770|Placebo Comparator|0, 0, 0, 0mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 0, 0, 0, 0 mg.
3048235|NCT02239770|Experimental|2, 2, 2, 2mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 2, 2, 2, 2 mg.
3048236|NCT02239770|Experimental|4, 4, 0, 4mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 4, 4, 0, 4 mg.
3048237|NCT02239757|Experimental|Right radial approach|Primary PCI performed through right radial approach.
3048238|NCT02239757|Experimental|Left radial approach|Primary PCI performed through left radial approach.
3048239|NCT02239744|Experimental|True air purification|One group of subjects used an intervention of true air purifiers placed in the center of the room.
3048240|NCT02239744|Sham Comparator|Sham air purification|This group of subjects used an intervention of sham air purifiers under the same conditions with true purifiers with the only difference being removal of the filter gauze in the sham purifiers.
3048241|NCT02239731|Experimental|FDX104 (4% Doxycycline)|Active ingredient: Doxycycline Concentration: 4% Route: Topical Dosage schedule: Twice daily, morning and evening. Prophylactic treatment to prevent the rash associated with EGFRI treatment. patients will apply a thin layer of the drug twice daily for five weeks to one half of face
3048242|NCT02239731|Placebo Comparator|Placebo foam|Active ingredient: None Route: Topical Dosage schedule: Twice daily, morning and evening. Patients will apply a thin layer of the placebo twice daily for five weeks to the opposite half of the face of which they received active treatment.
3048243|NCT02239718|Experimental|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
3048244|NCT02239718|Active Comparator|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
3048245|NCT02239705||Fluid challenge|Patients whose clinical conditions require bolus of fluids infusion to correct blood pressure and cardiac output
3048246|NCT02239705||Inotropic infusion|Patient whose clinical conditions require inotropic agents infusion to correct blood pressure and cardiac output
3048247|NCT02239692|Active Comparator|PICOPREP day-before dosing schedule|Both doses administered the day before colonoscopy.
3048248|NCT02239692|Experimental|PICOPREP tailored dosing schedule|First dose one day before colonoscopy or on the day of colonoscopy, dependent on the planned time for colonoscopy, and second dose on the day of colonoscopy.
3048249|NCT02239679|Experimental|ALA X3|Cryotherapy followed by 3 aminolevulinic acid + blue light (BLU-U) treatments
3048250|NCT02239679|Placebo Comparator|VEH|Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving cryotherapy and 2 or 3 subsequent Topical Solution Vehicle + BLU-U treatments. Subjects receiving VEH will be considered a single treatment group.
3048251|NCT02239679|Experimental|ALA X2|Cryotherapy followed by 2 aminolevulinic acid + BLU-U treatments
3048252|NCT02239666||Moderate to Severe Plaque Psoriasis|Prospective cohort study of usual care for subjects initiating therapy for plaque psoriasis on approved biologic agents. A non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
3048253|NCT02239653|Experimental|Physician communication|"The Milk. Water. Period intervention comprises brochures, posters, and key talking points for use by primary pediatricians to use in discussion with the parent about the child's beverages consumption."
3048254|NCT02239653|No Intervention|Usual care|
3048255|NCT02239627|Active Comparator|Steroid|Epidural steroid injection
3048257|NCT02239614|Experimental|Group 1: LAV (T=0), PIV (T=28)|"Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 0 of the study.~Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 28 of the study."
3048258|NCT02239614|Experimental|Group 2: PIV (T=0), LAV (T=28)|"Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 0 of the study.~Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 28 of the study."
3048259|NCT02239614|Experimental|Group 3: LAV (T=0), PIV (T=180)|"Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 0 of the study.~Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 180 of the study."
3048260|NCT02239614|Experimental|Group 4: PIV (T=0), LAV (T=180)|"Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 0 of the study.~Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 180 of the study."
3048261|NCT02239601|Experimental|Physical Therapy|4 Physical therapy treatment sessions provided prior to chemotherapy and a home program to continue throughout the trial.
3048262|NCT02239588|Experimental|Pure Canterbury milk powder|Oral consumption of infant formula (0-6 months) milk powder
3048263|NCT02239588|Active Comparator|Other infant formula milk powder|"Oral consumption of milk powder (other than the experimental product) selected by subjects' parents. The products including:~Yashili Ambery Infant Formula Milk Powder (Stage 1: 0-6 months)~Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)~Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)~Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)~Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)~Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)"
3048264|NCT02239588|Placebo Comparator|Breast milk|Oral consumption of breast milk
3048265|NCT02239562|Experimental|NORMAL Liver Function Single Ascending Dose 0.1|"Within each cohort (3 patients), patients with normal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to receive a single dose of sPIF or placebo as follows:~Cohort 1: Single dose 0.1 mg/kg sPIF or Placebo Day 1 given SQ"
3048266|NCT02239562|Experimental|NORMAL Liver Function Single Ascending Dose 0.5|"Within each cohort (3 patients), patients with normal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to receive a single dose of sPIF or placebo as follows:~Cohort 2: single dose 0.5 mg/kg sPIF or Placebo Day 1 given SQ"
3048267|NCT02239562|Experimental|NORMAL Liver Function Single Ascending Dose 1.0|"Within each cohort (3 patients), patients with normal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to receive a single dose of sPIF or placebo as follows:~Cohort 3: single dose 1.0 mg/kg sPIF or Placebo Day 1 given SQ"
3048268|NCT02239562|Experimental|ABNORMAL Liver Function Single Ascending Dose 0.1|"Within each cohort (3 patients), patients with abnormal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to receive a single dose of sPIF or placebo as follows:~Single dose 0.1 mg/kg sPIF or Placebo Day 1 given SQ"
3048269|NCT02239562|Experimental|ABNORMAL Liver Function Single Ascending Dose 0.5|"Within each cohort (3 patients), patients with abnormal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to receive a single dose of sPIF or placebo as follows:~Single dose 0.5 mg/kg sPIF or Placebo Day 1 given SQ"
3048270|NCT02239562|Experimental|ABNORMAL Liver Function Single Ascending Dose 1.0|"Within each cohort (3 patients), patients with abnormal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to receive a single dose of sPIF or placebo as follows:~Single dose 1.0 mg/kg sPIF or Placebo Day 1 given SQ"
3048271|NCT02239562|Experimental|Normal Liver Function Multiple Ascending Dose 0.1|"Within each cohort (3 patients), subjects with normal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to multiple doses of sPIF administered subcutaneously once a day for 5 consecutive days (Days 1 to 5):~Cohort 1: 0.1 mg/kg sPIF or Placebo Days 1-5 given SQ"
3048272|NCT02239562|Experimental|Normal Liver Function Multiple Ascending Dose 0.5|"Within each cohort (3 patients), subjects with normal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to multiple doses of sPIF administered subcutaneously once a day for 5 consecutive days (Days 1 to 5):~Cohort 2: 0.5 mg/kg sPIF or Placebo Days 1-5 given SQ"
3048273|NCT02239562|Experimental|Normal Liver Function Multiple Ascending Dose 1.0|"Within each cohort (3 patients), subjects with normal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to multiple doses of sPIF administered subcutaneously once a day for 5 consecutive days (Days 1 to 5):~Cohort 2: 1.0 mg/kg sPIF or Placebo Days 1-5 given SQ"
3048274|NCT02239562|Experimental|Abnormal Liver Function Multiple Ascending Dose 0.1|"Within each cohort (3 patients), subjects with abnormal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to multiple doses of sPIF administered subcutaneously once a day for 5 consecutive days (Days 1 to 5):~Cohort 1: 0.1 mg/kg sPIF or Placebo Days 1-5 given SQ"
3048275|NCT02239562|Experimental|Abnormal Liver Function Multiple Ascending Dose 0.5|"Within each cohort (3 patients), subjects with abnormal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to multiple doses of sPIF administered subcutaneously once a day for 5 consecutive days (Days 1 to 5):~Cohort 1: 0.5 mg/kg sPIF or Placebo Days 1-5 given SQ"
3048276|NCT02239562|Experimental|Abnormal Liver Function Multiple Ascending Dose 1.0|"Within each cohort (3 patients), subjects with abnormal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to multiple doses of sPIF administered subcutaneously once a day for 5 consecutive days (Days 1 to 5):~Cohort 1: 1.0 mg/kg sPIF or Placebo Days 1-5 given SQ"
3048277|NCT02239549|Experimental|Jumbo cold forceps polypectomy group|Polypectomy conducted with jumbo cold forceps
3048278|NCT02239549|Experimental|Cold snare polypectomy group|Polypectomy conducted with cold snare
3048279|NCT02239536|Experimental|Hot snare polypectomy|Intervention: Procedure: removal of eligible polyps using hot snare polypectomy technique
3048280|NCT02239536|Experimental|Hot snare polypectomy after saline injection|Intervention: Procedure: removal of eligible polyps using hot snare polypectomy after saline injection technique
3048281|NCT02239523|Active Comparator|Letter Group|Patients will be given discharge letter that includes recommendation to discuss further testing and treatment with their primary care physician.
3048282|NCT02239523|Experimental|Intervention Group|Patients will be given a pamphlet about osteoporosis and importance of treatment, have a bone density test (DEXA) arranged, be given a specific medication recommendation and monthly followup phone calls.
3048283|NCT02239510|Active Comparator|Senna|1 capsule (50 mg) Senna daily for 12 weeks
3048284|NCT02239510|Active Comparator|Linzess|1 capsule (145 mcg) once daily for 12 weeks
3048285|NCT02239497|Experimental|femoral block by US and NE and intravenous analgesia|preincisional femoral block by ultrasound and neurostimulation, with 20 ml bupivacaine 0,5% and epinephrine. ketoprofen, dipyrone and dexamethasone IV. Morphine IV to rescue analgesia
3048286|NCT02239497|Experimental|Intravenous analgesia|Intravenous analgesia with ketoprofen, dipyrone and morphine. IV morphine to rescue analgesia
3048287|NCT02239484|Experimental|Sequence 1|Tadalafil→Tamsulosin→Tadalafil+Tamsulosin
3048288|NCT02239484|Experimental|Sequence 2|Tadalafil+Tamsulosin→Tadalafil→Tamsulosin
3048289|NCT02239484|Experimental|Sequence 3|Tamsulosin→Tadalafil+Tamsulosin→Tadalafil
3048290|NCT02239458|Placebo Comparator|Placebo|Placebo intake during 3 months
3048291|NCT02239458|Active Comparator|Saxagliptin 5mg|Saxagliptin dose of 5mg for 3 months
3048292|NCT02239445|Active Comparator|chloral hydrate group|chloral hydrate 0.25 mg/kg oral solution diluted with oral syrup to 5 ml and 0.2 mL intranasal placebo (normal saline)
3048293|NCT02239445|Experimental|low dose dexmedetomidine Group|"Group L received intranasal dexmedetomidine at 1mcg/kg and 5 ml oral syrup~Undiluted preservative-free dexmedetomidine (AiBeiNing; Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) was prepared in a concentration of 100mcg/ml and dripped into both nostrils using a 1 mL syringe with the child in the Supine position."
3048294|NCT02239445|Experimental|high dose dexmedetomidine group|"Group H received intranasal dexmedetomidine at 2mcg/kg and 5 ml oral syrup~Undiluted preservative-free dexmedetomidine (AiBeiNing; Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) was prepared in a concentration of 100mcg/ml and dripped into both nostrils using a 1 mL syringe with the child in the Supine position."
3048295|NCT02239432||Suspected Adenocarcinoma of the Lung|Patients with suspected adenocarcinoma of the lung referred for surgical lung biopsy after multi-disciplinary team recommendation.
3048296|NCT02239432||Healthy Control|Age and sex-matched patients with no known lung disease or other chronic inflammatory disease or malignancy
3048297|NCT02239432||Age-matched controls with proven solid lung malignancy|Patients with biopsy-proven advanced solid malignancy of the lung
3048298|NCT02239419|Experimental|CO2-Enriched Tap Water (Carbothera)|CO2-enriched tap water (CO2 concentration, 1000-1200 ppm) maintained at a temperature of 37˚C. Tap water will be enriched with CO2 by the investigational Carbothera device.
3048299|NCT02239419|Placebo Comparator|Non-CO2-Enriched Tap Water|Non-CO2-enriched tap water (i.e. normal tap water) maintained at a temperature of 37˚C.
3048300|NCT02239406||Metal-on-Metal Revision|Patients who have a failed metal on metal total hip implant and are presenting for revision surgery
3048301|NCT02239393|Experimental|Autologous Mesenchymal Stem Cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0.
3048302|NCT02239393|Experimental|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0.
3048303|NCT02239380|Experimental|Lorazepam|Lorazepam intravenous formulation
3048304|NCT02239367|Experimental|Depression Decision Aid protocol|The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention. Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower the elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
3048305|NCT02239354|Experimental|Cohort 1|2 VC-01 implants
3048306|NCT02239354|Experimental|Cohort 2|4 or 6 VC-01 implants
3048307|NCT02239341|Active Comparator|Music Intervention (M)|The M intervention will be 30 minutes (same amount of time as E group), but the participants will simply be listening to the same music in bed with no exercise component. They will be wearing the heart rate monitor as in the E group. The M group will act as a control group for the E group.
3048308|NCT02239341|Experimental|Muscle Conditioning Intervention (E)|E (exercise) is 30 minutes in length and will consist of 5 minutes of warm-up, 20 minutes of light strengthening exercises using a theraband, and 5 minutes of cool-down. All exercises will be completed in bed. Each participant will be listening to the same music (as the M group) during exercise. A heart rate monitor will be worn throughout each session. The first session for each participant will be used to complete baseline measurements and to assess initial muscle strength. Difficulty level will be adjusted by using different strength therabands.
3048309|NCT02239328||Lung Cancer, Esophageal Cancer|Lung Cancer and Esophageal Cancer patients will complete the online PROMIS survey. No treatment intervention will be performed.
3048310|NCT02239315|Experimental|Tumor RNA Disruption Assay™ (RDA)|Tumor RNA Disruption Assay™ (RDA) to generate RDA score from fine needle aspiration biopsy samples of breast cancer obtained 7-14 days after the first, second and third cycles of neoadjuvant chemotherapy; and, if there is a change of chemotherapy regimen, after the first cycle of the new chemotherapy.
3048311|NCT02239289|Experimental|Biofeedback|Subjects will be provided with four sessions of supervised biofeedback training
3048312|NCT02239250|Experimental|Water filter and cookstove|All household that appear on Government approved lists as belonging to ubudehe 1 & 2 categories in the 72 sectors randomised as intervention sectors will be eligible to receive one free water filtering device and one free cookstove. All households will be given instructions of how to use the intervention.
3078262|NCT02038673|Experimental|Dose escalation part 10.0 mg BID|Oral
3048313|NCT02239250|No Intervention|Control|All household that appear on Government approved lists as belonging to ubudehe 1 & 2 categories in the 24 sectors randomised as control sectors will continue with their traditional cooking methods and drinking practices.
3048314|NCT02239237||Compound Kuh-seng Injection|Compound Kuh-seng Injection will be given to the patients, and the investigators will record all the information including ADR, application of Compound Kuh-seng Injection and the combined medications, etc.
3048315|NCT02239224|Experimental|ATYR1940|ATYR1940 : IV; 0.3, 1.0, or 3.0 mg/kg; once a week; Up to 12 weeks
3048316|NCT02239224|Placebo Comparator|Placebo|Placebo: IV; 0.3, 1.0, or 3.0 mg/kg; once a week; Up to 12 weeks
3048317|NCT02239211|Experimental|BTT1023|BTT1023 8mg/kg IV infusion, every 14 days (total of 7 infusion). Duration 1-2 hours per infusion.
3048318|NCT02239198|Experimental|C|Nutrition bar without omega-3 fatty acids
3048319|NCT02239198|Experimental|B|Nutrition bar without added minerals and vitamins
3048320|NCT02239198|Active Comparator|A|Complete nutrition bar
3048321|NCT02239185|Other|Hernial sac ligation in continuity|laparoscopic closure of hernia sac in continuity using 3 - 0 non-absorbable purse-string suture. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying.
3048322|NCT02239185|Other|Hernial sac disconnection|circumferential incision on the peritoneum at internal inguinal ring (IIR) with separation of hernia sac from the peritoneum. The proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
3048323|NCT02239172|Experimental|12.5 µg + Alhydrogel|vaccine
3048324|NCT02239172|Experimental|25 µg + Alhydrogel|vaccine
3048325|NCT02239172|Experimental|50 µg + Alhydrogel|vaccine
3048326|NCT02239172|Experimental|100 µg + Alhydrogel|vaccine
3048327|NCT02239159|No Intervention|Control|Electrodes will be attached, but stimulation will not be given
3048328|NCT02239159|Sham Comparator|Non-acupoint TES|TES is for transcutaneous electric stimulation.Stimulation will be given through electrodes attached to non-acupoints
3048329|NCT02239159|Experimental|Acupoint TES|Transcutaneous stimulation will be given through acupoints
3048330|NCT02239146|Experimental|rFXIII|
3048331|NCT02239146|Placebo Comparator|Placebo|
3048332|NCT02239133|Experimental|ProVATE vaginal pessary|"The ProVATE device is a disposable, single-use, vaginal pessary for the management of Pelvic Organ Prolapse (POP). The ProVATE device is similar to other ring pessaries currently on the market. Its features allow for easy and comfortable insertion and removal by the user herself at her home environment. The ProVATE device is provided in six (6) different sizes and is intended for prescription use only."
3048333|NCT02239120|Experimental|dabigatran etexilate 110 or 150 mg|Patients will be assigned Dabigatran 150 mg b.i.d. (unless they are 75 years or older, or have a Creatinine Clearance (CrCl) of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive Dabigatran 110 mg b.i.d.). All patients in this arm will also receive ASA placebo (q.d.)
3048334|NCT02239120|Active Comparator|ASA 100 mg|All patients will receive blinded ASA 100 mg q.d. and dabigatran placebo 150 mg b.i.d. (unless they are 75 years or older, or have a CrCl of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive placebo Dabigatran 110 mg b.i.d
3048335|NCT02239107|Experimental|N-Acetyl cysteine|Laparoscopic ovarian drilling followed by NAC 1200mg daily in two divided doses for five days starting cycle day 2 for 6 month
3048336|NCT02239107|Active Comparator|laparoscopic drilling group|laparoscopic drilling only will be done
3048337|NCT02239094|Other|Lurasidone (Latuda)|All study participants will receive open-label Latuda.
3048338|NCT02239081|Experimental|CTP-730, 5 mg|oral suspension, once daily.
3048339|NCT02239081|Experimental|CTP-730, 10 mg|Oral Suspension, once daily.
3048340|NCT02239081|Experimental|CTP-730, 20 mg|Oral Suspension, once daily.
3048341|NCT02239081|Experimental|CTP-730, 30 mg|Oral Suspension, once daily.
3048342|NCT02239081|Experimental|CTP-730, 40 mg|Oral Suspension, once daily.
3048343|NCT02239081|Experimental|CTP-730, 50 mg|Oral Suspension, once daily.
3048344|NCT02239081|Experimental|CTP-730, 60 mg|Oral Suspension, once daily.
3048345|NCT02239055||Focus Group 1|Staff Perceptions
3048346|NCT02239055||Focus Group 2|Staff Perceptions
3048347|NCT02239042|Sham Comparator|Low-level laser therapy (LLLT) Sham|LLLT Sham on the palatal donor site of connective tissue graft
3048348|NCT02239042|Experimental|Low-level laser therapy (LLLT)|LLLT on the palatal donor site of connective tissue graft
3048349|NCT02239029|Active Comparator|Platelet rich plasma|"Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.~Patients with bilaetral knee osteoarthritis randomized receive on dose of PRP in one knee and placebo with normal saline in the other side."
3048350|NCT02239029|Placebo Comparator|normal saline|Normal saline was injected into the other side of knee as the control group.
3048351|NCT02239003|Experimental|DAOIB|250-1500 mg/day, oral, for 24 weeks
3048352|NCT02239003|Placebo Comparator|Placebo|placebo, oral, for 24 weeks
3048353|NCT02238977|Active Comparator|Fluoxetine|Fluoxetine up to 20 mg orally daily for 12 weeks. Flexible dosing between a minimum of 10 mg daily and 20 mg daily as tolerated.
3048354|NCT02238977|Experimental|Bupropion|Bupropion sustained release (SR) 150 mg orally twice per week
3048355|NCT02238964|Active Comparator|Strattice™ Reconstructive Tissue Matrix|Strattice(TM) Reconstructive Tissue Matrix will be placed intra-peritoneally fashion. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl).
3048356|NCT02238964|Active Comparator|Standard closure|"Fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The technique recommended is the fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. This technique can include either interrupted or continuous sutures.~Closure of the muscle, soft tissues and skin is up to the discretion of the operating surgeon."
3048357|NCT02238951|Experimental|Mobile Health (mHealth)|Care coordination using mHealth technology enhancements
3048358|NCT02238951|Active Comparator|No mHealth|Care coordination without mHealth enhancements
3078263|NCT02038673|Experimental|Dose escalation part 20.0 mg BID|Oral
3048359|NCT02238938|Experimental|en-bloc resection|En- bloc resection is done after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily. Since the aim of this method is the total resection basally and laterally, only one session is intended.
3048360|NCT02238938|Active Comparator|piecemeal resection|"Piecemeal resection will be done by snare following marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps. High resolution endoscopes are mandatory.~After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done. This second session can be done by sigmoidoscopy."
3048361|NCT02238925|Experimental|CPX-351|"Single Arm Study (Patients may receive up to 2 Inductions and 4 Consolidations):~Induction 1: CPX-351 will be given intravenously at 100units/m2 on days 1, 3, and 5 over a 90 minute infusion.~Induction 2: CPX-351 will be given intravenously at 100units/m2 on days 1 and 3 over a 90 minute infusion.~Consolidations 1-4: CPX-351 will be given intravenously at 65units/m2 on days 1 and 3 over a 90 minute infusion."
3048362|NCT02238912|Experimental|Kandhaga Rasayanam- single arm|Kandhaga Rasayanam- 2grams twice a day for 45 days
3048363|NCT02238886|Experimental|Parenteral nutrition|Patients receives a goal-directed nutritional intervention combining oral intake and parenteral nutrition
3048364|NCT02238886|No Intervention|Standard treatment|patients receives a standard nutritional strategy of resting the bowel till clear signs of bowel recovery and feeding orally after bowel recovery
3048365|NCT02238873|Active Comparator|Pegfilgrastim +1|Pegfilgrastim will be given 24 hours (day +1) after completion of salvage chemotherapy
3048366|NCT02238873|Experimental|Pegfilgrastim +3|Pegfilgrastim will be given 72 hours (day +3) after completion of salvage chemotherapy
3048367|NCT02238860|Active Comparator|Entacavir|Entacavir 0.5 mg (OD) for 48 weeks
3048368|NCT02238860|Active Comparator|Tenofovir|Tenofovir 300 mg ,OD for 48 weeks
3048369|NCT02238847|Active Comparator|WallFlex Biliary RX Fully Covered Stent System|"Patients in this group will receive a fully covered study SEMS (self-expanding metal stent)~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System"
3048370|NCT02238847|Active Comparator|WallFlex Biliary RX Uncovered Stent System|"Patients in this group will receive an uncovered study SEMS (self-expanding metal stent).~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System"
3048371|NCT02238834|Experimental|SAD Cohorts 1-8 Experimental Arm|
3048372|NCT02238834|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
3048373|NCT02238834|Experimental|MAD Cohorts 1 through 4 Experimental Arm|Note: The planned MAD portion of the study was not conducted. Evaluation of FP-025 MAD is being conducted under a separate protocol (Study No. FP02C-17-001).
3048374|NCT02238834|Placebo Comparator|MAD Cohorts 1 through 4 Placebo Arm|Note: The planned MAD portion of the study was not conducted. Evaluation of FP-025 MAD is being conducted under a separate protocol (Study No. FP02C-17-001).
3048375|NCT02238821||resectable colorectal cancer|
3048376|NCT02238808|Experimental|Estradiol treatment|Estradiol 6 mg daily for 7-14 days
3048377|NCT02238795||Purpura fulminans|Patients diagnosed with Purpura fulminans in association with sepsis
3048378|NCT02238782|Experimental|selumetinib 75mg single dose|3 capsules of 25 mg administered orally
3048379|NCT02238769||Hepatocellular Carcinoma|18F-FluoroethylCholine PET will show the difference between HCC lesions and normal liver tissue
3048380|NCT02238756|Experimental|CV8102|
3048381|NCT02238756|Active Comparator|Rabipur|
3048382|NCT02238756|Experimental|CV8102 + Rabipur|
3048383|NCT02238730|Active Comparator|Ultrabrief Right Unilateral|Ultrabrief (0.25 ms) Right Unilateral Electroconvulsive Therapy
3048384|NCT02238730|Active Comparator|Brief Pulse Bitemporal|Brief Pulse (0.5 ms) Bitemporal Electroconvulsive Therapy
3048385|NCT02238717|Experimental|PF-06372865 (65mg)|
3048386|NCT02238717|Experimental|PF-06372865 (15mg)|
3048387|NCT02238717|Active Comparator|Pregabalin|
3048388|NCT02238717|Placebo Comparator|Placebo|
3048389|NCT02238704|Experimental|Regimen A|500mg elemental calcium (as CaCO3) + 200 microgram Vit D per administration, administered 2 times a day, at least 2hours apart with one administration of 60mg elemental iron (as FeSO4) at any time of the day
3048390|NCT02238704|Active Comparator|Regimen B|500mg elemental calcium (as CaCO3) + 200 microgram Vit D per administration, administered 3 times a day, at least 2hours apart with one administration of 60mg elemental iron (as FeSO4) at any time of the day
3048391|NCT02238691|Experimental|Mask ventilation with PEEP|15 subjects will undergo anesthetic induction with application of PEEP of 10 cm H2O during mask ventilation.
3048392|NCT02238691|No Intervention|Mask ventilation without PEEP|15 subjects will undergo anesthetic induction without PEEP during mask ventilation.
3048393|NCT02238678||Deep endometriosis patients|
3048394|NCT02238665||Ulcerative colitis|
3048395|NCT02238665||Crohn's disease|
3048396|NCT02238652|No Intervention|Control|
3048397|NCT02238652|Active Comparator|Intervention|Communication Systematic Pain Assessment and Treatment Medication Review Occupational therapy Safety
3048398|NCT02238639|Experimental|Active search for pulmonary embolism|All included patients will undergo D-dimer testing. A negative plasma highly sensitive D-dimer value (defined as a D-dimer level below the manufacturers assay threshold) will rule out pulmonary embolism, and no further examination will be performed. For patients with a positive D-dimer value, a multidetector computed tomographic pulmonary angiography (MDCT) will be performed.
3048399|NCT02238639|No Intervention|Standard management|All included patients will undergo standard clinical management of their exacerbations, as deemed appropriate by the attending physician.
3048400|NCT02238626|Placebo Comparator|Placebo (for MN-166)|Sugar pill manufactured for MN-166 10 mg tablets
3048401|NCT02238626|Experimental|MN-166|MN-166 10 mg tablets (up to 60 mg/day) by mouth 2-3 times a day for 6 months
3048402|NCT02238613|Experimental|radioactive stent|The radioactive stent carrying seeds iodine 125 is made of Polytetrafluoroethylene. It will be implanted in the common bile duct by ERCP(endoscopic retrograde cholangiopancreatography) of the irradiation group patients.
3048403|NCT02238613|Other|plastic stent|The plastic stent is made of polyethylene. It will be implanted in the common bile duct by ERCP(endoscopic retrograde cholangiopancreatography) of the conventional group patients.
3048404|NCT02238587|Placebo Comparator|Placebo/Ganoderma|In control group, oral placebos for 6 weeks. Then the patients in control groups are switched, Ganoderma Spores Powder Capsules are given for 6 weeks. The data pertaining to their life quality are collected using Quality of Life Questionnaire after the first 6 weeks and the second 6 weeks. The immunity status is also studied at the same time.
3048405|NCT02238587|Experimental|Ganoderma|In experimental group, Ganoderma Spores Powder Capsules for 12 weeks. The data pertaining to their life quality are collected using Quality of Life Questionnaire after the first 6 weeks and the second 6 weeks. The immunity status is also studied at the same time.
3048406|NCT02238574|Experimental|follow up & surgery|CIN positive with surgery and intensified follow up
3048407|NCT02238574|Active Comparator|follow up|CIN positive, only intensified outpatient follow up
3048408|NCT02238561||Elective major abdominal surgery|Patients undergoing elective major open or laparoscopic abdominal surgery at Plymouth Hospitals National Health Service (NHS) Trust (PHNT)
3048409|NCT02238548|Placebo Comparator|Control group|Regular cholera vaccination
3048410|NCT02238548|Experimental|Milk bolus|Cholera vaccination - raw milk - bolus
3048411|NCT02238548|Experimental|Milk controlled|Cholera vaccination - raw milk - controlled intake
3048412|NCT02238535|Active Comparator|Ventavis + Warfarin|Patients in this group will receive drug treatment - ventavis (2,0 ml - 6 time per day - during 5 days). Warfarin - INR=2,0-3,0
3048413|NCT02238535|Active Comparator|Warfarin|Patients in this group will receive drug treatment according to up-to-date guidelines (Warfarin - INR=2,0-3,0)
3048414|NCT02238522|Experimental|Dose Escalation Stage - ZEN003365|ZEN003365 will be administered orally as a single agent, enrolling LPM patients and AML patients
3048415|NCT02238522|Experimental|Dose Expansion Stage - ZEN003365|ZEN003365 will be administered orally as a single agent, enrolling LPM patients and AML patients
3048416|NCT02238509|Experimental|lapatinib and trastuzumab|ARM A: Lapatinib and trastuzumab (experimental arm). Patients with hormone receptor (HR) positive breast cancer will also receive endocrine therapy at the physician's discretion (preferred choice with fulvestrant).
3048417|NCT02238509|Experimental|trastuzumab plus chemotherapy|ARM B: Trastuzumab plus chemotherapy (control arm). Any type of chemotherapy in combination with trastuzumab will be allowed at the physician's discretion.
3048418|NCT02238496|Other|ARM B|Cytoreductive surgery planned (surgical cohort). After post-operative standard evaluations, patients will resume therapy. After anti-emetic prophylaxis, patients will receive the first divided dose of the perifosine loading dose after recovery from surgery. Patients will be observed for at least 30 minutes to ensure there has been adequate anti-emetic prophylaxis, and then patients will receive temsirolimus administered over 30-60 minutes IV. The remaining divided doses of the perifosine loading dose will then be administered. Patients will then return weekly for infusion of temsirolimus over 30-60 minutes IV. Dosing will be continuous although for the purposes of evaluation, a cycle will be defined as 4 weeks (28 days).
3048419|NCT02238496|Other|ARM A|No-Cytoreductive surgery planned (medical cohort). After anti-emetic prophylaxis, patients will receive the first divided dose of the perifosine loading dose. Patients will be observed for at least 30 minutes to ensure there has been adequate anti-emetic prophylaxis, and then patients will receive temsirolimus administered over 30-60 minutes IV. The remaining divided doses of the perifosine loading dose will then be administered. Patients will then return weekly for infusion of temsirolimus over 30-60 minutes IV. Dosing will be continuous although for the purposes of evaluation, a cycle will be defined as 4 weeks (28 days).
3048420|NCT02238483|Experimental|AZD7624|Active treatment
3048421|NCT02238483|Placebo Comparator|Placebo|Placebo Comparator
3048422|NCT02238470||Oral anticoagulants|Patients who will receive oral anticoagulants indefinitely for the secondary prevention of cardioembolic stroke
3048423|NCT02238457|Active Comparator|Low dose losartan|Low dose losartan
3048424|NCT02238457|Active Comparator|High dose losartan|High dose losartan
3048425|NCT02238444|Experimental|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for one year irrespective of the occurrence of portal vein thrombus.
3048426|NCT02238444|Active Comparator|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for one year.
3048427|NCT02238431|Experimental|Lucrin depot, artificial cycle start|intramuscular administration of Lucrin depot (half dose of 3.75mg) on the 5th day following oocyte retrieval
3048428|NCT02238431|Active Comparator|OCP active, artificial cycle start|to take active OCP tablets (1 per day) from the 10th day following oocyte retrieval for at least 21 days
3048429|NCT02238431|Experimental|Natural, menstrual period|to wait for the second bleed to commence the artificial FET cycle
3048430|NCT02238418|Experimental|Usual vitamin D supplementation|
3048431|NCT02238405|Experimental|Counseling|Intensive anti-smoking counseling
3048432|NCT02238405|No Intervention|Standard Care|Control group will receive current standard of care.
3048433|NCT02238392|Active Comparator|Group A|Adenosine testing after PVI and elimination of dormant conduction
3048434|NCT02238392|Active Comparator|Group B - Termination of AF|Termination of atrial fibrillation by catheter ablation
3048435|NCT02238379|Experimental|Oxytocin|Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
3048436|NCT02238379|Placebo Comparator|Placebo|Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
3048437|NCT02238366||Prostate cancer patients|Patients recently diagnosed with prostate cancer requiring ADT.
3048438|NCT02238353|Experimental|azelastine + fluticasone|azelastine 137 µg + fluticasone 50 µg combined applied twice daily one puff in each nostril duration: 4 weeks
3048439|NCT02238353|Placebo Comparator|placebo|twice daily one puff in each nostril duration: 4 weeks
3048440|NCT02238340|Experimental|Extended-release oxycodone 10mgr|Extended-release oxycodone 10 mgrs , started 12 hours before orthopaedic surgery
3048441|NCT02238340|Experimental|Extended-release oxycodone 20 mgr|Extended-release oxycodone 20 mgr , started 12 hours before orthopaedic surgery
3048442|NCT02238327||HIV positive normal pulmonary function|HIV positive DLCO percent predicted >=.80 FEV1/FVC percent predicted >=0.70
3048443|NCT02238327||HIV positive with pulmonary dysfuntion|HIV positive DLco percent predicted <=0.80% FEV1/FVC percent predicted<=0.70%
3048444|NCT02238314|Experimental|Tipranavir low dose|
3048445|NCT02238314|Experimental|Tipranavir high dose|
3048446|NCT02238301|Other|"Patients test (pregnant women with a eutrophic fetus)"|Test the type of mask, oxygen flow and duration of oxygenation, adjustment of MRI machine Adjustment of MRI machine (choice of antenna calibration, verifying Settings of each sequence, adaptation of the number of cuts for the duration of each sequence, checking the correct execution of the succession of sequences, settings of total examination time)
3048447|NCT02238301|Active Comparator|Pregnant women with a diagnosis of IUGR fetuses|Measure of the BOLD effect in the feto-placental units of IUGR fetuses
3048448|NCT02238301|Active Comparator|Pregnant women with eutrophic fetuses|Measure of BOLD effects of fetal-placental unit eutrophic fetuses
3048449|NCT02238288|Active Comparator|aminocaproic acid|Crushed tablets inserted in the dental socket post-extraction
3048450|NCT02238288|Other|Routine care after dental extraction|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
3048451|NCT02238275||Patients with hypertension|
3048452|NCT02238262||essential hypertension patients|
3048453|NCT02238249||paediatric patients with urticaria|
3048454|NCT02238236||Patients with allergic rhinitis, eczema/dermatitis, urticaria|
3048455|NCT02238223||Patients without experience in treatment with epinastine|
3048456|NCT02238210|Experimental|Atrovent® - common cold group|Treatment duration for common cold group - three time daily for 4 days
3048457|NCT02238210|Experimental|Experimental: Atrovent® - allergy group|Treatment duration for allergy group - three time daily for 14 days
3048458|NCT02238197||Chronic Obstructive Pulmonary Disease|
3048459|NCT02238184||Chronic Obstructive Pulmonary Disease|patients receiving Atrovent®
3048460|NCT02238184||Cronic Obstructive Pulmonary Disease|patients receiving Ventilat®
3048461|NCT02238171||Chronic Obstructive Pulmonary Disease|
3048462|NCT02238158||Chronic Obstructive Pulmonary Disease|
3048463|NCT02238145||Chronic Obstructive Airways Disease|
3048464|NCT02238132||Chronic Obstructive Airways Disease|
3048465|NCT02238119|Experimental|tiotropium + formoterol|
3048466|NCT02238119|Active Comparator|tiotropium|
3048467|NCT02238119|Active Comparator|formoterol|
3048468|NCT02238106|Experimental|Salmeterol inhalation powder, medium dose|administered via HandiHaler®
3048469|NCT02238106|Active Comparator|Salmeterol inhalation powder, low dose|administered via HandiHaler®
3048470|NCT02238106|Active Comparator|Salmeterol inhalation powder, high dose|administered via HandiHaler®
3048471|NCT02238106|Active Comparator|Serevent® Diskus®|administered via Diskus®
3048472|NCT02238106|Placebo Comparator|Placebo|administered via Diskus® or HandiHaler®
3048473|NCT02238093||Dialysis Patients|End-stage renal disease patients undergoing dialysis at the Hillel Yaffe Medical Center.
3048474|NCT02238080||Methoxy Polyethylene Glycol-Epoetin Beta|Participants with anemia and CKD who are on dialysis therapy, and who initiate erythropoiesis-stimulating agent (ESA) treatment with methoxy polyethylene glycol-epoetin beta or who are on stable methoxy polyethylene glycol-epoetin beta maintenance therapy, will be treated according to the usual standard of care and current best practice guidelines, and will be observed during the study period.
3048475|NCT02238067||Chronic Renal Anemia Participants|Participants with CKD who are not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, will be interviewed by physician who will complete the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
3048476|NCT02238054||ABSORB BVS|All patients with a coronary angioplasty procedure and the implantation of at least one ABSORB BVS
3048477|NCT02238041||GlucoClear System|
3048478|NCT02238028|Experimental|Wear respirator|The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual. After a three-week interval, the two groups exchanged their roles in wearing the respirator or not. The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
3048479|NCT02238028|No Intervention|Not wear respirator|The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual. After a three-week interval, the two groups exchanged their roles in wearing the respirator or not. The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
3048480|NCT02238015||surgery group|patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
3048481|NCT02238015||control group|patients' other eye that did not have surgery
3048482|NCT02238002||normal angle|normal anterior chamber and open angle eyes underwent cataract surgery
3048483|NCT02238002||narrow angle|shallow anterior chamber and narrow angle eyes underwent cataract surgery
3048484|NCT02237989|Active Comparator|paracetamol|The 1st group includes 19 patients given 1500mg/day paracetamol for three months
3048485|NCT02237989|Experimental|native collagen type 2 + paracetamol|The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months
3048486|NCT02237976|Experimental|Self-hypnosis|Patients are trained to practice self-hypnosis wen they are listed for lung transplantation. They are encourage to practice it before and after transplantation.
3048488|NCT02237963||Posterolateral thoracotomy|Surgeons perform a posterolateral thoracotomy
3048489|NCT02237963||Axillary thoracotomy|Surgeons perform an axillary thoracotomy
3048490|NCT02237950|Experimental|1% SPL7013 Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
3048491|NCT02237950|Placebo Comparator|Placebo Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
3048492|NCT02237937|Experimental|Normal dosage|"Selected antidepressants that are substrates of the P-glycoprotein:~Dosage:~paroxetine < 40 mg/d~sertraline < 100 mg/d~citalopram < 40 mg/d~escitalopram < 20 mg/d~venlafaxine < 225 mg/d~amitriptyline < 150 mg/d~amitriptylinoxide < 150 mg/d~nortriptyline < 150 mg/d~trimipramine < 150 mg/d"
3048493|NCT02237937|Experimental|High dosage|"Selected antidepressants that are substrates of the P-glycoprotein:~Dosage:~paroxetine < 80 mg/d~sertraline < 200 mg/d~citalopram < 80 mg/d~escitalopram < 40 mg/d~venlafaxine < 450 mg/d~amitriptyline < 300 mg/d~amitriptylinoxide < 300 mg/d~nortriptyline < 300 mg/d~trimipramine < 300 mg/d"
3048494|NCT02237924|Experimental|endostar + IMRT|
3048495|NCT02237924|Active Comparator|DDP + IMRT|
3048496|NCT02237911|Experimental|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
3048497|NCT02237911|Active Comparator|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
3048498|NCT02237911|No Intervention|Waited-list usual medical care|Usual medical care
3048499|NCT02237898|Experimental|MoMba Contingency Management|Study will provide access to the web-based MoMba Live Long application & Sensodrone™ carbon-monoxide sensor for purposes of researching the acceptability of the smartphone application, operating and functioning of it, and providing remote contingency management for smoking cessation to postpartum women.
3048500|NCT02237898|Active Comparator|Office contingency management|Traditional contingency management with financial incentives delivered in-person in the office for smoking cessation to postpartum women
3048501|NCT02237885|Experimental|Neurofeedback|
3048502|NCT02237859|Experimental|Vancomycin|Vancomycin 125 mg PO QD vs Placebo
3048503|NCT02237846|Active Comparator|Intra-articular knee injection of UC-MSC|Human umbilical cord tissue-derived mesenchymal stem cells administered into the knee joint once
3048504|NCT02237846|Active Comparator|IV injection of UC-MSC|Human umbilical cord tissue-derived mesenchymal stem cells administered once per day for 3 consecutive days
3048505|NCT02237833||Septic shock and vasopressor|Measuring cerebral oxymetry (SCO2) first 24 hours in septic shock and given vasopressors.
3048506|NCT02237820|Experimental|Dexamethasone|
3048507|NCT02237820|Active Comparator|Prednisone|
3048508|NCT02237807|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
3048509|NCT02237807|Experimental|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
3048510|NCT02237794||Patients Without Acute Heart Conditions|Patients without acute heart conditions who were hospitalized for other medical indications.
3048511|NCT02237781|Experimental|AMH levels|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists. Levels of AMH will be measured prior and during the ovarian stimulation.
3048512|NCT02237768|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
3048513|NCT02237768|Experimental|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
3048514|NCT02237755|Active Comparator|Clomiphene citrate|Administration of Clomiphene citrate in combination with gonadotropins according to a short stimulation GnRH antagonists protocol.
3048515|NCT02237755|Active Comparator|Gonadotropins|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists.
3048516|NCT02237742|Experimental|PF-06427878|
3048517|NCT02237729|Experimental|PF-06410293|
3048518|NCT02237729|Active Comparator|Adalimumab-US|
3048519|NCT02237729|Active Comparator|Adalimumab-EU|Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose
3048520|NCT02237703||Post-traumatic stress disorder (PTSD)|Post-traumatic stress disorder (PTSD)
3048521|NCT02237703||Trauma Control (TC)|Trauma Control (TC)
3048522|NCT02237703||Healthy Control (HC)|Healthy Control (HC)
3048523|NCT02237690|Experimental|doxorubicin hydrochloride liposome（Libaoduo）|Use the test drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang ),then use the reference drug(doxorubicin hydrochloride liposome，from Sunpharma) after at least 4-weeks.
3048524|NCT02237690|Active Comparator|doxorubicin hydrochloride liposome|Use the reference drug(doxorubicin hydrochloride liposome，from Sunpharma),then use the test drug drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang) after at least 4-weeks.
3048525|NCT02237677||Post-traumatic stress disorder (PTSD)|Post-traumatic stress disorder (PTSD)
3048526|NCT02237677||Healthy Controls (HC)|Healthy Controls (HC)
3048527|NCT02237664|Active Comparator|Patient-controlled paravertebral analgesia (PC-PVB)|Patient-controlled paravertebral analgesia
3048528|NCT02237664|Placebo Comparator|Continuous paravertebral analgesia (C-PVB)|Continuous paravertebral analgesia
3048529|NCT02237651||topical anesthesia multi-use device|anesthesia with multi-use device (Laryngeal atomizer, Karl Storz, Tuttlingen, Germany
3048530|NCT02237651||topical anesthesia Intranasal Mucosal Atomization|single-use product (LMA® MAD Nasal™ Intranasal Mucosal Atomization Device, Teleflex medical, Kernen Germany) for topical anesthesia
3048564|NCT02237404|Experimental|Remote monitoring of pacemakers|"Telemedicine System:~Patients have not to go to the hospital to be monitorized"
3048531|NCT02237638|Experimental|hVEGF26-104/RFASE vaccination|hVEGF26-104/RFASE is investigated in dose escalation in which hVEGF26-104 is escalated from 62.5 ug to 500 ug and RFASE is given in a fixed dose of 20 mg. Three patients are treated at each dose level. If 0 of the 3 patients are observed to have DLT, the dose level is escalated one step for the next cohort. If 1 of the 3 patients shows DLT, 3 additional patients are treated at that dose level. If none of these show DLT, the dose level is escalated for the next cohort; otherwise, the prior dose level is defined as the MTD. At the highest dose level 6 patients will be treated. The recommended dose for a phase II trial will be the lowest dose that results in the most effective VEGF neutralization, together with acceptable safety and toxicity.
3048532|NCT02237625||Medical History of HPP Patients|Patient clinical data will be collected related to the diagnosis, onset, progression, treatment course and outcome for patients with HPP.
3048533|NCT02237612|Experimental|Diagnostic (diffusion-weighted MRI)|Patients undergo diffusion-weighted MRI of the pelvis.
3048534|NCT02237586|Experimental|Group IA|"Adults with naturally acquired immunity and HbAA (Group IA, n=10)~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge will be administered once intravenously. If 50% or less of volunteers become parasitemic in Groups IA or IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
3048535|NCT02237586|Experimental|Group IS|"Adults with naturally acquired immunity and HbAS (Group IS, n=10)~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge will be administered once intravenously. If 50% or less of volunteers become parasitemic in Groups IA or IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
3048536|NCT02237586|Experimental|Group NI|"Adults without previous exposure to malaria and HbAA (Group NI, n=5)~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge administered once intravenously should lead to consistent infection in naïve adults (15/15 in prior studies) and thus should infect all volunteers in Group NI. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
3048537|NCT02237573|Experimental|Intervention|Written medical report and standardized medical advices
3048538|NCT02237573|Active Comparator|Control|Standardized medical advice only
3048539|NCT02237560|Experimental|Cybercycle-Game|Combined aerobic & cognitive exercise for 6 months, 3-5x/week.
3048540|NCT02237560|Active Comparator|Cybercyle-Tour|Aerobic exercise only for 6 months, 3-5x/week.
3048541|NCT02237560|Active Comparator|Game Only|Cognitive exercise only 6 months, 3-5x/week.
3048542|NCT02237547|Experimental|IV and IT UC-MSC and BMMC|Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells
3048543|NCT02237534|Active Comparator|Calcium carbonate|Start at a dose of 1,500 mg/day, and adjust it to lower serum phosphate concentration <4.5 mg/dL. Maximum dose is 3,000 mg/day.
3048544|NCT02237534|Experimental|Lanthanum carbonate|Start at a dose of 750 mg/day, and adjust it to lower serum phosphate concentration <4.5 mg/dL. Maximum dose is 1,500 mg/day. For patients with calcium carbonate at inclusion, calcium carbonate will be replaced with lanthanum carbonate of 750 mg/day.
3048545|NCT02237521||End-stage renal disease|Patients with normal glucose tolerance and end-stage renal disease
3048546|NCT02237521||Controls|Healthy controls with normal kidney function and normal glucose tolerance
3048547|NCT02237508|Experimental|Z7200|single dose (two inhalations)
3048548|NCT02237508|Active Comparator|Symbicort Turbohaler|single dose (two inhalations)
3048549|NCT02237508|Experimental|Z7200 with charcoal|single dose (two inhalations)
3048550|NCT02237508|Active Comparator|Symbicort Turbohaler with charcoal|single dose (two inhalations)
3048551|NCT02237508|Active Comparator|Symbicort Turbohaler replicate|single dose (two inhalations)
3048552|NCT02237495|Placebo Comparator|Saline|Normal saline as placebo is continuously infused right after anesthesia induction and lasts for 12 hrs with the same infusion rate as the comparator dexmedetomidine
3048553|NCT02237495|Experimental|dexmedetomidine|dexmedetomidine intravenous infusion starts right after anesthesia induction in the operating room and last for 12 hours into ICU with a infusion dose of 0.4 ug/kg/h. To avoid potential cause of bradycardia, no dexmedetomidine bolus is given.
3048554|NCT02237482|Experimental|Small periacetabular bone defects|Patients with cup loosening and small periacetabular bone defects
3048555|NCT02237482|Experimental|Large periacetabular bone defects|Patients with cup loosening and large periacetabular bone defects
3048556|NCT02237469||Prone and supine simulation|Women with breast cancer receiving simulation in prone and in supine position for adjuvant radiation treatment.
3048557|NCT02237443|Other|Post-induction|Anesthesia is induced with propofol and mask ventilation is commenced after patient is unresponsive to a jaw thrust prior to administration of rocuronium, vecuronium bromide, or succinylcholine
3048558|NCT02237430|Active Comparator|Manuel compression|Conventional manual compression
3048559|NCT02237430|Experimental|MynxGrip closure device|Closure device for femoral artery access closure
3048560|NCT02237417|Other|Healthy Control|
3048561|NCT02237417|Active Comparator|Individuals with Schizophrenia (Group A)|
3048562|NCT02237417|Active Comparator|Individuals with Schizophrenia (Group B)|
3048563|NCT02237404|No Intervention|Hospital monitoring of pacemakers|Patients have to go to the hospital to be monitorized
3048565|NCT02237391|Experimental|CIPAP Program|Complex Interdisciplinary Pain Assessment Program
3048566|NCT02237391|Other|Treatment as Usual (TAU)|Treatment as usual control group
3048567|NCT02237378|Experimental|FDG PET scan|A PET scan using F-18 FDG, N-13 Ammonia will be performed
3048568|NCT02237365|Experimental|81mg aspirin|Aspirin 81mg daily for 60 days
3048569|NCT02237365|Experimental|1000mg aspirin|Aspirin 1000mg daily for 60 days
3048570|NCT02237365|Placebo Comparator|Placebo|Visually matched placebo daily for 60 days
3048571|NCT02237352||Control|Subjects without diabetic nephropathy
3048572|NCT02237352||Diabetic nephropathy|Subjects with diabetic nephropathy
3048573|NCT02237339|Active Comparator|Allopurinol|Patients treated with Allopurinol 300mg daily for first month then 300mg twice daily for remainder trial.
3048574|NCT02237339|Placebo Comparator|Placebo tablet|Microcrystalline cellulose one tablet daily for first month then twice daily for remainder of trial.
3048575|NCT02237326|Active Comparator|Visual Inspection with Lugol's Iodine|Participants underwent colposcopic exam, followed by Visual Inspection with Lugol's Iodine (VILI) by a second, blinded clinician (the order of exams was reversed to eliminate potential interference with exam results due to iodine staining). Biopsy was done after the VILI.
3048576|NCT02237326|Active Comparator|Visual Inspection with Acetic Acid|Participants underwent Visual Inspection with Acetic Acid followed by colposcopy by a second clinician who was blinded to the screening test result.
3048577|NCT02237313|Experimental|prevalent cases|"40 prevalent cases correspond to patients with known pemphigus. Emphasis will be on included patients at different times of the course of their disease.~8 incident cases recruited through the center of Rouen and following an intervention program with psychological support and therapeutic education program"
3048578|NCT02237300|Experimental|VR based cue-exposure therapy|Throughout the six sessions, participants (n=30) will be exposed to different VR environments related to binge behavior, according to a previously constructed hierarchy. During exposure, patients will face high risk situations to diminish or to extinguish the conditioned response of anxiety when exposed to food related cues. In each session, the patient will be exposed to the corresponding step of the hierarchy. During the exposure session, the patient can handle the virtual foods using the laptop's mouse but cannot eat the foods (exposure with response prevention). Exposure will end when the anxiety level decreased by 40% in relation to the level registered at the initiation of the exposure session or after 60 minutes of exposure.
3048579|NCT02237300|Active Comparator|Additional Cognitive-behavioral treatment|Participants (n=30) in this condition will receive six CBT booster sessions (two sessions per week) over the course of three weeks to improve the output of treatment. CBT sessions are based on the approach described by by Eldredge and colleagues (Eldredge et al.,1997). In this treatment program, patients are trained to self-monitor their food patterns and to identify and manage thoughts, emotions, and environmental factors related to disrupted eating behaviors.
3048580|NCT02237287|Sham Comparator|wound dressing with VAC|After wound debridement wounds are treated for 2 weeks with VAC dressing alone
3048581|NCT02237287|Other|wound dressing with VAC and sNAG under Antiaggregation|In patients being under antiaggregation with Aspirin® 100mg daily, after wound debridement wounds are treated with VAC and sNAG
3048582|NCT02237287|Experimental|wound dressing with VAC and sNAG without antiaggregation|In patients NOT being under antiaggregation, after wound debridement wounds are treated with VAC and sNAG
3048583|NCT02237274|Experimental|Patients with Fontan circulation|High altitude exposition
3048584|NCT02237274|Other|Age and gender-matched healthy volunteers|High altitude exposition
3048585|NCT02237261|Experimental|Bendamustine, Bortezomib, Prednisone|Induction: Bortezomib: 1.3 mg/m2 subcutaneous for 7 days and Bendamustine: 90 mg/m2 intravenous for 2 days and in addition Prednison: : 60 mg/m2 per os for 4 days Consolidation: Bortezomib: 1.3 mg/m2 subcutaneous for 4 days and Bendamustine: 90 mg/m2 intravenous for 2 days and in addition Prednison 60 mg/m2 per os for 4 days
3048586|NCT02237235|Experimental|MMFS-202 -302|"MMFS-202: evening dose~MMFS-302: morning dose"
3048587|NCT02237235|Placebo Comparator|Placebo|Placebo
3048588|NCT02237222||Gait rehabilitation|"Multi-modal therapy program including physiotherapy with the aim of gait improvement, Lokomat or treadmill training, strength training, sports therapy.~Frequency and intensity are individually assigned."
3048589|NCT02237209|Experimental|RSV LID ΔM2-2 Vaccine|Participants will receive one dose of the RSV LID ΔM2-2 vaccine at study entry, delivered as nose drops.
3048590|NCT02237209|Placebo Comparator|Placebo Vaccine|Participants will receive one dose of placebo at study entry, delivered as nose drops.
3048591|NCT02237196|Experimental|AMG 157+Cat Immunotherapy|"AMG 157 will be administered every four weeks.~Cat immunotherapy will be administered weekly."
3048592|NCT02237196|Active Comparator|AMG 157 Placebo+Cat Immunotherapy|"Placebo for AMG 157 of similar appearance will be administered every four weeks.~Cat immunotherapy will be administered weekly."
3048593|NCT02237196|Experimental|AMG 157+Cat Immunotherapy Placebo|"AMG 157 will be administered every four weeks.~Placebo for Cat immunotherapy will be administered weekly."
3048594|NCT02237196|Placebo Comparator|Placebo-Placebo|"Placebo for AMG 157 will be administered every four weeks.~Placebo for cat immunotherapy will be administered weekly."
3048595|NCT02237183|Experimental|Arm I (iloprost QID)|Patients receive iloprost via inhalation using a nebulizer QID for 60 days.
3048596|NCT02237183|Placebo Comparator|Arm II (placebo QID)|Patients receive placebo via inhalation using a nebulizer QID for 60 days.
3048597|NCT02237183|Experimental|Arm III (iloprost BID)|Patients receive iloprost via inhalation using a nebulizer BID for 60 days.
3048598|NCT02237183|Placebo Comparator|Arm IV (placebo BID)|Patients receive placebo via inhalation using a nebulizer BID for 60 days.
3048599|NCT02237170||Castration Resistant Metastatic Prostate Cancer|Castration Resistant Metastatic Prostate Cancer with no history of prior systemic chemotherapy
3048600|NCT02237157|Other|Gemcitabine, Local Delivery|Gemcitabine; 4 cycles, two doses per cycle; dose escalation
3048601|NCT02237144|Experimental|Cash transfer|1500 taka ($18.75) per household distributed monthly
3048602|NCT02237144|Experimental|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
3048603|NCT02237144|Experimental|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
3048740|NCT02236247|Experimental|ivabradine|I(f) inhibitor, heart rate controller
3048604|NCT02237144|Experimental|Cash transfer + BCC|1500 taka ($18.75) per household distributed monthly Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
3048605|NCT02237144|Experimental|Food transfer + BCC|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
3048606|NCT02237131|Experimental|Oral contraceptives cyclic|Oral contraceptives containing 0.03 mg ethinyl estradiol and 3mg drospirenone will be administered. One tablet a day for 21 days followed by 7 days pill free. The regimen will be repeated for the duration of the trial.
3048607|NCT02237131|Active Comparator|Oral contraceptives continuous|Oral contraceptives containing 0.030 mg ethinyl estradiol and 3mg drospirenone will be administered. One tablet a day for the duration of the trial.
3048608|NCT02237118|Active Comparator|Mepitel One|Pain on dressing removal, by VAS
3048609|NCT02237118|Active Comparator|UrgoTul|Pain on removal by VAS
3048610|NCT02237105|Experimental|Cognitive Behavioral Therapy Group|This group will undergo Cognitive Behavioral Therapy (CBT) before having spinal surgery
3048611|NCT02237105|No Intervention|control group|This group will not undergo any psychological intervention before the spinal surgery.
3048612|NCT02237092|Experimental|Measurement of IAP|The data obtained are in inches of water column were translated in millimeters of mercury.
3048613|NCT02237079|Experimental|Bazedoxifene/Conjugated Estrogens (BZA/CE)|"Participants assigned to BZA/CE will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg. BZA/CE (bazedoxifene/conjugated estrogens) tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with 0.45/20 in black ink on one side. The recommended and only FDA approved dosage is one BZA/CE tablet daily, taken without regard to meals. Tablets should be swallowed whole. If a dose of BZA/CE is missed, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications."
3048614|NCT02237079|Placebo Comparator|Placebo|"Participants assigned to placebo will receive a daily tablet that matches the BZA/CE to maintain the blind. Placebo tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with 0.45/20 in black ink on one side. Also to assure the blind is maintain, participants in the placebo group will be given the same instructions for taking the study medication.Tablets should be swallowed whole. If a dose, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications, again to maintain the blind."
3048615|NCT02237066|Experimental|Chocolate PTA Balloon|Chocolate PTA Balloon Angioplasty
3048616|NCT02237066|Active Comparator|Standard PTA Balloon|Standard PTA Balloon Angioplasty
3048617|NCT02237053|Active Comparator|Glucagon with Octreotide and insulin|Overnight (10 hours) infusion of glucagon, then 3 hours infusion of glucagon with concurrent infusions of Octreotide and insulin.
3048618|NCT02237053|Placebo Comparator|Placebo, Glucagon with Octreotide and Insulin|Overnight (10 hours) infusion of saline, then 3 hour infusion of glucagon with concurrent infusions of Octreotide and insulin.
3048619|NCT02237053|Placebo Comparator|Placebo, with Octreotide and insulin|Overnight (10 hours) infusion of saline, then 3 hour infusion of saline with concurrent infusions of Octreotide and insulin.
3048620|NCT02237040|Experimental|treatment group|Patients are treated with the mandibular manipulation technique termly and mouth opening training
3048621|NCT02237027|Experimental|TasP group|HIV positive female sex workers receiving TasP using ART regimen as per Benin guidelines
3048622|NCT02237027|Experimental|PrEP group|HIV negative female sex workers receiving PrEP using Truvada
3048623|NCT02237001|Experimental|Treatment|Suture-based meniscal repair
3048624|NCT02236988|Experimental|Formulation of apremilast + test formulations 1, 2, and 3|A single oral 60 mg reference formulation of apremilast, given as 30 mg twice a day (BID), and single oral doses of 75 mg of each test formulation numbers 1, 2, and 3 given in 4 possible sequences (ADBC, BACD, CBDA, and DCAB). Each subject will be randomly assigned to a sequence which will determine the order in which each formulation is given. There will be at least 7, and not more than 10 days between each dose
3048625|NCT02236988|Experimental|Formulation of apremilast + test formulations 4, 5, and 6|A single oral 60 mg reference formulation (given as 30 mg twice a day),and single oral doses of 75 mg of each test formulation #s 4, 5, and 6 given in 4 possible sequences (AGEF, EAFG, FEGA, and GFAE). Each subject will be randomly assigned to a sequence which will determine the order in which each formulation is given. There will be at least 7, and not more than 10 days between each dose. If only 2 test formulations are available, there will be 6 possible sequences (AEF, EFA, FAE, AFE, EAF, FEA).
3048626|NCT02236988|Experimental|Formulation of apremilast + test formulations: 7 and 8|A single oral 60 mg reference formulation (given as 30 mg twice a day),and single oral doses of 75 mg of each test formulation #s 7 and 8 given in 6 possible sequences (AHI, HIA, IAH, AIH, HAI, and IHA). Each subject will be randomly assigned to a sequence which will determine the order in which each formulation is given. If only 1 test formulation is available, there will be 2 possible sequences (AH and HA).
3048627|NCT02236988|Experimental|Formulation of Apremilast + test formulations: 11, 12, 13, 14|A single oral 60 mg reference formulation (given as 30 mg twice a day),and single oral doses of 75 mg of each test formulation #s 11, 12, 13, and 14 given in 10 possible sequences (ALOMN, LMANO, MNLOA,NOMAL, OANLM, NMOLA, ONAML, AOLNM, LAMON, and MLNAO). Each subject will be randomly assigned to a sequence which will determine the order in which each formulation is given. There will be at least 7, and not more than 10 days between each dose.
3048628|NCT02236975|Experimental|BuMA Supreme Biodegradable drug coating coronary stent system|Implant BuMA Supreme stent only
3048629|NCT02236975|Active Comparator|Resolute Integrity durable polymer stent system|Implant Resolute stent
3048630|NCT02236962|Placebo Comparator|Placebo|lactose powder in equivalent capsule
3048631|NCT02236962|Experimental|Drug treatment|sympathetic agonist and thiazolidinedione
3048670|NCT02236689|Active Comparator|Arthroscopic tennis elbow release|This group will have arthroscopic tennis elbow release through a standard, two-portal technique,
3048632|NCT02236949|Experimental|Pain Practice Change Booster|Pain Practice Change Booster Intervention: 12 months after the EPIQ intervention, and every 4 months for 2 years, a 30-60 minute standardized booster session was delivered to a small group of champions in each hospital unit randomized to the intervention group. Two co-facilitators familiar with the EPIQ intervention conducted all booster sessions via teleconference. Booster sessions included reviewing the effectiveness knowledge translation strategies champions implemented over the past four months to sustain and improve targeted pain practices; determining the sustainability of the pain practice changes, developing a commitment to change plan of action for the next four months.
3048633|NCT02236949|No Intervention|Usual Care Group|No interventions associated with the study were conducted on these units.
3048634|NCT02236936|Active Comparator|Arm A - Standard of care|"Standard care of parenteral nutrition (with or without parenteral nutrition during radio-chemotherapy or radio-immunotherapy in combination with Cetuximab or Cisplatin.~Concomitant radiotherapy and immunotherapy (radio-immunotherapy) with Cetuximab or concomitant radiotherapy and chemotherapy (radio-chemotherapy) with Cisplatin"
3048635|NCT02236936|Experimental|Arm B - Parenteral over night nutrition|"Parenteral over night nutrition with ZentroOLIMEL 5.7% parenteral over night with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) 15 ml/kg body weight/day (weight loss >5% from baseline; parenteral nutrition increased up to 25 ml/kg body weight per day) during radio-chemotherapy or radio-immunotherapy in combination with Cetuximab or Cisplatin.~Concomitant radiotherapy and immunotherapy (radio-immunotherapy) with Cetuximab or concomitant radiotherapy and chemotherapy (radio-chemotherapy) with Cisplatin"
3048636|NCT02236923||Group A: Single procedure|Group A consists of patients recorded as having only had an ascending aortic dissection repair procedure.
3048637|NCT02236923||Group B: Multiple procedures|Group B consists of patients who had an ascending aortic dissection repair procedure together with any other surgical intervention.
3048638|NCT02236910|Experimental|Primary Therapy with Lu-DOTA-TATE|Lu-DOTA-TATE (Lutetium-177 Octreotate) will be administered by intravenous infusion to participants who have not been previously treated with Lu-DOTA-TATE
3048639|NCT02236910|Experimental|Secondary Therapy with Lu-DOTA-TATE|Patients who have received previous treatment with Lu-DOTA-TATE (Lutetium-177 Octreotate) under the special access program are eligible to be treated in this study. Patients will receive Lu-DOTA-TATE by intravenous infusion.
3048640|NCT02236897|Experimental|PET Scanning|Imaging of mGluR5 using PET scanning
3048641|NCT02236884|Experimental|no-scar transanal TME|no-scar transanal total mesorectal excision(TME) of rectal cancer
3048642|NCT02236871|No Intervention|Control|Maintain current milk and milk product intakes.
3048643|NCT02236871|Active Comparator|2 servings|Participants will be asked to consume 1 milk (250 ml) plus a yogurt (100-175 g) or cheese (up to 50 g) to reach an average of 2 servings of milk or milk products/d.
3048644|NCT02236871|Active Comparator|4 servings|Participants will be asked to consume recommended servings of milk or milk products/d for their age, so they will receive 1 milk (250 ml), a yogurt (175 g) and cheese (50 g) or more. This would provide ≥ 3 servings/d.
3048645|NCT02236858|Sham Comparator|Sham HEPA Air Cleaner|Sham HEPA Air Cleaner and Delayed Intervention. Homes in the control group will receive sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
3048646|NCT02236858|Active Comparator|HEPA Air Cleaner|HEPA Air Cleaner also containing carbon filters (Austin HealthMate HM400) and capable of removing PM and NO2 will be placed in the bedroom and room where the participant reports spending the most time. These air cleaners are suitably sized to provide clean air delivery rates for the rooms in which they will be placed. Participants will be instructed to run the air cleaners continually during the course of the study and the units will be modified to prevent them from being turned off by the participants.
3048647|NCT02236845|Experimental|Lacrima medical active device|
3048648|NCT02236845|Sham Comparator|Lacrima medical sham device|
3048649|NCT02236832|Experimental|FTD (frontotemporal dementia) patients|fronto-temporal demential patients
3048650|NCT02236832|Experimental|PSP patients|progressive supra nuclear palsy patients
3048651|NCT02236832|Active Comparator|healthy controls|healthy control education matched, age matched and sex matched with PSP and FTD patients
3048652|NCT02236832|Experimental|healthy participants|healthy participants that will participate to the TMS study.
3048653|NCT02236832|Experimental|healthy young participants|Healthy participants will be included for an EEG study
3048654|NCT02236806|Experimental|Arm 1|bisoprolol plus ramipril
3048655|NCT02236806|Active Comparator|Arm 2|Bisoprolol plus placebo
3048656|NCT02236806|Active Comparator|Arm 3|Ramipril plus placebo
3048657|NCT02236806|Placebo Comparator|Arm 4|Placebo
3048658|NCT02236793|Experimental|BioChaperone PDGF-BB|BioChaperone PDGF-BB administered every other day at the dose of 4µg/cm² for 20 weeks or until wound closure, associated with Standard of Care
3048659|NCT02236793|Placebo Comparator|Standard of Care|Normal saline solution applied every other day at the same volume for up to 20 weeks, associated with standard wound care
3048660|NCT02236767|Experimental|rTMS Treatment|NeuroStar Transcranial Magnetic Stimulation Therapy System
3048661|NCT02236754|Other|Healthy Controls|Pancreatic 18F-FP-DTBZ uptake will be measured with PET scanning in healthy controls: subjects with predicted normal BCM (healthy, normal weight, non-diabetic individuals who have stimulated insulin and c-peptide levels within the normal range).
3048662|NCT02236754|Other|Patients with T1D|Pancreatic 18F-FP-DTBZ uptake will be measured with PET scanning in patients with longstanding T1D: subjects with predicted reduced beta cell mass (subjects with established T1DM who have low or no measurable stimulated insulin and c-peptide levels).
3048663|NCT02236741||users of anti-parkinsonian drugs|
3048664|NCT02236728||Parkinson's disease patients|
3048665|NCT02236715||Chronic Obstructive Airways Disease|
3048666|NCT02236702||Asymptomatic control|Asymptomatic control
3048667|NCT02236702||Mildly symptomatic with depressive symptoms|Mildly symptomatic with depressive symptoms
3048668|NCT02236702||Moderately symptomatic with depressive symptoms|Moderately symptomatic with depressive symptoms
3048669|NCT02236702||Severely symptomatic with depressive symptoms|Severely symptomatic with depressive symptoms
3048671|NCT02236689|Placebo Comparator|Non Operative|control group will not undergo a second portal or muscle release.
3048672|NCT02236663|Experimental|App Based Safety Decision Aid|Personalized App-Based Safety Decision Aid
3048673|NCT02236663|Active Comparator|Control App|Usual Care Safety Plan
3048674|NCT02236650|Experimental|Primary Care Stepping Stones Triple P|Primary Care Stepping Stones Triple P program (PC-SS Triple P) - a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
3048675|NCT02236650|Active Comparator|Wait List Control (WLC)|Wait List Control - Participants who will have access to treatment as usual services during the 4 weeks between baseline and 4 week assessment time points and then will have the opportunity to receive PC-SS Triple P.
3048676|NCT02236637||mCRPC patients|Patients with metastatic castration-resistant prostate cancer treated according to routine clinical practice
3048677|NCT02236624|Experimental|Aerobic Exercise|
3048678|NCT02236611|Experimental|Umeclidinium 62.5 mcg|Randomized subjects will receive umeclidinium inhalation powder 62.5 mcg, once daily over a period of 12 weeks via a nDPI. Subjects will be instructed to take one dose each morning.
3048679|NCT02236611|Experimental|Glycopyrronium 44 mcg|Randomized subjects will receive glycopyrronium 44 mcg, once daily over a period of 12 weeks via a BREEZHALER inhaler. Subjects will be instructed to take one dose each morning.
3048680|NCT02236598|Experimental|K+ supplementation|K-supplement- Klor-Con® M10 is an immediately dispersing extended-release oral dosage form of potassium chloride containing 750 mg of microencapsulated potassium chloride, United States Pharmacopeia (USP) equivalent to 10 milliequivalent (mEq) of potassium in a tablet. Participants will be instructed to take two 10 mEq tablets twice daily in a blinded encapsulated form, for 3 months
3048681|NCT02236598|Experimental|Placebo|"Placebo - An inert powdered placebo will be identically encapsulated as the Klor-Con intervention tablets to maintain blinding. Participants will be instructed to take two tablets twice daily in a blinded encapsulated form, for 3 months~Subjects will be instructed to take the pills"
3048682|NCT02236585|Active Comparator|Patient-controlled epidural analgesia|Patient-controlled epidural analgesia
3048683|NCT02236585|Placebo Comparator|Continuous epidural analgesia|Continuous epidural analgesia
3048684|NCT02236572|Experimental|Aromatase Inhibitor plus Everolimus|Aromatase inhibitor plus everolimus by mouth daily for 26 weeks
3048685|NCT02236559|Active Comparator|Noninvasive positive pressure ventilation|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 > 88%."
3048686|NCT02236559|Experimental|High flow therapy|"Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 > 88%."
3048687|NCT02236546|Experimental|FDG-PET/CT|Patients undergo [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) up to 2 weeks prior to first dose of therapy, after completion of the first treatment course (day 21), and after completion of the fourth treatment course (day 84). Molecular assays on biopsied tissue obtained from a subset of patients will also undergo molecular assays, the results from which will be correlated with FDG-PET/CT data.
3048688|NCT02236533|Placebo Comparator|Control pasta|Volunteers were fed with control pasta, without B-glucans and spores of B. coagulans once a day for 12 weeks.
3048689|NCT02236533|Experimental|Probiotic Whole Grain Pasta|Volunteers were fed with probiotic fortified pasta, including B-glucans and spores of B. coagulans once a day for 12 weeks.
3048690|NCT02236520|Active Comparator|Spironolactone|50 mg capsule of Spironolactone administered orally 1 per day for 8 weeks
3048691|NCT02236520|Active Comparator|Chlorthalidone|25 mg capsule of Chlorthalidone administered orally 1 per day for 8 weeks
3048692|NCT02236520|Active Comparator|Diet|diet of 6 g salt per day for 8 weeks
3048693|NCT02236520|Placebo Comparator|Placebo|placebo capsule administered orally 1 per day for 8 weeks
3048694|NCT02236507|Other|children without anorectal disorders|All children will be investigated by 3D high resolution anorectal manometry procedure
3048695|NCT02236494|Active Comparator|General Health Information Pamphlet|This group will not receive a brief intervention in the ED. They will receive a pamphlet with general health information for older adults, as well as contact information for an outpatient alcohol treatment center where they have the option to follow-up for alcohol treatment at their discretion. The patient's readiness to change their alcohol habits will be measured using a 1-10 scale with a visual cue.
3048696|NCT02236494|Experimental|Brief Negotiated Interview|The BNI will follow standard steps (7, 63): 1. The research assistant (RA) will ask permission to discuss the patient's alcohol use with them. 2. They will provide feedback regarding the patient's alcohol use, and will review guidelines drinking in older adults. Where relevant, the RA will discuss how the patient's current visit may relate to their alcohol use. 3. The RA will assess the patient's readiness to change using a 1-10 scale, and will enhance motivation. 4. The RA will negotiate a goal for the patient's drinking and give advice. The patient will be asked to sign a drinking agreement.
3048697|NCT02236481|Experimental|Anakinra|100 mg of anakinra once daily by subcutaneous injection for 24 months
3048698|NCT02236481|Active Comparator|TNF alpha inhibitors|treatment with TNF-alpha inhibitors according to the relative summary of product charateristics
3048739|NCT02236260|Experimental|Local Anesthesia + Electroacupuncture|
3048699|NCT02236468|Experimental|new EHFP|Group newly participating in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
3048700|NCT02236468|Experimental|old EHFP+WASH|Group participating in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010 + WASH/malaria behavior change communication since 2014
3048701|NCT02236468|Other|new EHFP+WASH|Group newly participating in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014 + WASH/malaria behavior change communication since 2014
3048702|NCT02236468|Other|old EHFP+WASH+LNS distribution|Group participating in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010 + WASH/malaria behavior change communication and distribution of LNS since 2014
3048703|NCT02236455|Experimental|Audio Relaxation technique|Relaxation is a process that decreases the effects of stress on your mind and body. Relaxation techniques can help you cope with everyday stress and with stress related to various health problems, such as cancer and pain.
3048704|NCT02236455|Experimental|Medical Music Intervention|Music intervention is use to assist with relaxation and reduce stress levels in patients.
3048705|NCT02236455|Experimental|Nature Therapy without Music|Ecotherapy is the use of nature to reduce stress and to increase levels of well-being in patients.
3048706|NCT02236455|Experimental|Nature Therapy with Music|Nature therapy videos were produced with and without music for surgical patients.
3048707|NCT02236442|No Intervention|Usual care|First arm : Passive recording head pain, linked symptoms, treatment used and diagnosis.
3048708|NCT02236442|Experimental|After protocol recommendation care|Recording head pain, linked symptoms, treatment used and diagnosis after intervention that is recommendation to use global headache treatment protocol
3048709|NCT02236429|Experimental|recurrent bacterial vaginitis|
3048710|NCT02236416|Experimental|Intervention group|Physical exercise
3048711|NCT02236416|Other|Control group|Posture Education/Unchanged condition
3048712|NCT02236403|Experimental|Ivermectin 0.1% Metronidazole 1%|30 patients will receive the treatment and at 15 days a second visit will be done and changes in mite counts will be determinated and correlated with symtoms and signs.
3048713|NCT02236403|Placebo Comparator|Control|30 volunters with no signs of blepharitis and with eyelashes with no demodex .None intervention. Symptoms and signs will be compared with experimental group
3048714|NCT02236390|Active Comparator|Cognitive Processing Therapy-Cognitive|12 sessions of cognitive processing therapy-Cognitive
3048715|NCT02236390|Active Comparator|ERRT + CPT-C|5 sessions of Exposure, Relaxation, and Rescripting Therapy, followed by 12 sessions of Cognitive Processing Therapy- Cognitive
3048716|NCT02236390|Active Comparator|CPT-C + ERRT|12 sessions of Cognitive Processing Therapy - Cognitive, followed by 5 sessions of Exposure, Relaxation, and Rescripting Therapy
3048717|NCT02236377|Active Comparator|ERRT - Enhanced Exposure|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with enhanced exposure techniques
3048718|NCT02236377|Active Comparator|ERRT - Sleep and Relaxation|Exposure, Relaxation, and Rescripting Therapy protocol, 5 sessions, focused on sleep and relaxation
3048719|NCT02236377|Active Comparator|ERRT-Rescription|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with rescription but no exposure
3048720|NCT02236377|Active Comparator|ERRT-Sleep|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with enhanced sleep techniques
3048721|NCT02236364|Experimental|New device for OPTICAL determination of blood glucose level|
3048722|NCT02236351|Placebo Comparator|Control|Patients assigned to the Control Arm will be taught to apply their patches using the standard technique -- applying the patch evenly and flatly around the orbit.
3048723|NCT02236351|Experimental|Pinched Patch|Patients assigned to the Pinched Patch Arm will be taught to apply their patches after pinching the middle of the superior and inferior edges of the patch so that the patch is convex and the center is raised above the eye.
3048724|NCT02236338|Active Comparator|Radiofrequency Ablation|"Device: ClosureFAST radiofrequency catheter (VNUS Medical Technologies Inc, San Jose, CA).~Patients will have the intervention, ablation of the incompetent greater saphenous vein, using this device."
3048725|NCT02236338|Active Comparator|Laser Ablation|"Device: EVLT 980nm diode laser system (Angiodynamics, Queensbury, NY).~Patients will have the intervention, ablation of the incompetent greater saphenous vein, using this device."
3048726|NCT02236325|Experimental|DBT Brief Suicide Intervention|
3048727|NCT02236325|Active Comparator|Relaxation Training|
3048728|NCT02236312|Experimental|Botulinum Toxin 30 units|I.M. injection
3048729|NCT02236312|Experimental|Botulinum Toxin 45 units|I.M. injection
3048730|NCT02236312|Experimental|Botulinum Toxin 60 units|I.M. injection
3048731|NCT02236312|Placebo Comparator|Placebo|I.M. injection
3048732|NCT02236299|Placebo Comparator|saline placebo infusion|30 minute infusion of a saline placebo Right coronary artery percutaneous coronary intervention
3048733|NCT02236299|Experimental|GLP-1 infusion|30 minute infusion of GLP-1 Right coronary artery percutaneous coronary intervention
3048734|NCT02236286|Experimental|Exercise|Subjects will participate in a 90-minute, group (6 per group) exercise session 3 days per week for 6 weeks (18 sessions). The theoretical basis for our novel Agility Boot Camp (ABC) exercise program is based on research that identified the primary neurophysiological and cognitive constraints that limits balance and mobility in PD. The exercises are designed as a circuit with several types of movement-skills specifically focused on improving different postural domains with cognitive challenges such as memorized sequences and dual tasking.
3048735|NCT02236286|Active Comparator|Chronic Disease Management Education|Subjects will also receive (cross-over) six weeks of educational classes. The Education program will teach subjects, chronic disease self-management - how to live better with their parkinsonism. Classes will consist of 6 subjects per group meeting for 90 minute sessions, once a week for six weeks. Subject will do an additional 120 minutes of relaxation at home/week.
3048736|NCT02236273|Experimental|Conventional Text Message|Conventional text message reminder
3048737|NCT02236273|Experimental|Enhanced reminders|Enhanced text message reminders
3048738|NCT02236260|Active Comparator|Local anesthesia alone|
3048741|NCT02236247|Placebo Comparator|placebo|placebo pill will be administered orally twice daily
3048742|NCT02236234|Experimental|Vaccine|one group with HPV vaccine
3048743|NCT02236195|Experimental|Mocetinostat|Mocetinostat (MGCD0103) oral capsules three times weekly, 70 mg doses in first month, with increase to 90 mg doses if tolerated
3048744|NCT02236182|Experimental|Ipratropium Bromide low|delivered via RESPIMAT®
3048745|NCT02236182|Experimental|Ipratropium Bromide high|delivered via RESPIMAT®
3048746|NCT02236182|Placebo Comparator|Placebo|delivered via RESPIMAT®
3048747|NCT02236169|Experimental|Ipratropium bromide|
3048748|NCT02236169|Active Comparator|ATROVENT|
3048749|NCT02236156|Experimental|1% SPL7013 Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
3048750|NCT02236156|Placebo Comparator|Placebo Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
3048751|NCT02236143||MRI|Subjects undergoing MRI
3048752|NCT02236130|Active Comparator|General|General Anesthesia only
3048753|NCT02236130|Experimental|Regional|General Anesthesia combined with regional block
3048754|NCT02236117|Experimental|Intervention: Aerobic Training|The children included in the experimental group will make 10 weeks of aerobic training. The intensity of the race will be based on individual speed obtained in the last stage completed the progressive test, known as the maximal aerobic speed (MAV) in km/h. The running speed of the exercise protocol will be minimum 80% of the MAV in the protocol of continuous training. The intermittent progressive training is n * (10*15 s) to 100% MAV, and n from 2 to 6 series between the first and tenth week. The training protocol was adapted from previously described (Mandigout et al, 2002, Gamelin et al, 2009.). Acceptance of the exercise in a pediatric population has been previously observed by pilot study.
3048755|NCT02236117|No Intervention|physical education classes|
3048756|NCT02236104|Experimental|cough assist session|Mechanical insufflation-exsufflation contains 15 cycles durea 2-3 seconds. pressure level fixed +/-30 cm H2O.
3048757|NCT02236091||Inpatients|
3048758|NCT02236078|Experimental|CAP-susceptible/KAN-resistant|Capreomycin 1 gm to be administered intramuscularly daily for 10 days
3048759|NCT02236078|Experimental|High dose isoniazid|INH 900 mg daily to be administered orally for 10 days
3048760|NCT02236078|Experimental|rpoB mutant/Rifampicin-susceptible|Rifampin 600 mg daily to be administered orally for 10 days
3048761|NCT02236078|Experimental|RBT-susceptible/RMP-resistant|Rifabutin 300 mg daily to be administered orally for 10 days
3048762|NCT02236078|Experimental|MOX-susceptible/OFL-resistant|Moxifloxacin 400 mg daily to be administered orally for 6 days
3048763|NCT02236065|Experimental|UCB + G-CSF|UCB + G-CSF
3048764|NCT02236052|Experimental|Non-adjuvanted low dose of quadrivalent VLP vaccine|A single non-adjuvanted low dose of quadrivalent VLP vaccine
3048765|NCT02236052|Experimental|Non-adjuvanted medium dose of quadrivalent VLP vaccine|A single non-adjuvanted medium dose of quadrivalent VLP vaccine
3048766|NCT02236052|Experimental|Non-adjuvanted high dose of quadrivalent VLP vaccine|A single non-adjuvanted high dose of quadrivalent VLP vaccine
3048767|NCT02236052|Experimental|Adjuvanted low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
3048768|NCT02236052|Experimental|Adjuvanted high dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
3048769|NCT02236052|Placebo Comparator|Placebo|A single dose of Placebo
3048770|NCT02236039|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by a bronchoscopy 24 hours post exposure.
3048771|NCT02236039|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by a bronchoscopy 24 hours post exposure.
3048772|NCT02236026|Experimental|Supratherapeutic dose of Nestorone|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
3048773|NCT02236026|Placebo Comparator|Placebo|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
3048774|NCT02236026|Experimental|Moxifloxacin|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
3048775|NCT02236013|Experimental|ASP2215 Dose Escalation (Part 1)|Successive dose escalation cohorts will determine the maximum tolerated dose (MTD)
3048776|NCT02236013|Experimental|ASP2215 Dose Expansion (Part 2)|Once the MTD has been established in Part 1, up to 20 subjects will be enrolled into an expansion cohort
3048777|NCT02236013|Experimental|Alternative Anthracycline and Schedule (Part 3)|In Part 3, two cohorts will be enrolled to evaluate an alternative anthracycline and ASP2215 schedule
3048778|NCT02236000|Experimental|Neratinib and T-DM1|
3048779|NCT02235987|Other|Octreotide, then ascending DG3173|Interventions: octreotide and DG3173. Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
3048780|NCT02235974|Experimental|Acute/Early|Intervention: A 20-hour dose of early intensive upper extremity motor training therapy will be initiated within 30 days post-stroke.
3048781|NCT02235974|Experimental|Sub-acute/Outpatient|Intervention: A 20-hour dose of sub-acute intensive upper extremity motor training therapy will be initiated within 2 to 3 months post-stroke.
3048782|NCT02235974|Experimental|Chronic|Intervention: A 20-hour dose of chronic intensive upper extremity motor training therapy will be initiated 6 to 9 months post-stroke
3048783|NCT02235974|Placebo Comparator|Control|Intervention: Usual and customary care. No additional therapy will be initiated during the 1-year study.
3048784|NCT02235961|Experimental|Part 1|
3048785|NCT02235961|Experimental|Part 2|
3048786|NCT02235948|Experimental|folic acid|folic acid supplementation placebo controlled
3048787|NCT02235935||diabetic patients, hyperbaric chamber, diabetic retinopathy|
3048788|NCT02235922|Experimental|Dual task training|Dual task training
3048789|NCT02235922|Experimental|Conventional training|Conventional training
3049043|NCT02234089||Degarelix|
3048790|NCT02235909|Experimental|Azilsartan Medoxomil 10 mg|Once a day dosing
3048791|NCT02235909|Experimental|Azilsartan Medoxomil 20 mg|Once a day dosing
3048792|NCT02235909|Experimental|Azilsartan Medoxomil 40 or 80 mg|Once a day dosing
3048793|NCT02235909|Active Comparator|Losartan 25 or 50 mg|Once a day dosing
3048794|NCT02235896|Other|Education/Behavior Modification|Education/Behavior modification program
3048795|NCT02235870|Active Comparator|Treatment Group|In accordance with the randomization assignment, treatment arm subjects will receive a 6-month course of Balloon therapy with a nutrition and lifestyle program. Balloon treatment consists of placement of 3 balloons Obalon Intragastric Balloons in the first 3 months of therapy.
3048796|NCT02235870|Sham Comparator|Control Group|Control arm subjects will receive a single 6-month course of sham device therapy with a nutrition and lifestyle program. Sham treatment consists of placement of 3 shams in the first 3 months of therapy.
3048797|NCT02235857|Experimental|Liposorber® LA-15 System|All study patients who meet the study eligibility criteria will undergo the extracorporeal treatment using Liposorber® LA-15 System. The participants are to be treated with the system twice weekly for the 3weeks and then once weekly for the following 6 weeks.
3048798|NCT02235844|Experimental|Mesenchymal Stem Cells|Umbilical Cord Mesenchymal Stem Cells
3048799|NCT02235831|Experimental|DACP MF|DACP MF worn first, followed by DACP and DACP MF (Low Add) as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF will be worn bilaterally (in both eyes).
3048800|NCT02235831|Active Comparator|DACP|DACP worn first, followed by DACP MF and DACP MF (Low Add), as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP worn as monovision (distance correction in one eye and near correction in the other eye).
3048801|NCT02235831|Active Comparator|DACP MF (Low Add)|DACP MF (Low Add) worn first, followed by DACP and DACP MF, as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF (Low Add) worn bilaterally (in both eyes).
3048802|NCT02235818|Active Comparator|Kinesiotape (KT)|Kinesiotape was used only on the affected side as per the manufacturer instructions. With the elbow extended, wrist fully flexed and fingers pointed down 24, KT was applied with slight stretch (10-15%) and paper off tension to the lateral arm beginning just above the bony portion of lateral epicondyle. Once the top strand was anchored, KT was applied along the side of elbow such that hole in the tape was over lateral epicondyle of the elbow. Two strands of tape followed the lateral forearm and ended at around beginning of the distal one third of forearm. Once the support was applied, KT was gently rubbed to activate the glue.
3048803|NCT02235818|Active Comparator|Counterforce elbow brace|The counterforce brace was approximately 5cm wide with velcro attachment for adjustable girth. It had gel pack for extra support on extensor muscle mass. With the elbow extended, brace was applied 2.5cms below the lateral epicondyle. A feeling of comfortable compression, as reported by the patients was used to adjust the brace.
3048804|NCT02235805|Experimental|Magnesium Citrate|
3048805|NCT02235805|Placebo Comparator|Placebo|
3048806|NCT02235792|Experimental|Deep Brain Stimulation 37604 Activa PC+S|All subjects will undergo DBS using the 37604 Activa PC+S device (single arm study).
3048807|NCT02235779|Other|Cryobiopsy|
3048808|NCT02235766||CRT candidates patients|In accordance with the current ESC/ACCF/AHA indications for CRT in sinus rhythm, all patients in NYHA class II, III and IV with QRS complex greater than 120 msec and ejection fraction equal or less than 35% will be considered eligible to participate in this observational study.
3048809|NCT02235753|Experimental|High-intensity interval training, HIT-S|High-intensity aerobic interval training, short interval (HIT-S)
3048810|NCT02235753|Experimental|High-intensity interval training, HIT-L|High-intensity aerobic interval training, long interval (HIT-L)
3048811|NCT02235753|No Intervention|Usual care|control group
3048812|NCT02235740|Experimental|Afuresertib 125 mg+ Carfilzomib (Part 1)|Approximately 8 subjects will receive Afuresertib 125 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m^2: Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg (increased dosage of 27 mg/meter (m)^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
3048813|NCT02235740|Experimental|Afuresertib 150 mg+ Carfilzomib (Part 1)|Approximately 8 subjects will receive oral Afuresertib 150 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m^2: on Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg/m^2 (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
3048814|NCT02235740|Experimental|Afuresertib 100 mg+ Carfilzomib (Part 1)|An additional arm with 100 mg of afuresertib may be evaluated if the other 2 arms are not tolerated. Approximately 8 subjects will receive Afuresertib 100 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m^2: on Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg/m^2 (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
3048815|NCT02235740|Experimental|Afuresertib/carfilzomib (Part 2)|Approximately 50 subjects will receive Afuresertib Recommended Phase 2 Dose (RP2D) daily starting Cycle 1 Day 1 + Carfilzomib 20 mg/m^2 Cycle 1, Day 1, 2. Carfilzomib 27 mg (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15 and 16; Cycle Days 1, 2, 8, 9, 15 and 16 of each cycle; Cycle 3 and onwards, Days 1, 2, 8, 9 and 15 and 16 of each cycle.
3048816|NCT02235740|Active Comparator|Carfilzomib (Part 2)|Approximately 50 subjects will receive Carfilzomib 20 mg/m^2: Cycle 1, Day 1, 2. Carfilzomib 27 mg/m^2 (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9 15, and 16; Cycle 2, Days 1, 2, 8, 9, 15 and 16 of each cycle; Cycle 3 and onwards, Days 1, 2, 8, 9, 15 and 16 of each cycle.
3048817|NCT02235727|Experimental|GBR 900|Test treatment GBR 900
3048818|NCT02235727|Placebo Comparator|Placebo|Placebo Treatment
3048819|NCT02235714||Tetraplegia|Individuals with chronic tetraplegia
3048820|NCT02235714||Asthma|Individuals with mild asthma
3048821|NCT02235714||Able-bodied controls|Age matched able-bodied (AB) controls with no history of lung disease
3048822|NCT02235701|Experimental|aldoxorubicin|
3048823|NCT02235688|Experimental|aldoxorubicin|
3049044|NCT02234089||LHRH agonist|
3048824|NCT02235675|Experimental|Tack-It|Implant of the Intact Vascular Tack-It Endovascular System to repair post angioplasty dissections.
3048825|NCT02235662|Experimental|TFV IVR|TFV IVR is an intravaginal ring 55.0 mm in diameter, consisting of single segment of polyurethane tubing with an outer diameter of 5.5 mm and filled with white TFV-containing paste. Used for one month, the IVR delivers 8-10 mg/day TFV.
3048826|NCT02235662|Experimental|TFV/LNG IVR|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm: a longer segment containing white TFV paste and a shorter one (20 mm) with a white LNG core. Used for one month, the IVR delivers 8-10 mg/day TFV and 20 μg/day LNG.
3048827|NCT02235662|Placebo Comparator|Placebo Intravaginal Ring|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month.
3048828|NCT02235649|No Intervention|TAU|Treatment as usual
3048829|NCT02235649|Active Comparator|SOC+TAU|Social Cognition intervention + Treatment as Usual
3048830|NCT02235636||Laparoscopic group|
3048831|NCT02235636||Robotic group|
3048832|NCT02235623|Other|Stage 1- Single-stage Fowler-Stephens orchidopexy (FSO)|Stage 1 single surgery to clip the vessels to the testis, divide the spermatic vessels and bring the testis into the scrotum.
3048833|NCT02235623|Other|Stage 2- Two-stage Fowler-Stephens orchidopexy (FSO)|Stage 2 2 surgeries: 1st surgery-Clip vessels to testis. 2nd surgery done 6-12 months later, divide the spermatic vessels and bring the testis into the scrotum.
3048834|NCT02235610|No Intervention|Standard Group|"Recipients receive standard donor lungs as per current clinical practice.~No experimental procedures will be carried out."
3048835|NCT02235610|Experimental|EVLP Group|Recipients receive reconditioned EVLP donor lungs and current standard of care for lung transplant is administered.
3048836|NCT02235597||Patients and Staff of Community Clinics|Patients and Staff of Community Clinics who shared strategies and solutions to overcome barriers to accessing health care
3048837|NCT02235584|Experimental|Dexamethasone|This is a before-after study. All subjects are administered dexamethasone 2mg BID for 5 days.
3048838|NCT02235571|No Intervention|Control|These subjects are receiving standard patient education
3048839|NCT02235571|Experimental|iChoose Kidney Decision Aid|These subjects receive iChoose Kidney Decision Aid along with standard patient education
3048840|NCT02235558|Experimental|Verapamil|Super-selective intra-arterial administration of 10 mg verapamil immediately following successful intra-arterial thrombolysis
3048841|NCT02235545||St. Jude Medical Optisure Lead|Patients implanted with St. Jude Medical Optisure Lead
3048842|NCT02235532|Experimental|Foramen Herbal Aloe toothpaste|test group was asked to brush the teeth with Foramen Herbal Aloe toothpaste for 30 days once a day.
3048843|NCT02235532|Active Comparator|use of fluoride toothpaste (signal)|use of a fluoride toothpaste (signal) in control group once a day for 30 days .
3048844|NCT02235519|Active Comparator|Azilsartan low dosage|Patients will take azilsartan 40 mg during 12 weeks
3048845|NCT02235519|Active Comparator|Azilsartan high dosage|Patients will take azilsartan 80 mg during 12 weeks
3048846|NCT02235506|Experimental|epidural infusion|In epidural infusion group, a lumbar epidural catheter was placed at the L3-4 level using loss-ofresistance procedure. ropivacaine 0.2% and fentayl 2mcg/ml were infused at a rate of 5ml/hr from the end of operation,
3048847|NCT02235506|Experimental|femoral sciatic|In femoral sciatic group, the femoral and sciatic nerve are located using ultrasound and 0.2% ropivacain is injected. A catheter is inserted to femoral nerve. From the end of operation, 0.2% ropivacaine was infused through the femoral catheter at a rate of 5ml/hr.
3048848|NCT02235493||Retrospective Case Only|
3048849|NCT02235480|Experimental|Tazarotene Gel|once daily
3048850|NCT02235480|Placebo Comparator|Placebo Gel|once daily
3048851|NCT02235467|Active Comparator|ABA parent training|Applied Behavior Analysis parent training using videomodeling in 21 sessions
3048852|NCT02235467|No Intervention|ABA parent training control|
3048853|NCT02235454|Other|Glaucoma arm|Consecutive patients with glaucoma will undergo non-invasive OCT imaging
3048854|NCT02235441|Experimental|Cardiopulmonary Fitness|All eligible subjects will participate in treadmill exercise to measure cardiopulmonary fitness during chemoradiation therapy.
3048855|NCT02235428|Experimental|Ipratropium bromide|
3048856|NCT02235428|Active Comparator|Salbutamol|
3048857|NCT02235415||Motens|
3048858|NCT02235402|Experimental|Lacidipine|
3048859|NCT02235402|Active Comparator|Bendrofluazide|
3048860|NCT02235402|Placebo Comparator|Placebo|
3048861|NCT02235389||Administration of thrombolytic treatment with PHARAOH|Pre-Hospital Alteplase Remote Advice of Hospital (PHARAOH)
3048862|NCT02235389||Standard therapy with thrombolytic treatment in Hospital|
3048863|NCT02235376||critical care|
3048864|NCT02235363|Experimental|facelift|In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
3048865|NCT02235350|Experimental|Action Observation Treatment (AOT)|Conventional physiotherapy + Action Observation Treatment
3048866|NCT02235350|Sham Comparator|Observation of videos with no motor content (MNO)|Conventional physiotherapy + Observation of videos with no motor content (MNO)
3048867|NCT02235337|Experimental|Riboflavin|
3048868|NCT02235324|Experimental|Treatment (ziv-aflibercept, leucovorin calcium, fluorouracil)|"PHASE I:~Patients receive ziv‐aflibercept IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. At the time of progression, patients proceed to Phase II.~PHASE II:~Patients receive ziv‐aflibercept IV over 1 hour, leucovorin calcium IV over 1 minute, and fluorouracil IV over 46 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
3048869|NCT02235311|Active Comparator|Pantoprazole twice daily|Pantoprazole 40mg orally twice daily x 8 weeks after acute management of UGIB
3048870|NCT02235311|Active Comparator|Pantoprazole once daily|Pantoprazole 40mg orally once daily x 8 weeks after acute management of UGIB
3048871|NCT02235298|Experimental|Dapagliflozin|Dapaglifozin will be administered the dose of 5 mg once daily. Metformin regimen will be continued.
3048872|NCT02235298|Active Comparator|Metformin|Metformin (from 500 mg twice daily to a maximum of 1000 mg twice daily) regimen will be continued to achieve fasting glucose between 80 and 140 mg/dl.
3048873|NCT02235285|Experimental|breast augmentation,reoperation|A retrospective chart review was performed to examine a total of 162 patients received the same brand of implants for primary breast augmentation under sedative anesthesia (propofol infusion) in a single surgeon's practice.
3048874|NCT02235272|Experimental|XG-102|
3048875|NCT02235272|Placebo Comparator|Placebo|
3048876|NCT02235259|Experimental|XG-104 low dose|
3048877|NCT02235259|Experimental|XG-104 intermediate dose|
3048878|NCT02235259|Experimental|XG-104 high dose|
3048879|NCT02235259|Placebo Comparator|Placebo|Placebo
3048880|NCT02235246|Experimental|normal saline|
3048881|NCT02235246|Active Comparator|magnesium sulfate|
3048882|NCT02235233|Experimental|Patients with NASH|Each subject will be injected with ~2.5 mCi of Technetium Tc 99M Mebrofenin
3048883|NCT02235233|Active Comparator|Healthy Normal Volunteers|Each subject will be injected with ~2.5 mCi of Technetium Tc 99M Mebrofenin
3048884|NCT02235220|Experimental|Composite resin restoration|A canine guidance is reestablished by additive composite resin restorations of the canine cusp.
3048885|NCT02235207|Experimental|Neuromuscular exercise|The exercise group will participate in Fustra20 Neck & Back neuromuscular exercise program.
3048886|NCT02235207|No Intervention|Control group|Participants are encouraged to continue there usual physical activity and exercise
3048887|NCT02235194|Active Comparator|Amino Acids, Chromium - Picolinate|Verum drink containing the dietary supplements is taken with a test meal. INsulin and glucose response is documented for 180 minutes.
3048888|NCT02235194|Placebo Comparator|Placebo Drink|Placebo Drink containing aroma only is taken with a test meal. INsulin and glucose response is documented for 180 minutes.
3048889|NCT02235181|No Intervention|Standard Treatment|Women will be allocated to standard treatment, currently this is no treatment.
3048890|NCT02235181|Active Comparator|Arabin pessary|The Arabin cervical pessary will be inserted between 18 and 20+6 days gestation and removed between 35 and 36+6 weeks gestation unless Labour occurs sooner.
3048891|NCT02235168|Experimental|With rollator|Six minutes walking test with rollator
3048892|NCT02235168|Active Comparator|Without rolator|Six minutes walking test without rollator
3048893|NCT02235155||Pregnant women of 13-22 weeks gestation|Pregnant women of 13-22 weeks gestation will receive 200 mg mifepristone followed 24-48 hours later by 400 mcg sublingual misoprostol every three hours until complete expulsion.
3048894|NCT02235142|Experimental|Localised prostat cancer and androgen deficiency|
3048895|NCT02235129|Experimental|6 minutes walking test|
3048896|NCT02235116||Patients who responded to the survey|
3048897|NCT02235103||Clinical Pregnancy|Patients who are clinically pregnant after first treatment cycle with intra-uterine insemination.
3048898|NCT02235103||No Clinical Pregnancy|Patients who are not clinically pregnant after first treatment cycle with intra-uterine insemination.
3048899|NCT02235090|Sham Comparator|Zero-strength of direct current stimulation|Sham transdermal direct current stimulation of cervical spinal cord
3048900|NCT02235090|Experimental|100 microamperes direct current stimulation|Transdermal direct current stimulation of cervical spinal cord
3048901|NCT02235090|Experimental|1 milliampere direct current stimulation|Transdermal direct current stimulation of cervical spinal cord
3048902|NCT02235077|Active Comparator|Spironolactone|Spironolactone 25mg or 100 mg orally, once daily while in the hospital for 96 hours
3048903|NCT02235077|Placebo Comparator|Placebo|Placebo 25mg or 100mg orally, once daily while in the hospital for 96 hours
3048904|NCT02235064|Experimental|Sertraline|Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper
3048905|NCT02235064|Placebo Comparator|Placebo|Identical appearing capsule daily containing color-matched cellulose only
3048906|NCT02235051|Experimental|Arm I (exercise intervention)|Patients participate in a supervised Curves exercise program three days a week for 16 weeks. The circuit-style workout consists of 14 exercises constructed with pneumatic or hydraulic resistance that target opposing muscle groups in a concentric-only fashion. Each session at Curves will include two complete circuits which correspond to exercising for approximately 30 minutes followed by a standardized stretching routine.
3048907|NCT02235051|No Intervention|Arm II (no formal exercise intervention)|Patients do not participate in a formal exercise program for 16 weeks. Patients are then offered the Curves exercise intervention.
3048908|NCT02235038|Active Comparator|Low carbohydrate diet|
3048909|NCT02235038|Active Comparator|Moderate carbohydrate diet|
3048910|NCT02235038|Active Comparator|High carbohydrate diet|
3048911|NCT02235025|Other|Asymptomatic mild COPD|Subjects of this group have GOLD grade I COPD (post-bronchodilator FEV1 > 80% predicted and FEV1/FVC < 0.7). They also have a modified Medical Research Council (mMRC) score equal to zero and are free of respiratory symptoms including chronic cough and/or chronic expectoration and/or chronic wheeze.
3048912|NCT02235025|Other|Symptomatic mild COPD|Subjects of this group have GOLD grade I COPD (post-bronchodilator FEV1 > 80% predicted and FEV1/FVC < 0.7). They also have a modified Medical Research Council (mMRC) score > 0.
3048913|NCT02235025|Other|Healthy controls|Healthy controls have normal baseline spirometry (FEV1 > 80% predicted, FEV1/FVC > 0.7). They don't have any health problems, including cardiovascular, metabolic, neuromuscular, musculoskeletal, or respiratory diseases that could contribute to breathlessness or exercise limitation. They have a mMRC score equal to zero and do not complain any respiratory symptoms including chronic cough and/or chronic expectoration and/or chronic wheeze and/or chronic respiratory related medication.
3048914|NCT02235012|Experimental|Ketamine then placebo|Infusion of low dose Ketamine then infusion of a saline solution
3048915|NCT02235012|Experimental|Placebo then ketamin|Infusion of a saline solution then infusion of low dose Ketamine
3049128|NCT02233452|Active Comparator|Methadone|Group treated with methadone solution.
3048916|NCT02234999|Experimental|3mg [14C]-CC-122 (Single Dose)|Single oral capsule of 3mg [14C]-CC-122. given as a suspension under fasting conditions on Day 1
3048917|NCT02234986|Experimental|ENMD-2076|ENMD-2076, oral capsule Once daily dose 250 mg/day
3048918|NCT02234973||11 First Nations Community and Clinical Teams|11 Community & Clinical Teams in each First Nation community participated in the intervention.
3048919|NCT02234960||Cohort of RA Participants|Participants with RA treated with tocilizumab at a dose and duration at the discretion of physician in accordance with the summary of product characteristics as per routine clinical practice were observed for a period of 6 months with the length of entire study for 24 months.
3048920|NCT02234947||New onset of Type 1 Diabetes|The subjects with new onset of Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
3048921|NCT02234947||Antibody Positive Risk for Diabetes|The subjects with single or double antibody positive risk for Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
3048922|NCT02234947||Antibody Negative Risk for Diabetes|The subjects with antibody negative risk for Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
3048923|NCT02234947||Healthy Control|The subjects has no family history for Type 1 Diabetes. They will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
3048924|NCT02234934|Experimental|Lentiviral G1XCGD Gene Therapy|Transplantation with autologous CD34+ stem cells corrected with X1XCGD lentiviral vector after myeloreductive conditioning
3048925|NCT02234921|Experimental|DRibble Vaccine|Patients will receive cyclophosphamide 3 days prior to the first of 9 planned DRibble vaccine injections. Imiquimod will be applied following 6 injections. Patients will receive 2 HPV vaccinations (Human papillomavirus).
3048926|NCT02234908|Experimental|Contacts|Contacts are the household contacts of confirmed TB and drug-resistant TB patients.
3048927|NCT02234908|Other|Index|Index subjects are confirmed TB and drug-resistant TB patients who distribute referral cards to their household contacts.
3048928|NCT02234895|Experimental|Lateral wedge plus medial arch support|The lateral wedge plus medial support orthotic will be custom-made and designed using a 3D volumetric cast of the foot with the participant's foot in a subtalar joint neutral position. The cast will be balanced so that it rests in a neutral position then smoothed to address any irregularities and to allow for soft tissue splay. Polypropylene sheets of 3mm or 4mm thickness will be vacuum formed or milled directly to produce a ¾ length shell. An ethyl-vinyl-acetone (EVA) lateral post in the heel and forefoot of 5 degrees will be incorporated into the orthotic. The orthotic will be finished with a neoprene cover for improved comfort and patient compliance.
3048929|NCT02234895|Experimental|Lateral wedge|The lateral wedge only orthotic will be constructed of EVA, made to full length of the subject's footwear and incorporate a 5 degree posting. The wedge will be finished with a neoprene cover for improved comfort and patient compliance.
3048930|NCT02234882|Experimental|Rosuvastatin and BMS-663068|Treatment A: Rosuvastatin, single dose (SD) Treatment B: BMS-663068 administered on specified days Treatment C: Combination BMS-663068 and Rosuvastatin administered on specified days
3048931|NCT02234869|Experimental|Peginterferon beta-1a|Participants will receive peginterferon beta-1a, 125 µg subcutaneously once every 2 weeks during the 6-month comparator period of the study and during the 12-month extension period.
3048932|NCT02234869|Active Comparator|Interferon-β|Participants will continue to receive their standard-of-care interferon beta treatment for the first six months. During the 12-month extension period participants will switch to receive peginterferon beta-1a, 125 µg subcutaneously once every 2 weeks.
3048933|NCT02234856|No Intervention|conventional residency training|no intervention
3048934|NCT02234856|Experimental|Laparoscopic Hysterectomy trainer|Intervention: An educational video and web-based e-module will be created. The final product will be reviewed by the expert contributors. Once approved, these tools will be showcased to a voluntary focus group of Obstetrics and Gynecology residents at the University of Toronto. A quantitative assessment of effectiveness of this tool will be performed through the use of pre- and post-tests of knowledge. A qualitative needs assessment will also be performed using post-viewing surveys. If found to be effective, this educational tool will be incorporated in the University of Toronto Obstetrics and Gynecology residency curriculum.
3048935|NCT02234843|Experimental|BAY59-7939|Rivaroxaban (tablets and oral suspension) Dose: Age and body weight-adjusted dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban.
3048936|NCT02234843|Experimental|Standard of Care|Subcutaneous low molecular weight heparin (LMWH), subcutaneous fondaparinux and/or oral vitamin K antagonist (VKA) Dose : as per standard of care
3048937|NCT02234830|Experimental|Exoseal closure device|Closure device for femoral artery access closure
3048938|NCT02234830|Active Comparator|Angio-Seal closure device|Closure device for femoral artery access closure
3048939|NCT02234804|Experimental|Medtronic Resolute Integrity stent|Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium
3048940|NCT02234804|Experimental|OCT|OCT to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.
3048941|NCT02234804|Active Comparator|Angiography|Angiography to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.
3048942|NCT02234804|Active Comparator|Xience Prime stent|Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium
3048943|NCT02234791||gene mutation|
3048944|NCT02234778|Experimental|Study Treatment|Each subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period. TGI SVF material injection will be completed within 4 hours of cell separation.
3048945|NCT02234765|Active Comparator|Sleep Unit|Patients diagnosed and followed up in the Sleep Unit.
3048946|NCT02234765|Experimental|Primary Care|Patients diagnosed and followed up in the Primary Care.
3078264|NCT02038673|Experimental|Dose escalation part 16.0 mg BID|Oral
3048947|NCT02234752|Experimental|Galantamine ER, Memantine XR|Week 1, Galantamine ER 8 mg HS & Memantine XR 7 mg HS Week 2, Galantamine ER 16 mg HS & Memantine XR 14 mg HS Weeks 3-6, Galantamine ER 24 mg HS & Memantine XR 21 mg HS
3048948|NCT02234739|Experimental|active treatment|Chinese patients with invasive pulmonary aspergillosis treated by voriconazole, who has COPD as underlying condition
3048949|NCT02234726|Experimental|Early Childhood Development Program|"Treatment clusters will be assigned a trained Child Development Agent (CDA) who will have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases including malaria, diarrhea, and pneumonia and referral for diagnosis and treatment; and 4) organization and mentoring of biweekly caregiver meetings to discuss parenting and promote early childhood cognitive stimulation.~Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits."
3048950|NCT02234726|No Intervention|Control|Children residing in comparison health zones will only receive baseline and end line evaluations of their health and developmental status. There will be no active intervention in the comparison areas during the course of the study.
3048951|NCT02234713|Experimental|Behavioural Intervention/Feedback|The behavioral interventionist will contact the patient and parent by email and telephone to schedule a telephone call to review the downloaded adherence information and discuss barriers experienced by the patient/parent using a standard script. The behavioral feedback will be administered three times: at 1-, 2- and 3-months post-baseline.
3048952|NCT02234713|Active Comparator|Video Attention Control|The patients in this arm of the study will be emailed a link to an educational video about Pediatric MS and therapy for MS at three time points: 1-, 2-, and 3-months post-baseline.
3048953|NCT02234687|Placebo Comparator|Placebo|Placebo, one dose
3048954|NCT02234687|Experimental|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
3048955|NCT02234687|Experimental|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
3048956|NCT02234674|Active Comparator|Standard intensive CDP|This arm is the controlled group ; patients in that group will undergo a current practice performed in the lymphology unit.
3048957|NCT02234674|Experimental|Stendo group|This arm contitutes the group where the Stendo pulsating suit sessions are investigated in the frame of the CDP in replacement of the pressotherapy sessions.
3048958|NCT02234661|Experimental|CareerAdvance®|CareerAdvance® provides education, career coaching, and soft-skills training for parents while their children attend Head Start programs.
3048959|NCT02234661|No Intervention|Control Standard of CAP|Control participants access to CAP array of service
3048960|NCT02234648|Placebo Comparator|Placebo|The PLA supplement consisted of a commercially available, less than 5% fruit, cordial (Protein - Trace, Carbohydrate 260 mg•mL−1, Sodium 0.02 mg•mL−1, Fibre-Trace and Anthocyanins-Trace for colour), mixed with water, whey protein isolate (Arla Foods Ltd., Leeds, UK) and maltodextrin (MyProtein Ltd., Northwich, UK) until matched for carbohydrate and calorie content of the MC.
3048961|NCT02234648|Active Comparator|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency cherry (MC) juice mixed with 100mL of water. Independent analysis of MC (Atlas Biosciences, 2010) provided the following compositional data; Fat 0.028 mg•mL−1, Protein 31.47 mg•mL−1, Carbohydrate 669.4 mg•mL−1, Cholesterol < 0.01 mg•mL−1, Sodium 0.691 mg•mL−1, Calcium 0.137 mg•mL−1 and Iron 0.026 mg•mL−1. Additionally, according to the manufacturers guidelines (Cherry Active, Hanworth, UK),
3048962|NCT02234635|Other|monofocal IOLs group|monofocal IOLs group were implantation with Tecnis® ZCB00
3048963|NCT02234635|Active Comparator|Diffractive multifocal IOLs group|Diffractive multifocal IOLs group were implantation with Tecnis® ZMB00
3048964|NCT02234622|Experimental|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
3048965|NCT02234622|Active Comparator|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity physical activity with didactics about wellness topics.
3048966|NCT02234609|Other|adults with incisor dental caries lesion|modified ART class IV with glass ionomer cement
3048967|NCT02234596|Experimental|Nintedanib|
3048968|NCT02234583|Experimental|DS-5565|Participants receive 15 mg DS-5565 administered once or twice daily. Each participant's dose can be titrated up or down based on the investigator's decision. Analysis will be based on the dose modality at the time of data collection.
3048969|NCT02234570|Experimental|Group 1|N=8 subjects receive single oral dose 0.5mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
3048970|NCT02234570|Experimental|Group 2|N=8 subjects receive single oral dose 1mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
3048971|NCT02234570|Experimental|Group 3|N=8 subjects receive single oral dose 3mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
3048972|NCT02234570|Experimental|Group 4|N=8 subjects receive single oral dose 7.5mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
3048973|NCT02234570|Experimental|Group 5|N=8 subjects receive single oral dose 15mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
3048974|NCT02234570|Experimental|Group 6|N=8 subjects receive single oral dose 30mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
3048975|NCT02234570|Experimental|Group 7|N=8 subjects receive single oral dose 60mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
3048976|NCT02234557|Experimental|Tai Chi|Tai Chi instruction, 1 hour, twice per week Home Tai Chi practice with video, requesting 15-30 minutes, 3 times per week, monitored by practice log
3048977|NCT02234544|Placebo Comparator|Placebo + Cholecalciferol|The groups will be randomized to ezetimibe or placebo. All participants will receive orally a cholecalciferol capsule.
3048978|NCT02234544|Active Comparator|Ezetimibe + Cholecalciferol|The groups will be randomized to ezetimibe or placebo. All participants will receive orally a cholecalciferol capsule.
3049129|NCT02233452|Active Comparator|Ketamine|Group treated with ketamine solution
3049130|NCT02233452|Active Comparator|Methadone plus ketamine|Group treated with methadone plus ketamine solution
3049621|NCT02229929|Placebo Comparator|Part A: Placebo|Intravenous matched placebo
3048979|NCT02234531|Experimental|EVER TEACHER|"In EVER TEACHER group a specific feedback called virtual teacher will be displayed. The virtual teacher perform the correct movement to emulate, that is supposed to stimulate the motor adaptation exploiting a supervised learning mechanism. This feedback will give an on-line information on motor performance quality, allowing a real time visual comparison between patient's own execution and teacher one. During the experiment, patients will receive 1 hour of virtual reality-based therapy and the treatment will last 1 hour a day, five days weekly for four weeks."
3048980|NCT02234531|Other|NEVER TEACHER|In NEVER TEACHER group the subjects will be asked to perform the same exercises with the upper limb without the virtual teacher assistance. The treatment will last four weeks with daily sessions of 60 minutes, five times per week.
3048981|NCT02234518|Experimental|High quantity fiber food product|
3048982|NCT02234518|Experimental|Low quantity fiber food product|
3048983|NCT02234518|Placebo Comparator|Placebo|
3048984|NCT02234505|Experimental|Trans-tibial prosthesis users|prosthetic alignment perturbation
3048985|NCT02234492|Active Comparator|Rosuvastatin|Rosuvastatin 10mg once daily for 6 months.
3048986|NCT02234492|No Intervention|No rosuvastatin|No rosuvastatin- this group will continue with their current medical therapy for 6 months.
3048987|NCT02234479|Active Comparator|Hydrophor (Group A)|Group A (current standard of care): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily, starting at the onset of radiation therapy (RT) and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Hydrophor application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Hydrophor within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.
3048988|NCT02234479|Experimental|MediHoney (Group B)|Group B (study target): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Medihoney daily, starting at the onset of RT and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Medihoney application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Medihoney within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.
3048989|NCT02234466|Active Comparator|Oral Dexamethasone|"Oral dexamethasone- two 4mg tabs and one 2mg tab contained within a gelatin capsule Administered a single time, 2 hours pre-induction~Ondansetron 6mg IV will be administered at skin closure"
3048990|NCT02234466|Placebo Comparator|Gelatin pill|"Gelatin capsule contained within second gelatin capsule. Administered a single time, 2 hours pre-induction~Ondansetron 6mg IV will be administered at skin closure"
3048991|NCT02234453|Experimental|Cancer patients|Adult patients with solid tumours receiving systemic anti-cancer therapy who are able to use the Minicare H-2000.
3048992|NCT02234440|Experimental|Metformin|Metformin- 500 mg once daily as a starting dose, can be escalated to 2 g/day to control diabetes
3048993|NCT02234440|Active Comparator|Insulin|
3048994|NCT02234427|Experimental|Aspirin|
3048995|NCT02234401|Experimental|Non invasive ventilation (NIV)|Non invasive ventilation used for the first 7 days of study
3048996|NCT02234401|Active Comparator|Standard Care|High Flow Controlled Oxygen Therapy
3048997|NCT02234388||Registry Participants|All patients who participate in the UCTD Registry will be put into this cohort and observed over approximately 3 years.
3048998|NCT02234375|Experimental|Gadolinium enhancement|Gadolinium enhancement will be performed using intravenous Dotarem[recommended dose of 0.2 mL/kg (0.1 mmol Gd/kg )]
3048999|NCT02234362|Experimental|open-label vortioxetine|flexible-dose vortioxetine of 5-20 mg depending on tolerability
3049000|NCT02234349|Experimental|pancreas kidney transplant|Patients with pancreas kidney transplantation
3049001|NCT02234349|Experimental|kidney transplant subjects|Patients with kidney transplantation
3049002|NCT02234349|No Intervention|Control|
3049003|NCT02234336||Subjects with HCM|All subjects will undergo noncontrast echocardiography, contrast echocardiography and cardiac MRI.
3049004|NCT02234323|Experimental|rFVIIIFc|The dose for prophylaxis may be selected and adjusted based on the participant's response to dosing (i.e., available pharmacokinetics (PK) data, including FVIII activity levels, level of physical activity, and bleeding pattern), in the range of 25 to 65 international units per kilogram (IU/kg) at 3 to 5 day intervals. Dose may be increased up to 80 IU/kg if required.
3049005|NCT02234310|Experimental|rFIXFc|rFIXFc is administered by intravenous injection. A prophylaxis regimen will start prior to or immediately following the third occurrence of hemarthrosis (joint bleed). The recommended starting prophylactic dose of rFIXFc is 50 IU/kg weekly. Treatment will continue until the participant has reached at least 100 exposure days to rFIXFc. Optional episodic treatment doses are determined by the investigator and range from 25% Factor IX level for minor bleeding episodes to 100% for major episodes or prior to surgery. Single injections of rFIXFc up to 200 IU/kg are allowed.
3049006|NCT02234297|Experimental|BLZ-100|
3049007|NCT02234284|Experimental|Health Coaching|Patients randomized to the health coaching intervention would work with a trained health coach who would provide patient education self-management support, use action planning to help patient make changes to reach goals, as well as help coordinate patient care between the primary care provider and pulmonary specialist, identify gaps in care, and help patient access needed services
3049008|NCT02234284|No Intervention|Usual care|Usual care was chosen as the comparison group to provide maximum generalizability of the study, as usual care is the practical alternative for the target population. Usual care includes patient education classes, smoking cessation classes, psychosocial medicine and nutritional counseling.
3049009|NCT02234271|Active Comparator|Health Educator Arm|Health Educator for contraception information
3049010|NCT02234271|Experimental|Mobile Health Application Arm|Plan A Birth Control - iPad based application for contraception information
3049131|NCT02233439|Placebo Comparator|Placebo|a placebo identical in appearance to the galactagogue product
3049132|NCT02233439|No Intervention|No treatment|Usual care and breastfeeding support
3049011|NCT02234258|Experimental|Cognitive behavioral social skills|In Cognitive behavioral social skills training (CBSST), skills-based CBT is used to teach individuals how to correct inaccurate dysfunctional thoughts that interfere with goal-directed activities, including defeatist expectancies, low self-efficacy beliefs, and anomalous beliefs. SST focuses on behaviorally-based instruction of interpersonal social skills, utilizing role-modeling, rehearsal, corrective feedback, and positive reinforcement to facilitate learning. In the modified version of CBSST used in this project: 1) we will strengthen the focus on corrective feedback from successful social interactions; 2) focus on normalization and destigmatization of attenuated psychotic symptoms; 3) add motivational interviewing techniques to promote treatment engagement; and 4) use examples and role plays. CBSST will be delivered in three 6-session modules (i.e., Cognitive Skills, Social Skills, and Problem Solving Skills), a total of 18 90-minute group sessions.
3049012|NCT02234258|Active Comparator|Psychoeducation|The purpose of this alternative treatment is to match CBSST for the nonspecific effects of therapist contact and interest, social interaction and support. Common factors include client expectancy, providing a rationale for change, therapist factors and therapeutic alliance. The psychoeducation group will meet weekly, for a total of 18 90-minute sessions. Therapists will follow brief guidelines as to what they can and cannot do. In each session the therapists will ask how the previous week had been. Any crises will be dealt with, and advice will be offered to help with any immediate problems. No active CBT or SST techniques will be taught or used. Psychoeducational information about high risk for psychosis will be offered. There will be a focus on listening, reflecting and empathizing, and demonstrating uncritical acceptance and genuineness. Social exchanges amongst participants will be encouraged.
3049013|NCT02234245|No Intervention|Hospital monitoring of pacemakers|Patients have to go to the hospital to be monitorized
3049014|NCT02234245|Experimental|Remote monitoring of pacemakers|"Telemedicine System:~Patients have not to go to the hospital to be monitorized"
3049015|NCT02234232|Experimental|Aerobic exercise|"Cycling-participants will exercise for 15 minutes at the initial session followed by a weekly increase of 2 min and 3 seconds over 12 weeks. Participants will exercise 3 times per week and an intensity of somewhat hard (12-14 on the Borg scale). All exercises will be performed during hemodialysis."
3049016|NCT02234232|Experimental|Resistance|"Resistance training of lower limbs using ankle weights. Participants will complete 10-15 repetitions of 4 lower limb exercises: knee extension, straight leg raise, hip abduction, and hip flexion. Exercises will progress from 1 set of each exercise up to 3 sets of each exercise and with weight. Participants will exercise 3 times per week and an intensity of somewhat hard (12-14 on the Borg scale). All exercises will be performed during hemodialysis."
3049017|NCT02234232|Experimental|Combined aerobic and resistance|Participants will complete both the aerobic (cycling) and resistance (ankle weights) exercise prescriptions.
3049018|NCT02234232|Active Comparator|Flexibility|"A non-progressive flexibility regimen using a stretch band. Participants will perform 2 sets of the following exercises: seated pelvic tilt, seated calf stretch, supine hamstring stretch, and supine gluteal stretch. Participants will exercise 3 times per week and an intensity of very light (9 on the Borg scale). All exercises will be performed during hemodialysis."
3049019|NCT02234219|Active Comparator|Circular Anastomosis|
3049020|NCT02234219|Active Comparator|Heart-shaped Anastomosis|
3049021|NCT02234206|Experimental|Chandrakanthi choornam|"Chandrakanthi Choornam (CKC) - 12gm in milk~OD dose; Oral route~3 Months - duration~Intervention Drug: Chandrakanthi Choornam (CKC)"
3049022|NCT02234193|Active Comparator|Micro biopsies 2mm x control|2 mm diameter micro biopsies will be performed on all subjects.
3049023|NCT02234193|Active Comparator|Micro biopsies 1mm x control|1 mm diameter micro biopsies will be performed on all subjects.
3049024|NCT02234193|Active Comparator|Micro biopsies 0.8 mm x control|0.8 mm diameter micro biopsies will be performed on all subjects.
3049025|NCT02234193|Active Comparator|Micro biopsies 0.6 mm x control|0.6 mm diameter micro biopsies will be performed on all subjects.
3049026|NCT02234193|Active Comparator|Micro biopsies 0.5 mm x control|0.5 mm diameter micro biopsies will be performed on all subjects.
3049027|NCT02234193|Active Comparator|Micro biopsies 0.40 mm x control|0.4 mm diameter micro biopsies will be performed on all subjects.
3049028|NCT02234193|Active Comparator|Micro biopsies 0.20 mm x control|0.2 mm diameter micro biopsies will be performed on all subjects.
3049029|NCT02234180|Experimental|Arm I (regorafenib)|Within 6-12 weeks after surgery, patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
3049030|NCT02234180|Placebo Comparator|Arm II (placebo)|Within 6-12 weeks after surgery, patients receive placebo PO QD on days 1-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
3049031|NCT02234167|Other|Risk behaviour and infectious diseases|.(among IDU)
3049032|NCT02234154|Other|TOPS System|Post Marketing Study
3049033|NCT02234141|Experimental|Selonsertib 2 mg|Participants will receive selonsertib 2 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
3049034|NCT02234141|Experimental|Selonsertib 6 mg|Participants will receive selonsertib 6 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
3049035|NCT02234141|Experimental|Selonsertib 18 mg|Participants will receive selonsertib 18 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
3049036|NCT02234141|Experimental|Placebo|Participants will receive selonsertib placebo for 24 weeks, and may then be rerandomized 1:1:1 to selonsertib 2, 6, or 18 mg during the long-term treatment phase.
3049037|NCT02234128|Experimental|EVLP Double Lung Group|Toronto EVLP System™ administered to double lungs.
3049038|NCT02234128|Experimental|EVLP Single Lung Group|Toronto EVLP System™ administered to single lungs.
3049039|NCT02234128|No Intervention|Control Group|Those patients receiving a single or double lung via conventional transplant.
3049040|NCT02234115|Experimental|Leuprolide Mesylate 50mg|All subjects will be males with advanced prostate carcinoma. They will be injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects will be followed until day 336.
3049041|NCT02234102|Active Comparator|Paroxysmal Atrial Fibrillation (PAF)|Endoscopically guided laser ablation
3049042|NCT02234102|Active Comparator|Persistent Atrial Fibrillation|Endoscopically guided laser ablation
3049045|NCT02234076|Experimental|VRET|"Virtual Reality Exposure Therapy (VRET)~The experimental treatment VRET is offered with the Multi-Modal Memory Restructuring System (3MR system) and a therapy manual. Participants can use this system at home. Note: The 3MR system is offered via a computer screen, no head-mounted display (HMD) equipment is used in this study."
3049046|NCT02234076|Active Comparator|TAU|Treatment As Usual
3049047|NCT02234063|Experimental|Immediate Genetic Testing|Participants randomized to intervention will receive the APOL1 genetic test upon study enrollment.
3049048|NCT02234063|No Intervention|Control- Delayed Testing|Participants randomized to control will not receive the APOL1 genetic test upon study enrollment. They will be offered the option to take the test during their final follow-up study visit (12 months post enrollment).
3049049|NCT02234050|Experimental|Trabectedin|Patient will be treated with trabectedin
3049050|NCT02234050|Other|Local standard of care|Treatment in the control arm is left to the discretion of the investigator, according to the local standard of care.
3049051|NCT02234037|Experimental|Decitabine and Exercise|8-week program of physical conditioning and decitabine treatment in newly diagnosed AML patients ≥ 60 years of age who are not candidates for standard induction chemotherapy.
3049052|NCT02234024|Experimental|Supplementation of gangliosides|Supplementation of dairy-derived concentrated gangliosides
3049053|NCT02234011|Experimental|Ketamine/Placebo|Participants in this group will receive 5 sprays (10 mg each) of intranasal ketamine for the first treatment visit, then receive 5 sprays of placebo (saline solution) at the second treatment visit two weeks later.
3049054|NCT02234011|Experimental|Placebo/Ketamine|Participants in this group will receive 5 sprays of placebo (saline solution) for the first treatment visit, then receive 5 sprays (10 mg each) of intranasal ketamine at the second treatment visit two weeks later.
3049055|NCT02233998|Active Comparator|Mouth Rinse 1|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
3049056|NCT02233998|Active Comparator|Mouth Rinse 2|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
3049057|NCT02233998|Placebo Comparator|Mouth Rinse 3|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
3049058|NCT02233985|Active Comparator|Nebulized 0.9% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 0.9 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
3049059|NCT02233985|Experimental|Nebulized 3% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
3049060|NCT02233972|Experimental|Midazolam and Ginkgolides Meglumine Injection|Midazolam: tablet, 7.5 mg. Midazolam will be taken on Day 1 and Day 22. Ginkgolides Meglumine Injection: 25mg, intravenous drip, once a day. It will be used on Day 8 -Day 21, 14 days totally.
3049061|NCT02233972|Placebo Comparator|Midazolam and placebo|Midazolam: tablet, 7.5 mg. Midazolam will be taken on Day 1 and Day 22. Placebo: Sodium Chloride Injection, 250 ml, intravenous drip, once a day. It will be used on Day 8 -Day 21, 14 days totally.
3049062|NCT02233959||Healthy Adults|
3049063|NCT02233946|Experimental|screening w/ computer brief intervention|screening with computer-facilitated brief intervention
3049064|NCT02233946|No Intervention|Screening with Treatment as Usual|Screening with Treatment as Usual
3049065|NCT02233933|Active Comparator|argon plasma coagulation|argon plasma coagulation of radiation proctitis
3049066|NCT02233933|Experimental|argon plasma coagulator and hemospray|treatment of radiation proctitis with argon plasma coagulator followed by application of hemospray
3049067|NCT02233920||Chronic obstructive bronchitis patients|
3049068|NCT02233907||Chronic obstructive pulmonary disease patients|
3049069|NCT02233894||Chronic obstructive pulmonary disease patients|
3049070|NCT02233881||Chronic obstructive pulmonary disease patients|
3049071|NCT02233842||Tobacco Use in Cancer Pts & Survivors|Cognitive testing (e.g. participant interview) of tobacco use in patients (pts) who have cancer and who have survived cancer.
3049072|NCT02233816|Experimental|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
3049073|NCT02233816|Experimental|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
3049074|NCT02233816|Experimental|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
3049075|NCT02233816|Placebo Comparator|Placebo|A single dose of Placebo
3049076|NCT02233803|Experimental|Sequence 1: BFF 400/12mcg to BFF 320/9mcg|Subjects will receive Regimen A in Treatment Period 1 followed by Regimen B in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
3049077|NCT02233803|Experimental|Sequence 2: BFF 320/9mcg to BFF 400/12mcg|Subjects will receive Regimen B in Treatment Period 1 followed by Regimen A in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
3049078|NCT02233790|Experimental|Ticagrelor|
3049079|NCT02233790|Active Comparator|Clopidogrel|
3049080|NCT02233777|Experimental|Pregabalin capsules 150 mg of Dexa Medica|Each capsule contains 150 mg pregabalin.
3049081|NCT02233777|Active Comparator|Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland|Each capsule contains 150 mg pregabalin.
3049082|NCT02233764|Experimental|FeZnPM|The FeZnPM arm will consume iron- and zinc-biofortified pearl millet (ICTP8203-Fe).
3049083|NCT02233764|Active Comparator|CtrlPM|The CtrlPM arm will consume conventional pearl millet three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
3049084|NCT02233751|Experimental|Treatment A|Testosterone enanthate auto-injector (SC injection)
3049085|NCT02233751|Experimental|Treatment B|Testosterone enanthate auto-injector (SC injections)
3049086|NCT02233738|Experimental|Group Motivational Interviewing (GMI)|Group Motivational Interviewing (GMI) participants will receive four structured, back-to-back, 90-min sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
3049087|NCT02233738|Active Comparator|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to Group Motivational Interviewing (GMI) (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
3049088|NCT02233725|Active Comparator|Definity Perflutren Suspension|Injection of Definity Perflutren Injectable Suspension- which travels in the bloodstream throughout the body. These microbubbles are identifiable on ultrasound imaging, and studies of the liver and kidney have identified it as a useful adjunct to identifying vascular lesions. Areas of regular blood flow will not have as large a concentration of the microbubble agent as will areas that have increased blood flow and neovascularisation. It has been well documented that cancerous solid lesions undergo neovascularisation and have increased blood flow to the area.
3049089|NCT02233712|Experimental|Group 1|G17DT; 250 µg dose administered at 0, 1, and 3 weeks.
3049090|NCT02233712|Experimental|Group 2|G17DT; 100 µg dose administered at 0, 1, and 3 weeks.
3049091|NCT02233712|Experimental|Group 3|G17DT; 500 µg dose administered at 0, 1, and 3 weeks.
3049092|NCT02233712|Experimental|Group 4|G17DT; 500 µg dose administered at 0, 2, and 6 weeks.
3049093|NCT02233699|Experimental|XEN-D0501|4mg BID Days 1-13, 4mg once daily (OD) Day 14
3049094|NCT02233699|Placebo Comparator|Placebo to Match|BID Days 1-13, once daily (OD) Day 14
3049095|NCT02233686|Experimental|XEN-D0501|4mg BID Days 1-13, 4mg once daily (OD) Day 14
3049096|NCT02233686|Placebo Comparator|Placebo to Match|BID Days 1-13, once daily (OD) Day 14
3049097|NCT02233673|Experimental|Behavioral, incentives|Participants receive behavioral intervention and financial incentives for meeting gestational weight gain goals
3049098|NCT02233673|No Intervention|Standard care|Participants receive standard obstetrical care from their provider
3049099|NCT02233660|Experimental|Physical Therapy Group.|The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.
3049100|NCT02233660|Active Comparator|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
3049101|NCT02233647|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
3049102|NCT02233647|Experimental|Phendimetrazine Dose 1|"Subjects will be maintained on the low phendimetrazine dose. Cocaine will be administered acutely during low dose phendimetrazine maintenance.~Placebo will be administered acutely during low dose phendimetrazine maintenance."
3049103|NCT02233647|Experimental|Phendimetrazine Dose 2|"Subjects will be maintained on the intermediate phendimetrazine dose. Cocaine will be administered acutely during intermediate dose phendimetrazine maintenance.~Placebo will be administered acutely during intermediate dose phendimetrazine maintenance."
3049104|NCT02233647|Experimental|Phendimetrazine Dose 3|"Subjects will be maintained on the high phendimetrazine dose. Cocaine will be administered acutely during high dose phendimetrazine maintenance.~Placebo will be administered acutely during high dose phendimetrazine maintenance."
3049105|NCT02233634|Active Comparator|CAD Patients|Administration of Oxygen via a mask, Hyperventilation, Combination of Oxygen administration and Hyperventilation, long breath-holds
3049106|NCT02233634|Active Comparator|Healthy Volunteers (Control Group)|Administration of Oxygen via a mask, Hyperventilation, Combination of Oxygen administration and Hyperventilation, long breath-holds
3049107|NCT02233621|Experimental|PET with [18F]-FES|PET with [18F]-FES compared to histological analysis performed at least on one biopsy done during coelioscopy.
3049108|NCT02233608|No Intervention|Usual Care|The usual care group will receive generic pelvic floor muscle exercise (PMFX) instructions and demonstrations by the research coordinator at the initial post-operative time point. This will include instruction on how to engage the pelvic floor and specific PFMX prescription. Repetition volume will start at 20 repetitions per day during weeks 1-2; 60/day during weeks 3-4; and 90/day during weeks 5-6, and 100+/day for weeks 7-26. The total number of repetitions will be divided equally between rhythmic (contract and relaxed over one second) and sustained contractions (contract and hold for up to 10 seconds).
3049109|NCT02233608|Experimental|Advanced Pelvic Floor Exercise (APFX)|Participants in this group will receive detailed week-by-week description of the program. The program progresses participants through stages of training every two weeks, starting the introduction of basic PFMX, and slowly incorporates Pfilates and Hypopressives exercises until week 8, where patients will maintain the final stage of training until week 26 or urinary incontinence is completely resolved.
3049110|NCT02233595||Adjuvant chemotherapy|
3049111|NCT02233582|Experimental|ibuprofen plus ascent to high altitude|subjects randomized to this arm will take ibuprofen 200 mg 3 times daily during ascent and at altitude.
3049112|NCT02233582|Placebo Comparator|sugar pill plus ascent to high altitude|subjects randomized to this arm will receive the placebo
3049113|NCT02233569|Active Comparator|PH|Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.
3049114|NCT02233569|Active Comparator|VS|Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.
3049115|NCT02233556|Experimental|Memantine|This study has only one arm. i.e. Single dose of memantine 20mg
3049133|NCT02233439|Experimental|Herbal galactagogue|A commercially available product containing a combination of Silybum marianum 400 mg and Galega officinalis 150 mg, once a day for 6 weeks
3078265|NCT02038673|Experimental|Expansion part Urothelial Carcinoma|Oral
3049116|NCT02233543|Experimental|First QVA149 (indacaterol/glycopyrronium), then Placebo|Participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
3049117|NCT02233543|Experimental|First Placebo, then QVA149 (indacaterol/glycopyrronium)|Participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
3049118|NCT02233530|Experimental|CST intervention|"Outcomes at baseline will be compared with those immediately post intervention and at four weeks post-intervention.~In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. The investigators will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location. Individuals will be allocated to groups based on religion, gender and geographical location."
3049119|NCT02233517|Experimental|Cognitive Behavioral Therapy|"Cognitive-Behavioral Therapy for Anger and Aggression in Combat Veterans with PTSD (CBT-A) is a 12-week manualized group treatment protocol that is grounded in up-to-date research, and that specifically addresses the Energy and Drive Functions, Attention Functions, Emotion Functions, and Thought Functions that are hypothesized to underlie the limitations to Activities and Participation associated with PTSD-related anger and aggression. Each session lasts 90 minutes. The first session orients participants to the structure and philosophy of the program, provides a historical overview of PTSD, and introduces the concept of the survival mode of functioning (Chemtob et al., 1997). The remaining 11 sessions follow a standard format: 1) practice relaxation training (15-20 minutes); 2) review homework, introduce new material, and engage in group activities focused on implementing new skills and behaviors (70-80 minutes); and 3) review problems or concerns of group members."
3049120|NCT02233517|Active Comparator|Present Centered Therapy|"Present Centered Therapy (PCT) is an active, manualized treatment comparison condition for psychotherapy trials. PCT is designed to control for nonspecific factors of therapy such as contact with a trained therapist, rationale for treatment, and instillation of expectancy for therapeutic gains. The therapeutic approach was drawn from Yalom's group therapy model, which utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now. Previous large-scale randomized clinical trials of Veterans with PTSD have found reduced PTSD symptoms in the PCT comparison condition (Schnurr et al., 2003), and a survey of practice patterns within the VA suggests that similar present-focused approaches are routinely employed by VA mental health providers (Rosen et al., 2004). Consistent with recommendations in the PCT manual, training will emphasize the approach rather than specific interventions."
3049121|NCT02233491|Placebo Comparator|Control|This group will be counselled in clinic by clinicians about the risks of glucose intolerance and will receive leaflets outlining lifestyle modification advice. The leaflets include advice on healthy eating, exercise and the importance of weight loss. However there will be no dietician referral, psychosocial intervention or focused exercise and weight loss monitoring programme. Follow up will be at routine clinic visits only where lifestyle modification advice will be reinforced as per usual clinical practise.
3049122|NCT02233491|Active Comparator|Active intervention|This group will receive active lifestyle modification intervention and will consist of dietician referral, graded exercise programme and weight loss advice. The dietician will be supported by Clinical Psychology services and our collaboration with a recognised expert in behavioural change therapy. The dietician will be trained with motivational interviewing skills and psychological tools will be utilised to support the active lifestyle intervention.
3049123|NCT02233478|Active Comparator|Pomegranate Juice|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
3049124|NCT02233478|Active Comparator|Soybean Flour Protein|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
3049125|NCT02233478|Active Comparator|Soy Isolate Protein|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
3049126|NCT02233465|Experimental|IPOM Mesh-repair parastomal hernia|Mesh-repair of para-stomal hernia. Patients with para-stomal hernia requiring surgery are offererd enrollment in the study. Preoperatively a CT-scan of the abdomen and or a 3D ultrasonography of the stoma is performed. All patients in the stydy are operated with IPOM-mesh designed for treatment of parastomal hernia.
3049127|NCT02233465|No Intervention|No mesh-repair|Patients not attending the study
3049134|NCT02233413|Sham Comparator|Non-active LLLT helmet application|A helmet containing near infrared LED's (LLLT helmet) will be applied to the head, however, the LEDs will not be turned on / activated.
3049135|NCT02233413|Active Comparator|Active LLLT helmet application|A helmet containing near infrared LEDs (LLLT helmet) will be applied and the LEDs will be turned on/activated
3049136|NCT02233400|Experimental|Treatment|Group 1 (treatment) will receive IV acetaminophen (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
3049137|NCT02233400|No Intervention|Control|Group 2 (control) will receive IV normal saline (100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
3049138|NCT02233387|Experimental|[18F] HX4 PET imaging|injection with [18F] HX4 and PET imaging at baseline and after 20 Gy radiotherapy
3049139|NCT02233374|Experimental|Assessing response with MRI + PET.|"Pre-operative chemo/RT as per standard treatment. Intensity Modulated Radiotherapy (IMRT) / Volumetric Arc Therapy (VMAT) 45Gray/25 fractions with simultaneous integrated Boost of 50Gray/25 fractions + concurrent capecitabine chemotherapy.~Intervention 1 'Early MRI and PET/CT - 2 weeks after commencing chemo/RT' involves additional Multiparametric MRI + PET/CT 2 weeks into chemo/RT Intervention 2 :\'Late MRI and PET/CT 6 weeks post chemo/RT' involves additional Multiparametric MRI + PET/CT 6 weeks post chemo/RT"
3049140|NCT02233361|Experimental|Counseling|The intervention group will be informed in advance of a follow-up appointment six month after they have received their hearing aid. They will know that support will be given and time-use of the hearing aid will be checked out. Counseling on hearing aid use will be given.
3049141|NCT02233361|No Intervention|Counselling|The control group will not receive any information of a follow-up appointment. However, they will receive a notice on this after six month.
3049142|NCT02233348||ASD group|Subjects with DSM-IV ASD diagnosis
3049143|NCT02233348||Control group|Controls without lifetime ASD or a family history of ASD
3049144|NCT02233322|Experimental|iron supplements|all subjects will receive iron supplementation based on iron levels in blood
3049145|NCT02233309||Monitoring of pressures during caudal anesthesia|"Patients receiving caudal anesthesia as standard of care for a surgical procedure.~Our study adds a monitoring line to the needle for the caudal. The caudal itself is not part of the study."
3049146|NCT02233296|Experimental|Group A|Dosing Sequence: Administration of lasmiditan 200 mg in fed state in Dosing Period 1 followed by administration of lasmiditan 200 mg in fasted state in Dosing Period 2
3049147|NCT02233296|Experimental|Group B|Dosing Sequence: Administration of lasmiditan 200 mg in fasted state in Dosing Period 1 followed by administration in lasmiditan 200 mg fed state in Dosing Period 2.
3049148|NCT02233283|Active Comparator|Hypercaloric diet and basal|Volunteers fed a hypercaloric diet for one month will be submitted to a fasting period of ten hours duration
3049149|NCT02233283|Experimental|Hypercaloric diet and clamp|Volunteers fed a hypercaloric diet for one month will be submitted to a hyperinsulinemic and euglycemic clamp of ten hours duration
3049150|NCT02233283|Active Comparator|Isocaloric diet and basal|Volunteers fed a isocaloric diet for one month will be submitted to a fasting period of ten hours duration
3049151|NCT02233283|Experimental|Isocaloric diet and clamp|Volunteers fed a isocaloric diet for one month will be submitted to a hyperinsulinemic and euglycemic clamp of ten hours duration
3049152|NCT02233244|Other|CTX-4430 and midazolam|Midazolam 2 mg solution once, CTX-4430 100 mg tablet once per day for 7 days, Midazolam 2 mg solution once
3049153|NCT02233231|Active Comparator|Varenicline|Varenicline 0,5 mg x 1 day 1-3 Varenicline 0,5 mg x 2 day 4-6 Varenicline 2 mg x 1 day 7 to week 12
3049154|NCT02233231|Placebo Comparator|Placebo|Placebo tablets equivalent to IMP.
3049155|NCT02233218|Experimental|telmisartan, Amlodipine, Rosuvastatin|This arm is consist of 40 subjects. Telmisartan80mg + Amlodipine 10mg 9 days, Telmisartan80mg + Amlodipine 10mg , Rosuvastatin 20mg 5days Total 14days administration of investigational products to healthy male volunteers
3049156|NCT02233218|Experimental|Telmisartan, Amlodipine, Rosuvastatin|This arm is consist of 20 subjects. Rosuvastatin 20mg 5 days, Rosuvastatin 20mg , Telmisartan80mg + Amlodipine 10mg 9days, Total 14days administration of investigational products to healthy male volunteers
3049157|NCT02233205|Experimental|microbubbles & platinum and gemcitabine|In 30min after chemotherapy, inject ultrasonic microbubbles 1 ml once and inject 5 times in 20min and locate the ultrasonic probe on the lesion The chemotherapy of pancreatic is gemcitabine.The chemotherapy of liver metastases is oxaliplatin with taxol.
3049158|NCT02233179|Experimental|Removable Cast Walker|An offloading device that can be removed by the patients
3049159|NCT02233179|Active Comparator|Irremovable Cast Walker|A removable cast rendered irremovable using instant total contact cast, so patients cannot remove offloading device.
3049160|NCT02233153||Pre-Elder Friendly Surgical Intervention Group|Elder Acute Care and Emergency Surgery patients
3049161|NCT02233153||Post-Elder Friendly Surgical Intervention Group|Elder Acute Care and Emergency Surgery patients
3049162|NCT02233153||Pre-Elder Friendly Surgical Control Group|Elder Acute Care and Emergency Surgery patients
3049163|NCT02233153||Post-Elder Friendly Surgical Control Group|
3049164|NCT02233140|Experimental|Shockwave with manual manipulation|A shockwave (EPAT) therapy with two supervised manual manipulation per week
3049165|NCT02233140|Active Comparator|Manual manipulation|A Placebo (no) shockwave with two supervised manual manipulations per week
3049166|NCT02233127||Birth Cohort|The cohort will comprise approximately 3000 pregnant women and their unborn babies, enrolled to participate in the control arm of a cluster-randomized controlled intervention trial (NCT02130856).
3049167|NCT02233114|Experimental|Yogic exercises|Yogic exercises for lung disorders
3049168|NCT02233114|Active Comparator|physiotherapy|Physiotherapy during the yogic exercises
3049169|NCT02233101|Active Comparator|Oral Tranexamic Acid|Patients will receive either oral or intravenous Tranexamic Acid
3049170|NCT02233101|Active Comparator|Intravenous Tranexamic Acid|Patients will receive either oral or intravenous Tranexamic Acid
3049259|NCT02232425|Experimental|Drug: IX-01|Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
3049171|NCT02233088|Experimental|ELM Group|A 6-month group lifestyle intervention, consisting of 12 weekly and 6 bi-weekly 2-hour sessions. The sessions consist of 30-min physical activity, 30-min meal demonstration, and 60-min group behavioral intervention, with a focus on experiential learning in naturalistic setting. Sessions are facilitated by dietitian/personal trainer and behavioral specialist.
3049172|NCT02233088|Other|ELM Classes|A 6-month health education, consisting of 12 weekly and 6 bi-weekly 30-45 min sessions. The sessions consist of didactic classes, with a focus on health education curriculum. Sessions are facilitated by a health educator and medical providers.
3049173|NCT02233088|Active Comparator|ELM Individual|A 6-month intervention, that consists of educational manuals on physical activity, diet and stress reduction and recommended 3 medical visits every 3 months for medical counseling and feedback using 5A (Ask, Advise, Assess, Assist, and Arrange) framework . These Metabolic syndrome care materials and provider documentation will be embedded in electronic medical record system, and will be accessible to medical providers by usual means. This enhanced usual care by participant's usual health care provider focuses on metabolic syndrome and lifestyle modifications to reduce the risk of chronic disease.
3049174|NCT02233075|Experimental|REP 2139-Ca + Pegasys (TM)|REP 2139-Ca 500 mg QW for 15 weeks followed by REP 2139-Ca 250mg QW + Pegasys(TM) 180ug QW for 15 weeks followed by Pegasys(TM) 180ug QW for 33 weeks.
3049175|NCT02233062|Experimental|Semen quality|
3049176|NCT02233049|Experimental|R1: erlotinib versus dasatinib|EGFR+ only Tarceva® (erlotinib): 25 mg and 100 mg tablets. The prescribed dose is 125 mg/m²/day orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
3049177|NCT02233049|Experimental|R2: everolimus versus dasatinib|PTEN-loss only Votubia® (everolimus): 2.5 mg tablets. The prescribed dose is 5 mg/m²/day, orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
3049178|NCT02233049|Experimental|R3: erlotinib versus everolimus versus dasatinib|EGFR+ and PTEN-loss or inconclusive biopsy Tarceva® (erlotinib): 25 mg and 100 mg tablets. The prescribed dose is 125 mg/m²/day orally, once daily. Votubia® (everolimus): 2.5 mg tablets. The prescribed dose is 5 mg/m²/day, orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
3049179|NCT02233049|Experimental|Cohort Dasatinib|Neither EGFR overexpression nor loss of PTEN expression Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day
3049180|NCT02233023|Experimental|Pramixpexole|
3049181|NCT02233023|Active Comparator|Bromocriptine and other dopamine agonists|
3049182|NCT02233010||kidney function normal group|kidney function normal group : defined by the normal level of NGAL after post operation 4hrs
3049183|NCT02233010||kidney function decreased group|kidney function decreased group : defined by the increased level of NGAL after post operation 4hrs
3049184|NCT02232997|Active Comparator|Long Hydration|Long term hydration at routine speed(12h before and after procedure)
3049185|NCT02232997|Active Comparator|Short Hydration|Short term hydration at high speed(1h before and 4h after procedure)
3049186|NCT02232984||All study patients|All study patients will be implanted with a BSC quadripolar CRT-D and a currently approved quadripolar left ventricular lead. At the pre-discharge visit, multiple vectors will be tested in order to assess their respective performance.
3049187|NCT02232971|Placebo Comparator|Placebo|Isotonic Saline
3049188|NCT02232971|Experimental|Glucagon 0.1 mg|GlucaGen(r) 0.1 mg administration
3049189|NCT02232971|Experimental|Glucagon 0.2 mg|GlucaGen(r) 0.2 mg administration
3049190|NCT02232971|Experimental|Glucagon 0.3 mg|GlucaGen(r) 0.3 mg administration
3049191|NCT02232958|Experimental|Hyperbaric Oxygen treatment|administration of 100% Oxygen at 2 Atmospheres Absolute for 1 hour 1 daily, 5 days a week for 2 weeks
3049192|NCT02232945|Placebo Comparator|placebo|placebo of oseltamivir phosphate and placebo of Banlangen(Radix Isatidis) granules.
3049193|NCT02232945|Experimental|Banlangen granules & placebo|Banlangen(Radix Isatidis) granules and placebo of oseltamivir phosphate
3049194|NCT02232945|Active Comparator|oseltamivir phosphate & placebo|oseltamivir phosphate and placebo of Banlangen(Radix Isatidis) granules
3049195|NCT02232932|Experimental|CAPECITABINE-Radiotherapy -Liver Transplantation|Neoadjuvant Radio-Chemotherapy (RC) and Liver Transplantation (LT)
3049196|NCT02232932|Active Comparator|RESECTION|Liver resection
3049197|NCT02232919|Experimental|Deep Brain Stimulation|The design of this translation trial is a single-center, single cohort, open-label and non-masked study. The aim is to evaluate tolerability of chronic low-frequency electrical stimulation of the VMH, while achieving weight loss in morbidly obese subjects. The subjects must have a body-mass index [BMI] greater than 40, and no obesity co-morbidities, such as diabetes or cardiopulmonary abnormalities. Up to six subjects will be implanted in this protocol.
3049198|NCT02232906|Experimental|intravenous ferric carboxymaltose|
3049199|NCT02232893|Experimental|Daikenchuto (TU-100)|Daikenchuto (TU-100) 5g TID/3 times per day (15g/day)
3049200|NCT02232893|Placebo Comparator|Placebo|Placebo TID
3049201|NCT02232880|Active Comparator|abatacept|"Subjects randomized to abatacept weighing 60 to 100 kg will receive 750 mg, and those >100 kg will receive 1000 mg abatacept by intravenous infusion at 0 [randomization], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase."
3049202|NCT02232880|Placebo Comparator|placebo|"Subjects randomized to placebo will receive 100 ml normal saline by intravenous infusion at 0 [randomization], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase."
3049203|NCT02232867|Experimental|Arm and Leg Cycling Exercise Program|Multiple baseline test sessions will be used for the same participant to establish a meaningful baseline thus confirming consistency of all outcome measures prior to the intervention.
3049204|NCT02232854|Experimental|Depression training/supervision program|"A complex intervention, which will include:~Primary Health Care team training in depression~A focus group, after training~Telephone monitoring of patients~Web-based supervision of clinicians"
3049205|NCT02232854|No Intervention|Usual Care|Patients in the control group will receive all the interventions that are guaranteed for persons with depression in Chile: treatment in Primary Health Care clinics with the Primary Health Care team and referral to the regional specialized psychiatric service.
3049206|NCT02232841||Mechanical ventilation|Hospitalized adult patients with lung injury receiving mechanical ventilation and who also have received or will receive a CT scan as part of their standard care
3049207|NCT02232828|Experimental|Selective removal|
3049208|NCT02232828|Active Comparator|Stepwise removal|
3049209|NCT02232802|Experimental|Enoxaparin Sodium Chemi|Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.
3049210|NCT02232802|Experimental|Clexane|Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.
3049211|NCT02232789|Experimental|Mephedrone|Mephedrone 200 mg, single dose, oral administration
3049212|NCT02232789|Active Comparator|3,4-methylenedioxymethamphetamine|3,4-methylenedioxymethamphetamine (MDMA) 100 mg, single dose, oral administration
3049213|NCT02232789|Placebo Comparator|Lactose|Placebo, single dose, oral administration
3049214|NCT02232776|Experimental|Losartan|
3049215|NCT02232763|Experimental|Losartan|12 weeks of losartan or placebo with crossover to the other
3049216|NCT02232763|Experimental|Placebo|12 weeks of losartan or placebo with crossover to the other
3049217|NCT02232737|Experimental|0.8 mg nicotine|0.8 mg nicotine cigarettes
3049218|NCT02232737|Experimental|0.12 mg nicotine|0.12 mg nicotine cigarettes
3049219|NCT02232737|Experimental|0.03 mg nicotine|0.03 mg nicotine cigarettes
3049220|NCT02232724|Experimental|Dual time point FDG PET/CT|Choline PET/CT and dual time point FDG PET/CT
3049221|NCT02232698|Experimental|Sensor Based Glucose Monitoring System|Standard sensing system use for 6 months.
3049222|NCT02232698|Active Comparator|Standard Blood Glucose Monitoring|Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
3049223|NCT02232685|Experimental|Choline PET/CT|18F-Choline PET/CT
3049224|NCT02232672|Experimental|MeAIB PET/CT|Choline PET/CT and MeAIB PET/CT
3049225|NCT02232659|Experimental|Primary Arm|Use of the SynCardia 70cc TAH-t for Destination Therapy to support an HDE Application.
3049226|NCT02232659|Experimental|Secondary Arm|Use of the SynCardia 70cc TAH-t for Destination Therapy in a less-restrictive patient population to further characterize the use of the 70cc TAH-t for DT.
3049227|NCT02232646|Experimental|BBI503|
3049228|NCT02232633|Experimental|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily
3049229|NCT02232620|Experimental|BBI503|
3049230|NCT02232607|Experimental|Lacidipine, low dose|
3049231|NCT02232607|Experimental|Lacidipine, medium dose|
3049232|NCT02232607|Experimental|Lacidipine, high dose|
3049233|NCT02232607|Active Comparator|Placebo|
3049234|NCT02232594||chronic obstructive respiratory tract disease patients|
3049235|NCT02232581|Experimental|Alovudine - low|
3049236|NCT02232581|Experimental|Alovudine - medium|
3049237|NCT02232581|Experimental|Alovudine - high|
3049238|NCT02232581|Placebo Comparator|Placebo|
3049239|NCT02232568|Experimental|Feedback Arm|Orthopedic surgeons in the Feedback Arm will receive monthly reports providing individualized data on compliance with the FOCUS trial RBC transfusion guideline (pretransfusion Hb <8 g/dL for hip surgery patients in the postoperative period.) Feedback data will be anonymized, but surgeons will be able to see their own data in comparison with their peers.
3049240|NCT02232568|No Intervention|Control Arm|Orthopedic surgeons in the Control Arm will not receive any feedback on their use of RBC transfusion in hip surgery patients.
3049241|NCT02232555|Experimental|Duloxetine|
3049242|NCT02232555|Placebo Comparator|Placebo|
3049243|NCT02232542|Experimental|Duloxetine - low dose|
3049244|NCT02232542|Experimental|Duloxetine - high dose|
3049245|NCT02232542|Placebo Comparator|Placebo|
3049246|NCT02232529|Experimental|Part 1: MIN-101|"MIN-101~modified release formulation (MR),single oral dose between 16 and 64 mg"
3049247|NCT02232529|Experimental|Part 2: MIN-101 low dose|"MIN-101~single daily oral dose, low dose MR formulation, from Day 1 to Day 7"
3049248|NCT02232529|Placebo Comparator|Part 2: placebo|"placebo MIN-101~daily oral dose from Day 1 to Day 7"
3049249|NCT02232529|Experimental|Part 2: MIN-101 high dose|"MIN-101~single daily oral dose, low dose MR formulation, from Day 1 to Day 7"
3049250|NCT02232516|Experimental|Treatment (romidepsin, lenalidomide)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
3049251|NCT02232490|Experimental|hepcortespenlisimut-L|Experimental placebo-controlled clinical of hepcortespenlisimut-L (V5) therapeutic vaccine against HCC
3049252|NCT02232490|Placebo Comparator|placebo|placebo
3049253|NCT02232477|Experimental|Open-label treatment|laronidase 1.74 mg IT q 3 months for five years
3049254|NCT02232464||ADHD group|Adults with clinical diagnosis of ADHD according to the DSM-IV criteria
3049255|NCT02232464||Control group|Age-, sex-, and IQ-matched healthy controls without lifetime diagnosis with ADHD
3049256|NCT02232451|Experimental|ERCP with loop tip wire|ERCP with loop tip wire is an endoscopic procedure to treat biliary disease. Wire guide cannulation with loop-tip is a new procedure to improve rate of biliary cannulation and reduce complication, as post-procedure pancreatitis.
3049257|NCT02232451|Active Comparator|ERCP for cannulation|ERCP for cannulation of CBD with traditional technique
3049258|NCT02232438|Experimental|Behavioral activation therapy|Patients treated with Behavioral activation therapy will improve in mood and anxiety symptoms and psychosocial functioning at the end of the 6 weeks of treatment.
3049260|NCT02232425|Placebo Comparator|Placebo|Two to four capsules administered orally, 1-6 hours prior to sexual activity
3049261|NCT02232399|Active Comparator|Milrinone|In this arm the patients will receive Milrinone as an inotrope agent. Concentration: 0.2 mg/mL Infusion rate: 0.12 mL / kg / hr = Dose delivered 0.4 μg / kg / min --- Bolus dose: 1.44 ml / kg / hr in ten minutes (a maximum volume 0.24 ml / kg) = 48 μg / kg
3049262|NCT02232399|Experimental|Levosimendan|In this arm the patients will receive Levosimendan as an inotrope agent. Concentration: 0.05 mg/mL Infusion rate: 0.12 mL / kg / hr = Dose delivered 0.1 μg / kg / min --- Bolus dose: 1.44 ml / kg / hr in ten minutes (a maximum volume 0.24 ml / kg) = 12 μg/kg
3049263|NCT02232386|Experimental|Treatment|"Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Treatment duration with Ibrutinib will be based on what comes first of the following three options:~Treatment until progression or toxicity~Treatment until MRD negativity for 6 months~Treatment for 6 years. Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1."
3049264|NCT02232373|Sham Comparator|Normal FODMAP arm|Low FODMAP dietary advice; participants to supplement diet with oligofructose, a poorly digested carbohydrate that will restore FODMAP content to the diet.
3049265|NCT02232373|Experimental|Low FODMAP arm|Low FODMAP dietary advice; participants to supplement with maltodextrin (easily digestible carbohydrate)
3049266|NCT02232360|Experimental|Rosuvastatin and fenofibrate|Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
3049267|NCT02232360|Active Comparator|Rosuvastatin alone|Rosuvastatin 10 mg per day
3049268|NCT02232347|Experimental|ketamine|ketamine 5 mg/kg/h, continuous infusion for 48 hours
3049269|NCT02232347|Active Comparator|sufentanil|sufentanil 0,5 mcg/kg/h, continuous infusion for 48 hours
3049270|NCT02232334|Experimental|Osteopathic manual treatment|Global Osteopathic Manual treatment: each subject will be treated according to what restrictions or areas of poor mobility are found individually. No two subjects will receive the same overall treatment.
3049271|NCT02232334|No Intervention|Control--no change in current treatment of subject|The population will act as their own control prior to intervention of osteopathy, their will be a control period where the subject maintains current treatment of their gastroparesis. During that period they will fill out the GCSI measuring tool at the beginning of the control period and at the end. Those measurements will be compared to the GSCI results during the intervention period.
3049272|NCT02232321|Other|PsA MDA|
3049273|NCT02232308|Experimental|Nizatidine|Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
3049274|NCT02232308|Experimental|Lisinopril|Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
3049275|NCT02232308|Experimental|Nizatidine plus Lisinopril|Nizatidine (150 mg) and Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
3049276|NCT02232308|Placebo Comparator|Placebo|Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
3049277|NCT02232295|Active Comparator|Conventional group|Conventional group consist of Upper extremity task oriented functional exercises. Components of Task oriented training include weight bearing, supportive reactions, and reaching, grasping, holding and release activities.
3049278|NCT02232295|Experimental|Graded Motor imagery group and Conventional group|"Graded Motor imagery is a three stage process, was performed five days a week for six weeks of one hour duration. It comprises of:~Left Right discrimination training (Implicit Motor Imagery) - 2 weeks~Explicit Motor Imagery (Imagined movements) - 2 weeks~Mirror Therapy - 2 weeks"
3049279|NCT02232282|Sham Comparator|Minimal Acupuncture|"Fifteen (15) will be allocated in the control sham/minimal acupuncture + standard medical treatments of IC. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture."
3049280|NCT02232282|Active Comparator|Standard acupuncture treatment|Fifteen (15) will be allocated in the standard acupuncture treatment + medical management of IC. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
3049281|NCT02232269|Placebo Comparator|Water plus Felodipine|Felodipine extended-release tablet ,10 mg, single dose, 8 hours
3049282|NCT02232269|Active Comparator|Black Coffee|Black Coffee, 300 ml, 0 and 1 hour
3049283|NCT02232269|Experimental|Black Coffee plus Felodipine|"Black Coffee, 300 ml, 0 and 1 hour~Felodipine extended-release tablet ,10 mg, single dose, 8 hours"
3049284|NCT02232269|Active Comparator|Grapefruit Juice plus Felodipine|"Grapefruit Juice, 300 ml, 0 and 1 hour~Felodipine extended-release tablet ,10 mg, single dose, 8 hours"
3049285|NCT02232256|Experimental|CALPXT96|"1st treatment period: 4 weeks CALPXT96 (two capsules hs at bedtime)~2 week wash out period~2nd treatment period: 4 weeks placebo (two capsules hs at bedtime)"
3049286|NCT02232256|Placebo Comparator|Placebo|"1st treatment period: 4 weeks placebo (two capsules hs at bedtime)~2 week wash 'out' period~2nd treatment period: 4 weeks CALPXT96 (two capsules hs at bedtime)"
3049287|NCT02232243|Experimental|Hydroxychloroquine|Hydroxychloroquine 14 days
3049288|NCT02232217|Experimental|Cognitive Behavior Therapy Sleep|Children in this arm will receive instructions on the use of 'coping thoughts.' Common elements across the CBTcs sessions include reviewing progress, setting goals for change, problem solving to address challenges/barriers, and reinforcing progress
3049289|NCT02232217|Active Comparator|Education Control|Children in this arm will receive sleep and dietary education, as well as general coping strategies and controls for staff attention and seasonal effects that could influence changes in sleep and health outcomes.
3049330|NCT02231931|Experimental|E (Test) 1|Digoxin (1 tablet), Furosemide (0.5 mL oral solution), Metformin hydrochloride (1 film-coated tablet), Rosuvastatin (1 film-coated tablet), fasted
3049622|NCT02229929|Experimental|Part A: CR845 0.5 mcg/kg|Intravenous CR845, 0.5 mcg/kg
3049290|NCT02232204|Active Comparator|CBT for Insomnia in ICD Patients (CBT-I-ICD)|Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
3049291|NCT02232204|No Intervention|Waitlist Control (WLC)|Participants in the WLC group will not receive any treatment between the baseline and post-treatment assessments. After the final follow-up assessment, they will be offered the opportunity to receive CBT-I-ICD.
3049292|NCT02232191|Active Comparator|Nonoperative|Pneumococcal vaccine (Pneumovax-23) will be administered within 72 hours of injury. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
3049293|NCT02232191|Active Comparator|Angioembolization|Pneumococcal vaccine (Pneumovax-23) will be administered 14 days after embolization. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
3049294|NCT02232191|Active Comparator|Splenectomy|Pneumococcal vaccine (Pneumovax-23) will be administered 14 days after splenectomy. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
3049295|NCT02232178|Experimental|2 100mg Xaracoll implants|Bupivacaine HCl implant
3049296|NCT02232178|Experimental|3 100mg Xaracoll implants|Bupivacaine HCl implant
3049297|NCT02232178|Active Comparator|150mg Bupivacaine HCl injection|Bupivacaine HCl
3049298|NCT02232165|Experimental|Hypotension avoidance (MAP >= 65 mmHg)|Mean arterial blood pressure is maintained >= 65 mmHg for 7 days following acute SCI.
3049299|NCT02232165|Active Comparator|Induced hypertension (MAP >= 85 mmHg)|Induced hypertension with mean arterial blood pressure >= 85 mmHg for 7 days following acute SCI.
3049300|NCT02232152|Experimental|Treatment (6,8-bis(benzylthio)octanoic acid, fluorouracil)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-4 and fluorouracil IV over 46 hours on days 2-4. Courses repeat every 2 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
3049301|NCT02232139|No Intervention|Standard therapy group|Participant who will not receive midazolam for pharmacological anxiolytic premedication before general surgery
3049302|NCT02232139|Experimental|Midazolam group|Participant who will receive midazolam for pharmacological anxiolytic premedication before general surgery
3049303|NCT02232126|No Intervention|Usual Care|
3049304|NCT02232126|Experimental|Intervention|
3049305|NCT02232113|Experimental|CERA|We included HD patients with stable hematocrit (between 30~36%) under intravenous administration of CERA 100 μg once monthly for two months. Then they were shifted to receive CERA 50μg twice monthly for anther two months and finally they were shifted back to receive CERA 100 μg once monthly again for additional two months. Then we compared the hematocrit, nutrition status and inflammation markers every two months for 6 months totally. Those who had bleeding or received surgery or blood transfusion were excluded.
3049306|NCT02232100|Experimental|AMG10|Attentional bias modification group - 10 training sessions
3049307|NCT02232100|Placebo Comparator|10ACG|Attentional control group - 10 placebo sessions
3049308|NCT02232100|Experimental|18AMG|Attentional bias modification group - 18 training sessions
3049309|NCT02232100|Placebo Comparator|18ACG|Attentional control group - 18 placebo sessions
3049310|NCT02232087|Experimental|test product|salmeterol and fluticasone propionate
3049311|NCT02232087|Active Comparator|reference product|salmeterol and fluticasone propionate
3049312|NCT02232074|Experimental|Patient navigation enhanced with legal support|In addition to receiving standard navigation, patients will be connected with a Patient Navigator who is partnered with a lawyer from Medical-Legal Partnership to provide personalized assistance with regard to social-legal barriers.
3049313|NCT02232074|No Intervention|Standard patient navigation|These patients will receive standard patient navigation which will work to ensure that services are coordinated amongst medical personnel, while also addressing patients' needs.
3049314|NCT02232061|Other|Fingolimod|
3049315|NCT02232048||Corticosteroid Treatment|Patients in the internal medicine department who are being treated with corticosteroids will undergo Transthoracic Echocardiogram to determine change in heart function.
3049316|NCT02232035|Placebo Comparator|normal saline, active phase of labor|A single dose intravenous injection of normal saline (2ml) at the beginning of active phase of labor in the group.
3049317|NCT02232035|Experimental|diazepam, active phase of labor|A single dose intravenous injection of diazepam (10mg, 2ml) at the beginning of active phase of labor in the group.
3049318|NCT02232022|Experimental|NonCryptogenic Ischemic Stroke Patients|
3049319|NCT02232009|Other|Neonatal Scanner|
3049320|NCT02231996||gene mutation|
3049321|NCT02231983||Severe Combined Immunodeficiency|Case histories were analyzed to grasp important characteristics of the diseases. Distribution of lymphocyte subsets from peripheral blood were examined by flow cytometry. Amplify and identify exons from gene IL-2RG by PCR and agarose gel electrophoresis, and then followed by gene sequencing.
3049322|NCT02231970|Experimental|Endoscopic sleeve gastroplasty|The intervention is an endoscopic procedure: to perform endoscopic sleeve gastroplasty we used a cap-based flexible endoscopic suturing system (OverStitch™, Apollo, Inc. Austin, Texas) mounted on a double-channel endoscope (GIF-2T160; Olympus Medical Systems Corporation, Tokyo, Japan) to achieve full-thickness, running sutures through the gastric wall from antrum to fundus.
3049323|NCT02231957|Experimental|educational text message reminders|receipt of education-embedded text message vaccine reminders
3049324|NCT02231957|Active Comparator|conventional text message reminders|receipt of conventional text message vaccine reminders
3049325|NCT02231944|Experimental|Replenine®-VF|
3049326|NCT02231931|Experimental|A (Reference 1) Digoxin|1 tablet as single dose, fasted
3049327|NCT02231931|Experimental|B (Reference 2) Furosemide|oral solution, as single dose, fasted
3049328|NCT02231931|Experimental|C (Reference 3) Metformin hydrochloride|1 film-coated tablet as single dose, fasted
3049329|NCT02231931|Experimental|D (Reference 4) Rosuvastatin|1 film-coated tablet as single dose, fasted
3049623|NCT02229929|Experimental|Part A: CR845 1.0 mcg/kg|Intravenous CR845, 1.0 mcg/kg
3049331|NCT02231931|Experimental|F (Test 2)|Digoxin (1 tablet), Furosemide (0.5 mL oral solution), Metformin hydrochloride (2 film-coated tablets), Rosuvastatin (1 film-coated tablet), fasted
3049332|NCT02231931|Experimental|G (Test 3)|Digoxin (1 tablet), Furosemide (2.0 mL oral solution), Metformin hydrochloride (1 film-coated tablet), Rosuvastatin (1 film-coated tablet), fasted
3049333|NCT02231918|Experimental|MIRAPEX® - low|
3049334|NCT02231918|Experimental|MIRAPEX® - medium|
3049335|NCT02231918|Experimental|MIRAPEX® - high|
3049336|NCT02231905|Experimental|BI-Sifrol®|Tablets were administrated after switching from prior treatment of dopamine agonist (talipexole), treatment period consisted of an ascending period and a maintenance period, total duration was 4 to 12 weeks.
3049337|NCT02231892|Experimental|Real TMS|rTMS (frequency and intensity)
3049338|NCT02231892|Sham Comparator|Sham TMS|Sham setting on coil
3049339|NCT02231879|Other|A to B|Crossover Double Blind Study: Subjects will start with one drug for one year and crossover to the other drug for the second year.
3049340|NCT02231879|Other|B to A|Crossover Double Blind Study: Subjects will start with one drug for one year and crossover to the other drug for the second year.
3049341|NCT02231866|Experimental|Group 1|cAd3-EBO at 2x10(10)PU IM
3049342|NCT02231866|Experimental|Group 2|cAd3-EBO at 2x10(11)PU IM
3049343|NCT02231866|Experimental|Group 3|cAd3-EBO at 2x10(11)PU IM boost of Ebola DNA WT vaccine (VRC 206 participants)
3049344|NCT02231866|Experimental|Group 4A|cAd3-EBOZ at 1x10(10)PU IM
3049345|NCT02231866|Experimental|Group 4B|cAd3-EBOZ at 1x10(11)PU IM
3049346|NCT02231866|Experimental|Group 5|cAd3-EBO at 2x10(11)PU IM
3049347|NCT02231853|Experimental|-1|1x10e4 MVST/kg infusion
3049348|NCT02231853|Experimental|1|1x10e5 MVST/kg infusion
3049349|NCT02231853|Experimental|2|5x10e5 MVST/kg infusion
3049350|NCT02231853|Experimental|3|1x10e6 MVST/kg infusion
3049351|NCT02231853|Experimental|3B|1x10e6 MVSTr/kg infusion
3049352|NCT02231853|Experimental|4|5x10e6 MVSTr/kg infusion
3049353|NCT02231827|Experimental|Gait analysis|
3049354|NCT02231814|Experimental|Group 1|Crohn's Disease Exclusion Diet+Partial Enteral Nutrition (PEN): Crohns Disease Exclusion Diet + PEN
3049355|NCT02231814|Experimental|Group 2|Crohn's Disease Exclusion Diet alone with a calcium supplement
3049356|NCT02231801||Mother-Infant Dyad|Skin-to-skin holding of preterm infants by their mothers
3049357|NCT02231788|Experimental|Telminuvo®Tab. 40/2.5mg|Telminuvo®Tab.(Telmisartan/S-Amlodipine) 40/2.5mg
3049358|NCT02231788|Active Comparator|Telmitrend®Tab. 80mg|Telmitrend®Tab.(Telmisartan) 80mg
3049359|NCT02231775|Experimental|Dabrafenib + Trametinib + Surgery|"Starting Dose of Dabrafenib: 150 mg by mouth twice a day. Starting Dose of Trametinib: 2 mg by mouth once daily.~At Week 8 after starting Dabrafenib and Trametinib, participant has MRI and/or CT scans of brain to check status of disease. Participant also has CT scans of the chest, abdomen, and pelvis. If scans show disease has not spread or grown, surgery is scheduled. Participant continues taking study drugs until day of surgery. Study drugs continued after surgical recovery for up to an additional 44 weeks."
3049360|NCT02231762|Experimental|Lanreotide Autogel 120mg & Temozolomide|"Combination phase for first 6 months: Lanreotide Autogel 120 mg and Temozolomide.~Followed by either 6 months Lanreotide Autogel 120 mg maintenance or 6 months of no treatment."
3049361|NCT02231749|Experimental|Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg|Nivolumab 3 mg/kg combined with Ipilimumab 1 mg/kg solutions intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solutions intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3049362|NCT02231749|Active Comparator|Arm B: Sunitinib 50 mg|"Sunitinib 50 mg capsules by mouth once daily for 4 weeks then 2 weeks off, continuously until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~After completion of final analysis eligible participants may switch from receiving Sunitinib to receiving Nivolumab 3 mg/kg IV combined with Ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then Nivolumab 240mg flat dose IV every 2 weeks"
3049363|NCT02231736||Type 2 diabetes, HbA1c>7.5|
3049364|NCT02231736||Type 2 diabetes, HbA1c<7.5|
3049365|NCT02231723|Experimental|A: BBI608 in combination with Gemcitabine and nab-Paclitaxel|
3049366|NCT02231723|Experimental|B: BBI608 in combination with modified FOLFIRINOX|
3049367|NCT02231723|Experimental|C: BBI608 in combination with FOLFIRI|
3049368|NCT02231723|Experimental|D: BBI608 in combination with MM-398, 5-FU and leucovorin|
3049369|NCT02231710|Experimental|BPX-501 and AP1903|Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by AP1903 infusion on day 7
3049370|NCT02231697||XLMTM patients - deceased|Non-interventional, retrospective medical chart review
3049371|NCT02231697||XLMTM patients - living|Non-interventional, retrospective medical chart review
3049372|NCT02231684|Experimental|s.c. 0.5 mg (1 mg/ml) followed by s.c. 0.5 mg (3 mg/ml)|
3049373|NCT02231684|Experimental|s.c. 0.5 mg (3 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
3049374|NCT02231684|Experimental|s.c. 0.5 mg (3 mg/ml) followed by s.c. 0.5 mg (10 mg/ml)|
3049375|NCT02231684|Experimental|s.c. 0.5 mg (10 mg/ml) followed by s.c. 0.5 mg (3 mg/ml)|
3049376|NCT02231684|Experimental|s.c. 0.5 mg (1 mg/ml) followed by s.c. 0.5 mg (10 mg/ml)|
3049377|NCT02231684|Experimental|s.c. 0.5 mg (10 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
3049378|NCT02231684|Experimental|i.v. 0.25 mg (1 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
3049379|NCT02231684|Experimental|s.c. 0.5 mg (1 mg/ml) followed by i.v. 0.25 mg (1 mg/ml)|
3049380|NCT02231671|Experimental|Part 1: Absolute Bioavilability|Part 1 of this study is an absolute bioavailability study where the IV (intravenous) microtracer dose of ALS-008112 is administered 15-30 minutes after the oral dose to determine the bioavailability of the oral dose compared to the IV dose. The maximum microtracer IV dose administered in Part 1 of this study will not exceed a single dose of 100 μg [14C]-ALS-008112 containing NMT (not more than) 37.0 kBq (1000 nCi) 14C. Based upon previous clinical observations, it is anticipated that the single oral dose and IV microdose to be utilised in Part 1 will provide acceptable PK data and will be safe and well tolerated.
3049624|NCT02229929|Experimental|Part A: CR845 2.5 mcg/kg|Intravenous CR845, 2.5 mcg/kg
3049381|NCT02231671|Experimental|Part 2: Mass Balance|Part 2 of this study is an absorption, metabolism and excretion study, for which a single 375 mg [14C]-ALS-008176 (containing NMT 6.85 MBq (megabecquerel) (185 μCi) 14C) dose has been selected for evaluation based upon data from prior studies. Based upon previous clinical observations, it is anticipated that the dose to be utilised in Part 2 will provide acceptable PK data, will be safe and well tolerated and is within the therapeutic range.
3049382|NCT02231658|Experimental|Liraglutide|The highest injected once daily dose will be 1.8 mg s.c. for liraglutide.
3049383|NCT02231658|Experimental|Lixisenatide|The highest injected once daily dose will be 20µg s.c. for lixisenatide.
3049384|NCT02231645|Experimental|STN DBS group|Experimental protocol is executed in PD patients with STN DBS implant in STN DBS ON and OFF conditions
3049385|NCT02231645|No Intervention|Control group|Experimental protocol is executed in PD patients without STN DBS implant twice without experimental variable manipulation.
3049386|NCT02231632|Experimental|Live attenuated Poliomyelitis vaccine (human diploid cell)|6.15 lgCCID50(containing typeⅠattenuated poliomyelitis not lower than 6.0 lgCCID50，typeⅡnot lower than 5.0 lgCCID50，type Ⅲ not lower than 5.5 lgCCID50).
3049387|NCT02231632|Experimental|Poliomyelitis（Live）Vaccine(Monkey Kidney Cell),Oral|6.15 lgCCID50(containing typeⅠattenuated poliomyelitis not lower than 6.0 lgCCID50，typeⅡnot lower than 5.0 lgCCID50，type Ⅲ not lower than 5.5 lgCCID50).
3049388|NCT02231619|No Intervention|Demonstration of LSUPT at baseline|This group conduct a LSUPT on their own urine sample at baseline with assistance from a fieldworker.
3049389|NCT02231619|Active Comparator|Baseline verbal instruction of LSUPT|Verbal instruction on how to do LSUPT at baseline
3049390|NCT02231606|No Intervention|Group 1: Pure Control|Provision of glasses prescription only
3049391|NCT02231606|Experimental|Group 2: Free Glasses|Free glasses for all, no upgrade glasses offered
3049392|NCT02231606|Experimental|Group 3: Free + Upgrade Glasses 1|Free glasses for all, optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
3049393|NCT02231606|Experimental|Group 4: Free + Upgrade Glasses 2|Free glasses for all, optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
3049394|NCT02231593||Acromegalic patients|
3049395|NCT02231580|Experimental|BN82451B|BN82451B capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.
3049396|NCT02231580|Placebo Comparator|Placebo|Placebo capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.
3049397|NCT02231567|Experimental|Neurocognitive Rehabilitation|Rehabilitative approach based on exercises proposed as sensory-motor problems, whose solution involves the use of higher cognitive functions (attention, memory, language).
3049398|NCT02231567|Active Comparator|Traditional Rehabilitation|It is a rehabilitative approach based on exercises for the recovery of hip's range of motion, muscle strengthening exercises, stretching exercises of the hamstring muscles, adductor and iliopsoas and proprioceptive exercises.
3049399|NCT02231554|Experimental|Feldenkrais|The Feldenkrais method is a self education method that uses the somatic sensory-motor learning to enhance the functions of people in daily life activities through the awareness of their motor habits and the experience of more efficient alternatives.
3049400|NCT02231554|Active Comparator|Back School|The Back School teaches the patient, with theoretical and practical knowledge, how to defend his own back from the pain and how to prevent their disease, considering awareness and education as important parts of the therapeutic process .
3049401|NCT02231541|Experimental|Very low frequency magnetic fields|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues.
3049402|NCT02231541|Placebo Comparator|Turned off very low frequency magnetic fields|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues.
3049403|NCT02231528|Experimental|Use of ultrasound with active GPS|
3049404|NCT02231528|Active Comparator|Use of ultrasound with inactive GPS|
3049405|NCT02231515|Experimental|Pattern laser trabeculoplasty (PLT)|Pattern laser trabeculoplasty
3049406|NCT02231515|Active Comparator|Selective laser trabeculoplasty (SLT)|Selective laser trabeculoplasty (SLT)
3049407|NCT02231502|Experimental|Vegetable-based convenience food|"One time ingestion of a vegetable-based convenience product. Dietary restrictions will be observed (i.e. avoidance of some vegetables) for 3 days prior to the bioavailability assessment (a list of foods to avoid will be provided).~At least 7 days wash-out between each assessment visit."
3049408|NCT02231502|Active Comparator|Vegetable meal|"One time ingestion of a minimally processed vegetable meal. Dietary restrictions will be observed (i.e. avoidance of some vegetables) for 3 days prior to the bioavailability assessment (a list of foods to avoid will be provided).~At least 7 days wash-out between each assessment visit."
3049409|NCT02231489|Experimental|Treatment Sequence AB|Participants will receive treatment A (JNJ-42756493 tablet 10 milligram [mg] as single oral dose) along with JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, 2 hours after administration of JNJ-42756493 tablet on Day 1 in Treatment Period 1. Participants will receive treatment B (JNJ-42756493 capsule 10 mg as single oral dose) on Day 1 of Treatment Period 2.
3049410|NCT02231489|Experimental|Treatment Sequence BA|Participants will receive treatment B (JNJ-42756493 capsule 10 mg as single oral dose) along with 100 microgram (mcg) intravenous infusion over 5 minutes, 2 hours after administration of JNJ-42756493 capsule on Day 1 in Treatment Period 1. Participants will receive treatment A (JNJ-42756493 tablet as single oral dose) on Day 1 of Treatment Period 2.
3049411|NCT02231463||ultrasound measurement|"measuring subclavian vein Diameter in six Groups:~neutral positioning, PEEP 0 cm H2O, neutral positioning, PEEP 5cm H2O, neutral positioning, PEEP 10cm H2O, Trendelenburg positioning -20°, PEEP 0 cmH2O, Trendelenburg positioning -20°, PEEP 5 cmH2O, Trendelenburg positioning -20°, PEEP 10 cmH2O After these measurements a central venous catheter is used to measure the central venous pressure."
3049412|NCT02231450|Experimental|Patients with mild hepatic impairment (Group1)|8 patients with mild hepatic impairment will be administered a single oral dose of 60 mg Lu AE58054
3049625|NCT02229929|Placebo Comparator|Part B: Placebo|Intravenous matched placebo
3049413|NCT02231450|Experimental|Patients with moderate hepatic impairment (Group 2)|8 patients with moderate hepatic impairment will be administered a single oral dose of 60 mg Lu AE58054.
3049414|NCT02231450|Experimental|Healthy subjects (Group 3)|8 healthy subjects will be administered a single oral dose of 60 mg Lu AE58054.
3049415|NCT02231437||chronic obstructive respiratory tract disease patients|
3049416|NCT02231424||chronic obstructive respiratory tract disease patients|
3049417|NCT02231411|Active Comparator|Ventilation during DCC (V-DCC)|Measuring the volume of placental transfusion with ventilation (CPAP 5 cm H2O between inflations) in infants born by C/S or VG using, as an initial surrogate marker, Hematocrits at 12 hours of life (HOL)
3049418|NCT02231411|Active Comparator|DCC plus dry and stimulate|Measuring the volume of placental transfusions with delayed cord clamping alone (DCC) in infants born by C/S or VD using, as an initial surrogate marker, Hematocrits at 12 hours of life (HOL)
3049419|NCT02231398||Women who participated in nuMoM2b|
3049420|NCT02231385|Experimental|Acetic Acid|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
3049421|NCT02231385|No Intervention|Control Group|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
3049422|NCT02231372||chronic obstructive airways disease patients|
3049423|NCT02231359||chronic obstructive airways disease patients|
3049424|NCT02231346||chronic obstructive pulmonary disease patients|
3049425|NCT02231333|Experimental|S-adenosylmethionine (SAMe)|
3049426|NCT02231333|Active Comparator|pentoxiphylline (PTX)|
3049427|NCT02231320||Chronic Obstructive Pulmonary Disease patients|
3049428|NCT02231307|Placebo Comparator|SUBLIVAC FIX Birch 0 AUN/ml|
3049429|NCT02231307|Experimental|SUBLIVAC FIX Birch 40,000 AUN/ml|
3049430|NCT02231294||Idiopathic Parkinson's Disease Patients|
3049431|NCT02231281|Experimental|cART(TDF/AZT+3TC+LPV/r)|cART(TDF/AZT+3TC+LPV/r)
3049432|NCT02231281|Experimental|CTL infusion|cART plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion
3049433|NCT02231268||Depressive patients|
3049434|NCT02231255||Idiopathic Parkinson's disease patients|
3049435|NCT02231242|Experimental|Intrathecal Autologous Bone Marrow TNC|Procedure/Surgery: Intrathecal Autologous Bone Marrow TNC. Other Names: Autologous Stem Cell Transplantation Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) (10mcgr/kg of body weight) for 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the autologous TNC concentrate of 10 mL will be infused intrathecally.
3049436|NCT02231242|No Intervention|Control group|"Patients will be evaluated with the Gross Motor Functional Classification System initially, at one, three and six months, and then cross to the intervention arm."
3049437|NCT02231229|Experimental|PCR-based strategy|PCR-based strategy: after testing for isoniazid and rifampin resistance using a molecular testing with PCR (GenoType ®MTB DR plus), patients will receive HRZ combination therapy (INH , RIF, PZA) if no resistance is detected
3049438|NCT02231229|Active Comparator|conventional therapy|Conventional therapy: based on the standard of care in France: initiation of the standard 4 drug regimen INH, RIF, PZA, and EMB, until drug susceptibility testing (DST) results are available.
3049439|NCT02231216|Experimental|Rhinoseptoplasty and turbinectomy|Patients submitted to rhinoseptoplasty associated to Endoscopic partial turbinectomy.
3049440|NCT02231216|Active Comparator|Rhinoseptoplasty|Patients submitted only to rhinoseptoplasty, without turbinectomy procedure.
3049441|NCT02231203|Placebo Comparator|Placebo|2 infusions of NaCl, 2 ml/kg, one the night before operation and one the day after operation.
3049442|NCT02231203|Active Comparator|Omegaven|2 infusions of 2ml/kg, one the night before surgery and one the day after surgery
3049443|NCT02231190|Experimental|GSK1278863|Subjects will be given five oral doses of GSK1278863 100 mg (5mg if a low dose is elected for subjects enrolled after interim analysis). The first dose will be administered immediately after completion of eccentric exercise, and then at 4, 8, 24, and 48 hours
3049444|NCT02231190|Placebo Comparator|Placebo|Subjects will be given five oral doses of Placebo. The first dose will be administered immediately after completion of eccentric exercise, and then at 4, 8, 24, and 48 hours
3049445|NCT02231177|Experimental|BI 1744 CL/Tiotropium FDC|
3049446|NCT02231177|Active Comparator|BI 1744 CL|
3049447|NCT02231177|Active Comparator|Tiotropium|
3049448|NCT02231164|Placebo Comparator|Docetaxel and placebo|patients to receive backbone chemotherapy and placebo
3049449|NCT02231164|Experimental|Docetaxel and Nintedanib|patients to receive backbone chemotherapy and nintedanib
3049450|NCT02231151|Experimental|Pediatric Acute Care Professionals|Individuals must work in ER or ICU setting regularly or rotate through this setting with up to date BLS/PALS/ACLS certification. The participants will be required to rate the CPR based on accuracy for each video shown. The type of CPR error(s) shown to the individuals will be randomized.
3049451|NCT02231138|Experimental|Abelmoschus manihot (AM)|"age above 12 years old (including 12)：huangkui capsule are given orally at 2.5 g three times per day~age between 6-12 years old(including 6):huangkui capsule are given orally at 1.5 g three times per day~age under 6 years old：huangkui capsule are given orally at 1.0 g three times per day"
3049452|NCT02231125|Experimental|Abelmoschus manihot (AM)|Abelmoschus manihot (AM): Huangkui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
3049453|NCT02231125|Experimental|Losartan|Losartan potassium (Hangzhou MSD Pharmaceutical Co., Ltd.), 100 mg × 7 capsules/box.
3049454|NCT02231112|Experimental|Prone position whole breast RT|
3049455|NCT02231099|Experimental|prolift + m|surgery with mesh (prolift+M)
3049456|NCT02231099|Active Comparator|conventional vaginal prolapse surgery|conventional vaginal prolapse surgery; anterior colporrhaphy or posterior colporrhaphy or spinal ligament fixation
3049457|NCT02231086|Active Comparator|Standard adjuvant systemic chemotherapy|Standard adjuvant systemic chemotherapy according to the Dutch colon cancer guideline, using a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) schedule. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
3049458|NCT02231086|Experimental|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC will be performed simultaneously with primary tumor resection, or as a staged procedure (<10 days or 5-8 weeks postoperatively). The chemotherapy during oxaliplatin-HIPEC consists of an intravenous phase with leucovorin 20 mg/m2 (maximum 40 mg) and 5-fluorouracil 400 mg/m2 (maximum 800 mg) and an intraperitoneal phase with oxaliplatin 460 mg/m2 (maximal 920 mg). Standard adjuvant systemic chemotherapy according to the national guideline will be given within 3 weeks from HIPEC. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
3049459|NCT02231073|Experimental|Exercise: Agility Boot Camp-Cognitive|Subjects will participate in an 80-minute, group (6 per group) exercise session led by a certified exercise trainer knowledgeable in the Agility Boot Camp-Cognitive (ABC-C) program for 3x/week for 6 weeks. The exercise protocol is an adaptation of our Agility Boot Camp (ABC) exercise program for PD. The exercises are designed as a circuit to challenge movement-skills known to be impaired in PD. Stations will include: Gait training, PWR Moves ©, Agility course, Lunges, Boxing and Tai Chi. Each activity was chosen for its inherent focus on multi-directional movements, dynamic postural transitions, axial mobility, big movements and whole body motor sequencing. Each station (10-20 minutes) has 3 possible progression levels, based on: (1) divided attention with secondary cognitive tasks, (2) response inhibition, (3) limiting external sensory cues, and (4) increasing speed and resistance.
3049460|NCT02231073|Active Comparator|Education: Living with Parkinson's disease|The Education arm is a chronic disease education program to teach patients how to live better with their chronic condition. It was developed by our research team to be specific for people with Parkinson's disease. It will include content and discussion of topics such as sleep, nutrition, and medication management. Classes will consist of a group of subjects (up to 6) meeting with the trainer for 90-minute session, once a week for six weeks. In order to match dose of the education intervention with the exercise intervention, participants will be provided relaxation tapes to be used at home 5 times per week for 30 minutes for an overall education dose of 240 minutes; similar to the exercise dose.
3049461|NCT02231060||AIE after Cardiac Arrest|Male and female patients with AIE following CA.
3049462|NCT02231047|Experimental|64N Nutraceutical|Powdered 64N Nutraceutical 40 mg/kg/day mixed in 12 ounces of a culturally appropriate warm drink for 1 week (7 days).
3049463|NCT02231047|Sham Comparator|No 64N Nutraceutical|Culturally appropriate 12 ounce warm drink daily for 1 week (7 days).
3049464|NCT02231021|Experimental|alogliptin + pioglitazone|alogliptin 25 mg 1 tablet daily for 24 weeks pioglitazone 30 mg 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
3049465|NCT02231021|Active Comparator|alogliptin|alogliptin 25 mg 1 tablet daily for 24 weeks pioglitazone matching placebo 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
3049466|NCT02231021|Active Comparator|Pioglitazone|alogliptin matching placebo 1 tablet daily for 24 weeks pioglitazone 30 mg 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
3049467|NCT02231008|Experimental|Tasimelteon|Single dose oral capsule, daily dosage, for 21 weeks
3049468|NCT02231008|Placebo Comparator|Placebo|Placebo comparator
3049469|NCT02230995|Experimental|Fixed dose combination|Single dose empagliflozin/metformin
3049470|NCT02230995|Active Comparator|Single tablets combination|single doses empagliflozin and metformin
3049471|NCT02230969||peginterferon beta-1a|Plegridy will not be supplied for this study. The study will collect data in an observational manner from participants who are prescribed Plegridy by physicians, according to the approved label in the respective country.
3049472|NCT02230956|Experimental|OnabotulinumtoxinA 400 U|OnabotulinumtoxinA 400 U injection into the intra-articular space of the study knee on Day 1.
3049473|NCT02230956|Experimental|OnabotulinumtoxinA 200 U|OnabotulinumtoxinA 200 U injection into the intra-articular space of the study knee on Day 1.
3049474|NCT02230956|Placebo Comparator|Placebo|Placebo (Normal Saline) injection into the intra-articular space of the study knee on Day 1.
3049475|NCT02230930|Active Comparator|Massage with a spiky ball|Subjects are instructed to massage the apomorphine-induced skin reactions with a spiky ball 3 times a day for 2 minutes for 14 days.
3049476|NCT02230930|Active Comparator|Hydrocortisone cream 1%|Subjects are instructed to apply hydrocortisone cream 1% once daily for 14 days.
3049477|NCT02230930|Active Comparator|Subcutaneous hydrocortisone 10mg|Subjects are instructed to administer subcutaneous hydrocortisone (Solu-Cortef 10mg) prior to apomorphine via the subcutaneous infusion line which is used for administration of apomorphine, for 14 days.
3049478|NCT02230930|Active Comparator|Apomorphine 0.25% (2.5mg/ml)|Subjects are instructed to dilute apomorphine 0.5% (5mg/ml) with the same volume of physiologic saline (NaCl 0.9%) to 0.25% (2.5mg/ml). Apomorphine will be infused subcutaneously for 14 days.
3049479|NCT02230917|Experimental|Sotatercept|Sotatercept 0.2 mg/kg will be administered every 21 days for 12 doses subcutaneously into the upper arm, abdomen or thigh.
3049480|NCT02230917|Placebo Comparator|Placebo|0.2 mg/kg of normal saline will be administered subcutaneously in the upper arm, abdomen or thigh for 21 days for 12 doses.
3049481|NCT02230904|Experimental|Treatment Arm A-B|4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1)
3049482|NCT02230904|Experimental|Treatment Arm B-A|4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1)
3049483|NCT02230891|Active Comparator|Carvedilol|Approximately 70 subjects will be randomized to carvedilol
3049484|NCT02230891|Active Comparator|Spironolactone|Approximately 70 subjects will be randomized to spironolactone
3049485|NCT02230891|No Intervention|Usual care|Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers
3049626|NCT02229929|Experimental|Part B: CR845 1.0 mcg/kg|Intravenous CR845, 1.0 mcg/kg
3049486|NCT02230878|Experimental|JNJ-42847922, 5 milligram (mg) and Placebo|Participants will be receive either 5 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
3049487|NCT02230878|Experimental|JNJ-42847922, 10 mg and Placebo|Participants will be receive either 10 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
3049488|NCT02230878|Experimental|JNJ-42847922, 20 mg and Placebo|Participants will be receive either 20 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
3049489|NCT02230878|Experimental|JNJ-42847922, 40 mg and Placebo|Participants will be receive either 40mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
3049490|NCT02230865||Surgery|Minimally invasive repair of pectus excavatum
3049491|NCT02230839|Experimental|Exercise training protocol|
3049492|NCT02230839|Experimental|Energy restriction-induced weight loss|
3049493|NCT02230839|No Intervention|Health Education|
3049494|NCT02230826||Patients with Hip arthroplasty|Patients with Tornier implants.
3049495|NCT02230813||Oral antibiotic therapy|Consecutive adult patients attending the study Emergency Departments with cellulitis will be considered eligible for recruitment to the study. Only those patients deemed suitable for oral antibiotic therapy and planned for discharge will be recruited to the study. Oral antibiotic therapy prescribed will be dependent on local institutional prescribing guidelines. For the purposes of the sites enrolling participants, the antibiotic of choice is oral flucloxacillin 500 milligrams four times daily for seven days. We will be assessing the treatment failure rate for this cohort of patients; namely, the number of patients requiring the primary outcome (change from oral to intravenous antibiotic therapy). We will also assess this group of patient for the secondary outcomes listed above.
3049496|NCT02230800|Experimental|Tocovid SupraBio plus pentoxifylline (PTX)|Tocovid SupraBio* 200mg po bd plus pentoxifylline (PTX) 400mg po bd for 12 months.
3049497|NCT02230800|Placebo Comparator|Matching placebos|Matching placebos bd for 12 months.
3049498|NCT02230787|Active Comparator|Recession coverage without Emdogain|
3049499|NCT02230787|Experimental|Recession coverage with Emdogain|
3049500|NCT02230774||medical staff|Nurses and doctors oncall
3049501|NCT02230761|Experimental|XOPH5 Ointment|XOPH5 Ointment is the investigational drug to be studied.
3049502|NCT02230761|Placebo Comparator|Placebo Ointment|Placebo is an ointment that matches XOPH5 Ointment but lacks the active ingredient.
3049503|NCT02230735|Experimental|Bipivacaine 0.5% with epinephrine|Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
3049504|NCT02230735|Placebo Comparator|Normal Saline|Total of 14 ml of normal saline, 7ml into the right uterosacral ligament and 7ml into the left uterosacral ligament
3049505|NCT02230722|Active Comparator|Attention Control|The neutral 10-15 minute visit with the Care Manager will consist of a brief review of ATHENA-OT safety education and the patient's Pain Care Plan. The CM will answer patient questions, but will avoid using Motivational Interviewing communication. The Care Manager will review upcoming telephone check-in and assessment sessions.
3049506|NCT02230722|Experimental|Collaborative Care|Collaborative Care intervention in which one of two Care Managers delivering both interventions will assist primary care providers (PCPs) by using Motivational Interviewing to communicate computer-based ATHENA-OT (opioid therapy) decision support guidelines to veterans with chronic pain.
3049507|NCT02230709|Experimental|Dry needling|Dry needling treatment on the trigger point number 2 of the trapezius muscle.
3049508|NCT02230709|Active Comparator|"TENS and dry needling"|Application of TENS current after dry needling treatment.
3049509|NCT02230696|Experimental|Test Product|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray
3049510|NCT02230696|Active Comparator|Reference Product|
3049511|NCT02230696|Placebo Comparator|Placebo Product|Placebo nasal spray
3049512|NCT02230683|Experimental|IDN-6556 - Overall population|Overall evaluable population treated with IDN-6556 25 mg twice daily
3049513|NCT02230683|Experimental|IDN-6556 - Subgroup with Baseline HVPG < 12 mmHg|Subgroup for patients with Baseline HVPG < 12 mmHg that have been treated with IDN-6556 25 mg twice daily
3049514|NCT02230683|Experimental|IDN-6556 - Subgroup Baseline HVPG ≥ 12 mmHg|Subgroup for patients with Baseline HVPG ≥ 12 mmHg that have been treated with IDN-6556 25 mg twice daily
3049515|NCT02230670|Experimental|IDN-6556|25 mg BID of IDN-6556
3049516|NCT02230670|Placebo Comparator|Placebo|Placebo BID
3049517|NCT02230657|Active Comparator|Same day Discharge|
3049518|NCT02230657|Active Comparator|Next day discharge|
3049519|NCT02230644|Experimental|Audio enhanced|Enhanced Clinical Environment: participants wait for their operation in the enhanced audio-visual booth.
3049520|NCT02230644|Active Comparator|Other distraction method|Participants wait for their operation in a booth with another distraction such as the news on television
3049521|NCT02230644|No Intervention|Ordinary|Participants wait for their operation in an ordinary, unenhanced booth
3049522|NCT02230631||Part 1 (retrospective cross-sectional evaluation)|
3049523|NCT02230631||Part 2 (prospective observational evaluation)|
3049524|NCT02230618||Ryzodeg™|
3049525|NCT02230605|Experimental|Cognitive Exercise|The cognitive exercises will consist of a series of computer games focusing on five categories: memory, speed, attention, flexibility and problem-solving. Participants will be expected to complete 1 hour of Lumosity exercise daily for a minimum of 10 days prior to surgery. Participants will be instructed to complete no less than 15 minutes of exercise at a time throughout each day. Each hour of exercise, participants will work through at least 1 game under each category. Research assessments will include Mini-Mental State Examination, Self-Administered Gerocognitive Examination, Geriatric Depression Scale, Charlson Comorbidity Index, Short Form 36 Health Survey, Confusion Assessment Method, Memorial Delirium Assessment Scale and Postoperative Quality of Recovery Scale.
3049557|NCT02230423|Experimental|Patients receiving nose surgery|"Patients in need of nose surgery, before and after surgery; or only after successful surgery, then with or without Empty Nose Syndrome."
3049558|NCT02230410|Experimental|focal cryo ablation|in this pilot study 10 subjects with residual barrett's esophagus (less than 3 cm) post ablation will under go one CryoBalloon Focal Ablation treatment
3050090|NCT02226575|No Intervention|Control|Controls only dilivery standard care
3049526|NCT02230605|Placebo Comparator|Normal Activity|Participants randomized into the Normal Activity group will be encouraged to maintain their normal activity level prior to surgery. These participants are asked not to alter their normal daily routine of mental exertion (i.e. watching television, reading, puzzles, etc.) and not permitted to subscribe to Lumosity while in the research study. Research assessments will include Mini-Mental State Examination, Self-Administered Gerocognitive Examination, Geriatric Depression Scale, Charlson Comorbidity Index, Short Form 36 Health Survey, Confusion Assessment Method, Memorial Delirium Assessment Scale and Postoperative Quality of Recovery Scale.
3049527|NCT02230579|Experimental|Cohort SAD1 Fasted|Seven fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD8 will receive a single dose in a fed state
3049528|NCT02230579|Experimental|Cohort SAD2 Fasted|Seven fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD8 will receive a single dose in a fed state
3049529|NCT02230579|Experimental|Cohort SAD3 Fasted|Seven fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD8 will receive a single dose in a fed state
3049530|NCT02230579|Experimental|Cohort SAD4 Fasted|Seven fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD8 will receive a single dose in a fed state
3049531|NCT02230579|Experimental|Cohort SAD5 Fasted|Seven fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD8 will receive a single dose in a fed state
3049532|NCT02230579|Experimental|Cohort SAD6 Fasted|Seven fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD8 will receive a single dose in a fed state
3049533|NCT02230579|Experimental|Cohort SAD7 Fasted|Seven fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD8 will receive a single dose in a fed state
3049534|NCT02230579|Experimental|Cohort SAD8 Fed|Cohort SAD8, reusing volunteers from one of the previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability
3049535|NCT02230579|Experimental|Cohort MAD1|Multiple Ascending Doses of MMV390048 - to begin after the completion of the last single--dose cohort. Volunteers will either be fed or fasted, pending outcome of the food effect comparison in the SAD part of the study.
3049536|NCT02230579|Experimental|Cohort MAD2|Multiple Ascending Doses of MMV390048 - to begin after the completion of the last single--dose cohort. Volunteers will either be fed or fasted, pending outcome of the food effect comparison in the SAD part of the study.
3049537|NCT02230579|Experimental|Cohort MAD3|Multiple Ascending Doses of MMV390048 - to begin after the completion of the last single--dose cohort. Volunteers will either be fed or fasted, pending outcome of the food effect comparison in the SAD part of the study.
3049538|NCT02230566|Experimental|Group A: 4 mg/kg UX003|4 mg/kg UX003 QOW through Week 46
3049539|NCT02230566|Experimental|Group B: 8 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 8 weeks followed by 4 mg/kg UX003 QOW through Week 46
3049540|NCT02230566|Experimental|Group C: 16 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 16 weeks followed by 4 mg/kg UX003 QOW through Week 46
3049541|NCT02230566|Experimental|Group D: 24 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 24 weeks followed by 4 mg/kg UX003 QOW through Week 46
3049542|NCT02230553|Experimental|lapatinib + trametinib|lapatinib: oral tablets, once daily trametinib: oral tablets, once daily
3049543|NCT02230540|Experimental|Sequence A|"Catheterization with SelfCath (comparator) followed by measurement of residual urine.~Then catheterization with Product A in different positions. Measurement of residual urine at different positions."
3049544|NCT02230540|Experimental|Sequence B|"Based on results from sequence A, sequence B may or may not be initiated.~Catheterization with SelfCath (comparator) followed by measurement of residual urine.~Then catheterization with Product B in different positions. Measurement of residual urine at different positions."
3049545|NCT02230527|Active Comparator|Clopidogrel|Clopidogrel 75mg by mouth daily
3049546|NCT02230527|Experimental|Ticagrelor|Ticagrelor 90mg by mouth twice daily
3049547|NCT02230514|Experimental|XCEL-MT-OSTEO-ALPHA and surgery|"ex-vivo expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue"
3049548|NCT02230514|Other|Autologous iliac crest and surgery|Standard treatment
3049549|NCT02230501|Experimental|moderate diet regimen|"Week 1-4: replacement of breakfast and dinner with 1g PRMR /kg normal weight (=height in cm-100), a protein-rich lunch was allowed Week 5-12: replacement of dinner~For this arm a local subgroup (n=55) and a nation-wide subgroup (n=100) is planned."
3049550|NCT02230501|Experimental|stringent diet regimen|"Week 1: replacement of 3 main meals by 1g PRMR / kg normal weight (=height in cm - 100) Week 2-4: replacement of breakfast and dinner, a protein-rich lunch was allowed Week 5-12: replacement of dinner~For this arm a local subgroup (n=55) and a nation-wide subgroup (n=100) is planned."
3049551|NCT02230488|Active Comparator|Intensive Diabetes Case Management|Intensive Case Diabetes Management : A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE
3049552|NCT02230488|No Intervention|Control :Standard/ usual care|
3049553|NCT02230462|Experimental|Viewing of cancer excision defect|Patients in this arm of the study will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.
3049554|NCT02230462|No Intervention|No viewing of cancer excision defect|Patients in this arm of the study will not be invited to view their cancer excision defect prior to its reconstruction.
3049555|NCT02230436|Experimental|Early drain removal|Removing drain(s) on postoperative day 3 (n = 72)
3049556|NCT02230436|Experimental|Late drain removal|Removing drain(s) on postoperative day 4 or later (n = 72)
3049620|NCT02229942|Placebo Comparator|Placebo|Saline (with added albumin), two infusions two weeks apart, followed by infusions at 3, 6, 9 and 12 months.
3049559|NCT02230397|Other|plantaricin a (active product)|Volunteers applied the active product for an uninterrupted period of 8 weeks (on the right or on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage.
3049560|NCT02230397|Other|placebo product|Volunteers applied the placebo product for an uninterrupted period of 8 weeks (on the right or on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
3049561|NCT02230384|Experimental|Active JNJ Drug|200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
3049562|NCT02230384|Experimental|Placebo Pill|Placebo pill used for one week quit attempt, as part of crossover design.
3049563|NCT02230371|Experimental|Granisetron|Granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden) is injected into a maximum of six muscle sites in each patient. The most painful sites to palpation of the masticatory muscles is chosen, either in the same muscle (maximum 3 sites per muscle) or in a different. The injected volume into each site is0.5 mL, hence the maximum dose of granisetron a patient can receive is 3 mg per treatment. This is repeated after one and two weeks.
3049564|NCT02230371|Placebo Comparator|Control (placebo)|Placebo (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden) is injected into a maximum of six muscle sites in each patient. The most painful sites to palpation of the masticatory muscles is chosen, either in the same muscle (maximum 3 sites per muscle) or in a different. The injected volume into each site is 0.5 mL. This is repeated after one and two weeks.
3049565|NCT02230358|Other|Regional anesthesia (RA)|Regional anesthesia (RA) for a carotid endarterectomy Interventions: Regional anesthesia (RA), blood gas analysis, 'Transcranieller Doppler' (Transcranial Doppler ultrasonography), invasive arterial blood pressure measurement, arterial blood gas measurement, neurological control, Near-infrared spectroscopy (NIRS) monitoring, oxygen supply (not invasive 'Vigileo')
3049566|NCT02230358|Other|General anesthesia (GA)|General anesthesia (GA) for a carotid endarterectomy Interventions: General anesthesia, blood gas analysis, 'Transcranieller Doppler' (Transcranial Doppler ultrasonography), invasive arterial blood pressure measurement, arterial blood gas measurement, neurological control, NIRS monitoring, oxygen supply (not invasive 'Vigileo')
3049567|NCT02230345|Experimental|Probiotic yogurt|Daily administration, during two weeks, of two probiotic yogurts (200 mL each)
3049568|NCT02230345|Active Comparator|Acidified milk|Daily administration, over two consecutive weeks, of an isocaloric dose (compared to probiotics) of unfermented acidified milk
3049569|NCT02230332|Experimental|Alendronate|Alendronate in 10mg capsules taken once daily
3049570|NCT02230332|Placebo Comparator|Placebo|Placebo capsule taken once daily
3049571|NCT02230319|Experimental|Cryotherapy|Each patient will receive cryotherapy administered during weekly paclitaxel treatments by Elasto gel™ Hypothermia mitts and slippers. Patients will wear the mitts and slippers for 15 minutes prior to treatment start, for 60 minutes during treatment, and for 15 minutes following treatment completion, for a total of 90 minutes.
3049572|NCT02230306|Experimental|Cobimetinib in Combination with Vemurafenib|"Vemurafenib (960 mg twice a day) will be taken on Days 1 - 28 of each 28-day treatment cycle. The first dose of vemurafenib should be taken in the morning, and the second dose should be taken in the evening. Vemurafenib can be taken with or without a meal and should be taken with a glass of water.~Cobimetinib (60 mg once a day) will be taken on Days 1 - 21 of each 28-day treatment cycle. The cobimetinib tablet should be taken at approximately the same time each day in the morning with the vemurafenib dose, but no later than 4 hours after the scheduled time. Cobimetinib can be taken with or without a meal and should never be chewed, cut, or crushed and should be taken with a glass of water."
3049573|NCT02230293|Active Comparator|Conventional Group|Conventional treatment and follow up
3049574|NCT02230293|Experimental|Multidisciplinary Group|Multidisciplinary assistance
3049575|NCT02230280|Other|The intervention cohort.|A community transition and rehabilitation intervention that includes a mobile health solution
3049576|NCT02230267|Experimental|High intensity boot camp|Each of the two HIBCs will have 10 participants (20 total) with a 1:5 physical therapist-to-patient ratio. Each HIBC session will last 1.5 hours and will be held on 4 days of the week. Participants will be required to attend 3 of those 4 days but may attend all. Because this is a pragmatic trial, therapists will have some leeway to control the intensity and the modality of the exercise. However, the basic format of the HIBC will consist of the following exercise components: A. 30 minutes of moderate-high intensity aerobic exercise at 70%+ of estimated maximum heart rate; B. 15 minutes of strengthening the major muscle groups of the trunk and upper/lower extremities; C. 15 minutes of balance training; and, D. 15 minutes of rest and stretching. Participants will rotate through these four different exercise components in a circuit fashion.
3049577|NCT02230267|Active Comparator|Usual care arm|The low intensity exercise group will participate in the Fitness Counts Exercise Program (FCEP) which is a basic low intensity, sitting and standing exercise program (10 minutes of stretching, 10 minutes of aerobic exercise (60% of heart rate maximum), and 10 minutes of strengthening). This exercise program was developed by the National Parkinson Foundation and is commonly used in PD exercise classes. The physical therapist-to-patient ratio will be 1:5. As there are two clinical sites, there will be 10 participants in each of the two boot camps (20 total). The FCEP will be 1 hour daily on four days of the week. Participants will be required to attend 3 days per week but may attend more if they are able.
3049578|NCT02230254|Experimental|PROMUS POREMIER stent|Single-arm treatment group receiving interventional PROMUS PRIMIER study stent
3049579|NCT02230241||Cohort 1|Subjects of either gender and any race, aged ≥ 18 years, at moderate to very high CV risk, on lipid-lowering pharmacotherapy for at least 3 months (90 days), with no dose change for a minimum of 8 weeks (56 days). Before starting any study-related activities, the investigator should obtain written informed consent personally signed and dated by the subject.
3049580|NCT02230228|Experimental|ALK-001 capsules|
3049581|NCT02230215|Experimental|Patient-Specific Instrumentation|Patients to have a total knee replacement surgery completed using Patient-Specific Instrumentation
3049582|NCT02230215|No Intervention|Traditional Instrumentation|Patients to have a total knee replacement surgery done using traditional instrumentation.
3049583|NCT02230202||Healthy control|Healthy control that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
3049584|NCT02230202||Stage III or IV CKD patients|Stage III or IV CKD patients that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
3049585|NCT02230202||Post-transplant patients|Stage III or IV CKD Post-transplant patients that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
3049586|NCT02230189|Experimental|Non-allergic/Non-asthmatic subjects|Intervention: Segmental airway allergen challenge Group: Volunteers with neither asthma nor allergy (as established by skin prick testing)
3049587|NCT02230189|Experimental|Allergic/Non-asthmatic subjects|Intervention: Segmental airway allergen challenge Group: Volunteers with allergy (as established by skin prick testing) but without asthma
3049588|NCT02230189|Experimental|Allergic/Asthmatic subjects|Intervention: Segmental airway allergen challenge Group: Volunteers with both asthma and allergy (as established by skin prick testing)
3049589|NCT02230176|Experimental|177Lu-DOTA0-Tyr3-Octreotate or OCLU|7.4 GBq per injection (max: 4 injections)
3049590|NCT02230176|Active Comparator|Sunitinib|37.5 mg/day
3049591|NCT02230137|Experimental|Text message arm|
3049592|NCT02230137|No Intervention|No text message arm|
3049593|NCT02230124|Experimental|MRE|
3049594|NCT02230111|Experimental|Energy restriction plus CDR group|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. They will be told that they are on a low-calorie diet and strategies to increase CDR will be used.
3049595|NCT02230111|Experimental|Energy restriction without CDR group|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. To have a condition of energy restriction without CDR, they will not be told that they are on a low-calorie diet and non-restrictive messages will be used.
3049596|NCT02230098|Experimental|Remote Ischemic Conditioning|By use of short-term obstruction of the blood supply to the arm
3049597|NCT02230098|No Intervention|Before Remote Ischemic Conditioning|
3049598|NCT02230085||CPAP therapy|
3049599|NCT02230072|Experimental|fetoscopic surgical repair|Single arm study. All patients will receive the fetoscopic repair.
3049600|NCT02230059||Metastatic Castration-resistant Prostate Cancer|Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
3049601|NCT02230046|Experimental|Sequence 1 (ABC)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 1, Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 2 and Treatment C (new composition, 2*500 mg coated tablets) in Period 3.
3049602|NCT02230046|Experimental|Sequence 2 (BCA)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 1, Treatment C (new composition, 2*500 mg coated tablets) in Period 2 and Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 3.
3049603|NCT02230046|Experimental|Sequence 3 (CAB)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment C (new composition, 2*500 mg coated tablets) in Period 1, Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 2 and Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 3.
3049604|NCT02230046|Experimental|Sequence 4 (ACB)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 1, Treatment C (new composition, 2*500 mg coated tablets) in Period 2 and Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 3.
3049605|NCT02230046|Experimental|Sequence 5 (BAC)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 1, Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 2 and Treatment C (new composition, 2*500 mg coated tablets) in Period 3.
3049606|NCT02230046|Experimental|Sequence 6 (CBA)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment C (new composition, 2*500 mg coated tablets) in Period 1, Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 2 and Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 3.
3049607|NCT02230033|Experimental|Treatment A|Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1.
3049608|NCT02230033|Experimental|Treatment B|Itraconazole 200 mg (2 capsules of 100 mg) will be administered once daily orally from Day 1 until Day 32, along with single oral dose of JNJ-56021927 240 mg capsule on Day 4.
3049609|NCT02230033|Experimental|Treatment C|Gemfibrozil 600 mg oral tablet will be administered twice daily from Day 1 until Day 32, along with single oral dose of JNJ-56021927 240 mg capsule on Day 4.
3049610|NCT02230020||Nasal High Flow|All subjects are in this group
3049611|NCT02230007|Experimental|MEOPA|ENTONOX (MEOPA)gas Duration of treatment of a subject according to the protocol: 60 MINUTES Inhalation use
3049612|NCT02230007|No Intervention|Without MEOPA|Physiotherapit care without MEOPA
3049613|NCT02229994||Adults patients with chronic respiratory diseases|"- 200 adult patients with chronic respiratory diseases will be studied longitudinally and transversely (follow-up: 6 months) in 12 centres.~Sample 1 (n=110 patients) with COPD~Sample 2 (n=30 patients) with Diffuse interstitial lung diseases~Sample 3 (n=30 patients) with Pulmonary Arterial Hypertension primary or secondary (post embolic .....).~Sample 4 (n=30 patients) Adult with Cystic fibrosis"
3049614|NCT02229981|Experimental|ABC294640|Patients will receive ABC294640 orally in gelatin capsules BID.
3049615|NCT02229968|Experimental|Amicar (ε-aminocaproic acid)|Treatment group 1: Amicar 100 mg/kg (0.4 mL/kg) IV loading dose, followed by an intraoperative continuous infusion at 40 mg/kg/hr (0.16 mL/kg/hr) to be continued until skin closure.
3049616|NCT02229968|Placebo Comparator|normal saline|Treatment group 2: Equal volume of normal saline (placebo control) at the same rate as treatment group 1.
3049617|NCT02229955|Experimental|T-sporin eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
3049618|NCT02229955|Active Comparator|Restasis eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
3049619|NCT02229942|Experimental|Rituximab|Rituximab induction (two infusions two weeks apart) and maintenance (infusions at 3, 6, 9 and 12 months)
3049627|NCT02229903|Active Comparator|Active DTMS Treatment|Active DTMS Treatment constitutes the Deep Transcranial Magnetci Stimulation (DTMS) which is a new form of TMS which allows direct stimulation of deeper neruonal pathways than the standard TMS. The DTMS coil is designed to allow deeper brain stimulation without significant increase of electric fields included in superficial cortical regions.
3049628|NCT02229903|Sham Comparator|Sham Treatment|The Sham Treatment consists of an electrical field which cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
3049629|NCT02229890||Acute ischemic stroke within three hours after symptom onset|
3049630|NCT02229877|Experimental|Gefapixant + Omeprazole|"Gefapixant oral tablets (25mg, 50 mg, 150 mg) administered twice daily for 18 days~+ Omeprazole oral capsules (40 mg) administered twice daily for 8.5 days"
3049631|NCT02229864|Experimental|Coronary artery stenting: Absorb BVS|Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS)
3049632|NCT02229851|Experimental|NNC0195-0092 (somapacitan)|
3049633|NCT02229851|Active Comparator|Daily hGH|
3049634|NCT02229851|Placebo Comparator|Placebo|Switch to NNC0195-0092 (somapacitan) treatment in the extension period.
3049635|NCT02229838|Experimental|BIBB 1464 MS single rising dose fed|
3049636|NCT02229838|Experimental|BIBB 1464 MS tablet fasted|
3049637|NCT02229838|Active Comparator|BIBB 1464 MS solution fasted|
3049638|NCT02229838|Placebo Comparator|BIBB 1464 MS placebo|
3049639|NCT02229825|Experimental|Duloxetine low|
3049640|NCT02229825|Experimental|Duloxetine high|
3049641|NCT02229812||thrombolytic therapy in stroke|
3049642|NCT02229799||Stroke patients|
3049643|NCT02229786|Experimental|Buscopan® plus|
3049644|NCT02229786|Active Comparator|Buscopan®|
3049645|NCT02229786|Active Comparator|Paracetamol|
3049646|NCT02229786|Placebo Comparator|Placebo|
3049647|NCT02229773|Experimental|BIBB 1464 MS low dose|
3049648|NCT02229773|Placebo Comparator|Placebo|
3049649|NCT02229773|Active Comparator|Pravastatin|
3049650|NCT02229773|Experimental|BIBB 1464 MS medium dose|
3049651|NCT02229773|Experimental|BIBB 1464 MS high dose|
3049652|NCT02229760|Experimental|TPV/r (Tipranavir co-administered with low dose ritonavir)|
3049653|NCT02229747|Experimental|Meloxicam suspension|
3049654|NCT02229747|Active Comparator|Diclofenac suspension|
3049655|NCT02229747|Active Comparator|Nimesulide suspension|
3049656|NCT02229734|Experimental|Radiation plus Androgen Supression|Radiation plus Androgen Suppression give as stereotactic radiation 7gray (Gy) per week x 5 weeks and leuprolide 45mg every 6 months for 18 months
3049657|NCT02229721|Active Comparator|Syntocinon Nasalspray 32 IU|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
3049658|NCT02229721|Placebo Comparator|Placebo Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
3049659|NCT02229708|No Intervention|Usual Care|The Usual Obstetric Care group will receive usual advice about nutrition and activity during pregnancy from their obstetrician along with some additional information about pregnancy and childbirth through readings from The American College of Obstetricians and Gynecologists. In addition, participants will receive weekly text messages to maintain contact and ensure follow-up.
3049660|NCT02229708|Experimental|Healthy Lifestlye Group|The Healthy Lifestyle Group will take part in an individual, technology-based behavioral intervention program which will include specific information about nutrition and physical activity, and strategies for helping them make changes to their diet, physical activity, and weight-related behaviors during pregnancy. Participants will receive information through print materials, text messages, a private Facebook group, and in-person visits and phone calls from a health coach who is part of our research team.
3049661|NCT02229682|Experimental|Mild-dose IMRT|"Experimental: Mild-dose of 46Gy with IMRT~Drug:~gemcitabine：1250mg/m2 (iv drip) on days 1, oxaliplatin: 85 mg/m2 (iv drip) on day 1, and pegaspargase: 2500 IU/m2 (intramuscular injection) on day 1. Cycle is repeated every 14 days~IMRT： IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions."
3049662|NCT02229669|Experimental|Horizontal incisions|Coronally advanced flap was performed by using horizontal interdental incisions. An initial horizontal incision was made slightly coronal to the CEJ from the distal to the mesial papilla of the teeth with the recessions. A second incision, 1 to 2 mm apart and parallel to the first incision, was made apically. A sulcular incision was made to link the second incisions and the blade was inserted extending beyond the mucogingival junction, to create a uniform split-thickness flap. The tissue between the two incisions was partially removed to obtain a uniform receptor site that permitted primary closure. Approximation sutures to place the edge of the flap at the base of the remaining papilla were performed.
3049663|NCT02229669|Experimental|Oblique incisions|Coronally advanced flap was performed by using oblique incisions in interdental areas, according to the technique proposed by Zucchelli & De Sanctis (2000). Oblique submarginal interdental incisions were performed and continued with the intrasulcular incisions at the recession defects, resulting in a envelop flap that was raised with a split-full-split approach in the coronal-apical direction. During coronal advancement, each surgical papilla was dislocated with respect to the de-epithelized anatomic papilla by the oblique incisions. Interrupted sutures were performed to stabilize single surgical papilla over the interdental connective tissue bed.
3049664|NCT02229656|Experimental|radiotherapy and olaparib|Radiotherapy will be given with accelerated fractionation following the DAHANCA schedule Olaparib: dose escalation
3049785|NCT02228837|Experimental|Pear|12 weeks of consuming 2 medium-sized pears per day (1 in the morning and 1 in the evening at least 6-8 hours apart).
3049665|NCT02229643||Traumatic brain injury|Patients delivered within 4 h whose highest abbreviated injury score (AIS) was 3 or less (other than head injury) were considered to be isolated traumatic brain injury cases and were included in this study.
3049666|NCT02229630|Experimental|Pregnant women|Foetuses with intra-uterine growth restriction, between 28 and 32 weeks of gestation, with an estimated foetal weight < 5th percentile (Hadlock calculator)
3049667|NCT02229617|Active Comparator|Injectable testosterone|We will take a group of transgender males, already on a stable dosage of intramuscular testosterone, and then using their same type and dosage, switch them to the subcutaneous injection route. Weekly trough (just before their weekly injection) levels of total serum testosterone will be taken to compare the steady states of those two injection routes.
3049668|NCT02229604|Experimental|EA group|Patients choose this group will receive EA as a combination. Beside of EA, participants could receive oral medicine as the same as that of the drug group. The EA regimen has two point formulae, i.e. A (BL33) and B (ST25, EX-CA1 and RN4). The two formulae will be used alternatively. One session will last for 20 minutes, 5 sessions per week for the first 4 weeks and 3 sessions per week later (44 sessions in all).
3049669|NCT02229604|Active Comparator|drug group|Hormone replacement therapy (HRT), DHEA and herb decoction are allowed to be used for this group. Treatment course is not fixed. Immunosuppressive agents are not allowed.
3049670|NCT02229591||EFL patients|Patients with Expiratory Flow Limitation undergoing surgery
3049671|NCT02229591||Control group|Patients withouth Expiratory Flow Limitation undergoing surgery
3049672|NCT02229578||Lidocaine Treatment Group|Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
3049673|NCT02229578||Placebo Treatment Group|Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
3049674|NCT02229565|Other|Caucasian|Caucasian subjects having a biopsy or prostatectomy.
3049675|NCT02229565|Other|African American|African American subjects having a biopsy or prostatectomy.
3049676|NCT02229539|Experimental|doxepin rinse|"Patients receive 2.5 mL (25 mg) doxepin and 2.5 mL water orally. Doxepin rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.~Patients will complete the Oral Symptoms booklet per the protocol."
3049677|NCT02229539|Active Comparator|DLA (diphenhydramine, lidocaine and antacid) rinse|"Patients receive 5.0 mL DLA orally. DLA is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients receiving DLA during the continuation phase of the study, they and/or caregivers may be aware that they are receiving DLA.~Patients will complete the Oral Symptoms booklet per the protocol."
3049678|NCT02229539|Placebo Comparator|placebo rinse|"Patients receive 2.5 mL placebo and 2.5 mL water orally. The placebo rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.~Patients will complete the Oral Symptoms booklet per the protocol."
3049679|NCT02229526|Active Comparator|Low dose fish oil|
3049680|NCT02229526|Placebo Comparator|Low dose olive oil|
3049681|NCT02229526|Experimental|High dose fish oil|
3049682|NCT02229526|Placebo Comparator|High dose olive oil|
3049683|NCT02229513|No Intervention|Control|Normal cesarean technique.
3049684|NCT02229513|Experimental|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
3049685|NCT02229500|Active Comparator|Control|Inulin control, 10g/d for 7 days. Isotope and appetite measurements on day 7
3049686|NCT02229500|Experimental|Delivery system 1|Delivery system, 28.5% w/w propionate, 10g/d for 7 days. Isotope and appetite measurements on day 7.
3049687|NCT02229500|Experimental|Delivery system 2|Delivery system, 54% w/w propionate, 10g/d for 7 days. Isotope and appetite measurements on day 7.
3049688|NCT02229487|Active Comparator|Normal Sleepers|Prediabetes patients with normal sleep duration (7-8 hours/ night) as measured objectively
3049689|NCT02229487|Experimental|Short Sleepers|Prediabetes patients with short sleep duration (<6 hours/night) as measured objectively
3049690|NCT02229474|Experimental|CST intervention|"We will use a two-group stepped-wedge design. Group 1 will receive the intervention immediately. This will also allow group 2 to act as controls for group 1 and allow further analysis as a controlled trial, during secondary analysis.~In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. We will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location."
3049784|NCT02228837|Placebo Comparator|Placebo|12 weeks of consuming 50 g pear-flavored placebo powder mixed with 480 ml per day (1/2 in the morning and 1/2 in the evening at least 6-8 hours apart).
3049691|NCT02229474|No Intervention|Group 2|and group 2 will have their intervention delayed until after the end of the group 1 intervention. This will also allow group 2 to act as controls for group 1 and allow further analysis as a controlled trial, during secondary analysis.
3049692|NCT02229461|Experimental|IR ASA co-administered with naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg once daily (qd) in parallel with naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
3049693|NCT02229461|Experimental|IR ASA 30 min after naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
3049694|NCT02229461|Experimental|IR ASA 8 hours after naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 8 hours after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
3049695|NCT02229461|Active Comparator|IR ASA only|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd. A 3-day IR ASA 81 mg qd Run-Out period was followed.
3049696|NCT02229461|Experimental|IR ASA 30 min before naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes before naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
3049697|NCT02229461|Experimental|IR ASA 30 min after first dose of naproxen sodium bid|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after first dose of naproxen sodium (Aleve, BAY117031) 220 mg, followed by second dose of naproxen sodium 220 mg 12 hours after first dose, for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
3049698|NCT02229448||IgG4 UKN diagnosis|who ever been found with IgG4 sub class in blood sample or in his byposy
3049699|NCT02229435||eGFR <60ml/min|Patients with CKD with eGFR <60 ml/min (CKD-EPI or MDRD) 12/2004-08/2014 of Medical Laboratory, Prof. Schenk / Dr. Ansorge and Colleagues, GbR, Am Neustädter Feld 47, 39124 Magdeburg, Germany.
3049700|NCT02229422|Experimental|GA101/HDMP|"All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:~On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.~On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.~On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.~On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.~All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:~•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered."
3049701|NCT02229409|No Intervention|Control|Observation only, no behavioral intervention
3049702|NCT02229409|Experimental|Intervention|Intervention Walkadoo.
3049703|NCT02229396|Experimental|Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg|
3049704|NCT02229396|Experimental|Exenatide Once Weekly 2 mg Alone|
3049705|NCT02229396|Active Comparator|Dapagliflozin Once Daily 10 mg Alone|
3049706|NCT02229383|Experimental|Exenatide|Exenatide 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
3049707|NCT02229383|Placebo Comparator|Placebo|Placebo 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
3049708|NCT02229370||ECAA|all patients diagnosed with an extracranial carotid artery aneurysm
3049709|NCT02229357|Experimental|OrniFlu® inactivated vaccine|
3049710|NCT02229344||Newly Diagnosed Moderate to Severe Ulcerative Colitis|Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks before prior to enrollment will be observed.
3049711|NCT02229331||gait analysis|gait analysis
3049712|NCT02229318|Experimental|FruitiVits|Daily administration of FruitiVits dietary supplement
3049713|NCT02229305|Active Comparator|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
3049714|NCT02229305|Experimental|Modular Approach to Therapy for Children|Therapists used a modular manual (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita & Weisz, 2010) to help children with primary problems of anxiety, depression, trauma, and conduct.
3049715|NCT02229292|Active Comparator|Tranexamic acid|The active comparator consists of an intravenously administered bolus injection of 10ml of 100mg/ml tranexamic (1g in total) given as a single dose, after the onset of anesthesia, prior to surgery.
3049716|NCT02229292|Placebo Comparator|Saline|The placebo consists of an intravenously administered bolus injection of 10 ml of 9mg/ml sodium chloride given as a single dose after the onset of anesthesia, prior to surgery.
3049717|NCT02229279|Active Comparator|Teleconsulting|Teleconsulting
3049718|NCT02229279|No Intervention|No Teleconsulting|
3049719|NCT02229266|Experimental|NK cells|Infusion of haploidentical NK cells after immunosuppression with cyclophosphamide and fludarabine, followed by immunostimulatory treatment with interleukin-2
3049720|NCT02229266|Active Comparator|Control Intervention|1 cycle of consolidation chemotherapy with high-dose cytarabine
3049721|NCT02229253||Degarelix|Treatment according to standard clinical practice.
3049722|NCT02229240|Experimental|Albiglutide|Subjects will receive once-weekly subcutaneous injections of albiglutide 30 mg (with forced uptitration to albiglutide 50 mg at Week 4) in addition to intensification of background basal-bolus insulin therapy (with or without metformin) according to predefined titration algorithms.
3049723|NCT02229240|Placebo Comparator|Matching albiglutide placebo|Subjects will receive once-weekly subcutaneous injections of matching albiglutide placebo in addition to intensification of background basal-bolus insulin therapy (with or without metformin) according to predefined titration algorithms
3049749|NCT02229084|Active Comparator|Chemovax Schedule D|Chemovax Schedule D: Subjects will receive the first injection of vaccine on week 1, the subsequent two injections of the vaccine one week apart (week 2 and 3), the first cycle of chemotherapy on week 2 (along with second vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 5,8,11,14,17,20,23).
3049724|NCT02229227|Experimental|Albiglutide + Insulin Glargine Arm|During standardization period, subjects will transit from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. During treatment period, subject will receive Albiglutide 30 milligrams (mg) weekly subcutaneous (SC) injection and insulin lispro dose will be downtitrated to half that used in the standardization period. At Week 4, Albiglutide will be uptitrated to 50 mg weekly SC injection and insulin lispro will be stopped for the remainder of the treatment Period. Insulin lispro may be re-introduced after Week 8 according to pre-defined hyperglycemia thresholds. Insulin will be adjusted according to protocol-defined insulin titration algorithms
3049725|NCT02229227|Experimental|Insulin Glargine + Insulin Lispro Arm|During standardization period, subjects will transit from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. During treatment period, subject will continue with the same doses as at the end of the standardization period and doses will be adjusted according to protocol-defined insulin titration algorithms
3049726|NCT02229214|Experimental|VI-0521 (Qsymia)|"Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)~Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)~Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)~Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)"
3049727|NCT02229214|Placebo Comparator|Sugar pill|Days 1-28: Placebo
3049728|NCT02229201|Experimental|Propofol|intravenous anaesthetic
3049729|NCT02229201|Active Comparator|Sevoflurane|volatile anaesthetic
3049730|NCT02229188|Active Comparator|Problem Solving Therapy|Problem Solving Therapy is an evidence-based behavioral treatment for late life depression proven effective with different geriatric groups including ambulatory; medically ill; older adults with executive dysfunctions; and more recently, low-income, disabled older adults.
3049731|NCT02229188|Experimental|Evolution|Evolution is a plasticity intervention in the form of a video driving game that targets the cognitive conflict network.
3049732|NCT02229188|Placebo Comparator|Words|Words is a challenging crosswords type of game that will serve as the placebo comparator to Evo.
3049733|NCT02229175|Experimental|IVB + laser|Intravitreal bevacizumab (IVB) will be administered at baseline, month 1, and month 2, consistent with previous DME trials. Subvisible laser treatment will be administered at baseline. Patients will then undergo monthly surveillance, as they would with standard of care treatment, allowing for retreatment with monthly IVB and laser therapy every 3 months if defined retreatment criteria are met, as described below.
3049734|NCT02229175|Active Comparator|IVB only|IVB monthly at baseline, month 1, and month 2. Patients will then undergo monthly surveillance, as they would with standard of care treatment, allowing for retreatment with monthly IVB if defined retreatment criteria are met, as described below. Patients will also undergo sham laser treatment (patient will be placed in front of laser but no laser will be activated) to mask the patient to the treatment.
3049735|NCT02229162||90 seconds DCC|the initial 15-20 subjects (15 enrolled subjects who complete study) will have cord clamped at 90 seconds. Then data will be analyzed and evaluated by DSMB
3049736|NCT02229162||Two minutes DCC|If Data Safety Monitoring Board (DSMB) concurs, DCC will then be practiced for 2 minutes for second group, which is the minimum amount of time recommended to be defined as DCC.
3049737|NCT02229149|Experimental|Triple Therapy|"Physician's choice of chemotherapy plus trastuzumab plus pertuzumab~trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND~physician's choice of chemotherapy:~Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~Docetaxel 75 mg/m2 IV every 3 weeks; OR~Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.~AND pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks."
3049738|NCT02229149|Active Comparator|Double Therapy|"Physician's choice of chemotherapy plus trastuzumab~trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND~physician's choice of chemotherapy:~Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~Docetaxel 75 mg/m2 IV every 3 weeks; OR~Capecitabine 1500 mg PO BID 14 days on and then 7 days off."
3049739|NCT02229136|Experimental|Miracle Mouthwash plus Hydrocortisone|Miracle Mouthwash plus Hydrocortisone, swish and expectorate 10cc (10 mLs) 4 times per day, every day for 12 weeks.
3049740|NCT02229136|Active Comparator|Prednisolone|Prednisolone oral solution 15 mg/5 ml; swish and expectorate 10cc (10 mL) 4 times per day, every day for 12 weeks.
3049741|NCT02229123|Experimental|Intravenous levetiracetam|1 loading dose of 30, 40, 50 or 60 mg/kg administered intra-venously. Maintenance treatment: one intra-venous injection /8h, 8 doses in total for a 3-day treatment. Maintenance dose corresponds to the loading dose quarter i.e. 7.5, 10, 12.5 or 15 mg/kg.
3049742|NCT02229110|Active Comparator|Signal|In addition to usual care, there will be an automatic signal in the electronic medical record (EMR) upon opening that will show the reader that the patient is currently not treated in the correct treatment setting and it simultaneously will give advice to which treatment allocation this patient should be transferred to.
3049743|NCT02229110|No Intervention|No signal|Patients receive usual care, consisting of 4 office visits yearly
3049744|NCT02229097|Experimental|Normal then Coordinated|normal bolus during 2 weeks then coordinated bolus during 2 weeks
3049745|NCT02229097|Experimental|Coordinated then Normal|coordinated bolus during 2 weeks then normal bolus during 2 weeks
3049746|NCT02229084|Active Comparator|Chemovax Schedule A|Chemovax schedule A: Subjects will receive the first cycle of chemotherapy along with the first injection of vaccine on week 1, the subsequent two injections of the vaccine one week apart (week 2 and 3), second cycle of chemotherapy on week 4, and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22).
3049747|NCT02229084|Active Comparator|Chemovax Schedule B|Chemovax Schedule B: Subjects will receive the first cycle of chemotherapy on week 1, the first injection of vaccine on week 2, the subsequent two injections of the vaccine one week apart (week 3 and 4), second cycle of chemotherapy on week 4 (along with second vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22).
3049748|NCT02229084|Active Comparator|Chemovax Schedule C|Chemovax Schedule C: Subjects will receive three weekly injections of vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
3049750|NCT02229084|Active Comparator|Chemovax Schedule E|Chemovax Schedule E: Subjects will receive the first injection of vaccine on week 1, the subsequent two injections of the vaccine one week apart (week 2 and 3), the first cycle of chemotherapy on week 3 (along with third vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 6,9,12,15,18,21,24).
3049751|NCT02229071|Experimental|Donafenib(200mg)|Donafenib 200 mg orally twice daily,each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
3049752|NCT02229071|Active Comparator|Donafenib(300mg)|Donafenib 300 mg orally twice daily,each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
3049753|NCT02229058|Experimental|Albumin Bound Paclitaxel plus S-1|Abraxane 120 mg/m2, D1,D8;S-1 40~60mg QD D1-D14,every 3 weeks until disease progress or intolerable toxicity.
3049754|NCT02229045|Experimental|Albumin Bound Paclitaxel With 5-FU/CF|Albumin Bound Paclitaxel 150 mg/m2 (on day 1),5FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
3049755|NCT02229032||Dravet Sydrome|Patients with Dravet Syndrome who are self-seeking therapy with Charlotte's Web strain of medical marijuana with the assistance of a medical marijuana doctor, but are still naïve to therapy
3049756|NCT02229019|Experimental|Volunteer mealtime assistance|Trained volunteers will provide mealtime assistance to older hospital inpatients at one mealtime each weekday.
3049757|NCT02229006||Aneurysm surveillance|Radiation: 18F-NaF PET-CT
3049758|NCT02229006||Control patients|Radiation: 18F-NaF PET-CT
3049759|NCT02228993||Awake Craniotomy|
3049760|NCT02228993||General Anesthesia Craniotomy|
3049761|NCT02228980|Experimental|Subjects aged 6 to 35 months (Group 1)|Participants aged 6 months to 35 months will receive two 0.25 mL doses of SP Shz TIV given 28 days apart.
3049762|NCT02228980|Experimental|Subjects aged 3 to 17 years (Group 2)|Participants aged 3 years to 17 years will receive a single 0.5 mL dose of SP Shz TIV
3049763|NCT02228980|Experimental|Subjects aged 18 to 60 years (Group 3)|Participants aged 18 years to 60 years will receive a single 0.5 mL dose of SP Shz TIV
3049764|NCT02228980|Experimental|Subjects aged 61 years or older (Group 4)|Participants aged 61 years or older will receive a single 0.5 mL dose of SP Shz TIV
3049765|NCT02228967|No Intervention|Usual Care|Those participants assigned to the usual care control group will be given a brochure on safe drinking limits, will be reminded of the 6-month follow-up, and thanked for their time.
3049766|NCT02228967|Active Comparator|SBIRT|"Those assigned to the SBIRT intervention group will receive 1 of 3 tracks:~Brief Intervention (BI) for At Risk Individuals (scores lower than 15) - Brief motivational intervention with feedback related to their use and change strategies.~Brief Treatment (BT) for High Risk Individuals (scores of 16-19) - Brief Intervention on site and be offered 6 individual confidential sessions with a civilian Brief Treatment Counselor over the phone.~Referral to Treatment (RT) for Severe Risk Individuals (scores of 20-40) - Brief Intervention on site and will be given a list of services where they may self-refer for further assessment and support."
3049767|NCT02228954||Renal Cell Cancer|
3049768|NCT02228941||gene mutation|
3049769|NCT02228928|Experimental|CAPNP, 50 ug/cm2 capsaicin patch|50 ug/cm2 capsaicin patch, 49cm2, 1patch/4days
3049770|NCT02228928|Experimental|CAPNP, 100 ug/cm2 capsaicin patch|100ug/cm2 capsaicin patch, 49cm2, 1patch/4days
3049771|NCT02228928|Active Comparator|0.075% capsaicin cream|capsaicin cream qc/day
3049772|NCT02228928|Placebo Comparator|Placebo patch|
3049773|NCT02228902|Active Comparator|ferrous fumarate|12 patients receive ferrous fumarate, 12 patients receive ferrous gluconate
3049774|NCT02228902|Active Comparator|ferrous gluconate|12 patients receive ferrous fumarate and 12 patients receive ferrous gluconate
3049775|NCT02228889|Experimental|Strattice|Abdominal wall reconstruction with Strattice Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively
3049776|NCT02228889|Experimental|XenMatrix|Abdominal wall reconstruction with XenMatrix Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively
3049777|NCT02228863|Experimental|Early Inmotion and Botox|Concomitant use of Inmotion and botulinum toxin from the baseline
3049778|NCT02228863|Active Comparator|Botox, then Inmotion|Inmotion training 4 weeks after botulinum toxin injection
3049779|NCT02228863|Active Comparator|Inmotion, then Botox|From the baseline Inmotion, then Botox injection at 4 weeks after baseline
3049780|NCT02228863|Active Comparator|Late Inmotion and Botox|No intervention, then Inmotion and Botox injection at 4 weeks from the baseline
3049781|NCT02228850|Experimental|Alprostadil Cream (300mcg)|300 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, one dispenser for each administration
3049782|NCT02228850|Experimental|Alprostadil Cream (1000mcg)|1000 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, one dispenser for each administration
3049783|NCT02228850|Experimental|Alprostadil Cream (3000mcg)|3000 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, two dispensers for each administration
3049786|NCT02228824|Experimental|Very low nicotine content cigarettes|
3049788|NCT02228811|Experimental|DCC-2701 tablet|DCC-2701 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
3049789|NCT02228798||Rivaroxaban|Patients currently taking rivaroxaban that have atrial fibrillation and require surgery or a procedure.
3049790|NCT02228798||Dabigatran|Patients currently taking dabigatran that have atrial fibrillation and require surgery or a procedure.
3049791|NCT02228798||Apixaban|Patients currently taking apixaban that have atrial fibrillation and require surgery or a procedure.
3049792|NCT02228785|Experimental|100µg dose of G17DT|Patients in this arm received a 100µg dose of G17DT via intramuscular injection.
3049793|NCT02228785|Experimental|200µg dose of G17DT|Patients in this arm received a 200 µg dose of G17DT via intramuscular injection.
3049794|NCT02228785|Experimental|500µg dose of G17DT|Patients in this arm received a 500µg dose of G17DT via intramuscular injection.
3049795|NCT02228772|Experimental|MLN 9708|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~MLN 9708 will be given with standard multi-drug regimen for ALL . MLN 9708 will be administered on determined days during Induction therapy cycle and Consolidation cycle. If remission occurs and if eligible, the next stage with be either Stem Cell or Bone Marrow Transplant.~If not eligible to receive a transplant, the participant will continue on this study for the next 3 stages.~CNS Therapy~Consolidation 2~Continuation Therapy~No further MLN9708, the investigational drug, will be given after Consolidation 1 Standard chemotherapy -Vincristine, Cytarabine, Doxorubicin, Mercaptopurine, Cyclophosphamide, Methotrexate"
3049796|NCT02228759|Experimental|Adductor canal block|The study is an open label pilot study to determine the feasibility of same day discharge following total knee arthroplasty with the use of a fast track regimen employing motor sparing knee blocks. The study will be performed on 25 American Society of Anesthesiologists class (ASA) 1-2 patients satisfying the inclusion criteria and undergoing unilateral primary total knee arthroplasty. First and second patients of the day undergoing surgery between Monday to Thursday in a week will be accessed for the study.
3049797|NCT02228746|Experimental|Alpha-galacto-oliosaccharides|
3049798|NCT02228746|Placebo Comparator|Placebo|
3049799|NCT02228733|Experimental|KBP-5074: Cohort 1|Healthy Volunteers will receive one dose of KBP-5074
3049800|NCT02228733|Experimental|KBP-5074: Cohort 2|Healthy Volunteers will receive one dose of KBP-5074
3049801|NCT02228733|Experimental|KBP-5074: Cohort 3|Healthy Volunteers will receive one dose of KBP-5074
3049802|NCT02228733|Experimental|KBP-5074: Cohort 4|Healthy Volunteers will receive one dose of KBP-5074
3049803|NCT02228733|Experimental|KBP-5074: Cohort 5|Healthy Volunteers will receive one dose of KBP-5074
3049804|NCT02228733|Experimental|KBP-5074: Fed Group|Healthy Volunteers will receive one dose of KBP-5074
3049805|NCT02228720|Experimental|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
3049806|NCT02228707|Experimental|BIIB061|Participants receive BIIB061
3049807|NCT02228707|Placebo Comparator|Placebo|Participants receive matched placebo
3049808|NCT02228681|Experimental|Everolimus and Letrozole|Everolimus 10 mg daily and Letrozole 2.5 mg PO daily
3049809|NCT02228681|Active Comparator|Hormonal Therapy|Tamoxifen 20 mg PO BID; on alternating weeks (even numbered) weeks, Medroxyprogesterone Acetate 200 mg PO daily with Tamoxifen 20 mg PO BID
3049810|NCT02228655|Other|FMX-8|FMX-8 for injection, 15mg/kg, twice weekly, 29 days
3049811|NCT02228629|Experimental|Typical house shoe|Subject's typical shoes worn in and around home
3049812|NCT02228616|Experimental|Prucalopride plus Polyethylene glycol or lactulose|
3049813|NCT02228603|Experimental|high-intensity exercise|community-based group program: weekly supervised high-intensity exercise training during 8 weeks, followed by group counselling every third month for 12 months
3049814|NCT02228603|Active Comparator|web-based follow-up|web-based follow-up program: home-based group will be followed up by mail and telephone calls the first 8 weeks, then every third month for 12 months
3049815|NCT02228603|Other|control|control group will receive usual care: information about recommended physical activity and healthy lifestyle
3049816|NCT02228590|Other|APL-130277|open label baseline comparison
3049817|NCT02228564|Experimental|LIFESTREAM™|This is a single arm study. All subjects receive percutaneous transluminal angioplasty (PTA) and implantation of the LIFESTREAM™ covered stent.
3049818|NCT02228551|Other|ARC PPS|Augmented renal clearance Point prevalence study
3049819|NCT02228538||Total knee arthroplasty patients|ConforMIS iTotal (CR) knee implant system and off-the-shelf knee implant systems from various manufacturers
3049820|NCT02228525|Experimental|selinexor (KPT-330)|Patients with myelodysplastic syndromes who are refractory to hypomethylating agents (decitabine or 5-azacytidine) will receive oral selinexor at a starting dose of 60 mg twice weekly for 2 weeks, followed by 1 week of no therapy. Dose reductions are permitted for patients who are benefiting from selinexor but have poor tolerance. After discontinuation from treatment, patients will be followed by the study staff for survival status approximately every three months.
3049821|NCT02228512|Active Comparator|1|Treatment naive PEL (main cohort)
3049822|NCT02228512|Active Comparator|2|Treatment na(SqrRoot) ve large cell lymphoma arising in KSHV-MCD
3049823|NCT02228512|Active Comparator|3|Previously treated KSHV-NHL
3049824|NCT02228499||Asthma|children with asthma who were in middle school for the 2013-2014 school year will take surveys on health and quality of life
3049825|NCT02228499||Controls|Children with no history of asthma who were in middle school for the 2013-2014 school year will take surveys on health and quality of life
3049826|NCT02228486|Active Comparator|Cue Exposure Therapy and verum tDCS|During alcohol cue exposure, an active tDCS with a duration of 15 minutes and 2 mA is applied to the left dorsolateral prefrontal cortex (F3, anode) and a reference electrode placed over Fp2 (electrode positions determined by the international 10-20 system). The electrodes are rectangular (35cm2).
3049860|NCT02228239|Experimental|Sequence 3 (CAB)|Participants will receive Treatment C (placebo intranasally and placebo capsule) in Period 1, Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 2 and Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
3049827|NCT02228486|Placebo Comparator|Cue Exposure Therapy and sham tDCS|During alcohol cue exposure, a placebo tDCS is used with electrodes placed over the left dorsolateral prefrontal cortex (F3, anode) and a reference electrode placed over Fp2 (electrode positions determined by the international 10-20 system). The electrodes are rectangular (35cm2). There is a 20 second ramp going up until 2 mA and back to 0 again at the beginning and the end of the placebo stimulation with no active stimulation during the cue exposure.
3049828|NCT02228486|No Intervention|Waiting list control group|The Cue-Reactivity of patients assigned to this arm will be measured twice with an interval of 5 weeks. Afterwards, patients will take part in the cue exposure therapy like subjects assigned to the active arms of the study
3049829|NCT02228473|Experimental|Glycopyrrolate|Glycopyrrolate will be administered as the adjuncts of neuromuscular blocker reversal agent.
3049830|NCT02228473|Active Comparator|Atropine|Atropine will be administered as the adjuncts of neuromuscular blocker reversal agent.
3049831|NCT02228460|Experimental|GZ/SAR402671|GZ/SAR402671 15 mg once daily orally for 26 weeks.
3049832|NCT02228447|No Intervention|No intervention group|The control group will not receive any intervention during the one year of this study. Only the baseline, 6-12 months assessments (anthropometrics, PA, dietary intake, social cognitive mediators and sedentary behaviors). To prevent compensatory rivalry and resentful demoralization, the control school will be provided with a condensed version of the following 12-month assessments. The condensed version of the program will include the professional learning workshops for intervention schools and the intervention materials (i.e., nutrition and PA handbooks and PA leadership handbook).
3049833|NCT02228447|Experimental|Healthy habits, healthy girls group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
3049834|NCT02228434|Experimental|Tailored intervention group|"For the monitoring session, physical activity was assessed by accelerometer and dietary was assessed by diary. Based on the monitoring information, the individual tailored prescription, including the normative feedback and process feedback, were formed and delivered to children and parents. Children were encouraged to modify the behaviors according to the prescription.~Then, next monitoring circle was followed. In total, 7 monitoring round were completed."
3049835|NCT02228434|Experimental|Happy 10 exercise group|All the schools participating in this group were encouraged to take two Happy 10 sessions on each school day.
3049836|NCT02228434|Experimental|Nutrition education group|The nutrition intervention was mainly conducted based on the nutrition knowledge through health education lectures given by researchers. The lectures were given for eight times to students and twice to parents. Each lecture session lasted no less than 40 min.
3049837|NCT02228434|No Intervention|Control group|Receive no intervention
3049838|NCT02228408|Experimental|Hydralazine/Isorsorbide Dinitrate|"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.~Allowable Dosage Forms:~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35mg-3x/day ISD/HY 40 mg/75 mg-3x/day"
3049839|NCT02228408|Active Comparator|Placebo|Placebo will be administered Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.
3049840|NCT02228395|Experimental|PF-04958242 or Placebo|
3049841|NCT02228382|Experimental|Bosutinib|
3049842|NCT02228369|Experimental|Daily dose of AZD3759|Daily oral dose of AZD3759
3049843|NCT02228369|Experimental|Daily Dose of AZD9291|Daily oral dose of AZD9291
3049844|NCT02228343|Experimental|Ayurveda|Ayurvedic therapy
3049845|NCT02228330|Experimental|uni-lateral obturator nerve block|"Patients scheduled for TUR for bladder tumor Intervention: uni-lateral obturator nerve block.~non-blocked obtorator side of each patient will be used as control"
3049846|NCT02228317|Experimental|Telemedicine consultation|EMTs will systematically establish teleconsultation by either telephone or video with the EMDC-physician in all cases of non-critical illness
3049847|NCT02228304|Experimental|NT-503-3 ECT implantation|
3049848|NCT02228304|Active Comparator|Eylea® injected intravitreally every 8 weeks|Eylea® injected intravitreally every 8 weeks
3049849|NCT02228291|Placebo Comparator|Placebo|Cellulose
3049850|NCT02228291|Experimental|Citric flavonoid|Citric flavonoid
3049851|NCT02228278|Experimental|Group A|Group A will receive the typical clinic visits plus daily text messages
3049852|NCT02228278|Other|Group B|Group B will act as the control and will receive the typical clinic visits.
3049853|NCT02228265||Ancillary-Correlative (genetic analysis)|Patients undergo collection of blood and tissue samples at baseline, during administration of enzalutamide and after the time of disease progression for analysis via immunohistochemistry, comparative genome hybridization, and sequencing.
3049854|NCT02228252|Experimental|20 g whey protein (-15 min)|20 g whey protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
3049855|NCT02228252|Experimental|20 g whey protein (-30 min)|20 g whey protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 30 min prior to the main meal.
3049856|NCT02228252|Experimental|20 g casein|20 g casein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
3049857|NCT02228252|Experimental|20 g gluten protein|21.5 g gluten protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
3049858|NCT02228239|Experimental|Sequence 1 (ABC)|Participants will receive Treatment A (esketamine 84 milligram (mg) intranasally and 1 placebo capsule) in Period 1, Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 2 and Treatment C (placebo intranasally and placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
3049859|NCT02228239|Experimental|Sequence 2 (BCA)|Participants will receive Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 1, Treatment C (placebo intranasally and placebo capsule) in Period 2 and Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
3049926|NCT02227745||Dorzolamide hydrochloride (2%)|dorzolamide: diabetic patients with clinical significally macular edema with treatment photocoagulation dorzolamide (2%) application 1 drop every 8 hours for 4 weeks
3049861|NCT02228239|Experimental|Sequence 4 (CBA)|Participants will receive Treatment C (placebo intranasally and placebo capsule) in Period 1, Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 2 and Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
3049862|NCT02228239|Experimental|Sequence 5 (ACB)|Participants will receive Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 1, Treatment C (placebo intranasally and placebo capsule) in Period 2 and Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
3049863|NCT02228239|Experimental|Sequence 6 (BAC)|Participants will receive Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 1, Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 2 and Treatment C (placebo intranasally and placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
3049864|NCT02228226||MG-1treated group|MG-1treated group: Patients those who underwent arthroscopic Bankart repair for glenohumeral instability using MG-1
3049865|NCT02228213|Experimental|Treatment|500 mcg MIS416 500 at 0.2 mg/mL administered i.v. once weekly for 52 weeks
3049866|NCT02228213|Placebo Comparator|Saline|Saline administered i.v. once weekly for 52 weeks
3049867|NCT02228200|Experimental|Nurse-led care|Subjects in the nurse-led care arm received nurse-led care and routine care.
3049868|NCT02228200|Active Comparator|Routine care|Subjects in the routine care arm received routine care provided by the study hospital.
3049869|NCT02228187|Active Comparator|BCI Intervention|Subjects will undergo the Brain-Computer Interface Intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the intervention in the first 8 weeks of the trial.
3049870|NCT02228187|No Intervention|Waitlist Control Group|The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards. They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.
3049871|NCT02228174|Experimental|Sonography guided transcervical ablation of uterine fibroids|Sonography guided transcervical ablation of uterine fibroids with the Gynesonics Sonata system
3049872|NCT02228161|Experimental|Yoga exercise|Participatants will receive regular 60-minutes yoga classes twice a week for 3 months.
3049873|NCT02228161|No Intervention|Regular schedule of daily living|Participants will maintain regular schedule as usual.
3049874|NCT02228148|Experimental|NFS|Cochlear Nucleus Fitting Software
3049875|NCT02228148|Active Comparator|CSS|Cochlear Nucleus Custom SoundTM Suite
3049876|NCT02228135||Non post-tonsillectomy hemorrhage|Children who do not have post-tonsillectomy hemorrhage.
3049877|NCT02228135||Post-tonsillectomy hemorrhage|Children return to the hospital after surgery with post-tonsillectomy hemorrhage.
3049878|NCT02228122|Experimental|Aquacel® Ag+ Extra|
3049879|NCT02228109|Experimental|Acuvue Oasys for Presbyopia|Acuvue Oasys for Presbyopia contact lenses worn
3049880|NCT02228109|Experimental|PureVision2 for Presbyopia|PureVision2 for Presbyopia contact lenses worn
3049881|NCT02228109|Experimental|Biofinity Multifocal|Biofinity Multifocal contact lenses worn
3049882|NCT02228096|Experimental|CTL019|Pediatric patients with relapsed/refractory B-cell ALL
3049883|NCT02228083|Active Comparator|Safety of dental anesthesia|Application of local dental anesthesia with two cartridges (5,6 mL) of the lidocaine 2% with epinephrine 1:100.000 in heart failure patients in functional class III or IV.
3049884|NCT02228083|Other|Oral health profile|An oral health profile of patients with heart failure will be described based in oral clinical examination.
3049885|NCT02228070|Experimental|strabismus video goggles|
3049886|NCT02228057||operated group|all patients who had upper extremity artery surgery at least 6 months ago
3049887|NCT02228044|Experimental|Prevention Program|This is a cognitive-behavioral substance abuse, suicide, and HIV prevention program delivered in a workshop format to adolescent participants and their parents/legal guardians.
3049888|NCT02228044|No Intervention|Assessment Only|
3049889|NCT02228031|Experimental|Oxytocin|The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session.
3049890|NCT02228031|Placebo Comparator|Placebo|The placebo comparator group will receive sterile saline through intranasal administration, consisting of the same salt solution in which the hormone will be dissolved , but lacking the hormone itself.
3049891|NCT02228018|Experimental|CALSA and FRI repeatability|CT-Scan No medication used
3049892|NCT02228005|Experimental|Depression|Sertraline 50- 200mg
3049893|NCT02228005|No Intervention|Comparison group (non-depressed)|No intervention
3049894|NCT02227992|Experimental|EVARREST™ Sealant Matrix|EVARREST™ Sealant Matrix/Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
3049895|NCT02227992|Active Comparator|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
3049896|NCT02227979|Experimental|Group I|The PURPLE Cry Intervention group will get an 11-page booklet and 12-minute DVD to review.
3049897|NCT02227979|Active Comparator|Group II|The control intervention group will get 1 brochure and a DVD on infant safety to review.
3049898|NCT02227966|Experimental|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 7 days a week for 12 weeks (total of 84 applications)
3049899|NCT02227966|Sham Comparator|sham-YBand (YDT-201N)|sham-tDCS application 7 days a week for 12 weeks (total of 84 applications)
3049900|NCT02227953|Experimental|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 7 days a week for 12 weeks (total of 84 applications)
3049901|NCT02227953|Sham Comparator|sham-Yband (YDT-201N)|sham-tDCS application 7 days a week for 12 weeks (total of 84 applications)
3049925|NCT02227758||implanted chronic migraine patients|Patients diagnosed with chronic migraine, failed 3 or more preventative drugs, with at least moderate disability, and implanted with a St. Jude Medical Conformité Européenne approved implantable neurostimulation system
3078309|NCT02038426|Experimental|sports subjects|
3049902|NCT02227940|Experimental|Arm 1 (ceritinib MTD then with gemcitabine alone)|"Dose Escalation Cohort 1: Patients with advanced solid tumors for whom gemcitabine hydrochloride-based therapy is clinically appropriate receive ceritinib PO (QD on days 1-28 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Expansion Cohort 1E: Once the MTD of ceritinib has been determined, an additional 10 patients with ALK-positive advanced solid tumors who previously progressed on gemcitabine hydrochloride-based therapy receive ceritinib and gemcitabine hydrochloride as in the dose escalation cohort 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3049903|NCT02227940|Experimental|Arm 2 (ceritinib MTD then with gemcitabine and nab-paclitaxel)|"Dose Escalation Cohort 2: Patients with advanced pancreatic cancer receive ceritinib PO QD on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Expansion Cohort 2E: Once the MTD of ceritinib has been determined, patients with ALK-positive advanced solid tumors receive ceritinib, gemcitabine hydrochloride, and paclitaxel albumin-stabilized nanoparticle formulation as in the dose escalation cohort 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3049904|NCT02227940|Experimental|Arm 3 (ceritinib MTD then with gemcitabine and cisplatin)|"Dose Escalation Cohort 3: Patients with advanced solid tumors for whom gemcitabine hydrochloride and cisplatin-based therapy is clinically appropriate receive ceritinib PO QD on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Expansion Cohort 3E: Once the MTD of ceritinib has been determined, an additional 10 patients with ALK-positive advanced solid tumors receive ceritinib, gemcitabine hydrochloride, and cisplatin as in the dose escalation cohort 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3049905|NCT02227914|Experimental|Oprozomib with Sorafenib|"Phase 1b:~Oprozomib doses will be escalated in sequential groups of at least 2 subjects. Study subjects will receive oprozomib at dose levels of 90, 120, 150, 180, 210, or 240 mg + sorafenib to reach the dose levels of 600 or 800 mg total daily dose until the maximum tolerated dose (MTD) is reached.~Phase 2:~Study subjects who meet the entry criteria will receive oprozomib + sorafenib at the RP2D (recommended Phase 2 dose) established in the Phase 1b portion of the study."
3049906|NCT02227914|Active Comparator|Sorafenib|"Phase 2:~Study subjects who meet the entry criteria will receive sorafenib 400 mg twice a day (800 mg total daily dose)."
3049907|NCT02227901|Experimental|Treatment (tipifarnib, EBRT, temozolomide)|"TIPIFARNIB: Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~CONCURRENT CHEMOTHERAPY DURING RADIATION THERAPY: Within 5-9 days after starting tipifarnib, patients undergo EBRT daily and receive temozolomide PO daily for 6 weeks.~POST-RADIATION CHEMOTHERAPY: Beginning at week 10 post-radiation therapy, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for 1 year or 12 complete courses in the absence of disease progression or unacceptable toxicity."
3049908|NCT02227888|Experimental|N91115|Every 12 hour oral dosing of 50 mg N91115 for 14 days
3049909|NCT02227875|Experimental|Mylan's insulin Glargine|receive Mylan's insulin Glargine
3049910|NCT02227875|Active Comparator|Lantus®|receive Lantus®
3049911|NCT02227862|Experimental|Mylan's insulin glargine|Receive both Mylan's insulin glargine plus insulin lispro.
3049912|NCT02227862|Active Comparator|Lantus®|receive Lantus® plus insulin lispro
3049913|NCT02227849|Experimental|Canagliflozin (TA-7284) ＋GLP-1 analogue|
3049914|NCT02227836|Experimental|Allergy Patch Testing APT|Patients referred to Mayo Clinic Rochester with an establish diagnosis of EoE who are nonresponsive to proton pump inhibitor (PPI) medical therapy. Eligible patients will then meet with one of three investigators complete the Mayo Dysphagia Questionaire-30 Day (MDQ-30) following which a standardized Allergy Patch testing (APT) will be conducted. Thereafter, a standard clinically indicated Six Food Elimination Diet treatment completed. Patients will follow up with one of three investigators following the elimination diet who will be blinded to the results of the APT. During this visit responders and nonresponders will be identified and nonresponders will complete a directed elimination diet based on APT results.
3049915|NCT02227823|Experimental|significant decrement|Patients with significant decrement at electromyogram will be treated by pyridostigmine bromide 60mg 3 times a day for patients older than 18 and 1.5mg/kg 3 times a day for children less than 40kg
3049916|NCT02227823|No Intervention|no decrement|Patient without significant decrement will not receive any treatment and will be the control group
3049917|NCT02227810|Experimental|electrical stimulation|Participants will receive muscular electrical stimulation on quadriceps muscle for 20 min/session, twice daily for 10 days
3049918|NCT02227810|Sham Comparator|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
3049919|NCT02227797|Experimental|Voriconazole|
3049920|NCT02227784|Experimental|Atorvastatin + Evacetrapib|Atorvastatin 40 milligrams (mg) orally once daily for 28 days during lead in period. Atorvastatin 40 mg plus evacetrapib 130 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
3049921|NCT02227784|Active Comparator|Atorvastatin 80 mg|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 80 mg orally with placebo for blinding once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
3049922|NCT02227784|Active Comparator|Atorvastatin + Ezetimibe|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 40 mg plus ezetimibe 10 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
3049923|NCT02227784|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 40 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
3049924|NCT02227771||Patient with chronic total occlusion|
3050091|NCT02226562|Experimental|Potassium nitrate and sodium fluoride|3.0% weight by weight (w/w) potassium nitrate mouthwash with 0.02% sodium fluoride
3078310|NCT02038426|Other|control subjects|
3049927|NCT02227745||Placebo Sodium hyaluronate4mg|placebo: diabetic patients with clinically significant macular edema(focal), with photocoagulation sodium hyaluronate (0.5%) application 1 drop every 8 hours for 4 weeks
3049928|NCT02227732|Other|New Indwelling Pleural Catheter|
3049929|NCT02227719|Experimental|Test: CTI|CTI is titanium mesh
3049930|NCT02227719|Active Comparator|Control: Collagen membrane|Collagen membrane is used for ridge augmentation
3049931|NCT02227706|Experimental|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
3049932|NCT02227706|Active Comparator|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
3049933|NCT02227693|Experimental|avatrombopag 20-mg|20 mg avatrombopag (1 x 20 mg tablet and 2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
3049934|NCT02227693|Experimental|avatrombopag 40-mg|40 mg avatrombopag (2 x 20 mg tablets and 1 x 20 mg matching placebo tablet) once daily on Days 1 through 5
3049935|NCT02227693|Experimental|avatrombopag 60-mg|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
3049936|NCT02227693|Placebo Comparator|placebo l|Placebo (3 x 20-mg matching placebo tablets) once daily on Days 1 through 5
3049937|NCT02227680|Active Comparator|Music Therapy|Patients randomized to the music therapy group will receive 1-3 10-40 minute music therapy sessions during each of the days of their stay on the inpatient unit. Each participant randomized to the music therapy intervention will be given a personalized CD and one portable CD player with headphones which they may keep after the study has ended.
3049938|NCT02227680|Active Comparator|Massage Therapy|Patients randomized to the massage therapy group will receive 1-3 10-40 minute massage treatments during each of the days of their stay on the inpatient unit.
3049939|NCT02227680|No Intervention|Usual Care|The control group will continue to receive usual care while on the Family Medicine Inpatient Unit.
3049940|NCT02227667|Experimental|Patients with Advanced Colorectal Cancer|This will be a Simon two-stage design, single arm, phase II study. All subjects will receive MEDI4736 via IV infusion. Subjects will continue treatment for 12 months, or until progression of disease, initiation of alternative cancer therapy, unacceptable toxicity, or other reasons to discontinue treatment occur. Following the 12-month treatment period, subjects without evidence for progressive disease or other reason to discontinue treatment will be monitored without further treatment. Upon evidence of PD (with or without confirmation according to RECIST 1.1) during the monitoring period, administration of MEDI4736 may resume at the Q2W schedule, for up to another 12 months. The same treatment guidelines followed during the initial 12-month treatment period will be followed during the retreatment period, including the same dose and frequency of treatments and the same schedule of assessments.
3049941|NCT02227654|Experimental|Abnormal Ovarian Ultrasound|Abnormal Ovarian Ultrasound
3049942|NCT02227641|Experimental|Adoptive transfer of CMV/EBV specific T-cells|Repetitive adoptive T-cell transfer starting at day 30 after allogeneic stem cell transplantation.
3049943|NCT02227641|No Intervention|Control|Observation only.
3049944|NCT02227628|Placebo Comparator|Sugary Beverage|Sugary Beverage
3049945|NCT02227628|Experimental|Acai beverage|Acai Polyphenolics
3049946|NCT02227615|Placebo Comparator|Sugary beverage|Sugary beverage
3049947|NCT02227615|Experimental|Mango beverage|Mango polyphenolics
3049948|NCT02227602|Placebo Comparator|sugary beverage|sugary beverage
3049949|NCT02227602|Experimental|Mango beverage|Mango polyphenolics
3049950|NCT02227589|Experimental|MET/CBT-12 plus CBT-D|CBT-D is an integrated cognitive behavior therapy targeting depression, delivered by the same study therapist who delivers MET/CBT-12 to the adolescent. All adolescents receiving CBT-D remain in MET/CBT-12 with their study provider.
3049951|NCT02227589|Active Comparator|MET/CBT-12 plus D-TAU|D-TAU (Depression Treatment as Usual) consists of referral to a depression treatment provider in the community. In this study D-TAU will be enhanced by assistance from the study team in locating providers and, with consent, an assessment report about the adolescent from the study team to the provider. All adolescents receiving TAU for depression remain in MET/CBT-12 with their study provider.
3049952|NCT02227589|Active Comparator|MET/CBT-12 alone|MET/CBT-12 consists of two sessions of motivation enhancement therapy and 10 sessions of cognitive behavior therapy, targeting alcohol or cannabis abuse. All adolescents in the study receive MET/CBT-12 over 12 to 14 weeks.
3049953|NCT02227576|Experimental|Romiplostim|Romiplostim lyophilized formulation is a white, solide cake that is reconstituted with sterile water for injection.
3049954|NCT02227563|Experimental|Active tDCS|active tDCS
3049955|NCT02227563|Sham Comparator|control|sham (placebo) tDCS condition
3049956|NCT02227550|Experimental|Apixaban|Xa group: factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose)
3049957|NCT02227550|Active Comparator|Vitamin K antagonist|VKA group: any Vitamin K antagonist (VKA), INR 2-3 , min. 30 days prescribed as in clinical routine
3049958|NCT02227537||Adolescence idiopathic scoliosis|Patients must be at least 10 years of age with a risser score of 0, 1, or 2
3049959|NCT02227524|Experimental|No Device|Assistive device conditions
3049960|NCT02227524|Experimental|Single Point Cane|Assistive device condition
3049961|NCT02227524|Experimental|Four-Point Cane|Assistive device condition
3049962|NCT02227524|Experimental|Trekking Pole|Assistive device condition
3049963|NCT02227511|Active Comparator|fruit|Participants are given +7kCal/kg body weight of fruit to be eaten as snack in between regular meals
3049964|NCT02227511|Active Comparator|nuts|Participants are given +7kCal/kg body weight of nuts to be eaten as snack in between regular meals
3049965|NCT02227498|Experimental|Effect of Argus II on Functional Vision|All subjects enrolled in the study will be implanted with the Argus II Retinal Prosthesis. To evaluate safety and effectiveness of Argus II on visual function.
3049966|NCT02227485|Active Comparator|Chlorhexidine (0.2%)|Chlorhexidine (0.2%) mouth rinse, 10 ml for 2 minutes every night for 2 weeks and tooth bleaching (one time) after using mouth rinse.
3050092|NCT02226562|Other|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate (SMFP)
3049967|NCT02227485|Experimental|Punica granatum Pleniflora mouth rinse|Punica granatum Pleniflora (Golnaar) mouth rinse, 10 ml for 2 minutes every night for 2 weeks and tooth bleaching (one time) after using mouth rinse.
3049968|NCT02227472||Sickle Cell Disease|All participants who meet eligibility requirements and consent to the study will complete evaluation of cognitive and pre-academic skills, and parent questionnaires.
3049969|NCT02227459|Experimental|Experimental: Arm A|Once a week dosing
3049970|NCT02227459|Experimental|Experimental: Arm B|Twice a week dosing
3049971|NCT02227446|Experimental|Vancomycin Antibotic Powder|"Participants in the treatment group will receive the study intervention of a maximum dose of 1000mg of Vancomycin antibiotic powder in their wound bed, which is placed right before wound closure. Vancomycin antibiotic powder may be combined with normal saline as per clinical practice at the participating institution.~In addition, participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection."
3049972|NCT02227446|No Intervention|Standard of Care|Participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection. Participants in this group will not receive local Vancomycin antibiotic powder.
3049973|NCT02227433|Experimental|brentuximab vedotin (BV)|
3049974|NCT02227420|Experimental|Anakinra|Anakinra 100mg s.c. x 5
3049975|NCT02227407|Experimental|Energy expenditure, gait pattern, RGOs|using motion capture system and forceplates to monitor gait pattern while wearing reciprocating gait orthoses to calculate the mechanical energy cost
3049976|NCT02227394|Experimental|Z7200|"Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.~Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided."
3049977|NCT02227394|Active Comparator|Symbicort® Turbohaler|Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 320 mcg/9 mcg).
3049978|NCT02227381||Microarray / NGS test|
3049979|NCT02227368|Experimental|Ticagrelor|26 Weeks of ticagrelor 90mg twice a day plus aspirin placebo once daily
3049980|NCT02227368|Active Comparator|Aspirin|26 Weeks of aspirin 100mg once daily plus ticagrelor placebo twice a day
3049981|NCT02227355||PD Patients < 70 years of age|Patients with Parkinson's Disease (PD) <70 years of age.
3049982|NCT02227355||PD Patients ≥ 70 years of age|Patients with Parkinson's Disease (PD) ≥ 70 years of age.
3049983|NCT02227342|Experimental|Fecal Microbiota Transplantation|serial Fecal Microbiota Transplantation
3049984|NCT02227329|Experimental|Ethanol Lock and Normal Saline|All patients randomized to the ELT group will receive 3ml of 70% ethanol and saline flush.
3049985|NCT02227329|Active Comparator|Heparin and Normal Saline|All patients randomized to this group will receive Heparin lock + saline infusion (current standard of care).
3049986|NCT02227316|Experimental|Intravenous Ibuprofen|Ibuprofen 800mg IV piggyback and Saline IVP q 6 hours x 4 during uterine fibroid embolization
3049987|NCT02227316|Experimental|Intravenous acetaminophen|Acetaminophen 1 gram IV piggyback and Saline IVP q6 hours x 4 during uterine fibroid embolization
3049988|NCT02227316|Experimental|IV ibuprofen/IV acetaminophen|Ibuprofen 800 mg/ Acetaminophen 1 gram IV piggyback and Saline IVP 6 hours x 4 during uterine fibroid embolization
3049989|NCT02227316|Active Comparator|Intravenous placebo/Intravenous placebo|Saline/Saline IV piggyback and IVP Ketorolac 30 mg q6 hours x 4 during uterine fibroid embolization
3049990|NCT02227303|Other|Lifestyle counseling|
3049991|NCT02227290|Experimental|Naftin Cream, 2%|Once Daily
3049992|NCT02227290|Placebo Comparator|Placebo Cream|Once Daily
3049993|NCT02227277|Experimental|Conditional 12-week ART interruption|18 participants will receive peg-IFN-α2b (1 μg/kg/week) for 20 weeks.
3049994|NCT02227277|Experimental|Continuous ART|18 participants will receive peg-IFN-α2b (1 μg/kg/week) for 20 weeks.
3049995|NCT02227277|No Intervention|Control with continuous ART|18 participants will continue their current ART regimens and be observed for 20 weeks.
3049996|NCT02227264|Experimental|Cinacalcet|"Cinacalcet, Mimpara®: 30 mgx1 for four weeks. In case of persistent hypercalcemia after two weeks of treatment with Mimpara® 30 mgx1, the dosage of Mimpara® will be increased to 60 mg daily.~Second intervention: Parathyroid adenomectomy."
3049997|NCT02227251|Experimental|Selinexor (KPT-330)|60 mg dose of Selinexor, orally twice weekly on Days 1 and 3 (e.g., Monday and Wednesday or Tuesday and Thursday, etc.) of Weeks 1, 2, and 3 of each four week (28 day) cycle.
3049998|NCT02227238|Experimental|DTG arm|Subjects will receive one oral tablet of 50 mg DTG once daily plus two NRTIs selected by the investigator
3049999|NCT02227238|Active Comparator|LPV/RTV arm|Subjects will receive four oral tablets of200/50 mg LPV/RTV once daily or two oral tablets of 200/50 mg LPV/RTV twice daily plus two NRTIs selected by the investigator
3050000|NCT02227225||Postoperative Delirium|
3050001|NCT02227212|Experimental|Insulin glargine U300|Once daily subcutaneous injection for 4 weeks
3050002|NCT02227199|Experimental|Treatment (brentuximab, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin IV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
3050003|NCT02227186|No Intervention|Control arm|No school-located influenza vaccination clinic
3050004|NCT02227186|Experimental|School-located influenza vaccination clinics|School-located influenza vaccination clinics
3050053|NCT02226822||Adult patients with documented T2DM|Adult patients with documented history of type 2 diabetes mellitus who are initiating their second line oral or parenteral anti-diabetics medication after first line oral diabetic therapy
3050005|NCT02227173|Experimental|Single-Sequence, A B C|"Treatment A:~Single oral dose of montelukast, flurbiprofen, and digoxin on Day 1~Treatment B:~BMS-986020 orally twice daily (BID) on Day 8 through Day 10~Treatment C:~BMS-986020 orally BID, single oral dose of montelukast, flurbiprofen, and digoxin on Day 11; BMS-986020 BID on Day 12 through Day 17"
3050006|NCT02227160|Experimental|Psychosocial group intervention|Subjects will seek outpatient counseling, support groups, in addition to 10 weekly group meetings
3050007|NCT02227160|Active Comparator|Control|Subjects will seek outpatient counseling and support groups only
3050008|NCT02227147|Experimental|rhNGF 20 µg/ml|rhNGF 20 µg/ml eye drops solution, formulation containing anti-oxidant
3050009|NCT02227147|Placebo Comparator|Placebo|Vehicle: formulation containing anti-oxidant
3050010|NCT02227134|Other|Difficult Airway|Children with a history of difficult airway intubation.
3050011|NCT02227134|Other|Obstructive Sleep Apnea|Children with a history of obstructive sleep apnea.
3050012|NCT02227121|Experimental|VT/VF induction and defibrillation|Ventricular Tachycardia and Ventricular Fibrillation (VT/VF) induction and defibrillation will be carried out as the invention in all subjects undergoing study procedures.
3050013|NCT02227108|Experimental|Moxetumomab Pasudotox 40 mcg/kg|Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
3050014|NCT02227095|Experimental|After-school exercise program|40 min/day vigorous aerobic games after school
3050015|NCT02227095|Active Comparator|Sedentary after-school program|Attention-control condition similar to experimental condition with the exception of exercise
3050016|NCT02227082|Experimental|radiotherapy and olaparib|radiotherapy: 61.18 Gy olaparib: dose escalating
3050017|NCT02227069|Experimental|M518101|M518101 is applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks
3050018|NCT02227069|Placebo Comparator|M518101 Vehicle|M518101 vehicle is applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks
3050019|NCT02227069|Active Comparator|sodium lauryl sulfate|A solution of 0.2% sodium lauryl sulfate is applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a positive control.
3050020|NCT02227069|Sham Comparator|Saline|A solution of 0.9% saline is applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a negative control.
3050021|NCT02227056|Experimental|Methylphenidate treatment|On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
3050022|NCT02227056|No Intervention|Control|On three different days each participant will be re-evaluated without recieveing Methylphenidate.
3050023|NCT02227030|Experimental|BIIB 722 CL single rising dose|
3050024|NCT02227030|Experimental|BIIB 722 CL cross over|
3050025|NCT02227030|Placebo Comparator|Placebo solution|
3050026|NCT02227030|Placebo Comparator|Placebo tablet|
3050027|NCT02227017|Experimental|TPV/RTV capsules fed|
3050028|NCT02227017|Experimental|TPV/RTV capsules fasted|
3050029|NCT02227017|Active Comparator|TPV/RTV solutions fed|
3050030|NCT02227017|Active Comparator|TPV/RTV solutions fasted|
3050031|NCT02227004||MRI in patients with Pacemaker or ICD|Perform MRI in patients with pacemaker or ICD and evaluate patient and device safety
3050032|NCT02226991|Experimental|TPV/RTV/EFV|tipranavir (TPV) + ritonavir (RTV) from day 1 to day 24 efavirenz (EFV) from day 10 to day 23
3050033|NCT02226978|Experimental|TPV/r with valaciclovir|VAL 2 days (on days 1 and 13), TPV/r 12 days (on days 2 to 13)
3050034|NCT02226965|Experimental|PNT2258|"PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle. Treatment may continue unless there is disease progression or the occurrence of unacceptable toxicity for a total of 8 induction cycles of therapy. Subjects with CR/CMR, PR/PMR or SD/NMR at the end-of-cycle 8 scan then receive ongoing PNT2258 therapy at a dose of 100 mg/m2 on days 1-4 of a 28 day cycle until progressive disease, the occurrence of unacceptable toxicity, non-compliance, voluntary withdrawal or if in the opinion of the investigator the subject is no longer benefiting from exposure to PNT2258."
3050035|NCT02226952|Experimental|Group 1|BILN 2061 W, medium dose, in patients with genotype 1, minimal fibrosis
3050036|NCT02226952|Experimental|Group 2|BILN 2061 W, high dose, in patients with genotype 1, minimal fibrosis
3050037|NCT02226952|Experimental|Group 3|BILN 2061 W, high dose, in non-genotype 1 patients, minimal fibrosis
3050038|NCT02226952|Experimental|Group 4|BILN 2061 W, low dose, in patients with genotype 1, minimal fibrosis
3050039|NCT02226952|Experimental|Group 5|BILN 2061 W, medium dose, in patients with genotype 1, advanced fibrosis
3050040|NCT02226952|Placebo Comparator|Placebo|
3050041|NCT02226939|Experimental|BILN 2061 ZW|
3050042|NCT02226939|Placebo Comparator|Placebo|
3050043|NCT02226926|Experimental|Aggrenox|Dipyridamole extended release / Acetylsalicylic acid
3050044|NCT02226926|Active Comparator|Persantin Retard|Dipyridamole extended release
3050045|NCT02226926|Active Comparator|Acetylsalicylic acid|
3050046|NCT02226913|Experimental|lidocaine & sodium bicarbonate|2% lidocaine with 1: 80,000 epinephrine buffered with 0.18 mL of 8.4% sodium bicarbonate
3050047|NCT02226913|Active Comparator|lidocaine & placebo|2% lidocaine with 1:80,000 epinephrine with 0.18 mL of sterile distilled water
3050048|NCT02226900|Experimental|Hybrid Revascularization|The hybrid myocardial revascularization group will be accomplished by a two-step scheme, comprised by off-pump LIMA-to-left anterior descending grafting, followed by percutaneous coronary interventions with Promus Element (everolimus second generation drug eluting stent) for the remaining coronary lesions.
3050049|NCT02226900|Other|Conventional Surgical Coronary Bypass Grafting|Conventional Coronary Artery Bypass Grafts with in pump technique.
3050050|NCT02226887|Experimental|MESH|
3050051|NCT02226887|Active Comparator|NO MESH|
3050052|NCT02226861|Experimental|1|Subjects will receive CD34-selected stem cells followed by fixed dose ULG IL-2 (100,000 IU/m2) given subcutaneously for 12 weeks+Sirolimus until Day +60
3050054|NCT02226809||General anesthesia|Evaluation of RNMB. Application of accelerometry to patients after general anesthesia receiving at least one intermediate action nondepolarizing neuromuscular blocking agent dose
3050055|NCT02226796|Active Comparator|Prime Condition|The primed (PRIME) condition is an intervention that will consist of presentation of a-tDCS for 20 minutes prior to naming treatment, while the subject sits quietly and comfortably in a chair. After the 20-minute priming period, the a-tDCS will be removed and the participant will receive naming treatment for 60 minutes.
3050056|NCT02226796|Active Comparator|Non-Prime Condition|The non-prime (NONPRIME) condition is an intervention that will consist of 40 minutes of naming treatment only, followed by an additional 20 minutes of concurrent naming treatment with a-tDCS.
3050057|NCT02226783|Experimental|Treatment A AZD1722 salt tablet (fasted)|Part A-Treatment A: morning dose of AZD1722 salt tablet 5 to 10 minutes before start of intake of breakfast; evening dose 5 to 10 minutes before start of intake of dinner
3050058|NCT02226783|Experimental|Treatment B AZD1722 salt tablet (fed)|Part A Treatment B: morning dose of AZD1722 salt tablet 30 minutes after start of intake of breakfast; evening dose 30 minutes after start of intake of dinner
3050059|NCT02226783|Experimental|Treatment C AZD1722 salt tablet (fasted)|Part A Treatment C: morning dose AZD1722 HCl tablet then breakfast served 1 hour after dosing; evening dose 3 hours after start of intake of dinner and 1 hour before the next meal consumption
3050060|NCT02226783|Experimental|Treat D AZD1722 free-base tablet (fast)|Part B Treatment D: morning dose of AZD1722 free-base tablet administered 5 to 10 minutes before the start of intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner
3050061|NCT02226783|Experimental|Treat E AZD1722 free-base+Omeprazole|Part B Treatment E: morning dose of AZD1722 free base tablet administered 5 to 10 minutes before start of intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
3050062|NCT02226770|Other|ICD|Implantation of an Implantable Cardioverter Defibrillator (ICD) in patients with heart failure
3050063|NCT02226757|Experimental|Paclitaxel-trastuzumab|Paclitaxel-trastuzumab weekly
3050064|NCT02226744|Active Comparator|Focused breathing|Focused deep breathing techniques used to produce specific physiological and psychological states
3050065|NCT02226744|Active Comparator|Focused breathing 2|Focused deep breathing techniques used to produce specific physiological and psychological states
3050066|NCT02226731|Experimental|Early Belfort-Dildy balloon device|
3050067|NCT02226731|Other|Late Belfort-Dildy balloon device|
3050068|NCT02226718||questionnaire|
3050069|NCT02226705|Experimental|Multiple Surgeries|Patients undergoing transnasal endoscopic surgery
3050070|NCT02226692||nonspecific chronic low back pain|Physical examination and follow-up assessment by questionnaires at 2, 4, 6, and 12 months
3050071|NCT02226679|Experimental|Algisyl-LVR device implantation|Algisyl-LVR™ employed as a method of left ventricular augmentation and restoration in patients with dilated cardiomyopathy. Algisyl-LVR™ will be injected into the myocardium under direct visualization during the surgical procedure.
3050072|NCT02226666||Patients having MRI with Eovist|Subjects having a clinically ordered MRI with Eovist. Patients consenting for the study will be monitored before and after getting MRI contrast. For the study oxygen saturation (amount of oxygen level in the blood) and breathing will be monitored during the can. Breathing will be measured with a non-invasive respiratory monitoring device attached to the MR scanner. Each patient will answer survey questions after the scan about their experiences concerning MRI contrast.
3050073|NCT02226666||Patients having MRI with Multihance|Subjects having a clinically ordered MRI with Multihance. Patients consenting for the study will be monitored before and after getting MRI contrast. For the study oxygen saturation (amount of oxygen level in the blood) and breathing will be monitored during the scan. Breathing will be measured with a non-invasive respiratory monitoring device attached to the MR scanner. Each patient will answer survey questions after the scan about their experiences concerning MRI contrast.
3050074|NCT02226653|Experimental|Evacetrapib (reference)|Single oral dose of 1 tablet of evacetrapib on Day 1 of up to three of five periods
3050075|NCT02226653|Experimental|Evacetrapib (test)|Single oral dose of 2 tablets of evacetrapib on Day 1 of up to three of five periods
3050076|NCT02226640||Non-Diabetic Lean Athletes|Athletes with a Body Mass Index (BMI) less than or equal to 25 kg/m2.
3050077|NCT02226640||Non-Diabetic Lean No Diabetes History|Adults with a BMI < 25 kg/m2 and no family history of diabetes
3050078|NCT02226640||Non-Diabetic Lean Yes Diabetes History|Adults with a BMI < 25 kg/m2 and family history of diabetes
3050079|NCT02226640||Non-Diabetic Obese|Adults with BMI greater than or equal to 30 kg/m2.
3050080|NCT02226640||Non-Diabetic Obese Female PCOS|Female adults with BMI > 30 kg/m2 and Polycystic Ovarian Syndrome (PCOS).
3050081|NCT02226640||Diabetic No Medication|Have diabetes and currently receiving no medication or early treatment with one medication. Some participants receiving insulin may also be included in this study
3050082|NCT02226640||Diabetic GAD Ab+|Have diabetes with Latent Autoimmune Diabetes in Adults (LADA).
3050083|NCT02226640||Diabetic With NASH|Have diabetes with Nonalcoholic Steatohepatitis (NASH), which is chronic liver disease with fat in the liver, inflammation, and damage not associated with drinking alcohol.
3050084|NCT02226614|Experimental|head cooling|head cooling
3050085|NCT02226601|Active Comparator|Aprepitant|"Aprepitant~40 mg IV pre-operatively~40 mg PO post-op day #1~40 mg PO post-op day #2"
3050086|NCT02226601|Placebo Comparator|Placebo|"electrolyte (0.9% NaCl) infusion) pre-operatively~capsule without medication on post-op day #1~capsule without medication on post-op day #2"
3050087|NCT02226588|Experimental|Secondary prevention|Single sublingual dose of 800mcg (4 tablets) misoprostol administered to women with 350-500mL postpartum blood loss as estimated using a blood absorption mat or due to deteriorating postpartum condition of the woman as determined by provider's clinical judgment
3050088|NCT02226588|Active Comparator|Universal prophylaxis|Single oral prophylactic dose of 600mcg (3 tablets) misoprostol administered to all women within 1 minute of deliver of baby
3050089|NCT02226575|Experimental|Distress management|The distress management program (cognitive behavioral therapy) alongside standard care
3050093|NCT02226549|Experimental|LDV/SOF+VDV|Participants will receive LDV/SOF+VDV for 8 weeks.
3050094|NCT02226549|Experimental|LDV/SOF+VDV+RBV|Participants will receive LDV/SOF+VDV+RBV for 8 weeks.
3050095|NCT02226536|Placebo Comparator|control|Diet group Control group
3050096|NCT02226536|Active Comparator|fractioned diet without glucose|Fractioned diet without glucose
3050097|NCT02226523||ACS|subjects with final diagnosis of ACS, or non-ACS
3050098|NCT02226510|Placebo Comparator|Placebo|Placebo capsules (with an identical appearance to the active drug) and containing only microcrystalline cellulose PhEur
3050099|NCT02226510|Active Comparator|Metformin XL|In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day (metformin XL 500mg x2/day). They will continue on Metformin XL 500mg x2/day for two weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day (and stopped if this cannot be tolerated).
3050100|NCT02226497|Active Comparator|Arm I (standard outpatient supportive care)|Patients receive standard outpatient supportive care after completion of chemotherapy.
3050101|NCT02226497|Experimental|Arm II (home telemonitoring device)|Patients receive standard outpatient supportive care as in Arm I and use the home telemonitoring device for the duration of chemotherapy-induced cytopenia (up to 3-4 weeks).
3050102|NCT02226484|Experimental|Quercetin|Two 250 mg capsules of oral quercetin (Q) twice-a-day (BID) one hour before meals with a glass of water for 6 weeks.
3050103|NCT02226471||NW-NBP group|normal weight and blood pressure subjects
3050104|NCT02226471||NW-HTN group|Normal weight with hypertension subjects
3050105|NCT02226471||OB-NBP group|obese-normal blood pressure subjects
3050106|NCT02226471||OB-HTN group|Obese-hypertension subjects
3050107|NCT02226458|Experimental|EPI-743|15 mg/kg oral solution three times per day, maximum of 200 mg per dose
3050108|NCT02226445||ADHD medication and psychosocial counseling|
3050109|NCT02226432|Sham Comparator|Kinesics|- Classic Rehabilitation and Kinesic Therapy
3050110|NCT02226432|Sham Comparator|surgery|"- Surgery:~Selective Peripheral Neurotomy is surgical a method of section on suplying peripheral nerves of motor fascicles to relieve harmful spasticity. An intraoperative stimulation of motor fascicles is done, and those which abnormal spreading on far placed myotomes are more evident are chosen to be sectioned."
3050111|NCT02226432|Active Comparator|Magnetic Stimulation|- Postoperative Antagonistic Peripheral Magnetic Stimulation with 1.5 tesla intensity, infrathreshold 80 per cent of minimal intensity able to produce always muscle contraccion. Trials repeated twice a week in sessions of 30 minutes during 6 months
3050112|NCT02226419|Experimental|Break in L-carnitine treatment|Patients do not take their L-carnitine (Levocarnitine) treatment for 2-4 days until plasma carnitine and acylcarnitine have fallen. While patients abstain from taking the treatment, they are admitted for cardiac telemetry monitoring.
3050113|NCT02226406|Experimental|Legs Cycloergometer Group (A)|Patients randomized in this group will do 10 minutes of legs cycloergometer active exercise. Continuously evaluated with electric impedance tomography.
3050114|NCT02226406|Experimental|Hands Cycloergometer Group (B)|Patients randomized in this group will do 10 minutes of hand cycloergometer active exercise. Continuously evaluated with electric impedance tomography.
3050115|NCT02226406|Experimental|Walk in place (C)|Patients randomized in this group will do 10 minutes of active walk in place. Continuously evaluated with electric impedance tomography.
3050116|NCT02226393|Experimental|Prolonged exposure|See intervention description
3050117|NCT02226393|Active Comparator|Child-parent Play Therapy|see intervention description
3050118|NCT02226380|Experimental|mFOLFOX6,chemotherapy regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
3050119|NCT02226367|Active Comparator|prazosin hydrochloride|Prazosin hydrochloride taken orally. Titrated to a maximum dose 4 mg in the morning, 6 mg in the afternoon, and 10 mg at bedtime. (20 mg total daily at maximum dose) Dose increase will occur if the participant does not have unacceptable side effects.
3050120|NCT02226367|Placebo Comparator|placebo|Placebo. Oral capsule with comparable appearance to active treatment. Titrated in same manner as active treatment.
3050121|NCT02226354|Active Comparator|Flaxseed oil|9.73ml Flaxseed oil once daily, for 28 days
3050122|NCT02226354|Experimental|Ahiflower oil|9.73ml Ahiflower oil once daily, for 28 days
3050123|NCT02226341|Active Comparator|CellCept daily & ACTHar gel biw|Patients will be treated with CellCept 3 grams daily and ACTHar gel 80 U biw for 3 months. After 3 months, patients with complete response will stop ACTHar gel but continue CellCept 3 grams daily for another 3 months whereas patients with partial response will continue CellCept 3 grams daily and be offered the option to continue ACTHar 80 U biw for another 3 months. After 6 months, all patients will continue CellCept at a dose of 2 grams daily for another 18 months.
3050124|NCT02226341|Active Comparator|CellCept daily & ACTHar gel qod|Patients will be treated with CellCept 3 grams daily for 3 months, and ACTHar gel 80 U qod for the first month and ACTHar gel 80 U biw for the following 2 months. After 3 months, patients with complete response will stop ACTHar gel but continue CellCept 3 grams daily for another 3 months whereas patients with partial response will continue CellCept 3 grams daily and be offered the option to continue ACTHar 80 U biw for another 3 months. After 6 months, all patients will continue CellCept at a dose of 2 grams daily for another 18 months.
3050125|NCT02226328|Experimental|Propofol sedation|"Refract bolus propofol sedation as monotherapy administered by a sedation-trained nurse endoscopist.~Induction with 10-60 mg bolus, repeated every 45-60 sec. until moderate sedation.~Maintenance with 10-20 mg of propofol in case of discomfort."
3050126|NCT02226328|Active Comparator|Midazolam and Fentanyl sedation|"1-2 mg of Midazolam with 0.025-0.05 mg of fentanyl for induction 10 prior to procedure initiation.~Maintenance with 1 mg Midazolam in case of discomfort."
3050127|NCT02226315||Multiple gestations|Women with a multiple gestation who were evaluated with the MaterniT21 PLUS LDT and have passed their Estimated Date of Delivery (EDD).
3050128|NCT02226302||Female Group 2|Females with BMI >30 kg/m2 who are having a hysterectomy for benign conditions
3050129|NCT02226302||Females Group 1|Females with BMI <30 kg/m2 who are having a hysterectomy for benign conditions
3050130|NCT02226302||Males|2 males with BMI <30 kg/m2 and 2 males with BMI >30 kg/m2
3050131|NCT02226289|Experimental|bevacizumab-containing|bevacizumab with the latest received cytotoxic regimen
3050132|NCT02226276|Experimental|Diagnostic (copper Cu 64-DOTA-trastuzumab PET)|Patients undergo whole body fludeoxyglucose F 18 PET/CT. Patients then receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV and then undergo PET scans at 24 and 48 hours. Patients then receive ado-trastuzumab emtansine IV every 3 weeks until complete response or disease progression at the discretion of the treating oncologist. Patients undergo restaging by whole body fludeoxyglucose F 18 PET/CT every 6 weeks after initiation of treatment until disease progression.
3050133|NCT02226263|Experimental|probiotics Lactobacillus acidophilus boucardii strain.|Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks .The probiotic presentation used was powder in an envelope with 160mg (Carnot ® Laboratories), scientific products, Mexico, (Registration Number 274M91SSA). This was stored in a dry place at room temperature, avoiding sunlight.
3050134|NCT02226250|Experimental|3 Placebo Beverages|Sugar beverage 2 hr before meal and with meal and 2 hr after meal
3050135|NCT02226237|No Intervention|Control Group|in which patients received no specific treatment, only the usual general guidelines
3050136|NCT02226237|Experimental|group of pelvic floor exercises|in which patients were instructed to perform home exercises daily
3050137|NCT02226237|Experimental|anal electrostimulation group|in which patients, and are instructed to perform the exercises mentioned in the group of pelvic floor exercises, also underwent anal electrostimulation
3050138|NCT02226224||early gastric cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
3050139|NCT02226224||Locally Advanced Gastric Cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
3050140|NCT02226224||early esophagus cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
3050141|NCT02226224||locally advanced esophagus cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
3050142|NCT02226211|Experimental|air-Q group|
3050143|NCT02226211|Experimental|aura-i group|
3050144|NCT02226198|Active Comparator|Rosuvastatin|6-week treatment period, and after crossover finished a 12-week efficacy maintenance phase for all patients
3050145|NCT02226198|Placebo Comparator|Placebo|6 weeks treatment during crossover
3050146|NCT02226185|Experimental|Berberine hydrochloride|supplement of Berberine hydrochloride 0.3g two times per day for 2 years
3050147|NCT02226185|Placebo Comparator|placebo|identical-appearing placebo supplements for 2 years
3050148|NCT02226172|Experimental|Arm A|Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.
3050149|NCT02226172|Placebo Comparator|Arm B|Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
3050150|NCT02226159|Active Comparator|Lidocaine|Cervical transforaminal injection: 1.0 cc Lidocaine 1.0% with 1.0 cc normal saline
3050151|NCT02226159|Experimental|Lidocaine with Dexamethasone|Cervical transforaminal injection: 1.0 cc Lidocaine 1.0% with 1.0 cc of Dexamethasone (10 mg/cc)
3050152|NCT02226146|Experimental|Bertilimumab|Intravenous injection over 30 minutes of 10 mg/kg of Bertilimumab in physiological solution (PBS)
3050153|NCT02226133|Experimental|Exclusion of Left Atrial Appendage|Left Atrial Appendage (LAA) occlusion, using the LAAx, Inc. TigerPaw® System II (delivery system and implant/Fastener) using VATS techniques,
3050154|NCT02226120|Experimental|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
3050155|NCT02226107|Experimental|Peer-PN|Peer Patient Navigation
3050156|NCT02226107|Active Comparator|Pro-PN|Professional Patient Navigation
3050157|NCT02226094|Experimental|DWT device dose A|Deep Wave Trabeculoplasty (DWT) dose A (10 second spot treatments).
3050158|NCT02226094|Active Comparator|Ellex Tango SLT machine|Selective Laser Trabeculoplasty (SLT)
3050159|NCT02226094|Sham Comparator|DWT Sham|Deep Wave Trabeculoplasty (DWT) but device not applied to ocular surface.
3050160|NCT02226094|Experimental|DWT device dose B|Deep Wave Trabeculoplasty (DWT) dose B (20 second spot treatments).
3050161|NCT02226068|Other|CsA-ECP|Sequence of therapy: First ciclosporin was given and after relapse extra corporal photopheresis was given
3050162|NCT02226068|Other|ECP-CsA|Sequence of therapy: First extra corporal photopheresis was given and after relapse ciclosporin was given
3050163|NCT02226055||Arterial stiffness: CKDu patients|Cohort of 50 patients with CKD of unknown aetiology Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
3050164|NCT02226055||Arterial stiffness: CKD known cause|Cohort of 50 patients with CKD of known cause Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
3050165|NCT02226055||Arterial Stiffness: Healthy Sri Lankan volunteers|Cohort of 50 participants who are healthy Sri Lankan volunteers Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
3050166|NCT02226055||2nd aim: 250 CKDu patients for investigation of aetiology|"To recruit a cohort of up to 250 CKDu patients from specific CKDu clinics in Anuradhapura and Padavi-Sri Pura for detailed history, basic anthropometric tests, and further analysis of serum, and urine. Analysis for biomarkers of kidney damage, proteomics, exosomes, and DNA adducts will be used to seek information that may complement already collected data and help refine aetiological hypotheses.~Inclusion and Exclusion criteria as per CKDu cases in cohort 1"
3050167|NCT02226042|Experimental|Mindfulness-based Cognitive Therapy|Individuals currently in remission from depression will choose to enter the Mindfulness-based Cognitive Therapy (MBCT) arm and undergo the 8 week MBCT group programme
3050168|NCT02226042|No Intervention|Non-MBCT arm|Individuals currently in remission from depression will choose not to undergo the 8 week MBCT group programme
3050169|NCT02226042|No Intervention|Healthy volunteers|Individuals who have never experienced major depression
3050170|NCT02226029|Experimental|Lipid emulsion 1|Rapeseed oil 20%, sucrose FAE P-1670 0.7%, water 79.3%
3050171|NCT02226029|Experimental|Lipid emulsion 2|Rapeseed oil 20%, sodium stearoyl lactylate P45 veg 1.5%, water 78.5%
3050172|NCT02226016|Experimental|Ptosis|Device (measurement of levator strength in patients with upper lid ptosis)
3050173|NCT02226003|Experimental|Ertugliflozin 5 mg and Sitagliptin 100 mg|Ertugliflozin, 5 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks. Placebo to ertugliflozin, 10 mg, administered orally, once daily for 26 weeks.
3050174|NCT02226003|Experimental|Ertugliflozin 15 mg and Sitagliptin 100 mg|Ertugliflozin, 15 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
3050175|NCT02226003|Placebo Comparator|Placebo to Ertugliflozin and Placebo to Sitagliptin|Placebo to ertugliflozin, 5 mg and 10 mg, administered orally, once daily for 26 weeks. Placebo to sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
3050176|NCT02225990|Active Comparator|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
3050177|NCT02225990|Active Comparator|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
3050178|NCT02225990|Experimental|Experimental Group, Sub-Acute|This group consists of sub-acute stroke patients who are between three weeks and six months post-stroke and will receive the QualPro protocol. If the participant is an inpatient at Shands Rehabilitation Hospital at the beginning of the study, his/her first three weeks of research therapy sessions will take place at the Shands Rehabilitation Hospital. After being discharged, the remainder of the study sessions will take place at either UF Health Rehab Center- Magnolia Parke or in the North Tower (6th floor) physical therapy department of Shands Hospital.
3050179|NCT02225990|Experimental|Experimental Group, Chronic|This group consists of chronic stroke patients who are greater than six months post-stroke and will receive the QualPro protocol. The study sessions will take place at either UF Health Rehab Center-Magnolia Parke or in the North Tower (6th floor) physical therapy department of Shands Hospital.
3050180|NCT02225977||Gilenya treated - 1 month|Patient's taking continuous oral Gilenya at prescribed dose for 1 month.
3050181|NCT02225977||Gilenya treated - 3 months|Patient's taking continuous oral Gilenya at prescribed dose for 3 months.
3050182|NCT02225977||Gilenya treated - 6 months|Patient's taking continuous oral Gilenya at prescribed dose for 6 months.
3050183|NCT02225977||Gilenya treated - 12 months|Patient's taking continuous oral Gilenya at prescribed dose for 12 months.
3050184|NCT02225977||Gilenya qualified - untreated|Patient's qualifying to start treatment with oral Gilenya at prescribed dose but still as yet untreated.
3050185|NCT02225964||aMCIp,aMCIs|progressive aMCI,stable aMCI
3050186|NCT02225951|Active Comparator|Test group|Nutritional product as breakfast.
3050187|NCT02225951|Other|Control Group|Standard breakfast according to ADA recommendations for pregnant women diagnosed with Gestational Diabetes Mellitus.
3050188|NCT02225938||Intensive care survivors|Patients surviving an admission to an intensive care unit
3050189|NCT02225925|Experimental|Dynamic dosimetry brachytherapy|
3050190|NCT02225912|Experimental|PrevinC|PrevinC contains isopropyl alcohol, sesame oil, aloe vera oil extract, and lemon oil.
3050191|NCT02225912|Placebo Comparator|Control solution|The control solution (distilled water and lemon oil) was similar in color, oily consistency and odor to that of PrevinC.
3050192|NCT02225899||Subjects with Cystic Fibrosis|Cross-sectional, observational study
3050193|NCT02225899||healthy volunteers|Cross-sectional, observational study
3050194|NCT02225899||Subjects with CF in a vitamin D study|This is a longitudinal observational study in subjects enrolled in a high-dose vitamin D study. The investigator (Jessica Alvarez) does not assign the intervention to the subjects of the study.
3050195|NCT02225886|Experimental|Ascorbic acid|Patients will receive a 300 mg intravenous ascorbic acid, 3 times a week, postdialysis, except for the dialysis sessions when iv iron is administered.
3050196|NCT02225886|Placebo Comparator|Control group|Patients will receive 100 mL saline solution, 3 times a week, with associated medication, except but the dialysis sessions when iv iron is administered.
3050197|NCT02225873|Experimental|strength-endurance exercises|Group 1 (experimental) will carry out motor control exercises through cranio-cervical flexion training and strength-endurance exercises.
3050198|NCT02225873|Placebo Comparator|strength-endurance and proprioception|Group 2 (control) will carry out exercises to improve muscle strength-endurance and proprioception.
3050199|NCT02225860|Active Comparator|Diet and Water adjustment|Reduction in dietary salt and protein intake
3050200|NCT02225860|No Intervention|Control|Continue with usual diet
3050201|NCT02225847|Active Comparator|Control|Members of this group will continue with their daily life activities and will not receive gardening intervention. The control group will be given a set of psychometric assessments for health and quality of life evaluations and undergo a Functional Magnetic Resonance Imaging (fMRI) brain scan, followed by a second round of psychometric assessments and a fMRI brain scan administered seven to eight weeks after the initial baseline psychometric assessments and fMRI brain scan.
3050202|NCT02225847|Experimental|Gardening|Members of this group will be given a set of psychometric assessments for health and quality of life evaluations and a Functional Magnetic Resonance Imaging (fMRI) brain scan prior to receiving the gardening activities intervention. The gardening intervention will consist of twice weekly group sessions lasting 60 minutes in duration that will take place in a greenhouse. The duration of the experimental intervention will be six weeks for a total of 12 individual gardening activity sessions. Following the completion of the gardening intervention, a second round of psychometric assessments and a fMRI brain scan will be administered seven to eight weeks after the initial baseline psychometric assessments and fMRI brain scan.
3050203|NCT02225834|Experimental|early Atorvastatin treatment|Ischemic stroke patients treated with with atorvastatin 80 mg at admission until discharge
3050204|NCT02225834|No Intervention|no early treatment with atorvastatin|Ischemic stroke patients not treated with with atorvastatin 80 mg until discharge
3078940|NCT02034279|No Intervention|No albumin|Only antibiotics
3050205|NCT02225821|Active Comparator|antibiotic prophylaxis|a single gift of 1000 mg cefazolin in 10 cc of NaCl 0.9% (intervention group)
3050206|NCT02225821|Placebo Comparator|No antibiotic prophylaxis|a single gift of 10 cc NaCl 0.9%, given in the same manner (control group).
3050207|NCT02225808|Experimental|CBT for anxiety in autism|Cognitive-behavioral therapy (CBT) teaches skills for coping with anxiety and consist of 12 weekly sessions. CBT is conducted with child and parent.
3050208|NCT02225795|Experimental|Single Arm: All subjects|Hematopoietic stem cell transplantation
3050209|NCT02225782|Active Comparator|1.0 mg alteplase (tPA)|1.0 mg tPA to be injected at the catheter site for a maximum of 3 repeats if the catheter site occlusion is not resolved with 30 minute wait between each repeat
3050210|NCT02225782|Experimental|2.0 mg alteplase (tPA)|2.0 mg tPA to be injected at the catheter site for a maximum of 3 repeats if the catheter site occlusion is not resolved with 30 minute wait between each repeat
3050211|NCT02225769|Experimental|e-POCT|Febrile children managed using the e-POCT tool. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
3050212|NCT02225769|Active Comparator|ALMANACH|Febrile children managed using the ALMANACH algorithm. ALMANACH is an improved Integrated Management of childhood Illness (IMCI) algorithm based on mobile phones and tablets that has already been assessed for safety and efficacy.
3050213|NCT02225769|No Intervention|Routine practice|Febrile children managed according to routine care such as provided by routine health facility health workers.
3050214|NCT02225756|Experimental|Cyclosporine A dose 1|
3050215|NCT02225756|Experimental|Cyclosporine A dose 2|
3050216|NCT02225756|Placebo Comparator|Placebo|
3050217|NCT02225743||Joint Arthroplasty|Participants undergoing joint replacement
3050218|NCT02225717|Experimental|Non pregnant women|Healthy pregnancy : women 15-16 weeks of gestation, at 35-36 weeks of gestation, and >37 weeks of gestation and planed cesarean prior labor
3050219|NCT02225717|Experimental|Preterm Labor|Pregnant women admitted for preterm labor
3050220|NCT02225717|Experimental|Healthy pregnancy|Healthy pregnancy : women 15-16 weeks of gestation, at 35-36 weeks of gestation, and >37 weeks of gestation and planed cesarean prior labor
3050221|NCT02225704|Experimental|Radium-223 and enzalutamide|Radium-223 50kBq/kg by intravenous injection on day 1 of every 4 week cycle for maximum of 6 cycles Enzalutamide 160mg orally daily
3050222|NCT02225691|Experimental|paired testing of blood glucose|Patient will be randomly assigned to one of 2 arms, namely (i) paired testing (PT) arm; and (ii) control (CL) arm. Paired testing arm will undergo paired testing of blood glucose.
3050223|NCT02225691|No Intervention|control arm|Non-insulin patients will be randomly assigned to one of 2 arms, namely (i) paired testing (PT) arm; and (ii) control (CL) arm. Patients in the control arms will not undergo paired testing and will be managed as before.
3050224|NCT02225665|Experimental|Cohort 1|
3050225|NCT02225665|Experimental|Cohort 2|
3050226|NCT02225652|Experimental|FEC + filgrastim x 3 cycles q 14-21 days and Weekly Paclitaxel|"FEC (FLUOROURACIL 500 mg/m2 IV infusion of 30 minutes + EPIRUBICIN 60 mg/m2 IV infusion of 1 hour + CYCLOPHOSPHAMIDE 500 mg/m2 IV infusion of 30 minutes).~From day 7 until hematological recovery = Filgrastim 300 microg s.c. After 21 days from the last FEC cycle = Paclitaxel 100 mg/m2 IV infusion of 1hour (weekly for 8 cycles, at day 1)."
3050227|NCT02225639|Active Comparator|PRC-063|
3050228|NCT02225639|Placebo Comparator|Placebo|
3050229|NCT02225626|Experimental|BI 1060469 fed|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administr
3050230|NCT02225626|Experimental|BI 1060469 fasted|tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
3050231|NCT02225613|Active Comparator|Usual protocol|2 weeks conventional rehabilitation 3 weeks conventional rehabilitation
3050232|NCT02225613|Active Comparator|Spa protocol|2 weeks conventional rehabilitation 3 weeks aquatic rehabilitation
3050233|NCT02225600|Other|patients with BPD|cross-over administration of 40 IU oxytocin, 24 IU oxytocin and placebo
3050234|NCT02225600|Active Comparator|healthy patients|Cross-over of 40 IU oxytocin, 24 IU oxytocin and placebo
3050235|NCT02225587|Experimental|Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo|Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Pneumovax™ 23 0.5 intramuscular injection at Week 8, and Placebo 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
3050236|NCT02225587|Placebo Comparator|Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23|Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Placebo 0.5 intramuscular injection at Week 8, and Pneumovax™ 23 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
3050237|NCT02225574|Experimental|Advanced CML + Philadelphia positive Acute Leukemia-Group 1|"Phase 1 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 1 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.~Phase 2 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on Day 1 of a 28 day cycle.~Phase 2 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle."
3050238|NCT02225574|Experimental|Chronic Phase CML - Group 2|"Phase 1 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 1 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.~Phase 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle.~Phase 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle."
3050239|NCT02225561|Experimental|Intervention arm|Pharmaco- mechanical optimization
3050240|NCT02225561|Active Comparator|Mechanical optimization only|Mechanical optimization only
3050241|NCT02225548|Experimental|Selegiline and Tadalafil|Tadalafil 2.5mg for 4 weeks then oral selegiline 5mg daily for 2 weeks then increased to 5mg twice daily for 2 more weeks
3050242|NCT02225535|Placebo Comparator|Usual Care (NP)|Rural NP with client in-person, usual care
3050243|NCT02225535|Active Comparator|PT in-person|Urban PT travels to rural area to manage patient's back pain in-person.
3050670|NCT02222649|Experimental|Vitamin D3|Group supplemented with high single dose of 200,000 IU of vitamin D3 (cholecalciferol)
3050244|NCT02225535|Active Comparator|PT/NP Telehealth|Intervention: Rural NP is joined by PT via Telehealth for interprofessional videoconference with patient
3050245|NCT02225522|No Intervention|Standard Care|Patients in this arm receive standard genetic evaluation without the addition of next generation sequencing for the diagnosis of their presumed genetic condition
3050246|NCT02225522|Experimental|Rapid whole genome sequencing (StatSeq)|Patients in this arm will receive standard of care genetic evaluation and next generation sequencing of their genome to achieve rapid diagnosis of genetic conditions.
3050247|NCT02225509|Other|Patients with thyroid nodules|Patients with thyroid nodules with an indication for FNA biopsy to detect thyroid cancer. These patients will undergo FNA at the time of first visit and also when considered necessary by the clinician during the course of the study.
3050248|NCT02225496|Experimental|Transoral Robotic Surgery (TORS)|Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm. Functional assessment performed at pre-treatment, within 1-4 weeks post-op from TORS (before adjuvant therapy), and after completion of treatment at the following time points: 6 months (±2 months), 12 months (±2 months), and 24 months (±6 months). Functional measures include video-fluoroscopic examination of swallowing (modified barium swallow [MBS] study) with administration of the Performance Status Scale-Head and Neck (PSS-HN) and MD Anderson Dysphagia Inventory (MDADI) questionnaire.
3050249|NCT02225483||Hemophilia A|Boys with Factor VIII coagulant activity less than or equal to 1%.
3050250|NCT02225470|Experimental|Arm A, E7389 (Eribulin Mesylate)|The eribulin mesylate dose will be 1.4 mg/m2 administered as an intravenous bolus over 2 to 5 minutes on Days 1 and 8 of each 21-day cycle.
3050251|NCT02225470|Active Comparator|Arm B, Vinorelbine injection|The vinorelbine dose will be 25 mg/m2 administered as an intravenous bolus on Days 1, 8, and 15 of each 21-day treatment cycle.
3050252|NCT02225457|Experimental|Hypercaloric diet and polyphenols|"polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.~Hypercaloric diet will consist in a hypercaloric diet providing an excess of 50% KCal over daily requirements, and will last 30 days."
3050253|NCT02225457|Active Comparator|Hypercaloric diet and placebo|"Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.~Overfeeding will consist in a hypercaloric diet providing an excess of 50% KCal over daily requirements, and will last 30 days."
3050254|NCT02225444||OsteoAMP treatment group|The OsteoAMP treatment group contains patients randomized to receive their own bone (retrieved from the surgical site) augmented with the OsteoAMP growth factor to assist with posterolateral arthrodesis at 1 or 2 adjacent levels between L1-S1.
3050255|NCT02225431|Active Comparator|Standard saline infusion|All patients received standard intravenous saline hydration (0.9% sodium chloride, 1 ml/kg/h for 12 hours before and after procedure)
3050256|NCT02225431|Experimental|Double saline infusion|All patients received double dose of intravenous saline hydration (0.9% sodium chloride, 2 ml/kg/h for 12 hours before and after procedure)
3050257|NCT02225418|Sham Comparator|Placebo TQL block|30 ml single shot TQL block with saline 0,9%
3050258|NCT02225418|Active Comparator|Active TQL block|30 ml single shot TQL block with ropivacaine 0,75%
3050259|NCT02225405|Experimental|Nintedanib + Cisplatin + Docetaxel|"Run-In Phase: First-cycle chemotherapy doses fixed at Cisplatin 75 mg/m2 by vein on Day 1 and Docetaxel 75 mg/m2 by vein on Day 1. Starting dose of Nintedanib 150 mg by mouth twice a day every day from Day 2 of Cycle 1 through Day 7 of Cycle 3, except for the days that Cisplatin and Docetaxel given. Cycles repeated every 21 days +7 days/-3 days for a maximum of 3 cycles.~Expansion Phase: During expansion phase, participants receive priming therapy with Nintedanib single agent for 28 days (+/- 7 days) at the maximum tolerated dose from Run-In Phase. After priming therapy completed, participants receive 3 cycles of induction chemotherapy with Cisplatin, Docetaxel, and Nintedanib followed by surgery."
3050260|NCT02225392|Active Comparator|Delayed bronchial thermoplasty|"After randomisation they will wait for 25 weeks (control group) and then start with bronchial thermoplasty.~Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated."
3050261|NCT02225392|Experimental|Immediate bronchial thermoplasty|"After randomisation they start immediate with bronchial thermoplasty treatment.~Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated."
3050262|NCT02225379|Experimental|Hypo-Sense (non invasive sensor)|Parallel measurements of capillary blood glucose using reference method and data generated by the non- invasive study device (Hypo Sense) during approximately 4 hours, in which a hypoglycemic event will be induced.
3050263|NCT02225366|Experimental|Intra-Tumoral Injection of LL37|LL37 administered intratumorally in cutaneous or subcutaneous tumors at least 1 cm in diameter. Patients will receive weekly intratumoral injections of LL37 for up to 8 weeks. The injections will be given every 7 days (+/- 48 hours). Starting dose 250 µg/tumor.
3050264|NCT02225353|Experimental|Progesterone Cervical Pessary 6.3 g|90 pregnant women with Progesterone Cervical Pessary
3050265|NCT02225353|Experimental|Progesterone Cervical Pessary 7.7 g|90 pregnant women with Progesterone Cervical Pessary
3050266|NCT02225353|Active Comparator|Progesterone 200 mg vaginal capsules|90 pregnant women using Progesterone 200 mg vaginal capsules daily
3050267|NCT02225340||Controls|
3050268|NCT02225340||Familial hypercholesterolemia|
3050269|NCT02225327|Active Comparator|Fluad alone|56 Fluad recipients: one vaccine injection administered on Day 0
3050270|NCT02225327|Active Comparator|Fluad and PPV23 on the different arms|56 concomitant Fluad-PPV23 recipients on the different arms: one dose of each vaccine administered on Day 0
3079045|NCT02033499|Other|enhanced messaging|SMBG enhanced messaging
3050271|NCT02225327|Active Comparator|Fluad and PPV23 on the same arm|56 concomitant Fluad-PPV23 recipients on the same arm with 1 inch distance: one dose of each vaccine administered on Day 0
3050272|NCT02225327|Active Comparator|PPV23 alone|56 PPV23 recipients: one vaccine injection administered on Day 0
3050273|NCT02225314|Experimental|Brain Fitness|Brain Fitness is a computer-based cognitive training programs designed to augment auditory processing speed and accuracy over an 8-week period to individuals with PD and MCI at a community Parkinson's and Movement Disorders specialty clinic.
3050274|NCT02225314|Experimental|InSight|InSight is a computer-based cognitive training programs designed to augment visual processing and working memory over an 8-week period to individuals with PD and MCI at a community Parkinson's and Movement Disorders specialty clinic.
3050275|NCT02225314|Active Comparator|Active Control|An active control arm is necessary to model practice effects in an untreated group. Participants in this group will view and complete quizzes on a computerized learning program designed to improve knowledge about literature, art, and history.
3050276|NCT02225301|Experimental|iLook Out for Child Abuse|The online learning module is an interactive, multi-media, self-paced intervention that takes 1.5-2 hours to complete.
3050277|NCT02225288|Experimental|Group A|Period 1: Apply one E2022 tape to the designated site (back or upper arm) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or upper arm, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group A: 48 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
3050278|NCT02225288|Experimental|Group B|Period 1: Apply one E2022 tape to the designated site (back or upper arm) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or upper arm, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group B: 72 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
3050279|NCT02225288|Experimental|Group C|Period 1: Apply one E2022 tape to the designated site (back or chest) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or chest, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group C: 96 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
3050280|NCT02225288|Experimental|Group D|Period 1: Apply one E2022 tape to the designated site (back or chest) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or chest, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group D: 120 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
3050281|NCT02225275|Experimental|Lenalidomide + Obinutuzumab|Obinutuzumab given 100 mg by vein on Day 1, 900 mg by vein on Day 2 and 1000 mg on Day 8 and Day 15 for the first cycle, then 1000 mg on Day 1 for cycles 2 - 6 in a 28 day cycle. Lenalidomide given by mouth at 5 mg per day from day 9 until day 56, and at 10 mg per day from day 57 until progression or excessive toxicity.
3050282|NCT02225262|Experimental|CyberKnife Radiosurgery|
3050283|NCT02225236|Experimental|Classroom Intervention|The intervention focuses on training executive functioning (e.g., working memory and inhibition) and metacognition (i.e., the ability to predict, check, monitor, coordinate and control cognitive operations) using play activities and structured language and reinforcement.
3050284|NCT02225236|No Intervention|No treatment control|No intervention
3050285|NCT02225223|Other|No previous Radiation Therapy|Targeted radio-frequency ablation using the STAR™ Tumor Ablation System and vertebral augmentation using the StabiliT® Vertebral Augmentation System.
3050286|NCT02225223|Other|Failed/Refuse further Radiation Therapy|Targeted radio-frequency ablation using the STAR™ Tumor Ablation System and vertebral augmentation using the StabiliT® Vertebral Augmentation System.
3050287|NCT02225210|Experimental|Group dexmedetomidine ,dexmedetomidine|Continuous pump infusion dexmedetomidine with loading dose of 0.4μg.kg-1 for 10 minutes ,then followed by maintenance dose of 0.2~0.7µg.kg-1 to maintain Sedation-Agitation Scale between 3 and 4.
3050288|NCT02225210|Active Comparator|Group midazolam,midazolam,fentanyl|Quickly inject midazolam and fentanyl with loading dose of 0.1mg.kg-1 and 1 μg.kg-1 separately until attaining Sedation-Agitation Scale between 3 and 4,then followed by maintenance dose of 0.05~0.1mg.kg-1.h-1 and fentanyl 0.5~1μg.kg-1.h-1 separately.
3050289|NCT02225197|Experimental|CyberKnife Radiosurgery|
3050290|NCT02225093|Experimental|1:Caffeine, Dextromethorphan and Enzalutamide|1-sequence crossover here
3050291|NCT02225080||Duragen Secure|Have undergone a neurosurgical procedure where DuraGen® Secure has been implanted
3050292|NCT02225067|Experimental|C13-CAC|
3050293|NCT02225054|Placebo Comparator|Ropivacaine,Normal Saline,Saline Bolus|Ropivacaine 15 mL 0.5% Normal Saline mL 0.9% Saline Bolus
3050294|NCT02225054|Experimental|Ropivacaine,Dexmedetomidine,Saline Bolus|Ropivacaine15 mL 0.5% Dexmedetomidine0.5 u/kg Saline Bolus
3050295|NCT02225054|Active Comparator|Ropivacaine,Saline,Dexmedetomidine|Ropivacaine 15 mL 0.5% Normal Saline 1 mL 0.9% Dexmedetomidine single IV bolus 0.5 u/kg over 30 minutes
3050296|NCT02225028|Active Comparator|Physical Activity Counseling|Participants who are randomized to the physical activity counseling intervention group will work with a physical activity coach over the course of 6 months to come up with a physical activity program that works for each individual. Participants will have 16 phone calls and discuss goals and values, track physical activity, troubleshoot barriers, and work on keeping exercise interesting and motivating. Participants will also learn strategies for managing stress and battling unhelpful thoughts that may get in the way of activity. By the end of the intervention, the goal is to be regularly doing 150 minutes of physical activity each week. The physical activity coach will work with participants to ensure that they are increasing activity safely in order to prevent injuries.
3079339|NCT02031497|Active Comparator|Drink without sweeteners|
3050297|NCT02225028|No Intervention|Usual Care|Participants randomized to the usual care control group will receive a packet of exercise related-information at the end of the baseline assessment as well as a letter from study staff informing them of their randomization status and their test results. The letter will provide information on biological markers that are in the at-risk range, advice to seek medical advice regarding lifestyle changes such as diet and exercise and information on how to contact study staff regarding test results. We will offer to forward test results to their health care provider provided they furnish written release of information We will emphasize our interest in providing them with a follow-up assessment in 6 months.
3050298|NCT02225015|Active Comparator|FTGC at 1 month|Individuals randomized to the intervention group will receive a tailored cancer risk assessment via a follow-up telephone genetic counselling (FTGC) session within one month of study enrollment.
3050299|NCT02225015|No Intervention|Standard Care + FTGC in 12 months|Individuals randomized to the intervention group will receive a tailored cancer risk assessment at 12 months following study enrollment
3050300|NCT02224989|Experimental|Mind-Body Bridging|An awareness training program using mindfulness-based techniques.
3050301|NCT02224976|Experimental|Intensified training|Volunteers will increase exercise training by 30% from baseline
3050302|NCT02224963|Experimental|Preventive Problem-Solving Training|Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems. It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
3050303|NCT02224963|Active Comparator|Life and Health Review|Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
3050304|NCT02224950|Placebo Comparator|Control|"Non-medicated Emollient with no Clothing Covering Upper Limb - Baseline/Control Cells"
3050305|NCT02224950|Active Comparator|Sleeve 2|Non-medicated Emollient plus Lyocell/Chitosan Sleeve
3050306|NCT02224950|Placebo Comparator|Placebo Sleeve|Non-medicated Emollient plus Cotton Sleeve
3050307|NCT02224937|Experimental|Melatonin:Melatonincreme 12,5%|Application of melatonincream 12,5% on 80% of the body-surface at start of investigation.
3050308|NCT02224937|Placebo Comparator|Placebo|Application of placebo cream on 80% of the body-surface at start of investigation.
3050309|NCT02224924|Active Comparator|autologous blood patch injection (ABPI)|
3050310|NCT02224924|Experimental|BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug|
3050311|NCT02224911||Laser Interstitial Thermal Therapy|This is a minimally invasive procedure for focal treatment of prostate cancer.
3050312|NCT02224898||Definite/Suspected Chronic Pancreatitis|Patients with diagnosis of chronic pancreatitis with at least two of the following features: clinical course consistent with chronic pancreatitis, calcification in the pancreas on US/CT/EUS, ERCP showing ductal abnormalities (Cambridge Classification), exocrine insufficiency, histology showing irregular fibrosis, acinar cell loss, islet cell loss, and inflammatory cell infiltrates, or other features suggestive of chronic pancreatitis (such as pancreatic pseudocyst). The study group will also include patients with suspected chronic pancreatitis based on history of documented pancreatitis with lingering symptoms or signs of early chronic pancreatitis on imaging. Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
3050313|NCT02224898||Healthy Control Group|Patients with no history of chronic gastrointestinal symptoms lasting greater than 8 weeks, no gastrointestinal disease or condition diagnosis, and are not currently experiencing gastrointestinal symptoms. Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
3050314|NCT02224885|Other|addition of nCLE to help target biopsy|The patient, scheduled for a liver or lung CT-guided percutaneous biopsy or ablation will undergo a probe-based confocal laser endomicroscopy procedure after the imaging procedure. The objectives of this study are to demonstrate the technical feasibility and safety of doing endomicroscopic imaging during interventional radiology procedure and determine whether it is technically feasible to obtain images from Cellvizio during an interventional radiology procedure.
3050315|NCT02224872|Experimental|Bone marrow transplant|Thymoglobulin on days -9 to -7 Fludarabine on days -6 to -2 Cyclophosphamide on days -6, -5, 3, 4 TBI on day -1 BMT on day 0 Mesna on days 3, 4 Tacrolimus on days 5-365 Mycophenolic acid mofetil on days 5-35
3050316|NCT02224859|Other|Safety|"Following an initial examination of the scalp and head for baseline evidence of skin integrity (intact, without breaks, lacerations, etc.) and appearance (healthy/normal, no erythema/irritation, etc.) the HCP will place the CSD on the patient and secure the attached Velcro strap to hold the device in place~At specific time points (approximately 15 minutes, 1 hour, 3 hours and 6 hours) the HCP (through human intervention)will remove the CSD for examination and completion of the Skin Assessment Scale based on the appearance of the patient's scalp and adjacent areas of the head. Additionally, the patient's head will be observed for excessive scalp sweating/moisture accumulation."
3050317|NCT02224846|Experimental|2.5 mg/5 mg tadalafil|2.5 mg tadalafil orally once daily for 3 months (Period 1) and then 5 mg tadalafil orally once daily for 21 months (Period 2).
3050318|NCT02224846|Experimental|5 mg tadalafil|5 mg tadalafil orally once daily for 24 months (Period 1 and Period 2).
3050319|NCT02224833|Experimental|Intervention|
3050320|NCT02224833|No Intervention|Control|
3050321|NCT02224820|Experimental|Intravenous IdeS|One or two doses of IdeS in ascending doses
3050322|NCT02224807|Active Comparator|Progressive Resistance Training (PRT) and a healthy diet|PRT will be done with resistance bands; participants will receive instruction on three resistance band exercises (triceps, biceps, and shoulder overhead) from an American College of Sports Medicine (ACSM) certified exercise specialist. Participants also will receive dietary counseling from a registered dietitian on correcting nutrient deficiencies that are detected during analysis of their 2-day dietary recalls.
3050378|NCT02224521|Experimental|Cohort 3|Cohort 3 will be a 4-way complete crossover study with single doses of 20mg and 200mg of up to two capsule formulations taken forward from cohort 2 in 10 healthy adult subjects in the fasted state.
3050379|NCT02224521|Experimental|Cohort 4|The regimen for Cohort 4 will be either the highest dose (200mg) of the capsule formulation (A, B or C) taken forward from the previous cohorts or the solution formulation (200mg).
3050323|NCT02224807|Experimental|PRT and a healthy diet, plus weight loss|This arm will receive all components of the active comparator arm, plus counseling to achieve a weight loss of 1.5-2 pounds/week. Participants will be trained on how to achieve this caloric deficit through both dietary restriction and increased physical activity. Weight loss will be promoted via a healthy, nutritionally adequate diet consistent with American Cancer Society guidelines. Protein levels will be based on 0.8 g/kg body weight. The distribution of food groups will be customized for preferences. An exercise program will be tailored taking into account kcal expenditure for various activities at a specific body weight; expenditures of 200-400 kcal/day will serve as a goal. Aerobic training of large muscles (legs) will be emphasized to achieve a greater kcal deficit; ramping of intensity and volume over time will be pursued as per the ACSM guidelines. Participants will train once weekly while supervised by an exercise physiologist and daily at home.
3050324|NCT02224794||Fast-Track Group|includes subjects who complete the Fast-Track EVAR protocol
3050325|NCT02224794||Standard P-EVAR Group|includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are completed with bilateral percutaneous access
3050326|NCT02224794||Standard EVAR Group|includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are not completed with bilateral percutaneous access (i.e. converted to femoral cutdown or open surgical repair)
3050327|NCT02224781|Experimental|Arm A (immunotherapy)|"IMMUNOTHERAPY INDUCTION (COURSES 1-2): Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.~IMMUNOTHERAPY MAINTENANCE (COURSES 3-14): Patients receive nivolumab IV over 60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients re-register and cross over to Arm C."
3050328|NCT02224781|Experimental|Arm B (BRAF inhibitor therapy)|Patients receive dabrafenib PO BID and trametinib PO daily on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients re-register and cross over to Arm D.
3050329|NCT02224781|Experimental|Arm C (BRAF inhibitor therapy)|Patients receive dabrafenib PO BID and trametinib PO daily on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3050330|NCT02224781|Experimental|Arm D (immunotherapy)|"IMMUNOTHERAPY INDUCTION (COURSES 1-2): Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.~IMMUNOTHERAPY MAINTENANCE (COURSES 3-14): Patients receive nivolumab IV over 60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
3050331|NCT02224768||HCP and Patient inclusion|"HCP inclusion - HCP Experience with treatment of patients with study compound who have been exposed to risk minimization tools~Patient inclusion - Patients treated with study compound as per label who have been exposed to the risk minimization materials"
3050332|NCT02224755|Experimental|HeartMate 3 LVAS (HM3 LVAS)|Evaluation of the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
3050333|NCT02224755|Active Comparator|HeartMate II LVAS|Evaluation of the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
3050334|NCT02224742|Experimental|LeucoPatch|Usual care supplemented by the application of LeucoPatch centrifugates that comprise autologous fibrin patches containing living white cells and platelets
3050335|NCT02224742|Active Comparator|Usual care|Usual care provided in a multidisciplinary foot care clinic, in accordance with international guidelines
3050336|NCT02224729|Experimental|Bendamustine, Bortezomib, Dexamethasone (Standard)|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2; bortezomib SC on days 1, 8, 15, and 22; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 35 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than a VGPR or with more than 10% bone marrow plasmacytosis may receive 2 additional courses.
3050337|NCT02224716||Pre-intervention All patients admitted with a diagnosis of CAP|
3050338|NCT02224716||Post intervention All patient admitted with a diagnosis of CAP|
3050339|NCT02224703|Experimental|High Dose Level GWP42003-P|GWP42003-P oral solution (100 mg/mL cannabidiol in sesame oil with anhydrous ethanol with added sweetener [sucralose] and strawberry flavoring). The High Dose Level will be as recommended by the DSMC after assessment of safety and pharmacokinetic data from Part A of study GWEP1332.
3050340|NCT02224703|Experimental|Low Dose Level GWP42003-P|GWP42003-P oral solution (100 mg/mL cannabidiol in sesame oil with anhydrous ethanol with added sweetener [sucralose] and strawberry flavoring). The Low Dose Level will be defined as 50% of the High Dose Level.
3050341|NCT02224703|Placebo Comparator|Placebo Control|Excipients only. Patients will be split into two cohorts, half receiving High Dose Level dosing volumes and half receiving Low Dose Level dosing volumes.
3050342|NCT02224690|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
3050343|NCT02224690|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume matched to the 20 mg/kg/day dose, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
3050344|NCT02224677||Children with Craniofacial Microsomia|125 children with craniofacial microsomia will be asked to come in for two study visits - when they are about 12 months old and again when they are about 36 months old. Procedures for children at the first visit include: assessment of development, video, photographs, and a hearing evaluation. Procedures for the final study visit include: assessment of development, photographs (2D & 3D), video, saliva sample, hearing evaluation, speech assessment.
3050671|NCT02222649|Placebo Comparator|placebo group|Placebo capsules with starch
3050345|NCT02224677||Children without Craniofacial Microsomia|Please note: we are not recruiting this group through ClinicalTrials.gov 100 children without craniofacial microsomia will be asked to come in for two study visits - when they are about 12 months old and again when they are about 36 months old. Procedures for the first visit include: assessment of development, video, and photographs. Procedures for the final study visit include: assessment of development, photographs (2D & 3D), video, and speech assessment.
3050346|NCT02224677||Parents of Children with Craniofacial Microsomia|125-250 parents of children with craniofacial microsomia will be asked to complete three visits - when their child is about 12 months old, 24 months old, and 36 months old. Parents will be asked to complete an interview at the first visit. The second visit consists of a telephone interview where parents will be asked about their child's hearing and health history. At the final study visit, parents will be asked to complete more questionnaires, have their picture taken, and donate saliva.
3050347|NCT02224677||Parents of Children without Craniofacial Microsomia|Please note: we are not recruiting this group through ClinicalTrials.gov 100 parents of children without craniofacial microsomia will be asked to complete three visits - when their child is about 12 months old, 24 months old, and 36 months old. Parents will be asked to complete an interview at the first visit. The second visit consists of a telephone interview where parents will be asked about their child's hearing and health history. At the final study visit, parents will be asked to complete questionnaires and an interview.
3050348|NCT02224677||Teacher/Day Care Provider|When the children participants are around 36 months old, we will ask parents for permission to contact their child's teacher/day care provider. We would like the teacher/day care provider to fill out a questionnaire.
3050349|NCT02224664|Experimental|Cohort 3|Titration of PF-06649751 up to 5 mg QD
3050350|NCT02224664|Experimental|Cohort 4|Titration of PF-06649751 up to 15 mg QD
3050351|NCT02224664|Experimental|Cohort 5|Titration of PF-06649751 up to 15 mg QDi n subjects with Levodopa-induced dyskinesias (LID)
3050352|NCT02224664|Experimental|Cohort 6|Titration of PF-0649751 up to 25 mg QD
3050353|NCT02224651|Experimental|(1-1000mg) Immediate Release formulation|
3050354|NCT02224651|Placebo Comparator|Immediate Release Placebo arm|
3050355|NCT02224651|Experimental|(10-500) mg Modified Release formulation|
3050356|NCT02224651|Placebo Comparator|Modified Release Placebo arm|
3050357|NCT02224638|Active Comparator|TheraHoney HD|Honey product
3050358|NCT02224638|Active Comparator|SkinTegrity|Skin moisturizer
3050359|NCT02224625|Experimental|2% CHG Cloth|Chlorhexidine Gluconate 2%
3050360|NCT02224625|Placebo Comparator|Vehicle Cloth|Excipients on cloth
3050361|NCT02224625|Active Comparator|DynaHex (2% CHG)|Chlorhexidine Gluconate 2% solution
3050362|NCT02224625|Sham Comparator|Saline|0.9% sodium chloride
3050363|NCT02224625|Active Comparator|Sodium Lauryl Sulfate (SLS)|Sodium lauryl sulfate to produce mild irritation as a positive control
3050364|NCT02224612|Active Comparator|Children 4-5 yrs|4-5 year old children Medline Pediatric Face Mask KC Childs Face Mask
3050365|NCT02224612|Active Comparator|Children 6-9 yrs|6-9 year old children Medline Pediatric Face Mask KC Childs Face Mask
3050366|NCT02224612|Active Comparator|Children 10-12 yrs|10-12 year old children Medline Pediatric Face Mask KC Childs Face Mask
3050367|NCT02224599|Experimental|CYP, TAPA-pulsed DC vaccine, Imiquimod|TAPA-Pulsed DC Vaccine Cyclophosphamide Pill Imiquimod Topical Cream
3050368|NCT02224586||light treatment|clinical routine treatment according to the doctor's advice
3050369|NCT02224573|Experimental|GWP42003-P|
3050370|NCT02224560|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
3050371|NCT02224560|Experimental|GWP42003-P 10 mg/kg/day Dose|Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
3050372|NCT02224560|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD) volume matched to 1 of the 2 dose levels (10 or 20 mg/kg/day) administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 7 to 11 days according to the matched IMP group (7 or 11 days for the 10 or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
3050373|NCT02224547|Experimental|Radiotherapy|For centrally located T1 and T2 lesions 4 x 12 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 17 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
3050374|NCT02224534|Experimental|Ticagrelor and Clopidogrel.|The patients assigned to the TICA group have loading dose of ticagrelor 180 mg just after the randomization, and then ticagrelor 90 mg twice daily during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.
3050375|NCT02224534|Active Comparator|Clopidogrel|The patients assigned to the CLPD group have loading dose of clopidogrel 600 mg just after the randomization, and then clopidogrel 75 mg daily should be maintained during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.
3050376|NCT02224521|Experimental|Cohort 1|Subjects will be assigned to any of the 4 dosage regimen (A, B, C, D) in four periods. A= GSK2190915 Solution, 50mg single dose, fasted; B = GSK2190915 Capsule Formulation A, 50mg single dose (1 x 50mg capsule), fasted; C= GSK2190915 Capsule Formulation B, 50mg single dose (1 x 50mg capsule), fasted; D= GSK2190915 Capsule Formulation C, 50mg single dose (1 x 50mg capsule), fasted.
3050377|NCT02224521|Experimental|Cohort 2|The selected formulation will be dosed with GSK2190915 capsule formulation at 20mg (fasted), 100mg (fasted), 100mg (fed) and 200mg (fasted).
3050702|NCT02222480|Experimental|Fimasartan 120 mg, Hydrochlorothiazide 12.5 mg|Combination of Fimasartan/Hydrochlorothiazide 120/12.5mg
3050380|NCT02224521|Experimental|Cohort 5|Subjects will take milled and micronised tablet formulations of GSK2190915 in the fasted state in periods 1 and 2, and will take milled and micronised tablet formulations of GS2190915 in the fed state in periods 3 and 4.
3050381|NCT02224521|Experimental|Cohort 6|Tablet formulations (milled and micronised, different to the Cohort 5 formulations) of GSK2190915 will be dosed in the fasted and fed (after a light breakfast) states.
3050382|NCT02224508||Opioid Risk Reduction Initiative|Opioid risk reduction initiative for chronic opioid therapy patients implemented in Group Health integrated group practice clinics.
3050383|NCT02224508||Usual Care|Usual care for management of chronic opioid therapy patients implemented in Group Health network care settings.
3050384|NCT02224495|Placebo Comparator|Control|Standard of care
3050385|NCT02224495|Experimental|Structured exercise training|8-week outpatient exercise-training program, encompassing 3 sessions per week, including endurance and resistance training
3050386|NCT02224482|No Intervention|Control|Print materials
3050387|NCT02224482|Active Comparator|Intervention Group|PROGRESS
3050388|NCT02224469|Experimental|ECoG (electrocorticography) sensing|Use ECoG-based Brain Computer interface to control assistive technology
3050389|NCT02224456|Experimental|Tenofovir|Subjects will receive TDF 300 milligrams (mg) tablet once daily for 240 weeks in the study. Subjects who receive add-on rescue treatment may take LAM 100 mg, ETV 0.5 mg or LdT 600 mg per day upon investigator's decision in addition to TDF tablet.
3050390|NCT02224443|Experimental|Group A, dexmedetomidine , 0.3µg.kg-1.h-1|Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed Continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
3050391|NCT02224443|Experimental|Group B,dexmedetomidine , 0.5µg.kg-1.h-1|Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
3050392|NCT02224443|Placebo Comparator|Group C ,normal saline|Normal saline infusion will be given with the same infusion volume as group A and B
3050393|NCT02224430||schizophrenia/schizoaffective disorder|Participants with schizophrenia/schizoaffective disorder will be observed remotely and at weekly/biweekly laboratory visits over a period of 16 weeks or until relapse occurs.
3050394|NCT02224417|Other|Diabetes Educational Program (DEP) only|Participants will receive the Diabetes Educational Program, as required, which is part of usual care at the Polyclinic. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one).
3050395|NCT02224417|Other|DEP + Process Incentive Arm|Participants will receive the Diabetes Educational Program, as required. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one). They will also have the opportunity to earn financial incentives for meeting specified process goals.
3050396|NCT02224417|Other|DEP + Outcome Incentive Arm|Participants will receive the Diabetes Educational Program, as required. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one). They will also have the opportunity to earn financial incentives for meeting specified outcome goals.
3050397|NCT02224404|Experimental|Fast Gelling Dressing|
3050398|NCT02224391|Experimental|ABM Training - Smartphone|Participants complete 13 days of Attentional Bias Modification (ABM) training through a smartphone, designed to help in smoking cessation after first lab session. Participants attend 3 lab sessions consisting of questionnaire completion, event-related potential (ERP) electroencephalography (EEG), & urine collection. Counseling sessions held in person on day 15, then on phone on days 28, 42, and 56. An 8-week supply of Nicotine replacement therapy given on day 15.
3050399|NCT02224391|Sham Comparator|Sham Training - Smartphone|Participants complete 13 days of smartphone training after first lab session. Participants attend 3 lab sessions consisting of questionnaire completion, ERP EEG, & urine collection. Counseling sessions held in person on day 15, then on phone on days 28, 42, and 56. An 8-week supply of Nicotine replacement therapy given on day 15.
3050400|NCT02224378|Experimental|peep induced CVP|
3050401|NCT02224378|Active Comparator|passive leg raising(PLR)|
3050402|NCT02224365|Experimental|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
3050403|NCT02224365|Placebo Comparator|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
3050404|NCT02224352|Experimental|Single-Arm Study|Functional neuromuscular electrical stimulation of abdominal-wall muscles triggered by an airway pressure signal
3050405|NCT02224339||plaque neovascular and stress echo|After the SE and CEUS examination, patients will be grouped per the result of SE and CEUS as follows: group I: plaque neovascularization and normal wall motion; group II: plaque neovascularization and abnormal wall motion; group III: no plaque neovascularization and abnormal wall motion; group IV: no plaque neovascularization and normal wall motion.
3050406|NCT02224313|No Intervention|1.Premenopausal women|No treatment
3050407|NCT02224313|Experimental|2.Postmenopausal women with hormones|"Oral hormone therapy will be given to women in this group. Daily dose of oral estradiol 0.5 mg will be given the first 14 days after enrollment. Then a daily dose of oral estradiol 0.5 mg and progesterone 100 mg for 14 days will be given during the following 14 days."
3050408|NCT02224313|Experimental|3.Postmenopausal women with hormones|"Oral hormone therapy will be given to women in this group. Daily dose of oral estradiol 1 mg will be given the first 14 days after enrollment. Then a daily dose of oral estradiol 1 mg and progesterone 100 mg for 14 days will be given during the following 14 days."
3050409|NCT02224300|Experimental|Education|"Intervention group will receive the ELC for six weeks (15.9. - 26.10.2014) and comparison group will not receive it.~Members of the intervention group in will work in teams of 10 nurses with weekly questions (released in Mondays) based on patient-description existing in Moodle. One member of the team will send the solutions to questions once a week (in Thursdays) Moodle. Researcher will download the model-answer to Moodle once a week (in Fridays) and nurses will compare their answer to model answer (self-evaluation)."
3050410|NCT02224287|Other|Fluoroscopy|Technologist control of fluoroscopy Surgeon control of fluoroscopy
3050411|NCT02224274|Active Comparator|Clopidogrel|These patients will be treated with clopidogrel 600 mg loading and than 75 mg/24 h.
3050412|NCT02224274|Experimental|Ticagrelor|These patients will be treated with ticagrelor 180 mg loading and than 90 mg/12 h.
3050790|NCT02221973|Experimental|milk with 1.2g/d sterols and 8g/d hawthorn powder|
3050413|NCT02224261|Experimental|Physical Therapy|Physical therapy protocol includes manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active and action-assisted arm exercises
3050414|NCT02224261|Active Comparator|Control|Control protocol includes same progressive active and action-assisted arm exercises than the experimental group.
3050415|NCT02224248|Experimental|Health checks with fitness testing|
3050416|NCT02224248|Active Comparator|Health checks without fitness testing|
3050417|NCT02224235|Experimental|Group 1|COBRA PzF coronary stent followed by dual anti-platelet therapy (DAPT) for one week
3050418|NCT02224235|Active Comparator|Group 2|Resolute Integrity DES followed by dual anti-platelet therapy (DAPT) for at least 6 months
3050419|NCT02224235|Experimental|Group 3|COBRA PzF coronary stent followed by aspirin alone
3050420|NCT02224222||Patients undergoing vascular procedures|Including all non-interventional surgical procedures, excluding varix surgery
3050421|NCT02224222||Patients undergoing cardiac procedures|Including all non-interventional surgical procedures, excluding HTX
3050422|NCT02224209|Experimental|Staged angioplasty|"Using Abbott EPD systems (Accunet/Emboshield), a balloon, stent~Method of stage-1 angioplasty~The stent can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield) if distal filter cannot be used, balloon angioplasty can be performed under proximal protection device; Use a balloon with diameter of 2mm × 2cm for stage-1 dilation until angiography shows residual stenosis <70%.~Method of stage-2:~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield); Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation; After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
3050423|NCT02224209|Active Comparator|Routine single-stage CAS|"Using a balloon, stent~Routine stenting procedure:~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield); Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation; After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
3050424|NCT02224196|Experimental|manual ventilation|
3050425|NCT02224196|Active Comparator|pressure-controlled ventilation|
3050426|NCT02224183|Active Comparator|Education|Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.
3050427|NCT02224183|Active Comparator|Yoga|Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
3050428|NCT02224170|Experimental|Lidocaine group|
3050429|NCT02224170|Active Comparator|Dexamethasone group|
3050430|NCT02224157|Experimental|Symbicort 'as needed'+placebo Pulmicort bid|Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
3050431|NCT02224157|Active Comparator|Pulmicort bid + terbutaline 'as needed'|Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
3050432|NCT02224144|Experimental|Vitamin D3 plus Calcitriol|"1 pill of Vitamin D3 (cholecalciferol) 1000 IU daily for 12 months~1 pill of Rocaltrol (calcitriol) 0.5 mcg daily for 12 months"
3050433|NCT02224144|Placebo Comparator|Vitamin D3 plus Placebo|"1 pill of Vitamin D3 (cholecalciferol) 1000 IU per day for 12 months~1 pill of placebo (sugar pill) per day for 12 months"
3050434|NCT02224131|Experimental|Monitoring Arm|dose adjustment of both aspirin and clopidogrel in suboptimal responders identified based on a point of care assay(TEG)
3050435|NCT02224131|Active Comparator|Conventional Arm|fixed dose regiment of both aspirin and clopidogrel in all patients following stent deployment according to international guidelines
3050436|NCT02224118|Experimental|CNTO 3649 10 mcg/kg (single dose)|A single dose of 10 microgram per kilogram (mcg/kg) of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
3050437|NCT02224118|Experimental|CNT0 3649 30 mcg/kg (single dose)|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
3050438|NCT02224118|Experimental|CNTO 3649 100 mcg/kg (single dose)|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
3050439|NCT02224118|Experimental|CNTO 3649 300 mcg/kg (single dose)|A single dose of 300 microgram per kilogram (mcg/kg) of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
3050440|NCT02224118|Experimental|CNT0 3649 30 mcg/kg (multiple dose)|Participants with type 2 diabetes mellitus will be administered 30 mcg/kg CNTO 3649 as subcutaneous injection once a week for 4 weeks.
3050441|NCT02224118|Experimental|CNTO 3649 100 mcg/kg (multiple dose)|Participants with type 2 diabetes mellitus will be administered 100 mcg/kg CNTO 3649 as subcutaneous injection once a week for 4 weeks.
3050442|NCT02224118|Placebo Comparator|Placebo|Matching placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
3050443|NCT02224105|Experimental|BI 653048 BS|escalating doses
3050444|NCT02224105|Active Comparator|Prednisolone low|
3050445|NCT02224105|Active Comparator|Prednisolone high|
3050446|NCT02224105|Placebo Comparator|Placebo|
3050447|NCT02224092|Active Comparator|Active|Active is a multivitamin multimineral with phytonutrient product.
3050448|NCT02224092|Placebo Comparator|Placebo|Placebo is a sugar pill.
3050449|NCT02224079|Experimental|BIIB 722 CL|
3050450|NCT02224079|Placebo Comparator|Placebo|
3050451|NCT02224066|Experimental|Ticagrelor|Patients with high-on-treatment platelet reactivity (PRU ≥ 208)
3050452|NCT02224066|Active Comparator|Aspirin/Clopidogrel|Patients with high-on-treatment platelet reactivity (PRU ≥ 208)
3050453|NCT02224066|No Intervention|Registry arm|Patients with normal-on-treatment platelet reactivity (PRU < 208) will continue with Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI.
3050454|NCT02224053|Experimental|AZD9291 and omeprazole|Sequential treatments of AZD9291 + omeprazole followed by AZD9291 alone, with a washout period in between.
3050455|NCT02224040|Experimental|Ceftriaxone I.V|The participants in this arm will receive the following drug and dosage: adult: Ceftriaxone intravenous 2 gr once a day. Pediatric: intravenous 75 mg/kg ceftriaxone once a day (maximum dose 2.5 g/day). Patients will receive antibiotic treatment until defervescence and for 3 days afterwards. Patients will be hospitalized during the entire treatment course (including the afebrile period).
3050456|NCT02224040|Experimental|Ceftriaxone I.V+Azithromycin P.O|The participants in this arm will receive the following drugs and dosages: adult: 2 g intravenous ceftriaxone and 500 mg oral azithromycin once a day. Pediatric: intravenous 75 mg/kg ceftriaxone once a day and oral 20 mg/kg azithromycin suspension once a day. Patients will receive antibiotic treatment until defervescence and for 3 days afterwards. Patients will be hospitalized during the entire treatment course (including the afebrile period).
3050457|NCT02224040|Experimental|Azithromycin P.O|The participants in this arm will receive the following drug and dosage: adult: azithromycin oral 500 mg once a day. Pediatric: oral 20 mg/kg azithromycin suspension once a day (maximum dose 1000 mg/day). Patients will receive antibiotic treatment until defervescence and for 3 days afterwards.
3050458|NCT02224040|Experimental|Azithromycin P.O+Cefixime P.O|The participants in this arm will receive the following drugs and dosages: adult: 500 mg azithromycin and 400 mg cefixime. Pediatric: oral 20 mg/kg azithromycin suspension once a day and oral 10 mg/kg cefixime. Patients will receive antibiotic treatment until defervescence and for 3 days afterwards.
3050459|NCT02224027|Active Comparator|i-gel|Each novice performs i-gel insertion in difficult laryngoscopy scenario.
3050460|NCT02224027|Active Comparator|proceal laryngeal mask airway|Each novice performs proceal laryngeal mask airway insertion in difficult laryngoscopy scenario.
3050461|NCT02224027|Active Comparator|tracheal tube|Each novice performs tracheal intubation in difficult laryngoscopy scenario.
3050462|NCT02224014||Lendormin D tablets|
3050463|NCT02224001|Experimental|Asian rhinoplasty, septal cartilage|"A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts~The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result."
3050464|NCT02223988|Experimental|subglottic secretion drainage|
3050465|NCT02223975||Vulval Disease|Patients who have undergone vulval skin biopsy or surgery for a vulval condition within Gloucestershire Hospitals NHS Foundation Trust.
3050466|NCT02223962|Experimental|Physical activity|The fitbit Ultra was used to provide real-time feedback on physical activity. An experienced physiotherapist contacted the subjects 3 times a week to receive information about the amount of steps from the previous days. In agreement with the patient, a new goal for the coming weeks was set and patients were motivated to achieve their individual goal.
3050467|NCT02223962|Placebo Comparator|Usual Care|During the hospital stay, the patients in the control group will be informed about the beneficial effects of being physically inactive.They will not receive feedback about their activities performed and will not be stimulated to become more active.
3050468|NCT02223949|Experimental|Cook double balloon catheter|Insertion of the Cook double balloon catheter to the cervix until both balloons are properly located in the cervical canal. After properly located it is inflated with 20 ml of saline. Then both balloons are additionally inflated to a total of 80 ml each balloon. Twelve hours later the balloons are deflated and the device is removed.
3050469|NCT02223949|Active Comparator|PGE1 tablet insertion|Insertion of 25 mg PGE1 (Prostaglandin E1) tablet is inserted in the posterior fornix. The patient woll the be instructed to stay in bed for the next 60 minutes. After six hours a repeated dose will be administered. Total of 4 PGE1 doses within 24 hours.
3050470|NCT02223936|Other|children with Prenatal enlarged nuchal transluce|
3050471|NCT02223936|Other|Control|
3050472|NCT02223923|Experimental|Dose Escalation|AZD6738 PO 20 to 380mg BD increasing
3050473|NCT02223923|Experimental|AZD6738 - Expansion Phase|AZD6738 starting dose and regimen to be determined in dose escalation phase
3050474|NCT02223923|Experimental|AZD6738 + Radiotherapy (Head and Neck)|AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)
3050475|NCT02223923|Experimental|AZD6738 + Radiotherapy (Abdomen / Pelvis)|AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)
3050476|NCT02223910|Active Comparator|Motor Cortex|Feedback training of functional connectivity between motor cortex and the rest of the brain
3050477|NCT02223910|Placebo Comparator|Control region|Feedback training of functional connectivity between medial prefrontal cortex of healthy hemisphere and the rest of the brain
3050478|NCT02223897|Experimental|Conventional treatment, huc-MSCs|Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
3050479|NCT02223897|Placebo Comparator|Conventional plus placebo|Received conventional treatment and 50 ml saline once per week for the first month and once per month for 6 months(9 times in total).
3050480|NCT02223884|Experimental|weekly docetaxel and carboplatin|
3050481|NCT02223871|Experimental|ACT-451840 500 mg|All the participants were infected with Plasmodium falciparum parasites (malaria) using malaria-infected human erythrocytes. When the parasitemia reached 1000 counts/mL, all the participants received 500 mg of ACT-451840 as a single oral dose. Compulsory commencement of treatment with Riamet® (artemether-lumefantrine) to ensure complete clearance of any gametocytes, occurred 16 days after ACT-451840 administration (or earlier if required) for all participants. Primaquine was to be administered as a single dose only in participants for whom gametocytes were still identified after administration of Riamet® rescue medication
3050668|NCT02222662|Experimental|Parent massage tx group|Children in this group receive the parent-delivered massage intervention right after randomization.
3050791|NCT02221973|Experimental|milk with 1.8g/d sterols and 8g/d hawthorn powder|
3050482|NCT02223858|Experimental|Positive Activities (PA)|Patients in the PA arm will be asked to complete a 6-week program consisting of 6 at-home activities (1 completed per week) that have been shown to increase positivity. PA activities will be delivered using a combination of activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist will orient participants to the booklets and review the first activity at the end of an in-person baseline visit. The booklet contains all instructions patients need to complete the full program. However, the interventionist will conduct weekly telephone calls to provide additional support patients may need. During these calls, the interventionist will assess whether participants completed the previous week's activity, review instructions for the next week's activity, and help participants trouble-shoot anticipated barriers to completing the next activity.
3050483|NCT02223858|Active Comparator|Attention Control (AC)|Patients in the AC arm will be asked to complete a 6-week program consisting of at-home activities (1 completed per week) that are based on affectively neutral activities from control conditions in prior studies of PA interventions. Activities will be delivered using a combination of activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist will orient participants to the booklets and review the first activity at the end of an in-person baseline visit. The booklet contains all instructions patients need to complete the full program. However, the interventionist will conduct weekly telephone calls to provide additional support patients may need. During these calls, the interventionist will assess whether participants completed the previous week's activity, review instructions for the next week's activity, and help participants trouble-shoot anticipated barriers to completing the next activity.
3050484|NCT02223845|Experimental|Music|Played music during embryo transfer
3050485|NCT02223845|No Intervention|Control|No music played during embryo transfer
3050486|NCT02223832|Experimental|ACT-128800|"A single oral dose of 40 mg ACT-128800 will be administered as~1 capsule given in the fasted state in the morning"
3050487|NCT02223819|Experimental|Crizotinib|Subjects will receive 48 weeks (12 four-week cycles) of crizotinib 250 mg PO twice a day (BID). Subjects will be evaluated by routine bloodwork and physical exam every 4 weeks while they are receiving crizotinib and during follow up period.
3050488|NCT02223806|Active Comparator|Self-assessment of uterine tonus|Uterine tonus assessment every 15 minutes for 2 hours by educated patient, which is standard-of-care.
3050489|NCT02223806|Experimental|Midwife uterine tonus assessment|Uterine tonus assessment every 15 minutes for 2 hours by midwive.
3050490|NCT02223793|Experimental|No information on high risk factor levels but lifestyle advice|This arm of high risk participants will not be informed about their measured levels of the different cardiovascular risk factors at baseline. However, they will receive general information on how to lower risk factor levels in 8 weeks
3050491|NCT02223793|Experimental|No information on high risk factor levels nor lifestyle advice|In this arm, participants will not be informed about their measured levels of the different cardiovascular risk factors, nor receiving lifestyle advices at baseline
3050492|NCT02223793|Experimental|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will not be informed about their measured levels of the different cardiovascular risk factors at baseline, and receive general information on how to lower risk factor levels in 8 weeks
3050493|NCT02223780|Placebo Comparator|control|standard management
3050494|NCT02223780|Active Comparator|early palliative care|early palliative care
3050495|NCT02223767|Experimental|Verum TMS|10 Hz TMS over medial prefrontal cortex
3050496|NCT02223767|Experimental|Sham TMS|10 Hz sham TMS over medial prefrontal cortex
3050497|NCT02223754|Active Comparator|lotrafilcon B / etafilcon A|Subject randomized to this sequence will first be dispensed the lotrafilcon B contact lens and then the etafilcon A contact lens.
3050498|NCT02223754|Experimental|etafilcon A / lotrafilcon B|Subject randomized to this sequence will first be dispensed the etafilcon A contact lens and then the lotrafilcon B contact lens.
3050499|NCT02223741||Korean medicine conjugate rehabilitation|those with more than 30 days of herbal drugs or more than 12 times of acupuncture (Korean medical treatment) within six months in addition to conventional rehabilitation
3050500|NCT02223741||Conventional rehabilitation|those with one of the treatments; physical, occupational, speech-language or cognitive-behavioral therapies
3050501|NCT02223728|Experimental|Treatment Condition|Telehealth Lifestyle Program
3050502|NCT02223728|Sham Comparator|Attention Control Condition|Health Education Program
3050503|NCT02223715||CDI|
3050504|NCT02223702|Active Comparator|amoxicillin+metronidazole|amoxicillin+metronidazole group received a combination of 500 mg of amoxicillin and 500 mg metronidazole three times per day for 7 days.
3050505|NCT02223702|Experimental|moxifloxacin|The moxifloxacin group received 400 mg moxifloxacin, once in a day for 7 days.
3050506|NCT02223689||Skin Affix|Surgical adhesive
3050507|NCT02223676|Experimental|Intervention|Clinical pharmacists conduct medication history
3050508|NCT02223676|No Intervention|Control|standard procedures for admission is followed
3050509|NCT02223650|Experimental|Overminus Treatment|2.50D overminus spectacles
3050510|NCT02223650|Active Comparator|Non-overminus Treatment|spectacles without overminus or no spectacles
3050511|NCT02223637||Exposure group|Pregnant women exposed to Novartis Meningococcal quadrivalent CRM-197 conjugate vaccine
3050512|NCT02223624|Experimental|eccentric aerobic exercise group|Eccentric aerobic exercise group: Participants in this group will participate in an eccentric aerobic exercise rehabilitation program for a total of eight weeks, two sessions per week. Outcome measurements will be taken post exercise program and also after a 3 month follow-up period. Each session will be approximately 60 minutes in duration and include approximately 10 minutes of warm up (stretches), eccentric stepper aiming for 20 minutes, walking and light weights, followed by a five minute cool-down period.
3050546|NCT02223377|Active Comparator|Morphine|"Analgesia with equipotent doses of Morphine and Hydromorphone will be administered in titrated doses. Doses are 1ml=1mg of morphine or 0.2 mg of hydromorphone. Potency ratio of 1:5 (M: HM).~0.05mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml)"
3050547|NCT02223377|Active Comparator|Hydromorphone|"Analgesia with equipotent doses of Morphine and Hydromorphone will be administered in titrated doses. Doses are 1ml=1mg of morphine or 0.2 mg of hydromorphone. Potency ratio of 1:5 (M: HM).~0.05mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml)"
3050513|NCT02223624|Active Comparator|Concentric aerobic exercise group|"Concentric aerobic exercise group (usual care): The length of the concentric aerobic exercise based rehabilitation program will be the same as the study group- twice weekly exercise sessions for 8 weeks. Outcome measurements will also be taken after a 3-month follow-up period.~Participants in the concentric aerobic exercise group will participate in the same warm-up and cool down period as the eccentric group. They will also complete walking and light weights. To replace the 20 minutes of eccentric exercise, concentric participants will complete approximately 20 minutes of exercise bike, stair climbing and rowing as able with required rests."
3050514|NCT02223624|No Intervention|Waiting list control|Waiting list (no exercise): Participants assigned to this group will not receive any intervention during the study period. They will be assessed like other participants at baseline and after eight weeks, but not at three-month follow-up due to ethical concerns around withholding care known to be effective. Given that there is a waiting list for the current exercise program of 4-12 weeks, it is felt that delaying care for a set period of eight weeks is not of ethical concern. Following the completion of assessments, waiting list participants will be able to complete the traditional exercise program as usual but not as participants of the study's experimental groups.
3050515|NCT02223611|Experimental|S1 capsule plus Cisplatin|"S1: 40mg, bid, when body surface area (BSA)＜1.25 m2, 50mg; bid when 1.25 m2≤BSA＜1.5 m2; 60mg, bid when 1.5 m2≤BSA 60mg from day 1 to 14. Cisplatin: 75 mg/m2 on day 1.~3 weeks/4cycles"
3050516|NCT02223611|Active Comparator|Vinorelbine plus Cisplatin|"Vinorelbine: 25 mg/m2 intravenously on day 1, and day 8. Cisplatin: 75 mg/m2 intravenously on day 1.~3 weeks/4cycles"
3050517|NCT02223598|Experimental|Dose Escalation - CB-5083|CB-5083 will be administered orally, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with lymphoid hematological malignancies
3050518|NCT02223598|Experimental|Dose Expansion - CB-5083, Dexamethasone|CB-5083 will be administered orally, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with relapsed and refractory multiple myeloma; in addition, subjects who develop progressive disease at the end of Cycle 1, or beyond, may receive their current dose of CB-5083 in combination with oral or IV low dose Dexamethasone (40 mg)
3050519|NCT02223598|Experimental|Dose Expansion - CB-5083|CB-5083 will be administered orally, daily, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with diffuse large B-cell lymphoma (DLBCL) or Waldenstrom Macroglobulinemia, if such arm is opened, per Sponsor
3050520|NCT02223585|Experimental|Cross-over single arm|
3050521|NCT02223572|Experimental|osteoporotic hip fracture|
3050522|NCT02223559||right heart catheterization patients|
3050523|NCT02223546||healthy subject|healthy subject, every 3 hour measurement
3050524|NCT02223533|Experimental|Wound catheter|analgesia with wound catheter after colon surgery
3050525|NCT02223533|Active Comparator|morphine|analgesia with morphine after colon surgery
3050526|NCT02223520|Active Comparator|Mupirocin and Chlorhexidine|Participants will apply 2% intranasal mupirocin twice a day for five days and cleanse with 2% chlorhexidine cloths once a day for five days.
3050527|NCT02223520|Placebo Comparator|Placebo ointment and placebo cloths|Participants will apply 2% petrolatum intranasal placebo ointment twice a day for five days and cleanse with 2% non-medicated soap placebo cloths once a day for five days.
3050528|NCT02223507|Experimental|BIIR 561 CL|
3050529|NCT02223507|Placebo Comparator|Placebo|
3050530|NCT02223494|Experimental|Terbogrel|
3050531|NCT02223481|Experimental|Terbogrel low dose|
3050532|NCT02223481|Experimental|Terbogrel high dose|
3050533|NCT02223481|Placebo Comparator|Placebo|
3050534|NCT02223468||CASE-CONTROL|CASE: Liver transplant recipients (n=20) CONTROL: A healthy person with a similar age (±10 years) to the control selected from the same family setting (n=20)
3050535|NCT02223455|Placebo Comparator|Single Hand Hygiene Sign|Wards/units in this arm of the study will have the same hand hygiene sign posted by the hand sanitizer dispensers outside each patient room. The sign will not change.
3050536|NCT02223455|Active Comparator|Hand Hygiene Signs Changed Monthly|Hand hygiene signs will be changed monthly on wards/units randomized to this arm of the study. Signs will be posted by the hand hygiene sanitizer outside each patient room.
3050537|NCT02223455|Active Comparator|Hand Hygiene Signs Changed Weekly|Hand hygiene signs will be changed weekly on wards/units randomized to this arm of the study. Signs will be posted by the hand hygiene sanitizer outside each patient room.
3050538|NCT02223429|Experimental|OT + placebo|The OT + placebo group will self-administer no more than 1 ml solution of oxytocin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive OT first, and half will receive OT second.
3050539|NCT02223429|Experimental|AVP + placebo|The AVP + placebo group will self-administer no more than 1 ml solution of vasopressin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive AVP first, and half will receive AVP second.
3050540|NCT02223416|Experimental|RGB-10|
3050541|NCT02223416|Active Comparator|Forsteo|
3050542|NCT02223403|Experimental|submaximal steady state exercise|90 minutes after respective beetroot juice ingestion, subjects walked on treadmill at a pre-determined steady state workload for a total of 15 minutes with oxygen consumption recorded for the last 10 minutes
3050543|NCT02223403|Experimental|six minute walk test|subjects performed six-minute walk at self-determined pace 30 minutes after treadmill exercise was performed
3050544|NCT02223390|Experimental|Mental health treatment|The experimental condition, ImpACT, was developed in the pilot phase of the study. The intervention will be 4 sessions of individual psychological treatment related to stress, coping, and HIV adherence, followed by three group sessions. Sessions will follow an intervention manual and be delivered by a psychiatric nurse (or equivalent nonspecialist in mental health) who is supervised by a trained clinical psychologist.
3050545|NCT02223390|No Intervention|Standard of Care|Participants in standard of care will receive the three-session adherence counseling delivered in the clinic, along with referrals for trauma treatment.
3050548|NCT02223364|Active Comparator|Peripheral Nerve Block (PNB)|This group received a continuous femoral nerve block and a single injection sciatic nerve block consisting of the following: Peripheral nerve blocks with Bupivacaine.
3050549|NCT02223364|Active Comparator|Ropivacaine (PAI-R)|This group received intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
3050550|NCT02223364|Active Comparator|Liposomal Bupivacaine (PAI-L)|This group received Intra articular injection with liposomal bupivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
3050551|NCT02223351|Other|400mg ASP2151|400mg ASP2151 alone followed by 400mg ASP2151 + 600mg ritonovir
3050552|NCT02223351|Other|1200mg ASP2151|1200mg ASP2151 alone followed by 1200mg ASP2151 + 600mg ritonovir
3050553|NCT02223338|Active Comparator|Ciprofloxacin|"Ciprofloxacin:~Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These patients must have been instructed to use post-injection topical ciprofloxacin 0.3% 4x daily for 3 days. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops."
3050554|NCT02223338|Active Comparator|Standard Aseptic Technique|"Standard Aseptic Technique:~Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These injections must have been given with povidone-iodine only applied to the injection site and conjunctival fornix prior to injection, but no post-injection antibiotics were given. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops."
3050555|NCT02223325||Elderly, acute pancreatitis|No intervention
3050556|NCT02223325||Adults <65 y, acute pancreatitis|No intervention
3050557|NCT02223312|Experimental|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
3050558|NCT02223299|Experimental|Deplin w Supplements|deplin 15mg plus L-Tyrosine 6g/d and L-Tryptophan 2g/d for 30 days
3050559|NCT02223299|Placebo Comparator|Deplin w placebo|deplin 15mg daily plus Placebo A and Placebo B for 30 days
3050560|NCT02223286||ASGES (Treatment Group)|Patients who received a Corus CAD or Age/Sex/Gene Expression Score (ASGES) to aid in the diagnosis of obstructive CAD
3050561|NCT02223286||Non-ASGES (Control Group)|Patients who underwent usual care testing and did not receive a Corus CAD or Age/SEX/Gene Expression Score (ASGES) to aid in the diagnosis of obstructive CAD
3050562|NCT02223273|Experimental|Multifaceted Strategy|"Multifaceted Intervention~Simulation Based Team Training~Case Manager~Check lists~Reminders~Educational Materials"
3050563|NCT02223273|No Intervention|Usual Care|Hospital Standard Treatment
3050564|NCT02223260|Experimental|dabigatran|open label arm with dabigatran oral liquid formulation as single dose
3050565|NCT02223247|Experimental|TVB-2640|Oral TVB-2640 capsules or tablets of various dose strengths administered QD for 21 - 28 day dosing cycles, alone or in combination with certain standard chemotherapy agents
3050566|NCT02223234|Active Comparator|Control|Control- monthly mailed information on children's health
3050567|NCT02223234|Experimental|Email and 4 Home Visits|Weekly emails and 4 home visits with a health educator
3050568|NCT02223234|Experimental|Email and 2 Home Visits|Weekly emails and 2 home visits
3050569|NCT02223221|Experimental|With PGS|"IVF/ICSI cycles with PGS. Select embryos by SNP-array based PGS for the number of all chromosomes on day 5, only euploid embryos will be transferred.~A maximum of 2 embryos will be transferred for each treatment cycle. Up to 3 treatment cycles will be offered."
3050570|NCT02223221|Active Comparator|Without PGS|"IVF/ICSI cycles without PGS. Selection of embryos are based on blastocyst morphology criteria on day 5.~A maximum of 2 embryos will be transferred for each treatment cycle. Up to 3 treatment cycles will be offered."
3050571|NCT02223208|Experimental|Ro-CHOEP-21|During the Phase I It will administered Romidepsin (dose escalation) and the combination of CHOEP-21. During the Phase II It will administered Romidepsin (dose according to phase I) and the combination of CHOEP-21.
3050572|NCT02223182|Experimental|Viaskin Milk 150 mcg|
3050573|NCT02223182|Experimental|Viaskin Milk 300 mcg|
3050574|NCT02223182|Experimental|Viaskin Milk 500 mcg|
3050575|NCT02223182|Placebo Comparator|Viaskin Placebo|
3050576|NCT02223169|Experimental|Egg albumin-derived peptide|Each participant will consume 1 sachet of Egg albumin-derived peptide (3 g) each day mixed with a fruit juice drink for 42 days.
3050577|NCT02223169|Placebo Comparator|Placebo|Participants will consume one sachet of the placebo mixed with a fruit juice drink that will appear and taste similar to the albumin derived peptide sachet.
3050578|NCT02223156||MediYoga|
3050579|NCT02223156||Music relaxation|
3050580|NCT02223156||No treatment|
3050624|NCT02222922|Experimental|PF-06647020 Q2W|Investigational drug infused over 60 minutes once every 14 days (28 day cycle)
3050625|NCT02222922|Experimental|PF-06647020 combined with Avelumab|PF-06647020 combined with Avelumab administered by infusion
3050669|NCT02222662|Experimental|Parent massage wait-list control group|Children in this group receive the parent-delivered massage intervention 5 months after randomization.
3050581|NCT02223130|Experimental|Intervention Group|Participants will attend the baseline, first follow-up, and final follow-up study visits, at which they take computer surveys. After their baseline interview and before their first follow-up interview, participants attend the Intervention Group, which consist of 9 weekly group sessions. Each of the weekly sessions is led by a mental health professional and a peer facilitator who uses Cognitive Behavioral Therapy techniques to work with participants in tracking their cognitions, emotions, and behaviors in response to stressful/discrimination experiences.
3050582|NCT02223130|No Intervention|Waitlist Control|"Participants are not given the Intervention Group while they are enrolled in the study. Instead, they only attend the baseline, first follow-up, and final follow-up study visits, at which they take computer surveys.~After they have completed the study, participants from the first two cohorts are offered the option of attending an intervention group that is identical in content to the intervention group being studied.The third cohort is offered the intervention group after they have completed the first follow-up but before they complete the final follow-up due to timing and budgetary restraints. No data is collected and no incentives are given during these intervention groups."
3050583|NCT02223117|Experimental|Intervention|Thrombosomes
3050584|NCT02223117|Placebo Comparator|Placebo|Buffer/placebo Control
3050585|NCT02223104|Active Comparator|Sensura|Ostomy pouch
3050586|NCT02223104|Experimental|Flexima Active|Ostomy pouch
3050587|NCT02223091|Experimental|Consultation by a trained physician|The physicians of this group receive a free consultation training program on skills regarding consultations on complementary medicine for breast-cancer patients. The training was developed by a multi-professional team and is comprised of three parts: (1) online-training, (2) on-site-training, and (3) consultation manual. Each of the physicians will counsel 10 patients. The patients in this group therefore receive a consultation by a trained physician.
3050588|NCT02223091|Active Comparator|Consultation by an untrained physician|The physicians of the control arm receive no training. Each will counsel 10 patients. The patients in this group therefore receive a consultation by an untrained physician.
3050589|NCT02223078|Experimental|G17DT|Three 250 µg injections over a six week period (weeks 0,2 and 6)
3050590|NCT02223078|Placebo Comparator|Placebo|Three 250 µg injections of a placebo over a six week period (weeks 0,2 and 6)
3050591|NCT02223065|Experimental|Treatment A|Single oral dose of saxagliptin tablet coadministered with dapagliflozin tablet
3050592|NCT02223065|Experimental|Treatment B|Single oral dose of FDC (fixed-dose combination) tablet
3050593|NCT02223052|Experimental|CC-486 Arm 1 (Oral Azacitidine) Dosing Sequence 1|Two 150-mg tablets of CC-486 under fasting condition on PK dosing Day 1, followed by one 300-mg tablet of CC-486 on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
3050594|NCT02223052|Experimental|CC-486 Arm 2 (Oral Azacitidine) Dosing Sequence 1|One 300-mg tablet of oral CC-486 under fasting condition on PK dosing Day 1, followed by one 300-mg tablet of oral CC-486 under fed condition on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
3050595|NCT02223052|Experimental|CC-486 Arm 1 (Oral Azacitidine) Dosing Sequence 2|One 300-mg tablets of CC-486 under fasting condition on PK dosing Day 1, followed by two 150-mg tablets on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
3050596|NCT02223052|Experimental|CC-486 Arm 2 (Oral Azacitidine) Dosing Sequence 2|One 300-mg tablet of oral CC-486 under fed condition on PK dosing Day 1, followed by one tablet of 300-mg oral CC-486 under fasted conditions on PK dosing Day 2; if PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine of Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
3050597|NCT02223039|Experimental|AbGn-168H Low Dose|Subject to receive low dose of AbGn-168H intravenously
3050598|NCT02223039|Experimental|AbGn-168H High Dose|Subject to receive high dose of AbGn-168H intravenously
3050599|NCT02223039|Placebo Comparator|Placebo|Subject to receive placebo intravenously
3050600|NCT02223026|Experimental|Linagliptin/metformin fed|
3050601|NCT02223026|Active Comparator|Linagliptin/metformin fasted|
3050602|NCT02223013|Active Comparator|BIBV 308 SE solution|
3050603|NCT02223013|Experimental|BIBV 308 SE capsule L|
3050604|NCT02223013|Experimental|BIBV 308 SE capsule S|
3050605|NCT02223000|Active Comparator|BIBV 308 SE solution|
3050606|NCT02223000|Experimental|BIBV 308 SE capsule 1|
3050607|NCT02223000|Experimental|BIBV 308 SE capsule 2|
3050608|NCT02222987|Active Comparator|Terbogrel|
3050609|NCT02222987|Experimental|Terbogrel with Clopidogrel|
3050610|NCT02222987|Active Comparator|Clopidogrel|
3050611|NCT02222974|Experimental|BIIR 561 CL|
3050612|NCT02222974|Placebo Comparator|Placebo|
3050613|NCT02222961|Experimental|BIIR 561 CL|
3050614|NCT02222961|Placebo Comparator|Placebo|
3050615|NCT02222948|Experimental|Vatelizumab Dose 1|Vatelizumab dose 1 at Weeks 0, 2, 4 and 8
3050616|NCT02222948|Experimental|Vatelizumab Dose 2|Vatelizumab dose 2 at Weeks 0, 2, 4 and 8
3050617|NCT02222948|Experimental|Vatelizumab Dose 3|Vatelizumab dose 3 at Weeks 0, 2, 4 and 8
3050618|NCT02222948|Experimental|Vatelizumab Dose 4|Vatelizumab dose 4 at Weeks 0, 2, 4 and 8
3050619|NCT02222948|Placebo Comparator|Placebo|Placebo (for Vatelizumab) at Weeks 0, 2, 4 and 8
3050620|NCT02222935|Experimental|Balance exercise training|Balance exercise training - thrice week, 2 weeks, 10 repetition Maximum/ set, 2 sets
3050621|NCT02222935|Active Comparator|Routine Back exercise Program|Routine Back exercise Program - 10 Repetition Maximum / set, 2 sets, three times weekly, 2 weeks
3050622|NCT02222922|Experimental|PF-06647020 Q3W|Investigational drug infused over 60 minutes once every 21 days.
3050623|NCT02222922|Experimental|Drug-drug interaction (DDI)|PF-06647020 combined with fluconazole
3050626|NCT02222909|Experimental|Intervention CBOs|"Will receive co-developed IT intervention developed together with intervention group community based members. Set of primarily web based tools to improve connection with clients, Johns Hopkins Medicine and one another, referrals, and volunteer services."
3050627|NCT02222909|No Intervention|Control CBOs|Community Based Organizations that are being followed for data collection only for the period of one year
3050628|NCT02222896|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
3050629|NCT02222896|Placebo Comparator|Vehicle Cloth|Excipients on cloth
3050630|NCT02222896|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
3050631|NCT02222883||patients with primary diagnosis|patients with primary diagnosis of ovarian cancer for testing of BRCA status regarding germline and somatic mutation
3050632|NCT02222883||patients with platinum-sensitive recurrence|patients with platinum-sensitive recurrence of ovarian cancer for testing of BRCA status regarding germline and somatic mutation
3050633|NCT02222870|Experimental|Fluzone Study Group 1|Participants at 6 months to < 36 months age at enrollment
3050634|NCT02222870|Experimental|Fluzone Study Group 2|Participants at 3 years to < 9 years of age at enrollment
3050635|NCT02222844|No Intervention|Preoperative CT scan|CT-imaging of chest and abdomen / pelvis before surgery (standard treatment)
3050636|NCT02222844|Experimental|Preoperative MRI scan|Standard treatment plus an additional MRI scan before surgery
3050637|NCT02222844|No Intervention|Observational|Observational only
3050638|NCT02222831|Experimental|Day 0 - Study arm|"Day 0 denudation and time lapse culture on IVF-oocytes.:~After insemination the oocytes will subsequently be denuded and cultured in the EmbryoScope (day 0).~The embryo culture media will be collected at day 2-5."
3050639|NCT02222831|No Intervention|Day 1 - control arm|"After insemination oocytes in the control group will be incubated in a standard incubator overnight. On day 1 the oocytes in the will be denuded and further cultured in the EmbryoScope.~The embryo culture media will be collected at day 2-5."
3050640|NCT02222818|Other|Group A: CAFR first|Subjects randomized to Group A will receive CAFR first, then cross over to CAFRPlus.
3050641|NCT02222818|Other|Group B: CAFRPlus first|Subjects randomized to Group B will receive CAFRPlus first, then cross over to CAFR.
3050642|NCT02222805|Other|Early cord clamping (ECC)|Early (≤30 seconds) cord clamping of the umbilical cord after delivery.
3050643|NCT02222805|Other|Delayed cord clamping (DCC)|Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery.
3050644|NCT02222792||Septic patient group|The septic patient group will be comprised of patients presenting with bone and joint prosthetic device infection confirmed by intraoperative microbiological culture (at least 2 deep positive samples for the same bacterial strain).
3050645|NCT02222792||Non-septic patient group|The non-septic patient group will be comprised of prosthetic patients presenting with symptoms of mechanical loosening, and whose deep intraoperative samples have all proved negative
3050646|NCT02222792||Intermediate group|An intermediate group will be comprised of patients with only one deep positive sample.
3050647|NCT02222779||Patients with Parkinson´s Disease|
3050648|NCT02222779||Patient´s with Alzheimer´s Disease|
3050649|NCT02222779||Patients with Multiple Sclerosis|
3050650|NCT02222779||Patients with any other neurodegenerative diseases|
3050651|NCT02222766|Experimental|Parents and Tots Together Program|9-week group-based parenting program
3050652|NCT02222766|Active Comparator|Control|Minimal attention control- weekly mailed information on general child development for 9 weeks
3050653|NCT02222740|Experimental|Group 1|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER) Twice per day (BID) for 7 days, followed by 20 mg BID for 7 days, followed by 30 mg BID for 7 days
3050654|NCT02222740|Experimental|Group 2|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER) Twice Per Day (BID) for 7 days, followed by 30 mg BID for 7 days, followed by 40 mg BID for 7 days
3050655|NCT02222727|Active Comparator|Donepezil|Participants in the donepezil arm will receive the drug for 21 days as specified in the protocol in addition to current best medical treatment for aSAH patients.
3050656|NCT02222727|No Intervention|Control|Control group participants will not receive a placebo drug but will undergo cerebral blood flow imaging in the same manner as the donepezil patients. All other aspects of treatment will be identical to that of aSAH patients not involved in the study.
3050657|NCT02222714|Active Comparator|120 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
3050658|NCT02222714|Active Comparator|240 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
3050659|NCT02222714|Active Comparator|360 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
3050660|NCT02222714|Active Comparator|540 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
3050661|NCT02222714|Placebo Comparator|Placebo|Matching placebo, q12h for up to 5 doses
3050662|NCT02222701||Replacement|Composite resins with Alpha values for the marginal adaptation criteria were used as the positive control and were made with resin composite (Filtek Supreme, 3M ESPE), eith rubber dam isolation and the adhesive system L-Pop Prompt (3M-ESPE)
3050663|NCT02222701||No treatment|Composite resin restorations (Z100, 3M ESPE) in general clinically acceptable, did not receive treatment.
3050664|NCT02222701||Refurbishing|For this group, The dentists finished the occlusal, lingual or facial surfaces of defective RBC restorations with the medium series of aluminum oxide disks (Sof-Lex,3M ESPE) or carbide burs (12 and 30 blades,Brasseler USA, Dental Instrumentation,Savannah, Ga.) and then polished them with afine series of aluminum oxide disks (Sof-Lex, 3M ESPE) and diamond-impregnated composite polisher (ComposiPro Diacomp, Brasseler). For restorations in which proximal surface areas were affected, the clinicians smoothed them with interproximal aluminum oxide finishing strips (Sof-Lex Finishing Strips, 3M ESPE).
3050665|NCT02222688|Experimental|cirmtuzumab|The starting dose is 15 µg/kg. There is intra-patient dose escalation in the first 3 cohorts, followed by the standard 3+3 design for the next 5 cohorts until a maximum tolerated dose (MTD) or biologically active dose is reached. If there is a grade ≥ 2 adverse event in the cohorts with intra-patient dose escalation, the trial will switch to the standard 3+3 design without intra-patient dose escalation for all cohorts.
3050666|NCT02222675|Experimental|Sonographically assisted breast surgery|Sonographically assisted breast surgery
3050667|NCT02222675|Active Comparator|Conventional breast surgery|Conventional breast surgery
3050672|NCT02222636|Placebo Comparator|Group 1,Normal saline,1 milliliter|Patients will be assigned to receive intranasal normal saline 1 milliliter
3050673|NCT02222636|Experimental|Group 2,dexmedetomidine 1μg.kg-1,1 milliliter|Patients will be assigned to receive intranasal dexmedetomidine( 1μg.kg-1) 1 milliliter
3050674|NCT02222636|Experimental|Group 3,dexmedetomidine 2μg.kg-1,1 milliliter|Patients will be assigned to receive intranasal dexmedetomidine( 2μg.kg-1 )1 milliliter
3050675|NCT02222623|Active Comparator|glargine insulin|Basal glargine given once daily in the morning before breakfast plus standard hospital corrective doses of insulin aspart before meals and at bedtime.
3050676|NCT02222623|Active Comparator|NPH insulin|Basal NPH given twice daily before breakfast and at bedtime plus standard hospital corrective doses of insulin aspart before meals and at bedtime.
3050677|NCT02222610|Experimental|Cohort A|"Subject's will receive monthly treatment of an intravitreal injection of 0.5 mg ranibizumab for 48 weeks.~Starting at week 52, subject's will enter a treat & extend regime, if a subject achieves a dry macula. For a macula to be considered dry persistent or recurrent fluid must be resolved on SD-OCT. The interval between injections will not exceed 12 weeks. After a subject is extended beyond 4-weeks & develops recurrent disease activity, the eye is treated & the treatment interval for the next visit is reduced by 1 week, compared to the previous treatment interval. The interval between treatments will be reduced by 1-week intervals until a dry macula is again established. Once a dry macula is again achieved, the interval between visits will be extended by 1-week intervals again."
3050678|NCT02222610|Experimental|Cohort B|"Subject's receive monthly treatment of IVT of 0.5 mg ranibizumab for 48 weeks. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia based on 120° or greater wide field angiography. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks & 24 weeks & will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.~Starting at week 52, subject's will enter a treat & extend regime as described in cohort A."
3050679|NCT02222610|Experimental|Cohort C|"Subject's will receive 3 consecutive monthly doses of IVT 0.5 mg ranibizumab followed by PRN treatment with 0.5 mg ranibizumab intravitreal injection. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks & 24 weeks & will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.~Starting at week 52, subject's will enter a treat & extend regime as described in cohort A."
3050680|NCT02222597||positive infrascanner finding|
3050681|NCT02222584||IBD group|patients with with inflammatory bowel disease who are visiting the out-patient clinic of severance hospital from July 2014 to February 2015
3050682|NCT02222571|Active Comparator|Control|9-week parenting group focused on safety
3050683|NCT02222571|Experimental|Parents and Tots Together Program|Parents and Tots Together Program is a 9-week, group-based parenting intervention
3050684|NCT02222558|Experimental|Period 1: Single Dose|Period 1: Each study subject will receive an escalating single dose of TSX-002 (60, 90, 120, 180, 240 mg), with a minimum 3 day wash-out between each of the 5 escalating doses. After completing the 240 mg dose, a 7 day wash-out period will occur prior to Period 2.
3050685|NCT02222558|Experimental|Period 2: Two Times Daily Dosing 90 mg|Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days.
3050686|NCT02222558|Experimental|Period 3: Two Times Daily Dosing 120 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted two times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
3050687|NCT02222558|Experimental|Period 3: Three Times Daily Dosing 90 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted three times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
3050688|NCT02222558|Experimental|Period 3: Two Times Daily Dosing 180 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted two times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
3050689|NCT02222558|Experimental|Period 3: Three Times Daily Dosing 120 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted three times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
3050690|NCT02222545|Experimental|OMS721 low dose|Administration of OMS721 at a low dose
3050691|NCT02222545|Experimental|OMS721 medium dose|Administration of OMS721 at a medium dose
3050692|NCT02222545|Experimental|OMS721 high dose|Administration of OMS721 at a high dose
3050693|NCT02222532|Experimental|Tetronine|Oral T3 (Tetronine) is given 1 mcg/kg every 6 hourly through naso-gastric tube since induction of anesthesia for 60 hours
3050694|NCT02222532|Placebo Comparator|Placebo|Placebo (saccharin lactic) is given every 6 hourly through naso-gastric tube since induction of anesthesia for 60 hours
3050695|NCT02222519||Statin use group|patients taking statins for at least 3 months
3050696|NCT02222519||non statin use|no history of taking statin
3050697|NCT02222506|Experimental|KLOX BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for diabetic foot ulcers.
3050698|NCT02222493|Experimental|PF-06438179|
3050699|NCT02222493|Active Comparator|Infliximab|
3050700|NCT02222480|Experimental|Fimasartan 60 mg, Hydrochlorothiazide 12.5 mg|Combination of Fimasartan/Hydrochlorothiazide 60/12.5mg
3050701|NCT02222480|Experimental|Fimasartan 60 mg, Hydrochlorothiazide 25 mg|Combination of Fimasartan/Hydrochlorothiazide 60/25mg
3050703|NCT02222480|Experimental|Fimasartan 120 mg, Hydrochlorothiazide 25 mg|Combination of Fimasartan/Hydrochlorothiazide 120/25mg
3050704|NCT02222480|Placebo Comparator|Placebo|placebo
3050705|NCT02222467|Experimental|Klox BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for venous leg ulcers.
3050706|NCT02222454|Experimental|KLOX BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for pressure ulcers.
3050707|NCT02222441|Experimental|Fixed sequence modafinil DDI arm (Cohort 1)|Fixed sequence study with treatment A of palbociclib alone, followed by treatment B of palbociclib with modafinil in Cohort 1.
3050708|NCT02222441|Experimental|Fixed sequence pioglitazone DDI arm (Cohort 2)|For Cohort 2, fixed sequence study with treatment A of palbociclib alone, followed by treatment C of palbociclib with pioglitazone.
3050709|NCT02222428|Experimental|BI 1744 CL/BI 54903 XX FDC|
3050710|NCT02222428|Active Comparator|BI 54903 XX|
3050711|NCT02222428|Active Comparator|BI 1744 CL|
3050712|NCT02222415|Placebo Comparator|Training + placebo drink|Exercise + non-caloric placebo drink
3050713|NCT02222415|Experimental|Exercise + Protein drink|exercise + Drink containing Protein, Carbohydrates and Fat
3050714|NCT02222402|Experimental|INTRA-DIALYTIC EXERCISE TRAINING|"Using a modified cycle ergometer, aerobic exercise will be performed in a semi-recumbent position, 3 times per week during the first two hours of haemodialysis. The initial prescription will be set in the moderate intensity range of 40-60% of peak aerobic capacity, progressing to 75% level by the end of the intervention.~Twice per week patients will also complete lower extremity muscular conditioning exercise, using ankle weights, after the aerobic cycling exercise."
3050715|NCT02222402|No Intervention|HAEMODIALYSIS RENAL REPLACEMENT THERAPY|"Haemodialysis is the most common dialysis (renal replacement) treatment for kidney failure.~They may also receive dietary advice, counselling, input from social workers, and other forms of educational support."
3050716|NCT02222389|Experimental|CM for alcohol|CM for alcohol
3050717|NCT02222389|Experimental|CM for drugs|CM for drugs
3050718|NCT02222389|Experimental|CM for both substances|CM for both substances
3050719|NCT02222389|Other|Non-Contingent group|No CM for either substance, the Non-Contingent (NC) group
3050720|NCT02222376|Active Comparator|Conventional treatment|Weekly ulcer debridement and daily cleansing
3050721|NCT02222376|Experimental|Pirfenidone|Weekly ulcer debridement, daily cleansing, plus twice a day topical pirfenidone application
3050722|NCT02222363|Experimental|VLX600|Dose of VLX600 in patients with refractory advanced solid tumors
3050723|NCT02222350|Experimental|DS-8500a 10mg once daily|10mg DS-8500a tablet given orally once daily
3050724|NCT02222350|Experimental|DS8500a 75 mg once daily|75mg DS-8500a tablet given orally once daily
3050725|NCT02222350|Placebo Comparator|placebo to match DS-8500a tablet|placebo matching DS-8500a tablet
3050726|NCT02222337|Active Comparator|Nueva Vida Intervention|Nueva Vida Intervention consists of 8 sessions of a skills-building group held twice a month for 4 months. Latina survivors and their caregivers arrive at the group together, separate into different rooms to learn the coping and communication skills, and then join together for discussion of the topic.
3050727|NCT02222337|No Intervention|Usual Care|Usual care as provided by each of our 4 community-based organization partners. Usual care can include but is not limited to support groups, patient navigation, individual, couple or family therapy.
3050728|NCT02222324|Placebo Comparator|Treatment A|Placebo
3050729|NCT02222324|Experimental|Treatment B|E2609 Low dose
3050730|NCT02222324|Experimental|Treatment C|E2609 High dose
3050731|NCT02222324|Active Comparator|Treatment D|Moxifloxacin
3050732|NCT02222311||Autistic Children|Children diagnosed with autism spectrum disorder according to the criteria of the Diagnostic Statistical Manual-V will have blood samples taken for laboratory analysis.
3050733|NCT02222311||Healthy Children|Children with no developmental or physical diseases will have blood samples taken for laboratory analysis.
3050734|NCT02222311||Children with Attention Deficit Disorder|Blood samples from children with Attention Deficit Disorder will be measured for Vitamin D and oxidative stress markers.
3050735|NCT02222298|Experimental|VAAPS group|patients undergoing video assisted ablation of pilonidal sinus
3050736|NCT02222298|Active Comparator|conventional treatment group|patients undergoing conventional off-midline Bascom cleft lift procedure
3050737|NCT02222285|Placebo Comparator|Sequence 3: placebo/placebo|Placebo/placebo consists of placebo for 7 weeks followed by 7 weeks of placebo treatment
3050738|NCT02222285|Active Comparator|Sequence 2: placebo/ Treatment|Sequence 2: placebo/ Treatment , consists of placebo for 7 weeks followed by 7 weeks of treatment with Vayarin_005
3050739|NCT02222285|Active Comparator|Sequence one: Treatment/Treatment|Treatment/Treatment- consists of PS_005 for 7 weeks followed by 7 weeks of additional treatment with Vayarin_005
3050740|NCT02222259|Experimental|GA and Integrated Care Plan|Participants allocated to the intervention group will be seen in the geriatric oncology clinic where they will be assessed using a geriatric assessment. Based on the issues identified in the geriatric assessment, a care plan will be developed with the participant to address the issues.
3050741|NCT02222259|No Intervention|Standard oncology care|Participants randomized to standard oncology care will receive usual care from their oncology team.
3050742|NCT02222246|Experimental|Patient Specific dose of Morphine Sulfate or Hydromorphone|A patient-specific analgesic protocol for use in the ED to manage VOC crises. Following randomization, a patient's healthcare team will develop a specific analgesic protocol for use during future ED visits for VOC occurring during the study period (up to 5 visits). Treatment protocols will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous). Dosage and frequency will be based on a patient's prior treatment history.
3050743|NCT02222246|Active Comparator|Standard dose of Morphine Sulfate or Hydromorphone|A standardized analgesic protocol (based on recent NHLBI recommendations) for use in the ED to manage VOC crises. Treatment protocol will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous), with dosage based on weight. Repeat doses of opioids may be administered every 20-30 minutes as needed, although dosage will be maintained or provided at no more than 25% above the initial dose.
3050744|NCT02222233|Experimental|BI 671800 HEA delayed release (enteric coated) tablet|
3050745|NCT02222233|Experimental|BI 671800 HEA solution released in jejunum|BI 671800 HEA solution in the Enterion® capsule released in the jejunum
3050746|NCT02222233|Experimental|BI 671800 HEA solution released in ascending colon|BI 671800 HEA solution in the Enterion® capsule released in the ascending colon
3050747|NCT02222233|Experimental|BI 671800 HEA solution released in descending colon|BI 671800 HEA solution in the Enterion® capsule released in the descending colon
3050748|NCT02222233|Experimental|BI 671800 HEA particulate released in ascending colon|BI 671800 HEA as particulate in the Enterion® capsule released in the ascending colon
3050749|NCT02222220|Placebo Comparator|metoclopramide|61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode
3050750|NCT02222220|Experimental|metocliopramide|61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode
3050751|NCT02222207|Experimental|Regorafenib [A]|Part A: Patients will receive Regorafenib eye drops
3050752|NCT02222207|Experimental|Regorafenib [B1]|Part B: Regorafenib eye drops dose 1; plus sham IVT (Intravitreal therapy) once every 4 weeks
3050753|NCT02222207|Experimental|Regorafenib [B2]|Part B: Regorafenib eye drops dose 2; plus sham IVT (Intravitreal therapy) once every 4 weeks
3050754|NCT02222207|Experimental|Regorafenib [B3]|Part B: Regorafenib eye drops dose 3; plus sham IVT (Intravitreal therapy) once every 4 weeks
3050755|NCT02222207|Experimental|Regorafenib [B4]|Part B: Regorafenib eye drops dose 4; plus sham IVT (Intravitreal therapy) once every 4 weeks
3050756|NCT02222207|Experimental|Regorafenib [B5]|Part B: Regorafenib eye drops dose 5; plus sham IVT (Intravitreal therapy) once every 4 weeks
3050757|NCT02222207|Experimental|Regorafenib [B6]|Part B: Regorafenib eye drops dose 6; plus sham IVT (Intravitreal therapy) once every 4 weeks
3050758|NCT02222207|Active Comparator|Ranibizumab|Ranibizumab IVT once every 4 weeks; plus placebo eye drops to match the regorafenib eye drop regimens
3050759|NCT02222194||VAM|"Patients with operable and resectable cT1-2-selected T3 cN1cM0 NSCLC undergo VAM for mediastinal lymph node staging. After VAM, patients without tissue proof of N2/3 disease at surgical staging undergo a VATS or thoracotomy with systematic lymph node dissection during the same anaesthesia or at a later stage.~Sensitivity, NPV and accuracy of staging with VAM will be calculated. Provided N2 lymph node metastases are proven by VAM the patient goes off study protocol and can further be assessed/treated according to local clinical practice."
3050760|NCT02222181|Experimental|Pharmacotherapy follow-up|patients with Alzheimer's disease
3050761|NCT02222168|Experimental|1 BI 409306|tablet, fasted, oral administration with 240 ml water
3050762|NCT02222168|Experimental|2 BI 409306|tablet, fed, oral administration with 240 ml water
3050763|NCT02222168|Experimental|3 BI 409306|tablet, oral administration with 240 ml water at bed time
3050764|NCT02222155|Active Comparator|CCX168 low dose plus standard of care|Capsule, 10mg, twice daily, 12 weeks
3050765|NCT02222155|Active Comparator|CCX168 high dose plus standard of care|Capsule, 30 mg, twice daily, 12 weeks
3050766|NCT02222155|Placebo Comparator|Placebo BID plus standard of care|Capsule, placebo, twice daily, 12 weeks
3050767|NCT02222142||Isoflurane group|Isoflurane inhalational anesthesia during OPCAB
3050768|NCT02222142||Propofol group|Total intravenous anesthesia with propofol during OPCAB
3050769|NCT02222129|Active Comparator|Bupivacaine|Surgical site infiltration of 0.25% bupivacaine.
3050770|NCT02222129|Experimental|Liposomal bupivacaine|Surgical site infiltration of liposomal bupivacaine.
3050771|NCT02222116|Experimental|MGuard Prime|MGuard Prime
3050772|NCT02222116|Active Comparator|Control|BMS or DES
3050773|NCT02222103||Suspected obstructive sleep apnea in adults|Already scheduled in-lab sleep study
3050774|NCT02222090||patients who have been prescribed warfarin|
3050775|NCT02222090||patients who have been prescribed apixaba|
3050776|NCT02222064|Experimental|Mindfulness|8 week self-managed mindfulness based intervention
3050777|NCT02222051|Experimental|Tai Chi|Simplified 24 Yang Style 12 weeks, 1x/week, 60-90 minutes
3050778|NCT02222051|Active Comparator|Neck exercise|conventional neck exercises 12 weeks, 1x/week, 60 min stretching and strengthening, neck education
3050779|NCT02222051|No Intervention|Usual care|Usual care, no specific study intervention this group is offered Tai Chi or neck exercises at the end of the study
3050780|NCT02222038|Other|skin biopsy|4mm punch biopsy
3050781|NCT02222025|Experimental|Injury Prevention Programme|see intervention prescription
3050782|NCT02222025|No Intervention|Control|The coaches of the control group will receive the instruction to regularly perform a common warm-up consisting of running and ball-based exercises (sham treatment, no neuromuscular and stability exercises).
3050783|NCT02222012|Active Comparator|single channel|
3050784|NCT02222012|Experimental|"Two channels Multiway stimulator coil® (Brainsway Ltd.)"|
3050785|NCT02221999|Active Comparator|Chemotherapy only|Paclitaxel injection 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle；Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle； for 4 cycles
3050786|NCT02221999|Experimental|GnRHa|Paclitaxel 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle; Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle; for 4 cycles Gonadotropin-releasing hormone agonist （GnRHa）11.25 mg every 3 months or 3.6mg every month subcutaneously
3050787|NCT02221999|Experimental|letrozole|Paclitaxel 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle; Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle; for 4 cycles Letrozole 2.5mg/day
3050788|NCT02221986|Experimental|Interdisciplinary rehabilitation|"The intervention consists of 6 weeks intensive outpatient physiotherapy in conjunction with 0-6 weeks of occupational therapy if need is indicated. The physical intervention contains supervised group exercise of 90 minutes three times a week in groups up to four patients included continuously.~The occupational therapy intervention consists of individual training 60 minutes twice a week for patients having deficits in activity or participation levels measured by the Assessment of Motor and Process Skills (AMPS)."
3050789|NCT02221986|No Intervention|Care as usual|The control group receives usual standard of care (e.g. no training, individual training or group training in the municipality). The amount of training in this group is based on a questionnaire at the follow-up trials.
3050792|NCT02221973|Active Comparator|milk without sterols and hawthorn powder|
3050793|NCT02221960|Experimental|Monotherapy Arm|MEDI6383
3050794|NCT02221960|Experimental|Combination Arm|MEDI6383 and MEDI4736
3050795|NCT02221947|Active Comparator|Bryostatin 1|single dose of 25 μg/m2 bryostatin, intravenous infusion over 1 hour
3050796|NCT02221947|Placebo Comparator|placebo|single dose of placebo, intravenous infusion over 1 hour
3050797|NCT02221934|Experimental|Signal more likely to block nerve|Electrical signal delivered to nerve by Altius, a device designed for high-frequency nerve block
3050798|NCT02221934|Active Comparator|Signal less likely to block nerve|Electrical signal delivered to nerve by Altius, a device designed for high-frequency nerve block
3050799|NCT02221921|Experimental|MicroPort's Transcatheter Aortic Valve and Delivery System|single arm with intervention that percutaneous implantation of the MicroPort's Transcatheter Aortic Valve and Delivery System
3050800|NCT02221908||Patients brought to Hahnemann Hospital ED|
3050801|NCT02221895|Experimental|Early Follow-up|Postpartum follow up appointment 2-3 weeks after delivery
3050802|NCT02221895|Active Comparator|Traditional Follow-up|Postpartum follow up 6-8wk after delivery (current clinical standard)
3050803|NCT02221882|Experimental|LY3164530|LY3164530 in escalating dose cohorts given intravenously (IV) once on Days 1 and 15 or on Days 1, 8, 15, and 22 of a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
3050804|NCT02221869|Experimental|Xyrem|Active Xyrem at a dose ≤9 g/night
3050805|NCT02221869|Placebo Comparator|Xyrem Placebo|Xyrem placebo at a volume and regimen equivalent to the stable dose of Xyrem.
3050806|NCT02221856|Experimental|Motion View|
3050807|NCT02221856|Active Comparator|Conventional Orthodontic Treatment|
3050808|NCT02221830|Placebo Comparator|Placebo|Normal Saline (standard of care)
3050809|NCT02221830|Experimental|Treatment|normal saline + oxytocin
3050810|NCT02221817|Active Comparator|Blind|Trochanter injection
3050811|NCT02221817|Experimental|Ultrasound|Trochanter injection
3050812|NCT02221804|Experimental|COPD - reduced activity levels|COPD patients who have voluntarily decreased their daily physical activity levels to no more than 1500 steps/day for 14 days.
3050813|NCT02221804|Experimental|Healthy - reduced activity levels|Healthy age-matched controls who have voluntarily decreased their daily physical activity levels to no more than 1500 steps/day for 14 days.
3050814|NCT02221804|No Intervention|COPD - unchanged activity levels|
3050815|NCT02221791|Active Comparator|Pure Epicatechin|Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate
3050816|NCT02221791|Active Comparator|High flavan-3-ol cocoa|Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
3050817|NCT02221791|Placebo Comparator|Placebo|Participants will consume 70g white chocolate + placebo capsules
3050818|NCT02221778|Experimental|SBRT|SBRT according to the intervention description
3050819|NCT02221765|Experimental|Arm 1|"Visit 1 - sham visit: placebo 0.9% (w/v) saline single-dose, administered subcutaneously.~Visit: 2 - placebo 0.9% (w/v) saline single-dose, administered subcutaneously.~Visit 3 - single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg."
3050820|NCT02221765|Experimental|Arm 2|"Visit 1 - sham visit: placebo 0.9% (w/v) saline single-dose, administered subcutaneously.~Visit: 2 - single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.~Visit 3 - placebo 0.9% (w/v) saline single-dose, administered subcutaneously."
3050821|NCT02221752|Experimental|Folic acid|Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
3050822|NCT02221752|Experimental|Ferrous Sulfate + folic acid|Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate [60 mg elemental iron]) and the other with 0.40 mg folic acid from enrollment to delivery.
3050823|NCT02221739|Experimental|Ipilimumab + radiotherapy|Patients receive ipilimumab (Ipi) 3mg/kg i.v. over 90 minutes, within 24 hours of starting radiotherapy (RT) to the biopsied lesion, 6 Gy x5, later changed to 9.5 Gy x3 (conformally or by intensity modulated RT (IMRT) with image guidance to maximally spare normal tissue). Ipilimumab is repeated on days 22, 43 (for patients who consent to the first biopsy), and 64. Repeat biopsy is performed between day 22-29, and patients are re-imaged between day 81-88 and evaluated for response (defined as an objective response by irRC of the measurable metastatic sites outside the radiation field).
3050824|NCT02221726|Experimental|JNJ-35684-AAA-023: 5.5 cm^2 Patch|
3050825|NCT02221726|Experimental|JNJ-35684-AAA-023: 44 cm^2 Patch|
3050826|NCT02221713||Group A: perforated diverticulitis|Patients with acute diverticulitis will be recruited from the A&E department at King's, prior to commencement of antibiotics. Rectal swabs will be obtained from patients with a chief complaint of acute abdominal pain upon initial assessment, prior to initial antibiotics. All specimens will be initially frozen, but only patients specimens with an admitting diagnosis of acute diverticulitis and colonic imaging (CT imaging or visualization at surgery) will be analysed. This group will include patients with perforated diverticulitis (i.e., Hinchey III or IV).
3050827|NCT02221713||Group B: unperforated diverticulitis|Patients with acute diverticulitis will be recruited from the A&E department at King's, prior to commencement of antibiotics. Rectal swabs will be obtained from patients with a chief complaint of acute abdominal pain upon initial assessment, prior to initial antibiotics. All specimens will be initially frozen, but only patients specimens with an admitting diagnosis of acute diverticulitis and colonic imaging (CT imaging or visualization at surgery) will be analysed. This group will include patients with unperforated diverticulitis (Hinchey I or II).
3050828|NCT02221713||Group C: asymptomatic diverticulosis|Patients with asymptomatic diverticulosis will be recruited from the 2-week wait (2ww) colorectal cancer pathway. Patients presenting with a chief complaint of fresh PR bleeding, with no other complaints, will be recruited prior to diagnostic imaging, either by CT, CT colonography, or endoscopy. They will provide a stool sample or rectal swab prior to bowel cleansing, if required for their evaluation, as that may alter the microbiome. Those patient samples with diverticulosis (and or haemorrhoids, as the other most common cause of fresh PR bleeding) will be analysed.
3050864|NCT02221492|Experimental|granulocyte colony-stimulating factor plus plerixafor|G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7)
3079582|NCT02029833|Experimental|Regular Canola Oil|60% oleic acid
3050829|NCT02221713||Group D: normal controls|Patients with or without haemorrhoids, and no other colonic pathology will be recruited from the 2ww colorectal cancer pathway. These will be the normal controls. Patients presenting with a chief complaint of fresh PR bleeding, with no other complaints, will be recruited prior to diagnostic imaging, either by CT, CT colonography, or endoscopy. They will provide a stool sample or rectal swab prior to bowel cleansing, if required for their evaluation, as that may alter the microbiome. Those patient samples with diverticulosis (and or haemorrhoids, as the other most common cause of fresh PR bleeding) will be analysed.
3050830|NCT02221700|Experimental|Massage - 3 Times a Week for 4 Weeks|Two groups receive massage three times a week for 4 weeks.
3050831|NCT02221700|Experimental|Massage - 2 Times a Week for 6 Weeks|Two groups receive massage two times a week for 6 weeks.
3050832|NCT02221687|Experimental|Synbiotic formula|"Synbiotic formula : standard formula enriched with a prebiotic fiber and a probiotic strain~Dose : variable number of powder scoops, adapted to the infant's age and weight, and addition of the defined amount of water, according to the Dose and Drinking Amount table.~Route : oral, ad libitum~Duration of product intake:~Synbiotic IF : 5 months of consumption (from the inclusion until 6 months completed of age)~Synbiotic FoF: 6 months of consumption (from 6 to 12 months of age)"
3050833|NCT02221687|Placebo Comparator|Control formula|"Control formula : standard formula without pre and probiotic~Dose : variable number of powder scoops, adapted to the infant's age and weight, and addition of the defined amount of water according to the Dose and Drinking Amount table.~Route: oral, ad libitum~Duration of product intake:~Control IF : 5 months of consumption (from the inclusion until 6 months completed of age)~Control FoF : 6 months of consumption (from 6 to 12 months of age)"
3050834|NCT02221687|No Intervention|Breast-fed group|"- Breast milk as exclusive feeding (no more than one formula meal per day), from birth until at least 4 months of age. Then, when the mother decides to stop breastfeeding, the infants can consume any formula on parent's choice respecting forbidden products list.~Dose:~Breast milk : on demand~Route : oral, ad libitum~Duration of product intake:~Breast milk : at least 4 month (from birth until at least 4 months of age)"
3050835|NCT02221674|Experimental|Tapentadol|Tapentadol 4 mg/mL immediate release oral solution, single dose post-operatively.
3050836|NCT02221648|Placebo Comparator|Placebo|Subjects will be randomization to receive injections with either the study drug (abobotulinumtoxinA) or the placebo group. The subjects will be blinded to which intervention they will receive.
3050837|NCT02221648|Active Comparator|AbobotulinumtoxinA Treatment|Subjects will be randomized to receive intervention injections with the study drug arbobotulinumtoxinA.
3050838|NCT02221635||rTMS+Risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months.At the same time,risperidone (2-4mg) was took orally.
3050839|NCT02221635||Risperidone|Risperidone (2-4mg) was took orally.
3050840|NCT02221622|Experimental|Allopregnanolone 2 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
3050841|NCT02221622|Experimental|Allopregnanolone 4 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
3050842|NCT02221622|Experimental|Allopregnanolone 6-18 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
3050843|NCT02221622|Placebo Comparator|Placebo|Drug: Placebo injection (intravenous solution) once per week for 12 weeks
3050844|NCT02221609|Experimental|Treatment based on Movement System Impairment based model|Treatment based on Movement System Impairment based classification model is composed by patient education, analysis and modification of daily living activities and prescription of specific exercises
3050845|NCT02221609|Active Comparator|General exercise|The general exercise program consists of stretching exercises of the trunk and lower limbs muscles and strengthening exercises of the trunk muscles (Hayden et al., 2005; Rainville et al., 2004).
3050846|NCT02221596|Experimental|vitamin D + aerobic training|vitamin D capsules every weekday (10,000IU/day) and exercise
3050847|NCT02221596|Active Comparator|vitamin D + no aerobic training|vitamin D capsules every weekday (10,000IU/day) and no exercise
3050848|NCT02221596|Active Comparator|placebo + aerobic training|placebo capsule every weekday and exercise
3050849|NCT02221596|No Intervention|placebo + no aerobic training|placebo capsule every weekday and no exercise
3050850|NCT02221583|Experimental|Group 1|Astagraf XL + Mycophenolate mofetil then cross over to Prograf + Mycophenolate
3050851|NCT02221583|Experimental|Group 2|Prograf + Mycophenolate mofetil then cross over to Astagraf XL + Mycophenolate
3050852|NCT02221570|Active Comparator|Baclofen|Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
3050853|NCT02221570|Placebo Comparator|Placebo|placebo of baclofen
3050854|NCT02221557|Experimental|New alloplastic bone graft material|
3050855|NCT02221544|Experimental|rTMS treatment followed by Sham|A course of low-frequency repetitive transcranial magnetic stimulation (rTMS) delivered over the supplementary motor area (SMA) followed by rTMS maintenance period (1 month) and followed by sham treatment in order to show the efficacy of treatment
3050856|NCT02221544|Experimental|Sham treatment followed by rTMS|A course of sham followed by followed by sham maintenance period (1 month) and than followed by low-frequency repetitive transcranial magnetic stimulation (rTMS) delivered over the supplementary motor area (SMA) in order to show the effectiveness of rTMS
3050857|NCT02221531|Experimental|Short infusion|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
3050858|NCT02221531|Other|Bolus application|Carbetocin 100 microgram will be applied intravenously by bolus application over about 15 seconds
3050859|NCT02221518|Experimental|Patients with OCD|Behavioral: Exposure & Response Prevention (EX/RP)
3050860|NCT02221505|Experimental|LOP628 - Solid Tumor|with LOP628
3050861|NCT02221505|Experimental|LOP628 - AML|With LOP628
3050862|NCT02221505|Experimental|LOP628 - Solid Tumor Expansion|With LOP628
3050863|NCT02221492|Active Comparator|granulocyte colony-stimulating factor alone|G-CSF administered up to 8 days
3079583|NCT02029833|Experimental|High Oleic Canola Oil|70% oleic acid
3050865|NCT02221479|Active Comparator|Granulocyte colony-stimulating factor (G-CSF) alone|G-CSF administered up to 8 days
3050866|NCT02221479|Experimental|G-CSF plus plerixafor|G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7)
3050867|NCT02221466||diabetic patients|Diabetic patients given HBOT
3050868|NCT02221466||None diabetic patients|None diabetic patients given HBOT
3050869|NCT02221453|Other|Triamcinolone Acetonide Treatment|Triamcinolone Acetonide Injectable Suspension 40 mg/mL intravitreal injection
3050870|NCT02221440|Placebo Comparator|air, second stage of labor|"Patients randomized to the group will receive sham administered by nasal catheter.~The therapy will continue until after delivery"
3050871|NCT02221440|Experimental|oxygen, second stage of labor|"Patients randomized to the group will receive oxygen administered by low flow nasal oxygen at a flow rate of 2 L/min.~The therapy will continue until after delivery"
3050872|NCT02221427|Active Comparator|Static labour progression curve (F)|Guideline with the following expected labour progression: if the cervix dilates at least 1 centimetre per hour assessed after 4 hours. Labour dystocia is diagnosed if progression proceeds slower than this definition throughout the active phase of the first stage of labour. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours, three hours for women with epidurals or if the expulsion phase lasts longer than 60 minutes.
3050873|NCT02221427|Experimental|Dynamic progression curve (Z)|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes.
3050874|NCT02221414|Experimental|Treatment A (FDC)|
3050875|NCT02221414|Active Comparator|Treatment B (single agents)|
3050876|NCT02221401|Experimental|Treatment A (FDC)|
3050877|NCT02221401|Active Comparator|Treatment B (single agents)|
3050878|NCT02221388|Active Comparator|BI 671800 ED capsules|
3050879|NCT02221388|Experimental|BI 671800 HEA tablet in fasted state|
3050880|NCT02221388|Experimental|BI 671800 HEA EC tablet in fasted state|
3050881|NCT02221388|Experimental|BI 671800 HEA tablet in fed state|
3050882|NCT02221388|Experimental|BI 671800 HEA EC tablet in fed state|
3050883|NCT02221388|Experimental|BI 671800 HEA, 50 mg tablet in fasted state|
3050884|NCT02221375|Experimental|BHT low|
3050885|NCT02221375|Experimental|BHT medium|
3050886|NCT02221375|Experimental|BHT high|
3050887|NCT02221375|Experimental|BI 54903 XX low|
3050888|NCT02221375|Experimental|BI 54903 XX medium 1|
3050889|NCT02221375|Experimental|BI 54903 XX medium 2|
3050890|NCT02221375|Experimental|BI 54903 XX high|
3050891|NCT02221375|Experimental|BI 54903 XX medium single dose|
3050892|NCT02221375|Active Comparator|Ciclesonide|
3050893|NCT02221362||Observational|No interventions
3050894|NCT02221349|Other|oxalate liquid & gel plus SnF2 paste|Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Stannous fluoride paste, self applied
3050895|NCT02221349|Other|oxalate liquid & gel plus NaF paste|Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Sodium fluoride paste, self applied
3050896|NCT02221336|Placebo Comparator|Non-MONARCA II system|Use of smartphone for normal communicative purposes only. No self-monitoring and no feedback loop.
3050897|NCT02221336|Experimental|The MONARCA II system|Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop
3050898|NCT02221323|Experimental|Insulin lispro|
3050899|NCT02221310|Experimental|Gemtuzumab Ozogamicin|Conditioning therapy with Gemtuzumab Ozogamicin in combination with busulfan and cyclophosphamide chemotherapy followed by allogeneic stem cell transplantation.
3050900|NCT02221297|Experimental|Supplement product with plant stanol ester|
3050901|NCT02221297|Placebo Comparator|Placebo supplement product|
3050902|NCT02221284||Oral administration of one tablet (25 mg) of alogliptin|Oral administration of one tablet (25 mg) of alogliptin once daily
3050903|NCT02221271|Experimental|NPB-01|
3050904|NCT02221258|Experimental|FURESTEM-RA Inj.+DMARDs|FURESTEM-RA Inj. 1. 2.5x10^7 stem cells+DMARDs after registration FURESTEM-RA Inj. 2. 5.0x10^7 stem cells+DMARDs after registration FURESTEM-RA Inj. 3. 1.0x10^8 stem cells+DMARDs after registration
3050905|NCT02221245||Patients with Esophageal Cancer|Tumor Biopsy via Ultrasound Endoscopy
3050906|NCT02221232|Experimental|ZuraPrep Config 1|Isopropyl alcohol (IPA) 70% Standard scrub time.
3050907|NCT02221232|Experimental|ZuraPrep Config 2|Isopropyl alcohol (IPA) 70% Half scrub time.
3050908|NCT02221232|Placebo Comparator|ZuraPrep Vehicle|ZuraPrep without IPA
3050909|NCT02221232|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
3050910|NCT02221219|Placebo Comparator|immediate cord clamp & placebo IV solution|This Arm will receive immediate clamp of umbilical cord at birth, and an intravenous delivery of placebo drug solution (diluent for active drug, indomethacin) within the first 6hrs of life.
3050911|NCT02221219|Experimental|delay cord clamp & placebo IV solution|A delay in cord clamp for 45 seconds will be instituted in the delivery room. Placebo drug solution will be administered within 6hrs post-birth.
3050912|NCT02221219|Active Comparator|immediate cord clamp & indomethacin IV|Umbilical cord will be clamped immediately at birth. Indomethacin will be administered IV, starting within 6hrs of life (0.1mg/kg every 24 hrs for three total doses.This intervention is considered 'standard care' at many Neonatology medical facilities. The dose of indomethacin has been shown to be effective in reducing brain bleeds in preterm infants (although there are also data showing safety concerns).
3050913|NCT02221219|Experimental|indomethacin iv & delayed cord clamp|A delay in cord clamp of 45 seconds will be instituted in the delivery room. In addition, indomethacin will be administered iv (initiated within 6hrs of life), 0.1mg/kg every 24 hrs for three total doses.
3050914|NCT02221206|Active Comparator|Treatment|mini-screw implant anchorage-assisted retraction of maxillary incisors
3050915|NCT02221206|No Intervention|Control|regular maximum anchorage
3050916|NCT02221193|Experimental|site specific vs panoral disinfection|
3050917|NCT02221180|Experimental|Treatment Sequence ABDC|Treatment A (1 immediate release (IR) fixed dose combination [FDC] tablet containing canagliflozin 150 milligram [mg] and metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
3050918|NCT02221180|Experimental|Treatment Sequence BCAD|Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
3050919|NCT02221180|Experimental|Treatment Sequence CDBA|Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
3050920|NCT02221180|Experimental|Treatment Sequence DACB|Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
3050921|NCT02221167|No Intervention|Exclusive breastfeeding|Infants in the exclusive breastfeeding group will continue to breastfeed.
3050922|NCT02221167|Active Comparator|Donor Milk|"Infants in this arm will continue to breastfeed and will be given 10 ml of donor breast milk by syringe after each breastfeeding until their mother's milk comes in. (until the onset of lactogenesis II)"
3050923|NCT02221154|Experimental|Inofolic®|standard ovarian stimulation and Inofolic®
3050924|NCT02221154|Active Comparator|Gonadotropins;Folic Acid|standard ovarian stimulation without Inofolic®
3050925|NCT02221115|Other|Google Glass|Investigators using Google Glass during clinic visit
3050926|NCT02221115|No Intervention|No Google Glass|Investigator will not be using Google Glass during clinic visit
3050927|NCT02221102|Active Comparator|aspirin|Receiving a 100-mg dose of aspirin and placebo edoxaban from day 1 to day 30
3050928|NCT02221102|Experimental|edoxaban 30mg|Receiving a 30-mg dose of edoxaban and placebo aspirin from day 1 to day 30
3050929|NCT02221102|Experimental|edoxaban 60mg|Receiving a 60-mg dose of edoxaban and placebo aspirin from day 1 to day 30
3050930|NCT02221089|Experimental|Retaron|
3050931|NCT02221089|Placebo Comparator|Placebo|
3050932|NCT02221076|Experimental|Confocal Laser Endomicroscopy (CLE)|The patient will undergo a 10 minutes endomicroscopy procedure to obtain real time microscopical images of healthy and malignant tissue of the targeted organs.
3050933|NCT02221063|Active Comparator|low [thiamin] fortified fish sauce|Fish sauce will contain 2 mg thiamin hydrochloride / mL fish sauce + iron (as NaFeEDTA)
3050934|NCT02221063|Active Comparator|higher [thiamin] fortified fish sauce|Fish sauce will contain 8 mg thiamin hydrochloride / mL fish sauce + iron (as NaFeEDTA)
3050935|NCT02221063|Placebo Comparator|Placebo fish sauce|Fish sauce will contain only iron (as NaFeEDTA), no thiamin
3050936|NCT02221037|Experimental|GSK2862277|GSK2862277 will be administered as single orally inhaled aerosol over approximately 3 to 5 minutes; approximately 1-3 hours prior to the subjects scheduled surgery, before the initiation of pre-operative procedures. After surgery subject will undergo either ventilated or collapsed lung BAL procedure. Regular assessments will be conducted until the time of patient discharge. Subjects will be followed up as outpatients at Day 28
3050937|NCT02221037|Placebo Comparator|Placebo|Placebo will be administered as single orally inhaled aerosol over approximately 3 to 5 minutes; approximately 1-3 hours prior to the subjects scheduled surgery, before the initiation of pre-operative procedures. After surgery subject will be undergo either ventilated or collapsed lung BAL procedure. Regular assessments will conducted until the time of patient discharge. Subjects will be followed up as outpatients at Day 28
3050938|NCT02221024|Experimental|Flushing every 24 hours|Flushing with positive pressure with normal saline every 24 hours
3050939|NCT02221024|Active Comparator|Flushing every 12 hours|Flushing with positive pressure with normal saline every 12 hours
3050940|NCT02221011|Experimental|shock wave (three times)|E-SWT, Elettronica Pagani, Italy 3.5 bars 1500 beats in FCU, FCR 3 bars 4000 beats diffuse in intrinsic muscle Once a week for 3 weeks
3050941|NCT02221011|Sham Comparator|Sham shock wave|E-SWT, Elettronica Pagani, Italy Sham without energy, 1500 beats in FCU, FCR and 4000 beats diffuse in intrinsic muscle
3050942|NCT02221011|Experimental|Shock wave (one time)|E-SWT, Elettronica Pagani, Italy 3.5 bars 1500 beats in FCU, FCR 3 bars 4000 beats diffuse in intrinsic muscle Only one dose
3050943|NCT02220998|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
3050944|NCT02220998|Experimental|SOF+RBV|SOF+RBV for 12 weeks
3051034|NCT02220361|Experimental|hemabate+high dose dexmedetomidine group|received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline
3050945|NCT02220985|Experimental|Arm A (MRD)|"HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
3050946|NCT02220985|Experimental|Arm B (MRD)|"LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1.~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator."
3050947|NCT02220985|Experimental|Arm C (MUD)|"HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
3050948|NCT02220985|Experimental|Arm D (MUD)|"LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1.~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator."
3050949|NCT02220972|Experimental|Arm A: First on Perampanel with a crossover to Placebo|Treatment Arm A will initially receive perampanel 2 mg QD titrated up to 4 mg QD and finally to 6 mg QD with a crossover to placebo.
3050950|NCT02220972|Experimental|Arm B: First on Placebo with a crossover to Perampanel|Treatment Arm B will initially receive placebo with a crossover to perampanel 2 mg QD titrated up to 4 mg QD and finally to 6 mg QD.
3050951|NCT02220959|Experimental|walk test|morbid obese patients (BMI>40) undergoing laparoscopic sleeve gastrectomy walking 60 meters under 1 minute before and after the measurement of Forced vital capacity (FVC)
3050952|NCT02220946|Active Comparator|Vaginal Electrical Stimulation|A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. Each patient received a 20 minute session once a week for total 8 sessions
3050953|NCT02220946|Placebo Comparator|plasebo|sham electrical stimulation
3050954|NCT02220933|Experimental|MD1003|MD1003 100mg capsules, 1 capsule tid for 24 months
3050955|NCT02220933|Placebo Comparator|Placebo|Placebo capsule, 1 capsule tid for 12 months, then switch to MD1003 100mg capsule, 1 capsule tid for 12 months
3050956|NCT02220920|Experimental|Canagliflozin (TA-7284) ＋insulin|
3050957|NCT02220920|Placebo Comparator|Placebo＋insulin|
3050958|NCT02220907|Experimental|Teneligliptin/Canagliflozin|Patients receive Teneligliptin and Canagliflozin once daily for 52 weeks.
3050959|NCT02220894|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments
3050960|NCT02220894|Active Comparator|SOC Treatment|Participants receive carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m^2 IV on Day 1 of every 21-day cycle (Q3W) for a maximum of 6 cycles OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m^2 IV on Day 1 Q3W for a maximum of 6 cycles; participants with non-squamous histologies may go on to receive optional treatment with pemetrexed 500 mg/m^2 IV on Day 1 Q3W.
3050961|NCT02220881|Experimental|Mold making silicone toe separator|The subject in experimental group will use mold making silicone toe separator everyday
3050962|NCT02220881|Other|Observation|This group will follow the physician instruction of care for the hallux valgus
3050963|NCT02220868|Other|Sofossbuvir, Riabvirin, Stribild|Open-Label SIngle Arm of Sofosbuvir, Ribavirin and Stribild
3050964|NCT02220855|Experimental|BKM120|BKM120, 100mg capsule for oral use, taken once daily for two or more months for a maximum of one year. Each cycle is 28 days.
3050965|NCT02220842|Experimental|Arm 1 Cohort A (Safety Evaluation):Atezolizumab + Obinutuzumab|Relapsed/refractory FL and DLBCL participants will receive obinutuzumab alone on Days 1, 8, and 15 of Cycle 1 (Cycle length = 21 days), followed by atezolizumab and obinutuzumab on Day 1 of Cycles 2-8, and then atezolizumab alone on Day 1 of Cycle 9 and every cycle thereafter until unacceptable toxicities or disease progression.
3050966|NCT02220842|Experimental|Arm 1 Cohort B (Expansion): Atezolizumab + Obinutuzumab|Relapsed/refractory FL participants will receive atezolizumab and obinutuzumab as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
3050967|NCT02220842|Experimental|Arm 1 Cohort C (Expansion): Atezolizumab + Obinutuzumab|Relapsed/refractory DLBCL participants will receive atezolizumab and obinutuzumab as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
3050968|NCT02220842|Experimental|Arm 2 Cohort D (Safety Evaluation):Atezolizumab + Tazemetostat|Relapsed/refractory DLBCL participants will receive atezolizumab (on Day 1) and tazemetostat (on Days 1-21) of each 21-day cycle until unacceptable toxicities or disease progression.
3051035|NCT02220348|Experimental|linaclotide|Linaclotide 145 μg or 290 μg capsules, once daily for 3 days, oral administration
3050969|NCT02220842|Experimental|Arm 2 Cohort E (Expansion): Atezolizumab + Tazemetostat|Relapsed/refractory DLBCL participants will receive atezolizumab and tazemetostat as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
3050970|NCT02220829|Active Comparator|Preventive administration of Rapaflo|Rapaflo treatment will start on day one of radiation therapy (early administration- before symptoms onset) and continue for a total duration of 6 months: 8 mg daily during 4 months and 8 mg every other day for 2 months.
3050971|NCT02220829|Other|Standard care|Administration of alpha-blocker Rapaflo at the onset of symptomatic urinary problems caused by radiation therapy. 8 mg of Rapaflo is administered daily until disappearance of symptoms.
3050972|NCT02220816|Experimental|Competitive Training|The patients will receive only competitive activities designed to restore attention abilities. These include pencil-and-paper tasks completed under competitive circumstances and competitive virtual games specifically designed to treat different aspects of attention (divided, selective, sustained, etc).
3050973|NCT02220816|Active Comparator|Non-Competitive Training|The patients will receive conventional attentional training. Pencil and paper tasks focused on different aspects of attention (divided, selective, sustained, etc.) will be completed by all participant under individual or group-therapy sessions. No competitive training will be allowed.
3050974|NCT02220803|Active Comparator|Acetazolamide and CPAP|"Acetazolamide: Diamox®. Hard white capsule, 250 mg. The total treatment is 4 weeks (2+2 weeks). Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum dosage (750mg) following titration will be administered as morning (250 mg) and evening(500mg) dosages.Evening medication should be taken 2 hours before bedtime.~CPAP: Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines. The standard setting is a pressure delivery in the pressure range 5-15 mbar. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed at the end of each treatment regimen. Total duration of CPAP treatment is 4(2+2) weeks."
3050975|NCT02220803|Active Comparator|CPAP|Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed at the end of each treatment regimen. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 4(2+2) weeks.
3050976|NCT02220803|Experimental|Acetazolamide|Acetazolamide (Diamox®) 250 mg. Hard white capsule. The total length of acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum dosage (750mg) following titration will be administered as morning (250 mg) and evening(500mg)dosages.Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 300 ml of water (room temperature) in an upright body position and preferably in connection to a meal.
3050977|NCT02220777|Experimental|1. ASP8477 and placebo|Part 1: SAD in postmenopausal females and Part 2: SAD in vasectomized male
3050978|NCT02220777|Experimental|2. ASP8477 alone|Part 3, fasted or fed
3050979|NCT02220777|Experimental|3. omeprazole alone|Part 4, Drug-Drug Interaction
3050980|NCT02220777|Experimental|4. ASP8477 + omeprazole|Part 4: Drug-Drug Interaction
3050981|NCT02220764|Experimental|Tooth-supported|Long-span tooth-supported zirconia based fixed dental prostheses
3050982|NCT02220764|Active Comparator|Implant-supported|Long-span implant-supported zirconia based fixed dental prostheses
3050983|NCT02220751|Placebo Comparator|chronic periodontitis|Non-surgical periodontal therapy.
3050984|NCT02220751|Active Comparator|Chronic periodontitis + type 2 diabetes|Non-surgical periodontal therapy + systemic doxycycline non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before first scaling and root planning session.
3050985|NCT02220751|No Intervention|Control|Periodontal- and systemically healthy patients were included as control group.
3050986|NCT02220738|Experimental|ABT-957|ABT-957 administered twice-daily for 7 days
3050987|NCT02220738|Placebo Comparator|Placebo|Placebo administered twice-daily for 7 days
3050988|NCT02220725|Experimental|Andexanet|Andexanet (antidote)
3050989|NCT02220725|Placebo Comparator|Placebo|Placebo
3050990|NCT02220712|Experimental|Drug: OPC-14597 IMD|
3050991|NCT02220686|Experimental|Offer and Report Protocol|Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
3050992|NCT02220686|No Intervention|Usual Care|Physician will follow their institution's standard of care for smoking cessation.
3050993|NCT02220673|Experimental|BHT 0.1%|
3050994|NCT02220673|Experimental|BHT 0.5%|
3050995|NCT02220673|Placebo Comparator|Placebo for RMT-B|
3050996|NCT02220673|Placebo Comparator|Placebo for HFA-MDI|
3050997|NCT02220660|Active Comparator|Free dose combination|
3050998|NCT02220660|Experimental|Fixed dose combination|
3050999|NCT02220647|Experimental|Treatment A (FDC)|
3051000|NCT02220647|Active Comparator|Treatment B (single agents)|
3051001|NCT02220634|Experimental|Regadenoson|Intravenous infusion of the A2A agonist regadenoson has a preferential vasodilator effect on pulmonary vasculature that is comparable to iNO, the current gold standard for pulmonary vasoreactivity studies.
3051002|NCT02220621|Experimental|Treatment|After the hysteroscopic adhesiolysis, crosslinked hyaluronic acid gel is applied into the uterine cavity, then a Foleys balloon catheter is inserted into the uterine cavity.
3051003|NCT02220621|Active Comparator|Control|After hysteroscopic adhesiolysis, a Foleys balloon catheter is inserted into the unterine cavity.
3051068|NCT02220140|No Intervention|Control|Service as usual
3051069|NCT02220140|Experimental|Intervention group|Participants are offered access to the web based resilience program and are invited to join a short introduction course.
3051004|NCT02220608|Experimental|Arm 1: Dose Level 1 (Bortezomib & G-CSF)|G-CSF will be administered daily for 5 days (Days 1-5). On Day 4 at approximately 1800 hours, bortezomib will be administered. Apheresis will begin on Day 5 either 15 or 18 hours following Day 4 bortezomib dose; 20L of peripheral blood will be processed with a cumulative target collection goal of > 6.0x106 CD34+cells/kg. If the target collection goal is not met after one apheresis procedures, up to three additional days of G-CSF and apheresis may be repeated.
3051005|NCT02220608|Experimental|Arm 2: Dose Level 2 (Bortezomib & G-CSF)|G-CSF will be administered daily for 5 days (Days 1-5). On Day 4 at approximately 1800 hours, bortezomib will be administered. Apheresis will begin on Day 5 either 15 or 18 hours following Day 4 bortezomib dose; 20L of peripheral blood will be processed with a cumulative target collection goal of > 6.0x106 CD34+cells/kg. If the target collection goal is not met after one apheresis procedures, up to three additional days of G-CSF and apheresis may be repeated.
3051006|NCT02220595|Experimental|Carotid stenting|Carotid artery stenting for treatment of carotid artery stenosis
3051007|NCT02220595|Active Comparator|Carotid endarterectomy|Carotid artery endarterectomy for treatment of carotid artery stenosis
3051008|NCT02220543|Experimental|Back on Track intervention|Back on Track intervention is a biopsychosocial primary care intervention
3051009|NCT02220543|Active Comparator|Primary care as usual|Primary care as usual comprises maximally 12 individual regular physical therapy sessions for a maximum of 8 weeks.
3051010|NCT02220530||Sedation group|Colonoscopies performed with conscious sedation with iv midazolam and fentanyl
3051011|NCT02220530||Control group|Colonoscopies performed without sedation.
3051012|NCT02220517|Experimental|A: MR-guided in-bore prostate biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
3051013|NCT02220517|Experimental|B: MRI/US fusion-guided prostate biopsy|Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
3051014|NCT02220504|Experimental|Intervention group|Antipsychotic treatment discontinuation (DT)
3051015|NCT02220504|Active Comparator|Control group|Maintenance antipsychotic treatment (MT)
3051016|NCT02220491|Active Comparator|Whole-brain radiotherapy|"All subjects will have a non-contrast CT scan using a slice thickness of 2.5mm or less.~The Brain contour will be generated using the segmentation wizard and edits as required.~PTV_Brain is an expansion of the Brain by 5mm. 99% of PTV_Brain is to be covered by 95% of 20 Gy in 5 fractions using 6-10 MV photons in a parallel-opposed pair lateral beam arrangement."
3051017|NCT02220491|Experimental|Single-fraction radiotherapy|Immobilized in the mask, the subject will be imaged for radiotherapy planning with a CT slice thickness of 1.25 mm or less and an axial resolution of < 0.7 mm (CT field of view < 35 cm). Subjects that require contrast with GFR 45-59 will have pre-hydration, contrast dose modification and/or Mucomyst administration to preserve renal function, according to standard practice for radiological imaging at the institution.
3051018|NCT02220478|Active Comparator|Signature Cutting Guides|Patients indicated for a Posterior Lateral THA utilizing non implantable Signature Cutting Guides during surgery.
3051019|NCT02220478|Active Comparator|Conventional Instrumentation|Patients indicated for a Posterior Lateral THA utilizing non implantable Conventional Instrumentation during surgery.
3051020|NCT02220465|Experimental|PA+ Smoking Cessation (LMPA)|This intervention integrates low-to-moderate physical activity (PA) with evidence based smoking cessation programming. Over the 4-week treatment period, the intervention (1 in-person and 3 phone counseling sessions) focuses on (a) gradually increasing routine PA during the pre-quit period and maintaining PA post quit day (b) increasing daily PA (steps/day) using a weekly tailored algorithm with the goal of achieving 10,000 steps by Week 4 (quit day) and (c) training participants to use PA as a primary urge management strategy, thereby embedding PA within evidence-based smoking cessation counseling. Other components include additional smoking urge management skills, increasing motivation to quit, overcoming barriers and maintaining PA for quitting and staying smoke-free .
3051021|NCT02220465|Active Comparator|Standard Care Smoking Counseling (SCC)|The control intervention parallels the format of the LMPA intervention with focus only on behavioral and cognitive urge management strategies (avoiding/escaping high-risk situations, stimulus control) and minimizing the probability that participants in the control group would increase increase/use PA during the intervention period. Participants are provided a pedometer without any instructions or encouragement around increasing walking/steps during the 8-week intervention period.
3051022|NCT02220452|Experimental|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
3051023|NCT02220452|Active Comparator|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
3051024|NCT02220439||Case: non-rotavirus seroconverters|Infants not demonstrating seroconversion to rotavirus vaccination, as measured anti‐RV Immunoglobulin A < 20 U/ml
3051025|NCT02220439||Control: rotavirus seroconverters|Infants demonstrating seroconversion to rotavirus vaccination, as measured by anti‐rotavirus Immunoglobulin A > 20 U/ml
3051026|NCT02220426|Other|Xenon inhalation|Inhalation of 5 doses of 750ml of hyperpolarized 129Xe gas
3051027|NCT02220400|Experimental|Ketamine|Ketamine infusion group
3051028|NCT02220400|Placebo Comparator|Placebo|Normal saline infusion
3051029|NCT02220387||occupational COPD|"Consists of 2 subgroups~COPD patients with history of exposure to respirable silica dust~COPD patients with history of exposure to polycyclic aromatic hydrocarbons exhaust"
3051030|NCT02220387||smokers with COPD and healthy control|"Consists of 2 subgroups~patients with COPD, history of tobacco smoke and no history of occupational exposure~healthy subjects"
3051031|NCT02220374|Experimental|Supportive Finger Tape|Participants will be randomised to either placebo or supportive taping
3051032|NCT02220361|Placebo Comparator|placebo group|received 20 ml intravenous physiological saline
3051033|NCT02220361|Experimental|low dose dexmedetomidine group|received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline
3051036|NCT02220335|Experimental|Pulmonary Arterial Denervation (PADN)|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into ostium of the left PA, ostium of the right PA , and the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes were tightly in contact with the endovascular surface. About four to eight ablations at 10 W for 60 seconds each were performed in ostium of the left PA, ostium of the right PA , and the distal bifurcation area of the main PA.
3051037|NCT02220335|Active Comparator|Standard treatment|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.
3051038|NCT02220309||Anxiety and mood disorders|
3051039|NCT02220296|Experimental|Part 1 insulin 338|
3051040|NCT02220296|Placebo Comparator|Part 1 placebo|
3051041|NCT02220296|Experimental|Part 2 insulin 338|
3051042|NCT02220296|Active Comparator|Part 2 insulin glargine|
3051043|NCT02220270||patient with PDA or ASD|
3051044|NCT02220257||Newly diagnosed type 1 diabetes|
3051045|NCT02220244|Experimental|MD1003|MD1003 100mg capsule, 1 capsule TID for 12 months
3051046|NCT02220244|Placebo Comparator|Placebo|Placebo capsule, 1 capsule TID for 6 months, then switch to MD1003 100mg capsule, 1 capsule TID for 6 months
3051047|NCT02220231|Experimental|capnothorax group|After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
3051048|NCT02220218|Experimental|Treatment Sequence ABDC|Treatment A (canagliflozin and metformin immediate release [IR] fixed dose combination [FDC] tablet 50 milligram [mg]/500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
3051049|NCT02220218|Experimental|Treatment Sequence BCAD|Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
3051050|NCT02220218|Experimental|Treatment Sequence CDBA|Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
3051051|NCT02220218|Experimental|Treatment Sequence DACB|Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
3051052|NCT02220205|Active Comparator|PelvicSim|Participants randomized to this arm practice IUD insertion on the PelvicSim for 30 minutes.
3051053|NCT02220205|Placebo Comparator|Manufacturer model|Participants randomized to this arm practice IUD insertion on models provided by the IUD manufacturer for 30 minutes.
3051054|NCT02220192|Experimental|Focal LEEP|All patients will undergo focal treatment of high-grade cervical intraepithelial neoplasia using LEEP. A two-week follow-up assessment will evaluate the side effects of the treatment and any unusual symptoms. This will be done through a phone survey. At six months a clinic visit is required to assess whether there are any precancerous cells of the patient's cervix.
3051055|NCT02220179|No Intervention|control|service as usual
3051056|NCT02220179|Experimental|Intervention group 1|Participants are offered access to the web based resilience program
3051057|NCT02220179|Experimental|Intervention group 2|Participants are offered access to the web based resilience program and are also invited to join a short introduction course about the program
3051058|NCT02220166|Experimental|Triticum monococcum|60 days of daily administration of 100 grams of water biscuits of Triticum monococcum
3051059|NCT02220153|Experimental|UCB7665 Intravenous 1|Single dose calculated based on body weight for 60 minutes intravenous infusion.
3051060|NCT02220153|Experimental|UCB7665 Intravenous 2|Single dose calculated based on body weight for 60 minutes intravenous infusion.
3051061|NCT02220153|Experimental|UCB7665 Intravenous 3|Single dose calculated based on body weight for 60 minutes intravenous infusion.
3051062|NCT02220153|Experimental|UCB7665 Intravenous 4|Single dose calculated based on body weight for 60 minutes intravenous infusion.
3051063|NCT02220153|Experimental|UCB7665 Intravenous 5|Single dose calculated based on body weight for 60 minutes intravenous infusion.
3051064|NCT02220153|Experimental|UCB7665 Subcutaneous 1|Single dose calculated based on body weight for 60 minutes subcutaneous infusion.
3051065|NCT02220153|Experimental|UCB7665 Subcutaneous 2|Single dose calculated based on body weight for 60 minutes subcutaneous infusion.
3051066|NCT02220153|Placebo Comparator|Intravenous Placebo|Single dose placebo comparator for each active arm of intravenous infusion.
3051067|NCT02220153|Placebo Comparator|Subcutaneous Placebo|Single dose placebo comparator for each active arm of subcutaneous infusion.
3051070|NCT02220127|Experimental|8 mm collimator|GKR with a single shot of the 8 mm collimator
3051071|NCT02220127|Experimental|4 mm collimator|GKR with a single shot of the 4 mm collimator
3051072|NCT02220114|Other|Vigabatrin: Vigabatrin new ST formulation then Sabril®|"Sabril®: sachet for oral solution 500 mg, 50 to 100mg/Kg/day, twice a day, 14 days.~Vigabatrin new ST formulation: Soluble tablets 100 or 500 mg, 50 to 100mg/Kg/day, twice a day, 12 weeks."
3051073|NCT02220088|Experimental|TACE|Retreatment With Transarterial Chemoembolization
3051074|NCT02220088|Experimental|NON-TACE|treatment with other than TACE
3051075|NCT02220075||spontaneous group|maintain spontaneous breathing during the operation, and recording tidal volume, ET CO2, respiratory rate, peak airway pressure, SpO2
3051076|NCT02220075||controlled group|controlled ventilation(tidal volume 8ml/kg, ET CO2 35~40mmHg) during the operation, recording peak airway pressure, SpO2
3051077|NCT02220062|Active Comparator|EUS-CPN group|Group that be performed by Endoscopic ultrasound guided bilateral celiac plexus neurolysis
3051078|NCT02220062|Experimental|EUS-CGN group|Group that be performed by Endoscopic ultrasound guided celiac ganglia neurolysis
3051079|NCT02220049|Experimental|Velcade|Dose level Dose(mg/m²) d1-5, d8-12, d15-19 Cohort -2 Velcade 0.3 mg/m² Cohort -1 Velcade 0.4 mg/m² Cohort 1 Velcade 0.5 mg/m² Cohort 2 Velcade 0.6 mg/m² Cohort 3 Velcade 0.7 mg/m² Cohort 4 Velcade 0.8 mg/m² Cohort 5 Velcade 0.9 mg/m² Cohort 6 Velcade 1.0 mg/m² Cohort 7 Velcade 1.1 mg/m²
3051080|NCT02220036|Active Comparator|Magnesium Oxide|magnesium tablets, 250 milligram magnesium, 12 weeks, every day 1 tablet
3051081|NCT02220036|Placebo Comparator|Placebo|Placebo tablets, the same in color, odor and appearance with magnesium tablets, 12 weeks, one tablet every day
3051082|NCT02220023|Experimental|Nitric Oxide|40 ppm, one time administration, inhaled.
3051083|NCT02220010|Experimental|Pancreatic stent|If POPF grade B or C is detected on post operative day 3 or more, a pancreatic stent is endoscopically positioned in the pancreatic duct.
3051084|NCT02220010|No Intervention|Drain only|If POPF grade B or C is detected on post operative day 3 or more, only the per-operatively placed drain is used as treatment
3051085|NCT02219997|Experimental|ACRYSOF IQ IOL|ACRYSOF® IQ IOL with or without clear clip-on glasses worn for 3 hours
3051086|NCT02219997|Active Comparator|Clear IOL|Clear IOL with or without blue light filter clip-on glasses and clear clip-on glasses, worn in a cross-over fashion, as randomized, for 4 hours total
3051087|NCT02219984||patients anticoagulated|
3051088|NCT02219971|Experimental|Kukoamine B Mesilate 0.005mg/kg|Pre-test,open study: Kukoamine B Mesilate 0.005mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
3051089|NCT02219971|Experimental|Kukoamine B Mesilate 0.02mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.02mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
3051090|NCT02219971|Experimental|Kukoamine B Mesilate 0.04mg/kg +Placebo|"Dose Escalation: Kukoamine B Mesilate 0.04mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
3051091|NCT02219971|Experimental|Kukoamine B Mesilate 0.08mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.08mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
3051092|NCT02219971|Experimental|Kukoamine B Mesilate 0.12mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.12mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
3051093|NCT02219971|Experimental|Kukoamine B Mesilate 0.24mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.24mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
3051094|NCT02219971|Experimental|Kukoamine B Mesilate 0.48mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.48mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
3051095|NCT02219958||RAMP-HT and Non-RAMP-HT|
3051096|NCT02219945|Experimental|Group 1 - 20 PTB patients aged >18yrs|Group 1 - 20 TB patients aged > 18 yrs 5 min exhaled breath sampling with nose clamp
3051097|NCT02219945|Experimental|Group 2 - 20 TB suspects > 18 yrs|Group 2 - 20 non-TB patients > 18 yrs (screened for TB - but appear to test negative for TB, and diagnosed with other conditions including bronchiectasis, etc) 5 min exhaled breath sampling with nose clamp
3051098|NCT02219945|Experimental|group 3 - 20 lung patients, non-TB|Group 3 - 20 patients with a lung disease - no TB suspects (recruited from Lung Clinics in Yogyakarta; lung cancer, COPD, etc) 5 min exhaled breath sampling with nose clamp
3051099|NCT02219945|Experimental|Group 4 - 20 healthy controls|Group 4 - 20 apparently healthy matched controls 5 min exhaled breath sampling with nose clamp
3051100|NCT02219945|Experimental|Group 5 - 7 newly diagnosedMDR PTB pts|Group 5 - 7 newly diagnosed MDRTB patients enrolled before start of treatment, to be followed 8 months, until after end of treatment 5 min exhaled breath sampling with nose clamp
3051101|NCT02219945|Experimental|group 6 - cohort of TB suspects|300 more individuals, suspected to have TB - final diagnosis by standard procedures plus sputum culture plus follow-up for >2 years 5 min exhaled breath sampling with nose clamp
3051102|NCT02219932|Experimental|Fampridine 10 mg BID|Prolonged-release fampridine 10 mg twice daily (BID) for up to 24 weeks
3051103|NCT02219932|Placebo Comparator|Placebo|Matched placebo 10 mg BID for up to 24 weeks
3051104|NCT02219919|Experimental|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
3051105|NCT02219919|Active Comparator|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
3051106|NCT02219906|Placebo Comparator|Placebo|Placebo capsule given three times daily X 3 weeks
3051107|NCT02219906|Experimental|Resveratrol|Resveratrol 1 gram three times daily X 3 weeks
3051108|NCT02219893|Experimental|MOC31PE Immunotoxin|Drug to be instilled on day 1 after cytoreductive surgery and HIPEC.
3051163|NCT02219516|Experimental|Cohort 2: Moderate renal impairment|RDEA3170 15 mg once daily fasted
3051109|NCT02219880|Placebo Comparator|Placebo|Inert tablets matched for colour, size and consistency to active arm treatment. Both treatment arm tablets will match in appearance, and neither participants nor the trial clinicians will know what they are taking.
3051110|NCT02219880|Experimental|Kava - standardised 240mg kavalactones|Standardised 240mg kavalactones per day - fixed dose regime of two tablets of kava twice per day
3051111|NCT02219867|Experimental|Ketamine|Active Comparator
3051112|NCT02219854|Experimental|Laparoscopic gastrectomy|Laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
3051113|NCT02219854|Active Comparator|Open gastrectomy|Open distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
3051114|NCT02219841||No intervention group|Receive general life-style advice and information on heart healthy diet Undergo catheter ablation for AFib
3051115|NCT02219841||Life-style intervention|patients will receive personilized low-calorie diet menu and undergo supervised exercise in the cardiac rehabilitation facility for 3 months before ablation with an aim of loosing >10% of body weight. They will continue diet and exercise for 1 year following ablation procedure Will receive catheter ablation for AFib
3051116|NCT02219828|Placebo Comparator|Placebo|placebo sc
3051117|NCT02219828|Active Comparator|Anakinra|Anakinra 2mg/Kg up to 100mg (maximum dose)
3051118|NCT02219815|No Intervention|Standard Care|Patients in the standard care group will receive care as is currently delivered to patients awaiting cardiac surgery at each site. At present, patients are advised to rest and participate in very light intensity physical activity while awaiting surgery. At 1-2 weeks prior to their scheduled surgical date, the patient attends a single three hour cardiac pre-assessment with a nurse practitioner and cardiac anesthesiologist. In addition, a cardiac nurse counsels each patient on healthy behaviors (e.g. smoking cessation, diet, exercise).
3051119|NCT02219815|Experimental|Prehab Intervention|Patients in the Prehab group will receive, in addition to the standard of care, an eight-week comprehensive exercise therapy and education program at a community-based CR facility. Patients will be asked to complete at least two sessions of supervised, structured exercise class plus have the option to attend one additional exercise class per week for eight-weeks, with progression to a moderate to high-intensity interval program based on the supervised assessment of the patient's capabilities. Prehab participants will also attend four education sessions on topics such as risk factor reduction, medication use, cardiovascular physiology, smoking cessation, healthy eating, exercise, and stress management and promotion of self-managed care.
3051120|NCT02219802|Active Comparator|Drug-eluting stent|Treatment of infarct related laesion with a drug-eluting stent
3051121|NCT02219802|Experimental|Drug-coated balloon|After treatment of the infarct related artery with a drug-coated ballon, an additional BMS is advised to be used in case of residual stenosis > 50% or coronary artery dissection type > B.
3051122|NCT02219789|Experimental|Treatment (alisertib, fulvestrant)|Patients receive fulvestrant IM on day 1 (days 1 and 15 of course 1 only) and alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3051123|NCT02219776|Active Comparator|Chlorhexidine Standard of Care Arm|Use of Chlorhexidine to cleanse pre-operative surgery site
3051124|NCT02219776|Experimental|Benzoyl Peroxide Experimental Arm|Use of Chlorhexidine scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient
3051125|NCT02219750|Active Comparator|Preprandial premix therapy|switch twice-daily insulin Preprandial premix therapy mean that transition of advance insulin based on the basal insulin daily total dose at study entry divided into two equal dose of preprandial NovoMix 30. Patient discontinued all pre-study oral antidiabetic drug(OAD), including sulfonylureas, glinides, Thiazolidinedione(TZD) and Dipeptidyl peptidase-4(DPP-4) inhibitor but left metformin alone
3051126|NCT02219750|Active Comparator|Basal-plus insulin|switch twice-daily insulin Basal-plus insulin consisted of continued previous basal insulin and add-on once-daily insulin aspart(NovoRapid) before breakfast. The starting dose of insulin aspart was 4 unit(U) before breakfast and continued under previous basal insulin dose.
3051127|NCT02219737|Experimental|Treatment (ibrutinib, R-ICE)|Patients receive ibrutinib PO QD on days 1-21, rituximab IV on day 1, ifosfamide IV on day 3, carboplatin IVPB on day 3, and etoposide IVPB on days 2-4. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3051128|NCT02219724|Experimental|MOXR0916: Dose Escalation Stage|Participants in different cohorts (according to MOXR0916 dose received) will receive escalating doses of MOXR0916 to determine the MTD or maximum administered dose (MAD) for 21 to 42 days.
3051129|NCT02219724|Experimental|MOXR0916: Expansion Stage|Participants in different cohorts (according to different cancer types, prior therapy and mandatory procedures on study) will receive MOXR0916 at the highest dose level that has already been deemed to be tolerable in the dose escalation stage until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (approximately up to 3 years).
3051130|NCT02219711|Experimental|MGCD516|MGCD516 oral capsule, administered in escalating doses in Phase 1, beginning with daily dosing and exploring other regimens as necessary, in 21 or 28 days cycles
3051131|NCT02219698|Experimental|Symptomatic treatment|
3051132|NCT02219685|Experimental|LDV/SOF|Participants will receive LDV/SOF FDC for 12 weeks.
3051133|NCT02219685|Placebo Comparator|Placebo|Participants will receive LDV/SOF placebo for 12 weeks.
3051134|NCT02219685|Experimental|Open-Label Treatment Phase|Following Posttreatment Week 4, participants in the placebo group will be offered open-label treatment with LDV/SOF FDC for 12 weeks.
3051135|NCT02219672|Experimental|Triptolide group|cART for 6 months, and the experimental group will take Triplitode 2 tabs tid po for another 12 months
3051136|NCT02219672|Active Comparator|Comparator group|combined antiretroviral therapy (cART): TDF+3TC+LPV/r+RAL for 18 months
3051158|NCT02219542|Placebo Comparator|a standard general anesthesia|a standard general anesthesia and with transversus abdominis plane block 20 ml 0.9% sodium chloride
3051159|NCT02219542|Experimental|transversus abdominis plane block|a standard general anesthesia with transversus abdominis plane block 20 mL 0.25% ropivacaine
3051160|NCT02219529|Experimental|MCE|patients were assigned to swallow MCE first, followed by the gastroscopy
3051161|NCT02219529|Active Comparator|Standard gastroscopy|patients were assigned to swallow MCE first, followed by the gastroscopy
3051137|NCT02219659|Active Comparator|Sedation protocol with interruption|Continuous infusion of fentanyl and midazolam is started per protocol. Both drugs are titrated to target pain score (0 to 3) using Critical Care Pain Observation Tool (CPOT) and target sedation score (0 to -3) using Richmond Agitation Sedation Scale (RASS). Every morning both drugs are stopped (Daily Interruption) and patient's wakefulness is assessed per protocol. If patient's pain and RASS score stays withint the target, both drugs are kept off. If patient shows any signs and symptoms of pain or agitation (described in the study protocol), both drugs are restarted at a half dose of the previous dose and titrated to target pain and RASS score. Every morning both drugs are stopped and when patient is awake and met the SBT safety screen, 120-min CPAP trial is performed.
3051138|NCT02219659|Active Comparator|Sedation protocol without Interruption|Continuous infusion of fentanyl and midazolam is started per protocol. Both drugs are titrated to target pain score (0 to 3) using Critical Care Pain Observation Tool (CPOT) and target sedation score (0 to -3) using Richmond Agitation Sedation Scale (RASS). Daily interruption of fentanyl and midazolam is not performed. Every morning 120-min CPAP trial is performed as long as the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen.
3051139|NCT02219659|Active Comparator|Fentanyl push first|This arm attempts to manage patient's pain and agitation with anagesia first. Fentanyl IV pushes are administered every 5 minutes as needed to target pain and sedation score, up to 4 doses per hour. Every morning 120-min CPAP trial is performed as long as patient's RASS score is 0 to -2 and patient passes the SBT safety screen. If fentanyl IV push doses alone cannot manage patient's pain and agitation (could not reach the target score), notify the study team. Fentanyl infusion is started and titrated to target pain and sedation score up to 6 hours. If fentanyl infusion is titrated up twice consecutively and target pain and sedation score are not met, notify the study team. Propofol infusion is started and tritrated to target RASS score up to 6 hours.
3051140|NCT02219646|Experimental|Vardenafil|The study protocol consists of a Screening/Enrolment Phase lasting up to 4 weeks, a Treatment Phase of 24 weeks, and Follow-up/Observation Treatment-free Phase of 24 weeks after the Treatment Phase. During treatment phase, patients enrolled in the Study Group were treated with vardenafil 10 mg twice/daily.
3051141|NCT02219646|Placebo Comparator|Control|The study protocol consists of a Screening/Enrolment Phase lasting up to 4 weeks, a Treatment Phase of 24 weeks, and Follow-up/Observation Treatment-free Phase of 24 weeks after the Treatment Phase. During treatment phase, patients enrolled in the Control Group were treated with tablets twice/daily identical to the Study Group, but containing placebo.
3051142|NCT02219633|Experimental|LEO 39652 cream|Topical application
3051143|NCT02219633|Placebo Comparator|LEO 39652 cream vehicle|Topical application
3051144|NCT02219620|Experimental|Music, Imagery, Movement intervention|Music, Imagery, Movement intervention: psychosocial intervention incorporating Music, Imagery and Movement
3051145|NCT02219620|Active Comparator|Social Control|social control/interaction group
3051146|NCT02219607||epidural|
3051147|NCT02219607||general anesthesia|
3051148|NCT02219594|Experimental|Gemstone CT|Gemstone CT ：Discovery CT750 HD（high definition） ，GE（General Electric Co.） Healthcare, Milwaukee； CT image for patient with suspected in-stent restenosis which Gemstone CT or 320-detector row spiral CT was assigned randomly to patient
3051149|NCT02219594|Active Comparator|320-detector row spiral CT|320-detector row spiral CT：Aquilion One, Toshiba, Nasu, Japan. CT image for patient with suspected in-stent restenosis which Gemstone CT or 320-detector row spiral CT was assigned randomly to patient .
3051150|NCT02219581|Placebo Comparator|Placebo|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of placebo intravenously in addition to a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty. The first dose of placebo will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
3051151|NCT02219581|Experimental|Dexamethasone 10 mg|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of 10 mg dexamethasone. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting. Additionally, subjects will also receive a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty.
3051152|NCT02219581|Experimental|Dexamethasone 20 mg|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of 20 mg dexamethasone. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting. Additionally, subjects will also receive a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty.
3051153|NCT02219568|Experimental|obscure gastrointestinal bleeding|Those patients who developed obscure gastrointestinal bleeding either overt or occult bleeding who will then undergo video capsule endoscopy and CT enterography.
3051154|NCT02219555|Placebo Comparator|Randomized Placebo/salt water injection|1ml of 0.9% NaCl and 2 ml of 1% lidocaine placebo/salt water injection at the time of enrollment into the study. If patient had an injection but continues to have ongoing symptoms, they and their doctor will be free to choose any treatment for carpal tunnel syndrome, including either a second injection which would be the active drug, surgery or any other choice that they and their doctor agree to
3051155|NCT02219555|Active Comparator|Randomized Active medication injection|a mixture of one ml of triamcinolone acetonide, 240 mg/ml, and 2 ml of 1% lidocaine, active medication injection. If patient had an injection but continues to have ongoing symptoms, they and their doctor will be free to choose any treatment for carpal tunnel syndrome, including either a second injection which would be the active drug, surgery or any other choice that they and their doctor agree to
3051156|NCT02219555|No Intervention|None Randomized observational medication injection|Observational: Active medication injection Patients without randomization where any type of injection as prescribed by the physician is accepted If patient had an injection but continues to have ongoing symptoms, they and their doctor will be free to choose any treatment for carpal tunnel syndrome, including either a second injection, surgery or any other choice that they and their doctor agree to
3051157|NCT02219555|No Intervention|Observational: Surgical|"Patients who are going to have carpel tunnel release surgery are eligible for this arm.~If patient has ongoing symptoms, they and their doctor will be free to choose any treatment for carpal tunnel syndrome."
3051162|NCT02219516|Experimental|Cohort 1: Mild renal impairment|RDEA3170 15 mg once daily fasted
3051164|NCT02219516|Experimental|Cohort 3: Severe renal impairment|RDEA3170 15 mg once daily fasted
3051165|NCT02219516|Experimental|Cohort 4: Control subjects with normal renal function|RDEA3170 15 mg once daily fasted
3051166|NCT02219503|Experimental|Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir|Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 12 weeks
3051167|NCT02219490|Experimental|ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV)|ABT-450/r/ABT-267 and ABT-333 coadministered with or without ribavirin (RBV) for 12 or 24 weeks
3051168|NCT02219477|Experimental|Group 1: GT1B|ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) + ribavirin (RBV) for 12 weeks in hepatitis C virus (HCV) genotype (GT) 1b-infected participants
3051169|NCT02219477|Experimental|Group 2: GT1 Non-B|ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + dasabuvir 250 mg BID + RBV for 24 weeks in HCV GT1non-b (including GT1a)-infected participants
3051170|NCT02219477|Experimental|Group 3: GT4|ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + RBV for 24 weeks in HCV GT4-infected participants
3051171|NCT02219464|Active Comparator|Nasopharyngeal catheter|Patients in this arm will receive oxygen supplementation through the use of a Nasopharyngeal catheter. Sedation will be standardized to ensure consistency between groups.
3051172|NCT02219464|Other|Nasal Cannula|Patients will receive oxygen supplementation through the use of a traditional nasal cannula. Sedation will be standardized to ensure consistency between groups.
3051173|NCT02219451|Experimental|exercise training|We studied twenty-six chronic heart failure outpatients and they were assigned to 2 groups: Untrained (n=13) and trained (n=13).
3051174|NCT02219438|Experimental|Bolus|ropivacaine 0.2% administration as repeated, scheduled (one/h) bolus doses (8 mL) x8 h
3051175|NCT02219438|Active Comparator|basal|ropivacaine 0.2% administration as a continuous basal infusion (8 mL/h) x8 h
3051176|NCT02219425|Other|endometrial biopsy|
3051177|NCT02219412|Experimental|ticagrelor mono-therapy|Take ticagrelor 90 mg Bid for 2 weeks.
3051178|NCT02219412|Active Comparator|aspirin/ticagrelor dual-therapy|Take ticagrelor 90mg Bid plus Aspirin 100mg Qd and treated for 2 weeks.
3051179|NCT02219399|Experimental|300 mg DHA|300 mg DHA
3051180|NCT02219399|Placebo Comparator|Placebo|olive oil or high oleic acid sunflower oil placebo
3051181|NCT02219399|Experimental|600 mg DHA|600 mg DHA
3051182|NCT02219386|Active Comparator|Deep dry needling|The group of DDN receive this treatment and stretch
3051183|NCT02219386|Other|muscle stretch|The stretch applied was as described by Simons et al. (Simons et al., 1999). During the stretch the physiotherapist took up the slack, avoiding pain elicitation, maintaining the tension for four seconds and releasing the tension for eight seconds; this cycle was repeated three times
3051184|NCT02219373|Experimental|Gabapentin|"Gabapentin will be given in a liquid form, concentration 50mg/ml. Dose will be titrated as follows:~On Days 1-4 take:~20-30 kg 1.5 ml Qpm 30-45 kg 3 ml Qpm 45-70 kg 4.5 ml Qpm >70 kg 6 ml Qpm~On Days 5-8 take:~20-30 kg 1 ml Qam and 2 ml Qpm 30-45 kg 2 ml Qam and 4 ml Qpm 45-70 kg 3 ml Qam and 6 ml Qpm >70 kg 4 ml Qam and 8 ml Qpm~On Days 9-12 take:~20-30 kg 1.5 ml Qam and 3 ml Qpm 30-45 kg 3 ml Qam and 6 ml Qpm 45-70 kg 4.5 ml Qam and 9 ml Qpm >70 kg 6 ml Qam and 12 ml Qpm~On Day 13 take:~20-30 kg 2 ml Qam and 4 ml Qpm 30-45 kg 4 ml Qam and 8 ml Qpm 45-70 kg 6 ml Qam and 12 ml Qpm >70 kg 8 ml Qam and 16 ml Qpm"
3051185|NCT02219373|Experimental|Oxcarbazepine|"Oxcarbazepine will be given in liquid form, concentration is 60 mg/ ml.~Dose will be titrated as follows:~On Days 1-4 take:~20-30 kg 0.6 ml Qpm 30-45 kg 1.3 ml Qpm 45-70 kg 1.9 ml Qpm >70 kg 2.5 ml Qpm~On Days 5-8 take:~20-30 kg 0.4 ml Qam and 0.8 ml Qpm 30-45 kg 0.8 ml Qam and 1.7 ml Qpm 45-70 kg 1.3 ml Qam and 2.5 ml Qpm >70 kg 1.7 ml Qam and 3.3 ml Qpm~On Days 9-12 take:~20-30 kg 0.6 ml Qam and 1.3 ml Qpm 30-45 kg 1.3 ml Qam and 2.5 ml Qpm 45-70 kg 1.9 ml Qam and 3.8 ml Qpm >70 kg 2.5 ml Qam and 5 ml Qpm~On Day 13 take:~20-30 kg 0.8 ml Qam and 1.7 ml Qpm 30-45 kg 1.7 ml Qam and 3.3 ml Qpm 45-70 kg 2.5 ml Qam and 5 ml Qpm >70 kg 3.3 ml Qam and 6.7 ml Qpm"
3051186|NCT02219373|Placebo Comparator|Placebo|Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
3051187|NCT02219347|Other|DMARD cessation|All patients recruited to the study who have a Disease Activity in 28 Joints C-Reactive Protein (DAS28-CRP) score of < 2.4 and who do not have power Doppler synovitis on a 7-joint musculoskeletal ultrasound scan will stop their DMARD therapy. These patients will then be followed-up for a period of 6 months or until flare of their arthritis activity, whichever is sooner.
3051188|NCT02219334|Experimental|NoseFrida|If randomized to the NoseFrida group, the NoseFrida/filters will be given along with educational instruction of its use to the parents of patients admitted with bronchiolitis. The NoseFrida will be used by the parent to suction the nares of their infants/toddlers.
3051189|NCT02219334|No Intervention|NeoSucker|The NeoSucker (used for nasal suctioning) is part of the current standard of care for patients with bronchiolitis. The NeoSucker is used for removing nasal secretions by a nurse or respiratory therapist. The NeoSucker is a plastic tube which is used to suction the secretions. The bedside nurse will continue to use the NeoSucker as needed. NoseFrida will not be used for this sub group of patients.
3051190|NCT02219321|Active Comparator|Lidocaine infusion|A continuous intravenous infusion of lidocaine
3051191|NCT02219321|Placebo Comparator|Saline infusion|A continuous intravenous infusion of saline
3051192|NCT02219308|Experimental|Paracervical Block (PCB)|"Subject receives 2 mL 1% buffered Lidocaine anesthetic at anterior lip of cervix, where tenaculum will be placed.~Subject then receives paracervical block of 18 mL 1% buffered Lidocaine. Provider then places IUD."
3051193|NCT02219308|Sham Comparator|No Paracervical Block (Sham PCB)|"Subject receives 2 mL 1% buffered Lidocaine anesthetic at anterior lip of cervix, where tenaculum will be placed.~Subject then receives Sham paracervical block with capped needle. Provider then places IUD."
3051194|NCT02219295|Experimental|sweet -block|application of different sugars, artificial sweeteners and sweet-taste antagonists in a single dose in 300 ml tap water every week up to 7 times and collection of blood samples over 3 hours
3051195|NCT02219295|Experimental|bitter block|application of purified bitter tasting ingredients of vegetables and hop in 300 ml tap water , collection of blood samples for 3h (-15,0,15,30,60,120,180 min)
3051196|NCT02219295|Experimental|umami-block|"application of glutamate and glutamate +IMP~same procedure as above"
3051227|NCT02219074|Experimental|Sebacia microparticle and laser treatment|
3051197|NCT02219295|Other|gastroscopy|gastroscopy with and without oral intervention with artificial sweetener saccharin to take tissue samples from the upper bowel for the investigation of taste receptor cells in the upper bowel in human beings
3051198|NCT02219282|Active Comparator|Group Dentulous|Laryngeal Mask Unique insertion
3051199|NCT02219282|Experimental|Group Edentulous|Laryngeal Mask Unique insertion
3051200|NCT02219269||Medically complex contraception users|Cohort includes women of reproductive age with diverse medical conditions (listed in inclusion criteria) who are referred to Family Planning felowship-trained physicians, seeking contraception counseling and administration.
3051201|NCT02219256|Experimental|Cohort 1: TAK-079 0.0003 mg/kg|TAK-079 0.0003 mg/kg, infusion, intravenously, once.
3051202|NCT02219256|Experimental|Cohort 2-9: TAK-079 TBD|TAK-079, infusion, intravenously or subcutaneously, once. Dose to be determined from data collected in previous IV or SC Cohort(s)
3051203|NCT02219256|Placebo Comparator|Placebo to TAK-079|Placebo to TAK-079, infusion, intravenously or subcutaneously, once.
3051204|NCT02219243|No Intervention|Waitlist Control|This is a 1-month waitlist control to be compared with the active online interpretation training interventions. This is a no intervention control group
3051205|NCT02219243|Experimental|Active Interpretation Training|Online Interpretation Training Condition 2 provides three sessions of a computerized training. Each session will last approximately 20-30 minutes, and participants will undergo 1 session each week.
3051206|NCT02219243|Experimental|Placebo Interpretation Training|Online Interpretation Training Condition 1 provides three sessions of a computerized training. Each session will last approximately 20-30 minutes, and participants will undergo 1 session each week.
3051207|NCT02219230|Experimental|Prosthetic knee|Subjects crossed over between interventions (three different prosthetic knees). Knee conditions include 1) Active knee (Ossur Power Knee II); 2) Adaptive knee (Ossur Rheo); and 3) Passive knee (Various manufacturers)
3051208|NCT02219217|Experimental|No arms|All participants will be administered Tivicay® (dolutegravir 50 mg once daily) for 10 days, then will undergo a nine-day wash out period and then take Stribild® (245 mg of tenofovir disoproxil, 200 mg of emtricitabine, 150 mg of elvitegravir and 150 mg of cobicistat) for 10 days.
3051209|NCT02219204|Active Comparator|Acupuncture treatment|"This will be performed twice weekly for 30 days. There will be 8 sessions of acupuncture treatments in total.~The needles to be use around the eyes will have the dimensions of 0.25 (diameter) x 13mm (length), while 0.25 x 25mm needles will be used behind the ear (feng chi) and 0.30 X 25mm needles on the upper and lower limbs. These needles will remain in the points for 20 minutes. The depth of penetration will be about 1-2 mm."
3051210|NCT02219204|Active Comparator|Herbal treatment|"This formulation is called qi ju gan lu yin or Lycium berry, a chrysanthemum beverage. This is a modified version of qi ju di huang wan published previously. The senior TCM collaborator, Prof Wei QP has made this modification in order to treat the dry eye patients with lung-kidney yin deficiency."
3051211|NCT02219204|No Intervention|Eye drops|
3051212|NCT02219191|Experimental|puerarin tablet 50 mg|Patients were orally administrated with 50 mg puerarin tablet three times a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
3051213|NCT02219191|Active Comparator|Atorvastatin tablet 20 mg|Patients were orally administrated with 20 mg Atorvastatin tablet once a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
3051214|NCT02219178|Experimental|RsqVD|Oral lenalidomide 25mg days 1 - 14 of 21 day schedule Subcutaneous bortezomib 1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule Oral dexamethasone 20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
3051215|NCT02219165|Experimental|IVIG 2 g/kg|Intravenous human immunoglobulin Day 1: As soon as there is suspicion of TSS, randomisation will be performed in order for the study treatment to be administered within the 12h following PICU admission (or following the manifestation of the first signs of shock). Concurrently, the TSS antibiotherapy following Surviving Sepsis Campaign recommendations is given
3051216|NCT02219165|Placebo Comparator|Albumin 4%|Same study scheduling as the first arm. Only the study treatment given is different (albumin instead of IGIV)
3051217|NCT02219152|Experimental|tranexamic acid|tranexamic acid will be administrated using the bronchoscope
3051218|NCT02219152|Placebo Comparator|saline|the saline will be administrated using an infusion during the biopsy.
3051219|NCT02219139|Other|ESTA abutment Roxolid|"One study abutment per patient will be placed. After healing for 6 to 7 weeks, patients will be asked to stop oral hygiene at the study site for 2 weeks.~Sulcus fluid and plaque samples will be taken at the abutment site at several visits before and during abdication of oral hygiene.~The study finishes with biopsy visit. Afterwards a regular abutment will be placed and the patients will be treated according to the standard protocol of the clinic to obtain their final restoration."
3051220|NCT02219126|Experimental|Homogenized and pasteurized milk|Milk that has undergone homogenization ans pasteurization treatment
3051221|NCT02219126|Experimental|Nonhomogenized and nonpasteurized milk|Unhomogenized and unpasteurized milk (raw milk)
3051222|NCT02219113|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected intraarticularly into knee joint.
3051223|NCT02219100|Experimental|Home administration of mifepristone|This arm consisted of women who chose home administration of 200 mg mifepristone.
3051224|NCT02219100|No Intervention|Clinic administration of mifepristone|This arm consisted of women who underwent clinic administration of 200 mg mifepristone.
3051225|NCT02219087|Experimental|Liposomal Bupivacaine|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Liposomal bupivacaine (diluted to 60mL): 20mL into the posterior pocket, 20mL into the lateral, and 20mL into the medial, including all deep and superficial tissues of these areas.
3051226|NCT02219087|Active Comparator|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
3051235|NCT02219022|Active Comparator|Control group|Patient remain with their usual clinical treatment.
3051236|NCT02219022|Experimental|Experimental group|"Patients in experimental group participated in a 12-week progressive resistance training using a maximum repetition exercise in which patients performed 1 Maximum Repetition with the maximum bearable weight. Once the 1 Maximum Repetitionwas determined, training was divided into the following regimen: 2 series of 8 repetitions, the first with 50% and the second with 70% of 1 Maximum Repetition.~The exercises were knee extension and flexion and hip abduction and adduction, elbow extension and flexion, wrist extension and flexion and shoulder abduction and adduction and spine extension and flexion all performed in machines. The 1 Maximum Repetition load was reevaluated every 6 weeks.~Patient remain with their usual clinical treatment."
3051237|NCT02219009|Experimental|MIND1 System|
3051238|NCT02218996||Psychosocial treatment|Children and adolescents with anxiety disorders
3051239|NCT02218983|Experimental|Limited transthoracic echocardiogram (LTTE)|LTTE (SonoSite Ultrasound), which will be performed every 10 - 30 minutes, after each fluid challenge or transfusion, until two consecutive equivalent measurements are reached without fluid challenge or transfusion
3051240|NCT02218983|Active Comparator|Usual care|measurements on :blood pressure, heart rate, urine output, lactate, lactate clearance (after 6 hrs), base deficit, creatinine
3051241|NCT02218970|Experimental|strength training|Strength training for leg muscles during10 weeks, 3 times a week: hack squat and plantar flexion, standing upright in a hack squat machine and lying down in a calf rise machine. Exercises will be carried out at 85% of 1-RM intensity under supervision at the institution where participants are having their SUD treatment.
3051242|NCT02218970|Other|control|patients treated for substance-related disorder but not participating in strength training intervention (no training control group)
3051243|NCT02218957|Active Comparator|Standard RYGB|Standard RYGB
3051244|NCT02218957|Experimental|Extended Pouch RYGB|Restrictive/extended pouch RYGB
3051245|NCT02218944|Experimental|Response Inhibition Training: A|In the experimental condition, 20% of responses are no-go, with the majority of no-go responses paired with smoking images.
3051246|NCT02218944|Active Comparator|Response Inhibition Training: B|In the active comparator condition, 20% of responses are no-go trials, with no-go responses spread evenly across the various images.
3051247|NCT02218944|Placebo Comparator|Benign|A benign condition has also been added to control for the possibility that response inhibition training, regardless of target, increases behavioral control and hence decreases relapse likelihood. The benign condition has 50% no-go trials, with no-go responses spread evenly across images.
3051248|NCT02218931|Experimental|Targeted ESTEEM diet|"The ESTEEM dietary pattern is similar to that in a Mediterranean diet associated with reduced risk of pre-eclampsia.~The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants"
3051249|NCT02218931|No Intervention|Current clinical practice|The control group will be provided the usual antenatal dietary advice. This includes advice on healthy and physical activity in women with normal weight and obesity and overweight. Folic acid and vit D supplementation are provided as per national recommendations. Participants will provide outcome data at point of delivery and food frequency questionnaire at baseline and 36 weeks or delivery depending on which is sooner.
3051250|NCT02218931|Other|Non-randomised cohort|Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
3051251|NCT02218918|Active Comparator|Supervised Treadmill Walk Training|Based on 6 minute walk distance, treadmill speed initiated and progression on basis new 6 minute walk distance every 2 weeks
3051252|NCT02218918|Experimental|Supervised Ground walk training|Ground walk training progressed on the basis of 6 minute walk distance (70 - 90%), Weekly 3 days and for 6 weeks
3051253|NCT02218905|Experimental|Sit to stand test|One minute sit to stand in 40 inches armless chair. Fatigue, breathlessness and failure to maintain tempo will lead to decease the test
3051254|NCT02218892||Juvenil Idiopathic Arthritis|The group consists of children age 7-14 with an diagnosis of active Juvenile Idiopathic Arthritis.
3051255|NCT02218879||Patients with relapsing MS|
3051256|NCT02218866||Group 1|All participants will be examined by a neurologist to test sensation, reflexes, and strength and complete a few questionnaires. Tests will be performed to measure nerve function and small punch skin biopsies will be taken to assess nerve fiber density. Blood and urine tests will measure various markers of interest. Participants will be seen before and after their bariatric surgery.
3051257|NCT02218866||Group 2|"In addition to the procedures described for Group 1, participants in Group 2 will have the following procedures:~During bariatric surgery, a small biopsy from the liver and abdominal fat will be taken to examine how fat is processed within the body.~At the first visit, after a skin biopsy is taken, a small capsaicin patch will be placed on the lower thigh. The patch will remain in place for 48 hours and will cause the nerves in the immediate area to pull back from the skin. A biopsy will be taken from the patch area 48 hours, 1 month, and 3 months after the initial biopsy. This procedure will be repeated after surgery.~MRIs may be performed before and after bariatic surgery.~Participants may be asked to complete additional tests to evaluate nerve function"
3051258|NCT02218866||Group 3|Group 3 will comprise of individuals who are not overweight. Participants in this group will undergo a similar evaluation to Group 2.
3051259|NCT02218853||Bipolar I disorder, with psychosis|Individuals diagnosed with Bipolar I disorder, with psychotic features
3051260|NCT02218853||Bipolar I disorder, without psychosis|Individuals diagnosed with Bipolar I disorder, without psychotic features
3051261|NCT02218853||Healthy Controls|Must have no personal history of any psychotic or mood disorder, or a family history of psychotic or recurrent mood disorder among their first-degree relatives
3051262|NCT02218840||Behavioral|Evaluation of cigar smoking topography
3051263|NCT02218827|Experimental|dry eye patients|Loteprednol Etabonate (FML) topical treatment 1 drop 4 times daily for 1 month then Loteprednol Etabonate (FML) 1 drop 2 times daily for 1 month
3051305|NCT02218580|Experimental|Massage therapy & standard care|"Massage therapy will be provided by caregiver for 15 minutes at bedtime at home, every night, for a 2-week period.~Standard care will include medications routinely prescribed in the treatment of JIA, physiotherapy and occupational therapy exercises, splints, warmth application and acetaminophen."
3051432|NCT02217904|Experimental|MK-8591 1 mg|Single oral dose of MK-8591 1 mg
3051264|NCT02218814|Experimental|Adductor Canal Block:|Adductor Canal Nerve Block: The patient is placed in a supine position with the extremity to be blocked slightly externally rotated. On the medial thigh, at the midpoint between the inguinal crease and the medial condyle, 13-6-MHz linear ultrasound transducer (SonoSite HFL38x; Washington, US) is placed in a transverse orientation to visualize the femoral artery in short axis deep to the sartorius muscle. Sterile field and patient sedation achieved. A 21-gauge,100 mm, short-bevel needle (Stimuplex; B Braun) is inserted under ultrasound guidance in in-plane technique to position the needle tip anterolateral to the artery and just deep to the posterior fascia of the sartorius muscle. Once in position, 30 mL of Bupivacaine (100 mg) is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration. After completion of the procedure, a sterile dressing is placed over the needle insertion site.
3051265|NCT02218814|Active Comparator|Femoral Nerve Block|Femoral Nerve Block. The procedure is conducted with the patient in a supine position with a 13-6 MHz linear ultrasound transducer (SonoSite HFL38x; Washington, US) applied to the skin at the level of the inguinal crease. The femoral artery, fascia iliac, and femoral nerve are visualized. Sterile field and patient sedation achieved. A 22-gauge, 50-mm, short-bevel stimulating needle (Stimuplex; B Braun, Bethlehem, Pennsylvania) connected to twitch monitor B/Braun Stimuplex DIG RC is inserted under ultrasound guidance using an in-plane technique from lateral to medial until a quadriceps motor response is elicited at a current between 0.5 and 0.2 mA with a pulse width of 0.1millisecond from a twitch monitor . After negative aspiration, 30 mL of Bupivacaine (100 mg) is deposited adjacent to the femoral nerve and deep to the fascia iliac, with intermittent aspiration. After completion of the procedure, a sterile dressing is placed over the needle insertion site.
3051266|NCT02218801||Colorectal adenocarcinoma liver metastasis|Unresectable, borderline or initially unresectable liver metastasis from a colorectal cancer
3051267|NCT02218775|Experimental|LY2456302|LY2456302 dosed orally at 10 mg daily for 2 weeks in healthy volunteers
3051268|NCT02218762|Experimental|Sequence 1|Subjects will receive FSC 100/50 mcg delivered via the Ddpi (Treatment A) and FSC 100/50 mcg delivered via the Rdpi (Treatment B) in the sequence of A-B-B-A in four treatment periods of 10 days each. Subjects will receive both active treatment and matching placebo at the same time from two separate devices twice daily. There will be no wash-out between treatment periods
3051269|NCT02218762|Experimental|Sequence 2|Subjects will receive FSC 100/50 mcg delivered via the Ddpi (Treatment A) and FSC 100/50 mcg delivered via the Rdpi (Treatment B) in the sequence of B-A-A-B in four treatment periods of 10 days each. Subjects will receive both active treatment and matching placebo at the same time from two separate devices twice daily. There will be no wash-out between treatment periods
3051270|NCT02218749|Experimental|Initially triaged to physiotherapist|Initially triaged to physiotherapist
3051271|NCT02218749|Active Comparator|Initially triaged to physician|Initially triaged to physician
3051272|NCT02218736|Experimental|CERC-501|Oral dosing of 10 mg CERC-501 (formerly known as LY2456302) administered daily for 8 weeks
3051273|NCT02218736|Placebo Comparator|Placebo|Oral daily administration of 10 mg placebo for 8 weeks
3051274|NCT02218723|Active Comparator|Sequence ABECD|Subject will be administered treatment in sequence ABECD. Where, A: a single dose of FF [100 microgram (mcg) per blister from 0.6% blend] delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3051275|NCT02218723|Active Comparator|Sequence BCADE|Subject will be administered treatment in sequence BCADE. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3051276|NCT02218723|Active Comparator|Sequence CDBEA|Subject will be administered treatment in sequence CDBEA. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3051277|NCT02218723|Active Comparator|Sequence DECAB|Subject will be administered treatment in sequence DECAB. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3051306|NCT02218580|Active Comparator|Standard care|Standard care will include medications routinely prescribed in the treatment of JIA, physiotherapy and occupational therapy exercises, splints, warmth application and acetaminophen.
3051307|NCT02218567|Other|Patients|
3051308|NCT02218567|Other|Caregivers|
3051309|NCT02218554|Experimental|Study Group|Subject has been diagnosed with BRONJ
3051310|NCT02218554|No Intervention|Control Group|Subject has not developed any signs or symptoms of BRONJ
3051433|NCT02217904|Experimental|MK-8591 2 mg|Single oral dose of MK-8591 2 mg
3051278|NCT02218723|Active Comparator|Sequence EADBC|Subject will be administered treatment in sequence EADBC. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3051279|NCT02218723|Active Comparator|Sequence DCEBA|Subject will be administered treatment in sequence DCEBA. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3051280|NCT02218723|Active Comparator|Sequence EDACB|Subject will be administered treatment in sequence EDACB. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3051281|NCT02218723|Active Comparator|Sequence AEBDC|Subject will be administered treatment in sequence AEBDC. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3051282|NCT02218723|Active Comparator|Sequence BACED|Subject will be administered treatment in sequence BACED. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3051283|NCT02218723|Active Comparator|Sequence CBDAE|Subject will be administered treatment in sequence CBDAE. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3051284|NCT02218710||Growth hormone deficiency|
3051285|NCT02218710||healthy controls|
3051286|NCT02218697|Experimental|Co-Ad Group|Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of Pneumovax™ 23 vaccine at Day 0 and 1 dose of placebo at Day 28.
3051287|NCT02218697|Experimental|Control Group|Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of placebo at Day 0 and 1 dose of Pneumovax™ 23 vaccine at Day 28.
3051288|NCT02218684|Experimental|Telmisartan + Lacidipine - low dose|
3051289|NCT02218684|Experimental|Telmisartan + Lacidipine - medium dose|
3051290|NCT02218684|Experimental|Telmisartan + Lacidipine - high dose|
3051291|NCT02218684|Placebo Comparator|Placebo|
3051292|NCT02218671|Experimental|WE 941 OD under deglutition|
3051293|NCT02218671|Experimental|WE 941 OD under non-deglutition|
3051294|NCT02218658|Experimental|WE 941 OD|
3051295|NCT02218658|Active Comparator|Brotizolam|
3051296|NCT02218645|Experimental|WE 941 OD|
3051297|NCT02218645|Active Comparator|Brotizolam|
3051298|NCT02218632|Active Comparator|lactose-free diet|lactose-free diet (standard therapy) vs. lactose-free diet plus temporary oral galactose supplements
3051299|NCT02218632|Active Comparator|lactose free diet|lactose-free diet (standard therapy)
3051300|NCT02218619|Experimental|Taurourodeoxycholic Acid (TUDCA)|TUDCA 1750 mg/day x 12 months
3051301|NCT02218619|Placebo Comparator|Sugar pill (placebo)|Placebo at same dose, frequency, and duration as experimental treatment
3051302|NCT02218606|Experimental|Abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID|Arm 1: Abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID
3051303|NCT02218606|Experimental|Cabazitaxel 25 mg/m2 IV + abiraterone acetate 1000 mg po daily|Arm 2: Cabazitaxel 25 mg/m2 IV + abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID
3051304|NCT02218593|Experimental|WREX orthosis|WREX Orthosis
3051311|NCT02218541|Other|abutment margin 0.5 mm subgingival|when fabricating an abutment to support the crown, the margin will be placed 0.5 mm below the gumline
3051434|NCT02217904|Experimental|MK-8591 10 mg|Single oral dose of MK-8591 10 mg
3051312|NCT02218541|Other|abutment margin 1.5 mm subgingival|when fabricating the abutment to support the crown, the margin will be placed 1.5 mm below the gumline
3051313|NCT02218528|Placebo Comparator|Starchy meal|No Plant-based ingredient added to a starchy meal
3051314|NCT02218528|Active Comparator|Low dose added to starchy meal|Plant-based ingredient in low dose added to starchy meal
3051315|NCT02218528|Placebo Comparator|Starchy meal and side dish|No Plant-based ingredient added to starchy meal and side dish
3051316|NCT02218528|Active Comparator|Low dose added to starchy meal and side dish|Plant-based ingredient in low dose added to starchy meal and side dish
3051317|NCT02218528|Active Comparator|Medium dose added to starchy meal and side dish|Plant-based ingredient in medium dose added to starchy meal and side dish
3051318|NCT02218528|Active Comparator|High dose added to starchy meal and side dish|Plant-based ingredient in high dose added to starchy meal and side dish
3051319|NCT02218515|Other|Open Flap Debridement|Open Flap Debridement (Control Group)
3051320|NCT02218515|Experimental|Enamel Matrix Derivative|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)
3051321|NCT02218515|Experimental|Enamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
3051322|NCT02218502|Other|If simple rules are conclusive|All patients included will undergo an ultrasound scan in which both the RMI and simple ultrasound-based rules are applied. This scan will take place in the hospital of inclusion. For 80% of all patients, this will be the only intervention.
3051323|NCT02218502|Other|If simple rules are inconclusive|If the simple ultrasound-based rules, used in the first ultrasound scan, yield an inconclusive result (approx. 20% of all patients), patients are refered to the center hospital to undergo a second ultrasound (by an expert) and a DW-MRI scan. Furthermore, these group of patients will be asked to give an extra blood sample in order to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
3051324|NCT02218489|Placebo Comparator|Vehicle|Vehicle (placebo) dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease
3051325|NCT02218489|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% Ophthalmic Suspension dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease
3051326|NCT02218476|Other|APS Patient|
3051327|NCT02218463|Active Comparator|Cetaphil|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
3051328|NCT02218463|Active Comparator|Estradiol Cream 0.01%|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
3051329|NCT02218437|Experimental|MSC+ATG|The first agent MSC injection, began two weeks after ATG application; Each patient was injected three times, one time per week; Study on single dose tolerance and efficacy index; Each subjects received three dose groups of treatment.
3051330|NCT02218424|Experimental|Magnesium|Intravenous magnesium. After IV placed intraoperatively, a bolus dose of magnesium 30 mg/kg is given over 15 minutes, followed by a continuous infusion of magnesium at 10 mg/kg/hr until the completion of the procedure.
3051331|NCT02218424|Placebo Comparator|Placebo infusion|Intravenous normal saline will be given as placebo. An equal amount of volume normal saline will be given intravenously as the control group.
3051332|NCT02218411|Experimental|Exercise|Exercises routine based on the Otago exercise programme
3051333|NCT02218398|Experimental|Bronchodilator|Albuterol 3-4 times per day, steroids when necessary.
3051334|NCT02218398|No Intervention|No drug|No drug
3051335|NCT02218385||ForeCYTE Breast Aspirator|ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
3051336|NCT02218372|Experimental|Fidaxomicin|Oral Suspension or Tablets Taken q12h
3051337|NCT02218372|Active Comparator|Vancomycin|Oral Liquid or Capsules Taken q6h
3051338|NCT02218359|Experimental|Amikacin Fosfomycin Inhalation Solution|300 mg of amikacin and 120 mg of fosfomycin to be administered by aerosol via the AFIS Inline System.
3051339|NCT02218359|Placebo Comparator|Aerosolized Placebo|Aerosolized placebo to be administered by aerosol using the AFIS Inline System.
3051340|NCT02218346|Active Comparator|Treatment A (unfed)|Treatment A: Single oral dose of AG-221 mesylate at Hour 0 on Day 1, following a 10-hour overnight fast.
3051341|NCT02218346|Active Comparator|Treatment B (fed)|Treatment B: Single oral dose of AG-221 mesylate at Hour 0 on Day 1, 30 minutes after the start of a high-fat breakfast.
3051342|NCT02218333|Placebo Comparator|Control drink|An isocaloric drink to milk
3051343|NCT02218333|Experimental|Milk|Protein enriched milk (Styrk)
3051344|NCT02218320||Group A|Ten HIV-infected adults will be in Group A and take the HIV medication raltegravir in combination with tenofovir and emtricitabine as their provider-prescribed antiretroviral regimen.
3051345|NCT02218320||Group B|Ten HIV-infected adults will be in Group B and take the HIV medication dolutegravir in combination with tenofovir and emtricitabine as their provider-prescribed antiretroviral regimen.
3051346|NCT02218307|Active Comparator|Mupirocin|topical antibiotic
3051347|NCT02218307|Placebo Comparator|Placebo|Placebo control for mupirocin
3051348|NCT02218294|Experimental|[14C] BCX4161|Includes a radiolabelled dose of [14C] BCX4161 and unlabelled BCX4161
3051349|NCT02218281|Experimental|C2Q-Teen app|Smoking cessation treatment delivered through a smartphone app via mindfulness training.
3051350|NCT02218281|Active Comparator|NCI's QuitSTART app|Smoking cessation treatment delivered through a smartphone app by NCI, without mindfulness training.
3051351|NCT02218281|Active Comparator|Written smoking cessation materials only|Receipt of written smoking cessation materials.
3051352|NCT02218268||Pre-meal bolus then No meal bolus|"A meal replacement drink (Boost) and bolus of rapid insulin will be given to this group. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring.~Then 3 months later A meal replacement drink (Boost) will be given but the subject will not receive a meal bolus. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring"
3051425|NCT02217943|Active Comparator|Sleeve Gastrectomy|Subjects who receive a sleeve gastrectomy
3051353|NCT02218268||No meal bolus then Pre-meal bolus|"A meal replacement drink (Boost) will be given but the subject will not receive a meal bolus. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring.~Then 3 months later meal replacement drink (Boost) and bolus of rapid insulin will be given to this group. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring"
3051354|NCT02218255|Active Comparator|Day 3 eSET combined with Eeva|Traditional Morphology + Eeva™ results
3051355|NCT02218255|Active Comparator|Day 5 eSET combined with Eeva|Traditional Morphology + Eeva™ results
3051356|NCT02218255|No Intervention|Day 5 eSET with Traditonal Morphology|
3051357|NCT02218242|Experimental|Ultrasound|Intraoperative ultrasound
3051358|NCT02218229|Experimental|Shock waves|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
3051359|NCT02218229|No Intervention|Night splint|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study
3051360|NCT02218216|Experimental|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
3051361|NCT02218216|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
3051362|NCT02218203|Placebo Comparator|Placebo- 0mg/kg Lido|Placebo in combination with 0mg/kg LBM lidocaine
3051363|NCT02218203|Experimental|Placebo - 1mg/kg Lido|Placebo in combination with 1mg/kg LBM lidocaine
3051364|NCT02218203|Experimental|Placebo - 2mg/kg Lido|Placebo in combination with 2mg/kg LBM lidocaine
3051365|NCT02218203|Experimental|Placebo - 4mg/kg Lido|Placebo in combination with 4mg/kg LBM lidocaine
3051366|NCT02218203|Experimental|Low Dose Dex - 0mg/kg Lido|Low dose dextromethorphan in combination with 0mg/kg LBM lidocaine
3051367|NCT02218203|Experimental|Low Dose Dex - 1mg/kg Lido|Low dose dextromethorphan in combination with 1mg/kg LBM lidocaine
3051368|NCT02218203|Experimental|Low Dose Dex - 2mg/kg Lido|Low dose dextromethorphan in combination with 2mg/kg LBM lidocaine
3051369|NCT02218203|Experimental|Low Dose Dex - 4mg/kg Lido|Low dose dextromethorphan in combination with 4mg/kg LBM lidocaine
3051370|NCT02218203|Experimental|Medium Dose Dex - 0mg/kg Lido|Medium dose dextromethorphan in combination with 0mg/kg LBM lidocaine
3051371|NCT02218203|Experimental|Medium Dose Dex - 1mg/kg Lido|Medium dose dextromethorphan in combination with 1mg/kg LBM lidocaine
3051372|NCT02218203|Experimental|Medium Dose Dex - 2mg/kg Lido|Medium dose dextromethorphan in combination with 2mg/kg LBM lidocaine
3051373|NCT02218203|Experimental|Medium Dose Dex - 4mg/kg Lido|Medium dose dextromethorphan in combination with 4mg/kg LBM lidocaine
3051374|NCT02218203|Experimental|High Dose Dex - 0mg/kg Lido|High dose dextromethorphan in combination with 0mg/kg LBM lidocaine
3051375|NCT02218203|Experimental|High Dose Dex - 1mg/kg Lido|High dose dextromethorphan in combination with 1mg/kg LBM lidocaine
3051376|NCT02218203|Experimental|High Dose Dex - 2mg/kg Lido|High dose dextromethorphan in combination with 2mg/kg LBM lidocaine
3051377|NCT02218203|Experimental|High Dose Dex - 4mg/kg Lido|High dose dextromethorphan in combination with 4mg/kg LBM lidocaine
3051378|NCT02218190|Experimental|Alvimopan|Alvimopan 12mg once orally two hours prior to surgery and then 2 mg orally twice a day until post-operative day (POD) seven.
3051379|NCT02218190|Placebo Comparator|Placebo - Sugar Pill|Placebo Sugar Pill orally two hours prior to surgery and then one sugar pill orally twice a day until post-operative day (POD) seven
3051380|NCT02218177||Non-responders receiving aflibercept therapy|Non-responders to ranibizumab who are now receiving aflibercept therapy
3051381|NCT02218177||Non-responders receiving PDT combo therapy|patients who are non-responders to ranibizumab who have been switched to combination photodynamic therapy (PDT)
3051382|NCT02218177||Responders to ranibizumab|Patients who are responders to ranibizumab and are continuing monthly injections.
3051383|NCT02218164|Experimental|Capecitabine or 5-FU with Pegylated Interferon alpha-2b|"Participants will start the Capecitabine pills on day 1 thru day 14 and be off for 7 days (day 15-day 21).~Participants will receive 5-FU days 1-4 of each 21 day cycle.~Participants will receive the Interferon alpha-2b injection weekly every week. The three week period is referred to as one cycle.~After three cycles, new imaging studies will be performed that will measure how the disease is responding to treatment. Participants whose disease is stable or improved will undergo an additional 3 cycles of therapy and the imaging studies will be repeated. Again, participants whose disease is stable or improved will undergo a final 3 cycles of treatment (a total 27 weeks of treatment)."
3051384|NCT02218151|Experimental|Patient-Centered Medical Home (PCMH)|"Day-to-Day Care:~Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria.~Caregivers: identified by the subject as the person taking primary care of them will answer surveys and also collect stool samples to analyze in conjunction with those from subjects."
3051426|NCT02217930|Placebo Comparator|Placebo|"Placebo matched to WCK 2349, oral tablet(s)~Placebo matched to moxifloxacin overencapsulated tablet"
3051427|NCT02217930|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg positive control (overencapsulated tablet)
3051428|NCT02217930|Experimental|WCK 2349|WCK 2349 supratherapeutic dose determined in Part 1, oral tablet(s)
3051429|NCT02217917|Experimental|Cohort 1|Single ascending dose in 3 period cross-over design (with optional 4th period)
3051430|NCT02217917|Experimental|Cohort 2|Multiple ascending dose
3051385|NCT02218151|Active Comparator|Standard Care|"These subjects will begin as inpatients or outpatients, where advanced practice providers (APPs) (nurse practitioners and physician assistants) will perform histories and physical exams. Nurses will collect labs and providers will enter orders in our electronic health record (EHR). All steps will be repeated daily until discharge to home. Suitability for discharge is determined by standard clinical criteria including stable blood counts, freedom from active or severe complications (e.g. active infection, severe GVHD), and ability to care for self.~Caregivers: identified by the subject as the person taking primary care of them will answer surveys and also collect stool samples to analyze in conjunction with those from subjects."
3051386|NCT02218138|Experimental|Learning 2 BREATHE|Learning 2 BREATHE, Mindfulness-based group program
3051387|NCT02218138|Experimental|Colorado Blues|Colorado Blues, Cognitive-behavioral depression prevention group
3051388|NCT02218125|Experimental|Group 1- MVA Mosaic|Healthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered Modified Vaccinia Ankara (MVA) Mosaic at Week 0 and at Week 12.
3051389|NCT02218125|Placebo Comparator|Group 2 - Placebo|Healthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.
3051390|NCT02218125|Experimental|Group 3 - MVA Mosaic|Healthy volunteers previously vaccinated with Ad26.ENVA.01 will be administered MVA Mosaic at Week 0 and at Week 12.
3051391|NCT02218125|Placebo Comparator|Group 4- Placebo|Participants previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.
3051392|NCT02218112||OB - Bariatric surgery (gastric bypass)|Obese patients who will undergo a bariatric surgery (gastric bypass)
3051393|NCT02218112||OB- Control group|Obese patients who will not undergo surgery - Control group
3051394|NCT02218099|Experimental|1: Single dose of ASP8232|
3051395|NCT02218099|Experimental|2: Multiple doses of ASP8232 or placebo|
3051396|NCT02218086|Experimental|professionals|balancing on the slackline / wobbling board 3 times by 30 seconds balancing on the slackline with a fix visual anchor / moving visual anchor 3 times by 30 seconds
3051397|NCT02218086|Experimental|beginners|balancing on the slackline / wobbling board 3 times by 30 seconds pre-training compared to post-training
3051398|NCT02218073|Experimental|Treatment Sequence AB|Participants will receive 10 milligram (mg) JNJ-42756493 tablet orally on Day 1 of Period 1 and 100 microgram (mcg) of JNJ-61818549 as intravenous injection 2 hours after the intake of 10 mg JNJ-42756493 oral solution on Day 1 of Period 2.
3051399|NCT02218073|Experimental|Treatment Sequence BA|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection after the intake of 10 mg JNJ-42756493 oral solution on Day 1 of Period 1 and JNJ-42756493 10 mg tablet orally on Day 1 of Period 2.
3051400|NCT02218060|Experimental|Force|Patients receiving coronary CT angiography on the SOMATOM Force before clinically indicated cardiac catheterization or after clinically indicated nuclear stress test
3051401|NCT02218060|Other|Control|Patients who have already received comparable CT examinations on current routine 2nd generation dual-source CT systems
3051402|NCT02218047|Active Comparator|Best available therapy (BAT)|Best available therapy, as chosen by the investigator for patients who had been on HU in the 1 Year PROUD-PV study
3051403|NCT02218047|Experimental|Pegylated-Proline-interferon alpha-2b|AOP2014 for those patients who had been on AOP2014 in the PROUD-PV study
3051404|NCT02218034|Experimental|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
3051405|NCT02218034|Experimental|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
3051406|NCT02218034|Active Comparator|TAZORAC® Gel 0.1%|TAZORAC® Gel 0.1% (tazarotene gel 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
3051407|NCT02218034|Active Comparator|TAZORAC® Cream 0.1%|TAZORAC® Cream 0.1% (tazarotene cream 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
3051408|NCT02218021|Experimental|Samidorphan Dose 1|
3051409|NCT02218021|Experimental|Samidorphan Dose 2|
3051410|NCT02218021|Experimental|Samidorphan Dose 3|
3051411|NCT02218021|Placebo Comparator|Placebo|
3051412|NCT02218021|Active Comparator|Oxycodone Dose 1|
3051413|NCT02218021|Active Comparator|Oxycodone Dose 2|
3051414|NCT02218008|Experimental|High Dose|
3051415|NCT02218008|Experimental|Low Dose|
3051416|NCT02218008|Placebo Comparator|Placebo|
3051417|NCT02217995|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT will be delivered in ten 2.5 hour group sessions with 15 participants per group.
3051418|NCT02217995|No Intervention|Waitlist|Wait list as per usual.
3051419|NCT02217982|No Intervention|Control Group|Patients randomized to the standard therapy arm will be instructed to follow the normal dosing regimen for DMF with a food bolus of their choice prior to dosing. If severe symptoms (MAGIS >6.5) are noted at any time post randomization in any MAGIS category, crossover to the treatment arm will be allowed. Both groups will be asked to rate their GI symptoms over the past 24 hours using the MAGIS scale once daily.
3051420|NCT02217982|Active Comparator|Treatment Arm|Patients who are randomized to the treatment arm will be instructed to take 125 mg simethicone and one tablespoon of a high fat food (peanut butter)10 minutes prior to each DMF dose. If the average MAGIS score is greater than 3.5 in the diarrhea category they will also be instructed to take 2 mg loperamide three times daily.
3051421|NCT02217969|Experimental|Electronic alert to SLUScore increase|Patients whose anesthesia care team members are receiving alerts to increments in their SLUScore (progressive hypotensive exposures) are anticipated to be given interventions aimed at minimizing further hypotensive exposures. The decision of whether or not to intervene as well as the type(s) of interventions will be at the sole discretion of the patient's anesthesia care team
3051422|NCT02217969|No Intervention|Control (no alert)|Routine anesthesia care at the discretion of the anesthesia care team
3051423|NCT02217956|Experimental|HCIP + bevacizumab|"4 dose level of cisplatin are planned: Level 1 : 50 mg/m2 (start level) Level 2 : 60 mg/m2 Level 3 : 70 mg/m2 Level 4 : 80 mg/m2 Level -1: 40 mg/m2 (in case of DLT at level 1)~bevacizumab: Treatment starts between week 10 and 14 after HCIP. Dosage: 15 mg/kg for a total of 22 injections every 3 weeks for 15 months"
3051424|NCT02217943|Active Comparator|Roux-en-Y gastric bypass|Subjects who receive a Roux-en-Y gastric bypass
3051435|NCT02217904|Experimental|MK-8591 30 mg|Single oral dose of MK-8591 30 mg
3051436|NCT02217904|Experimental|MK-8591 0.5 mg|Single oral dose of MK-8591 0.5 mg
3051437|NCT02217904|Experimental|MK-8591 0.25 mg|Single oral dose of MK-8591 0.25 mg
3051438|NCT02217904|Experimental|MK-8591 30 mg Extended Observation|Single oral dose of 30 mg MK-8591 administered following >8 hour fast. Participants will be closely monitored for viral load for up to approximately 21 days prior to starting standard of care ART.
3051439|NCT02217891||participants from existing MSK protocol 12-245|"Participants' responses regarding the benefits and harms of incidental findings arising from tumor genomic profiling will be used to generate novel questionnaire items to assess the construct of perceived personal and clinical utility, which will be tested, along with items designed to assess knowledge about tumor genomic profiling and incidental findings.~Part 2, the investigators will conduct 30-minute cognitive interviews to assess participants' understanding and opinions about the novel items designed to assess perceived personal and clinical utility of incidental findings and knowledge about incidental findings arising from tumor genomic profiling."
3051440|NCT02217878|Active Comparator|Morphine|morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor
3051441|NCT02217878|Placebo Comparator|Placebo|sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor
3051442|NCT02217865||Colorectal Cancer Participants|Colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.
3051443|NCT02217865||Caregivers of Colorectal Cancer Participants|Caregivers of colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.
3051444|NCT02217852|Experimental|A1 nitrendipine|this arm will include Tibetan patients with hypertension whose BP is higher than 140/90mmHg but lower than 160/100mmHg and nitrendipine will be added (dose range 10mg-20mg bid).
3051445|NCT02217852|Experimental|A2 hydrochlorothiazide|this arm will include Tibetan patients with hypertension whose BP is higher than 140/90mmHg but lower than 160/100mmHg and hydrochlorothiazide will be added (dose range 12.5mg-25mg)
3051446|NCT02217852|Experimental|B1 captopril plus Hydrochlorothiazide|this arm will include Tibetan patients with hypertension whose BP is higher than 160/100mmHg and captopril plus Hydrochlorothiazide will be added (dose range：captopril 25mg-50mg tid, Hydrochlorothiazide 12.5mg-25mg qd).
3051447|NCT02217852|Experimental|B2 Beijing hypotensive No.0|this arm will include Tibetan patients with hypertension whose BP is higher than 160/100mmHg and Beijing hypotensive will be added (dose range：Beijing hypotensive No.0 one pile qd or less ).
3051448|NCT02217839|Experimental|DG3173|
3051449|NCT02217839|Experimental|DG3173+Octreotide|
3051450|NCT02217826|Experimental|DG3173|
3051451|NCT02217826|Placebo Comparator|Saline|
3051452|NCT02217826|Active Comparator|Octreotide|
3051453|NCT02217813|Experimental|1. Tafamidis|
3051454|NCT02217813|Experimental|2. Tafamidis|
3051455|NCT02217800|Other|Saline, then DG3173, then octreotide|Interventions: saline, DG3173 and octreotide. Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
3051456|NCT02217787|Other|fasted condition|
3051457|NCT02217787|Other|fed condition|
3051458|NCT02217774|Experimental|MGUIDE assisted implant placement|Implant placement, using MGUIDE MORE system for implant planning and placement
3051459|NCT02217748|Experimental|Survey questionnaire version 1|Name generator order: leisure, money, support
3051460|NCT02217748|Experimental|Survey questionnaire version 2|Name generator order: leisure, support, money
3051461|NCT02217748|Experimental|Survey questionnaire version 3|Name generator order: money, leisure, support
3051462|NCT02217748|Experimental|Survey questionnaire version 4|Name generator order: money, support, leisure
3051463|NCT02217748|Experimental|Survey questionnaire version 5|Name generator order: support, leisure, money
3051464|NCT02217748|Experimental|Survey questionnaire version 6|Name generator order: support, money, leisure
3051465|NCT02217735|Experimental|Writing Intervention - Expressive Arm|Participants are asked to write about the most traumatic or stressful experience of their entire lives in three, 20 minute writing sessions.
3051466|NCT02217735|Active Comparator|Writing Intervention - Neutral Arm|Participants are asked to write about what they did the day before, refraining from including emotional details.
3051467|NCT02217722|Experimental|Ulcerative Colitis Diet counseling|Patients will receive a structured novel diet termed the UCD for 6 weeks. . patients that completed induction phase with remission(PUCAI<10) will be asked if they are willing to adhere to the UCD for an additional 20 weeks.
3051468|NCT02217722|Experimental|Antibiotic Treatment|Patients failing to enter or maintain remission by 6 weeks, or with worsening disease at any time after week 2 will be considered failures on an intention to treat basis. Eligible patients at this time at aged 10 or above may receive a 14 day antibiotic course with Doxycycline, amoxicillin and metronidazole.In addition to the description above children who refused to UCD or with low adherence to UCD may be enrolled directly to this arm.
3051469|NCT02217709|Experimental|Treatment (phenelzine sulfate)|Patients receive phenelzine sulfate 30 mg by mouth (PO) twice daily (BID) (starting dose of 15 mg daily escalated to 30 mg BID over 16 plus or minus 5 days). Patients who have been treated at 30 mg BID for over 3 cycles with resolution of any and all toxicities to grade < or = 1 may increase the dose to a maximum of 45 mg BID at the discretion of the treating investigator. Treatment may continue in the absence of disease progression or unacceptable toxicity.
3051470|NCT02217696|Experimental|Computerized reading training first|Cross-over design: group first receives the intervention
3051471|NCT02217696|Experimental|Waiting Control First|Cross-over design: group first serves as waiting control
3051472|NCT02217683|No Intervention|Young blood transfusion|The first group of patients (n=30) will be randomized to receive leukoreduced blood transfusion stored for less than 10 days
3051473|NCT02217683|No Intervention|Old blood transfusion|This randomized group of patients (n=30) will receive leukoreduced blood transfusion stored for more than 30 days
3051556|NCT02217098|Active Comparator|GIC Restorations|Restorations using Glass Ionomer Cement
3051474|NCT02217683|Active Comparator|Old blood transfusion and Nitric Oxide|This randomized group of patients (n=30) will receive leukoreduced blood transfusion stored for more than 30 days while breathing nitric oxide (80 part per million) and oxygen
3051475|NCT02217670|Experimental|Metformin (test)|single oral dose of Metformin 1000 mg granules
3051476|NCT02217670|Active Comparator|Metformin (reference)|Single dose of Glucophage 1000 mg film-coated tablet
3051477|NCT02217657|Active Comparator|operator informed to contact force|Thermocool Smart Touch Catheter, operator informed to contact force (Biosense Webster)
3051478|NCT02217657|Experimental|operator blinded to contact force|Thermocool Smart Touch catheter, operator blinded to contact force information (Biosense Webster)
3051479|NCT02217644|Experimental|BI 653048 H3PO4 solution|single rising doses
3051480|NCT02217644|Experimental|BI 653048 H3PO4 low dose capsule|
3051481|NCT02217644|Experimental|BI 653048 H3PO4 high dose capsule|
3051482|NCT02217644|Placebo Comparator|Placebo|
3051483|NCT02217631|Experimental|BI 653048 BS H3PO4|dose escalation
3051484|NCT02217631|Active Comparator|Prednisolone low dose|
3051485|NCT02217631|Active Comparator|Prednisolone high dose|
3051486|NCT02217631|Placebo Comparator|Placebo|
3051487|NCT02217618|Experimental|LY2409021|Single oral dose of LY2409021.
3051488|NCT02217605|Experimental|Fructose|Oral Fructose Challenge (75 g fructose in 500 ml water) followed by 75 minutes 31P MRS
3051489|NCT02217579|Placebo Comparator|Control|Isocaloric food without the test protein and prebiotic fiber.
3051490|NCT02217579|Experimental|Protein|Dietary protein consumed as two daily servings of 5 grams protein/serving.
3051491|NCT02217579|Experimental|Fiber|Prebiotic fiber consumed as two daily servings of 8 grams protein/serving.
3051492|NCT02217579|Experimental|Protein plus prebiotic fiber|Protein and prebiotic fiber consumed as two daily servings of 5 grams protein/serving plus 8 grams fiber/serving.
3051493|NCT02217566|Experimental|Abiraterone Acetate|Participants will receive abiraterone acetate 1000 milligram (mg) orally once daily along with prednisone 5 mg orally once daily and androgen deprivation therapy (ADT) as per Investigator's discretion until prostate-specific Antigen (PSA) progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
3051494|NCT02217553|Experimental|vitamin D (cholecalciferol)|All study participants will receive vitamin D supplementation (soft gel capsule containing cholecalciferol 400 IU) to be consumed 2 soft gel capsules daily for three consecutive months. The effect on the platelet parameters specified above will be determined before start cholecalciferol supplementation and after three months.
3051495|NCT02217540|Experimental|Experimental Group|Experimental Group consist of the physiotherapy standard protocol and active movement plus accessory mobilizations of the humeral head using Mulligan Concept Mobilisation with Movement.
3051496|NCT02217540|Active Comparator|Control Group|Standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
3051497|NCT02217527|Experimental|JNJ Active Drug|200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
3051498|NCT02217527|Experimental|Placebo Pill|Placebo pill used for one week quit attempt, as part of crossover design.
3051499|NCT02217514|Experimental|Treatment sequence 1 in male subjects|Midazolam alone and 1 h after low dose BI44370BS in male subjects
3051500|NCT02217514|Experimental|Treatment sequence 1 in female subjects|Midazolam alone and 1 h after low dose BI44370BS followed by medium dose BI 44370 in an additional visit in female subjects
3051501|NCT02217514|Experimental|Treatment sequence 2|Midazolam before and 48 h after high dose BI44370BS
3051502|NCT02217514|Experimental|Treatment sequence 3|Midazolam before and 24 h after high dose BI44370BS
3051503|NCT02217514|Experimental|Treatment sequence 4|Midazolam before and 1 h after high dose BI44370BS
3051504|NCT02217501|Experimental|DAPT - clinically indicated duration+12m|Clopidogrel 75 mg daily and Acetylsalicylic acid (ASA) 75-100 mg daily for clinically indicated duration plus an additional 12 months
3051505|NCT02217501|Active Comparator|DAPT - clinically indicated duration|Clopidogrel 75 mg daily and Acetylsalicylic acid (ASA) 75-100 mg daily for clinically indicated duration with a minimum of 30 days
3051506|NCT02217488|Experimental|DG3173|
3051507|NCT02217488|Placebo Comparator|Vehicle|
3051508|NCT02217475|Experimental|Cenicriviroc|Cenicriviroc 150mg tablet once daily in the morning with food for 2 years
3051509|NCT02217475|Experimental|Placebo + Cenicriviroc|Placebo once daily in the morning with food for year 1 then Cenicriviroc 150 mg tablet once daily in the morning with food for year 2
3051510|NCT02217475|Placebo Comparator|Placebo|Placebo once daily in the morning with food for 2 years
3051511|NCT02217462||Pregnant women|
3051512|NCT02217449||HD|Prediction of histology
3051513|NCT02217449||Virtual Chromoendoscopy|Prediction of histology
3051514|NCT02217436|Experimental|iPad|iPad with age-appropriate applications, videos, and music
3051515|NCT02217436|Active Comparator|Standard Care|All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
3051516|NCT02217423|Experimental|Obstructive increased AC|"Patient with obstructive respiratory disease with increased abdominal circumference.~chest physiotherapy. Chest physiotherapy airway clearance modality. The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest wall (compression, vibration) and cough."
3051517|NCT02217423|Experimental|Obstructive disfunction with normal AC|"Patients with obstructive respiratory disease with normal abdominal circumference.~Patient with obstructive respiratory disease with increased abdominal circumference.~chest physiotherapy. Chest physiotherapy airway clearance modality. The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest wall (compression, vibration) and cough."
3051557|NCT02217098|Experimental|Compomer Restorations|Restorations using Compomer
3051558|NCT02217098|Experimental|Carbomer Restorations|Restorations using Glass Carbomer
3051518|NCT02217423|Experimental|Restrictive increased AC|"Patients with restrictive respiratory disease with increased abdominal circumference. chest physiotherapy chest wall expansion.~The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression) and incentive spirometry."
3051519|NCT02217423|Experimental|Restrictive disfunction with normal AC|"Patients with restrictive respiratory disease with normal abdominal circumference.~Chest physiotherapy chest wall expansion. The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression) and incentive spirometry."
3051520|NCT02217410|Experimental|Regimen A|CFZ533 administered with the contemporary standard of care (SoC) consists of concentration-controlled tacrolimus (Tac), combined with mycophenolic acid (MPA) and corticosteroids (CS).
3051521|NCT02217410|Experimental|Regimen B|CFZ533 administered with mycophenolatic acid (MPA) and corticosteroids (CS) with anti-IL2 induction
3051522|NCT02217410|Active Comparator|Regimen C|Standard of care (SoC) [concentration-controlled tacrolimus (Tac) combined with mycophenolic acid (MPA) and corticosteroids (CS) with anti-IL2 induction]
3051523|NCT02217397|Experimental|OA, CPAPm, combination therapy|
3051524|NCT02217371|Experimental|ADHD patient|
3051525|NCT02217371|Active Comparator|Healthy volunteers|
3051526|NCT02217358|Experimental|NBI endoscopy|150 patients with suspected lesion in larynx and hypopharynx on standard ENT white light endoscopy examination will undergo NBI endoscopy in order to compare the outcomes of these two examination methods
3051527|NCT02217345|Experimental|Growth hormone|Growth hormone (somatropin) administered by daily injection at 0.3 mg daily for women and 0.2 mg daily for men given for the duration of the 6 month study
3051528|NCT02217345|Placebo Comparator|Placebo|Placebo will be administered by daily injection in this double blind study design.
3051529|NCT02217332|Experimental|dexpramipexole|dexpramipexole 150 mg BID
3051530|NCT02217319|Active Comparator|Sevoflurane|Patients receive Sevoflurane 1 MAC (minimal alveolar concentration) after induction of anesthesia with propofol, remifentanil and atracurium for 30 minutes as preconditioning.
3051531|NCT02217319|Placebo Comparator|TIVA|Patients received the standard total intravenous anesthesia (TIVA) with propofol, remifentanil and atracurium.
3051532|NCT02217306||Contrast Sensitivity|Determine changes in contrast sensitivity frequences and visual function (visual acuity) after one month of treatment photocoagulation in macular edema
3051533|NCT02217293|Active Comparator|Pulsed Radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury
3051534|NCT02217293|No Intervention|Night splint|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study
3051535|NCT02217280|Experimental|Injection with Gadolinium|This group of patients identified by the PI as having cervical radiculopathy will receive gadolinium (the intervention) in their epidural cervical injection along with steroid (DepoMedrol). There is no control group in this study.
3051536|NCT02217267|Placebo Comparator|Placebo group|Normal Saline 50 ml intravenous infusion in 1 hour once a week 4 times
3051537|NCT02217267|Active Comparator|Lidocaine group|Lidocaine 3mg/kg in Normal Saline to 50 ml intravenous infusion in 1 hour once a week 4 times
3051538|NCT02217254|Active Comparator|two 3-minute cryoablations|two 3-minute cryoablations per pulmonary vein during an atrial fibrillation ablation procedure
3051539|NCT02217254|Active Comparator|One 3-minute cryoablation|One 3-minute cryoablation per pulmonary vein during an atrial fibrillation ablation procedure
3051540|NCT02217241|Experimental|Intervention|Students in the intervention group participated in a one-hour interactive, small-group handoff workshop facilitated by a study investigator. The workshop focused on the importance of specific handoff skills to patient safety.
3051541|NCT02217241|No Intervention|Control|
3051542|NCT02217228|Experimental|Sebacia microparticles and laser|Gold microparticle suspension + laser treatment x 3 over the course of two weeks
3051543|NCT02217228|Experimental|Vehicle suspension and laser|Vehicle suspension + laser treatment x 3 over the course of two weeks
3051544|NCT02217228|Experimental|Sebacia microparticles without laser|Gold microparticle suspension treatment x 3 over the course of two weeks
3051545|NCT02217215||Negative and Referral Cytology Results|CNDS Advanced Cervical Scan Colposcopy
3051546|NCT02217202||ConvaTec Ag|Use of ConvaTec Ag sugical cover dressing post-operatively until wound has healed.
3051547|NCT02217189|Experimental|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
3051548|NCT02217189|No Intervention|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment.
3051549|NCT02217176||endotracheal intubation|
3051550|NCT02217176||laryngeal mask airway|
3051551|NCT02217163|Experimental|Myeloma treatment|The combination therapy with Carfilzomib, Cyclophosphamide and dexamethasone will be used to treat eligible patients for upto 8 cycles following which they will undergo autologous bone marrow transplantation. Following this there will disease assessment and further treatment decided afterwards.
3051552|NCT02217150||Metastatic Lesions to the spine|Patients over the age of 18 receiving treatment using the DFINE Inc. STAR tumor ablation system for palliation of painful metastases of the spine.
3051553|NCT02217124|Experimental|Apple group|twenty four participants will be randomly selected for the apple group, in which they will receive 37.5 grams equal to 120kcal of dried apples twice a day for eight weeks. This snack of apples will be eaten once between breakfast and lunch and once between lunch and dinner and both will be consumed with an eight ounce bottle of water.
3051554|NCT02217124|Placebo Comparator|Muffin control|twenty four participants will be randomly selected to make up the muffin control group, in which one 120kcal muffin control snack will be consumed twice each day for eight weeks. The muffin control will be consumed one between breakfast and lunch and one between lunch and dinner, each snack will be consumed with an eight ounce bottled water.
3051555|NCT02217111|Experimental|voice therapy|
3051560|NCT02217072|Experimental|Parents as Tutors|Educational support intervention
3051561|NCT02217072|Experimental|school intervention|Educational support intervention
3051562|NCT02217059||Prehypertension|Using the JNC7 definition
3051563|NCT02217059||Stage I Hypertension|Using the JNC7 definition
3051564|NCT02217059||Stage II Hypertension|Using the JNC7 definition
3051565|NCT02217046|Experimental|device replacement|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
3051566|NCT02217046|No Intervention|control group|remove previously inserted cardiac device and the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
3051567|NCT02217033|Placebo Comparator|Purified Water|"In this arm, eligible subjects will begin to consume purified water (placebo) just prior to the 1st cycle of chemotherapy. Subjects will continue to consume the placebo through their chemotherapy and then for an additional 12 weeks after completing chemotherapy.~Subjects will consume a specific volume based on the following weight categories: <150 lb = 2 bottles/day; ≥150 lb and <225 lb = 3 bottles/day; ≥225 lb = 4 bottles/day. Subjects will consume placebo for a minimum of 168 days."
3051568|NCT02217033|Experimental|'R' (Electro-kinetically altered beverage)|"Patients randomized to this arm will begin to consume R (Electro-kinetically altered beverage) just prior to the 1st cycle of chemotherapy and continue it through their chemotherapy cycles and then for an additional 12 weeks after completing chemotherapy.~Subjects will consume a specific volume based on the following weight categories: <150 lb = 2 bottles/day; ≥150 lb and <225 lb = 3 bottles/day; ≥225 lb = 4 bottles/day. Subjects will consume R for a minimum of 168 days."
3051569|NCT02217020|Experimental|FOLFOXIRI|patients received FOLFOXIRI alone for 4 cycles before surgery.
3051570|NCT02217007|Experimental|SNC-102 sustained release tablet|SNC-102 oral tablet 4 weeks at 800mg BID plus 4 weeks at 1600mg in the morning and 800mg in the evening
3051571|NCT02216994|Other|surgery treatment|The patients with a predicting score of more than 5 are diagnosed with HD, and are performed surgery to remove the aganglionic bowel. The patients with a score less than 5 are mostly indicative of HAD, and receive conservative treatments that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments. one stage pull through procedure to remove the dysganglionic bowel segments.
3051572|NCT02216981|Experimental|Intensive Cognitive Behavioural Therapy|Intensive CBT (an average of 12-18 hours of CBT offered in an intensive format, delivered on 2-3 days per week over a period of 3 weeks)
3051573|NCT02216981|Active Comparator|Weekly Cognitive Behavioural Therapy|Weekly CBT (an average of 12-18 hours of CBT delivered in 60-90 minute sessions on a weekly basis)
3051574|NCT02216981|No Intervention|Wait list|Wait list (3 months). Participants randomized to wait list will commence treatment after 3 months, in the treatment condition to which they are re-randomized (either Intensive or Weekly CBT).
3051575|NCT02216968|Experimental|AA - Increase vegetable intake|"60 African-American (AA) preschool children will participate in the Intervention Group. 60 AA children will belong to the Control Group.~6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
3051576|NCT02216968|Experimental|HA - Increase vegetable intake|"60 Hispanic-American (HA) preschool children will participate in the Intervention Group. 60 HA children will belong to the Control Group.~6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
3051577|NCT02216942|Active Comparator|Vitapex|Endodontic treatment using Vitapex
3051578|NCT02216942|Experimental|Guedes Pinto Paste|Endodontic treatment using Guedes Pinto
3051579|NCT02216916|Experimental|HM781-36B|
3051580|NCT02216903||Yonsei AF Cohort|Patients with atrial fibrillation who undergoing catheter ablation of atrial fibrillation
3051581|NCT02216890|Experimental|SGN-CD70A|
3051582|NCT02216877|Placebo Comparator|Placebo|Oral placebo twice daily for 8 weeks. 12 subjects.
3051583|NCT02216877|Experimental|Mablet 360 mg once daily|Oral Mablet 360 mg once daily and oral placebo once daily for 8 weeks. 12 subjects.
3051584|NCT02216877|Experimental|Mablet 360 mg twice daily|Oral Mablet 360 mg twice daily for 8 weeks. 12 subjects.
3051585|NCT02216864|Experimental|Multiple Subcision|Subjects will receive multiple subcision treatments to their randomized side of the face 5 times total spaced 4 weeks apart.
3051586|NCT02216864|No Intervention|Control|Subjects will receive no intervention control on the other side of the face.
3051587|NCT02216851|Experimental|Restylane Perlane|Single injection of Restylane Perlane in nasal dorsum and/or nasal root
3051588|NCT02216851|No Intervention|No-treatment control|No-treatment control group do not receive any treatment during the main study period
3051589|NCT02216838|Experimental|botulinum toxin A|This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.
3051590|NCT02216838|Placebo Comparator|Saline Control|This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.
3051591|NCT02216825|Experimental|Delayed release capsule, L. reuteri NCIMB 30242|
3051592|NCT02216825|Experimental|Standard vegetarian capsule, L. reuteri NCIMB 30242|
3051593|NCT02216812|Experimental|500 mg vitamin C|Arm will take 1 pill of 500 mg vitamin C per day for 6 weeks
3051594|NCT02216812|Placebo Comparator|Placebo|Arm will take 1 placebo pill per day for 6 weeks
3079587|NCT02029807||Blood donors|Healthy adult volunteers donating blood
3051595|NCT02216799|Active Comparator|Regular Insulin incorporated in parenteral nutrition|Regular insulin ( Actrapid, 100 unit/mL0 Solution for injection, Insulin Human (rDNA), Novo Nordisk, will be added to parenteral nutrition to run over 24 hours as 80% of the total insulin requirement of the preceding day administered via subcutaneous sliding scale
3051596|NCT02216799|Active Comparator|Insulin glargine|Insulin glargine adminstred at daily night, calculated as 80% of the total insulin requirement of the preceding day from the insulin administered via subcutaneous sliding scale
3051597|NCT02216786|Experimental|Fulvestrant and AZD2014 (continuous)|Experimental arm
3051598|NCT02216786|Active Comparator|Everolimus and Fulvestrant|Comparator arm
3051599|NCT02216786|Active Comparator|Fulvestrant|Control 1
3051600|NCT02216786|Experimental|Fulvestrant +AZD2014 (intermittent)|Experimental arm
3051601|NCT02216773|Active Comparator|Portal vein embolization (PVE)|"Patients allocated to the PVE group will receive pre-intervention blood tests and a contrast enhanced CT scan of the abdomen. They will then have their portal vein embolized radiologically once their pre-intervention investigations have been completed and reviewed by the clinical team.~Post-intervention investigations (blood tests and CT scan) will take place 4 weeks after the completion of the PVE. At this point, they will be listed to receive their definitive surgical hepatectomy."
3051602|NCT02216773|Experimental|Radiofrequency assisted liver partition and ligation (RALPP)|"Patients allocated to the RALPP group will receive pre-intervention blood tests and a contrast enhanced CT scan of the abdomen. They will then have their right portal vein surgically ligated followed by radiofrequency ablation in situ splitting of the liver. Certain patients may additionally have a tumourectomy or wedge resection of the left liver lobe if clinically indicated. The RALPP procedure will occur once the patient's pre-intervention investigations have been completed and reviewed by the clinical team.~Post-intervention investigations (blood tests and CT scan) will take place 2 weeks after the completion of the RALPP. At this point, they will be listed to receive their definitive surgical hepatectomy."
3051603|NCT02216760|Active Comparator|Ripple Mapping guided VT ablation|Ripple Mapping (Imperial College) software (Biosense Webster) will be used to identify conduction channels within the ventricular scar substrate to guide ablation lesions in patients with monomorphic VT.
3051604|NCT02216760|Active Comparator|Conventional VT Ablation|Standard substrate ablation as per local operator preference will be used to guide ablation in the ventricular scar in patients with monomorphic VT.
3051605|NCT02216747|Active Comparator|prednisone 60 mg/meter square Body Surface Aera|A - 60 mg Prednisone/meter square Boby Surface Area( 30 twice)/day until there are 3 days of undetected protein in urine and tapering down to 40 mg ,30 mg, 20 mg ,10 mg and 5 mg and end.
3051606|NCT02216747|Active Comparator|prednisone 45 mg/meter square BSA|B- 45 mg prednisone / day until there are 3 days of undetected protein in urine and then 30 mg / day for two weeks and to 30,20,10,5 mg until treatment is ended.
3051607|NCT02216747|Active Comparator|prednisone 30 mg/meter squer BSA|C- treatment of twice daily prednisone 30 mg per day until there are 3 days of undetectible protein in urine and then tapering down to 20 ,10 ,5 until treatment is ended.
3051608|NCT02216734|Experimental|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
3051609|NCT02216734|No Intervention|Standard of Care Arm|Standard of Care: Nurses may identify HIV+ mothers lost to follow-up (LTFU); village health workers (VHWs) may conduct home visits to reduce LTFU of HIV+ mothers. LTFU activities are not standardised throughout all Ministry of Health and Child Care facilities.
3051610|NCT02216721||Non primary aldosteronism|Non primary aldosteronism patients undergoing usual anti hypertensive treatment
3051611|NCT02216721||Primary Aldosteronism|Patients with confirmed primary aldosteronism undergoing treatment
3051612|NCT02216708|Experimental|intravenous fluid for rehydration rapidly over 6 hours|intravenous fluid for rehydration rapidly over 6 hours
3051613|NCT02216708|Experimental|receive slow rehydration recommended by WHO (12 hours)|receive intravenous fluid followed by ORS (slow rehydration recommended by WHO) over 12 hours
3051614|NCT02216669|Experimental|DTP348|Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
3051615|NCT02216656|Placebo Comparator|Plascebo|
3051616|NCT02216656|Experimental|KHK7580 low dose|
3051617|NCT02216656|Experimental|KHK7580 middle dose|
3051618|NCT02216656|Experimental|KHK7580 high dose|
3051619|NCT02216656|Active Comparator|KRN1493|
3051620|NCT02216643|Experimental|thrombectomy (Solitaire and/or Penumbra)|mechanical thrombectomy with stentriever Solitaire and/or thromboaspiration with Penumbra System in patients with large vessel occlusion in cerebral anterior circulation vessels
3051621|NCT02216643|No Intervention|best medical treatment|best medical treatment in patients with acute ischemic stroke with anterior circulation large vessel occlusion
3051622|NCT02216630|Experimental|Adipose-Derived Stem Cell (ADSC) Therapy|This arm, as the sole arm, will consist of the ADSC treatment procedure. Intervention will consist of Adipose Derived Stem Cell (ADSC) Therapy
3051623|NCT02216617|Experimental|Induction chemotherapy TPA|"3 Cycles of induction chemotherapy TPA : (Taxotere, Cisplatin, Afatinib)~1 cycle = 3 weeks, three cycles of treatment in total (or 9 weeks)~Docetaxel 75 mg / m2 at D1 Cisplatin 75 mg / m 2 at D1 Afatinib: x mg / day D2 to D21 by level: (Level 1: 20 mg / day; Level 2: 30 mg / day; Level 3: 40 mg / day)"
3051624|NCT02216604|Experimental|Intervention group|Multimodal Exercise intervention (console-based training, age-specific resistance training and body awareness)
3051625|NCT02216604|No Intervention|Control|age, disease and gender matched
3051729|NCT02215863|Active Comparator|PCV13 and Fluad|437 concomitant Fluad-PCV13 recipients: one dose of each vaccine administered on Day 0
3051730|NCT02215863|Active Comparator|Fluad alone|437 Fluad recipients: one vaccine injection administered on Day 0
3051731|NCT02215863|Active Comparator|PCV13 alone|437 PCV13 recipients: one vaccine injection administered on Day 0
3051626|NCT02216591|Experimental|Active Cognitive Training (ACT)|The ACT group will complete 12 individual sessions across 6-10 weeks. Sessions will utilize four commercially available memory-training programs from PSSCogRehab 2012, published by Psychological Software Service. The four programs used will be: (1) Sequence recall of digits - auditory (SRD-A), (2) Sequenced Recall Reversed Digits - Auditory (SRRD-A), (3) Sequenced Recall of Words - Visual (SRW-V), and (4) Verbal memory - categorizing (VM-C). In each training session, participants will complete each of the four memory training programs twice.
3051627|NCT02216591|Sham Comparator|Control (CON)|The CON group will also complete 12 total sessions across 6-10 weeks. The same four computer programs from PSSCogRehab 2012, published by Psychological Software Service, will be used in the control group sessions. However, the control program will identify the correct responses to participants, such that they do not need to engage their working memory to answer the questions correctly.
3051628|NCT02216578|Experimental|cabozantinib|cabozantinib 60 mg oral daily
3051629|NCT02216565|Other|Medical treatment|Conventional medical non-interventional treatment
3051630|NCT02216565|Other|Endovascular treatment|Conventional medical treatment plus endovascular treatment
3051631|NCT02216552|Experimental|Resveratrol|Intervention: Resveratrol Oral supplementation of resveratrol (ResVida) 75 mg twice daily (with breakfast and dinner) for a total daily dose of 150 mg for the duration of 30 days.
3051632|NCT02216552|Placebo Comparator|Placebo|Intervention: Placebo Control Oral supplementation of placebo twice daily (with breakfast and dinner) for a total duration of 30 days.
3051633|NCT02216539|Experimental|Self-hypnosis|Patients trained to self-hypnosis before surgery
3051634|NCT02216539|Active Comparator|Usual pain management|Patients receiving the usual post-operative pain management protocols
3051635|NCT02216526|Experimental|Cetaphil® Restoraderm|Cetaphil® Restoraderm Body Wash, once daily for 8 weeks and Cetaphil® Restoraderm Body Moisturizer, twice daily for 8 weeks
3051636|NCT02216526|Experimental|Excipial|Excipial Kids Body Wash, once daily for 8 weeks and Excipial U Lipolotio (4% urea), twice daily for 8 weeks
3051637|NCT02216526|No Intervention|Standard skin care|Usual skin care routine of the nursing home resident
3051638|NCT02216513|Active Comparator|Desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline IV for 4 hours for 5 consecutive days
3051639|NCT02216513|Placebo Comparator|placebo|normal saline IV for 4 hours for 5 consecutive days
3051640|NCT02216500|Experimental|Ketogenic Therapy|Ketogenic Therapy will be administered.
3051641|NCT02216487|Experimental|HA-Irinotecan|HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan.
3051642|NCT02216474|Sham Comparator|Sham transcranial direct current stimulation (frontal cortex)|Transcranial direct current stimulation will be ramped up over 60 seconds and then ramped down gradually to encourage blinding to condition.
3051643|NCT02216474|Experimental|Anodal transcranial DC stimulation (frontal cortex)|Anodal transcranial direct current stimulation to prefrontal cortex for approximately 15 minutes plus ramp up and down time
3051644|NCT02216461|Experimental|Low dose of BIBW 2948 BS|
3051645|NCT02216461|Experimental|Medium dose of BIBW 2948 BS|
3051646|NCT02216461|Experimental|High dose of BIBW 2948 BS|
3051647|NCT02216461|Placebo Comparator|Placebo|
3051648|NCT02216448|Other|simulator training|Training knee simulator in Lab
3051649|NCT02216448|Other|OR training|Training in the OR - 2 knee arthroscopies.
3051650|NCT02216422|Experimental|Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir with RBV|Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) co-administered with weight-based Ribavirin (RBV; twice daily) for 12 weeks
3051651|NCT02216409|Experimental|Treatment (Hu5F9-G4)|Hu5F9-G4 monotherapy
3051652|NCT02216383|Experimental|Carbetocin|One dose of 100 micrograms intramuscular Carbetocin given for active management of the third stage of labour, immediately after the birth of the baby
3051653|NCT02216383|Active Comparator|Syntocinon|One dose of 10 International Units intramuscular Syntocinon given for active management of the third stage of labour, immediately after the birth of the baby
3051654|NCT02216383|Active Comparator|Syntometrine|One dose of 500micrograms/5 International Units intramuscular Syntometrine given for active management of the third stage of labour, immediately after the birth of the baby
3051655|NCT02216370||Cryptogenic Stroke or TIA|
3051656|NCT02216370||Healthy Volunteers|Healthy Volunteers as comparative group adjusted to investigated group by age and gender
3051657|NCT02216357|Active Comparator|Ifetroban, Oral Capsule|Ifetroban, Oral Capsule; 200 mg per dose (four - 50 mg capsules), once per day on Study Days 1, 2, and 3.
3051658|NCT02216357|Placebo Comparator|Placebo, Oral Capsule|Placebo, Oral Capsule; matching capsules for oral ifetroban dosing, four capsules once per day on Study Days 1, 2, and 3.
3051659|NCT02216344||Pulse Oximeter (the device)|The pulse oximetry devices were placed on subjects per the protocol. The subjects underwent gradual hypoxia and the output of the devices under test was compared to the SaO2 value as measured by a CO-Oximeter (the reference value), as outlined by ISO 80601, to ensure that the devices meet the specified performance claims.
3051660|NCT02216331|Experimental|Group 1 TMC207 alone|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 1.
3051661|NCT02216331|Experimental|Group 1 TMC207 and rifapentine|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 29 and 600 mg of rifapentine administered as 4 tablets of 150 mg per tablet on each of Study Days 20-41.
3051662|NCT02216331|Experimental|Group 2 TMC207 alone|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 1.
3051663|NCT02216331|Experimental|Group 2 TMC207 and rifampicin|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 29 and 600 mg of rifampicin administered as 4 capsules of 150 mg per capsule on each of Study Days 20-41.
3051664|NCT02216318|Placebo Comparator|red light|red light during the whole day
3051665|NCT02216318|Active Comparator|Blue light|Blue light during early day
3051666|NCT02216305|Active Comparator|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorroidal base with absorbable suture
3051732|NCT02215850|Experimental|SLC-0111|
3051667|NCT02216305|Active Comparator|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorroid. Other procedures will not be associated.
3051668|NCT02216292||Preterm Single Donor Milk Group|The prospective study group = preterm single donor milk group (PSDM-Group) from June 2012 - April 2013
3051669|NCT02216292||Control Group|Retrospective control group receiving no donor milk = control group from March 2011 - May 2012
3051670|NCT02216279|Experimental|Pulmonary Hypertension Patients|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
3051671|NCT02216279|Active Comparator|Control Non-Smoking Participants|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
3051672|NCT02216266|Active Comparator|Physostigmine|Physostigmine administered intravenously at a dose of 24 mg + 25 min a 0,04 mg/kg milligram(s)/kilogram
3051673|NCT02216266|Placebo Comparator|Sodium Chloride solution|solution administered intravenously 24 mg + 25 min a 0,04 mg/kg milligram(s)/kilogram
3051674|NCT02216253|Active Comparator|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|The combination of L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract will be administered in tablet twice a day 7 days before and after surgery
3051675|NCT02216253|Placebo Comparator|Placebo|Placebo tablet twice a day 7 days before and after surgery
3051676|NCT02216240|Active Comparator|Accident and emergency|Patients randomised to A&E were treated as per standard care and given no information other than that pertaining to the study.
3051677|NCT02216240|Experimental|Paramedic|Treatment at the scene by a paramedic. Valsalva manoeuvre with subsequent administration of 6mg and 12mg of adenosine unless the supraventricular tachycardia terminated. Patients were taken to accident and emergency if the tachycardia did not terminate, restarted, or the patient had continuing symptoms, a persistently abnormal ECG (other than T wave inversion) or was heamodynamically unstable. Prior to discharge from the ambulance patients received an information pack and a referral letter for their GP to refer them to an arrhythmia clinic.
3051678|NCT02216227|Experimental|Surgical Site Infection Checklist|"Patient has a known positive Staph aureus pre-op screening result (MRSA or MSSA):~ecolonize with intranasal Mupirocin ointment BID x 5 days~hlorhexidine gluconate (CHG) bathing (daily x 5 days, using wipes or liquid)~efazolin plus Vancomycin (no Vanco for MSSA positive)~Patient has a known negative Staph aureus pre-op screening result:~HG bathing (night before & morning of surgery using wipes or liquid)~efazolin~Patient was not screened or results are unknown at time of surgery:~ecolonize with intranasal Mupirocin ointment (start BID x 5 days; discontinue if negative screen)~HG bathing (start daily bath 5 days before operation if possible; at a minimum bathe the night before & morning of surgery using wipes or liquid)~efazolin plus Vancomycin"
3051679|NCT02216214|Experimental|Mirabegron|Initial dose may be titrated to a higher dose, depending on subject efficacy tolerability and Investigator discretion.
3051680|NCT02216214|Placebo Comparator|Placebo|Subjects randomized to placebo will start blinded product matched to the mirabegron 25 mg tablet and may also increase to 50 mg placebo after 4 or 8 weeks.
3051681|NCT02216188|Experimental|A: AFFITOPE® PD01A + Adjuvant|one injection of 15µg AFFITOPE® PD01A/ adjuvanted
3051682|NCT02216188|Experimental|B: AFFITOPE® PD01A + Adjuvant|one injection of 75µg AFFITOPE® PD01A/ adjuvanted
3051683|NCT02216188|Other|Control|Untreated control group
3051684|NCT02216175|Experimental|SLIT followed by Conventional OIT|Participants will receive up to 7 months of SLIT followed by 6 months conventional OIT to cow's milk
3051685|NCT02216175|Active Comparator|Conventional OIT|Participants will receive up to 7 months of low dose OIT, followed by 6 months conventional OIT to cow's milk
3051686|NCT02216175|Placebo Comparator|Delayed start OIT|Participants will receive up to 7 months placebo, followed by 6 months conventional OIT to cow's milk
3051687|NCT02216162|Experimental|A: Interventional adapted physical activity + enhanced geriatr|Geriatric (functionality, gait, nutrition) follow-up, biological tests, anti-aromatase agents blood dosing, clinical assessment. Weekly Taï-Chi exercises.
3051688|NCT02216162|Other|Arm B: control|Clinical follow-up according to the Guidelines, annual geriatric and nutritional assessment
3051689|NCT02216149|Experimental|S-1 plus oxaliplatin (SOX)|Oxaliplatin 130 mg/m2 d. 1 followed by oral S-1 25 mg/m2/day BID d1-14.
3051690|NCT02216149|Active Comparator|Oxaliplatin plus capecitabine (XELOX)|Intravenous oxaliplatin 130 mg/m2 d.1 followed by oral capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14.
3051691|NCT02216136||Breast Conservation Cohort|Breast Conservation group (Group A) with newly diagnosed breast cancer who decide to proceed with lumpectomy and radiation treatment.
3051692|NCT02216136||Mastectomy and Reconstruction Cohort|Mastectomy and Reconstruction group (Group B): This group will have mastectomy with immediate reconstruction (defined as reconstruction process starting at time of initial mastectomy surgery). They may or may not require chemotherapy and radiation depending on their cancer staging as well as multiple steps of their breast reconstruction.
3051693|NCT02216136||Mastectomy Cohort|Mastectomy group (Group C): This group will not have any reconstruction with their mastectomy. Neoadjuvant, chemotherapy and radiation will be part of care as necessary for stage of cancer.
3051694|NCT02216123|Experimental|Tafenoquine+ Chloroquine|All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg [2×CQ 300 mg] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily [OD] orally; OR, 620 mg [4×CQ 155 mg] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily [OD] orally). Tafenoquine 300mg (2×TQ 150 mg) will be given as a single oral dose on Day 1 or Day 2. Primaquine matching placebo will be given OD orally beginning on Day 1 or Day 2 and continue for 14 days total dosing. All subjects will be followed-up till 180 days.
3051733|NCT02215837|Sham Comparator|Chemotherapy|After accepting chemotherapy according to NCCN guidelines, patients will just regularly follow up.
3051734|NCT02215837|Experimental|Ag-D-CIK|After accepting chemotherapy according to NCCN guidelines,patients will receive 3 cycles of autologous tumor lysate pulsed D-CIK treatment.
3051735|NCT02215824|Experimental|BIWH 3|in escalating doses
3051736|NCT02215824|Placebo Comparator|Placebo|
3051695|NCT02216123|Experimental|Primaquine+ Chloroquine|All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg [2×CQ 300 mg] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily [OD] orally; OR, 620 mg [4×CQ 155 mg] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily [OD] orally). Primaquine 15mg will be given OD orally beginning on Day 1 or Day 2 and continue for 14 total dosing. Tafenoquine matching placebo will be given as a single oral dose on Day 1 or Day 2. All subjects will be followed-up till 180 days.
3051696|NCT02216110||Surgery group|Patients who underwent surgery as treatment of early gastric cancer
3051697|NCT02216110||ESD group|Patients who underwent endoscopic submucosal dissection (ESD) as treatment of early gastric cancer, instead of surgery
3051698|NCT02216097|Experimental|Treatment|
3051699|NCT02216097|Placebo Comparator|Placebo|
3051700|NCT02216084|Experimental|Recombinant ADAMTS13|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 3 subjects; Cohort 2: 3 subjects; Cohort 3: 8 subjects]. Subjects will be enrolled and dosed sequentially. Subjects will be recruited to the next dose level only after short-term safety has been demonstrated and reviewed by an independent Data Monitoring Committee (DMC) at the preceding dose level. The first 2 subjects in any cohort will be ≥ 18 years of age. The effects of the investigational product on vital signs, hematology, and clinical chemistry parameters (up to 96 ± 2 hrs blood sampling timepoint) will determine short-term safety. The DMC will recommend whether to proceed with the study or in case of a safety concern recommend remedial actions and/or to discontinue the study. Subject participation will continue until 28 ± 3 days after infusion of the investigational product. Subject participation in one Dose Cohort (1-3) is expected to be approximately 6-8 weeks.
3051701|NCT02216071|Active Comparator|Ciprodex®, RLD|Ciprodex®, Otic Suspension, Twice daily for 7 days
3051702|NCT02216071|Experimental|EXL CDOS|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension, Otic Suspension, Twice daily for 7 days
3051703|NCT02216058|Experimental|NOYA|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System
3051704|NCT02216045|Active Comparator|Peginterferon ,Ribavirin|drug :Peginterferon, Ribavirin,
3051705|NCT02216045|Experimental|Peginterferon, Ribavirin, camel milk|drug :Peginterferon, Ribavirin, camel milk
3051706|NCT02216032|Experimental|Treatment Group|We will deliver the TMW Curriculum to 100 Treatment families. The TMW Curriculum is comprised of 1) 12 educational modules, 2) animations and videos of real parent-child interactions to teach parents about the science behind child brain development, and model strategies for improving parents' child-directed speech, 3) video modeling and collaborative goal setting, and 4) quantitative linguistic feedback from Language ENvironment Analysis (LENA) recordings.
3051707|NCT02216032|Other|Control Group|We will deliver a Nutrition Curriculum to 100 Control families. The Nutrition Curriculum provides information about the importance of healthy nutrition for child development, strategies for healthy eating, and meal preparation.
3051708|NCT02216019||study cohort|Patient undergoing planned heart surgery with cardiopulmonary bypass
3051709|NCT02216006|Active Comparator|Control group, conventional ventilatory settings|"Handling of the airway during induction and intubation is performed in a conventional manner.~Initial ventilatory settings are also done in a conventional manner."
3051710|NCT02216006|Active Comparator|High fresh gas flow, high minute ventilation|"Handling of the airway during induction and intubation is performed in a conventional manner.~Immediately after confirming a successful intubation the effect of preoxygenation is eliminated with an anti-preoxygenation maneuver."
3051711|NCT02215993|Active Comparator|Prasugrel|After 300mg or 600mg loading dose of clopidogrel, this medication will be replaced by 60 mg prasugrel followed by 10mg per day for 30 days.
3051712|NCT02215993|Active Comparator|Ticagrelor|After 300mg or 600mg loading dose of clopidogrel, this medication will be replaced by 180 mg ticagrelor followed by 90mg twice a day for 30 days.
3051713|NCT02215980|Experimental|A|"Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21.~Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days until progression or intolerance."
3051714|NCT02215980|Experimental|B|"Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21~Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days, for a total of 9 cycles.~Maintenance until progression or intolerance:~- Lenalidomide: 10 mg/daily on days 1-21 of each 28-day cycle"
3051715|NCT02215967|Experimental|1|Dose Escalation with 5 dose levels based on the patients actual bodyweight
3051716|NCT02215954|Experimental|Treatment arm [1]: FE 999169|One sachet on the day before colonoscopy, and another sachet on the day of colonoscopy
3051717|NCT02215954|Experimental|Treatment arm [2]: FE 999169|Two sachets on the day before colonoscopy
3051718|NCT02215954|Active Comparator|Treatment arm [3]: Niflec|One to two pack(s) on the day of colonoscopy
3051719|NCT02215941|Experimental|TV-45070 7%|twice daily topical application to 7% body surface area for 7.5 days (15 applications)
3051720|NCT02215941|Experimental|TV-45070 21%|twice daily topical application to 21% body surface area for 7.5 days (15 applications)
3051721|NCT02215941|Experimental|TV-45070 53%|twice daily topical application to 53% body surface area for 7.5 days (15 applications)
3051722|NCT02215941|Placebo Comparator|Placebo|
3051723|NCT02215928||Ancillary-correlative (tumor genomic profiling)|Tissue samples are collected at baseline and blood for liquid biopsy is collected at baseline and every 6-8 weeks during active treatment. Tissue samples are analyzed via sequencing for tumor genomic profiling.
3051724|NCT02215915|Experimental|IVUS guided DES implantation|Stent size and length were selected by online IVUS measurements, and adjunct high-pressure dilation was performed according to the discretion of operators based on the IVUS criteria for stent optimization.
3051725|NCT02215915|Active Comparator|Angiography guided DES implantation|Stent size and length were chosen by visual estimation, and adjunct high-pressure dilation was performed if an optimal result was not achieved, which was defined as angiographic residual diameter stenosis 20% and absence of angiographically detected dissection.
3051726|NCT02215902|Experimental|Hemopurifier|Affinity plasmapheresis
3051727|NCT02215889|Experimental|Surgery|
3051728|NCT02215876|Experimental|Single Arm|Doxorubucin and Cyclophosphamide q2 or q3 weekly x 4 cycles plus Eribulin on days 1 and 8 of a 21 day cycle x 4 cycles
3051737|NCT02215811|Experimental|Mesenchymal stromal cells|
3051739|NCT02215785|Experimental|kiwifruit cohort|Patients that presented at Primary Care Centres with registered -Roma III criteria based- constipation and who accepted to participate in the study were followed-up for two weeks before intervention and three weeks under 3-daily kiwifruit intake.
3051740|NCT02215772|Experimental|BI 44370 BS|200 mg containing 2.43 megabecquerel (MBq) 14C-radioactivity
3051741|NCT02215759|Experimental|BI 44370 TA|
3051742|NCT02215759|Placebo Comparator|Placebo|
3051743|NCT02215746|Experimental|Treatment A|BI 44370 TA drinking solution 100 mg fasted
3051744|NCT02215746|Experimental|Treatment B|BI 44370 TA drinking solution 100 mg fed
3051745|NCT02215746|Experimental|Treatment C|BI 44370 TA drinking solution 200 mg fasted
3051746|NCT02215746|Experimental|Treatment D|BI 44370 TA drinking solution 200 mg fed
3051747|NCT02215746|Experimental|Treatment E|100 mg BI 44370 BS as two tablets 50 mg fasted
3051748|NCT02215746|Experimental|Treatment F|100 mg BI 44370 BS as two tablets 50 mg fed
3051749|NCT02215733||Patients prescribed antihypertensives|
3051750|NCT02215720|Experimental|Cetuximab + Temsirolimus|Cetuximab: 400mg/m² IV for 120 minutes Temsirolimus: 15mg IV for 60 minutes
3051751|NCT02215707|Experimental|Group 1|"Group 1: 5 doses of 2.7x10^5 PfSPZ Vaccine; homologous 3D7 CHMI~Grp 1 (n=15) gets 5 doses of 270,000 PfSPZ per dose (4 doses at 4 wk intervals, 2 month delay before 5th dose) by DVI. Grps 1 and 2 start immunizations together.~1 subj in each of Grps 1 and 2 will be immunized approx 24 hrs before rest of grp (pilot subjects). For Grp1/Grp 2 pilot subjects: 1st subject will be immunized, observed on site for minimum 1 hr; the 2nd subject may be immunized, will also be observed for minimum 1 hr. If no safety concerns are identified after 24 hrs that trigger the stopping rules, then rest of subjects in Grps 1 and 2 will be immunized.~Approx 3 wks after final dose, Grps 1 and 3 will undergo homologous CHMI (Pf3D7 strain) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1 and 3 will undergo 2nd homologous CHMI (3D7) with 6 Infectivity Controls. Subjects will be followed for 8 wks after last CHMI for safety purposes."
3051752|NCT02215707|Experimental|Group 2|"Grp 2: 5 doses of 2.7x10^5 PfSPZ Vaccine; heterologous 7G8 CHMI~Grp 2 (n=15) gets 5 doses of 270,000 PfSPZ/dose (4 doses at 4wk intervals, 2 month delay before 5th dose) by DVI. Grps 1 / 2 start immunizations together.~1 subj in each of Grps 1 / 2 will be immunized approx 24 hrs before rest of grp (pilot subjects). For Grp1/ 2 pilot subj: 1st subj will be immunized, observed on site for min 1 hr; 2nd subj may be immunized, will also be observed for min 1 hr. If no safety concerns after 24 hrs that trigger stopping rules, then rest of Grps 1 / 2 will be immunized.~Approx 3 wks after final dose, Grps 1/3 have homologous CHMI; 2-3 days later, Grp 2 will undergo heterologous CHMI (Pf7G8) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1/3 have 2nd homologous CHMI; 2-3 days later, Grp 2 will undergo 2nd heterologous CHMI (7G8 strain) with 6 Infectivity Controls. Subj will be followed for 8 wks after last CHMI for safety purposes."
3051753|NCT02215707|Experimental|Group 3|"Grp 3 (n=15) will receive 3 doses by DVI of 450,000 PfSPZ/dose (of PfSPZ Vaccine) at 8 wk intervals (starting approx. 4 wks after Grps 1 and 2 get 1st immunization).~3 subjects in Grp 3 will be immunized approx 24 hrs prior to rest of grp (pilot subjects). The 3 subjects will be immunized sequentially with min 2 hr observation period between subjects (and a 2 hr observation of 3rd subject as well). If no safety concerns identified in pilot subjects after 24 hours that trigger the stopping rules, the rest of subjects in Grp 3 will be immunized as scheduled.~Approx 3 wks after final dose, Grps 1 and 3 will undergo homologous CHMI (3D7 strain) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1 and 3 will undergo 2nd homologous CHMI (3D7) with 6 Infectivity Controls. Subjects will be followed for 8 wks after last CHMI for safety purposes."
3051754|NCT02215707|No Intervention|CHMI Controls.1|n = 6, infectivity controls for 1st homologous CHMI (3D7) occurring approximately 3 weeks after final immunization of Groups 1 and 3. This group does not receive the PfSPZ Vaccine.
3051755|NCT02215707|No Intervention|CHMI Controls.2|n = 6, infectivity controls for 1st heterologous CHMI (7G8) occurring approximately 3 weeks after final immunization of Group 2. This group does not receive the PfSPZ Vaccine.
3051756|NCT02215707|No Intervention|CHMI Controls.3|n = 6, infectivity controls for 2nd homologous CHMI (3D7) occurring approximately 24 weeks after final immunization of Groups 1 and 3. This group does not receive the PfSPZ Vaccine.
3051757|NCT02215707|No Intervention|CHMI Controls.4|n = 6, infectivity controls for 2nd heterologous CHMI (7G8) occurring approximately 24 weeks after final immunization of Group 2. This group does not receive the PfSPZ Vaccine.
3051758|NCT02215694|Experimental|probiotic group|consumed 2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
3051759|NCT02215694|Placebo Comparator|placebo group|consumed 2g of powder daily without probiotics
3051760|NCT02215681|Experimental|acupuncture|acupuncture treatment
3051761|NCT02215681|No Intervention|standard treament|watchful waiting
3051762|NCT02215668|No Intervention|No physical exercise|Women are never subjected to any exercise prior to mammography.
3051763|NCT02215668|Experimental|Physical exercise (Upper limb)|Women will be subjected to physical exercise on upper limb prior to mammography.
3051764|NCT02215668|Active Comparator|Group 2|Women are subjected to physical exercise in the lower limbs prior to mammography
3051765|NCT02215655|Active Comparator|Motivational interviewing|Motivational interviewing counselling will be administered to the subjects
3051766|NCT02215655|No Intervention|No intervention: control group|No motivational interviewing counselling will be administered to the subjects
3051767|NCT02215629|Experimental|Experimental VS4718|Oral VS-4718 administered BID during a 28 day cycle.
3051768|NCT02215616|Experimental|Laquinimod 0.5|
3051769|NCT02215616|Experimental|Laquinimod 1.0|
3051770|NCT02215616|Experimental|Laquinimod 1.5|NOTE- As of January 2016, this arm has been discontinued.
3051771|NCT02215616|Placebo Comparator|Placebo|
3051772|NCT02215603|No Intervention|Prolonged sitting|9 h of prolonged sitting
3051773|NCT02215603|Experimental|Prolonged sitting + interval standing bouts|Stand bout for 15-min every 30 minutes during the 9 hours of sitting
3051774|NCT02215603|Experimental|Moderate exercise bout + Prolonged sitting|30-min moderate-intensity exercise bout followed by 8 h of sitting
3051775|NCT02215603|Experimental|Moderate exercise bout + Prolonged sitting +Standing bouts|30-min moderate-intensity exercise bout and stand bout for 15-min every 30 minutes during the remaining 8 hours of sitting
3051776|NCT02215590|Experimental|Re-Step|"The system consists of a pair of special shoes whose sole height and angles change in a specific given order, thereby facilitating motor learning and problem solving in real time.~This unpredictable change will introduce a situation of necessary adaptation to keep balance."
3051777|NCT02215577|Experimental|In-situ split with portal vein ligature|In-situ liver split at time when portal vein ligature is performed
3051778|NCT02215577|Active Comparator|Portal embolization or ligation|Intervention: Preoperative portal embolization (+/-ablation) followed by liver resection, or local resections and/or ablations followed by lobectomy, two-stage hepatectomy
3051779|NCT02215564||No treatment|Young adults tested by PCR for B. pertussis carriage
3051780|NCT02215551||Study Group|"Younger than 90 years old. no communication barriers (e.g., English speaking, household telephone) Affirmative response to each of the three following questions: a) Do patients have pain, weakness, numbness, or tingling in their legs when walking standing? b) Does this pain, weakness, numbness or tingling in their legs interfere with their daily activities? c) Have patients tried at least one non-surgical treatment for their leg symptoms (e.g., physical therapy, pain medications, spinal injection)? Have been scheduled for surgery on lower back for a condition called lumbar spinal stenosis.~Whom have non degenerative causes of LSS such as tumor, infection, trauma, hemorrhage, or epidural lipomatosis, Prior lumbar spinal surgery, spondylolisthesis with spinal instability, significant cognitive impairment."
3051781|NCT02215538|Experimental|OROS methylphenidate|This was a 4-week double-blind arm. Medication was initiated at 18 mg/day and increased every 2 or 3 days by 9 mg based on treatment response and side effects. Maximum dose - 90 mg/day. Patients were seen weekly. Generally a stable dose was seen in 2 weeks and maintained the last 2 weeks of the arm. Side effects were assessed at each visit.
3051782|NCT02215538|Placebo Comparator|placebo|This arm was identical to the active medication arm except that placebo replaced the active medication.
3051783|NCT02215525|Experimental|UVA and Herbal|Twenty four daily one hour sessions using Extra-corporeal electro-magnetic irradiation device combined with Herbal Food Supplement Selenium containing tables as an Anti Oxidant (Tablet A) starting 10 days before the radiation sessions and to continue for 24 weeks
3051784|NCT02215525|Experimental|Herbal|Chronic HCV patients, non complicated will be treated by Herbal tablets only . 500 mg twice tablets every 6 hours daily for 6 months.
3051785|NCT02215512|Experimental|RRx-001 + WBRT|RRx-001 administered intravenously twice a week (10, 17, 33, 55 mg) in subjects with brain metastases receiving whole brain radiation therapy (WBRT).
3051786|NCT02215499|Active Comparator|Xyrem®|Oral suspension
3051787|NCT02215499|Experimental|JZP-386|Oral suspension
3051788|NCT02215499|Placebo Comparator|Placebo|Oral suspension
3051789|NCT02215473|Experimental|gingivitis mouth rinse|
3051790|NCT02215473|Experimental|periodontitis mouth rinse|
3051791|NCT02215473|Active Comparator|gingivitis no mouth rinse|
3051792|NCT02215473|Active Comparator|periodontitis no mouth rinse|
3051793|NCT02215460|Experimental|Full-mouth scaling (FMS)|
3051794|NCT02215460|Experimental|FMS chlorhexidine rinse|
3051795|NCT02215460|Experimental|FMS azithromycin tablets|
3051796|NCT02215460|Placebo Comparator|FMS placebo rinse|
3051797|NCT02215460|Experimental|Quadrant scaling (QS)|
3051798|NCT02215460|Experimental|QS chlorhexidine rinse|
3051799|NCT02215460|Experimental|QS azithromycin tablets|
3051800|NCT02215460|Placebo Comparator|QS placebo tablets|
3051801|NCT02215460|Placebo Comparator|FMS placebo tablets|
3051802|NCT02215460|Placebo Comparator|QS placebo rinse|
3051803|NCT02215447|Experimental|NAB-Paclitaxel with carboplatin|NAB paclitaxel (100 mg/m2 IVI) every week (d1,8,15) in three weekly cycle. Carboplatin (AUC=5 IVI) (d1) in three weekly cycle. Study treatment will continue until progressive disease, unacceptable toxicity, or ceased by patient or clinician preference.
3051804|NCT02215434|Placebo Comparator|Biolipid B2 (blanked/placebo)|"The study is a single-center, single-blind, placebo-controlled, parallel group trial.~It consists of a 4-week screening period plus a 12-week treatment phase. At the screening visit, all participants underwent a physical examination including vital signs and breast and pelvic examination.~They were randomly assigned in a 1:1 ratio to receive a transdermal vehicle biolipid B2 (identical placebo) provided by Evidence Pharmaceuticals Inc, SP,BRAZIL.~The testosterone and placebo emulsion were alcohol-free matrixes that were applied topically to the forearm daily for the period of 12 weeks."
3051805|NCT02215434|Active Comparator|Testosterone, Transdermal, Behavior|Testosterone 0.5%, daily, 3 months
3051806|NCT02215421|Experimental|Play Mommio for 2 months|"The objective is to build parent's skills in encouraging their child to eat vegetables. The player is asked to read a novella, Totally Frobisher (providing backstory to the game), and play a game called Mommio (a casual video game for parents of 3 to 5 year old children). The player calls Kiddio, the child character, to dinner, and offers a vegetable (V) (selected from among several). Kiddio refuses. The player is offered a selection of V parenting statements (from the scientific literature on food parenting) or manipulation of the environment (e.g. turning off the kitchen TV) to control the situation and encourage the child to eat the V. As problems arise (e.g. a permissive father saying he doesn't like vegetables), the player must select ways to cope. Players set a goal to do with their child at home what they learned in the game. Game episodes include food store shopping, eating in the car, at grandma's, and at a fast food store."
3051807|NCT02215421|No Intervention|No game play|No intervention control.
3051808|NCT02215408|No Intervention|Control|Patient received usual care from the provider in the local clinic.
3051809|NCT02215408|Experimental|CVRS Intervention|CVRS pharmacist followed the patient for 12 months in order to decrease the patient's risk of developing cardiovascular disease.
3051810|NCT02215395|Experimental|CVR treatment cycle|Women who meet all inclusion and no exclusion criteria will be randomized to the first treatment cycle with the CVR alone followed by the second treatment cycle with the CVR and miconazole (one of three dosing regimens) or the first treatment cycle with the CVR and miconazole followed by the second treatment cycle with the CVR alone.
3051811|NCT02215382|Active Comparator|sugammadex|
3051812|NCT02215382|Active Comparator|neostigmine + atropine|
3051842|NCT02215239|No Intervention|Working type B & Usual care|Participants: Workers tend to be standing during work hours. Intervention: Usual care. Duration: 16 weeks.
3051813|NCT02215369|Experimental|VenaCure EVLT 400 µm fiber Procedure Kit|Only one limb can be treated and included in this study; however, multiple IPV's within the study limb may be treated. All IPV's treated will be followed according to the study schedule.
3051814|NCT02215356|Active Comparator|Chemoradiotherapy|Etoposide 50mg/m2, ivgtt, d1-d5, cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles, while chest radiotherapy (total dose 60-66Gy, 2Gy per time, once a day, five times a week, a total of 30-33 times). Progressive patients will be administered oral icotinib 125 mg three times daily.
3051815|NCT02215356|Experimental|Icotinib with concurrent radiotherapy|Chest radiotherapy (total dose 60-66Gy, 2Gy per time, once a day, five times a week, a total of 30-33 times), while icotinib 125mg three times daily (375 mg per day) by mouth. Maintenance icotinib will be administered after radiotherapy. Progressive patients will receive chemotherapy, using the platinum-based two-drug chemotherapy regimen.
3051816|NCT02215343|Experimental|High fibre diet (wheat bran extract)|
3051817|NCT02215343|Experimental|High PUFA diet (fish oil supplement)|
3051818|NCT02215330|Placebo Comparator|Sugar pill|"Maltodextrin filled into capsules.~1 Pill starting dosage~Follow-up visits (every two weeks, beginning at week 4):~If subretinal fluid is present and the patient takes two pills a day dosage stays the same.~If no subretinal fluid is present, the patient will continue the present dosage for another 2 weeks and will then stop the medication.~If no subretinal fluid is present and the patient takes no medication everything stays the same.~If subretinal fluid is present again (recurrence) and the patient takes no medication, the medication will be re-started again, the patient has to take one tablet beginning at the following day"
3051819|NCT02215330|Experimental|Eplerenone|"Eplerenone 25mg pills triturated and filled into capsules.~1 Pill starting dosage~Follow-up visits (every two weeks, beginning at week 4):~If subretinal fluid is present and the patient takes two pills a day dosage stays the same.~If no subretinal fluid is present, the patient will continue the present dosage for another 2 weeks and will then stop the medication.~If no subretinal fluid is present and the patient takes no medication everything stays the same.~If subretinal fluid is present again (recurrence) and the patient takes no medication, the medication will be re-started again, the patient has to take one tablet beginning at the following day"
3051820|NCT02215317||OSA group|Patients found to have OSA based on an overnight sleep study
3051821|NCT02215317||Non-OSA group|Patients found not to have OSA based on an overnight sleep study
3051822|NCT02215304|Active Comparator|Bifidobacterium longum R0033|Bifidobacterium longum ssp infantis R0033, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
3051823|NCT02215304|Active Comparator|Lactobacillus helveticus R0052|Lactobacillus helveticus R0052, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
3051824|NCT02215304|Active Comparator|Bifidobacterium bifidum R0071|Bifidobacterium bifidum R0071, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
3051825|NCT02215304|Placebo Comparator|Placebo|potato starch 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
3051826|NCT02215291||Patients undergoing EGD or esophagoscopy|The cohort includes patients undergoing EGD or esophagoscopy for initial diagnosis or initial staging and mapping, surveillance of non-treated disease, and treatment (initial or ongoing) or post-treatment surveillance
3051827|NCT02215278|Experimental|low phytic acid bean (lpa variety)|
3051828|NCT02215278|Experimental|high iron biofortified bean variety|
3051829|NCT02215278|Experimental|normal iron, normal phytic acid bean|
3051830|NCT02215265|No Intervention|No adjuvant treatment|Group A
3051831|NCT02215265|Active Comparator|Postoperative radiotherapy 60 Gray|"Arm B1: postoperative radiotherapy (PORT) at a dose of 60 Gray (Gy) in 30 fractions over 6 weeks.~Group B: Patients with: T3 tumours (or T1-T2 tumours with additional risk factors), N2a (metastasis in single ipsilateral node 31-60 mm diameter) or N2b (metastasis in multiple ipsilateral nodes <61 mm diameter) disease, tumours with evidence of perineural and/or vascular invasion, or close margins (1-5mm) around the primary tumour specimen but with negative marginal biopsies."
3051832|NCT02215265|Experimental|Postoperative radiotherapy 50 Gray|"Arm B2: Postoperative radiotherapy (PORT) at a dose 50 Gray in 25 fractions over 5 weeks.~Group B: Patients with: T3 tumours (or T1-T2 tumours with additional risk factors), N2a (metastasis in single ipsilateral node 31-60 mm diameter) or N2b (metastasis in multiple ipsilateral nodes <61 mm diameter) disease, tumours with evidence of perineural and/or vascular invasion, or close margins (1-5mm) around the primary tumour specimen but with negative marginal biopsies."
3051833|NCT02215265|Active Comparator|Postoperative radiotherapy 60 Gray with Cisplatin|"Arm C1: postoperative radiotherapy at a dose of 60 Gray in 30 fractions over 6 weeks with concurrent Cisplatin chemotherapy (POCRT). Cisplatin may be given 3 weekly (100mg/m2 week 1 and week 4 of radiotherapy) or weekly (40mg/m2 weekly during radiotherapy), according to local practice.~Group C: Patients with tumours of any T or any N stage, which exhibit the following high risk pathological features will be included: positive (<1mm) margins around the primary tumour specimen but with negative marginal biopsies and/or evidence of cervical lymph node extracapsular spread."
3051834|NCT02215265|Experimental|Postoperative radiotherapy 60 Gray without chemotherapy|"Arm C2: Postoperative radiotherapy at a dose of 60 Gray in 30 fractions over 6 weeks without chemotherapy (Test Arm C2).~Group C: Patients with tumours of any T or any N stage, which exhibit the following high risk pathological features will be included: positive (<1mm) margins around the primary tumour specimen but with negative marginal biopsies and/or evidence of cervical lymph node extracapsular spread."
3051835|NCT02215252|Experimental|PF-05089771|
3051836|NCT02215252|Experimental|Placebo|
3051837|NCT02215252|Experimental|Pregabalin|
3051838|NCT02215252|Experimental|PF-05089771 + Pregabalin|
3051839|NCT02215239|Experimental|Working type A & Workplace intervention|Participants: Workers tend to be seated during work hours. Intervention: WHO Healthy Workplace Framework and Model. Duration: 16 weeks.
3051840|NCT02215239|No Intervention|Working type A & Usual care|Participants: Workers tend to be standing during work hours. Intervention: Usual care. Duration: 16 weeks.
3051841|NCT02215239|Experimental|Working type B & Workplace intervention|Participants: Workers tend to be standing during work hours. Intervention: WHO Healthy Workplace Framework and Model. Duration: 16 weeks.
3051843|NCT02215213|Active Comparator|Intervention Group|Arm 1 is receiving vitamin D supplementation in 2000 IU/day ,
3051844|NCT02215213|Active Comparator|Arm 2 intervention group|Arm 2 is receiving vitamin D supplementation in 4000/IU per day
3051845|NCT02215213|Active Comparator|Arm 3 control group|Arm 3 is receiving vitamin D supplementation in 400 IU/day
3051846|NCT02215200|Experimental|Anti-Thymocyte Globulin (ATG) and Placebo|"Anti-Thymocyte Globulin (ATG)/Placebo: Anti-Thymocyte Globulin (ATG) will be administered at a dose of 2.5mg/kg as two divided IV infusions of 0.5mg/kg and 2mg/kg. First dose (0.5mg/kg) will be infused over a minimum of 12 hours, and the second dose (2mg/kg) over a minimum of 8 hours. The second dose should be given no less than 12 and no more than 24 hours after the previous dose.~Placebo(for GCSF) treatment will begin 6 hours after completion of the ATG. Placebo will be given subcutaneously every 2 weeks for a total of 6 doses"
3051847|NCT02215200|Experimental|ATG plus Granulocyte colony stimulating factor (GCSF)|"Granulocyte colony stimulating factor (GCSF) is supplied in 0.6 mL prefilled syringes for subcutaneous injection. Each syringe contains 6 mg GCSF (based on protein weight), in a sterile, clear, colorless, preservative-free solution (pH 4.0) containing acetate (0.35 mg), sorbitol (30.0 mg), polysorbate 20 (0.02 mg), and sodium (0.02 mg) in water for injection, U.S. Pharmacopeial Convention (USP). The standard 6mg dose will be given with the exception of subjects who weigh less than 45 kg.~GCSF treatment will begin 6 hours after completion of the ATG / Placebo. GCSF will be given subcutaneously every 2 weeks for a total of 6 doses"
3051848|NCT02215200|Placebo Comparator|Placebo|Placebo for ATG will be administered by IV infusion in 2 doses. Placebo for GCSF will be administered subcutaneously every 2 weeks for a total of 6 doses
3051849|NCT02215187|Experimental|Problem-Solving Training|PST is a cognitive-behavioral intervention. Delivery of the PST + usual care condition will be administered to caregivers over the course of 6 one-hour per week, telephone calls/sessions that will entail education related to problem-solving skills/problem-solving model and application to caregiving and managing caregiver related problems.
3051850|NCT02215187|Sham Comparator|Attention Control|Attention/social contact control. Health education (non-skill focused).
3051851|NCT02215174|Experimental|Asians|Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
3051852|NCT02215174|Experimental|Caucasians|Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
3051853|NCT02215161|Experimental|Treatment (selinexor)|Patients receive selinexor PO on days 1 and 3 of weeks 1-3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3051854|NCT02215148||Brain injured patients with hyponatremia|Patients with acute brain injury who develop hyponatremia and are administered tolvaptan via the nasogastric tube, deemed necessary by the primary medical team.
3051855|NCT02215135|Experimental|Corifollitropin in PCOS|In GnRH antagonist protocol, a single dose corifollitropin alfa was administered for ovarian stimulation following rFSH daily injection to stimulate follicle development. GnRH agonist was given to trigger final oocyte maturation when three follicles reached 17 mm in size. The IVF or ICSI was planned then all embryos were elective cryopreserved.
3051856|NCT02215122|Experimental|MGR001|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via CRC749 inhaler.
3051857|NCT02215122|Experimental|Advair® Diskus®|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via Diskus® inhaler.
3051858|NCT02215122|Experimental|Seretide™ Accuhaler™|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via Accuhaler™ inhaler.
3051859|NCT02215109||BRVO, Retinal vessel diameter|The retinal vessel diameter was measured Branch Retinal Vein Occlusion patients after intravitreal bevacizumab injection.
3051860|NCT02215096|Experimental|Phase 1-Dose Escalation|Subject receiving a stable dose of enzalutamide 160 mg once daily will receive GSK2636771 following a modified 3+3 dose escalation procedure (Cohort -1: 200 mg, Cohort 1: 300 mg and Cohort 2: 400 mg) to evaluate the safety and PK for each combination dose level and to guide selection of the RP2D of the combination. If the combination doses in Cohort 1 are not tolerable, lower doses as defined in the de-escalation cohort (Cohort -1) will be evaluated. If the de-escalation cohort (Cohort -1) is not tolerable, further dose-escalation using a continuous daily dosing schedule for both compounds simultaneously will be terminated. Additional dose levels of GSK2636771 or alternative dosing schedules may be explored based upon ongoing assessment of safety and PK. Dose modification decisions will be made utilizing all available data at the end of each DLT determination period (28 days).
3051861|NCT02215096|Experimental|Phase 2- Dose Expansion|Additional 20 subjects will be assigned to receive GSK2636771 at the MTD or RP2D determined in the Dose-Escalation Phase while continuing treatment with enzalutamide to evaluate the long-term safety of the combination as well as the 12-week non-PD rate
3051862|NCT02215083|Experimental|L-Glutamine|All patients will receive 20-30 grams of l-glutamine daily for 9 weeks (+/- 1 week)
3051863|NCT02215070|Experimental|Pasireotide + Chemo|Pasireotide combined with Busulfan. Methotrexate will be given after the stem cell transplant.
3051864|NCT02215070|Experimental|Pasireotide + Total Body Irradiation|Pasireotide combined with Total Body Irradiation (TBI). Methotrexate will be given after the stem cell transplant.
3051865|NCT02215057|Experimental|Group 2|topical anesthetic drops patients were prepared for bilateral ICL/TICL procedure on the same day.Group I (1 eye) received topical anesthetic drops
3051866|NCT02215057|Experimental|Group 1|received topical anesthesia plus intracameral lidocaine 1% topical anesthesia plus intracameral lidocaine 1%'
3051867|NCT02215044|Experimental|BI 2536 in combination with gemcitabine|
3051868|NCT02215031|Experimental|BI 44370|
3051869|NCT02215031|Placebo Comparator|Placebo|
3051870|NCT02215018|Experimental|BI 44370 TA solution|
3051871|NCT02215018|Experimental|BI 44370 TA tablet|
3051872|NCT02215018|Placebo Comparator|Placebo solution|
3051873|NCT02215018|Placebo Comparator|Placebo tablet|
3051874|NCT02215005|Experimental|Telmisartan + Ramipril|5 days qd
3051875|NCT02215005|Active Comparator|Telmisartan|5 days qd
3051876|NCT02215005|Active Comparator|Ramipril|5 days qd
3051877|NCT02214992|Experimental|Telmisartan/Ramipril|Fixed dose combination tablet
3051878|NCT02214992|Active Comparator|Telmisartan + Ramipril capsule|
3051879|NCT02214992|Active Comparator|Telmisartan + Ramipril tablet|
3051880|NCT02214979|Experimental|Telmisartan/Ramipril|
3051881|NCT02214979|Active Comparator|Telmisartan + Ramipril capsule|
3051882|NCT02214979|Active Comparator|Telmisartam + Ramipril tablet|
3051883|NCT02214966|Experimental|Telmisartan/Ramipril, fed|
3051893|NCT02214927|Experimental|BI 11634 cross-over|sequence: 1. tablet 2. drinking solution
3051894|NCT02214914|Experimental|BI 11634 drinking solution|single rising dose
3051895|NCT02214914|Placebo Comparator|Placebo|
3051896|NCT02214914|Experimental|BI 11634 tablet|
3051897|NCT02214901|Experimental|BIBW 2948 BS in single rising doses|
3051898|NCT02214901|Placebo Comparator|Placebo|
3051899|NCT02214888|Experimental|BIRB 796 BS, low dose|
3051900|NCT02214888|Experimental|BIRB 796 BS, high dose|
3051901|NCT02214888|Placebo Comparator|Placebo|
3051902|NCT02214875|Experimental|CQI/BTS|"Experimental: CQI/BTS~CQI/BTS interventions will be applied through rapid structured cycles of data collection, testing of solutions and review of changes will be done. At each site, Quality Improvement Teams (QIT) will be established among facility staff. Local Government/State QI teams will provide oversight function of facility based QI initiatives. Break Through Collaborative Series (BTS) will hold quarterly in each study state at a central location with participants from intervention sites. Sessions will provide opportunity for teams to learn from each other; adapt and implement changes using the Plan-Do-Study-Act (PDSA) model. Process indicators will be used to measure quality improvement from the intervention sites and collaboratives."
3051903|NCT02214875|Other|Control|Facilities in control will continue will routine unstructured, irregular continuous quality improvement. Break Through Collaborative will not be applied to the control facilities.
3051904|NCT02214862|Experimental|[F18]-FDDNP|2-(1-{6-[(2-[F-18]fluoroethyl) (methyl)amino]-2-naphthyl} ethylidene) malononitrile Radiopharmaceutical tracer, intravenous, single dose of 360+/-20 megabecquerel
3051905|NCT02214849|Experimental|LATCH Intervention|Women enrolled in the WIC program and receiving breastfeeding peer counseling services will receive text messages to support them with their breastfeeding intentions. They will start receiving automated text messages starting in pregnancy and continuing throughout the first 6 months after giving birth. Messaging during pregnancy will emphasize what to expect in the hospital, the onset of lactation, skin-to-skin contact with baby, early and often breastfeeding in post-partum period, milk transfer (suck & swallow), positioning (with links), common breastfeeding problems and how to seek help. Throughout the study, participants will be able to respond to automated text messages with specific questions that will be received and answered by their WIC program peer counselors. Texting will also have prompts to respond occasionally (at minimum once every two weeks) to ensure that phone is still in service and that the participant in the intervention arm are receiving intervention.
3051906|NCT02214836|Experimental|Kidney stones|"Device: Verasonics Data Acquisition System (VDAS)~Other Names:~Verasonics Data Acquisition System (VDAS) Verasonics Ultrasound Engine Subjects will be imaged the Verasonics Data Acquisition System (VDAS) using conventional clinical outputs within FDA limits. The image processing has been modified.~Subjects in this arm will be imaged by ultrasound by the VDAS. Stone location and size will be determined and compared to clinical determination of stone location and size."
3051907|NCT02214823|Experimental|FES-Cycling|"Timeframe: Within 72 hours of ICU admission. Program: Standard care physiotherapy AND up to one hour of supine cycling daily using a cycle ergometer (RT300 supine model Restorative Therapies, Ltd or Letto 300.) attached to a six channel stimulator (SAGE) and 2 additional RT50 wireless stimulator channels.~One leg will undergo cycling alone without the electrodes turned on (sham) and the other leg will undergo cycling and muscle stimulation. Electrodes will be placed on all major lower limb muscles. Intervention will be provided individually and supervised by a physiotherapist in ICU only. Duration /Intensity: Up to 1 hour at least 5 times a week for 28 days or ICU discharge, if 20 sessions have not occurred at this time, intervention will continue until this is achieved. Intensity of muscle stimulation will be delivered at a level able to cause visible muscle contractions, confirmed by palpation.~A subgroup of 10 individuals will be involved in biomarker analyses."
3051908|NCT02214823|Active Comparator|Standard Care|"Both groups will receive usual medical and nursing care in the ICU and ward. Both groups (control and intervention) will receive standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.~A subgroup of 10 individuals will be involved in biomarker analyses. This will involve collection of muscle biopsy, blood and urine analyses at baseline and ICU discharge."
3051909|NCT02214810|Active Comparator|Control- Marcain|Group 1 will receive non-liposomal bupivacaine introduced into the soft tissue surrounding the fracture at the conclusion of the surgery.
3051910|NCT02214810|Experimental|Experimental- Exparel|Group 2 will receive a mixture of non-liposomal bupivacaine and Exparel introduced into the soft tissue surrounding the fracture at the conclusion of the surgery.
3051911|NCT02214797|Other|Presbyopic group - Low Add|"40 years and over Add of less than +1.50D~Control lens : Lotrafilcon B and Senofilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion. Each lenses will be worn for a week with a minimum 2 day washout period between the lens types. Each lens will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
3051912|NCT02214797|Other|Presbyopic group - Med Add|"40 years and over Add of +1.50D to +1.75D~Control lens : Lotrafilcon B and Senofilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
3051913|NCT02214797|Other|Presbyopic group - High Add|"40 years and over Add of +2.00D to +2.50D~Control lens : Lotrafilcon B and Senofilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
3051914|NCT02214797|Other|Non-presbyopic group|"18 to 39 years old No Add~Control lens : Lotrafilcon B and Etafilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
3051915|NCT02214784|Active Comparator|Active Neurotech Vital Device|50% of 140 patients on a 12 week treatment programme with the device used 5 days out of 7 for 30minutes over 12 weeks.
3052089|NCT02213679|Experimental|Guanidinoacetic acid|Supplementation with dietary guanidinoacetic acid
3051916|NCT02214784|Placebo Comparator|Modified Neurotech Vital Device|50% of 140 patients on a 12 week treatment programme with the device used 5 days out of 7 for 30 minutes over 12 weeks.
3051917|NCT02214771||1: CDI in patients treated with fidaxomicin|Diagnosed with a CDI and treated with fidaxomicin
3051918|NCT02214771||2: CDI in patients receiving treatment other than fidaxomicin|Diagnosed with a CDI, regardless of the prescribed treatment (not fidaxomicin)
3051919|NCT02214758|Other|Dietary counseling|
3051920|NCT02214758|Other|Oral health counseling|
3051921|NCT02214758|No Intervention|nutrition no counseling|
3051922|NCT02214758|No Intervention|oral health no counseling|
3051923|NCT02214745||Mentally retarded Israeli Arab children|
3051924|NCT02214745||Israeli Arab children with cerebral palsy|
3051925|NCT02214745||Israeli Jewish children with cerebral palsy|
3051926|NCT02214745||Mentally retarded Israeli Jewish children|
3051927|NCT02214732|Experimental|MBCT + Treatment as Usual (TAU)|"Behavioural: Mindfulness Based Cognitive Therapy~Participants in the MBCT group attend an 8 week course of a modified MBCT program for pregnant women, delivered by a licensed clinical psychologist."
3051928|NCT02214732|No Intervention|Treatment as Usual (TAU)|Participants in the TAU group access community resources for pregnant women experiencing psychological distress.
3051929|NCT02214719|Experimental|Baseline observation for EASI-IDM use|Baseline observation period to gather information on current practice about diabetes care
3051930|NCT02214706|Experimental|sirolimus topical 40microgram/cm2|sirolimus topical 40microgram/cm2
3051931|NCT02214706|Experimental|Pulsed Dye Laser + Erbium yag + sirolimus|Pulsed Dye Laser + Erbium yag laser + topical sirolimus
3051932|NCT02214706|Experimental|Pulsed Dye Laser + topical sirolimus|Pulsed Dye Laser + topical sirolimus
3051933|NCT02214706|Experimental|Pulsed Dye Laser|Pulsed Dye Laser
3051934|NCT02214693|Experimental|Group 1(Severe decrease in GFR)|Severe decrease in GFR
3051935|NCT02214693|Experimental|Group 2(Moderate decrease in GFR)|Moderate decrease in GFR
3051936|NCT02214693|Experimental|Group 3(Mild decrease in GFR)|Mild decrease in GFR
3051937|NCT02214693|Experimental|Group 4(Normal GFR)|Normal GFR
3051938|NCT02214680|Experimental|Combination of Brimonidine and Timolol|On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.
3051939|NCT02214667|Experimental|DDMI-IGT|Subjects randomized to the experimental condition will receive adapted versions of dual-diagnosis motivational interviewing ([DDMI] one session before release from jail) and integrated group therapy ([IGT] 12 community-based sessions over a 2-month period).
3051940|NCT02214667|Active Comparator|Usual care|Subjects randomized to the usual care condition will receive jail and community-based behavioral health services.
3051941|NCT02214654||ticagrelor，clopidogrel，antiplatelet drugs|
3051942|NCT02214641|Experimental|Lifestyle intervention|Resilient, Empowered, Active Living (REAL) Diabetes
3051943|NCT02214641|Active Comparator|Information Control|Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose.
3051944|NCT02214628|Experimental|Fovista® (anti-PDGF BB) plus anti-VEGF|"Subjects will be administered Fovista® (anti-PDGF BB) plus anti-VEGF as a Pre-Treatment or as a Simultaneous regimen followed by quarterly administration."
3051945|NCT02214615|Active Comparator|Carbamazepine|Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce. After 2 weeks of steady dose drug will be tapered down every 3 days.
3051946|NCT02214615|Placebo Comparator|Placebo|Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce to match dosing with carbamazepine. After 2 weeks of steady dose drug will be tapered down every 3 days.
3051947|NCT02214602|Experimental|Study group(Epirubicin)|in this arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor
3051948|NCT02214602|No Intervention|Control group|in this arm -control group- : patients will not receive immediate intravesical instillation of of epirubicin after compete transurethral resection of bladder tumor.
3051949|NCT02214589|Active Comparator|Oral glucose and NNS|Oral glucose and NNS
3051950|NCT02214589|Active Comparator|Oral glucose and facilitated tucking and NNS|Oral glucose, facilitated tucking and NNS
3051951|NCT02214589|Active Comparator|Facilitated Tucking and NNS|Facilitated tucking and NNS
3051952|NCT02214563|Active Comparator|Thrice-weekly cholecalciferol|Capsule containing 3,000 IU of cholecalciferol will be given at the end of each hemodialysis session. Dissolved with olive oil and coated by soft capsule made of gelatin and glycerin.
3051953|NCT02214563|Active Comparator|Monthly cholecalciferol|Capsules containing a dose equivalent to 9,000 IU/week will be given at the end of the first hemodialysis session in the 3rd week of each month. Dissolved with olive oil and coated by soft capsule made of gelatin and glycerin.
3051954|NCT02214563|Placebo Comparator|Thrice-weekly placebo|Olive oil coated by soft capsule made of gelatin and glycerin.
3051955|NCT02214563|Placebo Comparator|Monthly placebo|Olive oil coated by soft capsule made of gelatin and glycerin.
3051956|NCT02214550|No Intervention|Pain Discovery Aim|"255 Reproductive age women (18-45) will be identified and divided into 5 groups~Healthy Controls~Chronic Pain (Positive Controls)~Dysmenorrhea (D)~Dysmenorrhea with Cross Organ Sensitization (D+COS)~Painful bladder syndrome (PBS)/interstitial cystitis (IC)~After a screening, dysmenorrhea with COS and PBS participants will be compared with controls. Daily Diaries will be completed for 1-3 months. During the luteal phase of the participants' menstrual cycle or a predetermined time, participants will complete aim #1 testing consisting of a battery of questionnaires, bladder sensitivity testing, quantitative sensory testing (QST), a blood draw and EEG testing. All participants will also complete a yearly follow-up questionnaire for 5 years."
3052090|NCT02213679|Placebo Comparator|Placebo|Supplementation with cellulose
3051957|NCT02214550|No Intervention|D+COS-no OC|For Aim #2, ten participants in the Dysmenorrhea + COS group will not receive an OC intervention. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
3051958|NCT02214550|Active Comparator|D+COS-cyclic microgestin 1/20|For Aim #2, 26 participants in the Dysmenorrhea + COS group will receive cyclic OC. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
3051959|NCT02214550|Active Comparator|D+COS-continuous microgestin 1/20|For Aim #2, 26 participants in the Dysmenorrhea + COS group will receive continuous OC. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
3051960|NCT02214550|Active Comparator|PBS-continuous microgestin 1/20|For Aim #2, 26 participants in the Painful Bladder Syndrome group will receive continuous OC. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
3051961|NCT02214537|Experimental|MACS|Patients with MACS Selection
3051962|NCT02214524|Experimental|Bair hugger forced air warming therapy|Use of Bair Hugger forced-air warming system perioperatively to keep patient normothermia
3051963|NCT02214524|No Intervention|conventional warming care|conventional warming care
3051964|NCT02214511||MDD patients|emotional facial stimuli cyberball game
3051965|NCT02214511||healthy subjects|emotional facial stimuli cyberball game
3051966|NCT02214498|Active Comparator|Enalapril/hydrochlorothiazide|This arm will start with six weeks of administration of enalapril/hydrochlorothiazide in the evening and placebo in the morning, followed by six weeks of active treatment in the morning and placebo in the evening
3051967|NCT02214498|Placebo Comparator|Placebo|This arm will start with six weeks of morning administration of enalapril/hydrochlorothiazide in the morning and placebo in the evening, followed by six weeks of placebo in the morning and active treatment in the evening
3051968|NCT02214485|Experimental|integrated care (IC)|Subjects will receive such care twice weekly for 12 weeks.
3051969|NCT02214485|Experimental|lower extremity strength training (LEST)|Subjects will receive training twice weekly for 12 weeks
3051970|NCT02214472|Experimental|Biofeedback|Abdomino-thoracic muscle activity after a challenge meal will be recorded by EMG and the signal will be displayed on a monitor in front of the patients; in the biofeedback group, patients will be instructed to control muscle activity.
3051971|NCT02214472|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patients will take a pill of placebo.
3051972|NCT02214459|Experimental|mhealth counseling|DASH Mobile mhealth enhanced coaching
3051973|NCT02214446||primary caregivers of children newly diagnosed with cancer|Explore Factors related to Truth Telling in Primary Caregivers of Children Newly Diagnosed with Cancer
3051974|NCT02214433|Experimental|Part A Period 1 Debio 1450 IV Solution|Part A Debio 1450 IV solution infused over two hours on Day 1 after fasting
3051975|NCT02214433|Experimental|Part A Period 2 Debio 1450 Tablet|Debio 1450 Tablet oral dosing once on Day 5, after fasting
3051976|NCT02214433|Experimental|Part A Period 3 Debio 1450 Tablet|Debio 1450 Tablet oral dosing once on Day 9, 30 minutes after a high calorie, high fat breakfast, after fasting
3051977|NCT02214433|Experimental|Part A Period 4 Debio 1450 Tablet|After preparation with Pantoprazole, Pantoprazole taken with Debio 1450 Tablet oral dosing once on Day 14, after fasting
3051978|NCT02214433|Placebo Comparator|Part B Placebo All Cohorts|Placebo IV solution on days 1-5 and then Placebo Tablet or Capsule on Days 6-10, according to the cohort dosing schedule
3051979|NCT02214433|Experimental|Part B Debio 1450 Cohort 1|Debio 1450 IV solution, once daily on days 1-5, then Debio 1450 Tablet, once daily on days 6-10
3051980|NCT02214433|Experimental|Part B Debio 1450 Cohort 2a|Debio 1450 IV solution, once daily on day 1
3051981|NCT02214433|Experimental|Part B Debio 1450 Cohort 3|Debio 1450 IV solution, twice daily on days 1-5, then Debio 1450 Capsule, twice daily on days 6-10
3051982|NCT02214433|Experimental|Part B Debio 1450 Cohort 4|Debio 1450 IV solution, twice daily on days 1-5, then Debio 1450 Capsule, twice daily on days 6-10
3051983|NCT02214433|Experimental|Part B Debio 1450 Cohort 2b|Debio 1450 IV solution, once daily on days 1-5, then Debio 1450 Capsule, once daily on days 6-10
3051984|NCT02214433|Experimental|Part C Debio 1450|Debio 1450 (IV formulation in Period 1, capsule formulation in Periods 2, 4 and 5 (with Pantoprazole), and Debio 1450 oral solution in Period 3).
3051985|NCT02214420|Active Comparator|SMV+SOF|IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD)
3051986|NCT02214420|Active Comparator|SMV+SOF+RBV|IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD) + weight-based Ribavirin 1000-1200 mg/day
3051987|NCT02214407|Experimental|ARM A: DECITABINE (DACOGEN)|"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days.~Allopurinol, 300mg/d, will be started at the time of inclusion; hydration during treatment will be administered to all patients. In (the rare) case of necessity, prophylactic anti-emetics could be given.~Hydroxyurea may be added during the first 3 cycles if WBC counts > 30 G/L, and mandatory if WBC > 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L."
3051988|NCT02214407|Experimental|ARM B: HYDROXYUREA|"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Dose escalation will be performed by steps of 0.5 g/d, up to 4 g/d, if the WBC has been reduced by less than 20% and remains > 15 G/L. HY will then be adapted to maintain a WBC count between 5 and 10 G/L. HY will be lowered if platelets decrease by > 30 X 109/L (if initially below 100 X 109L). HY will be discontinued in cases of grade 4 thrombocytopenia or neutropenia, and reintroduced at a lower dose after recovery to grade ≤ 3. Persistent grade 4 thrombocytopenia or neutropenia after a 4 week discontinuation will mandate bone marrow evaluation."
3051989|NCT02214394|Experimental|Propofol|Subjects will be given Propofol during routine surgery and then using the SMART Device the breath will be captured and compared to blood plasma using High-performance liquid chromatography Analysis.
3052055|NCT02213939||CPB + Cytosorb|On pump myocardial revascularization with the use of the cytokine adsorbing circuit (Cytosorb)
3051990|NCT02214381|Active Comparator|Mycet/Cyclophosphamid|4 x Myocet 60 mg/m² q3w in combination with 4 x cyclophosphamide 600 mg/m² q3w depending on early response assessment by ultrasound or on toxicity profile.
3051991|NCT02214381|Active Comparator|Myocet/Cyclophosphamide/Paclitaxel|2 x Myocet 60 mg/m² q3w in combination with 2 x cyclophosphamide 600 mg/m² q3w followed by 6 x paclitaxel 80 mg/m² q1w depending on early response assessment by ultrasound or on toxicity profile.
3051992|NCT02214368|Experimental|NIV bundle group|early use of NIV, and combination fiberoptic bronchoscopy and sedation
3051993|NCT02214368|Other|Conventional treatment group|standard supplemental oxygen, and conventional application of noninvasive ventilation.
3051994|NCT02214342|Experimental|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
3051995|NCT02214342|No Intervention|Control|The control group will keep their normal activity without receiving any intervention.
3051996|NCT02214329|Experimental|Sensor-based exercise training|The intervention group receives sensor-based balance training with real-time joint feedback through an interactive interface on LC monitor screen.
3051997|NCT02214329|Active Comparator|In-home balance training|The control group performs similar exercise as intervention group at home without use of sensor or any joint feedback from sensor data.
3051998|NCT02214316|Experimental|Interventional 1|Interventional experimental arm with hypertonic saline
3051999|NCT02214303||Allergic asthma|Allergic asthma (sensibilisation to D. pteronyssinus, 5 grass mixture allergens or birch pollen allergens)
3052000|NCT02214303||Allergic rhinitis|allergic rhinitis patients (sensibilisation to D. pteronyssinus, 5 grass mixture allergens or birch pollen allergens)
3052001|NCT02214303||Control group|Healthy subjects
3052002|NCT02214290|Active Comparator|Caffeine|200 mg caffeine tablet produced by CVS Pharmacy, USA
3052003|NCT02214290|Placebo Comparator|Placebo|Placebo pill produced by NOW FOODS, USA
3052004|NCT02214290|Experimental|L-citrulline|L-citrulline capsule (750 g) provided by NOW FOODS
3052005|NCT02214277|Experimental|Test Arm|
3052006|NCT02214277|Active Comparator|Control Arm|
3052007|NCT02214277|Other|Safety Arm|
3052008|NCT02214264|Experimental|Loving-Kindness training|Participants receive Loving-Kindness meditation training for approximately 12 minutes.
3052009|NCT02214264|Experimental|Breath Awareness training|Participants receive Breath Awareness meditation training for approximately 12 minutes.
3052010|NCT02214264|Experimental|Gratitude training|Participants will receive Gratitude training for approximately 12 minutes.
3052011|NCT02214264|Other|Control|Participants write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
3052012|NCT02214251|Experimental|PK-16CH EXG system|PK-16CH EXG is a wireless physiological signal acquisition system for monitoring the bio-signals, such as EEG, ECG, and EMG. The system can concomitant EEG and EMG recording during ambulation.
3052013|NCT02214238|Active Comparator|Market released PAP device|Use of a market released PAP device
3052014|NCT02214238|Experimental|Modified PAP device|Us of the modified PAP device
3052015|NCT02214225|Experimental|Quadrivalent Influenza Vaccine (QIV)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
3052016|NCT02214225|Active Comparator|Trivalent Influenza Vaccine (TIV-1)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
3052017|NCT02214225|Active Comparator|Trivalent Influenza Vaccine (TIV-2)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the recommended influenza A (H1N1-, H3N2-like) strains and the alternate B strain for the Northern Hemisphere 2014/2015 influenza season).
3052018|NCT02214212|Active Comparator|Red Light (RL)|"Intervention/Device:~This patient group will receive 30 minutes of red light daily for a period of 10 days in the morning. Identical baseline and outcome testing will be completed for both arms."
3052019|NCT02214212|Experimental|Bright White Light (BWL)|"Intervention/Device:~This patient group will receive 30 minutes of bright white light daily for a period of 10 days in the morning. Identical baseline and outcome testing will be completed for both arms."
3052020|NCT02214199|Active Comparator|Exercise Therapy|Home exercises for 30 minutes (2/weeks) with muscle stretching and strengthening the shoulder girdle.
3052021|NCT02214199|Experimental|Manipulative Therapy Techniques|Lift Technique for mid-thoracic spine. Mobilization by low cervical spine on the upper lateral thoracic translation. Technical Dog flexion for high thoracic spine (T1-T4). Technical Dog flexion for mid-thoracic spine (T5-T8). Technical Dog flexed to low thoracic spine (T9-T12). Direct drive technology prone to mid-thoracic spine.
3052022|NCT02214186|No Intervention|Liberal Fluid therapy|The liberal group will receive 1500 mL of crystalloid solution during the cesarean section. This is the non-intervention arm once that 1500 ml of crystalloid is the amount usually used during caesarean.
3052023|NCT02214186|Active Comparator|Restrictive Fluid Therapy|The restrictive group will receive 250 mL of crystalloid solution during cesarean section.
3052024|NCT02214173|Experimental|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
3052025|NCT02214173|Placebo Comparator|placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
3052026|NCT02214160|Experimental|UX007|Participants will begin or continue treatment with daily open-label UX007 while maintaining their other dietary restrictions.
3052056|NCT02213939||CPB / Control|Controll group; on pump myocardial revascularization
3052057|NCT02213939||OPCAB / Control|Controll Group; off-pump myocardial revascularization
3052058|NCT02213926|Experimental|ACP-196 (acalabrutinib) Regimen 1|ACP-196 (acalabrutinib) Regimen 1
3052091|NCT02213666||Intracardiac and Transesophageal Echocardiography|Imaging of the right atrial appendage and left atrial appendage with ICE and TEE
3052092|NCT02213653|Experimental|Concomitant iron and I.V. epoietin zeta|
3052027|NCT02214147|Experimental|Alisertib: Normal hepatic function|Participants will receive alisertib 50 mg, orally, once, on Cycle 1 Day 1. Participants will then receive alisertib 50 mg twice daily (BID) for 7 days starting at Cycle 1 Day 8 through Cycle 1 Day 14 followed by a 14-day rest period. Starting at Cycle 2 Day 1, participants will receive alisertib 50 mg BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months.
3052028|NCT02214147|Experimental|Alisertib: Moderate hepatic impairment|Participants will receive alisertib 50 mg, orally, once, on Cycle 1 Day 1. Participants will then receive alisertib 30 mg BID for 7 days starting at Cycle 1 Day 8 through Cycle 1 Day 14 followed by a 14-day rest period. Starting at Cycle 2 Day 1, participants will receive alisertib 30 mg BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Patients may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months.
3052029|NCT02214147|Experimental|Alisertib: Severe hepatic impairment|Participants will receive alisertib 50 mg, orally, once, on Cycle 1 Day 1. Participants will then receive alisertib 20 mg BID for 7 days starting at Cycle 1 Day 8 through Cycle 1 Day 14 followed by a 14-day rest period. Starting at Cycle 2 Day 1, participants will receive alisertib 20 mg BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months.
3052030|NCT02214134||Lung cancer|Patients with diagnosis of lung cancer at any stage
3052031|NCT02214134||Malignant pleural mesothelioma|Patients with diagnosis of malignant pleural mesothelioma at any stage
3052032|NCT02214134||Thymic malignancy|Patients with diagnosis of thymic malignancy at any stage
3052033|NCT02214121|Other|Ticagrelor Dose 1a + Dose 2a|Part A: Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week repeated dosing Part B: Ticagrelor or placebo 4 weeks repeated dosing.
3052034|NCT02214121|Other|Ticagrelor Dose 1b + Dose 2b|Part A: Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week repeated dosing. Part B: Ticagrelor or placebo 4 weeks repeated dosing.
3052035|NCT02214108|Experimental|Phisical activity with Nintendo Wii|3 hours of weekly of physical activity, divided in 1 hour interday with Nintendo WII. games applied: Wii Boxing, Wii Tennis; Wii Bowling
3052036|NCT02214108|No Intervention|phisical activity with phisiotherapist|3 hours of weekly physical activity, divided in 1 hour interday. applying cardiovascular and muscular endurance static exercises.
3052037|NCT02214095|Active Comparator|glucosamine sulphate capsules|500 mg Glucosamine Compound, three times daily for 3 months following initial cause related therapy.
3052038|NCT02214095|Placebo Comparator|lactose capsules|lactose capsules three times daily for 3 months
3052039|NCT02214082|No Intervention|Next day discharge|this group will be discharged as is the standard practice at our facility; i.e. the day after the PCI procedure
3052040|NCT02214082|Experimental|Same Day Discharge|Patients in this arm will be discharged on the same day as their angioplasty.
3052041|NCT02214069||Patients with Atrial Fibrillation|Patients with Atrial Fibrillation admitted to the hospital for drug loading with Dofetilide or Sotalol willing to record and transmit heart rhythm using AliveCor.
3052042|NCT02214056||The study population|"There is only one group in this study. Please see the inclusion/exclusion criteria.~Intervention: Patient recruitment Intervention: Mobile team exam"
3052043|NCT02214043||Group 2|
3052044|NCT02214043||group 1|
3052045|NCT02214030|Active Comparator|Assiut Femoral Compression Device|the sheaths were removed 2 hours after PCI instead of conventional 6hours. To standardize compression times, AFCD were applied to patient and complete femoral artery compression were applied for 5 minutes, followed by a gradual release of pressure over the ensuing 8 minutes. Therefore each patient received a minimum of 13 minutes of compression, with further compression applied only if full hemostasis had not been achieved at that point with maximum of 30 minutes.
3052046|NCT02214030|Placebo Comparator|Manual compression|The intra-arterial sheaths were removed 6 hours after PCI in the MC group according to the standard local protocols.
3052047|NCT02214017|Active Comparator|Standard care|Diabetic patients attended usual procedure in the outpatient clinic with regular visits
3052048|NCT02214017|Experimental|Telemedicine group|After initial check-up in the outpatient dept. medical treatment, control of blood glucose, blood pressure, lipids, and education was executed via videotelephone in the telemedicine group. A videotelephone, TandBerg E20, in the telemedicine group was delivered and serviced by the Danish Tele Company, TDC.
3052049|NCT02214004|Experimental|Trastuzumab and Letrozole|- Concurrently initiate two drugs on Day 1 of Cycle 1
3052050|NCT02213991|Experimental|Intraoperative Radiotherapy|"Intervention:~Intraoperative Radiotherapy~* Operation day~Breast conservative surgery + Intraoperative radiotherapy 20 Gy~Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity. Purse string suture pulles up tissues and wraps up the applicator. IORT with 20Gy is followed. After IORT, applicator was out of the operative field, and usual wound closure will be done.~* Postoperative period~± Chemotherapy~WBRT (46 Gy) for 4~5 weeks~± Endocrine therapy or target therapy"
3052051|NCT02213965||Vasofix® Safety|Peripheral IV catheter Vasofix® Safety
3052052|NCT02213965||Introcan Safety®|Peripheral IV catheter Introcan Safety® IV catheter
3052053|NCT02213952|Experimental|Platelet-Rich Plasma|Our goal is to evaluate the efficacy of the autologous Platelet-Rich Plasma (PRP) in the treatment of vascular ulcers, comparing to the conventional treatment (cure with humid environment), in primary care patients with chronic venous ulcer.
3052054|NCT02213952|Active Comparator|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
3052059|NCT02213913|Experimental|Treatment (lenalidomide, DA-EPOCH-R)|"INDUCTION PHASE: Patients receive lenalidomide PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months."
3052060|NCT02213900|Experimental|Haloperidol|Randomized patients will receive 0.5mg Haloperidol immediately after surgery and Q8H following the initial dose for a total of 4 days.
3052061|NCT02213900|Placebo Comparator|Placebo|Randomized patients will receive a placebo solution immediately after surgery and Q8H following for a total of 4 days.
3052062|NCT02213887|Experimental|Start Pantoprazole|"Participants have been diagnosed with gastroesophageal reflux disease but have not started pharmacological treatment.~Intervention: Days 2-8"
3052063|NCT02213887|Experimental|Stop Pantoprazole|"Participants have been taking pantoprazole for more than 8 weeks and are asymptomatic for gastroesophageal reflux disease.~Intervention: Days 2-8"
3052064|NCT02213874|Other|Questionnaire|A questionnaire will be administered during the early stages of prenatal care & again during the postpartum period. The initial questionnaire will assess trust in the health care system, locus of control, religiosity, health literacy & collect information about demographics, contraceptive & reproductive history, future pregnancy intentions, & baseline knowledge about contraception. The postpartum questionnaire will repeat questions about future pregnancy & contraception intentions, trust in the health care system, knowledge of contraception and collect new information about characteristics of antenatal contraceptive counseling received including whether a provider recommended a specific method of contraception, the amount of counseling received, & the type of counseling received.
3052065|NCT02213861|Experimental|1.0% SHAPE Gelled Solution once daily|
3052066|NCT02213861|Experimental|0.5% SHAPE Gelled Solution twice daily|
3052067|NCT02213861|Experimental|1.0% SHAPE Gelled Solution twice daily|
3052068|NCT02213848|Experimental|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
3052069|NCT02213848|Placebo Comparator|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
3052070|NCT02213835|Other|Specific Carbohydrate diet (SCD)|
3052071|NCT02213822||Pts with Solid Tumors/ Hematological Cancer|Patients on this study must have either a suspected or confirmed solid tumor or hematological cancer. The intervention performed in this study is the molecular analysis of cancer. The samples will be taken at the time of the patient's planned diagnostic or staging procedure. If the patient is scheduled for surgery a sample of tissue not required for their diagnosis will be obtained and used for this research study. If the patient has undergone a previous diagnostic procedure, some of the stored tissue from that procedure will be submitted for molecular analysis as well.
3052072|NCT02213809|Experimental|Case method education in COPD|Two hours of case method education in COPD are given two times within 3 months to the general practitioners at nine primary health care centers. The education covers examination, including interpretation av spirometry, and treatment of patients with COPD. The learning outcomes are predefined and are the same in both arms. The same person will teach at both times of education.
3052073|NCT02213809|Active Comparator|Traditional education in COPD|Two hours of traditional education in COPD are given two times within 3 months to the general practitioners at nine primary health care centers.The education covers examination, including interpretation av spirometry, and treatment of patients with COPD. The learning outcomes are predefined and are the same in both arms. The same person will teach at both times of education.
3052074|NCT02213796|Other|1h infusion of 1 g meropenem|
3052075|NCT02213783|Active Comparator|Conventional arm|Infusion of 0.5 g of imipenem for 0.5 hr every 6 hr for 2-5 days
3052076|NCT02213783|Experimental|Extended infusion arm|Infusion of 0.5 g of imipenem for 4 hr every 6 hr for 2-5 days
3052077|NCT02213770||Intervention group|Group that followed high- intensity interval training program in TEX study.
3052078|NCT02213770||Control group|Followed up on a regular basis for HTx recipients in Norway.
3052079|NCT02213757|Experimental|Premarin vaginal cream|Premarin vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.
3052080|NCT02213757|Placebo Comparator|Placebo vaginal cream|Placebo vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.
3052081|NCT02213744|Experimental|MM-302 + trastuzumab|MM-302 + trastuzumab
3052082|NCT02213744|Active Comparator|Chemotherapy of Physician's Choice plus trastuzumab|Chemotherapy limited to one of the following: Gemcitabine, Capecitabine or Vinorelbine
3052083|NCT02213731|Other|Cryoballoon ablation|Subjects will wear holter monitors at baseline, 6 months and 12 months
3052084|NCT02213718|Experimental|Desflurane|desflurane (7%-8% end-tidal concentration), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h)
3052085|NCT02213718|Active Comparator|propofol|intravenous administration of sufentanil (1μg/kg), etomidate(0.3mg/kg) and vecuronium (0.08mg/kg). The anesthesia is maintained with propofol (TCI:3.5-4.0μg/min), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h).
3052086|NCT02213705|Experimental|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|Administration of allogeneic MSCs in the treatment of severe diffuse SSc or rapidly progressive and refractory to conventional treatments by prior cyclophosphamide
3052087|NCT02213692||Crush-clamping Method (group A)|Liver parenchymal is crushed by surgeon's fingers or basic surgical clamps to isolate small vessels and biliary radicals, and then divided by suture ligation, electrocautery, or vascular clips.
3052088|NCT02213692||Harmonic Scalpel Method (group B)|Liver parenchymal transection is transected by harmonic scalpel, and small vessels and biliary radicals (<3mm) is also divided by harmonic scalpel. Vessels and biliary radicals (≥ 3mm) were divided by suture ligation, electrocautery, or vascular clips.
3052093|NCT02213653|Experimental|Iron and I.V. epoietin zeta sequential|
3052095|NCT02213640|Experimental|Arm A Anodal tDCS and prismatic adaptation|anodal tDCS over the primary motor cortex : stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
3052096|NCT02213640|Placebo Comparator|Arm B: control|Prismatic adaptation with placebo stimulation
3052097|NCT02213627|Experimental|Corifollitropin alfa|From day 2-3 of mense, a single 100 microgram dose of corifollitropin alfa is administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
3052098|NCT02213627|Experimental|Recombinant FSH|From day 2-3 of mense, daily injections of 150 IU of recombinant FSH will be administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
3052099|NCT02213627|Experimental|HP-hMG|From day 2-3 of mense, daily doses of 225 IU of HP-hMG will be administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
3052100|NCT02213614|Experimental|Spring Lithium Water|"The Long term goal of this research project is the implementation of an effective, inexpensive therapy in communities with high risk of violence. Therapy will be based on a daily dietary supplement LIWA at appropriate doses.~The short-term objective is to prove that Lithium water (LIWA) as a daily supplement is an intervention that prevents gun violence from occurring, and is a factor that decrease the violence for gun in our communities Gun violence poses a serious threat to America's children and youth. Existing data clearly point to the need for improved strategies for keeping guns out of the hands of children and youth and those who would harm them."
3052101|NCT02213614|Experimental|Placebo: Natural Spring water|This group will be drink natural spring water for 4 months in tres cicles
3052102|NCT02213601|Experimental|Yoga|8-week Gentle Vinyasa Flow yoga intervention
3052103|NCT02213601|No Intervention|Wait-list Control Group|
3052104|NCT02213588|Active Comparator|AOX blend|Rosemary:Quercetin:Turmeric (300 mg total)
3052105|NCT02213588|Placebo Comparator|Placebo|Maltodextrin
3052106|NCT02213575|Other|Minocycline|Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.
3052107|NCT02213562|Experimental|200 mg CFO|200 mg of chrysanthemum flower oil
3052108|NCT02213562|Experimental|300 mg CFO|300 mg of chrysanthemum flower oil
3052109|NCT02213562|Experimental|400 mg CFO|400 mg of chrysanthemum flower oil
3052110|NCT02213549|Placebo Comparator|Placebo|3 placebo capsules/day for 12 weeks
3052111|NCT02213549|Experimental|Ume paste and ginger powder|3 experimental capsules/day for 12 weeks.
3052112|NCT02213536||VMAT WBRT|Patients requiring whole brain radiotherapy as part of their cancer managment.
3052113|NCT02213523|Experimental|Plant concentrate A|Plant concentrate A containing Rosemary:Quercetin:Turmeric 5:3:1 Low dose (300 mg) to high dose (600 mg)
3052114|NCT02213523|Experimental|Plant concentrate B|Plant concentrate B containing Holy Basil: Wasabi: Broccoli 5:5:1 Low dose (300 mg) to high dose (600 mg)
3052115|NCT02213523|Experimental|Plant concentrate C|Plant concentrate C containing Holy Basil:Rosemary:Broccoli seed:Turmeric 2:2:1:1 Low dose (300 mg) to High dose (600 mg)
3052116|NCT02213523|Experimental|Plant concentrate D|Plant concentrate D containing Rosemary:Licorice:Turmeric 1:1:1 Low dose (300 mg) to High dose (600 mg)
3052117|NCT02213510|Experimental|Zip Surgical Skin Closure device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
3052118|NCT02213510|Active Comparator|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
3052119|NCT02213484||Marfan syndrome|Individuals with a clinical diagnosis of Marfan syndrome
3052120|NCT02213484||Aortopathy syndrome|Individuals with one of the following clinical diagnoses: Loeys-Dietz syndrome, Turner syndrome, Ehlers-Danlos type IV syndrome, Thoracic Aortic Aneurysm and Dissection syndromes.
3052121|NCT02213471||Elevated risk for melanoma|Individuals at increased risk for melanoma due to past history of melanoma, family history of melanoma, the presence of many moles, the presence of a genetic mutation known to increase the risk of melanoma.
3052122|NCT02213458|Experimental|Navigated Care|Comprehensive longitudinal continuing care program
3052123|NCT02213458|No Intervention|Survey of Care|Control group that will undergo the same regular assessments as patients enrolled in Navigated Care
3052124|NCT02213432|Experimental|Day 1 vaccination|"Different timing of influenza vaccination: Day 1~Day 1 vaccination group: patients will be vaccinated against influenza at the day (Day 1) when chemotherapy starts."
3052125|NCT02213432|Active Comparator|Day 11 vaccination|"Different timing of influenza vaccination: Day 11~Day 11 vaccination group: patients will be vaccinated against influenza at the 11th days after chemotherapy starts"
3052126|NCT02213419|Experimental|ethanol double lavage|Endoscopic ultrasonography-guided double ethanol lavage
3052127|NCT02213406|Experimental|intervention group|Fat detection threshold test, intake of high and low fat yogurt, fMRI-measurements
3052128|NCT02213393|Experimental|Protein enriched products|The intervention group receives protein enriched products (CwC products) in the hospital and receives these also after discharge during 12 weeks.
3052129|NCT02213393|Active Comparator|Usual menu|The control group receives the usual protein and energy rich menu in the hospital and receives regular products, no protein enrichment, after discharge during 12 weeks.
3052130|NCT02213380|Other|group GA|Method of anesthesia: general anesthesia
3052131|NCT02213380|Other|group RA|Method of anesthesia: regional anesthesia
3052132|NCT02213367|Active Comparator|20 mg Bilastin|20mg Bilastine once daily
3052133|NCT02213367|Active Comparator|Bilastin 40mg|40 mg Bilastine once daily, intake of two tablets 20mg Bilastine
3052134|NCT02213367|Active Comparator|Bilastin 80mg|80 mg Bilastine once daily, intake of four tablets 20mg Bilastine
3052135|NCT02213354|Experimental|Group 2|60 subjects receive Sanofi A/H7N9 antigen 3.75 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
3052136|NCT02213354|Experimental|Group 6|60 subjects receive Sanofi A/H7N9 antigen 15 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
3052137|NCT02213354|Experimental|Group 5|60 subjects receive Sanofi A/H7N9 antigen 15 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 29 and Day 169
3052138|NCT02213354|Experimental|Group 4|60 subjects receive Sanofi A/H7N9 antigen 7.5 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
3052139|NCT02213354|Experimental|Group I|60 subjects receive Sanofi A/H7N9 antigen 3.75 mcg plus Novartis MF59 adjuvant intramuscularly (IM) on Day 1, Day 29 and Day 169
3052140|NCT02213354|Experimental|Group 3|60 subjects receive Sanofi A/H7N9 antigen 7.5 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 29 and Day 169
3052141|NCT02213341||Positive blood test to milk, egg, and/or peanut|Family history to atopy
3052142|NCT02213341||Negative blood test to allergy|A negative skin prick test to egg, milk, and peanut and a negative Immunoglobulin E (IgE) to egg, milk, and peanut.
3052143|NCT02213328|Experimental|Truvada|All participants will take Truvada, once daily by mouth for the first 12 weeks of the study. After Week 12 of the study, only participants who indicate a willingness to use Truvada PrEP and who do not have any medical reasons not to do so will continue to receive the Truvada tablets through Week 52.
3052144|NCT02213315|Experimental|100mg arm|100mg dose
3052145|NCT02213315|Experimental|150mg arm|150mg dose
3052146|NCT02213315|Placebo Comparator|Placebo|Placebo
3052147|NCT02213302|Placebo Comparator|Isotonic serum|placebo administration
3052148|NCT02213302|Active Comparator|Midazolam|midazolam intravenous administration 0.02mg/kg
3052149|NCT02213289|Experimental|HER2 Group|Trastuzumab
3052150|NCT02213289|Experimental|MET group|
3052151|NCT02213289|Experimental|EGFR Arm|ABT-806
3052152|NCT02213289|Experimental|FGFR2 Arm|TBD2
3052153|NCT02213289|Experimental|VEGFR2 Arm|Ramucirumab
3052154|NCT02213289|Experimental|MSI-H Arm|Nivolumab
3052155|NCT02213276|Experimental|Healthy males|Oral glucose tolerance test (OGTT) and intravenous glucose tolerance test (IVGTT).
3052156|NCT02213263|Experimental|PF-05280586|
3052157|NCT02213263|Active Comparator|MabThera®|
3052158|NCT02213250|Experimental|BeneFIX|
3052159|NCT02213224|Experimental|Perindopril|Perindopril 4mg qd taken in the morning;
3052160|NCT02213224|Experimental|Telmisartan|Telmisartan 80mg qd taken in the morning;
3052161|NCT02213224|Placebo Comparator|Amlodipine|Amlodipine；5mg qd taken in the morning.
3052162|NCT02213211|Experimental|Diagnosis and treatment of malaria|"School-based diagnosis and treatment of uncomplicated malaria using malaria RDTs and Artemether lumefantrine as part of Learner Treatment Kits (LTK) used by teachers.~Drug: Artemether lumefantrine (artemisinin-based combination therapy [ACT], Coartem). Three-day doses of 20mg/120mg, 40mg/240mg, 60mg/360mg and 80mg/480mg Coartem are provided, according to weight, upon a positive rapid diagnostic test (RDT) result."
3052163|NCT02213211|No Intervention|No intervention|No intervention provided
3052164|NCT02213198|Experimental|Engagement Focused Care|Engagement Focused Care which includes all components of standard treatment plus both group Access intake process with its flexibility of scheduling and the SDM intervention
3052165|NCT02213198|Active Comparator|Standard Care|Standard Care includes individual intake appointments which are traditional in outpatient service and all services of the clinic including counseling, access to a prescriber, care coordination, and access to home visits.
3052166|NCT02213185|Experimental|EMLA patches and SWI|EMLA patches 1.5 hrs before sterile water injections
3052167|NCT02213185|Active Comparator|EMLA patches and isotonic saline|EMLA patches 1.5 hrs before isotonic saline
3052168|NCT02213185|Placebo Comparator|Placebo patches and SWI|PLACEBO patches 1.5 hrs before sterile water injections
3052169|NCT02213185|Placebo Comparator|Placebo patches and isotonic saline|PLACEBO patches 1.5 hrs before isotonic saline
3052170|NCT02213172|Experimental|Bifidobacterium longum R0175|10 x 10^9 CFU per capsule, 1 capsule daily for 8 weeks
3052171|NCT02213172|Experimental|Lactobacillus paracasei HA-196|10 x 10^9 CFU per capsule, 1 capsule daily for 8 weeks
3052172|NCT02213172|Placebo Comparator|Placebo|1 capsule daily for 8 weeks
3052173|NCT02213159|Active Comparator|Dexmedetomidine|prior to anticipated end of surgery bolus of 1 microgram/kg Dexmedetomidine intravenously over 10 minutes followed by 0.5 micrograms/kilogram/hour intravenous infusion until removal of laparoscopes
3052174|NCT02213159|Active Comparator|Morphine|prior to anticipated completion of surgery morphine 0.08 mg/kilogram intravenous bolus over 10 minutes followed by a saline infusion until removal of the laparoscopes
3052175|NCT02213146|Experimental|BioChaperone human insulin|BioChaperone Human Insulin
3052176|NCT02213146|Active Comparator|Human insulin|Huminsulin® Normal
3052177|NCT02213146|Active Comparator|Insulin lispro|Humalog®
3052178|NCT02213133|Experimental|Selinexor (KPT-330)|oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly for the first 3 weeks of each 4-week cycle. Duration of treatment is open-ended and patients will dose as long as the dose is tolerated and participation is voluntarily given, until disease progression occurs.
3052179|NCT02213120||Dizziness|Patients with Dizziness
3052180|NCT02213107|Experimental|Enzalutamide and dutasteride|Two oral drugs.
3052181|NCT02213094|Experimental|Nicotinamide|500mg daily to the first 5 subjects enrolled then the second set of 5 subjects given 1000mg daily - after review of the first 5 by the data safety and monitoring board and FDA.
3052182|NCT02213081|Experimental|Ulipristal|25 patients with chronic, endometriosis-related pelvic pain refractory to medical and/or surgical therapies will receive 15mg ulipristal every other day (three times a week- Monday, Thursday, Saturday) for three months.
3052183|NCT02213068|Experimental|belatacept + MPA|"subjects continue MPA per SOC, receive bimonthly infusions of belatacept while gradually reducing and then discontinuing tacrolimus:~Belatacept: 5 mg/kg IV on Day 1, 15, 29, 43, and 57 post-conversion, then monthly thereafter.~Tacrolimus tapered over one month as follows:~Days 1- 14: SOC administration Day 15 (~ 2 weeks into study): 40-60% of the previous dose Day 21 (~ 3 weeks into study): 20-30% of the previous dose Day 30 (about 1 month): discontinue~MPA: administered according to SOC"
3052617|NCT02210130||patients HIV+ CSVD+|patients with HIV and cerebral small vessel disease
3052184|NCT02213068|Active Comparator|belatacept + Low-Dose Tac|"Belatacept: 5 mg/kg IV on Day 1, 15, 29, 43, and 57 post-conversion, then monthly thereafter.~Tacrolimus tapered over one month as follows:~Days 1- 14: SOC administration Day 15 (~ 2 weeks into study): 10% of the previous dose Day 21 (~ 3 weeks into study): 20% of the previous dose Day 30 (~ 1 month into study): 20% of the previous dose Target trough level ≤ 5 mg per ml of tacrolimus thereafter."
3052185|NCT02213068|Other|Tacrolimus + MPA standard treatment regimen|"Standard of Care treatment regimen:~Tacrolimus: administered orally twice daily (BID) The total initial dose of Tacrolimus is given at 0.1 mg/kg in two divided doses to achieve a stable 12-hour trough level of 8 - 12 ng/mL on Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.~MPA: dosed orally per package insert beginning on the day of transplantation. Methylprednisolone as sodium succinate is administered as 500 mg IV, 250 mg IV, 125 mg IV, on Days 0, 1, and 2 without corticosteroid taper.~MPA dose adjustments for gastrointestinal side effects or leukopenia will be made at the discretion of the investigator."
3052186|NCT02213055|Experimental|LICEMD|Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment.
3052187|NCT02213055|Active Comparator|Standard Head lice product|Parents/guardians who do not agree to use the investigational product and choose a standard head lice treatment will be asked to participate in the comparison arm of the study.
3052188|NCT02213042|Active Comparator|Lapatinib 1000mg + Trastuzumab in HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who are hormone receptor positive, an aromatase inhibitor of the investigator's choice is required.
3052189|NCT02213042|Active Comparator|Trastuzumab in HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Trastuzumab (loading dose of 8 mg/kg followed by the maintenance dose of 6 mg/kg IV q3weekly) along with chemotherapy of the investigator's choice or Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly along with chemotherapy of the investigators choice. Subjects randomized to this arm and hormone receptor positive will receive an aromatase inhibitor at the discretion of the investigator.
3052190|NCT02213042|Active Comparator|Lapatinib 1000mg + Trastuzumab in Non- HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of Non- HER2 Enriched (luminal A, luminal B or Basal type), Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who are hormone receptor positive, an aromatase inhibitor of the investigator's choice is required.
3052191|NCT02213029|Experimental|Oxytocin or Placebo challenge (Cohort 1)|Subjects will receive oxytocin and or placebo challenges as escalating intravenous (IV) infusions administered on the day of ovulation, followed by an IV bolus day 1 post ovulation, and an intramuscular (IM) injection day 2 post ovulation. The planed doses and routes of administration of oxytocin are as follows: IV infusion will be initiated at 5 milliunit/minute (mU/min) and maintained for 60 min, then the rate will be increased to 10 mU/min and maintained for 60 minutes, a final escalation to 20mU/min will be maintained for 60 minutes, after which the infusion will be stopped. For the IV bolus, a single 5 International unit (IU) IV bolus will be administered. For the IM dosing, a single 10 IU IM injection will be administered.
3052192|NCT02213029|Experimental|Epelsiban or Placebo (Cohort 2)|Subjects in Cohort 2A will receive first dose of epelsiban (25mg) or placebo after receiving initial oxytocin challenge with dose selected in Cohort 1 followed by 30 minutes washout period. Subjects will receive second dose of epelsiban (150mg) or placebo 12 hours after first dose. Based on the results of Cohort 2A, additional doses may be investigated with a new Cohort 2B (<150mg) and Cohort 2C (>200mg) with repeated oxytocin challenges.
3052193|NCT02213029|Experimental|Biopsy cohort (Cohort 3)|Subjects will receive first dose of epelsiban 150mg without oxytocin challenge followed by second dose of epelsiban 150mg 24 hours after the first dose. Subsequently one hour after the second dose, subjects will undergo endometrial biopsies.
3052194|NCT02213016|Sham Comparator|Transcranial magnetic stimulation|Sham repetitive Transcranial magnetic stimulation, 5 Hz, 5 sessions per week for three weeks: Total of 15 sessions.
3052195|NCT02213016|Active Comparator|Transcraneal magnetic stimulation|Active repetitive Transcranial magnetic stimulation, 5 Hz, 5 sessions per week for three weeks: Total of 15 sessions.
3052196|NCT02213016|Sham Comparator|Sham Comparator|Sham repetitive Transcranial magnetic stimulation, 5 Hz, 2 sessions per week for 7 1/2 weeks: Total of 15 sessions.
3052197|NCT02213016|Active Comparator|Active Comparator|Active repetitive Transcranial magnetic stimulation, 5 Hz, 2 sessions per week for 7 1/2 weeks: Total of 15 sessions.
3052198|NCT02213003|Experimental|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the omentum.
3052199|NCT02212990|Active Comparator|Acetaminophen Arm|Acetaminophen Suspension 160mg / 5mL Oral dose immediately following IIV and every 4 to 6 hours up to 24 hours (Maximum 5 oral doses)
3052200|NCT02212990|Placebo Comparator|Placebo Arm|Placebo Suspension Oral dose immediately following IIV and every 4 to 6 hours up to 24 hours (Maximum 5 oral doses)
3052201|NCT02212990|Active Comparator|Ibuprofen Arm|Ibuprofen Suspension 100mg / 5mL Oral dose immediately following IIV and every 6 to 8 hours up to 24 hours (Maximum 4 oral doses)
3052202|NCT02212977|Active Comparator|Suture|Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
3052203|NCT02212977|Experimental|Octylcyanoacrylate|Skin incision closure with topic skin adhesive Octylcyanoacrylate
3052204|NCT02212951|Experimental|BIOD-531 pre-meal|Subcutaneous injection of 0.6 U/kg immediately before the start of the standardized breakfast
3052205|NCT02212951|Active Comparator|Humalog Mix 75/25 pre-meal|Subcutaneous injection of 0.6 U/kg immediately before the start of the standardized breakfast
3052206|NCT02212951|Active Comparator|Humulin R U-500|Subcutaneous injection of 0.6 U/kg immediately before the start of a standardized breakfast
3052207|NCT02212951|Experimental|BIOD-531 post-meal|Subcutaneous injection of 0.6 U/kg 20 minutes after the start of the standardized breakfast
3052212|NCT02212912|Other|Improvement intervention|Improvement intervention is a multifaceted quality improvement method including evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators, a quality coordinator, and monitoring and feedback system of performance measures.
3052213|NCT02212912|Other|no intervention|The control group indicated that the physicians will not be provided with the information of multifacet improvement tools including evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators a quality coordinator, and monitoring and feedback system of performance measures. They just provide patients with routine care
3052214|NCT02212886|Experimental|GA Depot 80mg|Monthly IM injection
3052215|NCT02212886|Experimental|GA Depot 40mg|Monthly IM injection
3052216|NCT02212873|No Intervention|Control|Equal number of age-matched overweight and obese students will be selected from a control school. There will be no intervention, and students will participate in their usual health and physical education classes plus any other curriculum activities provided by the school.
3052217|NCT02212873|Experimental|MyBFF@school program|Students will participate in all 3 components of MyFF@school for a total of 32 weeks; 1-hour of SSG thrice weekly plus 30 to 45 minutes of either nutrition or psychology classes once a week. All students including those in the control arm will be assessed at baseline, week-16 and at end of the study. They will undergo anthropometric measurements, body fat assessment, clinical examination and fitness test by modified Harvard step-test.
3052218|NCT02212860|Experimental|Stereotactic Body Radiation Then Surgery|Stereotactic image-guided neoadjuvant ablative radiation (single dose, 21 Gy) followed by lumpectomy for stage I or IIA early stage breast carcinoma
3052219|NCT02212847|Experimental|vestibular stimulation|
3052220|NCT02212834||Mammograms|Surveillance mammograms in women with a personal history of breast cancer
3052221|NCT02212834||Breast MRI|Surveillance breast Magnetic Resonance Imaging (MRI) in women with a personal history of breast cancer
3052222|NCT02212821|Placebo Comparator|Placebo|intravenous infusion
3052223|NCT02212821|Experimental|Erythromycin|intravenous infusion
3052224|NCT02212808|Experimental|Antimicrobial restriction|All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario.
3052225|NCT02212808|Experimental|Post-antimicrobial prescription review|All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacists will review a list of patients receiving the targeted antibiotics on a daily basis to identify patients who have received one or more targeted antibiotics for 72 hours (± 24 hours). The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations.
3052226|NCT02212795|Experimental|A Group|1st oral administration of Zabofloxacin 183mg, 2nd oral administration of Zabofloxacin 367mg and 3rd oral administration of Levofloxacin 250mg
3052227|NCT02212795|Experimental|B Group|1st oral administration of Zabofloxacin 367mg, 2nd oral administration of Levofloxacin 250mg and 3rd oral administration of Zabofloxacin 367mg
3052228|NCT02212795|Experimental|C Group|1st oral administration of Levofloxacin 250mg, 2nd oral administration of Zabofloxacin 183mg and 3rd oral administration of Zabofloxacin 367mg
3052229|NCT02212782|Experimental|A Group|1st oral administration of Linagliptin 5mg and 2nd oral administration of DW1029M 1200mg and Linagliptin 5mg
3052230|NCT02212782|Experimental|B Group|1st oral administration of DW1029M 1200mg and Linagliptin 5mg and 2nd oral administration of Linagliptin 5mg
3052231|NCT02212769|Experimental|A Group|1st oral administration of Losartan 50mg and 2nd oral administration of Losartan 50mg and DW1029M 1200mg
3052232|NCT02212769|Experimental|B Group|1st oral administration of DW1029M 1200mg and Losartan 50mg and 2nd oral administration of Losartan 50mg
3052233|NCT02212756|Experimental|B Group|1st oral administration of Metformin 1000mg and 2nd oral administration of Metformin 1000mg and DW1029M 1200mg
3052234|NCT02212756|Experimental|A Group|1st oral administration of DW1029M 1200mg and Metformin 1000mg and 2nd oral administration of Metformin 1000mg
3052235|NCT02212730|Experimental|Pembro3 → Resection → Pembro17|Participants will receive pembrolizumab (Pembro), 200 mg intravenously (IV) every 3-week cycle for up to 3 cycles followed by standard of care (SOC) surgical resection; and then may receive post-resection Pembro 200 mg IV every 3 week cycle for up to 1 year (17 cycles)
3052236|NCT02212730|Experimental|Resection → Pembro17|Participants will receive SOC surgical resection; and then may receive post-resection Pembro 200 mg IV every 3 week cycle for up to 1 year (17 cycles)
3052237|NCT02212717|Active Comparator|EUS-guided gallbladder drainage|
3052238|NCT02212717|Active Comparator|Percutaneous cholecystomy|
3052239|NCT02212704|Experimental|Vestibular stimulation|This is the experimental paradigm applied in all participants
3052240|NCT02212691||Sickle cell disease|Sickle Cell Disease
3052241|NCT02212678|Experimental|N-acetylcysteine|Subjects will be provided 6000 mg/day of N-acetylcysteine (capsule) to be divided into 2 equal daily doses and taken orally for approximately 28 days
3052242|NCT02212665|Experimental|High intense interval training (HIIT)|3 x 20 sec, 3 x week
3052243|NCT02212665|Experimental|Increased daily activity detected by the pedometer|10.000 steps a day
3052244|NCT02212665|Experimental|Increased daily activity detected by te pedometer+HIIT|10.000 steps + 3 x 20 sec, 3 x week
3052245|NCT02212665|Experimental|Increased daily activity (pedometer)+group intervention|10.000 steps + group intervention
3052246|NCT02212665|No Intervention|Control group|
3052247|NCT02212652|Active Comparator|Standard of Care plus Vitamin D|If randomized to this arm, each participant will receive a 30 day supply of 10,000 IU of VitD3 for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
3052248|NCT02212652|Placebo Comparator|Standard of Care plus Placebo|If randomized to this arm, each participant will receive a 30 day supply of placebo supplements for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
3052249|NCT02212639|Experimental|Digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients <75 years and between 0.5-0.8 ng/ml in patients older than 75 years
3052250|NCT02212626|Experimental|Rotarex|After assessment of the lesion by angiography the occlusion is intraluminally crossed with the wire according to physician's discretion. The device is introduced and the catheter is activated while its tip is still proximal to the occlusion to allow lubrication of the spiral inside the catheter with the aspirated blood. The catheter is advanced into the occlusion with occasional retraction into the already recanalized lumen. Care must be taken to achieve sufficient cooling of the catheter tip and evacuation of the debris to get an appropriate blood flow along the catheter. In order to minimize peripheral embolization of clot the distal end of the occlusion should not be passed too fast before all loose material has been sucked back into the catheter. Several passages of the occlusion may be needed to clean out all wall-adherent thrombotic material. If residual underlying stenosis of >30% persist further endovascular treatment can be performed according to the physician's discretion.
3052251|NCT02212613|Experimental|Brexpiprazole|Brexpiprazole - Up to 2 mg/day, once daily dose, tablets, orally
3052252|NCT02212600||Population|We will include male and female patients who are over 50 years of age and who have an acute, displaced or undisplaced proximal humerus fracture caused by low energy trauma
3052253|NCT02212587|Experimental|TOBI Podhaler|
3052254|NCT02212574|Other|Chemotherapy|"Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1. Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15. Cisplatin is given directly into a vein over 8 hours on Day 1. This cycle lasts 42 days.~Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2. MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours. Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.This cycle lasts 28 days"
3052255|NCT02212561|Experimental|Treatment Arm|Interventions: Selinexor, Fludarabine, and Cytarabine. Methotrexate/hydrocortisone/cytarabine (intrathecal triples) will be given prior to cycle 1.
3052256|NCT02212548|Experimental|Hydrogel|The patient will be in the dorsal lithotomy position and prepared and draped. A transrectal ultrasound (TRUS) will be used for alignment of the needle and to ensure safe delivery. The hydrogel precursor and accelerator solutions will be mixed and connected to the Y connector that has been flushed with saline and to a syringe holder that ensures both syringe barrels are injected at the same time. After aspirating to ensure the tip of the needle is not intravascular, the perirectal space will be adequately dissected from the apex to midgland by injecting saline into the space between denonvilliers fascia and the anterior rectal space under TRUS guidance. Maintaining the needle position and angulation, the saline syringe is disconnected and the hydrogel system connected. After aspirating to ensure the needle tip is not in a blood vessel and under TRUS guidance, the 'PEG Hydrogel (SpaceOAR) is injected in a smooth, continuous technique.
3052257|NCT02212535|Experimental|Plerixafor|Adult patients affected by major sickle cell syndrome (SS or Sβ thalassemia)
3052258|NCT02212522||Isis-Diab patients|French T1D patients with genetic data (GWAS), and environmental data (questionnaire and environmental databases), clinical data
3052259|NCT02212522||Isis-Diab controls|French control population with genetic data (GWAS) and environmental data (questionnaire and environmental databases
3052260|NCT02212496||Cancer-associated stroke|Cryptogenic embolic stroke with active cancer
3052261|NCT02212496||Cryptogenic embolic stroke|Cryptogenic embolic stroke without active cancer
3052262|NCT02212483|Experimental|Intervention group|"After randomisation and agreement of the patient and the family, the  intervention group  will benefit from a first home intervention of a MIEC during the 4 weeks following inclusion, then a final visit at the end of the study after 12 months."
3052263|NCT02212483|Active Comparator|Control group|"The  control group  is one of the two comparative groups who will benefit from a first home intervention of a MIEC but without advices (only audit + sampling), then a final and a complete visit at the end of the study.~This group has been suppressed with the last amendment. But data of the subjects included in this group will be analyzed."
3052264|NCT02212483|Other|Non intervention group|"The  non intervention  group is the second comparative group with no initial visit, but will benefit from a complete home intervention of a MIEC at the end of the study."
3052265|NCT02212470|Active Comparator|Drug Eluting Balloon|Admiral In.Pact Drug Eluting Balloon
3052266|NCT02212470|Active Comparator|Nitinol Stent|Complete SE Self-expandible Nitinol stent
3052267|NCT02212457|Experimental|rMenB_0_2 Group|Subjects received two injections of Bexsero™ vaccine at Visit Month 0 and Visit Month 2, Havrix® vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
3052268|NCT02212457|Experimental|ABCWY_ 0_2 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 2, Havrix® vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
3052269|NCT02212457|Experimental|ABCWY_0_1 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 1, Havrix® vaccine at Visit Month 2 and Visit Month 12 and saline placebo at Visit Month 6.
3052270|NCT02212457|Experimental|ABCWY_0_6 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 6, Havrix® vaccine at Visit Month 1 and Visit Month 12 and saline placebo at Visit Month 2.
3052271|NCT02212457|Experimental|ABCWY_0_11 Group|Subjects received MenABCWY vaccine at Visit Month 1 and Visit Month 12, Havrix® vaccine at Visit Month 0 and Visit Month 6 and saline placebo at Visit Month 2.
3052272|NCT02212457|Experimental|ABCWY_0_2_6 Group|Subjects received MenABCWY vaccine at Visit Month 0, Visit Month 2 and Visit Month 6 and Havrix® vaccine at Visit Month 1 and Visit Month 12.
3052273|NCT02212444|Experimental|Dynamic elastomeric fabric orthoses (DEFO)|The DEFO will be provided after taking the baseline measures and orthoses measurements at the baseline session ~ 3 weeks later. The orthoses will be supplied via post and used for a period of 12 weeks.
3079696|NCT02028975|Other|Healthy volunteers|
3052274|NCT02212444|Active Comparator|Off-the-self orthotics|Off-the-shelf-Orthotics: Patients in the usual care group will be referred for off -the-shelf triplanar orthoses as indicated by a biomechanical assessment of foot posture while standing / walking on visit 1. The off the shelf orthotic will be provided after taking the baseline measures and orthoses measurements at the baseline session ~ 3 weeks later. The orthoses will be supplied via post and used for a period of 12 weeks.
3052275|NCT02212431|Experimental|Cysteamine|"Dosing will be in accordance with licensed use of cysteamine for cystinosis, i.e. 450mg qds.~Dose will be escalated:~450mg od for one week 450mg bd for one week 450mg tds for one week 450mg qds for two weeks"
3052276|NCT02212418|Experimental|Abdominal hypopressive technique|
3052277|NCT02212405|Sham Comparator|rTMS Sham + PET|An advanced sham coil will be used that mimicks the sound and sensation of real repetitive Transcranial Magnetic Stimulation. The repetitive Transcranial Magnetic Stimulation sham intervention is followed by radiotracer and PET.
3052278|NCT02212405|Experimental|rTMS 1Hz + PET|Deep repetitive Transcranial Magnetic Stimulation will be applied to the insula for 30 minutes. This will consist of 20 trains each comprising of 50 pulses at 1Hz. The inter-train interval is 15 seconds. The intervention is followed by radiotracer and PET.
3052279|NCT02212405|Experimental|rTMS 10Hz + PET.|Deep repetitive Transcranial Magnetic Stimulation will be applied to the insula for 30 minutes. This will consist of 34 trains each comprising of 30 pulses at 10Hz. The inter-train interval is 3 seconds. The intervention is followed by radiotracer and PET.
3052280|NCT02212392|No Intervention|control|This arm was not given any prophylactic antibiotics. Patients were managed in the surgical ward by post graduate residents under the supervision of consultants
3052281|NCT02212392|Experimental|Antibiotics|this arm was given IV antibiotics, prophylactically, right from the day of admission. They were given intravenous broad spectrum (MEROPENEM) twice daily at 12 hours interval for 7-10 days
3052282|NCT02212379|Experimental|raltegravir and etravirine|
3052283|NCT02212366|Experimental|Active TDCS|2-week course of daily (5 days/week) active bilateral anodal TDCS, duration 30 minute each session. Current 2 mA.
3052284|NCT02212366|Sham Comparator|Sham TDCS|2-week course of daily (5 days/week) Sham bilateral tDCS. Duration 30 minute each session.
3052285|NCT02212353||Site 1 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 1 in delivering to care to neck of femur patients.
3052286|NCT02212353||Site 2 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 2 in delivering to care to neck of femur patients.
3052287|NCT02212353||Site 3 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 3 in delivering to care to neck of femur patients.
3052288|NCT02212340|Experimental|TIVA group|Anesthesia is maintained with fresofol and remifentanil
3052289|NCT02212340|Active Comparator|Des group|Anesthesia is maintained with desflurane and remifentanil
3052290|NCT02212327||PD subjects|
3052291|NCT02212327||Controls|
3052292|NCT02212314|Experimental|Response Inhibition Training|Treatment group will receive immediate treatment after pre-test.
3052293|NCT02212314|No Intervention|Waitlist Crossover|Waitlist group will not receive intervention while treatment group is active, but waitlist group will be offered treatment after post-test is completed.
3052294|NCT02212301|Active Comparator|senofilcon A / lotrafilcon B|Subjects were randomized to one of two lens wear sequences. Subjects randomized to this sequence first wore the senofilcon A contact lens and then wore the lotrafilcon B contact lens.
3052295|NCT02212301|Active Comparator|lotrafilon B/ senofilcon A|Subjects were randomized to one of two lens wear sequences. Subjects randomized to this sequence first wore the lotrafilcon B contact lens and then wore the senofilcon A contact lens
3052296|NCT02212288||PKU patients|Adult PKU patients;Blood samples;Urine sample only at inclusion
3052297|NCT02212288||Healthy controls|Adult Healthy controls;Blood samples;Urine samples only at inclusion
3052298|NCT02212275|Experimental|Dextromethorphan in ASD|8-12 years old: > 30 boys will be recruited who have a known or suspected diagnosis of ASD confirmed by DSM-5 checklist and the ADOS-2 at screening. They will have the cortical metric measured 20 min prior to receiving DXM and 2 hours after receiving a single age and weight appropriate dose of DXM. The outcome reported is the difference in the cortical metric after the DXM dose and before the DXM dose.
3052299|NCT02212275|Active Comparator|Dextromethorphan in controls|30 typically developing boys 8-12 years old who have the cortical metric measured 20 min before receiving a single age and weight appropriate dose of DXM and 2 hours after the single dose of DXM. The reported value will be the difference between the cortical metric 2hrs after the single dose of DXM and the cortical metric 20 minutes prior to the single dose of DXM.
3052300|NCT02212262||Multiple Myeloma Patients|Patients with multiple myeloma will undergo a blood draw and a bone marrow aspirate. Extra bone marrow will be taken for study purposes only.
3052301|NCT02212262||Healthy subjects|Healthy subjects and multiple myeloma patients will undergo a blood draw
3052302|NCT02212249|Active Comparator|Systemic sclerosis|patients with systemic sclerosis
3052303|NCT02212249|Sham Comparator|primary raynaud disease|patients with primary raynaud disease
3052304|NCT02212236|Experimental|Psychological preparation + TAU|TAU=treatment as usual
3052305|NCT02212236|No Intervention|Treatment as usual|Usual care including medication, nursing, and psychologist support.
3052306|NCT02212223|Experimental|Group 1: Somali immigrant group, 10 µg (400 IU) vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 10 µg (400 IU) vitamin D3 to take for 6 months
3052307|NCT02212223|Experimental|Group 2: Somali immigrant group, 20 µg (800 IU) vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 20 µg (800 IU) vitamin D3 to take for 6 months
3052308|NCT02212223|Placebo Comparator|Group 3: Somali immigrant group, 0 µg vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 0 µg (0 IU) vitamin D3 to take for 6 months
3052309|NCT02212223|Experimental|Group 4: Original Finnish group, 10 µg (400 IU) vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 10 µg (400 IU) vitamin D3 to take for 6 months.
3052353|NCT02211950|Experimental|Treatment B|100 mg acarbose for 2 days, on the second day a single dose BI 44847 administered to white subjects
3052310|NCT02212223|Experimental|Group 5: Original Finnish group, 20 µg (800 IU) vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 20 µg (800 IU) vitamin D3 to take for 6 months.
3052311|NCT02212223|Placebo Comparator|Group 6: Original Finnish group, 0 µg vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 0 µg (0 IU) vitamin D3 to take for 6 months.
3052312|NCT02212210|Active Comparator|Methylprednisolone|1cc of 80mg methylprednisolone to be diluted with 1cc preservative free normal saline
3052313|NCT02212210|Placebo Comparator|Normal saline|2cc preservative free normal saline
3052314|NCT02212197|Experimental|CAM2032 3.75 mg|Single subcutaneous buttock injections of CAM2032 (leuprolide acetate FluidCrystal® injection depot) 3.75 mg on Days 0, 28 and 56.
3052315|NCT02212197|Experimental|CAM2032 7.5 mg|Single subcutaneous buttock injections of CAM2032 (leuprolide acetate FluidCrystal® injection depot) 7.5 mg on Days 0, 28 and 56.
3052316|NCT02212197|Active Comparator|Eligard 7.5 mg|Single subcutaneous buttock injections of Eligard® (leuprolide acetate) 7.5 mg on Days 0, 28 and 56.
3052317|NCT02212184|Sham Comparator|Control Group|Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
3052318|NCT02212184|Experimental|Intevention Group|"All patients will receive the Manual Diaphragm Release Technique, during 6 days of treatment. They will undertake four evaluations throughout treatment: before and immediately after the Day 1 (Baseline 1 and Post 1) and before and after Day 6 (Baseline 6 and Post 6).~In the other Days (2nd to 5th) patients will only receive the intervention and won't be evaluated."
3052319|NCT02212171|Experimental|TRIAP intervention|
3052320|NCT02212171|No Intervention|Usual care|Usual care: Patients in the control group will be treated according to Osakidetza recommendations.
3052321|NCT02212158|Experimental|motivational interviewing group|"Motivational Group Intervention:~Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies."
3052322|NCT02212145||Screened group|Screened group is defined as those individuals who were willing to participate in the cardiovascular prevention program and all the individuals who lived in Sollentuna during the intervention.
3052323|NCT02212145||Relatives to the screened group|Relatives to individuals included in the screened group, who lived in Stockholm County at least during one year at the time of the intervention.
3052324|NCT02212145||Control group|"Matched controls is going to be selected randomly from the population of Stockholm County minus Sollentuna Municipality with relevant background factors. The whole population will be used as a comparison group when evaluating the result from all the municipality of Sollentuna during 1988-1993."
3052325|NCT02212132||Patient|Neuropsychological evaluation, psychopathological assessment and fatigue
3052326|NCT02212132||Control group|Neuropsychological evaluation, psychopathological assessment and fatigue
3052327|NCT02212119|Placebo Comparator|Saline|Saline injection up to 5 cc in arm with paratonia (one time injection)
3052328|NCT02212119|Active Comparator|Botulinum Toxin|Up to 300 U (5 cc) of Botulinum toxin diluted 2:1 (2 cc per 100 U of Botulinum toxin) (one time injection)
3052329|NCT02212106|Experimental|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
3052330|NCT02212106|Active Comparator|Comparator Quadrivalent Influenza Virus Vaccine|The comparator vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season.
3052331|NCT02212093||pneumonia and mechanical ventilation|The data are collected retrospectively from this one group.
3052332|NCT02212080|Experimental|BAY1214784|Dose 1 to 7 of BAY1214784
3052333|NCT02212080|Placebo Comparator|Placebo|Placebo Dose 1 to 7 of BAY1214784
3052334|NCT02212067|Experimental|Semaglutide|Total of 12 visits
3052335|NCT02212067|Placebo Comparator|Placebo|Total of 12 visits
3052336|NCT02212067|No Intervention|Healthy subjects|Total of 2 visits
3052337|NCT02212054|Experimental|conservative & operative treatment|anal dilation; colon lavage; probiotics
3052338|NCT02212054|Active Comparator|operative treatment|one stage pull- through radical colectomy
3052339|NCT02212041|Experimental|Electronic cigarettes|Free disposable electronic cigarettes will be provided during 6 weeks to smokers with serious mental illness.
3052340|NCT02212028|Experimental|Prasugrel crush|Prasugrel 60mg loading dose as crushed tablets
3052341|NCT02212028|Active Comparator|Prasugrel tablets|Prasugrel 60 mg loading dose as whole tablets
3052342|NCT02212015|Experimental|Pazopanib + Paclitaxel|
3052343|NCT02212002||Control|Control group: infants born to GBS-negative mothers, who thus did not receive any antibiotic treatment before/at delivery.
3052344|NCT02212002||IAP|IAP group: infants born to GBS-positive mothers who have received adequate intrapartum antibiotic prophylaxis (IAP). According to the Institutional treatment protocol for GBS prophylaxis (derived from CDC guidelines), intravenous ampicillin is given every 4 hours until delivery (first dose 2 g, following doses 1 g each). IAP is considered adequate when the mother received at least two doses of ampicillin before delivery.
3052345|NCT02211989|Experimental|BI 14332 CL|single rising dose
3052346|NCT02211989|Placebo Comparator|Placebo|
3052347|NCT02211976|Experimental|Bisacodyl|
3052348|NCT02211976|Experimental|Simeticone|
3052349|NCT02211976|Experimental|Bisacodyl and simeticone|
3052350|NCT02211963|Experimental|BI 44847|
3052351|NCT02211963|Placebo Comparator|Placebo|
3052352|NCT02211950|Experimental|Treatment A|single dose BI 44847 administered to white subjects
3052354|NCT02211950|Experimental|Treatment C|single dose BI 44847 after a Japanese diet of 6 days administered to white subjects
3052355|NCT02211950|Experimental|Treatment D|single dose BI 44847 administered to asian subjects
3052356|NCT02211950|Experimental|Treatment E|single dose BI 44847 administered to african subjects
3052357|NCT02211937|Active Comparator|Treatment A|BI 44847 suspension high dose, fasted
3052358|NCT02211937|Experimental|Treatment B|BI 44847 tablet high dose, fasted
3052359|NCT02211937|Experimental|Treatment C|BI 44847 tablet high dose, fed
3052360|NCT02211937|Active Comparator|Treatment D|BI 44847 solution low dose, fasted
3052361|NCT02211937|Experimental|Treatment E|BI 44847 tablet low dose, fasted
3052362|NCT02211924|Experimental|BI 44847|single rising dose
3052363|NCT02211924|Placebo Comparator|Placebo|
3052364|NCT02211911|Experimental|Bisacodyl|
3052365|NCT02211911|Experimental|Sodium picosulfate|
3052366|NCT02211898|Experimental|BNS003|
3052367|NCT02211872|Experimental|Treatment A|BI 2536 BS single rising dose
3052368|NCT02211872|Experimental|Treatment B|BI 2536 BS multiple rising doses on three consecutive days (d1-3 schedule)
3052369|NCT02211859|Experimental|BI 2536|single escalating dose, followed by repeated administration in patients with clinical benefit
3052370|NCT02211846|Experimental|Mirabegron|Administered under fed and fasted conditions
3052371|NCT02211833|Experimental|BI 2536 with pemetrexed|combination therapy phase may be followed by BI 2536 monotherapy for eligible patients
3052372|NCT02211807||Patients initiating an Efavirenz|Patients initiating an Efavirenz-containing antiretroviral regimen
3052373|NCT02211807||Patients initiating an Efavirenz-free regimen|
3052374|NCT02211794||1 cohort|subject requires primary total knee arthroplasty with the Journey II BCS Total Knee System, including patella resurfacing due to degenerative joint disease (primary osteoarthritis, post-traumatic arthritis, avascular necrosis, rheumatoid arthritis)
3052375|NCT02211768|Experimental|1|Subjects will undergo FDG-PET and FLT-PET scans at least one day apart
3052376|NCT02211768|Other|2|Subjects will undergo FDG-PET scan
3052377|NCT02211755|Experimental|1|Starting doses are clofarabine at 1 mg/m(2) IV on days 1 through 5 of a 21-day cycle, and bortezomib at 0.8 mg/m2 subcutaneously on days 1 and 4 of a 21-day cycle.
3052378|NCT02211742|Active Comparator|dapagliflozin|10mg dapagliflozin per 24h for 3 days per cross-over phase (equals 2 x 30mg)
3052379|NCT02211742|Placebo Comparator|placebo sugar pills|placebo tablet, 1 per 24h for 3 days in total per cross-over phase (equals 2 x 3 tablets)
3052380|NCT02211729|Active Comparator|Seasonal malaria chemoprevention|Sulphadoxine-Pyrimethamine Amodiaquine Placebo Azithromycin
3052381|NCT02211729|Experimental|seasonal malaria chemoprevention plus AZ|Sulphadoxine-Pyrimethamine+ Amodiaquine + Azithromycin 4 rounds during malaria transmission season
3052382|NCT02211716|Experimental|BeGraft|Patient's treated with the BeGraft PMCF Stent Graft System from Bentley Innomed for the treatment of iliac lesions.
3052383|NCT02211703||Observation|This is an epidemiology study in which all the data from the subjects enrolled will be collected and analysis to investigate the current patient warming condition and actual perioperative hyperthermia rate in the elective operation with general anesthesia. During the whole procedure none intervention is administered.
3052384|NCT02211690|Experimental|dolutegravir 50mg with co-formulated emtricitabine-tenofovir|One-hundred eligible participants will receive dolutegravir (1 x 50mg tablet) with co-formulated emtricitabine-tenofovir (1 tablet) once daily for 28 days
3052385|NCT02211677||Low Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hb, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 1-4 called the low risk group.
3052386|NCT02211677||Intermediate Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hemoglobin, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 5-11 called the intermediate risk group.
3052387|NCT02211677||High Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hemoglobin, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 12-17 called the high risk group.
3052388|NCT02211664|Experimental|Passeo-18-Lux & Pulsar-18|"The interventional procedure sequence consists of the following steps:~pre-dilation of the lesion with a Passeo-18 balloon (mandatory)~dilation of the lesion with a Passeo-18 Lux drug releasing balloon (mandatory); a maximum of 2 Passeo-18 Lux balloons can be used per lesion (drug load cannot exceed 12µg)~stenting of the lesion with a Pulsar-18 stent (mandatory)~post-dilation of the lesion with a Passeo-18 balloon (not mandatory)"
3052389|NCT02211651||ObeseDYS|Obese subjects with dysfunctional vascularization and inflammation of placenta.
3052390|NCT02211651||ObeseNL|Obese subjects with normal vascularization and inflammation of placenta
3052391|NCT02211651||LeanNL|Lean subjects with normal vascularization and inflammation of placenta.
3052392|NCT02211638||Candesartan Cilexetil tablets (2 to 12 mg)|Candesartan Cilexetil tablets (2 to 12 mg), orally, once daily for up to 3 months
3052393|NCT02211625|Experimental|TRV734 125 mg|Part A, open-label will evaluate the the safety, PK and PD profile of a 125mg dose of TRV734 in which subjects are fasted, fed a standard meal, or fed a high-fat meal. Part A will also inform the dosing paradigm for Part B.
3052394|NCT02211625|Active Comparator|Multiple ascending dose study, active and placebo comparators|Part B will assess the safety, tolerability, PD and PK of TRV734. Subjects will be randomized in a ratio of 3:1:1 to receive either multiple doses of TRV734, oxycodone IR 10mg or placebo.
3052395|NCT02211612|Experimental|Saturated fatty acids (SFA)-group|Weight gain created by addition of muffins baked on saturated fat
3052396|NCT02211612|Experimental|Polyunsaturated fatty acids (PUFA)-group|Weight gain created by addition of muffins baked on polyunsaturated fat
3052397|NCT02211599|Experimental|15% protein meal and sweetened beverage|Breakfast and lunch will each contain 15% protein. A sweetened flavored beverage will be served with each meal; one drink will be sweetened with sugar and the other with sucralose (a non-nutritive sweetener). Order will be randomized.
3052398|NCT02211599|Experimental|30% protein meal and sweetened beverage|Breakfast and lunch will each contain 30% protein. A sweetened flavored beverage will be served with each meal; one drink will be sweetened with sugar and the other with sucralose (a non-nutritive sweetener). Order will be randomized.
3052399|NCT02211573|No Intervention|Control group|Patients of this group don't performed physical training
3052400|NCT02211573|Experimental|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
3052401|NCT02211560|Placebo Comparator|Placebo|Identical looking cellulose capsules
3052402|NCT02211560|Experimental|Phosphatidylserine|Phosphatidylserine-omega-3, DHA enriched
3052403|NCT02211547|No Intervention|Control|No treatment to be rendered following separator placement.
3052404|NCT02211547|Placebo Comparator|Placebo|Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
3052405|NCT02211547|Experimental|Treatment|Single blind laser treatment (the laser will be positioned and operated, and energy transfer will take place).
3052406|NCT02211534|Active Comparator|Pulsed Electromagnetic Field Device|Pulsed Electromagnetic Field therapy device; self-administered at home twice daily for 30 minutes.
3052407|NCT02211534|Sham Comparator|Sham Pulsed Electromagnetic Field Device|Inactive Pulsed Electromagnetic Field Therapy device; self-administered at home twice daily for 30 minutes.
3052408|NCT02211521|Experimental|PRP group|Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of autologous Platelet-Rich Plasma (3ml).
3052409|NCT02211521|Active Comparator|Hyaloronan group|Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of hyaluronic acid (3ml)
3052410|NCT02211508|Active Comparator|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device
3052411|NCT02211508|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
3052412|NCT02211495|Active Comparator|No device|Treated with best medical therapy
3052413|NCT02211495|Experimental|Device|As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg. They will wear it for 4 hours per day, 5 days a week.
3052414|NCT02211482|Other|Dolutegravir , lamivudine|Dolutegravir 50 mg QD plus lamivudine 300 mg QD
3052415|NCT02211469|Experimental|Panel 1: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
3052416|NCT02211469|Experimental|Panel 2: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
3052417|NCT02211469|Experimental|Panel 3: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
3052418|NCT02211469|Experimental|Panel 4: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
3052419|NCT02211456|Experimental|Participants|Having an ablation procedure with access to the left side of the heart
3052420|NCT02211443|Experimental|Single arm|"Two phase study of Recombinant full human Anti-epidermal growth factor receptor(EGFR) Monoclonal Antibody:~First phase: seven escalating single-dose groups : 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0 mg/kg~Second phase: multiple-dose groups 0.5, 1.0, 2.0, 3.0 mg/kg: weekly once for 4 doses; 5.0, 6.0 mg/kg: every two weeks for 2 doses; 4.0 mg/kg: weekly or every two weeks depends on the results of previous dose groups."
3052421|NCT02211430|Experimental|Cognitive-Behavioral Counseling (CBC)|Cognitive-Behavioral Counseling (CBC) consists of two 45-minute on-site intervention sessions (session 1 and 3), one 15 minute on-site session (session 2), and one 15-minutes phone session (booster session).
3052422|NCT02211430|Active Comparator|Best Practice (BP) Control|Best Practice (BP) Control Condition consists of two 10-15 min, on-site intervention sessions (session 1 and 3), one brochure pick-up (session 2), and receipt of a newsletter by mail (booster session).
3052423|NCT02211417|Experimental|DS107G|DS107G 2g capsules taken by mouth daily for 56 days.
3052424|NCT02211417|Placebo Comparator|Placebo|Placebo capsules 2g taken by mouth daily for 56 days.
3052425|NCT02211391|Experimental|Casein Protein|Casein protein (30g) will be consumed as the last food/caloric beverage and within 30 minute of sleep
3052426|NCT02211391|Placebo Comparator|Non-caloric Placebo|The non-caloric placebo beverage will will be consumed as the last food/caloric beverage and within 30 minute of sleep
3052427|NCT02211378|Experimental|Observer|Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
3052428|NCT02211378|Active Comparator|Hotseat|Trainees are in the 'hotseat' actively participating during all 3 simulation sessions
3052429|NCT02211352|Active Comparator|Active(Korean Red Ginseng) first group:|Korean Red Ginseng Capsules 2g,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
3052430|NCT02211352|Placebo Comparator|Placebo capsules|placebo Capsules(2g),daily, 8 week and than crossover to Korean Red Ginseng capsules(2g), daily 8week
3052431|NCT02211339|Experimental|Social skills intervention group|This group meets twice each week for 8 weeks. Peer tutor training is provided.
3052432|NCT02211339|Active Comparator|Social activity group|Staff led social activities organised in group setting, meeting twice each week for 8 weeks. Usual care.
3052433|NCT02211326|Experimental|genotype-guided group|Interventions：on day1~day3, patients received dose according to IWPC formula (PGx-1) included clinical variables and genotype data for VKORC1, CYP2C9*1, CYP2C9*2, and CYP2C9*3; on day4~day7, patients received dose according to Lenzini formula consisted of clinical variables, VKORC1, CYP2C9*2, CYP2C9*3 and previous INR and dosing information (PGx-2); and on day8, the clinicians adjusted the dose according to observed INR.The overall follow-up period is 12 weeks.
3052434|NCT02211326|Active Comparator|control group|Interventions：on day1~day3, patients were given initial dose (2.25mg); and starting from day4, the clinicians began to adjust the dose for patients according to observed INR.The overall follow-up period is 12 weeks.
3052435|NCT02211313|Active Comparator|Ureteral stent - soft, 6 French|Subjects randomized to soft stent, size 6 French
3052436|NCT02211313|Active Comparator|Ureteral stent - hydrophobic, 6 French|Subjects randomized to hydrophobic stent, size 6 French
3052437|NCT02211300|Experimental|Optiscanner values vs YSI|Matched samples up to 12 times per 24 hour period
3052438|NCT02211287|Experimental|Intervention|The intervention will include five key elements: a Project Nurse - ACP facilitator; family education on comfort care at the end of life for individuals with dementia using the 'Comfort Care at the end of life for persons with dementia' booklet; a family meeting with follow-up telephone call; documentation of ACP decisions, and orientation and education directed towards General Practitioners (GPs) and nursing home staff about the intervention.
3052439|NCT02211287|No Intervention|Usual care|Care will continue as usual for the nursing home residents
3052440|NCT02211274|Experimental|Study Group|Individuals who want to leave the CLC will be allowed to participate in the study, there will be no assignment to groups. Individuals who want to leave the CLC will undergo transition care planning using the investigators' standardized toolkit. The investigators will compare outcomes to administrative data from other similar VA nursing homes.
3052441|NCT02211261|Experimental|Cohort 1-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
3052442|NCT02211261|Experimental|Cohort 2-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
3052443|NCT02211261|Experimental|Cohort 3-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
3052444|NCT02211261|Experimental|Cohort 4-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
3052445|NCT02211261|Experimental|Cohort 5-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
3052446|NCT02211261|Experimental|Cohort 6-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
3052447|NCT02211261|Experimental|Cohort 7 PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
3052448|NCT02211261|Experimental|Cohort 8-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
3052449|NCT02211261|Experimental|Cohort 9-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
3052450|NCT02211248|Active Comparator|Conventional Group|Conventional treatment and follow up
3052451|NCT02211248|Experimental|Multidisciplinary Group|Multidisciplinary assistance
3052452|NCT02211209|Active Comparator|volanesorsen|300 mg volanesorsen administered subcutaneously once-weekly for 52 weeks
3052453|NCT02211209|Placebo Comparator|Placebo|Placebo administered subcutaneously once-weekly for 52 weeks
3052454|NCT02211196|Experimental|Health Services Research (smoking cessation intervention)|Participants complete a survey over approximately 10-15 minutes related to their provider's cessation advice and assistance with quitting.
3052455|NCT02211183|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
3052456|NCT02211183|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridement, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
3052457|NCT02211170|Experimental|BIBR 796 BS, low dose|
3052458|NCT02211170|Experimental|BIBR 796 BS, high dose|
3052459|NCT02211170|Placebo Comparator|Placebo|
3052460|NCT02211157|Experimental|BIBR 796 BS, fasted|dose escalation
3052461|NCT02211157|Experimental|BIBR 796 BS, fed|50 mg BIRB 796 BS (food effect)
3052462|NCT02211157|Placebo Comparator|Placebo|
3052463|NCT02211144|Experimental|BIRB 796 BS|in escalating doses
3052464|NCT02211144|Placebo Comparator|Placebo|
3052465|NCT02211131|Experimental|Talimogene Laherparepvec|Arm 1 Talimogene laherparepvec for 6 doses followed by surgical resection of melanoma tumor lesion(s).
3052466|NCT02211131|Other|Surgery|Arm 2: Surgical resection of melanoma tumor lesion(s)
3052467|NCT02211118|Experimental|IN-DEX|Subjects will be administered 1 mcg/kg or 1.5 mcg/kg intranasal dexemdetomidine (IN-DEX) and monitored for up to 5 hours.
3052468|NCT02211105||Laparoscopic Nissen Fundoplication|Patients whose GERD is being treated surgically through Laparoscopic Nissen Fundoplication.
3052469|NCT02211105||Transoral Incisionless Fundoplication|Patients whose GERD is being treated surgically through Transoral Incisionless Fundoplication.
3052470|NCT02211092|Experimental|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
3052471|NCT02211092|Other|Usual care|Access to usual community resources but no active lifestyle coaching.
3052472|NCT02211079|Experimental|JNJ-54861911 + Caffeine + Midazolam +Tolbutamide|JNJ-54861911, 50 milligram (mg) (2*25 mg tablets) orally once daily from Day 2 to Day 9 along with caffeine 100 mg (2*50 mg tablets), midazolam 2 mg (1 milliliter [mL], 2 mg/mL solution), and tolbutamide 500 mg tablet, orally on Day 1, 2, and 9.
3052473|NCT02211066|Active Comparator|Clopidogrel|Clopidogrel 75 mg will be administered daily for 1 year
3052474|NCT02211066|Experimental|Ticagrelor|Ticagrelor 90 mg will be administered daily for 1 year
3052475|NCT02211053|Active Comparator|Levothyroxine|Levothyroxine infusion 20 mg IV bolus then 10 mg/h infusion
3052476|NCT02211053|Placebo Comparator|Placebo|Infusion matched to intervention arm
3052477|NCT02211040|Experimental|No general practitioner involvement|The selection and motivation of adults will be conducted by a researcher in the waiting room. There is no extra motivation of the general practitioner.
3052478|NCT02211040|Experimental|General practitioner involvement|An intervention group in which general practitioners select and motivate adults to be more physical active and eat more fruit and vegetables.
3052479|NCT02211027|Experimental|Vaccine|The vaccine is composed of lethally irradiated semi-allogenic human fibroblasts (MRC-5) transfected with genomic tumor DNA from the patients own tumor.
3052480|NCT02211014|Experimental|acalabrutinib Regimen 1|Acalabrutinib Regimen 1
3052481|NCT02211014|Experimental|acalabrutinib Regimen 1 plus dexamethasone|acalabrutinib Regimen 1 plus dexamethasone
3052482|NCT02211001|Experimental|Pilates Group|The individuals were treated with Mat Pilates Method.
3052483|NCT02211001|Experimental|Segmented Dynamic Exercises Group|The individual were treated with ball exercises.
3052484|NCT02211001|Experimental|Global Postural Reeducation Group|The individuals were treated with postures of Souchard Method.
3052485|NCT02210988|Experimental|acupuncture|The acupuncture treatment for the intervention group was provided once daily for 2 weeks.
3052486|NCT02210975|Experimental|Electrical Stimulation Therapy|
3052487|NCT02210962|Experimental|essential fatty acids|The experimental treatment is a food supplement containing fish oil. The daily dose of 4 capsules provides 1320 mg of eicosapentaenoic acid and 880 mg of docosahexaenoic acid, 26 weeks intervention
3052488|NCT02210962|Placebo Comparator|olive oil|Placebo capsules contain olive oil and trace amount of fish oil to assure comparable taste, 26 weeks intervention
3052489|NCT02210949|Other|Erythropoietin Iron|"Erythropoietin and iron:~Administration of Erythropoietin (600 IU/kg (14.4 g/L)) twice weekly for three weeks .~Administration of Iron (Ferinject (iron(III)carboxymaltose)) intravenously 1000 mg once."
3052490|NCT02210936|Other|PDMP Data|
3052491|NCT02210923||Resistant hypertensive patients with Rheos system|"We will program 6 electrical device activation setting twice in a random order to see what happens with the aforementioned respiratory and cardiovascular variables. The following electrical settings will be programmed for 4 minutes each setting:~20 Hz, 3 Volts, 480 microseconds~20 Hz, 6 Volts, 480 microseconds~50 Hz, 3 Volts, 480 microseconds~50 Hz, 6 Volts, 480 microseconds~90 Hz, 3 Volts, 480 microseconds~90 Hz, 6 Volts, 480 microseconds"
3052492|NCT02210910|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
3052493|NCT02210910|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair, and placement of the InSpace™ system.
3052494|NCT02210884|Experimental|Vitamin D|Weekly oral dose of 15,000 IU of Vitamin D3
3052495|NCT02210884|Placebo Comparator|Placebo|Placebo capsule containing no vitamin D
3052496|NCT02210871|Experimental|Normal hepatic function|
3052497|NCT02210871|Experimental|Mild hepatic impairment|
3052498|NCT02210871|Experimental|Moderate hepatic impairment|
3052499|NCT02210871|Experimental|Severe hepatic impairment|
3052500|NCT02210858|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3052501|NCT02210845|Active Comparator|Financially incentivized weight loss|Participants can be assigned to the financially incentivized weight loss group in which they can receive 50 dollars at the end of the month if they achieve their monthly weight loss goal.
3052502|NCT02210845|Placebo Comparator|Standard of Care|Participants can be assigned to standard of care where they receive no intervention.
3052503|NCT02210845|Active Comparator|Supervised Exercise|Participants can be assigned to the supervised exercise arm which they will receive supervised professional training once a week.
3052504|NCT02210832|Experimental|Best practices for pregnant smokers|Five As plus referral to pregnancy-specific tobacco quit line
3052505|NCT02210832|Experimental|Best practices plus financial incentives|Best practices plus providing financial incentives contingent on biochemically verified abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks postpartum.
3052506|NCT02210832|No Intervention|Never-smoker comparison condition|We will follow a group of never-smoker pregnant women matched to smokers on key sociodemographic and obstetrical characteristics for purposes of comparisons in birth/health outcomes at delivery and through 1 year postpartum
3052507|NCT02210819||Rivaroxaban|Patients who will be treated for an acute venous thromboembolism (VTE) with rivaroxaban.
3052508|NCT02210819||Standard of care|Patients who will be treated for an acute venous thromboembolism (VTE) with current standard of care.
3052509|NCT02210806|Active Comparator|Treatment T1|One inhalation of 110 mcg A006 DPI. Total 110 mcg.
3052510|NCT02210806|Active Comparator|Treatment T2|One inhalation of 220 mcg A006 DPI. Total 220 mcg.
3052511|NCT02210806|Placebo Comparator|Placebo|One inhalation of placebo DPI . Total 0 mcg
3052512|NCT02210806|Active Comparator|Treatment R1|One inhalation of Proventil® MDI Total 90 mcg
3052513|NCT02210806|Active Comparator|Treatment R2|Two inhalations of Proventil® MDI, 180 mcg total
3052514|NCT02210793|Active Comparator|Transepithelial PRK|20 eyes to undergo a no touch , all-laser advanced surface ablation technique termed transepithelial PRK using the Amaris laser platform (Schwind eye-tech solutions Gmbh, Germany)
3052515|NCT02210793|Active Comparator|Conventional LASIK|20 eyes to undergo LASIK using a mechanical microkeratome (M2, Moria Surgical, Antony, France) and the Mel 80 excimer laser system(Carl Zeiss Meditec)
3052516|NCT02210780|Experimental|Group 1|
3052517|NCT02210780|Placebo Comparator|Group 2|
3052518|NCT02210767|Experimental|Walnut Diet|Provides ~2 oz. walnuts/day (2-3% of total calories from alpha-linolenic acid [ALA])
3052519|NCT02210767|Active Comparator|Walnut Control Diet|Provides same fatty acid profile (<7% SFA, 9% MUFA, 14-15% PUFA, 2-3% ALA) as Walnut Diet, but is devoid of walnuts and their bioactives
3052520|NCT02210767|Placebo Comparator|Low ALA Diet|Provides similar macronutrient and linoleic acid profile but replaces ALA with oleic acid (<7% SFA, 12% MUFA, 12% PUFA, 0.5% ALA)
3052521|NCT02210754|Experimental|E-cigarette 1|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)
3052522|NCT02210754|Experimental|E-cigarette 2|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/propylene glycol (PG) vehicle)
3052523|NCT02210754|Experimental|E-cigarette 3|blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)
3052524|NCT02210754|Experimental|E-cigarette 4|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)
3052525|NCT02210754|Experimental|E-cigarette 5|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)
3052526|NCT02210754|Active Comparator|Combustible Cigarette|Marlboro Cigarette
3052527|NCT02210728|Active Comparator|Medication only|Stimulant medication (methylphenidate or amphetamine product approved for clinical use in Canada), with dose optimized for each patient based on report of efficacy and side effects.
3052616|NCT02210143||Miller gingival recession|Gingival recessions classified according to Miller
3052528|NCT02210728|Active Comparator|Cognitive behavioral therapy + medication|Patients are first titrated to an optimal dose of stimulant medication. They then undergo the 12 weeks of group cognitive behavioral therapy.
3052529|NCT02210728|Experimental|Cognitive behavioral therapy alone|12 weeks of structured group cognitive behavioral therapy, focusing on acquisition of skills in organization, time management, goal attainment, cognitive restructuring, stress management, anger management, impulse control, self-esteem, and relationship management.
3052530|NCT02210715|Experimental|switch to Isentress|28 subjects will be prescribed Raltegravir at the standard dose of 400 mg p.o. b.i.d. for 24 months.
3052531|NCT02210715|Active Comparator|Continue usual antiretroviral therapy|28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
3052532|NCT02210702|Experimental|Ethinyl Estradiol 35mcg/Noethindrone 1mg|21 day supply of Ethinyl Estradiol 35mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum
3052533|NCT02210702|Experimental|Ethinyl Estradiol 20mcg/Norethindrone 1mg|21 day supply of Ethinyl Estradiol 20mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum
3052534|NCT02210702|No Intervention|No hormonal contraception|Women choosing copper IUD, spermicides, barrier methods, or sterilization (tubal ligation or partner vasectomy).
3052535|NCT02210689|Experimental|test product|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.)
3052536|NCT02210689|Active Comparator|reference product|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of Clindesse® (clindamycin phosphate vaginal cream 2% ) (Ther-Rx™)
3052537|NCT02210689|Placebo Comparator|placebo|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing vehicle of the test product (Watson Laboratories, Inc.)
3052538|NCT02210676|Experimental|Patients with Mallet Finger|All enrolled patients
3052539|NCT02210663|Experimental|veliparib (ABT-888)|
3052540|NCT02210650|Other|Ureteral stone removal|Group 1 will receive the standard treatment of having only the ureteral stone removed
3052541|NCT02210650|Other|Asymptomatic kidney stones and ureteral stone removed|Group 2 will include the step of having the asymptomatic kidney stones removed in addition to the ureteral stone
3052542|NCT02210637||Retrospective Cohort|Retrospective Cohort of scheduled outpatient appointment
3052543|NCT02210624|Experimental|Single arm|"Experimental: HYNR-CS inj.~Treatment group with HYNR-CS inj."
3052544|NCT02210611|Active Comparator|36 hours|Intrauterine insemination 36 hours after ovulation induction
3052545|NCT02210611|Active Comparator|42 hours|Intrauterine insemination 42 hours after ovulation induction
3052546|NCT02210598|Active Comparator|inpatient Foley balloon induction|"Inpatient Foley induction participants will be placed in the dorsal lithotomy position, a Foley catheter will be placed transcervically and its balloon filled with 60mL of sterile saline. One of two methods will be used to place the transcervical foley based on provider preference and determination of which method will offer the greatest chance for successful placement. Method A is placement of the foley blindly by palpation of the cervix. Method B utilizes direct visualization with sterile speculum placement. Method will be documented in the data collection forms. The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded."
3052547|NCT02210598|Experimental|outpatient Foley balloon induction|Patients randomized to the experimental group will undergo outpatient Foley induction of labor. Either of the above two described methods will be used to place an 18 French Foley catheter transcervically and its balloon filled with 60mL of sterile saline. The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours. When the patient returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.
3052548|NCT02210585|Active Comparator|Kneehab|5 sessions per week
3052549|NCT02210585|Placebo Comparator|Placebo|5 sessions per week
3052550|NCT02210572|Experimental|Bimuno Galacto-oligosaccharide|Dietary intervention
3052551|NCT02210572|Placebo Comparator|Low- FODMAPs diet|Dietary intervention
3052552|NCT02210559|Experimental|Arm A|FG-3019 + Gemcitabine + Nab-paclitaxel
3052553|NCT02210559|Other|Arm B|Gemcitabine + Nab-paclitaxel
3052554|NCT02210546|Experimental|Magnetic Resonance Imaging (MRI)|Patients will undergo MRI yearly
3052555|NCT02210546|Other|Mammography (Mx) + ultrasonography (US)|Patients will undergo yearly two-view (Mx) and breast US
3052556|NCT02210520|Experimental|laser|3 J/cm², 2 minutes in 6 points around the back spine
3052557|NCT02210520|Experimental|pulsatile ultrasound|1 W/cm², 2 minutes in 6 points around the back spine
3052558|NCT02210520|Experimental|continuous ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
3052559|NCT02210520|No Intervention|control|no treatment.
3052560|NCT02210507|Experimental|White cassava gari|A single meal containing 400 gm of garified non-biofortified (white) cassava with retinyl palmitate reference dose.
3052561|NCT02210507|Experimental|White cassava gari + red palm oil|A single meal containing 400 gm of garified non-biofortified (white) cassava with red palm oil.
3052562|NCT02210507|Experimental|Biofortified cassava gari|A single meal containing 400 gm of garified biofortified cassava.
3052563|NCT02210494|Experimental|Secretrol|
3052564|NCT02210481||GLUC-MAC-COHORT|post vitrectomy for retinal detachment or epimacular membrane patients
3052565|NCT02210468|Experimental|APIC-CF 4cc,|APIC-CF 4cc, once at first day
3052566|NCT02210468|Experimental|APIC-CF, 2cc|APIC-CF, 2cc, one at first day
3052567|NCT02210468|Placebo Comparator|Saline|
3052568|NCT02210455|Experimental|The Strongest Families FASD intervention|It is a web-based parent training program with a coach. The program is comprised of 11 sessions, each focusing on a different parenting strategy, delivered using easy to read text, instructional videos and audio clips. One Booster Session is conducted 1 month after completion of Session 11.
3052569|NCT02210455|Active Comparator|Psychoeducation|It is a static webpage on IRIS providing FASD information and resources, including recommended book titles, websites and organizations that may be helpful.
3052570|NCT02210442|Experimental|Educaguia intervention|Implementation of practice clinical guidelines with educational games
3052571|NCT02210442|Active Comparator|Control group|Implementation of clinical practice guidelines with standard practice care
3052572|NCT02210429|Active Comparator|IV Opioids|
3052573|NCT02210429|Active Comparator|Supraclavicular Single-Shot Block|
3052574|NCT02210429|Active Comparator|Supraclavicular Catheter|
3052575|NCT02210429|Active Comparator|Supraclavicular Angiocath|
3052576|NCT02210416||LAP repair|patients receiving laparoscopic inguinal hernia repair
3052577|NCT02210416||open repair|patients receiving open flat mesh repair of inguinal hernia
3052578|NCT02210403|Active Comparator|Upper limb motor function training + tDCS|Bi-hemispheric tDCS with motor function training
3052579|NCT02210403|Sham Comparator|upper limb motor function training + sham tDCS|sham tDCS with motor function training
3052580|NCT02210390|Experimental|Intervention|Psycho-education Sessions will be offered weekly basis
3052581|NCT02210390|No Intervention|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
3052582|NCT02210377|Experimental|Tianjiu (auto-moxibustion)|The participants in the Tianjiu group will be treated with Chinese herbal patches at acupoints on the abdomen and plantar, three times per week, for 4 hours each time during HD.
3052583|NCT02210377|Placebo Comparator|Non-Tianjiu (Non auto-MO)|The participants in the control group will be given placebo patches (brown clay patches) on the same sites.
3052584|NCT02210364|Experimental|lurbinectedin (PM01183) and capecitabine|
3052585|NCT02210351|Experimental|MRI test|
3052586|NCT02210338|Experimental|Karl Storz C-MAC|Intubation of patient using the Karl Storz C-MAC video laryngoscope
3052587|NCT02210338|Experimental|Bonfils Intubation Fibrescope|Intubation of patient using Bonfils Intubation Fibrescope
3052588|NCT02210325|Active Comparator|Ceftriaxone plus Azithromycin|A single intramuscular dose of 500 mg ceftriaxone plus a single oral dose of 1000 mg azithromycin
3052589|NCT02210325|Experimental|Solithromycin|A single oral dose of 1000 mg solithromycin
3052590|NCT02210312||elective non-cardiac surgery and non-neurosurgical procedures|300 Patients aged 60 years and older undergoing elective non-cardiac surgery and non-neurosurgical procedures in general anaesthesia or combined general/regional anaesthesia with a duration of operation of 120 minutes or longer. 80 age-, gender- and education-matched healthy controls.
3052591|NCT02210299|Other|Exposure study|2-6 months-old children and 12-18 months-old children
3052592|NCT02210286|Experimental|Magtein|All participants will orally take a total of 1800 mg/day for 60 days. Oral administration includes two pills 2 hours before bed time and one pill in the morning, each pill containing 600 mg of MgT-1219.
3052593|NCT02210273|Experimental|Treatment|Subjects undergoing treatment with the Solace Bladder Control Balloon on day 0
3052594|NCT02210273|Sham Comparator|Solace Sham Treatment|Subjects undergoing sham treatment on day 0, and treatment with the Solace Bladder Control Balloon at 3 months
3052595|NCT02210260|Active Comparator|Continuous infusion of local anaesthetic|Continuous infusion of local anaesthetic into the surgical wound
3052596|NCT02210260|Experimental|Spinal and infusion of local anaesthetic|A one off spinal anaesthetic plus a continuous infusion of local anaesthetic into the surgical wound
3052597|NCT02210247|Active Comparator|Cohort 1|Cohort 1 will receive a single dose of EXPAREL 266 mg on Day 1. No additional dose will be given.
3052598|NCT02210247|Active Comparator|Cohort 2|Cohort 2 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 4 at 72 hours.
3052599|NCT02210247|Active Comparator|Cohort 3|Cohort 3 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 3 at 48 hours.
3052600|NCT02210247|Active Comparator|Cohort 4|Cohort 4 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 2 at 24 hours.
3052601|NCT02210247|Active Comparator|Cohort 5|Cohort 5 will receive a single dose of EXPAREL 266 mg on Day 1 followed immediately by a second dose of EXPAREL 266 mg (total of 532 mg/40 mL).
3052602|NCT02210234|Active Comparator|50 grams of whole wheat bran cereal|This arm was randomized to eat 50 grams of whole wheat brand cereal during the day for 3 weeks.
3052603|NCT02210234|Active Comparator|100 grams of whole wheat bran cereal|This arm was randomized to eat 100 grams of whole wheat brand cereal the day for 3 weeks.
3052604|NCT02210208|Experimental|Mepitel® Ag|A dressing device used for surgical burn wounds with skin graft.
3052605|NCT02210208|Experimental|Mepilex® Transfer Ag|Donor site dressing device in the very same patient.
3052606|NCT02210195|Active Comparator|Experimental: aprepitant 125 mg/day|125 mg aprepitant daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
3052607|NCT02210195|Placebo Comparator|Placebo 125mg/d|Matched placebo pill given daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
3052608|NCT02210182|Experimental|Oral pentamidine|Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
3052609|NCT02210182|Placebo Comparator|Placebo|Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
3052610|NCT02210169|No Intervention|Intermittent infusion of vancomycin|Vancomycin will be administered intravenously over 1 hour. Doses will be given from one to four times a day according to corrected gestational age.
3052611|NCT02210169|Active Comparator|Continuous infusion of vancomycin|A loading dose of vancomycin will be given over 1 hour followed by a continuous infusion of vancomycin over a 24 hour period.
3052612|NCT02210156|Placebo Comparator|Placebo|Two envelopes of the product in 240 ml of water in a disposable cup, 90 days of actual consumption.
3052613|NCT02210156|Experimental|Omniplus Supreme|Two envelopes of the product in 240 ml of water in a disposable cup, 90 days of actual consumption.
3052614|NCT02210143||AERSA-I gingival recession|The AERSA classification was developed based on 15 mm2 which is the lowest cut-off point and the group of AERSA ≤ 15 mm2 named as AERSA-I (low risk group)
3052615|NCT02210143||AERSA-II gingival recession|AERSA > 15 mm2 named as AERSA-II (high risk group).
3081622|NCT02015897|Active Comparator|Physical TherapyB|Group B
3052618|NCT02210130||control HIV+ CSVD-|patients with HIV and without cerebral small vessel disease
3052619|NCT02210117|Experimental|Arm A - Nivolumab|Participants receive Nivolumab 3 mg/kg by vein every 2 weeks for a total of 6 weeks followed by cytoreductive nephrectomy. Nephrectomy will occur about 4 weeks after the last cycle of Nivolumab.
3052620|NCT02210117|Experimental|Arm B - Nivolumab + Bevacizumab|Participants receive Nivolumab at 3 mg/kg by vein every 2 weeks plus Bevacizumab 10 mg/kg by vein every 2 weeks for 6 weeks followed by cytoreductive surgery. Nephrectomy will occur about 4 weeks after the last cycle of Nivolumab.
3052621|NCT02210117|Experimental|Arm C - Nivolumab + Ipilimumab|Participants receive Nivolumab at 3 mg/kg by vein every 3 weeks plus Ipilimumab 1 mg/kg by vein every 3 weeks for 6 weeks followed by cytoreductive surgery. Nephrectomy will occur about 4 weeks after the last cycle of Nivolumab.
3052622|NCT02210117|Experimental|Maintenance - Nivolumab|"After finishing the last treatment, Cytoreductive surgery or biopsy will occur at week 10. For patients who have stable disease, clinical response, or even slight progression of disease post-operatively, they will begin maintenance Nivolumab 4-6 weeks post-surgery at 480 mg by vein every 4 weeks for 2 years or until disease progression or intolerable toxicity.~For patients who were previously a surgical candidate for cytoreductive nephrectomy or metastasectomy but changed to post treatment biopsy due to clinical necessity, they will not need post-operative restaging. Nivolumab treatment in this setting can be started as early as 1-2 weeks post-treatment biopsy."
3052623|NCT02210104|Experimental|Ipilimumab + Cyclophosphamide + CD4+T Cells|Starting Dose of Ipilimumab 1.0 mg /kg by vein on Days 1, 22, 43, and 64. Cyclophosphamide 300 mg/m2 administered intravenously 2 days prior to T cell infusion as an outpatient procedure. Antigen-specific CD4+ T cells administered at a dose 10^10 cells/m^2.
3052624|NCT02210091|Experimental|<6 years old|
3052625|NCT02210091|Experimental|≥6 to <12 years|
3052626|NCT02210078|Experimental|Cytotoxic T-Lymphocytes (CTL)|CTL dose infused will not be greater than 10e5 viable CD3+ T cells/kg. If patient has a partial response, stable disease or progressive disease, they will be eligible to receive one additional dose of CTL at a minimum of 2 weeks interval from the first CTL infusion.
3052627|NCT02210065|Experimental|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
3052628|NCT02210052|Experimental|Radiofrequency neurotomy subjects|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
3052629|NCT02210039|Experimental|SECM Probe Imaging|SECM probe will be guided to a pre-determined length in the esophagus and spiral imaging will be performed using the SECM Imaging System.
3052630|NCT02210026|Experimental|Experimental|Infants will be assessed on standard bubble nasal CPAP, then on Seattle-PAP bubble nasal CPAP, then again on standard bubble nasal CPAP.
3052631|NCT02210013||Caucasian women|200 Caucasian infertile women undergoing their first or second IVF cycle
3052632|NCT02210013||Indian women|200 Indian women undergoing their first or second IVF cycle.
3052633|NCT02210000|Placebo Comparator|Placebo|Subjects will receive camicinal matching placebo orally once daily (QD) from Day 1 to Day 84
3052634|NCT02210000|Experimental|Camicinal 25mg|Subjects will receive camicinal 25 mg orally QD from Day 1 to Day 84
3052635|NCT02209987|Experimental|GS-5745 SC|Participants will receive a single dose of GS-5745 by SC injection.
3052636|NCT02209987|Experimental|GS-5745 IV|Participants will receive a single dose of GS-5745 by IV infusion.
3052637|NCT02209974|Placebo Comparator|Inhaled Placebo|Inhaled placebo administered to healthy (n=7) and to a half (n=8) of COPD patients
3052638|NCT02209974|Experimental|Inhaled corticosteroids (Fluticasone, 0.5 mg)|Inhaled corticosteroids administered to the other half (n=8) of COPD patients
3052639|NCT02209961||glaucoma and ocular hypertension|glaucoma and ocular hypertension
3052640|NCT02209948|Experimental|Temozolomide|Those patients will take 6 additional Temozolomide cycles
3052641|NCT02209948|No Intervention|Without treatment|
3052642|NCT02209935|Active Comparator|Usual Care|Typically, usual care is when therapies are not initiated until the treating team places an order for each element of care (physical, occupational, speech, and emotional therapy consultation).
3052643|NCT02209935|Experimental|Early Rehabilitation Protocol|Physical, occupational, speech, and emotional evaluation and support personalized to the subject's severity of illness and developmental status.
3052644|NCT02209922|Active Comparator|Transcranial direct current stimulation|"ARM1: Transcranial direct current stimulation (tDCS) intervention and simultaneous balance training.~Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week."
3052645|NCT02209922|Sham Comparator|ARM 2|ARM2: Sham tDCS and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
3052646|NCT02209909|Experimental|aspirin continuation|Intervention : Low-dose aspirin (< 100mg/day) is used before OPCAB surgery in the aspirin continuation group.
3052647|NCT02209909|Experimental|aspirin discontinuation|Intervention: Low-dose aspirin is stopped more than 4 days before OPCAB surgery in the aspirin discontinuation group.
3052648|NCT02209896|Experimental|BlueWind Reprieve System|The Reprieve implant will be implanted for eligible patients. Implant parameters settings will be set according to patient's sensations.
3052649|NCT02209883||Group normal|The patients which have not clinical diagnosis of chronic obstructive lung disease.
3052650|NCT02209883||Group COPD|The patients which have chronic obstructive lung disease in clinical evaluation
3052651|NCT02209870||E-checklist group|The patients after CPR team using E-checklist system
3052652|NCT02209844|Experimental|BI 44847 powder|single rising dose reconstituted with natrosol solution
3052653|NCT02209844|Placebo Comparator|Placebo|reconstituted with natrosol solution
3052654|NCT02209831|Experimental|BIBR 796 BS + pantoprazole|
3052655|NCT02209831|Active Comparator|BIBR 796 BS without pantoprazole|
3052656|NCT02209818|Experimental|Laser Irradiation One Dose|Laser irradiation will be applied in one dose for patients in this group, but only on one side of the jaw. The other side of the jaw will receive a placebo procedure (i.e. a red light beam will be emitted on the gingival tissues as if they are irradiated by a laser beam).
3052657|NCT02209818|Experimental|Laser Irradiation Two doses|Laser irradiation will be applied in two doses for patients in this group, but only on one side of the jaw. The second dose will be given after 24 hour of the first one. The other side of the jaw will receive a placebo procedure (i.e. a red light beam will be emitted on the gingival tissues as if they are irradiated by a laser beam).
3052658|NCT02209805|Experimental|BIRB 796 BS, low dose|
3052659|NCT02209805|Experimental|BIRB 796 BS, high dose|
3052660|NCT02209805|Placebo Comparator|Placebo|
3052661|NCT02209805|Experimental|BIRB 796 BS, medium dose|
3052662|NCT02209792|Placebo Comparator|Placebo|
3052663|NCT02209792|Experimental|BIRB 796 BS, low dose|2 x 5 mg b.i.d.
3052664|NCT02209792|Experimental|BIRB 796 BS, medium dose 1|20 mg b.i.d.
3052665|NCT02209792|Experimental|BIRB 796 BS, medium dose 2|2 x 5 mg + 20 mg b.i.d.
3052666|NCT02209792|Experimental|BIRB 796 BS, high dose|3 x 20 mg b.i.d.
3052667|NCT02209779|Experimental|BIBR 796 BS, low dose|twice daily doses of 5 mg for 4 weeks
3052668|NCT02209779|Experimental|BIBR 796 BS, medium dose 1|twice daily doses of 10 mg for 4 weeks
3052669|NCT02209779|Experimental|BIBR 796 BS, medium dose 2|twice daily doses of 20 mg for 4 weeks
3052670|NCT02209779|Experimental|BIBR 796 BS, high dose|twice daily doses of 30 mg for 4 weeks
3052671|NCT02209779|Active Comparator|Placebo|
3052672|NCT02209766|Experimental|D5884|D5884 capsule, Per oral(po)
3052673|NCT02209766|Placebo Comparator|Placebo|Placebo capsule, po
3052674|NCT02209753|Experimental|BIRB 796 BS, low dose|
3052675|NCT02209753|Experimental|BIRB 796 BS, medium dose 1|
3052676|NCT02209753|Experimental|BIRB 796 BS, medium dose 2|
3052677|NCT02209753|Experimental|BIRB 796 BS, high dose|
3052678|NCT02209753|Placebo Comparator|Placebo|
3052679|NCT02209740||Tenofovir switch|Patients switched tenofovir to different antiretroviral regimen according to physicians decision
3052680|NCT02209727|Experimental|131I-Sibrotuzumab|single therapy dose administered over 60 minutes at week 4
3052681|NCT02209714|Experimental|BIIF 1149 BS|
3052682|NCT02209714|Placebo Comparator|Placebo|
3052683|NCT02209701|Experimental|Porfiromycin|
3052684|NCT02209688|Experimental|ESR 1150 CL dose escalation fasted|
3052685|NCT02209688|Experimental|ESR 1150 CL fed|
3052686|NCT02209688|Placebo Comparator|Placebo|
3052687|NCT02209675|Other|patients with elevated liver enzymes|Patients with elevated liver enzymes and/or hyperbilirubinemia post transplantation for hepatitis C virus related disease will have liver biopsy
3052688|NCT02209662|Experimental|APIC-PRP and Standard of Care|APIC-PRP
3052689|NCT02209662|Placebo Comparator|Placebo, Saline plus standard of care|Placebo, Saline plus standard of care
3052690|NCT02209649|Experimental|Telmisartan and Lacidipine FDC, formulation A|
3052691|NCT02209649|Experimental|Telmisartan and Lacidipine FDC, formulation B|
3052692|NCT02209649|Active Comparator|Lacidipine and Telmisartan, mono|
3052693|NCT02209636|Experimental|Lanthanum carbonate|Eligible subjects who are randomly assigned to the experimental arm will receive lanthanum carbonate (1500-4500 mg/day in divided doses) titrated to serum phosphorus levels.
3052694|NCT02209636|Placebo Comparator|placebo|Eligible subjects who are randomly assigned to the placebo arm will receive placebo tablets (identical to the active lanthanum carbonate tablets) to be taken 3 times daily and titrated to serum phosphorus levels.
3052695|NCT02209623||Pregnant Women receiving TDAP|
3052696|NCT02209610|Other|1|Patients with Heart Failure
3052697|NCT02209610|Other|2|Health Control Subjects
3052698|NCT02209597|Experimental|Wellbutrin XL® 300mg|Subjects will take each 300mg Wellbutrin XL product for 6 weeks, and then be switched to another product without washout, according to their randomization schedule. During the 2nd-3rd week on each product, subjects will visit the study clinic for a bupropion pharmacokinetic session, an objective assessment of depression and side effects
3052699|NCT02209597|Experimental|300mg bupropion XL 1|Subjects will take each 300mg bupropion XL product for 6 weeks, and then be switched to another product without washout, according to their randomization schedule. During the 2nd-3rd week on each product, subjects will visit the study clinic for a bupropion pharmacokinetic session, an objective assessment of depression and side effects
3052700|NCT02209597|Experimental|300mg bupropion XL 2|Subjects will take each 300mg bupropion XL product for 6 weeks, and then be switched to another product without washout, according to their randomization schedule. During the 2nd-3rd week on each product, subjects will visit the study clinic for a bupropion pharmacokinetic session, an objective assessment of depression and side effects
3052701|NCT02209597|Experimental|300mg bupropion XL 3|Subjects will take each 300mg bupropion XL product for 6 weeks, and then be switched to another product without washout, according to their randomization schedule. During the 2nd-3rd week on each product, subjects will visit the study clinic for a bupropion pharmacokinetic session, an objective assessment of depression and side effects.
3052702|NCT02209571|Experimental|Cystic Fibrosis|Breath test and venous blood markers in cystic fibrosis patients
3052703|NCT02209571|Active Comparator|Control|Breath test and venous blood markers in healthy subjects
3052704|NCT02209558|No Intervention|Standard Written Sternal Precautions|"Patients will receive education that is the standard of care at North Shore Long Island Jewish Health Systems in their post-operative sternal precautions."
3052705|NCT02209558|Experimental|Visual Sternal Precautions|"Patients will receive both standard of care written sternal precautions, as well as visual sternal precautions."
3052706|NCT02209545|Experimental|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
3052707|NCT02209545|Placebo Comparator|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
3052737|NCT02209389||Positive OctavaPink|Following a positive OctavaPink result, an MRI is performed and any additional testing (required by the MRI).
3052774|NCT02209142|Sham Comparator|control|a pan genomic screening by blood prelevement and psychometric data collection wil be performed on healthy subject
3052775|NCT02209129||women at high risk for breast cancer|
3052708|NCT02209532|Active Comparator|Blue - PINPOINT|The cervix will be injected 4 times with a 1ml solution of 1% Isosulfan blue followed by injection 4 times of 1 ml of 1.25 mg/ml solution of ICG. LN mapping with Blue dye will be performed until the investigator identifies all blue nodes or determines that blue nodes cannot be identified. Once complete, the Investigator will begin mapping with PINPOINT until all 'ICG' nodes are identified or the investigator determines that 'ICG' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.
3052709|NCT02209532|Active Comparator|PINPOINT - Blue|The cervix will be injected 4 times with 1 ml of a 1.25 mg/ml solution of ICG followed by injection 4 times of a 1 ml solution of 1% Isosulfan blue. LN mapping with PINPOINT will be performed until the investigator identifies all 'ICG' nodes or determines that 'ICG' nodes cannot be identified. Once complete, the Investigator will begin mapping with Blue dye until all 'blue' nodes are identified or the investigator determines that 'blue' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.
3052710|NCT02209519|Experimental|Metronidazole|Male Partner: metronidazole 500 mg PO BID x 7days Female Partner: metronidazole 500 mg PO BID x 7days
3052711|NCT02209519|Placebo Comparator|Placebo|Male Partner: one tablet PO BID for 7 days Female Partner: metronidazole 500 mg PO BID x 7days
3052712|NCT02209506|Experimental|Cohort 1A: MLN3126 100 mg Non-Japanese Participants|MLN3126 100 mg, administered orally as tablets once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
3052713|NCT02209506|Experimental|Cohort 2A: MLN3126 300 mg Non-Japanese Participants|MLN3126 300 mg, administered orally as tablets, orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
3052714|NCT02209506|Experimental|Cohort 3A: MLN3126 800 mg Non-Japanese Participants|MLN3126 800 mg, administered orally as tablets once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
3052715|NCT02209506|Experimental|Cohort 4A: MLN3126 TBD Non-Japanese Participants|The MLN3126 dose for this Cohort will be determined based on data collected from Cohort 3A. MLN3126, tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
3052716|NCT02209506|Experimental|Cohorts 1A - 4A: Matched Placebo Non-Japanese Participants|MLN3126 placebo-matching tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
3052717|NCT02209506|Experimental|Cohort 1B: MLN3126 100 mg Japanese Participants|MLN3126 100 mg, administered orally as tablets, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 though 15) in healthy, Japanese participants.
3052718|NCT02209506|Experimental|Cohort 2B: MLN3126 300 mg Japanese Participants|MLN3126 300 mg, administered orally as tablets, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, Japanese participants.
3052719|NCT02209506|Experimental|Cohort 3B: MLN3126 800 mg Japanese Participants|MLN3126 800 mg, tablets, orally, once on Day 1, followed by a 7 day washout period, followed by MLN3126 800 mg, tablets, orally, once daily for 7 days (Days 9 through 15) in healthy, Japanese participants.
3052720|NCT02209506|Experimental|Cohort 4B: MLN3126 TBD Japanese Participants|The MLN3126 dose for this Cohort will be determined based on data collected from Cohort 3B. MLN3126, tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, Japanese participants.
3052721|NCT02209506|Experimental|Cohorts 1B - 4B: Matched Placebo Japanese Participants|MLN3126 placebo-matching tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily for 7 days (Days 9 through 15) in healthy, Japanese participants.
3052722|NCT02209493|Experimental|Food supplementation: nopales|Consumption of 2 cups/day of cooked nopales (prickly pear cactus leaves) with each of two main meals for 2 weeks
3052723|NCT02209493|Sham Comparator|Food supplementation: cucumber|Consumption of 2 cups/day peeled and chopped cucumber with each of two main meals for 2 weeks
3052724|NCT02209480|Experimental|Alexander Technique|5 lessons of AT, each lasting up to 45 minutes, weekly intervals The lessons aimed at sensory awareness of everyday movements and movement sequences, such as sitting, walking, lying, or lifting in order to replace habitual patterns using conscious control; and different techniques were applied, such as demonstration, verbal instructions, hands on techniques and others
3052725|NCT02209480|Active Comparator|Heat pad application|5 treatments by means of a heat pad, 15-0 minutes, sitting or lying position, quiet room Heat pad: Zapp-Sack® contained certain grains and a ginger extract, and could be heated up in the microwave.
3052726|NCT02209480|Active Comparator|guided imagery|guided imagery relaxation technique , 45 minutes, 5 sessions in weekly rhythm including body scan, breathing relaxation, visualization
3052727|NCT02209467|No Intervention|Group balance training late start|Participants randomized to late start act as No intervention group during the study period.
3052728|NCT02209467|Experimental|Group balance training early start|Group balance training focusing on core stability exercises 2 times per week for 7 weeks and 2 home training sessions per weeks.
3052729|NCT02209454|Other|Enantyum® oral solution|25mg DKP.TRIS oral solution
3052730|NCT02209454|Other|Keral® tablet|25mg DKP.TRIS tablet
3052731|NCT02209428|Active Comparator|IDH wild type|Patients with IDH wild type, according to the result of genetic sequencing of their surgical resected specimens. Intervention: oral temozolomide, 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
3052732|NCT02209428|Experimental|IDH mutation|Patients with IDH mutations, according to the result of genetic sequencing of their surgical resected specimens. Intervention: oral temozolomide, 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
3052733|NCT02209415|Active Comparator|Standard outpatient follow-up|Outpatient clinic visits 3,6,9,12,18 and 24 mths after surgery
3052734|NCT02209415|Experimental|Intervention PET/CT and EUS|PET/CT and EUS at 3,6,9,12,18 and 24 months after surgery
3052735|NCT02209402|No Intervention|Usual Care|
3052736|NCT02209402|Experimental|Exercise Training|
3052738|NCT02209389||Negative OctavaPink - control|"For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and recalled for an MRI and any additional testing (required by the MRI).~MRI won't be performed to all negative OctavaPink results. Only one negative control will be assigned to each OctavaPink positive result."
3052739|NCT02209376|Experimental|Arm 1|
3052740|NCT02209363|Experimental|Positive airway pressure (PAP)|Auto-adjusting positive airway pressure
3052741|NCT02209363|Sham Comparator|nasal dilator strips|Sham treatment
3052742|NCT02209350|Active Comparator|Group 1|Operations technique on the abdominal aorta. Aorta-femoral bypass. Medication: after surgery all patients are prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
3052743|NCT02209350|Active Comparator|Group 2|Standard endovascular treatment (stenting) in patients with the iliac segment occlusive disease. Medication: after stenting all patients are prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
3052744|NCT02209337|Experimental|SRS-I|Implantation of SRS-I
3052745|NCT02209324|Experimental|ASP2151|
3052746|NCT02209311|Experimental|Tissue engineered construction implantation|
3052747|NCT02209298||CoreValve Transcatheter Valve|Medtronic CoreValve SystemTM is designed to replace the native or surgical bioprosthetic aortic heart valve without open heart surgery and without concomitant surgical removal of the failing valve. The support frame is manufactured by Nitinol, which has multi-level, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from a single layer of porcine pericardium into a tri-leaflet configuration. The bioprosthesis is processed with alpha-amino oleic acid (AOA™), which is a compound derived from oleic acid, a naturally occurring long-chain fatty acid. AOA™ is an antimineralization treatment shown to reduce both early and late valvular calcification.
3052748|NCT02209285|No Intervention|Control group|The control group will receive usual care, which is provided by the community care access centre (CCAC). Usual care may include in-home visits by regulated health care providers, personal support workers, and care coordination through the community care access centre. Case conferences may occur on an as-needed basis.
3052749|NCT02209285|Active Comparator|ACHRU - Community Partnership Program|Individuals in the intervention group will receive a six-month community intervention consisting of three components: (1) intensive case management and community navigation; (2) a maximum of two in-home visits by the care coordinator, two in-home visits by a Registered Nurse, and three in-home visits by the Occupational therapist or Physiotherapist, and six visits by a Personal Support Worker over 6 months in addition to usual home care services; and (3) monthly interprofessional team case conferences to develop an evidence-based, patient-centred community reintegration plan.
3052750|NCT02209272|Experimental|bacteriostatic saline|for ultrasound guided hip joint injection local anesthesia
3052751|NCT02209272|Active Comparator|buffered lidocaine|for ultrasound guided hip joint injection local anesthesia
3052752|NCT02209259|Experimental|Intervention Group 1|The first intervention group will be comprised of patients who will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS) after completing the standard PCS.
3052753|NCT02209259|Experimental|Intervention Group 2|The second intervention group will be comprised of patients who will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS) after completing a positively-adjusted version of the PCS.
3052754|NCT02209259|Experimental|Control|The third group (the control arm) will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS).
3052755|NCT02209246|Experimental|Intervention|The intervention group will be comprised of patients who will complete the PROMIS- CAT for pain interference, pain behavior and physical function prior to the encounter with the physician and then will complete the MISS-21 after the encounter.
3052756|NCT02209246|Experimental|Control|The control group will complete the PROMIS- CAT for pain interference, pain behavior and physical function after the encounter and after completing a satisfaction questionnaire (MISS-21).
3052757|NCT02209233|No Intervention|Control|If randomized to the control group, patients will not be receiving massage therapy.
3052758|NCT02209233|Experimental|Massage Therapy|If randomized to the intervention group, patients will receive massage therapy of the hand, arm, shoulder, and neck by the licensed massage therapist on duty. The massage will be given in a manner that is congruent with standard of care practices by the Heart and Surgical Hospital and the licensed massage therapist.
3052759|NCT02209220|Active Comparator|Automatic positive airway pressure|Automatic positive airway pressure treatment of obstructive sleep apnea
3052760|NCT02209220|Active Comparator|Continuous positive airway pressure|Continuous positive airway pressure for the treatment of obstructive sleep apnea
3052761|NCT02209207|Active Comparator|Continuous walking training|n=10 patients with COPD Walking intensity 60 percent of 6-minute walking test speed
3052762|NCT02209207|Active Comparator|Interval walking training|n=10 patients with COPD Walking intensity 120 percent of 6-minute walking test speed for 1 minute alternating with 1 minute of rest
3052763|NCT02209194||Aortoiliac Aneurysms Iliac Aneurysms|Endovascular repair of aortoiliac or iliac aneurysms
3052764|NCT02209181|Experimental|JNJ-10450232 250 mg|
3052765|NCT02209181|Experimental|JNJ-10450232 1000 mg|
3052766|NCT02209181|Placebo Comparator|Placebo|
3052767|NCT02209181|Active Comparator|Acetaminophen 1000 mg|
3052768|NCT02209168||Infertile Indian Population|200 Infertile Indian population
3052769|NCT02209168||Infertile arabian population|200 Infertile Arabian population
3052770|NCT02209168||Infertile caucasian population|200 Infertile Caucasian population
3052771|NCT02209155|Active Comparator|R-verapamil 75 mg tablet|375 mg/day; one in the morning, two in the afternoon and two at bedtime daily
3052772|NCT02209155|Placebo Comparator|Placebo|one in the morning, two in the afternoon and two at bedtime daily
3052773|NCT02209142|Experimental|pan-genomic screen|A pan-genomic screen by blood prelevement and psychometric data collection will be set-up on a subset of MDE and control samples to identify mRNA candidates for a transcriptional signature of MDE,
3053620|NCT02203526|Experimental|Arm 1- B (Second Cohort; original study design)|TEDDI-R with cytarabine
3052776|NCT02209116|Active Comparator|QB Open|Participants and their clinician will receive results of the Qb Test
3052777|NCT02209116|Other|Qb Blind|Participants and their clinician will be blind to the results of the Qb test
3052778|NCT02209103|Experimental|Citrus flavonoid|Citrus flavonoid
3052779|NCT02209103|Experimental|Citrus flavonoid formulation|Citrus flavonoid formulation
3052780|NCT02209103|Placebo Comparator|Placebo|Placebo
3052781|NCT02209090|Experimental|maternal modified sims position|"Women in this group will adopt the modified Sims position, lying on the side of the foetal back.~This position is maintained for the greater part of labour, at least 40 minutes, every hour. The mother can use other positions during resting time of no more than 20 minutes each hour, but never use a lateral position against the side of the foetal back."
3052782|NCT02209090|Sham Comparator|maternal free positions|Women can adopt the position they wish and which is most comfortable, except for lateral positions which can only be used for a maximum of 20 minutes each hour to avoid confounding factors.
3052783|NCT02209077|Experimental|Healthy Volunteers|OCT performed to collect data from the back of the eye
3052784|NCT02209077|Experimental|Glaucoma group|OCT performed to collect data from the back of the eye
3052785|NCT02209064|Other|EpiAccess|EpiAccess will be used to gain access to the normal, non-distended pericardial space in subjects presenting with the need for pericardial access as determined by the patient's physician.
3052786|NCT02209051|Active Comparator|AMNIOEXCEL|Human Amniotic Membrane Allograft
3052787|NCT02209051|Active Comparator|Standard of Care, Diabetic Foot Ulcers|Advanced wound care dressings and offloading of wound.
3052788|NCT02209038|Experimental|Expanded AD Choice|"Would you like to complete an advance directive with the assistance of any person(s) you choose?~4 answer choices:~Yes, I would like to complete a comprehensive version of an advance directive.~Yes, I would like to complete an expanded version of an advance directive.~Yes, I would like to complete a brief version of an advance directive.~No, I do not wish to complete an advance directive."
3052789|NCT02209038|No Intervention|Standard AD Choice|"Would you like to complete an advance directive with the assistance of any person(s) you choose?~2 answer choices:~Yes, I would like to complete an AD.~No, I do not wish to complete an advance directive."
3052790|NCT02209038|Experimental|Expanded Life-sustaining therapy Choice|"For each hypothetical illness state described in the living will:~4 answer choices:~No, I would not want life support.~Yes, I would want life support.~I would want life support if my doctor believes it could help, but I want to stop receiving life support if at any time my doctor believes it is only delaying the moment of my death.~I do not wish to specify a preference at this time."
3052791|NCT02209038|No Intervention|Standard Life-sustaining Therapy Choice|"For each hypothetical illness state described in the living will:~3 answer choices:~No, I would not want life support.~Yes, I would want life support.~I do not wish to specify a preference at this time."
3052792|NCT02209025|Placebo Comparator|Placebo drink|A drink with the same components as the theobromine drink except for the theobromine
3052793|NCT02209025|Experimental|Theobromine|500mg theobromine in a drink
3052794|NCT02209012||ALA|Subjects who received ALA in CP0108
3052795|NCT02209012||Vehicle|Subjects who received Vehicle in CP0108
3052796|NCT02208999||Neurostimulator Precision|Patients implanted or reimplanted with the neurostimulator Precision
3052797|NCT02208986|Active Comparator|0.2mg Triptorelin|Ovulation trigger with 0.2mg Triptorelin in one subcutaneous injection.
3052798|NCT02208986|Active Comparator|0.3mg Triptorelin|Ovulation trigger with 0.3mg Triptorelin in one subcutaneous injection.
3052799|NCT02208986|Active Comparator|Active Comparator: 0.4mg Triptorelin|Ovulation trigger with 0.4mg Triptorelin in one subcutaneous injection.
3052800|NCT02208973|Experimental|PBF-680 (5 mg)|5 mg of PBF-680
3052801|NCT02208973|Experimental|PBF-680 (10 mg)|10 mg of PBF-680
3052802|NCT02208973|Experimental|PBF-680 (20 mg)|20 mg of PBF-680
3052803|NCT02208973|Experimental|PBF-680 (40 mg)|40 mg of PBF-680
3052804|NCT02208973|Experimental|PBF-680 (60 mg)|60 mg of PBF-680
3052805|NCT02208973|Placebo Comparator|Placebo|Comparator to the doses of 5, 10, 20, 40 and 60 mg. ( subjects for each dose level 6 are located to active treatment and two to placebo
3052806|NCT02208960|Experimental|Neonatal Kit|Mothers in the neonatal kit clusters will receive a neonatal kit and training on how to use the kit components during their third trimester of pregnancy. The kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, 4% chlorhexidine (CHX) lotion, sunflower oil emollient, ThermoSpot, a Mylar infant sleeve, and a reusable, non-electric, heating device. Community Health Workers will be equipped with a hand-held battery operated scale to identify low birth weight newborns.
3052807|NCT02208960|Experimental|Neonatal Stimulation|During home visits in the 3rd trimester, mothers in the neonatal stimulation clusters will be taught 3 core messages pertaining to neonatal stimulation. First, mothers will be taught how to make eye contact and talk to their child. This type of interaction encourages social inclusion, attachment, and development of social-communication skills. Second, mothers will be taught techniques to foster responsive feeding and caregiving. Finally, mothers will be encouraged to sing songs and nursery rhymes, including those with gentle touch in order to support the development of communication skills, and introduce a tactile component to caregiving. These messages will be reiterated at subsequent home visits by the CHW after the baby is born.
3052808|NCT02208960|Experimental|Neonatal Kit and Neonatal Stimulation|Participants in this arm of the study will receive both a neonatal kit (described in Arm 1) and neonatal stimulation (described in Arm 2).
3052809|NCT02208960|No Intervention|Control (Standard Care)|"In control clusters, CHWs will visit the home according to the regular schedule (same as in the intervention clusters) and deliver the standard CHW post-natal care that consists of talking to mothers about:~Exclusive breastfeeding and proper nutrition for both the mother and the baby.~Ensuring warmth to the baby.~Full immunization and growth monitoring of newborn.~Hygiene and sanitation practices.~Family Planning and promote the proper use of Insecticides Treated Nets.~Identifying any danger sign/complication for both mothers and new-borns and refer for prompt treatment (within 24 hours) for management and treatment.~Promoting the use of services such as birth registration.~Giving advice on proper care of the umbilical cord."
3052886|NCT02208505|Experimental|Dexmedetomidine|we administrate the single-dose dexmedetomidine (0.5mcg/kg) with low-dose remifentanil infusion(TCI 1 ng/ml).
3052810|NCT02208947|Active Comparator|PREPARE|"Partnership HealthPlan of California (PHC) pays primary care physicians (PCPs) to discuss and document ACP with Medi-Cal beneficiaries aged 65 and older and those younger than 65 with a life-limiting illness (usual care). The control condition, or enhanced usual care, adds a packet of educational information about ACP and access to the PREPARE website and verbal encouragement by their PCP delivered during a routine clinic visit to usual care."
3052811|NCT02208947|Experimental|PREPARE + consumer financial incentive|The experimental condition adds a consumer-directed financial incentive to enhanced usual care (provider-directed financial incentive and educational packet with information about the PREPARE website). Specifically, subjects will receive an immediate financial reward upon completing self-directed ACP (e.g., PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
3052812|NCT02208934|Experimental|PBF-999 (5 mg)|5 mg of PBF-999
3052813|NCT02208934|Experimental|PBF-999 (10 mg)|10 mg of PBF-999
3052814|NCT02208934|Experimental|PBF-999 (20 mg)|20 mg of PBF-999
3052815|NCT02208934|Experimental|PBF-999 (40 mg)|40 mg of PBF-999
3052816|NCT02208934|Placebo Comparator|Placebo|Placebo for the 5, 10, 20 and 40 mg dose
3052817|NCT02208921||T2DM patients with Chronic Kidney Disease|T2DM patients with Chronic Kidney Disease
3052818|NCT02208908||Patient with cancer hospitalize inpalliative situation|"An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.~An assessment of the traceability of clinical assessment and appropriate treatment prescribed or will be conducted on day 3 and repeated the day of the release of hospitalization (or day 15) from information recorded in the patient record"
3052819|NCT02208895||Glucometer|Measure glucose of pleural fluid via glucometer
3052820|NCT02208895||in lab|Measure pleural fluid glucose in lab
3052821|NCT02208895||i-STAT|measure pleural fluid glucose via i-STAT
3052822|NCT02208882|Experimental|Panel 1: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
3052823|NCT02208882|Experimental|Panel 2: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
3052824|NCT02208882|Experimental|Panel 3: BMS-986120 or Placebo + Midazolam|BMS-986120 or Placebo (multiple dose) + Midazolam (single dose) by mouth as specified
3052825|NCT02208882|Experimental|Panel 4: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
3052826|NCT02208869||Patients diagnosed with FH|"Subjects of both sexes above the age of 18 with TC ≥7.5 mmol/L or LDL-C ≥4.9 mmol/L will be included in the Program. Clinical diagnosis of FH will be established using both the Dutch and the British criteria.~Those with secondary causes of hypercholesterolemia, such as untreated diabetes mellitus (HbA1c >8%) or hypothyroidism (thyroid-stimulating hormone >1.5 upper normal limit), renal failure (creatinine clearance <30 ml/min), holestatic liver diseases, including biliary cirrhosis, tumors with an active process in the last 5 years will be excluded from the study."
3052827|NCT02208856|Placebo Comparator|Placebo|
3052828|NCT02208856|Experimental|BIBR 796 BS food effect|
3052829|NCT02208856|Experimental|BIBR 796 BS|
3052830|NCT02208843|Experimental|Afatinib|Afatinib tablet once daily until progression
3052831|NCT02208830|Experimental|conventional program|The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
3052832|NCT02208830|Experimental|pulmonary rehabilitation|Duration of 8 week, twice weekly exercise program with: lower limb strength training and aerobic training per 30 minutes.
3052833|NCT02208817||Ill patients|Ill patients who require Paediatric Intensive Care or Paediatric High Dependency Care
3052834|NCT02208817||Well Controls|Matched controls who are well (PEWS<3)
3052835|NCT02208817||Parent feedback|Feedback from parents/carers of children recruited into the PRefill study
3052836|NCT02208817||Healthcare professionals feedback|Feedback from healthcare professionals who have cared for a child with the device on
3052837|NCT02208804|Experimental|Surefire Infusion System|Hepatic arterial administrations using the Surefire Infusion System
3052838|NCT02208804|Active Comparator|Standard End-hole Microcatheter|Hepatic arterial administrations using the standard end-hole microcatheter
3052839|NCT02208791|Active Comparator|Tacrolimus/MPS/Prednisone|This arm will be maintained with current conventional triple immunosuppression. Sirolimus will not be added to this arm
3052840|NCT02208791|Experimental|Sirolimus/Low Tacrolimus/MPS/Prednisone|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid..
3052841|NCT02208778|Experimental|Duloxetine|Duloxetine 30 mg a day (2 weeks), then 60 mg a day (4weeks), taken by mouth
3052842|NCT02208778|Placebo Comparator|Placebo (for Duloxetine)|Sugar pill: 1 capsule a day (2 weeks), then 2 capsules a day (4 weeks) taken by mouth
3052843|NCT02208778|Experimental|Remifentanil|Intravenous infusion with maximum estimated plasma target of 1.0 ng/ml, during less than 20 minutes
3052844|NCT02208778|Placebo Comparator|Placebo (for Remifentanil)|Intravenous infusion of normal saline, during less than 20 min
3052845|NCT02208765|Other|Study cohort|Any patient referred to the Nuclear Cardiology Laboratory of the University Hospital of Grenoble for myocardial perfusion imaging for diagnosis or prognosis evaluation of suspected or know coronary artery disease
3052846|NCT02208752|Active Comparator|Exercises|exericises on motor control and strengthening exercises on the Rotator Cuff
3052847|NCT02208752|Placebo Comparator|Control group- No exercises|No exercises
3052848|NCT02208739|Experimental|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy was given to all patients at baseline
3052849|NCT02208739|Active Comparator|Oral hygiene instructions|Oral hygiene instructions were given to all patients at baseline
3052850|NCT02208726|Placebo Comparator|Sucrose pillules|Unmedicated sucrose pillules will be taken once daily, in the morning, 30 minutes after breakfast, for 14 days, up to 7 days before the first academic examination.
3053669|NCT02203266|Active Comparator|Demonstration|Current best practice - inhaler technique education
3052851|NCT02208726|Experimental|Homeopathic homaccord|Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH. Pillules will be taken once daily, in the morning, 30 minutes after breakfast, for 14 days, up to 7 days before the first academic examination.
3052852|NCT02208713|Experimental|Stem cell recipient|The patients with FSHD who underwent muscle derived stem cell and Adipose derived mesenchymal stem cell with intramuscular injection.
3052853|NCT02208700|Experimental|Oxepa|Other: Therapeutic nutrition with EPA, GLA and antioxidants.
3052854|NCT02208700|Active Comparator|Jevity 1.5|Other: Jevity 1.5 Complete Balanced Nutrition with Fiber .
3052855|NCT02208687|Experimental|Energetic|Self management group program aimed at reconditioning and social participation
3052856|NCT02208687|Other|Control group|Usual care
3052857|NCT02208674|No Intervention|Usual Care|Primary care provider-delivered screening and treatment for risk factors (hypertension, albuminuria, dyslipidemia) per usual care.
3052858|NCT02208674|Experimental|Protocolized, pharmacist-delivered CKD Action Plan|Protocolized, pharmacist-delivered screening and treatment for risk factors (hypertension, albuminuria, dyslipidemia) per KDIGO and JNC-8 recommendations.
3052859|NCT02208648||Deceased|"Peri-operative mortality (within 90 days). Pairs of CT scans (deceased plus matched control) will be anonymised and stored on a secure server. Abbreviated Calcium scores will be generated for all patients in the trial by a trained radiologist using a calcium scoring method. The radiologist will be blinded to the group that the patient belongs to, to minimise bias. Scans (deceased patients and matched controls) will be analysed in batches of 30 pairs. Radiologist (s) will be blinded to group allocation. Scans will not be paired at the time of reading."
3052860|NCT02208648||Matched control|"Patients who survived beyond 90 days peri-operatively. Pairs of CT scans (deceased plus matched control) will be anonymised and stored on a secure server. Abbreviated Calcium scores will be generated for all patients in the trial by a trained radiologist using a calcium scoring method. The radiologist will be blinded to the group that the patient belongs to, to minimise bias. Scans (deceased patients and matched controls) will be analysed in batches of 30 pairs. Radiologist (s) will be blinded to group allocation. Scans will not be paired at the time of reading."
3052861|NCT02208635|Experimental|Biofortified Maize|Participants in this arm were fed zinc biofortified maize (~30 µg Zn/g).
3052862|NCT02208635|Experimental|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of ~60 µg Zn/g).
3052863|NCT02208635|Active Comparator|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (~15 µg Zn/g maize).
3052864|NCT02208622|Experimental|Study 1: Whey Supplement Day 1|Children in this arm received the whey supplement as part if their diet on day 1.
3052865|NCT02208622|Experimental|Study 1: Whey Supplement Day 2|Children in this arm received whey supplement as part of their diet on day 2.
3052866|NCT02208622|Experimental|Study 2: Whey Supplement|Children in this arm received a whey supplement as part of their diet.
3052867|NCT02208622|No Intervention|Study 2: Control|Children in this arm did not receive a whey supplement as part of their diet.
3052868|NCT02208609|Experimental|Maize Tortillas with 20% Amaranth|Children in this arm were fed maize tortillas fortified with 20% amaranth
3052869|NCT02208609|Experimental|Maize Tortillas without 20% Amaranth|Children in this arm were fed maize tortillas without amaranth
3052870|NCT02208596|Experimental|Group A|In group A, propofol (1%) was mixed with etomidate in the ration of 1:1 (volume). The mixture will be injected continuously until the eyelash reflex disappears. During the operation, supplementary mixture will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
3052871|NCT02208596|Experimental|Group B|In group B, propofol (1%) was mixed with etomidate in the ration of 7:5 (volume). The mixture will be injected continuously until the eyelash reflex disappears. During the operation, supplementary mixture will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
3052872|NCT02208596|Experimental|Group C|In group C, propofol (1%) will be injected continuously until the eyelash reflex disappears. During the operation, supplementary propofol will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
3052873|NCT02208583|Active Comparator|AR dependent CRPC|"Assignment to Treatment Group based on druggable gene mutations analysis:~CRPC patients without druggable gene mutations: Docetaxel & Prednisone; CRPC patients with druggable gene mutations: DP & Targeted drugs"
3052874|NCT02208583|Active Comparator|AR independent CRPC|"Assignment to Treatment Group based on druggable gene mutations analysis:~CRPC patients without druggable gene mutations: cisplatin & Etoposide; CRPC patients with druggable gene mutations: EP & Targeted drugs"
3052875|NCT02208570|Experimental|P(+)V(+)|PPV>14% before anesthesia induction, HES 6ml/kg infused
3052876|NCT02208570|Experimental|P(+)V(-)|PPV>14% before anesthesia induction, no additional volume infused
3052877|NCT02208570|Experimental|P(-)V(+)|PPV<14% before anesthesia induction, HES 6ml/kg infused
3052878|NCT02208570|Experimental|P(-)V(-)|PPV<14% before anesthesia induction, no additional volume infused
3052879|NCT02208557|Active Comparator|Control|Laparotomy closure will be done by continuous PDS suture following a SL:WL ratio of 4:1 only is used for midline laparotomy closure.
3052880|NCT02208557|Experimental|Reinforcement with Absorbable Mesh|"Closure of the midline laparotomy incision is reinforced with insertion of a rectangular segment (1 cm wide and the length corresponding to the incision) of a prosthetic commercially available GORE® BIO-A® Tissue Reinforcement prosthesis (W. L. Gore & Associates, Flagstaff, Arizona, USA) mesh. The BIO-A® prosthesis is inserted using a sandwich method between the edges of the incision and maintained in situ with a continuous polydioxanone (PDS) suture following a suture length to wound length (SL:WL) ratio of 4:1."
3052881|NCT02208544|Experimental|FDG-PET/CT-driven|"Following treatment based on FDG-PET/CT:~negative: watchful waiting including confirmatory ultrasound~positive: diagnostic thyroid surgery as planned"
3052882|NCT02208544|Other|Current Practice|diagnostic thyroid surgery despite results of FDG-PET/CT
3052883|NCT02208531|No Intervention|Control|
3052884|NCT02208531|Experimental|Psychosocial Stimulation and Nutritional Care|Psychosocial Stimulation and Nutritional Care will be provided to malnourished children and their mothers every fortnight in the Community Clinics for one year.
3052885|NCT02208518||Elastography analysis|Consecutive patients undergoing for upper endoscopy ultrasound
3052887|NCT02208505|Active Comparator|Remifentanil|we administrate the high-dose remifentanil infusion(TCI 2 ng/ml) alone.
3052888|NCT02208492|Experimental|Levetiracetam|
3052889|NCT02208492|Active Comparator|Carabamazepine|
3052890|NCT02208479||cardiac surgery|
3052891|NCT02208466|Experimental|Active rTMS/active fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of active low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of active low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.
3052892|NCT02208466|Experimental|Sham rTMS/active fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.
3052893|NCT02208466|Experimental|Sham rTMS/placebo fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of placebo fluoxetine by mouth daily.
3052894|NCT02208453|Experimental|InSpace implantation|InSpace device implantation
3052895|NCT02208440|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
3052896|NCT02208440|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridement, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
3052897|NCT02208427|Experimental|3M_RH|Rifapentine and Isoniazid for 3 months: weekly oral rifapentine 15 mg/kg plus isoniazid 15 mg/kg for 12 doses
3052898|NCT02208427|Active Comparator|9M_INH|Isoniazid for 9 months: daily oral isoniazid 5 mg/kg for 9 months
3052899|NCT02208414|Experimental|Crab or shrimp|Intervention: treated with crab and shrimp energy signature vial using NAET
3052900|NCT02208414|Placebo Comparator|Placebo|Treated with water vial
3052901|NCT02208401|Active Comparator|conventional cold snare polypectomy|conventional cold snare polypectomy
3052902|NCT02208401|Experimental|Cold snare polypectomy with suction|Cold snare polypectomy with suction
3052903|NCT02208388|Experimental|Computed tomography perfusion|Patients with Computed tomography perfusion
3052904|NCT02208388|Active Comparator|Fractional flow reserve|Patients with Fractional flow reserve
3052905|NCT02208375|Experimental|Olaparib + AZD2014 (continuous dosing)|"Dose Escalation Starting Dose of Olaparib: 100 mg by mouth twice a day starting on Day -3 for three days.~Dose Expansion Starting Dose of Olaparib: MTD from Dose Escalation Phase.~Dose Escalation Starting Dose of AZD2014: 25 mg by mouth twice a day starting on Day 1.~Dose Expansion Starting Dose of AZD2014: MTD from Dose Escalation Phase. During the expansion phase, both drugs started simultaneously"
3052906|NCT02208375|Experimental|Olaparib + AZD2014 (intermittent dosing)|"Dose Escalation Starting Dose of Olaparib: 100 mg by mouth twice a day starting on Day -5 for three days.~Dose Expansion Starting Dose of Olaparib: MTD from Dose Escalation Phase.~Dose Escalation Starting Dose of AZD2014: 125 mg by mouth twice a day starting on Day 1 for 2 Days, then 5 Days off.~Dose Expansion Starting Dose of AZD2014: MTD from Dose Escalation Phase. During the expansion phase, both drugs started simultaneously"
3052907|NCT02208375|Experimental|Olaparib + AZD5363 (intermittent dosing)|"Dose Escalation Starting Dose of Olaparib: 100 mg by mouth twice a day starting on Day -3 or -5 for three days or 300 mg by mouth twice a day if in Group 3.~Dose Expansion Starting Dose of Olaparib: MTD from Dose Escalation Phase.~Dose Escalation Starting Dose of AZD5363: 320 mg by mouth twice a day starting on Day 1 for 4 days, then 3 days off.~Dose Expansion Starting Dose of AZD5363: MTD from Dose Escalation Phase. During the expansion phase, both drugs started simultaneously."
3052908|NCT02208362|Experimental|Stratum I (T lymphocytes intratumoral)|"CLOSED TO ACCRUAL 03/02/2018~Patients receive IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intratumoral catheter over 5-10 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to intraventricular catheter for the optional infusions."
3052909|NCT02208362|Experimental|Stratum II (T lymphocytes intracavitary)|Patients receive IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intracavitary catheter over 5-10 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to intraventricular catheter for the optional infusions.
3052910|NCT02208362|Experimental|Stratum III (T lymphocytes intraventricular)|Patients receive IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intraventricular catheter over 5-10 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available.
3052911|NCT02208362|Experimental|Stratum IV (T lymphocytes intratumoral and intraventricular)|Patients receive IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intratumoral catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
3052966|NCT02207920|Experimental|Group 1|"At study entry and Month 1, participants will receive placebo for DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.~At Months 3 and 6, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid."
3053068|NCT02207296|No Intervention|Control group|Standard care using a hemodynamic protocol during general anesthesia
3081623|NCT02015897|Placebo Comparator|Physical TherapyA|Group A
3052912|NCT02208362|Experimental|Stratum V (T lymphocytes intratumoral and intraventricular)|Patients receive IL13 [EQ]BBzeta/truncated CD19[t]+ Tn/mem via intratumoral catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
3052913|NCT02208349|Experimental|Video Laryngoscopy|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
3052914|NCT02208349|Active Comparator|Direct Laryngoscopy|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
3052915|NCT02208336||Observational (electronic medical record review)|Patients' electronic medical records are reviewed for adherence, severe myelosuppression, and patient morbidity retrospectively and prospectively.
3052916|NCT02208323|Experimental|Bubble CPAP|Bubble CPAP for 28 days
3052917|NCT02208310|Active Comparator|Low Dose Vitamin D|Patients will be given 400 IU cholecalciferol once daily for 30 days. <-THIS IS THE Active Comparator Intervention. To maintain the blind, a random few will be given another round at the 30 day mark. For patients who enroll in the summer, a random few will again receive 400 IU cholecalciferol in March.
3052918|NCT02208310|Experimental|High Dose Vitamin D|Patients will be given cholecalciferol 10,000 IU daily for 30 days. <-THIS IS THE INTERVENTION. At that point, if their vitamin D levels remain below 50 ng/ml, the 30 day course will be repeated. For patients who enroll in the summer, levels will be rechecked in March and if <50 ng/ml, a 30 day course will be administered.
3052919|NCT02208297|Experimental|Loteprednol Etabonate Gel (BID)|Loteprednol Etabonate Gel 0.38% administered two times daily (BID)
3052920|NCT02208297|Placebo Comparator|Vehicle Gel (BID)|Vehicle gel administered two times daily (BID)
3052921|NCT02208284|Experimental|Cohort 1-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
3052922|NCT02208284|Experimental|Cohort 2-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
3052923|NCT02208284|Experimental|Cohort 3-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
3052924|NCT02208271||Control|pre-operative total hip patients with no existing total hip implant
3052925|NCT02208271||Metal on polyethylene|patients who have a failed metal on polyethylene total hip implant and are presenting for revision surgery
3052926|NCT02208271||Metal on Metal|patients who have a failed metal on metal total hip implant and are presenting for revision surgery
3052927|NCT02208245|Active Comparator|Ultrasound: Axillary block|For the axillary group, the ultrasound probe will be placed upright in the armpit to obtain a cross section of this region. After visualization of the nerves form the brachial plexus by ultrasound, 5 mL of ropivacaine 0.5% will be injected around each nerve to be blocked (median, ulnar, radial and musculocutaneous). If resistance to the injection of the solution is present or the patient complains of severe pain, the needle will be immediately repositioned.
3052928|NCT02208245|Active Comparator|Ultrasound: Infraclavicular block|For the infraclavicular group, the ultrasound probe will be placed in the infraclavicular region (the junction between the clavicle and the coracoid process) to obtain a cross-sectional imaging of the axillary artery. After visualization of the axillary artery by ultrasound, the block will be performed using the technique in plan for visualization of the needle. The needle is placed in position 6-8 hours of the artery, and 20 mL of ropivacaine 0.5% will be injected, observing a dispersal of local anesthetic around the artery.
3052929|NCT02208232||MC 6125 AS IOL|cataract surgery with implantation of intraocular lens MC 6125 AS in one eye
3052930|NCT02208219|Experimental|Music-supported Therapy (n=40)|Participants in this group will receive a Music-supported Therapy training at the Hospital during 1 month in addition to the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy).
3052931|NCT02208219|Experimental|home-based Music-supported Therapy(n=40)|Participants in this group will receive a Music-supported Therapy training at home during 1 month in addition to the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy).
3052932|NCT02208219|Active Comparator|Conventional treatment (n=40)|Participants in this group will receive the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy). In order to balance the number of treatment hours between arms, this group will receive extra time of Conventional Treatment during 1 month.
3052933|NCT02208193|Experimental|healthy controls group|Healthy volunteers
3052934|NCT02208193|Experimental|Alzheimer subjects group|"Group A Alzheimer group: patients with mild to severe stages of Alzheimer's disease: subgroup A1 Alzheimer group hospitalized at the Paul Spillmann Centre (Centre Paul Spillmann, CPS) (CHU de Nancy, France); subgroup A2 Alzheimer group monitored at the Resource and Research Memory Centre (Centre Mémoire de Ressources et de Recherche, CMRR) (CHU de Nancy, France)"
3052935|NCT02208180|Experimental|Return of genomic results on cardiovascular disease risk|Participants will receive genomic cardiovascular disease risk information.
3052936|NCT02208180|Active Comparator|Return of lifestyle results on cardiovascular disease risk|Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study.
3052937|NCT02208167|Other|Chronic HIV infection|HXTC infusion
3052938|NCT02208167|Other|Acute HIV infection|HXTC infusion
3053039|NCT02207426|Experimental|TOBI® / PARI LC® PLUS Nebulizer|Tobramycin 300mg nebulizer solution
3052939|NCT02208154|Active Comparator|Standard care|"Standard infection prevention measurements will be implemented before the baseline period and carried out throughout the entire trial. They consist of:~Chlorhexidine 2% body washings (CHX-BW) for all ICU patients. The face and neck of the patient will not be cleansed with Chlorhexidine to prevent irritation of the eyes and face.~A hand hygiene improvement program (HHIP) based on the program designed by the World Health organisation (WHO).~Standard oropharyngeal care consists of oral washing with sterile water (3-4 times daily) and tooth brush twice daily."
3052940|NCT02208154|Experimental|Chlorhexidine oral care (CHX-Oro)|Chlorhexidine digluconate oromucosal gel 1%, 2cm, to be administered 4 times daily, during invasive mechanical ventilation.
3052941|NCT02208154|Experimental|Selective oropharyngeal decontamination|Selective oropharyngeal decontamination (SOD) mouth paste containing colistin and tobramycin in a 2% concentration and nystatin 1 x 10^5 units, dosage 0.5g , to be administered 4 times daily during the entire period of invasive mechanical ventilation.
3052942|NCT02208154|Experimental|Selective digestive decontamination|Selective digestive decontamination (SDD), suspension via the nasogastric tube containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10^6 i.u., dosage 10ml, to be administered together with SOD (see above) 4 times daily during entire period of mechanical ventilation.
3052943|NCT02208141||lean and obese children and adolescents|study cohort may be stratified for lean (definded as BMI <1.28 SDS) and overweight/obese (definded as BMI>= 1.28 SDS) children for posthoc analyses no intervention
3052944|NCT02208128|No Intervention|Receptor-Tyrosinkinase-Inhibitor|Guidelines-oriented therapy with approved systemic medications for renal cell carcinoma individually for each patient (Receptor-Tyrosinkinase-Inhibitor) (e.g.Sunitinib, Pazopanib, Bevacizumab, Everolimus, Axitinib, Temsirolimus). With 1.progression turning to second line treatment with one of the upper mentioned medications. Third line therapy due to the individual molecular modifications for each patient.
3052945|NCT02208115|Experimental|Meal composition - High GI|Changing the glycaemic index of the meal consumed after exercise (High GI versus Low GI).
3052946|NCT02208115|Experimental|Meal composition - Low GI|Changing the glycaemic index of the meal consumed after exercise (High GI versus Low GI).
3052947|NCT02208089|Experimental|TransPRKCXL|Simultaneous combined transepithelial photorefractive keratectomy (TransPRK) and corneal collagen cross-linking (CXL)
3052948|NCT02208063|Experimental|Telavancin|7.5 mg/kg administered intravenously once every 24 hours daily over 60 minutes
3052949|NCT02208063|Active Comparator|Standard of care|Vancomycin, Daptomycin, synthetic penicillin or Cefazolin
3052950|NCT02208050|Other|Group 1|Patients will be randomised to a 8 week treatment period with the active drug followed by a 2 week washout period before an 8 week treatment period with placebo.
3052951|NCT02208050|Other|Group 2|Patients will be randomised to a 8 week treatment period with the placebo, followed by a 2 week washout period and a further 8 week treatment period with the active drug.
3052952|NCT02208037|Experimental|Tacrolimus/Methotrexate/Bortezomib|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Methotrexate, and Bortezomib.
3052953|NCT02208037|Experimental|Tacrolimus/Methotrexate/Maraviroc|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Methotrexate, and Maraviroc.
3052954|NCT02208037|Experimental|Tacrolimus/MMF/Cyclophosphamide|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Mycophenolate Mofetil (MMF), and Cyclophosphamide.
3052955|NCT02208024|Experimental|Stereotactic Body Radiation Therapy|5 fractions of 6.6 Gy delivered twice weekly with each fraction separated by greater than 48 hours over 15 days
3052956|NCT02207998|Experimental|Homeopathic complex and physiotherapy|"Homeopathic complex and physiotherapy: (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of 168 tablets; 56 tablets will be issued forth nightly to assess participant's compliance in taking their medicine. Participants will be given instruction to take two tablets, dissolved under the tongue 20 minutes away from meals, twice daily, starting from day one.~Physiotherapy treatment will consist of lower back classic massage, lumber joint manipulation and the application of a hot pack. Treatment sessions will last for 30 minutes, once every two weeks at the same physiotherapy practice from the same specific and identified physiotherapist."
3052957|NCT02207998|Placebo Comparator|Placebo and physiotherapy|"Placebo and Physiotherapy: Placebo will comprise of 168 unmedicated lactose tablets; 56 tablets will be issued forth nightly to assess participant's compliance in taking their medicine. Participants will be given instruction to take two tablets, dissolved under the tongue 20 minutes away from meals, twice daily, starting from day one.~Physiotherapy treatment will consist of lower back classic massage, lumber joint manipulation and the application of a hot pack. Treatment sessions will last for 30 minutes, once every two weeks at the same physiotherapy practice from the same specific and identified physiotherapist ."
3052958|NCT02207985|Experimental|Hematopoetic stem cell transplantation|Patients with pancreatic adenocarcinoma that have undergone Whipple surgery and show no sign of disease recurrence can be treated with hematopoietic stem cell transplantation to achieve an immunological anti-tumor effect.
3052959|NCT02207972|Active Comparator|Use of Ultrasound|Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started Infusion 12 ml/hr of 0.0625% Bupivacaine and Fentanyl 2mcg/ml
3052960|NCT02207972|Active Comparator|No ultrasound used|Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started Infusion 12 ml/hr of 0.0625% Bupivacaine and Fentanyl 2mcg/ml
3052961|NCT02207959|Experimental|Surveillance Endoscopy|White light examination, vital-dye enhanced fluorescence examination (VFI), High Resolution Microendoscope (HRME)
3052962|NCT02207946|Experimental|200 Units incobotulinumtoxinA (Xeomin)|Single injection cycle, total dose of up to 200 Units, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
3052963|NCT02207946|Placebo Comparator|Placebo|Single injection cycle, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
3052964|NCT02207933|Experimental|AP shifting group|
3052965|NCT02207933|Active Comparator|gait training group|
3053040|NCT02207426|Experimental|TOBI® Podhaler™|Tobramycin 112mg (4x28mg) inhalation powder
3053581|NCT02203747||Pseudophakic implanted with non-toric IOL|Subjects bilaterally implanted with non-toric IOL
3052967|NCT02207920|Experimental|Group 2|"At study entry and Month 1, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.~At Months 3 and 6, participants will receive placebo for DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid."
3052968|NCT02207920|Experimental|Group 3|"At study entry and Month 1, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.~At Months 3 and 6, participants will receive DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid."
3052969|NCT02207920|Experimental|Group 4|At study entry and Months 1, 3, and 6, participants will receive DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.
3052970|NCT02207907|Experimental|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
3052971|NCT02207907|Active Comparator|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
3052972|NCT02207881|Placebo Comparator|placebo|placebo gel, 25mg, 3 times up to 10 days
3052973|NCT02207881|Experimental|VDO gel|VDO gel 25mg, 3 times a day up to 10 days
3052974|NCT02207868||no treatment|
3052975|NCT02207855||Chloroprocaine|Neonates and infants who have received chloroprocaine for epidural anesthesia.
3052976|NCT02207842||Volatile anesthesia exposure|
3052977|NCT02207842||No volatile anesthesia exposure|
3052978|NCT02207829|Experimental|Umeclidinium 62.5 mcg + placebo|Subjects will receive UMEC Inhalation Powder 62.5 mcg once daily via nDPI plus placebo once daily via HANDIHALER inhaler for 12 weeks (24 weeks in Germany). Subjects will be instructed to take one inhalation each morning from both the nDPI and the HANDIHALER inhaler
3052979|NCT02207829|Active Comparator|Tiotropium 18mcg + placebo|Subjects will receive Tiotropium 18 mcg once daily via HANDIHALER inhaler plus placebo once daily via nDPI for 12 weeks (24 weeks in Germany). Subjects will be instructed to take one inhalation each morning from both the nDPI and the HANDIHALER inhaler
3052980|NCT02207816|Experimental|R3R Group|Infants/children assigned to the R3R group received 3 doses of RTS,S/AS01E on a 0-, 1-, 2-month schedule, and a booster dose of RTS,S/AS01E at Month 20 during the primary study MALARIA-055 PRI (NCT00866619).
3052981|NCT02207816|Active Comparator|R3C Group|Infants/children assigned to the R3C group received 3 doses of RTS,S/AS01E on 0-, 1-, 2-month schedule, and a dose of comparator vaccine at Month 20 during the primary study MALARIA-055 PRI (NCT00866619).
3052982|NCT02207816|Active Comparator|C3C Group|Infants/children assigned to the C3C group received 3 doses of a comparator vaccine on 0-, 1-, 2-month schedule, and a dose of comparator vaccine at Month 20 during the primary study MALARIA-055 PRI (NCT00866619).
3052983|NCT02207803|Experimental|Intervention|Experimental Transition Assistance Program
3052984|NCT02207803|No Intervention|Control|Control
3052985|NCT02207790|Experimental|E2609 low-dose and placebo in healthy Japanese subjects|Cohort 1 will consist of Japanese subjects randomized to a low-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
3052986|NCT02207790|Experimental|E2609 mid-dose and placebo in healthy Japanese subjects|Cohort 2 will consist of Japanese subjects randomized to a mid-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
3052987|NCT02207790|Experimental|E2609 high-dose and placebo in healthy Japanese subjects|Cohort 3 will consist of Japanese subjects randomized to a high-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
3052988|NCT02207790|Experimental|E2609 mid-dose and placebo in healthy White subjects|Cohort 4 will consist of White subjects randomized to a mid-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
3052989|NCT02207777|Experimental|Roux-en-Y gastric bypass (RYGB)|Subjects in this group are scheduled to undergo roux-en-Y gastric bypass surgery to obtain a 16-18% weight loss.
3052990|NCT02207777|Active Comparator|Low-calorie diet|Subjects in this group will participate in a low-calorie diet intervention to obtain a 16-18% weight loss.
3052991|NCT02207777|Experimental|Sleeve Gastrectomy (SG)|Subjects in this group are scheduled to undergo SG surgery to obtain a 16-18% weight loss.
3052992|NCT02207764|Experimental|Reiki Intervention|Each study participant in the intervention group will receive one Reiki intervention by a registered nurse trained in Advanced Level Reiki through the Usui Shiki Ryoho method.
3052993|NCT02207764|No Intervention|nursing presence control|Each patient in the control group will receive usual care including the study nurse presence for the 15-minute period.
3052994|NCT02207738|Experimental|microneedling radiofrequency device|microneedling radiofrequency
3052995|NCT02207738|Active Comparator|bipolar radiofrequency device|bipolar radiofrequency treatment
3052996|NCT02207725|Experimental|Andexanet|Andexanet (antidote)
3052997|NCT02207725|Placebo Comparator|Placebo|Placebo
3052998|NCT02207712|Active Comparator|Standard Arm|Those receiving only their prescribed ranibizumab treatment only
3052999|NCT02207712|Experimental|Intervention Arm|Noctura 400 Eye Mask in conjunction with their prescribed ranibizumab treatment.
3053000|NCT02207699|Experimental|Benzonatate 200 mg|
3053001|NCT02207699|Experimental|Benzonatate 800 mg|
3053002|NCT02207699|Active Comparator|Moxifloxacin 400 mg|
3053003|NCT02207699|Placebo Comparator|Placebo|
3053004|NCT02207686||von Hippel-Lindau disease|Patients with von Hippel-Lindau disease who have had at least one vHL-related tumor removed
3053005|NCT02207673|Active Comparator|Spikes as biomarker|"In arm  spikes the resection of epileptogenic tissue is guided by epileptiform spikes in the aECoG (current standard). (Independent of the randomisation ictiform spike patterns will always be resected.)"
3053006|NCT02207673|Experimental|HFOs as biomarker|"In arm HFOs resection of epileptogenic tissue is guided by HFOs in the aECoG (new). (Independent of the randomisation ictiform spike patterns will always be resected.)"
3053041|NCT02207413|Experimental|Influsplit Tetra_IP Adult Group|Subjects in the Influsplit Tetra_IP group aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by investigational process (IP) at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm.
3081969|NCT02013687|Experimental|10 µg + Alhydrogel|vaccine
3053007|NCT02207660||Cisplatin,P-HDFL|The general principles for patients schedule for P-HDFL regimen treatment were as followings: patients must have had white cell count > 3000/mm3, platelet count > 100000/mm3, a normal serum creatinine (≦1.5 mg/dL) or a measured creatinine clearance ([urine creatinine level (mg/dL) X 24-hr urine amount (mL)]/[serum creatinine level (mg/dL) X 1,440 min]) of ≧ 40 mL/min [12,15], total bilirubin ≦ 2 mg/dL, and transaminase (≦3X the upper normal limits). Also, patients needed to have measurable disease by radiographic studies (plain X-ray, CT or MRI scans), no serious active underlying medical issues, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
3053008|NCT02207647||Patients with syndromes requiring lumbar puncture|
3053009|NCT02207634|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference. Participants continued with their background statin therapy during the course of the study.
3053010|NCT02207634|Experimental|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference. Participants continued with their background statin therapy during the course of the study.
3053011|NCT02207621|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
3053012|NCT02207621|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
3053013|NCT02207621|Experimental|AR-13324 Ophthalmic Solution 0.02% BID|1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
3053014|NCT02207608|Active Comparator|BCG alone (Immucist®)|Group A receive BCG (Immucist® 81 mg, Sanofi-Aventis Group) alone
3053015|NCT02207608|Experimental|Hyaluronic acid|Group B receive BCG and HA 40 mg (Cystistat, Mylan, Pittsburgh, PA, U.S.A.).
3053016|NCT02207595|Experimental|UCB5857 Cohort 1|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
3053017|NCT02207595|Experimental|UCB5857 Cohort 2|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
3053018|NCT02207595|Experimental|UCB5857 Cohort 3|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
3053019|NCT02207595|Experimental|UCB5857 Cohort 4|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
3053020|NCT02207595|Experimental|UCB5857 Cohort 5|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
3053021|NCT02207582|Experimental|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
3053022|NCT02207582|Placebo Comparator|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
3053023|NCT02207569|Experimental|CoreValve Evolut R TAVR system|"The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:~Evolut R Transcatheter Aortic Valve (TAV)~EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath~EnVeo R Loading System (LS)"
3053024|NCT02207556|Experimental|Doxycycline|Doxycycline will be administered at dose of 100mg orally twice daily for 1 year.
3053025|NCT02207543|Experimental|Medical telephonecontact|Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
3053026|NCT02207530|Experimental|MEDI4736|MEDI4736 monotherapy
3053027|NCT02207517|Experimental|Office-based verg/accomm therapy (OBVAT)|OBVAT requires a participant to undergo a specific vision therapy regimen with 16 weekly, 60-minute in-office treatment sessions. Vision Therapists (O.D., M.D., Orthoptists, or specially-trained technicians) administer the therapy in the office. OBVAT procedures are then supplemented with various home therapy procedures
3053028|NCT02207517|Placebo Comparator|Office-based placebo therapy (OBPT)|"Office-based Placebo Therapy (OBPT) requires a participant to undergo a specific therapy regimen of 16 weekly, 60 minute, in-office treatment sessions. Vision therapists (optometrists, ophthalmologists, orthoptists, or specially-trained technicians) administer the therapy in the office. OBPT procedures are then supplemented with placebo home therapy procedures.~The procedures for OBPT are designed with the intent of not providing a beneficial training effect on vergence, accommodation, saccadic accuracy, or visual attention beyond normal activities. However, the procedures are designed to simulate real vision therapy in such a way that it will be difficult for participants and parents to know that they have been assigned to the control group and thus are not receiving bonafide OBVAT"
3053029|NCT02207504|Experimental|crizotinib and enzalutamide|"A traditional 3+3 dose escalation scheme will be used to identify the recommended phase 2 dose (RP2D) of crizotinib when used in combination with standard fixed dose enzalutamide.~Crizotinib- given orally daily-28 day cycle~Enzalutamide- given orally daily-28 day cycle"
3053030|NCT02207491|Experimental|AR-13324 Ophthalmic Solution 0.02% & Placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
3053031|NCT02207491|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop Timolol maleate twice daily (BID) in the morning (AM) & evening (PM) in both eyes (OU)
3053032|NCT02207478|Experimental|ENB-GS-TBLB-X-ray Group|The guide sheath(GS) is introduced into the lesion via Electromagnetic Navigation System. The locatable guide(LG) and GS are confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained with fluoroscopic guidance.
3053033|NCT02207478|Active Comparator|GS-TBLB-X-ray group|The GS is introduced into the lesion via the working channel of a bronchoscope with radiographic fluoroscopy. Once the location of the lesion is identified by fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
3053034|NCT02207465|Experimental|Single Arm|
3053035|NCT02207452|Other|Salbutamol + Ipratropium|Treatment period 1: Salbutamol 5mg nebulised, single Dose. Treatment period 2: Ipratropium 500mcg nebulised, single dose.
3053036|NCT02207452|Other|Ipratropium + Salbutamol|Treatment period 1: Ipratropium 500mcg nebulised, single dose. Treatment period 2: Salbutamol 5mg nebulised, single Dose.
3053037|NCT02207439|Experimental|Single Arm Phase 2|
3053038|NCT02207426|Experimental|TobrAir® 6.0|Tobramycin 75mg inhalation solution
3053042|NCT02207413|Active Comparator|Influsplit Tetra_LP Adult Group|Subjects in the Influsplit Tetra_LP aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by currently licensed process (LP) at Day 0. Influsplit Tetra™ vaccine produced by currently LP was administered intramuscularly in the deltoid region of left or non-dominant arm.
3053043|NCT02207413|Experimental|Influsplit Tetra_IP 3-17y Group|Subjects in the Influsplit Tetra_IP group aged between 3 years to <9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by investigational process (IP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by IP at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
3053044|NCT02207413|Active Comparator|Influsplit Tetra_LP 3-17y Group|Subjects in the Influsplit Tetra_LP group aged between 3 years to <9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by LP at Day 0. Influsplit Tetra™ vaccine produced by LP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
3053045|NCT02207413|Experimental|Influsplit Tetra_IP 6-35m Group|Subjects in the Influsplit Tetra_IP group aged between 6 months to 35 months received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by investigational process (IP). Influsplit Tetra™ vaccine produced by IP was administered intramuscularly the anterolateral region of left thigh for subjects below 12 months of age and in the deltoid region of left or non-dominant arm in subjects ≥ 12 months of age (Day 0) and in the anterolateral region of right thigh for subjects below 12 months of age and in the deltoid region of right or dominant arm in subjects ≥ 12 months of age (Day 28).
3053046|NCT02207413|Active Comparator|Influsplit Tetra_LP 6-35m Group|Subjects in the Influsplit Tetra_LP group aged between 6 months to 35 months received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Influsplit Tetra™ vaccine produced by LP was administered intramuscularly the anterolateral region of left thigh for subjects below 12 months of age and in the deltoid region of left or non-dominant arm in subjects ≥ 12 months of age (Day 0) and in the anterolateral region of right thigh for subjects below 12 months of age and in the deltoid region of right or dominant arm in subjects ≥ 12 months of age (Day 28).
3053047|NCT02207400|Experimental|Experimental Dentifrice|Participants were advised to brush their teeth with experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
3053048|NCT02207400|Active Comparator|Reference Dentifrice|Participants were advised to brush their teeth with reference dentifrice containing 1100ppm fluoride as sodium fluoride
3053049|NCT02207387|Experimental|MCW|Music Contingent Walking (MCW) group: study-specific musical device that measures gait and plays music in a portable manner as the participant is walking is set at a threshold individually calculated per participant, and the music will stop playing when walking strides fall below this threshold.
3053050|NCT02207387|Experimental|NCMW|Non-contingent Music Walking (NCMW) group: music on all the time regardless of the stride size.
3053051|NCT02207387|Experimental|NMW|Non-music walking (NMW/silent) group: no music on at all regardless of step size.
3053052|NCT02207387|Experimental|MCW+rasagiline|"Music contingent walking with rasagiline group: same paradigm as the previous MCW, but with rasagiline prescribed as adjunct therapy.~Dosage: 0.5 mg/day for the first 2 weeks to be subsequently increased to 1 mg/day"
3053053|NCT02207387|Experimental|MMW+rasagiline|"Non-music (silent) walking with rasagiline group: same paradigm as the previous NMW, but with rasagiline prescribed as adjunct therapy.~Dosage: 0.5 mg/day for the first 2 weeks to be subsequently increased to 1 mg/day"
3053054|NCT02207374|Experimental|Semaglutide 0.5 mg|
3053055|NCT02207374|Experimental|Semaglutide 1.0 mg|
3053056|NCT02207374|Active Comparator|One additional OAD + pre-trial treatment|The type and dosage of the additional OAD will be selected by the investigators according to the approved Japanese labelling including drug combinations and contraindications. One of DPP-4 inhibitor (dipeptidyl peptidase-4), SU (sulfonylurea), glinide, biguanide, α-GI (α-glucosidase inhibitor)or TZD (thiazolidinediones) will be selected as the additional OAD. For the subjects treated with OAD monotherapy as pre-trial treatment, the type and dosage of the additional OAD with a different mechanism of action from the pre-trial OAD should be chosen.
3053057|NCT02207361|Experimental|Paclitaxel, Carboplatin，injection|Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.
3053058|NCT02207361|Active Comparator|Paclitaxel, Epirubicin，injection|Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
3053059|NCT02207348|Experimental|Liraglutide 0.6 mg s.c. with FlexPen®|
3053060|NCT02207348|Experimental|Liraglutide 0.6 mg s.c. with the PDS290 pen-injector|
3053061|NCT02207335|Experimental|Gemcitabine，Capecitabine|Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14
3053062|NCT02207335|Active Comparator|Gemcitabine, Carboplatin|Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
3053063|NCT02207322|No Intervention|Standard transplant care|"Patient Enrollment and Caregiver Enrollment (within 72 hours of hospital)~-- Complete baseline data collection, and registration~Patient Randomization~Standard transplant oncology care~-- Palliative care consults only upon request~Longitudinal Data Collection (patient & family caregivers)~Week-2 of hospitalization~3-months, and 6-months post HSCT"
3053064|NCT02207322|Experimental|transplant with early palliative care|"Standard transplant oncology care with early palliative care~Patient Enrollment and Caregiver Enrollment (within 72 hours of patient enrollment)~--Complete baseline data collection, and registration Intervention description: Inpatient palliative care intervention description: 1st visit within 72 hours of randomization, At least twice weekly follow up visits~Longitudinal Data Collection (patient & family caregivers)~Week-2 of hospitalization~3-months, and 6-months post HSCT"
3053065|NCT02207309|Active Comparator|Pazopanib|800mg, oral, 24 months
3053066|NCT02207309|Placebo Comparator|Placebo|800mg, oral, 24 months
3053067|NCT02207296|Other|PVI group|Fluid optimisation using PVI
3053582|NCT02203734|Experimental|Moderate Pressure Massage|Moderate Pressure Massage Therapy
3053069|NCT02207270|Experimental|Same day discharge|Patients who experienced uncomplicated PCI as well as an uncomplicated 6-hour observation period, will be randomly assigned to same day discharge.
3053070|NCT02207270|Other|Overnight stay standard care|Patients who experienced uncomplicated PCI, as well as an uncomplicated 6-hour observation period, will be randomly assigned to an overnight stay, generally considered standard care.
3053071|NCT02207257|Experimental|Cohort 1|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 25 mg PER977 or placebo (n=10).
3053072|NCT02207257|Experimental|Cohort 2|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 50 mg PER977 or placebo (n=10).
3053073|NCT02207257|Experimental|Cohort 3|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 100 mg PER977 or placebo (n=10).
3053074|NCT02207257|Experimental|Cohort 4|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 300 mg PER977 or placebo (n=10). Study amendments expanded the cohort to include an additional 7 subjects (randomized 1:6 PER977:placebo) and up to an additional 4 placebo and 8 active subjects (ongoing).
3053075|NCT02207257|Experimental|Cohort 5|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 600 mg PER977 or placebo (n=10). A protocol amendment expanded the cohort to include an additional 2 placebo and up to an additional 4 active subject.
3053076|NCT02207244|Experimental|Group I|Participants will receive guselkumab 100 milligram (mg) at Weeks 0, 4, 12 and 20. Starting at Week 28, participants will receive guselkumab 100 mg or placebo through Week 72 depending upon randomized treatment group and PASI response. Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending upon randomized treatment group and PASI response. Placebo for adalimumab [two 0.8 milliliter (mL) injections] at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, 5, and every 2 week (q2w) through Week 23 to maintain the blind. All participants will receive guselkumab q8w starting at Week 76 through Week 252.
3053077|NCT02207244|Placebo Comparator|Group II|Participants will receive placebo for guselkumab at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response. Placebo for adalimumab (two 0.8 mL injections) at week 0, followed by one 0.8 mL injection at weeks 1, 3, and 5, and q2w through week 23. At week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20, starting at week 28, participants will continue to receive guselkumab 100 mg or placebo through week 72 depending upon PASI response. All participants will received guselkumab q8w starting at Week 76 through Week 252.
3053078|NCT02207244|Active Comparator|Group III|Participants will receive adalimumab 80 mg (two 40 mg [0.8 mL] injections) at Week 0 followed by adalimumab 40 mg at weeks 1, 3, 5, and q2w through week 23 and placebo for guselkumab at weeks 0, 4, 12, 16, and 20. Participants will receive guselkumab or placebo starting at week 28 through week 72 depending upon PASI response. All participants will received guselkumab q8w starting at Week 76 through Week 252.
3053079|NCT02207231|Experimental|Group I|Participants received Guselkumab 100 milligram (mg) at Weeks 0, 4, and 12 and every 8 weeks (q8w) thereafter through Week 252, placebo for guselkumab at Week 16, and placebo for adalimumab (two 0.8 milliliter [mL] injections) at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, and 5, and every 2 weeks (q2w) thereafter through Week 47.
3053080|NCT02207231|Placebo Comparator|Group II|Participants received Placebo for guselkumab at Weeks 0, 4, and 12, and placebo for adalimumab (two 0.8 mL injections) at Week 0, followed by one 0.8 mL injection at Weeks 1, 3, and 5, and q2w through Week 15. At Week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20 and q8w thereafter through Week 252, as well as placebo for adalimumab at Weeks 17, 19, 21, and 23, and q2w thereafter through Week 47.
3053081|NCT02207231|Active Comparator|Group III|Participants received Adalimumab 80 mg at Week 0 (two 40 mg [0.8 mL] injections) and 40 mg at Weeks 1, 3, 5, and q2w thereafter through Week 47, placebo for guselkumab at Weeks 0, 4, 12, 16, and 20, and q8w thereafter through Week 44 and guselkumab 100 mg at Weeks 52, 60, and q8w thereafter through Week 252.
3053082|NCT02207218||NovoEight®|
3053083|NCT02207205|Other|Catheter vs venipuncture blood samples|Evaluation of whether there is any difference in results of whole blood clotting time in blood samples drawn from an indwelling catheter versus direct venipuncture
3053084|NCT02207192||Morbidly obese|Consecutive morbidly obese adults (BMI over or equal to 40 kg/m2) scheduled for bariatric surgery were prospectively recruited.Subjects with respiratory and cardiac history (asthma, Chronic obstructive pulmonary disease, heart failure) were excluded.
3053085|NCT02207179|No Intervention|Single Arm|LumaScan Image Guided Surgery
3053086|NCT02207166||user group|volunteers who are willing to receive 40 minutes video monitoring and questionnaires while operation a electronic blood pressure measuring machines.
3053087|NCT02207153||Chronic Hemodialysis|Initiation of chronic hemodialysis or currently undergoing chronic hemodialysis at one of the study centres
3053088|NCT02207153||Peritoneal Dialysis|Initiation of chronic peritoneal dialysis or currently undergoing chronic peritoneal dialysis at one of the study centres
3053089|NCT02207140|Experimental|probiotic|HOWARU Restore
3053090|NCT02207140|Placebo Comparator|placebo|microcrystalline cellulose
3053091|NCT02207127||MRI, DISE, and Surgery|All participants will undergo MRI and DISE prior to undergoing surgical treatment of obstructive sleep apnea.
3053092|NCT02207114|No Intervention|Observational|9 blood biomarkers (including C reactive protein and Procalcitonin) will be assessed across 3 days. Results will not be shared with the subject's medical team. At 3 days, the definitive diagnosis of infection will be determined using Center for Disease Control (CDC) criteria; this will serve as the gold standard for determining biomarker test characteristics. Additional data to collect: demographics, comorbidities, medication use (like antibiotics), lab cultures, x-rays, sepsis resolution, length of hospital stay, and ultimate outcome (i.e., discharge, death). Phase I will identify the biomarker(s) providing the greatest negative predictive value in identifying patients at very low likelihood bacterial infection.
3053321|NCT02205580|Experimental|Sufentanil infusion rate 0.03μg•kg－1•h－1|Sufentanil infusion rate 0.03μg•kg－1•h－1 lasted for 48 hours
3053093|NCT02207114|Experimental|Biomarker Algorithm Intervention|"The Algorithm arm is equivalent to the intervention. Biomarker algorithm along with the patient's biomarker assay results will be given to clinical team to assist in deciding to continue antibiotics.~The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs."
3053094|NCT02207101|Active Comparator|E-OJ-01 (OXYJUN)|E-OJ-01 (OXYJUN). Dose: 01 capsule to be taken orally daily after lunch.
3053095|NCT02207101|Placebo Comparator|Placebo|Matching placebo capsules [for E-OJ-01 (OXYJUN)] composed of microcrystalline cellulose. Dose: 01 capsule to be taken orally daily after lunch.
3053096|NCT02207088|Experimental|3-DAA (Direct Acting Antivirals) with or without RBV|3-DAA (ombitasvir/paritaprevir/ritonavir 25 mg/150 mg/100 mg once daily [QD] and dasabuvir 250 mg twice daily [BID]) with or without ribavirin (RBV; dosed divided twice a day) for 12 or 24 weeks
3053097|NCT02207075||Subjects with SPMS|"Secondary progressive MS Subjects either untreated or on consistent treatment for six months prior to enrollment.~SPMS subjects will have two baseline [11C]PK-11195 PET scans (separated by 24 to 72 hours, test-retest) and subsequent scans at 6, 12 and 24 months. SPMS Subjects will have brain MRI's at baseline, 6, 12 and 24 months."
3053098|NCT02207075||Normal Control Subjects|Healthy Controls will have 2 baseline [C11]PK-1195 PET scans and 1 MRI.
3053099|NCT02207062|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity.
3053100|NCT02207049|Active Comparator|Three Meals (TM)|Preschoolers will be provided their caloric needs within three meals.
3053101|NCT02207049|Active Comparator|Meal plus Snack (M+S)|Preschoolers will be provided three meals and two snacks, with total amount of food provided in the day the same as the Three Meal (TM) arm.
3053102|NCT02207049|Active Comparator|Three Meal plus Snack (TM+S)|Preschoolers will be provided three meals and two snacks with total amount provided in the meals equal to the Three Meal (TM) arm and total amount provided in the snacks equal to Meal plus Snacks (M+S) arm.
3053103|NCT02207036|Experimental|Facebook intervention|Assignment to private group on Facebook with 3 months of content delivered to the group.
3053104|NCT02207036|Active Comparator|Referral|Referral to smokefree.gov website
3053105|NCT02207023|No Intervention|Memory Training Program|Participants will participate in 7 memory training coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.
3053106|NCT02207023|Experimental|Healthy Lifestyle Training Program|Participants will participate in 7 lifestyle coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.
3053107|NCT02207010|Experimental|AZD1775|Patients will receive a single dose (either 100 mg, 200 mg or 400 mg) of AZD1775, an oral agent, prior to surgery for resection of GBM
3053108|NCT02206997||Passive Insulation standard treatment|no active warming before start of anesthesia and no active warming at PACU
3053109|NCT02206997||Active prewarming treatment|active warming before start of anesthesia and active warming at PACU following recommendations of S3-guideline
3053110|NCT02206984|Active Comparator|tamoxifen|Tamoxifen is administered orally, at a dose of 20 mg,daily, for 21 days
3053111|NCT02206984|Active Comparator|Anastrozole|1mg given orally daily for 21 days
3053112|NCT02206984|Active Comparator|fulvestrant|500 mg, administered as two 250 mg IM injections, given on days 1 and 14
3053113|NCT02206971|Active Comparator|Feedback Group|receive a Smoking Cessation Manual, the opportunity for smoking cessation counseling on the phone, and urine analyses feedback via the mail plus a phone call to discuss the information
3053114|NCT02206971|No Intervention|Standard Care|receive a Smoking Cessation Manual and the opportunity for smoking cessation counseling on the phone
3053115|NCT02206958|Other|No treatment control group|No treatment control group
3053116|NCT02206958|Experimental|Behavioral Urinary Incontinence Treatment|12 week program combining behavioral treatments for urinary incontinence, physical activity, and toileting environmental modifications.
3053117|NCT02206945|Experimental|neurofeedback|Two imaging sessions of neurofeedback.
3053118|NCT02206945|Placebo Comparator|control feedback|Two imaging sessions of feedback
3053119|NCT02206932|Other|Sofosbuvir + Simeprevir|Subjects will be enrolled and treated with simeprevir 150 mg and sofosbuvir 400 mg once daily for 12 weeks
3053120|NCT02206906||Study Participants|All participants who meet eligibility requirements and who consent to participation will use an incentive intervention model.
3053121|NCT02206893|Experimental|Mobile: Professional and peer support|A mobile app that provides both professional support and peer support
3053122|NCT02206893|Experimental|Mobile: Peer support|A mobile app that provides peer support, but not professional support
3053123|NCT02206893|Experimental|Mobile: Professional Support|A mobile app that provides professional support, but no peer support
3053124|NCT02206893|Active Comparator|Mobile: No Support|A mobile app that provides neither peer support nor professional support
3053125|NCT02206893|Active Comparator|Web: No Support|A web app that provides neither peer support, nor professional support
3053126|NCT02206867|Experimental|LBAL|Developed by LG Life Sciences
3053127|NCT02206867|Active Comparator|Humira®|Abbvie
3053128|NCT02206854|Experimental|R-flurbiprofen|200 mg R-flurbiprofen in gelatine capsules once
3053129|NCT02206841||NAFLD|Patients with suspected nonalcoholic fatty liver disease will be screened. Of all patients fulfilling inclusion criteria, baseline characteristics will be obtained. In addition, laboratory, radiologic evaluations such as ARFI, SWE, and transient elastography will be performed. A diagnostic liver biopsy will be performed for analysis of steatosis and fibrosis. Parts of the remaining liver tissue will be stored by frozen tissue and paraffin block for future study. Several serum and plasma samples are collected of patients and stored for future analysis such as super-enhancer RNA (eRNA) expression, whole exome sequencing, RNA chip sequencing, RNA microarray, genomic DNA, and metabolomics.
3053130|NCT02206828||1 GROUP|Only 1 group not predetermined
3053131|NCT02206815|Active Comparator|Ticagrelor+Warfarin|Ticagrelor:Plain, round, yellow, film-coated tablet, 90mg; Warfarin:Plain, round, white, film-coated tablet, 2.5mg
3053132|NCT02206815|Active Comparator|Clopidogrel+Aspirin+Warfarin|Clopidogrel:Light red bisulfate tablets, containing one 75mg; Aspirin:Plain, round, white, film-coated tablet, 100mg; Warfarin:Plain, round, white, film-coated tablet, 2.5mg
3053133|NCT02206802||Predicted as non-responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as non-responders. 5% minoxidil topical foam will be administered to subjects in this group.
3053134|NCT02206802||Predicted as responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as responders. 5% minoxidil topical foam will be administered to subjects in this group.
3053135|NCT02206789|Active Comparator|penetrating keratoplasty|"each arm will have two groups A and B.. Only on topical steroids(prednisolone acetate1%) group A On topical steroids + 2% cyclosporine Group B . Methodology of drug administration In both agroups 1. Schedule of topical steroid administration : 6 times for 2 weeks; 5 times for 2 weeks; 4 times for a month; 3 times for a month, and, subsequently twice-a-day until 1 year is completed . Topical steroids will be withdrawn at the end of ine year.Systemic steroids may be administered in the initial 2 weeks at the discretion of the investigators.~3. Patients randomized to receive 2% cyclosporine will receive the same 3 times a day for 2years"
3053136|NCT02206789|Active Comparator|therapeutic keratoplasty|each arm will have two groups A and B.. Only on topical steroids(prednisolone acetate1%) group A On topical steroids + 2% cyclosporine Group B . Methodology of drug administration In both agroups 1. Schedule of topical steroid administration : 6 times for 2 weeks; 5 times for 2 weeks; 4 times for a month; 3 times for a month, and, subsequently twice-a-day until 1 year is completed . Topical steroids will be withdrawn at the end of ine year.Systemic steroids may be administered in the initial 2 weeks at the discretion of the investigators. (For all patients with fungal keratitis topical steroids will be administered only after 2 weeks post keratoplasty.) Until then diclofenac sodium0.1% may be used 3. Patients randomized to receive 2% cyclosporine will receive the same 3 times a day for 2years
3053137|NCT02206776|Placebo Comparator|Midazolam|A single dose of intranasal midazolam up to 4 mg
3053138|NCT02206776|Experimental|Ketamine|A single dose of intranasal ketamine up to 50 mg
3053139|NCT02206763|Experimental|MMB+erlotinib|Participants will receive MMB plus erlotinib.
3053140|NCT02206750|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
3053141|NCT02206750|Experimental|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
3053142|NCT02206737|Experimental|E-Cigarette|3 doses of e-cigarette to be given No nicotine Low dose nicotine High dose nicotine
3053143|NCT02206724|Experimental|STEREOTACTIC BODY RADIOTHERAPY|STEREOTACTIC BODY RADIOTHERAPY to the prostate gland
3053144|NCT02206711|Experimental|Single oral dose of [14C] BMS 955176|A single 180 mg oral dose of [14C] BMS-955176 containing approximately 80 microcurie of total radioactivity.
3053145|NCT02206711|Experimental|Nasoduodenal (ND) Tube Cohort|A single dose of [14C] BMS 955176 on Day 1 with ND placement 1 hour post dose to facilitate continuous bile collection though 8 hours post dose.
3053146|NCT02206685|Active Comparator|Treatment group|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes.
3053147|NCT02206685|Placebo Comparator|Control Group|The control group will receive a 20 ml normal saline placebo infusion over 10 minutes
3053148|NCT02206672|Other|Micro reinjection of autologus adipose tissue|
3053149|NCT02206659|Experimental|Telmisartan|2-week placebo run-in period followed by 6 weeks of treatment with telmisartan
3053150|NCT02206646||Metalyse|weight-adjusted dose
3053151|NCT02206633||Elderly, assisted living residents|Hydration Monitor ultrasound measurements
3053152|NCT02206620|Experimental|Donepezil|Donepezil 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
3053153|NCT02206620|Placebo Comparator|Placebo|Placebo 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
3053154|NCT02206607|Experimental|PF-04937319 IR MST|Reference formulation
3053155|NCT02206607|Experimental|PF-04937319 MR 1|Test MR #1
3053156|NCT02206607|Experimental|PF-04937319 MR 2|Test MR #2
3053157|NCT02206607|Experimental|PF-04937319 MR 3|Test MR #3
3053158|NCT02206594|Experimental|Descemetorhexis|
3053159|NCT02206581||young healthy adult athletes|Hydration Monitor measurement of the ultrasound velocity and measures of hydration status including urine specific gravity, plasma and urine osmolality in male and female young adults after undergoing 3% acute dehydration and a 2-hr rehydration period
3053160|NCT02206568|Experimental|URAL vs. Insulin lispro|Each subject will randomly be allocated to a treatment sequence consisting of 2 dosing visits during which the subject in a euglycaemic clamp setting will receive either a single dose of insulin lispro or URAL at predefined fixed dose levels in a randomized order.
3053161|NCT02206555|Experimental|Treatment group (TRUVADA)|Homosexual men and heterosexual men and women at high risk of HIV infection
3053162|NCT02206542|Experimental|Robot-assisted group|Electroacupuncture, physical therapy and upper limb rehabilitation robot
3053163|NCT02206542|Active Comparator|Control group|Electroacupuncture and physical therapy
3053164|NCT02206529|Active Comparator|Social Network Engagement+Std Treatment|"Social Network Engagement = content and activities to help the parent engage his/her social network in supporting healthy lifestyle behaviors.~Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)"
3053165|NCT02206529|Other|Standard Treatment|"This comparator arm consists of historical controls, participants in the FOCUS trial who received standard treatment.~Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)"
3053166|NCT02206516|Experimental|patients|Stimulation using tDCS will be administered daily, 5 days a week for 4 weeks. each session will last 22 minutes during which the anode electrode will be positioned over the right Inferior Frontal Gyrus (IFG) and the Katode electrode over the right Orbito Frontal Gyrus (OFG).
3053210|NCT02206204|Experimental|Group B2|Subjects in Group B2 receive moxifloxacin-matching placebo, orally on Day 2 and 400 mg moxifloxacin, orally on Day 24. Subjects receive placebo for selexipag, orally on Days 3 to 23.
3053211|NCT02206191||Mothers of 6-11 year olds|
3053358|NCT02205346||no treatment|no treatment
3053167|NCT02206503|Experimental|Cyclophosphamide; Lenalidomide; Dexamethasone|"MM Patients who experienced biochemical progression during Rd treatment without CRAB (signs of organ damage, multiple myeloma-related, as renal impairment and/or anemia and/or new bone lesions and/or hypercalcemia), will continue:~Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days.~Dexamethasone orally at the dose of 40 mg once a week.~Adding:~· Cyclophosphamide orally at the dose of 50 mg/day on days 1-21 every 28 days. CRd combination will be continued for 9-4week cycles. Patients will not receive any maintenance therapy."
3053168|NCT02206490|Active Comparator|Naltrexone Study Drug|Subjects will take naltrexone 4.5 mg daily for three months.
3053169|NCT02206490|Placebo Comparator|Naltrexone placebo|Subjects will take a 3 month course of a placebo pill identical in appearance to the naltrexone study drug.
3053170|NCT02206490|Active Comparator|dextromethrophan study drug|subjects will take a sustained release dextromethorphan pill twice a day.
3053171|NCT02206490|Placebo Comparator|dextromethoprhan placebo|Subjects will take a 3 month course of a placebo pill identical in appearance to the dextromethorphan study drug.
3053172|NCT02206477|Experimental|DMSO treatment group|The treatment group will be exposed to DMSO according to our built protocol. On the seventh post-operative day, the patient will be guided to set 10 cc of DMSO soaked gauze compresses on the breast, twice a day for 20 minutes, for the term of 6 weeks. This treatment will be holed for 24 hours on tissue expander inflation dates. A repeated course of compresses will be taken after adjuvant radiotherapy, starting 24 hours after the last therapy.
3053173|NCT02206477|Placebo Comparator|the control group|The control group will be treated with the same post-operative protocol, but with 0.9% saline instead of DMSO. On the seventh post-operative day, the patient will be guided to set 10 cc 0.9% saline soaked gauze compresses on the breast, twice a day for 20 minutes, for the term of 6 weeks. This treatment will be holed for 24 hours on tissue expander inflation dates. A repeated course of compresses will be taken after adjuvant radiotherapy, starting 24 hours after the last therapy.
3053174|NCT02206464|Experimental|Group 1|H7 DNA vaccine on Day 0 and H7N9 MIV at StudyWeek 16
3053175|NCT02206464|Experimental|Group 2|H7 DNA and H7N9 MIV administered on Day 0 and H7N9 MIV boost at Study Week 16
3053176|NCT02206464|Experimental|Group 3|H7N9 MIV on Day 0 and H7N9 MIV at Study Week 16
3053177|NCT02206438|Experimental|1)C-LMA group|
3053178|NCT02206438|Active Comparator|2)Air-Q group|
3053179|NCT02206425|Experimental|bortezomib + melphalan + prednisone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3053180|NCT02206425|Experimental|bortezomib + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3053181|NCT02206425|Experimental|carfilzomib + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3053182|NCT02206425|Experimental|bortezomib + lenalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3053183|NCT02206425|Experimental|carfilzomib + lenalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3053184|NCT02206425|Experimental|bortezomib + cyclophosphamide + dexamethasone|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3053185|NCT02206425|Experimental|bortezomib + cyclophosphamide + ascorbic acid|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib. Due to a potential drug-drug interaction between ixazomib and ascorbic acid, patients will receive ixazomib in the clinic in the morning and will be instructed to take ascorbic acid in the evening, followed by cyclophosphamide.
3053186|NCT02206425|Experimental|bortezomib + PLD + dexamethasone|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3053187|NCT02206425|Experimental|bortezomib + pomalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3053188|NCT02206425|Experimental|carfilzomib + pomalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3053189|NCT02206412||HMGB1 group|
3053190|NCT02206386|Experimental|MentalHealthTraining-Net|MHTraining-Net is an implementation strategy that uses a web-based platform with several long distance tools (e.g. e-learning modules, consultation, telephone calls, toolkits, and discussion boards) to deliver four types of implementation activities: infrastructure development, training and education, quality improvement, and social networking.
3053191|NCT02206386|Active Comparator|Enhanced Support|Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded trainings in the use of the protocol and depression screening posted by Brightree.
3053192|NCT02206360||Individuals at elevated risk for pancreatic cancer|Individuals with an elevated risk of developing pancreatic cancer as either equal to or greater than five times the general population risk, or five times the average risk (1.5%) of developing pancreatic cancer by age 70; that is a 7.5% lifetime risk.
3053193|NCT02206347|Other|attention focus|
3053194|NCT02206334|Experimental|Treatment (stereotactic body radiation therapy)|Patients undergo 3-5 fractions of image-guided stereotactic body radiation therapy to all existing metastases over 1-3 weeks with at least 40 hours between treatments for an individual metastasis.
3053195|NCT02206321||Navigation total knee arthroplasty|Navigation total knee arthroplasty
3053196|NCT02206321||Conventional total knee arthroplasty|Conventional total knee arthroplasty
3053197|NCT02206308|Experimental|single arm|Three escalating single-dose groups of chimeric anti-CD20 monoclonal antibody(SCT400) : 250 mg/m2 , 375 mg/m2，500 mg/m2, once a week for 4 doses;
3053198|NCT02206295|Experimental|Treatment Sequence AB|"Subjects will receive Treatment A in Period 1 followed by Treatment B in Period 2. There will be a washout period lasting at least 6 days between treatments.~Treatment A: up-titration from Day 1-18 will performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with 8 film-coated tablets, 200 μg each, b.i.d. from Day 19 to the morning dose of Day 23.~Treatment B: up-titration from Day 1-18 will be performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with one single film-coated tablet, 1600 μg, b.i.d. from Day 19 to the morning dose of Day 23."
3053199|NCT02206295|Experimental|Treatment Sequence BA|"Subjects will receive Treatment B in Period 1 followed by Treatment A in Period 2. There will be a washout period lasting at least 6 days between treatments.~Treatment A: up-titration from Day 1-18 will performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with 8 film-coated tablets, 200 μg each, b.i.d. from Day 19 to the morning dose of Day 23.~Treatment B: up-titration from Day 1-18 will be performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with one single film-coated tablet, 1600 μg, b.i.d. from Day 19 to the morning dose of Day 23."
3053200|NCT02206269||Alair System|This is a single arm study with Alair system used.
3053201|NCT02206256|Active Comparator|Low calorie diet|Low calorie diet 2 weeks pre-operatively
3053202|NCT02206256|Active Comparator|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
3053203|NCT02206243||Embozene|Patients receiving Embozene microspheres
3053204|NCT02206230|Experimental|Hypofractionated radiation therapy|Hypofractionated radiation therapy of 60 Gy in 20 fractions (3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week. After a 4-week break, temozolomide days 1-5 every 28 days for 6 cycles.
3053205|NCT02206230|Active Comparator|Standard radiation therapy|Standard radiation therapy of 60 Gy in 30 fractions (2 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week. After a 4-week break, temozolomide days 1-5 every 28 days for 6 cycles.
3053206|NCT02206217|No Intervention|Single vision spectacle lens|Single vision lens with power for correcting distance refraction.
3053207|NCT02206217|Experimental|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus at the same time.
3053208|NCT02206204|Experimental|Group A|Subjects in Group A receive selexipag on Days 3 to 23 and moxifloxacin-matching placebo on Days 2 and 24. Selexipag administered orally, twice a day, for 21 days according to the following multiple dose up-titration regimen: 400 μg on Days 3-5, 600 μg on Days 6-8, 800 μg on Days 9-11, 1000 μg on Days 12-14, 1200 μg on Days 15-17, 1400 μg on Days 18-20, and 1600 μg on Days 21-23 (only morning dose on Day 23).
3053209|NCT02206204|Experimental|Group B1|Subjects in Group B1 receive 400 mg moxifloxacin, orally on Day 2 and moxifloxacin-matching placebo, orally on Day 24. Subjects receive placebo for selexipag, orally on Days 3 to 23.
3053583|NCT02203734|Sham Comparator|Light Pressure Massage|Light Pressure Massage Therapy
3053212|NCT02206178|Experimental|acetaminophen|"The purpose of this study is to assess the effectiveness of acetaminophen in association with N-acetylcysteine.~The objective of this study is to evaluate if the association in healthy volunteers of acetaminophen and N-acétylcystéine~- decrease the antinociceptive effect of acetaminophen in comparison to a group control~- and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme"
3053213|NCT02206178|Placebo Comparator|placebo|"- decrease the antinociceptive effect of acetaminophen in comparison to a group control~- and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme"
3053214|NCT02206165|Experimental|Candesartan 8mg + Amlodipine 5mg|Candesartan 8mg + Amlodipine 5mg, po, q.d.
3053215|NCT02206165|Experimental|Candesartan 8mg + Amlodipine 10mg|Candesartan 8mg + Amlodipine 10mg, po, q.d.
3053216|NCT02206165|Experimental|Candesartan 16mg + Amlodipine 5mg|Candesartan 16mg + Amlodipine 5mg, po, q.d.
3053217|NCT02206165|Experimental|Candesartan 16mg + Amlodipine 10mg|Candesartan 16mg + Amlodipine 10mg, po, q.d.
3053218|NCT02206165|Active Comparator|Candesartan 8mg|Candesartan 8mg, po, q.d.
3053219|NCT02206165|Active Comparator|Candesartan 16mg|Candesartan 16mg, po, q.d.
3053220|NCT02206165|Active Comparator|Amlodipine 5mg|Amlodipine 5mg, po, q.d.
3053221|NCT02206165|Active Comparator|Amlodipine 10mg|Amlodipine 10mg, po, q.d.
3053222|NCT02206152|Placebo Comparator|Placebo|Normal Saline IV infusion given during a controlled hyperinsulinemic hypoglycemic insulin clamp
3053223|NCT02206152|Experimental|Treatment with N-Acetyl Cysteine|N-acetyl cysteine IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
3053224|NCT02206126|Experimental|Energy restriction group|The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
3053225|NCT02206126|No Intervention|Control group|The control group was advised not to change their food intake.
3053226|NCT02206113|Experimental|Standing workstation - 16 weeks|This arm, Standing workstation - 16 weeks, received the intervention of a standing workstation for 16 weeks. For the first 8 weeks, the participants were instructed how long to stand per hour for an 8 hour shift. The second 8 weeks their use was monitored for sustainability.
3053227|NCT02206113|Active Comparator|Standing workstation - second 8 weeks|This arm, Standing workstation - second 8 weeks, received the intervention of a standing workstation for 8 weeks of the study. For the first 8 weeks, the worked at their normal desks without an intervention. The second 8 weeks they received a standing workstation and their use was monitored.
3053228|NCT02206100|Experimental|Cohort 1|100 mg PER977 (10 subjects); the dose may be repeated two (2) times after an approximate one (1) hour interval for a maximum total of three (3) doses
3053229|NCT02206100|Experimental|Cohort 2|200 mg PER977 (10 subjects); the dose may be repeated once at approximately one hour for a maximum total of two (2) doses
3053230|NCT02206100|Experimental|Cohort 3|300 mg PER977 (10 subjects); the dose may be repeated once at approximately one hour after the initial dose for a maximum of total of two (2) doses
3053231|NCT02206100|Experimental|Cohort 4|4 x 25 mg PER977 (10 subjects); study drug will be administered every 30 minutes for a total of 4 doses (cumulative dose of 100 mg PER977)
3053232|NCT02206087|Experimental|Cohort 1|100 mg PER977 or placebo administered following heparin sodium
3053233|NCT02206087|Experimental|Cohort 2|200 mg PER977 or placebo administered following heparin sodium
3053234|NCT02206087|Experimental|Cohort 3|300 mg PER977 or placebo administered following heparin sodium
3053235|NCT02206087|Experimental|Cohort 4|400 mg PER977 or placebo administered as a single agent followed by 3-day wash-out. A second dose of 400 mg PER977 or placebo will be administered following heparin sodium injection
3053236|NCT02206087|Experimental|Cohort 5|500 mg PER977 or placebo will be administered following heparin sodium injection
3053237|NCT02206087|Experimental|Cohort 6|600 mg PER977 or placebo will be administered following heparin sodium injection
3053238|NCT02206074|Active Comparator|T2DM|Crossover design where participants will start in the Beetroot juice condition, and after a washout period, move into the other condition.
3053239|NCT02206074|Placebo Comparator|Placebo|Crossover design where participants will start in the placebo condition, and after a washout period, move into the other condition.
3053240|NCT02206061|Experimental|School-Based Asthma Care for Teens (SB-ACT)|"SB-ACT consists of 2 components: Motivational Interviewing (MI) and Directly Observed Therapy (DOT) For the first 6-8 weeks, the teen will visit the school nurse to receive a daily dose of preventive asthma medication as directly observed therapy (DOT). The purpose of DOT is to establish a relationship with the nurse, learn proper medication technique, and experience potential benefits of consistent preventive therapy.~The second component, Motivational Interviewing (MI) counseling , will start 4-6 weeks after the start of DOT. A counselor will conduct 3 in-person MI sessions with the teen at school to enhance the teen's motivation to adhere to their asthma treatment plan. The 3 sessions consist of an initial 40 minute counseling session (4-6 weeks after start of DOT), and two 30 minute follow-up sessions 2 and 6 weeks later. This component consists of an evidence-based self-management program to help the teen begin to transition to independence with preventive medication use."
3053241|NCT02206061|Active Comparator|Directly Observed Therapy|For the first 6-8 weeks after enrollment, the teen will visit the school nurse once a day to receive a daily dose of preventive asthma medication as directly observed therapy (DOT).
3053242|NCT02206061|Active Comparator|Asthma Education|Asthma educators will provide an in-school asthma education program that will match the time and attention of the MI counseling portion of the primary intervention. Each teen will receive three 1-on-1 educational sessions at school, and sessions will cover 3 main topics: 1) lung physiology and asthma basics, 2) triggers, symptoms, and warning signs, and 3) medications and self-advocacy.
3053243|NCT02206048|Experimental|High-Resolution Microendoscopy (HRME)|Before participant's cold knife cone biopsy (CKC), topical application of 0.01% proflavine solution applied to cervix. HRME probe applied to cervix and high-resolution images obtained. Participant undergoes cervical biopsies of any abnormal areas noted with colposcopy and/or HRME. Immediately following the CKC, the removed surgical specimen evaluated. Proflavine reapplied to surgical specimen and repeat evaluation with HRME performed and high-resolution images obtained.
3053617|NCT02203539|Experimental|bright light|Intervention: exposure to bright light
3053244|NCT02206035|Experimental|Tacrolimus, Methotrexate and Tocilizumab (Tac/MTX/Toc)|Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant. Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m2 Days +3, +6 and +11. Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1
3053245|NCT02206022|Experimental|Remifentanil|Patients who undergone a Central Venous Catheter (CVC) insertion under remifentanil infusion
3053246|NCT02206022|Placebo Comparator|Placebo|Patients who undergone a Central Venous Catheter (CVC) insertion under placebo infusion
3053247|NCT02206009|Experimental|Collagen membrane|First, the recipient site is prepared, and the collagen membrane hydrated. The collagen membrane is sutured firmly against the prepared vascular bed with a long-lasting suture material. The subject is requested to minimize the amount of manipulation to the area to maintain graft stability.
3053248|NCT02205996|Active Comparator|Controls|Weight-matched healthy controls. Euglycaemic Hypoglycaemic insulin clamp. Using hyperinsulinaemic clamps, blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
3053249|NCT02205996|Active Comparator|Type 2 diabetes|People with a known diagnosis of type 2 diabetes. Euglycaemic Hypoglycaemic Insulin clamp. Using hyperinsulinaemic clamps, blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
3053250|NCT02205983|Other|Healthy adult volunteers|96 healthy adult volunteers will receive either placebo, low dose hydromorphone, high dose hydromorphone, or buprenorphine.
3053251|NCT02205970|Active Comparator|TENS active|TENS (interactive): frequency (90 and 150 pps) and pulse duration (300 and 400μs)
3053252|NCT02205970|Sham Comparator|TENS sham|Placebo lasting 35 minutes.
3053253|NCT02205957||Training quality|Tunisian residents in anesthesiology and intensive care
3053254|NCT02205944|No Intervention|Control Group|The control group will receive routine vascular access pre-op teaching and care.
3053255|NCT02205944|Experimental|Normal Exercise Group|"Group 1 (Normal Exercise Group): progressive handgrip exercise~Group 2 (Restricted Blood Flow Exercise Group): progressive handgrip exercise with controlled tourniquet"
3053256|NCT02205931|Experimental|Ketogenic diet|8 week trial of the ketogenic diet (KD) therapy. Children allocated to KD therapy will have their diets individually calculated by a paediatric dietitian with consideration of daily calorie requirements, adequate protein intake for growth and vitamin and mineral supplementation. All diets will be implemented according to a classical KD protocol, i.e. based on a ratio of fat to carbohydrate and protein that will usually be between 2:1 and 4:1.
3053257|NCT02205931|Active Comparator|Antiepileptic drug therapy|The control intervention will be drug therapy with the most appropriate further antiepileptic drug (AED) for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy according to a standardised manual (consensus document) written following the initial workshop of the paediatric neurologists from all the trial centres.
3053258|NCT02205918||Sham TMS|"Participants in this group will receive one, 30 minute session of inactive (sham) TMS."
3053259|NCT02205918||Active TMS|Participants in this group will receive one, 30 minute session of 1hz TMS.
3053260|NCT02205905|Experimental|14C PER977|Open-label, single-dose, non-randomized study of 14C PER977 in six healthy male subjects
3053261|NCT02205892|Active Comparator|Lupeol|
3053262|NCT02205892|Placebo Comparator|Vehicle|
3053263|NCT02205879|Experimental|pregabalin|
3053264|NCT02205879|Placebo Comparator|Placebo|
3053265|NCT02205866|Active Comparator|Group A|Non Obese patients
3053266|NCT02205866|Experimental|Group B|Obese patients
3053267|NCT02205853|Other|The patient-directed (PD) strategy|A single-faceted patient-directed (PD) strategy that will embed the change at patient level.
3053268|NCT02205853|Other|The multi-faceted (MF) strategy|A multi-faceted (MF) strategy that will embed the change at the patient, professional and organizational levels.
3053269|NCT02205840|Experimental|SI-614|
3053270|NCT02205840|Placebo Comparator|Placebo Vehicle|
3053271|NCT02205827|No Intervention|Single-arm|healthy volunteers
3053272|NCT02205814|Experimental|Fasitibant low dose|Drug: solution for intra-articular injection
3053273|NCT02205814|Experimental|Fasitibant intermediate dose|Drug: solution for intra-articular injection
3053274|NCT02205814|Experimental|Fasitibant high dose|Drug: solution for intra-articular injection
3053275|NCT02205814|Placebo Comparator|PLACEBO|Drug: solution for intra-articular injection
3053276|NCT02205801|Active Comparator|superficial cervical block, active|After induction of general anesthesia the surgeon will perform a bilateral superficial cervical plexus block using 0.25% Marcaine.
3053277|NCT02205801|Placebo Comparator|local wound infiltration, placebo|After induction of general anesthesia the surgeon will perform local wound infiltration using 0.9% Saline.
3053278|NCT02205801|Active Comparator|local wound infiltration, active|After induction of general anesthesia the surgeon will perform a local wound infiltration using 0.25% Marcaine.
3053279|NCT02205801|Placebo Comparator|superficial cervical block, placebo|After induction of general anesthesia the surgeon will perform a bilateral superficial cervical plexus block using 0.9% saline.
3053280|NCT02205775|Placebo Comparator|twice placebo before PCI|
3053281|NCT02205775|Experimental|atorvastatin 80 + 40 mg pre PCI|
3053282|NCT02205775|Experimental|rosuvastatin 40 + 40 mg before PCI|
3053283|NCT02205775|Experimental|rosuvastatin 5 + ezetimibe 10 mg twice before PCI|
3053319|NCT02205593|Active Comparator|Haut Tief patient education|patient group receives the educational program with regular follow-up visits (baseline, 3 months, 6 months, 9 months).
3053320|NCT02205580|Experimental|Sufentanil infusion rate 0.02μg•kg－1•h－1|Sufentanil infusion rate 0.02μg•kg－1•h－1 lasted for 48 hours
3053618|NCT02203539|Experimental|blue-enriched light|Intervention: exposure to blue-enriched light
3053284|NCT02205762|Experimental|Stratum I|"Stratum I The combination of Prednisone and vinblastine is the standard first-line combination for patients needing systemic therapy (Stratum I). Patients with MS-LCH and involvement of risk organs, who do not respond to 6-12 weeks of standard therapy, will be immediately switched to alternative treatment approaches (Stratum III or Stratum IV).~Further therapy prolongation (12 vs. 24 months) and intensification (± mercaptopurine) will further reduce the reactivation rate and the permanent consequences."
3053285|NCT02205762|Experimental|Stratum II|"A uniform intensive 24-week course consisting of prednisolone, vincristine and cytosine-arabinoside will be introduced in Stratum II for eligible patients. It will be followed by a continuation therapy to total treatment duration of 24 months. Participants who after SL-IT (week 24) have a response (NAD or AD better) are eligible for randomization between the continuation arms INDOMETHACIN and 6-MP/MTX (mercaptopurine and Methotrexate)."
3053286|NCT02205762|Experimental|Stratum III|"Salvage treatment for risk LCH To assess the efficacy of the combination 2-CdA/Ara-C (Cytosine Arabinoside and 2-chlorodeoxyadenosine) in MS-LCH (patients with risk organ involvement, who fail to respond to front-line (Stratum I) therapy.~The initial therapy consists of 2 courses of 2-CdA/Ara-C. Continuation of outlined treatment to be assessed at assigned intervals in each stratum."
3053287|NCT02205762|Experimental|Stratum IV|To determine the overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT). Salvage treatment option for MS-LCH patients with risk organ involvement, who fail to respond to front-line therapy (Stratum I) OR to the salvage 2- CdA/Ara-C regimen (Stratum III).
3053288|NCT02205762|Experimental|Stratum V|"Stratum V Monitoring and Treatment of isolated tumorous and neurodegenerative CNS-LCH~- Special regimens will be offered to patients with isolated tumorous CNS-LCH (repeated 2-CdA courses) and to patients with clinically manifested ND-CNS-LCH (+/- extracranial LCH manifestations). For the last group monotherapy with Ara-C courses or (Intravenous immunoglobulin)IVIG will be offered depending on physician's choice."
3053289|NCT02205762|Experimental|Stratum VI|"Natural history and management of other SS-LCH not eligible for stratum I group 2.~Treatment Options- Management (mostly wait & see and topical treatment) is left to the discretion of the treating physician. All treatments and disease responses must be reported in the database. In the case of uncertainties please contact your National Coordinator.~Patients being followed on Stratum VI who have progression of disease to MSLCH, multifocal bone disease or CNS-risk bone lesions should be enrolled on Stratum I therapy.~Patients being followed on Stratum VI who develop isolated tumorous or neurodegenerative CNS-LCH should be enrolled on Stratum V."
3053290|NCT02205749|Other|Study-specific consent model|• Review plain language brochure describing consent to a biobank based on the study-specific model of consent
3053291|NCT02205749|Other|Broad consent model|• Review plain language brochure describing consent to a biobank based on the broad model of consent
3053292|NCT02205749|Other|Notice consent model|• Review plain language brochure describing consent to a biobank based on the notice model of consent
3053293|NCT02205736|Other|Living Room Visit participants|Latino women who received breast health education while attending a Living Room Visit.
3053294|NCT02205723|Experimental|Smartphone Asthma Control|Smartphone Asthma Control
3053295|NCT02205723|Active Comparator|Control|Control group
3053296|NCT02205710|Experimental|Computerized cognitive training|Series of gamified tasks.
3053297|NCT02205710|Placebo Comparator|Computerized game training|Series of gamified tasks.
3053298|NCT02205697|Experimental|Implementation intention|The entire cohort will be asked to create an implementation intention to increase their intake of fruit and vegetables over the study period.
3053299|NCT02205684|Experimental|Physical activity|Aerobic High Intensity Training (HIT)
3053300|NCT02205684|Active Comparator|Computer game skills training|Playing Nintendo Wii Sports
3053301|NCT02205671|Experimental|Intervention|Building Better Caregivers Small-group Workshop
3053302|NCT02205658||Autism|Individuals, aged 18-95 years, with a pre-existing diagnosis of Autism Spectrum Disorder with or without a co-morbid diagnosis of Sensory Processing Disorder.
3053303|NCT02205658||Sensory Processing|Individuals, aged 18-95 years, with a pre-existing diagnosis of Sensory Processing Disorder with no co-morbid diagnosis of Autism Spectrum Disorder
3053304|NCT02205658||Typical|Typically functioning individuals aged 13-95 years
3053305|NCT02205645|Experimental|FibroFix™ Meniscus scaffold|The test article for this study is the FibroFix™ Meniscus scaffold, which has been developed for repair of defects of the meniscus. It is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
3053306|NCT02205632|Other|High myopic patients with lacker craks|
3053307|NCT02205632|Other|High myopic patients without lacker cracks|
3053308|NCT02205619|Experimental|Ultrasonic instrumentation|Prior to extraction, the teeth (N = 12) were randomly included into ultrasonic instrumentation (Air Flow Master Piezon®, EMS SA, Nyon - Swiss) treatment group
3053309|NCT02205619|Experimental|Hand instrumentation|Prior to extraction, the teeth (N = 12) were randomly included into hand curette (Gracey curettes, American Eagle, Missoula, MT, USA) treatment group hand instrumentation (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA)
3053310|NCT02205619|Experimental|subgingival airpolishing with glycine|"Prior to extraction, the teeth (N = 12) were randomly included into air-polishing (Air Flow Master Piezon®, EMS SA, Nyon - Swiss) with the glycine powder (Air-flow® Powder Perio, EMS) treatment group.~subgingival airpolishing with glycine(Air-flow® Powder Perio, EMS SA, Nyon, Swiss)"
3053311|NCT02205619|Experimental|ultrasonic following airpolishing|Prior to extraction, the teeth (N = 12) were randomly included into ultrasonic following airpolishing ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) with the glycine powder treatment group
3053312|NCT02205606|Active Comparator|HGP0816 5mg|
3053313|NCT02205606|Active Comparator|HGP0816 10mg|
3053314|NCT02205606|Active Comparator|HGP0816 20mg|
3053315|NCT02205606|Experimental|HCP1306 5/10mg|
3053316|NCT02205606|Experimental|HCP1306 10/10mg|
3053317|NCT02205606|Experimental|HCP1306 20/10mg|
3053318|NCT02205593|Placebo Comparator|Control|patient group receiving regular follow-up visits (baseline, 3 months, 6 months, 9 months)
3053619|NCT02203539|Experimental|normal light|Intervention: exposure to normal light
3053322|NCT02205580|Experimental|Sufentanil infusion rate 0.04μg•kg－1•h－1|Sufentanil infusion rate 0.04μg•kg－1•h－1 lasted for 48 hours
3053323|NCT02205567||Group 2|1000 mg/day of Bergamot-derived product
3053324|NCT02205567||Group 1|500 mg/day of Bergamot-derived product
3053325|NCT02205554|Active Comparator|Omnitram-Tramadol-Placebo|Omnitram 20 mg every 6 hours for 9 doses, followed by Tramadol 50 mg every 6 hours for 9 doses, followed by Placebo every 6 hours for 9 doses.
3053326|NCT02205554|Active Comparator|Tramadol-Placebo-Omnitram|Tramadol 20 mg every 6 hours for 9 doses, followed by Placebo every 6 hours for 9 doses, followed by Omnitram 20 mg every 6 hours for 9 doses.
3053327|NCT02205554|Active Comparator|Placebo-Omnitram-Tramadol|Placebo every 6 hours for 9 doses, followed by Omnitram 20 mg every 6 hours for 9 doses, followed by Tramadol 50 mg every 6 hours for 9 doses.
3053328|NCT02205541|Experimental|Eculizumab|"300mg concentrate for solution for infusion. According to the patient body weight, there will be 3 to 5 injections administered in IV infusion at D0, D7, D14, D21 and D28.~Eculizumab (ECZ) will be administrated intravenously as a 30-minute injection."
3053329|NCT02205541|Placebo Comparator|Placebo|"Infusion of a solution with 5% glucose. The administration scheme will be the same as the Eculizumab arm : there will be 3 to 5 injections at D0, D7, D14, D21 and D28.~Placebo will be administrated intravenously as a 30-minute injection."
3053330|NCT02205528|Placebo Comparator|Treatment Period: Placebo QD|Participants will receive daily SC placebo injections during the 12-week, double-blind treatment period.
3053331|NCT02205528|Experimental|Treatment Period: NNC0090-2746 QD|Participants will receive daily 1.8-mg SC injections of NNC0090-2746 during the 12-week, double-blind treatment period.
3053332|NCT02205528|Active Comparator|Treatment Period: Liraglutide QD|Participants will receive open-label liraglutide via SC injection during the 12-week treatment period. The dose scheme will be as follows: 0.6 milligrams (mg) each day during Week 1, followed by 1.2 mg each day during Week 2, and 1.8 mg each day from Weeks 3 to 12.
3053333|NCT02205515|Other|Radiotherapy|SBRT or EBRT
3053334|NCT02205502|Experimental|Lidocaine|"Proper amount of lidocaine will be injected lacerated wound.~dosage form: fluid~dosage: not exceeding 1mg/kg~frequency: once~duration: n/a"
3053335|NCT02205502|Placebo Comparator|Normal saline|Normal saline will be used as a placebo for lidocaine
3053336|NCT02205489|Experimental|GZ402673 LEMTRADA|First course: Intravenous infusion for 5 consecutive days. Second course (will occur 12 months after the first course of treatment): Intravenous infusion for 3 consecutive days.
3053337|NCT02205476|Experimental|Group 1|The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 1 = 4 doses).
3053338|NCT02205476|Experimental|Group 2|The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 2 = 3 doses).
3053339|NCT02205463|Experimental|KD019|Patients with HER2+ metastatic or unresectable adenocarcinoma of the esophagus, gastroesophageal junction or stomach will receive trastuzumab and mFOLFOX-6 in combination with KD019 to evaluate the safety, toxicity and MTD of this regimen. There will be four dose cohorts for KD019. KD019 will be administered orally continuously daily on a 28 day cycle. Trastuzumab and mFOLFOX-6 will be administered as infusions every 2 weeks at standard doses without escalation. The sequence on the days when all agents are administered will be KD019 followed by trastuzumab and mFOLFOX-6.
3053340|NCT02205450||Children under 2 years with Prader-Willi Syndrome|
3053341|NCT02205437||Controls|Healthy subjects without psychotic disorder.
3053342|NCT02205437||Drug-naive patients|Drug-naive (never medicated) schizophrenia patients.
3053343|NCT02205437||Patients responder to treatment|Patients with a good clinical response to treatment (define by a marked improvement of positive symptoms) at 3 months and at 1 year.
3053344|NCT02205437||Patients non-responder to treatment|Patients with a poor clinical response to treatment at 3 months and at 1 year.
3053345|NCT02205437||Patients with metabolic side effects|Patients with metabolic side effects associated to treatment.
3053346|NCT02205437||Patients with non-metabolic side effects|Patients with no metabolic side effects associated to treatment.
3053347|NCT02205424||Ischaemic stroke patients|Patients who have suffered an ischaemic stroke, as determined clinically and verified with imaging (CT brain; MRI).
3053348|NCT02205424||Healthy control participants|People who have never suffered a stroke, and are matched to the ischaemic stroke patient group according to age, education, and vascular risk factors.
3053349|NCT02205411|Experimental|HeartAssist 5® VAD System|Implant of the HeartAssist 5® VAD System
3053350|NCT02205411|Active Comparator|Control VAD|
3053351|NCT02205398|Experimental|c-MET positive mCRC and HNSCC|c-MET positive and K/NRAS WT mCRC and c-MET positive HNSCC patients
3053352|NCT02205385|Active Comparator|Traditional Traction Neurectomy|"Patients will be randomized to either the current standard of care surgical treatment for neuromas (traction neurectomy) or the experimental intervention (targeted reinnervation). This arm involves the use of the current standard of care surgical treatment.~Patients will undergo the same pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). In the active comparator arm, gentle traction will be applied to the nerve while excising the neuroma (traction neurectomy) allowing the nerve to retract more proximally. It may be buried in healthy muscle to further pad the nerve ending. The intention is to place the inevitable recurrent end-neuroma away from superficial locations in which it is likely to become mechanically irritated."
3053353|NCT02205385|Experimental|Targeted Muscle Reinnervation|"Patients will be randomized to either the current standard of care surgical treatment for neuromas (traction neurectomy) or the experimental intervention (targeted reinnervation). This arm involves the use of the experimental surgical treatment.~Patients will undergo the same pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). Targeted muscle reinnervation involves transfer of residual nerves to otherwise redundant target muscles. Native motor innervation of the target muscle is cut, and the residual nerves—after excision of end-neuromas—are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle."
3053354|NCT02205372|Experimental|MT-3995|
3053355|NCT02205372|Placebo Comparator|Placebo|
3053356|NCT02205359|Experimental|aCRT ON|The aCRT algorithm has been developed to provide RV-synchronized LV pacing when intrinsic AV conduction is normal or BiV pacing otherwise
3053357|NCT02205359|Active Comparator|aCRT OFF|Standard CRT
3053359|NCT02205333|Experimental|MEDI6469 6 mg/kg|Participants received MEDI6469 6 milligram/kilogram (mg/kg) as a single intravenous (IV) administration on Day 1
3053360|NCT02205333|Experimental|MEDI6469 10 mg/kg|Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1
3053361|NCT02205333|Experimental|MEDI6469 2 mg/kg+Tremelimumab 3 mg/k|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 3 mg/kg as IV administration on Day 1 then every 4 weeks (Q4W) for 6 doses, after which every 12 weeks (Q12W) for 2 doses or until PD
3053362|NCT02205333|Experimental|MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 10 mg/kg as IV administration on Day 1 then Q4W for 6 doses after which Q12W for 2 doses or until progression of disease (PD)
3053363|NCT02205333|Experimental|MEDI6469 2 mg/kg+Durvalumab 3 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 3 mg/kg as IV administration on Day 1 then every 2 weeks (Q2W) for 12 months or until PD
3053364|NCT02205333|Experimental|MEDI6469 2 mg/kg+Durvalumab 10 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
3053365|NCT02205333|Experimental|MEDI6469 10 mg/kg+Durvalumab 10 mg/kg|Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
3053366|NCT02205333|Experimental|MEDI6469 2 mg/kg+Rituximab 375 mg/m^2|Participants received MEDI6469 2 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed complete response (CR) plus 1 cycle, or PD plus rituximab 375 mg/m^2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
3053367|NCT02205333|Experimental|MEDI6469 10 mg/kg+Rituximab 375 mg/m^2|Participants received MEDI6469 10 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed CR plus 1 cycle, or PD plus rituximab 375 mg/m2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
3053368|NCT02205320|Experimental|Treatment Sequence I (DRL, A, B)|Patients will receive study drugs in the following cross-over sequence: DRL_PG, Pegfilgrastim Form A, Pegfilgrastim Form B. Each drug is administered as a single, 6 mg, subcutaneous injection.
3053369|NCT02205320|Experimental|Treatment Sequence II (DRL, B, A)|Patients will receive study drugs in the following cross-over sequence: DRL_PG, Pegfilgrastim Form B, Pegfilgrastim Form A. Each drug is administered as a single, 6 mg, subcutaneous injection.
3053370|NCT02205320|Experimental|Treatment Sequence III (A, DRL, B)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form A, DRL_PG, Pegfilgrastim Form B. Each drug is administered as a single, 6 mg, subcutaneous injection.
3053371|NCT02205320|Experimental|Treatment Sequence IV (A, B, DRL)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form A, Pegfilgrastim Form B, DRL_PG. Each drug is administered as a single, 6 mg, subcutaneous injection.
3053372|NCT02205320|Experimental|Treatment Sequence V (B, A, DRL)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form B, Pegfilgrastim Form A, DRL_PG. Each drug is administered as a single, 6 mg, subcutaneous injection.
3053373|NCT02205320|Experimental|Treatment Sequence VI (B, DRL, A)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form B, DRL_PG, Pegfilgrastim Form A. Each drug is administered as a single, 6 mg, subcutaneous injection.
3053374|NCT02205307|Experimental|PINPOINT or SPY Elite|A low anterior resection will be performed according to the surgeon's standard practice with the addition of intraoperative imaging using PINPOINT near infrared fluorescence imaging or SPY Elite intraoperative imaging to assess colon and rectal tissue perfusion
3053375|NCT02205307|No Intervention|STANDARD|A low anterior resection will be performed according to the surgeon's standard practice
3053376|NCT02205294|No Intervention|Assessment Only|Subjects will have an osteopathic assessment to determine areas of tension in specific areas of the body. These areas include: the thoracic diaphragm, the heart and pericardium, the iliac fascia, the femoral sheath, the sartorius muscle, the pelvic diaphragm and the interosseous membrane (IM) of the lower extremity
3053377|NCT02205294|Active Comparator|Assessment and Treatment|Subjects will have an osteopathic assessment to determine areas of tension in specific areas of the body. These areas of tension will receive osteopathic treatment, using myofascial release techniques. These areas include: the thoracic diaphragm, the heart and pericardium, the iliac fascia, the femoral sheath, the sartorius muscle, the pelvic diaphragm and the interosseous membrane (IM) of the lower extremity
3053378|NCT02205281|No Intervention|Standard Care|
3053379|NCT02205281|Experimental|Lifestyle Intervention|
3053380|NCT02205268|Experimental|Neurofeedback training|20 sessions of near infrared spectroscopy neurofeedback training to increase activation to bilateral prefrontal cortex. Two sessions per week.
3053381|NCT02205255|Experimental|Azithromycin|N = 250 From day 1 up to and including day 3: 500 mg azithromycin PO once a day From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days
3053382|NCT02205255|Placebo Comparator|Placebo|N = 250 From day 1 up to and including day 3: 500 mg placebo PO once a day From day 4 up to and including day 90: 250 mg placebo PO once every 2 days
3053383|NCT02205242|Experimental|Azithromycin|"N = 250 From day 1 up to and including day 3: 500 mg azithromycin PO once a day From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days~N= 30 During 7 days post discharge from hospital (0 months), 3 months and 9 months, the patient will wear the Dynaport® which will register the patient's physical activity"
3053384|NCT02205242|Placebo Comparator|Placebo|"N = 250 From day 1 up to and including day 3: 500 mg placebo PO once a day From day 4 up to and including day 90: 250 mg placebo PO once every 2 days~N= 30 During 7 days post discharge from hospital (0 months), 3 months and 9 months, the patient will wear the Dynaport® which will register the patient's physical activity"
3053385|NCT02205229||Patients receiving a topical compounded medication|
3053386|NCT02205216|Active Comparator|Active tDCS|Active tDCS combined with a rehabilitative intervention consisting of cognitive training and sensory cueing.
3053387|NCT02205216|Sham Comparator|Sham tDCS|Sham tDCS combined with a rehabilitative intervention consisting of cognitive training and sensory cueing.
3053457|NCT02204722|Experimental|Group A|the group who has more than 10% of the BCR-ABL(IS) level for three months will maintain the dose, 400mg/day of Imatinib, after three months.
3053388|NCT02205203|Active Comparator|Face-to-Face w/ Anxiety Coach (FTF-AC)|In this condition therapists will provide 6 to 12 50-minute, face-to-face therapy sessions using Mayo Clinic Anxiety Coach. The sessions are expected to initially occur weekly and be within the office although the therapist can leave the office to conduct exposure. The therapist is expected to utilize Anxiety Coach within the session, encourage the patient to use the application to complete homework, and review progress in-session via the web-based portal.
3053389|NCT02205203|Experimental|Treatment as Usual (TAU)|In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure). Therapists can communicate with patients between sessions (e.g., phone calls), as long as this medium is not the primary mode of treatment.
3053390|NCT02205190|Other|Treatment AB|"Treatment A (1 day) → wash-out(7days) → Treatment B (1 day)~Treatment A : Fimasartan and Rosuvastatin~Treatment B : Fimasartan/Rosuvastatin combination"
3053391|NCT02205190|Other|Treatment BA|"Treatment B (1 day) → wash-out(7days) → Treatment A (1 day)~Treatment A : Fimasartan and Rosuvastatin~Treatment B : Fimasartan/Rosuvastatin combination"
3053392|NCT02205177|Active Comparator|Face-to-Face w/ Anxiety Coach (FTF-AC)|In this condition therapists will provide 6 to 12 50-minute, face-to-face therapy sessions using Anxiety Coach. The sessions are expected to initially occur weekly and be within the office although the therapist can leave the office to conduct exposure. The therapist is expected to utilize Anxiety Coach within the session, encourage the patient to use the application to complete homework, and review progress in-session via the web-based portal.
3053393|NCT02205177|Experimental|Minimal Contact w/ Anxiety Coach (MC-AC)|In this condition the therapist will meet with the patient and primary care giver for an initial 50-minute, face-to-face session to provide a tutorial on the use of Anxiety Coach. The therapist is expected to review the patient's progress via the web-based portal and communicate with the patient electronically at least once per week for a total of at least 6 and up to 12 weeks of intervention. Therapists will be allowed 2 additional face-to-face sessions if necessary and still remain in protocol.
3053394|NCT02205164|Experimental|Palonosetron + Aprepitant|Oral aprepitant will be given on days 1-3 (day 1, 125 mg 1 h before chemohterapy; days 2-3, 80 mg) multiple intravenous bolus of palonosetron 0.25 mg, 30 minutes before chemotherapy, every other single days, for a minimum of 2 administration (day 1, 3), in case of a 3 days chemotherapy regimen, and a maximum of 5 doses (day 1,3,5,7, 9) in case of a 10 days chemotherapy.
3053395|NCT02205164|Active Comparator|Palonosetron|multiple intravenous bolus of palonosetron 0.25 mg, 30 minutes before chemotherapy, every other single days, for a minimum of 2 administration (day 1, 3), in case of a 3 days chemotherapy regimen, and a maximum of 5 doses (day 1,3,5,7, 9) in case of a 10 days chemotherapy.
3053396|NCT02205151|Other|Treatment AB|"Treatment A (1 day) → wash-out(14days) → Treatment B (1 day)~Treatment A : Fimasartanm and Amlodipine~Treatment B : Fimasartan/Amlodipine combination"
3053397|NCT02205151|Other|Treatment BA|"Treatment B (1 day) → wash-out(14days) → Treatment A (1 day)~Treatment A : Fimasartanm and Amlodipine~Treatment B : Fimasartan/Amlodipine combination"
3053398|NCT02205138|Experimental|ALLOB® cells with ceramic scaffold|ALLOB® cells with ceramic scaffold Implantation
3053399|NCT02205112|Experimental|Nemonoxacin 500 mg|Nemonoxacin 500mg/250mL, intravenous administration, once daily for 7~14 days
3053400|NCT02205112|Active Comparator|Levofloxacin 500mg|Levofloxacin: 500mg/100mL, intravenous administration, once daily for 7~14 days
3053401|NCT02205099|Experimental|SKL15508 High Dose|SKL15508 High Dose
3053402|NCT02205099|Experimental|SKL15508 Medium Dose|SKL15508 Medium Dose
3053403|NCT02205099|Experimental|SKL15508 Low Dose|SKL15508 Low Dose
3053404|NCT02205099|Placebo Comparator|Placebo|Placebo
3053405|NCT02205086|Other|Diagnosis|Test diagnostic decision support software
3053406|NCT02205073|Placebo Comparator|Dosing Period 1|
3053407|NCT02205073|Active Comparator|Dosing Period 2|
3053408|NCT02205073|Experimental|Dosing Period 3|
3053409|NCT02205060|Experimental|virtual reality exposure therapy (VRET)|
3053410|NCT02205060|Experimental|cognitive and behavioral approaches therapy without VRET|
3053411|NCT02205047|Active Comparator|Standard chemotherapy|Cisplatin/capecitabine or cisplatin/5-fluorouracil
3053412|NCT02205047|Experimental|Experimental arm 1|Cisplatin/capecitabine plus trastuzumab or cisplatin/5-fluorouracil plus trastuzumab
3053413|NCT02205047|Experimental|Experimental arm 2|cisplatin/capecitabine plus trastuzumab and pertuzumab or cisplatin/5-fluorouracil plus trastuzumab and pertuzumab
3053414|NCT02205034|Active Comparator|first arm|4IU of oxytocin every other day
3053415|NCT02205034|Active Comparator|second arm|4 IU of oxytocin daily
3053416|NCT02205034|Active Comparator|third arm|4 IU of oxytocin twice daily
3053417|NCT02205021||All subjects|
3053418|NCT02205008|Active Comparator|Arm A|curative resection of the stomach with D2 plus intraperitoneal chemotherapy plus adjuvant systemic chemotherapy with S-1
3053419|NCT02205008|Placebo Comparator|Arm B|curative resection of the stomach with D2 plus adjuvant systemic chemotherapy with S-1
3053420|NCT02204995|Active Comparator|Trapeziectomy with LRTI|Trapeziectomy with Ligament Reconstruction and Tendon Interposition
3053421|NCT02204995|Active Comparator|Trapeziectomy|Trapeziectomy
3053422|NCT02204982|Experimental|IPI-145 + Rituximab|"IPI-145 is administered orally and supplied as 5 mg and 25 mg formulated capsules.~Rituximab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
3053423|NCT02204982|Placebo Comparator|Placebo + Rituximab|"Placebo is administered orally and supplied as formulated capsules to match the active 5 mg and 25 mg capsules.~Rituximab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
3053455|NCT02204735|Experimental|EVENING|Participants will be instructed to consume 20% of their energy intake in their first eating bout, 30% in their second eating bout, and 50% in their third eating bout. For example, a participant prescribed a 1200 kcal/d diet needs to consume 240 kcal in their first eating bout, 360 kcal in their second bout, and 600 kcal in their third bout. Participants will be provided with sample meal plans meeting this prescription.
3053424|NCT02204969|Sham Comparator|Transcranial magnetic stimulation|All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
3053425|NCT02204969|Placebo Comparator|lithia water|"Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water~Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels"
3053426|NCT02204956|Experimental|Sustained Care|A 40-minute, in-hospital motivational counseling session about smoking cessation, 8 Interactive Voice Response (IVR) phone calls and/or texts over 90 days, including the possibility of a warm transfer to a telephone tobacco quit line and up to 8-weeks of free transdermal nicotine patches.
3053427|NCT02204956|Active Comparator|Usual Care|A brief 5-10 minute tobacco education session that all hospitalized smokers will receive, delivered by a hospital nurse. During this session, they will be provided with written handouts describing the stages of readiness for change in quitting, self-monitoring of smoking, self-management of smoking situations, relapse prevention, managing stress, other quitting tips and use of nicotine replacement therapy.
3053428|NCT02204943|Experimental|Bone Biopsy and Circulating Tumor Cell Samples|
3053429|NCT02204930|Experimental|Haemostat|PeproStat
3053430|NCT02204917|Experimental|ceVUS with the use of OPTISON & VCUG in the same session|OPTISON will be resuspended just before the performance of ceVUS examination, and 0.5% OPTISON solution will be used for intravesical administration. The exact OPTISON dose (ml) will be adjusted according to the age-related bladder filling capacity with a dose (ml) range from 0.3 mL in newborns to 3 mL in 18 year-old children. VCUG exam will be performed using the same bladder catheter with intravesical administration of the x-ray contrast agent.
3053431|NCT02204904||Allo-HSCT prospective|Subjects who will be consented before they received an allo-HSC infusion. They will be consented and enrolled on the study during the Screening Period.
3053432|NCT02204904||Allo-HSCT partial prospective/retrospective|Subjects who will be consented after they received an allo-HSC infusion but before they reach 24 months post-infusion on or after January 1, 2013. Subjects in this cohort will participate prospectively in at least the Month 24 Visit in order to obtain prospective on-study data for this and all visits after Month 24
3053433|NCT02204904||Allo-HSCT retrospective|Subjects who received an allo-HSC infusion on or after January 1, 2013 and died before study data collection.
3053434|NCT02204891|Experimental|Probiotics in SIBO|Administration of probiotics in patients with IBS and SIBO
3053435|NCT02204891|Active Comparator|Probiotics|Administration of probiotics in patients with IBS without SIBO
3053436|NCT02204878|Placebo Comparator|A|1ml of saline was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. 1ml saline Q12h will be given within 72 hours after surgery
3053437|NCT02204878|Experimental|AT|Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
3053438|NCT02204865||Pacemaker/ICD with ApneaScan|Patients with HFREF due to receive a pacemaker or ICD with ApneaScan function
3053439|NCT02204852|Experimental|Iloprost+eptifibatide|Co-administration of 1 ng/kg/min Ilomedin® and 0.5 µg/kg/min Integrilin® as 48h continuous i.v infusions
3053440|NCT02204852|Placebo Comparator|Saline|Double dummy 0.9% saline as 48h continuous i.v infusion
3053441|NCT02204839|Experimental|Basal dose reduction|Total daily basal (Glargine, Lantus, Sanofi-Aventis, or Detemir, Levemir, Novo Nordisk) reduction of 20% versus normal basal dose.
3053442|NCT02204826|Experimental|V + KRG group (n = 20)|three capsules of KRG (500 mg/dose) daily and varicocelectomy.
3053443|NCT02204826|Active Comparator|non-V + KRG group|three capsules of KRG (500 mg/dose) daily
3053444|NCT02204826|Active Comparator|V + P group (n = 20)|placebo capsules and varicocelectomy
3053445|NCT02204826|Placebo Comparator|non-V + P group|non-V + P group (n = 20) placebo capsules
3053446|NCT02204813|Experimental|Post RYGB Surgery|Healthy, weight stable individuals, with previous Roux-en-Y gastric bypass surgery. No clinical evidence of type 2 diabetes before and after surgery. Each participant will receive placebo or the indicated doses of xenin-25.
3053447|NCT02204800||Small clear cell renal tumors (Wild Type)|No specific chromatin remodeling gene (CRG) alteration
3053448|NCT02204800||Small clear cell renal tumors (Mutant)|Specific chromatin remodeling gene (CRG) alteration
3053449|NCT02204787|Experimental|active tDCS|Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a 2 mA intensity during 20 minutes.
3053450|NCT02204787|Sham Comparator|Sham tDCS|Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a sham stimulation during 20 minutes. Initial stimulation followed by turning off the device as to ensure blinding.
3053451|NCT02204774||Dilatated or aneurysmatic Aorta|Complete cohort, which will be followed over 3 years
3053452|NCT02204761|Experimental|Treatment (proton beam radiation therapy)|Patients undergo proton beam radiation therapy per standard of care.
3053453|NCT02204748||DePuy Attune PS FB TKA|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system implanted by a single surgeon at least three months post-operative.
3053454|NCT02204735|Experimental|MORNING|Participants will be instructed to consume 50% of their energy intake in their first eating bout, 30% in their second eating bout, and 20% in their third eating bout. For example, a participant prescribed a 1200 kcal/d diet needs to consume 600 kcal in their first eating bout, 360 kcal in their second bout, and 240 kcal in their third bout. Participants will be provided with sample meal plans meeting this prescription.
3053456|NCT02204722|Experimental|Group B|the group who has more than 10% of the BCR-ABL(IS) level for three months will receive 600mg/day of Imatinib after three months.
3053458|NCT02204709|Experimental|Diploid Trout entrees|Subjects will consume a 200 gram portion of 2N trout (diploid; two sets of chromosomes) twice weekly in a prepared meal.
3053459|NCT02204709|Experimental|Triploid Trout entrees|Subjects will consume a 200 gram portion of 3N trout (triploid; three sets of chromosomes) twice weekly in a prepared meal.
3053460|NCT02204709|Experimental|Tilapia entrees|Subjects will consume a 200 gram portion of tilapia twice weekly in a prepared meal.
3053461|NCT02204696||Tonsillectomy|All participants will undergo baseline sleep study, a second preoperative sleep study after a period of watchful waiting, and a postoperative sleep study.
3053462|NCT02204683|Other|Aflibercept|Subjects who have had a vitrectomy previously
3053463|NCT02204683|Other|Aflibercept in Non-Vitrectomized eyes|Patients who have not had vitrectomy.
3053464|NCT02204670||Overweight Adolescents Performing Resistance Training|Overweight adolescents that meet pre-specified enrollment criteria will all undergo supervised resistance exercise for a 6-week period. Prior to training, all participants will undergo a single bout of resistance training to determine the acute release of Irisin with resistance training. This will be the primary exposure variable. After the acute session, all participants will perform resistance training three times per week for a period of 4 weeks. During each session participants will perform 3 sets of 8-12 repetitions (60-85% of 1RM) for major muscle groups (quadriceps, shoulders, and pectoral).
3053465|NCT02204657|Active Comparator|Continuous Glucose Monitoring System|Patients in this arm will receive Continuous Glucose Monitoring System (CGMS) at 28,32 and 36 weeks of gestation and their insulin titrated according to the CGMS results.
3053466|NCT02204657|No Intervention|Control|Patients in this arm will not receive any Continuous Glucose Monitoring System( CGMS) and the insulin titration will be made based on their fingerstick sugar readings.
3053467|NCT02204644|Experimental|Flumatinib mesylate tablets|Flumatinib mesylate tablets 600mg qd for 12 months
3053468|NCT02204644|Active Comparator|Imatinib mesylate tablets|Imatinib mesylate tablets 400mg qd for 12months
3053469|NCT02204631|Experimental|Head and Neck Educational Handbook|"Prior to starting treatment, patients will be approached for trial participation and baseline questionnaires (demographics, psychological distress, symptom burden, and illness perception).~After enrollment and baseline data collection, the participant will be given the handbook. The clinician giving out the handbook will give an overview of the handbook and flip through the important sections. The clinician will encourage the participant to bring it back and forth.~Participants will complete questionnaires at 3 weeks into treatment and 2 weeks after treatment has ended (information satisfaction, psychological distress, symptom burden, and illness perception)."
3053470|NCT02204631|No Intervention|Non Head and Neck Educational Handbook|"Prior to starting treatment, patients will be approached for trial participation and baseline questionnaires (demographics, psychological distress, symptom burden, and illness perception).~The first group of participants will not receive the handbook but will receive the current standard care in the head and neck disease center.~Participants will complete questionnaires at 3 weeks into treatment and 2 weeks after treatment has ended (information satisfaction, psychological distress, symptom burden, and illness perception).~At completion of Phase I, all 30 participants will also be given a copy of the handbook and an accompanying questionnaire."
3053471|NCT02204618|Experimental|cochlear implantation|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
3053472|NCT02204618|Other|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
3053473|NCT02204605|No Intervention|Control|Visits are not videotaped
3053474|NCT02204605|Experimental|Videoed Patients|Patients will have their visit videotaped.
3053475|NCT02204579|Experimental|NPSP795|intravenous
3053476|NCT02204566|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI Imaging system.
3053477|NCT02204540|Experimental|Monitoring by webcam|Participants will perform a task for a mock clinical study (e.g., swallowing a pill, consuming food) while being recorded and monitored by webcam.
3053478|NCT02204540|Active Comparator|In-person monitoring|Participants will perform a task for a mock clinical study (e.g., swallowing a pill, consuming good) while being monitored in-person.
3053479|NCT02204527|Experimental|vitamin D3|supplementation of 100.000 IU of vitamin D3
3053480|NCT02204527|Placebo Comparator|Placebo pill|Placebo
3053481|NCT02204514||Surgery for external snapping hip|
3053482|NCT02204501|Experimental|Vapendavir 528 mg QD|Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
3053483|NCT02204501|Experimental|Vapendavir 264 mg BID|Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
3053484|NCT02204488|Active Comparator|Total Joint Arthroplasty|Total Joint Arthroplasty
3053485|NCT02204488|Active Comparator|Trapeziectomy|Trapeziectomy
3053486|NCT02204475|Active Comparator|BOC/PR|All participants begin treatment with a 4-week lead-in of PR followed by 24 weeks of BOC/PR. At Treatment Week (TW) 28 TN participants who have undetectable HCV RNA at TW 8 will complete BOC/PR therapy. At TW 28 TN participants who have detectable HCV RNA at TW 8, as well as prior relapsers and prior partial responders, will continue on BOC/PR for an additional 8 weeks and then continue on PR for an additional 12 weeks. At TW 28 all cirrhotics and previous null responders will continue on BOC/PR for an additional 20 weeks.
3053487|NCT02204475|Experimental|Grazoprevir/Elbasvir|Participants will undergo treatment with grazoprevir 100 mg + elbasvir 50 mg for 12 weeks.
3053488|NCT02204462|Experimental|Newly diagnosed breast cancer|Patients with newly-diagnosed invasive and/or intraductal breast cancer detected by core needle or vacuum-assisted biopsy (i.e. index cancer). Patients will undergo FBnTP PET imaging for detection of malignant breast cancer.
3053489|NCT02204449|Experimental|Cardiac Rehabilitation Peer Mentorship|Trained cardiac rehabilitation (CR) peer mentors will visit cardiac inpatients in the hospital to provide patients with information on CR. During this visit the CR mentors will discuss the benefits of CR, stress the importance of getting a referral, and arrange a time to call the patient/participant at home to find out about their CR progress. One week post-discharge the peer mentor will mail a card to the patient to remind them of the planned call. Two weeks post-discharge the peer mentor will call the patient at home to determine if they were referred and if they are planning to attend CR. If any barriers are stated by patient the peer mentors will work with the patient to develop possible solutions. Patients can request up to two additional phone calls from the mentors.
3053490|NCT02204449|No Intervention|Usual Care|Cardiac inpatients will not be visited by the cardiac rehabilitation (CR) peer mentor. They will instead receive usual care involving care from health care providers (i.e. nurses and doctors) as well as allied health professionals such as physiotherapists. In addition, some may be visited by general volunteer cardiac mentors.
3053491|NCT02204436|Other|Emulsion and gel|A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
3053492|NCT02204423|Experimental|Trans-Radial PCI|
3053493|NCT02204410|Experimental|Omega-3 Fatty Acids and Stimulant Treatment|Participants will receive open-label treatment with Omega-3 Fatty Acids. All participants must also be treated with a stable dose of a traditional ADHD medication at the time of enrollment.
3053494|NCT02204397|Experimental|INGAP Peptide, Ustekinumab|INGAP Peptide, Ustekinumab subcutaneous
3053495|NCT02204384|Experimental|HFD Meal: high fiber from food|HFD Meal: high amount of fiber from diet food sources (total fiber 9.7g; soluble fiber 5.4g)
3053496|NCT02204384|Experimental|HFS Meal: High fiber from supplement|HFS Meal: high amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - Fiber Mais, Nestlé
3053497|NCT02204384|Experimental|UF Meal: usual amount of fiber|UF Meal: usual amount of fiber (total fiber 2.4g; soluble fiber 0.8g)
3053498|NCT02204371|Experimental|Part A- Dose Escalation phase|Part A will be an open label, dose-escalation study in which 4 cohorts of approximately 6 subjects will receive increasing doses of pazopanib for a maximum of 12 weeks. The dose in the first cohort will be 50mg per day and the maximum dose in a cohort will be 400 mg per day. Dose escalation will not occur if the predefined safety stopping criteria are met or at least 4 subjects in a cohort have demonstrated efficacy. Cohort 4 receiving 400 mg dosing schedule may involve cycles of up to 3 weeks of active treatment, followed by up to 3 weeks wash-out (instead of 12 weeks continuous dosing). Decision will be based on safety data obtained from lower doses
3053499|NCT02204371|Experimental|Part B-Dose Optimization phase|If efficacy is demonstrated in Part A with an acceptable safety profile, Part B will be initiated to further define the optimal dose(s) including dose duration/schedule and to provide further support for the proof of mechanism. Approximately 15 subjects will participate and will be randomised to active or placebo in a ratio of 3:2. This part of the study will be double-blind
3053500|NCT02204358|Experimental|autologous bone marrow stem cells|Using collagen scaffold loaded with autologous bone marrow stem cells to treat severe intrauterine adhesions or endometrial dysplasia.
3053501|NCT02204345|Experimental|RO5479599 + Carboplatin + Paclitaxel|RO5479599 800 milligrams (mg) will be administered in the Safety Run-In Phase by intravenous infusion q3w on Day 1 of 3-weekly cycles (each cycle of 21 days) in combination with carboplatin (to produce an area under the curve [AUC] of 6 mg/milliliter [mL]*minute) and paclitaxel 200 mg per square meter (mg/m^2) by intravenous infusion q3w for 4 to 6 cycles. Thereafter, RO5479599 will be continued as a monotherapy (carboplatin and paclitaxel may be continued at the investigator's discretion) until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
3053502|NCT02204332|Experimental|Cabazitaxel|"Cabazitaxel at a dose of 25 mg / m² in a 5% dextrose or 0.9% NaCl intravenously over 1 hour, every 3 weeks (1 cycle).~Besides, patient will be treated with BSC."
3053503|NCT02204332|Other|Best Supportive Care|Best Supportive Care (BSC), with evaluations every 3 weeks (1 cycle).
3053504|NCT02204319|Experimental|Cold Laser Treatment|Cold laser used off of the body over the vulvar involved area. The device to be used in this study is the Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device. Weekly visits x 6 with 5 minute treatments over vulva and sacral nerve roots each.
3053505|NCT02204306|Other|TSER *2/*2 *2/*3|Patients with TSER *2/*2 *2/*3 genotypes will be assigned to this group and receive standard chemotherapy contains fluorouracil. (FOLFOX 6/XELOX/SOX)
3053506|NCT02204306|Other|TSER*3/*3 (fluorouracil)|Patients with TSER*3/*3 genotype will be randomly assigned to fluorouracil group (FOLFOX 6/XELOX/SOX) or non-fluorouracil group (DC or DO).
3053507|NCT02204306|Other|TSER*3/*3 (non-fluorouracil)|Patients with TSER*3/*3 genotype will be randomly assigned to fluorouracil group (FOLFOX 6/XELOX/SOX) or non-fluorouracil group (DC or DO).
3053508|NCT02204293|Placebo Comparator|Placebo Injections|Placebo injections will be administered subcutaneously every 4 weeks.
3053509|NCT02204293|Active Comparator|Canakinumab|Canakinumab sc 4mg/kg BW up to 300mg every 4 weeks
3053510|NCT02204280||Type 2 Diabetic|Patiens with type 2 diabetic which conform to the WHO in 1999 diabetes diagnostic criteria.
3053511|NCT02204280||Diabetic With macro-or Microalbuminuria|Patients with diabetic with macro-or microalbuminuria.
3053512|NCT02204280||proteinuria,nondiabetic renal disease|Patients with proteinuria due to nondiabetic renal disease,such as IgA nephropathy,FSGS,Hypertensive renal damage and MN.
3053513|NCT02204280||healthy controls|Healthy person.
3053514|NCT02204267|Experimental|prolonged ECG monitoring|Regular stroke unit treatment and diagnostic procedures according to guidelines and additional prolonged ECG monitoring
3053515|NCT02204267|No Intervention|no additional ECG recording|Regular stroke unit treatment and diagnostic procedures according to guidelines
3053516|NCT02204254|Experimental|Radiofrequence|3 sessions of radiofrequency at 3 weeks intervals V1, V2 (W3 or W4) and V3 (between W6 and W8), with clinical examination, evaluation of tolerance, adverse events report, photos, surface biopsy (SSSB), and confocal microscopy (V1 and V3). Follow up visit V4 (M6) with clinical evaluation, photos, SSSB, confocal microscopy, adverse events report and treatment satisfaction.
3053517|NCT02204254|Placebo Comparator|Doxycycline|doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
3053518|NCT02204241|Experimental|CCyd|"Treatment schedule for 9 cycles of induction:~Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.~Carfilzomib given 20 mg/m2 IV once daily on Day 1-2 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8-9, 15-16 of Cycle 1, then for all subsequent doses 36/45/56/70 mg/m2 IV once daily on days 1-2, 8-9, 15-16, followed by 12-day rest period (day 17 through 28).~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib at the MTD defined by phase I study IV once daily on days 1-2, 15-16."
3053519|NCT02204228||TITAN™ Reverse Shoulder System (TRS)|TITAN™ Reverse Shoulder System (TRS) is a semi-constrained total shoulder construct.
3053520|NCT02204215|Experimental|electric acupuncture & conservative|Electric acupuncture therapy on four limbs 30 min each time, twice per day; or conservative treatment without electric acupuncture.
3053521|NCT02204202||Grade A0|Double-lung transplant recipients with no evidence of rejection who undergo both [18F]FDG and [18F]ISO-1 PET imaging scans
3053522|NCT02204202||Grades A2-3|Double-lung transplant recipients with mild to moderate rejection who undergo both [18F]FDG and [18F]ISO-1 PET imaging scans
3053523|NCT02204189|Experimental|TongFuSan|TongFuSan 1g per time, change every day, the duration is seven days
3053524|NCT02204176|Sham Comparator|Exercise info only|"Participants in the exercise information only group will engage in a group discussion with the principal investigator to discuss what constitutes regular physical activity and benefits of exercise and basic tips on the activity itself. Guidelines for prescribing suggested exercises will be based on recommendations from the U.S. Department of Health and Human Services (USDHHS, 2008) as well as risks associated with exercise and how they can be reduced."
3053525|NCT02204176|Experimental|Exercise info + implementation intentions|"Participants in the exercise information plus implementation intentions group will engage in a group discussion with the principal investigator to discuss all of the components from the exercise information only approach, but with more emphasis on how to create implementation intentions. Discussions will revolve around possible barriers to exercise plans and how to overcome/address those barriers by making specific plans of when and where to exercise, along with designating which types of exercises they will perform and for how long (or how many repetitions)."
3053526|NCT02204176|Experimental|Exercise info + implementation intentions + industriousness|"Participants in the exercise information plus implementation intentions plus industriousness training group will engage in a group discussion with the principal investigator to discuss all of the components from the second approach as well as include findings linking industriousness and exercise behavior. Participants will be directed to think about and generate solutions to how they can become more industrious and monitor their efforts despite the difficulties they may face and relate these solutions to help them engage in more exercise behavior."
3053527|NCT02204163|Experimental|Eutropin|Eutropin 0.24mg/kg/week
3053528|NCT02204163|Active Comparator|Genotropin|Genotropin 0.24mg/kg/week
3053529|NCT02204150|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI Imaging system.
3053530|NCT02204137||Completion of Questionnaires|"Participants will complete an assessment consisting of the Falls Risk Questionnaire, a primarily self-administered geriatric assessment (GA) developed by the Cancer and Aging Research Group, a quality of life scale (FACT GOG/NTX) and the Falls Efficacy Scale-International.~Each questionnaire contains approximately 150 questions and will take between 30 minutes and one hour to complete."
3053531|NCT02204124|Active Comparator|Control Group|In the control group, scissors, ligatures, clips and sutures will be used for dissection and hemostasis as necessary.
3053532|NCT02204124|Experimental|Thunderbeat™|-In the Thunderbeat™ group, dissection and hemostasis of vessels will be performed using the Thunderbeat™ device (Olympus, Japan).
3053533|NCT02204111||Control Cluster|Care as usual
3053534|NCT02204111||Treatment Cluster|Care as usual and patient directed, multidimensional treatment proposals
3053535|NCT02204098|Experimental|Arm 1: Endocrine Therapy & Mammaglobin-A DNA Vaccine|"Participants will be treated with neoadjuvant endocrine therapy, with the dose and agent to be determined by the treating physician~The schedule of vaccination is day 28 ± 7, day 56 ± 7 and day 84 ± 7 with at least 21 days between injection days.~All study injections will be given intramuscularly using an integrated electroporation administration system.~At each vaccination timepoint, patients will receive two injections of the mammaglobin-A DNA vaccine, one injection into each deltoid or lateralis."
3053536|NCT02204098|Active Comparator|Arm 2 - Endocrine Therapy Only|Participants will be treated with neoadjuvant endocrine therapy, with the dose and agent to be determined by the treating physician.
3053537|NCT02204085|Experimental|GO-203-2c|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle"
3053538|NCT02204085|Experimental|GO-203-2c + Decitabine|"Dose escalation will occur for GO-203-2c using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle. Decitabine will be administered at a dose of 20mg/m2 on days 8-12 of a 28-day treatment cycle."
3053539|NCT02204072|Experimental|BI 836845 & Enzalutamide|
3053540|NCT02204072|Active Comparator|Enzalutamide|
3053541|NCT02204059|Experimental|hMAb BIWA 4|Bivatuzumab: 186 Re-labelled humanised monoclonal antibody BIWA 4
3053542|NCT02204046|Experimental|BIWA 4|"Generic Name: Bivatuzumab~186Re-labelled humanised monoclonal antibody BIWA 4"
3053543|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - low dose|
3053544|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - medium dose|
3053545|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - high dose|
3053546|NCT02204033|Experimental|186 Re - labelled hMAb BIWA 4 - escalating dose|
3053547|NCT02204020|Experimental|5-azacytidine|5-aza SC or IV 32mg/m2 - 75mg/m2 (based on dose escalation)
3053548|NCT02204007|Experimental|3D imaging, surrogate bone model|3D imaging & surrogate bone model
3081970|NCT02013687|Experimental|30 µg + Alhydrogel|vaccine
3053549|NCT02204007|No Intervention|Standard of Care Preoperative Imaging|Patients receiving standard of care preoperative planning prior to total hip arthroplasty.
3053550|NCT02203994|Experimental|extracorporeal shock wave therapy (ESWT)|"one-time treatment of the spastic muscle/ spastic muscles (adductor muscles and/ or M. triceps surae) with extracorporeal shock wave therapy (device: Duolith® SD 1 T-Top (Storz Medical AG, Tägerwilen, Switzerland))"
3053551|NCT02203968|Placebo Comparator|Normal saline|Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
3053552|NCT02203968|Active Comparator|Fibrinogen concentrate|Fibrinogen concentrate (RiaSTAP™) is a freeze-dried lyophilised plasma product presented in powdered form. The powder is reconstituted with water for intravenous injection at a concentration of 20 mg fibrinogen per ml. The concentrate is formulated with human albumin, L-arginine, sodium citrate and sodium chloride. RiaSTAP™ is supplied as a purified lyophilisate in a 1g dosage form and is reconstituted in 50 ml of sterile water. The final volume of RiaSTAP™ to be infused in this study will therefore be 300 ml.
3053553|NCT02203955|Active Comparator|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally per day for 12 months
3053554|NCT02203955|Placebo Comparator|Maltodextrin|4 chews (maltodextrin) daily for 12 months
3053555|NCT02203942||Vaginal Infections (BV, VVC, trich)|NAAT testing Amsel criteria Nugent score yeast culture TV culture
3053556|NCT02203929||Phakic eyes|Phakic eyes will be monitored with 4 preoperative optical coherence tomography scans as these patients will undergo phacoemulsification and intraocular lens implantation prior to their macular hole surgery
3053557|NCT02203929||Pseudophakic eyes|Phakic eyes will be monitored with 2 preoperative optical coherence tomography scans as there is no surgical intervention prior to the macular hole treatment.
3053558|NCT02203916|Experimental|Azilsartan Medoxomil 40 mg|Azilsartan medoxomil 40 mg, tablets, orally, once daily for 6 weeks.
3053559|NCT02203916|Experimental|Azilsartan Medoxomil 80 mg|Azilsartan medoxomil 80 mg, tablets, orally, once daily for 6 weeks.
3053560|NCT02203916|Placebo Comparator|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for 6 weeks.
3053561|NCT02203903|Experimental|Tumor associated antigen lymphocytes (TAA-CTL)|"Tumor associated antigen lymphocytes (TAA-CTL). Four different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. This protocol is designed as a phase I dose-escalation study.~Each patient will receive at least one infusion according to the enrolled dose level, where the expected volume of infusion is 1 to 10 cc, according to the following dosing schedules.~Dose Level One: 5 x 106 cells/m2 Dose Level Two: 1 x 107 cells/m2 Dose Level Three: 2 x 107 cells/m2 Dose Level Four: 4 x 107 cells/m2"
3053562|NCT02203890||Apparently Healthy|Apparently healthy preschool children who attend 3 daycare centers of the Secretariat of Beneficials Works of the First Lady in Guatemalan Western Highlands
3053563|NCT02203877|Placebo Comparator|Maltodextrin|1 capsule/day for 16 weeks
3053564|NCT02203877|Experimental|Lactobacillus fermentum CECT5716|L.fermentum 3,00E+09cfu/day. 1 capsule/day for 16 weeks
3053565|NCT02203864|Experimental|BIBW2 with IL-2 secreting cell line|
3053566|NCT02203864|Experimental|BIBW2 without IL-2 secreting cell line|
3053567|NCT02203851|Experimental|ABBV-066|Dose increase when low response
3053568|NCT02203838|Experimental|RBP-7000 - 120-mg dose|RBP-7000 120-mg subcutaneous (SC) dose. A 14-day period of titration to a dose of 3- or 4mg oral risperidone before the first injection of RBP-7000
3053569|NCT02203825|Experimental|CM-CS1 T-cell infusion|"The treatment will consist of a single infusion of CM-CS1 cells.~The following dose levels will be evaluated:~Cohort 1: 1x 10^6 CM-CS1 T-cells Cohort 2: 3x 10^6 CM-CS1 T-cells Cohort 3: 1x 10^7 CM-CS1 T-cells Cohort 4: 3x 10^7 CM-CS1 T-cells"
3053570|NCT02203812|Experimental|Probiotic Arm|L. brevis CD2 Lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). Each lozenge contains at least 1 billion colony forming units of Lactobacillus brevis CD2.
3053571|NCT02203812|Placebo Comparator|Placebo Arm|Placebo lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). The placebo lozenge contains all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2).
3053572|NCT02203799|Experimental|Peanut Oral Immunotherapy (POIT)|The peanut OIT is taken in the form of peanut flour. It will be given in small cups containing the amount of flour that needs to be eaten for one dose. One dose should be taken per day.
3053573|NCT02203786|Active Comparator|Haloperidol|"Subjects randomized to pre-treatment drug sequence 1 (haloperidol on day 1 of each phase), or drug sequence 2 (haloperidol on day 2 of each phase).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol OR 3 visually identical placebo (lactose) capsules~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine.~Response measured to 15 min session of a commercial slot machine game."
3053574|NCT02203786|Active Comparator|Fluphenazine|"Subjects randomized to pre-treatment drug sequence 1 (fluphenazine on day 1 of each phase), or drug sequence 2 (fluphenazine on day 2 of each phase).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine OR 3 visually identical placebo (lactose) capsules~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine.~Response measured to 15 min session of a commercial slot machine game."
3053575|NCT02203773|Experimental|ABT-199 + Azacitidine|Treatment Naive Acute Myelogenous Leukemia
3053576|NCT02203773|Experimental|ABT-199 + Decitabine|Treatment Naive Acute Myelogenous Leukemia
3053577|NCT02203773|Experimental|ABT-199+Decitabine+Posaconazole|Treatment Naive Acute Myelogenous Leukemia
3053578|NCT02203760|Experimental|Pazopanib plus Gemcitabine|Arm A: Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
3053579|NCT02203760|Active Comparator|Pazopanib|Pazopanib 800 mg orally once daily
3053580|NCT02203747||Pseudophakic implanted with toric IOL|Subjects bilaterally implanted with toric IOL
3081971|NCT02013687|Experimental|100 µg + Alhydrogel|vaccine
3053584|NCT02203721|Experimental|TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|Bilaterally implanted with TECNIS Symfony Extended Range of Vision Intraocular Lens, Model ZXR00
3053585|NCT02203721|Active Comparator|TECNIS Monofocal IOL, Model ZCB00|Bilaterally implanted with TECNIS Monofocal Intraocular Lens, Model ZCB00
3053586|NCT02203708|Active Comparator|BPD prevention|Supportive Program for Mother with BPD (SuPMother-B) : BPD mothers participate to prevention program in groups or/and house calls.
3053587|NCT02203708|No Intervention|Usual care of BPD mothers|BPD mothers don't participate to Supportive Program (SuPMother-B).
3053588|NCT02203695|Experimental|SRT plus Enzalutamide|Arm 2 (experimental): (SRT) Salvage radiation therapy (Three dimensional conformal radiation therapy (3D-CRT)/IMRT [Intensity-modulated radiation therapy]) 66.6-70.2 Gy as 1.8 Gy M-F for 37-39 fx PLUS Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
3053589|NCT02203695|Placebo Comparator|SRT plus placebo|Arm 1 (control): Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT (Intensity-modulated radiation therapy)) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx PLUS Placebo PO daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
3053590|NCT02203682|Experimental|Doxycycline|Tablets Doxycycline 50 mg PO per day for 12 weeks
3053591|NCT02203682|Placebo Comparator|Placebo|Tablet placebo for 12 weeks
3053592|NCT02203669|Active Comparator|Structured In-Office Therapy|Structured In-Office Therapy: Study subjects will receive structured, therapist-supervised occupational/physical therapy twice per week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Patients in this arm will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These patients will also receive exercise and stretching handouts to use at home between therapy visits. Will complete the DASH at week 1 and week 4.
3053593|NCT02203669|No Intervention|No therapy|Study subjects in this arm will not receive post-operative occupational /physical therapy. Will complete the DASH at week 1 and week 4.
3053594|NCT02203669|Active Comparator|Home Therapy|Home Therapy: Study subjects will receive a handout of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist to complete independently at home for four (4) weeks. Will complete the DASH at week 1 and week 4.
3053595|NCT02203656|Placebo Comparator|Placebo Supplement|Daily placebo supplement for 30 days after discharge.
3053596|NCT02203656|Experimental|Nutritional Supplement|Daily nutritional supplement for 30 days after discharge.
3053597|NCT02203656|Experimental|In-home exercise + placebo|in-home exercise 3 times a week and daily placebo supplement for 30 days after discharge.
3053598|NCT02203656|Experimental|In-home exercise + nutrition|in-home exercise 3 times a week and daily nutritional supplement for 30 days after discharge.
3053599|NCT02203656|Experimental|Testosterone|Single testosterone injection within 24 hours of hospital discharge.
3053600|NCT02203643|Experimental|CCyd|"Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles. This treatment will be followed by autologous stem cell transplantation (ASCT). Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles, as consolidation treatment.~After the end of consolidation all patients will be randomized to receive:~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
3053601|NCT02203643|Experimental|CRd|"Carfilzomib Lenalidomide and Dexamethasone administered for 4 28-day cycles. This treatment will be followed by autologous stem cell transplantation (ASCT). Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles, as consolidation treatment.~After the end of consolidation all patients will be randomized to receive:~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
3053602|NCT02203643|Experimental|CRd long treatment|"Carfilzomib Lenalidomide and Dexamethasone administered for 4 28-day cycles. Stem cells collection will be performed. Carfilzomib Lenalidomide and Dexamethasone administered for 8 28-day cycles.~After that all patients will be randomized to receive:~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
3053603|NCT02203630|Active Comparator|Phenylephrine|Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
3053604|NCT02203630|Active Comparator|Norepinephrine|Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
3053605|NCT02203617|Experimental|educational baby books|books embedded with educational information (pediatric anticipatory guidance)
3053606|NCT02203617|Active Comparator|non-educational baby books|baby books given with same illustrations but no educational information
3053607|NCT02203617|No Intervention|no books|not given any baby books
3053608|NCT02203604|Experimental|Treatment (aldesleukin, ipilimumab)|"INDUCTION: Patients receive ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 and high-dose aldesleukin IV on days 22-26 and 43-47.~MAINTENANCE: Beginning on weeks 24, patients without disease progression or unacceptable toxicity receive ipilimumab IV over 90 minutes once every 12 weeks for up to 24 weeks in the absence of disease progression or unacceptable toxicity."
3053609|NCT02203591|Experimental|3M CHG/IPA Prep C|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
3053610|NCT02203591|Experimental|3M CHG/IPA Prep CH|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
3053611|NCT02203591|Active Comparator|ChloraPrep Clear|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
3053612|NCT02203591|Placebo Comparator|Normal Saline|0.9% sodium chloride with applicator
3053613|NCT02203578|Experimental|Supportive care (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3053614|NCT02203565|Experimental|Supportive care (Dakin's solution, radiation therapy)|Patients apply Dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks.
3053615|NCT02203552|Experimental|Arm I (minocycline hydrochloride)|Beginning 1 week prior to chemotherapy, patients receive minocycline hydrochloride orally PO BID for 9 weeks. Laboratory biomarker analysis will also be obtained weekly on protocol. Questionnaire administration weekly.
3053616|NCT02203552|Placebo Comparator|Arm II (placebo)|Beginning 1 week prior to chemotherapy, patients receive placebo PO BID for 9 weeks. Laboratory biomarker analysis will also be obtained weekly on protocol. Questionnaire administration weekly.
3053621|NCT02203526|Experimental|Arm 1- A (First Cohort; original study design)|TEDD-R (cycle 1) with ibrutinib; TEDDIR with cytarabine (cycles 2-6)
3053622|NCT02203526|Experimental|Arm 2- A (First Cohort; Amendment G.)|TEDDI-R and IT therapy with antifungals TEDDI
3053623|NCT02203526|Experimental|Arm 2- B (Second Cohort; Amendment G.)|TEDDI-R with cytarabine and voriconazole
3053624|NCT02203513|Experimental|1-prexasertib|Prexasertib monotherapy treatment
3053625|NCT02203500|Experimental|Lacidipine|
3053626|NCT02203500|Experimental|Telmisartan|
3053627|NCT02203500|Experimental|Lacidipine + Telmisartan|
3053628|NCT02203487|Experimental|BIIF 1149 BS - single rising dose|
3053629|NCT02203487|Placebo Comparator|Placebo|
3053630|NCT02203474|Experimental|Tiotropium HFA BAI 5 mcg|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
3053631|NCT02203474|Experimental|Tiotropium HFA BAI 10 mcg|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
3053632|NCT02203474|Experimental|Tiotropium HFA BAI 15 mcg|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
3053633|NCT02203474|Active Comparator|SPIRIVA HandiHaler|2 inhalations from one 18 mcg capsule daily
3053634|NCT02203474|Placebo Comparator|Placebo|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
3053635|NCT02203461|Experimental|Group I|STRIBILD® Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat
3053636|NCT02203461|Active Comparator|Group II|Truvada®/Kaletra® Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir
3053637|NCT02203461|Experimental|Group III|Truvada®/Prezista®/Norvir® Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir
3053638|NCT02203448||FACET WEDGE spinal system|The FACET WEDGE spinal system provides additional stability to a spinal segment to enhance fusion conditions.
3053639|NCT02203422|Experimental|combination treatment group|60 enrolled patients are randomly picked up to take cyclosporin A in combination with rhTPO at the indicated dose.
3053640|NCT02203422|Active Comparator|single treatment group|60 enrolled patients are randomly picked up to take cyclosporin A at the indicated dose.
3053641|NCT02203409||Laparoscopic ALPPS group|"Patients with small future liver remnant who are operated with the Associating Liver Partition and Portal vein ligation for Staged hepatectomy approach"
3053642|NCT02203396|Experimental|Severe Aplastic Anemia|Drug: rabbit ATG, Cyclosporine, Levamisole
3053643|NCT02203383||Pts with CSA for CRT implantation|Patients with heart failure (EF<40%) and moderate to severe CSA (>15 events per hour, >50% Central)
3053644|NCT02203383||No Sleep Apnoea for CRT implantation|Heart failure (EF < 40%) but no significant sleep apnoea (<5 events per hour).
3053645|NCT02203370||all patients|All patients will be measured throughout the procedure with both devices. There no further separation into groups as both sensors can be placed on the same patient.
3053646|NCT02203357|Active Comparator|20μg, 0-1-6|117 young adults were administered with 20μg of hepatitis B vaccine according to the 0-1-6 mon schedule.
3053647|NCT02203357|Experimental|60μg, 0-1|112 young adults were asministered with 60μg of hepatitis B vaccine according to the 0-1 mon schedule.
3053648|NCT02203357|Experimental|60μg, 0-2|125 young adults were asministered with 60μg of hepatitis B vaccine according to the 0-2 mon schedule.
3053649|NCT02203344||Light sedation|Light sedation is defined as RASS of +1 to -2.
3053650|NCT02203344||Deep sedation|Deep sedation is defined as RASS of -3 to -5
3053651|NCT02203331|Placebo Comparator|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
3053652|NCT02203331|Experimental|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
3053653|NCT02203331|Experimental|Anastrozole 300 µg/d + Levonorgestrel|Anastrozole 300 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
3053654|NCT02203331|Experimental|Anastrozole 600 µg/d + Levonorgestrel|Anastrozole 600 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
3053655|NCT02203331|Experimental|Anastrozole 1050 µg/d + Levonorgestrel|Anastrozole 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
3053656|NCT02203331|Active Comparator|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
3053657|NCT02203318||control|healthy children with normal bilateral testis
3053658|NCT02203318||undescended palpable testis|patient whose affected testis is not descended to the normal position but palpable and exist intact in the upper area
3053659|NCT02203318||non-paplpable testis|patient whose affected testis is not palpable during the physical examination
3053660|NCT02203305|Experimental|Cochlear Implant|Cochlear implantation of the affected ear
3053661|NCT02203305|Other|Control Group|A control group without the study intervention (cochlear implantation) will complete the test battery.
3053662|NCT02203305|Experimental|Cochear Implant: Asymmetric hearing loss|Cochlear implantation of the poorer hearing ear
3053663|NCT02203292|Active Comparator|Liberal|Liberal transfusion strategy. Patients will have red blood cells transfused only if Hb < 9.0 g/dL
3053664|NCT02203292|Experimental|Restrictive|Restrictive transfusion strategy. Patients will have red blood cells transfused only if Hb < 7.0 g/dL
3053665|NCT02203279|Experimental|Rebase II Fast|The direct chair-side relining materiel 'Rebase II Fast' will be used.
3053666|NCT02203279|Experimental|Flexacryl|The direct chair-side relining material Flexacryl will be used
3053667|NCT02203279|Experimental|Vertex|Vertex is a heat-cured resin material which is going to be used for indirect relining
3053668|NCT02203266|Experimental|Feedback|Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
3053670|NCT02203266|No Intervention|Control|Usual care in the community pharmacy setting
3053671|NCT02203253|Active Comparator|Thalidomide Group|Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
3053672|NCT02203253|Placebo Comparator|Placebo Group|Placebo (for Thalidomide) tablet 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
3053673|NCT02203240|Experimental|Cocoa|# servings of polyphenol-rich cocoa beverage per day
3053674|NCT02203240|Placebo Comparator|Placebo|3 servings of non-cocoa beverage per day
3053675|NCT02203227|Placebo Comparator|Placebo|Capsule containing 250 mg of placebo, two times a day
3053676|NCT02203227|Experimental|BioTurmin|Capsule containing 250 mg of BioTurmin (Curcuma longa rhizomes extract), two times a day
3053677|NCT02203227|Experimental|BioTurmin-WD|Capsule containing 250 mg of BioTurmin-WD (water dispersible curcuminoids), two times a day
3053678|NCT02203227|Experimental|MaQxan|Capsule containing 10 mg of MaQxan (Tagetes erecta flower extract), two times a day
3053679|NCT02203214||Ligamys|All patients treated with Ligamys can be included in the study. Patients must meet all of the inclusion criteria and none of the exclusion criteria to be enrolled.
3053680|NCT02203201||Study group|NCWS patients who had showed a negative celiac disease serology and a Marsh 0-1 duodenal histology, but who had displayed a positive EmA assay in the culture medium of the duodenal biopsies (EmA-biopsy).
3053681|NCT02203201||Control group|NCWS patients with negative EmA-biopsy.
3053682|NCT02203188|Experimental|Lid debridgement scaling|Perform lid debridgement scaling
3053683|NCT02203188|No Intervention|Control|No Treatment
3053684|NCT02203175|Placebo Comparator|Group C (plasebo): no pretreatment|saline injection
3053685|NCT02203175|Active Comparator|propofol and fentanyl|propofol 50 mg with fentanyl 50 mcgr iv during anesthesia induction ones time
3053686|NCT02203162|Experimental|cough reflex sensitivity|electronic cigarette exposure
3053687|NCT02203149|Experimental|Part 1 Grazoprevir 50 mg + Elbasvir|Non-cirrhotic participants take 50 mg grazoprevir in combination with 50 mg elbasvir by mouth (p.o.) once daily (q.d.) for 12 weeks during the blinded period of Part 1 and are followed-up for 24 weeks during the open-label period of Part 1.
3053688|NCT02203149|Experimental|Part 1 Grazoprevir 100 mg + Elbasvir|Non-cirrhotic participants take 100 mg grazoprevir in combination with 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 1 and are followed-up for 24 weeks during the open-label period of Part 1.
3053689|NCT02203149|Experimental|Part 2 Non-cirrhotic Immediate: Grazoprevir + Elbasvir|Non-cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2 and are followed-up for 24 weeks during the open-label period of Part 2.
3053690|NCT02203149|Placebo Comparator|Part 2 Non-cirrhotic Deferred: Placebo► Grazoprevir + Elbasvir|Non-cirrhotic participants take dose-matched placebo p.o. q.d. for 12 weeks during the blinded period of Part 2 followed by a 4-week follow-up. Afterwards, participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks and are followed-up for 24 weeks during the open-label period of Part 2.
3053691|NCT02203149|Experimental|Part 2 Cirrhotic: Grazoprevir + Elbasvir|Cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part 1) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2, and are followed-up for 24 weeks during the open-label period of Part 2.
3053692|NCT02203136||Muscle Invasive Bladder Cancer (MIBC)|During bladder cancer surgery, whole genome gene expression array assays obtained on tumor biopsy specimens. Analysis to determine biologic subtypes which will then be correlated with final pathology, identifying the subtype(s) associated with noc-MIBC. 3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
3053693|NCT02203123|Other|Ultrasound, inferior vena cava, aorta, normal saline|
3053694|NCT02203097|Experimental|Propofol|Propofol is administered to all patients via target-controlled infusion (TCI) to reach 4 mcg/ml constant plasma concentration according to the Schneider model during the course of the narcosis.
3053695|NCT02203084||Children with Chronic Medical Conditions|The Social Determinants Questionnaire will be administered to the three groups of children with chronic diseases (cystic fibrosis, diabetes mellitus type I, or chronic renal insufficiency). The questionnaire questions will be asked by a research assistant. Each participant will have the same general and background information questions then will have questions specific to their chronic medical condition.
3053696|NCT02203071||MSP with BioCartilage|Patients receiving marrow stimulating procedure with BioCartilage adjunct.
3053697|NCT02203071||MSP without BioCartilage|Patients receiving marrow stimulating procedure without BioCartilage.
3053698|NCT02203058|Experimental|Pursed-lips breathing|All patients performed both tests (six-minute walk test and Glittre ADL test) with pursed-lips breathing.
3053699|NCT02203058|Placebo Comparator|No pursed-lips breathing|All patients performed both tests (six-minute walk test and Glittre ADL test) without pursed-lips breathing.
3053700|NCT02203045|Active Comparator|Tourniquet|All lower extremities will be exsanguinated by elevation for 2 minutes. For lower extremities in the tourniquet group (TQT), a pneumatic tourniquet will be inflated according to standard practice (>200 mmHg). For the NOTQT group, the tourniquet will only be inflated during component cementation. In both groups, tourniquet will be deflated after bone cement has set. In both groups, electrocautery will be used as needed throughout the procedure.
3053701|NCT02203045|Experimental|Non- tourniquet|All lower extremities will be exsanguinated by elevation for 2 minutes. For lower extremities in the tourniquet group (TQT), a pneumatic tourniquet will be inflated according to standard practice (>200 mmHg). For the NOTQT group, the tourniquet will only be inflated during component cementation. In both groups, tourniquet will be deflated after bone cement has set. In both groups, electrocautery will be used as needed throughout the procedure.
3053702|NCT02203032|Experimental|Open-label ustekinumab|
3053703|NCT02203032|Experimental|Double-blind guselkumab|
3053704|NCT02203032|Experimental|Double-blind ustekinumab|
3053705|NCT02203019|Active Comparator|Propofol|Propofol will be administered for sedation.
3053706|NCT02203019|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered for sedation
3053707|NCT02203006|Other|OVIHD|Cohort and a blood sample collection will be done with data and blood of HIV infected patients
3053708|NCT02202993|Experimental|Mibefradil with Radiation|"Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.~This will be given concurrently with hypofractionated radiation therapy."
3053709|NCT02202980|Experimental|LDV/SOF+RBV 24 Weeks (Cohort 1 Group 1)|Participants who previously received ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus ribavirin (RBV) for ≥ 12 weeks without achieving sustained virologic response at 12 weeks following treatment (SVR12) will receive LDV/SOF+RBV for 24 weeks.
3053710|NCT02202980|Experimental|LDV/SOF+RBV 12 Weeks (Cohort 1 Group 2)|Participants who previously received a sofosbuvir-based regimen without achieving SVR12 were initially enrolled to receive LDV/SOF+RBV for 12 weeks (excluding participants who previously received LDV/SOF+RBV for ≥ 12 weeks). Participants who did not achieve sustained virologic response at 12 weeks were then moved to Cohort 1 Group 1.
3053711|NCT02202980|Experimental|LDV/SOF 12 Weeks GT2 (Cohort 2 Group 1)|Participants with genotype 2 (GT2) HCV infection will receive LDV/SOF FDC for 12 weeks.
3053712|NCT02202980|Experimental|LDV/SOF 8 Weeks GT2 (Cohort 2 Group 2)|Participants with GT2 HCV infection will receive LDV/SOF FDC for 8 weeks.
3053713|NCT02202980|Experimental|LDV/SOF 12 Weeks GT1/GT2/GT4 (Cohort 3 Group 1)|Participants with genotypes 1 (GT1), 2 (GT2), or 4 (GT4) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC for 12 weeks.
3053714|NCT02202980|Experimental|LDV/SOF+RBV 12 Weeks GT3 (Cohort 3 Group 2)|Participants with genotype 3 (GT3) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC plus RBV for 12 weeks.
3053715|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 4)|Treatment-naive participants with GT1 HCV infection without cirrhosis will receive VOX only on Day 1 followed by sofosbuvir/velpatasvir (SOF/VEL) + voxilaprevir (VOX) for 6 weeks.
3053716|NCT02202980|Experimental|SOF/VEL+VOX 4 Weeks GT1 (Cohort 5 Group 1)|Treatment-naive participants with GT1 HCV infection without cirrhosis will receive SOF/VEL+VOX for 4 weeks.
3053717|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 2)|Treatment-naive participants with GT1 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
3053718|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT3 (Cohort 5 Group 3)|Treatment-naive participants with GT3 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
3053719|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 4)|Treatment-experienced participants with GT1 HCV infection with cirrhosis who were previously treated with pegylated interferon (Peg-IFN)+RBV will receive SOF/VEL+VOX for 6 weeks.
3053720|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 5)|Treatment-experienced participants with GT3 HCV infection with cirrhosis who were previously treated with Peg-IFN+RBV will receive SOF/VEL+VOX for 6 weeks.
3053721|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 6)|Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with non-structural protein (NS3/4A) protease inhibitor (PI) will receive SOF/VEL+VOX for 6 weeks.
3053722|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 7)|Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with direct-acting antivirals (DAA) will receive SOF/VEL+VOX for 6 weeks.
3053723|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 8)|Treatment-experienced participants with GT3 HCV infection with or without cirrhosis who were previously treated with DAA will receive SOF/VEL+VOX for 8 weeks.
3053724|NCT02202967|Active Comparator|Misoprostol|Misoprostol
3053725|NCT02202967|Placebo Comparator|Placebo|Placebo
3053726|NCT02202954|Active Comparator|Guided Self-rehabilitation Contract|"In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.~The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary."
3053727|NCT02202954|No Intervention|Conventional rehabilitation|conventional therapy in the community
3053728|NCT02202941|Experimental|Procalcitonin guided treatment|Patients who will be randomized to this arm will receive antibiotics therapy based on procalcitonin-guided algorithm.
3053729|NCT02202941|Active Comparator|Conventional treatment|Patients who will be randomized to this arm will receive antibiotic therapy based on conventional practice.
3053730|NCT02202928|Sham Comparator|Chemo-radiotherapy|After accepting concurrent radiotherapy and chemotherapy according to NCCN guidelines, patients will just regularly follow up.
3053731|NCT02202928|Experimental|DC-CIK|After accepting concurrent radiotherapy and chemotherapy according to NCCN guidelines, patients will receive 3 cycles of autologous tumor lysate pulsed DC-CIK treatment.
3053732|NCT02202915|Experimental|Fidelity Checklist Arm|Therapists are receiving training using the fidelity Checklist
3053733|NCT02202902|Experimental|Group 1 : 1H magnetic resonance spectroscopy and CMRI|Group 1 : Cushing's syndrome patients with diabetes mellitus or glucose intolerance
3053734|NCT02202902|Experimental|Group 2 : 1H magnetic resonance spectroscopy and CMRI|Group 2: Cushing's syndrome patients with normal glucose intolerance
3053735|NCT02202902|Experimental|Group 3 : 1H magnetic resonance spectroscopy and CMRI|age-, sex- and BMI-matched healthy volunteers
3053736|NCT02202876|Active Comparator|Aim 1: CF Children|Cystic Fibrosis children aged 1 to 9 years with normal glucose tolerance receiving Oral Glucose Tolerance Test
3053737|NCT02202876|Active Comparator|Aim 1: Control Children|Children aged 1 to 9 years controls with normal glucose tolerance receiving Oral Glucose Tolerance Test
3053738|NCT02202876|Active Comparator|Aim 2: CF Teens|Cystic Fibrosis subjects 12 years of age or older with normal glucose tolerance eating High Glycemic Index Meal
3053739|NCT02202876|Active Comparator|Aim 2: CF Teens (Low Glycemic)|Cystic Fibrosis subjects 12 years of age or older with normal glucose tolerance eating Low Glycemic Index Meal
3053781|NCT02202603|Experimental|API optimization 5|Oral administration of pill with API, for PK optimization #5
3053740|NCT02202863|Experimental|Red Wine Grape Pomace Flour (WGPF)|Subjects were asked to maintain their regular eating habits and lifestyles for 16 weeks, except for the daily intake of 20 g of WGPF. WGPF was consumed in bread, biscuits or as flour mixed with water during lunch. Bread and biscuits with 20% WGPF were prepared especially in a bakery. WGPF intake was supervised every day at lunch. Participants were asked to consume the flour supplement with their regular meals on weekends.
3053741|NCT02202863|No Intervention|Control|Subjects were asked to maintain their regular eating habits and lifestyles for 16 weeks.
3053742|NCT02202850||Etanercept First|Adults patients with AS receiving Etanercept as first biologic, according to prevailing reimbursement criteria in Belgium
3053743|NCT02202850||Etanercept second|Adults patients with AS receiving Etanercept as second biologic, according to prevailing reimbursement criteria in Belgium
3053744|NCT02202837||Etanercept First|Adult patients with RA who receive etanercept as first biologic, according to prevailing Belgian reimbursement criteria
3053745|NCT02202837||Etanercept second|Adult patients who receive etanercept as second biologic, according to prevailing Belgian reimbursement criteria
3053746|NCT02202824|Experimental|Survey questionnaire version 1|Study participants will receive version 1 of the survey questionnaire
3053747|NCT02202824|Experimental|Survey questionnaire version 2|Study participants will receive version 2 of the survey questionnaire
3053748|NCT02202824|Experimental|Survey questionnaire version 3|Study participants will receive version 3 of the survey questionnaire
3053749|NCT02202811|Experimental|Obstructive Sleep Apnea|Forced Desynchrony, OSA
3053750|NCT02202811|Placebo Comparator|Control|Forced Desynchrony, Control
3053751|NCT02202798||Syringe device|Endotracheal tube cuff pressure measured by 2 new syringe devices.
3053752|NCT02202785|Experimental|MLN0264 1.8 mg/kg|MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
3053753|NCT02202772|Experimental|Gem and Low Cab|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 2.5mg/100ml; 1 time a week for 6 weeks; 2 hours
3053754|NCT02202772|Experimental|Gem and High Cab|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours
3053755|NCT02202772|Experimental|Gem, High Cab, and Low Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 66mg/100ml; 1 time a week for 6 weeks; 2 hours
3053756|NCT02202772|Experimental|Gem, High Cab, Mod Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 80mg/100ml; 1 time a week for 6 weeks; 2 hours
3053757|NCT02202772|Experimental|Gem, High Cab, High Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 100mg/100ml; 1 time a week for 6 weeks; 2 hours
3053758|NCT02202759|Experimental|MLN0264 1.8 mg/kg|MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 14 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
3053759|NCT02202746|Experimental|Cohort A: Lucitanib (CO-3810) 10 mg daily|10 mg of lucitanib daily in patients with FGFR1-amplified or 11q-amplified metastatic breast cancer.
3053760|NCT02202746|Experimental|Cohort C: Lucitanib (CO-3810) 10 mg daily|10 mg of lucitanib daily in patients with FGFR1 non-amplified and 11q non-amplified metastatic breast cancer.
3053761|NCT02202733|Other|Cooking|A skill-based cooking intervention for caretakers of an overweight/obese child aged 3-10 years.
3053762|NCT02202720|Experimental|sevoflurane|
3053763|NCT02202707|Other|Gabapentin|Open label single arm study. All participants will receive Gabapentin.
3053764|NCT02202694|Experimental|Intervention|Culturally Adapted Cognitive Behavior Therapy
3053765|NCT02202694|No Intervention|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
3053766|NCT02202681|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI Capsule and imaging will be performed using the OFDI system.
3053767|NCT02202668|Experimental|TRS|
3053768|NCT02202642|Experimental|limbal stem cells|"Using collagenase to isolate limbal stem cells and improve the technique of ex vivo expansion of limbal stem cells for the treatment of patients suffering from unilateral limbal stem cell insufficiency based on the concept of limbal stem cells need special cell-cell contact and cell-extracellular matrix interaction to support their survival"
3053769|NCT02202629|Placebo Comparator|Cherry flavoured beverage 1|10floz cherry flavoured test article
3053770|NCT02202629|Experimental|Cherry flavoured beverage 2|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
3053771|NCT02202629|Experimental|Cherry flavoured beverage 3|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
3053772|NCT02202629|Experimental|Cherry flavoured beverage 4|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
3053773|NCT02202616|Other|ULTIBRO BREEZHALER|Patients diagnosed with chronic obstructive pulmonary disorder (COPD) who are symptomatic (CAT score over 10) and who are treated with Tiotropium (SPIRIVA HANDALER) or Fluticasone propionate/Salmeterol- ADVAIR DISKUS (FDC).
3053774|NCT02202603|Active Comparator|Teriparatide group 1|Subcutaneous injection of Teriparatide
3053775|NCT02202603|Placebo Comparator|excipients|Oral pill without API
3053776|NCT02202603|Experimental|API|Oral administration of pill with API
3053777|NCT02202603|Experimental|API optimization 1|Oral administration of pill with API, for PK optimization #1
3053778|NCT02202603|Experimental|API optimization 2|Oral administration of pill with API, for PK optimization #2
3053779|NCT02202603|Experimental|API optimization 3|Oral administration of pill with API, for PK optimization #3
3053780|NCT02202603|Experimental|API optimization 4|Oral administration of pill with API, for PK optimization #4
3053899|NCT02201914|Experimental|Triptorelin plus daily FSH and LH|
3053782|NCT02202603|Experimental|API optimization 6|Oral administration of pill with API, for PK optimization #6
3053783|NCT02202603|Experimental|API optimization 7|Oral administration of pill with API, for PK optimization #7
3053784|NCT02202603|Active Comparator|Teriparatide group 2|Subcutaneous injection of Teriparatide
3053785|NCT02202603|Experimental|Excipients|Oral pill without API
3053786|NCT02202603|Experimental|API Optimized|expanded group size with API in optimized dosage and administration form.
3053787|NCT02202590|Experimental|Imaging|Subject will swallow the SECM capsule and Imaging will be performed using the SECM Imaging system.
3053788|NCT02202577|Experimental|Chlorhexidine - Isopropyl alcohol|Pre-operative skin preparation with Chlorhexidine Gluconate- Isopropyl alcohol
3053789|NCT02202577|Experimental|Povidone-Iodine Scrub and Paint|Pre-operative skin preparation with Povidone-Iodine Scrub and Paint
3053790|NCT02202564|Experimental|LT+ADV-TK|Liver transplantation and double-dose ADV-TK/ganciclovir administration The first ADV-TK dose was administered before closing the peritoneal layer; the second ADV-TK dose was administered 2 months after LT; ganciclovir was slowly administered 36 hours after LT and twice daily for 14 days.
3053791|NCT02202564|Active Comparator|LT|Orthotopic liver transplantation
3053792|NCT02202551|Experimental|ADS-5102|amantadine HCl extended release
3053793|NCT02202538|Experimental|Indego|Indego
3053794|NCT02202525||Essential arterial hypertension|Patients with essential arterial hypertension needing a new antihypertensive therapy
3053795|NCT02202512|Experimental|BI 1060469 low dose|Low-Dose,Tablet,oral administration with 240 ml water,over 10 days
3053796|NCT02202512|Experimental|BI 1060469 high dose|High-Dose,Tablets,oral administration with 240 ml water, over 10 days
3053797|NCT02202512|Active Comparator|Cimetidine|
3053798|NCT02202512|Active Comparator|Naproxen|
3053799|NCT02202512|Experimental|BI 1021958|High-Dose,Tablets,oral administration with 240 ml water, over 10 days
3053800|NCT02202499|Active Comparator|Extended Varenicline + Facilitated Extinction|Extended Varenicline plus Facilitated Extinction (EV+FE). Participants in the EV+FE condition will receive varenicline for a 4-week run-in period while continuing to smoke. In addition, the EV+FE condition will receive counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided. All groups will undergo periodic laboratory assessments and surveys.
3053801|NCT02202499|Active Comparator|Standard Varenicline (SV)|Participants in the Standard Varenicline (SV) condition will receive varenicline for the usual 1-week run-in period while continuing to smoke. All groups will undergo periodic laboratory assessments and surveys.
3053802|NCT02202499|Active Comparator|Extended Varenicline (EV)|Participants in the Extended Varenicline (EV) condition will receive varenicline for a 4-week run-in period while continuing to smoke. All groups will undergo periodic laboratory assessments and surveys.
3053803|NCT02202486||Migraine with aura|Brain MRI
3053804|NCT02202486||Migraine without aura|Brain MRI
3053805|NCT02202486||Chronic migraine|Brain MRI
3053806|NCT02202473|Active Comparator|Lamivudine|Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd
3053807|NCT02202473|Experimental|Lamivudine+Oxymatrine Capsules|Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd; oxymatrine Capsules (Chia Tai Tianqing Pharmaceutical Group Co., Ltd) 200 mg, po, tid.
3053808|NCT02202447|Experimental|EC1169|"PART A AND B: EC0652 is in development as a radioimaging agent for PSMA-expressing tumors. All patients receive a baseline 99mTc-EC0652 SPECT/CT scan for PSMA expression prior to Cycle 1 Day 1.~PART A: EC1169 given as IV bolus QW on Weeks 1 and 2 of a 3 week cycle. Dose based on dose escalation plan starting with 0.2 mg/m2~PART B: EC1169 cohort 1 - taxane naive mCRPC patients that have progressed while receiving (or subsequent to receiving) abiraterone and/or enzalutamide but must not have previously received taxane-based systemic chemotherapy for mCRPC (previous treatment with six cycles of docetaxel for metastatic castration-sensitive prostate cancer (mCSPC) is permissible).~PART B: EC1169 cohort 2 - taxane exposed mCRPC patients who have progressed while receiving (or subsequent to receiving) abiraterone and/or enzalutamide and who have progressed subsequent to receiving > 2 cycles of a taxane-based regimen for mCRPC."
3053809|NCT02202434|Experimental|Lotus Valve System - Randomized|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
3053810|NCT02202434|Active Comparator|CoreValve TAVR System - Randomized|Transcatheter aortic valve replacement (TAVR) with CoreValve Transcatheter Aortic Valve Replacement System
3053811|NCT02202434|Experimental|LOTUS Edge Valve System - Single-arm 29mm Roll-in Cohort|Transcatheter aortic valve replacement (TAVR) with 29mm LOTUS Edge Valve System
3053812|NCT02202434|Experimental|Lotus Valve Sytem - Single-arm 21mm Cohort|Transcatheter aortic valve replacement (TAVR) with 21mm Lotus Valve System
3053813|NCT02202434|Experimental|Lotus Valve System - Single-arm Continued Access Cohort|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
3053814|NCT02202434|Experimental|Lotus Valve System - Single-arm Roll-in Cohort|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
3053815|NCT02202434|Experimental|LOTUS Edge Valve System - Single-arm 29mm Registry Cohort|Transcatheter aortic valve replacement (TAVR) with 29mm LOTUS Edge Valve System
3053816|NCT02202434|Experimental|LOTUS Edge Valve System - Single-arm Edge Nested Registry|"Transcatheter aortic valve replacement (TAVR) with 23mm, 25mm and 27mm LOTUS Edge Valve System.~This arm is recruiting."
3053817|NCT02202421|Active Comparator|T-ABA Parent Training Only|Participants in the T-ABA Parent Training Only group will be given Targeted Applied Behavior Analysis (T-ABA) Intervention with five weeks of parent group training and five weeks of parent-therapists one-on-one sessions. They will also be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
3053818|NCT02202421|Experimental|T-ABA Parent Group + Individual Therapy|Participants in the T-ABA Parent Group plus Individual Therapy group will be given Targeted Applied Behavior Analysis (T-ABA) Intervention with five weeks of parent group training and five weeks of parent-therapists one-on-one sessions. They will also be offered eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions.
3053819|NCT02202408|Experimental|SKI2670|"Single-dose escalation/ Subjects received an oral single dose of SKI2670 capsule by dosing group~-Dosing Group 1, Dosing Group 2, Dosing Group 3, Dosing Group 4"
3053820|NCT02202408|Placebo Comparator|Placebo|Subjects received an oral single dose of placebo capsule matched to the SKI2670 dose (Placebo for SKI2670)
3053821|NCT02202395|Active Comparator|0.25mg|LTS 0.25mg,qd MTX qw
3053822|NCT02202395|Active Comparator|0.5mg|LTS 0.5mg, qd MTX qw
3053823|NCT02202395|Active Comparator|1.0mg|LTS 1.0mg,qd MTX qw
3053824|NCT02202395|Placebo Comparator|Placebo|Placebo qd MTX qw
3053825|NCT02202382|Placebo Comparator|non-V + P group|no surgery and placebo (12 weeks)
3053826|NCT02202382|Active Comparator|V + P group|Surgery with placebo (12 weeks)
3053827|NCT02202382|Active Comparator|non-V + KRG group|no surgery with KRG (korean red ginseng, 1.5 gm daily 12weeks)
3053828|NCT02202382|Experimental|V + KRG group|Surgery with KRG (1.5 gm daily 12weeks)
3053829|NCT02202369|Experimental|Multimodal Analgesia (MMA) Treatment|
3053830|NCT02202369|Active Comparator|Standard of Care Pain Managment Protocol|
3053831|NCT02202356|Experimental|ALS-008176 Single Dose|Single dose of ALS-008176 administered orally as a suspension
3053832|NCT02202356|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered orally as a suspension
3053833|NCT02202356|Experimental|ALS-008176 Multiple Doses|Multiple doses of ALS-008176 administered orally as a suspension
3053834|NCT02202356|Placebo Comparator|Placebo Multiple Doses|Multiple doses of placebo administered orally as a suspension
3053835|NCT02202343|Experimental|School-based health and nutrition education|
3053836|NCT02202330|Placebo Comparator|Standard Care, Organized Discharge|Stroke patients are given instructions before discharge regarding diet, need for rehabilitation, possible complications, medication use and information booklets are also handed out. This information is imparted by a multidisciplinary team consisting of a neuro physician, a stroke nurse, a dietitian and a physiotherapist. These are verbal instructions and handouts are written in English. On the day of discharge, or 24 hours prior to discharge, a discharge coordinator details the skills learnt . A detailed written discharge summary is given out detailing all aspects of care, follow-up, medications and test results.
3053837|NCT02202330|Experimental|Video Arm, Standard Discharge|"Intervention is as follows:~5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)~Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.~Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions."
3053838|NCT02202317|Experimental|Y90 Based PET/CT Scan|
3053839|NCT02202304|Experimental|Chlorhexidine/Thymol varnish|"Participants to the study will receive an application of either the placebo or the product being studied every 3 months. This will be applied on all abutment teeth using a microbrush by painting it over the surfaces of these teeth."
3053840|NCT02202304|Placebo Comparator|Placebo varnish|"Participants to the study will receive an application of either the placebo or the product being studied every 3 months. This will be applied on all abutment teeth using a microbrush and painting it on all the surfaces of these teeth.."
3053841|NCT02202291|Experimental|Patient with Raynaud's phenomenon|
3053842|NCT02202278||ovarian hyperstimulation patients|Moderate OHSS is defined as abdominal distension and discomfort, nausea with or without vomiting, ovarian enlargement (ovarian size of 8-12 cm) and ascites that revealed by ultrasonografic examination. Severe OHSS criteria is defined as ovarian enlargement, ascites with or without hydrothorax, haematocrit >45%, weight gain >2 kg, white blood cell count >15.000, oliguria, creatinine of 1.0-1.5, creatinine clearance of >50 ml/min, liver dysfunction.
3053843|NCT02202278||without ovarian hiperstimulation|Control group is composed of patients who underwent long luteal protocol but do not demonstrate symptoms of OHSS
3053844|NCT02202265|Active Comparator|Control diet (standard dietary)|Patients will receive a control diet based on standard dietary guidelines
3053845|NCT02202265|Experimental|Olive oil (30ml a day)|Patients will receive a control diet based on standard dietary guidelines + 30ml of olive oil a day
3053846|NCT02202265|Experimental|Nuts (30g a day)|Patients will receive a control diet based on standard dietary guidelines plus 30g of nuts a day
3053847|NCT02202252|Experimental|Single drain|"Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group.~Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography."
3053848|NCT02202252|Experimental|Double drain|"Insertion of double drains: Two negative pressure drains will be inserted into the axilla and below the lower flap in the double drains group.~Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography."
3053849|NCT02202239|Experimental|Group E|Etomidate was used in both induction and maintenance of anesthesia.
3053850|NCT02202239|Active Comparator|Group P|Propofol was used in both induction and maintenance of anesthesia.
3053851|NCT02202226|Experimental|Lu AF35700 oral solution (1 mg/mL)|Planned daily doses range from 5 mg/day to 30 mg/day for 3 weeks. Weekly doses up to 75 mg/week for 3 weeks.
3053852|NCT02202226|Placebo Comparator|Matching placebo|Oral solution
3053853|NCT02202213|Experimental|Lu AF11167 hard capsules; 0.25, 0.5 and 1 mg|"Part A: Lu AF11167 monotherapy Part B: Lu AF11167 adjunctive therapy to risperidone~Three times daily oral dosing for 14 days."
3053854|NCT02202213|Placebo Comparator|Matching placebo|Daily oral dosing matching the experimental arm.
3053855|NCT02202200|Experimental|PD-0332991|
3053856|NCT02202187|Experimental|GSK2140944|Dose range 100mg to 3000mg single dose
3053857|NCT02202187|Placebo Comparator|Matching Placebo|Placebo
3053858|NCT02202174||Supraglottic Airway Device|Patients will receive a supraglottic airway device as a primary means of ventilation. The following devices may be used: LMA Unique, LMA ProSeal, LMA Supreme, LMA Flexible, Ambu Aura-I, Ambu Aura Once, Air-Q, I-Gel, or other supraglottic airway device. Choice of the device will be clinician dependent and based on the patients body weight per manufacturer guidelines
3053859|NCT02202161|Experimental|GSK2330672 10 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 10 mg BID for 14 days.
3053860|NCT02202161|Experimental|GSK2330672 20 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 20 mg BID for 14 days.
3053861|NCT02202161|Experimental|GSK2330672 30 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 30 mg BID for 14 days.
3053862|NCT02202161|Experimental|GSK2330672 90 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 90 mg BID for 14 days.
3053863|NCT02202161|Placebo Comparator|GSK2330672-matched placebo|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by matching placebo (of GSK2330672) BID for 14 days.
3053864|NCT02202161|Active Comparator|Sitagliptin 50 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by Sitagliptin 50 mg BID for 14 days. In this study, sitagliptin 50 mg BID will be provided as open-label (unblinded) study treatment.
3053865|NCT02202148||alcohol withdrawal|
3053866|NCT02202135|Experimental|Ceftaroline fosamil|Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
3053867|NCT02202135|Active Comparator|Vancomycin plus aztreonam|Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function
3053868|NCT02202122||Study Group|OSA Scoring
3053869|NCT02202109|Active Comparator|CHWs facilited Self-Sampling|CHW and Self-sampling for Cervical Cancer. Home visit, self-sampler, collection of test
3053870|NCT02202109|Active Comparator|Mailed Self-Sampler|Mailed Self Sampler. Self sampler is mailed to participant; follow up by phone
3053871|NCT02202096|Experimental|Intervention (plus usual care)|Patient education: One-on-one visit Discharge planning: Assessment of barriers to discharge Medication reconciliation: Patient medication review Appointment before discharge: Additional measure to ensure awareness of next clinic visit Transition coach Patient-centered discharge instructions: Enhanced Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology Timely follow-up: Barriers to clinic follow-up visits will be discussed Timely PCP communication Follow-up telephone call Patient hotline: 24 hour follow-up following call to Ask My Nurse number
3053872|NCT02202096|No Intervention|Usual Care|Usual care-Standard of care that all colorectal cancer patients normally receive
3053873|NCT02202083|Experimental|oxytocin|"There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon.~This group is term gestaion,with bishop score less than 6."
3053874|NCT02202070|Experimental|Botox injection first, followed by placebo|50 units Botox injection in masseter and temporalis muscles in the first 3 months, then second injection of normal saline at placebo in second 3 months
3053875|NCT02202070|Experimental|Placebo injection first, followed Botox|Injection of normal saline at placebo in first 3 months, then 50 units Botox injection in masseter and temporalis muscles in the second 3 months.
3053876|NCT02202057||Parkinson's disease|Men and women with Parkinson's disease, between 45 and 85 years of age. The following will be done: Respiratory resistive load on inhalation and Fluoroscopic swallowing evaluation.
3053877|NCT02202057||Healthy adults|Men and women without Parkinson's disease, between 45 and 85 years of age. The following will be done: Respiratory resistive load on inhalation.
3053878|NCT02202044|Experimental|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks of Intravesical Intravesical BCG and EMDA/MMC
3053879|NCT02202031|Experimental|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
3053880|NCT02202031|Experimental|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
3053881|NCT02202018|Experimental|Active KT Intervention|CKD clinics receiving the active knowledge translation intervention.
3053882|NCT02202018|No Intervention|Usual standard of care|Clinics will continue their standard of care education and approach to use of home dialysis.
3053883|NCT02202005|Experimental|Nevirapine|
3053884|NCT02202005|Active Comparator|Viramune®|
3053885|NCT02201992|Experimental|Arm A (crizotinib)|Patients receive crizotinib PO BID on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3053886|NCT02201992|Active Comparator|Arm B (observation)|Patients undergo observation.
3053887|NCT02201979||Breast lift in combination with implants.|Patients undergoing breast lifts in combination with implants are studied using laser fluorescent imaging to evaluate blood supply.
3053888|NCT02201966||Female gymnasts with low back pain|Subset of competitive female gymnasts who report significant low back pain that affects their ability to perform gymnastics.
3053889|NCT02201966||Female gymnasts without low back pain|Subset of competitive female gymnasts who deny significant low back pain that affects their ability to perform gymnastics.
3053890|NCT02201953|Experimental|SOF/VEL 12 Weeks|SOF/VEL FDC for 12 weeks
3053891|NCT02201953|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
3053892|NCT02201940|Experimental|SOF/VEL|SOF/VEL for 12 weeks
3053893|NCT02201940|Placebo Comparator|Placebo|SOF/VEL placebo for 12 weeks
3053894|NCT02201927|Experimental|patient with right parietal lobe lesion|Patient with right parietal lobe lesion
3053895|NCT02201927|Experimental|patient stroke|patient with cerebral vascular accident
3053896|NCT02201927|Experimental|healthy volunteers|healthy volunteers
3053897|NCT02201914|Experimental|Clomiphene citrate|
3053898|NCT02201914|Experimental|Daily FSH and LH plus Cetrorelix|
3053900|NCT02201901|Experimental|SOF/VEL 12 weeks|Participants will receive SOF/VEL FDC for 12 weeks.
3053901|NCT02201901|Experimental|SOF/VEL+RBV 12 weeks|Participants will receive SOF/VEL FDC plus RBV for 12 weeks.
3053902|NCT02201901|Experimental|SOF/VEL 24 weeks|Participants will receive SOF/VEL FDC for 24 weeks.
3053903|NCT02201888|Experimental|Computer-assisted cognitive training|Patients in this arm of the trial carried out computerized online training drawn from the Feskits program (www.feskits.com), chosen to have attention, memory and executive function components. Specifically the sessions included the following exercises: sustained attention (4 minutes), attention/perception (5 minutes), working memory (8 minutes), auditory and visual memory (8 minutes), executive function (10 minutes), language (6 minutes), and games (4 minutes).
3053904|NCT02201888|Active Comparator|Computerized active condition|Patients allocated to this condition completed the same number of sessions as the cognitive training group but followed a computerized typing program (www.rapidtyping.com). This had similar design characteristics to the CRT condition, in that it was hierarchically organized with exercise level of difficulty being adjusted to the individual's level of performance and feedback being given at the end of each exercise. Additionally, patients in this condition played computerized games requiring typing (crosswords, word puzzles, etc) and were taught basic internet navigation by a supervisor. Exposure to the computer was of equivalent duration to the CRT condition.
3053905|NCT02201888|Placebo Comparator|Treatment as usual|Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities
3053906|NCT02201875||Healthy subjects|male, aged 18-65 moderately trained healthy, no treatment
3053907|NCT02201875||obstructive sleep apneas|patients with apnea/hypopnea index > 15 BMI < 30 Age < 50 yrs
3053908|NCT02201875||cardiac failure|NYHA class I to III ejection fraction < 40% age < 65 yrs BMI < 30
3053909|NCT02201862||Euploid Subjects|Subject's with fetal euploidy confirmed by chromosome analysis
3053910|NCT02201862||Aneuploid Subjects|Subject's with fetal aneuploidy confirmed by chromosome analysis
3053911|NCT02201849|Experimental|Study Drug|Oral capsules
3053912|NCT02201849|Active Comparator|Active Control|Oral capsules
3053913|NCT02201849|Placebo Comparator|Placebo|Oral capsules
3053914|NCT02201836|Active Comparator|One time music therapy session|One time music therapy session which consists of music meditation, including as assessment/evaluation of confined body breathing function as expressed through drawing and coloring post music imagery session. This is followed by an entrainment wind playing/breath expansion music therapy intervention. At the end of the session, the subjects are given a donated wind instrument for play at home.
3053915|NCT02201836|Active Comparator|Weekly group music therapy intervention|The weekly group music therapy intervention consists of children and teens using guided visualization and expressing their fears and or fantasies related to breathing with one another. This is followed by creative music improvisations with part-playing on flutes, slide whistles, recorders and melodicas.
3053916|NCT02201836|No Intervention|Control|
3053917|NCT02201823|Experimental|ABTL0812|ABTL0812 oral
3053918|NCT02201810|Experimental|2nd level intervention: Rate Reduction|Rate reduction intervention
3053919|NCT02201810|Experimental|2nd level intervention: Recycling|Recycling Group
3053920|NCT02201810|Experimental|2nd level intervention: Choice|Choice Group
3053921|NCT02201797|Experimental|DCE and DWI MRI|MRI SCAN 1 and MRI SCAN 2 must be completed no less than 2 calendar days (to ensure 24 hours for clearance of gadolinium) and no greater than 14 days apart, and both must be completed prior to new treatment initiation. The same MRI unit and configuration must be used for MRI SCAN 1 and MRI SCAN 2.
3053922|NCT02201784|Active Comparator|Levobupivacaine 0.5%|intrathecal administration of 15 mg of Levobupivacaine 0.5%
3053923|NCT02201784|Active Comparator|Ropivacaine 0.75%|intrathecal administration of 22.5 mg of Ropivacaine 0.75%
3053924|NCT02201771|Active Comparator|Aspirin|aspirin 100mg tablet by mouth daily for 12 months
3053925|NCT02201771|Experimental|Ticagrelor plus Aspirin|ticagrelor 90mg tablet by mouth twice daily and aspirin 100mg tablet by mouth daily for 12 months
3053926|NCT02201771|Experimental|Ticagrelor|ticagrelor 90mg tablet by mouth twice daily for 12 months
3053927|NCT02201758|Placebo Comparator|Placebo|Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
3053928|NCT02201758|Experimental|flaxseed lignan-enriched complex (FLC)|Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
3053929|NCT02201732|Experimental|Arm A : Operative hysteroscopy|operative hysteroscopy with direct visualization
3053930|NCT02201732|Active Comparator|Arm B : Aspirative curettage|curettage is the standard surgical treatment in most centers
3053931|NCT02201719||Hysterectomy Adenomyosis|Adenomyosis present
3053932|NCT02201719||Hysterectomy no adenomyosis|Adenomyosis not present
3053933|NCT02201706|Experimental|Multi-electrocoagulation retinectomy|Retinal re-detachment in eyes with silicone oil filled,a modified surgery named Multi-electrocoagulation retinectomy will be used to re-attach the retina.
3053934|NCT02201693|Experimental|Cyclic exclusive MODULEN IBD|Cyclic exclusive MODULEN IBD for 2 weeks every 8 weeks
3053935|NCT02201693|Experimental|MODULEN IBD supplementation (25% of caloric requirements)|MODULEN IBD supplementation (25% of caloric requirements) alone A Physician not involved in the study design and blinded to the treatment arm will perform the evaluation of the patients during each study visit.
3053936|NCT02201680||parents and children|Anxiety tests
3053937|NCT02201667|Experimental|Ticagrelor group|Patients wil be given 180 mg loading dose of ticagrelor and 300mg loading dose of aspirin followed by PCI, then will receive 90 mg ticagrelor twice daily with aspirin maintenance dose to 30 days after randomization.
3053938|NCT02201667|Active Comparator|Clopidogrel group|Patients will be given clopidogrel 300mg loading dose and 300mg loading dose of aspirin followed by PCI, then will receive 75mg clopidogrel once with aspirin maintenance dose to 30 days after randomization.
3053939|NCT02201654|Other|EBUS patients|All patients in our study are in the same arm, as each patient serves as their own internal control. More specifically, each enrolled patient will receive both traditional EBUS (with the usage of stylet) and experimental EBUS (EBUS without a stylet) at each lymph node that is included in the experimental analysis.
3053940|NCT02201641|Experimental|calcium silicate cement (Biodentine™)|calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
3053941|NCT02201641|Experimental|Cone Beam computed tomography (CBCT)|CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.
3053942|NCT02201641|Active Comparator|Periapical radiographs|Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.
3053943|NCT02201641|Active Comparator|Glass ionomer cement ( Fuji IX™)|Glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
3053944|NCT02201628|Experimental|Nasopharyngeal and oesophageal temperatures|An oesophageal and nasopharyngeal temperature probe will be placed and temperature will be measured at these site
3053945|NCT02201615|Experimental|Perineal Massage & Control|"Perineal Massage every 30 min, a 10 min 4 times in the first stage of labour, 1 times in the second stage of labour.~Control routine care procedure at the clinic."
3053946|NCT02201602|Experimental|Gliclazide|Gliclazide, 80 mg tablet, half to maximal dose, 3 weeks
3053947|NCT02201602|Active Comparator|Glibenclamide|Glibenclamide, 5 mg tablet, half to maximal dose, 3 weeks
3053948|NCT02201589|Experimental|Endovascular repair of ascending aorta|Endovascular repair with Valiant PS-IDE Stent Graft
3053949|NCT02201576|Experimental|Bortezomib|Five plasma exchanges, two cycles of bortezomib + dexamethasone, 4 courses of polyclonal intravenous immunoglobulins
3053950|NCT02201576|Active Comparator|Control|Five plasma exchanges, dexamethasone, 4 courses of polyclonal intravenous immunoglobulins
3053951|NCT02201563|Experimental|Minocycline|oral Minocycline 100 mg twice a day for 3 months.
3053952|NCT02201550||Liraglutide|Patients with type 2 diabetes undertaking treatment with liraglutide
3053953|NCT02201537|Other|Imag-NCT|"The ultrasound functional imaging will be performed at J15 (before the patient is discharged from service Transplantation) and at 3 and 12 months after the transplant.~The functional imaging examinations will be held as follows:~1st stage - the conventional Doppler ultrasound:~2nd stage - the elastography:.~Step 3 - CEUS: It is performed on an ultrasound machine with a specific module with the same probes as conventional ultrasound. It requires the injection of 1.5 ml of SonoVue ®, a contrast ultrasound.~Renal biopsy will be performed after the functional ultrasound at 3 and 12 months."
3053954|NCT02201524|Experimental|Cohort 1|200mg of PF-04965842 twice daily
3053955|NCT02201524|Experimental|Cohort 2|400mg of PF-04965842 once daily
3053956|NCT02201524|Experimental|Cohort 3|200mg of PF-04965842 once daily
3053957|NCT02201524|Placebo Comparator|Cohort 4|Placebo comparator daily
3053958|NCT02201511|Experimental|Arm 1|
3053959|NCT02201511|Experimental|2|
3053960|NCT02201511|Experimental|3|
3053961|NCT02201511|Experimental|4|
3053962|NCT02201498|Active Comparator|Formocresol/OZE|Conventional pulpotomy technique, with formocresol and zinc oxide eugenol
3053963|NCT02201498|Active Comparator|Biodentine|New technique, with biodentine
3053964|NCT02201485|Active Comparator|PTA in combination with stent-placement|In this group, the patients will undergo percutaneous balloon angioplasty with or without stent-placement angioplasty in combination with stent-placement.
3053965|NCT02201485|Active Comparator|PTA alone|In this group, the patients will undergo percutaneous balloon angioplasty alone. The patients will transfer to the stent placement in the following cases: 1) reocclusion with thrombosis; and 2) at least 2 reocclusion events.
3053966|NCT02201472|Experimental|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
3053967|NCT02201459|Active Comparator|Nilotinib|Control arm, this compound been licensed in this indication.
3053968|NCT02201459|Experimental|Peg-IFN alfa 2a (Pegasys®) and Nilotinib|Arm testing the efficacy of a combination of nilotinib and Peg-IFN alfa 2a as frontline therapy for first line chronic phase CML patients.
3053969|NCT02201446||ARDS patients|Eighty-one patients were enrolled consecutively over a two-year time period (2014-2015) and identified as ARDS prospectively according to the Berlin definitions of the European Society of Intensive Care Medicine and American Thoracic Society on ARDS. Exclusion criteria were an age of less than 16 years, pregnancy, chronic obstructive pulmonary disease according to medical history and failure to obtain informed consent.
3053970|NCT02201446||Healthy volunteers|Fifty-eight healthy volunteers recruited from the general population who had no significant medical history and no medications were categorized as control patients.
3053971|NCT02201433||medical staff and member of an association|"members of medical staff and member of an association of parents of premature infants.~This cohort is necessary to build protocol interview for part 2 of the study"
3053972|NCT02201433||fathers|fathers of preterm newborns
3053973|NCT02201433||fathers or médical staff|This cohort is build for data validation. We will include fathers who have experienced this situation. Caregivers of NICU who are not participating in the first part
3053974|NCT02201420|Experimental|Tc 99m tilmanocept|Subjects who are enrolled and will receive 50 micrograms tilmanocept radiolabeled with 2 millicuries of Tc 99m and undergo serial SPECT or SPECT/CT imaging.
3053975|NCT02201407||CHB Participants Treated With Peginterferon alfa-2a|As this is an observational study, treatment schedule will be at the clinician's discretion in accordance with local labeling and not directed by the protocol. Participants with CHB who are receiving peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics, and in line with the local labeling will be followed for the duration of treatment with peginterferon alfa-2a (48 weeks) and up to 24 weeks after peginterferon alfa-2a treatment (72 weeks in total).
3053976|NCT02201394|Experimental|Loading dose|Patients with stable CVD given a single ticagrelor loading dose and aspirin loading dose
3053977|NCT02201394|Experimental|Maintenance dose|Patients with stable CVD given ticagrelor maintenance dose and aspirin maintenance dose for one week.
3053978|NCT02201381|Experimental|Metabolic Treatment|"Subjects will take the following treatments and have their data collected from their medical records every 3 months.~Oral atorvastatin up to 80mg uid, for study duration.~Oral metformin up to 1000mg uid, increased to bid if tolerated after 2 weeks, for study duration.~Oral doxycycline 100mg uid, for study duration.~Oral Mebendazole 100mg uid, for study duration."
3053979|NCT02201368|Experimental|Triheptanoin|
3053980|NCT02201368|Active Comparator|MCT (Medium-Chain Triglycerides)|
3053981|NCT02201355|Experimental|chemoradiation|Hypofractionated, PET-directed, Intensity Modulated Radiotherapy Concurrent with Weekly Cisplatin Chemotherapy
3053982|NCT02201342|Experimental|Udenafil Dose Level 1 qd|Udenafil tablet dose Level 1 daily for 5 days
3053983|NCT02201342|Experimental|Udenafil Dose Level 1 bid|Udenafil Dose Level 1 twice daily for 5 days.
3053984|NCT02201342|Experimental|Udenafil Dose Level 2 qd|Udenafil tablet dose level 2 once daily for 5 days.
3053985|NCT02201342|Experimental|Udenafil Dose Level 2 bid|Udenafil tablet dose level 2 twice daily for 5 days
3053986|NCT02201342|Experimental|Udenafil Dose Level 3 qd|Udenafil tablet dose level 3 daily for 5 days
3053987|NCT02201342|No Intervention|No Drug|No drug
3053988|NCT02201329|Experimental|A|Volasertib escalating doses + azacitidine
3053989|NCT02201316|Experimental|Sequence 1 (ABC)|Subjects will receive treatments in the sequence ACB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
3053990|NCT02201316|Experimental|Sequence 2 (ACB)|Subjects will receive treatments in the sequence ACB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
3053991|NCT02201316|Experimental|Sequence 3 (BAC)|Subjects will receive treatments in the sequence BAC where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
3053992|NCT02201316|Experimental|Sequence 4 (BCA)|Subjects will receive treatments in the sequence BCA where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
3053993|NCT02201316|Experimental|Sequence 5 (CAB)|Subjects will receive treatments in the sequence CAB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
3053994|NCT02201316|Experimental|Sequence 6 (CBA)|Subjects will receive treatments in the sequence CBA where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
3053995|NCT02201303|Experimental|Part 1|Blood sample will be collected from the RSV-infected children <2 years and healthy adults participants. Escalating concentrations of CXCL1 will be added to whole blood in vitro and CD11b up regulation on peripheral blood neutrophils will be analyzed
3053996|NCT02201303|Experimental|Part 2|Blood sample will be collected from the RSV-infected children <2 years and healthy adults participants. Escalating concentrations of danirixin will be added to whole blood in vitro with a fixed concentration of CXCL1 to determine inhibition of CD11b expression on peripheral blood neutrophils
3053997|NCT02201290|Experimental|Eltrombopag|Eligible subject will be allocated to 1 of 3 age-defined cohorts. Cohort 1: between 12 and 17 years old, Cohort 2: between 6 and 11 years old, and Cohort 3: between 1 and 5 years old. For Cohorts 1 and 2, eltrombopag tablets will be administered, however, subjects in Cohort 2 may use eltrombopag powder for oral suspension (Eltrombopag PfOS) if they have difficulty swallowing tablets and are receiving a dose of eltrombopag of < 40 mg. For Cohort 3, either eltrombopag tablets or PfOS will be administered.
3053998|NCT02201277|Experimental|Denali|Denali IVC Filter
3053999|NCT02201277|Experimental|Option|Option IVC Filter
3054000|NCT02201264||Primary PCI for STEMI patients|Primary PCI for patients presenting with ST elevation MIs
3054001|NCT02201251|Experimental|Topiramate|Topiramate weight based dosing for participants 2 to less than (<) 10 years of age not to exceed 350 mg/day (milligram per day), as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
3054002|NCT02201251|Active Comparator|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 milligram per kilogram per day (mg/kg/day), as tolerated. The maximum recommended daily dosage is 3,000 milligram (mg).
3054003|NCT02201238|Experimental|Diclofenac sodium/menthol gel (in tube)|1% diclofenac sodium plus 3% menthol gel (in 30g aluminium tube). Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
3054004|NCT02201238|Experimental|Diclofenac sodium/menthol gel (in roll-on device)|1% diclofenac sodium plus 3% menthol gel (in roll-on applicator device supplied in 30g plastic bottles). Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
3054005|NCT02201238|Active Comparator|Diclofenac sodium tablets|50mg diclofenac sodium tablets administered orally, three times daily for three consecutive days with 6h between adjacent doses on the same day
3054006|NCT02201238|Active Comparator|Voltaren gel|Voltaren gel supplied in 100g aluminium tube. Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
3054007|NCT02201225|Active Comparator|Nutritional supplement with micronutrient|Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve twice daily
3054008|NCT02201225|Sham Comparator|Nutritional supplement without micronutrient|Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve twice daily
3054073|NCT02200796|Experimental|High Protein Meal|High Protein Meal (45g)
3054074|NCT02200796|Experimental|Control Meal|High Carbohydrate Control Meal (7 g of protein)
3054009|NCT02201212|Experimental|Everolimus|"Everolimus~Fixed doses orally once a day per each 28 day cycle~Participants will stay on study as long as they do not progress for a maximum of 24 months.~Tumor assessments will be performed after every 2 cycles for as long as they are on study."
3054010|NCT02201199|Active Comparator|insulin glargine U100|1 single dose
3054011|NCT02201199|Experimental|insulin glargine U200|1 single dose
3054012|NCT02201199|Experimental|insulin glargine U500|1 single dose
3054013|NCT02201186|Experimental|manuka honey enema treatment|Study patients diagnosed with acute pouchitis after bowel surgery for ulcerative colitis will perform manuka honey enemas twice a day for 30 days.
3054014|NCT02201173|Experimental|Locomotor Training|
3054015|NCT02201160|Active Comparator|omega 3|The subjects will take 4 capsules/day during 6 months. Each capsule of the active n-3 PUFA supplement contained 500 mg of fish oil (each capsule provides 300 mg of n-3 PUFA (EPA+DHA) with 3.75 U vitamin E to prevent peroxidation).
3054016|NCT02201160|Placebo Comparator|Sun Flower|The subjects will take 4 capsules/day during 6 months. The placebo capsule contained 500 mg of sunflower oil with 3.75 U vitamin E.
3054017|NCT02201147|Experimental|cold biopsy polypectomy|
3054018|NCT02201147|Experimental|Cold snare polypectomy|
3054019|NCT02201134|Other|sevoflurane|
3054020|NCT02201121|Experimental|phenylephrine group, dopamine group, ephedrine group|"phenylephrine group: use the phenylephrine to increase the SAP from low to high level.~dopamine group: use the dopamine to increase the SAP from low to high level. ephedrine group:use the ephedrine to increase the SAP from low to high level."
3054021|NCT02201108|Placebo Comparator|placebo|Matching placebo tablets
3054022|NCT02201108|Experimental|Teriflunomide|teriflunomide oral tablet, three dosages (3.5, 7 or 14 mg) to reach 14 mg adult equivalent
3054023|NCT02201095|No Intervention|Normal care|Normal care - no active warming
3054024|NCT02201095|Active Comparator|Forced air warming|Underbody forced air warming blanket
3054025|NCT02201095|Active Comparator|Conduction warming mattress|Underbody conduction warming mattress
3054026|NCT02201082|Experimental|Nebulization and airway clearance technique|nebulization combined to airway clearance
3054027|NCT02201082|Active Comparator|Nebulization|nebulization
3054028|NCT02201069|Experimental|health coaching|12 weeks of health coaching using weekly contact in the first month and biweekly contacts in months 2-3.
3054029|NCT02201056|Experimental|Cohort 1: TAK-935 15 mg|TAK-935 15 mg solution, orally, once, on Day 1.
3054030|NCT02201056|Experimental|Cohort 2: TAK-935 50 mg|TAK-935 50 mg solution, orally, once, on Day 1.
3054031|NCT02201056|Experimental|Cohort 3: TAK-935 200 mg|TAK-935 200 mg solution, orally, once, on Day 1.
3054032|NCT02201056|Experimental|Cohort 4: TAK-935 600 mg|TAK-935 600 mg solution, orally, once, on Day 1.
3054033|NCT02201056|Experimental|Cohort 5: TAK-935 900 mg|TAK-935 900 mg solution, orally, once, on Day 1.
3054034|NCT02201056|Experimental|Cohort 6: TAK-935 1350 mg|TAK-935 1350 mg solution, orally, once, on Day 1.
3054035|NCT02201056|Placebo Comparator|Cohorts 1-6: Placebo|TAK-935 placebo-matching solution, orally, once, on Day 1.
3054036|NCT02201043|Active Comparator|Thalidomide 150mg|Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks;100mg/qd.po.2weeks; 150mg/qd.po.to the end
3054037|NCT02201043|Active Comparator|Thalidomide 100mg|Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks; 100mg/qd.po.to the end
3054038|NCT02201043|Placebo Comparator|Placebo|Placebo po.
3054039|NCT02201030|Experimental|NBP606|13-valent pneumococcal conjugate vaccine
3054040|NCT02201030|Active Comparator|Prevnar13|13-valent pneumococcal conjugate vaccine
3054041|NCT02201004|Experimental|tofogliflozin|Tofogliflozin administered once daily for 52 weeks. Insulin administered as base treatment.
3054042|NCT02201004|Placebo Comparator|placebo|Placebo administered once daily for 16 weeks. After 16-weeks, Tofogliflozin administered once daily for 36 weeks. Insulin administered as base treatment.
3054043|NCT02200991|Experimental|Lixisenatide|"Lyxumia solostar: Initially started with 10 μg once-daily and increased up to 20 μg once daily (dose increased by 5 μg every week), subcutaneous injection in the abdomen, administered 30 minutes before breakfast. The period of administration is 4 weeks.~Lantus solostar as base treatment: Subcutaneous injection in the abdomen."
3054044|NCT02200991|Active Comparator|Sitagliptin - Januvia|"50 mg tablet, administered orally once-daily, 30 minutes before breakfast. The period of administration is 4 weeks.~Lantus solostar as base treatment: Subcutaneous injection in the abdomen."
3054045|NCT02200978|Active Comparator|ATO and chemotherapy|"Induction:~ATRA 25mg/m2 d1-CR ≯42 days; ATO 0.16mg/kg d5-CR ≯42 days; mitoxantrone (MA) 10mg/m2 d3, or 7mg/m2 d2-4 (high risk).~Consolidation 1:~ATRA 25mg/m2 d1-15; MA 10mg/m2 d1-2; Intrathecal injection (IT)：Ara-C 15mg (age < 1 year), or 20 mg (1-3 years), or 30 mg ( > 3 years), dexamethasone 2mg.~Consolidation 2:~ATRA 25mg/m2 d1-15; ATO 0.16mg/kg d1-15; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Consolidation 3:~ATRA 25mg/m2 d1-15; ATO 0.16mg/kg d1-15; MA 10mg/m2 d1; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Maintenance:~① ATO 0.16mg/kg.d w1-2; ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. ② ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. Rotation between ① and ② until the end of maintenance."
3054046|NCT02200978|Experimental|RIF and chemotherapy|"Induction:~ATRA 25mg/m2 d1-CR ≯42 days; RIF 0.135/kg d5-CR ≯42 days; mitoxantrone (MA) 10mg/m2 d3, or 7mg/m2 d2-4 (high risk).~Consolidation 1:~ATRA 25mg/m2 d1-15; MA 10mg/m2 d1-2; Intrathecal injection (IT)：Ara-C 15mg (age < 1 year), or 20mg (age 1-3 years), or 30mg (age > 3 years), dexamethasone 2mg.~Consolidation 2:~ATRA 25mg/m2 d1-15; RIF 0.135/kg d1-15; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Consolidation 3:~ATRA 25mg/m2 d1-15; RIF 0.135/kg d1-15; MA 10mg/m2 d1; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Maintenance:~① RIF 0.135/kg.d w1-2; ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. ② ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. Rotation between ① and ② until the end of maintenance treatment."
3054075|NCT02200783|Active Comparator|Radial|Cardiac catheterization and coronary angioplasty performed via standard radial artery technique.
3054076|NCT02200783|Active Comparator|Femoral|Cardiac catheterization and coronary angioplasty performed via standard femoral artery technique.
3054077|NCT02200783|Experimental|TripTable|Cardiac catheterization and coronary angioplasty performed with standard transradial technique plus using the TRIPTable device.
3054078|NCT02200770|Experimental|MEDI551|
3054079|NCT02200770|Placebo Comparator|Placebo|
3054047|NCT02200965|Active Comparator|Received a letter on 3 occasions|"My Diabetes, My Information, My Plan Document:~To deliver a structured, understandable, well designed, user friendly, user developed and approved document / letter to all people with diabetes that contains all information about their key care processes in diabetes to promote self-awareness, patient activation and process completion of their own diabetes outcomes.~This communication (3 mailings per patient (at 0 and 3 and 6 months) will be distributed to the 50% of the whole epidemiological base of people with diabetes (n=>16,000) with the non-interventional group (that will receive the same document once at 3 months) acting as control."
3054048|NCT02200965|Active Comparator|Received letter on 1 occasion|"My Diabetes, My Information, My Plan Document:~To deliver a structured, understandable, well designed, user friendly, user developed and approved document / letter to all people with diabetes that contains all information about their key care processes in diabetes to promote self-awareness, patient activation and process completion of their own diabetes outcomes.~This communication (3 mailings per patient (at 0 and 3 and 6 months) will be distributed to the 50% of the whole epidemiological base of people with diabetes (n=>16,000) with the non-interventional group (that will receive the same document once at 3 months) acting as control."
3054049|NCT02200952||Patients at risk of OHSS|Patients at risk of OHSS on the oocytes triggering day with an oestradiol > 4000pg/ml or a number of follicles greater than 24 of a diameter greater than 12 mm
3054050|NCT02200939|Experimental|Partial-thickness tear|Medium or large partial-thickness tear or very small full-thickness tear of the supraspinatus tendon surgically treated by implantation of the bioinductive implant.
3054051|NCT02200939|Experimental|Full-thickness tear|Medium or large full-thickness tear of the supraspinatus tendon surgically treated with the bioinductive implant adjunctive to surgical repair.
3054052|NCT02200926|Experimental|Placebo|The breathing was performed normally in this groups.
3054053|NCT02200926|Experimental|Loaded breathing training|subjects will trained to inspire deeply against the resistance setting by using BreathMAX® at the loaded of 18 cmH2O with breathing frequency control at 6 breaths/minute. Breathing pattern will be controlled at duty cycle of 0.4 (inspiratory time = 4 sec and total respiratory time = 10 sec). The training program will be performed at home for 30 minutes/day, 7 days/week for 8 weeks.
3054054|NCT02200926|Experimental|Unloaded breathing training|subjects will trained to inspire deeply (no resistance) with breathing frequency control at 6 breaths/minute. Breathing pattern will be controlled at duty cycle of 0.4 (inspiratory time = 4 sec and total respiratory time = 10 sec). The training program will be performed at home for 30 minutes/day, 7 days/week for 8 weeks.
3054055|NCT02200913|Experimental|core stabilization exercise|core stabilization exercise 2 times/week 10 weeks
3054056|NCT02200913|Experimental|general trunk strengthening exercise|general trunk strengthening exercise, 2 times/week, 10 weeks
3054057|NCT02200900|Active Comparator|Group 1 ( CPAP followed by HFNC)|In this group pharyngeal pressure, transcutaneous carbon dioxide concentration, tidal volumes and pharyngeal gas concentrations will be recorded on CPAP first followed by HFNC.
3054058|NCT02200900|Active Comparator|Group 2 (HFNC followed by CPAP)|In this group pharyngeal pressure, transcutaneous carbon dioxide concentration, tidal volumes and pharyngeal gas concentrations will be recorded on HFNC first followed by CPAP.
3054059|NCT02200887||Advanced Parkinsons Disease|Polysomnogram
3054060|NCT02200887||Parkinsons Disease with Dyskinesia|Polysomnogram
3054061|NCT02200887||De novo Parkinsons Disease|Polysomnogram
3054062|NCT02200887||Healthy Volunteers|Polysomnogram
3054063|NCT02200874||before NST-implementation (group A)|Patients with a NRS of 3 or more than 3 or NUTRIC score of 4 or more than 4 within the first three days after admittance to hospital. Time point: Before implementation of Nutrition Support Team (NST).
3054064|NCT02200874||After NST-implementation (group B)|Patients with a NRS of 3 or more than 3 or NUTRIC score of 4 or more than 4 within the first three days after admittance to hospital. Time point: After implementation of Nutrition Support Team (NST).
3054065|NCT02200848|Experimental|Lenalidomide, Ibrutinib, Rituximab|Rituximab on day 1, lenalidomide days 1-21 and ibrutinib continuously for 6 cycles or until disease progression or intolerance to the combination. Single agent ibrutinib will then be continued until disease progression or intolerance.
3054066|NCT02200822|No Intervention|non-intervention arm|continuation of neurohumoral blocker therapy based on maximum tolerated guideline recommended dose (this group is the control arm for as well withdrawal of beta blocker therapy as withdrawal of RAAS blocker therapy)
3054067|NCT02200822|Active Comparator|withdrawal of beta blockers|"Intervention arm with systematic withdrawal of beta blocker therapy at a reverse sequence of guideline recommended uptitration.~(this group is the experimental arm for beta blocker withdrawal. This group receives no intervention with regards to the withdrawal of RAAS blockade). Per 2 weeks:~bisoprolol: 10mg/d → 5 mg/d → 2,5 mg/d → 1,25 mg/d stop~metoprolol: 200 mg/d → 100 mg/d → 50 mg/d → 25 mg/d → stop~nebivolol: 10mg/d → 5 mg/d → 2,5 mg/d → 1,25 mg/d stop~carvedilol: 50 mg bid → 25 mg bid → 12,5 mg bid → 6,25 mg bid → stop"
3054068|NCT02200822|Active Comparator|withdrawal of RAAS blockers|"intervention arm with systematic withdrawal of spironolactone followed by withdrawal of ACE-I/ARB at a reverse sequence of guideline recommended uptitration (this group receives no intervention regarding the withdrawal of beta blockers. This group is the experimental arm for withdrawal of RAAS blockers)~first spironolactone/eplerenone: per two weeks: 25 mg/d→12,5 mg/d → stop~after 2 weeks stop spironolactone/eplerenone start withdrawal of ACE-I/ARB per two weeks:~captopril: 50 mg tid→25 mg tid→12,5 mg tid→6,25 mg tid→stop~enalapril: 10 mg bid→5 mg bid→2,5 mg bid→1,25 mg bid→stop~lisinopril: 20 mg/d→10 mg/d→5 mg/d→2,5 mg/d→stop~ramipril: 10 mg/d→5 mg/d→2,5 mg/d→1,25 mg/d→stop~candesartan: 32 mg/d→16 mg/d→8 mg/d→4 m/d→stop~valsartan: 160 mg bid→80 mg bid→40 mg bid→20 mg bid→stop"
3054069|NCT02200822|Active Comparator|withdrawal of RAAS - and beta blockers|"intervention arm with systematic withdrawal of spironolactone, secondly ACE-I/ARB and finally beta blockers. (this group is the experimental group for both study interventions (withdrawal of beta blockers and RAAS blockers)~First: spironolactone/eplerenone cfr reduction schedule supra~After 2 weeks of stop spironolactone withdrawal of ACE-I or ARB cfr reduction schedule supra~After 2 weeks of stop ACE-I/ARB withdrawal of beta blocker cfr reduction schedule supra"
3054070|NCT02200809|Experimental|MR-guided focal laser ablation|
3054071|NCT02200796|Experimental|Low Protein Meal|Low Protein Test Meal (15 g)
3054072|NCT02200796|Experimental|Moderate Protein Meal|Moderate Protein Meal (30 g)
3054083|NCT02200731|Experimental|FAMOS: psychosocial family intervention|The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience.
3054084|NCT02200731|No Intervention|Control|In Denmark, standard care after treatment does not include systematic psychosocial support. Families are able to seek support on their own or contact a support group offered by the Danish Cancer Society. However support specializing the families with childhood cancer survivors and their siblings after ending medial treatment is limited.
3054085|NCT02200718|Experimental|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA V Beta Peptides BV5S2, BV6S5 and BV13S1 emulsified in incomplete Freund's adjuvant
3054086|NCT02200718|Placebo Comparator|IFA Incomplete Freund's Adjuvant|IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil a surfactant system designed to make a water-in-oil emulsion
3054087|NCT02200705|Other|single arm, open label|Early stage Breast cancers up to 1.5cm
3054088|NCT02200692||plasma transfusion|Patients receiving plasma transfusion.
3054089|NCT02200679||Autism Spectrum Disorders|Cases were children living in target communities who are identified as positive based on questionnaire screen and the following diagnosis with DSM-Ⅳ, ADOS and ADI-R
3054090|NCT02200653|Experimental|Low dose of MICARDIS®|
3054091|NCT02200653|Experimental|High dose of MICARDIS®|
3054092|NCT02200653|Active Comparator|Low dose of COZAAR® / LORZAAR®|
3054093|NCT02200653|Active Comparator|High dose of COZAAR® / LORZAAR®|
3054094|NCT02200640|Experimental|Low dose of Micardis®|
3054095|NCT02200640|Experimental|High dose of Micardis®|
3054096|NCT02200640|Active Comparator|Low dose of COZAAR®|
3054097|NCT02200640|Active Comparator|High dose of COZAAR®|
3054098|NCT02200614|Experimental|Darolutamide (BAY1841788)|Metastasis-free survival (MFS) in patients with high-risk non-metastatic castration-resistant prostate cancer
3054099|NCT02200614|Placebo Comparator|Placebo|Metastasis-free survival (MFS) in patients with high-risk non-metastatic castration-resistant prostate cancer
3054100|NCT02200601|Experimental|Seipher Wellness|
3054101|NCT02200588||Patients|Patients followed in the First Episode Psychosis Clinical Program (PAFIP) with psychotic disorder
3054102|NCT02200588||Controls|Healthy subjects without psychotic disorder
3054103|NCT02200575||Patients with non-secondary, essential hypertension|
3054104|NCT02200562|Experimental|Ipilimumab and Dabrafenib|
3054105|NCT02200549|Experimental|Control group|Neither cycle training nor inspiratory muscle training.
3054106|NCT02200549|Experimental|Cycle training group|A 30-minute cycling training session is performed 3 days a week using calibrated cycle ergometer.
3054107|NCT02200549|Experimental|Combined group|A 30-minute Combined training session is performed 3 days a week using calibrated cycle ergometer and threshold loading device.
3054108|NCT02200536|Experimental|Test|Infant oral health promotion package
3054109|NCT02200536|Active Comparator|Control 1|Infant oral health pamphlet
3054110|NCT02200536|No Intervention|Control 2|
3054111|NCT02200523|Experimental|SARA electrode|new electrode
3054112|NCT02200523|Active Comparator|Gold cup|gold standard
3054113|NCT02200510|Other|Self-Management Group|Self-management intervention for Adolescents with SCD - 6 week self-management group
3054114|NCT02200510|Other|Patient Portal|Patient Portal Intervention for Adolescents with SCD - 6 week individual patient portal intervention
3054115|NCT02200484|Experimental|Parent Training/Obesity Prevention|Mother-child dyads randomized to the active intervention in the pilot study will be administered 8 weeks of a combined parenting training and obesity prevention program that was adapted through analysis of formative research interviews with adolescent mothers with feedback from an expert panel of multidisciplinary research team members and community members.
3054116|NCT02200484|Active Comparator|8-week Wellness Program (Control)|Participants randomized to control condition during intervention piloting will receive print-based health and wellness materials once weekly for 8-weeks + 2 follow up telephone calls at the beginning and conclusion of the 8-week program.
3054117|NCT02200471|Experimental|VeinViewer|VeinViewer will be used in conjunction with routine cosmetic dermatology procedures. Patients and physicians will complete questionnaires.
3054118|NCT02200458|Experimental|VeinViewer|Vascular imaging technology will be used to visualize peripheral vasculature.
3054119|NCT02200445|Experimental|Interleukin-2|"Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).~Each subject will receive an 8-week course of once-daily, subcutaneously administered IL-2. There will be three dose cohorts. Each subject will be recruited into a single dose cohort and receive a single dose level of IL-2 throughout the study.~The dose levels will be as follows:~Cohort 1: 0.3x10^6 IU/m^2/day.~Cohort 2: 1.0x10^6 IU/m^2/day.~Cohort 3: 1.5x10^6 IU/m^2/day.~Up to 6 subjects will be recruited to each dose cohort.~Once the maximum tolerated dose has been identified, a further 10 subjects will receive IL-2 at the maximum tolerated dose."
3054120|NCT02200432|No Intervention|Control|The study's current rule-based CTHC system is embedded within the Decide2Quit.org web service. Control smokers will receive the current Decide2Quit.org system, including informational web pages, an interactive quit plan, plus pushed email messages. The messages will be selected using the current rule-based CTHC system. The CTHC selects messages based on decision rules (e.g: readiness to quit, gender) using information from a smoker's baseline profile. Participants will receive one message per day for 30 days
3054121|NCT02200432|Experimental|Intervention|The PERSPeCT intervention smokers will receive all components of the Decide2Quit.org web service, but persuasive email messages will be selected by the PERSPeCT recommender system developed in Aim 2. PERSPeCT will use data (see Figure 1) to predict messages that would be most influential to the participant. Intervention smokers will receive one PERSPeCT-generated message per day for 30 days. With each message rating, the PERSPeCT system will further adapt to patient preferences.
3054122|NCT02200419|Other|Transfusion Algorithm|Hospitals will be randomized to the intervention arm of the study in a stratified manner.
3054241|NCT02199470||C-peptide sustained|C-peptide level between higher or equal to 0,08 ng/mL
3054242|NCT02199470||C-peptide not detectable|C- peptide level equal to or lower than 0,01 ng/mL
3054123|NCT02200406|Other|Desvenlafaxine|"Open-label pilot study~Desvenlafaxine will be administered during 56 consecutive days~Desvenlafaxine will be administered in the morning at a 50 mg dose during weeks 1 and 2, and at 50-100 mg doses (based on the study psychiatrist's judgment) during the 6 following weeks."
3054124|NCT02200393|Experimental|Abdominal FES|Participants in the Abdominal Functional Electrical Stimulation (AFES) group will receive AFES 5 times per week (20 to 40 mins per day), on four alternate weeks.
3054125|NCT02200380|Experimental|CDX-301|
3054126|NCT02200380|Experimental|CDX-301 and plerixafor|
3054127|NCT02200367|Experimental|e-mental health collaborative programme|It is a complex intervention to support primary care providers of rural primary care service to manage depressed patients. Primary care providers at the intervention sites were supported by psychiatrist using an electronic platform.Patients were monitored through a call center.
3054128|NCT02200367|Other|Usual Care|Patients in this arm received all the interventions that are guaranteed for the persons with depression in Chile: treatment in the primary clinics with the primary care team and referral to the regional specialized psychiatric service
3054129|NCT02200354|Experimental|pemetrexed with bevacizumab|pemetrexed rechallenge with bevacizumab pemetrexed (500mg/m2 day1) bevacizumab (15mg/kg day1)
3054130|NCT02200341|Experimental|MBCT|Mindfulness-Based Cognitive Therapy 8-week intervention
3054131|NCT02200341|Active Comparator|PRT-PsyEd|Progressive Relaxation Training and Psychoeducation 8-week intervention
3054132|NCT02200328|Experimental|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
3054133|NCT02200328|Placebo Comparator|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
3054134|NCT02200315|Experimental|No Antimicrobial prophylaxis|No use of antimicrobial prophylaxis during surgery
3054135|NCT02200289||Mother-infant pairs|Mother-infant pairs from the GRAPHS birth cohort study
3054136|NCT02200276|Other|Influenza Immunization|Influenza immunization in adults over age 75
3054137|NCT02200263|Experimental|Lutein plus Zeaxanthin|Participants randomized to this arm will receive 20 mg of Lutein (L) plus 20 mg of Zeaxanthin (Z) per day: Two pills (10 mg L+ 10 mg Z per pill) for the duration of one year.
3054138|NCT02200263|Placebo Comparator|Placebo softgels|Participants randomized to this arm will receive two pills per day of placebo-gels corresponding to the active compound in look and feel for the duration of one year
3054139|NCT02200250||Post Barretts Excision|Patients who have undergone an EMR for Barretts Oesophagus
3054140|NCT02200237|Placebo Comparator|Placebo|Phosphate Buffer Saline with adjuvant aluminium phosphate
3054141|NCT02200237|Experimental|EV71 with adjuvant aluminium phosphate|Inactive whole monovalent EV71 virion vaccine formulated with phosphate-buffered saline based adjuvanted aluminium phosphate 150 μg/0.5ml
3054142|NCT02200224|Experimental|Rapid Testing/Treatment Group|All subjects enrolled in the rapid testing group will receive rapid CT/NG and TV testing in addition to the CT/NG Nucleic Acid Amplification Test (NAAT) and wet mount testing that is currently used in the ED.
3054143|NCT02200224|No Intervention|Control|All subjects enrolled in the control group will receive CT/NG and TV testing according to the current standard of care for Johns Hopkins ED.
3054144|NCT02200211|Experimental|Binocular Treatment|Binocular computer game play 1 hour per day, 7 days per week (minimum of 4 days per week)
3054145|NCT02200211|Active Comparator|Patching Treatment|Patching 2 hours per day, 7 days per week
3054146|NCT02200198|Active Comparator|Inspiratory group|Inspiratory muscle training
3054147|NCT02200198|Sham Comparator|Sham group|Sham training
3054148|NCT02200198|Experimental|Expiratory group|Expiratory muscle training
3054149|NCT02200185|Placebo Comparator|IV titrated morphine|"patient will receive 2 mg morphine each 5 min, associated to continuous nebulisation of saline serum (placebo).~Morphine administration is stopped when VAS becomes under 50% and treatment failure is defined as VAS > 50%, 30 minutes after the beginning of the protocol."
3054150|NCT02200185|Experimental|Low dose nebulised morphine|"patient will receive 10 mg of morphine prepared with 4 ml saline serum (SS) and nebulised with 6 l/min flow during 10 minutes.~Nebulisation will be repeated 3 times, in addition, patients receive 2 ml IV SS every 5 minutes as placebo"
3054151|NCT02200185|Experimental|High dose nebulised morphine|"patient will receive 20 mg of morphine prepared with 3 ml saline serum (SS) and nebulised with 6 l/min flow during 10 minutes.~Nebulisation will be repeated 3 times, in addition, patients receive 2 ml IV SS every 5 minutes as placebo."
3054152|NCT02200172|Active Comparator|Melatonin|A single daily sublingually administered tablet of 3mg non-animal synthetic source melatonin (immediate-release) at 21.00 hours (±1 hour), starting on Study Day 1 and stopping on Study Day 28 of admission or earlier in the event of death or discharge.
3054153|NCT02200172|Placebo Comparator|Placebo|A single daily sublingually administered tablet of placebo at 21.00 hours (±1 hour), starting on Study Day 1 and stopping on Study Day 28 of admission or earlier in the event of death or discharge.
3054154|NCT02200159||dexmedetomidine|
3054155|NCT02200146|Active Comparator|Prednisone|Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
3054156|NCT02200146|Experimental|Hydroxychloroquine + Prednisone|Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
3054157|NCT02200133|Experimental|Individualized Survivorship Care Plan (SCP)|"Participant information sheet and instructions on how to use the SCP~Patient version of individualized SCP that includes but is not limited to: (1) a treatment summary that consists of disease characteristics and treatment details (including HCT), and (2) recommendations for preventive care and screening for late complications based on patient treatment exposures (age, type of transplant, use of TBI, corticosteroid exposure as part of HCT, and history of GVHD)~Newest Vital Sign nutrition label to measure health literacy and its instructions~Participants may receive other materials their transplant center routinely provides to patients for follow-up care (e.g., discharge summary or clinic note)"
3054328|NCT02198820||Loco Regional|All patients included who underwent surgery with loco regional anesthesia
3054331|NCT02198794|Experimental|SD-809- Part B|I week period of randomized withdrawal
3082192|NCT02012205|No Intervention|control|not cupping
3054158|NCT02200133|No Intervention|Usual care (no SCP)|"Materials that their transplant center routinely provides to patients for follow-up care~Newest Vital Sign nutrition label to measure health literacy and its instructions~Participants randomized to the usual care arm who complete the 6 month study assessments will receive their individualized SCP upon completion of the patient's participation. Participants who withdraw from the study or who do not complete the 6 month assessment will not receive the individualized SCP."
3054159|NCT02200107|Experimental|self management education|self management education program delivered by family doctor in primary care clinics and during and physical therapy design
3054160|NCT02200107|No Intervention|control|Routine follow up according to standard practice
3054161|NCT02200094||Outpatients with essential hypertension|
3054162|NCT02200081|Experimental|MGN1703|MGN1703, solution in Dulbecco's Phosphate-Buffered Saline (DPBS), 2 mL of 60 mg/4 mL (15 mg/mL), administered SC at 2 application sites twice weekly
3054163|NCT02200081|Other|Standard of care|Continous first line therapy
3054164|NCT02200068|Active Comparator|PHR Group|This group will have access to a personal health record website SANOIA in addition to all resources they use or find online
3054165|NCT02200068|No Intervention|Non-PHR Group|This group will not be informed of the Personal Health Record Website and will use Internet as they usually do.
3054166|NCT02200055|Experimental|Bioimpedance Assessment|"The only group will be those patients having major intra-abdominal surgical procedures.~Each patient involved in the study will be evaluated with a bioimpedance monitor ('Bodystat Quadscan 4000') to assess total body water, estimated body water, and intravascular body water volume preoperatively, postoperatively, and daily during the postoperative recovery period.~Bioimpedance Assessment"
3054167|NCT02200042|Experimental|Arm I (gemcitabine, cisplatin, radiation therapy)|Patients receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 60 minutes on days 1 and 8 for 1 course. Beginning 7-21 days from the last dose of chemotherapy, patients undergo 15 fractions of image-guided radiation therapy delivered over 19-26 or 27-34 days. Beginning 7 days after completion of radiation therapy, patients continue treatment with gemcitabine hydrochloride and cisplatin. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3054168|NCT02200042|Active Comparator|Arm II (gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV and cisplatin IV as in Arm I. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue gemcitabine hydrochloride at the discretion of the treating physician.
3054169|NCT02200029|Experimental|Ademetionine IV|
3054170|NCT02200029|Experimental|Ademetionine oral|
3054171|NCT02200016|Experimental|SAX|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters
3054172|NCT02200016|Active Comparator|LAX|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters
3054173|NCT02200003|Experimental|Attention Bias Modification|640 Trials (20 minutes) four times over four weeks
3054174|NCT02200003|Sham Comparator|Sham Attention bias modification|640 Trials (20 minutes) four times over four weeks
3054175|NCT02199977|Other|test only (free)|The participant is entitled to a free malaria rapid diagnostic test, but no ACT voucher.
3054176|NCT02199977|Other|test (free) & conditional ACT voucher|The participant is entitled to a free malaria rapid diagnostic test, and an ACT voucher conditional on a positive test result.
3054177|NCT02199977|Other|test only (not free)|The participant is entitled to a malaria rapid diagnostic test for a charge (i.e., not for free), but no ACT voucher.
3054178|NCT02199977|Other|test (not free) & conditional ACT voucher|The participant is entitled to a malaria rapid diagnostic test for a charge (i.e., not for free), and an ACT voucher conditional on a positive test result.
3054179|NCT02199964|Experimental|Cyclosporin 0.05% emulsion|used in the eye 4 times a day
3054180|NCT02199964|Active Comparator|Endura Refresh, Artificial Tears|Over the Counter artificial tears used in the eye 4 times a day
3054181|NCT02199951||Dihydroartemisinin and piperaquine|The patients will take Eurartesim® (DHA/PQP) with a dose regimen of one administration every 24 hours over a period of three days, i.e. at Day 1, then after 24 hours (Day 2) and after 48 hours (Day 3) from the first administration. The dose will be based on body weight. Two strengths of Eurartesim® will be provided for dosing in children and adults: 20/160mg and 40/320mg of DHA and PQP respectively. Body weight (kg) Daily dose (mg) Number of tablets per dose 20/160mg DHA/PQ 40/320mg DHA/PQ 5 to <7 10 mg DHA and 80 mg PQP ½ tablet 7 to <13 20 mg DHA and 160 mg PQP 1 tablet 13 to < 24 40 mg DHA and 320 mg PQP 1 tablet 24 to < 36 80 mg DHA and 640 mg PQP 2 tablets 36 to < 75 120 mg DHA and 960 mg PQP 3 tablets 75 to < 100 160 mg DHA and 1280 mg PQP 4 tablets > 100.
3054182|NCT02199938||musculoskeletal tumors|Patients with suspected or confirmed bone or soft tissue tumors undergoing biopsy or surgery
3054183|NCT02199925|Experimental|Gammaplex 5% IGIV|Gammaplex 5% IGIV administered intravenously
3054184|NCT02199912|Experimental|Patients with colorectal surgery|
3054185|NCT02199899|Experimental|BIIF 1149 BS - single rising doses|BIIF 1149 BS oral drinking solution and a BIIF 1149 BS tablet
3054186|NCT02199899|Placebo Comparator|Placebo|
3054187|NCT02199886|Experimental|BIBH 1|dose escalation: 0.5, 2, 10 or 20mg/m**2, 7 days prior to surgery
3054188|NCT02199873|Experimental|BIIX 1 XX - single rising dose|
3054189|NCT02199873|Placebo Comparator|Placebo|
3054190|NCT02199860|Experimental|SD I - single rising doses|
3054191|NCT02199860|Experimental|SD II - single rising doses|
3054192|NCT02199860|Experimental|SD II - single rising doses + Placebo|
3054193|NCT02199860|Placebo Comparator|Placebo|
3054194|NCT02199847|Experimental|Pharmaton® Caplets|
3054195|NCT02199847|Placebo Comparator|Placebo|
3054196|NCT02199834|Experimental|Peer group|24 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support to this group under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support. Half of the patients in this group will be randomized to receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
3054332|NCT02198794|Experimental|Placebo- Part B|I week period of randomized withdrawal
3054333|NCT02198781||Cohort|Basic science study
3054197|NCT02199834|Other|Refused peer group|Patients who fit the criteria of peers but refuse to be contacted by peer supporters will be signed as refused group. Half of the patients in this group will be randomized to receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
3054198|NCT02199834|Experimental|Report group|Patients in this group will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values twice a year through mails.
3054199|NCT02199834|No Intervention|Usual care|Patients will receive standard usual care with clinicians' follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
3054200|NCT02199821|Active Comparator|Soybean oil formula commonly used in the hospita|
3054201|NCT02199821|Experimental|Formula with soybean oil, medium-chain triglyce|
3054202|NCT02199808||7-9 year olds|These are children who are between 7 and 9 years old when they are tested.
3054203|NCT02199808||10-12 year olds|These are children who are between 10 and 12 years old when they are tested.
3054204|NCT02199795|Experimental|CCNMES|Contralaterally Controlled Neuromuscular Electrical Stimulation (CCNMES): CCNMES uses electrical stimulation to move the weaker ankle up and down. The user will control the stimulation using the other (stronger) ankle. A special sock is worn on the stronger ankle. When the stronger ankle is moved, a signal is sent from a sensor on the sock to the electrical stimulator. The stimulator then sends stimulation to the weaker ankle which causes it to move. Sound and light cues coming from the stimulator will tell the user when to move the stronger ankle and when to relax.
3054205|NCT02199795|Active Comparator|Cyclic NMES|Cyclic Neuromuscular Electrical Stimulation (NMES) uses automatic, repetitive electrical stimulation to stimulate the muscles in order to move the weaker ankle up and down.
3054206|NCT02199782|Active Comparator|Welsh|Participants will complete the cognitive assessment in Welsh and in English these will be compared to assess whether first language Welsh speakers perform better in Welsh.
3054207|NCT02199782|Active Comparator|English|Participants will complete the cognitive assessment in Welsh and in English these will be compared to assess whether first language Welsh speakers perform better in Welsh.
3054208|NCT02199769|Experimental|Clinical Decision Support|Visit-based, EMR-enabled case identification and real-time decision support to identify patients without diabetes who have a RBG>= 125mg/dL and no resulted diabetes screening.
3054209|NCT02199769|No Intervention|Usual care|Diabetes screening/testing and diagnosis per usual care at the discretion of the treating physician.
3054210|NCT02199756||Cesarean section|Women with cesarean section
3054211|NCT02199743|Active Comparator|Lurasidone|Lurasidone 40mg po qhs with food x 1 week; Lurasidone 80mg po qhs with food x 3 weeks
3054212|NCT02199743|Active Comparator|Haloperidol|Haloperidol 4mg po qhs with food x 1 week; Haloperidol 8mg po qhs with food x 3 weeks.
3054213|NCT02199743|Active Comparator|Perphenazine|Perphenazine 16mg po qhs with food x 1 week; Perphenazine 32mg po qhs with food x 3 weeks.
3054214|NCT02199717||Boys with Hemophilia|Accelerometer use for 1 week.
3054215|NCT02199704|Other|No control or comparison arm.|This case series study has no control or comparison arm. There is only one arm being evaluated (the self directed parenting intervention).
3054216|NCT02199691|Experimental|Study Group 1|Participants will receive MenACYW conjugate vaccine
3054217|NCT02199691|Active Comparator|Study Group 2|Participants will receive MENVEO® vaccine
3054218|NCT02199691|Experimental|Study Group 3|Participants will receive MenACYW conjugate vaccine, Tdap and HPV
3054219|NCT02199691|Active Comparator|Study Group 4|Participants will receive Tdap and HPV
3054220|NCT02199678|Placebo Comparator|Placebo|Placebo
3054221|NCT02199678|Active Comparator|ketamine 25 mg|ketamine
3054222|NCT02199678|Active Comparator|ketamine 35 mg|ketamine
3054223|NCT02199678|Active Comparator|ketamine 50 mg|ketamine
3054224|NCT02199665|Experimental|Selinexor, carfilzomib, dexamethasone|Patients receive selinexor PO, carfilzomib IV, and dexamethasone PO QD or IV. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3054225|NCT02199652|Placebo Comparator|placebo|placebo pill
3054226|NCT02199652|Experimental|prazosin|prazosin pill
3054227|NCT02199639||Spain|Group of patients with hemophilia recruited in the Region of Murcia (Spain) and evaluated in the Universidad Católica San Antonio between June and July 2014.
3054228|NCT02199639||El Salvador|"Group of patients with hemophilia recruited in the city of San Salvador (El Salvador) and evaluated in the Hospital Nacional Rosales and the Hospital Nacional de niños Benjamín Bloom from San Salvador in April 2014."
3054229|NCT02199639||Bolivia|Group of patients with hemophilia recruited in the city of Santa Cruz (Bolivia) and evaluated at the Hospital Nacional de niños in Santa Cruz August 2014.
3054230|NCT02199626|Experimental|CCE-2|Second generation of Colon capsule endoscopy in pediatric Crohn's disease
3054231|NCT02199613|Experimental|Treatment simplification|Open-label darunavir 800mg in conjunction with the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet, both taken together once daily with food
3054232|NCT02199600|Other|GMK Sphere Knee Replacement|Patients who comply with the protocol and received GMK Sphere component.
3054233|NCT02199587|Active Comparator|Endocrine test with medical clown|children who are referred to endocrine test will have the procedure with a medical clown, or without. The pain and anxiety perception of the child and caregivers will be compare between the two scenarios
3054234|NCT02199587|No Intervention|Endocrine test without medical clown|
3054235|NCT02199574|Experimental|EXPAREL|Single administration of EXPAREL 133 mg (10 mL).
3054236|NCT02199561|Experimental|Fecal Microbiota Transplant|Open label single arm delivering fecal transplant to each participant
3054237|NCT02199548||Study Participants|All enrolled participants will take part in a face-to-face interview.
3054238|NCT02199522|Experimental|titration induction of propofol|titration induction of propofol by Fresenius pump at the speed of 1 mg•kg-1•min-1
3054239|NCT02199522|No Intervention|convention induction of propofol|propofol 2mg•kg-1 intravenously by Fresenius pump at the speed of 250mg•min-1
3054240|NCT02199470||C-peptide minimal detectable|C-peptide level between 0,01-0,08 ng/mL
3054243|NCT02199457|Other|SVSS and reference devices|Vital signs will be measured on the same subject with the reference devices and with the SVSS. The subject will have blood pressure, pulse, blood oxygen, body temperature and respiration rate measured using standard equipment. The same subject will then use the investigational device which measures all vital signs at the same time, by placing the index finger on a sensor.
3054244|NCT02199444|Experimental|Sevelamer|The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
3054245|NCT02199444|Placebo Comparator|Placebo|The patients received placebo three times a day
3054246|NCT02199431|Experimental|Lu AF1167 capsule 0.5 mg|Single oral dose (day 1)
3054247|NCT02199431|Experimental|Lu AF11167 0.5 mg capsule + itraconazole 200 mg capsule|Itraconazole administered once daily for 7 days (day 3-9); Lu AF11167 administered as a single dose on day 8
3054248|NCT02199418|Experimental|Paclitaxel and Cisplatin|"Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.~Trastuzumab (only for human epidermal growth factor receptor-2(HER2)-positive patients): Loading dose: 4 mg/kg, Maintenance dose: 2 mg/kg, day 1 q day 8 for 16 weeks. Post-surgery: up to a total duration of 1 year"
3054249|NCT02199405|Experimental|massage and Sishi Daoyin|Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
3054250|NCT02199405|Active Comparator|conventional massage and cervical traction|Conventional massage , 15 minutes, three times one week for 4 weeks Cervical traction , 15 minutes, three times one week for 4 weeks
3054251|NCT02199392|Experimental|Lenvatinib 24 mg|The Pretreatment Phase will have two periods: Screening and Baseline 1. The Treatment Phase will have three periods: Treatment Period 1, Treatment Period 2, and Treatment Period 3 with a Baseline 2 assessment prior to Treatment Period 2 and a Baseline 3 assessment prior to Treatment Period 3. In the Treatment Phase, subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
3054252|NCT02199379|Experimental|Lenvatinib|Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
3054253|NCT02199366||Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
3054254|NCT02199353|Experimental|Stimulation of Activities Daily Living|"The experimental group received the Stimulation of Activities of Daily Living (SADL) programme which is a new treatment approach created by the authors of this study for the training of activities of daily living (ADL) through cognitive intervention. The programme is based on the reestablishment of the cognitive functions implied in the performance of basic activities of daily living.~The sequence of the sessions was always the same, varying the activities, subject, cognitive functions and BADL to work on. Each session started with an activity of temporal and space orientation, continued with the performance of the specific activity of the session and finished with a reminiscence activity.~The treatment was applied twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
3054255|NCT02199353|Active Comparator|Conventional ADLoccupational therapy|"The control group treatment was based on a conventional occupational therapy intervention for the management of ADL deficits. The compensation approach was used and environment modifications and simplification of activities were applied as the intervention method.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
3054256|NCT02199340|Experimental|Cystic fibrosis|"iStep exercise test~CPET exercise test"
3054257|NCT02199340|Active Comparator|Healthy control|- iStep exercise test
3054258|NCT02199327|Active Comparator|Mitomycin C|Mitomycin C 0.04% 4 times daily for 7 days and 7 days off until resolution of neoplasia (3-6 cycles).
3054259|NCT02199327|Active Comparator|Interferon alfa 2b|Interferon alfa-2b 1 million IU/ml 4 times daily until complete resolution of the tumor
3054260|NCT02199314|Experimental|desflurane MEP's|Transcranial motor evoked potentials are obtained once desflurane is at 3%, after desflurane has been on for at least 5 minutes.
3054261|NCT02199314|Experimental|pre- desflurane MEP's|Transcranial motor evoked potentials are recorded prior to the use of desflurane
3054262|NCT02199301|Experimental|BMTKT|Transplantation Conditioning for bone marrow transplantation (BMT) Kidney transplantation and BMT (BMTKT)
3054263|NCT02199288||Cohort|
3054264|NCT02199262|Experimental|control groupe|agitation diagnosis and management according to implemented guidelines= reminder implementation
3054265|NCT02199262|Experimental|music intervention + reminder|agitation diagnosis and management according to implemented guidelines+ music intervention
3054266|NCT02199262|Experimental|reflexology + reminder|agitation diagnosis and management according to implemented guidelines + reflexology
3054267|NCT02199249|Active Comparator|Open Reduction Tightrope fixation (OT)|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
3054268|NCT02199249|Active Comparator|Open Reduction screw fixation (OS)|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
3054269|NCT02199236|Experimental|endorectal brachytherapy, concurrent chemo and questionnaires|This is a phase I, dose-escalation study to evaluate the safety of endorectal brachytherapy with concurrent capecitabine or 5-fluoruracil (5-FU) in the management of locally recurrent/residual rectal or anal cancer in patients who have received pelvic external beam radiation therapy (EBRT) +/- chemotherapy. We will use magnetic resonance imaging (MRI) with dynamic contrast enhancement (DCE) and diffusion weighted imaging (DWI) series to contribute to the assessment of tumor response.
3054270|NCT02199223|Experimental|panitumumab + regorafenib|
3054329|NCT02198807|Experimental|Fosmidomycin-Piperaquine|Fosmidomycin sodium capsules 450 mg, dosage: 30mg/kg twice daily for 3 days Piperaquine phosphate tablets 320 mg, dosage: 16 mg/kg once a day for 3 days
3054330|NCT02198794|Experimental|SD-809- Part A|Dose titration for 6 weeks to determine a subject's optimal dose. Subject's dose is then maintained for the duration of the study.
3054271|NCT02199210|Experimental|Prompting forethought|"A demographic questionnaire will be filled out by each participant. After randomization, participants will be presented with the background information of the simulated scenario.Subsequently:~participants forethought will be prompted and each participant will be asked to report his/her forethought,~participants then will be asked to manage a simulated massive transfusion scenario,~at completion of the scenario, each participant will undergo individualized debriefing and a syllabus on massive transfusion will be briefly discussed with them and also provided as a reading material for learning."
3054272|NCT02199210|No Intervention|No prompting|"A demographic questionnaire will be filled out by each participants. After randomization, participants will be presented with the background information of the simulated scenario.Subsequently:~participants will sit and wait for a predetermined time before entering into the simulator,~participants then will be asked to manage a simulated massive transfusion scenario,~at completion of the scenario, each participant will be interviewed about their thought process before entering to the simulation room,~each participant will undergo individualized debriefing and a syllabus on massive transfusion will be briefly discussed with them and also provided as a reading material for learning."
3054273|NCT02199197|Experimental|treatment with radium Ra 223 dichloride and enzalutamide|Radium Ra 223 dichloride, 55 kBq/kg body weight, will be administered as a bolus intravenous (IV) injection (up to 1 minute) on Day 1 of each cycle. Enzalutamide 160 mg will be orally administered once a day (continuously).
3054274|NCT02199197|Active Comparator|Treatment with enzalutamide alone|Enzalutamide 160 mg will be orally administered once a day (continuously) for 6 cycles.
3054275|NCT02199184|Experimental|Relapsed/Refractory Burkitt Leukemia Group|"Ofatumumab 300 mg by vein on day 1 (before infusions) and 2,000 mg on days 2 and 11 during Cycle 1 only. Starting with Cycle 2, participants receive Ofatumumab 2,000 mg by vein on days 1 and 8 of Cycles 2 and 4, and day 1 and 11 of Cycle 3 for a total of 8 injections of ofatumumab. Etoposide 50 mg/m2/day by vein days 1- 4.~Doxorubicin 10 mg/m2/day by vein days 1-4. Vincristine 0.5 mg by vein days 1-4. Cyclophosphamide 750 mg/m2 by vein on day 5. Prednisone 60 mg by mouth twice a day on days 1-5. Rituximab 375 mg/m2 by vein on days 1 and 11 of Cycle 1 and 3 and days 2 and 8 of Cycle 2 and 4 replaces ofatumumab if insurance does not approve ofatumumab.~Pegfilgrastim (Neulasta) 6 mg within 72 hours after completion of chemotherapy. G-CSF 10 µg/kg/day until neutrophil recovery 1 x 109/L or higher can be substituted or can be added to Pegfilgrastim if neutrophils have not recovered to 1 x 109/L by day 21."
3054276|NCT02199184|Experimental|Newly Diagnosed Burkitt Leukemia Group|"Ofatumumab 300 mg by vein on day 1 (before infusions) and 2,000 mg on days 2 and 11 during Cycle 1 only. Starting with Cycle 2, participants receive Ofatumumab 2,000 mg by vein on days 1 and 8 of Cycles 2 and 4, and day 1 and 11 of Cycle 3 for a total of 8 injections of ofatumumab. Etoposide 50 mg/m2/day by vein days 1- 4.~Doxorubicin 10 mg/m2/day by vein days 1-4. Vincristine 0.5 mg by vein days 1-4. Cyclophosphamide 750 mg/m2 by vein on day 5. Prednisone 60 mg by mouth twice a day on days 1-5. Rituximab 375 mg/m2 by vein on days 1 and 11 of Cycle 1 and 3 and days 2 and 8 of Cycle 2 and 4 replaces ofatumumab if insurance does not approve ofatumumab.~Pegfilgrastim (Neulasta) 6 mg within 72 hours after completion of chemotherapy. G-CSF 10 µg/kg/day until neutrophil recovery 1 x 109/L or higher can be substituted or can be added to Pegfilgrastim if neutrophils have not recovered to 1 x 109/L by day 21."
3054277|NCT02199171|Experimental|HIPEC carboplatin|"Patients receive hyperthermic carboplatin intraperitoneally over 60 minutes during the planned surgical cytoreductive procedure.~Doses as appropriate for assigned dose level in 500 cubic centimeters (cc)"
3054278|NCT02199158|Experimental|Argon Laser Peripheral Iridoplasty|ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
3054279|NCT02199145|Other|Blood and urine analysis|creatinine, albumin, blood electrolytes, proteinuria /creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
3054280|NCT02199132||Nasopharyngeal Carcinoma|
3054281|NCT02199119|Experimental|Control|Sitting quietly for 30 min No TV No exercise
3054282|NCT02199119|Experimental|TV viewing only|watching TV for 30 min
3054283|NCT02199119|Experimental|Exercise only|exercising for 30 min
3054284|NCT02199119|Experimental|TV viewing and Exercise|30 min of moderate exercise on a treadmill while watching TV
3054285|NCT02199106|Experimental|Left temporal verum cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)~Intervention: Left temporal verum cTBS"
3054286|NCT02199106|Experimental|Left temporal placebo cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings~Intervention: Left temporal placebo cTBS"
3054287|NCT02199093|Experimental|Functional Rehabilitation of apraxia|The participants will be randomly assigned to an experimental group, to receive intervention in upper limb apraxia at home since two approaches, a rehabilitative and another compensatory (providing adaptive strategies at home). The treatment will be performed three times a week, 30 minutes a day, during a 4-week period.
3054288|NCT02199093|Active Comparator|Traditional health educative protocol|Control group will receive treatment with a traditional health educative protocol to improve his functionality in activities of daily living. The treatment will be performed twice in two month.
3054289|NCT02199080|Other|Atrial fibrillation|D-dimer assay before ablation of atrial fibrillation
3054290|NCT02199054|Placebo Comparator|Run-in Intervention|Control wheat pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of control wheat pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
3054291|NCT02199054|Active Comparator|Wheat-Safflower Oil Arm|Wheat-safflower oil pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of wheat-safflower oil pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
3054292|NCT02199054|Active Comparator|Soy-Safflower Oil Arm|Soy-safflower oil pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of soy-safflower oil pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
3054293|NCT02199041|Experimental|Treatment|"Interventions: cyclophosphamide, thiotepa, fludarabine, melphalan, mesna, granulocyte colony-stimulating factor (G-CSF), mycophenolate mofetil, tacrolimus, methylprednisolone, total lymphoid irradiation, and lymphocyte infusions.~Cells for infusion are prepared using the CliniMACS System."
3054294|NCT02199028|Experimental|Hyaluronidase|Infuse 1mL Hyaluronidase at time of infusion set placement and again on Day 3
3054295|NCT02199028|No Intervention|Control|Subjects will not receive Hyaluronidase during this week
3054296|NCT02199015|Experimental|Spasticity, Cerebral Palsy|To perform a Lateral spinal cord surgical implant of electrodes for electrical neuromodulation of a cohort of selectyed patients with refractory Spastic Cerebral Palsy To compare spasticity and speech trouble´s evolution on a cohort of treated patients, by evaluating their pre and post operative status into one year follow up.
3054297|NCT02199002|Other|healthy volunteers|healthy volunteers (no gastric complains)
3054298|NCT02199002|Other|PPI responders|proven reflux, good symptom relief upon PPI therapy
3054299|NCT02199002|Other|PPI non-responders|proven reflux disease, poor symptom control (less then 50% symptom reduction) upon PPI therapy (2x40mg omeprazole)
3054300|NCT02199002|Other|Barrett - no dysplasia|proven barrett with no dysplasia on biopsies
3054301|NCT02199002|Other|barrett - high grade dysplasia|proven barrett with high grade dysplasia on biopsies
3054302|NCT02198989|Experimental|peer support and yoga music therapy|"Patients in the group will receive peer support and yoga music therapy before bed.~Patients in the group will received the group education courses and clinical medical therapy."
3054303|NCT02198989|No Intervention|Control group|Patients in the group will received the group education courses and clinical medical therapy.
3054304|NCT02198976||Barrett's Oesophagus|Patients with Barrett's Oesophagus with either high grade dysplasia (HGD) or intramucosal cancer (IMC)
3054305|NCT02198963|Experimental|Hypochlorous acid Solution 106 mg/L|Occlusive patches will be used to apply approximately 0.02 mL of the Test Product RUT058-60 to abraded and non-abraded sites on the skin in the scapular region of each subject's back.
3054306|NCT02198963|Active Comparator|0.1% (w/v) Sodium Lauryl Sulfate|Occlusive patches will be used to apply approximately 0.02 mL of the Positive Control (0.1% Sodium Lauryl Sulfate) to abraded and non-abraded sites on the skin in the scapular region of each subject's back, once daily for 21 days.
3054307|NCT02198963|Placebo Comparator|0.9% Physiological Saline, USP|Occlusive patches will be used to apply approximately 0.02 mL of the Negative Control (0.9% Physiological Saline, USP) to abraded and non-abraded sites on the skin in the scapular region of each subject's back, once daily for 21 days.
3054308|NCT02198950||ICU patients|all patients admitted into the ICU
3054309|NCT02198937||Smokers|Healthy smokers
3054310|NCT02198937||Non-Smokers|Healthy non-smokers
3054311|NCT02198924|Experimental|Parecoxib and Celecoxib|"Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.~Patient-controlled intravenous analgesia (PCIA) with Morphine is administrated to all the subjects starting immediately post-anesthesia and ending at 24h after operation. As long as oral intake is feasible, both the two groups may receive centrally-acting analgesic Tramadol Hydrochloride Sustained release tablets (TRAMCONTIN) as rescue analgesia if VAS score≧3."
3054312|NCT02198924|Placebo Comparator|placebo|"Patients in the control group are supplied with the corresponding placebo with the same instructions.~Patient-controlled intravenous analgesia (PCIA) with Morphine is administrated to all the subjects starting immediately post-anesthesia and ending at 24h after operation. As long as oral intake is feasible, both the two groups may receive centrally-acting analgesic TRAMCONTIN (Tramadol Hydrochloride Sustained release tablets) as rescue analgesia if VAS score≧3."
3054313|NCT02198911|Active Comparator|Order 1|Gum chewing order for sessions, 1-3 respectively: NO GUM, MCC, C
3054314|NCT02198911|Active Comparator|Order 2|Gum chewing order for ice-cream sessions, 1-3 respectively: MCC, C, NO GUM
3054315|NCT02198911|Active Comparator|Order 3|Gum chewing order for ice-cream sessions, 1-3 respectively: C, NO GUM, MCC
3054316|NCT02198898|No Intervention|GUARDIX|no guadix
3054317|NCT02198898|Experimental|guadix|guadix treatment
3054318|NCT02198885||Control|This group receives the standard prehospital care en route to hospital, and they do not receive the FAST ultrasound en route.
3054319|NCT02198885||FAST|This group receives the FAST ultrasound en route to hospital.
3054320|NCT02198872|Experimental|Exercise, Aerobic (Water based)|Patients of this group will be submitted to an aerobic water based physical training
3054321|NCT02198872|Active Comparator|Land Group|Patients of this group perform physical training on bicycle.
3054322|NCT02198859|Experimental|Lithium|Oral lithium carbonate dose escalation: Level 1 of 600 mg/day, then escalating to Level 2 of 900 mg/day, then the final Level 3 of 1200 mg/day.
3054323|NCT02198846|Experimental|Insulin pump|insulin pump
3054324|NCT02198846|Active Comparator|conventional treatment|intensification of conventional treatment
3054325|NCT02198833|Experimental|Micro-Patterned Foley Catheter|Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
3054326|NCT02198833|Active Comparator|Standard-of-Care Foley Catheter|Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
3054327|NCT02198820||General|All patients included who underwent surgery with general anesthesia
3054335|NCT02198768||Ankle Fracture-Dislocation|Patients with ankle fracture-dislocations.
3054336|NCT02198755|Active Comparator|High Resolution Ultrasound|High Resolution Ultrasonography (HRUS) with a Hitachi-Aloka Noblus Scanner
3054337|NCT02198755|Active Comparator|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI)
3054338|NCT02198742|Active Comparator|Miller blade|Subjects must have >500 intubations in order to participate in this study. There is no placebo group, and each subject wil be his or her own control.
3054339|NCT02198742|Active Comparator|Truview PCD|Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable. There is no placebo group, and each subject wil be his or her own control.
3054340|NCT02198742|Active Comparator|Glidescope Cobolt|Subjects were required to watch a instructional video provided by the manufacterer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
3054341|NCT02198729|Active Comparator|Endoscopic Mucosal Resection|Participants randomised to this arm will receive standard of care Endoscopic Mucosal Resection for removal of their lesions.
3054342|NCT02198729|Experimental|Endoscopic Submucosal Dissection|Participants randomised to this arm will receive Endoscopic Mucosal Dissection to remove their lesion.
3054343|NCT02198716|Other|Drug eluting stent|Percutaneous coronary intervention
3054344|NCT02198716|Other|Bare Metal Stent|Percutaneous Coronary Intervention
3054345|NCT02198703|Experimental|AB-Life|1 capsule of AB-Life daily during 12 weeks consumed immediately before, after or during the breakfast. The daily dose corresponds to the intake of 1.8E+10 CFU. According to the product's stability and the duration of the experiment, all participants receive at least 1.2E+09 CFU/capsule/day by the end of the study.
3054346|NCT02198703|Placebo Comparator|Placebo|1 capsule of placebo daily during 12 weeks consumed immediately before, after or during the breakfast.
3054347|NCT02198690|Experimental|Mammography Decision Aid|Development and pilot testing of the decision aid (DA) has been described previously. In brief, the DA is written at a 6th grade reading level and includes information on 1) breast cancer risk factors for women >75 years; 2) health/life expectancy; 3) likely outcomes if screened and not screened with mammography; 4) competing mortality risks; 5) breast cancer treatments; and 6) a values clarification exercise. The last page asks users their intentions of being screened on a 15-point validated scale and invites users to share this information with their clinician. PCPs whose patients are randomized to receive the DA will be sent a copy of the DA via email and a link to an optional training on using the DA (5 informational slides and a 3-minute video).
3054348|NCT02198690|Placebo Comparator|Home safety pamphlet|To reduce response bias and to compensate for the time and attention required by the intervention group to read the DA, patients in the control arm will be provided a two page pamphlet on home safety for older adults developed by the American Geriatrics Society (AGS) Foundation for Health in Aging. PCPs whose patients are randomized to the receive the home safety pamphlet, will be sent an email informing them that their patient will be coming in early to read health educational materials for older adults as part of a study. We otherwise do not plan any intervention for control group PCPs because we do not want to change their usual behavior. However, if PCPs in the control arm request a copy of the educational materials then we will email them a copy of the home safety pamphlet.
3054349|NCT02198677|Experimental|AP|Anterior to posterior pressures 5x10 seconds per set with 10 seconds rest between each set
3054350|NCT02198677|Experimental|Lateral glides|Lateral glides 5x10 seconds per set with 10 seconds rest between each set
3054351|NCT02198664|Experimental|Peanut Protein Capsule|Biological: Capsules containing peanut flour, oral immunotherapy, will be used for dose escalation build-up, and maintenance phase
3054352|NCT02198651|Experimental|Open-Label Rescue Arm|Adalimumab sc every other week from Flare Week 0 to Flare Week 16
3054353|NCT02198651|Placebo Comparator|Placebo|SC every 3 weeks from Week 4 to Week 40
3054354|NCT02198651|Experimental|Open Label Adalimumab|Adalimumab sc every other week from Week 0 to Week 4
3054355|NCT02198651|Active Comparator|Adalimumab|Subcutaneous (SC) every three weeks in the Double-Blind period from Week 4 to Week 40
3054356|NCT02198638|Other|Patients or healthcare workers|
3054357|NCT02198625|No Intervention|FiO2 80%,Nonprotective Lung Ventilation|
3054358|NCT02198625|Experimental|FiO2 30%,Nonprotective Lung Ventilation|FiO2 30%,Nonprotective Lung Ventilation
3054359|NCT02198625|Experimental|FiO2 80%,protective Lung Ventilation|FiO2 80% and protective Lung Ventilation
3054360|NCT02198625|Experimental|FiO2 30%,protective Lung Ventilation|FiO2 30% and protective Lung Ventilation
3054361|NCT02198612|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
3054362|NCT02198599|Experimental|Mobility-enhancing-nursing intervention|A 30 day mobility enhancing-nursing intervention for patients with Multiple Scerosis and stroke to expand kinaesthetic competence in order to increase compensation of limitations, improve functionality, and quality of life
3054363|NCT02198599|No Intervention|Standard usual rehabilitation care|Participants in the control group will receive usual care, which is based on the principles of rehabilitation nursing. Based on patients functional ability (EBI data) the nursing process is used to determine objectives and interventions. The main focus is on providing a therapeutic environment and supporting and advancing abilities to perform the Activities of Daily Living, support mobility and kinesthetic perception.
3054364|NCT02198586||No treatment|The population of this study is 45 to 75 years old at the time of inclusion in the parent study (ClinicalTrials.gov ID: NCT01835717).
3054365|NCT02198560||Normal (Eyes without pathology)|
3054366|NCT02198547|Experimental|Ropivacaine Magnesium sulfate|"Locoregional anesthesia for valgus allux correction with ropivacaine 7,5 mg/ml and Mg 4 mg/Kg.~Sciatic block at popliteal level."
3054367|NCT02198547|Active Comparator|Ropivacaine|Patients undergoing allux valgus correction with locoregional anesthesia with ropivacaine 7,5 mg/ml, without MG
3054368|NCT02198534||ophthalomogically normal subjects|
3054369|NCT02198521||Bilateral Carpal Tunnel Syndrome (CTS)|
3054711|NCT02196142|Active Comparator|Cortisol first, Placebo second|Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)
3054370|NCT02198508|Active Comparator|DFX single treatment|a single oral dose of DFX 30 mg/kg once daily, (Exjade®, Novartis Pharmaceuticals Corporation, USA )
3054371|NCT02198508|Active Comparator|DFP single treatment|single oral dose of DFP 40 mg/kg/day twice a day, (Kelfer®, Cipla Ltd., India)
3054372|NCT02198508|Experimental|combination treatment|sequential oral doses of DFX 30 mg/kg/d, DFP 40 mg/kg/d and DFP 40 mg/kg/d (dosing interval: seven hours).
3054373|NCT02198495|Active Comparator|Ferric carboxymaltose|Supplementation of ferric carboxymaltose 500 mg at week 0, 10, 20, 30
3054374|NCT02198495|Active Comparator|Iron sucrose|Supplementation of iron sucrose 100 mg at week 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38
3054375|NCT02198482|Active Comparator|Daunorubicin, Cytarabine (DA)|"DA~Induction I:~Daunorubicin 60 mg/m² i.v., d 1-3~Cytarabine 100 mg/m² cont. i.v., d 1-7~Induction II:~Daunorubicin 50 mg/m² i.v. d 1-3~Cytarabine 100 mg/m² cont. i.v., d 1-5~Consolidation therapy:~Patients with genetic favourable risk and those patients not eligible for allogeneic HSCT due to comorbidities, high HCT-CI or patient wish will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine (MiDAC).~Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 1. Elderly patients (>60 yrs): 8 mg/m2 by i.v. infusion on day 1.~Intermediate-dose cytarabine:~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 1-3 Elderly patients (>60 yrs): 1000 mg/m2 q12h on days 1-3 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with MiDAC may be given prior to alloHSCT."
3054376|NCT02198482|Experimental|Volasertib, Daunorubicin, Cytarabine|"VDA~Induction I~Volasertib i.v., d1~Daunorubicin 60 mg/m² i.v., d 2-4~Cytarabine 100 mg/m² cont. i.v., d 2-8 Induction II~Volasertib i.v., d1~Daunorubicin 50 mg/m² i.v. d 2-4~Cytarabine 100 mg/m² cont. i.v., d 2-6~Consolidation therapy:~Patients with genetic favourable risk and those patients not eligible for allogeneic HSCT will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine in combination with Volasertib (V-MiDAC).~Volasertib i.v., d1~Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 2. Elderly patients (>60 yrs): 8 mg/m2 by i.v. on day 2.~Intermediate-dose cytarabine:~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 2-4 Elderly patients (>60 yrs): 1000 mg/m2 q12h on days 2-4 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with V-MiDAC may be given prior to alloHSCT."
3054377|NCT02198482|Experimental|Daunorubicin, Cytarabine, Volasertib|"DAV~Induction I~Volasertib i.v., d7~Daunorubicin 60 mg/m² i.v., d 1-3~Cytarabine 100 mg/m² i.v., d 1-7 Induction II~Volasertib i.v., d5~Daunorubicin 50 mg/m² i.v. d 1-3~Cytarabine 100 mg/m² cont. i.v., d 1-5~Consolidation therapy:~Patients with genetic fav. risk and those patients not eligible for alloHSCT will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine in combination with Volasertib (MiDAC-V).~Volasertib i.v., d4~Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 1. Elderly patients (>60 yrs): 8 mg/m2 by i.v. on day 1.~Intermediate-dose cytarabine:~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 1-3 Elderly patients (>60 yrs): 1000 mg/m2 q12h on days 1-3 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with MiDAC-V may be given prior to alloHSCT."
3054378|NCT02198469|Experimental|Er:YAG AFL-PDT|Eligible patients were successively randomised to receive treatment with a single session of Er:YAG AFL MAL-PDT or 2 sessions of MAL-PDT with a 1-week interval between sessions
3054379|NCT02198469|Active Comparator|MAL-PDT|Eligible patients were successively randomised to receive treatment with a single session of Er:YAG AFL MAL-PDT or 2 sessions of MAL-PDT with a 1-week interval between sessions
3054380|NCT02198456||3D echocardiography|
3054381|NCT02198443|Active Comparator|Tenofovir+emtricitabine|
3054382|NCT02198443|Experimental|Elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil|
3054383|NCT02198430||Patients|Patients with haemophilia recruited for multidisciplinary assessment of the main physical, functional and psychosocial variables.
3054384|NCT02198430||Control group|Children without hemophilia
3054385|NCT02198417|Experimental|Metformin|Metformin ER 1500 mg per day treatment for 12 weeks
3054386|NCT02198404|Experimental|sedation with propofol|propofol injection: induction with propofol at 20 mg/kg/h. When patient is sleeping, the dosage is deceased to 6 mg/kg/h
3054387|NCT02198391||3 x 1 tablet per day|Echinaforce Junior tablets (low dose)
3054388|NCT02198391||5 x 1 tablet per day|Echinaforce Junior tablets (high dose)
3054389|NCT02198378|Active Comparator|Morphine|Morphine group: administration of morphine will start with a 0.05 mg/kg bolus followed by reinjection of 2 mg every 5 minutes until effective analgesia is obtained, defined as NRS ≤ 3.
3054390|NCT02198378|Experimental|MEOPA and paracetamol|"The patient will be equipped with a facemask delivering MEOPA.The gas flow received by the patient is adapted to his/her ventilation.~During the same time, an intravenous injection of 1 g paracetamol will be administered."
3054391|NCT02198365||Group 2|Group 1: normal pap smear Group 2: cervical neoplasia
3054392|NCT02198352|Experimental|BIBN 4096 BS - in single rising doses|
3054393|NCT02198352|Placebo Comparator|Placebo|
3054394|NCT02198339|Experimental|BIBN 4096 BS - ranging dose|"sequential adaptive design, allocation of verum treated patients to dose groups not fixed in advance~IV infusion over 10 minutes"
3054395|NCT02198339|Placebo Comparator|Placebo|IV infusion over 10 minutes
3054396|NCT02198326|Experimental|BIBN 4096 BS - in single rising doses|
3054397|NCT02198326|Placebo Comparator|Placebo|
3054398|NCT02198313|Experimental|BIIX 1 XX - D1|
3054399|NCT02198313|Experimental|BIIX 1 XX - D2|
3054400|NCT02198313|Experimental|BIIX 1 XX - D3|
3054401|NCT02198313|Placebo Comparator|Placebo|
3054402|NCT02198300|Active Comparator|rDES Group|regular drug-eluting stent implantation in coronary lesion within bifurcation LucChopin Xience Promus Resolute Integrity Biomatrix Prolim
3054403|NCT02198300|Experimental|BiOSS LIM Group|BiOSS LIM® stent implantation into coronary lesion within bifurcation.
3054404|NCT02198287|Experimental|BIIX 1 XX, rising doses|
3054405|NCT02198287|Placebo Comparator|Placebo|
3054406|NCT02198274|Experimental|BIBH 1|
3054407|NCT02198261||Predicted as non-responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as non-responders. 5% minoxidil topical foam will be administered to subjects in this group.
3054408|NCT02198261||Predicted as responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as responders. 5% minoxidil topical foam will be administered to subjects in this group.
3054409|NCT02198248|Experimental|Low-dose glucocorticoid|"Prednisolone will be commenced with dose of 0.5mg/kg/day and will be tapered and off within 6 months. If a patient fails to achieve BVAS=0, an investigator can postpone the procedure of stopping prednisolone (prednisolone 5mg/day x 2 weeks, 4mg/day x 2 weeks, 3mg/day x 4 weeks, 2mg/day x 4 weeks, 1mg/day x 4 weeks, then off prednisolone). Once starting the procedure, prednisolone must be off after 16 weeks. Patients will also receive rituximab (375mg/m2/w x4).~After achieving remission, patients will be receive rituximab (1g/body or 0.5g/bodyx2) every 6 months as remission maintenance therapy."
3054410|NCT02198248|Active Comparator|High-dose glucocorticoid|"Prednisolone will be commenced with dose of 1.0mg/kg/day and will be tapered to 10mg/day within 6 months. Patients will also receive rituximab (375mg/m2/w x4).~After achieving remission, patients will be receive rituximab (1g/body or 0.5g/bodyx2) every 6 months as remission maintenance therapy. There's no limitation by the protocol regarding further prednisolone tapering."
3054411|NCT02198235|Active Comparator|Control NB + IV Dex + IV Bup|IV Dexamethasone (4 mg) + IV Buprenorphine (150 mcg)
3054412|NCT02198235|Active Comparator|Control NB + IV Dex|IV Dexamethasone (4 mg)
3054413|NCT02198235|Experimental|NB with Dex + Bup in block.|Dexamethasone (4 mg) Buprenorphine (150 mcg)
3054414|NCT02198209|Other|single arm|"Liraglutide (Victoza)~acute study: one injection of 0.6 mg s.c. before IVGTT~chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c)."
3054415|NCT02198196|Experimental|Weight Talk-Mindfulness|WT-M retain the evidence-based elements of WT-S (control condition), including the DASH diet, physical activity components, and an emphasis on self-monitoring. However, each call in WT-M will include an emphasis on mindfulness and stress management that will not be included in the control condition.
3054416|NCT02198196|No Intervention|Weight Talk-Standard|Weight Talk-Standard is a phone and web-based weight loss intervention offered by employers as a benefit to their employees. Weight Talk is based on the NIH Clinical Guidelines on Identification, Evaluation and Treatment of Overweight and Obesity in Adults and utilizes the curriculum developed for the Diabetes Prevention Program. Weight Talk-S contains no additional stress management techniques.
3054417|NCT02198183||Near-infrared spectroscopy|Casmed Fore-Sight Elite and Non-invasive Cardiac Output Monitor (NICOM)
3054418|NCT02198170|Experimental|ketoconazole-placebo|Treatment Period 1: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: Placebo orally once daily + single oral dose of 5 mg lenvatinib of fifth day on 19-day treatment period
3054419|NCT02198170|Experimental|placebo-ketoconazole|Treatment Period 1: Placebo orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period
3054420|NCT02198157|Active Comparator|intermittent urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will receive intermittent catheterization
3054421|NCT02198157|Active Comparator|continuous urinary catheter|nullipara women with epidural anaesthesia who pose urination difficulty will receive continuous catheterization
3054422|NCT02198144|Other|barbershop-based BP measurement|BP monitoring by barbershop based Barbers and BP lowering medication(s)
3054423|NCT02198131|Experimental|Supportive Care (pulsed dye laser)|Patients undergo pulsed dye laser monthly for three months.
3054424|NCT02198118|No Intervention|Control Group|Control group (CG) subjected only to evaluations and to no exercises.
3054425|NCT02198118|Experimental|Study Group|Study group (SG) instructed to perform domiciliary exercises for the upper limbs
3054426|NCT02198105||Femoropopliteal stenosis|"Consecutive patients with symptomatic peripheral artery disease due to femoro-popliteal stenosis/occlusion.~Intervention with Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon-PTA."
3054427|NCT02198092||Patient Group FAP|"Clinical diagnosis of familial adenomatous polyposis (FAP).~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients. Blood draws in FAP patients should always be accompanied by blood draws in their family member controls.~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
3054428|NCT02198092||Patient Group Lynch Syndrome|"Clinical diagnosis of Lynch Syndrome, also known as HNPCC.~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients.~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
3054429|NCT02198092||Patient Group MAP / MYH|"Clinical diagnosis of MYH-associated polyposis and presence of more than 20 colon polyps.~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. The follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients.~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
3054430|NCT02198092||Control Group (FAP Genetically-Related)|"Genetically related family member of enrolled FAP patient.~Controls, i.e. relatives of patients: Willingness to give blood at each routine follow-up as advised for the diseased relative.~The patients of the control group participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating FAP patients.~If colectomy is performed in a FAP patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery.~Blood draws in FAP patients should always be accompanied by blood draws in their family member controls."
3054432|NCT02198066|Other|Dry Sterile Dressing|Subjects in this study arm received a dry sterile dressing (Primapore®, Smith & Nephew), a one-piece, peel-and-stick, non-transparent dressing. This dressing is the standard of care at the study facility for this population and was left in place for either 24 to 48 hours.
3054433|NCT02198066|Active Comparator|Metallic Silver Dressing|Subjects in this arm received a metallic silver dressing (Acticoat Post-Op®, Smith & Nephew), a one-piece, peel-and-stick and non-transparent dressing. This dressing is an absorbent postoperative dressing consisting of a nanocrystalline silver-coated polyurethane layer, a white polyurethane foam and an adhesive coated waterproof polyurethane film layer. Acticoat Post-Op may be left in place over a wound for up to 7 days. The manufacturers note that the product should not be used in patients with known silver allergies and that it may cause transient discoloration of the skin.
3054434|NCT02198066|Active Comparator|Ionic Silver Dressing|Subjects in this arm received an ionic silver dressing (Dermanet Ag®, DeRoyal), a semi-transparent dressing that includes silver, alginate, and maltodextrin. The dressing was cut to fit the incision and then covered with a transparent dressing (Transseal®, DeRoyal). This dressing should not be used on patients with known sensitivity to alginates (a seaweed based component).
3054435|NCT02198053||Ticagrelor2|Ticagrelor with a loading dose of 180mg followed by 90 mg twice per day
3054436|NCT02198053||Ticagrelor1|Ticagrelor with a dose of 90mg followed by 90 mg twice per day .
3054437|NCT02198040|Experimental|Manual Therapy group|The treatment of this group consisted of two sessions per week, one hour each. We used joint traction, passive muscles stretching and Proprioceptive Neuromuscular Facilitation
3054438|NCT02198040|Experimental|Educational group|The treatment had education and home daily exercises for the improvement of the range of motion, biceps strength, perimeter of arm and the perception of pain in patients with haemophilia and arthropathy of the elbow.
3054439|NCT02198040|No Intervention|Control group|The control group did not receive any intervention. The patients in this group were assessed by the same reviewers (blinded to the study conditions) and under the same conditions, that patients in the experimental groups.
3054440|NCT02198027|Experimental|Bupivacaine infiltration|10 ml of 0.25 % Bupivacaine
3054441|NCT02198027|Placebo Comparator|Normal saline infiltration|10 ml of normal saline
3054442|NCT02198014|Experimental|Manual Therapy group|We employed joint traction, passive muscle stretching and isometric exercises, active resisted and proprioception exercises. The treatment in this group consisted of two sessions per week for one hour each.
3054443|NCT02198014|Experimental|Educational gruop|"This group received educational sessions and home exercises. The exercises are aimed at improving quadriceps strength, flexibility, range of motion and knee proprioception.~Each educational session of 90 minute every two weeks, with exercises daily home"
3054444|NCT02198014|No Intervention|Control group|The control group (group C) did not receive any treatment. The patients of this group were assessed by the same reviewers and under the same conditions as the subjects of the two intervention groups.
3054445|NCT02198001|Active Comparator|tooth extraction and insertion of PRF|Experimental: Atraumatic tooth extraction with antibiotics( amoxicillin clavulanate combination) .Insertion of PRF membrane in tooth-extraction site.
3054446|NCT02198001|Placebo Comparator|No PRF|Atraumatic extraction with antibiotic without PRF insertion
3054447|NCT02197988|Active Comparator|Transversus Abdominis Plane Block|Transversus Abdominis Plane Block Exparel 1.33% (20ml Volume)
3054448|NCT02197988|Active Comparator|Thoracic Epidural Anesthesia|Thoracic Epidural Anesthesia 0.125% bupivicaine with 2 mcg/ml Fentanyl
3054449|NCT02197975|Experimental|PT010 Dose 1|PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
3054450|NCT02197975|Experimental|PT010 Dose 2|PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
3054451|NCT02197975|Placebo Comparator|Placebo MDI|Placebo MDI. Administered as 2 inhalations
3054452|NCT02197962|Experimental|Extracorporeal radial shockwaves|Patients will receive 2,000 impulses of extracorporeal radial shockwave per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
3054453|NCT02197962|Placebo Comparator|Placebo Radial Shockwaves|Patients will receive 2,000 impulses of placebo radial shockwave per week, without any energy flow intensity. Frequency of 8Hz will appear in the screen. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
3054454|NCT02197949||Breast cancer patients with infiltrated axillary l|
3054455|NCT02197936||Peristalsis adenomyosis|with adenomyosis
3054456|NCT02197936||Peristalsis control|No adenomyosis
3054457|NCT02197923||Biopsy: adenomyosis|Myometrial biopsy Pipelle
3054458|NCT02197923||Biopsy: Healthy|Myometrial Biopsy Pipelle
3054459|NCT02197910|Active Comparator|High content of wheat bioactive peptides|100 gr pasta/day, containing around 15 mg bioactive peptides (High content of wheat bioactive peptides)
3054460|NCT02197910|Placebo Comparator|Low dose of wheat bioactive peptides|100 gr pasta/day, containing around 3 mg bioactive peptides
3054461|NCT02197897|Experimental|Tamoxifen|As a single-arm study (single group assignment), Tamoxifen citrate will be given to all patients at a 20mg/day dose for 12 weeks using a marker-lesion study design.
3054462|NCT02197884|Experimental|Itraconazole + JNJ-54861911 (Part 1)|Single dose of JNJ-54861911, 25 milligram (mg) tablet orally on Day 1 and Day 9 along with itraconazole 200 mg (2*100 mg capsule) orally once daily from Day 5 to Day 12.
3054463|NCT02197884|Experimental|Clarithromycin + JNJ-54861911 (Part 2)|Single dose of JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9 along with clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
3054464|NCT02197871|No Intervention|blank control|usual diet
3054465|NCT02197871|Experimental|nutrition supplementation|In addition to usual diet,the patients will be given enteral nutrition emulsion, which is a oral nutrition liquid composed of proteins,omega-3 fatty acids,carbohydrate,vitamins.Every package contains 200ml and provides 260 kcal energy.
3054466|NCT02197845|Experimental|Phase I: Recruitment into Specialty Care|Participants in the Phase I Experimental Arm are enrolled into SCD specialty care. PN's will contact patient up to 3 times to assure patients have had an initial visit by 3 months time.
3054467|NCT02197845|Experimental|Phase II: Patient Navigator Arm|Participants in the Phase II Experimental Arm follow routine clinical care and are assigned a Patient Navigator. A specially trained (SCD specefic)PN will work with participants for one year. Participants will be contacted by their Navigator weekly for the first 6 months, then biweekly for the second 6 months.
3054468|NCT02197845|No Intervention|Phase II: Passenger Arm|No Intervention. Participants in the Phase II Passenger Arm follow routine clinical care.
3054469|NCT02197832|Experimental|EA|in the cycle immediately preceding the scheduled FET treatment, an endometrial biopsy would be arranged on day 21-23 of the menstrual cycles and they will be instructed to use non-hormonal means of contraception during that cycle.
3054470|NCT02197832|Placebo Comparator|Control|The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix but not into the uterine cavity, only entering the endocervical canal as control.
3054471|NCT02197819|Experimental|External Rotation Brace|Shoulder placed in an external rotation brace for 4 weeks
3054472|NCT02197819|Active Comparator|Traditional Sling|Patient placed in traditional sling
3054473|NCT02197806|Experimental|AGN-199201|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
3054474|NCT02197806|Experimental|AGN-190584|1 drop of AGN-190584 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
3054475|NCT02197806|Experimental|AGN-199201 + AGN-190584 in One Eye|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
3054476|NCT02197806|Experimental|AGN-199201 + AGN-190584 in Both Eyes|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in both eyes, once and twice daily for 3 days each.
3054477|NCT02197793|Experimental|Community Mobilization Program|Intervention activities will map onto six mobilization domains identified as key components for communities to mobilize for change around testing, linkage and retention in care (Treatment as Prevention (TasP)).
3054478|NCT02197793|No Intervention|Control Arm|The control arm does not receive the Community Mobilization Intervention.
3054479|NCT02197767|Experimental|rituximab|rituximab 1000 mg infusion two weeks apart for a total of two infusions. Retreated with identical rituximab 1000 mg infusion two weeks apart at six months after the first infusion for a grand total of four infusions.
3054480|NCT02197754|Experimental|Polyphenol Diet|After 2 weeks of adaptation to a controlled diet, polyphenol-rich fruits (berries and apple) and beverages (tea) will be fed (8 wks) as part of a controlled diet (10 wks total).
3054481|NCT02197741||opiate without bolus|continuous opiate administration without bolus application
3054482|NCT02197741||opiate with bolus|continuous opiate administration with additional bolus application
3054483|NCT02197728|Active Comparator|Hohl uterine manipulator ®|Total laparoscopic hysterectomy is performed using the Hohl uterine manipulator ®
3054484|NCT02197728|Active Comparator|Colpo-Probe™ Vaginal Fornix Delineator|Total laparoscopic hysterectomy is performed using the Colpo-Probe™ Vaginal Fornix Delineator
3054485|NCT02197715|Experimental|computer-adaptive SAFE|Computer-adaptive SAFE will consist of 4 60-minute sessions. Sessions 1 and 2 will explore participants' reasons to become and rewards for becoming pregnant/having children or avoiding it, introduce reproductive biology in the context of different contraceptive methods and explore the participant's ambivalence toward using different contraceptive methods. Session 3 will provide in-depth coverage of contraceptive methods and the need for use of a barrier method. Session 4 will focus on effective strategies to communicate with a sexual partner. Computer-adaptive SAFE will use an audio computer-assisted self-interviewing (ACASI) format.
3054486|NCT02197715|Experimental|Face-to-face SAFE|Face-to-face SAFE will consist of 4 60-minute sessions using motivational interviewing techniques. Each session will be led by an experienced counselor. Sessions 1 and 2 will explore participants' reasons to become and rewards for becoming pregnant/having children or avoiding it, introduce reproductive biology in the context of different contraceptive methods and explore the participant's ambivalence toward using different contraceptive methods. Session 3 will provide in-depth coverage of contraceptive methods and the need for use of a barrier method, and relevant skills regarding how to use and negotiate use of contraceptive methods. Session 4 will focus on effective strategies to communicate with a sexual partner.
3054487|NCT02197715|Active Comparator|Usual Care|Usual care comprises four 60-minute provider-led individual care sessions about HIV, STIs, and their risks, as well as prevention methods. Contraceptive methods are discussed within this context. There will be no demand on participants to attend these sessions. Participants will receive written take-home materials to review on their own and/or with their sex partners.
3054488|NCT02197702|Placebo Comparator|Placebo|2 ml identical placebo taken by mouth at baseline and 3.5 months.
3054489|NCT02197702|Active Comparator|Vitamin D|Vitamin D (100,000IU) given in a 2 ml oral dose at baseline and 3.5months.
3054490|NCT02197689|Experimental|SMS Medication Reminder|763 patients were assigned to experimental group
3054491|NCT02197689|No Intervention|No SMS Reminder|435 patients were assigned to control group as no SMS reminder
3054492|NCT02197676|Experimental|SGI-110|
3054493|NCT02197663|Experimental|Acupuncture|The total course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.
3054494|NCT02197663|Sham Comparator|sham acupuncture|The total course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen.
3054495|NCT02197637|Experimental|ORAL VINORELBINE|Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle
3054496|NCT02197611||Validation group|Group of patients who we will consult the characteristics of the scale designed and will be made the statistical calculations of validity, reliability and reproducibility
3054497|NCT02197598|Experimental|Selincro® (nalmefene) 18 mg, tablets|One tablet orally for 12 weeks on days when the patient perceives a risk of drinking alcohol, preferably 1-2 hours prior to the anticipated risk of drinking.
3054498|NCT02197585|Experimental|Glue|Mesh fixation with glue
3054500|NCT02197572|Experimental|MLN0128|MLN0128 40 mg, capsules, orally, once, on Day 1, Cycle 1. MLN0128 may be continued at the discretion of the investigator at a dose of up to 30 mg, capsules, orally, once weekly (QW) until disease progression, unacceptable MLN0128-related toxicity, withdrawal of consent, or for up to 12 months (whichever occurs first).
3054501|NCT02197559||BMS group, DES group|All the participants in this group will be performed with bare-metal stents or drug -eluting stents
3054502|NCT02197546|Other|acupuncture plus local anesthesia|Bilateral acupuncture with 1.5 mm long indwelling fixed needles
3054503|NCT02197546|No Intervention|Local anesthesia alone|Standard therapy - local anesthesia alone without acupuncture
3054504|NCT02197533|Experimental|Written list|Patients in the intervention group will receive both verbal information and a written supplement (Appendix 1), produced during the discussion by CM or a fellow (not the individual who obtained consent), on treatment recommendations for OAB. They will leave clinic with this written list of recommendations and will be able to take it home with them.
3054505|NCT02197533|No Intervention|Control|Patients in the control group will receive the same verbal information on the treatment recommendations for OAB, however, these patients will not receive the written list of management strategies for their condition.
3054506|NCT02197520|Experimental|Insulin Peglispro (with Insulin Lispro)|Insulin peglispro, a once daily subcutaneous injection at bedtime for 5 weeks
3054507|NCT02197520|Active Comparator|Insulin Glargine (with Insulin Lispro)|Insulin glargine, a once daily subcutaneous injection at bedtime for 5 weeks
3054508|NCT02197507|Experimental|RA patients|
3054509|NCT02197494|Experimental|Test|Valsartan Tablets USP 320 mg DIVIS
3054510|NCT02197494|Active Comparator|Reference|Diovan® (Valsartan) 320 Tablets
3054511|NCT02197481|Active Comparator|Clamp-Crushing technique|liver transection during hepatectomy by the routine clamp-crushing technical without BiClamp forceps assisted
3054512|NCT02197481|Experimental|BiClamp forceps hepatectomy|The BiClamp forceps, a reusable bipolar sealing instrument for use in open surgery, was uniformly employed in all patients randomized to BiClamp forcep hepatectomy group in the present study.
3054513|NCT02197468||Probiotics|"Preterm infants given probiotics: GA 24-27 weeks/Birth weight < 1000 g~Preterm infants not given probiotics: GA 28-31 weeks/Birth weight 1000-1500 g~Full-term infants not given probiotics (control)"
3054514|NCT02197455|Experimental|Tofacitinib Administration|5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
3054515|NCT02197442|Experimental|Test|Valsartan Tablets USP 320 mg DIVIS
3054516|NCT02197442|Active Comparator|Reference|Diovan® (Valsartan) 320 Tablets
3054517|NCT02197429|Experimental|Acupuncture|Acupuncture
3054518|NCT02197429|No Intervention|Wait-list Control|Wait-list Control
3054519|NCT02197416|Experimental|dabigatran etexilate|
3054520|NCT02197403|Experimental|alcohol drinker & dexmedetomidine|dexmedetomidine, 200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1~1.0mcg/Kg infusion during surgery
3054521|NCT02197403|Active Comparator|alcohol drinker & propofol|Propofol (2% fresofol) 25~75mcg/kg/min continuous infusion
3054522|NCT02197403|Active Comparator|Non-alcohol drinker & dexmedetomidine|dexmedetomidine, 200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1~1.0mcg/Kg infusion during surgery
3054523|NCT02197403|Active Comparator|Non-alcohol drinker & propofol|Propofol (2% fresofol) 25~75mcg/kg/min continuous infusion
3054524|NCT02197390|Experimental|Health Care plus Public Health|The Health Care intervention involves the implementation of an obesity care model within a Federally Qualified Health Center (FQHC) and includes a Family Wellness Program delivered by Community Health Workers (CHWs). The Public Health intervention involves working with early care and education centers, schools, community recreation organizations, and restaurants to promote four health behaviors: fruit and vegetable consumption, physical activity, water consumption, and quality sleep.
3054525|NCT02197390|Experimental|Health Care|The Health Care intervention involves the implementation of an obesity care model within a Federally Qualified Health Center (FQHC) and includes a Family Wellness Program delivered by Community Health Workers (CHWs).
3054526|NCT02197390|Experimental|Public Health|The Public Health intervention involves working with early care and education centers, schools, community recreation organizations, and restaurants to promote four health behaviors: fruit and vegetable consumption, physical activity, water consumption, and quality sleep.
3054527|NCT02197390|Experimental|Control|No intervention.
3054528|NCT02197377|Active Comparator|Group LMA Unique|The supraglottic airway devices were deflated fully before insertion. Size 4 LMA was used for those with a weight of 50-70 kg and size 5 LMA for those between 70-100 kg. After insertion, each device was inflated with a hand-held airway manometer (Rusch, Germany) to an intracuff pressure of 60 cm H2O.
3054529|NCT02197377|Experimental|Group LMA Supreme|The supraglottic airway devices were deflated fully before insertion. Size 4 LMA was used for those with a weight of 50-70 kg and size 5 LMA for those between 70-100 kg. After insertion, each device was inflated with a hand-held airway manometer (Rusch, Germany) to an intracuff pressure of 60 cm H2O.
3054530|NCT02197364||ILD, Other respiratory diseases, Healthy control group|"ILD: those with interstitial lung disease.~Other respiratory diseases: those with other respiratory disease including pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease.~Healthy control group: those who is healthy."
3054531|NCT02197351|Experimental|Gastric Symptoms|Patients with gastric symptoms including dyspepsia undergoing upper endoscopy will undergo white light biopsy narrow band imaging guided biopsy protocolled biopsy
3054532|NCT02197338|Experimental|Short Wire, Small Tome|Short wire system, small sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
3054533|NCT02197338|Active Comparator|Short Wire, Standard Tome|Short wire system, standard sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
3054534|NCT02197338|Active Comparator|Long Wire, Small Tome|Long wire system, small sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
3054535|NCT02197338|Active Comparator|Long Wire, Standard Tome|Long wire system, standard sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
3054536|NCT02197325|Active Comparator|PICSO|Participants enrolled in the PICSO treatment Group will be treated with PICSO concomitant to pPCI in patients with anterior non ST-segment Elevation Myocardial Infarction or following pPCI in ST-segment Elevation Myocardial Infarction
3054537|NCT02197325|No Intervention|Parallel control|Participants enrolled in will receive treatment based on the standard guidelines for treatment of a myocardial infarction.
3054538|NCT02197312|Other|NobelProcera Bridge Shaded Zirconia|posterior region
3054539|NCT02197299|Experimental|Carnitine|Oral administration of 4.5 g L-carnitine L-tartrate (containing 3 g L-carnitine; Carnipure, Lonza Ltd., Switzerland) once daily for 24 weeks
3054540|NCT02197299|Placebo Comparator|Sugar pill|Oral administration of placebo sugar pill
3054541|NCT02197286|Experimental|Vitamin D (cholecalciferol)|Intervention: Capsules containing the active ingredient, cholecalciferol @ 4,000 international units (IU). One capsule daily, oral administration for 10 weeks.
3054542|NCT02197286|Placebo Comparator|Placebo|"Daily matching placebo gelatin capsule (also contains microcrystalline cellulose).~Capsules are identical in size, color and taste to experimental drug."
3054543|NCT02197273|Active Comparator|Standard of care analgesia|"Total Hip Arthroplasty (THA):~All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine~Injection into capsular tissue after placement of the acetabular component:~0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline~Total Knee Arthroplasty (TKA):~All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine All patients will receive an adductor canal block of 0.25% Bupivacaine w/epinephrine 30cc~Injection into posterior capsule of the knee:~0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline~Total Shoulder Arthroplasty (TSA):~All patients will receive a standard interscalene block with bupivacaine followed by indwelling catheter insertion with ropivacaine infusion to be left in place for two days."
3054544|NCT02197273|Experimental|Liposomal bupivacaine|"THA:~Standard of care analgesia, PLUS 266 mg of liposomal bupivacaine. Anterior capsule Inferior capsule Posterior capsule Short external rotator Gluteus maximus Subcutaneous tissue~TKA:~Standard of care analgesia, PLUS 266 mg of liposomal bupivacaine. Posterior knee capsule Anterior femoral periosteum Anterior tibial periosteum Subcutaneous tissue Pericapsular meniscal tissue~TSA:~All patients will receive a standard interscalene block with bupivacaine PLUS 266 mg of liposomal bupivacaine.~Posterior capsule Rotator cuff Subscapularis Humeral periosteum Subcutaneous tissue Deltopectoral muscle"
3054545|NCT02197260|Experimental|Protocol A|Antibiotics (3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days) during the first, non-surgical phase of periodontal therapy (T1), and placebo during the second, surgical phase (T2)
3054546|NCT02197260|Active Comparator|Protocol B|Placebo during the first, non-surgical phase of periodontal therapy (T1), and antibiotics (3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days) during the second, surgical phase (T2)
3054547|NCT02197247|Experimental|Rifampicin and AZD9291|Sequential treatments of AZD9291 alone followed by AZD9291 +rifampicin, followed by AZD9291 alone.
3054548|NCT02197234|Experimental|AZD9291 and simvastatin|Sequential treatments of simvastatin alone followed by AZD9291 alone, followed by simvastatin + AZD9291.
3054549|NCT02197221|Experimental|Bortezomib-Melphalan|Bortezomib will be administered on days: -6, -3 +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
3054550|NCT02197221|Active Comparator|Melphalan|Melphalan will be administered on day -2. The PBSC will be injected on day 0.
3054551|NCT02197208|Active Comparator|Spontaneous NC|Timing by the onset of LH surge as shown daily blood monitoring of serum estradiol and LH levels
3054552|NCT02197208|Experimental|hCG induced NC|Timing by giving hCG when the dominant follicle reaches >=17mm in diameter on ultrasound monitoring
3054553|NCT02197195|Experimental|Chocolate Milk Beverage|Chocolate milk beverage and sitting quietly
3054554|NCT02197195|Experimental|Chocolate Milk Beverage and Exercise|Chocolate milk beverage and exercising
3054555|NCT02197195|Experimental|Fruit Drink Beverage|Fruit drink beverage and sitting quietly
3054556|NCT02197195|Experimental|Fruit Drink Beverage and Exercise|Fruit drink beverage and exercising
3054557|NCT02197182|Experimental|LUXSOL Cream|LUXSOL Cream is a copper containing cream to be administered intravaginally before bedtime for 10 consecutive nights.
3054558|NCT02197182|Active Comparator|Metronidazole cream|Metronidazole cream is the active comparator drug to be self-administered intravaginally each night before bedtime for 10 consecutive nights. Dosage is per package insert.
3054559|NCT02197169|Experimental|DNX-2401 alone|Single intratumoral injection of DNX-2401
3054560|NCT02197169|Experimental|DNX-2401 + Interferon gamma (IFN-γ)|Interferon gamma (IFN-γ) beginning at Day 14
3054561|NCT02197156|Experimental|10 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 10 mg
3054562|NCT02197156|Experimental|20 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 20 mg
3054563|NCT02197156|Experimental|30 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 30 mg
3054564|NCT02197156|Experimental|40 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 40 mg
3054565|NCT02197156|Active Comparator|10 mg HC / 325 mg APAP|10 mg Hydrocodone (HC) / 325 mg acetaminophen (APAP)
3054566|NCT02197156|Placebo Comparator|Placebo|Matching placebo
3054567|NCT02197143|Experimental|Esomeprazole|40 mg Esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
3054568|NCT02197143|Experimental|Ranitidine|50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
3054569|NCT02197143|Experimental|placebo|150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
3054570|NCT02197130|Experimental|20 mg PF-02545920 BID|20 mg PF-02545920 BID
3054571|NCT02197130|Experimental|5 mg PF-02545920 BID|5 mg PF-02545920 BID
3054572|NCT02197130|Placebo Comparator|Placebo BID|Matching placebo
3054573|NCT02197117|Active Comparator|Remote ischemic conditioning|Standard blood pressure cuff placed on upper arm and inflated to 200 mmHg. The cuff is left inflated at this level for 5 minutes and then rapidly deflated to 0 mmHg left deflated for 5 minutes0 this cycle is repeated 4 times in total.
3054574|NCT02197117|Sham Comparator|Control|Standard blood pressure cuff placed on upper arm and left un-inflated for 40 minutes, and then cuff is removed.
3054575|NCT02197104|Experimental|Citocoline|
3054576|NCT02197091||Observational (communication in oncology treatment)|Patients complete questionnaires, including the FACIT-TS-G, the FACIT-Sp12, the MOS-SSS, and the DT. Doctors also complete a questionnaire. Patients' medical records may be reviewed, if necessary.
3054577|NCT02197078||Glitazones|
3054578|NCT02197078||Linagliptin|
3054581|NCT02197065|Experimental|Atorvastatin|Atorvastatin 40mg daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.
3054582|NCT02197065|Placebo Comparator|Sugar pill|Sugar pill (placebo) daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.
3054583|NCT02197052||Computer Based Survey Arm|Participants randomized to the computer based self-completed survey arm were issued a tablet computer to answer survey questions. All participants were encouraged to ask for technical assistance if needed at any point, and like in the face-to-face interviews, electronic survey could be re-initiated at the point of discontinuation after any interruption. Those in the tablet survey arm also could complete the survey in their preferred language and all were additionally given headsets so they could use audio assist with identical, pre-recorded questions in the selected language.
3054584|NCT02197052||Face-to-face interview arm|Participants randomized to this condition were interviewed in-person by a fully bilingual (English-Spanish), bi-cultural research assistant trained in cultural humility, standard research protocols and interviewing practices. Interviews were conducted in clinical rooms in respondent's preferred language, were easily interrupted for medical care, and the survey could be re-initiated at the point of discontinuation after any interruption. Participant responses during face-to-face interviews were recorded by the research assistant on paper and later recorded electronically.
3054585|NCT02197039||The High risk group|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole or pantoprazole immediately after successful endoscopic hemostasis. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole or pantoprazole infusion.~Patients are defined in the high risk group if they still have major stigmata of recent hemorrhage at the second-look endoscopy or have early recurrent bleeding before the schedule time for follow-up.~Recurrent bleeding is defined as: 1) continuous melena, hematochezia, or the presence of recurrent bloody aspirates through a nasogastric tube and 2) relapse of hemodynamic instability, including systolic blood pressure <90 mmHg, heart rate >120 beats per minute, or a drop in hemoglobin concentration by more than 2 g/dL."
3054586|NCT02197039||The control group|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole or pantoprazole immediately after successful endoscopic hemostasis. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole or pantoprazole infusion.~Patients are defined in the control group if they does not have recurrent bleeding before the schedule time for follow-up, and have only minor stigmata of hemorrhage or clean ulcer base at the second-look endoscopy.~Recurrent bleeding is defined as: 1) continuous melena, hematochezia, or the presence of recurrent bloody aspirates through a nasogastric tube and 2) relapse of hemodynamic instability, including systolic blood pressure <90 mmHg, heart rate >120 beats per minute, or a drop in hemoglobin concentration by more than 2 g/dL."
3054587|NCT02197026|Experimental|Synvisc group|injection of Synvisc® at day 1, day 8 and day 15; in the mean time it will be recommended to decrease or stop all other OA treatments
3054588|NCT02197026|Active Comparator|Osteoarthritis standard treatment group|Treatment will be left to the discretion of the investigator who could prescribe any therapies, except viscosupplementation product
3054589|NCT02197013||Introcan Safety 3|Closed IV Catheter
3054590|NCT02197013||Introcan Safety|IV catheter
3054591|NCT02197000|Experimental|DIM-Avail 100mg|women will receive DIM 100mg*1/d, a nutritional supplement for 24 months.
3054592|NCT02196987||Urination, urethral catheterisation|Act of urination during urethral catheterisation in males
3054593|NCT02196987||Lie, catheterisation, urethra|Urethral catheterisation without medical professional guidance
3054594|NCT02196974|Experimental|cryobiopsy|
3054595|NCT02196961|No Intervention|Observation|After complete resection of Merkel cell carcinoma, patients randomized to the observational arm will be observed only
3054596|NCT02196961|Experimental|Ipilimumab (closed treatment arm)|After complete resection of Merkel cell carcinoma, patients randomized to the treatment arm will receive ipilimumab as a single agent (3 mg/kg) administered intravenously over a 90 minute period every 3 weeks for a total of four doses, as tolerated, i.e. day 1 (week 1), day 22 (week 4), day 43 (week 7), day 64 (week 10).
3054597|NCT02196961|Experimental|Nivolumab|After complete resection of Merkel cell carcinoma, patients randomized to the treatment arm will receive nivolumab at a fixed dose of 480 mg by IV infusion every 4 weeks for up to one year (i.e.13 doses).
3054598|NCT02196948|Experimental|Electrolysis Percutaneous Therapeutic (EPTE)|Electrolysis Percutaneous Therapeutic (EPTE) consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon, to initiate a local inflammatory process allowing phagocytosis and repair of the affected tissue. The technique is pain-free since the electrical intensity is adapted to each patient. In addition, patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 4 weeks.
3054599|NCT02196948|Experimental|Eccentric exercise|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 4 weeks.
3054600|NCT02196935||ERCP/EUS|All patients who undergo ERCP and EUS for clinical indications will undergo a detailed prospective assessment of clinical course.
3054601|NCT02196922|Active Comparator|Standard of Care|Patients in the control group will receive standard of care at a Heart Failure clinic (primary and cardiac care as reimbursed by Medicare or sliding scale/uncompensated care). Standard of care patients will be contacted on a weekly basis in order to maintain comparable frequency of contact.
3054602|NCT02196922|Experimental|Telehealth Self Management (TSM)|TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
3054603|NCT02196909|Active Comparator|HIBM patient|motor function, muscle strength, NMR, 24h urine and serum collections at baseline, then annually
3054604|NCT02196909|Active Comparator|Controls|motor function, muscle strength, 24h urine and serum collections at baseline only
3054605|NCT02196896|Experimental|deprexis®|Patients in this arm use deprexis® as an additional treatment during their inpatient stay and as an aftercare intervention.
3054606|NCT02196896|Placebo Comparator|Information|Patients in this arm receive online information about depression as a placebo comparator in addition to their treatment during their inpatient stay and as an aftercare intervention.
3054607|NCT02196883|Active Comparator|MRI Pathology|
3054608|NCT02196883|Active Comparator|Physical Exam Pathology|
3054609|NCT02196857|Experimental|Azacytidine + Sorafenib|Azacitidine 75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) daily for 7 days per 28 day cycle. Sorafenib administered orally at a dose of 400 mg twice daily every day continuously.
3054610|NCT02196844|Experimental|Yoga Group|Couple-Based Hatha Yoga Program: 5-6 weeks of a yoga program, three sessions per week (up to 15 sessions) during radiation treatment. At fifth session, CD given for practicing yoga at home. 10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later. Saliva samples to measure the level of cortisol collected at baseline visit, at end of treatment, and 3 months after radiation therapy. 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
3054611|NCT02196844|Experimental|Wait-List Control Group|"10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule, at radiation treatment completion, and again 3 months later. Saliva samples to measure the level of cortisol collected at baseline visit, at end of treatment, and 3 months after radiation therapy. 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.~Participants given the option to take part in the couple-based Hatha Yoga program (off study) after they finish their last questionnaire packet."
3054612|NCT02196844|Experimental|Caregivers|"Yoga Group - Caregivers: 5-6 weeks of yoga during patient's radiation treatment. At fifth session, caregiver given CD for practicing yoga at home. During each week of patient's radiation, caregiver completes questionnaire about their feelings about yoga sessions. 10 questionnaires completed before patient's first radiation treatment, each week during radiation, 5 halfway through radiation, at radiation completion, and again 3 months later. Saliva samples collected at baseline visit, at end of treatment, and 3 months after patient's radiation therapy.~Waitlist-Control Group - Caregivers: 10 questionnaires completed before patient's first radiation treatment, each week during radiation, 5 halfway through radiation. at radiation completion, and again 3 months later. Saliva samples collected at baseline visit, at end of treatment, and 3 months after radiation therapy.~Caregivers given option to take part in yoga program after they finish their last questionnaire packet."
3054613|NCT02196831|Experimental|Tesamorelin|tesamorelin 2mg subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.
3054614|NCT02196831|Placebo Comparator|Placebo|placebo subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.
3054615|NCT02196818||Mpact Acetabular Shell|Monitor the performance of the Mpact cup in the treatment of patients with hip joint disease requiring a total hip replacement.
3054616|NCT02196805|Experimental|1|
3054617|NCT02196805|Experimental|2|
3054618|NCT02196792|Active Comparator|E-Poly/32 mm|E-Poly polyethylene liner in a titanium cup with a stem with 32 mm cobalt-chromium (CoCr) femoral head.
3054619|NCT02196792|Active Comparator|E-Poly/36 mm|E-Poly polyethylene liner in a titanium cup with a stem with 36 mm CoCr femoral head.
3054620|NCT02196792|Active Comparator|ArComXL/32 mm|ArComXL polyethylene liner in a titanium cup with a stem with 32 mm CoCr femoral head.
3054621|NCT02196792|Active Comparator|ArComXL/36 mm|ArComXL polyethylene liner in a titanium cup with a stem with 36 mm CoCr femoral head.
3054622|NCT02196779||Patients undergoing abdominoplasty|Skin circulation to abdominal flap is evaluated during surgery using laser fluorescent imaging.
3054623|NCT02196766|Active Comparator|Bioclean First Care EX combo, then Aosept Clearcare combo|Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the Aosept Clearcare / comfilcon A combination.
3054624|NCT02196766|Active Comparator|Aosept Clearcare combo, then Bioclean First Care EX combo|Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the Bioclean First Care EX / comfilcon A combination.
3054625|NCT02196753||CIED related infection|"All patients will undergo standard diagnostic process that will consist of: medical interview, physical examination, laboratory tests, blood cultures (3 sets, 1 hour apart, repeated after 24 hours and -if applicable - with fever peak above 38°C); imaging studies (echocardiography: transthoracic, and if there are no contraindications transesophageal, in case of negative or equivocal result repeated after 7-10 days, or in series if necessary, computed tomography scan for pulmonary embolism if indicated); if there are abnormalities in other systems, decisions concerning further diagnostics will be made by the physician in charge.~Apart from standard diagnostic procedures patients will undergo whole body PET CT scan to localize infection or inflammation.~Then the investigators team will make a decision concerning further treatment (antibiotics and complete device removal vs conservative treatment)."
3054626|NCT02196753||Non-infective|Control group consisting of 20 pts with implanted CIEDs who underwent PET CT due to non infectious indications and have no data for infectious process in follow-up
3054627|NCT02196740|Active Comparator|creosote|Creosote ，once，three weeks Triple Antibiotic Paste ，none
3054628|NCT02196740|Experimental|Triple Antibiotic Paste|Triple Antibiotic Paste,once,three weeks creosote,none
3054629|NCT02196727||Patients undergoing Bascom operation|
3054630|NCT02196714|Experimental|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
3054631|NCT02196714|Experimental|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
3054632|NCT02196714|Experimental|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
3054633|NCT02196714|Experimental|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
3054634|NCT02196701|Experimental|Adalimumab Plus Methotrexate|Participants received 40 mg adalimumab every other week and methotrexate, between 7.5 and 25 mg/week at the discretion of the Investigator, for 24 weeks.
3054635|NCT02196688|Active Comparator|treatment arm|treatment arm- subjects will receive Fruquintinib 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
3054636|NCT02196688|Placebo Comparator|control arm|control arm- subjects will receive Fruquintinib placebo 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
3054637|NCT02196675||VATS wedge resection or lobectomy|Single arm study Intervention: Device: Endocutter
3054638|NCT02196662|Experimental|Treatment A|IBD98-M: mesalamine-sodium hyaluronate 200mg-28.75mg X2
3054639|NCT02196662|Experimental|Treatment B|IBD98-M without HA: Mesalamine 200mg X2
3054640|NCT02196662|Experimental|Treatment C|Delzicol 200 mg X2
3054641|NCT02196649|Experimental|Endoscopic Clipping|Participants randomised to the arm will receive endoscopic clips to their defect following EMR.
3054642|NCT02196649|No Intervention|No Endoscopic Clipping|These participants will receive standard of care practice only.
3054643|NCT02196636|Experimental|Part 1: Single Ascending Dose (SAD)|Adaptive model per protocol
3054644|NCT02196636|Experimental|Part 2: Food Effect (FE)|Fasted versus Fed
3054645|NCT02196623|Experimental|Hypoxic Exercise|Supervised, progressive aerobic exercise for 8 weeks under hypoxic conditions
3054646|NCT02196623|Sham Comparator|Normoxic exercise|Supervised, progressive aerobic exercise for 8 weeks under normoxic conditions
3054647|NCT02196610||HEALTHY SUBJECTS group|A group of 20 healthy staff volunteers identified from the Division of Nephrology, Dept. of Medicine and the Kidney Research Centre at the Ottawa Hospital Research Institute will be invited to participate. Measurements of arterial stiffness will be performed by Applanation tonometry. Healthy status will be defined by a self-reporting questionnaire obtained over the phone prior to enrolment and 2 subsequent non-invasive measurements of arterial blood pressure (BP) prior to testing. Subjects will be included if diastolic BP is ≤ 90 mm Hg and systolic BP ≤ 140 mm Hg on 2 consecutive measurements.
3054648|NCT02196610||END-STAGE RENAL DISEASE (ESRD) group|A group of 20 patients with stage 5 Chronic Kidney Disease (estimated glomerular filtration rate <15 ml/min/m2), who attend chronic hemodialysis treatments at The Ottawa Hospital (TOH) will be invited to participate. Measurements of arterial stiffness will be performed in this group by Applanation tonometry.
3054649|NCT02196597||resection with RCT|rectal resection in the case of rectal carcinoma with preoperative radiochemotherapy
3054650|NCT02196597||resection without RCT|patients with rectal resection without preoperative radiochemotherapy
3054651|NCT02196571|Experimental|Exercise and lifestyle change|Women in the experimental group will be included in structured exercise programme two times per week with duration of 50 minutes.Participants will start with training sessions right after they are diagnosed with GDM and they will exercise until the end of the pregnancy or occurence of contraindications. Programme will consist of aerobic exercises (20 minutes), resistance exercises (20 minutes), plevic floor, stretching and relaxation exercises (10 minutes). Women in control group will receive standard antenatal care.
3054652|NCT02196571|No Intervention|Control|Standard antenatal care
3054653|NCT02196558|Experimental|E6011, 100 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase).100 mg group will receive E6011 subcutaneously, 1 ml. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).
3054654|NCT02196558|Experimental|E6011, 200 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase). 200 mg group will receive E6011 subcutaneously, 1 ml each at two sites. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).
3054655|NCT02196558|Experimental|E6011, 400 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks up to 10 weeks (treatment phase). 400 mg group will receive E6011 subcutaneously, 1 ml each at four sites or 2 ml each at two sites. If a subject intends to continue administrations, the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension Phase).
3054656|NCT02196545|Experimental|Exercise|Exercise, patients train on a specifically programmed movement trainer three times a week for 30 minutes (total duration 12 weeks)
3054657|NCT02196545|No Intervention|Treatment as usual|Treatment according to guidelines of German Society for Psychiatry, Psychotherapy and Nervous Diseases (DGPPN) and German Society of Neurology (DGN) without movement trainer exercise
3054658|NCT02196532||migraine group|Patients with migraine
3054659|NCT02196532||healthy control|Sex- and agematched healthy subjects
3054660|NCT02196519|Experimental|Test|All test arm subjects received Sylys Surgical sealant around anastomotic junction after closure.
3054661|NCT02196506|Experimental|Brexpiprazole + ADT|Brexpiprazole + ADT
3054662|NCT02196506|Placebo Comparator|Placebo + ADT|Placebo + ADT
3054663|NCT02196493|Experimental|Azithromycin|250mg azithromycin three times weekly for 12 weeks
3054664|NCT02196480|No Intervention|Methotrexate|JIA patients on stable dose of methotrexate vaccinated with PPV23
3054665|NCT02196480|Experimental|anti-TNF|JIA patients refractory to methotrexate immediately before the association of anti-TNF vaccinated with PPV23
3054666|NCT02196467|Experimental|Myoblast transplantation & strength|30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearms, resuspended in saline. The strength will be evaluated after 3 and 6 months and the presence of dystrophin after 3 or 6 months.
3054667|NCT02196467|Sham Comparator|Saline injection & strength|The same saline solution used in the previous arm, but without cells, will be injected similarly per centimeter cube in the Extensor carpi radialis of the contralateral patient's forearm. The strength will be evaluated after 3 and 6 months and the presence of dystrophin after 3 or 6 months.
3054712|NCT02196142|Active Comparator|Placebo first, Cortisol second|Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)
3054668|NCT02196454|No Intervention|Vaccine Information Statement|Study participants will receive the HPV Vaccine Information Statement (VIS) which is part of routine care.
3054669|NCT02196454|Experimental|Video & Vaccine Information Statement|Participants will view an educational video about the HPV vaccine with a male or female narrator. Participants will also receive the HPV Vaccine Information Statement (VIS) which is part of routine care.
3054670|NCT02196441|Experimental|Group 2|0.5% bupivacaine Deep topical fornix nerve block anaesthesia (DTFNB)
3054671|NCT02196441|Experimental|Group 1|2% tetracaine local anaesthetic drops
3054672|NCT02196428|Other|Telemonitoring and Teleconsultation|
3054673|NCT02196402||study population|"Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy for routine indications (screening, symptoms, surveillance).~Exclusion criteria:~patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer~patients with inadequate bowel preparation~patients in which cecal intubation was not achieved or scheduled for partial examinations~polyps could not be resected due to ongoing anticoagulation or could not be retrieved for pathologic assessment"
3054674|NCT02196389|Active Comparator|Nozovent|Nasal Dilator
3054675|NCT02196389|Active Comparator|Nasanita|Nasal Dilator
3054676|NCT02196389|Active Comparator|Breath Right|Nasal Dilator
3054677|NCT02196389|Active Comparator|Airmax|Nasal Dilator
3054678|NCT02196376||orthostatic tachycardia syndrome|participants with postural orthostatic tachycardia syndrome
3054679|NCT02196376||control subjects|participants not diagnosed with postural orthostatic tachycardia syndrome
3054680|NCT02196363||Pregnant mothers|No intervention
3054681|NCT02196350|Experimental|Intervention A: Diet|Intervention A: One week of very low calorie diet, 12 weeks of low calorie diet; exercise according to the Dutch Norm for Healthy Behaviour (Nederlandse Norm Gezond Bewegen).
3054682|NCT02196350|Experimental|Intervention B: Exercise|"Intervention B: Combination of strength and endurance training, 3 x per week 60 minutes according to the Exercise Program Diabetes (Beweegprogramma Diabetes).~Healthy isocaloric diet."
3054683|NCT02196350|Experimental|Intervention C: Diet and Exercise|"Intervention C: one week very low calorie diet, followed by 12 weeks healthy isocaloric diet.~One week exercise according to the Dutch Norm for Healthy Behaviour (Nederlandse Norm Gezond Bewegen) followed by 12 weeks strength and endurance training (3 x per week 60 minutes) according to the Exercise Program Diabetes (Beweegprogramma Diabetes)"
3054684|NCT02196350|No Intervention|Control - Historical data|Historical data from the GPs Information System from 60 newly diagnosed type 2 diabetes patients in the last five years will be used as control.
3054685|NCT02196337||Women of reproductive age|Age: 18-44 years
3054686|NCT02196337||Pregnant women|Age: 18-44 years
3054687|NCT02196337||Lactating women|Age: 18-44 years
3054688|NCT02196337||Young infants|Age: younger than 6 months
3054689|NCT02196337||Toddlers|Age: between 6 and 24 months
3054690|NCT02196337||School-aged children|Age: 6-12 years
3054691|NCT02196324|Active Comparator|serlopitant 5 mg tablets|serlopitant 5 mg tablets
3054692|NCT02196324|Placebo Comparator|Placebo tablets|Placebo tablets
3054693|NCT02196311||Supracondylar humerus fractures|We are looking to compare open reduction internal fixation versus circular external fixation for supracondylar humerus fractures.
3054694|NCT02196298|Experimental|Lokomat|16 sessions in total, 30 minutes each plus set-up time followed by 5 minutes of overground walking. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
3054695|NCT02196298|Active Comparator|Physiotherapy|16 sessions, 35 minutes. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
3054696|NCT02196285|Experimental|Double viral vaccine (MR)|Measles and rubella vaccine
3054697|NCT02196272|Experimental|Nurse-led email program through email|In addition to usual care and educational program, the intervention group will also receive email alerts and phone calls from the nurse care manager (NCM).
3054698|NCT02196272|No Intervention|Management of diabetic patients|Usual care, educational program and usual management of Diabetic patients
3054699|NCT02196259|Experimental|Initial MRI|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
3054700|NCT02196259|Experimental|Initial hospital|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
3054701|NCT02196259|Experimental|Depression MRI|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
3054702|NCT02196207|Experimental|Previously Untreated Severe Hemophilia A|Long-acting recombinant factor VIII Fc fusion protein, Eloctate (50 IU/kg weekly), will be administered prophylactically in previously untreated children with severe hemophilia A before the first bleed.
3054703|NCT02196194||tiotropium|
3054704|NCT02196181|Experimental|Arm I (continuous dosing)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-56. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
3054705|NCT02196181|Experimental|Arm II (intermittent dosing)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-7 and 29-56. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
3054706|NCT02196168|Experimental|Arm I (WEE1 inhibitor MK-1775, cisplatin)|Patients receive WEE1 inhibitor MK-1775 PO BID for 5 doses beginning on day 1 and cisplatin IV over 1 hour on day 1.
3054707|NCT02196168|Active Comparator|Arm II (placebo, cisplatin)|Patients receive placebo PO BID for 5 doses beginning on day 1 and cisplatin IV over 2 hour on day 1.
3054708|NCT02196155|Active Comparator|BTX-A|Botulinum A toxin is injected each 100 U in both gastrocnemius muscle-bellies and 50 U in the soleus muscle, i.e. a total of 250 U.
3054709|NCT02196155|Active Comparator|Cortisone|Depot Medrol is injected at the plantar fascia insertion site at the calcaneus
3054710|NCT02196155|Placebo Comparator|Saline|Placebo saline is injected in both gastrocnemius muscle-bellies and in the soleus muscle
3054713|NCT02196129|Experimental|Sinbaro-3|1cc Harpagophytum Procumbens(freeze drying) pharmacoacupuncture adminstered to 6 acupoints at the site of pain Administered once and once only before any interventions
3054714|NCT02196129|Placebo Comparator|Hwangryun(distillation)|1cc Hwangryun(distillation) pharmaco-acupuncture administered to 6 acupoints at the site of pain Administered once and once only before any other intervention
3054715|NCT02196116|Active Comparator|Group 1|Controls
3054716|NCT02196116|Experimental|Group 2|Cognitively-impaired subjects without dementia and without memory
3054717|NCT02196116|Experimental|Group 3|Cognitively-impaired subjects without dementia and with memory
3054718|NCT02196103|Experimental|Expectant management|
3054719|NCT02196090|Experimental|Single arm|Study uses the single case series design with only one arm. All participants in the one arm will have procedures with treatment as usual (Exposure and Response Prevention) alternating with procedures including the vagal maneuver (Cold Face Gel Mask).
3054720|NCT02196077|Experimental|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
3054721|NCT02196077|Experimental|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI)160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
3054722|NCT02196077|Experimental|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
3054723|NCT02196077|Experimental|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
3054724|NCT02196077|Experimental|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
3054725|NCT02196064||Safety of the three-drug combination TDF/FTC/RPV|A total of 176 patients will be included in this study, as well as 352 patients naive for RPV who initiated any ART that does not include RPV, who will serve as control group.
3054726|NCT02196051|Experimental|Exercise Training|Participants will engage in a single bout of elliptical exercise for 45 minutes (3X15 spaced by 5 minutes rest) at baseline. Subjects will be studied before and after this one bout to measure hepatic de novo lipogenesis. Participants will then take part in six weeks of exercise training on an elliptical trainer 3 times per week each time for 45 minutes. Hepatic de novo lipogenesis will be compared pre and post to examine wether improving muscle glucose uptake will decrease hepatic de novo lipogenesis as the glucose is taken up by muscle and not directed to the liver.
3054727|NCT02196038|Other|Attention Control|Usual care group with bi-weekly contact from study staff
3054728|NCT02196038|Active Comparator|multi-domain rehabilitation intervention|Individual, tailored, progressive, physical function rehabilitation intervention
3054729|NCT02196025|Experimental|Transcranial magnetic stimulation|Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
3054730|NCT02196012|Experimental|Lifestyle counseling|The intervention condition will contain multiple components: nutrition education, physical activity, social support, social media (Pinterest and Facebook), and smartphone applications for self-monitoring. Students in this condition will have access to the private study website, which will be the central platform for delivery of the program materials and social support. The website, developed using Wordpress.com, will include nutrition materials, exercise videos, a forum, and links to the study's Facebook and Pinterest pages
3054731|NCT02196012|Active Comparator|attention control condition|Students randomized to the attention control condition will receive educational emails three times per week. Nutrition materials will be sent once a week, and links to the YouTube exercise videos will be sent twice a week. At the start of the program, students will be emailed a link to the Pandora workout station. The materials sent to the control group will be the same materials posted on the website for the intervention group. Participants will access the emailed lessons and videos each week at their own convenience. Individuals in the attention control condition will not have access to the study website or social media pages.
3054732|NCT02195999||Individuals with DMD|"Magnetic Resonance Imaging is a non-invasive method to determine ventricular size, volumes, mass, and ejection fraction.~Pulmonary Function testing (PFT) are a series of non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.~Metabolic exercise testing using stationary bicycle (exercise capacity and MVO2) evaluates global cardiopulmonary functional status.~Echocardiogram with multiple-echo Dixon method helps to assess cross-sectional and longitudinal variations in myocardial structure."
3054733|NCT02195986|Experimental|Estradiol Vaginal Cream|Estradiol Vaginal Cream, 0.01%, administered once daily for 7 days.
3054734|NCT02195986|Active Comparator|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream, administered once daily for 7 days.
3054735|NCT02195986|Placebo Comparator|Placebo Vaginal Cream|Placebo Vaginal Cream, administered once daily for 7 days.
3054736|NCT02195973|Experimental|Paclitaxel + LDE225|Patients will receive intravenous paclitaxel on days 1, 8, and 15 every 28 days (3 weeks on followed by one week off). This constitutes one cycle. in addition to the paclitaxel oral LDE225 will be taken daily. Dosages of each drug will vary according to the study cohort and phase. The study consists of six cycles of treatment followed by clinic visits every 2-3 months for up to two years.
3054737|NCT02195960|Placebo Comparator|placebo|intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins
3054738|NCT02195960|Active Comparator|intake anthocyanin-rich corn extract|intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
3054739|NCT02195947|Experimental|Antagonist and Growth hormone|HMG IM daily was administrated from day 2 of the cycle. The GnRH antagonist (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
3054740|NCT02195947|No Intervention|Antagonist|HMG IM daily was administrated from day 2 of the cycle. The GnRH antagonist (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
3054925|NCT02194738|Active Comparator|E4512 Arm B (observation)|Patients undergo observation.
3054741|NCT02195934|Other|Standard orange juice (OJ) followed by blood OJ|This randomized 2-way cross over study will compare the effect of blood orange juice with that of a standard (blonde) orange juice consumed daily for 28 days, on markers of cardiovascular disease, with a 3 week washout period in between.
3054742|NCT02195934|Other|Blood orange juice followed by standard OJ|This randomized 2-way cross over study will compare the effect of blood orange juice with that of a standard (blonde) orange juice consumed daily for 28 days, on markers of cardiovascular disease, with a 3 week washout period in between.
3054743|NCT02195921|Experimental|Single point CV12|"choose single point:Zhongwan(CV12).Zhongwan(CV12):On the upper abdomen, 4 B-cun superior to the centre of the umbilicus, on the anterior median line.Manipulating until achieving a de Qi sensation,then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
3054744|NCT02195921|Experimental|Single point ST36|"choose another single point Zusanli（ST36）.Zusanli(ST36):On the anterior aspect of the leg, on the line connecting ST35 with ST41, 3 B-cun inferior to ST35，located on the tibialis anterior muscle..Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
3054745|NCT02195921|Experimental|Matching points ST36+CV12|"Choose both Zusanli(ST36) and Zhongwan（CV12）.Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
3054746|NCT02195921|Active Comparator|only antiemetics|The control group will receive standard antiemetics alone. Standard antiemetics for all groups are based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron , Tropisetron)and dexamethasone are supplied from the first day of chemtherapy,and lasting for 3-5days. If nausea and/or vomiting is persistent and failed to respond to the antiemetic treatment , based on the experience of each clinician, the other advanced 5-HT3 antagonist or a neurokinin 1 antagonist(NK-1) will be chosen.
3054747|NCT02195908|Experimental|Single point PC6|"choose single point: Neiguan(PC6).Neiguan(PC6): On the anterior aspect of the forearm,between the tendons of the palmaris longus and the flexor carpi radialis, 2 B-cun proximal to the palmar wrist crease.Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
3054748|NCT02195908|Experimental|Single point CV12|"choose another single point Zhongwan（CV12）. Zhongwan(CV12): On the upper abdomen, 4 B-cun superior to the centre of the umbilicus, on the anterior median line. Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
3054749|NCT02195908|Experimental|Matching points PC6+CV12|"Choose both Neiguan point(PC6) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
3054750|NCT02195908|Active Comparator|only antiemetic|The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.
3054751|NCT02195895|Experimental|Alendronate, Calcium, Vitamin D|"Drug: Weekly oral alendronate 70 mg for 12 months~Supplements: 1000 mg Calcium and 1000 IU Vitamin D daily for 12 months"
3054752|NCT02195882|Experimental|Exercise program|
3054753|NCT02195869|Experimental|Phase 1b: Dose Level 1|Ibrutinib PO administered daily
3054754|NCT02195869|Experimental|Phase 1b: Dose Level 2|Ibrutinib (PO) administered daily
3054755|NCT02195869|Experimental|Phase 1b: Dose Level 3|Ibrutinib (PO) administered daily
3054756|NCT02195869|Experimental|Phase 2|Ibrutinib (PO) administered daily for 18 months
3054757|NCT02195856|Active Comparator|Diseased condition|Crossover design where participants will start in the Beetroot juice condition, and after a washout period, move into the other condition.
3054758|NCT02195856|Placebo Comparator|Placebo|Crossover design where participants will start in the placebo condition, and after a washout period, move into the other condition.
3054759|NCT02195843|Active Comparator|Emperical|Anatomical optimization of device and leads
3054760|NCT02195843|Active Comparator|Electrical|Electrical optimization by RVLV Conduction Time with VectSelect
3054761|NCT02195830|Other|Single arm - Ultrasound|All participants will have an Ultrasound measurement of their inferior vena cava at enrolment as described in the intervention
3054762|NCT02195817|Other|Selincro® 18 mg with continuous psychosocial support: Cohort A|Selincro® as-needed; tablets, orally, 12-week Treatment Period in conjunction with continuous psychosocial support
3055011|NCT02194270|Active Comparator|Ambroxol hydrochloride - syrup - low dose|
3054763|NCT02195817|Other|Initial psychosocial support: Cohort B|Initial psychosocial support followed by usual care practice, 12-week Observational Period
3054764|NCT02195804|Experimental|Ranitidine HCL ODT Vanilla-Mint|
3054765|NCT02195804|Experimental|Ranitidine HCL ODT RM Vanilla-Mint|
3054766|NCT02195804|Active Comparator|Ranitidine HCL|Maximum Strength ZANTAC 150®
3054767|NCT02195791|Active Comparator|Pioglitazone|
3054768|NCT02195791|Placebo Comparator|Placebo|
3054769|NCT02195778||Young, 18 to 30|
3054770|NCT02195778||Middle, 31 to 50|
3054771|NCT02195778||Older, 51 to 70|
3054772|NCT02195765|Experimental|enamel matrix derivative|Open flap debridement associated with Enamel matrix derivative gel (Emdogain, Straumann)
3054773|NCT02195765|Active Comparator|Open flap debridment|Open flap debridement
3054774|NCT02195752||Prescribed Compounded Pain Cream|The study is limited to patients who have been prescribed treatment with a topical compounded pain cream as a component of their ordinary care by a qualified physician.
3054775|NCT02195739||Nicotine replacement therapy cohort|Cohort defined as patients in whom nicotine replacement therapy (in any preparation) was initiated at the index smoking cessation attempt as the first recorded smoking cessation intervention.
3054776|NCT02195739||Other smoking cessation therapy|Cohort defined as patients in whom other (non-nicotine replacement therapy) smoking cessation pharmacotherapy's were initiated at the index smoking cessation attempt (e.g. bupropion, varenicline) as the first recorded smoking cessation intervention
3054777|NCT02195739||Smoking cessation advice cohort|Cohort (control patients) defined as patients whose first recorded smoking cessation intervention involved smoking cessation advice leading to a quit attempt unassisted by pharmacological smoking cessation aids, at the index smoking cessation attempt.
3054778|NCT02195726|Sham Comparator|Sham remote ischemic preconditioning'|In the control group Sham remote ischemic preconditioning will be performed with inflation of 10 mmHg more than baseline
3054779|NCT02195726|Experimental|Remote ischemic preconditioning|"In the experimental group, patients will receive for four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg upper than baseline), followed by 5-minute intervals of reperfusion.~In subjects presenting with BMI > 30 a dedicated blood pressure cuff for obese patients will be used. Coronary angiography will be performed in 45 minutes from last inflation"
3054780|NCT02195713||Test- Accuryn Urine Output Monitor|Accuryn Anti-airlock Drainage System was attached to the Foley catheter and urine output / drainage line pressure was monitored.
3054781|NCT02195713||Control- Critcore Urine Output Monitor|A commercially available urine output monitor (Criticore, Bard Medical) was attached to the Foley catheter and urine output / drainage line pressure was monitored.
3054782|NCT02195700|Experimental|SD-809|SD-809 tablets taken twice daily for 12 weeks.
3054783|NCT02195700|Placebo Comparator|Sugar Pill|Placebo tablets taken twice daily for 12 weeks.
3054784|NCT02195687|Experimental|botulinum toxin type A|24U botulinum toxin Type A (BOTOX®) total dose injected into bilateral Crow's Feet Line areas on Day 1.
3054785|NCT02195687|Placebo Comparator|placebo|Placebo (Normal Saline) injected into bilateral Crow's Feet Line areas on Day 1.
3054786|NCT02195661|Active Comparator|Melatonin sleep EEG induced group|"All children who were referred to the neurophysiology department who were either unable to keep still for their EEG, or required a sleep EEG as part of their epilepsy work-up and whose caregivers agreed to the administering of sedation with melatonin. Melatonin by mouth (3mg for children < 15kg, 6mg for those > 15kg) 1 hour before the scheduled EEG by the unit nurse. Children who can swallow the capsules directly, those who cannot are given the contents of the powder in the capsule mixed in a few millilitres of water. If the child fails to fall asleep within one hour of administration of the melatonin then a second dose 3mg is given) ."
3054787|NCT02195661|Other|Comparison group for children sedated using previous practice|Since the choral hydrate had been withdrawn a direct comparison group was not possible. However a study performed the previous year in the department measured a several parallel useful outcomes. This study had addressed the usefulness of electroencephalograms in a South African population. A proportion of this group screened in 2012 in our unit underwent sleep studies, sedated with chloral (n=22). These patients were drawn from the same regional pool, with the same disease demographics, and the same sleep deprivation and procedural techniques to the current group. This group was screened for several common denominators to the current study themes, and comparison will be made between these, namely the proportion of patients with successful attainment of sleep studies, the proportion of studies with excessive artifact (precluding interpretation) and the usefulness of the data attained detailing whether the studies were able to assist or alter patient management.
3054788|NCT02195648|Experimental|Suboccipital inhibition|The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles.
3054789|NCT02195648|No Intervention|Control|No intervention will be done to the participants during the study. After study completion, the participants will be offered to receive the therapy.
3054790|NCT02195635|Experimental|Period 1|Single oral dose of 500 mg telotristat etiprate on Day 1
3054791|NCT02195635|Other|Period 2|Subcutaneous injections of 200 µg octreotide acetate three times daily with a single oral dose of 500 mg telotristat etiprate on Day 6
3054792|NCT02195622|Other|Lumenis VersaCut Morcellator|Lumenis VersaCut Morcellator will be utilized for prostate tissue morcellation
3054793|NCT02195622|Other|Wolf Piranha Morcellator|Wolf Piranha Morcellator will be utilized for prostate tissue morcellation
3054794|NCT02195609|Other|Omega-3|600 mg (EPA, DHA and Omega-3) twice a day
3054795|NCT02195609|Other|Soy Isoflavones|54.4mg oral twice a day
3054831|NCT02195349|Experimental|Healthy Subjects (no DTH)|One subject will be dosed with GSK2831781 (0.0003 mg/kg) and one with placebo. Depending on the safety data obtained for 28 days post dose along with the available PK data, a dose escalation may be done to the next planned dose (0.0015 , 0.0075, 0.04, 0.15 mg/kg). In case safety findings are noted then the cohort may be expanded to a maximum cohort size of 6:3 (GSK2831781: placebo) or the escalation will be stopped.
3054863|NCT02195089|Experimental|BLS_ILB_E710c 500mg|"Drug: BLS_ILB_E710c 500mg~Dosage and duration: 2 capsules per day for 20 days (week 1,2,4 & 8)"
3054796|NCT02195596|Experimental|High intensity aerobic exercise+strength|"The program consist in a Continuous High aerobic exercise and moderate intensity intervals (ShoshanaB et al, 2012) combined with muscular strength exercises and joint mobility. Patients come three times a week for six months to the primary health center. A fitness expert nurse is responsible for monitoring the performance and adapt to the physical condition of the patient.Each exercise session consists of warming up time period, period of work and back to calm. Exercise intensity during the work period increases progressively as the program progresses. Aerobic exercise is performed on a cycle ergometer or treadmill.Muscle strength exercises and joint mobility are performed with dumbbells and ankle weights adapted to each patient."
3054797|NCT02195596|Active Comparator|Low intensity aerobic exercise+strength|The control group performed an exercise program similar to intervention but at low intensity that is below 35 or 40% of heart rate reserve (HRR).
3054798|NCT02195583|Experimental|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
3054799|NCT02195583|Experimental|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
3054800|NCT02195583|Experimental|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
3054801|NCT02195583|Experimental|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
3054802|NCT02195583|Experimental|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
3054803|NCT02195583|Placebo Comparator|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
3054804|NCT02195570|Experimental|QSN with CM (QSN-CM).|Women will receive standard of care Quit Smoking Now tobacco education and support plus prize-based contingency management. Their smoking status will be monitored from quit date through 3 months postpartum via carbon monoxide and salivary cotinine levels. Women will earn chances to win prizes each time they test negative for smoking according to biochemical measures.
3054805|NCT02195570|Active Comparator|QSN Only|Women receive the standard of care Quit Smoking Now tobacco education and support only. Smoking status will be monitored from quit date through 3 months postpartum via carbon monoxide and salivary cotinine levels. Incentives are given for providing breath and salivary samples but are not contingent on smoking status.
3054806|NCT02195557||Synvisc®|
3054807|NCT02195544||Synvisc®|
3054808|NCT02195531|Active Comparator|Treatment|Participants will receive education and feedback tailored to the psychological profile of the receiving participant.
3054809|NCT02195531|Active Comparator|Control Group|Participants will receive education inconsistent with their profile.
3054810|NCT02195531|No Intervention|Standard of care|Participants will not receive education or feedback.
3054811|NCT02195518|Experimental|Tenofovir Disoproxil Fumarate|All enrolled subjects will receive open label TDF at a dose of 300 milligram (mg) orally once daily during the study period.
3054812|NCT02195505||Synvisc®|
3054813|NCT02195505||Usual treatment of knee|nonsteroidal antiinflammatory drugs, antalgics
3054814|NCT02195492||Synvisc®|
3054815|NCT02195479|Active Comparator|Treatment Arm A (VMP Alone)|Participants will receive velcade (bortezomib) 1.3 milligram per square meter (mg/m^2) as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 , orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
3054816|NCT02195479|Experimental|Treatment Arm B (D-VMP)|Participants will receive velcade 1.3 mg/m^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2, orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 mg/kg as IV infusion, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or study end. On days when daratumumab is given, dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab infusion as pre medication and prednisone substitute, and prednisone 60 mg/m2 once daily will be given on Days 2-4.
3054817|NCT02195466|Experimental|TPV + RTV + FCZ|
3054818|NCT02195453|Experimental|Yangzhengxiaoji Capsule|"Gemcitabine or Pemetrexed~Cisplatin~Yangzhengxiaoji Capsule four granules t.i.d po"
3054819|NCT02195453|Placebo Comparator|Placebo Capsule|"Gemcitabine or Pemetrexed~Cisplatin~Placebo Capsule four granules t.i.d po"
3054820|NCT02195440|Experimental|PRI-724|
3054821|NCT02195427|Experimental|TEOSYAL RHA Global Action/Juvederm Ultra XC|Split-face injection of TEOSYAL® RHA Global Action into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
3054822|NCT02195427|Experimental|TEOSYAL RHA Deep Lines/Juvederm Ultra XC|Split-face injection of TEOSYAL® RHA Deep Lines into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
3054823|NCT02195414|Experimental|NeoVas BCS|The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA-based polymer scaffold and contains the antiproliferative drug sirolimus.
3054824|NCT02195401||Sleeping in a cleanroom|Each child and his or her parent slept in a cleanroom for two weeks. Within 24 hours pre and post this two week experience blood and hair samples were taken from the children and the parents filled out rating scales.
3054825|NCT02195388||CR with AH|Patients after ACS with arterial hypertension treat with comprehensive cardiac rehabilitation
3054826|NCT02195388||N-CR with AH|Patients after ACS with arterial hypertension don't treat with comprehensive cardiac rehabilitation.
3054827|NCT02195388||CR without AH|Patients after ACS without arterial hypertension treat with comprehensive cardiac rehabilitation
3054828|NCT02195375|Experimental|Flutiform 500/20 µg BID|Flutiform 250/10 (2 puffs BID)
3054829|NCT02195375|Experimental|Flutiform 250/10 µg BID|Flutiform 125/5 (2 puffs BID)
3054830|NCT02195375|Active Comparator|Seretide Accuhaler 50/500 µg BID|Seretide Accuhaler 50/500 (BID)
3054862|NCT02195102||transcatheter aortic valve Replacement|Patients with symptomatic severe aortic stenosis who are not candidates for surgical aortic valve replacement because of coexisting illnesses.
3054832|NCT02195349|Experimental|Healthy Subjects (DTH)|Sentinel subjects (one dosed with GSK2831781 (0.0003 mg/kg) and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 1 placebo subject will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). After reviewing the safety data for 28 days the healthy subjects (DTH) will be escalated to the planned dose of GSK2831781 (0.0075, 0.04, 0.15 mg/kg) in 6:3 ratio with placebo.
3054833|NCT02195349|Experimental|Subjects with Psoriasis|Sentinel subjects (one dosed with GSK2831781 and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 2 placebo subjects will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). All subsequent cohorts do not require stratification for pre-existing ADAs. After reviewing the safety data for 28 days for minimum of 8 out of 9 subjects within the cohort and all subjects have completed dosing and the inpatient monitoring until Day 4, the subjects with psoriasis will be escalated to the planned dose of GSK2831781 (1.5 and 5 mg/kg) in 6:3 ratio with placebo.
3054834|NCT02195336|Experimental|dMRT, Bevacizumab, Chemotherapy|"dMRT: Magnetic Resonance Tomograph, Baseline, day 8, day 28, day 92, progression/relapse.~Bevacizumab: 7.5mg/kg every 3 weeks for 3 cycles. Standard of care NSCLC first-line chemotherapy, doublets containing paclitaxel and carboplatin are preferred, every 3 weeks for 3 cycles.~Thereafter Bevacizumab 7.5mg/kg every 3 weeks until progression/relapse or unacceptable toxicity."
3054835|NCT02195323|Experimental|MSC recipient|The patients with CKD who underwent intravenous injection of MSC.
3054836|NCT02195310|Experimental|Prevena™ Incision Management System|Subjects will receive sternal wound treatment in the operating room using Prevena™ Incision Management System according to the intended use
3054837|NCT02195310|Active Comparator|Conventional sterile wound dressings|Subjects will receive SCWT placed in the operating room, defined as using conventional sterile wound dressings (gauze).
3054838|NCT02195297|Active Comparator|ANTICELLULITE GMG GIULIANI|Each included subject applied ANTICELLULITE GMG GIULIANI mono-laterally (on the left or on right side according to a previously defined randomization list) once a day, at evening, for an uninterrupted period of 4 weeks.
3054839|NCT02195297|Active Comparator|SOMATOLINE|Each included subject applied SOMATOLINE CREAM mono-laterally (on the left or on right side according to a previously defined randomization list) once a day, at evening, for an uninterrupted period of 4 weeks.
3054840|NCT02195284|Experimental|Sub-study 1|Subjects will be randomized to either use ELLIPTA inhaler first and then DISKUS/ACCUHALER inhaler or use DISKUS/ACCUHALER inhaler first and then ELLIPTA inhaler
3054841|NCT02195284|Experimental|Sub-study 2|Subjects will be randomized to either use ELLIPTA inhaler first and then MDI (metered-dose inhaler) or use MDI first and then ELLIPTA inahler
3054842|NCT02195284|Experimental|Sub-study 3|Subjects will be randomized to either use ELLIPTA inhaler first and then TURBUHALER inhaler or use TURBUHALER inhaler first and then ELLIPTA inhaler
3054843|NCT02195271|Active Comparator|Melatonin|0,25mg/Kg sl before tDCS
3054844|NCT02195271|Experimental|tDCS|Transcranial direct current stimulation once time. Dose 2 mA, 20 seconds.
3054845|NCT02195258||salbutamol|
3054846|NCT02195245|No Intervention|Control|Control - Observational (non interventional) data is collected from current state of the art absorber devices.
3054847|NCT02195245|Experimental|memsorb|New CO2 filter - data is collected using the new CO2 absorber.
3054848|NCT02195232|Experimental|Isoquercetin|"Isoquercetin:~Cohort A: 500 mg, Once daily, 28 days or~Cohort B: 1000 mg, Once daily, 28 days~For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days."
3054849|NCT02195219|Experimental|open reduction internal fixation|open reduction internal fixation
3054850|NCT02195219|Active Comparator|non operative treatment|'sling rest and early functional recovery
3054851|NCT02195206||Healthy|Adult
3054852|NCT02195193|No Intervention|Usual Care (UC)|"The standard interventions from Clinical Pathway for Acute Coronary Syndromes in China-Phase 3 (CPACS-3) study that are limited to in-patient ACS care (refer to Usual Care [UC]), will be implemented in the participating hospitals, and hence will be received by all patients in both intervention (IC) and control (UC) groups; standardized cardiovascular disease education also will be provided to all participants.CPACS-3 registration number is NCT01398228"
3054853|NCT02195193|Experimental|Intervention Care (IC)|Besides of the UC, an nurse-coordinated integrated care model for Acute Coronary Syndromes(ACS) and depression will be delivered to intervention group, including ACS secondary prevention therapies at and after discharge, screening and treatment of depression during hospitalization and after discharge.
3054854|NCT02195180|Experimental|standard of care combined with ERY001|standard of care = Gemcitabine or folfox
3054855|NCT02195180|Sham Comparator|standard of care alone|standard of care = Gemcitabine or folfox
3054856|NCT02195167|Experimental|Dasotraline|"Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg. The language should precede the text that is currently there"
3054857|NCT02195154|Experimental|18F-DTBZ for Vascular Parkinsonism|This neuroimaging study includes the 18F-FP-(+)-DTBZ PET, MRI structure images, diffusion tensor imaging, susceptibility weighted imaging, resting state and gait-related imagery task functional MRI. Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject group, each subject will have 3 visits in this study. Safety measurement for 18F-FP-(+)-DTBZ will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
3054858|NCT02195141|Active Comparator|conventional fraction|Radiotherapy (25x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily
3054859|NCT02195141|Experimental|SIB|Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
3054860|NCT02195115|Active Comparator|Laparoscopic cholecystectomy|surgical removal of gallbladder
3054861|NCT02195115|Active Comparator|Non-operative treatment|Administration of amitriptyline 25mg daily, Low Fat-Low Cholesterol Diet
3054864|NCT02195089|Experimental|BLS_ILS_E710c 1000mg|"Drug: BLS_ILS_E710c 1000mg~Dosage and duration: 4 capsules per day for 20 days (week 1,2,4 & 8)"
3054865|NCT02195089|Experimental|BLS_ILS_E710c 1500mg|"Drug: BLS_ILS_E710c 1500mg~Dosage and duration: 6 capsules per day for 20 days (week 1,2,4 & 8)"
3054866|NCT02195076||Breast Cancer patients|
3054867|NCT02195076||Lung cancer patients|
3054868|NCT02195076||Healthy controls|
3054869|NCT02195063||Pain management|patients undergoing transdermal treatment for pain
3054870|NCT02195063||Scar care|patients undergoing transdermal treatment for scars
3054871|NCT02195063||Wound care|patients undergoing transdermal treatment for wounds
3054872|NCT02195063||UDT|patients receiving urinary drug tests
3054873|NCT02195050||Therapeutic target arm|Statin treated patients with and without raised triglycerides who do not have diabetes or dysglycemia. Statin treated patients with type 2 diabetes.Statin treated patients with CKD stages 4 and 5 (eGFR ≤30mL/min).
3054874|NCT02195050||Nerve function arm|Patients with severe hypertriglyceridaemia (fasting TG > 5.5mmol/l.) are recruited for nerve function assessment and corneal confocal microscopy.
3054875|NCT02195050||Genetic screening arm|For LAL deficiency screening, patients will be recruited over a 5 year period with a documented triglyceride level of more than 10 mmol/l at any time, low HDLC, raised ALT, combined hyperlipidaemia, or non-alcoholic fatty liver disease. Patients recruited from Manchester will be offered additional genetic testing for familial hypercholesterolaemia.
3054876|NCT02195024|Active Comparator|cardiac MRI group|• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
3054877|NCT02195024|No Intervention|No MRI group|Patients that refuse to undergo cMRI for any reason but accept to attend the trial can be further observed according to the protocol
3054878|NCT02195011|Experimental|Cohort 1: Regorafenib/SIR-Spheres/Regorafenib|"Regorafenib (one cycle) followed by SIR-Spheres followed by re-initiation of regorafenib 2-4 weeks after SIR-Spheres.~Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle. SIR-Spheres microspheres will then be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. Treatment with regorafenib will be re-started 2-4 weeks after SIR-Spheres administration."
3054879|NCT02195011|Experimental|Cohort 2: SIR-Spheres/Regorafenib|"SIR-Spheres followed by regorafenib to start 2-4 weeks after SIR-Spheres.~SIR-Spheres microspheres will be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. After SIR-Spheres microspheres have been administered, the treatment with regorafenib will be initiated 2-4 weeks after administration of SIR-Spheres. Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle."
3054880|NCT02194998|Experimental|Cohort A|Participants in Cohort A will receive the following medications for 24 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for participants with HCV genotype 1a only; participants with HCV genotype 1b will not receive RBV).
3054881|NCT02194998|Experimental|Cohort B|Participants in Cohort B will receive the following medications for 12 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for participants with HCV genotype 1a only; participants with HCV genotype 1b will not receive RBV).
3054882|NCT02194998|Experimental|Cohort C|Participants in Cohort C will receive the following medications for 24 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for participants with HCV genotype 1a only; participants with HCV genotype 1b will not receive RBV).
3054883|NCT02194998|Experimental|Cohort D|Participants in Cohort D will receive the following medications for 12 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for participants with HCV genotype 1a only; participants with HCV genotype 1b will not receive RBV).
3054884|NCT02194985|Experimental|migalastat HCl 150 mg|Migalastat HCl is a capsule provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken or a punch-out reminder is used on days between migalastat HCl.
3054885|NCT02194972|Experimental|soluble dietary fiber|pectin, a kind of soluble dietary fiber
3054886|NCT02194972|No Intervention|Placebo|Placebo
3054887|NCT02194959|Experimental|Peer PN|A scheduling phone call will be made to all patients within 14 days of their initial referral to the study. Following the scheduling of their appointment, each patient will be mailed an informational pamphlet with written instructions for the colonoscopy once they have scheduled the procedure. The first reminder PPN phone call will be made two weeks before a patient's scheduled colonoscopy. The second reminder PPN call will be made three days before the scheduled colonoscopy. For all calls, at least three attempts (at different times of the day and different days of the week) will be made to reach patients. All telephone calls will be audio-recorded to facilitate fidelity monitoring. All colonoscopy appointments will be made within the Division of Gastroenterology at each of the hospital sites. The Project Coordinator will be responsible for confirming completion (and no-shows) for all colonoscopy appointments.
3054888|NCT02194959|Active Comparator|Pro PN|Participants randomized to standard patient navigation received care that they would normally receive if they were not participating in the study with navigation from the GI staff, and three phone calls that involved scheduling and reminding the participant about their colonoscopy appointment.
3054889|NCT02194946|Active Comparator|CKD-related management group|"Patients in basic care group are provided with basic western medicine treatment according to Kidney Disease: Improving Global Outcomes(KDIGO) and The National Kidney Foundation Kidney Disease Outcomes Quality Initiative(KDOQI) guidelines but not prescribed any Chinese herbal medicine.~The basic western medicine treatment mainly includes dietary protein restriction(0.6g/kg·d, for Chinese), Blood pressure control, treating anemia with erythropoietin,treatment of abnormal calcium-phosphate metabolism, and treatment of fluid, electrolyte and acid-base disorders."
3054890|NCT02194946|Experimental|CM therapies group|Participants will receive CM therapies and CKD-related management concurrently. One or several the following CM patterns will be allowed: a. Chinese herbal formula via oral administration; b. Chinese patent medicine via oral administration; c. Chinese herbal formula via colonic administration; d. Chinese patent medicine via colonic administration.
3054891|NCT02194933|Experimental|Brexpiprazole 2 mg|Brexpiprazole 2 mg/day, once daily dose, tablet, orally
3054892|NCT02194933|Experimental|Brexpiprazole 4 mg|Brexpiprazole 4 mg/day, once daily dose, tablet, orally
3054893|NCT02194920||Parathyroid reimplantation|
3054894|NCT02194907||Anterior insula cortex activation|"Experimental - Device: Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior insula cortex.~The anterior insula is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing."
3054895|NCT02194907||Primary auditory cortex activation|"Placebo - Device: Functional Magnetic Resonance Imaging Participants in each group will be trained using functional magnetic resonance imaging to regulation brain activity in primary auditory cortex. The primary auditory cortex is a brain region that is NOT specifically involved in emotion processing. Activation of this region is NOT expected to improve emotion processing; and thus activation of this brain region serves as control/placebo condition in the current design (placebo comparator)."
3054896|NCT02194894|Active Comparator|NAFLD patients|Twenty patients with NAFLD will take 3g of APAP daily for 14 days. Serum liver chemistries and trough acetaminophen (APAP) concentrations will be measured on treatment days 0, 2, 4, 7, 9, 11, 14 and on follow up day 17
3054897|NCT02194894|Active Comparator|Healthy controls|Twenty healthy controls will take 3g of APAP daily for 14 days. Serum liver chemistries and trough acetaminophen (APAP) concentrations will be measured on treatment days 0, 2, 4, 7, 9, 11, 14 and on follow up day 17
3054898|NCT02194881||Ivacaftor 1|patients with CF who are homozygous or heterozygous for the G551D mutation and treated with Ivacaftor
3054899|NCT02194868||donors of hematopoietic stem|Adult and minor donors of hematopoietic stem
3054900|NCT02194868||patients requiring allogeneic hema|Adult and minor patients (recipients) requiring allogeneic hema
3054901|NCT02194855|Experimental|laparoscopic operation on rocuronium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
3054902|NCT02194855|Experimental|laparoscopic operation on cisatracurium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
3054903|NCT02194855|Experimental|conventional open surgery on rocuronium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
3054904|NCT02194855|Experimental|conventional open surgery on cisatracurium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
3054905|NCT02194842|Active Comparator|Enzalutamide|Enzalutamide will be given at a dose of 160 mg daily
3054906|NCT02194842|Experimental|Enzalutamide and Ra223|Ra223 will be administered 50kBq/kg standard dose monthly for 6 months and given in combination with enzalutamide at a dose of 160 mg daily.
3054907|NCT02194829|Experimental|Arm A (phase I, dose level 1)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Patients also receive WEE1 inhibitor MK-1775 PO daily on days 1, 2, 8, 9, 15, and 16.
3054908|NCT02194829|Experimental|Arm B (phase I, dose level 2)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, and WEE1 inhibitor MK-1775 as in Arm A.
3054909|NCT02194829|Active Comparator|Arm C (phase II, placebo)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride as in Arm A. Patients also receive placebo PO daily on days 1, 2, 8, 9, 15, and 16.
3054910|NCT02194829|Experimental|Arm D (phase II, WEE1 inhibitor MK-1775)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, and WEE1 inhibitor MK-1775 (recommended phase II dose) as in Arm A.
3054911|NCT02194816||Parkinson's Disease Patients|Any individuals who has a diagnosis of Parkinson's disease (PD), parkinsonism, or a parkinson's plus syndrome will be allowed to participate.
3054912|NCT02194803||Cohort with routine OCT monitoring|
3054913|NCT02194803||Cohort without routine OCT monitoring|
3054914|NCT02194790|Experimental|community-based Integrated CKD care|Standard CKD care + multidisciplinary team and home visit by community care team
3054915|NCT02194790|No Intervention|Conventional CKD care|standard CKD care
3054916|NCT02194777|Experimental|BIBN 4096 BS - in single rising doses|
3054917|NCT02194777|Placebo Comparator|Placebo|
3054918|NCT02194764|Experimental|Expirimental Formulation|Participants will be administered a single encapsulated dose of the test formulation (Model Naltrexone 50mg containing 2-butanol). Breath samples will be taken over 90 minutes (-5, 0, 5, 10, 20, 40, 60, 90). Subjects will then be randomly crossed over to the four interventions (Formulation 1, Formulation 2, Formulation 3, Formulation-free positive control) three formulations from the first part of the study and a control administration (a capsule-in-capsule design).
3054919|NCT02194751|Experimental|Oncoquest-L vaccine|Patients will receive a total of 5 single injections of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration.
3054920|NCT02194738|Experimental|A081105 Arm A (blinded erlotinib hydrochloride)|Blinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
3054921|NCT02194738|Placebo Comparator|A081105 Arm B (placebo)|Patients receive placebo PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
3054922|NCT02194738|Experimental|A081105 Arm C (unblinded erlotinib hydrochloride)|Unblinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3054923|NCT02194738|Active Comparator|A081105 Arm D (observation)|Patients (including patients previously randomized to placebo) undergo observation at least every 6 months for 2 years.
3054924|NCT02194738|Experimental|E4512 Arm A (crizotinib)|Patients receive crizotinib PO BID on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3054926|NCT02194738|Experimental|EA5142 Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
3054927|NCT02194738|Active Comparator|EA5142 Arm II (observation)|Patients are followed serially with imaging for 1 year.
3054928|NCT02194712||travellers|travellers with recent (<12 weeks) high risk water contact are included in the study and asked to provide samples for CAA testing
3054929|NCT02194699|Experimental|Tralokinumab|Tralokinumab subcutaneous injection
3054930|NCT02194699|Placebo Comparator|Placebo|Placebo subcutaneous injection
3054931|NCT02194686|Active Comparator|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
3054932|NCT02194686|Placebo Comparator|Dummy Placebo|One tablet twice per day for 12 weeks
3054933|NCT02194673|Experimental|Trans free palm margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
3054934|NCT02194673|Experimental|Interesterified palm based margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
3054935|NCT02194673|Experimental|IE soybean oil-based margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
3054936|NCT02194660||M- main hospital|Patient enrolled in the main hospital
3054937|NCT02194660||B- Beihu branch|Patients enrolled in the Beihu branch
3054938|NCT02194634|Experimental|Conbercept treatment group|Conbercept injection and sham laser treatment at day 0 for 1st time, the investigators will decide whether the subjects need to get repeated treatment according to monthly assessment.
3054939|NCT02194634|Active Comparator|Laser treatment group|Laser treatment and sham injection at day 0 for 1st time, the investigators will decide whether the repeated laser treatment is needed according to monthly results during the visit after 3 months.
3054940|NCT02194621|Experimental|Total Flavor Option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM (oral malodor) complex 1 ingredient - Total Flavor Option 1
3054941|NCT02194621|Experimental|Total Flavor Option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM (oral malodor) complex 2 ingredient. Total Flavor Option 2
3054942|NCT02194621|Placebo Comparator|Crest Toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste (currently marketed)
3054943|NCT02194608|Experimental|Telemedicine system|Participants will self-test blood glucose level, weight, and blood pressure and results will be uploaded and transmitted directly via a hometelehealth system to a central location (HUB). Blood draws will be administered at baseline and follow-up visits.
3054944|NCT02194608|No Intervention|Usual care|Participants will self-record their blood glucose levels, blood pressure and weight in a diary. Blood draws will be administered at baseline and follow-up visits.
3054945|NCT02194595|Experimental|Basal insulin and exenatide|Participants in this arm will undergo an 8-week course of treatment with exenatide and insulin glargine. Exenatide will be initiated at 5ug subcutaneous (sc) bid (before breakfast and before dinner) for the first 4 weeks, followed by 10ug bid for the next 4 weeks. Glargine sc injection at bedtime will be titrated to fasting glucose.
3054946|NCT02194595|Active Comparator|Basal insulin only|Participants in this arm will undergo an 8-week course of treatment with glargine sc injection at bedtime, titrated to target fasting glucose.
3054947|NCT02194595|Active Comparator|Basal Insulin and bolus insulin|Participants in this arm will undergo an 8-week course of multiple daily insulin injection therapy, consisting of titrated basal insulin glargine at bedtime and insulin lispro before each meal.
3054948|NCT02194569|Experimental|High citrate group|Blood flow according to weight.Target citrate concentration is 4,5 mmol/L blood flow delivered as prismocitrate 18/0 pre-filter. After correction for filtration fraction, the required further amount of substitution fluid is given post filter to achieve a hemofiltration rate of 30 ml/kg/hr. Blood citrate concentrations are tailored to achieve an iCa of 0.8-1.1 mg/dL.
3054949|NCT02194569|Experimental|Low citrate group|Blood flow according to weight. Target citrate concentration is 2.5 mmol/L blood flow delivered as prismocitrate 18/0 pre-filter. After correction for filtration fraction, the required further amount of substitution fluid is given post filter to achieve a hemofiltration rate of 30 ml/kg/hr. Blood citrate concentrations are tailored to achieve an iCa of 1.3-1.6 mg/dL.
3054950|NCT02194556|Experimental|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
3054951|NCT02194556|Active Comparator|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive icotinib (125 mg three times per day) as maintenance treatment until disease progression or intolerable toxicity.
3054952|NCT02194543||HD 3D|The patients received surgeries with HD 3D on their left eyes.
3054953|NCT02194543||Conventional|The patients received surgeries with conventional method on the other eye.
3054954|NCT02194530||Peanut allergic individuals|20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
3054955|NCT02194530||Allergic/atopic individuals (not peanut)|Subjects should not be allergic to peanut. 20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
3054956|NCT02194530||Non-allergic individuals|20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
3054957|NCT02194517|No Intervention|control (B)|Patients performing CHO and FP exchanges calculation with standard method.
3054958|NCT02194517|Experimental|ELKa (A)|Patients counting CHO and FP exchanges with ELKa toolset.
3054959|NCT02194504|No Intervention|No dietary advice|No dietary intervention
3054960|NCT02194504|Experimental|Dietary advice, Targeted|12-wk dietary advice
3054961|NCT02194504|Experimental|Dietary advice, Western|12-wk dietary advice
3054962|NCT02194491|Experimental|[11C]AS2471907 administration (Part 1)|Up to 4 single dose IV administrations (≤ 10 mL infused over approximately 1 minute) are planned, totaling less than 100 μg.
3054963|NCT02194491|Experimental|ASP3662 administration (Part 2)|The dose levels used in part 2 will depend on the ongoing analysis of EO (enzyme occupancy) from previously dosed subjects.
3054964|NCT02194478|Other|8 Week Meditation|Allina Health employees undergoing 8 week meditation intervention
3054965|NCT02194465|Experimental|6 milligrams (mg) LY2623091|6 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
3054966|NCT02194465|Experimental|13 mg LY2623091|13 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
3054967|NCT02194465|Experimental|24.5 mg LY2623091|24.5 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
3054968|NCT02194465|Experimental|13 mg LY2623091 + 20 mg tadalafil|Exploratory Arm: 13 mg LY2623091 and 20 mg of tadalafil with placebo for blinding administered orally once daily for 4 weeks.
3054969|NCT02194465|Experimental|20 mg tadalafil|Exploratory Arm: 20 mg tadalafil with placebo for blinding administered orally once daily for 4 weeks.
3054970|NCT02194465|Active Comparator|Spironolactone|25 mg titrated to 50 mg as tolerated of spironolactone administered orally once daily for 4 weeks.
3054971|NCT02194465|Placebo Comparator|Placebo|Placebo administered orally once daily for 4 weeks.
3054972|NCT02194452|Experimental|Diagnostic (gallium Ga 68-edotreotide PET/CT)|"Patients undergo gallium Ga 68-edotreotide PET/CT at baseline and 1-30 days after surgery.~Interventions: gallium Ga 68-edotreotide, positron emission tomography, computed tomography, laboratory biomarker analysis"
3054973|NCT02194439||hematopoietic stem cell transplant|procedure
3054974|NCT02194426|Experimental|MP0250|"see section intervention description below"
3054975|NCT02194413|Experimental|Arm 1 (healing touch)|"Patients receive daily HT sessions comprising pain drain, chakra connection, magnetic clearing, and mind clearing over 30 minutes from day 1 until 2 days before discharge from the hospital (therapeutic touch).~Interventions: therapeutic touch, quality-of-life assessment, and questionnaire administration"
3054976|NCT02194413|Active Comparator|Arm II (usual care)|"Patients receive routine nursing care from doctors and nurses from day 1 until 2 days before discharge from the hospital.~Interventions: quality-of-life assessment, and questionnaire administration"
3054977|NCT02194400|Placebo Comparator|Placebo|Saline infusion
3054978|NCT02194400|Experimental|RSLV-132|0.3 - 10 mg/kg experimental drug
3054979|NCT02194387|Experimental|Phone Coach + Texts + Resistance Training + Daily Self-Monitor|"Telephone Coaching: Participant has 30-45 minute telephone calls 1 time each week with a telephone coach trained in motivational interviewing.~Text Messaging: Participant receives 7-12 messages/week, 1-3 messages/day during the 16 week intervention period.~Resistance Training: Participant given set of resistance exercise bands, a list of exercises and instructional videos on how to do each exercise.~Daily Self-Monitoring: Participant enters additional information about their diet and activity every day through the FitBit website.~Questionnaire completion at baseline, 8 weeks and 16 weeks."
3054980|NCT02194387|Experimental|Phone Coach + Texts + Resistance Train + Weekly Self-Monitor|"Telephone Coaching: Participant has 30-45 minute telephone calls 1 time each week with a telephone coach trained in motivational interviewing.~Text Messaging: Participant receives 7-12 messages/week, 1-3 messages/day during the 16 week intervention period.~Resistance Training: Participant given set of resistance exercise bands, a list of exercises and instructional videos on how to do each exercise.~4 - 7 Days a Week Self-Monitoring: Participant enters additional information about their diet and activity 4-7 days per week through the FitBit website.~Questionnaire completion at baseline, 8 weeks and 16 weeks."
3054981|NCT02194387|Experimental|Phone Coach + Texts + Daily Self-Monitor|"Telephone Coaching: Participant has 30-45 minute telephone calls 1 time each week with a telephone coach trained in motivational interviewing.~Text Messaging: Participant receives 7-12 messages/week, 1-3 messages/day during the 16 week intervention period.~Daily Self-Monitoring: Participant enters additional information about their diet and activity every day through the FitBit website.~Questionnaire completion at baseline, 8 weeks and 16 weeks."
3054982|NCT02194387|Experimental|Phone Coach + Texts + Weekly Self-Monitor|"Telephone Coaching: Participant has 30-45 minute telephone calls 1 time each week with a telephone coach trained in motivational interviewing.~Text Messaging: Participant receives 7-12 messages/week, 1-3 messages/day during the 16 week intervention period.~4 - 7 Days a Week Self-Monitoring: Participant enters additional information about their diet and activity 4-7 days per week through the FitBit website.~Questionnaire completion at baseline, 8 weeks and 16 weeks."
3054983|NCT02194387|Experimental|Phone Coach + Resistance Training + Daily Self-Monitor|"Telephone Coaching: Participant has 30-45 minute telephone calls 1 time each week with a telephone coach trained in motivational interviewing.~Resistance Training: Participant given set of resistance exercise bands, a list of exercises and instructional videos on how to do each exercise.~Daily Self-Monitoring: Participant enters additional information about their diet and activity every day through the FitBit website.~Questionnaire completion at baseline, 8 weeks and 16 weeks."
3054984|NCT02194387|Experimental|Phone Coach + Resistance Training + Weekly Self-Monitor|"Telephone Coaching: Participant has 30-45 minute telephone calls 1 time each week with a telephone coach trained in motivational interviewing.~Resistance Training: Participant given set of resistance exercise bands, a list of exercises and instructional videos on how to do each exercise.~4 - 7 Days a Week Self-Monitoring: Participant enters additional information about their diet and activity 4-7 days per week through the FitBit website."
3054985|NCT02194387|Experimental|Phone Coach + Daily Self-Monitor|"Telephone Coaching: Participant has 30-45 minute telephone calls 1 time each week with a telephone coach trained in motivational interviewing.~Daily Self-Monitoring: Participant enters additional information about their diet and activity every day through the FitBit website.~Questionnaire completion at baseline, 8 weeks and 16 weeks."
3054986|NCT02194387|Experimental|Phone Coach + Weekly Self-Monitor|"Telephone Coaching: Participant has 30-45 minute telephone calls 1 time each week with a telephone coach trained in motivational interviewing.~4 - 7 Days a Week Self-Monitoring: Participant enters additional information about their diet and activity 4-7 days per week through the FitBit website.~Questionnaire completion at baseline, 8 weeks and 16 weeks."
3055012|NCT02194270|Active Comparator|Ambroxol hydrochloride - syrup - high dose|
3055013|NCT02194257|Experimental|[14C]-cyclohexane ambroxol oral solution + ambroxol lozenge|
3055014|NCT02194257|Experimental|[14C]-benzyl ambroxol oral solution + ambroxol lozenge|
3055015|NCT02194244|Experimental|Granules Fasted|
3055016|NCT02194244|Experimental|Granules Fed|
3054987|NCT02194387|Experimental|Email Coach + Texts + Resistance Training + Daily Self-Monitor|"Email Coaching: Participant called during first week to discuss the interventions. This call will last about 10-15 minutes. Participant then receives 1 email each week in Weeks 2-16 in which the coach provides feedback about participant's goals and asks 1-2 questions similar to what telephone coach would ask.~Text Messaging: Participant receives 8-12 messages/week, 1-3 messages/day during the 16 week intervention period.~Resistance Training: Participant given set of resistance exercise bands, a list of exercises and instructional videos on how to do each exercise.~Daily Self-Monitoring: Participant enters additional information about their diet and activity every day through the FitBit website.~Questionnaire completion at baseline, 8 weeks and 16 weeks."
3054988|NCT02194387|Experimental|Email Coach + Texts + Social Network + Weekly Self-Monitor|"Email Coaching: Participant called during first week to discuss the interventions. This call will last about 10-15 minutes. Participant then receives 1 email each week in Weeks 1-16 in which the coach provides feedback about participant's goals and asks 1-2 questions similar to what telephone coach would ask.~Text Messaging: Participant receives 8-12 messages/week, 1-3 messages/day during the 16 week intervention period.~Social Networking: Participant invited to use an online forum to discuss their fitness goals with other participants in study who are receiving social networking.~4 - 7 Days a Week Self-Monitoring: Participant enters additional information about their diet and activity 4-7 days per week through the FitBit website.~Questionnaire completion at baseline, 8 weeks and 16 weeks."
3054989|NCT02194387|Experimental|Email Coach + Texts + Daily Self-Monitor|"Email Coaching: Participant called during first week to discuss the interventions. This call will last about 10-15 minutes. Participant then receives 1 email each week in Weeks 1-16 in which the coach provides feedback about participant's goals and asks 1-2 questions similar to what telephone coach would ask.~Text Messaging: Participant receives 8-12 messages/week, 1-3 messages/day during the 16 week intervention period.~Daily Self-Monitoring: Participant enters additional information about their diet and activity every day through the FitBit website.~Questionnaire completion at baseline, 8 weeks and 16 weeks."
3054990|NCT02194387|Experimental|Email Coach + Texts + Weekly Self-Monitor|"Email Coaching: Participant called during first week to discuss the interventions. This call will last about 10-15 minutes. Participant then receives 1 email each week in Weeks 2-16 in which the coach provides feedback about participant's goals and asks 1-2 questions similar to what telephone coach would ask.~Text Messaging: Participant receives 8-12 messages/week, 1-3 messages/day during the 16 week intervention period.~4 - 7 Days a Week Self-Monitoring: Participant enters additional information about their diet and activity 4-7 days per week through the FitBit website.~Questionnaire completion at baseline, 8 weeks and 16 weeks."
3054991|NCT02194387|Experimental|Email Coach + Resistance Training + Daily Self-Monitor|"Email Coaching: Participant called during first week to discuss the interventions. This call will last about 10-15 minutes. Participant then receives 1 email each week in Weeks 1-16 in which the coach provides feedback about participant's goals and asks 1-2 questions similar to what telephone coach would ask.~Resistance Training: Participant given set of resistance exercise bands, a list of exercises and instructional videos on how to do each exercise.~Daily Self-Monitoring: Participant enters additional information about their diet and activity every day through the FitBit website.~Questionnaire completion at baseline, 8 weeks and 16 weeks."
3054992|NCT02194387|Experimental|Email Coach + Resistance Training + Weekly Self-Monitor|"Email Coaching: Participant called during first week to discuss the interventions. This call will last about 10-15 minutes. Participant then receives 1 email each week in Weeks 1-16 in which the coach provides feedback about participant's goals and asks 1-2 questions similar to what telephone coach would ask.~Resistance Training: Participant given set of resistance exercise bands, a list of exercises and instructional videos on how to do each exercise.~4 - 7 Days a Week Self-Monitoring: Participant enters additional information about their diet and activity 4-7 days per week through the FitBit website.~Questionnaire completion at baseline, 8 weeks and 16 weeks."
3054993|NCT02194387|Experimental|Email Coach + Daily Self-Monitor|"Email Coaching: Participant called during first week to discuss the interventions. This call will last about 10-15 minutes. Participant then receives 1 email each week in Weeks 1-16 in which the coach provides feedback about participant's goals and asks 1-2 questions similar to what telephone coach would ask.~Daily Self-Monitoring: Participant enters additional information about their diet and activity every day through the FitBit website.~Questionnaire completion at baseline, 8 weeks and 16 weeks."
3054994|NCT02194387|Experimental|Email Coach + Weekly Self-Monitor|"Email Coaching: Participant called during first week to discuss the interventions. This call will last about 10-15 minutes. Participant then receives 1 email each week in Weeks 1-16 in which the coach provides feedback about participant's goals and asks 1-2 questions similar to what telephone coach would ask.~4 - 7 Days a Week Self-Monitoring: Participant enters additional information about their diet and activity 4-7 days per week through the FitBit website.~Questionnaire completion at baseline, 8 weeks and 16 weeks."
3054995|NCT02194374|Experimental|ROR1R-CAR-T Cells|"Peripheral blood mononuclear cells (PBMC) collected via venipuncture and/or steady state leukapheresis at discretion of PI. Participants receive a cycle of lympho-depleting chemotherapy as chosen by treating physician 4 to 5 days before ROR1R-CAR-T cell infusion : Fludarabine, Cyclophosphamide, and Rituximab (FCR), Bendamustine and Rituximab (BR), or Fludarabine, Bendamustine, and Rituximab (FBR).~Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.~Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort."
3054996|NCT02194361|Experimental|Anthocyan capsules|
3054997|NCT02194361|Placebo Comparator|Placebo|
3054998|NCT02194348|Experimental|BIBN 4096 BS - in single rising doses|
3054999|NCT02194348|Placebo Comparator|Placebo|
3055000|NCT02194335|Experimental|BIBN 4096 BS - in single rising doses|
3055001|NCT02194335|Placebo Comparator|Placebo|
3055002|NCT02194322|Experimental|BIBN 4096 BS - in single rising doses|
3055003|NCT02194322|Placebo Comparator|Placebo|
3055004|NCT02194309|Experimental|Telmisartan low + amlodipine|
3055005|NCT02194309|Experimental|Telmisartan high + amlodipine|
3055006|NCT02194296|Experimental|Ambroxol hydrochloride - lozenge|
3055007|NCT02194296|Active Comparator|Ambroxol hydrochloride - syrup|Mucosolvan®
3055008|NCT02194283|Experimental|Ambroxol - in single rising doses|
3055009|NCT02194283|Placebo Comparator|Placebo|
3055010|NCT02194270|Experimental|Ambroxol hydrochloride - soft pastille|
3055019|NCT02194231|Experimental|Trabectedin|Patients will receive trabectedin treatment
3055020|NCT02194218|Experimental|Nevirapine XR 4 doses|
3055021|NCT02194218|Active Comparator|Nevirapine XR 2 doses|
3055022|NCT02194205|Experimental|COMBIVENT HFA|
3055023|NCT02194205|Placebo Comparator|Placebo HFA|
3055024|NCT02194205|Active Comparator|COMBIVENT (CFC)|
3055025|NCT02194205|Placebo Comparator|Placebo CFC|
3055026|NCT02194192|Experimental|Group E|Ephedrine 10 mg in Normal Saline 10 ml
3055027|NCT02194192|Active Comparator|Group O|Ondansetron 8 mg in Normal saline 10 ml
3055028|NCT02194192|Placebo Comparator|Group P|Normal saline 10 ml
3055029|NCT02194179|Experimental|NVP XR 400 mg (KCR 25%) fasted|
3055030|NCT02194179|Experimental|NVP XR 400 mg (KCR 25%) fed|
3055031|NCT02194179|Experimental|NVP XR 400 mg (KCR 20%) fasted|
3055032|NCT02194179|Experimental|NVP XR 400 mg (KCR 20%) fed|
3055033|NCT02194179|Experimental|NVP XR 300 mg (KCR 25%) fasted|
3055034|NCT02194179|Experimental|NVP XR 300 mg (KCR 25%) fed|
3055035|NCT02194179|Experimental|NVP XR 300 mg (KCR 20%) fasted|
3055036|NCT02194179|Experimental|NVP XR 300 mg (KCR 20%) fed|
3055037|NCT02194179|Active Comparator|NVP IR 200 mg (Viramune®)|
3055038|NCT02194166|Experimental|Pre-Randomization (Trastuzumab IV)|Trastuzumab IV will be given during the first 4 cycles for all participants before randomization for SC administration. A dose of 6 milligrams per kilogram (mg/kg) will be given every 3 weeks. All the participants will require a loading dose on Day 1 of Cycle 1, so they will receive 8 mg/kg followed by 6 mg/kg, 3 weeks later and then 3-weekly. Concurrent administration during the first 4 cycles of trastuzumab IV with paclitaxel/docetaxel will have to be performed in accordance with local hospital practice.
3055039|NCT02194166|Experimental|Group A: Trastuzumab SC (First Vial Formulation, then SID)|Participants will receive 7 cycles of SC trastuzumab 600 mg with assisted administration using a conventional syringe and needle (SC vial formulation) followed by 7 cycles of SC trastuzumab 600 mg SID administration after cross-over.
3055040|NCT02194166|Experimental|Group B: Trastuzumab SC (First SID, then Vial Formulation)|Participants will start with 7 cycles of SC trastuzumab 600 mg administration via SID and after cross-over will receive 7 injections of trastuzumab 600 mg with assisted administration using a conventional syringe and needle (SC vial formulation).
3055041|NCT02194153||Metalyse|Metalyse weight-adjusted
3055042|NCT02194140|Other|oral contrast|oral iodinated contrast material
3055043|NCT02194127|Experimental|Anthocyan capsules|capsules containing 160 mg standardised bilberry extract (25% anthocyanidines)
3055044|NCT02194127|Placebo Comparator|Placebo|
3055045|NCT02194114|Experimental|Dietary Protein Intake|One treatment Arm; Protein Diet: All patients will be fed the following five diets, in random order, each for 17-19 days: 0.6 g protein/kg/day, 0.8 g protein/kg/day, 1.0 g protein/kg/day, 1.15 g protein/kg/day, 1.3 g protein/kg/day.
3055046|NCT02194101||Supernormal oxygen delivery goal therapy|Patients will be aged over 70 yr and weight over 35 kg, and undergoing proximal femur fracture (PFF) surgery under peripheral nerve block and laryngeal mask airway anesthesia.
3055047|NCT02194088|Experimental|Pain medication: diclofenac and atropine|Diclofenac and Atropine combination drug Provided PO. This is a novel combination. Diclofenac 100mg + Atropine 1.2 mg in one single dose
3055048|NCT02194088|Placebo Comparator|placebo|Placebo capsules will be delivered in same number as the medication
3055049|NCT02194075|Active Comparator|Fluvoxamine+Methylphenidate Hydrochloride|"Fluvoxamine: tablet, 100mg-300mg/d, were treated with a course of 8 weeks.~Methylphenidate Hydrochloride: tablet, 18mg-36mg/d, were treated with a course of 8 weeks."
3055050|NCT02194075|Placebo Comparator|Fluvoxamine+sugar pill|"Fluvoxamine: tablet, 100mg-300mg/d, were treated with a course of 8 weeks.~sugar pill: tablet, 1-2 tablets/d, were treated with a course of 8 weeks."
3055051|NCT02194062|Active Comparator|fluticasone nasal spray|Group one will be prescribed fluticasone nasal spray ( to use 2-50 mcg sprays to each nostril two times per day)
3055052|NCT02194062|Active Comparator|budesonide respule in head upright|Group two will be prescribed budesonide respules (0.5 mg/2mL) to instill into each nostril in the upright position two times per day
3055053|NCT02194062|Active Comparator|budesonide head forward|Group three will be prescribed budesonide respules (0.5 mg/2mL) to use instill into each nostril in the head forward position two times per day with their head angled downwards by having their head lean forward off the side of a bed.
3055054|NCT02194049|Experimental|BKM 120, cisplatin, etoposide|Patients receive PI3K Inhibitor BKM120 PO QD on days 1-21, cisplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3055055|NCT02194036|Experimental|Learning oriented physiotherapy|Learning oriented physiotherapy is a treatment approach based on knowledge from neuroscience and particularly aimed to curb physical symptoms and ailments, but also to regain a sense of better physical balance and mental control. Therapy sessions are normally given every 2 weeks with individual homework lessons between. The therapy will last between 6 to 12 months depending on learning process and individual needs.
3055056|NCT02194036|Active Comparator|Widely Recognized Psychiatric Treatment|Standard Outpatient Treatment within the Psychiatric clinic
3055057|NCT02194023|Placebo Comparator|Placebo (PCB)|Placebo mouthrinse: physiological saline solution (0.9% w/w solution of NaCl in deionized water)
3055058|NCT02194023|Experimental|0.12%NF|0.12% Chlorhexidine digluconate new formulation
3055059|NCT02194023|Experimental|0.03%NF|0.03% Chlorhexidine digluconate new formulation
3055060|NCT02194023|Active Comparator|PAT (Perio-Aid Treatment)|Commercialized 0.12% Clorhexidine digluconate (Perio-Aid Treatment, Dentaid, Spain)
3055061|NCT02194010||Participants evaluated at INC sites|Participants being evaluated at the INC sites will participate in both the DSI and HMSN-R-ODS by completing these PROs during their visit.
3055062|NCT02194010||INC Contact Registry|INC Contact Registry completes the HMSN-R-ODS on web http://rarediseasesnetwork.epi.usf.edu/INC/
3055063|NCT02193997|Experimental|Fiber 1|Fiber bar containing inulin as fiber soucre taken once daily for 4 weeks
3055064|NCT02193997|Experimental|Fiber 2|Fiber bar containing soluble corn as fiber soucre taken once daily for 4 weeks
3083701|NCT02001857|Experimental|TachoSil|TachoSil
3055065|NCT02193997|Placebo Comparator|Placebo|Bar with low fiber content (placebo) once daily for 4 weeks
3055066|NCT02193984|Experimental|Peer support|Study participants are assigned a volunteer peer supporter who has been trained to offer support on diabetes management.
3055067|NCT02193984|No Intervention|Control|No intervention
3055068|NCT02193971|Active Comparator|BS-DES with prasugrel 10mg daily|BS-DES with prasugrel 10mg daily
3055069|NCT02193971|Active Comparator|BS-DES with prasugrel 5mg daily|BS-DES with prasugrel 5mg daily
3055070|NCT02193971|Experimental|BD-DES with prasugrel 10mg daily|BD-DES with prasugrel 10mg daily
3055071|NCT02193971|Experimental|BD-DES with prasugrel 5mg daily|BD-DES with prasugrel 5mg daily
3055072|NCT02193958|Experimental|Phase 1: Lowest dose of FF-10501-01|FF-10501-01 tablets BID every 14 days of a 28 day cycle.
3055073|NCT02193958|Experimental|Phase 1: 2x lowest dose of FF-10501-01|2x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
3055074|NCT02193958|Experimental|Phase 1: 4x lowest dose of FF-10501-01|4x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
3055075|NCT02193958|Experimental|Phase 1: 6x lowest dose of FF-10501-01|6x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
3055076|NCT02193958|Experimental|Phase 1: 8x lowest dose of FF-10101-01|8x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
3055077|NCT02193958|Experimental|Ph 2a: FF-10501-01 at 8x in MDS/CMML|FF-10501-01 tablets BID every 21 days of a 28 day cycle.
3055078|NCT02193958|Experimental|Ph1:8x lowest dose FF10101-01 for 21 day|FF-10501-01 tablets BID every 21 days of a 28 day cycle.
3055079|NCT02193958|Experimental|Ph1: 8x lowest dose FF-10101-01 28 day|FF-10501-01 tablets BID every 28 days of a 28 day cycle.
3055080|NCT02193958|Experimental|Ph1: 10X lowest dose FF-10501-01 14 day|10x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
3055081|NCT02193932|Experimental|EEG Triggered fMRI using Micro Maglink|EEG Triggered fMRI to be performed using the Micro Maglink
3055082|NCT02193919||cohort 1 placebo + UVB|cohort 1 placebo + UVB
3055083|NCT02193919||South Beach Diet + UVB|South Beach DIet + UVB
3055084|NCT02193919||Ornish Diet + UVB|Ornish Diet + UVB
3055085|NCT02193906|Experimental|Intervention group|Cognitive training.
3055086|NCT02193906|Placebo Comparator|Placebo group|Placebo task.
3055087|NCT02193893|Active Comparator|Stem/progenitor cells transplantation.|Intervention: Biological: Cell-based therapeutics Autologous bone marrow-derived stem/progenitor cells will be transplanted intrathecally (via a standard lumbar puncture) into early vs. progressive ALS subjects.
3055088|NCT02193893|Sham Comparator|Standard treatment of ALS|Symptomatic treatment of ALS without biologic cell-based treatment
3055089|NCT02193880|Other|Alpha-beta depleted T-cell infusion|Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
3055090|NCT02193867|Experimental|Cohort 1|Weekly IV infusions of sebelipase alfa
3055091|NCT02193854|Experimental|Mobile phone|"General practitioners (GPs) received TD consultation through Sana system.~Mobile phones with Sana system installed were provided to 10 rural GPs from three different districts of Mongolia."
3055092|NCT02193841|Active Comparator|C & P|Curettage with puncture (C & P) will be performed alone
3055093|NCT02193841|Active Comparator|C & P with Vitoss|A predetermined amount of Vitoss morsels will be injected following the curettage and puncture (C & P)
3055094|NCT02193828|Experimental|AA4500 0.25 mg|Collagenase clostridium histolyticum, single 0.25 mg injection
3055095|NCT02193828|Experimental|AA4500 0.40 mg|Collagenase clostridium histolyticum, single 0.40 mg injection
3055096|NCT02193828|Experimental|AA4500 0.60 mg|Collagenase clostridium histolyticum, single 0.60 mg injection
3055097|NCT02193828|Placebo Comparator|Placebo|Placebo, single 0.25 mg, 0.40 mg, or 0.60 mg injection
3055098|NCT02193815|Experimental|One Arm|Study treatments 1-6 Study drug, vehicle, Tofacitinib, vehicle, Daivonex solution and ointment
3055099|NCT02193802|Other|Endoscopy|"CHANCE is a single arm study: all patients will undergo one capsule endoscopy ( PillCam® SB3 capsules) of the small intestine AND one ileocolonoscopy.~The patients will be then treated according to the preference of their physician and a second capsule endoscopy AND an ileoconoscopy will be performed 16 weeks later.~Both exams will be evaluated locally by two independent investigators and all the recorded films will be evaluated and compared by four central readers."
3055100|NCT02193789|Experimental|Anastomosis site stricture|anastomosis site stricture after subtotal gastrectomy with Billroth-I anastomosis
3055101|NCT02193776|Experimental|DS-TB: J(loading dose/t.i.w.)PaZ|Subjects with DS-TB. J(loading dose/t.i.w.)PaZ: Bedaquiline 400mg once daily Days 1-14, 200mg three times per week Days 15-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
3055102|NCT02193776|Experimental|DS-TB: J(200mg)PaZ|Subjects with DS-TB. J(200mg)PaZ: Bedaquiline 200mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
3055103|NCT02193776|Experimental|MDR-TB: J(200mg)MPaZ|Subjects with MDR-TB. J(200mg)MPaZ: Bedaquiline 200mg once daily Days 1-56; plus moxifloxacin 400mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
3055104|NCT02193776|Active Comparator|DS-TB: HRZE|Subjects with DS-TB. HRZE tablets (Isoniazid 75mg plus rifampicin 150mg plus pyrazinamide 400mg plus ethambutol 275mg combination tablets) dosed once daily Days 1-56 per the Subject's weight as follows: 30-37kg: 2 tablets; 38-54kg: 3 tablets; 55-70kg: 4 tablets; 71kg and over: 5 tablets.
3055105|NCT02193763|Experimental|90 days and under--Interventional|Neonates aged 90 days and under randomized to ultrasound assisted lumbar puncture
3055106|NCT02193763|No Intervention|90 days and under--control|Neonates aged 90 days and under randomized to lumbar puncture using the anatomical landmark approach
3055107|NCT02193763|Experimental|Over 90 days--Interventional|Neonates aged over 90 days randomized to ultrasound assisted lumbar puncture
3055108|NCT02193763|No Intervention|Over 90 days--Control|Neonates aged over 90 days randomized to lumbar puncture using the anatomical landmark approach
3055109|NCT02193750|Placebo Comparator|Placebo|1 placebo muesli bars and 1 serving placebo muesli per day (0.55 g total fructans/GOS)
3055110|NCT02193750|Experimental|Moderate Oligosaccharide Group|1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)
3055111|NCT02193750|Experimental|High Oligosaccharide Group|1 intervention muesli bar and 1 serving intervention muesli per day (5.43 total fructans/GOS)
3055112|NCT02193737|Experimental|Early oral fluid recovery.|
3055113|NCT02193737|Active Comparator|Delayed oral fluid recovery.|
3055114|NCT02193724||Retinoblastoma|Participants identified with heritable retinoblastoma will undergo a skin biopsy or blood draw to collect cells for processing and analysis.
3055115|NCT02193711|Experimental|Topical Arthritis Cream|1-1.5 ml applied to the skin over the knee in the morning and at bedtime over the entire study period, for a total of 2-3 ml/day.
3055116|NCT02193711|Placebo Comparator|Placebo|1-1.5 ml applied to the skin over the knee in the morning and at bedtime over the entire study period, for a total of 2-3 ml/day.
3055117|NCT02193698|Experimental|Lenalidomide+Dexamethasone|Cycle1 : Lenalidomide 15mg/day (day 1-21) Cycle2-6 : Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
3055118|NCT02193685||Subjects with HAEC|There is no intervention involvement. The clinical data and biologic specimens collected during the study will serve as an invaluable resource for a wide spectrum of clinical and translational ancillary studies directly related to the aims and goals of the study.
3055119|NCT02193685||Subjects without HAEC|A subgroup of children who have Hirschsprung Disease may or may not develop enterocolitis; therefore we will be identifying the bio-markers in children with or without associated enterocolitis.
3055120|NCT02193672|Experimental|PET/CT + [18F]Fluciclatide|"At baseline: Participants have PET/CT imaging within 7 days prior to initiation of chemotherapy treatment. Participants monitored at 24 hours post scan via telephone.~On treatment: Participants have PET/CT imaging at end of the first cycle and prior to the initiation of the second cycle of chemotherapy. Participants assessed at 24 hours post scan via telephone call.~Baseline and on treatment PET/CT imaging performed with agent [18F] Fluciclatide."
3055121|NCT02193659|Experimental|Cereals|For 30 days, participants in group 1 took cereals with omega-3 in the breakfast with diet, group 2 took cereals and diet, and group 3 only received the diet. The energy intake of the designed diet was similar into the three groups (ranging 1900-2000 Kcal per day).
3055122|NCT02193633|Experimental|AZD2014 3 on/4 off & weekly paclitaxel|3 days on, 4 days off AZD2014 BD administered orally Days 1-3 each week in combination with paclitaxel administered via IV infusion on Day 1 each week, in 7-week cycles (6 weeks treatment followed by 1 week rest).
3055123|NCT02193633|Experimental|AZD2014 2 on/5 off & weekly paclitaxel|AZD2014 BD administered orally Days 1-2 each week in combination with paclitaxel administered via IV infusion on Day 1 each week, in 7-week cycles (6 weeks treatment followed by 1 week rest).
3055124|NCT02193620|Placebo Comparator|Placebo group|Placebo soft capsules
3055125|NCT02193620|Experimental|Study group|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap
3055126|NCT02193607|Active Comparator|No TVT-O|Improved reconstruction pelvic surgery
3055127|NCT02193607|Experimental|Combined surgery group|Improved reconstruction pelvic surgery TVT-O procedure
3055128|NCT02193594|Experimental|CCRT group|The patient in CCRT group will receive the preoperative concurrent chemoradiotherapy for 5 weeks and sequential radical D2 total gastrectomy and postoperative adjuvant chemotherapy of 6 cycles.
3055129|NCT02193594|Active Comparator|CT group|The patient in CT group will receive radical D2 total gastrectomy and postoperative adjuvant chemotherapy of 8 cycles.
3055130|NCT02193581||Suspicious skin lesions.|Patients with a suspicious skin lesion referred for a biopsy are tested using MDS
3055131|NCT02193568|Experimental|Arm I (light sedation)|Patients receive light sedation (awake) and undergo craniotomy.
3055132|NCT02193568|Active Comparator|Arm II (intubated general anesthesia)|Patients receive intubated general anesthesia and undergo craniotomy.
3055133|NCT02193555|Other|Non-presbyopic group|"Non-presbyopic group: age ranging from 7 to 39 years~At each scheduled lens fitting visit, subjects will be allocated one pair of CLs to correct their refractive error. One pair of control (Acuvue 1- Day Moist, etafilcon A) or prototype (Iteration X, etafilcon A) CLs will be allocated for each lens fitting/assessment visit. Lenses will be worn for approximately 1 hour per visit.~For each fitting visit, lenses will be fitted bilaterally."
3055134|NCT02193555|Other|Presbyopic group|"Presbyopic group: age 40 and above~At each scheduled lens fitting visit, subjects will be allocated one pair of CLs to correct their refractive error. One pair of control (Acuvue Oasys for Presbyopia, senofilcon A) or prototype (Iteration X, etafilcon A) CLs will be allocated for each lens fitting/assessment visit. Lenses will be worn for approximately 1 hour per visit.~For each fitting visit, lenses will be fitted bilaterally."
3055135|NCT02193542||Pregnant patient|Pregnant woman presenting for vaginal or cesarean delivery
3055136|NCT02193503|Experimental|treatment|MVX-1-loaded capsules and injection of irradiated autologous tumor cells
3055137|NCT02193490|Active Comparator|DNase|DNase 0.1% eye drops four times a day for 8 weeks
3055138|NCT02193490|Placebo Comparator|Vehicle|Drug vehicle eye drops four times a day for 8 weeks
3055139|NCT02193477|No Intervention|Control|Patients were given no TEAS.
3055140|NCT02193477|Experimental|TEAS Treatment|Patients were given 30min of TEAS before general anesthesia induction, 1th day and 2nd day after surgery.
3055141|NCT02193477|Sham Comparator|Sham TEAS|Patients were given 30min of sham TEAS before general anesthesia induction,1th day and 2nd day after surgery.
3055142|NCT02193464||inflammatory bowel disease|
3055143|NCT02193451|Experimental|Urodynamics|Invasive urodynamic cystometry including pressure flow studies, along with usual diagnostics in male LUTS
3055144|NCT02193451|Active Comparator|Usual care|Usual diagnostics in male LUTS; flow rate test, symptom score and bladder diary
3055145|NCT02193438|Active Comparator|Spice 1|Red chili pepper extract
3055146|NCT02193438|Active Comparator|Spice 2|Cinnamon extract
3055147|NCT02193438|Active Comparator|Spice 3|Refreshing agent
3055148|NCT02193438|Placebo Comparator|Placebo|Tomato juice
3055149|NCT02193412|Experimental|patients|"noxious stimulus~change in operating table slope: head-down tilt position~change in operating table slope: head-up tilt position"
3055150|NCT02193399|Experimental|Physiotherapy exercises|Strength exercises for the muscles proximal upper limbs and lower limbs and proprioception exercises
3055151|NCT02193399|No Intervention|Control group|Patients undergoing allogeneic transplantation without treatment of physiotherapy
3083702|NCT02001857|No Intervention|No TachoSil|No TachoSil
3055152|NCT02193386|Active Comparator|Usual Care|No intervention, no follow-up, only registration of usual therapy
3055153|NCT02193386|Experimental|Intervention period|Predefined, evidence-based program and support
3055154|NCT02193373|Active Comparator|Sub-Occipital Release|Osteopathic Manual Medicine
3055155|NCT02193373|Active Comparator|Rib-Raising|Osteopathic Manual Medicine
3055156|NCT02193373|Active Comparator|Stellate Ganglion Release|Osteopathic Manual Medicine
3055157|NCT02193373|Active Comparator|All techniques|Osteopathic Manual Medicine
3055158|NCT02193373|Sham Comparator|All Techniques-S|Sham Osteopathic Manual Medicine
3055159|NCT02193373|Sham Comparator|Sub-Occipital Release-S|Sham Osteopathic Manual Medicine
3055160|NCT02193373|Sham Comparator|Rib-Raising-S|Sham Osteopathic Manual Medicine
3055161|NCT02193373|Sham Comparator|Stellate Ganglion Release -S|Sham Osteopathic Manual Medicine
3055162|NCT02193360|Experimental|Single arm Dose Escalation|
3055163|NCT02193347|Experimental|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of a peptide that spans the mutated region of IDH1R132H (Isocitrate Dehydrogenase 1). The peptide is administered with GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) mixed with Montanide ISA 51.
3055164|NCT02193334|Active Comparator|KP-100IT|Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
3055165|NCT02193334|Placebo Comparator|Placebo|Intrathecal injection of placebo starting at 72 hours since the injury and repeating weekly 5 times
3055166|NCT02193321|Experimental|Amniotic membrane patch placement|One amniotic membrane patch will be placed on the epicardial surface of the heart immediately following a CABG procedure prior to wound closure.
3055167|NCT02193321|No Intervention|Control|Amniotic membrane patch will not be placed after CABG procedure prior to wound closure.
3055168|NCT02193308|Experimental|Telmisartan/Amlodipine FDC|
3055169|NCT02193308|Active Comparator|Telmisartan + Amlodipine mono|
3055170|NCT02193295|Experimental|Lifestyle Intervention|Caloric Restriction.
3055171|NCT02193295|Experimental|NAFLD|Placebo or ACC inhibitor treatment for 12 weeks
3055172|NCT02193282|Experimental|Arm A (blinded erlotinib hydrochloride)|Blinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
3055173|NCT02193282|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
3055174|NCT02193282|Experimental|Arm C (unblinded erlotinib hydrochloride)|Unblinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3055175|NCT02193282|Active Comparator|Arm D (observation)|Patients (including patients previously randomized to placebo) undergo observation at least every 6 months for 2 years.
3055176|NCT02193269|Placebo Comparator|sugar pill|0.0mg
3055177|NCT02193269|Active Comparator|Minocycline|200mg
3055178|NCT02193256|Active Comparator|Varenicline plus Prazosin|Varenicline: .5mg for 3 days then 1mg daily for 4 days (Week 1) then 2mg daily thereafter (Weeks 2-3). Prazosin: 1mg for 3 days, then 3mg for 4 days (Week 1), (2) 6mg for 3 days, then 8mg for 4 days (Week 2), and (3) 8mg (Week 3).
3055179|NCT02193256|Placebo Comparator|Varenicline plus Placebo|Varenicline: .5mg for 3 days then 1mg daily for 4 days (Week 1) then 2mg daily thereafter (Weeks 2-3). Placebo: placebo will be given instead of prazosin (Weeks 1-3)
3055180|NCT02193217|Experimental|MT-1303-Low|MT-1303-Low dose
3055181|NCT02193217|Experimental|MT-1303-High|MT-1303-High dose
3055182|NCT02193217|Active Comparator|Fingolimod|Fingolimod
3055183|NCT02193217|Placebo Comparator|Placebo|Placebo
3055184|NCT02193204|Experimental|Social Drinkers Depressive Symptoms|30 non-dependent light socially drinking (SD) smokers with depressive symptoms will be recruited to participate in two laboratory sessions (Stress and Neutral / Relaxing). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
3055185|NCT02193204|Experimental|Social Drinkers No Depressive Symptoms|30 non-dependent light socially drinking (SD) smokers without depressive symptoms will be recruited to participate in two laboratory sessions (Stress and Neutral / Relaxing). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
3055186|NCT02193204|Experimental|Alcohol Dependent, Non-Depressive|30 treatment-engaged 28-day abstinent, alcohol dependent (AD) smokers, without Depressive symptoms. All AD subjects will either be admitted to the Clinical Neuroscience Research Unit (CNRU) of the Connecticut Mental Health Center for five weeks of inpatient stay and study participation (inpatient), or they will be scheduled for a two night stay on the CNRU following 3 weeks of abstinence (outpatient). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
3055187|NCT02193204|Experimental|Alchohol Dependent Depressive Symptoms|30 treatment-engaged 28-day abstinent, alcohol dependent smokers with depressive symptoms. All AD subjects will either be admitted to the Clinical Neuroscience Research Unit (CNRU) of the Connecticut Mental Health Center for five weeks of inpatient stay and study participation (inpatient), or they will be scheduled for a two night stay on the CNRU following 3 weeks of abstinence (outpatient). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
3055188|NCT02193191|Experimental|Plerixafor|Patients will receive a single dose of subcutaneous plerixafor with peripheral blood studies at approximately 0-2 hours before, approximately 6-12 hours after, and approximately 20-48 hours after plerixafor administration, with leukapheresis in the last 3 patients on the protocol. Collected HPCs will be transferred to the MSKCC CTCEF to determine if the HPCs are amenable to transduction with a lentiviral vector encoding the normal ß- globin gene.
3055189|NCT02193178|Experimental|comfilcon A toric|Participants are habitual toric lens wearers and will be fitted with comfilcon A toric lenses.
3055190|NCT02193165|Active Comparator|Regimen 1|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash
3055191|NCT02193165|Active Comparator|Regimen 2|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
3055192|NCT02193165|Placebo Comparator|Regimen 3 - Control group|fluoride toothpaste + fluoride Mouthwash
3055284|NCT02192684|Active Comparator|pioglitazone|pioglitazone 45 mg, oral, daily
3055285|NCT02192684|Placebo Comparator|placebo|Placebo, one pill daily
3055193|NCT02193152|Experimental|Treatment: Pazopanib|"Pazopanib 800 mg daily should be taken orally without food at least one hour before or two hours after a meal.~One cycle of pazopanib is 28 days."
3055194|NCT02193139|Experimental|WL8713, 6 mg|6 mg WL8713 administered daily
3055195|NCT02193139|Experimental|WL8713, 12 mg|12 mg WL8713 administered daily
3055196|NCT02193139|Experimental|WL8713, 18 mg|18 mg WL8713 administered daily
3055197|NCT02193139|Experimental|WL8713, 24 mg|24 mg WL8713 administered daily
3055198|NCT02193139|Placebo Comparator|Placebo|placebo administered daily
3055199|NCT02193113|Experimental|KVD001 Injection Dose 1|Single 100 microliters (uL) intravitreal injection of KVD001 Injection Dose 1
3055200|NCT02193113|Experimental|KVD001 Injection Dose 2|Single 100uL intravitreal injection KVD001 injection Dose 2
3055201|NCT02193113|Experimental|KVD001 Injection Dose 3|Single 100uL intravitreal injection of KVD001 injection Dose 3
3055202|NCT02193100||13C-glucose|experimental (13C-glucose)
3055203|NCT02193100||No glucose|control (no glucose)
3055204|NCT02193087|Active Comparator|Group A: TDV Liquid + Placebo|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Liquid Formulation 1, diluted 1:5 with vaccine diluent, subcutaneous injection on Day 1, and TDV Liquid Formulation placebo-matching solution, subcutaneous injection, once on Day 90 (Month 3).
3055205|NCT02193087|Active Comparator|Group B: TDV Liquid|TDV Liquid Formulation 1, diluted 1:5 with vaccine diluent, subcutaneous injection on Day 1 and Day 90 (Month 3).
3055206|NCT02193087|Experimental|Group C: TDV Liquid|TDV Liquid Formulation 2, subcutaneous injection on Day 1 and Day 90 (Month 3).
3055207|NCT02193087|Experimental|Group D: TDV Lyophilized|TDV Lyophilized Formulation reconstituted with water, subcutaneous injection on Day 1 and Day 90 (Month 3).
3055208|NCT02193074|Experimental|nusinersen|
3055209|NCT02193074|Sham Comparator|Sham procedure|
3055210|NCT02193061|Active Comparator|ROTA 1|two doses of monovalent vaccine Rotarix followed by one dose of sterile water
3055211|NCT02193061|Active Comparator|ROTA 2|three doses of pentavalent vaccine RotaTeq
3055212|NCT02193061|Active Comparator|ROTA 3|one dose of monovalent Rotarix vaccine followed by two doses of pentavalent vaccine Rotateq
3055213|NCT02193061|Active Comparator|ROTA 4|one dose of pentavalent RotaTeq vaccine followed by two doses of monovalent vaccine Rotarix
3055214|NCT02193061|Active Comparator|ROTA 5|two doses of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix
3055215|NCT02193061|Active Comparator|ROTA 6|one dose of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix and a dose of pentavalent vaccine RotaTeq
3055216|NCT02193061|Active Comparator|ROTA 7|a dose of monovalent vaccine Rotarix followed by a dose of pentavalent vaccine and a dose of monovalent vaccine Rotarix
3055217|NCT02193048||Patients newly diagnosed with Crohn's disease|This study will evaluate a new clinical scoring system in patients receiving routine treatment
3055218|NCT02193035|Experimental|Single group|Patients with severe aortic stenosis treated with transcatheter aortic valve replacement (TAVR). Microparticle levels will be measured before and after TAVR.
3055219|NCT02193022|Experimental|Miltefosine|
3055220|NCT02193009|Experimental|SIPsmartER, behavioral intervention|Aimed at decreasing sugar-sweetened beverage consumption
3055221|NCT02193009|Active Comparator|Move More, behavioral intervention|Aimed at physical activity promotion
3055222|NCT02192996|Other|Probiotics supplementation|"Five very low birth weight (VLBW) infants enrolled within 2 days of birth, with a weight < 1300 g and gestational age < 29 weeks and without any malformation or metabolic disease at birth were supplemented with two daily doses of a mixture of Bifidobacterium breve and Lactobacillus salivarius , probiotic strains isolated from human milk during their first weeks of life. The lyophilized powder has contained at least 1x10^9 colony forming units (CFU) per doses of each one of the probiotic bacteria."
3055223|NCT02192983||chemotherapy regimen|those with XELOX regimen and those with EOX regimen
3055224|NCT02192970|Experimental|Bevacizumab|Pars plana vitrectomy will be performed in the typical manner. After laser retinopexy and prior to air-gas exchange, intravitreal bevacizumab will be administered through the trocar. Either perfluoropropane (C3F8) or sulfur hexafluoride (SF6) gas will then be administered for long-term retinal tamponade and the vitrectomy ports closed in the usual manner.
3055225|NCT02192970|No Intervention|Chart review|Review records over the past 5 years of patients who underwent vitrectomy for retinal detachment repair to found out the percentage of those who had re-detachment of the retina within 6 months after surgery.
3055226|NCT02192957|Other|Ottawa AF Cardioversion|elective electrical cardioversion for atrial fibrillation (AF) using the Ottawa AF protocol
3055227|NCT02192944|Active Comparator|Chloroquine|Chloroquine base 600 mg single dose
3055228|NCT02192944|Active Comparator|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine 120/960 mg single dose
3055229|NCT02192931|Active Comparator|Creatine monohydrate|5 grams of daily creatine monohydrate for 8 weeks
3055230|NCT02192931|Placebo Comparator|Placebo|5 g of placebo for 8 weeks
3055231|NCT02192931|No Intervention|Healthy Control|
3055232|NCT02192918|Experimental|Airbrush|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Participants will receive access to one of each of the following after the 6-month assessment at no cost: massage, pedicure, yoga class, and dance class. Participants will schedule these activities on their own and the study staff will arrange for payment for the appointment.
3055233|NCT02192918|Experimental|Airbrush Plus|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class. These activities are being given as healthy alternatives to the relaxation sensation of indoor tanning.
3055320|NCT02192463|Experimental|NVP ER 400 mg (KCR 25%) Medium Release|
3055321|NCT02192463|Experimental|NVP ER 300 mg (KCR 40%) Slow Release|
3055234|NCT02192918|Active Comparator|Delayed Airbrush Plus|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class.
3055235|NCT02192905|Experimental|Behavioral Weight Loss + Habit|Participants will receive 8 week of an online-delivered weight loss intervention adapted from the Diabetes Prevention Program Lifestyle Intervention and will use the Habit mobile app during the study.
3055236|NCT02192892|Experimental|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from Corn Soy Blend drum dried with α-amylase
3055237|NCT02192892|Placebo Comparator|CSB drum dried - α-amylase|CSB drum dried - α-amylase: Porridge from Corn Soy Blend drum dried without α-amylase
3055238|NCT02192892|Experimental|CSB + α-amylase|CSB + α-amylase: Porridge from Corn Soy Blend with α-amylase
3055239|NCT02192892|Placebo Comparator|CSB - α-amylase|CSB - α-amylase: Porridge from Corn Soy Blend without α-amylase
3055240|NCT02192892|Experimental|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
3055241|NCT02192892|Placebo Comparator|RSB - α-amylase|RSB - α-amylase: Porridge from Rice Soy Blend without α-amylase
3055242|NCT02192892|Active Comparator|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
3055243|NCT02192892|Active Comparator|Commercial porridge flour|Porridge from commercial porridge flour
3055244|NCT02192892|Active Comparator|Commercial porridge bar|Porridge from commercial porridge bar
3055245|NCT02192892|Experimental|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from Corn Soy Blend PLUS drum dried with α-amylase
3055246|NCT02192892|Placebo Comparator|CSB PLUS drum dried - α-amylase|CSB PLUS drum dried - α-amylase: Porridge from Corn Soy Blend PLUS drum dried without α-amylase
3055247|NCT02192892|Experimental|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
3055248|NCT02192892|Placebo Comparator|CSB PLUS - α-amylase|CSB PLUS - α-amylase: Porridge from Corn Soy Blend PLUS without α-amylase
3055249|NCT02192892|Experimental|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
3055250|NCT02192892|Placebo Comparator|RSB PLUS - α-amylase|RSB PLUS - α-amylase: Porridge from Rice Soy Blend PLUS without α-amylase
3055251|NCT02192892|Experimental|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
3055252|NCT02192892|Placebo Comparator|WSB PLUS - α-amylase|WSB PLUS - α-amylase: Porridge from Wheat Soy Blend PLUS without α-amylase
3055253|NCT02192892|Active Comparator|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
3055254|NCT02192879|Active Comparator|Thoracic Epidural|
3055255|NCT02192879|Active Comparator|Continuous Paravertebral Catheter|
3055256|NCT02192879|Active Comparator|Patient-Controlled Analgesia|
3055257|NCT02192866||Peanut allergic|No intervention(s) to be administered.
3055258|NCT02192866||Other food allergic|No intervention(s) to be administered.
3055259|NCT02192866||Controls|No intervention(s) to be administered.
3055260|NCT02192853|Experimental|Sitagliptin|Patients with Type 2 Diabetes Mellitus and healthy control subjects are given tablets of sitagliptin in either a dosage of 25, 100 or 200 mg tablet in 3 different days.
3055261|NCT02192853|Placebo Comparator|placebo|
3055262|NCT02192840|Active Comparator|rDES Group|"Regular drug-eluting stent implantation, one of the following:~Device: LucChopin (Balton, Poland) Device: Prolim (Balton, Poland) Device: Xience Pro (Abott Vascular) Device: Biomatrix (Biosensors) Device: Promus (Boston Scientific) Device: Cypher (Cordis) Device: Taxus (Boston Scientific) Device: Coroflex Please (BBraun) Device: Resolute Integrity (Medtronic)"
3055263|NCT02192840|Experimental|BiOSS Group|New dedicated bifurcation stent BiOSS Expert (Balton, Warsaw, Poland) implantation
3055264|NCT02192827|Experimental|Single Dose Dexamethasone|0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once
3055265|NCT02192827|Experimental|Two Dose Dexamethasone|0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once in the Emergency room, followed by another dose of dexamethasone at home, which will be prescribed from the ED. The second dose will be the same dosage, but will be prescribed and may be pill or liquid form.
3055266|NCT02192814|Experimental|Lacosamide (LCM)|"On Day - 1, LCM oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.~During the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.~The daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."
3055267|NCT02192788|Experimental|SBRT|Stereotactic Body Radiation Therapy for Oligometastases (SBRT)
3055268|NCT02192775|Experimental|MV-NIS + Cyclophosphamide|
3055269|NCT02192762|Experimental|Withdrawal regulation training|Withdrawal coping skills
3055270|NCT02192762|Active Comparator|Relaxation training|Relaxation skills instruction
3055271|NCT02192749|Experimental|Umbilical cord mesenchymal stem cells|
3055272|NCT02192736|Other|Intra-nasal infusion of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered intra-nasally
3055273|NCT02192723|Experimental|Typical antipsychotic|Haloperidol (6~20mg/day) and perphenazine (16~64mg/day) for 8 weeks.
3055274|NCT02192723|Active Comparator|Risperidone|Risperidone, 2~6mg/day, twice day, 8 weeks
3055275|NCT02192723|Active Comparator|Olanzapine|5~20mg/day
3055276|NCT02192723|Active Comparator|Quetiapine|400~750mg/day
3055277|NCT02192723|Active Comparator|Aripiprazole|Aripiprazole, 10~30mg/day, twice per day, 8 weeks
3055278|NCT02192723|Active Comparator|Ziprasidone|Ziprasidone, 80~160mg/day, twice per day, 8 weeks
3055279|NCT02192710|Active Comparator|Hypnovel® (midazolam)|Midazolam oral intake before anesthesia
3055280|NCT02192710|Experimental|Electronic tab|
3055281|NCT02192697|Experimental|Phase I dose-escalation group|Oral administration
3055282|NCT02192697|Experimental|Phase I EGFR-T790M mutation group|Oral administration
3055286|NCT02192671|Experimental|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and >50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
3055287|NCT02192671|Active Comparator|Radiofrequency ablation|RFA is performed in less than one week after clinical diagnosis.
3055288|NCT02192658||People with Disability (PWD) (N= 850)|"PWD will be identified thanks to the disability screening tool developped by the Washington Group (WG). This tool is based on the WHO International Classification of Functionning (ICF).~A stratified cluster sampling in 2 steps will be used in both, Yaounde and Ouagadougou. Each city will be divided in enumeration areas (EAs). First step : EAs will be drawn randomly with probability proportional to their size in number of households. Second step: in each EA, 30 households will be randomly drawn and each person living in these households will be screened for disability with the WG tool, according to the inclusion and exclusion criteria."
3055289|NCT02192658||Non-Disabled People (control group) (N= 850)|For each PWD, 1 non-disabled control person will be randomly chosen from the census list of the same enumeration area. Control will also be matched on age and sex.
3055290|NCT02192645|Experimental|Sanfujiu|"Formula for Sanfujiu: Huangjiezi; Xixin; Yanhusuo; and so on Acupoint for Sanfujiu: Different ten acupoints determined according to Chinese medicine theory for each time.~Timepoint: Five times of 3 years at Sanfu Point application: The patients will be treated with herbal cake-separated moxibustion on acupoints and lasted 60 minutes each time."
3055291|NCT02192645|Placebo Comparator|placebo|"Formula for placebo: Fuxiaomai; and so on. the appearance is similar as drugs of Sanfujiu Acupoint for placebo: Ten acupoints determined according to Chinese medicine theory are the same as Sanfujiu group of each timepoint .~Timepoint: Five times per year for 3 years. Point application: The patients will be treated with placebo on acupoints and lasted 60 minutes each time."
3055292|NCT02192645|No Intervention|waiting list|No intervention in the first year. Accept Sanfujiu in the second and the third years.
3055293|NCT02192632|Experimental|Epiduo- dermatologist's detailed instruction|After randomly assigned to side of epiduo application, half of total patients were also re-assigned into detailed instruction for application of epiduo from dermatologist
3055294|NCT02192632|Experimental|Epiduo- drug insert only gruop|After randomly assigned to side of epiduo application, half of total patients were also re-assigned into drug insert only group
3055295|NCT02192632|Placebo Comparator|BPO group|After randomly assigned to side of BPO application, patients apply BPO during 12 week
3055296|NCT02192619||observational|
3055297|NCT02192606|Active Comparator|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy
3055298|NCT02192606|Active Comparator|3D laparoscopy|The Storz 3D Laparoscopy System is the intervention we are studying at the time of the total laparoscopic hysterectomy.
3055299|NCT02192593|Experimental|Computer CBT|A 10-session computerized cognitive-behavioral therapy intervention
3055300|NCT02192593|No Intervention|Usual Care|
3055301|NCT02192580|Active Comparator|Omega-3|omega-3 (DHA+EPA) in divided 3 times/day in addition to standard regimens: Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
3055302|NCT02192580|No Intervention|Control|control group received just standard regimens without omega-3
3055303|NCT02192567|Experimental|DS-5573a does escalation (step 1) and expansion (step 2)|"Step 1 of this study will follow a 3+3 study design with a starting intravenous (IV) dose of 0.1 mg/kg.~Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg Step 2: 30 subjects will be enrolled and treated at the dose determined in Step 1."
3055304|NCT02192541|Experimental|Ganetespib and Ziv-Aflibercept|Ganetespib was administered intravenously, over 1 hour, weekly, on days 1, 8, and 15 of each 28-day cycle. Ziv-aflibercept was administered intravenously, over 1 hour, every 2 weeks, on days 1 and 15 of each 28-day cycle. Ganetespib was started at a dose level of 100 mg/m^2 + ziv-aflibercept at 3 mg/kg or 4 mg/kg.
3055305|NCT02192528||cardiac surgical patients|patients undergoing a cardiac surgical procedure
3055306|NCT02192515|Experimental|APD356 10 mg|Subjects will be randomized to APD356 10 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug.
3055307|NCT02192515|Experimental|APD356 20 mg|Subjects will be randomized to APD356 20 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug.
3055308|NCT02192515|Experimental|APD356 XR-20 mg|Subjects will be randomized to APD356 XR-20 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug on Day 1 and multiple doses of study drug on Day 8-14 once daily before breakfast.
3055309|NCT02192515|Experimental|APD356 10 mg and APD356 XR-20mg (orange tablet)|"Subjects will be randomized to Sequence A (8 subjects) or Sequence B (8 subjects) to receive study drug in the sequence shown below.~Sequence A: 10 mg tablet, 2 doses (12 hours apart) => XR-20 mg orange tablet, single dose => XR-20 mg orange tablet, q. d., multiple doses (fasted) => XR-20 mg orange tablet, q. d., multiple dose (fed)~Sequence B: XR-20 mg orange tablet, single dose => 10 mg tablet, 2 doses (12 hours apart) => XR-20 mg orange tablet, q. d., multiple dose (fed) => XR-20 mg orange tablet, q. d., multiple doses (fasted)"
3055310|NCT02192502|Experimental|HES 130/0.4 (Voluven)|6% HES 130/0.4 during surgery
3055311|NCT02192502|Active Comparator|human albumin 5%|human albumin 5% during surgery
3055312|NCT02192489|Experimental|CC-220 0.3mg|CC-220 0.3 mg capsules by mouth (PO) daily for 12 weeks
3055313|NCT02192489|Experimental|CC-220 0.6mg|CC-220 0.6mg capsules by PO daily for 12 weeks
3055314|NCT02192489|Placebo Comparator|Placebo|Identically matching placebo PO daily for 12 weeks
3055315|NCT02192476|Active Comparator|conventional|15 participants are allotted in this arm and each participants received conventional neuro rehabilitation programme 5 days a week for 6 weeks.
3055316|NCT02192476|Experimental|intervention|15 participants allotted in this arm and each participants received California tri-pull taping method along with conventional neuro rehabilitation was given 5 days a week for 6 weeks
3055317|NCT02192463|Experimental|Nevirapine (NVP) ER 300 mg (KCR 20%) Medium Release|
3055318|NCT02192463|Experimental|NVP ER 300 mg (KCR 25%) Medium Release|
3055319|NCT02192463|Experimental|NVP ER 300 mg (KCR 30%) Slow Release|
3055329|NCT02192450|Active Comparator|Insulin glargine|"Each treatment arm last for 12 months - 3 months of run-in/cross-over and 9 months of maintenance.~Patients will be randomised (1:1) to treatment with basal-bolus therapy with insulin aspart/degludec or insulin aspart/glargine in random order.~After 12 months of treatment patients will cross-over to the other basal-bolus therapy.~Insulin degludec and insulin glargine is administered once daily at the evening meal and insulin aspart is administered three times daily before the main meals."
3055330|NCT02192450|Experimental|Insulin degludec|"Each treatment arm last for 12 months - 3 months of run-in/cross-over and 9 months of maintenance.~Patients will be randomised (1:1) to treatment with basal-bolus therapy with insulin aspart/degludec or insulin aspart/glargine in random order.~After 12 months of treatment patients will cross-over to the other basal-bolus therapy.~Insulin degludec and insulin glargine is administered once daily at the evening meal and insulin aspart is administered three times daily before the main meals."
3055331|NCT02192437|Experimental|Methionine restricted diet|Intervention will be a Sulfur amino acid restricted diet (methionine). Control diet for 4 weeks followed by a washout for 3-4 weeks, then a methionine restricted diet (70%) for 4 weeks, followed by 3-4 weeks washout period and then a methionine restricted diet (90%) for 4 weeks.
3055332|NCT02192437|Experimental|Methionine and cysteine restricted diet|Intervention will be a Sulfur amino acid restricted diet (methionine and cysteine). Control diet for 4 weeks followed by a washout for 3-4 weeks then a methionine and cysteine restricted diet (50%) followed by 3-4 weeks washout period and then a methionine and cysteine restricted diet (65%) for 4 weeks.
3055333|NCT02192424|Active Comparator|Metformin alone|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy. Metformin will be initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months).
3055334|NCT02192424|Experimental|Metformin + Intermittent Insulin Therapy|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy, initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months). Participants will stop their metformin for 2 weeks every 3 months, during which time they will receive intermittent intensive insulin therapy for 2 weeks. The 2-week course of insulin therapy will be repeated at 3-, 6-, 9-, 12-, 15-,18- and 21-months, with final outcome measurement performed at 24-months.
3055335|NCT02192411|Active Comparator|Standard Lidocaine|50mL 1% lidocaine in 450mL normal saline
3055336|NCT02192411|Experimental|1/4 dose lidocaine|12.5mL 1% lidocaine in 487.5mL normal saline
3055337|NCT02192398|Active Comparator|Guanfacine (2mg)|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
3055338|NCT02192398|Active Comparator|Guanfacine (1mg)|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
3055339|NCT02192398|Placebo Comparator|Placebo|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
3055340|NCT02192372||metabolic syndrome|Presence of 3 or more of these components: high fasting glucose (fasting serum glucose ≥ 100 mg/dl or drug treatment for elevated blood glucose), abdominal obesity (given as waist circumference > 102 cm in men and > 88 cm in women), high blood pressure (≥130/≥85 mmHg or drug treatment for hypertension), hypertriglyceridemia (serum triglycerides ≥150 mg/dl), low high-density lipoprotein cholesterol (<40 mg/dl in men and <50 mg/dl in women).
3055341|NCT02192372||control|Age and sex adjusted control subjects
3055342|NCT02192359|Experimental|Treatment (hCE1m6-NSCs and irinotecan hydrochloride)|Patients receive carboxylesterase-expressing allogeneic neural stem cells intracranially over 1.5-4.5 hours on days 1 and 15 (day 1 only for patients at dose level 1) and irinotecan hydrochloride IV over 90 minutes on days 3 and 17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3055343|NCT02192346|Experimental|2.4 mg/kg α-TEA|Patients will receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
3055344|NCT02192346|Experimental|4.8 mg/kg α-TEA|Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
3055345|NCT02192346|Experimental|8.0 mg/kg α-TEA|Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.
3055346|NCT02192346|Experimental|9.6 mg/kg α-TEA|Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
3055347|NCT02192346|Experimental|12 mg/kg α-TEA|Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
3055348|NCT02192346|Experimental|16.8 mg/kg α-TEA|Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
3055349|NCT02192346|Experimental|19.2 mg/kg α-TEA|Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
3055350|NCT02192346|Experimental|22.3 mg/kg α-TEA|Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
3055351|NCT02192346|Experimental|26.8 mg/kg α-TEA|Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
3055352|NCT02192333|No Intervention|Arm I (usual care)|Participants receive usual care. After 12 months, participants may receive a survivorship clinic visit and boosters as in Arm II.
3055353|NCT02192333|Experimental|Arm II (survivorship care)|Participants attend a survivorship clinic visit that includes care plans, screening recommendations, physician coordination, health promotion education, symptom management and palliative care, late effects education, psychosocial and medical assessments, and referrals for services and care as appropriate. Participants also receive phone-based survivorship boosters over approximately 15-30 minutes at 4-8 weeks and 12-16 weeks after the initial clinic visit.
3055354|NCT02192320|Experimental|Atorvastatin and Dexamethasone|"Atorvastatin: 20 mg (every evening orally) for 5 weeks;~Dexamethasone: 0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)"
3055355|NCT02192320|Active Comparator|Atorvastatin|Atorvastatin: 20 mg (every evening orally) for 5 weeks
3055356|NCT02192307|Experimental|potassium oxalate gel|Professional application
3055357|NCT02192307|Active Comparator|Potassium oxalate liquid|Professional application
3055358|NCT02192294|Experimental|Bosutinib|
3055359|NCT02192281|Experimental|Playworks|Playworks was implemented during the entire school year, and outcome measures were collected in spring of the school year.
3055360|NCT02192281|No Intervention|Control|Playworks was not implemented at these schools.
3055361|NCT02192268|Active Comparator|HFOO|Children of the HFOO group will be subjected to two daily sessions of this resource which should be the same throughout her hospitalization with Shaker equipment.
3055362|NCT02192268|Active Comparator|Assisted Coughing|The children in the control group will be subjected to two daily sessions of assisted coughing.
3055363|NCT02192268|Active Comparator|PEP|The children will be subjected to PEP group two daily sessions of this resource which should be the same throughout her hospitalization with facial mask and valve Spring load with expiratory pressure of 10cmH2O.
3055364|NCT02192255|Experimental|Intervention phone call|The intervention arm consisted of one protocol-structured telephone call from an interventionist who was a nurse health manager (1 site), diabetes educator or diabetes educator trainee (1 site), or pharmacist (2 sites). Interventionists followed the same structured telephone interview protocol to ascertain whether the subject had started taking the new prescription. Those taking the new medication as prescribed received positive reinforcement. Those who either had not filled the prescription or were not taking the medication as directed, were asked about reasons for nonadherence and assisted in identifying and resolving barriers. The median call lasted < than 5 minutes, and up to 3 call attempts were made. Most intervention calls occurred within 2 to 6 weeks after the prescription date.
3055365|NCT02192255|No Intervention|Control arm - usual care|Those in the control arm received usual care.
3055366|NCT02192242|Experimental|Acute ischemic pain|acute ischemic pain was induced by treadmill testing in all patients investigated
3055367|NCT02192229|Active Comparator|intervention group|The intervention group will be supplemented with 50.000 IU vitamin D3 every week for 12 consecutive weeks
3055368|NCT02192229|Placebo Comparator|Placebo group|The placebo group will receive placebo Tablet which will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
3055369|NCT02192216|Experimental|Exercise & Chemotherapy|Following a control period during active chemotherapy the patients undergo ten weeks of supervised exercise comprised of resistance and aerobic training in combination with protein supplementation during ongoing chemotherapy.
3055370|NCT02192203|Experimental|Diclofenac + Menthol Gel|1% diclofenac, 3% menthol
3055371|NCT02192203|Active Comparator|Diclofenac Only Gel|1% diclofenac, 0.09% menthol
3055372|NCT02192203|Active Comparator|Menthol Only Gel|3% menthol
3055373|NCT02192203|Placebo Comparator|Placebo Only Gel|0.09% menthol
3055374|NCT02192190|Experimental|Dose 1 LY2951742 + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. Subcutaneous (SC) injections of dose 1 LY2951742 once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
3055375|NCT02192190|Experimental|Dose 2 LY2951742 + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of dose 2 LY2951742 once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
3055376|NCT02192190|Experimental|Dose 3 LY2951742 + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of dose 3 LY2951742 once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
3055377|NCT02192190|Experimental|Dose 4 LY2951742 + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of dose 4 LY2951742 once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
3055378|NCT02192190|Placebo Comparator|Placebo|Placebo capsule orally, once daily for approximately 16 weeks. Placebo SC once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
3055379|NCT02192190|Active Comparator|Celecoxib + Placebo|Celecoxib 200 milligram (mg) capsule orally once daily for approximately 16 weeks. Placebo SC once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
3055380|NCT02192177||Group 1|Pregnant subjects diagnosed with obstetric cholestasis who didn't have any foreknown systemic disease.
3055381|NCT02192177||Group 2|entirely healthy pregnant subjects, the control group.
3055382|NCT02192138|Experimental|Therapeutic thoracentesis|Patients with pleural effusion who require therapeutic thoracentesis will be enrolled into the study
3055383|NCT02192125|Experimental|REWIRE-System|The training system consists of a so-called Tymoplate® (Tyromotion, Austria), a medical device class 1 with CE certification and approval by the FDA for use in neurorehabilitation after stroke. The Tymoplate® is connected to a computer and allows by means of a base plate with integrated pressure sensors and custom-developed training software different postural biofeedback exercise.
3055384|NCT02192099|Experimental|GLYX-13 10 mg/kg|IV Dose of GLYX-13
3055385|NCT02192086|Experimental|goal directed fluid therapy|"The treatment group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).~a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe."
3055386|NCT02192086|Active Comparator|Control Group|"Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg * wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).~a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values)."
3055387|NCT02192073|Active Comparator|Suprapectoral Biceps Tenodesis|Suprapectoral Biceps Tenodesis involves detaching the long head of biceps from it's origin and reattaching it to humerus in the superior border of the pectoralis major insertion
3055677|NCT02190123||ACS patients treated with OAP|Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets
3055388|NCT02192073|Active Comparator|Subpectoral Biceps Tenodesis|Subpectoral Biceps Tenodesis involves detaching the long head of biceps from it's origin and reattaching it to humerus in the inferior border of the pectoralis major insertion
3055389|NCT02192060|Experimental|Test|Using of a suspension containing Triclosan
3055390|NCT02192060|Placebo Comparator|Control|Using of a suspension without Triclosan or other active ingredient
3055391|NCT02192047|Experimental|palm olein margarine|8 weeks
3055392|NCT02192047|Experimental|IE palm olein margarine|8 weeks
3055393|NCT02192047|Experimental|IE soybean oil-based margarine|8 weeks
3055394|NCT02192034|Experimental|Navigation Group|This group will receive standard clinic instructions for the colonoscopy and two additional phone calls from the patient navigator to discuss the purpose, preparation, and additional information regarding the colonoscopy procedure.
3055395|NCT02192034|Placebo Comparator|Control|This group will receive only clinic instructions without intervention from the patient navigator.
3055396|NCT02192021|Experimental|Micro needle array-Doxorubicin (MNA-D)|MNA-D application for all subjects
3055397|NCT02192008|Active Comparator|Part A|Cohort naive to typhoidal Salmonella challenged with either S. Typhi or S. Paratyphi
3055398|NCT02192008|Active Comparator|Part B|Cohort previously challenged with S. Typhi or Paratyphi re-challenged with either S. Typhi or S. Paratyphi.
3055399|NCT02191995|Experimental|body awareness yoga|body awareness yoga session prior to breakfast meal
3055400|NCT02191995|No Intervention|Control Arm|No intervention
3055401|NCT02191982|Experimental|Intervention|This arm will begin the Walk With Ease program after the completion of chemotherapy.
3055402|NCT02191982|Active Comparator|Wait List Control|The arm will begin the Walk With Ease program three months after completion of chemotherapy.
3055403|NCT02191969|No Intervention|Control|This group will be receiving adjuvant chemotherapy for colorectal cancer. They will not participate in the Walk With Ease program. They will be followed up using standard of care.
3055404|NCT02191969|Experimental|Intervention|"This group will be receiving adjuvant chemotherapy for colorectal cancer. They will participate in the Walk With Ease (WWE) program during the course of their chemotherapy treatment. They will be requested to initiate the WWE starting on Day 1 of adjuvant chemotherapy. Participants are asked to walk at a safe and comfortable pace, increasing their minutes per day at a rate they can sustain, with the ultimate goal of 30 minutes/day for at least 5 days/week. They are asked to maintain a daily walking log that is provided to them, entering total minutes per day.~Participants will be asked to do the walking program independently (self-directed, not in a formal group with an instructor) throughout chemotherapy."
3055405|NCT02191956|Active Comparator|Behavioral Parent Training|Standard of care intervention
3055406|NCT02191956|Experimental|Behavioral Parent Training - Enhanced|Standard of Care Behavioral Parent Training plus new delivery methods
3055407|NCT02191943|Active Comparator|Control (fluoride varnish)|
3055408|NCT02191943|Experimental|resin infiltration (Icon)|
3055409|NCT02191930|Experimental|B-CAP|Patients with ECOG of 2 or less (3 or less if caused by HL) and CIRS-G score of 6 or less (overall) and 3 or less per organ system receive 6 cycles of B-CAP (Brentuximab vedotin, cyclophosphamide, doxorubicine, predniso(lo)ne). Cycle length is 21 days
3055410|NCT02191930|Experimental|Brentoximab Vedotin only|Patients with CIRS-G score of 7 ore more receive Brentuximab Vedotin as single agent therapy for up to 16 cycles. Cycle length is 21 days
3055411|NCT02191917|Experimental|Measurement of Respiratory Muscle Strength|
3055412|NCT02191904|Active Comparator|Truview EVO2®|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively.
3055413|NCT02191904|Active Comparator|Airtraq®|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively
3055414|NCT02191904|Active Comparator|Direct laryngoscopy|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively
3055415|NCT02191891|Experimental|BI 836845 + afatinib|BI 836845 low or high dose (weekly IV infusion), afatinib 30mg or 40mg (once daily oral dosing)
3055416|NCT02191878|Experimental|Phase 1 Escalation / Phase 2 Expansion|"Phase 1 - dose escalation with intravenous infusion of TKM-080301 to determine MTD.~Phase 2 - dose expansion at the MTD."
3055417|NCT02191865|Experimental|Mild liver impairment|Patients with mild hepatic impaired function (Child-Pugh A)
3055418|NCT02191865|Experimental|Moderate liver impairment|Patients with moderate hepatic impaired function (Child-Pugh B)
3055419|NCT02191865|Experimental|Healthy volunteers|Healthy control subjects
3055420|NCT02191852|Experimental|Seresis®|2 capsules per day for a period of 16 consecutive weeks
3055421|NCT02191839|Active Comparator|alpha 1 antitrypsin|patients receive 4 grams of IV alpha 1 antitrypsin preoperatively
3055422|NCT02191839|Placebo Comparator|placebo|10 patients will randomely receive placebo
3055423|NCT02191826|Experimental|SOM0226 single dose|
3055424|NCT02191826|Experimental|SOM0226 multiple doses|
3055425|NCT02191813|Experimental|Seresis®|
3055426|NCT02191813|Placebo Comparator|Placebo|
3055427|NCT02191787|Experimental|Seresis® + Placebo|"2 capsules Seresis® o.d. for 5 days~2 capsules Placebo o.d. the day before treatment with Seresis®"
3055428|NCT02191774||Gestational length up to 63 days|Medical abortion at home using 200 mg of Mifepristone orally at the clinic followed by 0.8 mg Cytotec vaginally at home 48 hours later
3055429|NCT02191774||Gestational length 64-70 days|Medical abortion at home using 200 mg of Mifepristone orally at the clinic followed by 0.8 mg Cytotec vaginally at home 48 hours later
3055430|NCT02191761|Experimental|SM04755|
3056277|NCT02186314|Active Comparator|Apical stimulation|Pacemaker Biotronik: apical stimulation
3055431|NCT02191748|Active Comparator|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch. Saline, which doesn't affect repigmentation in vitiligo, will be injected into the patch at multiple sites spaced approximately 1 cm apart with 0.1-0.2 cc of saline injected at each site.
3055432|NCT02191748|Experimental|Needling and Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area. Triamcinolone (concentration: 2.5 mg/cc) will be injected into the patch at multiple sites spaced approximately 1 cm apart with 0.1-0.2 cc of triamcinolone injected at each site.
3055433|NCT02191748|No Intervention|No treatment|No treatment will be done to these vitiligo patches as a control.
3055434|NCT02191735||Troponin I|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI). Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
3055435|NCT02191735||Myoglobin|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI) and who have a RAMP Myoglobin test result that is within the test reportable range. Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
3055436|NCT02191735||CK-MB|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI) and who have a RAMP CK-MB test result that is within the test reportable range. Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
3055437|NCT02191735||NT-proBNP|Subjects who have undergone a routine test order of NT-proBNP or BNP for suspected Heart Failure (HF). Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
3055438|NCT02191722|Experimental|JIA patients|All participants will be evaluated before and after reading the comics booklet
3055439|NCT02191709|Experimental|Dextromethorphan syrup|Bisoltussin® Syrup
3055440|NCT02191709|Active Comparator|Dextromethorphan soft pastilles|Silomat® DMP soft pastilles
3055441|NCT02191683||Health of women before conception|Tanzanian women aged 18-40 years focusing on prevalence of anaemia, infections, nutritional status, and NCDs.
3055442|NCT02191683||480 women during pregnancy|"Describe how 1st and 2nd trimester anaemia compared to 3rd trimester anaemia alters foetal growth and newborns' body composition.~Evaluate anaemia's effect on villous branching in placenta, and uterine and umbilical artery blood flow.~Evaluate effect on vascular endothelial growth factor A/placental growth factor balance and insulin-like growth factor axis.~Determine which markers for foetal programming such as methylation of regulatory genes related to metabolism and haematopoiesis may be discovered early after exposure to anaemia."
3055443|NCT02191670||METALYSE®|
3055444|NCT02191657|Experimental|Cohort 1|Subjects in this arm were asymptomatic HIV-infected individuals who received a dose of 33 mg/kg deferiprone three times a day for a total daily dosage of 99 mg/kg
3055445|NCT02191657|Experimental|Cohort 2|Subjects in this arm were healthy volunteers who received a dose of 50 mg/kg deferiprone three times a day for a total daily dosage of 150 mg/kg
3055446|NCT02191657|Experimental|Cohort 3|Subjects in this arm were asymptomatic HIV-infected individuals who received a dose of 50 mg/kg deferiprone three times a day for a total daily dosage of 150 mg/kg.
3055447|NCT02191644|Placebo Comparator|Refined rice|
3055448|NCT02191644|Experimental|Whole grains and legumes|
3055449|NCT02191631|Experimental|Internet-delivered CBT|Participants will receive 12 weeks of internet-delivered cognitive behavior therapy with psychologist support.
3055450|NCT02191631|No Intervention|Wait list|Participants will receive no treatment for 12 weeks. After that period participants will receive Internet-delivered Cognitive Behavior Therapy.
3055451|NCT02191618|Other|WEB Aneurysm Embolization Device|"The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.~The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant."
3055452|NCT02191605|Experimental|electronic SBIRT (eSBIRT)|Participants in this condition will receive empathic exploration of their thoughts regarding marijuana use, provision of information on possible consequences of marijuana use during pregnancy and potential benefits of changing use (with permission), normed feedback, use of Motivational Interviewing techniques to elicit their own reasons for change, video testimonials modeling successful change, and information on change methods with optional goal setting.
3055453|NCT02191605|Experimental|Tailored texting|Participants in this condition will chose the frequency and time of text messages that will continue until childbirth or the participant opts out. The text messages will be a mix of marijuana targeted content (without directly referring to marijuana in a way that implies use by the participant) and general content related to healthy pregnancy; using appropriate humor and tips for community resources. Tailoring will focus on gestational age, self-efficacy, and social support.
3055454|NCT02191605|Experimental|eSBIRT & texting|Participants in this arm will receive both the computerized intervention and tailored text messaging intervention as described in the eSBIRT and Tailored texting arms.
3055455|NCT02191605|No Intervention|Assessment only|Participants in the arm will participant in screening and the baseline assessment conducted on the computer only. They will not receive an intervention.
3055456|NCT02191605|No Intervention|Screening only|Participants in this arm of the study will only answer the screening questions and will not be asked the baseline assessment or participate in an intervention.
3055457|NCT02191579|Active Comparator|BOTOX®|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks for up to 3 treatments.
3055458|NCT02191579|Active Comparator|Topiramate|Topiramate starting at a daily oral dose of 25 mg/day titrated up to a maximum dose of 100 mg/day for 36 weeks. Participants who discontinue topiramate are eligible to receive treatment with BOTOX®.
3055459|NCT02191566|Experimental|S-1/Oxaliplatin|S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months; Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
3055678|NCT02190110||Suspected pulmonary embolism patients|Adult patients (more than 18 years old) suspected of PE will be recruited at the time of the medical evaluation and before a final diagnosis is established
3055460|NCT02191553|Active Comparator|Control Group: Relaxation Techniques|Relaxation techniques which do not involve either formal or informal mindfulness training. Subjects in this group practice Jacobson's progressive muscular relaxation, emotional imagining and Schultz's autogenic training.
3055461|NCT02191553|Experimental|Loving Kindness Meditation (Metta)|Loving-kindness meditation following Kristin Neff protocol
3055462|NCT02191553|Experimental|Body Scan|Body scan as described in standard MBSR protocol
3055463|NCT02191553|Experimental|Sitting Practice|Sitting practice as mindfulness meditation described in standard MBSR protocols.
3055464|NCT02191540|Experimental|Abnoba Viscum F 20mg|
3055465|NCT02191527|Experimental|Point of Care Testing|The point-of-care devices will be located in the MCH services, where a trained lay counselor will do the tests.
3055466|NCT02191527|No Intervention|Laboratory Testing - Standard of care|
3055467|NCT02191501|Experimental|Pyloric restriction|Endoscopic method of pyloric restriction in order to decrease gastric emptying. The hypothesis is that this will cause and early and prolonged satiety which will inturn lead to decreased food consumption and lead to weight loss.
3055468|NCT02191488|Experimental|Experimental: 5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
3055469|NCT02191475|Active Comparator|glycopeptide plus carbapenem|The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy, dose of imipenem/cilastatin 500mg, IVdrip, 3~4 times/d, or meropenem 1g, IVdrip, 3 times/d; vancomycin for 15mg/kg,2 times/d, or linezolid 300mg, IVdrip, 2 times/d; these drugs are required to state organ function in patients with drug doses adjustment, treatment for 3-5 days.
3055470|NCT02191475|Experimental|Haizheng Li Xing ® plus tazocin ®|Tigecycline (Haizheng Li Xing ®) combined with piperacillin / tazobactam (tazocin ®), with or without antifungal therapy, dose of tigecycline first dose 100 mg, 50 mg, every 12 hours, piperacillin / tazobactam 4.5g, ivdrip, 3-4 times a day, each time the infusion of 3 hours, treatment for 3-5 days.
3055471|NCT02191462|Experimental|Niagen 100mg|1 Niagen capsule (1 x 100 mg capsule) and 9 Placebo capsules
3055472|NCT02191462|Experimental|Niagen 300mg|3 Niagen capsules (3 x 100mg capsule) and 7 Placebo capsules
3055473|NCT02191462|Experimental|1000mg Niagen|10 Niagen capsules (10 x 100mg capsule)
3055474|NCT02191436||Patients with haemophilia|Hemophilia patients (children, youth and adults) and parents of children with hemophilia under 18
3055475|NCT02191423|Experimental|postpartum depression|"Women suffering from postpartum depression, assessed by fMRI and then treated by dyadic psychotherapy~All participants will undergo two functional brain scans at the Tel Aviv Medical Center. The two scans will take place one week apart, one scan will include administration of oxytocin (24IU) and the other will include the use of placebo (the order in which the two different treatments is applied will be random).~All women in this group participate in 8-weeks of dyadic psychotherapy (DP) at the outpatient Psychiatric Department, Tel-Aviv Medical Center.~A final end-of-study clinical evaluation, will be conducted at the end of 8 weeks. The evaluation will include a psychiatric evaluation, the MADRS, and a physical examination, the mother-infant interaction will be videotaped, and the YIPTA, BDI, EPDS & STAI will be administered. Salivary OXT samples will be collected from the mother and from the infant and infants will undergo a developmental assessment."
3055476|NCT02191423|Other|normal controls|"Normal control women not suffering from postpartum depression assessed by fMRI~All participants will undergo two functional brain scans at the Tel Aviv Medical Center. The two scans will take place one week apart, one scan will include administration of oxytocin (24IU) and the other will include the use of placebo (the order in which the two different treatments is applied will be random).~A final end-of-study clinical evaluation, will be conducted at the end of 8 weeks. The evaluation will include a psychiatric evaluation, the MADRS, and a physical examination, the mother-infant interaction will be videotaped, and the YIPTA, BDI, EPDS & STAI will be administered. Salivary OXT samples will be collected from the mother and from the infant and infants will undergo a developmental assessment."
3055477|NCT02191410|Active Comparator|High Frequency Positive Pressure Ventilation|
3055478|NCT02191410|Placebo Comparator|Continuous Positive Airway Pressure|
3055479|NCT02191397|Experimental|Bupropion Treatment Arm|Subject will receive bupropion in 3 dose levels along with escitalopram matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive bupropion XL 150 milligram (mg) per day for a week. At dose level 2 (Week 1 to Week 4), bupropion XL dose will be increased to 300mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), bupropion XL dose will be maintained at 300mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of bupropion XL will be reduced to 150mg/day for 1 week before discontinuation.
3055480|NCT02191397|Active Comparator|Escitalopram Treatment Arm|Subject will receive escitalopram in 3 dose levels along with bupropion matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive escitalopram 10mg/day for a week. At dose level 2 (Week 1 to Week 4), escitalopram dose will be maintained at 10mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), escitalopram dose will be increased to 20mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of escitalopram 20mg/day, the dose will be reduced to 10 mg/day for 1 week before discontinuation, while those receiving 10mg/day will discontinuation directly.
3055481|NCT02191384|Experimental|Orcinoside 25mg per day|
3055482|NCT02191384|Experimental|Orcinoside 50mg per day|
3055483|NCT02191384|Experimental|Orcinoside 100mg per day|
3055484|NCT02191384|Experimental|Orcinoside 200mg per day|
3055485|NCT02191384|Experimental|Orcinoside 400mg per day|
3055486|NCT02191384|Experimental|Orcinoside 600mg per day|
3055487|NCT02191384|Placebo Comparator|placebo|
3055488|NCT02191371|Experimental|propofol|Propofol is used as a maintenance anesthetic to patients in the propofol group. Intervention: propofol infusion by target-controlled infusion for maintaining anesthesia propofol (Fresofol MCT 2%) target effect site concentration: 4~5 mcg/ml, during general anesthesia
3055719|NCT02189824|Experimental|Infusion of partially matched unrelated donor cells|
3055720|NCT02189811|Experimental|IPV|IPV at birth, 6 weeks, 10 weeks, 14 weeks, followed by tOPV at 18 and 22 weeks
3055489|NCT02191371|Experimental|desflurane|"Desflurane is used as a maintenance anesthetic to patients in the desflurane group.~Intervention: Desflurane administration for maintaining anesthesia desflurane (Suprane) inhalation as 6~8 vol% during general anesthesia"
3055490|NCT02191358||"Tested patients (prospective)"|Patients whose providers decide to have them undergo testing via the YouScript Personalized Prescribing System will be recruited for the study. Data will be gathered at baseline and 120 days later. The decision to utilize YouScript and all treatment decisions will be made at the discretion of the provider in accordance with their usual care practice, and will be made prior to the decision to participate in the study.
3055491|NCT02191358||"Untested patients (retrospective)"|Patients for comparison to the prospectively followed patients will be derived from Inovalon's MORE2 healthcare database. Patients meeting the same enrollment criteria (excluding the YouScript testing) will be matched on key characteristics to the tested patients. Outcomes will be compared between the prospectively enrolled patients undergoing pharmacogenetic testing with the YouScript Personalized Prescribing System at the discretion of their treating physician.
3055492|NCT02191345|No Intervention|10 minute break|Participants asked to take a 10 minute break as usual 3 times per week for 4 weeks
3055493|NCT02191345|Experimental|Guided Imagery|Participants listen to one of 6 pre-recorded guided imagery tracks 3 times per week for 4 weeks
3055494|NCT02191332||Viramune|
3055495|NCT02191319||Viramune®|Patients switching from protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) containing antiretroviral regimen to Viramune®
3055496|NCT02191306||HIV Positive Patients (Study Group)|
3055497|NCT02191306||Non HIV Positive Patients (Control)|
3055498|NCT02191293||Viramune®|
3055499|NCT02191280|Experimental|Antistax®, low dose|
3055500|NCT02191280|Experimental|Antistax®, high dose|
3055501|NCT02191280|Placebo Comparator|Placebo|
3055502|NCT02191267|Experimental|Presumed CTE Group|Interventions administered to the Presumed CTE Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, MRI/MRS Scans, and Genetic Analysis for Genetic Risk Score for Tau.
3055503|NCT02191267|Experimental|Control Group|Interventions administered to the Control Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, and MRI/MRS Scans.
3055504|NCT02191267|Experimental|AD Dementia Group|Interventions administered to the AD Dementia Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, MRI/MRS Scans
3055505|NCT02191254|Experimental|Antistax®|1 tablet per day for 12 weeks
3055506|NCT02191254|Placebo Comparator|Placebo|
3055507|NCT02191241|Experimental|Red Vine Leaf Extract|
3055508|NCT02191228|Experimental|Group 1|Linagliptin in subjects with normal renal function
3055509|NCT02191228|Experimental|Group 2|Linagliptin in patients with mild renal insufficiency (RI)
3055510|NCT02191228|Experimental|Group 3|Linagliptin in patients with moderate RI
3055511|NCT02191228|Experimental|Group 4|Linagliptin in patients with severe RI
3055512|NCT02191228|Experimental|Group 5|Linagliptin in patients with end-stage renal disease (ESRD)
3055513|NCT02191228|Experimental|Group 6|Linagliptin in patients with severe RI and Type 2 diabetes mellitus (T2DM)
3055514|NCT02191228|Experimental|Group 7|Linagliptin in patients with normal renal function and T2DM
3055515|NCT02191215||Nevirapine (Viramune®)|
3055516|NCT02191202||Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
3055517|NCT02191189|Active Comparator|Treatment A, p.o.|50 mg Nevirapine administered orally in 100 mL water
3055518|NCT02191189|Experimental|Treatment B, ascending colon|50 mg Nevirapine administered to the ascending colon via Enterion™ capsule
3055519|NCT02191189|Experimental|Treatment C, jejunum|50 mg Nevirapine administered to the jejunum via Enterion™ capsule
3055520|NCT02191189|Experimental|Treatment D, ileum|50 mg Nevirapine administered to the ileum via Enterion™ capsule
3055521|NCT02191189|Experimental|Treatment E, descending colon|50 mg Nevirapine administered to the descending colon via Enterion™ capsule
3055522|NCT02191176|Experimental|Dextromethorphan syrup - low dose|
3055523|NCT02191176|Experimental|Dextromethorphan syrup - high dose|
3055524|NCT02191176|Placebo Comparator|Placebo|
3055525|NCT02191163|Experimental|Antistax®|1 x 360 mg for 42 days
3055526|NCT02191163|Placebo Comparator|Placebo|
3055527|NCT02191150||Cohort 1|Patients with CKD
3055528|NCT02191137|Experimental|Riociguat 0.5mg to 2.5 mg|Single arm, open label
3055529|NCT02191124|Experimental|measurement-based care|MBC allows psychiatrists to individualize treatment decisions for each patient based on the change of psychopathology and tolerance toward antidepressants. Treatment decisions were made by treating psychiatrists according to ratings of self-report scales obtained at each treatment visit. Paroxetine was started at 20mg/day and then raised to 30mg/day by week 4, 40mg/day by week 6, 50mg/day by week 8 and 60mg/day by week 10. Mirtazapine was started at 15mg/day and raised to 30mg/day by week 1 and 45mg/day by week 4. Dose adjustments were dependent on how long a patient had received a particular dose, symptom changes and side effects.
3055530|NCT02191124|Active Comparator|Standard treatment|Patients in the ST group are treated by their psychiatrists according to their clinical needs as judged at each outpatient visit, receiving either open-label paroxetine (20-60mg/day) or mirtazapine (15-45mg/day) within the therapeutic dose range.
3055531|NCT02191111|Experimental|Task-focused facilitation|An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
3055532|NCT02191111|No Intervention|Control|These sites will continue practice as usual, with no contact from study staff.
3055533|NCT02191098|Experimental|ALT-803|ALT-803
3055564|NCT02190851|Experimental|electrical nerve stimulation (TENS)|"Two electrodes are attached around the internal malleolus and connected to the TENS unit, by UROSTIM 2.~The sessions last 20 minutes daily (frequency 10Hz, duration 200µs), at maximum intensity of painless stimulation, every day at the same time, on the right side for 3 months."
3055721|NCT02189811|Experimental|bOPV|bOPV at birth, 6, 10, and 14 weeks. followed by tOPV at 18 and 22 weeks of age
3056278|NCT02186314|Active Comparator|Bifocal stimulation|Pacemaker Biotronik: bifocal stimulation
3055534|NCT02191085|No Intervention|Standard Management|"Patients in the Standard Management arm will be assessed without any interventions.Patients will be assessed by a sleep respirologist and follow a management plan that is determined by the sleep physician and patient. This plan may involve polysomnography or the initiation of PAP therapy. If further testing is ordered, follow-up may occur with the physician or with an ACP, at the physician's discretion. For patients initiating PAP therapy, the decision to delegate follow-up to an ACP will be left up to the physician, as the intent of this study is to observe real-world practice and not to change the management of individual patients."
3055535|NCT02191085|Active Comparator|Fast Track|"In the Fast Track arm, an ACP will perform the initial assessment and will determine the management plan with the patient."
3055536|NCT02191072|Experimental|omalizumab|omalizumab 300mg subcutaneously once
3055537|NCT02191059|Experimental|Intermittent High Dose of Icotinib|"Intermittent High Dose of Icotinib in Combination With Docetaxel:~Icotinib 625mg tablet b ymouth three times per day for day1-2, Docetaxel 75mg/m2 injection intravenous drip for day 3, 3 weeks as 1 cycle"
3055538|NCT02191046|Active Comparator|syringe 20 ml|nasal irrigation with syringe by using buffer hypertonic saline about 100-240 ml until no nasal discharge
3055539|NCT02191046|Experimental|squeezable bottle|nasal irrigation with squeezable bottle by using buffer hypertonic saline about 100-240 ml until no nasal discharge
3055540|NCT02191033|Experimental|Text messaging|Smoking counseling, nicotine patch, text messaging
3055541|NCT02191033|Active Comparator|Standard of care|Smoking counseling, nicotine patch
3055542|NCT02191020|Experimental|Total glucosides of paeony & Acitretin Capsules|During the first week，0.6g，oral，b.i.d.During the other weeks，0.6g，oral，t.i.d
3055543|NCT02191020|Active Comparator|Acitretin Capsules|20mg/day oral,when subject's weight less than 70kg;otherwise,30mg/day oral.
3055544|NCT02191007|Experimental|Calcipotriol/Betamethasone and Calcipotriol|Calcipotriol/Betamethasone ointment 1/d for 4 weeks; Calcipotriol ointment bid for 6 weeks on-demand treatment period;
3055545|NCT02191007|Sham Comparator|Calcipotriol/Betamethasone and urea cream|alcipotriol/Betamethasone ointment 1/d for 4 weeks , urea cream 1/d for 6 weeks on-demand treatment period
3055546|NCT02191007|Active Comparator|Calcipotriol/Betamethasone|Calcipotriol/Betamethasone ointment 1/d for 4 weeks, Calcipotriol/Betamethasone ointment 1/d for 6 weeks on-demand treatment period
3055547|NCT02190994|No Intervention|A. Normal function, non-GC replacement|No glucocorticoid replacement will be given perioperatively.
3055548|NCT02190994|Active Comparator|B. Normal function, low-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1. 80mg hydrocortisone at day 2; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet at day 4 and day 5; 2.5mg at day 6;
3055549|NCT02190994|Active Comparator|C. Impaired function, low-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1. 80mg hydrocortisone at day 2; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet at day 4 and day 5; 2.5mg at day 6;
3055550|NCT02190994|Active Comparator|D. Impaired function, high-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1 and day 2. 60mg hydrocortisone at day 3; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet per day, since postoperative day 3.
3055551|NCT02190981||Ultrasound for Small Bowel Obstruction|Emergency department patients undergoing point-of-care ultrasound to evaluate for suspected small bowel obstruction
3055552|NCT02190968|Experimental|Mindful Mood Balance|An 8 session internet intervention targeting residual depressive symptoms.
3055553|NCT02190968|Active Comparator|Usual Depression Care|Usual Depression Care through Kaiser Permanente Colorado
3055554|NCT02190955||NEPTUNE contact registry patients|Patients and caregivers will be recruited from the Nephrotic Syndrome Study Network (NEPTUNE) Patient Contact Registry. Over 1000 patients and caregivers are members of the registry and have already provided permission to be contacted for future research studies. Analysis of the one-time online questionnaire will be done in collaboration with investigators from the NEPTUNE Consortium.
3055555|NCT02190942||Vasculitis Contact Registry Patients|Consent will be obtained from at least 20 randomly selected patients with each of the following self-identified diagnoses in the VCRC Patient Contact Registry: Behçet's disease, EGPA, GCA, GPA, MPA, PAN and TAK that have already completed the VCRC Diagnostic Questionnaires. Permission will be obtained to contact subjects' primary vasculitis care providers to request that the providers complete an online version of this questionnaire (or print copy, if they prefer), and request specific chart items from their office to further verify the data.
3055556|NCT02190929||Vasculitis Contact Registry Patients|Patients will be recruited from within the Vasculitis Clinical Research Consortium (VCRC) Patient Contact Registry to participate in an online questionnaire. More than 3000 patients, representing all the different types of idiopathic vasculitis, are currently enrolled into the on-line registry. The different types of vasculitis available for study include: Behçets disease, Churg-Strauss Syndrome, CNS Vasculitis, Giant Cell Arteritis, granulomatosis with polyangiitis (Wegener's granulomatosis), Henoch-Schöenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, or Takayasu's Arteritis.
3055557|NCT02190903|Active Comparator|General endotracheal anesthesia|Standard care general endotracheal anesthesia
3055558|NCT02190903|Active Comparator|Regional (spinal) anesthesia|Standard care spinal anesthesia
3055559|NCT02190890|Experimental|Dry needling: 4 local twitch responses|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until 4 local twitch responses were elicited.
3055560|NCT02190890|Experimental|Dry needling: 6 local twitch responses|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until 6 local twitch responses were elicited.
3055561|NCT02190890|Experimental|Dry needling: Until no more local twitch responses elicited|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until no more local twitch responses were elicited.
3055562|NCT02190890|Active Comparator|Control|The needle was inserted 1.5 cm away from the trigger point in the trapezius muscle and withdrawn without any consecutive insertion.
3055563|NCT02190877||Cohort 1: Subjects taking diuretic medication|All subjects will be in the same group, Cohort 1
3055565|NCT02190851|Placebo Comparator|Control group|The device will have been previously set to deliver a stimulation below the effective threshold. In all cases, the device displays 20mA. Stimulation sessions are 20 minutes daily, every day at the same time, on the right side for 3 months.
3055566|NCT02190838|Experimental|Dacarbazine with Metformin|32 patients will receive Dacarbazine 1000 mg/m^2 once every 28 days with Metformin 850 mg BID.
3055567|NCT02190838|Experimental|Dacarbazine and Melatonin|32 patients will receive Dacarbazine 1000 mg/m^2 once every 28 days with Melatonin 3 mg before sleep daily.
3055568|NCT02190838|Active Comparator|Dacarbazine|32 patients will receive Dacarbazine 1000 mg/m^2 once every 28 days
3055569|NCT02190812|Experimental|Forearm supporter|This study measured the effect of proper forearm supporter to alleviate pain and improve the wrist and grip strength in the subjects with tennis elbow.
3055570|NCT02190812|Experimental|Grip ball|In this study a portable grip ball training system is developed. This study use the grip ball to train the wrist muscle. It's expected to reduce the risk of injury of the elderly in their daily lives.
3055571|NCT02190799|Experimental|Convalescent plasma|Enrolled patients will receive 2 units of the convalescent plasma after meeting the eligibility criteria
3055572|NCT02190786|Experimental|KUX-1151, Low dose|
3055573|NCT02190786|Experimental|KUX-1151, Middle dose|
3055574|NCT02190786|Experimental|KUX-1151, High dose|
3055575|NCT02190773||Chronic periodontitis|Surgical periodontal treatment and GCF collection 3 months after treatment
3055576|NCT02190773||Agressive periodontitis|Surgical periodontal treatment and GCF collection 3 months after treatment.
3055577|NCT02190773||Control group|Periodontally healthy individuals
3055578|NCT02190760|Active Comparator|Group I (ISB-P)|Interscalene block with perineural injection of dexamethasone 0.1 mg/kg
3055579|NCT02190760|Active Comparator|Group II (ISB-S)|Interscalene block with systemically injection of dexamethasone 0.1 mg/kg.
3055580|NCT02190760|Active Comparator|Group III - ISB-C|Interscalene block without adjuvant.
3055581|NCT02190747|Experimental|Palovarotene dose level 1 (Cohort 1)|Doses of palovarotene in dose level 1 are 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days.
3055582|NCT02190747|Experimental|Palovarotene dose level 2 (Cohort 2)|Weight-adjusted doses of palovarotene in dose level 2 are 10 mg palovarotene once daily, followed by 5 mg once daily for 28 days.
3055583|NCT02190747|Experimental|Palovarotene dose level 3 (Cohort 2)|Weight-adjusted doses of palovarotene in dose level 3 are 5 mg palovarotene once daily, followed by 2.5 mg once daily for 28 days.
3055584|NCT02190747|Placebo Comparator|Sugar pill|The placebo comparator will be taken once daily for the same duration as the palovarotene dose groups in both Cohorts 1 and 2.
3055585|NCT02190734|Other|wheelchair, walking on treadmill, walking overground|Sitting in wheel chair Gait training on treadmill Gait training overground
3055586|NCT02190721|Experimental|tbo-filgrastim|Patients will receive subcutaneous doses of tbo-filgrastim 5 μg/kg body weight daily; each daily dose, to be administered at the investigative site
3055587|NCT02190708|Experimental|PQ912 & Midazolam & Omeprazole|day2 - day6 800mg PQ912 twice per day po day1 / day6 2.5 mg Midazolam once per day day1 / day6 20 mg Omeprazole once per day
3055588|NCT02190695|Active Comparator|Decitabine|Decitabine 20mg/m2 IV over 1hour daily times 5 days every 28 days
3055589|NCT02190695|Experimental|Decitabine and Carboplatin|Decitabine 20mg/m2 IV over 1hour daily times 5 days, plus Carboplatin AUC 5 IV over 1hour on day 8. repeat every 28 days.
3055590|NCT02190695|Experimental|Decitabine and Arsenic|Decitabine 20mg/m2 IV over 1 hour daily for 5 days plus Arsenic Trioxide 0.15mg/kg IV daily for 5 days. repeat every 28 days
3055591|NCT02190669||exercise in individuals without diabetes|exercise in individuals without diabetes
3055592|NCT02190669||exercise in type 1 diabetes|exercise in type 1 diabetes
3055593|NCT02190669||exercise in type 2 diabetes|exercise in type 2 diabetes
3055594|NCT02190656||Anterior resection|Patients having had an anterior resection for rectal cancer who are more than 12 months post surgery
3055595|NCT02190643|Experimental|Adherence condition|Brief smoking cessation counseling session (based on 5 A's approach) that includes a module focused on improving adherence to using the nicotine patch, plus 8-week supply of nicotine patches.
3055596|NCT02190643|Active Comparator|Standard condition|Brief smoking cessation counseling session (based on 5 A's approach) that does not include a module focused on improving nicotine patch adherence, plus 8-week supply of nicotine patches.
3055597|NCT02190630|Active Comparator|Part time (12hour) wear|the' Modified Clark Twin Block' will be worn part time
3055598|NCT02190630|Active Comparator|Full time (24hour) wear|the ' Modified Clark Twin Block' will be worn full time
3055599|NCT02190617|Active Comparator|Enhanced Clinic+ Unified Management Plan|"Patients in study arm will receive:~Enhanced Clinic Intervention~Enhanced Health Plan~Unified Management Plan"
3055600|NCT02190617|Active Comparator|CHW Home Visit Only|"Patients in study arm will receive:~CHW Home Visit~Usual clinic care with enhanced health plan"
3055601|NCT02190617|Active Comparator|Enhanced Clinic+ Unified Plan+ CHW|"Patients in study arm will receive:~CHW Home Visit~Enhanced Clinic intervention~Enhanced health plan~Unified asthma management plan"
3055602|NCT02190617|No Intervention|Usual Care|-Usual clinic care with enhanced healthplan
3055603|NCT02190604|Experimental|Part 1 Cohort 1: QBW251|Single dose of QBW251 10 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3055604|NCT02190604|Experimental|Part 1 Cohort 2: QBW251|Single dose of QBW251 25 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3055605|NCT02190604|Experimental|Part 1 Cohort 3: QBW251|Single dose of QBW251 75 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3055722|NCT02189811|Experimental|bOPV and IPV|bOPV at birth, 6, 10 weeks, and IPV+bOPV at 14 weeks, and tOPV at 18 and 22 weeks of age
3055606|NCT02190604|Experimental|Part 1 Cohort 4: QBW251|Single dose of QBW251 150 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3055607|NCT02190604|Experimental|Part 1 Cohort 5: QBW251|Single dose of QBW251 300 mg in healthy volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3055608|NCT02190604|Experimental|Part 1 Cohort 6: QBW251|Single dose of QBW251 500 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3055609|NCT02190604|Experimental|Part 1 Cohort 6: QBW251(fed)|Single dose of QBW251 500 mg (fed). single dose with food for a preliminary assessment of the effect of food on the absorption of QBW251 in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3055610|NCT02190604|Experimental|Part 1 Cohort 7: QBW251|Single dose of QBW251 750 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3055611|NCT02190604|Experimental|Part 1 Cohort 8: QBW251|Single dose of QBW251 1000 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3055612|NCT02190604|Placebo Comparator|Part 1 Placebo|Placebo to QBW251 in all cohorts of part 1 in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3055613|NCT02190604|Experimental|Part 2 Cohort 1: QBW251|Multiple doses of QBW25 150 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
3055614|NCT02190604|Experimental|Part 2 Cohort 2: QBW251|Multiple doses of QBW251 400 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
3055615|NCT02190604|Experimental|Part 2 Cohort 3: QBW251|Multiple doses of QBW251 750 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
3055616|NCT02190604|Experimental|Part 2 Cohort 4: QBW251|Multiple doses of QBW251 450 mg bid in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
3055617|NCT02190604|Experimental|Part 2 Cohort 5: QBW251|Multiple doses of QBW251 750 mg bid in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
3055618|NCT02190604|Placebo Comparator|Part 2 Placebo|Placebo to QBW251 in all cohorts of part 2 in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
3055619|NCT02190604|Experimental|Part 3 Cohort 1: QBW251|150 mg b.i.d. Multiple doses. Patients having a class III, IV, V, or VI mutation on one allele and any other CFTR mutation on the other allele in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
3055620|NCT02190604|Experimental|Part 3 Cohort 2: QBW251|450 mg b.i.d. Multiple doses. Patients having a class III, IV, V, or VI mutation on one allele and any other CFTR mutation on the other allele in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
3055621|NCT02190604|Experimental|Part 3 Cohort 3: QBW251|450 mg b.i.d. Multiple doses. Patients who are homozygous for the F508del mutation in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
3055622|NCT02190604|Placebo Comparator|Part 3 Placebo|Placebo to QBW251 in all cohorts of part 3 in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
3055623|NCT02190591|No Intervention|Pillow and Wedge|Receiving standard care for positioning during labor using pillows and wedges
3055624|NCT02190591|Experimental|Peanut Labor Ball|Use of the peanut labor ball within 30 minutes after epidural placement
3055625|NCT02190578|Experimental|Diagnostic: Reveal G4|Subjects tested with investigational devices and approved comparator assay algorithms for HIV
3055626|NCT02190565|Placebo Comparator|Placebo|Placebo consisting of two sham multivitamin and mineral tablets and two capsules of oil
3055627|NCT02190565|Active Comparator|Food supplement|Food supplement consisting of fish oil (omega 3 fatty acids DHA and EPA) and multivitamin and mineral tablets with extra iron and folic acid
3055628|NCT02190552||EmboTrap® Revascularization Device|The EmboTrap® Revascularization Device is the investigational device
3055629|NCT02190539|Experimental|Homeopathic treatment|A feasibility study examining whether patients with advanced breast cancer would follow a homeopathic protocol for three to six months.
3055630|NCT02190526|Experimental|Mesalazine(asacol 800 mg)|patients receive asacol (800 mg/TDS) and a placebo agent similar to amitriptyline (10 mg/HS) for 8 weeks
3055631|NCT02190526|Experimental|Amitriptyline|patients receive amitriptyline (10 mg/HS) and a placebo like asacol (800 mg/ TDS) for 8 weeks
3055632|NCT02190526|Placebo Comparator|placebo group|patients receive placebo like asacol (800 mg/TDS) and placebo similar to amitriptyline (10 mg/HS) for 8 weeks
3055633|NCT02190500||Mobile Stroke Unit Management|Acute ischemic stroke patients treated in the Mobile Stroke Unit
3055634|NCT02190500||Standard Management|Acute ischemic stroke patients receiving standard management
3055635|NCT02190487||TAS group|patients who had thoracic aortic surgery due to dissection
3055676|NCT02190136|Experimental|Protein Stretching/Yoga Training|Ingestion of Protein-rich diet 4-6 meals/day and stretching/yoga training 3 times per week
3055636|NCT02190474|Experimental|Mindfulness Group|These adolescents will be invited to participate in a group mindfulness meditation program based on a protocol refined by the investigative team. The weekly group meetings will be taught by an MBSR teacher at the Yale School of Medicine, with experience teaching mindfulness interventions to adults, children, and adolescents.
3055637|NCT02190461|Experimental|Early Respiratory Rehabilitation Programme|Starting the Early Respiratory Rehabilitation programme during the admission and continues it at home immediately after discharge for a period of 3 months.
3055638|NCT02190461|Active Comparator|Conventional Respiratory Rehabilitation Programme|Started a conventional Respiratory Rehabilitation programme at home one month after discharge from hospital and continues for 3 months.
3055639|NCT02190448|Experimental|study herbal tea|Supplementation of 3-5, 8 oz cups of study tea daily for 4 weeks.
3055640|NCT02190448|Placebo Comparator|herbal placebo tea|Supplementation of 3-5, 8oz cups of tea daily for 4 weeks.
3055641|NCT02190435|Experimental|ADAPT|Patients that receive intramedullary nail fixation with use of the Stryker ADAPT computer-assisted navigation system
3055642|NCT02190435|Active Comparator|Control|Patients that receive conventional technique intramedullary nail fixation without use of the Stryker ADAPT computer-assisted navigation system
3055643|NCT02190409|Experimental|Test, Control|Test: Minimum two tapered implants (Ankylosis, Dentsply Friadent) were placed to each patient. After surgical preparation of implant sockets, PRF that was prepared preoperatively was placed randomly to one of the sockets (PRF+). Acellular plasma portion of PRF was used to wet the implant placed into the PRF-coated socket Control: Other socket was selected as a control group (No Platelet Rich Fibrin used): In the control group no extra intervention used and the conventional procedure was done. Thus the readings of the experimental arm compared with this control.
3055644|NCT02190396||Group 1|Placental calcification of Grade 3
3055645|NCT02190396||Group 2|No placental calcification noted, the control group.
3055646|NCT02190383|Experimental|Habit Reversal Training|At first patients get informed about Tics in general. Then the individual Tics are specified and the tic-reaction is looked at further. The Tic-Symptoms are observed and the premonitory urge is specified. For all individual tics a specific reversal movement is developed. Relaxation methods are introduced.
3055647|NCT02190370|Experimental|Resources activation|At first patients get informed about Tics in general. Through different exercises existing resources and skills are activated and strengthened. Feeling of self-esteem and self-respect are strengthened. Also the emotional awareness is strengthened. Relaxation methods are also introduced.
3055648|NCT02190357|Experimental|rifaximin|400 mg bid,orally
3055649|NCT02190357|No Intervention|controlled group|no intervention
3055650|NCT02190344|Experimental|Functionality of 8-channel paddle coil system|
3055651|NCT02190331|Experimental|Interventional program|The training protocol is constituted by 4 strengthening exercises (Side Lying External Rotation, Prone Horizontal Abduction with External Rotation, Y to I exercise and Chin Tuck) and 3 stretching exercises(one- Sided Unilateral Self Stretch Exercise, one-sided Unilateral Self Stretch Exercise, Static Sternocleidomastoid Stretch and Static Levator Scapulae Stretch
3055652|NCT02190331|Active Comparator|Control group|The control group will only participate in the Physical Education classes
3055653|NCT02190318|Experimental|Losartan|Losartan is taken orally 100mg/d
3055654|NCT02190318|Experimental|spirolactone|spirolactone is taken orally 20mg/d
3055655|NCT02190318|Experimental|losartan in combination with spirolactone|Losartan is taken orally 100mg/d and spirolactone is taken orally 20mg/d
3055656|NCT02190318|Sham Comparator|blank control|patients with antihypertensives besides ACEI/ARBs and spirolactone.
3055657|NCT02190305|Experimental|Diagnostic: Multiplo HBc/HIV/HCV + Reveal HBsAg|Subjects tested with investigational devices and approved comparator assay algorithms for HIV and hepatitis B and C.
3055658|NCT02190292||PANS group|All current Swedish cases investigated with the Cunningham panel (approximately 150 individuals) will be invited to participate in the study. 50 of these will be re-assessed with the Cunningham panel.
3055659|NCT02190292||Psychiatric controls|60 individuals with psychiatric disorder (eg. ADHD, autism spectrum disorder, psychosis, major depression, obsessive-compulsive disorder) will be recruited.
3055660|NCT02190292||Healthy controls|25 age and sex matched children to the PANS group will be recruited.
3055661|NCT02190279|Experimental|Arm 1|Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.
3055662|NCT02190279|Experimental|Arm 2|Patients with biochemical prostate cancer relapse afterdefinitive treatment
3055663|NCT02190279|Experimental|Arm 3|Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.
3055664|NCT02190227|Other|Tumor RDA biopsy|Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.
3055665|NCT02190201|Experimental|videolaryngoscope|DLT intubation with McGrath videolaryngoscope
3055666|NCT02190201|Active Comparator|Direct laryngoscope|DLT intubation with Macintosh laryngoscope
3055667|NCT02190188|No Intervention|No specific treatment|No specific treatment after partial meniscectomy
3055668|NCT02190188|Other|Wedge Insole with 5mm wedge angel|Participants wear a wedge insole after partial meniscectomy
3055669|NCT02190188|Other|Knee Brace|Participants wear a knee brace after partial meniscectomy
3055670|NCT02190162|Active Comparator|Tantum Verde® mouthwash|solution of Tantum Verde
3055671|NCT02190162|Placebo Comparator|placebo mouthwash|saline with mint flavor
3055672|NCT02190149||ADVATE (Factor VIII)|Participants will remain on their current (pre-study) treatment regimen of ADVATE throughout the study period
3055673|NCT02190149||RIXUBIS (Factor IX)|Participants will remain on their current (pre-study) treatment regimen of RIXUBIS throughout the study period
3055674|NCT02190136|Active Comparator|Protein whole foods|Ingestion of 20-25 grams per serving consumed 4-6 times per day; 1 within an hour of waking in the morning and the other 2.5-3 hours apart during the day.
3055675|NCT02190136|Experimental|Protein Resistance Exercise Training|Ingestion of 4-6 protein-rich meals per day and 3 times per week of resistance functional training.
3056279|NCT02186301|Active Comparator|Erlotinib Mono-Therapy|
3055679|NCT02190097|Experimental|paleolithic diet|subjects in this arm are given detailed instructions and coaching in following a paleolithic type diet for 4 months, with the option to continue for another 4 months. studies of ovarian and metabolic parameters will be done at baseline, 2 and 4 months
3055680|NCT02190097|Active Comparator|American Diabetes Association diet|subjects in this arm are given detailed instructions and coaching in following an ADA type diet for 4 months, with the option to switch over to the paleolithic diet arm for another 4 months. studies of ovarian and metabolic parameters will be done at baseline, 2 and 4 months
3055681|NCT02190084|Active Comparator|transcranial magnetic stimulator|Neurostar repetitive transcranial magnetic stimulator. The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
3055682|NCT02190084|Sham Comparator|Sham coil treatment|Neurostar repetitive transcranial magnetic stimulator. 20 treatments identical in duration will be administered over a four week period.
3055683|NCT02190058|Experimental|DS-1971a|DS-1971a suspension, up to 4650mg/day
3055684|NCT02190058|Placebo Comparator|placebo|matching DS-1971a suspension
3055685|NCT02190045|Experimental|Wii-Fit program|Wii-Fit exercises will be adminstered for 45 minutes 3 days a week for 8 weeks
3055686|NCT02190045|Placebo Comparator|Cognitive remediation program|Cognitive remediation exercises will be adminstered for 45 minutes 3 days a week for 8 weeks
3055687|NCT02190032|Active Comparator|Control group|"Intubating a manufacturer-provided-angled double-lumen tube (=Conventional-angled group,MallinckrodtTM endotracheal tube, Covidien)"
3055688|NCT02190032|Experimental|Tube angle modification|The angle of the double lumen tube(MallinckrodeTM endotracheal tube) is modified individually.At sniffing position, the distal tip of the tube is placed at the patient's cricoid cartilage level and the tube is bent at the intersection point of the two airway axes (oropharyngeal axis and tracheal axis) with an angle between the two axes.
3055689|NCT02190019|Active Comparator|transcranial magnetic stimulator|Neurostar repetitive transcranial magnetic stimulator. The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 10 treatment sessions are given over a two week period.
3055690|NCT02190019|Sham Comparator|Sham coil treatment|Neurostar repetitive transcranial magnetic stimulator. 10 treatments identical in duration will be administered over a two week period.
3055691|NCT02190006||Polycystic ovarian syndrome|Women with polycystic ovarian syndrome undergoing ICSI
3055692|NCT02189993||Total Parenteral Nutrition Use|The cohort investigated consisted of patients with intestinal failure requiring total parenteral nutrition use.
3055693|NCT02189980|Placebo Comparator|Saline & nasal clip|Saline and nasal clip inhaled post-operatively
3055694|NCT02189980|Experimental|Aromatherapy blend & nasal clip|Aromatherapy blend and nasal clip inhaled post-operatively
3055695|NCT02189967|Active Comparator|conventional fractionation|radiotherapy with conventional fractionation (5 x 2Gy per week)
3055696|NCT02189967|Active Comparator|accelerated fraction|radiotherapy with accelerated fraction (7 x 2 Gy per week)
3055697|NCT02189954|Active Comparator|Group Routine Care|The placement according to the manufacturer's instructions.
3055698|NCT02189954|Experimental|Group Pressure Limiting|Cuff inner pressure was held below 44 mmHg
3055699|NCT02189941|Experimental|Deferiprone sustained-release (fed)|A single 1000 mg dose of deferiprone sustained-release following a high fat high calorie breakfast.
3055700|NCT02189941|Experimental|Deferiprone sustained-release (fasting)|A single 1000 mg dose of deferiprone sustained-release under fasting conditions.
3055701|NCT02189941|Active Comparator|Deferiprone immediate-release (fasting)|A single 1000 mg dose of Deferiprone immediate-release under fasting conditions.
3055702|NCT02189928|Experimental|With per-CID protocol|Usual care patients (thrombolysis or not ) with remote ischemic per-conditioning using an electronic tourniquet .
3055703|NCT02189928|Other|Without per-CID protocol|Usual care patients (thrombolysis or not).
3055704|NCT02189915|Experimental|Creatine monohydrate|
3055705|NCT02189902|Active Comparator|4000 IU/d of D3 by mouth for 12 weeks|4000 IU/d of D3 by mouth for 12 weeks
3055706|NCT02189902|Experimental|7000IU/d of D3 by mouth for 12 weeks|7000IU/d of D3 by mouth for 12 weeks
3055707|NCT02189889|Active Comparator|EPO and Feraheme|Patients in the treatment group will receive a subcutaneous injection of EPO 300U/kg at the Baseline visit, the Preoperative visit and on POD 2; and an infusion of Feraheme 510mg at the Baseline visit and the Preoperative visit.
3055708|NCT02189889|No Intervention|Control|The control group will receive no preoperative intervention for anemia. The exception being iron deficiency anemia found during baseline. If laboratory values indicate iron deficiency, oral iron will be recommended to take until surgery.
3055709|NCT02189876|Experimental|FemAALES|Females of African American Legacy Empowering Self Intervention. A nine session, theoretically grounded small group intervention.
3055710|NCT02189876|Active Comparator|Standard of Care|A one-time STD/family planning testing and counseling session provided to all study participants.
3055711|NCT02189863|Other|AOAMV, then AOAMF|Lotrafilcon B MV contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MF contact lenses worn for 2 weeks in Period 2
3055712|NCT02189863|Other|AOAMF, then AOAMV|Lotrafilcon B MF contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MV contact lenses worn for 2 weeks in Period 2
3055713|NCT02189850|Experimental|BLI800 - Dose 1|BLI800 oral solution
3055714|NCT02189850|Experimental|BLI800 - Dose 2|BLI800 oral solution
3055715|NCT02189837|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
3055716|NCT02189837|Active Comparator|Atorvastatin|Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
3055717|NCT02189837|Experimental|Evolocumab|Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
3055718|NCT02189837|Experimental|Evolocumab and Atorvastatin|Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
3055723|NCT02189811|Experimental|bOPV and IPV and IPV2|bOPV at birth, 6, 10 weeks and bOPV+IPV at 14 weeks and tOPV+IPV2 at 18 weeks and tOPV alone at 22 weeks of age
3055724|NCT02189811|Active Comparator|tOPV|tOPV at birth, 6, 10, 14, 18 and 22 weeks of age
3055725|NCT02189798|Experimental|Newly Implanted Group|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness. Patients retaining considerable low frequency acoustic hearing after the surgery, will be fitted with the EAS sound processor.
3055726|NCT02189798|Experimental|Existing Implanted Group|Adults unilaterally implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode with partial deafness will be fitted with the EAS sound processor.
3055727|NCT02189798|Experimental|EAS Extended Use Arm|Adults who are unilaterally implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode with partial deafness and completed the 12 Month visit using the EAS sound processor in either the Newly Implanted Group or Existing Implanted Group.
3055728|NCT02189785||Healthy Controls|
3055729|NCT02189772|Experimental|MDX (metadoxine extended release)|"Route of administration: oral~The dose of MDX (approximately 14-22 mg/kg) will be determined by the subject's weight at the baseline visit as follows:~40-49 kg 700 mg consisting of a 700 mg tablet~50-64 kg 1050 mg consisting of a 700 mg tablet, a 350 mg tablet~65-100 kg 1400 mg consisting of two 700 mg tablets"
3055730|NCT02189772|Placebo Comparator|placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
3055731|NCT02189759|Active Comparator|Continuous Kangaroo Mother Care to one hour after birth|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from birth to one hour after birth.
3055732|NCT02189759|Sham Comparator|Standard Kangaroo Mother Care to one hour after birth|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from birth to 1 hour after birth.
3055733|NCT02189759|Active Comparator|Continuous Kangaroo Mother Care to discharge|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from one hour after birth to discharge.
3055734|NCT02189759|Sham Comparator|Standard Kangaroo Mother Care to discharge|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from 1 hour after birth to discharge.
3055735|NCT02189746|Active Comparator|Continuous Kangaroo Mother Care to 1 hour after birth|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from birth to one hour after birth.
3055736|NCT02189746|Sham Comparator|Standard Kangaroo Mother Care to 1 hour after birth|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from birth to 1 hour after birth.
3055737|NCT02189746|Active Comparator|Continuous Kangaroo Mother Care to discharge|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from one hour after birth to discharge.
3055738|NCT02189746|Sham Comparator|Standard Kangaroo Mother Care to discharge|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from 1 hour after birth to discharge.
3055739|NCT02189733|Experimental|Caplacizumab - Treatment A|Single s.c. dose of reconstituted lyophilized solution of caplacizumab followed by single s.c. dose of liquid formulation of caplacizumab
3055740|NCT02189733|Experimental|Caplacizumab - Treatment B|Single s.c. dose of liquid formulation of caplacizumab followed by single s.c. dose of reconstituted lyophilized solution of caplacizumab
3055741|NCT02189707|Experimental|Probiotic Bifidobacterium 1x1010 cfu|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
3055742|NCT02189707|Experimental|Probiotic Bifidobacterium 1x109 cfu|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
3055743|NCT02189707|Placebo Comparator|Placebo powder in capsules|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
3055744|NCT02189694|Active Comparator|Insulin pump therapy|Glucose levels will be controlled for 3 consecutive nights using insulin pump therapy. Subjects will carry on with their normal conventional insulin pump therapy and will be allowed to freely implement therapeutic adjustments..
3055787|NCT02189408|Experimental|PRP|one intraoperative application of PRP in the interventional group
3055788|NCT02189408|No Intervention|Control|No application of any substance during knee arthroscopy
3055863|NCT02188966|Experimental|Geographical Information System|Availability of Geographical Information System data from ambulances destined for the Emergency Department of Regional Hospital Horsens.
3055745|NCT02189694|Active Comparator|Single-hormone closed-loop strategy|Glucose levels will be controlled by single-hormone closed-loop strategy for 3 consecutive nights. A member of the research team will be present at the diabetic camp to ensure protocol implementation and patient's safety. Glucose levels will be controlled by single-hormone closed-loop strategy between 22:00 until 7:00 next morning. Glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pump's parameters will then be changed manually to implement the computer generated recommendations.
3055746|NCT02189694|Active Comparator|Dual-hormone closed-loop strategy|Glucose levels will be controlled by dual-hormone closed-loop strategy for 3 consecutive nights. A member of the research team will be present at the diabetic camp to ensure protocol implementation and patient's safety. Glucose levels will be controlled by dual-hormone closed-loop strategy between 22:00 until 7:00 next morning. Glucose sensor readings will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses. Pumps' parameters will then be changed manually to implement the computer generated recommendations.
3055747|NCT02189681|Active Comparator|Group C|Patients in this group underwent Conventional landmark guided midline spinal anaesthesia.
3055748|NCT02189681|Experimental|Group P|This group had pre-procedure ultrasound guided L5S1 paramedian spinal anaesthesia performed
3055749|NCT02189668|Experimental|Non-operative|Non-operative management with antibiotics alone Zosyn (Piperacillin/Tazobactam) and then Augmentin unless penicillin allergic Cipro/Flagyl if penicillin allergic
3055750|NCT02189668|No Intervention|Surgery|Usual care with urgent appendectomy
3055751|NCT02189655|No Intervention|Group Control|Hyperbaric bupivacaine 0.5% 2.5 mL was administered intrathecally in 30 seconds.
3055752|NCT02189655|Experimental|Group Diluting with cerebrospinal fluid|Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
3055753|NCT02189642||Genito-Urinary/Urology Surgical Procedure Types|Pediatric patients undergoing circumcision, orchidopexy, hypospadias repair, hernia repair, cystoscopy, pyeloplasty, and ureteral reimplants or ureteral stents.
3055754|NCT02189642||Otolaryngology Surgical Procedure Types|Pediatric patients undergoing tonsil and/or adenoid removal, tympanostomy, tympanoplasty, and mastoidectomy.
3055755|NCT02189642||Orthopaedics Surgical Procedure Types|Patients undergoing hip and knee arthroscopies, hardware removal, and tendon lengthening.
3055756|NCT02189642||Plastic Surgery Surgical Procedure Type|Pediatric patients undergoing alveolar cleft repair.
3055757|NCT02189629|Experimental|CD5789 (trifarotene) cream|
3055758|NCT02189616|Other|regular care group|receive regular care which contains filling a paper asthma diary daily.
3055759|NCT02189616|Experimental|SMS reminder group|receive weekly mobile phone short message reminders for 3 months
3055760|NCT02189616|Experimental|SMS reminder and SMS consultation group|receive weekly mobile phone short message reminders and can consult asthma nurse by mobile phone short message when needed for 3 months
3055761|NCT02189603|Experimental|Senior group(over 65 years old)-HE|Anti-HEV IgG seronegative participants over 65 years old were enrolled. Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
3055762|NCT02189603|Active Comparator|Younger groups(16-65 years old)|Participants aged 16-65 years old were enrolled. Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
3055763|NCT02189603|No Intervention|Senior group(over 65 years old)-Cont|Anti-HEV IgG seropositive participants over 65 years old were enrolled. This is the safety control group, without any intervention.
3055764|NCT02189590|Experimental|air-Q|Patients will receive the air-Q with size based on manufacturer recommendations of body weight
3055765|NCT02189590|Experimental|i-gel|Patients will receive the i-gel with size based on manufacturer recommendations of body weight
3055766|NCT02189577|Experimental|CHF 5259|CHF 5259
3055767|NCT02189577|Placebo Comparator|Placebo|Placebo
3055768|NCT02189564|Active Comparator|Intrinsic reward|Feedback about good performance
3055769|NCT02189564|Experimental|Intrinsic and extrinsic reward|Feedback about good performance + money
3055770|NCT02189564|Experimental|Intrinsic reward (average performance)|Feedback about random selection of trials
3055771|NCT02189551|Active Comparator|Lokomat Pro|gait robot established on the market
3055772|NCT02189551|Experimental|Lokomat Pro FreeD|gait robot based on the Lokomat Pro with changes in guidance of the hip, approved for the Swiss market
3055773|NCT02189538|Experimental|ω-3 PUFA|Modular low fat diet (18%) including 9% as ω-3 PUFA
3055774|NCT02189538|Active Comparator|Low fat enteral diet|Modular low fat (18%)
3055775|NCT02189525||Sports induced concussion|Exposure to sports induced concussion
3055776|NCT02189525||Routine Athletic Exertion|Exposure to routine athletic exertion without sports-induced concussion (non-concussion control)
3055777|NCT02189512|Other|brain death organ donors|cases - blood sampling
3055778|NCT02189512|Other|abdominal aortic aneurysm repair|controls - blood sampling
3055779|NCT02189499|Experimental|Coronary Scaffold Implantation|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
3055780|NCT02189486||Prostate Cancer Cohort|Men with prostate cancer who have elected radical prostatectomy for their treatment of their prostate cancer within two years after prostate biopsy.
3055781|NCT02189473|Experimental|5 x 4 Gy in 1 week|radiotherapy with 5 x 4 Gy in 1 week (5 x 4 Gy per week)
3055782|NCT02189473|Active Comparator|10 x 3 Gy in 2 weeks|radiotherapy with 10 x 3 Gy in 2 weeks (5 x 3 Gy per week)
3055783|NCT02189460||Healthy adults|20 young adults aged between 30 and 50 years old. 20 middle aged adults aged between 50 and 70 years old. 20 older adults of 70 years old and more.
3055784|NCT02189447|Experimental|Refractive surgery|Patients with keratoconus treated with simultaneous photorefractive keratectomy and Corneal collagen cross-linking.
3055785|NCT02189434||Cytoreductive surgery|Patients having undergone cytoreductive surgery with or without HIPEC will have serum procalcitonin lab draws
3055786|NCT02189421|Other|Direct peroral cholangioscopy|Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
3055789|NCT02189395|Experimental|NPH and regular insuline group|For the group receiving NPH and regular 2/3 and 1/3 formula will be followed. If Nil per os (NPO), patient will receive NPH twice daily but AM dose will equal to PM dose. Regular insulin given along with NPH will be held while patient is NPO. A correctional dose of regular insulin will be given for any blood glucose >180 mg/dL. If subjects were not eating, they could also receive correctional doses of regular insulin. Correctional insulin could be given four times daily with meals or at bedtime.
3055790|NCT02189395|Active Comparator|glargine and humalog group|Half of the total insulin dose will be given as glargine once daily, either in the AM or in the PM, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as humalog; doses were divided equally between breakfast, lunch, and dinner. An additional correctional dose of humalog will be given for any blood glucose >180 mg/dL. If subjects were not eating, they received glargine once daily and could also receive correctional doses of humalog. Correctional humalog could be given four times daily with meals or at bedtime.
3055791|NCT02189382|Experimental|Potassium Oxalate Gel|Self Applied
3055792|NCT02189382|Other|Water|Self Applied
3055793|NCT02189369|Experimental|Day 3 embryo-Own-above cutoff|Day 3 embryo transfer for IVF with own oocytes, and prostaglandine levels with higher receptivty rates
3055794|NCT02189369|Experimental|Day 5 embryo-Own-above cutoff|Day 5 embryo transfer for IVF with own oocytes, and prostaglandine levels with higher receptivty rates
3055795|NCT02189369|Experimental|Day 3 embryo-Donor-above cutoff|Day 3 embryo transfer for IVF with donor oocytes, and prostaglandine levels with higher receptivty rates
3055796|NCT02189369|Experimental|Day 5 embryo-Donor- above cutoff|Day 5 embryo transfer for IVF with donor oocytes, and prostaglandine levels with higher receptivty rates
3055797|NCT02189369|Experimental|Day 3 embryo-Donor-lower cutoff|Day 3 embryo transfer for IVF with donor oocytes, and prostaglandine levels with lower receptivty rates
3055798|NCT02189369|Experimental|Day 5 embryo-Donor-lower cutoff|Day 5 embryo transfer for IVF with donor oocytes, and prostaglandine levels with lower receptivty rates
3055799|NCT02189369|Experimental|Day 3 embryo-own-lower cutoff|Day 3 embryo transfer for IVF with own oocytes, and prostaglandine levels with lower receptivty rates
3055800|NCT02189369|Experimental|Day 5 embryo-own-lower cutoff|Day 5 embryo transfer for IVF with own oocytes, and prostaglandine levels with lower receptivty rates
3055801|NCT02189356|Experimental|exercise programme|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group.
3055802|NCT02189356|Other|contol group|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group.
3055803|NCT02189343|Experimental|Dose Escalation Cohort|Dose Escalating Cohorts of ACY-1215 in combination with pomalidomide and dexamethasone.
3055804|NCT02189330|Experimental|Tafamidis|
3055805|NCT02189330|Experimental|Tafamudus Free Acid|
3055806|NCT02189330|Experimental|20 mg new soft gelatin capsule|
3055807|NCT02189330|Experimental|4 capsules of 20 mg tafamidis of commercial formulation|
3055808|NCT02189330|Experimental|4 capsules of 12.2 mg tafamidis of free acid tablet|
3055809|NCT02189317|Experimental|Exparel|This arm will receive Exparel
3055810|NCT02189317|No Intervention|Control|
3055811|NCT02189304|Experimental|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
3055812|NCT02189304|Experimental|PT009|PT009; Budesonide and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
3055813|NCT02189304|Active Comparator|Symbicort Turbohaler|Symbicort Turbohaler; Budesonide and Formoterol Fumarate Inhalation Powder taken as 2 inhalations
3055814|NCT02189291|Experimental|Immediate catheter removal|The indwelling Foley catheter will be removed prior to exiting the operating room.
3055815|NCT02189291|Active Comparator|Post op day 1 catheter removal|Patients assigned to this group will follow the standard of care at present, with removal of indwelling catheter on the morning of postoperative day 1.
3055816|NCT02189278|Experimental|Psychosocial Intervention|Telephone-based psychosocial intervention involving six telephone encounters. Each encounter focuses on teaching skills for improving adherence and overcoming barriers to obtaining recommended surveillance.
3055817|NCT02189278|No Intervention|Treatment as usual|Treatment as usual control.
3055818|NCT02189265||Full cohort|All singleton births in the Netherlands. Stillbirths are excluded from the denominator for all outcomes other than perinatal mortality, stillbirth and congenital anomalies.
3055819|NCT02189252|Active Comparator|E4:L4|Crossover Sequence
3055820|NCT02189252|Active Comparator|L4:E4|Crossover Sequence
3055821|NCT02189252|Active Comparator|E2:L4|Crossover Sequence
3055822|NCT02189252|Active Comparator|L4:E2|Crossover Sequence
3055823|NCT02189239|Active Comparator|Zeller Entspannung film coated tablets|Relaxing film coated tablets, 570 mg (Zeller Entspannung Filmtabletten), 3x1 tablet per day for the first three days (morning, midday, evening), at day four 2x1 tablet (morning, midday) preferably during meals with a glass of water.
3055824|NCT02189239|Placebo Comparator|Placebo tablets|Placebo medication is identical in presentation, color and shape, 3x1 tablet per day for the first three days (morning, midday, evening), at day four 2x1 tablet (morning, midday) during meals with a glass of water.
3055825|NCT02189239|Sham Comparator|No Treatment|No medication intake.
3055826|NCT02189226|Experimental|probe-based confocal laser endomicroscopy (pCLE) group|
3055827|NCT02189226|Active Comparator|chromoendoscopy (CE) group|
3055861|NCT02188992||Cohort 2|Patients with community acquired sepsis syndrome REQUIRING critical care admission due to severity of sepsis. These patients are recruited from the critical care areas (ICU/HDU).
3055862|NCT02188992||Cohort 3|Patients without sepsis syndrome. Age and gender matched to cohort 1, and recruited from Emergency Department.
3055998|NCT02188134||65 and older|No intervention will be administered
3055828|NCT02189213|Active Comparator|Sertraline, Fluoxetine, or Escitalopram|"Sertraline, Fluoxetine, or Escitalopram will be administered PO to treat anxiety disorders in children and adolescents. One of the following dosing schedules will be used:~Sertraline will be titrated from 25mg once a day orally up to 200mg once a day orally, for 12 weeks, or~Fluoxetine will be titrated from 10mg once a day orally up to 40mg once a day orally, for 12 weeks or~Escitalopram will be titrated from 10mg once a day orally up to 40mg once a day orally, for 12 weeks.~The titration will stop at the dose in which the participant shows a full response to the medication or experiences side effects that will inhibit titration."
3055829|NCT02189213|No Intervention|Control|There will be no intervention in this arm.
3055830|NCT02189200|Active Comparator|Oat bran group|oat bran (40g per day)
3055831|NCT02189200|Placebo Comparator|Placebo group|refined rice flour (40g per day)
3055832|NCT02189187|Experimental|Mindfulness Based Stress Reduction (MBSR) program|Mindfulness Based Stress Reduction (MBSR) is an 8-week program that consists of training in mindfulness practices, the application of mindfulness to daily life, and information about healthy living and the role played by thoughts and emotions in health.
3055833|NCT02189187|Active Comparator|Healthy Living Course (HLC)|Healthy Living Course (HLC) an 8-week psycho-educational program that consists of lectures and discussion on healthy living, stress management, time management, and unhealthy behaviors (e.g. smoking, drinking).
3055834|NCT02189174|Experimental|CLR457|
3055835|NCT02189161|Experimental|Radiofrequency Ablation|circumferential radiofrequency ablation (RFA) to the anal canal
3055836|NCT02189148||Cohort|"Each participant will :~give consent~provide a blood sample (10 ml)~be measured (weight and height for BMI calculation)~undergo a blood pressure measurement~have an ultrasound exam (uterine arteries Doppler, placental volume, thickness of the placenta)~answer to a short questionnaire (5 pages)"
3055837|NCT02189135|No Intervention|Usual care|Usual care from physician/ doctor
3055838|NCT02189135|Experimental|Telemedicine|Mobile wireless glucometer with feedback from physicians
3055839|NCT02189122|Active Comparator|Group 1:Aspirin/placebo|Group 1 will be randomized to the order in which they receive rapid-release aspirin (ASA), 81 mg), ASA 162.5 mg, and identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
3055840|NCT02189122|Active Comparator|Group 2:NHP-544C/placebo|Group 2 will be randomized to the order in which they receive NHP-544C 81 mg, NPH-544C 162.5 mg and identical-appearing placebo for five days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
3055841|NCT02189109|Experimental|Dose Escalation|NVX-108 (DDFP liquid emulsion) i.v. in conjunction with Radiation Treatment and Temozolimide. 0.05-0.35cc/kg.
3055842|NCT02189096||No change from current practice|"Phase 1 (4 months)~No change from current practice. Each Paramedic crew routinely documents patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be electronically captured. The data will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria [signs of systemic inflammation] and suspicion of infection) by the study investigators. An estimate will be made of the time of completion of the ePRF in relation to patient transport."
3055843|NCT02189096||NEWS and Sepsis Screening|"Phase 2 (4 months)~The ten crews will undertake implementation of NEWS and Sepsis Screening. Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.~If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, the patients transfer will be as per normal protocol but receiving ED staff will receive the information about NEWS score and Sepsis screening as part of a structured handover."
3055844|NCT02189096||Point of care lactate measurement|"Phase 3 ( 4 months)~The ten crews will undertake Point of Care Lactate measurement when NEWS ≥ 4 or when the patient screens positive for Sepsis. Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection).~If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge. The lactate level, along with the NEWS score and sepsis screening, will be given to the receiving ED staff as part of a structured handover."
3055845|NCT02189083|Experimental|High dose TSD|Subjects in this arm receive high dose (217 g/day) TSD for 16 weeks.
3055846|NCT02189083|Active Comparator|Low dose TSD|Subjects in this arm receive low dose (69 g/day) TSD for 16 weeks.
3055847|NCT02189070||Responders|Responding participants
3055848|NCT02189070||Non-responders|Non-responding participants
3055849|NCT02189057|Experimental|GeneSight guided treatment|GeneSight guided group will have their research psychiatrist make treatment recommendations based on AssureRx GeneSight genotyping results.
3055850|NCT02189057|Active Comparator|Treatment as usual group|Treatment as usual group will have treatment recommendations based on clinical judgment
3055851|NCT02189044|Other|exercises; muscle strength|Evaluate the effects of Pilates exercises on respiratory muscle strength in elderly women before and after eleven weeks of training
3055852|NCT02189031||Upper Extremity Amputee|Robust custom tactor to facilitate embodiment and proprioception
3055853|NCT02189031||Able Bodied|Bypass tactor
3055854|NCT02189018|Active Comparator|Control|Ad lib activity at home
3055855|NCT02189018|Experimental|Active Exercise|Active exercise on treadmill
3055856|NCT02189018|Experimental|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
3055857|NCT02189018|Experimental|Weight loss and active exercise|Weight loss plus active exercise on treadmill
3055858|NCT02189005|Experimental|PreCrea|Study dietary supplement (Precrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification program.
3055859|NCT02189005|Placebo Comparator|Placebo 600 mg capsules|Placebo was given to patients twice daily 30 mins before food for 90 days along with lifestyle modification program.
3055860|NCT02188992||Cohort 1|Patients with sepsis syndrome, without criteria for severe sepsis/septic shock. These patients are recruited from the emergency department.
3055864|NCT02188953|Experimental|ACCS100|Participants will consume 1 gram of ACCS100 at each meal (up to three times per day) for seven days. The ACCS100 will be administered by mixing a powder sachet into water.
3055865|NCT02188953|Placebo Comparator|Calcium carbonate|Participants will consume 1 gram of calcium carbonate at each meal (up to three times per day) for seven days. The calcium carbonate will be administered by mixing a powder sachet into water.
3055866|NCT02188940|Active Comparator|Exercise, dietary and behavioral therapy|The interventions of active comparator will be education program, dietary and behavioral therapy and exercise training.
3055867|NCT02188940|Sham Comparator|Dietary and behavioral therapy|The intervention in sham comparator will be education program, dietary and behavioral therapy and stretching and breathing exercise.
3055868|NCT02188927|Experimental|Implementation of ANL|"Intervention: Procedure : Implementation of routine Advanced Notification Letter included in Standard Invitation procedure~Advanced Notification Letter will be implemented in invitation procedure and send two weeks before Standard Invitation (Standard Invitation will be send six weeks before planned screening colonoscopy)"
3055869|NCT02188927|Active Comparator|No included ANL|Intervention: Behavioral : No included Advanced Notification Letter Sending Standard Invitation six weeks before planned screening colonoscopy
3055870|NCT02188914||Inhalant use disorder group|Subjects must have a diagnosis of inhalant use disorder, according to the DSM-5, who are under a treatment program for addictive disorders.
3055871|NCT02188914||Normal control group|Normal control without a history of drug abuse or dependency.
3055872|NCT02188901|Other|single arm|
3055873|NCT02188888||Tachycardic patients|Patients will receive a continuous esmolol infusion to maintain heart rate between 94 and 80 bpm. Norepinephrine will be titrated to achieve a MAP between 65 and 75 mmHg.
3055874|NCT02188875|Experimental|SMS Text Messages & Fitbit One|All study participants were provided a Fitbit One to facilitate self-monitoring of PA. Those who were randomly assigned to the intervention group were asked to indicate 3 preferred times of the day to receive text message prompts to do PA throughout the 6-week study period.
3055875|NCT02188875|Active Comparator|Fitbit One Only|An active control group was also provided the Fitbit One to facilitate self-monitoring of PA throughout the 6-week study period.
3055876|NCT02188862||Rheumatic heart disease cases|Patients with rheumatic heart disease as defined in the case criteria
3055877|NCT02188862||Population controls|Individuals from the general population divided into new controls (recruited specifically for this study) and existing controls (recruited to previous population genetics studies in the region)
3055878|NCT02188849|Experimental|Creatine|Creatine 5 g/ day
3055879|NCT02188849|Placebo Comparator|Placebo|Maltodextrin 5 g/day to be dissolved in water
3055880|NCT02188836|Experimental|Electromagnetic device|The electromagnetic stimulation was performed by using a device capable of generating an electromagnetic field around the fracture site. This was applied once a day, one hour for 8 weeks.
3055881|NCT02188836|Placebo Comparator|Placebo device|A device with the same characteristics to the real device, except for the generation of the electromagnetic stimulation. It generates sham stimulation.
3055882|NCT02188823|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate, ketogenic diet: carbohydrate intake 20-35 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.~Participants will also be taught information about exercise, sleep, mindfulness, and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
3055883|NCT02188810|Active Comparator|Group 1|Single dose of control vaccine (a single dose of 0.5 mL TIV).
3055884|NCT02188810|Experimental|Group 2|Single dose of the test article (0.25 mL TIV, which is 7.5 μg of each influenza strain with 0.5x PAL, i.e. 30 μg).
3055885|NCT02188810|Experimental|Group 3|Single dose of the test article (0.25 mL TIV, which is 7.5 μg of each influenza strain with 1x PAL, i.e. 60 μg).
3055886|NCT02188810|Experimental|Group 4|Single dose of the test article (0.25 mL of TIV which is 7.5 μg of each influenza strain with 2x PAL (i.e., 120 μg).
3055887|NCT02188810|Experimental|Group 5|Single dose of the test article (0.25 mL of TIV which is 7.5 μg of each influenza strain with 4x PAL (i.e., 240 μg).
3055888|NCT02188810|Experimental|Group 6|Single dose of the test article (0.125 mL of TIV with 4x PAL i.e., 240 μg).
3055889|NCT02188797|Experimental|Group MI risk reduction program|Participants receive four 1-hour group motivational interviewing sessions focused on reducing substance use and sexual risk behavior. They also receive an HIV information brochure and Community Resource Guide.
3055890|NCT02188797|No Intervention|Usual care control|Participant receive HIV information brochure and Community Resource Guide.
3055891|NCT02188784|Active Comparator|Polysaccharide iron complex 150 mg|oral Fe polysaccharide 150mg twice daily for 16 weeks
3055892|NCT02188784|Placebo Comparator|Placebo (for Polysaccharide Iron Complex 150 mg)|Oral placebo twice a day for 16 weeks
3055893|NCT02188771|Experimental|RegenoGel SP 2ml|"RegenoGel-SP is a new viscosupplement intended for the intra-articular treatment of OA.~Following signing the Informed Consent form (Visit 1), subjects who conform to the inclusion criteria will be evaluated for vital signs, blood hematology, chemistry, INR, aPTT and ECG, and will be subjected to a 30-40ml blood withdrawal that will be used for the production of autologous RegenoGel-SP. Subjects randomized to receive RegenoGel-SP will receive a single, intra-articular injection (Visit 2)."
3055894|NCT02188758||Adults - CFPE Treatment|Other: CF Pulmonary Exacerbation (CFPE) Treatment
3055895|NCT02188745|Experimental|Alternating Therapy|"Study will use an 8-week/16-week alternating regimen of 17B-estradiol/AI (aromatase inhibitor) therapy. Use of only one Aromatase inhibitor throughout the study is preferred.~17B-estradiol: One tablet containing 2 mg 17B-estradiol will be taken orally three times daily, for a total dose of 6 mg/day.~Letrozole: One tablet containing 2.5 mg letrozole will be taken orally once per day.~Anastrozole: One tablet containing 1 mg anastrozole will be taken orally once per day.~Exemestane: One tablet containing 25 mg exemestane will be taken orally once per day."
3055896|NCT02188732|Experimental|CBHH+AT|"Community Based Health Home + Automated Telehealth (CBHH+AT):~Community-Based Health Home (CBHH) PLUS Automated Telehealth: a wireless telehealth device programmed with psychiatric content corresponding to the primary psychiatric diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5-10 min. Branching logic tailors questions or feedback to the user's responses (e.g., if a participant endorses medication nonadherence, a question appears asking why medications were not taken). The device automatically provides specific instructions to participants demonstrating signs of high risk."
3055897|NCT02188732|Active Comparator|CBHH+SMT|"CBHH+SMT Community-Based Health Home (CBHH) PLUS Self-Management Training (SMT) of I-IMR~I-IMR integrates psychiatric illness self-management with strategies for medical illness self-management . The psychiatric component includes psychoeducation about illness and treatment, cognitive behavioral approaches to increase medication adherence, training and relapse prevention, teaching coping skills to manage persistent symptoms, and social skills training. The medical illness component consists of an individually tailored curriculum focused on managing physical illnesses using parallel skills and strategies taught for psychiatric illness self-management, as well as a nurse health care manager to facilitate coordination of necessary preventive and ongoing health care. The I-IMR curriculum consists of 10 modules delivered by an I-IMR specialist through eight months of weekly sessions customized to the specific needs and disorders of each client."
3055898|NCT02188732|Active Comparator|CBHH|Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW)
3055899|NCT02188719|Experimental|Cohort 1 - Treg-supportive IS only|3 subjects (Cohort 1a) at site 1 (UCSF) and 3 subjects (Cohort 1b) from site 2 (Mayo Rochester) will receive Treg-Supportive immunosuppression (IS) regimen and will not receive Donor-Alloantigen-Reactive T Regulatory Cells (darTregs). Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
3055900|NCT02188719|Experimental|Cohort 2 - darTreg infusion,50 million(range 25 to 60 million)|At least 3, and up to 6 subjects will receive a single infusion of 50 million darTregs. Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
3055901|NCT02188719|Experimental|Cohort 3 - darTreg infusion,200 million(range100-240 million)|At least 3, and up to 6 subjects will receive a single infusion dose of 200 million darTregs. Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
3055902|NCT02188719|Experimental|Cohort 4 - darTreg infusion,800 million(range 400-960 million)|Six subjects will receive a single infusion of 800 million darTregs.
3055903|NCT02188693||Gemcitabine, Experimental|Gemcitabine 1250 mg/m2, IV on day 1 of 21 day cycle,with a follow up for every 12 weeks until disease progression or the date of first documented death from any cause
3055904|NCT02188693||Observational|Observation for every 12 weeks until disease progression or the date of first documented death from any cause
3055905|NCT02188680|Active Comparator|Low FODMAPS diet and positive breath testing for fructose|Patients with breath testing positive have a low FODMAPS diet. The test will be considered as positive if we observe an increase of more than 20 ppm of H2 and/or CH4 on a sample with regard to the basal concentration
3055906|NCT02188680|Sham Comparator|negative breath testing for fructose|patients with negative breath test have a low FODMAPS diet
3055907|NCT02188667|Active Comparator|Providers of Novel Care|Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
3055908|NCT02188667|Sham Comparator|Providers of Usual Care|Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
3055909|NCT02188654|Experimental|Metformin|500 mg metformin
3055910|NCT02188654|Placebo Comparator|Placebo|500 mg of placebo tablets
3055911|NCT02188641|Other|Diet|Low-fat diet
3055912|NCT02188641|Other|Exercise|3-day/week exercise programme
3055913|NCT02188641|Other|Diet and exercise|healthy low fat diet and 3day/week exercise programme
3055914|NCT02188641|Other|Healthy lifestyle (Control) group|Control group was provided with health education using videotaped presentation
3055915|NCT02188628|Experimental|H-Man|H-Man is a novel, portable, inexpensive end-effector upper limb robot.
3055916|NCT02188628|Active Comparator|Additional Conventional Therapy|Repetitive goals based arm therapy
3055917|NCT02188615|Experimental|experimental group|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE
3055918|NCT02188615|Active Comparator|Radical Chemoradiotherapy|only Radical Chemoradiotherapy
3055919|NCT02188615|Active Comparator|Mckeown MIE|only Mckeown MIE
3055920|NCT02188602||High Chloride Dose|Patients receiving high dosing of chloride
3055921|NCT02188602||Low Chloride Dose|Patients receiving low dosing of chloride
3055922|NCT02188589|Other|Treatment group|Bilateral or unilateral implants
3055923|NCT02188576|Experimental|high dose TXA|"High dose TXA is the intervention.~A higher dose of tranexamic acid will be given to this arm as follows:~50 mg/kg loading dose and 5 mg/kg/h infusion"
3055924|NCT02188576|Experimental|Low Dose TXA|"Low dose TXA is the intervention.~A lower dose of TXa will be given as follows:~10 mg/kg loading dose and 5 mg/kg/h infusion"
3055925|NCT02188563|Experimental|Comprehensive intervention|New evidence-based comprehensive smoking cessation intervention including several elements that have proven successful in non-cancer patients but not used for cancer patients before.
3055926|NCT02188563|Active Comparator|Enhanced usual care|Intervention consistent with the U.S. Department of Health and Human Services guidelines for tobacco treatment.
3055999|NCT02188121|Experimental|Statin and/or Angiotensin Receptor Blocker|Simvastatin 20mg PO daily and/or Losartan 25mg PO daily
3055927|NCT02188550|Experimental|Single|This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented
3055928|NCT02188537|Experimental|Nelfinavir, Bortezomib, Dexamethasone|"The trial is designed as an add-on therapy, where nelfinavir is added to the approved bortezomib-containing therapy. Bortezomib and dexamethasone background treatment will be given in the Swissmedic-approved dose and schedule and according to international therapeutic standard."
3055929|NCT02188524|No Intervention|Control Group|No exercise program
3055930|NCT02188524|Experimental|Exercise Group|exercise program
3055931|NCT02188511|Experimental|Group A|Electronic cigarette (nicotine/placebo) - Day 8 Intervention: Electronic cigarette exposure will be limited to one day.
3055932|NCT02188511|Experimental|Group B|Electronic cigarette (nicotine/placebo) - Days 7 through 8 Electronic cigarette exposure will be limited to two days
3055933|NCT02188511|Experimental|Group C|Electronic cigarette (nicotine/placebo) - Days 6 through 8 Electronic cigarette exposure will be limited to 3 days
3055934|NCT02188511|Experimental|Group D|Electronic cigarette (nicotine/placebo) - Days 5 through 8 Electronic cigarette exposure will be limited to 4 days
3055935|NCT02188511|Experimental|Group E|Electronic cigarette (nicotine/placebo) - Days 4 through 8 Electronic cigarette exposure will be limited to 5 days.
3055936|NCT02188498||Polysomnography with Holter monitoring|Patients will undergo resting electrocardiogram (ECG) test at the beginning of the night and be monitored by a Holter device for the duration of the sleep study.
3055937|NCT02188485|Experimental|ENGAGE: a social engagement intervention|ENGAGE is a brief psychotherapy that specifically targets increased social engagement and activity. The study will use the ENGAGE manual developed by Drs. Alexopoulos, Arean and their colleagues, focusing on increased engagement in activities that allow subjects to be social (targeting thwarted belongingness) or contribute to the well-being of others (targeting perceived burdensomeness).
3055938|NCT02188485|No Intervention|Care-as-Usual|Care as usual in primary care with study assessments.
3055939|NCT02188472|Active Comparator|Penicillin V|Penicillin V 2 tablets of 330 mg twice dayly for 7 days
3055940|NCT02188472|Active Comparator|Trimethoprim|2 Tablet Trimethoprim of 100 mg twice daily for 7 days
3055941|NCT02188472|Placebo Comparator|Placebo|2 Placebo Tablets twice daily for 7 days
3055942|NCT02188459|Active Comparator|Bupropion|Bupropion 150 mg BID, PO for 10 weeks
3055943|NCT02188459|Placebo Comparator|Placebo|Placebo BID, PO for 10 weeks. The formulation appears identical to the bupropion capsules.
3055944|NCT02188446|Experimental|Smoking and alcohol cessation education|
3055945|NCT02188446|No Intervention|Standard treatment|Standard treatment is information about benefits of stopping drinking and smoking before surgery and if wanted, advice about who to contact to get support.
3055946|NCT02188433|Experimental|Cut down to quit (CDTQ)|"For those subjects who claim that they cannot quit smoking ≤7 days, they will receive a leaflet (i.e. include a roadmap of smoking reduction strategy) plus a brief intervention using the AWARD model: (a) Ask about smoking history, (b) Warn about the high risk, (c) Advise to quit as quitting can greatly reduce risks, and participants will be advised to cut down cigarette consumption at their own pace, but the process should not exceed 3 months. (d) Refer smokers to a smoking cessation clinic, and (e) Do it again: repeat the intervention and encourage smokers who fail to quit or relapse to reduce again during each telephone follow-up.~For the subjects have intention to quit smoking ≤7 days, the investigator will follow-up them after a week. For those who report quitted, they will be followed up as other participants. However, if they report failed to quit, they will receive the same interventions and will be followed-up as other participants in the experimental group."
3055947|NCT02188433|Active Comparator|Quit Immediately (QI)|QI group subjects will receive a smoking cessation booklet (provided by COSH) plus brief intervention using AWARD model similar to CDTQ group. For the subsequent telephone follow-up repeat the health warning that 'one in two smokers will be killed by smoking' and encourage smokers who fail to quit or relapse to try again.
3055948|NCT02188420|Experimental|Latency minus 3ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 3ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
3055949|NCT02188420|Experimental|Latency minus 5ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 5ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
3055950|NCT02188420|Experimental|Latency minus 7ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 7ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
3055951|NCT02188420|Active Comparator|Latency plus 100ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency + 100ms), known to have no effect, where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
3055952|NCT02188407|Experimental|Sevoflurane|Sevoflurane group (S group)- The group anaesthesied with sevoflurane
3055953|NCT02188407|Active Comparator|Propofol|Propofol 4-6 mg/kg/h iv
3055954|NCT02188394|Experimental|Anesthetic blockades with bupivacaine|Patients will receive a bilateral greater occipital nerve blockade with bupivacaine 0,5%
3055955|NCT02188394|Placebo Comparator|Isotonic saline injection|Patients will receive a bilateral occipital injection with isotonic saline
3055956|NCT02188381||Normal controls without hypertension|Control subjects will have a systolic BP <140mmHg with no cardiovascular disease. These subjects will provide a one time stool sample and a blood sample.
3055957|NCT02188381||Controlled hypertension|Subjects with controlled hypertension will provide a one time stool sample and a blood sample.
3055958|NCT02188381||Resistant hypertension|Resistant hypertension subjects will have systolic blood pressure (BP) ≥140 mmHg despite ≥3 anti-hypertensive medications of different classes. These subjects will provide a one time stool sample and a blood sample.
3055959|NCT02188381||Prior enrolled in NCT 02133872|These subject will be asked to provide two stool samples and two blood samples. One at baseline and one after 3 months of therapy.
3056280|NCT02186301|Experimental|Rociletinib Mono-Therapy|
3055960|NCT02188381||Remodeled Resistent Hypertension|Subjects with controlled hypertension will provide a one time stool sample and a blood sample.
3055961|NCT02188368|Experimental|A: POM 4mg+Steroids+(CFZ, BTZ, CY or CLA)|"POM 4 mg PO days 1-21 Steroids at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~BTZ (bortezomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~CFZ (carfilzomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~CLA (clarithromycin) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~CY (cyclophosphamide) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject)."
3055962|NCT02188368|Experimental|B: POM 3mg+PLD with or without steroids|"POM 3 mg PO days 1-21 Steroids (if the patient had received them) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~PLD at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject)."
3055963|NCT02188368|Experimental|C: POM MTD + other drugs|"Phase 1:~POM at escalating doses of 2 mg (Cycle 1), 3 mg (Cycle 2) or 4 mg (Cycle 3+) All other agents at the same dose and on the same days as the patients were receiving them in the lenalidomide-containing regimen they had failed~Phase 2:~POM at the MTD All other agents, at the same dose and on the same days as phase 1"
3055964|NCT02188342|Experimental|HIT exercise training|
3055965|NCT02188329||Households with children under 13|Interviews were conducted with the parent or guardian of a child or children under age 13.
3055966|NCT02188329||Home-based providers|Individuals who provide care in a home-based setting to children under age 13 who are not their own.
3055967|NCT02188329||Center-based providers|Directors of early care and education programs that provide care to children not yet in kindergarten.
3055968|NCT02188329||Center-based workforce|Classroom-assigned instructional staff sampled from each center-based provider who completed an interview.
3055969|NCT02188316|Active Comparator|Jumbo forceps polypectomy|89 patients were randomized to jumbo forceps arm and 120 diminutive colorectal polyps were removed by jumbo forceps polypectomy.
3055970|NCT02188316|Active Comparator|Hot biopsy electrocauterization|90 patients were randomized to hot biopsy forceps arm and 117 diminutive colorectal polyps were removed by hot biopsy electrocauterization.
3055971|NCT02188303|Experimental|LY2944876 (Single Dose)|Single escalating dose of LY2944876 administered subcutaneous (SC) on Day 1
3055972|NCT02188303|Placebo Comparator|Placebo (Single Dose)|Single dose of placebo matching LY2944876 administered SC on Day 1
3055973|NCT02188303|Experimental|LY2944876 (Multiple Dose, Cohort 4)|LY2944876 administered once daily SC on Days 1 - 7
3055974|NCT02188303|Placebo Comparator|Placebo (Multiple Dose, Cohort 4)|Placebo matching LY2944876 administered once daily SC on Days 1 - 7
3055975|NCT02188303|Experimental|LY2944876 (Multiple Dose, Cohort 5, Titrated)|LY2944876 in titrated doses administered once daily SC on Days 1, 4, 6, 8, 10 and 12
3055976|NCT02188303|Placebo Comparator|Placebo (Multiple, Cohort 5)|Placebo matching LY2944876 administered once daily SC on Days 1, 4, 6, 8, 10 and 12
3055977|NCT02188290||HAPLO group|Control group of all eligible patients who received an HSCT from a haploidentical donor without ATIR administration between 1 January 2006 and 30 June 2013
3055978|NCT02188290||MUD group|Control group of eligible patients who received an HSCT from a fully matched unrelated donor between 1 January 2010 and 31 December 2012
3055979|NCT02188290||MMUD group|Control group of eligible patients who received an HSCT from a 1-locus mismatched unrelated donor between 1 January 2010 and 31 December 2012
3055980|NCT02188290||UCB group|Control group of eligible patients who received a double umbilical cord blood transplantation between 1 January 2010 and 31 December 2012
3055981|NCT02188277|Experimental|Xeomin®|4-8 Units per kg body weight. Single injection cycle.
3055982|NCT02188277|Active Comparator|Botox®|4-6(8) Units per kg body weight. Single injection cycle.
3055983|NCT02188264|Experimental|Treatment (selumetinib and cyclosporine)|Patients receive selumetinib PO BID on day -7 of course 1 and then on days 1-28 (one dose on day 1 only). Patients also receive cyclosporine PO BID on day -3 of course 1 and then on days 1-28 (one dose on day 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3055984|NCT02188251|Experimental|Activamp|Capsules containing 225mg of Activamp (Gynostemma pentaphyllum extract), 1 capsule taken twice daily for 12 weeks
3055985|NCT02188251|Placebo Comparator|Placebo|1 capsule taken twice daily for 12 weeks
3055986|NCT02188238||Saliva Sample Collection|Collection of stimulated whole mouth saliva . Whole mouth saliva is collected through stimulation by inert gum, and collecting saliva in a sterile tube.
3055987|NCT02188225|Experimental|Acupuncture|12 sessions of acupuncture / 3 sessions weekly/ 20 minutes each session
3055988|NCT02188225|Active Comparator|fluoxetine|10 mg daily
3055989|NCT02188212|Other|NobelProcera Crown Shaded Zirconia|NobelProcera Crown Shaded Zirconia molar
3055990|NCT02188199||Knee Replacement|Patients undergoing knee replacement surgery
3055991|NCT02188199||Hip Replacement|Patients undergoing hip replacement
3055992|NCT02188186|Active Comparator|Conventional treatment|"Initial dual combination therapy with sulfonylurea and metfomin. Dose of sulfonylurea (glimepride 2-8 mg) and metfomin (500-2550 mg) can be ecalated at investigator's discreition at every visit.~Insulin therpy can be added as a rescue therapy at investigator's discreition."
3055993|NCT02188186|Experimental|Initial triple combination treatment|"Initial dual combination therapy with metformin, sitagliptin (Januvia 100 mg), and lobeglitazone (Duvie 0.5 mg).~Insulin therpy can be added as a rescue therapy at investigator's discreition."
3055994|NCT02188173||dexamethasone 700 ㎍ intravitreal implant|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
3055995|NCT02188160|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% ophthalmic suspension dosed QID for 28 days in subjects with dry eye disease
3055996|NCT02188160|Placebo Comparator|Vehicle|Vehicle (placebo) dosed QID for 28 days in subjects with dry eye disease
3055997|NCT02188147|Experimental|SWD 1000|Short Term Wearable Defibrillator
3056000|NCT02188121|No Intervention|Usual treatment|"We will compare the initial treatment intervention with usual treatment (control arm), with both arms superimposed on a system of regular monitoring base. The investigators will make no effort to alter or influence treatment or use of that treatment for subjects in the control arm. Note that our goal in the Control arm is to characterize usual treatment. We will not intervene in this care except in emergencies. Some patients who need care for metabolic syndrome may not be receiving it - just as they would if not in our trial."
3056001|NCT02188108|Experimental|Survey|Wisconsin Stone-QOL survey. Patients with kidney stones or a history thereof will complete a kidney stone-specific health-related survey at enrollment and post-enrollment at 3 months, 12 months, 24 months, and 36 months.
3056002|NCT02188095||Excia T®|
3056003|NCT02188082|Experimental|IvabRadine hemisulfate Sustained-release Tablets|5-15mg qd
3056004|NCT02188082|Placebo Comparator|placebo|5-15mg qd
3056005|NCT02188043|Other|Relay Model|AUDIT score 8+: Brief Motivational Intervention with alcohol therapist. AUDITscore16+:Brief Motivational Intervention and appointment at Alcohol Treatment Clinic
3056006|NCT02188043|No Intervention|Usual Referral Procedure|Hospital staff refer patient to Alcohol Treatment Clinic according to usual procedure
3056007|NCT02188030|Active Comparator|Group Exercise Training (GET).|Group Exercise Program. The participants allocated into the GET Group will receive a general exercise training realized in group of workers. Each training session started with a five minute swarm-up by slowly moving the neck, upper back, shoulder, arms and hands through pain-free range of motion; followed by 30 minutes of stretching and strengthening exercises for neck, upper back, shoulder, arms and hands, performed in the standing posture, sitting or lying. For resistance exercise, will be adopted 3 sets of 10 repetitions with a load of 80% of 1 repetitions maximum 12. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises.
3056008|NCT02188030|Active Comparator|Individual Exercise Training|Individual Exercise Program. The participants allocated into the IET Group will receive a individual and specific strength training with seven different exercises, based in training programme describe by Andersen et al. and Sundstrup et al . During the intervention period, the training intensity were progressively increased according to the principle of periodization and progressive overload. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises. Experienced instructors supervised every other training session.
3056009|NCT02188017|Active Comparator|80 units|80 units ACTHAR gel will be given twice a week for 22 weeks after initial loading
3056010|NCT02188017|Active Comparator|40 units|40 units of ACTHAR gel will be given twice a week for 22 weeks after loading
3056011|NCT02187991|Active Comparator|ER+/HER2- Paclitaxel Alone|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle
3056012|NCT02187991|Experimental|ER+/HER2- Paclitaxel plus Alisertib|Paclitaxel 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle; Alisertib 40 mg BID on days 1-3, 8-10, and 15-17 of a 28-day cycle
3056013|NCT02187991|Active Comparator|Triple Negative Paclitaxel Alone|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle
3056014|NCT02187991|Experimental|Triple Negative Paclitaxel plus Alisertib|Paclitaxel 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle; Alisertib 40 mg BID on days 1-3, 8-10, and 15-17 of a 28-day cycle
3056015|NCT02187978|Experimental|Early total enteral feeding (ETEF)|"Feeding will be initiated on D1 with 80ml/kg/day of expressed breast milk or LBW formula milk.~No intravenous fluid will be provided. Feeds will be advanced till 150ml/kg/day is attained."
3056016|NCT02187978|Active Comparator|Conventional enteral feeding (CEF)|"Feeding will be initiated on D1of life with 20ml/kg of expressed breast milk or LBW formula milk.~Remaining requirement as intravenous fluids. Feeds advanced by 20ml/kg/day for next 2 days and then 30ml/kg/day for the next three days until 150ml/kg/day is reached."
3056017|NCT02187952|Experimental|Behavioral feeding intervention|Behavioral feeding intervention will be conducted as usual. The intervention will not be altered for purposes of the study.
3056018|NCT02187952|No Intervention|Waitlist control|
3056019|NCT02187939|Active Comparator|Summer wellness program - nutrition & physical activity|The GROOVE condition uses conventional means to address health-related activities and content within the context of a science museum summer enrichment program. The emphasis is on nutrition, physical activity, and healthy lifestyle.
3056020|NCT02187939|Experimental|Summer program plus virtual world technology|The GROOVE+ condition enhances the conventional approach to address health-related activities and content within the context of a science museum summer enrichment program by employing technology and a 3-D virtual world as a key educational strategy. The emphasis is on nutrition, physical activity, and healthy lifestyle.
3056021|NCT02187926||Roflumilast|Roflumilast will be administered according to the prescribing information of the approved label in Greece.
3056022|NCT02187913|Experimental|Resistant starch|The test snack bar consumed has the resistant starch
3056023|NCT02187913|Experimental|Control|The control bar uses maltodextrin rather than the resistant starch.
3056024|NCT02187900|Experimental|TWH for the treatment of IgAN|Interventions :The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
3056025|NCT02187900|Active Comparator|MMF for IgAN|MMF for the treatment of IgAN for 6 months
3056026|NCT02187887|Experimental|Personalized normative feedback|Intervention participants receive feedback correcting their misperceptions of the drinking behavior and attitudes of fellow veterans
3056027|NCT02187887|No Intervention|Control|Control participants receive feedback correcting their misperceptions of the video game playing behavior and attitudes of fellow veterans
3056028|NCT02187874|Active Comparator|early umbilical cord occlusion|Cord clamping will be performed before 30 seconds after delivery, annoting the exact time of clampage and initiating reanimation and postnatal care procedures as usual. 60 second after delivery of the new born, 10 IU of Oxytocin will be administered intramuscularly.
3056052|NCT02187757|Placebo Comparator|Placebo 600 mg capsules|Placebo was given to patients twice daily 30 mins before food for 90 days along with lifestyle modification program.
3056053|NCT02187744|Experimental|PF-05280014|
3056054|NCT02187744|Active Comparator|Herceptin®|
3056055|NCT02187718|Other|SNPGA|Sentinel Node Procedure under General Anaesthesia
3056056|NCT02187718|Other|SNPLA|Sentinel Node Procedure under Local Anaesthesia
3056057|NCT02187705||Patients with normotension at baseline|
3056029|NCT02187874|Experimental|delayed umbilical cord occlusion|"One of the paediatricians will hold the newborn ( in vaginal deliveries between 20-30 cm under the mother, in C-sections between the legs of the mother) until clamping of the umbilical cord is indicated by a second paediatrician who will be controlling the time and overall state of the baby. The baby will be wrapped during this time in a thermal blanket in a flexed lateral decubitus position to minimise stress and heat loss. Time of clamping: after 30 to 60 seconds( preferably 60). If loss of the baby's wellbeing is suspected, the paediatrician will assess the newborn's heart rate , stopping the procedureif this falls under 100ppm, initiating at that moment the necessary reanimation procedures.~60 second after the delivery of the new born 10 IU of oxytocin will be administered intramuscularly."
3056030|NCT02187861|Experimental|Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)|Participants will receive venetoclax no more than 600 milligrams (mg) orally once daily continuously along with rituximab 375 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Day 1 of 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of the 28-day cycle. Safety run-in will continue until first 9 participants complete the safety observation window of 28 days. Participants will continue receiving the same treatment as decided for Arm B.
3056031|NCT02187861|Experimental|Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)|Participants will receive venetoclax 800 mg orally once daily for 1 year along with rituximab 375 mg/m^2 IV infusion on Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, 10, and 12. Each cycle will be of 28 days.
3056032|NCT02187861|Experimental|Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)|Participants will receive venetoclax at doses decided from safety run-in orally once daily continuously for 1 year along with rituximab 375 mg/m^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
3056033|NCT02187861|Active Comparator|Chemotherapy-Containing Cohort: Arm C (BR)|Participants will receive rituximab 375 mg/m^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
3056034|NCT02187848|Experimental|SAR408701 Main Dose Escalation cohort|Dose escalation administered intravenously, once every two weeks
3056035|NCT02187848|Experimental|SAR408701 Expansion cohort colorectal cancer (CRC)|Administered intravenously at the MTD, once every 2 weeks, to patients with colorectal cancer
3056036|NCT02187848|Experimental|SAR408701 Expansion cohort lung adenocarcinoma|Administered intravenously at the MTD, once every 2 weeks, to patients with carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expressing lung adenocarcinoma of at least 50% of tumor cells at or above 2+ intensity
3056037|NCT02187848|Experimental|SAR408701 Expansion cohort gastric adenocarcinoma|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5-expressing gastric adenocarcinoma
3056038|NCT02187848|Experimental|SAR408701 Loading Dose Escalation cohorts (Escalation bis)|Loading dose escalation administered intravenously at first cycle, followed by MTD, once every 2 weeks
3056039|NCT02187848|Experimental|SAR408701 Expansion Cohort Lung adenocarcinoma (Lung bis)|Administered intravenously at the MTD, once every 2 weeks, to patients with carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expressing lung adenocarcinoma of at least 1% but below 50% of tumor cells at or above 2+ intensity
3056040|NCT02187848|Experimental|SAR408701 Expansion Cohort colorectal cancer (CRC-L)|Loading dose of determined MTD-L administered intravenously at first cycle, followed by MTD, once every 2 weeks
3056041|NCT02187835||schizophrenia|patients with a diagnosis of schizohrenia
3056042|NCT02187835||control|healthy control group
3056043|NCT02187822|Experimental|Dose Escalation + Dose Expansion|"Dose Escalation followed by Dose Expansion.~Dose Escalation Phase: The maximum tolerated dose (MTD) for TPI 287 given concurrently with Fractionated Stereotactic Radiotherapy (FSRT) will be determined using the standard 3+3 study design.~Dose Expansion Phase: Participants will be treated with TPI 287 at MTD given concurrently with FSRT to further assess toxicity and tumor response."
3056044|NCT02187809|Experimental|Clobazam|A maximum of 2.0 mg/kg/day (maximum 80 mg/day) twice daily (BID); clobazam oral suspension (2.5 mg/mL) or clobazam scored tablets (10 mg), orally
3056045|NCT02187796||Normal Cognition|HIV+ individuals with no detectable neurocognitive impairment
3056046|NCT02187796||ANI (asymptomatic neurocognitive impairment)|"HIV+ individuals where impairment involves at least two cognitive domains, and results in neuropsychological testing performance at least 1 Standard Deviation (SD) below the appropriate mean age/education norm for:~Information processing speed~Sensory/motor skills~Short-term and long-term memory~Ability to learn new skills and solve problems~Attention, concentration, and distractibility~Logical and abstract reasoning functions~Ability to understand and express language~Visual-spatial organization Visual-motor coordination~Planning, synthesizing and organizing abilities"
3056047|NCT02187796||MCD (Mild Cognitive Disorder)|HIV+ individuals with cognitive impairment same as ANI but patient or caregivers report that cognitive deficit interferes with mental acuity, work efficiency, home making or social activity
3056048|NCT02187796||HAD (HIV-associated dementia)|"HIV+ individuals where impairment involves at least two cognitive domains and results in neuropsychological testing at least 2 SD below the appropriate mean age/education norm for:~Information processing speed~Short-term and long-term memory~Ability to learn new skills and solve problems~Attention, concentration, and distractibility~Logical and abstract reasoning functions~Ability to understand and express language~Visual-spatial organization Visual-motor coordination~Planning, synthesizing and organizing abilities Cognitive impairment significantly interferes with work, home life, social activities or ADL's."
3056049|NCT02187796||Healthy Controls (HIV-)|Our P300 COGNISION apparatus has been used only in subjects over the age of 60, whereas our participants in the HAND study will all be younger than 60. So, we cannot use COGNISION normative data base for comparison. We will add 10 HIV- healthy controls to our planned 40 HIV+ subjects. These HIV- participants will be age- and gender-matched to the HIV- Asymptomatic Neurocognitive Impairment (ANI) patients, and will undergo all the same assessments
3056050|NCT02187783|Experimental|LEE011|Adult patients with a diagnosis of a solid tumor or hematological malignancy that have been pre-identified as having relevant CDK4/6, cyclin D1/3, or p16 aberrations. Patients must have received at least one prior treatment for their recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options anticipated to result in a durable response.
3056051|NCT02187757|Experimental|PreLipid|Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90days along with lifestyle modification.
3056060|NCT02187692|No Intervention|TAU|Treatment as Usual (TAU) vs meta-cogntive training (MCT) condition will be contrasted. In the TAU patients attend regular day programm that includes psychoeducation, social training, vocational rehabilitation, psychotherapy. The MCT condition is an active condition that includes structuralized therapy modules twice a week for four weeks (eight modules in total). There will be no additional differences in the interventions between two groups. Participants will be randomized from patients from the same population into two conditions.
3056061|NCT02187692|Experimental|MCT|Treatment as Usual (TAU) vs meta-cogntive training (MCT) condition will be contrasted. In the TAU patients attend regular day programm that includes psychoeducation, social training, vocational rehabilitation, psychotherapy. The MCT condition is an active condition that includes structuralized therapy modules twice a week for four weeks (eight modules in total). There will be no additional differences in the interventions between two groups. Participants will be randomized from patients from the same population into two conditions.
3056062|NCT02187679|Experimental|Abobotulinum toxin A|Abobotulinum toxin A Injection
3056063|NCT02187666||Lumbar|Patients undergoing lumbar spinal surgery
3056064|NCT02187666||Cervical|Patients undergoing cervical spine surgery
3056065|NCT02187653||Lumbar|Patients undergoing lumbar surgery
3056066|NCT02187653||Cervical|Patients undergoing cervical surgery
3056067|NCT02187640|Experimental|Self-administered acupressure|A 10-day self-administered acupressure program was implemented by the participants who were adult psychiatric in-patients and randomly assigned into this treatment group. The patients would receive a 3-session training of this therapy conducted by a qualified acupressure therapist and each session lasted about an hour. They would be assessed by the trainer to ensure that they are able to identify the five acupoints and applied a constant and an appropriate pressure on each acupoint before actual implementation.
3056068|NCT02187640|Sham Comparator|Sham control group|Sham control group: Patients would receive 3-session training and be assessed by the trainer. However, they would be trained to locate five non-acupoints adjacent to the actual acupoints and with minimal pressure applied.
3056069|NCT02187627|Experimental|Part 1: Tracer Selection|Participants will receive a single dose of one tracer on one occasion and a single dose of a different tracer after 7 to 14 days and will be followed for 7 to 14 days for safety. At the end of Part 1, one tracer with the best performance will be selected for further study in Part 2.
3056070|NCT02187627|Experimental|Part 2A: Test-Retest|Participants will receive a single dose of selected tracer from Part 1 on one occasion and then same tracer will be administered after 6 weeks. Participants will be followed for 7 to 14 days after last PET tracer administration for safety.
3056071|NCT02187627|Experimental|Part 2B: Dosimetry|Participants will receive a single dose of selected tracer from Part 1 and will be followed for 7 to 14 days for evaluation of radiation dosimetry.
3056072|NCT02187614|Experimental|Diclofenac and Placebos|Participants in this group will receive a Diclofenac 75 mg intramuscular injection, and two placebo saline solutions intravenously.
3056073|NCT02187614|Active Comparator|Morphine and Placebos|Participants in this group will receive Morphine 0.1 mg/kg intravenously, along with an additional intravenous placebo and an intramuscular placebo injection.
3056074|NCT02187614|Active Comparator|Paracetamol and Placebos|participants in this group will receive intravenous Paracetamol 1 gm solution, along with an additional intravenous placebo and an intramuscular placebo injection.
3056075|NCT02187601|Experimental|CLD with MPBA and BID|Chronic Liver Disease (CLD) patients of all degrees will be offered to be tested on the MPBA (multi purpose breath analyzer) and BID (BreathID) on a walk- in basis with , proving they meet inclusion/exclusion criteria.
3056076|NCT02187601|Experimental|HV with MPBA and BID|Healthy volunteers (HV) with no known liver disease will undergo the breath test with the MPBA and the BID before and after substrate ingestion.
3056077|NCT02187588|Experimental|Eschscholtzia Californica - low dose|
3056078|NCT02187588|Experimental|Eschscholtzia Californica - high dose|
3056079|NCT02187588|Active Comparator|Ibuprofen|
3056080|NCT02187588|Placebo Comparator|Placebo|
3056081|NCT02187575|Experimental|UHAC 62 XX tablet|
3056082|NCT02187575|Active Comparator|UHAC 62 XX capsule|
3056083|NCT02187562|Experimental|Meloxicam/Aspirin|Meloxicam days 1-10 / Aspirin days 5-10
3056084|NCT02187562|Active Comparator|Aspirin|Aspirin 2 days
3056085|NCT02187549|Experimental|HYMOVIS|HYADD(TM) 4 Hydrogel Intra-Articular Injection
3056086|NCT02187549|Placebo Comparator|Placebo|Saline Intra-Articular Injection
3056087|NCT02187536|Experimental|Telmisartan combined with Simvastatin|Telmisartan once daily (day 1 to day 6) and Simvastatin given once (day 6)
3056088|NCT02187536|Active Comparator|Simvastatin and telmisartan placebo|Telmisartan placebo once daily (day 1 to day 6) and Simvastatin given once (day 6)
3056089|NCT02187523|Experimental|Telmisartan/HCTZ FDC|
3056090|NCT02187523|Active Comparator|Telmisartan and HCTZ individual tablets|
3056091|NCT02187510|Experimental|Umbilical cord milking|Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.
3056092|NCT02187510|Active Comparator|Delayed cord clamping|Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
3056093|NCT02187497|Experimental|Low dose of BIBR 277|
3056094|NCT02187497|Experimental|Medium dose of BIBR 277|
3056095|NCT02187497|Experimental|High dose of BIBR 277|
3056096|NCT02187484|Experimental|Single rising doses of BIBR 277|
3056097|NCT02187471|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule, twice daily (BID)
3056098|NCT02187471|Other|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
3056099|NCT02187471|Experimental|DS-5565 15 mg QD|Participants take one each of placebo tablet and capsule in the morning and one placebo capsule in the evening with one DS-5565 tablet once daily (QD)
3056100|NCT02187471|Experimental|DS-5565 15 mg BID|Participants take one placebo capsule with one DS-5565 tablet BID
3056281|NCT02186288||Adult ICU patients|
3084200|NCT01998620|Experimental|Ademetionine 1|Ademetionine 2000mg
3056101|NCT02187445|Experimental|Budesonide inhalation suspension|To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
3056102|NCT02187432||ADPKD|EuroCYST is and observational trail aiming to investigate disease progression across the different stages of disease and stage specific morbidity and mortality factors in a longitudinal observational multi center study and to evaluate the levels of and associations between the impacts of patients reported disease outcome (quality of life (QoL), pain, self-estimated health status, health burden).
3056103|NCT02187419|Active Comparator|5 Therapist-Delivered Hypnosis Session|Participants will complete five therapist-delivered hypnosis relaxation sessions with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
3056104|NCT02187419|Active Comparator|3 Therapist-Delivered Hypnosis Session|Participants will complete three therapist-delivered hypnosis relaxation sessions with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
3056105|NCT02187419|Active Comparator|5 Phone Calls; Hypnosis Recordings Only|Participants will complete five phone calls with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
3056106|NCT02187419|Active Comparator|3 Phone Calls; Hypnosis Recordings Only|Participants will complete three phone calls with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
3056107|NCT02187406|No Intervention|Control|
3056108|NCT02187406|Experimental|Traditional ankle athletic taping|Described by Purcell and Schuckman (2009)
3056109|NCT02187406|Experimental|modified ankle athletic taping|Described by Montag and Asmussen (1992)
3056110|NCT02187380||Control group|Pharmacists received no depression training, delivered usual care to patients starting a new treatment with depression.
3056111|NCT02187380||Intervention group|Pharmacists received a depression training day and provided structured medication counselling to patients starting a new treatment with antidepressants
3056112|NCT02187367|Experimental|EGF Vaccine|Patients in this arm will receive a low dose of cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51
3056113|NCT02187367|No Intervention|Best Supportive Care|Patients in this arm will receive best supportive care
3056114|NCT02187341|Experimental|5-HTP|200 mg 5-HTP capsule will be ingested 2h prior to reporting to the laboratory.
3056115|NCT02187341|Placebo Comparator|Placebo|For these visit subjects will ingest placebo (Sugar pill) capsule 2 hours before reporting to the laboratory.
3056116|NCT02187328|Experimental|Grapefruit juice|12.5 OZ Grapefruit juice: Subject will ingest grapefruit juice 12.5 OZ twice on the day of their scheduled laboratory visit. Once in the morning and once in the afternoon prior to their evening visit
3056117|NCT02187328|Placebo Comparator|Apple juice|10.5 OZ Apple juice: Subject will ingest apple juice 10.5 OZ twice on the day of their scheduled laboratory visit. Once in the morning and once in the afternoon 3 hours prior to their evening visit.
3056118|NCT02187315|Experimental|Melodie group|Induction chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy
3056119|NCT02187315|Other|Routine-chemotherapy group|Induction chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
3056120|NCT02187302|Experimental|CRLX101 + bevacizumab|"CRLX101 in combination with bevacizumab:~CRLX101 15 mg/m^2 IV on days 1 and 15 of a 28-day cycle;~bevacizumab 10 mg/kg IV on days 1 and 15 of a 28-day cycle."
3056121|NCT02187302|Active Comparator|Standard of Care|Standard of care treatment include one of the following agents to which the patient can have no prior exposure: sorafenib; everolimus; pazopanib; axitinib; bevacizumab; sunitinib, or other approved drug considered by the Medical Monitor to represent an acceptable standard of care therapy
3056122|NCT02187289|Active Comparator|Standard care|Weeks 1-12, Standard Care only (Compression Sleeve, daytime wear)
3056123|NCT02187289|Experimental|Standard Care plus Night-time Compression Bandages|Weeks 1 - 12, Daytime compression sleeve plus night-time compression by self-administered or assisted multi-layered Compression Bandages.
3056124|NCT02187289|Experimental|Standard Care Plus Night-time Compression System Garment|Weeks 1 - 12, Standard care (day-time sleeve) plus night-time use of a custom-made Night-time Compression System Garment
3056125|NCT02187276||Alzheimer disease or mixed dementia|Patients were evaluated four times. In the first consultation, without taking cholinesterase inhibitors (ChEI), after three, six and 12 months taking ChEI.
3056126|NCT02187263||hereditary DCM|
3056127|NCT02187263||inflammatory DCM|
3056128|NCT02187263||LVNC|
3056129|NCT02187263||HCM|
3056130|NCT02187263||ARVC|
3056131|NCT02187263||acute myocarditis|
3056132|NCT02187250|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 2x1000 mg BID per os.
3056133|NCT02187250|Active Comparator|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 0,6mg sc once per day for one week and increased to 1,2mg sc one per day.
3056134|NCT02187250|Active Comparator|roflumilast|In the roflumilast group roflumilast was initiated at a dose of 500 mg BID per os.
3056135|NCT02187237|Experimental|Laser therapy|
3056136|NCT02187224|Experimental|Progesterone|For the three days prior to each test day every participant in this arm will receive progesterone.
3056137|NCT02187224|Placebo Comparator|Placebo|For the three days prior to each test day every participant in this arm will receive placebo.
3056138|NCT02187211|Experimental|Minocycline Low Dose|Participants in this arm will receive a low dose (200mg/day) of Minocycline for 10 days
3056139|NCT02187211|Experimental|Minocycline High Dose|Participants in this arm will receive a high dose (400mg/day) of Minocycline for 10 days
3056140|NCT02187211|Placebo Comparator|Placebo|Participants in this arm will receive the Placebo for 10 days
3056141|NCT02187198|Experimental|Buprenorphine low dose|Participants in this arm will receive a low dose (less than or equal to 8/2mg) of buprenorphine for 12 weeks.
3056142|NCT02187198|Experimental|Buprenorphine high dose|Participants in this arm will receive a high dose (16-24mg) of buprenorphine for 12 weeks.
3056143|NCT02187185|Active Comparator|Sonicare Elite-Flexcare|Arm 1 participants will abstain from brushing and flossing teeth in selected sites which will typically be one maxillary and mandibular posterior sextant during a three week, no-hygiene phase via placement of acrylic stents. After the stent-induced biofilm overgrowth (SIBO) induction, the resolution phase of the study will involve a randomization that places half of the subjects on the Sonicare/Elite/Flexcare toothbrush. Thus, the resolution phase is a RCT designed to treat SIBO in subjects with varying levels of disease. Participants will reinstate normal full mouth oral hygiene and daily plaque control, exclusive of flossing, with dispensed dentifrice and toothbrush. Participants will be followed for four weeks during SIBO resolution.
3056144|NCT02187185|Active Comparator|Manual Toothbrush|Arm 2 participants will abstain from brushing and flossing teeth in selected sites which will typically be one maxillary and mandibular posterior sextant during a three week, no-hygiene phase via placement of acrylic stents. After the stent-induced biofilm overgrowth (SIBO) induction, the resolution phase of the study will involve a randomization that places half of the subjects on the manual toothbrush. Thus, the resolution phase is a RCT designed to treat SIBO in subjects with varying levels of disease. Participants will reinstate normal full mouth oral hygiene and daily plaque control, exclusive of flossing, with dispensed dentifrice and toothbrush. Participants will be followed for four weeks during SIBO resolution.
3056145|NCT02187172|Active Comparator|Ustekinumab (Stelara)|Ustekinumab (Stelara) subcutaneous injection 45mg (if person's weight is 100kg or less) or 90mg (if person's weight is greater than 100kg) at day 0 and week 4 followed by every 12-week dosing thereafter.
3056146|NCT02187172|Placebo Comparator|Placebo|Placebo subcutaneous injection will be given according to the same dose and schedule as the active comparator.
3056147|NCT02187159|Experimental|DS-5565 QD|Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening
3056148|NCT02187159|Experimental|DS-5565 BID|Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)
3056149|NCT02187159|Active Comparator|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
3056150|NCT02187159|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule BID
3056151|NCT02187146||ART population|Patients undergoing IVF/ICSI/FET treatment at the Birmingham Womens Fertility Centre 2013-2014
3056152|NCT02187133|Experimental|Treatment|Patients receive carfilzomib IV over 30 minutes twice weekly on days 1, 2, 8, 9, 15, and 16 or weekly on days 2, 9, and 16; bendamustine hydrochloride IV over 60 minutes on days 1 and 2; and rituximab IV over 30-90 minutes on day 9 (course 1 only) and day 1 (subsequent courses). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3056153|NCT02187120|Experimental|Tranexamic Acid|"As soon as possible after injury, emergency medical services clinicians will administer 1g Tranexamic Acid (10ml ampoule containing 100mg/ml Tranexamic Acid in water for injection) delivered intravenously using a slow push of the syringe.~As soon as possible after the patient arrives at hospital, clinicians will administer 1g Tranexamic acid (10ml ampoule containing 100mg/ml Tranexamic Acid in water for injection) added to up to one litre 0.9%w/v Sodium Chloride and the entire volume infused intravenously over 8 hours."
3056154|NCT02187120|Placebo Comparator|Placebo|"As soon as possible after injury, emergency medical services clinicians will administer a 10ml ampoule containing 0.9%w/v Sodium Chloride via intravenous injection using a slow push of the syringe (ampoules containing Sodium Chloride appear identical to the ampoules containing Tranexamic Acid).~As soon as possible after the patient arrives at hospital, clinicians will administer a second 10 ml ampoule containing 0.9%w/v Sodium Chloride added to up to one litre 0.9%w/v Sodium Chloride and the entire volume infused intravenously over 8 hours."
3056155|NCT02187107|Experimental|TMC114 + rtv|Every participant recieves 2 tablets of TMC114, 300 mg, combined with one tablet of rtv (ritonavir), 100mg, orally twice daily, every 12 hours
3056156|NCT02187094|Placebo Comparator|Placebo|One capsule of placebo administered as a single dose.
3056157|NCT02187094|Experimental|2 mg TC-6499|One capsule of 2 mg TC-6499 administered as a single dose.
3056158|NCT02187094|Experimental|5 mg TC-6499|One capsule of 5 mg TC-6499 administered as a single dose.
3056159|NCT02187094|Experimental|10 mg TC-6499|One capsule of 10 mg TC-6499 administered as a single dose.
3056160|NCT02187081|Experimental|Sorafenib+RFA|We give radiofrequency ablation plus Sorafenib for the treatment of HCC
3056161|NCT02187081|Active Comparator|RFA alone|We give Radiofrequency ablation alone for the treatment of HCC
3056162|NCT02187068|Experimental|Dexmedetomidine obese 1|10 obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.25 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
3056163|NCT02187068|Experimental|Dexmedetomidine obese 2|10 obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.5 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
3056164|NCT02187068|Experimental|Dexmedetomidine non-obese 1|10 non-obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.25 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
3056165|NCT02187068|Experimental|Dexmedetomidine non obese 2|10 non-obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.5 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
3056166|NCT02187055|Experimental|Tofacitinib 5 mg twice daily with methotrexate|
3056167|NCT02187055|Experimental|Tofacitinib 5 mg twice daily monotherapy|
3056168|NCT02187055|Active Comparator|Adalimumab with methotrexate|
3084201|NCT01998620|Experimental|Ademetionine 2|Ademetionine 1000mg
3056169|NCT02187042||Best supportive care|Metastatic and/or advanced renal cell carcinoma patients treated with sunitinib in first line and followed by standard care
3056170|NCT02187042||Experimental arm|Metastatic and/or advanced renal cell carcinoma patients treated with sunitinib in first line and followed by standard care plus call center
3056171|NCT02187029|Experimental|PF-06743649 dose level 1 (Cohort 1)|
3056172|NCT02187029|Placebo Comparator|Placebo for PF-06743649 (Cohort 1)|
3056173|NCT02187029|Experimental|PF-06743649 dose level 2 (Cohort 2)|
3056174|NCT02187029|Placebo Comparator|Placebo for PF-06743649 (Cohort 2)|
3056175|NCT02187016|Experimental|AirFloss + BreathRx|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with BreathRx rinse once a day.
3056176|NCT02187016|Experimental|AirFloss + Listerine|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with Listerine Cool Mint rinse once a day.
3056177|NCT02187016|Experimental|Dental Floss|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device once a day.
3056178|NCT02187016|Active Comparator|Manual Toothbrush|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute
3056179|NCT02187003|Experimental|Rivipansel Treatment Arm|
3056180|NCT02187003|Placebo Comparator|Placebo Treatment Arm|
3056181|NCT02186990|Active Comparator|propofol|
3056182|NCT02186990|Active Comparator|etomidate|
3056183|NCT02186990|Active Comparator|propofol-etomidate|
3056184|NCT02186977|Active Comparator|Intramuscular group|These subjects will receive one intramuscular injection of 1.0cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur-MSD) with syringe and needle in the deltoid region.
3056185|NCT02186977|Experimental|Intradermal group (Mantoux)|These subjects will receive one intradermal injection with mantoux technique in the forearm. 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur-MSD) will be injected.
3056186|NCT02186977|Experimental|Intradermal group (VAX-ID) A|These subjects will receive one intradermal injection with the newly developed intradermal injection device VAX-ID in the forearm. 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) will be injected.
3056187|NCT02186977|Experimental|Intradermal group (VAX-ID) B|These subjects will receive two intradermal injections with two newly developed intradermal injection devices VAX-ID in both forearms each 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) will be injected.
3056188|NCT02186964|Experimental|tension free primary closure|patients treated by tension free primary closure
3056189|NCT02186964|Experimental|karydakis|patients treated by Karydakis method
3056190|NCT02186964|Experimental|Limberg flap|patients treated by Limberg flap procedure
3056191|NCT02186951|Experimental|Amoxicillin clavulanic acid|Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
3056192|NCT02186951|Placebo Comparator|Placebo|Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
3056193|NCT02186938|No Intervention|Usual Care|Arterial line (radial, femoral, dorsalis pedis, or brachial), central line for access when needed, intubation vs tracheostomy, general anesthesia. We currently use stroke-volume variability monitoring (FloTrac) in all patients using the arterial line placed for blood pressure monitoring.
3056194|NCT02186938|Experimental|Treatment|The study will use a treatment algorithm for patients in the treatment group. This algorithm will aim to maintain a near-normal blood pressure and use goal directed therapy to achieve this. Currently the standard of care is to use IV fluid exclusively in these patients and anesthesia providers everywhere have been challenging that treatment plan. Our algorithm has an iterative approach assessing volume status, cardiac output and vascular tone in order, with interventions specified for each. Individual treatments have been proven safe and effective in this population, we believe this sequence may be the best current management system. By avoiding excessive fluid administration we expect to decrease ICU length of stay due to the comorbidities caused (pulmonary edema, bowl edema, glycocalyx damage).
3056195|NCT02186925||Bladder, Kidney and Prostate Cancer Patients|
3056196|NCT02186912|Experimental|mandible|Nobel Active Nobel Procera IBO
3056197|NCT02186912|Experimental|maxilla|Nobel Active Nobel Procera IBO
3056198|NCT02186899|Active Comparator|General Anesthesia Femoral continuous|General anesthesia plus continuous femoral nerve block
3056199|NCT02186899|Active Comparator|General anesthesia Femoral bolus|General anesthesia plus single shot femoral nerve block
3056200|NCT02186899|Active Comparator|Femoral Sciatic Obturator Nerve block|Ultrasound guided femoral plus sciatic plus obturator nerve block
3056201|NCT02186886|Other|Golimumab|Golimumab: Patients with body weight less than 80 kg initial dose of 200 mg, followed by 100 mg at week 2, then 50 mg every 4 weeks, thereafter // Patients with body weight greater than or equal to 80 kg initial dose of 200 mg, followed by 100 mg at week 2, then 100 mg every 4 weeks, thereafter
3056202|NCT02186873|Experimental|Treatment Group 1: Placebo then Golimumab|Participants will receive intravenous infusions of placebo at Weeks 0, 4 and 12. At Week 16, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Weeks 16, 20 and thereafter every 8 weeks up to Week 52.
3056203|NCT02186873|Experimental|Treatment Group 2: Golimumab|Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 16, participants will receive a placebo infusion to maintain the blind.
3056204|NCT02186860|Experimental|Third generation CAR-T cells|Patients receive third generation CAR-T cells transduced with a lentiviral vector on days 0, 2, 4 and 6 in the absence of disease progression or unacceptable toxicity Intervention: Genetic: CAR-T Cells
3056205|NCT02186847|Active Comparator|Arm I (chemoradiotherapy)|Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36 and undergo radiation therapy (3D-CRT or IMRT) QD 5 days a week for 6 weeks. Beginning 28-42 days after completion of radiation therapy, patients receive consolidation chemotherapy comprising paclitaxel IV and carboplatin IV on days 1 and 22. Treatment with consolidation chemotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
3056342|NCT02185898|Active Comparator|Leading U.S. tobacco-burning menthol cigarette|Leading U.S. menthol cigarette
3056206|NCT02186847|Experimental|Arm II (chemoradiotherapy, metformin hydrochloride)|Patients receive metformin hydrochloride PO BID or TID for 14 days. Beginning on day 15, patients undergo radiation therapy and receive paclitaxel and carboplatin as in Arm I and receive metformin hydrochloride BID or TID for 6 weeks. Beginning 28-42 days after completion of radiation therapy, patients receive consolidation chemotherapy as in Arm I and metformin hydrochloride PO BID or TID for 10 weeks.
3056207|NCT02186834|Experimental|Selinexor, Liposomal Doxorubicin and Dexamethasone|Combination Therapy: Phase I Dose Escalation followed by Phase 2 treatment at Recommended Phase 2 Dose (RP2D)
3056208|NCT02186821|Experimental|Ceritinib (LDK378)|Ceritinib will be dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
3056209|NCT02186808|Other|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
3056210|NCT02186795||Lumbar plexus|Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management with one to four multimodal oral pain medications (acetaminophen, celecoxib, oxycodone ER, gabapentin, pregabalin) administered preoperatively or in the first 48 hours postoperatively.
3056211|NCT02186795||Lumbar Epidural|Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.
3056212|NCT02186782|Active Comparator|Clomiphene citrate-Estradiol group|Women will receive clomiphene citrate and estradiol
3056213|NCT02186782|Active Comparator|Clomiphene citrate group|Women will receive clomiphene citrate and placebo
3056214|NCT02186769|Active Comparator|Risperdal® Consta®|25 Mg or 50 mg
3056215|NCT02186769|Experimental|L03004|25 mg or 50 mg
3056216|NCT02186756|Experimental|EMG-Biofeedback and Usual Care|"Patients in the intervention group started EMG-biofeedback training within three days after inclusion. In total 14 sessions of EMG-biofeedback training were applied. They started with three sessions of therapy in week 1-3 and had one session per week in week 4-8.~Patients were encouraged to do a home exercise program, in which they consciously relaxed the muscle analogously to the biofeedback session for about 15 minutes per day. Additionally, they should try to apply the techniques in stressful situations, for example appointments at the dentist's."
3056217|NCT02186756|No Intervention|Usual care|The patients in the control group had only two encounters with the therapist in the eight week interval. At these encounters pain was assessed by a visual analogue scale and their trapezius muscle activity was measured during 5 minutes analogously to the intervention group. However, afterwards they did not continue with muscle straining and relaxation.
3056218|NCT02186743|Experimental|Intervention Diet|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
3056219|NCT02186743|Active Comparator|Active control diet|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
3056220|NCT02186730|Experimental|Stressbsuters|"Computerised Cognitive Behaviour package consisting of eight 30-45 minute sessions of CBT designed for 12-18 year olds. Each Stressbusters session is an interactive presentation featuring narration synchronised with videos, animations, graphics and printouts.~The programme has a narrator guiding individuals through each of the eight sessions in a linear progression. Each session builds on the knowledge gained in previous sessions and on tasks carried out at home. Sessions contain flexible add-ons such as written fact sheets (for example about bullying, sleep problems) which can be printed out and taken away together with home practice related handouts from the programme (for example mood diary sheets). Session topics include getting activated, relapse prevention, challenging negative thoughts and problem solving"
3056221|NCT02186730|Active Comparator|Websites|Any individuals randomised to arm 2 of the trial will spend the equivalent time accessing currently available self help websites that provide information about low mood/depression. These four websites will be the same as those used in our initial feasibility study of which, based on our preliminary data, there is evidence for their usefulness.
3056222|NCT02186717|Experimental|Chewing gum|Chewing gum
3056223|NCT02186717|No Intervention|No Chewing Gum|No Chewing Gum
3056224|NCT02186704||ICD with DX system|Implantable cardioverter-defibrillator recipients with DX system
3056225|NCT02186704||Dual chamber ICD|Dual chamber implantable-cardioverter-defibrillator recipients (retrospective cohort from IMPACT study)
3056226|NCT02186704||Single chamber ICD|Single chamber implantable cardioverter-defibrillator recipients (retrospective cohort from Cornell registry)
3056227|NCT02186691|Experimental|RV and LV ejection fraction assesment|assesment RV and LV ejection fraction after PVR measured by MRI
3056228|NCT02186678|Experimental|assesment by 68Ga-DOTATATE PET-CT|
3056229|NCT02186665|Experimental|calcitriol ointment|calcitriol 3 mcg/g ointment
3056230|NCT02186665|Placebo Comparator|placebo|placebo comparator
3056231|NCT02186652|Other|Pantoprazole|
3056232|NCT02186639||COPD|40 COPD patients (20 non-frequent and 20 frequent-exacerbators). No intervention.
3056233|NCT02186639||Controls|"Subjects with no apparent lung disease and normal lung function testing. Matched for age, gender and smoking history (pack years).~No intervention."
3056234|NCT02186626|Experimental|WN/DEN4Δ30 Vaccine|Participants will receive one dose of the WN/DEN4Δ30 vaccine at study entry and one dose at Day 180.
3056235|NCT02186626|Placebo Comparator|Placebo|Participants will receive one dose of the placebo at study entry and one dose at Day 180.
3056236|NCT02186613|Experimental|Experimental|These mothers and their babies will receive Primary Care standard care (office visits at 1, 2, 4 and 6 months) plus the telephone support
3056237|NCT02186613|No Intervention|No intervention|Standard care (office visits at 1, 2, 4 and 6 months)
3056343|NCT02185898|Experimental|Electronic cigarette #1|VUSE® (menthol flavor, 29 mg nicotine)
3056344|NCT02185898|Experimental|Electronic cigarette #2|VUSE® (original flavor, 29 mg nicotine)
3056345|NCT02185898|Experimental|Electronic cigarette #3|VUSE® (original flavor, 14 mg nicotine)
3056238|NCT02186600|Active Comparator|Control|Women randomized to the control group will receive calcium and vitamin D intake for 12 months. Calcium intake will be determined by analyzing 3 day dietary intake of calcium at baseline and then prescribing calcium carbonate supplements to ensure women have ~1200 mg of calcium daily. Vitamin D intake will be determined using baseline measures of Serum 25 (OH) D. Subjects who have serum D levels of 30 ng/ml or greater will be prescribed 1,000 IU vitamin D3 daily; subjects with levels of 20-29 ng/ml will be prescribed 2,000 IU Vitamin D3; and subjects with levels of 10-19 ng/ml will be prescribed 3,000 IU Vitamin D3.
3056239|NCT02186600|Experimental|Risedronate|"Subjects in the risedronate group will take 35 mg of the bisphosphonate risedronate weekly for 12 months plus CaD. They will be asked to follow the protocol for administration of risedronate including taking the medication upon arising in the morning with an 8 ounce glass of water, remaining upright for at least 30 minutes, and having no oral intake except water for at least 30 minutes."
3056240|NCT02186600|Experimental|Exercise|Subjects in the exercise group will participate in bone-loading exercises three times weekly in addition to taking CaD for 12 months. Women will exercise at community Young Men's Christian Association's fitness centers (YMCA) and exercises will be monitored by on-site Exercise Trainers. Exercises will consist of high-impact weight-bearing exercises (jogging with weighted vests) and resistance exercises for upper and lower extremities. Progressive increases in weight loads will be prescribed to provide maximal strength gains.
3056241|NCT02186587|Other|ConforMIS|Subjects who receive a ConforMIS custom total knee implant.
3056242|NCT02186574|Active Comparator|Pre-emptive tenofovir|Tenofovir disoproxil
3056243|NCT02186574|Placebo Comparator|Placebo|Placebo
3056244|NCT02186561|Experimental|Pipeline™ Embolization Device|treatment with Pipeline™ Embolization Device
3056245|NCT02186548|Active Comparator|Closed surgical technique|After randomization, the PDC:s randomized to this arm, are to undergo closed surgical exposure, which is an intervention to correct the position of PDC:s.
3056246|NCT02186548|Active Comparator|Open surgical technique|After randomization, the PDC:s randomized to this arm, are to undergo open surgical exposure, which is an intervention to correct the position of PDC:s.
3056247|NCT02186535|Other|Daily dosing|Daily oral capsule of Vitamin D in 4000 IU/day with daily oral capsules of 1000mg of calcium
3056248|NCT02186535|Other|weekly dosing|Oral capsule Vitamin D 50,000 IU/week with a oral capsule of 1000mg of calcium, daily
3056249|NCT02186522||Critical Care Patients|Patients staying in the ICU for at least 48 hours, requiring external support of one or more organs (invasive ventilation, inotropes/vasopressors or renal replacement therapy) and who are not expected to die within 48 hours of study entry.
3056250|NCT02186509|Experimental|Alisertib, fractionated stereotactic radiosurgery|"CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.~MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity."
3056251|NCT02186496|Experimental|Candesartan and Amlodipine|Candesartan 8mg and Amlodipine 5mg, PO, 1days or 22days
3056252|NCT02186496|Experimental|CKD-330|CKD-330 8/5mg, PO, 1days or 22days
3056253|NCT02186483|Experimental|Metformin|Metformin and Rosuvastatin: Volunteers will be taken Metformin-Rosuvastatin-Co-administration
3056254|NCT02186483|Experimental|Rosuvastatin|Metformin and Rosuvastatin: Volunteers will be taken Rosuvastatin-Co-administration-Metformin
3056255|NCT02186483|Experimental|Co-administration|Metformin and Rosuvastatin: Volunteers will be taken Co-administration-Metformin-Rosuvastatin
3056256|NCT02186470|Experimental|Treatment (image-guided intensity-modulated APBI)|Patients undergo image-guided intensity-modulated APBI twice daily (BID) in the prone position over a period of 5-10 days for a total of 10 treatment. Within 4-6 weeks post-APBI, patients undergo lumpectomy.
3056257|NCT02186457|Experimental|Polymyxin B in Normal Saline|Polymyxin B (500,000 U) in 1 liter of 0.9% Normal Saline
3056258|NCT02186457|Placebo Comparator|Placebo: Normal Saline|0.9 % Normal Saline
3056259|NCT02186444||PHI Navigator|Personalized Health Information Navigator (PHIN).
3056260|NCT02186444||NCI Information Booklets (IB)|National Cancer Institute (NCI) Information Booklets (IB).
3056261|NCT02186431|Experimental|history of corneal infiltrative events|To quantify and compare baseline tear proteins and ocular response in contact lens wearers with a history of corneal infiltrative events
3056262|NCT02186431|Active Comparator|without a history of corneal infiltrative events|To quantify and compare baseline tear proteins and ocular response in contact lens wearers without a history of corneal infiltrative events.
3056263|NCT02186418|Experimental|Gene transfer|gene transfer - getting the body to make red blood cells that don't sickle in patients with sickle cell disease.
3056264|NCT02186405|Experimental|LEVOTHYROXINE|administration of levothyroxine
3056265|NCT02186392|No Intervention|Control department|The control department where the conventional light is installed.
3056266|NCT02186392|Experimental|Circadian Light luminaries|The department where the special circadian light is installed. The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
3056267|NCT02186379|Experimental|RePace Intervention Group|"Re-Pace intervention-five weekly intervention sessions lasting about 1 hour each.~Lab Test Meal-2 test meals 6-8 weeks apart."
3056268|NCT02186379|Active Comparator|Usual Care Control Group|One 25 minute education session (week 6) 2 lab test meals 6-8 weeks apart (baseline and week 6)
3056269|NCT02186366|Experimental|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks
3056270|NCT02186366|Active Comparator|Buspirone|Buspirone by mouth 5mg three times per day for 6week
3056271|NCT02186353|Experimental|Intact/minimally processed whole grains|Partial feeding study
3056272|NCT02186353|Experimental|Highly processed whole grains|Partial feeding study
3056273|NCT02186353|Active Comparator|Refined grains|Partial feeding study
3056274|NCT02186340|Experimental|Inspiratory muscle training|
3056275|NCT02186327|No Intervention|Standard care|The control arm will continue to receive standard care as they did prior to enrollment.
3056276|NCT02186327|Experimental|Integrative health coaching|Subjects in this arm will receive 6 sessions of integrative health coaching over a 3 month period, in addition to standard care.
3056282|NCT02186275|Experimental|Vitamin D3 3000 or 4000 UI/day then 2,000 UI/day|"3000 UI or 4,000 UI/day as induction therapy (according to weight) for 4 weeks then 2,000 UIday as maintenance therapy for 48 weeks.~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA))."
3056283|NCT02186275|Active Comparator|Vitamin D3 800 UI/day then 800 UI/day|800 UI/day as induction therapy for 4 weeks, then 800 UI/day as maintenance therapy for 48 weeks. The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA)).
3056284|NCT02186262||Primary gliomas, Recurrent gliomas|
3056285|NCT02186236||Lung and Colorectal cancer patients|Eligible people who consent to participation will provide urine (both in lung cancer and colorectal cancer) and blood (in lung cancer only) samples at pre-specified times.
3056286|NCT02186223|Experimental|The Angel® Catheter|All eligible subjects will receive an Angel® Catheter.
3056287|NCT02186210|Experimental|prewarming|prewarming during induction of anesthesia
3056288|NCT02186210|No Intervention|control|no prewarming during induction of anesthesia
3056289|NCT02186197||Shock and/or Respiratory Failure|
3056290|NCT02186184|Experimental|Orthokeratology in the first year|The participants would wear orthokeratology in the first year and then switch to spectacle in the second year
3056291|NCT02186184|Active Comparator|Spectacle in the first year|The participants would wear spectacle in the first year and then changed to orthokeratology in the second year
3056292|NCT02186171|Active Comparator|AMG 785|Arm is to receive monthly SC injections of AMG 785.
3056293|NCT02186171|Placebo Comparator|Placebo|Arm is to receive monthly SC injections of placebo.
3056294|NCT02186158|Experimental|Vitamin C|Each patient of this group will be received a direct intravenous injection of 2,5 ml ascorbic acid twice a day (at the morning and the lunchtime) from d1 to d2 included. From d3 to d7 included, ascorbic acid's capsules produced by the University Hospital Bordeaux's central pharmacy to keep the double blind way of this study will be given at patient at the morning and at the lunchtime.
3056295|NCT02186158|Placebo Comparator|Placebo|Each patient of this group will be received a direct intravenous injection of 2,5 ml NaCl 9% twice a day (at the morning and the lunchtime) from d1 to d2 included. From d3 to d7 included, mannitol's capsules produced by the University Hospital Bordeaux's central pharmacy will be given at patient at the morning and at the lunchtime.
3056296|NCT02186145|Experimental|Association of metronidazole; nystatin and dexamethasone|Intravaginal cream containing metronidazole (500 mg), nystatin ( 100.000 UI) and dexamethasone (0,32 mg) once a day. Period: 10 days.
3056297|NCT02186145|Active Comparator|Flagyl|Vaginal cream of metronidazole 500 mg, nystatin 100.000 UI - once a day. Period: 10 days
3056298|NCT02186132|Experimental|Atropine 0.6 mg|Atropine 0.6 mg intravenous
3056299|NCT02186132|Active Comparator|Atropine 1.2 mg intravenous|Atropine 1.2 mg intravenous
3056300|NCT02186119|Experimental|abicipar pegol 2 mg (group A)|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, and 20, followed by a sham procedure at weeks 12, 16, and 24.
3056301|NCT02186119|Experimental|abicipar pegol 2 mg (group B)|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, 16, and 24, followed by a sham procedure at weeks 12 and 20.
3056302|NCT02186119|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, 16, and 24, followed by a sham procedure at weeks 12 and 20.
3056303|NCT02186119|Active Comparator|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.
3056304|NCT02186106|Experimental|Loading dose substitution|Substituted with a highdose of cholecalciferol at study start
3056305|NCT02186106|No Intervention|Historic controls|Control subjects from journal archive
3056306|NCT02186093||Korea|patients in South of Korea
3056307|NCT02186093||United Kingdom|patients in England
3056308|NCT02186093||Spain|patients in Spain
3056309|NCT02186093||United State of America|patients in USA
3056310|NCT02186080|Experimental|Gemigliptin|Gemigliptin 50mg qd added to subjects current diabetes treatment
3056311|NCT02186080|Placebo Comparator|Placebo|Placebo (identical in appearance to gemigliptin)
3056312|NCT02186067|Experimental|Referral System|"Referral System:~Primary Level Secondary Level Tertiary Level"
3056313|NCT02186067|No Intervention|Control|Usual/routine care will be provided to the patients
3056314|NCT02186054|Other|Imaging- MRI examinations|Liver MRI imaging will be performed on 50 patients.
3056315|NCT02186041||De-Novo patients|Patients tested and de novo implanted with Interstim®. These patients will be followed-up for 5 years after the implant visit.
3056316|NCT02186041||Device replacement|Patients implanted with Interstim® for a device replacement. These patients will be followed-up for 5 years after the implant visit.
3056317|NCT02186041||Not-implanted patients|Patients who are tested and are not implanted with the Interstim® system. The data of the follow up of the test will be captured up to one year after the end-test visit
3056318|NCT02186028|Experimental|Vitamin D 400 IU|"Vitamin D-400IU/ml- 1ml daily~Neonates will be administered Vitamin D 400 IU orally daily by the mother or other caregiver for a period of six months. The neonates will be followed up for compliance at 2 weeks, 6, 10 and 14 weeks and thereafter at 6 months of age."
3056319|NCT02186028|Active Comparator|Vitamin D 200IU|"Vitamin D 400IU/ml : 0.5ml daily~Neonates will be administered Vitamin D 200 IU orally daily by the mother or other caregiver for a period of six months. The neonates will be followed up for compliance at 2 weeks, 6, 10 and 14 weeks and thereafter at 6 months of age."
3056320|NCT02186015|Experimental|Cholecalciferol|All participants will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
3056321|NCT02186002|Experimental|Group 1|A single oral dose of 10 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo.
3056346|NCT02185898|Experimental|U.S. Market-sample electronic cigarettes (two brands)|blu™ (any variety) and NJOY® (any variety)
3056492|NCT02184897|Experimental|PM group|Lenograstim is administered at 6 pm and apheresis is started at 8 am on D5
3056493|NCT02184884||MACE group|the patients with MACE after OPCAB
3056322|NCT02186002|Experimental|Group 2|A single oral dose of 50 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 50 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
3056323|NCT02186002|Experimental|Group 3|A single oral dose of 200 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 200 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
3056324|NCT02186002|Experimental|Group 4|A single dose of 500 mg ACT-451840 or placebo to be administered to subjects in the fasted state, followed by an observation period of 4 days. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 500 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
3056325|NCT02186002|Experimental|Group 5|A single oral dose of 1000 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 1000 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
3056326|NCT02186002|Experimental|Group 6|A single oral dose of ACT-451840 or placebo to be administered to subjects in the fed state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. The dose of ACT-451840 to be determined on the basis of the pharmacokinetic results for the previous groups
3056327|NCT02185989|Active Comparator|Electrical muscle stimulation and bicycling|Patients will undergo early electrical stimulation of the quadriceps and early leg bicycling in addition to routine care (which comprises early standard mobilization)
3056328|NCT02185989|No Intervention|Standard early passive/active rehabilitation|In this control group, patients will undergo routine care that comprises standard early passive/active rehabilitation delivered by physiotherapist with the assistance of ICU nurses
3056329|NCT02185976|Active Comparator|cartoon|paediatric patients undergoing general anesthesia. This group will choose a cartoon movie to watch throughout the preparation until the induction of anesthesia
3056330|NCT02185976|No Intervention|routine|paediatric patients undergoing general anesthesia
3056331|NCT02185963|Experimental|Rosuvastatin|Rosuvastatin will be started in type 2 DM and having 1 or more cardiovascular risk factors
3056332|NCT02185950|Experimental|Ultrasound group|Therapeutic ultrasound, 3 MHz, continuous with intensity 1W/cm2 will be applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) with exposure time of 2 minutes for each effective radiation area head (ERA), a total of 4 minutes of application in an area of 9X5 cm, and the application parameters with a matched control side of the patient, in a region with contralateral uninjured skin.
3056333|NCT02185950|Experimental|Group paraffin|Paraffin therapy is heated with thermostat own equipment, being applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) and control (uninjured), with a length of 9X5 cm, at a temperature of 38 ° C with appropriate brush in layers (4 layers), remaining for 20 minutes. After the period of application of paraffin will be removed and discarded, with no reuse.
3056334|NCT02185950|Experimental|Ultrasound group + endermotherapy|Therapeutic ultrasound, 3 MHz, continuous with intensity 1W/cm2 will be applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) with exposure time of 2 minutes for each effective radiation area head (ERA), a total of 4 minutes of application in an area of 9X5 cm. The application of endermotherapy will be held shortly after the therapeutic ultrasound in a timely manner across the surface of the scar, for about 2 seconds per head area with a negative pressure between 100-200 mmHg, a total of 4 minutes application in an area of 9 x 5 cm. The same application parameters will be performed with one hand matched control patient, in a region with contralateral uninjured skin.
3056335|NCT02185950|Experimental|Group paraffin + endermotherapy|Paraffin therapy is heated with thermostat own equipment, being applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) and control (uninjured), with a length of 9X5 cm, at a temperature of 38 ° C with appropriate brush in layers (4 layers), remaining for 20 minutes. After the period of application of paraffin will be removed and discarded, with no reuse.The application of endermotherapy will be held shortly after the paraffin therapy in a timely manner across the surface of the scar, for about 2 seconds per head area with a negative pressure between 100-200 mmHg, a total of 4 minutes application in an area of 9 x 5 cm. The same application parameters will be performed with one hand matched control patient, in a region with contralateral uninjured skin.
3056336|NCT02185937|No Intervention|water|imatinib intake with water
3056337|NCT02185937|Active Comparator|cola|imatinib intake with cola
3056338|NCT02185924|Experimental|CONTINUOUS FEMORAL BLOCK AND PARECOXIB|Continuous infusion of0,2% of ropivacaine at 10 ml/h and 2 mls (40 mg) of iv parecoxib
3056339|NCT02185924|Placebo Comparator|CONTINUOUS FEMORAL BLOCK AND PLACEBO|Continuous infusion of 0.2% ropivacaine at 10 ml/h and 2 mls of iv N/S0.9%
3056340|NCT02185911||Cohort 1|Patients with CKD
3056341|NCT02185898|Active Comparator|Leading U.S. tobacco-burning non-menthol cigarette|Leading U.S. non-menthol cigarette
3056494|NCT02184884||no MACE group|the patients without MACE after OPCAB
3056347|NCT02185885|Experimental|Increased bloodpressure during CPB|The cardiopulmonary bypass (CPB) procedure is conducted according to department guidelines with the modification that MAP is kept between 70 and 80 mm Hg. This is achieved by refract intravenous doses of phenylephrine to a total maximum of 2.0 mg, and after that continuous intravenous infusion of norepinephrine up to 0.4 μg/kg/min if necessary.
3056348|NCT02185885|No Intervention|Regular bloodpressure during CPB|The cardiopulmonary bypass (CPB) procedure is conducted in accordance with departmental guidelines, where MAP is sought to be ≥ 45 mm Hg. This is achieved by refract intravenous doses of phenylephrine to a total maximum of 2.0 mg, and after that continuous intravenous infusion of norepinephrine up to 0.4 μg/kg/min if necessary.
3056349|NCT02185872|Active Comparator|Aerobic and Resistance Training|Participants completed 24 exercise sessions based on current guidelines. Aerobic exercise (50 min) was performed on machines every session and resistance training (20 min) was performed on machines two sessions per week. Aerobic intensity was prescribed at 40-50% of heart rate reserve (HRR) Weeks 1-4 and 50-60% HRR Weeks 5-8. Resistance training was supervised by an ACE certified personal trainer. One-repetition maximums (1-RM) were assessed Week 1 (i.e., seated bicep curl, military press, seated lat pulldown, seated leg extension, triceps pulldown, bench press, reverse leg curl, seated leg press). For Weeks 2-3 participants completed, 3 sets of 15 reps at 50% 1-RM; Weeks 4-5, 3 sets of 12 reps at 60% 1-RM; Weeks 6-7, 3 sets of 10 reps at 70% 1-RM; Week 8, 3 sets of 8 reps at 75% 1-RM. Three sets of 15 unweighted crunches were completed each day. One minute of rest was taken between each set and each exercise.
3056350|NCT02185872|Experimental|High-intensity functional training|Participants completed a total of 24 sessions that were pre-programmed and led by a certified instructor (CrossFit Level 2), which lasted up to 60 minutes in duration. The first two class periods were structured as an introduction to common movements used in high-intensity functional training (HIFT; e.g., squats, deadlift, press, jerks, barbell, dumbbell, and medicine ball cleans, pullups, kettlebell swings, among others). No scheduled workouts were given on days 1 and 2. Beginning on day 3 each HIFT class consisted of 10-15 minutes of stretching and warmup, 10-20 minutes of instruction and practicing techniques and movements, and 5-30 minutes for the workout of the day, performed at vigorous intensity, relative to each person's ability and fitness level. All weights and movements were individually prescribed and recorded for each participant.
3056351|NCT02185859|Experimental|Perioperative lidocaine infusion|
3056352|NCT02185859|Experimental|Perioperative magnesium infusion|
3056353|NCT02185859|Active Comparator|Noraml saline infusion|
3056354|NCT02185846|Active Comparator|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
3056355|NCT02185846|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San.Ve Tic. A. Ş., Turkey, one tablet, once
3056356|NCT02185833|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
3056357|NCT02185833|Active Comparator|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
3056358|NCT02185820|Experimental|1|"Treatment schedule for 8 cycles of induction:~Carfilzomib = 20 mg/m2 IV once daily on days 1 of cycle 1 only followed by 27/36/45/56 mg/m2 days 8, 15 in cycle 1, then for all subsequent doses 27/36/45/56 mg/m2 IV once daily on days 1, 8, 15 followed by 13-day rest period (day 16 through 28).~Pomalidomide = 4 mg daily on days 1 - 21 every 28 days. Dexamethasone = 20 mg on days 1, 8, 15, 22 every 28 days.~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib = at the MTD achieved in the phase I of the study on days 1, 8, 15 in 28-days cycles.~Pomalidomide = 4 mg daily on days 1 - 21 every 28 days. Dexamethasone = 20 mg on days 1, 8, 15, 22."
3056359|NCT02185807|Active Comparator|video-assisted group|The video assistance patients watch a video in Cantonese or Mandarin explaining the surgery procedure and its risks, benefits and alternatives before discussion with their physicians, and receive face- to face discussion with their physicians as well.
3056360|NCT02185807|Placebo Comparator|control group|The control patients receive verbal information and discussion from their physicians.
3056361|NCT02185794|Experimental|Genotype 1a GS-9857±placebo (Cohort 1)|Participants with genotype 1a HCV infection will receive GS-9857 up to 300 mg with or without placebo to match GS-9857 under fasted conditions for 3 days.
3056362|NCT02185794|Experimental|Genotype 3 GS-9857±placebo (Cohort 2)|Participants with genotype 3 HCV infection will receive GS-9857 up to 300 mg with or without placebo to match GS-9857 under fasted conditions for 3 days.
3056363|NCT02185794|Experimental|Genotype 2 GS-9857±placebo (Cohort 3)|Participants with genotype 2 HCV infection will receive GS-9857 up to 300 mg with or without placebo to match GS-9857 under fasted conditions for 3 days.
3056364|NCT02185794|Experimental|GS-9857 600 mg (Cohorts 4-9)|Participants with genotypes 1a, 1b, 2, 3, or 4 HCV infection will receive GS-9857 up to 600 mg under fasted or fed conditions for 3 days.
3056365|NCT02185794|Experimental|GS-9857+SOF/GS-5816 (Cohort 10)|Participants with any genotype HCV infection will receive GS-9857 100 mg on Day 1 and GS-9857 100 mg plus SOF/GS-5816 on Days 2 and 3 with either a light or moderate-fat meal.
3056366|NCT02185781|Experimental|Autologous NK Cells infusions|
3056367|NCT02185768|Experimental|DC-BEADS + Idarubicine|Chemoembolization with DC BEAD loaded with idarubicine
3056368|NCT02185755|Active Comparator|Internet-Based Glucose Monitoring System|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and provide feedback limited to non-medicine related comments and suggestions.
3056369|NCT02185755|Other|Normal Medication Positive Control|The subjects will be prescribed a new medication as appropriate for normal therapy. This group will receive no biweekly feedback nor require to report online, but will see the endocrinologist every 3 months up to 6 months.
3056370|NCT02185742|Experimental|Strength Based Case Management|Strength Based Case Management
3056371|NCT02185742|No Intervention|Contemporary, HIV+ Jail Detainees|No intervention
3056372|NCT02185729|Active Comparator|Healthy Volunteer|Subjects receive 24 hours of infusion of 0.9% normal saline, dextrose (sugar) without fat, ClinOleic (olive oil-based), and Intralipid (soybean-derived fat)
3085130|NCT01992263|Experimental|Vitamin D (2000 IU)|
3056373|NCT02185716|Active Comparator|local infiltration|Group L (n=25) will be given total 30 ml 0.25 % levobupivacaine infiltration around trocar-site with injector in sterilized conditions without administering TAP block at the end of the operation
3056374|NCT02185716|No Intervention|Control|Only routine general anesthesia will be applied
3056375|NCT02185716|Experimental|TAP|Group T (n=25) will be given bilateral total 30 ml 0.25 % levobupivacaine administering TAP block under the guidance of ultrasound at the preoperative period.
3056376|NCT02185703|Experimental|Chordate System S020 in treatment mode|
3056377|NCT02185703|Sham Comparator|Chordate System S020 in placebo mode|
3056378|NCT02185690|Other|Binimetinib efficacy/safety|"This is a Phase I/Ib, open-label, dose-escalation, multi-center, non-randomized study designed to evaluate the safety and tolerability of oral Binimetinib in combination with carboplatin and pemetrexed.~Phase I part A standard 3+3 dose-escalation will be used to determine the maximum administered dose (MAD) and the RP2D for the combination in subjects with advanced non-squamous lung carcinoma.~Phase Ib part Once RP2D has been identified, an expansion cohort will be accrued; these patients will be stratified by KRAS genotype.~The RP2D will be expanded by enrolling additional patients, stratified by KRAS genotype, to a total of 30 patients eligible for the safety set (including those treated at the same dose combination in the dose-escalation phase of the study who are eligible for the safety set) to be evaluated for safety, tolerability, pharmacokinetics and biologic activity of MEK162."
3056379|NCT02185677||MSA-P|
3056380|NCT02185677||MSA-C|
3056381|NCT02185664|Active Comparator|Landmark technique|The landmark technique is the standard technique used for internal jugular vein cannulation.
3056382|NCT02185664|Experimental|Static Ultrasound technique|Static ultrasound technique was used to assist internal jugular vein cannulation.
3056383|NCT02185651|Active Comparator|Zavesca® 100 mg|"3 study participants are given Zavesca® prescription 100 mg for administration before ERT infusion. Week 0 infusion is completed at study site, with blood collection for anti-GAA antibody level before, during and after the ERT infusion. A punch muscle biopsy is completed the day after ERT infusion with pre-medication Zavesca®. Health Survey is completed.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
3056384|NCT02185651|Active Comparator|Zavesca® 300 mg|"3 study participants are given Zavesca® prescription 300 mg for administration before ERT infusion. Week 0 infusion is completed at study site, with blood collection for anti-GAA antibody level before, during and after the ERT infusion. A punch muscle biopsy is completed the day after ERT infusion with pre-medication Zavesca®. Health Survey is completed.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
3056385|NCT02185638|Experimental|A20-50|"A20-50 (2 capsules). Each capsule contains:~Yerba Mate (Ilex paraguariensis), Guarana seed (Paullinia cupana), Magnesium Oxide , Caffeine , Damiana (Turnera microphylla), Green tea (Camellia sinensis), Ginger (Zingiber Officinale), Kola nut (Cola acuminate or nitida), Pyridoxine Hydrochloride, Tibetan Ginseng root (Rhodiola crenulata), Schisandra (Schisandra Chinensis), Jujube (Ziziphus Jujuba) , Cocoa nut (Theobroma cacao), Chinese Skullcap (Scutellaria Baicalensis), Black tea leaf (Thea sinensis), Rice flour (to fill)~Dose = 2 capsules have a total of 200 mg of caffeine"
3056386|NCT02185638|Active Comparator|YGD|"YGD blend (2 capsules). Each capsule contains:~Yerba Maté (leaf) , Guarana (seed) , Damiana (leaf) , Rice flour: to fill ,~The 2 capsules of the YGD blend contain about 40 mg xanthines (caffeine and caffeine-like stimulants)."
3056387|NCT02185638|Placebo Comparator|Placebo|"Placebo (2 capsules). Each capsule contains:~Rice Flour"
3056388|NCT02185625|Experimental|Safe Delivery smartphone application|
3056389|NCT02185625|No Intervention|Control|
3056390|NCT02185612|No Intervention|Control|Participants will be randomized to a 1 year wait list. Participants take 0 month, 6 month, and 12 month surveys on depression, anxiety, alcohol and tobacco use, locus of control, and overall self-rated health.
3056391|NCT02185612|Experimental|Savings program|Participants will be randomized to the EARN.org online savings program for 6 months. Participants take 0 month, 6 month, and 12 month surveys on depression, anxiety, alcohol and tobacco use, locus of control, and overall self-rated health.
3056392|NCT02185599||Colposcopy with DySIS|The prospective arm will recruit patients referred for colposcopy and will be examined using DySIS.
3056393|NCT02185599||Standard colposcopy|The retrospective arm will collect historical data from colposcopy examinations performed using a standard colposcope.
3056394|NCT02185586|Experimental|LALC|lower abdominal laparoscopic cholecystectomy
3056395|NCT02185586|Experimental|SLC|single laparoscopic cholecystectomy
3056396|NCT02185586|Placebo Comparator|UALC|upper abdominal laparoscopic cholecystectomy
3056397|NCT02185573|No Intervention|Conventional Technique|Multi-layer filling technique
3056398|NCT02185573|Active Comparator|Bulk fill technique|Bulk fill technique
3056399|NCT02185573|Experimental|SonicFill technique|SonicFill technique
3056400|NCT02185560||BAY43-9006|NEXAVAR treatment group
3056401|NCT02185547|Experimental|ICBT in combination with sertraline treatment|Internet cognitive behavioral therapy in combination with sertraline treatment
3056402|NCT02185547|Active Comparator|ICBT|Only Internet cognitive behavioral treatment, no additional depression treatment
3056403|NCT02185534|Experimental|European clopidogrel tablets, 75 mg|Treatment A: a single oral dose of clopidogrel 75 mg film-coated tablet (Zyllt, KRKA - test)
3056404|NCT02185534|Active Comparator|Japanese clopidogrel tablets, 75 mg|Treatment B: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Brystol-Myer Squibb,Sanofi-Aventis, reference)
3056405|NCT02185534|Active Comparator|US clopidogrel tablets, 75 mg|Treatment C: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Sanofi-Aventis, reference)
3056406|NCT02185521|Experimental|visible HII - patient assessment|"Clinical team from study unit will observe the Hemodynamic Instability Index created by the HIRBA 2.0 system for individual subjects randomized into HII group arm.~If the HII value will cross the threshold, indicative of hemodynamic deterioration, subject from the study arm will receive intervention: clinical assessment."
3056577|NCT02184325|Experimental|Kiddi® Pharmaton Fizz, effervescent tablets|with reduced amount of minerals
3056407|NCT02185521|No Intervention|not visible HII|For subjects randomized into the control arm study team will collect patient's clinical information but the clinical care team will not have the ability to view the information generated by the HIRBA 2.0 system. Nurse will not observe the value of Hemodynamic Instability Index (HII) while accessing workstation desktop (during regular charting), not interpret HII value, and not share this information to the physician when indicative of potential patient hemodynamic instability.
3056408|NCT02185508||Lumbar spine surgery with IONM|Patients diagnosed with 1 or 2 level lumbar disk disease and radicular symptoms who underwent decompressive surgery, and for whom IONM records exist.
3056409|NCT02185495|Experimental|High-risk individuals|"The elder and heavy smokers, which are high-risk individuals for early lung cancer. These subjects will be examined using Observer nodule detection and  Computer-aided nodule detection."
3056410|NCT02185482|Experimental|Physician Supported Care|The intervention is an individualized, stepped-care depression treatment program provided by a depression clinical specialist primary care physician.
3056411|NCT02185482|Other|Usual care|Usual care patients will be advised to consult with their primary care physician regarding depression. Primary care physicians prescribe antidepressant medication and can refer patients to the Mental Health Services.
3056412|NCT02185469|Active Comparator|pneumatic retinopexy group|First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
3056413|NCT02185469|Active Comparator|vitrectomy group|Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment
3056414|NCT02185456|No Intervention|Healthy|Patients with no history of bacterial vaginosis. These women will be monitored monthly and with daily self swabs.
3056415|NCT02185456|Active Comparator|G1 BV in clinical & molecular remission|Patients will receive standard of care intervention, oral metronidazole 500 mg twice a day for 7 days. They will then be monitored to confirm that initial BV treatment was effective by Nugent and Amsel, and by the qPCR test (LbRC). These will be monitored with monthly visits and daily self swabs. Those who recur with symptomatic BV may enroll in the B2 arm for more aggressive treatment.
3056416|NCT02185456|Experimental|G2. Molecular conversion subarm|Half of G1 patients who convert to poor qPCR test results while remaining asymptomatic will be randomized into this G2 arm and receive intervention: 750 mg metronidazole/ 200 mg miconazole vaginal suppository daily for 7 days, with continued monthly visits and daily swabs.
3056417|NCT02185456|Active Comparator|B1 Initially poor qPCR responders|The B1 arm are patients who enter remission after standard of care treatment, oral metronidazole 500 mg twice a day for 7 days, but who have poor initial qPCR scores. Half of such patients will be randomized into B1, half into B2. B1 patients will be monitored with monthly visits and via daily swabs, but will receive no further treatment while BV negative. Patients who recur with BV may enroll as B2 patients for more aggressive treatment.
3056418|NCT02185456|Experimental|B2 BV Remission to conversion|A subgroup of B1 patients who convert to consistently poor qPCR scores during the study (conversion) will be randomized into Arm B2 and receive intervention: 750 mg metronidazole/ 200 mg miconazole vaginal suppository daily for 7 days. These patients will continue monthly visits and daily self swabs. B2 patients who recur with symptomatic BV will be dropped from the study and given other options for therapy.
3056419|NCT02185443|Experimental|SBRT|
3056420|NCT02185430|Placebo Comparator|Control group|saline solution
3056421|NCT02185430|Active Comparator|dexmedetomidine group|dexmedetomidine
3056422|NCT02185417|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide daily dose of 50 mg or 25 mg for duration of study
3056423|NCT02185417|Active Comparator|Chlorthalidone|Chlorthalidone daily dose of 25 mg or 12.5 mg for duration of study
3056424|NCT02185404|Experimental|wearing the GEMS|The long-term training will consist of four weeks of training with three training sessions performed each week. The training sessions will consist of up to forty minutes of training over up to eight shorter sessions of walking on the GEMS with breaks between walking sessions and as needed if the subject requests an additional break. Subjects will place the GEMS on their foot in which they have the shortest step length, as measured during the pre-training gait analysis. This is typically the healthy side foot. For split-belt treadmill sessions, the format will be exactly the same, but they will walk on a split-belt treadmill instead of the GEMS with the faster tread moving on the same foot that would wear the GEMS in the over-ground walking sessions.
3056425|NCT02185391|Experimental|fact-finding group|Intervention: Audience Response System and motivational telephone interview
3056426|NCT02185391|No Intervention|control group|
3056427|NCT02185378|Active Comparator|I:E ratio 1:2|We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.
3056428|NCT02185378|Active Comparator|I:E ratio 1:1|The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
3056429|NCT02185365||Developmental dysplasia of the hip (DDH)|Patients will complete 2 magnetic resonance imaging (MRI): T1-rho and dGEMRIC. The T1-rho MRI does not require the injection of a contrast agent, while the dGEMRIC MRI requires a gadolinium injection to visualize cartilage in the hip.
3056430|NCT02185352|Experimental|Inductional BEEP regimen|"Induction BEEP regimen:~Every 3 weeks a cycle for a total of 3 cycles (around 2 months)~Bevacizumab 15mg/kg IVF on D1~Etoposide 70 mg/m2 IVF QD, D2-4~Cisplatin 70 mg/m2 IVF on D2~WBRT:~3000cGy in 10 fractions"
3056431|NCT02185352|No Intervention|WBRT alone|"standard WBRT:~3000cGy in 10 fractions"
3056454|NCT02185196|Active Comparator|Vitamin D3|Vitamin D3, Doses form: 20,000 IU vitamin D3 in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days.
3056495|NCT02184871||intrahepatic cholangiocarcinoma|Patients committed to surgery and stratified according to exposure to different risk factors for ICC, basing on modified ReNaM questionnaire.
3056432|NCT02185339|Experimental|dNMB group|For patients randomized to the dNMB group, intravenous infusion of 0.6 mg/kg/h rocuronium will be administered 10 minutes after the administration of intubation dose or after the return of post-tetanic count (PTC), whichever comes first. Then, the infusion rate will be titrated according to PTC (target to keep PTC between 1 to 2). Infusion rate will be increased or be reduced at a rate of 0.1 mg/kg/h if PTC is > or < than 1-2 to maintain deep muscle relaxation throughout the surgery. Neuromuscular monitoring will be carried out by monitoring the adductor pollicis muscle in response to ulnar nerve stimulation. A dose of sugammadex (4 mg/kg) will be administered at the end of the surgery. Patients will be extubated when the train of four ratio is ≥0.9.
3056433|NCT02185339|Active Comparator|mNMB group|For patients randomized to the mNMB group, intravenous infusion of 0.2 mg/kg/h rocuronium will be administered 30 minutes after the administration of intubation dose or after the appearance of train-of-four (TOF) count >2, whichever comes first. Then, the infusion rate will be titrated according to TOF (target to keep TOF between 1 to 2). Infusion rate will be increased or reduced at a rate of 0.1 mg/kg/h if TOF is > or < than 1-2. A dose of sugammadex (2 mg/kg) will be administered at the end of the surgery. Patients will be extubated when the train of four ratio is ≥0.9.
3056434|NCT02185326|Experimental|Microflare and growth hormone|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
3056435|NCT02185326|No Intervention|Microflare protocol alone|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later
3056436|NCT02185313|Experimental|gaze holding|
3056437|NCT02185300|Experimental|Sequence ABCDE|Subject will be administered treatments in the sequence ABCDE where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 minutes(mins), re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 minutes, re-dispersed, and then taken by subject
3056438|NCT02185300|Experimental|Sequence BCDEA|Subject will be administered treatments in the sequence BCDEA where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
3056439|NCT02185300|Experimental|Sequence CDEAB|Subject will be administered treatments in the sequence CDEAB where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
3056440|NCT02185300|Experimental|Sequence DEABC|Subject will be administered treatments in the sequence DEABC where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
3056441|NCT02185300|Experimental|Sequence EABCD|Subject will be administered treatments in the sequence EABCD where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
3056442|NCT02185287||Lower urinary tract dysfunction, female, age: 18-40 years|
3056443|NCT02185287||Healthy female subjects, age: 18-40 years|
3056444|NCT02185261|Experimental|interferon Alfa-2b group|Acute leukemia patients who are minimal residual disease positive after hematopoietic stem cell transplantation receive interferon Alfa-2b
3056445|NCT02185248|No Intervention|Control Group|General clinical counseling in regards to child's BMI category and necessary changes to diet and activity regimen.
3056446|NCT02185248|Experimental|Wellness Plan|Received a wellness action plan. The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
3056447|NCT02185235|Experimental|Biofeedback & Electrical Stimulation|Twice a week, 20 minutes for each time. One course includes 18 times treatment.
3056448|NCT02185235|Active Comparator|Biofeedback & Pelvic Floor Training|Pelvic floor training every 20 minutes for each time, twice a week. and total for 18 times.
3056449|NCT02185222|Experimental|Cholecalciferol 100 000 UI (Unité Internationale)|Oral solution in single-dose : 100 000 UI per month
3056450|NCT02185222|Placebo Comparator|Placebo|Oral solution in single-dose per month
3056451|NCT02185209|Experimental|Placebo|Patients with periimplantitis undergoing surgical treatment with will receive placebo three times daily (TID)
3056452|NCT02185209|Active Comparator|amoxicillin + metronidazole|Patients with periimplantitis undergoing surgical treatment with amoxicillin (500 mg TID) + metronidazole (400 mg TID) for 7 days
3056453|NCT02185209|Active Comparator|phenoxymetylpencillin + metronidazol|Patients with periimplantitis undergoing surgical treatment with phenoxymetylpencillin, (800mg×2 TID) + metronidazol (400 mg TID) for 7 days
3056490|NCT02184910||gastritis and pepsinogen|
3056491|NCT02184897|Active Comparator|AM group|Lenograstim is administered at 8 am and apheresis is started at 10 am on D4.
3056455|NCT02185196|Placebo Comparator|Miglyol-oil|20,000 IU Miglyol-oil in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days.
3056456|NCT02185183|Experimental|AlequelTM|AlequelTM
3056457|NCT02185170|Experimental|Fluorescence assesment|"All patients undergo a transurethral resection.~There are four different steps in the study:~the first step: fresh prostatic tissue of 30 subjects will be use to asses the fluorescence signal and the entire chain,~the second step: fresh prostatic tissue of 10 subjects will be used to asses the immunolabelling protocol,~the third step: fresh prostatic tissue of 20 subjects will be used to asses the use of the FEMTO-ST institute medical device,~the four step: the fresh prostatic tissue from the 10 subjects of the second step will be evaluated to verify the preservation of morphological structure with the use of the Light-CT scanner."
3056458|NCT02185157|Experimental|Experimental: Dual Task exercises|Dual-task training, includes 18 sessions model of cognitive and 12 motor dual-task exercises model, were administered in groups of four participants in a comfortable environment, without distraction effects. The 50-minute sessions included 30 minutes of motor dual-task exercises, and then, the participants were divided into pairs. The first pair performed free walks during 10 minutes at their maximal speeds, while the other received individual cognitive dual-task training for the same time, and these activities will be exchanged, so that all pairs could walk and receive cognitive training.
3056459|NCT02185157|Other|Control intervention: Aerobic training|The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
3056460|NCT02185144|Experimental|PATH for Triples (PFT)|The Nurse Health Navigator (NHN) meets at least weekly with the experimental participants to implement the adherence component of PFT using approaches tailored to the communication and comprehension of the person that includes memory aids, education regarding side effects and other treatment aspects, engagement with participants' social networks and treatment providers, and active community outreach. PFT will be implemented for 6 months and participants will be followed for an additional 3 months to allow examination of potential decay of the intervention after it is withdrawn.
3056461|NCT02185144|Placebo Comparator|Treatment as Usual (TAU)|Participants in the the Treatment as Usual (TAU) group receive usual treatment after inpatient care.
3056462|NCT02185131|Active Comparator|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
3056463|NCT02185131|Active Comparator|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
3056464|NCT02185118|Experimental|oxygen plus isoflurane/sevoflurane|"All human peripheral blood mononuclear cells (PBMCs) were from patients with non sepsis/non SIRS/non infection.~The above cells were treated with oxygen or oxygen plus isoflurane/sevoflurane after stimulation of lipopolysaccharide/plasma from septic patients."
3056465|NCT02185105|Experimental|comfilcon A MTO|Subjects will be randomized to receive either the Test or Control lens as a matched pair at each visit per a predetermined randomization schedule.
3056466|NCT02185105|Active Comparator|comfilcon A|Subjects will be randomized to receive either the Test or Control lens as a matched pair at each visit per a predetermined randomization schedule.
3056467|NCT02185092|Placebo Comparator|Sugar Pill|1 pill orally daily
3056468|NCT02185092|Active Comparator|Lactobacillus GG|1 pill (2 x 10x 9 CFU) daily orally
3056469|NCT02185079|Active Comparator|Group C|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm. Access to epidural simulator for 2 days will be given.
3056470|NCT02185079|Experimental|Group M|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm as well.Trainees in this arm in addition will be subjected to training to proficiency based on the metrics developed for labor epidural catheter placement in a epidural simulator.
3056471|NCT02185066|Experimental|Group 1|"Single-dose crossover~Reference: Atorvastatin 20mg and Metformin XR 500mg~Test: CJ-30056 20/500mg~Once daily Oral administration with 7days of washout period"
3056472|NCT02185066|Experimental|Group 2|"Single-dose crossover~Test: CJ-30056 20/500mg~Reference: Atorvastatin 20mg and Metformin XR 500mg~Once daily Oral administration with 7days of washout period"
3056473|NCT02185053|Experimental|CPC-201|
3056474|NCT02185040|Experimental|CC-220 0.3mg Every Other Day (QOD)|Part 1: CC-220 0.3mg capsules by mouth every other day (QOD)
3056475|NCT02185040|Experimental|CC-220 0.3mg Every Day (QD)|"Part 1: CC-220 0.3mg capsules by mouth every day (QD)~ATEP: CC-220 0.3 mg capsules by mouth every day (QD)"
3056476|NCT02185040|Experimental|CC-220 0.6mg/0.3mg alternating dose QD|"Part 1: CC-220 0.6 mg and 0.3mg capsules PO on alternating days~ATEP:CC-220 0.6 mg and 0.3 mg capsules PO on alternating days"
3056477|NCT02185040|Experimental|CC-220 0.6mg QD|Part 1: CC-220 0.6mg capsules by mouth QD
3056478|NCT02185040|Placebo Comparator|Placebo QD|Part 1: Identically matching placebo capsules PO QD
3056479|NCT02185027||complications and compliance with GIHP recommendations|Description at 1 month post-intervention of an potential event
3056480|NCT02185014|Other|Arm 1|Subjects will receive the standard every other week dosing regimen until Week 40. Subjects have the ability to dose-escalate to weekly dosing and de-escalate back to every other week.
3056481|NCT02185001|Active Comparator|Surgical Treatment Group|Direct Medial Patellofemoral Ligament (MPFL) Repair
3056482|NCT02185001|Active Comparator|Conservative Treatment Group|Immobilization, stabilization bracing, and physical therapy
3056483|NCT02184988|Experimental|Botulinum neurotoxin, Type A|DWP-450 (Botulinum purified neurotoxin, Type A) Injection
3056484|NCT02184975|Experimental|Stitches|Cold Knife Conization with stitches
3056485|NCT02184975|Active Comparator|No stitches|Cold Knife Conization without stitches
3056486|NCT02184949||Primary Sample|All percutaneous coronary intervention patients who meet the primary eligibility criteria for this study.
3056487|NCT02184949||Subsample|Patients drawn from the main sample who specifically underwent a primary percutaneous coronary intervention procedure.
3056488|NCT02184936||acute ischemic stroke|
3056489|NCT02184923|Experimental|verticality measurements|
3056496|NCT02184858|Experimental|lisinopril|dose titration of investigational product (lisinopril) dependant on blood pressure, levels of renin and aldosterone and on adverse events.
3056497|NCT02184845|Experimental|NobelActive 3.0|
3056498|NCT02184832|Experimental|Low tryptophan diet|2 days of a low tryptophan diet
3056499|NCT02184832|Experimental|High tryptophan diet|2 days of a high tryptophan diet
3056500|NCT02184819|Active Comparator|levosimendan|study drug
3056501|NCT02184819|Placebo Comparator|placebo|placebo group
3056502|NCT02184806|Experimental|1- orthotopic graft|
3056503|NCT02184806|Experimental|2- heterotopic graft|
3056504|NCT02184793|Other|EMD (Inclinomax) then usual care|"EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on for 24h.~Usual care : recording the head of bed inclination degree with masked digital display and alarm off for 24h."
3056505|NCT02184793|Other|usual care then EMD (Inclinomax)|"Usual care : recording the head of bed inclination degree with masked digital display and alarm off for 24h.~EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on for 24h."
3056506|NCT02184780||GUSTO Neurocognitive Cohort|This study involves retrospective analysis of data from an existing cohort of 600 infants who were enrolled in the neurocognitve arm of the GUSTO study (Growing up in Singapore Towards Healthy Outcomes). GUSTO is a prospective observational cohort study done in Singapore, where subjects were followed up from in-utero up to 36 months of age and beyond. The infants have already undergone a rigorous battery of neurocognitive tests at 6, 18, 24 and 36 months of age and their detailed demographic and medical information are available.
3056507|NCT02184767|Experimental|ADASUVE®|oral inhalation using a single-use, hand-held, inhaler; dosage determined by the investigator according the participants weight
3056508|NCT02184754||MEI|
3056509|NCT02184741|Placebo Comparator|Placebo|Infusion of normal saline
3056510|NCT02184741|Experimental|GB-0998|Infusion of GB-0998 (Immunoglobulin)
3056511|NCT02184728|No Intervention|EMMA(TM)|"A small capnograph for measuring ET-CO2 - the EMMA capnometer~1"
3056512|NCT02184715|Active Comparator|Virtual reality video game|Participants received rehabilitation treatment and additional virtual reality system (30 minutes of interactive virtual reality system play, two times per week, in eight sessions over a 4-week span) for 1 month, followed by rehabilitation treatment for 1 month
3056513|NCT02184715|Placebo Comparator|Virtual reality system|received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system (30 minutes of interactive video game play, two times per week, in eight sessions over a 4-week span) during the one month of intervention period.
3056514|NCT02184702||shoulder arthroscopy|
3056515|NCT02184689|Experimental|Fexinidazole|
3056516|NCT02184676|Other|Children born to mother/father with type 1 diabetes|
3056517|NCT02184663|Active Comparator|Standard care without APA program|
3056518|NCT02184663|Experimental|standard care with APA program|
3056519|NCT02184650||Premature infants|Premature infants with a GA < 32 weeks
3056520|NCT02184637|Experimental|Cohort 1- TQ w/DHA+PQP|Tafenoquine (TQ) will be co-administered with Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP) on Day 1. DHA+PQP alone will be administered at 24 hours (h) (Day 2) and 48 h (Day 3) post first dose administration.
3056521|NCT02184637|Experimental|Cohort 2 - TQ w/AL|Tafenoquine co-administered with Artemether + Lumefantrine (AL) on Day 1. AL alone will be administered at 8h (Day 1), 24h and 36h (Day 2), 48h and 60 h (Day 3) post first dose administration.
3056522|NCT02184637|Experimental|Cohort 3 - DHA+PQP alone|Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP) will be administered on Day 1 and at 24 hours (Day 2) and 48 hours (Day 3) post first dose administration
3056523|NCT02184637|Experimental|Cohort 4 - AL alone|Artemether + Lumefantrine will be administered on Day 1 and 8h, 24 and 36h (Day 2), 48h and 60 h(Day 3) post first dose administration
3056524|NCT02184637|Experimental|Cohort 5 - TQ alone|A single dose of Tafenoquine will be administered on Day 1
3056525|NCT02184624|Experimental|Sub-Study 1|Subjects will be randomized to either use ELLIPTA inhaler first and then DISKUS/ACCUHALER inhaler or use DISKUS/ACCUHALER inhaler first and then ELLIPTA inhaler.
3056526|NCT02184624|Experimental|Sub-Study 2|Subjects will be randomized to either use ELLIPTA inhaler first and then MDI inhaler or use MDI inhaler first and then ELLIPTA inhaler.
3056527|NCT02184624|Experimental|Sub-Study 3|Subjects will be randomized to either use ELLIPTA inhaler first and then TURBUHALER inhaler or use TURBUHALER inhaler first and then ELLIPTA.
3056528|NCT02184624|Experimental|Sub-Study 4|Subjects will be randomized to either use ELLIPTA inhaler first and then HANDIHALER inhaler or use HANDIHALER inhaler first and then ELLIPTA inhaler.
3056529|NCT02184624|Experimental|Sub-Study 5|Subjects will be randomized to either use ELLIPTA inhaler first and then BREEZEHALER inhaler or use BREEZEHALER inhaler first and then ELLIPTA inhaler.
3056530|NCT02184611|Experimental|Umeclidinium bromide|Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive UMEC Inhalation Powder 62.5 mcg OD over a period of 24 weeks
3056531|NCT02184611|Placebo Comparator|Placebo|Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive matching placebo of UMEC Inhalation Powder OD over a period of 24 weeks
3056532|NCT02184598|Placebo Comparator|Placebo cognitive training|In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
3056533|NCT02184598|Experimental|Cognitive training|Cognitive training with 6 different games each of which gets progressively more difficult as children obtain proficiency.
3056534|NCT02184585|Experimental|Cohort 1: Fasted state|Treatment will be administered orally to 42 subjects in the fasted state. Subjects will be required to fast overnight (minimum 10 hours) and for a minimum of 4 hours after each dose. Subjects will participate in 3 treatment periods and assigned to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) in accordance with the randomization schedule generated by Clinical Statistics. The three treatment periods will be separated by a minimum washout period of 28 days
3056535|NCT02184585|Experimental|Cohort 2 : Fed state|Treatment will be administered orally to 42 subjects in the fed state (high fat breakfast). Dosing will take place within 30 minutes of the start of the meal. Subjects will participate in 3 treatment periods and assigned to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) in accordance with the randomization schedule generated by Clinical Statistics. The three treatment periods will be separated by a minimum washout period of 28 days
3056536|NCT02184572|Experimental|INV_MMR|Subjects receive 1 dose of the study vaccine Priorix co-administered with Varivax and Havrix vaccines at Day 0. Subjects recruited in the US also receive Prevnar 13 at Day 0.
3056537|NCT02184572|Active Comparator|COM_MMR|Subjects receive 1 dose of the licensed vaccine M-M-R II or M-M-R VaxPro Lot 1 or Lot 2 co-administered with Varivax and Havrix vaccines at Day 0. Subjects recruited in the US also receive Prevnar 13 at Day 0.
3056538|NCT02184559|Experimental|TAP block|
3056539|NCT02184559|Active Comparator|infiltration continues|
3056540|NCT02184533|Experimental|Treatment (sodium selenite and radiation therapy)|Patients receive sodium selenite PO 2 hours before daily radiation therapy treatments. Treatment continues for the duration of the course of radiation therapy in the absence of disease progression or unacceptable toxicity.
3056541|NCT02184520|Active Comparator|TRANSITION|Stabilization System
3056542|NCT02184520|Active Comparator|REVERE|Stabilization System
3056543|NCT02184507|Experimental|Supplement pre CABG|Consumption of the supplement 7 days before surgery and placebo 30 days post surgery
3056544|NCT02184507|Experimental|Supplement post CABG|Consumption of placebo 7 days before surgery and supplement 30 days post surgery
3056545|NCT02184507|Experimental|Supplement pre and post CABG|Consumption of the supplement 7 days before and 30 days post surgery
3056546|NCT02184507|Placebo Comparator|Placebo|Consumption of placebo 7 days before and 30 days post surgery
3056547|NCT02184494|Experimental|Blood Lactate Response in PD|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in a PD population. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
3056548|NCT02184494|Experimental|Blood Lactate Response in MS|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in an MS population. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
3056549|NCT02184494|Experimental|Blood Lactate Responses in Controls|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in healthy, older adults. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
3056550|NCT02184481|Experimental|Working memory training|Participants executed the training for three weeks, three times a week, half an hour per session. The training was a game in which the participant was a person who had to become strong to fight with a fantasy figure. The person could become stronger when giving the right answers in eight different working memory tasks. The level adapted to the working memory capacity of the participant.
3056551|NCT02184481|Placebo Comparator|Placebo training|Participants executed the training for three weeks, three times a week, half an hour per session. The training was a game in which the participant was a person who had to become strong to fight with a fantasy figure. The person could become stronger when giving the right answers in eight different working memory tasks. The level in the placebo condition was easy and did not adapt to the working memory capacity of the participant.
3056552|NCT02184468|Other|Dual dispatch|Simultaneously dispatching of EMS, firefighters and/or police in OHCA
3056553|NCT02184455|Experimental|DermGEN Decellularized Dermal Matrix|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
3056554|NCT02184442|Experimental|TAVR - SAPIEN XT|TAVR (transaortic valve replacement) with SAPIEN XT
3056555|NCT02184442|Active Comparator|TAVR - SAPIEN|TAVR (transaortic valve replacement) with SAPIEN is the control arm
3056556|NCT02184429|Experimental|Single Ascending Dose-1|Single ascending doses of PF-06669571 administered to healthy volunteers in a cross over study design
3056557|NCT02184429|Experimental|Single Ascending Dose-2|Single ascending doses of PF-06669571 administered to healthy volunteers in a cross over study design
3056558|NCT02184429|Experimental|Multiple Ascending Dose-1|Daily dose of PF-06669571 in healthy volunteers
3056559|NCT02184429|Experimental|Multiple Ascending Dose-2|Daily dose of PF-06669571 in healthy volunteers
3056560|NCT02184429|Experimental|Multiple Ascending Dose-3|Daily dose of PF-06669571 in healthy volunteers
3056561|NCT02184429|Experimental|Multiple Ascending Dose-4|Daily dose of PF-06669571 in healthy volunteers
3056562|NCT02184429|Experimental|Multiple Ascending Dose-5|Daily dose of PF-06669571 in healthy volunteers
3056563|NCT02184416||Observational Arm|"Patients will be enrolled when they start a treatment with Sutent in 1st line or Inlyta in 2nd line post Sutent treatment. The possible sequences of treatment under investigation will be:~Sutent (prospective) - Inlyta~Sutent (retrospective) - Inlyta~Sutent - not further active treatment (supportive care)~Sutent - other second line treatment (Nexavar (sorafenib), Votrient (pazopanib), Afinitor (everolimus), Torisel (temsirolimus), other))"
3056564|NCT02184390|Experimental|tutorial|Parents who receive access to the tutorial immediately
3056565|NCT02184390|No Intervention|wait list control|Parents who are assessed at the same time points as the intervention arm, but do no receive access to the tutorial
3056566|NCT02184377||RLN+SLN paralysis|unilateral recurrent laryngeal and superior laryngeal nerve paralysis
3056567|NCT02184377||RLN paralysis|unilateral recurrent laryngeal nerve paralysis
3056568|NCT02184364|Experimental|Low dose of Klimadynon®|
3056569|NCT02184364|Experimental|Medium dose of Klimadynon®|
3056570|NCT02184364|Experimental|High dose of Klimadynon®|
3056571|NCT02184364|Active Comparator|Oestrofeminal®|
3056572|NCT02184364|Placebo Comparator|Placebo|
3056573|NCT02184351|Experimental|Roxanes's clotrimazole troches|
3056574|NCT02184351|Active Comparator|Mycelex® troches|
3056575|NCT02184338|Experimental|BIRB 1017 BS in single rising doses|
3056578|NCT02184325|Active Comparator|Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula|
3056579|NCT02184325|Active Comparator|Comparator product|in the form of a product that is a market leader
3056580|NCT02184312|Experimental|Nevirapine XR low dose|
3056581|NCT02184312|Experimental|Nevirapine XR medium dose|
3056582|NCT02184312|Active Comparator|Nevirapine XR high dose|
3056583|NCT02184312|Active Comparator|Nevirapine (VIRAMUNE®)|commercial product
3056584|NCT02184299|Experimental|Nevirapine + Prednisone|"week 1-2: Nevirapine + Prednisone~week 3-24: Nevirapine alone"
3056585|NCT02184299|Active Comparator|Nevirapine|week 1-24: Nevirapine
3056586|NCT02184286|Experimental|Nevirapine + Saquinavir-sgc|
3056587|NCT02184273|Experimental|Magnesium metamizol|
3056588|NCT02184273|Placebo Comparator|Placebo|
3056589|NCT02184260|Experimental|Metamizole|
3056590|NCT02184260|Placebo Comparator|Placebo|
3056591|NCT02184247|Experimental|anhydrous theophylline, 350 mg|
3056592|NCT02184247|Active Comparator|anhydrous theophylline, 300 mg|
3056593|NCT02184234|Experimental|Antistax film coated tablets|
3056594|NCT02184221|Experimental|High frequency stimulation|alpha burst, 8~12Hz, run 2 seconds, rest 8 seconds, lasts 20 minutes each time
3056595|NCT02184221|Active Comparator|Low frequency stimulation|0.5Hz, run 0.5 seconds, rest 1.5 seconds, lasts 20 minutes each time
3056596|NCT02184208||Device utlization following extubation|
3056597|NCT02184208||Pulmonary mechanics|
3056598|NCT02184195|Experimental|Olaparib|Olaparib tablets po. 300 mg twice daily
3056599|NCT02184195|Placebo Comparator|Placebo|Placebo tablets twice daily
3056600|NCT02184182|Experimental|VLS ablation/portal ligation/hepatectomy|"Step1:~exploratory laparoscopy to exclude extrahepatic disease~right portal vein ligation if surgically feasible~RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)~radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1~Step 2: only if FRL/body weight > 0.5~- laparoscopic/laparotomic right trisectionectomy"
3056601|NCT02184169|Experimental|HLHS|Patients undergoing palliative repair.
3056602|NCT02184169|Active Comparator|TGA|Surgical repair of TGA.
3056603|NCT02184156|Experimental|Ampion < 5 kDa ultrafiltrate of 5% HSA|4 mL intra-articular injection of Ampion
3056604|NCT02184156|Placebo Comparator|Placebo solution|4 mL placebo intra-articular injection
3056605|NCT02184143|Experimental|CBPT intervention|CBPT program consisting of weekly phone calls.
3056606|NCT02184143|Active Comparator|Education intervention|Education program consisting of weekly phone calls.
3056607|NCT02184130|Experimental|TMS|
3056608|NCT02184117||All patients|Entire cohort undergoes paired testing
3056609|NCT02184104|Active Comparator|Aeroshot|A single 100 mg caffeine dose administered using the Aeroshot device.
3056610|NCT02184104|Active Comparator|Energy Drink|A single 100 mg caffeine dose administered as an oral solution.
3056611|NCT02184091|Experimental|Nevirapine|Single dose administration
3056612|NCT02184078|Experimental|single group|"Nevirapine:~Study days 15-28 dose given once a day (q.d.) Study days 29-42 dose given twice a day (b.i.d.)~Rifabutin:~Study Days 0 to 42"
3056613|NCT02184065||Meloxicam|
3056614|NCT02184052||Meloxicam|
3056615|NCT02184026|Experimental|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy-Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
3056616|NCT02184000||1. the control group healthy adult volunteers|
3056617|NCT02184000||2. patients with chronic hepatitis B or C|
3056618|NCT02184000||3. pacients with liver cirrhosis type B or C|
3056619|NCT02183987|Experimental|Active Knowledge Translation Group|CKD clinics receiving the active knowledge translation intervention.
3056620|NCT02183987|No Intervention|Passive Knowledge Translation Group|Clinics will have access to the Canadian Society of Nephrology (CSN) guidelines on the optimal timing of dialysis initiation (current practice). These guidelines have been published in the Canadian Medical Association Journal (CMAJ) and have been recently presented at the annual meeting of the Canadian Society of Nephrology.
3056621|NCT02183974|Experimental|Peptest|44 children at the age between 1 to 7 years diagnosed with bilateral or unilateral OME who underwent adenoidectomy and myringotomy with insertion of ventilation tube. Effusion was collected and analysed using Peptest, which contains monoclonal antibodies targeted against pepsin. Result of the Peptest was stated as positive (2 lines), negative (1 line) and invalid (no line).
3056622|NCT02183961|Experimental|Laryngopharyngeal reflux|EER was detected using three methods: oropharyngeal pH was monitored for 24 hours using the Restech system; detection of pepsin in middle ear fluid obtained during myringotomy was done using Peptest, and detection of pepsin in adenoid specimen was done immunohistochemically using antibody P3635Rb-h.
3056623|NCT02183948|Experimental|oxytocin|nasal spray
3056624|NCT02183948|Placebo Comparator|Placebo|nasal spray
3056625|NCT02183935|No Intervention|Lifestyle counseling, metformin|Age, gender and BMI matched controls will be managed by lifestyle counseling and metformin if indicated.
3056626|NCT02183935|Active Comparator|Duodeno - jejunal liner|Duodeno-jejunal liner (Endobarrier) will be implanted for the duration of 12 months. During this time subjects will be regularly monitored for investigated parameters. In addition, subjects will be carefully monitored upon device removal for additional 12 months.
3056627|NCT02183922|Placebo Comparator|light fruit jam|The placebo group received light fruit jam (15 g/day) during 12 weeks.
3056628|NCT02183922|Experimental|microencapsulated fish oil|The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.
3056629|NCT02183922|Experimental|microencapsulated conjugated linoleic acid|The microencapsulated conjugated linoleic acid group received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.
3056630|NCT02183909|Experimental|Study intervention|
3056631|NCT02183896|Experimental|Platelet-rich plasma (PRP)|Intra-articular injections in the hip of autologous platelet-rich plasma (PRP) at week 1 and 2 post-operatively. Dose 5 mL. PRP is derived from the patient's own blood.
3056632|NCT02183896|Placebo Comparator|Saline|Intra-articular injections in the hip of saline, solution week 1 and 2 post-operatively. Dose: 5 mL at each injection.
3056633|NCT02183883|Experimental|Afatinib|Afatinib, tablet, 40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision
3056634|NCT02183870|Experimental|Crizotinib|Patients are treated in this single-arm trial with oral crizotinib 250 mg b.i.d.. Treatment dose will be adjusted according to the protocol if indicated. Treatment will be conducted until disease progression or beyond disease progression according to the protocol if clinically indicated.
3056635|NCT02183857|Other|Ultrasound|Patients in group Ultrasound will have their femoral arterial lines inserted under the guidance of US. The Ultrasound equipment used is a SonoSite 180 PLUS with an L25/10- to 5-MHz linear array transducer (SonoSite, Inc., Bothell, WA)
3056636|NCT02183857|Other|Landmark|No Device is used. Patients in group Landmark will have their femoral line inserted using the blinded, external landmark-guided technique. After localization of the femoral artery by identifying the pulse in the femoral triangle immediately distal to the inguinal ligament.
3056637|NCT02183844|Experimental|Psychosocial Weight Intervention|Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
3056638|NCT02183831||Capsular tension ring non insertion group|The patients who had same cataract surgery procedure without CTR insertion
3056639|NCT02183831||Capsular tension ring insertion group|The patients who underwent capsular tension ring insertion just before IOL implantation during cataract surgery
3056640|NCT02183818||Healthy nonsmokers|Physical assessment, EKG, blood and urine draw, chest x-ray, pulmonary function test (PFT), and bronchoscopy
3056641|NCT02183818||Smokers with COPD|Physical assessment, EKG, blood and urine draw, chest x-ray, pulmonary function test (PFT), and bronchoscopy
3056642|NCT02183805|Experimental|Metastatic triple negative breast cancer|Abraxane,Cyclophosphamide,Carboplatin
3056643|NCT02183792|Experimental|Tolvaptan|Tolvaptan 30-60mg once daily (with rescue loop diuretic or metolazone)
3056644|NCT02183792|Active Comparator|Furosemide|Furosemide continuous infusion 5mg/h with option to titrate (with rescue metolazone)
3056645|NCT02183779|Experimental|Reynaud|patients with reynaud phenomena
3056646|NCT02183779|Experimental|Healthy|Healthy volunteers
3056647|NCT02183766|Placebo Comparator|Maltodextrin|6 mL once a day diluted in juice during 30 days.
3056648|NCT02183766|Active Comparator|Galactooligosaccharide prebiotic|6 mL once a day diluted in juice during 30 days.
3056649|NCT02183753|Active Comparator|Wood smoke|The dose of WSP to be used (500 µg/m3 for 2 hours) is based on prior studies which indicate the exposure is well tolerated, and is similar to that found in some indoor exposures in homes heated by wood burning (24-26). The route of administration (breathing air containing WSP at rest, nasally) is intended to mimic natural exposures.
3056650|NCT02183753|Placebo Comparator|clean air|Chapel Hill air which has been filtered to remove ambient air pollutants.
3056651|NCT02183740|Experimental|Multifaceted educational program|"A multifaceted educational program for nursing home staff consisting of:~One seven hours educational meeting (interactive workshop) conducted in the nursing home. Theoretical input and case-base discussions considering guidelines for nurse led assessment og interventions of patients fecal incontinence.The content will be made available as educational material.~Recruitment of one local opinion leader per nursing home unit.~Seven educational outreach meetings (1 hour 30 minutes per meeting) during the three months intervention period."
3056652|NCT02183740|No Intervention|Control|The control arm will not receive any educational program and will continue with usual care. Data with information about ordinary care will be gathered as part of the data collection procedure in the study.
3056653|NCT02183727|Experimental|L-C Ligament|Soft Tissue Regeneration's L-C Ligament is an investigation, interventional device intended for ACL reconstruction surgery within 18 weeks of acute rupture of the ACL and no previous surgical treatment. The L-C Ligament temporarily replaces the human anterior cruciate ligament (ACL) and provides a bioresorbable scaffold within and around which the native ACL will regenerate over time.
3056654|NCT02183727|Active Comparator|Hamstring Autograft|Hamstring autograft is the active comparator for this study. Autograft tissue is the gold-standard treatment for primary ACL reconstruction.
3056655|NCT02183714|Experimental|Songha Night ®|
3056656|NCT02183714|Placebo Comparator|Placebo|
3056657|NCT02183701|Experimental|Telmisartan|4 weeks placebo run-in, 6-weeks fixed dose period
3056658|NCT02183701|Active Comparator|Losartan + Hydrochlorothiazide|4 weeks placebo run-in, 6-weeks fixed dose period (Losartan 50 mg / HCTZ 12.5 mg)
3056659|NCT02183688|Experimental|ASA + paracetamol + caffeine|
3056660|NCT02183688|Active Comparator|ASA + paracetamol|
3056661|NCT02183688|Active Comparator|ASA|
3056662|NCT02183688|Active Comparator|Paracetamol|
3056663|NCT02183688|Active Comparator|Caffeine|
3056664|NCT02183688|Placebo Comparator|Placebo|
3056665|NCT02183675|Experimental|T/A/H|Telmisartan/Amlodipine/HCTZ fixed-dose combination
3056666|NCT02183675|Active Comparator|T/A|Telmisartan/Amlodipine fixed-dose combination
3056667|NCT02183675|Active Comparator|T/H|Telmisartan/HCTZ fixed-dose combination
3056668|NCT02183662|Experimental|BI 224436|
3056669|NCT02183662|Placebo Comparator|Placebo|
3056670|NCT02183649|Experimental|pentoxyverine citrate vs. placebo|All subjects were allocated to receive both verum and placebo in randomised order
3056671|NCT02183636|Experimental|Treatment 1 (T1)|Linagliptin/pioglitazone, FDC formulation C5
3056672|NCT02183636|Experimental|Treatment 2 (T2)|Linagliptin/pioglitazone, FDC formulation C8
3056673|NCT02183636|Active Comparator|Reference (R)|Linagliptin tablet and pioglitazone tablet (Actos®)
3056674|NCT02183623|Experimental|BI 1356 BS and Simvastatin|
3056675|NCT02183610|Experimental|[14C] BI 1356 as oral (p.o.) solution|
3056676|NCT02183610|Experimental|[14C] BI 1356 solution for i.v. infusion|
3056677|NCT02183597||Advanced breast cancer|Women with advanced breast cancer
3056678|NCT02183584|Experimental|Rifampicin and Linagliptin|
3056679|NCT02183571|Experimental|Glucophage® high dose|Part I: Treatment A + B
3056680|NCT02183571|Experimental|Glucophage® low dose|Part II: Treatment C+ D
3056681|NCT02183558|Experimental|OGTT by randomization|Women without risk factors for GDM are offered OGTT in gestational week 28
3056682|NCT02183558|Experimental|OGTT by indication|Women with risk factors for OGTT are offered diagnostic 2 hour OGTT in pregnancy week 28
3056683|NCT02183545|Experimental|BI 1060469|single rising doses given as tablet
3056684|NCT02183545|Placebo Comparator|Placebo|given as tablet (matching placebo of BI 1060469)
3056685|NCT02183532|Experimental|BI 1356 BS|
3056686|NCT02183519|Experimental|Healthy older adults|All participants will receive reflex and voluntary cough testing. This will include coughing on command (voluntary cough) and coughing in response to capsaicin (reflex cough). This data will me measured to determine the strength of the cough (from both voluntary and reflex cough) and cough sensitivity (reflex cough only). Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand the baseline characteristics of voluntary and reflex cough, whether older adults can modify the magnitude of their cough response with verbal and visual cues.
3056687|NCT02183519|Experimental|Parkinson's disease|All participants will receive reflex and voluntary cough testing. This will include coughing on command (voluntary cough) and coughing in response to capsaicin (reflex cough). This data will me measured to determine the strength of the cough (from both voluntary and reflex cough) and cough sensitivity (reflex cough only). Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand the baseline characteristics of voluntary and reflex cough, whether older adults can modify the magnitude of their cough response with verbal and visual cues.
3056688|NCT02183506|Active Comparator|Metformin|
3056689|NCT02183506|Experimental|BI 1356 BS and metformin|Daily administration of BI 1356 BS alone (day 1 to day 6) followed by the combined treatment of BI 1356 BS with metformin (day 7 to day 9)
3056690|NCT02183493|Experimental|Fed administration of BI 1356|
3056691|NCT02183493|Active Comparator|Fasted administration of BI 1356|
3056692|NCT02183480|Experimental|Linagliptin, low dose|
3056693|NCT02183480|Experimental|Linagliptin, medium dose|
3056694|NCT02183480|Active Comparator|Linagliptin, high dose|
3056695|NCT02183467|Experimental|BI 1356, low dose|
3056696|NCT02183467|Experimental|BI 1356, high dose|
3056697|NCT02183467|Placebo Comparator|Placebo|
3056698|NCT02183467|Active Comparator|Moxifloxacin|
3056699|NCT02183441|Experimental|BI 1356 plus ritonavir|Treatment A: 3 days of ritonavir, 1 day BI 1356
3056700|NCT02183441|Active Comparator|BI 1356|Treatment B: BI 1356 alone
3056701|NCT02183428|Experimental|BI 1356|"Treatment sequence AB_C or C_AB~Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by~Treatment B: 1 day of combined treatment of BI1356 and glyburide~Treatment C: 1 day of treatment with glyburide alone"
3056702|NCT02183428|Active Comparator|Glyburide|"Treatment sequence AB_C or C_AB~Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by~Treatment B: 1 day of combined treatment of BI1356 and glyburide~Treatment C: 1 day of treatment with glyburide alone"
3056703|NCT02183415|Experimental|BI 1356 BS, low dose|
3056704|NCT02183415|Experimental|BI 1356 BS, medium dose|
3056705|NCT02183415|Experimental|BI 1356 BS, high dose|
3056706|NCT02183415|Placebo Comparator|Placebo|
3056707|NCT02183402|Experimental|Digoxin with BI 1356|
3056708|NCT02183402|Active Comparator|Digoxin|
3056709|NCT02183389|Experimental|Treatment B: BI 1356 and Warfarin|BI 1356 for 12 days combined with a single dose of warfarin on day 6
3056710|NCT02183389|Active Comparator|Treatment A: Warfarin|Warfarin as single dose
3056711|NCT02183376|Experimental|BI 1356 - healthy subjects|
3056712|NCT02183376|Experimental|BI 1356 - mild liver impairment|
3056713|NCT02183376|Experimental|BI 1356 - moderate liver impairment|
3056714|NCT02183376|Experimental|BI 1356 - severe liver impairment|
3056715|NCT02183363|Experimental|BI 1356 - Tablet TFII|
3056716|NCT02183363|Experimental|BI 1356 - Tablet iFF|
3056717|NCT02183363|Active Comparator|BI 1356 - Tablet TFIIb|
3056718|NCT02183350|Experimental|BI 1356 BS - single rising dose|
3056719|NCT02183350|Placebo Comparator|Placebo|
3056720|NCT02183337|Experimental|BI 1356|"Treatment sequence AB_C or C_AB~Treatment A: 5 days BI 1356 until steady state followed by~Treatment B: combined treatment of BI 1356 with pioglitazone for 7 days~Treatment C: 7 days of treatment with Pioglitazone alone"
3056721|NCT02183337|Active Comparator|Pioglitazone|"Treatment sequence AB_C or C_AB~Treatment A: 5 days BI 1356 until steady state followed by~Treatment B: combined treatment of BI 1356 with pioglitazone for 7 days~Treatment C: 7 days of treatment with Pioglitazone alone"
3056722|NCT02183324|Experimental|Low dose of BI 1356 BS|
3056723|NCT02183324|Experimental|Medium dose of BI 1356 BS|
3056724|NCT02183324|Experimental|High dose of BI 1356 BS|
3056725|NCT02183324|Placebo Comparator|Placebo|
3056726|NCT02183311|Experimental|BI 1356 BS - single rising dose|
3056727|NCT02183311|Experimental|BI 1356 BS - multiple rising dose|
3056728|NCT02183311|Active Comparator|Placebo|
3056729|NCT02183298|Experimental|BI 1356 BS - single rising dose|
3056730|NCT02183298|Placebo Comparator|Placebo|
3056731|NCT02183285|Experimental|PHL 00747 capsules|
3056732|NCT02183285|Experimental|PHL 00747 tablets|
3056733|NCT02183285|Placebo Comparator|Placebo|
3056734|NCT02183272|Active Comparator|Intranasal Ketamine|0.2 mg / kg dose of intranasal ketamine for treatment of suicidality will be given in two separate doses on the day of admission to the hospital.
3056735|NCT02183272|Placebo Comparator|Intranasal Saline Placebo|0.2 mg / kg dose saline intranasal will be given in two separate doses on the day of hospital admission.
3056736|NCT02183259|Experimental|ESR 1150 CL capsule|
3056737|NCT02183259|Experimental|ESR 1150 CL ampoule|
3056738|NCT02183246|Experimental|Porfiromycin + Radiotherapy|
3056739|NCT02183246|Placebo Comparator|Placebo + Radiotherapy|
3056740|NCT02183233|Experimental|Eschscholtzia Californica|
3056746|NCT02183207|Experimental|PEG insertion arm via EG Scan|Percutaneous endoscopic insertion of gastrostomy via visualization through E.G. ScanTM
3056747|NCT02183194|Experimental|Lutonix Paclitaxel Drug Coated Balloon|
3056748|NCT02183181|Experimental|Meloxicam capsule|Capsules 15 mg
3056749|NCT02183181|Active Comparator|Meloxicam tablet|Tablets 15 mg
3056750|NCT02183168|Experimental|Meloxicam suppository|
3056751|NCT02183168|Experimental|Meloxicam tablet|
3056752|NCT02183168|Active Comparator|Indomethacin suppository|
3056753|NCT02183155|Experimental|Meloxicam - low|
3056754|NCT02183155|Experimental|Meloxicam - medium|
3056755|NCT02183155|Experimental|Meloxicam - high|
3056756|NCT02183155|Placebo Comparator|Placebo|
3056757|NCT02183155|Active Comparator|Extended-release indomethacin|
3056758|NCT02183142|Active Comparator|Mobic Germany|
3056759|NCT02183142|Experimental|Mobic China|
3056760|NCT02183129|Experimental|Meloxicam|
3056761|NCT02183129|Active Comparator|Diclofenac|
3056762|NCT02183116|Experimental|Meloxicam|
3056763|NCT02183103|Active Comparator|meloxicam rapid release tablet after an overnight fast|
3056764|NCT02183103|Experimental|meloxicam rapid release tablet after high fat breakfast|
3056765|NCT02183090|Experimental|Meloxicam ampoule|
3056766|NCT02183090|Active Comparator|Meloxicam tablet|
3056767|NCT02183077|Experimental|Meloxicam gel|
3056768|NCT02183077|Active Comparator|Meloxicam tablet|
3056769|NCT02183064|Experimental|Meloxicam|
3056770|NCT02183064|Active Comparator|Usual care prescription NSAID|
3056771|NCT02183051|Experimental|Meloxicam 15 mg|
3056772|NCT02183051|Experimental|Meloxicam 7.5 mg|
3056773|NCT02183051|Experimental|Meloxicam 3.75 mg|
3056774|NCT02183051|Experimental|Meloxicam 1.875 mg|
3056775|NCT02183051|Active Comparator|Ibuprofen 400 mg|
3056776|NCT02183051|Active Comparator|Ibuprofen 200 mg|
3056777|NCT02183051|Placebo Comparator|Placebo|
3056778|NCT02183038|Experimental|Meloxicam low & Placebo|
3056779|NCT02183038|Experimental|Meloxicam high & Placebo|
3056780|NCT02183038|Active Comparator|Naproxen sodium & Placebo|
3056781|NCT02183025|Experimental|Meloxicam 7.5 mg|
3056782|NCT02183025|Experimental|Meloxicam 15 mg|
3056783|NCT02183025|Active Comparator|Mefenamic acid 1500 mg|500 mg three times daily
3056784|NCT02183012|Experimental|A: Ibuprofen extrudate, fed state|
3056785|NCT02183012|Experimental|B: Ibuprofen extrudate, fasted state|
3056786|NCT02183012|Active Comparator|C: Ibuprofen lysinate tablet, fed state|
3056787|NCT02183012|Active Comparator|D: Ibuprofen lysinate tablet, fasted state|
3056788|NCT02183012|Active Comparator|E: Ibuprofen tablet, fed state|
3056789|NCT02183012|Active Comparator|F: Ibuprofen tablet, fasted state|
3056790|NCT02182999|Placebo Comparator|NaCl 0,9%|Continuous wound infiltration NaCl 0,9% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)
3056791|NCT02182999|Active Comparator|Ropivacaine|Continuous wound infiltration with Ropivacaine 0,2% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)
3056792|NCT02182986||Subjects Enrolled Pre-Transplant|"Subjects (N=706) Enrolled Pre-Transplant~Subjects with evidence of EBV infection prior to transplant~Subjects without evidence of EBV infection prior to transplant, who are at risk of developing EBV infection after transplant"
3056793|NCT02182986||Subjects Enrolled Post-Transplant|"Subjects (N=571) Enrolled 3 Yrs Post-Transplant~Subjects with evidence of EBV infection prior to transplant~Subjects without evidence of EBV infection prior to transplant, who are at risk of developing EBV infection after transplant"
3056794|NCT02182973||DHM|Infants identified with neonatal abstinence syndrome requiring pharmacologic management and who will not be fed own mother's milk
3056795|NCT02182960|Experimental|Ibuprofen|
3056796|NCT02182960|Active Comparator|Brufen|
3056797|NCT02182947|Experimental|Endoscopy Imaging|Wireless-video capsule endoscopy (WCE) compared to the findings of MRE magnetic resonance enterography in same group of patients.
3056798|NCT02182934|Experimental|Ginsana|
3056799|NCT02182934|Placebo Comparator|Placebo|
3056800|NCT02182908|Other|Non surgical aneurysm of abdominal aorta|PET-Scan
3056801|NCT02182895|Experimental|Saxagliptin group|DPP4 inhibitor therapy group will receive saxagliptin 2.5 to 5 mg daily in addition to correctional sliding scale insulin therapy before each meal and bedtime.
3056802|NCT02182895|No Intervention|Standard therapy group|Standard therapy group will receive basal-bolus insulin starting at a dose of 0.5 units/kg/day; given half as insulin glargine and half as insulin aspart. In addition, the standard therapy group will receive the correctional sliding scale insulin therapy before each meal and bedtime.
3056803|NCT02182882|Experimental|GINSANA|
3056804|NCT02182882|Placebo Comparator|Placebo|
3056805|NCT02182869|Experimental|Combivent® HFA|
3056806|NCT02182869|Active Comparator|Combivent® CFC|
3056807|NCT02182856|Experimental|Ipratropium bromide/salbutamol sulphate|"Randomised sequence of four different treatments~Ipratropium bromide 500 µg/salbutamol sulphate 3 mg~Ipratropium 500 µg~Salbutamol sulphate 3 mg~Salbutamol sulphate 6 mg"
3056808|NCT02182843|Experimental|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
3056809|NCT02182830|Experimental|Empagliflozin|starting dose 10mg; forced titration after 4 weeks 25mg dose
3056810|NCT02182830|Placebo Comparator|Placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
3056811|NCT02182817||GA-Exposed Group|Exposure to general anaesthesia below 1 year of age
3056812|NCT02182817||Unexposed Group|Age, race and gender-matched children not exposed to general anaesthesia or surgery from GUSTO cohort. (GUSTO: Growing Up Towards Healthy Outcomes in Singapore: a prospective longitudinal study providing normative data from the local population)
3085131|NCT01992263|Experimental|Vitamin D (4000 IU)|
3056813|NCT02182804|Experimental|Study|probe-based confocal laser endomicroscopy narrow band imaging with magnification
3056814|NCT02182791|Experimental|Nevirapine tablets|"once a day (q.d.) Day 2-15,~twice a day (b.i.d.) Study day 16-30"
3056815|NCT02182791|Active Comparator|EE/NET tablets|Single dose on Study Day 0 and 30
3056816|NCT02182778|Experimental|Gemcitabine/Cisplatin group|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
3056817|NCT02182778|Experimental|Gemcitabine/Cisplatin /S-1 group|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
3056818|NCT02182765|Experimental|Nevirapine|"Part I: Study days 15-43~Part II: Study day 44 to end of trial"
3056819|NCT02182765|Active Comparator|Amprenavir|"Part I: Study days 0 to 43~Part II: Study day 44 to end of trial"
3056820|NCT02182765|Active Comparator|Abacavir|"Part I: Study days 0 to 43~Part II Study day 44 to end of trial"
3056821|NCT02182752|Active Comparator|Ropivacaine - Tramadol|
3056822|NCT02182752|Active Comparator|Ropivacaine|
3056823|NCT02182739||Meloxicam|
3056824|NCT02182726||MOBEC|
3056825|NCT02182713|Experimental|Arm 1 - CombiventTM followed by Salbutamol|
3056826|NCT02182713|Active Comparator|Arm 2 - Salbutamol followed by CombiventTM|
3056827|NCT02182700|Experimental|Combivent® aerosol|
3056828|NCT02182687|Other|Arm A|Stereotactic Body Radiation Therapy (SBRT)
3056829|NCT02182687|Other|Arm B|Trans-Arterial Chemoembolization (TACE) Drug: Doxorubin
3056830|NCT02182674|Experimental|Combivent HFA|
3056831|NCT02182674|Active Comparator|Combivent (CFC)|
3056832|NCT02182661|Experimental|Ba253BINEB|
3056833|NCT02182648|Experimental|etomidate group|infusion of etomidate at 2 minutes before anesthesia induction
3056834|NCT02182648|Active Comparator|propofol group|infusion of propofol at 2 minutes before anesthesia induction
3056835|NCT02182648|Active Comparator|sevoflurane group|inhale sevoflurane for anesthesia induction and maintenance
3056836|NCT02182635|Experimental|Ba253BINEB|
3056837|NCT02182622|Experimental|Dose Level -1|Docetaxel 60mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 200mg oral daily
3056838|NCT02182622|Experimental|Dose Level 1|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice a day LDE225 200mg oral daily
3056839|NCT02182622|Experimental|Dose Level 2|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 400mg oral daily
3056840|NCT02182622|Experimental|Dose Level 3|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 800mg oral daily
3056841|NCT02182609|Experimental|99mTc-rhAnnexin V-128|
3056842|NCT02182596|Experimental|DAUNORUBICINE - ARACYTINE - MYLOTARG -|"Adaptive Bayesian method for dose-finding in phase I/II clinical trials based on treatment efficacy and toxicity (Thall, Russel, 1998), with successive patients cohorts and three combined dose levels:~DNR 45 mg/m2 IV days 1 to 3 + AraC 100 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.~DNR 60 mg/m2 IV days 1 to 3 + AraC 100 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.~DNR 60 mg/m2 IV days 1 to 3 + AraC 200 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.~Two consolidation courses for CR patients:~Amsacrine: 90 mg/m2 IV Day 1 Cytarabine: 1g/m2 twice a day IV Days 1 to 4 Mylotarg: 3 mg/m2 IV Day 1."
3056843|NCT02182583|Experimental|Ba253BINEB|
3056844|NCT02182583|Active Comparator|Ba253MDI|
3056845|NCT02182570|Experimental|WAL 801 CL|
3056846|NCT02182557|Experimental|WAL 801 CL Dry Syrup + Placebo|
3056847|NCT02182557|Active Comparator|Ketotifen Fumarate Dry Syrup + Placebo|
3056848|NCT02182544|Experimental|WAL801CL dry syrup + Placebo|
3056849|NCT02182544|Active Comparator|Ketotifen fumarate dry syrup + Placebo|
3056850|NCT02182531|Experimental|Epinastine and Pseudoephedrine combination|
3056851|NCT02182531|Active Comparator|Epinastine|
3056852|NCT02182531|Active Comparator|Pseudoephedrine|
3056853|NCT02182518|Experimental|Epinastine + Pseudoephedrine|
3056854|NCT02182518|Experimental|Epinastine|
3056855|NCT02182505|Experimental|Berodual® Respimat®, low dose|
3056856|NCT02182505|Experimental|Berodual® Respimat®, high dose|
3056857|NCT02182505|Active Comparator|Berodual® MDI Aerochamber®|
3056858|NCT02182492|Experimental|Glucocorticoid|Fluticasone propionate nasal spray
3056859|NCT02182492|Experimental|Clarithromycin|Clarithromycin tablet
3056860|NCT02182479|Experimental|Berodual® via Respimat®, high dose|
3056861|NCT02182479|Experimental|Berodual® via Respimat®, low dose|
3056862|NCT02182479|Active Comparator|Berodual® via MDI, high dose|
3056863|NCT02182479|Placebo Comparator|Placebo via Respimat®|
3056864|NCT02182479|Placebo Comparator|Placebo via MDI|
3056865|NCT02182466||Colonic endoscopy indicated|
3056866|NCT02182453|Experimental|BI 10773 - single rising dose|
3056867|NCT02182453|Placebo Comparator|Placebo|
3056868|NCT02182440|Placebo Comparator|Placebo|1 hour IV infusion once daily for 3 days
3056869|NCT02182440|Experimental|0.4 mg/kg (250 U/kg) recAP|1 hour IV infusion once daily for 3 days
3056870|NCT02182440|Experimental|0.8 mg/kg (500 U/kg) recAP|1 hour IV infusion once daily for 3 days
3056871|NCT02182440|Experimental|1.6 mg/kg (1000 U/kg) recAP|1 hour IV infusion once daily for 3 days
3056872|NCT02182414|Active Comparator|BI 207127 NA (TF-I)|trial part 1: 800 mg BI 207127 NA Trial formulation I (TF-I)
3056873|NCT02182414|Experimental|BI 207127 NA (TF-II)|trial part 1: 800 mg BI 207127 NA Trial formulation II (TF-II)
3056874|NCT02182414|Experimental|BI 207127 NA delayed release|trial part 1: 800 mg BI 207127 NA TF-II, delayed release
3056875|NCT02182414|Experimental|BI 207127 NA extended release (10% HPMC)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (10% Hydroxypropyl methyl cellulose (HPMC))
3056876|NCT02182414|Experimental|BI 207127 NA extended release (15% PEO)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (15% Polyethylene oxide (PEO))
3056877|NCT02182414|Experimental|BI 207127 NA extended release (20% HPMC)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (20% HPMC)
3056878|NCT02182414|Experimental|BI 207127 (TF-II), fed|trial part 2
3056879|NCT02182414|Experimental|BI 207127 (TF-II), fasted|trial part 2
3056884|NCT02182375|Experimental|BI 201335 NA|"400 mg raltegravir (bid) from day 1-14 and once on day 15;~240 mg BI 201335 NA (bid) from day 7-14 with a loading dose of 480 mg in the morning of day 6 and once on day 15"
3056885|NCT02182362|Experimental|BI 201335 NA in rising doses|single dose of BI 201335 NA on day 1, multiple dosing days 4-24
3056886|NCT02182362|Placebo Comparator|Placebo|
3056887|NCT02182362|Experimental|BI 201335 NA|highest tolerated dose of BI 201335 on day 1-28 in patients with Gilbert's syndrome
3056888|NCT02182349|Experimental|BI 201335 NA|multiple doses of BI 201335 NA soft gelatin capsule on days 1-8 and 11-15 and one single dose of [14C]-BI 201335 NA radiolabelled drug on day 9
3056889|NCT02182336|Experimental|BI 201335 NA|
3056890|NCT02182323|Experimental|BI 201335 in single rising doses|
3056891|NCT02182323|Placebo Comparator|Placebo|
3056892|NCT02182323|Experimental|BI 201335 NA fasted or fed|"two randomized sequences:~BI 201335 NA or placebo fasted~BI 201335 NA or placebo after high-fat breakfast"
3056893|NCT02182310|Placebo Comparator|BI 201335 placebo|crossover part
3056894|NCT02182310|Experimental|BI 201335 low dose|crossover part
3056895|NCT02182310|Experimental|BI 201335 high dose|crossover part
3056896|NCT02182310|Active Comparator|Moxifloxacin|crossover part
3056897|NCT02182310|Experimental|BI 201335 or Placebo|tolerability part in female subjects
3056898|NCT02182297|Experimental|BI 201335 NA in single rising doses|
3056899|NCT02182297|Placebo Comparator|Placebo|
3056900|NCT02182284|Experimental|BI 201335 NA - low dose|
3056901|NCT02182284|Experimental|BI 201335 NA - high dose|
3056902|NCT02182271|Experimental|BI 201335 ZW - single rising dose|
3056903|NCT02182271|Placebo Comparator|Placebo|
3056904|NCT02182258|Placebo Comparator|Placebo|
3056905|NCT02182258|Active Comparator|BIBF 1120 intravenous|
3056906|NCT02182258|Experimental|BIBF 1120 capsule|
3056907|NCT02182245|Experimental|Combination Therapy|
3056908|NCT02182245|Experimental|Monotherapy|
3056909|NCT02182232|Experimental|BIBF 1120 with paclitaxel and carboplatin|
3056910|NCT02182232|Experimental|BIBF 1120 monotherapy|
3056911|NCT02182219|Experimental|BIBF 1120|
3056912|NCT02182206|Experimental|BIBF 1120|
3056913|NCT02182193|Experimental|BIBF 1120 capsules charge 1|
3056914|NCT02182193|Experimental|BIBF 1120 capsules charge 2|
3056915|NCT02182193|Active Comparator|BIBF 1120 drinking solution|
3056916|NCT02182180||Protocol participants|All participants enrolled on the protocol
3056917|NCT02182167|Experimental|IV NAC|"Participants will receive IV N-acetylcysteine or placebo. The dosing regimen is based on the regimens used in paracetamol poisoning .~Initial dose: 150 mg/kg body mass of N-acetylcysteine/WFI infused in 200 mL of 5% dextrose intravenously over 60 minutes, followed by continuous infusion: 50 mg/kg body mass in 500 mL of 5% dextrose over next 4 hours, followed by 100 mg/kg body mass in 1 litre of 5% dextrose over 16 hours."
3056918|NCT02182167|Placebo Comparator|Placebo|Water
3056919|NCT02182154|Experimental|BIBF 1120 ES|
3056920|NCT02182141|Experimental|BIBF 1120|
3056921|NCT02182128|Experimental|BIBF 1120|
3056922|NCT02182115|Active Comparator|standard of care|Surgeon's routine for preoperative showering.
3056923|NCT02182115|Experimental|antiseptic bundle|"Patients to use study bundle for 5 days prior to scheduled surgery with the following medications to use at home.~Chlorhexidine gluconate soap applied for bathing daily.~Chlorhexidine gluconate mouthrinse used to rinse mouth twice daily.~Nasal mupirocin to applied inside nostrils twice daily."
3056924|NCT02182102|Experimental|BIBF 1120 + Pemetrexed|
3056925|NCT02182089||Dialysis patients with greater than 20% IDH|"Study Population:~The sample will be enriched for subjects prone to IDH, defined as patients who experience IDH for greater than 20% of HD treatments in the past 2 months. The study population will consist of 48 patients total, 75% of patients (n=36) prone to IDH and 25% of patients with less than 10% of IDH during the last two months (n=12)."
3056926|NCT02182089||Patients with less than 10% IDH|"Study Population:~The sample will be enriched for subjects prone to IDH, defined as patients who experience IDH for greater than 20% of HD treatments in the past 2 months. The study population will consist of 48 patients total, 75% of patients (n=36) prone to IDH and 25% of patients with less than 10% of IDH during the last two months (n=12)."
3056927|NCT02182076|Active Comparator|fasted administration of BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules in fasting state
3056928|NCT02182076|Experimental|fed administration of BIBF 1120|three 50 mg BIBF 1120 soft gelatine capsule immediately after a high fat, high caloric meal
3056929|NCT02182063|Experimental|BIBF 1120 low dose|
3056930|NCT02182063|Experimental|BIBF 1120 high dose|
3056931|NCT02182050|Experimental|BIBF 1120 ES low dose|
3056932|NCT02182050|Experimental|BIBF 1120 ES high dose|
3056933|NCT02182050|Placebo Comparator|Placebo|
3056934|NCT02182037|Experimental|BIBT 1011 BS|
3056935|NCT02182037|Placebo Comparator|BIBT 1011 BS placebo|
3056936|NCT02182024|Experimental|Dabigatran high dose in healthy subjects|healthy subjects with a creatinine clearance of >80 mL/m
3056937|NCT02182024|Experimental|Dabigatran high dose in mild renal impairment|patients with a creatinine clearance of >50 up to 80 mL/min
3056938|NCT02182024|Experimental|Dabigatran high dose in moderate renal impairment|patients with a creatinine clearance of >30 up to 50 mL/min
3056939|NCT02182024|Experimental|Dabigatran high dose in severe renal impairment|patients with a creatinine clearance of up to 30 mL/min
3056940|NCT02182024|Experimental|Dabigatran low dose in haemodialysis patients|patients requiring haemodialysis
3056941|NCT02182011|Experimental|Tenecteplase|Single i.v. bolus followed by infusion, weight adjusted
3056942|NCT02182011|Active Comparator|Alteplase|Single i.v. bolus followed by infusion
3056943|NCT02182011|Active Comparator|Streptokinase|I.V. infusion
3056944|NCT02181998|Active Comparator|tenecteplase + unfractioned heparin|
3056945|NCT02181998|Experimental|tenecteplase + enoxaparin|
3056946|NCT02181985|Active Comparator|TNK-tPA + heparin|
3056947|NCT02181985|Experimental|TNK-tPA + enoxaparin|
3056948|NCT02181985|Experimental|TNK-tPA + abciximab + heparin|
3056955|NCT02181933|Experimental|Nevirapine|Mother: two doses, Infant: one dose
3056956|NCT02181933|Active Comparator|Zidovudine (ZDV) + Lamivudine (3TC)|
3056957|NCT02181920|Experimental|Metamizole - Diclofenac|metamizole followed by diclofenac
3056958|NCT02181920|Experimental|Diclofenac - Metamizole|diclofenac followed by metamizole
3056959|NCT02181920|Experimental|Metamizole - Placebo|metamizole followed by placebo
3056960|NCT02181920|Experimental|Placebo - Metamizole|placebo followed by metamizole
3056961|NCT02181907|Experimental|UH-AC 62 XX tablet|
3056962|NCT02181907|Active Comparator|UH-AC 62 XX capsule|
3056963|NCT02181894||Orally intubated infants|Subjects will be <72 hours of age and orally intubated. Following consent, four measures will be reported (i.e. body weight, nasal to tragus length, suprasternal notch to xyphoid process and shoulder to elbow length). Measures will be compared against a chest x-ray and placement of ETT at the subjects lip to identify the most accurate method to place endotracheal tubes in the newborn.
3056964|NCT02181881|Active Comparator|DuoPACT|A 6-session HIV medication adherence support program for couples.
3056965|NCT02181881|Active Comparator|Life Steps|A 3-session HIV medication adherence support program for individuals.
3056966|NCT02181881|No Intervention|Treatment as usual (TAU)|HIV positive individuals will continue to follow their current HIV treatment plan.
3056967|NCT02181855|Other|Atypical GERD syptoms treated with GERD-X|Patients treated by means of full-thickness gastroplication
3056968|NCT02181842||Oral administration of 15-30 mg of pioglitazone|Oral administration of 15-30 mg of pioglitazone once daily before or after breakfast (the dose can be adjusted; however, the maximum daily dose should not exceed 45 mg)
3056969|NCT02181829|Experimental|Whole Lung IMRT|This is a single institution study involving patients with synovial sarcoma who have completed all standard therapy (e.g. surgery +/- radiation to the primary site) +/- any adjuvant chemotherapy. The sequence and types of therapy offered prior to WLI will likely vary based on primary tumor site, tumor resectability, extent of metastatic disease, performance status, and comorbidity. Each patient's therapy will be determined by the disease management team irrespective of participation on this protocol.
3056970|NCT02181816||Oral administration of azilsartan/amlodipine|Oral administration of azilsartan/amlodipine once daily at a dose of 20 mg/2.5 mg or 20 mg/5 mg
3056971|NCT02181803|Experimental|Monotherapy Panel A (Schizophrenia Participants)|MK-8189 escalating doses: 2 mg once-a-day (QD) Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 16 mg QD Days 12-14, or matching placebo.
3056972|NCT02181803|Experimental|Monotherapy Panel B (Schizophrenia Participants)|MK-8189 escalating doses: 4 mg QD Days 1-4, 8 mg QD Days 5-8, 14 mg QD Days 9-11 and 40 mg QD Days 12-14, or matching placebo.
3056973|NCT02181803|Experimental|Add-on Therapy (Schizophrenia Participants)|MK-8189 escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 10 mg QD days 9-11 and 20 mg QD Days 12-14, or matching placebo. If dose titration is well tolerated in initial participants, an alternate dose titration may be used for remaining participants: 4 mg QD Days 1-4, 8 mg QD Days 5-8, 16 mg QD Days 9-11 and 20 mg QD Days 12-14, or matching placebo.
3056974|NCT02181803|Experimental|Monotherapy (Healthy Participants)|MK-8189 escalating doses: 2 mg QD Days 1-4, 4 mg QD Days 5-8, 8 mg QD Days 9-11, and 16 mg QD Days 12-14, or matching placebo.
3056975|NCT02181790|Experimental|First Group|excimer laser treatment to one palm and/or one sole
3056976|NCT02181790|Experimental|Second Group|excimer laser treatment to both palms and/or soles
3056977|NCT02181777|Experimental|GRASP|GRoup trAining for Social skills in Psychosis
3056978|NCT02181777|Active Comparator|Standard care|Treatment as usual as provided by care team
3056979|NCT02181764|Experimental|KRN23|Single SC administration on day 1
3056980|NCT02181751|Experimental|Treatment Group|Children in the Treatment Group will receive treatment between 0 and 4 months from the study start date. The intervention will be a Trauma Focused Cognitive Behavioural Therapy Group.
3056981|NCT02181751|Other|Waitlist Group|Children in the wait-list group will receive treatment from 5-8 months of the studies start date. The intervention once this group receives treatment will be a Trauma Focused Cognitive Behavioural Therapy Group
3056982|NCT02181738|Experimental|Nivolumab (Cohort A, B, C and D)|"Cohort (A, B, C): Nivolumab: IV injection 3 mg/kg every 2 weeks~Cohort (D): Nivolumab: IV injection 240 mg every 2 weeks + Doxorubicin: 25 mg/m² + Vinblastine: 6 mg/m² + Dacarbazine 375 mg/m²"
3056983|NCT02181725|Experimental|Multimodal Rehabilitation Program|Multimodal Rehabilitation Program, consisting of a Graded Exposure Module (GE), a Combination Module (HMGE) and a Parent Module (PM)
3056984|NCT02181725|Active Comparator|Care as Usual|Care as usual is the care currently provided to adolescents with musculoskeletal chronic pain and is based on the principles of Graded Activity.
3056985|NCT02181712|Experimental|Mesenchymal stem cells|2- 4 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours.
3056986|NCT02181699|Experimental|KHK2823|single agent KHK2823 administered at selected dose levels
3056987|NCT02181686||Sentus QP group|Patients with standard indication for CRT-D therapy who will be implanted with Sentus QP LV lead and the BIOTRONIK HF-T QP device.
3056988|NCT02181686||VR-T/DR-T group|Patients with standard indication for ICD therapy who will be implanted with either single chamber ICD or dual chamber ICD of the Iperia ICD family
3056989|NCT02181673|Placebo Comparator|Treatment Group 1: Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20. At Week 24, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Week 24, 28 and thereafter every 8 weeks up to Week 52.
3056990|NCT02181673|Experimental|Treatment Group 2: Golimumab|Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 24, participants will receive a placebo infusion to maintain the blind.
3056991|NCT02181660|Experimental|Dose Escalation Cohort|ASP2215
3056992|NCT02181647|Experimental|Intervention|Safe Touches Personal Safety Training for Children
3056993|NCT02181647|Other|Comparison|Received Safe Touches after week-1 assessment completed (delayed intervention).
3057024|NCT02181387|Placebo Comparator|placebo|placebo capsule identical to the acetaminophen capsule will be administered every 6 hours to a maximum of 4 doses
3056994|NCT02181634|Experimental|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel 125 mg/m² IV and Gemcitabine 1000 mg/m² on days 1, 8 and 15 every 28 days until progression or unacceptable toxicity.
3056995|NCT02181621|Placebo Comparator|Solosite gel|Hydrogel with preservatives, used to create a moist wound environment.
3056996|NCT02181621|Active Comparator|Iodosorb|Cadexomer iodine gel
3056997|NCT02181582|Experimental|Emapunil Administration|Single Arm Study
3056998|NCT02181556|Experimental|FOLFIRI and aflibercept|FOLFIRI and aflibercept (4 mg/m²) each 14 days until progression of disease
3056999|NCT02181543|Experimental|Clonidine|Clonidine 1μg/Kg, IV, single dose, anesthesia intraoperative.
3057000|NCT02181543|No Intervention|No Clonidine|Usual care of Instituto de Medicina Integral Prof. Fernando Figueira.
3057001|NCT02181530||OZURDEX®|Retrospective data collection study of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) administered at least once in accordance with routine clinical practice. No treatment (intervention) is administered as part of this study.
3057002|NCT02181517|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
3057003|NCT02181517|Experimental|abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
3057004|NCT02181517|Active Comparator|ranibizumab 0.5 mg|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
3057005|NCT02181504|Experimental|abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
3057006|NCT02181504|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
3057007|NCT02181504|Active Comparator|ranibizumab 0.5 mg|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
3057008|NCT02181491|Experimental|P943 PET Scan|
3057009|NCT02181478|Experimental|Treatment (intra-osseous UCB with hMSC co-transplant)|"REDUCED INTENSITY CONDITIONING: Patients receive cyclophosphamide IV over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total-body irradiation on day -1.~GVHD PROPHYLAXIS: Patients receive cyclosporine PO or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO BID on days -5 to 100.~TRANSPLANT: Patients undergo a co-transplantation of an intra-osseous umbilical cord blood transplantation and a mesenchymal stem cell transplantation on day 0."
3057010|NCT02181465|Experimental|Group 1|One injection of G17DT followed by up to three booster injections depending on antibody response over 16 week period
3057011|NCT02181465|Experimental|Group 2|Three injections of G17DT with option of one booster after 16 weeks
3057012|NCT02181439|Other|Right irradiated sector|"The low-energy laser (LLLT Low Level Laser Therapy) SIROLaser Advance: laser diode (970nm) is applied twice at day 0 and at M1. For each patient, randomized in this arm, only the right maxillary canine is actually irradiated. Irradiation is performed by scanning an area from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction and the cement enamel junction (CEJ) to the bottom of the vestibule in the vertical direction as well in buccally as in Palatine.~The same procedure will be applied to the left non-irradiated area, the only difference being that the laser will not be activated (placebo, laser inactive). Indeed, only the beam director will be lit and a beep start and end will be heard by the patient. In addition, the practitioner evaluating obtention or not of the class I will not know either which area has been irradiated or not."
3057013|NCT02181439|Other|Left irradiated sector|"The low-energy laser (LLLT Low Level Laser Therapy) SIROLaser Advance: laser diode (970nm) is applied twice at day 0 and at M1. For each patient, randomized in this arm, only the left maxillary canine is actually irradiated. Irradiation is performed by scanning an area from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction and the cement enamel junction (CEJ) to the bottom of the vestibule in the vertical direction as well in buccally as in Palatine.~The same procedure will be applied to the right non-irradiated area, the only difference being that the laser will not be activated (placebo, laser inactive). Indeed, only the beam director will be lit and a beep start and end will be heard by the patient. In addition, the practitioner evaluating obtention or not of the class I will not know either which area has been irradiated or not."
3057014|NCT02181426|Placebo Comparator|0 mg of Ketorolac|participant receives 0 mg of Ketorolac
3057015|NCT02181426|Active Comparator|7.5 mg of Ketorolac|participant receives 7.5 mg of Ketorolac
3057016|NCT02181426|Active Comparator|15 mg Ketorolac|participant receives 15 mg of Ketorolac
3057017|NCT02181426|Active Comparator|30 mg Ketorolac|participant receives 30mg of Ketorolac
3057018|NCT02181413|Experimental|Ixazomib Citrate|Ixazomib citrate 3 mg, capsule, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib citrate 3 or 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26. Participants experiencing adverse events (AEs) attributed to study drug during any cycle may continue in the study but may have doses of study drug held or reduced by at least 1 dose level. Reduced doses are: 3 mg, 2.3 mg, 1.5 mg and discontinuation of study drug.
3057019|NCT02181413|Placebo Comparator|Placebo|Ixazomib citrate placebo-matching capsule, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib citrate placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26
3057020|NCT02181400|Active Comparator|NIR Laser Treatment 25 miiliwatts (mW)/cm2 dose|The Ellex Integre NIR (near Infrared Light) Laser dose of 25 milliwats(mW)/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
3057021|NCT02181400|Active Comparator|NIR laser treatment 100mW/cm2 dose|The Ellex Integre NIR Laser dose of 100 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
3057022|NCT02181400|Active Comparator|NIR laser treatment 200mW/cm2 dose|The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
3057023|NCT02181387|Active Comparator|acetaminophen|1000 mg every 6 hours during labor up to maximum 3 doses
3058419|NCT02172131|Experimental|BI 1744 CL|Single rising dose of BI 1744 CL as intravenous (i.v.) infusion
3057025|NCT02181361|Experimental|aspirin plus hirudin|14 days after stroke occurred, the experimental group gives hirudin two tables three times a day and aspirin 100mg, once daily.
3057026|NCT02181361|Active Comparator|Warfarin|14 days after stroke occurred,the control group gives an initial dose of 1.5mg,once daily. 3 days later,we check the international normalized ratio(INR) values and adjust the warfarin dose make INR between 2-3 steady.Then, we maintain this warfarin dose.
3057027|NCT02181348|Active Comparator|Intervention (Vitamin E supplementation)|Vitamin E 400 mg once daily for 3 months
3057028|NCT02181348|Placebo Comparator|placebo (edible oil)|
3057029|NCT02181335|Experimental|Respimat ® Budesonide low dose + Turbohaler® Placebo|
3057030|NCT02181335|Experimental|Respimat ® Budesonide high dose + Turbohaler® Placebo|
3057031|NCT02181335|Active Comparator|Turbohaler® Budesonide + Respimat Placebo®|
3057032|NCT02181322|Experimental|Meloxicam - low dose, fasted|
3057033|NCT02181322|Experimental|Meloxicam - medium dose, fasted|
3057034|NCT02181322|Experimental|Meloxicam - high dose, fasted|
3057035|NCT02181322|Experimental|Meloxicam - high dose, fed|
3057036|NCT02181309|Experimental|Meloxicam low dose, fasted|
3057037|NCT02181309|Experimental|Meloxicam medium dose, fasted|
3057038|NCT02181309|Experimental|Meloxicam high dose, fed|
3057039|NCT02181309|Active Comparator|Meloxicam high dose, fasted|
3057040|NCT02181296|Active Comparator|High concentration group|0.2% ropivacaine
3057041|NCT02181296|Active Comparator|Lower concentration group|0.1% ropivacaine
3057042|NCT02181283|Active Comparator|W+W|Web-delivered alcohol/prescribed drug misuse brief intervention with Web booster sessions (W+W).
3057043|NCT02181283|Active Comparator|W+P|Web-delivered brief intervention with Peer-delivered booster sessions (W+P).
3057044|NCT02181283|No Intervention|Enhanced Usual Care|Enhanced usual care.
3057045|NCT02181270|Experimental|high intensity exercise|High-intensity interval exercise (HIIE): Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be ~45 minutes
3057046|NCT02181270|Experimental|Continuous moderate exercise group|Continuous moderate exercise group (CME): Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
3057047|NCT02181257||prospective single-arm cohort.|
3057048|NCT02181244|Experimental|Egg, one a day, for breakfast|The intervention consists in feeding the subjects egg, one a day for breakfast during 5 weeks. At the end of the intervention, blood will be obtained to measure plasma lipids, glucose, insulin and inflammatory markers. All measurements will be finished 24 weeks after the intervention is finished. All data will be reported 1 year after completion of the study.
3057049|NCT02181244|Experimental|Oatmeal, one cup a day|In this arm, subjects will consume oatmeal for a period of 5 weeks. Blood samples will be taken and different parameters will be measured including plasma lipids, glucose, insulin and inflammatory markers. All these measurements will be finished 24 weeks after completion of the study. All data will be reported 1 year after completion of the study.
3057050|NCT02181231|Experimental|venlafaxine plus buprenorphine|Drug: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 3 PET/MRI session will occur: First will occur before taking buprenorphine, second will occur at approximately 8 weeks on buprenorphine. A one week washout will occur after second PET/MRI. Third PET/MRI will occur after 1 week washout.
3057051|NCT02181231|Placebo Comparator|venlafaxine XR plus placebo|Drug: venlafaxine XR plus placebo Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 PET/MRI sessions will occur. First will occur before taking buprenorphine, second will occur after 8 weeks on the drug.
3057052|NCT02181218|Experimental|Dose Level 0 (starting dose) (8 mg/m2 romidepsin)|"Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;~Gemcitabine IV over 30 minutes on Day 1~Oxaliplatin IV over 2 hours on Day 1~Dexamethasone orally on Days 1-4~Pegfilgrastim subcutaneously on Day 3~Drugs may be administered in any order on Day 1.~Each cycle is 21 days.~May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
3057053|NCT02181218|Experimental|Dose Level 1 (10 mg/m2 romidepsin)|"Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;~Gemcitabine IV over 30 minutes on Day 1~Oxaliplatin IV over 2 hours on Day 1~Dexamethasone orally on Days 1-4~Pegfilgrastim subcutaneously on Day 3~Drugs may be administered in any order on Day 1.~Each cycle is 21 days.~May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
3057054|NCT02181218|Experimental|Dose Level 2 (12 mg/m2 romidepsin)|"Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;~Gemcitabine IV over 30 minutes on Day 1~Oxaliplatin IV over 2 hours on Day 1~Dexamethasone orally on Days 1-4~Pegfilgrastim subcutaneously on Day 3~Drugs may be administered in any order on Day 1.~Each cycle is 21 days.~May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
3057055|NCT02181205|Experimental|placebo|sphenopalatine ganglion block performed with normal saline as the placebo
3057056|NCT02181205|Active Comparator|bupivacaine|sphenopalatine ganglion block performed with bupivacaine
3057057|NCT02181192|Experimental|delayed radiotherapy|PET/CT and Radiotherapy after achievement of PSA marginal value Additive imaging
3057058|NCT02181192|Active Comparator|instant radiotherapy|Instant Radiotherapy according to guidelines
3057059|NCT02181179|Active Comparator|Yoga|This will involve participating in at least two 60-minute Vinyasa yoga sessions each week for eight weeks (weeks 1-8). This will begin the week following a baseline laboratory appointment. These sessions will be conducted at a local Austin studio that has numerous locations in the area.
3057060|NCT02181179|No Intervention|Waitlist|If randomized to this group, participants will complete weekly assessments only and not yoga during their time in the study. Following full completion of the study (i.e., after week 10), participants will be compensated with a voucher for 2 free months of yoga.
3057061|NCT02181166|Experimental|kinesiotherapy + High voltage electrical stimulation|Same protocol group kinesiotherapy + high voltage electrial stimulation with two rectangular electrodes (3x5 cm) active silicon-carbon and an electrode rectangular dispersive (10x18cm) aluminum wrapped with a damp felt in water. The active electrodes are positioned in central myofascial trigger point of the upper trapezius muscle after application of water soluble gel. The dispersive electrode was placed in the lumbar region. The following parameters will be use: frequency of 10 Hz, twin pulses of 20μs to 100ms between pulses and the maximum voltage tolerated by voluntary until the motor threshold (visible muscle contraction) to increase every five minutes, totaling 30 minutes of stimulation. The negative polarity will be use.
3057062|NCT02181166|Experimental|Kinesiotherapy group|The volunteer will be subjected to the following protocol: These exercises involve stretching of the cervical, anterior and posterior chain of the upper trunk and active mobilization of the cervical, shoulder movements of flexion, extension, abduction and adduction of the shoulder and upper limb. The exercises lasted 50 minutes, with 10 minutes of walking, and stretching was performed with two repetitions of 20 seconds, and active mobilization exercises of three sets of eight repetitions and final relaxation of 10 minutes were performed.
3057063|NCT02181166|Experimental|kineshioterapy + isquemic compression|The same protocol group kinesiotherapy + ischemic compression in central myofascial trigger point of the upper trapezius muscle. This procedure was performed for 90 seconds.
3057064|NCT02181153|Other|siblings of patients with IBD|Blood and fecal samples from 100 siblings of children affected with IBD will be collected at the day of enrolment. Clinical risk factors for IBD will be also recorded in a case report form.
3057065|NCT02181153|Other|patients without family history of IBD|Blood and fecal samples of 100 healthy children without a family history of IBD will be collected at the day of enrolment. Clinical risk factors for IBD will be also recorded in a case report form
3057066|NCT02181140|Other|EUS guided FNA and fine needle punction|punction of endosonographically identified space-occupying process with aspirating fine needle and pro core fine needle in a randomized order
3057067|NCT02181127|Active Comparator|Glucagon-only Bionic Pancreas (active)|Glucagon-only Bionic Pancreas will deliver glucagon during 7 of the 14 days. The order of the glucagon days will be randomized in blocks of 2, with no more than 2 days in a row of glucagon.
3057068|NCT02181127|Placebo Comparator|Glucagon-only Bionic Pancreas (placebo)|Glucagon-only Bionic Pancreas will deliver placebo during 7 of the 14 days. The order of the placebo days will be randomized in blocks of 2, with no more than 2 days in a row of placebo.
3057069|NCT02181114|Experimental|Expert System Coaching|Patients in the intervention group will receive coaching based off the answers provided in the computer-based Expert System that is designed to track their readiness level to pursue a living donor kidney transplant.
3057070|NCT02181114|No Intervention|Control|Patients in the control group will only receive the standard of care education that is offered at the UCLA Kidney and Pancreas Transplant Center which consists of a powerpoint presentation on their Evaluation Day appointment.
3057071|NCT02181101|Experimental|AA-BA|FEC-DocGemzar adjuvant chemotherapy; zoledronic acid i.v. 5 years
3057072|NCT02181101|Experimental|AB-BA|FEC-Doc adjuvant chemotherapy; zoledronic acid i.v. 5 years
3057073|NCT02181101|Experimental|AA-BB|FEC-DocGemzar adjuvant chemotherapy; zoledronic acid i.v. 2 years
3057074|NCT02181101|Active Comparator|AB-BB|FEC-Doc adjuvant chemotherapy; zoledronic acid i.v. 2 years
3057075|NCT02181088|Experimental|Group 1 (ChAd63 RH5 low dose)|1 dose of ChAd63 RH5 5 x 10^9 vp intramuscularly
3057076|NCT02181088|Experimental|Group 2A (ChAd63 RH5 full dose)|1 dose of ChAd63 RH5 at 5 x 10^10 vp intramuscularly
3057077|NCT02181088|Experimental|Group 2B (ChAd63 RH5 full dose and MVA RH5 low dose)|1 dose of ChAd63 RH5 at 5 x 10^10 vp intramuscularly and 1 dose MVA RH5 at 1 x 10^8 pfu 8 weeks later intramuscularly
3057078|NCT02181088|Experimental|Group 2C (ChAd63 RH5 full dose and MVA RH5 full dose)|1 dose of ChAd63 RH5 at 5 x 10^10 vp intramuscularly and 1 dose MVA RH5 at 2 x 10^8 pfu 8 weeks later intramuscularly
3057079|NCT02181062|Experimental|Walking Intervention|"4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.~The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.~Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.~The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age."
3057080|NCT02181062|No Intervention|Wait-list control|After 3 months, participants will be invited to participate in the intervention. No additional measures or outcomes will be recorded.
3057081|NCT02181036|Experimental|family work shop|2 to 3 hours per session, one session per week, for a total of 6 weeks of family work shop
3057082|NCT02181023|Experimental|Aclidinium - Glycopyrronium|Patients will assume Aclidinium Bromide 322 dry powder by Genuair inhaler and Glycopyrronium 44 dry powder inhaler by Breezehaler inhaler (placebo) after 72 hours from inhalatory therapy washout (only short acting bronchodilators permitted). Then, after 72 hours of inhalatory drugs washout (only short acting bronchodilators permitted), they will receive Glycopyrronium Bromide 322 mcg via Breezehaler inhaler and Aclidinium Bromide 322 dry powder by Genuair inhaler (placebo).
3057083|NCT02181023|Experimental|Glycopyrronium - Aclidinium|Patients will assume Glycopyrronium Bromide 44 mcg dry powder by Breezehaler inhaler and Aclidinium Bromide 322 dry powder by Genuair inhaler (placebo) after 72 hours of inhalatory therapy washout (only short acting bronchodilators permitted). Then, after 72 hours of inhalatory drugs washout (only short acting bronchodilators permitted) they will receive Aclidinium Bromide 322 mcg via Genuair inhaler and Glycopyrronium Bromide 44 mcg dry powder by Breezehaler inhaler (placebo).
3057084|NCT02181010|Experimental|Intervention|The intervention is a multi-level, multi-component intervention designed to increase access to and consumption of healthier foods in low-income, urban, minority neighborhoods. Intervention components will occur at the policy level; food wholesaler level; small food retail outlet level; neighborhood level; household level.
3057116|NCT02180828|Experimental|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
3057117|NCT02180828|Active Comparator|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
3057085|NCT02181010|No Intervention|Control|Similar to many community- based public health research programs, the control arm will not receive any intervention components during the initial intervention period. However, after all assessments are completed they will receive a 'delayed intervention' protocol, where the community receives the intervention elements as described in the intervention arm after assessment measures have been completed.
3057086|NCT02180997|Experimental|Tamsulosin 1|Volunteers will be taken Tamsulosin and solifenacin
3057087|NCT02180997|Experimental|Solifenacin 1|Volunteers will be taken Tamsulosin and solifenacin
3057088|NCT02180997|Experimental|Co-administration 1|Volunteers will be taken Tamsulosin and solifenacin
3057089|NCT02180997|Experimental|Tamsulosin 2|Volunteers will be taken Tamsulosin and solifenacin
3057090|NCT02180997|Experimental|Solifenacin 2|Volunteers will be taken Tamsulosin and solifenacin
3057091|NCT02180997|Experimental|Co-administration 2|Volunteers will be taken Tamsulosin and solifenacin
3057092|NCT02180984|Active Comparator|BED randomized to rTMS|"30 obese individuals currently diagnosed with BED and meeting criteria for the study will be randomized to active rTMS treatment.~Intervention: Neurosoft device targeting the left DLPFC (neuro-navigational method).~Proposed schedule of treatment:~20 sessions of neuronavigated rTMS, one session per day, 3 days/week over approximately 7 weeks. Focal rTMS will be performed using a Neurosoft device and a 'figure of eight' coil. Brainscience Neuronavigation will be used to guide the placement of the coil to the target PFC region using a template MRI for all participants. The coil will be placed at a 45° angle to the mid-sagittal line to induce a posterior to anterior current in the underlying neural tissue. For the real treatment condition, stimulation will target the left DLPFC at 110% of the resting motor threshold. Each session of 10 Hz stimulation will apply 1000 pulses to the left hemisphere, with a duty cycle of 5s on and 55s off, for a total stimulation time of 20 min."
3057093|NCT02180984|Sham Comparator|Sham BED TMS|"30 obese individuals currently diagnosed with BED will be randomized to receive sham TMS treatment. Blinded to participants and study staff, except to the doctor applying the TMS treatment.~Intervention: Neurosoft device targeting the left DLPFC (neuro-navigational method).~Proposed schedule of treatment:~20 sessions of neuronavigated rTMS, one session per day, 3 days/week over approximately 7 weeks. Focal rTMS will be performed using a Neurosoft device and a 'figure of eight' coil. Brainscience Neuronavigation will be used to guide the placement of the coil to the target PFC region using a template MRI for all participants. The coil will be placed at a 45° angle to the mid-sagittal line to induce a posterior to anterior current in the underlying neural tissue. Sham treatment condition, will follow the same protocol however no real TMS will be delivered."
3057094|NCT02180984|No Intervention|Control (obese non BED)|15 controls, obese but without a current or past diagnosis of BED will complete the baseline measurements only.
3057095|NCT02180984|No Intervention|Controls (normal weight)|15 controls, normal weight and without a current or past diagnosis of BED will complete baseline measures only.
3057096|NCT02180971|Experimental|Positive CAG with EG test|A positive finding for coronary angiography with an ergonovine provocation test is defined as transient, total, or sub-total occlusion (>90% stenosis) with signs/symptoms of myocardial ischemia (chest pain and ischemic ECG change).
3057097|NCT02180971|Experimental|Negative CAG with EG test|Negative test: less than 70% luminal narrowing, without chest pain or ST-segment changes after ergonovine coronary injection
3057098|NCT02180958||Cerebral Arteriovenous Malformations|Adult patients requiring endovascular treatment of Cerebral Arteriovenous Malformations.
3057099|NCT02180945||Intracranial Dural Arteriovenous Fistula|Adult patients requiring endovascular treatment of Intracranial Dural Arteriovenous Fistulae.
3057100|NCT02180932|Experimental|periodontal disease|Saliva samples
3057101|NCT02180919|No Intervention|Control period|All patients with receive standard optimal medical care according to ESC Heart Failure guidelines, NICE COPD guidelines or other best practice care pathways as relevant to their condition.
3057102|NCT02180919|Experimental|Telemonitoring|telemonitoring will be carried out in the patient's home using the conformity European (CE) marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a television (TV) channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
3057103|NCT02180906||Patients with NSTI|Definition: An infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection in subcutis, muscle and/or fascia and are spreading along tissue structures.
3057104|NCT02180893|Experimental|Paravertebral block|Patient receiving a PVB prior to robotic mitral valve surgery
3057105|NCT02180893|Placebo Comparator|No block|Patients who did not receive PVB
3057106|NCT02180880|Experimental|Pregabalin and Oxcarbazpepine|Pregabalin and Oxcarbazepine
3057107|NCT02180867|Experimental|Regimen A (pazopanib hydrochloride, chemoradiation)|See Regimen A Detailed Description.
3057108|NCT02180867|Experimental|Regimen B (chemoradiation)|See Regimen B Detailed Description.
3057109|NCT02180867|Experimental|Regimen C (pazopanib hydrochloride, radiation therapy)|"INDUCTION PHASE: Patients receive pazopanib hydrochloride PO QD on weeks 1-9. Patients undergo radiation therapy on weeks 1-7.~SURGERY: Patients undergo surgery on week 10.~CONTINUATION PHASE: Patients receive pazopanib hydrochloride PO QD on weeks 13-25. Patients undergo radiation therapy on weeks 13-16 for a total of 50 Gy. Patients with impaired wound healing within 8 weeks of the date of surgery, are removed from protocol therapy effective the date 8 weeks after week 10 surgery."
3057110|NCT02180867|Experimental|Regimen D (radiation therapy)|"INDUCTION PHASE: Patients undergo radiation therapy on weeks 1-7.~SURGERY: Patients undergo surgery on week 10.~CONTINUATION PHASE: Patients undergo radiation therapy on weeks 13-16 for a total of 50 Gy. Patients with impaired wound healing within 8 weeks of the date of surgery, are removed from protocol therapy effective the date 8 weeks after week 10 surgery."
3057111|NCT02180854|Experimental|Intervention (8 hours)|EWS every 8 hours
3057112|NCT02180854|Active Comparator|Control (12 hours)|EWS every 12 hours
3057113|NCT02180841|Experimental|Soy 25g|Soy protein powder (25g/day)
3057114|NCT02180841|Experimental|Soy 50g|Soy protein powder 50 g/day
3057115|NCT02180841|Placebo Comparator|Control|Control powder
3057118|NCT02180815||ReVENT implanted group|
3057119|NCT02180802|Experimental|motivational intervieing group|The behavioral intervention targets were improved eating and physical activity behavior in order to reduce obesity levels. Each adolescent was encouraged to eat a variety of foods from each of the four major food groups and low-fat alternatives . Moreover, each adolescent was encouraged to achieve at least 60 minutes of moderate-to-vigorous intensity physical activity daily as recommended by the World Health Organization
3057120|NCT02180802|Experimental|motivational interviewi group with parental involvement|an additional single session with parents or guardians over 60 minutes in the clinic
3057121|NCT02180802|Active Comparator|Control|The patients received routine care
3057122|NCT02180789|Experimental|Harnalidge® OCAS®|
3057123|NCT02180776|Active Comparator|Group A|Patients assigned to group A wore the Summit 456 TLSO (intervention) for four weeks in phase 1 of the study, followed by four weeks of observation (control) in phase 2.
3057124|NCT02180776|Placebo Comparator|Group B|Patients assigned to group B started four weeks of observation (control) in phase 1, followed by four weeks of summit 456 TLSO (intervention) in phase 2 of the study.
3057125|NCT02180763|Experimental|Gammanorm® 165 mg/mL|
3057126|NCT02180750|Experimental|Intervention: Memory Work Therapy|Residential week intervention consisting of memory box, memory book, tree of life, Active Citizen book, all activities facilitated.
3057127|NCT02180750|Active Comparator|Control: standard care|Usual care services.
3057128|NCT02180737|Experimental|Dexmeditomedine|Dexmedetomidine will be initiated at 0.6 mcg/kg/hr and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hr.
3057129|NCT02180724|Experimental|Acalabrutinib Regimen 1|Acalabrutinib Regimen 1
3057130|NCT02180711|Experimental|acalabrutinib Regimen 1|acalabrutinib Regimen 1
3057131|NCT02180711|Experimental|acalabrutinib Regimen 2|acalabrutinib Regimen 2 + rituximab for relapsed, refractory, or treatment naive subjects
3057132|NCT02180698|Experimental|Treatment (TLR4 agonist GLA-SE, radiation therapy)|Patients receive TLR4 agonist GLA-SE intratumorally once weekly for 8 weeks. Within 2 weeks of starting treatment, patients also undergo radiation therapy over 2 weeks for a total of 5-6 fractions.
3057133|NCT02180685|Other|Anchor fixation|Medial fixation of the reconstruction at the medial femural condyle with suture anchors.
3057134|NCT02180685|Other|Screw fixation|Medial fixation of the reconstruction at the medial femural condyle with a screw.
3057135|NCT02180672|Active Comparator|Nasal steroids|Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).
3057136|NCT02180672|Placebo Comparator|Placebo|Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).
3057137|NCT02180659|Experimental|buprenorphine implants + placebo tablets|Four 80 mg Probuphine implants + daily SL placebo tablets
3057138|NCT02180659|Active Comparator|buprenorphine tablets + placebo implants|Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
3057139|NCT02180646|Active Comparator|High Carb then High Protein Breakfast|A high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat) followed by a 7-day washout period, and then 7 days of eating a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat).
3057140|NCT02180646|Active Comparator|High Protein then High Carb Breakfast|A high protein breakfast - 500 kcal followed by a 7-day washout period, and then 7 days of eating a high carbohydrate breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
3057141|NCT02180633||Fellow Eyes|Patients that suffer from unilateral idiopathic macular hole, and whose fellow eyes don't show any sign of retinal pathology.
3057142|NCT02180633||Controls|Healthy subjects age-matched to the other group, with no visible retinal pathologies.
3057143|NCT02180620|Experimental|No exercise|participants will remain sedentary during testing
3057144|NCT02180620|Experimental|Meal then exercise|45 min of resistance training will be performed after a standard meal
3057145|NCT02180620|Experimental|exercise then meal|45 min of resistance training will be performed prior to a standard meal
3057146|NCT02180607||Healthy Controls|Response to social feedback, monetary incentive delay, and go/no-go tasks
3057147|NCT02180607||MDD patients|Response to social feedback, monetary incentive delay, and go/no-go tasks
3057148|NCT02180581|Experimental|Probiotic (2 * 10^9 cfu/d)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12) and Lactobacillus Rhamnosus GG (LGG) in a dosage of 10^9 cfu/day of each strain. The probiotics are provided as powder in a sachet, and can be added to food or drink
3057149|NCT02180581|Placebo Comparator|Placebo|provided as powder in a sachet, and can be added to food or drink
3057150|NCT02180568|Experimental|Lipiodol|Lipiodol-guided lung localization technique
3057151|NCT02180568|Active Comparator|Hookwire|Hookwire-guided lung localization technique
3057152|NCT02180555||ICU patients|
3057153|NCT02180542||Ischemic stroke patients|Patients admitted with ischemic stroke from march 2012 to april 2014
3057154|NCT02180529|Experimental|Methylphenidate|On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention. Two hours after taking the drug participants will be assessed cognitively by means of Mindstreams and MoCA (Montreal Cognitive Assessment).
3057155|NCT02180529|Placebo Comparator|Placebo|Participants in the control group will receive placebo. On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of Placebo every day of intervention. Two hours after taking the placebo participants will be assessed cognitively by means of Mindstreams and MoCA (Montreal Cognitive Assessment).
3057156|NCT02180516||Meloxicam|
3057157|NCT02180516||Other NSAIDs|
3057158|NCT02180503|Experimental|BI 1356 BS - low dose|
3057159|NCT02180503|Experimental|BI 1356 BS - high dose|
3057160|NCT02180490|Experimental|UHAC 62 XX tablet|
3057161|NCT02180490|Active Comparator|UHAC 62 XX capsule|
3057162|NCT02180477|Experimental|UHAC 62 XX TF1 tablet|
3057163|NCT02180477|Experimental|UHAC 62 XX TF2 tablet|
3057164|NCT02180477|Active Comparator|UHAC 62 XX capsule|
3057165|NCT02180464|Experimental|LAS41004|Topical application of approximately 2 - 6 mg/cm2 to an area of 20 - 300 cm2, each once daily
3057249|NCT02179918|Experimental|PF-05082566 +MK-3475|PF-05082566 +MK-3475
3057166|NCT02180464|Active Comparator|control|Topical application of approximately 2 - 6 mg/cm2 of IMPs 1 and 2 to an area of 20 - 300 cm2, each once daily
3057167|NCT02180438|Experimental|Open label prospective single arm study of Stribild|
3057168|NCT02180425||Healthy Group|The subjects in this group do not have a history of acne.
3057169|NCT02180425||Acne Group, Topical Retinoid|These subjects have been prescribed a topical retinoid for their acne. They will participate in the study for a period of 1 month.
3057170|NCT02180425||Acne Group, Isotretinoin|These subjects have been prescribed isotretinoin for their acne. They will participate in the study for a period of 5-6 months.
3057171|NCT02180412|Experimental|Panhematin|Panhematin plus glucose
3057172|NCT02180412|Placebo Comparator|Placebo|Placebo (saline) plus glucose
3057173|NCT02180386|Experimental|Experimental group|Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
3057174|NCT02180373||vein graft bypass|patients who have had peripheral bypass
3057175|NCT02180373||SFA stent|Patients who have had SFA stenting
3057176|NCT02180360|Experimental|Capoeira training group|"The Capoeira training was performed during eight weeks, twice a week with duration of 60min each session, divided in 1) initial part: 10min warm-up with activities of low intensity or the ginga used in Capoeira; 2) main part: from the Basic Programmed Lesson (40min) and ; 3) final part: Capoeira presentation of 10min. In this last moment, the participants remained in a circle and, in pairs, executed the movements practiced earlier in the sessions. In order to perform the Basic Programmed Lesson, the activities were divided in four stages, composed by ginga and other movements: dodging, unbalancing, traumatizing and acrobatic. The volunteers would perform the initial part of the basic lesson (ex. 1st stage) and afterwards, when performing the subsequent part (ex. 2nd stage), would first repeat the 1st basic lesson, with the purpose of continuing the learning process and improving the previous lesson."
3057177|NCT02180360|No Intervention|Control group|The Control group did not perform any physical exercise during the intervention period (eight weeks).
3057178|NCT02180347||Multifocal contact lenses|Coopervision Proclear Multifocal
3057179|NCT02180347||Single vision contact lenses|Coopervision Proclear Sphere
3057180|NCT02180334|Experimental|Mosapride|"Mosapride citrate 5 mg (Gasmotin®): 1 tablet (5 mg) will be administered 1 hour before MMTT.~Linagliptin 5 mg (Trajenta®): 1 tablet (5 mg) per day should be taken for 7 days during run-in period. 1 tablet (5 mg) will be administered 1 hour before MMTT.~Acetaminophen 500 mg (Tylenol®): 3 tablets (1500 mg) will be administered at once with the mixed meal for calculating gastric emptying time."
3057181|NCT02180334|Placebo Comparator|Control|"Placebo drug: 1 tablet will be administered 1 hour before MMTT.~Linagliptin 5 mg (Trajenta®): 1 tablet (5 mg) per day should be taken for 7 days during run-in period. 1 tablet (5 mg) will be administered 1 hour before MMTT.~Acetaminophen 500 mg (Tylenol®): 3 tablets (1500 mg) will be administered at once with the mixed meal for calculating gastric emptying time."
3057182|NCT02180321|Active Comparator|Control|
3057183|NCT02180321|Experimental|Tranexamic acid|
3057184|NCT02180308|Experimental|PET/MRI|Patient receives PET/MRI
3057185|NCT02180295|Experimental|V212 Lot 1|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
3057186|NCT02180295|Experimental|V212 Lot 2|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
3057187|NCT02180295|Experimental|V212 Lot 3|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
3057188|NCT02180282|Experimental|Acne Treatment|Acne treatment using the M22-IPL acne filter
3057189|NCT02180269|Experimental|Cohort A|Single oral dose of either JNJ-54861911, 25 milligram (mg) tablet or matched placebo tablet on Day 1.
3057190|NCT02180269|Experimental|Cohort B|Single oral dose of either JNJ-54861911, 50 mg (2*25 mg tablets) or matched placebo tablets on Day 1.
3057191|NCT02180269|Experimental|Cohort C|Single oral dose of either JNJ-54861911, 100 mg (4*25 mg tablets) or matched placebo tablets on Day 1.
3057192|NCT02180256|Experimental|Endoscratching, non-RIF|Endometrial scratching. Women with no more than 1 previous unsuccessful embryo transfer. Pipelle in the first seven days of the menstrual cycle, just before starting controlled ovarian stimulation.
3057193|NCT02180256|No Intervention|Control, non-RIF|No intervention. Women with no more than 1 previous unsuccessful embryo transfer.
3057194|NCT02180256|Experimental|Endoscratching, RIF|Endometrial scratching. Women with 2 or more previous unsuccessful embryo transfers. Pipelle in the first seven days of the menstrual cycle, just before starting controlled ovarian stimulation.
3057195|NCT02180256|No Intervention|Control, RIF|No intervention. Women with 2 or more previous unsuccessful embryo transfers.
3057196|NCT02180243|Experimental|Yoga/Acupuncture|Eligible participants may be randomized to participate in iRest Yoga Nidra/ auricular acupuncture group classes.
3057197|NCT02180243|Active Comparator|Gulf War Health Education|Eligible participants may be randomized to participate in Gulf War Health Education group classes.
3057198|NCT02180230|Other|Shorty implants|Brånemark System Mk III Shorty and/or NobelSpeedy Shorty
3057199|NCT02180217|Experimental|LCI699|
3057200|NCT02180204|Experimental|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum dose: 25 mg
3057201|NCT02180204|Active Comparator|Alteplase|Alteplase 0.9 mg/kg IV - Maximum dose: 90 mg
3057202|NCT02180191||Obesity|27 obese individuals (20 men and 7 women with mean BMI: 39.98±5.56 kg/m2)
3057203|NCT02180191||Diabetes|26 patients with newly diagnosed type 2 diabetes (18 men and 8 women with mean BMI: 28.63±5.08 kg/m2)
3057204|NCT02180191||Control|Healthy control subjects (22 men and 6 women with mean BMI: 23.02±1.70 kg/m2)
3057205|NCT02180178||Consecutive patients undergoing coronary angiography|Consecutive patients undergoing coronary angiography at the University Medical Center Mainz - no inclusion criteria specified. The absorb substudy will include consecutive patients who received an Absorb scaffold based on clinical indication.
3057206|NCT02180165|Experimental|Posaconazole|300 mg posaconazole oral tablet (or 300 mg intravenous (IV) solution) twice on Day 1, followed by 300 mg oral tablet or IV solution once daily for up to 84 days
3057250|NCT02179905||Irritable bowel syndrome, Control|
3058420|NCT02172131|Placebo Comparator|Placebo|
3057207|NCT02180165|Active Comparator|Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
3057208|NCT02180152|Experimental|Postprandial walk|
3057209|NCT02180152|No Intervention|sedentary pregnant women|
3057210|NCT02180139|Experimental|Primary motor cortex (M1) stimulation|Treatment by transcranial direct current stimulation will be targeted to the motor cortex for all treatment sessions with Bilateral M1 with cathode to contralateral M1 and anode to ipsilateral M1, 15 minutes (Goal: decrease contralateral M1 excitability)
3057211|NCT02180139|Experimental|Cerebellum stimulation|Treatment with transcranial direct current stimulation will be targeted to the cerebellum at every session with anode to ipsilateral cerebellum with cathode to ipsilateral side of face, 15 minutes (Goal: increase ipsilateral cerebellum activation which exerts inhibitory effect on motor circuits)
3057212|NCT02180139|Experimental|Combined M1 and Cerebellum stimulation|Treatment with transcranial direct current stimulation will be placed with M1 anode contralateral + cerebellum anode. M1 will first be 'primed' with anode on contralateral M1, cathode on face, for 10 min, followed immediately by 15 min of cerebellar stimulation as in #2. (Goal: prime the contralateral M1 with increased excitability to engage a potentially larger effect from the following ipsilateral cerebellar stimulation that will be excited to exert inhibitory effect on the motor circuits including M1)
3057213|NCT02180139|Placebo Comparator|Sham stimulation|transcranial direct current stimulation will be given in placebo form. Sham stimulation: electrode placement will be same as M1. Sham tDCS will be applied by ramping down current intensity to 0 after 30 seconds following standard practice for sham tDCS.
3057214|NCT02180126||Positive ANCA|Patients with borderline positive ANCA results.
3057215|NCT02180113|Other|Fibroscan®|Fibroscan® is an active non implantable medical device using ultrasound. It has been designed to measure liver stiffness in a painless, rapid and non invasive manner. It is a diagnostic aid tool. In this study, Spleen Stiffness Measurement will be assessed using a dedicated FibroScan® device which has been developed specifically to assess spleen stiffness.
3057216|NCT02180100|Experimental|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
3057217|NCT02180100|Active Comparator|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
3057218|NCT02180087|Placebo Comparator|placebo group|Group 1 : Placebo group (P). 0 mg/kg ketoprofen IV every 6 hours for 48 hours (or 0 mg/kg every 24 hours) for 48 hours
3057219|NCT02180087|Other|ketopofen quarter dose|"Group 2 : Ketoprofen quarter dose (K ¼). 0,125 mg/kg ketoprofen IV every 6 hours (0,5 mg/kg every 24 hours) for 48 hours."
3057220|NCT02180087|Other|ketoprofen half-dose|"Group 3 : Ketoprofen half-dose (K ½). 0,25 mg/kg ketoprofen IV every 6 hours (1 mg/kg every 24 hours) for 48 hours."
3057221|NCT02180087|Other|Ketoprofen full dose|"Group 4 : Ketoprofen full dose (KPD). 0,5 mg/kg ketoprofen IV every 6 hours (or 2 mg/kg every 24 hours) for 48 hours"
3057222|NCT02180074||I|Women without PAD (ABI >1.0 and <1.4) or CAD, and < 2 risk factors for cardiovascular disease (to serve as healthy controls)
3057223|NCT02180074||II|Women without PAD (ABI>1.0 and <1.4) or CAD and > 2 risk factors for cardiovascular disease
3057224|NCT02180074||III|Women with PAD as defined by ABI <0.9 and a coronary angiogram without any significant coronary artery disease.
3057225|NCT02180074||IV|Women with CAD without PAD, as defined by >50% stenosis by coronary angiography and ABI >1.0 and <1.4.
3057226|NCT02180074||V|Women with both CAD and PAD.
3057227|NCT02180061|Experimental|Advanced Cutaneous Melanoma|Participants with advanced cutaneous melanoma received pembrolizumab, 2 mg/kg, intravenously (IV) over 30 minutes on Day 1 of each 3-week dosing cycle (Q3W).
3057228|NCT02180061|Experimental|Advanced Mucosal Melanoma|Participants with advanced mucosal melanoma received pembrolizumab, 2 mg/kg, IV over 30 minutes on Day 1 Q3W.
3057229|NCT02180048|Active Comparator|400 mg of caffeine/day (Two 200mg pills/day)|One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
3057230|NCT02180048|Active Comparator|200 mg of caffeine/day (One 200mg pill and one placebo pill)|This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
3057231|NCT02180048|Placebo Comparator|Two placebo pills/day|This arm will have participants consume two placebo pills each day.
3057232|NCT02180035|Experimental|Symbiotic & Nutritional intervention|Symbiotic (dietary fibers + probiotic bacteria) 6g sachet twice daily for 6 months, dietary prescription and nutritional counseling
3057233|NCT02180035|Placebo Comparator|Maltodextrin & Nutritional intervention|Maltodextrin (placebo for symbiotic) 6g sachet twice daily for 6 months, dietary intervention and nutritional counseling.
3057234|NCT02180022|Placebo Comparator|Placebo|Patients treated with placebo for 12 weeks
3057235|NCT02180022|Experimental|Onion peel extract|Patients treated with onion peel extract for 14 days
3057236|NCT02180009||normal control|healthy people
3057237|NCT02180009||sepsis|mild response to infection
3057238|NCT02180009||severe sepsis|infection with at least one organ dysfunction
3057239|NCT02180009||septic shock|patients with septic shock
3057240|NCT02179996|Active Comparator|Three vaccine injections|Infants in this study arm will receive three vaccine injections at two, three and four months after birth (vaccine: DTP-pertussis-Hib).
3057241|NCT02179996|Experimental|Two vaccine injections|Infants in this study arm will receive two vaccine injections at two and four months after birth (vaccine: DTP-pertussis-Hib).
3057242|NCT02179983|No Intervention|Standard care|Standard care for exacerbation and follow-up without rehabilitation
3057243|NCT02179983|Experimental|Pulmonary rehabilitation|6 weeks of exercise and patient education after exacerbation (pulmonary rehabilitation)
3057244|NCT02179970|Other|Plerixafor (Mozobil)|Plerixafor (Mozobil), continuous 7 day IV infusion. Starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
3057245|NCT02179957||CT and FFR|Coronary stenoses which have been analysed with both CT and FFR
3057246|NCT02179944||Participants|
3057247|NCT02179931|Experimental|Flupentixol/melitracen film-coated tablet|test treatment - 0.5 mg/10 mg; oral as a single dose
3057248|NCT02179931|Other|Flupentixol/melitracen coated tablet (Deanxit®)|reference treatment - 0.5 mg/10 mg, oral as a single dose
3057251|NCT02179892|Active Comparator|Group 1-Exparel|Bupivacaine Extended-Release Liposome Injection (Exparel)will be administered via TAP block procedure
3057252|NCT02179892|Active Comparator|Group 2-Bupivacaine and Dexamethasone IV|Bupivacaine and Dexamethasone Injection will be administered via TAP block procedure.
3057253|NCT02179879||Video validation group|This will include video taping of experts (defined as one who has performed more than 500 labor epidurals in preceding 5 year period) and novices (defined as one who has done less than 50 epidurals in preceeding 2 years) perfoming labor epidural
3057254|NCT02179866|Experimental|[14C]-labeled RO5285119|Single oral dose - drinking solution
3057255|NCT02179853|Experimental|Anakinra|This is a dose escalation study (4 mg/kg, 6 mg/kg and 8 mg/kg).
3057256|NCT02179840|Active Comparator|Intravenous|Anesthesia is maintained via intravenous agents. Mechanical ventilation adjustment will be performed.
3057257|NCT02179840|Active Comparator|Inhalational|Anesthesia is maintained via inhalational agents. Mechanical ventilation adjustment will be performed.
3057258|NCT02179814|Experimental|AMPT|"Experimental:~alpha-methyl-paratyrosine (AMPT, trade name: Demser), body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 time points over 24 hours"
3057259|NCT02179814|Sham Comparator|Diphenhydramine & placebo|Diphenhydramine (25mg, trade name in Switzerland: Benocten) at the first medication intake time point, placebo at the second to fourth intake time point (medication intake over 24 hours)
3057260|NCT02179788|Experimental|Standard care plus metformin|67% of stage 2 eligible mothers will be randomly allocated to this arm. Mothers will be instructed to thoroughly empty their breasts at least 8 times per day and to take the assigned study drug.
3057261|NCT02179788|Placebo Comparator|Standard Care plus placebo|"33% of Stage 2 eligible mothers will be randomly allocated to this arm. Mothers will be instructed to thoroughly empty their breasts at least 8 times per day (Standard Care) and to take the assigned study drug. The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~Days 1-7, take 1 capsule with evening meal~Days 8-14, take 3 capsules with evening meal~Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
3057262|NCT02179775|Active Comparator|propranolol|
3057263|NCT02179775|Active Comparator|Quince's oxymel|
3057264|NCT02179775|Placebo Comparator|placebo|
3057265|NCT02179762|Experimental|Arm I (moderate intensity exercise)|Patients perform moderate intensity exercise on a stationary bike for 20-50 minutes, three days a week for 16 weeks.
3057266|NCT02179762|Experimental|Arm II (HIIT exercise on a standard stationary bike)|Patients perform HIIT exercise on a standard stationary bike, three days a week for 16 weeks.
3057267|NCT02179762|Experimental|Arm III (HIIT exercise on a cybercycle)|Patients perform HIIT exercise on a cybercycle using racing or other games, three days a week for 16 weeks.
3057268|NCT02179749|Active Comparator|Experimental: mifepristone 600 mg daily|600 mg mifepristone daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
3057269|NCT02179749|Active Comparator|Experimental: mifepristone 1200 mg daily|1200 mg mifepristone daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
3057270|NCT02179749|Placebo Comparator|Placebo daily, 1-week|Placebo pills daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
3057271|NCT02179736|Experimental|Active treatment|
3057272|NCT02179723|Experimental|Leukosan Adhesive|Leukosan Adhesive applied to one wound (left or right)
3057273|NCT02179723|Active Comparator|Transcutaneous suture|Transcutaneous suture applied to second wound (left or right)
3057274|NCT02179710||Motivational Interviewing|Review of adherence dashboard by the investigator with the patient to facilitate and engage intrinsic motivation within the client in order to change behavior.
3057275|NCT02179697|Active Comparator|Surgery + Bracing vs. Bracing Alone|"Randomize between 2 treatments:~Treatment 1: Surgery + Bracing Treatment 2: Bracing alone"
3057276|NCT02179697|Other|Patient's choice|Patient will decide which group is best for him/her. The patient will be followed at the same points as Group 1.
3057277|NCT02179684|Experimental|Early surgery|Patienst with Bell´s Palsy with an early surgical intervention (< 3month), according to 'baby-sitter' method
3057278|NCT02179684|Active Comparator|Conventional treatment and follow-up|Patienst with Bell´s Palsy treated with conventional treatment and standardized physiotherapy according to Jaqueline Diels model.
3057279|NCT02179671|Experimental|Gefitinib with a Seq. Switch to a MEDI4736|Gefitinib once daily followed by MEDI4736
3057280|NCT02179671|Experimental|AZD9291 with a Seq. Switch to a MEDI4736|AZD9291 once daily followed by MEDI4736
3057281|NCT02179671|Experimental|Selumetinib+Docetaxel with a Seq. Switch to a MEDI4736|Selumetinib twice daily + docetaxel, followed by MEDI4736
3057282|NCT02179671|Experimental|Tremelimumab with a Seq. Switch to a MEDI4736|Tremelimumab every 4 weeks followed by MEDI4736
3057283|NCT02179658|Experimental|OPT-80 group|Oral
3057284|NCT02179658|Active Comparator|Vancomycin group|Oral
3057285|NCT02179645|Experimental|GRC 27864|Test Treatment GRC 27864
3057286|NCT02179645|Active Comparator|Celecoxib|Active Comparator Treatment
3057287|NCT02179645|Placebo Comparator|Placebo|Placebo Treatment
3057288|NCT02179632|Experimental|Disclosure intervention zero|Treatment Group 1: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. A. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. A, according to manufacturer, in 2012. Dr. A will be a physician the researchers have chosen who does not appear on the website and therefore did not receive any payments in 2012. Participants should report $0/not listed as the response. Following this stage, participants will be told that Dr. A does not appear on the website and therefore did not receive any payments.
3057327|NCT02179411|Active Comparator|renal transplant recipients grave|renal transplant recipients grave
3057328|NCT02179398|Experimental|Lab-score group|"Patients assessed through the Lab-score determination only: Lab-score ≥3 used as the sole marker for the detection of serious bacterial infection.~(WBC and band counts blinded to the physician in charge of the patient)"
3057289|NCT02179632|Experimental|Disclosure intervention low|"Treatment Group 2: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. B. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. B, according to manufacturer, in 2012. Dr. B will be a physician the researchers have chosen who received an aggregate amount that is a low payment (below $100) in 2012. Participants should report the dollar amount listed as the response. Following this stage, participants will be told the exact dollar amount for payments received by Dr. B in 2012."
3057290|NCT02179632|Experimental|Disclosure intervention high|"Treatment Group 3: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. C. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. C, according to manufacturer, in 2012. Dr. C will be a physician the researchers have chosen who received an aggregate amount that is a high payment (above $250) in 2012. Participants should report the dollar amount listed as the response. Following this stage, participants will be told the exact dollar amount for payments received by Dr. C in 2012."
3057291|NCT02179632|No Intervention|Control group|Control Group: The control group will not be exposed to the disclosure website, but will participate in another online information-seeking task. These participants will visit the Farmer's Almanac website and be asked to search for temperature reports.
3057292|NCT02179619|Experimental|Dermalax(Deep)|subject injected in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period
3057293|NCT02179619|Active Comparator|Restylane|Subject injected in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period
3057294|NCT02179606|Experimental|Dermalax Implant Plus|Subject injected in the nasolabial folds of one side of the face in the initial treatment period.
3057295|NCT02179606|Active Comparator|Restylane Sub-Q|Subject injected in the nasolabial folds of one side of the face in the initial treatment period.
3057296|NCT02179593|Other|2-Segment SARPE|Maxilla expansion using one sagittal section of the maxilla.
3057297|NCT02179593|Other|3-Segment SARPE|Maxilla Expansion using two parasagittal section of the maxilla.
3057298|NCT02179580|Experimental|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days
3057299|NCT02179580|Placebo Comparator|Placebo|Placebo at a rate of 3.0 g three times per day for 28 days
3057300|NCT02179567|Experimental|Doc/Bev|Docetaxel/Bevacizumab
3057301|NCT02179554||cardiopulmonary bypass|Patients undergoing elective surgery requiring cardiopulmonary bypass
3057302|NCT02179541||Group 1|All Group 1 patients were diagnosed with OME, diagnoses made by endoscopic-otoscopic examination findings and type-B tympanograms. They were all scheduled for ventilation tube insertion. Diagnosis of OME was confirmed during this surgery. All patients were examined by 4 mm 0-degree Storz endoscope and light source. The Adobe Photoshop Elements 7.0 program was used for RGB measurements. Viscosity was measured by the Brookfield DV-II+ProCP Viscometer.
3057303|NCT02179541||Group 2|Children in Group 2 had totally normal tympanic membranes and type A tympanograms. They had no hearing loss, Eustachian tube dysfunction, or any other ear-related problem, and were included in the study as healthy controls. Excluded from the study were patients presenting with acute otitis media, tympanosclerotic plaques, mental retardation, and children who were difficult to cooperate with. All subjects were examined by 4 mm 0-degree Storz endoscope and light source. The Adobe Photoshop Elements 7.0 program was used for RGB measurements.
3057304|NCT02179541||Group 1a|To determine whether higher or lower viscosity of an effusion impacted RGB values, the patient group was subdivided into two subgroups according to viscosity level. Patients with an effusion below the mean viscosity value of 450 cP (centipoise) were assigned to Group 1a.
3057305|NCT02179541||Group 1b|To determine whether higher or lower viscosity of an effusion impacted RGB values, the patient group was subdivided into two subgroups according to viscosity level. Patients with an effusion above the mean viscosity value of 450 cP (centipoise) were assigned to Group 1b.
3057306|NCT02179528|Active Comparator|etoposide,maintenance therapy|etoposide,25mg qd d1-20，repeat every 28 days
3057307|NCT02179528|No Intervention|blank control|blank control
3057308|NCT02179515|Experimental|A|Three cohorts will receive MVA-brachyury-TRICOM vaccine administered subcutaneously as either 1, 2, or 4 injections of study drug at monthly (28 days +/ 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.
3057309|NCT02179502|Experimental|GLPG1690 single dose|Single oral dose of GLPG1690 suspension or solid formulation - ascending doses
3057310|NCT02179502|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension or solid formulation
3057311|NCT02179502|Experimental|GLPG1690 multiple doses|Multiple oral doses of GLPG1690 suspension - ascending doses
3057312|NCT02179502|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
3057313|NCT02179489|No Intervention|Control|surgery alone
3057314|NCT02179489|Experimental|Hipec|Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC
3057315|NCT02179476|Experimental|Glyder|Glyder Facet Restoration Device
3057316|NCT02179463||Neoadjuvant Chemotherapy|undergo neoadjuvant chemotherapy before surgery
3057317|NCT02179450||Blepharospasm|Patients suffering from Blepharospasm
3057318|NCT02179450||Cervical Dystonia|Patients suffering from cervical dystonia
3057319|NCT02179450||Bilateral facial palsy|Patients suffering from bilateral facial palsy of inflammatory origin
3057320|NCT02179450||Healthy Control|Control subjects
3057321|NCT02179424|Experimental|Health talk + Workshop + Booklet + SMS|Health talk + workshop (Motivational intervention) + booklet + Short Message Service (SMS)
3057322|NCT02179424|Experimental|Face-to-face counseling + Booklet + SMS|Face to Face counseling (Motivational intervention) + Booklet + SMS
3057323|NCT02179424|Experimental|Phone counseling + Health talk + Booklet + SMS|Phone counseling (Motivational intervention) + Health talk + booklet + SMS
3057324|NCT02179424|Experimental|Phone counseling + Booklet + SMS|Phone counseling (Motivational intervention) + booklet + SMS
3057325|NCT02179411|Active Comparator|healthy volunteers|healthy volunteers
3057326|NCT02179411|Active Comparator|renal transplant recipients|renal transplant recipients
3057329|NCT02179398|Active Comparator|Control group|"Patients assessed through the following classically admitted biomarkers for the detection of serious bacterial infection: WBC count, band count and CRP determination.~(PCT and thus Lab-score blinded to the physician in charge of the patient)."
3057330|NCT02179385|Experimental|Health coaching|Patients receive health coaching via the phone, face to face or group support, according to patients' choice
3057331|NCT02179385|Placebo Comparator|Standard of Care|
3057332|NCT02179372|Experimental|Eicosapentaenoic acid|Subject with Cronn's Disease and/or Ulcerative colitis in clinical remission will receive 2 g/day of eicosapentaenoic acid for 6 months
3057333|NCT02179372|Placebo Comparator|Medium chain fatty acid (placebo)|Subjects with Crohn's Disease and/or Ulcerative colitis will be receive 2 g/day of medium chain fatty acid for 6 months
3057334|NCT02179359|Experimental|Reduced Toxicity Ablative Regimen|For use in patients with a matched sibling donor or unrelated UCB donor and DBA patients who are <12 years and/or have mild/moderate iron exposure.
3057335|NCT02179359|Experimental|Reduced Intensity Preparative Regimen|For use in patients with unrelated donor bone marrow and for DBA patients who are >12 years and/or have significant iron exposure.
3057336|NCT02179359|Experimental|Myeloablative Preparative Regimen|For use in patients with a matched sibling donor, unrelated umbilical cord blood and in those with severe thalassemia.
3057337|NCT02179346||Cartilage defects in the hip joint|NOVOCART® Inject Autologous Chondrocyte Implantation
3057338|NCT02179333||Subjects with Ataxia|Patients with a diagnosis of ataxia (Friedreich's ataxia or Spinocerebellar ataxia type 1-30) aged 18-80 years old will be recruited for the study.
3057339|NCT02179320|Active Comparator|Dry needling|Dry needling for myofascial pain syndrome, in the trapezius muscle.
3057340|NCT02179320|Sham Comparator|Sham needling|Superficial dry needling in the trapezius muscle
3057341|NCT02179307|Experimental|Arm label 1-Set, 3-Set|12-week progressive strength training protocol of different volumes
3057342|NCT02179294|Active Comparator|Pethidine|Pethidine is pain relief in labour
3057343|NCT02179294|Active Comparator|Remifentanil|Remifentanil intravenous patient controlled analgesia
3057344|NCT02179281|Experimental|Suspend Before Low feature turned ON|"MiniMed™ 640G system with the Suspend Before Low feature turned ON; continuously set on at 3,6 mmol/L (65 mg/dL). Suspend On Low Alert and Resume Basal Alert for the SmartGuard group should be set OFF.~Administered intervention: Medtronic MiniMed™ 640G system"
3057345|NCT02179281|Active Comparator|Suspend Before Low feature turned OFF|"MiniMed™ 640G system with the Suspend Before Low and Suspend On Low features are both turned OFF; Alert On Low is set at 65 mg/dL (3,6 mmol/L). Resume Basal Alert should be set OFF as well.~Administered intervention: Medtronic MiniMed™ 640G system"
3057346|NCT02179268|Active Comparator|sertraline & control|sertraline 50-150mg tables for 1 year,Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
3057347|NCT02179268|Active Comparator|citalopram & Control|citalopram 20-40mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
3057348|NCT02179268|Active Comparator|venlafaxine & control|venlafaxine 75-100mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
3057349|NCT02179268|Active Comparator|reboxetine & control|reboxetine 4-8mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
3057350|NCT02179255|Experimental|Human Growth Hormone|1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) plus FSH 450 to 600 units per day administered subcutaneous (SQ) daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
3057351|NCT02179255|Active Comparator|Follicle Stimulating Hormone|FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
3057352|NCT02179242|No Intervention|Control arm|This arm will receive routine care following their heart failure which includes no cardiac rehab intervention.
3057353|NCT02179242|Experimental|Cardiac rehab|This arm will receive cardiac rehab intervention 3 times per week for 4 weeks following discharge.
3057354|NCT02179229|Placebo Comparator|CONTROL|Patient in the CONTROL arm will receive a powder containing only tapioca-resistant starch comparable in colour, texture and taste to the synbiotic.
3057355|NCT02179229|Experimental|SYNBIOTIC|Patients in this group will receive Probinul neutro® a synbiotic preparation containing (perpacket): lyophilised bacteria (5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subsp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarius and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus thermophilus), prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
3057356|NCT02179216|Active Comparator|Hydration|•Group 1: First day, Orthostatic Hypotension test after hydration by three large glasses of clear liquid (33cl). Second day, Orthostatic Hypotension test with venous contention in the morning.
3057357|NCT02179216|Active Comparator|Venous contention|•Group 2: First day, Orthostatic Hypotension test after implementation of venous contention in the morning. Second day, Orthostatic Hypotension test after hydration by three large glasses of clear liquid (33cl).
3057358|NCT02179190|Experimental|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
3057359|NCT02179177|Active Comparator|Apixaban|Active drug Apixaban 2.5mg taken by mouth twice a day
3057360|NCT02179177|Placebo Comparator|Placebo|Sugar pills that look like Apixaban that will be taken by mouth twice a day
3057361|NCT02179151|Placebo Comparator|Placebo|Intervention: ZGN-440 Placebo for Injectable Suspension
3057362|NCT02179151|Experimental|ZGN-440 Injectable Suspension (1.8 mg)|Intervention: ZGN-440 for Injectable Suspension
3057363|NCT02179151|Experimental|ZGN-440 Injectable Suspension (2.4 mg)|Intervention: ZGN-440 for Injectable Suspension
3057364|NCT02179138|Other|TFV 1% Gel|TFV 1% gel with the user-filled paper applicator
3058421|NCT02172118|Experimental|severely renally impaired patients|
3057365|NCT02179125|Experimental|Bronchoscopic LVR-coil treatment|Bronchoscopic lung volume reduction with coil treatment
3057366|NCT02179099|Experimental|BTX mixed with TC-3 Gel|Patients will be treated with a single intravesical instillation of 40 ml TC-3 gel mixed with 300U BTX
3057367|NCT02179086|Active Comparator|Arm A1 (control)|"Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT QD, 5 days a week for 23 fractions plus a boost of 7 additional fractions.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
3057368|NCT02179086|Experimental|Arm B (photon IMRT)|"Patients undergo dose-escalated and -intensified photon IMRT QD, 5 days a week for a total of 30 fractions.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
3057369|NCT02179086|Active Comparator|Arm A2 (control)|"Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT as in Arm A1.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
3057370|NCT02179086|Experimental|Arm C (proton beam radiation therapy)|"Patients undergo dose-escalated and -intensified proton beam therapy QD, 5 days a week for a total of 30 fractions.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
3057371|NCT02179073||neurogenic bladder dysfunction|
3057372|NCT02179060||Cooling group|The RhinoChill® cooling is started as soon as possible to the patients with Cardiac arrest, and before the return of spontaneous circulation
3057373|NCT02179060||Control group|Standard care, no cooling during pre-hospital care
3057374|NCT02179047||stable angina, biomarker|patients with stable angina who received coronary angiography.
3057375|NCT02179034|Placebo Comparator|Tobacco Flavor|In this arm, subjects will receive tobacco flavor- without nicotine (placebo). Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
3057376|NCT02179034|Active Comparator|Low Dose Nicotine|In this arm, subjects will receive a low dose of nicotine (6 mg/ml) added to the tobacco flavor. Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
3057377|NCT02179034|Active Comparator|High Dose Nicotine|In this arm, subjects will receive a high dose of nicotine (12 mg/ml) added to the tobacco flavor. Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
3057378|NCT02179008|Experimental|DE-117 Low Dose ophthalmic solution|One drop Low Dose DE-117 in each eye QD for 90 days
3057379|NCT02179008|Experimental|DE-117 Low/Middle Dose ophthalmic solution|One drop DE-117 Low/Middle Dose ophthalmic solution in each eye QD for 90 days
3057380|NCT02179008|Experimental|DE-117 Middle Dose ophthalmic solution|One drop Middle Dose DE-117 in each eye QD for 90 days
3057381|NCT02179008|Experimental|DE-117 Middle/High Dose ophthalmic solution|One drop Middle/High Dose DE-117 in each eye QD for 90 days
3057382|NCT02179008|Experimental|DE-117 High Dose ophthalmic solution|One drop High Dose DE-117 in each eye QD for 90 days
3057383|NCT02179008|Active Comparator|latanoprost ophthalmic solution 0.005%|One drop latanaprost in each eye QD for 90 days
3057384|NCT02178995|No Intervention|Healthy Controls|"Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.~Healthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."
3057385|NCT02178995|Experimental|Participants With Epilepsy (Open-label)|Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After a four week treatment trial, their scores on the batteries and questionnaires were again assessed.
3057386|NCT02178995|Experimental|10mg, 20mg, Then Placebo (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
3057387|NCT02178995|Experimental|10mg, Placebo, Then 20mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
3057388|NCT02178995|Experimental|Placebo, 20mg, Then 10mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
3057389|NCT02178995|Experimental|Placebo, 10mg, Then 20mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
3057390|NCT02178995|Experimental|20mg, Placebo, Then 10mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
3057391|NCT02178995|Experimental|20mg, 10mg, Then Placebo - Double-blind|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
3057392|NCT02178995|Experimental|40mg, 20mg, Then Placebo (One Participant)|This study was originally intended to use 40mg, 20mg, and placebo doses rather than 20mg, 10mg, and placebo. This individual developed tachycardia (see adverse events) on the 40mg dose, and was withdrawn from the double-blind portion as a result. We removed the 40mg doses from this study and replaced them with 10mg doses. No other participant received a 40mg dose. This participant rejoined the open-label portion after consultation with his PCP due to significant perceived benefit from the MPH dose.
3057393|NCT02178982||standard treatments of ARDS|
3057394|NCT02178982||protocol treatment of ARDS|
3057395|NCT02178956|Experimental|BBI608 plus Paclitaxel|
3057396|NCT02178956|Placebo Comparator|Placebo plus Paclitaxel|
3057397|NCT02178943||Heart Transplant Recipients|Heart allograft recipients undergoing scheduled surveillance visits that are part of a long-term management plan.
3057398|NCT02178930|Other|Integrated self management support|The intervention involves the introduction of an interactive chronic disease support platform into doctor-patient consultations, in addition to a self-management support program. Specifically, the intervention comprises the following interlinked components: within consultation engagement; at home exploration; phone and web-based health coaching.
3057399|NCT02178930|No Intervention|Usual care|The control group will receive usual care from study sites until all study participants have completed 12 months of follow up from their Baseline Visits. At this point access to the study intervention will be expanded to include control sites.
3057400|NCT02178917|Experimental|patients with central neuropathic pain|Randomised to 20 neurofeedback therapy sessions
3057401|NCT02178917|Other|Control: patients with central neuropathic pain|Randomised to no neurofeedback treatment
3057402|NCT02178917|No Intervention|patients with no central neuropathic pain|Observed for development of central neuropathic pain
3057403|NCT02178904||Suspected Coronary Artery Disease|Subjects with symptoms suspicious of obstructive CAD who are referred for non-emergent clinically-indicated invasive coronary angiography or stress-rest MPI. Intervention: Procedure/Surgery: CT and stress test
3057404|NCT02178891|Other|short implants|
3057405|NCT02178878||Progress, Pain|Progress, Pain
3057406|NCT02178865||translocation carrier|balanced translocation carriers who have undergone IVF
3057407|NCT02178852|Experimental|TNS-active|TRIGEMINAL NERVE STIMULATION (TNS)
3057408|NCT02178852|Placebo Comparator|TNS-sham|TRIGEMINAL NERVE STIMULATION (TNS) - sham
3057409|NCT02178839|Experimental|β- glucan|8.5 g/d of Oat Supplement Containing 3g β- glucan
3057410|NCT02178839|Placebo Comparator|Maltodextrin|8.5 g/d Maltodextrin
3057411|NCT02178826|Experimental|Rapid Maxillary Expansion|A Rapid Maxillary Expander will be fitted and the palate will be expanded approximately 5mm.
3057412|NCT02178826|Placebo Comparator|Placebo group|A Sham appliance is fitted and activated for 10-14 days. The patients in this group will after it has been revealed they were randomized into the placebo group have a true Rapid Maxillary Expander fitted and the palate will be expanded approximately 5 mm.
3057413|NCT02178813|Experimental|Administration of minocycline|"All patients in the study will receive minocycline periprocedurally with the following schedule:~Day prior to procedure: 800mg p.o., 700mg p.o.~Day of procedure: 600mg i.v., 500mg p.o.~Day after procedure: 400mg p.o., 400mg p.o."
3057414|NCT02178800|Experimental|Group 1: GSK1265744|Participants in Cohorts 1 and 2 will receive one GSK1265744 tablet orally every day from study entry through Week 4. They will then receive an injection of GSK1265744—at Weeks 5, 17, and 29 for participants in Cohort 1 and at Weeks 5, 9, 17, 25, and 33 for participants in Cohort 2.
3057415|NCT02178800|Placebo Comparator|Group 2: Placebo|Participants in Cohorts 1 and 2 will receive one placebo tablet orally every day from study entry through Week 4. They will then receive an injection of placebo—at Weeks 5, 17, and 29 for participants in Cohort 1 and at Weeks 5, 9, 17, 25, and 33 for participants in Cohort 2.
3057416|NCT02178787||Type 2 diabetes mellitus|Head-up tilt, vasoreactivity, standing up.
3057417|NCT02178787||Non-diabetic controls|Head-up tilt, vasoreactivity, standing up.
3057418|NCT02178774||parturients|tissue oxymetry
3057419|NCT02178761|Active Comparator|Angioplasty alone|plain old balloon angioplasty alone
3057420|NCT02178761|Active Comparator|Stenting|Balloon angioplasty plus stenting
3057421|NCT02178761|Active Comparator|drug-eluting balloon|Balloon angioplasty with drug-eluting balloon
3057422|NCT02178761|Active Comparator|biodegradable vascular scaffold stent|Stenting with biodegradable vascular scaffold stent
3057423|NCT02178748|Experimental|Group 1|Group 1 (Schistosoma mansoni uninfected): 12-24 BCG-vaccinated volunteers with no helminth infection. Single dose of 1x10^8pfu MVA85A intramuscular vaccination at D0.
3057424|NCT02178748|Experimental|Group 2|Group 2 (Schistosoma mansoni infected): 12-24 BCG-vaccinated volunteers with helminth infection. Single dose of 1x10^8pfu MVA85A intramuscular vaccination at D0.
3057425|NCT02178735|Experimental|Anterior compartment prolapse|Woman with cystocele who underwent anterior vaginal tailored mesh surgery
3057426|NCT02178735|Experimental|Posterior compartment prolapse|Woman with rectocele, enterocele, uterine prolapse, vaginal stump prolpase who underwent posterior vaginal tailored mesh surgery
3057427|NCT02178735|Experimental|anterior and posterior prolapse|Woman with cystocele and rectocele/uterine prolapse/vaginal vault prolapse/enterocele who underwent anterior and posterior vaginal tailored mesh surgery
3057428|NCT02178722|Experimental|Phase 1: MK-3475 + INCB024360|Phase 1: MK-3475 + INCB024360 25 mg twice a day (BID) as starting dose, followed by dose escalations (Phase 1) until recommended phase 2 dose of INCB024360 is determined
3057429|NCT02178722|Experimental|Phase 2: MK-3475 + INCB024360|(recommended phase 2 dose)
3057430|NCT02178709|Experimental|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle~5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
3057431|NCT02178696|Experimental|Known Placebo First|"This arm gets a placebo that they know is a placebo (called inactive), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called active medication (which is also actually a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa or alternative as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated."
3057432|NCT02178696|Experimental|"Active (blinded) Placebo first group"|"This arm gets a placebo that they don't know is a placebo (called Active), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called inactive medication (which participants know is a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated."
3057433|NCT02178683|No Intervention|Tacrolimus and Mycophenolate Mofetil|Non-myeloablative allogeneic SCT from an HLA-Identical or non-identical family onor or unrelated donors, with fludarabine and low-dose TBI, with immunosuppression utilizing tacrolimus and MMF.
3057434|NCT02178670|Placebo Comparator|non-cancer stem cell vaccine|There is no cancer stem cell vaccine in this group
3057435|NCT02178670|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3057436|NCT02178670|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3057437|NCT02178670|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3057438|NCT02178657|Experimental|Bone marrow transplantation low dose|Intra-arterial autologous bone marrow mononuclear cells injection (dose 2x10^6 per kilogram)
3057439|NCT02178657|Experimental|Bone marrow transplantation high dose|Intra-arterial autologous bone marrow mononuclear cells injection (dose 5x10^6 per kilogram)
3057440|NCT02178657|No Intervention|Control|
3057441|NCT02178644|Experimental|Chemo with concomitant Capecitabine and KD018|Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
3057442|NCT02178631|Experimental|Deprexis|Online self-help
3057443|NCT02178631|Active Comparator|CAU|Care as usual
3057444|NCT02178618|Active Comparator|Partially covered biliary self expandable metal stent|
3057445|NCT02178618|Active Comparator|Uncovered biliary self expandable metal stent|
3057446|NCT02178605||Cervical arthrodesis candidates|Patients scheduled to undergo cervical arthrodesis to treat their spinal pathology will undergo cervical arthrodesis with rhBMP-2
3057447|NCT02178592|Experimental|Dolutegravir|Twice-daily DTG 50 mg plus dual NRTI during RIF-containing TB treatment (isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions or acceptable alternative RIF-containing regimens) and for 2 weeks following discontinuation of TB treatment, then once-daily DTG 50 mg with the same NRTI through Week 52
3057448|NCT02178592|Active Comparator|Efavirenz|Once-daily EFV 600 mg plus dual NRTI through Week 52 along with TB treatment including isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions.
3057449|NCT02178579||Multiple Myeloma (MM) treatment with bortezomib|No intervention planned.
3057450|NCT02178579||Multiple Myeloma (MM) treatment with carfilzomib|No intervention planned.
3057451|NCT02178566|Placebo Comparator|Inhaled Treprostinil Placebo|A dose of placebo resembling inhaled treprostinil will be administered to all study participants in the placebo comparator arm prior to each of their Pulmonary Rehab sessions. A dose of inhaled albuterol will be administered prior to each inhaled agent. Vitals signs will be taken prior to administering the dose and no medication will be given if the systolic blood pressure in < 85 mm Hg. Three puffs of inhaled trepostinil dose will be administered each time to all patients .
3057452|NCT02178566|Active Comparator|Inhaled Treprostinil|A dose of inhaled treprostinil will be administered to all study participants prior to each of their Pulmonary Rehab sessions. A dose of inhaled albuterol will be administered prior to each inhaled agent. Vitals signs will be taken prior to administering the dose and no medication will be given if the systolic blood pressure in < 85 mm Hg. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
3057569|NCT02177734|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 4 at a 21 day interval
3057570|NCT02177734|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK3277509A H7N9 vaccine formulation 5 at a 21 day interval
3057453|NCT02178553|Active Comparator|Epidural|In the epidural catheter (TEC) group, a thoracic epidural catheter will be placed at the level of T6-T8 and advanced 5 cm into the epidural space and a 3 ml test dose of lidocaine 1.5% will be administered before the induction of general anesthesia. Patients will be excluded from the study if the catheter cannot be placed. A bolus dose of 0.5 mg hydromorphone plus 4.5 ml 0.125% bupivacaine will be administered before surgical incision. An epidural infusion of 0.075% bupivacaine and 10 mcg/ml hydromorphone, prepared by the hospital pharmacy, will be started intraoperatively at a rate of 5 ml/hr.
3057454|NCT02178553|Active Comparator|Intercostal bupivicaine (Exparel)|In the intercostal block (ICB) group, liposomal bupivacaine 1.3% (4 ml) will injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and one interspace above and below. In addition, liposomal bupivacaine 1.3 % (4 ml) will be injected at each of the chest tube exit sites. Thus, a total of 20 ml liposomal bupivacaine 1.3% (260 mg) will be administered.
3057455|NCT02178540|Other|Open label|one dose (4 capsules) of placebo
3057456|NCT02178527|Experimental|Mulitfaceted podiatry Intervention|Foot and ankle exercises, foot orthoses, footwear provision
3057457|NCT02178527|Placebo Comparator|Usual podiatry care|Continued provision of usual NHS (National Health Service) podiatry care
3057458|NCT02178514|Experimental|Formula Feeding group by BabyNes Nutrition System|In this arm, all infants will be fed with BabyNes Nutrition System since enrollment until 12 month of age
3057459|NCT02178514|No Intervention|Breastfeeding group|used as reference to compare with formula feeding group
3057460|NCT02178501|Experimental|Omega-3 PUFA|OMEGA-3 PUFA 2000 mg once daily (1000 mg EPA and 1000 mg DHA)
3057461|NCT02178501|Placebo Comparator|Placebo|Placebo once daily
3057462|NCT02178488|Active Comparator|Cholecalciferol|150 patients with MRSA resistent Cholecalciferol 4000 international units (IU)/day for 12 month
3057463|NCT02178488|Placebo Comparator|Sugarpill|150 patients with MRSA resistent Placebo daily 12 month
3057464|NCT02178475||Chemotherapy + Pegfilgrastim|Patients with non-Hodgkin's lymphoma or breast cancer being treated with a permitted standard-dose chemotherapy regimen with a high FN risk (> 20%) and who had pegfilgrastim prophylaxis initiated in the first cycle of chemotherapy.
3057465|NCT02178462||Primary ovarian cancer patients|Intervention will not be administered.
3057466|NCT02178462||Primary endometrial cancer patients|Intervention will not be administered.
3057467|NCT02178462||Benign gynecological disease patients|Intervention will not be administered.
3057468|NCT02178462||Healthy controls|Intervention will not be administered.
3057469|NCT02178449|Experimental|Verum|Dexamethasone and Ropivacaine
3057470|NCT02178449|Active Comparator|Placebo|Ropivacaine and Saline
3057471|NCT02178436|Experimental|Group I (selinexor, gemcitabine, nab-paclitaxel)|Patients receive gemcitabine hydrochloride IV and paclitaxel albumin-stabilized nanoparticle formulation IV once weekly (Mondays) for 3 weeks. Beginning day 3 of course 1, patients also receive selinexor PO twice weekly (Mondays and Wednesdays) for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3057472|NCT02178436|Experimental|Group II (selinexor, gemcitabine, nab-paclitaxel)|Patients receive gemcitabine hydrochloride IV and paclitaxel albumin-stabilized nanoparticle formulation IV once weekly (Mondays) for 3 weeks. Patients also receive selinexor PO twice weekly (Mondays and Wednesdays) for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3057473|NCT02178423|Experimental|Ultrasound|Ultrasound for diagnosis of CVC position in children
3057474|NCT02178410|Active Comparator|Vitamin D + fish oil|
3057475|NCT02178410|Active Comparator|Vitamin D + fish oil placebo|
3057476|NCT02178410|Active Comparator|Vitamin D placebo + fish oil|
3057477|NCT02178410|Placebo Comparator|Vitamin D placebo + fish oil placebo|
3057478|NCT02178397|Experimental|EXPERIMENTAL ARM B|"INDUCTION chemotherapy: 4 cycles of~pemetrexed with cisplatin or carboplatin~or gemcitabine with cisplatin or carboplatin in combination with erlotinib~THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed in combination with erlotinib"
3057479|NCT02178397|Active Comparator|STANDARD ARM A|"INDUCTION chemotherapy: 4 cycles of~pemetrexed with cisplatin or carboplatin~or gemcitabine with cisplatin or carboplatin~THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed"
3057480|NCT02178384|Experimental|Altered-cast technique|Removable partial dentures will be made using altered-cast technique for free saddles.
3057481|NCT02178384|Active Comparator|Precision attachments|Removable partial dentures will be made using precision attachments which will be located on the distal abutment teeth.
3057482|NCT02178384|Active Comparator|Resilient layer|Removable partial dentures will be made using a resilient-layer on the distal extension of each appliance.
3057483|NCT02178371|No Intervention|Control|
3057484|NCT02178371|Experimental|mCIMT|"The study is conducted over a period of 5 weeks of treatment, using a movement restriction time healthy upper extremity of 2 hours daily.~The restriction applied in the study is performed with the closed hand position and thumb inside the fist through a transparent film that reaches the wrist joint.~In periods mCIMT, monitored the activities designed to enhance their functionality, based on motivation, avoiding frustrations are made."
3057485|NCT02178358|Experimental|LY2157299|150 milligrams (mg) LY2157299 administered orally, twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles).
3057486|NCT02178358|Experimental|LY2157299 + Sorafenib|"80 or 150 mg LY2157299 administered orally, BID for 14 days followed by 14 days with no study drug (28 day cycles).~400 mg sorafenib administered orally BID for 28 days."
3057487|NCT02178358|Placebo Comparator|Placebo + Sorafenib|"Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 day cycles).~400 mg sorafenib administered orally BID for 28 days."
3057488|NCT02178345||Surgical patients|The patients will undergo DW-MRI and (if patient is eligible and agrees) DCE-MRI study prior to surgery. The maximum time interval allowed between the MRI study and surgery will be six months.
3057489|NCT02178345||surveillance management patients|The patients will undergo DW-MRI and (if patient is eligible and agrees) DCE-MRI study while being on active surveillance.These patients can also receive the same DW and DCE MRI as a followup a year after the first.
3057571|NCT02177734|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
3057490|NCT02178332|Experimental|Yhteispeli, whole school programme|Yhteispeli-programme aims to support children's socio-emotional skills and well being at schools. Schools receive the Yhteispeli manual and teachers receive 3 and head masters 2 lecture days about use of Yhteispeli methods including group discussions and exercises. In addition every school is visited 4 times to support the use of Yhteispeli methods. (Lectures for the head masters March 2013 - November 2013, teachers August 2013 - January 2014)
3057491|NCT02178332|Active Comparator|Two theoretical lectures|Teachers receive two theoretical lectures on development of children's socio-emotional skills (3 hours in November 2013 and 3 hours in March 2014 ).
3057492|NCT02178319|Active Comparator|open group|the patients under go the open esophagogastric devascularization and splenectomy
3057493|NCT02178319|Experimental|laparoscopic group|the patients under go the laparoscopic esophagogastric devascularization and splenectomy
3057494|NCT02178306|Experimental|Telmisartan|
3057495|NCT02178293|Active Comparator|Benzidamine hydrochloride|
3057496|NCT02178293|Experimental|Ketoprofen lysine salt|
3057497|NCT02178280|No Intervention|unresectable hilar cholangiocarcinoma|control group
3057498|NCT02178280|Experimental|liver transplantation|liver transplantation combined with neoadjuvant radiochemotherapy
3057499|NCT02178267|Experimental|Lactobacillus reuteri|The study was performed by two groups. And these groups were constituted from the newborn preterm infants who are received probiotics (Lactobacillus reuteri) and no probiotics.
3057500|NCT02178254|Experimental|Sequence 3|N=10 subjects receive 3grams oral sachet of Monurol in Period 1; 1.0gram of Intravenous (IV) ZTI-01 for Period 2 (1-hour infusion); and 8.0 grams IV ZTI-01 for Period 3.
3057501|NCT02178254|Experimental|Sequence 1|N=10 subjects receive 1.0gram of Intravenous (IV) ZTI-01 for Period 1 (1-hour infusion); 8.0 grams IV ZTI-01 for Period 2 (1-hour infusion); and 3grams oral sachet of Monurol in Period 3.
3057502|NCT02178254|Experimental|Sequence 2|N=10 subjects receive 8.0 grams IV ZTI-01 for Period 1(1-hour infusion); 3grams oral sachet of Monurol in Period 2 and 1.0gram of IV ZTI-01 for Period 3 (1-hour infusion)
3057503|NCT02178241|Experimental|Treatment (eribulin mesylate and gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3057504|NCT02178228||Subjects over age 18|Subjects undergoing non-emergent small bowel or large bowel surgery and reconnection of bowel that are over the age of 18
3057505|NCT02178228||Subjects age 15-17|Subjects undergoing non-emergent small bowel or large bowel surgery and reconnection of bowel that are age 15-17 with one permission of one parent.
3057506|NCT02178215|Placebo Comparator|Placebo shower gel|•Wash forearm by prepared placebo shower gel twice a day
3057507|NCT02178215|Active Comparator|Holly Mangrove Shower Gel|•Wash forearm by Holly Mangrove Showver gel twice a day
3057508|NCT02178189|Active Comparator|Standard-calorie infant formula|Infants assigned to this arm were fed standard-calorie infant formula (20 kcal/oz) from 72 hours of life until 21 days of age.
3057509|NCT02178189|Experimental|High-calorie infant formula|Infants assigned to this arm were fed high-calorie infant formula (24 kcal/oz) from 72 hours of life until 21 days of age.
3057510|NCT02178176|Experimental|Education, encouragement, card sort|
3057511|NCT02178176|Active Comparator|Education, encouragement|
3057512|NCT02178163|Experimental|Ancillary-Correlative (comprehensive genomic analysis)|Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray. Based on the results of the genomic analysis, patients may begin therapy.
3057513|NCT02178150|Active Comparator|Magnesium Oxide|magnesium tablets, 250 milligram magnesium, 8 weeks, every day 1 tablet
3057514|NCT02178150|Placebo Comparator|Placebo|Placebo tablets, the same in color, odor and appearance with magnesium tablets, 8 weeks, one tablet every day
3057515|NCT02178137|Active Comparator|Glucosamine/Chondroitin|"Glucosamine/Chondroitin twice a day for a daily total dose of 1500 mg of Glucosamine and 1200 mg of Chondroitin.~Tablets will have 750 mg Glucosamine Sulphate and 600 mg of Chondroitin Sulphate. These will be taken twice a day after breakfast and dinner."
3057516|NCT02178137|Active Comparator|Diacerien|Diacerien 50 mg twice a day in capsule form. To be taken twice a day after breakfast and dinner
3057517|NCT02178137|Placebo Comparator|Placebo pill|Placebo tablets with Zinc sulfate twice a day. These will contain pharamacologically non active ingredients (Usually expedients).
3057518|NCT02178124|Experimental|dosage 1|drug : 9 people(87.5mg/25cm2) placebo : 3 people(0mg/25cm2)
3057519|NCT02178124|Experimental|dosage 2|"dosage2 period 1 : oral administration drug : 12 people(10mg)~dosage 2 period 2: transdermal administration drug : 9 people(175mg/50cm2) placebo : 3 people(0mg/50cm2)"
3057520|NCT02178111|Experimental|Never perform episiotomy|In this group the birth attendant will sought to avoid the use of episiotomy, and try not to carry out the procedure unless considered absolutely needed
3057521|NCT02178111|Active Comparator|Selective episiotomy|Patients will be subjected to the usual routine (selective episiotomy, ie, in the presence of indications described in the literature, according to the discretion of the physician or nurse assisting the birth)
3057522|NCT02178098|Experimental|ETC-1002|ETC-1002 180 mg/day
3057523|NCT02178098|Placebo Comparator|Placebo|Placebo control
3057524|NCT02178085|Experimental|Flow imaging|Glaucoma patients and healthy subjects who will undergo ocular flow imaging
3057525|NCT02178072|Other|HPV positive|HPV positive patients
3057526|NCT02178072|Other|HPV negative|HPV negative patients
3057527|NCT02178059|Experimental|Bricanyl Turbuhaler M3|0.4 mg terbutaline sulphate (delivered dose) per inhalation
3057528|NCT02178059|Active Comparator|Bricanyl Turbuhaler M2|0.5 mg terbutaline sulphate (metered dose) per inhalation
3057529|NCT02178046||Gingivitis|optical measurements
3057530|NCT02178033|Other|low-volume (2L) PEG|All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®*, Norgine, Harefield, United Kingdom); Bowel cleansing preparation is divided into two equal doses (each MOVIPREP® sachet dissolved in one liter of water, according to manufacturer's instruction). Each dose must be followed by at least 0.5 L of clear fluid at each administration, and should be taken in a maximum time of 2 hours. In this arm, both doses are taken the day before colonoscopy, starting on the evening at about 18:00. Solution intake should be completed before 22.00 h.
3057531|NCT02178033|Active Comparator|Split dose low-volume PEG solution|All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®*, Norgine, Harefield, United Kingdom); Bowel cleansing preparation is divided into two equal doses (each MOVIPREP® sachet dissolved in one liter of water, according to manufacturer's instruction). Each dose must be followed by at least 0.5 L of clear fluid at each administration, and should be taken in a maximum time of 2 hours. In this arm, the first dose is taken on the evening before colonoscopy (at about 20:00 h), the second one is taken early in the morning on the day of the procedure, starting about 4 h before the scheduled procedure time.
3057532|NCT02178020||knee arthroplasty, standard polyethylene|total knee arthroplasty with Standard Compression Molded tibial Polyethylene Liner
3057533|NCT02178020||knee arthroplasty, Highly Cross-Linked (XLP) polyethylene|knee arthroplasty with Highly Cross-Linked tibial Polyethylene Liner
3057534|NCT02177994|Experimental|Group A ceftriaxone after cord clamping|"165 patients pregnant at 37weeks or more undergoing elective cesarean section randomly distributed to receive~1 gm. ceftriaxone via l intravenous infusion single dose after cord clamping."
3057535|NCT02177994|Active Comparator|Group B ceftriaxone before skin incision|"165 patients pregnant at 37weeks or more undergoing elective cesarean section randomly distributed to receive~1 gm. ceftriaxone vial intravenous infusion single dose 30-60 minutes before skin incision."
3057536|NCT02177981|Active Comparator|Remote ischemic preconditioning|A blood pressure cuff will be placed on the left arm and three cycles of 5 min ischemia followed by 5 min reperfusion will be applied.
3057537|NCT02177981|Sham Comparator|Control|The cuff will be placed around the arm but not inflated.
3057538|NCT02177968||Elderly fallers or non-fallers|characteristics of these groups
3057539|NCT02177955|Placebo Comparator|midazolan|7.5 mg midazolan 45 minutes before the surgery
3057540|NCT02177955|Placebo Comparator|diazepam|10 mg diazepam 45 minutes before the surgery
3057541|NCT02177942|Experimental|Test beverage powder|30 grams of cereal beverage powder with protein and added micronutrients will be made up to 100 mL drink using luke warm water. Subjects will be administered two doses of the drink (100 mL each) everyday
3057542|NCT02177942|Active Comparator|Control beverage powder|30 grams of cereal beverage powder with low protein and no added micronutrients will be made up to 100 mL using luke warm water. Subjects will be administered two doses of the drink (100 mL each) everyday
3057543|NCT02177929|Experimental|adapted canoeing, handbike, conventional physiotherapy|Individuals are divided into three groups: one group adapted canoeing, one group of handbike and one grup of conventional physiotherapy.
3057544|NCT02177916|Experimental|Traditional teaching|
3057545|NCT02177916|Experimental|DVD|
3057546|NCT02177903|Other|Bair PawsPatient Adjustable Warming System|Bair PawsPatient Adjustable Warming System for active pre-warming
3057547|NCT02177903|Other|Passive pre-warming|Passive pre-warming
3057548|NCT02177890|Experimental|Transcutaneous vagal nerve stimulation|Active vagal nerve stimulation to the left auricular branch of the vagus nerve
3057549|NCT02177890|Placebo Comparator|Sham vagal nerve stimulation|Placebo vagal nerve stimulation - stimulator attached to the ear but rotated 180 degrees so that it is not stimulating the vagus nerve.
3057550|NCT02177864|Experimental|Fiber|
3057551|NCT02177864|Placebo Comparator|Placebo|
3057552|NCT02177851|Experimental|Single oral iron supplement per day (120 mg)|Single oral iron dose of 120 mg per day for 3 consecutive days
3057553|NCT02177851|Active Comparator|B.i.d. oral iron supplement (2x 60 mg)|Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days
3057554|NCT02177838|Experimental|Treatment (cetuximab, cisplatin, EBRT)|Patients receive cetuximab IV over 60-120 minutes for 3 weeks. Patients then undergo EBRT over 6-7 weeks. Patients achieving response continue weekly doses of cetuximab until radiation therapy is completed. Patients unable to achieve response or progression receive cisplatin IV over 1-2 hours on days 1, 22, and 43 of radiation therapy.
3057555|NCT02177825|Experimental|Imatinib Mesylate|Imatinib Mesylate at 110 mg/m2 up to 440mg/m2 PO per day for twelve months taken in one morning dose (if dose is less than 200 mg/day) or two doses (morning and evening)
3057556|NCT02177812|Experimental|Dose Escalation Phase (Part 1)|The safety and PK/PD data will be reviewed prior to the dose decision, and the dose escalation will be guided by the Neuenschwander -continuous reassessment method (N-CRM).The dose escalation will complete when RP2D is determined. The RP2D will be the MTD or a lower dose that provides adequate PK exposure and biologic activity with superior tolerability.
3057557|NCT02177812|Experimental|Expansion Phase (Part 2)|Once the MTD and/or RP2D has been determined in Part 1, an expansion cohort of up to 30 subjects will be enrolled in order to characterize the clinical activity and safety profile of the RP2D. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, or withdrawal of consent.
3057558|NCT02177799||gastroenteritis|
3057559|NCT02177786|Experimental|Selonsertib 2 mg|Participants will receive selonsertib 2 mg for 48 weeks.
3057560|NCT02177786|Experimental|Selonsertib 6 mg|Participants will receive selonsertib 6 mg for 48 weeks.
3057561|NCT02177786|Experimental|Selonsertib 18 mg|Participants will receive selonsertib 18 mg for 48 weeks.
3057562|NCT02177786|Placebo Comparator|Placebo to match selonsertib|Participants will receive placebo to match selonsertib for 48 weeks.
3057563|NCT02177773|Experimental|Ga-68 DOTA-TOC PET/CT|Patients receive gallium Ga 68-DOTA-TOC IV over 1-2 minutes. Within 55-70 minutes, patients then undergo a PET/CT scan over 30-40 minutes or a PET/MRI scan over 50 minutes.
3057564|NCT02177760|Experimental|Sirolimus|Sirolimus (0.05 mg/kg/day) day -5 for aGVHD prophylaxis through day +100 or until T-regulatory cells >9% of CD4 effector cells; whichever comes first.
3057565|NCT02177747|Experimental|Diabet patients|Smartphone ophthalmoscopy followed by traditional slit-lamp dilated ophthalmoscopy
3057566|NCT02177734|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 1 at a 21 day interval
3057567|NCT02177734|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 2 at a 21 day interval
3057568|NCT02177734|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 3 at a 21 day interval
3057665|NCT02177136|Experimental|Placebo|Subjects randomized to placebo will take placebo for 24 weeks.
3057572|NCT02177721|Experimental|Raxibacumab arm|This is an open-label, single arm study. The study will be implemented for subjects who receive FDA-approved raxibacumab as part of medical treatment of anthrax or for post-exposure prophylaxis.
3057573|NCT02177695|Experimental|Gemcitabine & Cisplatin|Gemcitabine, 1000 mg/m2, IV, Days 1&8, q 21 days x 4 cycles Cisplatin, 70 mg/m2, IV, Day 1, q 21 days x 4 cycles
3057574|NCT02177695|Experimental|Dose Dense MVAC|Methotrexate, 30 mg/m2, IV, Day 1, q 14 days x 4 cycles Vinblastine, 3 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Doxorubicin, 30 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Cisplatin, 70 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Filgrastim, 5 mcg/kg, SubQ/IV, Days 3-7, q 14 days x 4 cycles
3057575|NCT02177682|Experimental|Afuresertib|"Three subjects will be enrolled and given afuresertib 125 mg orally and monitored for toxicity. After completion of PK sampling in 3 days (Cycle 0), daily repeated dose of 125 mg will be given for 21 days (Cycle 1). If no DLT event is found after 21 days of repeated dosing, up to 6 subjects will be enrolled and given afuresertib 150 mg. If afuresertib 150 mg is assessed to be tolerable, up to 6 subjects can be enrolled and given afuresertib 200 mg. If afuresertib 200 mg is assessed to be intolerable, up to 6 subjects will be enrolled and given afuresertib 150mg or 175 mg. In any Dose levels, if DLT occurs in more than 2 subjects, that Dose level will be considered as intolerable."
3057576|NCT02177669||Normals without ocular disease|
3057577|NCT02177656|No Intervention|Usual care|Patients in the usual care group received six patient educational materials in the hospital, a baseline and follow-up phone call by blinded research assistants.
3057578|NCT02177656|Experimental|MI tailored intervention|The MI intervention was provided by a heart failure specialist nurse. The nurse conducted a home-based motivational interviewing intervention followed up by three phone calls over the course of 90 days. The intervention began with a conversation about the participant's self-identified goals. In the home intervention, the nurse focused on self-care areas that the participant identified as high priority. During the home-based intervention, the participant also set specific goals, which the nurse followed up with and reinforced over the follow-up phone calls.
3057579|NCT02177643|Active Comparator|Diacerein|Diacerein 50 mg immediate release capsule, once daily for the starting 28 days and Diacerein 50 mg immediate release capsule twice a day for the remains of the study.
3057580|NCT02177643|Placebo Comparator|Placebo|Placebo capsules once a day for the starting 28 days and two times daily for the remainder of the study.
3057581|NCT02177630||Magnetic resonance imaging and endomyocardial biopsy|Magnetic resonance imaging and endomyocardial biopsy
3057582|NCT02177617|Active Comparator|Botox only|Participants randomized to receive Botox injections alone.
3057583|NCT02177617|Active Comparator|Botox plus Physical Therapy|Participants randomized to receive Botox injection combined with Physical Therapy
3057584|NCT02177604|Experimental|Wingate HIT|7 days of high-fat overfeeding (50% excess calories) in conjunction 3 supervised sessions of Wingate High-intensity Interval Training.
3057585|NCT02177604|Experimental|Modified HIT|7 days of high-fat overfeeding (50% excess calories) in conjunction with 3 supervised sessions of Modified High-Intensity Interval Training
3057586|NCT02177604|Active Comparator|No Exercise Control|7 days of high-fat overfeeding (50% excess calories) with no supervised exercise
3057587|NCT02177591||CAD and MI|Patients with a history of coronary artery disease who have had a myocardial infarction in the past.
3057588|NCT02177591||CAD, no MI|Patients who have a history of coronary artery disease and have not had a myocardial infarction in the past.
3057589|NCT02177591||no CAD|Patients with no documented history of coronary artery disease.
3057590|NCT02177578|Experimental|Temozolomide plus radiation therapy to the tumor and SVZ|"Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).~Patients will receive 60 Gy of radiation therapy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan will include the tumor bed and MRI changes based on T1 post gadolinium series and FLAIR series, plus the bilateral subventricular zone Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan will include the tumor bed, areas of contrast enhancement on T1 post gadolinium series MRI plus the ipsilateral subventricular zone Will be prescribed to 14 Gy in 2 Gy fractions"
3057591|NCT02177578|Active Comparator|Temozolomide and neural progenitor cell sparing radiation|"Patients will receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).~Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan will include the tumor bed and MRI abnormalities based on T1 post gadolinium series and FLAIR series.~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan will include the tumor bed and MRI changes based on T1 post gadolinium series.~Will be prescribed to 14 Gy in 2 Gy fractions"
3057592|NCT02177565|Experimental|carrier plus BMSCs|carrier plus in vitro expanded autologous BMSCs
3057593|NCT02177565|Placebo Comparator|carrier alone (control).|Carrier alone
3057594|NCT02177552|Experimental|Experimental chemotherapy|Intravenous carboplatin (C) AUC5 day 1 plus intravenous docetaxel (T) 60 mg/m2 day 1 plus oral capecitabine (X) 1000 mg/m2 twice daily from day 1-14, every 4 weeks.
3057595|NCT02177552|Other|Standard chemotherapy|Intravenous epirubicin (E) 50 mg/m2 day 1 plus intravenous oxaliplatin (O) 130 mg/m2 day 1 plus oral capecitabine (X) 625 mg/m2 twice daily continuously, every 3 weeks
3057596|NCT02177539|Active Comparator|Cyclopentolate|
3057597|NCT02177539|Experimental|Cyclopentolate+tropicamide+phenylephrine|
3057598|NCT02177526|Other|Imaging - CT and MRI examinations|Abdominal and pelvic CT and pelvic MRI imaging will be performed in 30 patients.
3057599|NCT02177513|Active Comparator|1|
3057600|NCT02177513|Active Comparator|2|
3057601|NCT02177513|Active Comparator|3|
3057602|NCT02177513|Placebo Comparator|4|
3057603|NCT02177513|Active Comparator|5|
3057604|NCT02177500|Experimental|Telmisartan + hydrochlorothiazide and matching placebo|
3057605|NCT02177500|Experimental|Telmisartan and matching placebo|
3057606|NCT02177487|Experimental|Telmisartan + Hydrochlorothiazide|
3057607|NCT02177474|Experimental|Telephone based peer support|The telephone based peer support was delivered by 11 women with chd aged 54 to 73 years, living all over Germany. Participants could call according to their needs during scheduled times on workdays.
3057608|NCT02177474|Other|Waitlist Group|Waitlist condition with delayed telephone based peer support starting at 5 months
3057609|NCT02177461|Experimental|Telmisartan|
3057610|NCT02177461|Active Comparator|Enalapril|
3057611|NCT02177461|Experimental|Telmisartan + clonidine TTS1|
3057612|NCT02177461|Active Comparator|Enalapril + clonidine TTS1|
3057613|NCT02177448|Experimental|BIBR277 and placebo matching enalapril|
3057614|NCT02177448|Active Comparator|Enalapril and placebo matching BIBR277|
3057615|NCT02177435|Experimental|Telmisartan plus Hydrochlorothiazide|
3057616|NCT02177435|Experimental|Telmisartan|
3057617|NCT02177422|Experimental|Telmisartan|
3057618|NCT02177409|Experimental|Telmisartan|4-week placebo run-in, 8-week fixed dose period
3057619|NCT02177409|Active Comparator|Amlodipine|4-week placebo run-in, 8-week fixed dose period
3057620|NCT02177396|Experimental|Telmisartan|
3057621|NCT02177396|Active Comparator|Valsartan|
3057622|NCT02177383|Experimental|Docosahexaenoic acid|1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek) provides 1.14 g DHA/daily
3057623|NCT02177383|Placebo Comparator|Olive oil|1 liter/day of placebo beverage (containing 0.8% olive oil)
3057624|NCT02177370|Experimental|Fenoterol metered dose inhaler (MDI)|
3057625|NCT02177370|Active Comparator|DSCG MDI|
3057626|NCT02177357|Experimental|Pramipexole - escalation dose|
3057627|NCT02177357|Placebo Comparator|Placebo|
3057628|NCT02177344|Experimental|Low dose of ipratropium bromide|
3057629|NCT02177344|Experimental|High dose of Ipratopium bromide|
3057630|NCT02177344|Active Comparator|Atrovent|
3057631|NCT02177344|Placebo Comparator|Placebo|
3057632|NCT02177331|Experimental|Lacidipine|
3057633|NCT02177318||Patients with COPD|
3057634|NCT02177305|Experimental|Tiotropium dose group 1|0.02 mcg tiotropium solution
3057635|NCT02177305|Experimental|Tiotropium dose group 2|0.04 mcg tiotropium solution
3057636|NCT02177305|Experimental|Tiotropium dose group 3|0.08 mcg tiotropium solution
3057637|NCT02177305|Experimental|Tiotropium dose group 4|0.16 mcg tiotropium solution
3057638|NCT02177305|Experimental|Tiotropium dose group 5|0.28 mcg tiotropium solution
3057639|NCT02177305|Experimental|Tiotropium dose group 6|0.40 mcg tiotropium solution
3057640|NCT02177292|Experimental|IMRT & IGRT Radiation Therapy|In this study we will deliver a high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
3057641|NCT02177279|Other|Visit A- 120g wheat bran cereals|A morning vist where volunteers consumed 120g of wheat bran cereals with 125ml semi-skimmed milk
3057642|NCT02177279|Other|Visit B-40g wheat bran cereals|A morning vist where volunteers consumed 40g of wheat bran cereals with 375 ml semi-skimmed milk
3057643|NCT02177279|Other|Follow up-40g (8days), 120g (1day) wheat bran cereals|Volunteers follow their normal diet but they were asked to consume 40g wheat bran cereals with 125 ml semi-skimmed milk for eight days and on day nine 120g wheat bran cereals with 375ml semi-skimmed milk
3057644|NCT02177266|Placebo Comparator|Placebo|A placebo pill (identical to the study drug Colchicine) will be given in a double-blinded fashion to study participants randomized to placebo.
3057645|NCT02177266|Experimental|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
3057646|NCT02177253|Experimental|Ipratropium bromide / Salbutamol Inhalation solution|
3057647|NCT02177253|Placebo Comparator|Placebo Inhalation solution|
3057648|NCT02177253|Experimental|Ipratropium bromide Inhalation solution|
3057649|NCT02177253|Active Comparator|COMBIVENT Inhalation Aerosol (ipratropium bromide/salbutamol)|
3057650|NCT02177253|Placebo Comparator|Placebo Inhalation Aerosol|
3057651|NCT02177240|Active Comparator|GRS (GlideRite®)|GlideScope® intubation with GRS® stylet of a simulated difficult airway
3057652|NCT02177240|Active Comparator|FIS (Flex-it® )|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
3057653|NCT02177227|Experimental|Total Knee Arthroplasty with PSI|Total Knee Replacement with the use of the Attune TruMatch (TM) Patient-Specific Instrumentation
3057654|NCT02177227|No Intervention|Total Knee Replacement|Total Knee Replacement, as per Standard of Care
3057655|NCT02177214||ventral hernia|Adult patients scheduled for elective laparoscopic repair of ventral hernia, with inclusion of primary and incisional hernias. Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
3057656|NCT02177201|Sham Comparator|Group 1|intravenous administration of 10 ml/kg/h 0.9% saline solution
3057657|NCT02177201|Active Comparator|Group 2|intravenous administration of 20 ml/kg/h 0.9% saline solution
3057658|NCT02177188|Experimental|Haemorrhage simulation|
3057659|NCT02177175|Experimental|Carvedilol|Treatment in both carvedilol and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after randomization to a goal dose of 25mg twice daily.
3057660|NCT02177175|Placebo Comparator|placebo|Treatment in both carvedilol and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after randomization to a goal dose of 25mg twice daily.
3057661|NCT02177149|Active Comparator|Standard of Care|DBS using standard of care.
3057662|NCT02177149|Experimental|DBS Clinical Support System|DBS using Clinical Support System.
3057663|NCT02177136|Experimental|1.5 mg OCA titrating to 3 mg OCA|Subjects randomized to 1.5 mg OCA will take 1.5 mg OCA daily for 12 weeks. If tolerated, the dose will be increased to 3 mg OCA daily for an additional 12 weeks.
3057664|NCT02177136|Experimental|5 mg OCA titrating to 10 mg OCA|Subjects randomized to 5 mg OCA will take 5 mg OCA daily for 12 weeks. If tolerated, the dose will be increased to 10 mg OCA daily for an additional 12 weeks.
3057666|NCT02177123|Experimental|InnFocus MicroShunt Surgery|InnFocus MicroShunt implantation in a primary open angle glaucoma subject using an ab externo subconjunctival/subTenons access with direct connection to the anterior chamber of the eye.
3057667|NCT02177110||Study|Patients who have fresh frozen and FFPE tissue taken prior to treatment
3057668|NCT02177110||Control|Fresh frozen tissue and FFPE tissue is available
3057669|NCT02177097||40 patients (uTHA)|Patients undergoing primary uncemented total hip arthroplasty surgery.
3057670|NCT02177097||40 patients (hTHA)|40 patients undergoing primary hybrid total hip replacement surgery.
3057671|NCT02177097||40 patients (TKA)|40 patients undergoing total knee replacement surgery.
3057672|NCT02177084|Experimental|PTNS + conservative treatment|"PTNS consists in the insertion of a small electrode above the medial malleolus adjacent to the posterior tibial nerve. An adhesive surface electrode is placed under th arch of the foot. Both electrodes are connected to the neurostimulator that generates electricity. A neuromodulation session lasts 30 minutes.~The treatment plan includes 12 weekly sessions, followed by two sessions at 2-week intervals and the last one after one month. Two additional sessions of reinforcement (top-up) are provided at intervals of 6 months or earlier in case of worsening of symptoms"
3057673|NCT02177084|No Intervention|conservative treatment|
3057674|NCT02177071|No Intervention|INFLIXIMAB AND ANTI METABOLITE|continuing scheduled infliximab treatment and anti-metabolite
3057675|NCT02177071|Other|STOP INFLIXIMAB CONTINUING ANTI METABOLITE|discontinuing infliximab and continuing the anti-metabolite
3057676|NCT02177071|Other|CONTINUING INFLIXIMAB AND discontinuing anti-metabolites|CONTINUING INFLIXIMAB AND DISCONTINUING ANTI METABOLITE
3057677|NCT02177058|Experimental|Immediate INTERACT implementation|INTERACT Quality improvement program training and implementation between APR 2013 and MAR 2014
3057678|NCT02177058|Active Comparator|Delayed intervention with reporting|Quarterly surveys/data reporting between APR 2013 and MAR 2014. They receive INTERACT training starting on MAR 2014.
3057679|NCT02177058|No Intervention|Delayed intervention not reporting|No data collected from these nursing homes for one year since baseline. They receive INTERACT training starting on MAR 2014.
3057680|NCT02177045|Experimental|Microbubbles contrast media for US|Sonovue, Bracco, microbubbles contrast media
3057681|NCT02177032|Experimental|4-sites, 1-week without HRIG|"PCEC rabies vaccine, administered ID according to the 4-sites, 1-week regimen"
3057682|NCT02177032|Experimental|4-sites, 1-week with HRIG|"PCEC rabies vaccine, administered ID to adults, according to the 4-sites, 1-week regimen plus HRIG"
3057683|NCT02177032|Active Comparator|2-sites, TRC without HRIG|"PCEC rabies vaccine, administered ID according to the 2-sites, TRC regimen"
3057684|NCT02177032|Active Comparator|2-sites, TRC with HRIG|"PCEC rabies vaccine, administered ID to adults , according to the 2-sites, TRC regimen plus HRIG"
3057685|NCT02177019|Experimental|Development of personal health plan|Personal Health Plan
3057686|NCT02177006||Caregivers|Caregivers of children 2-6 years of age
3057687|NCT02177006||Pediatric clinicians|Pediatricians and nurse practitioners at Lake Forest Pediatric Associates
3057688|NCT02176993||Application of surface cooling|Surface cooling during 60 minutes.
3057689|NCT02176980|Active Comparator|Medical provider (MP) brief alcohol counseling & referral|"Screening of HCV-infected patients for alcohol use using the 10-item Alcohol Use Disorders Identification Test (AUDIT).~Patients self-administer the AUDIT.~HCV providers review the AUDIT with the patient.~If the patient is using any alcohol, the HCV provider conducts brief alcohol counseling using the FRAMES model, based on the evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) method.~Medical provider will explain the importance of alcohol abstinence in the presence of HCV infection.~Patient is referred to an alcohol treatment programs outside the liver clinic. Typical counseling will take the form of individual and group therapy."
3057690|NCT02176980|Experimental|Brief alcohol counseling & 6 months of HCV-alcohol treatment|"Steps 1 through 5 as described in comparator arm above.~6 months of group therapy, offered weekly.~6 months of individual therapy, in person or by phone, offered every two weeks.~Therapy content emphasizes interplay between alcohol use and liver health/HCV.~Informal collaboration between HCV providers and addictions therapists.~Shared EMR charting.~Referral to study-provided psychiatry as needed."
3057691|NCT02176967|Experimental|Group A (clinical observation)|Patients undergo clinical observation for 96 weeks in the absence of disease progression.
3057692|NCT02176967|Experimental|Group B (clinical observation, first-line chemotherapy)|Patients undergo clinical observation for 3 years in the absence of disease progression. Upon disease progression, patients undergo surgery or receive first-line chemotherapy comprising carboplatin IV over 1 hour on day 1 (courses 1, 2, 4, 6, and 7), etoposide IV over 1 hour on days 1-3 (courses 1, 3, 4, 5, and 7), cyclophosphamide IV over 1 hour on day 1 (courses 2, 3, 5, 6, and 8), and doxorubicin hydrochloride IV over 15 minutes on day 1 (courses 2, 4, 6 and 8). Treatment with chemotherapy repeats every 21 days for 2-8 courses in the absence of disease progression or unacceptable toxicity. Once a PR or better is achieved, patients undergo clinical observation for 3 years.
3057693|NCT02176967|Experimental|Group C (clinical observation, first-line chemotherapy)|Patients at high risk for deterioration and a poor outcome immediately receive first-line chemotherapy as in Group B. All other patients undergo clinical observation for 3 years in the absence of disease progression. Upon disease progression, patients receive first-line chemotherapy as in Group B. Once a PR or better is achieved, patients undergo clinical observation for 3 years.
3057694|NCT02176954|Experimental|Test A, Test B, Comparator|The subjects first test Coloplast Test A followed by Coloplast Test B and finally Comparator.
3057695|NCT02176954|Experimental|Test A, Comparator, Test B|The subjects first test Coloplast Test A followed by Comparator and finally Coloplast Test B.
3057696|NCT02176954|Experimental|Test B, Test A, Comparator|The subjects first test Coloplast Test B followed by Coloplast Test A and finally Comparator.
3057697|NCT02176954|Experimental|Test B, Comparator, Test A|The subjects first test Coloplast Test B followed by Comparator and finally Coloplast Test B.
3057698|NCT02176954|Experimental|Comparator, Test A, Test B|The subjects first test Comparator followed by Coloplast Test A and then Coloplast Test B
3057699|NCT02176954|Experimental|Comparator, Test B, Test A|The subjects first test Comparator followed by Coloplast Test B and then Coloplast Test A.
3057745|NCT02176668|Experimental|YH4808 NF 400|7 days repeat administration of YH4808 New Formulation 400mg after meal
3057700|NCT02176941||ATHEROMA group|"ATHEROMA group will include patients undergoing cardiovascular surgery or have pacemaker/defibrillator implantation and have a clinically significant atherosclerotic disease"
3057701|NCT02176941||Control Surgery group|"Control Surgery group will include patients undergoing other surgery or pacemaker/defibrillator implantation without evidence of clinical CV disease or history of previous CV disease."
3057702|NCT02176928|Active Comparator|AutoPAP|PAP treatment will be delivered for four months by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.
3057703|NCT02176928|Sham Comparator|Sham PAP|Sham PAP treatment will be delivered for four months by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events.
3057704|NCT02176915|Experimental|Group program|8-session group weight loss program and 4 follow-up phone counseling sessions
3057705|NCT02176915|Active Comparator|Print Materials|8 weekly mailings of print materials covering weight loss topics through US mail.
3057706|NCT02176902|No Intervention|Arm I (control)|Patients receive no intervention.
3057707|NCT02176902|Experimental|Arm II (fish oil)|Patients receive dietary counseling with research dietitian weekly for 1 month and then monthly for 11 months. Patients are given guidelines with recommended meals to follow a low-fat diet comprising 20% Kcal from fat, 15% Kcal from protein, and 65% Kcal from carbohydrates for 1 year. Patients also receive 4 fish oil capsules per day PO for 1 year.
3057708|NCT02176889|Experimental|Lactospore|One tablet once daily, 30 minutes before a meal, preferably in the morning for 30 days
3057709|NCT02176889|Placebo Comparator|Placebo|One tablet once daily, 30 minutes before a meal, preferably in the morning, for 30 days.
3057710|NCT02176876|Experimental|GS-5745|Participants will receive GS-5745 every 2 weeks for a total of 3 infusions.
3057711|NCT02176876|Placebo Comparator|Placebo to match GS-5745|Participants will receive placebo to match GS-5745 every 2 weeks for a total of 3 infusions.
3057712|NCT02176863|Experimental|2 g/kg Flebogamma 5% DIF|Flebogamma 5% DIF, 2 g/kg, intravenous infusion every 4 weeks over two days for 52 weeks
3057713|NCT02176863|Experimental|1 g/kg Flebogamma 5% DIF|Flebogamma 5% DIF, 1 g/kg, intravenous infusion every 4 weeks over two days for 52 weeks
3057714|NCT02176863|Placebo Comparator|Placebo|Normal Saline Solution, matching volume, intravenous infusion every 4 weeks over two days for 52 weeks
3057715|NCT02176850||Micardis®|
3057716|NCT02176837|Experimental|Sodium Nitrite|One dose cohort is planned, 64 nmol/min/kg sodium nitrite (0.1325 mg/hour/kg; 0.0442 ml/hour/kg at a concentration of 3mg/ml).
3057717|NCT02176824|Experimental|Triple Chronotherapy|Total Sleep Deprivation, Sleep phase advance, and Bright Light Therapy. Carex Health Brands Day-Light Classic 10,000 Lux
3057718|NCT02176824|Sham Comparator|Sham Triple Chronotherapy|Total sleep deprivation, Three day fixed wake schedule, and sham light therapy.
3057719|NCT02176824|Active Comparator|Treatment As Usual|Normal inpatient care including pharmacotherapy, psychotherapy, milieu therapy, and social work interventions.
3057720|NCT02176811||Non-alcoholic Fatty Liver Disese|no treatment
3057721|NCT02176811||healthy controls|no treatment
3057722|NCT02176785|Sham Comparator|Sham tDCS|tDCS will be applied, but then turned off after 30 seconds.
3057723|NCT02176785|Experimental|Anodal tDCS 2mA 10 Minutes|Anodal tDCS will be applied bi-frontally for 10 minutes at 2mA
3057724|NCT02176785|Experimental|Cathodal tDCS 2mA 10 Minutes|Cathodal tDCS will be applied Bi-Frontally for 10 minutes at 2mA
3057725|NCT02176772||Tuberculosis, no HIV and severe anemia|
3057726|NCT02176759|Experimental|Regular FePP|Rice (50g dry weight) fortified with 4mg regular FePP
3057727|NCT02176759|Experimental|Regular FePP with citrate added during extrusion|Rice (50g dry weight) fortified with 4mg regular FePP and citrate added during the extrusion process
3057728|NCT02176759|Experimental|Regular FePP with citrated added at consumption|Rice (50g dry weight) fortified with 4mg regular FePP and citrate shortly added before consumption
3057729|NCT02176759|Active Comparator|Ferrous sulphate|Rice (50g dry weight) fortified with 4mg ferrous sulphate
3057730|NCT02176746|Placebo Comparator|non-cancer stem cell vaccine|This is no cancer stem cells vaccine in this group
3057731|NCT02176746|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3057732|NCT02176746|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3057733|NCT02176746|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3057734|NCT02176733|Experimental|cyclosporine|
3057735|NCT02176720|No Intervention|Standard diagnostics without PET|Standard of care brain imaging modalities, predominantly MRI
3057736|NCT02176720|Experimental|FDOPA PET-CT|PET-CT with administration of FDOPA as an experimental radiopharmaceutical. This arm includes standard of care imaging plus FDOPA PET-CT
3057737|NCT02176707||Idiopathic pulmonary fibrosis sufferers|
3057738|NCT02176694|No Intervention|Standard Care|Aside from the asthma education provided at enrollment and placement of the SmartInhaler (i.e.,electronic monitoring device), adolescents will continue to receive usual care through their primary care providers.
3057739|NCT02176694|Experimental|Text Messaging|A technology based system which allows adolescents to compose, schedule and send one-time or recurring text messages to their own cell phones.
3057740|NCT02176681|Active Comparator|Insulin alone|Use the usual frequency and dose
3057741|NCT02176681|Experimental|Insulin and Vildagliptin|vildagliptin 50 mg/day during 3 months
3057742|NCT02176668|Experimental|YH4808 NF 100|7 days repeat administration of YH4808 New Formulation 100mg after meal
3057743|NCT02176668|Experimental|YH4808 OF 200|(Partial cross over design) 7 days repeat administration of YH4808 Old Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 New Formulation 200mg after meal,
3057744|NCT02176668|Experimental|YH4808 NF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg after meal
3057865|NCT02175784|Experimental|placebo group|oral
3057746|NCT02176668|Experimental|YH4808 NF 100|7 days repeat administration of YH4808 New Formulation 100mg before meal
3057747|NCT02176668|Experimental|YH4808 OF 200|(Partial cross over design) 7 days repeat administration of YH4808 Old Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 New Formulation 200mg before meal
3057748|NCT02176668|Experimental|YH4808 NF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before meal
3057749|NCT02176668|Experimental|YH4808 NF 400|7 days repeat administration of YH4808 New Formulation 400mg before meal
3057750|NCT02176655|Active Comparator|VVD-101|One sumatriptan succinate 12.5 mg combined with acetylsalicylic acid 325 mg (VVD-101) capsule taken after the onset of a delayed alcohol induced headache.
3057751|NCT02176655|Placebo Comparator|Placebo|One placebo capsule to match taken after the onset of a delayed alcohol induced headache.
3057752|NCT02176642|Active Comparator|Oxybutynin plus PTNS|Oxybutynin extended release (blinded tablet) 5mg by mouth daily for 6 weeks, Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.
3057753|NCT02176642|Placebo Comparator|Placebo plus PTNS|Placebo (blinded tablet) taken daily for 6 weeks. Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.
3057754|NCT02176629|Experimental|Condition virtual reality (VR)|The subject is placed in front of a Barcotm screen capable of displaying high quality images.
3057755|NCT02176629|Active Comparator|Condition classic cognitive stimulation (CSC)|It is proposed about using the test dam Zazzo suitable for elderly. This classic test measures sustained attention.
3057756|NCT02176616|Active Comparator|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
3057757|NCT02176616|Experimental|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
3057758|NCT02176603||Patients with Phenylketonuria|Patients with Phenylketonuria due to phenylalanine hydroxylase deficiency
3057759|NCT02176603||Control group|Control group of healthy volunteers
3057760|NCT02176590|Experimental|Power PATH|Classroom PATHS Social Emotional Learning Curriculum (for preschool classrooms) plus Coping Power parent intervention (teaches parents what children are learning in the classroom PATHS program and also provides parents with mental health intervention and parenting topics to promote family well-being)
3057761|NCT02176590|Active Comparator|Head Start as usual|Head Start as usual (will measure the effects of Head Start programming as usual on the primary outcomes)
3057762|NCT02176577|Experimental|Product 0405|Topically Active Investigational Product 0405
3057763|NCT02176564||Chronic obstructive pulmonary disease|Patients with COPD treated with inhaled bronchodilators
3057764|NCT02176551|Experimental|Product 0405|Topical active investigational Product 0405
3057765|NCT02176551|Placebo Comparator|Placebo for Product 0405|Topical Placebo for Product 0405
3057766|NCT02176538|Experimental|Product 0405|Topical active investigational Product 0405
3057767|NCT02176538|Placebo Comparator|Placebo for Product 0405|Topical Placebo for Product 0405
3057768|NCT02176525|Experimental|BI 207127 in patients with cirrhosis|multiple rising doses
3057769|NCT02176525|Experimental|BI 207127 in patients without cirrhosis|multiple rising doses
3057770|NCT02176525|Placebo Comparator|Placebo in patients without cirrhosis|
3057771|NCT02176512|Experimental|Sequence 1|"four treatment periods:~Treatment A~Treatment B~Treatment B~Treatment A"
3057772|NCT02176512|Active Comparator|Sequence 2|"four treatment periods:~Treatment B~Treatment A~Treatment A~Treatment B"
3057773|NCT02176499|Experimental|Telmisartan, low dose|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment ,1 week placebo wash-out (controlled sodium diet)
3057774|NCT02176499|Experimental|Telmisartan, high dose|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)
3057775|NCT02176499|Placebo Comparator|Placebo|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)
3057776|NCT02176486|Experimental|Cohort A: Ixazomib 0.5 milligram (mg)|Ixazomib 0.5 mg, capsules, orally, once, on Day 1, 8 and 15 in a 28-day cycles, Cycles 1 through 3.
3057777|NCT02176486|Experimental|Cohort B: Ixazomib 2 mg|Ixazomib 2 mg, capsules, orally, once, on Day 1, 8 and 15 in a 28-day cycles, Cycles 1 through 3.
3057778|NCT02176486|Experimental|Cohort C: Ixazomib 3 mg|Ixazomib 3 mg, capsules, orally, once, on Day 1, 8 and 15 in a 28-day cycles, Cycles 1 through 3.
3057779|NCT02176486|Experimental|Cohort D: Ixazomib 4 mg|Ixazomib 4 mg, capsules, orally, once, on Day 1, 8 and 15 in a 28-day cycles, Cycles 1 through 3.
3057780|NCT02176486|Placebo Comparator|Cohorts A through D: Placebo|Ixazomib placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle, Cycles 1 through 3.
3057781|NCT02176473|Experimental|Computerized Cognitive Behavioral Therapy|A computerized version of CBT has been developed in an effort to more widely disseminate the powerful effects of this psychotherapy modality, with studies showing efficacy comparable to that of traditional CBT.8 The present study aims to further investigate the feasibility of combining ECT and computerized CBT (c-CBT).
3057782|NCT02176460|Experimental|colchicine|0.5mg twice daily for 16 weeks
3057783|NCT02176460|Placebo Comparator|placebo tablet|1 tablet twice daily for 16 weeks
3057784|NCT02176434|Experimental|Tolerance|Combined kidney and hematopoietic stem cell transplantation from the same donor.
3057785|NCT02176421|Experimental|VOLBELLA® with lidocaine|Infra-orbital skin depressions injected with VOLBELLA® with lidocaine.
3057786|NCT02176408|Experimental|Behavioral Activation plus Exercise|"Six weekly 60-minute sessions plus three 60-minute biweekly booster sessions of behavioral activation treatment~Six weekly 30-minute sessions of the exercise intervention (with this intervention incorporated into the 60 minutes of the biweekly booster sessions)"
3057787|NCT02176408|Active Comparator|Behavioral Activation plus Stretching|"Six weekly 60-minute sessions plus three 60-minute biweekly booster sessions of behavioral activation treatment~Six weekly 30-minute sessions of the stretching intervention (with this intervention incorporated into the 60 minutes of the biweekly booster sessions)"
3057788|NCT02176395|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
3057789|NCT02176395|Placebo Comparator|placebo|Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
3057790|NCT02176395|No Intervention|healthy volunteer|
3057791|NCT02176382|Active Comparator|Standard dose teriparatide|teriparatide daily subcutaneous injection plus denosumab subcutaneous injection every 6 months
3057792|NCT02176382|Active Comparator|High dose teriparatide|teriparatide alternate dose daily subcutaneous injection plus denosumab subcutaneous injection every 6 months
3057793|NCT02176369|Experimental|vinorelbine|50 mg three times a week for a three weeks cycle
3057794|NCT02176369|No Intervention|Close observation/Best Supportive Care|Close observation/Best Supportive Care (BSC)
3057795|NCT02176356|Other|All Participants|JUVÉDERM® ULTRA XC and/or JUVÉDERM® ULTRA PLUS XC and/or JUVÉDERM® VOLUMA® XC injection into facial areas, volume as determined by the investigator on Day 1 with additional treatment at Day 14 if applicable. LATISSE® 1 drop applied to upper eyelid at the base of the eyelashes once daily in the evening for 17 weeks beginning on Day 1. BOTOX® Cosmetic 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas at Month 3.
3057796|NCT02176343|Experimental|ReSTOR Toric +2.5|AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL previously implanted during cataract surgery
3057797|NCT02176330|Active Comparator|Usual care|ePAQ-PF followed by a face to face consultation.
3057798|NCT02176330|Experimental|Virtual Clinic|ePAQ-PF followed by a telephone consultation.
3057799|NCT02176317|Experimental|Autologous Umbilical Cord Blood (UCB)|All participants will receive a single intravenous (into the vein) infusion of autologous umbilical cord blood cells.
3057800|NCT02176304|Active Comparator|Suprapatellar Knee Injection Site|Patients will be injected specified dose of lidocaine and depomedrol through suprapatellar-lateral knee entry site.
3057801|NCT02176304|Active Comparator|Anterolateral knee injection|Patients will be injected specified dose of lidocaine and depomedrol through anterolateral knee entry site.
3057802|NCT02176291|Experimental|Buprenorphine|Buprenorphine
3057803|NCT02176291|Placebo Comparator|Placebo|Placebo
3057804|NCT02176278|No Intervention|Usual Care Group|"Usual care (UC) group:~After undergoing a comprehensive assessment, all patients will receive UC in accordance to the practice of the health institution and return at 12 months for a repeat comprehensive assessment."
3057805|NCT02176278|Experimental|Empowered Care Group|"Empowered care (EC) group:~After undergoing a comprehensive assessment, all patients will be given a JADE comprehensive assessment report which is a personalize risk report with treatment targets and decision support with explanation from the doctor and nurse. In addition to receiving UC in accordance to the practice of the health institution, the nurse will provide telephone reminder to patient 3-monthly to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns. All patients will return at 12 month for a repeat comprehensive assessment."
3057806|NCT02176278|Experimental|Team-based, Empowered Care Group|"Team-based, empowered care (TEC) group:~After undergoing a comprehensive assessment, patients randomized to the TEC group will be given a JADE comprehensive assessment report which is a personalized risk report for patient empowerment. They will receive telephone reminders and doctor-nurse follow up at least 3 monthly to achieve multiple targets recommended. The patients will also be given JADE reports 3-monthly and return at 12 month for a repeat comprehensive assessment."
3057807|NCT02176265|Experimental|Qvanteq bioactive coronary stent system|Open-label, single arm, non-randomized study
3057808|NCT02176252|Experimental|AZD1722|Dose escalation from 5 mg to 90 mg BID
3057809|NCT02176239||Gammaplex® IVIg|
3057810|NCT02176226|Experimental|8-Week Single Arm Field Trial|Use of IntelliCare program for 8 weeks.
3057811|NCT02176213|Experimental|Pomalidomide, Cyclophosphamide, Dexamethasone|Three oral drugs will be given in 28-day cycles: Pomalidomide 4 mg daily x 21 days; cyclophosphamide 50 mg BID x 21 days; and dexamethasone 40 mg weekly x 3 (20 mg weekly if the patient aged ≥ 75 years old)
3057812|NCT02176200|Experimental|Berodual® Respimat®|
3057813|NCT02176200|Active Comparator|Berodual® HFA-MDI|
3057814|NCT02176187|Experimental|natural technique, without instructions|randomised sequence of Berodual® Respimat® and Berodual® MDI
3057815|NCT02176187|Experimental|optimal technique, with instructions|randomised sequence of Berodual® Respimat® and Berodual® MDI
3057816|NCT02176174||White|Self-reported ethnic group of Black, using the United Kingdom Census categories, as recorded in electronic health records.
3057817|NCT02176174||Black|Self-reported ethnic group of Black, using the United Kingdom Census categories, as recorded in electronic health records.
3057818|NCT02176174||South Asian|Self-reported ethnic group of South Asian, using the United Kingdom Census categories, as recorded in electronic health records.
3057819|NCT02176174||Mixed/Other|Self-reported ethnic group of Mixed or other, using the United Kingdom Census categories, as recorded in electronic health records.
3057820|NCT02176161|Experimental|Surgical Prostate Cancer Patients|"Radical Prostatectomy patients with:~High risk surgical pathology (Gleason 8 or higher, positive surgical margins, evidence of extra capsular extension or seminal vesicle invasion)~Prior Radiation Therapy OR~Prior Radiation Therapy with rising PSA.~Metformin Hydrochloride Extended Release 750mg twice per day for 9 months."
3057821|NCT02176161|Experimental|Radiation Patients|"Radiation Patients with Biochemical Recurrence (rising PSA).~Metformin Hydrochloride Extended Release 750mg twice per day for 9 months."
3057822|NCT02176148||Lupus control standard-of-care|Each person enrolled will be given fluocinonide 0.05% cream to apply twice daily to active areas.
3057823|NCT02176135|Experimental|Dose escalation|Auranofin 3 to 6 mg/day oral administration for 12 weeks
3057824|NCT02176122|Active Comparator|Meropenem|Meropenem 1g adm every 8 hours IV up to study day 4.
3057825|NCT02176122|Experimental|Piperacillin-tazobactam combination product|Piperacillin/tazobactam 4.5g adm every 6 hours IV up to study day 4.
3057826|NCT02176096|Experimental|Glycosade|
3057827|NCT02176083|Experimental|Intervention|Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness
3057828|NCT02176083|No Intervention|Control|Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness
3057829|NCT02176057|Experimental|Antibiotic|Azithromycin, suspension (liquid), 1 gram, one-time dose
3057830|NCT02176057|No Intervention|Observation|
3057831|NCT02176044|Placebo Comparator|Glucose infusion|Placebo infusion of sterile 5% glucose - 500ml infused over 4 hours.
3057832|NCT02176044|Active Comparator|Sodium Nitroprusside infusion|Sodium nitroprusside dissolved in 5% glucose solution. Infused at 0.5mcg/kg/min for 4 hours.
3057833|NCT02176031|Experimental|Natalizumab|"Natalizumab-~(Day 0 and 28) Fixed dose Intravenous infusion over one hour. 2 hours observation completion of the infusion~At 4 weeks, if there has been less than a complete response participants can be treated with a second dose of natalizumab.~If participants have no response after one dose, they will be not be given a second dose.~Participants who receive a second dose of natalizumab will be evaluated for response at day 56 after first treatment dose administered.~Participants will be assessed for response to therapy with natalizumab at day +28, day +56, day +100, day + 180, and day +365.~Commercial supplies of Methylprednisolone (or equivalent steroid) will be utilized. The formulation, preparation and route of administration will be as per package insert"
3057834|NCT02176018|Active Comparator|Nuedexta|One capsule will be taken (dextromethorphan HB and quinidine sulfate, 20 mg/10 mg) daily for seven days. On the eight day and for the remainder of the study 2 capsule will be taken twice a day. Medication will be taking daily for a total of 3 months.
3057835|NCT02176018|Placebo Comparator|Placebo|One capsule will be taken of placebo to match daily for seven days. On the eight day and for the remainder of the study 2 capsule will be taken twice a day. Medication will be taking daily for a total of 3 months.
3057836|NCT02176005|Active Comparator|Moxifloxacin|Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
3057837|NCT02176005|Experimental|moxifloxacin + DAV132|Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
3057838|NCT02176005|Experimental|DAV132|DAV132 oral, 7.5g x3/day for 7 days
3057839|NCT02176005|Placebo Comparator|Negative control|Negative control: 7.5g x3/day for 7 days
3057840|NCT02175979|Placebo Comparator|standard|standard of care
3057841|NCT02175979|Experimental|enriched enteral nutrition|enriched enteral tube feeding 1.5ml/ minute perioperative
3057842|NCT02175966|Experimental|Arm 1: DCV/ASV/BMS-791325+Sofosbuvir|"Initial Therapy:~Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 4 weeks~Sofosbuvir 400 mg tablet once daily orally for 4 weeks"
3057843|NCT02175966|Experimental|Arm 2: DCV/ASV/BMS-791325 + Sofosbuvir|"Initial Therapy~Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 6 weeks~Sofosbuvir 400 mg tablet once daily orally for 6 weeks"
3057844|NCT02175966|Experimental|Rescue Therapy: Arm 1:DCV/ASV/BMS-791325+RBV±PegIFNα-2a|"Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 12 weeks~Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks~With or without Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks"
3057845|NCT02175966|Other|Rescue Therapy: Arm 2: Sofosbuvir + RBV + PegIFNα-2a|"Sofosbuvir 400 mg tablet once daily orally for 12 weeks~Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks~Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks"
3057846|NCT02175953|Experimental|Interventiongroup|Psychotherapy
3057847|NCT02175953|No Intervention|Waitling list group|waiting list
3057848|NCT02175940||Myopic Choroidal Neovascularization patients|
3057849|NCT02175940||Control patients undergoing cataract surgery|
3057850|NCT02175927|Experimental|High Dose Amoxicillin|High dose amoxicillin/metronidazole-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg tid, Metronidazole 400mg qid
3057851|NCT02175927|Active Comparator|Tetracycline|Classical quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid
3057852|NCT02175914|Experimental|Erythromycin|Oral treatment with Erythromycin 500mg twice daily.
3057853|NCT02175901|Experimental|Amoxicillin/metronidazole|Amoxicillin/metronidazole-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, Metronidazole 400mg qid
3057854|NCT02175901|Active Comparator|Amoxicillin/clarithromycin|Amoxicillin/clarithromycin-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid
3057855|NCT02175888|Experimental|Oral iron supplement every day for 14 days|Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days
3057856|NCT02175888|Active Comparator|Oral iron supplement every second day for 28 days|Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days
3057857|NCT02175875||comatose patients|180 mg ticagrelor followed by 90 mg BID for comatose patients after cardiac arrest
3057858|NCT02175862||Trauma patients before PS-HEMS|"The before period was between december 1 2009 to april 30 2010 (five months)."
3057859|NCT02175862||Traume patients after PS-HEMS|"The after period was between may 1 2010 to april 30 2011 (12 months)."
3057860|NCT02175849||Drug resistant TB patients|Patients with rifampicin resistant TB or MDR-TB newly confirmed by drug susceptibility tests (DST)
3057861|NCT02175849||Contacts|Contacts of patients with newly detected rifampicin resistant TB or MDR-TB in households, schools, workplaces and other locations.
3057862|NCT02175836||SCD possitive versus SCD negative group|The total Heart Failure patients subgroup experiencing Sudden Cardiac Death surrogate end-points during follow up versus the patients subgroup that is free from Sudden Cardiac Death surrogate end-points.
3057863|NCT02175797|Other|Pacemaker + leads|all patients must have a MRI exam after pacemaker implantation
3057864|NCT02175784|Experimental|ipragliflozin group|oral
3057866|NCT02175771|Experimental|Fp MDPI 100 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg Fp for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3057867|NCT02175771|Active Comparator|FLOVENT HFA 110 mcg|"Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 440 mcg Fp for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3057868|NCT02175771|Experimental|Fp MDPI 200 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg Fp for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3057869|NCT02175771|Active Comparator|FLOVENT HFA 220 mcg|"Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 880 mcg Fp for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3057870|NCT02175771|Experimental|FS MDPI 100/12.5 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 100/12.5 mcg for a total daily dose of 200/25 mcg FS for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3057871|NCT02175771|Active Comparator|ADVAIR DISKUS 250/50 mcg|"Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 250/50 mcg for a total daily dose of 500/100 mcg FS for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3057872|NCT02175771|Experimental|FS MDPI 200/12.5 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 200/12.5 mcg for a total daily dose of 400/25 mcg FS for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3057873|NCT02175771|Active Comparator|ADVAIR DISKUS 500/50 mcg|"Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 500/50 mcg for a total daily dose of 1000/100 mcg FS for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3057874|NCT02175758|Experimental|SOF+RBV 7 days (PK Lead-in, Cohort 1)|Participants between and including the ages of 12 and 17 years old weighing ≥ 45 kg will receive SOF tablets (400 mg: 1 x 400 mg, or 4 x 100 mg) + RBV for 7 days. If participants are unable to swallow SOF tablets, they will receive SOF oral granules (400 mg: 8 x 50mg). Participants will receive RBV up to 1400 mg per day based on weight in a divided daily dose.
3057875|NCT02175758|Experimental|SOF+RBV 7 days (PK Lead-in, Cohort 2)|Following completion of study treatment in Cohort 1 and pending PK and safety results, participants between and including the ages of 6 and 11 years old weighing ≥ 17 kg and < 45 kg will receive SOF tablets (200 mg: 2 x 100 mg) + RBV for 7 days. If participants are unable to swallow SOF tablets, they will receive SOF oral granules (200 mg: 4 x 50mg). Participants will receive RBV up to 1400 mg per day based on weight in a divided daily dose.
3057876|NCT02175758|Experimental|SOF+RBV 7 days (PK Lead-in, Cohort 3)|Following completion of study treatment in Cohort 2 and pending PK and safety results, participants between and including the ages of 3 and 5 years will receive SOF based on their weight. Participants weighing ≥ 17 kg will receive 200 mg SOF (4 x 50 mg capsules containing granules) + RBV for 7 days and those weighing <17 kg will receive 150 mg SOF (3 X 50 mg capsules containing granules) + RBV for 7 days. Participants will receive RBV up to 1400 mg per day based on weight in a divided daily dose.
3057877|NCT02175758|Experimental|SOF+RBV 12 weeks (Genotype 2, Group 1)|During the Treatment Phase, participants between and including the ages of 12 and 17 years old with genotype 2 HCV infection will receive SOF (400 mg: 1 x 400 mg, or 4 x 100 mg) + RBV for 12 weeks. If participants are unable to swallow SOF tablets, they will receive SOF oral granules (400 mg: 8 x 50 mg). Participants will receive RBV up to 1400 mg per day based on weight in a divided daily dose.
3057878|NCT02175758|Experimental|SOF+RBV 12 weeks (Genotype 2, Group 2)|During the Treatment Phase, participants between and including the ages of 6 and 11 years old with genotype 2 HCV infection will receive SOF (200 mg: 2 x 100 mg) + RBV for 12 weeks. If participants are unable to swallow SOF tablets, they will receive SOF oral granules (200 mg: 4 x 50 mg). Participants between and including the ages of 3 and 5 will receive SOF based based on their weight. Participants weighing ≥ 17kg will receive 200 mg SOF (4 x 50 mg capsules containing granules) + RBV for 7 days and those weighing < 17kg will receive 150 mg SOF (3 x 50 mg capsules containing granules) + RBV for 7 days. Participants will receive RBV up to 1400 mg per day based on weight in a divided daily dose.
3057879|NCT02175758|Experimental|SOF+RBV 24 weeks (Genotype 3, Group 1)|During the Treatment Phase, participants between and including the ages of 12 and 17 years old with genotype 3 HCV infection will receive SOF tablets (400 mg: 4 x 100 mg) + RBV for 24 weeks. If participants are unable to swallow SOF tablets, they will receive SOF oral granules (400 mg: 8 x 50 mg). Participants will receive RBV up to 1400 mg per day based on weight in a divided daily dose.
3057918|NCT02175420|Experimental|BCG+TFV|BCG (SSI, Denmark) followed after 14 days by Typhim Vi
3057919|NCT02175407|Experimental|ASP1707 alone|
3057920|NCT02175407|Experimental|ASP1707 + itraconazole|
3057921|NCT02175394|Active Comparator|Microgynon®|Microgynon® once daily during period 1 (day 1 to day 14)
3057880|NCT02175758|Experimental|SOF+RBV 24 weeks (Genotype 3, Group 2)|During the Treatment Phase, participants between and including the ages of 6 and 11 years old with genotype 3 HCV infection will receive SOF (200 mg: 2 x 100 mg) + RBV for 24 weeks. If participants are unable to swallow SOF tablets, they will receive SOF oral granules (200 mg: 4 x 50 mg). Participants between and including the ages of 3 and 5 will receive SOF based based on their weight. Participants weighing ≥ 17kg will receive 200 mg SOF (4 x 50 mg capsules containing granules) and those weighing < 17 kg will receive 150 mg SOF. All participants between the ages of 3 and 5 will receive SOF oral granules (3 x 50 mg capsules containing granules). Participants between and including the ages of 3 and 11 years old will receive RBV up to 1400 mg per day based on weight in a divided daily dose.
3057881|NCT02175745|Experimental|Diagnostic (FDOPA-PET/CT or PET/MRI)|Patients receive 18F-fluoro-dihydroxyphenylalanine (18F-FDOPA) intravenously (IV) and then undergo positron emission tomography / computed tomography (PET/CT) or PET/magnetic resonance imaging (PET/MRI) scans 10 to 30 minutes later.
3057882|NCT02175732|Experimental|KnowIt|Please see the 'KnowIt' intervention description below. Diabetes education, behavioral management
3057883|NCT02175732|Experimental|OnTrack|Please see the 'OnTrack' intervention description below. Diabetes Distress Reduction, Problem Solving Therapy
3057884|NCT02175719||E2014|
3057885|NCT02175706|Active Comparator|Resolute Integrity®|The coating of Resolute Integrity consists of zotarolimus as antiproliferative agent and the BioLinx® polymer system. This polymer system consists of a blend of three different polymers: (1) the hydrophobic C10 polymer, which aids in the control of drug release; (2) the hydrophilic C19 polymer, which supports biocompatibility; and (3) polyvinyl pyrro-lidinone, which increases the initial drug burst and enhances the elution rate.
3057886|NCT02175706|Active Comparator|Promus Element®|"Promus Element utilizes everolimus, which has been shown to reduce tissue proliferation in the coronary vessels following stent implantation.~Promus Element is composed of the Element platform, a thin fluoropolymer coating, and Everolimus."
3057887|NCT02175693||E2014|
3057888|NCT02175680|Experimental|PRO 140|PRO 140 350mg weekly SQ injection.
3057889|NCT02175667|Experimental|Global Postural Reeducation|Participants receiving GPR treatment during 45 minutes to stretch muscular chains
3057890|NCT02175667|No Intervention|Control|Participants not receiving GPR treatment
3057891|NCT02175654|Experimental|Regorafenib|Regorafenib will be administered orally at the initial dosage of 160 mg per day for 3 weeks, followed by one week of rest, according to the 3/1 regimen
3057892|NCT02175641|Experimental|Peer-led Group Lifestyle Balance|Group-based behavioral healthy lifestyle program
3057893|NCT02175641|Active Comparator|Usual Care Services|Usual wellness and health care services offered to clients at the two supportive housing agencies.
3057894|NCT02175628|Experimental|Acoustic Angiography|All patients will be included in the experimental group.
3057895|NCT02175602|Experimental|Cohort 2|Sertraline (50 milligrams each morning) day 1-7, DCV 3DAA FDC + 75 mg BMS-791325 twice daily days 13 to 22, DCV 3DAA FDC + 75 mg BMS-791325 twice daily + Sertraline (50 milligrams each morning) days 23-29
3057896|NCT02175602|Experimental|Cohort 1|Escitalopram (10 milligrams each morning) day 1-7, DCV 3DAA FDC + 75 mg BMS-791325 twice daily days 13 to 22, DCV 3DAA FDC + 75 mg BMS-791325 twice daily + Escitalopram (10 milligrams each morning) days 23-29
3057897|NCT02175589|Other|Study group|Colchicine Cessation in FMF patients with one MEFV mutation
3057898|NCT02175589|No Intervention|Control group|The control group includes FMF patients that will be kept on a daily colchicine treatment
3057899|NCT02175576|Experimental|Vanguard XP Bicruciate Knee System|153 patients receive Vanguard XP Bicruciate Knee System
3057900|NCT02175576|Active Comparator|Vanguard CR Knee System|153 patients receive Vanguard CR Knee System
3057901|NCT02175563|No Intervention|Without feedback|Participants compress the chest of the manikin without smartphone based feedback app.
3057902|NCT02175563|Experimental|With feedback|Participants compress the chest of the manikin with a smartphone based feedback app.
3057903|NCT02175550|Experimental|NR CC|
3057904|NCT02175537|Experimental|Microclinic social induction training|BMI of 30 and over; or BMI of 25 and over and self-reported pre-diabetes or type II diabetes will receive the Microclinic Social Induction Diabetes and Obesity Program. The intervention is a training on diabetes self-management, disease monitoring, diabetes prevention, prevention of complications, health behavior change, and social network supports in order to improve chronic disease risk factors.
3057905|NCT02175537|No Intervention|Controls|Receiving no intervention but parallel primary and secondary outcome measures as intervention study arm
3057906|NCT02175524||Case|Patients proved to be oral and esophageal cancer and had the habit of areca nut chewing.
3057907|NCT02175524||Control|Patients proved to be oral and esophageal cancer and did not have the habit of areca nut chewing.
3057908|NCT02175511|Experimental|Cloud-based home BP monitoring|170 were assigned to the experimental group
3057909|NCT02175511|No Intervention|Traditional Care|212 patients were assigned to the traditional care group (paper-based data)
3057910|NCT02175498|Experimental|Homoeopathic medicines|4 pills once a week of the indicated similium for a period of one year
3057911|NCT02175485|Experimental|Fexofenadine HCl|2 tablets of Dellegra Combination Tablets (Fexofenadine Hydrochloride 30 mg+Pseudoephedrine Hydrochloride 60 mg/tablet), oral, administrated 2 hours after start of exposure with 8,000 grains/cubic meter of Japanese cedar pollen
3057912|NCT02175472|Active Comparator|Spectramax light therapy device|Light therapy device which emits a specific bandwidth combination and intensity of light.
3057913|NCT02175472|Sham Comparator|Control light device|Light therapy device, identical in appearance and operation to the Spectramax device, except that it produces a different bandwidth and intensity, which is not believed to produce a therapeutic response.
3057914|NCT02175446|Experimental|Experimental1|"Bevacizumab and eribulin~In this study all patients will receive:~Eribulin 1.23 mg/m2 on days 1, 8 every 3 weeks intravenously~Bevacizumab 15 mg/kg every 3 weeks intravenously or Bevacizumab 10 mg/kg every 2 weeks intravenously"
3057915|NCT02175433|Experimental|Dose Escalation of AGS67E|Dose escalation will first determine the maximum tolerated dose (MTD) of AGS67E without myeloid growth factor (GF) and then determine the MTD of AGS67 with GF
3057916|NCT02175433|Experimental|Dose Expansion of AGS67E|Once the MTD has been established, an expansion cohort of up to 12 subjects may be enrolled
3057917|NCT02175420|Active Comparator|TFV alone|Typhim Vi
3057922|NCT02175394|Experimental|Microgynon® and BI 1356|Microgynon® combined with BI 1356, once daily during period 2 (day 15 to day 21)
3057923|NCT02175381|Experimental|Carbo/GEM|
3057924|NCT02175368|Experimental|Adhese One F Upgrade|Adhese One F Upgrade (AOFU) is administered after phosphoric acid etching (etch-and-rinse protocol).
3057925|NCT02175355|Experimental|Low dose of Micardis®|
3057926|NCT02175355|Experimental|Medium dose of Micardis®|
3057927|NCT02175355|Experimental|High dose of Micardis®|
3057928|NCT02175355|Active Comparator|Hydrochlorothiazide|
3057929|NCT02175355|Placebo Comparator|Placebo|
3057930|NCT02175342|Experimental|Tiotropium-1.25 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 0.625 mcg/puff
3057931|NCT02175342|Experimental|Tiotropium-2.5 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 1.25 mcg/puff
3057932|NCT02175342|Experimental|Tiotropium-5 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 2.5 mcg/puff
3057933|NCT02175342|Experimental|Tiotropium-10 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 5 mcg/puff
3057934|NCT02175342|Experimental|Tiotropium-20 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 10 mcg/puff
3057935|NCT02175342|Placebo Comparator|Placebo Respimat|
3057936|NCT02175342|Active Comparator|Tiotropium-18 lactose powder Handihaler|
3057937|NCT02175342|Placebo Comparator|Placebo lactose powder Handihaler|
3057938|NCT02175329|Experimental|CAD/CAM veneering|CAD/CAM manufactured e.max CAD veneers on zirconia framework
3057939|NCT02175329|Active Comparator|manually layered|Manually layered veneering on CAD/CAM fabricated zirconia bridge framework
3057940|NCT02175316|Experimental|Experimental: EECP for DOMS|All enrolled subjects will receive EECP treatment Delayed Onset Muscle Soreness.
3057941|NCT02175303|Experimental|Decidual stromal cell therapy for toxicity and inflammation|Patients with toxicity, inflammation or hemorrhages will receive decidual stromal cells at approximately 1x10^6 cells/kg at one or more occasions at weekly intervals dependent on clinical response.
3057942|NCT02175290||Spinocerebellar Ataxia 3 Yemenite Jews patients|
3057943|NCT02175277|Experimental|Darbepoetin Alfa|Open label
3057944|NCT02175264||Patients and Families with isolated non syndromic CDH cases|
3057945|NCT02175251|Active Comparator|low frequency (1Hz)|low frequency
3057946|NCT02175251|Sham Comparator|Sham Comparator|Sham Comparator
3057947|NCT02175251|Experimental|high frequency (20Hz)|high frequency
3057948|NCT02175238|Experimental|BI 691751 after high fat breakfast|single dose BI 691751 after a standardised high fat breakfast
3057949|NCT02175238|Active Comparator|BI 691751 fasted|single dose BI 691751 in fasted state
3057950|NCT02175225|Experimental|Deferoxamine Mesylate|Deferoxamine Mesylate (32 mg/kg/day) given by an intravenous infusion for 3 consecutive days
3057951|NCT02175225|Placebo Comparator|Normal Saline|Normal saline (0.9% sodium chloride) given by intravenous infusion for 3 consecutive days
3057952|NCT02175212|Experimental|Long term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~Bicalutamide 50 mg tablet every day for 2 months~High dose conformal radiotherapy~Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"
3057953|NCT02175212|Active Comparator|Short term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~Bicalutamide 50 mg tablet every day for 2 months~High dose conformal radiotherapy"
3057954|NCT02175199|Experimental|AIR OPTIX COLORS|Lotrafilcon B contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days.
3057955|NCT02175199|Active Comparator|FreshLook COLORBLENDS|Phemfilcon A contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days with a 2-week replacement.
3057956|NCT02175186|Experimental|ALBIS|Albis Tab 2 tab twice a day 12weeks
3057957|NCT02175186|Placebo Comparator|Placebo|placebo Tab 2 tab twice a day 12weeks
3057958|NCT02175173||E2080|Children ages >= 4 years: Patients weighing 15.0-30.0 kg: oral daily dose of 200 mg in two divided doses after meals for the first 2 days. The dose will be increased by up to 200 mg/day every two days. The maintenance dose should be 1000 mg/day in two divided doses after meals. The dose can be increased or decreased within a range not exceeding 1000 mg/day, and should be increased by up to 200 mg/day at intervals not less than 2 days. Patients weighing >= 30.1 kg: Adults: oral daily dose of 400 mg in two divided doses after meals for the first 2 days, then increased by up to 400 mg/day every two days. The maintenance dose should be 1800 mg/day for patients weighing 30.1-50.0 kg, 2400 mg/day for patients weighing 50.1-70.0 kg, and 3200 mg/day for patients weighing 70.1 kg or over in two divided doses after meals. Dose can be increased or decreased within a range not exceeding the above maintenance dose, and should be increased by up to 400 mg/day at intervals not less than 2 days.
3057959|NCT02175160|Experimental|Braking and functionality with right knee osteoarthritis|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with right knee osteoarthritis
3057960|NCT02175160|Experimental|Braking and functionality with right knee arthroplasty|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with right total knee arthroplasty
3057961|NCT02175134|No Intervention|conventional diagnostic flow arm|Perform the laparoscopic biopsy as a discretion of attending physician's decision
3057962|NCT02175134|Experimental|two-step algorithm-based approach|"Perform the laparoscopic biopsy as a discretion of attending physician's decision, but if the below conditions are met, do not perform the laparoscopic biopsy.~Blood ELISPOT >= 6 spots or ascites adenosine deaminase > 20 IU/L, and~Ascites ELISPOT/Blood ELISPOT rato > 3"
3057963|NCT02175121|Placebo Comparator|Treatment A- Placebo|
3057964|NCT02175121|Experimental|Treatment B- PF-06291874|
3057965|NCT02175121|Experimental|Treatment C- PF-06291874|
3057966|NCT02175121|Experimental|Treatment D- PF-06291874|
3057967|NCT02175121|Experimental|Treatment E- PF-06291874|
3057999|NCT02174900|Active Comparator|G6PD normal 0.25 mg/kg PQ + AL|G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
3058000|NCT02174900|Active Comparator|G6PD normal 0.4 mg/kg PQ + AL|G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
3057968|NCT02175095|Experimental|Regorafenib and FLT-PET|After checking the eligibility for the study entry, patients will be scheduled to perform [18F]FLT-PET scans before and on 21st day from the administration of regorafenib. Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal. Standard anatomical response evaluation will be performed every 8 weeks (without regard to the cycles or schedules of chemotherapy). Additional [18F]FDG-PET will be performed before treatment and at 8 weeks (just once at the point of first response evaluation).
3057969|NCT02175082|Active Comparator|Forced exercise cycling|Cycling exercise at approximately 90 rpm
3057970|NCT02175082|Active Comparator|Self-selected pace cycling|Cycling at self selected rate, with same aerobic level as forced cycling group
3057971|NCT02175069|Experimental|Interscalene Nerve Block - 5ml|"ultrasound guided interscalene plexus block (UISB)~Ropivacaine 0.75%, 20ml Gadopentetate-Dimeglumine 0.05 mmol Shoulder Surgery"
3057972|NCT02175069|Active Comparator|Interscalene Nerve Block - 20ml|"ultrasound guided interscalene plexus block (UISB)~Ropivacaine 0.75%, 5ml Gadopentetate-Dimeglumine 0.0125 mmol Shoulder Surgery"
3057973|NCT02175056|Experimental|HL2351|1, 2, 4, 8, 12 mg/kg (SC) / Single-Dose
3057974|NCT02175056|Placebo Comparator|Placebo|1, 2, 4, 8, 12 mg/kg (SC) / Single-Dose
3057975|NCT02175056|Active Comparator|Kineret(Anakinra)|100 mg (SC) / Single-Dose
3057976|NCT02175043|Experimental|the operation to add in CFAE to conventional liner ablation|The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients
3057977|NCT02175043|Active Comparator|only doing conventional liner ablation|The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation
3057978|NCT02175030|Active Comparator|Copper T380 IUD|Randomized to copper T380 IUD for EC (emergency contraception)
3057979|NCT02175030|Active Comparator|LNG20 IUD|Randomized to LNG20 IUD for EC (emergency contraception)
3057980|NCT02175017|Experimental|ONO-4538|ONO-4538 water-soluble injection, 100 mg/vial, 3 times once every 2 weeks in each 6-week cycle
3057981|NCT02175004|Experimental|IONIS-TTR Rx|
3057982|NCT02174991|Experimental|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
3057983|NCT02174991|Experimental|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
3057984|NCT02174978|Experimental|Group 1: 10 µg FMP012 adjuvanted AS01B|FMP012 with AS01B adjuvant system: 10 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume. Doses administered intramuscular at week 0, 4, 8, and 24. On week week 27, there is a P falciparum Controlled Human Malaria Infection (CHMI) challenge.
3057985|NCT02174978|Experimental|Group 2: 30 µg FMP012 adjuvanted AS01B|FMP012 with AS01B adjuvant system: 30 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume administered intramuscular at week 2, 6, 10, and 24. On week week 27, there is a challenge with P falciparum Controlled Human Malaria Infection (CHMI).
3057986|NCT02174978|Other|Infectivity control|Non-immunized infectivity control challenged with P falciparum Controlled Human Malaria Infection (CHMI)
3057987|NCT02174965|Experimental|MiniHip (Corin U.K.)|MiniHip (Corin U.K.) femoral component
3057988|NCT02174965|Active Comparator|Metafix (Corin, U.K)|Metafix (Corin, U.K) conventional cementless stem
3057989|NCT02174952|Experimental|TAU+SH|Families allocated to receive their usual treatment + self-help (TAU+SH) will receive 12 weeks of a self-help version of the New Forest Parenting Programme in addition to the usual treatment they are receiving from their clinician. They will also receive an introductory DVD aimed at highlighting key components of the intervention.
3057990|NCT02174952|No Intervention|TAU|Families in the Treatment as Usual (TAU) condition will receive nothing additional to the treatment offered by their paediatrician or Child & Adolescent Mental Health Services (CAMHS) during the trial phase. Families in the TAU condition will be offered the self-help manual at the end of the trial.
3057991|NCT02174939|Active Comparator|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
3057992|NCT02174939|Placebo Comparator|Dummy Placebo|One tablet twice per day for 12 weeks
3057993|NCT02174926|Active Comparator|Conservative treatment|Written lifestyle guidance and fiber supplements
3057994|NCT02174926|Experimental|Elective laparoscopic sigmoid resection|
3057995|NCT02174913|Active Comparator|bispectral index|Bispectral index guides the target controlled infusion of propofol by keeping BIS 40-60 throughout operation.
3057996|NCT02174913|No Intervention|clinical signs|Clinical signs (heart rate, blood pressure and movement) guide target controlled infusion(TCI) of propofol.
3057997|NCT02174900|Experimental|G6PD deficient 0.25 mg/kg PQ + AL|G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
3057998|NCT02174900|Active Comparator|G6PD deficient receiving AL only|G6PD deficient males receiving Artemether-Lumefantrine (AL) combination
3058422|NCT02172118|Experimental|healthy volunteers|
3058423|NCT02172105|Experimental|BI 1744 CL|
3058001|NCT02174900|Experimental|G6PD-deficient 0.4 mg/kg PQ + AL|G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
3058002|NCT02174887|Experimental|Nab-paclitaxel + Gemcitabine|Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days The patients will receive 2 cycles of treatment every 28 days
3058003|NCT02174874||Oral Ondansetron|Arm that receive oral solution .8 mgms per ml ondansetron - Apotex Brand DIN 02291967
3058004|NCT02174874||Oral disintegrating tablets|Arm that receives the disintegrating tablets either 4mg or 8 mgs Glaxo Brand 4 mg DIN 02239372, 8 mg DIN 02239373
3058005|NCT02174861|Experimental|Erenumab|Participants received erenumab 70 mg once a month (QM) or 140 mg QM by subcutaneous injection for up to 52 weeks.
3058006|NCT02174848|Experimental|Deferiprone|All patients will receive deferiprone oral solution.
3058007|NCT02174835|Experimental|Cohort A - Period 1|Twice daily dosing orally for 7 days
3058008|NCT02174835|Active Comparator|Cohort A - Period 2|Twice daily dosing orally for 7 days
3058009|NCT02174835|Experimental|Cohort A - Period 3|Twice daily dosing orally for 7 days
3058010|NCT02174835|Experimental|Cohort B - Period 1|Twice daily dosing orally for 7 days
3058011|NCT02174835|Active Comparator|Cohort B - Period 2|Twice daily dosing orally for 7 days
3058012|NCT02174835|Experimental|Cohort B - Period 3|Twice daily dosing orally for 7 days
3058013|NCT02174822|Experimental|Paroxetine + AVP-786|Paroxetine once daily orally Days 1-20. AVP-786 twice daily orally for Days 13 - 20.
3058014|NCT02174822|Experimental|AVP-786 + paroxetine|AVP-786 twice daily orally Days 1-20. Paroxetine once daily orally for Days 9 - 20
3058015|NCT02174822|Experimental|Duloxetine + AVP-786|Duloxetine twice daily orally Days 1 - 13. AVP-786 twice daily orally Days 6 - 13.
3058016|NCT02174822|Experimental|AVP-786 + duloxetine|AVP-786 twice daily orally Days 1 - 13. Duloxetine twice daily Days 9 - 13.
3058017|NCT02174809|Experimental|5As|Physicians' use of the 5As tool to discuss gestational weight gain with their pregnant patients
3058018|NCT02174809|Active Comparator|Usual care|Usual care by physicians in addressing gestational weight gain with their pregnant patients
3058019|NCT02174796|Experimental|Surgical treatment group|"patients who chose to undergo a surgical correction (Ravitch or Nuss type intervention).~intervention: surgical correction (Ravitch or Nuss type intervention)."
3058020|NCT02174796|Experimental|Orthopedic treatment group|patients who chose an orthopedic treatment by vacuum bell. intervention : orthopedic treatment by vacuum bell.
3058021|NCT02174783|Active Comparator|Control group|Standard of care group
3058022|NCT02174783|Experimental|Mediterranean diet|Mediterranean diet for 6 months
3058023|NCT02174783|Experimental|Protein-Sparing Modified Fast (PSMF)|PSMF for 6 months
3058024|NCT02174770|Experimental|ACL BFR group|This group is patients with post-op from ACL reconstruction who are randomized into the blood flow restriction arm. They will receive BFR strength training as part of their post-operative physical therapy program for two months during normal post-op rehab.
3058025|NCT02174770|Active Comparator|ACL Standard Therapy|This group is patients with post-op from ACL reconstruction who are randomized into the standard therapy arm. They will receive ACSM guided-strength training as part of their post-operative physical therapy program.
3058026|NCT02174770|Other|Chronic Muscle Weakness|This is a crossover group where all subjects will be randomized to begin with either standard or blood flow restriction therapy for 4 weeks. After completion of the initial training, each subject will be switched to the opposite in an AB/BA crossover design.
3058027|NCT02174770|Experimental|Knee Arthroscopy BFR|This group is patients with post-op from soft-tissue only knee arthroscopy who are randomized into the blood flow restriction arm. They will receive BFR strength training as part of their post-operative physical therapy program for two months during normal post-op rehab.
3058028|NCT02174770|Active Comparator|Knee Arthroscopy Standard|This group is patients with post-op from soft-tissue only knee arthroscopy who are randomized into the standard physical therapy arm. They will receive ACSM-guided strength training as part of their post-operative physical therapy program during normal post-op rehab.
3058029|NCT02174757|Experimental|Inersan|Inersan - 2 Lozenges daily (one lozenge in morning and one lozenge in night) for 2 weeks. Each lozenge contains at least 1 billion CFU of Lactobacillus brevis CD2.
3058030|NCT02174757|Experimental|Inersan and Doxycycline together|"Doxycycline: 1 Tablet once daily (in afternoon) for 2 weeks. Each tablet contains 100 mg Doxycycline.~Inersan - 2 Lozenges daily (one lozenge in morning and one lozenge in night) for 2 weeks. Each lozenge contains at least 1 billion CFU of Lactobacillus brevis CD2."
3058031|NCT02174757|Active Comparator|Doxycycline|Doxycycline: 1 Tablet once daily (in afternoon) for 2 weeks. Each tablet contains 100 mg Doxycycline.
3058032|NCT02174744||numerical scale|
3058033|NCT02174731|Experimental|Roxadustat|
3058034|NCT02174731|Active Comparator|Epoetin alfa|
3058035|NCT02174718|Experimental|Daily 4000IU transdermal D patch|Only in the stage 2, Efficacy Study
3058036|NCT02174718|Active Comparator|Daily placebo patch plus oral placebo|Only in the stage 3, non-inferiority Study
3058037|NCT02174718|Active Comparator|Daily placebo patch plus oral vitamin D|Only in the stage 3 Non-inferiority Study
3058038|NCT02174718|Active Comparator|Daily 4000IU topical patch plus oral placebo|Only for the 3rd Stage of the study, Non-inferiority Study
3058039|NCT02174718|Placebo Comparator|Daily transdermal placebo patch|Only in the stage 2, Efficacy Study
3058040|NCT02174705|Experimental|Sucrose|Sucrose prior to vaccine injections
3058041|NCT02174705|Active Comparator|Rotavirus|Rotavirus prior to vaccine injections
3058042|NCT02174692|Experimental|Elderly|"Exercise One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum~2 minutes rest between sets"
3058043|NCT02174692|Experimental|Young|"Exercise~One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum~2 minutes rest between sets"
3058044|NCT02174666|Active Comparator|Red clover extract|Group recieving daily red clover extract containing isoflavones (80 mg/d), along with calcium (1040 mg/d), vitamin D (25µg/d) and magnesium (487mg/d).
3058045|NCT02174666|Placebo Comparator|Placebo group|Group recieving daily placebo extract (with no isoflavone content), calcium (1040 mg/d), vitamin D (25µg/d) and magnesium (487mg/d).
3058046|NCT02174653|Active Comparator|EPs® 7630|"Active Comparator 20 mg EPs® 7630 film-coated tablet~During the common cold free period: One film-coated tablet (20 mg) three times a day~During a common cold episode: Two film-coated tablets (1 x 20 mg and 1x placebo) three times a day (in the morning, midday and evening; total daily dose 60 mg) over the individual treatment duration of 14 consecutive days."
3058047|NCT02174653|Active Comparator|EPs(R) 7630|"Active Comparator 20 mg EPs® 7630 film-coated tablet~During the common cold free period: One film-coated tablet (20 mg) three times a day~During a common cold episode: Two film-coated tablets (2 x 20 mg = 40 mg) three times a day (in the morning, midday and evening; total daily dose 120 mg) over the individual treatment duration of 14 consecutive days."
3058048|NCT02174653|Placebo Comparator|Placebo|"During the common cold free period: One film-coated tablet (placebo) three times a day~During a common cold episode: Two film-coated tablet (placebo) three times a day (in the morning, midday and evening) over the individual treatment duration of 14 consecutive days."
3058049|NCT02174640|Active Comparator|Coffee|Coffee Beverage
3058050|NCT02174640|Placebo Comparator|Water|Water
3058051|NCT02174627|Experimental|Roxadustat|
3058052|NCT02174627|Placebo Comparator|Placebo|
3058053|NCT02174614|Active Comparator|Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
3058054|NCT02174614|Experimental|TAU plus Rapid Abstinence Initiation (RAI)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment
3058055|NCT02174614|Experimental|TAU plus RAI plus Cognitive Control Training (CCT)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized games 3 times per week for the first 4 weeks.
3058056|NCT02174601||colonoscopy group|
3058057|NCT02174588|Experimental|balanced propofol group|
3058058|NCT02174588|Active Comparator|propofol alone group|
3058059|NCT02174575|Active Comparator|Sevoflurane|Patients are randomized into 2 groups (Desflurane group and Sevoflurane group) depending on the anesthetic agents administered during anesthesia.
3058060|NCT02174575|Active Comparator|Desflurane|Patients are randomized into 2 groups (Desflurane group and Sevoflurane group) depending on the anesthetic agents administered during anesthesia.
3058061|NCT02174562|Experimental|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
3058062|NCT02174562|Placebo Comparator|Enhanced Usual Care|Usual care enhanced with education and controls for attention
3058063|NCT02174549|Experimental|Tirapazamine|Administration with dose escalated tirapazamine before embolization until maximally tolerated dose achieved.
3058064|NCT02174536|Active Comparator|Decidual Stromal cell therapy|Decidual stromal cell therapy (approximately 1x10^6 cells/kg) for hemorrhagic cystitis in addition to Misoprostol therapy (0,2mg, 3 times/day) on two occasions at weekly intervals.
3058065|NCT02174536|Placebo Comparator|Placebo|Receives placebo (masked i.v. infusion, same amount as an infusion of decidual stromal cells) in addition to Misoprostol therapy (0,2mg, 3 times/day).
3058066|NCT02174523|Experimental|40mg lurasidone|Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.
3058067|NCT02174523|Placebo Comparator|40mg lurasidone placebo|Single oral administration of 40 mg study drug placebo after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg placebo, once daily between Day 4 and Day 8.
3058068|NCT02174510|Experimental|20mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
3058069|NCT02174510|Experimental|80mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
3058070|NCT02174510|Experimental|40mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
3058071|NCT02174497||Control|Three day Bowel Preparation
3058072|NCT02174497||Study Arm|One day Bowel Preparation
3058073|NCT02174484||Pacemaker recipients|Patients implanted with a single or dual pacemaker and with Home-Monitoring system activated and periodic IEGM activated
3058074|NCT02174458||Bariatric Surgery only|Patients after Bariatric Surgery but no secondary reconstructive procedures
3058075|NCT02174458||Body Contouring surgery|Post-bariatric patients and patients with no history of bariatric surgery but after natural weight loss
3058076|NCT02174445|Experimental|Imatinib|Imatinib 400-800mg, daily, maximum 6 years
3058077|NCT02174445|Active Comparator|Nilotinib|Nilotinib, 300mg, twice daily, maximum 6 years
3058078|NCT02174432|Experimental|nalbuphine HCl ER 90 mg|nalbuphine HCl ER 90mg BID
3058079|NCT02174432|Experimental|nalbuphine HCl ER 120 mg|nalbuphine HCl ER 120 mg BID
3058080|NCT02174432|Experimental|nalbuphine HCl ER 180 mg|nalbuphine HCl ER 180 mg BID
3058081|NCT02174419|Experimental|nalbuphine HCl ER 90mg|nalbuphine HCl ER tablets 90 mg BID
3058082|NCT02174419|Experimental|nalbuphine HCl ER 180 mg|nalbuphine HCl ER tablets 180 mg BID
3058083|NCT02174419|Placebo Comparator|Sugar pill|Placebo tablets BID
3058119|NCT02174159|Experimental|Panel B: MK-8507 150 mg|Single oral dose of MK-8507 150 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast
3058209|NCT02173522|Experimental|Prostate artery embolization (PAE)|10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
3058084|NCT02174406||women scheduled for breast screening|"Each patient will have the following:~Screening whole breast ultrasound~DBT (Full field digital mammography + tomosynthesis views in the CC and MLO projections). The only change in patient management will be the addition of digital breast tomosynthesis views in patients scheduled for FFDM alone. DBT is currently clinically approved and being offered on a voluntary basis to patients scheduled for FFDM."
3058085|NCT02174393|Experimental|Microneedling Plus Universal Peel|"(1) Microneedling treatment by the MicroPen with a Post-Microneedling Skin Care Regimen and the (2) Universal Peel by Topix with a Post-Universal Peel Skin Care Regimen will both be performed on a monthly basis for a total of three treatment sessions each.~Microneedling will be done on Study Weeks 1, 5, and 9. Universal Peel will be done on Study Weeks 3, 7, and 11."
3058086|NCT02174380|No Intervention|Passive Household Contact Evaluation|Passive case finding refers to the current National TB program of voluntary self-reporting of symptomatic patients to the health system for diagnosis of TB and initiation of effective chemotherapy
3058087|NCT02174380|Experimental|Active Household Contact Evaluation|The intervention program includes households visits of all newly diagnosed TB cases enrolled in TB treatment within a DISA NTP clinic in SJL district. During the home visit health staff will evaluate all household contacts for symptoms of active TB. Any person reporting cough for >14 days will be asked to provide a spot sputum for microscopy and referred to the clinic for chest x-ray and clinical evaluation. All household contacts ≤19 years will be referred to the clinic for chest x-ray, pediatric clinical evaluation and initiation of treatment for active or latent TB as required. Counseling including TB infection control practices and importance of diagnosis and treatment completion for TB cases will be provided to household members.
3058088|NCT02174367||Psoriasis|Patients with moderate to sever psoriasis attending a tertiary referral center. patients will be evaluated with a questionnaire, measurement of height,weight, waist circumference, fasting bloods, abdominal ultrasound and transient elastography.
3058089|NCT02174354||Psoriasis|Patients with psoriasis taking methotrexate
3058090|NCT02174328|Experimental|acetylsalicylic acid|This group will receive 1 tablet of acetylsalicylic acid (100 mg) orally daily from 5-10 weeks gestation until the end of gestation, about week 36
3058091|NCT02174328|Placebo Comparator|Placebo|This group will receive 1 tablet of placebo orally each day from 5-10 weeks gestation until the end of gestation, about week 36
3058092|NCT02174315|Experimental|Contingency Management|
3058093|NCT02174315|No Intervention|Non-Contingent Control Group|
3058094|NCT02174289|Active Comparator|Active Bi-ventricular Pacing|
3058095|NCT02174289|Placebo Comparator|No Biventricular pacing|
3058096|NCT02174276|Active Comparator|TDF 48 weeks|Participants will receive TDF for 48 weeks.
3058097|NCT02174276|Experimental|TDF plus GS-4774 2 YU|Participants will receive TDF plus GS-4774 2 yeast units (YU) for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks.
3058098|NCT02174276|Experimental|TDF plus GS-4774 10 YU|Participants will receive TDF plus GS-4774 10 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks.
3058099|NCT02174276|Experimental|TDF plus GS-4774 40 YU|Participants will receive TDF plus GS-4774 40 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks.
3058100|NCT02174263|Experimental|Supportive care (tocilizumab)|Patients receive tocilizumab IV over 1 hour every 2 weeks for 12 weeks (weeks 1, 3, 5, 7, 9, and 11) and then every 4 weeks for 12 weeks (weeks 13, 17, and 21).
3058101|NCT02174250|Experimental|Istradefylline 40mg|Period 1: Day 1, istradefylline 40mg then crossover to Period 2
3058102|NCT02174250|Experimental|Rifampin 300mg BID + istradefylline 40mg|Period 2: Days 1-20 rifampin 300mg BID + istradefylline 40mg Day 8 only
3058103|NCT02174237|Experimental|LNP1892|Dosage Form: Tablet Two Parts. Part A: Single Ascending Dose (SAD) starting with 25 mg (Maximum 5 cohorts). Part B: Multiple Ascending Dose (MAD), 10 days dosing, Maximum 3 cohorts. Six subjects in each cohort will receive LNP1892
3058104|NCT02174237|Placebo Comparator|Placebo|Two subjects in each cohort will receive matching placebo.
3058105|NCT02174224|Experimental|SMC + BI + Case Management|This arm will include all interventions in Standard Medical Care + Brief Intervention Arm. Case management will also be given to this arm. General needs based assessments will be conducted by the outreach worker. These assessments will be done at the hospital or at the youth's home, whichever they prefer. This assessment tool addresses education, vocational training, employment, housing, medical insurance, follow-up care and pro-social activities. Although each youth in this arm will receive the same needs-based assessment, individual youth will have variable needs, which will guide each unique and individualized case management plan.
3058106|NCT02174211|Active Comparator|Non-vitrectomised, PVD present|
3058107|NCT02174211|Active Comparator|Non-vitrectomised, no PVD|
3058108|NCT02174211|Active Comparator|Previous Vitrectomy|
3058109|NCT02174198|Experimental|BioOss Collagen|Intervention: BioOss Collagen at the time of implant placement
3058110|NCT02174198|No Intervention|No Bone Graft|No placement of BioOss at the time of implant placement
3058111|NCT02174185||bladder cancer, conduit diversion|new patients with bladder cancer scheduled for radical cystectomy and subsequent conduit diversion
3058112|NCT02174185||bladder cancer, orthotopic neobladder|new patients with bladder cancer scheduled for radical cystectomy and subsequent orthotopic neobladder
3058113|NCT02174172|Experimental|Arm A: Atezolizumab with Ipilimumab|Participants will receive atezolizumab along with ipilimumab.
3058114|NCT02174172|Experimental|Arm B: Atezolizumab with Interferon alfa-2b|Participants will receive atezolizumab along with Interferon alfa-2b.
3058115|NCT02174172|Experimental|Arm C: Atezolizumab with PEG- interferon alfa-2a|Participants will receive atezolizumab along with PEG- interferon alfa-2a.
3058116|NCT02174172|Experimental|Arm D:Atezolizumab with PEG-interferon alfa-2a and Bevacizumab|Participants will receive atezolizumab along with PEG- interferon alfa-2a and bevacizumab.
3058117|NCT02174172|Experimental|Arm E: Atezolizumab with Obinutuzumab|Participants will receive atezolizumab along with obinutuzumab or atezolizumab alone.
3058118|NCT02174159|Experimental|Panel A: MK-8507 600 mg|Single oral dose of MK-8507 600 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast
3058202|NCT02173548|Active Comparator|Anakinra|Anakinra 100 mg given subcutaneously once daily for 12 weeks
3058120|NCT02174159|Experimental|Panel C: MK-8507 <=600 mg|Single oral dose of MK-8507 <=600 mg mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast. Inclusion of Panel C in the study, and the dose selected, will be decided pending evaluation of results for Panels A and B.
3058121|NCT02174146|Other|non-surgical therapy|non-surgical periodontal therapy with ultrasonic scalers and periodontal curettes
3058122|NCT02174133||patients after HTX|
3058123|NCT02174133||patients after LVAD implantation|
3058124|NCT02174133||patients with coronary heart disease|
3058125|NCT02174133||healthy volunteers|
3058126|NCT02174120|Experimental|Group A|During maintenance of anesthesia, etomidate was give by target controlled infusion, the effect-site concentration is 0.3 to 0.6 micrograms/ml to keep bispectral index between 40 to 60.
3058127|NCT02174120|Experimental|Group B|During maintenance of anesthesia, Propofol was give by target controlled infusion, the effect-site concentration is 2 to 4 micrograms/ml to keep bispectral index between 40 to 60.
3058128|NCT02174120|Experimental|Group C|During maintenance of anesthesia, etomidate will be given by target controlled infusion for 2 h first, and then propofol will be given by target controlled infusion, the effect-site concentration is 0.3 to 0.6 micrograms/ml and 2 to 4 micrograms/ml, respectively. Bispectral index should be kept between 40 to 60.
3058129|NCT02174107|Experimental|Arm A|Percutaneous vertebroplasty
3058130|NCT02174107|Experimental|Arm B|External radiotherapy
3058131|NCT02174094|Experimental|Clobazam|Clobazam - 1.0, 1.5 or 2.0 mg/kg/day (maximum 60 or 80 mg/day) twice daily (BID); Clobazam oral suspension 2.5 mg/mL, clobazam scored tablets 10 mg, orally
3058132|NCT02174094|Placebo Comparator|Placebo|Placebo to clobazam oral suspension 2.5 mg/mL and placebo to clobazam scored tablets 10 mg, orally
3058133|NCT02174068|Experimental|paracetamol|drug interaction between paracetamol and nefopam in healthy volunteers.
3058134|NCT02174055||Cancer Patients|This protocol aims to design, develop and pilot test a psychometric assessment for depression in older cancer patients. This study is comprised of three parts. 1 - Patient Interviews to Explore the Phenomenology of Depression in Older Cancer Patients. 1A- the research team will complete qualitative interviews with 15 depressed and 15 non-depressed older cancer patients.Part 1B- Phase 1b will include recruitment of 50 younger (age range 50 - 69) and 50 older (age >70) cancer patients at MSK. These participants will be asked to complete several existing depression measures.Part 2 - Instrument Development and EvaluationPart 3 - Pilot Testing the Draft Measure
3058135|NCT02174042|Experimental|Tangning Tongluo Capsule|Type 2 diabetes
3058136|NCT02174029||Ventilation- mandatory mode only|those patient ventilator days during which they had only received a mandatory mode of ventilation
3058137|NCT02174029||Ventilation- voluntary mode only|Those patient days on a mechanical ventilator who have not received prior mandatory ventilation during this episode of mechanical ventilation.
3058138|NCT02174029||voluntary with preceding mandatory|Those patient ventilator days where the patient had at least one prior day of mandatory mechanical ventilation during this episode of respiratory support.
3058139|NCT02174016|Experimental|Ketogenic diet|All subjects will be started on ketogenic diet formula feeding after enrollment for 2 weeks.
3058140|NCT02174003||Open Treatment Group|The Open Treatment Group (all participants in this study) will receive the active / WBH treatment in an open fashion.
3058141|NCT02173990|Experimental|Aflibercept-FOLFIRI|On day 1 of each cycle patients will receive aflibercept followed by irinotecan, 5-FU and leucovorin (FOLFIRI regimen). This treatment will be repeated every 2 weeks until RECIST progression or intolerance.
3058142|NCT02173977|Active Comparator|ARM A- Agonist/Antagonist protocol|The Ultrashort GnRH Agonist/antagonist method entails pre-treatment with oral contraceptive pills before the combination of GnRH ultrashort agonist and antagonist protocol
3058143|NCT02173977|Active Comparator|ARM B- Antagonist protocol|The standard IVF method entails Flexible Multidose GnRH Antagonist protocol during COH
3058144|NCT02173964|Experimental|pinaverium bromide|pinaverium bromide 50 mg tablet per oral administration one time
3058145|NCT02173964|Placebo Comparator|water|water ~100mL
3058146|NCT02173951|Active Comparator|arm 1 iron chelation|Active Comparator arm : iron chelation Included 32 thalassemia major patients with low serum ferritin (≥500) . They will receive low dose Deferiprone( DFP )on 50 mg/kg/d.
3058147|NCT02173951|Placebo Comparator|arm 2 blood transfusion|Placebo Comparator arm: blood transfusion only Included 32 thalassemia patients with low serum ferritin (≥500). They receive blood transfusion with no chelation. Patients will start deferiprone 75 mg/kg/d when reaching Primary end point which is elevation of SF to around 1000 ng/ml or more or Tsat > 90 % and or LPI > 0.6
3058148|NCT02173938||Treatment seekers|
3058149|NCT02173925||Functional dyspepsia group|Patients who had epigastric pain or discomfort with normal upper endoscopy and no organic evidence for explaining these symptoms
3058150|NCT02173925||Control group|Subjects with normal endoscopic finding who do not have any gastrointestinal symptoms
3058151|NCT02173912|Experimental|Sequence 1|"Single-dose crossover~Test: CJ-30059~Reference: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg~Once daily Oral administration with at least 14 days of washout period"
3058152|NCT02173912|Experimental|Sequence 2|"Single-dose crossover~Reference: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg~Test: CJ-30059~Once daily Oral administration with at least 14 days of washout period"
3058153|NCT02173899|Experimental|varicella-1|The second varicella vaccine and 1 year of the interval time between 2 doses
3058154|NCT02173899|Experimental|varicella-3|The second varicella vaccine and 3 years of the interval time between 2 doses
3058155|NCT02173899|Experimental|varicella-5|The second varicella vaccine and 5 years of the interval time between 2 doses
3058156|NCT02173886|Experimental|Bupropion|Bupropion SR and XL, single dosages of each separated by a wash-out period
3058157|NCT02173873|Experimental|one injection of ziv aflibercept intravitreal route|Intervention: Inject 0.05 ml of zaltrap into the vitreous of blind eyes with various diseases (AMD, CRVO) and monitor vision and OCT 1 day and 1 week after injection
3058203|NCT02173548|Placebo Comparator|Placebo|Matching Placebo
3058204|NCT02173535|Experimental|etafilcon test contact lens Variant AP|
3058205|NCT02173535|Experimental|etafilcon test contact lens Variant JG|
3058206|NCT02173535|Experimental|etafilcon test contact lens Variant CS|
3058158|NCT02173860|Active Comparator|FFR-guided revascularization|Patients with valvular heart disease scheduled for elective cardiac surgery and concomitant significant coronary artery disease will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions in vessels pre-specified as suitable for surgical revascularization. If the FFR is ≤0.80, then CABG will be performed. If the FFR is >0.80 then no graft will be placed in that particular vessel. Patients in whom FFR of a particular lesion is not possible can be included if at least one additional lesion is suitable for FFR measurement and grafting.
3058159|NCT02173860|Active Comparator|Angio-guided revascularization|Concomitant CABG will be performed as per clinical routine in all vessels with at least one stenosis > 50%. The vessel should be pre-specified as suitable for surgical revascularization before randomization. An internal mammary graft to the LAD should be attempted in all cases, if possible. Further revascularization strategy is left to the discretion of each center.
3058160|NCT02173847|Experimental|Penetrating keratoplasty|Femtosecond laser sculptured anvil graft. Diode laser welding of the flap in its final position. 12 months follow up study
3058161|NCT02173834|Other|Lean subjects|Lean, young, healthy, Caucasian, male subjects
3058162|NCT02173834|Other|Obese subjects|Obese, Young, Healthy, Caucasian, male subjects
3058163|NCT02173808|Experimental|Contraceptive|
3058164|NCT02173795|Experimental|Berodual® Respimat® - Berodual® MA HFA|"randomized sequence~Berodual® Respimat® (20 µg ipratropium bromide + 50 µg fenoterol hydrobromide per actuation for 49 days)~Berodual® MA HFA (20 µg ipratropium bromide + 50 µg fenoterol hydrobromide per puff for 49 days)"
3058165|NCT02173782|Experimental|Berodual® Respimat ® high dose|
3058166|NCT02173782|Active Comparator|Berodual® MDI|
3058167|NCT02173782|Experimental|Berodual® Respimat® low dose|
3058168|NCT02173782|Placebo Comparator|Placebo|
3058169|NCT02173769||Adults with COPD|
3058170|NCT02173756|Experimental|oral morphine gel|1 mg / ml of Morphine hydrochloride, presented in a 5 mL sterile syringe (single dose). Gel will be applied 8 times per day and for the duration of the mucositis (between 8 to 21 days).
3058171|NCT02173756|Placebo Comparator|placebo gel|1 mg / ml of Placebo gel that is presented in a 5 mL sterile syringe (single dose). Gel will be applied 8 times per day and for the duration of the mucositis (between 8 to 21 days).
3058172|NCT02173743|Experimental|PRP group|PRP during barbotage
3058173|NCT02173743|Other|Control group|Regular barbotage
3058174|NCT02173730|Experimental|BIBR 1048 MS without Pantoprazole|150 mg BIBR 1048 MS capsules administered twice daily over 6 days and once in the morning of the seventh day
3058175|NCT02173730|Experimental|BIBR 1048 MS with Pantoprazole|150 mg BIBR 1048 MS capsules administered twice daily over 6 days and once in the morning of the seventh day together with Pantoprazole. Pantoprazole administration (40 mg bid) started two days before administration og BIBR 1048 and ended in the morning of the seventh day.
3058176|NCT02173717|Experimental|Dabigatran etexilate|"Four treatments of 150 mg Dabigatran etexilate (single oral administration) in a fixed sequence.~Single oral administration of dabigatran etexilate on Day 1;~Oral administration of 600 mg rifampicin q.d. in the evening for 7 days (Days 2 to 8) followed by an oral morning dose of dabigatran etexilate on Day 9;~Single oral administration of dabigatran etexilate on Day 16, after 7 days of rifampicin washout;~Single oral administration of dabigatran etexilate on Day 23, after 14 days of rifampicin washout"
3058177|NCT02173704|Experimental|Bexsero + Routine Group|Subjects received three doses of Bexsero® vaccine at 2, 4, 6 months followed by a booster dose at 12 months, concomitantly administered with routine vaccines (i.e. combined Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® at 6 months of age; Priorix® and Varilrix® at 12 months of age.
3058178|NCT02173704|Active Comparator|Routine Group|Subjects received routine vaccines Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® vaccine at 6 months; Priorix® and Varilrix® vaccines at 12 months of age.
3058179|NCT02173691|Experimental|Tiotropium|
3058180|NCT02173691|Active Comparator|Salmeterol|
3058181|NCT02173691|Placebo Comparator|Placebo|
3058182|NCT02173678|Experimental|COMBIVENT® HFA|
3058183|NCT02173678|Active Comparator|COMBIVENT® CFC|
3058184|NCT02173678|Placebo Comparator|Placebo HFA-MDI (metered dose inhaler)|
3058185|NCT02173665|Experimental|BI 1356 BS - Powder in bottle (PIB)|
3058186|NCT02173665|Experimental|BI 1356 BS - Tablet|
3058187|NCT02173665|Active Comparator|Placebo|
3058188|NCT02173652|Experimental|BI 1356, high dose|Treatment A: 7 days of BI 1356 treatment given once daily
3058189|NCT02173652|Active Comparator|BI 1356, low dose|Treatment B: 7 days of BI 1356 treatment given twice daily
3058190|NCT02173639|Experimental|BI 1356/metformin|
3058191|NCT02173639|Experimental|BI 1356 + Metformin|
3058192|NCT02173626|Other|GSH Medical Staff|Volunteers from the Good Samaritan Hospital medical staff were included on a first come first serve basis
3058193|NCT02173613|Experimental|Procalcitonine|every 2 days, they will receive the dose of PCT and decide to stop antibiotic treatment according to the algorithm 2. They will notify the results of clinical evaluations in the electronics and all adverse event report forms.
3058194|NCT02173613|No Intervention|contrôle|Only clinical reassessments will be conducted and documented. Data on antibiotic will be listed and all adverse events. Data on the PCT from D2 to D4, D6, D8 and D15 output or will not be available to the prescriber.
3058195|NCT02173600|Experimental|Group-level Intensive Dietary Counselling|Active learning through 4-6 60-minute sessions workshop, enrolling 8-12 people each time.
3058196|NCT02173600|Active Comparator|Individual-level Intensive Dietary Counselling|Individualised dietary counselling delivered at the health-care point
3058197|NCT02173587|Experimental|Mussel oil capsules|Four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) per day for first two months and two mussel oil capsules (containing 400mg mussel oil and 400mg corn oil) per day thereafter for four months.
3058198|NCT02173587|Placebo Comparator|Corn oil capsuels|Four corn oil capsules (containing 1600mg corn oil) for first two months and two mussel oil capsules (containing 800mg corn oil) per day thereafter for four months.
3058199|NCT02173574|Experimental|Open-Label Single Arm Cohort|
3058200|NCT02173561|Experimental|Group Cognitive Processing Therapy-Cognitive Only|
3058201|NCT02173561|Experimental|Individual Cognitive Processing Therapy-Cognitive Only|
3058210|NCT02173522|No Intervention|Control|10 patients, matched to PAE patients by risk score, will receive RALRP without PAE. RALRP without PAE is the current standard of care treatment for prostate cancer at the Sylvester Comprehensive Cancer Center.
3058211|NCT02173509|Experimental|Educational multifaceted intervention|Multidisciplinary and multifaceted educational intervention about antibiotic prescription and dispense, in physicians and pharmacists.
3058212|NCT02173496||Colour contrast sensitivity|Colour contrast sensitivity
3058213|NCT02173483|Other|Quadriceps graft|Proximally from patella the Quadriceps graft is harvested and used as a knew anterior cruciate ligament after rupture.
3058214|NCT02173483|Other|Hamstrings Graft|The Hamstrings graft is harvested and used as a knew anterior cruciate ligament after rupture.
3058215|NCT02173470|No Intervention|Control|Routine clinical care (which includes a conventional chest X-ray).
3058216|NCT02173470|Experimental|CT scan|Routine clinical care, which includes a chest x-ray, with an additional ultra low-dose non contrast enhanced chest CT with IR (performed preoperatively).
3058217|NCT02173457|Experimental|Arm 1|Patients administrate Chiglitazar 32mg once daily for 24 weeks
3058218|NCT02173457|Experimental|Arm 2|Patients administrate Chiglitazar 48mg once daily for 24 weeks
3058219|NCT02173457|Active Comparator|Arm 3|Patients administrate Sitagliptin 100mg once daily for 24 weeks
3058220|NCT02173431||BMI 20 to 24.99|30 patients
3058221|NCT02173431||BMI 25 to 29.99|30 patients
3058222|NCT02173431||BMI 30 to 34.99|30 patients
3058223|NCT02173431||BMI 35 to 39.99|30 patients
3058224|NCT02173431||BMI 40 to 44.99|30 patients
3058225|NCT02173431||BMI 45 to 49.99|30 patients
3058226|NCT02173431||BMI more than 50|30 patients
3058227|NCT02173418|Experimental|Ropivacaine|Phrenic nerve block with Ropivacaine
3058228|NCT02173418|Placebo Comparator|Placebo|Phrenic nerve block with Sodium chloride
3058229|NCT02173405|Active Comparator|Treatment Group|20 patients randomly assigned to receive 100 U onabotulinumtoxinA reconstituted in 20 ml saline sequentially injected bilaterally into the pubococcygeus, iliococcygeus, coccygeus, obturator internus, and piriformis muscles.
3058230|NCT02173405|Placebo Comparator|Placebo group|20 patients randomly assigned to receive 20 ml of saline bilaterally into the same pelvic floor muscles.
3058231|NCT02173392|Experimental|Brodalumab (single 1.5mL pre-filled syringe)|A single 210 mg subcutaneous (SC) dose of Brodalumab administered using a single 1.5mL pre-filled syringe injection
3058232|NCT02173392|Experimental|Brodalumab (2 pre-filled syringes [1.0mL + 0.5mL])|A single 210 mg subcutaneous (SC) dose of Brodalumab administered using 2 (1.0mL + 0.5mL) pre-filled syringe injections
3058233|NCT02173379|Experimental|Absorb BVS|Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
3058234|NCT02173379|Active Comparator|XIENCE|Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) and XIENCE ProX (outside of the US only)
3058235|NCT02173366|Experimental|Change Club Intervention|
3058236|NCT02173353|Experimental|Pancreas cancer|Develope a stand, cradle or robotic arm to hold the ultrasound probe, to obtain an ultrasound just before a standard radiation therapy treatment is given.
3058237|NCT02173327|Other|Continuously Helm CPAP|Continuously helm CPAP for 6 hours
3058238|NCT02173327|Other|Intermittent Mask CPAP|Intermittent Mask CPAP for 10minuttes every 2 hours in a 18 hours period postoperative.
3058239|NCT02173314|Other|Family Search and Engagement (FSE)|Family Search and Engagement (FSE) is the intervention for Population 3; it involves intense search practices to identify possible permanency resources. The evaluation will be a descriptive study to analyze relationships between the intervention approach and outcomes.
3058240|NCT02173301|Experimental|XP23829 400 mg QD (once daily)|After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg QD for 12 weeks including titration period
3058241|NCT02173301|Experimental|XP23829 800 mg QD|After 4-week screening period, eligible subjects will be randomized to XP23829 800 mg QD for 12 weeks including titration period
3058242|NCT02173301|Experimental|XP23829 400 mg BID (twice daily)|After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg BID for 12 weeks including titration period
3058243|NCT02173301|Placebo Comparator|Placebo|After 4-week screening period, eligible subjects will be randomized to Placebo for 12 weeks
3058244|NCT02173288|Active Comparator|Standard medical therapy|Standard Medical therapy (n-15) with100 to 400mg spironolactone and/or 40 to 160mg furosemide.
3058245|NCT02173288|Active Comparator|Midodrine group|Standard medical therapy (n-15) with Midodrine 7.5 mg thrice a day
3058246|NCT02173288|Active Comparator|Tolvaptan group|Standard medical therapy (n-15) with Tolvaptan 15 mg twice a day
3058247|NCT02173288|Experimental|Tolvaptan plus midodrine arm|Standard medical therapy (n-15) with Tolvaptan 15 mg twice a day and Midodrine 7.5 mg thrice a day
3058248|NCT02173275||derivation cohort|n = 309
3058249|NCT02173275||validation cohort|n = 309
3058250|NCT02173262|Other|G-CSF|Participants will receive a daily injection of G-CSF while on chemotherapy for prevention of febrile neutropenia.
3058251|NCT02173262|Other|Ciprofloxacin|Participants will receive Ciprofloxacin 500 mg twice a day by mouth for 10 days of each cycle during chemotherapy for prevention of febrile neutropenia.
3058252|NCT02173249|Experimental|AC 170 0.24%|
3058253|NCT02173236|Experimental|platform-switched implants|platform-switched implants vs. platform-matched implants
3058254|NCT02173236|Active Comparator|platform-matched implants|platform-switched implants vs. platform-matched implants
3058287|NCT02173015|Experimental|High Fall Risk, Training|"Individuals who have a functional reach of 8 or less OR a unipedal stance time of 5 s or less, and qualify for compensatory step training."
3058288|NCT02173002|Active Comparator|Standard care|Standard care
3058289|NCT02173002|Experimental|myIBDcoach|myIBDcoach
3058290|NCT02172976|Experimental|FOLFIRINOX|Oxaliplatin 85mg/m², Irinotecan 180mg/m², 5-FU 400mg/m² Bolus i.v., 5-FU continuous Infusion 2400 mg/m² Natriumfolinate 400mg/m² 46h d1; qd15 6 cycles pre- and 6 cycles post- surgery
3058291|NCT02172976|Active Comparator|Gemcitabine|Gemcitabine 1000 mg/m² d1, d8, d15; qd 29; 6 cycles after surgery
3058292|NCT02172963|Experimental|Decidual Stromal Cell therapy for Hemorrhagic Cystitis|
3058255|NCT02173223|Experimental|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
3058256|NCT02173223|Experimental|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
3058257|NCT02173210||Prior preterm birth|Pregnant women with a prior preterm birth, eligible to receive 17 hydroxyprogesterone caproate (17OHPC)
3058258|NCT02173197||OT arm|"Through the initial evaluation of the complex patients' needs, the OT will propose a targeted intervention to the needs emerged and decide which approach will use to achieve the goal (i.e. compensatory or restorative).~We will describe the characteristics of the population included and identify common needs and problems of the complex patients through the COPM.~The needs and problems identified will be grouped into macro-areas, and the OT will propose the appropriate treatment on the basis of the area identified, the patient's needs and the available resources regardless of the origin of the disease."
3058259|NCT02173184|Placebo Comparator|Placebo|Placebo vehicle (0.9% NaCl solution)
3058260|NCT02173184|Experimental|Gynevac|Gynevac suspension for injection, a vaccine containing Lactobacillus strains 15, 34, 79, 84, 127 inactivated by formaldehyde in 0.9% NaCl solution
3058261|NCT02173171||Previously treated with T-VEC|Received at least 1 dose of talimogene laherparepvec on Amgen or BioVEX-sponsored clinical trial
3058262|NCT02173158|Experimental|lomitapide|Maximum tolerated dose of lomitapide (up to 60mg/day) in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.
3058263|NCT02173145|Active Comparator|Azithromycin first, Placebo second|Medication with Azithromycin 500mg/d 3x/week p.o. o.d. for 12 weeks or placebo.
3058264|NCT02173145|Active Comparator|Placebo first, Azithromycin second|Medication with Azithromycin 500mg/d 3x/week p.o. o.d. for 12 weeks or placebo. Placebo will be capsulated similar to verum and given 3 times a week.
3058265|NCT02173132|Active Comparator|acetyl-L-carnitine|2 g acetyl-L carnitine twice a day for 90 days
3058266|NCT02173132|Placebo Comparator|sugar pill|Placebo twice a day for 90 days
3058267|NCT02173119||HCC patients having MRI post-TACE|HCC patients who have undergone conventional lipiodol based chemoembolization.
3058268|NCT02173106|Experimental|Group A: steroid & Cyclosporin|oral methylprednisolone 0.4mg/kg/d and 3.5~5mg/kg/d cyclosporin for 6 months.
3058269|NCT02173106|No Intervention|Group B: no steroid & Cyclosporin|no steroid and cyclosporin and waiting for spontaneous remission for 6 months
3058270|NCT02173093|Experimental|Treatment (IL-2, GM-CSF, GD2Bi-aATC)|Patients receive IL-2 SC daily on days -2 to 35, GM-CSF SC twice weekly x 5 weeks, and GD2Bi-aATC IV over 30 minutes twice weekly x 4 weeks for a total of 8 infusions. Laboratory evaluations of immune responses are obtained prior and after immunotherapy.
3058271|NCT02173080||Polycystic liver disease patients|will receive PLD-Q, EORTC QLQ-30 symptoms subscale, EQ5D-VAS score and SF36
3058272|NCT02173080||ADPKD group without PLD|will receive PLD-Q
3058273|NCT02173080||Healthy controls|receive PLD-Q
3058274|NCT02173080||PLD patient focus group|to discuss and improve PLD-Q
3058275|NCT02173080||PLD clinical expert focus group|to discuss and improve PLD-Q
3058276|NCT02173067||2% lidocaine|35 patients received 5.4 mL of 2% lidocaine.
3058277|NCT02173067||2% lidocaine with epinephrine|35 patients recieved 5.4 mL of 2% lidocaine with 1:100,000 epinephrine.
3058278|NCT02173054|Placebo Comparator|Adapalene gel|"Evening~Wash face by prepared facial foam and dry your face~Apply adapalene gel all over the face"
3058279|NCT02173054|Placebo Comparator|Adapalene gel with placebo moisturizer|"Morning~Wash face by prepared facial foam and dry their face~Apply placebo cream all over the face~Evening~Wash face by prepared facial foam and dry your face~Apply adapalene gel all over the face~Apply placebo cream all over the face"
3058280|NCT02173054|Active Comparator|Adapalene gel with Eucerin|"Morning~Wash face by prepared facial foam and dry their face~Apply Eucerin cream all over the face~Evening~Wash face by prepared facial foam and dry your face~Apply adapalene gel all over the face~Apply Eucerin cream all over the face"
3058281|NCT02173041|Other|Standard Usual Care|Community program which follows with referral services
3058282|NCT02173041|Experimental|Prevention Awareness Groups (PAG)|Prevention Awareness Groups (PAG) is a community based integrated substance abuse prevention program targeting vulnerable populations. It comprises of community programs, physician led counseling followed by treatment follow up in community based clinic.
3058283|NCT02173028||Optimal beta blocker titration|We will compare the efficacy of two management strategies for beta-blocker up-titration: Standard in-office visits vs. Remote follow-up.
3058284|NCT02173028||Without optimal titration of beta blocker|This analysis will be conducted within the Cardiac Resynchronization Therapy observational study Modular Registry (CRT MORE - ClinicalTrials.gov Identifier: NCT01573091).
3058285|NCT02173015|No Intervention|Low Fall Risk|"Individuals who have a functional reach greater than 8 and a unipedal stance time greater than 5 s."
3058286|NCT02173015|No Intervention|High Fall Risk, No Training|"Individuals who have a functional reach of 8 or less OR a unipedal stance time of 5 s or less, but do not qualify for compensatory step training due to health concerns."
3058293|NCT02172950|Experimental|Previously treated patients (PTPs)|The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII‑SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule for the subject based upon the subject's pharmacokinetic (PK) profile, rVIII-SingleChain PK data, previous FVIII treatment regimen, and bleeding phenotype, if available.
3058294|NCT02172950|Experimental|Previously untreated patients (PUPs)|The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII‑SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule at their discretion, taking into consideration the World Federation of Hemophilia (WFH) guidelines, the type of bleeding episode, location of the bleeding, subject's age, and other disease characteristics.
3058295|NCT02172937|Experimental|Decidual Stromal Cells as last line treatment|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids without any signs of improvement will be given DSCs to evaluate a possible effect. DSCs will be thawed from the freezer in plasma.
3058296|NCT02172937|Active Comparator|Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids will be given DSCs as early as possible at one or more occasions at weekly intervals dependent on clinical response. DSCs will be thawed from the freezer in plasma.
3058297|NCT02172924|Active Comparator|Early Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids since no more than 7 days will be given Decidual Stromal Cell therapy.
3058298|NCT02172924|Active Comparator|Late Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids for longer than 7 days will be given Decidual Stromal Cell therapy.
3058299|NCT02172911|Experimental|INO-3112|1.1 ml of INO-3112 (6 mg of VGX-3100 and 1 mg of INO-9012)
3058300|NCT02172898||Heavily Drinking Controls|Heavy alcohol drinking will be defined as > 40 grams per day on average in women and > 60 grams per day on average in men for a minimum of 6 months and within the 6 weeks prior to study enrollment. Heavy drinkers, who have just become abstinent within prior 2 weeks, including those we convince to seek treatment as part of the recruiting process, are eligible for enrollment. Control subjects must meet the following criteria: (1) AST, ALT, and total bilirubin levels must be within normal range; (2) no prior history of known alcoholic liver disease; and (3) absence of hepatosplenomegaly (from physical examination or radiographic imaging) or stigmata of liver disease.
3058301|NCT02172898||Subjects with AH|Diagnosis of AH will be established on published criteria based on history of heavy alcohol consumption (defined as > 40 grams per day on average in women and > 60 grams per day on average for men for a minimum of 6 months and within the 6 weeks prior to study enrollment), clinical evaluation and appropriate laboratory testing (as defined as total bilirubin > 2 mg/dL and AST > 50 U/L). When diagnosis of AH remains in question, a liver biopsy (if clinically feasible and subject has no contraindications) will be required. We plan to enroll patients with AH in special population infected with hepatitis B (HBV), hepatitis C (HCV), or HIV.
3058302|NCT02172885|Experimental|Mesenchymal stem cells|Five Mesenchymal Stem Cell infusions
3058303|NCT02172872|Active Comparator|standard combination chemotherapy|
3058304|NCT02172872|Experimental|decitabine|
3058305|NCT02172859|Active Comparator|lumiVida™|lumiVida™ (2 x 0.5 g sachets to be dissolved in 150ml water/ day): First dose 2h after breakfast and second dose 60-90min before bed-time for 19 days.
3058306|NCT02172859|Placebo Comparator|Placebo|Placebo (2 x 0.5 g sachets of casein hydrolysate to be dissolved in 150ml water/ day): First dose 2h after breakfast and second dose 60-90min before bed-time for 19 days
3058307|NCT02172846|Experimental|Treatment (PBT, paclitaxel, and carboplatin)|"CHEMORADIATION THERAPY:~PBT daily 5 days a week over 3 weeks for a total of 15 fractions~Paclitaxel intravenously (IV) over 1 hour weekly for 3 weeks~Carboplatin intravenously (IV) over 30 minutes weekly for 3 weeks.~CONSOLIDATION CHEMOTHERAPY (B=beginning 4-6 weeks after completion of radiation therapy, patients may receive):~Paclitaxel IV over 1 hour on day 1~Carboplatin IV over 30 minutes on day 1~At the discretion of the treating physician~Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
3058308|NCT02172820|Experimental|Financial incentives|Participants receive financial incentives for completing exercise sessions.
3058309|NCT02172820|No Intervention|Control|Participants receive an equal amount of clinical contact but no financial incentives for completing exercise visits.
3058310|NCT02172807|Experimental|Tiotropium low & Placebo|Tiotropium 18 µg inhalation capsule and Placebo MDI
3058311|NCT02172807|Experimental|Tiotropium high & Placebo|Tiotropium 36 µg inhalation capsule and Placebo MDI
3058312|NCT02172807|Active Comparator|Oxitropium & Placebo|Oxitropium MDI (100 µg/puff) and Placebo inhalation capsules
3058313|NCT02172794|Experimental|tiotropium|
3058314|NCT02172794|Active Comparator|salmeterol|
3058315|NCT02172781|Experimental|Ipratropium - unit dose vial|
3058316|NCT02172781|Experimental|Tiotropium - inhalation capsule - low dose|
3058317|NCT02172781|Placebo Comparator|Placebo matching tiotropium - inhalation capsule|
3058318|NCT02172781|Placebo Comparator|Placebo matching to ipratropium - unit dose vial|
3058319|NCT02172781|Experimental|Tiotropium - inhalation capsule - high dose|
3058320|NCT02172768|Experimental|alternate dosing|treatment for 8 days with intravenous micafungin twice weekly
3058321|NCT02172768|Active Comparator|daily dosing|micafungin daily for 8 days
3058322|NCT02172755|Experimental|Elderly subjects|14 Elderly subjects aged 65 years or more; During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
3058323|NCT02172755|Experimental|Young subjects|16 young subjects aged between 18 and 40 years During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
3058324|NCT02172742|Experimental|BIA 2-093|"BIA 2-093 1200 mg (2 tablets 600 mg) ESL, Eslicarbazepine acetate~Concomitantly with a dose of digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day)."
3058325|NCT02172742|Placebo Comparator|Placebo|"Placebo (2 tablets matching BIA 2-093 600 mg tablets) PLC, Placebo~Concomitantly with a dose of digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day)."
3058326|NCT02172729|Experimental|ACB with lidocaine 5 mg/ml|Adductor canal block (ACB) with 20 ml lidocaine 5 mg/ml, single bolus
3058327|NCT02172729|Experimental|ACB with lidocaine 15 mg/ml|Adductor canal block with 20 ml lidocaine 15 mg/ml, single bolus
3058328|NCT02172716|Experimental|Nonsurgical periodontal treatment|Nonsurgical periodontal treatment will be conducted following a full-mouth approach; no antibiotics or chemical plaque control will be provided.
3058329|NCT02172703|Other|Non-invasive ICP measurement|non-invasive ICP measurement with NON-INVASIVE ICP ABSOLUTE VALUE METER (carried out simultainusly with standard invasive ICP measurement catheter and probes)
3058330|NCT02172690|Experimental|Laparoscopic Staging|For Patients diagnosed as Locally Advanced Gastric Cancer(cT2+NanyM0)by CT and EUS, undergo laparoscopic staging.
3058331|NCT02172677|Experimental|Healthy participants|Structural and functional MRI and memory assessment
3058332|NCT02172664|Active Comparator|Adhese Universal with self etch enamel etching|patients will receive one restoration on randomly selected study tooth utilizing the self-etch universal adhesive (Adhese Universal, Ivoclar Vivadent) with no separate enamel etching
3058333|NCT02172664|Experimental|selective etch protocol followed by Adhese Universal|patients will receive one restoration on randomly selected study tooth utilizing a 37% phosphoric acid solution followed by application of self-etch universal adhesive (Adhese Universal, Ivoclar Vivadent)
3058334|NCT02172651|Experimental|Vitamin D-Run in phase|One capsule of vitamin D3 10,000 IU orally once daily for 14 days until the date of surgery. To allow for some flexibility in the scheduling of surgery, patients can be treated with preoperative vitamin D3 for up to 28 days. On the morning of surgery, prior to operating, a second blood sample will be collected for follow-up 25(OH)D, calcium, and albumin determination. Colon and liver resection will occur per institutional standards of care, and malignant and adjacent benign tissue will be collected for the laboratory endpoints described in this protocol.
3058335|NCT02172638|Experimental|FAST-TRACK Group|Patients in this group will be managed according to an specifically designed FAST-TRACK protocol which will include: Preoperatory nutritional management and coaching by surgeon, anesthetist, nutritionist and specifically trained nurse personnel, reduced preoperatory fasting, avoiding use of intraabdominal drainages, specific anesthetic management to reduce intraoperative stress, avoiding use of Nasogastric tube, avoiding the need for major opioid in postoperatory analgesia and use of an standardized postoperatory management protocol directed to obtain an early oral intake and mobilization with a the goal of normal diet and deambulation in the 3rd day after surgery.
3058336|NCT02172638|Active Comparator|Classical management group|Patients assigned to this group will receive the standard management preformed in our center until now. This management includes a preoperatory control exclusively by the surgeon and anesthetist, minimum of 8h fasting previous to surgery, loose use of intraabdominal drainage , systematic use of nasogastric tube whenever rectum resection or omentectomy is performed, Postoperative analgesia following standing Vall d'Hebron protocols for Moderate-severe postoperative pain, which include use of combined analgesia with non opioids drugs and major Opioids, and usual flexible, non standardized postoperatory management with mobilization and oral intake progression depending on perceived evolution by attending surgeon.
3058337|NCT02172625|Placebo Comparator|Placebo Group|Corn starch and food coloring is the placebo comparator. Each subject will ingest 675 mg (1 pill) per day of the placebo comparator
3058338|NCT02172625|Experimental|Protandim Dietary Supplement|Each subject will ingest 675 mg per day (1 pill) of Protandim for about 90 days. Each pill contains 5 botanicals (Bacopa extract 150 mg, milk thistle 225mg, ashwagandha 150 mg, green tea 75 mg, turmeric 75 mg).
3058339|NCT02172612|Experimental|Arm 1 - Intervention|Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
3058340|NCT02172612|No Intervention|Arm 2 - Control|Those included in the control group will receive a generic brochure about medication safety and inappropriate medication use in the elderly.
3058341|NCT02172599|Experimental|multi-component intervention|"Sit-stand workstation provision~The multi-component intervention will align with the World Health Authority's promotion of a healthy workplace model, which emphasises that best-practice workplace health interventions should involve an integrated approach involving organisation and individual level approaches to behaviour change (WHO, 2010). Thus, participants will receive a sit-stand workstation with additional support to use the sit-stand workstation."
3058342|NCT02172599|Experimental|Sit-stand workstation only|"Sit-stand workstation provision~Participants in this arm will receive a sit-stand workstation. They will not receive any support to use the sit-stand workstation, except some health and safety advice upon installation."
3058343|NCT02172599|No Intervention|Usual practice (seated workstation)|This arm is the control group. They will continue to use their usual seated workstation for the duration of the study.
3058344|NCT02172586|Experimental|Telmisartan|
3058345|NCT02172586|Experimental|Telmisartan + Hydrochlorothiazide|
3058346|NCT02172586|Active Comparator|Losartan|
3058347|NCT02172586|Active Comparator|Losartan + Hydrochlorothiazide|
3058348|NCT02172573|Experimental|Pramipexole|
3058349|NCT02172573|Experimental|Bromocriptine|
3058350|NCT02172573|Placebo Comparator|Placebo|
3058351|NCT02172560||Premature withdrawal from tiotropium|
3058352|NCT02172547||COPD patients who stopped smoking during treatment|
3058353|NCT02172534|Experimental|Tiotropium bromide low|Single dose: 2.5 µg Tiotropium
3058354|NCT02172534|Experimental|Tiotropium bromide medium|Single dose: 5 µg Tiotropium
3058355|NCT02172534|Experimental|Tiotropium bromide high|Single dose: 10 µg Tiotropium
3058356|NCT02172534|Experimental|Tiotropium bromide low (28 days)|multiple dose: 2.5 µg Tiotropium
3058357|NCT02172534|Experimental|Tiotropium bromide medium (28 days)|Multiple dose: 5 µg Tiotropium
3058358|NCT02172534|Placebo Comparator|Placebo|single or multiple dose of Placebo
3058359|NCT02172521||COPD and proven hyperinflation|Patients with COPD and proven hyperinflation receiving tiotropium bromide 18 microgram
3058360|NCT02172508|Experimental|Tiotropium|
3058361|NCT02172508|Placebo Comparator|Placebo|
3058362|NCT02172495||Symptoms of COPD|Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms
3058363|NCT02172482||Symptoms of COPD|Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms
3058364|NCT02172469|Experimental|Tiotropium & Placebo|
3058365|NCT02172469|Active Comparator|Atrovent & Placebo|
3058366|NCT02172456|Experimental|Tiotropium|
3058367|NCT02172443|Experimental|tiotropium inhalation capsules|
3058368|NCT02172443|Active Comparator|Atrovent MDI|
3058369|NCT02172430|Experimental|Tiotropium|
3058370|NCT02172430|Active Comparator|Oxitropium bromide|
3058371|NCT02172417|Experimental|Cimetidine + Tiotropium followed by Tiotropium|
3058372|NCT02172417|Experimental|Ranitidine + Tiotropium followed by Tiotropium|
3058373|NCT02172404|Experimental|HandiHaler® vs. MDI|sequence during treatment phase: first Placebo capsule administered via HandiHaler then Ipratropium metered dose inhaler
3058374|NCT02172404|Experimental|MDI vs. HandiHaler®|sequence during treatment phase: first Ipratropium metered dose inhaler then Placebo capsule administered via HandiHaler Ipratropium metered dose inhaler
3058375|NCT02172391|Experimental|Tiotropium|Tiotropium inhalation powder capsules 18 mcg, one capsule once daily for 28 days
3058376|NCT02172391|Placebo Comparator|Placebo|Placebo inhalation powder capsules, one capsule once daily for 28 days
3058377|NCT02172378|Experimental|Tiotropium inhalation capsules|
3058378|NCT02172378|Placebo Comparator|Placebo inhalation capsules|
3058379|NCT02172352|Experimental|Ba 679 BR low dose|
3058380|NCT02172352|Placebo Comparator|Placebo inhalation powder|
3058381|NCT02172352|Experimental|Ba 679 BR middle dose|
3058382|NCT02172352|Experimental|Ba 679 BR high dose|
3058383|NCT02172339|Experimental|Tiotropium|group comparison (healthy, renal impairment)
3058384|NCT02172326|Experimental|Tiotropium inhalation capsules|
3058385|NCT02172313|Experimental|Fed conditions|Fasting for 10 hours overnight followed by a high-fat, high-calorie meal, after the meal dosing of the tablet with 240 mL of water and a post-dose fasting period of 4 hours
3058386|NCT02172313|Experimental|Fasting conditions|Fasting for 10 hours overnight followed by dosing of the tablet with 240 mL of water and a post-dose fasting period of 4 hours
3058387|NCT02172313|Experimental|Reference dosing condition|Fasting for 6 hours overnight followed by dosing of the tablet with 120 mL of water and a post-dose fasting period of 30 min
3058388|NCT02172300|Experimental|Tiotropium|Tiotropium inhalation capsules via HandiHaler
3058389|NCT02172300|Placebo Comparator|Placebo|Placebo inhalation capsules via HandiHaler
3058390|NCT02172287|Experimental|Tiotropium (Ba679 BR)|Tiotropium capsule once daily by oral inhalation
3058391|NCT02172287|Active Comparator|Salmeterol|Salmeterol inhalation aerosol twice daily
3058392|NCT02172287|Placebo Comparator|Placebo|"Tiotropium (Ba679 BR)- placebo one capsule once daily by inhalation~Salmeterol- placebo, inhalation aerosol twice daily"
3058393|NCT02172274|Experimental|[14C]-BI 10773 - oral solution|
3058394|NCT02172261|Experimental|Sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 and glimepiride once on day 1~Treatment C: Glimepiride once on day 1"
3058395|NCT02172261|Experimental|Sequence CAB|"Treatment C: Glimepiride once on day 1~Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 and glimepiride once on day 1"
3058396|NCT02172248|Experimental|Sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 once daily from day 1 to 4 and metformin twice daily from day 1 to 3 and once in the morning on day 4~Treatment C: metformin twice daily from day 1 to 3 and once in the morning on day 4"
3058397|NCT02172248|Experimental|Sequence CAB|"Treatment C: metformin twice daily from day 1 to 3 and once in the morning on day 4~Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 once daily from day 1 to 4 and metformin twice daily from day 1 to 3 and once in the morning on day 4"
3058398|NCT02172235|Active Comparator|Pioglitazone|
3058399|NCT02172235|Experimental|Pioglitazone + BI 10773 low|
3058400|NCT02172235|Experimental|Pioglitazone + BI 10773 medium|
3058401|NCT02172235|Experimental|Pioglitazone + BI 10773 high|
3058402|NCT02172235|Experimental|Pioglitazone low + BI 10773 medium|
3058403|NCT02172235|Experimental|Pioglitazone + BI 10773 1 hour after Pioglitazone|
3058404|NCT02172222|Experimental|Sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI10773 and linagliptin once daily from day 1 to 7~Treatment C: Linagliptin once daily from day 1 to 7"
3058405|NCT02172222|Experimental|Sequence CAB|"Treatment C: Linagliptin once daily from day 1 to 7~Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI10773 and linagliptin once daily from day 1 to 7"
3058406|NCT02172209|Experimental|BI 10773 tablet administered with food|50 mg BI 10773 after a standardised high fat breakfast
3058407|NCT02172209|Active Comparator|BI 10773 tablet administered to fasted subjects|50 mg BI 10773 p.o. after an overnight fast of at least 10 hours
3058408|NCT02172196|Experimental|Treatment sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5~Treatment C: Sitagliptin once daily from day 1 to 5"
3058409|NCT02172196|Experimental|Treatment sequence CAB|"Treatment C: Sitagliptin once daily from day 1 to 5~Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5"
3058410|NCT02172183|Experimental|CBT group|This group consist on a combined intervention: CBT group + psychopharmacological treatment. The group program was based on cognitive-behavioral principles and also motivational interviewing techniques to facilitate skills implementation. The treatment comprised 12 manualized sessions with an inattention module and an impulsivity module.
3058411|NCT02172183|Active Comparator|Psychopharmacological treatment|Participants were only visited to monitor their adherence and continuation on medications for ADHD (methylphenidate or atomoxetine) as prescribed by their psychiatrist.
3058412|NCT02172170|Experimental|BI 10773 single rising dose|
3058413|NCT02172170|Placebo Comparator|Placebo|
3058414|NCT02172157|Experimental|BI 1744 CL i.v. (intravenous) infusion|
3058415|NCT02172157|Active Comparator|BI 1744 CL Oral solution|
3058416|NCT02172144|Experimental|BI 1744 CL|
3058417|NCT02172144|Placebo Comparator|Placebo|
3058425|NCT02172092|Experimental|Ketoacidosis|Patients treated for diabetic ketoacidosis at the Intensive care unit, Vrinnevi Hospital, Norrköping.
3058426|NCT02172079|Experimental|Real mobilization-with-movement (MWM)|For the MWM group, an accessory posterior-lateral gliding movement in the humeral head combined with a movement of active shoulder flexion will be applied. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior aspect of the head of the humerus
3058427|NCT02172079|Sham Comparator|Sham mobilization-with-movement (MWM)|The sham condition will replicate the treatment condition except for the hand positioning. The therapist locates one hand over the belly of the pectoralis major muscle and the other over scapula without applying any pressure. The patient will be asked to move the arm in a similar manner as in the MWM group
3058428|NCT02172066|Experimental|Narrative Exposure Therapy (NET)|During NET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for emotions, cognitions, sensory information, and physiological reactions to link the traumatic events to an autobiographical context, namely time and place. In total the Individuals receive 6 sessions of NET, every session lasting between 1,5 and 2 hr depending on the needs of the participant.
3058429|NCT02172066|No Intervention|No treatment control|
3058430|NCT02172053|Active Comparator|Compensatory Workplace Exercise (CWE)|Comparative Group will receive a light training protocol including warming up, stretching and resisted exercise using elastic bands.
3058431|NCT02172053|Experimental|Individual Resistance Exercise (IRE)|Intervention group will receive training protocol including warming up, stretching a specific resistance training with increase progressive load.
3058432|NCT02172040|Experimental|Amlodipine+Celecoxib|Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
3058433|NCT02172040|Active Comparator|Amlodipine+Placebo|Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
3058434|NCT02172040|Placebo Comparator|Placebo+Celecoxib|Matched placebo tablet for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
3058435|NCT02172040|Sham Comparator|Placebo+Placebo|Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
3058436|NCT02172027||Lung Cancer, Pleural effusion|
3058437|NCT02172014|Experimental|Fentanyl|midazolam and fentanyl citrate infusion
3058438|NCT02172014|Placebo Comparator|Control|midazolam and normal saline infusion
3058439|NCT02172001|Experimental|Iron isomaltoside 1000|Iron isomaltoside 1000. Dose: 1000 mg, 1500 mg or 2000 mg
3058440|NCT02172001|Placebo Comparator|Placebo (NaCl 0,9%)|Sodium Chloride. Dose: 100 ml or 5 ml
3058441|NCT02171988|Active Comparator|Propranolol|Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
3058442|NCT02171988|Active Comparator|Bisoprolol|Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
3058443|NCT02171988|Active Comparator|Propranolol+pyridostigmine|Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
3058444|NCT02171988|Active Comparator|Bisoprolol+pyridostgmine|start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
3058445|NCT02171975|Active Comparator|Group C|Patients in this group underwent Conventional landmark guided midline spinal anaesthetic.
3058446|NCT02171975|Experimental|Group P|This group had their spinal anaesthetic done based on pre-procedure ultrasound guided paramedian spinal
3058447|NCT02171962|Experimental|Zilver® PTX® VI|
3058448|NCT02171949|No Intervention|Control group|
3058449|NCT02171949|Active Comparator|Bone marrow mononuclear cell therapy|
3058450|NCT02171936||chronic pain|
3058451|NCT02171923||Remitted depressed patients|Formerly depressed patients in remission for 6 months or more
3058452|NCT02171923||healthy controls|healthy subjects with no history of mental disorders
3058453|NCT02171910|Active Comparator|Doxapram|Propofol sedation with a doxapram 1mg/kg i.v. bolus at induction and an i.v. infusion 1mg/kg/h) during the procedure
3058454|NCT02171910|Placebo Comparator|Placebo|Propofol sedation with a placebo i.v. bolus at induction and a placebo i.v. infusion during the procedure
3058455|NCT02171897|Experimental|Patients treated with osteosynthesis|
3058456|NCT02171897|Experimental|Patients treated with total hip replacement|
3058457|NCT02171884||Group E1|Singletons born following ART via IVF/ICSI (short culture)
3058458|NCT02171884||Group EC1|Singletons born following ART via IVF/ICSI and freezing-thawing of the embryo
3058459|NCT02171884||Group T1|Singletons conceived naturally
3058460|NCT02171884||Group E2|Singletons born following ART with IVF/ICSI (prolonged culture)
3058461|NCT02171871|Experimental|CONTROL GROUP|"Healthy non-smoking volunteers (18-40 years old) will be subject, after giving their brief medical history, to IOS and to the nitrogen washout test. The IOS will be conducted in four positions (standing, sitting, right and left lateral decubitus), whereas the nitrogen washout test in two (sitting and decubitus).~Then the subjects will be exposed to a smoking environment for 20 minutes."
3058462|NCT02171858||stroke|Patients admitted to hospital who are diagnosed with stroke will be treated as usually a our center by observation, venous or arterial thrombolysis depending on extension, condition, thrombolysis feasibility.
3058463|NCT02171845||Foetus|
3058464|NCT02171832|Experimental|Mildly liver impaired patients|
3058465|NCT02171832|Experimental|Moderately liver impaired patients|
3058466|NCT02171832|Experimental|Healthy volunteers|
3058467|NCT02171819|Experimental|IVACFLU-A/H5N1, 7.5 mcg|IVACFLU-A/H5N1, 7.5 mcg HA per dose, given by intramuscular (IM) injection at Day 0 and Day 21.
3058468|NCT02171819|Experimental|IVACFLU-A/H5N1, 15 mcg|IVACFLU-A/H5N1, 15 mcg HA per dose, given IM at Day 0 and Day 21.
3058469|NCT02171819|Placebo Comparator|Placebo|phosphate buffered saline, given IM in 2 doses (2 separate injections---1 at Day 0 and another 21 days later.)
3058470|NCT02171806|Experimental|BI 1744 CL multiple rising doses|
3058471|NCT02171806|Placebo Comparator|Placebo|
3058486|NCT02171702|Experimental|BIBW 2992, fasted|food effect part: maximum tolerated dose of BIBW 2992
3058487|NCT02171702|Experimental|BIBW 2992, fed|food effect part: maximum tolerated dose of BIBW 2992
3058488|NCT02171689|Experimental|BIBW 2992 MA2|
3058489|NCT02171676|Experimental|Docetaxel + BIBW 2992|Dose escalation
3058490|NCT02171663|Experimental|BIBW 2992|
3058491|NCT02171650|Experimental|BIBW 2992|
3058492|NCT02171637|Experimental|BIBW 2992|
3058493|NCT02171624|Experimental|dabigatran etexilate|quinidine run-in, followed by dabigatran+quinine and dabigatran alone in randomized order
3058494|NCT02171624|Experimental|quinidine|quinidine run-in, followed by dabigatran+quinine and dabigatran alone in randomized order
3058495|NCT02171611|Experimental|Dabigatran etexilate pellets|
3058496|NCT02171611|Experimental|Dabigatran etexilate powder|
3058497|NCT02171611|Active Comparator|Dabigatran etexilate capsule|
3058498|NCT02171598|Experimental|Fixed sequence 1|multiple-dose, fixed-sequence with 2 periods of 4 days separated by a washout period of at least 14 days. A single dose of 300 mg clopidogrel will be given on top of 75 mg or 150 mg dabigatran in steady state.
3058499|NCT02171598|Experimental|Crossover|clopidogrel + dabigatran / clopidogrel / dabigatran in randomized order
3058500|NCT02171598|Experimental|Fixed sequence 2|intra-individual comparison with the fixed sequence of a single dose of 600mg clopidogrel alone and the combination of dabigatran 150 mg in steady state plus single dose of 600 mg clopidogrel
3058501|NCT02171585|Experimental|Dabigatran without Clarithromycin|
3058502|NCT02171585|Experimental|Dabigatran with Clarithromycin|
3058503|NCT02171572|Experimental|Dabigatran etexilate low|
3058504|NCT02171572|Experimental|Dabigatran etexilate high|
3058505|NCT02171559|Experimental|Dabigatran etexilate capsules after enoxaparin ampoules|
3058506|NCT02171559|Active Comparator|Dabigatran etexilate capsules without enoxaparin|
3058507|NCT02171546|Active Comparator|Dabigatran etexilate capsules|
3058508|NCT02171546|Experimental|Dabigatran etexilate capsules and quinidine sulfate tablets|
3058509|NCT02171546|Active Comparator|Fexofenadine tablets|
3058510|NCT02171546|Experimental|Fexofenadine and quinidine sulfate tablets|
3058511|NCT02171533|Experimental|Fixed sequence|Treatments will be given in a fixed sequence
3058512|NCT02171533|Experimental|Crossover|Treatments will be given in randomized sequences
3058513|NCT02171520|Experimental|Dabigatran etexilate generation I|
3058514|NCT02171520|Active Comparator|Dabigatran etexilate generation II|
3058515|NCT02171507|Active Comparator|Dabigatran etexilate|
3058516|NCT02171507|Active Comparator|Diclofenac|
3058517|NCT02171507|Experimental|Dabigatran etexilate + diclofenac|
3058518|NCT02171494|Experimental|IVAX warfarin|Treatment A: IVAX warfarin
3058519|NCT02171494|Active Comparator|BMS coumadin|Treatment B: BMS coumadin tablets
3058520|NCT02171481|Experimental|Dabigatran etexilate polymorph II|
3058521|NCT02171481|Active Comparator|Dabigatran etexilate polymorph I|
3058522|NCT02171468|Experimental|Dabigatran high dose|
3058523|NCT02171468|Experimental|Dabigatran low dose|
3058524|NCT02171455|Experimental|Dabigatran etexilate low dose|
3058525|NCT02171455|Experimental|Dabigatran etexilate medium dose|
3058526|NCT02171455|Experimental|Dabigatran etexilate high dose|
3058527|NCT02171442|Experimental|BIBR 953 ZW Intravenously|
3058528|NCT02171442|Active Comparator|BIBR 1048 Oral Solution|
3058529|NCT02171429|Active Comparator|Adalimumab + Etrolizumab Placebo|Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.
3058530|NCT02171429|Experimental|Etrolizumab + Adalimumab Placebo|Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
3058531|NCT02171429|Placebo Comparator|Etrolizumab Placebo + Adalimumab Placebo|Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
3058532|NCT02171416|Placebo Comparator|Placebo|Placebo s.c every 7 days
3058533|NCT02171416|Experimental|Rilonacept 160mg|Rilonacept s.c every 7 days
3058534|NCT02171403||Lactose intolerance|Patients with a positive lactose-breath test and complaints during the test
3058535|NCT02171403||Lactose malabsorption|Patients with a positive lactose-breath test and no complaints during the test
3058536|NCT02171403||Healthy controls|Subjects with a negative lactose-breath test
3058537|NCT02171390|Active Comparator|Daily testosterone transdermal gel|
3058538|NCT02171390|Active Comparator|Injectable Testosterone esters|Testosteron 250mg injection per 3-4 weeks for 6 months
3058539|NCT02171377|Experimental|Group 2 : quadricipital electrical stimulation|stimulation in addition to rehabilitation (30 min bilateral quadricipital electrical stimulation pd, 5 days per week, 8 weeks)
3058540|NCT02171377|Active Comparator|Group 1 : Pulmonary rehabilitation|Pulmonary rehabilitation 3 to 5 times per week, 8 weeks
3058541|NCT02171364|Experimental|virtual simulation|This intervention group is to choose the best effective method operation to patients by simulating 3D atrial computer model which consider patient's heart size and shape.
3058542|NCT02171364|Active Comparator|conventional ablation|The other intervention group is to operate the atrial fibrillation by physician's personal experience, not by virtual simulation.
3058543|NCT02171351|Experimental|effect of neuromuscular electrostimulation (NMES)|
3058544|NCT02171351|Experimental|effect of neuro electrostimulation (NES)|
3058545|NCT02171351|Experimental|effect of voluntary contractions (VC)|
3058546|NCT02171338|Other|Antibiotic treatment based on PCT-level|"Information regarding the PCT-levels in the intervention group is available to the treating doctor and the test subjects are randomized for treatment based on the level of PCT (PCT algorithm).~With a PCT ≥0.25 µg/l and ≥0.10 µg/l for pneumonia and AECOPD respectively antibiotic treatment is advised to be started."
3058547|NCT02171338|No Intervention|Control|"Test subjects randomized for standard treatment (control group) are treated in accordance with the existing treatment guidelines of Holbaek Hospital.~PCT-level will be measured but the treating doctor has no access to the result."
3059396|NCT02165670||Ischemic heart disease|Patients undergoing percutaneous coronary intervention (PCI)
3058548|NCT02171325|Experimental|irinotecan|irinotecan； 60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
3058549|NCT02171312||Concussion Cohort|Participants with possible concussion related dizziness will complete iDETECT battery testing and routine balance and vestibular testing.
3058550|NCT02171312||Healthy Controls|Participants without possible concussion related dizziness will complete iDETECT battery testing and routine balance and vestibular testing.
3058551|NCT02171299|Experimental|intervetional group (local anaesthetic)|intraoperative wound infiltration with ropivacaine 10%.
3058552|NCT02171299|No Intervention|control (no local anesthetic)|no infiltration of the wound with local anaesthetic
3058553|NCT02171286||No Treatment|
3058554|NCT02171273|Experimental|Chronic circadian disruption|Following a baseline of adequate time in bed, study participants will spend 3 weeks on a daily jet-lag schedule (where each day is longer than 24 hours).
3058555|NCT02171273|Experimental|Chronic sleep restriction|Following a baseline of adequate time in bed, study participants will have a shortened opportunity for sleep during each 24-hour day (for three weeks).
3058556|NCT02171273|Active Comparator|Control (sleep extension)|Following a baseline of adequate time in bed, study participants will continue to have adequate time in bed and opportunity for sleep during each 24-hour day, for 3 weeks.
3058557|NCT02171260|Experimental|E7389|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle. A cycle of therapy is considered to be 21 days. The starting dose for eribulin mesylate will be at 1.1 mg/m2 (Dose Level 1), which is approximately 80% of the adult maximum tolerated dose (MTD), and will be escalated up to no more than 2.2 mg/m2.
3058558|NCT02171247|Active Comparator|Isovue 370|Isovue 370 is a contrast agent with increased iodine concentration.
3058559|NCT02171247|Active Comparator|Visipaque 320|Standard protocol is Visipaque 320.
3058560|NCT02171234|Experimental|Group 1- 200 mg b.i.d. (twice daily)|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
3058561|NCT02171234|Experimental|Group 2 - 400 mg b.i.d.|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
3058562|NCT02171234|Experimental|Group 3- 800 mg o.d. (once daily)|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
3058563|NCT02171234|Experimental|Group 4 - either 800 mg b.i.d or 1200 mg o.d.|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
3058564|NCT02171221|Experimental|Oral DFP-11207|DFP-11207: daily oral dosing, 28 day treatment cycle
3058565|NCT02171208|Active Comparator|Reference, Test, Reference (RTR)|Doses will be separated by a washout period
3058566|NCT02171208|Active Comparator|Test, Reference, Reference (TRR)|Doses will be separated by a washout period
3058567|NCT02171195|Experimental|Group 1 (20 mg)|
3058568|NCT02171195|Experimental|Group 2 (50 mg)|
3058569|NCT02171195|Experimental|Group 3 (100 mg)|
3058570|NCT02171195|Experimental|Group 4 (200 mg)|
3058571|NCT02171195|Experimental|Group 5 (400 mg)|
3058572|NCT02171195|Experimental|Group 6 (600 mg)|
3058573|NCT02171195|Experimental|Group 7 (900 mg)|
3058574|NCT02171195|Experimental|Group 8 (1200 mg)|
3058575|NCT02171182||Qutenza patients w/ post-operative peripheral neuropathic pain|
3058576|NCT02171169||Transsacral lumbar interbody fusion|
3058577|NCT02171169||Transforaminal lumbar interbody fusion|
3058578|NCT02171143|Experimental|ASP2409 Dose Escalation|
3058579|NCT02171143|Placebo Comparator|Placebo Dose Escalation|
3058580|NCT02171130|Experimental|Intranasal glucagon|3 mg glucagon powder
3058581|NCT02171117|No Intervention|CT-group|standard induction and consolidation chemotherapy only, without microtransplantation
3058582|NCT02171117|Experimental|MST-group|standard induction and consolidation chemotherapy with microtransplantation
3058583|NCT02171104|Experimental|IMD - Except Haplo-identical|"Inherited Metabolic Disease (IMD) - Except Haplo-Identical~See intervention descriptions."
3058584|NCT02171104|Experimental|OP - Except Haplo-Identical|"Severe Osteoperosis (OP) - Except Haplo-Identical~See intervention descriptions."
3058585|NCT02171104|Experimental|OP and IMD -Haplo-Identical Only|"Severe Osteopetrosis (OP) and Inhterited Metabolic Disorders (IMD)~-Haplo-Identical Only~See intervention descriptions."
3058586|NCT02171104|Experimental|cALD SR-A (Standard-Risk, Regimen A)|See intervention descriptions.
3058587|NCT02171104|Experimental|cALD SR-B (Standard-Risk, Regimen B)|See intervention descriptions.
3058588|NCT02171104|Experimental|cALD HR-C (High-Risk, Regimen C)|See intervention descriptions.
3058589|NCT02171104|Experimental|cALD HR-D (High-Risk, Regimen D)|See intervention descriptions.
3058590|NCT02171091||study arm|One tracheal sample will be obtained using sterile (5 ml) sterile saline solution using irrigation and wall suction from each patient every day for 72 hours, total sampling time is approximately 10 seconds per specimen. Lung samples or fiberoptic obtained samples will be collected at same time intervals as the tracheal samples when possible and if they are done as standard of care. Samples will not be collected for research only and the time for this procedure will not be extended to collect extra tissue. A blood sample (10ml) will be collected simultaneously with the airway samples and also will be used for baseline control measurements.
3058591|NCT02171078||Alliance for Clinical Trials Database|Use existing data from clinical trials sponsored by one of the leading cancer cooperative groups to evaluate how risk of recurrence and side effects of treatment vary based on patient and cancer characteristics.
3058592|NCT02171078||National Cancer Database|Use existing data to evaluate the effectiveness of the latest imaging technology for detecting recurrence and improving survival in patients previously treated for breast cancer.
3058593|NCT02171078||Stakeholder Engagement|Engage cancer survivors, providers, and health outcomes researchers in the development of an improved patient-centered approach to guide post-treatment care, as well as identification of the highest priority strategies for prospective randomized trials.
3058594|NCT02171065|Sham Comparator|Guideline Directed Medical Therapy|Guideline Directed Medical Therapy
3058595|NCT02171065|Active Comparator|ABSORB BVS + Guideline Directed Medical Therapy|ABSORB BVS + Guideline Directed Medical Therapy
3058596|NCT02171052|Experimental|Dabigatran etexilate plus digoxin|
3058597|NCT02171052|Active Comparator|Dabigatran etexilate|
3058613|NCT02170961||acute heart failure (AHF)|patients consulting the emergency department for dyspnea. the diagnosis of AHF was based on clinical, biological (BNP) and echocardiographic data.
3058614|NCT02170961||Non acute heart failure (NAHF)|patients consulting the emergency department for dyspnea. the diagnosis of AHF was based on clinical, biological (BNP) and echocardiographic data.
3058615|NCT02170948|Experimental|Dex 0.5|Ropivacaine and Lidocaine plus Dexmedetomidine (0.5mg/kg) plus Normal Saline
3058616|NCT02170948|Experimental|Dex 1.0|Ropivacaine and Lidocaine plus Dexmedetomidine (1.0mg/kg) plus Normal Saline
3058617|NCT02170935|Experimental|BIBR 1048 capsule|
3058618|NCT02170922|Experimental|Sequence 1|BIBR 1048 MS tablet (fasted) - BIBR 1048 MS solution (fasted) - BIBR 1048 MS tablet after high fat meal
3058619|NCT02170922|Experimental|Sequence 2|BIBR 1048 MS solution (fasted) - BIBR 1048 MS tablet (fasted) - BIBR 1048 MS tablet after high fat meal
3058620|NCT02170909|Experimental|BIBR 1048 MS low dose|
3058621|NCT02170909|Experimental|BIBR 1048 MS medium dose|
3058622|NCT02170909|Experimental|BIBR 1048 MS high dose|
3058623|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule A+Pantoprazole|
3058624|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule B+Pantoprazole|
3058625|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule C+Pantoprazole|
3058626|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule D+Pantoprazole|
3058627|NCT02170896|Active Comparator|Period 1: BIBR1048 MS solution+Pantoprazole|
3058628|NCT02170896|Experimental|Period 2: BIBR1048 MS Capsule C|
3058629|NCT02170896|Experimental|Period 2: BIBR1048 MS Capsule D|
3058630|NCT02170896|Active Comparator|Period 2: BIBR1048 MS solution|
3058631|NCT02170883|Experimental|Interactive SMS|"Intervention with interactive SMS (text messaging) by which patients are asked to disclose their level of agreement with the following statement I follow my asthma medication plan and pharmacist follow-up"
3058632|NCT02170883|Active Comparator|Usual care|Pharmacist conducted patient education, counseling and action-plan
3058633|NCT02170870|Experimental|Exendin 9-39 and Lipid infusion|"Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).~Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
3058634|NCT02170870|Placebo Comparator|Placebo and lipid infusion|"Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).~Normal saline infusion will be prepared to match the appearance of Exendin 9-39"
3058635|NCT02170857|No Intervention|Open Curettage Only|patients will be treated by the conventional surgical method, i.e. open curettage without injecting any material.
3058636|NCT02170857|Experimental|Open Curettage with Hyaluronic Acid|Hyaluronic Acid injection will be employed in conjunction with the ordinary surgical procedure.
3058637|NCT02170844|Experimental|BIBR 1048 MS (Japanese)|Japanese subjects received an increasing dose (50 mg to 150 mg) of BIBR 1048 MS
3058638|NCT02170844|Placebo Comparator|BIBR 1048 MS Placebo (Japanese)|Japanese subjects will receive placebo of BIBR 1048 MS
3058639|NCT02170844|Experimental|BIBR 1048 MS (Caucasian)|Caucasian subjects received an increasing dose (50 mg to 150 mg) of BIBR 1048 MS
3058640|NCT02170844|Placebo Comparator|BIBR 1048 MS Placebo (Caucasian)|Japanese subjects will receive placebo of BIBR 1048 MS
3058641|NCT02170831|Experimental|BIBR 1048 MS low dose|
3058642|NCT02170831|Experimental|BIBR 1048 MS medium dose 1|
3058643|NCT02170831|Experimental|BIBR 1048 MS medium dose 2|
3058644|NCT02170831|Experimental|BIBR 1048 MS high dose|
3058645|NCT02170831|Placebo Comparator|BIBR 1048 Placebo|
3058646|NCT02170818|Experimental|Educational Workshop on Speaking-Up|Educational Workshop on Speaking-Up Before Simulated Case
3058647|NCT02170818|Sham Comparator|Unrelated Education|Unrelated Education (CPR) before simulated case (Educational Workshop on Speaking-up after case and debriefing)
3058648|NCT02170805|Experimental|Substudy 1|"Three treatments of single administrations of BIBR 1048 MS 50 mg with or without pantoprazole; randomised sequence~BIBR 1048 MS capsule formulation A without pantoprazole;~BIBR 1048 MS capsule formulation A with coadministration of 40 mg pantoprazole (bid);~BIBR 1048 MS powder plus solution without pantoprazole"
3058649|NCT02170805|Experimental|Substudy 2|"Three treatments of single administrations of BIBR 1048 MS 50 mg with or without pantoprazole; randomised sequence~BIBR 1048 MS capsule formulation B without pantoprazole;~BIBR 1048 MS capsule formulation B with coadministration of 40 mg pantoprazole (bid);~BIBR 1048 MS powder plus solution without pantoprazole"
3058650|NCT02170792|Experimental|BIBR 1048 MS with ranitidine|Low, medium or high dose in combination with ranitidine
3058651|NCT02170792|Experimental|BIBR 1048 MS without ranitidine|Low, medium or high dose
3058652|NCT02170779|Experimental|A Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
3058653|NCT02170779|Other|B Usual care|2 visits: baseline and given usual treatment of brochure for stretching, outcome measures
3058654|NCT02170766|Experimental|BIBR 1048 low1|"Two treatments of one single dose of BIBR 1048 12.5 mg without or with Pantoprazole~BIBR 1048 12.5 mg without Pantoprazole~BIBR 1048 12.5 mg with 40 mg Pantoprazole (bid)"
3058655|NCT02170766|Experimental|BIBR 1048 low2|"Two treatments of one single dose of BIBR 1048 25 mg without or with Pantoprazole~BIBR 1048 25 mg without Pantoprazole~BIBR 1048 25 mg with 40 mg Pantoprazole (bid)"
3058656|NCT02170766|Experimental|BIBR 1048 medium|"Two treatments of one single dose of BIBR 1048 50 mg without or with Pantoprazole~BIBR 1048 50 mg without Pantoprazole~BIBR 1048 50 mg with 40 mg Pantoprazole (bid)"
3058657|NCT02170766|Experimental|BIBR 1048 high|"Two treatments of one single dose of BIBR 1048 100 mg without or with Pantoprazole~BIBR 1048 100 mg without Pantoprazole~BIBR 1048 100 mg with 40 mg Pantoprazole (bid)"
3058658|NCT02170753|Experimental|Regional manual therapy|The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy
3058659|NCT02170753|Active Comparator|Standard physical therapy|The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
3058660|NCT02170740|Experimental|BIBR 1048 MS|
3058661|NCT02170740|Experimental|BIBR 1048 MS + Pantoprazole|
3059397|NCT02165657|Experimental|Excimer laser|Excimer laser treatment
3058662|NCT02170727|Experimental|Arm 1 : DCV/ASV/BMS-791325|DCV 30 mg (as the free base) / Asunaprevir (ASV) 200 mg / BMS-791325 75 mg FDC tablet orally twice daily for 12 weeks
3058663|NCT02170714||ASC|Consecutive children hospitalized for an episode of acute ASC, defined as a PUCAI > 65. All patients were treated according to the 2011 ECCO-ESPGHAN guidelines for ASC: all patients received intravenous (iv) corticosteroids (methylprednisolone 1.5-2 mg/Kg/day) for 5 days. Patients not responding to corticosteroids (i.e. PUCAI>65 at day 5) started Infliximab (IFX, 5 mg/Kg 0,2,6 then every 8 weeks) as second-line therapy. All therapies were decided at the discretion of the referral gastroenterologist and recorded on standardized case report forms. A follow-up of 2 years for the colectomy risk was evaluated for all patients.
3058664|NCT02170701|Experimental|BIBR 1048|Ascending doses (in mg) given twice daily
3058665|NCT02170688|Active Comparator|Fixed dose|50 subjects will receive contrast media based on a fixed dose. Each will receive 125 mL of Isovue 370 (370 mg of iodine/mL) administered at 4 mL/sec (1.48 gmI/sec for 31.25 sec).
3058666|NCT02170688|Active Comparator|Total body weight|25 subjects will receive contrast media dose based on the total body weight. Total body weight will be determined. Both men and women will receive contrast media at a dose of 0.7 gmI/kg (1.78 mL of Isovue 370/kg) or 0.30 gmI/lb (0.81 mL of Isovue 370/lb). The injection rate will be 0.058 mL/sec/kg (0.026 mL/sec/lb).
3058667|NCT02170688|Active Comparator|Calculated lean body weight|"25 subjects will receive contrast media dose based on the calculated lean body weight. Total body weight and height will be determined. From this data the lean body weight will be calculated.~Men will receive a dose of 0.86 gmI / kg LBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb LBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg LBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb LBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg)."
3058668|NCT02170688|Active Comparator|Measured lean body weight|"50 subjects will receive contrast media dose based on the measured lean body weight. Lean body weight will be determined using the Tanita body composition/analyzer scales. From this data the lean body weight will be calculated.~Men will receive a dose of 0.86 gmI / kg LBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb LBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg LBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb LBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg)."
3058669|NCT02170688|Active Comparator|Estimated lean body (eLBW) weight|25 subjects will receive contrast media dose based on the estimated lean body (eLBW) weight. Estimated lean body weight will be determined by using a unique software program which measures the sum of the posterior to anterior attenuation from the digital scout radiograph (abbreviated as sqrt PA) obtained during the standard planning scan of the abdominal/pelvic CT. Men will receive a dose of 0.86 gmI / kg eLBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb eLBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg eLBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb eLBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg).
3058670|NCT02170675|Experimental|Dabigatran etexilate + Ketoconazole|"Period 1 - Dabigatran etexilate~Period 2 - Dabigatran etexilate and single dose of 400 mg Ketoconazole on Day 8 and 9~Period 3 - Dabigatran etexilate and multiple doses of 400 mg Ketoconazole on Day 10 to 16"
3058671|NCT02170662|Active Comparator|Active drug|During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
3058672|NCT02170662|Active Comparator|Placebo|During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
3058673|NCT02170649|Experimental|Single Group|the volunteers received a single 800 mg BIA 2-093 following either a standard high fat content breakfast or 10 hours of fasting. Fed and fasting periods were separated by a washout period
3058674|NCT02170636|Experimental|Period 1: BIBR 1048 MS + Pantoprazole|"Five treatments with oral administration of 50 mg BIBR 1048 MS (bid for 3 days) and 40 mg Pantoprazole (bid). Randomised sequence.~BIBR 1048 MS Capsule E with pantoprazole; BIBR 1048 MS Capsule F with pantoprazole; BIBR 1048 MS Capsule G with pantoprazole; BIBR 1048 MS Tablet H with pantoprazole; BIBR 1048 MS Drinking solution with pantoprazole"
3058675|NCT02170636|Experimental|Period 2: BIBR 1048 MS|"Three treatments (fixed sequence) with oral administration of 50 mg BIBR 1048 MS (bid for 3 days).~BIBR 1048 MS Capsule E without pantoprazole;~BIBR 1048 MS Tablet H without pantoprazole;~BIBR 1048 MS Drinking solution without pantoprazole"
3058676|NCT02170623|Experimental|Period 1: BIBR 1048 MS with Pantoprazole|"Three treatments of different formulations of 50 mg BIBR 1048 MS (bid for 3 days) with 40 mg Pantoprazole (bid). Randomised sequence.~BIBR 1048 MS Capsule I with pantoprazole (bid for 3 days);~BIBR 1048 MS Capsule K with pantoprazole (bid for 3 days);~BIBR 1048 MS Drinking solution with Pantoprazole (bid for 3 days)"
3058677|NCT02170623|Experimental|Period 2: BIBR 1048 MS|"Three treatments of different formulations of 50 mg BIBR 1048 MS (bid for 3 days) without Pantoprazole. Fixed sequence.~BIBR 1048 MS Capsule K (bid for 3 days);~BIBR 1048 MS Drinking solution (bid for 3 days)"
3058678|NCT02170610|Experimental|BIBR 1048 MS capsule|
3058679|NCT02170610|Experimental|BIBR 1048 capsule with pantoprazole|
3058680|NCT02170610|Experimental|BIBR 1048 capsule with food|
3058681|NCT02170597|Experimental|BIBR 1018 MS HPMC capsule fasted|
3058682|NCT02170597|Experimental|BIBR 1048 MS HPMC capsule after high fat meal|
3058683|NCT02170597|Active Comparator|BIBR 1048 MS gelatine capsule fasted|
3058684|NCT02170584|Experimental|BIBR 953 ZW IV|
3058685|NCT02170584|Active Comparator|BIBR 1048 MS oral solution|
3058686|NCT02170584|Experimental|BIBR 1048 MS tablet|
3058687|NCT02170584|Placebo Comparator|BIBR 953 ZW IV Placebo|
3058688|NCT02170571|Experimental|Dabigatran etexilate|
3058689|NCT02170558||Patients implanted w/TM-Ardis|Patients who are receiving a TM-Ardis implant for degenerative disc disease will have a CT scan immediate post op (2 weeks) and again at 6 months to determine if fusion can be assessed with the study metal reduction software. Will utilize TM- Ardis implant and Metal Reduction CT software
3059442|NCT02165293|Experimental|RO7033877|
3058690|NCT02170545||Multi-Part Proximal Humerus Fracture|All participants that meet the entry criteria will be included in the study cohort.
3058691|NCT02170532|Active Comparator|levalbuterol + saline in a breath actuated nebulizer|0.5 ml. levalbuterol + 0.5ml saline in a breath actuated nebulizer
3058692|NCT02170532|Active Comparator|levalbuterol + ipratroprium in a breath actuated nebulizer|0.5 ml. levalbuterol + 0.5ml ipratroprium in a breath actuated nebulizer
3058693|NCT02170532|Active Comparator|levalbuterol MDI 2 puffs|levalbuterol metered dose inhaler 2 puffs
3058694|NCT02170532|Active Comparator|levalbuterol MDI + aerochamber max without pause 2 puffs|levalbuterol MDI + aerochamber max without pause 2 puffs
3058695|NCT02170532|Active Comparator|levalbuterol MDI + aerochamber max with 2 second pause 2 puffs|levalbuterol MDI + aerochamber max with 2 second pause 2 puffs
3058696|NCT02170519|Experimental|Phase 2: Inhaled Iloprost continuous|"Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized continuously at a dose of 5-30mcg/hour for as long as the attending physician deems it necessary to deliver vasodilator therapy."
3058697|NCT02170519|Experimental|Phase 1: Inhaled Iloprost 3 doses|"Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized three different times on hour apart. Thirty minutes after the last iloprost dose, INO will be added back at the previous (baseline) dose."
3058698|NCT02170506|Experimental|submental sensitive transcutaneous electrical stimulation.|Each Healthy subjects will be his own witness. Urostim 2 stimulation Arm
3058699|NCT02170467|Experimental|Control|Assessment of intestinal permeability in small intestine (Lactulose/ Mannitol ratio) in controls and camparison with pateints with anorexia nervosa.
3058700|NCT02170467|Experimental|patients with anorexia nervosa|Assessment of intestinal permeability in small intestine (Lactulose/ Mannitol ratio) in patients with anorexia nervosa before and after re-feeding.
3058701|NCT02170454|Active Comparator|rTMS|rTMS on pharyngeal cortical area in healthy subjects
3058702|NCT02170454|Placebo Comparator|Placebo|Sham rTMS on pharyngeal cortical area in healthy subjects
3058703|NCT02170441||Patients at risk for drug-resistant TB|No intervention
3058704|NCT02170428||growth and development|Growth and development of a random sample of healthy Danish infants
3058705|NCT02170415|Active Comparator|Intervention limb|"Medical review and analgesic optimisation.~Pain education (in the form of leaflet and website recommendations)~Psychological input for patients with evidence of psychological morbidity.~Protective analgesia - one pre-procedure dose of 150mg oral pregabalin.~Five days post-procedure oral pregablin twice daily at a dose of 75mg twice a day.~Patients offered a paravertebral block, local anaesthetic infiltrated around the wound by the surgeon.~Daily, focused visits from the hospital pain team.~Any patient displaying concerning pain symptoms, behaviour or who underwent prolonged (>3 hours surgery) may be booked for early 'preemptive' review in pain clinic."
3058706|NCT02170415|No Intervention|Usual care|These partcipants will receive usual care before, during and after their breast surgery
3058707|NCT02170402|Experimental|Previously Treated Patients (PTPs)|"PTPs will participate sequentially with:~Part 1: Pharmacokinetic parameters of ADVATE measured in subset of 24 participants, consisting of:~12 adults (>12 years of age)~12 children (≤12 years of age)~Part 2: On-demand treatment with ADVATE for 6 months~Part 3: Prophylaxis regimen with ADVATE for 6 months"
3058708|NCT02170389|Experimental|Treatment (AGS-003 immunotherapy, nephrectomy)|Patients receive 3 injections of renal cell carcinoma/cluster of CD40L RNA-transfected autologous dendritic cell vaccine AGS-003 ID once every 7 days during weeks 6-8 in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy on week 10.
3058709|NCT02170376|Experimental|Group 1|Placebo once-daily for 11 days 200 mg entacapone concomitantly with levodopa/carbidopa on Day 12
3058710|NCT02170376|Experimental|Group 2|25 mg BIA 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
3058711|NCT02170376|Experimental|Group 3|50 mg 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
3058712|NCT02170376|Experimental|Group 4|75 mg 9-1067 once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
3058713|NCT02170376|Placebo Comparator|Group 5|placebo once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
3058714|NCT02170363|Experimental|HeartMate 3|Left Ventricular Assist System (LVAS) to be used on Subjects with advanced refractory left ventricular heart failure
3058715|NCT02170350|Experimental|Brief mindful meditation practice|Patients use brief mindful meditation practice (sitting meditation in which the mind is guided to focus in the present, thinking of your existence, and allowing sensations to arise with an openness and curiosity) over 12 minutes daily for 14 days during radiation therapy.
3058716|NCT02170337|Experimental|AMG 282|AMG 282 administered as subcutaneous and intravenous doses.
3058717|NCT02170337|Placebo Comparator|Placebo|No active drug
3058718|NCT02170324|Experimental|GLP-1 agonism group|Exenatide injection 10 ug twice daily for 10 days subcutaneously.
3058719|NCT02170324|Placebo Comparator|Placebo group|0.9 % sodium choride 0.1 ml twice daily for 10 days subcutaneously.
3058720|NCT02170311|Experimental|Z-213 100mg|Group/Cohort Label: 100 mg iron Z-213 will be administered by intravenous infusion.
3058721|NCT02170311|Experimental|Z-213 500mg|Group/Cohort Label: 500 mg iron Z-213 will be administered by intravenous infusion.
3058722|NCT02170311|Experimental|Z-213 800mg|Group/Cohort Label: 800 mg iron Z-213 will be administered by intravenous infusion.
3058723|NCT02170311|Experimental|Z-213 1000mg|Group/Cohort Label: 1000 mg iron Z-213 will be administered by intravenous infusion.
3058724|NCT02170298|Placebo Comparator|Placebo|"Participants may be randomized into the placebo comparator arm. Participants in this group will be given a sugar pill titrated up to 70 mg daily over the course of 9 weeks.~Drug: Placebo"
3058725|NCT02170298|Experimental|Lisdexamfetamine|"Participants may be randomized into the experimental arm. Participants in this arm will be given lisdexamfetamine titrated up to 70 mg daily over the course of 9 weeks.~Drug: Lisdexamfetamine"
3058726|NCT02170285|Experimental|Interventional tDCS|The primary intervention will be cathodal (inhibitory) tDCS (see below).
3058727|NCT02170285|Sham Comparator|Sham tDCS|Sham subjects will undergo exactly the same tDCS protocol as outlined above. This includes the initial stimulation sequence, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist to automatically ramp down to off over 30 seconds after 120 seconds of stimulation.
3058728|NCT02170272|Experimental|Home-based Lymphedema Care Program|Home-based Lymphedema Care Program (HBLCP): Participants will undergo one training session with a lymphedema therapist, and then receive a self-care video and educational manual to review at home. After completion of training session, follow-up measures occur at 1, 2, and 3 months.
3058729|NCT02170259|Experimental|suboccipital technique|The suboccipital technique (ST) aims to release the spasm of the muscles affected in tension-type headaches and in general of suboccipital soft tissues, as they are responsible for the mobility dysfunction of the occiput-atlas-axis joint; this releases the facial restriction of this region.
3058730|NCT02170259|Experimental|The articulatory technique|- The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases.
3058731|NCT02170259|Experimental|Combined treatment|Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT.
3058732|NCT02170259|No Intervention|Control group|Control group. The control group was not applied a treatment technique
3058733|NCT02170246|No Intervention|Antiretroviral Therapy (ART) only|Acute HIV-infected subjects (n=7) will be randomly assigned to a group that will receive antiretroviral therapy (the current standard of care for HIV patients) for 72 weeks.
3058734|NCT02170246|Experimental|ART + Telmisartan|Acute HIV-infected subjects (n=14) will be randomly assigned to a group that will receive treatment with telmisartan in addition to ART. Subjects will receive 40mg telmisartan daily for 4 weeks, followed by 80mg telmisartan daily for 44 weeks, to be taken in conjunction with ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily. After telmisartan is stopped, subjects will continue to take ART for an additional 24 weeks (total 72 weeks).
3058735|NCT02170233||Sepsis|This group will contain patients meeting criteria for sepsis for enrollment in the study (target population).
3058736|NCT02170233||Normals|This group will be healthy patients who will have data points recorded for controls for the study to assess the reliability of these measures on healthy patients.
3058737|NCT02170220|Experimental|Vortioxetine 5 mg: Normal Hepatic Function Cohort|Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with normal hepatic function.
3058738|NCT02170220|Experimental|Vortioxetine 5 mg: Severe Hepatic Impairment Cohort|Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with severe hepatic impairment.
3058739|NCT02170207||30 mg of lansoprazole|30 mg of lansoprazole is mixed in physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 mL of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection.
3058740|NCT02170194|Experimental|Resilience Enhancement Group|The resilience enhancement group will begin with a 90-minute session with the study psychologist, which will include a brief introduction to cognitive behavioral therapy (CBT), but focus primarily on psychoeducational, relaxation techniques and planning positive activities. The majority of the time will be focused on reviewing techniques that promote stress management. Emphasis will be placed on relaxation approaches such as controlled breathing, meditation and yoga. Focus will also be aimed at reviewing how engagement in positive activities may help prevent avoidance, promote social support and wellness. Over the subsequent 6 weeks, daily text messages to all participants will accentuate the positive, including providing recommendations on beneficial activities to engage in, encouraging such activities including in vivo exposure, and fostering behavioral changes.
3058741|NCT02170194|Placebo Comparator|Control Group|"The control group will be provided with an initial informational session providing them with details of where they can get help if they have worsened symptoms over time. In addition, the psychologist will briefly review the apps, but not provide the same pscyhoeducational detail given to the resilience enhancement group. They will receive daily texts with inspirational aphorisms (e.g., Early to bed and early to rise makes a man healthy, wealthy, and wise.) for 6 weeks."
3058742|NCT02170181||OLIGOMETASTATIC ARM|SBRT to Oligometastases
3058743|NCT02170181||CONSOLIDATION ARM|SBRT as Consolidation to Residual Disease
3058744|NCT02170181||NORTON-SIMON ARM|SBRT to Debulk Gross Disease
3058745|NCT02170181||RE-IRRADIATION ARM|
3058746|NCT02170168||Orkdal region patients|cancer patients participating in a integrated palliative care program for diagnostics, treatment, care and follow-up in and between hospital care and 13 municipalities
3058747|NCT02170168||Romsdal county patients|control palliative care cancer patients in standard care, i.e. a local hospital in the county of Møre and Romsdal, Molde Hospital, and nine districts
3058748|NCT02170168||Orkdal region carers|carers of cancer patients participating in a integrated palliative care program for diagnostics, treatment, care and follow-up in and between hospital care and 13 municipalities
3058749|NCT02170168||Romsdal county carers|carers of cancer patients receiving standard care, i.e. in a local hospital in the county of Møre and Romsdal, Molde Hospital, and community care in nine districts
3058750|NCT02170168||Orkdal region health care providers|Health care providers for cancer patients participating in a integrated palliative care program for diagnostics, treatment, care and follow-up in and between hospital care and 13 municipalities
3058751|NCT02170168||Romsdal county health care providers|Health care providers for cancer patients receiving standard care, i.e. in a local hospital in the county of Møre and Romsdal, Molde Hospital, and community care in nine districts
3058752|NCT02170155||Patients with CSM|
3058753|NCT02170155||Patients with spinal injury (SCI)|
3058754|NCT02170155||Healthy controls|
3058755|NCT02170142||No treatment|All subjects studied are normal healthy neonates without a condition. MRI will be used to assess normal brain development.
3058785|NCT02169999|Experimental|Personalized Diabetes Care Website|Subjects are exposed to Personalized Diabetes Care website.
3058756|NCT02170129|Active Comparator|100% AAB|Surgical procedures were performed according to a lateral approach technique at the edentulous region distal to the position of the first premolar. A mucoperiosteal buccal flap was elevated, exposing the lateral bony wall of the sinus antrum. A round diamond bur, 2 mm in diameter, was used to outline the demarcation of the lateral window, which was removed, thus completely exposing the underlying Schneiderian membrane. The membrane was separated from the housing bone, and a tension-free reflection exposing the sinus walls was achieved by gently pushing it away using a large flat curette (Kramer-Nevins, Hu-Friedy, Chicago, IL). The established voids were then filled with 100% AAB (Bio-Oss) followed by sealing the open lateral window by the placement of a collagen membrane (Bio Gide) and primary soft tissue closure using Vicryl 4.0 sutures (Vicryl, Ethicon J&J International, Sint-Stevens-Woluwe, Belgium).
3058757|NCT02170129|Active Comparator|50% AAB plus 50% autologous bone|Surgical procedures were performed according to a lateral approach technique at the edentulous region distal to the position of the first premolar. A mucoperiosteal buccal flap was elevated, exposing the lateral bony wall of the sinus antrum. A round diamond bur, 2 mm in diameter, was used to outline the demarcation of the lateral window, which was removed, thus completely exposing the underlying Schneiderian membrane. The membrane was separated from the housing bone, and a tension-free reflection exposing the sinus walls was achieved by gently pushing it away using a large flat curette (Kramer-Nevins, Hu-Friedy, Chicago, IL). The established voids were then filled with 50% AAB (Bio-Oss) plus 50% autologous bone harvested locally with a bone scraper followed by sealing the open lateral window by the placement of a collagen membrane (Bio Gide) and primary soft tissue closure using Vicryl 4.0 sutures (Vicryl, Ethicon J&J International, Sint-Stevens-Woluwe, Belgium).
3058758|NCT02170116|Experimental|BIBR 1048 MS dose 1|
3058759|NCT02170116|Experimental|BIBR 1048 MS dose 2|
3058760|NCT02170116|Experimental|BIBR 1048 MS dose 3|
3058761|NCT02170116|Experimental|BIBR 1048 MS dose 4|
3058762|NCT02170116|Experimental|BIBR 1048 MS dose 5|
3058763|NCT02170116|Placebo Comparator|Placebo|
3058764|NCT02170103|Experimental|Ultrasound and microbubbles|Patients who provide emergent consent will be randomized to either conventional therapy for a heart attack, or conventional therapy and ultrasound with microbubbles. The ultrasound will be applied both before and after emergent heart catheterization, in order to break up the blood clots that are not only in the artery supplying the heart muscle, but also in the small branches (capillaries) that are fed by this artery.
3058765|NCT02170103|Other|Standard of care|Emergent PCI/antithrombotic/antiplatelet therapy with Echocardiogram to assess LVEF (Left Ventricular Ejection Fraction) and Aspirin, Plavix, or Direct Thrombin Inhibitor.
3058766|NCT02170090|Experimental|Gemcitabine plus Cisplatin|"Chemotherapy will be administered on days 1 and 8 every 3 weeks, Cisplatin (25 mg per square meter of body-surface area) and Gemcitabine (1000 mg per square meter)~and Observation"
3058767|NCT02170090|Active Comparator|Capecitabine|"Capecitabine will be administered from day 1 to 14 every 3 weeks (1250 mg per square meter of body-surface area, twice daily)~and Observation"
3058768|NCT02170077|Experimental|ODG - once-daily group|BIA 2-093 once-daily; Daily doses of BIA 2-093 were increased at four-weekly periods (400 mg, 800 mg and 1200 mg).
3058769|NCT02170077|Experimental|TDG - twice-daily group|BIA 2-093 twice-daily; Daily doses of BIA 2-093 were increased at four-weekly periods (400 mg, 800 mg and 1200 mg).
3058770|NCT02170077|Placebo Comparator|PLG - placebo group|placebo
3058771|NCT02170064|Experimental|Group 1 (2-6 yrs)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 1 (2-6 years), oral suspension 50 mg/mL was used. The dose was to be rounded to the nearest 25 mg unit."
3058772|NCT02170064|Experimental|Group 2 (7-11 years)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored)."
3058773|NCT02170064|Experimental|Group 3 (12-17 years)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored)."
3058774|NCT02170051|Experimental|CBSST-CCT|Cognitive Behavioral Social Skills Training-Compensatory Cognitive Training
3058775|NCT02170051|Active Comparator|Goal-focused supportive contact|Goal-focused supportive contact
3058776|NCT02170038|Experimental|Arm 1|Healthy premenopausal subjects will receive multiple oral doses of Microgynon for 21days
3058777|NCT02170038|Experimental|Arm 2|Healthy premenopausal subjects will receive a single intramuscular dose of Noristerat
3058778|NCT02170025|Experimental|Riociguat (Adempas, BAY63-2521)|Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
3058779|NCT02170025|Experimental|Placebo|Participants received matching placebo tid.
3058786|NCT02169999|No Intervention|No Exposure To Website|Subjects are not exposed to Personalized Diabetes Care website
3058787|NCT02169986|No Intervention|control group|Parents/caregivers will receive the standard of care.
3058788|NCT02169986|Experimental|electronic reminders|In this group, the parents/caregivers will receive two daily electronic reminders in addition to the standard of care.
3058789|NCT02169973|Experimental|Part A|3 to 5 participants will undergo Positron Emission Tomography (PET)/computed tomography scan after administration of 11C-MK-3168 on Day 1.
3058790|NCT02169973|Experimental|Part B|3 to 12 participants will undergo PET scan after administration of 11C-MK-3168 on Day 1. Participants will receive 2 single doses of JNJ-42165279: 100 mg on Days 1 and up to 250 mg on Day 8. Participants will undergo PET scans after 1 hour of each administration of JNJ-42165279 on Days 1 and 8, with 11C-MK-3168 administration.
3058791|NCT02169973|Experimental|Part C|4 to 8 participants will undergo PET scan after administration of 11C-MK-3168 on Day 1. Participants will receive once daily dose of JNJ-42165279 (up to 100 mg) from Day 1 to Day 7. Participants will undergo PET scans after 24 hour of administration of JNJ-42165279 on Days 1 and 7, with 11C-MK-3168 administration.
3058792|NCT02169960|Active Comparator|Middle School, General|OVK Resiliency Training Program - Cognitive Behavioral Therapy designed to modify negative thoughts and feelings. This program also includes a social problem-solving component.
3058793|NCT02169960|No Intervention|High School, General|No intervention - no Resiliency training, no online intervention for high school students who do not score at risk for development of mental health issues
3058794|NCT02169960|Active Comparator|Middle School, Top 10%|Smart, Positive, Active, Realistic X-factor thoughts (SPARX), Breaking Free, This Way Up online interventions offered to middle school students who score in the Top 10% of their grade for development of mental health issues. OVK Resiliency Training is also provided.
3058795|NCT02169960|Active Comparator|High School, Top 10%|Smart, Positive, Active, Realistic X-factor thoughts (SPARX), Breaking Free, This Way Up online interventions offered to middle school students who score in the Top 10% of their grade for development of mental health issues.
3058796|NCT02169947|Active Comparator|Weight loss core|Participants will receive a culturally adapted version of the Diabetes Prevention Program core (16 session) program.
3058797|NCT02169947|Experimental|Weight loss core plus maintenance|Participants will receive a culturally adapted version of the Diabetes Prevention Program core (16 session) program PLUS 12 maintenance sessions.
3058798|NCT02169934|Experimental|Radiolabeled TRV130|
3058799|NCT02169921|Experimental|TurboHawk|This study is designed as a single arm study. For angioplasty, the Atherectomy Catheter, TurboHawk is used in this arm. Spider FX, the Distal Embolus Protection Device, can concomitantly be used with TurboHawk
3058800|NCT02169908|Other|Occurrence of painful neuropathy|Assessment of neuropathic pain with two devices (Thermotest and von Frey hairs) and with the Neuropathic Pain Symptom Inventory.
3058801|NCT02169895|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~Every period with concomitant single oral administration of Prolopa® 100-25"
3058802|NCT02169895|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~Every period with concomitant single oral administration of Prolopa® 100-25"
3058803|NCT02169895|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~Every period with concomitant single oral administration of Prolopa® 100-25"
3058804|NCT02169895|Active Comparator|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~Every period with concomitant single oral administration of Prolopa® 100-25"
3058805|NCT02169882|Active Comparator|Rifampicin 450 mg (standard dose)|"Twenty patients will receive 1 tablet of 450 mg Rifampicin and 2 tablets of placebo once daily for 30 days.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT).~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
3058806|NCT02169882|Experimental|Rifampicin 900 mg per oral|"Twenty patients will receive 2 tablets of 450 mg Rifampicin and 1 tablet of placebo once daily for 30 days.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
3058807|NCT02169882|Experimental|Rifampicin 1350 mg per oral|"Twenty patients will receive 3 tablets of 450 mg Rifampicin and 0 tablet of placebo once daily for 30 days.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
3058808|NCT02169869|Experimental|Immediate postplacental IUD insertion|Women randomized to the immediate postplacental IUD group will receive their IUD within 60 minutes of placental delivery.
3058809|NCT02169869|Active Comparator|6 weeks postpartum IUD insertion|Subjects who are randomized for IUD insertion at their postpartum visit will be assisted in scheduling a postpartum visit and IUD placement with their usual obstetrical care provider.
3058810|NCT02169856|Other|control group|"control group was not given any EFTs (emotional freedom techniques) therapy for postoperative nausea and vomiting.~Following medications were given to both groups. details are in respective interventions.~Tab. Midazolam 7.5 mg Inj. Midazolam IV 0.7 mg/kg inj. propofol (2.5 mg/kg) inj. atracuium (0.5 mg/kg). sevoflurane (2.5 vol %) oxygen in air mixture (0.50 ratio) Inj. Cefuroxime 1.5 gm. IV Inj. Ketorolac 30mg IV Inj. Zantac 50 mg IV inj. Metoclopramide 10mg IV"
3058865|NCT02169440|Experimental|Group 1|Period 1: BIA 9-1067 + warfarin Period 2: warfarin
3058866|NCT02169440|Active Comparator|Group 2|Period 1: warfarin Period 2: BIA 9-1067 + warfarin
3058867|NCT02169427|Experimental|Opicapone (OPC)|100 mg OPC
3058811|NCT02169856|Experimental|EFTs study group|"EFTs (emotional freedom techniques) was applied to the patietns. one session of 5 to 10 min at 6 hours postoperatively.~Following medications were given to both groups. details are in respective interventions.~Tab. Midazolam 7.5 mg Inj. Midazolam IV 0.7 mg/kg inj. propofol (2.5 mg/kg) inj. atracuium (0.5 mg/kg). sevoflurane (2.5 vol %) oxygen in air mixture (0.50 ratio) Inj. Cefuroxime 1.5 gm. IV Inj. Ketorolac 30mg IV Inj. Zantac 50 mg IV inj. Metoclopramide 10mg IV"
3058812|NCT02169843|Experimental|Sevoflurane & Dexmedetomidine|inhale Sevoflurane + intravenous pumping Remifentanil 0.1µg/kg/min + intravenous inject cisatracurium besilate 0.08mg/kg in fixed time interval + finally add sufentanil 0.15µg/kg,and intravenous pumping Dexmedetomidine 0.2µg/kg/h.
3058813|NCT02169843|Active Comparator|Sevoflurane & Placebo|inhale Sevoflurane + intravenous pumping Remifentanil 0.1µg/kg/min + intravenous inject cisatracurium besilate 0.08mg/kg in fixed time interval + finally add sufentanil 0.15µg/kg,and intravenous pumping Placebo(for Dexmedetomidine )0.05ml/kg/h.
3058814|NCT02169830|Active Comparator|nortriptyline|Diet modification - nortriptyline and then if necessary topiramate
3058815|NCT02169830|Active Comparator|topiramate|Diet Modification topiramate and then nortriptyline if necessary
3058816|NCT02169817|Experimental|Enterogermina + Enterolyte|2 vials of Enterogermina per day for 5 days and Enterolyte according to investigator´s recommendation
3058817|NCT02169804|Experimental|70 years or older|Non-smoking healthy adult males >or equal to 70 years of age.
3058818|NCT02169804|Experimental|Under 60 years of age|Non-smoking healthy adult males<60 years of age.
3058819|NCT02169791|Experimental|Haploidentical Transplant|All patients will receive a haploidentical donor transplant using a conditioning regimen of Fludarabine (Flu), cyclophosphamide (cy) and total body irradiation (TBI) followed by MLN9708.
3058820|NCT02169778|Experimental|Intermittent energy restricted diet|The intermittent energy restricted group will undergo 3 nonconsecutive days of partial fasting per week. During the 3 days of partial fasting, participants will be asked to consume a very-low calorie diet (VLCD) providing 550kcal/day for women and 650kcal/day for men. The VLCD products provide 110kcal/pack and include a variety of shakes, smoothies and soups. For the feeding days a diet matching energy needs will be prescribed, using meal replacements (such as smoothies, soups and cereal bars) and conventional food. Drinking at least 2.5 liters of non-caloric liquids will be recommended.
3058821|NCT02169778|Experimental|Continuous energy restricted diet|The continuous energy restricted group will be prescribed a low calorie diet (LCD) with 33% energy restriction, using meal replacements (such as smoothies, soups and cereal bars) and conventional food. The diets' macronutrient composition of the two groups will be matched (50% carbohydrates, 20% protein and 30% fat).
3058822|NCT02169765|Active Comparator|Hepatic resection|Indications for HR were the presence of appropriate residual liver volume determined by volumetric computed tomography and lack of hepatic encephalopathy.
3058823|NCT02169765|Experimental|Radiofrequency ablation|Radiofrequency ablation is performed in less than one week after clinical diagnosis.
3058824|NCT02169752|Active Comparator|Ambrisentan|Subjects will be randomly assigned in a 1:1 ration according to the computer generated random numbers to receive either placebo (sugar pill) or ambrisentan.
3058825|NCT02169752|Placebo Comparator|Placebo|Subjects will be randomly assigned in a 1:1 ration according to the computer generated random numbers to receive either placebo (sugar pill) or ambrisentan.
3058826|NCT02169739|No Intervention|Medical therapy only|Intensive standard medical secondary prevention stroke treatment as per the recommendations of the American Heart Association/American Stroke Association national guidelines.
3058827|NCT02169739|Active Comparator|Ischemic Preconditioning + Medical|Patients will receive treatment with Cell Aegis remote ischemic preconditioning device once or twice daily for one year. The procedure will consist of up to four 5-minute cycles of bilateral upper extremity ischemia separated by five minutes of reperfusion. Patients will also receive intensive standard medical secondary prevention stroke treatment as per the American Heart Association/American Stroke Association national guidelines.
3058828|NCT02169726||Musculoskeletal injuries|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
3058829|NCT02169713|Experimental|Treatment Sequence 1|Tamsulosin HCl alone (with matching placebo for solifenacin and mirabegron) then followed by tamsulosin HCl with solifenacin and mirabegron
3058830|NCT02169713|Experimental|Treatment Sequence 2|Tamsulosin HCl with solifenacin and mirabegron then followed by tamsulosin HCl alone (with matching placebo for solifenacin and mirabegron)
3058831|NCT02169700|Experimental|Ischemic compression. Dry Needling|Ischemic compression was carried out after dry needling.
3058832|NCT02169700|Sham Comparator|Sham Ischemic compression. Dry Needling|Sham Ischemic compression was carried out after dry needling.
3058833|NCT02169700|No Intervention|Control group|No intervention. Control group
3058834|NCT02169687|Experimental|Hifu|
3058835|NCT02169661|Experimental|Burger and Beetroot Study|
3058836|NCT02169648|Experimental|ranibizumab|Experimental: Intravitreal injection of Ranibizumab
3058837|NCT02169635|Experimental|Macula buckle|Macular buckle: perform episcleral macular buckle surgery using a three-armed silicone capsule to support the posterior staphyloma in high myopia.
3058838|NCT02169609|Experimental|Dinutuximab. Immunotherapy|"Dinutuximab will be administered at 17.5 mg/m2/day for 4 days up to 5 courses. Each dose should be infused IV over approximately 10 hours.~Immunotherapy (sargramostim + isotretinoin + interleukin2) Sargramostim will be administered at 250 micrograms/m2/d by subcutaneous (SC) injection daily from Day 0 through 13 (daily with the infusion of Dinutuximab and for 3 days before and 7 days afterward).~Isotretinoin (13-cis-retinoic acid, or RA) (160mg/m2/day or 5.33mg/kg/day if < 12kg) PO divided into 2 doses daily x 14 days.~Interleukin-2 (IL-2) 3 MIU/m2/day will be given by continuous infusion for 4 days during the first week of each course 2 and 4 given on Days 0 - 3"
3058839|NCT02169596|Other|Coronary Artery Disease|Blood tests to assess platelet function and EndoPAT assessment for endothelial function testing before and after ticagrelor administration (90mg BD)
3058840|NCT02169596|Other|Healthy Normals|Blood tests to assess platelet function and EndoPAT assessment for endothelial function testing before and after ticagrelor administration (90mg BD)
3058909|NCT02169154|Placebo Comparator|Sodium lauryl sulfate|0.2% Sodium lauryl sulfate
3058910|NCT02169154|Placebo Comparator|Saline|0.9% saline
3058841|NCT02169583|Experimental|Part A (Cohort 1)|Approximately 8 subjects (6 Active, 2 Placebo) will be randomized to receive single escalating IV doses i.e.10 milligrams (mg), 25 mg and 100 mg, plus one oral 100 mg dose (on the last occasion) of GSK1325756 or matching placebo, with a 7-days washout between doses. Dose escalations will be based on review of PK and safety data from preceding dose level. The projected doses for each group are subject to modification based upon PK and safety data from preceding cohorts. Pharmacokinetic parameters will be reviewed from at least 4 active subjects from preceding dose before dose escalating to the next dose level. The maximum dose administered will be 100 mg. Additional subjects/Cohorts may be enrolled.
3058842|NCT02169583|Experimental|Part B (Cohorts 2 and 3)|Approximately 8 subjects (6 Active, 2 Placebo) per cohort will be randomized to receive escalating repeated IV doses of GSK1325756 or matching placebo (Cohort 2: 25 mg, Cohort 3: 50 mg) for 5 days. Repeated (BID) doses of GSK1325756 will begin the morning of Day 1 and continue through the morning of Day 5 (9 total doses). Dose escalations will be based on review of PK and safety data from preceding dose level. The projected doses for each group are subject to modification based upon PK and safety data from preceding cohorts. Pharmacokinetic parameters will be reviewed from at least 4 active subjects from preceding dose before dose escalating to the next dose level. The maximum dose administered will be 50 mg BID. Additional subjects/Cohorts may be enrolled.
3058843|NCT02169570|Active Comparator|Vitamin D|Vitamin D supplementation Anti Tuberculosis Treatment with 600,000 IU of (I/M) vitamin D3 for 3 doses at 0, 4 and 12 weeks and color and taste matched placebo for calcium for 3 months
3058844|NCT02169570|Placebo Comparator|Placebo|Anti Tuberculosis Treatment with placebo color matched for vitamin D and color and taste matched placebo for calcium
3058845|NCT02169570|Experimental|Vitamin D and Calcium|Vitamin D and Calcium supplementation Anti TuberculosisTreatment with 600,000 IU of (I/M) vitamin D3 for 3 doses at 0, 4 and 12 weeks with daily 1000 mg calcium carbonate for 3 months
3058846|NCT02169557|Experimental|Fexinidazole|
3058847|NCT02169544||RA patients who are prescribed Abatacept|Abatacept
3058848|NCT02169544||Patients who are prescribed other RA treatments|
3058849|NCT02169531|Experimental|ex vivo activated immune cells|Up to 20 patients diagnosed with type 2 diabetes mellitus and hyperglycemia will be enrolled and assigned to a single treatment group. Patients will give a small amount of peripheral blood and the blood will be processed and cultured in our laboratory. The ex vivo activated autologous blood cells will be infused intravenously back to patients. The treatment will be done twice a week for consecutive 4 weeks. The metabolic parameters of patients before and after the therapy will be compared to determine if the therapy is safe and effective.
3058850|NCT02169518||Diabetes Arm|Patients with Type 1 and Type 2 diabetes
3058851|NCT02169518||Bariatric Arm|Obese patients scheduled for bariatric surgery
3058852|NCT02169505|Experimental|Brentuximab Vedotin|"Brentuximab by vein over 30 minutes every 3 weeks for a total of 6 cycles starting between days 30 and 60 post allogeneic stem cell transplant (SCT).~Brentuximab dose based on actual body weight starting with an initial dose of 1.2 mg/kg for the first 2 cycles and dose increased to 1.8 mg/kg after the second cycle for all subsequent cycles."
3058853|NCT02169479|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
3058854|NCT02169479|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
3058855|NCT02169479|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
3058856|NCT02169479|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
3058857|NCT02169466|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
3058858|NCT02169466|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
3058859|NCT02169466|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
3058860|NCT02169466|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
3058861|NCT02169453|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
3058862|NCT02169453|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
3058863|NCT02169453|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
3058864|NCT02169453|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~Subjects were to attend four treatment periods and were to receive a different dose of BIA 9-1067 (25 mg, 50 mg and 100 mg) or placebo during each of these treatment periods."
3058868|NCT02169414|Experimental|BIA 9-1067 5 mg|1 capsule of 5 mg + 2 capsules of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
3058869|NCT02169414|Experimental|BIA 9-1067 15 mg|3 capsules of 5 mg for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
3058870|NCT02169414|Experimental|BIA 9-1067 50 mg|2 capsules of BIA 9-1067 25 mg + 1 capsule of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
3058871|NCT02169414|Placebo Comparator|Placebo|3 capsules of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
3058872|NCT02169401||Treated subjects|All subjects recruited and treated with the Axium Neurostimulator
3058873|NCT02169388|Experimental|Probiotic|Microbial composition using Probiotic，3 capsules / times, 2 times / day for 4 weeks
3058874|NCT02169388|Placebo Comparator|placebo|Microbiota modulation using placebo，3 capsules / times, 2 times / day for 4 weeks
3058875|NCT02169375|Experimental|Mu Rhythm with adaptation|
3058876|NCT02169375|Experimental|Mu Rhythm without adaptation|
3058877|NCT02169362|Experimental|Platelet Rich Plasma - Bio-Bandage™|Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)
3058878|NCT02169362|Sham Comparator|Saline Spray, Standard of Care|
3058879|NCT02169336|Experimental|DEX-IN 35mcg|DEX-IN 35mcg every 6 hours for 48 hours. DEX-IN 35mcg PRN for up to 3 additional days.
3058880|NCT02169336|Experimental|DEX-IN 50mcg|DEX-IN 50mcg every 6 hours for 48 hours. DEX-IN 50mcg PRN for up to 3 additional days.
3058881|NCT02169336|Placebo Comparator|IN Placebo|IN Placebo every 6 hours for 48 hours. IN Placebo PRN for up to 3 additional days.
3058882|NCT02169323|Experimental|Step-down|Step-down of the inhaled corticosteroid (ICS) dose
3058883|NCT02169297|Experimental|Ultrasound-Guided Sub-Paraspinal Block|Patients allocated to the treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location and an intravenous PCA post-operatively
3058884|NCT02169297|Placebo Comparator|PCA only|Patients allocated to the control group had two sham multi-perforated soaker catheters taped to their back and received intravenous PCA post-operatively
3058885|NCT02169284|Experimental|Group I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
3058886|NCT02169284|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
3058887|NCT02169271|Experimental|Arm I (acetylsalicylic acid)|Patients receive acetylsalicylic acid PO QD for 12 months.
3058888|NCT02169271|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 12 months.
3058889|NCT02169258|Placebo Comparator|Selective Strategy|non-invasive evaluation of possible myocardial ischemia by using DSE or dTS followed by coronary angiography if the test is positive for ischemia
3058890|NCT02169258|No Intervention|Registry|Clinical decisions are reached by consensus of operators, patients and family as usual care
3058891|NCT02169258|Active Comparator|Systemic Strategy|Routine coronary angiography before PTA without a previous non-invasive stress test
3058892|NCT02169245|Experimental|Average Protein and Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of protein and fiber for this age group for 2 weeks.
3058893|NCT02169245|Experimental|Average Protein and High Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of protein and higher than average amount of fiber for this age group for 2 weeks.
3058894|NCT02169245|Experimental|High Protein and Average Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of fiber and higher than average amount of protein for this age group for 2 weeks.
3058895|NCT02169245|Experimental|Higher Protein and Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with a higher than average amount of protein and fiber for this age group for 2 weeks.
3058896|NCT02169232|Active Comparator|Videolaryngoscope|Intubation by videolaryngoscope
3058897|NCT02169232|Active Comparator|Fiberoptic|Intubation by fibroscope
3058898|NCT02169219|Experimental|Glucocorticoids and Rituximab|This is a single-arm trial. All patients receive both rituximab and glucocorticoids. The protocol calls for the discontinuation of prednisone within two months of the baseline visit.
3058899|NCT02169206|Other|shoulder radiography|Bilateral shoulder AP standard plain x-ray in 0 and 90 degrees of arm abduction. Non-affected shoulder is used to be compared with the affected shoulder.
3058900|NCT02169193|Experimental|99mTc-Rhenium Sulfide Nanocolloid|99mTc-Rhenium Sulfide Nanocolloid
3058901|NCT02169180|Experimental|Ibrutinib|Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response [CR]), unacceptable toxicity, or end of treatment, whichever occurs first.
3058902|NCT02169167|Experimental|Resin salve treatment|The resin salve may be spread directly onto the diabetic ulcer, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the ulcer area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of ulcer secretion.
3058903|NCT02169167|Active Comparator|Octenidine treatment|Octenidine treatment is implemented with the similar manner as resin salve treatment by using sterile gauze that is impregnated with the octenidine dihydrochloride.
3058904|NCT02169154|Experimental|Diclofenac Sodium/Menthol Gel|1% diclofenac sodium + 3% menthol
3058905|NCT02169154|Active Comparator|Diclofenac Gel|1% diclofenac sodium + 0.09% menthol
3058906|NCT02169154|Active Comparator|Menthol Gel|3% menthol
3058907|NCT02169154|Placebo Comparator|Placebo Gel|0.09% menthol
3058908|NCT02169154|Active Comparator|Voltaren Gel|1% diclofenac sodium
3058958|NCT02168829|Active Comparator|Rivaroxaban|Rivaroxaban 15 mg daily
3058911|NCT02169141||PK of Levofloxacin-Capreomycin|Pharmacokinetics (PK) in M/XDR-TB patients receiving at least Levofloxacin and Capreomycin as part of their WHO treatment for M/XDR-TB
3058912|NCT02169128||Patients and their significant others|Patients affected by necrotizing fasciitis and their significant others
3058913|NCT02169115|Experimental|Omalizumab 150mg|
3058914|NCT02169115|Experimental|Omalizumab 300mg|
3058915|NCT02169115|Placebo Comparator|Placebo|
3058916|NCT02169102|Other|Control|
3058917|NCT02169102|Sham Comparator|Sham Laser|
3058918|NCT02169102|Experimental|Laser 1|Low Power Laser applied at 0.16 Joules/point. 2 points of laser irradiation
3058919|NCT02169102|Experimental|Laser 2|Low Power Laser applied at 16 Joules/point. 2 points of laser irradiation
3058920|NCT02169089|Experimental|Spironolactone|Spironolactone
3058921|NCT02169089|Placebo Comparator|Placebo|Placebo
3058922|NCT02169076|Active Comparator|CRT-On|Cardiac Resynchronization Therapy enabled on ICD/Pacemaker device
3058923|NCT02169076|Sham Comparator|CRT-Off|Cardiac Resynchronization Therapy disabled on ICD/Pacemaker device
3058924|NCT02169063|Experimental|Diagnostic (11C-acetate, 18F-fluoride, PET)|Patients receive carbon-11 acetate IV and fluorine F 18 sodium fluoride IV over 1 minute and undergo PET at baseline and at 6-12 weeks after systemic therapy starts.
3058925|NCT02169050||No intervention|There is no intervention to subjects in this study. All subjects are morbidly women seeking bariatric surgeries.
3058926|NCT02169037|Experimental|FIRM ablation|These patients will be treated by ablation of patient-specific rotors and focal sources (FIRM) alone.
3058927|NCT02169037|Active Comparator|Conventional AF ablation with PVI|These patients will treated by conventional AF ablation by pulmonary vein isolation (PVI) alone.
3058928|NCT02169024|Experimental|Expect With Me group prenatal care|receiving prenatal care through an Expect With Me group
3058929|NCT02169011|Active Comparator|Latissimus Dorsi Flap Reconstruction|Patients are allocated to delayed breast reconstruction with the Latissimus Dorsi flap and if needed an implant.
3058930|NCT02169011|Active Comparator|TAP Flap Reconstruction|Patients are allocated to delayed breast reconstruction with the TAP-flap and if needed an implant in combination with an acellular dermal matrix.
3058931|NCT02168998|No Intervention|No clown|Routine venipuncture without distraction
3058932|NCT02168998|Active Comparator|Clown|A medical clown is present in the procedure room during venipuncture
3058933|NCT02168985|Experimental|Attend TFH Program|Couples attend the three-day Faithful House Training program immediately
3058934|NCT02168985|No Intervention|Wait-listed for TFH Program|Couples attend The Faithful House program three-months after the initial group
3058935|NCT02168972|Experimental|Global mapping and ablation device|
3058936|NCT02168959|Active Comparator|Femoral nerve block|bupivacaine
3058937|NCT02168959|No Intervention|No femoral nerve block|No block
3058938|NCT02168946|Experimental|Vabomere|Vabomere (meropenem 2g plus vaborbactam 2g) IV q8h, for up to 14 days
3058939|NCT02168946|Active Comparator|Best Available Therapy|Subjects will receive Best Available Therapy (IV antibiotics)
3058940|NCT02168933|Active Comparator|active|308 nm excimer laser treatment
3058941|NCT02168933|Sham Comparator|placebo|Sham treatment in a blinded fashion. A protective cap will be applied to the laser handpiece to block laser light when treating the control side.
3058942|NCT02168920|Experimental|Aripiprazole, 2 mg/day|
3058943|NCT02168920|Experimental|Aripiprazole, 3 mg/day|
3058944|NCT02168920|Experimental|Aripiprazole, 6 mg/day|
3058945|NCT02168920|Placebo Comparator|Placebo|
3058946|NCT02168907|Experimental|Treatment (CPI-613, bendamustine hydrochloride, rituximab)|Patients receive 6,8-bis(benzylthio)octanoic acid intravenously IV over 2 hours on days 1-4 (week 1) and days 1 and 4 (weeks 2 and 3). Patients also receive bendamustine hydrochloride IV over 30 minutes on days 4 and 5 and rituximab on day 5 of week 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3058947|NCT02168894|Experimental|Group 1 - Acupuncture With Electrical Stimulation|Participants in Group 1 have acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
3058948|NCT02168894|Experimental|Group 2 - Acupuncture Sessions Without Electrical Stimulation|Participants in Group 2 have acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
3058949|NCT02168894|Active Comparator|Group 3 - Waitlist Group|Participants in Group 3 have acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
3058950|NCT02168881|Active Comparator|misoprostol|oral misoprostol in solution 25 microgram every 2 hours
3058951|NCT02168881|Active Comparator|dinoprostone|3 mgs dinoprostone vaginally every six hours
3058952|NCT02168868||Control Group of Children|Control Group of Children
3058953|NCT02168868||Children-Autism Spectrum Disorder|Children-Autism Spectrum Disorder
3058954|NCT02168855|Active Comparator|Active nicotine gum|
3058955|NCT02168855|Placebo Comparator|Inactive gum|
3058956|NCT02168842|Active Comparator|Isradipine|Oral capsule of up to 5 mg of isradipine taken twice daily for 36 months.
3058957|NCT02168842|Placebo Comparator|Placebo (for Isradipine)|Oral capsule taken twice daily for 36 months.
3058959|NCT02168829|Active Comparator|Acetylsalicylic acid (ASA)|ASA 75-160 mg daily (if intolerant to ASA, no antiplatelet therapy will be prescribed)
3058960|NCT02168816|Active Comparator|Midfoot|Individuals with an infection on the midfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
3058961|NCT02168816|Active Comparator|Hindfoot|Individuals with an infection on the hindfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
3058962|NCT02168816|Active Comparator|Toe|Individuals with an infection on the toe are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
3058963|NCT02168803|Experimental|Evacetrapib: Single Dose|Single oral dose of evacetrapib on Day 1
3058964|NCT02168803|Experimental|Evacetrapib: Multiple Dose 12 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 12 consecutive weeks
3058965|NCT02168803|Experimental|Evacetrapib: Multiple Dose 24 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 24 consecutive weeks
3058966|NCT02168803|Experimental|Evacetrapib: Multiple Dose 52 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 52 consecutive weeks
3058967|NCT02168790|Experimental|Amniotic membrane ring|Application of amniotic membrane device for 6-7 days.
3058968|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort 0|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort 0: Refametinib 30mg twice daily (b.i.d) + Regorafenib 80mg once daily (q.d), 3 weeks on/1 week off.
3058969|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort -1|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort -1: Refametinib 20mg b.i.d + Regorafenib 80mg q.d, 3 weeks on/1 week off.
3058970|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort -1a|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort -1a: Refametinib 20mg b.i.d + Regorafenib 120mg q.d, 3 weeks on/1 week off.
3058971|NCT02168764|Experimental|Treatment|Both arms of the study receive the ATI Neurostimulation System. Subjects are implanted with the ATI Neurostimulator and instructed to use the ATI Remote Controller to treat cluster attacks of at least moderate intensity by stimulating for 15 minutes before using any acute medications.
3058972|NCT02168764|Active Comparator|Control|Both arms of the study receive the ATI Neurostimulation System. Subjects are implanted with the ATI Neurostimulator and instructed to use the ATI Remote Controller to treat cluster attacks of at least moderate intensity by stimulating for 15 minutes before using any acute medications.
3058973|NCT02168751|Active Comparator|propofol|propofol doses to maintain hypnoses between 40-60 bis(Bispectral Index Scale)during the lung resection surgery
3058974|NCT02168751|Experimental|sevoflurane|Sevoflurane doses to maintain hypnoses between 40-60 bis(Bispectral Index Scale)during the lung resection surgery
3058975|NCT02168738|Active Comparator|13-C labeled PC-DHA|
3058976|NCT02168738|Active Comparator|13-C labeled TG-DHA|
3058977|NCT02168738|Experimental|13-C labeled AceDoPC-DHA|
3058978|NCT02168725|Experimental|briciclib|The starting dose of briciclib in the Escalation Stage will be 17 mg/week, with subsequent dose escalation levels of 35 mg, 70 mg, 140 mg, 280 mg, 560 mg, and 1120 mg. The dose of briciclib in the RPTD Confirmation Stage will be the dose as determined during the escalation stage. At each dose level, briciclib will be administered as a 2-hour intravenous infusion, once-a-week per 3-week cycles.
3058979|NCT02168712|Active Comparator|Moderate continuous exercise training|Moderate intensity continuous exercise training
3058980|NCT02168712|Experimental|Interval exercise training|High intensity interval exercise training
3058981|NCT02168699|Other|Ultrasound examination|Ultrasound examination of the axillary region in children
3058982|NCT02168686|Experimental|Dose 1|ADVM-043, at the lowest dose of three planned dose levels, of 8E13 total vg (equivalent to 1E12 vg/kg based on an 80-kg patient) administered IV
3058983|NCT02168686|Experimental|Dose 2|ADVM-043 at the intermediate dose of three planned dose levels, of 4E14 total vg (equivalent to 5E12 vg/kg based on an 80-kg patient) administered IV
3058984|NCT02168686|Experimental|Dose 3|ADVM-043 at the highest dose of three planned dose levels, of 1.2E15 total vg (equivalent to 1.5E13 vg/kg based on an 80-kg patient) administered IV
3058985|NCT02168686|Experimental|Dose 4|ADVM-043 administered at a dose that will be determined
3058986|NCT02168673||Group 1|Healthy non-smokers
3058987|NCT02168673||Group 2|Healthy non-smokers
3058988|NCT02168660|Active Comparator|Control Group|Standard vitamin D3 dose as per IOM (Institute of Medicine) recommendations; actual dose will be 5000 IU per week, which is just slightly higher than the IOM recommendation of 600 IU per day. Length of time proposed to be 4 months at 5000 IU D3 per week. End of study measures at 4 months to be HOMA-IR, BMI Z score, 25-OH D level.
3058989|NCT02168660|Experimental|Low-Normal Group|Initial D3 dose will be 30,000 IU per week; at 6 week intervals serum D3 levels will be checked, and dose adjustments made to reach target 25-OHD level of between 30-50 ng/mL (inclusive). Once within target, D3 dose will be continued for 4 months, and end of study measurements done (HOMA-IR, BMI Z score, 25-OHD level).
3058990|NCT02168660|Experimental|High-Normal Group|Initial D3 dose will be 60,000 IU/week; at 6 week intervals 25-OHD levels will be done, and dose adjustments made to achieve target level of 40-60 ng/mL (inclusive). Once within target range, De3 dose will be continued for 4 months, and end of study measures obtained (HOMA-IR, BMI Z score, 25-OHD level).
3058991|NCT02168647|Experimental|Behavioral Lifestyle counseling|Intervention group participants will take part in behavioral lifestyle counseling provided by a Registered Dietitian Nutritionist from week 14 of gestation through childbirth.
3058992|NCT02168647|Active Comparator|Control|Participants in the control arm will receive no form of lifestyle intervention.
3058993|NCT02168634|Experimental|Botulinum toxin|5U Botulinum toxin in 1cc normal saline, administered in one of the two itchy points
3058994|NCT02168634|Placebo Comparator|Normal Saline|1cc normal saline, administered in the other itchy point
3059040|NCT02168296|Placebo Comparator|No added Plant-based ingredient|No Plant-based ingredient added to starchy meal
3059041|NCT02168296|Active Comparator|Low dose added to starchy meal|Plant-based ingredient in low dose added to starchy meal
3058995|NCT02168621|Active Comparator|Full-mouth ultrasonic debridement|Motivation and instruction in proper oral hygiene. Before initiation of the subgingival debridement the patient must show sufficient self-performed infection control (full-mouth plaque score <30%). One session of full-mouth ultrasonic pocket/root debridement using a piezoceramic ultrasonic instrument. A follow-up visit after 2-4 weeks is scheduled for oral hygiene control and re-motivation/re-instruction if indicated. At 3 and 6 months re-evaluation is performed and re-instrumentation of all sites showing a remaining probing pocket depth of ≥5 mm carried out. Final evaluation at 18 months.
3058996|NCT02168621|Active Comparator|Section-wise scaling and root planing|Conventional treatment approach comprising motivation, oral hygiene instructions and section-wise scaling and root planing at required number of consecutive appointments with 1-2 week interval. Follow-up 2-4 weeks after the last session of SRP for oral hygiene control and re-instruction if indicated. At 3 and 6 months re-evaluation is performed and re-instrumentation of all sites showing a remaining pocket depth of ≥5 mm carried out. Final evaluation at 18 months.
3058997|NCT02168608|Experimental|Remote ischemia precondition|patients in this arm accepted RIPC procedure after induction of anesthesia
3058998|NCT02168608|Experimental|None remote ischemia precondition|patients in this arm didn't accept RIPC procedure after induction of anesthesia
3058999|NCT02168595|Experimental|Cohort 1|2 mg/kg GMI-1271 or matching placebo
3059000|NCT02168595|Experimental|Cohort 2|5 mg/kg GMI-1271 or matching placebo
3059001|NCT02168595|Experimental|Cohort 3|10 mg/kg GMI-1271 or matching placebo
3059002|NCT02168582||low back pain|
3059003|NCT02168569|Active Comparator|Cohort 1|5 sites, namely Manhiça, Dondo, Montepuez, Tete and Chokwe
3059004|NCT02168569|Active Comparator|Cohort 2|3 sites, namely Montepuez, Dondo and Chokwe
3059005|NCT02168556|Placebo Comparator|Standard of Care|Patient underwent urodynamic testing by receiving only standard of care with mailed information and during test teaching.
3059006|NCT02168556|Active Comparator|Music|Patient underwent urodynamic testing while listening to music that was 60 beats per minute and received standard of care information and teaching.
3059007|NCT02168556|Active Comparator|Video|Patient watched an informational video prior to urodynamic testing.
3059008|NCT02168543|Experimental|Alendronate|1% Alendronate gel once in periodontal pocket (Gums)
3059009|NCT02168543|Placebo Comparator|Placebo|Placebo gel once in periodontal pocket (Gums)
3059010|NCT02168530|Placebo Comparator|Placebo|
3059011|NCT02168530|Experimental|Vismodegib|
3059012|NCT02168517||Group I|Overweight osteoarthritis patients
3059013|NCT02168517||Group II|Normal weight osteoarthritis patients.
3059014|NCT02168517||Group III|Overweight healthy men.
3059015|NCT02168517||Group IV|Normal weight healthy men.
3059016|NCT02168504||Healthy controls|Healthy male and female subjects older than 18 years of age without the symptoms of Parkinson's disease. The ages of subjects in this group will be matching to the ages of subjects in Parkinson's disease group
3059017|NCT02168504||Parkinson's disease patients|male and female subjects older than 18 years of age at the early stage the disease
3059018|NCT02168491|Experimental|Intervention group|10 type 2 diabetic patients will be included to perform in this study and will be switched from premixed insulin to insulin glargine and lixisenatide
3059019|NCT02168478|Experimental|Patch Test Group|"All subjects are patched with the following: 1.Neo-Synalar Cream 2.Sodium Lauryl Sulfate and 3. Saline.~Test material is applied to the absorbent pad and allowed to remain in direct skin contact for a period of 48 hours."
3059020|NCT02168465|Other|teaching self-management of intermittent catheter|Single group pre-post test of feasibility, teaching self-management
3059021|NCT02168439|Experimental|Dexmedetomidine|Intranasal Dexmedetomidine 2 micrograms/kilogram once
3059022|NCT02168439|Experimental|Midazolam|Intranasal Midazolam 0.4 milligram/kilogram
3059023|NCT02168426|Active Comparator|Guardix|6g per body
3059024|NCT02168426|Active Comparator|Seprafilm|1 sheet per body
3059025|NCT02168400|Experimental|active tDCS|Subjects that are randomly assigned to this arm will receive 10 active transcranial direct current stimulation (tDCS) sessions
3059026|NCT02168400|Sham Comparator|sham tDCS|Subjects randomly assigned to sham-tDCS (transcranial direct current stimulation) will receive very low current stimulation at beginning and end of session, mimicking the feeling of current stimulation in the scalp, but not reaching levels that will stimulate brain function.
3059027|NCT02168387|Active Comparator|continuous high frequency oscillator (CHFO)|Subjects randomized to receive therapy with the CHFO will receive a 20 minute treatment every 6 hours for 48 hours.
3059028|NCT02168387|Active Comparator|medication|Subjects randomized to receive the medications will receive acetylcysteine and dornase alfa, two medications frequently used in the treatment of atelectasis. The medications will alternate every 6 hours for 48 hours.
3059029|NCT02168374|Experimental|Chlorhexidine - CHX|Deciduous teeth were filled with GIC containing 1.25% chlorhexidine.
3059030|NCT02168374|Experimental|Doxycycline - DOX|Deciduous teeth were filled with GIC containing 4.5% doxycycline.
3059031|NCT02168374|Placebo Comparator|Glass ionomer cement - GIC|Deciduous teeth were filled with GIC without chlorhexidine or doxycycline.
3059032|NCT02168361|Active Comparator|Standard|Pegylated Interferon Alfa-2b (1.5 ugm/kg/week subcutaneously) plus ribavirin (1000-1200 mg daily orally) plus sofosbuvir (400 mg daily) for 12 weeks
3059033|NCT02168361|Experimental|Simeprevir + Sofosbuvir|(SIM-SOF) which is Simeprevir + Sofosbuvir for 12 weeks
3059034|NCT02168348||Diabetic patients with a lesion on the foot|
3059035|NCT02168335|Experimental|Treatment group|"OrasaltsTM~1 level scoop of OrasaltsTM will be dissolved in warm water. Participants will rinse and gargle the mouth for 30 seconds, then expel and not swallow the mixture, twice daily"
3059036|NCT02168335|Placebo Comparator|Control group|"Sea salt~1 level scoop of sea salt will be dissolved in warm water. Participants will rinse and gargle the mouth for 30 seconds, then expel and not swallow the mixture, twice daily"
3059037|NCT02168322|Experimental|collagen membranes|collagen barrier that help in isolating unwanted tissues in periodontal regneration
3059038|NCT02168309|Other|Labetalol|Labetalol 200mg PO BID starting dose
3059039|NCT02168309|Other|Nifedipine|Nifedpine XL starting at dose 30mg PO daily
3059540|NCT02164617|No Intervention|control|routine care
3059042|NCT02168296|Active Comparator|High dose added to starchy meal|Plant-based ingredient in high dose added to starchy meal
3059043|NCT02168296|Active Comparator|Low dose added to liquid|Plant-based ingredient in low dose added to liquid
3059044|NCT02168296|Active Comparator|High dose added to liquid|Plant-based ingredient in high dose added to liquid
3059045|NCT02168283|Experimental|treatment arm|active fluid management includes 3 components: dietary counseling, diuretics, and intensive dialysis regimen
3059046|NCT02168283|Active Comparator|control arm|dietary counseling alone
3059047|NCT02168270|Experimental|Treatment (ascorbic acid, temozolomide)|Patients receive ascorbic acid IV over 90-120 minutes three times per week and temozolomide orally days 1-28. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3059048|NCT02168257|Experimental|RAM Cannula CPAP|CPAP provided by RAM Cannula
3059049|NCT02168257|Active Comparator|Binasal Prong CPAP|CPAP provided by binasal prong
3059050|NCT02168244|Active Comparator|Ice pack|Pre-treatment with ice - Ice applied to the skin 2-3 minutes before injecting biologic drug injection
3059051|NCT02168244|Active Comparator|Heating Pack|Pre-treatment with heat - Heat applied to the skin 2-3 minutes before injecting biologic drug injection
3059052|NCT02168244|No Intervention|No treatment before injection|No treatment applied to the skin 2-3 minutes before injecting biologic drug injection
3059053|NCT02168231||Complex abdominal wall repair Strattice|Complex abdominal wall repair Strattice
3059054|NCT02168218|Experimental|high protein|20% protein diet
3059055|NCT02168218|Active Comparator|low protein|7.5% protein diet
3059056|NCT02168205|Experimental|4 mg Pomalidomide - Fed|On Day 1, participants will receive a single oral dose of 4 mg pomalidomide under fed conditions.
3059057|NCT02168205|Experimental|4 mg Pomalidomide - Fasted|On Day 1, participants will receive a single oral dose of 4 mg pomalidomide under fasted conditions
3059058|NCT02168205|Experimental|4 mg Pomalidomide + caffeine - Non-smoking|Participants will remain in the clinical site for a total of 10 days. They will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, participants will receive a single oral dose of 4 mg pomalidomide.
3059059|NCT02168205|Experimental|4 mg Pomalidomide + caffeine - Smoking|Participants will be required to smoke approximately 20 cigarettes a day for 10 days. They will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, participants will receive a single oral dose of 4 mg pomalidomide.
3059060|NCT02168192|Placebo Comparator|Traditional Lecture|These subjects received a 10 minute power point lecture on BBN skills.
3059061|NCT02168192|Experimental|Simulation-Debrief|These subjects received a formal debrief process, reviewing their prior baseline simulation.
3059062|NCT02168179|Experimental|Supportive Care (KeraStat Skin Therapy)|Patients apply KeraStat Skin Therapy topically BID during radiation therapy.
3059063|NCT02168166|Active Comparator|Executive Function Training|"Two weeks of training of cognitive domain of executive functioning~Using online program (Scientific Brain Training Pro)~Four exercises"
3059064|NCT02168166|Placebo Comparator|Placebo Training|"Two weeks of training with exercises not affecting working memory, information processing speed, or cognitive load~Exercises maintain other traditional progressive aspects to preserve appearance of dynamic titration of difficulty levels~Using online program (Scientific Brain Training Pro)~Four exercises"
3059065|NCT02168153|Active Comparator|Chiropractic Manipulative Therapy|Participants will complete questionnaires and biomechanical assessments, and additionally receive CMT treatment.
3059066|NCT02168153|Placebo Comparator|Wait-List Control Group|Participants will complete questionnaires and biomechanical assessments
3059067|NCT02168140|Experimental|Treatment (CPI-613 and bendamustine hydrochloride)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-4 of week 1 and on days 1 and 4 of weeks 2 and 3. Patients also receive bendamustine hydrochloride IV over 30 minutes on days 4 and 5 of week 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3059068|NCT02168127|Experimental|Active drug group|PRC-063 - Active methylphenidate hydrochloride extended-release capsules drug group
3059069|NCT02168114|Experimental|Duchenne Muscular Dystrophy|This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
3059070|NCT02168114|Experimental|Non-affected Subjects|This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
3059071|NCT02168101|Experimental|MLN9708|"Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles. Up to 18 patients will be enrolled in a dose-escalation phase to determine the maximum tolerated dose (MTD). Once the MTD is determined, an additional 20 patients will be enrolled in an expansion phase at that dose.~Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy. Dosing will start at 2.3 mg. If acceptable tolerability is demonstrated, escalations will be made to 3 mg and to a maximum-planned dose (MPD) of 4 mg.~Expansion Phase: An additional 20 patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 orally on Days 1, 8, and 15 of each 28-day cycle for 6 cycles."
3059072|NCT02168088||Index case|Subjects who have died of sudden unexplained death
3059073|NCT02168088||Biologically related family member|Biologically related family member of the deceased individual
3059074|NCT02168075|Experimental|Group 1|0.25g/kgof 20% mannitol administered at drilling of skull.
3059075|NCT02168075|Experimental|Group 2|0.5g/kg of 20% mannitol administered at drilling of skull.
3059076|NCT02168075|Experimental|Group 3|1.0 g/kg of 20% mannitol administered at drilling of skull.
3059077|NCT02168075|Experimental|Group 4|1.5g/kg of 20% mannitol administered at drilling of skull.
3059078|NCT02168062|Active Comparator|Arm I (standard of care)|Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
3059079|NCT02168062|Experimental|Arm II (STAND clinic)|Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
3059080|NCT02168049|Experimental|Heart and Lung Function Monitioring|
3059081|NCT02168036||Patients with lung disease|General admission criteria for this project will require at least one of the following: (1) symptoms consistent with pulmonary disease with mediastinal lymph node involvement ; (2) chest X-ray and chest CT scan consistent with lung disease and mediastinal lymph node involvement; (3) Individuals with a lung biopsy consistent with lung disease and presenting with enlarged mediastinal lymph nodes; and (4) patients with diseases of organs with known association with lung disease and mediastinal lymph node involvement.
3059082|NCT02168023|Experimental|DACC impregnated dressing|Patients undergoing elective or emergency caesarean section with DACC impregnated dressing Sorbact Surgical Dressing ® (ABIGO Medical AB, Sweden) placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
3059083|NCT02168023|Active Comparator|Standard surgical dressing|Patients undergoing elective or emergency caesarean section with standard surgical dressing placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
3059084|NCT02168010|Experimental|Experiment|Test Drug Group: 2 times a day; 4 tablets per time (2 tablets of Analgecine and 2 tab. of placebo)
3059085|NCT02168010|Active Comparator|PosCtrl|PosCtrl: Positive Control Group. 2 times a day; 4 tablets / time (2 tab. of Neurotropin and 2 placebo tablets).
3059086|NCT02168010|Placebo Comparator|Placebo|Placebo Group: 2 times a day; 4 tablets / time (4 placebo tablets).
3059087|NCT02167984||at term newborns|Infant with GE >=37w
3059088|NCT02167984||preterm newborns|Infant with GE <37w
3059089|NCT02167971|Experimental|Active Coil|The patients assigned to this group will undergo repetitive Transcranial Magnetic Stimulation over 10 sessions (each one with 2,000 pulses) on left dorsolateral prefrontal cortex.
3059090|NCT02167971|Sham Comparator|Sham|The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
3059091|NCT02167958|Experimental|Treatment|"Day -6, -5 Fludarabine 30 mg/M2 IV over 30-60 minutes Cyclophosphamide 14.5 mg/kg IV over 1-2 hours*, Mesna 14.5 mg/kg IV in 4 divided doses~Day -4 through -2 Fludarabine 30 mg/M2 IV over 30-60 minutes~Day -1 Total Body Irradiation 200 cGy, donor apheresis~Day 0 T cell replete PBSC~Days 3, 4 Cyclophosphamide 50 mg/kg IV Mesna 50 mg/kg IV in 4 divided doses~Day 5 Begin tacrolimus ,mycophenolate, and G-CSF"
3059092|NCT02167945|Experimental|ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV)|ABT-450/r/ABT-267 and ABT-333 coadministered with or without ribavirin (RBV) for 12 or 24 weeks
3059093|NCT02167932||Breast Cancer Patients|Breast Cancer patients undergoing chemotherapy will participate in the Walk with Ease program during their treatment.
3059094|NCT02167919|Experimental|Prostatic artery embolization|Microspheres measuring 100-300 microns will be injected under fluoroscopic guidance into the left and right prostatic arteries for embolization.
3059095|NCT02167906|Experimental|hand oa patients|assess the carotid-femoral arterial stiffness determined by measuring the PWV
3059096|NCT02167906|Active Comparator|without Hand OA patients|assess the carotid-femoral arterial stiffness determined by measuring the PWV
3059097|NCT02167893||Subcutaneous administration of leuprorelin acetate|Subcutaneous administration of leuprorelin acetate once every 12 weeks as daily medicinal practice.
3059098|NCT02167867|Experimental|Lay End Users|Employees of the test sites (that were fitness centers or spas) who were provided with a User's Manual to operate the ZERONA Z6 to administer 6 40-minute evenly spaced treatments over 2 consecutive weeks to the front and back of the waist, hips and thighs of one Treatment Subject.
3059099|NCT02167867|Experimental|Treatment Subject Group|Treatment subjects received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) light-emitting diodes.
3059100|NCT02167854|Experimental|LJM716, BYL719 AND TRASTUZUMAB|A treatment cycle will consist of 28 days. Treatment doses for trastuzumab and LJM716 will be fixed at trastuzumab 2mg/kg weekly, and LJM716 20mg/kg weekly. The exception to this is if dose de-escalation results in treatment of patients at dose level 1, where LJM will be dosed at 10mg/kg weekly. On Arm A, BYL719 was administered orally once daily continuously at one of 5 dosing levels, beginning with dose level 3, 250mg orally daily. On Arm B, BYL719 will be administered orally once daily during 4 of 7 days in a week, at one of 5 dosing levels, beginning with dose level 3, 250mg orally daily. This means BYL719 will be given to patients on Arm B during days 1-4, 8-11, 15-18, and 22-25 of each cycle. The dose-finding phase will follow a Continuous Reassessment Methods (CRM) phase I biostatistical design.
3059101|NCT02167841|Experimental|Knee-Chest position|In this arm, the women will perform daily the Knee-Chest position between weeks 32-37. In week 37 the investigators will check via ultra sound if there was a successful version (if not, the woman would go to External Cephalic Version)
3059102|NCT02167841|No Intervention|External Cephalic Version|In this group the women will perform External Cephalic Version without doing maternal Knee-Chest position before.
3059103|NCT02167828|Experimental|Social Support|Participants will be trained to give one another ongoing, theory-based but personally-tailored advice, recommendations, and support to encourage entry to HIV medical care, remaining in care, and adhering to medication regimens when they are prescribed. The intervention's intent is to increase mutual support, positive attitudes, intentions, plans, and collective self-efficacy for care engagement.
3059104|NCT02167828|No Intervention|No Intervention|Participants in this arm will not receive an intervention.
3059105|NCT02167815|Active Comparator|Standard care|standard care ( such as alginate, hydrofiber or other treatment)
3059106|NCT02167815|Experimental|Intervention ( Mepilex XT)|
3059107|NCT02167789|No Intervention|PhD|
3059108|NCT02167776|Experimental|Church-based teaching|Teaching about male circumcision provided to church leaders in addition to standard teaching available from Ministry of Health.
3059109|NCT02167776|No Intervention|No church-based teaching|Standard of care. Teaching about male circumcision provided by Ministry of Health.
3059110|NCT02167763|Experimental|VeraCept Intrauterine Contraceptive|The VeraCept low-dose Intrauterine Copper Contraceptive
3059111|NCT02167763|Active Comparator|TCu380|A commercial standard T-shaped copper IUD (TCu380)
3059112|NCT02167750|Placebo Comparator|Cherry flavored beverage - Mix 1|Mix 1 flavored still beverage
3059113|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 2|Mix 2 flavored still beverage with phytochmicals and caffeine
3059114|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 3|Mix 3 flavored still beverage with phytochemicals and caffeine
3059115|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 4|Mix 4 flavored still beverage with phytochemicals and caffeine
3059116|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 5|Mix 5 flavored still beverage with phytochemicals and caffeine
3059117|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 6|Mix 6 flavored still beverage with caffeine
3059118|NCT02167737|Experimental|Bedside Decision Aid Group|This arm will include study participants who are randomized to the group utilizing the bedside decision aid, which has hospital staff arrange fall-risk reduction interventions (e.g., home safety checks, exercise programs, vision checks, etc.).
3059119|NCT02167737|Active Comparator|Control Arm|"Participants in the control/comparator arm will experience the same study procedures with the exception of not using the Bedside Decision Aid and instead being given the Centers for Disease Control (CDC) brochure, What You Can Do to Prevent Falls, and arranging for their own fall prevention strategies."
3059120|NCT02167724|Experimental|Patients with schizophrenia|
3059121|NCT02167711|Experimental|SIRT|
3059122|NCT02167698|Experimental|Airway pressure release ventilation arm|"This group of children would be ventilated using the Airway pressure release ventilation (APRV) mode.~Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups."
3059123|NCT02167698|Active Comparator|Low-tidal volume ventilation arm|Low-tidal volume ventilation using pressure-regulated volume control mode with target tidal volume of 6 ml/kg or less and other lung-protective strategies. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups
3059124|NCT02167685||CMX001|Subjects who have previously participated in CMX001-301 or other CMX001 study.
3059125|NCT02167672||Consumers|Women who have had a Hysterectomy in the previous 2 years
3059126|NCT02167672||Doctors|Obstetricians and Gynaecologists
3059127|NCT02167659|Experimental|BIS Assessment|"Patients will undergo measurements by trained staff. Measurements will be performed pre-op and at 3, 6, 12, 15*, 18, 21*, 24, and 36 months post-op. Measures include L-Dex, skin assessment and self-report forms. Patients with < 6.5 L-Dex units change will continue follow-up for 36 months. Patients with an L-Dex value change ≥ 6.5 will undergo circumference measurement and begin treatment for 4 weeks with a 23-32 mmHg compression sleeve with gauntlet. At the end of 4 weeks patients will have their arms measured. Those demonstrating improvement will continue with follow up. Those not demonstrating improvement will be removed from the study and their medical oncologist or surgeon will be notified.~*At discretion of the site PI or attending physicians."
3059128|NCT02167659|Active Comparator|Tape Measure|"Patients will undergo measurements by trained staff. Measurements will be performed pre-op and at 3, 6, 12, 15*, 18, 21*, 24, and 36 months post-op. Measures include arm volume (tape measure), skin assessment and self-report forms. Patients with no volume increase will continue follow-up for 36 months. Patients with a volume change of between ≥ 5% and < 10% in the at-risk limb will undergo L-Dex testing and begin treatment for 4 weeks with a 23-32 mmHg compression sleeve with gauntlet. At the end of 4 weeks patients will have their arms measured. Those demonstrating improvement will continue with follow up. Those not demonstrating improvement will be removed from the study and their medical oncologist or surgeon will be notified.~*At discretion of the site PI or attending physicians."
3059129|NCT02167646|Other|Bilaterally innervated flap|Two nerve branches attached with the flap for sensory reconstruction.
3059130|NCT02167633|Active Comparator|Decompression surgery plus fractionated radiotherapy|
3059131|NCT02167633|Experimental|Radiosurgery|Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in one fraction to cover as large a fraction as possible the defined target volume
3059132|NCT02167620|Placebo Comparator|Metformin|Metformin/ placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
3059133|NCT02167620|Placebo Comparator|Placebo|Metformin/ placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
3059134|NCT02167607|Active Comparator|Purple Potato|Active Comparator
3059135|NCT02167607|Placebo Comparator|White Potato|Placebo Comparator
3059136|NCT02167594|Experimental|PSP Subjects|Subjects will receive an IV injection, 370 megabecquerel (MBq) (10 millicurie [mCi]), single dose of florbetapir F 18 at screening. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of 18F-AV-1451 at baseline and at 9 months.
3059137|NCT02167594|Experimental|CBD subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at screening. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of 18F-AV-1451 at baseline and at 9 months.
3059138|NCT02167594|Experimental|Healthy volunteers|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of 18F-AV-1451 at baseline.
3059139|NCT02167581||epithelial odontogenic tumours|
3059140|NCT02167568||Corpus callosum agenesis/dysgenesis|patients with Corpus callosum agenesis/dysgenesis
3059141|NCT02167568||parents|parents of patients with corpus callosum agenesis/dysgenesis
3059142|NCT02167555|Active Comparator|Wild Bluberries|Active Comparator
3059143|NCT02167555|Placebo Comparator|Placebo|Placebo Comparator
3059144|NCT02167542|Experimental|NPPV group|Patients assigned to noninvasive positive pressure ventilation (NPPV) are connected to the ventilator through a face mask (VBM Endoscopy Mask) that is secured to the patient's face by the investigator.
3059145|NCT02167542|Active Comparator|CPAP valve group|Patients assigned to CPAP valve (Boussignac valve, Vygon, Inc) are connected to this device through a standard face mask that is secured to the patient's face with elastic straps.
3059209|NCT02167061|Experimental|(Part 1) E+M → DA-1229_01|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg E : Evogliptin 5 mg M : Metformin XR 1000 mg
3059146|NCT02167516|Experimental|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
3059147|NCT02167516|Active Comparator|glucosamine sulfate capsule|glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
3059148|NCT02167490|Active Comparator|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
3059149|NCT02167490|No Intervention|Arm 2: observation|No axillary staging
3059150|NCT02167477|Active Comparator|Laryngoscopy sequence 1|Macintosh laryngoscopy Storz C-MAC, standard blade Storz C-MAC, D-BLADE
3059151|NCT02167477|Active Comparator|Laryngoscopy sequence 2|Macintosh Storz C-MAC, D-BLADE Storz C-MAC, standard blade
3059152|NCT02167464|Active Comparator|Aldosterone Antagonist|Prescribe an aldosterone antagonist such as Spironolactone 12.5-25 mg daily as a starting dose with a maximum recommended dose of 50 mg daily.
3059153|NCT02167464|Active Comparator|Referral Hypertension specialist|Referral to a hypertension specialist
3059154|NCT02167464|Active Comparator|Renin treatment-guided therapeutics|Renin treatment-guided therapeutics. A treatment algorithm is provided to guide treatment based upon renin levels.
3059155|NCT02167464|Active Comparator|Renin-guided therapeutics and referral|Renin treatment-guided therapeutics and referral to hypertension specialist. Treatment based upon algorithm for treatment related to renin level in addition to referral to a hypertension specialist.
3059156|NCT02167451|Experimental|Maraviroc|Maraviroc administration will start on day -3 and will end on day +30 after stell cell transplant, making the total number of days of drug administration 34 days. Maraviroc will be administered twice daily orally or via enteral tube. Dosing of Maraviroc will be based on body surface area (starting with 100mg twice a day for BSA of 0.2 and up to 300mg twice a day for BSA greater than 1.73).
3059157|NCT02167438|Experimental|Investigational|Application of the Hem-Avert device.
3059158|NCT02167438|No Intervention|Control|No Application of the Hem-Avert device.
3059159|NCT02167425||Late Post-IMAT Cohort|Enrollment into the Late Post-IMAT Cohort will occur over a 9-month period in beginning in the second year of the intervention and will be followed by a 3-month period of follow-up after the close of enrollment.
3059160|NCT02167425||Early Post-IMAT Cohort|Enrollment into the Early Post-IMAT Cohort will occur over a 9-month period immediately following the intervention and will be followed by a 3-month period of follow-up after the close of enrollment.
3059161|NCT02167425||Late Pre-IMAT Cohort|Enrollment into the Late Pre-IMAT Cohort will begin one year prior to implementation of the intervention. Enrollment will occur over a 9-month period and will be followed by a 3-month period of follow-up after the close of enrollment.
3059162|NCT02167425||Early Pre-IMAT Cohort|Enrollment into the Early Pre-IMAT Cohort will begin two years prior to implementation of the intervention. Enrollment will occur over a 9-month period and will be followed by a 3-month period of follow-up after the close of enrollment.
3059163|NCT02167412||Syncope without POTS|Patients meeting syncope criteria without POTS. There will be no intervention for this study arm.
3059164|NCT02167399||smart phone inclinometer|For the smart phone analysis we will be using the tilt meter application which is a digital inclinometer application available on the I phone. The phone will be placed in the vertical position utilizing the bubble level feature of the application. The application will be set to display measurements to the closest tenth of the degree, set to log measurements every 0.2 seconds. The subject will stand with knee extended to 0 degrees and quadriceps muscle activated and upper extremity support on opposite side of stance limb. The phone will be placed in the vertical position on the anterior portion of the middle third of the subject's thigh attached using double sided adhesive tape. Being placed as close as possible to level when attached to the anterior thigh with subject in single limb stance with a reading of less than 1 deg as minimum for correct set-up prior to testing. Immediately prior to testing recording will be initiated logging measurements for later assessment.
3059165|NCT02167399||2-D video analysis|two dimensional video analysis by first placing markers on the subject at the midpoint of the femoral condyles, midpoint of the ankle malleoli, and the proximal thigh along a line from the anterior superior iliac spine (ASIS) to the knee marker. Testing will take place in front of a digital video camera with tape on the floor to give a reference point for the subject being tested. Participants will be tested twice on day 1 and then again 5-9 days later. Subjects will be allowed 2-3 practice trials prior to each test in order to allow the subject to feel comfortable with each test. Following the practice trials the subject will perform 3 trials of each test on bilateral lower extremities. This set up was consistent with the set up by Munro et al.
3059166|NCT02167386|Experimental|Enhanced PrEP Adherence|Enhanced PrEP Adherence: peer navigators, PrEP support group, on-line support group, text message reminders
3059167|NCT02167386|Active Comparator|Standard PrEP Adherence|Standard PrEP Adherence: support groups, case management
3059168|NCT02167373|No Intervention|Control|
3059169|NCT02167373|Experimental|Intervention|Cogito Companion Intervention. Participants will be provided with a mobile phone application that provides feedback on their mental health. The participants' clinicians will be provided with a desktop application to review their patients' results.
3059170|NCT02167360|Experimental|Single Arm|
3059171|NCT02167347|Experimental|Family Intervention|Culturally Adapted Family intervention for Psychosis Sessions will be offered weekly basis
3059172|NCT02167347|No Intervention|Control|"Caregiver ' s Patients who will be randomized to the treatment as usual arm will receive routine care"
3059173|NCT02167334|Experimental|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
3059174|NCT02167334|Active Comparator|Oxygenation with simple breathing mask|spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
3059175|NCT02167321|Active Comparator|Arm A|"Arm A; standard neoadjuvant chemoradiotherapy group~fluoropyrimidine based concurrent chemoradiotherapy-> TME -> adjuvant chemotherapy (Low risk: fluoropyrimidine-based chemotherapy, High risk: FOLFOX)"
3059176|NCT02167321|Experimental|Arm B|"Arm B : adjuvant FOLFOX group~Total mesorectal excision (TME) --> 12 cycles of FOLFOX every 2 weeks (or Total mesorectal excision (TME) --> Concurrent chemoradiotherapy + 12 cycles of FOLFOX every 2 weeks)"
3059177|NCT02167308|Active Comparator|Laser acupuncture group|Subjects will receive 24 activated laser acupuncture treatments. The laser will be applied for 10 seconds to each of the selected acupuncture points.
3059178|NCT02167308|Sham Comparator|Control group|Subjects in the control group will undergo sham laser acupuncture treatment with no laser power output. Acupuncture points, application duration, and total number of treatments will be identical to the Laser acupuncture group.
3059179|NCT02167295||Focus group|The focus groups will consist of 6 to 8 persons each (N = 32). The focus group discussions will last for about 60 to 90 minutes. The discussion topics will be based on previous literature and experience and will include reasons for betel quid chewing or for quitting, pros and cons of betel quid chewing, barriers to and facilitators of abstinence, health beliefs and experiences about betel quid chewing and other issues.
3059180|NCT02167295||In-depth interviews.|We will conduct 15 one-to-one interviews, each lasts for about 45 to 60 minutes. Participants will be interviewed by a trained interviewer using a structured interview. The interview will be designed to collect information on socio-demographic background, current and/or former betel quid use, other substance use (smoking and/or alcohol consumption), as well as other variables including usage parameters, psychosocial and environmental influences on betel quid chewing, barriers to and interest in quitting, and knowledge of adverse effects on health.
3059181|NCT02167295||Self-report questionnaire|This study is expected to enroll 30 participants who have smoking and betel nut chewing behaviors.Participants will complete 4 separate visits to CMUH, during which they will complete the same self-report questionnaire designed to measure withdrawal symptoms relating to betel quid chewing. To better measure betel quid withdrawal symptoms and to distinguish the 6 symptoms from those of smoking withdrawal, Participants will be required to attend one visit regular cigarette smoking and betel nut chewing behavior without restriction (as control), one visit after 12 hours of overnight betel quid deprivation (no cigarette deprivation), one visit after 12 hours of overnight cigarette deprivation (no betel quid deprivation), and one visit after 12 hours of both overnight betel quid and cigarette deprivation.
3059182|NCT02167269|Active Comparator|Baby EAR-JR|The subjects receive Baby EAR circuit from the start until primary and secondary outcomes are achieved. Then the fresh gas flow will be increased to 500 ml/kg/min for 10 minutes before switching to Jackson-Rees (JR) circuit and the procedure will be repeated.
3059183|NCT02167269|Active Comparator|JR-Baby EAR|The subjects receive Jackson-Rees (JR) circuit from the start until primary and secondary outcomes are achieved. Then the fresh gas flow will be increased to 500 ml/kg/min for 10 minutes before switching to Baby EAR circuit and the procedure will be repeated.
3059184|NCT02167256|Experimental|AZD0530 100mg daily|Patients in the experimental group (50%) will be started on this dose. After 2 weeks, patients with a plasma drug level of <100ng/ml will receive 125mg AZD0530 daily and remain in the same experimental group as patient receiving 100mg daily.
3059185|NCT02167256|Placebo Comparator|AZD0530 Placebo|50% of patients will receive placebo treatment for the duration of the study,
3059186|NCT02167243|Experimental|Reinforcement for performing BG testing|Subjects will receive reinforcement for BG testing. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.
3059187|NCT02167243|Active Comparator|No reinforcement for BG testing|Subjects will receive standard of care without reinforcement for Self Monitoring Blood Glucose
3059188|NCT02167230|Experimental|Jailed-balloon technique|Apply jailed-balloon technique to protect the side branch during coronary bifurcation PCI
3059189|NCT02167230|Active Comparator|Jailed-wire technique|Apply jailed-wire technique to protect the side branch during coronary bifurcation PCI
3059190|NCT02167217|Experimental|Oral Prednisolone|Oral Prednisolone 5mg/kg/ day on two consecutive days, Friday and Saturday with breakfast
3059191|NCT02167204|Experimental|Diagnostic (18F-FLT PET/CT)|Patients undergo 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy, completion of therapy, and 1 year after completion of therapy or time of suspected recurrence.
3059192|NCT02167191|Experimental|HIT|High intensity interval training sessions on an cycle ergometer
3059193|NCT02167178||Volunteers receiving 0.9% NaCl|Volunteers receiving 0.9% NaCl to optimise stroke volume
3059194|NCT02167178||Volunteers receiving gelofusine|Volunteers receiving gelofusine to optimise stroke volume
3059195|NCT02167165||Digoxin and AF|Patients consulting the emergency deprtment (ED) for AF and receiving Digoxin treatment
3059196|NCT02167152|Experimental|Ischemic Preconditioning Group|Participants randomized to this group will have a blood pressure cuff placed on each arm, and these cuffs will be inflated one at a time to a pressure calculated based on the person's blood pressure.
3059197|NCT02167152|Active Comparator|Control Group|Participants randomized to this group will have a blood pressure cuff placed on each arm, and these cuffs will be inflated one at a time to a set pressure (30mmHg, or millimeters of mercury on a blood pressure measuring machine).
3059198|NCT02167139|Experimental|SB5 (proposed biosimilar to adalimumab)|SB5 40 mg every other week via subcutaneous injection
3059199|NCT02167139|Active Comparator|Humira (adalimumab)|Humira 40 mg every other week via subcutaneous injection
3059200|NCT02167126|Experimental|Kinesio Taping|Kinesio Taping was applied as experimental group.
3059201|NCT02167126|Placebo Comparator|Micropore|Micropore Tape was used as placebo tape
3059202|NCT02167113||study population|
3059203|NCT02167100||Retained in Care|Each patient who had at least 2 practice visits separated by ≥90 days in a year involving HIV laboratory monitoring until 31st of March 2014.
3059204|NCT02167100||Lost to follow-up (LTFU)|Each patient who had at 2 practice visits separated by ≥90 days in a year involving HIV laboratory monitoring but did not maintain regular attendance at HHMP until 31st March, 2014.
3059205|NCT02167087|Experimental|Sentinel node mapping|Sentinel node mapping with indocyanine green injected orally and anally to the tumor.
3059206|NCT02167074|Active Comparator|25G FNA needle|Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
3059207|NCT02167074|Active Comparator|20G ProCore FNB needle|Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
3059208|NCT02167061|Experimental|(Part 1) DA-1229_01 → E+M|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg E : Evogliptin 5 mg M : Metformin XR 1000 mg
3059210|NCT02167061|Experimental|(Part 2) DA-1229_01 fast → fed|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg Fast : administration on an empty stomach Fed: administration after high-fat diet
3059211|NCT02167061|Experimental|DA-1229_01 fed → fast|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg Fast : administration on an empty stomach Fed: administration after high-fat diet
3059212|NCT02167048|Experimental|Normal-dose Psychostimulant, Low-dose|Normal-dose: Dose participants are currently taking as part of their prescription (on more than or equals to 20 mg/day of Psychostimulants) Low-dose: Half the normal dose
3059213|NCT02167048|Active Comparator|Low-dose Psychostimulants, Normal-dose|Normal-dose: Dose participants are currently taking as part of their prescription (on more than or equals to 20 mg/day of Psychostimulants) Low-dose: Half the normal dose
3059214|NCT02167048|No Intervention|No intervention, No intervention|This arm is completely no intervention, and is ONLY for healthy volunteers. We are testing healthy volunteers of the same age to give us an estimate of order effects to help us correct for better performance in the 2nd session due simply to taking the same tests twice (note: the tests are Version A and B).
3059215|NCT02167035|Active Comparator|Combigan BID|Combigan 0.2%/0.5% one drop BID
3059216|NCT02167035|Active Comparator|Simbrinza TID|Simbrinza 1/0.2% one drop TID
3059217|NCT02167022|Experimental|Intense Physiotherapy (Group 1)|30 minutes each of physical and occupational therapy each weekday for 12 weeks (intense physiotherapy) followed by the same therapies administered once a week for 36 weeks (the current standard of care).
3059218|NCT02167022|Experimental|Delayed Intense Physiotherapy (Group 2)|30 minutes each of physical and occupational therapy once a week for 36 weeks (the current standard of care) followed by the same therapies administered each weekday for 12 weeks (intense physiotherapy).
3059219|NCT02167009|Experimental|Prostate Artery Embolization|
3059220|NCT02166996|Active Comparator|A|Suture removal time 7 days.
3059221|NCT02166996|Experimental|B|Suture removal time 14 days.
3059222|NCT02166983|Experimental|Arm IA (Lumosity, relaxation, compensatory strategies)|Participants complete Lumosity cognitive exercises. Lumosity cognitive exercises are online video game-based activities that are designed to practice various cognitive skills including processing speed, attention, memory and executive function. Participants complete cognitive exercises at least 20 minutes a day, 5 days a week for 6 weeks. Participants also complete relaxation exercises (guided imagery, progressive muscle relaxation, and/or autogenics) at least 10 minutes a day for 6 weeks and compensatory strategies (the use of external devices such as a notebook, day planner, or smartphone for cuing, reminding, and organizing; the use of memory strategies such as repetition, paraphrasing, and active listening; and the use of executive strategies such as self-talk for planning and attention orientation) as much as possible.
3059223|NCT02166983|Experimental|Arm IB (Active Journaling, relaxation, compensatory strategy)|Participants complete Active Journal cognitive exercises. Active Journaling requires participants to keep a written diary or journal where she discusses what her thoughts and feelings about various events with a focus on describing the meaning of the activities and experiences, particularly new things that were learned. Active Journaling is a method of practicing various cognitive skills including communication, organization, memory and executive function. Participants complete cognitive exercises at least 20 minutes a day, 5 days a week for 6 weeks. Participants also complete relaxation exercises and compensatory strategies as in Arm IA.
3059224|NCT02166983|Experimental|Arm II (Lumosity only)|Participants complete Lumosity exercises as in Arm IA.
3059225|NCT02166970|Experimental|Single stent deployment|Metallic stent deployment in hilar obstruction. Insertion of metallic stent to the dominant targeted duct such as right anterior (segments V and VIII), right posterior (segments VI and VII) or left (segments II-IV).
3059226|NCT02166970|Active Comparator|Multiple stent deployment|Metallic stent deployment in hilar obstruction. Insertion of multiple metallic stent to the dominant targeted duct such as right anterior (segments V and VIII), right posterior (segments VI and VII) or left (segments II-IV).
3059227|NCT02166957||Long disruption > 5cm +/- loss of SES|
3059228|NCT02166957||Short disruption < 5cm|
3059229|NCT02166944|Experimental|tamoxifen|tamoxifen 40 mg daily for one year
3059230|NCT02166944|Placebo Comparator|placebo|placebo drugs
3059231|NCT02166931|Placebo Comparator|placebo|placebo with the same color, order, taste as BRAND'S® Essence of Chicken , 70cc daily for 2weeks
3059232|NCT02166931|Experimental|Chicken Essence|BRAND'S® Chicken Essence 70cc, daily for 2 weeks
3059233|NCT02166918||patients with schizophrenia|320 patients with a diagnosis of schizophrenia according to Diagnostic and Statistical Manual IV edition (DSM-IV) criteria, confirmed by the Structured Clinical Interview for DSM-IV - Patient Version (SCID -IP), will be included in the study.
3059234|NCT02166918||unaffected first-degree relatives|240 unaffected first-degree relatives of the recruited patients (120 unaffected parents and 120 unaffected siblings)
3059235|NCT02166918||healthy control|320 healthy control subjects.
3059236|NCT02166905|Experimental|Arm I (CDX-1401, poly ICLC)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 and poly ICLC as in Phase I.
3059237|NCT02166905|Experimental|Arm II (CDX-1401, poly ICLC, IDO1 inhibitor INCB024360)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401, poly ICLC, and IDO1 inhibitor INCB024360 as in Phase I.
3059238|NCT02166892|Active Comparator|Normal weight|Normal weight children will be served food in two different occasions using two sets of plates (same size). One set will be plane and the second is a specially designed plate that demonstrate the recommended food consumption and portion.
3059239|NCT02166892|Active Comparator|Overweight children|Overweight children will be served food in two different occasions using two sets of plates (same size). One set will be plane and the second is a specially designed plate that demonstrate the recommended food consumption and portion.
3059240|NCT02166879||Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)|Chart review from patients undergoing elective surgery.
3059241|NCT02166866||Experimental arm|
3059242|NCT02166853|Experimental|conventional group|"a conventional group, in which intravenous sedation with midazolam will be administered"
3059243|NCT02166853|Experimental|sevoflurane group|"a sevoflurane group, in which patients will inhale sevoflurane during a 48 hour-period, through dedicated devices"
3059244|NCT02166840|Experimental|Self expanding metal stent|Patients with self expanding metal stent inserted into bile duct.
3085132|NCT01992263|Placebo Comparator|Placebo|
3059245|NCT02166840|Active Comparator|Plastic stent|Patients with obstructive jaundice who got a plastic stent inserted into bile duct.
3059246|NCT02166827|Active Comparator|NeuroAD|NeuroAd Treatment, synchronized TMS and cognitive training stimulation
3059247|NCT02166827|Sham Comparator|Sham TMS+Cog|Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
3059248|NCT02166814|Experimental|Fimasartan and Rosuvastatin|Combination of Fimasartan and Rosuvastatin
3059249|NCT02166814|Active Comparator|Fimasartan|Fimasartan monotherapy
3059250|NCT02166814|Active Comparator|Rosuvastatin|Rosuvastatin monotherapy
3059251|NCT02166801|Active Comparator|Early intervention for infants|A 30w intensive intervention according to the small step program, with daily practice sections conducted by parents at home, with weekly support by therapists.
3059252|NCT02166801|Active Comparator|Usual care|Usual care means that the Children in this arm of the study participate in the established follow up program that is established at the Astrid Lindgrens Children's Hospital and offered to all Children that displays a delayed early gross and fine motor development.
3059253|NCT02166788|Other|Arm 1: Inguinal Lymphadenectomy|Inguinal Lymphadenectomy (IL) is removal of the easily accessible superficial groin lymph nodes (LNs) and has a median LN retrieval of 11 lymph nodes
3059254|NCT02166788|Other|Arm 2: Ilio-inguinal Lymphadenectomy|Ilio-inguinal Lymphadenectomy (I-IL) is the removal of the same superficial groin lymp nodes (LN) removed during an IL but also combined with the more surgically complex removal of the ipsilateral pelvic LN. About twice as many LN are removed with I-IL compared to IL.
3059255|NCT02166762|Experimental|QLV interval measurement|QLV measurements collected during implantation of CRT-D device
3059256|NCT02166749||Subtotal abdominal hysterectomy|107 women
3059257|NCT02166749||Total abdominal hysterectomy|105 women
3059258|NCT02166736|Experimental|Instantaneous wave-free ratio (iFR)|
3059259|NCT02166736|Active Comparator|Fractional Flow Reserve (FFR)|
3059260|NCT02166723||CRYOABLATION|Cryoballoon ablation will be applied to all patients with persistent atrial fibrillation. It consists on applying the Arctic Front Cryoballoon to the pulmonary veins and freezing the antrum. In addition debulking of the atrial roof will be performed by a single application of the cryoballoon to the left and right roof, the septal wall and the lateral ridge wall.
3059261|NCT02166710|Experimental|Adductor canal femoral nerve blockade|Patients will receive continuous adductor canal femoral nerve blockade for 48 hours with a catheter connected to a pump infusing bupivacaine 0.125% and multi-modal analgesia for pain management following total knee arthroplasty. Knee extensor muscle strength will be measured at different time-points prior and after surgery.
3059262|NCT02166710|Placebo Comparator|Simulated nerve blockade|Patients will receive a simulated continuous femoral nerve block at the level of the adductor canal for 48 hours with a catheter connected to a pump infusing bupivacaine 0.125% and multi-modal analgesia for pain management following total knee arthroplasty. Knee extensor muscle strength will be measured at different time-points prior and after surgery.
3059263|NCT02166697||Oral administration of 4-8 mg of candesartan cilexetil|Oral administration of 4-8 milligram (mg) of candesartan cilexetil once daily (increased up to 12 mg, as necessary)
3059264|NCT02166684|Experimental|Do-it-yourself devices|All subjects will use do-it-yourself devices for self-monitoring health parameters
3059265|NCT02166671|Experimental|HBV booster vaccination|
3059266|NCT02166658|Experimental|Single Arm|Patients receive Cabazitaxel 25 mg/m2 i.v. infusion. This trial is a single arm trial.
3059267|NCT02166645|Experimental|Prone position|Prone position per 48 hours after extubation
3059268|NCT02166645|Active Comparator|Supine position|Supine position per 48 hours after extubation
3059269|NCT02166632|Experimental|Intracapsular Injection|Patients in the experimental group will undergo direct injection of ExparelTM into the knee joint; once the total knee replacement (arthroplasty) has been completed, patients will receive a given amount of ExparelTM administered during surgery into the joint where the knee replacement (arthroplasty) (TKA) was performed.
3059270|NCT02166632|Active Comparator|Periarticular Injection|Patients in this group will undergo local injection of ExparelTM to help to reduce post-surgery pain. Once the total knee replacement (arthroplasty) has been completed, patients in this group will receive a given amount of ExparelTM administered during surgery into the soft tissues around the bone where the knee replacement (arthroplasty) (TKA) was performed.
3059271|NCT02166619|Experimental|tDCS + physical therapy|Firstly, patients will undergo electrophysiological evaluation: motor evoked potential, motor threshold and silent period in both hemispheres. After those procedures, bihemispheric tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the non-affected hemisphere. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions.
3059272|NCT02166619|Sham Comparator|Sham tDCS + physical therapy|Firstly, patients will undergo electrophysiological evaluation: motor evoked potential, motor threshold and silent period in both hemispheres. After those procedures, bihemispheric sham tDCS will be applied. Anodal electrode will be on the affected hemisphere and the cathodal electrode, on the non-affected hemisphere. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off after 30 seconds. After bihemispheric sham tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions.
3059273|NCT02166606||Pacemaker/Lead implant|"All enrolled subjects will receive an ImageReady Magnet Resonant (MR) Conditional Pacing System and the treatment assignment will be based on an all-comers consecutive basis."
3059274|NCT02166593|Experimental|Pravastatin 40mg/Fenofibrate160mg|Pravastatin (40mg/day) Fenofibrate (160mg/day)
3059275|NCT02166593|Active Comparator|Atorvastatin Sodium|Atorvastatin Sodium (10mg/day)
3059276|NCT02166567|Experimental|YoPro and FACS|Spermatozoa to be used for ICSI will be stained with the YoPro Dye and then be sorted with FACS to select non-YoPro stained spermatozoa, known to have significantly less fragmented DNA.
3059277|NCT02166567|Active Comparator|Swim-up|Spermatozoa will be processed using the conventional swim-up me
3059719|NCT02163434|Experimental|gabapentin|1800-2400mg/day divided tid or qid, orally.
3059278|NCT02166554|Placebo Comparator|Control Arm|Standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with saline placebo following surgery
3059279|NCT02166554|Experimental|Cross-linked Hyaluronan Hydrogel Arm|HyaRegen
3059280|NCT02166541|Experimental|INRS with BCSK|"Intensive Neurophysiological Rehabilitation System (INRS) including the Biomechanical correction of the spine according to Kozyavkin (BCSK).~The daily treatment for about 2 hours are in general equal for all children except for the type of spinal manipulation. Duration of all treatment will be noted in a Treatment Diary."
3059281|NCT02166541|Sham Comparator|INRS, traditional spinal manipulation|"Intensive Neurophysiological Rehabilitation System (INRS) including spinal manipulation by the traditional technique.~The daily treatment for about 2 hours are in general equal for all children except for the type of spinal manipulation. Duration of all treatment will be noted in a Treatment Diary."
3059282|NCT02166528||experiment group|patients with FPFD
3059283|NCT02166528||control group|patients without FPFD
3059284|NCT02166515||experiment group|patients with cervical cancer, endometrial cancers or ovary cancer
3059285|NCT02166515||control group|postmenopausal women with benign tumor
3059286|NCT02166502||Nevirapine|The patients in this study are newborn infants clinically prescribed combination antiretroviral treatment with nevirapine for prevention of mother-to-child HIV transmission.
3059287|NCT02166489|Experimental|mesenchymal stem cell transplantation|Intravenous injection of mesenchymal stem cell in patients with PKD
3059288|NCT02166476|Experimental|Meropenem-Vaborbactam|Meropenem-vaborbactam (meropenem 2 grams [g] plus vaborbactam 2 g), infused in 250 milliliters (mL) normal saline, administered intravenously (IV) over 3 hours, every 8 hours (q8h), with 100 mL saline administered over 30 minutes q8h. Levofloxacin tablets administered orally as a 500-milligram (mg) dose every 24 hours (q24h) after a minimum of 15 doses of IV meropenem-vaborbactam plus saline, if clinically indicated. Total treatment was 10 days, unless a participant had baseline bacteremia where up to 14 days of therapy could be administered IV.
3059289|NCT02166476|Active Comparator|Piperacillin-Tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g), infused in 100 mL normal saline, administered IV over 30 minutes, q8h, with 250 mL saline administered over 30 minutes q8h. Levofloxacin tablets administered orally as a 500-mg dose q24h after a minimum of 15 doses of IV piperacillin-tazobactam plus saline, if clinically indicated. Total treatment was 10 days, unless a participant had baseline bacteremia where up to 14 days of therapy could be administered IV.
3059290|NCT02166463|Active Comparator|Arm I (ABVE-PC)|Patients receive doxorubicin hydrochloride IV over 1-15 minutes on days 1-2, bleomycin sulfate IV over 10 minutes or SC on days 1 and 8, vincristine sulfate IV over 1 minute on days 1 and 8, etoposide IV over 60-120 minutes on days 1-3, prednisone PO BID on days 1-7, and cyclophosphamide IV over 30-60 minutes on days 1 and 2. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
3059291|NCT02166463|Experimental|ARM II (Bv-AVEPC)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Patients also receive doxorubicin hydrochloride, etoposide, prednisone, and cyclophosphamide as in Arm I and vincristine sulfate IV over 1 minute on day 8. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
3059292|NCT02166450||Control group|Denture wearers without clinical signs of denture-related stomatitis confirmed with negative Candida swabs.
3059293|NCT02166450||Denture-related stomatitis group|"Denture wearers with clinical signs of denture-related stomatitis, confirmed with positive Candida swabs.~Treated for fungal infection, with nystatin [100 000 IU every 6 h for 3 weeks, applied on the infected area of the mucous membrane of the palate and cheeks]."
3059294|NCT02166437||Alendronate|Patients treated with alendronate
3059295|NCT02166437||Minodronate|Patients treated with minodronate
3059296|NCT02166437||Denosmab|Patients treated with denosmab
3059297|NCT02166424|Active Comparator|Omega-3 polyunsaturated fatty acids|1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily
3059298|NCT02166424|Placebo Comparator|olive oil|2880mg olive oil daily
3059299|NCT02166411|Experimental|myomectomy using barbed sutures|.Myoma bed is sutured with barbed sutures
3059300|NCT02166411|Active Comparator|myomectomy using conventional sutures|Myoma bed is sutured with conventional sutures
3059301|NCT02166398|Active Comparator|Amosartan 5/50 tab|Amosartan 5/50 tab given by oral administration
3059302|NCT02166398|Experimental|UI15AML055MT tab|UI15AML055MT tab given by oral administration
3059303|NCT02166372||Obese diabetic patients|Diabetic patients with BMI over 25 Age 20 to 67 Diabetes medically controlled at our center for at least six months
3059304|NCT02166359|Active Comparator|Glucose group|Glucose use of 2.5% or 4.25% dextrose solution at least 4 hours
3059305|NCT02166359|Experimental|Extraneal (Icodextrin) group|Extraneal (Icodextrin) use at least 8 hours
3059306|NCT02166346|Experimental|Dalfampridine then Placebo|All subjects were randomized for the first double-blinded 8-week part of the study to the dalfampridine group. Then subjects were crossed over to the placebo arm for another 8 weeks.
3059307|NCT02166346|Experimental|Placebo the Dalfampridine|All subjects were randomized for the first double-blinded 8-week part of the study to the placebo arm. Then subjects were crossed over to the dalfampridine arm for another 8 weeks.
3059308|NCT02166333|Active Comparator|200 IU/d|200 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
3059309|NCT02166333|Active Comparator|1000 IU/d|1000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
3059310|NCT02166333|Active Comparator|2000 IU/d|2000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
3059311|NCT02166333|Active Comparator|4000 IU/d|4000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
3059312|NCT02166320|Active Comparator|Partially covered SEMS|Boston Scientific Ultraflex SEMS
3059313|NCT02166320|Experimental|Fully covered SEMS|Boston Scientific Wallflex Esophageal SEMS.
3059314|NCT02166294|Experimental|NEOX® CORD 1K|Cryopreserved, umbilical cord allograft (NEOX® CORD 1K) with off-loading instructions.
3059315|NCT02166294|Active Comparator|Pressure bandage|Standard of Care Pressure bandage with off-loading instructions
3059541|NCT02164604|Experimental|Ranibizumab|All eyes receive one intravitreal injection with 0.03ml ranibizumab
3059316|NCT02166294|Experimental|Standard of Care Cross over to NEOX|Subjects in the Standard of Care (pressure bandage) group that have not healed greater than 50% at the Week 12 visit, or have a wound that is worsening, will be offered participation in the cross-over arm of the trial. The cross-over arm of the study will be treated with NEOX CORD 1K and followed for 12 weeks.
3059317|NCT02166268|Active Comparator|Avanz Phleum pratense|Avanz Phleum pratense 15,000 SQ+ (standardised quality), suspension for subcutaneous injection.
3059318|NCT02166268|Placebo Comparator|Placebo|Placebo, suspension for subcutaneous injection.
3059319|NCT02166255|Experimental|Treatment (APN401)|Patients receive autologous siRNA-transfected peripheral blood mononuclear cells APN401 IV over 30 minutes.
3059320|NCT02166242|Experimental|experimental|patients pathologic diagnosis advanced non-small cell lung cancer who had received more than two lines standard treatment, according to NCCN Non-small cell lung cancer guideline, there were no standard treatment scheme for these patients. Approximately 40 patients will be included in the study, patients will received oral ethaselen dispersible tablet, 600 mg bid dose, patients may quit the study whenever they would like or investigator evaluate that progression disease has developed, or any grade of SAE developed during the study.
3059321|NCT02166229|Experimental|Divalproex sodium|Divalproex sodium will be initiated at 125 mg twice daily and increased monthly to a maximum dose of 500 mg twice daily.
3059322|NCT02166216||Healty subjects|Healthy subjects that participate in a high intensity, endurance bicycle race.
3059323|NCT02166190|Experimental|Radiofrequency Ablation (EndoHbp probe)|Radiofrequency Ablation using EndoHPB Probe
3059324|NCT02166190|Active Comparator|Stenting only|Stenting only
3059325|NCT02166177|Experimental|Autologous Regulatory T cell therapy|Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose)
3059326|NCT02166164|Experimental|Experiemental pain models|all study participants will be tested with the same experimental pain models: Brief thermal sensitization, Long thermal stimulation, and Heat-pain-detection threshold.
3059327|NCT02166151|Experimental|Omalizumab|Omalizimab 150 mg S.C. once a month for consecutive 3 months
3059328|NCT02166138|Experimental|Laser treated Group|Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits. Thus, patients in this group will be getting the Non-Abilative laser treatment.
3059329|NCT02166138|Placebo Comparator|Not Laser treated Group|Patients in this group will be given the laser treatment with the 1540 non-abilative laser device, but the device will not be set to provide treatment. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
3059330|NCT02166125||Endoscopic suturing|Any patient who has undergone clinically indicated and/or standard of care endoscopic suturing within the Gastrointestinal tract.
3059331|NCT02166112||Permacol mesh placement|No intervention performed
3059332|NCT02166099||SpyGlass Choledochoscopy procedure|Any patient who has undergone SpyGlass Choledochoscopy procedures for diagnosis and/or treatment of a pancreatico-biliary disorder
3059333|NCT02166086||Endoscopic imaging|Any patient who has undergone advanced imaging procedures for diagnosis and/or treatment of a pancreatico-biliary disorder.
3059334|NCT02166060|Experimental|Ivabradine|Ivabradine 5 mg twice a day or 7,5 mg twice a day
3059335|NCT02166047|Placebo Comparator|Placebo 4 Weeks (Cohort A)|Participants will receive placebo to match GS-9620 once a week for 4 weeks.
3059336|NCT02166047|Experimental|GS-9620 1 mg 4 Weeks (Cohort A)|Participants will receive GS-9620 1 mg once a week for 4 weeks.
3059337|NCT02166047|Experimental|GS-9620 2 mg 4 Weeks (Cohort A)|Participants will receive GS-9620 2 mg once a week for 4 weeks.
3059338|NCT02166047|Experimental|GS-9620 4 mg 4 Weeks (Cohort A)|Participants will receive GS-9620 4 mg once a week for 4 weeks.
3059339|NCT02166047|Placebo Comparator|Placebo 8 Weeks (Cohort B)|Participants will receive placebo to match GS-9620 once a week for 8 weeks.
3059340|NCT02166047|Experimental|GS-9620 1 mg 8 Weeks (Cohort B)|Participants will receive GS-9620 1 mg once a week for 8 weeks.
3059341|NCT02166047|Experimental|GS-9620 2 mg 8 Weeks (Cohort B)|Participants will receive GS-9620 2 mg once a week for 8 weeks.
3059342|NCT02166047|Experimental|GS-9620 4 mg 8 Weeks (Cohort B)|Participants will receive GS-9620 4 mg once a week for 8 weeks.
3059343|NCT02166047|Placebo Comparator|Placebo 12 Weeks (Cohort C)|Participants will receive placebo to match GS-9620 once a week for 12 weeks.
3059344|NCT02166047|Experimental|GS-9620 1 mg 12 Weeks (Cohort C)|Participants will receive GS-9620 1 mg once a week for 12 weeks.
3059345|NCT02166047|Experimental|GS-9620 2 mg 12 Weeks (Cohort C)|Participants will receive GS-9620 2 mg once a week for 12 weeks.
3059346|NCT02166047|Experimental|GS-9620 4 mg 12 Weeks (Cohort C)|Participants will receive GS-9620 4 mg once a week for 12 weeks.
3059347|NCT02166034|Experimental|garden intervention|Schools assigned to the garden intervention receive raised bed garden kits and access to a toolkit of garden-based curriculum
3059348|NCT02166034|No Intervention|Control|Wait-list control (no garden intervention + lessons) until end of the study.
3059349|NCT02166021|Experimental|IT- Treated|Injection to IT
3059350|NCT02166021|Experimental|IV - Treated|Injection to IV
3059351|NCT02166021|Experimental|IT and IV Treated|Injection to IT and IV
3059352|NCT02166008|Active Comparator|Repamipide|Rebamipide (100) 1 tab oral tid for 1 year or peptic ulcer occurred
3059395|NCT02165696|Active Comparator|Manual lymphatic drainage|Control group: 30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
3059353|NCT02166008|Placebo Comparator|placebo|A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient. It will be prescribed as the same regimen of Rabamipide.
3059354|NCT02165995|Experimental|Navigated Transcranial Magnetic Stimulation (nTMS)|Participant assessed by nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Motor mapping and speech mapping performed at these visits. This should take about 1½-2 hours to complete.
3059355|NCT02165982||Patients controles|Inpatients suffering from anorexia nervosa at Institut Mutualiste Montsouris
3059356|NCT02165982||Individus sains témoins|Healthy controls selected from the general population
3059357|NCT02165969|Experimental|endoscopic endonasal surgery with UPSIT|endoscopic endonasal surgery with UPSIT prior to surgery and at months 1, 3, 6, and 12 after surgery.
3059358|NCT02165956|Experimental|New Infant Cereal|The amount of cereal administered will be free and from 6 to 12 months of age.
3059359|NCT02165956|Active Comparator|Standard Infant Cereal|The amount of cereal administered will be free and from 6 to 12 months of age.
3059360|NCT02165943||Vitoss Bone Graft with BMA|Patients with a benign bone lesion of the extremity or pelvis for which surgical curettage age was recommended and who received Vitoss bone graft with BMA to fill the cavity.
3059361|NCT02165943||Vitoss bone graft|Patients with a benign bone lesion of the extremity or pelvis for which surgical curettage was recommended and who received Vitoss bone graft to fill the cavity.
3059362|NCT02165930|Experimental|Treatment A|
3059363|NCT02165930|Experimental|Treatment B|
3059364|NCT02165917|Placebo Comparator|Excision only|Laparoscopic excision of endometriotic lesions followed by 3 month of GnRH-Analogue administration
3059365|NCT02165917|Active Comparator|Excision plus hyaluronic acid gel|Standard Laparoscopic excision of endometriotic lesions plus application of 10 cc of a hyaluronic acid gel (Hyalobarrier® ), followed by 3 month of GnRH-analogue administration
3059366|NCT02165904|Experimental|Autologous Mesenchymal Bone Marrow Cell|All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow Cell
3059367|NCT02165891|Other|Urokinase|insertion of a chest drain with urokinase instillation
3059368|NCT02165891|Other|VATS|primary video-assisted thorascopic surgery Other interventions except drainage procedure are the same in both arms
3059369|NCT02165878||Children and adolescent|children and adolescent CKD patients of any etiology
3059370|NCT02165865|Experimental|upper extremity/ hand transplantation|hand transplant on unilateral dominant hand or bilateral upper extremity amputees
3059371|NCT02165852|Experimental|Papillectomy without injection|Conventional snaring mucoal resection without submucosal injection
3059372|NCT02165852|Active Comparator|Papillectomy with injection|Conventional mucosal resction method following injeciton of diluted epinephrine mixture.
3059373|NCT02165839|Active Comparator|Healthy Eating Education Learning (HEAL)|Healthy Eating Education Learning (HEAL) control group.
3059374|NCT02165839|Experimental|Brief Behavioral Therapy for Insomnia (BBT-I)|Brief Behavioral Therapy for Insomnia (BBT-I).
3059375|NCT02165826|Experimental|Roflumilast 500 μg once daily|Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
3059376|NCT02165826|Experimental|Roflumilast 500 μg every other day|Roflumilast 500 μg, tablets, orally, every other day, and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
3059377|NCT02165826|Experimental|Roflumilast 250 μg once daily|Roflumilast 250 μg, tablets, orally, once daily for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
3059378|NCT02165813|Active Comparator|Nitazoxanide|oral nitazoxanide suspension twice daily for 3 days
3059379|NCT02165813|Placebo Comparator|Placebo|oral placebo suspension twice daily for 3 days
3059380|NCT02165800|Active Comparator|O-PANP-TME|Open pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
3059381|NCT02165800|Experimental|L-PANP-TME|Laparoscopy-assisted pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
3059382|NCT02165787||patients|
3059383|NCT02165787||healthy control subjects|
3059384|NCT02165774|Active Comparator|sacral neuromodulation ON|active sacral neuromodulation (neuromodulator ON)
3059385|NCT02165774|Placebo Comparator|sacral neuromodulation OFF|placebo sacral neuromodulation (neuromodulator OFF)
3059386|NCT02165761|Active Comparator|GORE® Hybrid Vascular Graft|GORE® Hybrid Vascular Graft
3059387|NCT02165761|Other|Non-heparin bonded synthetic graft|Non-heparin bonded synthetic graft
3059388|NCT02165735|Experimental|Patient Empowerment|Participants will take part in six 90-minute sessions focused on development of basic information technology competency within a context that supports patient autonomy, competence and human relationships.
3059389|NCT02165735|No Intervention|Standard Care|Participants will be followed through usual source of care, without receiving the empowerment training.
3059390|NCT02165722|Experimental|Intervention: Toolkit|4 Pillars Toolkit
3059391|NCT02165722|No Intervention|No Intervention: Standard practice|11 Clinical Practices [control sites]
3059392|NCT02165709|Experimental|Salpingectomy|Participants will be offered a risk-reducing salpingectomy, and if they choose this options the surgeon will proceed with a salpingectomy.
3059393|NCT02165709|Active Comparator|Traditional sterilization|Participants will be offered a risk-reducing salpingectomy, and those that choose a traditional sterilization will be in this treatment arm.
3059394|NCT02165696|Experimental|Manual lymphatic drainage and compression bandaging|Experimental group: 30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
3059398|NCT02165644|Experimental|Acetazolamide|"Acetazolamide 250 mg QID oral for 4 days along with current standard of care which is Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.~If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration."
3059399|NCT02165644|Active Comparator|Standard of care|Subjects will receive only standard of care for subarachnoid hemorrhage which will include Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.
3059400|NCT02165631||Group A-Simbinza|Patients in Group A will receive Simbrinza (brinzolamide) 1%/0.2%, with instruction for three times daily (every 8hours) administration of the medication in both eyes for a minimum of 4 weeks and a maximum of 8 weeks of medication therapy.
3059401|NCT02165631||Group B-Timolol|Patients in Group B will receive Timolol 0.5%, with instructions for twice daily administration (every 12 hours) of the medication in both eyes for a minimum of 4 weeks and a maximum of 8 weeks of medication therapy.
3059402|NCT02165618|No Intervention|GCT|In a before phase, data on how the GCT operated (i.e. good clinical practice) was gathered.
3059403|NCT02165618|Active Comparator|GCT-RASP|Medication review, based on but not limited to the RASP list
3059404|NCT02165605|Experimental|HylaCare|HylaCare cream Each patient will be randomized blindly as to whether the study serum will be applied to the medial or lateral portion of the treated breast, using the nipple as the dividing line. The product and placebo will also be applied to the contra-lateral breast in the same fashion, as a further control. The study drug and placebo will be applied three (3) times daily, but not within 4 hours prior to radiation treatment.
3059405|NCT02165605|Placebo Comparator|Placebo|The patient is her own control.
3059406|NCT02165592||Patients with hemophilia|Patients with hemophilia who meet the inclusion criteria
3059407|NCT02165579||Age > 21, diabetes, osteomyelitis|1 Cohort, standard care, observational patients are: Diagnosis of diabetes mellitus Age ≥ 21 years Infectious Disease Society of America stage 3 infection
3059408|NCT02165566|Experimental|Regular-insulin,|regular-insulin or lispro-insulin at 0.04 units/kg/hour continuous infusion crossover and random assignement
3059409|NCT02165566|Experimental|Lispro insulin|patients randomly assigned in a crossover way to one of the 2 treatments
3059410|NCT02165553|Experimental|Hibiscus sabdariffa calyces extract as a cold drink|Subjects are asked to consume 250 ml of Hibiscus calyces drink after a high fat breakfast
3059411|NCT02165553|Placebo Comparator|Water|Subjects are asked to consume 250 ml of water after a high fat breakfast
3059412|NCT02165540|Experimental|Doula|Patients will have a doula support person during their procedure.
3059413|NCT02165540|No Intervention|Routine care/No Doula|Patients will have routine care with clinical staff only.
3059414|NCT02165527|Experimental|x-ray with iXDA scan|Tota body scan taken by the Lunar iXDA. During the scan, subject will be asked to lay on their back. Following the Lunar iDXA scan, the computer of the Luna iXDA will calculate bone length. The calculation of bone length will be compared to a calculation from the subject's conventional x-ray to determine accuracy.
3059415|NCT02165514|Experimental|Lunar iDXA (DEXA) scan|Spinal scans taken by DEXA scanner
3059416|NCT02165475|Experimental|Biofeedback|
3059417|NCT02165475|Experimental|medical treatment|
3059418|NCT02165475|Experimental|combination of the two treatments|
3059419|NCT02165462||Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task
3059420|NCT02165449|Experimental|Ketamine|
3059421|NCT02165436|Placebo Comparator|Control|No gum
3059422|NCT02165436|Active Comparator|Chewing Gum|Bubble gum-flavored sugar-free gum - chew for 15-30 minutes 5 times/day
3059423|NCT02165423|Experimental|Control|Ten parents will be randomized to the control group defined as 'usual care' and ten to the intervention group, stratified by type of transplant.
3059424|NCT02165423|Experimental|Intervention|Ten parents will be randomized to the control group defined as 'usual care' and ten to the intervention group, stratified by type of transplant.
3059425|NCT02165410|Experimental|Eye tracking and RMI|
3059426|NCT02165397|Experimental|Treatment Arm A (Ibrutinib + Rituximab)|Ibrutinib: 420 mg (3 capsules x 140 mg) orally administered daily beginning from Day 1 Rituximab: 375 mg/m2 IV per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
3059427|NCT02165397|Experimental|Treatment Arm B (Placebo + Rituximab)|Placebo: 3 capsules of placebo orally administered daily beginning from Day 1 Rituximab: 375 mg/m2 IV per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
3059428|NCT02165397|Experimental|Treatment Arm C (Ibrutinib)|Ibrutinib: 420 mg (3 capsules) orally administered daily beginning from Day 1
3059429|NCT02165384|Experimental|Hummingbird TTS|Ear tube placement with the Hummingbird TTS
3059430|NCT02165371|Experimental|Sinovuyo Caring Families Programme|12-week group-based parenting program (Sinovuyo Caring Family Programme) delivered in weekly 3 hour sessions. Program is manualized.
3059431|NCT02165371|No Intervention|No intervention|Control group receives not intervention
3059432|NCT02165358||Patients|Patients verified with either becker muscular dystrophy or limb-girdle muscular dystrophy type 2I
3059433|NCT02165358||Controls|Healthy controls matched for age and gender.
3059434|NCT02165345|Experimental|Tocilizumab|Participants will receive tocilizumab until the commercial availability of the drug or up to 5 years, whichever is earlier.
3059435|NCT02165332|Placebo Comparator|Part 1: Placebo|Saline solution, given as a minimum of a 2 hour infusion
3059436|NCT02165332|Experimental|Part 1: RO7033877|Single ascending dose
3059437|NCT02165332|Experimental|Part 2: RO7033877|Single-dose 4-way crossover
3059438|NCT02165319|Active Comparator|Barrel|Endotracheal tube with barrel-shaped cuff will be used during general anesthesia.
3059439|NCT02165319|Active Comparator|Tapered|Endotracheal tube with tapered-shaped cuff will be used during general anesthesia.
3059440|NCT02165306|Experimental|Intervention|Patients enrolled in the intervention arm will receive two educational sessions on the importance of medication and barriers to adherence
3059441|NCT02165306|Active Comparator|Active Comparator|Usual Care The usual care group received routine counseling performed by the neurologist/neurosurgeon and nurses.
3059443|NCT02165280|Active Comparator|Guided IMagery (GIM)|If randomized to GIM, they will then be given an audio Compact Disc. Patients will be instructed to listen to the recording least once per day in a calm location during the week leading up to surgery. They will then be seen prior to surgery in the surgical waiting area where they will evaluated for anxiety, preparedness and study compliance.
3059444|NCT02165280|No Intervention|Standard of Care (SOC)|"Each participant will complete a baseline set of questionnaires. The Pelvic Floor Distress Inventory (PFDI) is a 20 question self-administered questionnaire on the presence and both of pelvic floor symptoms .~The Pelvic Organ Prolapse Quantification System (POPQ) measures the topography of the vagina and is considered to be gold standard for quantifying prolapse .~The State-Trait Anxiety Inventory (STAI) has been used extensively in research and clinical practice since its introduction in 1966 and is the most widely cited measure of anxiety.~New measurements at the 6-week follow-up appointment will include the Patient Global Impression of Improvement (PGII), and a postoperative questionnaire eliciting overall satisfaction and development of new pelvic symptoms."
3059445|NCT02165267|Experimental|Arm 1: VRC01 (6 IV infusions)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Day 0, followed by IV infusions of 20 mg/kg of VRC01 administered in 100 mL of normal saline over at least 30 minutes to 1 hour at Days 28, 56, 84, 112, and 140.
3059446|NCT02165267|Experimental|Arm 2: VRC01 (3 IV infusions)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Day 0 and over at least 30 minutes to 1 hour at Days 56 and 112.
3059447|NCT02165267|Experimental|Arm 3a: VRC01 (1 IV infusion plus multiple SC injections)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Week 0, followed by SC injection of 5 mg/kg of VRC01 administered every 2 weeks for 20 weeks.
3059448|NCT02165267|Placebo Comparator|Arm 3b: Placebo for VRC01 (infusion plus injections)|Participants will receive an IV infusion of sodium chloride placebo administered in 100 mL of normal saline over 1 hour at Week 0, followed by SC injection of placebo for VRC01 administered every 2 weeks for 20 weeks.
3059449|NCT02165267|Experimental|Arm 4: 10 mg/kg of VRC01 (3 IV infusions)|Participants will receive an IV infusion of 10 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Month 0 and over at least 30 minutes to 1 hour at Months 2 and 4.
3059450|NCT02165267|Experimental|Arm 5: 30 mg/kg of VRC01 (3 IV infusions)|Participants will receive an IV infusion of 30 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Month 0 and over at least 30 minutes to 1 hour at Months 2 and 4.
3059451|NCT02165254|Other|high dose tai chi intervention|
3059452|NCT02165254|Other|standard dose tai chi intervention|
3059453|NCT02165228|Experimental|Mindfulness-based stress reduction|Stress reduction class and behavioral intervention
3059454|NCT02165228|Active Comparator|Nutrition Enhancement|Nutrition education class and behavioral intervention
3059455|NCT02165228|No Intervention|Control|No class or behavioral intervention
3059456|NCT02165215|Experimental|Etrolizumab (Maintenance Phase)|Participants who achieved a clinical response at Week 10 during induction phase and randomized to this arm will receive etrolizumab 105 milligrams (mg) subcutaneous (SC) injection every 4 weeks (Q4W) up to Week 62.
3059457|NCT02165215|Experimental|Etrolizumab (Open-Label Induction Phase)|All participants will receive treatment with open-label etrolizumab 105 mg SC injection Q4W up to Week 10.
3059458|NCT02165215|Placebo Comparator|Placebo (Maintenance Phase)|Participants who achieved a clinical response at Week 10 during induction phase and are randomized to this arm will receive placebo matched to etrolizumab up to Week 62.
3059459|NCT02165202|Active Comparator|Rilpivirine|Arm 1: Participants randomized to the active arm will receive rilpivirine 25 mg capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of TMC278 LA, 1200 mg dose, at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion 1200 mg of TMC278 LA will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
3059460|NCT02165202|Placebo Comparator|Placebo|Arm 2: Participants randomized to the placebo arm will receive placebo capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of saline (0.9% NaCI) at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion placebo will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
3059461|NCT02165189|Experimental|Simeprevir plus Sofosbuvir plus Ribavirin (Arm 1)|Participants will be administered simeprevir capsule 150 milligram (mg), sofosbuvir 400 mg tablet, and ribavirin 2 x 200 mg tablets (for participants weighing less than 75 kilogram [kg]) or 3 x 200 mg tablets (for participants weighing more than 75 kg weight), orally once daily up to 12 weeks.
3059462|NCT02165189|Experimental|Simeprevir plus Sofosbuvir (Arm 2)|Participants will be administered simeprevir capsule 150 mg and sofosbuvir 400 mg tablet orally once daily up to 12 weeks.
3059463|NCT02165189|Experimental|Simeprevir plus Sofosbuvir (Arm 3)|Participants will be administered simeprevir 150 mg capsule and sofosbuvir 400 mg tablet orally once daily 24 weeks.
3059464|NCT02165176|Experimental|10mg acute oral cannabis|10mg acute oral cannabis
3059465|NCT02165176|Experimental|25mg acute oral cannabis|25mg acute oral cannabis
3059466|NCT02165176|Experimental|50mg acute oral cannabis|50mg acute oral cannabis
3059467|NCT02165163|Experimental|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
3059468|NCT02165163|No Intervention|Control|The control group will keep their normal activity without receiving any intervention.
3059469|NCT02165150|Experimental|Wheelchair-bound Senior Elastic Band|WSEB interventions three times per week, 40 minutes per practice
3059470|NCT02165150|No Intervention|Control|routine care
3059471|NCT02165137||trauma patients|type and severity of patients, circumstances and trauma pre- and post-injury / -quality initiative
3059472|NCT02165124|Experimental|Intervention/Bariatric Embolization|
3059542|NCT02164578|Experimental|Rivaroxaban|Patients receive IMP in 5mg b.i.d. for 20 weeks.
3059543|NCT02164578|Active Comparator|Aspirin|Patients receive IMP in a dosage of 100mg once daily for 20 weeks.
3059473|NCT02165111|Experimental|Onabotulinumtoxin A|"One hand of each patient will be randomly selected for injection of Botulinum Toxin A (Onabotulinumtoxin A, 20 units/mL).~Injections are performed using a 30 gauge insulin syringe through the dorsal surface in seven locations: adjacent to the 2nd, 3rd, and 4th common digital arteries through the web spaces (10 units each=0.5mL each), and the radial side of the index finger metacarpal head, the ulnar side of the small finger metacarpal head, and each side of the thumb metacarpal head (5 units each= 0.25mL each). Total treatment dose of Botulinum Toxin A will not exceed 50 units per hand."
3059474|NCT02165111|Placebo Comparator|Placebo|"One hand of each patient will be randomly selected for injection of sterile saline solution (placebo).~Injections are performed using a 30 gauge insulin syringe through the dorsal surface in seven locations: adjacent to the 2nd, 3rd, and 4th common digital arteries through the web spaces (0.5 mL each), and the radial side of the index finger metacarpal head, the ulnar side of the small finger metacarpal head, and each side of the thumb metacarpal head (0.25 mL each)."
3059475|NCT02165098|Experimental|Cariprazine PR tablet B|Cariprazine prolonged release tablet B - fed
3059476|NCT02165098|Experimental|Cariprazine PR tablet A|Cariprazine prolonged release tablet A - fed
3059477|NCT02165098|Experimental|Cariprazine capsule|Cariprazine capsule - fasted
3059478|NCT02165098|Experimental|Cariprazine prolonged release tablet B|Cariprazine prolonged release tablet B - fasted
3059479|NCT02165098|Experimental|Cariprazine prolonged release tablet A|Cariprazine prolonged release tablet A - fasted
3059480|NCT02165085||Vascular-Ehlers Danlos syndrome|N=50 patients with vascular Ehlers-Danlos syndrome
3059481|NCT02165085||Spontaneous arterial dissection(s)|N=50 patients
3059482|NCT02165085||Healthy volunteers|n=100 Healthy volunteers
3059483|NCT02165059||Study Group|Patients undergoing surgical full thickness biopsy of the stomach and/or proximal jejunum for the clinical evaluation of GI neuromuscular disorder.
3059484|NCT02165059||Control Group|"Patient undergoing esophagectomy, sleeve gastrectomy for obesity, Roux-en-Y gastric bypass, Whipple surgery, transplant surgery.~Patients who are organ donors and undergoing surgery are also part of the control group."
3059485|NCT02165046|Experimental|SYN006 HFA MDI, 180/10 mcg/dose|SYN006 HFA MDI(Budesonide/Procaterol Hydrochloride, 180/10mcg), Single dose, 4 puffs
3059486|NCT02165046|Active Comparator|Pulmicort pMDI|Budesonide 200mcg, single dose, 4 puffs
3059487|NCT02165046|Active Comparator|Meptin Air 10mcg|Procaterol hydrochloride 10mcg, single dose, 4 puffs
3059488|NCT02165033|Experimental|Budesonide/Procaterol 180/10 X 4 puffs|Multiple dose of SYN006 HFA MDI (Budesonide 180ug + Procaterol 10ug/puff), 4 puffs each day for consecutive 7 days
3059489|NCT02165020|Experimental|Rectal toxicities after prostate hypofractionated radiotherapy|Rectal toxicities after prostate hypofractionated radiotherapy with hyaluronic acid
3059490|NCT02165007|Experimental|peripheral blood stem cell graft that are CD34+ selected|peripheral blood stem cell graft that are CD34+ selected. All patients will undergo reduced intensity conditioning regimen which followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device and Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year (see intervention).
3059491|NCT02164981|Active Comparator|Drug - Drug|Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
3059492|NCT02164981|Other|Placebo - Drug|Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside
3059493|NCT02164981|Placebo Comparator|Placebo - Placebo|Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
3059494|NCT02164968||Obstructive bronchitis|1-5 year old patients who have visited the TAYS emergency room due to obstructive bronchitis and have been instructed to begin a three-month period of inhaled corticosteroid (ICS) treatment as per national guidelines.
3059495|NCT02164955||Relapsed and Refractory Multiple Myeloma Patients|Single Cohort of Relapsed and Refractory Multiple Myeloma Patients treated with IMNOVID (pomalidomide)
3059496|NCT02164942||Single Arm|Specimen Collection
3059497|NCT02164929|Active Comparator|Paravertebral block|Bilateral PVB will be placed between T7-T10 interspaces preoperatively. Patients will be in a sitting position which allows easy identification of landmarks, and the patients are often more comfortable. Ultrasound will be used to identify the paravertebral space. At the appropriate dermatome under aseptic precautions, the needle (22-gauge, 8-10-cm short beveled spinal needle) will inserted 2.5-3 cm lateral to the most cephalad aspect of the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process 3 of the vertebra below at a variable depth (2-4 cm). A 10 mL ropivacaine 0.25% will be injected at both T7 and T9 levels on each side (40 mL in total).
3059498|NCT02164929|Active Comparator|TAP block|Bilateral posterior and subcostal TAP blocks guided by ultrasound will be performed in the preoperative holding area. A total of 80 mL ropivacaine 0.25% (4 injections, 20 mL per injection) will be injected evenly upon identification of the appropriate planes. In the event the placement of block is uncomfortable for the patients, it will be performed after induction of anesthesia. This approach is currently practiced in the OR. Extent and degree of anesthetic blockage will be measured using a 5-point sensation scale following the procedure at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).
3059499|NCT02164929|Active Comparator|Epidural|"An epidural catheter will be inserted between T8-10 in the preoperative holding area, and a test dose of 1.5% lidocaine with 1:200,000 epinephrine will be given. Extent and degree of anesthetic blockage will be measured using a 5-point sensation following the procedure and postoperatively at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).~A bolus does of epidural hydromorphone (400-800 mcg) will be given preoperatively. An infusion of bupivacaine 0.25% at 4-6 ml/hour will be commenced before incision, and if tolerated, continued throughout surgery. Adjustments that may be required secondary to specific patient hemodynamic status will be left to the discretion of the individual anesthesiologist and guided by the specific patient requirements."
3059544|NCT02164565|Experimental|Tranexamic Acid (TXA) treatment|Tranexamic Acid (TXA) treatment
3059545|NCT02164565|Experimental|control grup: without Tranexamic Acid (TXA) treatment.|control grup: without Tranexamic Acid (TXA) treatment.
3059546|NCT02164552||Vitamin D3 pills|Vitamin D3 (cholecalciferol) supplementation (50,000 IU/week for 8 weeks) followed by 1000 IU/day for 16 weeks
3059547|NCT02164552||Placebo pill|Placebo pills will be given 1 per week for 8 weeks followed by 1 per day for 16 weeks
3059500|NCT02164929|Active Comparator|No block (PCA alone)|Premedication with midazolam up to 2 mg. General anesthesia is induced with propofol 1-2.5 mg/kg. Dexamethasone 4 mg IV will be administered after induction of anesthesia. Anesthesia will be maintained with sevoflurane to keep a bispectral index of between 40-60. Neuromuscular blocking drug and reversal agent of choice may be used. Local infiltration with 10 mL of plain ropivacaine 0.25% will be administered at the surgical incision site at the end of surgery. Acetaminophen 1g IV will be administered following induction of anesthesia will be administered at the end of the procedure
3059501|NCT02164916|Active Comparator|Arm I (cetuximab, irinotecan hydrochloride)|Patients receive cetuximab IV and irinotecan hydrochloride IV on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm II.
3059502|NCT02164916|Experimental|Arm II (cetuximab, irinotecan hydrochloride, vemurafenib)|Patients receive cetuximab and irinotecan hydrochloride as in Arm I and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3059503|NCT02164903||Imatinib|Patients in first line treatment with imatinib for no more than 3 years.
3059504|NCT02164903||Dasatinib|Patients in first line treatment with dasatinib for no more than 3 years.
3059505|NCT02164890|Other|Pharmacokinetics of micafungin|
3059506|NCT02164877|Experimental|pectin|Patients allocated to experiment group will receive standard enteral nutrition formula(Fresubin) supplemented with 15g pectin each day for 4 weeks.
3059507|NCT02164877|Placebo Comparator|control|Patients allocated to control group will receive standard enteral nutrition formula(Fresubin) for 4 weeks
3059508|NCT02164864|Experimental|Dabigatran Etexilate 110mg|Patient to receive Dabigatran Etexilate 110mg twice a day (BID)
3059509|NCT02164864|Experimental|Dabigatran Etexilate 150mg|Patient to receive Dabigatran Etexilate 150mg twice a day (BID)
3059510|NCT02164864|Active Comparator|Warfarin|Warfarin doses to maintain INR
3059511|NCT02164838|Experimental|Axitinib|
3059512|NCT02164825|Experimental|Single-shot nerve block|Efficacy compared to epidural
3059513|NCT02164825|Active Comparator|Continuous epidural|Continuous epidural perfusion
3059514|NCT02164812|Experimental|Moxifloxacin, Placebo, Efavirenz|Moxifloxacin, Placebo, Efavirenz single dose as specified
3059515|NCT02164799||Shock|Patients found to have persistent hypotension after resuscitation or vasopressor requirement
3059516|NCT02164799||Pre-shock|Patients with markedly abnormal vital signs (Heart Rate (HR)>130, Respiratory Rate (RR)>24, Shock Index >1, Lactate > 4.0mmol/L, or Systolic Blood Pressure (SBP) <90mm/hg) without shock, as defined previously.
3059517|NCT02164786||Acute severe disease|
3059518|NCT02164773|Active Comparator|magnesium sulfate|magnesium sulfate 50mg caudal 1ml(5%) prepared after addition of 9ml of 0.9%normal saline to 1ml of 500mg(50%)of magnesium sulfate to be added to 1ml/kg of 0.25%of bupivacaine in caudal block in children undergoing lower abdominal surgery under sevoflurane anesthesia to prevent emergence agitation.
3059519|NCT02164773|Placebo Comparator|o.9%normal saline|0.9% of normal saline added to the conventional 0.25% bupivacaine in caudal block.
3059520|NCT02164760|Experimental|Dermal substitute with STSG|Novomaix dermal substitute in combination with STSG
3059521|NCT02164760|No Intervention|STSG alone|STSG alone
3059522|NCT02164747||Control group before telemedicine|Residents of nursing homes without telemedicine before implementation of telemedicine in nursing homes with telemedicine
3059523|NCT02164747||Control group after telemedicine|Residents of nursing homes without telemedicine after implementation of telemedicine in nursing homes with telemedicine
3059524|NCT02164747||Exposed group, before telemedicine|Residents of nursing homes with telemedicine prior implementation of telemedicine
3059525|NCT02164747||Exposed group, after telemedicine|Residents of nursing homes with telemedicine after implementation of telemedicine
3059526|NCT02164734|Active Comparator|Endotracheal intubation|Endotracheal intubation for surfactant administration, following remifentanil and atropine pre-medication
3059527|NCT02164734|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
3059528|NCT02164721|Other|CRT-D (Defibrillator)|Implantation of a three-lead CRT-D (Defibrillator) in all registered patients
3059529|NCT02164708|Experimental|Mindfulness Meditation|"The program progressively trained students in mindfulness of breathing, a form of meditation frequently employed secularly. The tutorials were held on campus five times weekly, led by a faculty member and a graduate student who were trained, experienced MM practitioners. The tutorials were one hour in duration and typically involved 40-45 minutes of guided MM followed by a question-answer period that addressed recent research findings. Program participation required attendance at one tutorial per week, and participants were encouraged to maintain autonomous MM practice."
3059530|NCT02164695|Active Comparator|PPCI plus RIPC|The patients randomized to PPCI plus RIPC group will receive RIPC during PPCI.
3059531|NCT02164695|Sham Comparator|PPCI only|The patients randomized to PPCI only group will receive PPCI only but the sham procedure of RIPC.
3059532|NCT02164682||IV PCA group|
3059533|NCT02164682||IV PCA+ caudal block group|
3059534|NCT02164656|Experimental|mindfulness training|8 week course in mindfulness for smokers
3059535|NCT02164643|Experimental|Florbetapir (18F)|
3059536|NCT02164643|Experimental|Flutemetamol (18F)|
3059537|NCT02164630|Experimental|Hope Therapy|Patients assigned to this arm will receive Hope Therapy in three individual intervention sessions. Intervention will be administered by an experienced therapist.Training focuses on effective goal setting and augmenting hopeful thinking.
3059538|NCT02164630|Other|Pain Education|Patients assigned to this arm will receive Pain Education in three individual intervention sessions. Intervention will be administered by an experienced therapist. Training will focus on understanding TMD-related pain and learning pain management techniques.
3059539|NCT02164617|Experimental|Wheelchair-bound Senior Elastic Band|Wheelchair-bound Senior Elastic Band (WSEB) exercise program has three phases: 1) warm-up: 6 movements to loosen up the body and elevate the energy for a safe transition to the next phase, 2) aerobic motions: 6 low-to-medium speed exercises to enhance the cardiovascular-respiratory workout, and 3) static stretching: 6 low-speed, gentle stretching exercises to build up muscle power/endurance and increase range of motion and flexibility. It is conducted three times per week, 40 minutes per practice.
3059548|NCT02164539|Experimental|Treatment Phase A|Eligible subjects will enter a 4-week run-in period and will receive fluticasone propionate/salmeterol. Subjects will then be randomized to receive fluticasone furoate 100 mcg, fluticasone furoate/umeclidinium bromide 100/15.6 mcg, fluticasone furoate/umeclidinium bromide 100/62.5 mcg, fluticasone furoate/umeclidinium bromide 100/125 mcg, fluticasone furoate/umeclidinium bromide 100/250 mcg, or fluticasone furoate/vilanterol 100/25 mcg, respectively for 4 weeks
3059549|NCT02164539|Experimental|Treatment Phase B|Subjects completing Treatment Phase A will be randomized to receive either fluticasone furoate/umeclidinium bromide100/250 mcg or fluticasone furoate/umeclidinium bromide/vilanterol 100/250/25 mcg for 1 week.
3059550|NCT02164539|Experimental|Treatment Phase C|Subjects completing Treatment Phase B will be randomized to receive either the same treatment as in Treatment Phase B, or the same treatment minus the umeclidinium bromide component, for 1 week.
3059551|NCT02164526||No treatment|
3059552|NCT02164513|Experimental|fluticasone furoate/umeclidinium bromide/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg QD (morning) for a period of 52 weeks via DPI
3059553|NCT02164513|Experimental|fluticasone furoate/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive FF/VI 100 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI)
3059554|NCT02164513|Experimental|umeclidinium bromide/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive UMEC/VI 62.5 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI
3059555|NCT02164500|Experimental|Ruxolitinib|
3059556|NCT02164487||B1 blood levels|
3059557|NCT02164474|Experimental|High-Intensity Interval Training (HIIT)|Participants will perform a series of high-intensity intervals with an interval length of 60-seconds at 90% of peak aerobic capacity workload, and a rest length of 60-seconds.
3059558|NCT02164474|Active Comparator|Moderate-Intensity Continuous Exercise|Participants will engage in exercise at 45% of peak aerobic capacity workload.
3059559|NCT02164461|Experimental|ADXS11-001|
3059560|NCT02164448|Experimental|dexmedetomidine group|
3059561|NCT02164448|Placebo Comparator|control group|
3059562|NCT02164435|Other|Renal Denervation|
3059563|NCT02164422|Experimental|Guanfacine 3mg/day|Guanfacine 3mg/day
3059564|NCT02164422|Experimental|Guanfacine 1.5mg/day|Guanfacine 1.5mg/day
3059565|NCT02164422|Placebo Comparator|Placebo|Placebo
3059566|NCT02164409||Patient|Subjects for this study will be either H. pylori positive with an active infection, cleared of an H. pylori infection or be both H. pylori antibody positive and have a malignancy of the gastrointestinal tract, specifically gastric adenocarcinoma.
3059567|NCT02164409||Control|A small subset of patients without H. pylori infection will be enrolled as well (n=30) to serve as a control group.
3059568|NCT02164396|Active Comparator|Spectacles Lens|Participant will discontinue soft contact lens wear and wear spectacles only. Spectacle lens refers to the habitual prescription glasses that the participant arrives to the testing center with; they are NOT prescribed or given to the participant by the investigator as part of the study protocol.
3059569|NCT02164396|Active Comparator|Habitual Soft Contact Lens|Participant will continue to wear their habitual soft contact lenses. Habitual lenses are the contact lenses used by the subjects prior to participating in the clinical trial. Various types/brands are used by subjects prior to participation.
3059570|NCT02164396|Experimental|Test Lens|Participants will be dispensed senofilcon A or narafilcon A depending on their habitual modality (reusable or daily disposable)
3059571|NCT02164383|Experimental|Mobile Games|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine patch plus behavioral cessation counseling with access to Mobile Games."
3059572|NCT02164383|Experimental|No Mobile Games|"This arm of the project will address the following question:~How effective is the following intervention:~Nicotine patch plus behavioral cessation counseling without access to Mobile Games."
3059573|NCT02164370||non-pregnant controls|Acid-base in healthy non-pregnant women in childbearing age
3059574|NCT02164370||healthy pregnant control group|healthy pregnant volunteers matched in gestational age to cases
3059575|NCT02164370||severe pre-eclampsia|Acid-base in severe pre-eclampsia
3059576|NCT02164357||EVT|Patients receiving endovascular treatment (EVT) within 4.5 hours after onset because intravenous thrombolytic therapy (IVT) is contraindicated
3059577|NCT02164357||IVT + EVT|Patients receiving intravenous thrombolytic therapy (IVT) followed by endovascular treatment (EVT) within 4.5 hours after onset
3059578|NCT02164357||IVT (intravenous thrombolytic therapy)|Patients that will received IVT only within 4.5 hours after onset
3059579|NCT02164344|Experimental|Probiotics|HIV-1 infected patients take daily dietary supplement with probiotics for at least 3 months
3059580|NCT02164331|Experimental|JNC guideline training|Providers will receive current JNC guideline training for treating patients with uncontrolled hypertension.
3059581|NCT02164331|No Intervention|Control|Provider patient panels will be assessed for number of uncontrolled hypertensives before receiving the JNC guidelines training. These baseline characteristics will serve as their control conditions.
3059582|NCT02164318|No Intervention|Control group|Standard of care
3059583|NCT02164318|Experimental|Handgrip training group|Perform isometric handgrip exercises for 15 minutes twice per day for a total of 30 minutes
3059584|NCT02164318|Experimental|Nitroglycerin ointment group|Apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
3059585|NCT02164318|Experimental|Combined handgrip training /Nitroglycerin ointment group|Perform isometric handgrip exercises for 15 minutes twice each day for a total of 30 minutes and apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
3059586|NCT02164305|Experimental|Strengthening group|4-week exercise training, 3 times a week, 30 minutes per visit.
3059587|NCT02164305|Experimental|Neuromuscular group|4-week exercise training, 3 times a week, 30 minutes per visit
3059588|NCT02164305|Sham Comparator|Control|Only have 2 assessments.
3059589|NCT02164292||ALPPS group|"Patients with small future liver remnant who are operated with the Associating Liver Partition and Portal vein ligation for Staged hepatectomy approach"
3059590|NCT02164279|Experimental|Progressor (ND)|Group of patients with an albuminuria > 100mg/L, by Urinary sample collection
3059591|NCT02164279|Experimental|Non-Progressor (non-ND)|Group of patients without an albuminuria > 100mg/L, by Urinary sample collection
3059592|NCT02164266|Experimental|Part 1: Healthy Volunteers|
3059593|NCT02164266|Experimental|Part 2: Patients with T2D, Group A|Low dose daily oral administration of RO6799477
3059594|NCT02164266|Experimental|Part 2: Patients with T2D, Group B|High dose daily oral administration of RO6799477
3059595|NCT02164253|Experimental|Deferiprone|Deferiprone, 25 to 30 mg/kg per day, oral use
3059596|NCT02164240|Experimental|Sunitinib alternated with Regorafenib|The treatment cycle is defined as 28 days. Treatment consists of 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each cycle. The starting dose level is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage and recommended phase II dose is determined. An alternative scheme of 4-week cycles of the same regimen but with 21 days of dosing followed by 7 days of rest will be studied in case of toxicities during d 22-28 of the starting 4-weeks continuous cycles. Tumor assessments performed at baseline and after every two dosing cycles to assess response. Toxicity monitored throughout the study.
3059597|NCT02164227|Experimental|respiratory pattern|Deep and slow inspiration is used in the initial and active stages, at which time the contractions vary from uncomfortable to strong, lumbosacral pain and cervical dilation may occur between 3 and 8 cm in this case the mother is driven to inspire slowly and the level of inspiratory reserve volume followed by slow exhalation to functional residual capacity; Sigh with post-expiratory pause that corresponds to a small spontaneous exhalation to relax occurs in tidal volume; Expiratory delay that corresponds to a prolonged propelled with the lips during the lull and expiration in the expiration time that corresponds to a slow inspiration followed by two or three puffs with the short lips will be used propelled.
3059598|NCT02164227|No Intervention|Control|Follows the service routine
3059599|NCT02164214|Experimental|patients PSORIATIC ARTHRITIS|etanercept Treatment
3059600|NCT02164214|Active Comparator|patients RHEUMATOID ARTHRITIS|etanercept Treatment
3059601|NCT02164188|No Intervention|control|Initially this control group will not receive an intervention (wait list). After 8 weeks this goup will receive the Flourishing protocol (cross over).
3059602|NCT02164188|Experimental|Flourishing protocol|This group will receive the intervention Flourishing protocol and after that it will not receive any other intervention (cross over).
3059603|NCT02164175||HeRO Graft|End stage renal disease patients who receive HeRO Graft implant for dialysis access
3059604|NCT02164162|Experimental|Experimental group|"Participants received 12 sessions of robotic assisted body weight-supported treadmill training on the Lokomat. Training occurred approximately 3 days/ week for 4 weeks, and each training session on the Lokomat lasted 30 minutes. All sessions were supervised by a trained research therapist. All participants started with 40% body weight-support and an initial treadmill speed of 1.5 km/h. Body weight-support was used primarily to facilitate an increase in walking speed; therefore, progression of training across subsequent sessions was standardized by preferentially increasing speed and then unloading body weight-support.~Speed was increased to a range of 2.2 to 2.5 km/h before body weight-support was decreased. There was an active attempt to enhance the level of training at each session."
3059605|NCT02164162|Active Comparator|Control group|Participants received 20 sessions of conventional physiotherapy. Training occurred approximately 5 days/week for 4 weeks, and each training session lasted 1 hour .Patients allocated to the Control Group performed a general exercise program and a conventional gait training with a 5-minute rest between them. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and dual task activities and balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation concept (lasting 30 minutes), with rhythmic initiation, slow reversal, and agonistic reversal exercises applied to the pelvic region, each 10 minutes long.
3059606|NCT02164149||Quality of colon cancer surgery|Patients with primary colon cancer
3059607|NCT02164136|Experimental|L-PANP-TME|Laparoscopy-assisted pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
3059608|NCT02164136|Active Comparator|O-PANP-TME|Open pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
3059609|NCT02164123|Experimental|Spinal mobilization|20 subjects will be randomized to this arm. A postero-anterior (PA) mobilization, to the fourth thoracic vertebra will be applied, for 3 sets of one minute. The subject will be comfortable prone lying.
3059610|NCT02164123|Active Comparator|Spinal Mobilization II|20 subjects will be randomized to this arm. A postero-anterior (PA) mobilization, to the fourth thoracic vertebra will be applied, for 3 sets of one minute, but in this case, the subject will be seated, in a position that influence the sympathetic trunk, at the thorax.
3059611|NCT02164123|Placebo Comparator|Placebo|20 subjects will be randomized to this arm. Only manual contact will be applied, without any oscillation. The subject will be comfortable prone lying. The intervention time is the same of the other arms.
3059612|NCT02164110|Experimental|Euvichol|"Number of doses and intervals: two doses/Weeks 0 and 2~Method of administration: oral administration~Dose of drug to be administered: 1.5 mL/dose"
3059613|NCT02164110|Active Comparator|Shanchol|"Number of doses and intervals: two doses/Weeks 0 and 2~Method of administration: oral administration~Dose of drug to be administered: 1.5 mL/dose"
3059614|NCT02164097|Experimental|ODSH and ICE Chemotherapy|"Patients will receive standard doses of ICE Chemotherapy:~Ifosfamide 1800 mg/m2 mixed with Mesna 360 mg/m2 IV over 2 hours on days 1, 2, 3, 4, and 5~Carboplatin 400 mg/m2 IV over 1 hour on days 1 and 2~Etoposide 100 mg/m2 IV over 1 hour on days 1, 2, 3, 4, and 5~ODSH will be administered as a 4 mg/kg bolus 30 minutes after the first ifosfamide dose followed immediately by a continuous intravenous ODSH infusion of 0.25 mg/kg/hour for five consecutive days, on days 1-5, for a total of 120 hours of continuous ODSH infusion."
3059615|NCT02164084|Experimental|SB204|SB204 8% topically twice daily for 4 days and once on Day 5
3059616|NCT02164084|Placebo Comparator|Vehicle Gel|Vehicle Gel topically twice daily for 4 days and once on Day 5
3059617|NCT02164071||Multiple Myeloma (MM)|Patients with Myltiple Myeloma, symptomatic or asymptomatic
3059652|NCT02163863|Active Comparator|Control|CR Bard LifeStent System, delivering a self-expanding Nitinol stent
3059618|NCT02164071||Myelodysplastic Syndromes or Acute Myeloid Leukemia|Patients with Myelodysplastic Syndromes (MDS), any International Prognostic Scoring System (IPSS) risk, or Acute Myeloid Leukemia (AML)
3059619|NCT02164071||Chronic Lymphocytic Leukemia (CLL)|Patients with Chronic Lymphocytic Leukemia
3059620|NCT02164058|Experimental|TandemHeart System + PCI|TandemHeart System prior to percutaneous coronary intervention
3059621|NCT02164058|Active Comparator|PCI|Percutaneous coronary intervention
3059622|NCT02164045|Experimental|BMS-663068- Fasted|BMS-663068 tablet twice a day by mouth on specified days
3059623|NCT02164045|Experimental|BMS-663068- Fed|BMS-663068 tablet twice a day by mouth on specified days
3059624|NCT02164032|Placebo Comparator|Insulin dilution buffer|"During a subsequent 4-week treatment phase subjects will be randomly assigned to receive intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia.~Ectopic lipid content and heart function will be assessed weekly by non-invasive 1H magnetic resonance spectroscopy."
3059625|NCT02164032|Active Comparator|Intranasal Insulin administration|"During a subsequent 4-week treatment phase subjects will be randomly assigned to receive intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia.~Ectopic lipid content and heart function will be assessed weekly by non-invasive 1H magnetic resonance spectroscopy."
3059626|NCT02164019|Active Comparator|long-stem cemented hemiarthroplasty (LSCH)|"(LSCH), Hip, Ball, Rod and Cement Replace the ball of the hip joint with a metal ball and a rod that is placed inside the thigh bone with cement to keep the implant in place. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary."
3059627|NCT02164019|Active Comparator|intramedullary nailing (IMN)|"Intramedullary nailing (IMN), Rod and Screws A metal rod is placed inside your thigh bone and secured in place by metal screws just below the hip and above the knee. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary."
3059628|NCT02164006|Experimental|TGR-1202 + brentuximab vedotin|TGR-1202 oral daily dose in combination with a fixed IV infusion of brentuximab vedotin
3059629|NCT02163993|Experimental|5mg Galcanezumab|5mg of galcanezumab given as subcutaneous (SQ) injections once every 28 days during a 12 week treatment period.
3059630|NCT02163993|Experimental|50mg Galcanezumab|50mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
3059631|NCT02163993|Experimental|120mg Galcanezumab|120mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
3059632|NCT02163993|Experimental|300mg Galcanezumab|300mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
3059633|NCT02163993|Placebo Comparator|Placebo|Placebo given as SQ injections once every 28 days during a 12 week treatment period.
3059634|NCT02163980|Placebo Comparator|Caudal ropivacaine + normal saline|1.5ml kg-1 ropivacaine 0.15% with normal saline (Control group, n=40).
3059635|NCT02163980|Experimental|Caudal ropivacaine + dexmedetomidine|1.5ml kg-1 ropivacaine 0.15% with dexmedetomidine 1 μg kg-1 (DEX group, n=40)
3059636|NCT02163967|Experimental|Cranial Electrical Stimulation|cranial electrical stimulation for 20 minutes at sham dose, 1mAmp and 2mAmp
3059637|NCT02163954|Active Comparator|Clopidogrel|Patients treated with clopidogrel for 14 days
3059638|NCT02163954|Experimental|Ticagrelor|Patients treated with ticagrelor for 14 days
3059639|NCT02163941|Experimental|Compassion Training|8 weeks of training in Cognitively-Based Compassion Training (CBCT). Classes will meet once per week for 2 hours and participants will be asked to meditate at home for 20 minute each day.
3059640|NCT02163915|Experimental|Cohort 1: TAK-137 0.5 mg|TAK-137 0.5 mg, tablets, orally once on Days 1-7.
3059641|NCT02163915|Experimental|Cohort 2: TAK-137 2 mg|TAK-137 2 mg, tablets, orally once on Days 1-7.
3059642|NCT02163915|Experimental|Cohort 3: TAK-137 5 mg|TAK-137 5 mg, tablets, orally once on Days 1-7.
3059643|NCT02163915|Experimental|Cohort 4: TAK-137 10 mg|TAK-137 10 mg, tablets, orally once on Days 1-7.
3059644|NCT02163915|Experimental|Cohort 5: TAK-137 TBD|TAK-137, tablets, orally once on Days 1-7. Dose to be determined from data collected in Cohorts 1-3.
3059645|NCT02163915|Experimental|Cohorts 1-5: Placebo|TAK-137 placebo-matching tablets, orally, once on Days 1-7.
3059646|NCT02163902|Experimental|ATX-101|Subjects treated with ATX-101 in previous studies ATX-101-11-22 and ATX-101-11-23.
3059647|NCT02163902|Placebo Comparator|Placebo|Subjects treated with placebo in previous studies ATX-101-11-22 and ATX-101-11-23.
3059648|NCT02163889||Candida Positive Patients|Symptomatic adult patients, confirmed via blood culture with species identification to be positive for Candida
3059649|NCT02163876|Experimental|HuCNS-SC cells|Intramedullary transplantation of HuCNS-SC cells in the cervical spine
3059650|NCT02163876|No Intervention|non-surgery arm|non-surgery arm
3059651|NCT02163863|Experimental|BioMimics 3D|The BioMimics 3D Stent System, delivering a self-expanding Nitinol stent with 3D helical centerline geometry.
3059653|NCT02163850|Experimental|Direct Flow Medical|Direct Flow Medical Transcatheter Aortic Valve Replacement System (TAVR)
3059654|NCT02163850|Active Comparator|Commercially Available|Medtronic CoreValve Transcatheter Aortic Valve Replacement System (TAVR) or Edwards SAPIEN Transcatheter Aortic Valve Replacement System (TAVR)
3059655|NCT02163837|Experimental|rifaximine|
3059656|NCT02163824|Active Comparator|KPI-121 0.25% QID|KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
3059657|NCT02163824|Active Comparator|KPI-121 1.0% BID|KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
3059658|NCT02163824|Placebo Comparator|Placebo A QID|Vehicle of KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
3059659|NCT02163824|Placebo Comparator|Placebo B BID|Vehicle of KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
3059660|NCT02163811|Experimental|VETPALS|VETPALS is a five session course utilizing adult learning methods to teach self-management for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA Puget Sound clinician in conjunction with a peer facilitator (Veteran with limb loss).
3059661|NCT02163811|Active Comparator|Individual Education Support Program|VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
3059662|NCT02163798|Experimental|Tai Chi Group|Participants in this group received a 12-week instructor-led Tai Chi training program.
3059663|NCT02163798|Experimental|Walking Group|Participants in this group received a 12-week instructor-led brisk walking training program.
3059664|NCT02163798|No Intervention|Control Group|Participants in the control group did not receive intervention during the 12 weeks, and were told that they would be provided two sessions of free health and fitness evaluation with an interval of three months (12 weeks).
3059665|NCT02163785|Active Comparator|Supine position|Abdominoperineal resection - perineal time- in supine position
3059666|NCT02163785|Experimental|Prone position|Abdominoperineal resection - perineal time- in prone position
3059667|NCT02163772|Experimental|Intracordal hyaluronate injection (HI)|The intervention of Intracordal hyaluronate (Restylane) injection is given in this group No other therapies are given
3059668|NCT02163772|No Intervention|Conservative management (CM)|In this arm, only observation is arranged. No therapy is given.
3059669|NCT02163759|Active Comparator|Adalimumab + Etrolizumab Placebo|Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.
3059670|NCT02163759|Experimental|Etrolizumab + Adalimumab Placebo|Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
3059671|NCT02163759|Placebo Comparator|Etrolizumab Placebo + Adalimumab Placebo|Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
3059672|NCT02163746|Active Comparator|CO2 (carbon dioxide) laser|Patients randomized to this group will undergo CO2 laser excision of the sinus tracts in affected axilla
3059673|NCT02163746|Active Comparator|Surgical Deroofing|Patients randomized to this group will undergo surgical deroofing of the sinus tracts in affected axilla
3059674|NCT02163733|Other|Fasted|AZD9291 tablets following a period of fasting
3059675|NCT02163733|Other|High-fat meal|AZD9291 tablets following a high-fat meal.
3059676|NCT02163720||Yondelis®-Caelyx®-relapse ovarian cancer|Yondelis®-Caelyx®-relapse ovarian cancer
3059677|NCT02163707|Other|Psilocybin Dose 1|0.3 mg/kg (approximately 20mg/70kg)
3059678|NCT02163707|Other|Psilocybin Dose 2|0.45 mg/kg (approximately 30 mg/70 kg)
3059679|NCT02163707|Other|Psilocybin Dose 3|0.6 mg/kg (approximately 40 mg/70 kg)
3059680|NCT02163694|Placebo Comparator|Placebo with Carboplatin and Paclitaxel|Placebo on Day -2 through 5 of a 21-day cycle. In addition, carboplatin and paclitaxel will be administered on Day 1 of a 21-day cycle.
3059681|NCT02163694|Experimental|Veliparib with Carboplatin and Paclitaxel|Veliparib on Day -2 through 5 of a 21-day cycle. In addition, carboplatin and paclitaxel will be administered on Day 1 of a 21-day cycle.
3059682|NCT02163681|Experimental|Hyperpolarized Helium 3 MRI of the chest|Using hyperpolarized helium-3 as an inhaled contrast agent for MRI, we will assess the lung ventilation.
3059683|NCT02163668|Experimental|Yoga group|8 months of progressive Yoga training
3059684|NCT02163668|No Intervention|Control group|No training, just pre and post testing
3059685|NCT02163655|Placebo Comparator|PLACEBO|PLACEBO: placebo, oral, every 24 hours for maximum 5 days
3059686|NCT02163655|Experimental|FUROSEMIDE|FUROSEMIDE: 20mg furosemide, oral, every 24 hours for maximum 5 days
3059687|NCT02163642||Non-CF Bronchiectasis|Cyranose® 320
3059688|NCT02163629|Experimental|psychotherapeutic intervention|"The psychotherapeutic intervention stress management is based on therapeutic, behavioral and cognitive strategies. They are active and put the patient actor of his adaptation of the heart transplantation entire process. The approached components are emotional, cognitive and behavioral (techniques of communication and problem solving)."
3059689|NCT02163629|No Intervention|Usual medical care|
3059690|NCT02163616|Experimental|PPH Treatment|800mcg sublingual misoprostol
3059691|NCT02163603||Pelvic osteotomy|
3059692|NCT02163590|Experimental|2Hz mobilisation|A bilateral postero-anterior mobilisation applied to the fourth thoracic vertebra, at a 2Hz frequency.
3059693|NCT02163590|Experimental|0,5Hz mobilisation|A bilateral postero-anterior mobilisation applied to the fourth thoracic vertebra, at a 0,5Hz frequency.
3059694|NCT02163590|Placebo Comparator|Placebo|A simulation technique, that mimic the other groups, in this case only manual contact will be applied, without any oscillation.
3059695|NCT02163577|Experimental|Burosumab Q4W|Burosumab subcutaneous (SC) injections every 4 weeks (Q4W). Dose is determined by the participant's weight and prescribed dose by their study doctor.
3059696|NCT02163577|Experimental|Burosumab Q2W|Burosumab SC injections every 2 weeks (Q2W). Dose is determined by the participant's weight and prescribed dose by their study doctor.
3059697|NCT02163564|No Intervention|Focus groups|The first part of the study is to conduct focus groups of adolescents with insomnia and depression. The treatment arm is informed by responses provided by teens in the focus group portion.
3059698|NCT02163564|Active Comparator|Treatment|A modified cognitive behavioral therapy for insomnia is the treatment intervention in this treatment arm.
3059699|NCT02163551||Spinal Cord Injury|Participants with spinal cord injury (n = 20) will be age 30-60 years with motor complete spinal cord injuries, otherwise known as American Spinal Injury Association (ASIA) classification A or B, between the levels of C3 and T12. Patients will have to be able to breathe independently without the use of a ventilator. Subjects will be divided equally into four different injury level categories. The four categories are high tetraplegia (C3 - C5), low tetraplegia (C6-C8), high paraplegia (T1-T6), and low paraplegia (T7-T12).
3059700|NCT02163551||Controls|Twenty healthy age-matched adults will also participate.
3059701|NCT02163538|Active Comparator|articulating Enseal|This group of women undergoing total laparoscopic hysterectomy is randomized to the the articulating Enseal energy device.
3059702|NCT02163538|Active Comparator|Ligasure device|This group of women undergoing hysterectomy is randomized to the Ligasure energy device.
3059703|NCT02163525|Active Comparator|Ablation vs Embolization|Women are randomized 1:1 to either global fibroid ablation (GFA) or uterine artery embolization (UAE)
3059704|NCT02163525|Active Comparator|Ablation vs Myomectomy|Women are randomized 1:1 to either global fibroid ablation (GFA) or myomectomy (laparoscopic or abdominal)
3059705|NCT02163512||Non-refractory ascites|
3059706|NCT02163512||Refractory ascites|
3059707|NCT02163499|Experimental|Sodium Zirconium Cyclosilicate|
3059708|NCT02163486|Active Comparator|Group U (UNIQUE)|Group LMA- UNIQUE, inserted according to described standard method. Between 30-40 kg, no.3. Between 50-70 kg, no. 4 Between 70-100 kg, no. 5. LMA-Unique Before SGAD is inserted, a water-based lubricant without local anesthetic, was spread on the surfaces that will touch the palate and LMA-U cuff was completely deflated.oup U (UNIQUE): Group Laryngeal Mask Airway-Unique.
3059709|NCT02163486|Experimental|Group I (I-GEL ): Group I-GEL|Group I (I-GEL): Between 30-60 kg, no. 3. Between 50-90 kg, no. 4. For > 90 kg no.5. I-GEL
3059710|NCT02163473||Septic patients|Blood Draw Biological samples: The investigators will collect blood and compare the expression of HIF complex in 3 distinct ways: between patients and controls, within the same patient in a time-dependent fashion, and between different patients.
3059711|NCT02163473||Healthy Control|The investigators will collect blood and compare the expression of HIF complex in 3 distinct ways: between patients and controls, within the same patient in a time-dependent fashion, and between different patients.
3059712|NCT02163460|Experimental|Drain|In group 1(Drain), a 4.8 mm diameter continuous closed-suction tubular drain : was placed between the aponeurosis and the subcutaneous tissue caudally to the incision.
3059713|NCT02163460|Experimental|Progressive Tension Sutures|Drains were not used in group 2, but separate absorbable polyglactin 920 2/0 sutures were placed from the subcutaneous mesh to the aponeurosis every 2 cm by means of the progressive tension suture (or Quilting Sutures) technique, as described by Pollock et al
3059714|NCT02163447|Active Comparator|3 dose SP pregnancy / 3 monthly DP infancy|"Women will be given SP (3 full strength tabs, 500 mg/25 mg) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
3059715|NCT02163447|Active Comparator|3 dose DP pregnancy / 3 monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
3059716|NCT02163447|Active Comparator|3 dose DP pregnancy / monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 4 weeks between 8 and 104 weeks of age."
3059717|NCT02163447|Active Comparator|monthly DP pregnancy / 3 monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
3059718|NCT02163447|Active Comparator|monthly DP pregnancy / monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days) every 4 weeks between 8 and 104 weeks of age."
3059720|NCT02163434|Experimental|metoclopramide|45-60mg/day divided tid or qid, orally
3059721|NCT02163421|Experimental|Vedolizumab SC 54 mg|Vedolizumab SC, once on Day 1.
3059722|NCT02163421|Experimental|Vedolizumab SC 108 mg|Vedolizumab SC, once on Day 1.
3059723|NCT02163421|Experimental|Vedolizumab SC 160 mg|Vedolizumab SC, once on Day 1.
3059724|NCT02163421|Active Comparator|Vedolizumab IV 300 mg|Vedolizumab IV, once on Day 1.
3059725|NCT02163408||Healthy Volunteers|100 healthy volunteers will take MRI with/without contrast using both conventional protocol and our developed protocol. Image quality and image contrast will be compared between the two protocols.
3059726|NCT02163408||Patients with Carotid Artery Disease|40 patients will take MRI with/without contrast using both conventional protocol and our developed protocol. Image quality, image contrast, and composition analysis will be compared between the protocols.
3059727|NCT02163395|Other|FullCeram implant|Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment hights of 4.0 or 5.5 mm
3059728|NCT02163382|Experimental|Neurovent Monitor XIII|1 hour Ventilation with NAVA
3059729|NCT02163369|Experimental|Peppermint and Lavender Essential Oils|
3059730|NCT02163356|Experimental|Primary therapy|Fenretinide/LXS oral powder 1500 mg/m2/day for 7 days plus ketoconazole 6 mg/kg/day for 7 days plus single dose vincristine (dose escalating) given on day 3. Starting dose of vincristine is 0.75 mg/m2/dose. Followed by 14 days of rest.
3059731|NCT02163343||No treatment|
3059732|NCT02163330|Active Comparator|Acetazolamide|active comparator group will receives 500 mg azetazolamide daily
3059733|NCT02163330|Placebo Comparator|sugar pill|placebo comparator group will receives placebo daily.
3059734|NCT02163317|Experimental|Treatment (MRI-guided focal SRS)|Patients undergo 3 fractions of MRI-guided focal SRS every other day for 1 week. Patients undergo additional MRI scans between the 2nd and 3rd fractionated treatments, at 6 months following the end of radiation therapy, and at 12 and 24 months.
3059735|NCT02163304|Active Comparator|Artificial Sweetner|Artificial Sweetener
3059736|NCT02163304|Placebo Comparator|Tasteless Solution|12 oz tasteless solution
3059737|NCT02163304|Active Comparator|Sucrose|12 oz 75 g sucrose beverage
3059738|NCT02163291|Experimental|paclitaxel liposome|S-1 plus paclitaxel liposome
3059739|NCT02163278|Experimental|DBPR108|
3059740|NCT02163278|Placebo Comparator|matching placebo|
3059741|NCT02163265|Experimental|Surgery|Patients suffering from Pectus excavatum and Pectus carinatum will be surgically treated
3059742|NCT02163252|Active Comparator|Standard|A 12-week internet-based weight loss program that involves weekly video lessons, a self-monitoring platform where participants submit their weight, calorie, and activity information, and weekly automated feedback.
3059743|NCT02163252|Experimental|Early intervention|Participants randomized to Early Intervention will receive the same internet-based weight loss program compared to the Standard group. In addition, Early Intervention participants achieving less than optimal weight loss following several weeks of treatment will be given the opportunity to come to the Weight Control and Diabetes Research Center for an individual visit. At this visit, an interventionist will discuss with the participant any barriers that he or she may be experiencing and recommend alternate strategies to assist in their weight loss. One such strategy would be to recommend the use of meal replacement products or portion controlled meals. In addition to this one-time visit, the interventionist will follow up with the participant via phone weekly, for 2 weeks following this in-person visit.
3059744|NCT02163239||10mm Cannula|Subjects that are scheduled for a robot-assisted laparoscopic single-incision surgery for cholecystectomy, benign hysterectomy or salpingo-oophorectomy under the care of the study investigator
3059745|NCT02163226|Experimental|Hypofractionated Radiation Therapy|Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row. Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
3059746|NCT02163226|Active Comparator|One Radiation Therapy Treatment|12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV). Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
3059747|NCT02163213|Other|Serum Bovine Immunoglobulin|"Serum-Derived Bovine Immunoglobulin (SBI) 5.0 g by mouth twice daily;~Effects of SBI will be compared with observations and measurements performed at baseline PRIOR to starting the SBI treatment"
3059748|NCT02163200||pressure of total hip replacement|Patients 60 y.o. or more both sex with a history of hip arthropathy without previous bedsores or CVA
3059749|NCT02163187|Experimental|InterStimTM the device on|The device will be set to stimulate for 4 weeks, then off for two weeks, and then the device will be on but will not stimulate for 4 weeks.
3059750|NCT02163187|Experimental|InterStimTM the device off|The device will be on but will not stimulate for 4 weeks, then off for two weeks, and then the device will be set to stimulate for 4 weeks.
3059751|NCT02163174|Active Comparator|Pentoxyfilline arm|Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics.
3059752|NCT02163174|Placebo Comparator|Placebo arm|Intravenous saline as a Placebo 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics.
3059753|NCT02163161|Experimental|Treatment A|
3059754|NCT02163161|Experimental|Treatment B|
3059755|NCT02163161|Experimental|Treatment C|
3059756|NCT02163148||Public Speaking Anxiety|Intervention to be administered: One speech exposure session.
3059757|NCT02163122|Experimental|NAC Followed by EEC|This arm will undergo allergy assessment first by NAC. After a rest and washout period, the same individuals will undergo assessment in an EEC.
3059758|NCT02163122|Experimental|EEC Followed by NAC|This arm will undergo allergy assessment first in an EEC. After a rest and washout period, the same individuals will undergo assessment by NAC.
3059798|NCT02162875|Experimental|MDA 2nd year CWT follwed by 2 years SBT|Treatment with praziquantel as arm 1 given by two years of community wide treatment (CWT) followed by two years of school-based treatment (SBT)
3059799|NCT02162875|Experimental|Praziquantel every second year CWT|Treatment with praziquantel given every second year as CWT
3088271|NCT01970878|Experimental|GP MDI (PT001)|
3059759|NCT02163122|Experimental|Dose-finding Phase|An initial group of 6 to 12 participants with cat allergy as defined by the eligibility criteria will undergo a single-visit, stepwise dose-escalating nasal allergen challenge only, with the aim of estimating the most appropriate single dose of allergen to use in the randomized phase. Eligible participants who participate in the dose-finding phase may proceed to the randomized phase of the trial after a minimum 28-day washout period.
3059760|NCT02163109||Critically-ill patients|Adult patients requiring intubation and mechanical ventilation on an intensive care unit, predicted to require a further 48 hours of artificial ventilation
3059761|NCT02163096||History of Wheezing, Benign Joint Hypermobility Syndrome|
3059762|NCT02163096||Asthma, Benign Joint Hypermobility Syndrome|
3059763|NCT02163083|No Intervention|Lymphadenectomy using standard Methods|Lymphadenectomy will be performed as a standard procedure
3059764|NCT02163083|Experimental|Lymphadenectomy using ICG|A fluorescent dye (indocyanine green) will be ultrasound-controlled preoperatively injected in the prostate. During robot-assisted radical intervention by DaVinci ® robot the lymphadenectomy is performed using the fluorescence lymphography.
3059765|NCT02163070|Experimental|whey drink|consumption of 220 milliliters of whey drink three times a week,
3059766|NCT02163070|Experimental|whey drink fortified with vitaminE|consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
3059767|NCT02163070|Experimental|vitaminE|consumption of 400 milligrams of vitamin E three times a week,
3059768|NCT02163070|No Intervention|D- control|control group: no intervention,
3059769|NCT02163057|Other|Surgery Cohort|1.1 mL of INO-3112 (VGX-3100 and INO-9012) delivered IM via CELLECTRA-5P device
3059770|NCT02163057|Other|Chemoradiation|1.1 mL of INO-3112 (VGX-3100 and INO-9012) delivered IM via CELLECTRA-5P device
3059771|NCT02163044||Statin|Patients on statin treatment
3059772|NCT02163031|Active Comparator|right radial approach|devices used in the coronary angiography by right radial approach
3059773|NCT02163031|Active Comparator|left radial approach|devices used in the coronary angiography by left radial approach
3059774|NCT02163018|Experimental|HAL-MPE1|Subcutaneous administration of increasing doses of HAL-MPE1.
3059775|NCT02163018|Placebo Comparator|Placebo|Subcutaneous administration of placebo
3059776|NCT02163005|Experimental|Gadolinium enhancement|Gadolinium enhancement will be performed using intravenous Dotarem[recommended dose of 0.2 mL/kg (0.1 mmol Gd/kg )]
3059777|NCT02162992||SLE and Anti-Ro antibodies Group|Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
3059778|NCT02162992||SLE without Anti-Ro antibodies Group|Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
3059779|NCT02162979|Experimental|Viagra|subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
3059780|NCT02162979|Placebo Comparator|Placebo comparator|subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
3059781|NCT02162966|Experimental|High Dose Colistin|High dose colistin protocol
3059782|NCT02162966|Active Comparator|Standard Dose Colistin|Standard dose of colistin
3059783|NCT02162940||patients taking statins|Visual anlogue score vas used to evaluate pain. The SF 36 test was used to evaluate quality of life.
3059784|NCT02162940||patients not taking statins|Visual anlogue score vas used to evaluate pain.The SF 36 test was used to evaluate quality of life.
3059785|NCT02162927|Experimental|Potassium Nitrate (N)|This involves 1 serving (2 pills) of potassium nitrate KNO3- (N) (8 mmols NO3-). The supplementation period is six days. This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
3059786|NCT02162927|Placebo Comparator|Potassium Chloride|This involves 1 serving (2 pills) of the nitrate-free placebo (PL) potassium chloride (8 mmol KCl) for a six-day supplementation period. This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
3059787|NCT02162914|Active Comparator|Regorafenib/active|Subjects randomized to be treated with Regorafenib (active product) will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off). Duration of one cycle is 28 days.
3059788|NCT02162914|Placebo Comparator|Regorafenib/placebo|Subjects randomized to be treated with Regorafenib (placebo) will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off). Duration of one cycle is 28 days.
3059789|NCT02162901|Experimental|Choice-Class with IVR Calls|Participants enrolled in this arm of the study will have chosen to attend one 2-hour class to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months.
3059790|NCT02162901|Experimental|Choice-DVD with IVR calls|Participants enrolled in this arm of the study will have chosen to watch a DVD at home to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
3059791|NCT02162901|Experimental|Random-Class with IVR calls|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will attend one 2-hour class to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
3059792|NCT02162901|Experimental|Random-DVD with IVR calls|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will be given a DVD to watch at home to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
3059793|NCT02162901|Active Comparator|Random-Class only|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will attend one 2-hour class to be introduced to the intervention and will receive a workbook to use at home.
3059794|NCT02162888|Other|Eagle-BDM; Teva-BDM; Teva-BDM|Eagle-BDM: IV Teva-BDM: IV
3059795|NCT02162888|Other|Teva-BDM; Eagle-BDM;Teva-BDM|Eagle-BDM: IV Teva-BDM: IV
3059796|NCT02162888|Other|Teva-BDM, Teva-BDM, Eagle-BDM|Eagle-BDM: IV Teva-BDM: IV
3059797|NCT02162875|Experimental|MDA once a year|Community wide treatment (CWT) once a year for four years with single dose praziquantel 40mg/kg
3060061|NCT02161146|Experimental|AGN-229666|One drop of AGN-229666 in each eye on Days 1 and 15.
3059800|NCT02162875|Experimental|MDA once a year SBT|Treatment with praziquantel as above given as 4 years of SBT
3059801|NCT02162875|Experimental|MDA given for 2 years as SBT|Treatment with praziquantel as above given for 2 years as SBT followed by 2 years without MDA
3059802|NCT02162875|Experimental|MDA as SBT 1year and 1 year without MDA|Treatment with praziquantel given as one years of SBT alternating with one year without treatment
3059803|NCT02162862|Other|Behavioral Counseling|Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I). This treatment phase focuses on treating insomnia, a nighttime component of sleep disturbance delivered in 1:1 sessions which can be completed in person or by phone, except for initial session.
3059804|NCT02162862|Other|Behavioral counseling + bupropion-SR|Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release). 8-week trial of bupropion-SR (target dose: 200-300 mg/day). bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.
3059805|NCT02162862|No Intervention|Healthy Control|The healthy control group includes individuals who are free of physical and psychiatric illness between the ages of 15-30.
3059806|NCT02162849|Experimental|Varenicline + Placebo Patch|"Varenicline dosing follows the recommended 12 week course: 0.5 milligram mg/day by mouth for Days 1-3, 0.5 mg twice a day for Days 4-7, and 1 mg twice a day thereafter. Participant takes Varenicline 1-10 days after Visit 1.~Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day.~Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone.~Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. During counseling on Day 8, participant sets a quit date for stopping smoking for about 1 week after participant starts taking the study drug/placebo. Some of the counseling sessions may be recorded by video and/or audio tape.~Study staff calls participant 1 day before quit date and 3 days after quit date to check on progress in quitting smoking."
3059807|NCT02162849|Experimental|Nicotine Patch + Placebo Tablet|"Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.~Starting on Day 8, and then every day after that, participant applies 1 nicotine patch.~Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone.~Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. During counseling on Day 8, participant sets a quit date for stopping smoking for about 1 week after participant starts taking the study drug/placebo.~Study staff calls participant 1 day before quit date and 3 days after quit date to check on progress in quitting smoking."
3059808|NCT02162836|Experimental|Cohort 1|Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
3059809|NCT02162823||Pancreatic cancer|Patients with pancreatic cancer and age&sex-matched controls without any cancer from a distinct population area (district of Stockholm). Patients with pancreatic cancer will be subjected to pancreatic surgery
3059810|NCT02162810|Active Comparator|oral steroids|Systemic high-dose steroids (30 mg/kg methylprednisolone) have been shown in a randomized, double-blind, placebo-controlled trial in humans not to negatively impact wound infection or dehiscence rates, instead benefitting patients in the postoperative period in ways such as decreasing pain. An acute course of oral systemic steroids has been routinely used in patients under the age of 12 with asthma exacerbations (liquid prednisolone at 1-2 mg/kg/day in 1-2 divided doses for up to 10 days, although usually given for 5 days, which is at least 19 times less than the dose proven to be safe in the randomized controlled trial mentioned above) and proven to be safe without adverse effects. Effect of prednisolone on the systemic response and wound healing after colonic surgery.
3059811|NCT02162810|Placebo Comparator|placebo-controlled|Simple Syrup will be used as the placebo
3059812|NCT02162797|Experimental|Placebo supplementation|Intervention Group B: Patients who will orally receive a placebo for 3 months.
3059813|NCT02162797|Experimental|zinc supplementation|Intervention group A. Patients who will orally receive zinc for 3 months.
3059814|NCT02162784|Experimental|Budesonide/procaterol 180/10mcg X1|HFA MDI, oral inhalation, 180/10mcg, one puff
3059815|NCT02162784|Experimental|Budesonide/Procaterol, 180/10mcg X2|HFA MDI, oral inhalation, two puffs
3059816|NCT02162784|Active Comparator|Albuterol HFA MDI 100 mcg X2|HFA MDI, oral inhalation, 100mcg, two puffs
3059817|NCT02162771|Experimental|CT-P10-CVP (Cyclophosphamide, Vincristine, Prednisone)|"Drug: CT-P10 (375 mg/m2 IV) given day 1 Drug: Cyclophosphamide (750 mg/m2 IV) given day 1 Drug: Vincristine (1.4 mg/m2 IV) given day 1 Drug: Prednisone (40 mg/m2 Oral) given days 1-5~CT-P10 will be administered upto maximum of 8 cycles during the Core Study Period with CVP (cyclophosphamide, vincristine, prednisone) every 3 weeks. CT-P10 or Rituxan will be administered alone as maintenance in patients who have a response during the Core Study Period."
3059818|NCT02162771|Active Comparator|Rituximab-CVP (Cyclophosphamide, Vincristine, Prednisone)|"Drug: Rituximab (375 mg/m2 IV) given day 1 Drug: Cyclophosphamide (750 mg/m2 IV) given day 1 Drug: Vincristine (1.4 mg/m2 IV) given day 1 Drug: Prednisone (40 mg/m2 Oral) given days 1-5~Rituximab will be administered upto maximum of 8 cycles during the Core Study Period with CVP (cyclophosphamide, vincristine, prednisone) every 3 weeks. CT-P10 or Rituxan will be administered alone as maintenance in patients who have a response during the Core Study Period."
3059819|NCT02162758|Experimental|Dexlansoprazole 60 milligram (mg) QD|Dexlansoprazole 60 mg, delayed-release capsules, orally, QD and dexlansoprazole 60 mg placebo-matching capsules, orally, once daily for up to 12 months.
3059820|NCT02162758|Experimental|Dexlansoprazole 60 mg BID|Dexlansoprazole 60 mg, delayed-release capsules, orally, BID for up to 12 months.
3059821|NCT02162745|Experimental|Isotonic solution (NaCl 0.9%)|Single nasal irrigation with 1 ml of isotonic solution (NaCl 0.9%) per each nostril
3059822|NCT02162745|Experimental|Hypertonic solution (NaCl 3%)|Single nasal irrigation with 1 ml of hypertonic solution (NaCl 3%) per each nostril
3059823|NCT02162745|No Intervention|Supportive care|Wiping the nose, positioning the child, changing a wet diaper, feeding.
3059866|NCT02162459||whey beverage|consumption of 52 grams of whey protein supplement following resistance exercise
3059824|NCT02162732|Experimental|Guided Therapy|A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
3059825|NCT02162719|Experimental|Ipatasertib + Paclitaxel|Participants will receive ipatasertib and paclitaxel in cycles of 28 days (4 weeks) each and study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
3059826|NCT02162719|Placebo Comparator|Placebo + Paclitaxel|Participants will receive placebo and paclitaxel in cycles of 28 days (4 weeks) each and study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
3059827|NCT02162693|Experimental|Mesenchymal progenitor cells|Administrated for intra-articular use of Mesenchymal progenitor cells
3059828|NCT02162693|Active Comparator|Sodium Hyaluronate|Administrated for intra-articular use of Sodium Hyaluronate.
3059829|NCT02162680|Active Comparator|lidocaine|1% lidocaine intradermal injection
3059830|NCT02162680|Active Comparator|bacteriostatic normal saline (BNS)|bacteriostatic normal saline (BNS) injection
3059831|NCT02162680|No Intervention|no local anesthetic|usual care practice of no local anesthetic administration
3059832|NCT02162667|Experimental|CT-P6|
3059833|NCT02162667|Active Comparator|Trastuzumab|
3059834|NCT02162654|Active Comparator|Remote ischemic preconditioning|Inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
3059835|NCT02162654|Sham Comparator|Sham preconditioning|Sham inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
3059836|NCT02162641||SCC of the anus|
3059837|NCT02162628||Exair for Total Repair|Total repair with Exair Prolapse Repair System alone or in combination with native tissue repair
3059838|NCT02162628||Total Native Tissue Repair|Total repair with native tissue only
3059839|NCT02162615||Restorelle Direct Fix A|Anterior/Apical prolapse repair with Restorelle Direct Fix A
3059840|NCT02162615||Native Tissue Repair Anterior|Anterior/Apical prolapse repair with native tissue only
3059841|NCT02162615||Restorelle Direct Fix P|Posterior/Apical prolapse repair with Restorelle Direct Fix P
3059842|NCT02162615||Native Tissue Repair Posterior|Posterior/Apical prolapse repair with native tissue only
3059843|NCT02162589||POEM for Achalasia|Any patient who has undergone clinically indicated and/or standard of care POEM for the treatment of Achalasia.
3059844|NCT02162576|Other|Propeller Health intervention group|All participants attached the Propeller sensor to their SABA medications and tracked the time and location of use for up to 13 months, to capture seasonal variation in medication use, symptoms and environmental triggers. The first 30-day run-in period served as a control period to assess levels of asthma control and SABA use; subject actuations were tracked, but participants and physicians did not receive their data or feedback. After the run-in period, participants received the full intervention for 12 months (see intervention for description).
3059845|NCT02162563|Experimental|Arm B: FOLFOXIRI & bevacizumab|"Patients with RAS or BRAF mutated and/or right-sided tumors will receive 5FU, irinotecan, oxaliplatin (FOLFOXIRI) and bevacizumab.~Intervention: FOLFOXIRI with bevacizumab"
3059846|NCT02162563|Active Comparator|Arm A: FOLFOX/FOLFIRI & bevacizumab|"Patients with RAS or BRAF mutated and/or right-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.~Intervention: FOLFOX/FOLFIRI with bevacizumab"
3059847|NCT02162563|Experimental|Arm D: FOLFOX/FOLFIRI & panitumumab|"Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus panitumumab.~Intervention: FOLFOX/FOLFIRI with panitumumab"
3059848|NCT02162563|Active Comparator|Arm C: FOLFOX/ FOLFIRI & bevacizumab|"Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.~Intervention: FOLFOX/FOLFIRI with bevacizumab"
3059849|NCT02162550|Experimental|Bydureon|injectable medication Bydureon
3059850|NCT02162550|Placebo Comparator|Placebo|a similar looking injectable
3059851|NCT02162537|Other|Arm A (standard arm)|Arm A: Initial Cerebral Radiotherapy and Chemotherapy (Cisplatin and pemetrexed with or without Bevacizumab)
3059852|NCT02162537|Other|Arm B (experimental arm)|Arm B: Chemotherapy (Cisplatin and pemetrexed with or without Bevacizumab) and Cerebral Radiotherapy if clinical or radiological progression brain
3059853|NCT02162524|No Intervention|No Exercise Control|Healthy Living Group
3059854|NCT02162524|Active Comparator|Aerobic Exercise Group|Persons are aerobically exercising.
3059855|NCT02162511|Experimental|ARM A Malignant TBI|Malignant diseases Conditioning including total body irradiation and chemotherapy
3059856|NCT02162511|Experimental|ARM B Malignant Non-TBI|Malignant diseases chemotherapy based conditioning
3059857|NCT02162511|Experimental|ARM C Non-malignant|Non-malignant diseases Chemotherapy based conditioning
3059858|NCT02162498|Experimental|Feeding buddies intervention|Sites receiving a comprehensive feeding buddy program implemented by the Window of Opportunity program.
3059859|NCT02162498|No Intervention|Standard of care|Sites from Window of Opportunity program who are not yet receiving the comprehensive feeding buddies program and are only receiving standard of care PMTCT support.
3059860|NCT02162485|Experimental|Salmeterol/fluticasone Easyhaler|Single dose of Salmeterol/fluticasone Easyhaler
3059861|NCT02162485|Experimental|Salmeterol/fluticasone Easyhaler with charcoal|Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration (Carbomix granules)
3059862|NCT02162485|Active Comparator|Seretide Diskus|Single dose of Seretide Diskus
3059863|NCT02162485|Active Comparator|Seretide Diskus with charcoal|Single dose of Seretide Diskus with concomitant charcoal administration (Carbomix granules)
3059864|NCT02162472||Adalimumab|Subjects will receive adalimumab as standard of care for psoriasis
3059865|NCT02162472||Methotrexate|Subjects will receive methotrexate as standard of care for psoriasis
3059867|NCT02162459||chocolate milk beverage|consumption of chocolate flavored milk following resistance exercise
3059868|NCT02162446|Other|68Ga-OPS202|68Ga-OPS202 will be administered in two sequentially ascending peptide doses
3059869|NCT02162433|Active Comparator|1. Awake extubation/dexmedetomidine|Awake extubation receiving dexmedetomidine.
3059870|NCT02162433|Placebo Comparator|2. Awake extubation/placebo|Awake extubation receiving placebo (normal saline).
3059871|NCT02162433|Active Comparator|3.Deep extubation/dexmedetomidine|Deep extubation receiving dexmedetomidine.
3059872|NCT02162433|Placebo Comparator|4. Deep extubation/placebo|Deep extubation receiving placebo (normal saline).
3059873|NCT02162420|Experimental|Treatment Plan for Dyskeratosis Congenita|Fludarabine based preparative regimen, including alemtuzumab, cyclophosphamide, fludarabine, and total body irradiation, followed by stem cell transplant for the treatment of dyskeratosis congenita.
3059874|NCT02162420|Experimental|Treatment for Severe Aplastic Anemia|Fludarabine based preparative regimen which includes: cyclophosphamide, fludarabine, rabbit ATG and total body irradiation. Followed by stem cell transplant.
3059875|NCT02162407|Experimental|Insulin detemir 60 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
3059876|NCT02162407|Experimental|Insulin detemir 120 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
3059877|NCT02162407|Active Comparator|Human insulin 6 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
3059878|NCT02162394||Referred for Holter monitoring|
3059879|NCT02162381|Experimental|methylphenidate provided|the study group will be given a single pill containing methylphenidate 10mg to be taken 2 hours before their visual field test
3059880|NCT02162381|Active Comparator|control|control group will not be given any placebo and will perform a repeat visual field testing without any prior preparation
3059881|NCT02162355|Experimental|GLPG0634 in Japanese subjects|Per panel, 6 Japanese healthy subjects will receive one of the three doses (50 mg, 100 mg or 200 mg) of GLPG0634 as tablets once daily for 10 days
3059882|NCT02162355|Placebo Comparator|Placebo in Japanese healthy subjects|Per panel, 2 or 4 (last panel only) Japanese healthy subjects will receive placebo as tablets once daily for 10 days
3059883|NCT02162355|Experimental|GLPG0634 in Caucasian subjects|In the last panel, 6 Caucasian healthy subjects will receive one dose of GLPG0634 (200 mg) as tablets once daily for 10 days
3059884|NCT02162355|Placebo Comparator|Placebo in Caucasian healthy subjects|In the last panel, 4 Caucasian healthy subjects will receive receive placebo as tablets once daily for 10 days
3059885|NCT02162342||Rehabilitative intervention|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
3059886|NCT02162329|Other|Healthy Control Group|Healthy participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete. Electroencephalography (EEG) and magnetic resonance imaging (fMRI) scan performed. These should take a total of about 90 minutes to complete.
3059887|NCT02162329|Experimental|Tibetan Meditation Group|Participants fill out several questionnaires at baseline, at completion of meditation classes, and at follow up visit. The forms should take about 30 minutes to complete. Participants complete computer tests to check memory and concentration taking about 20 minutes to complete. Electroencephalography (EEG) performed at baseline, at completion of classes, and at follow up visit. Participants have magnetic resonance imaging (fMRI) scan of brain at baseline, at completion of meditation classes, and at follow up visit. Tests, EEG, and fMRI should take a total of about 90 minutes to complete. Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
3059888|NCT02162329|Other|Wait-List Group|"Participants fill out several questionnaires at baseline and at follow up visit. The forms should take about 30 minutes to complete. Participants complete computer tests to check memory and concentration taking about 20 minutes to complete. Tests, EEG, and fMRI should take a total of about 90 minutes to complete. Participants receive the standard of care for cancer patients.~After 8 week follow up visit, Wait-List Group offered meditation program."
3059889|NCT02162316|Active Comparator|H.Pylori eradication therapy|A-cillin®, Pantoline® and Clari® is administered with a tablet of placebo (Motilitone®)
3059890|NCT02162316|Experimental|Motilitone®|30 mg is administered with 3 tablets of placebo (Patoline®, Clari® and A-cilin)
3059891|NCT02162303|Experimental|Colchicine|Colchicine 0.6 mg tablets,once daily, for 6 months
3059892|NCT02162303|Placebo Comparator|Placebo|Sugar,given once daily, over 6 months.To mimic active treatment.
3059893|NCT02162290|Experimental|Interval exercise|Exercise bouts in low and high intensities
3059894|NCT02162290|Experimental|Continuous exercise|Exercise continuously with moderate intensity
3059895|NCT02162277||Osteoporosis diagnostic kit|
3059896|NCT02162264||E2020|
3059897|NCT02162251||E2020|
3059898|NCT02162238|Placebo Comparator|purified water|Filtered water Pump water purified by the LSF-filtering device Intervention: Device: LSF-filtering device
3059899|NCT02162238|Experimental|zinc enriched purified water|Zinc water water purified and zinc-enriched by the LSF-filtering device Intervention: Device: LSF-filtering device
3059900|NCT02162225|Experimental|Beet Juice|"Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days.~On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28."
3059901|NCT02162212|Active Comparator|ADA guideline Instructed|The control intervention will be instruction in basic wellness activities according to the American Diabetes Association guidelines
3059902|NCT02162212|Experimental|Optimized Shoulder Movement Program|"The experimental intervention is the Optimized Shoulder Movement Program. Participants will be trained in a progressive home exercise program that includes passive stretching of end range shoulder flexion and external rotation, and active shoulder motion based on the participant's baseline activity count ."
3059903|NCT02162199|Experimental|Debio 1450|Debio 1450 40 mg, capsules, orally, once in the morning under fasted conditions
3060058|NCT02161185|Other|USL261|
3059904|NCT02162199|Placebo Comparator|Placebo|Placebo 0 mg, matching capsules, orally, once in the morning under fasted conditions
3059905|NCT02162173|Experimental|Endoscopy|All patients underwent the same endoscopy.
3059906|NCT02162160|Experimental|Probiotic creme|Women receing probiotic creme
3059907|NCT02162160|Placebo Comparator|placebo|Women receiving a moisturizer
3059908|NCT02162134|Other|no chewing gum.|the no chewing gum group was control and receive no chewing gum postoperatively. While they received all other medications like anesthesia, antibiotics etc
3059909|NCT02162134|Experimental|sugar free chewing gum|sugar free chewing was given to patients 4 hours after surgery then continue it 8 hourly (20 to 25 minutes each time) until oral feeding is started.
3059910|NCT02162134|Experimental|sugared chewing gum|sugared chewing gum will be given 4 hours after surgery then continue it 8 hourly (20 to 25 minutes each time) until oral feeding is started
3059911|NCT02162121|Experimental|Stimulating catheter|"After Spinal Anesthesia (Levobupivacaine 0,5% 15mg) all patients in the arm will receive continuous lumbar plexus block with stimulating catheter (Stimolong, Pajunk, Germany). Mepivacaine 1% 15 ml will be administrated. As post-operative analgesia Ropivacaine 0,2% will be continuous administrated."
3059912|NCT02162121|Active Comparator|Non-stimulating catheter|"After Spinal Anesthesia (levobupivacaine 0,5% 15mg) all patients in the arm will receive continuous lumbar plexus block with non-stimulating catheter (Stimolong, Pajunk, Germany). Mepivacaine 1% 15ml will be administrated. As post-operative analgesia Ropivacaine 0,2% will be continuous administrated."
3059913|NCT02162095||Chronic obstructive pulmonary disease|Approximately 100 participants with documented chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) < 0.7).
3059914|NCT02162095||Control|Approximately 100 participants with exclusion of chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) > 0.7).
3059915|NCT02162082|Experimental|stent or scaffold|implantation of stents or scaffolds after recanalization of coronary chronic total occlusions
3059916|NCT02162069|Experimental|transcatheter aortic valve replacement|Patients receive transcatheter aortic valve replacement.
3059917|NCT02162056|Experimental|use of bioresorbable vascular scaffolds|Implantation of bioresorbable vascular scaffold for coronary artery disease.
3059918|NCT02162043||Usability assessment|Patients without any experience with visual field testing will be recruited and tested with different versions of the developed self-test. This will help identify usability features that will make the test user-friendly.
3059919|NCT02162043||Hospital-based clinical trial|The new test will be evaluated on patients attending Manchester Royal Eye Hospital to provide an estimate of its diagnostic performance.
3059920|NCT02162043||Community-based trial|Patients attending Manchester Royal Eye Hospital's outpatient clinics will be recruited to trial the new test on their friends and family in order to evaluate the uptake and performance of the new test in a home environment without any researchers/clinicians presence.
3059921|NCT02162030|Other|Full ACT|Acceptance and Commitment Therapy
3059922|NCT02162030|Other|Modified ACT|Acceptance and Commitment Therapy
3059923|NCT02162017|Experimental|The lying flat intervention|Patients in lying flat intervention to be nursed lying flat (0°) immediately after diagnosis of acute stroke is made and to remain in this position for 24 hours
3059924|NCT02162017|Active Comparator|The sitting-up intervention|Patients in the sitting up intervention to be nursed with their head elevated (≥30°) by raising the head of the bed (or with extra pillows or wedge) immediately after the diagnosis of acute stroke is made, and to remain in this position for the next 24 hours
3059925|NCT02162004|Experimental|Continuous correction|The insulin pump is set to automatically deliver the patient's usual insulin basal rate. The insulin pump bolus calculator is run every 10 minutes by the attending physician. Bolus calculations are based on glucose sensor values.
3059926|NCT02162004|No Intervention|Control|Regular sensor-augmented pump therapy.
3059927|NCT02161991|Experimental|aprepitant group|Patients assigned to aprepitant group should receive aprepitant for the control of CINV, aprepitant 125 mg for day1, 80mg for day2 and day3.
3059928|NCT02161991|Placebo Comparator|placebo|Patients assigned to placebo group should receive placebo for the control of CINV compared with aprepitant group.
3059929|NCT02161965|Experimental|Rivaroxaban|"Rivaroxaban (oral tablet) for patients with atrial fibrillation:~20 mg once daily for patients with GFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with GFR of 15 to 49 ml.~Rivaroxaban (oral tablet) for patients with pulmonary embolism: 2 x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing"
3059930|NCT02161965|Active Comparator|vitamin K antagonists|Adjusted dose of warfarin or fluindione (oral tablet) titrated according to target international normalized ratio with a target range 2.0 to 3.0.
3059931|NCT02161952|Experimental|Pirfenidone|Pirfenidone 400 mg capsules, orally administered thrice daily to yield a daily dose of 1200 mg during two years.
3059932|NCT02161952|Placebo Comparator|Matched equivalent placebo|Matched equivalent placebo
3059933|NCT02161926|Experimental|obese men from 60 to 70 years old|Dietary restrictions in obese men (30<Body Mass Index<40 kg/m2)
3059934|NCT02161926|Active Comparator|obese men from 30 to 40 years old|Dietary restrictions in obese men (30<Body Mass Index<40 kg/m2)
3059935|NCT02161913|Active Comparator|SCI Education Control Group|The SCIEC condition is a 16-session, highly structured educational intervention that provides information on how SCI affects the body; methods for maximizing function, coping, and living with SCI; and staying healthy with SCI. It also includes general guidelines for improving health behavior. Each SCIEC session follows the same structure, beginning with a presentation of the objectives for the current session and a brief review of material from the previous session before introducing the session's topic and presenting information on one or two key problem areas. SCIEC utilizes a traditional didactic model with information delivered by an expert SCI educator in a classroom or lecture setting.
3059936|NCT02161913|Experimental|Multi-family Group Treatment|The MFG Program uses a structured problem-solving and skills training program to provide participants with SCI and their caregivers with tools and information to improve coping and help family members to connect through positive behavioral exchanges. MFG educators are health professionals with experience in management of SCI, such as physical therapists, recreational therapists, occupational therapists, and psychologists. MFG will last for 16 sessions across 9 months.
3059937|NCT02161900|No Intervention|Routine exercise|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
3059938|NCT02161900|Experimental|Yogic and Routine exrcises (exercise I)|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
3059939|NCT02161887||Complementary Medicine Group|Patients receiving chiropractic care, acupuncture, or meditation for chronic pain
3059940|NCT02161887||Conventional Medicine Group|Patients receiving conventional medicine care (physical therapy, medication management) for chronic pain.
3059941|NCT02161874|Experimental|T3 with DCD tapered implant|T3 with DCD tapered prevail implant
3059942|NCT02161874|Active Comparator|Nanotite certain tapered implant|Nanotite Certain tapered implant
3059943|NCT02161861|Experimental|group cFEE|"The group cFEE will be similarly inseminated with 105/ml motile spermatozoa and will be supplemented with cFEE 100µM during 18 hours.~The cFEE will increase the fusiogenic capacities of a gamete,"
3059944|NCT02161861|No Intervention|untreated group|control group
3059945|NCT02161848||Patients|Patients with verified singe large-scale mtDNA deletions and chronic progressive external ophthalmoplegia.
3059946|NCT02161848||Controls|Healthy controls matched for age and gender.
3059947|NCT02161848||Patient group as Controls|Patients with mitochondrial DNA 3243A>G mutations
3059948|NCT02161835|Experimental|Training|Participants exercise 3 times a week, 30 minute, on an ergometer bike.
3059949|NCT02161835|No Intervention|Control|Participants is tested with the 4 objective myotonia test and measurements of self-assessed myotonia by the Myotonia Behavior Scale is collected.
3059950|NCT02161822|Experimental|Simvastatin|single arm : Simvastatin
3059951|NCT02161809|Experimental|Physical Activity Intervention|This arm (10 summer day camps) will receive the Physical Activity intervention the first year and both healthy eating and physical activity the second and thrid years.
3059952|NCT02161809|Other|Healthy EAting Intervention|This arm (10 summer day camps) will receive the Healthy Eating intervention the first year and both healthy eating and physical activity the second and thrid years.
3059953|NCT02161796|Experimental|1: young male subjects|3x single dose of FG-4592 and a placebo
3059954|NCT02161796|Experimental|2: young female subjects|3x single dose of FG-4592 and a placebo
3059955|NCT02161796|Experimental|3: elderly male subjects|3x single dose of FG-4592 and a placebo
3059956|NCT02161796|Experimental|4: elderly female subjects|3x single dose of FG-4592 and a placebo
3059957|NCT02161783||Treatment|This regimen consists of cyclophosphamide and fludarabine with low dose total body irradiation (TBI), followed by hematopoietic stem cell infusion.
3059958|NCT02161770|Other|Normal hepatic function|Patients without a history or presence of hepatic disease
3059959|NCT02161770|Other|Mild hepatic impairment|Patients defined by the Child-Pugh classification system to be Child-Pugh A
3059960|NCT02161770|Other|Moderate hepatic impairment|Patients defined by the Child-Pugh classification system to be Child-Pugh B
3059961|NCT02161757|Experimental|Tralokinumab Dose Regimen 1|Tralokinumab subcutaneous injection
3059962|NCT02161757|Placebo Comparator|Placebo Dose Regimen 1|Placebo subcutaneous injection
3059963|NCT02161757|Experimental|Tralokinumab Dose Regimen 2|Tralokinumab subcutaneous injection
3059964|NCT02161757|Placebo Comparator|Placebo Dose Regimen 2|Placebo subcutaneous injection
3059965|NCT02161744|Experimental|ADSCs administration|Patients with Chronic Obstructive Pulmonary Disease will be treated with a single dose of autologous adipose derived stem cells. Stem cells will be isolated using standard Lipoaspiration procedure under sterile conditions.
3059966|NCT02161731|Active Comparator|Warfarin|15 milligram (mg) warfarin administered as a single oral dose on Day 1
3059967|NCT02161731|Experimental|Evacetrapib + Warfarin|Evacetrapib administered once daily (QD), orally, for 16 days with 15 milligram (mg) warfarin co-administered once orally on Day 10
3059968|NCT02161718|Experimental|Samidorphan + olanzapine (ALKS 3831)|Active study drug
3059969|NCT02161718|Placebo Comparator|Placebo + olanzapine|
3059970|NCT02161705|Experimental|Ropivacaine Group|Paravertebral block injections of study solution will occur using the landmark-based classic technique with a 22-gauge Tuohy needle to deliver 0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg).
3059971|NCT02161705|Placebo Comparator|Saline Group|Paravertebral block injections of normal saline (up to 0.8 mL/kg) will occur using the landmark-based classic technique with a 22-gauge Tuohy needle. Immediately after completion of the injections, patients will be repositioned supine and general anesthesia induced in the standard manner.
3059972|NCT02161692|Experimental|High dose chemotherapy|"Characterized by the following sequence:~High dose cyclophosphamide (7 grams/squared meter) x 1 cycle 2 cycles of high-dose etoposide and cisplatin~1 cycle of high dose carboplatin (Area Under the Curve 27) with stem cell rescue"
3059973|NCT02161692|Active Comparator|Conventional dose chemotherapy|Cisplatin, Etoposide, and Bleomycin (PEB) x 4 cycles
3059974|NCT02161679|Experimental|IMMU-132|IMMU-132 infusion is administered
3059975|NCT02161679|Active Comparator|IMMU-132 plus Carboplatin|IMMU-132 infusion and Carboplatin infusion are administered to the participants in this arm of study.
3059976|NCT02161666||Patients|Morbidly obese patients with normal glucose tolerance undergoing gastric bypass surgery
3059977|NCT02161666||Controls|Age, sex and BMI-matched healthy controls
3059978|NCT02161653|No Intervention|Prednisone|Prednisone 40 mg daily by mouth during 30 days.
3059979|NCT02161653|No Intervention|Pentoxifylline|Pentoxifylline 400 mg thrice in day by mouth during 30 days
3059980|NCT02161653|Experimental|Prednisone plus metadoxine|Prednisone 40 mg daily by mouth plus Metadoxine 500 mg thrice in day by mouth during 30 days.
3059981|NCT02161653|Experimental|Pentoxifylline plus metadoxine|Pentoxifylline 400 mg thrice in day by mouth plus Metadoxine 500 mg thrice in day by mouth during 30 days.
3060059|NCT02161172||Mild traumatic brain injury|Traumatic brain injury patients with Glasgow coma score (GCS) of 13-15.
3059982|NCT02161640||Control|Age/sex matched control participants, not suffering from inflammatory bowel disease or any other chronic inflammatory disease
3059983|NCT02161640||Inflammatory Bowel Disease|Patients with active or remissive inflammatory bowel disease
3059984|NCT02161627|Experimental|Automatic Control|Automatic Control using Saluda Medical External Trial System
3059985|NCT02161627|Active Comparator|Manual Control|Manual Control using Saluda Medical External Trial System
3059986|NCT02161614|Placebo Comparator|Placebo|Patients will use placebo for 30 days
3059987|NCT02161614|Experimental|Estradiol Valerate|patients will use estradiol valerate 1mg/day during 30 days
3059988|NCT02161601|Experimental|Correctly and incorrectly applied cricoid pressure|
3059989|NCT02161588|Experimental|Semaglutide|
3059990|NCT02161588|Placebo Comparator|Placebo|
3059991|NCT02161575|Experimental|Ranibizumab|All patients will receive 3 monthly intraveal injections of 0.5mg ranibizumab followed by monthly injections of ranibizumab 0.5mg for a further 3 months on a prn (as required) basis, as determined by the study doctor.
3059992|NCT02161562|Experimental|omalizumab 150mg|Participants received 150mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period (at 150mg or 300mg) may have been implemented based on protocol-defined assessment criteria.
3059993|NCT02161562|Experimental|omalizumab 300mg|Participants received 300mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period may have been implemented based on protocol-defined assessment criteria.
3059994|NCT02161549||Colonoscopy with MotusGi CleanUp System Rev 1.0|subjects indicated for colonoscopy procedure with CleanUp System Rev 1.0 , enrolled under protocol Rev 1.0
3059995|NCT02161549||Colonoscopy with MotusGi CleanUp System Rev 1.5|subjects indicated for colonoscopy procedure with CleanUp System Rev 1.5 , enrolled under protocol Rev 2.0
3059996|NCT02161536|Experimental|CleanC Colonoscopy|
3059997|NCT02161510|Experimental|Part I: MK-2248 200 mg (Panel A)|HCV participants will take MK-2248 200 mg by mouth once daily for 7 days.
3059998|NCT02161510|Experimental|Part I: MK-2248 ≤800 mg (Panel B)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
3059999|NCT02161510|Experimental|Part I: MK-2248 ≤800 mg (Panel C)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth for 7 days.
3060000|NCT02161510|Experimental|Part I: MK-2248 ≤800 mg (Panel D)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
3060001|NCT02161510|Experimental|Part II: MK-2248 200 mg (Panel E)|HCV participants will take MK-2248 200 mg by mouth once daily for 7 days.
3060002|NCT02161510|Experimental|Part II: MK-2248 ≤800 mg (Panel F)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
3060003|NCT02161510|Experimental|Part II: MK-2248 ≤800 mg (Panel G)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
3060004|NCT02161510|Experimental|Part II: MK-2248 ≤800 mg (Panel H)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
3060005|NCT02161510|Experimental|Part III: MK-2248 ≤800 mg (Panel I)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
3060006|NCT02161510|Experimental|Part III: MK-2248 ≤800 mg (Panel J)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
3060007|NCT02161484|Experimental|Continuous Lumbar Plexus Block with Parasacral Nerve Block|"Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.~A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected."
3060008|NCT02161484|Active Comparator|Lumbar Plexus Nerve Block|"Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.~No sham/placebo parasacral (sciatic) blocks will be performed in this group."
3060009|NCT02161471||Aortic coarctation|Patients after repair of coarctation of the aorta
3060010|NCT02161471||Tetralogy of Fallot|Patients after repair of tetralogy of Fallot
3060011|NCT02161471||TGA atrial switch|Patients with transposition of the great arteries after atrial switch (Senning procedure)
3060012|NCT02161471||TGA arterial switch|Patients with transposition of the great arteries after arterial switch operation
3060013|NCT02161471||Normal|Normal controls
3060014|NCT02161458|Experimental|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20mg for 2 weeks (upward titration as: 10mg for 5 days, then 20mg for 9 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 2 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
3060015|NCT02161458|Placebo Comparator|Placebo (sugar pill)|30 cognitively normal adults aged 60-85 will receive placebo for 2 weeks (upward titration as: 10mg for 5 days, then 20mg for 9 days) or 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 51 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 2 or 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
3060060|NCT02161159||Patients With Urinary Incontinence Due to iOAB|Patients with urinary incontinence due to iOAB treated with BOTOX® in accordance with physician standard practice.
3060016|NCT02161458|Experimental|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 5 days; then 30 mg for 46 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
3060017|NCT02161458|Experimental|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20mg for 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 51 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
3060018|NCT02161445||AHF group|patients with AHF diagnosed based on clinical, biological and echocardiographic findings.
3060019|NCT02161445||non AHF group|
3060020|NCT02161432|Experimental|Treatment A|single dose of BI 187004 in fasted state
3060021|NCT02161432|Experimental|Treatment B|single dose of BI 187004
3060022|NCT02161432|Experimental|Treatment C|single dose of BI 187004 in fed state
3060023|NCT02161419|Active Comparator|BAY1000394|Roniciclib 5 mg bid 3 days on / 4 days off in combination with chemotherapy (carboplatin/etoposide or cisplatin/etoposide) during 6 cycles (21 days each) followed by monotherapy
3060024|NCT02161419|Placebo Comparator|Placebo|Matching placebo 3 days on / 4 days off in combination with chemotherapy (carboplatin/etoposide or cisplatin/etoposide) during 6 cycles (21 days each) followed by monotherapy
3060025|NCT02161406|Active Comparator|Abatacept|125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
3060026|NCT02161406|Placebo Comparator|Placebo|125mg Placebo
3060027|NCT02161393|Experimental|Physical Activity Intervention|12 week home-based walking programme consisting of weekly physical activity consultations and a pedometer-driven walking programme
3060028|NCT02161393|Active Comparator|Pulmonary Rehabilitation Programme|6-week supervised outpatient programme consisting of twice-weekly exercise sessions and once-weekly education sessions.
3060029|NCT02161380|Experimental|1(Chronic)|injection of scAAV2-P1ND4v2
3060030|NCT02161380|Experimental|2(Acute)|injection of scAAV2-P1ND4v2
3060031|NCT02161380|Experimental|3(Presymptomatic)|injection of scAAV2-P1ND4v2
3060032|NCT02161367|Experimental|Simethicone, OVOL|Patients in the intervention arm will receive, in a blinded fashion, 160mg of simethicone orally four times a day for the first five postoperative days. Patients will be evaluated by a trained research assistant on a daily basis while in hospital. Passage of flatus, bowel movements, and postoperative pain will be evaluated at those visits. A two-week, and 30-day phone call to patients discharged from hospital will be done to assess for outcomes after discharge. Follow-up will end after the 30th postoperative day.
3060033|NCT02161367|Placebo Comparator|Oral Suspending Vehicle, Ora-Plus|Patients in the control arm will receive, in a blinded fashion, 160mg of the placebo orally four times a day for the first five postoperative days. The placebo will be prepared by pharmacy to be identical to the test drug formulation except for being pharmacologically inert. Patients will be evaluated by a trained research assistant on a daily basis while in hospital. Passage of flatus, bowel movements, and postoperative pain will be evaluated at those visits. A two-week, and 30-day phone call to patients discharged from hospital will be done to assess for outcomes after discharge. Follow-up will end after the 30th postoperative day.
3060034|NCT02161354|Experimental|2mg dose of NTC-510 or placebo|Subjects will be dosed with 2 mg of NTC-510 or placebo.
3060035|NCT02161354|Experimental|4 mg dose of NTC-510 or placebo|Subjects will be dosed as a split dose of 2 mg followed by 2 mg an hour later of NTC-510 or placebo.
3060036|NCT02161354|Experimental|6 mg dose of NTC-510 or placebo|Subjects will be dosed with 6 mg of NTC-510 or placebo.
3060037|NCT02161354|Experimental|2 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 2mg of NTC-510A or placebo
3060038|NCT02161354|Experimental|4 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 4 mg of NTC-510A or placebo
3060039|NCT02161354|Experimental|6 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 6 mg of NTC-510A or placebo
3060040|NCT02161328||ICU patients undergoing a dilatative tracheotomy.|
3060041|NCT02161315||Observation group|Steroid Aromatase Inhibitors
3060042|NCT02161315||Control group|Non-Steroid Aromatase Inhibitor
3060043|NCT02161302|Experimental|Active tDCS|tDCS will be applied in the head of the patients in 20 minute sessions, daily from Monday to Friday for 2 weeks (10 sessions total). The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area, and it will use a 2 mA current.
3060044|NCT02161302|Sham Comparator|tDCS Sham|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
3060045|NCT02161276|Experimental|TNTL capsule and Placebo|3-4 capsules 3 times a day Used before meals
3060046|NCT02161263||Quality of Vision after LASIK surgery|Questionnaire
3060047|NCT02161250|Experimental|Resistant starch|The test beverage consumed has the resistant starch.
3060048|NCT02161250|Experimental|Control|The control beverage uses maltodextrin rather than the resistant starch.
3060049|NCT02161237|Experimental|standard dose group|Oral
3060050|NCT02161237|Experimental|optimized dose group|Oral
3060051|NCT02161224|Experimental|1: FG-4592 in subjects with moderate hepatic impairment|
3060052|NCT02161224|Experimental|2: FG-4592 in healthy subjects|
3060053|NCT02161211|Experimental|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
3060054|NCT02161211|Experimental|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
3060055|NCT02161211|Experimental|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
3060056|NCT02161198|Experimental|Y-75|volunteers receive 3 packages twice a day up to 14 weeks
3060057|NCT02161198|Placebo Comparator|Placebo|volunteers receive 3 packages twice a day up to 14 weeks
3060062|NCT02161146|Placebo Comparator|Vehicle|One drop of Vehicle to AGN-229666 in each eye on Days 1 and 15.
3060063|NCT02161146|Active Comparator|Olopatadine|One drop of olopatadine in each eye on Days 1 and 15.
3060064|NCT02161146|Other|AGN-229666/Olopatadine|One drop of AGN-229666 in one eye and one drop of olopatadine in the other eye on Days 1 and 15.
3060065|NCT02161146|Other|AGN-229666/Vehicle|One drop of AGN-229666 in one eye and one drop of Vehicle to AGN-229666 in the other eye on Days 1 and 15.
3060066|NCT02161133|Experimental|Problem-Solving Therapy|Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
3060067|NCT02161133|Active Comparator|Health Education|Health education provides didactic information about Gulf War Illness
3060068|NCT02161120|Active Comparator|Traditional rye bread|As part of habitual diet participants are expected to consume 100-200 grams of traditional Finnish rye bread daily
3060069|NCT02161120|Experimental|Low-FODMAP rye bread|As part of habitual diet participants are expected to consume 100-200 grams of low-FODMAP rye bread daily
3060070|NCT02161107|Experimental|Grass-SPIRE 1|Grass-SPIRE regimen 1 given 2 weeks apart
3060071|NCT02161107|Experimental|Grass-SPIRE 2|Grass-SPIRE regimen 2 given 2 weeks apart
3060072|NCT02161107|Placebo Comparator|Placebo|Placebo given 2 weeks apart
3060073|NCT02161094|Experimental|Group 1: Physicians|Give incentives to physicians based on their patient's HbA1c improvement
3060074|NCT02161094|Experimental|Group 2: Diabetic patients|Give incentives to patients based on their own HbA1c improvement
3060075|NCT02161094|Experimental|Group 3: Both Physicians and Patients|Give incentives to both based on the HbA1c improvements from the physicians' patients
3060076|NCT02161094|No Intervention|Group 4: Control group|Receive no incentive but will be provided diabetes education booklet and group education courses for DM control as usual
3060077|NCT02161081|Experimental|Myocardial CT perfusion (21-second)|A total of 60 symptomatic patients will be randomized to dynamic CT perfusion protocol with 21-second scan duration.
3060078|NCT02161081|Active Comparator|Myocardial CT perfusion (30-second)|A total of 60 symptomatic patients will be randomized to dynamic CT perfusion protocol with 30-second scan duration.
3060079|NCT02161055|Experimental|Strict control group|"Intensive insulin therapy: Keep Target blood glucose levels between 4.4-7.0 mmol/L;~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours."
3060080|NCT02161055|Experimental|Moderate control group|"Intensive insulin therapy: Keep target blood glucose levels between 7.1 and 10.0 mmol/L.~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours"
3060081|NCT02161055|Experimental|Slight control group|"Intensive insulin therapy: Keep target blood glucose levels between 10.1 and 13.0 mmol/L.~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours."
3060082|NCT02161055|Active Comparator|Non-intensive insulin therapy|Rapid blood glucose levels were measured once every 2 hours. When blood glucose levels were ≤ 13.0 mmol/L, no intervention was performed; When blood glucose levels were > 13.0 mmol/L, regular insulin was subcutaneously injected separately. During fasting, insulin was injected once every 8 hours. During venous or enteral nutrition infusion, insulin was infused at 30 minutes before nutrition infusion. When blood glucose levels were ≤ 13.0 mmol/L, insulin infusion was terminated.
3060083|NCT02161042||fresh blood Transfusion|
3060084|NCT02161042||Old blood transfusion|
3060085|NCT02161029|Active Comparator|New drill biopsy instrument|To take biopsies from gastric submucosal tumors with a new drill biopsy instrument used with flexible endoscopes.
3060086|NCT02161029|Active Comparator|Conventional biopsy instrument|To take biopsies from gastric submucosal tumors with conventional biopsy forceps used with flexible endoscopes
3060087|NCT02161016|Other|map3 allogeneic bone graft|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
3060088|NCT02161003|Experimental|Stem Cells Isolation|"Stem cell isolation technique and Stem Cells Injection Technique The method of isolation of MSC from bone marrow will be carried out using the Ficoll-Paque technique for the isolation of mononucleated cells followed by the separation of MSC by adherence to plastic. Finally, the cells will be resuspended and counted using a hemocytometer.~Mononucleated cells will be cultured and incubated at 37°C in an atmosphere of 95% relative humidity and 5% CO2."
3060089|NCT02160990|Experimental|Exenatide|Participants randomized to this arm received 5 mcg exenatide subcutaneously twice daily for 30 days.
3060090|NCT02160990|Placebo Comparator|Placebo|Participants randomized to this arm received placebo subcutaneously twice daily for 30 days.
3060091|NCT02160977|Experimental|QS-TKA|patients underwent minimally invasive surgery quadriceps sparing total knee arthroplasty (MIS-QS TKA)
3060092|NCT02160977|Active Comparator|MIS-TKA|patients underwent minimally invasive surgery total knee arthroplasty (MIS TKA)
3060093|NCT02160951|Experimental|LGH447|LGH447, QD
3060094|NCT02160938||3 year follow-up cohort|"When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.~At as close to the age of 3 as possible, the following exams will be performed and are described below:~The Vineland-II Adaptive Behavior Scale (VABS)~Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)~Children will also be photographed (for review by the study dysmorphologist)"
3060095|NCT02160938||Limited follow-up cohort|Women with children who will not reach the age of 2 years 6 months by the end of our study but have a prenatally diagnosed CNV will be recruited into the limited follow-up study. Each center will describe the study to eligible women and will verbally obtain their permission to be contacted by the Study Follow-up Specialist. The Study Follow-Up Specialist will contact the patient, explain the study, and obtain full written informed consent.
3060096|NCT02160925|Experimental|Preoperative 99mTc-Sestamibi SPECT/CT|
3060097|NCT02160912||Ectoin Mund- & Rachenspray|treatment with Ectoin Mund- & Rachenspray 1%
3060098|NCT02160912||Emser Pastillen|treatment with Emser Pastillen
3060138|NCT02160639|Active Comparator|diabetes self management support|diabetes self management support in addition to usual care, which includes diabetes self management education
3060099|NCT02160899|Experimental|ISIS-APO(a)Rx|Drug: ISIS-APO(a)Rx Once-weekly dose administered subcutaneously of ISIS-APO(a)Rx from Day 1 to Day 78. Patients will receive 100 mg of ISIS-APO(a)Rx on Days 1, 8, 15, 22. Patients will receive 200 mg of ISIS-APO(a)Rx on Days 29, 36, 43, 50 unless down titrated. Patients will then receive 300 mg of ISIS-APO(a)Rx on Days 57, 64, 71, 78 unless down titrated.
3060100|NCT02160899|Placebo Comparator|Placebo (Normal Saline)|Drug: Placebo (Normal Saline) Once-weekly dose administered subcutaneously of Placebo from Day 1 to Day 78. Patients will receive 100 mg Placebo on Days 1, 8, 15, 22. Patients will receive 200 mg Placebo on Days 29, 36, 43, 50 unless down titrated. Patients will then receive 300 mg Placebo on Days 57, 64, 71, 78 unless down titrated
3060101|NCT02160886|Experimental|Child-goal|"The children will receive goal- directed task oriented interventions based on goals identified by the children themselves, using the Swedish version of the Perceived Efficacy and Goal Setting System (PEGS).~A PEGS interview will be performed with the children. The children identifies tasks they find difficult to perform and prioritize three tasks, they want to perform better, as goals for intervention."
3060102|NCT02160886|Experimental|Parent-goal|"The children will receive goal- directed task oriented interventions based on goals identified by the parents using the Canadian Occupational Performance Measure (COPM).~Using the COPM interview technique, the parents are encouraged to talk about an ordinary day to identify occupational performance issues their child is not able to perform. Identified performance issues are rated for importance and the parents selects the three most important issues as goals for intervention."
3060103|NCT02160873|Experimental|chocolate milk|In this arm, subjects receive chocolate milk
3060104|NCT02160873|Placebo Comparator|flavor-matched placebo|In this arm, subjects receive a flavor-matched placebo
3060105|NCT02160860||Children|Children
3060106|NCT02160847|Experimental|DRIVE program|Participants in the experimental group will receive the DRIVE curriculum (15 sessions) via weekly sessions conducted in their home by a DRIVE provider.
3060107|NCT02160847|No Intervention|Control Group|"The parents in the control group will be mailed information on nutrition, physical activity, and parent-child interactions. Information on nutrition will include guidelines provided by the MyPlate website (http://www.choosemyplate.gov/preschoolers.html) in addition to information on proper nutrition and suggest levels of physical activity for preschoolers. Lastly, parents will be provided with the free publication, Adventures in Parenting: How responding, Preventing, Monitoring, Mentoring, and Modeling Can Help You Be A Successful Parent, authored by National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development. Information covered in this document includes effective parenting strategies for children at specific ages."
3060108|NCT02160834|Experimental|B-MOBILE smartphone-based intervention (3-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
3060109|NCT02160834|Experimental|B-MOBILE Smartphone-Based Intervention (6-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
3060110|NCT02160834|No Intervention|Control|
3060111|NCT02160821|Experimental|Transversus Abdominis Plane Block|Transversus Abdominis Plane Block TAPB Ultrasound guided TAPB
3060112|NCT02160821|Experimental|Caudal Epidural Block|Caudal Epidural Block Caudal Block Neuraxial Block Ultrasound Guided Caudal Block
3060113|NCT02160808|Active Comparator|Secretin|Stimulate pancreatic secretion
3060114|NCT02160808|Placebo Comparator|Saline|Placebo should not stimulate the pancreas to release its fluids
3060115|NCT02160782|Experimental|LUM001|LUM001 administered orally once each day
3060116|NCT02160782|Placebo Comparator|Placebo|Placebo administered orally once each day during randomized withdrawal period
3060117|NCT02160756|Active Comparator|Treatment A|Single oral dose of JNJ-56021927 240 milligram (mg) softgel capsule on Day 1.
3060118|NCT02160756|Experimental|Treatment B|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
3060119|NCT02160756|Experimental|Treatment C|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
3060120|NCT02160756|Experimental|Treatment D|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
3060121|NCT02160743|Experimental|CJ-30056 20mg/500mg|fasting, fed
3060122|NCT02160743|Experimental|group 2|fed, fasting
3060123|NCT02160730|Experimental|R-roscovitine|• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.
3060124|NCT02160717||Turner Syndrome|Female with Turner Syndrome
3060125|NCT02160717||Healthy Controls|Healthy Female
3060126|NCT02160704|Experimental|Arm 1(IP)|Enclomiphene citrate capsules 25 mg 1x daily for 16 weeks
3060127|NCT02160704|Placebo Comparator|Arm 2 (Placebo)|Placebo capsule 1x daily for 16 weeks
3060128|NCT02160691|Experimental|Anxiety Meter|The Anxiety Meter (experimental) group will receive a real-time display of physiological arousal on the Anxiety Meter during the intervention period in visit #4.
3060129|NCT02160691|No Intervention|No Anxiety Meter|The control group will have the Anxiety Meter during the intervention period, but the marker will not move.
3060130|NCT02160678|Active Comparator|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G & W Laboratories, Inc.) - test product
3060131|NCT02160678|Other|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
3060132|NCT02160678|Placebo Comparator|Vehicle|Cream Vehicle (placebo) (G & W Laboratories, Inc.)- vehicle
3060133|NCT02160665|Placebo Comparator|Vehicle|Vehicle of Test product (G & W Laboratories, Inc.)
3060134|NCT02160665|Other|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
3060135|NCT02160665|Active Comparator|Test:Tazarotene Cream, 0.05%|Test: Tazarotene Cream, 0.05% (G & W Laboratories, Inc.)
3060136|NCT02160652||Patients|Patients with malignant ureteral obstruction, treated with laparoscopic ureteral re-implantation, who have a life expectancy of over 6 months and are willing and able to participate in the study.
3060137|NCT02160639|No Intervention|usual care|usual care includes diabetes self management education
3060139|NCT02160626|Placebo Comparator|A-101 Vehicle|A-101 Vehicle (placebo) Topical Solution
3060140|NCT02160626|Active Comparator|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
3060141|NCT02160626|Active Comparator|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
3060142|NCT02160613|Other|Open flap for periodontitis patients|Open flap debridement
3060143|NCT02160600|Experimental|split bolus|Patients will undergo diagnostic Split bolus DECT scan
3060144|NCT02160600|Experimental|Standard|Patients will undergo routine multiphase diagnostic CT
3060145|NCT02160587|Active Comparator|ZuraPrep|Irritation scores of the following applied to test sites will be compared: ZuraPrep, ZuraPrep without IPA, ChloraPrep, and 0.9% Physiological Saline.
3060146|NCT02160574|Active Comparator|ZuraPrep|ZuraPrep will be compared statistically to ZuraPrep without IPA and both to the Positive Control (0.1% Sodium Lauryl Sulfate). The degree of skin irritation caused by the Reference Product (ChloraPrep) and the Negative Control (0.9% Physiological Saline) will be graded.
3060147|NCT02160561|Experimental|Intervention Arm|Experimental - Intervention Arm patients who are in critical illness with acute respiratory failure and are mechanically ventilated will be placed in an upright reverse trendelenburg position
3060148|NCT02160548|Placebo Comparator|'Standard care'|Standard care= Intravenous fluids, Oxygen by face mask, Intubation if necessary, Mechanical ventilation (Engstrom Pro by GE) if necessary, Cardiac monitor (Infunix IP4050), Atropine (anti-muscarinic drug; G-Atropine) by intravenous route, Pralidoxime (acetylcholinesterase reactivating oxime drug; PAM-A) by intravenous route.
3060149|NCT02160548|Experimental|'Standard care+ 2.5 mg Salbutamol'|Standard care+ 2.5 mg Salbutamol= Nebulized salbutamol (Ventolin respiratory solution) 2.5 mg stat and once only with standard care
3060150|NCT02160548|Experimental|'Standard care+ 5 mg Salbutamol'|Standard care+ 5 mg Salbutamol= Nebulized salbutamol (Ventolin respiratory solution) 5 mg stat and once only with standard care
3060151|NCT02160535|Experimental|Treatment with OnabotulinumtoxinA|OnabotulinumtoxinA
3060152|NCT02160522||Cuffed ETT|Patients that are intubated with a cuffed endotracheal tube.
3060153|NCT02160509||- The patients who undergo ultrasonography in the ED|
3060154|NCT02160496|Active Comparator|20% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 20% protein, 30% fat and 50% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
3060155|NCT02160496|Active Comparator|27% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 27% protein, 30% fat and 43% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
3060156|NCT02160496|Active Comparator|35% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 35% protein, 30% fat and 35% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
3060157|NCT02160483|Experimental|Magnetic resonance imaging|Functional magnetic resonance imaging using arterial spin labelling, functional connectivity, diffusion tensor imaging, magnetic resonance spectroscopy to evaluate women with chronic pelvic pain and/ or endometriosis
3060158|NCT02160470|Experimental|Exposure with Retrieval|Exposure Therapy with Retrieval
3060159|NCT02160470|Experimental|Exposure with Compounding|Exposure Therapy with Compound Extinction
3060160|NCT02160470|Experimental|Exposure with Retrieval and Compounding|Exposure Therapy with Retrieval and Compound Extinction
3060161|NCT02160470|Active Comparator|Therapist-Guided Exposure Therapy|Therapist-guided Exposure Therapy
3060162|NCT02160457|Experimental|Intervention with IGA|Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis (IGA)
3060163|NCT02160457|No Intervention|Intervention without IGA|'Care as usual' - Individually tailored interdisciplinary interventions based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations BUT NOT (IGA).
3060164|NCT02160444|Experimental|CBT plus Parent as CBT Coach Training|CBT plus Parent as CBT Coach Training
3060165|NCT02160431|Experimental|CBT for pediatric OCD|Participants complete standard CBT for OCD
3060166|NCT02160418|No Intervention|Control|36 Participants will be sent a new toothbrush and will be asked to use it in place of their current brush. They also receive twice daily reminders via sms to brush their teeth.
3060167|NCT02160418|Experimental|Financial Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. They will also be offered financial incentives twice a day to brush their teeth.
3060168|NCT02160418|Experimental|Cognitive Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. Twice a week, they will receive text messages (SMS) with a short quiz question related to oral hygiene behavior and oral health. Participants will receive a reward if they answer correctly via text message.
3060169|NCT02160418|Experimental|Financial and Cognitive Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. Twice daily they receive financial incentives to brush their teeth. Twice a week, they will receive text messages (SMS) with a short quiz question related to oral hygiene behavior and oral health. Participants will receive a reward if they answer correctly via text message.
3060170|NCT02160405|Experimental|Normal diet|
3060171|NCT02160392||Endometrial biopsy|HIV + and HIV negative women underwent lower and upper genital tract sampling.
3060172|NCT02160379||post Roux-en-Y-gastric bypass|Formerly obese females 1-5 years after gastric bypass
3060173|NCT02160379||matched controls|non-operated females age-and weight-matched to post Roux-en-Y-gastric bypass subjects
3060174|NCT02160379||healthy young controls|non overweight (BMI between 19 and 25 kg/m2) healthy females
3060175|NCT02160366||Biomarker/Molecular Data Collection and Analyzation|Advanced cancer participants
3060176|NCT02160353|Experimental|Combined hormonal therapy|Abiraterone acetate: 1000mg/day (four 250g tablets, orally once a day) for 126 days Prednisolone; 5mg/day (1 tablet orally once a day, concomitant to abiraterone acetate) for 126 days GnRh agonist for 4 injections (at 28 day intervals)
3060177|NCT02160340||Vitreomacular adhesion|Male or female subjects aged over 40 years with vitreomacular adhesion
3060178|NCT02160314|Placebo Comparator|pad|absorbent pad control
3060180|NCT02160301|Experimental|Multimodal pain control|Oxycodone 5-15mg PO q4hrs prn pre- and post-op, Acetaminophen 1000mg IV once pre-op, Acetaminophen 1000mg PO q8hrs pre-op and x2 weeks post op, prn thereafter, Gabapentin 100mg/200mg PO a8hrs pre-op and x2 weeks post op, Dexamethasone 8mg IV once intra-op, Celecoxib 400mg PO once pre-op.
3060181|NCT02160301|Active Comparator|Standard pain control|Oxycodone 5-15mg PO q4hrs prn, Acetaminophen 1000mg PO q8hrs prn.
3060182|NCT02160288|Active Comparator|Botulinum Toxin-A|Patients will receive Botulinum Toxin-A (Botox) injected in the puborectalis muscle and external anal sphincter. We will use 100 units of Botox, a dose with a good safety profile that has been proven to work in previous studies performed in adults.
3060183|NCT02160288|Placebo Comparator|Normal saline|Patients will receive normal saline (placebo) injected in the puborectalis muscle and external anal sphincter.
3060184|NCT02160275|Active Comparator|Open Loop|4 days patient-managed insulin pump therapy with blinded continuous glucose monitoring
3060185|NCT02160275|Experimental|Closed Loop|4 days of automated blood glucose control with the Artificial Pancreas (Inreda Diabetic BV)
3060186|NCT02160262|Experimental|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed
3060187|NCT02160249|Experimental|Community-based rehabilitation and facility based care|"Community-based rehabilitation is delivered to participants and their caregivers at their home by a specialist CBR worker. It comprises psychoeducation, adherence support, rehabilitation (including self-care and social skills), family support groups and accessing existing community organisations. It also involves community awareness raising and education and mobilisation of community leaders.~Facility based care (usual care) consists of anti-psychotic medication prescribed by a nurse or clinical officer in a health centre and basic psycho-education."
3060188|NCT02160249|Active Comparator|Facility-based care|Facility based care (usual care) consists of anti-psychotic medication prescribed by a nurse or clinical officer in a health centre and basic psycho-education.
3060189|NCT02160236|Active Comparator|dexketoprofen trometamol|before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
3060190|NCT02160236|Active Comparator|tenoxicam|before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc
3060191|NCT02160236|Placebo Comparator|serum physiologic|before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
3060192|NCT02160223|Experimental|Sugammadex|Group S patients will receive 2 mg kg -1 sugammadex at the end of surgery
3060193|NCT02160223|Active Comparator|Neostigmine|Group N patients will receive 50 µg kg-1 neostigmine and 05 mg atropin at the end of surgery
3060194|NCT02160210|Experimental|Ultrafine Endoscope|The ultrafine endoscope for colonoscopy with water method is performed in screening the colorectal diseases.
3060195|NCT02160197|No Intervention|No Immobilisation|No immobilisation post op, allowing patients to weight bear as tolerated.
3060196|NCT02160197|Active Comparator|Functional Bracing|Immobilise patients in Functional brace, allowing patients to weight bear as tolerated.
3060197|NCT02160197|Active Comparator|Plaster Immobilisation|Immobilise patients in plaster, allowing patients to weight bear as tolerated.
3060198|NCT02160171||Term neonates|Term neonates who are undergoing continuous video amplified Electroencephalogram (aEEG)/Electroencephalogram (EEG) monitoring for clinical purposes (e.g. because seizures were suspected, or the neonate is being treated with therapeutic hypothermia). EEGs will be analysed off line by 'Algorithm for Neonatal Seizure Recognition'
3060199|NCT02160158|Experimental|Cohort 1|
3060200|NCT02160158|Experimental|Cohort 2|
3060201|NCT02160145|Experimental|Tolvaptan|Tolvaptan (OPC-41061)
3060202|NCT02160145|Placebo Comparator|Placebo|Placebo
3060203|NCT02160132|Experimental|A 1-2-3Group|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
3060204|NCT02160132|Active Comparator|B 1-3-5Group|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
3060205|NCT02160119||Healthy Controls|
3060206|NCT02160119||Autism Spectrum Disorders|
3060207|NCT02160106|Experimental|TEW-7197|Dose Escalation of TEW-7197: TEW 7191 tablets will be given once daily (QD) or twice daily (BID) for 5 days followed by 2 days without treatment in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
3060208|NCT02160080|Experimental|Boc+Peg-int alfa+Rbv|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
3060209|NCT02160067|Experimental|Treatment A|Second generation patch BTDS 12.6mg
3060210|NCT02160067|Experimental|Treatment B|Second generation patch BTDS 3.15mg
3060211|NCT02160067|Active Comparator|Treatment C|First generation patch BuTrans 20mg
3060212|NCT02160067|Active Comparator|Treatment D|First generation patch BuTrans 5mg
3060213|NCT02160054||Group 1|patients with kidney transplantation who converted the immunosuppressant from cyclosporine to Graceptor ®
3060214|NCT02160041|Experimental|BGJ398|BGJ398 will be dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
3060215|NCT02160028|Active Comparator|Standard information|This group is given anesthetics and standard information before dental treatment about the anesthetics.
3060216|NCT02160028|Experimental|Extended information|This group is given anesthetics and extended information before dental treatment about the anesthetics.
3060217|NCT02160015|Experimental|Treatment (lenalidomide, ibrutinib, rituximab)|Patients receive rituximab IV on day 1 (up to 6 courses), lenalidomide PO QD on days 1-21 (up to 12 courses), and ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3060218|NCT02160002|Active Comparator|Lower Weight (1600 grams)|Weaning from an incubator at a lower weight (1600 grams)
3060219|NCT02160002|Active Comparator|Higher Weight (1800 grams)|Weaning from an incubator at a higher weight (1800 grams)
3060220|NCT02159989|Experimental|Treatment (sapanisertib, ziv-aflibercept)|Patients receive sapanisertib PO QD on days 2-4, 9-11, 16-18, and 23-25 and ziv-aflibercept IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3060221|NCT02159976|Active Comparator|Sequential therapy|pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)
3060222|NCT02159976|Experimental|Modified bismuth quadruple therapy|pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)
3060223|NCT02159963|Experimental|Supervised training|8 weeks of high intensity training three times a week, once supervised. Followed by 8 weeks home based, unsupervised optional training.
3060224|NCT02159963|Experimental|Unsupervised training|"Participants have 8 weeks of non-intervention Control period, followed by 8 weeks of home based, unsupervised high intensity interval training."
3060225|NCT02159950|Experimental|Arm I (sipuleucel-T)|Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
3060226|NCT02159950|Experimental|Arm II (tasquinimod, sipuleucel-T)|Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
3060227|NCT02159937||Patients with metastatic cancer|Blood sampling by vena punction.
3060228|NCT02159924||Asymptomatic|
3060229|NCT02159911||200 mcg misoprostol|Misoprostol administered orally one hour before surgery
3060230|NCT02159911||400 mcg misoprostol|Misoprostol administered orally one hour before surgery
3060231|NCT02159898|Experimental|EndoMAXX Endoluminal Valve Technology (EVT)|EndoMAXX Endoluminal Valve Technology (EVT) Fully Covered Esophageal Stent with Valve
3060232|NCT02159898|Active Comparator|EndoMAXX|EndoMAXX Fully Covered Esophageal Stent
3060233|NCT02159885|Experimental|Telemonitoring|In this arm, subjects will receive usual care at the sleep clinic as well as telemonitoring of their use of their automatically adjusting continuous positive airway pressure pressure (APAP) machine. They will receiving phone calls for poor adherence and/or poor efficacy of treatment.
3060234|NCT02159885|No Intervention|Usual Care|"Subjects in this arm will receive usual care for management of obstructive sleep apnea and use of automatically titrating continuous positive airway pressure."
3060235|NCT02159872|Experimental|Omacetaxine|Omacetaxine 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle. Participant may continue taking the study drug for up to 24 cycles of treatment.
3060236|NCT02159859|Experimental|Ertapenem|Subjects with end stage renal disease (ESRD) who undergo hemodialysis three times a week and without infection will be administered one gram of ertapenem once over five minutes through infusion access after a hemodialysis session, and will have blood drawn at time 0, 0.5, 1, 2, 6, and 12 hours after the ertapenem administration and once prior to the next hemodialysis session
3060237|NCT02159846||Test Group and Control Group|20 patients with established T2DM were recruited from the M-OPD, HTAA, Kuantan; and equally divided into the Test and the Control groups (10 patients in each group).These patients were either fed with 4 g daily mixed herbs (on wet weight basis) or placebo (maize starch).
3060238|NCT02159846||Test Group & Control Group|20 patients with established T2DM were recruited from the M-OPD, HTAA, Kuantan; and equally divided into the Test and the Control groups (10 patients in each group).These patients were either fed with 4 g daily mixed herbs (on wet weight basis) or placebo (maize starch).
3060239|NCT02159833|Experimental|Intervention|Intranasal challenge with food protein or vehicle control
3060240|NCT02159820|Active Comparator|DTC Arm|Patients are randomly assigned to receive lower-dose decitabine treatment followed by TC regimen (ie, DTC arm).
3060241|NCT02159820|Active Comparator|TC regimen|Patients were randomly assigned to receive carboplatin plus paclitaxel (ie, TC arm).
3060242|NCT02159807|Active Comparator|1.25 mg Bupivacaine|This study is a comparison of three different dosages of the local anesthetic (Bupivacaine) that the investigator frequently use in the spinal. 1.25mg is one of them, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), and of its effects on the patient's blood pressure (risk of maternal's drop of the blood pressure with possible bad effects on the blood flow to the baby), on the patient's baby's heart rate (risk of slowing down of the baby heart rate as a consequence of decreased blood flow to the baby), and the patient's pain relief (higher dose of medications are usually more effective for maternal pain relief but have side effects that can be bad for the mother and the baby).
3060243|NCT02159807|Active Comparator|1.66 mg Bupivacaine|This study is a comparison of three different dosages of the local anesthetic (Bupivacaine) that the investigators frequently use in the spinal. 1.66mg is one of them, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), and of its effects on the patient's blood pressure (risk of maternal's drop of the blood pressure with possible bad effects on the blood flow to the baby), on the patient's baby's heart rate (risk of slowing down of the baby heart rate as a consequence of decreased blood flow to the baby), and the patient's pain relief (higher dose of medications are usually more effective for maternal pain relief but have side effects that can be bad for the mother and the baby).
3060244|NCT02159807|Active Comparator|2.5 mg Bupivacaine|This study is a comparison of three different dosages of the local anesthetic (Bupivacaine) that the investigators frequently use in the spinal. 2.5mg is one of them, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), and of its effects on the patient's blood pressure (risk of maternal's drop of the blood pressure with possible bad effects on the blood flow to the baby), on the patient's baby's heart rate (risk of slowing down of the baby heart rate as a consequence of decreased blood flow to the baby), and the patient's pain relief (higher dose of medications are usually more effective for maternal pain relief but have side effects that can be bad for the mother and the baby).
3060245|NCT02159794|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
3060246|NCT02159781|Experimental|periodontal treatmnent|
3060247|NCT02159768|Experimental|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
3060248|NCT02159755|Experimental|Treatment (ibrutinib, palbociclib)|Patients receive ibrutinib PO QD on days 1-28 and palbociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3060249|NCT02159742||Cohort 1|
3060250|NCT02159729|Placebo Comparator|Placebo|Subjects treated with placebo in previous ATX-101 studies
3060251|NCT02159729|Experimental|ATX-101 (1 mg/cm2)|Subjects treated with ATX-101 (1 mg/cm2) in previous phase 2 studies
3060252|NCT02159729|Experimental|ATX-101 (2 mg/cm2)|Subjects treated with ATX-101 (2 mg/cm2) in previous phase 2 studies
3060253|NCT02159729|Experimental|ATX-101 (4 mg/cm2)|Subjects treated with ATX-101 (4 mg/cm2) in previous phase 2 studies
3060254|NCT02159716|Experimental|Metastatic Pancreatic (ductal) adenocarcinoma (PDA)|
3060255|NCT02159716|Experimental|Serious Epithelial Ovarian Cancer|
3060256|NCT02159716|Experimental|Malignant Epithelial Pleaural Mesothelioma|
3060257|NCT02159703|Experimental|Single Arm Phase 2|
3060258|NCT02159677||Healthy Subjects|Healthy subjects aged 21-80 years with no history of present or past disabling back or neck pain, sciatica, cervical radiculopathy, or any generalized neuromuscular condition except for mild polyneuropathy or common mononeuropathies (e.g. carpal tunnel syndrome, ulnar neuropathy at the elbow.) Additionally, subjects cannot have any history of any moderate-to-severe ongoing medical condition producing generalized disability, such as advanced cardiac or renal disease, or metal spine implants of any type.
3060259|NCT02159677||Radiculopathy Subjects|Subjects aged 21-80 years with a history consistent with radiculopathy based on clinical, radiologic, and standard electrophysiological criteria, as determined by spine expert.
3060260|NCT02159677||Musculoskeletal Back Pain Subjects|Subjects aged 21-80 years with low back or neck pain without evidence to suggest neuropathic component; i.e. without radiation of pain, sensory loss or weakness.
3060261|NCT02159677||Undiagnosed Lower Back or Neck Pain Subjects|Subjects aged 21-80 years with a major complaint of lower back or neck pain.
3060262|NCT02159664|Experimental|didgeridoo practice|
3060263|NCT02159651||1: Dermatomyositis group|patients with interstitial pneumonia associated with dermatomyositis
3060264|NCT02159651||2: Polymyositis group|patients with interstitial pneumonia associated with polymyositis
3060265|NCT02159638|Other|comparisson CGM accuracy|Each patient will have both subcutaneous tissue CGM sensors (Guardian Enlite sensor and Dexcom G4 Platinum sensor) inserted at the same time. The HemoCue Analyser- venous blood and finger-stick blood in cuvette, will be used to measure the concentration of glucose
3060266|NCT02159625|Experimental|Abdominal Compression Elastic Support|To compress the abdomen at 15 mmHg for 3 hours during the course of hemodialysis treatment.
3060267|NCT02159612||FSHD|A cohort of adult danish patients with facioscapulohumeral muscular dystrophy is invited to perform a MRI scan.
3060268|NCT02159599|Active Comparator|Darunavir/Ritonavir + 2 nucleos(t)idos|Darunavir/Ritonavir ( (800mg/100mg) + Tenofovir/emtricitabine (300mg/200mg) or Abacavir/lamivudine (600 mg/300mg)
3060269|NCT02159599|Experimental|Darunavir/ritonavir + Lamivudine|Darunavir/Ritonavir (800mg7100mg) + lamivudine (300mg)
3060270|NCT02159560|Active Comparator|End holed catheter|Single holed, end holed epidural catheter
3060271|NCT02159560|Active Comparator|Three holed catheter|closed ended, three side holed epidural catheter
3060272|NCT02159547|Active Comparator|Dexketoprofen|50 mg intravenous dexketoprofen in 50 ml normal saline in 5 minutes infusion.
3060273|NCT02159547|Placebo Comparator|normal slaline|50 ml normal saline
3060274|NCT02159534|Experimental|Primebrain|"' Stimulation ' Infants group will receive Primebrain stimulation whose items were selected according to a Delphi process and discussed at the European Academy of Childhood Disability (2013).~This sensorimotor stimulation programme is administered at home by parents (trained and monitored by a physical therapist), once a day between term-age and 6 months of corrected age.~In addition, these infants undergo systematic monitoring for preterm and infants born with low birth weight as organized in Belgium ( INAMI convention )."
3060275|NCT02159534|Other|usual care|"Infants in the comparison group receive usual care for preterm and infants born with low birth weight as organized in Belgium ( INAMI convention )."
3060276|NCT02159521|Experimental|prospective, single-arm|EkoSonic endovascular system in the treatment of chronic deep vein thrombosis
3060277|NCT02159508|No Intervention|Individualised on-demand counselling|Individualized on-demand counselling group was assigned to receive baseline nutritional counselling, that consisted of one dietetic consultation before (chemo)radiotherapy. During (chemo)radiotherapy on-demand counselling group patients received further counselling only on demand.
3060278|NCT02159508|Experimental|Intensive nutritional counselling|Intensive nutritional counselling consisted of protocolled counselling given by a dietitian once at baseline and on the 2nd and 4th week of treatment and at the end of chemoradiotherapy.
3060279|NCT02159495|Experimental|Treatment (lymphodepletion, T-cell immunotherapy)|Patients undergo a lymphodepleting regimen 3-10 days prior to CD123+ CAR T cell infusion as determined by the principal investigator and the protocol team. Patients receive either cyclophosphamide IV on days -4 and/or -3; fludarabine phosphate and cyclophosphamide IV on days -5 to -3; fludarabine phosphate IV on days -5 to -3 and cyclophosphamide IV on days -4 and/or -3. Patients receive autologous or allogeneic CD123+ CAR Tcells IV over 15 minutes on day 0. Patients with evidence of disease at > 28 days, continuing expression of the CD123 antigen, and not having experienced a DLT may receive a second infusion of CD123+ CAR T cells after 28 days.
3060280|NCT02159482|Experimental|interferon-alfa-2a|Starting within 6 months after completion of the dendritic cell vaccine, a dose of interferon alfa-2a will be administered subcutaneously in the skin of the arm, thigh or abdomen every other day for a total of 6 injections.
3060281|NCT02159469|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
3060282|NCT02159456|Experimental|Continuous enteral feeding|Continuous enteral feeding via infusion pump is applied for at least 7 days after the start of enteral feeding
3060283|NCT02159456|Active Comparator|Intermittent enteral feeding|Intermittent enteral feeding via gravity-based infusion is applied for at least 7 days after the start of enteral feeding.
3060284|NCT02159443||Study Participants|Those who meet eligibility criteria and consent to participate in the study.
3060285|NCT02159430||HereditaryAngioEdema|Patients from the Eastern Sicily HAE register
3060286|NCT02159417|Experimental|Therapeutic Education|Intensive training individual or collective teaching
3060287|NCT02159404||Allergic Rhinoconjunctivitis|Patients with diagnosed Allergic Rhinoconjunctivitis
3060288|NCT02159404||Healthy controls|
3088272|NCT01970878|Experimental|FF MDI (PT005)|
3060289|NCT02159391|No Intervention|Usual Intervention|A standard intervention will be performed by nursing staff during hospital admission. Written information about the consequences of driving under the influence of alcohol and/or drugs will be provided. No psychological intervention.
3060290|NCT02159391|Experimental|Brief Motivational Interview|A Brief Motivational Interviewing will be performed during hospital admission by a psychologist experienced with this intervention.
3060291|NCT02159378|Other|GD with Insulin treatment|"At the end of the study patients will be divided into two groups: GD with Insulin treatment versus GD without Insulin treatment In each group, the serum fructosamines rate will be estimated with a confidence interval of 95% and compared from a Student test."
3060292|NCT02159378|Other|GD without Insulin treatment|"At the end of the study patients will be divided into two groups: GD with Insulin treatment versus GD without Insulin treatment In each group, the serum fructosamines rate will be estimated with a confidence interval of 95% and compared from a Student test."
3060293|NCT02159365|Experimental|Elotuzumab + Lenalidomide/Dexamethasone|Elotuzumab 10 mg/kg solution intravenously weekly in cycle 1 and 2, then every other week, Lenalidomide 25 mg tablet by mouth Days 1-21 of each cycle / Dexamethasone 40 mg tablet by mouth / solution intravenously weekly until progression or discontinuation of Elotuzumab
3060294|NCT02159352|Experimental|Group 1: Daclatasvir and Darunavir/Ritonavir|"Treatment A: Daclatasvir oral tablet on specific days~Treatment B: Daclatasvir tablet and Darunavir Tablet/Ritonavir capsule orally on specific days"
3060295|NCT02159352|Experimental|Group 2: Daclatasvir and Lopinavir/Ritonavir|"Treatment C: Daclatasvir oral tablet on specific days~Treatment D: Daclatasvir tablet and Lopinavir/Ritonavir tablet orally on specific days"
3060296|NCT02159339||gene-methylation|"gene-low-level of methylation: patients with early stage gastric carcinoma containing low-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.~gene-middle-level of methylation: patients with early stage gastric carcinoma containing middle-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.~gene-high-level of methylation: patients with early stage gastric carcinoma containing high-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.~gene-without of methylation: patients with early stage gastric carcinoma NOT containing methylated E-cadherin,GFRA1,p16,SRF or ZNF382 CpG island."
3060297|NCT02159326|Experimental|Arm1|single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
3060298|NCT02159326|Experimental|Arm2|multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment, a single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
3060299|NCT02159313|Experimental|BAY63-2521 with Non sparkling water|Single dose of a whole 2.5 mg riociguat tablet (fasted) with 240 mL of non-sparkling water at room temperature
3060300|NCT02159313|Experimental|BAY63-2521 with applesauce|Single dose of a crushed 2.5 mg riociguat tablet suspended in 50 mL applesauce, to be eaten with a spoon (fasted)
3060301|NCT02159313|Experimental|BAY63-2521 with water|Single dose of a crushed 2.5 mg riociguat tablet suspended in a glass with 25 mL water, to be drunk and flushed twice with 25 mL water in the same glass (fasted)
3060302|NCT02159313|Experimental|BAY63-2521 after breakfast|Single dose of a whole 2.5 mg riociguat tablet taken within 5 minutes after the last bite of a continental breakfast (fed) with 240 mL of non-sparkling water at room temperature
3060303|NCT02159300||Patients|Patients with fibromyalgia pain Intervention: experience brain activity recording
3060304|NCT02159300||Healthy Controls|Healthy controls without chronic pain of any type.
3060305|NCT02159287|Experimental|Low molecular-weight heparin|these patients will receive 1 mg of enoxaparin (clexane) per kilogram of body weight subcutaneous every 12 hour with warfarin 5mg QD and both drugs will be continued until the target INR level (2.5) is reached then clexane will be discontinued.
3060306|NCT02159287|Active Comparator|unfractionated heparin|This group will receive continuous intravenous unfractionated heparin sodium infusion 1000 unit per hour initially and then the dose will be adjusted to maintain a therapeutic aPTT level (two times to baseline) then warfarin will be started (5 mg QD).
3060307|NCT02159274||BCS without oncoplastic techniques|BCS without oncoplastic techniques
3060308|NCT02159274||BCS with oncoplastic techniques|BCS with oncoplastic techniques.
3060309|NCT02159261||Cohort 1|Female patients ≥ 18 years old requiring contraception.
3060310|NCT02159248|Experimental|Tolfenamic acid + gemcitabine + radiation|
3060311|NCT02159235||AIHD-patients (ICD-10 I21)|Patients suffering from acute ischemic heart disease according to ICD-10 I21
3060312|NCT02159235||CIHD-patients (ICD-10 I25)|patients suffering from chronic ischemic heart disease according to ICD-10 I25
3060313|NCT02159222|Experimental|Additional physical therapy|
3060314|NCT02159209||Drug Induced Renal Injury (DIRI)|This is a prospective observational cohort study of patients who have developed acute kidney injury Stage 2 or a glomerular disorder following exposure to specific drugs that have been associated with DIRI.
3060315|NCT02159196|Active Comparator|acetylcysteine and salbutamol|Nebulisation of 3 mL-solution of acetylcysteine (fluimucil 100mg/ml, a mucolytic) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml, a bronchodilator), administered every 6 hours (i.e., 4 times per day) within 24 hours after initiation of ventilation until tracheal extubation.
3060316|NCT02159196|Experimental|acetylcysteine or salbutamol|"Nebulisation on strict clinical indications; nebulisation of 3 mL-solution of acetylcysteine (fluimucil 100mg/ml, a mucolytic) in case of occurrence of persistent thick and tenacious sputum and only after active humidification is set.~Nebulisation of 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml, a bronchodilator) in case of occurrence of bronchospasm."
3060317|NCT02159183|Experimental|Standard Plus ESTA STL Roxolid implant|This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA).
3060318|NCT02159183|Active Comparator|Standard Plus STL implant|This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck.
3060319|NCT02159170|Experimental|NGF|injection of 50 µl NGF, once into the left volar forearm and injection of 50 µl NaCl (sodium chloride) once into the right volar forearm
3060320|NCT02159157|No Intervention|Arm A|"Physical Therapy consult for post op care and general physical activity recommendation 1-4 weeks prior to starting chemotherapy.~Phone calls designed to support the patient to maintain current activity level."
3060321|NCT02159157|Placebo Comparator|Arm B|"Physical Therapy consult for post-op care 1-4 weeks prior to starting chemotherapy.~Exercise prescription aimed at increasing physical activity by a minimum of 10 MET hours/week.~Motivational phone calls aimed at encouraging the patient to adhere to their exercise prescription."
3060322|NCT02159144|Experimental|healthy adults|
3060323|NCT02159131|Experimental|OC containing levonorgestrel and ethinyl estradiol + GSK126574|Eligible subjects will enter a run-in-period of 21 days (may extend to 49 days) to stabilize on OC containing levonorgestrel and ethinyl estradiol in order to synchronize the menstrual cycles of multiple subjects. Subjects completing run-in-period will enter Treatment period 1 and will be dosed OC once daily on Days 1 to 10. At day 11 subjects will enter Treatment period 2 and will be dosed with OC containing levonorgestrel and ethinyl estradiol + 744 once daily on Day 12 to 19. Subjects completing Treatment period 2 will have 7 OC free days (Day 22 to 28) during which withdrawal menses should occur. Subjects will then be followed up for 7 to 14 days (Day 28 to 35/49).
3060324|NCT02159118|Active Comparator|Manual bone marrow aspiration and biopsy procedure|Manual bone marrow aspiration and biopsy device
3060325|NCT02159118|Active Comparator|Powered bone marrow aspiration and biopsy procedure|Powered bone marrow aspiration and biopsy device
3060326|NCT02159105||Women undergoing cesarean delivery|"FAST scan and non-invasive hemoglobin measurement~Women undergoing cesarean delivery will undergo a non-invasive hemoglobin measurement both before and after surgery. An abdominal ultrasound will be performed to establish normal levels of intra-abdominal fluid after cesarean delivery."
3060327|NCT02159092|Experimental|Contingency Management|Monetary incentives are given for submitting negative saliva cotinine tests.
3060328|NCT02159092|No Intervention|Fixed Rate Control|Fixed amounts of payments are provided for submitting saliva samples
3060329|NCT02159079|No Intervention|Usual Care|Patients in the usual care arm will be managed exclusively by their treating clinician without input from study personnel.
3060330|NCT02159079|Experimental|Conservative Fluid Management Strategy|For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
3060331|NCT02159066|Experimental|LGX818 + MEK162|
3060332|NCT02159066|Experimental|LGX818 + MEK162 + LEE011|
3060333|NCT02159066|Experimental|LGX818 + MEK162 + BGJ398|
3060334|NCT02159066|Experimental|LGX818 + MEK162 + BKM120|
3060335|NCT02159066|Experimental|LGX818 + MEK162 + INC280|
3060336|NCT02159053|Experimental|Secukinumab 150 mg s.c. with loading|Secukinumab 150 mg at Baseline, Weeks 1, 2, and 3, followed by dosing every four weeks starting at Week 4.
3060337|NCT02159053|Experimental|Secukinumab 150 mg s.c. without loading|Secukinumab 150 mg at Baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2, and 3.
3060338|NCT02159053|Placebo Comparator|Placebo|Placebo at Baseline, Weeks 1, 2, 3, 4, 8, and 12, followed by dosing with Secukinumab 150 mg every four weeks starting at Week 16.
3060339|NCT02159040|Active Comparator|Azacitidine|75mg/m2 7days/28 day cycle
3060340|NCT02159040|Experimental|Azacitidine and Deferasirox|azacitidine 75mg/m2 7 days/28 day cycle deferasirox 10 mg/kg/day
3060341|NCT02159027|Placebo Comparator|placebo|placebo identical in appearance to maraviroc 150 and 300 mg tablets will be added to each subjects antiretroviral regimen at doses as recommended by the package insert
3060342|NCT02159027|Experimental|maraviroc|Maraviroc Tablets are available as 150 mg and 300 mg tablets. Each subject will add maraviroc to their current antiretroviral regimen with dosage based on recommendations as per maraviroc package insert
3060343|NCT02159014|Experimental|Phase 1|Facilitated group-based physical activity (aerobic dance), online physical activity (video based aerobic dance) and nutritional intervention (nutritional education, cooking skill training, access and use of NHS Change4Life Eat Well web resource).
3060344|NCT02159014|Active Comparator|Phase 2|Self-paced online physical activity (video based aerobic dance) intervention and use of NHS Change4Life Eat Well web resource.
3060345|NCT02159001|Active Comparator|ECT treatment right after recruitment|This group receives electroconvulsive therapy treatment right after they are recruited.
3060346|NCT02159001|Placebo Comparator|ECT after 4 weeks period.|This group receives electroconvulsive therapy treatment after 4 weeks waiting period.
3060347|NCT02158988|No Intervention|without HIPEC|"Preoperative chemotherapy 3 cycles, each cycle 21 days. Patients with negative or unknown HER-2 status receive Epirubicin 50 mg/m² infusion (maximum 100mg/d). Oxaliplatin 130 mg/m² infusion (maximum 260 mg/d) and capecitabine oral 625 mg/m² two times a day (maximum 2500 mg/d).~Patients with positive HER-2 status receive:~Cisplatin : 80 mg/m² infusion (maximum of 160 mg/d). Capecitabine: oral 1000 mg/m2 (two times a day maximum of 4000 mg/d), on day 1-14.~Trastuzumab: 8 mg/kg infusion (on cycle 1 and 6 mg/kg on cycle 2 and 3). CRS is performed and 4-12 weeks after CRS 3 cycles of postoperative chemotherapy have to be applied. In case of therapy failure patients will be continued to be treated by the responsible investigator according to his medical status."
3060348|NCT02158988|Experimental|With HIPEC|"Patients will be treated with a preoperative chemotherapy as described for the control group. EOX or CCT depending on the HER-2 status.~CRS will be performed 2 to 3 weeks after end of last chemotherapy cycle. HIPEC with mitomycin C and cisplatin either at the time of CRS or a delayed HIPEC within 5-7 days.~HIPEC:~Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied.~Patients may get a HIPEC intervention without surgical cytoreduction if contraindication to the drugs can be excluded.~In case of therapy failure patients will be continued to be treated by the responsible investigator according to his medical status."
3060349|NCT02158975|Experimental|MLN9708|MLN9708 4mg by mouth weekly (days 1, 8, 15) every 28 days.
3060376|NCT02158806|Placebo Comparator|Inert capsule|Matching capsule once daily for up to 24 weeks
3060377|NCT02158793|Experimental|Face Transplant recipient|Single Arm study, all participants will receive Craniomaxillofacial allotransplantation
3060350|NCT02158962|Experimental|Behavioral - Education|"3 Educational Sessions~Session 1 - Reducing Risk for Intimate Partner Violence (IPV); Session 2 - Reducing risk for Sexually Transmitted Infections including HIV (STI/HIV) Session 3 - A group session which reinforces skills for reducing IPV and STI/ HIV risk reduction."
3060351|NCT02158962|Active Comparator|Behavioral - Education|"3 Educational Sessions~Session 1 - Breast Health Education and Developing A Breast Cancer Risk Reduction Plan Session 2 - Reducing risk for overweight and obesity and Developing a Healthy Eating and Activity Plan Session 3 - A group session which integrates and reinforces skills from Sessions 1 and 2."
3060352|NCT02158949|Experimental|mROAD|1 week of twice daily text messages modeled after SBIRT interventions
3060353|NCT02158949|No Intervention|Usual Care|Usual care in ED
3060354|NCT02158936|Experimental|Eltrombopag|Eligible subject will receive a starting dose of eltrombopag of 200 milligrams (mg) (100 mg for subjects of East Asian heritage). Dose modifications of eltrombopag will be permitted by 100 mg increments (50 mg increments for East Asians) to a lowest dose of 100 mg (50 mg for East Asian heritage) or a maximum dose of 300 mg (150 mg for East Asian heritage) in order to maintain platelet counts at a safe and effective level (i.e. a level sufficient to avoid platelet transfusions and bleeding events). Subjects will receive azacitidine 75 mg/meter^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
3060355|NCT02158936|Placebo Comparator|Placebo|Eligible subject will receive eltrombopag matching placebo. Subjects will receive azacitidine 75 mg/meter^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
3060356|NCT02158923|Experimental|Individualized ventilation|Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.
3060357|NCT02158923|Experimental|Individualized vent. + postop. CPAP|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed. Postoperatively a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
3060358|NCT02158923|No Intervention|Standard ventilation|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, PEEP 6 cmH2O and FiO2 0.8. In these groups no recruitment maneuvers or optimal PEEP setting will be performed.
3060359|NCT02158923|Active Comparator|Standard vent. + postoperative CPAP|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, PEEP 6 cmH2O and FiO2 0.8. In these groups no recruitment maneuvers or optimal PEEP setting will be performed. Postoperatively, a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
3060360|NCT02158910||Aricept Group 1|Subjects starting at 5 mg Aricept and increasing their dose to 10 mg Aricept
3060361|NCT02158910||Aricept Group 2|Subject starting at 10 mg Aricept and increasing their dose to 23 mg Aricept
3060362|NCT02158897|No Intervention|Control|Participants will consume their normal diet. Body weight and physiological change at two time points (approximately 2-3 months apart) will be examined. The participants will be crossed over to the diet group.
3060363|NCT02158897|Experimental|Prolon Diet|Participants will be provided with a 5-day supply of fasting-mimicking diet, including energy bars, soups, drink packets and dietary supplements. Participants will diet for 3 cycles. Each one-month cycle consists of 5 days of dieting with a calorie intake estimated at 600-1200 calories per day. The rest of the month participants will eat normally. After 3 cycles, participants will be examined again after consuming their normal diet after 2-3 months.
3060364|NCT02158884|Other|IDEO brace|IDEO brace
3060365|NCT02158871|Experimental|Contact-based mental health education|"The Beyond Silence' program is 12 hours in length: six 1.5-2 hour in-person group sessions every other week, plus five online sessions between each of the in-person sessions."
3060366|NCT02158871|Active Comparator|Mental health literacy training|"Mental Health First Aid training consists of twelve hours of standardized, module-based mental health literacy training offered in a group format. It will be offered as 2 full-day training sessions (or four half-day sessions)."
3060367|NCT02158858|Experimental|CPI-0610 Monotherapy|In the Phase 2 portion, patients with Myelofibrosis who have failed JAK inhibitor therapy will be assigned to the monotherapy arm (CPI-0610 alone).
3060368|NCT02158858|Experimental|Combination|Patients with Myelofibrosis who are on a stable dose of a JAK inhibitor will be assigned to the combination therapy arm (CPI-0610 + Ruxolitinib)
3060369|NCT02158845|Active Comparator|LNG-IUS|LNG-IUS: levonorgestrel intrauterine system
3060370|NCT02158845|Active Comparator|GnRHa|GnRHa: leuprolide
3060371|NCT02158832|Experimental|Acupuncture + Electrical Stimulation|Acupuncture needles are inserted beneath the skin and electrical stimulation applied for 20 minutes.
3060372|NCT02158832|No Intervention|Control|Participants who are randomized to receive no intervention will still receive physical assessment.
3060373|NCT02158819|No Intervention|TKA with standard instrumentation|This arm consists of the Genesis II Total knee implant system or the Legion Primary total knee system with standard instrumentation
3060374|NCT02158819|Active Comparator|Total knee arthroplasty with Visionaire|This arm will consist of the Genesis II Total Knee Implant System or Legion Primary Total Knee System with the Visionaire patient-matched instrumentation
3060375|NCT02158806|Experimental|Aspirin|150 mg capsule once daily for up to 24 weeks
3060380|NCT02158754||Corus CAD (ASGES)|Subjects receiving CorusCAD (ASGES) gene expression test as part of their diagnostic workup for typical and/or atypical symptoms of obstructive coronary artery disease.
3060381|NCT02158754||Control|Matched subjects in the same practice that did NOT receive Corus CAD (ASGES) as part of their diagnostic workup.
3060382|NCT02158741|No Intervention|Usual Primary Care|Usual Primary Care will be received by half the participants during the course of the Study
3060383|NCT02158741|Active Comparator|Home Visits and educational support|Intervention comprised of Home Visits and group educational sessions. Home Visits and will be conducted by Diabetes Education staff in lieu of usual care conducted at the Diabetes clinic. Lifestyle support and educational will be offered in the form of monthly Diabetes Wellness Days offered in the community where nutrition, exercise and support will be given to help improve self-management of diabetes.
3060384|NCT02158728||ICD indicated subjects|"Subjects indicated for implantable cardioverter defibrillator (ICD)/ cardiac resynchronization therapy defibrillator (CRT-D) implant, ICD/CRT-D change-out, or indicated for an ICD/CRT-D and undergoing ablation or electrophysiology (EP) study (including Non-Invasive ElectroPhysiology Study [NIPS]).~Enrolled subjects are prepared for the indicated procedure as per investigational center's standard practice. The investigator will determine the best methodology for inducing or simulating SVT within the indicated procedure. Data is recorded by a data acquisition recording system. Recording should begin just before the indicated procedure and continue until completion of the procedure.The recorded data are collected."
3060385|NCT02158715||Smartphone positioning during Chest compression|
3060386|NCT02158702|Experimental|Pomalidomide and Dexamethasone|"PO pomalidomide 4mg from D1-21 and PO dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~PO or IV cyclophosphamide 300mg/m2 on D1, 8 and 15 can be added at the discretion of the treating physician to induce added response under the following circumstances: 1) If there is less than a MR after 3 cycles in the absence of disease progression, or 2) If there is disease progression within the first 3 cycles of Pomalidomide and Dexamethasone treatment.~Patients will be assessed every 28 days (+/-10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
3060387|NCT02158689|Active Comparator|human menopausal gonadotropin (hMG)|hMG at a dose of 300 IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
3060388|NCT02158689|Active Comparator|Letrozole|Letrozole (Femara; Novartis, East Hanover, NJ) at a dose of 5 mg/day will be initiated on the second or third day of spontaneous menstruation and continued for 5 days. Again on the second or third day of spontaneous menstruation, 150 IU of hMG will be started until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of hCG as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
3060389|NCT02158676|Experimental|Prebiotic|6 g/day of prebiotic (fructooligosaccharides) for 15 days.
3060390|NCT02158676|Experimental|Synbiotic|6 g/day of synbiotic (fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019) for 15 days.
3060391|NCT02158676|Placebo Comparator|Placebo|6 g/day of placebo (maltodextrin) for 15 days.
3060392|NCT02158663|Active Comparator|Right slow prefrontal rTMS|Repetitive Transcranial Magnetic Stimulation
3060393|NCT02158663|Active Comparator|Right fast prefrontal rTMS|Repetitive Transcranial Magnetic Stimulation
3060394|NCT02158650|Experimental|Video Group|Patients randomized to Group II will be emailed the educational video, pre- and post- knowledge assessments, and patient satisfaction survey with instructions on what order to fill them out. Group II patients will report to the treatment visit and undergo discussion of options and treatment as per standard of care. An additional knowledge assessment survey will be administered to Group II patients after discussion with treating physician.
3060395|NCT02158650|No Intervention|Control Group|Patients randomized to Group I will be come to the clinic for the treatment visit and discuss options and treatment as per standard of care. Pre- and post- discussion knowledge assessments and satisfaction surveys will be administered at the time of the treatment visit.
3060396|NCT02158637||Cancer patients receiving treatment|Patients receiving active treatment for cancer or initiating treatment for cancer in the next 7 days
3060397|NCT02158624|Experimental|Ranibizumab|
3060398|NCT02158611|Other|Lifestyle counseling|
3060399|NCT02158598|No Intervention|wash-out|2 months
3060400|NCT02158598|Experimental|Vitamin D chewable tablet supplementation|A chewable vitamin D tablet containing 1000 IU to be taken once a day for 2 months.
3060401|NCT02158598|Experimental|Vitamin D pill supplementation|A vitamin D pill containing 1000 IU to be taken once a day for 2 months.
3060402|NCT02158585|Placebo Comparator|Placebo|The placebo will match the lamotrigine dosage, frequency and duration.
3060403|NCT02158585|Active Comparator|Lamotrigine|Lamotrigine will be taken orally for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses are 25mg twice a day, 50mg twice a day, 100 mg twice a day and 150mg twice a day during titration; 150mg twice a day or 100mg twice a day for the 12-week study period; 150mg once a day, or 100mg once a day for Week 1 of the taper; and 75mg once a day, or 50mg once a day for Week 2 of the taper. Patients who withdraw at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
3060404|NCT02158572|Experimental|AG200-15|AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
3060405|NCT02158559|Experimental|Danhong Injection|Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
3060406|NCT02158559|Placebo Comparator|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
3060407|NCT02158546|Experimental|ALKS 5461|
3060408|NCT02158546|Placebo Comparator|Placebo|
3060409|NCT02158533|Experimental|High Dose|
3060410|NCT02158533|Experimental|Low Dose|
3060411|NCT02158533|Placebo Comparator|Placebo|
3060412|NCT02158520|Experimental|Arm A (bevacizumab and nab-paclitaxel)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may cross-over to Arm B within 2-4 weeks.
3060413|NCT02158520|Experimental|Arm B (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may cross-over to Arm A within 2-4 weeks.
3060414|NCT02158507|Experimental|Combination of Veliparib + Lapatinib|Lapatinib will be administered as a tablet at a dosage of 1250 mg/day continuously for 28 days starting on Day 1 of each cycle. Veliparib will be administered as a capsule at a dosage of 200 mg every 12 hours for 28 days starting on Day 2 of each cycle. A cycle of therapy is defined as 28 days. Treatment is administered on an outpatient basis. Patient response will be evaluated every 8 weeks according to the current Response Evaluation Criteria in Solid Tumors (RECIST) guidelines and performance of relevant scans and/or x-rays.
3060415|NCT02158494|Experimental|Neurostimulation|Balance and gait training using neurostimulation modulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
3060416|NCT02158494|Sham Comparator|Minimally perceivable stimulation|Balance and gait training using non-zero, minimally perceivable stimulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
3060417|NCT02158481|Active Comparator|Dietary ingredients: polyphenols and carotenoids|Dietary ingredients: polyphenols and carotenoids
3060418|NCT02158481|Placebo Comparator|Placebo product|Placebo product
3060419|NCT02158468|Active Comparator|Combined intrahospital pre- and postconditioning|After admission to hospital 3 cycles of preconditioning with 5-min inflation and 5-min deflation of a blood-pressure cuff. After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion).
3060420|NCT02158468|Active Comparator|Postconditioning|4 cycles of postconditioning (30s ischemia, 30s reperfusion) after primary PCI/stenting
3060421|NCT02158468|No Intervention|Control group|Standard infarction treatment without conditioning intervention
3060422|NCT02158455|Experimental|NT SVG grafts|NT SVG randomized for revascularization of left or right coronary territory
3060423|NCT02158455|Active Comparator|RA grafts|RA grafts randomized for revascularization of left or right coronary territory
3060424|NCT02158442|Experimental|Treatment Group|The Treatment Group received intravenous Timentin prior to their PILP procedure.
3060425|NCT02158442|Active Comparator|Control Group|The Control Group received standard dosings of intravenous Timentin plus other standard care.
3060426|NCT02158429|Active Comparator|3 Dimensional ultrasound|an additional 5-10 minutes of ultrasound using three dimensional technique
3060427|NCT02158429|Active Comparator|2 dimensional|an additional 5-10 minutes of ultrasound using standard two-dimensional technique
3060428|NCT02158416||Hematology-oncology|hematology-oncology outpatients requiring platelet transfusion
3060429|NCT02158403|Other|Clinical Management Recommendations|Clinical management recommendations for reducing pump thrombosis
3060430|NCT02158390|Experimental|Jasper-EMT with words and AAC|"Jasper-EMT with words and AAC~A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months."
3060431|NCT02158390|No Intervention|Community treatment as usual|Children access educational and speech-language interventions available to them through schools and community resources.
3060432|NCT02158377|Active Comparator|Tapered Screw-vent implants (TSV)|TSV implants to replace missing tooth/teeth
3060433|NCT02158377|Experimental|Trabecular Metal dental implants (TM)|TM dental implants to replace missing tooth/teeth
3060434|NCT02158364||Live attenuated measles/rubella combined vaccine|Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 mL of accompanying reconstitution fluid (water for injection [Japanese Pharmacopoeia]), and a 0.5-mL portion is typically administered subcutaneously as a single dose.
3060435|NCT02158351||Simple steatosis|We will run a cross-sectional observational study including two groups of human subjects: patients with simple steatosis (SS) or non-alcoholic steatohepatitis (NASH). Grouping in patients SS or NASH will be performed based on the histological diagnosis of the type of NAFLD obtained at operation (sleeve gastrectomy or cholecystectomy). BMI will be considered as a confounding variable to be statistically analyzed. Main hypothesis: GM can lead to liver inflammation in patients with liver fat accumulation.
3060436|NCT02158351||Non-alcoholic steato-hepatitis|We will run a cross-sectional observational study including two groups of human subjects: patients with simple steatosis (SS) or non-alcoholic steatohepatitis (NASH). Grouping in patients SS or NASH will be performed based on the histological diagnosis of the type of NAFLD obtained at operation (sleeve gastrectomy or cholecystectomy). BMI will be considered as a confounding variable to be statistically analyzed. Main hypothesis: GM can lead to liver inflammation in patients with liver fat accumulation.
3060437|NCT02158338||Asthma|Mothers of children thought to have asthma
3060438|NCT02158338||Non-asthma|Mothers of children without diagnosed respiratory problems
3060439|NCT02158325|Active Comparator|3.0-3.9 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0-3.9 mm in diameter)
3060440|NCT02158325|Experimental|4.0-5.0 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (4.0-5.0 mm in diameter)
3060441|NCT02158325|Active Comparator|5.1-6.0 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (5.1-6.0 mm in diameter)
3060442|NCT02158312|Experimental|transcranial direct current stimulation|bihemispheric transcranial direct current stimulation, anodal at ipsilesional M1 while cathodal at contralesional M1, for 20 minutes
3060443|NCT02158312|Placebo Comparator|sham stimulation|same as the experimental stimulation condition but only for 2 minutes
3060444|NCT02158299|Experimental|Avitene,Drainaging,reexamine|
3060445|NCT02158299|Experimental|Sapylin,Drainaging,reexamine|
3060447|NCT02158286||Esophagectomy, Emptying from gastric tube|Validate paracetamol clearance technique to scintigraphy for measuring emptying rate from the gastric tube.
3060448|NCT02158273|Active Comparator|TRICOR (fenofibrate)|
3060449|NCT02158273|Placebo Comparator|Sugar Pill|
3060450|NCT02158260|Experimental|position changing|During the examination, subjects changed position in the following sequence: left lateral head-down position, supine position, prone head-down position, right lateral head-down position, supine position, left lateral position, prone position, prone hip-high position, right lateral position and sitting position.
3060451|NCT02158260|No Intervention|free position|
3060452|NCT02158247||Conventional group, Touch and Read group|
3060453|NCT02158234|Experimental|Dose Escalation: SBRT and Cisplatin|Stereotactic Body Radiation Therapy (SBRT) and Cisplatin. Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy/ Cisplatin 15 mg/m^2
3060454|NCT02158221|Active Comparator|Migraine patients with high genetic load|PACAP intravenous infusion 1.5 microgram/min for 20 min
3060455|NCT02158221|Active Comparator|Migraine patients with low genetic load|PACAP intravenous infusion 1.5 microgram/min for 20 min
3060456|NCT02158208||Patients with HD|
3060457|NCT02158208||Controls|
3060458|NCT02158195||Patients|
3060459|NCT02158195||controls|
3060460|NCT02158182|Experimental|lactulose|
3060461|NCT02158182|Experimental|L-ornithine L-aspartate|
3060462|NCT02158182|Experimental|Rifaximin|
3060463|NCT02158182|Placebo Comparator|Placebo|
3060464|NCT02158156|Experimental|Excercise|10 weeks of home training on a cycle-ergometer. Exercise 30 minutes every other day or at least three times a week.
3060465|NCT02158143|Experimental|vitamin D3|
3060466|NCT02158130||Healthy Living|non exercise healthy living control group
3060467|NCT02158130||General Health|Exercise Group (8 KKW) One exercise group will obtain 8KKW (kcal/kg/week) over 3-4 sessions per week, which will result in each session lasting approximately 30 minutes. We will recruit 1 year post study intervention.
3060468|NCT02158130||Weight Loss|Exercise Group (20 KKW) Exercise group will obtain 20 KKW, perform in 4-5 sessions per week for approximately 50-70 minutes per session. We will recruit 1 year post study intervention.
3060469|NCT02158117|Experimental|nasal naloxone|8 and 16 mg/ml, comparator 1 mg/ml. Three daily occasions with at least 3 days washout between treatment (min 8 days).
3060470|NCT02158104||Latent trigger point in the upper trapezius muscle|
3060471|NCT02158091|Experimental|IPI-145|"Phase I-Dose escalation will occur using a standard 3-3 dose escalation beginning in dose level 1 with dose cohorts and escalation.~Each treatment cycle lasts 28 days (except cycle 1, which is 35 days) during which time IPI-145 will be taken twice daily. The study begins with 1 week of IPI-145 monotherapy.~Fludarabine, cyclophosphamide, rituximab (iFCR) - FCR will subsequently be introduced after 1 week and administered at standard dosing for up to 6 cycles, with dose reductions permitted. IPI-145 will be continued through the course of chemotherapy and for up to 2 years maintenance after completing chemotherapy Phase II - 20 additional patients treated with IPI-145 at the Recommended Phase II Dose (RP2D) + fludarabine, cyclophosphamide, rituximab (FCR) with standard dosing."
3060472|NCT02158065|No Intervention|Usual care|Patients will receive information (leaflet) and guidance on the benefits associated with increased physical activity in COPD patients and their health status
3060473|NCT02158065|Experimental|Coaching program|In addition to usual care, patients will receive the coaching program
3060474|NCT02158052|Experimental|Transplantation|Single arm combined bone marrow and kidney transplantation
3060475|NCT02158039|Experimental|Pancreatic Cyst Ethanol Injection|EUS-guided lavage of a pancreatic cyst with ethanol solution. The ethanol solution was diluted to 80% using normal saline. Final solution also contained 1% lidocaine except in patients allergic to local anesthetics. The ethanol solution was injected into pancreatic cysts at a volume equal to 90% of the aspirated cyst volume. In subjects undergoing re-treatment of a cyst, ethanol was diluted to 90% using normal saline, and injected in a volume equal to 100% of the aspirated cyst volume.
3060476|NCT02158026||infertility without polycystic ovarian syndrome|1000 women with infertility without polycystic ovarian syndrome who are already decided to be treated with ICSI will be recruited
3060477|NCT02158013|Active Comparator|Diltiazem, calcium channel blocker|Diltiazem gel 2% applied twice daily for 8 weeks
3060478|NCT02158013|Experimental|Levorag, Hibiscus plant extract|Levorag Emulgel applied twice daily for 8 weeks
3060479|NCT02158000|Active Comparator|Group A|In group A , 100 women with excessive endometrial fluid by transvaginal ultrasound during ICSI cycles are allocated to receive one tab / 8 hs of Diosmin ( 500mg) beginning from the day of ovum retrieval and for 3 days (till the day of embro trasfer) in addition to aspiration of the fluid by an IUI catheter.
3060480|NCT02158000|No Intervention|Group B|In group B (control group) 100 women with excessive endometrial fluid by transvaginal ultrasound during ICSI cycles, no thing will be done
3060481|NCT02157987|Experimental|bevacizumab|bevacizumab spray
3060482|NCT02157974|Experimental|PCOS, medication naive + Byetta|PCOS, medication naive; 10 girls with PCOS will receive 2 doses of Byetta.
3060483|NCT02157974|No Intervention|Control|Up to 25 girls without PCOS
3060484|NCT02157974|No Intervention|PCOS|Up to 10 girls with PCOS and 6 months of therapy with combined oral contraceptives prior to study procedures; Up to 10 girls with PCOS and 6 months of therapy with metformin prior to study procedures; Up to 45 girls with PCOS with no exposure to hormone therapy or metformin in the preceeding 6 months.
3060485|NCT02157961||General Practitioner / Family Physician in German Primary care|
3060486|NCT02157961||Medical Specialists|Working in the ambulatory setting
3060487|NCT02157948|Active Comparator|Denosumab CP2|Participants received 60 mg denosumab manufactured using the current CP2 process subcutaneously once every 6 months for 1 year.
3060488|NCT02157948|Experimental|Denosumab CP4|Participants received 60 mg denosumab manufactured using the new CP4 process subcutaneously once every 6 months for 1 year.
3060489|NCT02157935|Active Comparator|Symbicort pMDI|Symbicort pMDI, budesonide/formoterol, 160/4.5 μg x 2 actuations BID, for oral inhalation
3060490|NCT02157935|Active Comparator|Formoterol Turbuhaler|Formoterol Turbuhaler, 4.5 μg x 2 actuations BID, for oral inhalation
3060491|NCT02157922|Active Comparator|Alginate oligosaccharide|Inhalation of a dry powder OligoG in the first treatment period, and of placebo the second period
3060492|NCT02157922|Placebo Comparator|Placebo|Inhalation of placebo dry powder in the first treatment period, and OligoG in the second period
3060493|NCT02157909|Experimental|AOA Modified|Lotrafilcon B sphere modified design contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days.
3060494|NCT02157909|Active Comparator|AOA|Lotrafilcon B sphere contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days.
3060495|NCT02157896||Acute ischemic stroke|Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study, and had a score between 6 and 25 on the National Institutes of Health Stroke Scale (NIHSS).
3060496|NCT02157883|Experimental|AZD9291 alone, AZD9291+itraconozole|Sequential treatments of AZD9291 alone followed by AZD9291+itraconazole, with a washout period in between.
3060497|NCT02157870|Experimental|Arm 1: Paclitaxel + tgDCC-E1A MTD|80 mg/m^2 intravenous Paclitaxel and intraperitoneal (IP) tgDCC-E1A weekly for six treatments every 7 days at MTD found in Phase I of study.
3060498|NCT02157870|Active Comparator|Arm 2: Paclitaxel Alone|Weekly single agent intravenous Paclitaxel 80 mg/m^2 for six treatments every 7 days.
3060499|NCT02157844||COPD and OSA|Subjects with diagnosis of COPD and OSA
3060500|NCT02157844||COPD|Subjects with diagnosis of COPD
3060501|NCT02157844||OSA|Subjects with diagnosis of OSA
3060502|NCT02157844||controls|Gender, age, BMI matched controls
3060503|NCT02157831|Experimental|Subjects from UPCC 10903|
3060504|NCT02157818|Active Comparator|midazolam|midazolam IV bolus 0.05ml/kg bolus in 1minute. rescue drug(Midazolam) 1 mg, IV boluses for double blinding setting, we use saline, 0.4 mcg/kg IV bolus in 10 minutes and 0.5 mcg/kg/h, as placebo.
3060505|NCT02157818|Experimental|Dexmedetomidine|"Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.25-0.75 mcg/kg/h for RSS 3-5. Midazolam 1mg bolus IV pro re nata (PRN).~for double blinding setting, IV bolus 0.05ml/kg bolus in 1minute."
3060506|NCT02157805|Active Comparator|rare beef meat|beef meat cooked during 5 minutes at 55°C
3060507|NCT02157805|Active Comparator|well cook beef meat|beef meat cooked during 30 minutes à 90°C
3060508|NCT02157792|Experimental|Part A|This part will be 3 + 3 dose escalation study of M6620 in combination with gemcitabine as well as gemcitabine and cisplatin in participants with advanced solid tumors.
3060509|NCT02157792|Experimental|Part B|This part will be 3 + 3 dose escalation study of M6620 in combination with cisplatin or cisplatin and etoposide in participants with advanced solid tumors.
3060510|NCT02157792|Experimental|Part B2|This part will be 3 + 3 dose escalation study of M6620 in combination with irinotecan in participants with advanced solid tumors.
3060511|NCT02157792|Experimental|Part C1|This will be the expansion part of the study in which participants with advanced non-small cell lung cancer (NSCLC) will be administered M6620 in combination with gemcitabine.
3060512|NCT02157792|Experimental|Part C2|This will be the expansion part of the study in which participants with advanced triple negative breast cancer (TNBC) will be administered M6620 in combination with cisplatin.
3060513|NCT02157792|Experimental|Part C3|This will be the expansion part of the study in which participants with platinum-resistant advanced small cell lung cancer (SCLC) will be administered M6620 in combination with cisplatin or carboplatin.
3060514|NCT02157779|Experimental|Cognitive Behavioral Intervention|12 weekly individual sessions consisting of psychoeducation, and cognitive and behavioral anger management strategies
3060515|NCT02157779|Active Comparator|Supportive Intervention|12 weekly individual sessions consisting of psychoeducation, problem-solving strategies, and support
3060516|NCT02157766|Active Comparator|MNP with Asthma: Mindfulness Based Stress Reduction|
3060517|NCT02157766|No Intervention|MNP w/ Asthma: Wait List Control|
3060518|NCT02157766|Active Comparator|MNP, no asthma - Mindfulness Based Stress Reduction|
3060519|NCT02157766|Active Comparator|MNP, no asthma: Health Enhancement Program|
3060520|NCT02157766|No Intervention|MNP, no asthma - Wait List Control|
3060521|NCT02157766|Active Comparator|Long Term Meditator|
3060522|NCT02157740||Control group before telemedicine|Residents of nursing homes without telemedicine before implementation of telemedicine in nursing homes with telemedicine
3060523|NCT02157740||Control group after telemedicine|Residents of nursing homes without telemedicine after implementation of telemedicine in nursing homes with telemedicine
3060524|NCT02157740||Exposed group, before telemedicine|Residents of nursing homes with telemedicine prior implementation of telemedicine
3060525|NCT02157740||Exposed group, after telemedicine|Residents of nursing homes with telemedicine after implementation of telemedicine
3060526|NCT02157727||Exposed group, during Tele-expertise|Infants hospitalized in health facilities performing tele-expertise
3060527|NCT02157727||Exposed group, Prior Tele-expertise|Infants hospitalized in health facilities performing Tele-expertise prior implementation of Tele-expertise
3060528|NCT02157727||Control group, Prior Tele-expertise|
3060529|NCT02157727||Control group, during Tele-expertise|Infants hospitalized in health facilities not performing Tele-expertise while the exposed group use Tele-expertise
3060530|NCT02157714|Experimental|PRX002|PRX002
3060531|NCT02157714|Placebo Comparator|Placebo|Placebo
3060532|NCT02157701|Experimental|Polyherbal capsule|1 capsule taken with breakfast and 1 capsule with lunch. Capsules should be taken immediately prior to meals and not with carbonated beverages.
3060533|NCT02157701|Placebo Comparator|Placebo capsule|1 capsule taken with breakfast and 1 capsule with lunch. Capsules should be taken immediately prior to meals and not with carbonated beverages.
3060534|NCT02157688||case|Patient with a folliculitis Decalvans
3060535|NCT02157688||control|Control without folliculitis decalvans
3060536|NCT02157675|Experimental|Polyherbal capsule|Subjects take 1 capsule with breakfast and 1 capsule with lunch. Subjects should take capsules immediately prior to meals and not with carbonated beverages.
3060537|NCT02157675|Placebo Comparator|Placebo capsule|Subjects take 1 capsule with breakfast and 1 capsule with lunch. Subjects should take capsules immediately prior to meals and not with carbonated beverages.
3060538|NCT02157662||No coronary disease and risk factors >=3|
3060563|NCT02157506|Experimental|CXL-1427 Starting Dose|The Starting dose of CXL-1427 in the dose escalation arms will be 3mcg/kg/min
3060539|NCT02157662||Coronary disease and risk factors 0-1|Diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification38 and 0-1 risk factor (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor.
3060540|NCT02157662||No coronary disease and risk factors 0-1|
3060541|NCT02157662||Coronary disease and risk factors >=3|Subjects with diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification38 and 3 or more risk factors (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor
3060542|NCT02157649|Experimental|ER Tablet under Fasted Conditions|Administration of a single dose of two ER Tablets, combination of Codeine/Guaifenesin 30gm/600mg, to subjects under fasted conditions.
3060543|NCT02157649|Active Comparator|IR Tablet under Fasted conditions|IR Tablet combination tablet of Codeine/Guaifenesin 20mg/400mg administered under fasted conditions as a single tablet every 4 hours during a 12 hour study [three doses]
3060544|NCT02157649|Experimental|ER Tablet under Fed Conditions|Administration of a single dose of two ER Tablets, combination of Codeine/Guaifenesin 30gm/600mg, following a standard high-fat breakfast.
3060545|NCT02157636|Experimental|CPI-0610|
3060546|NCT02157623|Active Comparator|Red Light Photodynamic Therapy|Subject will be randomized to right or left side and assigned side will be treated with red light PDT after Levulan application
3060547|NCT02157623|Active Comparator|Blue Light Photodynamic Therapy|Subject will be randomized to right or left side and assigned side will be treated with blue light PDT after Levulan application
3060548|NCT02157610|Experimental|Standard Treatment (ST)|Participants receive free self-help materials mailed at baseline, 6, and 12 months. Participants receive a referral to the Oklahoma Quitline. Participants receive a 12-week supply of the nicotine patch and lozenge. Nicotine patch regime based on participant's self-reported smoking rate. REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months. Saliva test performed at 3, 6, 12, and 18 months.
3060549|NCT02157610|Experimental|Motivation + Problem Solving (MAPS)|Participants receive free self-help materials mailed at baseline, 6, and 12 months. Participants receive a referral to the Oklahoma Quitline.Participants receive a 12-week supply of the nicotine patch and lozenge. Nicotine patch regime based on participant's self-reported smoking rate. REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months. Saliva test performed at 3, 6, 12, and 18 months. 6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
3060550|NCT02157597|Active Comparator|Control Arm|"The control patients will have open display of the NIRS monitor in the OR, but recording without display in the CICU, along with a request to the surgical and intensive teams to react to the data in their usual way. The disparity between the OR and CICU reflect the current opinions of the clinicians in these different environments regarding the necessity of NIRS monitoring within their sphere of practice.~In this way, continuous recording of cerebral and somatic oximetry will be made in all patients. However for control patients the monitor display will be switched off in the CICU using a pre-programmed research mode, which permits both ongoing recording and also the display of technical error messages (such as inadvertent disconnections or probe displacement)."
3060551|NCT02157597|Experimental|NIRS based management|The trial interventions of NIRS based management consists of provision to the cardiac surgical and intensive care teams of a protocol to guide their interpretation of cerebral and somatic NIRS monitoring and interventions to try in the event of monitored desaturation during the pre- and post-bypass periods (when the circulation is perfused by the beating of the native heart). The investigators believe that there is insufficient data to inform an evidence-based protocol for the bypass phase of surgery, particularly regarding the interpretation of NIRS data under conditions of hypothermia.
3060552|NCT02157584|Experimental|Treatment A|Subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) on Day 1 in a fed condition. Days 2 to 5 will be Washout Days. On Day 6, subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) 1 in a fasted condition.
3060553|NCT02157584|Experimental|Treatment B|Subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) on Day 1 in a fasted condition. Days 2 to 5 will be Washout Days. On Day 6, subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) 1 in a fed condition.
3060554|NCT02157571|Experimental|Prulifloxacin|"Prulifloxacin film-coated tablet : 600 mg/tablet, oral administration of a single tablet.~Placebo of levofloxacin hydrochloride tablet, without active components."
3060555|NCT02157571|Active Comparator|Levofloxacin|"Levofloxacin hydrochloride tablet 500 mg/tablet, oral administration of a tablet daily.~Placebo of prulifloxacin film-coated tablet without active components."
3060556|NCT02157558|Experimental|All subjects|All subjects will receive a single oral dose of fexofenadine on Day 1 while fasting. Days 2 to 5 will be Washout days. On Day 6, subjects will begin a 5 day telotristat etiprate regimen. On Day 10 subjects will be given the morning telotristat etiprate dose concomitantly with a single dose of fexofenadine while fasting.
3060557|NCT02157545||pyridostigmine|administration of rocuronium to determine its potency.
3060558|NCT02157545||control arm (no pyridostigmine)|determination of potency of rocuronium in patients not taking pyridostigmine
3060559|NCT02157532|Active Comparator|Best standard treatment|intravenous r-tPA or any other medical management
3060560|NCT02157532|Active Comparator|Mechanical thrombectomy|Endovascular mechanical thrombectomy with stent-retrievers
3060561|NCT02157519|Experimental|Mobile Application Intervention|Participants in the intervention group will receive the mobile application for improving symptoms and adherence to oral chemotherapy along with their standard oncology care. The proposed elements of the mobile application include the following: 1) specification of an oral chemotherapy treatment plan; 2) weekly collection of patient-reported symptoms and medication adherence; and 3) delivery of real-time, tailored feedback to patients as well as immediate transmission of survey results to oncology clinicians.
3060562|NCT02157519|No Intervention|Standard Oncology Care|Participants in the control group will receive standard oncology care only.
3060595|NCT02157298|Experimental|dapagliflozin 5mg|dapagliflozin tablet 5mg
3060564|NCT02157506|Experimental|CXL-1427 Dose Level 2|The Second Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
3060565|NCT02157506|Experimental|CXL-1427 Dose Level 3|The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
3060566|NCT02157506|Experimental|CXL-1427 Dos Level 3|The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
3060567|NCT02157506|Experimental|CXL-1427 Dose Level 4|The forth level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
3060568|NCT02157506|Experimental|Expansion Cohort 1|Up to 16 Patients will be enrolled across 1 or more of the previously evaluated Dose escalation Levels as determined by the independent dose escalation committee
3060569|NCT02157506|Placebo Comparator|Placebo for Dose Escalation and Expansion Cohort|Each Dose escalation Arm of the study will have a placebo group in a 2:1 ratio to active treatment for the first 3 patients enrolled and 4:1 to active treatment in the remaining 5 patients so that the overall randomization ratio in each Dose escalation arm will be 3:1 active to placebo. In the expansion Cohort of the study, the ratio of patients randomized to receive a 6-hour infusion of active CXL-1427 or placebo will be 3:1
3060570|NCT02157493|Experimental|Arrowhead Business Group Curriculum|The Arrowhead Business Group (ABG) Curriculum is a 22-session youth entrepreneurship/life-skills intervention delivered by trained American Indian paraprofessionals from the community to mixed-gender groups of approximately 25 youth. The intervention is delivered over a 3 night/4 day camp along with weekend workshops once a month for 6 months during the academic year. Depending on the time of enrollment, subjects will receive follow-up assessments at 6-month intervals for up to 36-months post-intervention. (Subjects in this cohort will also receive the activities associated with the control condition.)
3060571|NCT02157493|Active Comparator|Recreational League Control Condition|The Recreational League Control Condition will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Sports and recreational activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
3060572|NCT02157480|No Intervention|control|usual follow-up for 6 weeks
3060573|NCT02157480|Experimental|electrostimulation 3 days per week|20 minutes ambulatory bi-quadricipital electrostimulation sessions three times per week for 6 weeks
3060574|NCT02157480|Experimental|electrostimulation 5 days per week|20 minutes ambulatory bi-quadricipital electrostimulation sessions five times per week for 6 weeks
3060575|NCT02157467|Experimental|Arm 1: NGMN/EE + BMS-955176|"Cycle 1- Active Ortho Cyclen QD on Days 1 to 21. Inert Ortho Cyclen tablets on Days 22 to 28~Cycle 2- Active Ortho Cyclen QD alone on Days 29 to 39 (11 days), followed by concomitant administration of active Ortho Cyclen QD + BMS-955176 80 mg QD on Days 40 to 49 (10 days)"
3060576|NCT02157454|Experimental|Website access|Two-week access to the colorectal cancer module of the website www.krankheitserfahrungen.de
3060577|NCT02157454|No Intervention|Control|Participants who are randomized to the control group don't have access to the website until they have finished the last questionnaire at 6 weeks follow up.
3060578|NCT02157441|Experimental|all patients|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
3060579|NCT02157428|Placebo Comparator|saline|patients received 20 ml of saline during 1 minute, after end of surgery.
3060580|NCT02157428|Active Comparator|flumazenil|patients received 1 mg of flumazenil, after end of surgery
3060581|NCT02157415|Experimental|Long-term catherized patients|Uro-Tainer Polihexanide 0.02% 100ml rinsing solution
3060582|NCT02157402|Experimental|Intervention Group|The intervention group will received activities and social events designed according 8 social marketing Benchmark criteria to promote healthy lifestyles.
3060583|NCT02157402|No Intervention|Control Group|The control group will not received any intervention activities and social events to promote healthy lifestyles.
3060584|NCT02157389|Experimental|placebo|Administration of a pharmacological placebo (sodium chloride) via transdermal application to investigate the influence on pain perception in chronic back pain patients and to investigate the influence of attitude and experience with medication on the placebo effect
3060585|NCT02157376|Experimental|Esomeprazole active treatment|iv esomeprazole 30 min intermittent infusions given for maximum 14 days
3060586|NCT02157376|Active Comparator|Cimetidine active treatment|iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
3060587|NCT02157363|Active Comparator|Repositioning Group|The patient is placed on a vacuum mattress in supine position for the abdominal part using a midline laparotomy. After completion of the abdominal part, the abdomen is closed and dressed in standard fashion and the patient is repositioned under full anesthesia is a left-lateral decubitus (LLD) position. After the thorax is sterile prepped and draped, a right dorso-lateral thoracotomy in the 4th to 6th intercostal space under preservation of body of the serratus muscle is performed.
3060588|NCT02157363|Experimental|Single positioning|The patient is placed on a vacuum mattress and in a left-screwed supine position for the entire operative procedure. The pelvis and the lower extremities are placed at 0° rotation, whereas the torso is rotated leftwards to an angle of 45° (Fig. 1). The patient is prepped and draped from the shoulders to the inguinal region. A midline laparotomy is done for the abdominal part and the abdomen closed afterwards. For the thoracic part, the operating table is tilted about 30° to the left, and a right anterolateral thoracotomy is performed in the 4th to 6th intercostal space.
3060589|NCT02157350|Experimental|Panretinal Laser Photocoagulation|See interventional description.
3060590|NCT02157337|Experimental|atrovastatin|
3060591|NCT02157337|Placebo Comparator|placebo|
3060592|NCT02157324|Experimental|acalabrutinib|Starts with acalabrutinib for 7 days, then combined with ACP-319 afterwards.
3060593|NCT02157324|Experimental|ACP-319|Starts with ACP-319 for 7 days, then combined with acalabrutinib afterwards.
3060594|NCT02157311|Experimental|Four consecutive days on treatment and 3 days off|All patients will take a combination of three HIV treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
3060596|NCT02157298|Placebo Comparator|Placebo|dapagliflozin tablet 5mg placebo
3060597|NCT02157285|No Intervention|Routine Counseling|Subjects randomized to receive routine counseling before selecting a method of contraception
3060598|NCT02157285|Experimental|Peer Mentor counseling|Subjects randomized to receive peer counseling before selecting a method of contraception
3060599|NCT02157272|Experimental|Rivaroxaban|Rivaroxaban 20mg qd, Rivaroxaban 15mg qd if creatinine clearance between 30-49 ml/min (calculated by Cockroft-Gault equation)
3060600|NCT02157272|Active Comparator|Warfarin|To Keep an INR between 2.0 and 3.0
3060601|NCT02157246|Other|Group A, pimonidazole, no CRT|Biopsy, Blood sample, F-MISO PET, pCT, functional MRI, Pimonidazole
3060602|NCT02157246|Other|Group B, CRT|Biopsy, Blood sample, F-MISO PET, pCT, functional MRI
3060603|NCT02157233|Experimental|Hot environment|Subjects will perform the intervention in a hot environment (33°C)
3060604|NCT02157233|Sham Comparator|Neutral environment|Subjects will perform the intervention in a neutral environment (22°C)
3060605|NCT02157220|Experimental|Randomised group 1|This study is looking at a group of patients with knee osteoarthritis or other pathology requiring total knee arthroplasty. This group of patients were randomised to receive either a mobile bearing prosthesis or a fixed bearing prosthesis.
3060606|NCT02157220|Experimental|Randomised group 2|This study is looking at a group of patients with knee osteoarthritis or other pathology requiring total knee arthroplasty. This group of patients were randomised to receive either a mobile bearing prosthesis or a fixed bearing prosthesis.
3060607|NCT02157207|Placebo Comparator|Placebo|Placebo will be ingested in front of laboratory personnel in two doses, separated by 30 minutes to increase absorption, consumed 90 and 60 minutes before the testing protocol. Placebo microcrystalline cellulose capsules will be of similar taste, color and appearance.
3060608|NCT02157207|Experimental|Antioxidant|"Supplementation will be ingested in front of laboratory personnel in two doses, separated by 30 minutes to increase absorption, consumed 90 and 60 minutes before the testing protocol. The first dose will consist of 300 mg of α-lipoic acid, 500 mg of vitamin C, and 200 IU of vitamin E, and the second dose will be 300 mg of α-lipoic acid, 500 mg of vitamin C, and 400 IU.~of vitamin E."
3060609|NCT02157181|Experimental|HCL, 2CdA +/- Rituximab|"Risk stratification~HCL variant will be treated with cladribine plus rituximab, independent of previous therapy~Relapses of HCL will be treated with cladribine plus rituximab, duration of remission of the previous therapy is < 3 years.~All repeated relapses (> 1st relapse) after previous therapies with purine analogues and/or interferon will be treated with cladribine plus rituximab.~Cladribine (LITAK®) 0.14 mg/kg daily Days 8-12 subcutaneous bolus injection Rituximab (Mabthera®) 375 mg/m2 daily Days 1, 8, 15, 22 infusion~Relapses of HCL will be treated with cladribine monotherapy, if the duration of remission of the previous therapy is > 3 years.~Cladribine (LITAK®) 0.14 mg/kg daily Days 1-5 subcutaneous bolus injection"
3060610|NCT02157168|No Intervention|Control Group|Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker. Those not invited will constitute the usual care control group.
3060611|NCT02157168|Other|Intervention Group|"Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker in the intervention group.~The intervention group will be made up of two sub groups. The group of individuals who accept the invitation to participate (IG1) in the intervention and receive it, and those randomized to the intervention group but who reject the opportunity to participate (IG2)."
3060612|NCT02157155|Experimental|Intervention|Insulin reduction and mimic infection with LPS
3060613|NCT02157155|No Intervention|Control|Normal insulin and no LPS
3060614|NCT02157142|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
3060615|NCT02157129|Experimental|LipoAerosol©|LipoAerosol© inhalation, 5x/d for 30min
3060616|NCT02157129|Other|Physiologic saline inhalation|Physiologic saline inhalation, 5x/d for 30min
3060617|NCT02157116|Experimental|Induction Chemotherapy|Cisplatin 75mg/m2 IV days 1, 15, 29; Docetaxel 75mg/m2 IV days 1, 15, 29; and Pegfilgrastim 6mg SC day 2, 16, 30
3060618|NCT02157103|Experimental|Bevacizumab|Cycle 1 (each cycle is 3 weeks): Bevacizumab 25 mg in 1 ml subcutaneously daily.
3060619|NCT02157090|Active Comparator|Herpes Patch SOS (Hansaplast®)|
3060620|NCT02157090|Active Comparator|Herpes vesicle patch of Compeed®|
3060621|NCT02157077|Experimental|Aflibercept|Patients will receive 2 mg of aflibercept by intravitreal injection every 4 weeks until week 8, followed by every 6 weeks to week 26
3060622|NCT02157051|Experimental|Treatment (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine with rhuGM-CSF ID every 28 days for 3 months and booster vaccines at 6 and 12 months in the absence of disease progression or unacceptable toxicity.
3060623|NCT02157038|Experimental|Procedures|RNA/DNA blood sample will be collected. Participant will complete questionnaires, MRI and strength and reflex testing.
3060624|NCT02157025|Experimental|Cartoon Intervention|Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry
3060625|NCT02157025|Active Comparator|Usual Care|Usual care procedures for Humphrey perimetry in young children
3060626|NCT02157012|Experimental|The condition of rheumatoid arthritis|
3060627|NCT02156999|Experimental|Osteoporosis|
3060628|NCT02156986||9 month old infant|
3060629|NCT02156986||12 month old infant|
3060630|NCT02156986||18 month old toddler|
3060631|NCT02156986||24 month old toddler|
3060632|NCT02156986||36 month old toddler|
3060677|NCT02156570|Experimental|Sofosbuvir and ribavirin|"Sofosbuvir tablet 400 mg daily Ribavirin tablet weight based dosing (1000mg <75 kg, 1200mg >/= 75kg) daily~Treatment will be for 6 weeks in all participants."
3060725|NCT02156336|Active Comparator|RANOLAZINE|"500 mg RANOLAZINE PO 2 times a day for 1 week (Week 1)~1000 mg RANOLAZINE PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)"
3060805|NCT02155764|Experimental|Octacalcium phosphate|Bone augmentation, after tooth extraction, with Octacalcium phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
3060633|NCT02156973|No Intervention|Group One Usual care|Patients attending for CT coronary angiography all receive an information leaflet with their appointment letter, and a brief verbal description of the scan by the radiographer immediately before it is undertaken, as standard care. All patients attending will be offered the opportunity to complete a short questionnaire (until all patients are recruited - anticipated to be 4 weeks). The Speilberger State-Trait Anxiety Index has been abbreviated and validated for use in outpatient settings to gauge levels of pre-procedural anxiety. This will be undertaken on arrival and repeated immediately before the scan, to see if patients feel better prepared after the standard interaction with staff.
3060634|NCT02156973|Experimental|Group Two Video information|The patient video will be introduced to Group Two once Group One has been completed. In addition to the information sheet these patients (again, for four weeks or until recruitment is complete) will be sent an internet hyperlink to its presence on YouTube (video-sharing website) and the Hospital website with their appointment letter. Patients who do not have internet access will be offered the opportunity to see the video in the preparation room while waiting for their scan. Questionnaires will be administered as before, again done twice to examine any late impact of the information on patient anxiety, and the patient will undergo their test.
3060635|NCT02156960|Experimental|Denosumab and/or teriparatide treatment|Denosumab and/or teriparatide treatment in osteoporotic patients
3060636|NCT02156947||Chronic cholecystitis|Laparoscopic cholecystectomy was performed. Gallbladder adhesion score and intraoperative findings of patients were assessed. Adhesion score, gallbladder perforation during the dissection, convertion to open cholecystectomy, operation time, drain usage and intraoperative complications were recorded.
3060637|NCT02156947||Acute cholecystitis|Laparoscopic cholecystectomy was performed. Gallbladder adhesion score and intraoperative findings of patients were assessed. Adhesion score, gallbladder perforation during the dissection, convertion to open cholecystectomy, operation time, drain usage and intraoperative complications were recorded.
3060638|NCT02156934|Experimental|Muscle derived stem cell|Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
3060639|NCT02156921|No Intervention|Control group|Self-guided training without app-based training (written hand-outs)
3060640|NCT02156921|Active Comparator|Intervention group|Self-guided training with app-based training
3060641|NCT02156908|Placebo Comparator|Placebo|
3060642|NCT02156908|Experimental|D-serine|D-serine
3060643|NCT02156895||Patients who are using Axitinib|
3060644|NCT02156882||TB patients and Tb suspects|Patients with confirmed tuberculosis who are treated by the National TB Programme
3060645|NCT02156869|Experimental|Intervention arm|The intervention was the use of a decision aid.
3060646|NCT02156869|No Intervention|Control arm|Usual care
3060647|NCT02156856||Hemodynamic optimisation|
3060648|NCT02156856||No hemodynamic optimisation|
3060649|NCT02156843|Experimental|Pyridorin|Pyridorin (pyridoxamine dihydrochloride) 300 mg oral BID (twice daily, every 12 hours) Capsule
3060650|NCT02156843|Placebo Comparator|Placebo|Placebo Oral Capsule taken BID (twice daily, every 12 hours)
3060651|NCT02156817||Late Preterm Infants (LPT)|34 weeks and 0-6 days gestational age
3060652|NCT02156817||Moderate preterm infants (MPT)|32 weeks and 0-6 days gestational age
3060653|NCT02156804|Experimental|Nivolumab (BMS-936558)|Nivolumab (BMS-936558) Intravenous solution every 2 weeks
3060654|NCT02156791|Experimental|gpASIT+TM|
3060655|NCT02156778|Active Comparator|Extended Standard Care (Stroke Card)|
3060656|NCT02156778|Active Comparator|Standard Care|
3060657|NCT02156752|Experimental|ACT|Behavioral weight loss plus techniques from Acceptance and Commitment Therapy
3060658|NCT02156752|Active Comparator|SR|Behavioral weight loss plus self-regulation techniques
3060659|NCT02156752|Active Comparator|WLO|Behavioral weight loss plus cooking tips and demonstrations
3060660|NCT02156739|Experimental|MRI with Gadoxetate + Gadopentetate Dimeglumine|Participants undergoing a follow-up MRI with initial administration of Gadoxetate by vein over about 1 minute. Then, at the 20 minute mark during MRI, participant receives Gadopentetate Dimeglumine by vein over about 1 minute.
3060661|NCT02156726||Low dose FCR in Elderly/Comorbid CLL|low dose FCR
3060662|NCT02156713|Experimental|CIMT Camp|Members of this study will participate in the group CIMT camp.
3060663|NCT02156700||Liver tumors|Measurement of tumor stiffness by Shear wave elastography - SWE™
3060664|NCT02156687|Active Comparator|Cololast, Inc. Restorell Y mesh|Y mesh
3060665|NCT02156687|Active Comparator|Coloplast, Inc. Restorelle Dual flat mesh|Dual flat mesh
3060666|NCT02156674|Experimental|Naglazyme®|weekly Naglazyme® infusion for 2 years
3060667|NCT02156661|Active Comparator|Oxytocin|"Oxytocin: Syntocinon-Spray, Novartis~intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT"
3060668|NCT02156661|Placebo Comparator|Placebo|Placebo nasal spray
3060669|NCT02156648|Other|Feasibility study|All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
3060670|NCT02156635|Experimental|Active tdcs / CIMT|Participants in the acute post-stroke stage will receive active tDCS associate to rehabilitation (CIMT)
3060671|NCT02156635|Sham Comparator|Sham stimulation / CIMT|Participants in the acute post-stroke stage will receive sham stimulation associate to rehabilitation (CIMT)
3060672|NCT02156622||Depression Care Manager|All enrolled in AIM 3 received decision support from Depression Care Manager
3060673|NCT02156609|Experimental|Percutaneous coronary intervention|Percutaneous ventricular support with the HeartMate PHP during high risk percutaneous coronary intervention
3060674|NCT02156596|Active Comparator|Intravenous NSAI|patients received 100 mg of ketoprofen (NSAID) by IV root and in parallel 3 nebulisation of serum saline (SS) over 30 minutes.
3060675|NCT02156596|Experimental|Nebulised Morphine|patients received 3 nebulisation of morphine (5 mg each) and in parallel 50 ml of SS by IV root over 30 minutes.
3060676|NCT02156583||Older, left ventricular assist device|Older heart failure patients undergoing left ventricular assist device implantation
3060724|NCT02156336|Placebo Comparator|PLACEBO|"500 mg PLACEBO PO 2 times a day for 1 week (Week 1)~1000 mg PLACEBO PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)"
3060678|NCT02156557|Experimental|peptide application|"Investigational Agent Administration~KCCFPAQ-GGGSK-(5-FITC)-NH2~1.2 mg lyophilized powder per single-use amber vial~Lyophilized powder reconstituted with 10 mL of 0.9% NaCl~Final concentration of 76.4 μM for single, one-time topical application~The entire 10 mL solution will be sprayed topically onto area of interest by the Clinical Research Associate (CRA)/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)"
3060679|NCT02156544|Experimental|CKD-519 25mg|CKD-519 25mg or placebo
3060680|NCT02156544|Experimental|CKD-519 50mg|CKD-519 50mg or placebo
3060681|NCT02156544|Experimental|CKD-519 100mg|CKD-519 100mg or placebo
3060682|NCT02156544|Experimental|CKD-519 200mg|CKD-519 200mg or placebo
3060683|NCT02156544|Experimental|CKD-519 400mg|CKD-519 400mg or placebo
3060684|NCT02156531|Placebo Comparator|Attention Control Condition|3.c.14.5. Arm 1: Attention Control Condition. The minimally effective attention-control group procedure is identical to the active CBM procedure except that during the presentation of the trials where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. Thus, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active versions of CBM in Arms 2 and 3.
3060685|NCT02156531|Experimental|Arm 2: Self-administered CBM only|3.c.14.6. Arm 2: Self-Administered CBM Only. Youth assigned to this arm will receive the self-administered active CBM intervention. As described above in detail, in the 80% of CBM trials where a neutral and disgust face are both presented, the probe always replaces the neutral face. Thus, participants are trained to disengage their attention from threat. These youth do not receive Adherence Promotion telephone calls.
3060686|NCT02156531|Experimental|Arm 3: Self-administered CBM + Adherence Promotion|3.c.14.7. Arm 3: Self-Administered CBM + Adherence Promotion. Youth assigned to this arm will receive both the self-administered active CBM intervention and the telephone coach calls to deliver the Adherence Promotion (AP) procedures. AP procedures are intended to compensate for the important nonspecific 'scaffolding' provided by research staff when CBM has been traditionally delivered in laboratories. This includes technical assistance with use of the program, support/encouragement, motivational enhancement, and brainstorming solutions to barriers to regular sessions. The addition of AP to the 3rd arm of this trial attempts to recreate much of this nonspecific, yet likely important, support of in-person interventions, which we hypothesize will lead to greater participant adherence to the program and therefore better clinical outcomes.
3060687|NCT02156518|Experimental|Vocal Function Exercises|Vocal Function Exercises
3060688|NCT02156518|Active Comparator|Vocal hygiene|Vocal hygiene
3060689|NCT02156505|Experimental|DoubleBare stent|Placement of double bare stent
3060690|NCT02156492|Experimental|Evacetrapib Single|Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.
3060691|NCT02156492|Experimental|Evacetrapib Multiple|Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib for 14 days.
3060692|NCT02156492|Active Comparator|Simvastatin|Part 2, Cohorts B, Participants will receive simvastatin orally, once daily on Days 1 - 4.
3060693|NCT02156492|Experimental|Evacetrapib and Simvastatin|Part 2, Cohorts B, Participants will receive evacetrapib orally once daily on Days 5 - 14 and simvastatin orally, once daily on Days 15 - 22.
3060694|NCT02156492|Active Comparator|Atorvastatin|Part 2, Cohorts C, Participants will receive atorvastatin orally, once daily on Days 1 - 4.
3060695|NCT02156492|Experimental|Evacetrapib and Atorvastatin|Part 2, Cohorts C, Participants will receive evacetrapib orally once daily on Days 5 - 14 and atorvastatin orally, once daily on Days 15 - 22.
3060696|NCT02156479||Allo-HSCT recipients|Patients receiving an allogeneic hematopoietic stem cell transplantation for the first time, being either CMV seropositive or receiving a graft from a CMV seropositive donor or both, donor and recipient are CMV seropositive
3060697|NCT02156466|Experimental|MSB0010841 30 mg|
3060698|NCT02156466|Experimental|MSB0010841 60 mg|
3060699|NCT02156466|Experimental|MSB0010841 120 mg|
3060700|NCT02156466|Experimental|MSB0010841 240 mg|
3060701|NCT02156466|Placebo Comparator|Placebo|
3060702|NCT02156453||Total knee arthroplasty|Patients undergoing uncomplicated total knee replacement
3060703|NCT02156440|Placebo Comparator|Placebo|Placebo capsules: one capsule taken 3 times per day with water. Subjects are to drink 6 to 8 glasses of water daily.
3060704|NCT02156440|Experimental|SierraSil Joint Formula 14|SierraSil Joint Formula 14 capsules: one capsule taken 3 times per day with water. Subjects are to drink 6 to 8 glasses of water daily.
3060705|NCT02156427|Experimental|VITICELL|In this arm, lesions will be treated by autologous epidermal cells suspension (containing hyaluronic acid) obtained after VITICELL kit's use, a class III medical device.
3060706|NCT02156427|Sham Comparator|PLACEBO|In this arm, lesions will be treated by a suspension of hyaluronic acid without epidermal cells.
3060707|NCT02156414||Clinically Localized Prostatic Neoplasm|Radical Prostatectomy Extended Lymphadenectomy
3060708|NCT02156401||Cohort 1: Suspect of Pulmonary Embolism (PE)|
3060709|NCT02156401||Cohort 2: Suspect of Deep Vein Thrombosis (DVT)|
3060710|NCT02156401||Cohort 3: Incidental Venous Thromboembolism (VTE)|
3060711|NCT02156388|Experimental|Ia-GW003 50μg/kg|2-3 subjects
3060712|NCT02156388|Experimental|Ia-GW003 150μg/kg|2-3 subjects
3060713|NCT02156388|Experimental|Ia-GW003 300μg/kg|3-6 subjects
3060714|NCT02156388|Experimental|Ia-GW003 400μg/kg|3-6 subjects
3060715|NCT02156388|Experimental|Ia-GW003 500μg/kg|3-6 subjects
3060716|NCT02156388|Experimental|Ia-GW003 600μg/kg|3-6 subjects
3060717|NCT02156388|Experimental|Ib-GW003 150μg/kg|6-8 subjects
3060718|NCT02156388|Experimental|Ib-GW003 300μg/kg|6-8 subjects
3060719|NCT02156375|Experimental|Ustekinumab 90 mg/mL|
3060720|NCT02156375|Experimental|Ustekinumab 5 mg/mL|
3060721|NCT02156362|Other|follow up|
3060722|NCT02156349|Other|Control Group|Patients treated by usual customary medical practice (Usual Care) in the out-patient facility i.e. Diabetes specialized medical practice, Medical Care Center or hospital outpatient clinic.
3060723|NCT02156349|Other|Intervention group|"Patients are treated according to the concept Integrated personalized diabetes management."
3060726|NCT02156323|Experimental|Treatment Sequence 1|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, RO7033877; Period 2, CMS; Period 3, RO7033877 + CMS. Each period is separated by a wash-out period of at least 6 days between last dose and start of next treatment.
3060727|NCT02156323|Experimental|Treatment Sequence 2|Participants will be randomized to one of two treatment sequences. Sequence 2 is: Period 1, CMS; Period 2, RO7033877; Period 3, RO7033877 + CMS. Each period is separated by a wash-out period of at least 6 days between last dose and start of next treatment.
3060728|NCT02156297||Induction Group|
3060729|NCT02156297||Consolidation Group|
3060730|NCT02156297||Salvage Group|
3060731|NCT02156297||Maintenance Group|
3060732|NCT02156297||Alleviatitive Group|
3060733|NCT02156284|Experimental|Empathic behaviour by nurses|Patients who received empathic behaviour was performed by a trained nurse.
3060734|NCT02156271|Active Comparator|ramelteon|Subjects will take ramelteon 8mg one time daily 30 minutes before bedtime with approximately 8 ounces of water. Subjects have a 2 out of 3 chance of receiving ramelteon.
3060735|NCT02156271|Placebo Comparator|placebo|15 subjects will be randomized to receive the placebo
3060736|NCT02156258||Cancer Cases|Collection of cancer cases using Full Field Digital Mammography (FFDM) Mammography and Digital Breast Tomosynthesis (DBT) Mammography
3060737|NCT02156258||Recall Cases|Collection of Imaging Recall Cases using FFDM Mammography and DBT Mammography
3060738|NCT02156258||Non-Cancer Cases|Collection of Non-Cancer Cases using FFDM Mammography and DBT Mammography
3060739|NCT02156245|Experimental|"Conventional group"|
3060740|NCT02156245|Experimental|"Combined group"|
3060741|NCT02156232|Active Comparator|TIPS,Emboliaztion|The covered stents were used for TIPS The SPSS will be embolized during the procedure of TIPS
3060742|NCT02156232|Active Comparator|TIPS alone|The covered stents were used for TIPS No embolization of SPSS will be performed during TIPS
3060743|NCT02156219||Under separation|Exposure to the separation of women and men in the metro of Mexico City.
3060744|NCT02156219||No treatment|Non exposure to the separation of women and men in the metro of Mexico City.
3060745|NCT02156206||123 women line|Women who call the 123 emergency line and have also immediate services from the 123 women emergency line
3060746|NCT02156206||No treatment|Women who call the 123 emergency line and do not have immediate services from the 123 women emergency line
3060747|NCT02156193|Experimental|Prophylactic clip|Before conventional snare polypectomy, hemoclips will be applied on the base of stalk.
3060748|NCT02156193|Active Comparator|No prophylactic management|Conventional snare polypectomy will be performed without any preventive management.
3060749|NCT02156180||Early stage oral cavity / oropharyngeal cancer|Exhaled breath
3060750|NCT02156167|Experimental|CP810 and Codacs™Test System|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
3060751|NCT02156154|Placebo Comparator|Intravenous 0.9% sodium chloride|0.9% sodium chloride infusion will be initiated before the surgical incision with 100 ml and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
3060752|NCT02156154|Experimental|Intravenous Acetaminophen|Acetaminophen infusion will be initiated before the surgical incision with 1 g and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
3060753|NCT02156141|Experimental|Supervised high intensity training|"8 weeks of supervised high intensity training, 10 minutes, 3 times a week (once a week supervised) on a cycle ergometer followed by 8 weeks of unsupervised optional training.~Participants: Patients with Kennedy's disease or healthy control subjects (individually matched with patients).~Participants: Patients with Kennedys disease and healthy control subjects."
3060754|NCT02156141|Experimental|Unsupervised High intensity training|"8 week control period with no training followed by 8 weeks of unsupervised high intensity training on a cycle ergometer.~Participants: Patients with Kennedy's disease."
3060755|NCT02156128|Experimental|Cogmed|Participants in a 3,5 week vocational rehabilitation program (containing cognitive therapy and physical exercise) are instructed to use a computer-based working memory training program (named CogMed) each weekday (5 days a week) for 5 weeks. Each training session consists of 8 different tasks and lasts 40-50 minutes.
3060756|NCT02156128|Active Comparator|Control group|These subjects will participate in the vocational rehabilitation program for 3,5 weeks. The program includes cognitive therapy (ACT) and physical activity, but no working memory training.
3060757|NCT02156076|Placebo Comparator|Arm A: Placebo (Matching with BMS-919373)|Placebo (Matching with BMS-919373) 0 mg tablets orally once daily for approximately 28 Days
3060758|NCT02156076|Experimental|Arm B: BMS-919373|BMS-919373 3 mg tablets orally once daily for approximately 28 days
3060759|NCT02156076|Experimental|Arm C: BMS-919373|BMS-919373 5 mg tablets orally once daily for approximately 28 days
3060760|NCT02156076|Experimental|Arm D: BMS-919373|BMS-919373 12 mg tablets orally once daily for approximately 28 days
3060761|NCT02156063|Experimental|NT100|NT100 Dose 1
3060762|NCT02156063|Placebo Comparator|Placebo|Placebo
3060763|NCT02156050|Active Comparator|OBLOO device (MEDIPREMA)|two sessions of 4 hours Phototherapy treatment
3060764|NCT02156050|Experimental|BBLOO Device (MEDIPREMA)|two sessions of 4 hours Phototherapy treatment
3060765|NCT02156037|Experimental|dashboard team care intervention|Dashboard team
3060766|NCT02156037|Active Comparator|usual diabetes team control|usual clinical diabetes team with no access to the diabetes dashboard
3060767|NCT02156024|Placebo Comparator|placebo|placebo drink, 1 dose at a time, twice a day, duration: 4 weeks
3060768|NCT02156024|Active Comparator|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
3060769|NCT02156011||Instrumented knee implant|"4-6 subjects with an instrumented TKA, that has been implanted within the study Kniemessprothese: Belastungsmessung bei Patienten mittels einer instrumentierten Knie-Endoprothese (EA4/069/06) approved and conducted at the Charité- Universitätsmedizin in Berlin, Germany, will be involved in this project."
3060802|NCT02155790|Experimental|Renal Denervation by Neurolysis|Infusion of 0.3 ml of dehydrated alcohol (96%-98%) into the peri-adventitial space of the renal artery, to achieve renal denervation by Neurolysis, via three simultaneous deployed needles, situated at the distal end of the Peregrine System Infusion Catheter.
3060770|NCT02155998||PREVENT study patients|Patients with locally advanced prostate cancer with high and very high risk of recurrence, who underwent surgery or radiotherapy within 3 months prior to enrolment, 18 years and older, consented to participate in this non-interventional study, being treated for prostate cancer in the oncology institutions / departments in the Russian Federation.
3060771|NCT02155985|Active Comparator|Aspirin 300 mg + aspirin 100 mg placebo|At week 0, participants were prescribed aspirin 300 mg (one tablet) and placebo for aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study product tablets to allow for a 4-week washout period.
3060772|NCT02155985|Active Comparator|Aspirin 100 mg + aspirin 300 mg placebo|At week 0, participants were prescribed a placebo for aspirin 300 mg (one tablet) and aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study product tablets to allow for a 4-week washout period.
3060773|NCT02155985|Placebo Comparator|Aspirin 300 mg + aspirin 100 mg placebos|At week 0, participants were prescribed a placebo for aspirin 300 mg (one tablet) and placebo for aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study products tablets to allow for a 4-week washout period.
3060774|NCT02155972|Active Comparator|Bifidobacterium infantis|Bifidobacterium infantis (Align) 10.00 million cfu capsule once daily
3060775|NCT02155972|Placebo Comparator|Placebo|Placebo capsule once daily
3060776|NCT02155959||one group|one group receiving a toric intraocular lens during cataract surgery.
3060777|NCT02155946|Experimental|Arm 1|Group receives active brain stimulation plus memory rehabilitation
3060778|NCT02155946|Sham Comparator|Arm 2|Group receives sham brain stimulation plus memory rehabilitation
3060779|NCT02155946|Active Comparator|Arm 3|Group receives active brain stimulation plus reminiscence training
3060780|NCT02155946|Active Comparator|Arm 4|Group receives sham brain stimulation plus reminiscence training
3060781|NCT02155933||Hyperandrogenemia|Peripubertal girls with hyperandrogenemia
3060782|NCT02155933||Controls|Peripubertal girls without hyperandrogenemia
3060783|NCT02155920|Experimental|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
3060784|NCT02155907||Rtest, Atrial fibrillation|Patients with ischemic stroke or TIA within the last week. Sinus rhythm on the surface ECG. Age ≥ 60 years. Given written informed consent
3060785|NCT02155894|Experimental|Disease control, Telemedicine, doctor|Using an online platform for self assessment and with the Flare instrument as decision support, the patients are contacted over the telephone by a doctor at week 13, 26, 39.
3060786|NCT02155894|Experimental|Disease control, Telemedicine, nurse|Using an online platform for self assessment and with the Flare instrument as decision support, the patients are contacted over the telephone by a nurse at week 13, 26, 39.
3060787|NCT02155894|No Intervention|Usual care|Usual care: control of disease activity with consultations in the outpatient clinic.
3060788|NCT02155881|Experimental|Ciclesonide 200 mcg|Ciclesonide 200 mcg nasal spray, 2 actuations (sprays) per nostril (50 mcg ciclesonide/actuation), daily, for 2 weeks.
3060789|NCT02155881|Placebo Comparator|Placebo|Ciclesonide placebo-matching nasal spray, 2 actuations (sprays) per nostril, daily, for 2 weeks.
3060790|NCT02155868|Experimental|Intervention|"Cerebral NIRS monitoring by means of FORE-SIGHT Universal Cerebral Oximeter MC-2030C.~Predefined protocol of interventions for correcting rSO2 desaturation (< 60%) during cardiac surgery and the first six hours after it."
3060791|NCT02155868|Placebo Comparator|Control|Only cerebral NIRS monitoring by means of FORE-SIGHT Universal Cerebral Oximeter MC-2030C during cardiac surgery and the first six hours after it.
3060792|NCT02155855|Experimental|Telemedicine|"Telemedicine group will test blood glucose at least 4 times a day Each time the meter time-stamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (<70 mg/dL > 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit."
3060793|NCT02155855|Active Comparator|Control|Control Subjects will continue routine care which requires blood glucose testing at least 4 times a day. Parents will use customary ways to communicate (pager, email, fax or phone) with the Diabetes team, if they are concerned about glycemic control..
3060794|NCT02155842|Experimental|High intensity endurance exercise|Four weeks comprehensive cardiac rehabilitation with moderate volume high intensity endurance exercise, followed by 6 months non-supervised endurance exercise
3060795|NCT02155842|Active Comparator|Moderate continuous endurance exercise|Four weeks comprehensive cardiac rehabilitation with moderate volume moderate intensity endurance exercise, followed by 6 months non-supervised endurance exercise
3060796|NCT02155829|Experimental|Riluzole|"Weeks 1 and 2: Riluzole 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeks~Weeks 3 to 8 (optional dose increase): 2 Riluzole 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks"
3060797|NCT02155829|Placebo Comparator|Placebo|"Weeks 1 and 2: Placebo 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeks~Weeks 3 to 8 (optional dose increase): 2 Placebo 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks"
3060798|NCT02155816|Placebo Comparator|Placebo|MCT (medium chain triglyceride)
3060799|NCT02155816|Experimental|Omega 3|Omega-3 fatty acid ethyl esters, 2 soft gels of total 1000mg (660mg EPA +340mg DHA)/day.
3060800|NCT02155816|Experimental|Omega 7 + 3|210mg of Omega-7 fatty acid and 1000mg (660mg EPA +340mg DHA) of Omega-3
3060801|NCT02155803|Experimental|Sarcoidosis related Calcium Dysregulation|Subjects with Sarcoidosis associated calcium dysregulation will be administered 80 units of Acthar Gel (adrenocorticotropic hormone) twice a week for 12 weeks. Clinical visits will be scheduled for -30 days, day of 1st dose and 4,8,12 and 16 week after 1st dose to monitor the health of subjects.
3060803|NCT02155777|No Intervention|No intervention|No intervention.
3060804|NCT02155777|Active Comparator|OrthoNovum 1/35|OrthoNovum 1/35
3060925|NCT02155036|No Intervention|Usual care|Usual care
3060806|NCT02155764|Active Comparator|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
3060807|NCT02155764|Active Comparator|Tricalcium phosphate|Bone augmentation, after tooth extraction, with Tricalcium phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
3060808|NCT02155751|Experimental|Full NELIP group|"These women (n=10) will receive the full NELIP intervention and will be introduced to both the dietary program and the exercise program as described above under detailed description."
3060809|NCT02155751|Experimental|Exercise program only/ELIP|These women (n=10) will only be given the exercise component (ELIP) of NELIP, as outlined below in interventions. Once dietary intake has been assessed, this group will not be given any dietary intervention but will be encouraged to eat a healthy, balanced diet. Access to the nutritionist in the clinic is available and encouraged.
3060810|NCT02155751|Experimental|Nutrition program only/NLIP|These women (n=10) will only be given the nutrition program (NLIP) of NELIP as outlined below in intervention. They will be encouraged to be more active but will not be given an exercise intervention.
3060811|NCT02155751|No Intervention|Control|A control group (n=30) of obese pregnant women will also be recruited and will be matched by pre-pregnancy BMI, maternal age and parity, with no intervention, but will attend the clinic for standard obstetric care and follow-up.
3060812|NCT02155738|Placebo Comparator|Placebo|100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
3060813|NCT02155738|Experimental|IV Acetaminophen|100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
3060814|NCT02155725|Experimental|Human Fibrinogen concentrate|2 vials (200ml) / 3g intravenous
3060815|NCT02155725|Placebo Comparator|Placebo|2 vials (200ml)
3060816|NCT02155712|Active Comparator|Triathlon Tritanium Knee|
3060817|NCT02155712|Active Comparator|Triathlon Knee|
3060818|NCT02155699|Experimental|Exercise 1|65% of V02 Max, 3x per week, 3 months
3060819|NCT02155699|Experimental|Exercise 2|85% of VO2 Max, 2x per week, 3 months
3060820|NCT02155699|No Intervention|Waitlist|Waitlist (three months)
3060821|NCT02155686|Experimental|Biosensors|Participants in this arm are equipped both with home telecare/automation and with biometric sensors
3060822|NCT02155686|Active Comparator|Automation|Participants in this arm are equiepd with home automation only
3060823|NCT02155673|Experimental|Low Dose GCS-100|Low dose of GCS-100
3060824|NCT02155673|Experimental|High Dose GCS-100|GCS-100 High dose
3060825|NCT02155660|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
3060826|NCT02155660|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
3060827|NCT02155660|Experimental|Benralizumab Arm C|Benralizumab administered subcutaneously
3060828|NCT02155660|Placebo Comparator|Placebo|Placebo administered subcutaneously
3060829|NCT02155647|Experimental|Avelumab|
3060830|NCT02155634|Experimental|Lenalidomide|Lenalidomide maintenance given until disease progression. Long term follow-up 5 years post last patient randomized.
3060831|NCT02155634|No Intervention|Observation|Observation until disease progression. Long term follow-up 5 years post last patient randomized.
3060832|NCT02155621|Experimental|Genome Sequencing|There is only one arm to this study.
3060833|NCT02155608|Experimental|Active TNS|Active TNS
3060834|NCT02155608|Sham Comparator|Sham TNS|Sham TNS
3060835|NCT02155595||500 with BP treatment|patients will undergo lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
3060836|NCT02155595||500 without BP treatment|patients will undergo lab tests, X-ray, bone scan or MRI, as needed
3060837|NCT02155582|Experimental|Arm 1|0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients
3060838|NCT02155582|Experimental|Arm 2|45 mg and 60 mg for the diabetic patients
3060839|NCT02155569|Active Comparator|Transperitoneal Cesarean|
3060840|NCT02155569|Active Comparator|Extraperitoneal Cesarean|
3060841|NCT02155556||Healthy volunteers|
3060842|NCT02155543|Experimental|Cohort 1: AGN-223575 Form A/Vehicle|One drop of AGN-223575 Formulation A in the study eye and one drop of AGN-223575 vehicle in the other eye on day 1, followed by one drop of AGN-223575 Formulation A twice daily in the study eye and 1 drop of AGN-223575 vehicle in the other eye twice daily for 6 days.
3060843|NCT02155543|Experimental|Cohort 2: AGN-223575 Formulation A BID|One drop of AGN-223575 Formulation A in both eyes on day 1, followed by one drop of AGN-223575 Formulation A twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation A in both eyes on day 15.
3060844|NCT02155543|Experimental|Cohort 3: AGN-223575 Formulation B BID|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
3060845|NCT02155543|Experimental|Cohort 4: AGN-223575 Formulation C BID|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
3060846|NCT02155543|Placebo Comparator|AGN-223575 Vehicle BID|One drop of AGN-223575 vehicle in both eyes on day 1, followed by one drop of AGN-223575 vehicle twice daily in both eyes for 13 days, and a single drop of AGN-223575 vehicle in both eyes on day 15.
3060847|NCT02155543|Experimental|Cohort 5: AGN-223575 Formulation C TID|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C three times daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
3060848|NCT02155543|Placebo Comparator|AGN-223575 Vehicle TID|One drop of AGN-223575 vehicle in both eyes on day 1, followed by one drop of AGN-223575 vehicle three times daily in both eyes for 13 days, and a single drop of AGN-223575 vehicle in both eyes on day 15.
3060849|NCT02155530|Experimental|High efficacy statin group (homogeneous)|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
3060850|NCT02155530|Active Comparator|Low efficacy statin group (homogeneous)|homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
3060926|NCT02155036|Active Comparator|Exercise|exercise intervention
3060851|NCT02155517|Experimental|Propofol Infusion|"Propofol will be administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider and Cortinez (arcomed ag, Medical System, Switzerland )..~The study will make in two stages:~STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.~STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes."
3060852|NCT02155504|Experimental|ASP3700 single ascending dose cohort|Part 1
3060853|NCT02155504|Placebo Comparator|Placebo single ascending dose cohort|Part 1
3060854|NCT02155504|Experimental|ASP3700 alone|Part 2
3060855|NCT02155504|Active Comparator|ASP3700 and itraconazole|Part 2
3060856|NCT02155491||Prospective cohort 1|In order to observe temporal trends in management of VTE a first cohort of 5000 consecutive unselected patients treated for acute VTE will be recruited. This cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis. They will be followed prospectively for 36 months.
3060857|NCT02155491||Prospective cohort 2|In order to observe temporal trends in management of VTE a second cohort of 5000 consecutive unselected patients treated for acute VTE will be recruited. Recruitment into the second cohort will commence when recruitment is completed in the first cohort. This cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis. They will be followed prospectively for 36 months.
3060858|NCT02155478|Other|AMO ZCB00|AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL
3060859|NCT02155478|Active Comparator|ISERT 250|ISERT 250 (HOYA, Japan): a standard IOL
3060860|NCT02155465|Experimental|Ruxolitinib and Erlotinib|"Phase I The study will follow a standard 3+3 dose escalation trial design. Three to six patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (21 days) before a dose escalation decision is made.~Phase II Once the MTD has been determined, patients will be enrolled in the phase 2 portion of the single-arm, two-stage, open-label study to determine efficacy of erlotinib and ruxolitinib. Patients will receive erlotinib and ruxolitinib at the MTD established in the phase I portion. The patient take their previous dose of erlotinib if it is less than 150mg daily."
3060861|NCT02155452||With ALA|Patients with malignant glioma. 25 patients will be provided the ALA for inducing fluorescence
3060862|NCT02155452||Without ALA|5 tumor tissue samples from ACTREC tumor tissue repository will be obtained. These would be malignant gliomas or other brain tumor samples where ALA is usually not administered and will be used as controls and for calibration purposes
3060863|NCT02155439|Active Comparator|Triamcinolone|kortikosteroid
3060864|NCT02155439|Active Comparator|5-fluorouracil|antimitotic drug
3060865|NCT02155426||Treatment|Treatment: Chemotherapy or targeted therapy
3060866|NCT02155400|Experimental|Prototype development|10 patients (this phase will be terminated once prototype is confirmed ready) Intervention: prototype device
3060867|NCT02155400|Active Comparator|Treatment arm - Prototype|- 18 patients Intervention: Prototype device (heating both sole of foot and popliteal fossa with compression)
3060868|NCT02155400|Active Comparator|Control arm - Forced Air Warming Blanket|18 patients Intervention: Forced air warming blanket (Bair hugger)
3060869|NCT02155400|Active Comparator|Comparison - Sole of foot only|9 patients heating sole of foot only Intervention: prototype device
3060870|NCT02155400|Active Comparator|Comparison - Popliteal fossa only|9 patients heating popliteal fossa only Intervention: prototype device
3060871|NCT02155387||Coronary artery bypass graft surgery|with cardiopulmonary bypass
3060872|NCT02155387||Pulmonary metastasectomy by thoracotomy|with one lung ventilation
3060873|NCT02155387||Minimal invasive mitral valve surgery|with cardiopulmonary bypass and one lung ventilation
3060874|NCT02155374|Active Comparator|Sliding scale insulin|Sliding scale insulin Glucose 7.8-12 mmol/l --> 2 IU insulin, glucose 12.1-17 mmol/l --> 4 IU insulin, glucose ≥17.1 mmol/l --> 6 IU insulin. In case of insufficient control, insulin doses will be increased
3060875|NCT02155374|Experimental|Intermediate acting insulin|Intermediate acting insulin, 0.01 IU / mg prednison / kg body weight with a maximum of 0.5 unit insulin per kg body weight. In case of age > 70 years or diminished renal function (GFR <30ml/min)
3060876|NCT02155361|Active Comparator|Topical Citrullus colocynthis fruit oil|Topical Citrullus colocynthis fruit oil (1%) 1 cc twice daily
3060877|NCT02155361|Placebo Comparator|Placebo (Vehicle)|Topical vehicle oil 1 cc twice daily
3060878|NCT02155348|Active Comparator|Multifocal group|Bilateral cataract surgery with implantation of multifocal IOLs
3060879|NCT02155348|Active Comparator|Monovision|Bilateral cataract surgery with monovision
3060880|NCT02155335|Experimental|Prefilled Syringe→Smartject™ Device|Golimumab 50 mg supplied in a prefilled syringe administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied in the Smartject 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab).
3060881|NCT02155335|Experimental|Smartject™ Device→ Prefilled Syringe|Golimumab 50 mg supplied in a Smartject administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied a prefilled syringe 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab.
3060882|NCT02155322|Experimental|PEG-IFN|6.0 μg/kg/week subcutaneous administration during the Induction Phase of 8 weeks followed by a dose of 3.0 μg/kg/week subcutaneous administration in the Maintenance Period (Week 8 to Month 12)
3060883|NCT02155309|Experimental|Scopolamine|0.2 mg intranasal scopolamine, single dose
3060884|NCT02155309|Placebo Comparator|Placebo|placebo intranasal (0.1 mg per nostril), single dose
3060999|NCT02154529|Experimental|Phase 1b, Arm 2|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 250mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
3061079|NCT02154074|Active Comparator|N1 group: Isoflurane & saline|for normal patients: inhale Isoflurane + the same volume of saline during operation
3060885|NCT02155296|Experimental|Schools receiving RPI|"This arm contains schools receiving RPI. RPI offers a continuum of practices that range from informal (e.g., using affective statements that communicate feelings) to formal (e.g., hosting a restorative circle where participants are encouraged to express emotions and form emotional bonds). The circles or group meetings that are designed to take place between school staff and students, are the crux of RPI. School staff are encouraged to use the restorative practices to build relationships and resolve staff issues (restorative staff community), as well as when interacting with parents (restorative approach with families). All restorative practices encourage acting with youth and setting high expectations. When a school becomes proficient in all 11 essential practices it is officially recognized as a Restorative Practices School."
3060886|NCT02155296|Experimental|Schools not receiving RPI|This arm is the control arm and consists of schools that are not receiving RPI.
3060887|NCT02155283|Other|Treatment Continuous Passive Motion|Single-arm; 3-week treatment plan using Kyrobak compared to baseline (before treatment)
3060888|NCT02155270|Active Comparator|Precut|A corneal precut of 600µm will be performed.
3060889|NCT02155270|Active Comparator|Stab incision|A stab incision without corneal precut will be performed.
3060890|NCT02155257|Active Comparator|Modafinil|Modafinil 200 mg will be administered orally one time
3060891|NCT02155257|Placebo Comparator|Placebo|A placebo will be administered orally one time
3060892|NCT02155257|Active Comparator|Gabapentin|Gabapentin 900 mg will be administered orally one time
3060893|NCT02155244||Common bile duct stones|Common bile duct stones traeted with ERCP
3060894|NCT02155244||CBDS|treated with ERCP combined with surgery
3060895|NCT02155231||previous enrolled|
3060896|NCT02155231||New Enrolled|
3060897|NCT02155218|Active Comparator|Standard Injection Rate|Subjects will be given a small amount of contrast (approximately 1 cc test bolus) followed by administration of the remainder of the volume of contrast they are getting for their clinical study. This will be approximately 30-40 cc, depending on patient size, given at an injection rate of 2 - 2.5 cc/second.
3060898|NCT02155218|Experimental|Patient Tailored Injection Rate|"Subjects will be given a small amount of contrast (approximately 1 cc test bolus) followed by administration of the remainder of the volume of contrast they are getting for their clinical study. This will be approximately 30-40 cc, depending on patient size. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the contrast - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves. The injection rate will vary from 1 to 3 cc/second."
3060899|NCT02155205|Experimental|Telotristat etiprate|Single dose of telotristat etiprate followed by a 7-day washout.
3060900|NCT02155205|Active Comparator|Moxifloxacin|Single dose of moxifloxacin followed by a 7-day washout.
3060901|NCT02155205|Placebo Comparator|Placebo|Single dose of placebo with a 7-day washout to follow.
3060902|NCT02155192||Cohort 1|Participants who participated in NCT01483599 (X-PLORE) study.
3060903|NCT02155192||Cohort 2|Participants who participated in NCT00267969 (PHOENIX 1) study.
3060904|NCT02155192||Cohort 3|Participants who participated in NCT00307437 (PHOENIX-2) study.
3060905|NCT02155192||Cohort 4|Participants who participated in NCT00454584 (ACCEPT) study.
3060906|NCT02155179||Good prognosis|Sperm samples >15mill/ml >30% progresive sperms
3060907|NCT02155179||bad prognosis|Sperm samples <5mill/ml <5% progresive sperms
3060908|NCT02155166|Active Comparator|intracervical anesthesia|Intracervical anesthesia with lidocaine 2%
3060909|NCT02155166|Active Comparator|ibuprofen|ibuprofen 400 mg
3060910|NCT02155153|Experimental|Sugar Free Chewing Gum|All patients receiving sugar free gum
3060911|NCT02155153|No Intervention|Control|Patients receiving no intervention
3060912|NCT02155140|Active Comparator|Jejunal feeding|Nutritional supplementation via their jejunostomies for six weeks post hospital discharge, with continued assessment for a further 18 weeks.
3060913|NCT02155140|No Intervention|No jejunal feeding|No jejunal feeding of patients for six weeks following hospital discharge, with continued assessment for a further 18 weeks
3060914|NCT02155127|Experimental|walking intervention|Subjects are randomized to walking/functional strength program with weekly coaching or usual care. The program is for 12 weeks. The intervention includes 3 lower extremity strengthening exercises, and progressive walking.
3060915|NCT02155127|No Intervention|usual care|these subjects receive information on walking program, however do not receive any coaching over 12 weeks
3060916|NCT02155101|Active Comparator|ART with 2 NRTIs plus LPV/r (or ATV/r)|2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).
3060917|NCT02155101|Experimental|Darunavir|"Dosage form: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side."
3060918|NCT02155088|Experimental|Combination Therapy: BYL719, Gemcitabine, (Nab)-Paciltaxel|Dose escalation, followed by expansion, of BYL719 in combination with Gemcitabine and (Nab)-Paclitaxel. BYL719: once daily. Gemcitabine: Days 1,8, 15 of 28-day cycle. (Nab)-Paclitaxel: Days 1,8, 15 of 28-day cycle.
3060919|NCT02155075|Experimental|Arm 1|"Testing phase (Phase II) Arm 1 - 180 participant will be enrolled for this arm. Participants will be enrolled to undergo MIRA device imaging. Following the MIRA device imaging procedure, the optimized risk model will assign a binary result to the participant.~All participants will recive standart of care, participants with negative screening exams and a positive MIRA device imaging result will additionally undergo MRI."
3060920|NCT02155075|Experimental|Arm 2|Testing phase (Phase II) Arm 2 - 150 participant will be enrolled for this arm. Participants will be enrolled to undergo MIRA device imaging. Following the MIRA device imaging procedure all participants in arm 2 will be following standard of care, MIRA device imaging will NOT change their clinical path.
3060921|NCT02155062|Experimental|Whole grain rye|3-4 portions per day of WG rye containing foods (approximately 20 WG per portion)
3060922|NCT02155062|Experimental|Whole grain wheat|3-4 portions per day of WG wheat containing foods (approximately 20 WG per portion)
3060923|NCT02155062|Placebo Comparator|Refined cereal|No intake of WG wheat or WG rye cereals, only refined cereals or non-AR containing WG cereals (e.g. WG rice or oats)
3060924|NCT02155049|Experimental|Prostaglandin Analogues|The patients will receive a single daily drop of bimatoprost for six months.
3060927|NCT02155023|Experimental|Insulin dosing and glucose sensors|To test the glucose sensors different levels of glycemia are needed. To provoke different glycemic levels the following intervention will be performed: Lunch (with fast glucose absorption characteristics) will be served. Up to 30 minutes after the usual insulin dosing time, the subjects will take his/her lunch dose of insulin adjusted to the chosen lunch plus additional approximately 25% (in the range of 0-50% according to the discretion of the Investigator) of insulin - in order to provoke moderate postprandial hypoglycaemia with glucose values < 70 mg/dl.
3060928|NCT02155010|Experimental|Dexmedetomidine|IV dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
3060929|NCT02155010|Active Comparator|Dexmedetomidine with heavy bupivacaine|IV dexmedetomidine infusion after intrathecal injection of heavy bupivacaine
3060930|NCT02154997||Type 1 and Type 2 Diabetes|pregnant women which have a known condition of type 1 or type 2 diabetes
3060931|NCT02154997||Gestational diabetes|pregnant women which have developed Gestational diabetes
3060932|NCT02154997||Control group|Pregnant women whom do not suffer from any altered glucose metabolism
3060933|NCT02154984|Experimental|Behavioral (time restricted diet)|Participants follow a time restricted diet, which restricts daily eating to an 8 hour time window between 12:00-8:00 pm. Participants are allowed to consume non-caloric beverages (water, black tea, black coffee, diet soda, etc.) during the fasting hours and required to record daily food consumption in the smartphone app for 6 months. Participants are also coached by telephone over approximately 10-15 minutes weekly for 1 month and then biweekly for 5 months.
3060934|NCT02154971||Patients|HIV infected for more than 10 years, aged over 40, treated with antiretroviral therapy
3060935|NCT02154971||Control|non-HIV (matched for age and gender)
3060936|NCT02154958||Unexplained infertility|
3060937|NCT02154932|Active Comparator|double dose misoprostol|2 doses, 3 and 1 hours, prior surgery (group B, 35 cases).
3060938|NCT02154932|Active Comparator|single dose Misoprostol|intra-vaginal single dose of 400 microgram Misoprostol 1 hour pre-operatively (group A, 34 cases)
3060939|NCT02154919||complete revascularization group|this group underwent second PCI procedure on the non-culprit vessels and reveived 100-120 IU/kg unfractionated heparin during PPCI, followed by 3 days administration of low molecular weight heparin or Fondaparinux sodium after procedure. Patients in the CP group and CR group after second PCI procedure were given conservative medicine such as Statins which were not contraindicated to the patients.
3060940|NCT02154919||conservative pharmacotherapy group|patients in conservative group undergoing pharmacotherapy after PPCI. The drugs were the same between two groups.
3060941|NCT02154906|Active Comparator|DFDBA|DFDBA used to graft intrabony defect
3060942|NCT02154906|Experimental|autologous platelet rich fibrin|autologous platelet rich fibrin used to graft intrabony defect
3060943|NCT02154893|Experimental|Device and exercise|Device with ultrasound and laser associated with therapeutic exercise
3060944|NCT02154893|Experimental|Device|Device with ultrasound and laser
3060945|NCT02154893|Placebo Comparator|Placebo|Without any treatment
3060946|NCT02154880|Active Comparator|HIV positive under 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
3060947|NCT02154880|Active Comparator|HIV negative under 50 yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
3060948|NCT02154880|Active Comparator|HIV positive over 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
3060949|NCT02154880|Active Comparator|HIV negative over 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
3060950|NCT02154867|Experimental|Fecal transplantation|Fecal transplantation of freshly prepared feces from healthy donor. Application by colonoscope in proximal half of colon.
3060951|NCT02154867|Placebo Comparator|Placebo fecal transplantation|Sham transplant subject's own feces. Application by colonoscope in proximal part of colon.
3060952|NCT02154854|Experimental|Group A - tacrolimus half-dose|"Immunosuppressive strategy with 50 % reduction of Advagraf® daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.~Drug: Tacrolimus targeted half-dose"
3060953|NCT02154854|Experimental|Group B - tacrolimus unchanged dose|Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf® and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose
3060954|NCT02154841|Experimental|Questionnaire, taste test, visual food test|The participants will complete a questionnaire that asks them about their taste preferences. They will also will be shown photos of various food stuffs and asked to choose their preferred meal. They will also be asked to put five sponge sticks (a single use item commonly used for mouth care) dipped in one of a five different liquids into their mouths and give their comments what each taste was and on how much they enjoyed it. These five liquids represent the four well-described tastes (sweet, sour, salty, bitter) and a more recently proposed taste, savoury. The intention of this part of the trial is to assess the patient's ability to detect alteration in pure taste and to identify if any of these tastes are preferred.
3060955|NCT02154828||Integrative practices|"Children included in this project are children 3 to 6 years with diagnosis F84.0 F84.1 according to CIM-10.~these children must be supported in care units that meet the criteria defined integrative practices."
3060956|NCT02154815||PPT|Patients with a pre-emptive kidney transplantation from deceased or living donors
3060957|NCT02154815||PDT|Patients who have experienced a pre-transplant dialysis period of less than 36 months
3060958|NCT02154802|Experimental|video: community member|Participant watches video of a community member
3060959|NCT02154802|Experimental|video: physician|Participant watches video of a physician
3060960|NCT02154802|Experimental|video: choice of video|Participant can choose to watch video of either the community member of the physician
3060961|NCT02154802|No Intervention|no video|
3060962|NCT02154789|Experimental|polidocanol|
3060963|NCT02154789|Active Comparator|cryotherapy|
3060964|NCT02154789|Active Comparator|infra-red coagulation|
3060965|NCT02154776|Experimental|LEE011 + buparlisib + letrozole|open label, dose escalation evaluating max tolerated dose of the triple combination
3060966|NCT02154763|Placebo Comparator|Control|Intraperitoneal Saline: 100mL normal saline administered as in intervention arm
3060967|NCT02154763|Experimental|Intraperitoneal ropivacaine|The abdomen will be entered and trocars placed in the usual manner. Using a standard suction/irrigation device and tubing, 200mg of Ropivacaine (0.2% Ropivacaine in 100mL Normal Saline) will be instilled into the abdomen at the start of the case, prior to dissection as follows. Under direct visualization, 50mL (of the 100mL) will be infused over the esophageal hiatus. The remaining 50mL will be infused throughout the abdomen. The infusion line will then be flushed with 30mL of Normal Saline to ensure the entire treatment dose is delivered, and no Ropivacaine remains in the tubing. The remainder of the surgery will proceed as usual.
3060968|NCT02154750|Active Comparator|Long, fixed AV delay|Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
3060969|NCT02154750|Experimental|Short, optimized AV delay|Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled
3060970|NCT02154737|Experimental|erlotinib and gemcitabine|"Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg~Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle."
3060971|NCT02154724|Other|aDBS|The aDBS (adaptive Deep Brain Stimulation) device is applied both in aDBS and in DBS modality, for two hours in random order for two days. The aDBS can be programmed to deliver aDBS controlled by local fields potential or conventional DBS.
3060972|NCT02154711||Mitochondrial Disease|Individuals with genetic diagnoses (nuclear or mitochondrial) of mitochondrial disease
3060973|NCT02154711||Unaffected|Healthy individuals, without mitochondrial disease
3060974|NCT02154698|Active Comparator|22-gauge Standard Needle|Participants will have each node sampled starting with the standard 22G needle on the first pass followed by the ProCore 22G needle on the second pass (for a total of 8 passes)
3060975|NCT02154698|Active Comparator|22-gauge ProCore Needle|Participants will have each node sampled starting with the ProCore 22G on the first pass followed by the standard 22G needle on the second pass (for a total of 8 passes)
3060976|NCT02154685|Other|Retrieval-Extinction: Smoking Cues|A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.
3060977|NCT02154685|Other|Non-Retrieval Extinction: Neutral Cues|This is the group that will not receive retrieval-extinction training and will be exposed to neutral cues.
3060978|NCT02154672||BRCA2 Carriers|All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing
3060979|NCT02154659|Other|postprandial reflux group|Esophageal pH monitoring is the current gold standard for diagnosis of gastroesophageal reflux disease. It provides direct physiologic measurement of acid in the esophagus and is the most objective method to document reflux disease, assess the severity of the disease and monitor the reflux acidity.
3060980|NCT02154659|Other|normal group|Esophageal pH monitoring is the current gold standard for diagnosis of gastroesophageal reflux disease. It provides direct physiologic measurement of acid in the esophagus and is the most objective method to document reflux disease, assess the severity of the disease and monitor the reflux acidity.
3060981|NCT02154646|Experimental|LY2157299 + Gemcitabine|150 mg LY2157299 is administered orally twice daily for 14 days followed by 14 days without study drug (28 day cycle.) Gemcitabine 1000 milligram per square meter will be administered intravenously (IV) on Days 8, 15, and 22 in each cycle (28 day cycle). Participants may continue to receive treatment until discontinuation criteria are met.
3060982|NCT02154633|Experimental|Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes
3060983|NCT02154633|Active Comparator|Delayed Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes
3060984|NCT02154620|No Intervention|Plaster cast|The patient will be treated in a dorsal plaster cast for 4 weeks following the injury to the wrist
3060985|NCT02154620|Experimental|Volar plate|The patient will undergo surgery to the injured wrist with a Synthes Two-column plate (TCP) with a volar approach. Cast will be worn 2 weeks after surgery.
3060986|NCT02154607|No Intervention|Symptomatic treatment|Symptomatic analgetic Treatment only was performed without any Manipulation of OLP lesions.
3060987|NCT02154607|Active Comparator|CO2-Laser Treatment|CO2-Laser Vaporisation was performed of OLP lesions under local anaesthesia.
3060988|NCT02154594|Experimental|Acacia|Rinse with 20 ml of Acacia catechu mouthwash twice daily for 15 days
3060989|NCT02154594|Active Comparator|Chlorhexidine gluconate|Rinse with 10 ml of chlorhexidine mouthwash twice daily for 15 days
3060990|NCT02154594|Placebo Comparator|Distilled water|Rinse with 10 ml distilled water twice daily for 15 days.
3060991|NCT02154581|Active Comparator|Type 1 implant and thin biotype|In this group, immediate implant placement (Type 1) is performed in patients with thin tissue biotype. In addition to implant placement bone grafting of the void between the implant and the fresh extraction socket, bone grafting the buccal aspect of the buccal plate (overcontouring) and soft tissue grafting (connective tissue) are performed.
3060992|NCT02154581|Active Comparator|Type 1 implant and thick biotype|In this group, immediate implant placement (Type 1) is performed including bone grafting of the void between the implant and the fresh extraction socket.
3060993|NCT02154568|Experimental|Hyperpolarized helium MRI of the chest|
3060994|NCT02154555|No Intervention|no debridement|The postoperative clinical visits will occur at one week, one month, and three months following surgery. During all three postoperative visits, no debridement will be performed.
3060995|NCT02154555|Experimental|debridement|The postoperative clinical visits will occur at one week, one month, and three months following surgery. During the one week postoperative visit, the randomized unilateral debridement will be performed. Debridement includes removing any crust or mucous in the nose. During the one month and three month visit, the PI will only examine the nose.
3060996|NCT02154542|Active Comparator|Experimental A|NAVA then standard mode
3060997|NCT02154542|Active Comparator|Experimental B|Standard mode then NAVA
3060998|NCT02154529|Experimental|Phase 1b, Arm 1|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 150mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
3061000|NCT02154529|Experimental|Phase 1b, Arm 3|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 300mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
3061001|NCT02154529|Experimental|Phase 1b, Arm 4|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 350mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
3061002|NCT02154529|Experimental|Phase 1b, Arm 5|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 400mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
3061003|NCT02154529|Experimental|Phase 2a, Group 1|Tesevatinib in combination with Trastuzumab. In the Phase 2a expansion group, tesevatinib will be orally administered to all subjects once daily at the MTD dose determined in Phase 1b in combination with Trastuzumab 8mg/kg every 3 weeks. Subjects will include those with HER2-positive breast cancer and brain metastases that have progressed after radiation therapy.
3061004|NCT02154529|Experimental|Phase 2a, Group 2|Tesevatinib in combination with Trastuzumab. In the Phase 2a expansion group, tesevatinib will be orally administered to all subjects once daily at the MTD dose determined in Phase 1b in combination with Trastuzumab 8mg/kg every 3 weeks. Subjects will include those with HER2-positive metastatic breast cancer who do not have brain metastases, or who have asymptomatic brain metastases, or who have minimally symptomatic brain metastases that do not require immediate radiation therapy or neurosurgery.
3061005|NCT02154529|Experimental|Phase 2a, Group 3|Tesevatinib in combination with Trastuzumab. In the Phase 2a expansion group, tesevatinib will be orally administered to all subjects once daily at the MTD dose determined in Phase 1b in combination with Trastuzumab 8mg/kg every 3 weeks. Subjects will be limited to those with HER2-positive metastatic breast cancer with pathologically confirmed leptomeningeal metastases with or without brain metastases. Brain metastases do not have to have progressed after radiation therapy in this group.
3061006|NCT02154516|Active Comparator|Control Total Hip Replacement Device|"Total Hip replacement surgery using control device consisting of a hard-on-soft bearing or a ceramic-on-ceramic bearing which includes:~R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem~OXINIUM heads on polyethylene liners or~Ceramic heads on ceramic liners (all uncemented components)"
3061007|NCT02154516|Experimental|Investigational Hard-on-Hard Total Hip Replacement Device|"Total Hip replacement surgery using an experimental device consisting of a hard-on-hard bearing which includes:~R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem~R3 ODH acetabular cup liners (sizes 38/50, 40/52, 42/54 and 44/56 mm)~R3 ODH femoral heads (sizes 38, 40, 42 and 44 mm)~Taper sleeves Ti -6AL-4V (sizes -4, +0, +4, and +8)"
3061008|NCT02154503|Experimental|Microneedling|"By randomization, the side for treatment will be determined. Topical anaesthetic will be then placed onto the treatment area under occlusion for thirty minutes to one hour. This will then be removed with 70% alcohol. The area will be rolled with microneedles in two planes: coronally and sagitally. In each plane, five passes will be made. Patients will restart application of Minoxidil the following day to both sides of the lesion.~The same half of the scalp will be treated for the rest of the sessions, with topical anaesthetic applied by patient 30 minutes to an hour prior to start of treatment session. Patients will undergo microneedling on alternate weeks for a total of six treatments in 12 weeks. If there is >30% growth seen after six weeks, then the entire area will be treated."
3061009|NCT02154490|Experimental|S1400A Arm I (MEDI4736) (CLOSED TO ACCRUAL 12/2015)|Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm I receive anti-B7H1 monoclonal antibody MEDI4736 IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
3061010|NCT02154490|Active Comparator|S1400A Arm II (CLOSED TO ACCRUAL 4/2015)|Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #2 4/22/15)
3061011|NCT02154490|Experimental|S1400A Arm III (MEDI4736)|For patients assigned to Arm 1, MEDI4736: Upon evidence of progression following discontinuation of 12 months of treatment, patients may restart treatment with Arm 3, MEDI4736 for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period. Patients will only be able to restart treatment once; thus a maximum of two 12- month periods will be allowed. Patients registered to Arm III receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
3061012|NCT02154490|Experimental|S1400B Arm I (taselisib) (CLOSED TO ACCRUAL 12/12/2016)|Patients with tumors positive for PI3KCA randomized to Arm I receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3061013|NCT02154490|Active Comparator|S1400B Arm II (CLOSED TO ACCRUAL 12/18/2015)|Patients with tumors positive for PI3KCA randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
3061014|NCT02154490|Experimental|S1400B Arm III (taselisib) (CLOSED TO ACCRUAL 12/12/2016)|Re-Registration Treatment with GDC-0032 (Taselisib). Upon progression patients in Arm 2 may be eligible for Re-Registration to receive GDC-0032. Patients will receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3061015|NCT02154490|Experimental|S1400C Arm I (palbociclib)|Patients with tumors positive for CDK4/6, CCND1, CCND2, and CCND3 randomized to Arm I receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3061016|NCT02154490|Active Comparator|S1400C Arm II (CLOSED TO ACCRUAL 12/18/2015)|Patients with tumors positive for CDK4, CCND1, CCND2, and CCND3 randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
3061017|NCT02154490|Experimental|S1400C Arm III (palbociclib)|Re-Registration Treatment with palbociclib. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive palbociclib. Patients will receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3061018|NCT02154490|Experimental|S1400D Arm I (AZD4547) (CLOSED TO ACCRUAL 04/12/2017)|Patients with tumors positive for FGFR1, FGFR2, and FGFR3 randomized to Arm I receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3061019|NCT02154490|Active Comparator|S1400D Arm II (CLOSED TO ACCRUAL 10/31/2016)|Patients with tumors positive for FGFR1, FGFR2, and FGFR3 randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
3061020|NCT02154490|Experimental|S1400D Arm III (AZD4547) (CLOSED TO ACCRUAL 10/31/2016)|Re-Registration Treatment with AZD4547. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive AZD4547. Patients will receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3061021|NCT02154490|Experimental|S1400E Arm I (CLOSED TO ACCRUAL 11/2014)|Patients with tumors positive for HGF/c-MET randomized to Arm I receive rilotumumab IV on day 1 and erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (permanently closed to accrual on 11/25/14)
3061022|NCT02154490|Active Comparator|S1400E Arm II (CLOSED TO ACCRUAL 11/2014)|Patients with tumors positive for HGF/c-MET randomized to Arm II receive erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (permanently closed to accrual on 11/25/14)
3061023|NCT02154490|Experimental|S1400F (durvalumab, tremelimumab)|Patients with disease progression during or after prior anti-PD-1 or anti-PD-L1 antibody monotherapy as their most recent line of treatment receive durvalumab (IV over 60 minutes) and tremelimumab (IV over 60 minutes) on day 1 for courses 1-4 and durvalumab IV alone on day 1 of course 5 and subsequent courses until disease progression or unacceptable toxicity. Courses repeat every 28 days.
3061024|NCT02154490|Experimental|S1400G (talazoparib)|Patients with tumors positive for homologous recombination repair deficiency receive talazoparib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3061025|NCT02154490|Experimental|S1400I Arm I (nivolumab, ipilimumab)|Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study randomized to Arm I receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third cycle. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3061026|NCT02154490|Active Comparator|S1400I Arm II (nivolumab)|Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study randomized to Arm II receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3061027|NCT02154477|Experimental|DM|All patient will receive insulin at one visit and saline at another visit
3061028|NCT02154464|Active Comparator|Paracetamol|
3061029|NCT02154464|Placebo Comparator|Placebo|
3061030|NCT02154438|Experimental|ketamine|ketamine 0.5mg/kg loading dose and followed by 0.5mg/kg/h during operation
3061031|NCT02154438|Placebo Comparator|Placebo|normal saline 0.5mg/kg loading dose and followed by 0.5mg/kg/h during operation
3061032|NCT02154425|Experimental|Pharmacokinetic samples|"Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose if Q2W dosing), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).~Included are mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
3061033|NCT02154412|Experimental|Respiratory training|Subjects will be seated in own wheelchair with head-up tilt. Assembled together, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) & an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. Subjects will perform maximal inspiratory and expiratory efforts against a pressure load. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
3061034|NCT02154412|No Intervention|No respiratory training|Participants will not participate in the respiratory muscle training.
3061035|NCT02154399|Experimental|Treatment (EF5)|Patients receive EF5 IV over 1-2.5 hours. Beginning 24-55 hours later, patients undergo tumor hypoxia measurement using a polarographic needle electrode and intraoperative tumor measurement before undergoing surgical biopsy or resection.
3061036|NCT02154386|Experimental|8-10 week healing group|dental implant placed (and bone core biopsy harvested) 8-10 weeks after tooth extraction/grafting
3061037|NCT02154386|Active Comparator|18-20 week healing group|dental implant placed (and bone core biopsy harvested) 18-20 weeks after tooth extraction/grafting
3061038|NCT02154360|Experimental|Aprepitant|"Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days.~6 participants will be receiving an antiretroviral regimen containing atazanavir/ritonavir (300/100 mg) daily plus two other antiretrovirals.~6 participants will be receiving an antiretroviral regimen containing darunavir/ritonavir (800/100 mg) daily plus two other antiretrovirals."
3061039|NCT02154347|Experimental|KAD-1229|
3061040|NCT02154347|Placebo Comparator|Placebo|
3061041|NCT02154334|Experimental|Cohort 1|One Intranasal spray of 14 milligram (mg) esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 (Treatment A). Two intranasal sprays of 50 microgram (mcg) mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg at time -1 hour prior to 1 intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg on Day 16 in Period 2 (Treatment B).
3061042|NCT02154334|Experimental|Cohort 2: Sequence 1|One Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 (Treatment A) and pretreatment with 2 sprays of oxymetazoline 0.05 percent (%) weight by volume (w/v) solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 2 (Treatment C).
3061043|NCT02154334|Experimental|Cohort 2: Sequence 2|Pretreatment with 2 sprays of oxymetazoline 0.05 percent (%) weight by volume (w/v) solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1 (Treatment C) and 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 2 (Treatment A).
3061044|NCT02154321||Attention Deficit Hyperactivity Disorder|This study aims to recruit 100 adult participants: 50 of which are adults diagnosed with Attention Deficit Hyperactivity Disorder and 50 healthy controls. All participants will perform a total of two tasks while connected to electroencephalogram (EEG) sensors; the first task is a resting state task and after that a cognitive challenge task (attention control). Study activity is performed in a single visit which lasts two hours. Participants will also be asked to complete some behavioral questionnaires.
3061045|NCT02154321||Healthy Control|This study aims to recruit 100 adult participants: 50 of which are adults diagnosed with Attention Deficit Hyperactivity Disorder and 50 healthy controls. All participants will perform a total of two tasks while connected to electroencephalogram (EEG) sensors; the first task is a resting state task and after that a cognitive challenge task (attention control). Study activity is performed in a single visit which lasts two hours. Participants will also be asked to complete some behavioral questionnaires.
3061046|NCT02154308|Experimental|IL-YANG influenza vaccine|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
3061047|NCT02154295|Active Comparator|Eagle Eye Platinum|Eagle Eye Platinum Catheter as the comparator.
3061048|NCT02154295|Active Comparator|Revolution|Revolution Catheter as the comparator
3061049|NCT02154295|Active Comparator|TVC Insight 40MHz|TVC Insight as comparative catheter.
3061050|NCT02154295|Active Comparator|Atlantis Pro|Atlantis Pro catheter as comparator
3061051|NCT02154282|Experimental|ipod games|Administered ipod games with cognitive testing before and after
3061052|NCT02154269|Experimental|G-CSF|Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
3061053|NCT02154269|Placebo Comparator|Saline|Subjects will be randomly assigned to receive saline for five days, during 4 cicles.
3061054|NCT02154256|Experimental|Increasing incentives|The investigators will offer incentives to users that begin low, and get higher over time.
3061055|NCT02154256|Experimental|Decreasing incentives|The investigators will offer incentives to users that start high, and decrease over time.
3061056|NCT02154256|Experimental|Stable incentives|The investigators will offer incentives that stay stable over time.
3061057|NCT02154256|No Intervention|Usual care control|The investigators will offer incentives that are identical to the incentives normally offered by the investigators' partner company.
3061058|NCT02154243|Experimental|Midodrine|Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV<15 will be given oral midodrine, 10 mg, once.
3061059|NCT02154243|Experimental|Intravenous fluid bolus|Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV>=15 will be given intravenous fluid bolus, 15 cc/kg, once.
3061060|NCT02154243|No Intervention|Control (no intervention)|Patients who are NOT diagnosed with orthostatic hypotension at their first physical therapy session will be given the interventions.
3061061|NCT02154230|Experimental|sulphate-bicarbonate-calcium water and low-calorie diet (SW-D)|"Experimental arm: Those patients assigned to this interventional arm of the study will be asked to follow a low-calorie diet. For the first 12 weeks, the diet will cover only basal metabolism expenditure ± 10%. At the end of this 12 weeks, for the following 12 weeks, patients will follow a maintenance diet which will cover both basal metabolism and physical activity expenditure. Patients will be invited to maintain the same level of physical activity preceding enrollment throughout the entire study period. During the first 4 weeks these patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature."
3061062|NCT02154230|Active Comparator|tap water and low-calorie diet (TW-D)|Active comparator: Those patients assigned to this interventional arm of the study will be asked to follow the same low-calorie diet of the experimental arm. During the first 4 weeks these patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Rome tap water at room temperature.
3061063|NCT02154217|Experimental|Bimatoprost|once daily
3061064|NCT02154217|Experimental|Latanoprost/Timolol|once daily
3061065|NCT02154191|Experimental|Surgical Intervention Group|The Surgical Intervention Group will undergo the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
3061066|NCT02154191|No Intervention|Non-Intervention Group (Control)|No Intervention.This group will consist of patients wait listed for surgery but further back in the queue.
3061067|NCT02154178|Experimental|Biomarker group|"Intervention group, in which the duration of empirical antifungal therapy will be based on the results of biomarkers.~Biomarker group"
3061068|NCT02154178|No Intervention|Control group|Control group, in which the duration of empirical antifungal therapy will be based on international recommendations (14 days).
3061069|NCT02154165|Active Comparator|Blue light wavelenght 460 nm|
3061070|NCT02154165|Active Comparator|Turquoise light wavelength 499 nm|
3061071|NCT02154152|Experimental|Homoeopathic Medicine Causticum|The drug namely Causticum 200C potency shall be administered as 4 globules, prescribed once a week for 3 months with placebo to follow for the remaining period.
3061072|NCT02154139||leuprorelin acetate|Subcutaneous administration of leuprorelin acetate once every 12 weeks
3061073|NCT02154126|Other|Accuracy assessment|
3061074|NCT02154113|Active Comparator|Velashape II device|Controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation.
3061075|NCT02154113|Active Comparator|Ultrashape|The UltraShape Contour I V3 uses focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption.
3061076|NCT02154100|Experimental|Tart Cherry|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
3061077|NCT02154100|Placebo Comparator|Placebo|12 weeks tart cherry juice taken in two doses of 240 ml per day.
3061078|NCT02154087|Experimental|HP802-247|
3088596|NCT01968798|Active Comparator|Aspirin|100 mg enteric-coated aspirin
3061080|NCT02154074|Experimental|N2 group: Isoflurane & Dexmedetomidine|for normal patients: inhale Isoflurane + intravenous pumping Dexmedetomidine during operation
3061081|NCT02154074|Active Comparator|D1 group: Isoflurane & saline|for diabetes patients: inhale Isoflurane + the same volume of saline during operation
3061082|NCT02154074|Experimental|D2 group: Isoflurane & Dexmedetomidi|for diabetes patients: inhale Isoflurane + intravenous pumping Dexmedetomidine during operation
3061083|NCT02154061|Experimental|IIV Flu Vaccine with Antibiotics|This arm will receive antibiotics prior and after IIV administration.
3061084|NCT02154061|Active Comparator|IIV Flu Vaccine|This arm will not take antibiotics in conjunction with IIV.
3061085|NCT02154048|Active Comparator|ropivacaine + dexamethasone|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an IV preservative-free dexamethasone 8 mg injection.
3061086|NCT02154048|Placebo Comparator|ropivacaine + placebo|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an intravenous (IV) normal saline placebo injection.
3061087|NCT02154048|Active Comparator|ropivacaine + dexamethasone + placebo|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with both 1:400,000 epinephrine and preservative-free dexamethasone 8mg and an IV normal saline placebo injection.
3061088|NCT02153983|Experimental|Colchicine|Experimental treatment with colchicine
3061089|NCT02153983|Placebo Comparator|Drug|Placebo capsules identical to
3061090|NCT02153957|Experimental|1|Enhanced PA home intervention group for the first 12weeks; followed by 12 weeks of PA maintenance ontheir own.
3061091|NCT02153957|Other|2|Usual physical activity (no intervention) for 12 weeks;followed by the enhanced PA home intervention for 12 weeks.
3061092|NCT02153931||Volunteers|Parents of children with NF1
3061093|NCT02153918|Experimental|A|PROSTVAC-V/TRICOM followed by PROSTVAC-F/ TRICOM boost monthly until radical prostatectom or off therapy PROSTVAC
3061094|NCT02153905|Experimental|1/Phase I Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MAGE-A3- A1 transduced PBL + high-dose aldesleukin
3061095|NCT02153905|Experimental|2/Phase II Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MAGE-A3- A1 transduced PBL + high-dose aldesleukin
3061096|NCT02153892|Other|Multi-center, prospective, single-arm study|To assess the safety and performance of the GDS Accucinch System when used percutaneously to reduce functional mitral regurgitation.
3061097|NCT02153879|Experimental|Fenofibrate|Fenofibrate 145 mg/day for 12 weeks
3061098|NCT02153879|Experimental|Niacin plus Laropiprant|Niacin 2g/day plus Laropiprant for 12 weeks
3061099|NCT02153866|Placebo Comparator|rotavirus|vaccinate one dose rotavirus vaccine for each of 700 participants aged 8~9months
3061100|NCT02153866|Placebo Comparator|measles-rubella|vaccinate one dose measles-rubella vaccine for each of 350 participants aged 8~9 months.
3061101|NCT02153866|Placebo Comparator|measles-mumps-rubella|vaccinate one dose measles-mumps-rubella vaccine for each of 350 participants aged 8~9 months.
3061102|NCT02153866|Experimental|rotavirus, measles-rubella|simultaneously vaccinate one dose rotavirus vaccine and one dose measles-rubella vaccine for each of 700 participants aged 8~9 months.
3061103|NCT02153866|Experimental|rotavirus, measles-mumps-rubella|simultaneously vaccinate one dose rotavirus vaccine and one dose measles-mumps-rubella vaccine for each of 700 participants aged 8~9 months.
3061104|NCT02153853||Rectal cancer|Patients undergoing laparoscopic surgery for rectal cancer at the Department of Gastrointestinal Surgery, Hvidovre Hospital, Copenhagen, Denmark.
3061105|NCT02153840|Experimental|PSORI-CM01（YXBCM01）granule|PSORI-CM01（YXBCM01）granule 1.1g os once a day for 12weeks.
3061106|NCT02153840|Experimental|PSORI-CM01（YXBCM01）granule low dose group|PSORI-CM01（YXBCM01） granule 5.5g os once a day for 12weeks.
3061107|NCT02153840|Placebo Comparator|placebo|Placebo granule 1.1g os once a day for 12weeks.
3061108|NCT02153827|Experimental|Eccentric External rotator training|Eccentric Shoulder External Rotators along with scapular retraction and posterior shoulder stretching exercises.
3061109|NCT02153827|Sham Comparator|General shoulder exercise|General shoulder exercise protocol of active flexion, abduction, scapular retraction and posterior shoulder stretching exercises.
3061110|NCT02153814|Sham Comparator|Control|Will undergo sham procedure twice
3061111|NCT02153814|Experimental|One Endometrial Scratch Procedure|Will undergo one sham procedure and one endometrial scratch procedure
3061112|NCT02153814|Experimental|Two Endometrial Scratch Procedures|Will undergo endometrial scratch procedure twice
3061113|NCT02153801|Active Comparator|Low Inferior Mesenterci Artery Ligation|The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.
3061114|NCT02153801|Other|High Inferior Mesenterci Artery Ligation|"For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.~For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter."
3061115|NCT02153788|Active Comparator|temazepam|After screening, all subjects meeting entry criteria will be placed on the same single blind study drug treatment, asked to complete a daily sleep diary, and return one week later. After one week subjects randomized to temazepam will be given temazepam 15 mg for 12 weeks.
3061116|NCT02153788|Placebo Comparator|Placebo|After screening, all subjects meeting entry criteria will be placed on the same single blind study drug treatment, asked to complete a daily sleep diary, and return one week later. After one week subjects randomized to placebo will be given placebo for 12 weeks.
3061117|NCT02153775|Experimental|Progressive muscle relaxation|Progressive muscle relaxation: single 20-minutes session
3061118|NCT02153775|No Intervention|Reading newspaper of the day|Reading newspaper of the day : single 20-minutes session
3061119|NCT02153762|Experimental|Right side|Patients were randomized to apply Locoid Lipocream on the right side of the target lesion followed by Hylatopic Plus lotion on the left side of the target lesion with the reverse order on the other side.
3061120|NCT02153762|Active Comparator|Left first|Patients were randomized to apply Locoid Lipocream on the left side of the target lesion followed by Hylatopic Plus lotion on the right side of the target lesion with the reverse order on the other side.
3061121|NCT02153749|Experimental|Cognitive Regulation of Craving|Training in craving regulation component of Cognitive Behavioral Therapy(CBT) for addictions.
3061122|NCT02153749|Experimental|Mindfulness-Based Regulation of Craving|Training in craving regulation component of Mindfulness Based Therapy(MBT) for addiction.
3061123|NCT02153749|No Intervention|No training control|No training sessions will be provided in this arm.
3061124|NCT02153736|No Intervention|Usual Care Group|This group of subjects will receive usual care provided in the medial system and community.
3061125|NCT02153736|Experimental|SPEEDI Intervention|This group will receive and parent and physical therapy provided intervention to increase the infants opportunities for play which will enhance development.
3061126|NCT02153723|Experimental|Copaxone|"Dose escalation:~Study drug will be administered once a week for 4 weeks, twice a week for 4 weeks and daily for 24 weeks. Drug is administered as a subcutaneous injection."
3061127|NCT02153710|Experimental|Phonomotor therapy|Experimental group
3061128|NCT02153710|Active Comparator|Semantic Feature Analysis therapy|Current standard of care therapy
3061129|NCT02153697|Experimental|Pigmanorm Cream, Q-switched Ruby laser,solar lentigines|Solar lentigines on the left back of the hand side are treated with Pigmanorm Cream once a day for 7 weeks. Solar lentigines on the right back of the hand side are treated with a Q-switched Ruby laser at Baseline and if required at day 28.
3061130|NCT02153684||Mild COPD, symptomatic|Smokers fitting GOLD 1B criteria for COPD
3061131|NCT02153684||Mild COPD, asymptomatic|Smokers fitting GOLD 1A criteria for COPD
3061132|NCT02153684||Symptomatic smokers, at risk for COPD|Smokers who do not meet spirometric criteria for COPD
3061133|NCT02153684||Healthy, non-smoking controls|Non-smokers, matched to smoking groups for age (>40 yrs of age) and gender
3061134|NCT02153671|Experimental|H5N2 primed|volunteers who previously received two intranasal doses of the live attenuated influenza vaccine (LAIV) in protocol LAIV H5N2-01
3061135|NCT02153671|Active Comparator|Volunteers who are LAIV H5N2 naive|naïve subjects who either received intranasal placebo in LAIV H5N2-01 or are newly recruited to this study
3061136|NCT02153658|No Intervention|Arm 1|Subjects followed the current hygiene instructions, standard washing in a shower with soap.
3061137|NCT02153658|Active Comparator|Arm 2|Subjects cleaned the foreskin with soapy water using a syringe once a day.
3061138|NCT02153658|Active Comparator|Arm 3|Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.
3061139|NCT02153645|Experimental|240mg Amantadine HCl ER tablets|Amantadine HCl ER Tablets 240mg daily for 12 weeks post two week titration phase.
3061140|NCT02153645|Experimental|320mg Amantadine HCl ER tablets|Amantadine HCl ER Tablets 320mg daily for 12 weeks post a two week dose titration phase.
3061141|NCT02153645|Experimental|Placebo Tablets for Amantadine|Placebo Tablets matching Amantadine HCl ER Tablets taken daily for 16 weeks.
3061142|NCT02153632|Experimental|240mg Amantadine HCl ER Tablets|Amantadine HCl ER Tablets 240mg daily for 22 weeks post two week titration phase.
3061143|NCT02153632|Experimental|320mg Amantadine HCl ER Tablets|Amantadine HCl ER Tablets 320mg daily for 22 weeks post two week titration phase.
3061144|NCT02153632|Placebo Comparator|Placebo Tablets for Amantadine|Placebo Tablets matching Amantadine HCl ER Tablets taken daily for 26 weeks.
3061145|NCT02153619|Experimental|Meaning-Centered Grief Therapy (MCGT)|Part 1: Open Trials. Participants (n = 5 for Step 1 & n = 5 for Step 2) will receive 16 1-hour (approx) weekly sessions MCGT, & all therapy sessions will be audio recorded. Will make every effort to complete 16 sessions in 16 weeks, due to normal life activities, this is considered an approximation (i.e. there may be weeks where sessions don't take place &/or weeks where more than 1 session takes place in a week). If participant provides us with permission, we will also video record the sessions. Assessments will be administered at 4 time points: pre-intervention (T1), mid-intervention (T2), post-intervention (T3), & at 3-months post-intervention (T4). They will provide their feedback about MCGT & the measures. PI will review the open trial sessions to help refine the MCGT manual & treatment integrity forms. Sessions for Step 1 participants in Part 1 will be held at the MSK Counseling Center. Sessions for Step 2 participants in Part 1 will be conducted via videoconferencing.
3061146|NCT02153619|Experimental|MCGT or Supportive Psychotherapy|Part 2: Pilot RCT. Will randomize 66 parents to 16 weekly 60-90 minute (approx) sessions of MCGT or SP delivered via videoconferencing. Again, sessions will be audio recorded. If the participant provides us with permission, we also audio/video record the sessions. We will examine aspects of study implementation & therapy process, including a) recruitment progress, b) implementation of the intervention, c) administration of the assessments, & d) retention. We will also examine acceptability, defined as measures of satisfaction at T3. Psychosocial outcomes will be assessed with self-report measures at 4 time points: pre-intervention (T1), mid-intervention (T2), post-intervention (T3), & at 3-months post-intervention (T4). Post-intervention qualitative exit interviews will assess acceptability of the intervention. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention .
3061147|NCT02153606|Active Comparator|Glycerin Suppository|
3061148|NCT02153606|Sham Comparator|Sham Suppository|
3061149|NCT02153593|Experimental|Tranexamic acid|Tranexamic acid, 1g intra-articular before closing the surgery wound
3061150|NCT02153593|Experimental|Fibrin glue|One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery
3061151|NCT02153593|Active Comparator|Usual hemostasia|Electrocauterization
3061217|NCT02153112|Experimental|Cohort 1, Group 3: 1 Dose|Toddlers 6 months to <1 year of age will receive one dose of 1 of the 4 formulations of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1, followed by placebo saline solution, IM, on Day 29.
3061254|NCT02152891|Experimental|CHAP-EMS/CP@clinic Program Intervention|12 month implementation of the intervention
3061152|NCT02153580|Experimental|Treatment (lymphodepletion,cellular immunotherapy)|"LYMPHODEPLETING REGIMEN: Patients receive a chemotherapy regimen based on disease type and extent of disease comprising of, and not limited to, any of the following agents: cyclophosphamide, bendamustine hydrochloride, fludarabine phosphate, etoposide. CELLULAR IMMUNOTHERAPY: Beginning 3-10 days later after lymphodepletion, patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes IV over 10-15 minutes on day 0. Patients with relapsed, residual or progressive disease may receive an optional second infusion of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T cells >= 28 days post T cell infusion.~Disease status: Patients with Non-Hodgkin lymphoma (NHL)."
3061153|NCT02153580|Experimental|Treatment (lymphodepletion, cellular immunotherapy)|"LYMPHODEPLETING REGIMEN: Patients receive a chemotherapy regimen based on disease type and extent of disease comprising of, and not limited to, any of the following agents: cyclophosphamide, bendamustine hydrochloride, fludarabine phosphate, etoposide. CELLULAR IMMUNOTHERAPY: Beginning 3-10 days later after lymphodepletion, patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes IV over 10-15 minutes on day 0. Patients with relapsed, residual or progressive disease may receive an optional second infusion of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes >= 28 days post T cell infusion.~Disease status: Patients with Chronic lymphocytic leukemia (CLL) and/or Prolymphocytic Leukemia (PLL)."
3061154|NCT02153567|Placebo Comparator|Control (Placebo) group|"Identical looking placebo (once daily)~Double blinding of study medication is achieved by repacking Escitalopram 5mg and 10mg as blue and green capsules respectively.. Identical appearing placebos packed in blue and green capsules will be used for the control group."
3061155|NCT02153567|Experimental|Escitalopram|Escitalopram 5mg & 10mg daily
3061156|NCT02153554|Experimental|Trained|Training civil servants in Medellin (Colombia) on attention to violence against women.
3061157|NCT02153554|No Intervention|Non trained|
3061158|NCT02153541|Placebo Comparator|Mineral oil|For those participants who receive mineral oil placebo, we do not anticipate any change in the usage of rescue inhalers, spirometer scores, asthma diaries, and expired fractionated nitrous oxide levels.
3061159|NCT02153541|Active Comparator|Antipyrine-benzocaine otic solution|Will be used on 50% of participants.
3061160|NCT02153528|Active Comparator|Standard TB treatment|Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
3061161|NCT02153528|Experimental|double rimfampicin|2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
3061162|NCT02153515|Experimental|Fingerprick of autologous blood (FAB)|Fingerprick of autologous blood (FAB) four times a day for 2 months
3061163|NCT02153502|Experimental|AVP-786|
3061164|NCT02153502|Placebo Comparator|Placebo|
3061165|NCT02153489|Experimental|Aclidinium bromide|Aclidinium bromide 400 μg administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening).
3061166|NCT02153489|Placebo Comparator|Placebo|Placebo administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening).
3061167|NCT02153476|Experimental|2.0mg of ALG-1001|2.0mg of ALG-1001
3061168|NCT02153476|Placebo Comparator|Intravitreal injection in 0.05cc balanced salt solution.|Balanced Salt Solution
3061169|NCT02153463|Experimental|Activity Counselling|Physical Activity Counselling weekly for 8 weeks
3061170|NCT02153463|No Intervention|Standard Care|Standard care with no change in medications for 8 weeks
3061171|NCT02153450|Experimental|Treatment (stereotactic radiosurgery, metformin hydrochloride)|"Patients receive metformin hydrochloride PO daily or BID on days -11 to -1. Patients then undergo stereotactic radiosurgery 5 days a week for 5 weeks and receive concurrent metformin hydrochloride* PO BID for 5 weeks. Patients undergo laparotomy on week 6 (or weeks 5-7). Systemic therapy continues as soon as it is considered feasible by the treating physicians.~*NOTE: Metformin hydrochloride should be stopped 2 days before laparotomy."
3061172|NCT02153437|Experimental|Arm A: BMS-919373|BMS-919373 oral Solution/tablet single dose for one day
3061173|NCT02153437|Active Comparator|Arm B: Sotalol|Sotalol oral Tablet single dose for one day
3061174|NCT02153437|Placebo Comparator|Arm C: Placebo for BMS-919373|Oral solution/tablet one single dose for one day
3061175|NCT02153424||NVAF patients in Mexico treated with Apixaban|All patients with NVAF at the sentinel site for the CNFV in Mexico who received at least 1 dose of Apixaban to reduce the risk of stroke or systemic embolism during the specified 24-month study period
3061176|NCT02153411||8645 asthmatic patients|Men and women, 18 years of age and older. Asthmatic since at least one year before inclusion. Patient's informed consent obtained.
3061177|NCT02153398|Experimental|Group 1: D961H sachet 10 mg|Age: ≥1 year Weight: <20 kg
3061178|NCT02153398|Experimental|Group 2: D961H capsule 10mg|Age: ≥1 year to 11years Weight: ≥20 kg
3061179|NCT02153398|Experimental|Group 3: D961H capsule 20 mg|Age: ≥1 year to 11years Weight: ≥20 kg
3061180|NCT02153398|Experimental|Group 4: D961H capsule 10 mg|Age: 12 to 14 years Weight: ≥20 kg
3061181|NCT02153398|Experimental|Group 5: D961H capsule 20 mg|Age: 12 to 14 years Weight: ≥20 kg
3061182|NCT02153385|Experimental|Yoga group|Two yoga sessions per week for 8 weeks
3061183|NCT02153385|No Intervention|Control group|Usual level of physical activity; no involvement in any yoga practice during the course of the study
3061184|NCT02153372|Experimental|BMC2012|The large bone defect was then be bridged as per clinical standard, filled with a clinically established scaffold (ß-TCP), and 1.3 x106/ml BMC were loaded per 1 ml ß-TCP in situ.
3061185|NCT02153359|Experimental|Air cleaner|A High Efficiency Particulate Air Cleaner (HEPA) intervention will be placed in the participant's home for one month. During the last week of the month, health assessments will be conducted, including in-home health questionnaires, symptom-, diet-, and activity- diaries/recalls, blood, urine and exhaled breath testing, repeated measures of home hand-held lung function, and in-clinic pulmonary function testing with broncho-provocation. Participants will wear a light backpack with air monitoring devices during the last week in order to measure their exposures to pollutants. Finally, at the end of the month, participants will be asked to report to the Johns Hopkins outpatient endoscopy suite for bronchoscopy, during which nasal and lower airway sampling will occur under conscious sedation.
3061255|NCT02152891|No Intervention|Control|Will complete a survey at baseline and at 1 year, no program or intervention provided
3061186|NCT02153359|Sham Comparator|sham air cleaner|A sham air cleaner will be placed in the participant's home for one month. During the last week of the month, health assessments will be conducted, including in-home health questionnaires, symptom-, diet-, and activity- diaries/recalls, blood, urine and exhaled breath testing, repeated measures of home hand-held lung function, and in-clinic pulmonary function testing with broncho-provocation. Participants will wear a light backpack with air monitoring devices during the last week in order to measure their exposures to pollutants. Finally, at the end of the month, participants will be asked to report to the Johns Hopkins outpatient endoscopy suite for bronchoscopy, during which nasal and lower airway sampling will occur under conscious sedation.
3061187|NCT02153346|Other|Arm 1|Intervention 1 & 2 are associated with Arm 1. All patients enrolled in the study will possibly receive both the valuation of lost productivity and work productivity and activity impairment questionnaires, which are outside of the patient's usual care.
3061188|NCT02153333||HRV Group|Subjects who had received 2 doses of HRV vaccine in previous studies.
3061189|NCT02153333||Placebo Group|Subjects who had received 2 doses of placebo in previous studies.
3061190|NCT02153320|Experimental|HBsAg + adjuvant 1 Group|Single blood sample taken from subjects who had received GSK candidate vaccine containing HBsAg together with an adjuvant 1 in study 287615 (NCT00508833).
3061191|NCT02153320|Experimental|HBsAg + adjuvant 2 Group|Single blood sample taken from subjects who had received GSK candidate vaccine containing HBsAg together with an adjuvant 2 in study 287615 (NCT00508833).
3061192|NCT02153320|Experimental|HBsAg + adjuvant 3 Group|Single blood sample taken from subjects who had received GSK candidate vaccines containing HBsAg together with an adjuvant 3 in study 287615 (NCT00508833).
3061193|NCT02153307|Experimental|Implantable loop recorders Reveal ICM LINQ®,|
3061194|NCT02153294|Experimental|Ventilation with lower tidal volumes|Use of low tidal volume (4 to 6 ml/kg PBW) after intubation and during all mechanical ventilation
3061195|NCT02153294|Other|Ventilation with higher tidal volumes|Use of high tidal volume (8 to 10 ml/kg PBW) after intubation and during all mechanical ventilation
3061196|NCT02153281|Experimental|Phenelzine treatment|Subjects will undergo a PET and MRI scan before and after the treatment.
3061197|NCT02153268|Experimental|single arm, Liposuction, BonoFill Transplantation|"Liposuction - will be performed on Visit 2 for all eligible subjects~BonoFill Transplantation - will be performed on Visit 6 for all eligible subjects"
3061198|NCT02153255||Children With Mucopolysaccharidosis Type IVa|
3061199|NCT02153242||Supra Ventricular Tachycardia (SVT)|Patients undergoing SVT studies
3061200|NCT02153229|Experimental|patients who undergo RP plus photofrin-based PDT|
3061201|NCT02153229|Experimental|patients who undergo RP alone|
3061202|NCT02153203|Experimental|Behavioral approach|The Prevent-Teach-Reinforce Model will be implemented with families in their home settings.
3061203|NCT02153203|Active Comparator|Educational approach|Each child's parent will participate in one 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior in children with autism spectrum disorders.
3061204|NCT02153190|Experimental|HYBRID-OPEN|"Patients are randomized on the schedule; hybrid period and after open period. During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.~During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times. Overall, an increase of time spent in range when using artificial pancreas in the hybrid period should be observed with a reduction of both hypo and hyperglycemia episodes."
3061205|NCT02153190|Experimental|OPEN-HYBRID|"Patients are randomized on the schedule: open period and after hybrid period. During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.~During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day. Overall, an increase of time spent in range when using artificial pancreas in the hybrid period should be observed with a reduction of both hypo and hyperglycemia episodes."
3061206|NCT02153177|Active Comparator|NSAID and pain medication arm|After a rotator cuff repair procedure subjects in the NSAID and pain medication arm will receive both Ibuprofen and Hydrocodone/Acetaminophen, and also Omeprazole.
3061207|NCT02153177|Active Comparator|pain medication arm|Patients in the pain medication arm will receive Hydrocodone/Acetaminophen after the rotator cuff repair procedure.
3061208|NCT02153151||In vitro effect of AMP-514|Patients undergo blood sample collection at baseline, during the second week of RT, at the end of RT, and at 1 month after the end of RT
3061209|NCT02153125|Experimental|Eplerenone|25mg eplerenone given daily for a week, followed by 50mg given for a total of 3 months since commencement of treatment
3061210|NCT02153125|Placebo Comparator|Placebo|
3061211|NCT02153112|Experimental|Cohort 1, Group 1: 1 Dose|Children 4 to <9 years of age will receive one dose of 1 of the 4 formulations of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1, followed by placebo saline solution, IM, on Day 29.
3061212|NCT02153112|Experimental|Cohort 1, Group 1: 2 Doses|Children 4 to <9 years of age will receive 2 doses of 1 of the 4 formulations of the norovirus bivalent VLP vaccine, intramuscularly (IM), on Day 1 and Day 29.
3061213|NCT02153112|Experimental|Cohort 1, Group 2: 1 Dose|Children 1 to <4 years of age will receive one dose of 1 of the 4 formulations of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1, followed by placebo saline solution, IM, on Day 29.
3061214|NCT02153112|Experimental|Cohort 1, Group 2: 2 Doses|Children 1 to <4 years of age will receive 2 doses of 1 of the 4 formulations of the norovirus bivalent VLP vaccine, intramuscularly (IM), on Day 1 and Day 29.
3061215|NCT02153112|Experimental|Cohort 1, Group 2a: 1 Dose|Children 1 to <4 years of age will receive one dose of 1 of the 4 formulations of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM), on Day 1, followed by placebo saline solution, IM, on Day 29.
3061216|NCT02153112|Experimental|Cohort 1, Group 2a: 2 Doses|Children 1 to <4 years of age will receive 2 doses of 1 of the 4 formulations of the norovirus bivalent VLP vaccine, intramuscularly (IM), on Day 1 and Day 29.
3061218|NCT02153112|Experimental|Cohort 1, Group 3: 2 Doses|Toddlers 6 months to <1 year of age will receive 2 doses of 1 of the 4 formulations of the norovirus bivalent VLP vaccine, intramuscularly (IM), on Day 1 and Day 29.
3061219|NCT02153112|Experimental|Cohort 2, Group 4: 2 Doses|Infants 6 weeks to <6 months of age will receive 2 doses of 1 of the 4 formulations of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM), on Days 1 and 56, followed by placebo saline solution, IM, on Day 112.
3061220|NCT02153112|Experimental|Cohort 2, Group 4: 3 Doses|Infants 6 weeks to <6 months of age will receive 3 doses of 1 of the 4 formulations of the norovirus bivalent VLP vaccine, intramuscularly (IM), on Days 1, 56 and 112.
3061221|NCT02153099|Experimental|Cohort 1: TAK-058 15 mg|TAK-058 15 mg, 100 mL oral solution, once on Day 1.
3061222|NCT02153099|Experimental|Cohort 2: TAK-058 30 mg|TAK-058 30 mg, 100 mL oral solution, once on Day 1.
3061223|NCT02153099|Experimental|Cohort 3: TAK-058 45 mg|TAK-058 45 mg, 100 mL oral solution, once on Day 1.
3061224|NCT02153099|Experimental|Cohort 4: TAK-058 5 mg|TAK-058 5 mg, 100 mL oral solution, once on Day 1.
3061225|NCT02153099|Experimental|Cohort 5: TAK-058 75 mg|TAK-058 75 mg, 100 mL oral solution, once on Day 1.
3061226|NCT02153099|Experimental|Cohort 6: TAK-058 150 mg|TAK-058 150 mg, 100 mL oral solution, once on Day 1.
3061227|NCT02153099|Placebo Comparator|Cohort 1-6: Placebo|TAK-058 placebo-matching, 100 mL oral solution, once on Day 1.
3061228|NCT02153086||Ramelteon 8 mg Tablets|
3061229|NCT02153073||Omega-3 fatty acid ethyl esters 2 g|Omega-3 fatty acid ethyl esters 2 g, administered orally once or twice daily after meals
3061230|NCT02153060|Experimental|20mg dexamethasone group|Dexamethasone 20 mg per day, 4 consecutive days
3061231|NCT02153060|Experimental|40mg dexamethasone group|Dexamethasone 40 mg per day, 4 consecutive days
3061232|NCT02153047|Experimental|Spirometry|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
3061233|NCT02153047|No Intervention|Brief smoking cessation advice|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
3061234|NCT02153034||Buruli ulcer patients, no intervention|Buruli ulcer patients administered standard standard care by the attending physician
3061235|NCT02153034||Healthy contacts, no intervention|Healthy volunteers who will be contacts of patients recruited or non-endemic controls. No intervention will be administered
3061236|NCT02153021|Placebo Comparator|Lifestyle counseling|alimentation information: a nutritionist provides nutritional orientation; exercise training: 3 days by week the patients will have specific sessions of resistance training (30 minutes) and aerobic training (30 minutes); phototherapy: all patients will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral. In Sham group,the equipment will be off.
3061237|NCT02153021|Active Comparator|Phototherapy|"phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral.~Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J"
3061238|NCT02153008||Symptomatic population for GAS|This study is a diagnostic study to aid in the detection of Strep throat. No intervention or medication is a part of this study.
3061239|NCT02152995|Experimental|Treatment (iodine I-124 PET/CT, trametinib, iodine I-131)|Patients undergo iodine I-124 PET/CT on day 5 of week 1. Beginning day 6, patients receive trametinib PO daily for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo second iodine I-124 PET/CT on week 5. If I-124 PET/CT shows enough iodine absorption, patients may receive iodine I-131 PO and continue receiving trametinib for another 2 days. If I-124 shows that the thyroid is not absorbing iodine, patients may continue trametinib at the doctor's discretion and do not receive iodine I-131.
3061240|NCT02152982|Experimental|Arm I (temozolomide, veliparib)|Patients receive temozolomide PO QD on days 1-5 and veliparib PO BID on days 1-7. Treatment repeats every 28 days for 6 courses in the absence of disease progression (confirmed progression) or unacceptable toxicity.
3061241|NCT02152982|Placebo Comparator|Arm II (temozolomide, placebo)|Patients receive temozolomide as in Arm I and placebo PO BID on days 1-7. Treatment repeats every 28 days for 6 courses in the absence of disease progression (confirmed progression) or unacceptable toxicity.
3061242|NCT02152969|Other|Part B|Arm to evaluate influence of Chlorthalidone on pharmacokinetics of amlodipine and telmisartan.
3061243|NCT02152969|Other|Part A|Arm to evaluate influence of amlodipine and telmisartan on pharmacokinetics of Chlorthalidone.
3061244|NCT02152956|Experimental|MGD006|MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART®) bi-specific antibody
3061245|NCT02152943|Experimental|Everolimus with Letrozole and Trastuzumab Escalation Group|"Everolimus and Letrozole should be administered orally once daily at the same time every day, either consistently with or consistently without food. Trastuzumab will be administered intravenously (IV) once every 3 weeks. A cycle will be considered 21 days.~Escalation Group Starting Dose of Everolimus: 5 mg by mouth daily.~Escalation Group Starting Dose of Trastuzumab: 4 mg/Kg loading dose by vein every 3 weeks, then 2 mg/Kg maintenance dose by vein every 3 weeks.~Escalation Group Letrozole Dose: 2.5 mg by mouth daily."
3061246|NCT02152943|Experimental|Other Types of Solid Tumors Expansion Group|"Expansion Group Starting Dose of Everolimus and Trastuzumab: Maximum tolerated dose from Escalation Group.~Expansion Group Letrozole Dose: 2.5 mg by mouth daily."
3061247|NCT02152943|Experimental|Breast Cancer Expansion Group|"Expansion Group Starting Dose of Everolimus and Trastuzumab: Maximum tolerated dose from Escalation Group.~Expansion Group Letrozole Dose: 2.5 mg by mouth daily."
3061248|NCT02152930|Active Comparator|Supervised Exercise Therapy|Standard treatment: Supervised Exercise Therapy during 12 weeks
3061249|NCT02152930|No Intervention|Controlled group|
3061250|NCT02152917|Active Comparator|Tranexamic acid|A dose of tranexamic acid (10mg/Kg) will be administered 20 minutes before inflating the pneumatic tourniquet and another dose 15 minutes after the tourniquet release.
3061251|NCT02152917|Active Comparator|Floseal®|Floseal® will be applied in regions of potential bleeding before the release of the pneumatic tourniquet.
3061252|NCT02152917|No Intervention|Control group|
3061253|NCT02152904||Peptic ulcer bleeding patients|Endoscopy
3061256|NCT02152878|Active Comparator|Active stimulation|Active stimulation (tDCS) will be used in the dose of 2mA /30 min per day, for 10 days and two extra sessions every other week (total of 12 sessions).
3061257|NCT02152878|Placebo Comparator|Sham stimulation|For Sham Transcranial Direct Current Stimulation, the device is automatically turned off after 30 seconds of stimulation and remains turned off.
3061258|NCT02152865|Active Comparator|Lupeol|Patients are supposed to apply lupeol on one side of face two times per day for 8 weeks
3061259|NCT02152865|Placebo Comparator|Control vehicle|Patients are supposed to apply vehicle control to another side of face two times per day for 8 weeks
3061260|NCT02152852|Experimental|Community Health Worker Intervention|Community Health Worker Intervention-home visits from community health workers providing education and support for self-management of type 2 diabetes, resources for diabetes control, and assistance in effective communication with medical providers
3061261|NCT02152852|No Intervention|Usual Care Control Group|Usual Care Control Group- Usual care is defined as services received by participants in the absence of the intervention plus information about community resources that support diabetes self-management (such as classes and support groups) and educational pamphlets.
3061262|NCT02152839|Experimental|Old Unilateral Exercise|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training
3061263|NCT02152839|Experimental|Young Unilateral Exercise|Young Individuals (18-30y) studied before and after 6 weeks unilateral resistance exercise training
3061264|NCT02152826|Experimental|potassium oxalate gel|Professional application
3061265|NCT02152826|Active Comparator|Potassium oxalate liquid|Professional application
3061266|NCT02152813|Active Comparator|1. Bilateral TENS (Bi-TENS) group|Subjects having bilateral electrical stimulation and task-orientated exercises
3061267|NCT02152813|Placebo Comparator|Unilateral TENS (Uni-TENS) group|Subjects having unilateral TENS over their affected lower limb only, and task-oriented exercises
3061268|NCT02152800|Experimental|Vacyless® 1000 mg|one Vacyless® 1000 mg tablets, 3 times daily for 7days
3061269|NCT02152800|Experimental|Vacyless® 500mg|Two Vacyless® 500mg tablets, 3 times daily for 7 days
3061270|NCT02152800|Active Comparator|Valtrex® 500 mg|Two Valtrex® 500 mg tablets, 3 times daily for 7days
3061271|NCT02152787|Experimental|1) propofol 1.0mg/kg group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
3061272|NCT02152787|Experimental|2) propofol 0.5mg/kg group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
3061273|NCT02152787|Placebo Comparator|3) normal saline group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
3061274|NCT02152774|Experimental|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.
3061275|NCT02152774|Experimental|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.
3061276|NCT02152761|Experimental|bimagrumab high dose|Approximately 70 patients who meet all inclusion criteria and none of the exclusion criteria will be treated with the bimagrumab high dose administered via intravenous infusion starting Day 1 until Week 20
3061277|NCT02152761|Experimental|bimagrumab medium dose|Approximately 70 patients who meet all inclusion criteria and none of the exclusion criteria will be treated with the bimagrumab medium dose administered via intravenous infusion starting Day 1 until Week 20
3061278|NCT02152761|Placebo Comparator|placebo|Approximately 70 patients who meet all inclusion criteria and none of the exclusion criteria will receive matching placbo administered via intravenous infusion starting Day 1 until Week 20
3061279|NCT02152761|Experimental|Bimagrumab low dose|Approximately 35 patients who meet all inclusion criteria and none of the exclusion criteria will be treated with bimagrumad low dose administered via intravenous infusion starting Day 1 until Week 20
3061280|NCT02152748||Glioblastoma|The aim of this study is to analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance in matched pre- and post-therapeutic glioblastoma samples.
3061281|NCT02152735|Active Comparator|Cleaning the uterine cavity|Cleaning the uterine cavity: participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus.
3061282|NCT02152735|No Intervention|Not cleaning the uterine cavity|These participants will have their uterine cavities left alone after complete delivery of the placenta. The placenta will be inspected after delivery to make sure it is complete, including the membranes.
3061283|NCT02152722||Total Body Irradiation Subjects|Subjects undergoing total body irradiation prior to chemotherapy. It is expected that all of these subjects will be receiving ablative radiation prior to bone marrow transplant. Breath will be collected before and after the first radiation exposure on each day of total body irradiation.
3061284|NCT02152709|Experimental|10µg/0.5ml hepatitis B vaccine|3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number: YHB2008063S1.
3061383|NCT02152059|Experimental|BIBF1120|BIBF1120 200 mg twice daily continuously
3061285|NCT02152709|Active Comparator|5µg/0.5ml hepatitis B vaccine|3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number:20080603.
3061286|NCT02152696|Active Comparator|Expectant Management|Subjects will have their PPUL expectantly managed using serum hCG monitoring.
3061287|NCT02152696|Active Comparator|Uterine evacuation with MTX for some|Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
3061288|NCT02152696|Active Comparator|Empiric treatment with MTX for all|Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
3061289|NCT02152683|Experimental|long protocol|Renova
3061290|NCT02152683|Experimental|short protocol|Renova
3061291|NCT02152670|Experimental|Baseline|Subjects will receive 2 baseline PET scans with the radioligands (11C)(+)PHNO and (11C)(+)raclopride
3061292|NCT02152670|Experimental|Dopamine Release|Subjects will receive 1 PET scan following a PO dose of 60mg of methylphenidate to facilitate dopamine release with the radioligand (11C)(+)PHNO
3061293|NCT02152670|Experimental|Endogenous Dopamine|Subjects will receive 2 PET scans following 48 hours of dopamine depletion via AMPT with the radioligands (11C)(+)PHNO and (11C)(+)raclopride
3061294|NCT02152657|Experimental|Mesenchymal stem cell transplantation|
3061295|NCT02152644||amyloid|unique cohort of Adult patients older than 21 years with carpal tunnel syndrome with surgical indication (moderate to severe symptoms that do not respond to conservative treatment physiotherapy, splinting, activity modification) for more than 6 months.
3061296|NCT02152631|Experimental|Abemaciclib|200 milligrams (mg) abemaciclib administered, orally, every 12 hours plus best supportive care (BSC) on Days 1 to 28 (28 day cycles).
3061297|NCT02152631|Active Comparator|Erlotinib|150 mg erlotinib administered, orally, every 24 hours plus BSC on Days 1 to 28 (28 day cycles).
3061298|NCT02152605|Experimental|Umeclidinium/Vilanterol 62.5/25 mcg once daily|The subjects will receive UMEC/VI 62.5/25 mcg, administered as one inhalation once-daily in the morning via a dry powder inhaler (DPI)
3061299|NCT02152605|Placebo Comparator|Placebo once daily|The subjects will receive placebo, administered as one inhalation once-daily in the morning via a DPI
3061300|NCT02152592|No Intervention|PCM/NAPR group|paracetamol 1000 mg orally four times a day for 48 hours postoperatively and naproxen 500 mg orally twice a day for 48 hours postoperatively (standard hospital pain protocol for treatment of acute postoperative pain at home after painful day-case surgery)
3061301|NCT02152592|Active Comparator|PCM/Oxy1 group|Controlled Release oxycodone 10 mg orally twice a day for 24 hours and paracetamol 1000 mg orally four times a day for 48 hours postoperatively
3061302|NCT02152592|Active Comparator|PCM/Oxy2 group|CR oxycodone 10 mg orally twice a day for 48 hours and paracetamol 1000 mg orally four times a day for 48 hours postoperatively
3061303|NCT02152579|Experimental|Isosorbide-5-mononitrate, tablet|Single treatment arm.
3061304|NCT02152566|Experimental|Diagnostic PSG/PG, PSG w. nasal high flow therapy|All patients recruited will undergo a diagnostic sleep study, either a full in laboratory attended polysomnography (PSG), or an in-home polygraphy (PG). If respiratory insufficiencies with Cheyne-Stokes respiration (CSR) are detected, these patients will undergo an overnight in laboratory attended PSG on a nasal high flow therapy device to test the primary endpoint of this study. Patients without respiratory insufficiencies after the first PSG/PG will take no further part in the trial.
3061305|NCT02152553|Active Comparator|Hydrocortisone|Near-physiologic doses of Hydrocortisone are being given to subjects. The first day between 09.00 and 12.00 0,024 mg Hydrocortisone/kg per hour. The first day between 12.00 and 20.00 0,012 mg Hydrocortisone/kg per hour. The first day between 20.00 and 24.00 0,008 mg Hydrocortisone/kg per hour. The second day between 00.00 and 11.00 0,030 mg Hydrocortisone/kg per hour. Hydrocortisone infusion: 0,4 ml Solu Cortef 100 mg (50 mg/ml) added in 999,6 ml sodium chloride 0,9% solution (1 mg Solu Cortef/ 50 ml total solution volume).
3061306|NCT02152553|Placebo Comparator|Placebo|The same volume of sodium chloride 0,9% as in the other arm where Hydrocortisone is given in saline 0,9% solution. The given volume of sodium chloride will variate chronically as in Hydrocortisone arm.
3061307|NCT02152540|Experimental|rTMS|Those receiving experimental treatment will receive 20 sessions of rTMS. The treatment will be delivered by trained medical personnel.
3061308|NCT02152540|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 sessions of sham rTMS. The treatment will be delivered by trained medical personnel.
3061309|NCT02152527||Trimetazidine|Patients for coronary artery bypass grafting surgery who had preoperative trimetazidine usage in standard ischemic coronary disease therapy.
3061310|NCT02152527||Control|Patients for coronary artery bypass grafting surgery who had standard therapy for ischemic coronary disease without trimetazidine.
3061311|NCT02152514|Active Comparator|Intrathecal Morphine/Sufentanil and PCA|Patients will receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will have a PCA for analgesia rescue in the post-operative period.
3061312|NCT02152514|Placebo Comparator|PCA alone|Patients will NOT receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will only have a PCA for analgesia in the post-operative period.
3061313|NCT02152501|Experimental|Exercise Energy Expenditure 300 kcal/day|Subjects will be randomly assigned to this group and will exercise energy expenditure of 300 kcal/day.
3061314|NCT02152501|Experimental|Exercise Energy Expenditure 600 kcal/day|Subjects will be randomly assigned to this group and will exercise energy expenditure of 600 kcal/day.
3061315|NCT02152475|Experimental|PDT with blue light and curcumin|PDT treatment was performed with light and curcumin.The irradiation parameters were: blue-light emitting diode (LED) illumination (455±30 nm), 400 mW of average optical power, 5 min of application, illumination area of 0.666 cm2, 600 mW/cm2 of intensity and 120 J/cm2 of fluence. The curcumin concentration of 30 mg/L was used.
3061316|NCT02152475|Active Comparator|Curcumin|The curcumin concentration of 30 mg/L was used.
3061380|NCT02152085|Experimental|Narrow pulse|Six-week treatment of electrical stimulation applied to the calf muscles with stimulus pulses that last 0.4 ms.
3061317|NCT02152475|Active Comparator|Blue light|The irradiation parameters were: blue-light emitting diode (LED) illumination (455±30 nm), 400 mW of average optical power, 5 min of application, illumination area of 0.666 cm2, 600 mW/cm2 of intensity and 120 J/cm2 of fluence.
3061318|NCT02152462|Other|Exergaming|Exercise Intervention: Participants in the Wii Fit exergaming group will have a goal of 150 min/wk of moderate intensity exercise for the last 5 mo of the 6 mo intervention. Heart rate (HR) monitors will quantify exercise intensity. Participants will exercise at a HR equal to 45-65% of their VO2max. Participants will be instructed by the exercise physiologist on how to achieve the required HR. The training will consist of 3 days/wk of supervised Wii Fit physical activity. Exercise duration will increase gradually from 75 to 150 min/wk by wk 477. Thereafter, women will maintain >150 min/wk of moderate-intensity physical activity. Participants will complete daily exercise diaries recording the type and duration of physical activity, and HR.
3061319|NCT02152462|No Intervention|Control|Control Group: After baseline testing the control group will be asked to maintain their current daily activities for the duration of the study. The control group will have the option to exercise at the Wii Fit stations following their completion of the study. They will receive the same measures as the exercise group.
3061320|NCT02152449|No Intervention|Control group|"Control group: systematic advice on swallowing, plus:~If no weight loss compared to usual weight: no intervention~if weight loss <5%: advice on a fat- and protein-enriched diet~if weight loss ≥5%: advice on a fat- and protein-enriched diet + 1 unit of ONS/day per os"
3061321|NCT02152449|Experimental|oral nutritional supplementation|"Experimental ONS Group: systematic advice on swallowing + systematic advice on a fat- and protein-enriched diet, plus:~if no weight loss compared to usual weight: 1 ONS/day per os~if weight loss <5% compared to usual weight: 2 ONS/day per os~if weight loss ≥5% compared to usual weight: 3 ONS/day per os"
3061322|NCT02152436||Before simulation-based curriculum|125 surgical interventions will be observed and outcomes will be measured before simulation-based curriculum
3061323|NCT02152436||After simulation-based curriculum|125 surgical interventions will be observed and outcomes will be measured after simulation-based curriculum
3061324|NCT02152423|Other|LOVENOX|patients are given a curative dose of Enoxaparin (LOVENOX)
3061325|NCT02152423|Active Comparator|ENOXAMED|patients are given a curative dose of Enoxaparin (ENOXAMED)
3061326|NCT02152410|Experimental|acupuncture group|The patient receives acupuncture session lasts between 20 to 30 minutes. Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA).
3061327|NCT02152410|Active Comparator|Morphine group|Each patient must receive a bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement (VAS> 30).
3061328|NCT02152397|Active Comparator|Therapist-led brief intervention (TBI)|"Participants will receive therapist-led, computer-assisted intervention sessions with a therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
3061329|NCT02152397|No Intervention|Enhanced usual care|Participants will receive therapist-led, computer-assisted control sessions with a therapist.
3061330|NCT02152384|Experimental|Insulin peglispro (with Insulin Lispro)|Insulin preglispro once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required
3061331|NCT02152384|Active Comparator|Insulin Glargine (with Insulin Lispro)|Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required
3061332|NCT02152371|Experimental|Dulaglutide + Insulin Glargine|1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
3061333|NCT02152371|Placebo Comparator|Placebo + Insulin Glargine|Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
3061334|NCT02152358|Active Comparator|Ganciclovir|Patients with a positive CMV PCR
3061335|NCT02152358|Placebo Comparator|Ganciclovir placebo|Patients with a positive CMV PCR
3061336|NCT02152358|Active Comparator|Aciclovir|Patients with a PCR positive for HSV
3061337|NCT02152358|Placebo Comparator|Aciclovir placebo|Patients with a positive PCR for HSV
3061338|NCT02152345|Experimental|Belatacept Immunosuppression|Renal transplant recipients will receive steroids (Methylprednisolone), rATG, Belatacept and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
3061339|NCT02152345|Active Comparator|Standard Immunosuppression (Tacrolimus)|Renal transplant recipients will receive standard immunosuppressive therapy, including steroids (Methylprednisolone), rATG, Tacrolimus and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
3061340|NCT02152332|Experimental|Treatment Sequence Group ADBC|Participant will receive Treatment A (JNJ-54861911, 50 milligram (mg) once daily for 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of second treatment regimen, then Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen followed by Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of fourth treatment regimen).
3061341|NCT02152332|Experimental|Treatment Sequence Group BACD|Participant will receive Treatment B (JNJ-54861911, 150 mg once daily for 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of second treatment regimen), then Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen) followed by followed by Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of fourth treatment regimen).
3061381|NCT02152085|Experimental|Wide pulse|Six-week treatment of electrical stimulation applied to the calf muscles with stimulus pulses that last 1 ms.
3061342|NCT02152332|Experimental|Treatment Sequence Group CBDA|Participant will receive Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 on second treatment regimen), then Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of third treatment regimen) followed by Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of fourth treatment regimen).
3061343|NCT02152332|Experimental|Treatment Sequence Group DCAB|Participant will receive Treatment D (JNJ-54861911-matched placebo once daily for 7 days plus moxifloxacin 400 mg on Day 7) followed by Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of second treatment regimen), then Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen) followed by Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 on fourth treatment regimen).
3061344|NCT02152319|Experimental|KHV reporting|Clinicians will view the motor symptom severity reports and videoconference to titrate medications.
3061345|NCT02152319|Active Comparator|Standard care|Subjects in this group will still use KHV at home to minimize any placebo effects that could be attributed to using the system; however, clinicians will view the motor symptom severity reports and videoconference to titrate medications solely for the experimental subjects.
3061346|NCT02152306|Experimental|Fimasartan and Amlodipine|Combination of Fimasartan and Amlodipine
3061347|NCT02152306|Active Comparator|Fimasartan|Fimasartan Monotherapy
3061348|NCT02152280|Experimental|Danhong Injection|Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
3061349|NCT02152280|Placebo Comparator|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
3061350|NCT02152267|Experimental|tDCS 1mA|the parameters used in the TDCS will be 1mA, cathodal over right DLPFC and anodal over supraorbital contralateral area.
3061351|NCT02152267|Experimental|tDCS 2mA|the parameters used in the TDCS will be 2mA, cathodal over right DLPFC and anodal over supraorbital contralateral area.
3061352|NCT02152267|Sham Comparator|tDCS Sham|the parameters used in the TDCS will be sham, cathodal over right DLPFC and anodal over supraorbital contralateral area.
3061353|NCT02152254|Active Comparator|Arm A: Targeted Therapy|Personalized treatment, targeted therapy against the alteration based on molecular profiling.
3061354|NCT02152254|Experimental|Arm B: Standard-of-Care Therapy|Standard-of-Care treatment not selected on basis of alteration analysis.
3061355|NCT02152241||Patients with IBD|Adult patients with IBD diagnosed during childhood
3061356|NCT02152228|Experimental|Oral Parathyroid Hormone (1-34)|Oral administration of EnteraBio's Oral Parathyroid Hormone (1-34)
3061357|NCT02152215|Active Comparator|Acellular dermal matrix membrane|An acellular dermal matrix membrane will be used as a barrier between the osseous graft and the soft tissue flap.
3061358|NCT02152215|Experimental|Polylactic acid membrane|A polylactic acid membrane will be used as a barrier between the osseous graft and the soft tissue flap.
3061359|NCT02152202|Experimental|Semi-upright position|Semi-upright position defined as 45 degrees incline from horizontal of the patients bed during nocturnal sleep, for two postoperative nights. Daytime naps will be excluded. A regular pillow may be used by the patients based upon the level of comfort and also to support the head in a neutral position.
3061360|NCT02152202|Other|Control group (Supine position)|In this group patients' bed will be set into Supine/0 degree angle during sleep in the night time. Patient will be managed according to routine care
3061361|NCT02152189||Screening population|
3061362|NCT02152176|Experimental|Patient Controlled Analgesy group|Titration of morphine by Patient Controlled Analgesy. The opioid titration will be performed by the patient using PCA (Vygon Freedom 5) according to the principle of self with a refractory period of 5 minutes.
3061363|NCT02152176|No Intervention|Control group|titration will be perform in the usual manner in accordance with the recommendations : a nurse will assess pain using a visual analog scale in the control group to assess the need for a new bolus of morphine
3061364|NCT02152163|Active Comparator|IV Ibuprofen 800 mg|IV Ibuprofen 800 mg
3061365|NCT02152163|Placebo Comparator|IV Saline|IV Saline
3061366|NCT02152150|Experimental|Iron bio-fortified pearl millet|Pearl millet variety ICTP8203-Fe (82 mg/kg iron content)
3061367|NCT02152150|Active Comparator|Control pearl millet|Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content)
3061368|NCT02152137|Experimental|efatutazone dihydrochloride, paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 and efatutazone dihydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3061369|NCT02152124||Controlled on LA-SMSA|Patients with controlled acromegaly on long-acting somatostatin analogs
3061370|NCT02152124||Controlled on LA-SMSA and pegvisomant|Patients with controlled acromegaly on long-acting somatostatin analogs and pegvisomant
3061371|NCT02152124||Controlled after surgery|Controlled acromegaly patients without need for medical therapy after surgery
3061372|NCT02152124||Healhy controls|Healthy volunteers
3061373|NCT02152124||Uncontrolled on LA-SMSA|Patients with uncontrolled acromegaly (i.e. with serum IGF-1 levels above age-specific thresholds and/or symptoms due to active acromegaly (e.g. excessive sweating, arthralgia)) on LA-SMSA monotherapy in maximal dosage
3061374|NCT02152111|Experimental|Dietary Supplement: Coconut flour|Diet hipoernergetic plus 26g/day coconut flour during three months (12weeks).
3061375|NCT02152111|Active Comparator|Nutritional Treatment|All patients received an individualized diet plan and balanced. The diet was calculated to the nutritional status and the protein 15-20% of total energy value, lipids 25-30% of daily energy intake and carbohydrate 50-60% of total energy value
3061376|NCT02152098|Experimental|Chronic Exercise|Chronic Exercise
3061377|NCT02152098|Experimental|Acute Early onset of rehabilitation|Acute Early onset of rehabilitation
3061378|NCT02152098|Experimental|Chronic control|Chronic control
3061379|NCT02152098|Experimental|Acute Delayed onset of rehabilitation|Acute Delayed onset of rehabilitation
3061382|NCT02152072||medical students|
3088597|NCT01968798|Placebo Comparator|Placebo|Placebo
3061384|NCT02152046||Spring loaded retractor|The Alfonso Eyelid Speculum, newborn size
3061385|NCT02152046||Screw retractor|Cook Eyelid Speculum, infant size
3061386|NCT02152033|Experimental|Home-based Continuing Care|The components of Home-based Continuing Care (HCC) include brief parent training, brief Young Adult (YA) orientation and recovery planning, telephone-based continuing care (TCC) and home-based contingency management. Both parent and YA participants will attend sessions with a family specialist.
3061387|NCT02152033|Other|Services as Usual|YAs completing residential care usually are referred to continuing outpatient services and/or self-help groups.
3061388|NCT02152020||Cancer survivors|
3061389|NCT02152007|Experimental|Split-body 1% sirolimus cream (TD201 1%)|This is a split-body design. Subjects will self-administer 1% topical sirolimus cream or placebo cream (no drug, vehicle control) on the plantar surface of each foot. At least one foot will be treated with topical sirolimus at some time during the study. Application will be one time daily for a total of 26 weeks. There will be an additional follow-up visit 3 months after the last application of study drug. The total duration of the study is 39 weeks.
3061390|NCT02151994|Experimental|BIA 5-1058|BIA 5-1058 (5, 25 and 100 mg) tablets
3061391|NCT02151994|Placebo Comparator|Placebo|tablets, visually matching active medication
3061392|NCT02151981|Experimental|AZD9291|AZD9291 80 mg, orally, once daily
3061393|NCT02151981|Active Comparator|Platinum-based doublet chemotherapy|pemetrexed 500mg/m2 + carboplatin AUC5 or pemetrexed 500mg/m2 + cisplatin 75mg/m2
3061394|NCT02151968|Active Comparator|Traditional blind peribulbar block|
3061395|NCT02151968|Experimental|Ultrasound-guided peribulbar block|
3061396|NCT02151955|Experimental|Individual parent infant intervention|Children and parents will be offered an assessment and then a tailored individual 10 to 15 week based attachment and parent intervention to promote parent child relationship.
3061397|NCT02151942||Control group|Procedure/Surgery : Endovascular Aneurysm Repair with no prior procedure rehearsal
3061398|NCT02151942||Rehearsal group|Procedure/Surgery : Endovascular Aneurysm Repair with prior procedure rehearsal
3061399|NCT02151929|Experimental|Bioresorbable Vascular Scaffold|Implantation of of an everolimus eluting bioresorbable scaffold in patients with STEMI treated with primary PCI
3061400|NCT02151929|Active Comparator|Everolimus Eluting stent|Implantation of of an everolimus eluting stent in patients with STEMI treated with primary PCI
3061401|NCT02151916|Experimental|Dental care, AG, MI & fluoride varnish|The intervention comprises four components; provision of dental care to the mother during pregnancy (2nd trimester), preventive treatment with fluoride varnish to the teeth of children, and two behavioral interventions, namely oral health anticipatory guidance and motivational interviewing with the caregiver/mother.
3061402|NCT02151916|Other|Delayed intervention|Three fluoride varnish applications to the teeth of children and oral health anticipatory guidance and motivational interviewing for the caregiver when the child is aged 24, 30 and 36 months. Dental care also will be offered to the mothers/caregivers in the delayed intervention group when their children are aged 2 to 3 years old. Before the children are aged 2 years, standard dental care will be the comparator, which usually involves provision of dental care only if the participant is in pain.
3061403|NCT02151903|Experimental|DI-Leu16-IL2|Patients will receive DI-Leu16-IL2 at the same assigned dose level, dosing schedule, and route of administration that they received during the parent clinical trial AO-101. Patients may continue to receive therapy through the duration of the study as long as they are having clinical benefit and not experiencing any untoward side effects.
3061404|NCT02151890|Experimental|Laparoscopic Stem Cell Transplantation.|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by IH staining by stem cell marker OCT4. Immunohistochemical expression of stem cell marker OCT4 was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS)Laparoscopic injected of stem cell Sample in the ovaries.. Participants were followed up monthly for a period of six months by hormonal (FSH, LH and E2), clinical (resuming menstruation), US (folliculometry), histopathological (HP), and IH expression of stem cell marker OCT4 of the endometrial biopsy (stem cell positivity according to ESS) outcome.
3061405|NCT02151877|Experimental|Nitric oxide on CPB|neonates receiving inhaled NO into the cardiopulmonary bypass circuit during cardiac surgery
3061406|NCT02151877|Placebo Comparator|control|neonates not receiving inhaled NO into the cardiopulmonary bypass
3061407|NCT02151864|Experimental|LDE225|LDE225 200mg-800mg oral daily
3061408|NCT02151851|Experimental|Certolizumab Pegol + Methotrexate|"Subjects will receive loading doses of CZP 400 mg (200 mg / prefilled syringe [PFS], ie, 2 injections) at Baseline, and Weeks 2 and 4; then CZP 200 mg (1 injection) Q2W until Week 22.~All subjects will continue their treatment on Methotrexate (MTX), with or without folic acid, at the same dose and route of administration as at entry (unless there is a need to reduce the dose for reasons of toxicity, minimum dose permitted 10 mg per week)."
3061409|NCT02151851|Placebo Comparator|Placebo + Methotrexate|"Subjects will receive Placebo (1mL / prefilled syringe [PFS], ie, 2 injections) at Baseline, and Weeks 2 and 4; then Placebo (1 injection) Q2W until Week 22.~All subjects will continue their treatment on Methotrexate (MTX), with or without folic acid, at the same dose and route of administration as at entry (unless there is a need to reduce the dose for reasons of toxicity, minimum dose permitted 10 mg per week)."
3061410|NCT02151825|Experimental|Synbiotic|3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
3061411|NCT02151825|Placebo Comparator|Placebo|3 capsules of Maltodextrin per day
3061412|NCT02151812|Experimental|Agent Paclitaxel-coated balloon|drug-coated balloon dilatation of the index lesion using a single Agent(TM) balloon that completely covers the restenotic lesion
3061413|NCT02151812|Active Comparator|SeQuent Please Paclitaxel-coated balloon|drug-coated balloon dilatation of the index lesion using a single SeQuent(R) Please balloon that completely covers the restenotic lesion
3061414|NCT02151799|Experimental|Body contouring surgery|
3061415|NCT02151786||Thirty milligrams of lansoprazole|Thirty milligrams of lansoprazole is mixed in physiological saline (JP) or 5 percent (%) glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 milliliter (mL) of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection.
3061416|NCT02151773||Live attenuated measles/rubella combined vaccine|Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 milliliter (mL) of accompanying reconstitution fluid (water for injection [Japanese Pharmacopoeia]), and a 0.5-mL portion is typically administered subcutaneously as a single dose.
3061417|NCT02151760|Experimental|18F-DCFPyL|
3061418|NCT02151747||Sanger|BRCA 1/2 test results by Sanger sequencing
3061419|NCT02151747||NGS|BRCA 1/2 test results by NGS
3061420|NCT02151734|Experimental|KALOMIN™ Tab.|KALOMIN™ Tab./Placebo to Umckamin syrup
3061421|NCT02151734|Active Comparator|Umckamin syrup|Umckamin syrup/Placebo to KALOMIN™ Tab.
3061422|NCT02151721|Experimental|vorinostat, gefitinib, combination|single arm vorinostat plus gefitinib
3061423|NCT02151708|Active Comparator|motilitone 90mg|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
3061424|NCT02151708|Active Comparator|motilitone 180mg|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
3061425|NCT02151708|Placebo Comparator|placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
3061426|NCT02151695|Active Comparator|Panretinal photocoagulation|
3061427|NCT02151695|Experimental|Aflibercept intravitreal injections|
3061428|NCT02151682|Active Comparator|Morphine prolonged release|10 mg or 30 mg tablets taken orally twice daily. Dose based on participant weight. The dose must not exceed a total of 200 mg per day for participants weighing 55 kg or more.
3061429|NCT02151682|Experimental|Tapentadol prolonged-release|25 mg and or 100 mg tablets taken orally. Dose based on participant weight. The dose must not exceed a total of 500 mg per day for participants weighing 55 kg or more.
3061430|NCT02151682|Other|Tapentadol after morphine|Participants that were randomized to morphine in part 1 of the open-label period can continue with tapentadol in part 2 of the trial. Participants will be rotated to tapentadol prolonged release with 70% of the current morphine equivalent dose or lower.
3061431|NCT02151682|Other|Tapentadol open-label extension|Participants that were randomized to tapentadol in part 1 of the open-label period can continue with tapentadol in part 2 of the trial. Participants will continue on the current dose and if necessary can modify their tapentadol prolonged release dosage.
3061432|NCT02151682|No Intervention|Observation period after tapentadol in part 1|Participants not completing Part 1 can enter the Observation Period.
3061433|NCT02151682|No Intervention|Observation period after morphine in part 1|Participants not completing Part 1 can enter the Observation Period.
3061434|NCT02151669|Experimental|Mediterranean Diet Group|Nutritional intervention to enhance the traditional Mediterranean diet pattern using new technology as an educational tool in primary care: DIET blog. Participants will be referred to a single annual visit and one group session per year for two years.
3061435|NCT02151669|No Intervention|Control group|Participants of control group will be referred to your doctor or nurse with reference to a report on specific according to your personal situation dietary recommendations.
3061436|NCT02151656|Experimental|F17464|Oral administration - During 6 weeks - 4 capsules daily
3061437|NCT02151656|Placebo Comparator|Placebo|Oral administration - During 6 weeks - 4 capsules daily
3061438|NCT02151643|Experimental|Group 1 - PT20 400 mg tid|"PT20 400 mg tid (1.2 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
3061439|NCT02151643|Experimental|Group 2 - PT20 800 mg tid|"PT20 800 mg tid (2.4 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
3061440|NCT02151643|Experimental|Group 3 - PT20 1600 mg tid|"PT20 1600 mg tid (4.8 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
3061441|NCT02151643|Experimental|Group 4 - PT20 3200 mg tid|"PT20 3200 mg tid (9.6 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
3061442|NCT02151643|Placebo Comparator|Group 5 - Placebo tid|"Matched Placebo (for PT20) tid administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
3061443|NCT02151630|Active Comparator|Pyruvic acid|Patients will receive pyruvic acid solution 70% prepared by solving of pyruvic acid in water/ethanol solution. Patients will be advised to apply the solution twice daily for a period of four weeks. Application of petrolatum to the surrounding normal skin protects against the corrosive effect of the concentrated acid.
3061444|NCT02151630|Active Comparator|Salicylic acid|Patients will receive a combination of salicylic acid 16.7%, lactic acid 16.7%, and collodion 100%. Patients will be advised to apply the solution twice daily for a period of four weeks. Application of petrolatum to the surrounding normal skin protects against the corrosive effect of the concentrated acid.
3061445|NCT02151617|Experimental|Cohort 1-PF-06743649 or placebo|Subjects will be randomized to receive PF-06743649 or placebo as 2 single doses in periods 1 and 2 either in the fed or fasted state followed by once daily dosing for 14 days in period 3
3061446|NCT02151617|Experimental|Cohort 2-PF-06743649 or placebo|
3061447|NCT02151617|Experimental|Cohort 3-PF-06743649 or placebo|
3061448|NCT02151617|Experimental|Cohort 4-PF-06743649 or placebo|
3061449|NCT02151617|Experimental|Cohort 5-PF-06743649 or placebo|
3061450|NCT02151604|Experimental|129 Xenon MR Imaging|Xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
3061486|NCT02151344|Experimental|Cohort 1|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0 and one dose at Day 28. They will then receive one dose of the inactivated subvirion H7N9 vaccine 1 month later.
3061451|NCT02151591|Experimental|CBT for SA|Cognitive-behavioral therapy for smoking and alcohol (CBT for SA) entails weekly counseling for 12-weeks. Sessions are focused on providing personalized, health feedback to motivate participants to make changes in smoking and drinking and teaching skills that will help them sustain changes in both behaviors. Skills target heavy drinking smokers' social environments and negative affect (i.e., anger, stress, anxiety, boredom). Participants in this condition will also receive 12 weeks of varenicline (Chantix).
3061452|NCT02151591|Other|Standard Smoking Counseling (SC)|Smoking counseling alone (SC) entails weekly counseling for 12-weeks. Sessions are focused on developing and implementing a smoking quit plan. Participants in this condition will also receive 12 weeks of varenicline (Chantix).
3061453|NCT02151578|No Intervention|nothing at home level|No intervention at community level. The study drugs (arthemeter/Lumefantrine and Cotrimoxazole) available at the health facility drug stores level and prescribed exclusively to sick children attending to the health facility for care seeking. No Community Heath Worker /Key Opinion leader (CHWs/KOLs) selected in those clusters
3061454|NCT02151578|Experimental|Home management of malaria|"At the community level, the Community health workers/ keay opinion leader (HWs/KOLs) trained and equipped to provide the antimalarial drug (arthemeter/Lumefantrine ) to any child with fever (hot body) without any other signs of complications like impaired consciousness, convulsions, etc"
3061455|NCT02151578|Experimental|Home management of malaria and pneumonia|"At the community level, the Community health workers/ key opinion leader (HWs/KOLs) trained and equipped to provide the antimalarial drug (arthemeter/Lumefantrine ) or antibiotic (Cotrimoxazole) to any child with fever (hot body) without any other signs of complications like impaired consciousness, convulsions, etc. The treatment decision making for the CHWs/KOLs based on the algorithm"
3061456|NCT02151565|Experimental|HTEMS|High-tone external muscle stimulation 5 times within 10 days
3061457|NCT02151565|Active Comparator|TENS|Transcutaneous electrical nerve stimulation 5 times within 10 days
3061458|NCT02151552|Experimental|Endotoxin and [18F](+/-)NOS|All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation. They will also be imaged before and after endotoxin instillation with the novel PET tracer [18F](+/-)NOS.
3061459|NCT02151539||Observational (medical chart review)|Study data are collected and managed using REDCap tools at baseline and on days 5, 28, and 56.
3061460|NCT02151526|Experimental|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product (autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human beta-A-T87Q-globin gene)
3061461|NCT02151513||Cancer Pain|Placement of an intrathecal pump
3061462|NCT02151500|Experimental|Stress and Health Interview|Stress and Health Interview is an experiential assessment technique
3061463|NCT02151500|No Intervention|Wait-list Control|Standard medical care until the 6-week follow-up is completed
3061464|NCT02151487|Sham Comparator|Ropivacaine|Ropivacaine 0.5% 25 ml alone for supraclavicular block
3061465|NCT02151487|Active Comparator|Ropivacaine, dexamethasone|25 ml 0.5% ropivacaine + 4 mg dexamethasone
3061466|NCT02151487|Active Comparator|Ropivacaine, clonidine|25 ml 0.5% ropivacaine + 100 mcg clonidine
3061467|NCT02151487|Active Comparator|Ropivacaine, dexamethasone, clonidine|25 ml 0.5% ropivacaine + 4 mg dexamethasone + 100 mcg clonidine
3061468|NCT02151474|Experimental|INCB047986 4 mg QD|INCB047986 4 mg will be orally self-administered once daily (QD) for 28 days.
3061469|NCT02151474|Experimental|INCB047986 8 mg QD|INCB047986 8 mg will be orally self-administered once daily (QD) for 28 days.
3061470|NCT02151474|Experimental|INCB047986 12 mg QD|INCB047986 12 mg will be orally self-administered once daily (QD) for 28 days.
3061471|NCT02151474|Experimental|INCB047986 placebo QD|INCB047986 placebo will be orally self-administered once daily (QD) for 28 days.
3061472|NCT02151461|Experimental|Low Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
3061473|NCT02151461|Experimental|Mid Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
3061474|NCT02151461|Experimental|High Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
3061475|NCT02151461|Experimental|Metformin Monotherapy|3 Capsules BID each containing 166.7 mg of metformin with dose escalation to 283.3 mg capsules BID (1,700 mg/Day) at Day 14.
3061476|NCT02151448|Experimental|vaccine + chemokine modulatory regimen|"Cycle 1, at least 4 weeks after surgery, will include the DC vaccine and oral celecoxib only. Cycle 2, approximately week 4, will include the DC vaccine, celecoxib, and the CKM regimen. Week 5 will be a week of rest and discontinuation of oral celecoxib. Weeks 6-18, if directed by their local oncologists, standard of care chemotherapy. Week 19 is a week of rest. Cycle 3, week 20, will include the DC vaccine, celecoxib, and the CKM regimen. Cycle 4, week 23, will include the DC vaccine, celecoxib, and the CKM regimen.~CKM regimen includes an additional 200 mg dose of celecoxib, intravenous rintatolimod, and intravenous interferon alfa-2b. The CKM regimen is given on days Tuesday through Friday of Cycles 2-4."
3061477|NCT02151435||Patients with IPF|Observation of longitudinal biomarkers in IPF patients
3061478|NCT02151422|Experimental|Breathing exercises|Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
3061479|NCT02151409|Experimental|NNC 0151-0000-0000 i.v.|Dose escalation trial
3061480|NCT02151409|Experimental|NNC 0151-0000-0000 s.c.|Dose escalation trial
3061481|NCT02151409|Placebo Comparator|Placebo|
3061482|NCT02151396|Experimental|Cogmed Working Memory Training|Cogmed (TM) working memory training following standard, recommended administration procedures
3061483|NCT02151383|Experimental|Serelaxin|Serelaxin will be administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours.
3061484|NCT02151370||Cohort|
3061485|NCT02151357|Experimental|DCBCI0901|DCBCI0901 7.5mg/m2, iv infusion for day 1-day 5 and day 15-day 20
3061568|NCT02150850||Cases|Patients who have sustained an AFF that consent to participating in the registry and undergoing EOS® imaging.
3061487|NCT02151344|Experimental|Cohort 2|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0 and one dose at Day 28. They will then receive one dose of the inactivated subvirion H7N9 vaccine 2 months later.
3061488|NCT02151344|Experimental|Cohort 3|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0. They will then receive one dose of the inactivated subvirion H7N9 vaccine 2 months later.
3061489|NCT02151344|Experimental|Cohort 4|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0. They will then receive one dose of the inactivated subvirion H7N9 vaccine 1 month later.
3061490|NCT02151344|Experimental|Cohort 5|Participants will receive one dose of the inactivated subvirion H7N9 vaccine at Day 0 and one dose at Day 28.
3061491|NCT02151331|Experimental|REP + EF|Replication Effective Programs (REP) augmented with External Facilitation (EF)
3061492|NCT02151331|Experimental|REP + EF/IF|Replicating Effective Programs (REP) augmented with External and Internal Facilitation (EF + IF)
3061493|NCT02151305|Experimental|Total intravenous anesthesia group|This group received propofol and remifentanil for the maintenance of general anesthesia.
3061494|NCT02151305|Experimental|Inhalation anesthesia group|This group received sevoflurane for the maintenance of general anesthesia.
3061495|NCT02151279|Placebo Comparator|control group|Chitosan as wine fining agent
3061496|NCT02151279|Active Comparator|Shrimp allergic patients|Chitosan as wine fining agent
3061497|NCT02151266|Experimental|Exercise and Cognitive retraining|Aerobic exercise; Computerized cognitive retraining program; Heart failure education; Home visits; telephone follow-up.
3061498|NCT02151266|Experimental|Exercise only|Each participant will be provided with an individualized target heart rate (THR)zone based on treadmill results. Under the supervision of a research nurse, participants will begin the walking sessions at 60% of THR and increase to 70% by week 5. Participants will walk a minimum of 5 times per week for a duration of 30 minutes.
3061499|NCT02151266|Sham Comparator|Stretching and Flexibility|Stretching and flexibility movements; heart failure education; home visits; telephone follow-up.
3061500|NCT02151253|Experimental|Armodafinil First, Then Placebo|"During double-blind treatment subjects took armodafinil for 4 weeks before crossing over to placebo for 4 weeks. Pill is taken once daily, before 8 am.~Armodafinil/placebo was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects."
3061501|NCT02151253|Placebo Comparator|Placebo First, Then Armodafinil|"During double-blind treatment subjects took placebo for 4 weeks before crossing over to armodafinil for 4 weeks. Pill is taken once daily, before 8 am.~Armodafinil/placebo was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects."
3061502|NCT02151240|Experimental|Arm I|Foscarnet Sodium and Sodium Chloride Injection 3g: 250ml, IV; Second administration: Foscarnet Sodium and Sodium Chloride Injection 3g: 250ml, IV
3061503|NCT02151240|Active Comparator|Arm II|First administration: Acyclovir for Injection 0.25g + 0.9% Sodium Chloride Injection 250ml, IV; Acyclovir for Injection 0.25g + 0.9% Sodium Chloride Injection 250ml, IV; Second administration: Acyclovir for Injection 0.25g+ 0.9% Sodium Chloride Injection 250ml, IV
3061504|NCT02151227||magnesium intake categories|comparators: categories of magnesium intake except lowest category of magnesium intake , controls: lowest category of magnesium intake
3061505|NCT02151214|Experimental|Parenteral nutrition|Parenteral nutrition will be administered to the patients
3061506|NCT02151214|No Intervention|Normal per os nutrition|The patients will eat orally
3061507|NCT02151201|Experimental|Influenza vaccination video education|Influenza vaccination video education
3061508|NCT02151201|Placebo Comparator|Hand Washing video education|Hand Washing vaccination video education
3061509|NCT02151188|Other|Bread and water|co-ingestion control session
3061510|NCT02151188|Experimental|bread with cow milk co-ingestion|co-ingestion bread with cow milk
3061511|NCT02151188|Experimental|bread with soy milk co-ingestion|co-ingestion bread with soy milk
3061512|NCT02151188|Experimental|preload cow milk|preload cow milk 30 min, then bread
3061513|NCT02151188|Experimental|preload soy milk|preload soy milk 30 min, then bread
3061514|NCT02151175|Experimental|LIFUP|
3061515|NCT02151162|Experimental|Stress management plus omega-3|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
3061516|NCT02151162|Active Comparator|Stress management plus placebo|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
3061517|NCT02151162|Active Comparator|Psychoeducation leaflet plus omega-3|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
3061518|NCT02151162|Active Comparator|Psychoeducation leaflet plus placebo|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
3061519|NCT02151149|Other|Arm A: nab-Paclitaxel and Carboplatin (Every 21 days)|nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, and 15 and Carboplatin AUC = 6 mg*min/mL IV following nab-paclitaxel infusion on Day 1 of every 21-day treatment cycle
3061520|NCT02151149|Other|Arm B: nab-Paclitaxel and Carboplatin (Every 28 days)|nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1, 8, and 15 of each 21-day treatment followed by one-week break and Carboplatin AUC = 6 mg*min/mL IV following nab-paclitaxel infusion on Day 1 of each 21-day treatment followed by one-week break
3061569|NCT02150850||Controls|For each case we will identify one age- (± 5 years), sex-, height- (± 6 cm) and cumulative bisphosphonate or denosumab exposure ( ±2 years) matched control who has not sustained an AFF to undergo EOS® imaging.
3088848|NCT01967225|Active Comparator|Linezolid|
3061521|NCT02151136|Experimental|TootSweet (24% sucrose) + standard care|In addition to standard care (topical anesthetic (Ametop or EMLA) + upright holding + distraction + pacifier, if used), a maximum of 2 ml TootSweet will be administered orally in 0.25 ml aliquots 2 minutes prior to the needle insertion, at the time of needle insertion, and repeated at 2 minute intervals until the completion of the procedure
3061522|NCT02151136|Placebo Comparator|Sterile water + standard care|In addition to standard care (topical anesthetic (Ametop or EMLA) + upright holding + distraction + pacifier, if used), a maximum of 2 ml sterile water will be administered orally in 0.25 ml aliquots 2 minutes prior to the needle insertion, at the time of needle insertion, and repeated at 2 minute intervals until the completion of the procedure
3061523|NCT02151123||Diagnosed colon cancer patients|Patients undergoing colectomy for colonic adenocarcinoma.
3061524|NCT02151110|Placebo Comparator|Placebo|Placebo
3061525|NCT02151110|Experimental|Cohort 1|Medi4920
3061526|NCT02151110|Experimental|Cohort 2|MEDI4920
3061527|NCT02151110|Experimental|Cohort 3|MEDI4920
3061528|NCT02151110|Experimental|Cohort 4|MEDI4920
3061529|NCT02151110|Experimental|Cohort 5|MEDI4920
3061530|NCT02151110|Experimental|Cohort 6|MEDI4920
3061531|NCT02151110|Experimental|Cohort 7|MEDI4920
3061532|NCT02151097||High risk prostate cancer|Men ≥18 years of age diagnosed with high risk prostate cancer, defined as clinical stage ≥T2c, or Prostate Specific Antigen (PSA)>20 ng/ml, or Gleason Score 8-10, scheduled to have radical prostatectomy.
3061533|NCT02151084|Experimental|Arm A (Continuous Dosing)|"Run-In: Selumetinib, orally, BID for 7 days (Day -7 to Day -1)~On treatment: Selumetinib, orally, BID from Day 1-21 of every 28 day cycle. Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle."
3061534|NCT02151084|Experimental|Arm B (Sequential Dosing)|"Run-In: Selumetinib, orally, BID for 5 days (Day -7 to Day -3) with 2 days washout~On treatment: Selumetinib, orally, BID from Day 1-5 and 8-19 of every 28 day cycle.~Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle."
3061535|NCT02151084|Experimental|Arm C (Standard Care)|Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle.
3061536|NCT02151071|Other|Breast conserving surgery|Females ≥ 30 years of age with a diagnosis of invasive breast cancer or ductal carcinoma in situ (DCIS), scheduled for BCS +/- SLNB or ALND
3061537|NCT02151058|Other|Negative Control, 035000513007|Colgate® Regular Cavity Protection
3061538|NCT02151058|Experimental|Experimental Mouth Rinse, 19545-118|
3061539|NCT02151058|Active Comparator|Active Comparator: Mouth Rinse 037000089872|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint
3061540|NCT02151045|Active Comparator|Non target epidural infiltration at L3-L4 stage|"In this control arm, there are patients with a non target posterior epidural space infiltration of corticoids done at L3-L4 stage on scan control.~These patients must have a discal hernia confirmed by scanner or RMI"
3061541|NCT02151045|Experimental|Epidural infiltration on contact of disco radicular conflict|"In this experimental arm, there are patients with an epidural infiltration of corticoids done in lateral on contact of disco radicular conflict on scan control.~These patients must have a discal hernia confirmed by scanner or RMI"
3061542|NCT02151032||Colorectal Cancer Screening Booklet + Audio CD|Participants read the booklet about colorectal cancer screening tests, and listen to an audio CD that will narrate the booklet. Questionnaire completion before and after viewing the program.
3061543|NCT02151032||Video with Non-Moving Images on iPad|Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad. Questionnaire completion before and after viewing the program.
3061544|NCT02151032||Video with Animated Images on iPad|Participants watch a video with animated images about colorectal cancer screening tests on an iPad. Questionnaire completion before and after viewing the program.
3061545|NCT02151019|Experimental|Experimental Arm|50.4 Gy / 28# external beam pelvic radiotherapy delivered using IMRT
3061546|NCT02151019|No Intervention|Control Arm|50.4 Gy / 28# external beam pelvic radiotherapy delivered using a 3-Dimensional (3-D) planned technique
3061547|NCT02151006|Active Comparator|DHEA|women will receive DHEA 6 weeks before starting IVF/ICSI
3061548|NCT02151006|No Intervention|Control|
3061549|NCT02150993|Experimental|Arm A : TDF + FTC (or 3TC) + ZDV|Tenofovir + Emtricitabine or Lamivudine + Zidovudine
3061550|NCT02150993|Experimental|TDF+FTC (or 3TC) +LPV/r|Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir
3061551|NCT02150993|Experimental|Arm C : TDF +FTC (or 3TC) + RAL|Tenofovir + Emtricitabine or Lamivudine + Raltegravir
3061552|NCT02150967|Experimental|BGJ398|To estimate anti-tumor activity of BGJ398
3061553|NCT02150954|Active Comparator|foley bulb induction with low dose pitocin|Subjects in this arm will receive a standard infusion protocol of pitocin starting at 1 milliunit/minute (mius/min) and increasing 2 milliunits per minute every 30 minutes.
3061554|NCT02150954|Active Comparator|foley bulb with standard incremental pitocin infusion protocol|Subjects in this arm will receive a fixed low dose pitocin infusion protocol of 2 mius/min.
3061555|NCT02150941|Experimental|BioVac Direct Suction Device|Experimental arm
3061556|NCT02150941|Active Comparator|Standard Endoscopy Suction|Control arm
3061557|NCT02150928|Experimental|Erwinaze / Erwinase|
3061558|NCT02150915|Experimental|new acupoint|Subjets in this arm receive acupuncture therapy in a new acupoint (leopard spot needling technique)
3061559|NCT02150915|Active Comparator|classical acupoint|Subjects in this arm receive acupuncture therapy in a classical acupoint in the pericardial conduit (leopard spot needling technique)
3061560|NCT02150902|Experimental|Augmented- WACA|Augmented- wide area circumferential catheter ablation for atrial fibrillation
3061561|NCT02150902|Active Comparator|WACA|Wide area circumferential catheter ablation procedure for atrial fibrillation
3061562|NCT02150889|No Intervention|Lean Trained|Metabolic control
3061563|NCT02150889|Experimental|Obese or Overweight|Running Program Yoga Program
3061564|NCT02150863|Active Comparator|Ultrapulse laser alone|
3061565|NCT02150863|Active Comparator|Ultrapulse laser plus Cellutome Harvesting system|
3061566|NCT02150863|No Intervention|Control|
3061567|NCT02150850||Registry|Patients who have who have sustained an AFF that consent to participating in the registry only.
3061660|NCT02150239||postoperative pain|
3061570|NCT02150837||5 & 2 & 2 Plan|MWCC members who used the Medifast 5 & 2 & 2 Meal Replacement Plan for weight loss.
3061571|NCT02150837||4 & 2 & 1 Plan|MWCC members who used the Medifast 4 & 2 & 1 Meal Replacement Plan for weight loss.
3061572|NCT02150824|Experimental|BI 187004 low dose mono QD|patient to receive one tablet containing low dose of BI 187004 or matching placebo
3061573|NCT02150824|Experimental|BI 187004 medium dose mono QD|patient to receive one tablet containing medium dose mg of BI 187004 or matching placebo
3061574|NCT02150824|Experimental|BI 187004 high dose mono QD|patient to receive one tablet containing high dose of BI 187004 or matching placebo
3061575|NCT02150824|Experimental|BI 187004 high dose QD add on|patient to receive one tablet containing high dose of BI 187004 or matching placebo add on to metformin background dose
3061576|NCT02150811||Hunner's ulcer|
3061577|NCT02150798|Experimental|High fat and low carbohydrate diet|High fat low carbohydrate diet composition was 40 % of carbohydrates, 40 % of lipids (12 % saturated, 18 % monounsaturated and 10% polyunsaturated, ) and 20 % of protein for two months
3061578|NCT02150798|Active Comparator|Control diet|the standard diet composition was 50 % of carbohydrates, 30 % of lipids (10 % saturated, 10 % polyunsaturated, and 10 % monounsaturated) and 20 % of protein for two months
3061579|NCT02150785|Experimental|Adminstering Streptokinase|treatment with 15,000 units/Kg of streptokinase in ischemic stroke patients with symptoms onset for less than 3 hours
3061580|NCT02150772|Other|Shear Wave Elastography|All included patients have SWE performed
3061581|NCT02150759|Experimental|Dexmedetomidine-ketamine|Dexmedetomidine-ketamine group
3061582|NCT02150759|Active Comparator|Dexmedetomidine-fentanyl|Dexmedetomidine-fentanyl group
3061583|NCT02150746||Pancreatic Cancer CTC|Peripheral/Central Venous Blood Draw Peritoneal Wash
3061584|NCT02150733|Experimental|Group 1 - Normal hepatic function|Subjects with normal hepatic function
3061585|NCT02150733|Experimental|Group 2 - Mild hepatic impairment|Subjects with mild hepatic impairment by Child-Pugh classification scores
3061586|NCT02150733|Experimental|Group 3 - Moderate hepatic impairment|Subjects with moderate hepatic impairment by Child-Pugh classification scores
3061587|NCT02150733|Experimental|Group 4 - Severe hepatic impairment|Subjects with severe hepatic impairment by Child-Pugh classification scores
3061588|NCT02150720|Experimental|Tranexamic acid|Tranexamic acid, 1g intra-articular before closing the surgery wound
3061589|NCT02150720|Experimental|Fibrin glue|One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery,
3061590|NCT02150720|Active Comparator|Usual hemostasia|Electrocauterization
3061591|NCT02150707||Dipeptidyl-Peptidase IV Inhibitors|Newly started on DPP4 inhibitor for hyperglycaemia
3061592|NCT02150707||Glucagon-Like Peptide 1|Newly started on GLP-1 for hyperglycaemia or obesity
3061593|NCT02150694|Experimental|Apelin agonist infusion|Studies to measure change in blood flow in response to apelin agonists (1/10/100nmol) using forearm venous occlusion plethysmography and Aellig hand vein technique.
3061594|NCT02150694|Experimental|Apelin receptor antagonist infusion|Aellig hand vein technique will be used to investigate the change in vein diameter in response to an apelin blocking agent
3061595|NCT02150694|Experimental|Apelin agonist/antagonist co-infusion|Forearm blood flow study to measure blood flow by forearm venous occlusion plethysmography following intraarterial infusion of apelin receptor agonists and antagonist.
3061596|NCT02150681|Experimental|Mindfulness-based cognitive therapy|8 class sessions of mindfulness therapy given in a group setting, with one 2-hr session per week for 8 weeks.
3061597|NCT02150668|Experimental|HOPS Intervention|School counselors deliver HOPS intervention to students during the school day. This includes 16, 20-minute sessions with the student and two joint family meetings.
3061598|NCT02150668|Active Comparator|HSI Intervention|School counselors deliver the HSI intervention which focuses on improving focus and efficiency of work completion. This consists of 16, 20-minute sessions, with the student and two joint family meetings.
3061599|NCT02150655|Experimental|Probiotic|Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 oral capsules
3061600|NCT02150655|Placebo Comparator|Placebo|Sugar pill
3061601|NCT02150642||Neurological Injury|
3061602|NCT02150642||No Neurological Injury|
3061603|NCT02150629||SCI patients|
3061604|NCT02150629||Healthy subjects|
3061605|NCT02150616|Experimental|Moderate altitude sojourn|Sojourn at moderate altitude (2048 m)
3061606|NCT02150616|Experimental|Low altitude sojourn|Sojourn at low altitude (490 m, baseline)
3061607|NCT02150616|Active Comparator|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
3061608|NCT02150616|Placebo Comparator|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights
3061609|NCT02150603||Adults with congenital heart disease|
3061610|NCT02150590|Active Comparator|Oxygen|oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
3061611|NCT02150590|Placebo Comparator|Sham oxygen|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
3061612|NCT02150577|Experimental|Implementation|Evidence Based Quality Improvement
3061613|NCT02150577|No Intervention|Control|Usual Quality Improvement
3061614|NCT02150564|Other|Navigation only group|Sonowand system will be used for navigation control arm as well as sononavigation experimental arm.Navigation will be used to plan the craniotomy and throughout the procedure as desired by the operating surgeon. At no point of time however will the Ultrasound be used.
3061615|NCT02150564|Experimental|SonoRCT Test group|Surgery to resect the tumor with the aid of sononavigation. In addition to the navigation function, the Ultrasound will be available at all times. This study will help in assessing the usefulness sononavigation in improving radicality of resection in malignant gliomas and also to access the accuracy of SonoWand in predicting residue.
3061616|NCT02150551|Experimental|Mesenchymal Stromal Cells (MSCs)|A fixed dose of Mesenchymal Stromal Cells (MSCs) will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.
3061617|NCT02150538|Active Comparator|Right ventricular stimulation|patients with conventional Right Ventricular Stimulation (only RV) with optimized algorithms for minimization of pacing
3061618|NCT02150538|Experimental|Biventricular Stimulation|Patients with biventricular stimulation (Right Ventricle and Left Ventricle)
3061619|NCT02150525|Experimental|Arm I (oral omega-3 fatty acid)|Patients received 3.5g oral omega-3 fatty acid daily for 6 months. Questionnaire administration, pills counts, and medication diaries were collected at monthly intervals.
3061620|NCT02150525|Placebo Comparator|Arm II (placebo)|Patients received equivalent, matched oral placebo (seven capsules) daily for 6 months. Questionnaire administration, pills counts, and medication diaries were collected at monthly intervals.
3061621|NCT02150512|Experimental|Transpulmonary thermodilution (TPTD)|The intervention group (TPTD guided therapy) follows a fluid resuscitation protocol based on stroke volume variation (SVV) and extravascular lung water (EVLW). Initial trigger for fluid loading when circulatory insufficiency is present will be SVV.
3061622|NCT02150512|Active Comparator|Surviving Sepsis Guidelines (SSG)|The standard group (SSG guided therapy) follows a fluid resuscitation protocol based on the Surviving Sepsis Campaign recommendations. Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg).
3061623|NCT02150499|Experimental|levalbuterol tartrate HFA inhalation aerosol plus placebo HFA|Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol
3061624|NCT02150499|Experimental|levalbuterol tartrate HFA inhalation aerosol plus levalbuterol|Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.
3061625|NCT02150473|Experimental|Adalimumab|receive adalimumab 40 mg eow injections in combination with MTX for 24 weeks
3061626|NCT02150473|Placebo Comparator|Placebo|receive placebo injections in combination with MTX for 24 weeks
3061627|NCT02150460|Experimental|One-site peribulbar injection|Injection of a mixture of lidocaine 2% + adrenaline 0.125mg/ml + hyaluronidase 15 International Units (IU)/ml into the inferior medial orbital compartment
3061628|NCT02150460|Active Comparator|Two-site peribulbar injection|Injection of a mixture of lidocaine 2% + adrenaline 0.125mg/ml + hyaluronidase 15IU/ml into the infero-temporal and supero-nasal orbital compartments
3061629|NCT02150447|Active Comparator|Intervention group|Proton pump inhibitor (lansoprazole) therapy for the prevention of gastric cancer bleeding
3061630|NCT02150447|Placebo Comparator|Placebo group|Placebo for the prevention of gastric cancer bleeding
3061631|NCT02150434|Sham Comparator|Compressed Air|compressed air delivered at a fixed flow of 2 L/min
3061632|NCT02150434|Active Comparator|Oxygen constant flow|oxygen delivered at a fixed flow of 2L/min
3061633|NCT02150434|Experimental|Automated oxygen titration|oxygen at a variable flows delivered by the FreeO2
3061634|NCT02150421||e-book|study the course materials by using e-book
3061635|NCT02150408|Experimental|assesment by 68Ga-DOTATATE PET-CT|
3061636|NCT02150395|Experimental|music therapy|pt received a protocolized music therapy intervention that included altered state induction, music driven guided visualiztion, and psychoeducation on relaxation techniques to be used during simulation for radiation therapy. Prescribed pre-recorded music program provided to be used during simulation.
3061637|NCT02150395|No Intervention|control|no intervention
3061638|NCT02150369||Patient, care partner, primary nurse case|In Phase I of this pilot, a case is comprised of the metastatic RCC patient receiving IL-2, their care partner, and their primary nurse. In Phase II, the IL-2 patient can either have MM or metastatic RCC. The care partner for this study will be the family member or friend staying with the IL-2 patient throughout treatment.
3061639|NCT02150356|Experimental|Aleurone|Diet based in aleurone-enriched products for a period of 8 weeks.
3061640|NCT02150356|Placebo Comparator|Control|Diet based on refined cereal products for a period of 8 weeks.
3061641|NCT02150343|Experimental|HMD-SPIRE Treatment 1|4 x 12 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart
3061642|NCT02150343|Experimental|HDM-SPIRE Treatment 2|4 x 12 nmol HDM-SPIRE 4 weeks apart followed by a second course of 4 x 12 nmol HDM-SPIRE 4 weeks apart
3061643|NCT02150343|Experimental|HDM-SPIRE Treatment 3|4 x 20 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart
3061644|NCT02150343|Placebo Comparator|Placebo|8 x placebo 4 weeks apart
3061645|NCT02150330|Active Comparator|DHEAS in DOR Group|Additional usage of DHEAS supplement in patients with DOR under ovarian hyper-stimulation protocol.
3061646|NCT02150330|Active Comparator|Normal Control|Patients under ovarian hyper-stimulation protocol. No DHEAS supplement.
3061647|NCT02150330|Active Comparator|Shame DOR Group|Patients with DOR under ovarian hyper-stimulation protocol. No DHEAS supplement.
3061648|NCT02150317|Active Comparator|TACE+Sorafenib|TACE followed by Sorafenib
3061649|NCT02150317|Experimental|TACE|TACE alone
3061650|NCT02150304||intravenous aminophylline|intravenous aminophylline use during spinal anesthesia
3061651|NCT02150304||no intravenous aminophylline|no use of intravenous aminophylline during spinal anesthesia
3061652|NCT02150291|Active Comparator|Group A|one capsule of 5 mg of Folic acid twice daily and a tablet of Neurobion three times per day during hepatitis C treatment
3061653|NCT02150291|Active Comparator|Group B|Patients will receive one capsule of 5 mg of Folic acid twice daily during hepatitis C treatment
3061654|NCT02150291|Active Comparator|Group C|Patients will receive a tablet of Neurobion three times per day during hepatitis C treatment
3061655|NCT02150291|Placebo Comparator|Group D|Patients will receive matching placebo capsule to take during hepatitis C treatment
3061656|NCT02150278|Experimental|Brief intervention|The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
3061657|NCT02150265|No Intervention|Waiting list control group|6 week waiting list
3061658|NCT02150265|Experimental|Individual cognitive behavioral therapy with SMART|SMART manual cognitive behavioral therapy individual weekly sessions for 6 weeks
3061659|NCT02150252|Experimental|BY HWT，placebo-BY HWT ， Gait parameter|
3061661|NCT02150226|Experimental|Experimental: Zirconia monolithic crowns and bridges|Evaluation of Lava Plus zirconia dental crowns and bridges
3061662|NCT02150213|Experimental|BGG492|This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to > 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day
3061663|NCT02150200|Other|A group : Conventional hospitalization|Patients discharged after 3 days hospital stay after laparoscopic hysterectomy
3061664|NCT02150200|Experimental|B group : shorter stay|Patients going home within 24 hours discharged the first day after laparoscopic hysterectomy.
3061665|NCT02150187|Experimental|HCap Formula|Pill of HCap Formula every other day for 6 month during the treatment phase; Follow up phase: nothing.
3061666|NCT02150187|Placebo Comparator|Placebo|Same as treatment with placebo pills
3061667|NCT02150174|Experimental|Patients with schizophrenia|
3061668|NCT02150174|Active Comparator|Healthy subjects|
3061669|NCT02150161|Experimental|lidocaine/ ketamine infusion|lidocaine 1mg/Kg bolus, followed by continuous infusion 1 mg/kg/h AND ketamine 1mg/Kg bolus followed by continuous infusion 1 mg/kg/h
3061670|NCT02150161|Active Comparator|fentanyl|iv fentanyl, 3ug/kg bolus
3061671|NCT02150148|Experimental|Mentored Gardening Intervention|Participants in this arm will be provided with either a raised bed garden or 4 earthboxes, gardening supplies, and plants and seeds. A master gardener from the Cooperative Extension will mentor them over the course of a year to plant three gardens (spring, summer and fall).
3061672|NCT02150148|Other|Wait-List|Participants in this arm will be provided with the same gardening supplies as the other group, but will receive them one year after enrollment in the study. They also will receive instruction from a master gardener from the Cooperative Extension at this time as well.
3061673|NCT02150135|Experimental|Oncothermia group|Patients were treated with oncothermia 2 or 3 times a week. Treatment was performed for about 1 hours per each visits.
3061674|NCT02150122|Experimental|10 micrograms (400 IU) vitamin D3|Participants will be given a daily supplement containing 10 micrograms (400 IU) vitamin D3 to take for 5 months.
3061675|NCT02150122|Experimental|20 micrograms (800 IU) vitamin D3|Participants will be given a daily supplement containing 20 micrograms (800 IU) vitamin D3 to take for 5 months.
3061676|NCT02150122|No Intervention|Placebo|Participants will be given a placebo, similar in appearance to the vitamin D3 tablets, to take for 5 months.
3061677|NCT02150109|Experimental|Persons With Diabetes|Untrained subjects WITH Diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System).
3061678|NCT02150109|Experimental|Persons With and Without Diabetes|Untrained subjects WITH/WITHOUT Diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System).
3061679|NCT02150096|Active Comparator|Continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
3061680|NCT02150096|Active Comparator|Pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
3061681|NCT02150096|Active Comparator|low level laser therapy group|the group will be treated with 3J during 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
3061682|NCT02150096|No Intervention|control group|group of women no treated, only evaluated in two moments and this group will be compared with orthers: laser, pulsed ultrasound and continuous ultrasound.
3061683|NCT02150083|Experimental|OR retrograde fill|At completion of sling placement in the operating room, the bladder will be filled retrograde via a cystoscope with 300 mL sterile saline or water to inspect for bladder perforation. The cystoscope is removed and the foley catheter is NOT replaced for the duration of the surgery. The surgery is completed and the patient is transferred to the post-anesthesia care unit. Once she is able to ambulate, she will be instructed to void. The voided volume and residual volume will be recorded.
3061684|NCT02150083|No Intervention|PACU retrograde fill|At completion of sling placement in the operating room, the bladder will be filled retrograde via a cystoscope with 300 mL sterile saline or water to inspect for bladder perforation. The cystoscope is removed and the foley catheter is replaced for the duration of the surgery and when complete the patient is transferred to the post-anesthesia care unit. Once she is able to ambulate, she will undergo a retrograde bladder fill with 300 mL of normal saline. The foley catheter will be removed and she will be instructed to void. The voided volume and residual volume will be recorded.
3061685|NCT02150070|Experimental|Intravenous ASP2408|
3061686|NCT02150070|Experimental|Subcutaneous ASP2408 low dose|
3061687|NCT02150070|Experimental|Subcutaneous ASP2408 middle dose|
3061688|NCT02150070|Experimental|Subcutaneous ASP2408 high dose|
3061689|NCT02150070|Placebo Comparator|Intravenous Placebo|
3061690|NCT02150070|Placebo Comparator|Subcutaneous Placebo|
3061691|NCT02150057|No Intervention|Control Group|This group receives no experimental bracing intervention in the study.
3061692|NCT02150057|Experimental|Experimental Group|Breg Fusion Osteoarthritis knee unloading brace
3061693|NCT02150044|Experimental|Tympanostomy tube|Performance and safety of tympanostomy tube delivery system
3061694|NCT02150031|Other|Control|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction).~No prophylactic Chlorhexidine regimen.~Local anesthesia with lidocaine plus adrenaline (1:100,000).~Tooth extraction."
3061695|NCT02150031|Active Comparator|CHX-Mouthwash|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction).~Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®, Johnson and Johnson, Barcelona, Spain).~Local anesthesia with lidocaine plus adrenaline (1:100,000).~Tooth extraction."
3061696|NCT02150031|Active Comparator|CHX-MW/SUB_IR|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction).~Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and subgingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done with the Heraeus Citojet Intraligamental Syringe (Kulzer Heraeus S.A., Madrid, Spain) at six points on each tooth (3 points on the vestibular surface and 3 on the palatine surface).~Local anesthesia with lidocaine plus adrenaline (1:100,000).~Tooth extraction."
3089820|NCT01960608||low income group|the income 25% below the quartile
3061697|NCT02150031|Active Comparator|CHX-MW/SUPRA_IR|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction).~Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and then supragingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done continuously around the tooth to be extracted by a conventional syringe.~Local anesthesia with lidocaine plus adrenaline (1:100,000).~Tooth extraction."
3061698|NCT02150018||non invasive ventilation (NIV)|
3061699|NCT02150005|Experimental|Periodontal treatment|The test group received oral hygiene instructions, supragingival and subgingival scaling and root planning using curettes and an ultrasonic appliance.
3061700|NCT02150005|No Intervention|Control|
3061701|NCT02149992|Experimental|Myo-inositol, folic acid|"myo-inositol, oral, 2g, two times per day for 5 total days~folic acid, oral 200 micrograms, two times per day for 7 days~Continuous Glucose Monitoring Surveillance device for 7 days during study period~Capillary glucose monitoring 4 times per day"
3061702|NCT02149979|Experimental|Temperature Controlled Laser Soldering|Efficacy and safety of Temperature Controlled Laser Soldered wound incisions closure
3061703|NCT02149966|Experimental|AG-348|Multiple oral doses of AG-348
3061704|NCT02149966|Placebo Comparator|Placebo|Multiple oral doses of placebo.
3061705|NCT02149953|Experimental|Glycine intake|Dietary supplement: Glycine intake
3061706|NCT02149940|Experimental|clinical pharmacy intervention|
3061707|NCT02149927|Experimental|Sevoflurane|Single arm: dose escalation of study medication
3061708|NCT02149914|Experimental|PPI treatment|Patients with GERD would be assessed by ANSWatch. Ryodoraku, UGI endoscopy, and GerdQ before taking PPIs and after taking PPI 20mg tablet by mouth everyday for 4 weeks.
3061709|NCT02149901|Experimental|Pseudoephedrine + 480 ml water|Pseudoephedrine 30 mg PO 45 minutes before water 480 ml
3061710|NCT02149901|Placebo Comparator|Pseudoephedrine + 50 ml water|Pseudoephedrine 30 mg PO 45 minutes before water 50 ml
3061711|NCT02149901|Experimental|Placebo + 480 ml water (optional)|Placebo PO 45 minutes before water 480 ml
3061712|NCT02149901|Placebo Comparator|Placebo + 50 ml water (optional)|Placebo PO 45 minutes before water 50 ml
3061713|NCT02149888|Experimental|Tenofovir/emtricitabine|MSM receiving once daily TDF/FTC-based (Truvada®) pre-exposure prophylaxis
3061714|NCT02149875|Experimental|Dl-3-n-butylphthalide|Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days
3061715|NCT02149875|Experimental|Cerebrolysin|Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days
3061716|NCT02149875|Placebo Comparator|Placebo|Intravenous infusion of 100 ml saline intravenous q.d. for 10 days
3061717|NCT02149862|Experimental|cancer|patients with an indication of partial or total bladder resection will have urine infrared analysis
3061718|NCT02149862|Placebo Comparator|control group|"Lithiasic patients should be operated a urinary calculation, without catheter double J, will have urine infrared analysis"
3061719|NCT02149849|No Intervention|Standard lateral positioning|
3061720|NCT02149849|Experimental|Modified lateral positioning|Modified lateral positioning. This will ensure less pressure and stretch on shoulder than standard lateral positioning.
3061721|NCT02149836|Experimental|ezogabine|Ezogabine dosage plan to 900mg and then tapered down
3061722|NCT02149823|Active Comparator|Intranasal Oxytocin Group 1|Placebo on visit 1, oxytocin 24IU on visit 2, then 40 IU on visit 3
3061723|NCT02149823|Active Comparator|Intranasal Oxytocin Group 2|oxytocin 24IU on visit 1, placebo on visit 2, then oxytocin 40IU on visit 3
3061724|NCT02149823|Active Comparator|Intranasal Oxytocin Group 3|oxytocin 40IU on visit 1, oxytocin 24IU on visit 2, then placebo on visit 3.
3061725|NCT02149823|Active Comparator|Intranasal Oxytocin Group 4|after visit 4, placebo on subsequent visit , then oxytocin 40IU at following visit
3061726|NCT02149823|Active Comparator|Intranasal Oxytocin Group 5|after visit 4, oxytocin 40IU on subsequent visit, then placebo at following visit
3061727|NCT02149810|Experimental|Automatic Self Transcending Meditation and Treatment as Usual|Participants in the ASTM group will undergo ASTM training in groups of four .This involves participating in four, 90-120 minutes sessions each of four consecutive days. This will be followed by once weekly 45-60 minute follow up sessions for 12 weeks. In addition participants will be asked to practice ASTM at home for 20 minutes twice daily over the study period (24 weeks). Participants will be asked to log practice frequency and any other noteworthy observations in the log sheet provided to them.
3061728|NCT02149810|No Intervention|Treatment as Usual|Participants randomized to control arm (TAU) will continue to receive their treatment as usual including antidepressant medications and/or psychotherapy
3061729|NCT02149797|Active Comparator|Four port laparoscopic cholecystectomy|This group of patients undergone classical four port laparoscopic cholecystectomy
3061730|NCT02149797|Active Comparator|SILC-Pick'n roll-Beginning (group I)|"This group of patients undergone single-incision laparoscopic cholecystectomy using our new technique called Pick'n roll, this group was designed new intervention's beginning arm."
3061731|NCT02149797|Active Comparator|SILC-Pick'n roll-Experienced (group II)|"This group of patients undergone single-incision laparoscopic cholecystectomy using our new technique called Pick'n roll, this group was designed new intervention's experienced arm."
3061732|NCT02149784|Experimental|Surgical treatment group|Unresectable mCRC patients who respond to chemotherapy will receive surgical resection of primary tumor.
3061733|NCT02149784|No Intervention|Chemotherapy group|Unresectable mCRC patients who were respond to chemotherapy will continue with chemotherapy.
3061734|NCT02149771|Experimental|TACE&Stents|chemoembolization combined with endovascular stents and iodine-125 seed strand implantation
3061735|NCT02149771|Active Comparator|TACE|Transartery chemoembolisation（TACE） by administering Doxorubicin and Oxaliplatin mixed with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
3061736|NCT02149758|Experimental|Etoricoxib|Etoricoxib 60 mg once daily
3061737|NCT02149758|Placebo Comparator|matching placebo|matching placebo once daily
3061738|NCT02149745|Experimental|Calling the patient's name|The anesthesiologist tries to recover the patient's consciousness by calling the patient's name
3062231|NCT02146534|Placebo Comparator|placebo|placebo pill BID PO for 14 weeks
3061739|NCT02149745|Experimental|Not calling the patient's name|The anesthesiologist tries to recover the patient's consciousness by giving verbal stimulus other than the patient's name
3061740|NCT02149719|Experimental|Desensitisation to peanut|Desensitisation using boiled peanut
3061741|NCT02149719|Experimental|Control|Subjects allocated to the control group will undergo routine care for 12 months, following which they will be offered the active treatment with boiled peanut (as a one-way cross-over intervention).
3061742|NCT02149706|Experimental|NeuroVax|NeuroVax
3061743|NCT02149706|Placebo Comparator|IFA Incomplete Freund's Adjuvant|Incomplete Freund's Adjuvant IFA
3061744|NCT02149693|Experimental|high-fidelity simulation and teamwork training|high-fidelity simulation and teamwork training
3061745|NCT02149693|Active Comparator|traditional resuscitation training|traditional resuscitation training
3061746|NCT02149680||Experimental group|Patient who has had an epidural blood patch following accidental dura puncture during pregnancy
3061747|NCT02149680||Control Group|Women in the same group, equal numbers of those with or without epidurals, without accidental dural puncture, similar parity would constitute the control group. They would be chose at random, 10 times the number in the experimental group (n = 600).
3061748|NCT02149667||Total Hip Arthroplasty|Single study group previously implanted with the following combination of components: MicroPort Orthopedics Femoral Stems, DYNASTY® BioFoam® Acetabular Components, DYNASTY® A-Class® Cross Linked Polyethylene Liners, and MicroPort Orthopedics Metal or Ceramic Femoral Heads
3061749|NCT02149641||Nasopharyngeal cancers|Intensitiy modulated radiotherapy with chemotherapy
3061750|NCT02149628|Active Comparator|desflurane|use desflurane as a primary anesthetics during anesthesia guided by bispectral index (BIS)
3061751|NCT02149628|Experimental|propofol|propofol infusion with target-controlled infusion(TCI) device guided by BIS
3061752|NCT02149615|Experimental|isotretinoin|Retinal nerve fibre layer measurement in patients under isotretinoin treatment
3061753|NCT02149615|Active Comparator|lymecycline|Retinal nerve fibre layer measurement in patients under lymecycline treatment
3061754|NCT02149615|Active Comparator|minocycline|Retinal nerve fibre layer measurement in patients under minocycline treatment
3061755|NCT02149615|Active Comparator|doxycycline|Retinal nerve fibre layer measurement in patients under doxycycline treatment
3061756|NCT02149602||oropharyngeal and hypopharyngeal HNSCC|Intensity Modulated Radiotherapy HPV positive and HPV negative
3061757|NCT02149589|Experimental|Focal ARDS|In Focal ARDS prone position will be promote early, with low PEEP and moderate Vt.
3061758|NCT02149589|Other|non focal ARDS|In non-Focal ARDS, Recruitment maneuvers, high PEEP and low V twill be used
3061759|NCT02149576|Active Comparator|LDCT Surveillance Program Group|This cohort will follow a strict schedule of Low Dose Computed Tomography Imaging scans and clinical visits 3, 6, and 12 months after surgery. At each encounter, a history, physical examination, and review of the LDCT results will be performed. Patients with normal clinical and imaging findings will proceed to the next scheduled clinical encounter. Patients with abnormal findings will be managed according to predetermined algorithms.
3061760|NCT02149576|Other|Historical Control Group|The control group will be a retrospective cohort taken from 1-year before the implementation of the LDCT surveillance program. The post-operative follow-up of these participants was not standardized, but rather left up to the discretion of the individual surgeons, and involved chest radiograph imaging as opposed to Low Dose Computed Tomography.
3061761|NCT02149563|Active Comparator|Treatment|One hundred participants will receive home treatment with oxygen-enriched air (40% O2) through a nasal tube during the night (7 hours) for one month.
3061762|NCT02149563|Placebo Comparator|Placebo|100 participants will receive regular air treatment (21% O2) through a nasal tube (identical to the procedure providing 40% O2) for one month
3061763|NCT02149550|Active Comparator|NF135 n=5|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes
3061764|NCT02149550|Experimental|NF135 n=2|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes
3061765|NCT02149550|Experimental|NF135 n=1|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito
3061766|NCT02149550|Active Comparator|NF166 n=5|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes
3061767|NCT02149550|Experimental|NF166 n=2|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes
3061768|NCT02149550|Experimental|NF166 n=1|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito
3061769|NCT02149537|Experimental|hydroxyurea|500mg of hydroxyurea/day during 6 months
3061770|NCT02149537|No Intervention|No treatment|No hydroxyurea treatment during 6 months
3061771|NCT02149524|Active Comparator|Herceptin (trastuzumab)|Intravenous administration
3061772|NCT02149524|Experimental|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
3061773|NCT02149511||SCI subjects|
3061774|NCT02149511||healthy control subjects|
3061775|NCT02149498||Parkinson Disease (PD)|Idiopathic PD patients (according to the UK PD Society brain bank clinical diagnostic criteria (bradykinesia plus at least one other cardinal feature of PD, no atypical features or secondary cause)
3061776|NCT02149498||Healthy Controls|Healthy individuals
3061777|NCT02149472||Pregnant women with PPH|All pregnant women in participating hospitals are asked for their informed consent (n = 9.500). All women will complete a bleeding score generating questionnaire during their pregnancy. Only from women developing postpartum haemorrhage > 1000 cc blood samples will be drawn (n = 600).
3061778|NCT02149459|Experimental|treatment arm|Partial brain re-irradiation combined with metabolic intervention (low carbohydrate diet and/or metformin treatment)
3061779|NCT02149446|Experimental|Surgisis reinforcement of staple line|The stapler used to divide the pancreas is reinforced with Surgisis (COOK Medical).
3061780|NCT02149446|No Intervention|No reinforcement of staple line|The stapler used to divide the pancreas is not reinforced with any material
3061966|NCT02148198|Placebo Comparator|placebo, then 5g NWT-03|7 days 5g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
3061781|NCT02149433|Experimental|Prednisone versus placebo|Prednisone 2mg/kg orally once a day x 7 days, 1 mg/kg orally once a day x 7 days and then 0.5 mg/kg orally once a day x 7 days
3061782|NCT02149420|Experimental|VAY736 dose 1|
3061783|NCT02149420|Experimental|VAY736 Dose 2|
3061784|NCT02149420|Placebo Comparator|Placebo|
3061785|NCT02149407|Active Comparator|Glycerin group (GG)|"Glycerin group GG will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery."
3061786|NCT02149407|Active Comparator|Rectal stimulation group (SG)|"Rectal stimulation SG by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall."
3061787|NCT02149407|Sham Comparator|Control group (CG)|"Control group CG will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes."
3061788|NCT02149394|Experimental|Ice|The concealment of allocation was performed through the use of individual opaque envelopes numbered externally in sequence, containing information of the group randomly defined. This step was carried out by a researcher who did not take part in data collection.Thirst intensity was measured within the range from 1 to 10 according to the numeric visual analogue scale.The experimental group received an ice popsicle made of 10 mL mineral water.The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice was supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort.
3061789|NCT02149394|Active Comparator|Water|The concealment of allocation was performed through the use of individual opaque envelopes numbered externally in sequence, containing information of the group randomly defined. This step was carried out by a researcher who did not take part in data collection.Thirst intensity was measured within the range from 1 to 10 according to the numeric visual analogue scale. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
3061790|NCT02149381|Experimental|CBASP|Cognitive Behavioral System of Psychotherapy is a manual-based group intervention for chr depression (20 weeks).
3061791|NCT02149381|Active Comparator|Befriending|Befriending is a social support intervention
3061792|NCT02149381|Active Comparator|Treatment as usual|Conventional psychiatric outpatient treatment (individual counseling)
3061793|NCT02149355||controls|teeth molding in subjects without congenital fourth nerve palsy
3061794|NCT02149355||congenital fourth nerve palsy|teeth molding in patients suffering from congenital fourth nerve palsy
3061795|NCT02149342|Experimental|HAL cream and MAL cream|0.2% HAL (Hexvix, Photocure) mixed with Unguentum M (Allmiral) and MAL (Metvix, Galderma) used in a randomized split-face design
3061796|NCT02149329|Experimental|Short treatment|Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
3061797|NCT02149329|No Intervention|Extended treatment|Extended treatment with imipenem-cilastatin or meropenem for at least 6 more days. The treatment with a carbapenem will be continued until patients have been treated for at least 9x24 hours and have been afebrile (tympanic membrane temperature <37,5°C) for at least five consecutive days or until resolution of neutropenia (ANC > 0,5 x10^9/L), whichever comes first.
3061798|NCT02149316|Experimental|RIPC+RIPostC|
3061799|NCT02149316|Sham Comparator|control|
3061800|NCT02149303||Dabigatran|
3061801|NCT02149290||Trends-equipped LifeVest 4000|Subjects using the LifeVest 4000 modified to collect Trends data
3061802|NCT02149277|Active Comparator|Filgrastim|Injection Filgrastim 300 ug intravaginally during an IVF cycle or during an embryo transfer
3061803|NCT02149277|Placebo Comparator|Sodium Chloride|Injection of 1 ml of Sodium Chloride intravaginally during an IVF cycle or during an embryo transfer cycle.
3061804|NCT02149264|Experimental|Testosterone gel (FE 999303)|Subjects received at least one dose of testosterone gel (23 mg), which was further titrated, if needed (upto three doses [69 mg]), based on serum testosterone concentrations. Testosterone gel was delivered using an applicator to the contralateral shoulder/upper arm.
3061805|NCT02149251||Pre-genetic diagnosis|Women in this group had ICSI and PGD to exclude genetically affected children or for sex selection
3061806|NCT02149251||Control group|This group will include women who had IVF without PGD
3061807|NCT02149238|Active Comparator|flavanol rich drink intervention|flavanol rich drink
3061808|NCT02149238|Active Comparator|methylxanthine rich drink intervention|methylxanthine rich drink
3061809|NCT02149238|Active Comparator|flavanol + methylxanthine rich drink intervention|flavanol + methylxanthine rich drink
3061810|NCT02149225|Experimental|APVAC1 and 2 vaccine plus polyICLC and GMCSF concurrent to TMZ|
3061811|NCT02149212|Active Comparator|Clinical Treatment|Phlebotonics: Aminaftone 75 mg BID Limb elastic compression support (Elastic stockings: Venosan / Elastic Bandages: Atamed) Unna boot dressing
3061812|NCT02149212|Active Comparator|Iliac vein stenting|Wallstent
3061813|NCT02149199|Experimental|Symbicort 'as needed'+placebo Pulmicort bid|Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
3061814|NCT02149199|Active Comparator|terbutaline 'as needed'+placebo Pulmicort bid|terbutaline Turbuhaler 0.4 mg 'as needed' + placebo Pulmicort 200 μg Turbuhaler bid
3061815|NCT02149199|Active Comparator|Pulmicort bid + terbutaline 'as needed'|Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
3061816|NCT02149186|Experimental|Rehabilitation|
3061817|NCT02149173|Experimental|Diagnostic (F-18 FES PET/CT)|Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.
3061818|NCT02149160|Experimental|FRM-0334; Arm 1|low dose, Capsule, Once Daily, Day 1 through Day 28
3061819|NCT02149160|Experimental|FRM-0334; Arm 2|high dose, Capsule, Once Daily, Day 1 through Day 28
3061820|NCT02149160|Placebo Comparator|Placebo Comparator; Arm 3|Placebo, Capsule, Once Daily, Day 1 through Day 28
3061967|NCT02148185|Experimental|MT-1303|
3061821|NCT02149147||Physical Activity Variety|participants will complete the Self-Efficacy questionnaire, the Physical Activity Enjoyment Scale, the Behavioral Regulation in Exercise-2 questionnaire, and an Outcome Expectations questionnaire. Participants will be instructed to wear the SenseWear® armband which will measure physical activity-related energy expenditure for the course of the study. The armband will be worn every day for at least 10 hours per day. In addition, participants will be asked to complete a physical activity diary to record their physical activity as well as additional information about the environment in which the physical activity was conducted. Participants will be instructed to engage in their normal physical activity regimen, wear the armband, and complete the physical activity diary for 3 weeks.
3061822|NCT02149134|Experimental|New extensively hydrolyzed casein formula|Subjects with cow's milk allergy treated with a new formula
3061823|NCT02149121|Experimental|CT-P10|rituximab, CT-P10(experimental drug), 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
3061824|NCT02149121|Active Comparator|Rituxan|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
3061825|NCT02149121|Active Comparator|MabThera|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
3061826|NCT02149108|Experimental|Nintedanib (BIBF 1120) + BSC|
3061827|NCT02149108|Placebo Comparator|Placebo + BSC|
3061828|NCT02149095|Experimental|TransCon PEG treprostinil|Dosing will begin at 0.116 mg/kg TransCon PEG treprostinil subcutaneous injection and the dose escalated in subsequent cohorts to MTD.
3061829|NCT02149082||Infrascanner exam|Infrascanner Model 2000 exams may be conducted either before or after an associated head CT for pediatric patients presenting to the emergency department (ED) or pediatric intensive care unit (PICU) with a known or suspected traumatic head injury undergoing a head CT scan to evaluate for the presence or absence of an intracranial hematoma. The time between the head CT scan and the Infrascanner exam will be within 6 hours. The exam involves placing a sensor on the designated areas of the head with the most common locations for traumatic hematoma. Readings from the monitor evaluating each region will be evaluated and recorded. The 8-point exam can be accomplished within 5 minutes or less.
3061830|NCT02149056||Impaired Glucose Tolerance|
3061831|NCT02149043||Ulcerative Colitis patients|30 patients with active ulcerative colitis will be put throe thermography and colonoscopy. Their stool will be tested for fecal calprotectin and their blood for CRP and other laboratory measures.
3061832|NCT02149043||Healthy volunteers|30 healthy individuals matching sex and BMI to those of ulcerative colitis patients will be put throe thermography and have their stool tested for fecal calprotectin and their blood for CRP.
3061833|NCT02149030|Active Comparator|A1|A1) Cytological screening in A1 and A3. Frequent information of screening results for cytology and/or HPV DNA at the ages of 22 (cytology only), 25 and 30.
3061834|NCT02149030|No Intervention|A2|A2) infrequent information of screening results, only at the age 30 years.
3061835|NCT02149030|Other|A3|A3) Cytological screening in A1 and A3. With at least 1000 participants is enrolled for interim safety analysis when the 1992 birth cohort is 25 years of age and cytology results are being revealed.
3061836|NCT02149017|Experimental|SNUBH-NM-333(18F), Safety, Efficacy|10 young controls, 10 cognitively normal elderly, and 10 Alzheimer's disease patients
3061837|NCT02149004||Site Bonn|
3061838|NCT02149004||Site Heidelberg|
3061839|NCT02149004||Site Munich|
3061840|NCT02149004||Site Hamburg|
3061841|NCT02149004||Site Hannover|
3061842|NCT02149004||Site Cologne|
3061843|NCT02149004||Site Freiburg|
3061844|NCT02149004||Site Frankfurt|
3061845|NCT02149004||Site Essen|
3061846|NCT02148991||Irbesartan|Patients on irbesartan treatment
3061847|NCT02148978|Experimental|Saxagliptin administration|Saxagliptin Administration- The participants in this study will undergo an OGTT (Oral Glucose Tolerance Test) at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin. After 6 weeks of treatment the participants will return to perform a second OGTT.
3061848|NCT02148965|Experimental|Lifestyle intervention|Physical Exercise / Physical Activity. Exercise intervention, three weekly sessions. Each session will last around 60 minutes and will include aerobic exercises (treadmill or stationary cycling) and strength training (with focus on major muscle groups and pregnancy-specific exercises to help alleviate low back pain and work abdominal and pelvic floor muscles to prevent urinary incontinence).
3061849|NCT02148965|No Intervention|Control Group|A group of eligible women, twice as large as the intervention group, will not receive the exercise intervention but will be followed-up equally to compare outcomes in the future.
3061850|NCT02148952|Experimental|Intervention Health Facility|WHO Safe Childbirth Checklist Program
3061851|NCT02148952|No Intervention|Control Health Facility|Matched control facilities providing comparison for intervention facilities
3061852|NCT02148913|Active Comparator|Cohort 1: Carfilzomib 15 mg/m2|Carfilzomib 15 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.
3061853|NCT02148913|Active Comparator|Cohort 2: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.
3061854|NCT02148913|Active Comparator|Cohort 2b: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -2, -1 and +5 IV over 10 minutes.
3061855|NCT02148913|Active Comparator|Cohort 3: Carfilzomib 27mgm2|Carfilzomib 27 mg/m2 on days -2, -1 and +5 IV over 10 minutes.
3061856|NCT02148900||Marfan|Diagnosis of Marfan syndrome, according to Ghent criteria.
3061857|NCT02148900||Marfan Related Disorders|Diagnosis of Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, or Familial Thoracic Aortic Aneurysm and Dissection.
3061858|NCT02148900||Control Subjects|Unaffected by Marfan or Marfan related disorders.
3061859|NCT02148887||SCI patients with upper limb impairment - Upper limb training|
3061860|NCT02148887||SCI patients with lower limb impairment - Lower limb training|
3061861|NCT02148887||Healthy controls - Upper limb training|
3061862|NCT02148887||Healthy controls - Lower limb training|
3061863|NCT02148887||Healthy controls - No intervention|
3061864|NCT02148874||Flu Shot|pregnant women receive a seasonal influenza virus vaccination
3061865|NCT02148861|Experimental|Insulin 287 + placebo|Subjects will receive one of two treatment combinations: either insulin 287 + placebo or insulin degludec + placebo. Dose escalation design (4 dose levels).
3061866|NCT02148861|Active Comparator|Insulin degludec + placebo|Subjects will receive one of two treatment combinations: either insulin 287 + placebo or insulin degludec + placebo. Dose escalation design (4 dose levels).
3061867|NCT02148848|Active Comparator|Early bisphosphonate use|"Give risedronate (actonel) at 2 weeks after hemiarthroplasty for an osteoporotic femoral neck fracture. In addition, calcium and vitamin D supplementation will be given to all patients.~Risedronate (35 mg) 1 tablet orally once a week"
3061868|NCT02148848|No Intervention|Late bisphosphonate use|"Give only calcium and vitamin D supplementation during the first 3 months after the surgery.~Bisphosphonate, risedronate (Actonel), will be given at 3 months after surgery for an osteoporotic femoral neck fracture."
3061869|NCT02148835|Active Comparator|Triomeg|Sausage: Triomeg
3061870|NCT02148835|Placebo Comparator|Control sausage|Sausage: Control
3061871|NCT02148822||Malnourished|Children with either height for age z score or body mass index for age z score below 2 standard deviations according to the World Health Organization Growth Standards for children younger than 5 years and the 2007 WHO Growth Reference for children of 5 years or older.
3061872|NCT02148822||Not malnourished|Children with either height for age z score or body mass index for age z score equal or higher than 2 standard deviations according to the World Health Organization Growth Standards for children younger than 5 years and the 2007 WHO Growth Reference for children of 5 years or older.
3061873|NCT02148809|Experimental|Blood Volume Analysis, Fluid|Preop I-131 is given and the BVA is performed, 6 hours after surgery the same procedure will be done to compare the TBV at both points
3061874|NCT02148796|Active Comparator|Broncho-Vaxom|One capsule of Broncho-Vaxom for children contains: 3.5 mg of lyophilized bacterial lysates of Haemophilus influenzae, Streptococcus (pneumonia, pyogenes and sanguinis (viridans)), Klebsiella (pneumoniae and ozaenae), Staphylococcus aureus and Moraxella catarrhalis. The content of the capsule will be mixed with a palatable liquid such as fruit juice.
3061875|NCT02148796|Placebo Comparator|Placebo|A placebo capsule will be used that will be indistinguishable from the active study drug.
3061876|NCT02148783|Experimental|methylphenidate administration|All participants will receive oral methylphenidate 60 mg before the second TMS study. The participants will receive oral methylphenidate 60 mg before the second PET scan. Subjects will then be treated with oral methylphenidate, using a forced titration. Dose titration will be incremental within 6 days (dose-escalation phase) , starting at 5 mg orally twice daily for 3 days, and 10 mg twice daily for the next 3 days. Then the dose will be increased to 30 mg twice daily starting from day 7 given twice daily for additional 3 weeks.
3061877|NCT02148770|Experimental|Neurofeedback|Neurofeedback training: Up-regulation of DLPFC.
3061878|NCT02148770|Sham Comparator|Neurofeedback SHAM|Neurofeedback training: Sham-regulation of DLPFC.
3061879|NCT02148757|Other|DVT|Doppler Ultrasound
3061880|NCT02148744|Experimental|XmAb7195 or Placebo|
3061881|NCT02148731||Comprehensive Geriatric Assessment (CGA)|Functional status, Comorbidities, Objective physical performance, Nutrition, Cognition, Depression, Social support
3061882|NCT02148718|Experimental|Adalimumab|Participants received adalimumab for 12 weeks (160 mg at Week 0; 80 mg at week 2; then adalimumab 40 mg every other week starting at Week 4).
3061883|NCT02148705|Experimental|NexoBrid Gel|NexoBrid Gel is applied to the burn wound at a dose of 2 g NexoBrid sterile powder mixed with 20g sterile Gel Vehicle per 1% of TBSA (~ surface of an adult palm) for four hours.
3061884|NCT02148705|Placebo Comparator|Gel Vehicle|Gel Vehicle is applied to the burn wound at a dose of 20 g sterile Gel per 1% of TBSA (~ surface of an adult palm) for four hours.
3061885|NCT02148705|Active Comparator|Standard of Care (SOC)|Subjects in the SOC group may be treated with a combination of surgical and non-surgical eschar removal procedures, according to the investigator's judgment.
3061886|NCT02148692|Experimental|Higher PEEP|PEEP of 12 cmH2O or higher and lung recruitment maneuvers
3061887|NCT02148692|Active Comparator|Lower PEEP|PEEP of 4 cmH2O without lung recruitment maneuvers
3061888|NCT02148679|Experimental|DASH/SRD|"Patients receive Heart Failure Society of America pamphlet, How to eat a low sodium diet at hospital discharge~Study staff will phone patients at weeks 2 and 3 to confirm patients' understanding of dietary instructions~Intervention: pre-prepared, home delivered DASH/SRD-compliant meals for 4 weeks after hospital discharge"
3061889|NCT02148679|Placebo Comparator|Attention Control|"Patients receive Heart Failure Society of America pamphlet, How to eat a low sodium diet at hospital discharge~Study staff will phone patients at weeks 2 and 3 to confirm patients' understanding of dietary instructions"
3061890|NCT02148666||experimental : intracoronary stem cells|intracoronary stem cells will be injected in infarct related artery.
3061891|NCT02148653|Experimental|Multifunctional diet (MFD)|Subjects eat a diet designed according to the Nordic Nutrition Recommendations with the addition of important amounts of various functional food concepts: Low GI and GI-modulating food items; Natural antioxidant-rich items, Long chain omega-3 fatty acid-rich fish; Betaglucan-rich barley and oat food/drinks; Cholesterol-modulating foods.
3061892|NCT02148653|Experimental|Control diet|Subjects eat a diet designed according to the Nordic Nutrition Recommendations but lacking the functional items included in the MFD.
3061893|NCT02148640|Experimental|CT-P13|Infusions of biosimilar infliximab (Remsima) with same dose and frequency as pre-inclusion treatment with innovator infliximab (Remicade)
3061894|NCT02148640|Active Comparator|INX|Continued infusions of innovator infliximab (Remicade) with same dose and frequency as prior to inclusion
3061895|NCT02148627|Experimental|LY3041658 (IV)|Single dose of LY3041658, administered as a slow intravenous (IV) infusion in escalating dose cohorts.
3061896|NCT02148627|Experimental|LY3041658 (SC)|Single dose of LY3041658 administered subcutaneously (SC).
3061897|NCT02148627|Placebo Comparator|Placebo|Single dose of placebo (0.9% sodium chloride injection) administered as a slow IV infusion.
3061898|NCT02148614|Placebo Comparator|Placebo|Subjects will be randomly assigned to treatment with placebo or LibramedR with a double blind clinical trial.
3061899|NCT02148614|Active Comparator|Libramed|Subjects will be randomly assigned to treatment with placebo or LibramedR with a double blind clinical trial.
3061900|NCT02148601|Experimental|Fecal Microbiota Transplantation|Fecal microbiota transplantation from healthy donors will be infused by colonoscopy
3062003|NCT02147977|Placebo Comparator|olive oil|Capsules of 500 mg. 2 g a day.
3061901|NCT02148601|Active Comparator|Standard Antibiotic Therapy|Standard antibiotic therapy according to European Guidelines (vancomycin and metronidazole) will be administered to the patients
3061902|NCT02148588|Experimental|Pain testing|"Completion of NPSI questionnaire~Sensory mapping of the affected limb~Quantitative Sensory Testing~Patients will have a peripheral nerve blockade"
3061903|NCT02148575|Experimental|Self-Management Group|"Managing Cancer Care: A Personal Guide (MCC) is a set of magazine-format, printed modules that includes information about key self-management topics, worksheets, conversation starters, and targeted links to local and internet resources, among other features."
3061904|NCT02148575|Active Comparator|Symptom Management Group|Participants in the Symptom Management Group will be given a symptom management toolkit that provides information on the most commonly experienced symptoms and side effects of cancer treatment, including fatigue, nausea, and sleep problems, among others. Each chapter includes information on when and why the symptom may occur, how the symptom can be managed, and when to call a provider.
3061905|NCT02148562||Chronic Hepatitis B|Diagnosis of Hepatitis B related liver disease in a pre-advanced stage
3061906|NCT02148562||End stage liver disease|Diagnosis of advanced liver disease related to Hepatitis B
3061907|NCT02148549|Experimental|Optimal chemotherapy courses|Neoadjuvant chemotherapy 4 courses of FIRINOX early 5 patients, and 8 courses of FIRINOX subsequent 5 patients
3061908|NCT02148536||HPS-TIPS group|
3061909|NCT02148523|Experimental|Weekly Adherence Report|Adherence report to subject every 7 days.
3061910|NCT02148523|Experimental|Weekly Adherence Peer-Comparison Report|Adherence report to subject every 7 days with tailored comparison messages based on subject's adherence.
3061911|NCT02148523|Other|Usual Care|Usual care with GlowCap.
3061912|NCT02148510|Experimental|Monobloc|Treatment with an appliance that holds the lower jaw in a fixed protruded position
3061913|NCT02148510|Active Comparator|Bibloc|Bibloc device where a maxillary splint is connected to a mandibular splint by a connector allowing a slight opening of the jaw without compromizing the protrusion (Narval)
3061914|NCT02148497|Other|Dry Eye Disease or Sjogren's Disease|Capturing images of the tear surface using the multi-colored Placido disk
3061915|NCT02148497|Other|Control|Capturing images of the tear surface using the multi-colored Placido disk
3061916|NCT02148484|Experimental|1|Prolonged exposure for adolescents
3061917|NCT02148484|Active Comparator|2|Client centered therapy
3061918|NCT02148471||Healthy controls|Healthy living liver donors with healthy liver on imaging and/or liver histology
3061919|NCT02148471||Simple steatosis|Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of simple steatosis
3061920|NCT02148471||Nonalcoholic steatohepatitis|Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of steatohepatitis
3061921|NCT02148471||Minimal findings|Patients undergoing liver biopsy because of suspected fatty liver but nonspecific findings on liver histology. This group was initially used as a control group. Later in the study, this group was replaced by healthy donors as true healthy controls.
3061922|NCT02148458|Other|Control group|Western diet for 8 weeks, followed by 8 weeks of Western diet with intermittent fasting.
3061923|NCT02148458|Experimental|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting.
3061924|NCT02148445|Active Comparator|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
3061925|NCT02148445|Experimental|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
3061926|NCT02148432|Experimental|dexmedetomidine 0.5 mcg/kg/hr|
3061927|NCT02148432|Active Comparator|dexmedetomidine 1.0 mcg/kg/hr|
3061928|NCT02148406|Experimental|Arm I (YST intervention)|Patients undergo YST intervention comprising four individualized, 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation during outpatient chemotherapy sessions in weeks 2, 4, 6, and 8. Patients practice awareness - noticing the current state and establishing relaxed breathing for 5 minutes; movement - 7 minutes of gentle movements coordinated with the breath (such as raising and lowering the arms); breathing practice - 3 minutes of inhaling cool air as if through a straw; and meditation - 5 minutes of focus on letting go of physical and mental tension. Patients review a handout describing the YST and to encourage patients to practice daily with strategies to increase adherence to home practice. Patients also receive an audio recording of the YST and devices to play the recording and are asked to keep a home practice log.
3061929|NCT02148406|Active Comparator|Arm II (attention control)|Patients attend four 30-minute sessions with an interventionist in weeks 2, 4, 6, and 8. During these sessions, patients are encouraged to discuss their experiences while receiving chemotherapy and do not receive instruction of movement, meditation or breathing practices. Patients will also be asked to write brief diary entries daily at home.
3061930|NCT02148393|Active Comparator|Control|In the control group, following oocyte retrieval, intensified luteal phase support for fresh embryo transfer (with Pregnyl®, Utrogestan® and Progynova®) will be performed. Fresh ET in the uterine cavity will be performed on the 5th day of embryo development at blastocyst stage under ultrasound guidance whenever possible.
3061931|NCT02148393|Experimental|Intervention|"Elective vitrification with subsequent-cycle embryo thawing/transfer (CryoBioSystem®) will be performed. Hence, no luteal phase support will be provided immediately after oocyte retrieval. Instead, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation.~On the day of embryo transfer, blastocyst(s) will be warmed one by one until one or two blastocysts are suitable for transfer. ET to the uterine cavity will be performed under ultrasound guidance whenever possible."
3061932|NCT02148380|Experimental|chemotherapy group(B)|pemetrexed plus carboplatin pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) every 4 weeks for up to six cycles, then continued to receive pemetrexed(500 mg/m(2) on day 1) alone every 4 weeks
3062072|NCT02147535|Experimental|Methylphenidate|
3061933|NCT02148380|Experimental|combination therapy group(A)|pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) combined with gefitinib (250 mg/day on days 5-21) and repeated every 4 weeks for up to six cycles,then continued to receive pemetrexed combined with gefitinib every 4 weeks.
3061934|NCT02148380|Experimental|gefitinib group (group C)|received gefitinib( 250 mg/day)alone. All therapies of 3 groups were continued until progression or unacceptable toxicity or death
3061935|NCT02148367|Active Comparator|Erythropoietin (EPO)|Participants (n=20) will receive EPO with a dose of 40,000 IU EPO subcutaneously (s.c.) once weekly for 4 weeks.
3061936|NCT02148367|Placebo Comparator|placebo|Participants (n=10) will receive placebo s.c. once weekly for 4 weeks
3061937|NCT02148354|Experimental|Group with support by the therapist.|Intervention group that do the Smiling is Fun program and receives support by the therapist (a brief weekly two-minute call without clinical content).
3061938|NCT02148354|Experimental|Group without support by the therapist|Intervention group that do the Smiling is Fun program and does not receive support by the therapist.
3061939|NCT02148354|Other|Waiting list control group|"Control group that could access the Smiling is Fun program after waiting for 12 weeks.~After that time, those participants still interested were randomly assigned to one of two intervention conditions (with or without support by the therapist)."
3061940|NCT02148341|Experimental|Community of Practice Facilitation|Medical Centers assigned to this arm will recieive the communtiy of practice facilitation. In this process we will contact existing members of the community of practice (called the Heart Failure Network) at the facility as well as attempt to identify new providers and other staff at the facility with an interest in improving heart failure care. The facilitation includes: describing the national H2H program, providing talking points and strategies for local providers to obtain support from their local facility to initiate local projects related to H2H, providing a forum for successful sites to describe how they initiated projects to sites yet to initiate projects.
3061941|NCT02148341|Experimental|Usual Care|Medical centers in this arm will hear of H2H through usual routs (calls with facilty Directors and Chiefs of staff).
3061942|NCT02148328|Experimental|Trivalent virosomal influenza vaccine|Trivalent virosomal influenza vaccine will be administered intramuscularly (injection of a substance into a muscle) on Day 1 in healthy participants.
3061943|NCT02148328|Active Comparator|Commercial vaccine 1|Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
3061944|NCT02148328|Experimental|Quadrivalent virosomal influenza vaccine|Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
3061945|NCT02148328|Active Comparator|Commercial vaccine 2|Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
3061946|NCT02148315|Experimental|garden intervention|garden kit and access to garden-based lessons
3061947|NCT02148315|No Intervention|no garden|control - receives garden and lessons at end of study
3061948|NCT02148302|Experimental|Harvesting Device (CelluTome©)|"open-label trial designed to evaluate the safety and effectiveness of Epidermal grafting plus multi-layer compression therapy versus multi-layer compression alone in the healing of venous leg ulcers.~Epidermal grafting will be applied up to three times in the treatment arm: at day zero, week 4 and week 8.~A run-in period of two weeks followed by twelve weeks of active treatment"
3061949|NCT02148302|No Intervention|Control: SOC alone|The Standard of Care therapy in this study is multi-layer compression therapy. A number of compression bandaging systems are commercially available. The trial will utilize Coban-2 (3M, Minneapolis, MN).
3061950|NCT02148289|Active Comparator|Nitrate rich beverage|Nitrate rich beverage will contain 140ml nitrate rich beetroot juice + 200ml blackcurrant juice containing 12.7mmol nitrate
3061951|NCT02148289|Placebo Comparator|Nitrate free beverage|Nitrate free beverage will 140ml water + 200ml blackcurrant juice containing <0.5mmol nitrate
3061952|NCT02148276||Research Participants|All participants will complete two measures of social harm at monthly research appointments for a three month period. The social harms assessments will be (1) the ACASI-SHQ that was developed in Phase 1 and (2) the HIV Vaccine Trials Network (HVTN) Social Impact Assessment.
3061953|NCT02148263|Experimental|Full-Time Senofilcon A Contact Lens Wear|This group will start wearing contact lenses 8 or more hours per day on the first day of wear
3061954|NCT02148263|Experimental|Graduated Senofilcon A Contact Lens Wear|This group will start wearing contact lenses on a graduated schedule (day 1 = 2 hours, day 2 = 4 hours, day 3 = 6 hours, day 4 = 8 hours, day 5 = 8 or more hours).
3061955|NCT02148250|Active Comparator|Subjects wtih type 2 diabetes|100 syringe units of U-500 regular insulin
3061956|NCT02148250|Active Comparator|Subjects with type 2 diabetes|200 syringe units of U-500 insulin
3061957|NCT02148237|No Intervention|Treatment as Usual|Participants in Treatment as Usual (TAU) will receive standard breastfeeding (BF) services from the WIC program and participate in research assessments. Standard services include an on-site and home-visiting lactation consultant, occasional one-on-one peer counseling, and an enhanced food package for BF women.
3061958|NCT02148237|Experimental|Contingency Management|These participants will receive usual WIC care. The frequency, duration, content, and size of the meetings and participation requirements will be the same as for the TAU group, except that this group will also receive contingency management (CM). Members will demonstrate breastfeeding and receive cash incentives weekly if they breastfeed.
3061959|NCT02148224||healthy without diabetes|
3061960|NCT02148211||Exposed cohort|Pregnant women, residing in the US and vaccinated with any of the 4 GSK seasonal Inactivated Influenza Vaccines (sIIVs) during pregnancy or within 28 days preceding conception.
3061961|NCT02148198|Active Comparator|1g NWT-03, then placebo|7 days 1g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
3061962|NCT02148198|Placebo Comparator|placebo, then 1g NWT-03|7 days placebo, followed by 7days 1g NWT-03, separated by a 5-day wash-out period
3061963|NCT02148198|Active Comparator|2g NWT-03, then placebo|7 days 2g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
3061964|NCT02148198|Placebo Comparator|placebo, then 2g NWT-03|7 days placebo, followed by 7days 2g NWT-03, separated by a 5-day wash-out period
3061965|NCT02148198|Active Comparator|5g NWT-03, then placebo|7 days 5g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
3062491|NCT02144857|Active Comparator|Anti IL12/23 regimen|ustekinumab 45 mg
3061968|NCT02148172|Active Comparator|Standard Plyometric Training|Participants will undergo treatment 2 times a week for 8 weeks with plyometric exercises deemed to be consistent with best practice delivered at a standard dosage of sets and repetitions.
3061969|NCT02148172|Experimental|Plyometric Training with BWS|Participants will undergo treatment 2 times a week for 8 weeks with plyometric exercises deemed to be consistent with best practice with a treatment volume of sets and repetitions that exceeds standard practice. Higher number of practice trials will be completed with body weight support (BWS) to reduce load. Participants will start at 30 percent of body weight and will be slowly weaned away over time.
3061970|NCT02148159||Cachexia Acupuncture-A|"Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points that are selected based on the potential mechanisms of cachexia. Intervention will be done by a licensed acupuncturist who has over 5 years of experience as an independent clinician and has experience particularly in the management of cancer related symptoms. Acupuncture treatment will consist of 8 sessions over 8 week period.~Acupuncture needles: Single-use, sterile stainless steel and disposable [acupuncture needles-Peace Classic Needles®, Acu-Market] Other name: Mechanism based acupuncture"
3061971|NCT02148159||General Acupuncture-B|"General Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points. These points are the real acupuncture points; however, these points are not specific to cachexia management. Participants will receive the acupuncture treatment over 8 weeks (total of 8 sessions) in the same manner as the experimental group; the only difference will be the place(type) and number of points targeted.~Acupuncture needles: single-use, sterile stainless steel and disposable needles [Peace Classic Needles®, Acu-Market] Other name: General acupuncture"
3061972|NCT02148146|Other|Omegaven|No placebo or comparator arm. Only intervention arm with Omegaven.
3061973|NCT02148133|Experimental|Eltrombopag|Subjects will be assigned the investigational product (eltrombopag 25 mg/day) orally once a day under fasting condition. The dose adjustment will be done every 2 weeks according to the platelet count (increased by eltrombopag 25 mg/day every 2 weeks according to the platelet count up to 100 mg/day).
3061974|NCT02148120|Active Comparator|CHF1535 NEXThaler 100/6, 1 puff|Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg
3061975|NCT02148120|Active Comparator|CHF1535 NEXThaler 100/6 µg, 4 puffs|Beclometasone Dipropionate 400 µg + Formoterol Fumarate 24 µg
3061976|NCT02148120|Experimental|CHF1535 NEXThaler 200/6 µg, 1 puff|Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg
3061977|NCT02148120|Experimental|CHF1535 NEXThaler 200/6 µg, 4 puffs|Beclometasone Dipropionate 800 µg + Formoterol Fumarate 24 µg
3061978|NCT02148120|Placebo Comparator|Placebo NEXThaler|Placebo
3061979|NCT02148107|Experimental|BI 691751 Dose 1|multiple dose given over 14 days
3061980|NCT02148107|Experimental|BI 691751 Dose 2|multiple dose given over 14 days
3061981|NCT02148107|Experimental|BI 691751 Dose 3|multiple dose given over 14 days
3061982|NCT02148107|Experimental|BI 691751 Dose 4|multiple dose given over 14 days
3061983|NCT02148107|Experimental|BI 691751 Dose 5|multiple dose given over 14 days
3061984|NCT02148107|Experimental|BI 691751 Dose 6|multiple dose given over 14 days
3061985|NCT02148107|Placebo Comparator|Placebo|Placebo
3061986|NCT02148094|Experimental|Truvada|Participants will be initiated on PrEP and asked to select one of two PrEP delivery options. Participants will return to the study site every three months for an additional follow-up visit. At follow-up visits, participants will receive HIV testing and counselling, pregnancy testing, syndromic screening for STIs, and clinical diagnosis of adverse events. Those who test HIV-positive will be discontinued on PrEP, exited from the study and referred for HIV care and treatment. Those who have an adverse event will be clinically evaluated to determine whether they should suspend PrEP use and will be provided with the appropriate management for the adverse event. Participants who test HIV-negative will receive patient-centred counselling around PrEP.
3061987|NCT02148081||Critically ill children|
3061988|NCT02148068||Bariatric Surgery - Gastric Bypass|This population will undergo a laparoscopic roux-en-y gastric bypass
3061989|NCT02148068||Bariatric Surgery - Sleeve Gastrectomy|This group will undergo a laparoscopic sleeve gastrectomy
3061990|NCT02148055|Other|A group of 20 pregnant patients.|20 patients referred for intrauterine spontaneous fetal death explored by MRI and autopsy.
3061991|NCT02148042||Anorexics|
3061992|NCT02148042||Controls|
3061993|NCT02148029|Active Comparator|Control|Standard care: anticoagulation, compression & ad-lib ambulation
3061994|NCT02148029|Experimental|Exercise|Standard care + Interventional Exercise therapy
3061995|NCT02148016|Experimental|LSCs and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
3061996|NCT02148016|Active Comparator|Amniotic membrane only (Traditional Technique)|Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.
3061997|NCT02148016|Experimental|PRK, LSCs, and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
3061998|NCT02148016|Active Comparator|PRK only (Traditional Technique)|PRK alone will be performed.
3061999|NCT02148003|Active Comparator|RFA at 90 degrees Celsius|Radiofrequency ablation (RFA) of the lumbar facets nerve supply will be performed at 90 degrees Celsius
3062000|NCT02148003|Active Comparator|RFA at 80 degrees Celsius|Radiofrequency ablation (RFA) of the lumbar facets nerve supply will be performed at 80 degrees Celsius
3062001|NCT02147990|Experimental|Rociletinib Mono-Therapy|
3062002|NCT02147977|Active Comparator|dietary supplement: n-3 PUFA|"n-3 polyunsaturated fatty acids from fish oil~capsules of 500 mg. 2 g a day."
3062004|NCT02147964|Experimental|Acyline; T Gel; placebo dutasteride, placebo ketoconazole|"All men will receive Acyline 300 ug/kg subcutaneous (SQ) injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.~Group 1: placebo oral ketoconazole + placebo oral dutasteride for 4 months"
3062005|NCT02147964|Experimental|Acyline; T gel; Ketoconazole; placebo|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.~Group 2: oral ketoconazole 400 mg + placebo oral dutasteride for 4 months"
3062006|NCT02147964|Experimental|Acyline; Tgel; Ketoconazole; Dutasteride|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.~Group 3: Ketoconazole 400mg orally daily + Dutasteride 2.5 mg orally on day 1, followed by 0.5mg daily for 4 months"
3062007|NCT02147964|Experimental|Acyline; Tgel; HCG|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.~Group 4: Human Chorionic gonadotropin (HCG) 60 IU injection every other day for 4 months."
3062008|NCT02147938||1: early conversion from Prograf® to Advagraf®|patients converted during the first 6 months post-transplantation
3062009|NCT02147938||2: late conversion from Prograf® to Advagraf®|patients converted between 6 and 12 months post-transplantation
3062010|NCT02147925|Active Comparator|Liraglutide|Liraglutide combined with metformin
3062011|NCT02147925|Active Comparator|Insulin glargine|Insulin glargine combined with metformin
3062012|NCT02147925|Active Comparator|Sitagliptin|Sitagliptin combined with metformin
3062013|NCT02147912|Active Comparator|Aerobic exercise|A six week aerobic exercise intervention in COPD depressed population.
3062014|NCT02147912|No Intervention|Control sample|"Only participants randomized in the arm named Aerobic exercise will receive a six weeks aerobic exercise intervention."
3062015|NCT02147899|Experimental|SYM-1219 Low Dose|Administered orally
3062016|NCT02147899|Experimental|SYM-1219 High Dose|Administered orally
3062017|NCT02147899|Placebo Comparator|Placebo|Administered orally
3062018|NCT02147886|Experimental|Cabaletta 15gr|Cabaletta 15gr
3062019|NCT02147886|Experimental|Cabaletta 30gr|Cabaletta 30gr
3062020|NCT02147873|Active Comparator|azacitidine with birinapant|Azacitidine 75 mg/m2 IV on days 1-5, 8 & 9 OR days 1-7 and birinapant 13 mg/m2 IV twice a week (days 1 & 4) for 3 out of 4 weeks
3062021|NCT02147873|Placebo Comparator|Azacitidine and placebo|Azacitidine 75mg/m2 IV days 1-5, 8 & 9 OR days 1-7 and placebo IV twice a week (days 1 & 4) for 3 out of 4 weeks
3062022|NCT02147860|Placebo Comparator|Sensor Augmented Pump Therapy|Each camp participant will be randomized to full day and night CLC or sensor augmented pump therapy for up to 7 days/6 nights. The subject will wear a continuous glucose monitoring system (CGM) to measure sensor glucose and a physiological monitor to measure heart rate and 3-axis accelerometer for 24-72 hours.
3062023|NCT02147860|Experimental|Diabetes Assistant (DiAs) with USS Virginia|"With the use of the UVA Artificial Pancreas (DiAs), the study will assess safety and feasibility and are not powered for statistical significance. These studies are intended to train staff on system function and obtain data regarding safe and feasible system use.~Camp participants will be randomized to either closed-loop control using the DiAs or sensor-augmented pump therapy only. These studies would generate up to 120 days of closed-loop data and 120 comparable days of open-loop data."
3062024|NCT02147847|Experimental|Video game based training 1|Video Game play with training strategy 1
3062025|NCT02147847|Experimental|Video game based training 2|Video Game play with training strategy 2
3062026|NCT02147834|Active Comparator|Ranolazine|"Ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
3062027|NCT02147834|Placebo Comparator|Sugar pill|"Sugar pill that looks like the drug ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
3062028|NCT02147821|No Intervention|Standard|Standard treatment will be defined as current practice whereby two mediastinal chest tubes are used for drainage, as well as an additional pleural tube if the pleura is opened during surgery. As part of current standard practice, the pleural and mediastinal spaces will be suctioned during the achievement of hemostasis prior to the insertion of chest tubes.
3062029|NCT02147821|Experimental|Intervention|The treatment arm of the study will involve standard placement of the mediastinal tubes with the exclusion of the pleural tube.
3062030|NCT02147808|Experimental|All subjects|All subjects will receive a single oral midazolam dose on Day 1 while fasting. Days 2 to 4 will be Washout days. On Day 5, subjects will begin a 5-day regimen of telotristat etiprate. On Day 9, subjects will receive a morning dose of telotristat etiprate with a single dose of midazolam while fasting.
3062031|NCT02147795||Control cohort|Standard care before implementation (pre-implementation)
3062032|NCT02147795||PBM cohort|After implementation of PBM program (post-implementation)
3062033|NCT02147782||control|Healthy people from physical examination centers are recruited as controls.
3062034|NCT02147782||CKD1|"with clinical one or more symptoms and signs of kidney injury listed as below：~Urinary albumin ( urinary albumin excretion rate≥30 mg/24 h.albumin-creatinine ratio≥3mg/mmol)~urinary sediments abnormality~renal tubular lesions~renal histological abnormalities~abnormal structure showed by imaging~history of renal transplantation~GFR≥90（ml/min/1.73m²)"
3062035|NCT02147782||CKD2|with clinical symptoms and signs of kidney injury, and 60<=GFR<=89（ml/min/1.73m²)
3062036|NCT02147782||CKD3|with clinical symptoms and signs of kidney injury, and 30<=GFR<=59（ml/min/1.73m²)
3062037|NCT02147782||CKD4|with clinical symptoms and signs of kidney injury, and 15<=GFR<=29（ml/min/1.73m²)
3062038|NCT02147782||CKD5|with clinical symptoms and signs of kidney injury, and GFR<15（ml/min/1.73m²)
3062039|NCT02147769||Preterm infants monitored with NIRS|All infants enrolled in the study will be monitored with cerebral near-infrared spectroscopy (NIRS monitoring) to measure cerebral oxygenation levels in the first 96 hours of life. Mean arterial blood pressure will simultaneously be monitored.
3062107|NCT02147288|No Intervention|Lipoabdominoplasty on JP Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
3062108|NCT02147288|No Intervention|Ventral Hernia Repair (VHR) on JP Drains|Standard of Care
3062492|NCT02144857|Active Comparator|Cyclosporine regimen|Cyclosporine 2.5-3 mg/kg
3062040|NCT02147756|Active Comparator|CO2RE|Fractional CO2 laser system that utilizes a sealed off, all metal carbon dioxide gas tube that is Radio Frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The system has a programmable 2 axis scanning laser beam device that allows the physician to select the skin area coverage from a selection of predetermined patterns in different sizes based on the skin area to be treated. The versatility of the fractional CO2RE system enables precise, effective and simultaneous treatment of the skin's surface in the middle, and deep dermal levels.
3062041|NCT02147756|Active Comparator|RePair|Fractional CO2 system that comprises an infrared laser controlled by an embedded processor and a handpiece that directs the laser treatment. The device laser has a wavelength of 10.6μm and its tissue chromophore is water. It delivers multiple low energy pulses in microscopic spots as the handpiece glides over the skin surface. The selected energy determines the depth and width for each microscopic treatment zone (MTZs).
3062042|NCT02147743|Experimental|CCP+MDFT|Multidimensional Family Therapy (MDFT) is a multisystemic, flexible intervention system (Liddle, 2002). It is a strengths-based approach promoting protective factors and reducing risk factors for delinquency, substance use, and school problems. MDFT organizes interventions in key areas of the teen's life: self of the adolescent (includes HIV-STD risk behaviors), parenting, family environment, and school/vocational functioning.
3062043|NCT02147743|Other|CCP+SAU|Services as Usual (SAU) are determined on a case-by-case basis by the CCP Case Manager. SAU includes a variety of services offered by a number of community partners.
3062044|NCT02147730||surgical patients|all surgical patients undergoing gastrectomy, knee-hip-shoulder arthroplasty, hallux valgus surgery, hernia repair, saphenectomy, cesarean section,colectomy, hysterectomy, nephrectomy mastectomy during study period
3062045|NCT02147717|Experimental|Laser stimulation|"Laser stimulation plus opioid treatment before ETS. Low level laser acupuncture, 670 nm, 10Hz, 0,3 J per acupoint, 6 points per neonate (Zu san li, He Gu, Nei Guan) marquage CE, premio 30 laser duo de Sedatelec. Overall 3 minutes of treatment.~This sequence will be repeated 4 times during the study (1 hour before surgery and every 12 hours after surgery)"
3062046|NCT02147717|Placebo Comparator|fake laser stimulation|newborns have the same preparation procedure as the intervention to put them under the same conditions group. The laser pen is turned off, off-voltage
3062047|NCT02147704|Other|Goup I|Group I: Fimasartan 60 mg in a low-sodium intake period --> Fimasartan 60 mg in a high-sodium intake period
3062048|NCT02147704|Other|Group II|Group II: Fimasartan 60 mg in a high-sodium intake period --> Fimasartan 60 mg in a low-sodium intake period
3062049|NCT02147691|Experimental|Azelaic acid 15%, Brimonidine 0.33 % Gel|"Azelaic acid 15% to the face each AM followed 30 minutes later by Brimonidine 0.33%~Azelaic acid 15% to the face each PM"
3062050|NCT02147691|Active Comparator|Brimonidine 0.33% Gel|Brimonidine 0.33% Gel
3062051|NCT02147678|Experimental|Group E|Etomidate/remifentanil group. Patients in group E will be given etomidate and remifentanil during the operation, the speeds are 10~15 μg/kg/min and 0.2~0.4 μg/kg/min, respectively.
3062052|NCT02147678|Experimental|Group P|Propofol/remifentanil group. Patients in group P will be given propofol and remifentanil during the operation, the speeds are 50~75 μg/kg/min and 0.2~0.4 μg/kg/min, respectively.
3062053|NCT02147665|Experimental|Hookah smoking|Healthy habitual Hookah smokers will undergo microneurography, myocardial contrast echocardiogram or venous occlusion plethysmography before and after Hookah smoking.
3062054|NCT02147652|Experimental|Personalized music|
3062055|NCT02147639|Experimental|Sodium Nitrate|Patients will ingest a single oral dose of sodium nitrate (~8.4 mmol)
3062056|NCT02147639|No Intervention|Baseline|This is a baseline study visit, which will serve to assess inclusion and exclusion criteria, as well as provide untreated measurments of skeletal muscle blood flow and perfusion.
3062057|NCT02147639|Experimental|Dose-escalation trial|This is an optional study visit, where subjects will ingest twice the dose of sodium nitrate (~16.8 mmol).
3062058|NCT02147639|Placebo Comparator|Placebo-control trial|This is an optional study visit, where patients will ingest a placebo.
3062059|NCT02147639|Experimental|Increased exercise intensity|This is an optional study visit, where patients will be asked to repeat all of the blood flow assessments, but the exercise intensity will be increased.
3062060|NCT02147626|Active Comparator|Information and Screening Group|Intervention: The patient website will include the AHA Class I Lifestyle recommendations (translated to an 8th grade reading level and with a link to the publication), a link to the online National Institutes of Health (NIH) DASH website, and the NIH smoking cessation website
3062061|NCT02147626|Experimental|HH4M Intervention Arm|Intervention: The HH4M patient website will include information and tools. These resources are customized to help new mothers achieve the AHA Class I Lifestyle recommendations for women with a history of preeclampsia.
3062062|NCT02147613|Experimental|High intensity interval training|High intensity interval training - 3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
3062063|NCT02147613|Active Comparator|Moderate intensity exercise training|3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
3062064|NCT02147600||Chronic plaque psoriasis|Patients suffering from chronic plaque psoriasis, treated with adalimumab (40mg) subcutaneously every other week after an initial dose of 80 mg. Treatment duration of at least 24 weeks.
3062065|NCT02147587|Experimental|Tofacitinib 5 mg BID (oral) (70 subjects)|Zoster vaccine will be administered to subjects on background methotrexate; treatment with 5 mg tofacitinib twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
3062066|NCT02147587|Placebo Comparator|Placebo tofacitinib BID (oral) (70 subjects)|Zoster vaccine will be administered to subjects on background methotrexate; treatment with placebo twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
3062067|NCT02147574|Experimental|antiperistaltic ileosigmoid anastomosis|To assess the operative results after laparoscope subtotal colectomy with antiperistaltic ileosigmoid anastomosis for the slow-transit constipation.
3062068|NCT02147561|Experimental|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
3062069|NCT02147548|Experimental|etifoxine (Anxiolytic)|etifoxine, 100 mg, a single oral intake
3062070|NCT02147548|Active Comparator|lorazepam|lorazepam, 2 mg, a single oral intake
3062071|NCT02147548|Placebo Comparator|Placebo|2 capsules of Placebo, a single oral intake
3062073|NCT02147522|Experimental|A Helping Hand (AHH)|Participants receive DHS-PCMH usual care from their respective county health clinic providers plus the AHH intervention provided by study promotoras. AHH intervention includes 6 weekly in-person or via-telephone intervention sessions followed by 3 monthly telephone booster sessions aimed at reducing the burden and strain on patients, families, and care providers by assessing, enhancing, and facilitating patient depression and co-morbid illness self-care management, and activating patient communication with clinic medical providers.
3062074|NCT02147522|No Intervention|Usual Care (UC)|"Participants receive DHS Patient Centered Medical Home (PCMH) clinic team usual care from their respective county health clinic providers.~PCMH model has available DHS medical providers and social workers for depression care and refer patients when indicated to community mental health clinics. Problem-Solving Therapy (PST) is available in some of participating clinics."
3062075|NCT02147509|Experimental|Severe dry eye|"0.02% Fm, SH~0.02% Fm, SH, AS~0.02% Fm, SH, 0.05% CsA~0.02% Fm, SH, tBCL (0.05% CsA: 0.05% cyclosporin A; tBCL: therapeutic bandage contact lenses; 0.02% Fm: 0.02% Fluorometholone; AS: Autologous Serum; SH: Sodium Hyaluronate)"
3062076|NCT02147496|Experimental|2% M.F. Milk|Dietary treatment: 2% m.f. milk
3062077|NCT02147496|Experimental|1% M.F. Chocolate Milk|Dietary treatment: 1% m.f. chocolate milk
3062078|NCT02147496|Experimental|1.5% M.F. Drinkable Yogurt|Dietary treatment: 1.5% m.f. drinkable yogurt
3062079|NCT02147496|Experimental|Tropical Punch|Dietary treatment: fruit-flavoured beverage
3062080|NCT02147496|Experimental|Water|Dietary treatment: calorie-free control
3062081|NCT02147483|Active Comparator|Treatment as usual|Treatment as usual as prescribed by clinician.
3062082|NCT02147483|Experimental|Mindfulness Based Relapse Prevention|Mindfulness based relapse prevention will be provided in eight in person sessions to prevent alcohol use.
3062083|NCT02147470|Other|prerenal AKi, acute tubular necrosis and hepatorenal syndrome|All subjects will undergo CEUS with the use of Definity to measure renal blood flow. At the same time clinical tools (urine output, response to volume expansion, urine sodium, urine output, fractional excretion of sodium and urea and urine microscopy) will be used to differentiate between prerenal AKI, ATN and HRS. the quantity and patterns of RBF measured by CEUS will be compared between these three groups.
3062084|NCT02147457||ELBW (CASES)|Extremely low birth weights, born in 2000-2005, birth weight below 1000 grams, who were initially admitted (2000-2005) at the Neonatal Intensive Care Unit, UZ Leuven Belgium and have been well characterized and documented in the postnatal period.
3062085|NCT02147457||CONTROLS|Survivors (CASES) (n = 140) will be matched with two healthy controls. One control will be matched to sex, birth year and residential area and will be suggested by the index patient (e.g. school friend, neighbor), the second control will be age and sex matched from the area of the field.
3062086|NCT02147444||Non-valvular atrial fibrillation|"Patients diagnosed with non-valvular atrial fibrillation~Patients who are treated or will be treated with rivaroxaban"
3062087|NCT02147431|Experimental|Semaglutide|
3062088|NCT02147431|Placebo Comparator|Placebo|
3062089|NCT02147418||Group 1: HPV-positive Cancer|Oropharyngeal cancer patients testing positive for human papillomavirus (HPV)
3062090|NCT02147418||Group 2: HPV-positive Cancer|Oropharyngeal cancer patients who test positive for human papillomavirus (HPV)
3062091|NCT02147418||Group 3: Healthy Controls|Patients with benign conditions
3062092|NCT02147379|Experimental|Lurasidone|Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.
3062093|NCT02147379|No Intervention|Treatment as usual|Patients randomized to this arm will continue their usual treatment.
3062094|NCT02147366|Experimental|Behavioral (Lifestyle)|Only standard lifestyle modifications The prehypertensives and stage I hypertensives will be randomized to receive each of the two three experimental conditions: music along with standard lifestyle modifications or only standard lifestyle modifications in random order over the course of three months.
3062095|NCT02147366|Experimental|Behavioral (Music & lifestyle changes)|Experimental: Music along with standard lifestyle modifications The prehypertensives and stage I hypertensives will be randomized to receive each of the two three experimental conditions: music along with standard lifestyle modifications or only standard lifestyle modifications in random order over the course of three months.
3062096|NCT02147353|Active Comparator|Sinecatechins 15% Ointment & Cryotherapy|Cryotherapy and then Sinecatechins 15% Ointment 1 week later.
3062097|NCT02147353|Placebo Comparator|Cryotherapy Alone|Cryotherapy will be standardized in all subjects and for all treated lesions: EGW lesions will be treated with 2 sprays, 5 seconds each, with a 5 second interval. All subjects will be treated with the same cryo-spray regimen.
3062098|NCT02147340||Heart failure patients with ICD|Heart failure patients with ICD and RPM system equipped with sensors for the measurement of weight and pressure
3062099|NCT02147301|Experimental|DEB-TACE|"Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):~Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first"
3062100|NCT02147288|Experimental|Breast Recon with acellular dermal matrix (ADM) on NPWT|
3062101|NCT02147288|Experimental|Lipoabdominoplasty on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the lipoabdominoplasty patients enrolled in this arm.
3062102|NCT02147288|Experimental|Abdominoplasty on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the abdominoplasty patients enrolled in this arm.
3062103|NCT02147288|Experimental|Ventral Hernia Repair (VHR) on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the VHR patients enrolled in this arm.
3062104|NCT02147288|Experimental|Panniculectomy on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the panniculectomy patients enrolled in this arm.
3062105|NCT02147288|No Intervention|Breast Recon with ADM on Jackson-Pratt (JP) Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
3062106|NCT02147288|No Intervention|Abdominoplasty on JP Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
3090449|NCT01956305|Placebo Comparator|Placebo|placebo to match DS-7309
3062109|NCT02147288|No Intervention|Panniculectomy on JP Drains|Standard of care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
3062110|NCT02147275||hypertension disease|patients have hypertension disease, whether well-controlled or uncontrolled, more than 3 year
3062111|NCT02147262|Active Comparator|ACA-doxy 14 days|patients with chronic atrophic acrodermatitis treated with doxycycline for 14 days
3062112|NCT02147262|Active Comparator|ACA-doxy 28 days|patients with chronic atrophic acrodermatitis treated with doxycycline for 28 days
3062113|NCT02147249|Experimental|erythema migrans patients treated with antibiotics|adult patients with erythema migrans will be treated with oral antibiotics
3062114|NCT02147223|Active Comparator|Flavanol rich product A|250 mg flavanols
3062115|NCT02147223|Active Comparator|Flavanol rich product B|500 mg flavanols
3062116|NCT02147223|Active Comparator|Flavanol rich product C|750 mg flavanols
3062117|NCT02147223|Placebo Comparator|Flavanol free product|flavanol free
3062118|NCT02147210||1-Case|patients who developed CTG secondary to antibody-mediated kidney rejection (AMR), diagnosed by microscopic analysis.
3062119|NCT02147210||2-Control|patients with antibody-mediated kidney rejection (AMR) but without CTG
3062120|NCT02147197|Experimental|Ulipristal acetate 5 mg|Ulipristal acetate 5 mg
3062121|NCT02147197|Experimental|Ulipristal acetate 10 mg|Ulipristal acetate 10 mg
3062122|NCT02147197|Placebo Comparator|Placebo|Placebo
3062123|NCT02147184||SSRI Group|Participants within one month of starting an SSRI
3062124|NCT02147184||Unmedicated Group|No treatment with SSRIs
3062125|NCT02147171|Active Comparator|Active lutein group|44 participants taking VisionAce daily for a period of 1 year
3062126|NCT02147171|Placebo Comparator|Placebo group|44 participants taking placebo daily for a period of 1 year
3062127|NCT02147158|Experimental|Placebo followed by UPA 5 mg|Placebo followed by UPA 5 mg
3062128|NCT02147158|Experimental|Placebo followed by UPA 10 mg|Placebo followed by UPA 10 mg
3062129|NCT02147158|Experimental|UPA 5 mg followed by UPA 5 mg|UPA 5 mg followed by UPA 5 mg
3062130|NCT02147158|Experimental|UPA 5 mg followed by Placebo|UPA 5 mg followed by Placebo
3062131|NCT02147158|Experimental|UPA 10 mg followed by UPA 10 mg|UPA 10 mg followed by UPA 10 mg
3062132|NCT02147158|Experimental|UPA 10 mg followed by Placebo|UPA 10 mg followed by Placebo
3062133|NCT02147145||Observation Cohort|
3062134|NCT02147132|Experimental|Order 1|Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
3062135|NCT02147132|Experimental|Order 2|Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
3062136|NCT02147132|Experimental|Order 3|Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
3062137|NCT02147132|Experimental|Order 4|Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
3062138|NCT02147119||Patients post- cardiac catheterisation|
3062139|NCT02147106||Videoconsultation|Performing two videoconsulations with the treating medical oncologist
3062140|NCT02147093|Other|Control (sphere) /Test (multi-focal)|Subjects were first fitted with Control lens (sphere) and a pair of reading glasses for one week. Subjects were then fitted with the Test lens (multi-focal) for one week.
3062141|NCT02147093|Other|Test (sphere) /Control (multi-focal)|Subjects were first fitted with the Test lens (multi-focal) for one week. Subjects were then fitted with Control lens (sphere) and a pair of reading glasses for one week.
3062142|NCT02147080|Experimental|Tailored Intervention|Subject has access to the tailored web intervention
3062143|NCT02147080|Active Comparator|Skin Cancer Foundation Website|Subject has access to the pre-existing Skin Cancer Foundation website
3062144|NCT02147080|No Intervention|Assessment Only Condition|Subjects will only complete assessments
3062145|NCT02147067|Experimental|Ranolazine|Ranolazine 1,000 mg twice daily
3062146|NCT02147067|Placebo Comparator|Placebo|Placebo twice daily
3062147|NCT02147054|Active Comparator|Rocuronium with >95% inhibition|"IV Rocuronium to be given:~Bolus dose of Rocuronium 0.3 mg/kg to achieve >95% inhibition as indicated by Train of Four monitoring~Continuous infusion of 1.5 mg/kg/hr to maintain level of inhibition~To continue until two rises in butyrylcholinesterase seen or for a maximum of 5 days"
3062148|NCT02147054|Active Comparator|Rocuronium with 50% inhibition|"IV Rocuronium to be given:~Bolus dose of Rocuronium 0.3 mg/kg to achieve 50% inhibition as indicated by Train of Four monitoring~Continuous infusion of 1.5 mg/kg/hr to maintain level of inhibition~To continue until two rises in butyrylcholinesterase seen or for a maximum of 5 days"
3062149|NCT02147054|No Intervention|No Rocuronium|No Rocuronium will be given
3062150|NCT02147041|Experimental|EGCG(Epigallocatechin Gallate)|EGCG(Epigallocatechin Gallate)(500 mg, three times a day, 12 weeks)
3062151|NCT02147041|Placebo Comparator|placebo|cellulose (500mg, three times a day, 12 weeks)
3062152|NCT02147028|Experimental|Hippocampal sparing whole brain RT|30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
3062153|NCT02147028|Active Comparator|Control: Conventional whole brain RT|30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
3062154|NCT02147015|Experimental|Personalized variable dose of glucocorticoids arm|Use of personalized variable dose of glucocorticoids according to a rating scale starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, Inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA), Long-Acting Muscarinic Antagonists(LAMA), short-acting beta2-agonist (SABA), and other physical treatments.
3062232|NCT02146521||patients undergoing CT|Emergency department's patients undergoing CT scanning for evaluation of acute abdominal pain and tenderness
3062155|NCT02147015|Other|Experiential dose of glucocorticoids arm|Use of glucocorticoids at doses according to normal clinical practice, together with other necessary treatments, including antibiotics, ICS, LABA, LAMA, SABA, and other physical treatments.
3062156|NCT02147015|Other|Fixed dose of glucocorticoids arm|Use of fixed term of glucocorticoids (40mg) starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, ICS, LABA, LAMA, SABA, and other physical treatments.
3062157|NCT02147002|Active Comparator|omega 3 acids 1|Patients with CKD stage I (GFR 90 and more ml/min/1,73 m2)
3062158|NCT02147002|Active Comparator|omega 3 acids 2|Patients with CKD stage II (GFR 80-89 ml/min/1,73 m2)
3062159|NCT02147002|Active Comparator|omega 3 acids 3|Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2)
3062160|NCT02147002|Active Comparator|omega 3 acids 4|Patients without diabetes mellitus, hypertensions,CKD with normal level of creatinine in serum
3062161|NCT02146989||Cerebral Palsy|Children and adolescents with spastic unilateral Cerebral Palsy (with perinatal acquired hypoxic ischemic incidents), aged 7 to 18 years, MACS levels I-III.
3062162|NCT02146989||Healthy controls|Children and adolescents without Cerebral Palsy
3062163|NCT02146976|Experimental|Propofol|introvenious infusion of propofol
3062164|NCT02146976|Experimental|Inhaled anaesthetic (Sevoflurane)|sevoflurane (1.0-1.3% Minimum Alveolar Concentration)
3062165|NCT02146963||alcohol withdrawal|
3062166|NCT02146950||LCS12|New users of LCS12
3062167|NCT02146950||Mirena|New users of Mirena
3062168|NCT02146950||Copper IUD|New users of copper IUDs
3062169|NCT02146937|Experimental|Combination therapy- bicalutamide and finasteride|3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily
3062170|NCT02146924|Experimental|Treatment (cellular immunotherapy)|Patients receive lymphodepleting regimen per treating physician's discretion 3-14 days before the T-cell infusion. Patients receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells IV over 15 minutes on day 0. Patients who have evidence of disease, whose tumor(s) continue to express the appropriate antigen target may receive an optional second infusion of CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells after 28 days.
3062171|NCT02146924|Active Comparator|Arm II (cellular immunotherapy)|Patients receive lymphodepleting regimen per treating physician's discretion 3-14 days before the T-cell infusion. Patients receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T cells IV over 15 minutes on day 0. Patients who have evidence of disease, whose tumor(s) continue to express the appropriate antigen target may receive an optional second infusion of CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T cells after 28 days.
3062172|NCT02146911|Experimental|Bupropion|Bupropion hydrochloride SR, Sandoz Canada, Boucherville, Quebec. Dispense for 12 weeks. One tablet (150mg) once daily for first three days, then twice daily for the remainder of 12 weeks.
3062173|NCT02146911|Experimental|Varenicline|Varenicline tartrate (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet or two 0.5mg tablets) twice daily for the remainder of 12 weeks.
3062174|NCT02146898|Active Comparator|Lateral|patient placed in the lateral postion for spinal anesthesia
3062175|NCT02146898|Active Comparator|Sitting|patient placed in the sitting position for spinal anestheisa, then supine
3062176|NCT02146898|Active Comparator|Recline|patient placed in the sitting position for spinal anesthesia administration. After spinal placed, the patient turned to a 30-degree upperbody tilt, followed by a slow recline to supine over 5 minutes
3062177|NCT02146885||Weight Control|Weight Control
3062178|NCT02146872||Very Premature CAD|Patients who have received a coronary intervention procedure on the basis of atherosclerosis before the age of 40
3062179|NCT02146872||Healthy middle-aged 1st degree relatives|Healthy 1st degree relatives aged 30-65 years of patients with very premature CAD.
3062180|NCT02146872||PCAD families|Families severely affected by premature CAD
3062181|NCT02146859||general anesthesia|Patient having general anesthesia
3062182|NCT02146846||Imatinib, CML|Patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in this study
3062183|NCT02146833|Experimental|Selinexor Dosing Regimen 1|80 mg twice weekly for 4 weeks (8 doses per 28-day cycle)
3062184|NCT02146833|Experimental|Selinexor Dosing Regimen 2|80 mg once weekly for 4 weeks (4 doses per 28-day cycle)
3062185|NCT02146833|Experimental|Selinexor Dosing Regimen 3|60 mg twice weekly for 2 weeks, then 1 week off (4 doses per 21-day cycle)
3062186|NCT02146820|Experimental|Picosecond Laser System|
3062187|NCT02146807|Experimental|Picosecond Laser System|
3062188|NCT02146794|Experimental|Renal denervation|renal denervation
3062189|NCT02146781|Placebo Comparator|0.80 mL Saline Placebo Cohort 1|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan and are skin test positive or negative at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens.~Cohort # 1: Subjects will receive four 0.200 mL volume intradermal injections of saline control as a placebo control using the Biojector device.~Intervention: Saline Control via Intradermal route."
3062190|NCT02146781|Experimental|2.16 mg of CryJ2-DNA-LAMP plasmid vaccine Cohort 2|"Healthy male and female subjects 18 to 63 years of age who have lived in Japan and are skin test positive at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain cedar pollen seasons.~Cohort # 2: Subjects receive four (4) injections of 0.200 mL volumes (2.7 mg/mL) for a single dose of 2.16 mg of CryJ2-DNA-LAMP plasmid vaccine; intradermally (ID) administered using the Biojector device (each dose administered by separate Biojector device injections at different skin sites. These subjects will receive the same batch vaccine used in Phase 1A and 1B~Intervention: Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection"
3062229|NCT02146547|Active Comparator|Paliperidone palmitate|The first two administrations of paliperidone palmitate (150 mg at visit 3 and 100 mg one week later) need to be administered deep into the deltoid muscle in order to attain therapeutic concentrations rapidly. No oral supplementation with paliperidone is needed. Following the second dose, monthly maintenance doses can be administered in either the deltoid or gluteal muscle. The recommended monthly maintenance dose is 75 mg, although some patients may benefit from lower doses within the recommended range of 25 to 150 mg based on individual patient tolerability and/or efficacy.
3062191|NCT02146781|Experimental|1.08 mg CryJ2-DNA-LAMP plasmid vaccine Cohort 3|"Healthy male and female subjects 18 to 63 years of age who have lived in Japan and are skin test positive at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain cedar pollen seasons.~Cohort # 3: Subjects will receive two (2) injections of 0.200 mL (2.7 mg/mL) for a single dose intradermally (ID) for a single dose of 1.08 mg CryJ2-DNA-LAMP plasmid vaccine administered using the Biojector device, each dose administered by separate Biojector device injections at different skin sites. These subjects will receive the same batch vaccine used in Phase 1A and 1B~Intervention: Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection"
3062192|NCT02146742|Experimental|1. ASP1707 lowest dose|
3062193|NCT02146742|Experimental|2 ASP1707 higher dose|
3062194|NCT02146742|Experimental|3. ASP1707 Highest dose|
3062195|NCT02146729|Experimental|Percutaneous Pedicle Screw Fixation|Percutaneous Pedicle Screw Fixation
3062196|NCT02146729|Active Comparator|Open Treatment|Midline posterior incision with instrumentation.
3062197|NCT02146716|No Intervention|Control|
3062198|NCT02146716|Experimental|Energetic Resonance by Cutaneous Stimulation|Energetic Resonance by Cutaneous Stimulation session in addition to standard treatment for patients with withdrawal alcohol symptoms.
3062199|NCT02146703|Experimental|gemcitabine and S-1|
3062200|NCT02146690|Other|osteopathic manipulative treatment|newborns will receive osteopathic manipulative evaluation and treatment during the entire period of hospitalization plus usual care
3062201|NCT02146690|Other|sham|newborns will receive sham treatment for the entire period of hospitalization plus usual care
3062202|NCT02146690|Other|usual care|newborns allocated in the usual care arm will receive standard care only
3062203|NCT02146677|Other|Sham|newborns will be osteopathically evaluated and softly touched
3062204|NCT02146677|Other|Usual care|newborns will be undergone usual routine neonatology care
3062205|NCT02146677|Other|OMT|newborns will receive osteopathic evaluation and treatment according to international guidelines. Osteopathic treatment use will be indirect techniques.
3062206|NCT02146664|Experimental|DLBS1033|DLBS1033 enteric-coated tablet is administered at the dose of 490 mg, one tablet three times daily, everyday for eight weeks of study period
3062207|NCT02146664|Placebo Comparator|Placebo|Placebo is administered one tablet three times daily, everyday for eight weeks of study period
3062208|NCT02146651|Experimental|BioChaperone insulin lispro 0.2U/Kg|BioChaperone insulin lispro 0.2U/Kg
3062209|NCT02146651|Experimental|BioChaperone insulin lispro 0.1U/Kg|BioChaperone insulin lispro 0.1U/Kg
3062210|NCT02146651|Experimental|BioChaperone insulin lispro 0.4U/Kg|BioChaperone insulin lispro 0.4U/Kg
3062211|NCT02146651|Active Comparator|Humalog® 0.2U/Kg|Humalog® 0.2U/Kg
3062212|NCT02146638|Active Comparator|Morphine|Patients received morphine 0.02 mg/Kg/h infused at 2 ml/h for 24 hours. The infusion contained morphine and saline.
3062213|NCT02146638|Experimental|Fentanyl|Patients received Fentanyl 0.3 mcg/Kg/h infused at 2 ml/h for 24 hours. The infusion contained morphine and saline.
3062214|NCT02146625|Experimental|Dose level 1 of CJ-40002|"Single dose~8 volunteers will be administered dose level 1 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
3062215|NCT02146625|Experimental|Dose level 2 of CJ-40002|"Single dose~8 volunteers will be administered dose level 2 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
3062216|NCT02146625|Experimental|Dose level 3 of CJ-40002|"Single dose~8 volunteers will be administered dose level 3 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
3062217|NCT02146625|Experimental|Dose level 4 of CJ-40002|"Single dose~8 volunteers will be administered dose level 4 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
3062218|NCT02146625|Experimental|Dose level 5 of CJ-40002|"Single dose~8 volunteers will be administered dose level 5 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
3062219|NCT02146612||Group Receiving Supplement|Amino acid supplement group
3062220|NCT02146599||Pseudophakic|
3062221|NCT02146586||Dystrophinopathies|
3062222|NCT02146586||Gold Standard Clinical Evaluators (GS-CEs)|
3062223|NCT02146586||Sites Clinical Evaluators (CEs)|
3062224|NCT02146573|Experimental|CCI Provider for Parent-patient dyad|Parents and patients are randomly assigned to a Continuity Care Intensivist (CCI) Provider who has received specialized communication training. The parent-patient dyad will receive standardized care from the CCI throughout their time in the PICU in addition to being assigned a rotating physician of record.
3062225|NCT02146573|No Intervention|Usual Care for Parent-patient dyad|Patients and parents randomly assigned to usual care in the PICU which includes the rotation of the physician of record approximately every 7 days. There is no standardized process by which patients may be assigned a primary attending who would follow them throughout their stay. In the usual care arm it may never happen that they are assigned a primary intensivist, regardless of the length of their hospitalization.
3062226|NCT02146547|Active Comparator|aripiprazole oral|the recommended starting dose for aripiprazole is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals.Aripiprazole is effective in a dose range of 10 to 30 mg/day.
3062227|NCT02146547|Active Comparator|Aripiprazole depot|"The recommended starting and maintenance dose of aripiprazole depot is 400 mg. Titration of the dose of this medicinal product is not required. It should be administered once monthly as a single injection (no sooner than 26 days after the previous injection).~After the first injection, treatment with 10 mg to 20 mg oral aripiprazole should be continued for 14 consecutive days to maintain therapeutic aripiprazole concentrations during initiation of therapy.~If there are adverse reactions with the 400 mg dosage, reduction of the dose to 300 mg once monthly should be considered."
3062228|NCT02146547|Active Comparator|Paliperidone|The recommended dose of paliperidone for the treatment of schizophrenia is 6 mg once daily, administered in the morning. Initial dose titration is not required. Some patients may benefit from lower or higher doses within the recommended range of 3 mg to 12 mg once daily. Dosage adjustment, if indicated, should occur only after clinical reassessment. When dose increases are indicated, increments of 3 mg/day are recommended and generally should occur at intervals of more than 5 days.
3062230|NCT02146534|Experimental|fampridine|extended release fampridine 10mg BID PO for 14 weeks
3090450|NCT01956292||Intraparenchimal cerebral haemorrhage|
3062233|NCT02146508|Experimental|Endoscopic treatment|Participants undergo upper GI endoscopy with endoscopic mucosal resection (EMR) and/or radiofrequency ablation (RFA) of esophageal squamous dysplasia (ESD). After initial therapy participants undergo repeat endoscopy every 3 months for a year, with re-biopsy and re-treatment of residual ESD as appropriate.
3062234|NCT02146495|Active Comparator|Amygdala EEG-NF|Amygdala activity based EEG-NF
3062235|NCT02146495|Placebo Comparator|Sham EEG-NF|Sham EEG-NF
3062236|NCT02146495|No Intervention|Change in drug therapy|Pain and sleep quality measured after a change in drug therapy performed by the treating physician irrespective of the study - an observational arm
3062237|NCT02146495|Active Comparator|A/T EEG-NF|EEG-NF based on alpha/Theta ratio
3062238|NCT02146482|No Intervention|Control|Did not receive an intervention during the active portion of the study (i.e. 12 weeks). After the active portion of the study, this group was given a sit-stand computer workstation.
3062239|NCT02146482|Experimental|Sit-stand computer workstation|Given a sit-stand computer workstation to use at their place of work
3062240|NCT02146469|Experimental|None varicella vaccine history|2 doses with an 3 months interval
3062241|NCT02146469|Experimental|1 year after first dose|A second dose with an 1 year interval
3062242|NCT02146469|Experimental|3 years after first dose|A second dose with an 3 year interval
3062243|NCT02146469|Experimental|5 years after first dose|A second dose with an 5 year interval
3062244|NCT02146469|Experimental|Testing group for conbined immunization|1 dose Varicella vaccine and 1 dose MMR given at the same time
3062245|NCT02146469|Placebo Comparator|Control group for conbined immunization|1 dose MMR
3062246|NCT02146456|No Intervention|Colloid|During the operation, Lactate Ringer's solution is used as the maintenance fluid, and colloid is infused for the compensation of the intraoperative blood loss.
3062247|NCT02146456|Experimental|Tranexamic acid|"During the operation, Lactate Ringer's solution is used as the maintenance fluid, and colloid is infused for the compensation of the intraoperative blood loss.~In addition, 1 g of tranexamic acid in 100 ml normal saline is administered intravenously over 30 min after finishing the procedure of hip implant insertion."
3062248|NCT02146443|Active Comparator|Baseline|Completion of the star shaped manual dexterity test, five rounds clockwise and five rounds counter clockwise without any intervention. Time and number of errors are recorded. Measurement of static arm strength with the stretched arm test. test subject is asked to hold a 2.5 kg weight in stretched arm for as long as possible. Maximum endurance time is recorded.
3062249|NCT02146443|Active Comparator|Fatigue|Prior to completion of the star shaped manual dexterity test, the test subject is asked to stand up still and hold a 2.5-kg weight with the dominant arm fully extended as long as possible without moving. Maximum endurance time is recorded. After this, the test subject completes the the star shaped manual dexterity test and time and number of errors are recorded.
3062250|NCT02146443|Active Comparator|Stress|During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test. Completion time and number of errors are recorded.
3062251|NCT02146443|Active Comparator|Fatigue and Stress|The test subject will be fatigued prior to the test (as detailed in the fatigue arm), and asked to identify cards during completion of the star shaped manual dexterity test (as detailed in the stress arm). Completion time and number of errors are recorded.
3062252|NCT02146430|Experimental|DS-5565 QD|Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening
3062253|NCT02146430|Experimental|DS-5565 BID|Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)
3062254|NCT02146430|Active Comparator|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
3062255|NCT02146430|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule BID
3062256|NCT02146417|Active Comparator|Normal pressure pneumoperitoneum & deep neuromuscular block|Normal pressure pneumoperitoneum
3062257|NCT02146417|Experimental|Low pressure pneumoperitoneum & deep neuromuscular block|Low pressure pneumoperitoneum
3062258|NCT02146404|Active Comparator|Euglycemia|Plasma glucose levels will be clamped at a constant value of ~5.0 mmol/l
3062259|NCT02146404|Experimental|Hypoglycemia|Plasma glucose levels will be clamped at a stable value of ~3.0 mmol/l
3062260|NCT02146391|Experimental|Androxal 25 mg|
3062261|NCT02146378||Vyndaqel|
3062262|NCT02146365||PATH-wSP 300 + Booster|2 doses of PATH-wSP 300 mcg + Pentavac PFS Booster + Synflorix (3 separate injections) 8 weeks apart
3062263|NCT02146365||PATH-wSP 600 + Booster|2 doses of PATH-wSP 600 mcg + Pentavac PFS booster + Synflorix (3 separate injections) 8 weeks apart
3062264|NCT02146365||PATH-wSP 300|2 doses of PATH-wSP 300 mcg + 2 injections of saline (3 separate injections) 8 weeks apart
3062265|NCT02146365||PATH-wSP 600|2 doses of PATH-wSP 600 mcg + 2 injections of saline (3 separate injections) 8 weeks apart
3062266|NCT02146365||Booster control|1 dose of Pentavac PFS booster + 1 injection Synflorix and 1 injection of saline (3 separate injections) followed 8 weeks later by 3 injections of saline
3062267|NCT02146365||PCV primed only|a group of toddlers who were not included in the VAC-010 study and who have not received either Pentavac PFS boost or Synflorix.
3062268|NCT02146352|Experimental|Treatment|AXIOS Stent with Electrocautery Enhanced Delivery System
3062269|NCT02146339|Experimental|Unfortified-3g-5g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
3062270|NCT02146339|Experimental|Unfortified-5g-3g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
3062271|NCT02146339|Experimental|3g-5g milk polar lipid fortified-unfortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
3090451|NCT01956279|Experimental|Arm 1|Pregnenolone
3062272|NCT02146339|Other|3g-Unfortified-5g milk polar lipid fortified cheese product|"Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
3062273|NCT02146339|Experimental|5g-unfortified-3g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
3062274|NCT02146339|Other|5g-3g milk polar lipid fortified-unfortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
3062275|NCT02146326|Active Comparator|Motivational Interviewing-Mental Health Staff|
3062276|NCT02146326|Active Comparator|BREATHE-Mental Health Staff|
3062277|NCT02146326|Active Comparator|Motivational Interviewing-Clients|
3062278|NCT02146326|Active Comparator|BREATHE-Clients|
3062279|NCT02146313|Experimental|Dose-escalation Cohort|DMUC4064A will be administered to participants at a starting dose of 1.0 milligram per kilogram (mg/kg) by IV infusion q3w and would be monitored for DLTs for 21 days after first infusion of Cycle 1 (cycle length=21 days).
3062280|NCT02146313|Experimental|Platinum-resistant Ovarian Cancer Dose-expansion Cohort|Platinum-resistant Ovarian Cancer participants will be administered with the identified RP2D during the Dose-escalation of DMUC4064A q3w IV for up to until disease progression or death, whichever occurs first.
3062281|NCT02146313|Experimental|Unresectable Pancreatic Cancer Dose-expansion Cohort|Unresectable pancreatic cancer participants will be administered with the identified RP2D during the dose-escalation of DMUC4064A q3w IV for up to until disease progression or death, whichever occurs first.
3062282|NCT02146300|Experimental|Allergen and xylometatsolin|Two separate exposure sessions: 1) nasal birch pollen exposure 2) nasal xylometazoline exposure
3062283|NCT02146287|Active Comparator|Early Cycled Light|Infants received day night cycling of light on a 12-hour on and 12-hour off basis beginning at 28 weeks PMA
3062284|NCT02146287|Active Comparator|Late Cycled Light|Infants received day night cycling of light on a 12-hour on and 12-hour off basis beginning at 36 weeks PMA
3062285|NCT02146274||Ischemic Stroke Patients|Patients who have had an ischemic stroke that are hospitalized in an acute-care setting.
3062286|NCT02146261|Experimental|1|Subcutaneous administration of E6011 50 mg
3062287|NCT02146261|Experimental|2|Subcutaneous administration of E6011 100 mg
3062288|NCT02146261|Experimental|3|Subcutaneous administration of E6011 200 mg
3062289|NCT02146261|Experimental|4|Subcutaneous administration of E6011 400 mg
3062290|NCT02146261|Placebo Comparator|5|Subcutaneous administration of placebo
3062291|NCT02146248|Experimental|HSG Studies|"Women will be given combined oral contraceptives and Depo-medroxyprogesterone acetate (DepoProvera®).~2 HSG studies will be done prior to hormonal treatment, 1 after the pill treatment, and depending on whether the tubes appear patent, 1 more after the depoProvera treatment, and a final HSG after another 2 weeks on the pill."
3062292|NCT02146235|Experimental|Treatment Group - Music Therapy|The experimental group participates in once weekly group music therapy session for 6 weeks using playing of simple wind instruments, singing, and music visualization. The Music therapy session lasts 45 min. and encourages patients to use breathing techniques to achieve a relaxation response. Extructured techniques involving singing, music improvisation supports breath pattens and provides supporting coping styles. The use of wind instruments involves a focus of breathing efficiently and elongating the exhalation to prolong musical tones and transferring breath control. Music Visualization involving deep breathing techniques provides optimal mind-body connection, influences breathing rhythms through more indirect means while reducing stress, accessing altered states and encourages healing imagery.
3062293|NCT02146235|No Intervention|Standard Pulmonary Rehabilitation|"Pulmonary rehabilitation is a program to people with chronic lung diseases like COPD, emphysema, and chronic bronchitis lead full, satisfying lives and restore them to their highest functional capacity. Pulmonary rehab is aimed to improve quality of life by:~Decreasing respiratory symptoms and complications Encouraging self-management and control over daily functioning Improving physical conditioning and exercise performance Improving emotional well-being Reducing hospitalizations~Pulmonary rehab programs include:~Medical management Exercise Breathing retraining Education Emotional support Nutrition counseling"
3062294|NCT02146222|Experimental|Arm I (high dose X-82, docetaxel)|Patients receive high dose VEGFR/PDGFR dual kinase inhibitor X-82 PO QD on days 2-15. Beginning course 2, patients also receive docetaxel IV over 60 minutes on day 1.
3062295|NCT02146222|Experimental|Arm II (low dose X-82, docetaxel)|Patients receive low dose VEGFR/PDGFR dual kinase inhibitor X-82 PO QD on days 2-15 and docetaxel IV as in Arm I.
3062296|NCT02146209|Experimental|Test Product Formula A|Metronidazole benzoate
3062297|NCT02146209|Active Comparator|Reference Product Formula B|Flagyl 125 mg/5 ml oral suspension
3062298|NCT02146209|Active Comparator|Reference Product Formula C|Flagyl 400 mg Tablets
3062299|NCT02146196|Experimental|Heart failure, robotic assisted training|4 weeks robotic assisted training with the Lokomat®
3062300|NCT02146196|Experimental|Post cardiac surgery|One week robotic assisted gait training with the Lokomat®
3062301|NCT02146183|Placebo Comparator|placebo / Corn starch|Carbohydrate-containing composition that comprises 2 g carbohydrate per kg of body weight. This composition will be 500 mg placebo starch corn.
3062302|NCT02146183|Active Comparator|Carbohydrate steviol glycosides|500 mg steviol glycosides.
3062303|NCT02146170||Single group|Patients with histologically or cytologically confirmed SCLC, SCLC, ESCC, PNET, and TET
3062304|NCT02146157|Active Comparator|herb and mineral combination product|Subjects will consume 3 herb and mineral combination product softgels daily, 1 softgel immediately before each of the 3 largest meals, throughout the 12-week supplementation period.
3062305|NCT02146157|Placebo Comparator|placebo|Subjects will consume 3 softgels daily, 1 softgel immediately before each of the 3 largest meals, throughout the 12-week supplementation period
3062306|NCT02146144|No Intervention|no peeling|where the ILM peeling will not be made
3062307|NCT02146144|Active Comparator|active peeling|where the ILM peeling will be made
3062308|NCT02146131|Active Comparator|Standard FB with fluoroscopy|Administration of moderate or deep sedation, introduction of standard adult bronchoscope into the airway. Following application of topical anesthesia on vocal cord, trachea, bronchoscope is advanced distally under direct visualization. Localization of the lesion using fluoroscopy followed by the acquisition of pathologic and cytologic specimens using standard bronchial brush and standard transbronchial biopsy forceps. Evaluation of acquired samples for pathology. Performance of a portable chest X-ray to look for pneumothorax (PTX).
3062309|NCT02146131|Active Comparator|R-EBUS with ultrathin bronchoscope|"Administration of moderate or deep sedation, introduction of ultrathin bronchoscope into the airway. Following application of topical anesthesia on vocal cord, trachea, bronchoscope is advanced distally under direct visualization. Attempt to definitively locate the lesion with mechanical R-EBUS probe.~Acquisition of pathologic and cytologic specimens using standard bronchial brush and standard transbronchial biopsy forceps. Performance of a portable chest X-ray to look for PTX."
3062310|NCT02146118|Experimental|Erlotinib and Silibin|
3062311|NCT02146105|Experimental|Yoga For Knee Osteoarthritis|An tailored arthritis-specific yoga program for women with knee osteoarthritis with the aim of increasing leg strength and alleviating knee pain related to the disease.
3062312|NCT02146092|Active Comparator|Standard physiotherapy|Standard physiotherapy includes routine physiotherapy care as per current institutional standards. This consists of two daily visits by the physiotherapist. During the visits, the patient will be taught deep breathing and will be instructed to practice it 10 times every hour. They are also shown shoulder movements and lung expansion exercises. They will receive a sheet summarizing the exercises for future reference. The patient is discharged from physiotherapy when they are ambulatory, on room air, and able to clear their respiratory secretions independently, although they will be asked to continue the exercises on their own until 30 days from surgery.
3062313|NCT02146092|Experimental|Incentive Spirometry|"Patients in the Incentive Spirometry arm will receive standard physiotherapy care in addition to training and use of an incentive spirometer. The physiotherapy care includes routine care as per current institutional standards.~They will also receive an incentive spirometer on the first postoperative day and will be taught how to use it with an accompanying instructional sheet for later reference. Teaching will emphasize slow deep breathing, sustained vacuum pressure, and gradual increase in difficulty. Patients will be instructed to use the spirometer 10 times every hour until 30 days after surgery."
3062314|NCT02146079|Experimental|Semaglutide 0.5 mg|Dose-escalation trial
3062315|NCT02146079|Placebo Comparator|Semaglutide placebo 0.5 mg|
3062316|NCT02146079|Experimental|Semaglutide 1.0 mg|Dose-escalation trial
3062317|NCT02146079|Placebo Comparator|Semaglutide placebo 1.0 mg|
3062318|NCT02146053|Active Comparator|Ferrous sulfate|ferrous sulfate taken at mealtimes twice daily during 1 week of the treatment period.
3062319|NCT02146053|Placebo Comparator|Placebo|placebo taken at mealtimes twice daily during 1 week of the treatment period.
3062320|NCT02146027|Experimental|Fermented Milk Drink Yakult 40|"Lactobacillus casei Shirota, contained in the Fermented Milk Drink Yakult 40~Once daily Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10^8 CFU/g). Intervention will be used for 12 weeks."
3062321|NCT02146027|Placebo Comparator|Placebo|"The placebo would be an analogous product without Live Lactic Bacteria (Lactobacillus casei Shirota) presented in the same bottle and similar flavor.~Both, Yakult 40 and placebo should be stored refrigerated between 1° and 10°C and"
3062322|NCT02146014|Experimental|Transcranial Direct Current Stimulation|These subjects will receive real transcranial direct current stimulation.
3062323|NCT02146014|Placebo Comparator|Sham tDCS|These subjects will receive sham transcranial direct current stimulation (placebo)
3062324|NCT02146001|Active Comparator|Moderate-to-vigorous activity group|This group will target achieving the current recommendations for physical activity in older adults. This is 150 minutes of moderate-to-vigorous activity per week.
3062325|NCT02146001|Experimental|Reducing sedentary behavior group|This group will target a 60 minute per day reduction in sedentary behavior using an objective activity monitor.
3062326|NCT02145988|Experimental|DLBS1033|DLBS1033 tablet is administered at the dose of 490 mg, one tablet three times daily, every day for twelve weeks of study period
3062327|NCT02145988|Placebo Comparator|Placebo|Placebo tablet is administered one tablet three times daily, every day for twelve weeks of study period
3062328|NCT02145975|Experimental|Fentanyl|"Procedure: Fentanyl for rescue of acute postoperative pain in the postanesthesia care unit~Intervention:~The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized."
3062329|NCT02145975|Active Comparator|Morphine|"Procedure: Morphine for rescue of acute postoperative pain in the postanesthesia care unit~Intervention:~The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized."
3062330|NCT02145962|Active Comparator|Forearm tissue exposure with ELF-MF|This study arm should include subjects with diabetic foot ulcers recruited at the medical services site of the Autonomous University of Nuevo Leon, Monterrey, Mexico. These study patients should receive treatment in the forearm region.
3062331|NCT02145962|Active Comparator|Thorax tissue exposure with ELF-MF|This study arm should include subjects with diabetic foot ulcers recruited at the IMSS Regional General Hospital N. 1 and Servicios de Salud de Morelos, Cuernavaca, Mexico. These study patients received treatment in the thorax region.
3062399|NCT02145468|Experimental|Losmapimod|Losmapimod 7.5 mg twice daily oral tablet
3062400|NCT02145468|Placebo Comparator|Placebo|Placebo twice daily oral tablet
3062332|NCT02145949|Experimental|Essential Amino Acids (EAA)|"Aim 1: Twice-daily ingestion of 20 g of EAA for 1 wk before through 6 wk after TKA.~Supplement composition for the EAAs: histidine, 2.2 g (11% of total); isoleucine, 2.0 g (10%); leucine, 3.6 g (18%); lysine, 3.2 g (16%); methionine, 0.6 g (3%); phenylalanine, 3.2 g (16%); threonine, 2.8 g (14%); and valine, 2.4 g (12%).~Aim 2: Twice-daily ingestion of 23 g of EAA for 1 wk before through 6 wk after TKA.~Supplement composition for the EAAs: histidine, 2.2 g (9% of total); isoleucine, 2.0 g (9%); leucine, 6.8 g (29%); lysine, 3.2 g (14%); methionine, 0.6 g (3%); phenylalanine, 3.2 g (14%); threonine, 2.8 g (12%); and valine, 2.4 g (10%)."
3062333|NCT02145949|Placebo Comparator|Placebo (Alanine)|"Aim 1: Twice-daily ingestion of 20 g of Alanine (Non-essential amino acid) for 1 wk before through 6 wk after TKA.~The placebo supplement consists of 20 g (100%) alanine.~Aim 2: Twice-daily ingestion of 23 g of Alanine (Non-essential amino acid) for 1 wk before through 6 wk after TKA.~The placebo supplement consists of 23 g (100%) alanine."
3062334|NCT02145936|Experimental|oleic acid diet|Participants are provided with meals enriched in oleic acid (18:1)
3062335|NCT02145936|Experimental|palmitic acid diet|Participants are provided with meals enriched in palmitic acid (18:0)
3062336|NCT02145936|Experimental|stearic acid diet|Participants are provided with meals enriched in stearic acid (18:0)
3062337|NCT02145923|Other|allogeneic MMSCs infusion|Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent high-dose chemotherapy. After finalization of high-dose chemotherapy subjects will receive bone marrow derived allogeneic multipotent mesenchymal stromal cells intravenous infusion two hours prior to autologous peripheral blood cells infusion.
3062338|NCT02145910|Experimental|WBRT + Vemurafenib|Patients undergo WBRT once daily (QD) for 10 doses
3062339|NCT02145910|Experimental|SRS + Vemurafenib|Patients undergo SRS (gamma knife, tomotherapy, cyberknife, or megavoltage LINAC radiation therapy) on day 1
3062340|NCT02145897|Experimental|Autologous Stromal Vascular Fraction|single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
3062341|NCT02145897|Experimental|Autologous Adipose Derived MSCs|One dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
3062342|NCT02145897|Active Comparator|Control|
3062343|NCT02145884|Experimental|timolol maleate 0.5% gel|timolol gel 1 to 2 drops twice a day to lesions for 4 months
3062344|NCT02145871|Active Comparator|Standard fluid management|The non-intervention group will receive maintenance crystalloid fluid at 10cc/kg/h. Blood loss will be replaced 1:1 with albumin. Transfusion will follow transfusion criteria. Fluid management will not be dependent on the EV1000
3062345|NCT02145871|Experimental|Goal directed fluid therapy (GDT)|In the GDT arm, patient's SV will be optimized before induction with crystalloid boluses prior to induction of general anesthesia. The GDT arm will have fluid therapy guided by the Edwards EV1000-clinical platform and maintenance crystalloid fluid will be 3cc/kg/h. During the surgical procedure when SVV rises above 12 an albumin bolus will be administered at 250 ml increments until the SVV falls below 8. Transfusion will follow transfusion criteria.
3062346|NCT02145845|Experimental|Treatment|Injectable SIS
3062347|NCT02145832|Experimental|Fluconazole|"Fluconazole Kabi, Fresenius 2mg/ml~Fluconazole will be administered at a loading dose of 25 mg/kg on the first day and followed by a maintenance dose of 12 mg/kg or 20 mg/kg once daily, depending of corrected gestational age (GA) at the beginning of treatment:~12 mg/kg/day for neonates corrected GA (GA + postnatal age) < 30 weeks~20 mg/kg/day for neonates corrected GA (GA + postnatal age) ≥ 30 weeks~The infusion will last two hours."
3062348|NCT02145832|Experimental|Micafungin|"Mycamine 50mg - 10 mg/mL of micafungin~Micafungin will be administered as a loading dose of 15 mg/kg on the first day of treatment and followed by a maintenance dose of 10 mg/kg once daily.~The infusion will last two hours."
3062349|NCT02145819|Placebo Comparator|A: spontaneous LH peak|In group A, embryos are thawed 4 days after LH surge, with a re-evaluation and transfer 5 days after LH surge.
3062350|NCT02145819|Active Comparator|B: hCG|In group B, embryos are thawed 5 days after hCG administration, with a re-evaluation and transfer 6 days after hCG.
3062351|NCT02145793|Active Comparator|ADHD Group Curriculum|Participants assigned to the group visit intervention agree to participate in 5 group visits every 3 months rather than individual ADHD follow-up visits to the clinic. Parents and children participate in separate but simultaneously run groups. Group portion is 60 minutes and then parent-child dyads complete individual visits for medication titration and physical exam.
3062352|NCT02145793|No Intervention|Control|Participants continue to go to the clinic for 5 routine ADHD follow-up visits to the clinic every 3 months as usual clinical protocol.
3062353|NCT02145780|Experimental|2g of grape polyphenol extract supplement|Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
3062354|NCT02145780|Placebo Comparator|2g of placebo (lactose)|Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
3062355|NCT02145767|Experimental|Progesterone|Progesterone 200mg suppository administered vaginally at bedtime until 34 completed weeks of pregnancy.
3062356|NCT02145767|Placebo Comparator|Placebo|Similar appearing suppository containing vehicle alone administered vaginally at bedtime until 34 completed weeks of pregnancy.
3062357|NCT02145754|Active Comparator|MKP media versus BSK-H media|one half of skin specimen obtained from erythema migrans patients was cultivated for Borrelia burgdorferi sensu lato in MKP media and the other half in BSK-H media
3062358|NCT02145741|Experimental|BI 836845|Patients to receive low, middle, and high doses of BI 836845 intravenously (IV)
3062359|NCT02145728|Experimental|Individual Cognitive Functional Therapy|The intervention being tested has four main components: (1) a cognitive component, for each patient, their vicious cycle of pain will outlined in a diagram based on their findings from the examination and the Orebro Musculoskeletal Pain Screening Questionnaire; (2) specific movement exercises designed to normalize maladaptive movement behaviours; (3) targeted functional integration of activities in their daily life previously, reported to be avoided or provocative by the patient; and (4) a physical activity and lifestyle programme.
3062401|NCT02145455|Active Comparator|Mechanical alignment|Patients in this arm will have the Unity Total Knee Replacement System implanted using a surgical technique that utilizes mechanical alignment via measured resection to establish knee alignment.
3062360|NCT02145728|Active Comparator|Group Exercise Classes|6 classes will take place in total. The class has 3 components each week. First, a 30 minute talk and discussion on chronic pain, and some tips for participants. Second, a 40 minute exercise circuit, involving aerobic exercise, and gentle stretching and strengthening exercises. Finally, a 5 minute relaxation/mindfulness session will take place at the end. The total time involved is approximately 1 hour and 15 minutes.
3062361|NCT02145715|Experimental|Velcade, Thalidomide, Dexamethasone (VTD) + Panobinostat|"Up to 16 cycles of VTD+Panobinostat followed by panobinostat maintenance for 1 year or until disease progression.~Induction - Cycles 1-16 (21-day cycle)~Velcade: 1.3mg/m2 (subcutaneous) on days 1 and 8~Thalidomide: 100mg (PO)on days 1 -21~Dexamethasone: 20 mg (PO) on days 1, 2, 8 and 9~Panobinostat: 10mg, 15mg or 20mg days 1, 3, 5, 8, 10 and 12 Dose depends on cohort entry at registration during the dose escalation phase. The recommended dose will be used during the expansion phase.~Panobinostat monotherapy maintenance for 1 year. Panobinostat will be given at the same dose as the recommended dose during expansion phase"
3062362|NCT02145702|Experimental|Exercise Group|Subjects randomized to this group will start 12 weeks of supervised aerobic exercise after baseline testing.
3062363|NCT02145702|Experimental|Control Group|Subjects randomized to this group will continue with 12 weeks of Standard Care. After 12 weeks, the subjects will cross over to the exercise arm and undergo baseline testing again and then start 12 weeks of exercise intervention.
3062364|NCT02145689|Experimental|onabotulinumtoxinA Dose 1|Up to 4 treatments of onabotulinumtoxinA Dose 1 injected into muscles of the study limb on fulfillment of the retreatment criteria.
3062365|NCT02145689|Experimental|onabotulinumtoxinA Dose 2|Up to 4 treatments of onabotulinumtoxinA Dose 2 injected into muscles of the study limb on fulfillment of the retreatment criteria.
3062366|NCT02145676|Experimental|onabotulinumtoxinA 500U|OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1.
3062367|NCT02145676|Experimental|onabotulinumtoxinA 300U|OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1.
3062368|NCT02145676|Placebo Comparator|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
3062369|NCT02145650||All Participants|Patients with a diagnosis of CP, MS, Stroke, SCI, or TBI will be evaluated for spasticity by their healthcare provider. Patients diagnosed with spasticity requiring treatment will be enrolled in the study. There is no intervention administered in this study.
3062370|NCT02145637|Experimental|Afatinib plus Ruxolitinib combination (single arm)|
3062371|NCT02145624|Active Comparator|Repevax|Repevax in pregnancy
3062372|NCT02145624|Active Comparator|Boostrix-IPV|Boostrix-IPV in pregnancy
3062373|NCT02145624|No Intervention|unvaccinated|unvaccinated mothers
3062374|NCT02145611|Active Comparator|vildagliptin|Vildagliptin: Dosage: 100 mg/day; Duration: 12 weeks
3062375|NCT02145611|Active Comparator|glibenclamide|Glibenclamide: Dosage: 5 mg to 20 mg; Duration: 12 weeks
3062376|NCT02145598|Experimental|Lenalidomide|Lenalidomide 10mg/day
3062377|NCT02145598|Placebo Comparator|Placebo|Placebo
3062378|NCT02145585||Robotic pharmacological system|Robotic pharmacological system/Automated anesthesia delivery system
3062379|NCT02145572||Obese adolescents with type 2 diabetes|
3062380|NCT02145572||Obese adolescents without diabetes|
3062381|NCT02145572||Healthy non-obese adolescents|
3062382|NCT02145559|Experimental|Metformin XR|All eligible patients with histologically-confirmed advanced solid tumors will be started on sirolimus (3 mg daily) alone for the first 7 days. On day 8, patients will recieve metformin XR (500 mg daily with the evening meal)(through day 21). On day 15, patients randomized to metformin XR will have their dose increased to 1000 mg daily if there is no grade ≥ 2 toxicity due to metformin XR. Patients who develop grade 2 toxicity due to metformin will be maintained on metformin XR 500 mg daily for the rest of the study, while patients who develop > grade 2 toxicity will be taken off study. From day 22 onwards, all patients will be on combination of sirolimus and metformin.
3062383|NCT02145559|Active Comparator|Delayed Metformin|All eligible patients with histologically-confirmed advanced solid tumors will be started on sirolimus (3 mg daily) alone for the first 7 days. On day 8, patients will be randomized to receive no metformin for two weeks (through day 21). From day 22 onwards, all patients will be on combination of sirolimus and metformin. Patients who were initially not randomized to metformin XR will begin taking it at 500 mg daily with an evening meal and titrated up to 1000 mg daily after one week, as above. Each cycle will be 4 weeks.
3062384|NCT02145546|Experimental|Amiodarone|Patient will take Amiodarone orally
3062385|NCT02145546|Experimental|Sotalol|Patients will take sotalol orally
3062386|NCT02145546|Experimental|Propafenone|Patients will take propafenone orally
3062387|NCT02145546|No Intervention|Control|Patients will take no antiarrhythmic drugs except β-blocker
3062388|NCT02145533||Group I|patient with ruptured aneurysms
3062389|NCT02145533||Group II|patients with non-ruptured aneurysms
3062390|NCT02145533||Group III|Healthy volunteers
3062391|NCT02145520|Experimental|Magnesium sulfate|Magnesium sulfate. Single dose intravenous over one hour.
3062392|NCT02145520|Placebo Comparator|placebo|"Treatment will be delivered to enrolled patients as currently practice in PEC (Epinephrine nebulization +5%hypertonic saline with/without dexamethasone).~•All patients will be randomized to receive either Magnesium sulfate over 1 hour or placebo.•Bronchiolitis severity score (BSS) will be recorded at 0, 4, 8, 12, 16,20,24,36,48,60,72 hours, and on discharge."
3062393|NCT02145507|Other|Arm 1: Room Temperature Storage/Filtration|In vitro whole blood storage, leukoreduction and processing of donated whole blood.
3062394|NCT02145507|Other|Arm 2 : Cold storage|In vitro analysis of whole blood following refrigerated storage for > 66 hours prior to leukoreduction and subsequent processing of packed red blood cells.
3062395|NCT02145494|Experimental|Treatment|Radiotherapy
3062396|NCT02145481|No Intervention|Survey development|Patients with coronary artery disease will be given a survey to complete assessing their knowledge, communication with physicians, involvement, and treatment preferences after completing the treatment decision-making process.
3062397|NCT02145481|Experimental|Decision Aid|Patients with stable coronary artery disease will be given a decision aid to review prior to making a treatment decision.
3062398|NCT02145481|Active Comparator|CAD Education|Patient with coronary artery disease will be given a general educational handout on coronary artery disease.
3062402|NCT02145455|Active Comparator|Anatomic alignment|Patients in this arm will have the Unity Total Knee Replacement System implanted using a surgical technique that utilizes anatomic alignment via ligament balancing with the tibial cut perpendicular to the tibial anatomic axis.
3062403|NCT02145442|Experimental|Obex|Obex®, two oral sachets daily during three months.
3062404|NCT02145429|Experimental|problem solving therapy + Behavioral Treatment of Insomnia|Problem Solving Therapy + Brief Behavioral Treatment of Insomnia as needed
3062405|NCT02145429|No Intervention|Enhanced Usual Care|Care as usual with scheduled assessments of clinical status
3062406|NCT02145403|Experimental|Carfilzomib|Carfilzomib will be administered IV over 30 minutes, starting at dose level 1 (20 mg/m2 IV) on Day +1, +2, +6 and +7.
3062407|NCT02145390|Experimental|TURBT, NAC and Chemoradiation|"Transurethral Resection of the Bladder Tumor & Cystoscopy (TURBT);~Neoadjuvant Chemotherapy (NAC), per standard of care: Cisplatin and Gemcitabine therapy, within 8 weeks following the TURBT and cystoscopic evaluation;~For subjects with complete response (CR): Chemoradiation within 6 weeks after post-neoadjuvant evaluation. Intensity Modulated Radiation Therapy (IMRT/VMAT); Cisplatin therapy per standard of care;~For subjects who have pT1 or worse tumor response: Radical Cystectomy, per standard of care, within 12 weeks post-neoadjuvant chemotherapy evaluation;~Expanded Prostate Cancer Index Composite Short Form 12 (EPIC SF-12);~International Prostate Symptom Score (IPSS)."
3062408|NCT02145377|Experimental|PXVX0200 10E8 then placebo|PXVX0200 10E8 on day 0; Placebo on day 14
3062409|NCT02145377|Experimental|Placebo, then PXVX0200 10E8|Placebo on day 0; PXVX0200 10E8 on day 14
3062410|NCT02145377|Experimental|PXVX0200 10E9 then Placebo|PXVX0200 10E9 on day 0; Placebo on day 14
3062411|NCT02145377|Experimental|Placebo then PXVX0200 10E9|Placebo on day 0; PXVX0200 10E9 on day 14
3062412|NCT02145377|Active Comparator|Shanchol|Two doses of Shanchol, on day 0 and day 14
3062413|NCT02145364|Experimental|Ultherapy® treatment of acne scars|Subjects receiving dual depth treatment of acne scars using the 7MHz,3.0mm and 10MHz,1.5mm transducers.
3062414|NCT02145351|Active Comparator|Pacing off|In this crossover study design, subjects will be randomized to pacing on or pacing off, and will switch to the opposite group midway through the study. They will be compared to themselves when pacing is on vs pacing off for endpoints of interest.
3062415|NCT02145351|Experimental|Pacing on|In this crossover study design, subjects will be randomized to pacing on or pacing off, and will switch to the opposite group midway through the study. They will be compared to themselves when pacing is on vs pacing off for endpoints of interest.
3062416|NCT02145338|Experimental|Antibiotic prophylaxis|Nitrofurantoin or Trimethoprim or Cefalexin. Daily antibiotic prophylaxis: nitrofurantoin 50 mg (or 100 mg dependent on participant weight), or trimethoprim 100 mg, or cefalexin 250 mg.
3062417|NCT02145338|Other|No prophylaxis|The control arm will be a strategy of no prophylaxis. Participants will self‐monitor their symptoms as usual and report to their General Practitioner if they develop symptoms and signs suggestive of UTI requiring treatment.
3062418|NCT02145325|Experimental|Expanded Tregs|Immune cells in the blood will be removed by leukopheresis procedure and stored for later manufacture of subject's Expanded Tregs cellular product. Two months following subject's kidney transplantation, subject will be given an Expanded Tregs infusion intravenously in the Northwestern Clinical Research Unit.
3062419|NCT02145312|Experimental|BYL719|BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
3062420|NCT02145299|Experimental|TruePath CTO Device|"The TruePath™ CTO Device (Boston Scientific Corporation, Natick, MA) is a new solution for intraluminal treatment of chronic total occlusions (CTO). It is the longest available crossing device (165 cm), and has a diamond-coated distal tip that can rotate at 13,000 rpm. Its profile is similar to a 0.018 guidewire, and includes a shapeable distal tip allowing 1:1 torque response. In addition, it provides audio and visual navigation during CTO crossing."
3062421|NCT02145299|Active Comparator|CROSSER CTO Device|"The CrosserTM CTO Recanalization Catheter (Crosser system) (Bard Peripheral Vascular Inc. Tempe, AZ, USA), which serves as a control in this investigation, gained U.S. FDA approval for peripheral indications in 2011. The device is similar in both design and indications to the TruePath device, with the exception that the Crosser system uses vibrational angioplasty to achieve CTO crossing."
3062422|NCT02145286|Experimental|Radiation Therapy|Stereotactic Body Radiation Therapy
3062423|NCT02145273|Experimental|Intervention|Subjects screen positive for depression and are offered a group Therapy intervention for depression: Interpersonal Psychotherapy for Depression Group.
3062424|NCT02145273|No Intervention|Control|Subjects screen positive for depression and are offered Treatment as usual: External referral.
3062425|NCT02145273|No Intervention|comparison|Subjects screen negative for depression: no referral or intervention.
3062426|NCT02145260|Active Comparator|Lower dialysate sodium|Dialysate sodium concentration of 138 mmol/L
3062427|NCT02145260|Experimental|Higher dialysate sodium|Dialysate sodium concentration of 142 mmol/L
3062428|NCT02145247|Active Comparator|Normal adult women|"Images of the both ovaries will be obtained using vaginal ultrasound and the number, size, and spatial arrangement of ovarian follicles will be noted for both ovaries in each subject.~On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~Blood samples will be obtained at T = -0.5, 0, and +24 hours.~Blood sample will be used for DNA testing to identify genes that may be associated with androgen production.~One to two weeks after hCG stimulation testing each subject will come to the CTRI for an Oral Glucose Tolerance Test (OGTT). Each subject will ingest 75 gm of a glucose solution and blood samples will be obtained at 0, 15, 30, 60, 120 and 180 minutes after the glucose load."
3062429|NCT02145247|Active Comparator|Women with PCOS|"Images of the both ovaries will be obtained using vaginal ultrasound and the number, size, and spatial arrangement of ovarian follicles will be noted for both ovaries in each subject.~On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~Blood samples will be obtained at T = -0.5, 0, and +24 hours.~Blood sample will be used for DNA testing to identify genes that may be associated with androgen production.~One to two weeks after hCG stimulation testing each subject will come to the CTRI for an Oral Glucose Tolerance Test (OGTT). Each subject will ingest 75 gm of a glucose solution and blood samples will be obtained at 0, 15, 30, 60, 120 and 180 minutes after the glucose load."
3062611|NCT02144129|No Intervention|Inactive Control Group|sedentary non-training control group
3062430|NCT02145234|Experimental|SAD Panel 1:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
3062431|NCT02145234|Experimental|SAD Panel 2:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
3062432|NCT02145234|Experimental|SAD Panel 3:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
3062433|NCT02145234|Experimental|SAD Panel 4:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
3062434|NCT02145234|Experimental|SAD Panel 5:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
3062435|NCT02145234|Experimental|MAD Panel 1:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 multiple subcutaneous administrations weekly"
3062436|NCT02145234|Experimental|MAD Panel 2:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
3062437|NCT02145234|Experimental|MAD Panel 3:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
3062438|NCT02145234|Experimental|MAD Panel 4:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
3062439|NCT02145234|Experimental|MAD Panel 5:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administration every 2 weeks~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
3062440|NCT02145234|Experimental|MAD Panel 6:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
3062441|NCT02145234|Experimental|MAD Panel 7:BMS-986089/Placebo|"BMS-986089 a single subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 a single subcutaneous administration every 2 weeks"
3062442|NCT02145221|Experimental|Music therapy|Music therapy post surgery
3062443|NCT02145221|No Intervention|No intervention|
3062444|NCT02145208|Experimental|Medi-Tate iTind|TIND System
3062445|NCT02145195|Experimental|Vitamin D (10 microgram/day)|Tablets with 10 microgram vitamin D3 (cholecalciferol) daily for 20 weeks.
3062446|NCT02145195|Experimental|Vitamin D (20 microgram/day)|Tablets with 20 microgram vitamin D3 (cholecalciferol) daily for 20 weeks.
3062447|NCT02145195|Placebo Comparator|Placebo control|Tablets with 0 microgram vitamin D daily for 20 weeks.
3062448|NCT02145182|Experimental|Active|Eculizumab will be administered by intravenous (IV) infusion over 25-45 minutes for two doses (on day of transplant then 18-24 hours later).
3062449|NCT02145182|Placebo Comparator|Placebo|Placebo will be administered by intravenous (IV) infusion over 25-45 minutes for two doses (on day of transplant then 18-24 hours later).
3062450|NCT02145169|Experimental|Nitrous Oxide arm|Patients will receive a 50/50 mixture of Oxygen and Nitrous oxide via non breather mask
3062451|NCT02145156|Experimental|Tailored intervention|Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
3062452|NCT02145156|Other|Untailored Intervention|Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
3062453|NCT02145156|Other|Usual Care|Intervention: survey-only. Participants in the usual care arm will not view any educational materials or complete the baseline survey.
3062454|NCT02145143|Experimental|thyroid cancer patients|Patients will have lesional dosimetry with 124I PET/CT performed to quantify the baseline iodine avidity of index metastatic lesion(s). Patients will then receive vemurafenib (960 mg orally BID) for about 4 weeks, after which a second 124I PET/CT will be performed. For patients in whom the second 124I PET/CT demonstrates that > or = 2000 cGy can be achieved in at least one tumor with < 300 mCi of 131I, Thyrogen-stimulated standard dosimetry & therapeutic 131I will be performed/administered concurrently with vemurafenib. The drug will then be discontinued & tumor assessments will be conducted with serial radiologic scan(s) & thyroglobulins (scans will be performed at baseline, before 131I, 3-4 months following 131I, & 6 months after 131I). Patients whose tumors fail to demonstrate adequate iodine incorporation following vemurafenib to warrant 131I therapy, the study drug will be discontinued, a final tumor assessment will be performed, & the patient will be taken off the study.
3062455|NCT02145130|Experimental|denovoDerm|Autologous tissue-engineered dermal substitute
3062456|NCT02145130|Experimental|denovoSkin|Autologous tissue-engineered dermo-epidermal skin substitute
3062457|NCT02145117|Other|MBSR Training|Mindfulness Based Stress Reduction (MBSR) Training
3062458|NCT02145104|Experimental|Arm A|cilinidpine 10mg + valsartan 160mg
3062459|NCT02145104|Experimental|Arm B|cilnidipine 5mg + valsartan 160mg
3062460|NCT02145104|Active Comparator|Arm C|valsartan 160mg
3062461|NCT02145091|Experimental|One all-day session|"Participants will complete on all-day study session with a moderately-high dose of psilocybin.~Preparation will include two days of screening, and an additional 8 hours of session preparation over at least 2 days. Follow-up will consist of an interview and MRI scan one day after the all-day session, a questionnaire follow-up 2 months after the all-day session, and a final follow-up 12-18 months after the all-day session."
3062462|NCT02145091|Experimental|Two all-day sessions|"Participants will complete two all-day study sessions, the first with placebo and the second with a moderately-high dose of psilocybin.~Preparation will include two days of screening and 8 hours of session preparation over at least 2 days, before the first all-day session. Follow-up will consist of an interview and MRI scan one day after each all-day session, a questionnaire follow-up 2 months after each all-day session, and a final follow-up 12-18 months after the second all-day session."
3062489|NCT02144870|Active Comparator|Resources activation|At first patients get informed about Tics in general. Through different exercises existing resources and skills are activated and strengthened. Feeling of self-esteem and self-respect are strengthened. Also the emotional awareness is strengthened. Relaxation methods are also introduced.
3062490|NCT02144857|Active Comparator|Anti-TNFa regimen|Etanercept 50 mg
3062463|NCT02145091|Experimental|Three all-day sessions|"Participants will complete three all-day study sessions, the first two with placebo and the third with a moderately-high dose of psilocybin. The majority of participants (over 90%) will be assigned to either one or two all-day sessions. A small minority of participants (less than 10%) will be assigned to three all-day sessions.~Preparation will include two days of screening and 8 hours of session preparation over at least 2 days, before the first all-day session. Follow-up will consist of an interview and MRI scan one day after each all-day session, a questionnaire follow-up 2 months after each all-day session, and a final follow-up 12-18 months after the third all-day session."
3062464|NCT02145091|Experimental|MRI of the acute effects of psilocybin|This is an optional arm consisting of two sessions where either placebo, a very-low dose of psilocybin, or a moderately-low dose of psilocybin will be administered. During each session, participants will undergo MRI scanning shortly after the administration of each dose. Study sessions may occur over one or two days. Participants who have previously completed an all-day session with psilocybin in this study will be eligible to volunteer for this arm.
3062465|NCT02145078|Experimental|Treatment (chemotherapy regimen)|Patients receive 1 of 4 chemotherapy regimens at the discretion of the primary oncologist following institutional guidelines, including cisplatin, carboplatin, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. After course 2, patients may continue treatment off-study at the discretion of the treating physician.
3062466|NCT02145065|Active Comparator|Plain Balloon Angioplasty|Plain Balloon Angioplasty
3062467|NCT02145065|Experimental|microcrystalline Paclitaxel Coated Balloon (PAK)|plain balloon angioplasty followed by mcPCB dilation
3062468|NCT02145052|Active Comparator|Continuous suture|0 non-looped PDS using a tapered needle starting at the superior and the inferior portions of the wound. Fascia is then approximated with at least 1cm distance from the edge of the fascia and 1cm advancement. The two sutures are then knotted in the center with 8 square knots.
3062469|NCT02145052|Active Comparator|Interrupted Suture|Using a tapered needle, 0 non-looped PDS interrupted figure of eight suture 1cm from the edge and advancing 1cm between each suture.
3062470|NCT02145039|Experimental|Haploidentical stem cell transplant|This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
3062471|NCT02145026|Experimental|Epoetin Beta|Participants will receive epoetin beta at an initial dose of 30,000 International Units (IU) per week administered subcutaneously (SC). Response will be firstly evaluated at Week 4 and the subsequent dose will be based on the response: if hemoglobin level reaches greater than or equal to (>/=)12 grams per deciliter (g/dL) at any time, epoetin beta will be discontinued until hemoglobin levels are less than or equal to (</=) 10 g/dL; if the hemoglobin level increases less than (<) 1 g/dL from screening level and hemoglobin level ˂12 g/dL, a 60,000 IU per week epoetin beta will be administered SC until Week 12; if the hemoglobin level increases >/=1 g/dL from screening level and hemoglobin level ˂12 g/dL, a 30,000 IU per week epoetin beta will be continued until Week 12.
3062472|NCT02145013||Portal hypertension|Hepatectomy
3062473|NCT02145013||No portal hypertension|Hepatectomy
3062474|NCT02145000|Experimental|Rotavirus vaccine (BRV-PV)|Live attenuated bovine-human [UK] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine (BRV-PV) contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is in lyophilized form and supplied with 2.5 ml of citrate bicarbonate buffer that is added for reconstitution just before oral administration.
3062475|NCT02145000|Placebo Comparator|Placebo|Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
3062476|NCT02144974||Patients undergoing total pelvic exenteration|Patients undergoing total pelvic exenteration for gynecological malignancies and reconstruction of the pelvic floor with a TMG flap.
3062477|NCT02144961||Ultrasound|Breast ultrasound in female patients who are post-mastectomy pursuing autologous tissue breast reconstruction surgery.
3062478|NCT02144948|Experimental|E.-coli-Nissle|10 patients will be enrolled Intervention: E.-coli-Nissle (Mutaflor), oral suspension Dose: 1 ml / day frequency: qd
3062479|NCT02144935||myelitis, transverse|Observational study with two groups or cohorts: online survey participation and in person physical examination with survey participation. The surveys can be completed by the child and parent, or if too young to participate, parent only. The survey asks about how the child is doing 3.6 and 1 year after diagnosis.
3062480|NCT02144922|Placebo Comparator|Control|Patients continue taking their antihypertensive medication alone.
3062481|NCT02144922|Active Comparator|Pitavastatin|Pitavastatin 4 mg is given to study patients after a baseline assessment and continued for 1 year without further dose titration. Patients continue taking their antihypertensive medication during the entire follow-up period.
3062482|NCT02144909|Experimental|Partners in Care with Semi-Structured Support Group|Partners in Care with Semi-Structured Support Group: participants will receive the Partners in Care intervention followed by 6 semi-structured support groups, conducted every other week for 3 months. Half of the support groups will be conducted by professionals with diabetes specific knowledge, e.g., pharmacists, physicians, nutritionists. While the other half will be conducted by the trained diabetes self-management facilitator.
3062483|NCT02144909|No Intervention|Partners in Care Standard Follow-up|Participants will receive the Partners in Care intervention followed by monthly healthy lifestyle tips related to diabetes self-management
3062484|NCT02144896|Experimental|Ankle splinting|Older adults will have one leg randomly assigned to ankle splinting for 4 weeks. The non-splinted leg will serve as the control.
3062485|NCT02144896|No Intervention|No Ankle Splinting|The non splinted leg will serve as the control
3062486|NCT02144883|Active Comparator|Materials|Self-help materials mailed to subjects home.
3062487|NCT02144883|Experimental|Telephone Counseling and Materials|Subjects received up to 9 telephone counseling calls plus self-help quit kit and 5 additional mailings
3062488|NCT02144870|Active Comparator|Habit Reversal Training|At first patients get informed about Tics in general. Then the individual Tics are specified and the tic-reaction is looked at further. The Tic-Symptoms are observed and the premonitory urge is specified. For all individual tics a specific reversal movement is developed. Relaxation methods are introduced.
3062493|NCT02144844|Experimental|Insight-Plus Cognitive Behavioral Intervention|Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
3062494|NCT02144844|No Intervention|Treatment as Usual (TAU)|Treatment as Usual (TAU) Control
3062495|NCT02144831|Active Comparator|anti-thrombotic treatment|10 days of ASA (75-325 mg) + Clopidogrel (75mg) anti-thrombotic treatment
3062496|NCT02144831|Active Comparator|anti-thrombotic|30 days of ASA (75-325 mg) + Clopidogrel (75mg) anti-thrombotic treatment
3062497|NCT02144818|Active Comparator|GnRH agonist|
3062498|NCT02144818|Active Comparator|hCG|
3062499|NCT02144818|Active Comparator|dual triggering: GnRH agonist and hCG|
3062500|NCT02144805|Active Comparator|Suturing in a single layer|The technique used for single layer to close the uterine incision following cesarean sectio
3062501|NCT02144805|Active Comparator|Suturing in two layer|The technique used for two layer technie to close the uterine incision following cesarean sectio
3062502|NCT02144792|Active Comparator|Control group (healthy persons)|Normal controls take a [11C] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
3062503|NCT02144792|Active Comparator|Patients with drug-resistant epilesy|Patients with drug-resistant epilepsy take a [11C] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
3062504|NCT02144792|Active Comparator|Patients with drug-sensitive epilepsy|Patients with drug-sensitive epilepsy take a [11C] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
3062505|NCT02144779|Active Comparator|Usual care|No treatment for this group
3062506|NCT02144779|Experimental|Assigned to palliative care team|The intervention group will be assigned to a palliative care team member that will facilitate communication and meetings between families and the medical team
3062507|NCT02144766|Experimental|Ropivacaine|caudal block with 1 ml/kg of ropivacaine 0.2%
3062508|NCT02144766|Placebo Comparator|saline|caudal block with 1 ml/kg of saline
3062509|NCT02144753|Experimental|NTX-1|NTX-1 (18 g)
3062510|NCT02144753|Active Comparator|Psyllium|psyllium (15 g)
3062511|NCT02144740|Other|NWT-03, then placebo|4 weeks 2g NWT-03 followed by placebo , separated by a 4wk wash-out period
3062512|NCT02144740|Other|Placebo, then NWT-03|4 weeks placebo followed by 2g NWT-03, separated by a 4wk wash-out period
3062513|NCT02144727|Active Comparator|D2 distal subtotal gastrectomy|D2 distal subtotal gastrectomy D2 includes Nos.1.3,4sb,4d,5,6,7,8a,9,11p,and 12a nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
3062514|NCT02144727|Experimental|D1+ distal subtotal gastrectomy|D1+ distal subtotal gastrectomy D1+ includes Nos.1,3,4sb,4d,5,6,7,8a,and 9 nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
3062515|NCT02144714|Experimental|SB5|SB5, single dose of 40 mg via subcutaneous injection (study drug)
3062516|NCT02144714|Active Comparator|EU sourced Humira®|EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
3062517|NCT02144714|Active Comparator|US sourced Humira®|US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
3062518|NCT02144701|Experimental|Arm I (Lactobacillus rhamnosus GG)|Patients receive Lactobacillus rhamnosus GG PO QD for 1 year.
3062519|NCT02144701|No Intervention|Arm II (no intervention)|Patients receive no intervention.
3062520|NCT02144688|Experimental|Change in ARVs to improve cognition|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
3062521|NCT02144675|Experimental|Arm I (choline magnesium trisalicylate and chemotherapy)|Patients receive choline magnesium trisalicylate PO every 8 hours on days 0-7, idarubicin IV on days 1-3, and cytarabine IV continuously on days 1-7.
3062522|NCT02144675|Active Comparator|Arm II (chemotherapy)|Patients receive idarubicin IV on days 1- 3 and cytarabine IV continuously on days 1-7.
3062523|NCT02144662|Experimental|Ranibizumab|Ranibizumab
3062524|NCT02144649|No Intervention|Group I (control, no juice)|Patients consume no tomato juice.
3062525|NCT02144649|Experimental|Group II (tangerine tomato juice)|Patients will consume two 5.5 oz. cans of tangerine tomato juice every day until their scheduled surgery. (approximately 4 weeks)
3062526|NCT02144649|Experimental|Group III (red tomato juice)|Patients consume two cans of red tomato juice daily until their scheduled surgery (approximately 4 weeks).
3062527|NCT02144636|Experimental|treament|herbalife protein shake along with exercise
3062528|NCT02144636|No Intervention|control|diet and exercise only
3062529|NCT02144623|Experimental|Valproate|
3062530|NCT02144610|Experimental|Gene Therapy HGF Plasmid (AMG0001)|Randomized subjects will receive 4 sets of intramuscular injections of HGF plasmid two weeks apart starting at Day 0 and again at Month 3 (first cycle) and at Month 9 and again at Month 12 (second cycle) in muscles of the affected lower limb.
3062531|NCT02144610|Placebo Comparator|Placebo|Randomized subjects will receive 4 sets of intramuscular injections of matching placebo two weeks apart starting at Day 0 and again at Month 3 (first cycle) and at Month 9 and again at Month 12 (second cycle) in muscles of the affected lower limb.
3062532|NCT02144597|Active Comparator|2-week LCD|A 2-week liquid formula low-calorie diet (LCD) will be administered for 2 weeks prior to Roux-en-Y gastric bypass. The diet will provide 800kcal per day in the form of powdered milkshakes and soups
3062533|NCT02144597|Active Comparator|6-week LCD|A 6-week liquid formula low-calorie diet (LCD) will be administered for 6 weeks prior to Roux-en-Y gastric bypass. The diet will provide 800kcal per day in the form of powdered milkshakes and soups
3062534|NCT02144597|Active Comparator|Control diet|A conventional food diet will be followed for 2 weeks prior to Roux-en-Y gastric bypass. The diet, prescribed as a standard of care at Imperial Weight Centre by the bariatric dietitian will provided 800-1000kcal/day.
3062612|NCT02144116|Experimental|Experimental group|Patients with fibromyalgia included in a dance-movement therapy programme
3062535|NCT02144584|Placebo Comparator|Placebo plus standard of care|Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will titrate up on the dose of placebo until taking twice daily. Participants will continue for 90 days with placebo. Continue with standard of care for other treatment of stroke.
3062536|NCT02144584|Active Comparator|Memantine plus standard of care|Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will use a titration schedule starting at 7mg daily for 1 week, increasing by 7mg (1 capsule) per week until at a goal dose of 28mg daily (goal dose) as recommend by the manufacturer. Participants will continue memantine for 90 days. Continue with standard care for stroke.
3062537|NCT02144571|Experimental|Lifestyle|Diet and physical activity intervention group. Measurements taken at baseline, 12 weeks and 1 year.
3062538|NCT02144571|No Intervention|Wait-list control|No-treatment control group. Measurements taken at baseline, 12 weeks and 1 year. People in the control condition can elect to take the intervention after 1 year.
3062539|NCT02144558|Experimental|Spinal cord injured (SCI) men, para or tetraplegic|SCI men will have 4 medical visits associated to sperm retrieval (penile vibratory stimulation (PVS) or masturbation)
3062540|NCT02144545|Experimental|Bougie Size 33Fr Distance pylorus 2 cm|Sleeve gastrectomy with a 33Fr bougie size and 2 cm distance from the pylorus.
3062541|NCT02144545|Experimental|Bougie Size 33Fr Distance pylorus 5 cm|Sleeve gastrectomy with a 33Fr bougie size and 5 cm distance from the pylorus
3062542|NCT02144545|Experimental|Bougie Size 42Fr Distance pylorus 2 cm|Sleeve gastrectomy with a 42Fr bougie size and 2 cm distance from the pylorus
3062543|NCT02144545|Experimental|Bougie Size 42Fr Distance pylorus 5 cm|Sleeve gastrectomy with a 42Fr bougie size and 2 cm distance from the pylorus
3062544|NCT02144532|Experimental|Patients with EDS hypermobility type|Patients with EDS hypermobility type wearing compression garment then compression garment removal
3062545|NCT02144519|Experimental|Immediate Intervention|Over the 3 year project, this arm receives the Healthy Eating and Physical Activity intervention after year 1 (baseline) for a total of 2 years (year 2 and 3).
3062546|NCT02144519|Experimental|Delayed Intervention|Over the 3 year project, this arm serves as the no treatment control/comparison group for year 1 and 2 (2 years of baseline) and receives the Healthy Eating and Physical Activity intervention in year 3 for a total of 1 year.
3062547|NCT02144506|Experimental|T&E|"Home-based exercises program T&E.This exercise program proposes 50 exercises with a booklet, cards and an electronic tablet. The participants choose their exercises on the basis of a rating scale of perception of exercise difficulty."
3062548|NCT02144506|Active Comparator|OTAGO|"Programm OTAGO is a home-based exercises program."
3062549|NCT02144493||Patients with recurrent CBD stone|
3062550|NCT02144493||Patients without recurrent CBD stone|
3062551|NCT02144480|Experimental|Intensive training|intensive aerobic training in moderate intensity day5 postoperatively. 30 minutes per sessions, 2 sessions per day, 10 sessions per week. There will be 20 sessions in total.
3062552|NCT02144480|Sham Comparator|traditional training|traditional rehabilitation
3062553|NCT02144454|Active Comparator|Meal rich in saturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in saturated fats
3062554|NCT02144454|Experimental|Meal rich in monounsaturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in monounsaturated fats
3062555|NCT02144454|Experimental|Meal rich in n-6 polyunsaturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in n-6 polyunsaturated fats
3062556|NCT02144441|Experimental|Patient self-administered insulin|The study's only arm
3062557|NCT02144428||Cow's milk allergy|Subjcets with a sure diagnosis of cow'a milk allergy on exclusion diet
3062558|NCT02144415|Experimental|EB-1020 400 mg|EB-1020 400 mg, administered as four 100-mg IR capsules and 4 matching placebo capsules
3062559|NCT02144415|Experimental|EB-1020 800 mg|EB-1020 800 mg, administered as eight 100-mg IR capsules
3062560|NCT02144415|Active Comparator|lisdexamfetamine 150 mg|lisdexamfetamine 150 mg, administered as 3 capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 matching placebo capsules
3062561|NCT02144415|Active Comparator|d-amphetamine 40 mg|d-amphetamine 40 mg, administered as 4 capsules, each containing two 5-mg d-amphetamine tablets and 4 matching placebo capsules
3062562|NCT02144415|Placebo Comparator|Placebo|Placebo, administered as 8 matching placebo capsules
3062563|NCT02144402|Active Comparator|infant formula with DHASCO|standard infant formula with docosahexaenoic acid (DHA)
3062564|NCT02144402|Experimental|infant formula with DHASCO-B|standard infant formula with DHA-B
3062565|NCT02144389|Active Comparator|Praziquantel (PZQ)|A single dose of praziquantel (40 mg/kg) was administered orally on day-1 only, and after 7 days, 1 g of corn oil/soybean oil (50%/50%), for 15 consecutive days of school.
3062566|NCT02144389|Experimental|Arachidonic acid (ARA)|A single daily dose of 1 g microbial arachidonic acid-rich oil administered orally for 15 consecutive days of school.
3062567|NCT02144389|Experimental|PZQ + ARA|A single dose of PZQ (40 mg/kg) was administered orally on day-1 only, and after 7 days, followed the next day by 1 g of microbial ARA-rich oil, administered orally as a single dose on 15 consecutive days of school.
3062568|NCT02144376|Placebo Comparator|Maltodextrin|7 days without use of laxatives other than standardised rescue therapy 7 grams maltodextrin taken 3 times daily, at least 4 hours apart, for up to 7 days
3062569|NCT02144376|Active Comparator|Ispaghula|7 days without use of laxatives other than standardised rescue therapy 7 grams ispaghula/ psyllium taken 3 times daily, at least 4 hours apart, for up to 7 days
3062570|NCT02144350|Experimental|Intervention|patients will undergo daily hyperbaric oxygen sessions in addition to IV steroids for 10 days.
3062571|NCT02144350|Sham Comparator|Sham|Patients will undergo sham hyperbaric air sessions in addition to IV steroids for 10 days
3062608|NCT02144142|Experimental|Moisturizer with each subject's own antimicrobial bacteria|Each subject will have a moisturizer containing their own antimicrobial bacteria species spread over their arms in the clinic
3062609|NCT02144129|Experimental|active WB-EMS|2 sessions/week with 20 min of active WB-EMS application
3062784|NCT02142920|Experimental|[14C] PF 05212384|Receive PF-05212384 89 mg Dose
3062572|NCT02144337|Experimental|Intervention group|Steps To Active Kids (STAK) programme (6 weeks) includes: StreetDance DVD designed to be completed at home (4 weeks in total). A dance routine is taught over 4 weeks with new elements introduced each day. Activity diary aims to encourage children to record daily activities in a logbook and to educate children about physical activity. Step counter: Children are given a pedometer and encouraged to record steps in the activity diary and to set personal goals to increase their steps. Weekly group activity sessions for 4 - 6 weeks. Involve a circuit of activity stations varying in intensity. The group sessions are designed to be fun and non-competitive. Children can record their scores at each station and monitor their own progress.
3062573|NCT02144337|No Intervention|Control group|Control group. Children in the Control group are asked to continue normal daily activities.
3062574|NCT02144324|Experimental|Tandem Appliance|This group of patients will receive the new appliance which is called the Tandem Appliance
3062575|NCT02144324|No Intervention|Traditional Treatment|Patients in this group will be treated by the traditional Face Mask appliance.
3062576|NCT02144311|Experimental|MRI with DW-MRI & DCE-MRI & FDG PET/CT|Study participants will have 1 scan within the 7 days immediately preceding surgery (PET/CT as standard of care and MRI as a research exam). MRI and PET/CT scanning procedures will be identical to those used in routine clinical examinations of the abdomen and pelvis.
3062577|NCT02144298||cold blood cardioplegia|observe the perioperative course of sublingual microcirculatory alterations in patients undergoing coronary artery bypass grafting (CABG) using cold blood cardioplegia.
3062578|NCT02144298||cristalloid cardioplegia|observe the perioperative course of sublingual microcirculatory alterations in patients undergoing coronary artery bypass grafting (CABG) using cristalloid cardioplegia.
3062579|NCT02144285|Experimental|LY3113593 IV (Part A)|Single dose of LY3113593 administered intravenous (IV) at a minimum of six dose levels
3062580|NCT02144285|Placebo Comparator|Placebo IV (Part A)|Single dose of placebo matching LY3113593 administered IV
3062581|NCT02144285|Experimental|LY3113593 SC (Part A)|Single dose of LY3113593 administered subcutaneous (SC)
3062582|NCT02144285|Placebo Comparator|Placebo SC (Part A)|Single dose of placebo matching LY3113593 administered SC
3062583|NCT02144285|Experimental|LY3113593 IV (Part B)|Single dose of LY3113593 administered IV
3062584|NCT02144285|Placebo Comparator|Placebo IV (Part B)|Single dose of placebo matching LY3223593 administered IV
3062585|NCT02144272|Experimental|LY3114062 (SC)|LY3114062 given as a single subcutaneous (SC) dose, in escalating dose cohorts starting at 2 mg.
3062586|NCT02144272|Experimental|LY3114062 (IV)|LY3114062 given once intravenous (IV).
3062587|NCT02144272|Placebo Comparator|Placebo|Placebo (sodium chloride injection) given as a single SC dose.
3062588|NCT02144259|Active Comparator|DMPA group|Subjects randomized to receive DepoProvera(DMPA) immediately post-partum.
3062589|NCT02144259|Active Comparator|Implanon group|Subjects randomized to receive Implanon immediately post-partum.
3062590|NCT02144259|No Intervention|Control group|Subjects selecting their own method of contraception or no contraception.
3062591|NCT02144246|Other|Pre-intervention|Patients will act as their own controls. Will have no hormones for 3 months
3062592|NCT02144246|Experimental|Post-intervention|Ortho-cyclen (or a generic equivalent) which is Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg
3062593|NCT02144233|Experimental|Occlusal adjustmen therapy|Occlusal adjustment therapy consists of the elimination of premature tooth contacts during retruded jaw closure, and the reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance). A resin-composite, placed mainly in the canine tooth, can be used to increases the flatter LG on the habitual chewing side; overcorrection is expected to compensate for a masticatory preference on the opposite side to the handedness.
3062594|NCT02144233|Placebo Comparator|Placebo occlusal adjustment therapy|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
3062595|NCT02144220|Experimental|Virtual care visit|One-time virtual care visit for Parkinson disease.
3062596|NCT02144207|Active Comparator|Glidescope: Unrestricted View|Unrestricted view of the larynx.
3062597|NCT02144207|Active Comparator|Glidescope: Restricted View|Restricted view of the larynx.
3062598|NCT02144194|Experimental|Maintenance treatment|"Initial treatment Vinorelbine-Docetaxel Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks for 6 cycles~Followed by:~Oral Vinorelbine 60mg/m2 D1, D8 or 80mg/m2 D1, D8 (dose schedule at investigator's discretion) Every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue"
3062599|NCT02144194|Experimental|Observation arm|"Initial treatment: Vinorelbine-Docetaxel Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks for 6 cycles~Patients in the observation arm will not be administered any treatment after Vinorelbine-Docetaxel"
3062600|NCT02144181|Active Comparator|Group A|Subjects will receive two low-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive one low-density Ulthera System Treatment.
3062601|NCT02144181|Active Comparator|Group B|Subjects will receive three low-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive two low-density Ulthera System Treatments.
3062602|NCT02144181|Active Comparator|Group C|Subjects will receive two high-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive one high-density Ulthera System Treatment.
3062603|NCT02144181|Active Comparator|Group D|Subjects will receive three high-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive two high-density Ulthera System Treatments.
3062604|NCT02144168|Active Comparator|prebiotics-free enteral formula|Patients in this arm will be receiving standard, prebiotics-free enteral formula : Osmolite 1 cal
3062605|NCT02144168|Experimental|prebiotics containing enteral formula|Patients in this arm will be receiving prebiotics containing enteral formula:Ensure Fos for 14 days
3062606|NCT02144155|Experimental|Oxytocin: 24 IU - 168 IU|Oxytocin twice daily for 3 weeks
3062607|NCT02144155|Sham Comparator|Vehicle placebo|Placebo for 3 weeks
3062610|NCT02144129|Experimental|Passive WB-EMS|2 sessions/week with 20 min of passive WB-EMS application in a resting supine position
3062613|NCT02144116|Active Comparator|Control group|Patients with fibromyalgia who receive a standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
3062614|NCT02144103|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected into subtenon space of patient's eye.
3062615|NCT02144090|Experimental|Fractional flow reserve|Fractional flow reserve measurement
3062616|NCT02144077|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
3062617|NCT02144077|Active Comparator|methyl-aminolevulinate|Topical application of Metvix creme containing 160 mg/g methyl-aminolevulinate. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
3062618|NCT02144064|Active Comparator|Group A(heparin group)|Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
3062619|NCT02144064|No Intervention|Group B|group B (n = 100) receive no thing
3062620|NCT02144051|Experimental|AZD5312|"AZD5312 will be given intravenously (IV) as an infusion, over one hour. For the purpose of planning, each 4 week period (28 days) will be called a Cycle. AZD5312 will initially be administered 4 times within the first 11 days, (on Days [1, 4, 8 and 11]± 2), with no dosing on sequential days. Patients will receive weekly treatments on Days 15 and 22 to complete Cycle~1. During the subsequent cycles, patients will receive weekly treatment on Days 1, 8, 15 and 22 (±2)."
3062621|NCT02144038|Experimental|Phase Ib: LGH447 + BYL719|Dose-escalation, LGH447 in combinatinon with BYL719
3062622|NCT02144038|Experimental|Phase II: LGH447 + BYL719|LGH447 + BYL719 (dosing according to MTD/RP2D from Phase Ib portion of the study)
3062623|NCT02144038|Experimental|Phase II: LGH447 alone|LGH447 alone (dosing according to single-agent RDE)
3062624|NCT02144025|Experimental|Topical cyclosporine|This is a single arm study of patients who have received allogeneic bone marrow transplants performed with a reduced intensity conditioning regimen. In this arm, patients who are candidates to this trial, will receive topical cyclosporine twice a day for 12 months to prevent ocular graft versus host disease.
3062625|NCT02144012|Experimental|Arm A: Trastuzumab emtansine|Participants will be administered trastuzumab emtansine once every three weeks (Q3W). Participants may remain on study treatment until investigator assessed disease progression, unacceptable toxicity, or Sponsor study termination occurs, whichever occurs first.
3062626|NCT02144012|Active Comparator|Arm B: Trastuzumab + Docetaxel|Participants will be administered trastuzumab plus docetaxel Q3W. Participants may remain on study treatment until investigator assessed disease progression, unacceptable toxicity, or Sponsor study termination occurs, whichever occurs first.
3062627|NCT02143999||Cohort|
3062628|NCT02143986||Macrophagic activation syndrome|
3062629|NCT02143986||Still's disease|
3062630|NCT02143986||Hyperferritinemia|
3062631|NCT02143986||Sepsis|
3062632|NCT02143973|Experimental|nalbuphine HCl ER 60mg|nalbuphine HCl ER 60mg BID
3062633|NCT02143973|Experimental|nalbuphine HCl ER 90mg|nalbuphine HCl ER 90mg BID
3062634|NCT02143973|Experimental|nalbuphine HCl ER 120mg|nalbuphine HCl ER 120mg BID
3062635|NCT02143960|Active Comparator|Velashape III device|Controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation
3062636|NCT02143960|Active Comparator|Noninvasive Cryolipolysis Device|A noninvasive device that reduces fat by freezing fat cells
3062637|NCT02143947|Experimental|Full Contact Orthosis|Full Contact Orthosis
3062638|NCT02143947|Experimental|Maximal Arch Subtalar Stabilization|Maximal Arch Subtalar Stabilization Orthoses
3062639|NCT02143934|Active Comparator|Primaquine|Primaquine, 0.5mg/kg/day, 20 days directly observed treatment Chloroquine, 25mg/kg total dose, divided over 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD
3062640|NCT02143934|Placebo Comparator|Placebo|Placebo, 20 days directly observed treatment Chloroquine, mg/kg, 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD
3062641|NCT02143921|Experimental|Training Intervention|One service provider group received training
3062642|NCT02143921|No Intervention|Control|Control group service providers did not received intervention training
3062643|NCT02143908|Placebo Comparator|placebo supplementation|2000 mg placebo tablets/day
3062644|NCT02143908|Active Comparator|Supplementation|lysine 2000 mg tablets/day supplementation
3062645|NCT02143882|Experimental|LAIV|All children will receive LAIV, currently available as the marketed product Fluenz
3062646|NCT02143856|Experimental|100 mg GLPG1205 fasted|Single dose of 100 mg GLPG1205 as two capsules of 50 mg after an overnight fast
3062647|NCT02143856|Experimental|100 mg GLPG1205 fed|Single dose of 100 mg GLPG1205 as two capsules of 50 mg exactly 30 minutes after the start of a high-fat, high-calorie breakfast
3062648|NCT02143843|Experimental|Treatment|Treatment with the ForSight VISION5 Product in both eyes (OU).
3062649|NCT02143830|Experimental|Arm A: Good Risk Patients|Patients 18 years old or younger with marrow aplasia or single lineage cytopenias will be receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days), as used in our most current study that led to > 90% survival rates . Busulfan pharmacokinetics will not be used. All patients will receive rabbit ATG (4 doses x 4 days) prior to and granulocyte-colony stimulating factor (G-CSF) after transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells for all patients will be peripheral blood stem cells mobilized by treatment of the donor with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). Enrollment on this arm will include up to 50 patients.
3062691|NCT02143570|Experimental|Darifenacin + Physiotherapy|Patients allocated to this group will receive Darifenacin 7.5mg daily in addition to physiotherapy for 12 weeks. This dose may be increased up to 7.5mg twice daily in follow-up visits in cases of refractory symptoms.
3062692|NCT02143570|Active Comparator|Physiotherapy|Patients allocated to this arm will receive a tailored pelvic floor exercise programme in addition to a matching placebo pill.
3062650|NCT02143830|Experimental|Arm B: Intermediate Risk Patients|"Patients 18 years old or younger with MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). Busulfan pharmacokinetics will be used in this arm, as the dose of busulfan is higher. All patients will receive rabbit ATG (thymoglobulin) (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for prophylaxis against GVHD. The source of the stem cells for all patients will be peripheral blood stem cells induced and mobilized by treatment of the donor. T-cell will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).~The maximum number of patients enrolled in this arm will be 10."
3062651|NCT02143830|Experimental|Arm C: High Risk Patients|Patients 19 years old or older with marrow aplasia or MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). In this study, we will test whether outcomes can be improved, yet engraftment maintained, with a slightly reduced dose of busulfan. Patients will receive rabbit ATG (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells will be peripheral blood stem cells collected from donors treated with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). The maximum number of patients enrolled will be 10.
3062652|NCT02143817|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 8 wk.
3062653|NCT02143817|Experimental|Whole body vibration training plus L-citrulline|Lower-body exercise training on a vibration platform combined with L-citrulline supplemetation (6 grams/day)
3062654|NCT02143817|Experimental|Whole body vibration training & placebo|Lower-body exercise training on a vibration platform combined with placebo supplementation (6 grams/day)
3062655|NCT02143817|Experimental|L-citrulline supplementation|(6g per day)containing L-citrulline
3062656|NCT02143791||Burst stimulation|At permanent implant with the Prodigy system, patients will be programmed with Burst stimulation
3062657|NCT02143778|Experimental|Compensated cirrhotic patients|A methacetin breath test will be performed on patients who are undergoing the HVPG procedure due to their clinical indication of compensated cirrhosis.
3062658|NCT02143765|Experimental|Mitiglinide|Mitiglinide 10 mg three times a day, orally, for 12 weeks
3062659|NCT02143765|Active Comparator|Acarbose|Acarbose 50 mg three times a day, orally, for 12 weeks
3062660|NCT02143752||Mindfulness|Smokers enter a Mindfulness Training for Smokers course
3062661|NCT02143752||Quit Line|Smokers attempt smoking cessation with the help of the Wisconsin Tobacco Quit Line
3062662|NCT02143739||Newly diagnosed asthma patients|The patient population will be outpatients, men or women, ≥18 years of age, Newly diagnosed asthma patients who are not on inhaled gluococorticosteroid within 3 months.The patient population should not have COPD(chronic obstructive pulmonary diseases) history, or asthma exacerbation.
3062663|NCT02143726|Active Comparator|sorafenib|Patients receive sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over and receive everolimus 10 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3062664|NCT02143726|Experimental|sorafenib and everolimus|Patients receive sorafenib 400 mg PO twice daily and everolimus 5 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3062665|NCT02143713|Experimental|Elagolix Dose 1|Elagolix dose 1 for 6 month treatment period
3062666|NCT02143713|Experimental|Elagolix Dose 2|Elagolix dose 2 for 6 month treatment period.
3062667|NCT02143700||Stable and exacerbated patients|Patients diagnosed of chronic obstructive pulmonary disease in a stable or exacerbated situation. Cognitive assessment of these patients will be performed.
3062668|NCT02143687|Experimental|Moderate altitude sojourn|Sojourn at moderate altitude (2048 m)
3062669|NCT02143687|Experimental|Low altitude sojourn|Sojourn at low altitude (490 m, baseline)
3062670|NCT02143687|Active Comparator|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
3062671|NCT02143687|Placebo Comparator|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights
3062672|NCT02143674|Experimental|INTERVENTION|Muscle stretching and Strength Training
3062673|NCT02143674|Experimental|Educated about physical exercises|
3062674|NCT02143661||Critically ill patients in the newly designed ICU rooms|Critically ill patients treated in one of the newly designed ICU rooms.
3062675|NCT02143661||Critically ill patients in the conventional ICU rooms|Critically ill patients treated in one of the conventional rooms on the same ICU.
3062676|NCT02143648|Experimental|nalbuphine HCl ER 60mg|nalbuphine HCl ER tablets 60 mg BID
3062677|NCT02143648|Experimental|nalbuphine HCl ER 120mg|nalbuphine HCl ER tablets 120 mg BID
3062678|NCT02143648|Placebo Comparator|Sugar pill|Placebo tablets BID
3062679|NCT02143635|Experimental|Arm A|
3062680|NCT02143635|Experimental|Arm B|
3062681|NCT02143635|Experimental|Arm C|
3062682|NCT02143635|Experimental|Arm D|
3062683|NCT02143622|Experimental|LJM716+cetuximab|
3062684|NCT02143609|Active Comparator|Oxygen|oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
3062685|NCT02143609|Placebo Comparator|Sham oxygen|sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
3062686|NCT02143596|Active Comparator|Bun/Cr based hydration|receive intravenous normal saline infusion and adjust infusion rate by Bun/Cr followed in the first 72 hours
3062687|NCT02143596|No Intervention|control|receive intravenous normal saline infusion as clinician's adjustment
3062688|NCT02143583||AllerT 100 μg|patients having received AllerT at a first dose of 50 μg and 4 maintenance doses of 100 μg in study AN004T
3062689|NCT02143583||AllerT 50 μg|patients having received AllerT at a first dose of 25 μg and 4 maintenance doses of 50 μg in study AN004T
3062690|NCT02143583||Placebo|Patients having received Placebo (i.e., adjuvant alone) delivered in the same manner as AllerT in study AN004T
3062731|NCT02143310|Experimental|EVP|Subject who use the EVP
3062693|NCT02143557|Experimental|Fat-Modified Breast Milk|Infants in this arm of the study were fed their own mother's breast milk where the fat layer was removed by centrifugation. Prior to feeding, extra energy and nutrients were added to the defatted breast milk.
3062694|NCT02143557|Active Comparator|MCT-formula group|Infants in this arm of the study were fed a MCT-containing medical food which is the current standard of care.
3062695|NCT02143544|Active Comparator|Preoperative intra-aortic balloon pump.|Intervention: Preoperative placement of the intra-aortic balloon pump.
3062696|NCT02143544|No Intervention|Control|No preoperative placement of the intra-aortic balloon pump.
3062697|NCT02143531|Active Comparator|Group I|Patients will receive 4 mg of Ondansetron IV upon occurrence of nausea or vomiting
3062698|NCT02143531|Active Comparator|Group II|Patients will receive 1mg of Haloperidol IV upon occurrence of nausea or vomiting
3062699|NCT02143518|Experimental|100 µg Na-GST-1/Alhydrogel|High Dose Na-GST-1/Alhydrogel® Only
3062700|NCT02143518|Experimental|30 µg Na-GST-1/Alhydrogel + CpG 10104|Low Dose Na-GST-1/Alhydrogel® Plus 500 µg CpG 10104
3062701|NCT02143518|Experimental|100 µg Na-GST-1/Alhydrogel + CpG 10104|High Dose Na-GST-1/Alhydrogel® Plus 500 µg CpG 10104
3062702|NCT02143505|Experimental|Ca plus vit D|elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements for 3 years
3062703|NCT02143505|Placebo Comparator|placebo|identical-appearing placebo supplements for 3 years
3062704|NCT02143479||1:early conversion from Prograf® to Advagraf®|patients converted from Prograf® to Advagraf® in the first 3 months after transplantation
3062705|NCT02143479||2:late conversion from Prograf® to Advagraf®|patients converted from Prograf® to Advagraf® between 3 months and one year after transplantation
3062706|NCT02143466|Experimental|AZD6094|AZD9291 in combination with AZD6094
3062707|NCT02143466|Experimental|Selumetinib|AZD9291 in combination with selumetinib
3062708|NCT02143466|Experimental|MEDI4736|AZD9291 in combination with MEDI4736. Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study.
3062709|NCT02143466|Experimental|AZD6094 (monotherapy)|AZD6094 in monotherapy (for Japan only)
3062710|NCT02143453|Experimental|High intensity interval training|
3062711|NCT02143453|Experimental|Endurance training|
3062712|NCT02143440|Other|Newly diagnosed type 2 patients|The initial assessment of daily insulin dose.
3062713|NCT02143427|Experimental|Social Skills Training|Social Skills Training child-focused and subsequent social competence training which combines patient- and parent-/teacher and peer-focused interventions
3062714|NCT02143427|Active Comparator|Treatment Program with techniques to activate resources|Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training child-focused
3062715|NCT02143414|Experimental|Cohort I (blinatumomab, POMP)|"INDUCTION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28. Treatment repeats every 42 days for 2 courses in the absence of disease progression or unacceptable toxicity.~RE-INDUCTION: Patients not achieving CR or CRi after Induction, receive blinatumomab IV continuously over 24 hours on days 1-28 in the absence of disease progression or unacceptable toxicity.~POST-REMISSION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28. Treatment repeats every 42 days for 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive prednisone PO on days 1-5, vincristine sulfate IV on day 1, mercaptopurine PO on days 1-28, and methotrexate PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 18 courses in the absence of disease progression or unacceptable toxicity."
3062716|NCT02143414|Experimental|Cohort II (dasatinib, prednisone, blinatumomab)|"INDUCTION: Patients receive dasatinib PO BID on days 1-84 and prednisone PO on days 1-24 with tapering on days 25-32 in the absence of disease progression or unacceptable toxicity.~RE-INDUCTION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28. Treatment repeats every 42 days for 2 courses in the absence of disease progression or unacceptable toxicity.~POST-REMISSION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28 and dasatinib PO QD on days 1-42. Treatment repeats every 42 days for 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive dasatinib PO BID on days 1-28 and prednisone PO on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3062717|NCT02143401|Experimental|Treatment (navitoclax, sorafenib tosylate)|Patients receive navitoclax PO QD on days 1-21 (days 1-28 course of 1 only) and sorafenib tosylate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3062718|NCT02143388|Experimental|Concurrent chemoradiation + adjuvant chemotherapy|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
3062719|NCT02143388|Active Comparator|Concurrent chemoradiation|IMRT combine with cisplatin concurrent chemotherapy
3062720|NCT02143375|Experimental|810 Diode Laser|810 nm Diode Laser, contact, continuous wave,320micron,
3062721|NCT02143362|Experimental|Dexmedetomidine group|"Infusion of dexmedetomidine(0.8μg/kg) at10 minutes before anesthesia induction.~Infusion of dexmedetomidine at 0.4 μg•kg-1•h-1during anesthesia maintenance.~The infusion rate of dexmedetomidine was reduced to 0.1 μg•kg-1•h-1 for awaken test."
3062722|NCT02143362|Placebo Comparator|Control group|"Infusion normal saline(0.8μg/kg) at 10 minutes before anesthesia induction.~Infusion normal saline at 0.4 μg•kg-1•h-1 during anesthesia maintenance.~The infusion rate of normal saline was reduced to 0.1 μg•kg-1•h-1 for awaken test."
3062723|NCT02143349|Experimental|Coleus forskohlii extract|Ingestion of 250 mg capsle (Coleus forskohlii extract) twice a day for 12 weeks
3062724|NCT02143349|Placebo Comparator|Placebo|Ingestion of 250 mg capsule (placebo) twice a day for 12 weeks
3062725|NCT02143336|Experimental|Subcuticular suture|Subcuticular suture (absorbable) for skin closure
3062726|NCT02143336|Active Comparator|Skin staples|Standard skin staples for wound closure
3062727|NCT02143323|Active Comparator|Glutathione S-Transferase Theta1(GSTT1)/Mu1(GSTM1) wild/wild|Augmentin tablet
3062728|NCT02143323|Active Comparator|GSTT1/GSTM1 wild/null type|Augmentin tablet
3062729|NCT02143323|Active Comparator|GSTT1/GSTM1 null/wild type|Augmentin tablet
3062730|NCT02143323|Active Comparator|GSTT1/GSTM1 null/null type|Augmentin tablet
3062732|NCT02143297||SAHS negative|Subjects derived to the sleep unit due to suspicion of suffering from sleep apnea which finally do not have the disease according to standard PSG
3062733|NCT02143297||SAHS positive|Subjects derived to the sleep unit due to suspicion of suffering from sleep apnea which finally have the disease according to standard PSG
3062734|NCT02143284|Experimental|Endoscopy exploratory single arm|Exploratory single arm, the system will be used in otherwise standard procedures, and will be reviewed in terms of performance, usability, ease of use and safety.
3062735|NCT02143271|Experimental|KHK7580|
3062736|NCT02143258|Experimental|Neurointerventional|Stenting of the venous sinus is the neuro-interventional treatment that is being offered to patients with idiopathic intracranial hypertension that are refractory to medical management.
3062737|NCT02143245|Experimental|percutaneous synovial biopsy|
3062738|NCT02143232|Experimental|Remote patient monitoring (Telus RPM)|The remote monitoring device (Telus RPM) is used by every patient in the study post operatively at home.
3062739|NCT02143219|Other|FOLFIRINOX|FOLFIRINOX (D1-D15, for maximum 12 cycles) = Oxaliplatine + Folinic acid + Irinotecan + 5-FU
3062740|NCT02143206||Exercise Method|Patients attend exercise 80 minute exercise sessions of which 30 minutes includes aerobic exercise on a NuStep and Biodex elliptical machine. Patients pain levels are scored when using the NuStep then when using the Biodex and these scores are compared to determine which machine give the best outcome for pain management
3062741|NCT02143193|Experimental|Skin to Skin Contact|implement mother-baby Skin-to-Skin contact immediately after vaginal birth
3062742|NCT02143193|No Intervention|Standard of Care|standard care for newborn and mother immediately after vaginal birth
3062743|NCT02143167|Experimental|SR-fampridine/placebo|24 weeks of SR-fampridine followed by four weeks of inactive placebo.
3062744|NCT02143167|Experimental|Placebo/SR-fampridine|24 weeks of inactive placebo followed by four weeks of SR-fampridine
3062745|NCT02143154||GBS positive women|Women wih GBS positive bacteruria with plan for treatment with vancomycin in labor, or women with positive GBS screening cultures with a plan to receive vancomycin in labor
3062746|NCT02143141|Active Comparator|duramorph|duramorph 150 mcg administered spinally with placebo capsules administered by mouth every 6 hours x 4 doses during first 24 hours
3062747|NCT02143141|Experimental|no duramorph|no duramorph is administered spinally for surgery; subjects receive acetaminophen 1 G orally x 4 doses during first 24 hours postoperatively
3062748|NCT02143128||ESScore reliability|Same patients evaluated by two or more health professionals
3062749|NCT02143128||ESScore|Tool used for evaluation of patients after surgery
3062750|NCT02143128||ESScore without evaluation|Scored by tool, but not evaluated by it
3062751|NCT02143128||No ESScore|Regular ward routines
3062752|NCT02143102||Training set|Data from subjects in the training set will be utilized to further develop the vascuCAPTM classifiers.
3062753|NCT02143102||Testing set|Data from subjects in the testing set will be used to assess the study endpoints.
3062754|NCT02143089|Active Comparator|Group 1|Use of urinary catheterization in Cesarean section
3062755|NCT02143089|No Intervention|Group 2|NO urinary catheterization during Cesarean section
3062756|NCT02143076||Sickle Cell Disease|Participants will complete three questionnaires during the course of the study: Demographic Questionnaire, Medical Adherence Measure Questionnaire, and Acceptability Questionnaire. All questionnaires will be completed in a private clinic room.
3062757|NCT02143063|Active Comparator|standard care|standard care
3062758|NCT02143063|Active Comparator|standard care plus traditional contingency managment|prize contingency management on a traditional twice weekly schedule for cocaine abstinence
3062759|NCT02143063|Experimental|standard care plus variable interval contingency management|prize contingency management on a variable interval schedule for cocaine abstinence
3062760|NCT02143050|Experimental|Dabrafenib, Trametinib and Metformin|Dabrafenib 150 mg PO BID until progression or unacceptable toxicity. Trametinib 2 mg PO QD until progression or unacceptable toxicity. Metformin 500 mg PO BID x 2 weeks, then 850 mg PO BID until progression or unacceptable toxicity.
3062761|NCT02143037|Active Comparator|Control Group|usual care
3062762|NCT02143037|Experimental|Experimental Group|usual care plus prize contingency management for attending treatment
3062763|NCT02143024|Experimental|Family-based depression intervention|The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker
3062764|NCT02143024|Active Comparator|Usual care plus educational materials|Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.
3062765|NCT02143011|Other|orange juice|no sugar
3062766|NCT02143011|Other|sugar beverage|no sugar
3062767|NCT02142998|Active Comparator|GERD Symptoms|
3062768|NCT02142998|Active Comparator|No GERD Symptoms|
3062769|NCT02142985|Experimental|colloid solution|vascular filling with 500 ml of colloid solution (Plasmagel) over 30 minutes
3062770|NCT02142959|Experimental|omaveloxolone (RTA 408) Lotion 0.5%|Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
3062771|NCT02142959|Experimental|omaveloxolone (RTA 408) Lotion 3%|Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
3062772|NCT02142959|Placebo Comparator|Lotion vehicle/Placebo|Lotion vehicle/placebo will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
3062773|NCT02142946||RIS MS patients|Radiologically Isolated Syndrome (RIS) MS patients
3062774|NCT02142946||CIS MS patients|Clinically Isolated Syndrome (CIS) patients during a stable phase
3062775|NCT02142946||RRMS patients|Relapsing-remitting (RR) MS patients during a stable phase
3062776|NCT02142946||SPMS Patients|Secondary progressive MS patients (SPMS)
3062777|NCT02142946||PPMS Patients|Primary progressive MS patients (PPMS)
3062778|NCT02142946||Controls|Age and gender matched controls
3062779|NCT02142946||CI Patients|Cochlear Implant patients pre- and post-operatively
3062780|NCT02142946||UVL Patients|Unilateral vestibular loss patients in acute and compensated state
3062785|NCT02142894||Symptomatic|Patients with bacteriologically confirmed and untreated TB disease tested with CST001 assay.
3062786|NCT02142881|Experimental|Antihypertensive medication intensification|
3062787|NCT02142881|Other|Usual care|
3062788|NCT02142855|No Intervention|Old Control|Older individuals (65-75 y) with no exercise intervention
3062789|NCT02142855|Experimental|Old Concentric|Older individuals (65-75 y) studied before and after 8 weeks concentric exercise training
3062790|NCT02142855|Experimental|Old Eccentric|Older individuals (65-75 y) studied before and after 8 weeks eccentric exercise training
3062791|NCT02142855|No Intervention|Young Control|Young individuals (18-30 y) with no exercise intervention
3062792|NCT02142855|Experimental|Young Concentric|Young individuals (18-30 y) studied before and after 8 weeks concentric exercise training
3062793|NCT02142855|Experimental|Young Eccentric|Young individuals (18-30 y) studied before and after 8 weeks eccentric exercise training
3062794|NCT02142842|Experimental|Treatment|Autologous stromal vascular fraction (SVF) and platelet rich plasma (PRP) will be injected into joints of 16 patients with grade 2, 3 radiographic OA severity with 16 patients as control.
3062795|NCT02142829|Active Comparator|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
3062796|NCT02142829|Active Comparator|On-Q Pain Ball|Device for delivering bupivacaine.
3062797|NCT02142816|Active Comparator|Doppler|Fluid directed by oesophageal doppler
3062798|NCT02142816|Active Comparator|PVI|Fluid therapy directed by Pleth Variability Index
3062799|NCT02142803|Experimental|Treatment (TORC1/2 inhibitor INK128, bevacizumab)|Patients receive TORC1/2 inhibitor INK128 PO QD on days 1-28 and bevacizumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3062800|NCT02142790|Experimental|paclitaxel liposome injection weekly|paclitaxel liposome injection 100mg/m2 administered by intravenous on day1 and day8 of a 21-day cycle for at least 4cycles or till progression or intolerable
3062801|NCT02142790|Experimental|paclitaxel liposome injection every 3 weeks|paclitaxel liposome injection 175mg/m2 administered by intravenous on day1 of a 21-day cycle for at least 4cycles or till progression or intolerable
3062802|NCT02142777|Experimental|Investigational|All study subjects will take a 10mg pill by mouth twice daily over a 6 week period. Subjects will receive either placebo or S -Equol. They will not know which they are receiving.
3062803|NCT02142764|Experimental|Multiple Sclerosis|Human Leukocyte Antigen (HLA)-A2 patients whose Multiple Sclerosis has just been diagnosed
3062804|NCT02142764|Other|Control|HLA-A2 patients hospitalized in the neurology department who are not affected with a neuroimmunological disorder
3062805|NCT02142764|Experimental|Multiple Sclerosis patients treated|HLA-A2 Multiple Sclerosis patients treated by Natalizumab therapy
3062806|NCT02142751|Experimental|Fosfomycin sodium intravenous|4g every 6 hours iv (60 min infusion)
3062807|NCT02142751|Active Comparator|Meropenem intravenous|1g every 8 hours (15-30 min infusion)
3062808|NCT02142751|Other|Ceftriaxone intravenous|1g every 24h (2-4 min)
3062809|NCT02142738|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles.
3062810|NCT02142738|Active Comparator|Paclitaxel+Carboplatin|Participants receive paclitaxel 200 mg/m^2 and carboplatin Area Under the Curve (AUC) 5 or 6, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for participants with non-squamous histologies for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
3062811|NCT02142738|Active Comparator|Pemetrexed+Carboplatin|Participants receive pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6, IV infusion on Day 1 of each 21-day cycle for 4-6 cycles; participants with non-squamous histologies may then receive pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle as maintenance therapy for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
3062812|NCT02142738|Active Comparator|Pemetrexed+Cisplatin|Participants receive pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 Q3W maintenance for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
3062813|NCT02142738|Active Comparator|Gemcitabine+Carboplatin|Participants receive gemcitabine 1250 mg/m^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and carboplatin AUC 5 or 6, administered as IV infusion on Day 1 of a 21-day cycle, for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
3062814|NCT02142738|Active Comparator|Gemcitabine+Cisplatin|Participants receive gemcitabine 1250 mg/m^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and cisplatin 75 mg/m^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
3062815|NCT02142725|Experimental|LT-02|LT-02 0.8g four times daily
3062816|NCT02142725|Experimental|B: LT-02|LT-02 1.6g twice daily
3062817|NCT02142725|Placebo Comparator|Placebo|LT-02 Placebo
3062818|NCT02142712|Active Comparator|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
3062819|NCT02142712|Active Comparator|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
3062820|NCT02142712|Experimental|Dextromethorphan|"Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care.~If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration."
3062821|NCT02142712|Experimental|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
3062822|NCT02142699|Active Comparator|Heme arginate 1mg/kg|"This is the lower of the 2 doses of Heme arginate (HA). This will be given as a single dose of 1mg/kg on the first study visit.~This is given over 1 hour intravenously."
3062823|NCT02142699|Active Comparator|Heme arginate 3mg/kg|"This is the larger dose, Heme arginate 3mg/kg (up to a maximum dose of 250mg)~This will be given intravenously, as a single dose on the first study visit, over one hour."
3062824|NCT02142686|Active Comparator|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm.
3062825|NCT02142686|Active Comparator|Filling pressure 50.|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg in this group
3062826|NCT02142686|Active Comparator|illing pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm Hg.
3062827|NCT02142673|Active Comparator|Filling pressure 80|The hysteroscope filling pressure will be 80mm Hg
3062828|NCT02142673|Active Comparator|Filling pressure 60|The hysteroscope filling pressure will be to 50mm Hg
3062829|NCT02142673|Active Comparator|Filling pressure 40|The hysteroscope filling pressure will be to 40mm Hg
3062830|NCT02142660||Sprayshield|Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie
3062831|NCT02142647|Active Comparator|meat group|Infants in this group will receive complementary foods with high protein content mainly from meat
3062832|NCT02142647|Active Comparator|dairy group|infants in this group will receive complementary foods mainly from dairy
3062833|NCT02142634|Experimental|A|Budesonide granules 9 mg
3062834|NCT02142634|Placebo Comparator|B|Placebo granules
3062835|NCT02142621|Active Comparator|transpyloric tube feeds|Continuous transpyloric tube feeds administered through an oral/nasal feeding tube.
3062836|NCT02142621|Active Comparator|gastric tube feeds|Continuous gastric tube feeds administered through an oral/nasal feeding tube.
3062837|NCT02142608|Experimental|BR55|BR55, a new ultrasound contrast agent
3062838|NCT02142595|Experimental|dexmeditomidine group D|The sedative solution was prepared as a 10µg /ml dexmedetomidine in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
3062839|NCT02142595|Experimental|Midazolam group M|The sedative solution was prepared as a 0.375mg/ml midazolam or normal saline in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
3062840|NCT02142595|No Intervention|group control|normal saline in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
3062841|NCT02142582|Active Comparator|WHO ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
3062842|NCT02142582|Active Comparator|Commercial ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
3062843|NCT02142569|Active Comparator|Chinese Red Yeast Rice (CRYR)|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the CRYR arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 CRYR and 2 Sugar Pill/Placebo capsules for 12 weeks.
3062844|NCT02142569|Active Comparator|Tocotrienol-enriched Fraction of Palm Oil (TRF)|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the TRF arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 TRF and 2 Sugar Pill/Placebo capsules for 12 weeks.
3062845|NCT02142569|Active Comparator|CRYR + TRF|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the TRF + CRYR arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 CRYR and 2 TRF capsules for 12 weeks.
3062846|NCT02142569|Placebo Comparator|Sugar Pill|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the placebo (sugar pill) arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 4 placebo tablets for 12 weeks. Additionally during a two-week run-in period, subjects will be asked to follow the American Heart Association Step 1 dietary regimen and to take a placebo capsule daily to determine their ability to comply with the diet and a pill regimen.
3062847|NCT02142556|Experimental|Quetiapine XR|Patients had schizophrenia and fulfilled the criteria including having a score of 4 (moderate) or greater on any of the 7 items of the Positive and Negative Syndrome Scale (PANSS) Positive Symptom Subscale and needed to switch from previous antipsychotics due to insufficient efficacy or insufficient tolerability (N=61). They will receive the intervention of administration of quetiapine XR.
3062848|NCT02142543|Placebo Comparator|placebo|placebo powder containing zinc oxide, karaya gum, and yellow dye, which was added to imitate the color of the original powder, applied twice a day until the ulcer had resolved, an expected average of 3-5 days
3062849|NCT02142543|Experimental|2-DeNT powder|2-DeNT powder containing dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum, applied twice a day until the ulcer had resolved, applied twice a day until the ulcer had resolved, in an expected average of 3 to 5 days
3062850|NCT02142530|Experimental|Carfilzomib/ Belinostat|"Carfilzomib and Belinostat will be administered on a 28-day schedule.~Carfilzomib will be given on days 1-2, 8-9, and 15-16 of each cycle, beginning at a dose of 20 mg/m2 (dose level 0).~Belinostat will be given on days 1-5 beginning at a dose of 600 mg/m2.~Belinostat dosing will precede carfilzomib dosing on days when both drugs are administered. In dose level 1 and beyond, carfilzomib will be given at a dose of 20mg/m2 with cycle 1, and then escalated with cycle 2~A maximum of four dose levels are planned with carfilzomib escalated no higher than 20/36 mg/m2 and belinostat escalated no higher than 900 mg/m2."
3062883|NCT02142257||AspireAssist Aspiration Therapy|Morbidly obese individuals who meet the criteria for and have chosen to participate in Aspiration Therapy using the AspireAssist.
3062851|NCT02142517|Active Comparator|Duct to mucosa PJ group|Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
3062852|NCT02142517|Active Comparator|Invagination PJ group|Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
3062853|NCT02142504|Experimental|GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)|Intramuscular (IM) norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
3062854|NCT02142504|Experimental|GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)|IM norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
3062855|NCT02142504|Placebo Comparator|Saline Placebo + GI.1/GII.4 15/15 μg (No MPL)|IM saline placebo on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP ) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
3062856|NCT02142478||Adapted scheme|Participants referred by their GP practices to Centre A will take part in the Adapted Exercise for Health (EFH) scheme.
3062857|NCT02142478||Standard scheme|Participants referred by their GP practices to Centre B will take part in the Standard Exercise for Health (EFH) scheme.
3062858|NCT02142452|Experimental|mobile health intervention|Behavioral intervention. Women with excessive weight gain in pregnancy will be recruited in their 3rd trimester. They will begin with a 5 week group session on weight management. After they deliver the baby, they will begin receiving text messages supporting behavior change they learned in their 3rd trimester. They will follow up at 6 weeks postpartum and 4 months postpartum.
3062859|NCT02142452|Placebo Comparator|Control Group|Women will receive usual prenatal care from their OB. Postpartum, they will receive a monthly newsletter relevant to the new mother on her nutrition and physical activity. They will be followed at 6 weeks postpartum and 4 months postpartum.
3062860|NCT02142439|Experimental|Intervention group 1|Exercise counseling 1 time/week, Strength training 3 times/week, dose: 5 RM x 3 sets.
3062861|NCT02142439|Experimental|Intervention group 2|Exercise counseling 1 time/week. Strength training 3 times/week, dose: 10 RM x 3 sets.
3062862|NCT02142439|Experimental|Intervention group 3|Exercise counseling 1 time/week. Strength training 3 times/week, dose: 30 RM x 3 sets
3062863|NCT02142439|No Intervention|Control group|Exercise counseling 1 time/week
3062864|NCT02142413||Acute Ischemic Stroke|Patients older than 18 years with an acute ischemic stroke (according to WHO criteria), stroke onset within 2 days, language: German, MRI compatibility, admission to the stroke unit at the Charité, Campus Benjamin Franklin.
3062865|NCT02142400|Experimental|DS-1093|Group 1 will receive 10mg, group 2 will receive 25mg of DS-1093
3062866|NCT02142400|Placebo Comparator|placebo|placebo to match DS-1093 dosage
3062867|NCT02142387|Other|newer CPR training|the out of hospital cardiac arrest victims who were given bystander CPR by whom trained as newer BLS training program with dispatcher assisted CPR simulation.
3062868|NCT02142361|Active Comparator|Omafilcon A/Enfilcon A|Subject's habitual hydrogel toric lenses Omafilcon A will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
3062869|NCT02142361|Active Comparator|Ocufilcon D/Enfilcon A|Subject's habitual hydrogel toric lenses Ocufilcon D will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
3062870|NCT02142361|Active Comparator|Methafilcon B/ Enfilcon A|Subject's habitual hydrogel toric lenses Methafilcon B will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
3062871|NCT02142348||osteoprosis research|
3062872|NCT02142335|Experimental|Rituxan/Abraxane|This is a single arm study. All patients recieve treatment.
3062873|NCT02142309|Experimental|Glimepiride|up to 4 mg/day
3062874|NCT02142309|Experimental|Vildagliptin|50 mg bid
3062875|NCT02142309|Experimental|Pioglitazone|up to 30 mg/day
3062876|NCT02142309|Experimental|Canagliflozin|300 mg/day
3062877|NCT02142296|Other|Eylea|The intravitreal dose of Eylea will be 2mg (50ul) per injection. The medication will be supplied in single use vials. Given monthly for 3 months and then every 8 weeks until week 52. This is an open-label study.
3062878|NCT02142283|Experimental|Trevo Thrombectomy Procedure|Trevo Thrombectomy Procedure and Medical Management
3062879|NCT02142283|Active Comparator|Medical Management|Medical Management
3062880|NCT02142270||Victims of cardiac arrest, either SCD or aborted SCA|
3062881|NCT02142270||Premature death|"All residents of districts of interest will be surveyed during 3 years. premature deaths occurring in residents of districts of interest will be checked for past medical history, circumstances of death, and autopsy report (if possible). Investigators will also analyze the employment of resuscitation attempts during the timeframe of sudden cardiac arrest (SCA) in various patient populations throughout African countries.~The arm group of the study is every resident of the district of interest"
3062882|NCT02142257||Gastric Bypass|Morbidly obese individuals who meet the criteria for and have chosen to undergo Gastric Bypass surgery.
3063978|NCT02135250|Experimental|Xinkeshu tablet|4 Xinkeshu tablets are given three times per day
3062884|NCT02142244|Experimental|Near infra red sentinel node biopsy|Sentinel node biopsy adding indocyanine green injection at the tumor/biopsy site during the surgical procedure to the standard technique (blue die and lymph scintigraphy) and near infra red light for fluorescence. The indocyanine green saline solution - 5mg diluted in 10ml. will be injected in 4 points around the biopsy site - 4ml each - total 0.8mg - single procedure.Near infra red lens and camera will be used to detect the fluorescence and localize the sentinel node for biopsy.
3062885|NCT02142231|Placebo Comparator|Laser Acupuncture|Subjects and Therapists are blinded. Instead of a real Laser Acupuncture device (able to elicit physiologic responses) them is given a sham-laser device only radiating non-energetic red LED-light. Without palpation, therapists treat the acupoint Heart 7, on both wrists, each for 1 minute, with additional 18 minutes of resting time after.
3062886|NCT02142231|Active Comparator|Acupuncture|Acupuncture at the acupoint Heart 7, on both wrists, each for 1 minute, eliciting a deqi-response, additional stimulation and total needle-in time of 20 minutes (2 minutes treatment and 18 minutes of resting time)
3062887|NCT02142205|Experimental|BG00002 (natalizumab)|300 mg IV infusion every 4 weeks
3062888|NCT02142192|Experimental|natalizumab|natalizumab 300mg SC every 4 weeks for up to 12 treatment administrations (i.e. Day 1 through Week 44)
3062889|NCT02142179|Experimental|KARE Intervention|KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
3062890|NCT02142179|No Intervention|A traditional curriculum education.|The control group will receive a traditional curriculum education.
3062891|NCT02142166|Experimental|SAB analysis|"Patients with acute aneurysmal SAH, confirmed by CT or MRI, or lumbar puncture~Daily (21 days) analysis of Biomarker in serum, in liquor and in micro-dialysate"
3062892|NCT02142166|Experimental|Control|"Patients who undergo a lumbar puncture for myelography as part of the investigation of a cervical or lumbar foraminal stenosis without cranial or myeläre pathology -or- Patients who receive perioperative prophylactic lumbar drainage without cranial or myeläre pathology~Single analysis of Biomarker in serum and liquor"
3062893|NCT02142153|Experimental|F901318 0.25 mg/kg|Single intravenous infusion over 4 hours
3062894|NCT02142153|Placebo Comparator|0.25 mg/kg placebo|Single intravenous infusion over 4 hours
3062895|NCT02142153|Experimental|F901318 0.75 mg/kg|Single intravenous infusion over 4 hours
3062896|NCT02142153|Placebo Comparator|Placebo 0.75 mg/kg|Single intravenous infusion over 4 hours
3062897|NCT02142153|Experimental|F901318 1.5 mg/kg|Single intravenous infusion over 4 hours
3062898|NCT02142153|Placebo Comparator|Placebo 1.5 mg/kg|Single intravenous infusion over 4 hours
3062899|NCT02142153|Experimental|F901318 mg/kg|Single intravenous infusion over 4 hours
3062900|NCT02142153|Placebo Comparator|Placebo 3 mg/kg|Single intravenous infusion over 4 hours
3062901|NCT02142153|Experimental|F901318 5 mg/kg|Single intravenous infusion over 4 hours
3062902|NCT02142153|Placebo Comparator|Placebo 5 mg/kg|Single intravenous infusion over 4 hours
3062903|NCT02142140|Experimental|Medication Monitoring & Case Management|All children entered into this study will be prescribed medication for their ADHD symptoms (usually a long-acting stimulant). Based on the individual needs of the child and family, they could receive the following interventions - Academic and organization skills, social skills training and parent training. Participants randomized to this group will meet with the study clinicians 4 times a year for medication monitoring and adjustment. This group will also receive a monthly call from a case manager who will explore the child's academic, social and emotional functioning. Depending on the needs of the child and family, the case manager may offer 1 to 5 intervention sessions with the child (e.g. social skills, anger management), the family (e.g. family counselling), and the school (e.g. consultation with the teacher).
3062904|NCT02142140|Active Comparator|Community Follow-up Group|All children entered into this study will be prescribed medication for their ADHD symptoms (usually a long-acting stimulant). Based on the individual needs of the child and family, they could receive the following interventions - Academic and organization skills, social skills training and parent training. Families randomized to this group will be referred to their pediatricians or family physicians for medication follow-up and their local Community Health Clinic (CLSC) for other psychosocial interventions that may be required and available.
3062905|NCT02142127|Experimental|14C-labelled GFT505 120 mg|
3062906|NCT02142114|Active Comparator|Eye injection by 30 gauge needle|Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size (may be that day or within 1 week of the 1st injection). When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
3062907|NCT02142114|Active Comparator|Eye injection by 32 gauge needle|
3062908|NCT02142101||GFR >60|5 patients with polycystic kidney disease with eGFR > 60 ml/min.
3062909|NCT02142101||GFR 15-60|5 patients with polycystic kidney disease with eGFR between 15-60 ml/min.
3062910|NCT02142101||GFR <15|5 patients with polycystic kidney disease with eGFR <15 ml/min.
3062911|NCT02142088|Other|Glucose Monitoring|Each patient will undergo simultaneous Glucose monitoring with 2 devices. One is GlySure's intervascular continuous measurement sensor (test device) introduced through a CVC, and the other measures glucose intermittently from repeated venous blood samples drawn through an indwelling ventflon style catheter
3062955|NCT02141763|Placebo Comparator|Placebo|0.9% sodium chloride aqueous solution (physiological saline, preservative free) of pharmacopoeia (USP/Ph.Eur) quality in a 10 mL glass vial
3063979|NCT02135237|Active Comparator|Control Group|Standard Care
3062912|NCT02142075|Experimental|Daptomycin, IV|"Patients with creatinine clearance ≥30 ml/min will receive 10 mg/kg of daptomycin (Cubicin®) once daily,~Patients with creatinine clearance <30 ml/min will receive the same daptomycin dose (10 mg/kg) but less frequently, every 48h instead of every day"
3062913|NCT02142062||Venography and IVUS imaging guiding treatment|
3062914|NCT02142049|Experimental|Part 1: Dose Level 1|Ibrutinib 560 mg PO + DA-EPOCH-R
3062915|NCT02142049|Experimental|Part 1: Dose Level 2|Ibrutinib 560 mg (PO) +lenalidomide 15 mg (PO) + DA-EPOCH-R
3062916|NCT02142049|Experimental|Part 1: Dose Level 3|Ibrutinib 560 mg (PO) +lenalidomide 20 mg (PO) + DA-EPOCH-R
3062917|NCT02142049|Experimental|Part 1: Dose Level 4|Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
3062918|NCT02142049|Experimental|Part 2: Dose Level MTD|Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
3062919|NCT02142036|Experimental|ATI based targeted therapy.|EMA-approved ATI based targeted therapy. Patients will receive therapy based on molecular aberrations identified in the metastatic lesion.
3062920|NCT02142010|Other|paclitaxel liposome injection plus cisplatin|
3062921|NCT02141997|Active Comparator|Adalimumab 40 mg EOW|Adalimumab 40 mg every other week (EOW) for 11 weeks.
3062922|NCT02141997|Experimental|ABT-122 60 mg EOW|ABT-122 60 mg every other week (EOW) for 11 weeks.
3062923|NCT02141997|Experimental|ABT-122 120 mg EOW|ABT-122 120 mg every other week (EOW) for 11 weeks.
3062924|NCT02141997|Experimental|ABT-122 120 mg EW|ABT-122 120 mg every week (EW) for 11 weeks.
3062925|NCT02141984||Patients with Polyarticular JIA or ERA|Patients with polyarticular juvenile idiopathic arthritis (JIA) or enthesitis-related arthritis (ERA)
3062926|NCT02141971||Non-demented; Ages 30-40|Four non-demented Down syndrome patients between the ages of 30-40 years old
3062927|NCT02141971||Non-demented; Ages 40-50|Four non-demented Down syndrome patients between the ages of 40-50 years old
3062928|NCT02141971||Demented; Ages 50-60|Four demented Down syndrome patients between the ages of 50-60 years old
3062929|NCT02141958|Experimental|Fenretinide|Fenretinide will be administrated orally once per day for 21 consecutive days, in up to three treatment cycles of ascending doses, with a minimum of 7-day drug-free period between cycles. Twelve (12) patients will be on Fenretinide.
3062930|NCT02141958|Placebo Comparator|Placebo|Four (4) patients will be on Placebo.
3062931|NCT02141932|Experimental|Bed-side pocket-size ultrasound|All participants will be examined bed-side by pocket size ultrasound for the assessment of the carotid arteries and the heart. All participants will then be examined by reference imaging in specific ultrasound laboratories and when appropriate computer tomography or magnetic resonance imaging.
3062932|NCT02141919|Experimental|Stereotactic Ablative Radiation Therapy|Stereotactic Ablative Radiation Therapy (SABR)
3062933|NCT02141906|Experimental|Oncozene-DEB-TACE|"Screening Visit (procedures should be done within 28 days of treatment day):~Study visit assessments will be performed prior to Oncozene-DEB-TACE delivery (except pharmacokinetic blood draw).~Labs may be done within 3 days of the procedure. All visits can be completed +/- 10 days of planned visit day~Follow up after completion of treatment every 4-6 weeks:"
3062934|NCT02141893|Active Comparator|CALMA|Participants only received a family education intervention (previously tested) known as CALMA
3062935|NCT02141893|Experimental|Calma plus|Participants in Arm 2 received the CALMA family education intervention and physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs.
3062936|NCT02141880||Treatment|All subjects will be under the same protocol which is eating and drinking on one afternoon.
3062937|NCT02141867||Noncardiac surgical patients|Noncardiac surgery patients 16 years or older undergoing inpatient surgery
3062938|NCT02141854|Experimental|FS MDPI 200 / 12.5 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 200 mcg (for a total daily dose of 400 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
3062939|NCT02141854|Experimental|FS MDPI 100 / 12.5 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
3062940|NCT02141854|Experimental|Fp MDPI 200 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg for 12 weeks.
3062941|NCT02141854|Experimental|Fp MDPI 100 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg for 12 weeks.
3062942|NCT02141854|Placebo Comparator|Placebo MDPI|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of placebo for 12 weeks.
3062943|NCT02141828|Experimental|EPZ-5676|EPZ-5676 Dose escalation and expansion cohorts
3062944|NCT02141815|Experimental|Arabinoxylan-oligosaccharides|Arabinoxylan-oligosaccharides 10g BID
3062945|NCT02141815|Placebo Comparator|Maltodextrine|Maltodextrine BID
3062946|NCT02141802|Active Comparator|Control|Normal standing time
3062947|NCT02141802|Experimental|Doubling standing time|Doubled standing time calculated by doubling baseline standing time
3062948|NCT02141789|Experimental|Outpatient Cognitive Behavioral Psychotherapy|Outpatient Cognitive Behavioral Therapy is a well-known and frequently applied psychotherapy approach that does not need further description.
3062949|NCT02141776|Sham Comparator|Sham Controlled Arm|The subjects randomized to this group will not receive stimulation daily for four weeks.
3062950|NCT02141776|Active Comparator|Transcranial direct current stimulation (t-DCS)|The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
3062951|NCT02141763|Experimental|240/160/160 mg of UCB4940|240 mg loading dose + 160 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
3062952|NCT02141763|Experimental|160/80/80 mg of UCB4940|160 mg loading dose + 80 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
3062953|NCT02141763|Experimental|80/40/40 mg of UCB4940|80 mg loading dose + 40 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
3062954|NCT02141763|Experimental|560/320/320 mg of UCB4940|560 mg loading dose + 320 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
3062956|NCT02141737|Placebo Comparator|Group C|Induction protocol: patients will be given 2 ml normal saline solution, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
3062957|NCT02141737|Experimental|Group L1|Induction protocol: patients will be given 2 ml diluted lidocaine injection in which 20 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
3062958|NCT02141737|Experimental|Group L2|Induction protocol: patients will be given 2 ml diluted lidocaine injection in which 30 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
3062959|NCT02141737|Experimental|group L3|Induction protocol: patients will be given 2 ml lidocaine injection in which 40 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
3062960|NCT02141724||neuromuscular patients|neuromuscular patients using wheelchair
3062961|NCT02141711|Experimental|Cohort 1: TAK-438 10 mg|TAK-438 10 mg tablets, orally, once, daily, for 7 days.
3062962|NCT02141711|Experimental|Cohort 2: TAK-438 20 mg|TAK-438 20 mg tablets, orally, once, daily, for 7 days.
3062963|NCT02141711|Experimental|Cohort 3: TAK-438 40 mg|TAK-438 40 mg tablets, orally, once, daily, for 7 days.
3062964|NCT02141711|Experimental|Cohort 4: TAK-438 30 mg|TAK-438 30 mg tablets, orally, once, daily, for 7 days.
3062965|NCT02141711|Placebo Comparator|Cohorts 1-4: Placebo|TAK-438 placebo-matching tablets, orally, once, daily, for 7 days.
3062966|NCT02141698|Experimental|Cohort 1: TAK-438 1 mg|TAK-438 1 mg, tablets, orally, once on Day 1.
3062967|NCT02141698|Experimental|Cohort 2: TAK-438 5 mg|TAK-438 5 mg, tablets, orally, once on Day 1.
3062968|NCT02141698|Experimental|Cohort 3: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once on Day 1.
3062969|NCT02141698|Experimental|Cohort 4: TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once on Day 1.
3062970|NCT02141698|Experimental|Cohort 5: TAK-438 15 mg|TAK-438 15 mg, tablets, orally, once on Day 1.
3062971|NCT02141698|Experimental|Cohort 6: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once on Day 1.
3062972|NCT02141698|Experimental|Cohort 7: TAK-438 30 mg|TAK-438 30 mg, tablets, orally, once on Day 1.
3062973|NCT02141698|Experimental|Cohort 8A: Food-effect|TAK-438 20 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 20 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
3062974|NCT02141698|Experimental|Cohort 8B: Food-effect|TAK-438 20 mg, tablets, orally, under fed conditions, once on Day 1, Period 1.
3062975|NCT02141698|Experimental|Cohort 9: TAK-438 Multiple Dose 1|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
3062976|NCT02141698|Experimental|Cohort 10: TAK-438 Multiple Dose 2|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
3062977|NCT02141698|Experimental|Cohort 11: TAK-438 Multiple Dose 3|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
3062978|NCT02141698|Experimental|Cohort 12: Ethnic Bridging|TAK-438 tablets, dose 1, orally, on Days 1-7 of Period 1, followed by a 4-week washout period followed by TAK-438 tablets, dose 2, orally, Days 1-7 of Period 2, followed by a 4-week washout period, followed by esomeprazole tablets, 40 mg, orally, on Days 1-7 of Period 3. TAK-438 doses to be determined from data collected in Cohorts 9-11.
3062979|NCT02141698|Placebo Comparator|Cohorts 1-7: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1
3062980|NCT02141698|Placebo Comparator|Cohorts 9-11: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1, where available, if required.
3062981|NCT02141685||IVF patients undergoing aCGH Testing|Women undergoing fresh IVF treatment and array-comparative genomic hybridization testing (aCGH), as recommended based on medical need by the clinical site reproductive endocrinologist.
3062982|NCT02141672|Experimental|Voclosporin Low Dose|Voclosporin, oral, 23.7 mg BID
3062983|NCT02141672|Experimental|Voclosporin High Dose|Voclosporin, oral 23.7 mg BID until Week 2, then voclosporin, oral, 39.5 mg BID
3062984|NCT02141672|Placebo Comparator|Placebo|"Low dose: Voclosporin placebo, oral, 3 capsules BID~High dose: Voclosporin placebo, oral, 3 capsules BID until Week 2 then voclosporin placebo, oral, 5 capsules BID"
3062985|NCT02141659|Experimental|TAK-385|"TAK-385 will be taken orally every morning at least 30 minutes before the first meal of the day.~320-360mg(loading dose), 40-160mg(maintenance dose)"
3062986|NCT02141646|Experimental|Motivational interviewing|
3062987|NCT02141646|Experimental|Behavioral skills training|
3062988|NCT02141633|Experimental|smokers|participants with smoking history ( > 10 pack/year) will be enrolled and perform airway blood flow and echocardiogram before and 15 minutes after albuterol inhalation
3062989|NCT02141633|Experimental|non-smokers|healthy life-time non smokers will be enrolled and perform airway blood flow and echocardiogram before and 15 minutes after albuterol inhalation
3062990|NCT02141620|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo.
3062991|NCT02141620|Experimental|n-Acetylcysteine|Subjects will be maintained on oral n-acetylcysteine.
3062992|NCT02141607||Hemorrhagic Shock|"Hypovolemic shock characterized by:~Hypotension: systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.~Rapid loss of significant amount of blood~Lactate levels ≥ 2 mmol/L"
3062993|NCT02141607||Cardiogenic shock|"State of inadequate circulation of blood because of ventricular failure due to acute cardiac conditions, concomitant presence of:~Hypotension: systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.~Need for a continuous infusion of inotropic drugs~Cardiac Index <2.2 L/min/m2 or use of inotropic drugs (dobutamine/isoprenaline/phosphodiesterase inhibitors or levosimendan)~Signs of reduced heart function~Cardiac overload or altered left/right ventricular function"
3063193|NCT02140307|No Intervention|Wait-list control|This arm is an inactive wait-list control.
3063194|NCT02140294|Experimental|Polymeric nutritional supplement|
3062994|NCT02141607||Septic shock|"Septic shock is defined as sepsis-induced hypotension, defined as systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.~Only community medical acquired sepsis with a sepsis onset within 48 hours from hospital admission (i.e. different from nosocomial infection).~Lactate levels ≥ 2mmol/L."
3062995|NCT02141607||control group|"The control group will consist on:~5 healthy blood donors: serving only for the purposes of obtaining reference values for proteomics analysis~a cohort of 20 patients hospitalized for sepsis OR cardiac syndromes not developing shock: will be recruited from patients admitted to the hospital during the study period. The clinical status of the patients will be assessed during hospitalization to ascertain shock and AHF development. Shock development will be an exclusion criteria."
3062996|NCT02141594||Early glaucoma|The study group consisted of consecutive unilateral glaucoma patients, categorized as early stage by Hodapp-Anderson-Parrish classification.
3062997|NCT02141594||Normal subjects|Normal control subjects had a normal ocular examination, Intraocular pressure (IOP) <22 mmHg, no past history of high IOP, no family history of glaucoma, normal optic disc morphology and visual field in both eyes. One eye of control subject was randomly selected.
3062998|NCT02141581|Experimental|Group A Fluzone® (IM)|"Participants in this group will be randomized to the trivalent inactivated influenza vaccine (TIV), Fluzone®, administered intramuscularly (IM)~2011-2012, 2012-2013 or 2013-2014 Fluzone was used as appropriate for the current year of study"
3062999|NCT02141581|Experimental|Group B Fluzone® Intradermal (ID)|"Participants in this group will be randomized to the trivalent inactivated influenza vaccine (TIV), Fluzone® Intradermal, administered intradermally (ID)~2011-2012, 2012-2013 or 2013-2014 Fluzone Intradermal was used as appropriate for the current year of study"
3063000|NCT02141581|Experimental|Group C 2011-2012 FluMist®|"Participants in this group will be randomized to 2011-2012 live attenuated influenza vaccine, FluMist®, administered intranasally.~FluMist was only used in the first year of study."
3063001|NCT02141568|Experimental|Intervention Group for Prospective Study|"Intervention: Medical and psychological treatment at the Soroka UMC functional neurology outpatient clinic. Treatment will be conducted by a multidisciplinary staff. Patients will undergo an initial meeting with a neurologist and afterwards will be directed to other members of the team (psychologist, physical therapist) on a case by case basis."
3063002|NCT02141568|No Intervention|No Intervention|Patient records will be analyzed via Clalit Health Service electronic records. No additional intervention will occur
3063003|NCT02141555|Active Comparator|Vaginal misoprostol|Participants will insert four misoprostol tablets (total of 800 micrograms) deeply into the vagina with their fingers.
3063004|NCT02141555|Experimental|Buccal Misoprostol|Participants will place two tablets of misoprostol between their gum and cheek on each side (total 800 micrograms), then swish and swallow the remnants after 30 minutes.
3063005|NCT02141542|Experimental|Tremelimumab and MEDI3617|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Tremelimumab-Fixed doses of Tremelimumab are given once per cycle~MEDI3617-MEDI3617 is administered twice per cycle"
3063006|NCT02141529|Active Comparator|Unipolar PRF|Unipolar pulsed radiofrequency thermocoagulation, intraarticularly in knee joint, 42oC of temperature during ten minutes
3063007|NCT02141529|Experimental|Bipolar PRF|Bipolar pulsed radiofrequency thermocoagulation, intraarticularly in knee joint, 42oC of temperature during ten minutes
3063008|NCT02141516|Experimental|Group A|Complement deficiency
3063009|NCT02141516|Experimental|Group B|asplenia/splenic dysfunction
3063010|NCT02141516|Active Comparator|Group C|age-matched healthy controls
3063011|NCT02141490|Experimental|1|Ferumoxytol +MRI
3063012|NCT02141477|Experimental|Omacetaxine + Decitabine|"Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.~Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I."
3063013|NCT02141451|Experimental|Treatment|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
3063014|NCT02141438||Cohort 1|Single-arm cohort study
3063015|NCT02141425|Experimental|ASP015K low dose|
3063016|NCT02141425|Experimental|ASP015K medium dose|
3063017|NCT02141425|Experimental|ASP015K high dose|Optional, depending on safety review and regulatory authority input
3063018|NCT02141425|Placebo Comparator|Placebo|
3063019|NCT02141412|Active Comparator|Group I|Patients in Group I will receive dexmedetomidine 0.25 µg/kg IV (over 10 min) at closure of sevoflurane
3063020|NCT02141412|Active Comparator|Group II|Patients in Group II will receive dexmedetomidine 0.5 µg/kg IV (over 10 min) at closure of sevoflurane
3063021|NCT02141412|Active Comparator|Group III|Patients in Group III will receive dexmedetomidine 1 µg/kg IV (over 10 min) at closure of sevoflurane
3063022|NCT02141412|Placebo Comparator|Group IV|Patients in Group IV will receive same volume of normal saline at closure of sevoflurane
3063023|NCT02141399|Experimental|ALKS 5461|
3063024|NCT02141386|Experimental|Treatment A|plasticity-based, adaptive, computerized cognitive remediation (PACR)
3063025|NCT02141386|Active Comparator|Treatment B|"Ordinary Computer Games (an active control condition)"
3063026|NCT02141373|Experimental|Glubran 2|Glubran 2 will be used at end of surgery
3063027|NCT02141373|No Intervention|Standard Surgery|
3063028|NCT02141360|Experimental|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
3063029|NCT02141360|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
3063030|NCT02141347|Other|Part A|Dose escalation of tremelimumab mono therapy for advanced solid malignancies
3063031|NCT02141347|Other|Part B|Combination therapy of tremelimumab and MEDI4736 for advanced solid malignancies
3063032|NCT02141347|Other|Part C|Fixed dose of tremelimumab for malignant mesothelioma
3063033|NCT02141321|Experimental|Misoprostol|Women will receive two sub lingual tablets each containing 200 micro gram misoprostol (Misotac), receiving a total dose of 400 micro grams. Two hour later, Cu T 380A IUD (PREGNA) will be inserted.
3063034|NCT02141321|Placebo Comparator|Placebo|Women will receive two sub lingual placebo tablets which will be similar in size, color, odor and shape to the misoprostol tablets. Two hour later, Cu T 380A IUD (PREGNA) will be inserted.
3063035|NCT02141308||Rare Chorioretinal Disease|Up to 150 patients diagnosed with a rare retinal or choroidal disease will be considered and evaluated for enrollment in this study.
3063036|NCT02141295|Experimental|Part 1 (Induction): Vanucizumab + mFOLFOX-6|Participants will receive vanucizumab at a dose of 2000 milligram (mg) as intravenous (IV) infusion; oxaliplatin at a dose of 85 mg per meter-squared (mg/m^2) as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
3063037|NCT02141295|Experimental|Part 1 (Maintenance): Vanucizumab + 5-FU + Folinic acid|Participants will receive vanucizumab at a dose confirmed during induction as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
3063038|NCT02141295|Active Comparator|Part 2 (Induction): Bevacizumab + mFOLFOX-6|Participants will receive bevacizumab at a dose of 5 milligram per kilogram (mg/kg) as IV infusion; oxaliplatin at a dose of 85 mg/m^2 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
3063039|NCT02141295|Experimental|Part 2 (Induction): Vanucizumab + mFOLFOX-6|Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; oxaliplatin at a dose of 85 mg/m^2 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
3063040|NCT02141295|Active Comparator|Part 2 (Maintenance): Bevacizumab + 5-FU + Folinic acid|Participants will receive bevacizumab at a dose of 5 mg/kg as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
3063041|NCT02141295|Experimental|Part 2 (Maintenance): Vanucizumab + 5-FU + Folinic acid|Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
3063042|NCT02141282|Experimental|ABT-199 after ibrutinib therapy|Single daily doses increasing weekly as tolerated
3063043|NCT02141282|Experimental|ABT-199 after ibrutinib or idelalisib therapy|Single daily doses increasing weekly as tolerated
3063044|NCT02141282|Experimental|ABT-199 after idelalisib therapy|Single daily doses increasing weekly as tolerated
3063045|NCT02141256|Experimental|Protein enriched products|Protein enriched products will be given to elderly residents of a care home for 10 days. Does this lead to an increased protein intake or do elderly compensate for the extra amount of protein?
3063046|NCT02141243|Experimental|Group A|"All participants will receive both the lingual frenotomy and sham procedure. Group A infants will receive lingual frenotomy for intervention #1 and a sham procedure for intervention #2. Newborns that continue to have difficulty with breastfeeding after both interventions will undergo intervention #3, a labial frenotomy.~Lingual frenotomy: tongue will be elevated, expose frenulum with a grooved director or 2 cotton tipped applicators, and then incise frenulum tissue with a straight scissor.~Sham/placebo procedure: infant brought into a procedure room and kept there for as long as the average experimental procedure would take (~5 minutes).~Maxillary labial frenotomy: 0.1 ml of 1% lidocaine will be injected into the area, upper lip lifted, frenum stretched, and a laser, (iLaseTM 940 ± 15 nm) or scissors, will be used to release its attachment to the level of the periosteum."
3063047|NCT02141243|Experimental|Group B|"All participating infants will receive both the lingual frenotomy and sham procedure. Group B infants will receive the sham procedure for intervention #1 and a lingual frenotomy for intervention #2. Newborns that continue to have difficulty with breastfeeding after both interventions will undergo intervention #3, a labial frenotomy.~Sham/placebo procedure: infant brought into a procedure room and kept there for as long as the average experimental procedure would take (~5 minutes).~Lingual frenotomy: tongue will be elevated, expose frenulum with a grooved director or 2 cotton tipped applicators, and then incise frenulum tissue with a straight scissor.~Maxillary labial frenotomy: 0.1 ml of 1% lidocaine will be injected into the area, upper lip lifted, frenum stretched, and an iLaseTM 940 ± 15 nm laser used to release its attachment to the level of the periosteum."
3063048|NCT02141230|Experimental|Alli® 60 mg|Participants purchasing Alli®
3063049|NCT02141217|Active Comparator|Amoxicillin/clavulanate|Amoxicillin/ clavulanate 1 g bd for for at least 5 days upto seven days depending on treament response
3063050|NCT02141217|Active Comparator|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon treatment response
3063051|NCT02141204|Experimental|HRV Liq Group|Subjects aged 6 to 10 weeks at the time of first vaccination who receive two oral doses of Liquid Human Rotavirus Vaccine according to a 0, 1 month schedule.
3063052|NCT02141204|Active Comparator|HRV Lyo Group|Subjects aged 6 to 10 weeks at the time of first vaccination who receive two oral doses of Lyophilized Human Rotavirus Vaccine according to a 0, 1 month schedule.
3063053|NCT02141191|Experimental|HS/sham|Subjects will utilize inhaled hypertonic saline (7%) delivered using the tPAD device during one session and perform a sham treatment with the tPAD during the other. The order will be randomized.
3063054|NCT02141191|Experimental|sham/HS|Subjects will utilize inhaled hypertonic saline (7%) delivered using the tPAD device during one session and perform a sham treatment with the tPAD during the other. The order will be randomized.
3063055|NCT02141178|Active Comparator|Bupivacaine|Patients will received 0.5% Bupivacaine subcutaneously for local anesthesia during surgery
3063056|NCT02141178|Experimental|Exparel|Patients will received Exparel subcutaneously for local anesthesia during surgery
3063057|NCT02141165|Experimental|Primary.|Diagnosis, autoCPAP, follow up.
3063058|NCT02141165|Active Comparator|Hospital|Diagnosis, autoCPAP, follow up
3063195|NCT02140294|Active Comparator|Standard Nutritional Treatment|
3063059|NCT02141152||gastric cancer|This study will recruit a total of 130 gastric cancer patients. It is expected to recruit about 250 gastric cancer patients per year. Since the incidence of each mutation is low, the different types of mutations are assumed to be mutually exclusive. So, about 30% of these patients are expected to have a mutation with a target drug. Overall response (OR) is the primary endpoint of this study. OR rate (ORR) will be compared between the group (called targeted group) of patients who have a mutation with a target drug and that (called untargeted group) of patients who have no mutation. The ORR is expected to be about 25% for the targeted group and about 5% for the untargeted group. With N=130 gastric cancer patients, about 39 patients will belong to the targeted group and about 91 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 89% of power. The study on gastric cancer will take 7 months for patient accrual.
3063060|NCT02141152||colorectal cancer|This study will recruit a total of 130 colorectal cancer patients. It is expected to recruit about 300 colorectal cancer patients per year. About 25% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The median ORR is expected to be about 25% for the targeted group and about 5% for the untargeted group. With N=130 colorectal cancer patients, about 33 patients will belong to the targeted group and about 97 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 87% of power. The study on colorectal cancer will take about 6 months for accrual.
3063061|NCT02141152||biliary tract cancer/pancreatic cancer|This study will recruit a total of 78 biliary tract cancer/pancreatic cancer patients. It is expected to recruit about 100 biliary tract cancer/pancreatic cancer patients per year. About 20% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The ORR is expected to be about 35% for the targeted group and about 5% for the untargeted group. With N=78 biliary tract cancer/pancreatic cancer patients, about 16 patients will belong to the targeted group and about 62 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 87% of power. The study on biliary tract cancer/pancreatic cancer will take about 7 months for accrual.
3063062|NCT02141152||Rare cancer|Rare cancer is hepatocellular carcinoma, melanoma and neuroendocrine tumor. This study will recruit a total of 87 hepatocellular carcinoma/rare cancer patients. It is expected to recruit about 150 biliary tract cancer/pancreatic cancer patients per year. About 25% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The ORR is expected to be about 30% for the targeted group and about 5% for the untargeted group. With N=87 biliary tract cancer/pancreatic cancer patients, about 22 patients will belong to the targeted group and about 65 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 86% of power. The study on biliary tract cancer/pancreatic cancer will take about 7 months for accrual.
3063063|NCT02141152||genitourinary cancer|
3063064|NCT02141139|No Intervention|Control arm|no medication or acetaminophen
3063065|NCT02141139|Experimental|NSAIDS (ketorolac intravenous, ibuprofen)|ketorolac IV (just before surgery) and ibuprofen for 1 weeks
3063066|NCT02141126|Experimental|Resistance training|Usual care and resistance exercises.
3063067|NCT02141126|Other|Usual care|Usual inpatient physiotherapy
3063068|NCT02141113|Active Comparator|Guanfacine Hydrocholride|"mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)"
3063069|NCT02141113|Placebo Comparator|Sugar Pill Guanfacine Hydrocholride|"mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)"
3063070|NCT02141100|Experimental|6-thioguanine, 6-mercaptopurine and methotrexate|"This is the only treatment arm; all eligible patients will receive standard methotrexate/6-mercaptopurine (6MP/MTX) maintenance therapy supplemented with 6-thioguanine (6TG).~Patients are enrolled when they have 12 to 3.5 months remaining of their maintenance therapy. After dose reduction in 6MP to 2/3 of the current dose 6TG therapy is initiated with a starting dose of 2.5 mg/m2/day. The 6TG dose will hereafter be increased at 2.5 mg/m2/day every 14 days until a max. of 12.5 mg/m2/day is reached or until the thiopurine metabolite profile (Ery-TGN/Ery-MeMP) has been increased by at least a factor 5."
3063071|NCT02141074|Experimental|50 EDs (exposure days)|
3063072|NCT02141061|Experimental|Telapristone Acetate, Proellex Formulation A (Treatment A)|Subjects who meet the eligibility criteria will be randomized to receive either 12 mg Treatment A or 12 mg Treatment B as their first assigned treatment. After a 7-day washout period subjects will receive the alternative treatment.
3063073|NCT02141061|Experimental|Telapristone Acetate, Proellex Formulation B (Treatment B)|Subjects who meet the eligibility criteria will be randomized to receive either 12 mg Treatment A or 12 mg Treatment B as their first assigned treatment. After a 7-day washout period subjects will receive the alternative treatment.
3063074|NCT02141048|Experimental|Positive Parenting Skills Training|Participants assigned to the intervention group will receive the Positive Parenting Skills Training.
3063075|NCT02141048|No Intervention|Wait-list control|Participants assigned to the wait-list control group will receive no intervention for the duration of this trial. Only after the one-year follow-up assessment has been completed will they receive the Positive Parenting Skills Training.
3063076|NCT02141035|Experimental|Acetyl-l-carnitine|Acetyl-l-carnitine will be administered for 2 months duration at a dosage of 3000 mg/d starting at the time of decompression surgery.
3063077|NCT02141035|Placebo Comparator|Placebo|Placebo will be given for 2 months starting at the time of decompression surgery
3063078|NCT02141022|Experimental|PACR Program: Plasticity based, Adaptive Cognitve Remediation|PACR Program Use: To use PACR, the participant navigates to the PACR study web site. The participant then logs into the PACR (using a study provided screen name and study identification number). A game-like experience begins, where the participant is presented with games in a set order. Each game consists of targeted exercises that contain the core science stimuli and tasks. The scheduling mechanism ensures that a participant progresses through the exercises in a defined order, generally moving from more simple (early sensory processing) exercises to more complex (multimodal, cognitive control) exercises over the course of the three-month experience.
3063196|NCT02140281|Experimental|Sequence 1 (Treatment A/B)|Subjects will be randomised to receive Treatment A in Period 1 followed by Treatment B in period 2
3063079|NCT02141022|Active Comparator|Ordinary Computer Games|Active Control Program Use (Ordinary Computer Games): The active control program is composed of 13 ordinary computer games matched to the PACR condition overall. This condition is designed to be a face-valid approach to cognitive remediation. The control condition is also designed to account for nonspecific treatment effects, including placebo response, interactions with research personnel, and experience with computers and computer-related activities, and any halo or expectation effect on study assessments.
3063080|NCT02141009|Other|Prevnar 13|Prevnar 13, 1 administration of 1 single dose (0.5mL)
3063081|NCT02140996|Experimental|Ad-sig-hMUC-1/ecdCD40L vector vaccine|Experimental: Ad-sig-hMUC-1/ecdCD40L vector vaccine This trial has six cohorts with 3 subjects planned for each cohort. Subjects in the 1st cohort will receive 1 dose of vaccine injection at the lowest planned dose of the vector, 1 x 10^9 VP. If none of the patients in the 1st cohort experience Dose limiting toxicity (DLT), a 2nd cohort will receive 1 dose of 1x10^10 VP. If none of the patients in the 2nd cohort experience DLT, the dose escalation will continue with the 3rd cohort receiving 1 doses of 5 x 10^10 VP per injection. The patients in the 4th cohort will receive 1 injection of 1x10^11 if no DLT occurs in the preceding cohort. Additional patients will be added to cohort 5 or 6 if DLTs are encountered in the first 3 patients tested in each of these cohorts.
3063082|NCT02140983|Active Comparator|Liraglutide|90 days of liraglutide treatment at adjusting dose, up to 1.8mg/day
3063083|NCT02140983|Placebo Comparator|Placebo|90 days of placebo pen, up to 1.8mg/day.
3063084|NCT02140970|Experimental|Liquid ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
3063085|NCT02140970|Placebo Comparator|Liquid placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
3063086|NCT02140957|Experimental|Educational Intervention|Parents in this arm received a 5 minute educational intervention on bottle cessation plus standard nutritional counseling.
3063087|NCT02140957|Placebo Comparator|Control|Parents in this arm received a placebo which consisted of standard nutritional counseling alone.
3063088|NCT02140944||Pre-Transplant Cohort|HIV-1 infected participants, enrolled prior to transplant, who receive a heterozygous or homozygous CCR∆32 cord blood transplant
3063089|NCT02140944||Post-Transplant Cohort|HIV-1 infected participants, enrolled within 2 years after transplant, who receive a homozygous CCR∆32 cord blood transplant
3063090|NCT02140931|Active Comparator|Angiogenic Cell Precursors|Intra-muscular injections of Angiogenic Cell Precursors (ACPs) in the ischemic leg
3063091|NCT02140931|Placebo Comparator|Cell culture medium|Intra-muscular injections of cell culture medium in the ischemic leg
3063092|NCT02140918|Experimental|Fludrocortisone 100 μg|"100 μg/day (25 µg four times daily) of fludrocortisone during 5 days~Investigations the sixth day"
3063093|NCT02140918|Experimental|Fludrocortisone 200 μg|"200 μg/day (50 µg four times daily) of fludrocortisone during 5 days~Investigations the sixth day"
3063094|NCT02140918|Experimental|Fludrocortisone 400 μg|"400 μg/day (100 µg four times daily) of fludrocortisone during 5 days~Investigations the sixth day"
3063095|NCT02140918|Placebo Comparator|Placebo|"Placebo (four times daily) during 5 days~Investigations the sixth day"
3063096|NCT02140905||Patients undergoing hemodialysis.|Subjects participating in the study
3063097|NCT02140892|Experimental|respiratory physical therapy manual technique|respiratory physical therapy manual technique- Autogenic Drainage
3063098|NCT02140892|Experimental|respiratory physical therapy technique- IPV|respiratory physical therapy technique- Intrapulmonary Percussive Ventilation
3063099|NCT02140892|No Intervention|standart medical care|standard medical care
3063100|NCT02140879|Placebo Comparator|Capsule 1|Placebo is a mixture of corn and soy oils.
3063101|NCT02140879|Active Comparator|Capsule 2|Active supplement group, will take capsules containing oil '2' which is an algal oil.
3063102|NCT02140866|Experimental|Hand Exercise|The intervention group will receive an exercise program for the hand/arm in combination with a compensatory intervention program (CIP).
3063103|NCT02140866|Active Comparator|Compensatory Intervention Program (CIP)|The control group will receive the Compensatory Intervention Program (CIP) only.
3063104|NCT02140853||MDR group|patients of MDR pathogen infection
3063105|NCT02140853||non-MDR group|patients of non-MDR pathogen infection
3063106|NCT02140827|Experimental|IMP education|patients in this group are educated about bowel preparation by instant messaging program and meanwhile a booklet was also sent to them.
3063107|NCT02140827|No Intervention|normal education|patients in this group are educated about bowel preparation on the day of reservation by nurse for about 15 minutes and meanwhile a booklet was also sent to them.
3063108|NCT02140814|Experimental|Niacinamide|All subjects in this study will take niacinamide at a dose of 30 mg per kilogram of body weight by mouth daily, in two divided daily doses, for 12 months.
3063109|NCT02140801|Experimental|Ticagrelor|Ticagrelor 90mg tablet, twice daily
3063110|NCT02140801|Experimental|Clopidogrel|Clopidogrel 75mg tablet, daily
3063111|NCT02140788|Active Comparator|Metformin|Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added metformin will receive metformin 250 mg BID days 1-3, 500 mg BID days 4-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate a dose escalation will have the metformin dose reduced to the previously tolerated lower dose.
3063112|NCT02140788|Active Comparator|Fish Oil|Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added fish oil will receive OmegaBrite 500 mg gel cap BID days 1-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate the dose escalation to 1000 mg BID will have the fish oil dose reduce to 500 mg BID.
3063113|NCT02140788|Active Comparator|Metformin and Fish Oil|Subjects will continue to take the clozapine prescribed as standard of care. Subjects will receive Metformin and Fish Oil as part of the study.
3063114|NCT02140788|No Intervention|No medication added|Subjects will continue to take the clozapine prescribed as standard of care. Subjects will not receive Metformin or Fish Oil.
3063197|NCT02140281|Experimental|Sequence 2 (Treatment B/A)|Subjects will be randomised to receive Treatment B in Period 1 followed by Treatment A in period 2
3063198|NCT02140268|Active Comparator|Midazolam 7.5 mg|Volunteers will receive Midazolam 7.5 mg administered by mouth as a syrup
3063115|NCT02140775|Experimental|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
3063116|NCT02140775|Active Comparator|Supportive Counseling|Supportive Counseling sessions will follow the same schedule and the Behavioral Activation Counseling, meeting for one hour every two weeks. The content of the sessions will be guided by the participant. The counselor will provide an accepting environment for the participant to explore his/her feelings about these topics.
3063117|NCT02140762|Experimental|MenABCWY|Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months
3063118|NCT02140762|Active Comparator|Placebo/MenACWY|Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months
3063119|NCT02140749|Experimental|sc-FOS 2g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 2 g/day (4 weeks)
3063120|NCT02140749|Experimental|sc-FOS 4g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 4 g/day (4 weeks)
3063121|NCT02140749|Experimental|sc-FOS 8g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 8 g/day (4 weeks)
3063122|NCT02140736||Patients with chemo-induced symptomatic anemia|
3063123|NCT02140723||preoperative short course radiation|preoperative short course radiation with 8 weeks delay of surgery
3063124|NCT02140710|Active Comparator|Osteopathic treatment group|visceral osteopathic treatment algorithm
3063125|NCT02140710|No Intervention|Control group|no intervention
3063126|NCT02140697|Experimental|Hippophae rhamnoides L. Leaf Extract|Hippophae rhamnoides L. Leaf Extract 3g/day
3063127|NCT02140697|Placebo Comparator|Placebo|Placebo 3g/day
3063128|NCT02140684||eNO monitoring|Patients undergoing eNO monitoring at the index prescription date
3063129|NCT02140684||No eNO monitoring|
3063130|NCT02140671||Patients with an asthma diagnosis|
3063131|NCT02140671||Patients where there is diagnostic doubt|
3063132|NCT02140658|Active Comparator|multiple health education interventions|The first group will receive health education manuals and Digital Video Disc (DVD) during hospitalization and regular text message during 6 months after discharge.
3063133|NCT02140658|Placebo Comparator|conventional health education|The second group will receive conventional health education during hospitalization except health education manuals, text message and Digital Video Disc (DVD)
3063134|NCT02140645||Linagliptin1|T2DM patients initiating Linagliptin (DPP-4 comparison)
3063135|NCT02140645||Other DPP4|T2DM patients initiating a non-linagliptin DPP-4 inhibitor
3063136|NCT02140645||Linagliptin2|T2DM patients initiating Linagliptin (glitizaone comparison)
3063137|NCT02140645||Glitazones|T2DM patients initiating Thiazolidinediones (glitazones)
3063138|NCT02140645||Sulfonylurea|T2DM patients initiating any medication in the Sulfonylurea class
3063139|NCT02140645||Linagliptin3|T2DM patients initiating Linagliptin (Sulfonylurea comparison)
3063140|NCT02140632|Experimental|Local steroid injection|"The local injection of steroid is performed by the same investigator after the randomization. Using a sterile technique, 20mg methylprednisolone acetate premixed with lidnocaine is injected using a 25-gauge x 5/8 needle. The needle is inserted medially to the palmaris longus tendon at the distal palmar crease in the wrist at an angle of 45-degree to the forearm. The steroid is injected at approximately 1cm below the skin. The needle will be repositioned if there is any resistance to injection, or any pain or paraesthesia in the median nerve territory."
3063141|NCT02140632|Active Comparator|Wrist splinting|After randomization, the hands of the patients in the splinting group are splinted in neutral position with standard cotton-polyester splint. Patients are encouraged to use the splints during nighttime whenever possible for one month.
3063142|NCT02140619|Active Comparator|multiple health education interventions|The group will receive health education manuals and Digital Video Disc (DVD) during hospitalization and regular text message during 1 year after discharge.
3063143|NCT02140619|Placebo Comparator|conventional health education|The second group will receive conventional health education during hospitalization except health education manuals, text message and Digital Video Disc (DVD)
3063144|NCT02140606|Experimental|Cafusertib Hydrochloride + Cytarabine|Cafusertib (d1 and 15 - one hour iv.) + LD ARA C 2x20 mg/d s.c. Patient to receive escalating dose of cafusertib hydrochloride.
3063145|NCT02140593|Placebo Comparator|Standard neuromuscular blockade|Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment decided by the attending anesthetist combined with saline infusion (placebo).
3063146|NCT02140593|Active Comparator|Deep neuromuscular blockade|Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level post tetanic count (PTC) of 0-1 combined with bolus saline (placebo) mimicking standard treatment.
3063147|NCT02140580|Active Comparator|Minimally invasive surfactant therapy|Minimally invasive surfactant therapy - delivery of exogenous surfactant to the lung via brief catheterisation of the trachea with an instillation catheter in a preterm infant who is being supported with continuous positive airway pressure (CPAP) via nasal prongs or mask. Poractant alfa (Curosurf) at a dosage of 200 mg/kg will be administered over 15 - 30 seconds. Total duration of the procedure will be less than 5 minutes, followed by reinstitution of CPAP.
3063148|NCT02140580|Sham Comparator|Continuation on CPAP|Standard control treatment. After randomisation, infants will receive a sham treatment from a treatment team not engaged in clinical care. This will not involve removal of prongs or discontinuation of CPAP but will require setting up intubation equipment, screening the baby, testing suction unit, repositioning of the baby and changing the baby's monitoring. CPAP will thereafter continue.
3063149|NCT02140567||Syncope Prediction|All enrolled patients that performed the tilt table test
3063150|NCT02140554|Experimental|Group A|Subjects will have rescue cells collected by bone marrow harvest, and will receive treatment of LentiGlobin BB305 Drug Product manufactured with autologous CD34+ hematopoietic stem cells collected by bone marrow harvest transduced with LentiGlobin BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.
3063199|NCT02140268|Experimental|AZD1722 15 mg|Volunteers will received AZD1722 15 mg administered by mouth, as a tablet
3090452|NCT01956279|Placebo Comparator|Arm 2|Placebo
3063151|NCT02140554|Experimental|Group B|"Group B1:~Subjects will have rescue cells collected by bone marrow harvest, and will receive treatment of LentiGlobin BB305 Drug Product manufactured with autologous CD34+ hematopoietic stem cells collected by bone marrow harvest transduced with LentiGlobin BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.~Group B2:~Plerixafor mobilization and apheresis will be used for collection of rescue cells and exploratory manufacturing development. Subjects will receive treatment of LentiGlobin BB305 Drug Product manufactured with autologous CD34+ hematopoietic stem cells collected by bone marrow harvest transduced with LentiGlobin BB305 lentiviral vector encoding the human beta-A-T87Q globin gene."
3063152|NCT02140554|Experimental|Group C|Plerixafor mobilization and apheresis will be used for collection of rescue cells, and subjects will receive treatment of LentiGlobin BB305 Drug Product manufactured with autologous CD34+ hematopoietic stem cells collected by plerixafor mobilization and apheresis transduced with LentiGlobin BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.
3063153|NCT02140541||Blood eosinophil count ≤ 400/µl|
3063154|NCT02140541||Blood eosinophil count > 400/µl|
3063155|NCT02140528|Experimental|Mesenchymal stem cell receipients|Transplantation of allogenic adipose derived mesenchymal stem cells in patients with tibial fracture.
3063156|NCT02140528|Placebo Comparator|Placebo|Placebo injection in the site of fracture in patients with tibia fracture.
3063157|NCT02140515|Active Comparator|Luveris|Evaluation the effect of Luveris protocol on Induction of ovulation in Patients with Hypogonadotropic Hypogonadism
3063158|NCT02140515|Active Comparator|Gonal-F& Luveris|Evaluation the effect of Gonal-F& Luveris protocols of Induction of ovulation in Patients with Hypogonadotropic Hypogonadism
3063159|NCT02140502||Men undergoing prostate biopsy|
3063160|NCT02140489|Experimental|Sequence 1|amosartan → rosuvastatin → amosartan and rosuvastatin
3063161|NCT02140489|Experimental|Sequence 2|rosuvastatin → amosartan and rosuvastatin → amosartan
3063162|NCT02140489|Experimental|Sequence 3|amosartan and rosuvastatin → amosartan → rosuvastatin
3063163|NCT02140476|Experimental|Thyroid Goiter|Benign thyroid disease with a nodule equal or lesser than 4 cm in diameter of any gender or ethnical origin. Half of these patients will undergo either bipolar or conventional thyroidectomy.
3063164|NCT02140476|Active Comparator|Papillary Thyroid Cancer|Patients of any gender or ethnical origin with papillary thyroid cancer no greater than 4 cm in diameter. Half of these patients will undergo either bipolar or conventional thyroidectomy.
3063165|NCT02140463||metastatic cancer|metastatic gastrointestinal cancer metastatic genitourinary cancer other rare cancer lung cancer
3063166|NCT02140450|Active Comparator|Timolol|Timolol eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
3063167|NCT02140450|Active Comparator|Brimonidine|Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
3063168|NCT02140450|Active Comparator|Acetazolamide|Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection
3063169|NCT02140450|Active Comparator|Mannitol|Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
3063170|NCT02140450|Sham Comparator|Placebo|Artificial tears, 2 drops, 1-2 hours before intravitreal injection
3063171|NCT02140437|Experimental|Fulvestrant and anastrozole|Anastrozole 1 mg PO QD Fulvestrant 500mg IM d1,15, 29 and 4 weeks after
3063172|NCT02140437|Active Comparator|Anastrozole|Anastrozole 1 mg PO QD
3063173|NCT02140424||youth with type 1 diabetes|
3063174|NCT02140424||healthy controls|
3063175|NCT02140411|Experimental|Ranibizumab|Ranibizumab treatment
3063176|NCT02140398|Experimental|Currettage|Endometrial Currettage (endometrial scrapping) will be performed at the time of laparoscopic ovarian drilling
3063177|NCT02140398|No Intervention|Nothing|No endometrial curettage at time of Laparoscopic ovarian drilling
3063178|NCT02140385|Active Comparator|Abdominoplasty-Scarpa's fascia preservation|Scarpa's fascia preservation Lymphoscintigraphy 3D imaging Abdominal ultrasound
3063179|NCT02140385|Active Comparator|Abdominoplasty-Scarpa's fascia ablation|Scarpa's fascia ablation Lymphoscintigraphy 3D imaging Abdominal ultrasound
3063180|NCT02140372|Experimental|Volunteer group|Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
3063181|NCT02140359|No Intervention|Control Group: Usual Care|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet with case managers according to the usual procedures for new residents and will be given a standard case manager interaction.
3063182|NCT02140359|Experimental|Motivational Network Interview Recipients|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet roughly every two weeks with a case manager and answer questions about their social network, will be shown visual feedback about their networks, and will participate in a motivational interview conducted by the case managers. The questions and visualizations will be facilitated by an electronic tool for presenting screens with questions, capturing responses, processing and visualizing social network data.
3063183|NCT02140346|Experimental|28 day repeat dose (low dose)|
3063184|NCT02140346|Experimental|28 day repeat dose (high dose)|
3063185|NCT02140333|Experimental|Erlotinib 100mg|Erlotinib 100mg
3063186|NCT02140333|Active Comparator|Erlotinib 150mg|Erlotinib 150mg
3063187|NCT02140320|Experimental|Single dose (healthy volunteers)|
3063188|NCT02140320|Experimental|14 day repeat dose (healthy volunteers)|
3063189|NCT02140320|Experimental|14 day repeat dose (asthma patients)|
3063190|NCT02140320|Experimental|28 day repeat dose (healthy volunteers)|
3063191|NCT02140307|Experimental|Meditation training, group format|"The course Relaxation Response-based Mental Health Promotion (publicly referred to as Open and Calm) is given in group format.~The intervention entails 9 courses (1 per week of 2.5 hrs), a course book (120 pages), audio support (6 guided meditative practices), access to a webpage with additional information, and the possibility of two personal sessions with the intervention instructor (a certified psychologist)."
3063192|NCT02140307|Active Comparator|Meditation training, individual format|"The course Relaxation Response-based Mental Health Promotion (Open and Calm) is given by the same instructor as for group formats using precisely the same material and methods, but in about 6-9 (as to each persons' individual needs and preferences) face-to-face meetings."
3063200|NCT02140268|Experimental|AZD1722 15 mg and Midazolam 7.5 mg|Volunteers will receive AZD1722 15 mg tablet and Midazolam 7.5 mg syrup, by mouth
3063201|NCT02140255|Other|Early Intensive ART|
3063202|NCT02140242|Active Comparator|daunorubicin 60 mg/m2|study part 1 - dose daunorubicin standard dose daunorubicin in induction 1 (60 mg/m2) on days 3-5
3063203|NCT02140242|Active Comparator|Double induction|study part 2: induction cycles double induction (only patients with good response)
3063204|NCT02140242|Experimental|Single induction|study part 2: induction cycles single induction (only patients with good response)
3063205|NCT02140229|Active Comparator|Usual care|Usual care and follow-up every 3 months
3063206|NCT02140229|Experimental|US-driven therapy|Clinical evaluation according to DAS28 + US every 3 months
3063207|NCT02140229|Active Comparator|ACR/EULAR remission criteria-driven therapy|Clinical evaluation according to DAS28 + ACR/EULAR remission criteria every 3 months
3063208|NCT02140216||Day 0 blood transfusion|Patients undergoing elective spine surgery receiving intra- or immediate-postoperative red cell blood transfusion.
3063209|NCT02140216||Day 1 or 2 blood transfusion|Patients undergoing elective spine surgery receiving first red cell blood transfusion on day 1 or 2 after surgery.
3063210|NCT02140216||No blood transfusion|Patients undergoing elective spine surgery receiving no blood transfusion.
3063211|NCT02140203|Active Comparator|Young Yoga Group|People who are younger than 60 year-old They have received Yoga training in one-year experimental period
3063212|NCT02140203|No Intervention|Young Control Group|People who are younger than 60 year-old No Yoga training through out the one-year experimental period
3063213|NCT02140203|No Intervention|Aged Control Group|People who are equal or older than 60 year-old They have not received any yoga training during the one-year experimental period
3063214|NCT02140203|Active Comparator|Aged Yoga Group|People who are equal or older than 60 year-old They have received any yoga training during the one-year experimental period
3063215|NCT02140164|Experimental|Minocycline|Oral administration of minocycline
3063216|NCT02140151|No Intervention|Sham|Sham Injection
3063217|NCT02140151|Active Comparator|Quarterly Ranibizumab 0.5mg|Quarterly intravitreal injection of 0.5mg ranibizumab
3063218|NCT02140138|Experimental|Arm A (i.d. vaccinations with needle free injection device)|"Duration: Patients in Arm A will receive a total of 4 vaccinations with CV9104 in weeks 1, 2, 3 and 5. These patients will undergo radical prostatectomy at least 1 week but not later than 2 weeks after the 4th vaccination (week 6 or 7). After surgery high risk or very high risk patients will be offered to receive 2 additional vaccinations with CV9104 at week 8 and 10 post surgery.~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).~Administration site: Skin of the lateral parts of the upper arms (over the deltoid regions) and the lateral part of the thighs.~Dose: 2 x 80 μg mRNA per injection (2 x 100 μL), equals 160 μg mRNA per RNActive® drug product component"
3063219|NCT02140138|Experimental|Arm B (i.d. vaccination by conventional injection)|"Duration: Patients in Arm B will receive a total of 4 vaccinations with CV9104 in weeks 1, 2, 3 and 5. These patients will undergo radical prostatectomy at least 1 week but not later than 2 weeks after the 4th vaccination (week 6 or 7). After surgery high risk or very high risk patients will be offered to receive 2 additional vaccinations with CV9104 at week 8 and 10 post surgery.~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).~Administration site: Skin of the medial part of the upper arms and thigh~Dose: 2 x 160 μg mRNA per injection (2 x 200 μL), equals 320 μg mRNA per RNActive® drug product component"
3063220|NCT02140138|Other|Arm C (i.d. vaccination with needle free injection device)|"Duration: Patients in Arm C will receive no vaccination before radical prostatectomy. After surgery high risk or very high risk patients will be offered to receive 6 vaccinations with CV9104 at week 8, 9, 10, 12, 14 and 16 after surgery.~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).~Administration site: Skin of the lateral parts of the upper arms (over the deltoid regions) and the lateral part of the thighs.~Dose: 2 x 80 μg mRNA per injection (2 x 100 μL), equals 160 μg mRNA per RNActive® drug product component"
3063221|NCT02140125|Experimental|ASP2408 low dose group|
3063222|NCT02140125|Experimental|ASP2408 middle dose group|
3063223|NCT02140125|Experimental|ASP2408 high dose group|
3063224|NCT02140125|Placebo Comparator|Placebo group|
3063225|NCT02140112|Active Comparator|Trichuris suis ova|TSO 2500 x 2 doses every 2 weeks followed by TSO 7500 x 6 doses every 2 weeks
3063226|NCT02140112|Placebo Comparator|Placebo|Placebo 8 doses every 2 weeks
3063227|NCT02140099|Experimental|Healthy Relationships Education/Skills|The experimental intervention is the group-based, 15-session Healthy Relationships Plus Program (HRPP). In this study, the HRPP will be offered in a condensed 8-day format (July 8-11 and 14-17, 2014). On days 1 to 7, participants will attend the program for 2 hours, and on day 8, participants will attend the program for 1 hour. The program will be facilitated by high school teachers. Eight HRPP groups will run concurrently during the study period.
3063228|NCT02140099|Other|Classroom Activities|The control condition is a group-based, 15-session program focusing on typical Classroom Activities. The primary activity is to create a school welcome packet for incoming Grade 9 students, with other activities including reading and physical exercise. The control condition will be offered on 8 consecutive weekdays (July 8-11 and 14-17, 2014). On days 1 to 7, participants will attend the control program for 2 hours, and on day 8, participants will attend the control program for 1 hour. The control group will be facilitated by bachelor's level research assistants and pre-service teachers. Eight control groups will run concurrently during the study period.
3063229|NCT02140086|Experimental|Buteyko based Remedial Breathing Therapy|Buteyko based Remedial Breathing Therapy
3063230|NCT02140086|No Intervention|Waiting List|Training in the course of the study
3063231|NCT02140073|Experimental|omeprazole+domperidone SR|patients with GERD receive omeprazole 20mg + domperidone SR 30mg , 2 capsules in the morning
3063232|NCT02140073|Active Comparator|omeprazole|omeprazole 40mg in the morning
3063233|NCT02140060|Experimental|TravA/Brinz|Dose Level A / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
3063234|NCT02140060|Experimental|TravB/Brinz|Dose Level B / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
3063235|NCT02140060|Experimental|TravC/Brinz|Dose Level C / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
3063236|NCT02140060|Active Comparator|AZOPT|Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks
3063237|NCT02140060|Active Comparator|TRAV Z|Brinzolamide suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks
3063238|NCT02140060|Active Comparator|TRAV Z + AZOPT|Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks
3063239|NCT02140047|Experimental|MT-2301-Low|
3063240|NCT02140047|Experimental|MT-2301-High|
3063241|NCT02140047|Active Comparator|ActHib|
3063242|NCT02140034|Experimental|Study Arm: Extensive Peritoneal Lavage|The peritoneal cavity of subject will be washed with 10 liters of warmed normal saline (1 liter per cycle for 10 cycles) . The abdomen will be closed as per standard
3063243|NCT02140034|No Intervention|Control Arm: Standard Treatment|The peritoneal cavity of subjects will be washed with 2 liters or less of warmed normal saline. The abdomen will be closed as per standard.
3063244|NCT02140021|Experimental|Anal Pap Test + Anoscopy|Women with high-grade dysplasia or squamous cell carcinoma of the cervix, vagina, or vulva undergo a pap test and anoscopy.
3063245|NCT02140008|Experimental|I-gel group|
3063246|NCT02140008|Active Comparator|Air-Q group|
3063247|NCT02139995|Experimental|Transfusion trigger based on WCTS-CP|Determination of whether a patient need red blood cells transfusion or which hemoglobin level should be maintained is based on WCTS-CP
3063248|NCT02139995|Active Comparator|Transfusion trigger based on experience|Determination of whether a patient need red blood cell transfusion or which hemoglobin level should be maintained is base on the physician's experience
3063249|NCT02139982|Other|group MC(phase 1)|specific nerve block:musculocutaneous nerve block
3063250|NCT02139982|Other|group UL( phase 1)|specific nerve block:ulnar nerve block
3063251|NCT02139982|Other|group RA (phase 1)|specific nerve block:radial nerve block
3063252|NCT02139982|Other|group ME (phase 1)|specific nerve block:median nerve block
3063253|NCT02139982|Experimental|group A(phase 2)|30ml ropivacaine 0.125%
3063254|NCT02139982|Experimental|group B(phase 2)|30ml ropivacaine 0.2%
3063255|NCT02139982|Experimental|group C(phase 2)|30ml ropivacaine 0.25%
3063256|NCT02139982|Experimental|group D(phase 2)|30ml ropivacaine 0.375%
3063257|NCT02139982|Experimental|group E(phase 2)|30ml ropivacaine 0.5%
3063258|NCT02139982|Experimental|group F(phase 2)|30ml ropivacaine 0.75%
3063259|NCT02139969||GreenLight XPS Laser System|
3063260|NCT02139956||stress urinary incontinence|group 1 women with stress urinary incontinence by ultrasonography
3063261|NCT02139956||continent group|group 2 women without stress urinary incontinence by ultrasonography
3063262|NCT02139943|Experimental|Canagliflozin 100 mg|Each participant will receive 100 mg of canagliflozin once daily for 18 weeks.
3063263|NCT02139943|Experimental|Canagliflozin 300 mg|Each participant will receive 300 mg of canagliflozin once daily for 18 weeks.
3063264|NCT02139943|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily for 18 weeks
3063265|NCT02139930|Active Comparator|Normal Nicotine Control Group|These subjects will smoke normal nicotine content Spectrum brand cigarettes for 20 weeks.
3063266|NCT02139930|Experimental|Immediate Nicotine Reduction Group|This group will immediately be switched to smoking very low nicotine content (VLNC) Spectrum brand cigarettes. They will smoke these cigarettes for 20 weeks.
3063267|NCT02139930|Experimental|Gradual Nicotine Reduction Group|This group will smoke progressively lower nicotine content Spectrum brand cigarettes for a period of one month each until they end up smoking the same VLNC cigarettes as the immediate reduction group.
3063268|NCT02139917|Experimental|Transitional Palliative Care|"Transitional palliative care include:-~telephone follow up for early identification of signs and symptoms~home visit for spiritual support"
3063269|NCT02139917|No Intervention|Customary care|"Customary care receive care :-~hospital based medical follow up~general nursing assessment and advice"
3063270|NCT02139904|Placebo Comparator|Active Symptom Control|Active symptom control includes palliative care and standard care methods used to manage symptoms
3063271|NCT02139904|Active Comparator|Vinorelbine|Active symptom control (ASC) as per local practice plus vinorelbine administered at a dose of 60mg/m2 orally on day 1, day 8 and day 15 on a 3- weekly cycle, incrementing to 80mg/m2 weekly on a 3-weekly cycle in the absence of any significant toxicity for subsequent cycles. Patients will continue chemotherapy until evidence of radiological progression (or unacceptable toxicity or patient withdrawal).
3063272|NCT02139891|Experimental|"MultiPoint Pacing On"|Patients will be randomized to the MPP-ON Arm vs MPP-OFF in in crossover fashion with 3 months in each period.
3063273|NCT02139891|Active Comparator|"MultiPoint Pacing Off"|Patients will be randomized to the MPP-OFF arm vs MPP-ON in crossover fashion with 3 months in each period.
3063274|NCT02139878|Experimental|Wild blueberry juice|240 ml wild blueberry juice
3063275|NCT02139878|Placebo Comparator|Placebo wild blueberry juice|240 ml placebo wild blueberry juice
3063276|NCT02139865|Experimental|30%|Training at 30% 1RM
3063277|NCT02139865|Experimental|80%|Training at 80% 1RM
3063278|NCT02139852|Experimental|capsaicin|Capsaicin
3063279|NCT02139852|Placebo Comparator|Placebo|
3063280|NCT02139839|Placebo Comparator|Gelatin pill first|
3063282|NCT02139826|Experimental|IX-01 Capsule while Fasting|Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods
3063283|NCT02139826|Experimental|IX-01 Aqueous Dispersion while Fasting|Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods
3063284|NCT02139826|Experimental|IX-01 Capsule after Food|Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods
3063285|NCT02139813|Experimental|Laparoscopic Omega Loop Bypass|Laparoscopic Mini-gastric bypass
3063286|NCT02139813|Active Comparator|Laparoscopic Roux-en-Y Gastric ByPass|Procedure of reference in bariatric surgery
3063287|NCT02139800|Active Comparator|Control Arm-Standard of care|Control Arm-Respiratory support using Standard of Care positive-end expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O compared to Sustained Inflation intervention
3063288|NCT02139800|Experimental|Sustained Intervention|Administer delivery room respiratory support using a Sustained Inflation (SI) intervention and expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O
3063289|NCT02139787|Experimental|Radio Story|Participants listen to a radio story about a family's' success with preventing or managing hypertension or obesity through diet and physical activity; the focus was for the entire family to implement healthful lifestyle behaviors so the children can learn as well.
3063290|NCT02139787|Active Comparator|Control -listened to a brochure|Participants received an audio version of a standard brochure about hypertension or obesity prevention.
3063291|NCT02139774||Active Survelliance|Men age 65 and older who are undergoing active surveillance as primary treatment for their prostate cancer.
3063292|NCT02139774||Radiation|Men age 65 and older who are undergoing radiation only as primary treatment for their prostate cancer.
3063293|NCT02139774||Endocrine Therapy|Men age 65 and older who are undergoing endocrine therapy as primary treatment for their prostate cancer.
3063294|NCT02139774||Surgery|Men age 65 and older who are undergoing surgery as primary treatment for their prostate cancer.
3063295|NCT02139761|Active Comparator|l-tetrahydropalmatine (l-THP)|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
3063296|NCT02139761|Placebo Comparator|Placebo|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
3063297|NCT02139748|Active Comparator|Dental Implant & ADM|Dental implant placement plus simultaneous grafting use one layer of ADM.
3063298|NCT02139748|Experimental|Dental Implant & ADM & bone xenograft|Dental implant placement plus simultaneous grafting use one layer of ADM with bovine xenograft.
3063299|NCT02139735|Experimental|Ultrasound|3 MHz (Mega Hertz) ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ (Temporomandibular joint) and masseter muscles bilaterally
3063300|NCT02139735|Experimental|Ultrasound associated with stretchting|"3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally.~Active stretching of the masseter muscles with mouth opening and closed lips"
3063301|NCT02139735|Experimental|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
3063302|NCT02139722|No Intervention|Provider Panel Notification (PPN) Alone|The comparison procedures consist of a panel notification given to providers and an audio-visual presentation on diet and exercise given to patients.
3063303|NCT02139722|Experimental|Video Doctor, PA + PPN|Video Doctor (VD) and Provider Alert (PA) intervention combined with Provider Panel Notification (PPN)
3063304|NCT02139709|Experimental|Ganglioside|1.0 gram ZETA dairy lipid powder (Fonterra NZ)
3063305|NCT02139709|Placebo Comparator|Placebo|1.0 gram milk fat fraction void of ganglioside
3063306|NCT02139696||MS patients initiating fingolimod|Patients will be imaged using PET and MRI at baseline, and twice during treatment.
3063307|NCT02139683|Experimental|HIFU treatment|HIFU treatment in patient diagnosed with fibroadenoma
3063308|NCT02139670||pregnant womens|
3063309|NCT02139657|Experimental|RIG-C|Single 20 IU/kg dose of RIG-C by intramuscular injection
3063310|NCT02139644|Experimental|FS MDPI 100 / 12.5 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3063311|NCT02139644|Experimental|FS MDPI 50 / 12.5 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg (for a total daily dose of 100 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3063312|NCT02139644|Experimental|Fp MDPI 100 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg for a total daily dose of 200 mcg for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3063313|NCT02139644|Experimental|Fp MDPI 50 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg for a total daily dose of 100 mcg for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3063314|NCT02139644|Placebo Comparator|Placebo MDPI|"The placebo multidose dry powder inhaler was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart).~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3063315|NCT02139631|Experimental|Healthy volunteers|The volunteers initially underwent a clinical examination, spirometry and echocardiography to prove the health state. Then, different levels of positive end expiratory pressure (PEEP) is applied by the noninvasive ventilation in all individuals and the hemodynamic repercussions are evaluated by the doppler echocardiography
3063316|NCT02139618|Experimental|Methyl Aminolevulinate (MAL)|1 gram of Topical Methyl Aminolevulinate (MAL) applied to the whole face 30 minutes before sun exposure for 2 hours (3 sessions , 2 to 4 weeks apart)
3063317|NCT02139618|Placebo Comparator|Placebo|1 gram of placebo cream applied to the whole face 30 minutes before sun exposure for 2 hours (3 sessions , 2 to 4 weeks apart)
3063318|NCT02139605|Active Comparator|D2 Lymphadenectomy|Intervention D3 Lymphadenectomy
3063319|NCT02139605|Experimental|D3 Lymphadenectomy|Comparator D2 Lymphadenectomy
3063320|NCT02139592||brentuximab vedotin (recombinant) Intravenous infusion|Intravenous infusion of 1.8 mg/kg (body weight) of brentuximab vedotin (recombinant) administered once every three weeks
3063321|NCT02139579|Experimental|Avastin|bevacizumab 7.5mg/kg+paclitaxel 200mg/m2＋carboplatin area under curve(AUC)=6, every 3 weeks，maximum 4 cycles
3063322|NCT02139566|Experimental|Hi-tech video consent|This group will be shown a professionally animated video that presents the major components of the informed consent document. Intervention is Video Consent (high-tech) PDF informed consent document.
3063323|NCT02139566|Experimental|Low-tech video consent|"Participants in this arm will be provided with informed consent information through viewing a talking head video produced by a non-professional presenter, with widely available and inexpensive video equipment. Intervention is video consent (low-tech), PDF informed consent document."
3063324|NCT02139566|Experimental|FAQ consent|"Participants in this arm will be provided with informed consent content through an interactive frequently asked questions format, in which the participant will click on a question and be shown text that provides an answer to that question. Major informed consent topics will have one or more question and answer pairs. Intervention is FAQ format consent, PDF informed consent document"
3063325|NCT02139566|Active Comparator|Standard consent process|Participants in this arm will be provided with informed consent content by being shown a standard informed consent document in a scrolling window within the browser window, PDF informed consent document
3063326|NCT02139553|Experimental|Rhythmic rehabilitation|Patients undergo a first evaluation, and a second evaluation one month later to determine their natural evolution. The following month, patients get 12 sessions of rhythmic therapy. A third evaluation is organized straight after this month and a fourth evaluation, 3 months after to assess the after-effects of the therapy.
3063327|NCT02139540|Other|N2O/Placebo|First session: Nitrous oxide Second session: placebo
3063328|NCT02139540|Other|Placebo/N2O|First session: Placebo Second session: Nitrous Oxide
3063329|NCT02139514|Active Comparator|Virtual Reality Social Cognition Training|Virtual Reality Social Cognition Training
3063330|NCT02139514|No Intervention|Control|Participants in the Control condition will be offered treatment following the Control condition.
3063331|NCT02139501|Experimental|rhTPO, 300Units/kg ,daily for 14 consecutive days|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,daily for 14 consecutive days
3063332|NCT02139501|Experimental|rhTPO, 300Units/kg ,one times every other day for 7 times|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,one times every other day for 7 times.
3063333|NCT02139501|Experimental|rhTPO, 300Units/kg ,daily for 7 consecutive days|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,daily for 7consecutive days.
3063334|NCT02139488||neoadjuvant or definitive chemoradiation|Esophageal cancer patients planned for neoadjuvant or definitive chemoradiation.
3063335|NCT02139475||Colonoscopy|patients undergoing colonoscopy after colorectal cancer surgery
3063336|NCT02139462|Experimental|Standard training|Therapists will receive standard training in FBT.
3063337|NCT02139462|Experimental|Novel training|Therapists will receive a novel, more efficient training in FBT
3063338|NCT02139449||ICD/CRT registry|
3063339|NCT02139436|Experimental|FES-row-training|Subjects will perform 6 months of FES-row-training.
3063340|NCT02139436|Other|Wait-list time control|Subjects will wait for 6 months before performing 6 months of FES-row-training.
3063341|NCT02139436|Active Comparator|Arms-only-row-training|Subjects will perform 6 months of arms-only row training followed by 6 months of FES-row-training
3063342|NCT02139423|Experimental|All newborns who fail universal newborn|CMV PCR
3063343|NCT02139410||IGF-1 1st and 2nd quartile|Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment
3063344|NCT02139410||IGF-1 3rd and 4rd quartile|Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment
3063345|NCT02139397|Experimental|DFMO and Bortezomib|Subjects will take DFMO by mouth 2 times a day for each day of a 21 day cycle and Bortezomib will be given by IV push on days 1, 4, and 8 of each 21 day cycle.
3063346|NCT02139371|Experimental|64Cu-DOTA-AE105 PET|One injection of 64-Cu-DOTA-AE105 (app. 200 Mbq IV) followed by 3 PET scans 1,3 and 24 hours post injection
3063347|NCT02139358|Experimental|Dose Escalation / Phase II Treatment|Single arm, non-randomized, open label phase I/II multisite Simon two stage minimax trial. Gemcitabine plus trastuzumab and pertuzumab.
3063348|NCT02139345|Experimental|TC-A PS|Subject will be implanted with the TC-A PS Total Knee Replacement System
3063349|NCT02139345|Active Comparator|TC-PLUS Solution PS|Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System.
3063350|NCT02139332|Active Comparator|Resource & Referral group|Individuals randomized to the control group will receive a resource & Referral service immediately after their baseline research visit.
3063351|NCT02139332|Experimental|PFR Group|Individuals randomized to the Immediate group will receive the intervention program immediately after completing the baseline assessment.
3063352|NCT02139319|Experimental|Botulinum toxin|Single intra-articular injection
3063353|NCT02139319|Placebo Comparator|Placebo|Single intra-articular injection
3063354|NCT02139306|Experimental|Ataluren (PTC124®)|Oral powder for suspension taken 3 times per day (10-, 10-, and 20-mg/kg morning, midday and evening, respectively) for 48 weeks
3063355|NCT02139306|Placebo Comparator|Placebo|Matching placebo taken 3 times per day for 48 weeks
3063356|NCT02139293|Experimental|auricular vagus nerve stimulation|"Study participants (healthy) are treated with auricular vagus nerve stimulation using five needle electrodes connected to an electrical stimulation device (PrimeStim). After acclimatization the stimulation is turned on for 20 minutes followed by 20 minutes of paused stimulation, 20 minutes of stimulation, and 10 minutes paused stimulation. This intervention is repeated on four consecutive days, whereas at each intervention only one of the four stimulation points (and one fixed reference point) is stimulated. Needle electrodes are applied at each study visit.~Stimulation points in the auricle are stimulated in random order. One stimulation pattern is tested. Stimulation amplitudes are adjusted with respect to a distinct but comfortable sensation at the auricle.~During the described protocol various biosignals are continuously recorded, including ECG, respiration, blood perfusion, oxygen saturation, transcutaneous oxygen tension, blood pressure and skin temperature."
3063357|NCT02139280|Active Comparator|Arm 2: Cyclophosphamide 3 gms/m(2)|Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 3 gms/m(2).
3063358|NCT02139280|Experimental|Arm 1: 1.5 gms/m(2) Cyclophosphamide|Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 1.5 gms/m(2).
3063359|NCT02139267|Experimental|1mg of GX-188E per dose|1mg of GX-188E per dose will be administered on 1mg group participants through intramuscular route using EP device. The injection points are at 0 week, 4 week and 12 week.
3063360|NCT02139267|Experimental|4mg of GX-188E per dose|4mg of GX-188E per dose will be administered on 4mg group participants through intramuscular route using EP device. The injection points are at 0 week, 4 week and 12week.
3063361|NCT02139254||Low risk|Pregnant women with a low risk for metabolic diseases
3063362|NCT02139254||High risk|Pregnant women with a high risk for metabolic diseases
3063363|NCT02139241|Experimental|Ramosetron|Intravenous administration of ramosetron 0.3 mg before the induction of general anesthesia
3063364|NCT02139241|Placebo Comparator|Control|Intravenous administration of 2ml normal saline before the induction of general anesthesia
3063365|NCT02139228|Experimental|Hib CRM197|"Subjects treated with 3 doses of CRM 197 -conjugate Haemophilus influenzae type b vaccine (study vaccine): 2 doses given one month apart during study V37_07 (NCT01044316) and a booster dose of the same vaccine six months after, during study V37_07E1 (NCT01226953).~No vaccine was administered during this trial"
3063366|NCT02139228|Active Comparator|Hib TT|"Subjects treated with 3 doses of Tetanus Toxoid-conjugate Haemophilus influenzae type b vaccine (comparator vaccine): 2 doses given one month apart during study V37_07 (NCT01044316) and a booster dose of the same vaccine six months after, during study V37_07E1 (NCT01226953).~No vaccine was administered during this trial"
3063367|NCT02139202|Other|Full Program|"The intervention will (1) use the GlowCaps, a remote monitoring and reminder pill bottle; (2) be assigned an engagement advisor from the study team; (3) be asked to provide the study team with names and contact information of up to 3 family members or friends as support partners for medication adherence. The study team will contact these people in order listed until 1 agrees to serve in this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on medication adherence for the first three months; and (5) will determine their preferences for Way to Health platform communication methods during the study.~The group receiving the program intervention will also have their claims data analyzed for the 1 months post-enrollment."
3063368|NCT02139189|Experimental|P-ECM Implant|P-ECM Implant into damaged ischemic and/or infarcted myocardium
3063369|NCT02139176|Active Comparator|Patient referral|Women are given an invitation to give to a male partner inviting them to come to the clinic for important pregnancy information
3063370|NCT02139176|Experimental|contract referral|Same as control. However, if the male partner does not present, a community worker will trace the partner in the community.
3063371|NCT02139163||patients with pneumonia|
3063372|NCT02139150|Experimental|Serial FLT PET Imaging|"Patients will receive a target injection of up to 10 mCi of FLT. Optionally, dynamic PET imaging over a chosen index lesion (based on size and/or high FDG-avidity on preceding CT and/or FDG PET/CT scans done for clinical purpose such as staging), may be performed. Otherwise, static PET images are obtained at approximately 60 min (+15 min) post FLT injection. In general this body scan will cover at least the region from skull base to the upper thigh for extracranial malignancies; depending on the specific location, extremities maybe also be scanned (e.g., extremity sarcoma), or the scan may be restricted to the brain (e.g. glioma)."
3063373|NCT02139137|Experimental|High Interference Control Condition|Computerized training program requiring participants to repeatedly practice controlling interference on a cognitive task
3063374|NCT02139137|Active Comparator|Low Interference Control Condition|Computerized training program requiring participants to minimally practice controlling interference on a cognitive task
3063375|NCT02139124|Placebo Comparator|Placebo|Placebo Arm
3063376|NCT02139124|Active Comparator|PRC-063 25 mg and Placebo|PRC-063 25 mg and placebo capsule by mouth once daily
3063377|NCT02139124|Active Comparator|PRC-063 45 mg and Placebo|PRC-063 45 mg and placebo capsule by mouth once daily
3063378|NCT02139124|Active Comparator|PRC-063 70 mg and Placebo|PRC-063 70 mg and placebo capsule by mouth once daily
3063379|NCT02139124|Active Comparator|PRC-063 100 mg and Placebo|PRC-063 100 mg and placebo capsule by mouth once daily
3063380|NCT02139111|Placebo Comparator|Placebo|Placebo Arm
3063381|NCT02139111|Active Comparator|PRC-063 25 mg and Placebo|PRC-063 25 mg and placebo capsule by mouth once daily
3063382|NCT02139111|Active Comparator|PRC-063 45 mg and Placebo|PRC-063 45 mg and placebo capsule by mouth once daily
3091719|NCT01948115|Placebo Comparator|Medical air|
3063383|NCT02139111|Active Comparator|PRC-063 70 mg and Placebo|PRC-063 70 mg and placebo capsule by mouth once daily
3063384|NCT02139111|Active Comparator|PRC-063 85 mg and Placebo|PRC-063 85 mg and placebo capsule by mouth once daily
3063385|NCT02139098|Experimental|Amitriptyline flexible dosing|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights/placebo
3063386|NCT02139098|Experimental|Zolpidem flexible dosing|5 mg capsule zolpidem before going to bed on 8 out of 17 nights/placebo
3063387|NCT02139098|Active Comparator|Amitriptyline fixed dosing|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
3063388|NCT02139098|Active Comparator|Zolpidem fixed dosing|5 mg capsule zolpidem before going to bed on 8 out of 17 nights
3063389|NCT02139098|Active Comparator|Amitriptyline continuous dosing|50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
3063390|NCT02139085|Active Comparator|GSV Electrocoagulation|GSV Electrocoagulation Source: Electrosurgical Generator(FX-Valley Lab; USA) Energy: 60 Watts x 10 seconds
3063391|NCT02139085|Active Comparator|GSV Radiofrequency|GSV Radiofrequency Source: Closure FAST(Covidien, USA) Energy: 60 Joules / cm
3063392|NCT02139072||CoaguChek XS|INR measured by CoaguChek XS in patients with APL at visit 1 and visit 2, in addition to routine measure by standard lab draw
3063393|NCT02139072||Standard Lab Draw|INR measured by standard lab draw at visit 1 and visit 2 for non-APL patients, in addition to routine measurement by CoaguChek XS
3063394|NCT02139059|Active Comparator|initial urinary drainage|initial urinary drainage to stabilize renal functions before ureteroscopy
3063395|NCT02139059|Active Comparator|direct ureteroscopy|direct ureteroscopy without initial urinary drainage
3063396|NCT02139046|Active Comparator|Febuxostat IR 40 mg|Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day (for participants with estimated glomerular filtration rate (eGFR) ≥ 60 mL/min) or every other day (if eGFR ≥ 15 - ≤ 59 mL/min), or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3063397|NCT02139046|Active Comparator|Febuxostat IR 80 mg|Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3063398|NCT02139046|Experimental|Febuxostat XR 40 mg|Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3063399|NCT02139046|Experimental|Febuxostat XR 80 mg|Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3063400|NCT02139046|Placebo Comparator|Placebo|Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3063401|NCT02139033|Experimental|Arm 1|Retain 1-2 drops, bilaterally, BID
3063402|NCT02139020||No treatment|"Patients with squamous cell carcinoma of the head and neck, targeted therapies, plasma samples:~Group 1 = patients treated with radiation therapy and cetuximab according to Bonner et al [11]~Group 2 = patients treated with cetuximab in combination with chemotherapy according to Vermorken et al. [10]~Group 3 = patients treated with a molecular targeted agent as a part of a clinical study"
3063403|NCT02139007|Active Comparator|Continuation Arm|Alendronate continuation arm
3063404|NCT02139007|Active Comparator|Discontinuation Arm|Alendronate discontinuation arm
3063405|NCT02138994|Active Comparator|Triple Antibiotic Ointment Neosporin|Daily direct application to the wound, covered with conventional dressing. Dressing should be changed daily or as directed by the health care provider.
3063406|NCT02138994|Experimental|Next Science Wound Gel|Daily direct application to the wound, covered with a conventional non-alginate dressing. Dressing should be changed daily or as directed by the health care provider.
3063407|NCT02138981|Active Comparator|Immediate Resection|patients received immediate surgical hepatic resection
3063408|NCT02138981|Experimental|Chemoembolization and Response-Dependent Resection|patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
3063409|NCT02138968|Experimental|Multidimensional intervention|Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
3063410|NCT02138968|No Intervention|Usual care|Usual care
3063411|NCT02138955|Experimental|Liposomeal curcumin ascending dose phase 1b|
3063412|NCT02138942|Experimental|The study population|"See inclusion/exclusion criteria.~Intervention: LIR"
3063413|NCT02138929|Experimental|Everolimus + LDE 225|"Dose Escalation: Everolimus at a dose of 10 mg by mouth daily with dose escalation of LDE 225 from 200 mg - 800mg by mouth daily. Study cycle is 28 days.~Dose Expansion: Everolimus at a dose of 10 mg by mouth daily. LDE 225 at MTD from Dose Escalation. Study cycle is 28 days."
3063414|NCT02138916|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
3063415|NCT02138916|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
3063416|NCT02138916|Placebo Comparator|Placebo|Placebo administered subcutaneously
3063417|NCT02138903||ZEEP and tubing-spontaneous ventilation|Prospective clinical study in ICU with ventilated patients eligible to weaning trials of mechanical ventilation (ZEEP and tubing-spontaneous ventilation) comparing hemodynamic and cardiac effects evaluated by trans-thoracic echocardiography.
3063418|NCT02138903||trans-thoracic echocardiography|Prospective clinical study in ICU with ventilated patients eligible to weaning trials of mechanical ventilation (ZEEP and tubing-spontaneous ventilation) comparing hemodynamic and cardiac effects evaluated by trans-thoracic echocardiography.
3063421|NCT02138877|Active Comparator|After coming stent|Dismembered pyeloplasty with insertion of an after coming stent
3063422|NCT02138877|Active Comparator|Stentless|Stentless dismembered pyeloplasty
3063423|NCT02138864|Experimental|18F-FP-(+)-DTBZ only|PET tracer: 18F-FP-(+)-DTBZ
3063424|NCT02138851|Experimental|Ficus Carica|Ficus Carica 300g/day
3063425|NCT02138851|Placebo Comparator|Placebo|Placebo 300g/day
3063426|NCT02138838|Active Comparator|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
3063427|NCT02138838|Experimental|Cinacalcet|In addition to standard of care participants received cinacalcet at a starting dose (based on dry body weight) of 0.20 mg/kg administered once a day by mouth. Dose adjustments and withholding were based on ionized calcium levels, plasma iPTH, and corrected calcium levels.
3063428|NCT02138825|Experimental|Riociguat (Adempas, BAY63-2521)|In the main study treatment phase participants received Riociguat titrated to optimal dose within range of 0.5 mg TID (3 times a day) to 2.5 mg TID for 10 weeks followed by maintenance period of 16 weeks. This phase was followed by a long-term extension phase, which included a blinded sham titration phase of 10 weeks followed by an open-label extension phase. During the open-label extension phase participants were to be treated with Riociguat until commercial access in the indication of pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP) or until an agreed time point is defined with the individual country, local regulatory authority and the Sponsor's global team.
3063429|NCT02138825|Placebo Comparator|Placebo|In the main study treatment phase participants received sham titration within range of 0.5 mg TID to 2.5 mg TID for 10 weeks followed by maintenance period of 16 weeks. This phase was followed by a long-term extension phase, which included a blinded titration phase to optimal dose of Riociguat of 10 weeks followed by an open-label extension phase. During the open-label extension phase participants were to be treated with Riociguat until commercial access in the indication of PH associated with IIP or until an agreed time point is defined with the individual country, local regulatory authority and the Sponsor's global team.
3063430|NCT02138812|Experimental|BAY1161909 + Paclitaxel|- Investigating the combination of BAY1161909 with Paclitaxel (75 mg) and (90 mg) in an intermittent dosing schedule - Expansion Cohort
3063431|NCT02138799|Experimental|1: single dose of enzalutamide|
3063432|NCT02138799|Experimental|2: multiple doses of rifampin and single dose of enzalutamide|
3063433|NCT02138786|Experimental|selinexor|orally twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday)
3063434|NCT02138773|Experimental|Fed, formulation-A|drug administered at 0.5h after the start of a standard breakfast
3063435|NCT02138773|Experimental|Fed, formulation-B|drug administered at 0.5h after the start of a standard breakfast
3063436|NCT02138773|Experimental|Fasted, formulation-A|drug administered under fasted condition (fasting for at least 10 hours)
3063437|NCT02138773|Experimental|Fasted, formulation-B|drug administered under fasted condition (fasting for at least 10 hours)
3063438|NCT02138760|No Intervention|MRI guided cognitive fusion biopsy|Men in this arm will undergo MRI followed by systematic biopsy and then additional cognitive (freehand) biopsies of MRI suspicious targets
3063439|NCT02138760|Experimental|UroNav fusion biopsy|Men in this arm will undergo MRI followed by systematic biopsy and then additional UroNav fusion biopsy of MRI suspicious targets
3063440|NCT02138747|Experimental|AB: Mirabegron/Tolterodine ER|In the treatment sequence AB participants received 25 mg of mirabegron (Myrbetriq) oral controlled absorption system (OCAS) modified-release tablets and 4 mg of placebo-to-match (PTM) tolterodine ER (Detrol LA) orally once a day during period 1. In the period 2, participants received 4 mg of tolterodine ER and 25 mg of PTM mirabegron orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron or mirabegron PTM was increased to 50 mg for the remainder of the treatment period.
3063441|NCT02138747|Experimental|BA: Tolterodine ER /Mirabegron|In the treatment sequence BA participants received 4 mg of tolterodine ER and 25 mg of PTM mirabegron (OCAS) modified-release tablets orally once a day during period 1. In the period 2, participants received 25 mg of mirabegron and 4 mg of PTM tolterodine ER orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron or mirabegron PTM was increased to 50 mg for the remainder of the treatment period.
3063442|NCT02138747|Experimental|AA: Mirabegron/Mirabegron|In treatment sequence AA participants received 25 mg of mirabegron and PTM tolterodine ER 4 mg capsules during period 1 and 2 orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron was increased to 50 mg for the remainder of the treatment period.
3063443|NCT02138747|Experimental|BB: Tolterodine ER /Tolterodine ER|Participants received 4 mg of tolterodine ER and PTM mirabegron 25 mg OCAS modified-release tablets orally once a day during period 1 and period 2.
3063444|NCT02138734|Experimental|ALT-803+BCG|(Phase Ib and IIb) for BCG-naive patients
3063445|NCT02138734|Active Comparator|BCG alone|(Phase IIb) for BCG-naive patients
3063446|NCT02138721|No Intervention|No local treatment|Routine care in metastatic prostate cancer.
3063447|NCT02138721|Experimental|Local treatment|Radical Prostatectomy (RP) + routine care in metastatic prostate cancer.
3063448|NCT02138708|Experimental|Shunt closed|patients with heart disease and shunt who, following hemodynamic exploration, will be selected for closure of their shunt
3063449|NCT02138695||Yonsei AF Cohort|Patients with atrial fibrillation who undergoing catheter ablation of atrial fibrillation
3063450|NCT02138682||l-123 Ioflupane|Study group includes those clinically diagnosed with Parkinson disease who are aged 75 and older who have agreed to donate brain tissue at time of death and are able to participate in the imaging scan process.
3063451|NCT02138669|Other|Intacs Device|INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
3063452|NCT02138656|Active Comparator|Best standard care only - not blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice.~Parents aware that infant is not receiving chiropractic treatment"
3063453|NCT02138656|Sham Comparator|Best Standard Care and Sham - Blind|Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus sham chiropractic treatment. Parents unaware of whether infant is receiving real treatment or sham.
3091996|NCT01946204|Placebo Comparator|Treatment Arm B: Placebo|
3063454|NCT02138656|Experimental|BSC & Chiropractic - Not blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus real chiropractic treatment.~Parents aware that infant is receiving chiropractic treatment."
3063455|NCT02138656|Experimental|BSC & Chiropractic - Blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus real chiropractic treatment.~Parents not aware that infant is receiving chiropractic treatment."
3063456|NCT02138643|Active Comparator|Endoscopic surgery|Patients with symptomatic achalasia confirmed by clinical and laboratory tests, which meet the criteria for inclusion and exclusion. These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)
3063457|NCT02138643|Sham Comparator|Laparoscopic surgery|Patients with symptomatic achalasia confirmed by clinical and laboratory tests, which meet the criteria for inclusion and exclusion. These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
3063458|NCT02138630|Placebo Comparator|Placebo|
3063459|NCT02138630|Experimental|Capsaicin|"Single Capsule, Capsimax 100 mg, ingested 60 min prior to exercise"
3063460|NCT02138617|Experimental|*1/*1 Genotype|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 310 mg/m2,(IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
3063461|NCT02138617|Experimental|*1/*28 Genotype|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 260 mg/m2, FOLFIRI (IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
3063462|NCT02138617|Experimental|*28/*28|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 180 mg/m2, FOLFIRI (IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
3063463|NCT02138591|Experimental|Vitamin D3|"Vitamin D3 (cholecalciferol) 50,000 IU by mouth daily for each of the five days prior to surgery.~Blood draw pre-operatively Blood draw post-operative Day 1 Blood draw post-operative Day 2"
3063464|NCT02138591|Placebo Comparator|Placebo pill|Placebo pill by mouth daily for each of the five days prior to surgery. Blood draw pre-operatively Blood draw post-operative Day 1 Blood draw post-operative Day 2
3063465|NCT02138578|Experimental|Randomized SBRT|Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Stereotactic Body Radiation Therapy (SBRT) will receive SBRT delivered in fractions of 20 Gy, approximately every other day, for a total of three treatments. If the target is deemed too close to organs at risk, 5 fractions of up to 10 Gy per fraction will be prescribed.
3063466|NCT02138578|Active Comparator|Randomized RFA|Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Radiofrequency Ablation (RFA) will receive RFA.
3063467|NCT02138578|Active Comparator|Non-Randomized SBRT|Patients with renal cell carcinoma's greater than or equal to 4 cm in diameter, and up to 8 cm in diameter, may be placed in the non-randomized stereotactic body radiation therapy arm. Patients with tumors not amenable to RFA, those with metastatic disease, and those who elect a noninvasive means of treatment will also be eligible to receive treatment in the non-randomized SBRT cohort.
3063468|NCT02138565|Experimental|Bariatric surgery|
3063469|NCT02138552|Active Comparator|OCT 0.1% vs. Placebo|0.1 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
3063470|NCT02138552|Active Comparator|OCT 0.15% vs. Placebo|0.15 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
3063471|NCT02138552|Active Comparator|OCT 2.0% vs. Placebo|0.2 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
3063472|NCT02138539|Active Comparator|4% Hydroquinone|4% hydroquinone applied to one side of the face.
3063473|NCT02138539|Experimental|Herbal depigmenting agent|Herbal depigmenting agent applied on the other side of the face.
3063474|NCT02138526|Active Comparator|fasted|Intake of pazopanib in agreement with drug label - fasted state
3063475|NCT02138526|Experimental|Continental breakfast|Intake of a reduced equivalent pazopanib dose with a continental breakfast
3063476|NCT02138513|Experimental|Online MBCT|
3063477|NCT02138513|Experimental|group MBCT|
3063478|NCT02138513|No Intervention|Treatment as usual|3 months waiting list, subsequent assignment to group or online MBCT
3063479|NCT02138500|Experimental|Cohort 1: PF-06372865 10 mg|
3063480|NCT02138500|Experimental|Cohort 2: PF-06372865 TBD dose|
3063481|NCT02138500|Experimental|Cohort 3: PF-06372865 TBD dose|
3063482|NCT02138487|Active Comparator|Restricted postoperative activity|"Women in the restricted postoperative activity group must abstain from exercise and heavy lifting for 3 months postoperatively"
3063483|NCT02138487|Experimental|Liberal postoperative activity|"Women in the liberal postoperative activity group will be allowed to resume their normal activities without restriction."
3063484|NCT02138474|Experimental|Lacticum acidum homaccord|Lacticum acidum homaccord 30 mL bottle of medicated sucrose pillules take 5 pillules of the medication in the morning and in the evening for 4 weeks
3063485|NCT02138474|Placebo Comparator|Placebo|Unmedicated sucrose pillules, take 5 pillules twice daily for 4 weeks
3063486|NCT02138461||bimatoprost|These patients take bimatoprost topically for glaucoma.
3063487|NCT02138461||latanoprost group|These patients take latanoprost topically for glaucoma.
3063488|NCT02138448|Experimental|Intervention practices|Intervention practices will implement an interactive preventive health record in addition to their standard personal health record functionality.
3063489|NCT02138448|No Intervention|Control practices|Control practices will continue to field their existing personal health record
3063490|NCT02138435||VSD-patients|Patients who had VSD closure between 1990 and 1995. They will be tested by a MRI exercise test and a gas-exchange exercise test measuring cardiac output.
3063491|NCT02138435||Control|A group of healthy control subjects. They will be tested by a MRI exercise test and a gas-exchange exercise test measuring cardiac output.
3063492|NCT02138422|Placebo Comparator|Placebo|Placebo administered intravenously every 2 weeks
3063493|NCT02138422|Active Comparator|Xilonix|Xilonix administered intravenously every 2 weeks
3063494|NCT02138409|Experimental|ON FSS 100 µg|Participants classified as opioid-naïve (ON), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, and further randomized to a dose of 100 µg
3063788|NCT02136420|Experimental|Manual Control,No training,promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
3063495|NCT02138409|Experimental|ON FSS 200 µg|Participants classified as opioid-naïve (ON), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, and further randomized to a dose of 200 µg
3063496|NCT02138409|Experimental|OE FSS 400 µg|Participants classified as opioid-experienced (OE), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, at a dose of 400 µg
3063497|NCT02138409|Placebo Comparator|ON PSS|Participants classified as opioid-naïve (ON) and randomized to receive one dose of matching placebo sublingual spray (PSS) 10 minutes before treatment procedure
3063498|NCT02138409|Placebo Comparator|OE PSS|Participants classified as opioid-experienced (OE) and randomized to receive one dose of matching placebo sublingual spray (PSS) 10 minutes before treatment procedure
3063499|NCT02138396|Experimental|FSS first, then FCI|At each of two treatment visits participants fast for 10 hours before dosing, and receive naltrexone before and after dosing. Participants in this group receive a single dose of fentanyl sublingual spray (FSS) at the first visit. After a washout period of at least seven days, they receive a single intramuscular fentanyl citrate injection (FCI) at the second treatment visit.
3063500|NCT02138396|Experimental|FCI first, then FSS|At each of two treatment visits participants fast for 10 hours before dosing, and receive naltrexone before and after dosing. Participants in this group receive a single intramuscular fentanyl citrate injection (FCI) at the first visit. After a washout period of at least seven days, they receive a single dose of fentanyl sublingual spray (FSS) at the second treatment visit.
3063501|NCT02138383|Experimental|Dose Escalation and Dose Expansion|"Dose Escalation: To find the dose of enzalutamide that can be safely given with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer.~Dose Expansion: To find the effect on tumor of the combination of enzalutamide, gemcitabine and nab-paclitaxel."
3063502|NCT02138370||stage II and III colorectal cancer|
3063503|NCT02138357|Placebo Comparator|Placebo Patch|"The Placebo is in the form of a patch. We will be using placebo patches labeled 5mcg/hour, 10mcg/hour, and 20mcg/hour that will be changed every 7 days.~Each subject will participate in this arm of the study for four weeks."
3063504|NCT02138357|Experimental|buprenorphine transdermal delivery system (BTDS)|"buprenorphine transdermal delivery system (BTDS), brand name Butrans. Butrans is in the form of a patch. We will be using 5mcg/hour, 10mcg/hour, and 20mcg/hour patches that will be changed every 7 days.~Each subject will participate in this arm of the study for four weeks."
3063505|NCT02138344||SCI subjects|Chronic and traumatic SCI subjects
3063506|NCT02138344||Healthy control subjects|
3063507|NCT02138344||Subjects with peripheral nerve diseases|
3063508|NCT02138331|Experimental|Exosomes|The exosomes have exosome-associated proteins such as the tetraspanin proteins, CD9 and CD81, Alix, Tsg101, and RNA that consists primarily of short RNAs of less than 300 nm. Some of these RNAs are microRNAs that are predominantly pre-microRNAs..Additionally, CB-SC displayed very low immunogenicity as indicated by expression of a very low level of major histocompatibility complex (MHC) antigens and failure to stimulate the proliferation of allogeneic lymphocytes.
3063509|NCT02138318|Other|chromoendoscopy|
3063510|NCT02138318|Other|High definition (HD) endoscopy|
3063511|NCT02138305|Other|Patients referred for CABG|"Patients who after undergoing standard of care diagnostic coronary angiography will be referred for CABG~ComboMap XT Guidewire~'SPY' NIRF During CABG"
3063512|NCT02138292|Experimental|Trametinib (2mg)/Digoxin (0.25mg)|"Trametinib (2mg) will be administered orally on a daily basis.~Digoxin (0.25mg) will be administered orally on a daily basis.~On a 8-week cycle, duration of treatment can last from 8 to 104 weeks."
3063513|NCT02138279||Male and female adults 18+ years of age|
3063514|NCT02138266||Non-Pathologic Adults age 18-28 yrs|Non-Pathologic Adults age 18-28 yrs
3063515|NCT02138266||Non-Pathologic Adults age 29-80 yrs|Non-Pathologic Adults age 29-80 yrs
3063516|NCT02138266||Pathologic Adults age 29-80 yrs|Pathologic Adults age 29-80 yrs
3063517|NCT02138253|Experimental|IDN-6556|IDN-6556 25 mg BID
3063518|NCT02138253|Placebo Comparator|Placebo|Placebo BID
3063519|NCT02138240|Experimental|Social network intervention|"Individuals will be recruited and trained to be Peer Educators who will participate in group sessions and then communicate this information with members of their social network (Sidekick) and work to make changes to reduce intake of sugar-sweetened beverages. Peer Educators will participate in 6 core group sessions over a 6-week period as well as 3 additional booster sessions over the subsequent 3 months after completing the core curriculum. All sessions will be delivered by a facilitator and assistant facilitator using a guide."
3063520|NCT02138227|Active Comparator|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills.
3063521|NCT02138227|Active Comparator|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
3063522|NCT02138214|Experimental|Arm I (no CND)|Patients undergo total thyroidectomy alone.
3063523|NCT02138214|Experimental|Arm II (CND)|Patients undergo total thyroidectomy with ipsilateral prophylactic CND.
3063524|NCT02138214|Active Comparator|Arm III (SOC)|Patients who are not eligible for randomization into Arm I or Arm II, Standard of Care (SOC) group. No specific trial intervention, treated as per patient and physician preference
3063525|NCT02138201||control|individuals with normal bladder function
3063526|NCT02138201||neurogenic bladder|individuals suffering from neurogenic lower urinary tract dysfunction
3063527|NCT02138188||T1D patients on CSII|Patients affected by Type 1 Diabetes on insulin pump therapy
3063528|NCT02138175||Patients at risk for bleeding|Patients at risk for bleeding
3063529|NCT02138162|Experimental|1:Single dose of enzalutamide in hepatically impaired subjects|Single dose of enzalutamide
3063530|NCT02138162|Experimental|2:Single dose of enzalutamide in healthy subjects|Single dose of enzalutamide
3063531|NCT02138149||spinal cord injury|individuals with neurogenic lower urinary tract dysfunction
3063532|NCT02138149||control group|individuals with physiologic bladder function
3063533|NCT02138136|Experimental|Lubiprostone|Lubiprostone 12 or 24 mcg twice daily (BID)
3063607|NCT02137603|No Intervention|Admission|Patients are admitted to the inpatient unit following appendectomy for suppurative appendicitis and treated per the current standard of care.
3063534|NCT02138123|Experimental|IOL-shell technique|In this group, before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
3063535|NCT02138123|Active Comparator|Conventional procedure|In this group, a Sensar IOL (AMO Laboratories) was implanted in the capsular bag with the injector system after the lens material was completely removed. The nuclear fragmentation was performed using the Phaco-chop technique, which was then followed by ultrasound emulsification of the nuclear fragments piece by piece. Due to lack of cortical shell within the capsular bag, special care was taken to carry out the emulsification of the last nuclear fragment at a relatively more anterior anatomical position between the iris plan and the anterior chamber.
3063536|NCT02138110|Experimental|Neuro-Spinal Scaffold|
3063537|NCT02138097||Glitazones|
3063538|NCT02138097||Linagliptin|
3063539|NCT02138097||Meglitinides|
3063540|NCT02138097||Metformin|
3063541|NCT02138097||Non-insulin injectables|
3063542|NCT02138097||Saxagliptin|
3063543|NCT02138097||Sitagliptin|
3063544|NCT02138097||Sulfonylurea|
3063545|NCT02138084|Experimental|Cohort 1: BMS-663068 + Rifabutin|"Regimen A: BMS-663068 tablet by mouth as specified~Regimen B: BMS-663068 tablet with Rifabutin capsule by mouth as specified"
3063546|NCT02138084|Experimental|Cohort 2: BMS-663068 + Rifabutin + Ritonavir|"Regimen A: BMS-663068 tablet by mouth as specified~Regimen C: BMS-663068 tablet, Rifabutin capsule and Ritonavir (RTV) capsule by mouth as specified"
3063547|NCT02138071||Individual|Treatment in the 'Individual group therapy' will include physiotherapy protocols usually used by physiotherapist working at Maccabi Healthcare Services (Exercises, Modalities, Maual therapy and Back Care education)
3063548|NCT02138071||group|Participants in group therapy will receive 6-8 group treatments (6-12 pateints per group) which will also include exercises and back-care education. No intervention will be done by the investigator.Therapists will use protocols commonly used in Maccabi Healthcate Services.
3063549|NCT02138058|Placebo Comparator|Placebo|a 12 week placebo matching tablets plus 4 sessions of a manualized cognitive restructuring intervention
3063550|NCT02138058|Experimental|topiramate|a 12 week topiramate flexible dose administration plus 4 sessions of a manualized cognitive restructuring intervention
3063551|NCT02138045|Placebo Comparator|Placebo treatment|"Placebo solution will be slowly titrated to maximum tolerable dose in order to minimize potential side-effects, hence treatment will follow:~First and second week: 0.6 mg/day; Third and fourth week: 1.2 mg/day and Fifth and to sixth week: 1.8 mg/day."
3063552|NCT02138045|Active Comparator|Liraglutide treatment|"Liraglutide will be slowly titrated to maximum tolerable dose in order to minimize potential side-effects, hence treatment will follow:~First and second week: 0.6 mg/day; Third and fourth week: 1.2 mg/day and Fifth and to sixth week: 1.8 mg/day."
3063553|NCT02138032|Experimental|Gains Framed Message|gains framed visual fridge magnet and information sheet about smoking cessation (benefits of quitting smoking)
3063554|NCT02138032|Experimental|Loss Framed Message|loss framed visual fridge magnet and information sheet about smoking cessation (losses of continued smoking)
3063555|NCT02138019|Experimental|Fibrin glue|In ophthalmic field, the use of organic glues has provided good results for the repair of leaking blebs and perforated corneal ulcers, conjunctival closure in strabismus surgery, surgery for retinal detachment, cataract surgery, trabeculectomy, and mucous membrane grafting to repair lesions of the conjunctival fornix. In this study, the investigators try to evaluate the effect of Fibrin Glue assisted external eye surgery.
3063556|NCT02138006|Experimental|Intensive insulin treatment|Intensive insulin treatment
3063557|NCT02138006|Active Comparator|Standard insulin treatment|Standard insulin treatment
3063558|NCT02137993|Experimental|A-prexa|A-prexa 5, 10mg
3063559|NCT02137993|Active Comparator|Zyprexa|Zyprexa 5, 10mg
3063560|NCT02137967|Experimental|NaOCl pulpotomy|Use 2.5% NaOCl as pulpotomy medication
3063561|NCT02137967|Active Comparator|FC pulpotomy|Use 20% Formocresol as pulpotomy medicament
3063562|NCT02137954|Active Comparator|lidocaine|Lidocaine. Initial dose IV will be 5 mg/kg per day during the first 24 hours the 8 mg/kg per day
3063563|NCT02137954|Placebo Comparator|placebo|
3063564|NCT02137941|Active Comparator|techniques to optimize potential (TOP)|
3063565|NCT02137941|Active Comparator|heart coherence (HC)|
3063566|NCT02137941|Placebo Comparator|controls|
3063567|NCT02137928|Experimental|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months)
3063568|NCT02137928|Active Comparator|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months
3063569|NCT02137902|Experimental|Tobacco/Physical Activity Intervention|Includes a psychosocial component that utilizes a counselor-facing computer-assisted intervention with tailored counseling feedback focused on increasing intrinsic motivation, goal setting for tobacco and physical activity, adherence with nicotine replacement therapy, and self-monitoring with a pedometer-based walking program. The intervention will provide 12 weeks of nicotine replacement therapy for participants.
3063570|NCT02137902|Experimental|Diet plus BP/CHOL Intervention|Consists of a psychosocial component that includes counselor-facing computer-assisted intervention with tailored counseling feedback focused on increasing intrinsic motivation, goal setting for managing hypertension and hypercholesterolemia, and adherence with antihypertensives and statins with supportive dietary changes. The intervention provides a cookbook of heart healthy regional recipes and medication bag for storing medications.
3063571|NCT02137889|Experimental|Arm 1- relapsed/refractory CLL patients|Patients with relapsed/refractory CLL with two or three prior treatment regimens
3063572|NCT02137889|Experimental|Arm 2 - rituximab or ofatumumab refractory CLL patients|Patients with relapsed/refractory CLL with four or more prior treatment regimens
3063608|NCT02137590|Experimental|Spanish Black Radish|Spanish Black Radish product
3063609|NCT02137577|Experimental|DEB catheter|use DEB catheter(trade name: Lotus/Tulip) to treat the stenosis or occlusion in below popliteal artery of experimental arm
3093230|NCT01937754|Active Comparator|Nitric Oxide supplement|
3063573|NCT02137863|Placebo Comparator|Control|"Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.~During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.~100 ml/10min 0.9 % NaCl administered intravenously just before the angiography.~1 ml/kg/h 0.9 % sodium chloride administered intravenously during the procedure and was continued 1 hour after the angiography."
3063574|NCT02137863|Active Comparator|Dexmedetomidine|"Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.~During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.~Dexmedetomidine was diluted as 1 μg/ml. 1 μg/kg/10min dexmedetomidine administered intravenously just before the angiography.~1 μg/kg/h dexmedetomidine administered intravenously during the procedure and was continued 1 hour after the angiography."
3063575|NCT02137850|Experimental|50 EDs (exposure days)|
3063576|NCT02137837|Placebo Comparator|Arm 1: fulvestrant + everolimus placebo + anastrozole placebo|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral placebo daily for both everolimus and anastrozole. This treatment regimen will continue until disease progression or toxicity.
3063577|NCT02137837|Experimental|Arm 2: fulvestrant + everolimus + anastrozole placebo|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral everolimus and an oral placebo for anastrozole daily. This treatment regimen will continue until disease progression or toxicity.
3063578|NCT02137837|Experimental|Arm 3: fulvestrant + everolimus + anastrozole|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive everolimus and anastrozole by mouth daily. This treatment regimen will continue until disease progression or toxicity.
3063579|NCT02137824|Experimental|sinus floor elevation|
3063580|NCT02137811||Patients that received MICK assay|Patients with pathological diagnoses of cancer or leukemia who have had a MiCK assay (CorrectChemo) test performed
3063581|NCT02137798|Experimental|CARTOUNIVU|Radiofrequency catheter ablation of atrial fibrillation will be performed using fluoroscopy image integrated 3-dimentional electroanatomical mapping system
3063582|NCT02137798|Active Comparator|CARTO3|Radiofrequency catheter ablation of atrial fibrillation will be performed using 3-dimentional electroanatomical mapping system without fluoroscopy image integration technique
3063583|NCT02137785|Experimental|ALA|
3063584|NCT02137785|Placebo Comparator|Vehicle|
3063585|NCT02137772|Experimental|Letermovir|Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 days post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
3063586|NCT02137772|Placebo Comparator|Placebo|Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
3063587|NCT02137759|Active Comparator|Std RT/TMZ (Cohort 1)|"Standard radiation therapy~Standard temozolomide"
3063588|NCT02137759|Experimental|Std RT/TMZ + belinostat (Cohorts 2a, 2b)|"Standard radiation therapy~Standard temozolomide~Belinostat"
3063589|NCT02137746|Experimental|DCVAC/PCa Arm|Dendritic Cells DCVAC/PCa Experimental therapy
3063590|NCT02137733|Active Comparator|Bisoprolol group|Daily oral administration of bisoprolol 0.625 mg tablet once a day should be given (Step 1). If tolerability is confirmed by an investigator, the dose should be increased to 1.25 mg (bisoprolol 0.625 mg, 2 tablets; or bisoprolol 2.5 mg, half tablet; once daily) (Step 2). In the same manner, the doses should be increased to 2.5 mg (bisoprolol 2.5 mg, 1 tablet; or bisoprolol 5 mg, half tablet; once daily, Step 3), to 3.75 mg (bisoprolol 2.5 mg, 1.5 tablets once daily, Step 4), and to 5 mg (bisoprolol 2.5 mg, 2 tablets; or bisoprolol 5 mg, 1 tablet; once daily, Step 5).
3063591|NCT02137733|Active Comparator|Carvedilol group|Daily oral administration of carvedilol 1.25 mg, 1 tablet twice a day (after breakfast and supper) should be given (Step 1). If tolerability is confirmed by an investigator after administering 2.5 mg/day of carvedilol, the dose should be increased to 5 mg (carvedilol 2.5 mg, 1 tablet twice daily) (Step 2). In the same manner, the dose should be increased to 10 mg (carvedilol 2.5 mg, 2 tablets twice daily, Step 3), to 15 mg (carvedilol 2.5 mg, 3 tablets twice daily, Step 4), and to 20 mg (carvedilol 10 mg, 1 tablet twice daily, Step 5).
3063592|NCT02137720|Experimental|Telephonic Diabetes Self-Management Support|This group receives all the Educational Print Materials received by the comparison condition plus telephone calls from a health educator to provide tailored diabetes self-management training and support. Participants with significant emotional distress at baseline also receive additional calls focused on distress management.
3063593|NCT02137720|Active Comparator|Educational Print Materials|Participants randomized to this arm will receive print materials on diabetes, glycemic control, self-management, and distress/depression.
3063594|NCT02137707||Gilenya treatment|Gilenya oral form once a day
3063595|NCT02137694|Other|PapU-APV|No drug and no placebo will be used in this study. For the study participants, only their medical history data and vaginal auto-takings ( APV) and urinary will be collected.
3063596|NCT02137681|Experimental|2 cycles|2 cycles RTX
3063597|NCT02137681|Active Comparator|standard 4 cycles|standard 4 cycles RTX
3063598|NCT02137668|Experimental|Oral Vancomycin|Every participant with PSC or BA will received the same Arm of Oral Vancomycin
3063599|NCT02137642|Active Comparator|RM-131|
3063600|NCT02137642|Placebo Comparator|Placebo|
3063601|NCT02137629||Korean patients|All Korean patients intended to be treated with Vidaza® according to the approved package insert
3063602|NCT02137616|Active Comparator|risperidone|low dosage of antipsychotic drug
3063603|NCT02137616|Active Comparator|olanzapine|low doseage of antipsychotic
3063604|NCT02137616|Active Comparator|quetiapine|low doseage of antipsychotic
3063605|NCT02137616|Active Comparator|aripiprazole|low doseage of antipsychotic
3063606|NCT02137603|Experimental|Fast track|Patients discharged home the same day following appendectomy
3063610|NCT02137577|Active Comparator|common PTA balloon catheter|use common PTA balloon catheter(trade name:Amphirion Deep) to treat stenosis or occlusion in below popliteal artery of control group
3063611|NCT02137564|Experimental|Treatment (gamma secretase inhibitor PF-03084014)|Patients receive gamma secretase inhibitor PF-03084014 PO BID on days 1-21. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with PR, CR, or SD at the end of 4 courses may receive an additional 4 courses of gamma secretase inhibitor PF-03084014 in the absence of disease progression or unacceptable toxicity.
3063612|NCT02137551|Experimental|ABM Intervention in FQHC|Pharmacy technicians within El Rio will implement the ABM
3063613|NCT02137551|Experimental|ABM Intervention in a Supermarket Pharmacy|Pharmacists within Fry's will implement the ABM
3063614|NCT02137551|No Intervention|Usual care|Patients will refill prescriptions at their usual pharmacy in the customary way.
3063615|NCT02137538|Active Comparator|Letrozole|Letrozole 2.5 mg daily
3063616|NCT02137538|Active Comparator|Anastrozole|Anastrozole 1 mg daily
3063617|NCT02137525|Active Comparator|Morphine 6 mg|Placebo Sublingual Spray (PSS) + Intravenous Morphine (IVM 6 mg), every 30 minutes for two hours as needed (or until rescue), maximum exposure morphine 30 mg
3063618|NCT02137525|Experimental|Fentanyl 100 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 100 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 500 µg
3063619|NCT02137525|Experimental|Fentanyl 200 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 200 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 1000 µg
3063620|NCT02137525|Experimental|Fentanyl 400 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 400 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 2000 µg
3063621|NCT02137512|Experimental|Closed-Loop Control System|A control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes in the home environment.
3063622|NCT02137499|Active Comparator|Healthy subjects|Healthy subjects, free from vascular disease
3063623|NCT02137499|Experimental|Superficial venous insufficiency|Clinically symptomatic and ultrasound evidence of superficial venous insufficiency
3063624|NCT02137499|Experimental|Deep venous insufficiency|Clinically symptomatic and ultrasound evidence of deep venous insufficiency
3063625|NCT02137499|Experimental|Deep venous obstruction|Clinically symptomatic and ultrasound evidence of deep venous obstruction
3063626|NCT02137473|Active Comparator|Bovine protein-based fortifier|
3063627|NCT02137473|Experimental|Human milk-based fortifier|
3063628|NCT02137460||Young normal controls|"age : 20 ~ 55~without dementia, MCI, or other major neurological/psychiatric illness"
3063629|NCT02137460||Elderly normal controls|"age : 55 ~ 90~without dementia, MCI, or other major neurological/psychiatric illness"
3063630|NCT02137460||MCI (Mild cognitive impairment)|"age : 55 ~ 90~without major neurological/psychiatric illness~concern regarding a change in cognition, lower performance in episodic memory domains that is greater than would be expected for the subject's age and educational background and preservation of independence in functional abilities"
3063631|NCT02137460||AD (Alzheimer's diseases)|"age: 55 ~ 90~National Institute of Aging and the Alzheimer's Association (NIA-AA) Probable AD dementia"
3063632|NCT02137447|Experimental|Negative Pressure Wound Therapy|"After the completion of the operation, incisional skin closure was performed using sutures or staples and the wound was then covered with the Negative Pressure Wound therapy Prevena Incision Management System (Kinetic Concepts Inc) as per the manufacturer's instructions of use. Continuous negative pressure was applied at 125 mm Hg.~For inpatients, wounds were assessed every 48 hours by inspection and palpation. The dressing was not routinely removed, but the surrounding skin was assessed for cellulitis. The NPWT dressing was removed between post-operative day 5 and 7"
3063633|NCT02137434|Placebo Comparator|Low calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of albumin and sugar containing 40 mg of calcium, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
3063634|NCT02137434|Experimental|High dietary calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of skimmed milk containing 540 mg of dietary calcium, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
3063635|NCT02137434|Experimental|High supplementary calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of albumin and sugar containing 540 mg of supplementary calcium from calcium carbonate, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
3063636|NCT02137421|Experimental|CAD, Metabolic syndrome .|"Arm1:coronary artery disease with metabolic syndrome . Intervention:Resveratrol (3, 4´, 5 trihydroxystilbene), 50 micromolar,12hour treatment .~Each experiment repeats three times ."
3063637|NCT02137421|Experimental|Healthy subjects .|"Arm2:healthy subjects Intervention:Resveratrol (3, 4´, 5 trihydroxystilbene), 50 micromolar,12hour treatment .~Each experiment repeats three times ."
3063638|NCT02137408|Active Comparator|200 mg docosahexaenoic acid|Participants will be randomized to 200 mg of docosahexaenoic acid (DHA) administered PO daily (1-200mg capsule of DHA). This is a standard dose used in prenatal vitamins. Participants will be supplemented by mouth daily between 18-20 weeks gestation through 6 weeks post-partum.
3063639|NCT02137408|Active Comparator|1000 mg docosahexaenoic acid|Participants will be randomized to 1000 mg of docosahexaenoic acid (DHA) administered PO daily (5- 200mg capsules of DHA). Participants will be supplemented daily PO between 18-20 weeks gestation through 6 weeks post-partum.
3063640|NCT02137395|Experimental|Dexamethasone|Patients are received dexamethasone via intravenous (iv) route of 0.5 mg.kg-1 (maximum dose of 8 mg) in group D at the induction of anesthesia.
3063641|NCT02137395|Placebo Comparator|Placebo|An equal volume of saline iv in group S at the induction of anesthesia.
3063642|NCT02137382|Experimental|Creon N, then Creon®|Subjects first received Creon N for 5 days. After a washout period of 3 to 14 days, they received Creon® for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to <10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.
3063716|NCT02136901|Active Comparator|Control Arm|The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
3063643|NCT02137382|Experimental|Creon® , then Creon N|Subjects first received Creon® for 5 days. After a washout period of 3 to 14 days, they received Creon N for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to <10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.
3063644|NCT02137369|Active Comparator|Escitalopram|Escitalopram, pill form, 20mg-40mg, daily, for 12 weeks
3063645|NCT02137369|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) CBT will include 16 1-hour sessions provided over 12 weeks.
3063646|NCT02137356|Experimental|treatment arm|standard dose pelvic radiation therapy, standard dose capecitabine, dose-escalated selinexor treatment
3063647|NCT02137343|Experimental|Rilotumumab|Rilotumumab plus Cisplatin and Capecitabine (CX).
3063648|NCT02137343|Placebo Comparator|Placebo|Rilotumumab-placebo plus Cisplatin and Capecitabine (CX).
3063649|NCT02137330|Experimental|Obalon Arm|Children swalowed up to 3 intragastric balloons
3063650|NCT02137330|No Intervention|Dietary and lifestyle changes Arm|
3063651|NCT02137317|Experimental|LAPPE/DP|In the LAPPE experiment the farmer will work as usual (mixing/loading/application/cleaning). wearing the LAPPE solution and carrying a new hand pressured backpack sprayer with a standardized nozzle. Conditions such as dosage, work practices and weather conditions will remain uncontrolled but be observed. After one week this process will be repeated wearing the DP solution.
3063652|NCT02137317|Active Comparator|DP/LAPPE|In the DP experiment the farmer will work as usual (mixing/loading/application/cleaning) wearing the DP solution and carrying his usual backpack sprayer with his usual nozzle. Conditions such as dosage, work practices and weather conditions will remain uncontrolled but be observed. After one week this process will be repeated wearing the LAPPE solution.
3063653|NCT02137304|Experimental|neuromuscular patients|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)
3063654|NCT02137291||Left-sided double-lumen tube|Lung isolation with a left-sided double-lumen tube (BronchoCath, Mallinckrodt Medical, Cornamaddy, Athlone, Westmeath, Ireland)
3063655|NCT02137291||Modified right-sided double-lumen tube|Right-sided double-lumen tube modified in accordance with Bussières et al. in Can J Anesth 2007
3063656|NCT02137278|Active Comparator|Stop/reduce vasoactive drugs|Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment
3063657|NCT02137278|Experimental|Vasoactive drug therapy|Continue current vasoactive therapy
3063658|NCT02137265|Active Comparator|Clomiphene citrate|Clomiphene citrate 50 mg daily during 4-6 months
3063659|NCT02137265|Placebo Comparator|Placebo|Placebo (1 pill daily) during 4-6 months
3063660|NCT02137252|Experimental|Naltrexone|The treatment schedule includes a daily dose of double-blinded naltrexone vs. placebo for 5 weeks. Treatment will be initiated at 25 mg/day (or equivalent placebo) during the first week to improve tolerability. The dose will be escalated to 50 mg/day (or equivalent placebo) after one week barring significant early improvement in fatigue or adverse events precluding dose escalation, and participants will continue to take 50 mg/day (or 25 mg/day if dose is not escalated) for 4 weeks to complete a 5-week treatment period.
3063661|NCT02137252|No Intervention|Monitoring Phase|Brief self-report questionnaire (Functional Assessment of Chronic Illness Therapy-Fatigue Subscale; FACIT-F)
3063662|NCT02137252|Placebo Comparator|Sugar Pill|daily dose placebo for 5 week treatment period
3063663|NCT02137239|Experimental|Belatacept + Everolimus|Thymoglobulin (i.v. infusion) induction, daily (or less frequently, as tolerated) not to exceed 10 days, to reach a total cumulative dose between 3.0 and 5.5 mg/kg; belatacept (infusion) regimen of 10 mg/kg i.v. on Day 1, Weeks 1, 2, 4, 8 and 12 post transplant and then a maintenance dose of 5 mg/kg every 4 weeks after 12 weeks post transplant; everolimus (tablet) daily dosing at 3.0 mg/day, 2 divided doses, starting on Day 3 dosing adjusted based on blood sample tests; methylprednisolone (infusion) prior to each Thymoglobulin infusion and prednisone (tablet), once methylprednisolone is no longer needed. (Corticosteroids to be discontinued by Day 7 or as soon thereafter as thymoglobulin infusions are completed)
3063664|NCT02137239|Experimental|Tacrolimus + Mycophenolate mofetil|Thymoglobulin (i.v. infusion) induction, daily (or less frequently, as tolerated) not to exceed 10 days, to reach a total cumulative dose between 3.0 and 5.5 mg/kg; tacrolimus (tablet) daily dosing beginning at 0.1 mg/kg/day, then adjusted based on blood sample tests; MMF (tablet) daily dosing between 0.5 to 2.0 g/day divided in 2 doses (up to 3 g/day if African Americans/Blacks); methylprednisolone (infusion) prior to each Thymoglobulin infusion and prednisone (tablet), once methylprednisolone is no longer needed. (Corticosteroids to be discontinued by Day 7 or as soon thereafter as thymoglobulin infusions are completed)
3063665|NCT02137226|Experimental|BI 695501|one injection every 2 weeks for 48 weeks (25 injections in total)
3063666|NCT02137226|Active Comparator|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
3063667|NCT02137213|Experimental|Arm A: Naloxone then placebo|Subjects assigned to Arm A will receive methadone with naloxone for one week and then methadone with placebo for one week
3063668|NCT02137213|Experimental|Arm B: Placebo then naloxone|Subjects assigned to Arm B will receive methadone with placebo for one week and then methadone with naloxone for one week
3063669|NCT02137200|Active Comparator|Delayed pushing|
3063670|NCT02137200|Experimental|Immediate pushing|
3063671|NCT02137187|Experimental|Drug therapy|Control Arm: optimized drug therapy (plus implantable defibrillator (ICD) according to guidelines)
3063672|NCT02137187|Active Comparator|Device: AV junction ablation & CRT|AV junction ablation + CRT (CRT-P or CRT-D according to guidelines) + optimized drug therapy
3063673|NCT02137174|Active Comparator|Home and school visits|
3063674|NCT02137174|No Intervention|Control|
3063675|NCT02137161|Active Comparator|Dexamethasone+Tobramycin eye drop|An antibiotic and steroid eye drop association will be given starting the day after the surgery for two weeks, dosed QID for the first week and BID for the second week, to 31 patients.
3063676|NCT02137161|Experimental|Bromfenac|Bromfenac eye drops (BID for two weeks starting the day after surgery) plus an antibiotic and steroid eye drop association (QID for the first week and BID for the second week) will be given concurrently to 31 patients.
3063677|NCT02137135|Experimental|follicular phase|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
3063678|NCT02137135|Active Comparator|luteal phase|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
3063679|NCT02137122|Experimental|Cognitive Training|Participants will undergo 60 hours of cognitive training. Cognitive training will involve computerized games that stress elements of cognition. The training control will be the same tasks set at an easy difficulty setting. The group will undergo either transcranial direct current stimulation or sham stimulation.
3063680|NCT02137122|Placebo Comparator|Training Control|Participants will undergo 60 hours of training control. Training control will involve the same computerized games as in the cognitive training condition but are set at an easy difficulty setting. The group will undergo either transcranial direct current stimulation or sham stimulation.
3063681|NCT02137109||natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab per the local label specifications.
3063682|NCT02137096||High Dose Conditioning|Single arm - receives high dose Etoposide phosphate, Ifosfamide, and Carboplatin followed by Autologous Stem Cell Transplantation
3063683|NCT02137083|Experimental|Docetaxel Plus Fulvestrant|"Docetaxel:75mg/m2 D2 every 21 days~Fulvestrant:500mg D1, D15, D29, D57, every 28 days later"
3063684|NCT02137083|Active Comparator|Docetaxel|Docetaxel:75mg/m2 D2 every 21 days
3063685|NCT02137070||Bariatric Surgery Candidates|Participants who are intending to have bariatric surgery for weight loss at local surgical centers or UFHEALTH & Shands Hospital.
3063686|NCT02137070||Non surgical/Community volunteers|Healthy adults with body mass index >35 who will not undergo bariatric surgery for weight loss
3063687|NCT02137057||control ( patients without diabetes)|patients without diabetes
3063688|NCT02137057||DM ( patients with diabetes)|patients with diabetes
3063689|NCT02137044|Experimental|Collaborative Care (CC)|Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care was delivered through an interdisciplinary team, organized around a CC manager (CCM) who guided the patient through various aspects of care during the 16-week treatment phase. The team also included the patient's MS physician and the CC Supervisors, a group of clinicians who were experts of the study domain . The CCM offered all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient had both pain and depression, he or she received care management and collaborative medical management for both.
3063690|NCT02137044|No Intervention|Usual Care|Subjects assigned to usual care were informed by the CCM of their depressive and pain symptoms and that they should consult with their MS or primary care provider about possible care for these conditions. Study personnel did not make any further attempts to influence usual care participants' depression or pain management unless a psychiatric emergency arose (e.g., suicidal ideation was detected at baseline or any of the outcome assessments).
3063691|NCT02137031|Experimental|Mini Link REAL-Time Transmitter|
3063692|NCT02137018|Active Comparator|laparotomy with PPL mesh implantation|control group: laparotomy with PPL mesh implantation (traditional method)
3063693|NCT02137018|Experimental|laparotomy with PPL fixation by BP|laparotomic surgery with PPL mesh fixation by BP (new fixing method)
3063694|NCT02137018|Active Comparator|laparoscopy with PPL mesh implantation|control group: laparoscopy with PPL mesh implantation (traditional method)
3063695|NCT02137018|Experimental|laparoscopy with PPL fixation by BP|laparoscopic surgery with PPL mesh fixation by BP (new fixing method)
3063696|NCT02137005||Cerebral Palsy|Patients with cerebral palsy who were seen at the Center for Gait and Movement Analysis (CGMA) at Children's Hospital Colorado as children.
3063697|NCT02136992|Placebo Comparator|Placebo (without active ingredient)|placebo will be taken two tablets 3 times a day during the whole study process.
3063698|NCT02136992|Experimental|Pirfenidone（200mg）|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
3063699|NCT02136979|Active Comparator|Propofol group|patients with propofol-based anesthesia
3063700|NCT02136979|Active Comparator|Sevoflurane group|patients with sevoflurane-based anesthesia
3063701|NCT02136966|Experimental|Programme|"Distribution of Micronutrients powders (MNP)~Intensive counseling on Infant and Young Child Nutrition~Cooking demonstrations"
3063702|NCT02136966|No Intervention|Controle|"Usual Infant growth monitoring and promotion activities~No distribution of micronutrients powders~No Intensive counseling~No cooking demonstrations"
3063703|NCT02136953|Experimental|Exercise|12-weeks of structured, individual aerobic exercise, 3 times a week, increasing from 15-30 minutes to 30-40 minutes per session.
3063704|NCT02136953|Active Comparator|Cognitive Behavioural Therapy (CBT)|12-weeks of manual-based group CBT, 2 hours per week, 8 participants per group.
3063705|NCT02136953|Experimental|Exercise and CBT|Combined 12-week Exercise program and CBT.
3063706|NCT02136953|No Intervention|Waitlist Condition|12-week waitlist control condition, after which participants will have the chance to receive CBT group treatment.
3063707|NCT02136940|Experimental|AMA0076 0.1%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
3063708|NCT02136940|Experimental|AMA0076 0.25%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
3063709|NCT02136940|Experimental|AMA0076 0.50%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
3063710|NCT02136940|Placebo Comparator|Placebo|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
3063711|NCT02136927|Experimental|SPARC1210|Intravenous administration of SPARC1210
3063712|NCT02136927|Active Comparator|Reference1210|Intravenous administration of Reference1210
3063713|NCT02136914|Experimental|ADS-5102|ADS-5102 (amantadine HCl extended release)
3063714|NCT02136914|Placebo Comparator|Placebo|Placebo
3063715|NCT02136901|Experimental|Investigational arm|The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
3063786|NCT02136420|Placebo Comparator|Manual Control, No training, placebo|subject does test with no hyper gravity training and placebo drug only
3063717|NCT02136888|Experimental|Group A|"Ponesimod will be administered orally, once daily for 22 days starting on Day 2, and will comprise the following multiple-dose up-titration: 3 days of 10 mg (Days 2 to 4), 3 days of 20 mg (Days 5 to 7), 5 days of 40 mg (Days 8 to 12), 3 days of 60 mg (Days 13 to 15), 3 days of 80 mg (Days 16 to 18), and 5 days of 100 mg (19 to 23).~Placebo matched for ponesimod will be given on Day −1. Placebo tablets matched for moxifloxacin will be administered on Days 1 and 24."
3063718|NCT02136888|Experimental|Group B|Placebo matched for ponesimod will be administered orally, once daily on Day −1 and on Day 2 through Day 23. In half of Group B subjects, 400 mg moxifloxacin will be administered orally on Day 1 and a matching placebo tablet on Day 24. In the other half of Group B subjects, a matching placebo tablet will be administered on Day 1 and 400 mg moxifloxacin on Day 24.
3063719|NCT02136875|Experimental|Double dose of Advair for AECOPD|Double dose of Salmeterol + Fluticasone Propionate (Advair) Self-administered prescription Self-management education on the use of a self-administered prescription
3063720|NCT02136836||gastric adenocarcinoma|
3063721|NCT02136823|Placebo Comparator|sugar pill|sugar pill, oral administration, placebo capsule
3063722|NCT02136823|Experimental|riluzole|50mg tablet, single oral dose, one day (single dose)
3063723|NCT02136823|Experimental|isradipine|5mg capsule, single oral dose, one day (single dose)
3063724|NCT02136823|Experimental|memantine|5mg tablet, single oral dose, one day (single oral dose)
3063725|NCT02136823|Experimental|therapeutic stretching|Manual therapeutic stretching of tested muscle by licensed clinician
3063726|NCT02136797|Experimental|CMVpp65-CTL T-cells|The T-cells to be infused will be selected from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 10^6 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
3063727|NCT02136784|Experimental|morphine sulfate|30mg, single dose,
3063728|NCT02136784|Experimental|hydrocodone|10mg single dose
3063729|NCT02136784|Experimental|hydromorphone HCI|4mg single dose
3063730|NCT02136784|Experimental|oxycodone|10 mg single dose
3063731|NCT02136784|Experimental|buprenorphine|4 mg single dose
3063732|NCT02136784|Placebo Comparator|oral tablet placebo|single dose
3063733|NCT02136784|Placebo Comparator|sublingual tablet placebo|single dose
3063734|NCT02136771|Active Comparator|Vitamin D3|The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3; producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks
3063735|NCT02136771|Placebo Comparator|Placebo|Oily drops as placebo
3063736|NCT02136758|Experimental|Lifestyle modification|The intervention group participated in individualized therapeutic lifestyle plans to reduce cardiovascular risk. Participants were introduced to factors contributing to cardiovascular disease and met individually with a registered dietitian, exercise physiologist, stress management instructor, and psychologist to learn effective strategies for integrating healthy changes into their current lifestyle.
3063737|NCT02136758|No Intervention|Usual care controls|Control group received standard care from their primary physicians, but did not participate in any component of the lifestyle program or receive any information, advice, or counseling regarding healthy lifestyle behaviors.
3063738|NCT02136745|Experimental|Relaxation Response Mind-Body Intervention|The Relaxation Response Mind-Body Intervention (RR-MBI) involved a 9-week group program conducted by a nurse practitioner or psychologist skilled in MBI, which included a GI-specific session conducted by a physician. The groups met once weekly for 1.5 hours. The program was multidimensional and included daily elicitation of the RR using a variety of methods (including breath focus, single-pointed focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills, health enhancing behaviors, and the promotion of optimism and acceptance. Throughout the course of treatment, participants were asked to elicit the RR at home each day for 15-20 minutes.
3063739|NCT02136732|Experimental|Active self-management intervention|Participants will receive home visits and phone calls from a registered nurse and social worker. The registered nurse and social worker will provide participants one on one coaching, education, support and referrals to community resources to help them manage their chronic conditions.
3063740|NCT02136732|Active Comparator|Attention control phone calls|Participants will receive an initial visit and then a phone call every other month from a social services aide who can provide information about community resources that might be helpful.
3063741|NCT02136719|Active Comparator|Group A|bimanual uterine compression immediately after delivery of placenta for 5 minutes in 260 women
3063742|NCT02136719|No Intervention|Group B|no intervention (260 women).
3063743|NCT02136706|No Intervention|10/30 min rest/stress|Rest and stress T99m-MPI obtained 10 minutes and 30 minutes after tracer injection. After the myocardial perfusion imaging the investigators will have 10 minute waiting period to take images and then wait the 30 minutes, standard of care to take the images.
3063744|NCT02136693|Placebo Comparator|Placebo|3.5 g /day of inert compound for 180 days after STARR
3063745|NCT02136693|Experimental|Psyllium fiber|3.5 g /day of pure Psyllium fiber for 180 days after STARR
3063746|NCT02136680|Active Comparator|Patients at Intervention Site|Staff receives CASA Education
3063747|NCT02136680|No Intervention|Patients at CONTROL site|Staff does not receive CASA Education
3063748|NCT02136680|Experimental|STAFF - Intervention site|Staff with CASA Education
3063749|NCT02136680|No Intervention|STAFF - WITHOUT intervention|Staff WITHOUT CASA Education
3063750|NCT02136667||Exposed|Women with a history of preeclampsia 10 years ago
3063751|NCT02136667||Unexposed|Women with a history of uncomplicated pregnancy 10 years ago
3063752|NCT02136654|Experimental|Culturally tailored diabetes program|"Culturally tailored diabetes program~culturally tailored diabetes education~lifestyle counselling~medication adherence counseling~peer supporter~communication training~family member involvement"
3063753|NCT02136654|No Intervention|Usual Care|Usual Care includes continuing to visit primary care physician for ongoing diabetes management Printed diabetes education materials.
3063787|NCT02136420|Experimental|Manual Control, Training, promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
3093231|NCT01937754|Placebo Comparator|Placebo|
3063754|NCT02136641|Active Comparator|Midazolam|1. Sedation with Midazolam 0.03 mg / kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
3063755|NCT02136641|Experimental|Midazolam+Fentanyl Combination|2. Sedation with Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
3063756|NCT02136641|Experimental|Midazolam+Ketamine Combination|3. Sedation with Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
3063757|NCT02136628|Experimental|RTL|"The method consists of two lines of suture, each, over the fascial wound edge. It starts with a suture strand (in this study was used PDS number 0) in one end of the fascial wound where the suture is run longitudinally and parallel to the aponeurotic edge. The needle should go in and out at intervals of 1 cm away and always kept at 0.5 cm from the edge of the fascia. Upon reaching the opposite angle of the wound suture strand another repeating the same process on the fascial edge otherwise used. The ends of the two suture strands are tied in fascial angles.~Thus the fascial wound is sutured with two lines of strengthening its edges. Then proceed to close the wound with continuous súrgete always ensuring that the suture lines remain anchored on suture reinforcement."
3063758|NCT02136628|No Intervention|Control|Conventional midline mass closure technique. Upon completion of the surgical procedure was the closure of abdominal wall which will be made with the number 0 monofilament PDS, starting with knot at one end of the wound, continuous with continuous súrgete, moving each point to a centimeter away from the other. Each point will be a distance of one centimeter from the edge of the fascia. At the opposite end of the wound the same procedure was initiated and found the two suture lines at the midpoint of the wound will proceed to tying the two sutures with 4 square knots.
3063759|NCT02136615||overweight and obese male volunteers|BMI between 23-40 kg/m2
3063760|NCT02136589|Experimental|Dicrofenac|
3063761|NCT02136576|Active Comparator|Sensodyne|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
3063762|NCT02136576|Active Comparator|Crest Cavity Protection & MI Paste Plus|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
3063763|NCT02136576|Active Comparator|Clinpro 5000|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
3063764|NCT02136563||Darbepoetin alfa|
3063765|NCT02136550|Experimental|Smoking cessation|36 smokers will participate in the study and will be evaluated at baseline, 6 months e 12 months of the smoking cessation program. If they quit the program, they will be asked to continue the study.
3063766|NCT02136537|Active Comparator|Best medical therapy|Claudicants treated according to local protocol - no added treatment
3063767|NCT02136537|Experimental|Best medical therapy plus NMES|In addition to best medical therapy, subjects will receive bilateral neuromuscular stimulation of their legs, 4 hours per day.
3063768|NCT02136524|Experimental|Capsule formulation|
3063769|NCT02136524|Experimental|Tablet formulation|
3063770|NCT02136498|Active Comparator|mHealth self-help + varenicline|Participants in this control arm received standard cognitive-behavioral self-help materials delivered via a mobile health (mHealth) program + a standard course of varenicline.
3063771|NCT02136498|Experimental|mHealth MyMAP program + varenicline|Participants in the experimental arm received standard cognitive-behavioral self-help materials delivered via a mHealth program + additional personalized support features (automated, tailored advice managing nicotine withdrawal symptoms and medication side-effects & secure messaging with a cessation counselor; i.e., MyMAP program) + a standard course of varenicline.
3063772|NCT02136485|Experimental|MBSR|8 weekly sessions each lasting 2.5 hours
3063773|NCT02136485|Other|Control|Control arm - waiting list control, once the intervention group has completed MBSR the control group will be invited to participate in MBSR
3063774|NCT02136472||Subfertile women|"Women who visit the fertility clinic of the Maastricht University Medical Centre who start with a basic fertility work-up. Women diagnosed with an unexplained subfertility or with (signs of) a decreased ovarian reserve are asked for further participation in the study of the cardiovascular profile.~As a control group parous women with an uncomplicated pregnancy more than 6 months ago will be asked for participation."
3063775|NCT02136459|Experimental|Small tube size|Size 6.5 ETT for female, size 7.0 ETT for male
3063776|NCT02136459|Active Comparator|Large tube size|Normal tube size, size 7.5 for female, size 8 for male
3063777|NCT02136446|Experimental|EchoGlo™ Peripheral Nerve Block Catheter|Echogenic nerve block catheter (test)
3063778|NCT02136446|Active Comparator|Pajunk® EpiLong Catheter|Non-echogenic nerve block catheter (control)
3063779|NCT02136433|Experimental|Tablet - self exercise|"Existing tablet Apps that encourage finger movement in a fun manner while playing a game will be used. The apps will be taught to the participants and then they will be requested to exercise alone (or with family) everyday for one hour in addition to their regular rehabilitation sessions (Occupational, Physical Therapy, speech).~The intervention will include 15-20 sessions of 60 minutes of self-training using a tablet."
3063780|NCT02136433|Active Comparator|GRASP self exercise|"GRASP (Graded Repetitive Arm Supplementary Program)(Harris et al., 2009)is an arm and hand exercise program developed for individuals with stroke with upper extremity impairments GRASP provides a method for patients to undertake a self-directed arm and hand exercise program.~The exercises will be taught to the participants and then they will be requested to exercise alone (or with family) everyday for one hour in addition to their regular rehabilitation sessions (Occupational, Physical Therapy, speech).~The intervention will include 15-20 sessions of 60 minutes of self-training"
3063781|NCT02136420|Experimental|Tilt perception, Training, placebo|placebo
3063782|NCT02136420|Placebo Comparator|Tilt perception, No training, placebo|subject does test with no hypergravity training and placebo drug only
3063783|NCT02136420|Experimental|Tilt perception, Training, promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
3063784|NCT02136420|Experimental|Tilt perception,No training,promethazine|promethazine 25 mg, one time 120 minutes prior to experiment. No hypergravity training
3063785|NCT02136420|Experimental|Manual Control, Training, placebo|placebo
3063789|NCT02136420|Experimental|Perceptual thresholds,drug then placebo|"Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with promethazine then once with placebo, separated by >4 days.~This arm corresponds to results published in Diaz-Artiles et al 2017."
3063790|NCT02136420|Experimental|Perceptual thresholds,placebo then drug|"Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with placebo then once with promethazine, separated by >4 days.~This arm corresponds to results published in Diaz-Artiles et al 2017."
3063791|NCT02136407||Blood donors|N=540
3063792|NCT02136407||Thrombocyte donors|N=75
3063793|NCT02136394||Severe/moderate acid reflux|
3063794|NCT02136394||Mild/absent acid reflux|
3063795|NCT02136381|Experimental|LEAP intervention|A newly developed internet-based lifestyle programme (Living, Eating, Activity and Planning through retirement (LEAP)) will promote three key health and social behaviours; healthy eating following a Mediterranean diet, increasing physical activity and improve social connectedness.
3063796|NCT02136381|Other|Control|"Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).~This website contains general information on improving life style and health."
3063797|NCT02136368|Experimental|Multi-Modal, Mind Motor Exercise (M4)|Attend 60 minute exercise class three times per week for 24 weeks. Exercise class includes 45 minutes of multi-modal exercise and 15 minutes of mind-motor exercise.
3063798|NCT02136368|Active Comparator|Multi-Modal Exercise (M2)|Attend 60 minute exercise class three times per week for 24 weeks. Exercise class includes 45 minutes of multi-modal exercise and 15 minutes of balance and range of motion exercises.
3063799|NCT02136355|Experimental|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
3063800|NCT02136342|Experimental|chlorogenic acid|
3063801|NCT02136329|Experimental|Sildenafil|All subjects in groups 1-6 will receive SIldenafil but in escalating doses.
3063802|NCT02136316|Experimental|ASP7962 low dose|
3063803|NCT02136316|Experimental|ASP7962 medium dose|
3063804|NCT02136316|Experimental|ASP7962 high dose|
3063805|NCT02136316|Placebo Comparator|Placebo|
3063806|NCT02136303|Placebo Comparator|S1-Placebo|placebo capsule with all ingredients, but without active compound, intervention for 4 weeks, S1: Dosage-dependency
3063807|NCT02136303|Experimental|S1-1L|capsule containing 1 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
3063808|NCT02136303|Experimental|S1-2L|capsule containing 2 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
3063809|NCT02136303|Experimental|S1-5L|capsule containing 5 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
3063810|NCT02136303|Experimental|S2-Kale_extract|
3063811|NCT02136303|Experimental|S2-Kale_purée|
3063812|NCT02136303|Placebo Comparator|S3-Placebo|
3063813|NCT02136303|Experimental|S3-AMD-Patients|
3063814|NCT02136303|Experimental|S3-non-AMD|
3063815|NCT02136303|Placebo Comparator|S1-Placebo-Tagetes|capsule containing all ingredients, but without active compound, intervention for 4 weeks, S1: Dosage-dependency
3063816|NCT02136303|Experimental|S1-1L-Tagetes|capsule containing 1 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
3063817|NCT02136303|Experimental|S1-2L-Tagetes|capsule containing 2 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
3063818|NCT02136303|Experimental|S1-5L-Tagetes|capsule containing 5 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
3063819|NCT02136303|Experimental|S1-10L-Tagetes|capsule containing 10 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
3063820|NCT02136290|Other|Usual Care|Weight loss counseling
3063821|NCT02136290|Experimental|Prepackaged meal|Prepackaged meals
3063822|NCT02136277||Colorectal patients|Subjects undergoing colorectal surgery
3063823|NCT02136264|Active Comparator|PCFA interventional dietary counselling|personalized categorical food avoidance dietary counselling
3063824|NCT02136264|Sham Comparator|conventional DASH diet counselling|"DASH = conventional dietary approach to stop hypertension"
3063825|NCT02136251||shoulder replacement|Subjects who had shoulder replacement surgery at The University of Nebraska and The Nebraska Medical Center at least 5 or more years ago and autologous bone graft around the anchor-peg glenoid prosthesis was used.
3063826|NCT02136238|Active Comparator|Prosthetic hand 1 (Hosmer 5XA)|This arm of the study included unilateral transradial amputees who who were assessed while using prosthetic hand 1
3063827|NCT02136238|Active Comparator|Prosthetic hand 2 (TRS Grip 3)|This arm of the study included unilateral transradial amputees who who were assessed while using prosthetic hand 2
3063828|NCT02136238|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
3063829|NCT02136225|Experimental|Counseling|Intervention: Means restriction counseling. Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun in the home where youth are present.
3063830|NCT02136225|Experimental|Counseling and locking devices|Intervention: Means restriction counseling and locking devices. Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present. Parents will also receive locking devices to store their guns securely.
3063831|NCT02136225|No Intervention|Control group|Youth in the control group will receive usual care.
3063832|NCT02136212|Experimental|Approach-positive AAT|Participants will receive 4 sessions over 2 weeks of a computerized AAT procedure designed to increase automatic approach responses for positive social cues.
3063833|NCT02136212|Placebo Comparator|Control AAT|Participants will receive 4 sessions over 2 weeks of a computerized AAT procedure in which there is no contingency between arm movement and positive social cues.
3063859|NCT02136043|Experimental|Group 2|Insertion of catheter into nasal cavity carried out by health professional. Fixation of catheter during treatment with helmet.
3063834|NCT02136199|Other|Active Implementation of Share EBM Toolkit|Investigators led implementation of tailored activities and tactics (Shared EBM Toolkit) designed to promote the use of the decision aids in clinical encounters (i.e. journal clubs, value map streaming).
3063835|NCT02136199|Other|Passive Implementation of Share EBM Toolkit|Locally supported dissemination of Shared EBM Toolkit designed to promote the use of the decision aids in clinical encounters.
3063836|NCT02136186|No Intervention|Standard of care|patients will receive standard of care discharge instructions
3063837|NCT02136186|Active Comparator|Philips Telehealth|patients will be discharged with a telemonitoring device for 30 days
3063838|NCT02136173|Experimental|sequential balloons|effect of weight loss by applying sequential balloons
3063839|NCT02136147||Children with ADHD medication|Identified responders and non-responders in children/adolescents starting medication for treatment of ADHD in public child and adolescent psychiatric services in Stockholm and on Gotland.
3063840|NCT02136147||Lisdexamphetamine medication|Identified responders and non-responders in children/adolescents starting medication with lisdexamphetamine in public child and adolescent psychiatric services in Stockholm and on Gotland.
3063841|NCT02136147||Atomoxetine medication|Identified responders and non-responders in children/adolescents starting medication with atomoxetine in public child and adolescent psychiatric services in Stockholm and on Gotland.
3063842|NCT02136147||Methylphenidate medication|Identified responders and non-responders in children/adolescents starting medication with methylphenidate in public child and adolescent psychiatric services in Stockholm and on Gotland.
3063843|NCT02136147||Guanfacine medication|Identified responders and non-responders in children/adolescents starting medication with guanfacine in public child and adolescent psychiatric services in Stockholm and on Gotland.
3063844|NCT02136134|Experimental|Daratumumab+VELCADE+dexamethasone|Daratumumab, VELCADE and dexamethasone
3063845|NCT02136134|Active Comparator|VELCADE+dexamethasone|VELCADE and dexamethasone
3063846|NCT02136121|Experimental|da Vinci Sp Surgical System|da Vinci Sp Surgical System - Robotic - assisted single-port surgery
3063847|NCT02136108|Experimental|OPENtext|OPENtext will target cognitive, affective, and behavioral strategies through a single, brief in-person assessment, followed by 12 weeks of theoretically-informed text messages, a core set of information organized in a 'frequently asked questions' structure, interactive peer support, static resources on key patient-identified topics, and a library of peer stories accessible throughout the study period.
3063848|NCT02136108|Active Comparator|OPENnav|Peer Navigation is currently offered to some individuals in this Medicaid population but not all. Peer navigators interact with patients by phone/text and at home visits. Efforts focus on drivers of a patient's ED use, and may include providing or identifying patient support, improving health literacy, assisting with transportation vouchers, health education, family support, accessing housing services, and orienting to other community support services.
3063849|NCT02136095|Experimental|IFC-group|The investigators included patients undergoing laparoscopic cholecystectomy by a single surgeon between September and December 2013 at a single centre university department with unrestricted referral of patients. The included patients represented all patients undergoing laparoscopic cholecystectomy by one surgeon during the study period. All patients underwent intra-operative fluorescent cholangiography (IFC) with concomitant angiography, according to a standardized protocol, during their laparoscopic cholecystectomy.
3063850|NCT02136082|Experimental|Asha Support + Training|Asha Support + Training: 1) Group discussions delivered over a six month period that cover four main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; and d) Healthy Eating for Self and Family; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen.
3063851|NCT02136082|Experimental|Asha Support + Food|Asha Support + Food 1) Group discussions delivered over a six month period that cover three main categories a) Staying Healthy; b) Caregiving; and c) Staying Upbeat; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen; 4) Food supplementation of high protein food such as urad dal or tur dal.
3063852|NCT02136082|Experimental|Asha Support + Training + Food|Asha Support + Training + Food: 1) Group discussions delivered over a six month period that cover four main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; and d) Healthy Eating for Self and Family; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen; 4) Food supplementation of high protein food such as urad dal or tur dal.
3063853|NCT02136082|Active Comparator|Asha Support Only|Asha Support Only 1) Group discussions delivered over a six month period that cover three main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen.
3063854|NCT02136069|Experimental|etrolizumab + placebo (IV)|Participants will receive ertolizumab (SC) Q4W until Week 52 along with placebo matched to infliximab as IV until Week 46
3063855|NCT02136069|Active Comparator|infliximab + placebo (injection)|Participants will receive IV Infusion of Iinfliximab at Weeks 0,2, and 6, then every 8 weeks until Week 46 partnered with placebo matched to ertolizumab SC Q4W until Week 52
3063856|NCT02136056|Experimental|Self-management program (SMP)|Participants in the experimental group receive six weekly group-sessions of self-management and patient education; specifically targeting self-management of the return to work process and disease symptoms.
3063857|NCT02136056|No Intervention|Treatment as usual|Participants in the control-group receive standard rehabilitation care and follow-up in the job-center.
3063858|NCT02136043|Experimental|Group 1|Insertion of catheter into nasal cavity carried out by patient. Fixation of catheter during treatment with patient´s hand.
3063860|NCT02136030|Experimental|Lipo-AB|
3063862|NCT02136017||Changchun biologial's vaccine|Changchun Biological's vaccine group is the population injected with this vaccine.
3063863|NCT02136004|Experimental|Closer VSS|Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
3063864|NCT02135991|Experimental|Project CHOICE + Getting To Outcomes|Boys and Girls Club sites will receive a) training and materials for Project CHOICE and b) training, ongoing technical assistance for two years, and materials for Getting To Outcomes
3063865|NCT02135991|Active Comparator|Project CHOICE only|Boys and Girls Club sites will receive a) training and materials for Project CHOICE
3063866|NCT02135978|Experimental|One-to-one training group for shoulder home exercise program|Patients will attend two sessions of one-to-one training with a physical therapist to learn the shoulder home exercise program. The sessions are 4 weeks apart. They will also review a handout on techniques to protect their shoulder during wheelchair propulsion and transfers.
3063867|NCT02135978|Active Comparator|Enhanced training group for shoulder home exercise program|Patients will attend four classes held each week for 4 consecutive weeks. The classes are led by a physical therapist and a peer mentor (with a spinal cord injury). Two to four research patients are in each class. Classes begin with an interactive education presentation on techniques and recommendations to protect the shoulder during transfers, wheelchair propulsion, raises and activities of daily living. This is followed by performance of the home exercise program. Patients will be called every 3 to 6 months by a peer mentor to receive encouragement, praise, and/or problem solve barriers to exercise.
3063868|NCT02135978|No Intervention|Historical control group|Historical control group has received no intervention. Eligibility criteria, outcome measures and study duration for historical control group is matched for the experimental group and active comparator.
3063869|NCT02135965|Experimental|Albuterol 2mg|2 mg of Albuterol is in a pill form or placebo
3063870|NCT02135965|Experimental|Albuterol 4mg|4mg of Albuterol or placebo is given in pill form
3063871|NCT02135965|Experimental|Caffeine 100mg|100mg of Caffeine or placebo is given in a pill form.
3063872|NCT02135965|Experimental|Caffeine 200mg|200mg of Caffeine or placebo is given in a pill form
3063873|NCT02135965|Experimental|Albuterol 2mg & Caffeine 100mg|100mg of Caffeine in combination with Albuterol 2mg or placebo is given in a pill form.
3063874|NCT02135965|Experimental|Albuterol 2mg and Caffeine 200mg|200mg of Caffeine in combination with Albuterol 2mg or placebo is given in a pill form.
3063875|NCT02135965|Experimental|Albuterol 4mg and Caffeine 100mg|100mg of Caffeine in combination with Albuterol 4mg or placebo is given in a pill form.
3063876|NCT02135965|Experimental|Albuterol 4mg and Caffeine 200mg|200mg of Caffeine in combination with Albuterol 4mg or placebo is given in a pill form.
3063877|NCT02135952|Active Comparator|SRP+MTZ+AMX|Scaling and root planing (SRP) + metronidazole (MTZ; 400 mg thrice a day [TID] for 14 days) + amoxicillin (AMX; 500 mg TID for 14 days)
3063878|NCT02135952|Placebo Comparator|SRP+placebo|Scaling and root planing + placebo
3063879|NCT02135939|Active Comparator|American Heart Association diet|Participants randomized into this arm will follow an American Heart Association diet plan for 8 weeks.
3063880|NCT02135939|Experimental|Whole-food plant-based vegan diet|Participants randomized into this arm will be asked to follow a whole-food plant-based vegan diet plan for 8 weeks.
3063881|NCT02135926|Active Comparator|Best medical care|Best clinical care in dedicated stroke unit
3063882|NCT02135926|Active Comparator|Thrombectomy|All subjects randomly assigned to the thrombectomy arm, except those with rapidly improving neurologic symptoms or no angiographic evidence of occlusion, will be treated with the endorsed study devices (stent retriever).
3063883|NCT02135913|Experimental|Viatamin D|All children enrolled into the study will be prescribed standard of care vitamin D.
3063884|NCT02135900|Experimental|Heliox|Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.
3063885|NCT02135887||MB-6+FOLFOX chemotherapy|MB-6, 6 capsules tid be taken with meals plus FOLFOX chemotherapy, will be given for 18 weeks
3063886|NCT02135887||Placebo+FOLFOX chemotherapy|Placebo, 6 capsules tid be taken with meals plus FOLFOX chemotherapy, will be given for 18 weeks
3063887|NCT02135874|Experimental|Newly Diagnosed Mixed Phenotype Acute Leukemia|"Induction:~Clofarabine 15 mg/m2 by vein Days 1-4. Idarubicin 10 mg/m2 by vein on Days 1-3. Cytarabine 1,000 mg/m2 by vein on Days 1-4. Vincristine 2 mg by vein Days 1, 8, and 15. Dexamethasone 40 mg by vein over about on Days 1-4 and 15-18. For patients with CD20 positive disease Rituximab 375 mg/m2 by vein on Days 1 and 8.~Consolidation:~Clofarabine 15 mg/m2 by vein on Days 1-3. Idarubicin 6 mg/m2 by vein on Days 1-2. Cytarabine 1,000 mg/m2 by vein on Days 1-3. Vincristine 2 mg by vein on Days 1, 8, and 15. Dexamethasone 40 mg by vein on Days 1-4 and 15-18.~For patients with CD20 positive disease Rituximab 375 mg/m2 by vein on Days 1 and 8.~Participants receive the study drugs for 1-2 induction cycles and then up to 6 consolidation cycles."
3063888|NCT02135874|Experimental|Relapsed Mixed Phenotype Acute Leukemia|"Induction:~Clofarabine 15 mg/m2 by vein Days 1-4. Idarubicin 10 mg/m2 by vein on Days 1-3. Cytarabine 1,000 mg/m2 by vein on Days 1-4. Vincristine 2 mg by vein Days 1, 8, and 15. Dexamethasone 40 mg by vein over about on Days 1-4 and 15-18. For patients with CD20 positive disease Rituximab 375 mg/m2 by vein on Days 1 and 8.~Consolidation:~Clofarabine 15 mg/m2 by vein on Days 1-3. Idarubicin 6 mg/m2 by vein on Days 1-2. Cytarabine 1,000 mg/m2 by vein on Days 1-3. Vincristine 2 mg by vein on Days 1, 8, and 15. Dexamethasone 40 mg by vein on Days 1-4 and 15-18.~For patients with CD20 positive disease Rituximab 375 mg/m2 by vein on Days 1 and 8.~Participants receive the study drugs for 1-2 induction cycles and then up to 6 consolidation cycles."
3063889|NCT02135861|Experimental|Healthy volunteers|All subjects will undergo MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.
3063890|NCT02135861|Experimental|Heart failure patients|All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system.
3063891|NCT02135861|Experimental|Acute decompensated heart failure|All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system
3063892|NCT02135848|Experimental|GSK1278863|Study Drug
3063893|NCT02135848|Placebo Comparator|Placebo|Placebo
3063894|NCT02135835|Experimental|Shenfu Zhusheye|80 ml Shenfu Zhusheye + 70 ml 5% glucose injection, ivdrip, once a day for 7 days.
3063895|NCT02135835|Placebo Comparator|5% glucose injection|150 ml 5% glucose injection, ivdrip, once a day for 7 days.
3063896|NCT02135822|Experimental|nanoparticle albumin-bound paclitaxel, gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 and 8, in combination with gemcitabine which is given at 1000 mg/m2, on day 1 and 8, each 21-day cycle. Number of cycle: 6 cycles.
3063897|NCT02135809|Experimental|FCSEMS|Patients will receive the WallFlex Pancreatic Stent.
3063898|NCT02135796||Sepsis/Septic Shock|Individuals who are admitted to the Intensive Care Unit (ICU) with an infection called Sepsis or Septic Shock. This group will receive tansthoracic echocardiography as part of the study.
3063899|NCT02135783|Experimental|Decompressive Craniectomy|Decompressive Craniectomy afte Hematoma Removal in Patients with Intracerebral Hemorrhage
3063900|NCT02135783|Active Comparator|non-Decompressive Craniectomy|non-Decompressive Craniectomy afte Hematoma Removal in Patients with Intracerebral Hemorrhage
3063901|NCT02135770|Experimental|Unfractionated Heparin|Low dose unfractionated Heparin 10 unit/kgBW/hour continuous infusion
3063902|NCT02135770|Placebo Comparator|Placebo|Normal saline packed in same form with trial drugs.
3063903|NCT02135744|No Intervention|Control|Group of patients undergo standard care as determined by the primary inpatient team
3063904|NCT02135744|Experimental|Bundle|Group of patients that receive the screening and educational tool
3063905|NCT02135731|No Intervention|Paper|Usual care -medication review on paper
3063906|NCT02135731|Experimental|Computer|Medication review software with pictures
3063907|NCT02135718||Group 1|Subjects will use the ELLIPTA inhaler once daily for 5 to 9 days during the first period followed by the MDI inhaler twice daily for 5 to 9 days during the second period.
3063908|NCT02135718||Group 2|Subjects will use the MDI inhaler twice daily for 5 to 9 days during the first period followed by the ELLIPTA inhaler once daily for 5 to 9 days during the second period.
3063909|NCT02135705||Lomitapide|Lomitapide as prescribed by Physician.
3063910|NCT02135692|Experimental|Mepolizumab 100 mg|All subjects will receive mepolizumab 100mg administered SC into the upper arm or thigh approximately every 4 weeks.
3063911|NCT02135679||Cohort 1|Patients with early stage NSCLC undergoing stereotactic radiotherapy
3063912|NCT02135679||Cohort 2|Patients with locally advanced NSCLC undergoing standard chemoradiotherapy
3063913|NCT02135679||Cohort 3|Patients with stage I-III NSCLC undergoing standard, fractionated radiotherapy alone
3063914|NCT02135679||Cohort 4|Patients with locally advanced NSCLC undergoing standard chemoradiotherapy with the novel signal transduction inhibitor, nelfianvir.
3063915|NCT02135679||Cohort 5|Patients with resectable stage IIIa NSCLC undergoing pre-operative chemoradiotherapy
3063916|NCT02135679||Cohort 6|(Patients with suspected (no tissue diagnosis) early stage NSCLC undergoing stereotactic radiotherapy)
3063917|NCT02135666|Experimental|2-dose Primed Group|Adolescent subjects in this group received 2 doses of Twinrix Adult (720/20) (licensed as Ambirix in the EU) according to a 0, 6 months schedule in the primary study HAB-084 (208127/084).
3063918|NCT02135666|Experimental|3-dose Primed Group|Adolescent subjects in this group received 3 doses of Twinrix Junior (360/10) according to a 0, 1, 6 months schedule in the primary study HAB-084 (208127/084).
3063919|NCT02135653||Feasibility|
3063920|NCT02135653||Phase II|
3063921|NCT02135640|Experimental|denosumab 60 mg|solution
3063922|NCT02135640|Experimental|denosumab 120 mg|solution
3063923|NCT02135640|Placebo Comparator|placebo|solution
3063924|NCT02135627|Experimental|Control group|Current standard endoscopic therapy such as epinephrine injection, sclerotherapy, mechanical (endoclip). contact electrocautery/thermal, and non-contact electrocalcautery (APC) ± radiation therapy, angioembolization, and/or surgery.
3063925|NCT02135627|Active Comparator|TC-325|TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.
3063926|NCT02135614|Experimental|Presatovir|Participants will receive a single dose of presatovir.
3063927|NCT02135614|Placebo Comparator|Presatovir placebo|Participants will receive a single dose of presatovir placebo.
3063928|NCT02135601|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
3063929|NCT02135601|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
3063930|NCT02135575|Experimental|Premenopausal women|The Premenopausal women are randomized to exercise by spinning (cycle)
3063931|NCT02135575|Experimental|Postmenopausal women|The Postmenopausal women are randomized to exercise by spinning (cycle)
3063932|NCT02135562|Experimental|Supportive Care (PSMF)|Participants will take part in a Protein-Sparing Modified Fast (PSMF) Intervention for weight loss. Participants will undergo a dietary intervention high in protein for 6 weeks or until they have loss 15% of their body weight. This intervention will be followed by weight maintenance in which participants reintroduce non-starchy vegetables to their diet. At this time participants will also receive informational material and dietary education which teaches participants how to read nutrition labels and calculate carbohydrate loads in foods. Participants are given the Obesity and Weight-Loss Quality of Life Questionnaire to survey the impact of the intervention
3063933|NCT02135549|Experimental|SugarDown 4 grams|SugarDown 4 gram dose in tablet form, before meals, daily for one week
3063934|NCT02135549|Experimental|SugarDown 8 grams|SugarDown 8 gram dose in tablet form, before meals, daily for one week
3063935|NCT02135549|Placebo Comparator|Placebo|Placebo dose in tablet form, before meals, daily for one week
3063936|NCT02135536|Experimental|NGM282 Dose 1|NGM282 Dose 1
3063937|NCT02135536|Experimental|NGM282 Dose 2|NGM282 Dose 2
3063938|NCT02135536|Experimental|NGM282 Dose 3|NGM282 Dose 3
3063939|NCT02135523|Experimental|single arm: involved-field radiation therapy group|
3063940|NCT02135510|Active Comparator|metoclopramide|
3063941|NCT02135510|Active Comparator|dexamethason|
3063942|NCT02135510|Active Comparator|palonosetron|
3063943|NCT02135484|Experimental|Alpharadin|Participants treated with standard dosing of Alpharadin 50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
3063946|NCT02135458|Experimental|Telemonitoring|Home-based patient management using AUTONOM@DOM telemonitoring system to record and transmit heart rate, blood pressure and weight; along side conventional care (patient therapeutic education or personalised care program)
3063947|NCT02135458|Active Comparator|Conventional care|Conventional care including patient therapeutic education or personalised care program
3063948|NCT02135445|Experimental|TAK-385|TAK-385 320 mg, tablets, orally, once, on Day 1, followed by TAK-385 120 mg, orally, once daily for 24 weeks. Each participant may have one upward dose adjustment of 40 mg for efficacy and/or one downward dose adjustment of 40 mg for safety during the study.
3063949|NCT02135445|Active Comparator|Degarelix|Degarelix 240 mg, injection, subcutaneous, on Day 1, followed by degarelix 80 mg, injection, subcutaneous, once every four weeks, for 24 weeks.
3063950|NCT02135432|Experimental|Ivacaftor (VX-770)|twice a day administration of Ivacaftor: 150mg
3063951|NCT02135432|Placebo Comparator|Placebo|matching placebo
3063952|NCT02135419|Experimental|Arm I (treatment)|Patients are directed to receive either topical or ablative treatment at the discretion of the clinician. Patients receiving topical treatment apply imiquimod intra-anally, peri-anally or both thrice weekly for up to 16 weeks, fluorouracil twice daily for 5 days every 2 weeks for up to 16 weeks, or trichloroacetic acid every 3 weeks up to 12 weeks. Patients receiving ablative treatment using infrared photocoagulation therapy, hyfrecation/electrocautery (thermal ablation therapy), or laser therapy. Patients may undergo excision under anesthesia if the clinician believes none of the other treatment approaches will be effective. The number and timing of such treatments will be at the discretion of the investigator. Patients with persistent HSIL should continue a protocol-approved treatment or a new protocol treatment should be considered. All participants will have samples collected for laboratory biomarker analysis.
3063953|NCT02135419|Active Comparator|Arm II (active monitoring)|Patients undergo active monitoring with examinations for clinical observation every 6 months. Every 12 months, patients undergo biopsies of visible lesions. Patients have cytology sampling performed at every visit. All participants will have samples collected for laboratory biomarker analysis.
3063954|NCT02135406|Experimental|Multiple Myeloma Patients|Adult subjects (18 years or older) with multiple myeloma and with poor prognosis by virtue of having relapsed/progressive disease within one year of first autologous stem cell transplantation.
3063955|NCT02135393|Experimental|13C5-folic acid or 13C5-6S-5-FormylTHF|Physiological 500 nmol (220 µg folic acid equivalent) dose of dietary supplement 13C5-folic acid or 13C5-6S-5-FormylTHF given to subjects with in situ transjugular intrahepatic portosystemic stent at the time of routine venography patency check followed by regular portal venous sampling for 85 minutes at pre determined intervals and then physiological 500 nmol dose of 13C-6S-5-FormylTHF or 13C5-folic acid respectively at the next annual routine venography patency check followed by portal venous sampling for 85 minutes
3063956|NCT02135380|Other|Autologous Stromal Vascular Fraction|Single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.
3063957|NCT02135380|Other|Autologous Adipose Derived MSCs|3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.
3063958|NCT02135380|Active Comparator|Control|"corticosteroids i.e. Prednisolone ≤10mg/day or ≤20 mg every alternate day~Immunosuppressants like Cyclophosphamide or Azathioprine at a dose of 2mg/kg/day not exceeding 150 mg/day~Antioxidants like N-acetylcysteine (NAC) at a dose upto 1800 mg/day.~Pirfenidone at dose upto 1200 to 1800 mg/day"
3063959|NCT02135367|Experimental|PRP|This group of patients will be treated by three weekly Platelet rich Plasma intra-articular injections in the knee.
3063960|NCT02135367|Active Comparator|HA|"This group of patients will be treated by three weekly hyaluronic acid (HA) intra-articular injections in the knee.~The HA used is Hyalubrix 30 mg/2ml (Fidia Farmaceutici Spa, Padova, Italy)"
3063961|NCT02135354|Experimental|Azithromycin|"N = 250~From day 1 up to and including day 3: 500 mg azithromycin PO once a day~From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days"
3063962|NCT02135354|Placebo Comparator|Placebo|"N = 250~From day 1 up to and including day 3: 500 mg placebo PO once a day~From day 4 up to and including day 90: 250 mg placebo PO once every 2 days"
3063963|NCT02135341|Experimental|Group A: Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
3063964|NCT02135341|Experimental|Group B: Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
3063965|NCT02135328|Experimental|Radio Story|Participants listen to a radio story about a family's' success with preventing or managing type 2 diabetes through diet and physical activity; the focus was for the entire family to implement healthful lifestyle behaviors so the children can learn as well.
3063966|NCT02135328|Active Comparator|Audio brochure|Participants received an audio version of a standard brochure about type 2 diabetes prevention and management.
3063967|NCT02135315|Experimental|intensive controle group|the end point in this group was to maintain the systolic blood pressure (SBP) between 110 and 120 mmHg using continuous Isosorbide Dinitrate (RISORDON) perfusion associated, if needed, with Labetalol (TRANDATE) continuous perfusion.
3063968|NCT02135315|Active Comparator|standard control group|the end point in these group was to maintain the systolic blood pressure between 120 and 140 mmHg using a continuous perfusion of Isosorbide Dinitrate (RISORDON) or other drugs depending on the physician choice.
3063969|NCT02135302|Experimental|Impaired hepatic function|A single 1.5 mg/kg dose of eravacycline will be administered intravenously on Day 1 as a 60 minute infusion to each hepatically impaired subject.
3063970|NCT02135302|Experimental|Healthy subjects|A single 1.5 mg/kg dose of eravacycline will be administered intravenously on Day 1 as a 60 minute infusion to each healthy subject.
3063971|NCT02135289||IMID patients|Patients with IMID
3063972|NCT02135289||Control - subjects without IBD|Patients without IBD
3063973|NCT02135276|Experimental|End stage renal disease (ESRD) subjects|A single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes
3063974|NCT02135276|Experimental|Normal healthy subjects|A single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes
3063975|NCT02135263|Experimental|Methylphenidate|
3063976|NCT02135263|Experimental|Enalapril|
3063977|NCT02135250|Experimental|placebo|the placebo is not drug
3063980|NCT02135237|Experimental|Experimental Group|Standard Care plus Prize Contingency Management for Alcohol Abstinence
3063981|NCT02135224|Active Comparator|Fentanyl|20 microgram per hour
3063982|NCT02135224|Placebo Comparator|Normal saline|0.4 ml per hour
3063983|NCT02135211|Experimental|Lifestyle counseling|This is a single arm, quasi-experimental, pre- and post- test study design to test the feasibility and acceptability of a multiple risk factor, lifestyle intervention in patients receiving surgical treatment for lung cancer or those suspected of having lung cancer.
3063984|NCT02135198|Experimental|2 mg AZD7325|2 mg AZD7325 in orange capsule, Size 0, single oral dose
3063985|NCT02135198|Experimental|10 mg AZD7325|10 mg AZD7325 in orange capsule, Size 0, singe oral dose
3063986|NCT02135198|Placebo Comparator|Placebo|10 mg Microcrystalline cellulose in orange capsule, Size 0, single oral dose
3063987|NCT02135185|Experimental|Rehabilitation effort|custom work endurance combining dietary management adapted to the nutritional status and an APA. Included patients benefit from support for 19 weeks from the start of treatment
3063988|NCT02135185|Active Comparator|Control|Control with dietary management adapted to the nutritional status
3063989|NCT02135172|Experimental|Sitting|During the sitting treatment condition, walking and standing will be restricted. Participants will be in a designated room with access to a computer, books/magazines throughout the day. Participants will have a cannula fitted and the first of the half-hourly blood samples will be taken (time point: -1hr). Participants will then be asked to sit quietly for 60 minutes to achieve a steady state. Following this, participants will have another blood sample taken and then be provided with a standardised mixed meal breakfast (09:00am) (time point: 0h). Blood sampling will continue at 30 minutes intervals for 3 hours following breakfast. A second, lunch meal (12:00pm), will be then be consumed over 15 minutes. Blood sampling will then continue at 30 minute intervals for 3 hours following lunch.
3063990|NCT02135172|Experimental|Standing|This is the same as the sitting condition, but participants will be asked to break their sitting time by standing close to their chair for 5 minutes, after 15 and 45 minutes of each hour following breakfast. The standing protocol will be repeated after lunch. Individuals will be asked to stand in the same position with no further instructions provided. In total, individuals will accumulate 12 bouts (60 minutes) of standing throughout the test period.
3063991|NCT02135172|Experimental|Walking|This is identical to the standing condition, but the breaks in sitting time will be punctuated with 5 minute bouts of light-intensity treadmill walking (equivalent to around 4.0km•h-1) rather than standing. In total, individuals will accumulate 12 bouts (60 minutes) of light-intensity activity throughout the test period. The light-intensity walking activity undertaken here replicates the low-grade ambulatory activity associated with everyday life.
3063992|NCT02135159|Experimental|TDM1 concommitant with RT|T-DM1 (First injection day 1) followed by brain sequential RT (start day D3), second injection T-DM1 day 22.
3063993|NCT02135159|Experimental|TDM1 during and after RT|Brain sequential RT (start day 1) followed by T-DM1 (First injection day 15), second injection T-DM1 day 36.
3063994|NCT02135159|Experimental|RT before TDM1|Brain sequential RT (start day 1) followed by T-DM1 (First injection day 22), second injection T-DM1 day 43.
3063995|NCT02135159|Experimental|TDM1 before RT|T-DM1 (First injection day 1) followed by brain sequential and concomitant RT (start day D18), second injection T-DM1 day 22.
3063996|NCT02135146|Active Comparator|Plasmalyte 3ml/kg/hr group|
3063997|NCT02135146|Active Comparator|Plasmalyte 6ml/kg/hr group|
3063998|NCT02135133|Experimental|Idelalisib & Ofatumumab|Idelalisib will be given orally continuously at 150 mg BID. On day 57, ofatumumab will begin with the 300 mg dose, given after idelalisib is taken. Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8). The overall induction treatment period will then be 8 months, comprised of two months of single agent idelalisib followed by 6 months of ofatumumab with idelalisib. After the completion of the induction treatment, idelalisib will continue indefinitely in arbitrarily defined 28 day cycles in all participants who have not had excessive toxicity and do not have progressive disease.
3063999|NCT02135120|Active Comparator|Morphine group|Patients will receive a combined spinal epidural anesthesia technique with intrathecal morphine
3064000|NCT02135120|Active Comparator|Morphine-femoral group|Patients will receive a combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block
3064001|NCT02135120|Active Comparator|Morphine-femoral-sciatic group|Patients will receive a combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block
3064002|NCT02135107|Experimental|Arm A|
3064003|NCT02135107|Experimental|Arm B|
3064004|NCT02135107|Experimental|Arm C|
3064005|NCT02135107|Experimental|Arm D|
3064006|NCT02135094|Experimental|Active ultrasound therapy device|Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours on days when their trapezius muscle pain score is at least a 3 on a scale of 0-10 (NRS). The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity
3064007|NCT02135094|Placebo Comparator|Placebo ultrasound therapy device|Patients apply the Sam Ultrasonic Diathermy Device for 4 hours on days when their trapezius muscle pain score is at least a 3 on a scale of 0-10 (NRS). The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
3064008|NCT02135081||Single Ventricle|"Subjects will be single ventricle patients who will be prospectively recruited when they are at the first stage of Fontan reconstruction; they will be followed throughout all 3 stages with cerebral blood flow measurements and brain MRIs.~Additional single ventricle patients who will not participate in the study for all 3 stages but who may participate for one of two. For example, patients who completed their Stage I and hemi Fontan/bidirectional Glenn operations before this study began will be recruited before Fontan stage completion. Also, patients whose Stage I and hemi Fontan/bidirectional Glenn surgeries will be completed during the study, but who will not complete all 3 surgical stages before this project ends. Cerebral blood flow measurements and brain MRIs will be completed after each surgical stage which occurs during study participation."
3064046|NCT02134873|Active Comparator|0.1ml 24% sucrose no opioids|0.1ml 24% sucrose no opioids
3064047|NCT02134873|Active Comparator|0.5ml 24% sucrose no opioids|0.5ml 24% sucrose no opioids
3064009|NCT02135081||Normal Control Group|Children likely to have a normal brain MRI will be asked to participate. After the brain MRI is obtained as part of routine clinical care, and a normal brain scan is confirmed, measurement of cerebral blood flow using velocity mapping in the jugular veins and the aorta will be performed. This will add approximately 10 minutes to the scan but no extra sedation medications will be administered to obtain this data.
3064010|NCT02135068|Experimental|CL and exercise with proactive snacking|Subject will consume oral glucose prior to starting exercise regimen while on the Medtronic MiniMed Closed Loop (CL) System
3064011|NCT02135068|Active Comparator|CL and exercise without proactive snacking|Subject will not consume oral glucose prior to starting exercise regimen while on the Medtronic MiniMed Closed Loop (CL) System
3064012|NCT02135055|Experimental|Normal immune function|The value of monocyte human leukocyte antigen-DR (mHLA-DR) is equal to or more than 15000 monoclonal antibody.
3064013|NCT02135055|Experimental|Moderate immunosuppression|The value of mHLA-DR is equal to or more than 10000 and less than 15000 monoclonal antibody.
3064014|NCT02135055|Experimental|Sever immunosuppression|The value of mHLA-DR is equal to or more than 5000 and less than 10000 monoclonal antibody.
3064015|NCT02135055|Experimental|Immune paralysis|The value of mHLA-DR is less than 5000 monoclonal antibody.
3064016|NCT02135042|Active Comparator|Arm I (chemoradiation, cisplatin, fluorouracil)|Patients receive PF regimen comprising cisplatin IV over 60-120 minutes and fluorouracil IV over 96 hours continuously beginning at least 4 weeks after completion of IMRT. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
3064017|NCT02135042|Experimental|Arm II (chemoradiation, gemcitabine hydrochloride, paclitaxel)|Patients receive GT regimen comprising paclitaxel IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 at least 4 weeks after completion of IMRT. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3064018|NCT02135042|Active Comparator|Arm III (chemoradiation, cisplatin, fluorouracil)|Patients receive PF regimen as in Arm I of Phase II.
3064019|NCT02135042|Experimental|Arm IV (chemoradiation, observation)|Patients undergo clinical observation.
3064020|NCT02135029|Experimental|Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)
3064021|NCT02135029|Active Comparator|Atorvastatin|
3064022|NCT02135029|Placebo Comparator|Placebo|
3064023|NCT02135016|Experimental|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
3064024|NCT02135016|Experimental|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
3064025|NCT02135016|Placebo Comparator|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
3064026|NCT02135003|Experimental|Buddy arm, Standard of care arm|"Standard of care: Patients enrolled for pre-ART care received general health education, clinical monitoring, CD4 testing and other clinically indicated investigations, treatment of opportunistic infections, and cotrimoxazole prophylaxis.~Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. buddies attended at least two HIV health education. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments"
3064027|NCT02134990|Experimental|Oshadi D and Oshadi R with Docetaxel|Oshadi D and Oshadi R anti cancer agents with Docetaxol chemotherapy
3064028|NCT02134977||Leuprorelin Acetate|Subcutaneous administration of leuprorelin acetate 11.25 mg once every 12 weeks
3064029|NCT02134964|Experimental|OLT1177 Capsules|"A total of 5 patients in each cohort will receive OLT1177 Capsules:~Cohort 1 will receive a single 100 mg dose of OLT1177~Cohort 2 will receive a single 300 mg dose of OLT1177~Cohort 3 will receive two 1000 mg doses of OLT1177 (seven days apart)~Cohort 4 will receive 100 mg doses of OLT1177 QD for 8 days~Cohort 5 will receive 300 mg doses of OLT1177 QD for 8 days~Cohort 6 will receive 1000 mg doses of OLT1177 QD for 8 days"
3064030|NCT02134964|Placebo Comparator|Placebo Capsules|"A total of 1 patient in each cohort will receive Placebo Capsules:~Cohort 1 will receive a single placebo capsule~Cohort 2 will receive three placebo capsules~Cohort 3 will receive ten placebo capsules (seven days apart)~Cohort 4 will receive a single placebo capsule QD for 8 days~Cohort 5 will receive three placebo capsules QD for 8 days~Cohort 6 will receive ten placebo capsules QD for 8 days"
3064031|NCT02134951|Experimental|ketamine|IV infusion of ketamine 0.23mg/kg bolus over 1 minutes followed by 0.58 mg/kg/hr over 30 minutes then 0.29mg/kg/hr over 64 minutes
3064032|NCT02134951|Placebo Comparator|Placebo|Placebo group will receive normal saline
3064033|NCT02134938|Experimental|Konjac Glucomannan|650g KJM-G
3064034|NCT02134938|Experimental|Half Control/Half Konjac Glucomannan|325g KJM-G
3064035|NCT02134938|No Intervention|Control|0g KJM-G
3064036|NCT02134925|Experimental|Arm I (MUC1 peptide-poly-ILCLC adjuvant vaccine)|Participants receive MUC1 peptide-poly-ICLC adjuvant vaccine SC in weeks 0, 2 and 10 and a booster injection in week 53.
3064037|NCT02134925|Placebo Comparator|Arm II (saline)|Participants receive saline SC in weeks 0, 2, and 10 and a booster injection in week 53.
3064038|NCT02134912|Experimental|Arm I (crizotinib, pemetrexed disodium)|Patients receive crizotinib PO BID on days 1-21 and pemetrexed disodium IV over 10 minutes on day 1.
3064039|NCT02134912|Experimental|Arm II (pemetrexed disodium)|ARM II: Patients receive pemetrexed disodium IV over 10 minutes on day 1. Upon disease progression or symptomatic deterioration, patients may crossover to Arm I.
3064040|NCT02134899|Experimental|Everolimus|everolimus based immunosuppression
3064041|NCT02134899|Active Comparator|Calcineurin|Calcineurin inhibitors maintenance
3064042|NCT02134886|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3064043|NCT02134873|Active Comparator|0.1ml 24% sucrose concurrent opioids|0.1ml 24% sucrose concurrent opioids
3064044|NCT02134873|Active Comparator|0.5ml 24% sucrose concurrent opioids|0.5ml 24% sucrose concurrent opioids
3064045|NCT02134873|Active Comparator|1.0ml 24% sucrose concurrent opioids|1.0ml 24% sucrose concurrent opioids
3093440|NCT01936233|Experimental|Aspirin AND Lamivudine|
3064048|NCT02134873|Active Comparator|1.0ml 24% sucrose no opioids|1.0ml 24% sucrose no opioids
3064049|NCT02134860|Active Comparator|Isocaloric diet|3 daily meals
3064050|NCT02134860|Active Comparator|Alternate daily fasting|One meal (25% of caloric need) every second day and four meals (175% of caloric need) every second day
3064051|NCT02134847|Experimental|Intervention cohort|This cohort will work on the SCS intervention schedule
3064052|NCT02134847|No Intervention|Control cohort|This group will work on a traditional schedule
3064053|NCT02134834|Experimental|Ascending single dose of OP0595|
3064054|NCT02134834|Placebo Comparator|Normal Saline|
3064055|NCT02134821||Low pain sensitivity group|total Pain Sensitivity Questionnaire score <6.5
3064056|NCT02134821||High pain sensitivity group|total pain sensitivity questionnaire score ≥ 6.5
3064057|NCT02134808|Active Comparator|Creatine|Subjects randomized to this study arm will receive 10 grams of creatine daily for 8 weeks.
3064058|NCT02134808|Placebo Comparator|Placebo|Subjects randomized to this study arm will receive 10 grams of placebo daily for 8 weeks.
3064059|NCT02134795|Experimental|TNM (trade name), a form of brainstem stimulation|ThermoNeuroModulation (TNM) device with a standardized active neuromodulation waveform will be used for all patients. The device will be used twice for ~19 minutes each time. There will be a gap of roughly 1 hour between the two device applications.
3064060|NCT02134782|Experimental|Individualized Yoga Intervention Group|Yoga will be administered individually by a trained yoga instructor, and offered daily for 21 days (excluding weekends and holidays). There will be a common structure for all sessions that will include relaxation and breathing exercises. Additional poses focused on strength, flexibility, and balance will be incorporated at low, moderate or high intensity levels based upon the wishes and abilities of the child and parent and the judgment of the yoga instructor. The target intensity will be documented and may change with each yoga session. Each yoga session will vary in duration between 15 and 45 minutes. Modifications will be made to accommodate devices such as central venous lines, particularly if accessed. For children who are in isolation, the research team will follow hospital policies and procedures.
3064061|NCT02134782|Active Comparator|iPad Activity Control Group|For those randomized to the control group, visits by the same yoga instructors will occur at the same schedule as the yoga intervention. Contact will be offered daily excluding weekends and holidays, for 21 days. The yoga instructor will offer games, music, movies or books on a study-supplied iPad, which will be loaned to the child for 3 weeks. The instructor will offer to interact with the child (for example, read to, or play games with the child) for a maximum of 45 minutes (the maximum length of yoga sessions). This approach will allow us to control for contact frequency and the individual providing contact, and consequently, to better measure the independent effect of yoga. These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities.
3064062|NCT02134769|No Intervention|Control|No use of Bionecteur; handling according to institutional guideline
3064063|NCT02134769|Active Comparator|Bionecteur|Use of Bionecteur; handling according to institutional guideline
3064064|NCT02134756|Experimental|NutraStem Active|Daily supplementation with NutraStem Active; 2 capsules per day for 28 days
3064065|NCT02134756|Placebo Comparator|Placebo|Daily supplementation with placebo; 2 capsules per day for 28 days
3064066|NCT02134743|Experimental|Experimental Group|At this group the patients will receive dental implants which have a modified SLA surface. These surface have wettability, which could improve and accelerate the osseointegration.Intervention: implant placement.
3064067|NCT02134743|Active Comparator|Control Group|The patient of this group will receive implant with conventional surface, SLA (Sandblasted and Acid-Etched Surface).Intervention: implant placement.
3064068|NCT02134730|No Intervention|Wait list|Schools in waitlist condition will be offered the intervention after the 12-months follow up. Waitlist means that the schools work as usual with issues of mental health.
3064069|NCT02134730|Experimental|FRIENDS for life|The intervention is delivered for 10 consecutive weeks, 60 minutes per session.
3064070|NCT02134717|Experimental|sarcoidosis stage II|All subjects with active stage II sarcoidosis with or without skin disease will receive the drug maraviroc 300mg to be taken orally twice a day for 6 weeks duration.
3064071|NCT02134704|Experimental|Scoliosis Group|
3064072|NCT02134704|Experimental|Healthy Volunteers Group|
3064073|NCT02134691|Experimental|Prolonged Exposure|Behavioral: Prolonged Exposure (PE) PE is a 16 week, 90 minute culturally informed treatment program.
3064074|NCT02134691|Active Comparator|Applied Relaxation|Behavioral: Applied Relaxation (AR) AR is a 16 week, 90 minute treatment program.
3064075|NCT02134678|Experimental|self-system therapy|self-system therapy for depression
3064076|NCT02134678|Active Comparator|cognitive therapy|cognitive therapy for depression
3064077|NCT02134665||severe acute pancreatitis|patients who received vancomycin therapy and whose serum vancomycin level was monitored, and who also had diagnosed as severe acute pancreatitis.
3064078|NCT02134665||Pneumonia|patients who received vancomycin therapy and whose serum vancomycin level was monitored, and who also had diagnosed as pneumonia.
3064079|NCT02134652||Suspected Dengue|Children with an acute febrile illness, and two of the following: headache, retro-orbital pain, myalgias, arthralgia, rash, hemorrhagic manifestations, or plasma leakage (i.e. shortness of breath, abdominal distention/pain) will all receive a diagnostic bedside ultrasound.
3064080|NCT02134639||Patient who is suspected of endocrine tumors|According to symptomatology, biology or imaging or pathological context
3064081|NCT02134626|Experimental|Simvastatin|Arm 1: Simvastatin 40mg / pill, one pill once a day for three months
3064082|NCT02134626|Placebo Comparator|Placebo pill|Arm 2: Placebo one pill once a day for three months
3064083|NCT02134613|Experimental|anti-TNF-alpha scintigraphy|99mTc-anti-TNF-alpha Scintigraphy will be compared with MRI results, analysed and discussed by physicians who are in charge of the patients.
3064084|NCT02134600|Experimental|Omega-3 enriched fruit juice|Single arm study: Omega-3 enriched fruit juice in increasing dosage
3064085|NCT02134587|Other|Subjects post educational intervention|Multifaceted educational intervention in pharmacovigilance
3064086|NCT02134574||hematologic malignancy|hematologic malignancy with a sampling of blood
3064087|NCT02134561|Other|All subjects|psychological interview, MRI, neurological tests, cognitive tests
3064088|NCT02134535||laboratory specimens|cervical biopsies vaginal biopsies blood
3064089|NCT02134522|Experimental|C-PAP intervention|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
3064090|NCT02134509|Experimental|Experimental App|This is a 3-week smartphone-based training program that trains behavioral strategies for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
3064091|NCT02134509|Active Comparator|Active comparator app|This is a 3-week smartphone application for smoking cessation in which smokers self-monitor their smoking habits, mood, and experience, to quit smoking with a target quit date of 3 weeks.
3064092|NCT02134496|No Intervention|no assessment of motorfunction in PACU|no assessment of motorfunction after spinal anesthesia in PACU
3064093|NCT02134496|Active Comparator|motorfunction assessment in PACU|Assesment of motorfunction after spinal anesthesia
3064094|NCT02134483|Experimental|Parathyroid allo-transplantation|patients who have permanent hypoparatyroidism
3064095|NCT02134470|Experimental|Testosterone|Chemical testing of saliva is an objective method to quantify steroid hormones. Recent studies indicate that salivary testosterone is significantly higher than in other body fluids. Therefore, saliva may serve as pre-screening parameter to select suspicious cases for further target evaluation. The aim of the present project is to detect administered testosterone in saliva and compare these levels to those in blood and urine. Therefore, each participant represents its own control.
3064096|NCT02134457|Experimental|Ranibizumab 0.12 mg|"20 µl of the 6 mg/ml ranibizumab concentration will be applied intravitreally. After an initial response the same dose as in the first injection can be re-applied after at least four weeks post injection.~A maximum number of 3 regular re-injections can be applied."
3064097|NCT02134457|Experimental|Ranibizumab 0.20 mg|"20 µl of the 10 mg/ml ranibizumab concentration will be applied intravitreally. After an initial response the same dose as in the first injection can be re-applied after at least four weeks post injection.~A maximum number of 3 re-injections can be applied."
3064098|NCT02134444|Experimental|Experimental Group|Experimental group will receive the assigned intervention which is a game-based rehabilitation program delivered at home.
3064099|NCT02134444|Active Comparator|Control group|Control group will receive a vestibular rehabilitation program which will include the Herdman gaze stabilization exercises and balance training program.
3064100|NCT02134431||HIV positive|HIV-positive subjects ages 10-14 years old and 18-21 years old taking tenofovir in their antiretroviral regimen.HIV positive subjects will undergo lower endoscopy (specifically either flexible sigmoidoscopy or colonoscopy) with biopsies to obtain colorectal tissue samples. HIV-1 levels and tenofovir levels in tissue will be measured.
3064101|NCT02134431||HIV negative|HIV-negative subjects ages 10-14 years old and 18-21 years old. HIV negative subjects will undergo lower endoscopy (specifically either flexible sigmoidoscopy or colonoscopy) with biopsies to obtain colorectal tissue samples. These tissue samples will be pretreated with tenofovir and challenged with laboratory HIV-1.
3064102|NCT02134418|Experimental|Irony CBT training|CBT of irony comprehension
3064103|NCT02134418|No Intervention|No Intervention|No Intervention
3064104|NCT02134405|Experimental|Rebamipide and Esomeprazole|Rebamipide tablets 100mg tid for 8 weeks Esomeprazole tablets 20mg od for 8 weeks
3064105|NCT02134405|Active Comparator|Rebamipide and placebo|Placebo drug with Rebamipide 100mg tid
3064106|NCT02134392|Experimental|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline given by colonoscopy or enema.
3064107|NCT02134379||Heart Failure|Subjects have implanted Medtronic device and a primary diagnosis of left ventricular systolic dysfunction
3064108|NCT02134366|Experimental|Clobazam|Subjects who are assigned the clobazam treatment group will receive a 10mg loading dose followed by a maintenance dose of 5-25 mg bid starting 12 hrs after the loading dose. If subjects are found to have failed to respond to treatment with clobazam, the physician investigator has the ability to either start another AED or increase the dose of clobazam depending on the clinical situation. Subjects still being treated with clobazam at discharge will be given a 30 day supply of clobazam.
3064109|NCT02134366|Active Comparator|Clonazepam|Subjects who are assigned to the clonazepam treatment group will receive a dose of 1-2mg clonazepam dose tid. Following the initial treatment if a physician investigator determines that the subject's treatment has failed, the investigator has the option of treating the subject with clobazam at which point the individuals would be treated in the same method as those originally assigned to the clobazam treatment group.
3064110|NCT02134366|Active Comparator|Lorazepam|Subjects who are assigned to the lorazepam treatment group will receive a 1-2mg dose of lorazepam qid. Following the initial treatment if a physician investigator determines that the subject's treatment has failed, the investigator has the option of treating the subject with clobazam at which point the individuals would be treated in the same method as those originally assigned to the clobazam treatment group.
3064111|NCT02134353|Experimental|Experimental arm A|Active treatment. Inhaled Mannitol
3064112|NCT02134353|Placebo Comparator|Arm B - Control|Arm B
3064113|NCT02134340|Experimental|[I-124]-CPD-1028 PET/CT|"Administration of [I-124]-CPD-1028 Injection followed by a maximum of 3 PET/CT imaging sessions.~A pre-targeting dose of CPD-1061 may be given prior to injection of [I-124]-CPD-1028."
3064114|NCT02134327|Experimental|Premedication with Midazolam|
3064115|NCT02134314|Experimental|C1-Inhibitor (Berinert) (Human) (C1INH)|35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
3064116|NCT02134314|Placebo Comparator|Normal Saline|35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
3064117|NCT02134301|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
3064118|NCT02134288|Active Comparator|Belatacept|Belatacept 10mg/kg administered intravenously on days 1, 4, 15, and 28, weeks 8 and 12. Then continue at 5mg/kg every 4 weeks throughout the completion of the study.
3064119|NCT02134288|Active Comparator|Everolimus|Everolimus 1.5 mg/kg twice a day by mouth, the dose will be adjusted after Day 3.
3065638|NCT02123875|Other|Physiotherapy intervention arm|Caregiver delivered, home based physiotherapy
3064120|NCT02134275|Experimental|Whole body vibration training|Whole body vibration training (timed stand on vibration platform) 3 20-minute sessions per week for 6 months
3064121|NCT02134275|Placebo Comparator|Control group|No significant changes to diet, exercise and lifestyle.
3064122|NCT02134262|Experimental|Dose Level -1|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
3064123|NCT02134262|Experimental|Dose Level 1|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
3064124|NCT02134262|Experimental|Dose Level 2|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
3064125|NCT02134262|Experimental|Dose Level 3|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
3064126|NCT02134249|Active Comparator|Group A (Diosmin group)|In group A, (Diosmin group), 2 tab / 8 hs Diosmin ( 500mg) will be given from at day of HCG injection and for 14 days.
3064127|NCT02134249|Active Comparator|Group B(Cabergoline group)|while in group B (Cabergoline group), 1 tab/day Cabergoline(Dostinex)( 0.5 mg) will be given at day of HCG injection and for 8 days .
3064128|NCT02134223|Experimental|dialectical behavior therapy|Primary intervention group: receiving one year of dialectical behavior therapy
3064129|NCT02134223|Placebo Comparator|treatment as usual|Comparison group: receiving one year of treatment as usual
3064130|NCT02134223|No Intervention|Receiving no treatment at all|Healthy control group
3064131|NCT02134210|Active Comparator|Enbrel (etanercept)|Enbrel 50mg twice weekly times 12 weeks
3064132|NCT02134210|Experimental|CHS-0214|CHS-0214 50mg twice weekly times 12 weeks
3064133|NCT02134197|Experimental|Lupartumab Amadotin (BAY1129980)|Dose escalation with consecutive expansion at MTD (maximum tolerated dose) with BAY1129980.
3064134|NCT02134184|Experimental|CMV negative group|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
3064135|NCT02134184|Experimental|CMV positive group|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
3064136|NCT02134184|Experimental|Recent CMV Converters|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
3064137|NCT02134171|Experimental|Biological investigations|From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide [BNP]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
3064138|NCT02134158|Experimental|sham and then anodal|visit 2 sham stimulation (120 seconds) and visit 3 anodal stimulation (30 minutes)
3064139|NCT02134158|Experimental|anodal and then sham|visit 2 anodal stimulation (30 minutes) and visit 3 sham stimulation (120 seconds)
3064140|NCT02134145||Self Selected Investors|A self selected crowdfunding backers from teh Scanadu Scout Crowdfunding campaign.
3064141|NCT02134132|Active Comparator|platelet rich plasma|The patients with diabetic foot ulcer who receive PG treatment.
3064142|NCT02134132|Placebo Comparator|Placebo|The patients with diabetic foot ulcer who receive placebo.
3064143|NCT02134119|Experimental|Echinacea-based dietary supplement|Echinacea-based dietary supplement 8,000mg/day or 16,000mg/day by mouth for 35-days
3064144|NCT02134119|Placebo Comparator|Sugar pill|Placebo given 8,000mg/day by mouth
3064145|NCT02134106|Active Comparator|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000 Units (U)/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 million units (MU) 8 hourly for 5 days will be prescribed.
3064146|NCT02134106|Experimental|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
3064147|NCT02134093|Placebo Comparator|Normal saline|Continuous pump infusion of normal saline with identical volume, compared with the low dose and high dose group,until the end of surgery
3064148|NCT02134093|Experimental|High dose group, dexmedetomidine|Continuous pump infusion dexmedetomidine at 1μg/kg for 15 minutes before anesthesia induction ,then continuous pump infusion dexmedetomidine at 0.4μg/kg/h until the end of surgery
3064149|NCT02134093|Experimental|Low dose group, dexmedetomidine|Continuous pump infusion dexmedetomidine at 0.5μg/kg for 15 minutes before anesthesia induction ,then continuous pump infusion dexmedetomidine at 0.2μg/kg/h until the end of surgery
3064150|NCT02134080|Active Comparator|PF-04457845|PF-04457845 will be administered orally at 4mg daily for four weeks.
3064151|NCT02134080|Placebo Comparator|Placebo|Placebo (sugar pill) will be administered orally at 4mg daily for four weeks.
3064152|NCT02134067|Experimental|TAS-119|"TAS-119 tablets, oral, dose-escalating, 28-day cycle.~Paclitaxel (90mg/m2) is administered IV in combination with TAS-119 in each of the arms."
3064153|NCT02134054||Biologic|Patients on treatment with biologics (infliximab or adalimumab)
3064154|NCT02134041||traumatic brain injury|mild traumatic brain injury
3064155|NCT02134041||without TBI|without TBI
3064156|NCT02134028|Experimental|dupilumab treatment|"For patients coming from the DRI12544 study: dupilumab loading dose sc on Day 1, followed by 1x Dose every 2 weeks added to current controller medications.~For patients coming from other studies: dupilumab 1x Dose sc every 2 weeks added to current controller medications."
3064157|NCT02134015|Experimental|Placebo + erlotinib|Placebo infusion every 3 weeks and oral erlotinib 150 mg/day
3065639|NCT02123862||Prostate Cancer|
3065640|NCT02123862||Breast Cancer|
3064158|NCT02134015|Experimental|Patritumab + erlotinib|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks) and oral erlotinib 150 mg/day
3064159|NCT02134002|Experimental|Disulfiram|disulfiram 250 mg/day
3064160|NCT02134002|Placebo Comparator|Placebo|Placebo
3064161|NCT02133989|Experimental|Ticlopidine+Ginko biloba|Switch to ticlopidine + ginko biloba
3064162|NCT02133989|Active Comparator|Clopidogrel|Keep clopidogrel
3064163|NCT02133976|Active Comparator|cognitive therapy|Cognitive therapy will be delivered to decrease pain interference
3064164|NCT02133976|Active Comparator|mindfulness training|Mindfulness training will be delivered to decrease pain interference
3064165|NCT02133976|Active Comparator|behavior therapy|Behavior therapy will be delivered to decrease pain interference
3064166|NCT02133976|Active Comparator|treatment as usual|Subjects will engage in their usual care for low back pain.
3064167|NCT02133963||women with no history of depression|Non-Probability Sample of women with no history of depression
3064168|NCT02133963||women with a past depression history|Non-Probability Sample of women with a past history of depression
3064169|NCT02133950|Experimental|freeze all embryos following PGD|no fresh embryo transfer; elective cryopreservation of all embryos after PGD
3064170|NCT02133950|Active Comparator|elective fresh embryo transfer|
3064171|NCT02133937|Experimental|High Concentration Liquid Formulation (HCLF)|
3064172|NCT02133937|Active Comparator|Lyophilized formulation|
3064173|NCT02133924|Experimental|Natalizumab with steroids|"For subjects whose GVHD assay is Ann Arbor score 3, the study treatment will consist of two drugs, prednisone (or methylprednisolone) and natalizumab.~Protocol treatment must start within 3 days of the subject's diagnosis of acute GVHD."
3064174|NCT02133911|No Intervention|Controls|
3064175|NCT02133911|Experimental|Ranolazine|Initial dose is 375 mg bid. After 2 - 4 weeks the dose is increased to 500 mg bid and after another 2-4 weeks to 750 mg bid. In case of side effects the dose of the drug is to be decreased to the highest dose that the patient is still able to tolerate.
3064176|NCT02133898|Other|L-methyfolate|Single-arm open label administration of L-methylfolate 15mg once daily for 90 days
3064177|NCT02133885|Active Comparator|Minocycline Group|These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
3064178|NCT02133885|Placebo Comparator|Placebo Group|These subjects will start with placebo (this will look like minocycline) for 16 weeks, followed by a washout period for 3 weeks, then will receive a minocycline for 16 weeks, followed by a washout period for 3 weeks, then will finish with placebo for 16 weeks.
3064179|NCT02133872|Active Comparator|Minocycline 100mg Group|Subjects will be randomized to receive Minocycline 100mg.
3064180|NCT02133872|Active Comparator|Minocycline 200mg Group|Subjects will be randomized to receive Minocycline 200mg
3064181|NCT02133859||Chronic Heart Failure patients using ASV|Patients with chronic heart failure who are using or willing to use adaptive servo ventilation (ASV) therapy will be enrolled. Respiratory data will be collected from this group every 3 months over a 12 month period
3064182|NCT02133846|Experimental|TPI-287 low dose|2 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
3064183|NCT02133846|Experimental|TPI-287 moderate dose|6.3 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions).
3064184|NCT02133846|Experimental|TPI-287 high dose|20 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
3064185|NCT02133846|Placebo Comparator|Placebo|0.9% sodium chloride as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
3064186|NCT02133833|Experimental|Quantum Spectrum Radiation Emitter|five pieces of Quantum Spectrum Radiation Emitter will be placed on the affected shoulder daily for three weeks.
3064187|NCT02133820|Active Comparator|12 hourly capsule fasted|4 mg 12 hourly capsule - strong pain killer fasted
3064188|NCT02133820|Active Comparator|12 hourly capsule fed|4 mg 12 hourly capsule - strong pain killer fed
3064189|NCT02133820|Experimental|12 hourly capsule with antagonist fasted|4 mg 12 hourly capsule strong painkiller with antagonist fasted
3064190|NCT02133820|Experimental|12 hourly capsule with antagonist fed|4 mg 12 hourly capsule strong painkiller with antagonist fed
3064191|NCT02133807|Experimental|Specific Lp(a) apheresis & Atorvastatin|"Specific Lp(a) apheresis was performed with Lp(a) Lipopak immunosorbent columns (POCARD Ltd., Moscow, Russia) with sheep polyclonal monospecific antibodies against human Lp(a)/apo(a) weekly during 18 months. On the background - standard medical therapy in accordance with the recommendations for secondary prevention of CHD."
3064192|NCT02133807|No Intervention|Atorvastatin|Standard medical therapy in accordance with the recommendations for secondary prevention of CHD
3064193|NCT02133794|Experimental|Tomosynthesis|
3064194|NCT02133781|Experimental|Age 8-17 years (identical twins )|Participants will be randomized to receive either Fluzone® 2009-2010 Formula or FluMist® 2009-2010 Formula
3064195|NCT02133781|Experimental|Age 18-30 years (non-twins)|Participants will be receive Fluzone® 2009-2010 Formula
3064196|NCT02133781|Experimental|Age >70 years (non-twins)|Participants will receive Fluzone® 2009-2010 Formula
3064197|NCT02133755|Other|Bromocriptine mesylate (Cycloset)|Cycloset 1.6 to 3.2 mg daily for 3 months
3064198|NCT02133742|Experimental|Dose finding phase and dose expansion phase|To test the maximum tolerated dose of MK-3475 at 2 mg/kg every three weeks intravenous infusion in combination with approved axitinib dose
3064199|NCT02133729|Experimental|Gestational diabete|
3064200|NCT02133716|Experimental|expressed breast milk|"A single dose of expressed breast milk was administered through a sterile syringe in the mouth 2 minutes before venopuncture to neonates, accompanied at all times provided the technique allows it to non-nutritive sucking and containment.~The doses administered: 0.1ml in infants less than 27 weeks , 0.25 ml for infants 27-31 weeks , 0.5 ml for infants 32-37 weeks."
3064234|NCT02133469|Active Comparator|Hib vaccine|Randomized group of 1634 subjects to be administered a single dose of Hib Vaccine(PCV7 vaccine offered at end of study).
3064235|NCT02133456||SIBP's vaccine|SIBP's vaccine group is the population injected with this vaccine.
3064201|NCT02133716|Active Comparator|sucrose 24% oral|"A single dose of sucrose was administered through a sterile syringe in the mouth 2 minutes before venopuncture to neonates, accompanied at all times provided the technique allows it to non-nutritive sucking and containment.~The doses administered: 0.1ml in infants less than 27 weeks , 0.25 ml for infants 27-31 weeks , 0.5 ml for infants 32-37 weeks."
3064202|NCT02133703|Experimental|Mutation Carrier: Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool.
3064203|NCT02133703|Experimental|Mutation Carrier: Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support intervention without a preference clarification tool.
3064204|NCT02133703|Active Comparator|Mutation Carrier: Enhanced Print DA|BRCA1/2 carriers randomized to this arm will be sent a print-based decision aid with a print preference clarification tool.
3064205|NCT02133703|Active Comparator|Mutation Carrier: Print DA|BRCA1/2 carriers randomized to this arm will receive a print decision aid without a preference clarification tool.
3064206|NCT02133703|Experimental|Inconclusive Results: DA|Participants who receive inconclusive results who are randomized to this arm will have access to an Internet decision tool designed to facilitate management decision making
3064207|NCT02133703|No Intervention|Inconclusive Results: Usual care|Participants who receive inconclusive/uninformative results who are randomized to this arm will receive usual care but no additional decision support intervention
3064208|NCT02133690|Experimental|Vaccine Arm|3 doses, 4 weeks apart, of Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent
3064209|NCT02133690|Placebo Comparator|Placebo group|3 doses, 4 weeks apart, of Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents
3064210|NCT02133677|Experimental|temozolomide+WBRT|temozolomide: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks WBRT:30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week)
3064211|NCT02133664|Experimental|lipoic acid and omega-3 fatty acids|lipoic acid and omega-3 fatty acids
3064212|NCT02133664|Placebo Comparator|placebo|placebo oil and placebo lipoic acid
3064213|NCT02133638|Active Comparator|Sevoflurane|Sevoflurane Based Volatile Induction and Maintenance of Anaesthesia
3064214|NCT02133638|Active Comparator|Propofol|Propofol Based Total Intravenous Anesthesia
3064215|NCT02133625|Experimental|Pioglitazone and Carboplatin|"MTD Determination~Pioglitazone: 45 mg Once Daily by mouth,Cycle 1Days 1-28; Subsequent cycles: Days 1-21~Carboplatin:6 AUC IV 60 minute infusion (or per institutional policy) Cycle 1: Day 8; Subsequent cycles: Day 1"
3064216|NCT02133625|Experimental|MTD Expansion Carboplatin and Pioglitazone|"MTD Expansion:~Carboplatin alone on cycle 1, day 1.~Pioglitazone Over days 15-21 of the cycle pioglitazone will be administered alone.~On cycle 2, day 1, both carboplatin and pioglitazone will be administered. Cycle 2 and onward are 21-day cycles, with pioglitazone administered once daily and carboplatin administered once every 3 weeks"
3064217|NCT02133612|Experimental|single arm paclitaxel and cisplatin|
3064218|NCT02133599|Other|Iohexol|All patients will receive two Iohexol clearance tests, 5 mL each time before cycle 1 and 4 of HDMTX
3064219|NCT02133586|Placebo Comparator|Clean Air - O3|"Day #1: Two-hour exposure to clean, filtered air with intermittent exercise. Day #2: Two-hour exposure to 300ppb ozone (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.~Day #3: Follow-up (no exposure)"
3064220|NCT02133586|Experimental|NO2-O3|"Day #1: Two-hour exposure to 500ppb nitrogen dioxide with intermittent exercise.~Day #2: Two-hour exposure to 300ppb ozone (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.~Day #3: Follow-up (no exposure)"
3064221|NCT02133586|Placebo Comparator|Clean Air - NO2|"Day #1: Two-hour exposure to clean, filtered air with intermittent exercise. Day #2: Two-hour exposure to 500ppb nitrogen dioxide (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.~Day #3: Follow-up (no exposure)"
3064222|NCT02133586|Experimental|O3 - NO2|"Day #1: Two-hour exposure to 300ppb ozone with intermittent exercise. Day #2: Two-hour exposure to 500ppb nitrogen dioxide (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.~Day #3: Follow-up (no exposure)"
3064223|NCT02133573|Experimental|Progesterone|Vaginal gel, 90mg twice a day (BID)
3064224|NCT02133573|Placebo Comparator|Vaginal Lubricant|Vaginal twice a day (BID)
3064225|NCT02133560|Other|Medication Administration + Education|Subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip during months 1-3 and completing the medication administration log during months 1-6. During months 1-6 subjects will meet with study staff and receive educational materials on a monthly basis. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
3064226|NCT02133534|Experimental|Atorvastatin|Subjects will be treated with atorvastatin 10 mg/day for 30 days. The study team will obtain one blood and urine sample at baseline prior to starting atorvastatin therapy, and again after 30 days of drug therapy. The study team will do ultrasound imaging of the arm in which a probe will be placed over the blood vessels to measure the diameter of the artery and how this changes after a blood pressure cuff is inflated and then deflated. Subjects will take one nitroglycerine tablet during the ultrasound imaging.
3064227|NCT02133521|Placebo Comparator|Placebo|Placebo 3 x 1 tablet, given everyday for 28 days of study period
3064228|NCT02133521|Experimental|DLBS1033|DLBS1033 enteric-coated tablet 3 x 490 mg daily, given everyday for 28 days of study period
3064229|NCT02133508||NSCLC Participants|Participants with advanced non-small cell lung cancer (NSCLC), treated in second-line with erlotinib, presenting wild-type, not tested or unknown Epidermal Growth Factor Receptor (EGFR) status, and with stable disease at the first revaluation after start of erlotinib therapy.
3064230|NCT02133495|Experimental|open label|Non Cadaveric human BellaDerm Acellular dermal tissue
3064231|NCT02133482|Experimental|BI 639667|single rising doses given as oral solution
3064232|NCT02133482|Placebo Comparator|Placebo|placebo solution
3064233|NCT02133469|Experimental|PCV7 (Vaccine)|Randomized group of 1634 subjects to be administered a single dose of PCV7 (Hib vaccine offered at end of study).
3064456|NCT02132000|Experimental|toremifene|toremifene,60mg/day
3064236|NCT02133443|Active Comparator|Pressure Support Ventilation|Device: PSV - pressure support ventilation
3064237|NCT02133443|Active Comparator|Neurally Adjusted Ventilatory Assist|Device: Partial ventilator support with partial ventilation mode (NAVA)
3064238|NCT02133430|Experimental|Bispectral index (BIS) group|Bispectral index as measured by a BIS Processor is used to guide doses of anesthetic for maintaining the BIS values of 40-60
3064239|NCT02133430|No Intervention|Control group|Clinical signs is used to guide doses of anestheitics.
3064240|NCT02133417||Women|Women with mammographically-detected breast lesions
3064241|NCT02133404|Experimental|ASP7991 group|receiving ASP7991 and Cinacalcet-placebo
3064242|NCT02133404|Active Comparator|Cinacalcet group|receiving Cinacalcet and ASP7991-placebo
3064243|NCT02133391|Active Comparator|Practice-based reminder/recall or Usual care arm|"Practices participating in state immunization registry invited to reminder/recall (R/R) webinar trainings and provided educational materials to encourage immunization within their practices (child and adolescent trials only)~Patients not randomized to the collaborative centralized R/R arm will receive usual care from their provider, which does not include R/R (adult trials only)"
3064244|NCT02133391|Experimental|Collaborative centralized R/R|Collaborative centralized reminder/recall (R/R) effort will be conducted by state immunization registry in collaboration with accountable care organizations and practices
3064245|NCT02133378|Experimental|Hemopatch|Use of Hemopatch on bleeding spot
3064246|NCT02133378|Sham Comparator|Control|Traditional techniques hemostasis (dry or wet gauze compression or similar)
3064247|NCT02133365|Active Comparator|Mindfulness and Interoceptive Exposure|Atrial fibrillation patients will receive 4-5 manualized, individualized sessions of Mindfulness and Interoceptive Exposure.
3064248|NCT02133365|No Intervention|Medical care as usual|Atrial fibrillation patients will receive medical and cardiac care as usual.
3064249|NCT02133352|Experimental|Ranolazine|Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.
3064250|NCT02133339|Experimental|TRN-157|
3064251|NCT02133339|Placebo Comparator|Placebo|
3064252|NCT02133326|Experimental|Caldolor|800 mg of Caldolor® will be infused at the rate of 5-7 minutes as per the manufacturer's guidelines or
3064253|NCT02133326|Experimental|Ofirmev|1000 mg of Ofirmev® will be infused at the rate of 15 minutes as per the manufacturer's guidelines.
3064254|NCT02133313||Peritoneal Dialysis Patients|Patients on Peritoneal Dialysis
3064255|NCT02133300|Experimental|electrical stimulation|Compex 3 professional NMES for 60' per day
3064256|NCT02133300|No Intervention|control|
3064257|NCT02133287|Experimental|AVI® Arsenic trioxide drug eluting stent|Study group: Arsenic trioxide drug eluting stent delivery system (AVI®)
3064258|NCT02133287|Active Comparator|Firebird2® sirolimus eluting stent system|Control group: sirolimus eluting cobalt-chromium alloy stent system(Firebird 2®)
3064259|NCT02133274|No Intervention|Standard oncologic care|Standard oncologic care
3064260|NCT02133274|Experimental|Early Palliative Care|A first medical consult at the Palliative Care Service will be scheduled after 2 to 3 weeks from the study inclusion and every 3 to 4 weeks thereafter.
3064261|NCT02133274|Experimental|Psychosocial plus early Palliative Care|Five weekly sessions of a Brief Psychosocial Intervention based of Behavioral Cognitive Therapy plus early palliative care. Regarding the early Palliative Care, a first medical consult at the Palliative Care Service will be scheduled after 2 to 3 weeks from the study inclusion and every 3 to 4 weeks thereafter.
3064262|NCT02133248||kidney recipient waitlist|Subjects on waitlist for Kidney transplant who are sensitized
3064263|NCT02133248||chronic antibody mediated rejection|Kidney transplant recipient who are diagnosed with chronic antibody mediated rejection
3064264|NCT02133248||control|Normal subjects-no kidney transplant or chronic rejection
3064265|NCT02133235|Active Comparator|conventional|insertion of endobronchial blocker and auscultation, fiberoptic confirmation and reposition
3064266|NCT02133235|Experimental|auscultation|insertion endobronchial blocker by auscultation without conventional bronchoscopic reposition
3064267|NCT02133222|Experimental|Metastatic (stage IV) melanoma|
3064268|NCT02133209|Active Comparator|Stress Management for Headaches|This intervention involves a standardized stress management for headaches (SMH) group intervention that focuses on stress and general stress management skills for managing migraine headaches.
3064269|NCT02133209|Active Comparator|Mindfulness Based Stress Reduction|Intervention involves a standardized mindfulness-based stress reduction (MBSR) group intervention following the guidelines originally conceived and developed by the Center for Mindfulness in Medicine, Health Care and Society at the University of Massachusetts. The intervention also included an extended period of training in addition to the usual 8 weeks.
3064270|NCT02133196|Experimental|Arm 1/High-Dose Aldesleukin|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus young TIL plus high-dose Aldesleukin
3064271|NCT02133196|Experimental|Arm 2/Low-Dose Aldesleukin|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus young TIL plus low-dose Aldesleukin
3064272|NCT02133183|Experimental|Arm I (sapanisertib before and after surgery)|Patients receive sapanisertib PO according to the results from Part I. Patients also undergo surgery on day 0. Within 45 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3064273|NCT02133183|Experimental|Arm II (sapanisertib after surgery)|Patients undergo surgery on day 0. Within 45 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3064274|NCT02133170|Active Comparator|Psychopharmacological + MBCT|psychopharmacological treatment plus Mindfulness Based Cognitive Therapy (MBCT)
3064275|NCT02133170|Active Comparator|psychopharmacological + psychoeducation|psychopharmacological treatment plus structured group psychoeducation;
3064276|NCT02133170|Other|Psychopharmacological treatment.|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
3064277|NCT02133157|Experimental|Sulfatinib capsule|cohort 1: Sulfatinib single oral dosing;after 7days,Sulfatinib continuous oral dosing ( once a day) 28days as a cycle.
3064278|NCT02133144|Experimental|High fat diet|Intervention: overeating high fat diet (1000 extra calories per day) for 3 weeks
3064279|NCT02133144|Experimental|High carbohydrate diet|Intervention: overeating high carbohydrate diet (1000 extra calories per day) for 3 weeks
3064280|NCT02133131|Experimental|GT1:NC Grazoprevir/Elbasvir+SOF 4wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC with SOF 400mg once daily (q.d.) by mouth for 4 weeks (n=30 planned).
3064281|NCT02133131|Experimental|GT1:NC Grazoprevir/Elbasvir+SOF 6wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=30 planned).
3064282|NCT02133131|Experimental|GT1:C Grazoprevir/Elbasvir+SOF 6wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=20 planned).
3064283|NCT02133131|Experimental|GT1:C Grazoprevir/Elbasvir+SOF 8wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=20 planned).
3064284|NCT02133131|Experimental|GT3:NC Grazoprevir/Elbasvir+SOF 8wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=15 planned).
3064285|NCT02133131|Experimental|GT3:NC Grazoprevir/Elbasvir+SOF 12wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=15 planned).
3064286|NCT02133131|Experimental|GT3:C Grazoprevir/Elbasvir+SOF 12wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=10 planned).
3064287|NCT02133118||Patients on metformin mono-therapy who receive add-on|
3064288|NCT02133105|Active Comparator|Levosimendan|Levosimendan administration is initiated with a loading dose of 12μg/kg given over 10 min followed by a continuous infusion of 0.1 μg/kg/min for 65 min.
3064289|NCT02133105|Active Comparator|Dobutamine|Dobutamine is given as a continuous infusion without a bolus dose. The infusion rate is started at 5.0 μg/kg/min for 10 minutes, and thereafter increased to 7,5 μg/kg/min for 65 min.
3064290|NCT02133092||Patients with respiratory syncytial virus (RSV) infection|The RSV infection is laboratory confirmed
3064291|NCT02133079|Experimental|gp96 group|autologous gp96 vaccination + basal treatment
3064292|NCT02133066|Active Comparator|US-Assisted site marking for Lumbar Punctures (LP)|Mindray M7 Ultrasound marking
3064293|NCT02133066|Placebo Comparator|Routine lumbar puncture|"These patients will receive no ultrasound-assisted site marking prior to lumbar puncture; The patients will simply have a standard-of-care spinal tap performed by the clinician"
3064294|NCT02133053||Ectoin Group|Ectoin Allergy Nasal Spray (Medical Device, drug-like)
3064295|NCT02133053||Beclomethasone Group|Beclomethasone nasal spray
3064296|NCT02133040||T3 > 4 nmol/l|Acute hyperthyroidism with a T3 > 4 nmol/l
3064297|NCT02133027|Experimental|Rouviere's Sulcus|Rouviere's sulcus is a 2 to 5 cm sulcus running to the right of the liver hilum anterior to the caudate process and usually containing the right portal triad or its branches.Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
3064298|NCT02133027|Other|traditional anatomy method|Ratcheted grasper is inserted through the lateral 5-mm port to retract the gallbladder fundus in cephalad fashion. An atraumatic grasper is inserted through the middle 5-mm port to retract the gallbladder infundibulum laterally, exposing the anteromedial aspect of the triangle of Calot.
3064299|NCT02133014|Experimental|surgical operation therapy|Using the method of laparoscopic-assisted percutaneous catheter drainage of SAP.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline.
3064300|NCT02133014|No Intervention|conventional therapy|using the method of conventional conservative therapy without surgical management.
3064301|NCT02133001|Experimental|Esketamine|Esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) will be administered by intranasal route using nasal spray pump as two times a week, for 4 weeks. Dose may be reduced to 56 mg per day based on Investigator's discretion.
3064302|NCT02133001|Placebo Comparator|Placebo|Matching Placebo solution will be administered by intranasal route using nasal spray pump as two times a week, for 4 weeks.
3064303|NCT02132988|Experimental|OPT-822/OPT-821|
3064304|NCT02132975|Experimental|With motorised probe handler|The surgeon use the motorised probe handler to do the biopsy
3064305|NCT02132975|Experimental|Without motorised probe handler|The surgeon do the biopsy as he usually do.
3064306|NCT02132962|Active Comparator|Healthy controls|Amino acid infusion
3064307|NCT02132962|Active Comparator|Cirrhosis|Amino acid infusion
3064308|NCT02132949|Experimental|Cohort A: ddAC, Paclitaxel, Pertuzumab, Trastuzumab|ddAC: dose dense doxorubicin and cyclophosphamide. Participants will receive doxorubicin and cyclophosphamide every 2 weeks (q2w) for 4 cycles, followed by paclitaxel for 12 weeks, with pertuzumab and trastuzumab given every 3 weeks (q3w) (8 cycles of chemotherapy in total prior to surgery) from the start of paclitaxel. Following surgery, participants will receive further adjuvant pertuzumab and trastuzumab q3w (13 cycles), such that a total of 17 cycles of pertuzumab and trastuzumab therapy are given during the study.
3064309|NCT02132949|Experimental|Cohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab|FEC: 5-fluorouracil, epirubicin and cyclophosphamide. Participants will receive 5-fluorouracil, epirubicin, and cyclophosphamide given q3w for 4 cycles, followed by docetaxel q3w for 4 cycles, with pertuzumab and trastuzumab given q3w (8 cycles of chemotherapy in total prior to surgery) from the start of docetaxel. Following surgery, participants will receive further adjuvant pertuzumab and trastuzumab q3w (13 cycles), such that a total of 17 cycles of pertuzumab and trastuzumab therapy are given during the study.
3064310|NCT02132936|Experimental|LEO 90100|LEO 90100 aerosol foam, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per can, applied once daily up to 12 weeks
3064311|NCT02132936|Placebo Comparator|Aerosol foam vehicle|Aerosol foam vehicle, 60 g per can, applied once daily for up to 12 weeks
3064312|NCT02132936|Active Comparator|Calcipotriol BDP gel|Calcipotriol BDP gel, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per bottle, applied once daily up to 12 weeks
3064313|NCT02132936|Placebo Comparator|Gel vehicle|Gel vehicle, 60 g per bottle, applied once daily up to 12 weeks
3064314|NCT02132923||Patients with respiratory syncytial virus (RSV) infection|The RSV infection is laboratory confirmed
3065641|NCT02123862||Colorectal Cancer|
3065642|NCT02123862||Solid Tumor|
3064315|NCT02132910|Experimental|RESTORE Intervention|"First you will receive an initial assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about yourself, your pain and your current medication use.~For the first four weeks you will receive twice-weekly, individualized, hour-long RESTORE sessions from a specially trained RESTORE instructor.~For the next four weeks, you will receive weekly, individualized, hour-long RESTORE sessions from a RESTORE instructor.~At weeks four and eight, you will repeat the assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about pain and medication use.~At three and six months, you will be contacted by telephone or email to answer questionnaires about pain, physical function, and behavioral health."
3064316|NCT02132910|No Intervention|Control Group 2|"First you will receive an initial assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform so simple physical assessments, and answer questions about yourself, your pain and your current medication use.~You will be contacted once a week for eight weeks by phone or email to answer questions about your pain level.~At weeks four and eight, you will repeat the assessment of pain, physical function and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about pain and medication use.~At three and six months, you will be contacted by telephone or email to answer questionnaires about pain, physical function, and behavior health."
3064317|NCT02132897|Other|TR (Test - Reference)|Sequence : Auration CR 400 Single Dose/Tegretol CR 400 Single Dose
3064318|NCT02132897|Other|RT (Reference - Test)|Sequence: Tegretol CR 400 Single Dose/Auration CR 400 Single Dose
3064319|NCT02132884|Active Comparator|Arm A (standard of care treatment)|Patients receive standard of care treatment based on the discretion of the treating physician.
3064320|NCT02132884|Experimental|Arm B (genetic sequencing and targeted therapy)|Patients undergo collection of tissue and blood samples for analysis via sequencing. Upon disease progression following front-line treatment, patients receive specific targeted therapy based on the mutational status obtained during sequencing.
3064321|NCT02132871||1|
3064322|NCT02132858||Ancillary-Correlative (genetic mutation analysis)|Patients undergo collection of blood and tissue samples for analysis via sequencing.
3064323|NCT02132845|Active Comparator|Arm A (standard of care therapy)|Patients undergo collection of tissue and blood samples for analysis via next generation sequencing. Patients receive standard of care therapy based on the discretion of the treating physician.
3064324|NCT02132845|Experimental|Arm B (target-directed therapy)|Patients undergo collection of tissue and blood samples for analysis via next generation sequencing. Based on the results of the next generation sequencing, patients receive target-directed therapy.
3064325|NCT02132832|Experimental|Buspirone|Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
3064326|NCT02132832|Placebo Comparator|Placebo|Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
3064327|NCT02132819|Placebo Comparator|Feeding During Transfusion|The feeding process will be continued during the transfusion
3064328|NCT02132819|Active Comparator|witholding feeds|At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded
3064329|NCT02132806|Experimental|OFD with piezosurgery|Open flap debridement with Piezosurgery
3064330|NCT02132806|Experimental|OFD with piezosurgery+biomaterial|Open flap debridement with Piezosurgery with biomaterial mp3
3064331|NCT02132806|Experimental|OFD with piezosurgery+mp3+bracket|Open flap debridement with Piezosurgery with biomaterial mp3 + bracket
3064332|NCT02132793|Active Comparator|Anger Management Therapy|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
3064333|NCT02132793|Experimental|Anger Management Therapy & RELAX app|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
3064334|NCT02132767|Active Comparator|Rhythm control|"Rhythm Control in post-operative AF~Amiodarone and/or DC-cardioversion~Amiodarone Initial Dose~Oral: 400 mg po TID for 3 days is recommended~For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose~Oral: at least 200 mg/day to be continued until 60 days after randomization~If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started~DC-Cardioversion - frequency and duration determined by medical professional as medically needed"
3064335|NCT02132767|Active Comparator|Rate control|"Rate Control in post-operative AF~Beta-blocker and/or Calcium channel blockers and/or Digoxin~Dose, frequency and duration determined by medical professional as medically needed"
3064336|NCT02132754|Experimental|MK-4166|Participants receive MK-4166 at assigned dose, intravenously over 30 minutes, on Day 1 of each 21-day cycle, for up to 4 cycles.
3064337|NCT02132754|Experimental|MK-4166+Pembrolizumab|Participants receive MK-4166 at assigned dose, intravenously over 30 minutes on Day 1 of each 21-day cycle for up to 4 cycles and receive pembrolizumab 200 mg, intravenously over 30 minutes on Day 1 of each 21-day cycle for up to 24 months.
3064338|NCT02132741||Treated hypertension|Patients on treatment for hypertension
3064339|NCT02132741||CKD-ESRD|Pre- & post haemodialysis
3064340|NCT02132741||Healthy individuals|Healthy volunteers
3064341|NCT02132741||CKD|Pre-dialysis CKD & those with a functional renal transplant
3064342|NCT02132741||Hypertension|Untreated
3064343|NCT02132728|No Intervention|Control group|In the group with 11 volunteers, the control group did no change in normal food intake.
3064344|NCT02132728|Experimental|Flaxseed group|In this group with 14 volunteers, they received 50% carbohydrate, 31% fat, 19% protein and 60 g of flaxseed powder / day during the period of study.
3065643|NCT02123862||Benign Condition|
3064345|NCT02132728|Experimental|Rice and low carb group|In this group with 13 volunteers, they received 35% carbohydrate, 46% fat, 19% protein and 60g of raw rice powder / day during the period of study.
3064346|NCT02132728|Experimental|Flaxssed and low carb group|In this group with 14 volunteers, they received 32% carbohydrate, 47% fat, 21% protein and 60 g of flaxseed powder / day during the period of study.
3064347|NCT02132715|Active Comparator|Resistance exercise|Traditional isotonic lower-extremity resistance training
3064348|NCT02132715|Experimental|KAATSU exercise|Lower-extremity exercise with blood flow mildly restricted
3064349|NCT02132702|Experimental|Ekso treatment|
3064350|NCT02132689|Active Comparator|Actilyse|Thrombolytic therapy: Patients treated with initial thrombolytic therapy (Actilyse) followed with anticoagulant therapy (unfractionated/low-molecular weight heparin).
3064351|NCT02132689|Active Comparator|UHF/LMWH|Anticoagulation therapy: Patients treated with anticoagulation therapy only (unfractionated/low-molecular weight heparin).
3064352|NCT02132676||Active treatment, SMA-only|This will be all those invited to attend a Shared Medical Appointment (SMA), where the Peer-to-Peer (P2P) program is not being offered.
3064353|NCT02132676||Active treatment, SMA+P2P|This will be all those invited to attend a Shared Medical Appointment (SMA) where the Peer-to-Peer (P2P) program is being offered.
3064354|NCT02132676||Inactive controls|This will be a randomly selected sample of those not offered participation in a Shared Medical Appointment (SMA).
3064355|NCT02132663|Experimental|Infant formula containing an alternate source of DHA|
3064356|NCT02132663|Active Comparator|Marketed routine infant formula|
3064357|NCT02132650|Experimental|ACC|Rehabilitation of walking using accurate (ACC) walking tasks
3064358|NCT02132650|Active Comparator|SS|Rehabilitation of walking using typical steady state (SS) walking
3064359|NCT02132637|Experimental|Insulin Peglispro|Standard dose of insulin peglispro administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin peglispro administered once, SQ on day 3 of the inpatient stay.
3064360|NCT02132637|Experimental|Insulin Glargine|Standard dose of insulin glargine administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin glargine administered once, SQ on day 3 of the inpatient stay.
3064361|NCT02132624|Experimental|CAR T cells|Autologous 3rd generation CD19-targeting CAR T cells
3064362|NCT02132611|Experimental|Diamondback 360® Coronary OAS Micro Crown|Diamondback 360® Coronary Orbital Atherectomy System Micro Crown
3064363|NCT02132598|Experimental|Cabozantinib (XL184)|"Patients will receive cabozantinib at 60 mg orally once daily and continue on treatment until disease progression, death or unacceptable adverse events.~Treatment cycles are 4 weeks in duration"
3064364|NCT02132585||Sjogren|Sjogren Patients evaluated with Speckle tracking echocardiography
3064365|NCT02132585||Control|Controls Speckle tracking echocardiography
3064366|NCT02132572||Natrelle BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
3064367|NCT02132559||DHEA administration,no treatment|The patients of study group received DHEA 25 mg orally,three times a day before the IVF cycle. Except for IVF, the control group of patients did not receive any pre-treatment.
3064368|NCT02132546|Experimental|Chlorhexidine 0,2%|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.2% CHX.
3064369|NCT02132546|Experimental|Chlorhexidine 0,2% with ADS|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.2% CHX with ADS.
3064370|NCT02132546|Experimental|Chlorhexidine 0,12%|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.12% CHX.
3064371|NCT02132533|Experimental|Nifedipine|Women with preterm labor will receive nifedipine.
3064372|NCT02132533|Experimental|Placebo|Women with preterm labor will receive placebo.
3064373|NCT02132520|No Intervention|Control|Subjects receiving standard-of-care physical therapy only.
3064374|NCT02132520|Sham Comparator|Sham rTMS + Real BCI Training|Subjects will receive sham rTMS followed by real BCI training.
3064375|NCT02132520|Active Comparator|Real rTMS + Real BCI Training|Subjects will receive real rTMS followed by real BCI training.
3064376|NCT02132494|Experimental|Physical activity|60 minutes of daily physical activity during one school year
3064377|NCT02132494|No Intervention|Control|
3064378|NCT02132481|Experimental|EMA Only|See intervention
3064379|NCT02132481|Experimental|EMI Only|See intervention
3064380|NCT02132481|Experimental|EMA+EMI|See intervention
3064381|NCT02132481|Active Comparator|Neither - RSAU|See intervention
3064382|NCT02132468|Experimental|fosbretabulin tromethamine|Fosbretabulin 90 mg/vial; 60 mg/m2, IV infusion over 10 minutes; 1x/wk; three 3-week cycles
3064383|NCT02132455|Experimental|3 minutes in the right side colon|Colonoscopy, at least 3 minutes in the right side colon from the total withdrawal time
3064384|NCT02132455|Experimental|4 minutes in the right side colon|Colonoscopy, at least 4 minutes in the right side colon from the total withdrawal time
3064385|NCT02132455|No Intervention|6 minutes whole withdrawal time|Colonoscopy, at least 6 minutes whole withdrawal time regardless of time spent in any segment
3064386|NCT02132455|Experimental|8 minutes whole withdrawal time|Colonoscopy, at least 8 minutes whole withdrawal time regardless of time spent in any segment
3064387|NCT02132442|Experimental|Vitamin D supplementation|Ergocalciferol 50,000 IU per week for 6 weeks, then bi-weekly for 6 mo
3064388|NCT02132442|Placebo Comparator|Placebo|Placebo capsules, on capsule per week for 6 weeks, then bi-weekly for 6 mo.
3064389|NCT02132429|Experimental|AMG 333|Subjects will receive a single oral dose of AMG 333 daily for 14 days.
3064390|NCT02132429|Placebo Comparator|Placebo|Subjects will receive a single oral dose of placebo daily for 14 days.
3064391|NCT02132416|Active Comparator|Surgical management|Operative fixation of unstable thoracic cage injuries and chest wall deformity. Thoracic Epidural anaesthesia will be offered. Paracetamol, Opioids and NSAID will be used as pain medication.
3064392|NCT02132416|Active Comparator|Conservative management|Conservative management of unstable thoracic cage injuries and chest wall deformity. Thoracic epidural anaesthesia will be offered. Paracetamol, Opioids and NSAID will be used as pain medication.
3064393|NCT02132403|Experimental|IMPRIME PGG, BTH1704, & Gemcitabine|Imprime PGG with BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day cycle with Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day cycle.
3064394|NCT02132390|Experimental|Arm I|Patients who didn't have CIA receive oral toremifene daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity
3064395|NCT02132390|Experimental|Arm II|Patients who had CIA receive toremifene as in arm I
3064396|NCT02132390|Experimental|Arm III|Patients without CIA receive oral toremifene and goserelin for ovarian function suppression
3064397|NCT02132390|Experimental|Arm IV|Patients with CIA receive oral toremifene and goserelin for ovarian function suppression.
3064398|NCT02132364|Other|optimised follow-up|optimised follow-up will be done by nursing personnel associated with a caregiving member of his social circle.
3064399|NCT02132364|No Intervention|typical follow-up|no intervention
3064400|NCT02132351||Hepatologists|Doctors working as hepatologists
3064401|NCT02132338|Experimental|The Education Health Program|Intervention forth knowledge and attitudes necessary for self-care
3064402|NCT02132325|Experimental|Dignity Therapy|
3064403|NCT02132312|Experimental|OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
3064404|NCT02132312|Active Comparator|Phenylephrine HCl|Phenylephrine diluted in balanced salt solution (BSS) and administered as irrigation solution
3064405|NCT02132299|Experimental|Group 1|Three volunteers will receive 3 ascending doses of PfSPZ Vaccine by IV administration four weeks apart. The three doses are 3x10^4, 1.35x10^5, and 2.7x10^5 PfSPZ. This is the safety group that will be inoculated first before all others for demonstration of safety and will be followed up for assessment of safety after the completion of the three doses. The follow up will be at weeks 1, 2, 4, 8 and 24 after completion of vaccination. Volunteers in Group 1 will not undergo CHMI. Group 1 is unblinded.
3064406|NCT02132299|Experimental|Group 2(A)|Group 2: Two sub groups: 2A and 2B. Grp 2A (n=20) receives 5 vaccinations IV of 1.35x10^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 2 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 2 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
3064407|NCT02132299|Placebo Comparator|Group 2(B)|Group 2: Two sub groups: 2A and 2B. Grp 2B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 2 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
3064408|NCT02132299|Experimental|Group 3(A)|Group 3: Two sub groups: 3A and 3B. Grp 3A (n=20) receives 5 vaccinations IV of 2.7x10^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 3 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 3 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
3064409|NCT02132299|Placebo Comparator|Group 3(B)|Group 3: Two sub groups: 3A and 3B. Grp 3B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 3 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
3064410|NCT02132299|Experimental|Group 4|The fourth group will include 6 volunteers who will be unblinded and will receive 5 vaccinations of 2.7 x 10^5 PfSPZ Vaccine by IV administration. Four vaccinations at 4 weeks intervals of 2.7x10^5 PfSPZ will be given and the fifth dose will be administered 8 weeks after the 4th. Volunteers from Group 4 will start their vaccinations 48 hours after the four safety volunteers from Group 3 have received their first dose, at each dosing time point. This group will participate in only one CHMI assessment at 24 weeks to assess duration of protection at 24 weeks.
3064411|NCT02132299|Placebo Comparator|Group 5|The 5th group will be divided into 3 sub groups 5A, 5B, 5C, who will be screened and recruited to serve as unblinded controls for the 1st and 2nd CHMI at 3 and 24 weeks. They will participate only in the screening and 4 weeks follow up of the 1st and 2nd CHMI assessments. Group 5A (n=2) will be challenged at the time of the 3-week CHMI of Group 2. Group 5B (n=2) will be challenged at the time of the 3-week CHMI of Group 3. Groups 5A and 5B will supplement the 4 NS- injected volunteers as infectivity controls, totaling 6 altogether. Group 5C (n=6) will be challenged at the time of the 24-week CHMI for Groups 3 and 4.
3064412|NCT02132286|Experimental|Quetiapine -XR (extended release)|Quetiapine-XR (extended release) 150-300mg- treatment in MDD patients with S/Lg alleles in MDD
3064413|NCT02132286|Active Comparator|Citalopram|Citalopram 10-20 mgm/day treatment for 8 weeks in MDD with S/Lg alleles
3064414|NCT02132273|Experimental|Educational Story|Participants receiving this intervention will have access to the educational story as they prepare for the overnight sleep study.
3064415|NCT02132273|No Intervention|Typical Preparation|Participants will receive traditional materials, directions, what to bring list, only. They will not recieve access to educational story
3064416|NCT02132260|Experimental|Naftifine Hydrochloride Cream 2%|Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.)
3064417|NCT02132260|Active Comparator|Naftin® Cream 2%|Naftin® (Naftifine Hydrochloride) Cream 2%
3064418|NCT02132260|Placebo Comparator|Placebo Topical Cream|Placebo Topical Cream
3064419|NCT02132247|Experimental|Flector Patch|Flector Patch is a transdermal delivery system containing 180 mg of diclofenac hydroxyethylpyrrolidine. The patch will be used twice-a-day for up to two weeks, or until pain resolution, whichever comes first.
3064420|NCT02132234|Experimental|Biological treatment|"Patients with high disease activity receiving biological treatment according to rheumatologic indication:~etanercept 50 mg s.c. every week~adalimumab 40 mg s.c. every 2 weeks~certolizumab 400 mg s.c. every 2 weeks for 4 weeks, then 200mg every 2 weeks~infliximab 3 or 5 mg/kg i.v. 2 and 6 weeks from the first admission, then every 8 weeks"
3064421|NCT02132234|Placebo Comparator|control group|Patients with high disease activity receiving other than biological treatment and receiving placebo.
3064422|NCT02132221|Experimental|Cognitive Behavioral Therapy (CBT)|cognitive therapy (10 weekly sessions)
3064423|NCT02132221|No Intervention|no CBT- wait list|no cognitive therapy
3064424|NCT02132208||Trauma|Severe trauma patients admitted in the resuscitation room of our emergency department.
3064425|NCT02132195|Active Comparator|Adrenocorticotropic hormone (ACTH)|"Patients will receive ACTH twice weekly subcutaneously The initial dosing will be based on body surface area (BSA): 80 IU/1.73 m2~The patients will receive the initial dose for 6 months. At 6 months, the dose will be reduced by 50%. Patients who have side effects may have the dose reduced by 50% during the initial 6 months. A second dose reduction would still occur at 6 months (25% of initial dose)."
3064426|NCT02132195|No Intervention|No treatment|Patients in this treatment arm will receive no treatment to prevent relapses of nephrotic syndrome. A relapse, if it occurs, will be treated with prednisone and the patient will leave the no treatment arm of the study. There is an option for the patient to elect to be placed in the active treatment arm of the trial (rescue therapy).
3064427|NCT02132182||Patients newly diagnosed with osteosarcoma|Blood draw
3064428|NCT02132169|Experimental|AC-170 0.24%|
3064429|NCT02132169|Placebo Comparator|AC-170 0%|
3064430|NCT02132143|Experimental|Progression-free survival&Concurrent chemoradiotherapy|"The first day of radiotherapy given pemetrexed(Powder for Injection) 500mg/m2 + cisplatin(Powder for Injection) 75mg/m2, two cycles of chemotherapy given during radiotherapy; then continue to give two cycles of consolidation chemotherapy, 21 days as a cycle.~Intensity-modulated radiation therapy(IMRT),5000cGy～6000cGy/5～6W."
3064431|NCT02132143|Active Comparator|Progression-free survival&sequential chemoradiotherapy|Patients received adjuvant chemotherapy for four cycles,pemetrexed(Powder for Injection) 500mg/m2 + cisplatin(Powder for Injection) 75mg/m2, 21 days as a cycle.Then accept the Intensity-modulated radiation therapy(IMRT),5000cGy～6000cGy/5～6W.
3064432|NCT02132130|Experimental|CGF166 dose 20 uL|single dose volume #1
3064433|NCT02132130|Experimental|CGF166 dose 30 and 40 uL|single dose volume #2
3064434|NCT02132130|Experimental|CGF166 dose 40 uL|single dose volume #3
3064435|NCT02132130|Experimental|CGF166 dose 60 uL|single dose volume #4
3064436|NCT02132130|Experimental|CFG166 dose 30 uL|Single dose volume #5
3064437|NCT02132117|Experimental|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 29 days.
3064438|NCT02132117|Placebo Comparator|Vehicle|Vehicle to Oxymetazoline HCL Cream applied to the face once daily for 29 days.
3064439|NCT02132104|Experimental|amnion graft in severe IUA|patients, who are with severe IUA, treated by uterine application of amnion membrane + Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.
3064440|NCT02132104|Sham Comparator|non-amnion graft in severe IUA|patients, who are with severe IUA, treated by Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.
3064441|NCT02132091|Experimental|Intermittent Fasting|Intermittent Fasting
3064442|NCT02132091|Experimental|Intermittent Fasting + Antioxidants|Intermittent Fasting; 400 IU Vitamin E; 1000 mg Vitamin C
3064443|NCT02132078||Lung transplant recipients with uncomplicated diverticulitis|Retrospective data analysis of treatment, outcome and recurrency-rate
3064444|NCT02132078||Lung transplant recipients with complicated diverticulitis|Retrospective data analysis of treatment, outcome and recurrency-rate
3064445|NCT02132065|No Intervention|Standard pain keller|
3064446|NCT02132065|Experimental|TAP block|Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
3064447|NCT02132039|Active Comparator|12-step sitting Tai Chi Chuan|The intervention is a simplified Tai Chi Chuan exercise, which consists of 12 steps, including weight shifting in different sitting positions, trunk and upper limb movements, and alternate thigh lift in a smooth and coordinated manner.
3064448|NCT02132039|Placebo Comparator|Control|We provide participants in the control group with a level of social contact equivalent to the intervention group, which comprises structured conversations on topic other than physical activity.
3064449|NCT02132026|Active Comparator|Alendronic Acid|50 patients will receive once weekly Alendronic Acid tablets (70mg).
3064450|NCT02132026|Placebo Comparator|Alendronic Acid placebo|25 patients will receive alendronic acid placebo tablets.
3064451|NCT02132026|Active Comparator|Denosumab|50 patients will receive 6 monthly denosumab injections
3064452|NCT02132026|Placebo Comparator|Denosumab Placebo|25 patients will receive a 6 monthly placebo injection.
3064453|NCT02132013|Experimental|Intervention SUBLIME|Intervention group
3064454|NCT02132013|No Intervention|Control|Regular care
3064455|NCT02132000|Active Comparator|tamoxifen|tamoxifen,20mg/day
3064457|NCT02131987||Dislocation|Patients operated with hip hemiarthroplasty for a femoral neck fracture with a postoperative dislocation of the prosthesis
3064458|NCT02131987||Non-dislocated|Patents without dislocation of a hemiarthroplasty for a femoral neck fracture
3064459|NCT02131961|Experimental|Study arm|Collagenase ointment topical application, once daily for 14 days, modified Contact Cast System, applied at days 0,3, and 7.
3064460|NCT02131948|Experimental|Intranasal insulin|40 IU of intranasal insulin
3064461|NCT02131948|Placebo Comparator|Intranasal placebo|Placebo comparator to intranasal insulin
3064462|NCT02131935||ISR Group|Patients Group Experienced In-Stent Restenosis (ISR)
3064463|NCT02131935||Non-ISR|Patients Group Without in-stent restenosis (ISR)
3064464|NCT02131922|Placebo Comparator|Hygenization Treatment|Basic oral hygiene instructions Supragingival plaque removal
3064465|NCT02131922|Experimental|Intensive Treatment|One-Stage Full-Mouth Disinfection. Scaling and root planing, four quadrants in one session. Extraction of radix relicta. Subgingival chlorhexidine (PerioKIN) (0.2%) in all pockets. Oral hygiene instructions.
3064466|NCT02131909|Experimental|mirror therapy|5 sessions mirror therapy 15 minutes per week for 5 weeks
3064467|NCT02131909|Placebo Comparator|bimanual rehabilitation exercises|5 sessions control therapy 15 minutes per week for 5 weeks
3064468|NCT02131896|Experimental|Mediterranean Diet|Mediterranean Diet
3064469|NCT02131896|Active Comparator|Regular nutritional instructions|Regular nutritional instructions
3064470|NCT02131883|Experimental|Group-Cognitive Behavioral Therapy|Group-Cognitive Behavioral Therapy for 7 patients and 2 therapists, 3 hours sessions a week in 12 weeks and a 3 hours booster session 12 weeks after
3064471|NCT02131883|Other|Wait-List with treatment as usual|Wait-List with treatment as usual waiting in 9 months for the intervention with group-CBT
3064472|NCT02131870|Active Comparator|L plantarum DSM 9843|
3064473|NCT02131870|Placebo Comparator|Placebo|
3064474|NCT02131857|Experimental|Staff|active interventional program based on Mindfulness training
3064475|NCT02131857|Experimental|Parents|active interventional program based on Mindfulness training
3064476|NCT02131857|Experimental|Patients with CF|active interventional program based on Mindfulness training
3064477|NCT02131844|Experimental|Facilitated early mobilization|Early mobilization facilitated by a dedicated health professional
3064478|NCT02131844|Active Comparator|Usual care|Instructions about early mobilization covered in a preoperative education session
3064479|NCT02131831||cirrhosis|
3064480|NCT02131818|Experimental|Amoxicillin|The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days
3064481|NCT02131818|Placebo Comparator|Placebo|The patient will be received placebo 2 capsules orally bid pc for 5 days
3064482|NCT02131805|Experimental|Electronic Skin Surface Brachytherapy|The patient will undergo quality of life assessment and skin imaging (ultrasonography and reflectance confocal microscopy). Brachytherapy will be performed over six outpatient visits over 2-3 weeks, on non-consecutive days. Patients will then be followed for 5 years. Reflectance confocal microscopy is optional for the participating sites.
3064483|NCT02131792|Experimental|Lateral Rectus Muscle Slanted Recession|Slanted recession of the lateral rectus muscle for the intermittent exotropia with convergence weakness
3064484|NCT02131779|Experimental|Co-Educational Workshops|Community health advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part health series with men and women dyads. Technical assistance and support will be given as needed to community health advisors. Workshop sessions will include didactic lecture, group discussions, video and group exercises.
3064485|NCT02131779|Active Comparator|Men's Workshops|Community health advisors will be trained using traditional/classroom methods and provided with technical assistance/support as needed to deliver 4 part educational sessions to men only groups to relay information about making an informed decision about prostate cancer screening. Workshop sessions will include didactic lecture, group discussions, video and group exercises.
3064486|NCT02131766|Experimental|USS Virginia Closed Loop Control|"The subject will be admitted to the research house/hotel and will be discharged after 5 nights. The subject will be trained on DiAs and on how to respond to the system's alerts. The study team will provide supervision while DiAs is active but will be primarily responsible for using the system, with the study team serving as a back-up when needed. The DiAs will be initiated by 11:00 PM and will be discontinued before breakfast. The staff will be monitoring the subject remotely. The subject will be permitted to leave the research house if blood glucose value is between 80-249 mg/dL. The subject will need to remain within a 30 miles of the research house/hotel during the day and return by 6:00 PM. The subject will need to follow the Glycemic Treatment Guidelines during 7:00 AM - 11:00 PM.~A limited number of UVA and UPadova subjects will be asked to wear the DiAs at home for 5 days at the conclusion of research house admission."
3064487|NCT02131766|Placebo Comparator|Sensor Augmented Pump Therapy|The subject will wear the continuous glucose monitor with the study insulin pump for a full 7 day period (approximately 7 consecutive 24 hour periods). The subject will follow their usual regimen. The subject will be asked to use the bolus calculator function on your insulin pump and enter the carbohydrate information that you eat during the week. The subject will be asked to record any bolus insulin treatments that are provided with an insulin pen or needle injection. The subject may be asked to download equipment twice during this week: 1) one or two days after starting the sensor to ensure the accuracy of the data, and 2) at the end of the week.
3064488|NCT02131753|Other|Cladribine s.c. injection, HCL treatment|Cladribine 0.14 mg/kg body weight for 5 consecutive days (d 1 - 5) as subcutaneous bolus injection for patients with hairy cell leukemia needing treatment
3064489|NCT02131740|Experimental|Eye rubbing intervention|eye rubbing performed for 1 minute in horizontal direction, clockwise rest for 5 seconds eye rubbing for a further 1 minute
3064490|NCT02131740|Active Comparator|No eye rubbing|no eye rubbing - comparator
3064491|NCT02131727|Experimental|Hand Hygiene Improvement Intervention|Hand Hygiene Improvement Intervention: Participants receive a 4 minute training video about actions to take to reduce risk of respiratory and GI infections that includes hand hygiene practices, along with educational posters and hand hygiene supplies.
3064567|NCT02131090|Experimental|Lock-it Plus|Participants in this arm of the study will receive the Lock-it Plus dressing to secure the epidural catheter
3093441|NCT01936233|Active Comparator|Lamivudine|
3064492|NCT02131727|Placebo Comparator|Ask Me 3|Participants in the control group received a 4 minute training video about the Ask Me 3 program for clearer communication with health care providers, a brochure, and a key chain containing principles for clear communication with health care providers.
3064493|NCT02131714|Active Comparator|counseling and exercises|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character. They also had to perform once daily application of hot packs on both sides of the face for 20 minutes and after that they must perform active free therapeutic exercise of mouth opening for 10 times
3064494|NCT02131714|Placebo Comparator|lifestyle counseling|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character.
3064495|NCT02131701|Active Comparator|Training group|The training group received individualized information about moderate training and was also offered training in group twice a week during 12 months. The training included both endurance training (nordic walking, water gymnastics) and training in gym.
3064496|NCT02131701|Active Comparator|Prescription of exercise|Individualized sessions for exercise prescription aiming at moderate exercise of 30 minutes at least 5 days a week
3064497|NCT02131688|Experimental|Mitoxantrone Hydrochloride Liposome|
3064498|NCT02131675||Boost shake|children that have had type 1 diabetes for more than 1 year
3064499|NCT02131662|Experimental|VPR 4 mg|
3064500|NCT02131662|Experimental|VPR 2 mg|
3064501|NCT02131662|Experimental|VPR 1 mg|
3064502|NCT02131662|Experimental|VPR 0.5 mg|
3064503|NCT02131662|Placebo Comparator|Placebo|
3064504|NCT02131649|Experimental|18F-FCH PET/MRI Scan|Patients will undergo an injection of 18F-fluoromethyl-choline at 3.6 MBq/kg followed by whole body PET/CT imaging. Patients will also undergo a whole body MRI including T2 weighted, Diffusion weighted and Gadolinium Contrast Enhanced sequences. Patients with suspicion for recurrence may undergo biopsy if lesions identified on PET/CT or MRI are accessible for biopsy
3064505|NCT02131636|Experimental|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
3064506|NCT02131636|Placebo Comparator|Vehicle|Vehicle to AGN-199201 applied to the face once daily for 29 days.
3064507|NCT02131623||Validation Group|Subjects with ALGS or PFIC and/or their caregivers
3064508|NCT02131610||Obstructive slep apnea patients|Patients with OSA
3064509|NCT02131610||Control group|Subjects without OSA
3064510|NCT02131597|Experimental|SGI-110|Patients treated with SGI-110 60 mg/m2 subcutaneously daily for 5 days every 4 weeks until treatment failure or for a maximum of 2 years.
3064511|NCT02131584|Experimental|Ruxolitinib|Ruxolitinib starting dose 10 mg administered twice daily by mouth, approximately 12 hours apart. Symptom questionnaire completed at baseline, then 2 weeks after study dose, and again at 3 months.
3064512|NCT02131571||HIV patients older than 50 years|HIV infected patients older than 50 years in current follow up
3064513|NCT02131558|Experimental|ICG Dye|Patients received injections of Indocyanine green (ICG) for sentinel lymph node (SLN) visualization using near-infrared (NIR) imaging.
3064514|NCT02131545|Experimental|Quetiapine|Quetiapine 25 mg
3064515|NCT02131532|Experimental|Psychological intervention|"This is a brief psychological intervention which targets patients' mood, their beliefs about their ability to overcome fatigue, and the scheduling of daily activities, with an aim to increase physical activities in daily life and finally reduce the level of fatigue.~Each participant will meet a therapist in six face-to-face sessions. Each session will be about one hour and be two weeks apart. During the sessions, the participant will discuss with the therapist their problems related to fatigue and work through an intervention manual to learn skills to overcome these problems."
3064516|NCT02131519||internal jugular vein catheter|pediatric patients required internal jugular vein catheter
3064517|NCT02131506|Experimental|Lapatinib, Caelyx|"Lapatinib is given at escalating doses orally and continuously on days 1-21.~Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1."
3064518|NCT02131493|Active Comparator|Gemcitabine|Gemcitabine：1000mg/m2，iv 30min，d1, d8,d15 q4w, 6 cycles
3064519|NCT02131493|Experimental|S-1+ Gemcitabine|S-1：40~60mg bid，d1~14; (S-1 dosage：BSA <1.25m2，40mg bid，1.25m2≤BSA≤1.5m2，50mg bid，BSA>1.5m2， 60mg bid) Gemcitabine：1000mg/m2，iv 30min，d1, d8 q3w, 8 cycles
3064520|NCT02131480|Experimental|Soft tissue|
3064521|NCT02131480|Experimental|Uterus|
3064522|NCT02131467|Experimental|Perampanel|Perampanel 2 mg tablets will be initiated once daily at bedtime. The dose will be titrated over 6 weeks starting at 2 mg OD at baseline visit for 1 week, followed by 2mg increases every 1 week to a maximum of 12 mg/day. If side effects occur then patients will be decreased to previous dose level. If unable to tolerate increases, patients will enter the maintenance phase at previously tolerated dose, for minimum 4 weeks. Patients reaching 12 mg (maximal dose) will be maintained at that dose for 4 weeks. Taper will be over 2 weeks 1 tablet every 2 days from a maximum of 6 tablets per day to stop.
3064523|NCT02131454|Experimental|Education and Inhalation technique training|Training in technique of drug inhalation in asthma and COPD patients and education about the role of inhalation therapy in the course of the disease.
3064524|NCT02131454|No Intervention|Education|Basic education about asthma and COPD.
3064525|NCT02131441|Other|laparoscopic hepatectomy|laparoscopic hepatectomy
3064526|NCT02131441|Other|open liver resection|open liver resection
3064527|NCT02131402|Experimental|enfilcon A / omafilcon A|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
3064528|NCT02131402|Active Comparator|enfilcon A / ocufilcon D|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
3064568|NCT02131090|Experimental|Epifix|Participants in this arm of the study will receive the Epifix dressing to secure the epidural catheter
3064529|NCT02131402|Active Comparator|enfilcon A / methafilcon A|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
3064530|NCT02131389|Other|Iconacy Hip System|Iconacy hip system prosthesis components
3064531|NCT02131376|Active Comparator|Cortical renorrhaphy|Cortical renorrhaphy is performed after partial nephrectomy using a running barbed suture on MH (36mm) needle. Polymer locking clips are used to maintain tension. A base layer running stitch is performed prior to the cortical renorrhaphy.
3064532|NCT02131376|Experimental|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
3064533|NCT02131363|Experimental|Ingrowing Toenail Treatment Kit|"Ingrowing Toenail Treatment Kit consists of 3 components:~Toe nail clip: one clip to be applied each week, for 6 weeks.~Aerosol spray: to be applied up to 5 times a day, no more than one spray per hour.~Nail adhesive: used to attach the clip to the nail."
3064534|NCT02131350|Experimental|Ranibizumab with Photocoagulation|
3064535|NCT02131337|Other|Contact force lesions|
3064536|NCT02131324|Active Comparator|Clobetasol Propionate Cream, 0.05%|applied twice a day for 15 days
3064537|NCT02131324|Experimental|DFD06 Cream|applied twice a day for 15 days
3064538|NCT02131311|Experimental|pessary|disposable, single-use pessary
3064539|NCT02131298|Other|Fixed sequence|Fixed sequence study with treatment A of palbociclib alone, followed by treatment B (palbociclib with itraconazole)
3064540|NCT02131285|Experimental|Sensory training|Experimental group received balance rehabilitation aimed at improving motor strategies and sensory strategies. Subjects in this group were treated to improve recovery of sensory impairment and were given exercises in the impaired sensory conditions, inhibiting the reliable sensory systems and forcing the Central Nervous System to use the impaired ones.
3064541|NCT02131285|No Intervention|No sensory strategy|Control group received usual care rehabilitation which did not include training of sensory strategies.
3064542|NCT02131272|Experimental|Insulin detemir and diet/exercise|Current OADs i.e. metformin or other OADs are continued unchanged
3064543|NCT02131272|Active Comparator|Insulin NPH and diet/exercise|Current OADs i.e. metformin or other OADs are continued unchanged
3064544|NCT02131259||Afatinib|
3064545|NCT02131246|Experimental|Faster-acting insulin aspart|Each subject will be allocated to two treatments (in random sequence).
3064546|NCT02131246|Active Comparator|NovoRapid®|Each subject will be allocated to two treatments (in random sequence).
3064547|NCT02131233|Experimental|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily plus placebo to raltegravir 1 tablet orally twice daily plus TRUVADA™ orally once daily for 96 weeks
3064548|NCT02131233|Active Comparator|Raltegravir|Raltegravir 400 mg tablet orally twice daily plus placebo to reformulated raltegravir 2 tablets orally once daily plus TRUVADA™ orally once daily for 96 weeks
3064549|NCT02131220|Experimental|Prourokinase|Intracoronary bolus infusion of 20mg prourokinase using selective catheter
3064550|NCT02131220|Active Comparator|Tirofiban|Intracoronary tirofiban bolus infusion using selective catheter (10ug/kg)
3064551|NCT02131220|Placebo Comparator|Normal saline|Intracoronary saline bolus infusion using selective catheter (20ml)
3064552|NCT02131207||Diagnostic (MRI and biopsy)|Participants undergo pelvic magnetic resonance imaging (MRI). Within 1-2 weeks, patients undergo scheduled prostate biopsy.
3064553|NCT02131194|Experimental|Lenstatin|Lenstatin (2) capsules orally per day for (6) months
3064554|NCT02131194|Placebo Comparator|Sugar Pill|Placebo manufactured to mimic Lenstatin (2) capsules orally per day for (6) months
3064555|NCT02131181||Delirium|Patients with delirium and patients without delirium
3064556|NCT02131155|Experimental|Afatinib (BIBW2992)|Once daily
3064557|NCT02131155|Placebo Comparator|Placebo|Once daily
3064558|NCT02131142|Experimental|BioFreedom|
3064559|NCT02131129|Experimental|rTMS|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
3064560|NCT02131129|Sham Comparator|Sham|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
3064561|NCT02131116|Experimental|IMT|Integrated Metacognitive Therapy
3064562|NCT02131116|No Intervention|TAU|No intervention group/Treatment as Usual
3064563|NCT02131103|Active Comparator|Early ( < 24hr)|Early percutaneous coronary intervention means performed coronary intervention between 3-24 hours after successful fibrinolytic therapy.
3064564|NCT02131103|Active Comparator|Delay ( > 24 hours)|Delay percutaneous coronary intervention means received coronary intervention >24 hours to 2 weeks after successfully fibrinolytic therapy.
3064565|NCT02131103|Active Comparator|Early|"We randomized the patients into two groups early (≤ 24 hours) and delay group (> 24 hours) All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct."
3064566|NCT02131090|Experimental|Tegaderm TM|Participants in this arm of the study will receive the Tegaderm dressing to secure the epidural catheter
3064569|NCT02131077|Experimental|treatment|ALLO-ASC-TI injection
3064571|NCT02131064|Active Comparator|Trastuzumab (TCH) + Pertuzumab|Participants will receive pertuzumab 840 milligrams (mg) (loading dose) and 420 mg (maintenance dose) intravenous (IV) infusion followed by trastuzumab 8 milligrams per kilogram (mg/kg) (loading dose) and 6 mg/kg (maintenance dose) IV infusion followed by docetaxel 75 milligrams per square meter (mg/m^2) IV infusion and carboplatin at a dose to achieve an area under the curve (AUC) of 6 milligrams per milliliter* minute (mg/mL*min) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period. Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w for rest of the cycles (12 cycles) in adjuvant period (up to a total of 18 cycles).
3064572|NCT02131064|Experimental|Trastuzumab Emtansine (T-DM1) + Pertuzumab|Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab emtansine 3.6 mg/kg IV infusion q3w for a total of 18 cycles (6 cycles of neoadjuvant period and 12 cycles of adjuvant period).
3064573|NCT02131051||Azelastine group|Azelastine nasal spray Azelastine eye drops
3064574|NCT02131051||Ectoin group|Ectoin Allergy Nasal Spray Ectoin Allergy Eye Drops
3064575|NCT02131038||Ectoin group|Ectoin Allergy Nasal Spray
3064576|NCT02131038||Cromolyn group|Cromolyn sodium
3064577|NCT02131012|Experimental|Celecoxib|1-4 mg intravitreal injection ofCelecoxib
3064578|NCT02130999|Experimental|Sequence A|"Single oral dose of tasimelteon 20 mg on Day 1~Single I.V. dose of tasimelteon 2 mg on Day 6"
3064579|NCT02130999|Experimental|Sequence B|"Single I.V. dose of tasimelteon 2 mg on Day 1~Single oral dose of tasimelteon 20 mg on Day 6"
3064580|NCT02130986|Experimental|Procalcitonin (PCT) group|Procalcitonin (PCT) level; Results of procalcitonin level to treating clinician; Provide procalcitonin guideline to treating clinician; Telephone Visit at Day 15 and Day 30
3064581|NCT02130986|Active Comparator|Usual Care group|Telephone Visit at Day 15 and Day 30
3064582|NCT02130973|Active Comparator|Standard Clinical Practice Regimen|Standard Clinical Practice (Daily) Regimen: 18 months of daily subcutaneous Forteo followed by denosumab therapy for 18 months (18 months of Forteo then 3 injections of Prolia at 18, 24 and 30 months).
3064583|NCT02130973|Experimental|Experimental (cyclic) regimen|Experimental (Cyclic) Regimen: three separate 6-month cycles of daily subcutaneous Forteo, each followed by one subcutaneous injection of Prolia (Forteo from 0 to 6 months, and then from 12 to 18 months and then from 24 to 30 months, for a total dose of 18 months; 3 injections of Prolia at 6, 18 and 30 months).
3064584|NCT02130947|Experimental|Exercise Intervention Arm|The exercise intervention will consist of a combination of aerobic (cardiovascular exercise) and strength training (emphasis of the intervention) 3 times per week for 12 weeks with each session lasting ~1.5 hours.
3064585|NCT02130947|No Intervention|Non-Exercise Control Arm|Participants in the Non-Exercise Control Arm will not exercise for 12 weeks.
3064586|NCT02130934||childhood cancer survivors|Cardiac 3D MRI
3064587|NCT02130921|No Intervention|Control|Community Health Workers (CHWs) in the control group will be invited to one group lecture didactically reviewing medical ethics, and the attending CHWs will be requested to pay a home visit to participating IDUs and FMs after the lecture.
3064588|NCT02130921|Experimental|Intervention|"Intervention for CHWs: 3 sessions will cover the understanding stigma and its impact, self-protection and universal precaution adherence, effective communication with patients and family members, and motivational enhancement for behavioral change.~Intervention for IDUs: CHWs who participate in the intervention will be required to conduct 3 individual sessions with participating IDUs covering the following topics: physical health, risk reduction behaviors, mental health, and community integration.~Intervention for FMs: CHWs who participate in the intervention will be required to conduct 2 group sessions with participating FMs covering the following topics: healthy family routine, coping with caregiver burdens, enhance family relationships, support positive behavior change."
3064589|NCT02130908|Experimental|Lean fish|
3064590|NCT02130908|Experimental|Fatty fish|
3064591|NCT02130908|Experimental|Lean meat|
3064592|NCT02130895|Experimental|Intervention|STOPP Criteria Decision Support Content Intervention arm will receive CDS suggestions based on the STOPP criteria.
3064593|NCT02130895|No Intervention|Control|Control arm will provide care as usual during the intervention period.
3064594|NCT02130882|Active Comparator|1|Monthly benralizumab (30 mg) administered as 1 mL sc
3064595|NCT02130882|Placebo Comparator|2|Monthly placebo administered as 1 mL sc
3064596|NCT02130869|Experimental|Group A: Neuroblastoma|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group A participants receive busulfan, melphalan, CD133+ selected autologous stem cell infusion, hu14.18K322A, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.~Cells for infusion are prepared using the CliniMACS System."
3064597|NCT02130869|Experimental|Group B: Lymphoma|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group B participants receive bendamustine, etoposide (or etoposide phosphate), cytarabine, melphalan, CD133+ selected autologous stem cell infusion, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.~Cells for infusion are prepared using the CliniMACS System."
3064598|NCT02130869|Experimental|Group C: High-Risk Tumors|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group C participants receive melphalan, etoposide (or etoposide phosphate), carboplatin, CD133+ selected autologous stem cell infusion, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.~Cells for infusion are prepared using the CliniMACS System."
3064599|NCT02130856|Experimental|Neonatal Kit|The neonatal kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, 4% chlorhexidine (CHX) lotion, sunflower oil emollient, ThermoSpot, a Mylar infant sleeve, and a reusable, non-electric, heating device. Lady Health Workers will be equipped with a hand held electric scale to identify low birth weight newborns.
3064633|NCT02130635|Placebo Comparator|Part A: PLACEBO|Subjects will receive 2 inhalations of placebo once daily for 14 consecutive days
3064634|NCT02130635|Experimental|Part B: GSK2269557 100 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 100 mcg and 3 x Placebo = total dose of 100 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
3064635|NCT02130635|Experimental|Part B: GSK2269557 200 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 200 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
3064600|NCT02130856|No Intervention|Control (Standard care)|"In the control arm, Lady Health Workers will visit the home according to the regular schedule (same as in the intervention clusters) and will deliver the standard post-natal care consisting of:~be present at delivery (though not conduct the delivery) and thorough examination of newborn and mother post delivery~check mother for vaginal bleeding and abnormal blood pressure and make referral to nearest health facility as appropriate~refer any newborn with congenital anomaly or evidence of asphyxia~if unable to attend delivery for any reason, visit within first 24 hours post delivery~assess newborn in first month of life during visits and provide basic treatment for acute respiratory infections, pneumonia, and diarrhea in the home~encourage breastfeeding"
3064601|NCT02130843||MALE PATIENTS BEFORE UDS|MALE PATIENTS BEFORE UDS WITH DIFFICULT CATHETERIZATION
3064602|NCT02130830|Experimental|Topical anesthesia|Application of topical 2,5% lidocaine + 2,5% prilocaine gel to the anal canal before the procedure
3064603|NCT02130830|Placebo Comparator|Placebo|Application of placebo gel into the anal canal before the procedure
3064604|NCT02130817|Experimental|Belatacept|"Belatacept (nujolix):~Tacrolimus withdrawal~Standard of care(SOC) treatment:~Plasmapheresis/Intravenous Immunoglobulin G (IVIG) therapy~Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg starting in the operating room.~Maintenance immunosuppression:~Myfortic: Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.~Steroids: Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30."
3064605|NCT02130804|Experimental|Salsalate|Salsalate (4 g/day)
3064606|NCT02130804|Placebo Comparator|Placebo|Placebo (4 g/day)
3064607|NCT02130791|Experimental|PSD then TSD|baseline sleep, five nights sleep restriction, four nights recovery sleep, one night total sleep deprivation, one night recovery sleep
3064608|NCT02130791|Experimental|TSD then PSD|baseline sleep, one night total sleep deprivation, four nights recovery sleep, five nights sleep restriction, one night recovery sleep
3064609|NCT02130778|Active Comparator|Saline infusion|infusion of saline
3064610|NCT02130778|Active Comparator|Saline infusion with GLP1|infusion of saline with GLP1
3064611|NCT02130765|No Intervention|Drug with ICD/CRT-D|Implantable cardioverter defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D) with routine drug therapy
3064612|NCT02130765|Active Comparator|Cardiac catheter ablation with ICD/CRT-D|Cardiac catheter ablation with ICD/CRT-D with routine drug therapy
3064613|NCT02130752|Experimental|Ultrasonic scalpel surgery group|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes; some great vessels can ligation by nylon, silk line or Hemolock.
3064614|NCT02130752|Experimental|Monopolar electrocautery surgery group|During the procedures of the abdominal approach D2 distal gastrectomy, use monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes; some great vessels can ligation by nylon, silk line or Hemolock.
3064615|NCT02130739||thoracic epidural anesthesia|thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy
3064616|NCT02130726|Experimental|Minimally-invasive Gastrectomy|Patients allocated to the 'Minimally-invasive Gastrectomy' group will undergo minimally-invasive/laparoscopic total gastrectomy. If, during surgery, laparoscopic resection does not seem feasible, the procedure may be converted to an open one.
3064617|NCT02130726|Active Comparator|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive total resection of the stomach via laparotomy. This group is considered the control group
3064618|NCT02130713|Active Comparator|Group A, antibiotics|Prulifloxacin 600 mg
3064619|NCT02130713|Active Comparator|Group B, antibiotics plus nutraceuticals|Prulifoxacin plus Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg
3064620|NCT02130700|Experimental|Chemotherapy-Naive Patients|VT-464: given orally twice daily in 28-day cycles
3064621|NCT02130700|Experimental|Previous Chemotherapy Patients|VT-464: given orally twice daily in 28-day cycles
3064622|NCT02130700|Experimental|AR Positive 1 - 9% TNBC|VT-464: given orally once daily in 28-day cycles
3064623|NCT02130700|Experimental|Male ER Positive|VT-464: given orally once daily in 28-day cycles
3064624|NCT02130700|Experimental|AR Positive >10% TNBC|VT-464: given orally once daily in 28-day cycles
3064625|NCT02130687|Active Comparator|Amlodipine|Subjects in this arm will receive calcium channel blocker therapy with amlodipine 5mg daily for 3 days then 10mg daily for 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
3064626|NCT02130687|Experimental|Ramipril|Subjects will receive ACE-inhibitor therapy with ramipril 5mg daily for 3 days, followed by 10mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
3064627|NCT02130687|Active Comparator|Valsartan|Subjects will receive ARB therapy with valsartan 160mg daily for 3 days, followed by 320mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
3064628|NCT02130674|Experimental|Dipeptiven|0.75 g/ kg/ d Dipeptiven ( L- alanine- L- glutamine; 82 mg/ ml L- alanine, 134.6 mg/ ml L- glutamine; Fresenius Kabi, Switzerland) continuous intravenous infusion
3064629|NCT02130661|Experimental|Part A|Subjects will receive 250 mg of rilapladib once daily (QD) for 14 days (Days 1-14)
3064630|NCT02130661|Experimental|Part B|Subjects will receive 25 mg of rilapladib QD for 1 day (Day 1), 200 mg of itraconazole twice daily (BID) for 1 day (Day 8) and QD for 2 days (Days 9-10). Subjects will receive 25 mg of rilapladib + 200 mg of itraconazole for 1 day (Day 11) and 200 mg of itraconazole QD for 6 days (Day 12-17)
3064631|NCT02130648||Prenatal diagnosis|Prenatal diagnosis witch A sampling of blood de 14 ml
3064632|NCT02130635|Experimental|Part A: GSK2269557 1000 MCG|Subjects will receive 2 inhalations (2 x GSK2269557 500 mcg = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
3064708|NCT02130232|Active Comparator|Usual Care|Usual Medical Care
3064636|NCT02130635|Experimental|Part B: GSK2269557 500 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg and 3 x Placebo = total dose of 500 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days, once daily for 14 consecutive days
3064637|NCT02130635|Experimental|Part B: GSK2269557 700 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg, 2 x GSK2269557 100 mcg and 1 x Placebo = total dose of 700 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
3064638|NCT02130635|Experimental|Part B: GSK2269557 1000 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
3064639|NCT02130635|Experimental|Part B: GSK2269557 2000 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 2000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
3064640|NCT02130635|Placebo Comparator|Part B: PLACEBO|Subjects will receive 4 inhalations of placebo once daily for 14 consecutive days
3064641|NCT02130622|Experimental|Promethazine|Promethazine 12.5 mg P.O. t.i.d. for 4 weeks
3064642|NCT02130622|Placebo Comparator|Sugar Pill|Placebo P.O. t.i.d. for 4 weeks
3064643|NCT02130609|Experimental|Skintel|
3064644|NCT02130596|Experimental|Acceptance-Based Behavioral Intervention|
3064645|NCT02130596|Active Comparator|Nutritional Counselling|
3064646|NCT02130583|Experimental|Positive Affect Skills Training|Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
3064647|NCT02130583|Active Comparator|Treatment as Usual|Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
3064648|NCT02130570|Experimental|Multi-Model Intensive Discharge Program|
3064649|NCT02130570|No Intervention|Usual Care|
3064650|NCT02130557|Experimental|Bosutinib|Bosutinib, 400 mg, oral administration once a day
3064651|NCT02130557|Active Comparator|Imatinib|Imatinib, 400 mg, oral administration once a day
3064652|NCT02130531|Experimental|Cohort 1|"Two dose periods in any sequence (subjects will be assigned to 1 of 2 possible sequences):~Emixustat HCl Tablet Strength B (mid dose); 1 tablet once daily & 1 placebo tablet once daily for 7 days~Emixustat HCl Tablet Strength A (low dose); 1 tablet twice daily for 7 days"
3064653|NCT02130531|Experimental|Cohort 2|"Three dose periods in any sequence (subjects will be assigned to 1 of 6 possible sequences):~Emixustat HCl Tablet Strength A (low dose); 1 tablet daily for 7 days~Emixustat HCl Tablet Strength B (mid dose); 1 tablet daily for 7 days~Emixustat HCl Tablet Strength C (high dose); 1 tablet daily for 7 days"
3064654|NCT02130518|Experimental|Auriclosene (AIS)|Auriclosene Irrigation Solution, 0.2%, 8 treatments over 4 weeks
3064655|NCT02130518|Placebo Comparator|Auriclosene Vehicle Solution|Auriclosene Vehicle Solution, 8 treatments over 4 weeks
3064656|NCT02130505|Active Comparator|T2DM|Patients with type 2 diabetes mellitus, defined as having met the diagnostic criteria as outlined by the World Health Organization
3064657|NCT02130505|Active Comparator|FCH|Patients with familial combined hyperlipidemia, defined as familial hyperlipidemia with a dominant inheritance pattern, elevated plasma apolipoprotein (apo) B concentrations (>1.2 g/L) and elevated triglyceride (TG) levels (>1.7 mmol/L) at the time of diagnosis
3064658|NCT02130505|Active Comparator|FH|Patients with familial hyperlipidemia, defined as having met the diagnostic criteria as outlined by the world Health Organization
3064659|NCT02130505|Active Comparator|Healthy controls|Healthy controls
3064660|NCT02130492|Experimental|FDG arm|Patients will receive increasing doses of FDG.
3064661|NCT02130479|Experimental|Contingency Management-Family Engagement|The Contingency Management-Family Engagement or CM-FAM model integrates behavioral (e.g., drug testing linked with consequences) and cognitive behavioral (e.g., functional analyses of drug use, self-management and drug refusal skills training) strategies based on the Community Reinforcement Approach with effective family engagement strategies used in Multisystemic Therapy.
3064662|NCT02130479|Active Comparator|Treatment as Usual|Standard community-based substance abuse treatment services.
3064663|NCT02130466|Experimental|Pembro+D+T (Parts 1, 2 & 3)|Participants receive pembrolizumab intravenously (IV) on Days 1 and 22 of each 6-week cycle; dabrafenib capsules, 150 mg/day total, orally, in a divided dose (twice per day, or BID) starting on Day 1, through study treatment discontinuation; and trametinib tablets, 2 mg, orally, once daily (QD) starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
3064664|NCT02130466|Placebo Comparator|Placebo+D+T (Part 3)|Participants receive placebo IV on Days 1 and 22 of each 6-week cycle; dabrafenib capsules, 150 mg/day total, orally, in a divided dose BID starting on Day 1, through study treatment discontinuation; and trametinib tablets, 2 mg, orally, QD starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
3064665|NCT02130466|Experimental|Pembro+T (Parts 1 & 2)|Participants receive pembrolizumab IV on Days 1 and 22 of each 6-week cycle and trametinib tablets, 2 mg, orally, QD starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
3064666|NCT02130466|Experimental|Pembro+D (Parts 1 & 2)|Participants receive pembrolizumab IV on Days 1 and 22 of each 6-week cycle and dabrafenib capsules, 150 mg/day total, orally, in a divided dose BID starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
3064667|NCT02130466|Experimental|Pembro+T Concurrent Dosing (Parts 4 & 5)|Participants receive trametinib tablets, 1.5 mg monotherapy, orally, QD for 4 weeks. Starting with Week 5, participants receive pembrolizumab IV on Day 1 of each 3-week cycle and a concurrent dosing schedule for trametinib tablets, 1.5 mg, orally, QD starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
3064668|NCT02130466|Experimental|Pembro+T Intermittent Dosing (Parts 4 & 5)|Participants receive trametinib 1.5 mg monotherapy, orally QD for 2 weeks. Starting with Week 3, participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle and an intermittent dose schedule for trametinib tablets, 1.5 mg, orally, QD with 1 week OFF trametinib and 2 weeks ON trametinib through completion of 2 years of treatment or through study treatment discontinuation.
3064669|NCT02130453|Experimental|ReSTE Cardiac Imaging|Echocardiography strain measurement performed taking about 10 minutes. After resting strain measurement done, first set of nuclear images performed. Once these images are completed, participant given Regadenoson 0.4 mg by vein over about 10 seconds. Within 2 to 4 minutes of receiving the Regadenoson, measurements repeated. These measurements will take about 2 minutes to complete.
3064670|NCT02130453|Other|SPECT Cardiac Imaging|After resting strain measurement done, first set of nuclear images taken. Once these images are completed, participant given Regadenoson 0.4 mg by vein over about 10 seconds. Within 2 to 4 minutes of receiving Regadenoson, measurements repeated. These measurements take about 2 minutes to complete. At about 30 minutes after Regadenoson given, participant will have final images for the nuclear portion of the testing.
3064671|NCT02130440|Active Comparator|Resveratrol nasal spray|2 sprays per nostril 3 times a day for a period of two months
3064672|NCT02130440|Placebo Comparator|Placebo|2 sprays per nostril 3 times a day for a period of two months
3064673|NCT02130427|Experimental|NSCLC|
3064674|NCT02130427|Experimental|Head & Neck|
3064675|NCT02130427|Experimental|GI|
3064676|NCT02130427|Experimental|Gynecologic|
3064677|NCT02130414|Active Comparator|Sandimmun® IV|Sandimmun® IV 2mg/kg as a 24 hour infusion (2mg/kg/day)
3064678|NCT02130414|Experimental|CyCol® capsules|CyCol®: 75 mg OD & BID for 7 days
3064679|NCT02130414|Experimental|CyCol® capsules 37.5 mg|CyCol®: 37.5 mg OD or BID for 7 days
3064680|NCT02130414|Experimental|CyCol® capsules, 150 mg|CyCol®: 150 mg OD or BID for 7 days
3064681|NCT02130401|Experimental|TNM (thermoneuromodulation device)|A standardized active thermal neuromodulation waveform will be used for all patients. The device is non-invasive and does not use electrical stimulation.
3064682|NCT02130388|Other|Renal Insufficiency|Based on creatinine clearance
3064683|NCT02130388|Other|Renal Sufficiency|Based on creatinine clearance
3064684|NCT02130375|Experimental|stress urinary incontinence|Women with stress urinary incontinence
3064685|NCT02130362||Adalimumab (Humira) Treatment|Pediatric patients who are prescribed and treated with adalimumab
3064686|NCT02130362||Immunosuppressant Therapy|Pediatric patients who are being prescribed and treated with immunosuppressant therapy
3064687|NCT02130349||Crohns Disease|IBD patients diagnosed with Crohn's disease
3064688|NCT02130349||Ulcerative colitis|IBD patients diagnosed with ulcerative colitis
3064689|NCT02130349||IBD-Undefined|IBD patients with undefined IBD
3064690|NCT02130336|Experimental|Aerobic interval training|"Frequency: Exercise 3 times a week. Twice under supervision and home exercise once a week.~Duration: Totally 40 minutes in one session. Intensity: 10-minute warm-up and 5-minute cool-down at 40% maximal heart rate (HRmax), participants and exercise 4-minute high-intensity training at 85-90% HRmax and 4 times separated by 3-minute active recovery at 70% HRmax.~Type: Using treadmill while under supervision."
3064691|NCT02130336|Experimental|Continuous moderate-intensity exercise|"Frequency: 5 times a week. Twice under supervision and home exercise 3 times a week.~Duration: Totally 45 minutes per session. Intensity: 10-minute warm-up at 40% maximal heart rate (HRmax), 30-minute moderate intensity exercise at 50-70% HRmax and 5-minute cool-down at 40% HRmax Type: Using treadmill under supervision."
3064692|NCT02130336|No Intervention|Control group|Subjects in control group will receive general exercise knowledge and counseling.
3064693|NCT02130323|Active Comparator|Loop Electrosurgical Excision Procedure|Excision of the cervical transformation zone by way of the loop electrosurgical excision procedure (LEEP) or cold knife conization (CKC).
3064694|NCT02130323|Experimental|Imiquimod|Imiquimod 12.5mg intravaginally once weekly for 16 weeks
3064695|NCT02130310|Experimental|CureXcell®|CureXcell® injection will be administered about every 4 weeks for up to 3 treatments, or until ulcer closure, whichever occurs first.
3064696|NCT02130310|Placebo Comparator|Placebo injection|The placebo will be administered by injecting normal saline at each centimeter of the ulcer bed.
3064697|NCT02130297|Active Comparator|Group 1 - day 1|Group 1 will receive laser therapy to half of the scar the day of the excision.
3064698|NCT02130297|Active Comparator|Group 2 - day 10|Group 2 will receive laser therapy at the time of suture removal or post-operative day 10.
3064699|NCT02130297|Active Comparator|Group 3 - week 9|Group 3 will receive laser treatment to half the scar at the 9 week postop visit.
3064700|NCT02130284|Experimental|Predictive Low Glucose Management (PLGM)|To evaluate the safety of the Predictive Low Glucose Management feature in insulin pump algorithm with the Enlite 3 Sensor
3064701|NCT02130271||Healthy|"Healthy subjects with no pain.~Radioactive dye~PET/MRI~Blood draw"
3064702|NCT02130271||Sciatica|"Subjects with sciatica and scheduled for an epidural steroid injection (ESI).~Radioactive dye~PET/MRI~Blood draw"
3064703|NCT02130258|Other|>30% Pain Relief|All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received greater than 30% pain relief.
3064704|NCT02130258|Other|<30% Pain Relief|All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received less than 30% pain relief.
3064705|NCT02130245|Active Comparator|Early cholecystectomy|Laparoscopic cholecystectomy well be done after the immediate admission
3064706|NCT02130245|Active Comparator|Delayed cholecystectomy|Laparoscopic cholecystectomy after a period of conservative treatment
3064707|NCT02130232|Experimental|Lifestyle Intervention|The goal of the intervention is to help women achieve the lower bound of the GWG range recommended by the Institutes of Medicine (IOM) for a given prepregnancy BMI category (i.e., 11 lbs for obese women and 15 lbs for overweight women). The pregnancy lifestyle intervention will be delivered by trained study dieticians via individual counseling sessions: 2 in-person and 11 telephone sessions delivered on a weekly basis, followed by telephone sessions delivered every other week through the end of pregnancy.
3064709|NCT02130219|Experimental|Chronic daily headache group|"Patients with chronic daily headache with suspicion of intracranial hypertension selected. Selection based on clinical symptoms (headache description, leading symptoms)and para-clinical pathological findings (optical nerve papilla edema). Not enough evidence to diagnose any other headache type. Simultaneous CSF pressure measurements and non-invasive ICP measurement will be performed.~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT."
3064710|NCT02130219|Experimental|Multiple sclerosis group|"Multiple sclerosis (MS) group patients selected based on clinical symptoms and brain MRI changes typical for the disease. Diagnosis based on McDonalds criteria. CSF test for oligoclonal bands required as supporting diagnostic criteria. Patients selected with disease relapse symptoms. Simultaneous noninvasive ICP and CSF pressure measured.~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT"
3064711|NCT02130219|Experimental|Stroke group|"Patients selected for this group have stroke/intracranial hemorrhage that might be complicated with intracranial hypertension. Stroke/intracranial hemorrhage diagnosed based on clinical findings and changes on brain CT/MRI. Patients with stroke less than 33% of middle cerebral artery territory included. Patients with intracranial hemorrhage 20-40 ml volume included. Patients unable to cooperate or sign informed consent excluded.~Bilateral non-invasive ICP measurements performed. Results compared with brain MRI/CT lesion volume, mid-line shift.~Interventions: non-invasive intracranial pressure measurement; brain MRI/CT"
3064712|NCT02130219|Experimental|Normal pressure hydrocephalus group|"Patients meeting normal pressure hydrocephalus diagnosis criteria selected to compare invasive CSF pressure versus non-invasive ICP.~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT"
3064713|NCT02130206|Active Comparator|Caries Free|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
3064714|NCT02130206|Placebo Comparator|Caries Free - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
3064715|NCT02130206|Active Comparator|Caries Active|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
3064716|NCT02130206|Placebo Comparator|Caries Active - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
3064717|NCT02130193|Experimental|Part A|Subjects will receive 50 mg danirixin twice daily (BID) orally for 14 days. If the exposure to danirixin is lower than expected, after 14 days of dosing, then the dose may be increased to 75 mg BID for Part B.
3064718|NCT02130193|Experimental|Part B|Subjects will be randomized to receive either danirixin BID or placebo BID treatment along with standard care of treatment for 52 weeks. Subjects completing Part A and meeting the eligibility criteria for Part B could also be randomized in Part B.
3064719|NCT02130180||ED T1DM and hyperglycemia without criteria for DKA|
3064720|NCT02130180||Well controlled T1DM|
3064721|NCT02130180||ED DKA|
3064722|NCT02130167|Experimental|0.01% Atropine|
3064723|NCT02130167|Active Comparator|0.05% Atropine|
3064724|NCT02130154||Young males|Healthy, Lean, Caucasian, Young males
3064725|NCT02130154||Old males|Healthy, Lean, Caucasian, Older males
3064726|NCT02130141|Experimental|Dark chocolate, dietary counselling|Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
3064727|NCT02130141|Active Comparator|Dietary counselling|Usual snacks are limited.
3064728|NCT02130128|Experimental|Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the LungPoint ATV System
3064729|NCT02130102||Users of ModuLAAr|A group of volunteers (aged 60+), living in assisted living homes, will be provided with module based technical solutions to improve their independency and quality of life.
3064730|NCT02130089|Other|All patients|Intensive tailored education
3064731|NCT02130076||Stop|Patients with stable RA stopping TNF inhibition
3064732|NCT02130076||Continue|Patients with stable RA continuing TNFi therapy
3064733|NCT02130063|Experimental|iron isomaltoside 1000 (Monofer®)|iron isomaltoside 1000 (Monofer®)
3064734|NCT02130063|Active Comparator|iron sucrose (Venofer®)|iron sucrose (Venofer®)
3064735|NCT02130050||OSA Patient|•male patients aged 30 to 65 yr who are newly diagnosed as severe OSA (AHI >=30/hr)
3064736|NCT02130050||Control subjects:|•male control subjects are recruited from Heath Check-up Center. Subjects who are matched with OSA patients at age (+/-2 yrs), body height (+/-3cm) and body weight (<100 kg: +/-3kg, >100 kg: +/-4kg) are screened. Only subjects who are not sleepy (ESS<10) and have no OSA (AHI<5/hr PSG)
3064737|NCT02130037|Active Comparator|psychotherapy only|
3064738|NCT02130037|Experimental|application|
3064739|NCT02130024|Experimental|Ranibizumab|139 patients will receive 0.5mg ranibizumab following a treat and extend regimen.
3064740|NCT02130024|Experimental|Aflibercept|139 patients will receive 2.0mg aflibercept following a treat and extend regimen.
3064741|NCT02130011|No Intervention|without feeding/fluid instructicon|Ten patients treated with preoperative chemoradiotherapy without feeding/fluid instructions
3064742|NCT02130011|Experimental|with feeding/fluid instructions|Ten patients treated with preoperative chemoradiotherapy with feeding/fluid instructions
3064743|NCT02129998||Standard IVF/ICSI treatment|
3064744|NCT02129985|Experimental|Exenatide|patients were all received a short-term intensive insulin therapy,then randomised to Exenatide group(10 ug two times a day for three months)
3064745|NCT02129985|Active Comparator|Metformin|patients were all received a short-term intensive insulin therapy,then randomised to metformin group(850mg two times a day for three months)
3064746|NCT02129972|Experimental|video capsule endoscopy|
3064747|NCT02129959||laparoscopy|laparoscopic cholecystectomy, laparoscopic gastrectomy, laparoscopic colectomy, laparoscopic appendectomy, laparoscopic assisted vaginal hysterectomy, robot-assisted laparoscopic radical prostatectomy
3064748|NCT02129946|Active Comparator|Resistant Starch Bagels|Bagels made from high-resistant starch flour (provides 24g resistant starch per day)
3064749|NCT02129946|Placebo Comparator|Control Bagels|Bagels made from wheat flour
3094610|NCT01928472|Experimental|Group A|H7N9c low dose with adjuvant
3064750|NCT02129933|Experimental|Tracer bevacizumab-IRDye800CW|"Two days prior to the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform), all patients will receive the fluorescent tracer bevacizumab-IRDye800CW intravenously.~*amendement June 2015: topical administration of bevacizumab-800CW"
3064751|NCT02129920||NVAF, acute ischemic stroke/TIA|Consecutive acute ischemic stroke/TIA patients with nonvalvular atrial fibrillation and treated with rivaroxaban
3064752|NCT02129894|Active Comparator|abdominal binder|Post cesarean section patients will get a abdominal binder placed
3064753|NCT02129894|No Intervention|No Abdominal Binder|Post cesarean section patients will not have abdominal binder
3064754|NCT02129881|Experimental|Autologous regulatory T Cell Product|"Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed below:~Prednisolone Day 0: 500 mg IV (250mg pre‐op, 250mg intra‐op) Day 1: 125 mg IV Day 2 to 14: 20.0 mg/day oral Week 3 to 4: 15.0 mg/day oral Week 5 to 8: 10.0 mg/day oral Week 9 to 12: 5.0 mg/day oral Week 13 to 14: 2.5 mg/day oral Week 15 to End: Cessation Mycophenolate Mofetil (MMF) Day ‐7 to ‐2: 500 mg/day oral Day ‐1 to 14: 2000 mg/day oral Week 3 to 36: 1000 mg/day oral Week 37 to 40: 750 mg/day oral Week 41 to 44: 500 mg/day oral Week 45 to 48: 250 mg/day oral Week 49 to End: Cessation Tacrolimus Day ‐4 to 14: 3‐12 ng/ml oral Week 3 to 12: 3‐10 ng/ml oral Week 13 to 36: 3‐8 ng/ml oral Week 37 to End: 3‐6 ng/ml oral"
3064755|NCT02129868|Experimental|Closed-loop on day 1 of CGM sensor life|Glucose level is controlled by the automated closed-loop glucose control system on day 1 after CGM sensor insertion.
3064756|NCT02129868|Active Comparator|Closed-loop on day 3 of CGM sensor life|Glucose level is controlled by the automated closed-loop glucose control system on day 3 or 4 after CGM sensor insertion.
3064757|NCT02129842||Atrial Fibrillation|
3064758|NCT02129829||Observational Group|Patients whose viral load, ALT value and fibrosis status does not meet EASL criteria for treatment and are observed 6 monthly
3064759|NCT02129829||Treatment Group (Tenofovir disoproxil)|Patients who meet EASL treatment criteria who receive Tenofovir disoproxil
3064760|NCT02129816|Active Comparator|Bryophyllum|50% in 350mg Lactose, 2-2-2
3064761|NCT02129816|Placebo Comparator|Placebo|Lactose 350mg, 2-2-2
3064762|NCT02129816|Experimental|Solifenacin|10mg in 350mg Lactose, 2-2-2
3064763|NCT02129803|Experimental|Experimental Therapy|High-Flow, 20 LPM (via Optiflow cannula) Heated (34C) Humidified Air
3064764|NCT02129803|Placebo Comparator|Control Therapy (Low Flow)|Low FLow, 5 LPM (via Optiflow cannula) Room Temperature (23-26C) Ambient Air
3064765|NCT02129790|Experimental|Mentalization-Based Therapy|Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A will include psychoeducation and coping strategies.
3064766|NCT02129777|Experimental|Blinded period: Namilumab 300 mg + namilumab 150 mg|Namilumab 300 mg (2 separate injections of 150 mg), subcutaneous injection, on Day 1, followed by namilumab 150 mg subcutaneous injection, on Days 15, 43 and 71.
3064767|NCT02129777|Experimental|Blinded period: Namilumab 160 mg + namilumab 80 mg|Namilumab 160 mg (2 separate injections of 80 mg), subcutaneous injection, on Day 1, followed by namilumab 80 mg subcutaneous injection, on Days 15, 43 and 71.
3064768|NCT02129777|Experimental|Blinded period: Namilumab 100 mg + namilumab 50 mg|Namilumab 100 mg (2 separate injections of 50 mg), subcutaneous injection, on Day 1, followed by namilumab 50 mg subcutaneous injection, on Days 15, 43 and 71.
3064769|NCT02129777|Experimental|Blinded period: Namilumab 40 mg + namilumab 20 mg|Namilumab 40 mg (2 separate injections of 20 mg), subcutaneous injection, on Day 1, followed by namilumab 20 mg subcutaneous injection, on Days 15, 43 and 71.
3064770|NCT02129777|Placebo Comparator|Blinded period: Placebo|Placebo (2 separate injections), subcutaneous injection, on Day 1, followed by placebo, subcutaneous injection, on Days 15, 43 and 71.
3064771|NCT02129777|Experimental|Open label: Namilumab 80 mg|Namilumab 80 mg subcutaneous injection, at Week 0 and every 4 weeks thereafter up to 52 weeks (active extension period) - if appropriate on the basis of treatment response.
3064772|NCT02129777|Experimental|Open label: Namilumab 150 mg|Namilumab 150 mg, subcutaneous injection, from Week 8 and then every 4 weeks thereafter up to 52 weeks (active extension period) - if appropriate on the basis of treatment response.
3064773|NCT02129764|Experimental|Prednisone|Prednisone will be given 30mg/day for 2 weeks and then tapered off.
3064774|NCT02129764|Active Comparator|Allopurinol|Allopurinol will be given 100 mg/day initially, and then titrated to 200 mg/day.
3064775|NCT02129751|Experimental|bupropion hydrobromide|study drug
3064776|NCT02129751|Placebo Comparator|placebo|placebo
3064777|NCT02129738|Experimental|LoFric|LoFric catheters
3064778|NCT02129725|Experimental|sildenafil citrate|In the parent study, subjects are randomized to sildenafil 25 mg tid.
3064779|NCT02129725|Placebo Comparator|placebo oral capsule|In the parent study, subjects are randomized to matching placebo
3064780|NCT02129712|Placebo Comparator|Non-adaptive cognitive training|Non-adaptive cognitive training
3064781|NCT02129712|Experimental|Adaptive cognitive triaining|Adaptive cognitive training
3064782|NCT02129699|Other|None, standard chemotherapy only|"4 - 6 cycles of standard chemotherapy + best supportive care including any bone protective agent except denosumab.~Standard chemotherapy consis of a combination of platinum-based doublet agents plus gemcitabine or pemetrexed."
3064783|NCT02129699|Experimental|Standard chemotherapy + Denosumab|"4 - 6 cycles of standard chemotherapy + denosumab 120 mg, administered subcutaneously every 3-4 weeks until unacceptable toxicity, patient refusal, or patient's death. Denosumab should be administered on day 1 of each cycle, before or after the administration of chemotherapy. After stop of first-line chemotherapy, denosumab must be continued life-long, regardless of tumour progression and concomitantly with subsequent lines of systemic treatment, as long as tolerable for the patient.~Standard chemotherapy consis of a combination of platinum-based doublet agents plus gemcitabine or pemetrexed."
3064784|NCT02129686|Experimental|Immediate Acupuncture Group|"Immediate acupuncture arm will receive acupuncture 3 times per week during week 1 and week 2, then 2 times per week from week 2 to week 8 for a total of 18 sessions. The crossover will take place after 8th week.~The immediate acupuncture arm will enter a follow-up phase without acupuncture for 8 weeks from week 9 to week 16, while the standard usual care will be provided."
3065137|NCT02127320|Experimental|Sequence 5|Ezetimibe 10mg → Rosuvastatin 20mg → Rosuvastatin 20mg and Ezetimibe 10mg
3064785|NCT02129686|Active Comparator|Delayed Acupuncture Group|The patients on the usual care/delayed acupuncture arm will continue their standard usual care with their physicians and care team. The crossover will take place after 8th week. After crossover, the patients initially on the usual care/delayed acupuncture arm will receive the identical acupuncture protocol but a less frequent schedule from week 9 to week 16: 2 times per week at week 9, then 1 time per week from week 10 to week 16 for a total of 9 sessions
3064786|NCT02129673|Experimental|VS101 Insert Dose A|VS101 Insert Dose A placed under the conjunctiva
3064787|NCT02129673|Experimental|VS101 Insert Dose B|VS101 Insert Dose B placed under the conjunctiva
3064788|NCT02129673|Experimental|VS101 Insert Dose C|VS101 Insert Dose C placed under the conjunctiva
3064789|NCT02129673|Active Comparator|Latanoprost 0.005% eye drops|Latanoprost 0.005% eye drops administered once daily on the eye
3064790|NCT02129660|Experimental|Dose 1 of DRM04B|DRM04B
3064791|NCT02129660|Experimental|Dose 2 of DRM04B|DRM04B
3064792|NCT02129660|Active Comparator|Dose 1 of DRM04|DRM04
3064793|NCT02129660|Active Comparator|Dose 2 of DRM04|DRM04
3064794|NCT02129660|Placebo Comparator|Vehicle|Vehicle
3064795|NCT02129647|Experimental|Axitinib|5 mg axitinib orally twice daily, with increase to 7 mg orally twice daily and 10 mg orally twice daily after 2 and 4 weeks, respectively, provided no adverse reactions (i.e., not exceeding grade 2 toxicities) and normotensive and not receiving antihypertension medications. Axitinib will be given continuously in 28-day cycles until disease progression or unacceptable toxicity.
3064796|NCT02129634|Active Comparator|CB-PTA arm|After successful crossing of the trial lesion, a conventional angioplasty balloon with a diameter matching the trial vessel is advanced over the guidewire and is inflated at the trial lesion site, according to the normal practice of the operator. Comparisons of pre- and post-angioplasty percentage stenosis will be made in the same angiographic projection(s).
3064797|NCT02129634|Experimental|DEB-PTA arm|After successful crossing of the trial lesion, angioplasty with a conventional angioplasty balloon is performed before DEB-PTA. This is because the paclitaxel coating may be scrapped off the balloon if the DEB is used to cross the trial lesion. A conventional angioplasty balloon with a diameter matching the trial vessel is advanced over the guidewire and is inflated at the trial lesion site, according to the normal practice of the operator. A DEB with a diameter matching the trial vessel and lesion length is then advanced over the 0.018 inch guidewire and inflated at the trial lesion site for 60 seconds. If the lesion length is longer than the length of the balloon, a second inflation with another DEB will be required. The maximal total lesion length of the treated lesions will not exceed 20cm. Comparisons of pre- and post-angioplasty percentage stenosis will be made in the same angiographic projection(s).
3064798|NCT02129608|Active Comparator|LLLT|Low Level Laser Therapy (LLLT) once a week for 12 weeks
3064799|NCT02129608|Active Comparator|Lorcaserin|locarserin monotherapy - 10 mg, twice daily for 12 weeks
3064800|NCT02129608|Active Comparator|LLLT and Lorcaserin|LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks
3064801|NCT02129595|Active Comparator|resveratrol|resveratrol will be given for 30 or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
3064802|NCT02129595|Placebo Comparator|placebo|A placebo will be given for 30 or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
3064803|NCT02129582|Experimental|Treatment (TMI, fludarabine, busulfan, allogeneic HPCT)|"CONDITIONING: Patients undergo TMI BID on days -10 to -7. Patients also receive fludarabine phosphate IV over 1 hour on days -6 to -2 and busulfan IV or PO on days -5 and -4.~TRANSPLANT: Patients undergo allogeneic hematopoietic progenitor cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive anti-thymocyte globulin IV on days -3 and -2, tacrolimus IV or PO beginning on day -1 for at least 6 months with taper beginning at 4 months, and methotrexate IV on days 1, 3, 6, and 11."
3064804|NCT02129569|Experimental|Arm I (psychoeducational and behavioral interventions)|Participants meet with a nurse in-person for approximately 30 minutes to receive information about strategies for cognitive self-management of distress and an individualized walking prescription to gradually increase their walking to 30 minutes per day, 5 times per week. Participants wear a pedometer for at least 3 consecutive days during weeks 1, 6, and 12. Participants are also contacted by the nurse via telephone at 1 and 3 weeks for supplemental counseling support.
3064805|NCT02129569|Active Comparator|Arm II (control)|Participants meet with a nurse in-person for approximately 20 minutes to receive NCI educational booklets and a link to the ACS website. Participants are also contacted by the nurse via telephone at 1 and 3 weeks but the calls are primarily social in nature and do not include counseling support.
3064806|NCT02129556|Experimental|MK-3475 with trastuzumab|"Phase Ib: MK-3475 at dose of 1 mg/kg, 2 mg/kg or 10 mg/kg (i.v.) together with trastuzumab 6mg/kg by (i.v.) once every 3 weeks.~Phase II: MK-3475 at a flat dose of 200mg (i.v.) together with trastuzumab 6mg/kg (i.v.) once every 3 weeks until progression, lack of tolerability, or 24 months of treatment.~A dose of 8mg/kg trastuzumab will be used in cycle 1 if prior treatment with trastuzumab was stopped more than 3 months before."
3064807|NCT02129543||SCT Donors and Recipients|"Stem-cell transplant donors and recipients~- Blood Draw"
3064808|NCT02129530|Experimental|Community Social Mobilization Program|A manualized intervention developed with Sonke Gender Justice Network using a workshop intervention manual and a community mobilization toolkit will be used.
3064809|NCT02129530|No Intervention|Control Arm|The Control Arm does not receive the Community Mobilization Intervention
3064810|NCT02129517|Experimental|Arm I (IMPACT Intervention)|Oncology nurses watch tailored, web-based informational video clips addressing knowledge, attitudes, subjective norms, and perceived behavioral control (barriers of discussing clinical trials with patients). They also watch role-play video clips to help improve perceived behavioral control and address attitudinal barriers.
3064811|NCT02129517|Active Comparator|Arm II (online educational materials)|Oncology nurses view online clinical trials educational materials developed based upon NCI clinical trials educational materials for health care providers. The educational materials contain text and tables as presented on the NCI Website.
3064812|NCT02129504|Experimental|coronal advanced technique|root coverage with the porcine collagen matrix using the coronal advanced technique (standard technique)
3064813|NCT02129504|Experimental|extended flap technique|root coverage with the porcine collagen matrix using the extended flap technique (new surgical technique)
3064814|NCT02129491||Pediatric Stroke and Hemiplegia|Any infant or child with acute stroke or hemiplegia
3064815|NCT02129478|Experimental|Olanzapine|
3064816|NCT02129452||CDR (Clinical dementia rating) 0|10 participants complaining subjective memory problem and acquiring CDR 0
3064817|NCT02129452||CDR 0.5|10 participants complaining subjective memory problem and acquiring CDR 0.5
3064818|NCT02129452||CDR 1|10 participants with mild cognitive impairment and acquiring CDR 1
3064819|NCT02129452||CDR 2|10 participants with moderate to severe cognitive impairment and acquiring CDR 2
3064820|NCT02129439|Experimental|SB012|"SB012 will be available in this clinical trial in a concentration of 7.5 mg/ml hgd40 in 30ml PBS. The maximum daily dose will not exceed 225mg.~The study will be continued until 18 subjects have completed the four-week treatment phase according to te protocol. 12 of the 18 subjects will receive verum SB012 (in a 2:1 randomization SB012:Placebo)"
3064821|NCT02129439|Placebo Comparator|Placebo|"Placebo will be administered with an identical volume of 30ml PBS.~The study will be continued until 18 subjects have completed the four-week treatment phase according to te protocol. 6 of the 18 subjects will receive placebo (in a 2:1 randomization SB012:Placebo)"
3064822|NCT02129426|Experimental|Dexmedetomidine and Ketamine|Subjects will already be getting Dexmedetomidine and Ketamine for their routine care.
3064823|NCT02129426|Active Comparator|Dexmedetomidine and Midazolam|Subjects will already be getting Dexmedetomidine and Midazolam for their routine care.
3064824|NCT02129413|Experimental|Delta system treatment|
3064825|NCT02129400|Experimental|10min Xenon 15%, FiO2 75%|10 minutes of 15 % xenon-inhalation (with 75 % FiO2)
3064826|NCT02129400|Experimental|10min Xenon 30%, FiO2 60%|10 minutes of 30 % xenon-inhalation (with 60 % FiO2)
3064827|NCT02129400|Experimental|30min Xenon 15%, FiO2 75%|30 minutes of 15 % xenon-inhalation (with 75 % FiO2)
3064828|NCT02129400|Experimental|30min Xenon 30%, FiO2 60%|30 minutes of 30 % xenon-inhalation (with 60 % FiO2)
3064829|NCT02129400|Experimental|45min Xenon 15%, FiO2 75%|45 minutes of 15 % xenon-inhalation (with 75 % FiO2)
3064830|NCT02129400|Experimental|45min Xenon 30%, FiO2 60%|45 minutes of 30 % xenon-inhalation (with 60 % FiO2)
3064831|NCT02129400|Experimental|90min Xenon 15%, FiO2 75%|90 minutes of 15 % xenon-inhalation (with 75 % FiO2)
3064832|NCT02129400|Experimental|90min Xenon 30%, FiO2 60%|90 minutes of 30 % xenon-inhalation (with 60 % FiO2)
3064833|NCT02129400|Placebo Comparator|10min air medicinalis, FiO2 75%|10 minutes of air medicinalis (with 75 % FiO2)
3064834|NCT02129400|Placebo Comparator|10min air medicinalis, FiO2 60%|10 minutes of air medicinalis inhalation (with 60 % FiO2)
3064835|NCT02129400|Placebo Comparator|30min air medicinalis, FiO2 75%|30 minutes of air medicinalis inhalation (with 75 % FiO2)
3064836|NCT02129400|Placebo Comparator|30min air medicinalis, FiO2 60%|30 minutes of air medicinalis inhalation (with 60 % FiO2)
3064837|NCT02129400|Placebo Comparator|45min air medicinalis, FiO2 75%|45 minutes of air medicinalis inhalation (with 75 % FiO2)
3064838|NCT02129400|Placebo Comparator|45min air medicinalis, FiO2 60%|45 minutes of air medicinalis inhalation (with 60 % FiO2)
3064839|NCT02129400|Placebo Comparator|90min air medicinalis, FiO2 75%|90 minutes of air medicinalis inhalation (with 75 % FiO2)
3064840|NCT02129400|Placebo Comparator|90min air medicinalis, FiO2 60%|90 minutes of air medicinalis inhalation (with 60 % FiO2)
3064841|NCT02129374|Experimental|Direct repair of pars defect|The pars defect was repaired with 4.5mm cortical screw.
3064842|NCT02129374|No Intervention|Conservative treatment|The pars defect of spondylolysis was not repaired with cortical screw.
3064843|NCT02129361|Experimental|Adapted Screening and Brief Intervention|Adapted Screening and Brief Intervention: Participants will be screened for substance use, receive education regarding the effects of substance misuse, participate in a motivation interview, and participate in a booster session one month later
3064844|NCT02129361|Active Comparator|Screening & Education Attention Control|Screening & Education Attention Control: Participants will be screened for substance use, receive education regarding the effects of substance misuse, and participate in a booster session one month later
3064845|NCT02129348|Active Comparator|Lithium Treatment Group|"The patient will be started on lithium 150mg/day, with subsequent dose titration to 300mg/day at the 2-week visit, 450mg/day at the 4-week visit, and 600mg/day (maximum daily dose) if tolerated and based on real lithium blood level. Blood will be drawn at each study visit. This upward dose titration will occur only if clinically indicated (absence of response at lower doses without intolerable side effects).~Patients who develop side effects, e.g., tremor, falls, will have their dose reduced."
3064846|NCT02129348|Placebo Comparator|Placebo Group|"The patient will be started on placebo 150mg/day, with subsequent dose titration to 300mg/day at the 2-week visit, 450mg/day at the 4-week visit, and 600mg/day (maximum daily dose) if tolerated and based on sham lithium blood level. Blood will be drawn for sham lithium levels at weeks 2, 4, 6, 8, and 12. This upward dose titration will occur only if clinically indicated (absence of response at lower doses without intolerable side effects).~Patients who develop side effects, e.g., tremor, falls, will have their dose reduced."
3064847|NCT02129335||stress|patient with glioblastoma diagnosis and partners
3064848|NCT02129322|Active Comparator|Sorafenib|Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential : Sorafenib maintenance
3064849|NCT02129322|Experimental|S-1 and Sorafenib|Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential : 4 cycles of S-1 + Sorafenib maintenance
3064850|NCT02129309|Experimental|Systemic Apelin infusion|"Study 2a - Haemodynamic studies to investigate the response to systemic infusions of 3 apelin agonists in healthy volunteers~Study 2b - Haemodynamic studies to investigate the response to 3 apelin agonists in COPD patients with elevated pulmonary artery pressures"
3064851|NCT02129309|Experimental|Apelin infusion - forearm|"Study 1a - A validation dose study of 3 apelin agonists using forearm plethysmography to evaluate changes in forearm blood flow: performed in healthy volunteers and COPD patients with elevated pulmonary artery pressures.~Study 1b- A validation dose study of apelin receptor antagonist using forearm plethysmography to evaluate changes in forearm blood flow, in healthy volunteers and COPD patients with elevated pulmonary artery pressures."
3065821|NCT02122679|Active Comparator|Study group|Receive tranexamic acid in operating room.
3064852|NCT02129296|Active Comparator|hemiosphere® BALLOON|Balloon filled with air according to the manufacturing company orders 600 or 720 ml air
3064853|NCT02129296|Active Comparator|Fluid filled balloon|Balloon filled with saline and methylene blue according to the manufacturing company orders
3064854|NCT02129283|Experimental|Simulation training|End-of-life simulation training of critical care physicians and nurses using standardized patients to improve communication and interpersonal skills.
3064855|NCT02129283|No Intervention|Control|No simulation training
3064856|NCT02129270|Active Comparator|Lidocaine HCl 2%|Lidocaine HCl 2% (200mg/10ml) 10 ml.
3064857|NCT02129270|Experimental|Lidocaine HCl 1%|Lidocaine HCl 1% (100mg/10ml) 15-20 ml.
3064858|NCT02129257|Experimental|FOLFIRI-AFLIBERCEPT|Aflibercept 4 mg/kg administered over 1 hour on Day 1, followed by FOLFIRI regimen. Treatment will be repeated every 2 weeks. FOLFIRI regimen: Irinotecan 180 mg/m² intravenous (IV) infusion and folinic acid 400 mg/m² IV infusion followed by: 5-fluorouracil (5-FU) 400 mg/m² IV bolus followed by: 5-FU 2400 mg/m² continuous IV infusion over 46 hours. FOLFIRI administration will immediately follow the aflibercept one. In the absence of PD after 6 months of the combination of chemotherapy and aflibercept, the patient will be treated with a maintenance therapy with aflibercept alone until PD or unacceptable toxicities, investigator's decision or patient's refusal of further treatment or death, whichever comes first.
3064859|NCT02129244|Active Comparator|NCM Plus Intervention|The researchers designed the NCM-Plus intervention by integrating the domains of the Chronic Care Model with added attention to linkage to care, building on evidence-based guidelines and the team's pilot findings. In the NCM bundle, the researchers provide extensive details on both proximal and distal outcome variables. Nurse case managers will be hired and trained to improve disease management for patients with MDR-TB and HIV. Specific measurable responsibilities will be implemented by each NCM at sites randomized to receive the intervention. The NCM-patient interaction will occur at the MDR-TB treatment inpatient or outpatient facility.
3064860|NCT02129244|No Intervention|Standard/Usual Care|Usual care is defined as standardized programmatic management of MDR-TB/HIV without care coordination. Nurses are present as part of the team, but with no special coordination role, leaving the MDR-TB physician solely responsible for treatment outcomes with little support. Physicians see patients weekly during the intensive phase and the patient receives basic daily nursing care without coordination of care, active monitoring of Adverse Drug Reactions (ADR)s or HIV care integration. This care transitions to monthly visits with the physician in the continuation phase, again with very little nursing involvement in care coordination.
3064861|NCT02129231|Placebo Comparator|placebo|calcined magnesia 100 mg tablets once a day for 16 weeks
3064862|NCT02129231|Active Comparator|ezetimibe/simvastatin|ezetimibe/simvastatin 10/20 mg tablets once a day for 16 weeks
3064863|NCT02129231|Active Comparator|rosuvastatin|rosuvastatin 20 mg tablets once a day for 16 weeks
3064864|NCT02129218|Experimental|Cohort 1: Low glycemic load with standard diet|Patients follow a low glycemic load diet with a standard dietary intervention for 12 weeks.
3064865|NCT02129218|Experimental|Cohort 2: Low glycemic load with intensified diet|Patients follow a low glycemic load diet with intensified dietary intervention for 12 weeks.
3064866|NCT02129218|Active Comparator|Cohort 3: Medium glycemic load with standard diet|Patients follow a medium glycemic load diet with standard dietary intervention for 12 weeks.
3064867|NCT02129218|Active Comparator|Cohort 4: Medium glycemic load with intensified diet|Patients follow a medium glycemic load diet with intensified dietary intervention for 12 weeks.
3064868|NCT02129205|Experimental|PF-06650808|
3064869|NCT02129192|Experimental|T80/A5/H12.5 mg FDC|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet
3064870|NCT02129192|Active Comparator|T80/H12.5 FDC + A5 mono|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet and Amlodipine 5 mg capsule
3064871|NCT02129179|Experimental|GLP-1|
3064872|NCT02129166|Placebo Comparator|Dasatinib|In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
3064873|NCT02129166|Active Comparator|Dasatinib+Imatinib|"In this group, subjects will take imatinib prior to dasatinib administration.~Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose"
3064874|NCT02129153|Experimental|LIFT (Parent information)|"LIFT (Parent information): during their child's 7th and 8th grade years research staff will 1. communicate with parents about their child's academic and behavioral performance in school, roughly twice-monthly 2. invite parents to participate in a 2-hour parent support session to help teach parents to communicate better with their child and support better academic and behavioral performance in school~students take a baseline survey then 3 surveys (one/year)~parents take a baseline survey then 2 surveys (one/year)"
3064875|NCT02129153|No Intervention|Usual care group|"Usual care control group/No Intervention consists of neither communication of academic information to parents nor invitation to parent support sessions.~students take a baseline survey then 3 surveys (one/year)~parents take a baseline survey then 2 surveys (one/year)"
3064876|NCT02129140||Hernia graft/mesh|Hernia repair patients implanted with biologic hernia graft during surgery
3064877|NCT02129127|Experimental|Drug Coated Chocolate|Paclitaxel Coated Chocolate Balloon Angioplasty
3064878|NCT02129114|Experimental|ReDura Onlay|The Dural Repair Patch manufactured by Guangzhou Medprin Regenerative Medical Technologies Co., Ltd.
3064879|NCT02129114|Active Comparator|DuraGen|Dural Graft Matrix manufactured by Integra LifeSciences (U.S.) Corporation.
3064880|NCT02129101|Experimental|Treatment (azacitidine, sonidegib, decitabine)|"Patients receive azacitidine SC or IV on days 1-7, sonidegib PO QD on days 1-28 or 1-7* or decitabine IV on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: Sonidegib PO QD is given on days 1-7 if in combination with azacitidine or on days 1-28 is given if in combination with decitabine."
3064881|NCT02129088|Experimental|Cohort 1|Participants will receive esketamine 14 milligram (mg) as intranasal spray into each nostril on Day 1.
3064882|NCT02129088|Experimental|Cohort 2|All participants will receive esketamine 14 mg as intranasal spray into each nostril on Day 1 of Period 1 as Treatment A and esketamine 14 mg as intranasal spray followed by intranasal administration of placebo solution after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Period 2 as Treatment B in a fixed sequence.
3065012|NCT02128191|Active Comparator|Oral ibuprofen|Initial dose of 10 mg/kg of oral ibuprofen, followed by 2 doses of 5 mg/kg 24 and 48 h later
3064883|NCT02129075|Experimental|Arm I (CDX-301, CDX-1401, and poly-ICLC)|Patients receive recombinant flt3 ligand SC on days -7 to -1, 1-3, and 22-28 of course 1 and on days 1-3 of course 2 only; DEC-205/NY-ESO-1 fusion protein CDX-1401 SC or ID on days 1 and 2; and poly-ICLC SC on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3064884|NCT02129075|Active Comparator|Arm II (CDX-1401 and poly-ICLC)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3064885|NCT02129075|Experimental|Arm III (CDX-301, CDX-1401, and poly-ICLC)|Patients receive recombinant flt3 ligand SC on days -7 to -3 and 22-26 of course 1 only and DEC-205/NY-ESO-1 fusion protein CDX-1401 and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3064886|NCT02129075|Experimental|Arm IV (CDX-301, CDX-1401, and poly-ICLC)|Patients receive recombinant flt3 ligand SC on days -7 to -3 of course 1 only, and DEC-205/NY-ESO-1 fusion protein CDX-1401 and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3064887|NCT02129062|Experimental|Treatment (ibrutinib)|Ibrutinib 560 mg orally daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3064888|NCT02129049|Experimental|Supportive care (Enhancing Connections Telephone Program)|See Detailed Description.
3064889|NCT02129023|Experimental|exergame|Participants were asked to use exergame (Xbox 360) half hour for three times per week in the 12-week study period.
3064890|NCT02129023|No Intervention|control|Participants were not asked to use exergames.
3064891|NCT02129010||Subarachnoid hemorrhage with and without Terson syndrome|Patients with aneurysmatic subarachnoid hemorrhage with and without Terson syndrome
3064892|NCT02128997|Experimental|Closed Incision Wound vacuum (Prevena)|Closed incision wound vacuum (Prevena)
3064893|NCT02128997|No Intervention|Routine Wound Care|This arm includes patients having a cesarean section with routine wound care
3064894|NCT02128984|Experimental|Vitafos Junior|Symbiotic Formula with DHA and antioxidants
3064895|NCT02128984|Active Comparator|Standard Formula|Standard isocaloric and isonitrogenous formula.
3064896|NCT02128971|Active Comparator|Ferrochel® 90 mg|Ferrochel® capsule 90 mg OD for 30 days
3064897|NCT02128971|Active Comparator|Sumalate® 90 mg|Sumalate® capsule 90 mg OD for 30 days
3064898|NCT02128971|Active Comparator|Ferrous Fumarate 90 mg|Ferrous Fumarate capsule 90 mg OD for 30 days
3064899|NCT02128971|Active Comparator|Ferrous Sulfate 90 mg|Ferrous Sulfate capsule 90 mg OD for 30 days
3064900|NCT02128971|Active Comparator|Ferric glycinate 90 mg|Ferric glycinate capsule 90 mg OD for 30 days
3064901|NCT02128971|Active Comparator|Placebo|Placebo capsule OD for 30 days
3064902|NCT02128958|Experimental|CF102|orally q12h
3064903|NCT02128958|Placebo Comparator|Placebo tablets of CF102|orally q12h
3064904|NCT02128945|Experimental|FLUDATEP|[18F] - Fludarabine PET/CT
3064905|NCT02128932|Experimental|Semaglutide 0.5 mg/week|
3064906|NCT02128932|Experimental|Semaglutide 1.0 mg/week|
3064907|NCT02128932|Active Comparator|Insulin glargine|
3064908|NCT02128919|Experimental|Active tDCS|tDCS 2 ma for 20 minutes with anode at DLPFC once a day for 5 days
3064909|NCT02128919|Sham Comparator|Sham tDCS|tDCS 2 ma for 40 seconds with anode at DLPFC for 5 days
3064910|NCT02128906|Active Comparator|Cisplatin-IMRT|Cisplatin 40 mg/m2 weekly x 7; IMRT: once daily, M-F, 7 weeks (70 Gy)
3064911|NCT02128906|Active Comparator|Docetaxel-Cetuximab-IMRT|Docetaxel 15 mg/m2 weekly x 7; Cetuximab 400 mg/m2 load, one week prior to IMRT; Cetuximab 250 mg/m2 weekly x 7; IMRT: once daily, M-F, 7 weeks (70 Gy)
3064912|NCT02128893|Experimental|Isavuconazole alone|Isavuconazole three times a day on Days 1 and 2 and once a day on Days 3, 4, and 5
3064913|NCT02128893|Experimental|Isavuconazole and Esomeprazole|Esomeprazole daily for 10 days starting on Day 1 and isavuconazole three times a day on Days 6 and 7 and once a day on Days 8, 9, and 10
3064914|NCT02128880|Experimental|CARRII|CARRII: This is a highly interactive Internet intervention consisting of 6 Cores of Intervention material, including Core 1, Overview, Core 2: Your Risk for AEP, Core 3: Drinking, Core 4: Contraception, Core 5: Thoughts and Decisions, and Core 6: Commit to It.
3064915|NCT02128880|Active Comparator|Patient Education|CARRII Education: This is a static website containing educational information on the following topics: What is Alcohol Exposed Pregnancy (AEP)?, Fetal Alcohol Spectrum Disorders, Impact of AEP, Prevalence of AEP, Causes and Prevention of AEP, Treatment for AEP, and Links to related information.
3064916|NCT02128867|Experimental|Assisted Autogenic Drainage (AAD)|airway clearance technique for infants :Assisted Autogenic Drainage
3064917|NCT02128867|Experimental|bouncing and AAD|airway clearance technique for infants : bouncing combined with AAD
3064918|NCT02128867|Experimental|bouncing|bouncing . intervention to relax the infant
3064919|NCT02128854|Experimental|Tablets Intervention|Individuals randomized to this arm will receive: 1) peripheral devices for monitoring blood glucose, blood pressure, and weight; 2) 8 weekly tablet-delivered education and skills training sessions; 3) two booster sessions delivered via tablet-based videoconferencing at 3 and 6 months.
3064920|NCT02128854|No Intervention|Usual Care|Apart from study visits, individuals randomized to the Usual Care group will receive usual care for diabetes management as provided by their primary care physician. The provider will be responsible for determining changes in the treatment regimen and determining the timing of follow-up visits for diabetes care. Between scheduled office encounters, contact will be initiated by the individual.
3064921|NCT02128841|Experimental|All patients|CATHAR is a prospective, open-label, pilot, phase 2 study with independent evaluation of all outcomes. The trial is based on a Bayesian design by incorporating historical information for the control group for all analyses.
3064922|NCT02128828|Experimental|cenicriviroc|cenicriviroc 50 mg tablets, number of tablets adjusted for other antiretroviral medications or other drugs, given once daily
3064923|NCT02128815|Experimental|Coaching|diabetes health coaching + usual diabetes self-management education
3064924|NCT02128815|No Intervention|Usual Care|Usual care or self-management education
3064925|NCT02128802|Experimental|Surgical Gastric Bypass|Patients will undergo surgical gastric bypass according to standard institutional protocols
3064926|NCT02128802|Experimental|Medical Weight Loss Management|Patients will receive best practices medical management for weight loss under current institutional protocols
3064927|NCT02128789|No Intervention|Control Condition|Subjects receive usual care and support. No study intervention provided
3064928|NCT02128789|Experimental|Elder Tree Condition|Elder Tree website. Subjects receive usual care, support and access to the study intervention website.
3064929|NCT02128776|Active Comparator|Usual Care|Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
3064930|NCT02128776|Active Comparator|Comprehensive care medical home|Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
3064931|NCT02128763|Experimental|Omega-3 supplements|Total 2000 mg EPA and 1000 mg DHA per day taken in 5 gelcaps
3064932|NCT02128763|Placebo Comparator|Placebo|Olive oil-5 gelcaps per day
3064933|NCT02128750|Experimental|revascularization group|Subjects in this arms have an contrast echographie with sonovue(r) then a revascularization and finnaly an other contrast echographie with sonovue.
3064934|NCT02128737|No Intervention|Control|10 hours time-in-bed all nights of study
3064935|NCT02128737|Experimental|1 Recovery Night|2 baseline nights, five nights sleep restriction, 1 recovery night, five nights sleep restriction, 4 recovery nights
3064936|NCT02128737|Experimental|3 Recovery Nights|2 baseline nights, five nights sleep restriction, 3 recovery nights, five nights sleep restriction, 2 recovery nights
3064937|NCT02128737|Experimental|5 Recovery Nights|2 baseline nights, five nights sleep restriction, 5 recovery nights, five nights sleep restriction, 1 recovery nights
3064938|NCT02128724|Experimental|BKM120 plus radiotherapy|Three cohorts of patients will be treated with escalating doses of oral BKM120. The doses will be 50mg, 80mg and 100mg, once daily. Patients will be treated with BKM120 for a total of fourteen days. One week after commencing BKM120, patients will start palliative radiotherapy treatment. Radiotherapy treatment will be delivered as 20Gy in 5 fractions over a one week period. There will be an expansion cohort at the MTD. Patients in an optional fourth cohort will take BKM120 for 4 weeks at the MTD.
3064939|NCT02128698|Experimental|Protein and computer-assisted exercise|Patient group which takes daily protein supplements and is advised to do exercise 4 times per week by using Nintendo Wii Balance Board and Wii Fit Plus Software during 6 months after bariatric surgery.
3064940|NCT02128698|Placebo Comparator|Placebo and computer-assisted exercise|Patient group which takes daily control product and is advised to do exercise 4 times per week by using Nintendo Wii Balance Board and Wii Fit Plus Software during 6 months after bariatric surgery.
3064941|NCT02128698|Active Comparator|Protein and usual exercise|Patient group which takes daily protein supplements and is advised to do exercise 4 times per week by using written exercise instructions during 6 months after bariatric surgery.
3064942|NCT02128698|Active Comparator|Placebo and usual exercise|Patient group which takes daily control product and is advised to do exercise 4 times per week by using written exercise instructions during 6 months after bariatric surgery.
3064943|NCT02128685|Active Comparator|Dydrogesterone|Patients allocated to the dydrogesterone group will receive oral dydrogesterone 40mg stat, followed by 10mg orally three times a day, and placebo will be used in the control group accordingly. Patients will be followed up with weekly pelvic ultrasound till 12 completed weeks of gestation or 1 week after the bleeding stopped, whichever is longer.
3064944|NCT02128685|Placebo Comparator|Placebo pill|Patients allocated to the dydrogesterone group will receive oral dydrogesterone 40mg stat, followed by 10mg orally three times a day, and placebo will be used in the control group accordingly. Patients will be followed up with weekly pelvic ultrasound till 12 completed weeks of gestation or 1 week after the bleeding stopped, whichever is longer.
3064945|NCT02128672|Active Comparator|Conventional SCS lead|Conventional Thoracic-lumbar SCS lead placement
3064946|NCT02128672|Experimental|SCS Experimental Lead Placement|Experimental SCS lead placement in a novel position
3064947|NCT02128659|Experimental|SHE Project|Receives SHE Project Intervention during Week 1 of enrollment
3064948|NCT02128659|Active Comparator|Wait-List Control|Receive SHE Project intervention during Week 2 of Enrollment
3064949|NCT02128646|Experimental|Treatment Group 1|Treatment Group patients will receive an opioid-sparing, multimodal, postsurgical pain regimen consisting of intraoperative local wound infiltration with 266 mg EXPAREL followed by, when not contraindicated, administration of a 30 mg dose of IV ketorolac at the end of surgery. Patients scheduled in Treatment Group 1 will have an open surgery for abdominal hernia repair.
3064950|NCT02128646|Experimental|Treatment Group 2|Treatment Group patients will receive an opioid-sparing, multimodal, postsurgical pain regimen consisting of intraoperative local wound infiltration with 266 mg EXPAREL followed by, when not contraindicated, administration of a 30 mg dose of IV ketorolac at the end of surgery. Patients scheduled in Treatment Group 2 will have a laparoscopic abdominal hernia repair.
3064951|NCT02128646|Active Comparator|Control Group 1|Patients scheduled in Control Group 1 will have an open surgery for abdominal hernia repair. The Control Group patients will receive traditional treatment.
3064952|NCT02128646|Active Comparator|Control Group 2|Patients scheduled in Control Group 2 will have laparoscopic abdominal hernia repair. The Control Group patients will receive traditional treatment.
3064953|NCT02128633|Placebo Comparator|placebo|"Individuals that were randomized for treatment  A  . The product tested were always delivered in a transparent plastic syringe with 10 mls marking identified by the letters  A  . The syringes were given to individuals in an opaque plastic envelope sealed and delivered along with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (Placebo gel)."
3065013|NCT02128191|Placebo Comparator|Normal saline|Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
3065014|NCT02128178|Active Comparator|ENOXAPARIN 2 HOURS BEFORE|Giving 40 mg enoxaparin SQ 2 hours before surgery and daily for 10 days thereafter
3065015|NCT02128178|Active Comparator|Enoxaparin 40 mg 12 hours before|Enoxaparin 40 mg 12 hours before surgery and once daily for 10 days thereafter
3064954|NCT02128633|Experimental|Experimental gel|"Individuals that were randomized for treatment  B  - The product was delivered in a transparent plastic syringe with 10 mls identified by the letter  B . The syringes were given to individuals in an opaque plastic envelope sealed and with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (5% sodium fluoride, potassium oxalate 5%, strontium chloride 10% ) ."
3064955|NCT02128633|Active Comparator|Positive control|"Individuals that were randomized for treatment  C  . The product tested were always delivered in a transparent plastic syringe with 10 mls marking identified by the letters  C  . The syringes were given to individuals in an opaque plastic envelope sealed and delivered along with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (Fluoride neutral NaF gel 2 %)."
3064956|NCT02128620|No Intervention|Control Group|Users randomized to the www.sjekkdeg.no A version, consisting en the educative web app, not including the Game-Based Appointment System
3064957|NCT02128620|Experimental|Intervention Group|Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
3064958|NCT02128607|Active Comparator|Real SNAG|A real sustained natural apophyseal glide (SNAG / Mulligan technique) applied on the lumbar spine from a sitting position, and in a trunk flexion direction with the use of the belt.
3064959|NCT02128607|Placebo Comparator|Sham SNAG|A sham (placebo) sustained natural apophyseal glide (SNAG / Mulligan technique) applied on the lumbar spine from a sitting position, and in a trunk flexion direction with the use of the belt.
3064960|NCT02128594|Experimental|Standard of Care|Standard of care
3064961|NCT02128581|Placebo Comparator|Saline|a saline infusion will be started and maintained till the end of the study at 1300 (300 minutes).
3064962|NCT02128581|Active Comparator|Exendin-9,39 @ 300|Exendin-9,39 @ 300pmol/kg/min
3064963|NCT02128581|Active Comparator|Exendin-9,39 @ 750|Exendin-9,39 @ 750pmol/kg/min
3064964|NCT02128568|Active Comparator|Waitlist + YRI only|Participants will complete the assessment and collection of biomarkers and be placed on a waitlist. Once the trial of the first arm has been concluded, participants complete another round of assessments and are offered the YRI sessions. The epigenetic biomarkers collected will be compared with the experimental arm.
3064965|NCT02128568|Experimental|YRI only|Immediately following assessment and collection of biomarkers, participants will be offered the YRI sessions.
3064966|NCT02128555|Active Comparator|Arthrodesis|Ankle arthrodesis (fusion)
3064967|NCT02128555|Experimental|Total Ankle Replacement|Total Ankle Replacement
3064968|NCT02128542|Experimental|Sofosbuvir+RBV 12 weeks|Participants will receive sofosbuvir+RBV for 12 weeks.
3064969|NCT02128529||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease will undergo a single visit with the collection of data from his/her records.
3064970|NCT02128516|Active Comparator|whey protein|whey protein
3064971|NCT02128516|Placebo Comparator|placebo|placebo
3064972|NCT02128516|Experimental|pea protein|pea protein
3064973|NCT02128503|Other|HBV DNA level monitoring|Group with HBV DNV level being monitored regularly
3064974|NCT02128490|Active Comparator|Febuxostat IR 40 mg|Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3064975|NCT02128490|Active Comparator|Febuxostat IR 80 mg|Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3064976|NCT02128490|Experimental|Febuxostat XR 40 mg|Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3064977|NCT02128490|Experimental|Febuxostat XR 80 mg|Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3064978|NCT02128490|Placebo Comparator|Placebo|Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3064979|NCT02128464|Active Comparator|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
3064980|NCT02128464|Active Comparator|Patient specific cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
3064981|NCT02128451|Active Comparator|Meperdine group|15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
3064982|NCT02128451|Active Comparator|Fentanyl group|15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
3064983|NCT02128425|Experimental|FOLFOXIRI|FOLFOXIRI
3064984|NCT02128425|Active Comparator|FOLFOX|FOLFOX
3065016|NCT02128165|Active Comparator|BMI more than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI above 45
3065017|NCT02128165|Active Comparator|BMI less than 45 BMI|Air filled gastric balloon (Heliosphere)those BMI below 45
3065018|NCT02128152|Experimental|Ekso Training Safety and Efficacy|
3065822|NCT02122679|Placebo Comparator|Placebo group|Receive placebo in the operating room
3064985|NCT02128412|Active Comparator|Stent oversize group|"Oversized stent deployed at low pressure:~A stent premounted on a balloon with a nominal diameter halfway between the lumen diameter and the true vessel diameter (approximated by external elastic lamina) as assessed by IVUS. This will be based on the smallest of the vessel reference diameters proximal and distal to the lesion. In addition the vessel diameter must be greater than this diameter throughout the length of the lesion. This stent will be implanted at an inflation pressure of 10 atmospheres or less for at least 15 seconds and a second IVUS will be performed to assess the end point."
3064986|NCT02128412|Active Comparator|High pressure group|"Stent deployed at high pressure:~A stent premounted on a balloon with a nominal diameter approximately equal to the vessel segment lumen reference diameter as previously assessed by IVUS will be used. This stent will be implanted at an inflation pressure of 14 atmospheres or more for at least 15 seconds and a second IVUS will be performed to assess the end point"
3064987|NCT02128399||patients before and after intervetion|
3064988|NCT02128386||Renal sympathetic denervation|Olmesartan 40 mg once daily + Amlodipine 5 or 10 mg once daily + Hydrochlorothiazide 25 mg one daily plus renal sympathetic denervation
3064989|NCT02128386||Intensified antihypertensive treatment|Olmesartan 40 mg once daily + Amlodipine 5 or 10 mg once daily + Hydrochlorothiazide 25 mg one daily plus second-line antihypertensive agents (e.g. mineralocorticoid receptor antagonists or alpha-1-blockers)
3064990|NCT02128373|Active Comparator|Arm I (usual care)|Participants receive usual care (care from physician, physician nurse, and social worker) for 5 weeks. During the week 5 office visit, distance caregivers are not present. In the pre-physician interview patients will verbally complete the FACT, POMS-B, Tension-Anxiety subscale, Distress Thermometer. Distance caregivers will verbally complete the POMS-B, Tension-Anxiety subscale, and Distress Thermometer
3064991|NCT02128373|Experimental|Arm II (usual care with CLOSER intervention)|Participants receive usual care (care from physician, physician nurse, and social worker) for 5 weeks. During the week 5 office visit, distance caregivers will use a computer-assisted intervention to be present electronically with video and audio feed to provide psychosocial support. In the pre-physician interview patients will verbally complete the FACT, POMS-B, Tension-Anxiety subscale, Distress Thermometer. Distance caregivers will verbally complete the POMS-B, Tension-Anxiety subscale, and Distress Thermometer. Up to 96 hours after the week 5 visit, patients and caregivers will be interviewed about their experience during the intervention
3064992|NCT02128360|Active Comparator|Minimal stimulation protocol|Low dose Letrozole 2.5 mg over 5 days, starting from cycle day 2, overlapping with low dose gonadotropins, starting from day 3 of the Letrozole at 150 units per day. GnRH antagonist to avoid premature LH surge will be introduced when one or more of the growing follicles reached approximately 14 mm in size
3064993|NCT02128360|Active Comparator|High dose protocol|High dose of gonadotropins (≥300 IU/day) starting from cycle day 3. GnRH antagonist will be introduced to avoid premature LH surge when one or more of the growing follicles will reach approximately 14 mm in size
3064994|NCT02128347|Other|Electronic Patient Portal|RelayHealth is a web-based application that allows patients and healthcare workers to communicate through a secure, password protected online portal with data transfer capabilities. Effectiveness of the portal in improving several health outcomes from baseline-12 months will be assessed in this study.
3064995|NCT02128334||Patients with advanced prostate carcinoma|
3064996|NCT02128321|Experimental|Isavuconazole + Repaglinide + Caffeine|Isavuconazole three times a day on Days 5 and 6 and once a day on Days 7 through 17, repaglinide on Days 1 and Day 14, caffeine on Days 3 and 16
3064997|NCT02128308|Experimental|Levofloxacin and Streptomycin added|Levofloxacin and Streptomycin added : Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Levofloxacin 750mg (500mg x 1.5 tab) qd, Streptomycin 1g IM qd
3064998|NCT02128308|Experimental|Moxifloxacin and Kanamycin added|Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Moxifloxacin 400mg (400mg x 1 tab) qd, Kanamycin 1g IM qd
3064999|NCT02128295|Experimental|Primiparous mothers|Mother who are primiparous
3065000|NCT02128295|Experimental|Multiparous mothers|Mothers who are multiparous
3065001|NCT02128282|Experimental|CX-4945 and cisplatin plus gemcitabine|"CX-4945 capsules at the combination MTD on Days 0, 1 and 2, and Days 7, 8 and 9.~PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21 day cycle."
3065002|NCT02128282|Active Comparator|Cisplatin plus Gemcitabine|Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21 day cycle.
3065003|NCT02128269|Experimental|ALXN1007- Open label study|ALXN1007
3065004|NCT02128256|Experimental|Cerament G injection|Cerament G is injected to fill a bone defect after debridement of the infected bone.
3065005|NCT02128243|Experimental|Arm A: De-escalation therapy|Patients in Arm A will continue with S-1 de-escalation phase starting at week 13 until disease progression, toxicities requiring discontinuation, withdrawal of consent, pregnancy, death or lost to follow up whichever occurs first. In patients with drug-related severe toxicity S-1 dose will be adjusted or study treatment will be terminated.
3065006|NCT02128243|Experimental|Arm B: Chemotherapy by Investigator's choice|Patients in Arm B will continue to receive the same polychemotherapy as during induction therapy until tumor progression, toxicities requiring discontinuation, withdrawal of consent, pregnancy, death or loss to follow up whichever occurs first.
3065007|NCT02128230|Experimental|Study Treatment|
3065008|NCT02128217|Experimental|Cohort 1: SOF+weight-based RBV for 12 wks|Participants in Cohort 1 were assigned Sofosbuvir (SOF)+weight-based ribavirin (RBV) for 12 weeks. Follow-up visits occurred through to 24 weeks after the end of treatment.
3065009|NCT02128217|Experimental|Cohort 2: LDV/SOF for 8 wks|Participants in Cohort 2 were assigned Ledipasvir/Sofosbuvir for 8 weeks. Follow-up visits occurred through to 24 weeks after the end of treatment.
3065010|NCT02128204|Experimental|HYADERMIS LA Facial Dermal Implant|Subjects will be randomly assigned to receive experiment treatment, lidocaine contained hyaluronate facial dermal filler, in one side of the face.
3065011|NCT02128204|Active Comparator|Hya-Dermis Facial Dermal Implant|Subjects will be randomly assigned to receive control treatment, hyaluronate facial dermal filler, in one side of the face.
3066057|NCT02120976|Experimental|Dose 8 JTT-252|Tablets, single dose in fed condition
3065019|NCT02128126|Experimental|ISA101/ISA101b|The maximum total treatment duration for a patient is six cycles (1 cycle is 21 days) for a total of 18 weeks. On day 15 of cycles 2, 3 and 4 patients are to receive the vaccination scheme of ISA101/ISA101b. Patients will be vaccinated with a fixed dose of ISA101/ISA101b every three weeks for a total of three rounds of vaccination. Four dose levels of ISA101 have been tested. ISA101b will be tested in bridging cohorts.
3065020|NCT02128113|Placebo Comparator|Placebo ophthalmic solution|Placebo ophthalmic suspension, one drop, applied twice daily for a maximum of 28 days
3065021|NCT02128113|Experimental|0.5% omaveloxolone (RTA 408) opthalmic suspension|0.5% omaveloxolone ophthalmic suspension, one drop applied twice daily for a maximum of 28 days
3065022|NCT02128113|Experimental|1% omaveloxolone (RTA 408) opthalmic suspension|1% omaveloxolone ophthalmic suspension, one drop applied twice daily for a maximum of 28 days
3065023|NCT02128100|Experimental|Folririnox with SBRT|"Folfirinox~Oxaliplatin 85 mg/m² for over 2 hours,~Leucovorin 400n mg/m² for over 2 hours,~Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~Fluorouracil 2400 mg/m² as a slow infusion over 46 hours~SBRT 5 treatments of stereotactic body radiation therapy (SBRT) over the course of two weeks with a minimum of 36 hours in between each treatment."
3065024|NCT02128087|No Intervention|Control group|This study arm will receive care as usual.
3065025|NCT02128087|Experimental|Two-way SMS intervention group|"Two-way messages allow the recipient of the SMS message (the patient) to respond to the messages (We hope you are feeling well today. Reply 1 if well, 2 if unwell) to request a follow-up call from the clinic."
3065026|NCT02128087|Experimental|One-way SMS intervention group|"Clients will receive a weekly one-way SMS with the message We hope you are feeling well today. There will be no prompt for response."
3065027|NCT02128074|Experimental|KRX-0502|KRX-0502 (ferric citrate)
3065028|NCT02128061|Active Comparator|R-miniCHOP|"All patients will be treated with R-miniCHOP at a three-weeks interval for 6 cycles CYCLOPHOSPHAMIDE IV: 400 mg/m² Day 1 (D1) DOXORUBICINE IV : 25 mg/m² D1 VINCRISTINE IV : 1 mg Total Dose (TD) D1 PREDNISONE PO : 40 mg/m² D1 to D5 RITUXIMAB SC* : 1400 mg TD D1~*The first cycle of rituximab is delivered by IV at the dose of 375 mg/m2"
3065029|NCT02128061|Experimental|R2-miniCHOP|"All patients will be treated with R2-miniCHOP at a three-weeks interval for 6 cycles CYCLOPHOSPHAMIDE IV: 400 mg/m² D1 - DOXORUBICINE IV : 25 mg/m² D1 - VINCRISTINE IV : 1 mg TD D1 - PREDNISONE PO : 40 mg/m² D1 to D5 - RITUXIMAB SC* : 1400 mg TD D1 LENALIDOMIDE PO** :10 mg TD D1 to D14~*The first cycle of rituximab is delivered by IV at the dose of 375 mg/m2"
3065030|NCT02128048||Heavy smokers|Assessment of body composition and muscle function
3065031|NCT02128035|No Intervention|Without Lead Shield|"All routine measures to reduce radiation exposure (including lead aprons, lead collar, lead lenses, movable ceiling suspended lead shield with a long lead skirt attached to its lower margin) will be used as done routinely and will be left to the operators' discretion.~The LEAD SHIELD will not be used in this group.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
3065032|NCT02128035|Experimental|With Lead Shield|"All routine measures to reduce radiation exposure (including lead aprons, lead collar, lead lenses, movable ceiling suspended lead shield with a long lead skirt attached to its lower margin) will be used as done routinely and will be left to the operators' discretion.~In this group, a LEAD SHIELD will be used. The Pelvic lead shield will be draped on patient from umbilicus to knees.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
3065033|NCT02128022|Experimental|GLP-1 (7-36) amide and Glibenclamide|Patients will receive 5mg Glibenclamide orally prior to PCI and infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min during PCI
3065034|NCT02128022|Experimental|Glibenclamide alone|Glibenclamide 5 mg orally prior to PCI
3065035|NCT02128022|Active Comparator|GLP-1 (7-36) amide|GLP-1 (7-36) amide
3065036|NCT02128022|No Intervention|Saline control|0.9% saline only (no treatment with GLP-1 (7-36) amide or glibenclamide)
3065037|NCT02128009||osteoporosis,non-osteoporosis|
3065038|NCT02127996|Placebo Comparator|Normal Saline|Infusion of Normal Saline during Percutaneous Coronary Intervention
3065039|NCT02127996|Experimental|GLP-1|Infusion of GLP-1 (7-36) amide during elective percutaneous coronary intervention
3065040|NCT02127983|Experimental|Early intervention|Early intervention arm engaging informal providers Received the intervention early in the first 12 months
3065041|NCT02127983|Active Comparator|Delayed intervention|Delayed intervention arm, engaging informal providers Received the intervention after one year
3065042|NCT02127970|Experimental|Single-Dose Dalbavancin|Single-dose of dalbavancin 1500 mg intravenous (IV) infusion over 30 minutes on Day 1 followed by dalbavancin-matching placebo IV infusion over 30 minutes on Day 8 for participants with creatinine clearance (CrCl) ≥30 mL/min or with CrCl <30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl <30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin dose was 1000 mg.
3065043|NCT02127970|Experimental|Two-Dose Dalbavancin|Two-dose regimen of dalbavancin 1000 mg IV infusion over 30 minutes on Day 1 followed by 500 mg IV infusion over 30 minutes on Day 8 for participants with CrCl ≥30 mL/min or with CrCl <30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl <30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin doses were 750 mg on Day 1 and 375 mg on Day 8.
3065044|NCT02127957|Other|Exercise|Exercise group will have 6 visit and 8 phone call. Subject will have to do prescribed exercice for 1h, 3 times a week for 12 weeks.
3065045|NCT02127957|No Intervention|Control|Control group will have 4 visit and 3 phone call. They will receive standard counselling for exercise in cystic fibrosis, but no prescribed exercice will be given.
3065046|NCT02127944||FERTILE GROUP|WOMEN HAVE NO INFERTILITY PROBLEMS AND HAVE AT LEAST ONE CHILD
3065047|NCT02127944||UNEXPLAINED INFERTILE GROUP|WOMEN WITH INFERTILITY PROBLEMS,NO HISTORY OF PREGNANCY AND HAVE NO CHILDREN
3065048|NCT02127931|Experimental|Video Game Diagnostic Tool|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD.
3065049|NCT02127918||ESES treated with clobazam|The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
3065050|NCT02127905|Other|CD34+ selected cells|use of unrelated bone marrow or peripheral blood for hematopoietic stem cell transplantation with CD34+ selected cells
3065051|NCT02127892|Other|unrelated BM with T cell depletion|Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
3065052|NCT02127892|Other|unrelated cord blood|Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).
3065053|NCT02127892|Other|haplo BM with T cell depletion|If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
3065054|NCT02127892|Other|unrelated PBSC with T cell depletion|The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
3065055|NCT02127879|Experimental|Transcranial Magnetic Stimulation|Active Treatment 10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC)
3065056|NCT02127879|Sham Comparator|Transcranial Magnetic Stimulation with sham coil|Sham coil Treatment 10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC)
3065057|NCT02127866|Experimental|CHF 5259 25 µg plus Foster 100/6 µg|
3065058|NCT02127866|Experimental|CHF 5259 50 µg plus Foster 100/6 µg|
3065059|NCT02127866|Experimental|CHF 5259 100 µg plus Foster 100/6 µg|
3065060|NCT02127866|Active Comparator|Foster 100/6 µg|
3065061|NCT02127853|Experimental|Gabapentin|gabapentin pretreatment
3065062|NCT02127853|Placebo Comparator|Placebo|placebo drug pretreatment
3065063|NCT02127840|Experimental|Synacthen|Synacthen infusion during adrenal venous sampling
3065064|NCT02127840|No Intervention|Without Synacthen|Adrenal venous sampling without Synacthen
3065065|NCT02127827|Experimental|investigational device off|
3065066|NCT02127814|Experimental|L. reuteri|
3065067|NCT02127814|Placebo Comparator|Identical Placebo|
3065068|NCT02127801|Experimental|Group A|Participants in group A will receive REGN1908-1909
3065069|NCT02127801|Experimental|Group B|Participants in group B will receive placebo
3065070|NCT02127788||Micafungin|Patients affected with haemopathy (or affected with solid tumor for paediatric patients) under antifungal prophylaxis with micafungin.
3065071|NCT02127775|Experimental|Sequence B|Day 1: Lesinurad 400 mg (manufactured at Site 2); Day 5: Lesinurad 400 mg (manufactured at Site 1)
3065072|NCT02127775|Experimental|Sequence A|Day 1: Lesinurad 400 mg (manufactured at Site 1); Day 5: Lesinurad 400 mg (manufactured at Site 2)
3065073|NCT02127762|Experimental|Mindfulness Based Stress Reduction|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
3065074|NCT02127762|No Intervention|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
3065075|NCT02127749|Experimental|Control|Subjects are not pretreated with antibiotics Subjects receive 2 ng/kg endotoxin intravenously
3065076|NCT02127749|Experimental|Antibiotics|Subjects are pretreated with broad-spectrum antibiotics: Vancomycin, Metronidazole, Ciprofloxacin Subjects receive 2 ng/kg endotoxin intravenously
3065077|NCT02127736|Experimental|Experimental group|
3065078|NCT02127736|Placebo Comparator|Control group|
3065079|NCT02127723|Other|Macrolane|Att subjects will be treated with Macrolane
3065080|NCT02127710|Experimental|AZD6094 600 mg daily continuously|All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD). Treatment will be given continuously.
3065081|NCT02127697|Experimental|NVA237|Participants will receive NVA237 once daily in addition to their background therapy during the 52- week treatment period. All participants will receive salbutamol/ albuterol as rescue medication.
3065082|NCT02127697|Placebo Comparator|Placebo|Participants will receive placebo to NVA237 in addition to their background therapy during the 52-week treatment period. All participants will receive salbutamol/ albuterol as rescue medication.
3065083|NCT02127684|Active Comparator|Standard Dosing Group|Standard Dosing Group will receive intravitreal injections of 0.3mg. ranibizumab at baseline, week 4 and 8 )sham injections at week 2 and 6). After week 8 retreatment will be given monthly if edema is greater than 290um or ETDRS visual acuity score <83
3065084|NCT02127684|Experimental|Frequent dosing group|Frequent dosing subjects will be evaluated and treated every two weeks through week 8 with intravitreal injection of 0.3mg ranibizumab. Subjects will then be evaluated monthly through week 24 and will receive treatment with ranibiumab based on residual edema and visual acuity
3065085|NCT02127671|Experimental|IDEAL intervention|Individual cardiovascular risk reduction counseling, coordination with primary care providers to ensure appropriate management of risk factors, and collaboration with mental health staff and social supports. All participants will be offered group exercise classes, and programs will be provided with instruction to provide more healthy meals.
3065086|NCT02127671|Other|Control|All participants will be offered group exercise classes, and programs will be provided with instruction to provide more healthy meals.
3065087|NCT02127658|Active Comparator|Hygiene education|Participants will receive specific hygiene instructions according to existing recommendations.
3065088|NCT02127658|Active Comparator|Hygiene education and Decolonization|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite [Clorox; The Clorox Company] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupiricin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
3065089|NCT02127645|Experimental|Early Rectal Cancer|patients with T1 - T2, N0, G1-2 rectal cancer
3065090|NCT02127632|Active Comparator|Group ETT (endo tracheal tube)|Group ETT (Endotracheal tube Group). In the ETT group for women no. 7-7.5 tube will use. ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
3065136|NCT02127320|Experimental|Sequence 4|Rosuvastatin 20mg and Ezetimibe 10mg → Ezetimibe 10mg → Rosuvastatin 20mg
3065091|NCT02127632|Experimental|Group LM-S(Laryngeal mask supreme Group)|Experimental: Group LM-S Group LM-S (Laryngeal mask supreme Group) For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) will insert.
3065092|NCT02127606|Experimental|Vibration with tilt-table standing|Participants in this arm will undergo alternating side-to-side, whole body vibration while standing on a tilt table for multiple treatments for a total of approximately 14 minutes for 3 sessions over 3 different days
3065093|NCT02127593|Experimental|First NGM/EE (Wet Process), then NGM/EE (Dry Process)|Participants will receive 1 tablet (formulated by wet process) containing norgestimate 250 microgram (mcg) and ethinyl estradiol 35 mcg, orally on Day 1 of Period 1, followed by 1 tablet (formulated by dry process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 2, wherein Period 1 and Period 2 are separated by a wash out period of at least 10 days.
3065094|NCT02127593|Experimental|First NGM/EE (Dry Process), then NGM/EE (Wet Process)|Participants will receive 1 tablet (formulated by dry process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 1, followed by 1 tablet (formulated by wet process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 2, wherein Period 1 and Period 2 are separated by a wash out period of at least 10 days.
3065095|NCT02127580||with BAV|Patients undergoing TA-TAVI WITH predilation of the AV (Group A)
3065096|NCT02127580||without BAV|Patients undergoing TA-TAVI WITHOUT predilation of the AV
3065097|NCT02127567|Experimental|Online writing tool|Participants will be provided the corresponding CONSORT item(s), key elements from the explanation and elaboration of the CONSORT 2010 and NPT extension along with examples of good reporting
3065098|NCT02127567|Other|writing with no specific support.|The control intervention will only consist of the title of the domain and a large text box where the participant will be asked to describe this part of the study for their study protocol. The participant will also have the option to indicate any important or necessary information that is not available in the provided study protocol.
3065099|NCT02127554||Electric coagulation|Patients with anterior epistaxis, treated with electric coagulation
3065100|NCT02127554||Chemical coagulation|Patients with anterior epistaxis, treated with chemical coagulation
3065101|NCT02127554||Outpatient tamponade|Patients with posterior epistaxis, treated with tamponade as an outpatient
3065102|NCT02127554||Inpatient tamponade|Patients with posterior epistaxis, treated with tamponade and kept in the hospital.
3065103|NCT02127554||Surgery|Patients with posterior epistaxis, treated with surgery as inpatients
3065104|NCT02127554||Foley balloon catheter|Patients with posterior epistaxis, treated as inpatients with Foley balloon catheter
3065105|NCT02127554||Combined treatment|Patients with posterior epistaxis, treated as inpatients with a combination of methods
3065106|NCT02127541|Experimental|Ga -exendin PET/CT, In- exendin SPECT/CT, MRI|This is a cross-over study comparing three imaging methods (68Ga-DOTA-exendin-4 PET/CT, 111In-DOTA-exendin-4 SPECT/CT, MRI) in the same patient.
3065107|NCT02127515|Experimental|Non Invasive Prenatal Testing|Blood sample
3065108|NCT02127515|Active Comparator|Invasive Prenatal Testing|CVS or amniocentesis
3065109|NCT02127502||Critically ill patients sepsis suspected|
3065110|NCT02127489|Active Comparator|Midazolam|1 mL/kg bupivacaine 0.25%.
3065111|NCT02127489|Placebo Comparator|saline|5mL rectal saline
3065112|NCT02127476|Experimental|KHK6640|KHK6640
3065113|NCT02127476|Placebo Comparator|Placebo|Placebo
3065114|NCT02127463|Experimental|MC-1101 active|Topical Drug 1% Ophthalmic Solution Topically, two times per day; morning and bedtime
3065115|NCT02127463|Placebo Comparator|MC-1101 Vehicle Control|"Topical Drug:~Ophthalmic Solution Topically, two times per day; morning and bedtime"
3065116|NCT02127450||Case: NS-CARB positive|Patient with a clinical sample positive for a NS-CARB Enterobacteriaceae
3065117|NCT02127450||Control 1: non-NS-CARB positive|Patient with clinical sample positive for a non-NS-CARB Enterobacteriaceae
3065118|NCT02127450||Control 2 : negative sample|Patient having had clinical sample(s) being stayed negative since the beginning of his admission and up to 3 days after the detection of the case
3065119|NCT02127437|Experimental|A - treated group|
3065120|NCT02127437|Placebo Comparator|B - control group|
3065121|NCT02127424|Experimental|Combination of the nurse-driven HIV targeted screening and the|Nurses will offer screening to all patients at EDs, aged 18-64 years old, identified as high-risk by a self-administered questionnaire, not know to be HIV positive, accepting to participate by providing an informed consent and not being seen at ED for post-exposure prophylaxis or unstable medical illness. The questionnaire was previously tested in one ED. In case of reactive rapid test result, blood specimen will be collected for standard enzyme-linked immunosorbent assay and Western blot confirmation. A follow-up visit with an on-site infectious disease specialist will be arranged within the following 48 hours.
3065122|NCT02127424|Active Comparator|Current practice (no intervention)|Physician-directed HIV diagnostic testing
3065123|NCT02127411|Experimental|Mindfulness-based relapse prevention|Mindfulness-Based Relapse Prevention
3065124|NCT02127411|No Intervention|Waitlist|this group will stay in the waitlist until the end of follow-up assessments, when they will receive the intervention
3065125|NCT02127398|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
3065126|NCT02127385||IUGR|
3065127|NCT02127359||Lung/Colon Adenocarcinomas|Metastatic lung and colon adenocarcinomas
3065128|NCT02127346||Chronic Periodontitis|"Male patients~Patients are suffering from chronic periodontitis~Patients do not have any systemic diseases~Subjects should have 20 teeth at least~Age: 30 years or greater"
3065129|NCT02127346||Healthy Volunteers|"Males~Healthy with no systemic diseases or periodontitis~30 years old at least~20 teeth are present at least"
3065130|NCT02127333||CAD patients with COPD|
3065131|NCT02127333||CAD patients without COPD|
3065132|NCT02127333||healthy volunteers|
3065133|NCT02127320|Experimental|Sequence 1|Rosuvastatin 20mg → Ezetimibe 10mg → Rosuvastatin 20mg and Ezetimibe 10mg
3065134|NCT02127320|Experimental|Sequence 2|Rosuvastatin 20mg and Ezetimibe 10mg→ Rosuvastatin 20mg → Ezetimibe 10mg
3065135|NCT02127320|Experimental|Sequence 3|Ezetimibe 10mg → Rosuvastatin 20mg and Ezetimibe 10mg → Rosuvastatin 20mg
3065138|NCT02127320|Experimental|Sequence 6|Rosuvastatin 20mg → Rosuvastatin 20mg and Ezetimibe 10mg → Ezetimibe 10mg
3065139|NCT02127294|Experimental|Transcatheter closure group|Migraine patients with patent foreman ovale (PFO)，who meet the criteria and agree to conduct closure of patent foramen ovale will be selected to this group.
3065140|NCT02127294|No Intervention|Contrast group|Migraine patients with PFO，who meet the criteria but don't agree to conduct closure of patent foramen ovale will be selected to this group.
3065141|NCT02127281|Active Comparator|Prevena|Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
3065142|NCT02127281|No Intervention|Control|A standard of care sterile wound dressing will be placed.
3065143|NCT02127268|Active Comparator|Arm T|Will be treated with Thymosin-α1 1.6mg twice a week from day 1 of chemotherapy
3065144|NCT02127268|No Intervention|Arm B|With best support according to NCCN Guideline
3065145|NCT02127255|Active Comparator|A (Acupuncturist 1)|Manual acupuncture implemented by acupuncturist 1 (clinical experience >15 years)
3065146|NCT02127255|Active Comparator|B (Acupuncturist 2)|Manual acupuncture implemented by acupuncturist 2 (clinical experience < 5 years)
3065147|NCT02127242|Experimental|air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
3065148|NCT02127242|No Intervention|hepatectomy group|Hepatic resection using an open approach is performed for all segments affected by biliary stenosis and the affected bile duct drainage area.Hepaticojejunostomy is performed in patients with common bile duct stenosis and in those considered to be at high risk for recurrence.
3065149|NCT02127229|No Intervention|Blinded observation of ERCP|Blind observation of disposable accessories use.
3065150|NCT02127229|Experimental|Endoscopist informed of cost per procedure|Endoscopists informed following each ERCP.
3065151|NCT02127216|No Intervention|Standard of Care Group - A|The control group
3065152|NCT02127216|Active Comparator|MOSES - Group B|Individual patients using application and pedometer without healthcare provider support
3065153|NCT02127216|Active Comparator|MOSES - Group C|Individual patients using application and pedometer with healthcare provider support
3065154|NCT02127216|Active Comparator|MOSES - Group D|Peer patient teams using application and pedometer without healthcare provider support
3065155|NCT02127216|Active Comparator|MOSES - Group E|Peer patient teams using application and pedometer with healthcare provider support
3065156|NCT02127203||Chronic Periodontitis group (ChP)|20 patients aged > 45 years and have presence of ≥2 non-adjacent sites per quadrant that were not first molars or incisors, with probing depth (PD) ≥5 mm, which bleed on gentle probing. The demonstrated radiographic bone loss ≥30% of the root length, patient with poor oral hygiene, the amount of accumulated plaque commensurate with the amount of clinical attachment level (CAL)
3065157|NCT02127203||Resistant Control group (R)|20 age-sex matched patients who are > 45 years exhibit no signs of periodontal disease as determined by the absence of the evidence of interproximal (CAL ≤ 1mm), PD > 3 mm at any site, whole-mouth bleeding scores <10% and have no clinical signs of gingival inflammation .
3065158|NCT02127203||Aggressive Periodontitis group (AgP)|20 patients who are aged < 35 years and diagnosed with rapid attachment loss with periodontal pocket depth (PD) > 4 mm around at least three teeth other than the first molars and incisors. Rapid bone destruction (>50%bone loss at diseased sites). Weak relationship between dental plaque and the severity of gingival inflammation.
3065159|NCT02127203||Young Control group (YC)|20 age- and sex matched patients who are < 35 years and exhibit no signs of periodontal disease.
3065160|NCT02127190|Placebo Comparator|CXA-10 placebo emulsion|single intravenous dose of CXA 10 placebo emulsion
3065161|NCT02127190|Experimental|CXA-10 Emulsion|single ascending intravenous doses of CXA-10 emulsion
3065162|NCT02127177|Experimental|Cpap|
3065163|NCT02127177|No Intervention|No Cpap|
3065164|NCT02127164|Experimental|"Veraflo device, Dakin's solution"|
3065165|NCT02127151|Experimental|BMN 673|BMN 673 daily until progression, death, unacceptable toxicity, withdrawal of consent or any other criterion felt by the Investigator to preclude continuation of treatment.
3065166|NCT02127138|Experimental|ATP technique|This arm plan to enroll 158 subjects，Sirolimus-eluting Drug stent implantation via Active transfer of Plaque technique in the treatment of unprotected distal left main bifurcation lesions.In the ATP technique treatment of bifurcation lesions, by the balloon pre-dilation in the target side branch, the plaque will be actively transferred from side branch to main vessel. Subsequently, the plaque will be fixed by the expansive stent in main vessel. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI or stent in SB is recommended if there is at least one of following: residual stenosis>70%, >type B dissection and TIMI flow<3.
3065167|NCT02127138|Active Comparator|Provisional T stenting technique|This arm plan to enroll 158 subjects.Sirolimus-eluting Drug stent implantation via Provisional T Stenting technique in the treatment of unprotected distal left main bifurcation lesions.Provisional T stenting technique is the typic step-T stenting. In brief, two wires are advanced to distal MV and SB. Pre dilation is left at operator's discretion, however, pre dilating SB is not encouraged. Kissing balloon inflation before stenting MV is left at operator's discretion. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI is recommended if there is at least one of following: residual stenosis>70%, >type B dissection and TIMI flow<3.
3065168|NCT02127125|Active Comparator|Type2 Diabetes Mellitus|"Type 2 Diabetes Mellitus (36 completers)~12 subjects will receive the synbiotic~12 subjects will receive sevelamer~12 subjects will receive maltodextrin (placebo)"
3065169|NCT02127125|Active Comparator|Obese with NGT|"Obese (BMI = 30-37 kg/m2) normal glucose tolerant (36 completers)~12 subjects will receive the synbiotic~12 subjects will receive sevelamer~12 subjects will receive maltodextrin (placebo)"
3065170|NCT02127125|Active Comparator|Lean with NGT|"Lean (BMI< 26 kg/m2) normal glucose tolerant (36 completers)~12 subjects will receive the synbiotic~12 subjects will receive sevelamer~12 subjects will receive maltodextrin (placebo)"
3065171|NCT02127112|Active Comparator|Block Allograft plus Matrix Allograft|The positive control treatment will include a block allograft plus a demineralized bone matrix moldable allograft.
3065172|NCT02127112|Experimental|Moldable Matrix Allograft|In the test arm of the study the treatment will include a demineralized bone matrix moldable allograft.
3065173|NCT02127099||Patients with OSA|Post operative patients with OSA
3065174|NCT02127099||Post-operative Patients without OSA|All post operative patients without OSA
3065175|NCT02127086|Experimental|Intervention Group|The study design is a non-randomized quasi-experimental cohort design with two cohorts who will be sequentially studied. In phase 1, patients will comprise the usual care group (UCG), or control cohort, defined as receiving pain assessment and management practices that nurses are currently performing on the study units. In phase 2 the PAIN Algorithm coupled with analgesic order sets will be introduced to nurses and physicians on all participating units as the intervention. Patients enrolled in this phase will be considered the intervention group (IG), also called the experimental cohort. Nurses will be enrolled from the participating inpatient units to provide data on the clinical utility of the PAIN Algorithm.
3065176|NCT02127086|No Intervention|Usual Care Group|The study design is a non-randomized quasi-experimental cohort design with two cohorts who will be sequentially studied. In phase 1, patients will comprise the usual care group (UCG), or control cohort, defined as receiving pain assessment and management practices that nurses are currently performing on the study units. In phase 2 the PAIN Algorithm coupled with analgesic order sets will be introduced to nurses and physicians on all participating units as the intervention. Patients enrolled in this phase will be considered the intervention group (IG), also called the experimental cohort. Nurses will be enrolled from the participating inpatient units to provide data on the clinical utility of the PAIN Algorithm
3065177|NCT02127073|Experimental|Oxytocin|Subjects would receive 4 IU of intranasal oxytocin; one spray in each nostril, single-use.
3065178|NCT02127060|Experimental|Vitamin C|in postoperative time, vitamin C administered orally with other pain analgesics.
3065179|NCT02127060|Placebo Comparator|Placebo drug|in postoperative time, vitamin C do not administered.
3065180|NCT02127047|Experimental|Sitagliptin|Patients receive Sitagliptin (100mg/d) without further intervention
3065181|NCT02127047|Experimental|Sitagliptin and exercise|Patients receive sitagliptin (100mg/d) and follow a physical training intervention program
3065182|NCT02127034|Experimental|Digoxin / digoxin + solifenacin and mirabegron|Digoxin alone then followed by digoxin with solifenacin and mirabegron
3065183|NCT02127034|Experimental|Digoxin + solifenacin and mirabegron / digoxin|Digoxin with solifenacin and mirabegron then followed by digoxin alone
3065184|NCT02127021|Experimental|Norzyme® 40000 IU|Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
3065185|NCT02127021|Placebo Comparator|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal. The formulation and the form of placebo is same with the Norzyme® 40000 IU. Placebo contains microcrystalline cellulose as the main component, titanium oxide, colloidal silica, yellow iron oxide, brown iron oxide, black iron oxide, magnesium stearate, triethyl citrate, talc, and simethicone emulsion in very small amount
3065186|NCT02127008|Experimental|Resection of epidural fat|During surgical procedure, epidural fat was resected fully.
3065187|NCT02127008|Active Comparator|No resection of epidural fat|During surgical procedure, the epidural fat was not resected.
3065188|NCT02126995|Experimental|Metadoxine Immediate/Slow-release|Flexed and fixed-dose Metadoxine Immediate/Slow-release 700 mg and 1400 mg administered orally once daily
3065189|NCT02126995|Placebo Comparator|Placebo|Placebo tablet identical in appearance to study investigational product. Administered orally once daily
3065190|NCT02126982||Clopidogrel hydrogen sulfate (CHS)|Clopidogrel hydrogen sulfate, 75 mg / day
3065191|NCT02126982||Clopidogrel Besylate (CB)|Clopidogrel Besylate , 75 mg / day
3065192|NCT02126969|Experimental|Chemotherapy plus Radiation Therapy|Low dose fractionated radiation - 80cGy with chemotherapy
3065193|NCT02126969|Active Comparator|Chemotherapy without Radiation|Chemotherapy only
3065194|NCT02126956|Experimental|ACT-128800|Subjects received a single oral dose of 40 mg 14C-labeled ACT-128800 (one capsule)
3065195|NCT02126943||Opsumit (macitentan)|10 mg tablets
3065196|NCT02126930|Active Comparator|Routine care|"The patients in this receive routine care.~Intervention: Routine care"
3065197|NCT02126930|Experimental|Pharma consult|"The patients in this arm will have a pharmaceutical consult upon hospital discharge.~Intervention: Pharma consult"
3065198|NCT02126917|Experimental|HC-ER + 40% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 40% Alcohol.
3065199|NCT02126917|Experimental|HC-ER + 20% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 20% Alcohol.
3065200|NCT02126917|Experimental|HC-ER + 0% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 0% Alcohol.
3065201|NCT02126904||IVR group|
3065202|NCT02126891|Experimental|Canoeists|13 canoeists from a training center of the French canoeing team
3065203|NCT02126891|Experimental|Military|10 young recruits in military school of officers in ground forces of the French army
3065204|NCT02126878|Active Comparator|Kenaglog 20mg|20mg/ 2ml and local anesthetic
3065205|NCT02126878|Active Comparator|Kenalog 40mg|40mg/ 2ml with local anesthetic
3065206|NCT02126878|Active Comparator|Kenalog 80mg|80mg/ 2ml and local anesthetic
3065207|NCT02126865|Experimental|BI 1060469 Healthy|Multiple rising dose qd for 15 days
3065208|NCT02126865|Placebo Comparator|Placebo to BI 1060469|Matching placebo as tablet for 15 days
3065209|NCT02126865|Experimental|BI 1060469 asthmatics|Multiple rising dose qd for 29 days
3065210|NCT02126865|Placebo Comparator|Placebo to BI 1060469 asthmatics|Matching placebo as tablet for 29 days
3065211|NCT02126852|Experimental|AMG (one-dimensionally) versus EMG|Neuromuscular monitoring in patients scheduled for surgery under general anesthesia
3065212|NCT02126852|Experimental|AMG (three-dimensionally) versus EMG|Neuromuscular monitoring in patients scheduled for surgery under general anesthesia
3065213|NCT02126839|Placebo Comparator|Placebo MDPI QID|Placebo multidose dry powder inhaler (MDPI) administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 3 weeks.
3094611|NCT01928472|Experimental|Group B|H7N9c medium dose with adjuvant
3065214|NCT02126839|Experimental|Albuterol MDPI 180 mcg QID|Albuterol multidose dry powder inhaler (MDPI) 90 mcg/inhalation administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for a total daily dose of 720 mcgs for 3 weeks.
3065215|NCT02126826|Placebo Comparator|Placebo to BI 1026706|Multiple Rising Doses Placebo to BI 1026706
3065216|NCT02126826|Experimental|BI 1026706|Multiple Rising Doses BI 1026706
3065217|NCT02126813|Active Comparator|500 ml.|A bladder volume of 500 ml. or more, and incapability of voluntary micturition, is used as interventional threshold for urinary bladder catheterization.
3065218|NCT02126813|Experimental|800 ml|A bladder volume of 800 ml. or more, and incapability of voluntary micturition, is used as interventional threshold for urinary bladder catheterization.
3065219|NCT02126787|Experimental|Intensive Group Analytic Psychotherapy|Intensive Group Analytic Psychotherapy in a day clinic setting
3065220|NCT02126787|Experimental|Intensive GCBT|Intensive transdiagnostic cognitive-behavioral group therapy in a day clinic setting
3065221|NCT02126787|No Intervention|Wait-list control group|
3065222|NCT02126774||focal epilepsy|observational study
3065223|NCT02126761|Active Comparator|Group 1|aTIV
3065224|NCT02126761|Experimental|Group 2|aTIV + 1X MF59
3065225|NCT02126761|Experimental|Group 3|aTIV + TIV
3065226|NCT02126761|Experimental|Group 4|aTIV + aTIV
3065227|NCT02126761|Active Comparator|Group 5|aTIV (Left deltoid) Saline (Right deltoid)
3065228|NCT02126761|Experimental|Group 6|aTIV+2X MF59 (Left deltoid) Saline (Right deltoid)
3065229|NCT02126761|Experimental|Group 7|aTIV (Left deltoid) aTIV (Right deltoid)
3065230|NCT02126748|Experimental|Intrapulmonary Percussive Ventilation|20 min of IPV administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
3065231|NCT02126748|Active Comparator|Assisted Autogenic Drainage|20 min of AAD administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
3065232|NCT02126748|No Intervention|control|20 min of bouncing administered tot the patient inhalation 4ml hypertonic saline 3% 3x/day
3065233|NCT02126722||Patients with dyspepsia on PPI|One hundred patients on PPI will be enrolled among the patients with dyspepsia referred for gastroscopy at Homerton University Hospital. On the day of the endoscopic procedure the patients will bring a stool sample for the detection of faecal Helicobacter pylori antigen. Subsequently, a gastroscopy with multiple biopsies will be performed and during the exam NISO Biomed EndoFaster test, as well as the Clo test, will be carried out.
3065234|NCT02126722||Patients with dyspepsia not on PPI|Fifty patients not on PPI will be enrolled among the patients with dyspepsia referred for gastroscopy at Homerton University Hospital. On the day of the endoscopic procedure the patients will bring a stool sample for the detection of faecal Helicobacter pylori antigen. Subsequently, a gastroscopy with multiple biopsies will be performed and during the exam NISO Biomed EndoFaster test, as well as the Clo test, will be carried out.
3065235|NCT02126709|Experimental|Treatment Arm|"Name: Repigel Active ingredient: Povidone iodine Dosage form: Liposomal hydrogel Administration route: Topical Strength: 3%~Application of study cream twice a day during the 8 week study period~It will be applied once in the morning and once in the night~We recommend the application to occur after the face is washed~One Finger Tip Unit is required per application to the entire face~The gel should be left on and not washed of for at least15 -30 minutes"
3065236|NCT02126709|Placebo Comparator|Placebo Arm|"Name: Neutrogena hydroboost gel Active ingredient: NA Strength: NA Dosage form: Water gel Administration route: Topical~Application of placebo cream twice a day during the 8 week study period~It will be applied once in the morning and once in the night~We recommend the application to occur after the face is washed~One Finger Tip Unit is required per application to the entire face~The gel should be left on and not washed of for at least15 -30 minutes"
3065237|NCT02126696||Patients on anti-retroviral therapy|The cohort consists of patients on first-line anti-retroviral therapy since at least 6 months, followed at one of the facilities involved in the study.
3065238|NCT02126683|Experimental|Plaquenil first|Start Plaquenil 200mg BID orally since enrollment Duration: 6 months
3065239|NCT02126683|Experimental|Plaquenil later|Start Plaquenil 200mg BID orally since the 25th week after enrollment Duration: 6 months
3065240|NCT02126670|Placebo Comparator|ACT01 plus Comp01|ACT01 Cream in combination with Comp01 Cream, once daily, 29 days
3065241|NCT02126670|Active Comparator|ACT01 plus Comp02|ACT01 Cream in combination with Comp02 Cream, once daily, 29 days
3065242|NCT02126670|Active Comparator|ACT01 plus Comp03|ACT01 Cream in combination with Comp03 Cream, once daily, 29 days
3065243|NCT02126670|Other|ACT01 plus Comp04|ACT01 Cream in combination with Comp04 Cream, once daily, 29 days
3065244|NCT02126657|Other|Single Arm|Single arm study - pre and post peel assessment
3065245|NCT02126644|Other|Single Arm|Single arm of 10 patients - efficacy and safety assessed pre and post peel
3065246|NCT02126618||women with lower urinary tract symptoms|
3065247|NCT02126592||PCOS cohort|Women with PCOS
3065248|NCT02126592||Control cohort|Women without PCOS
3065249|NCT02126579|Experimental|Arm A (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA administered in one skin location rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
3065250|NCT02126579|Experimental|Arm B (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
3065251|NCT02126579|Experimental|Arm C (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Resiquimod will be applied to the vaccine site immediately after the vaccine administration.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
3065252|NCT02126579|Experimental|Arm D (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Resiquimod will be applied to the vaccine site immediately after vaccine administration.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
3065320|NCT02126085|Experimental|No Intubation|Conscious sedation and non-invasive ventilatory support + endovascular recanalisation
3066058|NCT02120976|Experimental|Dose 9 JTT-252|Tablets, single dose in fasted condition
3065253|NCT02126579|Experimental|Arm E (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
3065254|NCT02126579|Experimental|Arm F (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Resiquimod will be applied to the vaccine site immediately after vaccine administration.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
3065255|NCT02126579|Experimental|Arm G(Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Resiquimod will be applied to the vaccine site immediately after vaccine administration.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
3065256|NCT02126579|Experimental|Arm E2|"Peptide Vaccine (LPV7) + IFA + PolyICLC vaccines administered in one skin location. Each vaccine will be administered in the same skin site for all 6 vaccines.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
3065257|NCT02126566|Experimental|Single Arm|Administration of light therapy - measurement of results before and after therapy
3065258|NCT02126553|Experimental|Lenalidomide|Lenalidomide starting dose: 10 mg by mouth on days 1- 28 of a 28 day cycle. If after one cycle, the patient has persistent evidence of (1) minimal residual disease or (2) morphologically active disease AND is tolerating their starting dose of lenalidomide, their dose may be increased to the next higher dose level for the remainder of the study. A maximum of 2 dose escalations per patient are allowed if well tolerated.
3065259|NCT02126540|Experimental|Primary Cohort|Main cohort; treatment Arm with Pantheris Atherectomy System
3065260|NCT02126527|Experimental|Treatment (auranofin and sirolimus)|Patients receive auranofin PO QD and sirolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3065261|NCT02126514|Experimental|AZD3293|7 subjects will receive AZD3293
3065262|NCT02126501|No Intervention|Sudden wean|When ready Nasal Continuous Positive Airway Pressure (NCPAP) will be removed from the neonate
3065263|NCT02126501|Active Comparator|Gradual pressure wean|NCPAP will be removed by gradually decreasing pressure over 24 hours once the weaning is decided
3065264|NCT02126488|Experimental|treadmill perturbation|treadmill slip perturbation
3065265|NCT02126488|Placebo Comparator|treadmill placebo|treadmill training placebo
3065266|NCT02126488|Sham Comparator|observation|observation training
3065267|NCT02126475||Healthy volunteers|
3065268|NCT02126475||Park patients|
3065269|NCT02126462|Experimental|30 µg Na-GST-1 + 30 µg Na-APR-1 (M74)|30 µg Na-GST-1/Alhydrogel plus 5 µg GLA-AF co-administered with 30 µg Na-APR-1 (M74)/Alhydrogel plus 5 µg GLA-AF
3065270|NCT02126462|Active Comparator|Hepatitis B vaccine|Hepatitis B vaccine co-administered with saline
3065271|NCT02126462|Experimental|100 µg Na-GST-1 plus 100 µg Na-APR-1 (M74)|100 µg Na-GST-1/Alhydrogel plus 5 µg GLA-AF co-administered with 100 µg Na-APR-1 (M74)/Alhydrogel plus 5 µg GLA-AF
3065272|NCT02126449|Experimental|Fasting mimicking diet|Short term fasting using Fasting mimicking diet around neoadjuvant chemotherapy (AC>T)
3065273|NCT02126449|No Intervention|regular diet|Standard neoadjuvant chemotherapy (AC>T)
3065274|NCT02126436|Active Comparator|Acupuncture|"Eight treatments of acupuncture will be given to participants twice weekly over four weeks. A combination of body and auricular acupuncture will be given and treatment will be pragmatic.~In addition the group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff)."
3065275|NCT02126436|Other|Usual care|The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
3065276|NCT02126423||1st intravitreal injection|Conjunctival and nasopharyngeal swabs are obtained from each treatment-naive patient receiving their 1st intravitreal injection
3065277|NCT02126423||>20 intravitreal injections|Conjunctival and nasopharyngeal swabs are obtained from each patient with >20 intravitreal injection therapies.
3065278|NCT02126397|Active Comparator|polyps resection with Laser Diode|application of the laser diode by hysteroscopy to remove the endometrial polyp
3065279|NCT02126397|Active Comparator|polyps resection with bipolar electrode|application of the bipolar electrode Versapoint by hysteroscopy to remove the endometrial polyp
3065280|NCT02126384|Experimental|pneumovax|Single arm, open label pneumovax vaccination of healthy subjects
3065281|NCT02126371|Other|Active|LEO32731
3065282|NCT02126358|Placebo Comparator|Gemigliptin|only Gemiglitpin (Gemiglitpin/Rosuvastatin FDC:Placebo , Rosuvastatin :Placebo)
3065283|NCT02126358|Placebo Comparator|Rosuvastatin|only Rosuvastatin (Gemiglitpin/Rosuvastatin FDC:Placebo , gemigliptin :Placebo)
3065284|NCT02126358|Experimental|FDC|Gemigliptin & Rosuvastatin (Gemiglitpin only:Placebo ,Rosuvastatin only:Placebo)
3065285|NCT02126345||MASTER SL|
3065286|NCT02126332|Other|Conventional group|"2 groups: a  conventional group  in which available guidelines on analgesia are applied, and an  EA  group in which patients receive thoracic EA for at least 3 days."
3065287|NCT02126332|Experimental|EA group (Epidural anesthesia )|"2 groups: a  conventional group  in which available guidelines on analgesia are applied, and an  EA  group in which patients receive thoracic EA for at least 3 days."
3065288|NCT02126319|Experimental|Cognitive Affective Preparation|"Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)"
3065321|NCT02126072|Experimental|Alcohol|The study is a randomized single blinded trial in cross over design. Subjects are randomized to drink alcohol in one session and water in another session.
3065322|NCT02126072|Active Comparator|Water|Water in the same volume as the volunteer would have to drink in wine according to the protocol.
3094612|NCT01928472|Experimental|Group C|H7N9c high dose with adjuvant
3065289|NCT02126319|Active Comparator|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
3065290|NCT02126306|Placebo Comparator|Placebo|Normal saline administered orally daily as a placebo
3065291|NCT02126306|Active Comparator|Beta Glucosylceramide|Beta glucosylceramide administered orally daily
3065292|NCT02126293|Experimental|Zinc deficient patients|If the patient is found to be zinc deficient (serum zinc < 11.5 μmol/L), the family will be contacted by the RA to commence zinc supplement: zinc citrate (Zinc Lozenges, manufactured by Douglas Laboratories Inc, London, ON, Health Canada NPN 80032476) for 3 months. As per the NPN licence the dose is 10 mg (1 lozenge) orally once a day for children age 4-8 years, and 10 mg twice a day for children age 9-18 years. This should give enough time to restore serum zinc to normal in most patients.
3065293|NCT02126293|Active Comparator|Zinc sufficient patients|Zinc sufficient patients will repeat blood and urine tests in 3 month time to compare the changes with intervention arm.
3065294|NCT02126280||Subclinical atherosclerosis|In vitro estimation of individual reactivity of monocytes in study participants with asymptomatic atherosclerotic plaques found in carotid arteries by ultrasound examination
3065295|NCT02126280||Healthy subjects|In vitro estimation of individual reactivity of monocytes in study participants without ultrasound signs of subclinical carotid atherosclerosis
3065296|NCT02126280||Diffuse intimal thickening|In vitro estimation of individual reactivity of monocytes in study participants with diffuse intima-media thickening of carotid arteries found at ultrasound examination
3065297|NCT02126267|Experimental|Full mouth disinfection - FMD|n = 10: Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days
3065298|NCT02126267|Experimental|FMD + chlorhexidine (FMD-CX)|n = 15: Same as FMD with the inclusion of chlorhexidine in office (application of chlorhexidine (CX) (1%) gel in pockets after scaling, brushing tongue for 1 min. with CX (1%) gel and mouthwash at the beginning and end of each session with CX 0.2% for 30 seconds (with the form of a gargle in the last 10 seconds)). In addition, use was made of homemade CX 0.2% for 60 days after the scaling in a single phase.
3065299|NCT02126267|Experimental|FMD + azithromycin (FMD-AZ)|n = 15: Same as with the FMD include the use of azithromycin (500 mg) once daily for 3 consecutive days. Medication was started the same day as the end of the scaling.
3065300|NCT02126267|Experimental|Scaling and root planing (SRP)|(n = 13): scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;
3065301|NCT02126267|Experimental|SRP + azithromycin (SRP-AZ)|n = 11: Same as scaling and root planing group (SRP) with inclusion of the use of azithromycin (500 mg) once daily for 3 consecutive days. Medication was started the same day as the end of the last scaling hemi-arch;
3065302|NCT02126267|Experimental|SRP + chlorhexidine (SRP-CX)|n = 13 : Same as group scaling and root planing (SRP) with the inclusion of home use of CX 0.2% for 60 consecutive days after the end of the first session of scaling
3065303|NCT02126254|No Intervention|Control group|Control group will be treated in the cardiology and internal medicine departments according to the guidelines for the management of Heart Failure
3065304|NCT02126254|Active Comparator|Hemodynamic group|Hemodynamic group patients will be examined in the cardiology and internal medicine departments and treated according to the NICaS system in addition to current guidelines. Patients in this group will be tested within 12 hours from hospitalization and thereafter on an everyday basis until discharge
3065305|NCT02126241|Experimental|NICaS guided CRT optimization|For each subject, we will determine a set of AV and VV delays values, for which the NICaS measured CO will be maximum. In each patient, the CRT device will then be programmed according to these values.
3065306|NCT02126215||Study group - MRI CO2 stress test|This is a pilot study to assess feasibility of using MRI CO2 stress testing to predict POD.
3065307|NCT02126202|No Intervention|Conservative therapy|Optimized medical therapy
3065308|NCT02126202|Experimental|Invasive therapy|Coronary angiography and revascularization if feasible
3065309|NCT02126189||Head and neck cancer|All patients presenting to the Head and Neck Cancer Clinic at the Princess Alexandra Hospital, Brisbane, Australia are invited to participate.
3065310|NCT02126163|Experimental|Treatment Group|The treatment group will receive three interactive Computer Tailored Intervention (CTI) sessions during the course of six months, which will include tailored feedback based on the user's responses, and two assessment only follow-up sessions at twelve and eighteen months.
3065311|NCT02126163|No Intervention|Control Group|The control group will receive four assessment only sessions during 18 months.
3065312|NCT02126150||Ethnicity|
3065313|NCT02126137|Experimental|Ezetimibe|Ezetimibe administered by mouth 10 mg BID for 12 weeks
3065314|NCT02126124|Active Comparator|Active dTMS Treatment|Brainsway Deep TMS Treatment
3065315|NCT02126124|Sham Comparator|Sham Treatment|Brainsway Sham Treatment
3065316|NCT02126111|Active Comparator|DEPIGOID phleum|The active treatment arm receive active phleum pollen immunotherapy (Depigoid 100% phleum). Depigmented and polymerized allergen extract of Phleum pollen for subcutaneous injection.
3065317|NCT02126111|Placebo Comparator|DEPIGOID Placebo & DEPIGOID Phleum|"This arm receive DEPIGOID Placebo during the first year, and DEPIGOID Phleum during the second year of study.~DEPIGOID Placebo contains the same composition as in the active DEPIGOID Phleum with the only difference being the exclusion of the phleum pollen allergen extract."
3065318|NCT02126098||Adults who diagosed ANCA-vasculitis|"Patients with Wegener's granulomatosis or microscopic polyangiitis were eligible to participate in the study if they had~Positive serum assays for proteinase 3-ANCA or myeloperoxidase-ANCA~manifestations of severe disease,11 and a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 3 or more (scores range from 0 to 63, with higher scores indicating more active disease)"
3065319|NCT02126085|Active Comparator|Intubation|Intubation and invasive mechanical ventilation + endovascular recanalisation
3066059|NCT02120963|Experimental|intervention program|Person-centered physical therapy intervention program
3065323|NCT02126059|Experimental|Cognitive stimulation|One cognitive stimulation session per week for a continuous 10 weeks, each session contains 50 minutes, totally 10 session topics related to cognitive stimulation.
3065324|NCT02126059|Experimental|Aroma-massage|One hand and shoulder massage session per week for a continuous 10 weeks, each session contains 30 minutes, totally 10 session massage.
3065325|NCT02126059|Experimental|reminiscence|One reminiscence session per week for a continuous 10 weeks, each session contains 50 minutes, totally 10 session topics related to reminiscence.
3065326|NCT02126059|No Intervention|Control|Control group remain regular activities
3065327|NCT02126046|Other|Hi-HSC-CBT|
3065328|NCT02126033|Experimental|celiac disease|
3065329|NCT02126020|Experimental|topical infliximab|topical infliximab 10 mg/mL QID x 3 months followed by BID x 9 months
3065330|NCT02126007|Experimental|Sleep and Rhythm Intervention|This arm receives a 4-week behavioral intervention aimed at improving sleep and circadian rhythms, and thereby reducing fatigue.
3065331|NCT02126007|Placebo Comparator|Dietary Modifications|This arm receives a 4-week placebo intervention focused on dietary modifications for reducing fatigue.
3065332|NCT02125994|Active Comparator|Ropivacaine 0.5%|Ultrasound guided Intercalene nerve block with ropivacaine 0.5 %
3065333|NCT02125994|Active Comparator|Ropivacaine 0.375 %|Ultrasound guided Intercalene nerve block with ropivacaine 0.375 %
3065334|NCT02125981|Experimental|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
3065335|NCT02125981|Placebo Comparator|Control|taking placebo drug
3065336|NCT02125968|Active Comparator|interactive video game|"Participants in interactive video game group receive six 20-min sessions of hot pack therapy combined 20-min of diathermy therapy over the low back followed by 15-min interactive video game intervention, for 3 times per week for a 2-week duration.~Short- and medium-term therapeutic effects of interactive video game intervention for patients with chronic low back pain will be assessed."
3065337|NCT02125968|Sham Comparator|therapeutic exercise|"Participants received six 20-min sessions of hot pack therapy combined 20-min of diathermy therapy over the low back followed by 15-min supervised therapeutic exercise,for 3 times per week for a 2-week duration.~short- and medium-term therapeutic effects of video game play therapy for patients with chronic low back pain will be evaluated."
3065338|NCT02125955|Experimental|Prebiotic fiber|The intervention group will consume an 8 gram dose of prebiotic fiber one time per day approximately 30 minutes prior to their evening meal.
3065339|NCT02125955|Placebo Comparator|Placebo|The placebo group will consume an isocaloric dose of placebo (maltodextrin; 3.3 grams) one time per day approximately 30 minutes prior to their evening meal.
3065340|NCT02125942|Experimental|meditation|Central Meditation and Imagery Therapy
3065341|NCT02125942|No Intervention|wait list|waiting list
3065342|NCT02125929|Experimental|robotic arm|robotic surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 50
3065343|NCT02125929|Experimental|Laparoscopic surgery|laparoscopic surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 50
3065344|NCT02125929|Experimental|Open surgery|Open surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 100
3065345|NCT02125916|Experimental|COLD without long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
3065346|NCT02125916|Experimental|COLD with long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
3065347|NCT02125916|Experimental|ILD without long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
3065348|NCT02125916|No Intervention|Controls|Driving in the simulator one time without oxygen therapy
3065349|NCT02125903|Active Comparator|Continuous Adductor Canal Block (CACB)|"Continuous Adductor Canal block performed with:~loading dose 0,375% Ropivacaine 15ml (56,25mg) start infusion 0,2% Ropivacaine 6ml/h~Procedure: Femoral Nerve Block. Adductor Canal Block Drug: Ropivacaine"
3065350|NCT02125903|Active Comparator|Continuous Femoral Nerve Block (CFNB)|"Continuous Femoral Nerve Block performed with:~loading dose 0,375% Ropivacaine 15ml (56,25mg) start infusion 0,2% Ropivacaine 6ml/h~Procedure: Femoral Nerve Block. Adductor Canal Block Drug: Ropivacaine"
3065351|NCT02125890|Experimental|Tranexamic Acid|We will be administering Tranexamic Acid in patients with ruptured abdominal aortic aneurysms to determine if this has an effect on primary outcome measures as significant bleeding, blood transfusion requirements.
3065352|NCT02125877|Active Comparator|Deferasirox dispersible tablet (DFX-DT)|Iron chelation naïve participants received DFX-DT 20 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 5 to 10 mg/kg/day, with a maximum dose of 40 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose.
3065353|NCT02125877|Experimental|Deferasirox film-coated tablet (DFX-FCT)|Participants received DFX-FCT 14 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 3.5 to 7 mg/kg/day, with a maximum dose of 28 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose
3065354|NCT02125864|Experimental|Aflibercept|
3065355|NCT02125851|Experimental|Xanthan Gum|"A total of 12 subject will be administered sucralose slurry and the xanthan gum slurry. Six will get sucralose first (then an hour later the xanthan gum) and 6 will receive the xanthan gum first (then an hour later the sucralose slurry).~The sucralose slurry will which will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 10 grams of sucralose and 1 millicurie (mCi) of Tc99m-Sulfur Colloid.~The xanthan gum-budesonide slurry will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 1ml of xanthan gum gel, crystallized orange flavoring agent, and 1mCi of Tc99-Sulfur colloid."
3065356|NCT02125851|Experimental|Honey|"A total of 12 subject will be administered sucralose slurry and the honey slurry. Six will get sucralose first (then an hour later the honey) and 6 will receive the honey first (then an hour later the sucralose slurry).~The sucralose slurry will which will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 10 grams of sucralose and 1 millicurie (mCi) of Tc99m-Sulfur Colloid.~The honey-budesonide slurry will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 6ml of honey and 1mCi of Tc99-Sulfur Colloid."
3065535|NCT02124512|Experimental|Arm 1 Rifaximin SSD|Subjects randomized to this arm of the study will receive 80 mg per day Rifaximin SSD
3065357|NCT02125838|Active Comparator|Group ETT|Group endotracheal tube In the endotracheal tube group for women no. 7-7.5 tube will use. ETT:Rüschelit, Teleflex Medical Sdn. Bhd. Malaysia. Ref:112482
3065358|NCT02125838|Experimental|Group LMS|Laryngeal mask airway-supreme Group In the LMS group for <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) will insert.
3065359|NCT02125825||Parkinson's disease on levodopa|Individuals with Parkinson's disease who are taking levodopa to treat motor symptoms
3065360|NCT02125812|Placebo Comparator|scaling and root planing|scaling and root planing
3065361|NCT02125812|Experimental|scaling and systemic moxifloxacin|scaling and root planing combined with systemic moxifloxacin
3065362|NCT02125799|Experimental|Accelerated HF-rTMS|Twice daily rTMS sessions involving 10 Hz in 75 trains of 4 seconds duration, with 26 seconds intertrain intervals (6,000 pulses per day) at 120% of the resting motor threshold.
3065363|NCT02125786|Experimental|Stratum 1: Local Failure|"Participants exhibit an initial pattern of failure that is local (disease confined to primary site). Treatment is surgery and a second course of focal irradiation. The total dose for the second course of irradiation will be 54Gy.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
3065364|NCT02125786|Experimental|Stratum 2: Metastatic Failure|"Participants exhibit an initial pattern of failure that is metastatic (neuraxis metastatic disease without equivocal evidence of local failure). Treatment is surgery and craniospinal irradiation. Craniospinal irradiation (36-39.6Gy) will include focal boost treatment of metastatic sites (54-59.4Gy) depending on location, extent of resection and target volume.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
3065365|NCT02125786|Experimental|Stratum 3: Local and Metastatic Failure|"Participants exhibit an initial pattern of failure that is both local and metastatic (neuraxis metastatic disease with equivocal evidence of local failure). Treatment is surgery and craniospinal irradiation.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
3065366|NCT02125786|Experimental|Stratum 4: Local Failure|"Local Failure Participants exhibit an initial pattern of failure that is local (disease confined to primary site). Age is >36 months at time of enrollment to <21 years. Tumor shows presence of 1g gain. Treatment is optional craniospinal irradiation.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
3065367|NCT02125773|Experimental|Informed Risk Score|Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator.
3065368|NCT02125773|No Intervention|Control|Subjects in the control arm will not be provided with the results of the risk calculators.
3065369|NCT02125760|Sham Comparator|Inspiratory Muscle Training (IMT)|Patients with subacute stroke in a neurorehabilitation setting.
3065370|NCT02125760|Experimental|High-intensity IMT|Patients with subacute stroke in a neurorehabilitation setting.
3065371|NCT02125747|Other|No Respiratory Therapy|Patients with acute exacerbation of chronic obstructive pulmonary disease. Patients received conventional treatment.
3065372|NCT02125747|Experimental|Respiratory therapy|Patients with acute exacerbation of chronic obstructive pulmonary disease. Patients received conventional treatment and Respiratory Therapy
3065373|NCT02125734|Experimental|Treatment sequence 1|QVA149 from day 1 to day 28 and tiotropium from day 29 to day 56
3065374|NCT02125734|Experimental|Treatment sequence 2|Tiotropium from day 1 to day 28 and QVA149 from day 29 to day 56
3065375|NCT02125721|Experimental|Increasing doses of CBTD|Intervention: CBTD 0-3 gm
3065376|NCT02125708|Other|OvulaRing®|Twenty patients with verified PPROM between gestation week 22 and 27 should be included. After gynecological and physical examination within verification of PPROM women will be informed about the study and invited to participate in this study. Subsequently informed consent will be obtained and the OvulaRing® placed into the vaginal fornix.
3065377|NCT02125695||Healthy Volunteers|Skin taping; blood sampling; optional biopsy
3065378|NCT02125695||Cutaneous lupus erythematosus|This group consists of participants affected with lupus (DLE, SCLE). Skin taping; blood sampling; optional skin biopsy (DLE participants); required skin biopsy (SCLE participants)
3065379|NCT02125695||Atopic dermatitis|Skin taping; blood sampling; optional skin biopsy
3065380|NCT02125682|Active Comparator|low dose|patients receiving 10 mg of atorvastatin daily
3065381|NCT02125682|Active Comparator|High dose|Patients receiving 80 mg of atorvastatin daily
3065382|NCT02125669|Active Comparator|Laser Treatment|Pulsed dye laser 595nm
3065383|NCT02125669|Sham Comparator|SHAM Treatment|using the pulsed dye laser (PDL) laser without releasing a pulse
3065384|NCT02125656|No Intervention|Regular Sleep|A single night of regular sleep
3065385|NCT02125656|No Intervention|Sleep Deprivation|A single night of sleep deprivation
3065386|NCT02125656|Experimental|HIIT + Regular Sleep|2 weeks of HIIT and after a single night of regular sleep.
3065387|NCT02125656|Experimental|HIIT + Sleep Deprivation|2 weeks of HIIT and after a single night of sleep deprivation
3065388|NCT02125643|Active Comparator|Caffeine Pill|The caffeine will be administered.
3065389|NCT02125643|Placebo Comparator|Placebo/Flour Pill|The flour will be administered.
3065390|NCT02125630||Systemic therapy|Standart chemotherapy
3065391|NCT02125630||Primary surgery|Standart surgery
3065392|NCT02125617||Castration-resistant prostate cancer, Progression after taxane|Treated with abiraterone 1000 mg/day Prednisolone 10 mg/day
3065393|NCT02125604|Experimental|Dimethyl Fumarate|Dimethyl fumarate administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.
3065394|NCT02125591|Experimental|Active PoNS CN-NINM|Active CN-NINM PoNS - Active cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
3065395|NCT02125591|Sham Comparator|Sham PoNS CN-NINM|Sham CN-NINM PoNS - Sham cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
3065536|NCT02124512|Placebo Comparator|Arm 2 Placebo|Placebo
3065396|NCT02125578|Experimental|BIIB017 (PEGylated Interferon Beta-1a)|Varying doses (63 mcg up to 188 mcg) of BIIB017 will be administered SC every other week for a total of 6 weeks.
3065397|NCT02125578|Experimental|BIIB017 (PEGylated Interferon Beta-1a) and Placebo|Varying doses (63 mcg up to 188 mcg) of BIIB017 will be administered SC every 4 weeks for a total of 6 weeks. To ensure blinding, each subject will receive placebo every other week.
3065398|NCT02125578|Placebo Comparator|Placebo|Placebo dose will be administered SC every other week for a total of 6 weeks.
3065399|NCT02125565|Experimental|Local Anaesthesia|These subjects received an injection of lidocaine 1% 2ml subcutaneously prior to arterial puncture
3065400|NCT02125565|No Intervention|No Local Anaesthesia|Patients underwent arterial puncture directly with NO prior anaesthesia
3065401|NCT02125552|Experimental|Ultrasound guided intravenous access|This group will have their IV placed by ultrasound guidance.
3065402|NCT02125552|Placebo Comparator|Traditional intravenous access|The patients randomized to traditional IV access will have their IVs placed by standard technique.
3065403|NCT02125539|Experimental|Navigating my Journey program|Client participants of counselors who were randomized to the experimental condition will receive the following intervention: The online Navigating my Journey relapse prevention program is an adjunct to outpatient treatment. We will ask client participants to complete at least 12 Navigating my Journey sessions and discuss them with their counselors.
3065404|NCT02125539|Active Comparator|Attention Control|Client participants of counselors who were randomized to the control condition will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
3065405|NCT02125526|Active Comparator|IABP group|After primary percutaneous coronary intervention, IABP will be implanted for 12-24 hours to alleviate persisting ischemia
3065406|NCT02125526|No Intervention|Control group|After primary percutaneous coronary intervention, this group undergoes standard treatment according to the guidelines
3065407|NCT02125513|Active Comparator|Arm A: 3 courses|Patients will receive 3 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15.
3065408|NCT02125513|Experimental|Arm B: 6 courses|Patients will receive 6 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15.
3065409|NCT02125500|Experimental|Sofosbuvir/Ledipasvir|"Non-cirrhotic patients will receive SOF/LDV Fixed Dose Combination (FDC) for 12 weeks.~Cirrhotic patients will receive SOF/LDV Fixed Dose Combination (FDC) for 24 weeks."
3065410|NCT02125487|Active Comparator|Low-Fidelity Simulation|Teaching using traditional method
3065411|NCT02125487|Experimental|Hybrid Simulation|Teaching using Hybrid Simulation of breast examination
3065412|NCT02125474|Experimental|[177Lu] DOTA-TATE|We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-[DOTA 0, Tyr 3] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
3065413|NCT02125461|Experimental|MEDI4736|MEDI4736 (intravenous infusion)
3065414|NCT02125461|Placebo Comparator|PLACEBO|Placebo (matching placebo for intravenous infusion)
3065415|NCT02125448||Resectable esophageal cancer|Neoadjuvant chemoradiotherapy. MRI and PET-CT.
3065416|NCT02125435|Experimental|ASP2408 dose escalation cohort|
3065417|NCT02125435|Placebo Comparator|Placebo dose escalation cohort|
3065418|NCT02125422|Experimental|Cefaly tDCS|"Cathodal Cefaly tDCS is delivered over the visual cortex at 2 mA of intensity, for 20 minutes, for 5 consecutive days in 9 HV. The anode is placed over the left DLPFC.~2 mA anodal tDCS is delivered over the visual cortex, for 20 minutes, for 5 consecutive days in 9 HV"
3065419|NCT02125409|Experimental|Group 1|Group 1, individuals will be treated with ASA for 1 week; then blood and tissue samples (during the screening colonoscopy) will be collected at from 6-7 h after the last dose of ASA.
3065420|NCT02125409|Experimental|Group 2|Group 2, individuals will be treated with ASA for 1 week; then blood and tissue samples (during the screening colonoscopy) will be collected at 24 hours after the last dose.
3065421|NCT02125396|Experimental|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
3065422|NCT02125396|Active Comparator|Transarterial chemoembolization|Adjuvant transarterial chemoembolization [5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)]
3065423|NCT02125383|Experimental|Active tDCS|Receives 20 minutes of anodal tDCS three times while sleeping during the night.
3065424|NCT02125383|Sham Comparator|Sham tDCS|Receives 20 minutes of sham tDCS three times while sleeping during the night.
3065425|NCT02125370||Nicotine Replacement Therapy|
3065426|NCT02125357|Other|A - Abiraterone Acetate|Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care, or until PSA progression then cross-over to Arm B.
3065427|NCT02125357|Other|B - Enzalutamide|160mg PO OD as per standard of care, or until PSA progression then cross-over to Arm A.
3065428|NCT02125344|Experimental|PM(Cb)|"PM(Cb):~paclitaxel 80mg/m² 18 times weekly simultaneously with NPLD (Myocet®)20mg/m² 18 times weekly simultaneously with carboplatin AUC 1.5 18 times weekly (only in patients with TNBC) Patients with HER2-positive disease will receive trastuzumab 6 (8) mg/kg every 3 weeks and pertuzumab 420 (840) mg every 3 weeks simultaneously to all cycles."
3065429|NCT02125344|Active Comparator|ETC|"ETC:~epirubicin 150mg/m² every 2 weeks for 3 cycles followed by paclitaxel 225 mg/m² every 2 weeks for 3 cycles followed cyclophosphamide 2000 mg/m² every 2 weeks for 3 cycles. Patients with HER2-positive disease will receive trastuzumab 6 (8) mg/kg every 3 weeks and pertuzumab 420 (840) mg every 3 weeks simultaneously to all T and C cycles."
3065430|NCT02125331|Other|PDM-SuperSTAT|PDM-SuperSTAT Arm (minimum of 55 evaluable patients): GE DINAMAP® SuperSTAT algorithm delivered by the PDM acquisition module connected to the CARESCAPE Monitor B650
3065431|NCT02125331|Other|PSM-Datex-Ohmeda|PSM-Datex-Ohmeda Arm (minimum of 45 evaluable patients): Datex-Ohmeda delivered by the PSM acquisition module connected to the CARESCAPE Monitor B650
3065432|NCT02125318|Experimental|Anagrelide CR (GALE-401)|
3065433|NCT02125305|Experimental|Metformin|Metformin 750mg(D1), Metformin 500mg(D2)
3065434|NCT02125292|Experimental|Mesalamine (Vanilla Yogurt)|One 500mg capsule contents sprinkled onto 1 tablespoon of low-fat vanilla yogurt
3065435|NCT02125292|Experimental|Mesalamine (Applesauce)|One 500mg capsule contents sprinkled onto 1 tablespoon of applesauce
3065436|NCT02125292|Experimental|Mesalamine (Dosing Cup)|One 500mg capsule contents emptied into a dosing cup and taken with water
3065437|NCT02125279|Experimental|Calcitriol ointment|
3065438|NCT02125266|Experimental|Low Dose V404 PDS|Sustained intravitreal delivery of methotrexate (0.6 mg)
3065439|NCT02125266|Experimental|High Dose V404 PDS|Sustained intravitreal delivery of methotrexate (2.3 mg)
3065440|NCT02125253|Experimental|Mometasone Furoate Nasal Spray, 50 mcg|Mometasone Furoate Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
3065441|NCT02125253|Active Comparator|Nasonex Nasal Spray, 50 mcg|Nasonex (mometasone furoate monohydrate) Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
3065442|NCT02125253|Placebo Comparator|Placebo Nasal Spray|Placebo of Mometasone Furoate Nasal Spray. 4 actuations per day for 14 days.
3065443|NCT02125240|Experimental|Icotinib|125 mg three times daily (375 mg per day) by mouth
3065444|NCT02125240|Active Comparator|Placebo|1 tablet three times daily by mouth
3065445|NCT02125227|Experimental|Group 1 of Study A|single dosing of Rosuvastatin and Metformin 14 days later, single dosing of YH14755
3065446|NCT02125227|Experimental|Group 2 of Study A|single dosing of YH14755 14 days later, single dosing of Rosuvastatin and Metformin
3065447|NCT02125227|Experimental|Group 1 of Study B|single dosing of YH14755 with fasting state 14 days later, single dosing of YH14755 after having breakfast
3065448|NCT02125227|Experimental|Group 2 of Study B|single dosing of YH14755 after having breakfast 14 days later, single dosing of YH14755 with fasting state
3065449|NCT02125214|Experimental|ASA 1-2|ASA 1-2 patients 20-40 yr
3065450|NCT02125201|Experimental|intranasal fentanyl|Intranasal Fentanyl 1.5-2 mcg/kg
3065451|NCT02125201|Active Comparator|intravenous fentanyl|Intravenous Fentanyl 1-1.5 mcg/kg
3065452|NCT02125188|Experimental|Desmopressin|Desmopressin 3ug/kg in saline 100ml ivdrip before surgery
3065453|NCT02125188|Placebo Comparator|saline|saline 100ml ivdrip before surgery
3065454|NCT02125175|Experimental|Hypofractionated IMRT boost Radiotherapy|
3065455|NCT02125162|Experimental|Treatment A|BCX4161 400 mg formulated as hard gelatin capsules given orally under fasting conditions x1
3065456|NCT02125162|Experimental|Treatment B|BCX4161 400 mg formulated as soft gelatin capsules given orally under fasting conditions x1
3065457|NCT02125162|Experimental|Treatment C|BCX4161 400 mg formulated as soft gelatin capsules given orally after a high-fat breakfast x1
3065458|NCT02125149|No Intervention|Control|Standard of care
3065459|NCT02125149|Experimental|Intervention|Exercise intervention from 12 week gestation until delivery
3065460|NCT02125136|Experimental|Gem/nab-Pac|2 further cycles Gem/nab-Pac (duration of each cycle 28 days)
3065461|NCT02125136|Experimental|FOLFIFINOX|4 cycles combination therapy with 5-fluorouracil/folinic acid, irinotecan, oxaliplatin (FOLFIFINOX) - duration of each cycle 14 days
3065462|NCT02125123|Experimental|Nutritional Supplement and Counseling|Two servings a day; ready-to-feed nutritional supplement plus dietary counseling
3065463|NCT02125123|Active Comparator|Counseling|Dietary Counseling
3065464|NCT02125110|Experimental|study group (cohort PELAGIE)|100 children included in the cohort PELAGIE
3065465|NCT02125110|Experimental|pilot group (no cohort PELAGIE)|10 children not included in the PELAGIE cohort to optimise MRI
3065466|NCT02125097|Experimental|Intracranial Aneurysm Treatment|Barrel™ Vascular Reconstruction Device (VRD) is Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio < 2.
3065467|NCT02125084|Experimental|Everolimus and Enzalutamide|"Dose Escalation Phase (18 patients): 3-6 patients will be treated at each dose level until the Maximum Tolerated Dose (MTD) is determined.~Everolimus: Orally (PO) once daily (dose to be determined;~Enzalutamide: 160mg (four 40mg capsules) PO continuous daily dosing.~Dose Expansion Phase (23 patients): Everolimus and Enzalutamide to be administered using the MTD determined in the dose escalation phase."
3065468|NCT02125071||Hepabig|Those who receiving I.V. Hepabig injection used for prevention of hepatitis B relapse after liver transplantation
3065469|NCT02125058|Other|Transcutaneous sutures|Transcutaneous sutures
3065470|NCT02125058|Other|Intracutaneous sutures|Intracutaneous sutures
3065471|NCT02125045|Experimental|L-GSH|Glutathione 100 mg tablets twice a day
3065472|NCT02125045|Placebo Comparator|Placebo|Matching placebo will be administered for 4 weeks in a double blind fashion.
3065473|NCT02125032|Active Comparator|Transcranial pulsed electromagnetic fields (T-PEMF)|One group receives 8 weeks of active T-PEMF treatment and another group receives 8 weeks of placebo T-PEMF. Both treatments to be performed 30 minutes once a day.
3065474|NCT02125032|Placebo Comparator|Trancranial electromagnetic pulsed fields (T-PEMF)|8 weeks of T-PEMF treatment placebo.
3065475|NCT02125019||Breast cancer patients|This is a single arm study evaluating feasibility of evaluating gait and parameter changes in patients with early stage breast cancer undergoing adjuvant taxane chemotherapy.
3065476|NCT02125006|Experimental|Interdisciplinary program including MBSR|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
3065477|NCT02125006|No Intervention|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
3065478|NCT02124993||Sleeve gastrectomy surgery Participants|Male or female who will undergo a sleeve gastrectomy for obesity by Dr. Drake Bellanger.
3065537|NCT02124499||All patients|Patients undergoing elective surgery with anesthesia
3065570|NCT02124291|Active Comparator|Assisted Hatching|Mechanical Assisted Hatching - artificial rupture of the embryo external glycoprotein layer (Zona Pellucida) before embryo transfer.
3065479|NCT02124980|Experimental|Recovery Line plus Treatment-as-Usual (RL+TAU)|The Recovery Line is an automated computer-based IVR system that provides CBT-based modules. The RL+TAU condition will include the customized therapeutic recommendations developed in Phase 1, and the contact reminders messages and time frame that maximized system use in Phase 2. Patients will receive an orientation, 24-hour access, encouragement to use the system from clinic staff reminder, and technical assistance line for system problems. Patients will receive 12 weeks of system access.
3065480|NCT02124980|No Intervention|Treatment-as-Usual|Treatment-as Usual involves daily methadone and associated psychosocial services. Patients are required to attend 1 group session per month and are encouraged to attend open drop-in groups available daily covering a range of topics.
3065481|NCT02124967|Experimental|Exercise|A one hour exercise session which includes both aerobic activity and resistance training
3065482|NCT02124954|Experimental|Digoxin with/without TA-8995|Digoxin with/without TA-8995
3065483|NCT02124954|Experimental|Midazolam with/without TA-8995|Midazolam with/without TA-8995
3065484|NCT02124941|Experimental|1H MRS|All subjects will undergo three magnetic resonance spectroscopy (1H-MRS) scans, including before and after two-weeks of placebo and NAC administration.
3065485|NCT02124941|Experimental|[18F]-FDG PET scan|All subjects will undergo [18F]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
3065486|NCT02124941|Experimental|[11C]APP311 PET scan|All subjects will undergo [11C]APP311 PET imaging to investigate whether there are differences in synaptic integrity / neuronal plasticity in the brains of individuals abstinent from cocaine compared to healthy controls at baseline.
3065487|NCT02124941|Active Comparator|Medication (NAC & placebo) administration|Upon completion of baseline (abstinence) 1H-MRS scanning at 7T, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.
3065488|NCT02124928||carotid artery stenosis|Patients with symptomatic or asymptomatic carotid artery stenosis indicated for carotid endarterectomy, who provide written informed consent, will be included in this study. The investigators will compare patients ultrasonographic data, serum laboratory analyses and histomorphological preferances to look for biomarkers for the plaque instability.
3065489|NCT02124915||Transtibial amputees|
3065490|NCT02124902|Experimental|Neoadjuvant docetaxel and carboplatin|
3065491|NCT02124889|Experimental|Weekly surveys|Subjects will take the multivitamin, and will also receive weekly Internet surveys asking them questions about the multivitamin treatment.
3065492|NCT02124889|No Intervention|Control|Subjects will take the multivitamin but will not receive surveys.
3065493|NCT02124876||Transtibial amputees|
3065494|NCT02124863|Experimental|Intrapulmonary Percussive Ventilation|number of refluxes during 20 min of IPV ( rate : 300/min, p = 10cmH2O) at least 120 min after feeding
3065495|NCT02124850|Experimental|Motolimod plus cetuximab|Cohort 1: motolimod plus cetuximab
3065496|NCT02124850|Experimental|Motolimod, cetuximab, and nivolumab|Cohort 2: motolimod, cetuximab, and nivolumab
3065497|NCT02124837|No Intervention|Control group|Participants continue their normal lunch routine.
3065498|NCT02124837|Experimental|Relaxation exercise during lunch break|Participants perform relaxation exercises during each lunch break during work for a period of 2 working weeks.
3065499|NCT02124837|Experimental|Park walk during lunch break|Participants go for a walk in the closest park nearby each lunch break during work for a period of 2 working weeks.
3065500|NCT02124824|Experimental|Arm 1: Control|Control
3065501|NCT02124824|Experimental|Arm 2: Heart Failure|Heart Failure
3065502|NCT02124811|Experimental|High CRP|Subjects with a High Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
3065503|NCT02124811|Experimental|Low CRP|Subjects with a Low Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
3065504|NCT02124798|Experimental|Single arm|Subjects will self-administer belimumab SC into thigh or abdomen using the autoinjector device for 8 weekly doses; 4 of the doses will be administered under observation in the clinic and 4 of the doses will be administered outside the clinic and without observation
3065505|NCT02124785|Experimental|HAV Group|Subjects who were previously vaccinated with Havrix in primary studies.
3065506|NCT02124772|Experimental|Part A|Trametinib Dose-Escalation: Trametinib is administered orally once daily (OD) under fasting conditions. The starting dose of trametinib (0.0125 milligram per kilogram per dose [mg/kg/dose]) is 50% of the recommended fixed dose in adults (2 mg OD). The second dose level (0.025 mg/kg) is equivalent to the recommended dose in adults (2 mg PO daily). The third dose level (0.040 mg/kg) is equivalent to the maximum tolerated dose [MTD] in adults (3 mg PO daily).
3065507|NCT02124772|Experimental|Part B|Tumor-Specific Expansion: Trametinib is administered orally once daily under fasting conditions in 4 disease-specific cohorts of subjects Trametinib will be continued until disease progression.
3065508|NCT02124772|Experimental|Part C|The trametinib dose administered in Part C will be the trametinib monotherapy RP2D from Part A. The monotherapy RP2D of dabrafenib in children will be established on a separate trial (BRF116013). The specifics for Part C will be determined following completion of enrollment into Part A.
3065509|NCT02124772|Experimental|Part D|The trametinib and dabrafenib doses administered in Part D will be the combination trametinib and dabrafenib RP2D from Part C.
3065510|NCT02124759|Active Comparator|High fat diet|"The high fat diet will provide 60% of energy from fat (of which 50% from saturated fat), 15% of energy as CHO and 25% from protein.~subjects will be randomized to receive, in a double-blind fashion~placebo, maltodextrin, 6 g three times a day~synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion CFU/g)three times a day]~sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day)"
3065568|NCT02124304|Experimental|Healthy|Thera-Band elastic and manual resistance neck exercises for neck strengthening
3065511|NCT02124759|Active Comparator|Low fat diet|"The low fat diet will provide 55% of energy from CHO, 20% from fat, and 25% from protein.~subjects will be randomized to receive, in a double-blind fashion~placebo, maltodextrin, 6 g three times a day~synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion CFU/g)three times a day]~sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day)"
3065512|NCT02124746|Experimental|Cohort 1|Participants previously enrolled in Study CCL09191E will receive momelotinib for approximately 4 years.
3065513|NCT02124746|Experimental|Cohort 2|Participants previously enrolled in Study YM387-II-02 will receive momelotinib for approximately 4 years.
3065514|NCT02124746|Experimental|Cohort 3|"Participants previously enrolled in Study GS-US-354-0101 will receive momelotinib for up to 4 years.~Cohort 3 was closed and all enrolled participants were discontinued from this study because parent Study GS-US-354-0101 was terminated."
3065515|NCT02124746|Experimental|Cohort 4|Participants previously enrolled in Study GS-US-352-1672 will receive momelotinib for approximately 4 years.
3065516|NCT02124733|Active Comparator|Group 1: 30 minutes|The first 4 patients enrolled will be considered Group 1, and will receive 30 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated in terms of erythema immediately post-PDT (Day 1) and on Day 4 . If there is no clinical reaction on Side A after 2 patients, then the dose will be advanced to the next Group. If the post-PDT reaction (erythema at Day 4) on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of the 4 patients, then the protocol will advance to Group 2
3065517|NCT02124733|Active Comparator|Group 2: 45 minutes|Patients in this group will receive 45 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated for erythema response immediately post-PDT and at Day 4. If there is no clinical reaction on Side A after 2 patients, then the dose will be advanced to the next Group. If the post-PDT reaction (erythema at Day 4) on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of the 4 patients, then the protocol will advance to Group 3.
3065518|NCT02124733|Active Comparator|Group 3: 60 minutes|Patients in this group will receive 60 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated for erythema responses immediately post-PDT and at Day 4. If the post-PDT reaction on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of patients, then the protocol will terminate after 15 patients (total for all groups) have been treated.
3065519|NCT02124720|Experimental|Mobile application|Use of the iSTIM mobile application 2 to 4 times per week over approximately 8 to 16 weeks
3065520|NCT02124707|Experimental|Carboplatin, Paclitaxel and Cetuximab|A 6 week course of weekly carboplatin, paclitaxel, and cetuximab will be administered to 38 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Once protocol therapy is complete, cetuximab may be continued if the patient and physician agree. Within 3 weeks of the end of protocol therapy, response will be assessed, and if the patient has achieved at least stable disease, the treating physician may continue to treat with weekly cetuximab at their discretion until disease progression. Patients will be followed for a maximum of 3 years after the end of the 6 week treatment phase.
3065521|NCT02124694|Experimental|HTUG and IPT|This arm includes the Historical Trauma and Unresolved Grief intervention (HUTG) combined with group Interpersonal Psychotherapy (IPT).The HTUG/IPT arm is 12 two-hour sessions delivered weekly on average, except for weather delays, over 16 weeks. HTUG/IPT includes sessions on identifying relationship issues which may trigger depressive symptoms, using group support, and connecting the impact of collective tribal trauma and losses with personal lifespan and current losses. HTUG/IPT is aimed at reducing depressive symptoms related to interpersonal conflicts and grief. HTUG is a Tribal Best Practice which may serve to engage AI in IPT, an empirically supported treatment for depression.
3065522|NCT02124694|No Intervention|IPT Only|IPT is a standard empirically supported treatment. This IPT Only group is not receiving the experimental HTUG component and is being compared to the combined HTUG with IPT.
3065523|NCT02124681|Placebo Comparator|Placebo|Placebo PO
3065524|NCT02124681|Experimental|Hydroxychloroquine|Hydroxychloroquine sulfate 400mg PO QD
3065525|NCT02124668|Experimental|Enzalutamide|Enzalutamide
3065526|NCT02124655|Experimental|Essential oils/0.2% chlorhexidine/Sterile water|A) 20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1). -----14 days----- B) 10 mL rinses for 30 seconds with 0.2% chlorhexidine/2 times daily (1/0/1). -----14 days----- C) 20 mL rinses for 30 seconds with sterile water (1/0/1).
3065527|NCT02124642|Active Comparator|Folic acid, 400 mcg/day|A daily 400 microgram (mcg) dose of folic acid will be taken orally, along with the recommended intake for pregnancy of other vitamins, minerals and docosahexaenoic acid (DHA), beginning at enrollment until delivery. The 400 mcg dose approximates the current Recommended Dietary Allowance (RDA) for pregnant women of 600 mcg Dietary Folate Equivalents (400 mcg folic acid ≈ 600 mcg DFEs; conversion factor based on higher bioavailability of folic acid is: 1 mcg folic acid = 1.7 mcg DFE).
3065528|NCT02124642|Experimental|Folic acid, 800 mcg/day|A daily 800 microgram (mcg) dose of folic acid will be taken orally, along with the recommended intake for pregnancy of other vitamins, minerals and docosahexaenoic acid (DHA), beginning at enrollment until delivery. The 800 microgram dose, which is considerably higher than the current RDA, represents an amount commonly found in over-the-counter prenatal vitamin formulations.
3065529|NCT02124616||Neuromuscular diseases|Prospective cohort of children with inherited or acquired neuromuscular diseases.
3065530|NCT02124603||single group|Patients undergone cataract surgery
3065531|NCT02124590|Experimental|Acute Exercise|Repeated isometric leg exercises at varying intensities and a second visit with aerobic bike exercise for 30 minutes at 50% peak VO2.
3065532|NCT02124564|Experimental|Lacosamide|Open-label, single-arm
3065533|NCT02124525|Placebo Comparator|N-acetylcysteine|"Subjects receiving N-acetylcysteine (NAC): 6 pills/ day of N-acetylcysteine 500mg.~Duration: 12 weeks"
3065534|NCT02124525|Placebo Comparator|Placebo|Placebo will be taken for 12 weeks
3065538|NCT02124486|Active Comparator|Dietetic Intervention|Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers diet programme.
3065539|NCT02124486|Experimental|Bariatric surgery|Patients randomised to the bariatric surgery arm will be referred to the bariatric surgery pathway and, if judged suitable according to the bariatric surgery clinic's screening processes, undergo bariatric surgery.
3065540|NCT02124486|No Intervention|Matched obese control group|To evaluate the baseline difference in ICP between IIH patients and a matched obese control cohort we will recruit 20 obese but otherwise healthy participants who will undergo the same baseline visit as the main trial participants and then exit the study.
3065541|NCT02124486|No Intervention|MRI Test run|5 patients will undergo double baseline MR scans to validate the novel MR sequences being used in the main trial.
3065542|NCT02124473|Experimental|Homeopathy|A range of homeopathic potencies were used as per the individualized requirement, decided by the treating physicians.Each dose, administered orally, (in centesimal potencies).
3065543|NCT02124473|Placebo Comparator|Placebo|Placebo, identical in appearance, consisted of 83.1% ethanol in 10 ml distilled water and was served in identical amber-coloured glass vials
3065544|NCT02124460|No Intervention|Enhanced Primary Care|"We will provide current best practice to the control arm. Patients with a BMI greater than or equal to the 85th percentile will be flagged in the electronic health record. Clinicians are also provided with clinical decision support tools for pediatric weight management. We will encourage providers to schedule a follow up visit for weight management or make a referral to Harvard Vanguard Medical Associates nutritionists for children in this arm. We will also provide this group with a community resource guide and educational text messages."
3065545|NCT02124460|Experimental|Health Coaching|The intervention for this study will consist of the same best practices received by the enhanced primary care group well as the following three elements: visits with a health coach, connection to community resources and an interactive text messaging program.
3065546|NCT02124447|Active Comparator|PEG+E|Split dose 4 liter polyethylene glycol with electrolytes
3065547|NCT02124447|Active Comparator|PEG+Asc|Split dose 2 liter polyethylene glycol with ascorbic acid
3065548|NCT02124447|Active Comparator|P+MC|Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid
3065549|NCT02124447|Active Comparator|sulfate|Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution
3065550|NCT02124434||Laparoscopic Sleeve Gastrectomy|Patients undergoing Laparoscopic Sleeve Gastrectomy surgery for morbid obesity
3065551|NCT02124421|Active Comparator|CRS with adjuvant IV/IP chemotherapy|Patients undergo cytoreductive surgery (CRS) alone with IV/IP combination adjuvant chemotherapy. Day 1: IV paclitaxel (135 mg/m2), day 2: IP cisplatin (75 mg/m2), and day 8: IP paclitaxel (60 mg/m2) given every 21 days for a total of 6 cycles. Standard of care treatment. Administration of quality of life questionnaires throughout study duration of follow-up
3065552|NCT02124421|Experimental|CRS/HIPEC with adjuvant IV chemotherapy|Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) administered using carboplatin for 90 minutes. Adjuvant systemic IV combination chemotherapy with carboplatin and paclitaxel (Carboplatin AUC 6, Paclitaxel 175mg/m2) will be given every 21 days for a total of 6 cycles. Administration of quality of life questionnaires throughout study duration of follow-up
3065553|NCT02124408|Experimental|Intervention group|Personalized Behavioral Intervention
3065554|NCT02124408|No Intervention|Control group|
3065555|NCT02124395||Primary Hyperoxaluria|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
3065556|NCT02124395||Cystinuria|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
3065557|NCT02124395||Dent Disease|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
3065558|NCT02124395||APRT deficiency|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
3065559|NCT02124369|Other|Abraxane & gemictabine|Abraxane, IV, 125mg/m2 and gemcitabine, IV, 1000mg/m2, on days 1,8 & 15 per 28 day cycle, up to a maximum of 6 cycles.
3065560|NCT02124356||Emergency High-risk Abdominal Surgery|
3065561|NCT02124343|Experimental|Interval Exercise|"Subjects will undertake an interval exercise session (on a harnessed treadmill) (HP Cosmos Mercury 4.0, HP Cosmos Sports and Medical Gmbh, Nussdorf-Traustein,Germany) based on the average speed calculated from the 6 minute walk test (6MWT).~Intervals are based on the work previously done by Mador et al., 2009 who used intervals of 150% (for 1 minute) followed by intervals of 75% (for 2 minutes) based on 80% average speed from the 6 minute walk test.~This study repeated these intervals 7 times with a duration of 23 minutes in total for the exercise intervention with the 75% intervals at the start and at the end of the exercise session. No warm up was undertaken for this method as it was a walking exercise test and the risk of injury was minimised with use of the harnessed treadmill."
3065562|NCT02124330|Experimental|montmorillonite 5 g|5g Montmorillonite + 15 g protein (ratio 1:3)
3065563|NCT02124330|Experimental|Montmorillonite 3 g|3g Montmorillonite + 15 g protein (ratio 1:5)
3065564|NCT02124330|Experimental|Montmorillonite 1 g|1g Montmorillonite + 15 g protein (ratio 1:15)
3065565|NCT02124330|No Intervention|Control|A control goup will intake 15 g of protein alone
3065566|NCT02124317|Experimental|nanoparticle albumin-bound paclitaxel, S-1|nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycle: 6 cycles.
3065567|NCT02124304|Experimental|Cervical Pain|Thera-Band elastic and manual resistance neck exercises for neck strengthening
3065569|NCT02124291|No Intervention|No Assisted Hatching|No Assisted Hatching
3065571|NCT02124278|Experimental|PUL-042 Inhalation Solution|Fixed dose combination of Pam2CSK4 acetate (Pam2) and ODN M362 (ODN) administered as an inhalation solution. Single dose administration by nebulization. Starting dose will be 2.9 micrograms Pam2: 4.25 micrograms ODN. Up to 7 doubling doses may be tested.
3065572|NCT02124278|Placebo Comparator|Sterile water for injection|Sterile water for injection administered by nebulization
3065573|NCT02124265|Experimental|Ceralyte 90|Ceralyte® will be administered during the first 24-hours post-burn. Fluid requirements will be calculated according to the Parkland Formula with 50% administered during the first 8 hours and the second 50% administered over the next 16 hours. During the first 2 hours IV fluids will be started at the Parkland goal minus 250cc, which will be administered using Ceralyte via oral, NG, or dobhoff tube. ORT and IV fluids will be monitored with additional doses given hourly. Urine output will be monitored hourly and gastric residuals will be monitored every 2 hours, with adjustments made as needed to ensure adequate fluid resuscitation.
3065574|NCT02124252|No Intervention|Control|Women will be offered HPV testing within the health facilities in the communities randomized to this arm. Women who test HPV positive will be referred to care at the sub-district and district hospitals (current standard of care).
3065575|NCT02124252|Active Comparator|Standard Intervention|Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
3065576|NCT02124252|Active Comparator|Enhanced Intervention|Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
3065577|NCT02124239|Experimental|Scalp|Treatment of scalp with 0.027% ingenol mebutate once daily for 3 days
3065578|NCT02124239|Experimental|Arm|Treatment of arm with 0.06% ingenol mebutate once daily for 4 days
3065579|NCT02124239|Experimental|Face|Treatment of face with 0.027% ingenol mebutate once daily for 3 days
3065580|NCT02124226|Experimental|Methotrexate|Starting dose of 7.5 mg/week + folic acid the day after for 3 weeks as add-on therapy to their existing medication. Study treatment dosage will be increased, the maintenance dose will be 10 mg/week + folic acid the day after for 27 weeks
3065581|NCT02124226|Placebo Comparator|Matched placebo|Placebo pills
3065582|NCT02124213|Experimental|Cohor 1 - 30 mg|Cohort will include approximately 4 HVs/completers who will receive a single 30 mg dose of PF-06412562.
3065583|NCT02124213|Experimental|Cohort 2 ( adaptive dose, optional)|Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1.
3065584|NCT02124213|Experimental|Cohort 3 ( adaptive dose, optional)|Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.
3065585|NCT02124200|Other|EGO/CE4, 9mg nicotine|
3065586|NCT02124187|Experimental|eCig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
3065587|NCT02124187|Sham Comparator|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
3065588|NCT02124187|Placebo Comparator|Nicotine free inhalator|nicotine free inhalator for 12 weeks
3065589|NCT02124174|Experimental|Vidaza and Valproic Acid|Vidaza and Valproic Acid
3065590|NCT02124161|Other|13vPnC+SIIV/Placebo|
3065591|NCT02124161|Other|Placebo+SIIV/13vPnC|
3065592|NCT02124148|Experimental|Prexasertib + Cisplatin (Part A)|"Part A: Prexasertib and cisplatin administered intravenously (IV) once every 21 days.~Part A2: Prexasertib and cisplatin administered IV every 21 days; G-CSF administered subcutaneously (SC) starting approximately 24 hours after each prexasertib dose every 21 days.~Part A3: Cisplatin administered IV on day one and prexasertib administered IV on day two once every 21 days.~Part A Expansion: Part A, A2, and/or A3 may be expanded at the recommended dose.~Participants may remain on treatment until discontinuation criteria are met."
3065593|NCT02124148|Experimental|Prexasertib + Cetuximab (Part B)|"Part B: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days.~Part B2: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days; G-CSF administered SC starting approximately 24 hours after each prexasertib dose every 14 days.~Part B3: Cetuximab administered IV with prexasertib administered IV once every 14 days.~Part B Expansion: Part B, B2 and/or B3 may be expanded at the recommended dose.~Participants may remain on treatment until discontinuation criteria are met."
3065594|NCT02124148|Experimental|Prexasertib + Pemetrexed (Part C)|"Part C: Pemetrexed administered IV on day one and prexasertib administered IV on day one and two every 21 days.~Participants may remain on treatment until discontinuation criteria are met."
3065595|NCT02124148|Experimental|Prexasertib + 5-FU (Part D)|"Part D: Leucovorin administered IV on day one, 5-FU administered IV bolus on day one and by continuous IV on days one to three (46 hours), and prexasertib administered IV on day three every 14 days.~Participants may remain on treatment until discontinuation criteria are met."
3065596|NCT02124148|Experimental|Prexasertib + LY3023414 (Part E)|"Part E: Prexasertib administered IV on day one and LY3023414 administered orally twice daily every 14 days.~Part E will be expanded at the recommended dose in participants with advanced or metastatic cancer, participants with PIK3CA mutations (E2 expansion), or with advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer (E3 expansion).~Participants may remain on treatment until discontinuation criteria are met."
3065597|NCT02124135|Active Comparator|Clinic-based counseling|Participants in this arm will receive 1 baseline phone call with the registered dietitian to get preliminary dietary counseling tailored to their family's needs. They will then have 3 sessions in-person in a group setting with another family and the registered dietitian where a set dietary curriculum geared at promoting weight loss and/or maintenance of a healthy weight will be emphasized. All in-person visits will take place in the clinic setting.
3065598|NCT02124135|Experimental|Restaurant-based counseling|Participants in this arm will receive 1 baseline phone call with the registered dietitian to get preliminary dietary counseling tailored to their family's needs. They will then have 3 sessions in-person in a group setting with another family and the registered dietitian where a set dietary curriculum geared at promoting weight loss and/or maintenance of a healthy weight will be emphasized. All in-person visits will take place in a restaurant, while dining.
3065635|NCT02123901|Active Comparator|Walking meditation & No exercise|
3065636|NCT02123888|Experimental|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy.
3065599|NCT02124122|Experimental|Lactobacillus|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period that corresponds to a dose of the closely related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic. The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid found in the original BioGaia strain (L. reuteri ATCC 55730).
3065600|NCT02124122|Placebo Comparator|Placebo|Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm, Sweden).
3065601|NCT02124083|Experimental|Vorinostat|Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.
3065602|NCT02124044|Experimental|HIV/HCV GT-1b, 24 wks ASV/DCV|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
3065603|NCT02124044|Experimental|HIV/HCV GT-1a/1b, 12 wks ASV/DCV with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
3065604|NCT02124018||Post-MI patients|"Asymptomatic post-MI patients late after MI or 40 days after STEMI-NSTEMI with preserved ejection fraction and absence of active ischemia Programmed ventricular stimulation will be performed in high-risk patients based on non-invasive evaluation.~ICD implantation will be performed in patients with induced VT in programmed ventricular stimulation"
3065605|NCT02124005|Experimental|Femoral block, ultrasound, bupivacaine|
3065606|NCT02123992|Active Comparator|Elevate Apical and Posterior|The experimental arm of the study will include the implantation of the Elevate Posterior surgical mesh for the treatment of posterior vaginal prolapse
3065607|NCT02123992|Active Comparator|Native Tissue Repair|The control arm of the study will include the treatment of posterior vaginal prolapse using standard surgical sutures
3065608|NCT02123979|Placebo Comparator|placebo patch|Neupro® transdermal patch/placebo randomly allocated like a flip of a coin applied to your skin at the dose of 8 mg/day or a matching placebo patch after the oral surgery procedure is completed.
3065609|NCT02123979|Experimental|Neupro® transdermal patch|Neupro® transdermal patch/placebo randomly allocated like a flip of a coin applied to your skin at the dose of 8 mg/day or a matching placebo patch after the oral surgery procedure is completed.
3065610|NCT02123966|Experimental|Topical Sirolimus + Steroid|A four week supply of topical sirolimus will be dispensed. The treatment instructions will be to rinse and spit (NOT swallow) with one teaspoon (5 mL) of sirolimus solution 0.1mg/mL, combined with one teaspoon (5 mL) of steroid solution (dexamethasone 0.1%, clobetasol 0.05%, or budesonide 0.03%, based on the ongoing topical steroid prescription at the time of study enrollment) four times a day for 5 minutes at a time, and not to eat or drink for 15 minutes afterwards.
3065611|NCT02123953|Experimental|TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once, daily, Days 1 to 7.
3065612|NCT02123953|Experimental|TAK-438 15 mg|TAK-438 15 mg, tablets, orally, once, daily, Days 1 to 7.
3065613|NCT02123953|Experimental|TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once, daily, Days 1 to 7.
3065614|NCT02123953|Experimental|TAK-438 30 mg|TAK-438 30 mg, tablets, orally, once, daily, Days 1 to 7.
3065615|NCT02123953|Experimental|TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once, daily, Days 1 to 7.
3065616|NCT02123953|Placebo Comparator|Placebo|TAK-438 placebo-matching tablets, orally, once, daily, Days 1 to 7.
3065617|NCT02123940|Experimental|nasal humidified high flow therapy|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
3065618|NCT02123940|Other|standard strategy|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
3065619|NCT02123927|Experimental|Step 1: TAK-438 1 mg|TAK-438 1 mg, tablets, orally, once on Day 1.
3065620|NCT02123927|Experimental|Step 2: TAK-438 5 mg|TAK-438 5 mg, tablets, orally, once on Day 1.
3065621|NCT02123927|Experimental|Step 3: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once on Day 1.
3065622|NCT02123927|Experimental|Step 4: TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once on Day 1.
3065623|NCT02123927|Experimental|Step 5: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once on Day 1.
3065624|NCT02123927|Experimental|Step 6: TAK-438 80 mg|TAK-438 80 mg, tablets, orally, once on Day 1.
3065625|NCT02123927|Experimental|Step 7: TAK-438 120 mg|TAK-438 120 mg, tablets, orally, once on Day 1.
3065626|NCT02123927|Placebo Comparator|Steps 1-7: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1.
3065627|NCT02123927|Experimental|Step 8A: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 10 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
3065628|NCT02123927|Experimental|Step 8 B: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, under fed conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 10 mg, tablets, orally, under fasted conditions, once on Day 1, Period 2.
3065629|NCT02123927|Experimental|Step 9A: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 40 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
3065630|NCT02123927|Experimental|Step 9B: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, under fed conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 40 mg, tablets, orally, under fasted conditions, once on Day 1, Period 2.
3065631|NCT02123927|Placebo Comparator|Steps 8 (A & B) and 9 (A & B): Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 placebo-matching tablets, orally, once on Day 1, Period 2.
3065632|NCT02123914|Experimental|Aerobic exercise with Vit. C & Aerobic exercise|
3065633|NCT02123914|Active Comparator|exercise without vit. c supplement & no exercise|
3065634|NCT02123901|Experimental|Walking meditation & Walking|
3065644|NCT02123849|Experimental|Arm I (continuous aspirin)|Participants receive aspirin PO QD for 12 weeks.
3065645|NCT02123849|Experimental|Arm II (intermittent aspirin)|Participants receive placebo PO QD during weeks 1, 3, 5, 7, 9, and 11 and aspirin PO QD during weeks 2, 4, 6, 8, 10, and 12.
3065646|NCT02123836|Experimental|NK cells|Peripheral blood cell will be collected by apheresis from donors. Peripheral blood mononucleated cells will be cultured with irradiated K562-mb15-41BBL cells and low dose (10 IU/mL) IL-2 for 10 days. After T-cell depletion, expanded activated NK cells will be infused. Before infusion, patients will receive immunosuppressive therapy to promote temporary engraftment of NK cells. After infusion, they will receive IL-2 to support NK cell viability and expansion in vivo. The effects of NK cell infusion will be determine by comparing MRD levels before and after treatment.
3065647|NCT02123823|Active Comparator|Everolimus 10mg + Exemestane 25mg|Phase II - Daily everolimus oral administration 10mg + daily exemestane 25 mg orally
3065648|NCT02123823|Experimental|BI836845 + Everolimus + Exemestane|Phase II - BI 836845 recommended dose will be administered intravenously once every week, in addition to daily everolimus (oral administration at recommended dose) + daily exemestane 25 mg orally
3065649|NCT02123823|Experimental|PhI - BI836845 + Everolimus + Exemestane|Phase I - Dose escalation (24-48 patients) BI 836845 low or high dose, Everolimus 5mg, 7,5mg or 10 mg and Exemestane 25mg
3065650|NCT02123810|Other|Control|The investigators measure quality of chest compressions before nightshift. Control group
3065651|NCT02123810|Other|OFF|The investigators measure quality of chest compressions before nightshift. After night shift group
3065652|NCT02123797||Multidisciplinary Clinic Patients|: 150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients
3065653|NCT02123797||Serial Care Patients|150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients = 450 patients Since Baptist Health Care System manages >800 new cases each year, 300 of which are expected to be seen in multidisciplinary clinic, in practice, we conservatively expect to be able to recruit 150 cases from multidisciplinary clinic and 300 matched serial care controls (1:2 match) in 18 months.
3065654|NCT02123784||Rotator cuff tear|Patients which demonstrate a full-thickness tear of the rotator cuff tendon and meet the inclusion criteria.
3065655|NCT02123771||Helicobactor Pylori Infection|Comparison on the presence/absence of GGT antigen in the stool will be compared between H. pylori-positive and H. pylori-negative subjects. Rapid urease test result from the respective patients will be used as the golden standard. Should the GGT antigen in stool samples show promise in distinguishing between H. pylori-infected and uninfected individuals, sensitivity and specificity of the stool antigen test can then be established.
3065656|NCT02123758|Experimental|Cohort 1|Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of abiraterone acetate + prednisone (AAP) + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AA and prednisone. Breakfast will be offered approximately 30 minutes after intake of JNJ-56021927. Treatment cycles will be of 28 days.
3065657|NCT02123758|Experimental|Cohort 2|Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of AAP + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Days 7 and 36, participants will receive AA and prednisone together. On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AAP. Treatment cycles will be of 28 days.
3065658|NCT02123745|Experimental|Infiltrated Tissue|The ivWatch Model 400 monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
3065659|NCT02123732|Experimental|DbXell|Drug: DbXell three times daily for 12 weeks and then switching to Placebo of DbXell for 12 additional months Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
3065660|NCT02123732|Placebo Comparator|Placebo|Drug: Placebo of DbXell Placebo of DbXell three times daily for 12 weeks and then switching to DbXell for 12 additional weeks Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
3065661|NCT02123719||Patients post liver transplantation|Patients after liver transplantation
3065662|NCT02123719||Control group|Patients with an abdominal incisional hernia without a history of immunosuppresion
3065663|NCT02123693|Experimental|Osteopathic Manipulative Treatment|5 sessions of treatment will be carried out: the first 3 weekly, and the remaining 2 after 15 days. The type of treatment will be based on indirect techniques
3065664|NCT02123693|Sham Comparator|Sham therapy|5 sessions of treatment will be carried out: the first 3 weekly, and the remaining 2 after 15 days. The type of treatment will be based on specific parameters set out previously based on a predetermined protocol
3065665|NCT02123693|Other|No intervention|Patients in this group will not receive any type of intervention, both therapeutic than fictitious, and will not be evaluated by any operator
3065666|NCT02123667||Asthmatic patients|asthmatic patients 18 to 65
3065667|NCT02123667||Healthy volunteers|Volunteers 18 to 65
3065668|NCT02123654|Experimental|Arm 1: DCV 3DAA + Placebo for DCV/Placebo for ASV|DCV 3DAA tablet orally twice daily for 12 weeks + Placebo for DCV tablet orally once daily and Placebo for ASV capsule orally twice daily for 24 weeks (Double blind)
3065669|NCT02123654|Active Comparator|Arm 2: DCV/ASV + Placebo for DCV 3DAA|Daclatasvir 60 mg tablet orally once daily and Asunaprevir 100 mg capsule orally twice daily for 24 weeks + Placebo for DCV 3DAA tablet orally twice daily for 12 weeks (Double blind)
3065670|NCT02123654|Experimental|DCV 3DAA|DCV 3DAA (open label) Tablet orally twice daily for 12 weeks
3065671|NCT02123641|Active Comparator|Heavy resistance training|Heavy resistance training of the lower and upper extremities three times weekly for 52 weeks.
3065672|NCT02123641|Experimental|Moderate intensity training|Home-based moderate intensity training of the lower and upper extremities three times weekly for 52 weeks.
3065673|NCT02123641|Experimental|Control|No training
3065674|NCT02123628|Active Comparator|antibiotic therapy|"patients are treated with a 6 week-duration of antibiotic therapy :~Rifampin IP and PO twice daily, 10mg/kg /12H~Levofloxacin IV and PO 500-750mg once daily~Doxycycline PO 200mg once daily~Trimethoprim- sulfamethoxazole IV and PO 800/160mg thrice daily~Fusidic acid PO 500mg twice daily~Linezolid IV and PO 600mg twice daily~Ciprofloxacin IV and PO 750to 1000mg/12h~Cefotaxime IV 100mg/kg in three IV infusions daily~Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily~Cefepime IV ou intra-muscularly 2g /8-12h"
3065675|NCT02123628|Active Comparator|12 week-duration of antibiotic therapy|"patients are treated with a 12 week-duration of antibiotic therapy :~Rifampin IP and PO twice daily, 10mg/kg /12H~Levofloxacin IV and PO 500-750mg once daily~Doxycycline PO 200mg once daily~Trimethoprim- sulfamethoxazole IV and PO 800/160mg thrice daily~Fusidic acid PO 500mg twice daily~Linezolid IV and PO 600mg twice daily~Ciprofloxacin IV and PO 750to 1000mg/12h~Cefotaxime IV 100mg/kg in three IV infusions daily~Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily~Cefepime IV ou intra-muscularly 2g /8-12h"
3065676|NCT02123615|Experimental|Gadolinium For abdomen|"Gadolinium For abdomen Total Persistent % subdermally, For abdomen Total Persistent % subcutaneously, and For abdomen Relative Prolongation Ability Score.~Gadolinium Magnevist® (gadopentetate dimeglumine)~1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg), subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
3065677|NCT02123615|Experimental|Gadolinium For lower back|"1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg), subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.~Gadolinium For lower back Total Persistent % subdermally, For lower back Total Persistent % subcutaneously, and For lower back Relative Prolongation Ability Score."
3065678|NCT02123615|Experimental|subjects (%) of any infections|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
3065679|NCT02123615|Experimental|Annual rate of any infections|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
3065680|NCT02123615|Experimental|subjects (%) with Antibiotic use|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
3065681|NCT02123615|Experimental|Annual rate with Antibiotic use|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
3065682|NCT02123615|Experimental|subjects (%) with Days out of work|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
3065683|NCT02123615|Experimental|Annual rate with Days out of work|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
3065684|NCT02123615|Experimental|(%) with hospitalized infections|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
3065685|NCT02123615|Experimental|Annual rate hospitalized infections|Annual rate hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
3065686|NCT02123615|Experimental|Adverse Injection Local Reactions|Adverse Injection Local Reactions as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3065687|NCT02123615|Experimental|Adverse Reactions Headache|Headache as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3065688|NCT02123615|Experimental|Adverse Reactions Fever|Fever as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3065689|NCT02123615|Experimental|Adverse Reactions Nausea|Nausea as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3065690|NCT02123615|Experimental|Adverse Reactions Vomiting|Vomiting as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3065813|NCT02122757|Active Comparator|Anodal Cefaly tDCS|2 mA anodal tDCS is delivered over the visual cortex, for 20 minutes, everyday for 2 months, in 15 patients.
3066060|NCT02120963|No Intervention|Control group|Health care as usual
3065691|NCT02123615|Experimental|Adverse Reactions Fatigue|Fatigue as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3065692|NCT02123615|Experimental|Adverse Reactions Diarrhea|Diarrhea as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3065693|NCT02123615|Experimental|Adverse Reactions Asthma|Asthma as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3065694|NCT02123615|Experimental|Adverse Reactions Oropharyngeal|Oropharyngeal as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3065695|NCT02123615|Experimental|Adverse Reactions Abdominal Pain|Abdominal Pain as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3065696|NCT02123602|Experimental|Core stabilization|This arm will receive 3 weeks of core stabilization training followed by 3 weeks of lower extremity stretching and strengthening as appropriate to address impairments noted in the examination and to progress function.
3065697|NCT02123602|Active Comparator|Lower extremity training only|This arm with receive 6 weeks of impairment based stretching and strengthening to restore function.
3065698|NCT02123589|Experimental|Deep sedation|Injection of 0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -5 and -3
3065699|NCT02123589|Experimental|Deep and daily interruption of sedation|Injection of 0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -5 and -3.and from the second day after subject was admitted in ICU, daily interruption of sedation will be taken .
3065700|NCT02123589|Experimental|Light sedation|Injection of 0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -2 and +1.
3065701|NCT02123576|Experimental|Treatment|Pentoxyfylline 400mg three times a day or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR <10 for 90 days in addition to standard AMO therapy
3065702|NCT02123576|Placebo Comparator|Placebo|This is a standard placebo pill.
3065703|NCT02123563|Experimental|Ultrason Essential oils rinse|Ultrasonic debridement followed by twice daily home use of an essential-oils mouth rinse (20mL, 30 seconds for each rinse) for 3 months
3065704|NCT02123563|Placebo Comparator|Ultrason Placebo rinse|Ultrasonic debridement followed by twice daily home use of a placebo rinse (20mL, 30 seconds for each rinse) for 3 months
3065705|NCT02123537|Experimental|Bioness L300 Foot Drop System|Participants will use the Bioness L300 Foot Drop System for walking daily during the 12 weeks of the study.
3065706|NCT02123524|Experimental|Rivaroxaban|Rivaroxaban 10mg tablet daily for 45 days
3065707|NCT02123524|Placebo Comparator|Control|Placebo tablet daily for 45 days
3065708|NCT02123511|Experimental|Arm I (acetylcysteine)|Patients receive acetylcysteine oral rinse and gargle or swish for 60 seconds then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
3065709|NCT02123511|Placebo Comparator|Arm II (placebo)|Patients receive a placebo oral rinse and gargle or swish for 60 seconds and then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
3065710|NCT02123498|Experimental|Single Arm|
3065711|NCT02123485|Experimental|low frequency rTMS|Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation, administered with 2 sessions each week
3065712|NCT02123485|Sham Comparator|Sham-rTMS|Sham right prefrontal rTMS 2 times a week
3065713|NCT02123472|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
3065714|NCT02123472|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
3065715|NCT02123459|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods
3065716|NCT02123459|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods
3065717|NCT02123446|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
3065718|NCT02123446|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
3065719|NCT02123433|Experimental|13-valent vaccine|
3065720|NCT02123420|Other|Implant outcome|"This study was designed as a randomised, controlled, split-mouth trial. all enrolled patients needed single bilateral fixed implant-supported prosthesis in molar area.~A total of 18 consecutive patients were enrolled. In each eligible patient, the right molar was randomly selected to receive either Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Goteborg, Sweden) with Platform Switching (PS) or Regular Platform (RP)"
3065814|NCT02122744|Active Comparator|Super Rapid Magstim Stimulator rTMS QP|rTMS QP is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients
3065868|NCT02122328|Experimental|Sequential procedure|Sequential laser photocoagulation of communicating vessels
3065721|NCT02123420|Other|Implant outome|"This study was designed as a randomised, controlled, split-mouth trial. all enrolled patients needed single bilateral fixed implant-supported prosthesis in molar area.~A total of 18 consecutive patients were enrolled. In each eligible patient, the left molar was randomly selected to receive either Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Goteborg, Sweden) with Platform Switching (PS) or Regular Platform (RP)"
3065722|NCT02123407|Experimental|Carbon Nanoparticles|Carbon Nanoparticles could be used in this arm.The drug is injected into the subserosa of stomach.Injections of 1.0 ml of Carbon Nanoparticles (0.2 ml in each cardinal point adjacent to the lesion) will be performed about 10 minutes before surgery.Then,gastrectomy with D2 dissection will be performed.
3065723|NCT02123407|Active Comparator|Gastrectomy with D2 dissection|Gastrectomy with D2 dissection will be performed in the control arm,no Carbon Nanoparticles or other coloring materials used
3065724|NCT02123394|Placebo Comparator|Placebo|The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
3065725|NCT02123394|Experimental|McKenzie method|The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
3065726|NCT02123381|Experimental|Arm A|All patients in the arm receive cetuximab combined with preoperative radiotherapy at first. 4-6 weeks after the rdiaotherapy，patients receive right thoracotomy with three incisions radical surgery.
3065727|NCT02123368|Active Comparator|Hialuronic acid|Single intraarticular injection of Hyaluronic acid (Hyal One)
3065728|NCT02123368|Active Comparator|Hyaluronic acid and MSC 10|Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells
3065729|NCT02123368|Active Comparator|Hyaluronic acid AND MSC 100|Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells
3065730|NCT02123355|Experimental|Dexmedetomidine|Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
3065731|NCT02123355|Sham Comparator|Normal saline|Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
3065732|NCT02123342|No Intervention|Exercise programme only|Participants randomized in this condition will not receive SMS reminders to execute the myPAtHS exercise programme.
3065733|NCT02123342|Experimental|SMS reminder|Participants in this study arm will receive SMS reminders to motivate them to execute the myPAtHS exercise programme.
3065734|NCT02123329|Active Comparator|Control arm|Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
3065735|NCT02123329|Experimental|Intervention arm|Participants assigned to the intervention arm will participate in a face-to-face 4-session program at the pharmacy delivered by the study pharmacist at 2-4-week intervals over 8 weeks in addition to nicotine replacement therapy. The sessions will be set at a date and time that is convenient for both the pharmacist and the participant. The pharmacist will deliver the program at a time different from his or her pharmacy duty regular time.
3065736|NCT02123316|Active Comparator|Pangramin Plus D. pteronyssinus|Pangramin Plus D. pteronyssinus 100% for subcutaneous injection
3065737|NCT02123316|Placebo Comparator|Placebo|Placebo for subcutaneous injection
3065738|NCT02123303||Veterans|
3065739|NCT02123290|Experimental|Plasmodium falciparum|Patients with Plasmodium falciparum malaria
3065740|NCT02123290|Experimental|Plasmodium vivax|Patients with Plasmodium vivax malaria
3065741|NCT02123277|Experimental|concept proof|Balloon catheter for the Eustachian tube
3065742|NCT02123264|Active Comparator|Zoledronic acid|Zoledronic acid: 5 mg/year x 2 years
3065743|NCT02123264|No Intervention|No intervention|No intervention
3065744|NCT02123251|Experimental|Financial Incentives|Participants (160) in the Incentive Group will: 1) continue to receive usual care; 2) are eligible to receive financial incentives based on completion of recommended ADA benchmarks and achievement of goals that are founded on evidence based guidelines for diabetes; and 3) be compensated for completion of surveys.
3065745|NCT02123251|Experimental|Control|Participants (160) in the Control Group will continue to receive usual care and be compensated for the completion of surveys only. They will not receive financial incentives.
3065746|NCT02123238|Other|Control|standard of care positioning (0 degree)
3065747|NCT02123238|Other|30 degree|30 degree bed positioning
3065748|NCT02123238|Other|60 degree|60 degree bed positioning
3065749|NCT02123212|Experimental|Mt. Sinai|Cluster randomization with EHR Alert intervention
3065750|NCT02123212|Experimental|Henry Ford Health System|Simple randomization with mailer intervention
3065751|NCT02123212|Experimental|University of Alabama, Birmingham|Crossover randomization with in-person recruitment intervention
3065752|NCT02123199||Indacaterol/QAB149|Patients treated with Indacaterol for COPD prior to enrollment in study
3065753|NCT02123186||newborns testing for SMA|
3065754|NCT02123173||non-intubated|VATS, non-intubated
3065755|NCT02123173||intubated|VATS, intubated
3065756|NCT02123160|Experimental|Child Parent Psychotherapy (CPP)|Following Time 1 (pre-treatment) assessment, mother-child patient dyads will be randomly assigned to either Child Parent Psychotherapy (CPP) treatment or control (usual treatment) group. CPP treatment will be conducted by a CPP study clinician over approximately six months (24 weekly sessions). CPP includes developmental guidance and fostering affect regulation , continuity in daily living, reciprocity between mother and child, and helping the mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma.
3065815|NCT02122744|Placebo Comparator|Placebo|rTMS QP placebo (coil perpendicular to the scalp) is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients.
3066497|NCT02117908|Experimental|CPAP +4 cm H2O|CPAP +4 cm H2O pressure using ResMedTM face mask
3065757|NCT02123160|Active Comparator|Usual Treatment|Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred for usual treatment via referral to therapists in the community and at Columbia University Medical Center, for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Additionally, control patient dyads will be monitored through regular contact with the study research assistant. If the research assistant detects worsening of depressive symptoms or the presentation of new symptoms, a licensed study clinician will follow up to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
3065758|NCT02123147||Sjogren's syndrome|Patients who are diagnosed with Sjogren's syndrome. Blood will be collected once every 3-6 months for up to 3 years.
3065759|NCT02123147||Healthy Control|Patients who are diagnosed with healthy control. Blood will be collected once every 6 months for up to 3 years.
3065760|NCT02123134|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3065761|NCT02123134|Experimental|ATX-101|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3065762|NCT02123121|Placebo Comparator|Vegetable cellulose|Participants will orally consume one capsule of vegetable cellulose following each of their main meals (i.e. breakfast, lunch, and dinner) for 90 days.
3065763|NCT02123121|Active Comparator|Resveratrol 1000 mg/day|Participants will orally consume one capsule of Resveratrol following each of their main meals (i.e. breakfast, lunch, and dinner) totaling 1000 mg/day for 90 days.
3065764|NCT02123121|Active Comparator|Resveratrol 1500 mg/day|Participants will orally consume one capsule of Resveratrol following each of their main meals (i.e. breakfast, lunch, and dinner) totaling 1500 mg/day for 90 days.
3065765|NCT02123108|Active Comparator|Basiliximab|"Basiliximab~Basiliximab Peri-transplant~• 40mg IV infusion within 4 hours of transplant x1~Basiliximab Post-transplant • 20mg IV infusion Post Operative Day #4 (POD 4) x1~Tacrolimus (with basiliximab induction)~• Post Operative Day #7 (POD 7) or subclinical acute rejection (SCr) < 1.8 mg/dl to one year: 0.03-0.1mg/kg q12h~Mycophenolate/mycophenolic acid will be started Post Operatively Day 1: 720 mg po bid will be administered once the patient is able to tolerate PO medication.~Corticosteroids • Intraoperative: hydrocortisone 1000mg intravenous push (IVP)~Followed by:~• Standard steroid taper:"
3065766|NCT02123108|No Intervention|Tacrolimus Group|"Tacrolimus (without basiliximab induction); standard of care group~Beginning Post Operative Day #1 to six months: 0.03-0.1 mg/kg q12h po to maintain whole blood trough concentration of 7-10 ng/mL~Six months to one year: maintain whole blood trough concentration of 5-8ng/mL~Mycophenolate/mycophenolic acid will be started Post Operatively Day 1. Immediately post transplant, while subjects have nasogastric (ng) tube; this will be delivered as CellCept (mycophenolate mofetil) oral suspension 1,000 mg BID administered via the ng tube. Enteric coated mycophenolic acid (Myfortic) - 720 mg po bid will be administered once the patient is able to tolerate PO medication.~Corticosteroids • Intraoperative: hydrocortisone IVP~Followed by:~• Standard steroid taper"
3065767|NCT02123082|Other|Single-Lumen Ureteroscope|Subjects enrolled in this study arm will have their procedure performed using the single lumen ureteroscopes. This scope is currently employed in clinical practice, including at UC Irvine Medical Center.
3065768|NCT02123082|Experimental|Dual Lumen Ureteroscope|Subjects enrolled in this study arm will have their procedure performed using the dual lumen ureteroscopes. This scope is currently employed in clinical practice, including at UC Irvine Medical Center.
3065769|NCT02123069||Women with uterine fibroids|"Brachial artery catheter~Acetylcholine~Nitroprusside~Norepinephrine~Nitroprusside and phenylephrine"
3065770|NCT02123069||Women without uterine fibroids|"Brachial artery catheter~Acetylcholine~Nitroprusside~Norepinephrine~Nitroprusside and phenylephrine"
3065771|NCT02123056|Active Comparator|Metoprolol|Metoprolol 50 mg po tablets will be provided for final dosing range (25 mg po BID to 100 mg po BID) for study duration (1 year). Patients will be started at 50 mg po BID and titrated over 2 weeks to target of 100 mg po BID.
3065772|NCT02123056|Placebo Comparator|Placebo|Matching placebo will be identical in appearance to the active treatment pill. Patients will be started at 50 mg po BID and titrated over 2 weeks to target of 100 mg po BID.
3065773|NCT02123043|No Intervention|Control|The control group will not experience any wheelchair training or 'practice' with a manual wheelchair.
3065774|NCT02123043|Experimental|Motor learning-based training|The motor learning-based training, like the 'practice' condition, will consist of six visits over three weeks. Each visit will involve two 5-minute wheeling trials with 10-minutes of rest between trials. The motor learning-based training will focus on variable practice and sporadic feedback.
3065775|NCT02123043|Active Comparator|Practice wheeling|To provide a comparable amount of exposure to wheelchair propulsion, the practice group will participate in the same number of visits and wheeling time as the motor-learning based training group. This will allow us to determine whether the motor-learning based training is superior to exposure through practice. The practice group will come to the lab six times over three weeks and wheel for two 5-minute trials with a 10-minute rest break in between. Participants randomized to this group will receive no feedback.
3065776|NCT02123030||Experimental|patients with pulmonary disease; and, patients with known or suspected lung or other cancers
3065777|NCT02123030||Control|healthy subjects (for example, family members of the patient or graduate students
3065778|NCT02123017|Experimental|90 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 30 grams of crystalline lactulose x three doses
3065779|NCT02123017|Experimental|135 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 45 grams of crystalline lactulose x three doses
3065780|NCT02123017|Experimental|180 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 60 grams of crystalline lactulose x three doses
3065781|NCT02123004|Experimental|Ticagrelor|"Investigational product/Dosage form and strength/Manufacturer:~ticagrelor/tablet /90mg/AstraZeneca 180mg loading dose for one day ,then 90mg per day for 4 weeks"
3065782|NCT02123004|Active Comparator|Clopidogrel|"Investigational product/Dosage form and strength/Manufacturer:~clopidogrel/tablet /75mg/Sanofi 300mg loading dose for one day ,then 75mg per day for 4 weeks"
3065816|NCT02122731|Experimental|Amiloride|This is a non-randomized and non-controlled study with only one treatment arm with amiloride.
3065783|NCT02122991||Able-Bodied Controls|Subjects must be between the ages of 30 and 64 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 22 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), unstable/uncontrolled seizures, neurodegenerative disease, Severe Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, any significant systemic illness or unstable medical condition (uncontrolled diabetes, hypo- or hyperthyroidism, systemic cancer), history of schizophrenia or bipolar disorder or any active psychosis, or alcohol/substance abuse or dependence (<6 months).
3065784|NCT02122991||Spinal Cord Injury|Subjects must be between the age of 30 and 64 years old, be English-literate and able to provide informed consent. They must be at least 1 year from the date of their spinal cord injury. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 22 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), unstable/uncontrolled seizures, neurodegenerative disease, Severe Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, any significant systemic illness or unstable medical condition (uncontrolled diabetes, hypo- or hyperthyroidism, systemic cancer), history of schizophrenia or bipolar disorder or any active psychosis, or alcohol/substance abuse or dependence (<6 months).
3065785|NCT02122978|Active Comparator|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
3065786|NCT02122978|Experimental|MBSCT 8 week course|Mindfulness Based Self Compassion Therapy
3065787|NCT02122978|Active Comparator|Mindfulness Based Self-Compassion - Audio guided|MBSC - minimal contact
3065788|NCT02122965|Experimental|Pharmacist-led medication review|Pharmacist-led medication review in the ED
3065789|NCT02122965|No Intervention|Usual care|Usual care includes nurse-led medication reconciliation.
3065790|NCT02122952|Experimental|Cohort 1|6.7 X 10^13 vg/kg of AVXS-101 delivered one-time through a venous catheter inserted into a peripheral vein (n=3)
3065791|NCT02122952|Experimental|Cohort 2|2.0 X 10^14 vg/kg of AVXS-101 delivered one-time through a venous catheter inserted into a peripheral vein (n=12)
3065792|NCT02122939|Experimental|Escitalopram|
3065793|NCT02122926|Experimental|Intensive discharge intervention|"The intervention is a multi-modal program consisting of the following:~Inpatient protocol for adjusting the discharge diabetes regimen;~Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;~Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);~Visiting nurse intervention after discharge;~Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;~Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and~Follow-up with PCP or endocrinologist within 1 week of discharge."
3065794|NCT02122926|No Intervention|Usual Care|Patients in the control arm of this study receive usual care.
3065795|NCT02122913|Experimental|Larotrectinib|"Escalation- Multiple doses of larotrectinib.~Expansion- The MTD dose and/or the appropriate dose for furher clinical investigation of larotrectinib found during the Escalation Phase."
3065796|NCT02122887|No Intervention|control group|no intervention for 3 months
3065797|NCT02122887|Experimental|experimental group|Peace-Building Intervention Process- The intervention process consists of eight sessions and adheres to a manualized protocol that we developed. Each session lasts 120 minutes.
3065798|NCT02122874|Active Comparator|Diet|The patients follow only a 1200 Kcal diet
3065799|NCT02122874|Experimental|Diet +PENS dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
3065800|NCT02122861|Experimental|ID-LV305|Dose escalation and expansion cohort including treatment of melanoma
3065801|NCT02122848|Experimental|Bilevel|The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
3065802|NCT02122835|Other|heart failure|aerobic exercise training
3065803|NCT02122835|Other|heart failure plus type 2 diabetes|aerobic exercise training
3065804|NCT02122822|Experimental|gp96 group|autologous gp96 vaccination + basal treatment
3065805|NCT02122809|Experimental|Chiauranib|Patients take a single dose of Chiauranib capsules for the pharmacokinetic study,then off for 5 days before the first cycle begins. In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle.
3065806|NCT02122796|Experimental|Acupuncture|Two sessions of acupuncture, at least twelve hours apart, post-mastectomy.
3065807|NCT02122796|No Intervention|Standard of Care|Standard of care post-mastectomy.
3065808|NCT02122783|Active Comparator|Conventional brace resistance (hardstop)|Default intervention
3065809|NCT02122783|Experimental|ADR™ brace resistance|Condition using the novel elastomer to provide brace support
3065810|NCT02122770|Experimental|MLN4924 + Fluconazole|"Part A: MLN4924, 8 milligram per square meter (mg/m^2), intravenously, once on Days 1 and 8; and fluconazole, 400 milligram (mg), tablets, orally, once on Day 4, and 200 mg, once daily on Days 5-10.~Part B: MLN4924, at a dose previously deemed tolerable, given on Days 1, 3, and 5 of each 21-day Cycle (Study C15010, Clinicaltrials.gov Identifier # NCT01862328) in combination with docetaxel or carboplatin + paclitaxel at standard dose regimen on Day 1 of each 21-day Cycle."
3065811|NCT02122770|Experimental|MLN4924 + Itraconazole|"Part A: MLN4924, 8-mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part A (safety lead-in step): MLN4924, 15mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part A: MLN4924, 20mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part B: MLN4924, at a dose previously deemed tolerable given, on Days 1, 3, and 5 of each 21-day Cycle (Study C15010, ClinicalTrails.gov Identifier # NCT01862328) in combination with docetaxel or carboplatin + paclitaxel at standard dose regimen on Day 1 of each 21-day Cycle."
3065812|NCT02122757|Placebo Comparator|Sham Anodal Cefaly tDCS|2 mA placebo anodal tDCS (the direct current is delivered just for 30 seconds) is applied over the visual cortex for 20 minutes, everyday for 2 months, in 15 patients
3065817|NCT02122718|Experimental|Allopurinol|
3065823|NCT02122666||Metabolic Syndrome|Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass
3065824|NCT02122666||Control|Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass
3065825|NCT02122653|Experimental|Older WT|Older people with weight training
3065826|NCT02122653|Experimental|Older WT and ES|Older people with weight training combined electrical stimulation.
3065827|NCT02122653|No Intervention|Young control group|Young people with control group
3065828|NCT02122627|Experimental|Vitamin D|colecalciferol 16.800 IU per week
3065829|NCT02122627|Placebo Comparator|Placebo|placebo
3065830|NCT02122614|Experimental|Experimental group|
3065831|NCT02122614|Active Comparator|Control group|
3065832|NCT02122601|Other|LBSA0103|single arm , LBSA0103 only
3065833|NCT02122588||OVATAR study patients|Females with serous and endometrioid ovarian, peritoneal and fallopian tube cancer 18 years and older, diagnosed 3 months before enrolment into the study or later, consented to participate in this non-interventional study, who are being treated for OC, FTC (Fallopian Tube Cancer) and PC (Peritoneal Cancer) in the oncology hospitals/departments in the Russian Federation.
3065834|NCT02122549|Experimental|HWD1000|Subjects using HWD1000
3065835|NCT02122536|Active Comparator|Xeomin right side; Xeomin to left side of face|Patients were randomized as to which side of the face was treated with Xeomin.
3065836|NCT02122536|Active Comparator|Botox right side; Botox to left side|Patients were randomized as to which side of the face was treated with Botox.
3065837|NCT02122523|Experimental|SLN identification with NIR-dye-subserosa injection|Near-Infrared (NIR) dye Indocyanin Green (ICG) to identify nodes with a newly developed NIR laparoscope. The investigators compared two different injection techniques; subserosal and submucosal injection.
3065838|NCT02122523|Active Comparator|SLN identification with NIR-dye-submucosal injection|Near-Infrared (NIR) dye Indocyanin Green (ICG) to identify nodes with a newly developed NIR laparoscope. The investigators compared two different injection techniques; subserosal and submucosal injection.
3065839|NCT02122510|Active Comparator|dexmetomedine group|dexmetomedine group will receive pre-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe labeled G 2.
3065840|NCT02122510|Active Comparator|Bupivacaine group|Bupivacaine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline in 20 ml syringe labeled G 2.
3065841|NCT02122497||abdominal aortic aneurysm (AAA) endovascular|endovascular aortic repair
3065842|NCT02122497||abdominal aortic aneurysm (AAA) open|open surgical repair
3065843|NCT02122497||abdominal aortic occlusive disease (AOD)|open surgical repair
3065844|NCT02122484|Placebo Comparator|Control group|Patients taking placebo
3065845|NCT02122484|Experimental|Colchicine|Active treatment group
3065846|NCT02122471|Experimental|Plecanatide 3.0 mg|Plecanatide tablets 3.0 mg QD for 12 weeks
3065847|NCT02122471|Experimental|Plecanatide 6.0 mg|Plecanatide tablets 6.0 mg QD for 12 weeks
3065848|NCT02122471|Placebo Comparator|Placebo|Matching placebo tablets QD for 12 weeks
3065849|NCT02122458|Active Comparator|hearing impaired vs hearing impaired + PTSD|The investigators will have two treatment groups fitted with mild-gain open-fit hearing aids and will be monitored across 6 months.
3065850|NCT02122458|Other|delayed treatment|A third group will consist of a delayed treatment group. This group will be monitored over 12 months with hearing aids fitted at 6 months.
3065851|NCT02122458|No Intervention|Diagnostic Testing|Battery of auditory and auditory related assessment tasks.
3065852|NCT02122445|Experimental|Low Back Pain|Lower body exercises before and after the application of Cramer Sports Motion tape
3065853|NCT02122432|Experimental|Teledermatology|"General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association and sends them to the dermatologist using a secured email server.~Dermatologist answer is standardized."
3065854|NCT02122432|No Intervention|Usual care|Usual care for dermatologic conditions requiring an expertise from a dermatologist involves the general practitioner 1) giving the patient a paper letter containing at least the following information: date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes) and 2) telling him to see the dermatologist of his choice (patient manages his appointments alone).
3065855|NCT02122419||lateral|spinal anesthesia performed during lateral position
3065856|NCT02122419||sitting|spinal anesthesia performed during sitting position
3065857|NCT02122406||Patients RA-BIO|Patients with rheumatoid arthritis treated with biological drugs (infliximab, adalimumab, etanercept, abatacept, tocilizumab, golimumab, certolizumab, rituximab)
3065858|NCT02122393|Active Comparator|Sertraline|
3065859|NCT02122393|Active Comparator|Cognitive Behavioural Therapy|
3065860|NCT02122393|Active Comparator|Combined Therapy|
3065861|NCT02122380|Experimental|Group A|Sitagliptin 100 mg by mouth daily for 30 days followed by Placebo daily for 30 days
3065862|NCT02122380|Experimental|Group B|Placebo daily for 30 days followed by Sitagliptin 100 mg daily for 30 days
3065863|NCT02122367|Experimental|stroke volume variation, pleth variability index|"stroke volume variation: recorded using the FloTrac/Vigileo system (Edwards Lifesciences)~pleth variability index: recorded using the Masimo Radical-7 monitor (Masimo Corporation, Irvine, CA, USA)"
3065864|NCT02122354|Experimental|Survey + videogame|"Hide and Seek videogame"
3065865|NCT02122341|Experimental|BackStop|Patients randomized to the Experimental arm will receive the BackStop gel during their ureteroscopic lithotripsy to prevent retrograde migration of stones or stone fragments.
3065866|NCT02122341|No Intervention|Control|Patients randomized to the control group will not use any devices to prevent retrograde migration of stones and stone fragments during their ureteroscopic lithotripsy.
3065867|NCT02122328|Active Comparator|Selective procedure|Selective laser photocoagulation of communicating vessels.
3094613|NCT01928472|Experimental|Group D|H7N9c high dose without adjuvant
3065869|NCT02122315|Experimental|Physical therapy plus dry needling|Best-evidence physical therapy intervention in addition to a single session of TrP-DN targeted to active TrPs in the neck-shoulder muscles.
3065870|NCT02122315|Active Comparator|Physical therapy|Best-evidence physical therapy intervention
3065871|NCT02122302|Experimental|Web-based health assessment|
3065872|NCT02122289|Experimental|Application of Smartphone|Weekly questionnaire on Smartphone
3065873|NCT02122289|Placebo Comparator|No application Smartphone|No Weekly questionnaire on Smartphone
3065874|NCT02122276|Experimental|SCI|SCI participated in a 4-month robot-assisted passive ankle exercise regimen.
3065875|NCT02122263||NAFLD after sleeve gastrectomy surgery|
3065876|NCT02122250|Experimental|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
3065877|NCT02122250|Active Comparator|Static web-based materials|Static version of the interactive web-based materials
3065878|NCT02122237|Experimental|Cathodal Cefaly tDCS|Cathodal Cefaly tDCS is delivered over the visual cortex at 2 mA of intensity, for 20 minutes, everyday for 2 months, in 14 patients. The anode is placed over the left DLPFC.
3065879|NCT02122224|Experimental|Group 1|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
3065880|NCT02122224|Experimental|Group 2|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
3065881|NCT02122224|Experimental|Group 3|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
3065882|NCT02122224|Experimental|Group 4|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
3065883|NCT02122211|Experimental|Betaine supplement|Will use powdered betaine (BetaPower, Dupont Nutrition) that is commercially available for food uses. This powder will be delivered as capsules containing 0.5 gram of powdered betaine which will be administered as eleven capsules twice per day (6 in the morning, 5 in the evening) for a daily total of 6 grams of betaine.
3065884|NCT02122198|Placebo Comparator|Placebo|Monthly placebo injections for 6 months under parent study (FAME) protocol (NCT01712230)
3065885|NCT02122198|Active Comparator|GnRH agonist|"Monthly injections of leuprolide acetate 3.75mg for 9 months; first 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study protocol.~Weekly application of estradiol patch 0.075mg/d months 6-9.~Daily medroxyprogesterone acetate 5mg by mouth for 12 days at week 30."
3065886|NCT02122185|Experimental|Metformin plus chemotherapy|Patients receive metformin hydrochloride PO BID and standard chemotherapy for 6 -8 cycles. Treatment with metformin hydrochloride continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
3065887|NCT02122185|Placebo Comparator|Placebo plus chemotherapy|Patients receive placebo PO BID and standard chemotherapy for 6 -8 cycles. Treatment with placebo continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
3065888|NCT02122172|Experimental|Treatment (afatinib)|Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3065889|NCT02122159|Experimental|MA09-hRPE Cellular Therapy|MA09-hRPE cells for transplantation will be provided by Ocata Therapeutics as a suspension frozen to the temperature of liquid nitrogen (approximately -196 °C). They will be processed at UCLA under GMPs according to protocol. Following vitrectomy performed under general anesthesia or waking sedation at the surgeon's discretion, hRPE cells will be introduced into a subretinal bleb formed by the injection of balanced salt solution (BSS). Direct viewing will guide the implantation of thawed and washed MA09-hRPE cells, resuspended in BSS, into the created bleb over a period of one minute. To avoid cell reflux, the cannula used to introduce the cells will be held in position for an additional minute. A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.
3065890|NCT02122146|Experimental|PF-06664178|Experimental
3065891|NCT02122133||PC 400|Patients treated with the PC 400 according to the IFU
3065892|NCT02122133||Conventional Embolic Coils|These are any approved embolic coils on the market used as part of the standard of care for treating intracranial aneurysms.
3065893|NCT02122120||Before HEN|Patients with tube feeding with kitchen diet for at least twelve months
3065894|NCT02122107||breast cancer survivors who had received chemotherapy|Participants will complete all assessments at enrollment and approximately (+/- 4 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
3065895|NCT02122107||breast cancer survivors who had not received chemotherapy|Participants will complete all assessments at enrollment and approximately (+/- 4 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
3065896|NCT02122107||non-cancer controls matched by age,education, and race|Participants will complete all assessments at enrollment and approximately (+/- 4 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
3065897|NCT02122094|Experimental|Sexual Health Promotion Intervention|The SHP Intervention consists of seven core and five optional modules covering topics related to sexual health. It is delivered in both community (outreach) settings and i clinic-based settings.
3065936|NCT02121782|Experimental|Quadrivalent influenza vaccine(Part A)|Day 1: GC3110A, 0.5ml, intramuscular, a single dosing
3065898|NCT02122081|Experimental|Treatment (OSMI, allogeneic transplant)|"CONDITIONING REGIMEN: Patients undergo organ-sparing marrow irradiation BID on days -6 to -4 and receive cyclophosphamide IV over 1-2 hours every 24 hours on days -3 to -2. Patients with an unrelated donor also receive anti-thymocyte globulin every 24 hours on days -4 to -2.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 and continuing for at least 6 months and methotrexate IV on days 1, 3, 6, and 11.~TRANSPLANT: Patients undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0."
3065899|NCT02122068|Experimental|Central Meditation and Imagery Therapy|Meditation and mindfulness 4 week program
3065900|NCT02122068|Active Comparator|Relaxation cd|Listening to a relaxation cd
3065901|NCT02122055|Experimental|Propofol/Dexmedetomidine|"Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.~After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning."
3065902|NCT02122055|Experimental|Midazolam/Dexmedetomidine|"Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.~After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning."
3065903|NCT02122042|Experimental|HBOT|Group will be treated with HBOT for 60 treatments in 3 months.
3065904|NCT02122042|Other|Control/Crossover|Control for 3 months without treatment, and then HBOT for 60 treatments in 3 months.
3065905|NCT02122029|Experimental|Bariatric Surgery|
3065906|NCT02122029|Experimental|Lifestyle counselling|
3065907|NCT02122016|Experimental|SmartCare|A computer driven weaning ventilator, using closed-loop ventilation, taking into account patients lung mechanics and exhaled CO2.
3065908|NCT02122016|Active Comparator|Conventional weaning protocol|A conventional weaning protocol consisting of a daily weaning screen, which is performed by physiotherapist. All patients who are mechanically ventilated for more than 24 hours are given a spontaneous breathing trial.
3065909|NCT02122003|Experimental|sorafenib|Sorafenib 400 mg bid
3065910|NCT02121990|Experimental|Cisplatin, Paclitaxel, bevacizumab & olaparib|All treatments will be given in the outpatient setting. A cycle is 21 days. The sequence of infusions on Day 1 will be IV paclitaxel (135 mg/m2), then IV bevacizumab (15 mg/kg, beginning Cycle 2). On Day 2 patients will receive IP cisplatin (75 mg/m2). Patients will be given twice-daily treatment with oral olaparib in cycles 1-6 for 7 consecutive days, starting on Day 2 (Days 2-8). IP paclitaxel (60 mg/m2) will be given on Day 8. Sequential cohorts of 3 patients will receive escalating doses of olaparib (50mg BID, 100mg BID, 200mg BID).
3065911|NCT02121977|Active Comparator|Elevate Anterior and Apical|Prolapse repair with mesh
3065912|NCT02121977|Active Comparator|Native Tissue Repair|Prolapse repair with sutures
3065913|NCT02121964|Other|Capsulectomy|Capsulectomy in Direct Anterior Total Hip Arthroplasty
3065914|NCT02121964|Other|Capsulotomy|Capsulotomy in Direct Anterior Total Hip Arthroplasty
3065915|NCT02121951|Active Comparator|Local Anesthetic infiltration and MAC|"Local Anesthetic infiltration with 1% lignocaine~MAC with IV Midazolam Img\ml and Fentanyl 10 mic\ml"
3065916|NCT02121951|Experimental|Quadratus Lumborum block and MAC|"QL block with 0.25% levobupivacaine (Chirocaine, Abbott, Ireland) and 1% lignocaine~MAC with IV Midazolam Img\ml and Fentanyl 10 mic\ml"
3065917|NCT02121938||very low birth weight infants|Very low birth weight infants weighing 1500 grams at birth or less
3065918|NCT02121912|Experimental|FPH Pilairo Q CPAP mask|The Sleep Technician will fit the FPH Pilairo Q CPAP mask to the participant.
3065919|NCT02121912|Active Comparator|Any other market released nasal or nasal-pillow CPAP mask|The Sleep Technologist will fit the participant with any market released nasal or nasal-pillow CPAP mask
3065920|NCT02121886|Experimental|Parietal peritoneum|
3065921|NCT02121873||Women with and without breast cancer|Nipple aspirator, ductal lavage microcatheter, blood draw
3065922|NCT02121860|Experimental|Chil-Pugh Class A|All subjects with mild hepatic impairment received a single 50 mg oral dose of IDN-6556
3065923|NCT02121860|Experimental|Chil-Pugh Class B|All subjects with moderate hepatic impairment received a single 50 mg oral dose of IDN-6556
3065924|NCT02121860|Experimental|Chil-Pugh Class C|All subjects with severe hepatic impairment received a single 50 mg oral dose of IDN-6556
3065925|NCT02121860|Experimental|Normal Hepatic Function|All healthy volunteers subjects received a single 50 mg oral dose of IDN-6556
3065926|NCT02121847|Experimental|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily and carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
3065927|NCT02121834|Experimental|LY3050258|Daily dose of LY3050258 for 28 days: Cohort A 10 mg, Cohort B 30 mg, Cohort C 90 mg, Cohort D 180 mg and Cohort E 360 mg.
3065928|NCT02121834|Placebo Comparator|Placebo|Daily dose of placebo matching LY3050258 for 28 days.
3065929|NCT02121821|No Intervention|Control|A control group of pregnant women receiving no intervention (i.e. no SMS reminders).
3065930|NCT02121821|Experimental|SMS reminder messages|The intervention group will be composed of pregnant women receiving SMS reminder messages via the SMS Mother Reminder system.
3065931|NCT02121808|Experimental|Supine|NIPPV and Tidal volume
3065932|NCT02121808|Experimental|Beach-chair (Back : 25 deg)|NIPPV and Tidal volume
3065933|NCT02121808|Experimental|Proclive (Global 25 deg)|NIPPV and Tidal volume
3065934|NCT02121795|Experimental|F/TAF + 3rd Agent|Participants will receive F/TAF (200/25 mg or 200/10 mg) plus FTC/TDF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks. Dosing of F/TAF will be dependent on the third agent of the participants' pre-existing treatment regimen.
3065935|NCT02121795|Active Comparator|FTC/TDF + 3rd Agent|Participants will receive FTC/TDF plus F/TAF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks.
3065937|NCT02121782|Experimental|Quadrivalent influenza vaccine(Part B)|Day 1: GC3110A, 0.5ml, intramuscular, a single dosing
3065938|NCT02121782|Active Comparator|Trivalent influenza vaccine(Part B)|Day 1: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing
3065939|NCT02121756|Experimental|Dipyridamole|ARM A: Dipyridamole 100 mg 4 times daily for 24 weeks
3065940|NCT02121756|Active Comparator|Placebo, then Dipyridamole|ARM B: Dipyridamole placebo 1 capsule 4 times daily for 12 weeks, then Dipyridamole 100 mg 4 times daily for 12 weeks.
3065941|NCT02121743|Experimental|Strattice|a strattice (10 x 10) will be used during the surgery, prior to the colostomy's conception
3065942|NCT02121743|Placebo Comparator|No strattice|the colostomy is not reinforced with a mesh
3065943|NCT02121730||Kidney Transplantation|Patients who had undergone renal transplantation for 10 years in the interregion Northwest (Normandy, Picardy and Nord-Pas de Calais).
3065944|NCT02121717|Experimental|Arm 1|Patients administrate Chiglitazar 32mg once daily for 52 weeks
3065945|NCT02121717|Experimental|Arm 2|Patients administrate Chiglitazar 48mg once daily for 52 weeks
3065946|NCT02121717|Placebo Comparator|Arm 3|Patients administrate placebo for 24 weeks.From week 25 to 52, patients are randomly switched to Arm 1 and Arm 2, and receive the treatment accordingly.
3065947|NCT02121704|No Intervention|Controll Group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. The Magnetic Endoscope Imaging (Scope Guide) function WILL NOT BE USED during the investigation.
3065948|NCT02121704|Active Comparator|Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. The Magnetic Endoscope Imaging (Scope Guide) function WILL BE USED during the investigation.
3065949|NCT02121691|Experimental|Walk by Faith|Intervention arm
3065950|NCT02121691|No Intervention|Comparison|Non-intervention arm
3065951|NCT02121678|Experimental|Run-in - Aerobic - Resistance|"Week -12 to 0: Run-in period with no training~Week 0 to 12: Aerobic training on ergometer bicycle~Week 12 to 24: Resistance training with dumbbells"
3065952|NCT02121678|Experimental|Run-in - Resistance - Aerobic|"Week -12 to 0: Run-in period with no training~Week 0 to 12: Resistance training with dumbbells~Week 12 to 24: Aerobic training on ergometer bicycle"
3065953|NCT02121665|Experimental|Probiotic (Inersan) Arm|Inersan Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
3065954|NCT02121665|Placebo Comparator|Placebo Arm|Placebo Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
3065955|NCT02121652|Active Comparator|Healthy eating control|Healthy eating control involves healthy eating content delivered in a 90 minute group session with two follow up phone calls.
3065956|NCT02121652|Experimental|Cognitve behaviroal therapy|Cognitive behavioral therapy for insomnia includes content on sleep restriction, stimulus control, relaxation, cognitive restructuring and sleep hygiene content delivered in a 90 minute group intervention with two follow up phone calls.
3065957|NCT02121639|Experimental|AZD5363|AZD5363
3065958|NCT02121639|Placebo Comparator|Placebo|Placebo
3065959|NCT02121626||Chemotheraphy Treatement|The study will be limited to NHS patients to reduce complications associated with the need for additional funding authorisations from private health care providers for algorithm-instigated investigations. It is not envisaged that participation in other studies running within the GI unit at The Royal Marsden Hospital will preclude entry into this study except in the event of those rare studies where the study is specifically measuring toxicity of treatment as the primary end point.
3065960|NCT02121613|Experimental|Permixon® 160 mg & Placebo|
3065961|NCT02121613|Placebo Comparator|Placebo|
3065962|NCT02121613|Other|Tamsulosine LP & Placebo|Active control arm
3065963|NCT02121600|Other|Docetaxel|Patients who will be receiving Docetaxel as cancer treatment will be assigned to Arm 1. All patients in this cohort will have a [F-18]-FCH PET scan with full body MRI scan
3065964|NCT02121600|Other|Abiraterone|Patients who will be receiving Abiraterone as cancer treatment will be assigned to Arm 2. All patients in this cohort will have a [F-18]-FCH PET scan with full body MRI scan.
3065965|NCT02121587||Pain self-management course|This is a single group observational cohort study. Participants are adults with persistent musculoskeletal pain who choose to participate in an optional, six week pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment for individual patients.
3065966|NCT02121574||Zero-flux and ingestible thermometer|Ingestion of a capsule thermometer pre-operatively Attachment of a zero flux temperature electrode intraoperatively Standard oesophageal thermometer
3065967|NCT02121561|Experimental|Self-Acceptance Group Therapy|Participants receive Self-Acceptance Group Therapy
3065968|NCT02121548|Placebo Comparator|Outreach|Gets outreach materials and info on where to get screened by CHW.
3065969|NCT02121548|Active Comparator|CHW Outreach|Comprehensive CHW outreach including home visit, detailed 1:1 education, patient navigation
3065970|NCT02121548|Active Comparator|CHW Outreach and HPV Self-Sampling|Same as Arm 2 with a CHW outreach but also option of doing HPV home self-sampling
3065971|NCT02121535|Experimental|T80/A5/H12.5 mg FDC|A Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination (FDC) tablet
3065972|NCT02121535|Active Comparator|T80/A5 mg FDC+H12.5 mg mono|A Telmisartan 80 mg/ Amlodipine 5 mg fixed dose combination (FDC) tablet and a Hydrochlorothiazide 12.5 mg tablet
3065973|NCT02121522|Experimental|BI 144807|twice daily
3065974|NCT02121509|Experimental|FDC first, fasted|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
3065975|NCT02121509|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
3065976|NCT02121509|Experimental|FDC first, fed|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
3065977|NCT02121509|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
3066055|NCT02120976|Experimental|Dose 6 JTT-252 or Placebo|Tablets, single dose in fasted condition
3065978|NCT02121496|Experimental|Resources for Postpartum Parenting|Behavioral intervention will include techniques to help mothers get their infants to cry/fuss less and sleep more to determine if this has an effect on prevalence of postpartum depression in low SES women and if it improves the quality of mother-infant interaction and subsequent child development.
3065979|NCT02121496|No Intervention|Control Group|This group will not receive the coaching tips to help babies cry less and sleep more.
3065980|NCT02121483|Experimental|empagliflozin high dose|Patient to receive a high dose of empagliflozin
3065981|NCT02121483|Experimental|empagliflozin medium dose|Patient to receive a medium dose of empagliflozin
3065982|NCT02121483|Experimental|empagliflozin low dose|Patient to receive a low dose of empagliflozin
3065983|NCT02121457|No Intervention|Control Group|This group did not receive any intervention.
3065984|NCT02121457|Experimental|Treatment Group|This group took one Brazil nut daily during 6 months.
3065985|NCT02121444||Cohort 1|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect auto-injector
3065986|NCT02121431|Experimental|Online-Delivered Parenting Intervention|The Online-Delivered Parenting Intervention, which is based on the Triple P--Positive Parenting Program system of interventions, is an interactive website designed to engage and activate the participant through sequenced, personalized, interactive, and video-based content. The intervention emphasizes a self-regulatory process, parent specification of goals, practical and straightforward parenting strategies, modeling, and action activation.
3065987|NCT02121431|Active Comparator|Staff-Delivered Parenting Intervention|The Staff-Delivered Parenting Intervention is based on the Triple P--Positive Parenting Program system and involves 10 face-to-face sessions with each family. This intervention is the well-established Level 4 Standard Triple P program.
3065988|NCT02121418|Experimental|Treatment (decitabine, cytarabine)|Patients receive decitabine IV daily on days 1-10 and cytarabine IV QD on days 1-7. Treatment repeats every 28-35 days for 2 courses in the absence of disease progression or unacceptable toxicity. After course 3, patients achieving remission will receive 1-2 more courses of therapy at the same dose. Patients in remission with significant side effects will receive decitabine and cytarabine at decreased doses. Patients not achieving remission will not receive any more treatment.
3065989|NCT02121405|Experimental|Primary surgery|The patients receive primary rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with TME. To patients with pathological confirmed positive circumferential margin (CRM), postoperative concurrent radiochemotherapy is required that starts in 3 months post operation with capecitabine. Capecitabine and Oxaliplatin (CapeOx) chemotherapy starts in 4 weeks post operation to total of 6 cycles/18 weeks. To patients with pathological confirmed negative CRM, radiotherapy is omitted. The stage III patients receive 8 cycles/6 months CapeOx chemotherapy. The stage II patients with low microsatellite instability (MSI) receive 8 cycles/6 months Capecitabine chemotherapy. The stage II patients with high MSI and stage I patients do not receive adjuvant therapy.
3065990|NCT02121405|Active Comparator|Preoperative radiochemotherapy|All of the patients receive conventional concurrent radiochemotherapy with capecitabine for 5 weeks. Then all of the patients receive 2 cycles/6 weeks capecitabine chemotherapy. Patients receive rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with total mesorectal excision 8 weeks post radiotherapy. All of the patients receive 5 cycles/15 weeks capecitabine adjuvant chemotherapy.
3065991|NCT02121392|Sham Comparator|Epidural Catheter without Adductor Canal Nerve Block Catheter|Patients randomized to the sham catheter will have a sham catheter placed on the skin and obscured with an opaque dressing and attached to a functional pump which will not be turned on.
3065992|NCT02121392|Experimental|Epidural Catheter with Adductor Canal Nerve Block Catheter|Patients will receive a continuous adductor canal block placed under ultrasound guidance under the supervision of an attending physician who is fellowship trained.
3065993|NCT02121379|No Intervention|control|stretching exercise
3065994|NCT02121379|Experimental|pulmonary rehablitation|warming up exercise strengthening exercise aerobic exercise cool down
3065995|NCT02121366|Experimental|Insulinoma|Patients with Insulinomas will received EUS-guided ethanol ablation therapy
3065996|NCT02121353|Experimental|PF582|PF582 is provided as single use vials and will be administered by intra‐vitreal injection on Day 1, 28 and 56.
3065997|NCT02121353|Active Comparator|Lucentis|Lucentis® is provided as single use vials and will be administered by intra‐vitreal injection on Day 1, 28 and 56.
3065998|NCT02121340|Experimental|Behavioral Activation|CC-DDR is a novel mental health/ophthalmologic intervention that we are designing to treat depression and lower HbA1C levels in older AAs with mild-to-moderate DR and comorbid depression. Community Health Workers, who match participants in race and cultural background, will work with ophthalmologists in the retina clinic to educate participants on the links between depression, HbA1C, and DR, and will extend care into the home where they will use Behavioral Activation to treat depression and improve diabetes self-management skills.
3065999|NCT02121340|No Intervention|Usual Care|Usual Care
3066000|NCT02121327|Active Comparator|usual care|usual care group receive regular outpatient treatment
3066001|NCT02121327|Experimental|disease management|desease management program include self management education by nurse on 6months.
3066002|NCT02121314|Active Comparator|Fasting-Fed|blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE as iv therapy; on day 2, HRZE as oral therapy in fasting condition (2 hours before meals); and on day 3 HRZE as oral therapy in fed condition (after meals).
3066003|NCT02121314|Active Comparator|Fed-Fasting|blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE therapy as iv therapy; day 2, HRZE as oral therapy in fed condition, and on day 3, HRZE as oral therapy in fasting condition
3066004|NCT02121301|Experimental|Arm 1|Low Dose - SkQ1
3066005|NCT02121301|Experimental|Arm 2|High Dose - SkQ1
3066006|NCT02121301|Placebo Comparator|Arm 3|Placebo - SkQ1 (Vehicle)
3066007|NCT02121288|Experimental|Ticagrelor|oral ticagrelor 90 mg (yellow) tablet
3066008|NCT02121288|Active Comparator|Clopidogrel|oral clopidogrel 75 mg (pink) tablet
3066009|NCT02121275||Laparoscopic surgery|Patients undergoing laparoscopic surgery under general anaesthesia, patients undergo ultrasound of the lungs and electric impedance tomography at 4 times during anaesthesia
3066056|NCT02120976|Experimental|Dose 7 JTT-252 or Placebo|Tablets, single dose in fasted condition
3066010|NCT02121262|Experimental|700 μg dexamethasone|700 μg dexamethasone intravitreal injection in the study eye on day 1, month 5, and month 10.
3066011|NCT02121262|Other|Laser Photocoagulation|Laser photocoagulation on day 1, and on months 3, 6, and 9, if retreatment indicated.
3066012|NCT02121249|Experimental|Robot assisted pedicle screw fixation|posterior lumbar interbody fusion using Robot assisted pedicle screw fixation (Renaissance, Mazor Robotics Ltd, Caesare, Israel)
3066013|NCT02121249|Active Comparator|Free hand technique|using Free hand technique, posterior lumbar interbody fusion (No specific device)
3066014|NCT02121236||Patients with benign radiolucent lesions|
3066015|NCT02121223|Active Comparator|Control|Patients in control group will receive current standard therapy for STEMI: manual thrombus aspiration + Promus Element stent implantation ( with a pressure less than 12 atm), but not post-dilatation
3066016|NCT02121223|Experimental|Post-dilatation|Patients in this group will receive high pressure post-dilatation with a Quantum Maverick balloon after manual thrombus aspiration + Promus Element stent implantation
3066017|NCT02121210|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg subcutaneous (SC) injection every two weeks (q2w) for 24 weeks.
3066018|NCT02121210|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w for 24 weeks.
3066019|NCT02121184|Active Comparator|Group A|Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. Oxytocin management will continue as per the routine oxytocin protocol
3066020|NCT02121184|Experimental|Group B|Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. A half-dose oxytocin will be initiated and not increased until 60 minutes after.
3066021|NCT02121171|Experimental|Ologen Collagen Matrix Intervention|Combined trabeculotomy-trabeculectomy with subconjuncitval Ologen matrix implant implantation is a new procedure that has less post operative complications with good results, it is to be applied in children.
3066022|NCT02121171|Active Comparator|Combined trabeculotomy-trabeculectomy|Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
3066023|NCT02121158|Other|1|ICD implantation in addition to Optimal Medical Therapy
3066024|NCT02121158|Active Comparator|2|Optimal Medical Therapy
3066025|NCT02121145|Experimental|Vivotif + Typherix primary immunization|Vivotif + Typherix primary immunization
3066026|NCT02121145|Experimental|Vivotif booster|Volunteers previously immunized with Vivotif, now receiving a Vivotif secondary immunization
3066027|NCT02121145|Experimental|Typherix booster|Volunteers previously immunized with Typherix, now receiving a Typherix secondary immunization
3066028|NCT02121145|Experimental|Vivotif + Typherix booster|Volunteers previously immunized with Vivotif and Typherix, now receiving Vivotif and Typherix as secondary immunization
3066029|NCT02121132||No treatment|
3066030|NCT02121119|Active Comparator|Lidocaine|0.5% lidocaine infusion hour to 5 ml Baxter Infusor elastomeric pump 5 ml / hr.
3066031|NCT02121119|Placebo Comparator|Bupivacaine|Infusion of 0.1% bupivacaine hour to 5 ml Baxter Infusor elastomeric pump 5 ml / hr.
3066032|NCT02121106|Experimental|Cognitive Remediation|Participants in this group will receive active cognitive remediation.
3066033|NCT02121106|Sham Comparator|Sham Cognitive Remediation|Participants in this group will receive a sham comparison, which is a computerized exposure to the same exercises as the active intervention, but with cognitively complex elements removed and no titration of the difficulty of tasks.
3066034|NCT02121093|No Intervention|alpha band of the EEG and electromyographic activity|- 20 will be in the evaluation group (EG); then review the alpha band of EEG and EMG activity.
3066035|NCT02121093|Experimental|Vibration|"• 20 vai participar no grupo de baixa freqüência de vibração estimulação (LFVS);~20 no grupo de estimulação da vibração de média freqüência (MFVS);~20 vai participar no grupo de alta freqüência de vibração estimulação (HFVS). then review the alpha band of EEG and EMG activity."
3066036|NCT02121080|Experimental|Cohort 1|Dosing regimen 1
3066037|NCT02121080|Experimental|Cohort 2|Dosing regimen 2
3066038|NCT02121080|Experimental|Cohort 3|Dosing regimen 3
3066039|NCT02121080|Experimental|Cohort 4|Dosing regimen 4
3066040|NCT02121080|Experimental|Cohort 5|Dosing regimen 5
3066041|NCT02121067|Experimental|LNG-IUS placed at 2 weeks postpartum|Enrolled women will have the LNG-IUS placed at two-weeks (14-20 days) postpartum
3066042|NCT02121041|No Intervention|Usual Care|Participants in the usual care arm will have 2 ABPM sessions during the study, but ABPM will not be used to make a diagnosis or dictate anti-hypertensive treatment. Any recommendations for anti-hypertensive treatment will be made only via regular clinical care.
3066043|NCT02121041|Active Comparator|ABPM Guided|Participants in the ABPM-guided arm will undergo 3 ABPM sessions. Results of ABPM will be used to make diagnoses and dictate anti-hypertensive treatment as applicable. Anti-hypertensive medications may include: Amlodipine, Chlorthalidone and/or Losartan.
3066044|NCT02121028||Intracranial Atherosclerotic Disease, Stroke/TIA|Stroke/TIA due to high grade IAD ≤21 days from symptom onset.
3066045|NCT02121015|Active Comparator|Self-Directed|Access to the e-health intervention (an interactive website with didactic material and interactive tools) for participants to use at their own pace for 8 weeks (Self-Directed)
3066046|NCT02121015|Experimental|Share|Access to the same e-health intervention + an internet social networking component consisting of up to 12 other pregnant women (Share).
3066047|NCT02121002|Experimental|Diclofenac Sodium Topical Gel, 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
3066048|NCT02121002|Active Comparator|Voltaren Topical Gel, 1%|Voltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
3066049|NCT02121002|Placebo Comparator|Vehicle Diclofenac Sodium Topical Gel|Vehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks
3066050|NCT02120976|Experimental|Dose 1 JTT-252 or Placebo|Tablets, single dose in fasted condition
3066051|NCT02120976|Experimental|Dose 2 JTT-252 or Placebo|Tablets, single dose in fasted condition
3066052|NCT02120976|Experimental|Dose 3 JTT-252 or Placebo|Tablets, single dose in fasted condition
3066053|NCT02120976|Experimental|Dose 4 JTT-252 or Placebo|Tablets, single dose in fasted condition
3066054|NCT02120976|Experimental|Dose 5 JTT-252 or Placebo|Tablets, single dose in fasted condition
3094819|NCT01927094|Active Comparator|Control|ORS-ad libitum
3066061|NCT02120950|Active Comparator|Eylea plus sham PDT|Patients receive Eylea 2mg plus SHAM PDT as indicated
3066062|NCT02120950|Experimental|Eylea plus active PDT|Patients receive Eylea 2mg plus ACTIVE PDT as indicated
3066063|NCT02120937|Experimental|MBCT-C Therapy|Mindfulness Based Cognitive Therapy for Children is a manualized psychotherapeutic intervention that combines mindfulness techniques with certain features of cognitive behavioral therapy. This particular protocol for youth includes weekly group sessions, regular home practice, and the core curriculum of formal mindfulness practices (e.g., body scan, sitting, movement, and walking meditations).
3066064|NCT02120924|Active Comparator|Finacea|Finacea® (azelaic acid) Gel, 15% (Intendis)
3066065|NCT02120924|Experimental|Azelaic Acid|Azelaic Acid, 15% topical gel (Watson Laboratories, Inc.)
3066066|NCT02120924|Placebo Comparator|Vehicle Gel|Gel Vehicle of the test product (Watson Laboratories, Inc.)
3066067|NCT02120911|Experimental|Pertuzumab, trastuzumab|Pertuzumab, trastuzumab
3066068|NCT02120898|Active Comparator|Zyclara® (imiquimod)|Reference listed drug: Zyclara 2.5% cream (Medicis)
3066069|NCT02120898|Experimental|Imiquimod|Imiquimod 2.5% cream (Actavis)
3066070|NCT02120898|Placebo Comparator|Vehicle cream|Cream vehicle of the test product (Actavis)
3066071|NCT02120885|Experimental|Exercise group|physical activity intervention
3066072|NCT02120885|No Intervention|Control group|
3066073|NCT02120872|Active Comparator|PRF and SMV Group|sites treated with Open Flap Debridement with Platelet Rich Fibrin along with Simvastatin
3066074|NCT02120872|Sham Comparator|PRF Group|sites treated with Open Flap Debridement with autologous Platelet Rich Fibrin
3066075|NCT02120872|Other|OFD Group|sites treated with Open Flap Debridement i.e. conventional flap surgery
3066076|NCT02120859|Experimental|FFR - guided DEB angioplasty|DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis < 40% and FFR > 0.8.
3066077|NCT02120859|Other|DEB angioplasty with provisional bare metal stenting|In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
3066078|NCT02120846|Experimental|Flywheel leg-press resistance exercise|Participants from the resistance exercise group will perform a 12-wk unilateral flywheel resistance training program with the paretic limb. Four sets of seven coupled concentric and eccentric actions will be completed in the leg press device using flywheel technology twice weekly. Power in each set and repetition will be measured. During all training sessions, subjects will receive visual real-time feedback of power and force produced during each concentric-eccentric action.
3066079|NCT02120846|No Intervention|Control|Daily routines
3066080|NCT02120833|Active Comparator|EPI|
3066081|NCT02120833|Experimental|NEE|
3066082|NCT02120820|Active Comparator|Multisensory environment|Multisensory environment (MSE): 30 minutes/session, twice a week for 10 weeks
3066083|NCT02120820|Active Comparator|Massage therapy|Massage therapy (MT): 15 minutes/session, twice a week for 10 weeks
3066084|NCT02120820|Other|Control group|Control group: usual care for 10 weeks, with attention and interactions with the caregivers only.
3066085|NCT02120820|Active Comparator|Massage in multisensory environment|Participants receive 15 minutes massage therapy in multisensory environment (MT-MSE), twice a week for 10 weeks.
3066086|NCT02120807|Experimental|certolizumab, cisplatin and pemetrexed|Patients will receive certolizumab with 6 cycles of cisplatin & pemetrexed. Cycle of chemo will be 3 weeks. Certolizumab will be adm in the following fashion: first dose administered at the time of treatment initiation, second dose will be given after 2 weeks of treatment, third dose after four weeks of treatment, & subsequent doses given every 4 weeks thereafter. Patients will be monitored for progression of disease using RECIST 1.1 with scans to be performed every 6 weeks. Posttreatment biopsies will be performed at the time of treatment discontinuation. Two dose levels of certolizumab will be tested, 200mg & 400mg. A non-therapeutic cohort of 10 patients with adenocarcinomas who will be undergoing standard of care treatment with platinum based chemotherapy + pemetrexed +/- bevacizumab will be consented for blood draws before each cycle of treatment. This blood will be analyzed for cytokines and will serve as a reference for the experimental arm.
3066087|NCT02120794|Experimental|530G insulin pump|Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
3066088|NCT02120781|Experimental|Azficel-T (autologous fibroblasts)|Azficel-T will be injected into the vocal fold(s) three times at two week intervals.
3066089|NCT02120781|Placebo Comparator|Control|Sterile saline will be injected into the vocal fold(s) three times at two week intervals.
3066090|NCT02120768|Experimental|Barrier resection|"Barrier resection was defined as en bloc removal of tumor with surrounding barriers. The barriers include muscular fascia, vascular adventitia, epineurium and periosteum, in some cases where there is no barrier, 3-5cm of healthy tissue is considered equivalent. Barrier resection was developed according to the above characteristics of STSs, which featured with the fact that sarcomas take the path of least resistance and initially grow within the anatomical compartment in which they arose, and the phenomenon that skip metastases are limited within the same anatomic compartment in which the primary lesion is located.Further surgery would be 1cm resection if a recurrence occurs."
3066091|NCT02120768|Active Comparator|1 cm resection|Surgical margin width is determined mainly by the distance from the tumor edge to the periphery of the specimen, different margin width of 1-5cm has been recommended for obtaining a safe margin,but the local recurrence rate remains to be 10-25%. Further surgery would be barrier resection if a recurrence occurs.
3066092|NCT02120755|Active Comparator|AmnioClear™|AmnioClear™ Human Allograft Amniotic Membrane
3066093|NCT02120755|No Intervention|Standard of Care|Standard moist wound dressing (saline wet-to-moist or a hydrogel dressing)
3066094|NCT02120742|Experimental|Social Norming|"The first group will receive SMS message reminders framed as social norming (ie Most of your peers wear helmets)."
3066095|NCT02120742|Experimental|Fear Appeal|"The second group will receive SMS message reminders framed as fear appeals (ie Not wearing your helmet increases your chance of dying in an accident)."
3066096|NCT02120742|Placebo Comparator|Control|The third group will act as the control and receive texts that relate to general road safety, but not helmet use.
3066097|NCT02120729|No Intervention|Standard of Care|500 patients assigned to standard-of-care pharmacotherapy, for whom CYP2D6 genotype is determined but not utilized to guide drug prescription and psychotropic therapy follows the institutional norm.
3066098|NCT02120729|Active Comparator|Genotype-guided Care|1000 patients assigned to genetically-guided pharmacotherapy, for whom CYP2D6 genotype is determined but not utilized to guide drug prescription as part of psychotropic therapy.
3066099|NCT02120716|Experimental|Health Check-Up of Expectant Moms|Participants receive computer delivered intervention (Health Check-up for Expectant Moms)
3066100|NCT02120716|No Intervention|Time and attention matched control group|Participants will be presented a brief series of videos of television shows, with subsequent ratings of subjective preference
3066101|NCT02120703|Active Comparator|gabapentin|
3066102|NCT02120703|Active Comparator|Pregabalin|
3066103|NCT02120690|Experimental|Trigeminal nerve stimulation - active|10-day TNS interventional protocol over an 10-day follow-up
3066104|NCT02120690|Sham Comparator|Trigeminal nerve stimulation|10-day sham interventional protocol over an 10-day follow-up
3066105|NCT02120677|Experimental|Itraconazole ointment|Patients with histologically proven BCC will be eligible for study enrollment. 50% itraconazole compounded in petrolatum jelly will be applied under occlusion for up to 3 to 7 days.
3066106|NCT02120664|Experimental|Amyloid Negative Subjects|Approximately 10 cognitively normal young subjects will receive a single i.v. bolus injection of approximately 370 megabecquerel (MBq) (10 millicurie [mCi]) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.
3066107|NCT02120664|Experimental|Amyloid Positive Subjects|Approximately 25 subjects with a range of amyloid density comprised of subjects clinically diagnosed with Alzheimer's Disease (AD) and subjects at risk for elevated amyloid density will receive a single i.v. bolus injection of approximately 370 MBq (10 mCi) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.
3066108|NCT02120651|Active Comparator|Fibrin monomer|40 patients, the material was ready to use in the case of the fibrin monomer it was maintained in cooling according to the indications of lab maintenance and it was taken out a few minutes before using the material to prepare it according to instructional use and thus ensure that the conditions of maintenance of equipment are appropriate to the best outcome with their use.
3066109|NCT02120651|Placebo Comparator|Hemostatic sponge|40 patients, the material was ready to use in the case of the hemostatic sponge was cut into small size, prepared and impregnated with hydrocortisone as in the standard procedure.
3066110|NCT02120638|Active Comparator|Pyrazinamide Sensitive Comparator|"Pyrazinamide containing regimen: Regimen B1 - 6ZAmkLfxClrPto\6ZlfxClrPto~Six months of chemotherapy with Pyrazinamide,Amikacin,Levofloxacin,Clarithromycin,plus Prothionamide,followed by~Six months of Pyrazinamide,Levofloxacin,Clarithromycin,plus Prothionamide"
3066111|NCT02120638|Experimental|Pyrazinamide Resistant Comparator|"Regimen without Pyrazinamide: Regimen B2 - 6HAmkLfxClrPto\18HlfxClrPto~Six months of chemotherapy with Isoniazid,Amikacin,Levofloxacin,Clarithromycin,plus Prothionamide,followed by~Eighteen months of Isoniazid,Levofloxacin,Clarithromycin,plus Prothionamide"
3066112|NCT02120625||Lumbar MB RFN|Patients undergoing lumbar medial branch radiofrequency ablation using the Nimbus MEE Probe who undergo MRI and EMG validation testing of efficacy of intended lesion production.
3066113|NCT02120612||Historical Control Group|Historical Control Group will be assessed for knowledge prior to the implementation of the educational program.
3066114|NCT02120612||Naloxone Education Intervention Group|Group to begin receiving the Naloxone Education Intervention on the signs of opioid overdose and appropriate use of naloxone.
3066115|NCT02120599|Active Comparator|corn-soy-blend|This is the control group for the study, which will receive the Malawi standard of care. The treatment provided to women randomized to this arm of the study includes daily iron (60 mg) and folic acid (400 mcg) supplementation, along with 4 kg/2 weeks corn-soy blend (~357 gm/d CSB).
3066116|NCT02120599|Experimental|corn-soy-blend + multiple micronutrients|The treatment provided to women randomized to this arm of the study includes 200gm/d CSB along with a standard maternal multiple micronutrient tablet, which together provide a comparable amount of energy, protein and micronutrients to the ready-to-use supplemental food. The micronutrient supplement known as the United Nations Children's Emergency Fund (UNICEF) / World Health Organization (WHO) / United Nations University (UNU) international multiple micronutrient preparation (UNIMMAP) is widely available and has been used in many settings worldwide in pregnant women.
3066117|NCT02120599|Experimental|ready-to-use supplementary food|RUSF-P (ready-to-use supplementary food) provides 750 kcal/d, 20 g protein/d, and 200% of RDA/d for most micronutrients during pregnancy (except for vitamins A, B3, folic acid, minerals iodine, magnesium, and calcium which will remain near 100%)
3066118|NCT02120586|No Intervention|Control group|Usual care
3066119|NCT02120586|Experimental|Respiratory training group|"Participants will breathe against a load ≥ 50% of their baseline MIP, after which loads will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.~Intervention: Inspiratory Muscle training (12-weeks)"
3066120|NCT02120586|Experimental|Peripheral training group|"Participants will load ≥ 50% of their maximum muscle force (Kg), after which load will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.~Intervention: Peripheral muscle training (12-weeks)"
3066121|NCT02120573|Active Comparator|medical students|medical students took part in workshop
3066122|NCT02120573|Active Comparator|general population|general population took part in workshop
3066123|NCT02120573|Active Comparator|nonmedical students|all students from different subjects, non medical and paramedical
3066178|NCT02120170|No Intervention|No hemoclipping if there were no bleeding during polypectomy|The patients of group 2 will be performed hemoclipping only for the immediate bleeding during colon polypectomy
3066498|NCT02117908|Sham Comparator|ShamCPAP|shamCPAP using ResMedTM CPAP face mask modified for technical sham
3066124|NCT02120560|Active Comparator|Interrupted Anticoagulation|Patients randomized to undergo atrial fibrillation ablation with interrupted anticoagulation with apixaban (5mg twice daily; 2.5mg twice daily >80 years old, Cr > 1.5, wt < 60kg), rivaroxaban (20mg daily; 15mg daily CrCl < 50 mL/minute), dabigatran (150mg twice daily; 75mg twice daily CrCl < 30mL/minute), or warfarin (dosed case-by-case).
3066125|NCT02120560|Active Comparator|Uninterrupted anticoagulation with warfarin|Patients randomized to undergo atrial fibrillation ablation with uninterrupted anticoagulation with warfarin (dosed case-by-case).
3066126|NCT02120547|Experimental|Cenicriviroc in mild liver impaired|Subjects with mild liver impaired will receive cenicriviroc, 1 tablet once daily, for 14 days. Matching healthy subjects will receive Cenicriviroc, 1 tablet once daily, for 14 days.
3066127|NCT02120547|Experimental|Cenicriviroc in moderate liver impaired|Subjects with moderate liver impaired will receive cenicriviroc, 1 tablet once daily, for 14 days. Matching healthy subjects will receive Cenicriviroc, 1 tablet once daily, for 14 days.
3066128|NCT02120534||Sepsis group|Forty seven patients are critically ill with evidence of sepsis during ICU stay (sepsis group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be monitored.
3066129|NCT02120534||SIRS group|Forty seven patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be monitored.
3066130|NCT02120521||Sepsis group|Sixty patients are critically ill with evidence of sepsis during ICU stay (sepsis group) and sixty patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of sTREM-1 and MNDA will be monitored.
3066131|NCT02120521||SIRS group|Sixty patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of sTREM-1 and MNDA will be monitored.
3066132|NCT02120508|Experimental|1 Hz rTMS, real|1 Hz rTMS over unaffected hemisphere for 15 minutes
3066133|NCT02120508|Sham Comparator|1Hz rTMS, sham|1Hz sham rTMS, over unaffected hemisphere for 15 minutes
3066134|NCT02120495|Experimental|intraoral condylectomy via coronoid process resction|This procedure has no facial nerve injury and skin scar,little injury to TMJ anatomy and function.
3066135|NCT02120482|Experimental|Combined apheresis|Patients will be treated by semiselective immunoadsorption combined with membrane filtration
3066136|NCT02120469|Experimental|Treatment (everolimus, eribulin mesylate)|Patients receive everolimus PO QD on days 1-21 and eribulin mesylate IV on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3066137|NCT02120456|Experimental|LEO 43204|Open-label, dose-escalation, 2-day treatment
3066138|NCT02120456|Experimental|LEO 43204 Dose 0.1%|LEO 43204 dose 0.1% once daily for two consecutive days
3066139|NCT02120456|Experimental|LEO 43204 Dose 0.075%|LEO 43204 dose 0.075% once daily for two days
3066140|NCT02120456|Placebo Comparator|Placebo|Placebo once daily for two days
3066141|NCT02120443|Experimental|Non-Infiltrated Tissue|The ivWatch Model 400 monitored a common peripheral IV site over a 24 hour observation period.
3066142|NCT02120430|Active Comparator|Early administration of the video|Video delivered at one month of child's life
3066143|NCT02120430|Experimental|Late administration of the video|Video delivered at seven months of child's life
3066144|NCT02120417|Experimental|Treatment A - Capecitabine and ruxolitinib|
3066145|NCT02120417|Active Comparator|Treatment B - Capecitabine and placebo|
3066146|NCT02120404|No Intervention|Control group (GC)|Control group: no esmolol administration
3066147|NCT02120404|Experimental|Group 10 (G10)|Esmolol titrated in order to reduce heart rate by 10% as compared to baseline heart rate
3066148|NCT02120404|Experimental|Group 20 (G20)|Esmolol titrated in order to reduce heart rate by 20% as compared to baseline heart rate
3066149|NCT02120391|Sham Comparator|Control (Arm A)|"Patients randomized to Arm A(control group) will receive an iPhone application without any of the adherence intervention turned on. The control phone application will allow patients to record their medications and how many refills they have remaining. The application will also provide patients with links about their medication.~No adherence intervention will be done to these patients."
3066150|NCT02120391|Experimental|Cases (Arm B)|"Patients randomized to Arm B will receive an iPhone application with the adherence intervention turned on. The study coordinator will help with the installation of the iPhone application.~Participants in this group will not need to pay for the iPhone application."
3066151|NCT02120365|Experimental|Parampanel 6mg|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with daily perampanel 2mg days prior to each test day, and then observed dosing moderate 6mg dose perampanel in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses (target BrAc=20mg%, 60mg%, and 100mg%) in a step-wise fashion.
3066293|NCT02119286|Experimental|FF/VI 100/25 mcg + Placebo|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of matching placebo via a DPI once-daily in the morning for 12 weeks.
3066152|NCT02120365|Placebo Comparator|Placebo|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with placebo 7 days prior to each test day, and then observed dosing of placebo in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses (target BrAc=20mg%, 60mg%, and 100mg%) in a step-wise fashion.
3066153|NCT02120365|Experimental|Parampanel 10 mg|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with daily perampanel 2mg 7 days prior to each test day, and then observed dosing of high dose parempanel (10mg) in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses (target BrAc=20mg%, 60mg%, and 100mg%) in a step-wise fashion.
3066154|NCT02120352|Experimental|GSK744 LA 600 mg + TMC278 LA 900 mg every 8 weeks (Q8W)|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subject will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subject will receive following IM doses: Day 1 only - GSK744 LA 800 mg (loading dose delivered as two 400 mg IM injections) + TMC278 LA 900 mg IM. Week 4 only - GSK744 LA 600 mg IM (second loading dose, no TMC278).Week 8 - GSK744 LA 600 mg IM + TMC278 LA 900 mg IM every 8 weeks for 96 weeks.
3066155|NCT02120352|Experimental|GSK744 LA 400 mg + TMC278 LA 600 mg every 4 weeks (Q4W)|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subjects will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subjects will receive following IM doses: Day 1 only - GSK744 LA 800 mg (loading dose delivered as two 400 mg IM injections) + TMC278 LA 600 mg IM. Week 4 - GSK744 LA 400 mg IM + TMC278 LA 600 mg IM every 4 weeks for 96 weeks
3066156|NCT02120352|Active Comparator|Oral Control Arm|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subjects will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subjects will receive an oral regimen of 30 mg of GSK744 and ABC/3TC once daily for 96 weeks (or 104 weeks if going on to the Extension Period)
3066157|NCT02120339|Experimental|Carvedilol|Carvedilol 0-3.125 mg daily Escalating to 6.25 twice a day
3066158|NCT02120326|Experimental|active tDCS|
3066159|NCT02120326|Placebo Comparator|simulated tDCS|
3066160|NCT02120313|Active Comparator|inpatient rehabilitation|After discharge, patients participate in daily physical therapy for 3 weeks in a rehabilitation hospital.
3066161|NCT02120313|Experimental|outpatient rehabilitation|After discharge, patients participate in daily physical therapy for 3 weeks in an outpatient rehabilitation center.
3066162|NCT02120300|Experimental|LDV/SOF GT 1 or 4|Participants with chronic genotypes (GT) 1 or 4 HCV infection will receive LDV/SOF for 12 or 24 weeks. Treatment-experienced cirrhotic participants with genotype 1 HCV infection will receive LDV/SOF for 24 weeks.
3066163|NCT02120300|Experimental|SOF+RBV 12 wks GT 2|Participants with chronic genotype 2 HCV infection will receive SOF+RBV for 12 weeks.
3066164|NCT02120300|Experimental|SOF+RBV 24 wks GT 3|Participants with chronic genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
3066165|NCT02120287|Experimental|BZ-SRS with Bevacizumab|"All patients will receive Border Zone Stereotactic Radiosurgery (BZ-SRS) and additionally receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by 10 mg/kg/day every 14 days until progression.~One to 14 days before BZ- SRS procedure, patients at centers with MRS experience will undergo standard brain MRI /MRS"
3066166|NCT02120274|No Intervention|Control|Pegylated Interferon-Alfa plus ribavirin for 48 weeks
3066167|NCT02120274|Experimental|Vitamins|Pegylated Interferon-Alfa plus ribavirin for 48 weeks together oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level. Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
3066168|NCT02120261|Experimental|Saline|Trigger point injection with 1 mL of normal saline solution
3066169|NCT02120261|Active Comparator|Lidocaine & Tramcinolone Acetonide|Trigger point injection with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL)
3066170|NCT02120248|No Intervention|Control|Participants receive standard WIC breastfeeding support but do not have contact with a breastfeeding peer counselor
3066171|NCT02120248|Other|Low Intensity|Participants will receive four scheduled phone calls from a peer counselor. Two prenatal calls and 2 postpartum.
3066172|NCT02120248|Active Comparator|High Intensity|Participants will receive eight scheduled phone contacts from a peer counselor. Two are prenatal and 6 are postpartum.
3066173|NCT02120222|Experimental|Treatment (selinexor)|Patients receive selinexor PO BIW. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Blood will be collected for correlative studies to perform pK (pharmacokinetics) and pDn (pharmacodynamics) analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
3066174|NCT02120196|Experimental|rifaximin|Arm 1: 109 patients will be treated with 1200 mg of rifaximin daily for 6 months.
3066175|NCT02120196|Active Comparator|norfloxacin|Arm 2: 109 patients will be treated with 400 mg of norfloxacin daily for 6 months.
3066176|NCT02120183|Experimental|Psycho-educational support group therapy|4 week psycho-educational support group focusing on topics specific to psychosocial and emotional aspects of the cancer caregiving role
3066177|NCT02120170|Active Comparator|Hemoclipping during colon polypectomy for all lesion|The enrolled patients of group 1 will be performed hemoclipping for all polypectomy lesion irrespective of the presence of immediate bleeding.
3066179|NCT02120157|Experimental|1: Acute Lymphoblastic Leukemia/Lymphoma|"Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days*~Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV+~Day 0: Infuse unmanipulated bone marrow~Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV# Mesna 40 mg/kg IBW/day IV#~Day +5: Begin tacrolimus 0.015mg/kg/ IBW dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day~Day +30 Assess chimerism and disease status in bone marrow~Day +35 Discontinue MMF~Day +60 Assess chimerism and disease status in bone marrow~Day 180 Discontinue tacrolimus"
3066180|NCT02120157|Experimental|2: Acute Lymphocytic Leukemia/Lymphoma|"Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV+~Days -3 through -1: TBI 200 cGy twice a day for 3 days~Day 0: Infuse unmanipulated bone marrow~Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV~Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day~Day +30 Assess chimerism and disease status in bone marrow~Day +35: Discontinue MMF~Day +60: Assess chimerism and disease status in bone marrow~Day 180 Discontinue tacrolimus"
3066181|NCT02120144|Experimental|Intervention|15 young patients (<65 years old) and 15 older patients (>64 years old) are submitted to an observation phase and an imagination phase of walking at a precise rythm for 10 minutes
3066182|NCT02120144|Active Comparator|Reading|15 young patients (<65 years old) and 15 older patients (>64 years old) are submitted to a reading phase on a computer for 10 minutes.
3066183|NCT02120131||test envelope|envelope flap
3066184|NCT02120131||control, trapezodal|standard incision
3066185|NCT02120118|Experimental|Radiation; Hyperthermia; Chemotherapy|Patients will be treated with radiotherapy with 50Gy/22fx/6 weeks, plus hyperthermia 42℃ ± 0.5℃ for 40 minutes within 2hr after irradiation, once a week since the 1st week of radiation for a total of 6 times. The regimen of concurrent chemotherapy will cisplatin 30mg/m2 and taxotere 20mg/m2 per week for 6 weekly cycles.
3066186|NCT02120105||Cystinuria|
3066187|NCT02120092|Active Comparator|Clopidogrel + ASA|
3066188|NCT02120092|Placebo Comparator|Clopidogrel + Placebo|
3066189|NCT02120092|Active Comparator|Ticagrelor + ASA|
3066190|NCT02120092|Placebo Comparator|Ticagrelor + Placebo|
3066191|NCT02120079|Active Comparator|Lotemax|Lotemax (loteprednol etabonate) 0.5% is a prescription-only, preserved ophthalmic suspension supplied by Bausch & Lomb, Inc. Lotemax (loteprednol etabonate) 0.5% has been approved by the FDA for treatment of ocular inflammation with a maximum dosing frequency of 24 drops per eye per day. It is a C-20 ester-based corticosteroid, with a potent anti-inflammatory efficacy, but decreased impact on intraocular pressure (IOP) compared to other corticosteroids, which may increase IOP. The medication will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
3066192|NCT02120079|Active Comparator|Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)|Soothe Tired Eyes Lubricant Eye Drop (Bausch & Lomb Inc.) is a preserved artificial tear which is used to relieve the dryness of the eye and to prevent further irritation. Its active ingredient is glycerin 1%. The artificial tear will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
3066193|NCT02120066|Other|Vitrectomy|
3066194|NCT02120053|Experimental|Bone substitute material group|Immediate denture placement following extractions and alveolar sockets filling with bone substitute material
3066195|NCT02120053|Active Comparator|Conventional protocol|Immediate denture placement following the conventional protocol
3066196|NCT02120040|Other|Hemangioblastoma (HB) of the Central nervous system (CNS)|
3066197|NCT02120027|Experimental|Ibodutant 10 mg|Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will continue on ibodutant 10 mg for additional 28 weeks of treatment via mock-re-randomisation at week 25 .
3066198|NCT02120027|Placebo Comparator|Placebo|Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the placebo arm will be re-randomised at week 25 in a 1:1 ratio to ibodutant or placebo for additional 28 weeks of treatment.
3066199|NCT02120014|Experimental|Heart Failure Reduced EF|"Patient prior to clinically ordered right heart catheterization identified patients will have a blood volume measurement completed in the nuclear medicine laboratory. Patients will receive an intravenous administration of low dose iodinated I-131 labeled albumin. Blood specimens (6 cc each) will be drawn at 6 minute intervals times 6. The analysis will be completed following the testing.~Venous plethysmography will be completed on eligible patients prior to the clinically indicated right heart catheterization. Calf and forearm venous compliance will be measured.~Measurements form the right heart catheterization will be recorded for analysis."
3066200|NCT02120014|Experimental|Heart Failure Preserved EF|"Patient prior to clinically ordered right heart catheterization identified patients will have a blood volume measurement completed in the nuclear medicine laboratory. Patients will receive an intravenous administration of low dose iodinated I-131 labeled albumin. Blood specimens (6 cc each) will be drawn at 6 minute intervals times 6. The analysis will be completed following the testing.~Venous plethysmography will be completed on eligible patients prior to the clinically indicated right heart catheterization. Calf and forearm venous compliance will be measured.~Measurements form the right heart catheterization will be recorded for analysis."
3066201|NCT02120001|Experimental|ETT cleaning maneuver|Patients randomized to the treatment group will undergo an ETT cleaning maneuver with endOclear three times a day (every 8 hours) for the whole intubation period in addition to the standard of care.
3066202|NCT02120001|No Intervention|Standard of care|In the protocol no intervention is planned for the control group, which will therefore be treated with blind suctioning as per caregiver clinical decision.
3066203|NCT02119988|Experimental|TIPS combined with embolization|"The covered stents were used for TIPS~The gastroesophageal collaterals will be embolized during the procedure of TIPS"
3066204|NCT02119988|Experimental|TIPS alone|"The covered stents were used for TIPS~No embolization of any collateral will be performed during TIPS"
3066205|NCT02119975|Placebo Comparator|Placebo working memory training|
3066206|NCT02119975|Experimental|Working memory training|
3066207|NCT02119962|Experimental|Working memory training|
3066208|NCT02119962|Placebo Comparator|Placebo training|
3066209|NCT02119949|Experimental|Working memory training|
3066210|NCT02119949|Placebo Comparator|Placebo training|
3066211|NCT02119936|Experimental|Heart Rate Variability Biofeedback Tool|Intervention: Participants will be taught how to use the Heart Rate Variability Biofeedback tool (emWave 2) as a mechanism to reduce stress and anxiety, then use the tool, coupled with deep breathing exercises, to visualize their stress reduction.
3066212|NCT02119923|Experimental|Working memory training|
3066213|NCT02119923|Placebo Comparator|Placebo training|
3066214|NCT02119910|Experimental|Technology Supported Manual|Participants in this arm will receive behavioral intervention for a period of 5 consecutive days. A total of 3, 45-minute meals will be held at regularly scheduled times (e.g., 9:00 a.m., 10:30 a.m., and 12:00 p.m.) each day for a total of 15 meals throughout treatment.
3066215|NCT02119910|No Intervention|Waitlist|Participants will serve as the control condition.
3066216|NCT02119897|Experimental|Low Level Light Therapy (LLLT)|"LLLT: The LLLT device will be positioned next to the face and neck for a total of 6 exposures: Right face, Midline face, Left face, Left neck, Midline neck, Right neck~Dose per anatomic site 50mW/cm2, 60 sec = 3.0J/cm2~Route: Extraoral~Total Treatment Time (all sites): 6 min~Schedule: Participants will be treated daily (including weekends and holidays) beginning on the first day of HCT conditioning and continuing through day +20 or hospital discharge if prior to day +20.~Evaluation: Participants will undergo formal mucositis and toxicity assessments at baseline and daily from day -1 through day +20, with a final assessment on the last day of treatment."
3066217|NCT02119884|Experimental|Terlipressin group|Patients receive terlipressin 2 mg IV bolus
3066218|NCT02119884|Active Comparator|High Dose Octreotide group|Patients receive Octreotide 50 μg/h with an initial bolus of 100 μg
3066219|NCT02119871|Experimental|Bilateral Open Pleurae|Bilateral open pleurae and usage of right pulmonary vein drainage
3066220|NCT02119871|Active Comparator|Right pleura open|Opening of right pleura and usage of left ventricular apical drainage.
3066221|NCT02119858|Experimental|Diagnostic (ICG, diffuse optical imaging, surgery)|Patients receive indocyanine green transperineally and undergo diffuse optical imaging during robot-assisted laparoscopic radical prostatectomy with bilateral lymph node dissection using the da Vinci Robotic Surgical System.
3066222|NCT02119845|Experimental|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
3066223|NCT02119832|Experimental|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
3066224|NCT02119819|Experimental|Dose 1 LY2944876|Dose 1 of LY2944876 given subcutaneously (SC) once weekly for 24 weeks.
3066225|NCT02119819|Experimental|Dose 2 LY2944876|Dose 2 of LY2944876 given SC once weekly for 24 weeks.
3066226|NCT02119819|Experimental|Dose 3 LY2944876|Dose 3 of LY2944876 given SC once weekly for 24 weeks.
3066227|NCT02119819|Experimental|Dose 4 LY2944876|Dose 4 of LY2944876 given SC once weekly for 24 weeks.
3066228|NCT02119819|Experimental|Exenatide extended-release|2 milligrams (mg) exenatide extended-release given SC once weekly for 24 weeks.
3066229|NCT02119819|Placebo Comparator|Placebo|Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.
3066230|NCT02119806|Active Comparator|Benzodiazepine group|"Premedication 0.02mg/kg-0.1mg/kg of Benzodiazepine ;~Maintenance 0.8 minimum alveolar concentration of inhaled anesthetic (MAC) and 10-30mcg/kg of fentanyl;~Postoperative 10-100mcg/kg/min of propofol"
3066231|NCT02119806|Active Comparator|Non-benzodiazepine group|"Premedication 0-50mg of propofol and/or 0-250mcg of fentanyl;~Maintenance 0.8 minimum alveolar concentration of inhaled anesthetic (MAC) and 10-30mcg/kg of fentanyl;~Postoperative 10-100mcg/kg/min of propofol"
3066232|NCT02119793|Experimental|YVOIRE® contour|
3066233|NCT02119780|Experimental|YVOIRE® contour|
3066234|NCT02119780|Active Comparator|Restylane SubQ™|
3066235|NCT02119767||Natural gradients|Patients requiring an elective PCI who present with either non-ST-segment elevation myocardial infarction (NSTEMI) or chronic stable angina who will have natural gradients sampled using the LBS
3066236|NCT02119767||Induced gradients|Patients requiring an elective PCI who present with either non-ST-segment elevation myocardial infarction (NSTEMI) or chronic stable angina who will have induced gradients sampled using the LBS
3066237|NCT02119754|Experimental|Plurogel PN|Plurogel PN
3066238|NCT02119741||Affected Interdental Papillae Group|This is the only group in which the material will be used
3066239|NCT02119728|Active Comparator|Arm I (standard of care surgery)|Patients undergo standard of care surgery on day 1.
3066240|NCT02119728|Experimental|Arm II (HPPH, photodynamic therapy)|Patients receive HPPH IV over 1 hour on day 0. Approximately 24 hours later, patients undergo photodynamic therapy on day 1.
3066241|NCT02119715|Experimental|Pegylated rhG-CSF 100μg/kg|Chemotherapy naive patients receiving chemotherapy and Pegylated rhG-CSF（HHPG-19K） 100µg/kg in cycle 2 to 4
3066242|NCT02119715|Experimental|Pegylated rhG-CSF 150μg/kg|Chemotherapy naive patients receiving chemotherapy and Pegylated rhG-CSF（HHPG-19K)150 μg/kg in cycle 2 to 4
3066243|NCT02119715|Active Comparator|G-CSF 5 μg/kg/d|Chemotherapy naive patients receiving chemotherapy and rhG-CSF 5μg/kg/day in cycle 2 to 4
3066244|NCT02119702||Infected Cohort|Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment, engaged in care with ART treatment history available.
3066245|NCT02119702||Uninfected Cohort|Perinatally HIV-exposed, perinatally-uninfected participant at or beyond their 18th birthday at enrollment. Must have been previously or currently enrolled in PHACS AMP or PHACS SMARTT, and may have horizontally-acquired HIV infection.
3066246|NCT02119689||Diabetic Patients|Mild, Moderate and Severe Retinopathy
3066247|NCT02119689||Healthy Controls|Age and sex matched Healthy Controls
3066248|NCT02119676|Experimental|Ruxolitinib plus regorafenib|
3066249|NCT02119676|Active Comparator|Placebo plus regorafenib|
3066250|NCT02119663|Experimental|Ruxolitinib plus capecitabine|
3066251|NCT02119663|Active Comparator|Placebo plus capecitabine|
3066252|NCT02119650|Experimental|Ruxolitinib plus Pemetrexed/Cisplatin|
3066253|NCT02119650|Active Comparator|Placebo plus Pemetrexed/Cisplatin|
3066254|NCT02119585||Patients undergoing OLT|insertion of nasogastric tube for measurements of chest wall mechanics
3066399|NCT02118610|Experimental|l-tetrahydropalmatine|l-tetrahydropalmatine (30 mg BID)
3066255|NCT02119572|Experimental|peer support|Patients are divided into small groups and assigned with peer leaders for twelve months according to their residence. Besides the same training and follow-ups as the control arm, patients from intervention groups are suggested and encouraged to take part in the group activities with the peer leaders per month. And if possible, casual activities (such as phone call, chatting, short message; physical exercise, group member family visiting，going to supermarket together, etc.)are also recommended
3066256|NCT02119572|Active Comparator|usual education|Patients attend the usual self-management education and communicate with the professionals every two months, getting the information on diabetes diet, exercise, glucose monitor, etc. besides that the group members should attend three follow ups at baseline,6 and 12 months.
3066257|NCT02119559|Other|CTC assay, Cetuximab|Detection & characterization of viable CTC in the peripheral blood.
3066258|NCT02119546|Experimental|Exercise intervention|Aerobic exercise and dual-task training
3066259|NCT02119546|Active Comparator|Stretch exercise|Stretch exercise & sitting balance
3066260|NCT02119520|Active Comparator|Platelet rich fibrin + atorvastatin|In Platelet rich fibrin+ATV group PRF combined with 10 µl of 1.2% ATV was inserted into the depth of the IBD
3066261|NCT02119520|Sham Comparator|Platelet rich fibrin|In Platelet rich fibrin group PRF was inserted into the depth of the IBD.
3066262|NCT02119520|Other|Open flap debridement|open flap debridement was followed by no grafting or regenerative intervention.
3066263|NCT02119507|Experimental|Curodont Repair|Single application on Day 0.
3066264|NCT02119507|Other|No treatment - control|"No treatment as control - wait and see."
3066265|NCT02119481|Experimental|Mindfulness-based stress reduction|Mindfulness-based stress reduction training
3066266|NCT02119481|Active Comparator|Expressive writing condition|Expressive writing
3066267|NCT02119481|No Intervention|Waiting-list control condition|Waiting list
3066268|NCT02119468|Experimental|Treatment (ixazomib citrate, dexamethasone, pomalidomide)|Patients receive ixazomib orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3066269|NCT02119455|Experimental|Vibration Device+Fixed Appliance Tx +Female|Female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment in conjunction with vibration therapy (daily use of OrthoAccel Aura device for 20 minutes/day) during the study period.
3066270|NCT02119455|No Intervention|No Vibration Device+Fixed Appliance Tx+Female|Female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment only and no vibration treatment.
3066271|NCT02119455|Experimental|Vibration Device+Orthodontic Tx+Male|Male subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment in conjunction with vibration therapy (daily use of OrthoAccel Aura device for 20 minutes/day) during the study period.
3066272|NCT02119455|No Intervention|No Vibration Device+Fixed Appliance Tx+Male|Female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment only and no vibration treatment.
3066273|NCT02119442|Other|Transcatheter Valve Implantation|Intervention, Transcatheter Valve Implantation with Melody or Sapien bioprosthetic valve Standard of care intervention.
3066274|NCT02119429|Placebo Comparator|Wheat Germ Oil|Participants will be instructed to consume 2 wheat germ oil capsules ,2g, per day for 12 weeks.
3066275|NCT02119429|Experimental|Pumpkin Seed Oil|Participants will be instructed to consume 2 pumpkin seed oil capsules ,2g, per day for 12 weeks
3066276|NCT02119416|Experimental|1mg/kg Caffeine|Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg
3066277|NCT02119416|Experimental|2mg/kg caffeine|Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg
3066278|NCT02119416|Experimental|Placebo|Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg
3066279|NCT02119403|Experimental|Hand Held NitrousTM|There are no other interventions to this device
3066280|NCT02119390|Other|Standard Care|Participants in the Standard Care group will complete a demographic questionnaire at the time of consent as well as other questionnaires during the course of the study. They will receive standard clinical care.
3066281|NCT02119390|Experimental|Pill Trial+|Participants in the Pill Trial+ group will complete a demographic questionnaire at the time of consent as well as other questionnaires during the course of the study. They will receive standard clinical care plus three 25-minute individualized, behavioral, staff-delivered intervention sessions at HAART initiation, and 1-, and 3-month follow-up visits. Two brief booster sessions will also be provided following sessions 1 (in clinic) and 2 (by phone).
3066282|NCT02119377||Transgender and Transsexual People|Transgender and transsexual (trans) people aged 18 years or older living in Australia were invited to complete a questionnaire assessing a range of mental and physical health domains.
3066283|NCT02119364|Active Comparator|Working memory training|After baseline assessment participants will be randomized to active training or treatment as usual (waiting). The active group will start training immediately and will have 6 weeks to perform the 25 training sessions.
3066284|NCT02119364|No Intervention|Passive control group|"The control group will receive treatment as usual (special education, physiotherapy etc)."
3066285|NCT02119351|Active Comparator|ViaValve™ Safety IV Catheter|Insertion of the ViaValve™ Safety IV Catheter
3066286|NCT02119351|Active Comparator|ProtectIV® Plus Safety IV Catheter|Insertion of the ProtectIV® Plus Safety IV Catheter
3066287|NCT02119338|Experimental|5-ala preoperatively|A dose of 5-ala will be taken by mouth approximately 3 hours before going to surgery.
3066288|NCT02119325|Experimental|Test|Fibre rich Health Food Drink packed as 30g individual sachet, administered as a single serve in 200 mL of luke warm water
3066289|NCT02119325|Placebo Comparator|Placebo|No Fibre Health Food Drink packed as 25g individual sachet, administered as single serve in 200 mL of luke warm water
3066290|NCT02119299|Experimental|SMART device|Use of Sensor Monitored Alimentary Restriction Therapy (SMART) device
3066291|NCT02119286|Experimental|FF/VI 100/25 mcg + UMEC (62.5mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation UMEC (62.5mcg) via DPI once-daily in the morning for 12 weeks.
3066292|NCT02119286|Experimental|FF/VI 100/25 mcg + UMEC (125mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of UMEC (125mcg) via a DPI once-daily in the morning for 12 weeks.
3066294|NCT02119273|Experimental|Steroid|The steroid arm will take prednisone 10mg tabs starting 7 days prior to surgery with a taper (4 tabs/day for 3 days, 3 tabs/day for 3 days, 2 tabs/day for 3 days, 1 tab/day for 3 days).
3066295|NCT02119273|Placebo Comparator|Placebo|The placebo arm will receive placebo pills identical in appearance to prednisone 10mg pills. They will start taking them 7 days prior to surgery with a taper (4 tabs/day for 3 days, 3 tabs/day for 3 days, 2 tabs/day for 3 days, 1 tab/day for 3 days).
3066296|NCT02119260|Experimental|Cohort 1|Eight subjects will be randomized to 1 of 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2798745 + 1 placebo dose). GSK2798745 will be administered in a liquid form (suspension or solution) in this cohort. In each treatment period, the subjects will be fasting from the prior midnight to four hours post-dose (Day 1).
3066297|NCT02119260|Experimental|Cohort 2|Twelve subjects will receive GSK2798745 in three single-dose treatment periods in a fixed sequence. The actual dose-selected will be determined based on review of emerging safety and exposure data from Cohort 1. The dosing will be done in 3 study periods for investigating bioavailability and food effects. In Period 1, subjects will be fasting from midnight to four hours post-dose and will receive GSK2798745 in a liquid form (suspension or solution). In Period 2, subjects will be fasting from midnight to four hours post-dose and will receive a capsule formulation of GSK2798745. In Period 3, subjects will receive GSK2798745 capsule following a standard high fat/high calorie meal.
3066298|NCT02119260|Experimental|Cohort 3|Sixteen subjects will be randomized to 2 repeat dose cohorts with 8 subjects in each cohort in a ratio of 6:2 (treatments: placebo). Food intake timing will be determined based on data from Cohorts 1 and 2 (if Cohort 2 is conducted before Cohort 3). Doses will be administered once daily from Day 1 through Day14. Based on data from Cohort 1, the second dose in the repeat-dose period may be skipped to estimate the time invariance in PK. Dosing may be altered to twice daily based on the results obtained in the initial study cohort. Subjects will be fasted from midnight to 4 hours after dosing on Day 1 and Day 14 that entail serial PK sampling. Meal timings on other days will be based on previous cohort data.
3066299|NCT02119260|Experimental|Cohort 4|Eighteen stable HF subjects will be randomized in this cohort with a treatment:placebo ratio of 1:1. If required, an additional number of subjects (up to 24 total) will be randomized. An additional separate dose group of approximately 18 to 24 subjects may be randomized to GSK2798745 or placebo to gain additional safety, tolerability,pharmacokinetic and pharmacodynamic information, if needed. The subjects will receive GSK2798745 in a single dose (at least the first 6 subjects) followed by a 7 -days repeat dose. Based on data from the cohorts 1, 2 and 3, the dose will be 2.4 mg (initial) in the first group utilizing the capsule formulation administered with or without food.
3066300|NCT02119260|Experimental|Cohort 5|Eight HF subjects will be randomized in this cohort with a treatment: placebo ratio of 3:1. This cohort will evaluate safety, pharmacokinetics, and lung permeability (DLco and DLno) in a boarder, more general population of patients with HF, NYHA Class II or III. Subjects will receive GSK2798745 or placebo (based on randomization) for 7 days. The dose will be 2.4 mg utilizing the capsule formulation administered with or without food. Subjects will remain in house from Day -1 until Day 4 and be fitted with a remote monitoring device; Day 5, 6 and 8 visits will be in home (on Days 5 and 6, they will receive study medication, collect samples for pharmacokinetic analysis, and assess vital signs); and subjects will return to the clinic for Day 7 visit.
3066301|NCT02119247|Experimental|CHF6001 dry powder for inhalation via NEXThaler®|4 inhalations of CHF 6001 NEXThaler®
3066302|NCT02119247|Active Comparator|CHF 6001 DPI capsules for inhalation via Aerolizer|3 inhalations of CHF 6001 capsules via Aerolizer®
3066303|NCT02119234|Experimental|CHF5993 pMDI + Spacer|CHF 5993 pMDI (Beclometasone/formoterol/glycopyrrolate 100/6/25 mcg per actuation) x 4 inhalations administered using Aerochamber Plus Flow-vu VHC spacer
3066304|NCT02119234|Active Comparator|CHF5993 pMDI|CHF 5993 pMDI (Beclometasone/formoterol/glycopyrrolate 100/6/25 mcg per actuation) x 4 inhalations administered using standard actuator only
3066305|NCT02119234|Placebo Comparator|Placebo pMDI|Placebo pMDI x 4 inhalations
3066306|NCT02119221|Experimental|[14C]Copanlisib|
3066307|NCT02119208|Experimental|Lifestyle counseling|
3066308|NCT02119195|No Intervention|No treatment|The composite resin restorations had marginal defects, but were clinically acceptable, did not receive treatment
3066309|NCT02119195|No Intervention|Positive control|Composite resins with alpha value in marginal adaptation criteria
3066310|NCT02119195|Experimental|Intervention|For this group, defective areas were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3M ESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure
3066311|NCT02119182||Comprehensive Assessment with MRI|"In-Person Outcome Assessment at 2 weeks, 6 months, and 12 months.~Phone Outcome Assessment at 3 months.~3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months.~Blood Draw for Plasma, DNA, Serum, RNA at baseline, 2 weeks, and 6 months."
3066312|NCT02119182||Comprehensive Assessment without MRI|"In-Person Outcome Assessment at 2 weeks, 6 months, and 12 months.~Phone Outcome Assessment at 3 months.~Blood Draw for Plasma, DNA, Serum, RNA at baseline, 2 weeks, and 6 months."
3066313|NCT02119182||Brief Assessment|Telephone outcome assessment at 2 weeks, 3 months, 6 months, and 12 months.
3066314|NCT02119169|Experimental|pigtail catheter|Pigtail catheter for pleural drainage of recurrent hepatic hydrothorax
3066315|NCT02119156|Experimental|Treatment Holiday Group|Subjects in the Treatment Holiday Group will undergo a 6 month belimumab treatment holiday while remaining on standard of care SLE therapy, then re-start belimumab therapy for 6 months while receiving standard of care SLE therapy.
3066316|NCT02119156|Active Comparator|Control Group|Subjects in the Control Group will continue to receive monthly belimumab therapy, in addition to standard of care SLE therapy for 52 weeks.
3066317|NCT02119156|No Intervention|Long-Term Discontinuation Group|Subjects in the Long-Term Discontinuation Group have elected to discontinue further belimumab therapy and will remain on standard of care SLE therapy as directed by the investigator, and agree to return for monthly visits for 52 weeks.
3066318|NCT02119143|Active Comparator|Vitamines and minerals|41 middel aged subjects receive vitamin and mineral supplementation
3066319|NCT02119143|Placebo Comparator|cellulose|41 middle aged subjects get the placebo
3066400|NCT02118610|Placebo Comparator|Sugar Pill|
3066320|NCT02119130|No Intervention|TST only|Tuberculin skin test for all eligible patients, to be placed and read by clinic staff. Thereafter, for 2 years, annual TST provided for patients with TST negative/unknown history. IPT to be provided to patients with a positive TST for whom active TB has been ruled out.
3066321|NCT02119130|Experimental|QGIT|QGIT for all eligible patients, to be done at routine CD4 blood draw. Thereafter, for 2 years, annual QGIT at CD4 blood draw for patients with QGIT negative/unknown history. IPT to be provided to patients with a positive QGIT for whom active TB has been ruled out.
3066322|NCT02119117|Placebo Comparator|sugar pill|Group 2 will receive a placebo of CoQ10
3066323|NCT02119117|Experimental|CoQ10|Patients will be divided into 2 groups. Group 1 will be treated with an oral supplement, 125 mg/twice daily of CoQ10 (NeoQ10, Theralogix, Rockville, Maryland, USA) for 3 months prior to IVF. This dosage will equate to a Cmax of 6.89 ug/ml (Liu and Artmann, 2009).
3066324|NCT02119104||Prevenar (13v)|
3066325|NCT02119091|Experimental|Moxifloxacin|Single oral dose 400 mg
3066326|NCT02119091|Placebo Comparator|Placebo|Single oral dose
3066327|NCT02119078|Active Comparator|ACE Service|Admission to the Acute Care for Elders (General Medicine Team 1) service. (See Intervention, below)
3066328|NCT02119078|No Intervention|Standard care (other General Medicine teams)|Admission to one of the 4 non-ACE general medicine teaching teams at OHSU.
3066329|NCT02119065||Health Services Research (PET/CT scan)|Patients receive routine pre-therapy technetium Tc 99m-labeled macroaggregated albumin. Patients then undergo routine radioembolization with yttrium Y 90 resin microspheres. Within 36 hours after radioembolization, patients undergo PET/CT imaging.
3066330|NCT02119052|Experimental|OCTEOTRIDE|octeotride 20 mg, intramuscular injection monthly for 3 years
3066331|NCT02119052|Placebo Comparator|Placebo|Placebo (saline soluction), intramuscular injection monthly for 3 years
3066332|NCT02119039|Experimental|RGTA OTR 4120 (CACICOL20)|
3066333|NCT02119039|Active Comparator|Genteal HA|
3066334|NCT02119026|Active Comparator|A|"capecitabine and irinotecan (XELIRI) plus bevacizumab (AVASTIN)~Capecitabine : 800mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on day 1 q3w combined with irinotecan 200mg/m2 iv. d 1 q3w . Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance~At disease progression irinotecan will be replaced by oxaliplatin (arm A). Bevacizumab will be continued."
3066335|NCT02119026|Active Comparator|B|"capecitabine and oxaliplatin (XELOX) plus bevacizumab (Avastin)~Arm B:~Capecitabine: 1000mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on d1 q3w combined with oxaliplatin 130mg/m2 iv. d 1 q3w Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance~At disease progression oxaliplatin will be replaced by irinotecan (arm B). Bevacizumab will be continued."
3066336|NCT02119013|Experimental|OCTEOTRIDE|Octeotride, 20 mg monthly intramuscular injection for 3 years
3066337|NCT02119013|Placebo Comparator|PLACEBO|Placebo (salin soluction), intramuscular injection monthly for 3 years
3066338|NCT02119000|Experimental|PEG electrolytes 2L/2L split dose|
3066339|NCT02119000|Active Comparator|Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose|
3066340|NCT02118987|Experimental|Omalizumab|300mg of omalizumab under the skin every four weeks at three separate visits representing a treatment period of 12 weeks. During this treatment period, patients will continue receiving their regularly scheduled chemotherapy desensitizations per the prescribed treatment schedule from the patient's oncologist.
3066341|NCT02118974|Experimental|Robot-assisted|Robot-assisted hysterectomy
3066342|NCT02118974|Experimental|Laparoscopic Hysterectomy|Laparoscopic Hysterectomy
3066343|NCT02118961|Experimental|BK1301|
3066344|NCT02118961|Active Comparator|DT toxoid|
3066345|NCT02118948|Experimental|Abuse-focused intervention|Participants attend 5 weekly, 2-hour intervention sessions focused on the psychological consequences of abuse, current sexual risk behavior, and the link between the two.
3066346|NCT02118948|Active Comparator|Sexual behavior-focused intervention|Participants attend 5 weekly, 2-hour intervention sessions focused on current sexual risk behavior.
3066347|NCT02118935|Active Comparator|Previously marketed cow's milk-based infant formula|
3066348|NCT02118935|Experimental|Marketed cow's milk-based infant formula with prebiotics|
3066349|NCT02118922||Healthy volunteers|Volunteers with normal corneas
3066350|NCT02118922||Patients with keratoconus|Patients diagnosed with keratoconus
3066351|NCT02118922||post-LASIK no complications|Subjects who underwent LASIK refractive surgery with no complications
3066352|NCT02118922||post-LASIK who developed ectasia|patients who underwent LASIK refractive surgery and developed ectasia as a complications
3066353|NCT02118909|Experimental|Part 1 (Pracinostat + Itraconazole)|Single-dose pracinostat and itraconazole dosing every day for 8 days
3066354|NCT02118909|Experimental|Part 2 (Pracinostat + Ciprofloxacin)|Single dose pracinostat and ciprofloxacin 2 times a day for 7 days
3066355|NCT02118896|Experimental|1: FK506E (MR4)|Single open arm of FK506E (MR4). Since this was an extension study for many studies, generally the dose given at enrollment was to be continued. The investigator was permitted to adjust the subject's dose and modify the MR4 dose regimen as deemed necessary to minimize Adverse Events (AEs) and maintain effective immunosuppression. MR4 capsules were taken orally, once daily in the morning. MR4 capsules were to be swallowed with fluid (preferably water) on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal. MR4 was supplied as 0.5 mg, 1 mg and 5 mg capsules in amber glass bottles or in blister packs.
3066356|NCT02118883|Other|Essentia Water|Essentia Water, electrolyzed high-pH water
3066357|NCT02118883|Other|Bottled Water|Purified bottle water
3066358|NCT02118870|Active Comparator|DAPT 360 days|Treatment 360 days DAPT
3066359|NCT02118870|Active Comparator|DAPT 90 days|Treatment 90 days DAPT
3066360|NCT02118857||Omnivore, vegetarian and vegan subjects.|These subjecs followed the diet from at least two years.
3066361|NCT02118844|Active Comparator|Moderate rocuronium neuromuscular blockade|rocuronium bolus is given if needed to maintain moderate neuromuscular blockade (TOF-count 2-4) during gastrojejunal anastomosis
3066362|NCT02118844|Experimental|deep rocuronium neuromuscular blockade|rocuronium bolus is given if needed to maintain deep neuromuscular blockade (here defined as a Posttetanic Count 1 - 5) during gastrojejunal anastomosis
3066467|NCT02118116|No Intervention|Wait-list Control|No training, wait-listed for ASIST at a later date
3066363|NCT02118831|Active Comparator|Aflibercept Blood Sample Collection|Blood samples will be collected from patients receiving aflibercept following the first and third dose of standard care therapy.
3066364|NCT02118831|Active Comparator|Bevacizumab Blood Sample Collection|Blood samples will be collected from patients receiving bevacizumab following the first and third dose of standard care therapy.
3066365|NCT02118831|Active Comparator|Ranibizumab Blood Sample Collection|Blood samples will be collected from patients receiving ranibizumab following the first and third dose of standard care therapy.
3066366|NCT02118818||NO rheumatic heart disease by echo|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD. We will be using next generation sequencing to identify these differences.
3066367|NCT02118818||Rheumatic heart disease by echo|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD. We will be using next generation sequencing to identify these differences.
3066368|NCT02118805||Patients with ALS|No intervention is used in this study. The health of muscle is monitored over time.
3066369|NCT02118805||Patients with Myasthenia Gravis|No intervention is used in this study. The health of muscle is monitored over time.
3066370|NCT02118805||Patients with Muscle Disease|No intervention is used in this study. The health of muscle is monitored over time.
3066371|NCT02118805||Patients with Stroke|No intervention is used in this study. The health of muscle is monitored over time.
3066372|NCT02118805||Patients with Parkinson's Disease|No intervention is used in this study. The health of muscle is monitored over time.
3066373|NCT02118805||Healthy Volunteers|No intervention is used in this study. The health of muscle is monitored over time.
3066374|NCT02118792|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
3066375|NCT02118792|Placebo Comparator|Matching vehicle control|Matching vehicle control, applied twice daily for up to 28 days
3066376|NCT02118779|Experimental|Behavioural change intervention|Cognitive behavioural therapy (CBT) combined with exercise
3066377|NCT02118779|No Intervention|Standard Patient Management|Standard care like usual (i.e. annual checks with neurologist, checks with cardiologist, if needed physical therapy)
3066378|NCT02118766|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
3066379|NCT02118766|Placebo Comparator|Matching vehicle control|Matching vehicle control, applied twice daily for up to 28 days
3066380|NCT02118753|No Intervention|ischemic preconditioning|"After baseline recordings of contractile function, the investigators will assign 2 trabeculae of each patient to either a stimulus for (1) ischemic preconditioning (IP) or (2) no IP. Subsequently, the trabeculae will be exposed to 90 min of ischemia, followed by 120 minutes of recovery. The investigators will measure the recovery of contractile function in both trabeculae.~This experiment serves as a positive control, to ensure that our model is still working properly."
3066381|NCT02118753|Experimental|eplerenone|In the next patients, a similar ischemia-reperfusion experiment will be performed, but now the 2 trabeculae will be randomized to pretreatment with eplerenone or DMSO. The percentage recovery (compared to baseline) of contractile force of the trabeculae at the end of reperfusion will serve as the primary endpoint.
3066382|NCT02118727|Active Comparator|Memantine|20mg taken by mouth every day BID for 32 weeks
3066383|NCT02118727|Placebo Comparator|Placebo|Placebo (for Memantine) taken by mouth everyday BID for 32 weeks
3066384|NCT02118714|Experimental|Atrasentan|Atrasentan daily (QD) for 26 weeks
3066385|NCT02118701|Experimental|SDM care planning|
3066386|NCT02118688|Placebo Comparator|Placebo|"Drug: Placebo~Placebo suspension administered PO/NG/FT q12h to mimic risperidone~Placebo suspension administered PO/NG/FT q8h to mimic trazodone"
3066387|NCT02118688|Active Comparator|Risperidone alone|"Drug: Risperidone~Initiate risperidone at 1 mg PO/NG/FT q12h~Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose~Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)"
3066388|NCT02118688|Active Comparator|Trazodone alone|"Drug: Trazodone~Initiate trazodone dosing at 50 mg PO/NG/FT q8h~Trazodone dose can be titrated upwards every 24 hours by 25 mg per dose~Maximum trazodone daily dose 600 mg per day (200 mg every 8 hours)"
3066389|NCT02118688|Active Comparator|Risperidone and Trazodone combination|"Drug: Risperidone~Initiate risperidone at 1 mg PO/NG/FT q12h~Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose~Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)~Drug: Trazodone~Initiate risperidone at 1 mg PO/NG/FT q12h~Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose~Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)"
3066390|NCT02118675||Age 5-17 years|Participants age 5 - 17 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA) BodPod Circumferences Ultrasound
3066391|NCT02118675||Age 18-80 years|Participants age 18-80 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA) BodPod Circumferences Ultrasound
3066392|NCT02118662|Experimental|Male Cohort|"Eight Male participants per cohort will complete the following:~Energy Expenditure during seated in an office chair during normal rest. Energy Expenditure during seated and typing. Energy Expenditure during Treadmill walking work condition. Energy Expenditure during cycling work condition"
3066393|NCT02118662|Experimental|Female Cohort|"Eight femalel participants per cohort will complete the following:~Energy Expenditure during seated in an office chair during normal rest. Energy Expenditure during seated and typing. Energy Expenditure during Treadmill walking work condition. Energy Expenditure during cycling work condition"
3066394|NCT02118649|Experimental|Game|Participants will play a video game directing their gaze to on-screen targets.
3066395|NCT02118636||Aromatase inhibitor therapy|Subjects who are starting treatment with any of the three aromatase inhibitor (AI) medications
3066396|NCT02118623|Active Comparator|Level 1|Moderated discussion board only
3066397|NCT02118623|Active Comparator|Level 2|Moderated discussion board plus psychoeducation
3066398|NCT02118623|Active Comparator|Level 3|Moderated discussion board plus psychoeducation plus interactive psychosocial tools.
3095350|NCT01923545|Experimental|DA-3031 6mg|PEG-G-CSF
3066401|NCT02118597||Triple Combination Therapy|Participants who demonstrated genotype 1 chronic hepatitis C infection and had a history of unsuccessful treatment with pegylated interferon (peginterferon) alfa + ribavirin, and who were subjected to receive a triple combination therapy with simeprevir or boceprevir plus peginterferon alfa-2a and ribavirin were observed.
3066402|NCT02118584|Experimental|Part 1: Open-label Extension|Participants with moderate to severe UC who were enrolled in the Phase II OLE study or the Phase III studies, and who meet the eligibility criteria for enrollment will receive open-label etrolizumab in Part 1 (OLE).
3066403|NCT02118584|No Intervention|Part 2: Safety Monitoring|All participants from Part 1 (OLE), participants whose PML follow-up is not completed within the Phase II OLE study, and participants transferring from the Phase III double-blind studies after the 12-week safety follow-up will be monitored for PML (92 weeks).
3066404|NCT02118558|Experimental|Negative Pressure Wound Therapy (NPWT)|
3066405|NCT02118558|Active Comparator|standard prophylactic therapy|
3066406|NCT02118545||vWF and postoperative Outcome|An independent prospective validation cohorts will be obtained from 4 different Institutions: 2 in Vienna , 1 in Salzburg and 1 in Bern
3066407|NCT02118532|Experimental|IN.PACT Admiral|
3066408|NCT02118519|Active Comparator|mesenchymal stem cells|Autologous Mesenchymal Stem Cells primed prior to intra articular injection into knees of patients with advanced articular cartilage injury
3066409|NCT02118519|Active Comparator|mesenchymal cells&platelet lysate|Autologous Mesenchymal Stem Cells primed prior to intra articular injection with platelet lysate into knees of patients with advanced articular cartilage injury
3066410|NCT02118506|Active Comparator|Physical practice|"Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Physical practice: is the execution of the motor action."
3066411|NCT02118506|Experimental|Mental and physical practice|"Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Mental practice: is defined as motor imagery training with the aim of improving the engine performance. Is the imagination of a motor action without its physical implementation.~Physical practice: is the execution of the motor action."
3066412|NCT02118493|Experimental|Benign Biliary Stenosis, Laser|Subjects that undergo the experimental intervention, that being single use of a laser excision catheter.
3066413|NCT02118480|Experimental|cognitive remediation program: REHACOP|Cognitive rehabilitation program (REHACOP) including intervention in: attention, memory, processing speed, language, executive functioning and social cognition during 3 months, 3 times per week
3066414|NCT02118480|Active Comparator|Occupational Therapy|The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood) during 3 months, 3 times per week.
3066415|NCT02118467|Active Comparator|Norepinephrine and epinephrine|"Patients will receive norepinephrine infusion per standard protocol. Dose range will be 0.03-0.3 mcg/kg/minute. Norepinephrine concentration will be 16 mg/250 mL. If a second vasopressor is required, epinephrine will be added. Dose range of epinephrine will be 0.03-0.3 mcg/kg/minute. Epinephrine concentration will be 16 mg/250 mL. The drugs norepinephrine and epinephrine will be mixed and blinded by the research pharmacy. The research pharmacist will list the dose ranges in mL/hr; this will allow the bedside nurse to program the medication per standard protocol.~If the patient's shock is not adequately treated with the highest doses of both norepinephrine and epinephrine, additional, open-label norepinephrine will be added, and titrated to achieve target blood pressure. If the patient's shock is not adequately treated with three vasopressors, additional open-label epinephrine will be added, and titrated to achieve target blood pressure."
3066416|NCT02118467|Active Comparator|Phenylephrine and vasopressin|"Patients will receive phenylephrine infusion per standard protocol. Dose range will be 0.3 to 3.0 mcg/kg/minute. Phenylephrine concentration will be 160 mg/250 mL. If a second vasopressor is required, vasopressin will be added. Dose range of vasopressin will be 0.1 to 0.6 milliunits/kg/minute. Vasopressin concentration will be 40 units/250 mL. The drugs phenylephrine and vasopressin will be mixed and blinded by the research pharmacy. The research pharmacist will list the dose ranges in mL/hr; this will allow the bedside nurse to program the medication per standard protocol.~If the patient's shock is not adequately treated with the highest doses of both phenylephrine and vasopressin, additional, open-label norepinephrine will be added, and titrated to achieve target blood pressure. If the patient's shock is not adequately treated with three vasopressors, additional open-label epinephrine will be added, and titrated to achieve target blood pressure."
3066417|NCT02118454|Experimental|Daily IVR calls|"The Daily IVR Calls Intervention: consisting of two (2) automated voice calls (intervention messages) each day for six months, PLUS one IVR assessment call (consisting of four [4] questions) every week for 6 months"
3066418|NCT02118454|Active Comparator|Weekly IVR Survey Only|The Weekly IVR Survey Only control condition: consisting of standard care, PLUS one IVR assessment call (consisting of four [4] questions) every week for 6 months.
3066419|NCT02118441|Active Comparator|direct palpation|Radial artery catheter insertion will be conducted by direct palpation and use of anatomic knowledge by the Anesthesiologist.
3066420|NCT02118441|Active Comparator|Ultrasound|"Radial artery catheter insertion will be conducted by ultrasound guidance. A Sono-site ilook 25 Ultrasound (Sono-site, Inc., Bothell, WA, USA) with a 10-5 MHz linear array ultrasound transducer will be used.~At the discretion on the Anesthesiologist, an out-of-plane (i.e. needle plane at right angles to ultrasound plane) will be used. Colour flow doppler may also be used to identify the artery if necessary."
3066421|NCT02118428|Experimental|Mirasol|Mirasol-treated whole blood
3066422|NCT02118428|Placebo Comparator|Control|Untreated control whole blood
3066423|NCT02118415|Experimental|Interventional|Interventional group: activated autologous NK cell treatment
3066424|NCT02118415|No Intervention|Control group|Control group: BSC
3066425|NCT02118402|Active Comparator|Fortified maize porridge (MNP)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, maltodextrin carrier (added up to 11g)
3066426|NCT02118402|Active Comparator|Fortified maize porridge (MNP+Fe)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g)
3066427|NCT02118402|Active Comparator|Fortified maize porridge (MNP+Fe+GOS)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA plus 7.5 g of galactooligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g)
3066428|NCT02118389|Experimental|Glucerna,Meal Replacement|Glucerna 52g instead of night meal 5weeks
3066429|NCT02118376|Experimental|exenatide|exenatide, 5ug, bid, 3months
3066430|NCT02118350|Experimental|Mat Pilates training|Mat Pilates training performed two times at week for 16 weeks.
3066431|NCT02118350|No Intervention|Control|
3066432|NCT02118337|Experimental|0.1 mg/kg MEDI0680 Q2W; 3 mg/kg durvalumab Q2W|MEDI0680 and Durvalumab in combination
3066433|NCT02118337|Active Comparator|Nivolumab|Nivolumab monotherapy at the selected dose
3066434|NCT02118337|Experimental|0.5 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W|MEDI0680 and Durvalumab combination
3066435|NCT02118337|Experimental|0.1 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W|MEDI0680 and Durvalumab in combination
3066436|NCT02118337|Experimental|2.5 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W|MEDI0680 and Durvalumab in combination
3066437|NCT02118337|Experimental|10 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W|MEDI0680 and Durvalumab in combination
3066438|NCT02118337|Experimental|20 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W|MEDI0680 and Durvalumab in combination
3066439|NCT02118337|Experimental|20 mg/kg MEDI0680 Q2W; 750 mg durvalumab Q2W|MEDI0680 and Durvalumab in combination
3066440|NCT02118324|Experimental|Exercise treatment|Participants will be instructed to use the exergaming program at home for 30 mins, 3-5 times per week.
3066441|NCT02118324|No Intervention|Control group|No intervention is provided.
3066442|NCT02118311|Experimental|TREG|T regulatory cells after non-myeloablative (using fludarabine, cyclophosphamide, and total body irradiation) umbilical cord transplant.
3066443|NCT02118311|Experimental|Non-Myeloablative Only|Non-myeloablative (using fludarabine, cyclophosphamide, and total body irradiation) umbilical cord transplant.
3066444|NCT02118298||Multiple Sclerosis|Ages 18 - 66, 10 years or less of MS,
3066445|NCT02118298||Demographically matched controls|Ages 18 - 66, No known neurological disorder, no learning disorder, and no psychiatric disturbance that is actually interfering with life.
3066446|NCT02118285|Experimental|Treatment|Haploidentical donor NK cells and IL-2 are infused intraperitoneally (IP) after a non-myeloablative preparative regimen of cyclophosphamide and fludarabine. INCB024360, at the assigned dose, begins 2 days before the NK cell infusion and continues twice daily for 90 days.
3066447|NCT02118272|Other|Physica KR|
3066448|NCT02118259|Other|The study population|"See inclusion and exclusion criteria.~Intervention: Before-after study"
3066449|NCT02118246|Experimental|Dry Needling|The taut band of trigger point in vastus lateralis muscle; localized between the thumb and index finger, was needled forward and backward repeatedly until there were no more local twitch response
3066450|NCT02118246|Experimental|Kinesio Tape|Y technique with 25% tension on the tails was applied. Direction of the technique was insertion to origin of the muscle and zone of the trigger point was placed at the center of Y strip.
3066451|NCT02118233||Carotid Endarterectomy (CEA)|Surgical Revascularization- Carotid Endarterectomy (CEA)
3066452|NCT02118233||Carotid Angioplasty and Stenting (CAS)|Surgical Revascularization- Carotid Angioplasty and Stenting (CAS)
3066453|NCT02118233||Control Group- Medical Management|Control Group- Medical Management
3066454|NCT02118220|Other|Concussion Questionnaire|"The questionnaire is specifically designed to elicit occurrence and symptoms of a concussion. If the patient answers yes to question 2a, which asks At the time of the injury do you recall a blow to the head, neck, face or body that resulted in sustained symptoms of concussion (e.g., headache, dizziness, confusion, nausea, vomiting, etc.)?, the research team will administer the 22 item self-reporting symptom scale in the above mentioned SCAT3. The responses obtained from the questionnaire will be used to determine the incidence of symptomatic concussions, either known or unrecognized, in pediatric patients sustaining an orthopedic injury requiring surgical repair."
3066455|NCT02118207|Experimental|Control dives 1st|Subjects in this group complete the first 3 dives as control dives and the second 3 dives preceded by aerobic exercise
3066456|NCT02118207|Experimental|Predive exercise 1st|Subjects complete the first 3 dives preceded by the intervention of aerobic exercise and the second 3 with no exercise as control dives
3066457|NCT02118194||Paraplegia, spinal cord injury|An exoskeleton-assisted walking system for people with paralysis from spinal cord injury at thoracic level 1 and below (paraplegia) will be used.
3066458|NCT02118181|No Intervention|Control|
3066459|NCT02118181|Experimental|HMB|Group taking oral supplementation with Beta-hydroxy-beta-methylbutyrate
3066460|NCT02118168||No treatment|"All patients that participated to the therapeutic phase II trial of the Tat vaccine ISS T-002 and that received at least 3 immunizations and reached 48-weeks of follow-up."
3066461|NCT02118155|Sham Comparator|Connective tissue graft (CTG)|The gingival recession defects were treated by connective tissue graft surgical procedure and received the sham application os low-intensity laser therapy.
3066462|NCT02118155|Experimental|Connective tissue graft plus laser (CTG+L)|The gingival recession defects were treated by connective tissue graft associated with the application of a LILT protocol
3066463|NCT02118142|Active Comparator|Betaine|6 gram dose of betaine delivered in encapsulated form
3066464|NCT02118142|Placebo Comparator|Dextrose|6 gram dose of dextrose delivered in encapsulated form
3066465|NCT02118129|Experimental|Behavioural intervention|Behavioural intervention consisting of an educational video component and use of a handheld mobile app to track vitamin D intake.
3066466|NCT02118129|Placebo Comparator|Control group|Wait-list control group
3066468|NCT02118116|Experimental|ASIST|Applied Suicide Intervention Skills Training is a 2-day, 14 hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The course, facilitated by 2 trained facilitators, allows for a maximum enrollment of 30 participants.
3066469|NCT02118116|Experimental|ASIST uncontrolled arm|The ASIST workshop will be offered to participants who refuse to be part of the waitlist control arm. This is due to the reality in gathering data in these communities. Many times it is not possible for participants to be waitlisted, and therefore we would still want to gather data on those that refuse to participate in the RCT design and will collect uncontrolled data on these participants only.
3066470|NCT02118103|Experimental|Spinal Manipulation|bilateral lumbar spine manipulation
3066471|NCT02118103|No Intervention|No Intervention - control|no intervention
3066472|NCT02118090|Experimental|Chloroquine|Patients treat with chloroquine sulfate (NIVAQUINE) 10 mg/kg/day - 3 days
3066473|NCT02118090|Active Comparator|DHA-PP|Patient treat with DHA 40 mg and PP 320 mg, (Duo-Cotecxin®) The approximate total adult dose is 2-4 mg/kg for DHA and 20mg/kg for PP
3066474|NCT02118077|Experimental|G17DT|250 µg administered at Weeks 0,1,3 and 24 by intramuscular injection, followed by additional injections (boosters) of 250 µg every 6 months at investigator's discretion.
3066475|NCT02118077|Placebo Comparator|Placebo|Placebo administered at Weeks 0, 1, 3, and 24 by intramuscular injection followed by additonal injections of placebo every 6 months.
3066476|NCT02118064|Experimental|G17DT-Irinotecan|500µg dose of G17DT intramuscular injection in combination with 125 mg/m^2 intravenous infusion of Irinotecan over 90 minutes.
3066477|NCT02118051|Experimental|CFA , hMG,Ganirelix,choriogonadotropin alfa,progesterone.|"Corifollitropin Alfa (CFA) 150 ug from the 2nd day of the cycle for 7 days. hMG 300 IU/24h, if required from the 8th day of the Controlled Ovarian Stimulation , until the day human chorionic gonadotropin ( hCG.) Ganirelix 0.25 mg,Dose: 250μg/24h since the day observe a follicle> 14mm. Recombinant choriogonadotropin alfa,Dose: 6,500 IU, pods, when follicles> 17 mm are observed.~Micronized natural progesterone. Route of administration: vaginal. Dose: 400mg/24, from embryo transfer until the day of b-hCG."
3066478|NCT02118051|Active Comparator|hMG ,Ganirelix,choriogonadotropin alfa,progesterone|"Human Menopausal Gonadotropin (hMG). Dose: 300 IU/24h from the 2nd day of the cycle throughout the stimulation.~Ganirelix 0.25 mg,Dose: 250μg/24h since the day observe a follicle> 14mm. Recombinant choriogonadotropin alfa,Dose: 6,500 IU, pods, when follicles> 17 mm are observed.~Micronized natural progesterone. Route of administration: vaginal. Dose: 400mg/24, from embryo transfer until the day of b-hCG."
3066479|NCT02118038||HELPMOM1|corresponds to the cohort of patients in whom psychological state will be studied in the immediate waning PPH then during a 6 months through appropriate questionnaires
3066480|NCT02118038||HELPMOM2|corresponds to the cohort of patients enrolled in group HELPMOM1 who experienced a cardiac abnormality in the initial management and will therefore be included in a cardiac monitoring
3066481|NCT02118025||Off-pump coronary artery bypass graft|Patients operated on with off-pump coronary artery bypass graft, beating heart surgery.
3066482|NCT02118025||Mini extracorporeal circulation bypass|Patients operated on with mini extracorporeal circulation bypass. A modified extracorporeal system.
3066483|NCT02118012|Active Comparator|Chlorcyclizine &amp; RBV|Chlorcyclizine HCl and Ribavirin
3066484|NCT02117999|Experimental|Transepithelial corneal cross-linking using iontophoresis|Transepithelial corneal cross-linking using iontophoresis
3066485|NCT02117999|Active Comparator|Standard corneal cross-linking|Standard corneal cross-linking
3066486|NCT02117986|Experimental|loading dose of colistin|Patients will receive a loading dose of colistin (6 million international units) followed by a maintenance dose of 3 million international units of colistin every 8 hours intravenous
3066487|NCT02117986|Active Comparator|without loading dose of colistin|Patients will receive 3 million international units of colistin every 8 hours intravenous
3066488|NCT02117973|Active Comparator|Conventional Technique using Persona prosthesis|The surgeon will realize the implantation of the Persona prosthesis according to the surgical technique. Potential variables such as methodology for determining tibial rotation, measuring of bone cuts, and any intra-operative adjustments will be captured on the operative case report form.
3066489|NCT02117973|Experimental|iAssist Technique using Persona prosthesis|iAssist is an electronic displacement sensor based instrumentation system that provides intra-operative verification at each surgical step (bone cuts alignment and resection level); in order to help reduce bone cuts errors. iAssist features simple and intuitive instrumentation that is based on conventional total knee arthroplasty instrumentation. iAssist should take less than 2-3 minutes (on average) to setup
3066490|NCT02117960|Active Comparator|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
3066491|NCT02117960|Placebo Comparator|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
3066492|NCT02117947|Experimental|Behavioral Counseling|Behavioral counseling used evidence-based smoking cessation intervention components as well as a theoretically-framed focus on behavioral shaping to promote the adoption of smoke-free homes and cars. Sessions included two, 1-hour in-home counseling and seven, 5-15 minute telephone follow-up sessions over 16 weeks. Content included health ed around the benefits of eliminating children's exposure to secondhand smoke; skills training around adoption and maintenance of smoke-free environments; goal setting, problem solving, and positive reinforcement for progress toward goals; coping skills training for smoking urge and mood management; and home support for maternal smoking behavior change achieve through family contracts and home detailing promoting pro-smoke-free home norms.
3066493|NCT02117947|Active Comparator|Self-help control|The self-help control group received a comprehensive self-help manual that outlined all of the goals and strategies covered in counseling, however, counseling was not provided to this group.
3066494|NCT02117934|Experimental|HEPLISAV|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and placebo (saline injection) at Week 24, followed by a 52-week safety follow-up from the last active dose of HEPLISAV.
3066495|NCT02117934|Active Comparator|Engerix-B|1.0 mL Engerix-B (20 mcg HBsAg adsorbed on 500 mcg of aluminum hydroxide) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and 24, followed by a 32-week safety follow-up from the last dose of Engerix-B.
3066496|NCT02117921|Experimental|MBS therapy education|
3095351|NCT01923545|Active Comparator|Leucostim®|G-CSF
3066499|NCT02117895|Experimental|Pancreatectomy & celiac plexus resection|Left celiac plexus resection will be performed besides standard distal pancreatectomy. Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
3066500|NCT02117895|Active Comparator|Pancreatectomy|Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
3066501|NCT02117882||minimally invasive approach test|minimally invasive lateral approach
3066502|NCT02117882||control lateral traditional approach|standard surgical approach
3066503|NCT02117869|Experimental|Low furanocoumarin hybrid grapefruit juice|3 consecutive daily doses of 200ml low furanocoumarin hybrid grapefruit juice plus midazolam 5mg orally on the third day.
3066504|NCT02117869|Active Comparator|Regular grapefruit juice|3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.
3066505|NCT02117869|Other|water (control)|3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
3066506|NCT02117856|Active Comparator|1 implant|"Participants receive the following:~1 implant placed surgically in the mandibular midline; Soft reline of the existing complete lower denture; 2.25mm ball patrix placed on 1 healed implant; and Reline with 1 retentive matrix in the lower denture."
3066507|NCT02117856|Active Comparator|2 implants|"Participants receive the following:~2 implants placed surgically in the mandibular canine sites; Soft reline of the existing complete lower denture; 2.25mm ball patrices placed on 2 healed implants; and Reline with 2 retentive matrices in the lower denture."
3066508|NCT02117843|Experimental|AVI® Arsenic trioxide drug eluting stent|The Arsenic trioxide as AVI eluting drug, biodegradable polylactic acid as drug carrier.
3066509|NCT02117830|Experimental|Androxal 25 mg|
3066510|NCT02117830|Experimental|Androxal 250 mg|supratherapeutic dose
3066511|NCT02117830|Placebo Comparator|Placebo|
3066512|NCT02117830|Other|Moxifloxacin 400 mg|positive control
3066513|NCT02117817|Experimental|Treatment (BKM120 in Combination with Weekly Nabpaclitaxel)|
3066514|NCT02117804||High ESDP Score|Patients with 10 or greater score on the Early Screen for Discharge Planning at the time of admission.
3066515|NCT02117804||Low ESDP Score|Patients with 9 or lower score on the Early Screen for Discharge Planning at the time of admission.
3066516|NCT02117791||Group 1|Riociguat treatment group
3066517|NCT02117778|Active Comparator|Interscalene|Continuous Interscalene Nerve Block
3066518|NCT02117778|Active Comparator|Supraclavicular|Continuous Supraclavicular Nerve Block
3066519|NCT02117778|Active Comparator|Suprascapular|Continuous Suprascapular Nerve Block
3066520|NCT02117765|Experimental|Treatment|"Four cohorts of 5 subjects will be recruited:~Group 1: Five subjects will be given Ustekinumab 45mg SC at 0, 4, 16, 28 and 40 weeks.~Group 2: Five subjects will be given Ustekinumab 90mg SC at 0, 4, 16, 28 and 40 weeks.~Group 3: Five subjects will be given Ustekinumab 45 mg SC at 0,4 and 16 weeks.~Group 4: Five subjects will be given Ustekinumab 90mg SC at 0, 4 and 16 weeks."
3066521|NCT02117752|Experimental|Dapsone Gel Subset 1|Dapsone gel, dapsone gel vehicle and controls applied to the skin by separate occlusive patches every 24 hours for 21 days followed by a 10 to 17 day rest period then one application each of dapsone gel and dapsone gel vehicle by patch for 48-hours.
3066522|NCT02117752|Experimental|Dapsone Gel Subset 2|Dapsone gel, dapsone gel vehicle and negative control applied to the skin by separate occlusive patches every 48 to 72 hours for 21 days followed by a 10 to 17 day rest period then one application each of dapsone gel and dapsone gel vehicle by patch for 48-hours.
3066523|NCT02117739|Experimental|All Participants|Dapsone gel and dapsone gel vehicle applied to the skin by separate occlusive patches twice a week for 21 days followed by a 10 to 17 day rest period then another application of dapsone gel and dapsone gel vehicle by patch.
3066524|NCT02117726|Experimental|Dexmedetomidine,midazolam|Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02~0.1mg/kg/h, for 24 hours.Dexmedetomidine will be added at 0.2~1.4μg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of dexmedetomidine, continuous intravenous infusion of midazolam could be used at 0.02~0.1mg/kg/h, until the target level is reached.
3066525|NCT02117726|Active Comparator|Propofol,midazolam|Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02~0.1mg/kg/h, for 24 hours.Propofol will be added at 0.3~4mg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of propofol, continuous intravenous infusion of midazolam could be used at 0.02~0.1mg/kg/h, until the target level is reached.
3066526|NCT02117713|Experimental|LUM001|Participant will receive LUM001 as oral solution once daily based on participant's weight. The dose will be escalated from 14, 35, 70, 140 and 280 microgram per kilogram per day (mcg/kg/day) for 4-week dose escalation period. During 8-weeks of dose optimization period, drug will be adjusted in titrated manner and will continue dosing to complete the stable dosing and safety monitoring periods for up to 96 weeks of cumulative LUM001 exposure in this study. Dosing during, long-term optional follow-up treatment periods 1 and 2 will be maintained at the same dose levels as at weeks 96 and 144 for participants rolling over into these treatment periods respectively.
3066527|NCT02117700|Experimental|N-acetyl cysteine-1|N-acetyl cysteine 600 mg once/day + Placebo once/day for 16 weeks
3066528|NCT02117700|Experimental|N-acetyl cysteine-2|N-acetyl cysteine 600 mg twice/day for 16 weeks
3066529|NCT02117700|Placebo Comparator|Placebo|Placebo twice/day for 16 weeks
3066530|NCT02117687|Active Comparator|OPTIVE FUSION™|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
3066531|NCT02117687|Active Comparator|VISMED® Multi|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
3066532|NCT02117674|Active Comparator|standard forward-viewing colonoscopy|polyp detection with standard forward-viewing colonoscopy polyp detection in the right colon with scope retroflexion
3066533|NCT02117674|Active Comparator|full-spectrum colonoscopy|polyp detection with full-spectrum colonoscopy polyp detection in the right colon with scope retroflexion
3066534|NCT02117661|Experimental|L-carnitine capsules|2000 mg daily (2x 500 mg capsules twice a day - BID) for six months
3066535|NCT02117661|Placebo Comparator|Cellulose capsules|2x capsules twice a day - BID (4 total per day) for six months
3066536|NCT02117648|Experimental|Abemaciclib Alone Period 1|50 mg single oral dose of Abemaciclib was administered in Period 1 Day 1.
3066537|NCT02117648|Experimental|Abemaciclib + Clarithromycin Period 2|Clarithromycin 500 milligram (mg) orally twice daily for 12 days. Single oral dose of Abemaciclib 50 mg on Period 2 Day 5. Clarithromycin dosing continued for 7 days following the single dose of Abemaciclib.
3066538|NCT02117648|Experimental|Abemaciclib Safety Extension|After completing Period 2, eligible participants continued to receive 200 mg Abemaciclib every 12 hours (Q12H) on a 28-day cycle in a safety-extension phase until discontinuation criteria were met.
3066539|NCT02117635|Experimental|allogeneic human neural stem cell|"CTX DP~human neural stem cell product, single dose once only injection"
3066540|NCT02117622||Patients with diabetes mellitus requiring insulin therapy|
3066541|NCT02117609|Experimental|New DELICAL formula|New high-protein oral nutrient supplement
3066542|NCT02117609|Active Comparator|Standard DELICAL formula|Standard isoenergetic isoprotein formula
3066543|NCT02117596|Other|Sirolimus|Single arm
3066544|NCT02117583|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3066545|NCT02117583|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3066546|NCT02117583|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3066547|NCT02117583|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3066548|NCT02117570|Experimental|High dose of C. difficile vaccine|
3066549|NCT02117570|Experimental|Low dose of C. difficile vaccine|
3066550|NCT02117570|Placebo Comparator|Placebo|
3066551|NCT02117557|Experimental|Single incision laparoscopic surgery|Transumbilical single incision laparoscopic surgery will be performed for patients in this group.And addition of only one trocar through the stoma for drainage tube is allowed.
3066552|NCT02117557|Active Comparator|Conventional laparoscopic surgery|Conventional laparoscopic surgery for colorectal cancer will be performed for patients in this group.
3066553|NCT02117544|Other|New MF, then AOAMF|Lotrafilcon B multifocal contact lenses (new), followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (in both eyes) for about 1 hour.
3066554|NCT02117544|Other|AOAMF, then New MF|Lotrafilcon B multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses (new). Each product worn bilaterally (in both eyes) for about 1 hour.
3066555|NCT02117518||no treatment|T1D patients at ages 0-25
3066556|NCT02117505|Experimental|Group 1 (Formulation 2 Then Formulation 1)|Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in first treatment period; followed by JNJ-54781532 formulation 1 as 150 mg orally (5*30 mg tablet=150 mg) in second treatment period. A washout period of at least 7 days will be maintained between each treatment period.
3066557|NCT02117505|Experimental|Group 2 (Formulation 1 Then Formulation 2)|Single-dose of JNJ-54781532 formulation 1 will be administered as 150 mg oral tablet (5*30 mg tablet=150 mg) in first treatment period; followed by JNJ-54781532 formulation 2 as 150 mg oral tablet in second treatment period. A washout period of at least 7 days will be maintained between each treatment period.
3066558|NCT02117492|Experimental|Vertical Cuff|Vaginal cuff closure will be done vertically.
3066559|NCT02117492|Experimental|Horizontal Cuff|Vaginal cuff closure will be done horizontally.
3066560|NCT02117479|Experimental|Ruxolitinib plus capecitabine|
3066561|NCT02117479|Active Comparator|Placebo plus capecitabine|
3066562|NCT02117466|Other|Standard dose cetuximab|Uptake of 89Zr-cetuximab: continue standard dose (500mg/m2 bsa) (standard care)
3066563|NCT02117466|Experimental|Dose escalation cetuximab|No 89Zr-cetuximab uptake: dose escalation in a 3x3 cohort design (with maximal 50% dose increase each cohort; with a maximum of 2000 mg/m2 bsa every two weeks)
3066564|NCT02117453|Experimental|Group I|Rosuvastatin 20 mg/day
3066565|NCT02117453|Placebo Comparator|Group II|Placebo
3066566|NCT02117427|Experimental|Group A|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
3066567|NCT02117427|Experimental|Gtoup B|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
3066568|NCT02117427|Experimental|Group C|MDGN201 TARGTEPO secreting EPO (55-65 IU/Kg/day)
3066569|NCT02117414|Experimental|MRI Group|Subjects randomized to the MRI group will undergo a series of MRI scans at the MRI visit (9-12 weeks post-implant).
3066570|NCT02117414|Sham Comparator|Control Group|Subjects randomized to the Control group will wait for 1 hour without having a series of MRI scans at the waiting period visit (9-12 weeks post-implant).
3066571|NCT02117401|Experimental|group 1|age: 2 to 12 months induction dosage of mivacurium chloride: 0.15 mg/kg administration: intravenous injection for 20 s
3066572|NCT02117401|Experimental|group 2|age: 2 to 12 months induction dosage of mivacurium chloride: 0.15 mg/kg administration: intravenous injection for 40 s
3066573|NCT02117401|Experimental|group 3|age: 2 to 12 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
3066574|NCT02117401|Experimental|group 4|age: 2 to 12 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
3066575|NCT02117401|Experimental|group 5|age: 13 to 35 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
3066576|NCT02117401|Experimental|group 6|age: 13 to 35 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
3066577|NCT02117401|Experimental|group 7|age: 13 to 35 months induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
3066578|NCT02117401|Experimental|group 8|age: 13 to 35 months induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
3066579|NCT02117401|Experimental|group 9|age: 3 to 6 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
3066580|NCT02117401|Experimental|group 10|age: 3 to 6 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
3066581|NCT02117401|Experimental|group 11|age: 3 to 6 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
3066582|NCT02117401|Experimental|group 12|age: 3 to 6 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
3066583|NCT02117401|Experimental|group 13|age: 7 to 14 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
3066584|NCT02117401|Experimental|group 14|age: 7 to 14 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
3066585|NCT02117401|Experimental|group 15|age: 7 to 14 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
3066586|NCT02117401|Experimental|group 16|age: 7 to 14 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
3066587|NCT02117388|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
3066588|NCT02117388|Experimental|Sleep Restriction|Sleep Restriction therapy will limit the time participants spend in bed in order to make sure they are sleepy enough to fall asleep quickly.
3066589|NCT02117388|Experimental|Combined Therapy Treatment for Insomnia|Combined Therapy involves combining Sleep Restriction and Cognitive Therapy so that the two therapies reinforce each other.
3066590|NCT02117375|Experimental|Patients with multiple sclerosis|80 patients / clinical Follow-up at M0, M6, M12, M18, M24, M30, M36, M42, M48, M54 and M60 / spinal cord MRI follow-up at M0, M12, M24, M36 and M60 / brain MRI follow-up at M0, M12, M24, M36 and M60
3066591|NCT02117375|Experimental|Healthy volunteers|20 healthy volunteers (stability of spinal cord imaging) / spinal cord MRI follow-up at M0 and M24
3066592|NCT02117362|Experimental|Cohort 1|1 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
3066593|NCT02117362|Experimental|Cohort 2|2 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
3066594|NCT02117362|Experimental|Cohort 3|4 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
3066595|NCT02117362|Experimental|Cohort 4|8 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
3066596|NCT02117349|Experimental|Raplixa plus gelatin sponge|During surgery subjects randomized to this arm will be treated with Raplixa and a gelatin sponge.
3066597|NCT02117349|Other|Gelatin sponge alone|During surgery subjects randomized to this arm will be treated with only gelatin sponge.
3066598|NCT02117336|Experimental|P1446A-05|
3066599|NCT02117310|Experimental|ICG|Angiography with administered ICG
3066600|NCT02117297|Experimental|Gemtuzumab Ozogamicin|Consolidation therapy with GO will be administered between days 60 and 180 post transplantation when the ANC is >1000/mm3 and platelet count is >40,000/mm3 untransfused x 3 days after AlloSCT and again at minimum 8 weeks later.
3066601|NCT02117284||Coronary artery disease|All patients present to participating nuclear imaging facilities for diagnosis of CAD and/or risk stratification with Rubidium PET. Subjects will be enrolled according to the clinical indications listed in the approved Ruby-Fill product monograph.
3066602|NCT02117271|Placebo Comparator|nasal dilator strip|Breathe Right ® nasal dilator strip used during sleep
3066603|NCT02117271|Experimental|continuous positive airway pressure|nasal continuous positive airway pressure used during sleep
3066604|NCT02117258|Experimental|Z-360 60mg+Gemcitabine|Z-360 60 mg will be taken orally, twice daily (BID) after a meal.
3066605|NCT02117258|Experimental|Z-360 120mg+Gemcitabine|Z-360 120 mg will be taken orally, twice daily (BID) after a meal.
3066606|NCT02117258|Experimental|Z-360 240mg+Gemcitabine|Z-360 240 mg will be taken orally, twice daily (BID) after a meal.
3066607|NCT02117258|Placebo Comparator|Placebo+Gemcitabine|Placebo will be taken orally, twice daily (BID) after a meal.
3066608|NCT02117232|Experimental|Visualization balloon|"Colonoscopy performed with the use of Visualization balloon"
3066609|NCT02117232|Active Comparator|Traditional CO2-insufflation colonoscopy|"Traditional colonoscopy performed with CO2 insufflation without Visualization balloon"
3066610|NCT02117219|Experimental|MEDI4736 Evaluate MEDI4736 in MDS|Evaluate MEDI4736 monotherapy and MEDI4736 in combination with azacitidine after monotherapy progression in MDS
3066611|NCT02117219|Experimental|MEDI4736 + tremelimumab|Evaluate MEDI4736 in combination with tremelimumab
3066612|NCT02117219|Experimental|MEDI4736 + tremelimumab + azacitidine|Evaluate MEDI4736 in combination with tremelimumab and azacitidine
3066613|NCT02117206|Active Comparator|L-Arginine|Femoral arterial infusion of 2 g L-Arginine for 30 min
3066614|NCT02117206|Placebo Comparator|Nacl|Femoral arterial infusion of Nacl for 30 min
3066615|NCT02117193|Placebo Comparator|Alcohol intake|1 g/kg of etanol combined. Beer without alcohol in the same volume will be used to placebo condition.
3066616|NCT02117193|Active Comparator|sleep deprivation|one night of sleep deprivation will be compared to 8h of normal sleep.
3066617|NCT02117180|Other|FODMAP's diet|A diet low in Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols (FODMAPs)
3066618|NCT02117167|Experimental|Substudy 1: targeted agent|Arm A1/ targeted arm: targeted maintenance from a list of 6 targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing,
3066619|NCT02117167|Active Comparator|Substudy 1: standard maintenance therapy|Arm B1/ standard arm pemetrexed Intra venous 500 mg/m2, every 3 weeks, standard maintenance left to the investigator's choice
3066620|NCT02117167|Experimental|Substudy 2: Immunotherapy|Arm A2/ Immunotherapy arm: maintenance with MEDI4736 for patient without actionable genomic alterations or non eligible to Targeted substudy 1, MEDI4736 Intra-venous 10 mg/kg, Q2W
3066621|NCT02117167|Active Comparator|Substudy 2: standard maintenance therapy|Arm B2/ standard arm pemetrexed Intra venous 500 mg/m2, every 3 weeks, standard maintenance left to the investigator's choice
3066622|NCT02117154||HbA1c, 6-day Professional CGM|6-day Continuous Glucose Monitoring System (Medtronic iPro2 Professional CGM) will be deployed on a same patient for 3 times, which is one month apart
3066623|NCT02117141|Experimental|HC-ER 20 mg capsule (fasted)|Single oral dose of a HC-ER 20 mg capsule (fasted)
3066624|NCT02117141|Experimental|HC-ER 20 mg capsule (fed)|Single oral dose of HC-ER 20mg capsule (fed)
3066625|NCT02117128|Experimental|Tranexamic acid, IA group|Tranexamic acid 1g, intra-articular injection, post-operationally
3066626|NCT02117128|Active Comparator|Tranexamic acid, IV group|Tranexamic acid, 1g, intravenous injection, post-operationally
3066627|NCT02117128|Experimental|Tranexamic acid, IV+IA group|Tranexamic acid, 1g, intravenous injection, post-operationally; Tranexamic acid, 1g, intra-articular injection, post-operationally
3066628|NCT02117115|Experimental|CT scan with contrast|
3066629|NCT02117102|Experimental|bladder and lumbar stimulation|Apply bladder and lumbar stimulation
3066630|NCT02117102|No Intervention|Control group|Ordinary pediatric urine collection bag
3066631|NCT02117089|Experimental|Device-assisted rehabilitation|
3066632|NCT02117076|Active Comparator|gabapentin immediate release|Gabapentin IR is the immediate release form of the medication. Subjects randomized to gabapentin IR will be started out at a dose of 300mg per day, taken one hour before bedtime for the first week. Daily dose will be increased by 300 mg daily every 4 days until 1200 mg of gabapentin IR is reached or until a stable, tolerated dose of gabapentin IR that relieves symptoms has been maintained for 2 weeks (IRLS scores less than 15). Those patients who cannot tolerate gabapentin IR will be allowed to down titrate by one dose level (300 mg daily), before dropping out of the study.
3066633|NCT02117076|Active Comparator|gabapentin enacarbil extended release|Horizant is the extended release form of gabapentin enacarbil. Subjects randomized to Horizant will take 600mg at 5 pm. After four days of stable dosing of Horizant, subjects in this study group will be evaluated by phone for changes in RLS symptoms and Patient Global Impression scale to determine if a dose increase is warranted. Subjects in this group may be titrated up to 1200 mg daily during the 2 week titration period.
3066634|NCT02117063|Experimental|Go Girls! Fitness Support Group|
3066635|NCT02117050|Experimental|Rebif® via Rebidose® auto-injector|
3066636|NCT02117037|Other|study of PEC markers and chemokines/ chemokine recep|blood sample for dosage and study of PEC markers and chemokines/ chemokine receptors
3066637|NCT02117024|Experimental|Viagenpumatucel-L Plus Metronomic Cyclophosphamide|Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.
3066638|NCT02117024|Active Comparator|Chemotherapy Alone|Patients will be treated with a physician's choice regimen until progression.
3066639|NCT02117011|Other|Physical activity|An 8-week structured, moderate-intensity aerobic training exercise regimen concurrent with their radiation therapy (N=15),
3066640|NCT02117011|No Intervention|Control|Patients will continue with usual care, which includes radiation treatment.
3066641|NCT02116998|Experimental|GEN-004 with Aluminum Hydroxide|
3066642|NCT02116998|Placebo Comparator|Placebo|
3066643|NCT02116985|Experimental|Dual-Loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
3066644|NCT02116985|Placebo Comparator|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
3066645|NCT02116972|Experimental|FX006 16 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
3066646|NCT02116972|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
3066647|NCT02116972|Placebo Comparator|Placebo|Normal Saline Single 5 mL intra-articular (IA) injection
3066648|NCT02116959|Experimental|Cohort 1|"Patients will receive alternating treatments beginning with systemic chemotherapy then followed by IA (intra-arterial) therapy.~Bilateral retinoblastoma patients will be in Cohort 1.~For bilateral Bilateral retinoblastoma patients where one eye is stage A or B and the other eye is C, D, or E, only the higher stage eye (C, D, E) will be treated with IA chemotherapy unless the stage A or B eye is not amenable or has failed local therapy."
3066649|NCT02116959|Experimental|Cohort 2|Patients will receive only IA (intra-arterial) therapy for more limited disease.
3066650|NCT02116946|Experimental|Leukocyte-rich Platelet Rish Plasma + exercise|Leukocyte-rich PRP injection and a 12 week exercise program.
3066651|NCT02116946|Experimental|Leukocyte-poor Platelet Rich Plasma + exercise|Leukocyte-poor PRP injection and a 12 week exercise program.
3066652|NCT02116946|Placebo Comparator|Saline + exercise|Saline injection and a 12 week exercise program.
3066653|NCT02116933|Active Comparator|Level I|A small, level I study will compare autologous fat grafting alone to stromal vascular fraction SVF enriched autologous fat grafting int he same patient. One breast will be treated with AFG alone and act as the control, and the other breast will be treated with SVF enriched AFG adn act as the experimental side exploring the efficacy of adipose derived stem cells.
3066654|NCT02116933|Active Comparator|Level II|A larger, level II study comparing Autologous Fat Grafting to SVF enriched AFG in different patients. In this study, patients can choose to have AFG in both breasts or SVF enriched AFG in both breasts. The two patient groups will be compared. Here the group with the AFG in both breasts will be the control and the SVF enriched AFG in both breasts will be the experimental group exploring the efficacy of adipose derived stem cells.
3066655|NCT02116920||VIA Positive|Those patients having acetowhite lesion over cervix on visual inspection after application of acetic acid
3066656|NCT02116907|Experimental|Perampanel|14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
3066657|NCT02116894|Experimental|PF-03446962 plus regorafenib|
3066658|NCT02116881||Open colorectal surgery|Patients scheduled to undergo open colorectal surgery from Department of Colorectal Surgery at Cleveland Clinic
3066659|NCT02116881||Laparoscopic colorectal surgery|Patients scheduled to undergo laparoscopic colorectal surgery from Department of Colorectal Surgery at Cleveland Clinic
3066660|NCT02116868|Experimental|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex. The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed. Administration of antihypertensive drugs or vasopressors is also guided.
3066661|NCT02116868|No Intervention|Standard practice (ST)|Anesthesia and analgesia is left to the discretion of the anesthesiologist in charge. The anesthesiologist is blinded to the results of pupillometry.
3066662|NCT02116855|Experimental|tertiary prophylaxis prophy on Hemophilia A patiets|A multi centre 2 year long term tertiary prophylaxis study designed with a three step escalating dose protocol adjusted by individual joint bleeding patterns/frequencies to study the effect and cost saving of 3 low dose /cost prophylaxis regimens in boys with severe hemophilia A and arthropathy in China. Each patient will start treatment with a low dose regimen in step I and be assessed every 3 months according to the escalating criteria.
3066663|NCT02116842|Experimental|0.075% bupivacaine|Consenting patients randomised to receive 0.075% bupivacaine and 40 µg fentanyl.
3066664|NCT02116842|Experimental|0.1% bupivacaine|Consenting patients randomised to receive 0.1% bupivacaine and 40 µg fentanyl.
3066665|NCT02116829|Experimental|Danish butter, dairy|
3066666|NCT02116829|Active Comparator|Olive oil, refined|
3066667|NCT02116816|Experimental|Polyphenol|Polyphenol preparations
3066668|NCT02116803|Experimental|dovitinib|Participants were given single agent dovitinib starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications were given at the discretion of the investigator based on guidance provided in the protocol and investigative brochure (IB).
3066669|NCT02116803|Experimental|dovitinib + fulvestrant|Participants were given dovitinib and fulvestrant coadministration starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.
3066670|NCT02116790|Placebo Comparator|Control Group|10 participants will be given two pills: both will be placebos
3066671|NCT02116790|Active Comparator|Standard Treatment / Positive Control Group|10 participants will be given two pills: both will be Naproxen (each pill = 250mg, total dose = 500mg)
3066672|NCT02116790|Active Comparator|Experimental Group #1|10 participants will be given two pills: one will be Naproxen (250 mg) and the other will be of Sinemet (carbidopa/levodopa 12.5mg/50mg)
3066673|NCT02116790|Active Comparator|Experimental Group #2|10 participants will be given two pills: one will be Naproxen (250 mg) and the other will be of Sinemet (carbidopa/levodopa 25mg/100mg )
3066674|NCT02116777|Experimental|Treatment (talazoparib, temozolomide)|Patients receive talazoparib PO QD or BID on days 1-6 and temozolomide PO QD on days 2-6. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3066675|NCT02116738|Experimental|Flap Transposition Technique|Flap Transposition Technique
3066676|NCT02116725|Experimental|Shower gel with zinc|Zinc gel is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
3066677|NCT02116725|Placebo Comparator|Plain shower gel|Plain shower gel is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
3066678|NCT02116725|Sham Comparator|Distilled water|Distilled Water is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
3066679|NCT02116712|Experimental|Saracatinib|"Only one arm: Intervention is Saracatinib. We plan to study three escalating doses of oral saracatinib; 50, 125 and 175 mg. Saracatinib is given orally once a day.~More regarding dose escalation is included in intervention below."
3066680|NCT02116699|Experimental|oropharyngeal mother's milk|0.2 mL every 2 hours for 48 hours beginning within 96 hours post-birth, followed by 0.2 mL every 3 hours until 32 weeks post conceptional age
3066681|NCT02116699|Placebo Comparator|oropharyngeal sterile water|0.2 mL every 2 hours for 48 hours beginning within 96 hours post-birth, followed by 0.2 mL every 3 hours until 32 weeks post conceptional age
3066682|NCT02116686||Heart failure patients with sleep apnea syndrom|For heart failure patients, a standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the America Academy of Sleep Medicine (AASM) recommendations (RemLogic® software, Broomfield, USA).
3066683|NCT02116673|Other|Control|The control arm receives usual care discharge instructions.
3066684|NCT02116673|Experimental|Cognitive rest|The intervention is providing discharge instructions instructing cognitive rest and graduated return to usual activities in patients whom have experienced minor traumatic brain injury.
3066685|NCT02116660|Experimental|Raltegravir plus Nevirapine plus Lamivudine|Raltegravir 400 mg oral twice daily, plus nevirapine 200 mg oral once daily for 14 days followed by nevirapine 200 mg oral twice daily, plus lamivudine 150 mg oral twice daily for 96 weeks
3066686|NCT02116660|Active Comparator|Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine|Tenofovir/emtricitabine 300/200 mg oral once daily plus 1) lopinavir/ritonavir 400/100 mg oral twice daily or 800/200 mg oral once daily, or 2) atazanavir/ritonavir 300/100 mg oral once daily, or 3) darunavir/ritonavir 800/100 mg oral once daily or 600/100 mg oral twice daily
3066687|NCT02116647|Experimental|Psychoanalytic therapy|manualized psychoanalytic psychotherapy
3066688|NCT02116647|No Intervention|Control Group|Standard care
3066689|NCT02116634|Experimental|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
3066690|NCT02116621|Experimental|Trialist Intervention|Clinician and patient set up N-of-1 trial 4-12 weeks in length to compare two treatments for chronic pain. Patient uses Trialist smartphone app to monitor pain and associated side effects daily throughout length of N-of-1 trial. After trial ends, the patient reviews graphical displays of N-of-1 trial results with clinician.
3066691|NCT02116621|No Intervention|Control-Usual Care|Receive usual care from clinician for chronic pain, do not use Trialist smartphone app
3066692|NCT02116608|Active Comparator|Group 1: Betadine|Apply locally as needed.
3066693|NCT02116608|Active Comparator|Group 2: Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
3066694|NCT02116608|Active Comparator|Group 3: Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
3066695|NCT02116595|Experimental|feeding a high acid diet x 24 hrs|2 diets, one low and one high net acid loads
3066696|NCT02116595|Active Comparator|low acid diet|
3066697|NCT02116582|Experimental|Enzalutamide|Participants received 160 mg of enzalutamide orally once daily until they experienced an adverse event, disease progression, started new anti-cancer therapy, withdrew consent, or other protocol-specified criteria.
3066698|NCT02116569|Experimental|Daratumumab 8 milligram per kilogram (mg/kg)|Participants will be administered intravenously with daratumumab at a dose of 8 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation.
3066699|NCT02116569|Experimental|Daratumumab 16 mg/kg|Participants will be administered intravenously with daratumumab at a dose of 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation.
3066700|NCT02116556|Active Comparator|Prednisone|Prednisone PO 40mg/day for 30 days plus standard supportive care measurements
3066701|NCT02116556|Experimental|Prednisone plus Rifaximin|Prednisone PO 40mg/day for 30 days plus Rifaximin PO 1200 mg/day for 90 days plus standard supportive care measurements
3066702|NCT02116543|Experimental|TD-6450|TD-6450 capsules
3066703|NCT02116543|Placebo Comparator|Placebo|Placebo capsules
3066704|NCT02116530|Experimental|Olanzapine + Chemotherapy + Antiemetic treatment|"Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as the following anti-nausea/vomiting drugs:~Ondansetron (8 mg orally or intravenously) or granisetron (1 mg intravenously or 2 mg orally) or palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone (12 mg orally on the day of chemotherapy and 8 mg orally days 2, 3, 4 post chemotherapy), plus~Fosaprepitant (150 mg intravenously on the day of chemotherapy) or aprepitant (125 mg orally on the day of chemotherapy and 80 mg orally on days 2 and 3 post chemotherapy), plus~olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3, 4 post chemotherapy)"
3066705|NCT02116530|Active Comparator|Placebo + Chemotherapy + Antiemetic treatment|"Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as usual anti-nausea/vomiting drugs:~Ondansetron (8 mg orally or intravenously) or granisetron (1 mg intravenously or 2 mg orally) or palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone (12 mg orally on the day of chemotherapy and 8 mg orally days 2, 3, 4 post chemotherapy), plus~Fosaprepitant (150 mg intravenously on the day of chemotherapy) or aprepitant (125 mg orally on the day of chemotherapy and 80 mg orally on days 2 and 3 post chemotherapy), plus~placebo"
3066706|NCT02116517|Experimental|green tea extract first|green tea extract (EGCG) 500mg tid for 6 weeks, then wash-out for 2 weeks, and finally cellulose 500mg tid for 6 weeks total 14 weeks
3066707|NCT02116517|Placebo Comparator|Placebo first|cellulose 500mg tid for 6 weeks, then wash-out for 2 weeks, and finally EGCG 500mg tid for 6 weeks total 14 weeks
3066708|NCT02116504|Other|Global population|"All included patients :~Sampling of blood"
3066709|NCT02116491|No Intervention|Closed suction system|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Cloesd suction system was performed which the patient remained connected to the ventilator. The catheter was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
3066710|NCT02116491|Experimental|Visual Sputum Suctioning System|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Closed suction system was performed which the patient remained connected to the ventilator. The double-lumen catheter of the Visual Sputum Suctioning System integrated with a 0.9-mm micro-imaging fiber was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
3066711|NCT02116478|Experimental|gastrocnemius recession|gastrocnemius recession
3066712|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Test 1|single oral dose of levodopa carbidopa immediate release tablets
3066713|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Ref. 1|single oral dose of levodopa carbidopa immediate release tablets
3066714|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Test 2|single oral dose of levodopa carbidopa immediate release tablets
3066715|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Ref. 2|single oral dose of levodopa carbidopa immediate release tablets
3066716|NCT02116452|No Intervention|Breast Milk|Breast FED newborns
3066717|NCT02116452|Placebo Comparator|Standard Formula|Standard Formula FED newborns
3066718|NCT02116452|Active Comparator|Supplemented Formula|GOS/PDX Formula FED newborns
3066719|NCT02116439||Violent events|People in this group were observed to manifest violence.
3066720|NCT02116439||Victims|People in this group are the victims of the other group.
3066721|NCT02116426||The study population|"The study population includes all adult patients taken in charge by the emergency ambulance services of the participating centers for non-traumatic chest pain for suspected Acute Coronary Syndrome (ACS) without ST segment elevation.~Intervention: Blood work in the ambulance Intervention: Blood work upon arrival in the emergency room Intervention: Blood work at 3 hours post-arrival in the emergency room"
3066722|NCT02116413||The study population|"The study population consists of patients admitted to intensive care, sedated and under controlled ventilatory support with septic shock criteria defined by severe sepsis associated with hypotension despite fluid resuscitation of 20-40 ml / kg and requiring vascular filling according to the following criteria:~oliguria <0.5 ml / kg / h for at least 2h skin mottling Arterial Lactate > 2 mmol / l SvcO2 <70% or SvO2 <65% Patient on noradrenaline.~Severe sepsis is defined as a systemic inflammatory response associated with a suspected or proven infection and hypotension before filling, a lactate> 4 mmol / l or organ dysfunction.~Intervention: Fluid challenge Intervention: Cardiac ultrasound"
3066723|NCT02116400||Suicidal|"Patients in this group have had suicidal behaviour according to the C-SSRS score.~Intervention: Interview Intervention: Neuropsychological testing Intervention: Serum concentration of lithium or sodium divalproate."
3066724|NCT02116400||Not suicidal|"Patients in this group have not had suicidal behaviour according to the C-SSRS score.~Intervention: Interview Intervention: Neuropsychological testing Intervention: Serum concentration of lithium or sodium divalproate."
3066725|NCT02116387|Active Comparator|Routine Physical Therapy|"Patients randomized to this arm will follow a classic, routine, physical therapy program.~Intervention: Routine Physical Therapy"
3066726|NCT02116387|Experimental|I-Moove Physical Therapy|"Patients randomized to this arm will follow a physical therapy program using the I-Moove device.~Intervention: I-Moove Physical Therapy"
3066727|NCT02116374||HIV-1 patients|
3066728|NCT02116361|Placebo Comparator|Placebo for onabotulinumtoxinA 50 U|Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
3066729|NCT02116361|Experimental|onabotulinumtoxinA 50 U|OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
3066730|NCT02116361|Placebo Comparator|Placebo for onabotulinumtoxinA 30 U|Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
3066731|NCT02116361|Experimental|onabotulinumtoxinA 30 U|OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
3066732|NCT02116348|Experimental|Cerebrolysin|Nerve growth factor Cerebrolysin will be given to the intervention group
3066733|NCT02116348|No Intervention|Conventional|These children will receive conventional treatment for cerebral palsy
3066734|NCT02116335|Experimental|Bosentan|Sub-Chronic (3 days) Bosentan 250mg/day.
3066735|NCT02116335|Placebo Comparator|Placebo|Stress response and endothelial function will be determined following a three day treatment of placebo
3066736|NCT02116322|Experimental|Pancreatic mass|Patients with pancreatic mass presenting for EUS-FNA
3066737|NCT02116309|Active Comparator|Rectal Indomethacin only|Patients in this group will receive 20 ml of normal saline sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin.
3066738|NCT02116309|Active Comparator|Rectal Indomethacin plus papillary spray of Epinephrine|Patients in this group will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin.
3066739|NCT02116296|Other|LIfestyle counseling|
3066740|NCT02116270|Other|Control group|Patients in this group control (normal renal function) are followed in the urology department. A blood sample is performed on the day of inclusion.
3066741|NCT02116270|Experimental|Severe renal failure|Patients in this group suffer from renal failure stage 4 and are not under dialysis. A blood sample is performed on the day of inclusion.
3066742|NCT02116270|Experimental|Peritoneal dialysis|Patients with renal failure, under peritoneal dialysis for at least 3 months. A blood sample is performed on the day of inclusion.
3066743|NCT02116270|Experimental|Hemodialysis|Patient with renal failure, under hemodialysis for at least 3 months. A blood sample is performed on the day of inclusion.
3066744|NCT02116257|Experimental|Propacetamol|
3066745|NCT02116257|Placebo Comparator|PCA regimen|routine PCA drug
3066746|NCT02116244|Experimental|Civamide Nasal Spray|Civamide Nasal Spray 0.01% 20ug/dose (20ul), 10ul in each nostril, twice daily for 12 weeks
3066747|NCT02116231|Experimental|Concurrent chemoradiotherapy|Concurrent chemoradiotherapy: IMRT was given to the patients with regimen of 66Gy-76Gy to the gross target volume of nasopharynx,66-70Gy to the gross target volume of positive nodes, 60-62Gy the high risk clinical target volume, 50-56Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy.
3066748|NCT02116231|Active Comparator|IMRT alone|IMRT is given to the patients with regimen of 66Gy-76Gy to the gross target volume of nasopharynx,66-70Gy to the gross target volume of positive nodes, 60-62Gy the high risk clinical target volume, 50-56Gy to the low risk clinical target volume.
3066749|NCT02116218|Experimental|acupuncture|Experimental group would receive acupuncture at specific acupoints for 15 minutes.
3066750|NCT02116218|Sham Comparator|seed|Control group would receive another intervention that we would put Vaccaria seeds near the acupoints but without acupressure for the same period.
3066751|NCT02116205|Experimental|Vaccine + Placebo at 1.0 mg|1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 56 and 168. 1.0 mg placebo administration on Study Day 28.
3066752|NCT02116205|Experimental|Vaccine at 1.0 mg|1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 28, 56 and 168.
3066753|NCT02116205|Experimental|Vaccine + Placebo at 2.0 mg|2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 56 and 168. 2.0 mg placebo administration on Study Day 28.
3066754|NCT02116205|Experimental|Vaccine at 2.0 mg|2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 28, 56 and 168.
3066755|NCT02116192|Active Comparator|General Healthy Diet|Control: General Healthy Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat)
3066756|NCT02116192|Experimental|Low-fructose, reduced carbohydrate diet|"Intervention: Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)~● Aim for less than 25g fructose daily."
3066757|NCT02116179|Experimental|DVD Intervention|DVD Intervention presented at one 90 minute group session
3066758|NCT02116179|No Intervention|Wait list Control Group|Group will get no intervention until after 90 day follow up
3066759|NCT02116166||Young|Young (20-35 years old)
3066760|NCT02116166||Old|Older (70-99 years old)
3066823|NCT02115776|Experimental|Amoxicillin-Potassium Clavulanate|Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. before any dental manipulation and following endotracheal intubation
3066824|NCT02115776|Active Comparator|Chlorhexidine (CHX)|Receiving a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation
3066761|NCT02116140|Experimental|[C11]Acetate HED PET|"AMEND is a single centre substudy of the ADVENT-HF trial. This substudy is a clinical physiologic proposal designed to determine the effects of long-term (6 months) ASV on cardiac energetics and SN function in patients with chronic stable HF and sleep apnea extending our previous evaluation of short-term CPAP in patients with OSA and HF.~All subjects consenting to the ADVENT primary trial will be eligible to participate in the substudy.~Substudy consenting patients will have [11C]acetate and [11C]HED PET imaging; HR variability; plasma norepinephrine (NE) levels, urine normetanephrine levels within 2 weeks of the sleep study. Baseline measurements will be repeated after 6 months in all patients."
3066762|NCT02116127|Experimental|Active tDCS|The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
3066763|NCT02116127|Sham Comparator|Sham tDCS|The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
3066764|NCT02116114|Experimental|Aquatic exercises|"3 times a week~heating~aerobic training~slowdown"
3066765|NCT02116114|No Intervention|control group|The control group participated in the study only to usual care , conventional medical treatment orientation about the disease , methods of energy conservation and evaluation.
3066766|NCT02116101|Active Comparator|Bright Momchilovtsi yogurt|Bright Momchilovtsi yogurt Contains 1×106cfu/g prebiotics including Lactobacillus bulgaricus and Streptococcus thermophilus
3066767|NCT02116101|Placebo Comparator|Bright Dairy Beverage|Dairy beverage product without prebiotics
3066768|NCT02116088|Active Comparator|Receiving Teacher Coaching|Teachers who currently take part in teacher coaching
3066769|NCT02116088|No Intervention|Waiting for Teacher Coaching|Teachers who are currently waiting for taking part in teacher coaching
3066770|NCT02116075|Experimental|Epidural Steroid|80mg depo-medrol 9mL 1% lidocaine
3066771|NCT02116075|Active Comparator|Epidural Prolotherapy|10ml of 5% generic dextrose
3066772|NCT02116062|Other|Amniotic membrane transplantation|
3066773|NCT02116062|Other|Pterygium surgery|
3066774|NCT02116062|Other|Penetrating keratoplasty|
3066775|NCT02116049|Active Comparator|Attention Control Case Management|"Comprehensive Risk Counseling and Services (CRCS) will be used to guide the case management activities. CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs. CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients. This project's case management will mimic the experimental condition with a meeting schedule reflective of the experimental arm plus a booster session at 3 months."
3066776|NCT02116049|Experimental|Disclosure Intervention|The experimental condition is a 4-session + 3 month booster intervention. Session 1 includes an introduction to the project, goal setting, assessment of disclosure strategies or tactics utilized, and disclosure triggers. Session 2 focuses on the costs and benefits of disclosing to casual sexual partners and previous best and worst disclosure experiences. Session 3 begins with the delivery of the encouraging messages and review of the disclosure strategies already employed. Session 4 is a continuation of session 3 activities with an additional focus on expanding the participant's repertoire of strategies; discussion of methods of sexual negotiation, and rehearsal. The booster session includes a discussion of what strategies have been used in the preceding months, which strategies worked and how can these be enhanced, which strategies did not work with opportunities for troubleshooting, and an examination of rewards experienced or costs encountered.
3066777|NCT02116036|Experimental|Rivaroxaban|Rivaroxaban 20mg po daily
3066778|NCT02116023|Experimental|Orange flavored beverage - Test1|240ml processed whole orange low dose
3066779|NCT02116023|Experimental|Orange flavored beverage - Test2|240ml processed whole orange high dose
3066780|NCT02116023|Placebo Comparator|Orange flavored beverage - Placebo|240ml orange beverage
3066781|NCT02116010|Active Comparator|E. coli, Standard of care : Silver Sulfadiazine|Burn wounds infected by E. coli treated with Standard of care : Silver Sulfadiazine
3066782|NCT02116010|Experimental|E. coli, Phages cocktail|Burn wounds infected by E. coli treated with Pherecydes Pharma Phages cocktail
3066783|NCT02116010|Active Comparator|P. aeruginosa, Standard of care : Silver Sulfadiazine|Burn wounds infected with P. aeruginosa treated with Standard of care : Silver Sulfadiazine
3066784|NCT02116010|Experimental|P. aeruginosa, Phages cocktail|Burn wounds infected by P. aeruginosa treated treated with Pherecydes Pharma Phages cocktail
3066785|NCT02115997|Experimental|Rituximab|Participants will receive IV infusion of rituximab once weekly from Week 1 to 4. Participants will also receive one pulse of methylprednisolone, followed by a tapering dose of oral prednisolone at the discretion of the investigator. Methylprednisolone may be repeated up to total of 3 pulses at the discretion of the investigator.
3066786|NCT02115984|Experimental|Chemotherapy & Panagen|Panagen 5 mg tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the preparation immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
3066787|NCT02115984|Placebo Comparator|Chemotherapy & Placebo|Placebo tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the placebo tablets immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
3066825|NCT02115776|Experimental|Amoxicillin-Potassium Clavulanate-CHX|Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. and a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation
3066788|NCT02115971|Experimental|Jumping exercise|"Physical therapy with a focus on specific jumping exercise. The jumping exercise will be performed for 12 weeks (3x/week), with a break of day between workouts. The 40-minute workout is completed 2 times under supervision in the clinic's internal training group for outpatients. 1 time they train on their own at home, based on a defined training program. The training process is documented by the training protocol.~The incipient exercise intensity is taking personal performance into account. The exercise intensity is increased by a progressive scheme."
3066789|NCT02115971|Active Comparator|Strength exercise|"Physical Therapy with a focus on stability and strength exercise. Strength exercise arm has also same duration of 12 weeks with comparable intensity. The program is according to a predetermined program. The 60-minute training is completed twice under supervision in the clinic's internal training group for outpatients.There is no contact with participants of other group.~Between the two exercise sessions there is a training free day. The training process is documented by the training protocol. The incipient exercise intensity is considering personal performance. The intensity is increased after workout usual principles. The exercises are described with clear image and load parameters. The training exercises are regularly monitored."
3066790|NCT02115958|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3066791|NCT02115958|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3066792|NCT02115958|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3066793|NCT02115958|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3066794|NCT02115945|Experimental|epidural block|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life. The DN4 test was used to evaluate neuropathic pain.
3066795|NCT02115945|Active Comparator|femoral block|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life. The DN4 test was used to evaluate neuropathic pain.
3066796|NCT02115932|Experimental|Strength & Balance Training Intervention|Subjects in this arm will undergo once weekly home-based strength and balance training for a period of 8 weeks.
3066797|NCT02115932|No Intervention|Control|Subjects in this arm will not undertake any procedures or activities related to the study. They will continue with their prescribed medication and other medical advice from their treating physician as per usual.
3066798|NCT02115919|Experimental|Cohort A|Cohort A participants will undergo perilesional Multikine injections (200IU) once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.
3066799|NCT02115919|Experimental|Cohort B|Cohort B participants will undergo perilesional Multikine injections 400IU once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.
3066800|NCT02115906||Acromegalic patients|Acromegalic patients before and after initiation of individual therapy will be investigated by 1H/31P magnetic resonance spectroscopy, thyroid sonography and oral glucose tolerance testing
3066801|NCT02115906||Healthy control subjects|Age and Body mass index matched control subjects will be investigated by 1H/31P magnetic resonance spectroscopy and oral glucose tolerance testing
3066802|NCT02115893|Active Comparator|Sodium Nitrate|Dietary Supplement: Sodium nitrate 800 mg of nitrate in sodium nitrate added with water to get a 140 mL solution (BASF, Ludwigshafen, Germany)
3066803|NCT02115893|Placebo Comparator|Sodium Cloride|Dietary Supplement: Sodium chloride 800 mg of sodium chloride added with water to get a 140 mL solution (Frisia Zout BV, Harlingen, The Netherlands)
3066804|NCT02115880|Experimental|Prevention programme|
3066805|NCT02115880|No Intervention|Control (treatment as usual)|
3066806|NCT02115867|Active Comparator|Probiotic|"Probiotic arm Liquid broth~1 mL/kg every morning for 90 days"
3066807|NCT02115867|Placebo Comparator|Placebo|"Placebo arm Liquid broth~1 mL/kg each morning for 90 days"
3066808|NCT02115854||bacteriologically confirmed tuberculosis|
3066809|NCT02115841|Experimental|E1|Experiment 1 will measure the cortical excitability change after TENS intervention.
3066810|NCT02115841|Experimental|E2|Experiment 2 will measures implicit sequential motor task performance and cortical hemodynamic response using near infrared spectroscopy (NIRS) during motor execution. Cortical excitability will also be measured contemporary
3066811|NCT02115828|Experimental|Vismodegib|Vismodegib Treatment arm will receive Vismodegib by mouth 150 mg daily up to 1 year.
3066812|NCT02115815|Placebo Comparator|Placebo|Sterile saline for human use from commercial source, liquid
3066813|NCT02115815|Experimental|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
3066814|NCT02115815|Experimental|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
3066815|NCT02115815|Experimental|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
3066816|NCT02115815|Experimental|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
3066817|NCT02115815|Experimental|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
3066818|NCT02115815|Experimental|MEDI7510 (80 mcg RSV sF)|Participants will receive a single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
3066819|NCT02115802|Experimental|Activa PC+S|Specific features of LFP recorded from the deep brain nuclei will be examined for possible correlation with different natural behaviors, such as movement, walking, or speech.
3066820|NCT02115789||Survey Group|Adult male or female volunteers.
3066821|NCT02115776|No Intervention|Control|Receiving no prophylaxis
3066822|NCT02115776|Active Comparator|Amoxicillin|Receiving 2 g Amoxicillin intravenously before any dental manipulation and following endotracheal intubation
3066826|NCT02115763|Experimental|Caffeine|There is only one arm, it receives both caffeine and placebo.
3066827|NCT02115750|Active Comparator|Enbrel (etanercept)|Enbrel 50mg weekly times 24 weeks.
3066828|NCT02115750|Experimental|CHS-0214|CHS-0214 50mg weekly times 24 weeks.
3066829|NCT02115737|Experimental|Dialectical Behavior Therapy Skills Group|Twelve week skills based group therapy include four modules: mindfulness, emotion regulation, distress tolerance, and walking the middle path
3066830|NCT02115737|Experimental|Psychoeducation group treatment|The comparison group used in the present study is based on a publicly available treatment manual from the Services for Teens At Risk (STAR) Center at the University of Pittsburgh
3066831|NCT02115724|Experimental|Antioxidant Cocktail|Following an overnight fast, blood samples, flow-mediated dilation, and nitroglycerin mediated dilation (NMD; 0.4mg sub-lingual nitroglycerin spray) will be performed at baseline and 2 hours following either a single dose oral antioxidant cocktail (1000 mg Vitamin C, 600 IU vitamin E, 600 mg Alpha Lipoic Acid) or placebo on two days separated by at least 72 hours.
3066832|NCT02115724|Other|Biopsy|Following an overnight fast, a subcutaneous gluteal/hip fat biopsy sample will be obtained from each subject under local anesthesia, with adipose tissue (~2x1.5x1.5cm) to be harvested and placed immediately in physiological saline solution (PSS): Small arteries, 100 to 150 um in diameter, will be dissected from the fat under a dissecting microscope, transferred to an arteriographic bath chamber, and cannulated for pressurized myography.
3066833|NCT02115711|Experimental|Community health worker|Home visits by community health worker to deliver the multi-component behavioural intervention targeted at the individual's hypertension, diabetes or smoking.
3066834|NCT02115711|No Intervention|Usual care|Patients will receive usual care in the community
3066835|NCT02115698|Active Comparator|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
3066836|NCT02115698|Experimental|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
3066837|NCT02115698|Active Comparator|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
3066838|NCT02115698|Active Comparator|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
3066839|NCT02115698|Placebo Comparator|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
3066840|NCT02115685|No Intervention|One day testing|Aim 1 will be to measure bloodflow during exercise of the legs (below the injury). This aim will examine the control of bloodflow and muscle contractions and how it changes after spinal cord injury.
3066841|NCT02115685|Experimental|Effects of long term training|Aim 3 will then look at changes in bloodflow during exercise after training. Three different eight week exercise training programs will be tested including 1) treadmill training at high intensity as defined by 70-80% of HRR or 15-17 RPE 2) treadmill training at low intensity as defined by 30-40% of HRR or <13 RPE
3066842|NCT02115672|Experimental|BL-8040|Patients with chronic phase CML on Imatinib therapy (400 mg/day) achieving less than an optimal response will be treated with sc injections of BL-8040, while continuing Imatinib. The first part of the study will include escalating dose groups. Up to 4 dose levels will be investigated starting at dose level 1. Patients will be accrued in a conventional 3+3 design. Applying this study design, the first cohort of 3 patients will be treated at dose level 1 (0.5 mg/kg) on Day 1, 15, 29 and 43. Patients will continue taking Imatinib 400 mg/day throughout the study. Dose escalation will continue until the maximal tolerated dose (MTD) is established and protocol specific stopping rules for toxicity are met. If no MTD is reached, dose escalation will continue up to dose level 4 (1.25 mg/kg).
3066843|NCT02115659|Placebo Comparator|Placebo|Placebo plus standard treatment. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
3066844|NCT02115659|Experimental|Triptolide-Containing Formulation|Triptolide-Containing Formulation (1mg/kg/d) was prescribed; Dosage will be adjusted if necessary according to the adverse events monitoring.
3066845|NCT02115646|Experimental|fractionated carbon dioxide laser|fractionated carbon dioxide laser
3066846|NCT02115633|Experimental|Walkasins ON then OFF|Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a 1 hour rest period they will be retested with Walkasins turned off.
3066847|NCT02115633|Experimental|Walkasins OFF then ON|Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a 1 hour rest period they will be retested with Walkasins turned on.
3066848|NCT02115620|Experimental|Telemedicine|Patients will be followed using frequent communication of symptom status and physiologic data and remote consultations with Heart Failure specialists.
3066849|NCT02115607|Experimental|Definity infusion|Infusion of Definity (Perflutren Lipid Microspheres)
3066850|NCT02115594|Experimental|Fulvestrant + Entinostat|Arm A: Fulvestrant (500 mg on C1D1, C1D15, C2D1, and on Day 1 of each subsequent cycle) plus entinostat (5 mg PO once weekly)
3066851|NCT02115594|Active Comparator|Fulvestrant + Placebo|Arm B: Fulvestrant (500 mg on C1D1, C1D15, C2D1, and on Day 1 of each subsequent cycle) plus placebo (5 mg PO once weekly)
3066852|NCT02115581|Experimental|Coenzyme Q10|"Known cases of idiopathic dilated cardiomyopathy who received supplementation of coenzyme Q10 as a part of their medical regimen.~Dosage administered: 2 milligram/kilogram/day in 2 or 3 divided doses, these being increased to the maximum dose of 10 milligram/kilogram/day according to tolerance or the appearance of sideeffects."
3066853|NCT02115581|Placebo Comparator|Placebo|known cases of idiopathic dilated cardiomyopathy who received placebo
3066854|NCT02115568||Long-term safety follow-up|To be eligible, subjects must have actively participated in a Juventas (JVS-100) sponsored trial under IND 14203.
3066855|NCT02115555|Experimental|HIT-aided approach|Adolescents and their parents randomized to this arm will be oriented on a HIT system. The system transmits self monitoring blood glucose self monitoring blood glucose data to a secure web portal. The subject will receive messages from the HIT system on the meter based upon the Self Monitored Blood glucose tests.
3066856|NCT02115555|Experimental|Contracted conflict management system|Adolescent-parent pairs will meet with a health educator to establish a behavioral contract that will set patient-centered self-management goals for the adolescent.
3066899|NCT02115334|Experimental|professional-based group|professional therapists delivering the PHPA
3066857|NCT02115555|Experimental|HIT plus contracted conflict management|Adolescents and their parents randomized to this arm will be oriented on a HIT system. The system transmits self monitoring blood glucose data to a secure web portal. The subject will receive messages from the HIT system on the meter based upon the tests. In addition, adolescent-parent pairs will meet with a health educator to establish a behavioral contract that will set patient-centered self-management goals for the adolescent. This arm combines arms 1 and 2.
3066858|NCT02115542|Experimental|Regorafenib Monotherapy|Regorafenib is administered as monotherapy during the study. 160 mg once daily (QD) will be administered for 3 weeks on /1 week off. One cycle is 28 days.
3066859|NCT02115529|Active Comparator|Cesamet (nabilone)|0.5 mg capsule containing Cesamet (single dose) given preoperatively
3066860|NCT02115529|Placebo Comparator|Placebo|identical capsule containing placebo (single dose) given preoperatively
3066861|NCT02115516|Experimental|Stage A: Grp A1 - 3,200 PfSPZ Challenge|Group A1 (PfSPZ Challenge) (n=9) receives three injections of 3,200 PfSPZ Challenge intravenous (IV) at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 19, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
3066862|NCT02115516|Experimental|Stage A: Grp A2 - 12,800 PfSPZ Challenge|Group A2 (PfSPZ Challenge) (n=9) starts when Group A1 receives the second immunization. Group A2 receives three injections of 12,800 PfSPZ Challenge IV at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 23, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
3066863|NCT02115516|Experimental|Stage A: Grp A3 - 51,200 PfSPZ Challenge|Group A3 (PfSPZ Challenge) (n=9) starts when Group A2 receives the second immunization. Group A3 receives three injections of 51,200 PfSPZ Challenge IV at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. This group is scheduled to be unblinded with all other groups in Stage A Week on 27.
3066864|NCT02115516|Placebo Comparator|Stage A: Grp A1 - 0.9% Sodium Chloride|Group A1 (placebo) (n=5) receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 19, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
3066865|NCT02115516|Placebo Comparator|Stage A: Grp A2 - 0.9% Sodium Chloride|Group A2 (placebo) (n=5) starts when Group A1 receives the second immunization. Group A2 receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 23, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
3066866|NCT02115516|Placebo Comparator|Stage A: Grp A3 - 0.9% Sodium Chloride|Group A3 (placebo) (n=5) starts when Group A2 receives the second immunization. Group A3 receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. This group is scheduled to be unblinded with all other groups in Stage A on Week 27.
3066867|NCT02115516|Experimental|Stage B: Grp B1 - 51,200 PfSPZ Challenge|Group B1 (n=5) will receive the optimal PfSPZ Challenge immunizing dose from the dose-escalation phase (Stage A; 51,200 PfSPZ Challenge (NF54)), using the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), but for five instead of ten weeks. Group B1 will receive 3 injections of 51,200 PfSPZ Challenge (NF54) on days 0, 14 and 28. All volunteers in Group B1 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
3066868|NCT02115516|Placebo Comparator|Stage B: Group B1 - 0.9% Sodium Chloride|Group B1 (placebo) (n=2) will receive three injections of 0.9% Sodium Chloride on days 0, 14 and 28. This group will follow the the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), but for five instead of ten weeks. All volunteers in Group B1 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
3066895|NCT02115360|Active Comparator|fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
3066896|NCT02115347|Experimental|Ertugliflozin 15 mg - Moderate Hepatic Impairment|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
3066869|NCT02115516|Experimental|Stage B: Grp B2 - 51,200 PfSPZ Challenge|Group B2 (n=5) will receive 3 injections of 51,200 PfSPZ Challenge on days 0, 14 and 28, using same std chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), for 5 instead of 10 wks. But Group B2 will receive extended-release azithromycin (ER-AZ, 2g) on the day of 1st PfSPZ Challenge and monitored for parasitemia by quantitative real time polymerase reaction (qPCR). In case that all CQ+ER-AZ treated volunteers are parasite-free until Day 11 following first PfSPZ Challenge injection, it will indicate that ER-AZ effectively killed the parasites in the liver prior to development of parasitemia. With demonstration of the effectiveness of ER-AZ, the 2nd and 3rd immunizations will be done under ER-AZ alone, otherwise CQ prophylaxis will continue and ER-AZ will not be administered for the 2nd and 3rd injections. Group B2 will undergo homologous CHMI with PfSPZ Challenge, 10 weeks after the last immunization.
3066870|NCT02115516|Placebo Comparator|Stage B: Group B2 - 0.9% Sodium Chloride|Group B2 (placebo) (n=2) will receive three injections of 0.9% Sodium Chloride on days 0, 14 and 28, using the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), for 5 instead of 10 wks. But Group B2 will receive ER-AZ, 2g on the day of 1st placebo injection and monitored for parasitemia by qPCR. In case that all CQ+ER-AZ treated volunteers are parasite-free until Day 11 following 1st injection, it will indicate that ER-AZ effectively killed the parasites in the liver prior to the development of parasitemia. With demonstration of the effectiveness of ER-AZ, the 2nd and 3rd immunizations will be done under ER-AZ alone, otherwise CQ prophylaxis will be continued and ER-AZ will not be administered for 2nd and 3rd injections. Group B2 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after last immunization.
3066871|NCT02115516|Experimental|Stage B: Grp B3 - 51,200 PfSPZ Challenge|Group B3 (n=9) volunteers will receive CQ and PfSPZ Challenge simultaneously every five days with one additional dose of CQ five days after the third PfSPZ Challenge injection. A 10 mg/kg CQ base loading dose is given at the time of first PfSPZ Challenge inoculation, followed by 5 mg/kg CQ base on the day of second and third inoculation and five days after the last PfSPZ Challenge inoculation. Group B3 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
3066872|NCT02115516|Placebo Comparator|Stage B: Group B3 - 0.9% Sodium Chloride|Group B3 (placebo) (n=2) volunteers will receive CQ and 0.9% Sodium Chloride simultaneously every five days with one additional dose of CQ five days after the third placebo injection. A 10 mg/kg CQ base loading dose is given at the time of first placebo injection, followed by 5 mg/kg CQ base on the day of second and third injections and five days after the last placebo injection. Group B3 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
3066873|NCT02115503||Cohort 1|Cohort 1 will consist of those having primarily Class I antibody development post-transplant
3066874|NCT02115503||Cohort 2|Cohort 2 will include those having primarily Class II antibody development post-transplant
3066875|NCT02115503||Cohort 3|Cohort 3 will consist of the remaining subjects that have a mix of Class I and II antibodies.
3066876|NCT02115490||Osteoporosis_with_Bisphosphonates|This group of patients are taking Bisphosphonates orally in their treatment
3066877|NCT02115490||Osteoporosis-without-Bisphosphonates|This group of patients has not taken Bisphosphonates in the course of treatment
3066878|NCT02115477||Group with lymphadenectomy|The group of women with high risk endometrial cancer who undergoes pelvic and/or paraaortic lymphadenectomy at primary surgery
3066879|NCT02115477||Group without lymphadenectomy|The group of women with low risk endometrial cancer who do not have lymphadenectomy at primary surgery
3066880|NCT02115464|Experimental|Metformin plus Chemo-radiotherapy|Metformin orally 500 mg twice daily for the first week, 1500 mg a day in week 2 and 2000 mg a day at week 3 and then for a period of 12 months. Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
3066881|NCT02115464|Active Comparator|Chemo-radiotherapy|Concurrent cisplatin based chemotherapy with or without consolidation and radiotherapy of 60-63 Gy for 6 weeks.
3066882|NCT02115451||Surgical treatment|Patients who undergo rehabilitation and anterior cruciate ligament reconstruction, other surgical interventions may be performed
3066883|NCT02115451||Nonsurgical treatment|Patients who undergo rehabilitation without anterior cruciate ligament reconstruction, other surgical interventions may be performed
3066884|NCT02115438||Occupational Stress|
3066885|NCT02115425||Age 10-17|Participants age 5 - 17 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA)
3066886|NCT02115425||Age 18-80|Age 18-80 years Participants age 18-80 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA)
3066887|NCT02115412||medication non-adherence|
3066888|NCT02115399||ADStaph-|Atopic Dermatitis without a history of Eczema Herpeticum and without S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group.
3066889|NCT02115399||ADStaph+|Atopic Dermatitis without a history of Eczema Herpeticum and with S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group.
3066890|NCT02115399||NAStaph-|Non-atopic healthy participants without S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group
3066891|NCT02115399||NAStaph+|Non-atopic healthy participants with S. aureus skin colonization. As the NAStaph+ phenotype is expected to be rare, as many participants as possible will be enrolled in this group; however, we do not expect to enroll 45 participants in this group.
3066892|NCT02115386|Experimental|Nilotinib|
3066893|NCT02115373|Experimental|MSC2156119J|
3066894|NCT02115360|Active Comparator|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 100 iu of calcitonin will be injected epidurally in Bupivacain-Calcitonin-fentanyl (BC) Group,
3066897|NCT02115347|Other|Ertugliflozin 15 mg - Healthy Participants|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
3066898|NCT02115347|Experimental|Ertugliflozin 15 mg - Mild Hepatic Impairment|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
3066900|NCT02115334|Experimental|parents-based group|parents executing the PHPA
3066901|NCT02115334|Active Comparator|control group|health education only
3066902|NCT02115321|Experimental|Part A: CP-B GZR 50 mg + EBR 50 mg|CP-B participants take GZR 50 mg + EBR 50 mg once daily (q.d.) by mouth for 12 weeks.
3066903|NCT02115321|Experimental|Part A: NC GZR 100 mg + EBR 50 mg|NC participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
3066904|NCT02115321|Experimental|Part B: CP-B GZR 100 mg + EBR 50 mg|CP-B participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
3066905|NCT02115321|Experimental|Part C: CP-B GZR 50 mg or 100 mg + EBR 50 mg|CP-B participants take GZR 50 mg or GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks (GZR dose chosen based on results of Part A CP-B arm).
3066906|NCT02115308|Other|Regadenoson|Regadenoson is a single-use, pre-filled syringe containing 0.4 mg/5 mL of regadenoson.
3066907|NCT02115295|Experimental|Frontline, Untreated AML/MDS|"Induction Phase:~Cladribine 5 mg/m2/day by vein on Days 1 - 5. Age < 60 years: Cytarabine 2 grams/m2 by vein on Days 1 - 5. Age > or = 60 years: Cytarabine 1.5 grams/m2 by vein on Days 1 - 5. Idarubicin 10 mg/m2/day by vein on Days 1 - 3.~Consolidation Phase:~Cladribine 5 mg/m2/day by vein on Days 1 - 3. Age < 60 years: Cytarabine 1.5 grams/m2 by vein on Days 1 - 3. Age > or = 60 years: Cytarabine 1 grams/m2 by vein on Days 1 - 3. Idarubicin 8 mg/m2/day by vein on Days 1 - 2.~One cycle of therapy is considered 4 weeks. After last dose of study drug, participant called every 6 -12 months by a member of the study staff to ask about any side effects they may be having. The phone call should take about 5-10 minutes.~AML patients with known FLT3-ITD or FLT3 kinase domain mutations allowed to receive Midostaurin at the recommended dose of 50 mg orally twice daily on days 6-20 during induction, and then on days 6-20 during consolidation."
3066908|NCT02115295|Experimental|Relapsed or Refractory AML|"Relapsed or refractory AML requiring salvage chemotherapy.~Induction Phase:~Cladribine 5 mg/m2/day by vein on Days 1 - 5. Age < 60 years: Cytarabine 2 grams/m2 by vein on Days 1 - 5. Age > or = 60 years: Cytarabine 1.5 grams/m2 by vein on Days 1 - 5. Idarubicin 10 mg/m2/day by vein on Days 1 - 3.~Consolidation Phase:~Cladribine 5 mg/m2/day by vein on Days 1 - 3. Age < 60 years: Cytarabine 1.5 grams/m2 by vein on Days 1 - 3. Age > or = 60 years: Cytarabine 1 grams/m2 by vein on Days 1 - 3. Idarubicin 8 mg/m2/day by vein on Days 1 - 2.~One cycle of therapy is considered 4 weeks. After last dose of study drug, participant called every 6 -12 months by a member of the study staff to ask about any side effects they may be having.~AML patients with known FLT3-ITD or FLT3 kinase domain mutations allowed to receive Midostaurin at the recommended dose of 50 mg orally twice daily on days 6-20 during induction, and then on days 6-20 during consolidation."
3066909|NCT02115295|Experimental|Secondary AML|"Secondary AML who have received treatment for their antecedent myeloid disorder.~Induction Phase:~Cladribine 5 mg/m2/day by vein on Days 1 - 5. Age < 60 years: Cytarabine 2 grams/m2 by vein on Days 1 - 5. Age > or = 60 years: Cytarabine 1.5 grams/m2 by vein on Days 1 - 5. Idarubicin 10 mg/m2/day by vein on Days 1 - 3.~Consolidation Phase:~Cladribine 5 mg/m2/day by vein on Days 1 - 3. Age < 60 years: Cytarabine 1.5 grams/m2 by vein on Days 1 - 3. Age > or = 60 years: Cytarabine 1 grams/m2 by vein on Days 1 - 3. Idarubicin 8 mg/m2/day by vein on Days 1 - 2.~One cycle of therapy is considered 4 weeks. After last dose of study drug, participant called every 6 -12 months.~AML patients with known FLT3-ITD or FLT3 kinase domain mutations allowed to receive Midostaurin at the recommended dose of 50 mg orally twice daily on days 6-20 during induction, and then on days 6-20 during consolidation."
3066910|NCT02115282|Experimental|Arm A (exemestane, entinostat)|"Patients receive exemestane PO QD on days 1-28 and entinostat PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pre/perimenopausal female patients and all male patients also receive goserelin acetate SC on day 1."
3066911|NCT02115282|Placebo Comparator|Arm B (exemestane, placebo)|"Patients receive exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pre/perimenopausal female patients and all male patients also receive goserelin acetate SC on day 1."
3066912|NCT02115269||primary headaches|Adults taking IndoProCaf for acute treatment of their primary headache attacks (migraine and/or episodic tension-type headache) as per routine clinical practice
3066913|NCT02115256|Active Comparator|Intravenous Terbutaline|0.25 mL of Intravenous Terbutaline
3066914|NCT02115256|Active Comparator|Intravenous Nitroglycerine|IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
3066915|NCT02115243|Other|Ipi/ILI|Patients will receive ipilimumab followed by ILI.
3066916|NCT02115230|Experimental|Renal denervation + medical therapy|Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
3066917|NCT02115230|No Intervention|Medical therapy|Standard optimized medical therapy for diastolic heart failure
3066918|NCT02115217|Experimental|Leukotape K, basketball training|Use of Leukotape K to ensure stability of the ankle in basketball players
3066919|NCT02115204|Experimental|EC-Doc|4 cycles epirubicin + docetaxel (90/600) i.v., q = 3 weeks, followed by 4 cycles docetaxel (100) i.v., q = 3 weeks
3066920|NCT02115204|Active Comparator|CMF/CEF|6 cycles cyclophosphamide, methotrexate, 5-fluorouracil (CMF) (600/40/600) i.v., day 1 + 8, q = 4 weeks or 6 cycles cyclophosphamide, epirubicin, 5-fluorouracil (CEF) (500/100/500) i.v., day 1, q = 3 weeks
3066921|NCT02115191|Experimental|2-octylcyanoacrylate|Application of 2-octylcyanoacrylate
3066922|NCT02115191|Active Comparator|Surgical reintervention|Surgical reintervention for urethrocutaneous fistula repair
3066923|NCT02115178||Lithotomy or Prone position|
3066924|NCT02115165|Experimental|Cabazitaxel|
3066925|NCT02115152|Active Comparator|FEC|Patients will be randomized to received 4 cycles of fluorouracil, epirubicin and cyclophosphamide before surgery, and 4 cycles of docetaxel after surgery.
3066926|NCT02115152|Experimental|XEC|Patients will be randomized to received 4 cycles of capecitabine, epirubicin and cyclophosphamide before surgery, and 4 cycles of docetaxel and capecitabine after surgery.
3066927|NCT02115139|Experimental|Ipilimumab|Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1
3066928|NCT02115126|Active Comparator|LMP2A-loaded conventional DC vaccine|Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded DC vaccine
3066929|NCT02115126|Experimental|LMP2A-loaded DC vaccine + DUK-CPG-001|Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded DC vaccine co-administered with a Toll-like receptor 9 (TLR9) ligand, DUK-CPG-001
3066930|NCT02115113|Experimental|Group A (Tacrolimus Elimination Arm)|
3066931|NCT02115113|Active Comparator|Group B (Tacrolimus Minimization Arm)|
3066932|NCT02115100|Active Comparator|pulmonary vein+renal artery denervation|Procedure: pulmonary vein and renal artery denervation
3066933|NCT02115100|Active Comparator|Pulmonary vein isolation|Procedure: Pulmonary vein isolation
3066934|NCT02115087|Experimental|ultrasound guided rectus sheath block|Ultrasound guided rectus sheath block
3066935|NCT02115087|Active Comparator|iv morphine|0.1 mg.kg-1 loading dose of morphine by intravenous route in intraoperative period
3066936|NCT02115074|Experimental|Fluvastatine Celebrex|dose escalation for Fluvastatine
3066937|NCT02115061|Active Comparator|Cyanoacrylate|"This group owned fourteen patients who met all the inclusion criteria. These will be treated with cyanoacrylate.~Treatment: cyanoacrylate"
3066938|NCT02115061|Sham Comparator|Coil + cyanocrylate|"This group had fourteen patients who met all inclusion criteria. These will be treated with coil + cyanoacrylate.~Treatment: coil + cyanoacrylate"
3066939|NCT02115048|Active Comparator|Arm A|Continuous regimen of oral Letrozole 2.5 mg daily
3066940|NCT02115048|Experimental|Arm B|Continuous regimen of oral Letrozole 2.5 mg daily plus oral Afatinib 30 mg daily
3066941|NCT02115035|Experimental|Vermurafenib|Vermurafenib dosing will be given twice daily by oral administration in cycles of 28 days
3066942|NCT02115022||Potentially resectable pancreatic cancer|Patients with a confirmed pancreatic mass (suspected neoplastic) deemed resectable or borderline resectable on multislice (at least 16 simultaneously acquired slices) pancreatic protocol computed tomography (CT), fit and willing to undergo surgery with a curative (R0) intent.
3066943|NCT02114983||first episode of suspected DVT of the lower limbs|patients with first suspected episode of DVT of the lower limbs
3066944|NCT02114970|Other|Focus Group- paper and tablet consent|Participation in a focus group of other older adults, lasting 120 minutes. Participants will answer semi-structured questions in a group format, describing their impressions of both a prototype tablet-delivered and a paper consent.
3066945|NCT02114970|Active Comparator|Randomized- paper consent|Participants will review a mock paper consent form with a study clinician, and complete a series of questionnaires assessing their comprehension of material covered and general experience with the paper informed consent form.
3066946|NCT02114970|Active Comparator|Randomized- Tablet-delivered consent|Participants will review a mock tablet-delivered consent form with a study clinician, and complete a series of questionnaires assessing their comprehension of material covered and general experience with the tablet-delivered informed consent.
3066947|NCT02114957|Experimental|study herb|
3066948|NCT02114944||NIV|Patients with acute respiratory failure or dyspnea and DNI order treated with noninvasive ventilation
3066949|NCT02114944||CPAP|Patients with dyspnea or acute respiratory failure and DNI order treated with continuous positive airways pressure (CPAP)
3066950|NCT02114944||Standard oxygen|Patients with dyspnea and/or acute respiratory failure and DNI order, treated with standard oxygen therapy either via face mask or nasal cannula
3066951|NCT02114944||HFNC|Patients with dyspnea and/or acute respiratory failure and DNI order treated with high-flow nasal cannula (HFNC).
3066952|NCT02114931|Experimental|ABP 501|Participants received ABP 501 40 mg subcutaneously (SC) every other week for up to 18 months.
3066953|NCT02114918|Experimental|Attention Modification Program|Active computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief. AMP is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word.
3066954|NCT02114918|Placebo Comparator|Attention Control Condition|Control computer-based attention training task, which is not designed to modify biased attention patterns in anxious patients. ACC is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. In this case, the probe randomly replaces the neutral word or the threat word.
3066955|NCT02114905|Experimental|OTs Trained and Deliver CBIT|CBIT certified clinicians will train OTs in delivering CBIT to affected youth. OTs will be supervised in the practice of CBIT with youth in the New York City and Birmingham areas. Pre- and post-treatment assessment measures will be collected from 16 families (8 from each site) to evaluate intervention acceptability, feasibility, and fidelity. Patient and parent satisfaction of CBIT-OT will also be documented.
3066956|NCT02114892|Experimental|Resveratrol|Resveratrol capsules, 500 mg, three times per day before meals during 90 days
3066957|NCT02114892|Placebo Comparator|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals during 90 days
3066958|NCT02114879|Active Comparator|Standard of Care Rehabilitation|
3066959|NCT02114879|Experimental|Enhanced Medical Rehabilitation|
3066960|NCT02114840|Experimental|Pronator quadratus preservation|Pronator quadratus preservation
3066961|NCT02114840|Active Comparator|Pronator quadratus non repair|
3066962|NCT02114840|Active Comparator|Pronator quadratus repair after disruption|
3066963|NCT02114827|Experimental|Video|"Patients will view the 23-minute Guide to Stem Cell Transplantation video depicting the HSCT experience"
3066964|NCT02114827|Active Comparator|FAQ Sheet|Patients will receive HSCT FAQ sheet developed by the NCI at the NIH
3066965|NCT02114814|Experimental|Diabetes Self Management|Diabetes Self Management
3066966|NCT02114814|Active Comparator|General Health Education|General Health education
3066967|NCT02114801|Experimental|manual brushing|manual brushing; Oral-B®, Stages 4, Rio de Janeiro, Rio de Janeiro;
3066968|NCT02114801|Experimental|electric toothbrush linked|electric toothbrush linked; Braun - Oral-B®, D2010K, Rio de Janeiro, Rio de Janeiro
3066969|NCT02114801|Experimental|off electric toothbrush|off electric toothbrush; Braun - Oral-B®, D2010K, Rio de Janeiro, Rio de Janeiro
3066970|NCT02114788||group 1|No intervention
3066971|NCT02114788||Group 2|Intervention with interactive website
3067035|NCT02114359|Active Comparator|Fluoropyrimidine monochemotherapy|
3066972|NCT02114775|Active Comparator|Recombinant Growth Hormone|Double blind placebo/Genotropin cross over design for 6 months with cross over at 3 months. Then open label Genotropin from month 6 - 12.
3066973|NCT02114775|Active Comparator|Sildenafil|Double blinded placebo/Sildenafil crossover design for 6 months with crossover at month 3. Then open label Sildenafil from months 6-12.
3066974|NCT02114762|Experimental|Balloon dilation of the Eustachian tube|Insertion and inflation of balloon into Eustachian tube for up to 1 minute
3066975|NCT02114749|Experimental|volunteers in daily life activities|a set of wearable respiration and cardiac monitoring devices
3066976|NCT02114736|Experimental|Rectus femoris tenotomy|Surgical release of the proximal tendon of the rectus femoris
3066977|NCT02114736|Active Comparator|Botulinum toxin in the rectus femoris muscle|Botulinum toxin (200U Botox) injection in the rectus femoris muscle
3066978|NCT02114723|Active Comparator|Medical Taping Concept|"3 band of a special and hypoallergenic tape, called Cure Tape ® (2 strips of 12 x 5 cm and 1 strip of 20 cm x 5 cm) are attached to the abdominal and lower back. One piece of 12 cm in length is applied right from below the navel and reached to where the pubic hair below, and another piece of 12 cm in length is applied to make a cross shape with the first piece (inside 11-12 dermatomes area). The piece of 20cm in length is placed horizontally to the lower back.~The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears"
3066979|NCT02114723|Placebo Comparator|Cross tape|Two pieces of special and squared tape of 2.5 x 2 cm called Cross Tape ® are attached to the external side of the thigh at the hip joint area (outside 11-12 dermatomes area)
3066980|NCT02114710|Experimental|Hydrocortisone|little doses of hydrocortisone
3066981|NCT02114710|No Intervention|Placebo|Placebo
3066982|NCT02114697|Active Comparator|Lifestyle modification|Lifestyle modification is tailored to each participant and includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake.
3066983|NCT02114697|Experimental|Statin therapy|Participants will receive statin medication along with instruction about regular exercise.
3066984|NCT02114684|Active Comparator|Moxifloxacin|"A Moxifloxacin-containing oral regimen of Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Moxifloxacin (M), substituting Moxifloxacin for Ethambutol, daily for 24 weeks, see information below.~Intensive phase 7 days a week for 8 weeks Continuation phase - 7 days a week for 16 weeks~RH(150,75mg), Z (500mg), M (400mg) Dosage and number of tablets dispensed is dependent on participants weight band."
3066985|NCT02114684|Active Comparator|Ethambutol|"An Ethambutol oral regimen of Isoniazid (H), Rifampicin(R), Pyrazinamide (Z), Ethambutol(E), daily for 24 weeks duration, substituting Ethambutol for Moxifloxacin.~Intensive phase 7 days a week for 8 weeks Continuation phase - 7 days a week for 16 weeks.See details below.~(150,75,400,275 mg) RHZE Dosage and number of tablets dispensed is dependent on participants weight band."
3066986|NCT02114671|Experimental|Faldaprevir QD high dose|capsules, oral administration with 240 ml water, fed conditions
3066987|NCT02114671|Experimental|Faldaprevir QD low dose|tablets/capsules, oral administration with 240 ml water, fed conditions
3066988|NCT02114671|Placebo Comparator|Placebo|capsules, oral administration with 240 ml water, fed conditions
3066989|NCT02114671|Active Comparator|Ciprofloxacin|tablets, oral administration with 240 ml water, fed conditions
3066990|NCT02114658|Experimental|Arm 1|Sorafenib 400 mg bid continuous dose
3066991|NCT02114645|Active Comparator|LongGnRH agonist protocol(controlgroup)|Long GnRH agonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate
3066992|NCT02114645|Experimental|Long protocol-leuprolide acetate|Long GnRH agonist protocol Luteal Phase Support: Vaginal progesterone+oral estradiol valerate subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer
3066993|NCT02114645|Active Comparator|GnRHantagonist protocol(control group)|GnRH antagonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate
3066994|NCT02114645|Experimental|antagonist protocol-leuprolide acetate|GnRH antagonist protocol Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate + subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer
3066995|NCT02114632|Active Comparator|Polyunsaturated fatty acids|"6 capsules of food supplement Eye q per day divided in two daily doses (558 mg EPA, 174 mg DHA, 60 mg GLA per day)"
3066996|NCT02114632|Placebo Comparator|placebo|6 capsules of olive oil per day divided in two daily doses.
3066997|NCT02114619|Active Comparator|Low dose of I-131|Patients with Graves' disease who will be treated with I-131, using 100 microcurie per gram (uCi/gr) of thyroid weight
3066998|NCT02114619|Active Comparator|Intermediate dose|Patients with Graves' disease who will be treated with 150 microcurie (uCi) of I-131 per gram of thyroid weight.
3066999|NCT02114619|Active Comparator|High dose|Patients with Graves' disease who will be treated with I-131 using 200 uCi/gr of thyroid weight.
3067000|NCT02114606|Experimental|EoE Patients|Patients who have been diagnosed with EoE as per recent guidelines, and who have active eosinophilia and active symptoms. This will include patients who are newly diagnosed with EoE, patients who have stopped treatment but have had a flare, or patients who have not responded to EoE treatment. Samples will be taken once at a single time point using the Cytosponge™ Cell Collection Device (Cytosponge). To determine the utility of Cytosponge for monitoring treatment response in patients with EoE, the investigators will enroll patients with EoE who are undergoing either topical steroid or dietary treatment. Patients will be followed and tissue will be assessed over time with both Cytosponge and endoscopy; samples will be taken at up to 6 time points.
3067001|NCT02114593|Experimental|Parent support program|Parent support program
3067002|NCT02114593|No Intervention|Standard activities|Standard activities
3067003|NCT02114580|Experimental|Aerobic exercise|
3067004|NCT02114580|Active Comparator|stretching exercise|
3067005|NCT02114567|Experimental|PSV ventilation|AECOPD Patients who were ventilated wiht PSV, PEEP was titrated and set at 0, 40%, 80% and 120% PEEPi. Pressure support was set to get the tidal volume of 6ml/kg.
3067006|NCT02114567|Experimental|NAVA ventilation|AECOPD patients who were ventilated with NAVA, PEEP was titrated and set at 0, 40%, 80% and 120% PEEPi. NAVA level was set to get the tidal volume of 6ml/kg.
3067036|NCT02114346|Experimental|Atorvastatin|Patients in the atorvastatin group receive 80 mg atorvastatin (2 x atorvastatin 40 mg tablets) once daily from 24 hours before to 48 hours after administration of contrast material.
3067007|NCT02114528|Active Comparator|Anti-arrhythmic drug therapy|Oral and/or intravenous loading doses of Sotalol, mexiletine, procainamide or amiodarone as first line therapy. Drug chosen is preference of the treating physician. May use single or combination of AAD. Loading doses as per standard dosing guidelines for VT. Subjects on amiodarone should receive oral maintenance dose of at least 200 mg/day.
3067008|NCT02114528|Active Comparator|Catheter ablation|Ventricular tachycardia (VT) Catheter ablation, using a standardized VT ablation procedure protocol.
3067009|NCT02114515|Other|Usual Care|Hospital usual care
3067010|NCT02114515|Experimental|Usual Care + PArTNER|Patient Navigator, peer-led telephone support line, usual care
3067011|NCT02114502|Experimental|Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT|Busulfan test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5. Palifermin 60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2. SAHA 1,000 mg by mouth on Days -8 to -3. Gemcitabine loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3. Carfilzomib 27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1. SAHA 1,000 mg by mouth on Days -7 to -3. Melphalan 60 mg/m2 by vein on Days -3 and -2. Stem cell transplant on Day 0. Dexamethasone 8 mg by vein twice a day from Day -9 PM to Day -2 PM. Caphosol oral rinses 30 mL four times a day from Day -9 until discharge. Oral glutamine 15 g four times a day, swished, gargled and spit on Day -9 until discharge. Pyridoxine 100 mg by vein or mouth three times a day from Day -1.
3067012|NCT02114489|Experimental|Ibandronate|Unique perfusion of ibandronate 3 mg IV
3067013|NCT02114489|Placebo Comparator|Placebo|Unique perfusion of NaCl 3mg IV
3067014|NCT02114476|Placebo Comparator|nonhormonal contraception|nonhormonal intrauterine device tubal sterilization
3067015|NCT02114476|Experimental|progestin implant|Jadelle
3067016|NCT02114463|Experimental|Local analgesic|This group uses local analgesia infusion pump of 0.2% ropivacaine 360ml through periarticular infiltration for postoperative analgesia.
3067017|NCT02114463|Active Comparator|Intravenous analgesic|This group is treated with intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg.
3067018|NCT02114450|Experimental|Robot-assisted Rehabilitation|Participants will receive Robot-assisted training with the H2 lower limb powered exoskeleton. They will perform walking and other lower limb exercises (as applicable) while wearing the H2 lower limb powered exoskeleton. Training will involve 3 sessions per week for 4 weeks, each lasting about 1.5 hours.
3067019|NCT02114450|Active Comparator|Supervised motor practice|Participants in this group will perform walking and other lower limb exercises (as applicable) under the supervision of a research physical therapist. Training will be for 3 sessions per week for 4 weeks, each session lasting about 1.5 hours.
3067020|NCT02114437|Experimental|Closed-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
3067021|NCT02114437|Placebo Comparator|Opened-loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits to maintain NI at approximately 36 within a range of 26 to 46 to the extent possible.
3067022|NCT02114424|Active Comparator|Positional vibrator belt|Positional belt to avoid supine sleep.
3067023|NCT02114424|No Intervention|No Night balance|the first 2 months without Night Balance
3067024|NCT02114411||Dyspeptic patients|Patients (45 years and older, both genders) with dyspepsia referred for the GastroPanel test and gastroscopy with multiple bisopies at Homerton University Hospital (London, United Kingdom).
3067025|NCT02114398|Experimental|usual treatment|usual treatment
3067026|NCT02114398|Experimental|usual treatment + sophrology|usual treatment + sophrology
3067027|NCT02114385|Experimental|V503 (9vHPV)|0.5 mL intramuscular injection at Day 1, Month 2 and Month 6
3067028|NCT02114385|Active Comparator|GARDASIL|0.5 mL intramuscular injection at Day 1, Month 2 and Month 6
3067029|NCT02114372||CogState Brief Battery|Enrolled participants will be randomized in a balanced manner to CogState brief battery in both the Main Study and the SubStudy. CogState consists of four tasks that respectively measure the functions of attention, processing speed, visual learning, and working memory. The CogState Brief Battery is an approximately 15 minute computerized battery with demonstrated reliability, validity, and short term stability, that was developed expressly for maximal sensitivity to detect change. CogState can be administered via the internet or on a stand-alone computer and is available in over 50 languages.
3067030|NCT02114372||Clinical Drug Research Assessment System (CDR-AS)|Enrolled participants will be randomized in a balanced manner to CDR-AS in both the Main Study and the SubStudy. CDR-AS is fully automated system that targets the core aspects of cognitive function crucial for everyday behavior which are vulnerable to numerous insults including aging, fatigue, disease, pathology, trauma, diet, and pharmaceuticals. CDR-AS is an approximately 20-minute computerized battery designed to reliably measure changes in cognitive function in clinical trial situations.
3067031|NCT02114372||Delis Kaplan Executive Function System (DKEFS)|Enrolled participants will be randomized in a balanced manner to DKEFS in the Main Study and at one site of the SubStudy. The DKEFS is a paper and pencil measure of verbal and nonverbal executive functions and has been normed and validated for children and adults from 8-89 years of age. The measure consists of nine subtests. For the purposes of this study, the Trail Making Test (TMT) and Verbal Fluency subtests will be used.
3067032|NCT02114372||COGNITO|Enrolled participants will be randomized in a balanced manner to COGNITO at the other site of the SubStudy. COGNITO is an approximately 45 to 60 minute computerized neuropsychometric examination based on well-known cognitive tests designed for both cognition research and clinical assessment. COGNITO assesses reaction time, primary and working memory, visuospatial and verbal secondary memory, implicit learning, language skills, functional and semantic categorization of visual data, focused and divided attention, and crystallized intelligence. Responses are made via a tactile screen which permits the recording of response latency (deducting reaction time provides an estimation of information processing time).
3067033|NCT02114372||Retinal Imaging (Ancillary Study)|Participants enrolled in the Ancillary Study will be tested using a retinal imaging system, a scanning ophthalmoscope which uses infrared and blue light to obtain confocal images of the retina to quantify retinal amyloid beta plaques.
3067034|NCT02114359|Experimental|Platinum/fluoropyrimidine combination chemotherapy|
3067037|NCT02114346|Placebo Comparator|Placebo|Patients in the placebo group receive 2 placebo tablets once daily from 24 hours before to 48 hours after administration of contrast material.
3067038|NCT02114333|Active Comparator|A - Live zoster vaccine|"No previous zoster vaccine; stratified between age groups 50-59 and 70-85~First dose live vaccine, Zostavax (0.65ml, subcutaneous)~Second dose placebo, normal saline (0.65ml. subcutaneous)"
3067039|NCT02114333|Active Comparator|B - recombinant zoster vaccine|"No previous zoster vaccine; stratified between age groups 50-59 and 70-85~First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)~Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)"
3067040|NCT02114333|Active Comparator|C - Live zoster vaccine|"One previous dose of zoster vaccine at least 5 years previously, age 70-85~First dose live vaccine, Zostavax (0.65ml, subcutaneous)~Second dose placebo, normal saline (0.65ml. subcutaneous)"
3067041|NCT02114333|Active Comparator|D - recombinant zoster vaccine|"One previous dose of zoster vaccine at least 5 years previously, age 70-85~First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)~Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)"
3067042|NCT02114320|Experimental|EUS-BD-1|EUS-BD-1 inserts a partially covered self-expanding metallic (hybrid) stent with a dedicated introducer for EUS-BD
3067043|NCT02114320|Experimental|EUS-BD-2|EUS-BD-2 inserts a fully covered self-expanding metallic stent
3067044|NCT02114307|Active Comparator|REVITIVE IX: actual device|Trial participants will receive the true Revitive IX device
3067045|NCT02114307|Sham Comparator|REVITIVE IX: sham device|Trial participants will receive a sham device
3067046|NCT02114294|Experimental|Isolated hip strengthening|Isolated hip strengthening (abduction, external rotation, extension)
3067047|NCT02114294|Active Comparator|Quadriceps based training|Quadriceps based training (mini-squat, straight leg raising, terminal extensions)
3067048|NCT02114294|Other|Active control|Patients receive standardised information concerning patellofemoral pain syndrome, but receive no prescribed exercise regime. They are encouraged to remain active.
3067049|NCT02114281|Experimental|Care|Patient with dental care
3067050|NCT02114281|Active Comparator|Not care|Patient with not dental care
3067051|NCT02114268|Experimental|MEDI8897 300 milligram (mg) Intravenous (IV)|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
3067052|NCT02114268|Experimental|MEDI8897 1000 mg IV|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
3067053|NCT02114268|Experimental|MEDI8897 3000 mg IV|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
3067054|NCT02114268|Experimental|MEDI8897 100 mg Intramuscular (IM)|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
3067055|NCT02114268|Experimental|MEDI8897 300 mg IM|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
3067056|NCT02114268|Placebo Comparator|Placebo|Participants received placebo on Day 1.
3067057|NCT02114255|Experimental|BCG vaccination|BCG vaccination
3067058|NCT02114255|Placebo Comparator|NaCl 0.9%|administration of NaCl 0.9%.
3067059|NCT02114242||Parkinson's disease patients|Patients suffering from Parkinson desease
3067060|NCT02114242||multiple system atrophy patients|"Patients suffering from probable multiple system atrophy according to clinical consensus criteria and age > 30"
3067061|NCT02114242||progressive supranuclear palsy|Patients suffering from progressive supranuclear palsy and age > 40
3067062|NCT02114229|Experimental|(A) Alisertib alone|"Stratum A: Patients with recurrent/progressive AT/RT or extra-CNS malignant rhabdoid tumors (MRT).~Interventions: alisertib, 35 cycles of 3 weeks each (up to 105 weeks). Surgical resection, if indicated."
3067063|NCT02114229|Experimental|(B) Alisertib, chemotherapy, radiation therapy|"Stratum B: Children < 36 months old with newly diagnosed AT/RT. AT/RT those with synchronous extraneural AT/RT (Stratum D1) may also be treated on this arm.~Interventions:~B1 or D1: Induction chemotherapy using methotrexate, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by focal radiation therapy; followed by induction therapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib. Those <12 months who are not ready for focal radiation therapy will receive consolidation chemotherapy using alisertib, cyclophosphamide, carboplatin and etoposide while RT is delayed. Surgical resection, if indicated.~B2, B3, D2 or D3: Induction chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by consolidation with topotecan and cyclophosphamide or optional craniospinal irradiation; followed by maintenance alisertib. Surgical resection, if indicated."
3067064|NCT02114229|Experimental|(C) Alisertib, chemotherapy, radiation therapy|"Stratum C: Children ≥36 months old with newly diagnosed AT/RT.~Participants with synchronous extraneural AT/RT (Stratum D4) will also be treated as those assigned to Stratum C.~Interventions: Craniospinal radiation therapy; followed by consolidation chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib, surgical resection, if indicated."
3067065|NCT02114216|Sham Comparator|control group|Subjects who do not show mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and do not complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
3067066|NCT02114216|Active Comparator|ERD group|Subjects who have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and/or complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
3067067|NCT02114216|Active Comparator|NERD group|Subjects who do not have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
3067068|NCT02114203|Experimental|cohort 1 PF-04447943|
3067069|NCT02114203|Experimental|cohort 2 PF-04447943|
3067070|NCT02114203|Placebo Comparator|placebo comparator|
3067071|NCT02114203|Experimental|optional cohort of PF-04447943|
3067072|NCT02114190|Experimental|Adolescent Mindful Eating Group|Adolescents will participate in a 8 week mindful eating programs tailored for adolescents.
3067104|NCT02114021|Placebo Comparator|distilled water|betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
3067176|NCT02113501||HGT1b|HGT1b bladder cancer patients will undergo a 2nd TUR after BCG induction. If negative, continue with maintenance BCG followed by conventional follow-up (cystoscopy and cytology every 6months).
3067073|NCT02114190|Experimental|Parent Intergrated Group|This intervention incorporates a family systems perspective into mindful eating interventions for adolescents. This intervention will consist of 11 sessions in an 8 week period, with sessions 2,7, and 11 incorporating family sessions. The purpose of the family sessions are to increase overall family motivation for behavior change, involve family members in identifying specific targets of change and establishing agreed upon strategies.
3067074|NCT02114177|Experimental|Arm 1 (Simeprevir/Sofosbuvir)|150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
3067075|NCT02114177|Experimental|Arm 2 (Simeprevir/Sofosbuvir)|150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks.
3067076|NCT02114164|Active Comparator|AirSeal System|This group receives the AirSeal System for intraoperative insufflation.
3067077|NCT02114164|Active Comparator|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
3067078|NCT02114151|Experimental|Arm 1 (Simeprevir/Sofosbuvir)|100 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
3067079|NCT02114138||Surgical Group|Adults undergoing major in hospital surgery; pathogenesis of perioperative acute kidney injury; urine collection
3067080|NCT02114138||Healthy Control|Healthy Adult volunteers who are willing to provide a 200 ml urine sample.
3067081|NCT02114125|No Intervention|Usual Care Group:|Usual care consists of standard institutionalized services provided by physicians, nurses, and support staff (e.g., nurse assistants, social workers) in long-term care facilities.
3067082|NCT02114125|Experimental|High-intensity physical activity (5PA)|The intervention conducts the group-based physical activity, 5 days per- week for 8 weeks.
3067083|NCT02114125|Experimental|Low-intensity PA and CT(3PA+2CT)|The intervention conducts 3 days per-week physical activity and 2 days per-week cognitive training for 8 weeks.
3067084|NCT02114125|Experimental|High-intensity PA and CT (5PA+5CT)|The intervention conducts the individual-based, multi-domains cognitive training, 5days per- week and group-based physical activity, 5 days per- week and for 8 weeks.
3067085|NCT02114125|Experimental|Low-intensity cognitive training (2CT)|The intervention conducts the individual-based, multi-domains cognitive training, 2 days per- week for 8 weeks.
3067086|NCT02114125|Experimental|High-intensity cognitive training (5CT)|The intervention conducts the individual-based, multi-domains cognitive training, 5 days per- week for 8 weeks.
3067087|NCT02114112|Experimental|Group A-NCPAP Cycling group|Infants in Group A were cycled between NCPAP and nasal prongs. For the first 12 hours, infants received 10 hours of NCPAP and 2 hours of 1 litre per minute of nasal prongs (NP). For the next 12 hours, infants received 8 hours of NCPAP and 4 hours of NP. In the subsequent 24 hours, infants alternated between 6 hours of NCPAP and 6 hours of NP. In the last 24 hours of intervention they alternated between 4 hours of NCPAP and 8 hours of NP.
3067088|NCT02114112|Active Comparator|Group B-Continuous NCPAP|Infants randomized to group B received continuous NCPAP at a CPAP distending pressure of 4 cm of water for 72 hours. Both the groups after 72 hours of intervention were weaned to 1litre per minute NP. During the intervention period all infants were scored using the ACoRN respiratory score on a 12 hourly basis.
3067089|NCT02114099|Experimental|Atorvastatin|prescribe Atorvastatin to see its effect
3067090|NCT02114086||breast cancer|observation of intraoperative radiotherapy
3067091|NCT02114073|Experimental|Cyclosporine|In the first postoperative day following a standard, fornix-based trabeculectomy, ophthalmic emulsion of Cyclosporine A, 2%, every 4 hours for the first postoperative week and every 6 hours for the next 3 weeks will be prescribed for the patients.
3067092|NCT02114073|Active Comparator|Betamethasone|In the first postoperative day following a standard, fornix-based trabeculectomy, betamethasone eye drop, every 4 hours for the first postoperative week and every 6 hours for the next 3 weeks will be prescribed for the patients.
3067093|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M 25μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
3067094|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 50μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
3067095|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 75μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
3067096|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 25μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
3067097|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 50μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
3067098|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 75μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
3067099|NCT02114060|Placebo Comparator|Placebo|0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection.
3067100|NCT02114034||Non-severe asthma|"Children Controlled without treatment or with low doses of inhaled corticosteroids (<500 mg / day beclometasone equivalent) asthma~and Children with normal EFR~and Children who did not have more severe exacerbation (assessed taking oral corticosteroids) in the previous year~and Children not admitted in the previous year for asthma"
3067101|NCT02114034||Severe asthma|"Asthmatic child who, despite treatment with a combination of inhaled corticosteroids (at least 800 mcg / day equivalent Beclomethasone) bronchodilators and long-acting or properly taken daily leukotriene (inhaler technique and compliance verified) presents one of the 3 criteria following:~Persistence of symptoms or chronic use of bronchodilators short duration of action at least three times a week for at least 3 months~exacerbations in the previous year:~at least one care unit admission or continued resuscitation~at least two hospitalizations for acute severe asthma requiring IV therapy~at least 2 courses of oral corticosteroids for exacerbations~post BD FEV <80% or UARS post BD> 150% predicted"
3067102|NCT02114021|Experimental|betamethasone gel|betamethasone gel (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
3067103|NCT02114021|Experimental|lidocaine jelly|lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
3067105|NCT02114008|Active Comparator|Abbreviated fasting|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin).
3067106|NCT02114008|Active Comparator|Traditional fasting|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test).
3067107|NCT02113995|Active Comparator|ACERTO|"Patients received 400 ml of a beverage containing water and 50 g of maltodextrin 6 hours before the operation. They received orally extra 200 ml of this beverage containing water and 25 g of maltodextrin 3 hours before the operation. Regarding the intravenous fluids, they received 1 to 1.5 liter of crystalloid fluids (ringer lactate) in the intraoperative. In the immediate postoperative they were programmed to receive 2 liters of crystalloid fluids (ringer lactate) and 1 to 2 liters in the first day of the postoperative period. The venous hydration was suspended as soon as they started to drink liquids.~Prophylaxis of nausea and vomiting with dexamethasone 8 mg at the beginning of the anesthesia and ondansetron 4-8 mg after the surgery. In the postoperative period we utilized analgesics such as dipyrone and ketorolac and, if necessary, low doses of morphine and antiemetics like ondansetron."
3067108|NCT02113995|Active Comparator|Traditional care|"The analgesia in the postoperative period of the group control was performed with dipyrone, tramadol hydrochloride, and morphine. The prophylaxis of nausea and vomiting with dexamethasone 8 mg in the beginning of the anesthesia and the metoclopramide at the end of the surgery. During the anesthetic induction antibiotic prophylaxis (cefazolin 3 grams/day for 2 days) was administrated.~The control group were submitted to the protocol of traditional fasting with at least 8 hours. Patients in this group received 1 to 2 liters of crystalloid fluid (ringer lactate) in the intraoperative, and they received 3 to 4 liters of crystalloid fluids (ringer lactate, saline 0.9% and/or dextrose 5%). In the immediate postoperative, 2 to 3 liters in the first day of postoperative and, finally, 1 to 2 liters in the second day of the postoperative."
3067109|NCT02113982|Experimental|Relapse/Refractory Acute Myeloid Leukemia|Intervention: SL-401
3067110|NCT02113982|Experimental|Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Intervention: SL-401
3067111|NCT02113969|Experimental|Vaginal Pessary|Pessary users for at least 12 months
3067112|NCT02113956|Experimental|Guy2Guy (G2G)|G2G is a 6-week HIV prevention program delivered daily via text messaging to 14-18 year old males who self-identify as gay, bisexual, and/or queer. In addition to program content, participants are paired with another participant (i.e., a Text Buddy) with whom they can text throughout the program to provide support; and an on-demand advice line, G2Genie, which shares information about condoms, sex, relationships, and the lesbian, gay, bisexual, transgender (LGBT) community.
3067113|NCT02113956|No Intervention|Healthy Lifestyle Control|The attention-matched control arm message content consists of information publicly available online related to living a healthy lifestyle. Content discussed includes: STD information, nutrition and sleep hygiene, self-esteem and body image, bullying, and drugs and alcohol. The control arm is 6-weeks in length (Week 6 is a review booster) and is delivered via text messaging. Messages are didactic and not tailored to user sexual experience. Additionally, the Text Buddy and G2Genie intervention program components are not available.
3067114|NCT02113930||Idiopathic CD4 lymphocytopenia|Constitution of a biobank of frozen cells, plasma and serum samples
3067115|NCT02113930||Genetic Study|High rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC)
3067116|NCT02113917||hemophagocytic syndrome|patient with hemophagocytic syndrome
3067117|NCT02113904|Experimental|Adalimumab|
3067118|NCT02113891|Experimental|Eculizumab|Eculizumab will be given in addition to standard immunosuppression regimen (tacrolimus, mycophenalte mofeti, prednisone)
3067119|NCT02113878|Experimental|BKM120|"Participants will be enrolled in cohorts of 3- 6 per dose level. Once the MTD is reached, an additional 10 patients will be treated at that dose level and an amendment will be submitted to declare the dose.~BKM120 will start 2 weeks prior to first dose of cisplatin and radiation start. During the study, BKM120 will be administered orally daily for 45 days. Starting dose 40 mg.~Cisplatin: Starting Dose 30 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).~Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks."
3067120|NCT02113865||Grupo 0|Null or mild fibrosis
3067121|NCT02113865||Grupo 1|Cirrhosis
3067122|NCT02113865||Grupo 2|HCC diagnosis
3067123|NCT02113839|Active Comparator|No frequent exacerbators|"Patients without exacerbations: 0 or 1 that did not required hospitalization in the previous year.~Interventions:~Spirometry~Emogas analysis~Modified Borg Dyspnea Scale~CO Exhaled breath~P01~FeNO"
3067124|NCT02113839|Active Comparator|Frequent exacerbators|"Patients with frequent exacerbations: ≥2 or ≥1 if it required hospitalization in the previous year.~Interventions:~Spirometry~Emogas analysis~Modified Borg Dyspnea Scale~CO Exhaled breath~P01~FeNO"
3067125|NCT02113826|Experimental|Pazopanib|Pazopanib 800mg po qd until disease progression
3067126|NCT02113813|Experimental|ASP8273 Dose Escalation cohort (part 1)|oral
3067127|NCT02113813|Experimental|ASP8273 Response Expansion cohort (part 1)|oral
3067128|NCT02113813|Experimental|ASP8273 and Midazolam RP2D Expansion cohort (part 2)|oral
3067129|NCT02113813|Experimental|Food Effect Fasted cohort (part 2)|oral
3067130|NCT02113813|Experimental|Food Effect Fed cohort (part 2)|oral
3067131|NCT02113813|Experimental|Exon 20 Cohort (part 2)|oral
3067132|NCT02113800|Experimental|Single Arm|"Patients receive Everolimus orally, 10 mg/day.~The end of study will be performed when tumor progression has been observed for 28 patients. Patients who are still under treatment at that time may continue with chemotherapy at the discretion of the investigator, but will be excluded from the study."
3067133|NCT02113787|Active Comparator|Pharmacokinetic study, topamed|"For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in first visit day.~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in second visit day.~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in third visit day.~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in third visit day."
3067265|NCT02112851|Placebo Comparator|Orange flavored beverage|240ml orange beverage
3095352|NCT01923519|Experimental|allergic rhinitis|
3067134|NCT02113787|Active Comparator|Pharmacokinetic study, topamax|"For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in first visit day.~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in second visit day.~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in third visit day.~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in third visit day."
3067135|NCT02113774|No Intervention|no therapy|
3067136|NCT02113774|Active Comparator|antimicrobial treatment according to in-vitro susceptibility|
3067137|NCT02113748|Experimental|Downhill walking training|Exercise training including treadmill walking with a negative inclination.
3067138|NCT02113748|Active Comparator|Conventional walking training|Exercise training including treadmill walking without inclination. Possible to progress training intensity with positive inclinations.
3067139|NCT02113735|Experimental|Group 1|H.P. Acthar® Gel , 64 U, 0.8 mL daily
3067140|NCT02113735|Placebo Comparator|Group 2|Placebo, 0.8 mL, daily
3067141|NCT02113735|Experimental|Group 3|H.P. Acthar® Gel , 32 U, 0.4 mL, 2x daily
3067142|NCT02113735|Placebo Comparator|Group 4|Placebo, 0.4 mL, 2x daily
3067143|NCT02113735|Experimental|Group 5|H.P. Acthar® Gel , 16 U, 0.2 mL, 2x daily
3067144|NCT02113735|Placebo Comparator|Group 6|Placebo, 0.2 mL, 2x daily
3067145|NCT02113722|Active Comparator|Left cardiac sympathetic denervation|Left cardiac sympathetic denervation
3067146|NCT02113722|Placebo Comparator|Standard of care|Continuing medical therapy
3067147|NCT02113709|Experimental|Visual improvement|To see how efficiently visual improvement occurs by Full-time Occlusion therapy with an eye patch in severe amblyopia.
3067148|NCT02113696|Experimental|Placebo group|Placebo Capsules
3067149|NCT02113696|Experimental|Omega 3 intake|Omega 3 intake, morbid obesity
3067150|NCT02113683||MMS test|therapy monitoring of patients with colo-rectal or stomach disease or with melanoma
3067151|NCT02113670|Experimental|SUI 1|Patients will perform urodynamic study before and after instillation of 50 ml of air
3067152|NCT02113657|Experimental|Ipilimumab|Ipilimumab administered by vein at a dose of 3 mg/kg once every 3 weeks for a total of 4 doses.
3067153|NCT02113644||Overweight or obese children|Overweight or obese children according to the International Obesity Task Force (IOTF) criteria following the lifestyle intervention in the Centre for Overweight Adolescent and Children's Healthcare
3067154|NCT02113644||Lean children|Lean children according to the International Obesity Task Force (IOTF) criteria admitted at de pediatric ward for a planned surgery, for example the correction of floppy ears
3067155|NCT02113631|Active Comparator|Telaprevir|Telapravir was administer with Peg-IFN and Ribavirin as per package insert Dose Telaprevir : PO, tablet 1125 mg BID for 12 weeks
3067156|NCT02113631|Active Comparator|Boceprevir|Boceprevir was administer with Peg-IFN and Ribavirin as per package insert Dose Boceprevir PO capsule, 800mg TID for up to 44 weeks
3067157|NCT02113618|Active Comparator|Cogmed Training|Cogmed® working memory training is a computer program that will be administered online. The program consists of 7 verbal and non-verbal working memory tasks and gives immediate performance feedback to the subject undergoing training.
3067158|NCT02113618|Placebo Comparator|Standard training|Individuals randomised to the placebo arm will receive a standard training online program from Cogmed also consisting of 90 trials to be performed 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level.
3067159|NCT02113605|Experimental|Cognitive behavior therapy|All included children are treated with a face-to-face exposure-based cognitive behaviour therapy for 10 weeks. There will be no comparison arm.
3067160|NCT02113592|Experimental|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
3067161|NCT02113592|No Intervention|Treatment as usual|Patients in this arm will receive care as usual and utilize services as they currently exist in the health plan system.
3067162|NCT02113579|Experimental|KOX|"After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.~Fluoride Toothpaste / Crest® Cavity Protection Regular and Experimental Mouth Rinse 12027-033"
3067163|NCT02113579|Placebo Comparator|PLA|"After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.~Fluoride Toothpaste/Crest® Cavity Protection Regular and Placebo Mouth Rinse"
3067164|NCT02113566|Placebo Comparator|Placebo|2 capsules identical to comparator, 3 times daily on Day 1 and Day 2. On Day 3 only one dose will be taken. The intervention is Acetaminophen 1000mg.
3067165|NCT02113566|Active Comparator|Ibuprofen|2oomg capsules (400 mg per dose), 3 times daily on Day 1 and Day 2. On Day 3 only one dose will be taken. The intervention is Acetaminophen 1000mg.
3067166|NCT02113553|Experimental|Triptorelin|Triptorelin 3.75 administered every 28 days, for 4 to 7 injections depending on the number of cycles of chemotherapy
3067167|NCT02113540|Placebo Comparator|placebo group|taking atorvastatin like placebo 12 hours before the procedure
3067168|NCT02113540|No Intervention|long term statin group|taking atorvastatin for a long time before entering the study (their routine treatment)
3067169|NCT02113540|Experimental|preoperation statin group|taking atorvastatin 12 hours before the procedure
3067170|NCT02113527||Epigastric pain syndrome (EPS)|Patients suffering from functional dyspepsia characterized by epigastric pain syndrome according to Rome III criteria
3067171|NCT02113527||Postprandial distress syndrome (PDS)|Patients suffering from functional dyspepsia characterized by postprandial distress syndrome according to Rome III criteria
3067172|NCT02113527||Healthy subjects|Healthy subjects as control group
3067173|NCT02113514||Normal Pap smear|Women with normal pap test.
3067174|NCT02113514||Abnormal Pap smear|Women with abnormal pap test.
3067175|NCT02113501||HGT1a|HGT1a bladder cancer patients will undergo BCG induction and maintenance followed by conventional follow-up (cystoscopy and cytology at 3months and then every 6months).
3067266|NCT02112851|Experimental|Orange flavored beverage - Test1|240ml processed whole orange low dose
3067177|NCT02113488||Control: P|Patients who did attend a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
3067178|NCT02113488||Case: A|Patients who did not attend (A) a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
3067179|NCT02113488||Control: C|Patients who cancelled (C) a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
3067180|NCT02113449|Experimental|Treatment Group|Participants will receive one dose of nasal carbon dioxide (CO2) in the study clinic under medical supervision, followed by an additional six days of at home use, up to 4 times per day.
3067181|NCT02113436|Experimental|Fluticasone propionate (FP)/ Salmeterol xinafoate (SLM)|Subject will receive 1 or 2 inhalation of SLM 25mcg plus FP 50mcg twice daily in the first treatment period for 8 weeks and will continue to receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.
3067182|NCT02113436|Active Comparator|Fluticasone propionate (FP)|Subject will receive 1 or 2 inhalation of FP 50mcg twice daily in the first treatment period for 8 weeks and will receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.
3067183|NCT02113423|Experimental|recurrent T1-2 NPC,no treatment|3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT
3067184|NCT02113410|Experimental|Sit 'N' Fit Chair Yoga (SNFCY)|Willing and eligible subjects randomized to Sit 'N' Fit Chair Yoga will attend twice-weekly 45-minute yoga sessions for 8 weeks, for a total of 16 sessions.
3067185|NCT02113410|Active Comparator|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) will attend twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
3067186|NCT02113397||Continuous Therapy|TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day cycle colistimethate 75 mg inhaled two times daily. Repeat cycle.
3067187|NCT02113397||Cyclic therapy|TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day period during which no inhaled antibiotics are used. Repeat cycle.
3067188|NCT02113384||Observational study|Patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.
3067189|NCT02113371|Experimental|Intervention|The intervention consists of monthly scripted, peer-led social support sessions covering health and safety topics.
3067190|NCT02113371|No Intervention|Control|Usual practices with regard to health and work conditions.
3067191|NCT02113358|Experimental|Normovolemic group (keeping SVV<10% in supine; <15% in prone)|"The anesthesiologist will infuse Voluven (Fresenius Kabi, Bad Homburg, Germany) 250 ml if stroke volume variation is over 10% during the surgery to keep the normovolemia.~If total Voluven use is over 1500ml and then the anesthesiologist will infuse Saline 250 ml instead.~The maintenance of basal fluid, criteria to use inotropes (If cardiac index is below 2.5 l/min/m2 ) are the same standards in the both groups."
3067192|NCT02113358|Active Comparator|Restricitve group (keeping SVV < 18% in supine; <23% in prone)|"The anesthesiologist will infuse Voluven (Fresenius Kabi, Bad Homburg, Germany) 250 ml if stroke volume variation is over 18% during the surgery to keep the normovolemia.~If total Voluven use is over 1500ml and then the anesthesiologist will infuse Saline 250 ml instead.~The maintenance of basal fluid, criteria to use inotropes (If cardiac index is below 2.5 l/min/m2 ) are the same standards in the both groups."
3067193|NCT02113345|Experimental|lifestyle counseling|Metamemory Cognitive Intervention
3067194|NCT02113332|Experimental|Liraglutide|Liraglutide injected once per day for 24 weeks. Dose is 1,8 mg or highest tolerable dose.
3067195|NCT02113332|Placebo Comparator|Placebo|Placebo injected once per day for 24 weeks. Dose is 1,8 or highest tolerable dose.
3067196|NCT02113319|Experimental|dasatinib|
3067197|NCT02113306|Experimental|t-VNS|"electrical stimulation of the concha of the ear~30sec trains of 0.25msec-duration monophasic square wave pulses at 25Hz, with a stimulation intensity not exceeding 0.5 mA"
3067198|NCT02113306|Sham Comparator|sham t-VNS|"Sham stimulation of the earlobe will be conducted by positioning the electrode upside down~30sec trains of 0.25msec-duration monophasic square wave pulses at 25Hz, with a stimulation intensity not exceeding 0.5 mA"
3067199|NCT02113293|Experimental|CyclASol®|CyclASol®
3067200|NCT02113293|Placebo Comparator|Placebo|Placebo (vehicle)
3067201|NCT02113280|Active Comparator|Physiotherapy|Physiotherapy
3067202|NCT02113280|Experimental|Arthroscopy|Arthroscopy
3067203|NCT02113267|Experimental|Mometasone furoat|Mometasone furoate monohydrate. 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
3067204|NCT02113267|Placebo Comparator|Placebo spray|Placebo. 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
3067205|NCT02113254|Experimental|Healthy volunteer|
3067206|NCT02113241|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
3067207|NCT02113241|Placebo Comparator|Placebo|Placebo capsules, 10 mg, one per day before breakfast during 90 days.
3067208|NCT02113228||Short Bowel Syndrome|Verify the total energy expenditure in patients with short bowel syndrome using the doubly labeled water method.
3067209|NCT02113228||Control Group|Verify the total energy expenditure in patients without short bowel syndrome using the doubly labeled water method.
3067210|NCT02113215||Young Males|Males, age 18-35 years. 9-hour Stable isotope infusion
3067211|NCT02113215||Young Females|Females, age 18-35 years. 9-hour Stable isotope infusion
3067212|NCT02113215||Older Males|Males, age 60-75. 9-hour Stable isotope infusion
3067213|NCT02113215||Older Females|Females, age 60-75. 9-hour Stable isotope infusion
3067214|NCT02113202|Experimental|Tracer dose: 4.5 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 4.5 mg of the fluorescent tracer bevacizumab-IRDye800CW.
3067215|NCT02113202|Experimental|Tracer dose: 10 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 10 mg of the fluorescent tracer bevacizumab-IRDye800CW.
3067267|NCT02112851|Experimental|Orange flavored beverage - Test2|240ml processed whole orange high dose
3067216|NCT02113202|Experimental|Tracer dose: 25 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 25 mg of the fluorescent tracer bevacizumab-IRDye800CW.
3067217|NCT02113189|Experimental|Walking program with ankle brace|This group will receive bilateral off-the-shelf ankle braces as well as a customized walking program.
3067218|NCT02113189|Experimental|Individualized walking program|This group will receive a customized walking program.
3067219|NCT02113189|Experimental|Walking program with custom braces|This group will receive bilateral custom-fabricated ankle braces as well as a customized walking program.
3067220|NCT02113176|Experimental|Minocycline|"200 mg IV/placebo~Followed by 100 mg IV BID x 7days~Followed by 200 mg tablet QD x 14days"
3067221|NCT02113176|Placebo Comparator|Placebo|
3067222|NCT02113163|Active Comparator|Cohort A - Low Dose|Metformin Eicosapentaenoate 1500 mg or Metformin HCl 500 mg and Vascepa 1000 mg
3067223|NCT02113163|Active Comparator|Cohort B - High Dose|Metformin Eicosapentaenoate 3000 mg or Metformin HCl 1000 mg and Vascepa 2000 mg
3067224|NCT02113150|Active Comparator|remifentanil|remifentanil, short acting opioid
3067225|NCT02113150|Active Comparator|ketamine|ketamine, intravenous anesthetic
3067226|NCT02113137|Experimental|group 1: drug|Drug: group 1: drug: chlorine dioxide 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks
3067227|NCT02113137|Experimental|group 2: device:|group 2: device: small tooth brush for tongue cleaning small tooth brush for tongue cleaning
3067228|NCT02113124||Chronic brain injury|Individuals in this group have suffered a brain injury more than 2 years prior to study. Ages range from 21 to 70.
3067229|NCT02113124||Uninjured control|This group of individuals have no history of brain injury. Ages range between 21 and 70.
3067230|NCT02113111||Fasting|Patients being admitted to an internal integrative medicine hospital and referred to therapeutic fasting therapy
3067231|NCT02113098|Experimental|Treadmill, ankle load|The experimental group will perform gait training on a treadmill with added load to the non-paretic lower limb
3067232|NCT02113098|Active Comparator|Treadmill|The control group (active comparator) will perform gait training on a treadmill
3067233|NCT02113085|Experimental|Self-determination enhancement|Self-determination enhancement through one-on-one coaching and mentoring workshops
3067234|NCT02113072|Experimental|Probiotics & Beclomethasone|"It will be supplied in lyophilized form, in each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.~Beclomethasone HFA 50mcg spray - 100 mcg/day as initial treatment for primary and wheezing in this age group, at doses considered minimal, for 4 months."
3067235|NCT02113072|Active Comparator|Beclomethasone & Placebo|The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics. It will be supplied in lyophilized form in each sachet containing 1 g of placebo, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
3067236|NCT02113059||Liver resection|Patients undergoing a hemihepatectomy.
3067237|NCT02113046|Active Comparator|pancreatico-jejunal anastomosis|patients in which the finnish binding pancreatico-jejunal anastomosis is techically possible to perfom during distal pancreatic resektion
3067238|NCT02113046|Active Comparator|traditional anastomosis|pancreatic resections with traditional stump closure
3067239|NCT02113033|Experimental|Treated with Equilia system|Implantation and activation of the Vagus Nerve Stimulator, nerve electrode and cardiac lead
3067240|NCT02113020|Experimental|TAK-233|Oral administration
3067241|NCT02113020|Placebo Comparator|Placebo|Oral administration
3067242|NCT02113007|Experimental|Rituximab plus Temozolomide|Rituximab: 375 mg/m2 IV, days 1, 3, and 5 Temozolomide: 150 mg/m2 PO, days 1-5
3067243|NCT02112994|Experimental|sebelipase alfa|Intravenous infusion of sebelipase alfa: 1mg/kg every other week
3067244|NCT02112981|Experimental|Sirolimus Eluting Coronary Stent|BioMime Sirolimus Eluting Stent of Meril Life Sciences
3067245|NCT02112981|Active Comparator|Everolimus-eluting Coronary stent|XIENCE family (V, Xpedition or Prime) of Everolimus-eluting stent system of Abbott Vascular Inc.
3067246|NCT02112968|Experimental|Proscan|Ametropia Lasik treatment of virgin eyes.
3067247|NCT02112968|Experimental|Zyoptix|Wavefront based ametropia Lasik treatment of virgin eyes.
3067248|NCT02112968|Experimental|Supracor|Ametropia Lasik treatment of virgin eyes with presbyopia.
3067249|NCT02112955|Experimental|Stroke self-management program|The program is aimed at enhancing community-dwelling stroke survivors' post-stroke recovery.
3067250|NCT02112955|Active Comparator|Usual care|Usual care provided to stroke survivors discharged to their home.
3067251|NCT02112942|Experimental|Group A|Healthy subjects, sequential dose escalation, IDX21459 capsules or Matching Placebo capsules, once daily, up to 7 days
3067252|NCT02112942|Experimental|Group B|HCV subjects genotype 1, IDX21459 capsules, once for 1 day
3067253|NCT02112942|Experimental|Group C|HCV subjects genotype 1, IDX21459 capsules or Matching Placebo capsules, once daily, for 7 days
3067254|NCT02112929|Experimental|Inhalation of hyperpolarized xenon|One litre of hyperpolarized xenon to be inhaled during MRI scan of the lungs
3067255|NCT02112916|Active Comparator|Arm A (combination chemotherapy)|Patients receive combination chemotherapy without bortezomib. See Detailed Description.
3067256|NCT02112916|Experimental|Arm B (combination chemotherapy, bortezomib)|Patients receive combination chemotherapy with bortezomib. See Detailed Description.
3067257|NCT02112903|Experimental|Encapsulated vortioxetine IR tablet, 20 mg|Single oral dose
3067258|NCT02112903|Experimental|Vortioxetine MR capsule 20 mg (pH 5.5)|Single oral dose
3067259|NCT02112903|Experimental|Vortioxetine MR capsule 20 mg (pH 6.0)|Single oral dose
3067260|NCT02112903|Experimental|Vortioxetine MR capsule 20 mg (pH 7.0)|Single oral dose
3067261|NCT02112890||Study Group|A random sample of subjects constituting adolescents and young adults (≥10 - ≤25 years of age) that participated in the ENSANUT 2012 in Mexico.
3067262|NCT02112877|Experimental|Veniti Vici™ Venous Stent System|
3067263|NCT02112864|Experimental|dexamethasone 10 mg|Dexamethasone 10 mg will be given as a single-dose, pre incision, intravenously
3067264|NCT02112864|Placebo Comparator|normal saline|Patients in this group will receive 2.5 mL of normal saline intravenously, pre-incision
3067268|NCT02112838|Active Comparator|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
3067269|NCT02112838|Active Comparator|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
3067270|NCT02112838|Placebo Comparator|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
3067271|NCT02112825|Experimental|Exercise|12 weeks of blended supervised-home based exercise 3-4 times per week for 30-45 minutes
3067272|NCT02112825|No Intervention|control|Control group asked to continue usual activities
3067273|NCT02112812|Experimental|Eradication therapy|The patients who were positive for H.pylori infection are entered into an eradication therapy protocol which includes oral esomeprazole 40mg daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
3067274|NCT02112799|Experimental|NVR 3-778|NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
3067275|NCT02112799|Placebo Comparator|Placebo for NVR 3-778|Placebo for NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
3067276|NCT02112799|Experimental|NVR 3-778 and Pegasys|NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days
3067277|NCT02112799|Active Comparator|Pegasys|Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days
3067278|NCT02112786|Active Comparator|Intermittent then Continuous|This group will be set to intermittent stimulation first, then after the wash out period they will be switched to continuous stimulation.
3067279|NCT02112786|Active Comparator|Continuous Then Intermitent|This group will be set to continuous stimulation first, then switch to intermittent after the wash out time period.
3067280|NCT02112760|Experimental|Patient|To evaluate the effect of specific stabilization intervention in recurrent low back pain participants
3067281|NCT02112747|No Intervention|Arm 1: website access only|There is no intervention with this arm. Completion of the website is part of enrollment.
3067282|NCT02112747|Experimental|Arm 2: patient navigator|"The intervention consists of participants receiving the services of a patient navigator to address individual barriers to adhering to the personal prescription for colon and rectal cancer screening."
3067283|NCT02112747|No Intervention|Arm 3: genetic counseling|There is no intervention in this arm. Patients diagnosed as positive for Lynch Syndrome use genetic counseling to discuss medical and family history and genetic risk of CRC, including genetic factors such as DNA mismatch repair genes, autosomal dominant inheritance, cancer risks associated with LS, screening recommendations, and genetic testing. There is no intervention. This is standard care.
3067284|NCT02112747|Experimental|Arm 4:Gen. counselor & patient navigator|Participants diagnosed positive for Lynch syndrome use genetic counseling as in Arm 3 and in addition receive the services of a patient navigator to address individual barriers to adhering to the CRC screening recommendations.
3067285|NCT02112734|Active Comparator|vitamin D|400 IU /daily cholecalciferol/vitamin D
3067286|NCT02112734|Placebo Comparator|placebo|carrier formulation minus vitamin D
3067287|NCT02112721|Experimental|Vitamin D Group|Each participant will be given an initial stat dose of 2500 μg (100,000 IU) of Ostelin (Reckitt Benckiser). Thereafter, participants will take 100 μg/day (4,000 IU, 4 tablets) Ostelin daily for a period of 16 weeks.
3067288|NCT02112721|Placebo Comparator|Placebo group|Each participant will be given an equivalent number of placebo tablets
3067289|NCT02112708|Experimental|Rational-Emotive-Behavioral Therapy|A social worker held eight 30 minutes sessions fortnightly of Rational-Emotive-Behavioral Therapy. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
3067290|NCT02112708|Active Comparator|Control Group|The control group (GC) will take the usual medical care for dysthimia, according with up-dated guidelines.
3067291|NCT02112695|Experimental|sportswomen|3 micrograms [11C]diprenorphine
3067292|NCT02112695|Experimental|control subjects|3 micrgrams [11C]diprenorphine
3067293|NCT02112682|Active Comparator|Completion axillary treatment|Completion axillary treatment according to the Dutch breast cancer guideline
3067294|NCT02112682|No Intervention|No completion axillary treatment|
3067295|NCT02112669|Experimental|AV fistula with VasQ|Implant VasQ over AV fistula
3067296|NCT02112669|No Intervention|AV fistula|AV fistula without any adjunct device
3067297|NCT02112656|Experimental|ThermoDox 50 mg/m2|ThermoDox plus standardized RFA using standardized treatment dwell time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm
3067298|NCT02112656|Placebo Comparator|Dummy infusion|standardized RFA alone using standardized treatment dwell time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm
3067299|NCT02112643|Active Comparator|Selenium|100 micrograms of sodium selenite will be taken orally twice daily (total 200 micrograms daily) for 6 months.
3067300|NCT02112643|Placebo Comparator|Sugar pill|A placebo pill will be taken orally twice daily for 6 months.
3067301|NCT02112630|Experimental|Group 1 - Response Guided Therapy|"Treatment naive and documented relapsers : Subjects who have never been previously treated with P-IFN +/- ribavirin therapy and those who have documented relapse after P-IFN +/- ribavirin therapy.~Subjects in group 1 will receive P-IFN alfa 2a or P-IFN alfa 2b and ribavirin for a 4 week lead-in followed by the addition of boceprevir. Based on the patient's HCV-RNA levels at Treatment Week (TW) 8, TW12 and TW24 treatment with be continued for a total duration of 28 to 48 weeks.Subjects will be followed through treatment and up to 24 weeks post treatment."
3067302|NCT02112630|Experimental|Group 2 - Fixed Duration Therapy|"Partial/Null Responders /Undefined Previous Response, Compensated cirrhosis: Subjects who have compensated cirrhosis, and/or were previously treated with P-IFN +/- ribavirin without SVR (including partial responders, null responders, and those previously treated without adequate documentation of response).~Subjects in Group 2 will all be assigned to fixed duration therapy.Patients will be treated with P-IFN alfa 2a or P-IFN alfa 2b and ribavirin for a 4 week lead-in followed by the addition of boceprevir for a total of 48 weeks of therapy. Subjects will be followed through treatment and up to 24 weeks post treatment."
3067303|NCT02112617|Experimental|Proton Beam Radiation Therapy (PBRT)|Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
3067304|NCT02112604||Ventilated patients|Patients who have been extubated within 24 hours and have been mechanically ventilated for at least 24 hours. Alice PDx, pulmonary function tests, muscle strength tests, grip strength measurements, ventilator, Sedatives and muscle relaxants given in the ICU
3067305|NCT02112591|Active Comparator|Transobturator suburethral tape (TOT)|transobturator approaches for the placement in mid-urethral position of polypropylene tape that is 1.5cm wide
3067306|NCT02112591|Experimental|S-TOT|transobturator subtrigonal tape: S-TOT
3067307|NCT02112578|Experimental|Meclizine|Meclizine 25 mg, tablets
3067308|NCT02112578|Active Comparator|Dimenhydrinate|Dimenhydrinate 50 mg, soft Capsgel
3067309|NCT02112565|Experimental|Treatment (RNR inhibitor COH29)|Patients receive RNR inhibitor COH29 PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3067310|NCT02112552|Experimental|Treatment (paclitaxel, carboplatin, radiotherapy)|"CHEMOTHERAPY: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IP on day 1. Treatment repeats every 21 days for up to 6 courses (weeks 1-18) in the absence of disease progression or unacceptable toxicity.~RADIATION: At provider discretion, patients may undergo 3D conformal or IMRT 5 days a week for 5 weeks (weeks 19-23)."
3067311|NCT02112539||ADP Blockers|platelet aggregation in response to antiplatelet drugs
3067312|NCT02112526|Experimental|ACP-196|ACP-196
3067313|NCT02112513||salivary estriol measurement|Serum Estriol measurement via different assays is complex, expensive, labor intensive, time consuming, and generally performed at specific reference labs. Salivary Estriol level is an ideal potential surrogate for serum Estriol. It is convenient, non-invasive, and expedient. It may not, however, be as sensitive as serum estriol concentrations at detecting the association with glucocorticoid response. This study will collect both samples to determine which one is better suited for clinical use in this condition.
3067314|NCT02112513||serum estriol measure|we will determine if changes in maternal serum estriol represent a biomarker of response to antenatal corticosteroids as evidenced by neonatal development of RDS
3067315|NCT02112513||Betamethasone pharmacokinetic|we will determine if pharmacokinetic parameters and neonatal outcomes after antenatal corticosteroid use are associated with genetic polymorphisms in drug metabolizing enzymes, transporters, and steroid pathway genes
3067316|NCT02112513||betamethasone concentration and genetics|we will determine if maternal betamethasone concentrations and genetics are associated with maternal estriol changes or RDS development
3067317|NCT02112500|Experimental|Mesenchymal Stem Cell Infusion|Mesenchymal stem cells cultured and extracted from bone marrow of enrolled patients are infused.
3067318|NCT02112487|Experimental|Macitentan|10 mg once daily
3067319|NCT02112474|Experimental|Spinal Cord Stimulation Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
3067320|NCT02112474|Experimental|Spinal Cord Stimulation Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
3067321|NCT02112461|Experimental|Intervention Group|SCP-Hospice Alert
3067322|NCT02112461|No Intervention|Usual Care|Caregiver calls into monitoring system to report the patient's end of life symptoms but does not receive feedback about the symptoms and the hospice nurse does not receive the information.
3067323|NCT02112448|Active Comparator|Continuous infusion|Patients in this group will received morphine/midazolam drips at 0.3 mg/kg/hour each. They will be given doses of morphine 0.05 mg/kg/dose every 2 hours as needed for pain score 4 or more. Midazolam will also be given as needed (0.05 mg/kg/dose every 1 hour)
3067324|NCT02112448|Active Comparator|As needed dosing|Patients in this arm will be given doses of morphine 0.05 mg/kg/dose every 2 hours as needed for pain score 4 or more. Midazolam will also be given as needed (0.05 mg/kg/dose every 1 hour)
3067325|NCT02112435|Active Comparator|Narval ORM ® or SomnoDent ®|Mandibular advancement splint (Narval ORM ® or SomnoDent ®)
3067326|NCT02112435|Experimental|Somnyx ®|Active mandibular advancement splint (Somnyx ®)
3067327|NCT02112422|Active Comparator|Control|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR. The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
3067328|NCT02112422|Experimental|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR. The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
3067329|NCT02112409|Experimental|cell salvage and hemodilution technique|cell salvage technique throughout scoliosis corrective surgery; Acute normovolemic hemodilution technique commenced after induction of anaesthesia and prior the starting of surgery.
3067330|NCT02112409|Active Comparator|cell salvage|cell salvage technique throughout scoliosis corrective surgery
3067331|NCT02112396|Experimental|Immediate Intervention|Subjects receive 12 sessions of Community Reinforcement and Family Training (CRAFT) immediately after study inclusion
3067332|NCT02112396|Other|Waiting list group|Waiting list group members receive the Community Reinforcement and Family Training CRAFT intervention after the first follow-up (3 months post study inclusion)
3067333|NCT02112383|Experimental|Internet-based cognitive behavior therapy|
3067334|NCT02112383|Experimental|Cognitive behavior group therapy|
3067335|NCT02112370|Placebo Comparator|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection.
3067336|NCT02112370|Experimental|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection.
3067337|NCT02112357||Targeted genetic sequencing of tumour specimen|
3067338|NCT02112344|Experimental|Total mucosal irradiation|
3067339|NCT02112331|Experimental|Raw human milk / pasteurized human milk|"Raw human milk compared to pasteurized human milk. Two meals administration (20mL/kg) per day during 6 days in a randomized order, with an intragastric tube : one with raw milk and one with pasteurized milk.~In order to characterise gastric effluents at different postprandial times after ingestion and to measure gastric lipolysis and proteolysis, at each administration two gastric samples will be collected with the intragastric tube :~one before the meal,~and one either 35, 60 or 90 minutes (randomized time frame) after the meal."
3067340|NCT02112331|Experimental|Pasteurized human milk / pasteurized-homogenized human milk|"Pasteurized human milk compared to pasteurized-homogenized human milk. Two meals administration (20mL/kg) per day during 6 days in a randomized order, with an intragastric tube : one with pasteurized milk and one with pasteurized-homogenized milk.~In order to characterise gastric effluents at different postprandial times after ingestion and to measure gastric lipolysis and proteolysis, at each administration two gastric samples will be collected with the intragastric tube :~one before the meal,~and one either 35, 60 or 90 minutes (randomized time frame) after the meal."
3067341|NCT02112305|Experimental|isotonic magnesium sulphate|2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) on three occasional at 20 minutes interval
3067342|NCT02112305|Active Comparator|50% magnesium sulphate|magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose
3067343|NCT02112292|Experimental|T-C-P|Order of administrations: tetrahydrocannabinol - cannabidiol - placebo
3067344|NCT02112292|Experimental|T-P-C|Order of administrations: tetrahydrocannabinol - placebo - cannabidiol
3067345|NCT02112292|Experimental|C - T - P|Order of administrations: cannabidiol - tetrahydrocannabinol - placebo
3067346|NCT02112292|Experimental|C - P - T|Order of administrations: cannabidiol - placebo - tetrahydrocannabinol
3067347|NCT02112292|Experimental|P - T - C|Order of administrations: placebo - tetrahydrocannabinol - cannabidiol
3067348|NCT02112292|Experimental|P - C - T|Order of administrations: placebo - cannabidiol - tetrahydrocannabinol
3067349|NCT02112279|Experimental|Microbiota Transplant|Close relative or purchased donor microbiota transplant will be administered via colonoscopy; Donor microbiota applied via colonoscopy
3067350|NCT02112266|Other|no mail support|no mail support during follow-up
3067351|NCT02112266|Other|mail support|
3067352|NCT02112253|Experimental|Deep brain stimulator ventral electrode up to 2 mA|The ventral contact within the anterior globus pallidus interna near the ansa lenticularis is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 2 mA amplitude is reached; whichever comes first.
3067353|NCT02112253|Experimental|Deep brain stimulator ventral electrode up to 3 mA|The ventral contact within the anterior globus pallidus interna near the ansa lenticularis is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 3 mA amplitude is reached; whichever comes first.
3067354|NCT02112253|Experimental|Deep brain stimulator dorsal electrode up to 2 mA|The dorsal contact within the superior half of the anterior globus pallidus interna is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 2 mA amplitude is reached; whichever comes first.
3067355|NCT02112253|Experimental|Deep brain stimulator dorsal electrode up to 3 mA|The dorsal contact within the superior half of the anterior globus pallidus interna is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 3 mA amplitude is reached; whichever comes first.
3067356|NCT02112253|Active Comparator|Deep brain stimulator empirical programming|Any of the four electrode contacts on each of the two deep brain stimulation leads can be activated in any combination with any amplitude, frequency or pulse width settings to achieve optimized clinical control of motor tics whilst minimizing side effects. Both programmer and patient may be unblinded. The assessors are blinded to stimulation settings.
3067357|NCT02112240|Experimental|Surgery with pre- and intra-op imaging|Subjects will have a preoperative flexible sigmoidoscopy where they will receive an endoscopic injection of 99mTc-sulfur colloid (up to 0.5 mCi) and 3 to 5 cc of circumferential endoscopic injections of Spot. A SPECT/CT will be performed prior to surgery to identify lymph nodes in the rectum. Subjects will proceed to their standard surgery. Intraoperative mobile gamma camera imaging of the rectum will occur before and after resection in attempt to identify sentinel lymph nodes.
3067358|NCT02112227|Active Comparator|Discharge planning services|Proven effective discharge-planning services will be grouped into 'patient-centered care transitions in heart failure' patients. This will be known as the PACT-HF model.
3067359|NCT02112227|No Intervention|Standard Care|Standard of care will be provided to HF patients at discharge.
3067360|NCT02112214|Active Comparator|Intervention group|10-day bismuth-based quadruple therapy for H. pylori positive subjects
3067361|NCT02112214|Placebo Comparator|Placebo group|Placebo for H. pylori positive subjects
3067362|NCT02112201|Experimental|Integrated intervention for parents and adolescent girls|Twelve session parent education and support group; twelve session one-on-one adolescent skills training intervention
3067363|NCT02112201|No Intervention|Treatment as usual|Treatment as usual
3067364|NCT02112188||Chinese patients with advanced cancer|This is a study to adapt the IMCP intervention to be culturally and linguistically tailored for Chinese cancer patients. This study will be carried out in two phases: 1) formative research and 2) adaptation. For this application we will continue the formative research (phase 1) by conducting 20 to 30 indepth interviews with Chinese immigrants with advanced cancer to inform the adaptation of the intervention. Results of the patient in-depth interviews will inform how to adapt the IMCP process and session themes to reflect the needs of the community. In the adaptation phase (phase 2) the Breitbart IMCP research team (including Drs. Breitbart, Lichtenthal, and Applebaum), Drs. Leng, Gany, and Ms. Huang will discuss a priori adaptations to the intervention. Potential changes to the process and content will be discussed. Adaptations will be incorporated in a modified IMCP-Ch treatment manual, therapist checklist/outline and Treatment Integrity Coding Manual.
3067365|NCT02112175|Experimental|Lenalidomide|Treatment Arm A: lenalidomide 10 mg/day orally from Days 1 to 21; given in 28-day cycles for up to disease progression.
3067366|NCT02112162|Experimental|Diagnostic (FDG PET/MRI, gene expression)|FDG PET/MRI at baseline and at 2-4 weeks before surgery (after neoadjuvant chemoradiation). Tissue samples for gene expression at baseline and during surgery
3067399|NCT02112032|Experimental|Dose Level 2|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 2 µg/kg every week by subcutaneous injection for up to 2 years
3067400|NCT02112032|Experimental|Dose Level 3|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 3 µg/kg every week by subcutaneous injection for up to 2 years
3067367|NCT02112149|Experimental|LIVESTRONG Program|Participants randomized to the LIVESTRONG exercise program will attend a 12-week LIVESTRONG Program at one of the participating YMCA's in the greater Boston area or CT. We will have monthly teleconferences to discuss the study, recruitment, and the exercise program. Lastly, throughout the 12-week program, participants will record their attendance at the LIVESTRONG program as well as any exercise done outside of the program. We will provide them with a Physical Activity Log book to record their exercise.
3067368|NCT02112149|No Intervention|Wait-List Control|Baseline data will be collected from all study participants before randomization. If a participant is randomized to wait-list control, then he/she will be told that he/she will start the LIVESTRONG program after three months and after he/she returns to Yale or DFCI to complete the 3-month clinic visit.
3067369|NCT02112136|Other|GeneQuest|"No drug will be administrated in this study~Blood collection"
3067370|NCT02112123|Placebo Comparator|Placebo|Matching placebo given for 5 days (qd po)
3067371|NCT02112123|Active Comparator|Icariin - 100 mg/day|Icariin given at 100 mg/day (qd po) for 5 days
3067372|NCT02112123|Active Comparator|Icariin - 200 mg/day|Icariin given at 200 mg/day (qd po) for 5 days
3067373|NCT02112123|Active Comparator|Icariin - 400 mg/day|Icariin given at 400 mg/day (qd po) for 5 days
3067374|NCT02112123|Active Comparator|Icariin - 840 mg/day|Icariin given at 840 mg/day (qd po) for 5 days
3067375|NCT02112123|Active Comparator|Icariin - 1680 mg/day|Icariin given at 1680 mg/day (qd po) for 5 days
3067376|NCT02112110|Experimental|BMS-791325 (oral) and [13C]-BMS-791325 (IV)|BMS-791325 single dose tablet orally and [13C]-BMS-791325 single dose solution intravenously on specific days
3067377|NCT02112097|Experimental|For Left Upper Arm|"For Left Upper Arm Total Persistent % subdermally, For Left Upper Arm Total Persistent % subcutaneously, and For Left Upper Arm Relative Prolongation Ability Score.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
3067378|NCT02112097|Experimental|For Right Upper Arm|"For Right Upper Arm Total Persistent % subdermally, For Left Upper Arm Total Persistent % subcutaneously, and For Left Upper Arm Relative Prolongation Ability Score.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
3067379|NCT02112097|Experimental|sPGA 50 n(%)|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, and Efficacy of Enbrel subcutaneously at Week 36 vs. Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, and Efficacy of Enbrel subdermally at Week 36. sPGA 50 n(%) clear or minimal is the % of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and % of patients with a reduction of PASI of at least 50% from baseline."
3067380|NCT02112097|Experimental|PASI 75 n(%)|"PASI 75 n(%)~Response to treatment defined as the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI, as PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, and PASI 75 n(%) subcutaneously at Week 36 vs. PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, and PASI 75 n(%) subdermally at Week 36."
3067381|NCT02112097|Experimental|Adverse Injection site reactions|Injection site reactions as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3067382|NCT02112097|Experimental|Adverse Reactions with Heart failure|Heart failure as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3067383|NCT02112097|Experimental|Adverse Reactions Allergic Reactions|Allergic Reactions as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3067384|NCT02112097|Experimental|Adverse Reactions Blood/low blood counts|Blood problems/low blood counts as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3067385|NCT02112097|Experimental|Adverse Reactions with Nervous system|Nervous system problems, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes, as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3067386|NCT02112097|Experimental|Adverse Reactions with Infections|Infections (upper respiratory infection, pyelonephritis, bronchitis, septic osteomyelitis, wound infection, pneumonia, foot abscess, leg ulcer), as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3067387|NCT02112097|Experimental|Adverse Reactions with Malignancies|Malignancies (lymphoma, basal & squamous skin cancer, non-cutaneous solid tumor, & Wegener's granulomatosis), as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3067388|NCT02112097|Experimental|Adverse Reactions with Immunogenicity|Immunogenicity as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3067389|NCT02112097|Experimental|Adverse Reactions with Autoantibodies|Autoantibodies, Lupus-like syndrome, autoimmune hepatitis, as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3067390|NCT02112084|No Intervention|Usual Care|Usual care participants do not receive an intervention.
3067391|NCT02112084|Experimental|Individualized DPM|Individualized DPM
3067392|NCT02112071|Experimental|Exercise|blended supervised-hombased exercise training 3-4 times/week for 12 weeks
3067393|NCT02112071|No Intervention|control|control group asked to continue usual activities
3067394|NCT02112058|Experimental|Program|A series of relationship and marriage education workshops for groups of couples that was offered in the first four to five months of enrollment in the program. Complementing the workshops was a second component, offered for the year after enrollment, that consisted of supplemental activities: educational and social events that were intended to build on and reinforce lessons from the curricula. The third component was family support services.
3067395|NCT02112058|No Intervention|Control|Business as usual
3067396|NCT02112045|Experimental|Granix and high dose melphalan (HDM)|"Granix on Day -7 through Day -2.~HDM intravenously (IV) on Day -2.~Autologous stem cell transplantation on Day 0"
3067397|NCT02112045|Active Comparator|High dose melphalan (HDM)|"HDM intravenously (IV) on Day -2.~Autologous stem cell transplantation on Day 0."
3067398|NCT02112032|Experimental|Dose Level 1|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 1 µg/kg every week by subcutaneous injection for up to 2 years
3067401|NCT02112019|Experimental|Sialoendoscopy with saline|By performing a sialoendoscopy, the ducts of the salivary glands are rinsed with saline and possible strictures are dilated
3067402|NCT02112019|Active Comparator|Sialoendoscopy: saline and hydrocortisone|By performing a sialoendoscopy, the ducts of the salivary glands are rinsed with saline and hydrocortisone and possible strictures are dilated
3067403|NCT02112019|No Intervention|Control: no treatment|
3067404|NCT02112006|Experimental|distal injection|0.5% bupivacaine injected in the forearm
3067405|NCT02112006|Active Comparator|proximal injection|20-30ml of 0.5% bupivacaine
3067406|NCT02111993|Active Comparator|Standard Defibrillation Testing|Standard Defibrillation Threshold Testing is a procedure in which a low energy shock will be delivered to the heart to induce ventricular fibrillation (VF) followed by a rescue shock to restore sinus rhythm. Process is repeated after 5 minutes.
3067407|NCT02111993|Active Comparator|Upper Limit of VulnerabilityTesting|Upper Limit of Vulnerability Testing is a procedure in which four 18J shocks will be delivered at specified intervals. If VF is induced, then a 25 J rescue shock will be delivered.
3067408|NCT02111980|Experimental|RF Assure Scanning|The patient's CIED will be interrogated prior to the study to obtain a baseline reading. The patient will be asked to lie down on the RF Assure® Detection Mat with a sponge placed underneath his or her shoulder. The RF Assure® mat and wand will be activated to detect the sponge. The sponge will be removed from underneath the patient's shoulder, and the RF system will be re-activated to obtain a clear reading. The patient's CIED will be re-interrogated to determine if the RF Assure system caused any changes to the CIED parameters or function.
3067409|NCT02111967||Diabetes mellitus type 2, Metformin|The case group consists of patients with diagnosed diabetes mellitus type 2 treated with Metformin.
3067410|NCT02111967||Diabetes mellitus type 2|The control group consists of patients with diagnosed diabetes mellitus type 2 which do not have metformin treatment
3067411|NCT02111954||F-18-FCH & Ga-68-NODAGA-MJ9|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9
3067412|NCT02111941|Experimental|Treatment (vaccine therapy)|"INDUCTION PHASE: Patients receive folate receptor alpha peptide-loaded dendritic cell vaccine ID on day 1. Treatment repeats every 3 weeks for 5 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive folate receptor alpha peptide-loaded dendritic cell vaccine ID on day 1. Treatment repeats every 3 months for 7 courses in the absence of disease progression or unacceptable toxicity."
3067413|NCT02111928||NovaTears®|
3067414|NCT02111915|Other|Enhanced Usual Care (EUC)|EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services
3067415|NCT02111915|Experimental|THPP-P|Trial participant s who are in the THPP group will receive, in addition to EUC, 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
3067416|NCT02111889|Experimental|one|
3067417|NCT02111876||AHRF follow-up|
3067418|NCT02111863|Experimental|Lymphocyte Depleting Prep Regimen|Patients will receive a lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of 4-1BB selected tumor infiltrating lymphocytes (TIL) plus IV aldesleukin.
3067419|NCT02111850|Experimental|1/Phase I Experimental Therapy|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Anti-MAGE-A3-DP4 TCR PBL + high-dose aldeskin
3067420|NCT02111850|Experimental|2/Phase II Experimental Therapy|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Anti-MAGE-A3-DP4 TCR PBL + high-dose aldeskin
3067421|NCT02111837|Placebo Comparator|Standard infant formula|Standard infant formula fed ad libitum
3067422|NCT02111837|Experimental|Standard infant formula with PL1|Standard infant formula enriched with PL1 lipid fraction fed ad libitum
3067423|NCT02111837|Experimental|Standard infant formula with PL2|Standard infant formula enriched with PL2 lipid fraction fed ad libitum
3067424|NCT02111824|Experimental|Group 2|During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the the lung biopsy.
3067425|NCT02111824|Experimental|Group 3|During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the lung biopsy. An intravenous (IV) needle placed in the vein to give indocyanine green (IC-Green). Fiber Optic camera will be used to view tissue before biopsy via insertion catheter.
3067426|NCT02111824|No Intervention|Group 1|Control Group consists of twelve patients who have undergone biopsy of a peripheral lung lesion by using repetitive CT-guidance. Review of medical records only, no further intervention.
3067427|NCT02111811|Experimental|Veterans Work and Health Initiative|CBT based intervention focused on work productivity
3067428|NCT02111811|No Intervention|usual care|usual care group (Behavioral Health lab care at the PVAMC)
3067429|NCT02111798|Placebo Comparator|placebo|Participants will be randomized to receive active or placebo medication after being stratified according to their initial response to a contingency management intervention (i.e. whether or not they stop using cocaine when offered financial incentives to do so).
3067430|NCT02111798|Active Comparator|Bupropion XL|Participants will be randomized to receive active or placebo medication after being stratified according to their initial response to a contingency management intervention (i.e. whether or not they stop using cocaine when offered financial incentives to do so). Active medication is bupropion XL 300mg/day.
3067431|NCT02111785|Active Comparator|Burr Hole Craniostomy randomized|Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
3067432|NCT02111785|Experimental|Dexamethasone randomized|Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
3067433|NCT02111785|Other|Burr hole craniostomy observational|Observational cohort of patients selecting burr hole craniostomy
3067434|NCT02111785|Other|Dexamethasone observational|Observational cohort of patients treated with dexamethasone protocol
3067435|NCT02111772|Experimental|Asthmatic subjects|Subjects with Asthma whose cold and chest symptoms will be evaluated one week before and 4 weeks after an inoculation with rhinovirus.
3067436|NCT02111772|Active Comparator|Without Asthma|Subjects without asthma whose cold and chest symptoms will be evaluated one week before and 4 weeks after an inoculation with rhinovirus
3067437|NCT02111759|Other|knee flexion angle 2|30 degrees of knee flexion during ACL graft fixation
3067438|NCT02111759|Other|knee flexion angle 1|0 degrees of knee flexion during ACL graft fixation
3067439|NCT02111746|Experimental|Exparel®|Patients in this group will receive will receive the study drug [bupivacaine liposomal injectable suspension (Exparel®)] and Patient Controlled Analgesia (PCA). Exparel® is an FDA-approved bupivacaine liposome injectable suspension produced by Pacira Pharmaceuticals.
3067440|NCT02111746|Active Comparator|Regular Bupivacaine|Patients in this group will receive will receive the standard regular bupivacaine hydrochloride (HCl) and PCA. Bupivacaine HCl is an FDA-approved injectable suspension. The standard non-liposomal bupivacaine will be from Hospira pharmaceuticals
3067441|NCT02111733|Experimental|Hs-TnT|Hs-TNT dosage
3067442|NCT02111720|Experimental|Maybe, Maybe Not|The intervention is an individual-level 4-session + 3 month booster series designed to assist persons with HIV in making decisions regarding the disclosure of their HIV serostatus to family members.
3067443|NCT02111720|Active Comparator|Comprehensive Risk Counseling and Services|Comprehensive Risk Counseling and Services (CRCS) will be used to provide the attention-placebo control (CDC, 2006). CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.
3067444|NCT02111707|Active Comparator|Rectal Indomethacin pre-ERCP|Patients will receive rectal indomethacin 100mg 30 minutes before procedure (ERCP).
3067445|NCT02111707|Active Comparator|Rectal Indomethacin post-ERCP|Patients will receive rectal indomethacin 100mg immediately after procedure (ERCP)
3067446|NCT02111694|Experimental|Clear versus Opaque Bottle|This is a within-subject study; all infants will be exposed to both conditions. Order of presentation will be counterbalanced across infants.
3067447|NCT02111681|Experimental|Calypso-based Deep Inspiration Breath Hold (DIBH)|"This trial will investigate the feasibility of implanted anchored Beacon ® electromagnetic lung transponders (Calypso ®) to guide and monitor deep-inspiration breathhold (DIBH) treatments in patients with inoperable thoracic malignancies.~Bronchoscopic Calypso Beacon Implantation, Simulation - Free-breathing scan - 4D CT scan,- DIBH CT scan Radiation - Treatment setup, - Calypso signal recording, - RT treatment with DIBH with or without visual biofeedback Follow-up - 3 and 6 months after RT with diagnostic CT chest"
3067448|NCT02111655|Other|Clasical Surveillance of AVF|"Classical evaluation of AVF includes:~Vital sings and predialysis physical examination of AVF every dialysis session.~Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session.~Weekly ktv test using biosensors or monthly if using monocompartimental Daugirdas equation.~Quarterly recirculation with urea method.~Following Spanish Nephrology VA guidelines will be consider as alarm criteria:~1.25% Increased venous pressure. 2.25% Decreased pump blood flow. 3.0,2 ktv decreased compared with previous measurement. 4.> 10% recirculation using urea method. 5.Prolonged coagulation time or cannulation difficulties in 3 consecutive dialysis sessions.~6.Pathologic physical examination with any other criteria."
3067449|NCT02111655|Experimental|Second generation surveillance of AVF|"In addition to the classical surveillance and monitoring methods, in the experimental group Doppler ultrasound and transonic dilution method will be performed on a quarterly basis.~In addition to the classical alarm criteria and derived from the results in Doppler ultrasound an transonic dilution method the following alarm criteria would also be considered in the experimental group:~25% or higher decreased in QA compared with previous measurement.~QA lower than 500 ml/min.~Stenotic area with a higher than 50% reduction of blood vessel lumen would be considered as alarm criteria only if it comes with a haemodynamic repercussion criteria defined as Peak systolic velocity (PSV) higher than 400 cm/sc, aliasing, or PSV ratio stenosis/pre-stenosis higher than 3."
3067450|NCT02111642|Experimental|Online risk calculator used|Online risk calculator tool for the development of postoperative de novo stress urinary incontinence used during preoperative counseling session.
3067451|NCT02111642|Placebo Comparator|Online risk calculator not used|Online risk calculator tool for the development of postoperative de novo stress urinary incontinence not used during preoperative counseling session.
3067452|NCT02111629|Experimental|Fluconazole and Secnidazole|
3067453|NCT02111616|Active Comparator|Standard of Care (SCP)|Patient will attend a transition visit at the conclusion of cancer treatment. Patient will receive an individualized cancer survivorship care plan based on their cancer type and treatment.
3067454|NCT02111616|Experimental|Intervention Arm (SCP + PCP visit)|"Patient will attend a transition visit at the conclusion of cancer treatment. Patient will receive an individualized cancer survivorship care plan based on their cancer type and treatment.~SCP plus Coordinated PCP Visit: Care coordinators will schedule patient appointment with PCP within 4 weeks of treatment."
3067455|NCT02111603|Other|Colesevelam|1875 mg of Colesevelam orally twice daily for 10 days
3067456|NCT02111590||IVIG to SCIG|Patients with CIDP or MMN in maintenance therapy with IVIG every 3rd to 6th week are shifted to weekly SCIG treatment in unaltered dose.
3067457|NCT02111590||SCIG to SCIG|Patients with CIDP or MMN in maintenance therapy with SCIG (Subcuvia(R) or Hizentra(R)) are shifted to treatment with Gammanorm(R) in unaltered weekly dose.
3067458|NCT02111577|Experimental|DCVAC with Standard of Care Chemotherapy|Combination therapy with Dendritic Cells DCVAC and Standard of Care Chemotherapy (Docetaxel and prednisone)
3067459|NCT02111577|Active Comparator|Standard of Care Chemo and Placebo|Blinded combination therapy of Placebo and Standard of Care Chemotherapy (Docetaxel and prednisone) as Comparator
3067460|NCT02111564|Experimental|Rivaroxaban|Each patient will receive either 10 mg or 7.5 mg rivaroxaban tablet once daily orally (by mouth) for 45 days. The dosing will depend on a creatinine clearance at screening.
3067461|NCT02111564|Placebo Comparator|Placebo|Each patient will receive matching placebo tablet once daily orally (by mouth) for 45 days.
3067462|NCT02111551|Experimental|DMXB-A 75 mg|DMXB-A 75 mg dose followed by a second dose of 37.5 mg at 2 hours to maintain the blood level
3067463|NCT02111551|Experimental|DMXB-A 150 mg|DMXB-A 150 mg followed by a second dose of 75 mg at 2 hours to maintain the blood level
3067464|NCT02111551|Placebo Comparator|Sugar Pill|placebo comparator dose followed by a second placebo dose at 2 hours to maintain blind
3067465|NCT02111538||Amyloidosis|Consecutive adult patients affected by systemic immunoglobulin light-chain (AL) amyloidosis
3067573|NCT02110836|Experimental|Sucrose ingestion|Sucrose ingestion during exercise at a rate of 1.8 g/min.
3067466|NCT02111512|Other|Egg allergic children|Children with a physician diagnosis of egg allergy will be recruited to receive the intranasal LAIV as part of a safety surveillance study
3067467|NCT02111499|Experimental|formulation 1|topical treatment, once daily for 4 weeks
3067468|NCT02111499|Experimental|formulation 2|topical treatment, once daily for 4 weeks
3067469|NCT02111499|Experimental|formulation 3|topical treatment, once daily for 4 weeks
3067470|NCT02111499|Experimental|formulation 4|topical treatment,once daily for 4 weeks
3067471|NCT02111499|Placebo Comparator|formulation 5|topical treatment, once daily for 4 weeks
3067472|NCT02111499|Active Comparator|formulation 6|topical treatment, once daily for 4 weeks
3067473|NCT02111486|Experimental|breakfast #1|breakfast food containing high viscosity fibre
3067474|NCT02111486|Experimental|breakfast #2|breakfast food containing low viscosity fibre
3067475|NCT02111486|Placebo Comparator|Control|breakfast food without viscous fibre
3067476|NCT02111473|Other|testosterone|testosterone 250 mg injection per 3-4 weeks for 6 months
3067477|NCT02111460|Experimental|Radiotherapy|Systemic Chemotherapy Combined with Loco-regional Radiotherapy
3067478|NCT02111460|Active Comparator|Chemotherapy|Chemotherapy alone without Loco-regional Radiotherapy
3067479|NCT02111447|Active Comparator|Sevoflurane, propofol, Nasal oxygen|After securing the IV, sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. A bolus of propofol will not be administered. Oxygen will be delivered via nasal prongs at 2 liters per minute. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min also after 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be administered if the child moves or if signs of light anesthesia are noticed. The propofol infusion may also be increased in response to light anesthesia.
3067480|NCT02111447|Active Comparator|Sevoflurane, Propofol, LMA|After securing the IV, weight appropriate LMA will be inserted and sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. Oxygen in air will be delivered via LMA. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min after another 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be given if the child moves or exhibits signs of light anesthesia. The propofol infusion may also be increased in response to light anesthesia.
3067481|NCT02111447|Active Comparator|Sevoflurane, sevoflurane, LMA|After securing the IV, weight appropriate LMA will be inserted and sevoflurane continued at 3% inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. The sevoflurane may be increased or decreased in 0.5% increments as needed.
3067482|NCT02111447|Active Comparator|Sevoflurane, isoflurane, LMA|After securing the IV, weight appropriate LMA will be inserted , sevoflurane will be discontinued and isoflurane will be administered at 2 % inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. Isoflurane may be increased or decreased in 0.5% increments as needed.
3067483|NCT02111434|Experimental|testosterone|testosterone gel per day for 6 months testosterone 250 mg injection per 3-4 weeks for 6 months
3067484|NCT02111421|Experimental|parturients|Parturients after the umbilical cord was clapped in cesarean section were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points.
3067485|NCT02111421|Experimental|nonpregnant women|Nonpregnant women were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points.
3067486|NCT02111408||Acute stroke|No interventions. Only tests for depression, sleepapnea and autonomic dysfunction.
3067487|NCT02111382|Experimental|CV4 (4th ventricle technique) technique|Will be conduced a real cranial osteopathic medicine technique.
3067488|NCT02111382|Sham Comparator|CV4 sham|This group will received only a sham manual therapy technique.
3067489|NCT02111382|No Intervention|Control|The participants will be in supine position for 5 minutes without any visual or verbal contact.
3067490|NCT02111369|Experimental|Propranolol/Botulinum|After baseline analysis, patient will be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times per day (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile. After second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
3067491|NCT02111356|Experimental|Pinhole glasses|All subjects perform ophthalmic examinations before and after the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
3067492|NCT02111343|Experimental|Computer-based auditory training (CBAT)|The CBAT programmes in the current study were specifically designed to improve speech-in-noise and dichotic listening skills of children diagnosed with CAPD. All the training programmes were designed to be installed on home-user's computer, and they were visually attractive and appealing to children. The development of the software (non commercial) for the speech-in-noise and dichotic listening training was done by two different teams in the United Kingdom and Singapore, respectively.
3067493|NCT02111343|No Intervention|Control|No intervention other than participants' regular school activities
3067494|NCT02111330|Experimental|Dose I - 80 mg PBF-509|one 80 mg PBF-509 capsule
3067495|NCT02111330|Placebo Comparator|Dose I - Placebo|one Placebo capsule
3067496|NCT02111330|Experimental|Dose II - 160 mg PBF-509|Two 80 mg PBF-509 capsule
3067497|NCT02111330|Placebo Comparator|Dose II - Placebo|Two Placebo capsule
3067498|NCT02111330|Experimental|Dose III - 240 mg PBF-509|three 80 mg PBF-509 capsule
3067499|NCT02111330|Placebo Comparator|Dose III - Placebo|Three Placebo capsule
3067500|NCT02111317|Experimental|ASP015K and verapamil|Single dose of ASP015K, then repeat dose of verapamil, then a second single dose of ASP015K while continuing verapamil
3067501|NCT02111304|Active Comparator|Part A (Adults)|In Part A, approximately 170 adult patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 500 mg or placebo TID for up to 3 days
3067637|NCT02110420|Experimental|CC-90001 30mg (Single Dose)|
3067502|NCT02111304|Active Comparator|Part B (Pediatric)|"Following completion of Part A, the data and safety monitoring board (DSMB) will review the unblinded data to assess safety and efficacy and conduct a futility analysis prior to proceeding to Part B.~Following the DSMB recommendation of dose and dosing schedule for pediatric patients, Part B will be initiated. Approximately 156 pediatric patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 or placebo at the recommended dose and dosing regimen."
3067503|NCT02111291|Experimental|SANTYL®|
3067504|NCT02111291|Sham Comparator|Supportive Care|
3067505|NCT02111278|Experimental|lumbar Manipulation|Patients randomized to this treatment group will receive lumbar manipulation during the first 2 physical therapy visits. Patient will receive 4 weeks of physical therapy 2 visits per week.
3067506|NCT02111278|Placebo Comparator|Sham Manipulation|Patients randomized to this treatment group will receive a sham manipulation during the first 2 physical therapy visits. Patient will receive 4 weeks of physical therapy 2 visits per week.
3067507|NCT02111265|Experimental|Propofol|Target controlled infusion propofol, the effect compartment concentration is 3-4μg/ ml for induction and maintenance of anesthesia.
3067508|NCT02111265|Experimental|Etomidate|Target controlled infusion etomidate, the effect compartment concentration is 0.5-1.0μg/ ml for induction and maintenance of anesthesia.
3067509|NCT02111252|Experimental|TAK-850 0.5 mL|A single dose of 0.5 mL TAK-850 (15 µg of hemagglutinin [HA] antigen per strain) is injected into the deltoid muscle.
3067510|NCT02111239|No Intervention|No imaging|No preoperative imaging is performed for this group
3067511|NCT02111239|Experimental|CTA|Patients randomized to this group will undergo a preoperative CTA scan.
3067512|NCT02111239|Experimental|MRA|Patients randomized to this group will undergo a preoperative MRA scan.
3067513|NCT02111226|Active Comparator|Passive SMS Group|Passive SMS messages focused on lifestyle adjustment
3067514|NCT02111226|Experimental|Active SMS Group|Active SMS messages based on hypertension clinical practice guidelines including rational for taking antihypertensive medication and reminders to see the health care practioner if BP is above target.
3067515|NCT02111213|Active Comparator|Promotora for physical activity|Weekly sessions with a volunteer promotora at a community center. A promotora is a trained, lay health worker. The promotora will provide guidance, advice and support to participants to encourage them to be more physically active.
3067516|NCT02111213|Placebo Comparator|Attention-Control (Nutrition Education) Group|Participants will receive periodic, comprehensive health assessments and periodic informational sessions about heart-healthy nutrition (i.e., reducing saturated and trans fats, increasing vegetables and fruit, increasing whole grains). These informational sessions will be in a small group format and will control for the time and attention that the experimental arms will receive.
3067517|NCT02111213|Experimental|Carmen system|Weekly sessions with the virtual advisor accessed through a computer located at a community center. Carmen is the virtual advisor and will provide guidance, advice and support to participants to encourage them to be more physically active.
3067518|NCT02111200|Active Comparator|Sodium Benzoate arm|Sodium benzoate 5.5 g/m2/day divided into three equal doses per day (maximum dose 12 g/day) for 3 days
3067519|NCT02111200|Active Comparator|Sodium Phenylbutyrate arm|Sodium phenylbutyrate 7.15 g/m2/day divided into three equal doses per day (maximum dose of 20 g/day) for 3 days
3067520|NCT02111200|Active Comparator|Mix Arm|Sodium Phenylbutyrate 3.575 g/m2/day and Sodium Benzoate 2.75 g/m2/day will be given in three equal doses per day for 3 days
3067521|NCT02111187|Active Comparator|LDE225 (Arm1)|Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
3067522|NCT02111187|No Intervention|Observation Arm (Arm2)|Observation Arm (Arm2) will receive no treatment prior to prostatectomy.
3067523|NCT02111174|Experimental|Scrambler Therapy|The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
3067524|NCT02111174|Sham Comparator|Sham Therapy|The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas not thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
3067525|NCT02111161|Active Comparator|IVIG (Privigen)|Intravenous polyspecific immunoglobulin G (Privigen). Dosage: 25 g/day (250 ml) for three consecutive days
3067526|NCT02111161|Placebo Comparator|Saline 0.9%|0.9% saline for Intravenous administration. Dosage: 250 ml for three consecutive days.
3067527|NCT02111148|Active Comparator|urea and creatinine|urea and creatinine detected in vaginal fluid wash after injecting of 5 ml saline intavaginally
3067528|NCT02111148|Active Comparator|Nitrazine|Biochemical description of Nitrazine in the vaginal wash
3067529|NCT02111148|Active Comparator|saline|5ml saline will be injected in vagina of each patient in both groups within 24 hours of membrane rupture.
3067530|NCT02111135|Experimental|Group 1|b-OPV, m-IPV HD and m-OPV2
3067531|NCT02111135|Active Comparator|Group 2|b-OPV, t-IPV and m-OPV2
3067532|NCT02111122|Experimental|Sodium Oxybate|"Treatment (500mg Natrii oxybas/ml) will be administered every day at night time for 6 weeks each orally by the patient itself. If necessary, the investigator will make sure that a relative or caregiver is able to assist in daily treatment administration. The dosage starts at 3g per night and is adapted in steps of 1.5g during visits and telephone screenings and always noted in the medication log-book. The maximal dosage is 9g per night."
3067533|NCT02111122|Placebo Comparator|Placebo|"Treatment will be administered every day at night time for 6 weeks each orally by the patient itself. If necessary, the investigator will make sure that a relative or caregiver is able to assist in daily treatment administration. As with the active compound, placebo will be given with a starting dose of 3g per night and is adapted in steps of 1.5g during visits and telephone screenings and always noted in the medication log-book. The maximal dosage is 9g per night."
3067534|NCT02111109||Traumatic injury|
3067535|NCT02111096|Experimental|LY2409021|20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
3067536|NCT02111096|Active Comparator|Sitagliptin|100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
3067537|NCT02111096|Placebo Comparator|Placebo|Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
3067538|NCT02111083|Active Comparator|Insulin Lispro A|Insulin Lispro A 20 units (U) of strength 200 units per milliliter (U/mL) (U-200)administered subcutaneously (SC) once in two of four study periods.(Two doses of test [T]).
3067539|NCT02111083|Experimental|Insulin Lispro B|Insulin Lispro B 20 units (U) of strength 100 U/mL (U-100) administered SC once in two of four study periods.(Two doses of reference [R]).
3067540|NCT02111070|Experimental|ILYANG Inactivated split influenza vaccine|IL-YANG FLU Vaccine Vial INJ 0.5mL by intramuscular injection
3067541|NCT02111057||Perioperative RA|Patients with Rheumatoid Arthritis undergoing a primary or secondary total hip replacement, between the ages of 18 and 75.
3067542|NCT02111044|Active Comparator|Octreotide|Octreotide 100 mcg sc three times daily (t.i.d) for 4 weeks
3067543|NCT02111044|Experimental|ITF2984 500 mcg|ITF2984 500 mcg sc twice a day (b.i.d) for 4 weeks
3067544|NCT02111044|Experimental|ITF2984 1000 mcg|ITF2984 1000 mcg sc b.i.d for 4 weeks
3067545|NCT02111044|Experimental|ITF2984 2000 mcg|ITF2984 2000 mcg sc b.i.d for 4 weeks
3067546|NCT02111031||Case|Patients with documented (histologically/pathologically confirmed) mBC diagnosis, at lease 65 years of age at documented mBC diagnosis, and actively treated by a physician at a participating cancer center who routinely (i.e., test at lease every quarter) use CTC testing (excluding patients who sought consults or second opinions).
3067547|NCT02111018|Active Comparator|CVVH|
3067548|NCT02111018|Experimental|CytoSorb Device|
3067549|NCT02111005||Smoking Aggressive Periodontitis group|This group comprises 20 patients who are smokers and aged < 35 years and diagnosed with rapid attachment loss with periodontal pocket depth (PD) > 4 mm around at least three teeth other than the first molars and incisors. Rapid bone destruction (>50%bone loss at diseased sites). Weak relationship between dental plaque and the severity of gingival inflammation.
3067550|NCT02111005||Smoking Chronic Periodontitis group|This group comprises 20 patients who are smokers and aged > 45 years and have presence of ≥2 non-adjacent sites per quadrant that were not first molars or incisors, with probing depth (PD) ≥5 mm, which bleed on gentle probing. The demonstrated radiographic bone loss ≥30% of the root length, patient with poor oral hygiene, the amount of accumulated plaque commensurate with the amount of clinical attachment level (CAL)
3067551|NCT02111005||Non-smoking Aggressive Periodontitis grp|This group comprises 20 patients who are age- and sex- matched to the 'Smoking Aggressive Periodontitis group' and are non-smokers suffering from aggressive periodontitis.
3067552|NCT02111005||Non-smoking Chronic periodontitis grp|This group comprises 20 patients who are age- and sex-matched to the 'Smoking Chronic Periodontitis group' and are non-smokers suffering from chronic periodontitis.
3067553|NCT02110992|Experimental|Docetaxel + Stereotactic Radiation|Docetaxel 15mg/m2 IV weekly for 3 weeks. SBRT 25-40 Gy in 5 fractions given twice weekly with each treatment separated by > 48 hours.
3067554|NCT02110979|Experimental|PDA|Subjects receive an internet-based patient decision aid video. The PDA is viewed outside of the doctor's office via a personal computer in preparation for regularly scheduled face to face interaction between patients and clinicians.
3067555|NCT02110979|No Intervention|Usual care|Patients receive usual care as determined by their clinician.
3067556|NCT02110966|Experimental|Mepivacaine plus Tramadol|1.3 ml of Mepivacaine 2% epinephrine 1:100000 mixed with 0.5 ml of Tramadol (50mg/ml) will be used for the anesthetic blockade in the experimental group
3067557|NCT02110966|Active Comparator|Mepivacaine|The control group will receive the inferior alveolar nerve block using 1.8 ml of Mepivacaine 2% epinephrine 1: 100000.
3067558|NCT02110953|Experimental|Treatment (irinotecan-eluting beads)|Patients receive irinotecan-eluting beads via hepatic artery embolization every 3 weeks for a total of 2 treatments in the absence of disease progression or unacceptable toxicity. Patients with bi-lobular disease and no evidence of progression in the treated lobe may repeat treatment at the discretion of the treating physician.
3067559|NCT02110940|Active Comparator|Conservative Physiotherapy|Subjects will be referred to the physiotherapy department to receive conventional physiotherapy treatment.
3067560|NCT02110940|Experimental|Neurodynamic mobilization exercise|"The experimental group will be given three neurodynamic mobilization exercises which focus more on lower limbs and the major innervating cutaneous nerves - saphenous nerve, sciatica nerve and femoral nerve.~Subjects will be instructed to practice everyday, each action repeat for 10 times."
3067561|NCT02110927|Experimental|Transcutaneous microcurrent|This group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensitivity threshold and a maximum of 1 milliampere (mA). Every 20 minutes changed from 25 hertz (Hz) to 10 Hz
3067562|NCT02110927|Placebo Comparator|Control group|Control group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, but microcurrent device was switched off.
3067563|NCT02110914|Experimental|Coaching|10 coaching sessions over a period of 6 - 9 months. The intervention is life coaching based on principles of the co-active coaching model.
3067564|NCT02110914|No Intervention|Control|Standard care
3067565|NCT02110901|Active Comparator|PRT-201|PRT-201 administered at the time of radiocephalic fistula creation
3067566|NCT02110901|Placebo Comparator|Placebo|Placebo administered at the time of radiocephalic fistula creation. The placebo is identical in appearance and composition to PRT-201 but lacks the active ingredient.
3067567|NCT02110888|Experimental|SCS + PNS|Mutlticolumn SCS lead + Monocolumn SCS lead
3067568|NCT02110888|Active Comparator|SCS|Mutlticolumn SCS lead
3067569|NCT02110875||CONTROLS|Age- and Gender-Matched Controls
3067570|NCT02110862||Ulcerative colitis patients with ileal-pouch-anal anastomosis|
3067571|NCT02110849||Prostate Cancer Patients|Prostate cancer patients who received proton radiation therapy
3067572|NCT02110836|Active Comparator|Glucose ingestion|Glucose ingestion during exercise at a rate of 1.8 g/min.
3067638|NCT02110420|Experimental|CC-90001 60mg (Single Dose)|
3067574|NCT02110810|Experimental|Indomethacin|100 mg of Indomethacin suppository immediately afterwards while still under sedation
3067575|NCT02110810|Placebo Comparator|2.6-g suppository of glycerin|suppository of 2.4 g of glycerin immediately afterwards while still under sedation
3067576|NCT02110797|Other|RETT patients|
3067577|NCT02110784|Experimental|Eurartesim tablets|Eurartesim 320 mg piperaquine / 40 mg dihydroartemisinin film coated tablets. one or more tablets according to the body weight, once a day dor three consecutive days.
3067578|NCT02110771|Experimental|GAÏA - facial affect recognition targeted|"GAÏA:20hours individual cognitive remediation with therapist, 10 tasks at home, 10 week-treatment cognitive remediation targeted on facial affects recognition. exercises were designed by Gaudelus and Franck (2012) and tutoractiv'company. It includes photos, computer and role games exercises.Computer based exercises have 5 difficulty levels.~2 sessions of one hour per week with therapist.~Tasks at home are given once a week and targeting functional outcomes associated with facial affects recognition impairment."
3067579|NCT02110771|Active Comparator|RECOS - attentional process targeted|"RECOS (Cognitive REmediation for Schizophrenia): 20 hours individual cognitive remediation with therapist, 10 tasks at home, 10 week-treatment.~RECOS is a validated cognitive remediation program, developed by P. Vianin and SBT company. It includes paper and pen and computer based exercises. The original program proposes 5 modules targeting 5 cognitive functions, each patient participated in the module corresponding to his/her most altered cognitive function. In this study, all patients randomized in this arm are allocated in the attentional module.Every computer exercises have 10 difficulty levels.~2 sessions of one hour per week with therapist.~Tasks at home are given once a week and targeting functional outcome"
3067580|NCT02110758||Patient focus groups and observations|Patients diagnosed with cancer who are receiving care at an oncology practice implementing the Patient-Centered Oncology Care model
3067581|NCT02110758||Clinicians and staff|Clinicians and staff employed at an oncology practice implementing the Patient-Centered Oncology Care model
3067582|NCT02110758||Patient survey|Patients with any active treatment for cancer (including radiation, surgery, or drug therapy) receiving care in southeastern Pennsylvania
3067583|NCT02110745|Experimental|Sevofluorane|Sevofluorane 8% in induction
3067584|NCT02110745|Experimental|Propofol|Propofol 2.5 mg/kg intravenous in induction
3067585|NCT02110732|Active Comparator|Lactobacillus rhamnosus GG|Lactobacillus rhamnosus GG 8-9 x 10 -9 pmy 2x2 for 3 weeks
3067586|NCT02110732|Placebo Comparator|Crystalline cellulose|Crystalline cellulose
3067587|NCT02110719|Active Comparator|Standard|"Patients will be given the following:~no preoperative medications~intraoperative medications per anesthesia~postoperatively, patients will receive ibuprofen, tylenol and narcotics as needed"
3067588|NCT02110719|Active Comparator|Multimodal|"Patients in the multimodal arm will receive the following:~preoperative celebrex and gabapentin~intraoperative IV acetaminophen, dexamethasone, zofran~postoperative scheduled IV acetaminophen, PO celebrex and gabapentin, and as needed PO narcotics~patient will be discharged on scheduled ibuprofen and acetaminophen for 3 days followed by as needed use as well as as needed narcotics"
3067589|NCT02110706|Placebo Comparator|Placebo|The placebo group will receive a vehicle control infusion
3067590|NCT02110706|Experimental|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
3067591|NCT02110693|Other|Interviewer and tablet administration|All participants were administered the TAPS Tool via interviewer and tablet computer self-administration in the same session.
3067592|NCT02110680|Active Comparator|TENS 1|TENS at posterior tibial nerve area
3067593|NCT02110680|Sham Comparator|TENS 2|TENS at shoulder area
3067594|NCT02110667||Prostate cancer, post-prostatectomy|
3067595|NCT02110654|Active Comparator|mometasone furoate nasal spray|mometasone furoate nasal spray,200ug qd, 6 months
3067596|NCT02110654|Experimental|mometasone furoate nasal spray combined with montelukast|montelukast tablet,10mg,qd + mometasone furoate nasal spray, 200ug qd,6 months
3067597|NCT02110641|Active Comparator|In-Person or Telephone-Based Counseling|The exact same information, content, schedule, and 30 minute sessions will be provided to telephone-based participants as offered to participants who receive in-person counseling. Participants will be taught diet, exercise and behavior change strategies via the telephone (weekly calls for month 1, every other week for months 2-3, and monthly for months 4-6). All lessons and diet and physical activity logs will be mailed to them at the beginning of the program. Participants will record their daily diet and exercise in the logs.
3067598|NCT02110641|No Intervention|Usual Care/Wait List|At 6-months the participants in the Wait List group may choose to participate in the 11 sessions either in-person or via telephone or a combination of the two modes of delivery. They will also be offered the opportunity to return to Yale at 12-months (immediately after the end of the 6-month counseling sessions) to have weight and DEXA measured.
3067599|NCT02110628|Experimental|Roux-en-Y+Pouch Group|Abdominal approach D2 total gastrectomy with Roux-en-Y+Pouch anastomosis. Roux-en-Y+Pouch anastomosis: closed the stump of duodenum, cut off the jejunum from the 20cm of Treitz ligament, pouch reconstruction a J pouch with a length of 15 cm was constructed by connecting the 2 Jejunal lumina, œsophago-P type jejunum Storage bag anastomosis (duct-to-duct / duct-to-duct, before the colon/after the colon), jejunum - jejunum anastomosis (duct-to-duct / duct-to-duct), the distance between anastomotic were 40cm-60cm.
3067600|NCT02110628|Experimental|Roux-en-Y group|Abdominal approach D2 total gastrectomy with Roux-en-Y anastomosis. Roux-en-Y anastomosis : closed the stump of duodenum, cut off the jejunum from the 20cm of Treitz ligament, œsophago-jejunal anastomosis (duct-to-duct / duct-to-duct, before the colon/after the colon), jejunum - jejunum anastomosis (duct-to-duct / duct-to-duct), the distance between anastomotic were 40cm-60cm
3067601|NCT02110615|Experimental|Primary Care Practice Changes|The clinical intervention components included (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. Healthy Weight Clinics (HWC); (4) integrating community health workers into the primary care and HWC teams; and (5) health center environmental changes to support behavior change modification.
3067639|NCT02110420|Experimental|CC-90001 120mg (Single Dose)|
3067640|NCT02110420|Experimental|CC-90001 240mg (Single Dose)|
3067602|NCT02110602|Experimental|Initial Diet - high in amino acid levels|"Visit 1 (Day 1): Screening Visit~Visit 2 (14-21 days after Visit 1): Begin high amino acid diet~Visit 3 (4 days after Visit 2): Completion of high amino acid diet~Visit 4 (3 days after Visit 3): Begin low amino acid diet~Visit 5 (4 days after Visit 4): Completion of low amino acid diet, completion of study"
3067603|NCT02110602|Experimental|Initial Diet - low in amino acid levels|"Visit 1 (Day 1): Screening Visit~Visit 2 (14-21 days after Visit 1): Begin low amino acid diet~Visit 3 (4 days after Visit 2): Completion of low amino acid diet~Visit 4 (3 days after Visit 3): Begin high amino acid diet~Visit 5 (4 days after Visit 4): Completion of high amino acid diet, completion of study"
3067604|NCT02110589|Experimental|Patient Group 1|"Testing of Epidetect:~Adult Patients with difficult to control tonic-clonic (convulsant) epilepsy undergoing hospitalised video telemetry monitoring. Patients will be hospitalised as part of their normal investigation of the epilepsy and patients will be consented 1 week before hospitalisation. Epidetect will be used in conjunction with the normal EEG monotoring and video telemetry. The patient will be fitted with the topical sensors at the start of monotoring and then depending on the seizure activity will wear the sensors until enough data is gathered. Hospitalisation under these circumstances typically lasts no more than five days, so monitoring with the topical sensor will be no longer than this."
3067605|NCT02110589|Experimental|Patient Group 2|"Testing of Epidetect:~Paediatric patients (over 7 years) where parental consent will enable the epilepsy monitor to be used at home for 1 week and brought back in for analysis along with video evidence. This will not constitute any change in normal care or treatments, and the video evidence provided represents enhanced care through accurate seizure diary reporting. Suitable families and children will be selected and consented through scheduled clinics in paediatric neurology."
3067606|NCT02110589|Experimental|Patient group 3|"Testing of Epidetect:~Patients where the epilepsy is suspected to be psychogenic (pseudo-seizures) rather than organic epilepsy. We will test whether the epilepsy monitor will be able to differentiate between epilepsy and psychogenic seizures in the medical setting when patients are hospitlised for seizure investigation. Suitable patients will be selected and consented through scheduled clinics in paediatric neurology (under 16) and adult neurology."
3067607|NCT02110589|Experimental|Patient Group 4|"Testing of Epidetect:~Internal negative Controls. Juveniles or adults with other forms of epilepsy that do not have a hypertonic (increased muscle stiffening) phenotype e.g. absence seizures."
3067608|NCT02110589|Other|Control Group 1|"Testing of Epidetect:~Volunteers who do not have a history of seizures / epielsy, head trauma, migraine, neurological or muscular-skeletal disorders. This is to produce the baseline data for the Monitor."
3067609|NCT02110576||Healthy Controls|Healthy controls in general good health, without chronic disease/illness, including but not limited to: cancer, diabetes mellitus, renal disease, cardiac disease, hypertension, lung disease, liver disease, complications of morbid obesity, autoimmune/inflammatory disease, or any condition of sufficient severity that it requires daily medication to manage
3067610|NCT02110563|Experimental|DCR-MYC|Patient groups (cohorts) will receive a single dose level of DCR-MYC; the dose level of DCR-MYC will be increased in subsequent cohorts
3067611|NCT02110550|No Intervention|IPS.emmax crown|
3067612|NCT02110550|Experimental|IPS.emmax endocrown|Patients with excessively undermined and endodontically treated molars will receive the IPS.emmax endocrown as the restoration of choice.
3067613|NCT02110537|Experimental|Active Acupuncture + flecainide|The participants in this group receive verum acupuncture treatment once a week for 10 weeks and flecainide 75 mg twice daily.
3067614|NCT02110537|Sham Comparator|Sham acupuncture + flecainide|The participants in this group receive sham acupuncture treatment once a week for 10 weeks and flecainide 75 mg twice daily.
3067615|NCT02110524|Experimental|CVI Drug Coated Balloon|
3067616|NCT02110511|Experimental|alpha-gal & blended lentils|3 capsules of alpha-gal taken with blended lentils
3067617|NCT02110511|Experimental|alpha-gal & whole lentils|3 calpsules of alpha-gal taken with whole lentils
3067618|NCT02110511|Experimental|alpha-gal & no lentils|3 capsules of alpha-gal taken with no lentils control
3067619|NCT02110511|Placebo Comparator|Placebo & blended lentils|3 capsules of placebo taken with blended lentils
3067620|NCT02110511|Placebo Comparator|Placebo & whole lentils|3 capsules of placebo taken with whole lentils
3067621|NCT02110511|Placebo Comparator|Placebo & no lentils|3 capsules of placebo taken with no lentils control
3067622|NCT02110485|Experimental|Patient Activation Tool|Patients and their caregivers will receive the patient activation tool in addition to standard consultation
3067623|NCT02110485|No Intervention|Standard Consultation|Patients and their caregivers will receive standard consultation alone
3067624|NCT02110472|Other|Presbia Flexivue Microlens Corneal Inlay|Presbia Flexivue Microlens implanted in corneal pocket in nondominant eye
3067625|NCT02110459|Experimental|Mild renal impairment|3h IV POL7080 infusion
3067626|NCT02110459|Experimental|Moderate renal impairment|3h IV POL7080 infusion
3067627|NCT02110459|Experimental|Severe renal impairment|3h IV POL7080 infusion
3067628|NCT02110459|Experimental|End stage renal disease arm 1|3h IV POL7080 infusion
3067629|NCT02110459|Experimental|End stage renal disease arm 2|3h IV POL7080 infusion
3067630|NCT02110459|Experimental|Normal Renal function|3h IV POL7080 infusion
3067631|NCT02110446|Experimental|SS-1|SS-1 is composed of the powder of Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. Patients take 6 gram of experiment medicine three times per day.
3067632|NCT02110446|Placebo Comparator|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
3067633|NCT02110433|Other|Placebo group|Patients will be managed per consensus guidelines Clinicians could see the patients as many times as necessary in order to optimize their therapy and could make BNP measurement (but not using Home BNP monitoring)
3067634|NCT02110433|Experimental|Cordiva System (R)|Patient will see their cardiologist every three months and benefit from telemonitoring of their weight and general well being through a specific communicant device.
3067635|NCT02110433|Active Comparator|BNP and Cordiva (R) monitoring system|In this group, patients and doctors have access to the platform detailed above (Cordiva (R) monitoring system) and had also access to BNP home monitoring (BNP heartcheck).
3067636|NCT02110420|Experimental|CC-90001 10mg (Single Dose)|
3067647|NCT02110420|Experimental|CC-90001 480mg (single dose)|CC-90001 480mg will be administered as a single oral dose
3067648|NCT02110420|Experimental|CC-90001 720mg (single dose)|CC-90001 720mg will be administered as a single oral dose
3067649|NCT02110420|Experimental|CC-90001 480mg (multiple doses)|CC-90001 480mg will be administered daily for 14 days
3067650|NCT02110407|Sham Comparator|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
3067651|NCT02110407|Experimental|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with transcranial direct current stimulation (tDCS)
3067652|NCT02110394||bendamustine and rituximab|
3067653|NCT02110381|Active Comparator|Device Guided Breathing/Combination Therapy|Participants will first do device guided breathing for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.
3067654|NCT02110381|Active Comparator|Isometric Hand Grip/Combination Therapy|Participants will first do isometric hand grip exercises for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.
3067655|NCT02110368|Active Comparator|AndroGel|AndroGel (testosterone gel) 1.62% Metered-Dose Pump. One actuation 20.25 mg
3067656|NCT02110368|Experimental|Testosterone Gel|Testosterone Topical Gel, 1.62% Metered Pump. One actuation of 20.25 mg.
3067657|NCT02110355|Experimental|AMG 232 with Trametinib and Dabrabenib|Arm 1 of Part 1 and 2 and Part 3
3067658|NCT02110355|Experimental|AMG 232 with Trametinib|Arm 2 of Part 1 and 2
3067659|NCT02110355|Active Comparator|Trametinib and Dabrafenib|Part 3
3067660|NCT02110342|Experimental|Treatment|
3067661|NCT02110329|No Intervention|stage II-III colon cancer treated with surgery|stage II-III colon cancer treated with surgery
3067662|NCT02110316|Other|Bioavailability|1 arm, different dosage form
3067663|NCT02110303|Experimental|18F-F Positive - Ticagrelor|Ticagrelor oral tablets, one (90mg) tablet, twice daily, 12 month duration
3067664|NCT02110303|Placebo Comparator|18F-F Positive - Placebo|Identical placebo, one tablet, twice daily, 12 month duration
3067665|NCT02110303|Experimental|18F-F Negative - Ticagrelor|Ticagrelor oral tablets, one (90mg) tablet, twice daily, 12 month duration
3067666|NCT02110303|Placebo Comparator|18F-F Negative - Placebo|Identical placebo, one tablet, twice daily, 12 month duration
3067667|NCT02110290||Children with Physical Disabilities|This group includes children 8-18 years old participating in an adapted ski/snowboarding program with any type of physical disability, including cerebral palsy, traumatic brain injury, spinal cord injury, and amputation.
3067668|NCT02110277|Experimental|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
3067669|NCT02110264|Experimental|Vivitrol (XR-NTX)|50 participants will be randomized to the long-acting naltrexone condition (XR-NTX) which will include monthly injections of study drug.
3067670|NCT02110264|Experimental|XR-NTX+PN|50 participants will be randomized to receive long-acting naltrexone (XR-NTX) and will be assigned to a patient navigator (PN).
3067671|NCT02110264|Active Comparator|ETAU|50 participants will be randomized to the drug-education/treatment-as-usual group.
3067672|NCT02110251|Experimental|Supervised exercise therapy|Adequacy of initial therapy, Investigation degree of confusion and dementia, Preoperative preparation, Life-style coaching, Supervised Exercise therapy.
3067673|NCT02110251|No Intervention|Walking advice|Standard care and a oral walking advice.
3067674|NCT02110238|Active Comparator|Euflexxa|Euflexxa® (hyaluronic acid of bacterial origin)
3067675|NCT02110238|Experimental|Supartz|SUPARTZ® (hyaluronic acid of avian origin)
3067676|NCT02110225|Experimental|rhNGF 60µg/ml|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
3067677|NCT02110225|Experimental|rhNGF 180 µg/ml|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes.
3067678|NCT02110225|Placebo Comparator|Vehicle|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes.
3067679|NCT02110212|Active Comparator|U/S Surgery and CCC|Ultrasound (U/S) cataract surgery and continuous curvilinear capsulorhexis (CCC).
3067680|NCT02110212|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the femtosecond laser device.
3067681|NCT02110186|Experimental|Discectomy and dynamic stabilization|Discectomy with posterior dynamic stabilization
3067682|NCT02110186|Active Comparator|Discectomy alone|Discectomy
3067683|NCT02110186|Active Comparator|Discectomy and fusion|Discectomy with internal fixation and fusion
3067684|NCT02110160||patients with bone dominant metastatic ER+ breast cancer|
3067685|NCT02110147|Experimental|Uridine Triacetate to Replace Uridine|Replacement therapy for oral uridine with oral administration of uridine triacetate in patients with hereditary orotic aciduria who have received (or would reasonably be expected to receive) clinical benefit from treatment with exogenous uridine. The starting dose of uridine triacetate will be 60 mg/kg/day which may be escalated to 300 mg/kg/day of oral uridine triacetate. The dose may be given once a day or as equally divided doses twice a day.
3067686|NCT02110134|Experimental|Revlite Laser System|Revlite Laser System for the Treatment of Melasma
3067687|NCT02110121|Experimental|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
3067688|NCT02110121|Experimental|Revlite Laser System|Revlite Laser System for the Treatment of Unwanted Tattoos
3067689|NCT02110108|Experimental|Revlite Laser System|Revlite Laser System
3067690|NCT02110095|Experimental|Picosure Laser System|Picosure Laser System for the treatment of unwanted tattoos
3067691|NCT02110082|Experimental|Cohort 1: Urelumab + Cetuximab|Urelumab every 3 weeks with Cetuximab weekly through Intravenous infusion
3067692|NCT02110082|Experimental|Cohort 2: Urelumab + Cetuximab|Urelumab every 3 weeks with Cetuximab weekly through Intravenous infusion
3067693|NCT02110069|Active Comparator|Vincristine|"Induction phase: participants assigned to vincristine will receive vincristine weekly at a dose of 0.05mg/kg/dose IV (for participants less than 10kg) or a dose of 1.5 mg/m2/dose (for participants greater than 10kg) for 2 months.~Maintenance: if participants continue to receive vincristine weekly for 2 months, every 2 weeks for 5 months and every 3 weeks for 5 months."
3067694|NCT02110069|Experimental|Sirolimus|"Sirolimus will be administered at a dose of 0.8mg/m2/dose twice a day on a continuous dosing schedule throughout the trial for participants randomized to Sirolimus or for participants who fail vincristine may cross-over to the sirolimus arm.~Sirolimus trough levels will be maintained between 10-15 ng/ml."
3067695|NCT02110056|Experimental|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with transcranial direct current stimulation (tDCS)
3067696|NCT02110056|Sham Comparator|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
3067697|NCT02110043|Experimental|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with anodal transcranial direct current stimulation (tDCS)
3067698|NCT02110043|Sham Comparator|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
3067699|NCT02110030|Experimental|Transcutaneous nerve stimulation|"The group with transcutaneous nerve stimulation (TENS) received electrical stimulation for 15 sessions at a frequency of 80 Hz and with a pulse width of 150 ns.~The group with TENS received electrical stimulation by using an approved electrotherapy device (Endomed 182, Enraf-nonius, Germany). The TENS was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: supraspinatus fossa and the insertion of the rotator cuff (channel 1) and V deltoid  (channel 2)."
3067700|NCT02110030|Active Comparator|Interferential Currents|The group with Interferential Currents (IC) received a base frequency of 4000 Hz by using the same approved electrotherapy device than the TENS group (Endomed 182, Enraf-nonius, Germany).
3067701|NCT02110017|Other|Patients with schizophrenia|"Twenty patients suffering from schizophrenia (DSM-IV-R), with medication and medical care. No recent relapse of the psychotic disease, nor change in medications.~No neurological comorbidity.~After anatomic scans, each subject will go through the fMRI social cognition task."
3067702|NCT02110017|Other|Healthy subjects|"Twenty healthy subjects (no mental or neurological disease)~After anatomic scans, each subject will go through the fMRI social cognition task."
3067703|NCT02110004|Other|Ablation procedure|Collect intra-cardiac signals
3067704|NCT02109991|Experimental|CG-100 device|
3067705|NCT02109978||Responders|Patients with Type 2 diabetes that have been taking a second- or third-line glucose-lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R agonists, SGLT2 inhibitors, Glitazone or insulin) for at least 4 months.
3067706|NCT02109978||Progressors|Patients with Type 2 diabetes that progressed to requiring insulin treatment ≤10 years from diagnosis or have had no requirement for insulin treatment >10 years from diagnosis.
3067707|NCT02109965|Active Comparator|Control|Use midazolam or propofol for sedation
3067708|NCT02109965|Experimental|Dexmedetomidine|Use dexmedetomidine for sedation
3067709|NCT02109939|Active Comparator|GeneSight Psychotropic Tested|Subjects being tested with GeneSight Psychotropic
3067710|NCT02109939|Placebo Comparator|Treatment As Usual|This group of subjects will not see their GeneSIght results or know whether or not they are in either arm.
3067711|NCT02109926||Cases: testicular cancer patients|
3067712|NCT02109926||Group A controls|Sperm donors and husbands of women with fertility disorders All controls must have a normal spermogram
3067713|NCT02109926||Group B controls|Husbands of women with a pathological pregnancy
3067714|NCT02109913|Other|Everolimus plus exemestane|Biomarker study in patients receiving standard treatment
3067715|NCT02109900||Serum Progesteron Levels|
3067716|NCT02109887||PCP with true CMV co-infection|
3067717|NCT02109887||PCP with innocent bystander CMV|
3067718|NCT02109887||PCP without any evidence of CMV|
3067719|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 5/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
3067720|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 15/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
3067721|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 50/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
3067722|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 150/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
3067723|NCT02109874|Placebo Comparator|Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl|Placebo: Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl. This is the identical buffer solution in which IC31 is formulated.
3067724|NCT02109861|Experimental|Melphalan|A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan
3067725|NCT02109861|Experimental|Bortezomib|A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib
3067726|NCT02109861|Experimental|Dexamethasone|A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
3067727|NCT02109848||keratoconus|
3067728|NCT02109848||post-keratoplasty|
3067729|NCT02109848||post-DSAEK|Descemet's stripping automated endothelial keratoplasty (DSAEK)
3067730|NCT02109835||Asymptomatic type 2 diabetes|Patients without previous history of coronary artery disease
3067731|NCT02109822||CF patients with pulmonary exacerbations|Patients with CF who are hospitalized with a pulmonary exacerbation treated with intravenous antibiotics.
3067732|NCT02109809|Experimental|Supportive Care (TLI)|Patients undergo LD-TLI daily for 1-2 days.
3067733|NCT02109796|Experimental|hemiplegic patient|anodal transcranial direct current stimulation
3067734|NCT02109796|Sham Comparator|patient control|Sham transcranial direct current stimulation
3067735|NCT02109783|Active Comparator|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
3067736|NCT02109783|Active Comparator|Caffeine 2 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
3067737|NCT02109783|Placebo Comparator|Caffeine 0 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
3067738|NCT02109770||Mother child diads or triads|Families with child affected by genetic anomaly, microdeletion, microduplication, or chromosomal anomaly
3067739|NCT02109757|Experimental|Software intervention and education|This group will receive software intervention and education before and after receiving one-on-one education, thus showing if benefit or effect occurs simply due to having the software input before receiving education.
3067740|NCT02109757|Active Comparator|Education only|This group will not receive software intervention prior to and after one-on-one education, only afterwards.
3067741|NCT02109744|Experimental|A|Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Rapamycin 6mg (loading dose) will be administered on day 6; thereafter 2 mg/day on days 11-22 in cycle 1 and on days 6-22 in subsequent cycles. (Arm A: for patients with non-morphologic M4/M5 subtypes).
3067742|NCT02109744|Experimental|B|Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Ribavirin will be dosed from day 11-day 28 beginning with dose level 1 (1000mg orally twice daily). Number of patients with Dose Limiting Toxicities (DLT) at a given dose level is 0 of out of 3: enter 3 patients at the next dose level (dose Level 2- 1200mg orally twice daily; and then dose Level 3-1400 mg orally twice daily).(Arm B: For patients with morphologic M4/M5 subtypes).
3067743|NCT02109731|Experimental|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
3067744|NCT02109718|Experimental|Open Dressings with Petrolatum Jelly|participants randomized to this arm had their wounds dressed with Open Dressing with Petrolatum Jelly
3067745|NCT02109718|Active Comparator|Silver Sulfadiazine Gauze Dressing Group|Participants randomized to this arm had their wounds dressed with Silver Sulfadiazine Gauze Dressing.
3067746|NCT02109705||Alzheimer`s Disease|
3067747|NCT02109705||other Dementia|
3067748|NCT02109705||cognitive healthy|
3067749|NCT02109692|Other|cohort|blood sample : doage of miRNA
3067750|NCT02109679|Experimental|Treatment A|multiple doses BI 187004
3067751|NCT02109679|Experimental|Treatment B|multiple doses BI 187004 + multiple doses metformin
3067752|NCT02109679|Experimental|Treatment C|multiple doses metformin
3067753|NCT02109666||RA patients treated with Abatacept|RA patients are treated with Abatacept IV according Summary of Product Characteristics (SmPC) in Europe and Product Monograph in Canada
3067754|NCT02109653|Experimental|LGX818|Adult patients, with confirmed diagnosis of BRAF V600E mutant advanced or metastatic NSCLC who have progressed on or after at least one prior systemic anticancer therapy.
3067755|NCT02109640|Experimental|Targinact|Oral Targinact 10-20mg bd following laparoscopic segmental colectomy
3067756|NCT02109640|Active Comparator|Oxycodone|Oral oxycodone 10-20mg bd following laparoscopic segmental colectomy
3067757|NCT02109627|Experimental|Ficlatuzumab, Cytarabine|"Ficlatuzumab 5-20 mg/kg; intravenous; Days 0, 14, 28, 42; Number of cycles: until progression or unacceptable toxicity develops.~Cytarabine 2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops."
3067758|NCT02109614|Experimental|Extended release Niacin|Taking 1500-2000mg niacin daily
3067759|NCT02109614|Placebo Comparator|No Naicin|Placebo Comparator arm will be taking 1500mg of placebo daily
3067760|NCT02109601|Active Comparator|Control|Control patients receive iPad tablets during their hospital stay with only LIMITED bedside training from a research assistant on how to access and effectively use their patient portal.
3067761|NCT02109601|Experimental|Intervention|Intervention patient receive iPad tablets during their hospital stay with EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
3067762|NCT02109588|No Intervention|Control|Sedentary pregnant women
3067763|NCT02109588|Experimental|Exercise group|"Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate"
3067764|NCT02109575||Heart Transplant Recipients|Up to 10 cc of blood will be drawn from heart transplant recipients at various time points prior to and after transplant. Blood draw is the only research activity that study participants will undergo. In addition to blood draw, data will be collected from clinical records representing the participant's transplant course such as the medical record, imaging, and biopsy slides with pathology reports.
3067765|NCT02109562|Experimental|RBP-7000 90 mg|Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 90 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
3067766|NCT02109562|Experimental|RBP-7000 120 mg|Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 120 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
3067874|NCT02108847|Sham Comparator|Fascia Iliaca Block - Saline|Ultrasound guided fascia iliaca block performed preoperatively with 40 mL of Saline.
3067767|NCT02109562|Placebo Comparator|Placebo|Risperidone tablets given during the screening period to check for sensitivity. Placebo administered by subcutaneous injection on Days 1 and 29 for a total of two injections.
3067768|NCT02109549||Diabetes and metformin|Patients with diabetes mellitus treated with metformin only.
3067769|NCT02109549||Insulin-diabetes without metformin|Patients with insulin-dependent diabetes mellitus not treated with metformin
3067770|NCT02109549||Controlgroup|The remaining patients serve as control group.
3067771|NCT02109536||Staff Gastroenterologists.|Staff Gastroenterologists ability to recognize loops will be assessed using an magnetic endoscopic imager.
3067772|NCT02109523|Experimental|Intervention|Patients enrolled in the intervention arm will receive two educational sessions on the importance of medication and barriers to adherence
3067773|NCT02109523|Active Comparator|Usual Care|The usual care group received routine discharge counseling performed by the cardiologists and nurses.
3067774|NCT02109510|Experimental|Nonintubated sedation anesthesia|nonintubated single port thoracoscopic bullectomy using local anesthesia under sedation Drug: Dexmedetomidine IV loading dose of 1ug/kg for 10 minutes and maintain dosage of 0.3-1 ug/kg/hr, ketamine IV 2-4 mg/kg/hr and intercostal nerve block with 2% lidocaine 2cc Device: facial O2 Mask
3067775|NCT02109510|Active Comparator|Intubated general anesthesia|intubated single port thoracoscopic bullectomy under general anesthesia Drug: propofol 2mg/kg IV , rocuronium 0.6mg/kg IV,1.2-2.4% sevoflurane, N20 50% 02 at fresh gas flow of 4L/min Device: double lumen endotracheal tube intubation
3067776|NCT02109497|Other|Caffeine Dosing|Single dose of caffeine 100 mg administered
3067777|NCT02109484|Experimental|Cohort A P2-VP8 30 mcg|Cohort A toddlers (24-35 mo) receiving P2-VP8 Subunit Vaccine (30 mcg)
3067778|NCT02109484|Placebo Comparator|Cohort A Placebo|Cohort A toddlers (24-35 mo)
3067779|NCT02109484|Experimental|Cohort A P2-VP8 60 mcg|Cohort A toddlers (24-35 mo) receiving high dose P2-VP8 Subunit Vaccine (60mcg)
3067780|NCT02109484|Experimental|Cohort B P2-VP8 10mcg|Cohort B infants receiving P2-VP8 Subunit Vaccine (10mcg)
3067781|NCT02109484|Placebo Comparator|Cohort B placebo|Cohort B infants aged 6 to < 8 weeks receiving placebo
3067782|NCT02109484|Experimental|Cohort B P2-VP8 30mcg|Cohort B infants aged 6 to < 8 weeks receiving P2-VP8 Subunit Vaccine (30mcg)
3067783|NCT02109484|Experimental|Cohort B1 P2-VP8 60mcg|Cohort B1 Infants aged 6 to < 8 weeks receiving P2-VP8 Subunit Vaccine (60mcg)
3067784|NCT02109484|Experimental|Cohort A P2-VP8 10mcg|Cohort A toddlers (24-35 mo) receiving P2VP8 Subunit Vaccine (10mcg)
3067785|NCT02109471||corneal opacities|
3067786|NCT02109458|Experimental|Assessing peripheral pulmonary nodules|To evaluate the feasibility and safety of a procedure path including convex Endobronchial Ultrasound (EBUS) lymph node sampling, navigation guided bronchoscopy (NB) and navigation guided transthoracic needle aspiration (N-TTNA).
3067787|NCT02109445|Experimental|Phase 1|PF-03084014 in combination with gemcitabine and nab-paclitaxel
3067788|NCT02109445|Experimental|Phase 2 Arm A|PF-03084014 in combination with gemcitabine and nab-paclitaxel
3067789|NCT02109445|Active Comparator|Phase 2 Arm B|Gemcitabine plus nab-Paclitaxel
3067790|NCT02109432|Other|Pedal Desk|"Participants will complete three 2-week conditions in the following order:~Self-directed Pedal Desk~Facilitated Pedal Desk~Facilitated Pedal Desk with Pedometer"
3067791|NCT02109419||Control|Mini Mental State Exam (MMSE) score 29-30; inclusive
3067792|NCT02109419||Mild Cognitive Impairment|MMSE score 25-28; inclusive
3067793|NCT02109419||Dementia|MMSE score 10-24; inclusive
3067794|NCT02109406|Experimental|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
3067795|NCT02109406|Experimental|AZD 2115 Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
3067796|NCT02109406|Placebo Comparator|Placebo MDI|Placebo MDI administered as two inhalations BID
3067797|NCT02109393|Experimental|MIRT group|"This group underwent a 4-weeks MIRT exploiting the use of a treadmill-plus (treadmill associated with visual cues and auditory feedbacks).~Inclusion criteria: a) diagnosis of idiopathic PSP in accordance to the NINDS-SPSP International Criteria (Litvan et al., 1996), b) age between 55 and 85 c) ability to walk unassisted for at least 6 meters, d) stable dopaminergic drugs dosage in the month preceding the admission to the study. Exclusion criteria: a) any others significant neurological or orthopedic disorders, b) osteoarthritis, osteoporosis, cutaneous lesions and/or other pressure wounds, c) body weight exceeding 135 kg (the weight limit for the use of Lokomat®), respiratory and cardiovascular diseases."
3067798|NCT02109393|Experimental|MIRT+Lokomat group|"This group underwent a 4-weeks MIRT involving the use of Lokomat® for 5 days per week in spite of treadmill-plus.~Inclusion criteria: a) diagnosis of idiopathic PSP in accordance to the NINDS-SPSP International Criteria (Litvan et al., 1996), b) age between 55 and 85 c) ability to walk unassisted for at least 6 meters, d) stable dopaminergic drugs dosage in the month preceding the admission to the study. Exclusion criteria: a) any others significant neurological or orthopedic disorders, b) osteoarthritis, osteoporosis, cutaneous lesions and/or other pressure wounds, c) body weight exceeding 135 kg (the weight limit for the use of Lokomat®), respiratory and cardiovascular diseases."
3067799|NCT02109380|Experimental|Bed rest|One week of bed rest.
3067800|NCT02109367||Pelvic mass|Women with pelvic masses undergoing surgical excision
3067801|NCT02109354|Active Comparator|HIV Regimen + Tetanus and HBV Vaccines|Participants will receive a tetanus vaccine injection (tetanus toxoid vaccine), followed by 2 injection of an experimental canarypox HIV vaccine (ALVAC-HIV; months 1, 2), than 2 injection of a protein HIV vaccine boost (AIDSVAX B/E; months 4, 7), followed by a hepatitis B vaccine series (months 7.5, 8.5, 13)
3067802|NCT02109354|Active Comparator|HIV Vaccine Regimen|Participants will receive a placebo for tetanus vaccine by injection (placebo tetanus toxoid vaccine), followed by 2 injection of an experimental canarypox HIV vaccine (ALVAC-HIV; months 1, 2), than 2 injection of a protein HIV vaccine boost (AIDSVAX B/E; months 4, 7), followed by a placebo for hepatitis B vaccine series (months 7.5, 8.5, 13)
3067803|NCT02109354|Placebo Comparator|Tetanus and HBV Vaccines|Participants will receive a tetanus vaccine injection (tetanus toxoid vaccine), followed by 2 injection of a placebo for the experimental canarypox HIV vaccine (placebo for ALVAC-HIV; months 1, 2), than 2 injection of a placebo protein HIV vaccine boost (placebo for AIDSVAX B/E; months 4, 7), followed by a hepatitis B vaccine series (months 7.5, 8.5, 13)
3067875|NCT02108834|Active Comparator|nerve block|cervical plexus block with ropivacaine
3067804|NCT02109341|Experimental|Nab-FOLFIRI|"In the phase I study, all pts enrolled in this arm will receive Nab-FOLFIRI: Irinotecan, 180 mg per square meter of body surface area (m2 ) + Leucovorin, 400 mg/m2 and 5-Fluorouracil, 400 mg/m2 given as a bolus followed by 2400 mg/m2 given as a 46-hour continuous infusion, plus Nab-p per cohort escalation assignment starting with 90 mg/m2 every 2 weeks. Pts continued treatment until a total of 12 administrations, disease progression or unacceptable toxicity.~Pts enrolled in arm A for phase II will receive the dose of Nab-FOLFIRI as determined in the Phase I and in the same sequence."
3067805|NCT02109341|Experimental|Nab-FOLFOX|"In the phase I study, all pts enrolled in this arm will receive Nab-FOLFOX: Oxaliplatin 85 mg/m2 +Leucovorin, 400 mg/m2 and 5-Fluorouracil, 400 mg/m2 given as a bolus followed by 2400 mg/m2 given as a 46-hour continuous infusion, plus Nab-p per cohort escalation assignment starting with 90 mg/m2, every 2 weeks.~Pts continued treatment until a total of 12 administrations, disease progression or unacceptable toxicity.~Pts enrolled in arm B for phase II will receive the dose of Nab-FOLFOX as determined in the Phase I and in the same sequence"
3067806|NCT02109328|Experimental|Alisertib + Paclitaxel|After the first single arm phase with Alisertib monotherapy (20 patients, primary endpoint: response-rate), 110 patients will be randomized 1:1 in the second part of the trial.
3067807|NCT02109328|Placebo Comparator|Paclitaxel + Placebo|Weekly paclitaxel + oral Placebo
3067808|NCT02109315|Experimental|Liraglutide endovenous 6 mg|Liraglutide endovenous de 0.6 mg. one time a day
3067809|NCT02109315|Experimental|Vitamine C|C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
3067810|NCT02109289|Experimental|Methotrexate and Etanercept|Patients already taking Methotrexate prior to the study will continue taking 15 mg weekly and start Etanercept 50 mg every week for 16 weeks
3067811|NCT02109276|Active Comparator|Spheric Sensar(R) 3-piece IOL|This group of patients with Fuchs endothelial dystrophy and cataract will undergo cataract extraction and be randomized to receive a Spheric Sensar(R) 3-piece IOL
3067812|NCT02109276|Experimental|Aspheric Tecnis(R) 3-piece IOL|This group of patients with Fuchs endothelial dystrophy and cataract will undergo cataract extraction and be randomized to receive an Aspheric Tecnis(R) 3-piece IOL
3067813|NCT02109263|Experimental|saccharose|20% saccharose
3067814|NCT02109263|Placebo Comparator|breast-feeding|breast-feeding
3067815|NCT02109250||all Belgian patients treated with Caprelsa® (vandetanib)|It is planned to include all Belgian patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who have been prescribed Caprelsa® (vandetanib).
3067816|NCT02109237|Experimental|Bronchiolitis Obliterans 2 & 3|Assessment of sleep disorders and treatment if required
3067817|NCT02109237|Active Comparator|Bronchiolitis Obliterans 0|Assessment of sleep disorders and treatment if required
3067818|NCT02109224|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3067819|NCT02109211|Other|Standard care - Magill forceps|Patients will be intubated, as per standard care, with Magill forceps.
3067820|NCT02109211|Experimental|Altered Magill forceps|Patients will be intubated with modified Magill forceps.
3067821|NCT02109198|Experimental|Active CN-NINM PoNS|Active CN-NINM PoNS - Active cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
3067822|NCT02109198|Placebo Comparator|Sham PoNS CN-NINM|Sham CN-NINM PoNS - Sham cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
3067823|NCT02109185|Active Comparator|Mometasone Furoate Monohydrate Nasal Spray,50 μg/act.|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Mometasone Furoate Monohydrate Nasal Spray per nostril once daily for 14 days. Total Daily Dose = 4 × 50 μg = 200 μg.
3067824|NCT02109185|Active Comparator|Nasonex® Nasal Spray, 50 μg/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Nasonex® Nasal Spray per nostril once daily for 14 days, Total Daily Dose = 4 × 50 μg = 200 μg.
3067825|NCT02109185|Active Comparator|Nasonex® Nasal Spray Suspnsn, 50 μg/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Nasonex® Nasal Spray Suspension per nostril once daily for 14 days, Total Daily Dose = 4 × 50 μg = 200 μg.
3067826|NCT02109185|Placebo Comparator|Placebo Nasal Spray, 50 μL/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays of placebo nasal spray per nostril once daily.
3067827|NCT02109172|Experimental|TD-4208 44 mcg twice daily|TD-4208 inhalation solution 44 mcg twice daily for 7 days
3067828|NCT02109172|Placebo Comparator|Placebo|Placebo inhalation solution twice daily for 7 days
3067829|NCT02109172|Experimental|TD-4208 175 mcg once daily|TD-4208 inhalation solution 175 mcg once daily, placebo once daily
3067830|NCT02109159|Experimental|emotional content|A short online video with emotional content, an interview with a postpartum hemorrhage survivor and her husband talking about their experience.
3067831|NCT02109159|Active Comparator|less emotional content|A short online video with less emotional content, the WOMAN trial coordinator talks about the experience of a postpartum hemorrhage survivor and her husband.
3067832|NCT02109146|Experimental|TACE|Patients after surgery receive Transcatheter Arterial Chemoembolization (TACE)
3067833|NCT02109146|Active Comparator|Control|Patients after surgery do not receive TACE
3067834|NCT02109133|Experimental|Deep neuromuscular blockade|Deep neuromuscular blockade
3067835|NCT02109133|Active Comparator|moderate neuromuscular blockade|moderate neuromuscular blockade
3067836|NCT02109120||carotid endarterectomy (CEA)|CEA patients with vein blood collection
3067837|NCT02109107|Experimental|Erchonia EZ6 Laser|The Erchonia EZ6 Laser is a 6 headed scanner composed of 6 independent 17 milliWatts (mW), 635 nanometer (nm) red laser diodes mounted in scanner devices. It is a variable frequency, pulsed wave laser device.
3067838|NCT02109094||Pregnant|
3067839|NCT02109094||Not Pregnant|
3067840|NCT02109081|Experimental|Dexamethasone|Patients will be administered dexamethasone 10 mg at induction of anesthesia
3067841|NCT02109081|Placebo Comparator|Placebo-2.5 cc of saline|Patients will be administed placebo at induction of anesthesia
3067842|NCT02109068|Active Comparator|In-Person Counseling|Participants randomized to in-person counseling will meet via in-person or via telephone (but at least 3 of the 11 sessions must be in person) weekly for month 1, then every other week for months 2, and 3, and then monthly for months 4-6 at Yale University. The meetings will last 30 minutes. Participants will turn in their diet and exercise logs and also be weighed. A lesson will then be discussed (see above for content).
3067843|NCT02109068|Active Comparator|Telephone-based Counseling|The exact same information, content, schedule, and 30 minute sessions will be provided to telephone-based participants as offered to participants who receive in-person counseling. Participants will be taught diet, exercise and behavior change strategies via the telephone (weekly calls for month 1, every other week for months 2-3, and monthly for months 4-6). All lessons and diet and physical activity logs will be mailed to them at the beginning of the program. Participants will record their daily diet and exercise in the logs. Every four weeks, participants will return, via stamped, addressed envelopes, the logs to the study office.
3067844|NCT02109068|No Intervention|Usual Care|Immediately after randomization, participants in the Usual Care Group will be provided written information that emphasizes the importance of a healthy lifestyle. Usual care participants will be encouraged to follow the American Cancer Society (ACS) nutrition and physical activity guidelines. Upon completion of the study (at 6 months), usual care participants will be offered all the educational material, as well as an in-person or telephone counseling session.
3067845|NCT02109055|Experimental|Pilates|Regarding upper limb exercises the limit of flexion and abduction less than 90°, with the exercises involving only the movement of flexion and extension of elbow shoulder will be respected. Along with patient data will be an exercise protocol based on the Pilates method that will be performed by a trained team of physiotherapists. Before and after the exercises the data of heart rate, blood pressure, oxygen saturation and subjective feeling of perceived exertion using the Modified Borg scale will be listed.
3067846|NCT02109055|Active Comparator|Convencional Physiotherapy|The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy.
3067847|NCT02109042|Experimental|Blosozumab|Weekly SC injections of blosozumab for 6 weeks.
3067848|NCT02109029|Experimental|LY2605541|Priming dose of LY2605541 followed by a constant infusion for up to 36 hours
3067849|NCT02109029|Active Comparator|Human Insulin|Variable intravenous (IV) infusions of human insulin for up to 36 hours
3067850|NCT02109029|Placebo Comparator|Sinistrin|IV infusion of sinistrin, used as needed to achieve a steady state for up to 16 hours
3067851|NCT02109016|Experimental|Lucitanib|Lucitanib given orally once daily on a continuous schedule. Starting dose is 10 mg/day.
3067852|NCT02109003|Experimental|Continuous control of Pcuff followed by manual control|Patients receive continuous control of cuff pressure with Pressure easy® device for 24h, followed by discontinuous control (every 4 hours) with a manual manometer for 24 h.
3067853|NCT02109003|Active Comparator|Manual control of Pcuff followed by continuous control.|Patients receive the reverse sequence (manual control followed by continuous control of Pcuff)
3067854|NCT02108990|Experimental|Acetaminophen 1000mg|Acetaminophen 1000mg capsule orally three times a day
3067855|NCT02108990|Experimental|Acetaminophen 500mg|500mg Acetaminophen orally three times a day
3067856|NCT02108977|Experimental|Videoconferencing Genetic Consultation|Patients will travel to CBOC and receive genetic counseling session via videoconferencing
3067857|NCT02108977|Active Comparator|Teleconferencing Genetic Consultation|Patients will receive genetic counseling session via telephone (usual treatment)
3067858|NCT02108964|Experimental|Phase I part|180 patients with EGFR mutations (Recruitment is completed)
3067859|NCT02108964|Experimental|Phase II part|At least 40 patients who have advanced NSCLC and EGFR activating mutations (i.e. L858R and/or ex19del). These patients must be treatment naïve and must have not received any systemic antineoplastic therapy for advanced NSCLC. Note: patients who have received no more than 1 cycle of antineoplastic therapy in the advanced setting are allowed.
3067860|NCT02108951|Experimental|Nilotinib|Nilotinib was administered orally at 300 mg BD at approximately 12 hour intervals which had to be taken without food. The capsules were to be swallowed whole with water and no food should have been consumed for at least 2 hours before and at least 1 hour after the dose was taken. Prior to the first dose of nilotinib, patients were required to have an imatinib or dasatinib washout period of at least 3 days. Therapy with nilotinib was to be continued for up to 24 months while on study.
3067861|NCT02108938||Case|Subject's with Crohn's disease at least 18 years of age
3067862|NCT02108938||Control|"Findings from this study will be compared to controls. These controls will come from the well documented CNS changes which have been found in patients with IBS and chronic pancreatitis (HS-IRB# 2013-1561 and HS-IRB 2009-0171)."
3067863|NCT02108925|Experimental|Supplementary oxygen|Study subjects receive, in randomized order, either supplementary 30% oxygen or air (21% Oxygen) from a gas tight bag
3067864|NCT02108912|Experimental|Traditional outpatient|Traditional outpatient physical therapy
3067865|NCT02108912|Experimental|ESTT outpatient|ESTT (early standardized task-specific training) in outpatient rehabilitation
3067866|NCT02108899|Experimental|Patients with schizophrenia|
3067867|NCT02108899|Active Comparator|Healthy subjects|
3067868|NCT02108886|Experimental|Montelukast|Intervention group
3067869|NCT02108886|Placebo Comparator|Placebo|Placebo
3067870|NCT02108873||Retrospective Cohort|Adult patients who had scheduled an appointment for outpatient primary care. Patients were divided into two groups, including those who attended their scheduled appointment and those who missed it.
3067871|NCT02108860|Experimental|Blinded abatacept|Participants will receive blinded abatacept 125 mg administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission by treatment month 6.
3067872|NCT02108860|Placebo Comparator|blinded placebo|Participants will receive blinded placebo. Placebo will be administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission by treatment month 6.
3067873|NCT02108847|Experimental|Fascia Iliaca Block - Ropivacaine|Ultrasound guided fascia iliaca block performed preoperatively with 40 mL of 0.2% ropivacaine.
3067876|NCT02108834|Placebo Comparator|Placebo|placebo saline
3067877|NCT02108821|Experimental|Fecal Microbiome Transplantation|Fecal Microbiome Transplantation will be done at the time of EGD and colonoscopy. A parent or sibling or a healthy relative will be tested for several infections like hepatitis, H. Pylori, HIV, syphilis, ova and parasites, culture and C.diff. They will fill out a donor questionnaire used for blood donors prior to the sample collection. After eligibility criteria have been met, appropriate consent has been obtained, and the screening labs have been assessed, the fecal transplant procedure will take place in the procedure center at Children's Hospital of Pittsburgh. Fresh stool sample will be obtained from the donor. The fecal sample will be prepared for transplantation in a designated area in the procedure center. Frequency: once. Duration: Approximately 1 hour
3067878|NCT02108808|Active Comparator|Prasugrel or Clopidogrel|Prasugrel 60mg or Clopidogrel 600mg loading dose, as clinically indicated
3067879|NCT02108808|Experimental|Ticagrelor|Ticagrelor 180mg loading dose
3067880|NCT02108795|Experimental|remifentanil group|Remifentanil 0.05 ug/kg/min is infused to the patients.
3067881|NCT02108795|Placebo Comparator|control|Normal saline 0.2 ml/kg/hour is infused to the patients
3067882|NCT02108782|Experimental|Treatment (dovitinib lactate)|Patients receive dovitinib lactate PO on days 1-5, 8-12, 15-19, and 22-26. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3067883|NCT02108769|Experimental|Yogic Breathing|"Chanting Om~Sharp deep inhalation through nostrils~Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.~Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.~Yogic Breathing:~Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.~Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.~Hold breath in this position for about 16 seconds.~Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.~Go to step a)."
3067884|NCT02108769|Active Comparator|Attention Control|The participants will read a text of their choice for 20 minutes.
3067885|NCT02108756|Experimental|L-pantoprazole sodium|
3067886|NCT02108756|Active Comparator|Panmeilu|
3067887|NCT02108743|Active Comparator|Albuterol|2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
3067888|NCT02108743|Placebo Comparator|Placebo|Normal saline placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
3067889|NCT02108730||non-focal congenital hyperinsulinism|13 children and one adult with non-focal congenital hyperinsulinism
3067890|NCT02108717|Experimental|Group I|"The raters in this group one firstly reviewed the CT scans numbered from one to 60 using LCD monitor and after mandatory rests of 20 minutes, reviewed the remaining CT examinations numbered from 61 to 120 using iPhone with TeamViewer at their first visit.~They visited twice with an interval of four weeks and reviewed the CT scans using revered devices at each session."
3067891|NCT02108717|Experimental|Group II|"The raters in this group II firstly reviewed the CT scans numbered from one to 60 using iPhone with TeamViewer and 61 to 120 with the LCD monitor.~They visited twice with an interval of four weeks and reviewed the CT scans using revered devices at each session."
3067892|NCT02108704|Active Comparator|Helicobacter pylori eradication therapy|Amoxycillin 1gm twice a day (BD) Clarithromycin 500mg BD Omeprazole 20mg BD
3067893|NCT02108704|Placebo Comparator|Placebo|Maltodextrin
3067894|NCT02108691|Experimental|Glycin max(L.) Merr. pell extract|
3067895|NCT02108691|Placebo Comparator|Placebo|
3067896|NCT02108678|Experimental|ACT-ME|ACT-ME is designed to reduce behavioral avoidance and to enhance acceptance-based coping. It includes: 1) Behavioral Change Training involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations; and 3) Migraine education whereby each of the educational topics listed below will be covered without detailed discussion of the topics.
3067897|NCT02108678|Experimental|Migraine Education Only|The MEO workshop will last six hours and involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine. The group leaders will present one educational topic at a time and the participants will discuss and reflect about issues and experiences related to the topic. If necessary, the group leaders will raise specific discussion questions to facilitate group dialogue and participant involvement. However, information on coping practices will be omitted.
3067898|NCT02108665|Other|Radiographic hysterosalpingography|Realisation in first: radiographic hysterosalpingographyresonance then imaging hysterosalpingography
3067899|NCT02108665|Other|Magnetic resonance imaging hysterosalpingography|Realisation in first : magnetic resonance imaging hysterosalpingography then a radiographic hysterosalpingography
3067900|NCT02108652|Experimental|Cohort 2: Participants With Second-line or Beyond Treatments|Participants with advanced disease who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting will receive atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.
3067901|NCT02108639|Experimental|DCV 3DAA FDC + BMS-791325|"Group A to D: DCV 3DAA FDC + BMS-791325 oral tablets on specific days~Group E: DCV 3DAA FDC + BMS-791325 oral tablets on specific days"
3067902|NCT02108626|Active Comparator|E-Cigarette with nicotine|Electronic cigarette with cartridge fluid containing nicotine
3067903|NCT02108626|Placebo Comparator|E-Cigarette without nicotine|Electronic cigarette with cartridge fluid containing no nicotine (placebo)
3067904|NCT02108613|Experimental|Intervention|The intervention arm will receive sexual health counselling, exercise sessions, nutrition education, and will be assigned a peer support volunteer.
3067905|NCT02108613|No Intervention|Control|The control group will receive sexual health counseling.
3068125|NCT02106975|Placebo Comparator|5% Dextrose in Water|50ml every 6 hours for 96 hours
3067906|NCT02108600|No Intervention|Standard of Care|Will continue usual immunosuppression and not receive any specific intervention.
3067907|NCT02108600|Experimental|Tocilizumab (TCZ) Group|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
3067908|NCT02108587|Experimental|optical coherence tomography for diagnosis|Patients undergo optical coherence tomography over 10-15 minutes.
3067909|NCT02108574|Placebo Comparator|Placebo Filter|Placebo device
3067910|NCT02108574|Active Comparator|Rhinix Nasal Filter|Actual Rhinix Nasal Filter
3067911|NCT02108561||Breast Cancer|Post Surgical Her2 testing
3067912|NCT02108548|Experimental|Part 1: ASP7657 Single Ascending Dose|
3067913|NCT02108548|Experimental|Part 1: ASP7657 Single Ascending Dose - Food Effect|
3067914|NCT02108548|Placebo Comparator|Part 1: Placebo|
3067915|NCT02108548|Experimental|Part 2: ASP7657 Multiple Ascending Dose|
3067916|NCT02108548|Experimental|Part 2: ASP7657 Multiple Ascending Dose Elderly|
3067917|NCT02108548|Placebo Comparator|Part 2: Placebo|
3067918|NCT02108548|Active Comparator|Part 2: Naproxen|
3067919|NCT02108535|Experimental|Nanocrystalline silver|Flexible polyester low-grip coated nanocrystalline silver dressing. The dressing was applied to the lesion after being soaked in sterile distilled water. About this compresses to bandage movements will have been added and comes to avoid tourniquet bandage on-site maintenance, temperature of the affected area, cushioning and absorption of wound exudate when present. Is finished with the application of crepe bandages in the form of flakes containment curative and maintenance of pressure. This procedure aids in the bloodstream, and avoids the increased edema. The bandage is started from the periphery to the central region, avoiding tourniquet. The exchanges were performed every three days.
3067920|NCT02108535|Active Comparator|Silver sulphadiazine|Ranges for rayon containing cream 1% silver sulphadiazine were used. Involving this layer bandages for dressings were added in movements back and forth to avoid the tourniquet, providing maintenance of the temperature of the affected area, cushioning and absorption of wound exudate when present. This application was completed with crepe bandages to contain the dressing and maintain pressure. This procedure aids in the bloodstream, and avoids the increased edema. The bandage is started from the periphery to the central region, scales, avoiding the tourniquet. Dressing changes were performed daily.
3067921|NCT02108522|Experimental|Multivirus Specific T cells|"Partially HLA-matched multivirus specific T cells (VSTs) will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused after discussion with the principal investigator, patient and/or guardian and the treatment team.~If after the first treatment there is persistent infection, the option to receive more treatments. These additional treatments might be with cells from the same donor or another donor's whose cells. This second product will be administered at the same dose level 28 days after the initial infusion, and subsequent infusions should be at least 14 days apart."
3067922|NCT02108483|Experimental|All participants|Dapsone gel and dapsone gel vehicle applied to the skin by separate occlusive patches on Day 1.
3067923|NCT02108470|No Intervention|Dental consultation without OHQoL assessment|Dentist performs consultation in the traditional method
3067924|NCT02108470|Experimental|Dental consultation using OHIP|Dental consultation using OHIP incorporating OHRQoL issues.
3067925|NCT02108457|Experimental|Proton subjects|
3067926|NCT02108457|Experimental|IMRT subjects|
3067927|NCT02108444||group with HBV reactivation|group with hepatitis B virus reactivation
3067928|NCT02108444||group without HBV reactivation|group without hepatitis B virus reactivation
3067929|NCT02108431|Experimental|balloon catheter for transurethral bladder-drainage|intraoperatively placement of transurethral catheter after robot-assisted radical prostatectomy
3067930|NCT02108431|Active Comparator|balloon catheter for suprapubic bladder-drainage|intraoperatively placement of suprapubic catheter after robot-assisted radical prostatectomy
3067931|NCT02108418|Experimental|TG-2349 as the original formulation|400 mg, 2 syringes
3067932|NCT02108418|Experimental|TG-2349 as a new capsule formulation|400 mg, 4 capsules
3067933|NCT02108405||Sepsis|Sepsis Forty eight patients developed septic complication during ICU stay (sepsis group).
3067934|NCT02108405||SIRS group|SIRS group Forty seven patients were critically ill without evidence of infectious organism (SIRS group).
3067935|NCT02108379|Experimental|Rhinix Nasal Filters|All included will receive rhinix nasal filters
3067936|NCT02108366|Placebo Comparator|Placebo|Placebo + oseltamivir 75mg bid for 5 days
3067937|NCT02108366|Experimental|Celecoxib|Celecoxib 200mg daily + oseltamivir 75mg bid for 5 days
3067938|NCT02108353|Active Comparator|Melatonin 2mg|The study medication will be compared to placebo control.
3067939|NCT02108353|Placebo Comparator|Placebo|The study medication will be compared to placebo control.
3067940|NCT02108340|Experimental|Microwave radiometry|Patients diagnosed with acute appendicitis will undergo a measurement of the temperature of the appendix with the use of microwave radiometry in a room temperature of 20 -24 degrees celsius.
3067941|NCT02108327|Experimental|surgical blade|
3067942|NCT02108327|Active Comparator|Unipolar electrocautery|
3067943|NCT02108314|No Intervention|Control Group|Participants in the control arm were blinded as to the hypothesis of the study, undergoing a series of questions in about general health behaviours before their consultation, allowing the investigators to determine eligibility for the study. The associated participant information sheets for the control arm did not specifically mention breast cancer screening, maintaining blinding throughout. There was no reminder to the physician to promote mammography to participants. The physician continued with his or her usual counseling on health screening and mammography, if any. A 3-minute health promotion video by the Singapore Heart Foundation on healthy eating habits was administered to each participant, followed by a post-consultation questionnaire. The entire process took approximately 10 minutes.
3067944|NCT02108314|Active Comparator|Video Screening and Counselling|The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
3067945|NCT02108301|Experimental|tacrolimus-cyclosporine A|conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
3067946|NCT02108288|Experimental|OPC-1085EL ophthalmic solution|Once daily
3067947|NCT02108288|Active Comparator|Carteolol long-acting ophthalmic solution|Once daily
3067948|NCT02108288|Active Comparator|Latanoprost ophthalmic solution|Once daily
3067949|NCT02108262|Experimental|CSL112 - low dose|CSL112 (low dose) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.
3067950|NCT02108262|Experimental|CSL112 - high dose|CSL112 (high dose) is to be administered as an IV infusion once weekly for 4 consecutive weeks.
3067951|NCT02108262|Placebo Comparator|Placebo|Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.
3067952|NCT02108249||Annex Group|Patients prospectively treated with Annex™ Adjacent Level System
3067953|NCT02108249||Retrospective Control|Patients previously treated for adjacent level disease using other systems
3067954|NCT02108236|No Intervention|Blank control group|A control group of patients is put on a waiting list for no intervention and remaining unchanged lifestyle.
3067955|NCT02108236|Active Comparator|intervention group|An intervention group of patients is put on a waiting list for acupuncture treatment.
3067956|NCT02108223|Active Comparator|fix dose r-FSH (Gonal-f)|The patients who had normal ovarian response were included as the control group (Group 1). The dose of r-FSH (Gonal-f) was continued for the fix dose until the day of hCG in Group 1
3067957|NCT02108223|Active Comparator|r-LH supplementation to r-FSH|On day 7 of the stimulation, if at least six follicles between 6-10mm were present but there was no follicle over 10 mm on transvaginal ultrasound, E2 level was under 180 pg/ml, it has been considered that the patients had suboptimal response to the stimulation and were divided into Group 2. Group 2 received supplemental r-LH ( Lutropin alpha; Luveris, Merck Serono, France), 75IU/day to r-FSH (Gonal-f) treatment.
3067958|NCT02108223|Active Comparator|r-FSH (Gonal-f)|Group 3: Daily 75 IU/L r-FSH was added to r-FSH treatment until the end of ovarian stimulation.
3067959|NCT02108210|Experimental|Anakinra|This therapy will consist of once daily subcutaneous injections (100mg/day) during a period of 4 weeks. Patients will be monitored at week 1 and week 4 after starting medication for development of side effects. Therapy will be stopped in case of severe side effects, interfering disease or pregnancy. During the intervention period, use of co-medication is only allowed when used for ≤14 consecutive days, on the condition that there are no known interactions with anakinra. Oral contraceptives and/or paracetamol can be used without a limitation. During the follow-up period, there are no limitations regarding the use of medication. All co-medication will be registered precisely and reported afterwards.
3067960|NCT02108210|Placebo Comparator|Placebo|"Patients in the placebo group will also receive once daily subcutaneous injection during a period of 4 weeks. Placebo injections will be identically in appearance compared to the Anakinra injections. Patients in the placebo group will have the same visits and monitoring for side effects as the patients randomized to the other treatment arm.~During the intervention period, use of co-medication is only allowed when used for ≤14 consecutive days, on the condition that there are no known interactions with anakinra. Oral contraceptives and/or paracetamol can be used without a limitation. During the follow-up period, there are no limitations regarding the use of medication. All co-medication will be registered precisely and reported afterwards."
3067961|NCT02108197|Experimental|CPAP Intervention|Continuous positive airway pressure (S9, ResMed)
3067962|NCT02108197|No Intervention|Wait-list|Wait list controls
3067963|NCT02108184|Experimental|Sequential therapy 10 days|1.(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 5 days
3067964|NCT02108184|Active Comparator|Sequential therapy 14 days|(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days
3067965|NCT02108184|Active Comparator|Concomitant therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 10 days
3067966|NCT02108184|Active Comparator|Concomitant therapy 14 days|(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days
3067967|NCT02108171|Active Comparator|dexmedetomidine|intranasal dexmedetomidine
3067968|NCT02108171|Placebo Comparator|placebo|intranasal saline
3067969|NCT02108158|Experimental|Azzalure 10 Speywood units/injection|Azzalure (botulinum toxin type A), powder for solution for injection, Total dose 50 s.U (5 x 10s.U)
3067970|NCT02108158|Active Comparator|Azzalure, 10 Speywood units/injection|Azzalure (botulinum toxin type A), powder for solution for injection, Total dose 50 s.U (5 x 10s.U)
3067971|NCT02108145|Active Comparator|unilateral metal stent insertion|unilateral metal stent insertion was performed either left or right hepatic lobe as can be drainage more liver volume
3067972|NCT02108145|Experimental|bilateral metal stent insertion|percutaneous transhepatic biliary drainage plus bilateral metal stent.The bare stents were used for PTBS
3067973|NCT02108132|Experimental|Cellular therapy|Cellular therapy : injection of mesenchymal stem cells subjected to hepatogenic induction
3067974|NCT02108119|Active Comparator|Probiotics|
3067975|NCT02108119|Placebo Comparator|Control placebo|
3067976|NCT02108106|Experimental|AG-348|Single oral dose of AG-348
3067977|NCT02108106|Placebo Comparator|Placebo|Single oral dose of placebo
3067978|NCT02108093|Experimental|RAP (retrograde autologous priming) group|In the RAP (retrograde autologous priming) group, the priming solution is partially replaced by the patient's own circulating blood, before initiation of CPB. After initiation of cardiopulmonary bypass the priming volume is approximately 900 ml.
3067979|NCT02108093|No Intervention|Control group|In the control group, the priming volume of the arterial and venous line will not be replaced by patient's own blood. The priming volume of cardiopulmonary bypass is 1300 ml in the control group.
3067980|NCT02108028||Cohort 1|Patients with children
3067981|NCT02108028||Cohort 2|Patients living independently
3067982|NCT02108028||Cohort 3|Non-Patient Participants
3067983|NCT02107963|Experimental|Arm 1|Dose escalation of anti-GD2 CAR T cells
3067984|NCT02107963|Experimental|Arm 2|Dose expansion of anti-GD2 CAR T cells
3067985|NCT02107950|Experimental|DCVAC/OvCa in parallel with chemotherapy|Combination therapy with DCVAC/OvCa and Standard of Care
3067986|NCT02107950|Active Comparator|Standard of Care|Standard of Care carboplatin and gemcitabine
3067987|NCT02107937|Experimental|DCVAC/OvCa with Standard of Care|DCVAC/OvCa in parallel with chemotherapy (Standard of Care)
3067988|NCT02107937|Experimental|DCVAC/OvCa sequentially chemotherapy|DCVAC/OvCa sequentially after chemotherapy
3067989|NCT02107937|Active Comparator|Standart of Care|Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
3067990|NCT02107924||APPI of TKR-Stimulan|Surgery Stimulan beads 2.4 G Tobramycin 2.0 G Vancomycin
3067991|NCT02107924||APPI of TKR-historical|Surgery 2.4 G Tobramycin 2.0 G Vancomycin
3067992|NCT02107911||men who have sex with men|MSM who seek voluntary HIV counseling and testing service at the Anonymous Clinic, TRC-ARC, including those who describe risky sexual exposure to HIV within the preceding 72 hours and meet nPEP criteria.
3067993|NCT02107898|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every two weeks (Q2W) added to stable lipid-modifying therapy (LMT).
3067994|NCT02107898|Experimental|Alirocumab 75 mg/Up to 150 mg Q2W|"Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels above pre-specified threshold at Week 8 as defined in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012 i.e.~≥100 mg/dL (2.59 mmol/L) in heFH participants or in non-familial hypercholesterolemia (non-FH) participants who had a history of documented coronary heart disease (CHD)~≥120 mg/dL (3.10 mmol/L) in non-FH participants who had a history of documented diseases or other risk factors as categorized in primary prevention category III"
3067995|NCT02107885|Experimental|DS-1971|single ascending dose of 5mg, 10mg, 30mg, 90mg, 250mg, 500mg, 1000mg, 1500mg.
3067996|NCT02107885|Placebo Comparator|placebo|placebo matching each of the DS-1971 dosages.
3067997|NCT02107872|Experimental|dosing cohort 1|Patients will receive REGN1500 or placebo in dosing cohort 1
3067998|NCT02107872|Experimental|dosing cohort 2|Patients will receive REGN1500 or placebo in dosing cohort 2
3067999|NCT02107872|Experimental|dosing cohort 3|Patients will receive REGN1500 or placebo in dosing cohort 3
3068000|NCT02107872|Experimental|dosing cohort 4|Patients will receive REGN1500 or placebo in dosing cohort 4
3068001|NCT02107872|Experimental|dosing cohort 5|Patients will receive REGN1500 or placebo in dosing cohort 5
3068002|NCT02107859|Experimental|Ataluren (PTC124)|Ataluren (PTC124)
3068003|NCT02107846|Experimental|50 Units|PRX-112 50 Units daily for 5 days
3068004|NCT02107846|Experimental|100 Units|PRX-112 100 Units daily for 5 days
3068005|NCT02107846|Experimental|200 Units|PRX-112 200 Units daily for 5 days
3068006|NCT02107846|Experimental|400 Units|PRX-112 400 Units daily for 5 days
3068007|NCT02107833|Experimental|2 mg|OPRX-106 2 mg oral once daily for 5 days
3068008|NCT02107833|Experimental|8 mg|OPRX-106 8 mg oral once daily for 5 days
3068009|NCT02107833|Experimental|16 mg|OPRX-106 16 mg oral once daily for 5 days
3068010|NCT02107820|Active Comparator|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
3068011|NCT02107820|Experimental|'Bladder Training (BT) and PTNS|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
3068012|NCT02107807|Experimental|Arm 1: aH5N1 adult|aH5N1 healthy and non-healthy adults
3068013|NCT02107807|Experimental|Arm 2: aH5N1 elderly|aH5N1 healthy and non-healthy elderly
3068014|NCT02107807|Active Comparator|Arm 4: aTIV elderly|aTIV healthy and non-healthy elderly
3068015|NCT02107807|Active Comparator|Arm 3: aTIV adult|aTIV healthy and non-healthy adults
3068016|NCT02107794|Active Comparator|Decision Aid|Observation of clinical encounter using the decision aid, via video, audio or written notes.
3068017|NCT02107794|No Intervention|Usual Care|Observations in clinical encounters, either video, audio, or observational notes.
3068018|NCT02107781||Patients with open abdomen|Patients in a critical care unit with abdomen that was not closed during initial operation & will have intra-abdominal pressure monitoring using the AbViser abdominal compartment pressure measuring device.
3068019|NCT02107768|Experimental|Exercise recommendation|Patients randomized to the control group receive general advice for physical training and activity but no specific training or other rehabilitation efforts
3068020|NCT02107768|Experimental|Aerobic exercise|"The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added. The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20, Rate of Perceived Exertion (Borg 's RPE scale)~Two fitness goals was to be achieved during the training session:~1. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.~2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) .Which corresponds to 85% of maximum heart rate."
3068089|NCT02107261|Active Comparator|Prior treatment with botulinum toxin|Individuals with musician's dystonia who have been previously treated with botulinum toxin.
3068090|NCT02107248|Active Comparator|Sleep position: supine|Subjects will be instructed to sleep in a supine position during the first eight weeks after a total hip replacement following a posterolateral surgical approach
3095353|NCT01923519|Experimental|allergic rhinitis and asthma|
3068021|NCT02107755|Experimental|Treatment (ipilimumab, stereotactic radiosurgery)|Patients receive ipilimumab IV over 90 minutes on day 1 in weeks 1, 4, 7, and 10. Treatment repeats every 3 weeks for up to 4 total doses in the absence of disease progression or unacceptable toxicity. At approximately 5-6 weeks, patients undergo stereotactic radiosurgery over 2-3 days per week. Patients with stable disease or confirmed partial or complete response after completion of ipilimumab therapy at week 12 may receive re-induction ipilimumab at the discretion of the treating physician.
3068022|NCT02107742|Experimental|Injection speed|each participant receives 3 injections with the same amount of lidocaine subcutaneously on the abdomen, given over 15, 30 and 45 seconds
3068023|NCT02107729|Experimental|Needle gauge small|injection needle 23 G
3068024|NCT02107729|Experimental|Needle gauge normal|injection needle 25 G
3068025|NCT02107729|Experimental|Needle gauge large|injection needle 27 G
3068026|NCT02107716|Experimental|Bicarbonate|Each participant will receive two lidocaine injections on the abdomen with different pH
3068027|NCT02107703|Experimental|Abemaciclib + Fulvestrant|150 milligrams (mg) Abemaciclib given orally once every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
3068028|NCT02107703|Placebo Comparator|Placebo + Fulvestrant|Placebo will be supplied as capsules administered orally every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
3068029|NCT02107690|Experimental|low temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
3068030|NCT02107690|Experimental|room temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
3068031|NCT02107690|Experimental|body temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
3068032|NCT02107664||Radiation therapy for bone cancer pain|The group includes all cancer diagnoses, and different fractions of RT planned.
3068033|NCT02107651||NOAC|Patients admitted for GI bleeding while in treatment with NOAC
3068034|NCT02107638|Experimental|OMM treatment arm|Subject will receive osteopathic manipulative treatment protocol for Parkinson's disease (PARK-OMM), twice a week for 6 weeks.
3068035|NCT02107638|Active Comparator|Counseling|Subjects will receive counseling sessions weekly to match the face to face time with a physician during the OMM treatment arm. No OMM will be performed during this 6 week counseling study period.
3068036|NCT02107625|Experimental|Diet A i.e. Low FODMAP diet|The patients are thoroughly informed verbally and in writing how to eat according to the low FODMAP diet. The diet imply restrictions in carbohydrate intake and the patients need to follow a list with yes/no-foods for 4 weeks.
3068037|NCT02107625|Experimental|Diet B, i.e. Traditional IBS diet|The patients are thoroughly informed verbally and in writing how to eat according to traditional IBS dietary advices. The diet imply adapting to regular dietary habit with meals 6 times a day, no to big meals, to chew food thoroughly, to peel fruits and vegetables, no carbonated beverages, no chewing gum, no soft drinks, no sugar-free candies, or cookies. Reduce spicy foods, coffee, alcohol, onion, pulses, and fatty foods. Keep strictly to the dietary advice for 4 weeks.
3068038|NCT02107612|Experimental|Integrated system to insert two splinted (bar) miniimplants|Participants were randomly assigned to experimental group following a simple randomization procedure (computer-generated list of random numbers). Allocation by telephone was carried out with an independent collaborator.
3068039|NCT02107612|Active Comparator|Denture|Participants were randomly assigned to comparator group following a simple randomization procedure (computer-generated list of random numbers). Allocation by telephone was carried out with an independent collaborator.
3068040|NCT02107599|Experimental|Physician Readers|Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir(18F) as part of this study.
3068041|NCT02107586|Active Comparator|Biceps tenodesis|32 subjects in the study will receive biceps tenodesis as a surgical intervention
3068042|NCT02107586|Active Comparator|Biceps tenotomy|32 subjects in the study will receive biceps tenotomy as a surgical intervention
3068043|NCT02107573|Active Comparator|Rotator cuff repair without Suprascapular Nerve decompression|approximately 17 subjects in the study will receive traditional rotator cuff repair surgical intervention with no suprascapular nerve decompression surgical intervention
3068044|NCT02107573|Active Comparator|Rotator Cuff Repair with Suprascapular Nerve decompression|approximately 17 subjects in the study will undergo rotator cuff repair with arthroscopic suprascapular nerve decompression surgical intervention
3068045|NCT02107547|Active Comparator|Biceps tenodesis|32 subjects in the study will receive biceps tenodesis as a surgical intervention
3068046|NCT02107547|Active Comparator|Labral repair|32 subjects in the study will receive labral repair as a surgical intervention
3068047|NCT02107534|Experimental|parent training (dyslexia)|Participants take part in parent training, five two-hour sessions held biweekly.
3068048|NCT02107534|No Intervention|wait list control group|Participants of the waiting list control group had the possibility to take part in the parent training after the follow-up was completed.
3068049|NCT02107521|Active Comparator|ICSI group|In this group, sperm selected for injection will be morphologically evaluated under 400x magnification
3068050|NCT02107521|Experimental|IMSI group|In this group, sperm selected for injection will be morphologically evaluated under 6600x magnification
3068051|NCT02107495||CHF-confirmed subjects|Subjects 21 years of age or greater with clinically confirmed heart failure or have presented to the clinical site with signs, symptoms and/or risk factors suggestive of heart failure.
3068052|NCT02107495||Subjects with potentially co-morbidities|non-CHF subjects 21 years or greater, with potentially confounding comorbidities such as diabetes, renal insufficiency, hypertension and chronic obstructive pulmonary disease (COPD).
3068053|NCT02107495||Apparently healthy subjects|Apparently healthy subjects (meeting inclusion criteria) greater than 45 years of age, with no prior history of myocardial infarction (MI), acute coronary syndrome (ACS) congestive heart failure (CHF) or any other cardiac-related disease.
3095354|NCT01923519|Experimental|witnesses|
3068054|NCT02107482|Active Comparator|Levia Narrow Band UVB|Levia Narrow Band UVB dosing for subjects with skin type I: starting dose of 195 mj/cm2, for subjects with skin type II: starting dose of 330 mj/cm2, for subjects with skin type III: starting dose of 390 mj/cm2, for subjects with skin type IV: starting dose of 495 mj/cm2, for subjects with skin type V: starting dose of 525 mj/cm2, for subjects with skin type VI: starting dose of 600 mj/cm2. The dose will be increased by 15% with each treatment, as long as there are no side effects with treatment such as burning or redness.
3068055|NCT02107482|Sham Comparator|Levia sham/visible-light source|the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
3068056|NCT02107469|Experimental|Ancient herbal treatment|"Phyllanthus niruri 3g fine dry powder 3 times a day with warm water before meals for 8 weeks~Sida cordifolia 7g coarse dry powder 2 times a day prepared as traditional decoction before meals for 8 weeks. Decoction: Take provided measurement cup full of water (112ml) and soak one portion (pe-packed) of the powder for 12 hours, then boil it until the upper level has been reduced to 1/4, filter, cool down to room temperature, drink"
3068057|NCT02107469|Experimental|Modern extract herbal treatment|"Phyllanthus niruri extract 2 capsules 3 times a day with warm water before meals for 8 weeks~Sida cordifolia roots extract 2 capsules 2 times a day with warm water before meals for 8 weeks"
3068058|NCT02107469|Placebo Comparator|Placebo|"Phyllanthus niruri placebo 2 capsules 3 times a day with warm water before meals for 3 weeks~Sida cordifolia placebo 2 capsules 2 times a day with warm water before meals for 3 weeks"
3068059|NCT02107456|Experimental|Dry Needling|The taut band of trigger point in upper trapezius muscle; localized between the thumb and index finger, was needled forward and backward repeatedly until there were no more local twitch response
3068060|NCT02107443|Experimental|Arm I: Geriatric Assessment Intervention|At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA and receive the intervention; GA summary plus GA targeted recommendations which is provided to the oncology team to discuss and implement if they so choose.
3068061|NCT02107443|Active Comparator|Arm II: Usual Care|At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA (no GA summary or recommendations are provided).
3068062|NCT02107430|Experimental|DCVAC/PCa arm post radiotherapy|Dendritic Cells DCVAC/PCa Experimental therapy post radiotherapy
3068063|NCT02107430|Active Comparator|Standard radiotherapy|Standard care
3068064|NCT02107417|Experimental|Experimental Group (EG) - TENS active|Experimental Group (EG) - TENS active: who will receive the application of active TENS. The participants of these group will receive TENS active within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.
3068065|NCT02107417|Sham Comparator|Control Group (CG)- Placebo TENS|Control Group (CG) who will be administering the placebo TENS.The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, . It has an application time of 60 minutes The TENS-placebo will be applied where no current will be emitted.
3068066|NCT02107404|Experimental|DCVAC/PCa Arm|Dendritic Cells DCVAC/PCA Experimental therapy
3068067|NCT02107404|No Intervention|Standard Therapy|No Intervention
3068068|NCT02107391|Experimental|DCVAC/PCA added Standard Hormone Therapy|Combination therapy with Dendritic Cells DCVAC/PCa added on to a Standard of Care Hormone Therapy
3068069|NCT02107391|Active Comparator|Standard of Care Hormone Therapy|Standard of Care Hormone Therapy as an Active Comparator Goserelin Acetate Leuprolide Acetate
3068070|NCT02107378|Experimental|DCVAC/OvCa in parallel with chemo (SoC)|Combination therapy with DCVAC/OvCa and Standard of Care (SoC)
3068071|NCT02107378|Active Comparator|Standard of Care (Chemotherapy)|Standard of Care as an Active Comparator (Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy)
3068072|NCT02107365|Experimental|Asunaprevir, Daclatasvir, Ribavirin, Peg-Interferon alpha-2a|Quadritherapy from Day 0 to Week 24
3068073|NCT02107352||Naltrexone|50mg/day
3068074|NCT02107352||Acamprosate|1332mg/day if patient weights less than 60 kg, 1998mg/day if patient weights more than 60 kg
3068075|NCT02107352||Baclofen|30 mg/day
3068076|NCT02107352||Placebo|
3068077|NCT02107339|Experimental|methadone group|Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
3068078|NCT02107339|Active Comparator|Hydromorphone group|Patients will receive hydromorphone 2 mg at the end of the surgical procedure
3068079|NCT02107326|Experimental|Webdia Software use|Use of Webdia Software during 3 months by the patient. Monthly review of blood glucose values by the medical team and automatic adjustment of insulin doses by the team.
3068080|NCT02107326|No Intervention|Observation|No use of the software. No intervention.
3068081|NCT02107313|Other|Fed Cohort|PBT2 250 mg is administered orally following a high fat breakfast
3068082|NCT02107313|Other|Fasted Cohort|PBT2 250 mg is administered orally following a 10 hour period of fasting
3068083|NCT02107300|Experimental|NeutraSal|NeutraSal, dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks.
3068084|NCT02107300|Placebo Comparator|Placebo|Placebo dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks.
3068085|NCT02107287|Experimental|IMRT Hypofractionated|Neo-adjuvant hormone therapy for three months followed by IMRT combined with a 24-month hormonal therapy.
3068086|NCT02107274|Active Comparator|Azithromycin and Placebo for Azithromycin|Patients randomised to the treatment arm are to receive 1000 mg of azithromycin once a week for 12 weeks followed by placebo for azithromycin once weekly for another 12 weeks
3068087|NCT02107274|Placebo Comparator|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
3068088|NCT02107261|Active Comparator|Naive to botulinum toxin|Individuals with musicians dystonia who have not been treated previously with botulinum toxin.
3068091|NCT02107248|Experimental|Sleep position: no restrictions|Patients do not have any restrictions in sleeping position during the first eight weeks after a total hip replacement following a posterolateral surgical approach
3068092|NCT02107235|Experimental|Rigosertib + Cisplatin + Radiation|"Oral rigosertib will be started 7 days before initiation of concurrent treatment with cisplatin and radiation therapy and will be administered on a continuous basis for a fixed duration of 8 weeks. Three oral rigosertib escalating doses will be sequentially evaluated: 70 mg 3 times a day (TID), 140 mg TID and 280 mg TID.~Cisplatin will be administered intravenously at a dose of 40 mg/m^2 on Days 1, 8, 15, 22, 29, 36, and 43 of the 7-week concurrent treatment course.~The prescribed radiotherapy dose will be 70 Gray (Gy) in 2 Gy once-daily fraction size (total of 35 fractions) over the 7-week concurrent treatment course. The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, 5 fractions per week."
3068093|NCT02107222|No Intervention|mechanical ventilation (MV)|mechanical ventilation according to guidelines
3068094|NCT02107222|Experimental|MV + ECCO2-R(PALP-Device/MaquetCP)|MV according to the guidelines plus CO2-Removal with PALP
3068095|NCT02107209|Experimental|Bronchoscopic Lung volume reduction using Autologous blood.|Injection of 30 ml autologous blood plus 3ml calcium chloride plus 3 ml tranexamic acid per segment via fiber-optic bronchoscope
3068096|NCT02107209|Active Comparator|Bronchoscopic Lung volume reduction using Fibrin glue|injection of 30 ml locally prepared fibrin glue per segment via triple lumen balloon catheter passing through fiberoptic bronchoscopy
3068097|NCT02107196|Experimental|Ibodutant 10 mg|Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will be re-randomised at week 13 in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.
3068098|NCT02107196|Placebo Comparator|Placebo|Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant at week 13 for additional 4 weeks of treatment.
3068099|NCT02107183|Experimental|Nasal high-flow oxygen therapy|High-flow, fully humidified oxygen delivered through nasal cannula (Optiflow, Fisher & Paykel Healthcare) after extubation up to ICU discharge
3068100|NCT02107183|Active Comparator|Venturi mask oxygen therapy|Oxygen delivered through standard Venturi mask after extubation up to ICU discharge
3068101|NCT02107170|Experimental|Sevoflurane & remifentanil|sevoflurane at 0.5 to 1.5 minimum alveolar concentrations plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
3068102|NCT02107170|Active Comparator|propofol & remifentanil|propofol (50 - 150 µg/kg/min) plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
3068103|NCT02107157|Experimental|755nm Alexandrite laser with cap array|
3068104|NCT02107144|Experimental|trimetazidin|Patients, who are trimetazidine (TMZ) naïve, will be randomly assigned to receive trimetazidine plus previous medications (TMZ group) 48h before scheduled PCI- Paients that are TMZ naïve and randomized to TMZ group will be given oral loading of 70mg TMZ.
3068105|NCT02107144|No Intervention|Control|Patients, who are TMZ naïve, will be randomly assigned to receive just previous cardiac medication (Control group).
3068106|NCT02107131|Experimental|Intravitreal ranibizumab 0.3mg|
3068107|NCT02107118|Active Comparator|ARM 1: AdMSC: adipose stem cells|AdMSC: Autologous adipose tissue-derived mesenchymal stem cell. Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured.
3068108|NCT02107118|Placebo Comparator|ARM 2 Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
3068109|NCT02107105||Rectal Cancer Participants|Rectal cancer participants who have not yet had surgery for rectal cancer or had surgery up to 2 years ago.
3068110|NCT02107092|Experimental|Sodium Zirconium Cyclosilicate|Open label oral administration of sodium zirconium cyclosilicate 10g once daily for 11 months.
3068111|NCT02107079|Active Comparator|melatonin 1 mg immediate release tablet|
3068112|NCT02107079|Active Comparator|melatonin 2,5mg immediate release capsule|
3068113|NCT02107079|Active Comparator|melatonin 0.1 mg oromucosal tablet|
3068114|NCT02107066|Active Comparator|attention control|Women randomized to attention control will receive the same attention as women randomized to exercise intervention, i.e., weekly phone calls for 6 months. Each call is about 15 min. Women in the attention control will receive information on ovarian cancer health education topics.
3068115|NCT02107066|Experimental|exercise|Women randomized to exercise will receive telephone-counseling weekly for 6 months to increase their exercise
3068116|NCT02107053|Experimental|IV iron + PJ|Each patient will serve as a self control
3068117|NCT02107053|Experimental|No IV iron + PJ|Each patient will serve as a self control
3068118|NCT02107053|Experimental|IV iron no PJ|Each patient will serve as a self control
3068119|NCT02107027|Active Comparator|nMARQ catheter (circular catheter)|Group treated with the circular ablation catheter for atrial fibrillation ablation
3068120|NCT02107027|Active Comparator|Navistar catheter (conventional catheter)|Group treated with the conventional ablation catheter for atrial fibrillation ablation
3068121|NCT02107014|Other|Low Dose Naltrexone (LDN)|Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
3068122|NCT02107001||Patients with pleuritic chest pain|Study investigators will perform lung ultrasound in each patient with pleuritic chest pain at inclusion
3068123|NCT02106988|Experimental|Chemotherapy + Radiation Therapy|"Radiation therapy delivered for a total dose of 50.4 to 54 Gy over 28 to 30 treatments. Within seven days of starting radiotherapy, the first cycle of chemotherapy started and repeated every 3 weeks for a total of 3 cycles.~DeVIC on day 1 of every cycle. Dexamethasone 40 mg by vein Days 1-3, Etoposide 67 mg/m2 by vein on Days 1-3, Ifosfamide 1 g/m2 by vein on Days 1-3, Mesna 0.4 g/m2 by vein on Days 1-3 with Ifosfamide, Mesna 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump, Carboplatin 200 mg/m2 by vein on Day 1. Cycles repeated every 21 days."
3068124|NCT02106975|Active Comparator|Ascorbic Acid|200mg/kg/day divided over 4 doses. Administered every 6 hours for 96 hours
3068126|NCT02106962|Experimental|Clotting time Using Tranexamic Acid 5%|Measure Native AV Fistula clotting time after dialysis using 5% Tranexamic Acid compared to normal Clotting time of Native AV Fistula after dialysis
3068127|NCT02106962|Experimental|Clotting Time Using Tranexamic Acid 25%|Measure Native AV Fistula clotting time after dialysis using 25% Tranxemic Acid compared to normal clotting time of native AV Fistula after dialysis
3068128|NCT02106949|Experimental|SMS|The patients of the test group receive a first SMS 48 hours after their discharge from the hospital then a total of 10 messages distributed over six months: 48 hours, S1, S2, M1, M2, M3, M4, M5, M6 and M13.
3068129|NCT02106949|No Intervention|Without SMS|The patients of the group benefit from the usual care.
3068130|NCT02106923|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs 3 single tablets under fasted conditions
3068131|NCT02106923|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs 3 single tablets under fed conditions
3068132|NCT02106923|Experimental|Low dose, fasted|2 fixed dose combination (FDC) tablets vs 4 single tablets under fasted conditions
3068133|NCT02106910||Dysplastic BE s/p RFA|Patients with Barrett's Esophagus (BE) with low grade dysplasia (LGD) or high grade dysplasia (HGD) and achieved complete eradication of BE via radiofrequency ablation (RFA).
3068134|NCT02106910||BE|Patients with a diagnosis of BE, presenting for routine care endoscopy for surveillance or treatment of their BE
3068135|NCT02106897|Experimental|Part 1, Cohort 1: BIIB059 0.05 mg/kg IV|BIIB059 0.05 mg/kg IV dose, Once on Day 1
3068136|NCT02106897|Experimental|Part 1, Cohort 2: BIIB059 0.3 mg/kg IV|BIIB059 0.3 mg/kg IV dose, Once on Day 1
3068137|NCT02106897|Experimental|Part 1, Cohort 3: BIIB059 1 mg/kg IV|BIIB059 1 mg/kg IV dose, Once on Day 1
3068138|NCT02106897|Experimental|Part 1, Cohort 4: BIIB059 3 mg/kg IV|BIIB059 3 mg/kg IV dose, Once on Day 1
3068139|NCT02106897|Experimental|Part 1, Cohort 5: BIIB059 10 mg/kg IV|BIIB059 10 mg/kg IV dose, Once on Day 1
3068140|NCT02106897|Experimental|Part 1, Cohort 6: BIIB059 20 mg/kg IV|BIIB059 20 mg/kg IV dose, Once on Day 1
3068141|NCT02106897|Experimental|Part 1, Cohort 7: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Once on Day 1
3068142|NCT02106897|Placebo Comparator|Part 1, Cohort 1-6: Placebo IV|Matching placebo IV dose, Once on Day 1
3068143|NCT02106897|Placebo Comparator|Part 1, Cohort 7: Placebo SC|Matching placebo SC dose, Once on Day 1
3068144|NCT02106897|Experimental|Part 2, Cohort 8: BIIB059 20 mg/kg IV|BIIB059 20 mg/kg IV dose, Once on Day 1
3068145|NCT02106897|Placebo Comparator|Part 2, Cohort 8: Placebo IV|Matching placebo IV dose, Once on Day 1
3068146|NCT02106897|Experimental|Part 3a, Cohort 9: BIIB059 20 mg SC|BIIB059 20 mg SC dose, Every 4 weeks for 2 doses
3068147|NCT02106897|Experimental|Part 3a, Cohort 10: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Every 4 weeks for 2 doses
3068148|NCT02106897|Experimental|Part 3a, Cohort 11: BIIB059 150 mg SC|BIIB059 150 mg SC dose, Every 4 weeks for 2 doses
3068149|NCT02106897|Experimental|Part 3a, Cohort 12: BIIB059 300 mg or less SC|BIIB059 300 mg or less SC dose, Every 2 weeks for 3 doses
3068150|NCT02106897|Placebo Comparator|Part 3a, Cohort 9-12: Placebo SC|Matching placebo SC dose, Every 4 weeks for 2 doses or every 2 weeks for 3 doses
3068151|NCT02106897|Experimental|Part 3b, Cohort 13: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Every 4 weeks for 2 doses
3068152|NCT02106897|Experimental|Part 3b, Cohort 14: BIIB059 300 mg or less SC|BIIB059 300 mg or less SC dose, Every 2 weeks for 3 doses
3068153|NCT02106897|Placebo Comparator|Part 3b, Cohort 13-14: Placebo SC|Matching placebo SC dose, Every 4 weeks for 2 doses or every 2 weeks for 3 doses
3068154|NCT02106884|Experimental|Arm A|Abraxane (nab-paclitaxel) - IV - 125 mg/m2 - 3xq4wks Gemcitabine - IV - 1000 mg/m2 - 3xq4wks
3068155|NCT02106884|Active Comparator|Arm B|Gemcitabine - IV - 1000 mg/m2 - 3xq4wks
3068156|NCT02106871|Placebo Comparator|Placebo|Placebo daily for 4 weeks
3068157|NCT02106871|Active Comparator|Sildenafil|50mg sildenafil daily for 4 weeks
3068158|NCT02106858||Group 1|Patients treated by Physician with Stivarga under approved local prescriptions
3068159|NCT02106845|Experimental|P-gp probe substrate(digoxin)+regorafenib|
3068160|NCT02106845|Experimental|Group B: BCRP probe substrate (rosuvastatin) + regorafenib|
3068161|NCT02106832|Experimental|Ciprofloxacin DPI 28 Days on/off (Cipro 28)|Subjects received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).
3068162|NCT02106832|Experimental|Ciprofloxacin DPI 14 Days on/off (Cipro 14)|Subjects received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).
3068163|NCT02106832|Placebo Comparator|Placebo 28 Days on/off (Placebo 28)|Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).
3068164|NCT02106832|Placebo Comparator|Placebo 14 Days on/off (Placebo 14)|Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).
3068165|NCT02106819||Cerebellar Ataxia subjects|40 individuals with either hereditary or sporadic ataxia will have testing of emotional communication ability and may have magnetic resonance imaging (MRI) of the brain.
3068166|NCT02106819||Healthy Control subjects|40 age matched controls will have testing of emotional communication ability and may have magnetic resonance imaging (MRI) of the brain.
3068167|NCT02106806|Experimental|Zinc chemotherapy|Patients in colorectal chemotherapy supplemented with zinc
3068168|NCT02106806|Placebo Comparator|Placebo chemotherapy|Patients in colorectal chemotherapy with placebo
3068169|NCT02106806|Other|Zinc Control|Healthy volunteers supplemented with zinc
3068170|NCT02106806|Other|Placebo Control|Volunteers received placebo
3068208|NCT02106585|Experimental|Dose 7 JTT-251 or Placebo|Tablets, single dose in fed condition
3068209|NCT02106585|Experimental|Dose 8 JTT-251 or Placebo|Tablets, single dose in fed condition
3068171|NCT02106793|Experimental|Mitomicin C|Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
3068172|NCT02106793|Placebo Comparator|Placebo|Identical placebo solution
3068173|NCT02106780|Experimental|1: ASP1707|
3068174|NCT02106767|Active Comparator|Rosuvastatin|
3068175|NCT02106767|Experimental|Rifampin plus rosuvastatin|
3068176|NCT02106754|Experimental|Brief Intervention|Youth may receive brief intervention from their provider based on randomization.
3068177|NCT02106754|Active Comparator|Treatment As Usual|Youth may receive treatment as usual from their provider based on randomization.
3068178|NCT02106754|Experimental|Brief Intervention with Coaching|Youth may receive brief intervention with coaching from their provider based on randomization.
3068179|NCT02106741|Experimental|Relaxation acupressure|
3068180|NCT02106741|Active Comparator|Stimulating acupressure|
3068181|NCT02106741|No Intervention|Wait-list control|
3068182|NCT02106728|Experimental|Multi-Family Therapy|Multi-family group therapy involving eight to ten families who meet as a group with two therapists for a duration of 8, 1.5h sessions.
3068183|NCT02106728|Active Comparator|Supportive Family Therapy|Family supportive counseling consists of people with eating disorders and their family members meeting with a family therapist. This is treatment as usual in the Eating Disorders Program at University Health Network.
3068184|NCT02106715|Active Comparator|Training|Two exercises for training of core stability and mobility.
3068185|NCT02106715|No Intervention|Control|Control group without training
3068186|NCT02106702|Active Comparator|FAP counseling|Control arm utilizing the standard of care: access to services provided by the Forensic AIDS Project for up to 90 days after release
3068187|NCT02106702|Experimental|Navigator enhanced case-management|Experimental arm: access to Navigator enhanced case-management services for one year after release
3068188|NCT02106689|Experimental|Needle free system|"Intervention will consist of the gonadotropin BRAVELLE being injected using the Comfort-in™ needle free system for the duration of a standard superovulation cycle"
3068189|NCT02106689|Active Comparator|Standard needle injection system|Control patients will undergo their superovulation cycle using the gold standard subcutaneous needle injection system for their gonadotropin injections
3068190|NCT02106676||Pregnant women with PCOS and offspring|Exposures of interest: Polycystic ovary Syndrome (PCOS) according to Rotterdam
3068191|NCT02106676||Pregnant women without PCOS and offspring|Exposures of interest: Pregnant women without polycystic ovary Syndrome (PCOS) according to Rotterdam
3068192|NCT02106663|Active Comparator|Circumferential Pulmonary Vein Ablation|Contiguous ablation lesions will be performed to encircle the two left and right pulmonary veins (PVs), guided by 3D electroanatomic mapping (Carto, Biosense Webster, Inc. or ESI NavX, St. Jude, Inc.) with a 3D LA geometry created either by using the roving mapping catheter or by importing a pre-recorded 3D CT image of the left atrium. After completion of the circumferential ablation, PV isolation will be confirmed by the mapping catheter, and further focal ablation performed as required until electrical PV isolation is confirmed (entrance block at a minimum).
3068193|NCT02106663|Active Comparator|Segmental Pulmonary Vein Isolation|Electrical potentials recorded in the pulmonary vein (PV) ostium using a circular mapping catheter, representing myocardial connections between the left atrium and PVs will be ablated at or just proximal to the PV ostium in the PV antrum. Ablation will be performed segmentally at multiple sites guided by the mapping catheter around the PV ostium or antrum, until mapping demonstrates elimination of all PV potentials (entrance block at a minimum).
3068194|NCT02106650|Experimental|Folotyn and Leucovorin|"Folotyn will be administered by IV push at a dose of 30 mg/m2 once weekly for 6 weeks in each cycle, followed by 1 week of rest (no treatment).~Leucovorin (25 mg tablets) will be taken orally tid for 2 days for a total of six doses (150 mg cumulative weekly dose), beginning 24 hours after each dose of Folotyn is administered.~Folic acid and Vitamin B12 is given prior to initiation of Folotyn."
3068195|NCT02106637|Active Comparator|study groups|study groups will receive Varenicline
3068196|NCT02106637|Placebo Comparator|control group|Participants allocated to the control group will receive placebo
3068197|NCT02106624|Experimental|High Nitrogen|In this arm, daily nitrogen supply is as much as 2.5-3.0 g per kilogram (lean mass weight)
3068198|NCT02106624|Active Comparator|conventional nitrogen|In this arm, daily nitrogen supply is 1.2-1.5g per kilogram (lean mass weight) as recommended by ESPEN guideline
3068199|NCT02106611||Hodgkin Lymphoma Survivor|This is a prospective cross-sectional study of 200 HL survivors whose treatment included mediastinal RT at initial diagnosis or relapse, and are at least 5 years from last HL treatment.
3068200|NCT02106598|Experimental|Phase 1 - Breast and Gynecologic Malignancies|Participants will be investigated comprising 2 different regions of the body (breast and gynecologic malignancies). Each cohort will be analyzed separately to assess the feasibility of conducting pre-operative SLN mapping using real-time optical detection procedures and intradermal single- or double-dose injection/s of non-radioactive cRGDY-PEGCy5.5-C dots about the primary tumor site.
3068201|NCT02106598|Experimental|Phase 2 - Melanoma|The first 20 participants will be enrolled and imaged at a fixed optimized dose (5 nanmoles) and volume (up to 1ml) of fluorescent cRGDY-PEGCy5.5-C dots will be locally administered about the primary tumor site, while varying the timing interval between the injection and visualization of fluorescence signal in optically-active nodes, in order to maximize detection of metastases. Fixed optimized dose, volume, and timing intervals from these studies will then be applied to another 40 enrolled participants to assess efficacy.
3068202|NCT02106585|Experimental|Dose 1 JTT-251 or Placebo|Tablets, single dose in fed condition
3068203|NCT02106585|Experimental|Dose 2 JTT-251 or Placebo|Tablets, single dose in fed condition
3068204|NCT02106585|Experimental|Dose 3 JTT-251 or Placebo|Tablets, single dose in fed condition
3068205|NCT02106585|Experimental|Dose 4 JTT-251 or Placebo|Tablets, single dose in fed condition
3068206|NCT02106585|Experimental|Dose 5 JTT-251 or Placebo|Tablets, single dose in fed condition
3068207|NCT02106585|Experimental|Dose 6 JTT-251 or Placebo|Tablets, single dose in fed condition
3068210|NCT02106585|Experimental|Dose 9 JTT-251 or Placebo|Tablets, single dose in fasted or fed condition followed by a single dose in the alternate fed or fasted condition
3068211|NCT02106572|Experimental|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900
3068212|NCT02106572|Active Comparator|Mitomycin C|intravesical instillation of Mitomycin C
3068213|NCT02106559|Experimental|Treatment (surgery, porfimer sodium, PDT)|Patients receive porfimer sodium IV over 3-5 minutes. Beginning 24 hours later, patients undergo tumor resection and/or radical pleurectomy followed by intraoperative photodynamic therapy to the pleural space.
3068214|NCT02106546|Experimental|veliparib and carboplatin and paclitaxel|veliparib on Days -2 to 5 (7days) and carboplatin and paclitaxel on Day 1 of a 21 day cycle
3068215|NCT02106546|Placebo Comparator|placebo and carboplatin and paclitaxel|placebo on Days -2 to 5 (7days) and carboplatin and paclitaxel on Day 1 of a 21 day cycle
3068216|NCT02106533|Experimental|Group 1 peak VO2 <17.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP.
3068217|NCT02106533|Experimental|Group 2 peak VO2 > 17.5 < 24.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
3068218|NCT02106533|Experimental|Group 3 peak VO2 > 24.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill . Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
3068219|NCT02106520|Experimental|Bevacizumab 25mg|Three administrations of 25 mg of Bevacizumab spaced of 14 days
3068220|NCT02106520|Experimental|Bevacizumab 50mg|Three administrations of 50 mg of Bevacizumab spaced of 14 days
3068221|NCT02106520|Experimental|Bevacizumab 75mg|Three administrations of 75 mg of Bevacizumab spaced of 14 days
3068222|NCT02106520|Placebo Comparator|Placebo|Three administrations of placebo spaced of 14 days
3068223|NCT02106507|Experimental|Progressive Metastatic Castration-Resistant Prostate Cancer|This is a single-institution Phase 1b dose-escalation study in which eligible patients with progressive mCRPC will receive oral doses of apalutamide in combination with everolimus.
3068224|NCT02106494|Experimental|APF530 500 mg SC|APF530 500 mg (granisetron 10 mg) SC and ondansetron placebo IV (0.15 mg/kg) and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1 in association with HEC
3068225|NCT02106494|Active Comparator|ondansetron 0.15 mg/kg IV|Ondansetron 2 mg/mL solution to be administered at 0.15 mg/kg IV (up to a maximum of 16 mg) and APF530 placebo SC and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1
3068226|NCT02106481|Active Comparator|Femoral Nerve Catheters|Patients will receive a Single Shot Femoral Nerve Block along with a conventional continuous femoral nerve catheter
3068227|NCT02106481|Active Comparator|Single Shot Femoral Nerve Blocks|Patients will receive a Single Shot Femoral Nerve Block and a sham catheter post op.
3068228|NCT02106468|Active Comparator|prednisone 50 mg tablet|This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
3068229|NCT02106468|Active Comparator|Omega-3 capsules 1000 mg|This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
3068230|NCT02106455||17.5 mg of sodium risedronate|17.5 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once daily after waking for 8 consecutive weeks.
3068231|NCT02106442||75 mg of sodium risedronate|75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking.
3068232|NCT02106429||PAD and CLI patients|Subjects undergoing non emergent lower extremity revascularization
3068233|NCT02106416|Experimental|PET/MRI|Patient receives PET/MRI
3068234|NCT02106403|Experimental|Prototype disinfectant spray formulation|0.13% w/w Benzalkonium Chloride (BAC) and 1% Menthone Glycerin Acetal (MGA). After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
3068235|NCT02106403|Active Comparator|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
3068236|NCT02106403|Placebo Comparator|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
3068237|NCT02106390|Experimental|rMenB+ACWY|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
3068238|NCT02106390|Active Comparator|rMENB|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
3068239|NCT02106390|Active Comparator|MenACWY|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
3068240|NCT02106364|Experimental|LY2605541|LY2605541 administered by subcutaneous (SQ) injection once daily for 52 weeks. Initial dose is 10 units (10 U) and is titrated by investigator. Participants may continue oral antihyperglycemic medication (OAM) as prescribed by their personal physician.
3068241|NCT02106364|Active Comparator|Insulin Glargine|Insulin glargine administered by SQ injection once daily for 52 weeks. Initial dose is 10 U and is titrated by investigator. Participants may continue OAM as prescribed by their personal physician.
3068242|NCT02106351|Experimental|Group A|Group A - Treatments 1, 2, 3 and 4: Dysport 16 Units (U)/kg in one upper extremity (the study limb).
3068243|NCT02106351|Experimental|Group B|Group B - Treatments 1, 2, 3 and 4: Dysport 8 U/kg in one upper extremity (the study limb).
3068329|NCT02105779|Experimental|Targeted Cognitive Training|40 hours of BFP auditory training
3068244|NCT02106351|Experimental|Group C|"Group C - Treatment 1: Dysport 2 U/kg in one upper extremity (the study limb).~Group C - Treatments 2, 3 and 4: Dysport 8 or 16 U/kg in one upper extremity (the study limb)."
3068245|NCT02106338|Experimental|Cohort A|10 subjects (8 active, 2 placebo) receive a single oral dose of 200 mg CRS3123 or placebo every 12 hours for 10 days
3068246|NCT02106338|Experimental|Cohort B|10 subjects (8 active, 2 placebo) receive a single oral dose of 100 or 400 mg CRS3123 or placebo every 12 hours for 10 days
3068247|NCT02106338|Experimental|Cohort C|10 subjects (8 active, 2 placebo) receive a single oral dose of 600 mg CRS3123 or placebo every 12 hours for 10 days
3068248|NCT02106325|Experimental|Ketamine|IV Ketamine .25mg/kg
3068249|NCT02106325|Placebo Comparator|Diphenhydramine|25mg Diphenhydramine
3068250|NCT02106312|Other|Radiation|Dose reduction of preoperative radiotherapy in MLS from 50 Gy to 36 GY.
3068251|NCT02106299|Experimental|Regen Sling|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a Regen Sling (medprin).
3068252|NCT02106299|Active Comparator|tension-free vaginal tape-obturator|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (gynecare™, USA).
3068253|NCT02106286|Active Comparator|Bisoprolol|Patients not betablocked at baseline receive an acute 72hr dose of beta blocker therapy before CPET
3068254|NCT02106286|No Intervention|No Bisoprolol|No beta blocker given
3068255|NCT02106273||Bronchial blocker|Pilot study to enroll ASA class I-III patients age between 18-70 years who undergoes thoracic surgery which require one-lung ventilation.
3068256|NCT02106260|Experimental|CLS003|
3068257|NCT02106247|Experimental|1 BI 1181181 low dose|tablet
3068258|NCT02106247|Experimental|BI 1181181 high dose|tablet
3068259|NCT02106247|Experimental|Placebo|tablet
3068260|NCT02106234|Active Comparator|Control: NO prophylactic iv hydration|"Control group:~Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed."
3068261|NCT02106234|No Intervention|Standard care: prophylactic iv hydration|"Standard care group:~Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will receive the standard intravenous prophylactic hydration treatment with normal saline as prescribed."
3068262|NCT02106221|Experimental|Intervention|Financial incentives will be provided based on performance in areas determined to be of high-value.
3068263|NCT02106221|Active Comparator|Control|Financial incentives are a flat rate which can be reduced if an appropriate amount of effort or improvement is not met
3068264|NCT02106208|Experimental|Cheese diet|A 4-week experimental diet with all meals and foods be provided to participants, including 90g of regular cheddar cheese daily per 2500 kcal. The diet will contain 13% of saturated fat (SFA), 14% of mono-unsaturated fat (MUFA), 5% of polyunsaturated fat (PUFA) and 53% of carbohydrate (CHO).
3068265|NCT02106208|Experimental|Butter diet|A 4-week experimental diet with all meals and foods be provided to participants, the diet will contain 13% of SFA mostly from butter. The diet will contain 14% of MUFA, 5% of PUFA and 53% of CHO.
3068266|NCT02106208|Experimental|CHO diet|A 4-week experimental diet with all meals and foods will provided to participants. The diet will contain 60% of CHO, 6% of SFA, 14% of MUFA and 5% of PUFA.
3068267|NCT02106208|Experimental|MUFA diet|A 4-week experimental diet with all meals and foods be provided to participants. The diet will contain 21% of MUFA, 6% of SFA, 5% of PUFA and 53% of CHO.
3068268|NCT02106208|Experimental|PUFA diet|A 4-week experimental diet with all meals and foods will be provided to participants. The diet will contain 12% of PUFA, 14% of MUFA, 6% of SFA and 53% of CHO.
3068269|NCT02106195|Experimental|KD025|KD025 200 mg (two 100 mg capsules) orally once daily for 28 days
3068270|NCT02106182|Experimental|Silodosin|Silodosin, 8 mg, once daily, orally administered with dinner for 12 weeks
3068271|NCT02106169|Experimental|Therapeutic education group|"At first, all patients will be invited to participate in a study of troop having for objective to estimate their quality of life. Then, the doctors offer patients randomized to therapeutic education to have a therapeutic education before the 4th month.~The sessions will be led by a multidisciplinary equip. Each child and his family will have a therapeutic session (2 times 2 hours)."
3068272|NCT02106169|No Intervention|Control group|At first, all patients will be invited to participate in a study of troop having for objective to estimate their quality of life. Then, the patients randomized in this group will have the habitual medical care.
3068273|NCT02106156||Chronic Hepatitis C|Participants with chronic hepatitis C planned for treatment with peginterferon alfa-2a alone or in combination with ribavirin according to routine clinical practice will be observed in this study.
3068274|NCT02106143|Experimental|RejuvenAir™ Radial Spray Cryotherapy|Subjects will receive Rejuvenair Radial SCT prior to lobectomy.
3068275|NCT02106130|Experimental|R - R+M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
3068276|NCT02106130|Experimental|R+M - R|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
3068277|NCT02106130|Experimental|M - R+M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
3068278|NCT02106130|Experimental|R+M - M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
3068279|NCT02106117||neutropenic patients|Patients receiving treatment for hematological malignancies expected to result in prolonged neutropenia (neutrophil counts <0.5 x 10 ^9/L for more than seven days).
3068280|NCT02106104|Experimental|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
3068281|NCT02106104|Active Comparator|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
3068282|NCT02106091|Experimental|AFM11|IV (intravenous) infusion, dose escalation
3068283|NCT02106078|Active Comparator|Level 1|Moderated discussion board only
3068284|NCT02106078|Active Comparator|Level 2|Moderated discussion board plus psychoeducation
3068285|NCT02106078|Active Comparator|Level 3|Moderated discussion board plus psychoeducation plus interactive psychosocial tools
3068286|NCT02106065|Experimental|ESBR-i|Education and Skill-Building Rehabilitation (in-clinic)
3068287|NCT02106065|Experimental|ESBR-v|Education and Skill-Building Rehabilitation (over video telehealth)
3068288|NCT02106065|Active Comparator|UC|Usual Care plus supplemental paper education materials
3068289|NCT02106052|Active Comparator|Aerobic exercise|
3068290|NCT02106052|Other|Stretching and toning exercise|
3068291|NCT02106039|Experimental|intensive monitoring|more intensive monitoring strategy of blood glucose and clinical review
3068292|NCT02106039|No Intervention|standard monitoring|glucose monitoring followed the prevailing practice at each site
3068293|NCT02106026|No Intervention|Conventional|All expectant mothers received the usual information about the advantages of maternal milk during pre-natal period. Nurses provided the information in personalized dialogue with the women during obstetric consultations.
3068294|NCT02106026|Experimental|Preventive education|It was provided by the nurses during obstetric consultation in pre-natal period and averaged 30 minutes in duration. The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures. The nurses encouraged participation and gave the education in personalized dialogue with the woman. The information was reinforced with an illustrated explanatory leaflet.
3068295|NCT02106013||Low HDL-C|Study participants with HDL-C levels below the 10th percentile (HDL-C ≤32 mg/dL)
3068296|NCT02106013||Intermediate HDL-C|Study participants with HDL-C levels between 40th and 60th percentiles (40≤HDL-C≤67 mg/dL)
3068297|NCT02106013||High HDL-C|Study participants with HDL-C levels above the 90th percentile (HDL-C ≥78mg/dL)
3068298|NCT02106000||Arm 1: Non-pregnant females|Inhalation profiles will be recorded for non-pregnant females
3068299|NCT02106000||Arm 2: Pregnant females|Inhalation profiles will be recorded for the women in the 3rd stage of labour
3068300|NCT02105987|Experimental|ABC/DTG/3TC|Subject will take ABC 600 mg/DTG 50 mg/3TC 300 mg FDC once daily in the morning or the evening, at approximately the same time each day for 24 weeks. After Week 24, subjects will continue on this treatment arm for an additional 24 weeks.
3068301|NCT02105987|Active Comparator|Comparator|Subjects will continue on their current Combination antiretroviral therapy (cART) regimen for 24 weeks. At Week 24, subjects will switch to ABC/DTG/3TC FDC for an additional 24 weeks.
3068302|NCT02105974|Experimental|Fluticasone Furoate/Vilanterol 100/25 Inhalation Powder|Inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)
3068303|NCT02105974|Experimental|Vilanterol 25 Inhalation Powder|Long-acting beta2-agonist (LABA)
3068304|NCT02105961|Experimental|Arm 1|Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
3068305|NCT02105961|Experimental|Arm 2|Each subject will receive 300 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
3068306|NCT02105961|Experimental|Arm 3|Each subject will receive placebo (0.9percent sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) their baseline standard of care COPD medication
3068307|NCT02105948|Experimental|Arm 1|Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with optimized standard of care background therapy.
3068308|NCT02105948|Placebo Comparator|Arm 2|Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) along with optimized standard of care background therapy.
3068309|NCT02105935||Normative study|male and female athletes, ages 8-14.
3068310|NCT02105935||Baseline|male and female athletes, ages 8-18.
3068311|NCT02105922|Active Comparator|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
3068312|NCT02105922|Experimental|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
3068313|NCT02105922|Active Comparator|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
3068314|NCT02105909|Experimental|obese subjects|DNA analysis
3068315|NCT02105909|Placebo Comparator|lean subjects|DNA analysis
3068316|NCT02105883|No Intervention|Scenario C (control)|no badge
3068317|NCT02105883|Active Comparator|Scenario B (badge)|Use of Identification badge during scenarios (roles and places)
3068318|NCT02105870|Experimental|Intracoronary abciximab (Reopro)|Intracoronary abciximab (Reopro)
3068319|NCT02105870|Placebo Comparator|Control group|Intracoronary Reopro
3068320|NCT02105857|No Intervention|Standard care|Patients receiving the standard rehabilitation protocol
3068321|NCT02105857|Experimental|grade A+ knee mobilization|Patients receiving the standard rehabilitation protocol plus grade A+ knee mobilization
3068322|NCT02105844||Atrial Fibrillation|Cohort Study on patients with atrial fibrillation in Switzerland
3068323|NCT02105831||CEU skeletal muscle perfusion imaging|Heart failure with LVAD Contrast ultrasound skeletal muscle perfusion imaging
3068324|NCT02105818||Systemic sclerosis|Patients with diagnosed systemic sclerosis treated in the Reha Rheinfelden, Switzerland (European Centre for the Rehabilitation of Scleroderma).
3068325|NCT02105805|Experimental|low energy diet|low energy diet treatment
3068326|NCT02105805|Active Comparator|Nordic recommendation|Nordic recommendation, no restrictions on energy
3068327|NCT02105792||Responders|Patients with Type 2 diabetes about to commence a second- or third-line glucose-lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R agonists, SGLT2 inhibitors or Glitazone or insulin).
3068328|NCT02105792||Progressors|Patients with Type 2 diabetes that progress to requiring insulin treatment ≤10 years from diagnosis or have no requirement for insulin treatment >10 years from diagnosis.
3068330|NCT02105779|Experimental|Social Cognitive Training|40 hours of auditory training and 10 hours social exercises
3068331|NCT02105766|Experimental|1|The first cohort of patients will be male donor - femalerecipients to see if this new regimen will yield higher rate of durable donor leukocyte chimerism. We will also measure anti-A, anti-B, and/or other red cell antibody titers from this initial cohort to determine the feasibility of transplanting patients with pre-existing antibodies (major ABO mismatch or other anti-donor red cell antibody).
3068332|NCT02105766|Experimental|2|The second cohort of patients will be patients with preexisting antibodies (major ABO mismatch or otheranti-donor red cell antibody). The primary endpoint forthis group will be different than the first cohort (section 11.1 and 11.2). It is very likely that red cell aplasia (6 months to 2 years posttransplant) and prolonged duration of red cell transfusion are expected in this second group, thus a later time point to determine treatment success is justified.
3068333|NCT02105753|Experimental|1210nm axillary laser treatments|two laser treatments right axilla and one treatment left axilla
3068334|NCT02105753|Experimental|1210nm laser treatments to the axilla|two laser treatments left axilla and one treatment right axilla
3068335|NCT02105740|Experimental|Hypnosis|Use of hypnosis in the reduction of the levels of pain, depression and anxiety.
3068336|NCT02105740|Active Comparator|Control|Comparison of the effects of hypnosis between the control group and the experimental group regarding pain, anxiety and depression with the application of the scales.
3068337|NCT02105727|Experimental|Salt reduction|Community-based salt reduction
3068338|NCT02105701|Experimental|Grazoprevir + Elbasvir 12 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg fixed-dose combination (FDC) tablets once daily (q.d.) by mouth for 12 weeks.
3068339|NCT02105701|Experimental|Grazoprevir + Elbasvir + RBV 12 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules twice daily (b.i.d.) by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 12 weeks.
3068340|NCT02105701|Experimental|Grazoprevir + Elbasvir 16 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 16 weeks.
3068341|NCT02105701|Experimental|Grazoprevir + Elbasvir + RBV 16 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 16 weeks.
3068342|NCT02105688|Experimental|Immediate Treatment Arm|In Part A, participants receive grazoprevir 100 mg plus elbasvir 50 mg FDC (MK-5172A) once daily for 12 weeks (blinded) and are followed-up for 24 weeks.
3068343|NCT02105688|Placebo Comparator|Deferred Treatment Arm|In Part A, participants receive placebo to MK-5172A FDC once daily for 12 weeks (blinded), followed by 4 weeks of follow-up. Afterwards, participants receive 12 weeks of open-label treatment with the MK-5172A FDC and are followed-up for 24 weeks.
3068344|NCT02105675|Experimental|DCVAC/PCa add on to Standard of Care|Combination therapy with Dendritic Cells DCVAC/PCa and Standard of Care
3068345|NCT02105675|Active Comparator|Standard of Care|Docetaxel as an Active Comparator
3068346|NCT02105662|Experimental|Grazoprevir+Elbasvir|Participants receive a fixed-dose combination (FDC) of grazoprevir 100 mg plus elbasvir 50 mg once daily for 12 weeks and are followed-up for 24 weeks.
3068347|NCT02105649|Experimental|calf muscle strengthenig group|"experimental group~will receive the same selected physical therapy program in addition to manual and mechanical strengthening exercises and electrical stimulation program for calf muscles of both lower limbs."
3068348|NCT02105649|Other|No calf muscle strengthening group|"control group~will receive only the selected physical therapy program"
3068349|NCT02105636|Experimental|Arm A: Nivolumab|Nivolumab 3mg/kg intravenous (IV) Solution for Injection every 2 weeks until disease progression
3068350|NCT02105636|Active Comparator|Arm B: Cetuximab/Methotrexate/Docetaxel|"Cetuximab intravenous (IV) Solution for Injection 400 mg/m2 (first dose) then 250 mg/m2 weekly until disease progression~OR~Methotrexate intravenous (IV) Solution for Injection 40 or 60 mg/m2 weekly until disease progression~OR~Docetaxel intravenous (IV) Solution for Injection 30 or 40 mg/m2 weekly until disease progression"
3068351|NCT02105623|Active Comparator|Standard Therapy|Risk factor control Diet Exercise
3068352|NCT02105623|Experimental|Rosuvastatin therapy|Risk factor control Rosuvastatin
3068353|NCT02105610|Experimental|volatile anesthetics (desflurane, isoflurane, sevoflurane)|
3068354|NCT02105610|Active Comparator|total intravenous anesthesia|
3068355|NCT02105597|Experimental|Mobile application|
3068356|NCT02105597|No Intervention|Standard care|
3068357|NCT02105584|Experimental|LAA closure device|Implantation of LAA closure device
3068358|NCT02105571|Experimental|Intervention|Intervention activities take place over a 6-month period for each participant, and include a weight loss competition with self-monitoring and feedback; computer-based training units on healthy weight loss, healthy eating, exercise, and sleep; and up to four motivational interviews with a health coach by cell phone.
3068359|NCT02105571|No Intervention|Control|"Continued work conditions and Usual Practices in that workplace"
3068360|NCT02105558|Experimental|Epidural anesthesia|Trial of labor after cesarean with an epidural for anesthesia: Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered.
3068361|NCT02105558|Experimental|Combined spinal and epidural anesthesia|Trial of labor after cesarean with a combined spinal and epidural (CSE) for anesthesia: the epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr.
3068362|NCT02105545|Experimental|Cancer Treatment Options|Blood samples and, for some patients, buccal (mouth cell) samples will be collected at diagnosis and/or relapse. Solid tumor samples will be collected in the normal course of treatment, from biopsy, blood or other specimens. For blood-based cancers such as leukemia, blood and bone marrow specimens will be collected before treatment begins, on day 29 and possibly at a later time point if relapse occurs.
3068363|NCT02105532|Active Comparator|Restrictive Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
3068364|NCT02105532|Active Comparator|Liberal Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
3068365|NCT02105519|No Intervention|The group receiving no influenza vaccine|Participants in this group will not receive any influenza vaccine (negative control group).
3068366|NCT02105519|Experimental|One dose of AdimFlu-S group|Participants in this group will receive one dose of the seasonal trivalent influenza vaccine (one dose of AdimFlu-S group), formulation 2013-2014, at the initiation of the study. Each administered dose contain 15 ug virus antigen for each virus strain.
3068367|NCT02105519|Experimental|Two dose of AdimFlu-S group|Participants in this group (Two dose of AdimFlu-S group)will receive the seasonal trivalent influenza vaccine, formulation 2013-2014, at the week 0 and 4 weeks after the initiation of the study. Each administered dose contain 15 ug virus antigen for each virus strain.
3068368|NCT02105506|Experimental|Tachosil patch|Tachosil patch (9.5 x 4.8 cm), containing human fibrinogen (5.5 mg/cm2) and human thrombin (2.0 IU/cm2), applied during surgery. Up to 7 patches per participant may be applied.
3068369|NCT02105493|Active Comparator|500 microgram of Nitroglycerin|500 mcg nitroglycerin was given intra-arterially through the sheath at the end of a transradial procedure
3068370|NCT02105493|Placebo Comparator|Saline 5 mL|0,9% Saline 5 mL was given intra-arterially through the sheath at the end of a transradial procedure
3068371|NCT02105467|Experimental|Immediate Treatment Group|Participants received blinded grazoprevir 100 mg / elbasvir 50 mg fixed-dose combination (FDC) tablet orally once daily for 12 weeks followed by a 24-week follow-up period
3068372|NCT02105467|Placebo Comparator|Deferred Treatment Group|Participants received blinded placebo tablet orally once daily for 12 weeks; after a 4-week unblinding/washout period participants received open label grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks. Follow-up was continued for an additional 24 weeks.
3068373|NCT02105454|Experimental|GZR 100 mg + EBR 50 mg + RBV for 12 weeks|Participants receive grazoprevir 100 mg once per day (QD), elbasvir 50 mg QD, and RBV 800 - 1400 mg total daily dose divided twice per day (based on body weight) for 12 weeks
3068374|NCT02105441||cochlear implant|How well patients with cochlear implants understand speech in noise with implant on, compared to implant off.
3068375|NCT02105428|No Intervention|Sedentary Control|Participants will be randomized to an exercise training program or sedentary control group. The sedentary will not perform any structured physical activity or exercise. Participants will be encouraged to maintain their sedentary lifestyle and will be monitored by an accelerometer to track physical activity.
3068376|NCT02105428|Experimental|Aerobic Exercise Training|Participants will perform 12-weeks of aerobic exercise training
3068377|NCT02105415|Active Comparator|Etomidate|
3068378|NCT02105415|Experimental|Ketamine / Propofol Admixture|
3068379|NCT02105402|Experimental|Intervention Group - PROMPT therapy|Prompts for Restructuring Oral Muscular Phonetic Targets (PROMPT)
3068380|NCT02105402|No Intervention|Waitlist or Delay Group|Participants in this group are on the waitlist for 10 weeks
3068381|NCT02105389|Experimental|Individualized Yoga Intervention|Individualized Yoga Intervention sessions will be administered by a trained yoga instructor three times weekly (or up to a maximum of five times per week) for three consecutive weeks. There will be a common structure for all sessions that will include relaxation and breathing exercises as well as a series of poses focused on strengthening, flexibility, and balance. There will be low, moderate and high intensity regimens prescribed depending on the wishes and abilities of the child and parent and the judgment of the yoga instructor.
3068382|NCT02105376|Experimental|Trigeminal Nerve Stimulation (TNS)|"TNS active group~TNS will be applied by the external simulator EMS400. The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 200 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia (approximately 0.5-2mA). The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed on the forehead just above the supraorbital foramen bilaterally."
3068383|NCT02105376|Placebo Comparator|Sham|"TNS sham~The placebo intervention will consist of an initial stimulation until a mild paresthesia is achieved, and then turn off the machine after 60 seconds, after which period there is a tendency of reduction natural feeling secondary to skin sensitization paresthesia."
3068384|NCT02105363||Age 11-15|
3068385|NCT02105363||Age 16-20|
3068386|NCT02105363||Age 21-25|
3068387|NCT02105363||Age 26-30|
3068388|NCT02105363||Age 31-35|
3068389|NCT02105363||Age 36-40|
3068390|NCT02105363||Age 41-45|
3068391|NCT02105363||Age 46-50|
3068392|NCT02105363||Age 51-55|
3068393|NCT02105363||Age 56-60|
3068394|NCT02105363||age 61-65|
3068395|NCT02105363||Age 66-70|
3068396|NCT02105363||Age 71-75|
3068397|NCT02105363||Age 76-80|
3068398|NCT02105363||Age 81-85|
3068399|NCT02105363||Age 86-90|
3068400|NCT02105363||Age 91-95|
3068401|NCT02105363||Age 96-100|
3068402|NCT02105363||Age 0-5|
3068403|NCT02105363||Age 6-10|
3068404|NCT02105350|Experimental|MEK 162, gemcitabine, and oxaliplatin|MEK 162 (30 mg or 45 mg by mouth), twice a day, every day. Gemcitabine (1000 mg/m2 by vein), followed by oxaliplatin (85 mg/m2 by vein) every 2 weeks.
3068405|NCT02105337||tegaderm placement|all pts will have tegaderm placed prior to goggles for VEP
3068406|NCT02105324|Experimental|Bionic Pancreas|Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 5 days.
3068447|NCT02105012|Placebo Comparator|Placebo MDI|Placebo MDI administered as 2 inhalations BID
3068448|NCT02104999|Other|Point-of-care test for CRP|Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
3068407|NCT02105324|Experimental|Usual Care|Usual Care diabetes management in a diabetes camp environment including a nurse or nursing student assigned to each cabin and review and adjustment of the insulin regimen daily by a physician or nurse practitioner, all participants using the participant's own insulin pump and a continuous glucose monitor if they use one as part of their usual care, for 5 days.
3068408|NCT02105311|Experimental|Selective laser trabeculoplasty|Treating with the selective laser trabeculoplasty
3068409|NCT02105311|Active Comparator|Travoprost|Using eye drop: travoprost
3068410|NCT02105285|Experimental|OPC-1085EL ophthalmic solution|Once daily
3068411|NCT02105285|Active Comparator|Carteolol long-acting ophthalmic solution|Once daily
3068412|NCT02105272|Experimental|OPC-1085EL ophthalmic solution|Once daily
3068413|NCT02105272|Active Comparator|Latanoprost ophthalmic solution|Once daily
3068414|NCT02105259|Experimental|Psychodynamic Internet Treatment|Psychodynamic Internet Treatment for social anxiety disorder during 10 weeks and guided by a psychologist
3068415|NCT02105259|Active Comparator|Waiting list with support|Behavioral: supportive check-ups via the Internet during 10 weeks
3068416|NCT02105246|Experimental|Referral to home-based cardiac rehabilitation|Referral to a home-based cardiac rehabilitation program (intervention).
3068417|NCT02105246|Active Comparator|Referral to center-based cardiac rehabilitation|Referral to a center-based cardiac rehabilitation program (standard of care).
3068418|NCT02105233|Experimental|BMG|brain mimicking fluid
3068419|NCT02105220||Obese|"We will enroll patients with BMI≥40 kg/m2 to describe the impact of obesity on chest wall compliance and respiratory mechanics.~Respiratory mechanics assessment: We will assess respiratory mechanics through different end expiratory pressure settings and recording airway and esophageal pressure tracings."
3068420|NCT02105220||Intraabdominal Hypertension|"We will enroll patients with IAP≥12 mmHg to describe the impact of intraabdominal hypertension on chest wall compliance and respiratory mechanics.~Respiratory mechanics assessment: We will assess respiratory mechanics through different end expiratory pressure settings and recording airway and esophageal pressure tracings."
3068421|NCT02105207|Experimental|Lung Ultrasound|In Patients allocated to this arm Lung ultrasound for detection of interstitial syndrome will be performed before chest radiography.
3068422|NCT02105207|Experimental|Chest Radiography|In Patients allocated to this arm chest radiography will be performed for the detection of indirect signs of pulmonary congestion/ADHF without ultrasound evaluation.
3068423|NCT02105194|Experimental|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
3068424|NCT02105181|Other|Fully covered metal stent (FCMS)|There is one arm in the study : the intervention consists on placing a device which is a fully covered metal stent in the biliary tract of all patients
3068425|NCT02105168|Experimental|Experimental arm|Blood sample Tumorous biopsy Healthy material sample
3068426|NCT02105155|Experimental|Conversion at day 7 ± 3|Conversion from Prograf to Advagraf at D7 ± 3
3068427|NCT02105155|Active Comparator|Conversion at day 90±5|Conversion from Prograf to Advagraf at 90±5
3068428|NCT02105142|Active Comparator|Computer Decision Support|ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
3068429|NCT02105142|Active Comparator|ADHD Group visits|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
3068430|NCT02105142|Active Comparator|ADHD Group Visits plus Online Discussion Portal|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Online discussion portal access granted to parent participants and will allow parents to communicate with each other in between in-person group visits
3068431|NCT02105129|Experimental|HMPL-523|Single/Multiple Ascending Dose. oral administration, a single dose of 5, 20, 50, 100, 200 and 300 mg (Part A) and multiple dose of HMPL-523 at dose level based on result of Part A
3068432|NCT02105129|Placebo Comparator|Placebo|Placebo: oral administration
3068433|NCT02105116|Experimental|Standard chemotherapy followed by allogenic therapy|INDUCTION CHEMOTHERAPY: Patients receive standard induction chemotherapy with fludarabine phosphate IV over 1 hour QD for 5 days and cytarabine IV over 4 hours for 5 days. G-CSF 5 mcg/kg will be started at day14 if day14 bone marrow does not have >5% leukemic blasts. Treatment may continue for 1 or 2 courses at the discretion of the treating physician. If the patient enters a complete remission they are eligible for ALLOGENEIC CELLULAR THERAPY: Patients eligible for the experimental therapy undergo irradiated Donor Lymphocyte Infusion (DLI) of 3 x 10^8 CD3+ cells/kg at 8 weeks. Patients with stable disease may repeat irradiated DLI every 8-12 weeks in the absence of disease progression or unacceptable toxicity.
3068434|NCT02105103|Other|Accu-Chek® Insight Insulin Pump|
3068435|NCT02105090|Placebo Comparator|Sodium chloride 0.9%|Sodium chloride 0.9% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
3068436|NCT02105090|Experimental|Articaine hydrochloride 1%|Articaine hydrochloride 1% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
3068437|NCT02105090|Experimental|Articaine hydrochloride 2%|Articaine hydrochloride 2% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
3068438|NCT02105077||Xenon|Patients undergoing surgery with xenon-based general anesthesia
3068439|NCT02105064|Active Comparator|Active rTMS|rTMS over Supplementary Motor Area, 1hz, no pauses, 20 minutes per sessions. Total: 20 sessions.
3068440|NCT02105064|Sham Comparator|Sham|Sham stimulation, 20 minutes per session, total 20 sessions
3068441|NCT02105038|Experimental|Knob|Steering in a driving simulator using a steering wheel spinner knob.
3068442|NCT02105038|Active Comparator|No Knob|Steering in a driving simulator immediately following surgical treatment of hip fractures.
3068443|NCT02105012|Experimental|BD MDI 320 µg|Budesonide metered dose inhaler (BD MDI) 320 µg (PT008) administered as 2 inhalations BID
3068444|NCT02105012|Experimental|BD MDI 160 µg|BD MDI 160 µg (PT008) administered as 2 inhalations BID
3068445|NCT02105012|Experimental|BD MDI 80 µg|BD MDI 80 µg (PT008) administered as 2 inhalations BID
3068446|NCT02105012|Experimental|BD MDI 40 µg|BD MDI 40 µg (PT008) administered as 2 inhalations BID
3068449|NCT02104986|Experimental|3 courses of Velbe-Bleomycin-Cisplatin|3 VBP (Velbe-Bleomycin-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
3068450|NCT02104986|Experimental|4 courses of Velbe-Bleomycin-Cisplatin|4 VBP (Velbe-Bleomycin-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
3068451|NCT02104986|Experimental|3 courses Vepeside-ifosfamide-Cisplatin|3 VIP (Vepeside-ifosfamide-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
3068452|NCT02104986|Experimental|4 courses Vepeside-ifosfamide-Cisplatin|4 VIP (Vepeside-ifosfamide-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
3068453|NCT02104973|Experimental|Lifestyle counseling|After obtaining the approval of schools and parents, will be established in schools, units in which individual attention is given to children, parents and teachers that request: the advice is aimed at training users on healthy diet and constant physical activity. Workshops with children, in which selected topics will be discussed based on the analysis of depth interviews with children, parents and teachers, and information on habits and resources gathered through questionnaires will be conducted. The intervention included the provision of information and feedback with the population through a website. The work will include participation in the selection of foods sold in schools.
3068454|NCT02104973|No Intervention|Control|Usual care
3068455|NCT02104960||PROOF|Healthy inhabitants of the city of Saint-Etienne, France, and aged 65 years at the inclusion date. (NCT00759304)
3068456|NCT02104947|Experimental|idarucizumab|idarucizumab Only 1 treatment, no placebo or comparator
3068457|NCT02104934|No Intervention|Local Infiltration Analgesia|The Local Infiltration Analgesia group will receive local infiltration of ropivacaine 150mg, ketorolac 30mg, morphine 10mg, adrenaline 200mcg and vancomycin 500mg in a total volume of 75mls by the surgeon.
3068458|NCT02104934|Active Comparator|Adductor Canal Block|The Adductor Canal Block group of patients will receive intravenous ketorolac 30mg intra-operatively and an adductor canal block at the end of surgery. The block will be performed under real time ultrasound guidance and 30mls of 0.5% ropivacaine (150mg) is injected with a Stimuplex A100, 21G needle.
3068459|NCT02104921||Neuromuscular Disease Patients|Amyotrophic lateral sclerosis patients, myopathy patients, muscular dystrophy patients, myasthenia gravis patients, radiculopathy patients, mononeuropathy patients
3068460|NCT02104921||Healthy volunteers|
3068461|NCT02104908|Experimental|paravertebral nerve|Injection with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1)
3068462|NCT02104908|Other|lumbar and sacral plexus block|a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;
3068463|NCT02104895|Active Comparator|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
3068464|NCT02104895|Experimental|Partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI)
3068465|NCT02104882|Experimental|Intraoperative Radiotherapy|Following conventional frameless neuronavigation-guided microsurgical tumor resection, patients will receive IORT with 20-40 Gy (prescribed to the applicator surface). Not later than 4 weeks, radiochemotherapy (RCT) will be initiated, consisting of a total EBRT dose of 60 Gy (delivered in fractions of 2 Gy) and concomitant chemotherapy with temozolomide (50 mg/m2/d). Four weeks after RCT, cycling chemotherapy with temozolomide (150-200mg/m2/d/cycle) will be applied.
3068466|NCT02104869|Active Comparator|Recommended dose (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).~Dose: single 0.5 mL dose."
3068467|NCT02104869|Active Comparator|Healthy adults|"Intervention: trivalent influenza vaccine (inactivated and fragmented).~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).~Dose: single 0.5 mL dose."
3068468|NCT02104869|Experimental|Single double dose (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).~Dose: single 1.0 mL dose."
3068469|NCT02104869|Experimental|Two sequential doses (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).~Dose: two 0.5 mL doses 21 days apart."
3068470|NCT02104856||Alair System (Bronchial Thermoplasty)|Asthma patients undergoing Bronchial Thermoplasty treatment with commercially available Alair device as per Directions For Use.
3068471|NCT02104843|Experimental|Arm 1: DCV/ASV/BMS-791325 FDC + BMS-791325 + Rosuvastatin|"Treatment A: Rosuvastatin tablet orally on specified days~Treatment B: Daclatasvir, Asunaprevir and BMS-791325 Fixed dose combination (FDC) + BMS-791325 tablet orally on specified days~Treatment C: Daclatasvir, Asunaprevir and BMS-791325 FDC + BMS-791325 + Rosuvastatin tablet orally on specified days"
3068472|NCT02104830|Experimental|Empegfilgrastim 6 mg|Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
3068473|NCT02104830|Experimental|Empegfilgrastim 7.5 mg|Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
3068474|NCT02104830|Active Comparator|Filgrastim|Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy and placebo #1 in dose 1.0 ml subcutaneously, 24 h after the chemotherapy.
3068477|NCT02104804|Experimental|Saxagliptin 5mg|Saxagliptin 5mg, administered to subjects with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
3068478|NCT02104804|Placebo Comparator|Placebo|Placebo administered to subjects with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
3068479|NCT02104791||procalcitonin in blood|-Group 1: Healthy preterm Group: will include 50 pregnant females all at 24-34 weeks of gestational age .
3068480|NCT02104791||plasma of blood|-Group 2: Preterm premature rupture of membrane Group include 50 pregnant women
3068481|NCT02104791||procalcitonin,prematureruptureofmembrane in blood|"Complete history including (special habits like smoking and alcohol taking, menstrual history especially LMP, medical diseases, past obstetric history including duration, mode of delivery for each pregnancy, and if there were fetal or maternal complications).~Physical examination including (general condition, height, weight, vital signs).-Ultrasound to execlude multiple pregnancies, IUFD and to confirm oligohydraminos in group2.~The venous blood samples will be taken for measuring of -Procalcitonin in mothors -CRP and WBCs in mothers to detect infection -CRP in neonates of mothers of group 2.~They will be asked for their permission and consent."
3068482|NCT02104778|Experimental|Dexamethasone|Dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
3068483|NCT02104778|Placebo Comparator|Control|Normal saline 1 ml is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
3068484|NCT02104778|Experimental|epinephrine|Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
3068485|NCT02104765|Experimental|LY2951742 Single Dose 1|Dose 1 of LY2951742 given subcutaneously once
3068486|NCT02104765|Experimental|LY2951742 Single Dose 2|Dose 2 of LY2951742 given subcutaneously once
3068487|NCT02104765|Experimental|LY2951742 Single Dose 3|Dose 3 of LY2951742 given subcutaneously once
3068488|NCT02104765|Experimental|LY2951742 Single Dose 4|Dose 4 of LY2951742 given subcutaneously once
3068489|NCT02104765|Experimental|LY2951742 Multiple Dose|LY2951742 given subcutaneously once every 4 weeks for 8 weeks
3068490|NCT02104765|Placebo Comparator|Placebo Single Dose|Placebo given subcutaneously once
3068491|NCT02104765|Placebo Comparator|Placebo Multiple Dose|Placebo given subcutaneously once every 4 weeks for 8 weeks
3068492|NCT02104752|Experimental|Curcumin|Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).
3068493|NCT02104752|Placebo Comparator|Sugar Pill|Matched placebo, 2 capsules twice daily.
3068494|NCT02104739|Experimental|Exenatide, then Saxagliptin, then Placebo|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
3068495|NCT02104739|Experimental|Exenatide, then Placebo, then Saxagliptin|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
3068496|NCT02104739|Placebo Comparator|Saxagliptin, then Exenatide, then Placebo|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
3068497|NCT02104739|Experimental|Saxagliptin, then Placebo, then Exenatide|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
3068498|NCT02104739|Experimental|Placebo, then Exenatide, then Saxagliptin|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
3068499|NCT02104739|Experimental|Placebo, then Saxagliptin, then Exenatide|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
3068500|NCT02104739|Experimental|Exenatide, then Saxagliptin, then Placebo, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
3068501|NCT02104739|Experimental|Exenatide, then Placebo, then Saxagliptin, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
3068502|NCT02104739|Experimental|Saxagliptin, then Exenatide, then Placebo, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
3068503|NCT02104739|Experimental|Saxagliptin, then Placebo, then Exenatide, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
3068504|NCT02104739|Experimental|Placebo, then Exenatide, then Saxagliptin, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
3068505|NCT02104739|Experimental|Placebo, then Saxagliptin, then Exenatide, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
3068506|NCT02104726|Active Comparator|Blind Steroid Injection|Blind Steroid Injection for patients with OA deemed qualified for it clinically
3068507|NCT02104726|Active Comparator|Fluoroscopy guided steroid injection|Fluoroscopy guided Steroid Injection for patients with OA deemed qualified for it clinically. We want to see which one is better.
3068508|NCT02104713|Experimental|Allogeneic (MSC's) Application to the Burn Wounds|"Allogeneic (MSC's) Application to the Burn Wounds. The 1st group of 5 will be started on the lowest dose. If there are no adverse reactions, the 2nd group of 5 will receive a higher dose. This will be repeated for the 3rd and 4th groups with each receiving a higher dose.~Up to 2 administrations of cells per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart."
3068509|NCT02104700|Active Comparator|Rilpivirine/Emtricitabine/Tenofovir|"Immediate switch: RILPIVIRINE/ EMTRICITABINE /TENOFOVIR FDC QDAY at randomization."
3068551|NCT02104466|Experimental|TAU + 12 wks of acupuncture 2x/week|Participants randomized to this arm will receive usual care with adjunctive acupuncture twice per week for a period of 12 weeks.
3068510|NCT02104700|Active Comparator|Nevirapine/Lamivudine/ plus other NNRTI|"Delayed switch: Continue NEVIRAPINE 200MG BID + LAMIVUDINE 300MG + OTHER NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI) through 24 weeks then switch to RILPIVIRINE 25MG/ EMTRICITABINE 200MG/TENOFOVIR 300MG FDC QDAY and then follow through 48 weeks."
3068511|NCT02104687|Active Comparator|Flow|The Flow therapeutic algorithm will be responsible for adjustment of intraoperative interventions - volumotherapy and administration of vasoactive drugs, with the aim to maintain the CI value >2.5 l/m/m2 (FTc - flow time <330 ms was chosen as variable defining preload; PV, peak velocity <70 ms-1 will be used as a variable defining contractility; SVR, total systemic vascular resistance between 1000-1800 cdyn.s/cm5m2 will be used as variable defining after load). After the desired values of CI have been obtained, no further increase of therapeutic intervention (fluids, vasoactive drugs) will be performed.
3068512|NCT02104687|Active Comparator|Press|The Press therapeutic algorithm will be responsible for adjustment of intraoperative interventions based upon standard pressure parameters and will include volumotherapy and administration of vasoactive drugs, with the aim to maintain the desired values of MAP of 65-105 mmHg and CVP 8-12 mmHg. After the desired values of MAP and CVP have been obtained, no further increase of therapeutic intervention (fluids, vasoactive drugs) will be performed.
3068513|NCT02104674|Placebo Comparator|Placebo|
3068514|NCT02104674|Active Comparator|Singulair (montelukast)|
3068515|NCT02104674|Experimental|lebrikizumab|
3068516|NCT02104661|Experimental|OxCarbazepine Treatment|Treated for 48 weeks with OxCarbazepine 150mg twice a day alongside current DMDs.
3068517|NCT02104661|Placebo Comparator|OxCarbazepine Placebo|Treated for 48 weeks with matched placebo 1 tablet twice a day alongside current DMDs
3068518|NCT02104648|Placebo Comparator|Part A: Placebo|
3068519|NCT02104648|Experimental|Part A: RO4602522|
3068520|NCT02104648|Experimental|Part B: RO4602522 Multiple Doses|
3068521|NCT02104648|Experimental|Part B: RO4602522 Single Dose|
3068522|NCT02104648|Experimental|Part B: moxifloxacin Single Dose|
3068523|NCT02104635|No Intervention|Control group|The control group receives standard of care from Jacaranda clinic and does not receive any additional post-partum check-in from a community health worker.
3068524|NCT02104635|Experimental|CHW-Visit|The CHW-Visit group will receive a visit at their home from a community health worker (CHW) three days after delivery. The CHW will administer a checklist designed to identify maternal and newborn complications and will provide information about positive maternal health and care behaviors. The CHW will encourage women to return to the clinic at 7 days to receive a well-baby check.
3068525|NCT02104635|Experimental|CHW-Phone|The CHW-Visit group will receive a phone call from a community health worker (CHW) three days after delivery. The CHW will administer a checklist designed to identify maternal and newborn complications and will provide information about positive maternal health and care behaviors. The CHW will encourage women to return to the clinic at 7 days to receive a well-baby check.
3068526|NCT02104622|Experimental|ReWalk training|
3068527|NCT02104609||Normal weight women|Levonorgestrel 1.5mg by mouth once
3068528|NCT02104609||Obese women|Levonorgestrel 1.5mg by mouth once
3068529|NCT02104609||Extremely obese women|Levonorgestrel 1.5mg by mouth once
3068530|NCT02104596|Experimental|Xylitol injection|Intraarticular injection of Xylitol
3068531|NCT02104596|Placebo Comparator|Control|
3068532|NCT02104583|Experimental|Eleclazine 3 mg|Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 20 months.
3068533|NCT02104583|Experimental|Eleclazine 6 mg|Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 6 mg daily as maintenance for up to approximately 20 months.
3068534|NCT02104583|Placebo Comparator|Placebo|Participants will receive a single loading dose of placebo to match eleclazine followed by placebo to match eleclazine once daily for up to approximately 20 months.
3068535|NCT02104570|Other|Control|In this session, participants will be evaluated before and after a muscle fatigue protocol, with no intervention.
3068536|NCT02104570|Experimental|Kinesio taping with tension|A kinesio taping technique for the deltoid muscle will be applied before fatigue protocol and removed after in the end of the evaluation session. Subjects will be evaluated before taping, after taping and after the fatigue protocol.
3068537|NCT02104570|Sham Comparator|Kinesio taping without tension|A kinesio taping technique will be applied on the deltoid muscle without tension (tension is considered to be the therapeutic effect) before fatigue protocol and removed after in the end of the evaluation session. Subjects will be evaluated before taping, after taping and after the fatigue protocol.
3068538|NCT02104557||prevention of pregnancy|Non intervention
3068539|NCT02104557||management of endometriosis-associated pain|Non intervention
3068540|NCT02104531||Shoulder Pain|No intervention. Subjects will have a standard static MRI taken of their shoulder, and also complete a series of shoulder motions using video fluoroscopy.
3068541|NCT02104531||Healthy Subjects|No intervention. Subjects will receive a standard shoulder MRI and perform shoulder motions while being measured with video fluoroscopy.
3068542|NCT02104518||G6PD testing|Blood samples will be tested for G6PD activity levels
3068543|NCT02104505|Active Comparator|700 mg Gamma Tocopherol daily x 14days|Gamma Tocopherol supplement
3068544|NCT02104505|Placebo Comparator|Placebo|Safflower oil capsules
3068545|NCT02104492|Experimental|Intervention group|a 12-week respiratory muscles training program (RMTP) with ORYGEN Dual® device and peripheric resistive muscle training program
3068546|NCT02104492|Active Comparator|Control Group|Peripheric resistive muscle training program and Health Education Program.
3068547|NCT02104479||Immunocompromised Patients|Immunocompromised patients with suspected IPA who have Pleural effusions act as the observed study population
3068548|NCT02104479||Control Group|Patients without Immunosuppression with pleural effusions
3068549|NCT02104466|No Intervention|Treatment as Usual (TAU)|Participants randomized to this arm will receive usual care with no acupuncture.
3068550|NCT02104466|Experimental|TAU + 12 wks of acupuncture 1x/week|Participants randomized to this arm will receive usual care with adjunctive acupuncture once per week for a period of 12 weeks.
3068688|NCT02103426|Experimental|Part 2: ASP0113 CMV-seropositive healthy cohort|4 IM injections of ASP0113
3068552|NCT02104453|Experimental|E-C clamp mask holding technique|"the airway maneuver that press the mask against the patient's face (using the C of our thumb and forefinger) while pulling the jaw forward (using the E of our other fingers behind the mandible), and leaves one hand free to squeeze the bag."
3068553|NCT02104453|Experimental|two-handed ventilation with jaw thrust|the airway maneuver performed with thumbs point toward feet, palms press down and other fingers perform jaw thrust
3068554|NCT02104453|Experimental|triple airway maneuver|the airway maneuver performed with two-handed mask ventilation, jaw thrust and head-tilt chin-lift technique
3068555|NCT02104440|Experimental|Patients with cytopenia after allo-HSCT|Patients with cytopenia after allo-HSCT
3068556|NCT02104427|Experimental|TG-0054 combined with G-CSF|1. G-CSF: 10 μg/kg/day, administrated via SC injections from Day 1 to Day 8; 2. TG-0054: 3.14 mg/kg, administrated via 15-min IV infusion from Day 5 to Day 9 as needed to reach the target collection goal
3068557|NCT02104414|Active Comparator|Exparel|266mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
3068558|NCT02104414|Active Comparator|Bupivacaine HCl with epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
3068559|NCT02104414|Placebo Comparator|Normal Saline|30mL Normal Saline
3068560|NCT02104401|Experimental|tDCS|tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
3068561|NCT02104388|Experimental|SJP-0035 Ophthalmic Solution|Patients randomized to the SJP-0035 Ophthalmic solution will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
3068562|NCT02104388|Placebo Comparator|Vehicle of SJP-0035 Ophthalmic Solution|Patients randomized to the placebo arm will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
3068563|NCT02104375|Experimental|L-citrulline|L-citrulline (6 g/day for 2 weeks)
3068564|NCT02104375|Placebo Comparator|Maltodextrin|6g/day of placebo (maltodextrin)
3068565|NCT02104362|Other|exclusive single-fraction irradiation|
3068566|NCT02104349|Experimental|Mindfulness meditation|Subjects who are instructed on use of the mindfulness meditation technique
3068567|NCT02104349|No Intervention|Control|Subjects will receive standard surgery treatment without any mindfulness intervention.
3068568|NCT02104336|Experimental|EPI-743|15 mg/kg EPI-743 to be administered three times per day for 1 year
3068569|NCT02104323|Experimental|Endostatin，treatment effect evaluation|Patients receive continuous intravenous Endostatin drug pumping during the course of treatment. The drug dosage is 7.5mg/m2/d. Every course of treatment lasts three months. Patients are designed to receive total three courses of treatment if there is no disease progression. The interval between two courses is one month.
3068570|NCT02104310|Experimental|Fluorine-18-L-dihydroxyphenylalanine|18F-DOPA PET imaging will be used to guide radiotherapy treatment volumes and patients will be followed post-treatment to analyze response and patterns of failure
3068571|NCT02104297|Active Comparator|Deksmedetomidine infusion|To prevent agitation deksmedetomidine infused during operation and at the end of surgery agitation scor measured by Riker sedation agitation scale.
3068572|NCT02104297|Experimental|Remifentanil infusion|To prevent agitation remifentanil infused during operation at the end of surgery agitation scor measured by Riker sedation agitation scale.
3068573|NCT02104297|Placebo Comparator|Saline infusion|Saline infused during operation and at the end of surgery agitation scor measured by Riker sedation agitation scale.
3068574|NCT02104284|Other|Normal controls, methacholine positive|methacholine and mannitol bronchial challenge tests: Positive methacholine challenge tests in normal controls
3068575|NCT02104284|Other|Normal controls, mannitol|methacholine and mannitol bronchial challenge tests: Positive mannitol challenge tests in normal controls.
3068576|NCT02104284|Active Comparator|Asthma, Methacholine|methacholine and mannitol bronchial challenge tests: Positive methacholine challenge tests in asthmatics
3068577|NCT02104284|Active Comparator|Asthma, Mannitol|methacholine and mannitol bronchial challenge tests: Positive mannitol challenge tests in asthmatics
3068578|NCT02104271|Experimental|Argon Plasma Coagulation|"Argon Plasma Coagulation (APC) treatment will be delivered using a spray-painting technique, with short applications at 40W power and argon gas flow of 1.2 L/min. The APC equipment consists of a high frequency electrosurgical generator combined with a source of argon gas (Argon + SS601MC 4 , WEM Electronic Equipment Ltda , Ribeirão Preto , Brazil ). A flexible catheter of 2.3 mm diameter ( WEM ) Teflon coated and with a hint of heat resistant ceramic is inserted through the working channel of the colonoscope and connected to the current generator and the gas source for APC implementation."
3068579|NCT02104271|Active Comparator|Historical control|"Argon Plasma Coagulation (APC) treatment was delivered using a spray-painting technique, with short applications at 40-50W power and argon gas flow of 2.0 - 2.5 L/min. The APC equipment consists of a high frequency electrosurgical generator combined with a source of argon gas (Argon + SS601MC 4 , WEM Electronic Equipment Ltda , Ribeirão Preto , Brazil ). A flexible catheter of 2.3 mm diameter ( WEM ) Teflon coated and with a hint of heat resistant ceramic is inserted through the working channel of the colonoscope and connected to the current generator and the gas source for APC implementation."
3068580|NCT02104258|Active Comparator|Physiotherapy ASPETAR|"The patients will follow the ASPETAR Hamstring Rehabilitation Protocol, which is a standardised physiotherapy protocol, including range of motion exercises, progressive strengthening exercises, core stability training and agility exercises [10].~The ASPETAR protocol consist of predefined rehabilitation stages including sports specific stages. Specific functional based criteria for progression will be utilized for each of the six rehabilitation stages. No pain provocation when performing the exercises will be allowed.~The rehabilitation will be initiated as soon as possible after inclusion and the patients will be supervised by experienced physiotherapists in the Rehabilitation Department at Aspetar 3 to 5 days per week."
3068689|NCT02103426|Experimental|Part 2: ASP0113 CMV-seronegative healthy cohort|4 IM injections of ASP0113
3068690|NCT02103426|Experimental|Part 2: ASP0113 CMV-seronegative dialysis cohort|4 IM injections of ASP0113
3069432|NCT02098382||Dilapan-S|125 Patients with / without caesarean section in their medical history
3068581|NCT02104258|Active Comparator|Physiotherapy ASPETAR+|"The patients will follow the ASPETAR+ Hamstring Rehabilitation Protocol. ASPETAR+ is similar to ASPETAR, but consists of additional lengthening exercises which will be initiated early in the rehabilitation phase.~ASPETAR+ consist of predefined rehabilitation stages including sports specific stages. Specific functional based criteria for progression will be utilized for each of the six rehabilitation stages. No pain provocation when performing the exercises will be allowed.~The rehabilitation will be initiated as soon as possible after inclusion and the patients will be supervised by experienced physiotherapists in the Rehabilitation Department at Aspetar 3 to 5 days per week."
3068582|NCT02104245|Experimental|Ciprofloxacin dispersion for inhalation|Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin
3068583|NCT02104245|Placebo Comparator|Placebo|Liquid formulation of empty liposomes
3068584|NCT02104232|Experimental|THPP-I|TPs in the THPP-I group receive, in addition to enhanced usual care (EUC), between 6 to 14 sessions of THPP (simple cognitive behaviour therapy) starting from their recruitment in the second/ third trimester until up to 6 months after child birth. Sessions will be delivered by peers on an individual basis at a location of convenience to the TPs.
3068585|NCT02104232|Other|Enhanced usual care (EUC)|Enhanced usual care (EUC) will comprise communicating the results of the screening to the mother through an information sheet on self-care for mental health, communicating the results to the mother's gynaecologist, providing the gynaecologist with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
3068586|NCT02104193|Experimental|simvastatin|they will receive simvastatin in addition to radiation therapy
3068587|NCT02104193|Active Comparator|control|they will receive radiation therapy only
3068588|NCT02104180|Active Comparator|TulleGras M.S.|
3068589|NCT02104180|Active Comparator|Urgotul|
3068590|NCT02104167||Operated Subjects|ROIC interbody cage with VerteBRIDGE plating
3068591|NCT02104154||symptoms of liver disease|Device: Samsung LABGEO PT10 Hepatic Panel
3068592|NCT02104141||Operated Subjects|ROIA Interbody Cage with VerteBRIDGE plating
3068593|NCT02104128|Experimental|Depressed patient given bupropion|All depressed patients will be given open label bupropion
3068594|NCT02104128|No Intervention|Control pts given no intervention|Control participants will be assessed at the same time points as the depressed group, but will be given no drug
3068595|NCT02104115|Other|Gluten free white bread|Sliced loaf of gluten free white bread
3068596|NCT02104115|Other|Normal gluten content white wheat bread|Sliced loaf of normal gluten content white wheat bread
3068597|NCT02104115|Other|High gluten content white wheat bread|Sliced loaf of high gluten content white wheat bread
3068598|NCT02104102|Experimental|Mirror group|Composed of 30 volunteers who carry out the mirror therapy, whose name shall Mirror Group (MG).
3068599|NCT02104102|Experimental|Control Group - kinesiotherapy|Called by Control Group (CG), composed of 30 volunteers who will carry out the kinesiotherapy with the same sequence of movements for the Mirror Therapy that the MG, but without the view in the mirror, since it will be blocked.
3068600|NCT02104089||Endovascular treatment|Zenith® t-Branch™ Thoracoabdominal Endovascular Graft
3068601|NCT02104076|Experimental|Evolution® Biliary Stent-Fully Covered|
3068602|NCT02104063||MRI-PET|Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
3068603|NCT02104050|Placebo Comparator|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
3068604|NCT02104050|Experimental|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
3068605|NCT02104037|Experimental|Liraglutide treated patients|
3068606|NCT02104024||Kidney transplant recipients|CEUS in Kidney Transplant recipients
3068607|NCT02104024||Pancreas transplant recipients|CEUS in pancreas transplant recipients
3068608|NCT02104011|Experimental|Patient|
3068609|NCT02103998|Experimental|T4 + KI|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
3068610|NCT02103998|Placebo Comparator|D5W - 5% dextrose water|Receive the same volume as study drug but as D5W placebo
3068611|NCT02103985|Experimental|Treatment A|Participants will receive 100 mg JNJ-39823277 under fed (after a high fat) condition.
3068612|NCT02103985|Experimental|Treatment B|Participants will receive 100 mg JNJ-39823277 under fasted condition.
3068613|NCT02103972|Placebo Comparator|Maltodextrin|Maltodextrin
3068614|NCT02103972|Active Comparator|GM080|GM080
3068615|NCT02103959|Experimental|CMX-2043 2.4 mg/Kg|Bolus injection of investigational product given prior to the cardiac catheterization and placebo given 24 hours after the first dose.
3068616|NCT02103959|Experimental|CMX-2043 3.6 mg/kg|Bolus injection of investigational product given prior to the cardiac catheterization and placebo given 24 hours after the first dose.
3068617|NCT02103959|Experimental|CMX-2043 2.4 mg/kg given twice|Bolus injection of investigational product given prior to the cardiac catheterization and again 24 hours after the first dose.
3068618|NCT02103959|Placebo Comparator|Placebo comparator|Placebo comparator (PBS) given prior to cardiac catheterization and again 24 hours after the first dose.
3068619|NCT02103946|Active Comparator|Serratus anterior muscle plane block|Serratus anterior muscle plane block with general anesthesia MARCAINE® 0.25%w/v solution for injection. DIPRIVAN® (propofol), 2 to 2.5 mg/kg NIMBEX® (cisatracurium besylate) Injection, 0.15-0.2 mg\Kg Fentanyl, 1-2 mic\Kg Paracetamol, 1000 mg\6 hours Fam® (Ketorolac), 30 mg
3068620|NCT02103946|Active Comparator|Paravertebral block|Paravertebral block with general anesthesia. MARCAINE® 0.25%w/v solution for injection. DIPRIVAN® (propofol), 2 to 2.5 mg/kg NIMBEX® (cisatracurium besylate) Injection, 0.15-0.2 mg\Kg Fentanyl, 1-2 mic\Kg Paracetamol, 1000 mg\6 hours Fam® (Ketorolac), 30 mg
3068621|NCT02103907|No Intervention|Wait list|Wait list control group. Participants will be placed on the wait list and asked to maintain their current routine and level of activity during the 10 week period. Control group participants will receive the dynamic balance training program in a single training session after the followup (second testing session at 10 weeks).
3068691|NCT02103426|Placebo Comparator|Part 2: Placebo CMV-seropositive healthy cohort|4 placebo IM injections
3068622|NCT02103907|Experimental|Treatment (balance training)|Targeted dynamic balance training. Dynamic balance training will consist of progressive exercise training over three phases, with exercises emphasising dynamic balance control, muscle strength and proprioception. Exercises will be performed four times per week for ten weeks. Exercises will be taught and supervised by a trained kinesiologist. Difficulty of exercises will be increased progressively over time by increasing resistance, time of timed exercises, and distance of walking exercises. Exercises will be progressed to different exercises in each new phase (total 3 phases). Participants will complete six treatment sessions at the university (during weeks 1, 2, 3, 5, 7, and 9) that will be included in the total number of sessions per week. All other sessions will be performed at home.
3068623|NCT02103894|Experimental|[18F]T807 ([18F]MNI-777)|At the [18F]MNI-777 PET imaging visit, subjects will be injected with no more than 10 mCi (370 MBq) of [18F]MNI-777).
3068624|NCT02103881|Experimental|Ketamine|Patients enrolled in this arm will be given 500 mg of intramuscular ketamine for their severe agitation they experience in the prehospital environment.
3068625|NCT02103881|Experimental|Haloperidol|Patients enrolled in this arm will be given 10 mg of intramuscular haloperidol for their severe agitation they experience in the prehospital environment.
3068626|NCT02103868|No Intervention|Control|No active intervention will be given for tobacco cessation.
3068627|NCT02103868|Experimental|Medium Intervention|Tobacco Cessation Counseling : Medium intervention in the form of 3 contact sessions will be given for tobacco cessation.
3068628|NCT02103868|Experimental|Low intensity intervention|Tobacco Cessation Counseling: Only a single contact session will be done for tobacco cessation.
3068629|NCT02103855|Experimental|belatacept|"Belatacept 5 mg/kg IVPB q 2 wks x 5 doses followed by 5 mg/kg IVPB q month. The belatacept dose will be infused IV over 30 minutes.~Day 14: Reduce tacrolimus dose by 25% Day 30: Reduce tacrolimus dose by additional 25% Day 45: Reduce tacrolimus dose by additional 25% Day 60: Stop tacrolimus."
3068630|NCT02103842|Experimental|Omega-3 fatty acids|Participants will take 3.9g/day of Eicosapentaenoic acid and docosahexaenoic acid for 4 months
3068631|NCT02103829|Active Comparator|Condition #1|Condition #1 will consist of Brief Intervention #1, a brief online suggestion that takes less than 1 minute to complete.
3068632|NCT02103829|Experimental|Condition #2|Condition #2 will consist of Brief Intervention #1 and Brief Intervention #2 that together take less than a minute to complete.
3068633|NCT02103829|Experimental|Condition #3|Condition #3 will consist of Brief Intervention #1 and Brief Intervention #3, which, together, will take less than 8 minutes to complete.
3068634|NCT02103829|Experimental|Condition #4|Condition #4 will consist of Brief Intervention #1, Brief Intervention #2, and Brief Intervention #3, which, together, will take less than 8 minutes to complete.
3068635|NCT02103816|Experimental|SmartLipo Triplex laser system along with the SideLaze800 hand|
3068636|NCT02103790|Experimental|Home NIV installation|
3068637|NCT02103777|Active Comparator|High dose caffeine|High dose (loading 40 mg/kg/day equivalent to 20 mg /kg/day of caffeine base and maintenance of 20 mg/kg/day equivalent to 10 mg /kg/day of caffeine base)
3068638|NCT02103777|Active Comparator|Low dose caffeine|Low dose (loading 20 mg/kg/day equivalent to 10 mg /kg/day of caffeine base and maintenance of 10 mg/kg/day equivalent to 5 mg /kg/day of caffeine base) caffeine.
3068639|NCT02103764|Experimental|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
3068640|NCT02103764|Active Comparator|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
3068641|NCT02103738||Arm 1 (Monthly)|0.5 mg intravitreal injections of Ranibizumab monthly for the duration of the study.
3068642|NCT02103738||Arm 2 (Treat and Extend)|Three consecutive months of 0.5 mg Ranibizumab intravitreal injections (Day 1, Month 1, and Month 2). Monthly injections will continue until evidence of disease stability is observed. Specifically, monthly treatment will continue until visual acuity is deemed stable as indicated by a gain in visual acuity of ≤ 3 ETDRS letters from the prior month, no clinical evidence of lesion growth, fluid or blood, and no intraretinal or subretinal fluid on OCT. When this is achieved, the intervals between each subsequent injection will be extended by 2 weeks (intervals of 6 weeks, 8 weeks, 10 weeks, to a maximum of 12 weeks) until clinical or diagnostic evidence of disease instability is observed based on OCT findings and/or BCVA ETDRS.
3068643|NCT02103725|Experimental|pimecrolimus 10 mg/g cream|Active drug
3068644|NCT02103725|Placebo Comparator|Vehicle cream|Placebo drug
3068645|NCT02103712||Hypospadias|
3068646|NCT02103699||Hepatitis C virus infected patients receiving simeprevir|
3068647|NCT02103686|Active Comparator|Immediate release capsule|Immediate release capsule treatment under fasted condition
3068648|NCT02103686|Experimental|sustained release tablet|sustained release tablet treatment under fasted condition
3068649|NCT02103686|Experimental|sustained release tablet (high fat meal)|sustained release tablet under high fat meal condition.
3068650|NCT02103673|Experimental|DAOIB|Drug: DAOIB 250-1500 mg/day by mouth for 6 weeks
3068651|NCT02103673|Placebo Comparator|Placebo|Placebo by mouth per day for 6 weeks
3068652|NCT02103660|Active Comparator|Depo-Medroxyprogesterone Acetate|Half of women will be randomized to receive Depo-Medroxyprogesterone Acetate injections every 13 weeks
3068653|NCT02103660|Active Comparator|Progestin Implant (Jadelle)|Half of women will be randomized to receive progestin implant.
3068654|NCT02103647|Active Comparator|Immediate release capsule(lyrica capsule 150mg)|Immediate release capsule repeat treatment for 3days under fasted condition
3068655|NCT02103647|Experimental|sustained release tablet|sustained release tablet repeat treatment for 3days under fasted condition
3068656|NCT02103634|Experimental|Lesion Imaging|Image patients with the standard of care of a FDG PET/CT and the experimental method of the NaF PET/MRI and compare the number of images found within and between patients to determine the most effective way of looking at breast cancers metastasized to bone
3068692|NCT02103426|Placebo Comparator|Part 2: Placebo CMV-seronegative healthy cohort|4 placebo IM injections
3068693|NCT02103426|Placebo Comparator|Part 2: Placebo CMV-seronegative dialysis cohort|4 placebo IM injections
3068694|NCT02103413|Experimental|EUS-BD|EUS-BD using a fully or partially covered self-expanding metallic stent will be performed by EUS guided 19 G needle puncture.
3068657|NCT02103621|Experimental|Unifed Protocol (UP) for Discontinuation|Unified Protocol (UP) for Discontinuation is delivered in 14 weekly individual sessions of 45-60 minutes followed by 3 booster sessions scheduled at two, four and eight weeks thereafter. The UP is a cognitive behavioral treatment that focuses on increasing emotional awareness and cognitive flexibility, preventing behavioral and emotional avoidance, and situational and interoceptive emotion-focused exposure. Participants will also receive 7 biweekly medication management sessions over 14 weeks with a study psychiatrist to facilitate gradual taper of SRI medication.
3068658|NCT02103621|Active Comparator|Taper and Monitoring (TAP-M)|Taper and Monitoring (TAP-M) is delivered in biweekly individual sessions over 14 weeks, with booster sessions at two, four, and eight weeks thereafter. TAP-M consists of assessment and monitoring. Participants will also receive 7 biweekly medication management sessions over 14 weeks with a study psychiatrist to facilitate gradual taper of SRI medication.
3068659|NCT02103608|Experimental|Percentage of hair reduction|
3068660|NCT02103595|Other|Accu-Chek FlexLink Plus cross over to Accu-Chek FlexLink|
3068661|NCT02103595|Other|Accu-Chek FlexLink cross over to Accu-Chek FlexLink Plus|
3068662|NCT02103582|Placebo Comparator|control|Participants who are randomized to the 'control arm' will be asked to maintain their current daily activities for 12 weeks. They will also be required to visit the study site 3 times per week for 12 weeks to view videos on different wellness topics. Control participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Control participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
3068663|NCT02103582|Experimental|intervention|Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
3068664|NCT02103569|Experimental|Arm 1: FDC of NE/EE + DCV 3DAA FDC + BMS-791325|"Cycle 1- Low dose FDC of Norethindrone and Ethinyl Estradiol tablet orally on specified days~Cycle 2- High dose FDC of Norethindrone and Ethinyl Estradiol tablet orally on specified days and High dose FDC of Norethindrone and Ethinyl Estradiol + FDC of Daclatasvir, Asunaprevir and BMS-791325 + BMS-791325 tablets orally on specified days"
3068665|NCT02103556|Active Comparator|Mineral oil|4ml daily (adjusted as needed), for 4 weeks
3068666|NCT02103556|Active Comparator|Olive oil|4ml daily (adjusted as needed), for 4 weeks
3068667|NCT02103556|Active Comparator|Flaxseed oil|4 ml daily (adjusted as needed), for 4 weeks
3068668|NCT02103543|Active Comparator|Physical Therapy first|patients will undergo physical therapy 3-4 sessions followed by lumbar interlaminar epidural steroid injection
3068669|NCT02103543|Active Comparator|lumbar epidural steroid first|lumbar interlaminar epidural steroid injection followed by patients will undergo physical therapy 3-4 sessions
3068670|NCT02103530|Experimental|FLT PET/CT|Patients who had FLT PET/CT
3068671|NCT02103517|Experimental|Omega-3 fatty acid capsules|Omega-3 fatty acid capsules, 4 g/day, requiring intake 2 capsules (1g each one) in the morning and two at night for 3 months.
3068672|NCT02103517|Placebo Comparator|corn oil|Corn oil in similar presentation as omega-3 fatty acid capsules, requiring intake 2 capsules in the morning and two at night for 3 months.
3068673|NCT02103504|Other|DePuy Attune TKA|DePuy Attune posterior stabilized fixed bearing total knee replacement
3068674|NCT02103491|Active Comparator|Salt administration|Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol).
3068675|NCT02103491|Placebo Comparator|Placebo administration|In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose).
3068676|NCT02103478|Experimental|Phase 1 ASTX727 Dose Escalation|ASTX727 is given by mouth daily X 5 consecutive days. Dosing details will vary in the first 3 courses of therapy for pharmacokinetic measurements. Based on safety and pharmacokinetic results the dose will be modified for subsequent cohorts. Dose escalation will continue until target pharmacokinetics are achieved or until a safe dose is exceeded. This dose will be carried forward into Phase 2.
3068677|NCT02103478|Active Comparator|Phase 2 ASTX727 Dose Confirmation|Subjects will compare one cycle of daily x 5 IV decitabine vs. one cycle of daily x 5 oral decitabine and E7727 for PK and PD. They will be randomized 1:1 as to the order the cycles are administered. In cycle 3 or greater the oral combination will be administered.
3068678|NCT02103465|Experimental|Rotigotine|80 patients with late onset PD are randomized in 2 parallel groups, ratio 1:1.
3068679|NCT02103465|Placebo Comparator|Placebo|80 patients with late onset PD are randomized in 2 parallel groups, ratio 1:1.
3068680|NCT02103452|Experimental|ovarian endometrioma|Ovarian and endometrial samples
3068681|NCT02103452|Experimental|normal ovary|Ovarian and endometrial samples
3068682|NCT02103439|Experimental|Algeron|Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg)
3068683|NCT02103439|Active Comparator|PegIntron|PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg).
3068684|NCT02103426|Experimental|Part 1: ASP0113 CMV-seropositive healthy cohort|5 mg single dose IM injection
3068685|NCT02103426|Experimental|Part 1: ASP0113 CMV-seronegative healthy cohort|5 mg single dose IM injection
3068686|NCT02103426|Placebo Comparator|Part 1: Placebo CMV-seropositive healthy cohort|single dose IM injection
3068687|NCT02103426|Placebo Comparator|Part 1: Placebo CMV-seronegative healthy cohort|single dose IM injection
3068695|NCT02103413|Experimental|PTBD|PTBD with 8.5F catheter will be inserted under fluoroscopic and/or ultrasonography guidance by experienced interventional radiologists.
3068696|NCT02103400|Experimental|Experimental group|Patients hospitalized for community-acquired pneumonia
3068697|NCT02103400|Active Comparator|Control group|Patients hospitalized for community-acquired pneumonia
3068698|NCT02103387|Experimental|Cognitive Behavioral Training|Cognitive Behavioral Training 5 weekly 1.5-hour sessions of group-based cognitive behavioral training
3068699|NCT02103387|Experimental|Relaxation Training|Relaxation Training 5 weekly 1.5-hour sessions of group-based relaxation training
3068700|NCT02103387|Active Comparator|Health Education Control|Health Education Control 5 weekly 1.5 sessions of group-based health education training
3068701|NCT02103374|Experimental|Atrovent + Bricanyl or Atrovent + Ventolin|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form Atrovent 0,5mg/1ml Bricanyl 5mg/2ml Ventolin 5mg/2,5ml
3068702|NCT02103374|Placebo Comparator|Placebo|1 capsule per day lactose (in addition to the standard optimized treatment)
3068703|NCT02103361||Stelara (ustekinumab) exposed|Stelara (ustekinumab)-exposed pregnant women
3068704|NCT02103348||Mild-to-Moderate Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
3068705|NCT02103348||Severe Asthma|"Major Criteria: (1 required)~Treatment with oral corticosteroids for at least 6 of the previous 12 months~Treatment with high-dose inhaled corticosteroids for at least 10 of the previous 12 months~Minor Criteria: (2 required)~Daily treatment with an asthma controller medication in addition to inhaled, or~Asthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis (defined as at least 5 of 7 days), or~Persistent airway obstruction with baseline FEV1 <80% predicted, or~≥ 1 urgent visits for asthma in the previous 12 months, or~≥ 3 systemic corticosteroid bursts in the previous 12 months, or~Prompt deterioration with a reduction in oral or inhaled corticosteroid dose, or~A near-fatal asthma event (i.e., intubation) in the past."
3068706|NCT02103348||Healthy Controls|Those without asthma or other chronic lung disease.
3068707|NCT02103335|Experimental|Single Group Assignment|Combination Pomalidomide, low-dose Dexamethasone, and Marizomib:
3068708|NCT02103322|Experimental|Imatinib Mesylate Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.
3068709|NCT02103322|Active Comparator|Gleevec Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.
3068710|NCT02103309|Other|DACP, then 1DAM|Nelfilcon A contact lenses worn first, then etafilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable mode.
3068711|NCT02103309|Other|1DAM, then DACP|Etafilcon A contact lenses worn first, then nelfilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable mode.
3068712|NCT02103296|Active Comparator|Infant Blood|Control group. Admission labs to be drawn directly from the infant.
3068713|NCT02103296|Experimental|Cord Blood|Admission labs to be drawn from the infant's cord blood
3068714|NCT02103283|Experimental|Teprotumumab|Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
3068715|NCT02103270|Placebo Comparator|Oat Flour 600 mg|Arm C that is maintained on placebo (oat flour) throughout the study; this arm will receive 600 mg oat flour beginning on week 104. This will be true even if a subject in the placebo group meets criteria at week 104
3068716|NCT02103270|Active Comparator|Peanut Protein 4,000mg|Arm A on peanut OIT until week 104 (maintenance) and once meeting criteria [i.e. 1) on OIT treatment for minimum 104 weeks, 2) taking daily maintenance dose of 4,000 mg protein for at least 13 weeks, 3) no severe reactions to home dosing from Week 91-Week 104, and 4) no reactions at the Week 104 DBPCFC] will be assigned to avoid peanut (i.e. will consume 600 mg oat flour daily) and will proceed to tolerance and desensitization phase.
3068717|NCT02103270|Active Comparator|Peanut Protein 300 mg|Arm B on peanut OIT until week 104 and once meeting criteria specified in description of Arm A, will be assigned to be maintained on 300 mg peanut protein (i.e. 600 mg peanut flour) daily and will proceed to the tolerance and desensitization testing phase.
3068718|NCT02103257|Experimental|Sequential icotinib plus chemotherapy|Sequential icotinib plus chemotherapy : pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
3068719|NCT02103257|Active Comparator|Icotinib|Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
3068720|NCT02103244|Experimental|carboplatin|An adjusted dosing algorithm will be applied to calculate the dose of carboplatin. in 24 patients blood will be obtained in order to determine the pharmacokinetics of carboplatin after adjusted dosing
3068721|NCT02103231||Full Term Birth|History of full term birth (>37 weeks gestation) including sub-group with diagnosis of hypertension
3068722|NCT02103231||Preterm Birth|History of preterm birth (<37 weeks gestation) including subgroup with diagnosis of hypertension
3068723|NCT02103218|Experimental|Risky sex prevention|education, activities, empowerment, racial pride building
3068724|NCT02103218|Active Comparator|Healthy behaviors|General health education, activities
3068725|NCT02103205|Active Comparator|Low iron, with lactoferrin|Low iron, with lactoferrin
3068726|NCT02103205|Active Comparator|Low iron, no lactoferrin|Low iron, no lactoferrin
3068727|NCT02103205|Placebo Comparator|Normal iron, no lactoferrin|Normal iron, no lactoferrin
3068728|NCT02103192|Experimental|Control plus low level nutrient fortification|Control plus low level nutrient fortification
3068729|NCT02103192|Experimental|Control plus increasing level nutrient fortification|Control plus increasing level nutrient fortification
3068730|NCT02103192|Placebo Comparator|Caffeine-free, carbonated soft drink|Caffeine-free, carbonated soft drink
3068731|NCT02103179||ECC patients|Extrahepatic cholangiocarcinoma patients treated by surgical treatment
3068732|NCT02103166|Experimental|Hyoscine bromide|20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
3068733|NCT02103166|Placebo Comparator|Physiological serum|100 ml of physiological serum (0.9% NaCl).
3068734|NCT02103153|Experimental|Picosure Laser System|
3069433|NCT02098369|Other|Usual care|Written education material (basic)
3068735|NCT02103140|Experimental|Facility-Based Exercise Intervention|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
3068736|NCT02103140|No Intervention|Control|After baseline testing, the control group will be asked to maintain their current daily activities and exercise habits for the duration of the study (6 months). The control group will have measurements at the same time periods as the participants in the intervention arm through the completion of the study. Participants will be seen for follow-up at 3 and 6 months (study completion). The participants in the control group will receive the same incentives as those in the intervention arms (gift cards). Since the women in the control group are obese, with components of metabolic syndrome, and at relatively high risk for breast cancer, we are providing healthy lifestyle information to the group, via text messages.
3068737|NCT02103140|Experimental|Home-Based Exercise Intervention|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
3068738|NCT02103127|Experimental|755nm Alexandrite laser with lens array|
3068739|NCT02103114|Experimental|Anti-thrombin III|
3068740|NCT02103114|Placebo Comparator|Placebo|
3068741|NCT02103101|Other|Study cohort|"Measurement of Plasma Concentrations of NOACs Identification of ABCB1 polymorphisms coding for P-gp~All patients aged over 18 and less than 80 years admitted for a serious adverse event (bleeding or thrombo-embolic complication) while under treatment with any of the following oral anticoagulant agents: dabigatran, rivaroxaban or apixaban. Blood samples will be drawn to measure plasma concentrations of the oral anticoagulant agent at the time of the adverse event, and presence of polymorphisms of ABCB1 will be investigated."
3068742|NCT02103088|Experimental|Sexual and urological intervention|Standard care and the PROCAN intervention consisting of i) DVD instruction in pelvic floor muscle training ii) group instructions in pelvic floor muscle training by physiotherapist including three individually follow-up and ii) up to six couple sessions performed by a sexual nurse counselor.
3068743|NCT02103088|No Intervention|Control|Standard care consists of:systematic offer of medical treatment for erectile dysfunction, if not contra indicated. The medical treatment will consist of either daily treatment with Cialis 5 mg or phosphodiesterase type 5 inhibitor on demand before sexual activity. Alternatively use of alprostadil as either urethral pin or penile injection. Furthermore standard treatments include preoperative instruction in pelvic floor muscle training, regular outpatient visits and possible referral to rehabilitation in accordance with the rules that apply to the Danish Health legislations. In case of prolonged incontinence the patients may on request be referred to a private practicing physiotherapist.
3068744|NCT02103075|Experimental|The SCA|
3068745|NCT02103075|Experimental|The age-matched control|
3068746|NCT02103075|Experimental|The young control|
3068747|NCT02103062|Experimental|Abraxane (nab®paclitaxel)|Abraxane (nab®paclitaxel) 125 milligrams per meter squared on days 1, 8 and 15 of a 28 day cycle
3068748|NCT02103049|Other|Ezetimibe, dyslipidemia, kidney transplant|
3068749|NCT02103036|Experimental|Core Stability Exercises|"Core Stability Exercises:~20 sessions, distributed daily, from Monday to Friday. The first 5 sessions are common in all patients in the study, and involves the application of infrared light (IR) (10 minutes) and TENS (20 minutes) to treat acute pain. From session number 6 to session 20, the patients will receive IR + TENS 2 days a week, and the other 3 days IR+TENS+Core Stability Exercises (25-30 minutes)."
3068750|NCT02103036|Experimental|Traditional Back School|"Traditional Back School:~20 sessions, distributed daily, from Monday to Friday. The first 5 sessions are common in all patients in the study, and involves the application of infrared light (IR) (10 minutes) and TENS (20 minutes) to treat acute pain. From session number 6 to session 20, the patients will receive IR + TENS 2 days a week, and the other 3 days IR+TENS+Traditional Back School (25-30 minutes)."
3068751|NCT02103023|Experimental|ID TIV + imiquimod|imiquimod ointment followed by intradermal influenza vaccine
3068752|NCT02103023|Sham Comparator|ID sham + imiquimod|imiquimod ointment followed by sham intradermal influenza vaccine
3068753|NCT02103023|Active Comparator|IM TIV + aq|aqueous cream followed by intramuscular influenza vaccine
3068754|NCT02103023|Active Comparator|ID TIV + aq|aqueous cream followed by intradermal influenza vaccine
3068755|NCT02103010||HNC patients|head and neck cancer patients
3068756|NCT02102984|Active Comparator|covered stents|endoscopic placement of covered biliary stents
3068757|NCT02102984|Active Comparator|uncovered biliary stents|endoscopic placement of uncovered biliary stents
3068758|NCT02102971||Hepatocellular carcinoma|Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
3068759|NCT02102958|Experimental|Experimental|DSME with Nonvisual Foot Examination
3068760|NCT02102958|Active Comparator|Comparison|DSME with Usual Foot Examination Instruction
3068761|NCT02102945|Other|Computed tomography perfusion|Participants will undergo CT perfusion of the head after cooling following cardiac arrest.
3068762|NCT02102932|Experimental|12.5 mg empagliflozin/850 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/850 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 850 mg metformin tablets single dose in randomized order
3068763|NCT02102932|Experimental|5 mg empagliflozin/850 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/850 mg metformin and single Empagliflozin(5mg) and metformin (850mg) tablets single dose in randomized order
3069013|NCT02101086|Experimental|Autologous Cord Blood Transfusion|Autologous cord blood transfusion 10 mL per kg for anemia
3068764|NCT02102932|Experimental|12.5 mg empagliflozin/500 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/500 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 500 mg metformin tablets single dose in randomized order
3068765|NCT02102932|Experimental|5 mg empagliflozin/500 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/500 mg metformin and single Empagliflozin(5mg) and metformin (500mg) tablets single dose in randomized order
3068766|NCT02102919|Experimental|Intervention group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (start with 3 up to 6 Hz, noise 4) T1 - intervention 4 weeks (SR-WBV (start with 3 up to 6Hz, noise 4 & virtual games) - T2
3068767|NCT02102919|Sham Comparator|Sham Comparator|T0 - intervention 4 weeks (SR-WBV 1 Hz, noise 1) - T1 - intervention 4 weeks (SR-WBV 1 Hz, noise 1 & Aktiv Tramp) - T2
3068768|NCT02102906|Experimental|TMS treatment|Patients will receive a single session of 20 single pulses of TMS to motor cortex contralateral to affected upper limb at 120% motor threshold, with verbal encouragement throughout. Half of the patients recruited will be randomised to a 3 month delay during which they will receive treatment as normal.
3068769|NCT02102880|Other|Healthy Subjects|
3068770|NCT02102854|Active Comparator|Standard dose rATG|Standard dose rATG given as daily infusions of 1.5 mg/kg x 4-5 days
3068771|NCT02102854|Experimental|Single dose rATG|Single dose rATG give as 2 consecutive 3 mg/kg IV infusions to be completed over a 24-36 hour duration
3068772|NCT02102841|Experimental|Skin biopsy|5mm skin punch biopsy on forearm
3068773|NCT02102841|Experimental|Skin suction blister|Skin suction blister induced on forearm
3068774|NCT02102841|Experimental|Mantoux, skin biopsy, suction blister|0.1ml tuberculin purified protein derivative (PPD) is injected intradermally into an area of non-lesional skin on the volar aspect of each of the patient's forearms. This is followed by a skin biopsy on one arm and induction of a skin suction blister on the other arm.
3068775|NCT02102828|Placebo Comparator|Aspirin only|Patients receive aspirin therapy alone
3068776|NCT02102828|Experimental|extended compression & aspirin|Patients receive aspirin and extended compression therapy using Cothera V-Pulse system
3068777|NCT02102815|Experimental|Dexamethasone|Preoperative dexamethasone 8 mg (if body wight < 80 kilograms) or 12 mg (if body weight >/= 80 kilograms) mixed with NSS to 50 mL IV slowly push over 5 minutes
3068778|NCT02102815|Placebo Comparator|Placebo|Preoperative intravenous normal saline 50 mL slowly push over 5 minutes
3068779|NCT02102802|Active Comparator|Low or medium dose MDMA|Participants receive 30 mg MDMA possibly followed 1.5 to 2 h later by 15 mg or participants receive 75 mg MDMA possibly followed by 37.5 mg MDMA
3068780|NCT02102802|Experimental|Full dose MDMA|Participants will receive 125 mg MDMA possibly followed 1.5 to 2 h later by 62.5 mg MDMA
3068781|NCT02102789|Experimental|Systemic chemotherapy|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
3068782|NCT02102789|Experimental|Systemic chemotherapy combined with HAI|"Patients will receive mFOLFOX6+HAI every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15. 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
3068783|NCT02102776|Active Comparator|MMC after pterygium excision|Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision. The conjunctival defect will be left bare without graft.
3068784|NCT02102776|Active Comparator|AMT after Pterygium Excision|Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision. No mitomycin C will be applied.
3068785|NCT02102776|Active Comparator|CAG after Pterygium Excision|A conjunctival autograft will be harvested from the superior side of the operating eye's bulbar conjunctiva. Then the graft will be sutured to cover the conjunctival defect after pterygium excision. No mitomycin C will be applied.
3068786|NCT02102750|Experimental|tafluprost|
3068787|NCT02102737|Experimental|6-DIG and clamp|injection of 6-DIG and hyperinsulinemic euglycemic clamp
3068788|NCT02102724|Experimental|Fish Oil|Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.
3068789|NCT02102724|Placebo Comparator|Placebo|Participants will receive 1 gram of oleic sunflower oil for 12 weeks.
3068790|NCT02102711|Experimental|vitaminA drops|3000 IU/kg/die of Vitamin A oral drops, for 4 weeks.
3068791|NCT02102711|No Intervention|control|Control of matched infants not supplemented with vitamin A ( beyond standard/routine needed)
3068792|NCT02102698|Experimental|Ecopipam|Ecopipam is a selective antagonist of the dopamine D1/D5 receptor family that is being studied as a treatment for Tourette's Syndrome
3068793|NCT02102698|Placebo Comparator|Placebo|Placebo is the inactive comparator
3068794|NCT02102685|Active Comparator|VAC Therapy|active comparator: 14 patients within the first three days the VAC therapy was placed , proceeding as follows : organize the material , bandage removal , cleaning of the wound with irrigation solution , cut the sponge and placement on the wound , use of polyvinyl alcohol and / or silver foam, insertion of the tube seal and connection to the containing recipient.
3068795|NCT02102685|Placebo Comparator|Traditional Therapy|14 patients: after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
3068796|NCT02102672|Placebo Comparator|Sugar pill|Placebo 1 pill bid, 3 months
3068797|NCT02102672|Experimental|Trimetazidine|Trimetazidine 35 mg bid for 3 months
3068798|NCT02102659|Experimental|Upper Limit Nutrition Support Therapy|"Upper limit nutrition support therapy will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium."
3069047|NCT02100878||Lean adolescents|
3068799|NCT02102659|Active Comparator|Formula Nutrition Support Therapy|"Formula nutrition support therapy will be used in patens assigned in this group based on Harris Bendiest Formula."
3068800|NCT02102646|Active Comparator|Triptorelin|Triptorelin 22,5mg/24th week intramuscularly
3068801|NCT02102646|Active Comparator|orchiectomy|Androgen deprivation therapy by bilateral subcapsular orchiectomy
3068802|NCT02102633|Experimental|Dabigatran|Dabigatran 150 mg orally
3068803|NCT02102633|Experimental|Dabigatran + Bosutinib|Dabigatran 150 mg co-administered with Bosutinib 500 mg orally
3068804|NCT02102620|Experimental|IAI triamcinolone hexacetonide|"Intra-articular injection with corticosteroid . The study group was called triamcinolone hexacetonide / lidocaine (TH / LD) and a control group, called lidocaine (LD).~Patients in TH / LD group underwent corticosteroid IAI scheme in its most symptomatic interphalangeal (IP) joint composed with triamcinolone hexacetonide(TH) (20mg/ml) and 2% lidocaine without vasoconstrictor. The IAI was realized in the 0.3 ml dose (6mg) of TH for PIP and 0.2 ml (4 mg) of HT for DIP, always associated with 0.1 mL of 2% lidocaine. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day)."
3068805|NCT02102620|Placebo Comparator|IAI lidocaine|Intra-articular injection with lidocaine. The LD group patients underwent IAI with only 2% lidocaine without vasoconstrictor in its most symptomatic IP joint. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day) . Both groups of patients underwent only one IAI in the most symptomatic joint and on a single occasion.
3068806|NCT02102607||age|subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
3068807|NCT02102594|Experimental|Bortezomib (Velcade)|
3068808|NCT02102581||short time tourniquet|60 patients were randomly divided into 2 groups (30 cases/group): group A using the tourniquet throughout the operation, and group B using the tourniquet starting from the implantation of prosthesis to the completion of the operation(short time).
3068809|NCT02102568||diagnostic|quality of life score and dosage
3068810|NCT02102555|Active Comparator|IV acetaminophen|Patients in the IV acetaminophen arm will receive a one gram dose of IV acetaminophen in the pre-operative area prior to their surgery.
3068811|NCT02102555|Placebo Comparator|Placebo|Patients in the placebo arm will receive normal saline in the pre-operative area.
3068812|NCT02102542||Antisialagouge|A group of patients enrolled to prove efficacy of Glyco-P for reduction of secretions.
3068813|NCT02102542||Bradycardia|A group of patients enrolled to prove efficacy of Glyco-P for modest increase of heart rate.
3068814|NCT02102542||For reversal of neuromuscular blocking agents|Group of patients enrolled to prove efficacy of Glyco-P when used in combination with neostigmine to reserve neuromuscular blocking agents.
3068815|NCT02102529||bowel endometriosis|laparoscopic colonic resection
3068816|NCT02102516|Experimental|SPRIX(intranasal ketorolac tromethamine)|Based on subject weight
3068817|NCT02102503|Experimental|MI and Medication review|The intervention starts three months post-discharge after the standard treatment at the out-patients clinic. A medication review focused on cardiovascular drugs, and a counselling session with a clinical pharmacist using Motivational Interviewing (MI)-approach, and a follow-up phone call two weeks later. For patients with negative beliefs about medicines, three additional MI-sessions in clinic or by phone are planned together with the patient. Irrespective of beliefs the intervention ends with a second medication review and counselling session, which is coordinated with the 12-months post-discharge follow-up in primary care.
3068818|NCT02102503|Active Comparator|Standard treatment|Standard treatment at the cardiology out-patient clinic. Follow-up by nurse after two weeks and by physician after two months.
3068819|NCT02102490|Experimental|Abemaciclib|200 milligrams (mg) abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.
3068820|NCT02102477|Experimental|Prostatectomy/Surgery|Patients with locally advanced prostate adenocarcinoma recieves Prostatectomy/Surgery with or without adjuvant or salvage radiotherapy
3068821|NCT02102477|Active Comparator|Radiotherapy with adjuvant androgen deprivation therapy|Patients with locally advanced prostate adenocarcinoma treated with adjuvant androgen deprivation therapy
3068822|NCT02102464|Experimental|LipiFlow|Single 12-minute LipiFlow treatment
3068823|NCT02102464|No Intervention|Untreated Control|Untreated Control (No Intervention)
3068824|NCT02102464|Experimental|Crossover LipiFlow Treatment|Crossover LipiFlow treatment of the untreated control group after 3 months
3068825|NCT02102438|Experimental|Trastuzumab and weekly chemotherapy|"Treatment schedule Weekly paclitaxel and Carboplatin at 80mg/m2 and Area under the curve (AUC) of 2, respectively. Weekly trastuzumab will be combined with chemotherapy (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg). Chemotherapy will be given at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.~After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles."
3068826|NCT02102425||Chronic kidney disease, PD|Patients with or without bandage over exit site
3068827|NCT02102412|Experimental|single arm|single arm patients underwent colonoscopy with aer-o-scope followed by conventional colonoscopy to assess if any mucosal damage occurred with the experimental device.
3068828|NCT02102399|Experimental|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
3068829|NCT02102399|Experimental|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
3068830|NCT02102386||CerOx|Patients will be monitored using the CerOx monitor. Probes will be attached bi-laterally in the OR to the forehead.
3068831|NCT02102373|Active Comparator|low-fiber diet|Patients received low-fiber diet for 24 hours before colonoscopy
3068832|NCT02102373|Active Comparator|clear liquid diet|Patients received clear liquid diet for 24 hours before colonoscopy
3068894|NCT02101918|Experimental|Treatment (ziv-aflibercept, perfusion CT)|Patients receive ziv-aflibercept IV over 60-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography perfusion imaging at baseline, day 21 of course 1, and at time of progression.
3068833|NCT02102360|Experimental|Minimally invasive surgical technique (MIST)|A minimally invasive surgical technique was performed to access mandibular furcation defects in the test group, aiming to perform minimal flap reflection, minimal wound, and gentle handling of the soft and hard tissue in periodontal surgery. The use of a microsurgical approach provides magnification and optimal illumination of the surgical site improving visual acuity. Further advantages may be the reduction of flap reflection during surgery, consequently advantages in wound healing process and benefits in patient's perceptions of the procedure. A less invasive surgical procedure may lead to a less cell demand in the healing process, and a potentially reduced morbidity. The minimally invasive surgical procedures were performed using microscope.
3068834|NCT02102360|Experimental|Conventional surgical technique (CST)|A conventional surgical technique was performed to access mandibular furcation defects in the control group.
3068835|NCT02102347|Experimental|exercise group|An exercise program will be performed to increase range of motion, improve motor learning and strengthen the muscles of the lower limb. The program will include exercises 2 times a week for four weeks. The first week the exercises will be performed with 2 sets of 15 repetitions and the remaining weeks 3 sets of 15 repetitions for each exercise. To exercise will be performed with the resistance of cinnamon, It will be recommended weight by 70% of one repetition maximum painless assigned individually per patient.
3068836|NCT02102347|Experimental|phototherapy group|And, Phototherapy will be administered with a portable nine-diode cluster. The portable nine-diode cluster will be used overlapping three quadrants of the knee in random sequence: medial quadrant, lateral quadrant and posterior quadrant.with one 905-nm diode (mean power: 1 milliwatt ; peak power: 10 megawatt; spot size: 0.44 cm2), four 875-nm diodes (mean power of each diode: 17.5 milliwatt; spot size: 1 cm2) and four 670-nm diodes (mean power of each diode: 15 mW; spot size: 1 cm2); frequency: 1000 Hz; 300-second irradiation time in each quadrant; total energy: 39.3 Joules per quadrant. Phototherapy will be included in the exercises group.
3068837|NCT02102347|Placebo Comparator|Phototherapy placebo|Phototherapy will be administered with a portable nine-diode cluster. The portable nine-diode cluster will be used overlapping three quadrants of the knee in random sequence: medial quadrant, lateral quadrant and posterior quadrant), with one 905-nm diode (mean power: 0 milliwatt; peak power: 0 watt; spot size: 0.44 cm2), four 875-nm diodes (mean power of each diode: 0 milliwatt; spot size: 1 cm2) and four 670-nm diodes (mean power of each diode: 0 milliwatt; spot size: 1 cm2); frequency: 0 Hz; 300-second irradiation time in each quadrant; total energy: 0 Joules per quadrant. Phototherapy will be included in the exercises group.
3068838|NCT02102334||Unilateral osteoarthritis|Patients operated with a total hip replacement due to unilateral osteoarthritis of the hip. Radiographic measurements of the postoperative radiographs.
3068839|NCT02102321|Experimental|albendazole|albendazole 400 mg
3068840|NCT02102321|Active Comparator|placebo|placebo
3068841|NCT02102308|Experimental|Exercise|Multicomponent exercise
3068842|NCT02102308|Placebo Comparator|Education classes|Education classes
3068843|NCT02102295|Active Comparator|Experimental toothpaste|L-ascorbic acid 2-phosphate magnesium salt / fluoride
3068844|NCT02102295|Placebo Comparator|Control toothpaste|fluoride
3068845|NCT02102282||Subject study|Patients with breast cancer during pregnancy
3068846|NCT02102269|Active Comparator|actimove sling|standard orthosis: actimove sling
3068847|NCT02102269|Experimental|shoulderlift|newly developed orthosis: shoulderlift
3068848|NCT02102269|No Intervention|controle group|no orthosis
3068849|NCT02102256|Experimental|Experimental|Device Implantation
3068850|NCT02102243|Experimental|Hyperinsulinemic euglycemic clamp|"We will perform following procedures:~DEFINITY® infusion Flow mediated vasodilation Endothelial cell collection Microvascular perfusion assessment using Definity Microneurography"
3068851|NCT02102243|Experimental|Initial Saline Infusion|"We will perform the following procedures:~DEFINITY® infusion Human Recombinant Regular Insulin infusion Dextrose infusion Flow mediated vasodilation Endothelial cell collection Microvascular perfusion assessment using Definity Microneurography"
3068852|NCT02102230|Experimental|CBT-I-MA|Group CBT-I with Adjunct Mobile Application
3068853|NCT02102230|Active Comparator|CBT-I|Group CBT-I only
3068854|NCT02102230|Placebo Comparator|PC|quasi-desensitization
3068855|NCT02102217|Experimental|Precious arm|Postoperative controls according to the PRECious protocol, which entails standardized measurement of CRP levels on postoperative day three, four and five. If CRP levels exceed 140 mg/l additional CT-scan imaging will be conducted.
3068856|NCT02102217|No Intervention|Control|Standard postoperative controls. Additional testing will only be conducted on demand.
3068857|NCT02102204|Experimental|Etelcalcetide|Participants received etelcalcetide three times a week (TIW) by bolus injection at the end of hemodialysis. The minimum etelcalcetide dose in this study was 2.5 mg and the maximum dose was 15 mg. Etelcalcetide dose was titrated to maintain parathyroid hormone levels within 2x to 9x the upper limit of normal based on the reference range of the assay used at the individual study center.
3068858|NCT02102191|Active Comparator|cigarette|common cigarette sold in the stores
3068859|NCT02102191|Active Comparator|e-cigarette|e-cigarette (Ovale Elips)
3068860|NCT02102178|Experimental|Group 1 (Intensive occupational therapy)|"All patients received pharmacological treatment for pain in accordance with the World Health Organization (WHO)'s analgesic ladder and occupational therapy follow-up, with guidance regarding activities of daily living (ADLs).~They also carried out therapeutic activities such as embroidery onto gauze (tapestry), weaving a scarf on a nail frame and playing dominos."
3068861|NCT02102178|Active Comparator|Group 2 (Regular occupation therapy)|All patients received pharmacological treatment for pain in according to WHO's analgesic ladder and only guidance regarding ADLs from the occupational therapist.
3068862|NCT02102165|Experimental|metastatic lesion biopsy|biopsy of metastatic lesion will be performed at program inclusion or maximum 6 months prior to inclusion. Sample of primary tumor must be available at inclusion.
3068863|NCT02102152|Active Comparator|TOBI / Placebo|TOBI / Placebo.
3068864|NCT02102152|Active Comparator|Placebo / TOBI|Placebo / TOBI
3068969|NCT02101385|Other|Control Arm B (Observation/Standard Therapy)|Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
3068970|NCT02101372|Active Comparator|treatment as usual|
3068865|NCT02102139|Experimental|DXM + Propofol|"DXM (1 µg kg -1) was loaded intravenously for 10 min before anaesthesia induction.During DXM loading, the depth of anaesthesia was monitored using a bispectral index (BIS) monitor. Electrocardiogram, heart rate, pulse oximetry, and non-invasive arterial blood pressure were monitored at 2-min intervals.~Anaesthesia was induced with propofol 3.5 μg mL 1 and remifentanil 5 ng mL 1 at an effect site concentration using a target-controlled infusion (TCI) device. Anaesthesia was maintained with propofol and remifentanil continuous infusions.~During surgery except the study period, propofol and remifentanil doses were adjusted to maintain BIS value of 40-60 and systolic blood pressure (SBP) within ±20% from baseline respectively."
3068866|NCT02102139|Placebo Comparator|Saline + Propofol|"Saline (1 µg kg -1) was loaded intravenously for 10 min before anaesthesia induction.During saline loading, the depth of anaesthesia was monitored using a bispectral index (BIS) monitor. Electrocardiogram, heart rate, pulse oximetry, and non-invasive arterial blood pressure were monitored at 2-min intervals.~Anaesthesia was induced with propofol 3.5 μg mL 1 and remifentanil 5 ng mL 1 at an effect site concentration using a target-controlled infusion (TCI) device. Anaesthesia was maintained with propofol and remifentanil continuous infusions.~During surgery except the study period, propofol and remifentanil doses were adjusted to maintain BIS value of 40-60 and systolic blood pressure (SBP) within ±20% from baseline respectively."
3068867|NCT02102126|Experimental|Renal denervation|Subjects are treated with the renal denervation procedure after randomization and are maintained on baseline anti-hypertensive medications
3068868|NCT02102126|No Intervention|Control group|Subjects are maintained on baseline anti-hypertensive medications.
3068869|NCT02102113|Other|No Family History of Psychosis (FHN)|Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions.
3068870|NCT02102113|Experimental|Family History of Psychosis (FHP)|Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions.
3068871|NCT02102100|Placebo Comparator|Tobacco flavor|Tobacco Flavor + IV saline, Tobacco Flavor + IV nicotine (0.25 mg/70kg), Tobacco Flavor + IV nicotine (0.5 mg/70kg)
3068872|NCT02102100|Active Comparator|Low dose menthol|Low dose menthol + IV saline, Low dose menthol + IV nicotine (0.25 mg/70kg), Low dose menthol + IV nicotine (0.5 mg/70kg)
3068873|NCT02102100|Active Comparator|High dose menthol|High dose menthol + IV saline, High dose menthol + IV nicotine (0.25 mg/70kg), High dose menthol + IV nicotine (0.5 mg/70kg)
3068874|NCT02102087|Experimental|Initial Specimen Diversion Device (ISDD)|The ISDD will be used in conjunction with standard blood culture bottles.
3068875|NCT02102087|Active Comparator|Lab standard practice (LSP)|A standard blood culture kit will be used.
3068876|NCT02102061|Experimental|multidisciplinary intervention|
3068877|NCT02102061|No Intervention|control|
3068878|NCT02102048|Active Comparator|Atazanavir|patients that switch cART to boosted or unboosted ATV
3068879|NCT02102048|No Intervention|other Protease Inibithors|patients that continue the previous cART without changes.
3068880|NCT02102035|Other|Dorsal digital island flap|The flap is used to cover the soft-tissue defects of the fingers.
3068881|NCT02102022|Experimental|ADI-PEG 20|
3068882|NCT02102009|Experimental|Vitafos|Complete enteral formula
3068883|NCT02102009|Active Comparator|Dietary Advise|Dietary advise according to the hospital routine clinical practice.
3068884|NCT02101996||Healthy|Not insulin resistant
3068885|NCT02101996||Insulin resistant|Insulin resistant by an insulin clamp
3068886|NCT02101983|Experimental|Outpatient HiDAC Consolidation|Patients will receive 2 cycles of 1.5 grams/m2/day of intravenous cytarabine once daily for six consecutive days. Toxicity will be monitored through the duration of treatment. Observation will be complete upon count recovery and resolution of toxicity after the second cycle.
3068887|NCT02101983|Active Comparator|Quality of Life Comparison Group|Patients receiving outpatient intravenous cytarabine will complete the EORTC QLQ-C30 quality of life form on the last day of each cycle of chemotherapy.
3068888|NCT02101970|Experimental|Weight Loss + Omega-3 FA|Participants will be instructed to follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of Omega-3 FA (fatty acids) a day beginning 2 weeks after starting their diet and exercise routine. Omega-3 FA will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.Each Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
3068889|NCT02101970|Active Comparator|Weight Loss + Placebo|Participants will be instructed to exercise and follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of placebo a day beginning 2 weeks after starting their diet and exercise routine. Placebo capsule will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.
3068890|NCT02101957|Experimental|RP103|RP103 capsule, 16 capsules per day
3068891|NCT02101957|Placebo Comparator|placebo|placebo capsule, 16 capsules per day
3068892|NCT02101944|Experimental|Treatment (dexamethasone, carfilzomib, wild-type reovirus)|Patients receive dexamethasone IV, carfilzomib IV over 30 minutes, and wild-type reovirus IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3068893|NCT02101931|Experimental|Urine spectral analysis|The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking Amino levulinic Acid and the samples will be analyzed by photodynamic diagnostic procedure. Amino levulinic Acid gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).The above samples is taken in a four side polished quartz cuvette of 1cmx1cmx4cm and put into the table top spectral scan. This consists of a 5 mw, blue diode laser, of 405nm wavelength. The collimated laser beam falls on the urine sample and excites fluorescence and Raman signals from the porphyrin molecules which have been metabolized from the oral administration of Amino levulinic Acid.
3068971|NCT02101372|Experimental|Psychoeducation Group|
3068972|NCT02101359|Experimental|T2380|"Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.~At the beginning of surgery, 200 μL of T2380 were administrated intracamerally."
3068895|NCT02101905|Experimental|Group A (lapatinib ditosylate, surgery)|Patients receive lapatinib ditosylate PO BID on days -2 to 0. Within 3-5 hours after last dose of lapatinib ditosylate, patients undergo surgical resection of tumor on day 0. Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3068896|NCT02101905|Active Comparator|Reference Group (surgery, lapatinib ditosylate)|Patients undergo surgery on day 0. Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3068897|NCT02101892|Active Comparator|Amitriptyline|Amitriptyline, 25 mg per os, daily, evening, for 8 weeks; starting dose is 12.5 mg for 2 days
3068898|NCT02101892|Placebo Comparator|placebo|sugar pills
3068899|NCT02101879||Breast cancer Her2 positive|Trastuzumab & Pertuzumab & Taxanes
3068900|NCT02101866|Experimental|Vapendavir 300 mg tablet|Vapendavir 300 mg tablet single dose with up to 7 day washout period followed by two vapendavir 132 mg capsules single dose
3068901|NCT02101866|Experimental|Two Vapendavir 132 mg capsules|Two Vapendavir 132 mg capsules single dose with up to 7 day washout period followed by Vapendavir 300 mg tablet single dose
3068902|NCT02101853|Active Comparator|Arm A (HR and IR control)|Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, and then undergo allogeneic HSCT.
3068903|NCT02101853|Experimental|Arm B (HR and IR blinatumomab)|Patients receive Blinatumomab Block 1 over 5 weeks, Blinatumomab Block 2 over 5 weeks, and then undergo allogeneic HSCT.
3068904|NCT02101853|Active Comparator|Arm C (LR control)|Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, Continuation 1 over 8 weeks, Continuation 2 over 8 weeks, and then Maintenance.
3068905|NCT02101853|Experimental|Arm D (LR blinatumomab)|Patients receive Block 2 over 4 weeks, Blinatumomab Block 2 over 5 weeks, Continuation 1 over 8 weeks, Blinatumomab Block 3 over 5 weeks, Continuation 2 over 8 weeks, Blinatumomab Block 3 over 5 weeks, and then Maintenance.
3068906|NCT02101840|Active Comparator|Apo-Oxycodone CR®|a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
3068907|NCT02101840|Active Comparator|OxyNEO®|a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
3068908|NCT02101840|Placebo Comparator|Placebo|a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
3068909|NCT02101827||Hysteroscopic surgery|Women who received hysteroscopic surgeries or examinations
3068910|NCT02101814|Other|Bariatric surgery|Roux-en-Y gastric bypass procedure is being performed by surgery in all patients in this study.
3068911|NCT02101801|Other|freshwater|receives vegetables from freshwater farms
3068912|NCT02101801|Active Comparator|recycled wastewater|receives vegetables from farms using recycled wastewater irrigation
3068913|NCT02101788|Active Comparator|Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)|Patients receive clinician's choice of either letrozole PO QD on days 1-28, tamoxifen citrate PO BID on days 1-28, paclitaxel IV over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients developing progressive disease may cross over to Arm B.
3068914|NCT02101788|Experimental|Arm B (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3068915|NCT02101775|Experimental|Arm I (WEE1 inhibitor MK-1775, gemcitabine hydrochloride)|Patients receive WEE1 inhibitor MK-1775 PO on days 1, 2, 8, 9, 15, and 16 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3068916|NCT02101775|Active Comparator|Arm II (placebo, gemcitabine hydrochloride)|Patients receive placebo PO on days 1, 2, 8, 9, 15, and 16 and gemcitabine hydrochloride as patients in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3068917|NCT02101762||Silver Coated Catheters|Subjects that had previously received silver coated Foley catheters.
3068918|NCT02101762||ERASE CAUTI Non-Silver Coated Catheters|Subjects that received non-silver catheters from an ERASE CAUTI tray.
3068919|NCT02101749|Active Comparator|trivalent inactivated influenza (INTANZA)|Intradermal injection
3068920|NCT02101749|Active Comparator|trivalent inactivated influenza (VAXIGRIP)|Intramuscle injection
3068921|NCT02101736|Experimental|Experimental Agent XL184 (Cabozantinib)|"Cohort A (≥ 16 years - closed to accrual): Starting cabozantinib of 40 mg daily by mouth per cycle. Duration of each cycle is 28 days. Subjects will dose escalate after 2 cycles to 60 mg based on dose tolerability. Subjects who do not tolerate 40 mg will dose reduce to 20 mg. Doses will be capped at 60 mg.~Cohort B (3 - 15 years). The starting cabozantinib dose is 30 mg/m2/day by mouth per cycle. Duration of each cycle is 28 days. Subjects will dose escalate after 2 cycles to 40 mg/m2/day based on dose tolerability. Subjects who do not tolerate 30 mg/m2/day will dose reduce to 23 mg/m2/day. Doses will be capped at 60 mg/day max daily dose~Each cohort will enroll up to 24 evaluable subjects with a target minimum of 17 evaluable subjects per cohort."
3068922|NCT02101723|Active Comparator|Micronutrient Powder (MNP) + Zn/Fe|Micronutrient Powder with 5 mg Zn and 12 mg Fe
3068923|NCT02101723|Active Comparator|MNP + Zn|Micronutrient Powder with 5 mg Zn
3068924|NCT02101723|Placebo Comparator|Control|Placebo sachets without micronutrients
3068925|NCT02101710|Experimental|Elantan SR 60 mg fed|Elantan SR 60 mg is orally administered on Day 1 of treatment period 1 for Fed group 2 and on Day 1 of treatment period 2 for Fed group 1.
3068926|NCT02101710|Experimental|Imdur SR 60 mg fed|Imdur SR 60 mg is orally administered on Day 1 of treatment period 1 for Fed group 1 and on Day 1 of treatment period 2 for Fed group 2.
3068927|NCT02101710|Experimental|Elantan SR 60 mg fasted|Elantan SR 60 mg is orally administered on Day 1 of treatment period 1 for Fasted group 2 and on Day 1 of treatment period 2 for Fasted group 1.
3068928|NCT02101710|Experimental|Imdur SR 60 mg fasted|Imdur SR 60 mg is orally administered on Day 1 of treatment period 1 for Fasted group 1 and on Day 1 of treatment period 2 for Fasted group 2.
3068973|NCT02101359|Active Comparator|Mydriatics and anesthetic|"Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.~Topical Mydriatic treatments were instilled three times before surgery."
3068929|NCT02101697|Experimental|HIV Stigma Reduction Intervention|The HIV stigma reduction arm group will participate in a promising intervention designed to reduce HIV stigma among health professionals. The intervention builds on results of our previous research, identifying prevalence and drivers of stigma and discrimination in Indian healthcare settings among PLHIV, health care providers, and uninfected patients.The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.
3068930|NCT02101697|Placebo Comparator|Time Matched Control Group|The time-matched control group will also receive three sessions; two administered by computers and one in small group format to control for attention effects. However, rather than AIDS stigma, the content will be focused on diabetes management (a disease not considered to be stigmatized).
3068931|NCT02101684|Experimental|Orteronel 300mg b.i.d.|Orteronel 300mg BID (600mg per day) will be administered to all included patients in a 28 days cycle schedule.
3068932|NCT02101671||trendelemburg positioning|Patients undergone laparoscopic surgery in trendelemburg position
3068933|NCT02101671||Not trendelemburg positioning|Patients undergone laparoscopic surgery not in trendelemburg position
3068934|NCT02101658||weight data assessors|students recruited to weigh individuals in a research-based clinic
3068935|NCT02101645|Experimental|LIDC treatment and bioimpedance monitoring of venous ulcers.|Lower extremity venous ulcers will be treated using periodical LIDC stimulation. Wound healing and edema reduction efforts will be monitored using bioimpedance based monitoring.
3068936|NCT02101632|Experimental|Bee Venom|Bee Venom Ointment 0,0005%
3068937|NCT02101632|Placebo Comparator|Vaseline|Vaseline ointment
3068938|NCT02101619||Moderate aortic stenosis.|
3068939|NCT02101619||Severe aortic stenosis.|
3068940|NCT02101606|Experimental|Tenecteplase|
3068941|NCT02101593|Experimental|ADI-PEG 20|
3068942|NCT02101580|Experimental|ADI-PEG 20|
3068943|NCT02101567|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
3068944|NCT02101567|Active Comparator|Oxytocin and Methergine (methyl ergometrine)|The second group of patients included in the study will be given Oxytocin 5 IU ampoule by intravenous infusion and Methergine 0.2 mg IV after delivery of fetal head.
3068945|NCT02101554|Experimental|Embeda|One arm, open label, active
3068946|NCT02101541|Experimental|FIRM ablation|"The first part of this within-patient trial investigate the efficacy of focal impulse and rotor modulation in 20 patients with paroxysmal atrial fibrillation, evaluated by continuous pre- and post-procedural heart rhythm monitoring.~The second part consists of 20 patients with persistent or longstanding persistent atrial fibrillation following the same scheme."
3068947|NCT02101528||PD Patients|"PD patients with a diagnosis of clinically probable idiopathic PD in Hoehn-Yahr stage 2-3, with the ability to walk without any assistance, with mini-mental state examination score ≥26, without any relevant comorbidity or vestibular/visual dysfunctions limiting locomotion or balance."
3068948|NCT02101528||Controls|age and sex matched healthy volunteers
3068949|NCT02101515|Placebo Comparator|Usual Labor|Immediate delivery after 3 hours with epidural or 2 hours without epidural
3068950|NCT02101515|Experimental|Extended|"Immediate delivery after 4 hours with an epidural or 3 hours without an epidural~Intervention: one additional hour for the second stage of labor~Length of second stage in extended arm is 3 hours without epidural and 4 hours with epidural."
3068951|NCT02101502|Active Comparator|Institutional Capacity|Questioner for institutional employee about Institutional Capacity
3068952|NCT02101502|Active Comparator|Educational Effectiveness|Questioner for medical and assistant staffs about Educational Effectiveness
3068953|NCT02101502|Active Comparator|Health-care|Questioner for medical, assistant staffs and patients about Quality Assurance System in Health-care
3068954|NCT02101489|Active Comparator|Intraop Foley catheter measurement|20 women will have intraoperative Foley catheter measurement of the urethral length
3068955|NCT02101489|No Intervention|Without intraop Foley cath measurement|20 women without intraoperative Foley catheter measurement of the urethral length
3068956|NCT02101476|Active Comparator|Percocet|Oxycodone/APAP (acetaminophen)
3068957|NCT02101476|Active Comparator|Xartemis|
3068958|NCT02101463|Other|surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)|
3068959|NCT02101450|No Intervention|Intra-abdominal removal of the placenta|The uterus will be left in the abdominal cavity and the placenta will be manually removed with uterine massage as soon as possible. After removal of the placenta, the uterus will be dragged out of the abdominal cavity. The cesarean incision will be sutured with no. 1 Vicryl ®. Uterus will be replaced in the abdominal cavity. Intra-abdominal cavity will be cleaned by aspirator and mounted-gauze tampon. The weight of the placenta will be measured. The weight of the gauze tampons will be measured with gravimetric method before and after use.
3068960|NCT02101450|Experimental|Extra-abdominal removal of the placenta|"No drug or device is used. The uterus will be dragged out of the abdominal cavity, prior to removal of the placenta.~The placenta will be manually removed with uterine massage as soon as possible. The cesarean section will be completed as described in No intervention group."
3068961|NCT02101424||Overdose|
3068962|NCT02101411||APT, PRU|
3068963|NCT02101398|Experimental|F7A|Anodal electrode set on the left Broca's area and cathodal electrode set on its right homologue. Active stimulation.
3068964|NCT02101398|Experimental|F7C|Cathodal electrode set on the left Broca's area and anodal electrode set on its right homologue. Active stimulation.
3068965|NCT02101398|Experimental|T5A|Anodal electrode set on the left Wernicke's area and cathodal electrode set on its right homologue. Active stimulation.
3068966|NCT02101398|Experimental|T5C|Cathodal electrode set on the left Wernicke's area and anodal electrode set on its right homologue. Active stimulation.
3068967|NCT02101398|Sham Comparator|Sham|Electrodes set on the left Broca's area and its right homologue or electrodes set on the left Wernicke's area and its right homologue, but no stimulation will be delivered.
3068968|NCT02101385|Experimental|Arm A (Genomically Directed Monotherapy)|Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). Clinical and laboratory monitoring and dose-reductions will follow the FDA package insert guidelines.
3068974|NCT02101346|Experimental|Healthy, Round 1|For feeding of 5 different fatty acid meals in order to assess the monocyte response ex vivo Mixed high fat diet Low fat diet Saturated fat diet Monounsaturated fat diet Polyunsaturated fat diet
3068975|NCT02101346|Experimental|Healthy, Round 2|"For feeding of 2 different fatty meals, in order to assess the molecular monocyte response and track the fate of fats.~Saturated fat Triolein 13C"
3068976|NCT02101333|Experimental|TOCILIZUMAB MONTHLY DURING 6|intravenous injection, 8 mg/kg, monthly during 6 months
3068977|NCT02101320|No Intervention|Group 1|Patients with a resection of the lesions according to the procedure SNOLL without the use of TReCam.
3068978|NCT02101320|Experimental|Group 2|Patients with a resection of the lesions according to the procedure SNOLL with the use of TReCam.
3068979|NCT02101307||RA Patients on RoActemra/Actemra treatment|
3068980|NCT02101294|Experimental|Interossei Lumbricals Neuro Interface|Comparison of report of symptoms of carpal tunnel syndrome when typing with standard QWERTY keyboard to report of symptoms of carpal tunnel syndrome when typing with Interossei Lumbricals Neuromuscular Technology Interface Therapy device.
3068981|NCT02101281|Experimental|Group 1|20 patients will be treated with the first planned dose, i.e. 20 µg/mL
3068982|NCT02101281|Experimental|Group 2|After completion of Group 1 treatment, data on primary efficacy and safety variables will be reviewed to identify the appropriate dose for Group 2
3068983|NCT02101268|Experimental|Arm 1: Momelotinib|Participants will receive momelotinib for 24 weeks during the randomized treatment phase, after which they will be eligible to receive momelotinib in an extended treatment phase for up to an additional 204 weeks.
3068984|NCT02101268|Active Comparator|Arm 2: Best Available Therapy (BAT)|Participants in the BAT treatment arm will receive treatment at doses and schedules determined by the investigator in accordance with standard of care. Therapy may be changed at any time during the study except during the screening period. After completion of the randomized treatment phase, participants will be eligible to receive momelotinib for the duration of the study during the extended treatment phase for up to 204 weeks.
3068985|NCT02101255|Experimental|Curodont Repair|Application on Day 0 and Day 360
3068986|NCT02101255|Active Comparator|Fluoride|Application on Day 0, Day 180, Day 360, Day 540
3068987|NCT02101242||Orthopedic surgery of the shoulder|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation during change from supine position to beach chair position.
3068988|NCT02101242||Gynecological, urological or general surgery|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation during change from supine position to Trendelenburg position.
3068989|NCT02101242||Cardiac surgery|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation in patients undergoing cardiac surgery with cardiopulmonary bypass (heart-lung machine).
3068990|NCT02101229|No Intervention|unsual treatment|The patient will have his usual treatment in this arm
3068991|NCT02101229|Experimental|The Diabeloop algorithm|In this arm, the insulin Asp(B28) dose is calculated by the algorithm based on the usual treatment of the patient, the ratio I / C, the intensity of physical activity and blood glucose sensor.
3068992|NCT02101216|Experimental|Pharmacokinetics of low dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 50 mg (1 tablets) to 6 subjects
3068993|NCT02101216|Experimental|Pharmacokinetics medium dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 100 mg (2 tablets) to 6 subjects
3068994|NCT02101216|Experimental|Pharmacokinetics of high dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 200 mg (4 tablets) to 6 subjects
3068995|NCT02101216|Experimental|Bioequivalence of Prurisol (350 mg)|Single dose of Prurisol™ 350 mg (7 x 50 mg tablets)
3068996|NCT02101216|Active Comparator|Bioequivalence of Ziagen (300 mg)|Single dose of Ziagen 300 mg (1 x 300mg tablet)
3068997|NCT02101203|Experimental|Placebo|40 subjects administered placebo
3068998|NCT02101203|Experimental|Testosterone + Buspirone|40 subjects administered 0.5 mg Testosterone + 10 mg Buspirone hydrochloride
3068999|NCT02101190|Experimental|Group 1 - Hepatic impaired subjects|Group 1 - subjects with moderate chronic hepatic impairment treated with BIA 9-1067
3069000|NCT02101190|Experimental|Group 2 - Healthy subjects|Group 2 - healthy subjects treated with BIA 9-1067
3069001|NCT02101177||Patients under Dual therapy|- 1500 patients who started treatment between April 1st 2013 and March 31st 2014 and will be seen for their week 60 visit between July 1st 2014 and June 30th 2015 (Cohort A).
3069002|NCT02101177||Early Defaulters|- 1000 patients recruited between July 1st 2014 and estimated March 31st 2015, of which 200 are expected to be early defaulters and will be contacted by the study team (Cohort B).
3069003|NCT02101164|Active Comparator|Treatment Group A|1 dose of denosumab every 4 weeks for 2 doses, followed by 1 dose of pamidronate every 4 weeks for 2 doses.
3069004|NCT02101164|Active Comparator|Treatment Group B|1 dose of pamidronate every 4 weeks for 2 doses, followed by 1 dose of denosumab every 4 weeks for 2 doses.
3069005|NCT02101151|Experimental|Vitamin D3 group|supplemented with 6000IU cholecalciferol/day for 3 months, followed by 3000 IU cholecalciferol/day for next 3 months
3069006|NCT02101151|Placebo Comparator|Placebo group|Placebo (starch) capsules identical to vitamin D capsules in appearance
3069007|NCT02101138|Experimental|Dexpramipexole|Dexpramipexole treatment
3069008|NCT02101125|Experimental|BMS-986020 + Rosuvastatin (Treatment A, B and C)|"Cohort 1: Rosuvastatin Tablet Single dose and BMS- 986020 orally on specific days~Cohort 2 (Administered 4 hrs, after the morning dose of BMS-986020): Rosuvastatin Tablet Single dose and BMS- 986020 orally on specific days"
3069009|NCT02101112|Experimental|Apixaban, 10 mg (whole tablets)|Participants received a single dose of apixaban, 10 mg, given orally as 2 5-mg whole commercial tablets (reference)
3069010|NCT02101112|Experimental|Apixaban, 10 mg (crushed and suspended in water)|Participants received a single dose of apixaban, 10 mg, given by mouth as 2 5-mg whole commercial tablets crushed and suspended in 30 mL of water
3069011|NCT02101112|Experimental|Apixaban, 10 mg (crushed and mixed with applesauce)|Participants received a single dose of 10 mg, given by mouth as 2 5-mg apixaban commercial tablets crushed and mixed with 30 g of applesauce
3069012|NCT02101099||Patients undergoing colonoscopy|Patients who are undergoing outpatient colonoscopy for colorectal cancer screening or for symptoms suggestive of colonic diseases.
3069048|NCT02100878||Obese adolescents|
3069014|NCT02101086|Active Comparator|Allogeneic blood transfusion|Allogeneic blood transfusion 10 mL per kg for anemia
3069015|NCT02101073|Experimental|ALX-0061 low dose i.v.|
3069016|NCT02101073|Experimental|ALX-0061 high dose i.v.|
3069017|NCT02101073|Experimental|ALX-0061 low dose s.c.|
3069018|NCT02101073|Experimental|ALX-0061 middle dose s.c.|
3069019|NCT02101073|Experimental|ALX-0061 high dose s.c.|
3069020|NCT02101060|Experimental|exercise|16-week progressive aerobic and resistance exercise training
3069021|NCT02101060|No Intervention|control|usual care controls
3069022|NCT02101047|Experimental|phenylephrine 50mcg bolus|Phenylephrine 50 mcg bolus dosing with continuous placebo infusion
3069023|NCT02101047|Experimental|Phenylephrine 100 mcg bolus|Phenylephrine 100 mcg bolus dosing wtih continuous placebo infusion.
3069024|NCT02101047|Experimental|Phenylephrine continuous infusion 100mcg/min|Continuous phenylephrine infusion of 100 mcg/min with placebo bolus dosing.
3069025|NCT02101034|Experimental|Phase I: Dose Level 1|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
3069026|NCT02101034|Experimental|Phase I: Dose Level 2|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
3069027|NCT02101034|Experimental|Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
3069028|NCT02101034|Experimental|Phase II Arm 2: Cetuximab-Resistant HPV-Unrelated SCCHN|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
3069029|NCT02101034|Experimental|Phase II Arm 3:|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
3069030|NCT02101021|Experimental|Momelotinib|Participants will receive momelotinib plus nab-paclitaxel and gemcitabine.
3069031|NCT02101021|Placebo Comparator|Placebo|Participants will receive placebo to match momelotinib plus nab-paclitaxel and gemcitabine.
3069032|NCT02101008|Other|Disulfiram and chelated zinc|There is only one arm. All patients are treated wtih disulfiram and chelated zinc.
3069033|NCT02100995|Experimental|STOP Intervention|The STOP treatment includes content designed to simultaneously and explicitly target both chronic pain and obesity. Treatment components are drawn from evidence-based interventions for chronic pain and obesity, separately.
3069034|NCT02100995|Active Comparator|Standard Care Weight (SCW)|The weight loss intervention includes content focused around nutrition and eating habits, stimulus control and behavioral change, and physical activity. This content has been chosen because of its demonstrated effectiveness and importance in behavioral interventions to reduce weight.
3069035|NCT02100995|Active Comparator|Standard Care Pain (SCP)|The chronic pain intervention is focused around reconceptualization of pain, decreasing catastrophizing, and increasing self-efficacy for pain. This content has been chosen because of its demonstrated effectiveness and importance in non-pharmacological interventions to improve pain management.
3069036|NCT02100982|Other|Care As Usual|Before the office visit with the PCP, patient participants in the Care As Usual arm will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
3069037|NCT02100982|Experimental|Customized Care|Before the office visit with the PCP, patient participants in the intervention group will interact with the computer based components of the customized care intervention while in the waiting room. The research staff will help the participant use an iPad in the waiting room and direct them to the Discussion Prioritization tool (DPT). After participants use the DPT, the program automatically generates a customized questions prompt list (QPL) which will be printed out in the office. Study staff will hand the QPL to intervention patients to bring to their office visit with the PCP. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
3069038|NCT02100969|Experimental|Hizentra|Hizentra is a subcutaneous (under the skin) immunoglobin (SCIg). Participants will receive weekly Hizentra. Dose and rate depend on the visit and how each participant tolerates the drug. Max flow rate not to exceed 100 mL per hour.
3069039|NCT02100956|Experimental|oxytocin|oxytocin 100 micrograms administered intrathecally (IT)
3069040|NCT02100956|Placebo Comparator|normal saline|preservative free normal saline: 3 milliliters administered intrathecally (IT)
3069041|NCT02100943||OSA in Pregnancy|Pregnant women between 32 0/7 prior to 35 6/7 weeks gestation
3069042|NCT02100930|Experimental|Neuroblastoma|This is a single-arm, open label, open access study to provide the anti-GD2 murine IgG3 MoAb 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) to patients with high-risk neuroblastoma (NB). This immunotherapy has shown efficacy against minimal residual disease (MRD) in such patients.
3069043|NCT02100917|Experimental|DMB-3111|6 mg/kg is once given in intravenous drip infusion taking 90 min
3069044|NCT02100917|Active Comparator|trastuzumab|6 mg/kg is once given in intravenous drip infusion taking 90 min
3069045|NCT02100904||Women undergoing radiofrequency ablation.|All women in the trial will be in this group who receive treatment with radiofrequency ablation (Acessa).
3069046|NCT02100891|Experimental|Allogeneic HCT + Donor NK Cell Infusion|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
3069049|NCT02100865|Experimental|Solar powered oxygen|Solar panels used to drive an oxygen concentrator to deliver at stream of oxygen at approximately 90% FiO2 and a rate of 1-5L/min.
3069050|NCT02100865|Active Comparator|Oxygen from cylinders|Conventional oxygen delivery from compressed gas cylinders
3069051|NCT02100852|Experimental|TGR-1202 + Obinutuzumab + Chlorambucil|TGR-1202 is an oral daily dose with obinutuzumab at a fixed IV infusion and chlorambucil as an oral dose on specified days.
3069052|NCT02100839|Experimental|AEM-28|"Single Ascending Dose: Single IV dose for each cohort; dose range 0.032 mg/mL to 3.54 mg/mL~Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks; dose range 1 mg/kg to 3.54 mg/kg."
3069053|NCT02100839|Placebo Comparator|Normal Saline|"Single Ascending Dose: Single IV dose for each cohort.~Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks."
3069054|NCT02100826|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
3069055|NCT02100826|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
3069056|NCT02100813|Other|Part 1: LEO 43204|Open-label, dose escalation, 2 days treatment
3069057|NCT02100813|Active Comparator|Part 2: LEO 43204 x dose|X dose for 2 days treatment
3069058|NCT02100813|Active Comparator|Part 2: LEO 43204 Y dose|Y dose for 2 days treatment
3069059|NCT02100813|Placebo Comparator|Part 2: Placebo|Placebo for 2 days treatment
3069060|NCT02100800|Experimental|COPD Group|30 patients with diagnosis of COPD
3069061|NCT02100800|Sham Comparator|Control Group|10 volunteers with extrapulmonary neoplasia
3069062|NCT02100787|Experimental|TheraTears lubricating drops|TheraTears lubricating eye drops to be used 1 drop in both eyes four times a day (QID)
3069063|NCT02100774||healthy male adults|no added micronutrient, tomato puree, lutein supplement, vitamin E supplement, vitamin D supplement
3069064|NCT02100761||invasive pulmonary aspergillosis|Patients with invasive pulmonary aspergillosis and will be treated with voriconazole according to their physician decision in five hospital, Jinan, China
3069065|NCT02100748|Experimental|TRV130 1 mg|TRV130 1 mg IV Q4H x 48 h
3069066|NCT02100748|Experimental|TRV130 2 mg|TRV130 2 mg IV Q4H x 48 h
3069067|NCT02100748|Experimental|TRV130 3 mg|TRV130 3 mg IV Q4H x 48 h
3069068|NCT02100748|Experimental|TRV130 4 mg|TRV130 4 mg IV Q4H x 48 h
3069069|NCT02100748|Active Comparator|Morphine|Morphine 4 mg IV Q4H x 48 h
3069070|NCT02100748|Placebo Comparator|Placebo|Placebo (D5W) IV Q4H x 48 h
3069071|NCT02100735|Experimental|Sedation protocol|Sedation protocol is a document that will be used to guide the adjustment of sedation in the ICU.
3069072|NCT02100735|Active Comparator|Standard of care|Current practices
3069073|NCT02100722|Active Comparator|FFR guided PCI|Patients undergoing PCI will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions. If the FFR is ≤0.80, then PCI will be performed with the Medtronic Resolute Integrity drug-eluting stent (DES) as per usual routine. If the FFR is >0.80 then PCI will be deferred. Only those sites with prior experience measuring FFR will be included in the FAME 3 trial. These patients in whom FFR of a particular lesion was not possible will be included in all analyses based on the intention to treat principle.
3069074|NCT02100722|Active Comparator|CABG|CABG will be performed as per clinical routine at each participating center. Both off-pump and on-pump surgery are acceptable, as long as the surgeon and the site are experienced in the particular technique. An internal mammary graft to the LAD should be attempted in all cases, if feasible. Complete arterial revascularization is strongly recommended, however, each center should use a conduit strategy with which they are most comfortable. All vessels ≥ 1,5 mm in diameter and with ≥ 50% stenosis should be bypassed, if technically feasible.
3069075|NCT02100709|No Intervention|Control Arm|This arm will perform the pulmonary rehabilitation as specified with no respiratory assistance.
3069076|NCT02100709|Active Comparator|Intervention Arm|This arm will conduct the pulmonary rehabilitation program with BiLevel Noninvasive Ventilation assistance from a ResMed ventilator.
3069077|NCT02100696|Experimental|Cohort 1: Etrolizumab (Open-label Induction Phase)|All participants will receive treatment with open-label etrolizumab 105 milligram (mg) subcutaneous injection every 4 weeks for 14 weeks.
3069078|NCT02100696|Experimental|Cohort 2: Etrolizumab (Double-blind Induction Phase)|All participants will receive treatment with etrolizumab 105 mg subcutaneous injection every 4 weeks for 14 weeks.
3069079|NCT02100696|Placebo Comparator|Cohort 2: Placebo (Double-blind Induction Phase)|All participants will receive treatment with placebo matched with etrolizumab.
3069080|NCT02100696|Experimental|Etrolizumab (Maintenance Phase)|Participants who achieved a clinical response at Week 14 during induction phase (etrolizumab open-label and double blind arm) and randomized to this arm will receive etrolizumab 105 mg subcutaneous injection every 4 weeks up to week 66.
3069081|NCT02100696|Placebo Comparator|Placebo (Maintenance Phase)|Participants who achieved a clinical response at Week 14 during induction phase (etrolizumab open-label and double blind arm, placebo double blind arm) and are randomized to this arm will receive placebo matched to etrolizumab.
3069082|NCT02100683||PDA Coil|Patients age 6 months to 21 years weighing > 5kg with an angiographically confirmed PDA with a minimum diameter of < 4 mm.
3069083|NCT02100670|Experimental|1% diclofenac sodium plus 3% menthol|1% diclofenac sodium plus 3% menthol gel supplied in 30 gram (g) tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
3069084|NCT02100670|Experimental|1% diclofenac sodium plus 0.09% menthol|1% diclofenac sodium plus 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
3069085|NCT02100670|Experimental|3% menthol|3% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
3069086|NCT02100670|Placebo Comparator|Placebo with 0.09% menthol gel|Placebo with 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
3069125|NCT02100410|Experimental|Iteration 2-87-2|Delefilcon A toric contact lenses T3 and T4 worn contralaterally (1 in each eye) for approximately 30 minutes
3070354|NCT02091973|Experimental|Everolimus|everolimus dosing to tough level 6-10 ng/ml
3069087|NCT02100657|Experimental|plitidepsin + bortezomib + dexamethasone|"Plitidepsin will be administered as a 3-hour (h) intravenous (i.v.) infusion on Day (D) 1 and 15, every four weeks (q4wk).~Bortezomib will be administered as a subcutaneous (s.c.) injection on D1, 4, 8 and 11, q4wk, for a maximum of eight cycles.~Dexamethasone will be taken orally on D1, 8, 15 and 22, q4wk"
3069088|NCT02100644|Experimental|Lamotrigine|The study objective is to examine whether the VPA dose can be reduced by additional administration of LTG in Japanese pre-menopausal female epilepsy patients, whose seizures are well controlled by VPA monotherapy. Then VPA is the standard product in this stuudy, not the investigational product.
3069089|NCT02100631|Experimental|PXVX0200|PXVX0200 Single dose; liquid suspension after reconstitution with buffer; > 2x108 CFU in a liquid suspension
3069090|NCT02100631|Placebo Comparator|Placebo|Placebo physiological saline
3069091|NCT02100618|Experimental|HPV Group 1|Subjects who were aged 9-14 years at study entry and received two doses of the HPV-16/18 vaccine according to a 0,6-months schedule in the study HPV-048 PRI (NCT00541970).
3069092|NCT02100618|Active Comparator|HPV Group 2|Subjects who were aged 15-25 years at study entry and received three doses of the HPV 16/18 vaccine according to a 0,1,6-months schedule in the study HPV-048 PRI (NCT00541970).
3069093|NCT02100605|Active Comparator|Phytosun, decongestant, nasal spray|"Phytosun, decongestant, nasal spray~Nasal spray 20 ml contains:~22g/l hypertonic seawater Essential oils of Eucalyptus, Niaouli and Wild menthol~Instructions for use:~Shake the bottle before use~Tilt the bottle to one side; press the nozzle firmly for at least one second, repeat until obtaining the 1st spray.~Spray in each nostril with the head upright"
3069094|NCT02100605|Placebo Comparator|Isotonic saline, nasal spray|"Isotonic saline, nasal spray~20 ml nasal spray contains Isotonic water solution 0.9% sodium chloride"
3069095|NCT02100592|Experimental|Erigo treated|Early rehabilitation treatment on Erigo Hocoma, a tilt table with integrated stepping device within 3 - 30 days from injury
3069096|NCT02100579|Active Comparator|Active Group|Ultrasound-guided adductor canal blockade with 10 ml of 0.25% bupivacaine
3069097|NCT02100579|Placebo Comparator|Control Group|Ultrasound-guided sham block with 10 ml of preservative free normal saline
3069098|NCT02100566|Experimental|Behavioral Counseling|Provide an advance directive document to patients along with counseling that either focuses on care giver burden or on patient autonomy.
3069099|NCT02100566|No Intervention|Standard AD|The topic of advance directives (AD) is introduced but patient receives an AD document only upon request.
3069100|NCT02100553|Other|Non-Obese|BMI <30 kg/m^2
3069101|NCT02100553|Other|Obese|BMI >= 30 kg/m^2
3069102|NCT02100540|Placebo Comparator|I placebo capsule|I placebo capsule
3069103|NCT02100540|Experimental|II RDC 0.3mg capsule|II RDC 0.3mg capsule
3069104|NCT02100540|Experimental|III RDC 0.6mg capsule|III RDC 0.6mg capsule
3069105|NCT02100527|Experimental|PF-05175157|
3069106|NCT02100527|Placebo Comparator|Placebo|
3069107|NCT02100514|Experimental|Bococizumab (PF-04950615; RN316)|Bococizumab (PF-04950615; RN316)
3069108|NCT02100514|Placebo Comparator|placebo|
3069109|NCT02100501||Atkins diet group|pediatric patients diagnosed with intractable epilepsy. Their ages ranged between 1 to 18 years amd indicated to dietary therapy. the targeting number of patients was 53. enrolled patients are assigned to randomly in one of KD group or Atkins group.
3069110|NCT02100501||Ketogenic diet group|pediatric patients diagnosed with intractable epilepsy. Their ages ranged between 1 to 18 years amd indicated to dietary therapy. the targeting number of patients was 51. enrolled patients are assigned to randomly in one of KD group or Atkins group.
3069111|NCT02100488|Active Comparator|Open-loop insulin infusion system|Standard Open-loop intensive insulin treatment with continuous insulin infusion (CSII). Commercially available insulin infusion systems will be used.
3069112|NCT02100488|Experimental|Closed-loop insulin infusion system|Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the by the software under investigation (CL4M Controls) based on blood glucose estimations from CGM.
3069113|NCT02100475|Experimental|Insulin degludec/liraglutide + Metformin|
3069114|NCT02100475|Active Comparator|Insulin degludec/liraglutide + Insulin Aspart + Metformin|
3069115|NCT02100462|Experimental|Chlorthalidone 12.5 mg|Chlorthalidone 12.5 mg by mouth once daily for 2 weeks
3069116|NCT02100462|Experimental|Hydrochlorothiazide 25 mg|Hydrochlorothiazide 25 mg by mouth once daily for 2 weeks
3069117|NCT02100462|Active Comparator|Aspirin 81 mg|Aspirin 81 mg by mouth once daily for 2 weeks
3069118|NCT02100449|Other|Lung ultrasound and Doppler, pneumonia|In this group, a lung ultrasound examination using pulsed-wave Doppler will be performed in patients with high clinical suspicion of pneumonia on Day 0 and on Day 3 to 5. A bronchoalveolar lavage will also be performed on Day 0.
3069119|NCT02100449|Other|Lung ultrasound and Doppler, atelectasis|Patients without clinically active pulmonary disease but presenting a consolidation of suspected atelectatic nature. Fever, hypothermia, leucocytosis and leucopenia will not be present. Tracheal secretions will remain unchanged. There will be no deterioration of oxygenation. In this group, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0 only.
3069120|NCT02100436|Experimental|Cohort 3-8 years old|up to 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
3069121|NCT02100436|Experimental|Cohort 6-35 months old|up to 100 subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart. up to 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
3069122|NCT02100436|Experimental|Cohort 9-17 years old|up tp 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
3069123|NCT02100423|Experimental|Treatment (curcumin, cholecalciferol)|Patients receive curcumin PO daily on days 1-28 and cholecalciferol PO daily on days 8-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving partial response or better may receive treatment for a total of 2 years.
3069124|NCT02100410|Experimental|Iteration 2-87-1|Delefilcon A toric contact lenses T1 and T2 worn contralaterally (1 in each eye) for approximately 30 minutes
3069126|NCT02100410|Experimental|Iteration 2-87-3|Delefilcon A toric contact lenses T5 and T6 worn contralaterally (1 in each eye) for approximately 30 minutes
3069127|NCT02100397|Experimental|Dose|A dose of S.paratyphi will be given to up to 20 participants to determine the attack rate.
3069128|NCT02100384|Active Comparator|Ultrasonics|Ultrasonic instrumentation for peri-implant maintenance
3069129|NCT02100384|Active Comparator|Scalers|Titanium Scalers instrumentation for peri-implant maintenance
3069130|NCT02100371|Experimental|BMS-833923|BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
3069131|NCT02100358||acute cholecystitis|acute cholecystitis
3069132|NCT02100332||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease will undergo a single visit with the collection of data from his/her records.
3069133|NCT02100319||Azilsartan at a dose of 20 to 40 mg, orally, once daily|Azilsartan tablets
3069134|NCT02100306|Experimental|Patients|"Patients will receive:~Auditory Feedback 100% Auditory Feedback 50% alternate"
3069135|NCT02100293|Active Comparator|standard dose rocuronium group|pretreatment of saline 100ml and rocuronium 0.6 mg/kg
3069136|NCT02100293|Active Comparator|low dose rocuronium group|pretreatment of saline 100ml and rocuronium 0.45 mg/kg
3069137|NCT02100293|Active Comparator|low dose rocuronium plus magnesium group|pretreatment of magnesium sulfate 30 mg/kg and rocuronium 0.45 mg/kg
3069138|NCT02100280|Experimental|deep block|After induction of anesthesia, continuous neuromuscular monitoring is started after calibration and stabilization of the signal as recommended by good clinical research practice; 50 Hz tetanic stimulation for 5 s, calibration, stabilization for at least 2 min 2. After stabilization, rocuronium 0.6 mg/kg is administered IV within 5 s for tracheal intubation. Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block.
3069139|NCT02100280|No Intervention|moderate block|After induction of anesthesia, continuous neuromuscular monitoring is started after calibration and stabilization of the signal as recommended by good clinical research practice; 50 Hz tetanic stimulation for 5 s, calibration, stabilization for at least 2 min 2. After stabilization, rocuronium 0.6 mg/kg is administered IV within 5 s for tracheal intubation. Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
3069140|NCT02100267|Experimental|Asthma patients|
3069141|NCT02100267|Experimental|Healthy volunteers|
3069142|NCT02100254|Experimental|Arm I (personal narrative)|Participants view videos with information about CRC and screening delivered by personal narrative.
3069143|NCT02100254|Active Comparator|Arm II (fact-based message)|Participants view videos with information about CRC and screening delivered by informative fact-based message.
3069144|NCT02100241|Experimental|Active stretching with currents|Active stretching performed while currents are applied on hamstring muscles.
3069145|NCT02100241|Experimental|Active stretching|Active stretching are performed.
3069146|NCT02100241|No Intervention|Control group|Routine clinical practice
3069147|NCT02100228|Experimental|Apixaban|
3069148|NCT02100228|Active Comparator|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
3069149|NCT02100215|Experimental|Expert Modeling|Participants will have access to 70 minutes of expert modeling videos available over 5 weeks on an online learning management system. The investigator will be the expert model in the videos. Expert modeling videos will address content related to seven concepts: Taking report with a graphic organizer worksheet, prioritizing patient care, delegating to unlicensed assistive personnel, safety checks in patient rooms, focused physical assessments, safe medication administration, and using a standardized healthcare provider communication tool on the telephone.
3069150|NCT02100215|Active Comparator|Voice Over PowerPoint|Participants will have access to 60 minutes of voice over PowerPoint slides, available over 5 weeks on an online learning management system, specifically to match exposure and content with the expert modeling video group. The script for PowerPoint will contain content related to the aforementioned seven concepts. There will be static photos, but no expert modeling videos, on PowerPoint slides. The investigator will narrate the voice over PowerPoint.
3069151|NCT02100215|Placebo Comparator|Reading|Participants will have access to articles, policies, and procedures on an online learning management system. The estimated time required for participants to review these materials is 45 minutes
3069152|NCT02100202|Placebo Comparator|Placebo|Capsules containing 250 mg of placebo, two times a day
3069153|NCT02100202|Experimental|BioTurmin|Capsules containing 250 mg of BioTurmin (Curcuma longa rhizomes extract), two times a day
3069154|NCT02100202|Experimental|BioTurmin-WD|Capsules containing 250 mg of BioTurmin-WD (water dispersible curcuminoids), two times a day
3069155|NCT02100202|Experimental|MaQxan|Capsules containing 10 mg of MaQxan (Tagetes erecta flower extract), two times a day
3069156|NCT02100189|Experimental|Screening (esophageal cytology, FISH)|Participants swallow the capsule (Oesotest from Actimed) and then wait 10 minutes before the sponge is pulled out through the esophagus by gentle traction on the string. Cytology samples from the sponge are harvested and analyzed by FISH. Participants then undergo standard EGD or upper endoscopy.
3069157|NCT02100176||Rotigotine and MIRT|Group 1 - 20 Patients with PD (H&Y stages 1,5-2) in therapy only with Rotigotine will undergo a Multidisciplinary intensive rehabilitation treatment (MIRT).
3069158|NCT02100176||Control group, only Rotigotine|Group 2 - 20 Patients with PD (H&Y stages 1,5-2)
3069159|NCT02100163|Experimental|Virtual Reality Hypnosis|The patient receives VRH daily.
3069160|NCT02100163|Experimental|Audio Hypnosis|The patient receives Audio Hypnosis daily.
3069161|NCT02100163|Experimental|Standard Treatment|The patient receives the standard treatment. This is a control group and there are no interventions.
3069162|NCT02100150|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
3069163|NCT02100150|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and water
3069164|NCT02100137||Women with endometrial hyperplasia|
3069297|NCT02099149||Controls|Infants born to GBS colonized mother who do not develop GBS disease
3069165|NCT02100124|Experimental|Reproductive Life Planning (RLP)|RLP is an online adaptation of the Centers for Disease Control and Prevention (CDC) reproductive life planning toll that guides women to identify their reproductive goals and individual requirements for contraception.
3069166|NCT02100124|Experimental|Reproductive Life Planning Plus (RLP+)|RLP+ additionally includes contraceptive action planning, aimed at helping women select solutions for potential problems they may encounter with contraceptive adherence.
3069167|NCT02100124|Active Comparator|Information-only control|The information-only control will deliver on-line information about their contraceptive benefits coverage and information about all FDA-approved contraceptive methods.
3069168|NCT02100111||Participants with advanced or metastatic BCC|Participants with BCC who received any treatment including surgeries, radiation, photodynamic therapy, chemotherapy, supportive/palliative care, or other therapies, will be included as a part of study.
3069169|NCT02100085||Observational group|Subjects in the period less than 48 weeks after the final administration of GX-188E
3069170|NCT02100072|Experimental|Nd:YAG 1440 nm laser|
3069171|NCT02100059|Experimental|Electrical Stimulation (TENS)|The TENS (transcutaneous electrical nerve stimulation) electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
3069172|NCT02100046|Experimental|ethosuximide|The purpose of this study is to assess the effectiveness of ethosuximide (Zarontin®) on the pain symptoms and quality of life in patients with neuropathic traumatic pain compared to a control group.
3069173|NCT02100046|Other|control group|The purpose of this study is to assess the effectiveness of ethosuximide (Zarontin®) on the pain symptoms and quality of life in patients with neuropathic traumatic pain compared to a control group.
3069174|NCT02100033|Experimental|acupuncture|acupuncture manipulation
3069175|NCT02100020|Experimental|Direct Referral to Physical Activity|The REF group will be referred to a centre-based community exercise program in their respective community (either the MacWheelers or Revved Up) by a clinical neurologist where they will be prescribed exercise based on the PAGs for adults with MS, and according to their individual capabilities.
3069176|NCT02100020|No Intervention|Control|The CON group will be provided with a print copy of the PAGs and a link to an online resource for physical activity information.
3069177|NCT02100007|Experimental|ME-344|ME-344 IV, 10 mg/kg on Days 1, 8, 15 and 22 of each 28 day cycle Topotecan IV, 4 mg/m2 on Days 1, 8 and 15 of each 28 day cycle
3069178|NCT02099994|Experimental|A - AM|Ad35-GRIN 5 x 10^10 vp IM at week 0, MVA.HIVconsv 2 x 10^8 pfu IM at week 8.
3069179|NCT02099994|Experimental|B - DDDAM|pSG2.HIVconsv DNA 4 mg or saline placebo at weeks 0, 4 and 8. Ad35-GRIN 5 x 10^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10^8 pfu or saline placebo at week 20.
3069180|NCT02099994|Experimental|C - DeDeDeAM|"Electroporated pSG2.HIVconsv 4 mg or electroporated saline placebo at weeks 0, 4 and 8.~Ad35-GRIN 5 x 10^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10^8 pfu or saline placebo at week 20."
3069181|NCT02099981|Experimental|Control Group|Control subjects will receive AG.
3069182|NCT02099981|Experimental|Type 1 diabetes|Type 1 diabetic subjects will receive AG.
3069183|NCT02099968|Experimental|Comprehensive Lifestyle Modification|
3069184|NCT02099968|Active Comparator|DASH|
3069185|NCT02099955|No Intervention|Screening Study|To determine the prevalence and severity of vitamin D deficiency and glucose tolerance in persons with chronic SCI.
3069186|NCT02099955|Experimental|Pulmonary Arm|"Vitamin D3 Supplementation and Pulmonary Function:~To determine the relationship between levels of vitamin D and overall pulmonary function, as measured by PFTs (spirometry and body plethysmography).~To determine effects of vitamin D supplementations on overall pulmonary function and selected biomarkers of inflammation (FeNO, pH, 8- isoprostane levels)."
3069187|NCT02099955|Experimental|Endocrine Arm|"Vitamin D3 Supplementation and Endocrine Function:~To determine the effect of vitamin D replacement therapy on carbohydrate metabolism and insulin resistance in persons with vitamin D deficiency (<20ng/ml) and IGT, mild DM (e.g. fasting serum glucose <140 mg/dL) and/or IR."
3069188|NCT02099929|Experimental|Coffee with Sugar|300mL of Coffee with 30g of Sugar
3069189|NCT02099929|Experimental|Coffee without Sugar|300mL of Coffee without Sugar
3069190|NCT02099929|Experimental|Decaffeinated Coffee without Sugar|300mL of Decaffeinated Coffee without Sugar
3069191|NCT02099929|Sham Comparator|Water with Sugar|300mL of Water with 30g of Sugar
3069192|NCT02099929|Sham Comparator|Water without Sugar|300mL of Water without Sugar
3069193|NCT02099916|Active Comparator|gonadotropins plus DHEA|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists. Prior to the stimulation will be treated with DHEA 25 mg PO tid for 12 weeks.
3069194|NCT02099916|Active Comparator|Gonadotropins|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists.
3069195|NCT02099903|No Intervention|Medical therapy for heart failure|Standard optimized medical therapy for heart failure.
3069196|NCT02099903|Experimental|Renal denervation + medical therapy.|Transcatheter Renal Denervation with irrigated radiofrequency catheter + standard medical therapy.
3069197|NCT02099890|Experimental|Anti-inflammatory Supplementation|Omega-3 pill (500 EPA / 250 DHA) taken orally 3 times daily, Vegetation Protein Powder (45g) taken orally once daily, InflanNox capsule (400mg curcumin) taken 3 times daily, Anti-oxidant Network capsule (615mg) taken twice daily, Chlorella tablet (1000mg) taken 6 times daily
3069198|NCT02099877||Nulliparous requesting epidural|"Nulliparous parturients ≥ 37 weeks gestation, with ASA I or II, with an uncomplicated course of singleton vertex pregnancy requesting epidural analgesia for pain relief will be included.~When the patient requests analgesia, cervical dilatation will be verified by the obstetric resident/attending. Then epidural analgesia will be initiated with a test dose of 3mL of 2% lidocaine and epinephrine 15 µg and a dose of fentanyl 100 µg diluted to a total volume of 10 mL with preservative- free normal saline. Before placement of the epidural, venous blood (2 mL) will be drawn into special tubes. Genotyping of OPRM1: p.118A/G will be also performed."
3069298|NCT02099149||Cases|Infants with culture confirmed GBS disease
3069299|NCT02099136|Experimental|Group I (placebo)|Patients receive placebo PO BID for 14 days.
3069199|NCT02099864|Experimental|Treatment (Enzalutamide)|Patients receive enzalutamide PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo a tumor biopsy of a metastatic site at study entry (prior to initiation of enzalutamide) and after the time of progression. Per the investigator, patients may continue treatment beyond progression.
3069200|NCT02099851|Experimental|Carotid body ablation|Patients undergoing the unilateral endovascular ablation of the right or left carotid body.
3069201|NCT02099838|Experimental|Pioglitazone and Metformin|Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks.
3069202|NCT02099838|Placebo Comparator|Placebo|Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks.
3069203|NCT02099825|Experimental|Anxious Adult Males|One time dosage of d-cycloserine and mifepristone at Session 2 prior to public speaking exposure sessions.
3069204|NCT02099825|Active Comparator|Non-Anxious Adult Males|One time dosage of d-cycloserine and mifepristone at Session 2 prior to public speaking exposure sessions.
3069205|NCT02099812||Obese|Obese individuals
3069206|NCT02099812||Non-obese|Non-obese individuals
3069207|NCT02099799|Active Comparator|Pedometer and Internet Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
3069208|NCT02099799|No Intervention|Usual Care|Verbal instructions and written materials about exercise.
3069209|NCT02099786|Experimental|COMP-VA|Hearing testing at each treatment and at 1 month following treatment.
3069210|NCT02099786|Experimental|Usual Care|Hearing testing done according to Audiology Clinic protocol
3069211|NCT02099786|Other|Program evaluation|Testing done to evaluate aims of the study
3069212|NCT02099786|No Intervention|Control|Hearing and distortion product otoacoustic emission testing at intervals aligned with COMP-VA cisplatin treatment intervals
3069213|NCT02099773||support workers & AAC users|Support workers who use KeyWordSigning in the communication with their client who has an intellectual disability
3069214|NCT02099773||support workers & KWS users|Support workers who use aided AAC in the communication with their client who has an intellectual disability
3069215|NCT02099760||STD testing (GC/Ct/trich)|
3069216|NCT02099747|Active Comparator|hATG + CsA|Control Arm
3069217|NCT02099747|Experimental|hATG + CsA + Eltrombopag|Experimental
3069218|NCT02099734||A: suspicion of germ cell tumor and/or a testicular mass|patients with testicular GCTs and non-GCT testicular tumors, extragonadal male GCTs, and female GCTs,
3069219|NCT02099734||B: family members of Group A|relatives of patients with GCTs or testicular tumors
3069220|NCT02099734||C: healthy controls unrelated to Group A or B|healthy controls who are unrelated to Groups A or B and do not have a personal history of cancer nor a family history of GCT or non-GCT testicular tumors
3069221|NCT02099721|Active Comparator|Group A: Secondary prevention patients- device implant|"Patients who are guideline indicated for an ICD/CRT-D for secondary prevention of sudden cardiac arrest.~These subjects receive an ICD/CRT-D implant."
3069222|NCT02099721|No Intervention|Group B: Secondary prevention patients - no device implant|"Patients who are guideline indicated for an ICD/CRT-D for secondary prevention of sudden cardiac arrest.~These subjects choose not to receive an ICD/CRT-D implant."
3069223|NCT02099721|Active Comparator|Group C: 1.5 Prevention patients - device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF).~These subjects receive an ICD/CRT-D implant."
3069224|NCT02099721|No Intervention|Group D: 1.5 prevention patients - no device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF).~These subjects choose not to receive an ICD/CRT-D implant."
3069225|NCT02099721|Other|Group E: Primary, non-1.5 patients - device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they do NOT fall into the 1.5 prevention group. These patients do not have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF) which would put them into the 1.5 prevention group.~These subjects receive an ICD/CRT-D implant."
3069226|NCT02099721|No Intervention|Group F: Primary, non-1.5 patients - no device|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they do NOT fall into the 1.5 prevention group. These patients do not have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF) which would put them into the 1.5 prevention group.~These subjects choose not to receive an ICD/CRT-D implant."
3069227|NCT02099708||Lansoprazole 15 mg|Lansoprazole 15 mg, capsules or orally disintegrating (OD) tablets, orally, once, daily for up to 12 months.
3069228|NCT02099695|Active Comparator|Oxybutynin Chloride|"Tablet~Dose 5,0 or 10 mg/ day"
3069229|NCT02099695|Placebo Comparator|Placebo|- Tablet
3069230|NCT02099682||Lansoprazole 15 mg|Lansoprazole 15 mg orally once daily
3069231|NCT02099669|Experimental|Liberal transfusion strategy|"Intervention: Red Blood Cell transfusions. Transfuse pRBC at a higher threshold- maintain Hb level between 110 and 120 g/L: to achieve this, 2 units of pRBCs are transfused when Hb level is < 105 g/L and 1 unit of RBCs when Hb level is 105-110 g/L.~Transfusions administered more frequently."
3069300|NCT02099136|Experimental|Group II (low-dose celecoxib)|Patients receive low-dose celecoxib PO BID for 14 days.
3069301|NCT02099136|Experimental|Group III (higher dose celecoxib BID)|Patients receive higher dose celecoxib PO BID for 14 days.
3069232|NCT02099669|Active Comparator|Restrictive transfusion strategy|Intervention: Red Blood Cell transfusions. Transfuse pRBC at standard of care thresholds- maintain Hb level between 85 and 100 g/L: to achieve this, 2 units of packed red blood cells (pRBCs) will be transfused when the Hb level is < 80 g/L and 1 unit of pRBCs when Hb level is 80-85 g/L: standard administration
3069233|NCT02099656|Experimental|Lebrikizumab|Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab on Days 1 and 8, and on Weeks 4 and 8.
3069234|NCT02099656|Placebo Comparator|Placebo|Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab matching placebo on Days 1 and 8, and on Weeks 4 and 8.
3069235|NCT02099617|Experimental|Drug Eluting Stent|Synergy II
3069236|NCT02099617|Active Comparator|Bare Metal Stent|Omega or Rebel
3069237|NCT02099604|Experimental|Vitamin D|Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin
3069238|NCT02099604|No Intervention|Standard of Care|Pegylated Interferon Alpha 2b + Ribavirin
3069239|NCT02099591|Experimental|Age group: > = 12y to < 18y - Lower dose|
3069240|NCT02099591|Experimental|Age group: > = 12y to < 18y - Higher dose|
3069241|NCT02099591|Experimental|Age group: > = 6y to < 12y - Lower dose|
3069242|NCT02099591|Experimental|Age group: > = 6y to < 12y - Higher dose|
3069243|NCT02099591|Experimental|Age group: > = 6mo to < 6y - Lower dose|
3069244|NCT02099591|Experimental|Age group: > = 6mo to < 6y - Higher dose|
3069245|NCT02099578|Placebo Comparator|Control Group|Freeze-dried placebo powder - two doses of 25 g/day for 8 weeks
3069246|NCT02099578|Active Comparator|25 g of Freeze-dried Strawberry Powder|Freeze-dried strawberry and placebo powder - one dose of 25 g/day of each for 8 weeks
3069247|NCT02099578|Experimental|50 g of Freeze-dried Strawberry Powder|Freeze-dried strawberry powder - two doses of 25 g/day for 8 weeks
3069248|NCT02099565||OPTIMA study patients|The study population will consist of OPTIMA study patients who have not been lost for follow-up and have given a written informed consent.
3069249|NCT02099552||XLHED|Those with the condition of XLHED
3069250|NCT02099539|Experimental|ALT-803|
3069251|NCT02099500|Experimental|Stem Cell Injection|Non-Randomized
3069252|NCT02099487|Experimental|Radiation|To evaluate safety and feasibility of hypofractionated Intensity Modulated Radiotherapy
3069253|NCT02099474|Experimental|Raltegravir|All women have been prescribed raltegravir before study participation.
3069254|NCT02099461|Other|No treatment|Participants received no treatment and underwent percutaneous core needle breast biopsies on Day 1 and Day 28.
3069255|NCT02099461|Experimental|Denosumab 60 mg|Participants received 60 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.
3069256|NCT02099461|Experimental|Denosumab 120 mg|Participants received 120 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.
3069257|NCT02099448||Elective Cardiac Catheterization|
3069258|NCT02099435||Hemospray to treat lower GI bleeds|
3069259|NCT02099409|Experimental|Starting with FLORENCED2 followed by open loop|Start 2 Overnight periods with closed loop through FLORENCED2 Device , followed by 2 overnight periods with open loop.
3069260|NCT02099409|Experimental|Start open loop followed by FLORENCED2|Start with 2 overnight periods with open loop , followed by 2 overnight with closed loop FLORENCED2
3069261|NCT02099396|Experimental|docetaxel+lobaplatin|"Pretreatment: 15 mg dexamethasone is administered orally every day since one day before administration with docetaxel for continuous three days. Dexamethasone 10 mg i.v. and promethazine 25mg im are administered 30 min before administration with docetaxel to prevent anaphylactic responses.~Intravenous infusion with docetaxel 75mg/m2 for one hour is carried out on the first day of each cycle for 21 days; intravenous infusion with lobaplatin 30 mg/m2 for two hours is carried out on the second day; q3wkb"
3069262|NCT02099396|Experimental|gemcitabine+lobaplatin|"Pretreatment: 15 mg dexamethasone is administered orally every day since one day before administration with docetaxel for continuous three days. Dexamethasone 10 mg i.v. and promethazine 25mg im are administered 30 min before administration with docetaxel to prevent anaphylactic responses.~Intravenous infusion with gemcitabine 675mg/m2 for 90 min is carried out on the first day and the eighth day of each cycle for 21 days; intravenous infusion with lobaplatin 30 mg/m2 for two hours is carried out; intravenous infusion with docetaxel 75mg/m2 for one hour is carried out on the first day; q3wkb"
3069263|NCT02099383|Active Comparator|normal saline, bolus|Patients of study group will receive intravenous normal saline 20cc per kilogram of body weight, one third of which will be given as a bolus followed by delivery of the remaining two third as a constant infusion over a period of 8 hours.
3069264|NCT02099383|No Intervention|normal saline, control|Patients of control group will receive intravenous normal saline 60 cc per hour.
3069265|NCT02099357|Placebo Comparator|Placebo|Daily supplementation with 3g of dextrose during eight weeks and placebo ampoules each two weeks.
3069266|NCT02099357|Experimental|Creatine|Daily supplementation with 3g of monohydrate creatine during eight weeks. Placebo ampoules each two weeks.
3069267|NCT02099357|Active Comparator|Vitamin D|Daily supplementation with 3g of dextrose during eight weeks. Vitamin D supplementation, 25000 IU each two weeks.
3069268|NCT02099344|Active Comparator|Artegraft|Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
3069269|NCT02099344|Active Comparator|Propaten|Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
3069270|NCT02099331|Experimental|Melatonin|The investigators will administer melatonin at 40mg by mouth (two 20 mg tablets), nightly prior to sleep. The administration will start 2 days prior to the scheduled surgery date and will continue until post-operative day 3.
3069271|NCT02099331|Placebo Comparator|Placebo|The investigators will administer matching Placebo by mouth (two tablets to match Melatonin), nightly prior to sleep. The administration will start 2 days prior to the scheduled surgery date and will continue until post-operative day 3.
3069272|NCT02099318|Active Comparator|Active SRP cases|SRP cases: After patients have provided written informed consent, the CT and/or MRI images obtained as part of routine preoperative care will be used to construct the model that the neurosurgeons will use in the SRP. No new or additional images will be obtained as part of this study, and the SRP modeling will rely on neuroimaging conducted as part of standard preoperative assessment. For SRP cases, prior to performing surgery, surgeons will plan and rehearse patient-specific cerebral aneurysm surgery. Similarly to the CT/MRI studies, the SRP will be available for the surgeons during the surgery for evaluation of optional surgery approaches.
3069273|NCT02099318|Placebo Comparator|Control cases|Control cases: The control group will be randomly selected according to a predetermined alternating sequence of consecutive prospectively video recorded aneurysm cases. Informed consent from all patients in both the control and SRP groups will be obtained.
3069274|NCT02099305|Experimental|Intervention|Receive Adolescent Depression Awareness Program (ADAP) intervention
3069275|NCT02099305|No Intervention|Wait list control|no intervention
3069276|NCT02099292|Experimental|Rituximab and DexaBEAM|Rituximab and DexaBEAM
3069277|NCT02099279||echocardiography examination|
3069278|NCT02099266|Experimental|Hyperbaric Oxygen Treatment|Administration of hyperbaric oxygen the morning of UCB transplant.
3069279|NCT02099253|Experimental|Youth Group|People in this group, aged 18~39,were accepted an initial dose of 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
3069280|NCT02099253|Experimental|Middle-aged Group|People in this group, aged 40~64,were accepted an initial dose of 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
3069281|NCT02099253|Experimental|Older Group|People in this group, aged 65~80,were accepted an initial dose of 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
3069282|NCT02099240|Active Comparator|Intravenous antibiotics|Intravenous antibiotics for the full duration of therapy
3069283|NCT02099240|Active Comparator|oral antibiotics|intravenous antibiotic therapy plus early switch to oral antibiotic therapy
3069284|NCT02099227||Ultrasound|those who received point-of-care ultrasound as part of their emergency department evaluation/ treatment for suspected soft tissue infections
3069285|NCT02099227||No Ultrasound|those who did not receive point-of-care ultrasound as part of their emergency department evaluation/ treatment for suspected soft tissue infections
3069286|NCT02099214|Experimental|Patients with HFE hereditary haemochromatosis|"The patients (40) will undergo a medical examination in order to analyse their medical history, cardiovascular parameters and check inclusion and non-inclusion criterions.~Then will be performed :~An electrocardiogram~Blood tests : iron and cardiac markers (serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP), beta-hCG if needed, serum bank~A 3Tesla cardiac MRI repeated twice (in order to respect the reproducibility criterion)~A 3Tesla abdominal MRI~An echocardiography at rest."
3069287|NCT02099214|Experimental|Healthy volunteers|"The healthy volunteers (10 men and 10 women) will undergo :~A urinary pregnancy test (if applicable)~A 3Tesla cardiac MRI repeated twice (in order to respect the reproducibility criterion)~An echocardiography at rest."
3069288|NCT02099201|Experimental|Group A1|Ten subjects will receive ACT-389949 40 mg and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
3069289|NCT02099201|Experimental|Group A2|Ten subjects will receive ACT-389949 (Predicted to be 200 mg) and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
3069290|NCT02099201|Experimental|Group A3|Ten subjects will receive ACT-389949 (Predicted to be 800 mg) and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
3069291|NCT02099201|Experimental|Group B1|Ten subjects will receive ACT-389949 200 mg and 3 subjects will receive placebo, every 3 days for 13 days (a total of 5 doses), administered orally, in the morning, following an overnight fast.
3069292|NCT02099201|Experimental|Group B2|Ten subjects will receive ACT-389949 (provisionally 200 mg) and 3 subjects will receive placebo, every 2 days for 9 days (a total of 5 doses), administered orally, in the morning following an overnight fast. The actual dose will depend on the emerging data from Group B1.
3069293|NCT02099201|Experimental|Group C1|10 subjects will receive ACT-389949 and 3 subjects on placebo. The actual dose will depend on the emerging data from the previous groups but will be within the dose range or lower than the dose range tested in Part A. The dosing schedule will be one of those already tested in Part A and/or Part B.
3069294|NCT02099201|Experimental|Group C2|10 subjects will receive ACT-389949 and 3 subjects on placebo. The actual dose will depend on the emerging data from the previous groups but will be within the dose range or lower than the dose range tested in Part A. The dosing schedule will be one of those already tested in Part A and/or Part B.
3069295|NCT02099188|Experimental|Multimodality treatment|"Squamocellular Carcinoma, Sinonasal Undifferentiated Carcinoma:~Docetaxel at 75 mg/m2 as IV infusion on Day 1 q3w~Cisplatin at 80 mg/m2 as IV infusion on Day 1 q3w~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 1 to Day 4 q3w~Small cell carcinoma neuroendocrine type, Pure neuroendocrine carcinoma and grade III-IV Esthesioneuroblastoma.~Cisplatin at 33 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.~Etoposide at 150 mg/m2/day as IV infusion from Day 1 to Day 3 q3w . Second cycle and every other cycle~Adriamycin at 20 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.~Ifosfamide at 3000 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.~Intestinal Type Adenocarcinoma with functional p53.~Leucovorin* at 250 mg/m2/day as IV infusion from Day 1 to Day 5 q3w.~Cisplatin at 100 mg/m2 as IV infusion on Day 2 q3w~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 2 to Day 5 q3w~Followed by radiotherapy"
3069296|NCT02099175|Experimental|Multimodality treatment|"Squamocellular Carcinoma, Sinonasal Undifferentiated Carcinoma:~Docetaxel at 75 mg/m2 as IV infusion on Day 1 q3w~Cisplatin at 80 mg/m2 as IV infusion on Day 1 q3w~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 1 to Day 4 q3w~Small cell carcinoma neuroendocrine type, Pure neuroendocrine carcinoma and grade III-IV Esthesioneuroblastoma:~First Cycle and every other cycle:~Cisplatin at 33 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Etoposide at 150 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Second Cycle and every other cycle:~Adriamycin at 20 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Ifosfamide at 3000 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Intestinal Type Adenocarcinoma with functional p53:~Leucovorin* at 250 mg/m2/day as IV infusion from Day 1 to Day 5 q3w~Cisplatin at 100 mg/m2 as IV infusion on Day 2 q3w~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 2 to Day 5 q3w~Followed by Radiotherapy"
3069302|NCT02099136|Experimental|Group IV (higher dose celecoxib QD)|Patients receive same dose of celecoxib PO as Group III QD for 14 days.
3069303|NCT02099136|Experimental|Group V (high-dose celecoxib)|Patients receive high-dose celecoxib PO QD for 14 days.
3069304|NCT02099123|Experimental|Atorvastatin|40 mg atorvastatin (2 x 20 mg atorvastatin), taken orally once daily
3069305|NCT02099123|Placebo Comparator|Placebo|Placebo (2 x 20 mg placebo) taken orally once daily
3069306|NCT02099110|Experimental|Ertugliflozin 5 mg + sitagliptin 100 mg|Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
3069307|NCT02099110|Experimental|Ertugliflozin 15 mg + sitagliptin 100 mg|Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
3069308|NCT02099110|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, oral, once daily for 52 weeks
3069309|NCT02099110|Experimental|Ertugliflozin 15 mg|Ertugliflozin, oral, once daily for 52 weeks
3069310|NCT02099110|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, oral, once daily for 52 weeks
3069311|NCT02099097|Active Comparator|Standard Care|"usual care, which consists of four (face-to-face or telephone) counseling sessions with a trained nurse who has expertise in helping cancer patients quit smoking. This is the same as the treatment an MSK patient who enrolls in the MSK smoking cessation program would receive.~To collect further data to improve the game intervention, the investigators will conduct semi-structured telephone interviews with patients who were randomized to the treatment arm but did not play the game during the one month intervention period. The purpose of the interviews is to elicit qualitative feedback on any barriers that may have prevented participants from playing. At the completion of the intervention period, patients will be asked if they would like to participate in a telephone interview. Telephone interviews will take about twenty minutes and will be held at a time that is convenient for the patient."
3069312|NCT02099097|Experimental|Smoking Cues Coping Skills Game (SC+SCCS/Quit IT).|Smokers randomly assigned to SC+SCCS/Quit IT will receive all the components of Standard Care. The patient will be oriented and trained face-to-face (during their hospitalization) on use of the game by study staff using an iPad. The orientation and training session will comprise: 1) Overview of the game and its objectives; 2) discussion of the rules of the game; 3) watching a 10 minute tutorial given by the game narrator (avatar); 4) answering all patient questions; and 5) evaluation of the patient's comprehension of game play via a 17 question survey. Once patients have access to QuitIT, they will also receive a set of Coping Cards
3069313|NCT02099084|Experimental|Teduglutide First, then Placebo|Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days, followed by a 14-day washout period, and placebo administered subcutaneously for 7 days.
3069314|NCT02099084|Placebo Comparator|Placebo First, then Teduglutide|Placebo administered subcutaneously for 7 days, followed by a 14-day washout period, and Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days.
3069315|NCT02099071|Experimental|Group 1|Six subjects will receive a single oral dose of ACT-389949 1 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
3069316|NCT02099071|Experimental|Group 2|Six subjects will receive a single oral dose of ACT-389949 5 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
3069317|NCT02099071|Experimental|Group 3|Six subjects will receive a single oral dose of ACT-389949 20 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
3069318|NCT02099071|Experimental|Group 4|"Subjects will participate in two different treatment periods separated by a washout of 7-10 days between the study drug administrations.~In the first treatment period six subjects will receive a single oral dose of ACT-389949 50 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.~In the second treatment period, subjects randomized to ACT-389949 will receive a single oral dose of ACT-389949 50 mg in fed condition, 30 minutes after the start of a high fat and high calorie breakfast."
3069319|NCT02099071|Experimental|Group 5|Six subjects will receive a single oral dose of ACT-389949 100 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
3069320|NCT02099071|Experimental|Group 6|Six subjects will receive a single oral dose of ACT-389949 200 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
3069321|NCT02099071|Experimental|Group 7|Six subjects will receive a single oral dose of ACT-389949 500 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
3069322|NCT02099071|Experimental|Group 8|Six subjects will receive a single oral dose of ACT-389949 1000 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
3069323|NCT02099058|Experimental|Arm D (ABBV-399 plus Nivolumab)|ABBV-399 to be evaluated with Nivolumab.
3069324|NCT02099058|Experimental|Monotherapy ABBV-399 (21-day dosing cycles)|ABBV-399 will be administered at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate ABBV-399.
3069325|NCT02099058|Experimental|Arm A (ABBV-399 plus Erlotinib)|ABBV-399 to be evaluated with Erlotinib.
3069326|NCT02099058|Experimental|Monotherapy ABBV-399 (28-day dosing cycles)|ABBV-399 will be administered at escalating dose levels in 28-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate ABBV-399.
3069327|NCT02099045||Ultrasound examination|All patients over the age of 18 presenting in the emergency department.
3069328|NCT02099032|Experimental|3g milk polar lipid fortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks.
3069329|NCT02099032|Experimental|5 g milk polar lipid fortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks.
3069330|NCT02099032|Placebo Comparator|Unfortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks
3069331|NCT02099006|Experimental|Medications|Each study subject will be sequentially exposed to each of the study drugs and the placebo in a random order. The study is designed as a double blinded, crossover study.
3069578|NCT02097342|Placebo Comparator|Placebo|Tablet Placebo per oral, once daily will be given to 10 patients for 6 months
3069332|NCT02099006|Placebo Comparator|Placebo|The compounding base alone will be used as a placebo. Each participant will be given each drug and the placebo sequentially in random order.
3069333|NCT02098993|Experimental|Unfractionated heparin|"Subjects will be randomized within 24 hours of diagnosis to one of two treatment arms, Arm A, anticoagulation and standard of care, or Arm B, no anticoagulation and standard of care. Weight-adjusted UFH will be given at doses of 80 units per kilogram followed by 18 units per kilogram per hour intravenously for 7 days, or until discharge, if discharge is shorter than 7 days. UFH will be monitored by standard protocol to maintain the activated partial thromboplastin time in the therapeutic range per institutional guidelines.~The experimental arm will receive standard of care, too, which will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions."
3069334|NCT02098993|No Intervention|Standard of care|Standard care will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions.
3069335|NCT02098980|Active Comparator|Dietary Supplement: Vitamin D|Vitamin D supplement 4000 IU/day for 6 months
3069336|NCT02098980|Placebo Comparator|Placebo|Placebo for 6 months
3069337|NCT02098967|Experimental|Acute myeloid leukemia patients|
3069338|NCT02098967|Experimental|Cohort 0|
3069339|NCT02098967|Experimental|Solid tumor patients|
3069340|NCT02098954|Experimental|experimental|patients will received a 28 days gemcitabine platinum combined with erlotinib scheme(gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for 150mg/day, day 9-21 every cycle, after 4 cycles, erlotinib should be used daily), after 4 cycle of combined chemotherapy, patients will receive erlotinib for further treatment until progression disease.
3069341|NCT02098941||Topiramate|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with topiramate as mono or add-on therapy with conventional drugs.
3069342|NCT02098941||Levetiracetam|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with levetiracetam as mono or add-on therapy with conventional drugs.
3069343|NCT02098941||Oxcarbazepine|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with oxcarbazepine as mono or add-on therapy with conventional drugs.
3069344|NCT02098928|Active Comparator|Hand-acupuncture group|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
3069345|NCT02098928|Placebo Comparator|Electric-acupuncture group|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
3069346|NCT02098915|Experimental|intravenous metoclopramide|the experimental arm will receive intravenous metoclopramide
3069347|NCT02098915|Placebo Comparator|control arm|the control arm will receive placebo
3069348|NCT02098902|Experimental|Smart Moms Intervention|This arm will receive the Smart Moms intervention immediately following randomization.
3069349|NCT02098902|No Intervention|Waitlist control group|This arm will receive a modified version of the Smart Moms intervention after the 6-month assessment.
3069350|NCT02098889|Active Comparator|hyoscine-N-butyl bromide|A single dose intravenously(IV) 20ml hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose 20ml IV NaCl) on the active phase of labor
3069351|NCT02098889|Placebo Comparator|Saline(0,9NaCl)|Placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
3069352|NCT02098876|Active Comparator|Resolute Integrity DES|Resolute Integrity zotarolimus eluting stent
3069353|NCT02098876|Active Comparator|Xience Xpedition DES|Xience Xpedition everolimus eluting stent
3069354|NCT02098837|Active Comparator|Immediate switch|Patients will be randomised to switch from a boosted PI to dolutegravir at baseline.
3069355|NCT02098837|Active Comparator|Deferred switch|Patients will be randomised to switch from a boosted PI to dolutegravir after 48 weeks.
3069356|NCT02098824|Active Comparator|Galantamine|Single administration of capsule containing 16 mg Galantamine
3069357|NCT02098824|Placebo Comparator|Placebo|Single oral administration of capsule containing placebo
3069358|NCT02098824|Active Comparator|Methylphenidate|Single administration of capsule containing 10 mg Methylphenidate
3069359|NCT02098811|Experimental|1064nm laser Treatment Before Abdominoplasty|Patient will be treated with 1064nm Laser prior to abdominoplasty
3069360|NCT02098811|Experimental|940nm Laser Treatment Before Abdominoplasty|Patient will be treated with 940nm Laser prior to abdominoplasty
3069361|NCT02098798||HD|High Definition Colonoscopy alone
3069362|NCT02098798||HD + iSCAN|HD colonoscopy + iSCAN
3069363|NCT02098798||HD + Dye|High definition colonoscopy + dye spraying chromoendoscopy
3069364|NCT02098785|Experimental|Caffeine citrate (Peyona) 400mg|Caffeine Citrate (Peyona) 400mg single dose (20ml oral solution)
3069365|NCT02098772|Experimental|Custodiol-N|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
3069366|NCT02098772|Active Comparator|Custodiol|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
3069367|NCT02098759|Experimental|epilepsy early diagnosis|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges, and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
3069395|NCT02098590|Other|Control group challenged by NF54|[Control group] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF54 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
3069618|NCT02097069|Experimental|Subgroup D|Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
3069368|NCT02098759|Experimental|standard epilepsy diagnosis|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges, and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
3069369|NCT02098746||Pioglitazone/glimepiride|Pioglitazone/glimepiride 15 mg/1 mg, orally once daily before or after breakfast.
3069370|NCT02098733||Pioglitazone/glimepiride|Pioglitazone/glimepiride 15 mg/1 mg or 30 mg/3 mg, orally once daily before or after breakfast
3069371|NCT02098720|Experimental|Conbercept|Subjects will receive Conbercept injections at a dose of 0.5 mg/eye, once a month for first 3 months. In the next 3 months, the investigator will decide whether repeat injections are needed based on the monthly assessment results.
3069372|NCT02098707||30 Parkinson disease patients|30 patients (12 M, 18 F, mean age 66,8 ± 8,7) diagnosed with PD in stage 3 of Hoen&Yahr (mean Unified Parkinson Disease Rating Scale [UPDRS] III 18.8±10.5) will undergo a balance training using a stabilometric platform.
3069373|NCT02098694|Experimental|Physiotherapy follow-up|Consultation at Physiotherapy-led Outpatient Clinic every 4 month.
3069374|NCT02098694|No Intervention|Usual care|Consultation every 4 months, twice a year by rheumatologist as usual, once a year by nurse.
3069375|NCT02098668||Normal, pathological cycle, infertility|healthy women PCOS Endometriosis hyperprolactinemia fertility treatment
3069376|NCT02098655||30 patients with PD|30 patients (12 M, 18 F, mean age 66,8 ± 8,7) with PD in stage 3 of H&Y will undergo training of balance using a stabilometric platform
3069377|NCT02098655||12 healthy volunteers|12 healthy volunteers (3 M, 9 F, mean age 66,5 ± 6,0) served as controls will undergo training of balance using a stabilometric platform
3069378|NCT02098642||Patients with passive joint mobilization|Patients diagnosed with PD according to the Gelb et al in Hoen&Yahr stage 3, with Freezing of Gait and treated with a Multidisciplinary intensive rehabilitation treatment (MIRT), including the mobilization of the metatarsophalangeal joint of the hallux
3069379|NCT02098642||No passive joint mobilization|Patients diagnosed with PD according to the Gelb et al in Hoen&Yahr stage 3, with Freezing of Gait and treated with a Multidisciplinary intensive rehabilitation treatment (MIRT)
3069380|NCT02098629|Active Comparator|Milrinone+Esmolol|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
3069381|NCT02098629|Placebo Comparator|Saline infusion|Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion.
3069382|NCT02098616|Experimental|Arm 1|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 8 weeks
3069383|NCT02098616|Experimental|Arm 2|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 6, 8 or 12 weeks
3069384|NCT02098616|Experimental|Arm 3|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 4 weeks
3069385|NCT02098616|Experimental|Arm A|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 8 weeks
3069386|NCT02098616|Experimental|Arm B|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 6, 8 or 12 weeks
3069387|NCT02098616|Experimental|Arm C|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 4 weeks
3069388|NCT02098603|No Intervention|Testing Only|
3069389|NCT02098603|Experimental|Testing & Intervention|
3069390|NCT02098590|Experimental|NF54 CPS-immunization challenged by NF135.C10|Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a heterologous malaria challenge infection by exposure to the bites of 5 NF135.C10 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
3069391|NCT02098590|Experimental|NF54 CPS-immunization challenged by NF166.C8|Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a heterologous malaria challenge infection by exposure to the bites of 5 NF166.C8 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
3069392|NCT02098590|Other|NF54 CPS-immunization challenged by NF54|[Negative control group, to assess effectiveness of CPS-immunization.] Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a homologous malaria challenge infection by exposure to the bites of 5 NF54 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
3069393|NCT02098590|Other|Control group challenged by NF135.C10|[Control group] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF135.C10 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
3069394|NCT02098590|Other|Control group challenged by NF166.C8|[Control group] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF166.C8 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
3069427|NCT02098395|Experimental|Liraglutide 1.2 mg + insulin|
3069428|NCT02098395|Experimental|Liraglutide 0.6 mg + insulin|
3069396|NCT02098577||PD patients cross-over treatment|30 PD patients (according to Gelb et al) in Hoen&Yahr stage 3, underwent cross-over treatment with the ability to walk without any assistance with mini-mental state examination score >26.
3069397|NCT02098577||PD patients stabilometric platform|30 PD patients (according to Gelb et al) in Hoen&Yahr stage 3, underwent stabilometric platform treatment, with the ability to walk without any assistance with mini-mental state examination score >26.
3069398|NCT02098564|Active Comparator|strong sense of coherence control group|Patients with a strong sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
3069399|NCT02098564|Experimental|strong sense of coherence intervention|Patients with a strong sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
3069400|NCT02098564|Active Comparator|weak sense of coherence control group|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
3069401|NCT02098564|Experimental|weak sense of coherence intervention|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
3069402|NCT02098564|Experimental|medium sense of coherence intervention|Patients with a medium sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
3069403|NCT02098564|Active Comparator|medium sense of coherence control group|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
3069404|NCT02098551||Four (4)|"Group 1: Birch pollen-related atopic dermatitis (AD) (n=15) Group 2: Birch pollen allergic patients without AD (n=5) Group 3: Allergic individuals without birch pollen allergy (n=5) Group 4: Non-allergic individuals (n=5)~Patients will be tested by SPT and APT:~SPT: Histamine, buffer, commercial birch pollen extract, rBet v 1, rBet v 1 fragment 1, rBet v 1 fragment 2, and equimolar rBet v 1 fragment mix (20 and 40 μg/ml) in duplets.~APT: birch pollen extract, rBet v 1, rBet v 1 fragment 1, rBet v 1 fragment 2, equimolar mix of rBet v 1 fragments (160 μg/application); negative control with vaseline"
3069405|NCT02098538|Experimental|patients with adenoid cystic carcinoma|This is a single-arm phase II study of patients with progressive, recurrent/metastatic adenoid cystic carcinoma (R/M ACC) treated with regorafenib.
3069406|NCT02098525||HIV associated CM patients|The study population is all adult HIV positive patients with CM at Ramathibodi Hospital.
3069407|NCT02098512|Experimental|Allogeneic Transplant and Immunotherapy|We intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from HLA matched sibling or unrelated adult donor followed by post-AlloSCT Brentuximab Vedotin in patients with poor risk Hodgkin Lymphoma.
3069408|NCT02098499|Active Comparator|Haloperidol and Diphenhydramine|Haloperidol 5mg IV X1 and Diphenhydramine 25mg IV X1
3069409|NCT02098499|Active Comparator|Metoclopramide and Diphenhydramine|Metoclopramide 10mg IV X1 and Diphenhydramine 25mg IV X1
3069410|NCT02098486|Active Comparator|Ceftraxone|ceftriaxone (2 g/day, diluted in 40 cc of 5% dextrose water, infused more than 30 min)
3069411|NCT02098486|Active Comparator|Moxifloxacin|Intravenous moxifloxacin (400 mg/day, infused more than 60 min)
3069412|NCT02098473|Experimental|RPC4046 Low Dose|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, low dose
3069413|NCT02098473|Experimental|RPC4046 High Dose|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, high dose
3069414|NCT02098473|Placebo Comparator|Placebo|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks
3069415|NCT02098460|Placebo Comparator|Probucol,Cilostazol|Atorvastatin + Probucol-placebo + Cilostazol-placebo
3069416|NCT02098460|Placebo Comparator|Cilostazol|Atorvastatin + Probucol+ Cilostazol-placebo
3069417|NCT02098460|Active Comparator|Probucol, Cilostazol|Atorvastatin + Probucol + Cilostazol
3069418|NCT02098447|Experimental|auricular vagal nerve stimulation|"Study participants (healthy and diabetics) are treated with auricular vagal nerve stimulation using four needle electrodes connected to an electrical stimulation device (PrimeStim). After an acclimatization phase the stimulation is turned on for 20 minutes followed by 20 minutes of paused stimulation, 20 minutes of stimulation, and another 10 minutes paused stimulation. This intervention is repeated on four consecutive days. Needle electrodes stay fixed over the whole study period.~Two different stimulation schemes are tested, each being assessed twice in random order. Stimulation amplitudes are adjusted with respect to a distinct but comfortable sensation at the auricle.~During the described protocol various biosignals are continuously recorded, including ECG, respiration, blood perfusion, oxygen saturation, transcutaneous oxygen tension, blood pressure and skin temperature."
3069419|NCT02098434|Experimental|Montreal Imaging Stress Task|Math task to induce stress response
3069420|NCT02098421|No Intervention|Control|No oxytocin while the Foley bulb is in place
3069421|NCT02098421|Experimental|Oxytocin|Use of oxytocin while the Foley bulb is in place
3069422|NCT02098421|Experimental|PROMS Foley and oxytocin|Subjects who are induced due to premature rupture of membranes randomized to use of Foley bulb and oxytocin once the bulb is removed.
3069423|NCT02098421|No Intervention|PROMS no Foley bulb|Subjects who are induced due to premature rupture of membranes randomized to no Foley bulb.
3069424|NCT02098408|Experimental|Standard treatment + cognitive remediation|The cognitive remediation therapy targets neurocognition as well as social cognition.
3069425|NCT02098408|Active Comparator|Standard treatment|Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling
3069426|NCT02098395|Experimental|Liraglutide 1.8 mg + insulin|
3069434|NCT02098369|Experimental|Proactive|Written education material (basic) Additional education material PELICAN-Proactive [In addition to the usual care, participants will receive educational material and a proactive telephone peer coaching program (coaches call participants)]
3069435|NCT02098369|Experimental|Reactive|Written education material (basic) Additional education material PELICAN-Reactive [In addition to the usual care, participants will receive educational material and a reactive telephone peer coaching program (participants call coaches)]
3069436|NCT02098356|Experimental|Low bicarbonate|Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
3069437|NCT02098343|Experimental|Phase Ib. APR-246 + Carboplatin/PLD.|Dose escalation of APR-246.
3069438|NCT02098343|Experimental|Phase II: Arm A. APR-246 + Carboplatin/PLD.|Experimental
3069439|NCT02098343|Active Comparator|Phase II: Arm B. Carboplatin/PLD.|Active Comparator
3069440|NCT02098330|Active Comparator|: Ginkgo biloba & methylprednisolone|Patients receive Ginkgo biloba & methylprednisolone per oral.
3069441|NCT02098330|Placebo Comparator|Ginkgo biloba|Patients receive Ginkgo biloba per oral.
3069442|NCT02098317|Experimental|TREATED GROUP|this group will treated with pearls containing DHA plus Vitamin D3 (500 mg and 800 IU, respectively) given orally in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 24 weeks
3069443|NCT02098317|Placebo Comparator|PLACEBO GROUP|this group will treated with identical placebo pearls given orally in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 24 weeks
3069444|NCT02098304|Other|Sound and Unsound Molars|Imaging of unrestored sound molars (ICDAS 0), and third Molars (ICDAS 1,2 or 3) with the Calcivis Caries Activity Imaging System
3069445|NCT02098291|Experimental|G17DT|
3069446|NCT02098278|Experimental|CAT-2003 or Placebo|All patients will receive placebo for 1 week, and CAT-2003 for 12 weeks during the 13 week treatment period.
3069447|NCT02098265|Active Comparator|Control|All subjects enrolled will be asked to complete the study interventions which include behavioral assessments, magnetic resonance imaging, functional electric stimulation treatment or Transcranial Magnetic Stimulation, and EEG.
3069448|NCT02098265|Experimental|Patient|All subjects enrolled will be asked to complete the study interventions which include behavioral assessments, magnetic resonance imaging, functional electric stimulation treatment or Transcranial Magnetic Stimulation, and EEG.
3069449|NCT02098252|Active Comparator|Interventional therapy|"Interventional therapies include:~neurosurgery (surgical resection when the lesion is considered by a multidisciplinary team to be safely 'operable'); radiation therapy (when the AVM is smaller than 3 cm, and considered to not be safely 'operable'); radiosurgery, alone or in combination, with or without endovascular procedure; curative embolization (when the lesion is considered curable by embolization).~Patients with AVMs that the multidisciplinary team judges could potentially benefit from endovascular treatment prior to surgical resection or radiation therapy will then also be pre-randomly allocated to embolization or to no embolization."
3069450|NCT02098252|No Intervention|Conservative management (medical management)|The conservative, or medical management arm, involves pharmacological therapy as deemed appropriate for medical symptoms as determined by the treating investigator. Should patients in the conservative management arm develop hemorrhage or infarction related to their AVM, they then potentially become candidates for interventional therapy.
3069451|NCT02098239|Active Comparator|Group A|Jaundiced patients with bilirubin value >80 μmol/L. Received G17DT immediately prior to biliary stenting.
3069452|NCT02098239|Active Comparator|Group B|Patients to be treated following biliary decompression or for immediate treatment if non-jaundiced. Received G17DT 2 weeks after biliary stenting when bilirubin was <40 μmol/L.
3069453|NCT02098213|Active Comparator|Immediate Spa treatment|Three week course of spa treatment soon after randomization
3069454|NCT02098213|Sham Comparator|Late Spa treatment|Three week course of spa treatment soon after 4,5 months visit
3069455|NCT02098200|Experimental|Percutaneous treatment of TR by TriCinch|Percutaneous treatment of Tricuspid Regurgitation with TriCinch System
3069456|NCT02098187|Active Comparator|Below target dose MP-3180|0.5 µmol/kg (0.186 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
3069457|NCT02098187|Active Comparator|2 times above target dose MP-3180|2 µmol/kg (0.744 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
3069458|NCT02098187|Active Comparator|4 times above target dose MP-3180|4 µmol/kg (1.488 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
3069459|NCT02098187|Active Comparator|At target dose MP-3180|1 µmol/kg (0.186 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
3069460|NCT02098174|Experimental|Healthy participants|MP-3180 (1 µmol/kg or 0.372 mg/kg) was administered by IV injection (2.5 mL to 3.5 mL for participant weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes. The iohexol comparator (Omnipaque 300, 5 mL) was then administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
3069461|NCT02098161|Experimental|LCL-161|Starting dose of LCL-161 1500 mg by mouth on Days 1, 8, 15, and 22 of each 28 day cycle. Participants remain on study treatment, in the absence of disease progression or toxicity warranting discontinuation of therapy, as long as there is evidence of clinical benefit, as judged by the treating physician.
3069462|NCT02098148|Experimental|Xenon/Placebo|Participants in this group will receive three treatments of 25% xenon followed by 3 treatments of placebo (room air).
3069463|NCT02098148|Experimental|Placebo/Xenon|Participants in this group will receive three treatments of placebo (room air) followed by three treatments of 25% xenon.
3069464|NCT02098135|Experimental|ArmeoSenso|The ArmeoSenso system is an easy to set up and use upper limb rehabilitation system for the home environment. It consists of a motion capture system based on wearable sensors in combination with a personal computer as well as a therapy software that provides an ergonomic user interface, therapy games and automated assessments.
3069465|NCT02098122||Tetraplegia|
3069466|NCT02098122||Paraplegia|
3069539|NCT02097524|Experimental|Sarilumab - dose 2|Single SC injection of Sarilumab, dose 2, plus methotrexate background treatment (dispensed and dosed according to local practice)
3069540|NCT02097524|Active Comparator|Tocilizumab - dose 1|Single intravenous (IV) administration of Tocilizumab, dose 1, plus methotrexate background treatment (dispensed and dosed according to local practice)
3069467|NCT02098109|Experimental|XM02 Filgrastim (Granix) and Plerixafor|"XM02 Filgrastim (Granix) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)~Plerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)~Apheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)~Patients who undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be followed through Day +100 post-infusion (+/- 30 days) to assess for transplant outcomes (neutrophil and platelet engraftment, and readmission rate). Patients who successfully mobilize > 2.0 x 10^6 CD34+ cells/kg but do not undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be discontinued from follow-up."
3069468|NCT02098109|Active Comparator|Filgrastim (Neupogen) and Plerixafor|"Filgrastim (Neupogen) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)~Plerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)~Apheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)~Patients who undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be followed through Day +100 post-infusion (+/- 30 days) to assess for transplant outcomes (neutrophil and platelet engraftment, and readmission rate). Patients who successfully mobilize > 2.0 x 10^6 CD34+ cells/kg but do not undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be discontinued from follow-up."
3069469|NCT02098096|Experimental|Negative Work|Negative work exercise via isokinetic knee extension/flexion will be performed twice per week for 12 weeks.
3069470|NCT02098096|Placebo Comparator|Stretching|A home exercise program consisting of stretches for the major lower extremity muscles groups will be performed twice per week for 12 weeks.
3069471|NCT02098070||Knee Pain Population|Participants who have responded to the questionnaire with self-reported pain.
3069472|NCT02098070||Non-Knee Pain Population|Participants who have responded to the questionnaire, no self-reported pain.
3069473|NCT02098057|Placebo Comparator|Placebo|A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio
3069474|NCT02098057|Active Comparator|Gluten|A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio
3069475|NCT02098044||Professional footballers|Retired professional footballers
3069476|NCT02098044||Control Population|members of the general public recruited from the east midlands region
3069477|NCT02098031|No Intervention|control|
3069478|NCT02098031|Experimental|intervention|Nutritional intervention (nutrition education)
3069479|NCT02098018|Active Comparator|Program 1|Program 1
3069480|NCT02098018|Active Comparator|Program 2|Program 2
3069481|NCT02098005|Active Comparator|Usual care|usual care evidence-based physiotherapy
3069482|NCT02098005|Experimental|modern neuroscience approach|modern neuroscience approach
3069483|NCT02097992|Experimental|SD placebo and MD roflumilast then MD placebo|Participants will receive placebo (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily.
3069484|NCT02097992|Experimental|SD placebo and MD placebo then MD roflumilast|Participants will receive placebo (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.
3069485|NCT02097992|Experimental|SD roflumilast and MD placebo then MD roflumilast.|Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.
3069486|NCT02097992|Experimental|SD roflumilast and MD roflumilast then MD placebo|Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily
3069487|NCT02097979|Experimental|Glaucoma Educational Intervention|
3069488|NCT02097979|No Intervention|Delayed Intervention|
3069489|NCT02097953|Experimental|Daptomycin and Rifampin|Drug: Daptomycin Daptomycin 6 mg/kg will be given by IV infusion on the first study day Drug: Rifampin Rifampin 600 mg capsules will be given orally once daily for 14 days starting on study day 2 Drug: Daptomycin Daptomycin 6 mg/kg will be given by IV infusion on study day 15
3069490|NCT02097940|Active Comparator|treatment|The treatment group performed of proprioceptive exercises with shifts and one-leg jumps.
3069491|NCT02097940|No Intervention|control|The control group remained in soccer training
3069492|NCT02097927|Experimental|High energy, low sensory|Mango-flavour beverage
3069493|NCT02097927|Experimental|Low energy, high sensory|Mango-flavour beverage
3069494|NCT02097927|Experimental|High energy, high sensory beverage|Mango-flavour beverage
3069495|NCT02097914|No Intervention|Control|Participant receives usual care.
3069496|NCT02097914|Experimental|Intervention|Educational print materials and coaching call: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and once coaching call.
3069497|NCT02097901|Experimental|Microfracture|Rotator Cuff Repair AND Microfracture at rotatorcuff footprint
3069498|NCT02097901|Active Comparator|NO microfracture|Rotator cuff reinsertion without microfracture
3069499|NCT02097875|Experimental|BLZ-100|A single dose of BLZ-100 (1, 3, 6, 12 or 18 mg) will be administered by intravenous injection approximately 48 hours prior to planned excision of skin tumor.
3069500|NCT02097849|Active Comparator|Non-Pegylated IFN Treated Plus Vaccinations|"Participants on a stable approved dose of a non pegylated IFN for ≥3 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL"
3069501|NCT02097849|Experimental|Tecfidera Treated Plus Vaccinations|"Participants on a stable approved dose of Tecfidera (240 mg BID) for ≥6 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL"
3069502|NCT02097836|Experimental|Single subject case series|Targeted training, 5-6 days a week for 6 months, minimum of 20 minutes per day
3069577|NCT02097342|Experimental|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
3069503|NCT02097823|Experimental|Aprepitant First, Olanzapine Second|"Will receive aprepitant (weight based dose, see below) in first cycle of chemotherapy and olanzapine (weight based dose, see below) in the second cycle of chemotherapy. All doses will be given starting 30 minutes before chemotherapy on day 1.~Olanzapine dosing:~>60kg - 10mg orally daily for 4 doses 40-59.9kg - 5mg orally daily for 4 doses 20-39.9kg - 2.5mg orally daily for 4 doses <20kg - 1.25mg orally daily for 4 doses~Aprepitant dosing:~>40kg - 125mg orally on day 1, then 80mg orally daily on days 2,3 35-39.9kg - 80mg orally daily for 3 doses 20-34.9kg - 40mg orally daily for 3 doses <20kg - 1.5-2mg/kg orally daily for 3 doses"
3069504|NCT02097823|Experimental|Olanzapine First, Aprepitant Second|"Will receive olanzapine (weight based dose, see below) in first cycle of chemotherapy and aprepitant (weight based dose, see below) in the second cycle of chemotherapy. All doses will be given starting 30 minutes before chemotherapy on day 1.~Olanzapine dosing:~>60kg - 10mg orally daily for 4 doses 40-59.9kg - 5mg orally daily for 4 doses 20-39.9kg - 2.5mg orally daily for 4 doses <20kg - 1.25mg orally daily for 4 doses~Aprepitant dosing:~>40kg - 125mg orally on day 1, then 80mg orally daily on days 2,3 35-39.9kg - 80mg orally daily for 3 doses 20-34.9kg - 40mg orally daily for 3 doses <20kg - 1.5-2mg/kg orally daily for 3 doses"
3069505|NCT02097810|Experimental|Entrectinib (RXDX-101)|Oral entrectinib (RXDX-101)
3069506|NCT02097797|Experimental|Fecal Transplantation|patients receiving the fecal transplant (fecal microbiota from a healthy donor)
3069507|NCT02097797|Sham Comparator|Sham Transplantation|patients receiving the vehicle (Physiological serum)
3069508|NCT02097784|Other|cirrhosis with portal hypertension,ascite and acute kidney|
3069509|NCT02097771|Active Comparator|LMA SupremeTM|
3069510|NCT02097771|Sham Comparator|Ambu AuraOnce|
3069511|NCT02097758|Experimental|transcatheter device closure|Choosing device size using three dimensional image and the formula without sizing balloon
3069512|NCT02097745|Experimental|MabThera/Rituxan|
3069513|NCT02097732|Active Comparator|B: No induction|Participants will undergo stereotactic radiosurgery (SRS) followed 2-3 weeks later by ipilimumab, which is given once every 3 weeks for a total of 4 doses.
3069514|NCT02097732|Experimental|A: Induction|Patients will receive 2 doses of ipilimumab, which is given once every 3 weeks, prior to stereotactic radiosurgery (SRS), followed by 2 more doses of ipilimumab, for a total of 4 doses.
3069515|NCT02097719|Active Comparator|bimatoprost 0.01% and hypromellose 0.3%|Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
3069516|NCT02097719|Active Comparator|travoprost 0.004% and timolol 0.5%|Travoprost 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
3069517|NCT02097706|Active Comparator|NMDA receptor antagonist|20mg/daily for 8 weeks (56 days)
3069518|NCT02097706|Placebo Comparator|Placebo tablet|1 capsule/daily for 8 weeks (56 days)
3069519|NCT02097693||dyston-dyskinetic cerebral palsy|Young patients with dyston-dyskinetic cerebral palsy who receive DBS in the GPi
3069520|NCT02097680|Experimental|Letrozole|
3069521|NCT02097680|Placebo Comparator|Placebo comparator|
3069522|NCT02097654||Hospitalized Elderly|
3069523|NCT02097641|Experimental|Human Mesenchymal Stem Cells|A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
3069524|NCT02097641|Placebo Comparator|Plasma-Lyte A|A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
3069525|NCT02097628|Active Comparator|pressure-controlled ventilation|pressure-controlled ventilation: a peak airway pressure that provided a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column, respiratory rate 12-16 times per minute.
3069526|NCT02097628|Experimental|volume-controlled ventilation|volume-controlled ventilation: tidal volume 8-12ml/kg, respiratory rate 12-16 times per minute.
3069527|NCT02097615|Experimental|chlorhexidine gluconate|application every 24 hours, six weeks
3069528|NCT02097615|Other|Other: deionized water|application every 24 hours, six weeks
3069529|NCT02097589|Experimental|Pneumovax-Atorvastatin|10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days. Pneumovax 23 injected once, intramuscularly at Day 7.
3069530|NCT02097589|Placebo Comparator|Pneumovax-Placebo|10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days. Pneumovax 23 injected once, intramuscularly at Day 7.
3069531|NCT02097576|Active Comparator|NeilMed Saline Sinus Rinse|Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
3069532|NCT02097576|Active Comparator|Saline mixed with Manuka Honey|Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
3069533|NCT02097563|Experimental|High Intensity Training|High intensity training: clinician attends a 6-hr live workshop in family-focused treatment techniques, and then, after taking on a case, gets weekly technical consultation sessions (by telephone) in FFT from an expert after every session;
3069534|NCT02097563|Active Comparator|Low Intensity Training|Low Intensity Training: clinician completes online workshop in FFT and then, after taking on a case, gets telephone consultation sessions after every third session.
3069535|NCT02097550|Experimental|eHealth Intervention|Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
3069536|NCT02097550|No Intervention|Standard of care|These patients will receive the standard of care from their physician.
3069537|NCT02097537|Experimental|Methacholine Chloride|children with bronchial asthma
3069538|NCT02097524|Experimental|Sarilumab - dose 1|Single subcutaneous (SC) injection of Sarilumab, dose 1, plus methotrexate background treatment (dispensed and dosed according to local practice)
3070355|NCT02091973|Experimental|Tacrolimus|Tacrolimus dosing to target tough level 5-10 ng/ml
3069541|NCT02097524|Active Comparator|Tocilizumab - dose 2|Single IV administration of Tocilizumab, dose 2, plus methotrexate background treatment (dispensed and dosed according to local practice)
3069542|NCT02097511|Experimental|Sarpogrelate pretreatment and Metoprolol|Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days and Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day
3069543|NCT02097511|Active Comparator|Sarpogrelate and Metoprolol|Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day
3069544|NCT02097511|Active Comparator|Metoprolol only|Metoprolol Tartrate 100 mg once a day
3069545|NCT02097498|No Intervention|Simulation only|One group will be randomized to receive simulation training similar to that required for certification. Paramedics in this group will then complete a second simulation scenario
3069546|NCT02097498|Experimental|Directed feedback|One group will review their baseline simulation scenario with a member of the research staff while providing specific feedback for errors made during the first simulation. Paramedics in this group will then complete a second simulation scenario.
3069547|NCT02097498|Experimental|Basic Videolaryngoscopy|One group will review a series of instructional videos related to common airway management errors. Paramedics in this group will then complete a second simulation scenario.
3069548|NCT02097485|Active Comparator|Abametapir Lotion 0.74% w/w|Topically administered to hair and scalp for 10 minutes application.
3069549|NCT02097485|Placebo Comparator|Vehicle Lotion|Administered to scalp and hair for 10 minutes application.
3069550|NCT02097472|Experimental|Adult Cohort 1, PATH-wSP, 600 mcg|A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.
3069551|NCT02097472|Placebo Comparator|Adult Cohort 1, Saline|A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
3069552|NCT02097472|Experimental|Adult Cohort 2, PATH-wSP, 1000 mcg|A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.
3069553|NCT02097472|Placebo Comparator|Adult Cohort 2, Saline|A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
3069554|NCT02097472|Experimental|Toddler Cohort 1 PATH-wSP 300 mcg+Active control|A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
3069555|NCT02097472|Experimental|Toddler Cohort 1 PATH-wSP 300 mcg+Saline|A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
3069556|NCT02097472|Active Comparator|Toddler Cohort 1: Active Control Only|A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
3069557|NCT02097472|Experimental|Toddler Cohort 2 PATH-wSP 600 mcg+Active control|A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
3069558|NCT02097472|Experimental|Toddler Cohort 2 PATH-wSP 600 mcg+saline|A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
3069559|NCT02097472|Active Comparator|Toddler Cohort 2: Active Control Only|A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
3069560|NCT02097459|Experimental|Failed group|Patients who have recurrence of menstruation after changing endocrine therapy to anastrozole and then go back to the original SERMs therapy.
3069561|NCT02097459|Experimental|Succeeded group|Patients who have no recurrence of menstruation after changing endocrine therapy and then go on with anastrozole therapy.
3069562|NCT02097459|Active Comparator|No chang group|Patients who don't change the endocrine therapy and go on with the original tamoxifen or toremifene therapy.
3069563|NCT02097446|Experimental|GUARDIX-FL|Patients will be treated with 1 or 2 sheet of GUARDIX-FL after ovarian cystectomy(Operative Day).
3069564|NCT02097446|Active Comparator|Interceed|Patients will be treated with 1 or 2 sheet of interceed after ovarian cystectomy(Operative Day).
3069565|NCT02097433|Experimental|Dacomitinib|
3069566|NCT02097420|Other|Single device arm|Mitral valve replacement
3069567|NCT02097407|Experimental|Group D : Dexmedetomidine + propofol group|In Group D, DEX (1 µg kg-1) was intravenously loaded for 10 min before induction of anaesthesia.
3069568|NCT02097407|Placebo Comparator|Group C : Saline + propofol group|In Group C, 0.9% of normal saline (1 µg kg-1) was loaded 10 min before induction of anaeshtesia.
3069569|NCT02097394|Active Comparator|Combizym|These patients who have cutted colon polyps will eat the digestion enzyme(Combizym) regularly.
3069570|NCT02097394|Active Comparator|Bifidobacteri|These patients who have cutted colon polyps will eat Bifidobacteri regularly
3069571|NCT02097394|Active Comparator|Combizym + Bifidobacteri|These patients who have cutted colon polyps will eat drugs (Combizym + Bifidobacteri) regularly
3069572|NCT02097394|Active Comparator|control|these patients who have cutted colon polyps will not eat any drugs
3069573|NCT02097381|Other|naïve for cART that met the criteria to start treatment|"patients naïve for antiretroviral treatment that met the criteria to start cART according to International Guidelines.~These patients will be studied for primary and secondary outcomes after a short term antiretroviral therapy."
3069574|NCT02097368||neuromuscular patient|Patients affected by neuromuscular pathology will be explored by tongue strength measurement, respiratory function measurement, swallowing tests and Magnetic resonance imaging
3069575|NCT02097355|Experimental|TriVox Active|Provider using TriVox for clinical care
3069576|NCT02097355|No Intervention|TriVox Delayed-start|Providers not using TriVox for clinical care
3069579|NCT02097342|Active Comparator|Voglibose|Tablet Voglibose (0.2mg) per oral, thrice daily (with meals) will be given to 10 patients for 6 months
3069580|NCT02097329|Experimental|Cohort 1: Palbociclib under fed conditions|
3069581|NCT02097329|Experimental|Cohort 2: Palbociclib under fed conditions|
3069582|NCT02097316|Experimental|JewelPump|JewelPump for the first treatment period followed by the usual pump for the second treatment period
3069583|NCT02097316|Active Comparator|Usual insulin pump|Patients in the arm 2, will have the usual insulin pump for the first treatment period, followed with the second period which they will have the JewelPump.
3069584|NCT02097303|Other|Single arm|All subjects receive concurrent administration of Radium Ra223 Dichloride and Abiraterone Acetate plus Prednisone
3069585|NCT02097290|Experimental|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
3069586|NCT02097277|Placebo Comparator|Treatment A: Placebo (Matching with BMS-986036 - Daily)|Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks
3069587|NCT02097277|Experimental|Arm 2: Treatment B: BMS-986036 (1 mg Daily)|BMS-986036 1 mg subcutaneous injection once daily for 12 weeks
3069588|NCT02097277|Experimental|Treatment C: BMS-986036 (5 mg Daily)|BMS-986036 5 mg subcutaneous injection once daily for 12 weeks
3069589|NCT02097277|Experimental|Treatment D: BMS-986036 (20 mg Daily)|BMS-986036 20 mg subcutaneous injection once daily for 12 weeks
3069590|NCT02097277|Experimental|Treatment E: BMS-986036 (20 mg Weekly)|"BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks~Followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks"
3069591|NCT02097264|Experimental|NNC0109-0012|
3069592|NCT02097264|Active Comparator|Adalimumab|
3069593|NCT02097238|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
3069594|NCT02097225|Experimental|Treatment (dabrafenib, trametinib, onalespib)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28, and onalespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3069595|NCT02097199||Sports group|The cohort will consist of about 55 female and 55 male individuals aged 30-65 years with mostly sedentary work (>6 hours/day) doing no or less physical activity (<30 minutes quick walking/day) who want to engage more in physical activity (at least 150 minutes of at least moderate intensity per week). The gain in workload will be objectified and quantified by performing a bicycle stress test at the beginning of the study and after 8 months of physical engagement.
3069596|NCT02097186|Experimental|Remote ischaemic preconditioning|Remote ischaemic preconditioning will be performed in the same manner as several previous trials. Immediately after induction of anaesthesia, a standard, CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
3069597|NCT02097186|No Intervention|Control to remote preconditioning group|Patients randomised to this group will receive routine pre-operative, peri-operative and post operative care.
3069598|NCT02097173|Other|SC MTX followed by IM MTX|1 subcutaneous injection of 30 mg methotrexate administered by a prefilled pen (50mg/mL) followed by 1 intramuscular injection of 30 mg methotrexate (comparator) after a wash-out phase of 1 week
3069599|NCT02097173|Other|IM MTX followed by SC MTX|1 intramuscular injection of 30 mg methotrexate (comparator) followed by 1 subcutaneous injection of 30 mg methotrexate by a prefilled pen (50mg/mL) after a wash-out phase of 1 week
3069600|NCT02097160|Active Comparator|Control Group 1|regular fortified milk + regular cheese/yogurt
3069601|NCT02097160|Experimental|Intervention Group 2|Vitamin D fortified yogurt and cheese; vitamin D dose increment of 252 IU vs grp 1
3069602|NCT02097160|Experimental|Intervention Group 3|Vitamin D fortified yogurt and cheese, vitamin D dose increment of 420 IU vs grp 1
3069603|NCT02097147|Experimental|Vilazodone 20 mg|Vilazodone 10 mg once daily for 7 days, followed by vilazodone 20 mg once daily for 28 days.
3069604|NCT02097147|Experimental|Vilazodone 40 mg|Vilazodone 10 mg once daily for 7 days, followed by vilazodone 20 mg once daily for 7 days, followed by vilazodone 40 mg once daily for 21 days
3069605|NCT02097147|Active Comparator|Paroxetine 20 mg|Paroxetine 10 mg once daily for 7 days, followed by paroxetine 20 mg for 28 days
3069606|NCT02097147|Placebo Comparator|Placebo|Placebo once daily for 35 days
3069607|NCT02097134|Experimental|Treatment (melphalan)|Patients receive melphalan IA on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3069608|NCT02097121|Experimental|OnabotulinumtoxinA Dose A|OnabotulinumtoxinA Dose A injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
3069609|NCT02097121|Experimental|OnabotulinumtoxinA Dose B|OnabotulinumtoxinA Dose B injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
3069610|NCT02097121|Experimental|OnabotulinumtoxinA Dose C|OnabotulinumtoxinA Dose C injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
3069611|NCT02097108|Other|Raltegravir|Patients will be offered to switch their protease inhibitor containing regimen to a raltegravir (400mg twice daily, orally) based regimen while maintaining the same background therapy.
3069612|NCT02097095||Vaccine group|TB vaccine GSK 692342 (M72/AS01E) administered on study TB-018
3069613|NCT02097095||Placebo Comparator|Placebo administered on study TB-018
3069614|NCT02097082|Experimental|STANZA Drug-eluting Resorbable Scaffold|Treatment of Superficial Femoral Artery (SFA) lesion with resorbable scaffold
3069615|NCT02097069|Other|Subgroup A|folic acid 400 mcg/day
3069616|NCT02097069|Experimental|Subgroup B|myo-inositol 2000 mg twice a day
3069617|NCT02097069|Experimental|Subgroup C|D-chiro-inositol 250 mg twice a day
3069619|NCT02097056|Experimental|donepezil HCl 23 mg|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
3069620|NCT02097043|Experimental|[Group 1] DA-7218|200mg, By mouth or orally (PO) & intravenous(IV) administration
3069621|NCT02097043|Placebo Comparator|[Group 1] Placebo|Placebo, By mouth or orally (PO) & intravenous(IV) administration
3069622|NCT02097043|Experimental|[Group 2] DA-7218|400mg, By mouth or orally (PO) administration
3069623|NCT02097043|Placebo Comparator|[Group 2] Placebo|Placebo, By mouth or orally (PO) administration
3069624|NCT02097043|Experimental|[Group 3] DA-7218|600mg, By mouth or orally (PO) administration
3069625|NCT02097043|Placebo Comparator|[Group 3] Placebo|Placebo, By mouth or orally (PO) administration
3069626|NCT02097030|Active Comparator|etafilcon A lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
3069627|NCT02097030|Active Comparator|nelfilcon A lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
3069628|NCT02097030|Active Comparator|filcon II 3 lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
3069629|NCT02097017|Active Comparator|lidocaine spray group|
3069630|NCT02097017|Placebo Comparator|placebo arm|
3069631|NCT02097017|No Intervention|no intervention|
3069632|NCT02097004|Experimental|Concomitant:Pegasys, Euvax B, Baracrude|"Peginterferon alfa-2a: once weekly 180 μg subcutaneous injection for 48 weeks~HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks~Continue Entecavir(0.5mg) for 100 weeks(once daily)"
3069633|NCT02097004|Experimental|Sequential:Pegasys, Euvax B, Baracrude|"Peginterferon alfa-2a: once weekly 180 μg or weight base dose subcutaneous injection for 48 weeks~HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 52, 56, 60 and 76 weeks~Continue Entecavir(0.5mg) for 100 weeks(once daily)"
3069634|NCT02097004|Active Comparator|Control Group|"Continue Entecavir(0.5mg) for 100 weeks(once daily)~After EOS(100W), injection(once weekly) a Peginterferon alfa-2a for 48 weeks"
3069635|NCT02096991|Active Comparator|Glass|consume beverage in glass first and cross over to other interventions
3069636|NCT02096991|Experimental|Can 1|consume one canned beverage and a glass bottled beverage first and cross over to other interventions
3069637|NCT02096991|Experimental|Can 2|Consume two canned beverage first and cross over to other interventions
3069638|NCT02096978|Experimental|Osteotome preparation|Procedure/Surgery: Preparing the osteotomy to accept a standard implant device
3069639|NCT02096978|Active Comparator|Drill preparation|Preparing the osteotomy to accept a standard implant device
3069640|NCT02096965|Experimental|Tolvaptan first, then Placebo|Tolvaptan twice daily in first intervention period and placebo twice daily in second intervention period. (after washout period)
3069641|NCT02096965|Experimental|Placebo first, then Tolvaptan|Placebo twice daily in first intervention period and Tolvaptan twice daily in second intervention period. (after washout period)
3069642|NCT02096952|Experimental|Methylphenidate extended-release liquid|Methylphenidate extended-release liquid formulation
3069643|NCT02096939||Primary aldosteronism|Patients with primary aldosteronism, who undergo surgery or will be started on antihypertensive medication, including mineralocorticoid receptor antagonists
3069644|NCT02096939||Essential hypertension|Patients with essential hypertension who will be started on antihypertensive medication
3069645|NCT02096926|Placebo Comparator|Placebo|placebo
3069646|NCT02096926|Active Comparator|Ibuprofen|400 mg PO
3069647|NCT02096913|Active Comparator|Dolormin® extra (Ibuprofen) 4 weeks|
3069648|NCT02096913|Active Comparator|Dolormin® extra (Ibuprofen) 12 weeks|
3069649|NCT02096900|Active Comparator|zolpidem|zolpidem given orally 0.25mg/kg pre-operatively single dose
3069650|NCT02096900|Active Comparator|midazolam|midazolam will be given at 0.5mg/kg, pre-operatively single dose
3069651|NCT02096887|Other|Patient Education|Patient Education
3069652|NCT02096874|Other|Bevacizumab|Each study subject will recieve Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month.
3069653|NCT02096861|Experimental|CT-P13 - CT-P13|CT-P13 followed by CT-P13 from Week 30
3069654|NCT02096861|Active Comparator|CT-P13 - Remicade|CT-P13 followed by Remicade from Week 30
3069655|NCT02096861|Active Comparator|Remicade - Remicade|Remicade followed by Remicade from Week 30
3069656|NCT02096861|Experimental|Remicade - CT-P13|Remicade followed by CT-P13 from Week 30
3069657|NCT02096835|Experimental|Acustimulation|Transcutaneous electrical acupoint stimulation (TEAS) starts 30 min before surgery and lasts until patient leaves the postanesthetic care unit.Dexamethasone 10mg i.v. after induction.
3069658|NCT02096835|Active Comparator|Tropisetron|Tropisetron 5mg iv. at the start of skin closure.Sham transcutaneous electrical acupoint stimulation.Dexamethasone 10mg i.v.after induction.
3069659|NCT02096835|Sham Comparator|Control|Sham transcutaneous electrical acupoint stimulation. Dexamethasone 10mg i.v.after induction.
3069660|NCT02096822|Active Comparator|non-nutritive sucking alone|After randomization, baby will receive heel stick procedure with non-nutritive sucking and sterile water.
3069661|NCT02096822|Experimental|Facilitated tucking + non-nutritive sucking|After randomization, baby will receive heel stick procedure with non-nutritive sucking and sterile water combined with facilited tucking.
3069662|NCT02096809|Experimental|One week loading of Bone Anchored Hearing Aid (BAHA)|Bone Anchored Hearing Aid (BAHA) loading after one week
3069663|NCT02096796||persons without arm pump|
3069664|NCT02096796||persons with arm pump|
3069665|NCT02096783|Active Comparator|Arm I (standard counseling)|Patients receive standard counseling at both the pre-operative and 2-4 week post-operative visit.
3069666|NCT02096783|Experimental|Arm II (standard counseling, scripted intervention)|Patients receive standard counseling at the pre-operative visit and the scripted sexual health intervention at the 2-4 week post-operative visit.
3069709|NCT02096510|Active Comparator|cortef tablets|the patient regular treatment by Cortef 5 mg, produced by Nycomed Pharma two times or three times a day.
3069667|NCT02096783|Experimental|Arm III (standard counseling, scripted intervention)|Patients receive standard counseling and the scripted sexual health intervention at the pre-operative visit and standard counseling at the 2-4 week post-operative visit.
3069668|NCT02096783|Experimental|Arm IV (standard counseling, scripted intervention)|Patients receive standard counseling and the scripted sexual health intervention at both the pre-operative and 2-4 week post-operative visit.
3069669|NCT02096757|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules; 4.4gm/day (Nordic Naturals, Watsonville, CA, USA) 2 weeks prior to surgery and continued for 4 weeks after.
3069670|NCT02096757|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day (Nordic Naturals, Watsonville, CA, USA) 2 weeks prior to surgery and continued for 4 weeks after.
3069671|NCT02096744|Experimental|Catapres-TTS-3 crossover 1|subject to receive 0.3 mg/24 hr Catapres-TTS-3 Oppanol (T1) first, followed by Catapres-TTS-3 Vistanex (R1)
3069672|NCT02096744|Experimental|Catapres-TTS-3 crossover 2|subject to receive 0.3 mg/24 hr Catapres-TTS-3 Vistanex (R1) first, followed by Catapres-TTS-3 Oppanol (T1)
3069673|NCT02096744|Experimental|Catapres-TTS-1 crossover 1|subject to receive 0.1 mg/24 hr Catapres-TTS-1 with Oppanol (T2) and Vistanex (R2) simultaneously
3069674|NCT02096731||LABA + tiotropium|
3069675|NCT02096731||LABA mono|
3069676|NCT02096731||neither tiotropium nor LABA|
3069677|NCT02096731||tiotropium + LABA|
3069678|NCT02096731||tiotropium mono|
3069679|NCT02096718|Experimental|Afatinib in moderate renal impaired|Single Dose Afatinib in moderate renal impaired subjects
3069680|NCT02096718|Experimental|Afatinib in severe renal impaired|Single Dose Afatinib in severe renal impaired subjects
3069681|NCT02096718|Other|Afatinib in healthy subjects|Single Dose Afatinib in healthy subjects matched by gender, race, age and BMI to moderate and severe renal impaired subjects
3069682|NCT02096705|Experimental|Group 1: Dapagliflozin|Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin
3069683|NCT02096705|Placebo Comparator|Group 2: Dapagliflozin Placebo|Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin
3069684|NCT02096692||ICD System Therapy|Patients with a ProMRI ICD System
3069685|NCT02096679|Experimental|[14C]-AZD9291 20mg (oral solution)|Volunteers will receive 20 mg [14C]-AZD9291 containing a nominal 1 μCi activity, administered by mouth, as a solution.
3069686|NCT02096666|Experimental|Single arm|
3069687|NCT02096653|Experimental|X-ray guided intra-articular injection|Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine into the SI (sacroiliac joint) cavity under fluoroscopic guidance
3069688|NCT02096653|Active Comparator|Landmark-guided SI joint injection|Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine at the point of maximal tenderness (3 ml)
3069689|NCT02096640|Active Comparator|Percutaneous dilatation tracheostomy: Smiths Medical|Type of surgical teqnique for tracheostomy: Percutaneous dilatation tracheostomy. The set for the tracheostomy is bought from Smiths Medical TM.
3069690|NCT02096640|Active Comparator|Open surgery tracheostomy|Type of surgical teqnique for tracheostomy: Open surgical tracheostomy
3069691|NCT02096627||conventional|Patients who undergo routine cataract surgery using conventional phacoemulsification technique
3069692|NCT02096627||FLACS|Patients who undergo femtosecond laser assisted cataract surgery
3069693|NCT02096614|Experimental|Low dose TBI-1201 with pre-treatment 1|TBI-1201(5*10^8) single-dose administration with pre-treatment of cyclophosphamide alone.
3069694|NCT02096614|Experimental|High dose TBI-1201 with pre-treatment 1|TBI-1201(5*10^9) single-dose administration with pre-treatment of cyclophosphamide alone.
3069695|NCT02096614|Experimental|High dose TBI-1201 with pre-treatment 2|TBI-1201(5*10^9) single-dose administration with pre-treatment of cyclophosphamide and fludarabine.
3069696|NCT02096614|Experimental|TBI-1201 with pre-treatment 1 or 2|Arm1, 2 or 3, which is considered as optimal.
3069697|NCT02096601|Experimental|ND0612|Levodopa and carbidopa SC solution
3069698|NCT02096601|Active Comparator|Oral levodopa and carbidopa|Oral levodopa and carbidopa
3069699|NCT02096588|Experimental|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily. Treatment will start 7 days prior to the planned doxorubicin/cyclophosphamide chemotherapy initiation and will continue for a total of 25 weeks.
3069700|NCT02096588|Active Comparator|No drug|Participant not randomized to simvastatin will participate in all aspects of the study, including planned doxorubicin/cyclophosphamide chemotherapy, with the exception of simvastatin administration.
3069701|NCT02096575|Experimental|Nitrous oxide administration|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. All patients will receive local anesthesia via a standardized paracervical block with 18 cc of 1% lidocaine buffered with 2 ml of 8.4% sodium bicarbonate and 0.2 ml of 4 units of vasopressin.~In addition, the Nitrous oxide group will receive two placebo pills. Nitrous oxide will be administered via a disposable scented nasal mask to blind patients to the intervention. Nitrous oxide will be administered at a fixed ratio of 60% nitrous oxide and 40% oxygen. The nasal mask will be placed on the patient's nose and the nitrous oxide will be administered continuously."
3069702|NCT02096575|No Intervention|Standard care group|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. All patients will receive local anesthesia via a standardized paracervical block with 18 cc of 1% lidocaine buffered with 2 ml of 8.4% sodium bicarbonate and 0.2 ml of 4 units of vasopressin.~The standard care group will receive one 5/325 mg Percocet, and 1 mg of lorazepam, 30 minutes before the procedure. The standard care group will receive oxygen by mask intraoperatively."
3069703|NCT02096562|Placebo Comparator|B - No compression stockings|normal therapy - no compression stockings
3069704|NCT02096562|Active Comparator|A - Use of compression stockings|Patients use compression stockings for 10 days after surgery
3069705|NCT02096536|Other|Vancomycin|All included patients receive vancomycin for medical reasons. Decision for start of therapy is made by the treating physician.
3069706|NCT02096523|Experimental|platelet disease|patients with inherited platelet disorders
3069707|NCT02096523|Experimental|Healthy|Healthy family members of patients with inherited platelet disorders
3069708|NCT02096510|Experimental|continuous subcutaneous hydrocortisone|continuous subcutaneous hydrocortisone infusion (CSHI), Solu-Cortef ® 50mg/ml infusate
3069710|NCT02096510|Experimental|ultradian subcutaneous hydrocortisone|ultradian subcutaneous hydrocortisone infusion, Solu-Cortef ® 50mg/ml infusate
3069711|NCT02096497||Vascular pattern 1|
3069712|NCT02096497||Vascular pattern 2|
3069713|NCT02096497||Vascular pattern 3|
3069714|NCT02096497||Vascular pattern 4|
3069715|NCT02096497||Vascular pattern 5|
3069716|NCT02096497||Vascular pattern 6|
3069717|NCT02096497||Vascular pattern 7|
3069718|NCT02096497||Vascular pattern 8|
3069719|NCT02096497||Vascular pattern 9|
3069720|NCT02096497||Vascular pattern 10|
3069721|NCT02096497||Vascular pattern 11|
3069722|NCT02096484|Experimental|Metacognitive Therapy|Individuals randomly assigned to the metacognitive therapy group will undergo group metacognitive therapy for generalized anxiety disorder.. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes.
3069723|NCT02096484|Experimental|Mindfulness Meditation Therapy|Individuals randomly assigned to the mindfulness meditation therapy group will undergo group mindfulness meditation therapy for generalized anxiety disorder. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes.
3069724|NCT02096471|Experimental|Agent PD-0325901|The primary aim of the study will be to assess quantitative radiographic response in a target lesion. Subjects will receive PD-0325901 by mouth on a bid dosing schedule of 2 mg/m2/dose with a maximum dose of 4 mg bid. Each course is 4 weeks duration, and subjects will receive drug on a 3 week on/1 week off schedule. Subjects may receive additional courses beyond course 8 only if there is at least 15% reduction in volume of the target tumor. Subjects who have a 20% or greater reduction in target tumor volume at the end of 12 courses can continue on therapy for up to an additional year (maximum of 24 total courses). However, subjects who do not achieve at least 15% reduction in volume of the target tumor after 8 courses (~8 months) will be considered treatment failures and taken off study.
3069725|NCT02096458|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg delayed-release orally disintegrating tablets at Assessment 1 Day 1, Assessment 2 Day 1, and Assessment 3 Day 1.
3069726|NCT02096445|Experimental|Robot group|"Receive robot-assisted neurocognitive therapy instead of conventional neurocognitive therapy.~(4 x 45 min/week)"
3069727|NCT02096445|Active Comparator|Control group|Receive dose-matched conventional neurocognitive therapy
3069728|NCT02096432|Experimental|Behavioral: Behavioral Activation|Behavioral Activation includes the following components: empowering education, referral to treatment, care Management, and behavior activation
3069729|NCT02096432|Other|Usual Community Care|Community standard care as usual
3069730|NCT02096419|No Intervention|control group|Patients in this group will receive standard clopidogrel dose
3069731|NCT02096419|Experimental|interventional group|"Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).~They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.~On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity >18U and <18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if >46U; not changed if 19-46U; decreased by 75 mg if <19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients >70 years 150 mg)"
3069732|NCT02096406|Other|ACE/ARB Continuation|ACE/ARB will be continued up to and including the morning of surgery.
3069733|NCT02096406|Other|ACE/ARB withdrawal|ACE/ARB will be discontinued medication 48 hours prior to surgery
3069734|NCT02096393|Experimental|Patient specific instrumentation|The patient will undergo using patient specific instrumentation
3069735|NCT02096393|Active Comparator|Standard instrumentation|The patient will undergo surgery using standard instrumentation
3069736|NCT02096380||one cycle induction chemotherapy|"Drug: docetaxel, cisplatin and fluorouracil~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~Other Names:~docetaxel, cisplatin and fluorouracil"
3069737|NCT02096380||three cycles induction chemotherapy|"Drug: docetaxel, cisplatin and fluorouracil~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~Other Names:~docetaxel, cisplatin and fluorouracil"
3069738|NCT02096367|Experimental|Hemiplegia after vascular stroke|"Muscle vibration stimulation~Gait analysis with Gait Rite : quantitative and spatio-temporal gait parameters~Kinematic gait analysis in lower limb measured by optoelectronic system (Optitrack).~Analysis of static posture on force platform~Evaluation of the gait on treadmill during 2 minutes"
3069739|NCT02096354|Experimental|RRx-001 followed by irinotecan|Once-weekly intravenous RRx-001 at a dose of 4 mg on Days 1, 8, 15, and 22 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab)
3069740|NCT02096354|Active Comparator|Regorafenib followed by irinotecan|Regorafenib daily on Days 1- 21 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab)
3069741|NCT02096341|Experimental|RRx-001|RRx-001 will be administered as subcutaneous injections twice weekly for at least 8 weeks. At least three subjects must complete 2 weeks of treatment with RRx-001 at each dose level, before escalation to the next higher RRx-001 dose level; 2 doses—16 and 27 mg/m2— will be tested.
3069742|NCT02096328|Experimental|POL7080, Anti-pseudomonal antibiotics|POL7080 daily co-administered with standard of care treatment
3069743|NCT02096315|Experimental|POL7080|POL7080 administered daily
3069744|NCT02096302|Experimental|Experimental Formula|Infant formula with a novel probiotic CECT7210
3069745|NCT02096302|Active Comparator|Standard Formula|Standard infant formula without probiotics
3069746|NCT02096289|Experimental|Thioridazine|Up to 3 dose levels of thioridazine will be assessed sequentially: 25 mg Q6H (Level I), 50 mg Q6H (Level II) and 100 mg Q6H (Level III). The duration of thioridazine therapy is for a total of 21 days (Days 1-22 on study). All patients will receive cytarabine 1 g/m2 administered as a 2 hour infusion for 5 consecutive days (Days 6-10 on study).
3095357|NCT01923493|Experimental|tuina|tuina treatment
3069747|NCT02096276||Exposed cohort|A group of subjects who voluntarily report vaccine-exposed pregnancies to the registry.
3069748|NCT02096263|Experimental|Infanrix hexa Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Infanrix hexa (lot A, lot B or lot C as per the group allocation) co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and Hiberix at 15-18 months of age by intramuscular injection in the anterolateral thigh.
3069749|NCT02096263|Active Comparator|Pediarix Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pediarix and ActHIB co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and ActHIB at 15-18 months of age by intramuscular injection in the anterolateral thigh.
3069750|NCT02096263|Active Comparator|Pentacel Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pentacel and Engerix co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Pentacel at 15-18 months of age by intramuscular injection in the anterolateral thigh.
3069751|NCT02096250|Experimental|NaFeEDTA|NaFeEDTA
3069752|NCT02096250|Experimental|Ferrous fumarate|Ferrous fumarate
3069753|NCT02096250|Experimental|NaFeEDTA + ferrous fumarate|NaFeEDTA + ferrous fumarate
3069754|NCT02096237|Experimental|apheresis, IgE adsorber|9 apheresis treatments with the new IgE adsorber in a period of 3 months with 3 cycles of 3 treatments each every month.
3069755|NCT02096237|No Intervention|Conventional drug treatment|Patients treated with conventional asthma treatment as prescribed before study entry. No intervention in prescription
3069756|NCT02096224|Experimental|Sevoflurane|Sevoflurane will be administered as the maintenance agent of general anesthesia.
3069757|NCT02096224|Active Comparator|Desflurane|Desflurane will be administered as the maintenance agent of general anesthesia.
3069758|NCT02096211|Other|CERAMAX COC 36mm Acetabular Cup|The CERAMAX 36mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic.The insert is available in several inner diameter sizes, including 36mm; only 36mm inserts will be utilized in this PAS. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper.
3069759|NCT02096198||Other CERAMAX COC 36mm Acetabular Cup|The CERAMAX COC 36mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic. The insert is available in several inner diameter sizes, including 36mm; only 36mm inserts will be utilized in this PAS. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper.
3069760|NCT02096185|Experimental|3 dimensional tomosynthesis imaging|Breast specimen to be x-rayed using both conditions 3 dimensional tomosynthesis imaging 2 dimensional conventional digital imaging
3069761|NCT02096185|Experimental|2 dimensional digital imaging|Breast specimens to be x-rayed under both conditions 3 dimensional tomosynthesis imaging 2 dimensional digital imaging
3069762|NCT02096159|Experimental|Antibiotics|trimethoprim-sulfamethoxazole oral suspension, 4 mg/kg (0.5 mL/kg) twice daily for 10 days
3069763|NCT02096159|Placebo Comparator|Placebo|placebo oral suspension, 0.5 mL/kg twice daily for 10 days
3069764|NCT02096146|Other|TMT Fusion Plate|Patients are treated with TMT Fusion Plate to encourage bony fusion of the 1st TMT joint.
3069765|NCT02096146|Other|Two crossed screws|Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion .
3069766|NCT02096133|Experimental|Cholecalciferol|Patients receive 1dd 100ug vitamin D3 (drops) for 16 weeks
3069767|NCT02096133|Placebo Comparator|Placebo comparator|placebo drops during 16 weeks
3069768|NCT02096120||All patients|
3069769|NCT02096107|Active Comparator|Low intensity Tacrolimus|Low tacrolimus, everolimus, and steroids
3069770|NCT02096107|Other|Standard of Care|Tacrolimus, mycophenolate mofetil and steroids
3069771|NCT02096094|Experimental|Chlorhexidine bath|This arm is composed with 27 healthy volunteers which will perform full body bath with wipes impregnated with 2% chlorhexidine and with shampoo with 0.15% chlorhexidine.
3069772|NCT02096094|Placebo Comparator|Control bath|This arm is composed with 27 healthy volunteers which will perform full body bath with wipes and shampoo without chlorhexidine.
3069773|NCT02096081|Experimental|IncobotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
3069774|NCT02096081|Active Comparator|OnabotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
3069775|NCT02096068|Experimental|Study group|"Application of Dexmedetomidine (Dexdor®) perioperatively for a maximum of 48 hours~Dosing Scheme:~during operation and mechanical ventilation: 0,7μg/kgABW/h; recovery time until extubation: 0,4μg/kgABW/h; after extubation: 0,2-1,4μg/kgABW/h"
3069776|NCT02096068|Placebo Comparator|Control group|Application of placebo for a maximum of 48 hours
3069777|NCT02096068|No Intervention|POCD control group|A non-surgical control group of 15 ASA II/III- patients is collected for measuring the learning experience during the cognitive testings. The participants are matched on age, education, and gender to the study patients.
3069778|NCT02096055|Experimental|Group A - SGI-110 for 5 Days|"Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days.~Patients who achieve a complete response (CR) or complete remission without platelet recovery (CRp) during induction may receive up to 24 months of maintenance therapy every 4 to 8 weeks.~Maintenance Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days."
3069779|NCT02096055|Experimental|Group B - SGI-110 + Idarubicin|"Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Idarubicin 6 mg/m2 by vein daily for 2 days.~Patients who achieve a completed response (CR) or complete remission without platelet recovery (CRp) during induction may receive up to 24 months of maintenance therapy every 4 to 8 weeks.~Maintenance Phase: SGI-110 60 mg/m2 SQ daily for 5 days. Idarubicin 6 mg/m2 by vein on Day 1."
3070486|NCT02091063|Experimental|Phase Ib: Arm B: ACY-1215 BID|Phase Ib: ACY-1215 160mg PO BID
3069780|NCT02096042|Experimental|Brentuximab Vedotin|Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle (+/- 3 days).
3069781|NCT02096042|Experimental|Brentuximab Vedotin + 5-Azacytidine|"Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle. All patients receive 5-azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle. Patients receive 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days. Patients can receive up to a total of 12 cycles of treatment (weekly + monthly combined)."
3069782|NCT02096029|Experimental|Nicotine Replacement Therapy (NRT)|2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
3069783|NCT02096029|Active Comparator|Ask, Advise, Refer (physician brief advice)|Ask, Advise, Refer (physician brief advice)
3069784|NCT02096016||Human Papilloma Virus test|"Patients treated with surgery alone for uterine cervical neoplasms attending surveillance at Dept. of Obstetrics and Gynecology, Oncogynecological unit, Aarhus University Hospital from 01.01.14 From 01.01.15 patients will be recruited from Oncogynecologic units at Aalborg University Hospital and Rigshospitalet. Recruitment of patients from these institutions has not been successful and has been closed.~It is expected due to political decisions that the cervical cancer patients from the uptake area of Aalborg University Hospital will be treated at Aarhus University Hospital and they will then be eligible for the study"
3069785|NCT02096003|Active Comparator|Intrathecal morphine|0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections
3069786|NCT02096003|Experimental|Intrathecal hydromorphone|50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.
3069787|NCT02095990|Experimental|Hydroquinone|"Hydroquinone 4% Cream will be applied in one side of the face while the other side of the face receives placebo.~Half of the patients will receive Hydroquinone on the right side of the face and the other half on the left side.~It will be applied daily, at night, during 8 weeks."
3069788|NCT02095990|Placebo Comparator|Placebo|"Placebo cream (vehicle of Hydroquinone 4% cream), will be applied in one side of the face, while the other side receives the active treatment.~Half of the patients will receive Hydroquinone on the right side of the face and the other half on the left side.~It will be applied daily, at night, during 8 weeks."
3069789|NCT02095977|Other|participants|all subjects meeting inclusion and none of exclusion criteria
3069790|NCT02095964||Cardiac Syndrome X|
3069791|NCT02095964||Control Group|
3069792|NCT02095951|Experimental|Pre-emptive Ethanol Lock Therapy Group|Participants receive ethanol lock before blood cultures grow germ
3069793|NCT02095951|Active Comparator|Standard Ethanol Lock Therapy Group|Participants receive ethanol lock if and only after blood cultures grow germ
3069794|NCT02095938|Experimental|Solian|Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician
3069795|NCT02095925||cancer patients|Patients with stage III or IV esophageal carcinoma, gastric carcinoma, intestinal carcinoma, pancreatic carcinoma, ovarian cancer, breast carcinoma, prostate cancer, urothelial cell carcinoma or lung carcinoma (small cell or non-small cell) who have started chemotherapy no more than 3 months ago
3069796|NCT02095899|Experimental|Rufinamide|- oral Rufinamide administration as ad-on to Oxycodone
3069797|NCT02095899|Placebo Comparator|Manitol|- oral Placebo administration - as ad-on to Oxycodone
3069798|NCT02095886|Experimental|Cohort 1 Arm ABDC: BMS-955176 (Treatment A, B, D and C)|BMS-955176 single dose by mouth as specified
3069799|NCT02095886|Experimental|Cohort 1 Arm BCDA: BMS-955176 (Treatment B, C, D and A)|BMS-955176 single dose by mouth as specified
3069800|NCT02095886|Experimental|Cohort 1 Arm DABC: BMS-955176 (Treatment D, A, B and C)|BMS-955176 single dose by mouth as specified
3069801|NCT02095886|Experimental|Cohort 1 Arm CDAB: BMS-955176 (Treatment C, D, A and B)|BMS-955176 single dose by mouth as specified
3069802|NCT02095886|Experimental|Cohort 2 Arm EFGH: BMS-955176 (Treatment E, F, G and H)|BMS-955176 single dose by mouth as specified
3069803|NCT02095886|Experimental|Cohort 2 Arm FGHE: BMS-955176 (Treatment F, G, H and E)|BMS-955176 single dose by mouth as specified
3069804|NCT02095886|Experimental|Cohort 2 Arm HEFG: BMS-955176 (Treatment H, E, F and G)|BMS-955176 single dose by mouth as specified
3069805|NCT02095886|Experimental|Cohort 2 Arm GHEF: BMS-955176 (Treatment G, H, E and F)|BMS-955176 single dose by mouth as specified
3069806|NCT02095873|Experimental|Glo1-inducer then placebo|Glyoxalase 1 Inducer (8 weeks), then washout (6 weeks), then Placebo (8 weeks).
3069807|NCT02095873|Experimental|Placebo then Glo1-inducer|Placebo (8 weeks), then washout (6 weeks), then Glyoxalase 1 Inducer (8 weeks).
3069808|NCT02095860|Experimental|Treatment A: DCV 3DAA FDC fasted state|DCV 3 Direct Acting Antiviral (DAA) Fixed Dose Combination (FDC) tablet by mouth once on specified days in fasted state
3069809|NCT02095860|Experimental|Treatment B: DCV 3DAA FDC with high-fat meal|DCV 3DAA FDC tablet by mouth once on specified days with high-fat meal
3069810|NCT02095860|Experimental|Treatment C: DCV 3DAA FDC with light meal|DCV 3DAA FDC tablet by mouth once on specified days with light meal
3069811|NCT02095847|Experimental|Hysteroscope Imaging|All patients entered in study will undergo cervical dilation after induction of general anesthesia. Once the cervix has been dilated, a hysteroscope will be introduced in the uterine cavity to evaluate for presence of tumor. Location and size of tumor documented. White-light images obtained using the High-Resolution Microendoscopy (HRME) camera introduced through the hysteroscope. Once completed; the hysteroscope will be removed and the uterine cavity will be infused with 10 mL of proflavine (an acridine dye) (0.01% Proflavine (10ml)). A resectoscope will then be introduced in the uterine cavity and fluorescent images obtained using the HRME camera. The resectoscope will then be used to remove all tumor as guided through HRME images. The entire imaging and tumor resection process is estimated to take 45 minutes or less.
3070532|NCT02090686|Active Comparator|Minimal Cupping|
3069812|NCT02095834|Experimental|Carfilzomib + Bendamustine + Dexamethasone|Bendamustine, carfilzomib + dexamethasone with gradual dose-escalation in phase I and at MTD in the extension cohort. Bendamustine administered before carfilzomib on Days 1 and 2 of cycles 1 - 3 and on Day 1 of each subsequent cycle by vein at 50 mg/m2, 70 mg/m2, 90 mg/m2 during the dose escalation portion of the study, and at the MTD or a maximum dose of 90 mg/m2 during the extension cohort. Carfilzomib (20‐20/56 mg/m2 ) administered by vein on Days 1, 2, 8, 9, 15, and 16 of a 28‐day cycle for Cycles 1-12 and on Days 1, 2, 15, and 16 for a 28‐day cycle for maintenance Cycles 13 and higher. Dexamethasone 20 mg by mouth or vein administered weekly on Days 1 , 2, 8, 9, 15, 16, 22 and 23 of cycles 1 - 3, on days 1, 2, 15 and 16 for cycles 4 - 12, then on days 1 and 2 of each subsequent cycle.
3069813|NCT02095821||Humoral rejection, plasma exchange therapy|
3069814|NCT02095808|Experimental|Surgery|"The 13C-glucose solution will be given intravenously. It will be started at about the same time as the start of surgery, according to the study guidelines.~The 13C-glucose IV solution will be stopped once the surgeon has removed the tumor tissue."
3069815|NCT02095795|Experimental|Technological Rehabilitation|Patients in the experimental group received a multimodal treatment intervention consisting of 60 minutes of conventional treatment according to the Bobath approach (Bobath B. Adult hemiplegia: evaluation and treatment. Oxford: Butterworth-Heineman, 1990) followed by 30 minutes of robotic gait training on the Lokomat robotic system with the supervision of an expert rehabilitator. Patients started the first session with 50% weight unload and 1.5 Km/h gait speed, performances increments are allowed only in the following sessions. Each patient received 20 sessions over a period of 4 weeks (5 sessions per week).
3069816|NCT02095795|Active Comparator|Control Rehabilitation|Patients in the control group received the same number of treatment sessions of a similar duration as those in the experimental group but they received activities of overground walking exercises targeted to improve walking in substitution of the robotic gait trainer.
3069817|NCT02095782|Experimental|chemotherapy and erlotinib|Intercalated combination of chemotherapy and erlotinib in 1st line setting for patients with advanced stage non-small-cell lung cancer with low abundant activating EGFR mutation
3069818|NCT02095756|Experimental|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of melasma
3069819|NCT02095743|Experimental|PICC line|Use of a PICC line for chemo administration (PowerPICC SOLO²)
3069820|NCT02095743|Active Comparator|Implanted Port|Use of an implanted port for chemo administration
3069821|NCT02095730|Active Comparator|Epi-On Continuous|Continuous beam of UV light treating cornea with surface epithelium present
3069822|NCT02095730|Active Comparator|Epi-Off Continuous|Continuous beam of UV light treating cornea without surface epithelium present
3069823|NCT02095730|Active Comparator|Epi-On Pulsed|Pulsed beam of UV light treating cornea with surface epithelium present
3069824|NCT02095730|Active Comparator|Epi-Off Pulsed|Pulsed beam of UV light treating cornea without surface epithelium present
3069825|NCT02095717|Experimental|Curcumin|curcumine capsule
3069826|NCT02095717|Placebo Comparator|Placebo|placebo capsule
3069827|NCT02095704|Experimental|paracetamol oral solution|dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
3069828|NCT02095704|Experimental|paracetamol tablet|dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
3069829|NCT02095691|Experimental|Resistant Hypertension|The Celsius® ThermoCool® Renal Denervation catheter will serve to treat resistant hypertension.
3069830|NCT02095678|Experimental|HCC or metastaic Liver Lesions|Patients with HCC or metastatic liver lesions who are refered to the abdominal imaging and biopsy clinic will have a liver biopsy performed. 3-5 days after a clinical MRI indicating a cancerous lesion, patients will return for the free-breathing MRI and a liver biopsy. These images will be compared to the clinical MRI and to images of the benign lesions.
3069831|NCT02095678|Active Comparator|Benign Liver Lesion|Patients with benign liver lesions will be referred to the study team. 3-5 days after a clinical MRI an experimental, free-breathing MRI will be performed on these patients. The results will be compared to their clinical MRI images and to images of HCC or metastatic lesions
3069832|NCT02095665|Active Comparator|Narcotic analegesic only|"Drug:~Tylenol #3 1 tablet every six hours as necessary"
3069833|NCT02095665|Active Comparator|Mirabegron and narcotic analgesia|"Drug :~Mirabegron 50 mg oral daily~Drug:~Tylenol #3 1 tablet every six hours as necessary"
3069834|NCT02095665|Active Comparator|Tamsulosin and narcotic analgesia|"Drug:~Tamsulosin 0.4mg oral daily Drug: Tylenol #3 1 tablet every six hours as necessary"
3069835|NCT02095665|Experimental|Mirabegron, Tamsulosin and narcotic|"Drug:~Mirabegron 50 mg oral daily~Drug:~Tamsulosin 0.4mg oral daily~Drug:~Tylenol #3 1 tablet every six hours as necessary"
3069836|NCT02095639||ECT and Treatment Resistant Depression|Subjects will be those with diagnosis of major depressive disorder that have not responded to many different treatments and who are planning to take electroconvulsive therapy (ECT). This group will receive two [18F]FEPPA PET scans, one baseline and one after an average of 2.5 weeks of ECT treatments.
3069837|NCT02095626|Experimental|AP301|Treatment group
3069838|NCT02095626|Placebo Comparator|Saline solution|
3069839|NCT02095613|Active Comparator|Corn-soy-blend plus|food A type of ground meal called corn-soy-blend plus
3069840|NCT02095613|Active Comparator|Ready-to-use-supplementary food|food A nutrient dense food comprised of peanuts, oil, multivitamins.
3069841|NCT02095600|Experimental|Radiosurgical thalamotomy|
3069842|NCT02095587|Experimental|Mild Hepatic Impairment|
3069843|NCT02095587|Experimental|Moderate Hepatic Impairment|
3069844|NCT02095587|Experimental|Healthy Subjects|
3069845|NCT02095587|Experimental|Severe Hepatic Impairment|Optional arm based on results from Arms 1, 2, and 3
3069846|NCT02095574|Experimental|[14C]ABT-199|Subjects with relapsed or refractory Non-Hodgkin's Lymphoma
3069847|NCT02095561|Experimental|HPV Self testing|HPV self testing offered by CHWs during home visits
3069848|NCT02095561|No Intervention|HPV at health centers|Community Health Workers instructed women about cervical cancer and HPV testing and advised them on how to seek screening at health centers.
3069849|NCT02095548|Experimental|SM04690, 0.03mg/2mL|Single, intra-articular injection of SM04690, 0.03mg/2mL
3069850|NCT02095548|Experimental|SM04690, 0.07mg/2mL|Single, intra-articular injection of SM04690, 0.07mg/2mL
3069851|NCT02095548|Experimental|SM04690, 0.23mg/2mL|Single, intra-articular injection of SM04690, 0.23mg/2mL
3069852|NCT02095548|Placebo Comparator|Placebo|Single, intra-articular injection of placebo
3069853|NCT02095535||Study group|All study participants
3069854|NCT02095522|Experimental|Colchicine|Colchicine 1mg per day for one month
3069855|NCT02095522|Placebo Comparator|Placebo|Placebo 1mg per day
3069856|NCT02095509|Active Comparator|Subcutaneous Enoxaparin|Subcutaneous enoxaparin 40 mg every 24 hours for three days
3069857|NCT02095509|Active Comparator|Intravenous Enoxaparin|40 mg enoxaparin daily as continuous intravenous infusion for three days (72 hours)
3069858|NCT02095496|Experimental|Intellivent-ASV|Patients will receive Intellivent-ASV ventilation during 12 hours
3069859|NCT02095496|Active Comparator|Conventional ventilation|Patients will receive pressure support ventilation during 12 hours
3069860|NCT02095470|Experimental|videolaryngoscope group|video laryngoscopy was done for them
3069861|NCT02095470|Placebo Comparator|traditional laryngoscope|comparison to active group with routine laryngoscope
3069862|NCT02095457|Active Comparator|Frequent Monitoring and Feedback|In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy
3069863|NCT02095457|Sham Comparator|Infrequent monitoring without feedback|In the control arm, patients will infrequently fill short monitoring questionnaires, the results of which are not fed back to their therapists and staff. The frequency of monitoring is between about once a year
3069864|NCT02095444|Experimental|Menstrual blood stem cells|1x10*7 cells/kg, IV(in the vein) twice a week. Number of course for two weeks.
3069865|NCT02095431||with AKI and without AKI|development of AKI by sCr and by novel biomarkers
3069866|NCT02095418|Experimental|Mycophenolate mofetil, Corticosteroids|"Mycophenolate mofetil: 500-1500mg/day, bid, PO~Corticosteroids: 500mg for the first dosage. It will be tapered at least 5mg for 14days and withdrawn"
3069867|NCT02095418|Active Comparator|Corticosteroids, Mycophenolate mofetil|"Mycophenolate mofetil: 500-1000mg/day, bid, PO~Corticosteroids 500mg for the first dosage. It will be tapered at least 5mg for 3months(± 2 weeks) and withdrawn."
3069868|NCT02095405|Active Comparator|Caffeine arm|"SVT group: Caffeine tablets, 5 mg/kg.~AF group: Caffeinated substances and Dark Chocolate"
3069869|NCT02095405|Placebo Comparator|Placebo arm|"SVT group: Placebo~AF group: Decaffeinated substances and White Chocolate"
3069870|NCT02095392|Experimental|P1000/Ca0|
3069871|NCT02095392|Experimental|P1000/Ca500|
3069872|NCT02095392|Experimental|P1000/Ca1000|
3069873|NCT02095392|Placebo Comparator|Placebo|
3069874|NCT02095379||oligosecretary|Multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day)
3069875|NCT02095366|Experimental|IN Sufentanil AND IV Placebo|Patient receives silmutaneously intranasal sufentanil spray AND intraveinous placebo administration
3069876|NCT02095366|Active Comparator|IV Morphine AND IN Placebo|Patient receives silmutaneously intraveinous morphine administration AND intranasal placebo spray
3069877|NCT02095340|Experimental|Positive Training|
3069878|NCT02095340|Sham Comparator|Neutral Training|
3069879|NCT02095314|Experimental|Pentavalen|Pentabio Vaccine One dose corresponds to 0.5ml The vaccine shall be given intramuscularly
3069880|NCT02095301|Experimental|Control plus herbal extract|Control plus herbal extract
3069881|NCT02095301|Placebo Comparator|Caffeine-free, carbonated soft drink|Caffeine-free, carbonated soft drink
3069882|NCT02095288||Healthy volunteers|Blood draw
3069883|NCT02095275||Acute kidney injury|ICU patients with Acute kidney injury
3069884|NCT02095262|Active Comparator|STAR2|Reactive auditory training
3069885|NCT02095262|Experimental|Treasure Hunter|Interactive auditory training
3069886|NCT02095262|Experimental|Submarine|Interactive auditory training
3069887|NCT02095249|Other|Pimonidazole|
3069888|NCT02095236|Experimental|experimental|Radioopaque fiducial markers or electro-magnetic transponders will be implanted into or in close proximity of the tumor. During a radiotherapy treatment session image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors The data will help to characterize tumor and organ motion during one treatment session which may in fact have impact on dose distribution
3069889|NCT02095223|Experimental|Electromyographic Biofeedback Group|Participants in the electromyographic biofeedback supplemented exercise will be instructed on correct setup and use of the electromyographic biofeedback unit. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group. Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
3069890|NCT02095223|Active Comparator|Traditional Exercise Group|Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
3069891|NCT02095210|Experimental|[68Ga]ABY-025 PET imaging|Radiolabeled [68Ga]ABY-025
3069892|NCT02095197|Other|No Catheter delivery|"Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.~No Catheter Delivery will be used to deliver the medication."
3069893|NCT02095197|Active Comparator|Catheter targeted delivery|"Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.~Catheter targeted delivery will be used to deliver the medication."
3069894|NCT02095184|Active Comparator|Cohort 1: Normal Weight Anastrozole|Cohort 1: Patients with BMI < 25.0 kg/m2 treated with anastrozole
3069895|NCT02095184|Active Comparator|Cohort 2: Overweight Anastrozole|Cohort 2: Patients with BMI ≥ 25.0-29.9 kg/m2 treated with anastrozole
3069896|NCT02095184|Active Comparator|Cohort 3: Obese|Cohort 3: Patients with BMI ≥ 30 kg/m2 treated with anastrozole
3069897|NCT02095184|Active Comparator|Cohort 4: Normal Weight Letrozole|Cohort 4: Patients with BMI < 25.0 kg/m2 treating with letrozole
3069898|NCT02095184|Active Comparator|Cohort 5: Overweight Letrozole|Cohort 5: Patients with BMI ≥ 25.0-29.9 kg/m2 treating with letrozole
3069899|NCT02095184|Active Comparator|Cohort 6: Obese Letrozole|Cohort 6: Patients with BMI ≥ 30 kg/m2 treating with letrozole
3069900|NCT02095171|Experimental|PRX002|
3069901|NCT02095171|Placebo Comparator|Placebo|
3069902|NCT02095158|Experimental|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 52 weeks.
3069903|NCT02095145|Experimental|Group I (pomegranate-extract pill)|Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
3069904|NCT02095145|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD for 52 weeks (+/- 1 week).
3069905|NCT02095132|Experimental|Treatment (irinotecan hydrochloride, adavosertib)|Patients receive irinotecan hydrochloride PO and adavosertib PO on days 1-5. Treatment repeats every 21 days for 18 courses in the absence of disease progression or unacceptable toxicity.
3069906|NCT02095106|Other|Traditional cast first|Patients in this group will first receive a traditional fiberglass cast for two weeks, after which this cast will be removed and a waterproof cast applied.
3069907|NCT02095106|Other|Waterproof cast first|Patients in this group will receive a waterproof cast for 2 weeks, after which the waterproof cast will be removed and a traditional fiberglass cast will be applied for an additional two weeks.
3069908|NCT02095093|Experimental|Intellijoint HIP|Patient's will have their leg length and hip offset determined intraoperatively using Intellijoint HIP.
3069909|NCT02095093|Active Comparator|Outrigger|Control patients will have their leg length and hip offset determined intra-operatively using the standard at Mount Sinai Hospital, which is a pin and outrigger system.
3069910|NCT02095080|Experimental|Leucine intake|Dietary supplement: Leucine intake
3069911|NCT02095067|Experimental|Video consultation|Patients in this arm receive video consultation from physician at the emergency medical dispatch center
3069912|NCT02095067|No Intervention|Telephone consultation|Patients receiving prehospital care by ambulance personnel whom receive telephone consultation/supervision by physician at the emergency medical dispatch center.
3069913|NCT02095054|Experimental|Regorafenib + Cetuximab|"Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle. Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group.~Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle. Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group.~Symptom questionnaire completed at each study visit."
3069914|NCT02095041||Healthy Term infants|
3069915|NCT02095028|Experimental|Dietary and lifestyle intervention|Intervention group:Based on standard care,intensive dietary and lifestyle intervention was provided. Initiated from the first trimester to delivery,every 2-4 weeks follow-up
3069916|NCT02095028|No Intervention|Standard care group|Standard care group:Participants received one group session in which prenatal general dietary, nutrition guideline, physical activity and recommendation for gestational weight gain introduced by a registered dietitian in 1.5hours.Participants received their regularly scheduled visits without additional dietary and lifestyle follow-up and guidance.
3069917|NCT02095015||Analysis population|All subjects enrolled in the study who meet the eligibility criteria
3069918|NCT02094989||diagnostic|
3069919|NCT02094976|Active Comparator|Group C|Group C means active comparator group which use chest rolls intraoperatively for prone position.
3069920|NCT02094976|Active Comparator|Group W|Group W means experimental group which use Wilson frame intraoperatively for prone position.
3069921|NCT02094976|Experimental|Group J|Group J means experimental group which use Jackson surgical table intraoperatively for prone position.
3069922|NCT02094963|Experimental|Ticagrelor|
3069923|NCT02094963|Active Comparator|Clopidogrel|
3069924|NCT02094950|Experimental|Lung Cancer Patient with Dyspnea|
3069925|NCT02094937|Experimental|Arm 1 FF/VI 100/25 mcg|Subjects will receive Fluticasone Furoate/Vilanterol 100/25 mcg once-daily via a dry powder inhaler for 8 weeks in the open-label treatment period.
3069926|NCT02094937|Experimental|Arm 2 FF 100 mcg|Subjects will receive Fluticasone Propionate matching placebo twice-daily (morning and evening) and Fluticasone Furoate 100 mcg once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
3069927|NCT02094937|Experimental|Arm 3 FP 250 mcg|Subjects will receive Fluticasone Propionate 250 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
3069928|NCT02094937|Experimental|Arm 4 FP 100 mcg|Subjects will receive Fluticasone Propionate 100 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
3069929|NCT02094924|Experimental|Sequence 1|Participants in this arm will receive treatment A in period 1 and treatment B in period 2. Subjects will receive a single reference FDC tablet of 16mg candesartan cilexetil/12.5mg HCTZ as Treatment A administered orally with 240mL of water and a single 16mg candesartan cilexetil/12.5mg HCTZ FDC tablet (GSK587323) as Treatment B.
3069930|NCT02094924|Experimental|Sequence 2|Participants in this arm will receive treatment B in period 1 and treatment A in period 2. Subjects will receive a single reference FDC tablet of 16mg candesartan cilexetil/12.5mg HCTZ as Treatment A administered orally with 240mL of water and a single 16mg candesartan cilexetil/12.5mg HCTZ FDC tablet (GSK587323) as Treatment B.
3069931|NCT02094911|Experimental|Combined lifestyle intervention|Lifestyle counselling (nutrition and physical activity) by dietician and physiotherapist during 10-month intervention period
3069932|NCT02094911|Other|Usual care group|Subjects receive brochures on healthy lifestyle at baseline, and during the 10-month intervention period only usual care as provided by their own general practitioner.
3070533|NCT02090686|No Intervention|No Intervention|Waiting list
3069933|NCT02094898|Experimental|Ketamine infusion|This trial was conducted in 2 phases. During the acute-phase, i.v. ketamine was administered thrice-weekly for up to 2 weeks.Those who achieved depressive symptom remission received continuation-phase treatment that consisted of once-weekly i.v. ketamine infusions for 4 additional weeks. Remission could occur after any of the 6 acute-phase infusions, at which point the next infusion was the first (of four) continuation-phase infusions. Individuals who remitted during acute-phase and completed continuation-phase treatment had 4 additional weekly post-continuation follow-up visits.
3069934|NCT02094885|Experimental|Bioseal Fibrin Sealant|A porcine-derived fibrin sealant consisting of thrombin and fibrinogen
3069935|NCT02094885|Other|Manual compression|Manual compresssion (MC) include any active or inactive adjunctive treatment to hemostasis methods currently used based on each surgeons surgical practice except for the use of other fibrin sealants.
3069936|NCT02094872|Experimental|Arm I (molecularly targeted therapy)|Patients undergo collection of tissue and blood samples for DNA and RNA analysis via sequencing. Based on the results of the DNA and RNA analysis, patients receive molecularly targeted therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
3069937|NCT02094859||GlucoClear System|
3069938|NCT02094846|Active Comparator|Voice messages|This group receive voice messages to reinforce given information about diet, physical activity, glycemic index
3069939|NCT02094846|Placebo Comparator|Messages|This group received voice messages with fun facts.
3069940|NCT02094833|Experimental|Group A|Participants will receive 3 injections of the study vaccine (DTaP-IPV-Hep B-PRP~T combined vaccine) at 2, 4, and 6 months of age
3069941|NCT02094833|Active Comparator|Group B|Participants will receive 2 injections of monovalent Hep B vaccine (Euvax B®) at age 1 and 6 months and 3 injections of DTaP IPV//PRP~T vaccine (Pentaxim™) at age 2, 4, and 6 months
3069942|NCT02094820||Single Group Study|Questionnaires
3069943|NCT02094807|Other|Conservative management|Not operated. Thoracic epidural anesthesia will be used togeteher with paracetamol. If not sufficient opioids and NSAID will be added.
3069944|NCT02094807|Active Comparator|Operative management|Operative fixation of rib fractures. Thoracic epidural anesthesia will be used togeteher with paracetamol. If not sufficient opioids and NSAID will be added.
3069945|NCT02094794|Experimental|Treatment (TMLI, chemotherapy)|Patients undergo image guided TMLI on days -9 to -5, receive etoposide IV on day -4 and cyclophosphamide IV on day -2, and undergo allogeneic peripheral blood stem cell or bone marrow transplant on day 0.
3069946|NCT02094781|Experimental|Whey protein and creatine supplement|Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
3069947|NCT02094781|Active Comparator|Whey protein only supplement|Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
3069948|NCT02094781|Placebo Comparator|Placebo|Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
3069949|NCT02094768|Experimental|Reduced Fat Milk|20 oz. reduced fat (2%) milk per day
3069950|NCT02094768|Experimental|Sugar Sweetened Soda|24oz. soda per day
3069951|NCT02094755||Single cohort|Single cohort will receive blood draw.
3069952|NCT02094742|Other|all-commers|All patients will undergo a biopsy of their metastatic lesion and have a blood sample taken for molecular screening purposes. No drugs are administered or other interventions are performed.
3069953|NCT02094729|Experimental|BAN2401 2.5 mg/kg|Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401
3069954|NCT02094729|Experimental|BAN2401 5 mg/kg|Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401
3069955|NCT02094729|Experimental|BAN2401 10 mg/kg|Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401
3069956|NCT02094729|Placebo Comparator|Placebo|Intravenous infusions of placebo for 60 +/- 10 minutes.
3069957|NCT02094716|Experimental|Permethrin Foam 4%/ Permethrin Foam 4%|First treatment with Permethrin Foam 4% with potential to re-treat with Permethrin Foam 4%, if necessary.
3069958|NCT02094716|Experimental|Permethrin Foam 5%/ Permethrin Foam 5%|First treatment with Permethrin Foam 5% with potential to re-treat with Permethrin Foam 5%, if necessary.
3069959|NCT02094716|Placebo Comparator|Vehicle Foam / Permethrin Foam 4%|First treatment with Vehicle with potential to re-treat with Permethrin Foam 4%, if necessary.
3069960|NCT02094716|Placebo Comparator|Vehicle / Permethrin Foam 5%|First treatment with Vehicle with potential to re-treat with Permethrin Foam 5%, if necessary.
3069961|NCT02094703|Experimental|levofloxacin and solifenacin succinate|Levofloxacin 500 mg tablet and solifenacin succinate 5 mg tablet by mouth once daily for 3 days
3069962|NCT02094703|Active Comparator|levofloxacin and placebo|Levofloxacin 500 mg tablet and placebo (for solifenacin succinate) by mouth once daily for 3 days
3069963|NCT02094690|Active Comparator|Device Hyperboloid|"5 min of bilateral mastication alternated with the device hyperboloid The exercises should begin one day before the onset of Radiotherapy (RT) and kept until the end of RT.~Repeated 4x a day (after breakfast, lunch, dinner and before going to bed)."
3069964|NCT02094690|Active Comparator|Device Therabite|"10 repetitions holding the device Therabite for 30 seconds~5 min of bilateral mastication alternated with the device hyperboloid The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT.~Repeated 4x a day (after breakfast, lunch, dinner and before going to bed)."
3069965|NCT02094690|No Intervention|Control|The control group (GEC) will not receive any of the protocols tested in the study, but together with the other groups, will receive the regular treatment offered by the institution, which is made up of guidance and advice given by the hospital´s nursing team about the radiotherapy treatment. Currently, patients do not receive any information as far as trismus is concerned.
3069966|NCT02094677|Active Comparator|filcon II 3 and etafilcon A|Participants were randomized to a test and control lens for each group in a contralateral design.
3069967|NCT02094677|Active Comparator|filcon II 3 and nelfilcon A|Participants were randomized to a test and control lens for each group in a contralateral design.
3069968|NCT02094664|No Intervention|Standard oxygen via nasal cannula|Standard therapy
3069969|NCT02094664|Active Comparator|Heated and humidified oxygen|Heated and humified oxygen
3069970|NCT02094651|Experimental|divalproex sodium|divalproex sodium will be administered in sprinkle capsule formulation, target dose of 30mg/kg, drug will be administered for 12 weeks
3069971|NCT02094651|Placebo Comparator|Placebo|Blue and white capsules with equivalent amount of lactose spheres/beads inside Placebo will be formulated to look identical to the active medication
3069972|NCT02094638||Tanreqing|Inpatient using the Tanreqing Injection
3069973|NCT02094625|Experimental|N-Acetylcysteine Intervention|"This is a dose-finding study using a traditional 3+3 dose escalation scheme. Up to 18 subjects (3 dose levels as per below) will be enrolled to determine the maximum tolerated dose (MTD). The MTD is defined as per traditional 3+3 criteria of less than or equal to one dose-limiting toxicity at the dose level. Once the MTD is determined, subjects will be equally distributed at the safe dose levels (less than or equal to the MTD) to determine the optimum dose to achieve NAC levels in the blood necessary for hearing protection.~As of August 2018: The dose-escalation phase was completed and dose-level three was selected for expansion in 9 subjects."
3069974|NCT02094625|No Intervention|Observation only|"Subjects who are ineligible to receive the study drug NAC will have the option to enroll for study assessments only including laboratory testing and hearing assessments identical to the experimental intervention arm. This is a cohort of convenience for which we anticipate up to 36 children will be enrolled over the course of the study."
3069975|NCT02094612|Active Comparator|Usual Care|Usual clinic ADHD care
3069976|NCT02094612|Experimental|Usual Care plus Assessment|Usual clinic ADHD care plus the Quotient®
3069977|NCT02094599|Experimental|All Enrolled Participants|Each participant receives all treatments (of placebo, dronabinol 10 mg and dronabinol 30 mg) in a 5-way crossover design. At each treatment visit, participants receive a single dose, contained in two syringes of oral solution and three capsules. When dronabinol is in syringes, placebo is in capsules, and when dronabinol is in capsules, placebo is in syringes. When assigned to take placebo only, placebo is in both the syringes and the capsules.
3069978|NCT02094586|Experimental|PXVX0200|PXVX0200 Single dose; liquid suspension after reconstitution with buffer; > 2x108 CFU in a liquid suspension
3069979|NCT02094586|Placebo Comparator|Placebo|Placebo physiological saline
3069980|NCT02094573|Experimental|Brigatinib 90 mg|Brigatinib 90 mg, tablets, orally, once daily in each cycle of 28 days until disease progression or intolerable toxicity.
3069981|NCT02094573|Experimental|Brigatinib 90 mg - 180 mg|Brigatinib 90 mg, tablets, orally, once daily for 7 days followed brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in cycle 2 and onward cycles of 28 days until disease progression or intolerable toxicity.
3069982|NCT02094560|Experimental|Small cell lung cancer|Histologically- or cytologically-confirmed, limited and extensive SCLC disease with progression after first or second line treatment
3069983|NCT02094560|Experimental|Non small cell lung cancer|Histologically- or cytologically-confirmed diagnosis of NSCLC with Stage IIIB or IV after failure of at least two lines of therapy
3069984|NCT02094560|Experimental|biliary tract cancer|Histologically or cytologically confirmed diagnosis of biliary tract cancer progress after first line therapy
3069985|NCT02094547|Experimental|New infant formula|New infant formula with key ingredients.
3069986|NCT02094547|Active Comparator|Standard infant formula|Standard infant formula
3069987|NCT02094534|Experimental|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules, ORMD-0801
3069988|NCT02094534|Placebo Comparator|Placebo|Fish oil in capsules, identical in appearance to ORMD-0801
3069989|NCT02094521|Experimental|NNC0113-0987|
3069990|NCT02094495||breast cancer group|Taking tamoxifen
3069991|NCT02094482|Other|OSAS Palatal Implant|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate .
3069992|NCT02094469|Other|Cilostazol|Cilostazol 50mg and 100mg
3069993|NCT02094456|Experimental|Endoscopic clipping of diverticula|Endoscopic clipping of diverticula Follow-up colonoscopy
3069994|NCT02094443|Experimental|Alisporivir 300 mg BID|Alisporivir (ALV) 300 mg twice daily (BID) with ribavirin for 12 or 24 weeks based on Week 2 response, with a safety follow-up of at least 4 weeks, during which patients did not receive any study medication
3069995|NCT02094443|Experimental|Alisporivir 400 mg BID|ALV 400 mg twice daily (BID) with ribavirin for 12 or 24 weeks based on Week 2 response, with a safety follow-up of at least 4 weeks, during which patients did not receive any study medication
3069996|NCT02094430|Experimental|FGTW|
3069997|NCT02094417|Experimental|AMG531 (Dose 1)|
3069998|NCT02094417|Experimental|AMG531 (Dose 2)|
3069999|NCT02094417|Experimental|AMG531 (Dose 3)|
3070000|NCT02094417|Experimental|AMG531 (Dose 4)|
3070001|NCT02094404||Children at the ED<18yr|
3070002|NCT02094391|Experimental|Ipilimumab|
3070003|NCT02094391|No Intervention|No Ipilimumab|
3070004|NCT02094378|Experimental|Esketamine-Placebo|Participants assigned to treatment sequence 1 will receive 84 mg esketamine intranasally on Day 1 of Period 1 and then receive placebo intranasally on Day 1 in Period 2. Periods 1 and 2 will be separated by 7 days.
3070005|NCT02094378|Placebo Comparator|Placebo-Esketamine|Participants assigned to treatment sequence 2 will receive placebo intranasally on Day 1 of Period 1 and then receive 84 mg esketamine intranasally on Day 1 in Period 2. Periods 1 and 2 will be separated by 7 days.
3070006|NCT02094365|Experimental|ALS-008176|ALS-008176 drug substance for oral suspension
3070007|NCT02094365|Placebo Comparator|vehicle alone|Vehicle alone
3070008|NCT02094352|Experimental|Ketamine Infusion + Epidural Infusion + Booster Infusion|"Inpatient: Patients will receive a subanesthetic continuous intravenous infusion of KETAMINE 500mg/500ml in 0.9% Sodium Chloride with an epidural infusion.~Outpatient: Patients will receive three ketamine booster infusions over the course of three months."
3070247|NCT02092727|Experimental|Behavioral Intervention|A variety of dialysis facility-level, behavioral interventions will be examined.
3070009|NCT02094352|Placebo Comparator|Control Group + Epidural Infusion + Booster Infusion|"Inpatient: Patients will receive a subanesthetic continuous intravenous infusion of SALINE 500mg/500ml in 0.9% Sodium Chloride with an epidural infusion.~Outpatient: Patients will receive three saline booster infusions over the course of three months."
3070010|NCT02094339|Experimental|Local analgesic|This group uses local analgesia infusion pump of 0.2% ropivacaine 360ml through periarticular infiltration for postoperative analgesia.
3070011|NCT02094339|Active Comparator|Nerve Block|People in this group will receive a postoperative pain management by continuous lumbar plexus block with 0.2% ropivacaine.
3070012|NCT02094339|Active Comparator|Intravenous analgesic|This group is treated with intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg.
3070013|NCT02094313|Experimental|atovastatin|
3070014|NCT02094300|Experimental|Endovascular|
3070015|NCT02094287|Experimental|verum, instruction, conditioning|This group received dimetindene and instructions about dimetindene and its effectiveness. One classical conditioning process with saline was applied during the skin prick test procedures.
3070016|NCT02094287|Experimental|verum, instruction, no conditioning|This group received dimetindene and instructions about dimetindene and its effectiveness. No conditioning process were applied
3070017|NCT02094287|Experimental|placebo, instruction, conditioning|This group received a placebo (saline) as intravenously administered substance. But instructions about receiving dimetindene and its effectiveness were given. One classical conditioning process was applied during the skin prick test procedures.
3070018|NCT02094287|Experimental|verum, no instruction, no conditioning|Dimetindene was covertly administered (unawareness of treatment). No instruction and no conditioning were given.
3070019|NCT02094274|Experimental|LAS40468|Single dose, administered via Genuair® dry powder inhaler (DPI)
3070020|NCT02094274|Active Comparator|Salmeterol/fluticasone propionate|Single dose, Seretide® (salmeterol fluticasone propionate) administered via Accuhaler™
3070021|NCT02094274|Placebo Comparator|Placebo|Single dose administered via Genuair® or Accuhaler™ dry powder inhaler (DPI)
3070022|NCT02094261|Experimental|AZD9291|Once daily tablet 80 mg
3070023|NCT02094248|Experimental|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000U/ml, s.c injection
3070024|NCT02094248|Placebo Comparator|control|Normal saline，1ml/day, s.c injection
3070025|NCT02094235|Experimental|1|E6005 0.2% ointment applied twice a day to eczema areas
3070026|NCT02094235|Experimental|2|E6005 0.05% ointment applied twice a day to eczema areas
3070027|NCT02094235|Placebo Comparator|3|Placebo ointment applied twice a day to eczema areas
3070028|NCT02094196||Controls, highrisk for AD|Community-based ad-hoc participants, high risk for alcohol dependence, matched to inpatients by sociodemographics
3070029|NCT02094196||Controls, low risk for AD|Community-based ad-hoc participants, low risk for alcohol dependence, matched to inpatients by sociodemographics
3070030|NCT02094196||Alcohol detoxification|Inpatients with alcohol dependence from local psychiatric hospital wards (18-65 years old)
3070031|NCT02094183|Experimental|GLP-1|GLP-1 and low calorie diet
3070032|NCT02094183|Experimental|Control|low calorie diet
3070033|NCT02094157|Active Comparator|Bridged regimen|Bridged regimen Warfarin therapy is stopped for 5 days before surgery and restarted in the evening of surgery at double the usual dose for two days. Bridging with low-molecular-weight heparin at therapeutic dose is given for 2½ days before surgery.
3070034|NCT02094157|Experimental|Tapered warfarin regimen|Tapered warfarin regimen Warfarin is given at half the usual maintenance dose for 3-6 days before surgery depending on the INR at the baseline visit. A double dose is given in the evening of surgery. No bridging with LMWH is used.
3070035|NCT02094144|Other|exercise group (brisk walking program)|The intervention is named brisk walking program. It consists on achieve 40 minutes of brisk walking 3d/wk for 6 months (two supervised sessions and one session performed one their own per week with a detailed program). The intensity of the program is adapted to the heart rate work and gradually increases over the 6-month program
3070036|NCT02094144|Other|control group (physical activity habits)|The Intervention consists on maintain the lifestyle and especially their physical activity habits during 6 months
3070037|NCT02094131|Experimental|Cliniflo group (CG)|Training using flow-oriented incentive spirometry Cliniflo
3070038|NCT02094131|Experimental|Voldyne group (VG)|Training using volume-oriented incentive spirometry Voldyne
3070039|NCT02094131|No Intervention|Control group (CONG)|No intervention. Assessment and reassessment after 5 weeks.
3070040|NCT02094118|Active Comparator|Standard of care red blood cell transfusion|Red blood cells that are administered in the normal fashion.
3070041|NCT02094118|Experimental|Point-of-Care washed red blood cell transfusion|Red blood cells that are washed at the point-of-care.
3070042|NCT02094105|Experimental|screening|endoscopy examination with iodine staining
3070043|NCT02094105|No Intervention|control|1/10 sampling questionnaire interview for control group.
3070044|NCT02094092|Placebo Comparator|ProTectis drops|Arm A.
3070045|NCT02094092|Placebo Comparator|Placebo drops|Arm B
3070046|NCT02094079||L-T4 treated hypothyroid pregnant women|L-T4 treated pregnant women
3070047|NCT02094066|Active Comparator|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
3070048|NCT02094066|Sham Comparator|serum physiologic|preoperative 100 cc serum physiologic
3070049|NCT02094053|Experimental|E2020 3 mg|3 mg of E2020 (oral) once daily, for 24 weeks
3070050|NCT02094053|Experimental|E2020 5 mg|5 mg of E2020 (oral) once daily, for 24 weeks
3070051|NCT02094053|Placebo Comparator|Placebo|placebo (oral) once daily, for 24 weeks
3070052|NCT02094040|Experimental|Follow-up visit|Receive municipality-based follow-up visit including primary physician.
3070053|NCT02094040|No Intervention|Usual care|Does not receive follow-up visit
3070054|NCT02094027|Experimental|Guided Self Help|Guided Self Help intervention to reduce binge eating
3070055|NCT02094027|Placebo Comparator|Treatment As Usual|No intervention for binge eating (treatment as usual in the form of bariatric surgery)
3070285|NCT02092467|Experimental|Treatment Arm 1|
3070286|NCT02092467|Experimental|Treatment Arm 2|
3070056|NCT02094014||Aphasic/Apraxic Participants|"The aphasic/apraxic participant group will include 30 adults who have had strokes affecting their ability to communicate verbally, broadly classified as aphasic and including individuals with and without apraxia of speech (AOS).~Participants will speak under Masked Auditory Feedback, Altered Auditory Feedback, and Normal Auditory Feedback."
3070057|NCT02094014||Neurologically Healthy Participants|"The neurologically healthy participant group will include 15 adults with no history of stroke or developmental speech or language disorder.~Participants will speak under Masked Auditory Feedback, Altered Auditory Feedback, and Normal Auditory Feedback."
3070058|NCT02094001|Experimental|Riociguat therapy|After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
3070059|NCT02093988|Experimental|Topical and Intravenous TXA|
3070060|NCT02093988|Active Comparator|Intravenous TXA only|
3070061|NCT02093975|Experimental|Video consultation|Patients in this arm receive video consultation from physician in doctor manned rapid response vehicle.
3070062|NCT02093975|Active Comparator|Telephone consultation|Patients receiving prehospital care by ambulance personnel whom receive telephone consultation/supervision by physician in rapid response vehicle.
3070063|NCT02093962|Experimental|TH-302 and pemetrexed|TH-302 in combination with pemetrexed
3070064|NCT02093962|Active Comparator|Placebo and pemetrexed|Matching placebo in combination with pemetrexed
3070065|NCT02093949||Studied|Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation
3070066|NCT02093949||Control|The validation set included a cohort of 47 patients with symptomatic drug-refractory AF who underwent ablation using a conventional approach.
3070067|NCT02093936||Healthy non exposed|Healthy patients with no pulmonary symptoms that were not exposed to occupational or environmental exposure
3070068|NCT02093936||Healthy exposed|Healthy patients with no pulmonary symptoms that were exposed to occupational or environmental exposure
3070069|NCT02093936||Non-healthy exposed|Patients with pulmonary symptoms or diseases that were exposed to occupational or environmental exposure
3070070|NCT02093936||Non-healthy non-exposed|Patients with pulmonary symptoms or diseases that were not exposed to occupational or environmental exposure
3070071|NCT02093923|Experimental|DX-2930, Dose level 1|30 mg of DX-2930 administered twice, two weeks apart
3070072|NCT02093923|Experimental|DX-2930, Dose level 2|100 mg of DX-2930 administered twice, two weeks apart
3070073|NCT02093923|Experimental|DX-2930, Dose level 3|300 mg of DX-2930 administered twice, two weeks apart
3070074|NCT02093923|Experimental|DX-2930, Dose level 4|400 mg of DX-2930 administered twice, two weeks apart
3070075|NCT02093923|Placebo Comparator|Placebo|Placebo administered twice, two weeks apart
3070076|NCT02093910|Experimental|Monosialotetrahexosylganglioside|each patient in this arm received velcade+dexamethasone (VD) regimen（bortezomib,1.3mg/㎡，subcutaneously injection，d1,8,15,22；dexamethasone,20mg d1-2, 8-9,15-16,22-23）every 4 weeks; and monosialotetrahexosylganglioside was used at the dosage of 100mg/d intravenously at d1-2,8-9,15-16,22-23 every cycle.
3070077|NCT02093897|Experimental|rVIII-SingleChain|Subjects will be assigned to either an on-demand or prophylaxis regimen and will receive rVIII-SingleChain as an intravenous (IV) infusion. Subjects assigned to a prophylaxis regimen will be treated with 15 to 50 IU/kg of rVIII-SingleChain every second day or 2 to 3 times per week, or at the investigator's discretion, based on available PK data, the FVIII treatment regimen used before enrollment and/or the subject's bleeding phenotype. The dose for on-demand treatment of a bleeding episode is based on the recommendations of the World Federation of Hemophilia (WFH), with a minimum dose of 15 IU/kg. All subjects were to be treated for a minimum of 50 EDs. For the PK evaluation, the subjects will receive a single IV dose of 50 IU/kg of rVIII-SingleChain on Day 1 at the start of the PK evaluation period.
3070078|NCT02093884|Experimental|Text Messaging Intervention|Patients in the text messaging group will receive educational and motivational text messages.
3070079|NCT02093884|Active Comparator|Standard Referral|Patients in the standard referral arm will receive paper based information about the Family Planning Clinic.
3070080|NCT02093871|Experimental|ThermalCore Hyperthermia System|Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
3070081|NCT02093858||olanzapine|15-25mg/day for 24 weeks
3070082|NCT02093845|Active Comparator|SYNERGY|Coronary implantatation of the SYNERGY everolimus-eluting stent
3070083|NCT02093845|Active Comparator|Biomatrix Neoflex|Coronary implantation of the biolimus-eluting Biomatrix NeoFlex stent
3070084|NCT02093832||Total hip arthroplasty|
3070085|NCT02093819|Experimental|BI 416970 single rising dose part|single rising dose given as tablet
3070086|NCT02093806||CT of the temporal bone|
3070087|NCT02093793|Experimental|High Rate Spinal Cord Stimulation|PRECISION SCS Adapted for High-Rate SCS
3070088|NCT02093793|Active Comparator|Commercial Rate Spinal Cord Stimulation|PRECISION SCS Adapted for High-Rate SCS
3070089|NCT02093780|Experimental|Alberta Anti-inflammatory Diet|Patients randomized into this group will receive a dietary menu plan that contains anti-inflammatory foods/nutrients that have been shown to be effective in the management of IBD in previous studies. The main aim of this diet will be to increase dietary intakes of prebiotics/probiotics, omega 3 fatty acids, fiber (soluble), antioxidants and decrease dietary intake of red and processed meat.
3070090|NCT02093780|Active Comparator|Canada's Food Guide Diet|"Patients that have been randomized into this group will receive simple dietary recommendations based on the Canada's Food Guide. The details of Canada's Food Guide can be available here:~http://www.hc-sc.gc.ca/fn-an/food-guide-aliment/index-eng.php"
3070091|NCT02093767|Active Comparator|7.5g dose Synergy1|7.5 g/day dose of Synergy1 (oligofructose enriched inulin 1:1) for 9 weeks. The daily dose is dispersed in two sachets of 3.75 g each which are consumed at breakfast and dinner
3070092|NCT02093767|Active Comparator|15g Synergy1|15 g/day dose of Synergy1 (oligofructose enriched inulin 1:1) for 9 weeks. The daily dose is dispersed in two sachets of 7.5 g each which are consumed at breakfast and dinner
3070093|NCT02093741||ADVATE - 2mL|
3096721|NCT01914341|Experimental|Music|pentatonic live music
3070094|NCT02093728|Experimental|selumetinib; itraconazole; selumetinib + itraconazole|Volunteers will receive selumetinib 25mg alone; itraconazole 200mg pre-dosing; selumetinib 25mg and itraconazole 200mg; all adminstered by mouth as a capsule
3070095|NCT02093728|Experimental|selumetinib; fluconazole; selumetinib + fluconazole|Volunteers will receive selumetinib 25mg alone administered by mouth as a capsule; fluconazole 400mg and fluconazole 200mg pre-dosing, administered by mouth as a tablet; selumetinib 25mg and fluconazole 200mg.
3070096|NCT02093715||RSV|Infant with acute bronchiolitis due to RSV
3070097|NCT02093715||Co- Infection|Infant with acute bronchiolitis due to RSV and other respiratory virus
3070098|NCT02093715||Other|Infant with acute bronchiolitis due to non-RSV respiratory virus
3070099|NCT02093715||Unknown|Infant with acute bronchiolitis with negative PCR results for respiratory viruses
3070100|NCT02093715||Control|Healthy infants
3070101|NCT02093702|Active Comparator|Unstructured Physical Activity and Exercise Education Delivery|50 subjects will receive the standard approach to physical activity and exercise education from a Certified Diabetes Educator.
3070102|NCT02093702|Experimental|Structured Physical Activity and Exercise Education Delivery|50 subjects will receive physical activity and exercise education and behaviour counseling from a qualified Exercise Specialist (Registered Kinesiologist). These subjects will receive access to a community health and fitness centre as well as exercise instruction and on-going support and motivation from a YMCA Wellness Coach who focuses on establishing healthy behaviors towards the attainment of personal goals. Subjects will be requested to complete a lifestyle questionnaire at each appointment with their Wellness Coach. Subjects will receive a Physical Activity and Exercise Journal that will help them keep track of their weekly physical activity and exercise activities.
3070103|NCT02093689|Experimental|Part 1 OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
3070104|NCT02093689|Experimental|Part 2 OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
3070105|NCT02093689|Placebo Comparator|Part 2 Placebo|Placebo contains 20mM sodium citrate diluted in BSS and administered as irrigation solution.
3070106|NCT02093676|Experimental|parents counseling|parents counseling guided by the experiment protocol
3070107|NCT02093663|Experimental|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the subjects weight<br>&lt;br&gt;-900 mg/day for subjects weighing 18 to less than or equal to 23kg<br>&lt;br&gt;-1200 mg/day for subjects weighing &gt;23 to less than or equal to35kg<br>&lt;br&gt;-1800 mg/day for subjects weighing &gt;35 to less than or equal to 50kg<br>&lt;br&gt;-2400 mg/day for subjects weighing &gt;50 to less than or equal to 90kg.
3070108|NCT02093663|Experimental|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the subjects weight<br>&lt;br&gt;<br>&lt;br&gt;•1800 mg/day for subjects weighing 18 to less than or equal to 23kg<br>&lt;br&gt;•2400 mg/day for subjects weighing &gt;23 to less than or equal to35kg<br>&lt;br&gt;•3600 mg/day for subjects weighing &gt;35 to less than or equal to 50kg<br>&lt;br&gt;•4800 mg/day for subjects weighing &gt;50 to less than or equal to 90kg.
3070109|NCT02093650|Active Comparator|Black cohosh extract|black cohosh extract 80 mg daily
3070110|NCT02093650|Placebo Comparator|Placebo|Matching placebo
3070111|NCT02093637|Placebo Comparator|Placebo acupuncture|Placebo acupuncture up to 5 acupuncture needles* in each ear (up to 10 needles total) at points identified by point-finder to have no electrical conductance) plus usual operative and post-operative care (narcotic and non-narcotic pain medication).
3070112|NCT02093637|Experimental|Battlefield Acupuncture|Usual operative and post-operative care (narcotic and non-narcotic pain medication) plus Battlefield Acupuncture (up to 5 acupuncture needles* in each ear (up to 10 needles total), identified by a point-finder.
3070113|NCT02093637|No Intervention|standard therapy|standard therapy
3070114|NCT02093611|Placebo Comparator|Placebo|This arm will serve as the placebo supplementation.
3070115|NCT02093611|Active Comparator|ATP|This arm will serve as the treatment intervention, ATP
3070116|NCT02093598|Experimental|Temsirolimus|25 mg administered intravenously, infused over a 30- to 60-minute period once weekly for 28 days (Total doses: 4 doses).
3070117|NCT02093585|Experimental|Tenofovir to abacavir|Patients switching from tenofovir (245 mg QD) to abacavir (600 mg QD)
3070118|NCT02093585|Experimental|Abacavir to tenofovir|Patients switching from abacavir (600 mg QD) to tenofovir (245 mg QD)
3070119|NCT02093572|Experimental|Control|Subjects randomized to this group will consume 3 standard meals/day during the 2 week intervention period of the study.
3070120|NCT02093572|Experimental|Breakfast skipping|Subjects randomized to this group will consume 2 meals/day (omit breakfast - with caloric intake equal to consuming 3 meals/day) during the 2 week intervention period of the study.
3070121|NCT02093559|Experimental|Brief Counseling Intervention|The brief counseling intervention will utilize MI and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address HIV risk behaviors and determine readiness for change in substance use.
3070122|NCT02093559|No Intervention|Control Group|The control group will have access to brochures and be offered referral to services requested. SFDPH Community Behavioral Health Services (CBHS) provides immediate access to substance abuse treatment in San Francisco, including office- and clinic-based methadone and buprenorphine treatment. Given the pilot nature of this study, the control group will not be a full attention control; we will account for an attention effect due to assessment alone.
3070123|NCT02093546||Blood Draw and Biopsy|Participant undergoes blood draw and biopsy prior to start of therapy. After 28 days of therapy, a blood draw and an additional biopsy of the same site obtained prior to beginning cycle 2. Blood draw obtained at first tumor assessment point at pre-cycle 3 and at progression. Participants undergo an additional blood draw at 72 hours after initiation of therapy. Participants offered an optional biopsy of the same site at 72 hours after initiation of therapy and at progression of disease. If participant undergoes biopsy at any timepoint during trial as part of standard of care treatment, tissue used for protocol assessment.
3070124|NCT02093533|Experimental|Eculizumab|Patient Body weight ≥40 kg: initial phase 900 mg weekly x 4 and maintenance phase 1200 mg at week 5; then 1200 mg every 2 weeks Patient Body weight 30 - <40 kg : initial phase 600 mg weekly x 2 and maintenance phase 900 mg at week 3; then 900 mg every 2 weeks
3070125|NCT02093520|Active Comparator|MILD|The MILD procedure is an image-guided minimally-invasive lumbar decompression
3070126|NCT02093520|Active Comparator|Epidural Steroid Injection (ESI)|An epidural steroid injection (ESI) is a combination of a corticosteroid with a local anesthetic pain relief medicine.
3070127|NCT02093507|Experimental|parents manipulation|parents manipulation
3070128|NCT02093507|No Intervention|no manipulation|no manipulation
3070129|NCT02093494|Experimental|Initial Specimen Diversion Device (ISDD)|The ISDD will be used to collect the blood culture.
3070130|NCT02093494|Active Comparator|Lab standard practice (LSP)|The ISDD will not be used to collect the blood culture. Standard blood culture specimen collection kits will be utilized.
3070131|NCT02093481|Experimental|+ ind. CHO + prim|Test meal: ate intrinsic indigestible carbohydrates 3 days prior to measurements of variables (priming)
3070132|NCT02093481|Experimental|- ind. CHO + prim|Reference:ate no intrinsic indigestible carbohydrates 3 days prior to measurements of variables (priming)
3070133|NCT02093481|Experimental|+ ind. CHO - prim|Test meal: ate intrinsic indigestible carbohydrates 1 day prior to measurements of variables (no priming)
3070134|NCT02093481|Experimental|- ind. CHO - prim|Reference: ate no indigestible carbohydrates the day prior to measurements of variables (no priming).
3070135|NCT02093468|Placebo Comparator|Saline|Saline administered IV for 12 hours
3070136|NCT02093468|Experimental|Lower Dose|MST-188 loading dose 100 mg/kg IV for 1 hour followed by 25 mg/kg/hr for 11 hours
3070137|NCT02093468|Experimental|Higher Dose|MST-188 loading dose 200 mg/kg IV for 1 hour followed by 75 mg/kg/hr for 11 hours
3070138|NCT02093455|Active Comparator|Chardonnay Seed Flour (CSF)|Prepackaged capsules taken 3 times per day. During the first month, the total dose will be 15 g/d. For months 2-4, the total dose will be 30 g/d.
3070139|NCT02093455|Placebo Comparator|Placebo|Pre-packaged capsules taken 3 times per day. For the first month, a total of 15 g/d. During months 2 - 4, a total of 30 g/d.
3070140|NCT02093442|Experimental|Endometrial injury|Women allocated to this group will be submitted to endometrial injury before undergoing endometrial preparation for embryo transfer.
3070141|NCT02093442|No Intervention|Control|Women allocated to this group will NOT be submitted to endometrial injury before undergoing endometrial preparation for embryo transfer.
3070142|NCT02093429|Experimental|INCB047986 4 mg|Participants will receive INCB047986 4 mg once daily for at least 16 weeks.
3070143|NCT02093429|Experimental|INCB047986 6 mg|Participants will receive INCB047986 6 mg once daily for at least 16 weeks.
3070144|NCT02093429|Experimental|INCB047986 10 mg|Participants will receive INCB047986 10 mg once daily for at least 16 weeks.
3070145|NCT02093416||Group 1: Control Group|BMI <30 There are 20 controls in this group
3070146|NCT02093416||Group 2|BMI 30-35 There were 12 controls in this class
3070147|NCT02093416||Group 3|BMI 35-40 There were 9 controls in this clas
3070148|NCT02093416||Group 4|BMI >40 There were 9 controls in this class
3070149|NCT02093403|Experimental|Treatment (decitabine and selinexor)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10 and selinexor PO on days 11, 13, 18, 20, 25 and 27. Treatment repeats every 31 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive decitabine IV over 1 hour on days 1-5 and selinexor PO on days 6, 8, 13, 15, 20 and 22. Courses repeat every 31 days in the absence of disease progression or unacceptable toxicity."
3070150|NCT02093390|Experimental|TAK-385 + fluconazole|TAK-385 40 mg, tablet, orally once on Day 1 and fluconazole 400 mg, tablet, orally on Day 6 then 200 mg, tablet, orally once daily on Days 7 to 9 followed by a single dose of TAK-385 in combination with fluconazole 200 mg on Day 10 then fluconazole 200 mg, tablet, orally once daily alone on Days 11 to 14.
3070151|NCT02093390|Experimental|TAK-385 + atorvastatin|TAK-385 40 mg, tablet, orally once on Day 1 and atorvastatin 80 mg, tablet, orally once daily on Days 6 to 9 followed by a single dose of TAK-385 in combination with atorvastatin 80 mg on Day 10 then atorvastatin 80 mg, tablet, orally once daily alone on Days 11 to 14.
3070152|NCT02093377|No Intervention|Control|optimal medical therapy for the management of myocardial infarction according to the current guidelines of the European Society of Cardiology alone
3070153|NCT02093377|Active Comparator|Adaptive servo-ventilation|optimal medical therapy for the management of myocardial infarction according to the current guidelines of the European Society of Cardiology plus treatment of sleep apnea with adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia). Dose: The optimal ASV settings will be determined during 1-2 nights monitored by polygraphy within 5 days after PCI.
3070154|NCT02093351|Experimental|Cohort 1 - Tamoxifen|Olaparib-alone Steady state PK, Tamoxifen-alone steady state PK, Combined olaparib and Tamoxifen steady state PK.
3070155|NCT02093351|Experimental|Cohort 2 - Anastrozole|Olaparib-alone Steady state PK, Anastrozole-alone steady state PK, Combined olaparib and Anastrozole steady state PK.
3070156|NCT02093351|Experimental|Cohort 3 - Letrozole|Olaparib-alone Steady state PK, Letrozole-alone steady state PK, Combined olaparib and Letrozole steady state PK.
3070157|NCT02093338|Experimental|fermentum 3x|Lactobacillus fermentum CECT5716 at 3x10e9 cfu/day
3070158|NCT02093338|Experimental|fermentum 6x|Lactobacillus fermentum CECT5716 at 6x10e9cfu/day
3070159|NCT02093338|Experimental|fermentum 9x|Lactobacillus fermentum CECT5716 at 9x10e9cfu/day
3070160|NCT02093338|Placebo Comparator|maltodextrin|maltodextrin
3070161|NCT02093325|Experimental|eltrombpag|Eligible patients will be enrolled randomly in 2:1 ratio to Investigational Drug (Eltrombopag) arm, 50 mg/day, or placebo arm for 7 days.
3070162|NCT02093325|Placebo Comparator|Eltrombopag/placebo|Eligible patients will be enrolled randomly in 2:1 ratio to Investigational Drug (Eltrombopag) arm, 50 mg/day, or placebo arm for 7 days
3070163|NCT02093312|No Intervention|Control group|The control group is not offered any home food-delivery service, but continues with their habitual diet
3070164|NCT02093312|Experimental|Intervention group|The intervention group is offered home food-delivery service
3070165|NCT02093299||Stroke|clopidogrel 75 mg
3070166|NCT02093286||Pentabio Vaccine|1 dose of Pentabio vaccine, 0.5 ml Will be given intramuscularly
3070167|NCT02093273|Active Comparator|tOPV commercial batch (Bio Farma)|tOPV (Bio Farma) one dose correspond to 2 drops (0.1ml)
3070168|NCT02093273|Experimental|tOPV pilot batch|tOPV (Bio Farma), one dose correspond to 2 drops (0.1ml)
3070353|NCT02091986|Active Comparator|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
3070169|NCT02093260|Experimental|Vaccine|"Vaccine~Flubio (Influenza HA) vaccine~2 doses for infants and children (6 months - 8 years old)~1 doses for children (9-11 years old)~The vaccine will be given intramuscularly"
3070170|NCT02093234|Active Comparator|Mobile health care application|Patients will be assisted with managing their health by a cell phone application used to promote self care for patients with diabetes.
3070171|NCT02093234|Active Comparator|Community Health Worker (CHW)|CHWs assist study patients in managing there health care in various ways.
3070172|NCT02093234|Experimental|CHWs and mobile health care application|Patients will receive assistance in managing their health from both CHWs and the mobile health cell phone application
3070173|NCT02093221|Experimental|Alpha1-PI 180 mg/kg/wk, 26 weeks|180 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
3070174|NCT02093221|Experimental|90 mg/kg/wk Alpha1-PI, 26 weeks|90 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
3070175|NCT02093221|Placebo Comparator|Placebo, 26 weeks|Weekly infusions of placebo for 26 weeks.
3070176|NCT02093221|Experimental|180 mg/kg/wk Alpha1-PI, 13 weeks|180 mg/kg weekly infusions of Alpha1-PI for 13 weeks.
3070177|NCT02093221|Experimental|90 mg/kg/wk Alpha1-PI, 13 weeks|90 mg/kg weekly infusions of Alpha1-PI for 13 weeks
3070178|NCT02093221|Placebo Comparator|Placebo, 13 weeks|Weekly infusions of placebo for 13 weeks.
3070179|NCT02093195|Experimental|Bosentan|Bosentan,125mg,po,bid combined with inhaled Symbicort turbuhaler, 320/9μg, bid.
3070180|NCT02093195|Active Comparator|Control|Inhaled Symbicort turbuhaler, 320/9μg, bid.
3070181|NCT02093169|Experimental|Part A: Lu AF35700|
3070182|NCT02093169|Experimental|Part B: Lu AF35700|
3070183|NCT02093156||training cohort|the training cohort was used to establish the bowel preparation score (BPS)
3070184|NCT02093156||validation cohort|the validation cohort was used to verify the BPS (bowel preparation score)
3070185|NCT02093143|Experimental|Remifentanil|"The general anesthesia during the diagnostic panendoscopy of the upper airway will associate the target controlled infusion of propofol (pharmacologic model of Schnider et al.) and of remifentanil (pharmacologic model of Minto et al.) in the remifentanil group.~The arm will be randomized prior to the beginning of the surgical procedure and blinded to the investigator and to the practitioner in charge of the patient.~Two milligrams of remifentanil will be diluted in 40 cc of sodium chloride 0,9% in a 50 ml syringe."
3070186|NCT02093143|Placebo Comparator|Placebo|"The general anesthesia during the diagnostic panendoscopy of the upper airway will consist in the target controlled infusion of propofol alone (pharmacologic model of Schnider et al.) in the placebo group.~The placebo is a 40 ml sodium chloride 0,9% solution in a 50 ml syringe. No one can distinguish the syringe of placebo from the syringe of remifentanil."
3070187|NCT02093130|Experimental|Pomegranate Juice|Eight ounces of 100% Pomegranate Juice daily
3070188|NCT02093130|Placebo Comparator|Placebo|Eight ounces of Placebo juice daily. The Placebo is engineered to look and taste the same as the Pomegranate Juice and contains the same vitamins and minerals as the Pomegranate Juice. Because the Placebo juice does not come from actual pomegranates, it does not contain the polyphenols contained in the Pomegranate Juice.
3070189|NCT02093117|Experimental|Recruitment maneuver|The recruitment maneuver will involve application of continuous positive airway pressure of 30 cm of water for 30 seconds.
3070190|NCT02093117|Sham Comparator|Sham recruitment maneuver|The sham recruitment maneuver will involve application of continuous positive airway pressure of 5 cm of water for 30 seconds.
3070191|NCT02093091|Sham Comparator|Vitremer|Dental caries was removed from primary molars and was filled with the conventional filling material;Vitremer (n = 30). The right molars was always filled by Vitremer. A split-mouth design was used in the present clinical trial. Twenty nine children were involved in the present study and every one had one bilateral identical pair of carious molars except one child that had two identical pairs. This design was performed to enhance the accuracy of the present study.
3070192|NCT02093091|Active Comparator|Ketac Nano|Dental caries was removed from primary molars and was filled with the recent filling material; Ketac Nano (n=30). The left molars was always restored with Ketac Nano filling material.
3070193|NCT02093078||CARD|"Intervention: CARD~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
3070194|NCT02093078||Control Arm|
3070195|NCT02093052|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up - 10 session intervention to enhance nurturance and following the lead
3070196|NCT02093052|Active Comparator|Developmental Education for Families|Developmental Education for Families - 10 session intervention that targets cognitive development
3070197|NCT02093052|No Intervention|Low-risk|Low-risk comparison group
3070198|NCT02093039|Experimental|Decision aid group|Women allocated to the decision aid group received an invitation to participate in the national breast cancer screening program and the specially-designed decision aid (a leaflet), by mail.
3070199|NCT02093039|No Intervention|Control group|Women in the control group received an invitation and the usual standard information by mail.
3070200|NCT02093026|Experimental|Rituximab|Participants will receive rituximab 1 gram intravenously (IV) on Days 1 and 15 of each course of retreatment. In addition, participants will receive methotrexate 10-25 milligrams per week (mg/week) orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid greater than or equal to (>=) 5 mg/week or equivalent. Participants will receive retreatment (next course of rituximab repeat treatment) within 2 weeks of meeting the retreatment criteria as defined in the protocol (minimum of 24 weeks after the first [Day 1] infusion of the last course of rituximab). Repeat treatment will be based on the investigator's decision of prior clinical response to rituximab, clinical need and evidence of active disease (Disease Activity Score in 28 joints >=2.6). Retreatment with rituximab will be continued until withdrawal of consent or study treatment completion on 31 December 2011, whichever is sooner.
3070201|NCT02093013|Experimental|Integrated care program|
3070202|NCT02093013|No Intervention|Control group|This group kept receiving usual care from their health care professionals.
3070203|NCT02093000||Bevacizumab|Participants who have received the induction phase of 4-6 cycles of bevacizumab plus platinum doublet chemotherapy will be treated with bevacizumab as maintenance treatment, according to approved label and local reimbursement.
3070204|NCT02092987|Experimental|NYU Caregiver Intervention|"The first component consists of 2 individual and 4 family counseling sessions. These sessions last between 1 and 1.5 hours. The second component of the intervention is participation in a caregiver support group . The third component of the treatment is ad hoc counseling. New psychiatric and behavioral problems of patients, which are generally more stressful than the need for assistance with activities of daily living or physical limitations, often precipitate ad hoc calls from caregivers."
3070205|NCT02092987|Active Comparator|REACH OUT|All aspects of the REACH OUT Intervention involve problem solving techniques and the development of written action plans. The goal of this intervention is to engage the caregiver in joint problem-solving with the objective of creating a written action plan targeting specific caregiving problems. The basic steps of problem solving are: 1.Define the problem. 2. Set goals 3. Brainstorm with caregiver and List possible solutions on a pad of paper, 4. Select solutions, 5. Develop an action plan based on these solutions, 6. Implement the action plan, track progress, and make adjustments as needed.
3070206|NCT02092974|Experimental|tDCS + SSRI|
3070207|NCT02092974|Placebo Comparator|tDCS + placebo|
3070208|NCT02092974|Sham Comparator|sham-tDCS + SSRI|
3070209|NCT02092974|Placebo Comparator|sham-DCS + placebo|
3070210|NCT02092961|Experimental|Dosing Group A|Oral treatment and subcutaneous injection.
3070211|NCT02092961|Active Comparator|Dosing Group D|Oral treatment and subcutaneous injection.
3070212|NCT02092961|Placebo Comparator|Dosing Group E|Placebo bid for 6 weeks followed by switch to 100 mg fostamatinib bid for 24 weeks, plus placebo subcutaneous injection every 2 weeks.
3070213|NCT02092948|Experimental|All patients|Patients will receive one intravenous dose of 4 mg, 20mg or 40 mg of A11 minibody labeled with 5 mCi (185 MBq) of 124I, followed by [124I] PSCA-Minibody PET/CT imaging of the whole body.
3070214|NCT02092935|Experimental|SMT19969|200 mg capsule of SMT19969 twice a day for 10 days with alternating 200 mg placebo twice a day
3070215|NCT02092935|Active Comparator|Vancomycin|125 mg capsule four times a day for 10 days
3070216|NCT02092922|Experimental|Filanesib|
3070217|NCT02092909|Experimental|IMO-8400 at escalating dose levels|IMO-8400 at escalating dose levels by subcutaneous injection
3070218|NCT02092896|Placebo Comparator|Placebo + Insulin + Study 2|Study 2: Cognitive performance test
3070219|NCT02092896|Experimental|Liraglutide + Insulin + Study 2|Study 2: Cognitive performance test
3070220|NCT02092896|Experimental|Liraglutide + Insulin + Study 1|Study 1: Gastric emptying test
3070221|NCT02092896|Placebo Comparator|Placebo + Insulin + Study 1|Study 1: Gastric emptying test
3070222|NCT02092883|Experimental|Infantile Spasms|
3070223|NCT02092870|Experimental|Treatment of Chronic Wound|Patients will receive a single treatment with ASCs in the form of multiple injections of cells within and immediately surrounding the wound. Cells will be delivered using a 1 cc syringe with an appropriate gauge and length needle. Each injection will have a volume less than 250 micro-liters. The number of injections will be determined by the surgeon as a function of total wound volume.
3070224|NCT02092857|Active Comparator|34 mg/100 kcal arachidonic acid|10 weeks exclusive feeding with infant formula containing 34 mg/100 kcal of arachidonic acid
3070225|NCT02092857|Active Comparator|25 mg/100 kcal arachidonic acid|10 weeks exclusive feeding with infant formula containing 25 mg/100 kcal of arachidonic acid
3070226|NCT02092857|Placebo Comparator|Infant formula without arachidonic acid|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
3070227|NCT02092844|Experimental|CBT for Menopausal Insomnia (CBTMI)|CBTMI is a combination of Cognitive Behavioral Therapy for Insomnia (CBTI) and Cognitive Behavioral Therapy for Hot Flashes (CBTH).
3070228|NCT02092844|Placebo Comparator|Enhanced Treatment as Usual|In the Enhanced Treatment as Usual/Information Control group, participants continue with clinical care of their choosing, but will be enhanced by the provision of 3 American Academy of Sleep Medicine (AASM) brochures.
3070229|NCT02092831|Experimental|Crossover sequence 1|
3070230|NCT02092831|Experimental|Crossover sequence 2|
3070231|NCT02092831|Experimental|Crossover sequence 3|
3070232|NCT02092831|Experimental|Crossover sequence 4|
3070233|NCT02092818||Group 1|Patients who have been prescribed Adempas for a medically appropriate use
3070234|NCT02092805|Sham Comparator|Sham rTMS|Sham-rTMS was applied using the same parameters but with the coil elevated and angled away from the head to reproduce some of subjective sensation of rTMS.
3070235|NCT02092805|Active Comparator|Real rTMS|The active group recieved real-rTMS over the motor cortical area corresponding to the hand of painful side. Each train consist of 2000 pulses at 20 Hz and 80% RMT (total duration 10s). The treatment was repeated every day for 5 consecutive days in week for two weeks (the total number of sessions had be given was 10 sessions).
3070236|NCT02092792|Experimental|Dose-Escalation Phase|
3070237|NCT02092792|Experimental|Dose-expansion cohort|
3070238|NCT02092779||Obese patients, no treatment|
3070239|NCT02092766|Experimental|IV artesunate|Intravenous artesunate 2.4 mg/kg body weight STAT, then 2.4 mg/kg at 12, 24, 48 and 72 hours (5 doses total)
3070240|NCT02092766|Active Comparator|IV quinine|Intravenous quinine dihydrochloride 20 mg salt/kg body weight loading dose over 4 hours, then 10 mg/kg over 2 hours 8 hourly until 72 hours (9 doses total)
3070241|NCT02092753|Placebo Comparator|Standard diet|Standard diet (SD): Nutrition following the standard recommendations of the German society for nutrition
3070242|NCT02092753|Experimental|Ketogenic diet|"Nutritional intervention: Ketogenic diet (KD).~Intervention: Nutritional support (hospital) + self support (outpatient phase) with KD"
3070243|NCT02092753|Experimental|Logi diet|"Nutritional intervention: low glycämic and insulinemic diet (LOGI)~Intervention: Nutritional support (hospital) + self support (outpatient phase) with LOGI"
3070244|NCT02092740||Seminoma|Seminoma
3070245|NCT02092740||Non-Seminoma|Non-Seminoma
3070246|NCT02092727|No Intervention|Control|Standard of care arm will receive no specific interventions, but will have access to standard educational materials and quality improvement through End Stage Renal Disease Network 6.
3070248|NCT02092714||Ancillary-correlative (molecular analysis)|Previously collected tissue samples are analyzed via mutational sequencing and immunohistochemistry.
3070249|NCT02092701|Experimental|cholecalciferol|
3070250|NCT02092688||Study group|Study group: women between 24 and 36 6/7 weeks of gestation that present with self-reported signs, symptoms or complaints suggestive of preterm labor
3070251|NCT02092688||Control group|Control group: women between 24 and 36 6/7 weeks of gestation without signs or symptoms of PTL
3070252|NCT02092675||COPD patients - frequent exacerbator|COPD patients with 2 and more exacerbation in one year
3070253|NCT02092675||COPD patients - non frequent exacerbator|COPD patients with less than 2 exacerbation during one year
3070254|NCT02092675||control group - healthy smokers|healthy smokers, they do not have COPD
3070255|NCT02092662||Stroke|Stroke patients at the subacute phase
3070256|NCT02092662||Healthy controls|healthy age-matched voluntiers
3070257|NCT02092649|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
3070258|NCT02092649|Placebo Comparator|Placebo Pill|Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.
3070259|NCT02092636|Experimental|NIR/US Diagnostic Group|These patients will include women who have breast lumps/lesions visible by ultrasound and are prescribed follow up with an ultrasound-guided biopsy at the UCHC Cancer Center for evaluation and diagnosis of actual/suspected breast abnormalities.
3070260|NCT02092636|Experimental|NIR/US Neoadjuvant Chemotherapy Group|These patients will include women who have breast lumps/lesions visible by ultrasound and have been diagnosed with breast cancers and will undergo neoadjuvant chemotherapy. These patients may be identified from the diagnostic group or after initial diagnosis. Patients will only be enrolled to one of the two groups.
3070261|NCT02092636|Other|NIR/US Process Validation Group|This group will contain data from about five women who did not have ultrasound visible lumps on the day of the planned biopsy. Data from the NIR/US scan will be used to validate instrument measurements.
3070262|NCT02092623|Other|Transvaginal posterior mesh surgery|All study patients undergo transvaginal mesh operation.
3070263|NCT02092610|Active Comparator|Standard Implant BI300|The product was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
3070264|NCT02092610|Experimental|Novel Implant BI300|The product was the novel titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
3070265|NCT02092597|Active Comparator|GLP-1 agonist|Exenatide 5 ug s.c. bid for the 1st month, 10 ug s.c. bid for the next 2 months
3070266|NCT02092597|Active Comparator|DPP-4 inhibitor|Linagliptin 5 mg tbl qd for 3 months
3070267|NCT02092597|Active Comparator|Sulfonylurea derivate|Gliclazid 30 mg tbl qd for 3 months
3070268|NCT02092584|Active Comparator|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
3070269|NCT02092584|Placebo Comparator|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
3070270|NCT02092571|Experimental|Treatment A|1 ring intravaginal for 7 days, produced from the new process
3070271|NCT02092571|Experimental|Treatment B|1 ring intravaginal for 7 days, produced from the legacy process
3070272|NCT02092558||Female 1|Owing to the absence of an established treatment modality for squamous metaplasia of the urinary bladder in children, we developed our own treatment modalities. Children presenting with recurrent urinary tract infections on medical interview, were subjected to ultrasonography of the urinary system, repeated urinalysis, and urine culture tests. Then, on the basis of antibiogram findings, antibiotic and chemotherapeutic treatment was administered to eliminate the bacteriological factors. Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months.
3070273|NCT02092558||Male 2|Owing to the absence of an established treatment modality for squamous metaplasia of the urinary bladder in children, we developed our own treatment modalities. Children presenting with recurrent urinary tract infections on medical interview, were subjected to ultrasonography of the urinary system, repeated urinalysis, and urine culture tests. Then, on the basis of antibiogram findings, antibiotic and chemotherapeutic treatment was administered to eliminate the bacteriological factors. Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months.
3070274|NCT02092545|Other|Ketogenic diet|Weight management on a male population of retired NFL athletes.
3070275|NCT02092532|Other|Intravitreal Aflibercept Injection|All patients will receive monthly IAI 2.0 mg intravitreally for 3 months (Baseline, Months 1 and 2), followed by mandatory IAI 2.0 mg every 2 months (Months 4, 6, 8 and 10) for 12 months.
3070276|NCT02092519|Active Comparator|Needle without sideport (NA-220H-8022)|EUSFNA using needle without sideport (NA-220H-8022)
3070277|NCT02092519|Active Comparator|Needle with sideport (NA-230H-8020)|EUSFNA using needle with sideport (NA-230H-8020)
3070278|NCT02092506|Active Comparator|triple therapy|10 day triple therapy (PPI, amoxicillin 1g, clarithromycin 500mg twice daily)
3070279|NCT02092506|Active Comparator|Concomitant therapy|10-day concomitant therapy (PPI, amoxicillin 1g, clarithromycin 500mg, metronidazole 400mg twice daily).
3070280|NCT02092506|Active Comparator|sequential therapy|10-day sequential therapy (PPI and amoxicillin 1 g twice daily x 5 days followed by PPI, clarithromycin 500mg, metronidazole 400mg twice daily x 5days)
3070281|NCT02092493|No Intervention|Non-ScopeGuide|This arm will have patients undertaking the procedure without ScopeGuide. All outcome measures will be recorded as usual
3070282|NCT02092493|Experimental|ScopeGuide|Patients have their colonoscopy done with ScopeGuide
3070283|NCT02092480|Experimental|Intervention|After baseline data collection, four schools will be randomly assigned to the intervention arm, those receiving the If I Were Jack programme. RSE teachers will deliver the intervention to all participating Year 11 pupils during four weekly lessons of the 'Learning for Life and Work' strand of the Key Stage 4 curriculum.
3070284|NCT02092480|No Intervention|Control|After baseline data collection, three schools will be randomly assigned to the control arm. Participating pupils will not receive the If I Were Jack intervention and will continue with normal RSE practice.
3070287|NCT02092467|Active Comparator|Treatment Arm 3|TNF inhibitor Arm - adalimumab will be used in US, Canada and Puerto Rico; etanercept will be used in all other countries.
3070288|NCT02092454|Experimental|Benzocaine|Topical otic solution, every 1-2 hours, for up to 3 days
3070289|NCT02092454|Placebo Comparator|Placebo|Topical otic solution, every 1-2 hours, for up to 3 days
3070290|NCT02092441|Active Comparator|Alcohol prep pad group|isopropyl alcohol prep pad
3070291|NCT02092441|Placebo Comparator|Normal Saline prep pad|normal saline prep pad
3070292|NCT02092428|Experimental|Image Quality|Healthy volunteers and patients will undergo non-contrast MRI or contrast-enhanced MRI to compare image quality between contrast and non-contrast scans.
3070293|NCT02092428|Experimental|Diagnostic Accuracy|Healthy volunteers and patients will undergo non-contrast MRI or contrast-enhanced MRI to assess the diagnostic accuracy of coronary MRI in detecting CAD as compared to conventional x-ray angiography
3070294|NCT02092415|Experimental|Normal subjects|Normal subjects, all of whom undergo brief application of junctional tourniquet
3070295|NCT02092402|Placebo Comparator|Fecal transplantation of own stool|Autologous fecal transplantation (own stool)
3070296|NCT02092402|Experimental|Fecal transplantation (stool from donor)|Allogeneic fecal transplantation (from donor)
3070297|NCT02092389||Moderate to Severe Ulcerative Colitis|Patients with moderate to severe ulcerative colitis (UC) who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant (azathioprine [AZA]/ 6-mercaptopurine [6-MP]); or who are intolerant to or have medical contraindications for such therapies and are hence prescribed adalimumab for the treatment of moderate to severely active UC.
3070298|NCT02092376|Active Comparator|Intervention|The loading dose of 300 000 IU is divided into three doses (100 000 IU) and will be given over the first months. All patients in the intervention group will receive the first loading dose of 100 000 IU at day of discharge. The second (2 weeks) and third (4 weeks postoperative) administration will be given based on the 25-hydroxy vitamin D concentration. After the last respectively third loading dose a maintenance dose of 3420 IU per day should maintain the high 25-hydroxy vitamin D concentration. It should be administered for up to 46 weeks (until follow-up visit)
3070299|NCT02092376|Placebo Comparator|Placebo|The placebo loading dose (oil) is divided into three administrations and will be given over the first months. All patients in the placebo group will receive the first placebo loading dose at day of discharge. After the last placebo loading dose a maintenance dose of 3420 IU per day should maintain the 25-hydroxy vitamin D concentration. It should be administered for up to 46 weeks (until follow-up).
3070300|NCT02092363|Experimental|Drug: OMP-54F28, Paclitaxel and Carboplatin|
3070301|NCT02092350|Experimental|Immediate Treatment|Participants receive grazoprevir 100 mg tablet, orally, once per day (QD) + elbasvir 50 mg tablet, orally, QD, for 12 weeks.
3070302|NCT02092350|Experimental|Deferred Treatment|Participants receive placebos to both grazoprevir and elbasvir for 12 weeks, and after a 4-week break, grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks.
3070303|NCT02092350|Experimental|Intensive PK|Participants receive grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks with intensive PK testing.
3070304|NCT02092337|Experimental|computer assisted speech training|computer assisted speech training
3070305|NCT02092324|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO every other day, QD, or BID on days 1-28. Each patient will be followed for a maximum of 96 weeks (24 cycles, 1 cycle is 4 weeks long). If the study drug continues to be effective, the patient may be eligible to continue on study drug past 24 cycles.
3070306|NCT02092311|Experimental|Combined Microscopic Varicocelectomy|Patients in this arm were operated with Combined Mini-incision Microscopic approach
3070307|NCT02092311|Active Comparator|Inguinal and Subinguinal Varicocelectomy|Patients in this arm have the same including criteria as Experimental arm but they were operated with conventional and currently popular approach of Microscopic Inguinal and Sub inguinal varicocelectomy suggested by Goldstien and associates
3070308|NCT02092298|Experimental|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Laparoscopic HIPEC consists of Mitomycin C 30 mg and Cisplatin 200 mg for 60 minutes, performed 2-8 weeks after completion of systemic chemotherapy. Loading dose Sodium Thiosulfate 7.5 gm/M2 infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by infusion pump over 12 hours.
3070309|NCT02092285|Experimental|Golimumab|The first induction dose of subcutaneous (SC) golimumab 200 mg was administered at Day 0. The second induction dose of SC golimumab 100 mg was administered two weeks later at Week 2. Responders at Week 6 received a maintenance dose of golimumab (50 mg for participants with a body weight <80 kg or 100 mg for participants with a body weight ≥80 kg) every 4 weeks during the Maintenance Phase for 48 weeks, yielding a total of 54 weeks treatment.
3070310|NCT02092272|Experimental|instructional exercise video source|instructional exercise video source
3070311|NCT02092272|No Intervention|Standard Therapy|Standard Therapy
3070312|NCT02092246|Active Comparator|Ultrasound Machine Guided Injection|Use of ultrasound machine guidance in needle placement into the knee joint
3070313|NCT02092246|Active Comparator|Unguided Injection|Needle placement performed without ultrasound machine guidance
3070314|NCT02092233||Blinded, Prospective Arm|The diagnostic accuracy for lesions from individuals suspected of having a herpes infection will be evaluated in prospectively collected, left-over de-identified, clinical specimens accrued between pre-defined dates.
3070315|NCT02092233||Blinded, Pre-selected Arm|For specimen types that are less common, banked, pre-selected, positive clinical specimens will be tested.
3070316|NCT02092220|Experimental|Bionic Pancreas|Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.
3070317|NCT02092220|Active Comparator|Usual Care|Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.
3070318|NCT02092207|Experimental|KL7016 900mg|
3070319|NCT02092207|Placebo Comparator|Placebo|
3070320|NCT02092207|Experimental|KL7016 600mg|
3070321|NCT02092194|Active Comparator|Standard Dose online HDF|Proposed target convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
3070322|NCT02092194|Experimental|High Dose online HDF|Proposed target convection volume; 33-43 L/treatment (140-180 mL/min).
3070323|NCT02092181|Active Comparator|Mirabegron|1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 md daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or , for those in the placebo arm, two placebo tablets.
3070324|NCT02092181|Placebo Comparator|Placebo|1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 md daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or , for those in the placebo arm, two placebo tablets.
3070325|NCT02092168|Experimental|BIA 9-1067 30 mg (once daily) - Elderly Subjects|BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
3070326|NCT02092168|Experimental|BIA 9-1067 30 mg (once daily) - Young Subjects|BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
3070327|NCT02092155||Indwelling tunneled pleural catheter|
3070328|NCT02092142|Experimental|Vaccinated|The vaccine will be administered subcutaneously in the upper outer aspect of the arm (triceps area) with 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 (which equals 30 μg)
3070329|NCT02092129||Acromegaly|Patients with acromegaly who have received surgical treatment
3070330|NCT02092116|Other|Part A|"Pre-treatment phase of 2-4 weeks (Visit 1- Visit 2a) followed by viral reactivation phase of 3 weeks (Visit 2 to Visit 7) consisting of one cycle of romidepsin infusions at a dosing of 5 mg/m2 on days 0, 7, and 14.~Post-activation phase of ~9 weeks (Visit 8 to Visit 11) to assess the effect of romidepsin on the size of latent HIV-1 reservoir."
3070331|NCT02092116|Other|Part B|"Pre-treatment phase of 2-4 weeks (Visit 1-Visit 2) followed by a therapeutic HIV-1 immunization phase of 12 weeks (Visit 2 to Visit 7) in which 1.2 mg Vacc-4x was administered together with 0.06 mg rhuGM-CSF at Visits 2, 3, 4, 5, 6 and 7 follow by a follow-up period of 2 weeks (Visit 8).~A viral reactivation phase of 3 weeks (Visit 9-Visit 11) consisting of one cycle of 3 romidepsin infusions (5 mg/m2) followed by a post-treatment observation phase of ~9 weeks (Visit 12-Visit 13) to assess the effect of the investigational treatment on the size of the latent HIV-1 reservoir.~A monitored antiretroviral pause of up to 16 weeks (Visit 14-Visit 33)."
3070332|NCT02092103|No Intervention|Delayed Clamping|"The American Congress of Obstetricians and Gynecologists (ACOG) recommends delayed cord clamping for preterm infants. Infants randomized to this group will follow the protocol below:~Infant held at or below level of perineum (vaginal delivery) or incision (cesarean delivery)~Once infant is delivered designated RN starts timer~Infant warming bag on delivery table~Infant placed into warming bag then wrapped in a towel~Assistant to deliver preps cord clamps~Registered Nurse (RN) notifies provider at 30 seconds~Cord clamped and cut~Infant handed off to waiting staff~Exceptions: Placental separation, cord stops pulsating, need for immediate resuscitation, all would result in clamping prior to 30 seconds"
3070333|NCT02092103|Experimental|Cord Milking|"Infants randomized to the cord milking group will follow the protocol below:~Infant held at or below level of perineum (vaginal delivery) or incision (cesarean delivery)~Infant held and the cord is milked from perineum to infant four times~Assistant to deliver preps cord clamps~Cord clamped and cut~Infant handed off to waiting staff"
3070334|NCT02092090|No Intervention|Control|Dietary advice at baseline only
3070335|NCT02092090|Experimental|Dietary sodium reduction|Dietary advice and reduced-sodium added-potassium salt substitute
3070336|NCT02092077|Experimental|TV-1106 0.554 mg|
3070337|NCT02092077|Experimental|TV-1106 0.924 mg/kg|
3070338|NCT02092077|Experimental|TV-1106 1.20 mg/kg|
3070339|NCT02092077|Active Comparator|somatropin 0.033 mg/kg/day|Dosages may be adjusted according to findings and as necessary
3070340|NCT02092051|Experimental|Continuous glucose monitoring|Continuous glucose monitoring with DexCom G4 platina during 6 months
3070341|NCT02092051|No Intervention|Conventional therapy|Conventional therapy during 6 months using only SMBG for glucose monitoring
3070342|NCT02092038|Experimental|Preoperative chemoradiation|Stereotactic biopsy of brain tumor, then partial brain irradiation and temozolomide, followed by craniotomy and tumor resection, followed by temozolomide
3070343|NCT02092025||Azilsartan 20mg to 40mg, orally, once daily|
3070344|NCT02092012|Active Comparator|dexketoprofen trometamol|ıv 50 mg dexketoprofen trometamol after anesthesia induction
3070345|NCT02092012|Active Comparator|dexmedetomidine|ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
3070346|NCT02091999|Experimental|Part A enfortumab vedotin Dose Escalation (Dose Levels 1-4)|All subjects will receive a single 30 minute intravenous (IV) infusion of enfortumab vedotin once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
3070347|NCT02091999|Experimental|Part B enfortumab vedotin Renal Insufficiency Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at a dose level below and escalated up to the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
3070348|NCT02091999|Experimental|Part B enfortumab vedotin NSCLC Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
3070349|NCT02091999|Experimental|Part B enfortumab vedotin Ovarian Cancer Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
3070350|NCT02091999|Experimental|Part C enfortumab vedotin CPI Treated Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15). A cycle is 4 weeks. Subjects will continue treatment until disease progression, intolerability of enfortumab vedotin, Investigator decision or consent withdrawal.
3070351|NCT02091986|Active Comparator|Symbicort pMDI 80/2.25 µg|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
3070352|NCT02091986|Active Comparator|Symbicort pMDI 80/4.5µg|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
3070356|NCT02091960|Experimental|Enzalutamide + Trastuzumab|Participants received 160 mg enzalutamide orally once daily and 6 mg/kg trastuzumab administered by intravenous infusion or subcutaneous injection every 21 days. Participants continued on treatment until disease progression, unacceptable toxicity or any other discontinuation criteria were met.
3070357|NCT02091947|Experimental|experimental group|Real FMS, 5 Hz, 20 minutes per day, for 10 weekdays.
3070358|NCT02091947|Sham Comparator|sham group|sham FMS, 5 Hz, 20 min per day, for 10 weekdays.
3070359|NCT02091934|Active Comparator|Wavefront-guided PRK|Wavefront-guided PRK
3070360|NCT02091934|Active Comparator|Wavefront-optimized PRK|Wavefront-optimized PRK
3070361|NCT02091921|Experimental|Experimental|All subjects will receive study drug.
3070362|NCT02091908|Experimental|Arm 1: aH5N1 adult|aH5N1 healthy and non-healthy adults
3070363|NCT02091908|Experimental|Arm 2: aH5N1 elderly|aH5N1 healthy and non-healthy elderly
3070364|NCT02091908|Active Comparator|Arm 3: aTIV adult|aTIV healthy and non-healthy adults
3070365|NCT02091908|Active Comparator|Arm 4: aTIV elderly|aTIV healthy and non-healthy elderly
3070366|NCT02091895|Experimental|endo group|colon polyp, early colon cancer, colorectal submucosal tumor, ileocecal ulcers
3070367|NCT02091882|Experimental|MIND1 System|
3070368|NCT02091869|Experimental|Paper Asthma Action Plan|Participants will utilize a paper-based asthma action plan to record asthma symptoms, peak flows, and medication usage.
3070369|NCT02091869|Experimental|Mobile Phone|Participants will record asthma symptoms, medication usage, and peak flow data on their phones.
3070370|NCT02091856|Experimental|Conventional-CBT (C-CBT)|This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the mindfulness paradigm.
3070371|NCT02091856|Experimental|Religious CBT (R-CBT)|This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the general Christian belief.
3070372|NCT02091856|No Intervention|Wait List Control Group (WLCG)|This arm represents the wait-list comparison group.
3070373|NCT02091843|Experimental|DBS of the Amygdala-30 days|Deep brain stimulation of the amygdala BLn starting at 30 days post-operatively.
3070374|NCT02091843|Experimental|DBS of the Amygdala-90 days|Deep brain stimulation of the amygdala BLn starting at 90 days post-operatively.
3070375|NCT02091830||Non-surgical treatment|
3070376|NCT02091817|Other|Control group|Control group will be administered oxytocin and placebo, in a double-blind randomized order.
3070377|NCT02091817|Experimental|congenital prosopagnosia|Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.
3070378|NCT02091804|Active Comparator|Wait-List group|Individuals randomized to the control group will receive the intervention program immediately after their 3-month research visit.
3070379|NCT02091804|Experimental|Immediate Group|Individuals randomized to the Immediate group will receive the intervention program immediately after completing the baseline assessment.
3070380|NCT02091791|Experimental|LT10|"Long duration (30 minutes) traction sessions of low force (10% of body weight) for 2 weeks (5 sessions/week)."
3070381|NCT02091791|Experimental|LT50|"Long duration (30 minutes) traction sessions of high force (50% of body weight) for 2 weeks (5 sessions/week)."
3070382|NCT02091778|Experimental|Fast Gelling Dressing|
3070383|NCT02091765|No Intervention|Minimal intervention control group|Women who are assigned to the control group will be contacted by telephone by a member of the study staff to inform them about this allocation. They will receive a booklet per mail that addresses 80 questions about sexuality and cancer. Six weeks later, they will receive an empathetic phone call from one of the sexologists, during which there is also time available to discuss further questions the participants may have concerning sexuality and cancer. The purpose of keeping in contact with the control group, as opposed to a pure waiting list control group, is creating the opportunity to provide some control for a possible attention placebo-effect. The final questionnaire will be completed twenty weeks post study entry, after which women will be given the opportunity to undergo the internet-based cognitive behavioral program.
3070384|NCT02091765|Experimental|Internet-based cognitive behavioral therapy|"Each woman who is allocated to the intervention group is assigned a personal sexologist (therapist) who guides her through the internet-based cognitive behavioral therapy (CBT) program and provides feedback on the homework assignments. The CBT program comprises a maximum of ten treatment modules that can be used in varying order. Each module contains three interventions and a personal evaluation form to report on the intervention. Each intervention comprises the following elements: 1) introduction, 2) psycho-education about symptoms, 3) homework assignments (e.g. relaxation techniques (pelvis); discuss intimacy with partner; sensate focus) and 4) reporting back to the therapist and receiving feedback on the homework assignments. Each week there are two practice sessions of 30 minutes each and one hour per week to report on/evaluate the intervention. The therapy has a mean duration of 20 weeks."
3070385|NCT02091752|Experimental|Ruxolitinib|All participants received ruxolitinib.
3070386|NCT02091739|Experimental|IncobotulinumtoxinA (Xeomin) (100 Units)|"Main period (1 treatment cycle): Subjects to receive 100 Units.~Extension period (3 treatment cycles): Subjects to receive 100 Units per treatment cycle.~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
3070387|NCT02091739|Experimental|IncobotulinumtoxinA (Xeomin) (75 Units)|"Main period (1 treatment cycle): Subjects to receive 75 Units.~Extension period (3 treatment cycles): Subjects to receive 75 Units per treatment cycle.~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
3070388|NCT02091739|Placebo Comparator|Placebo|"Main period (1 treatment cycle): Subjects to receive placebo injection.~Extension period (3 treatment cycles): Subjects will be randomized to receive either 75 or 100 Units IncobotulinumtoxinA per treatment cycle.~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
3070389|NCT02091726|Experimental|Unicirc with tissue adhesive|Circumcision with Unicirc instrument, followed by wound sealing with cyanoacrylate
3070390|NCT02091713||Experimental/Functional movement screen|300 subjects from three different combat units will undergo functional movement screening
3070391|NCT02091700||Normals|Subjects with normal visual and retinal function will be enrolled
3070392|NCT02091674|Experimental|Hyaluronic acid|All subjects administered hyaluronic acid
3070393|NCT02091661|Active Comparator|Radical retropubic prostatectomy|The surgery arm underwent radical retropubic prostatectomy, performed by a technique described by Walsh.surgery started with dissection of the pelvic lymph nodes. If there were no signs of metastasis in frozen sections, the operation was continued with retropubic radical prostatectomy. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible. The degree to which the surgeon preserve the nerves is categorized as non-nerve-sparing, unilateral nerve-sparing, or bilateral nerve-sparing.The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 6 to 9 days to facilitate bladder emptying.
3070394|NCT02091661|Active Comparator|External beam radiotherapy|External beam radiotherapy is carried out with intensity-modulated radiation technique. The treatment is designed to maximize the radiation dose to the prostate and seminal vesicles and minimize exposure to surrounding structures, including the bladder and rectum. Radiation to the prostate was delivered in fractionated doses divided over multiple treatments (180 to 200 centigray (cGy) daily fractions, 5 days per week) for a total dose to the prostate of 68 to 77 gray (Gy), prescribed at 90% to 100% of the isodose line.
3070395|NCT02091648|Experimental|I Can Cope Intervention|"Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques."
3070396|NCT02091648|Active Comparator|Standard Education Intervention|"this group will receive the standard American Lung Association Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute recommendations for asthma education."
3070397|NCT02091648|No Intervention|No treatment control|"This group will receive no treatment during the course of the study and will have the option to receive the Open Airways program after their participation in the study is complete."
3070398|NCT02091635|Active Comparator|Motilitone|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
3070399|NCT02091635|Placebo Comparator|Placebo (for Motilitone)|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
3070400|NCT02091622|Other|Educative intervention|Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses.
3070401|NCT02091622|No Intervention|No intervention|No intervention.
3070402|NCT02091609|Experimental|group : implants and oral hygiene|dental floss
3070403|NCT02091609|Experimental|implants and oral hygiene|dental interproximal brush
3070404|NCT02091596|Placebo Comparator|PluroGel|PluroGel
3070405|NCT02091596|Experimental|PluroGel N|PluroGel N
3070406|NCT02091583|Placebo Comparator|Butter, sunflower and safflower oil|The oil (50g/day) is given in muffin and cookies made with refined wheat flour (3 g/day)daily for 4 weeks.
3070407|NCT02091583|Active Comparator|High Oleic Canola Oil and DHA (HOCO-DHA)|The oil (50g/day) is given in muffin and cookies made with refined wheat flour (3 g/day) daily for 4 weeks.
3070408|NCT02091583|Active Comparator|Barley Beta-glucan|The Barley beta-glucan (3 g/day) is given in muffin and cookies made with a combination of butter, sunflower and safflower oil (50 g/day) daily for 4 weeks.
3070409|NCT02091583|Active Comparator|HOCO-DHA and Barley beta-glucan|The oil and beta-glucan (50g and 3g/day, respectively) is given in muffin and cookies daily for 4 weeks.
3070410|NCT02091570|Placebo Comparator|Nutrition bar|50 g nutrition bar
3070411|NCT02091570|Experimental|Nutrition Bar 1|50 g nutrition bar with additional 2 g of milk-based nutrient
3070412|NCT02091570|Experimental|Nutrition bar 2|50 g nutrition bar with additional 3 g of milk-based nutrient
3070413|NCT02091557||GnRH-analogue|CA125 levels and VAS pain score changes will be assessed after GnRH-a administration in all patients
3070414|NCT02091544||Lifestyle intervention|lifestyle intervention
3070415|NCT02091531|Experimental|MLN0128|Patients will be treated with the established phase II dose of MLN0128 (4mg po daily continuously; 1 cycle=4 weeks) to assess mechanisms of sensitivity and resistance in men with CRPC who have received either enzalutamide and/or abiraterone.
3070416|NCT02091518|Experimental|MRI|"Add-On Research Patients will include patients who are scheduled for a routine clinical MRI who meet the eligibility requirements for this protocol. Protocol participation will consist of an add-on research. MRI scan, which will be performed any point during of the routine clinical MRI scan.~Volunteers will be subjects expressing interest in participation and who meet the eligibility requirements for this protocol. No contrast enhanced research MRIs including gadolinium-based or other contrast agents will be performed in volunteers."
3070417|NCT02091505|Experimental|Intravitreal injection of Ranibizumab|
3070418|NCT02091492|Active Comparator|Teriparatide|Teriparatide 20µg daily subcutaneous injection for 12 weeks after proximal humerus fracture
3070419|NCT02091492|Placebo Comparator|Placebo-Teriparatide|Placebo-Teriparatide 20 µg daily subcutaneous injection for 12 weeks after proximal humerus fracture
3070420|NCT02091479|Experimental|UFH Early group|anticoagulant (UFH or LMWH) reintroduction at 48h to 72h after hemorrhage
3070421|NCT02091479|Active Comparator|UFH Late group|anticoagulant (UFH or LMWH) réintroduction 120h to 144h after hemorrhage
3070422|NCT02091466|Active Comparator|Pre-warming|The intervention is to warm patients before the anesthesia procedure in experimental groups
3070423|NCT02091466|No Intervention|Control|Patients received no active warming before the anesthesia procedure in control groups
3070424|NCT02091453|Experimental|attention training acute|20 hours of attention training, APT training, or multiprofessional rehabilitation
3070425|NCT02091453|Experimental|attention training subacute|20 hours of attention training, APT training, or multiprofessional rehabilitation
3070426|NCT02091440|Other|HW005 Ventricular Assist System|Implant of the HW005 Ventricular Assist System.
3070427|NCT02091414|Experimental|MMF, CsA, Corticosteroids|Participants received mycophenolate mofetil (MMF) 1.0 grams (g), orally (PO), twice daily (BID) from within 24 hours of transplantation through Week 24. Participants also received an initial loading dose of cyclosporine A (CsA) 4 to 6 milligrams per kilogram (mg/kg) within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 nanograms per milliliter (ng/mL) through Week 24. Participants also received corticosteroids as per the practice of each participating center.
3070428|NCT02091401|Active Comparator|IV|Women randomized into this treatment group will receive magnesium sulfate via an IV loading dose administered manually by study staff and an IV maintenance regimen.
3070429|NCT02091401|Experimental|Springfusor|Women randomized into this treatment group will receive magnesium sulfate via IV infusion (with the Springfusor® pump).
3070430|NCT02091388|Experimental|LY03004 25 mg|5 intramuscular injections 25 mg over 113 days
3070431|NCT02091388|Active Comparator|Risperdal® Consta® 25 mg|5 intramuscular injections 25 mg over 113 days
3070432|NCT02091375|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received 20 mg/kg/day of GWP42003-P administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
3070433|NCT02091375|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume-matched to the 20 mg/kg/day dose level, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
3070434|NCT02091362|Placebo Comparator|Placebo|Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods.
3070435|NCT02091362|Experimental|LY2409021|Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods.
3070436|NCT02091349|Placebo Comparator|Group A- placebo|control- snack bar or muffin containing no fiber
3070437|NCT02091349|Experimental|Group B- polydextrose|polydextrose- randomly bonded polysaccharide of glucose which is poorly digested in small intestine
3070438|NCT02091349|Experimental|Group C- soluble corn fiber|Soluble corn fiber made from corn starch and contains oligosaccharides with random glyucosyl bonds and may contain minor amounts of monosaccharides
3070439|NCT02091336|Active Comparator|Glyburide|Glyburide 2,5 mg
3070440|NCT02091336|Active Comparator|Metformin|Metformin 500mg bid
3070441|NCT02091323|Experimental|BMI<28kg/m2|Indicators monitored preoperatively and at 1,3,6,12 months after surgery in BMI<28kg/m2 group.
3070442|NCT02091323|Other|control|Indicators monitored preoperatively and at 1,3,6,12 months after surgery in BMI>28kg/m2 group as well.
3070443|NCT02091310|Placebo Comparator|Placebo (Study Part I)|Hard gelatin capsules, oral administration, 5 or 6 capsules per day before breakfast with a glass of water
3070444|NCT02091310|Experimental|GFT505 300 mg (Study Part I)|Hard gelatin capsules dosed at 60mg, oral administration, 5 capsules per day before breakfast with a glass of water
3070445|NCT02091310|Experimental|GFT505 360 mg (Study Part I)|Hard gelatin capsules dosed at 60mg, oral administration, 6 capsules per day before breakfast with a glass of water
3070446|NCT02091310|Placebo Comparator|Placebo (Study Part II)|Hard gelatin capsules, oral administration, 4 to 6 capsules per day before breakfast with a glass of water
3070447|NCT02091310|Experimental|GFT505 120 mg (Study Part II)|Hard gelatin capsules dosed at 60mg, oral administration, 2 capsules per day plus 2 to 4 capsules of placebo per day before breakfast with a glass of water
3070448|NCT02091310|Experimental|GFT505 xx mg (Study Part II)|Supra-therapeutic dose: hard gelatin capsules dosed at 60mg, oral administration, 4 to 6 capsules per day before breakfast with a glass of water
3070449|NCT02091310|Active Comparator|Moxifloxacin 400 mg (Study Part II)|On days 1 to 13, 4 to 6 placebo capsules per day, then one 400 mg moxifloxacin tablet (Izilox®, Bayer Pharmaceuticals Corporation) administered orally on Day 14
3070450|NCT02091297|Active Comparator|TAP BLOCK|One unique regional technique for lower abdominal surgery, that has been shown effective for Cesarean Section in particular, is the transversus abdominis plane (TAP) block, which blocks T6-L1 sensory nerve branches and provides anesthesia to the anterior abdominal wall. The TAP block has been recommended and shown in case reports, but not clinically studied with trials, for patients on methadone or buprenorphine, to improve post-operative pain control. A long active local anesthetic, called ropivacaine, will be used to provide this anesthesia.
3070451|NCT02091297|Active Comparator|Common Care|Common care refers to the common way pain is treated after Cesarean Section: a long-acting spinal or epidural opioid such as morphine, plus oral and IV opioids and non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.
3070452|NCT02091297|Active Comparator|Patient Controlled Epidural Analgesia|For post-Cesarean analgesia, another regional technique that has been employed for superior pain control is continued epidural analgesia with local anesthesia and an opioid, either in addition or instead of long acting neuraxial opioids (Cohen). One study revealed equal analgesic efficiency, higher patient satisfaction scores, and less side effects with patient controlled epidural ropivacaine compared to epidural morphine (Chen). This is an especially attractive option for opioid dependent patients, but like the TAP block, has been not studied whether or not it lessens acute or chronic postoperative cesarean section, in the setting or in the absence of neuraxial opioids.
3070453|NCT02091284|Experimental|real tDCS|Five sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
3070454|NCT02091284|Sham Comparator|sham-tDCS|Five sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current will be delivered for 20 seconds and will be turned off for the rest of the stimulation period. In this way, subjects will experience the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
3070567|NCT02090439|Experimental|standard treatment with Silodosin|Silodosin
3070455|NCT02091245|Experimental|KPT-330|KPT-330 will be administered twice a week on Days 1 and 3 for four weeks. Starting dose 30 mg/m2.In the dose-escalation cohort, three patients will initially be enrolled at each dose level and will be monitored for a DLT during the 28-day treatment cycle before dose escalation may occur.
3070456|NCT02091219|Experimental|25(OH)D3|20 micrograms/day by mouth for 16 weeks
3070457|NCT02091219|Experimental|Vitamin D3|2,400 IU/day by mouth for 16 weeks
3070458|NCT02091206|Experimental|GWP42003-P 5 mg/kg/day Dose|Participants received GWP42003-P 5 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 5 mg/kg/day over 3 days and remained at this dose for the rest of the 21-day treatment period (19 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
3070459|NCT02091206|Experimental|GWP42003-P 10 mg/kg/day Dose|Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the rest of the 21-day treatment period (15 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
3070460|NCT02091206|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the rest of the 21-day treatment period (11 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
3070461|NCT02091206|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume matched to one of the 3 dose levels (5, 10, or 20 mg/kg/day), administered orally, half in the morning and half in the evening for 21 days. To maintain the blinded aspect of the study, participants titrated the placebo dose over 3 to 11 days according to the matched investigational medicinal product (IMP) group (3, 7, and 11 days for the 5, 10, or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the rest of the 21-day treatment period. The 21-day treatment period was followed by a 10-day taper (10% per day of the matched dose) period.
3070462|NCT02091193||Placebo to Krill Oil|Group 2 receives supplement B for four weeks, undergoes a two week washout period, and then receives supplement A for another four weeks. Measurements are taken at baseline, after supplement B completion and after supplement A completion. Participants are informed which supplement was krill oil and which was placebo following completion of this phase of the study. Group 2 participants are given an option to also take an additional 17 weeks of Krill Oil and return for a follow up evaluating the long term use of krill oil.
3070463|NCT02091193||Krill Oil to Placebo|Group 1 receives supplement A for four weeks, undergoes a two week washout period, and then receives supplement B for another four weeks. Measurements are taken at baseline, after supplement A completion and after supplement B completion. Participants are informed which supplement was krill oil and which was placebo following completion of this phase of the study. Group 1 participants are given an option to also take an additional 17 weeks of Krill Oil and return for a follow up evaluating the long term use of krill oil.
3070464|NCT02091180|Experimental|Mannitol|Patients will receive 0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
3070465|NCT02091180|Placebo Comparator|Control|Patients will receive normal saline
3070466|NCT02091167|Experimental|real tDCS|Five sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
3070467|NCT02091167|Sham Comparator|sham-tDCS|Five sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current will be delivered for 20 seconds and will be turned off for the rest of the stimulation period. In this way, subjects will experience the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
3070468|NCT02091154|Experimental|USDA Regulations Only|Implement USDA Regulations in assigned school cafeterias during the intervention period.
3070469|NCT02091154|Experimental|USDA Regulations and Marketing Kit|Implement new USDA regulations in assigned schools along with the Marketing Kit during the intervention period.
3070470|NCT02091154|Experimental|USDA Regulations and SLM|Implement USDA Regulations and Smarter Lunchrooms Makeover in assigned schools during intervention period.
3070471|NCT02091154|No Intervention|Control|Schools assigned to this intervention made no changes to their lunchroom or menus.
3070472|NCT02091141|Experimental|Trastuzumab Plus Pertuzumab|Participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion as loading dose, followed by 6 mg/kg IV infusion every 3 weeks; and pertuzumab 840 mg IV infusion as loading dose, followed by 420 mg IV infusion every 3 weeks.
3070473|NCT02091141|Experimental|Erlotinib|Participants will receive erlotinib 150 milligrams (mg) orally once daily in each 28-day cycle.
3070474|NCT02091141|Experimental|Vemurafenib Plus Cobimetinib|Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle; and cobimetinib 60 mg orally once daily for 21 days on and 7 days off in each 28-day cycle.
3070475|NCT02091141|Experimental|Vismodegib|Participants will receive vismodegib 150 mg orally once daily in each 28-day cycle.
3070476|NCT02091141|Experimental|Alectinib|Participants will receive alectinib 600 mg orally BID in each 28-day cycle.
3070477|NCT02091141|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 mg IV infusion every 3 weeks.
3070478|NCT02091128||Females with classic galactosemia and POI|
3070479|NCT02091115|Placebo Comparator|Dairy drink|Patients received dairy drink for 60 days and were instructed to consume a glass of 150 mL daily.
3070480|NCT02091115|Active Comparator|Dairy drink with probiotic culture|Patients received dairy drink with probiotic culture for 60 days and were instructed to consume a glass of 150 mL daily.
3070481|NCT02091102|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
3070482|NCT02091089|Experimental|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
3070483|NCT02091076|Experimental|Silk with bioactive coated dressing|Silk fibroin coated with bioactive layer, apply once only
3070484|NCT02091076|Active Comparator|Control|Bactigras wound dressing, apply once only
3070485|NCT02091063|Experimental|Phase Ib: Arm A: ACY-1215 QD|Phase Ib: ACY-1215 160mg PO QD
3070568|NCT02090439|No Intervention|standard treatment|
3070487|NCT02091063|Experimental|Phase II: ACY-1215|Phase I dosing schedule has been determined. 160 mg BID dosing will be administered for Phase II.
3070488|NCT02091050|Other|HDR Brachytherapy 24Gy (4 x 6Gy)|Vaginal vault brachytherapy, associated or not with external beam radiotherapy.
3070489|NCT02091024|Experimental|ECG (Ecklonia cava extract)|ECE 200mg, twice a day
3070490|NCT02091024|Placebo Comparator|Placebo|Placebo 200mg, twice a day
3070491|NCT02091011||Cohort group|Subjects who have been implanted within 30 days with a commercially available Boston Scientific ICD or a CRT-D device
3070492|NCT02090998|Active Comparator|SPG Nerve Block with Lidocaine 5% gel|Sphenopalatine Ganglion Nerve Block (SPG Nerve Block) will be administed weekly for 4 weeks using 5% Lidocaine gel This intervention (a nerve block) will treat the headache for the time period investigated
3070493|NCT02090998|Active Comparator|Amitriptyline / Elavil|Amitriptyline / Elavil 10 mg once a day for one week then Amitriotyline 20 mg once a day for three weeks This intervention will treat the headache for the time period investigated
3070494|NCT02090985|Experimental|Lipomodelling|Lipomodelling of peri-stomal skin contour abnormalities
3070495|NCT02090972||Patients with fracture|"fracture within the last 14 days~no other fractures within the last 6 month~patients >60 years"
3070496|NCT02090972||Control Patients|"patients hospitalized for an internal reason~no other fractures within the last 6 month~patients >60 years"
3070497|NCT02090959|Experimental|Ataluren|10, 10, 20 mg/kg for 96 weeks.
3070498|NCT02090946||parental experiences|interviews
3070499|NCT02090933|Experimental|Treatment (celecoxib)|Participants undergo UV-irradiation to the right buttock at baseline, receive celecoxib PO BID for 10 days, and then undergo UV-irradiation to the left buttock.
3070500|NCT02090920||Nifedipine|Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
3070501|NCT02090907|Experimental|Levothyroxin|In the treatment group, daily doses of 100 mg of Levothyroxine will be administered every morning, half an hour before breakfast.
3070502|NCT02090907|Placebo Comparator|Placebo|In the placebo group treatment regimen and advices are identical to that of the treatment group, except for using a pharmacologically neutral agent, with complete resemblance to the real treatment.
3070503|NCT02090894|Experimental|UV Light|
3070504|NCT02090881|Experimental|ultrasound scan in ages 2-16 years|Children aged 2-16 years of age with Sickle Cell Disease and under the care of consultant haematologist as part of the NHS screening programme.
3070505|NCT02090868||Pre Introduction|Pre tool introduction cohort 22 patient participants who will receive standard care (no patients were recruited)
3070506|NCT02090868||Nurses|12 nurse participants who will take part in 2 focus group interviews and a teaching session (6 nurse participants were recruited)
3070507|NCT02090868||Post Introduction|Pre tool introduction cohort 22 patient participants who's ability to eat and drink orally will be assessed using the Oral Intake Screening Tool (no patient participants were recruited)
3070508|NCT02090855||Flutemetamol (18F)|There are no interventions in this study. This study is to assess the images taken previously from another study, GE-067-007.
3070509|NCT02090842|Experimental|Whey protein isolate|Subjects are asked to supplement their habitual diet with 56 g of whey protein isolate a day for 8 weeks.
3070510|NCT02090842|Experimental|Ca-caseinate|Subjects are asked to supplement their habitual diet with 56 g of Ca-caseinate a day for 8 weeks.
3070511|NCT02090842|Other|Maltodextrin|Subjects are asked to supplement their habitual diet with 54 g of maltodextrin a day for 8 weeks.
3070512|NCT02090829|Placebo Comparator|Placebo Group|"Placebo Comparator: Intranasal Placebo Intranasal placebo The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril)."
3070513|NCT02090829|Active Comparator|Experimental Group|"Intranasal oxytocin (Trade name: Syntocinon) Pharmacological class: The pharmacologic and clinical properties of Syntocinon are identical with the naturally occurring hormone oxytocin, which is released from the posterior pituitary.~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal oxytocin (24 IU) per day for 5 days.~One dose of 24 IU equals 6 spray puffs (3 puffs in each nostril). Oxytocin will be imported from Victoria Pharmacy Zurich- Switzerland."
3070514|NCT02090816||Surgery of liver and lung|Patients carriers of both liver and right lung metastases in the same time
3070515|NCT02090803||Graft of autologous hematopoietic stem cells|
3070516|NCT02090790|Active Comparator|iv dexamethasone|perioperative 2ml 8 mg ıv dexamethasone
3070517|NCT02090790|Active Comparator|femoral dexamethasone|femoral block was performed postoperative 30 ml 0,5 % bupivacaine added 2 ml 8 mg dexamethasone
3070518|NCT02090790|Placebo Comparator|serum physiologic|
3070519|NCT02090777|Other|Health Coach|Health Coach is conducted to see if it improves ophthalmic care for glaucoma patients.
3070520|NCT02090764|Experimental|Ozenoxacin|ozenoxacin cream 1%
3070521|NCT02090764|Placebo Comparator|Placebo|Placebo cream
3070522|NCT02090751||No Maculopathy|Aged 50 to 80 with no macular disease
3070523|NCT02090751||Early Maculopathy|Aged 50 to 80 with early AREDS defined 2,3 age related maculopathy
3070524|NCT02090738|Experimental|Arm1|Treatment group
3070525|NCT02090738|Active Comparator|Arm2|Control group
3070526|NCT02090725|Experimental|3-4 Diaminopyridine (DAP)|
3070527|NCT02090712||Reperfusion strategies|Patients submitted to thrombolysis with tenecteplase after acute myocardial infarction will be transferred to a tertiary center and angiography with the intention to treat the culprit artery will be performed in 3 - 48 hours (preferably first 24 hours).
3070528|NCT02090712||Primary PCI|Patients with contra-indication to thrombolytics or able to reach the catheterization laboratory within 90 minutest will be transferred for primary angioplasty, according to current guidelines.
3070529|NCT02090699||Myocardial Iron Overload|chronic blood transfusion related myocardial iron overload
3070530|NCT02090699||Healthy Volunteers|age matched healthy volunteers
3070531|NCT02090686|Active Comparator|Pulsatile Cupping|
3070534|NCT02090673||Group1:Type 2 diabetic patients treated with Exenatide therapy|Korean patients who are at least 18 years old, diagnosed with type 2 diabetes, and are treated with Exenatide in an ambulatory care setting according to the approved label
3070535|NCT02090660|Experimental|VATS wedge lung resection|
3070536|NCT02090647|Active Comparator|titanium 1|titanium abutment type 1
3070537|NCT02090647|Active Comparator|titanium 2|titanium abutment type 2
3070538|NCT02090647|Active Comparator|zirconia 1|zirconia abutment type 1
3070539|NCT02090647|Active Comparator|zirconia 2|zirconia abutment type 2
3070540|NCT02090647|Active Comparator|titanium nitrate|titanium nitrate abutment
3070541|NCT02090634|Experimental|Personalized Reminder Texting + Psychoeducation (iTAB)|Participants in the individualized Texting for Adherence Building (iTAB) arm will receive daily text messaging reminders for antiretroviral and psychotropic medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Participants will also receive a text message that assesses mood. Finally, participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications.
3070542|NCT02090634|Active Comparator|Psychoeducation (CTRL)|Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. They will also receive daily text messages to assess mood, but these messages will not receive the medication reminder text messages.
3070543|NCT02090621|Experimental|Extracorporeal Photopheresis|Extracorporeal Photopheresis
3070544|NCT02090608|Experimental|Paricalcitol|In patients identified by the inclusion criteria, data will be collected at baseline , during administration of oral Paricalcitol (PCT) (after 1, 3 and 6 months), and three months after PCT withdrawal. PCT will administered at dosage of 1 mcg/day; this dosage was chosen as it is not associated with excessive decline of parathyroid hormone (PTH) levels in most patients
3070545|NCT02090595|Experimental|MBCT-C|Mindfulness-Based Cognitive Therapy for Anxious Children (MBCT-C) is a 12-week manualized group therapy program for children with anxiety disorders. The program involves teaching children to pay attention to anxiety-related thoughts, emotions, and physical sensations with openness and non-judgment.
3070546|NCT02090595|Other|Waitlist Control|Education and Therapy
3070547|NCT02090582|Other|Structured Palliative Care|
3070548|NCT02090582|Other|Usual Care|
3070549|NCT02090569|Experimental|Functional micro-Doppler sonography|
3070550|NCT02090556||Cohort 1:|RA patients naive of Abatacept and any other biologic agents
3070551|NCT02090556||Cohort 2:|RA patients naive of Abatacept and who previously failed one or more biologic agents
3070552|NCT02090543||Group 1|300 AF patients, with at least 3 month of anticoagulation therapy with VKAs (VKA-experienced patients)
3070553|NCT02090543||Group 2|300 AF patients, with at least 3 month of rivaroxaban therapy (rivaroxaban-experienced patients)
3070554|NCT02090530||Advanced Cancer Patients|Individuals with advanced or refractory cancer must be identified by study personnel or their treating physician, deemed eligible for this study, and voluntarily agree to be enrolled in this protocol through an informed consent. Biospecimen collection includes a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
3070555|NCT02090517|Active Comparator|Pulsed Dye Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with pulsed dye laser.
3070556|NCT02090517|Active Comparator|Long Pulsed Alexandrite Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with long pulsed alexandrite laser.
3070557|NCT02090517|Active Comparator|Pulsed Dye Laser Plus Nd:YAG Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with pulsed dye laser plus Nd:YAG laser.
3070558|NCT02090517|Active Comparator|Electrodesiccation|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with electrodesiccation.
3070559|NCT02090517|No Intervention|No Treatment|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will receive no treatment.
3070560|NCT02090504|Experimental|Sodium oxybate (SMO)|"Patients randomized to the first arm of the study will receive:~SMO (sodium oxybate 175 mg/ml suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10 (If patient's weight is > 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml);~placebo (tablets): 1 tablet at 8.00 a.m., 1 tablet at 12.00 p.m., 1 tablet at 7.00 p.m. from day 1 to day 10."
3070561|NCT02090504|Active Comparator|Oxazepam|"Patients randomized to the second arm of the study will receive:~OXAZEPAM (tablets): 60mg at 8.00 a.m., 60mg at 12.00 p.m., 90mg at 7.00 p.m. from day 1 to day 5, 30mg at 8.00 a.m., 30mg at 12.00 p.m., 30mg at 7.00 pm, on days 6 and 7, and 15mg at 8.00 a.m., 15mg at 12.00 p.m., 15mg at 7.00 p.m. from day 8 to day 10;~placebo (suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10, (If patient's weight is > 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml)."
3070562|NCT02090478|Sham Comparator|No change in dietary sugar levels|Group met with a dietician as often as the control group to discuss diet, but the dietician gave them advice geared toward no change in dietary sugar levels
3070563|NCT02090478|Experimental|Low sugar group|Subjects met with a dietician who discussed diet records. After the first month (baseline, regular diet), the dietician made suggestions geared toward reducing calories from simple sugars by 40%. This will be achieved by replacing sugar calories with complex carbohydrates and fats, while maintaining energy balance (same number of calories as the baseline month).
3070564|NCT02090465||all eligible patients|Treatment with Picato according to Summary of Product Characteristics (SmPC)
3070565|NCT02090452|Experimental|Transmission of vital signs, ecg, chat|Data from patients transported in ambulances with equipment which enables real time transmission of vital signs, ecg and chat from ambulances to the emergency department.
3070566|NCT02090452|No Intervention|No transmission of data|Patient transported with conventional ambulances without the possibility to transmit real time patient related data.
3070569|NCT02090426|No Intervention|Standard Care|Individuals in the standard care arm receive standard discharge planning from the hospital with no followup by Link2Care team members.
3070570|NCT02090426|Experimental|Link2Care|Participants are assigned to a multidisciplinary care team (Link2Care) comprised of a registered nurse, licensed practical nurse, social worker, intervention specialist, community health worker, and health coaches. A representative from the care team engages with the patient at bedside during the hospital admission and plans for the immediate period following discharge. The Program, as a whole, involves a series of home visits, scheduling of and accompaniment to initial primary care and specialty care visits, and support for individuals as they navigate various social service agencies to enroll in public programs including TANF, SNAP, and programs that promote housing stability.
3070571|NCT02090413|Experimental|DMF + ASA 150 mg BID|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA 150 mg is taken BID from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
3070572|NCT02090413|Experimental|DMF + ASA 75 mg QAM|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA 75 mg is taken in the morning (QAM) and ASA-Placebo is taken in the evening (QPM) from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
3070573|NCT02090413|Experimental|DMF + ASA-Placebo BID|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA-Placebo is taken BID from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
3070574|NCT02090400|Other|Bazedoxifene & Calcium/Vit D|Bazedoxifene 20mg oral once a day and calcium 500mg and 400 IU vitamin D (OSTINE)
3070575|NCT02090400|Other|Calcium/Vit D|Calcium 500mg and 400 IU vitamin D (OSTINE )daily.
3070576|NCT02090387|Active Comparator|Control ONS|ONS without AN777
3070577|NCT02090387|Experimental|Investigational ONS|ONS containing AN777
3070578|NCT02090374|Experimental|TLR agonist nasal challenge in non-atopic patients|
3070579|NCT02090374|Experimental|TLR agonist nasal challenge in atopic patients|
3070580|NCT02090374|Experimental|Tuberculin nasal challenge in subjects with latent TB|
3070581|NCT02090374|Experimental|Tuberculin nasal challenge healthy subjects|
3070582|NCT02090374|Experimental|Timothy grass pollen nasal challenge in hay fever subjects|
3070583|NCT02090374|Experimental|Timothy grass pollen nasal challenge in asthmatic subjects|
3070584|NCT02090374|Experimental|Timothy grass pollen nasal challenge in non-atopic subjects|
3070585|NCT02090374|Experimental|Resiquimod nasal challenge in allergic asthma|
3070586|NCT02090361|Experimental|skin graft with dermal matrix|Epidermization of the defect by applying a thin layer of autologous epidermis with addition of a dermal matrix
3070587|NCT02090361|Placebo Comparator|skin graft - classic procedure|Epidermization of the defect by applying a thin layer of autologous epidermis
3070588|NCT02090348|Experimental|dimethyl fumarate|DMF at a dose of 120 mg twice a day (BID) for the first 7 days and 240 mg BID for the remainder of study period (up to 12 months)
3070589|NCT02090335|Experimental|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
3070590|NCT02090335|Active Comparator|Fitness Club Membership|Fitness club membership with education in using the exercise equipment.
3070591|NCT02090322|Experimental|Bevacizumab|"The treatment for Retinopathy of prematurity is Intravitreal bevacizumab. We want to compare two dosages (0.500 and 0.625mg) and demonstrate that 0.500mg there isn't lower in efficacy than 0.625mg.~When the baby have the diagnosis or Retinopathy of prematurity we are going to inyect the eye that have te problem, then we are going to explore until this illness disappear. It is only one intervention"
3070592|NCT02090309|Active Comparator|Hydrocortisone injection|I.V Hydrocortisone 100 mg single bolus.
3070593|NCT02090309|Placebo Comparator|normal saline|I.V normal saline 0.9% a single bolus of 5 ml.
3070594|NCT02090296|Placebo Comparator|Sugar water|Placebo arm
3070595|NCT02090296|Active Comparator|Hydroxyurea|Treatment Arm
3070596|NCT02090283|Experimental|SD-101 dermal cream (6%)|All subjects will apply SD-101 dermal cream topically, once a day to the entire body for the duration of the study.
3070597|NCT02090270||Ischemic stroke|Sudden onset of focal neurologic deficit lasting more than 24 hours, with cerebral hemorrhage ruled out by brain CT, in the absence of obvious causes of embolic stroke.
3070598|NCT02090270||Control|Patients admitted to an internal medicine department for indications other than stroke or acute myocardial ischemia.
3070599|NCT02090257|Experimental|TRANSIT, behavioral|The intervention group will receive more guidance during their transition from a pediatric center to the adult center
3070600|NCT02090257|No Intervention|Usual Care Group|The usual care group will receive a standard transfer of care from a pediatric center to an adult center.
3070601|NCT02090244|No Intervention|Control|Standard care postoperatively.
3070602|NCT02090244|Experimental|Teriparatide|One injection daily for 4 weeks
3070603|NCT02090231|Experimental|Real 5 Hz rTMS|real 5 Hz rTMS, 10 minutes per day, for 10 weekdays.
3070604|NCT02090231|Sham Comparator|sham 5 Hz rTMS|sham 5Hz rTMS, 10 minutes per day, for 10 weekdays.
3070605|NCT02090218|Active Comparator|I-Gel|I-Gel supraglottic airway device
3070606|NCT02090218|Active Comparator|LTS, ETI or other airway practice|Laryngeal tube, endotracheal tube or other current airway management practice
3070607|NCT02090205|Placebo Comparator|Non-ventilation during CPB|This group of patients will not be ventilated during the cardio-pulmonary bypass. They will be disconnected from the respirator.
3070608|NCT02090205|Experimental|Ventilation with CPAP|This group will receive a ventilation with CPAP (at least 5 cmH2O) and FiO2 50%-80%
3070609|NCT02090205|Experimental|Ventilation with 5 act/minute|This group will receive 5 respiratory acts/minute. Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
3070644|NCT02089919|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3070645|NCT02089906||Chinese Elderly|multi-center cross-sectional study
3070646|NCT02089893||Healthy subjects|Healthy subjects
3070610|NCT02090192|Experimental|WBV training|"Whole-body vibration training was performed on a commercial Galileo machine (Germany). Participants were required to stand on the moveable rectangular platform and positioned their feet at an equal and standardized distance from the axis of rotation so that the vertical vibration amplitude was 1-3 mm. The frequency was set at 6-26 Hz. The vibration protocol consisted of four to five bouts (60 seconds for each bout), and three to five times a week for 12 weeks. The positions taken by the subjects differed according to their function. Participants who could stand independently were instructed to adopt a partial squat position with slight flexion at the hips, knees, and ankle joints to damp the vibrations approximately at the pelvic level."
3070611|NCT02090192|Experimental|WBV+ PRT training|
3070612|NCT02090192|Active Comparator|PRT training|
3070613|NCT02090192|Placebo Comparator|Control group|
3070614|NCT02090179||MPS IIIB|Those with a definitive diagnosis of MPS IIIB (Sanfilippo B Syndrome).
3070615|NCT02090166|Other|lung cancer diagnosis|"4 arms will be included in the study:~The groups sample size is as follows:~Group 1 - Healthy non smoker- 75 subjects Group 2 - Healthy smoker- 75 subjects Group 3 - Patients diagnosed as having COPD- 150 subjects Group 4 - Patients with diagnosis of lung cancer- 650 subjects~A blood test will be taken from each patient."
3070616|NCT02090153|Experimental|S-1 plus LV|All patients were orally treated with S-1 in doses of 40 mg (body surface area (BSA)<1.25 m2), 50 mg (1.25≤BSA<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-7 in combination with LV given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest. Treatment courses were repeated every 2 weeks.
3070617|NCT02090140|Experimental|ADSC Application|Patients undergo an arthroscopic surgical procedure, ADSC application, followed by physical therapy.
3070618|NCT02090140|Active Comparator|Microfracture Arm|Patients undergo an arthroscopic surgical procedure, microfracture, followed by physical therapy.
3070619|NCT02090114|Experimental|Post-abiraterone or post-enzalutamide or post-castration only|Men with castration-resistant prostate cancer who have progressed on either abiraterone or enzalutamide or castration-only therapy will be enrolled to this arm. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with either abiraterone 1000 mg by mouth daily or enzalutamide 160 mg by mouth daily, depending on which drug they previously received or remain on LHRH agonist alone for one month to re-establish a castrate level of testosterone (<50 ng/dL).
3070620|NCT02090101|Experimental|ANAKINRA|LV5FU2 + bevacizumab + anakinra
3070621|NCT02090088||All Subjects|All Subjects
3070622|NCT02090075|Active Comparator|apixaban|apixaban 5 mg or 2.5 mg po bid
3070623|NCT02090075|Placebo Comparator|warfarin|warfarin with target INR of 2-3
3070624|NCT02090049|Experimental|Puravita Breakfast|Puravita Breakfast is a high protein and high fiber soft bread that contains 22% fruit (figs, apricots, raisins and prunes), a selection of cereals: wheat, oat and spelt and no added sugar.
3070625|NCT02090049|Placebo Comparator|Control breakfast|White bread (85g) with jam (10g) and margarine (2g) adjusted for energy, fat, and sugar levels and for energy density.
3070626|NCT02090036|Active Comparator|artemether-lumefantrine+placebo|In the artemether-lumefantrine arm, the first dose of artemether-lumefantrine will be administered concomitantly with a single-dose placebo. A volume of normal saline will be measured based on weight bands and then will be given to patients.
3070627|NCT02090036|Experimental|artemether-lumefantrine+primaquine|All the recruited patients will be treated with a six doses, 3 days artemether-lumefantrine treatment regimen. However, patients randomized to the artemether-lumefantrine+primaquine arm will be given 0.25 mg/kg single-dose primaquine concomitantly with artemether-lumefantrine first dose.
3070628|NCT02090023||NHIRD obstructive sleep apnea|Secondary database from community-based National Health Insurance Research Database
3070629|NCT02090023||NTUH obstructive sleep apnea cohort|Primary database from enrollment of retrospective NTUH hospital-based cohort
3070630|NCT02090010|Active Comparator|GroupC|Group C means Control group which use Seldinger technique for subclavian catheterization. The aimed vessel(subclavian vein) is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and the needle is removed. After that catheter is passed over the guidewire into the vessel.
3070631|NCT02090010|Experimental|Group MS|Group MS means experimental group which use modified Seldinger technique for subclavian catheterization. The aimed vessel is punctured with the needle that is covered with guiding sheath. After vessel is punctured, guiding sheath is instatntly slid over the needle into the vessel. The needle is removed, guidewire is advanced through the sheath, central catheter is placed into the vessel.
3070632|NCT02089997||75 mg of sodium risedronate|75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking.
3070633|NCT02089984|Experimental|Internet-Based Training|On-line tutorial followed by live remote training via videoconferencing
3070634|NCT02089971||Young Chinese adults|cross-sectional, observational study of community dwelling young Chinese adults
3070635|NCT02089958||Laparoscopic incisional hernia repair|Incisional hernia, LIPOM
3070636|NCT02089945||transcatheter aortic valve implantation|This study recruits individuals that are undergoing transcatheter aortic valve implantation.
3070637|NCT02089932|Placebo Comparator|group B: control bupivacaine group|Patient in this group will receive 25 ml bupivacaine 0.5% plus 1 ml normal saline peri-neurally
3070638|NCT02089932|Experimental|Group B-DEX 25 : Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (25 microgram) Dexmedetomidine peri-neurally
3070639|NCT02089932|Experimental|Group B-DEX 50:Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (50 microgram) Dexmedetomidine peri-neurally
3070640|NCT02089932|Experimental|Group B-DEX 75:Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (75microgram) Dexmedetomidine peri-neurally
3070641|NCT02089919|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3070642|NCT02089919|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3070643|NCT02089919|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3070649|NCT02089867|Experimental|Ezetimibe|The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
3070650|NCT02089867|Experimental|Plant sterols|The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
3070651|NCT02089867|No Intervention|Control group|No additional therapy, statin maintenance
3070652|NCT02089867|Experimental|Ezetimibe + plant sterols|The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
3070653|NCT02089854|Experimental|endocrine therapy|toremifene 60mg PO. per day for premenopausal and perimenopausal patients; anastrozole 1mg PO. per day for postmenopausal patients
3070654|NCT02089854|No Intervention|observation|
3070655|NCT02089841|Experimental|Artemether/lumefantrine|In this single-arm study, patients will be treated with Artemether/lumefantrine, and the first, third and fifth doses of the drug will be given under the direct observation of the health workers. The patients will be followed-up for 42 days, on day 1, 2, 3, 7, 14, 21, 28 and 42 to assess the efficacy of the drug.
3070656|NCT02089828|Experimental|autologous purified CD34+ cell|transplantation of autologous purified CD34+ cell
3070657|NCT02089828|Active Comparator|autologous PB-MNC|transplantation of autologous peripheral blood mononuclear cells
3070658|NCT02089815|Experimental|Home based exercise|simple designed home based exercise program
3070659|NCT02089815|Active Comparator|fall prevention education and counseling|fall prevention education & counseling : home modification, vision screening, avoid sedative drugs use, proper shoes, report dizziness and fall to doctors
3070660|NCT02089802|Experimental|Normal plasma level patients and low plasma level patients.|"Patients with normal Pazopanib plasma trough levels; normal plasma level patients (NPLP).~Patients with low Pazopanib plasma trough levels, low plasma level patients (LPLP)."
3070661|NCT02089789||CDG|Patients with a suspected CDG based on biochemical tests or a confirmed CDG based on enzymatic or molecular tests will be eligible to enroll in this protocol
3070662|NCT02089763|Experimental|PEG-BCT-100|pegylated recombinant human arginase 1
3070663|NCT02089750|Active Comparator|Orthotics|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period.
3070664|NCT02089750|Active Comparator|Orthotics Plus Chiropractic Care|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period in addition to receiving Chiropractic Care 1-4 times per week during the first 6 weeks of the 12 week study period.
3070665|NCT02089750|Other|Wait List|The group serves as a cross-over control group. Subjects are asked to avoid any new therapies for the first 6 weeks of the 12 week study and during the last six weeks they are fitted for the custom-made shoe orthotics.
3070666|NCT02089737||Panitumumab 6 mg/kg|Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks
3070667|NCT02089724||vemurafenib/other BRAF inhibitors|
3070668|NCT02089711||Japanese healthy subjects|subjects with healthy eyes
3070669|NCT02089698|Active Comparator|Reversed tip|Reversed Kelman tip
3070670|NCT02089698|Experimental|Mini-flared|Mini-flared Kelman tip
3070671|NCT02089685|Experimental|Pembrolizumab + PegIFN-2b|Participants in Part A receive pembrolizumab intravenously (IV) at assigned dose every 3 weeks + PegIFN-2b subcutaneously (SC) at assigned dose once a week in each 6-week cycle.
3070672|NCT02089685|Experimental|Pembrolizumab + IPI Q3W|Participants in Parts 1A and 1B receive pembrolizumab IV at assigned dose every 3 weeks + IPI IV at 1 mg/kg every 3 weeks (Q3W) for a total of two 6-week cycles.
3070673|NCT02089685|Experimental|Pembrolizumab + IPI Q6W|Participants in Part 1C receive pembrolizumab IV at assigned dose every 3 weeks + IPI IV at 50 mg every 6 weeks (Q6W) for a maximum of four 6-week cycles.
3070674|NCT02089685|Experimental|Pembrolizumab + IPI Q12W|Participants in Part 1C receive pembrolizumab IV at assigned dose every 3 weeks + IPI IV at 100 mg every 12 weeks (Q12W) for a maximum of eight 6-week cycles.
3070675|NCT02089672||Atrial flutter patients|Atrial flutter patients undergoing catheter ablation
3070676|NCT02089659|Experimental|Part 1: Participants with Moderate Hepatic Insufficiency|A single doravirine tablet administered orally with approximately 240 mL water on the morning of Day 1 after an overnight fast. All participants in this arm will have moderate hepatic insufficiency based on the Child-Pugh scale, and at least 4 participants will have a score >=2 on the laboratory parameters of the Child-Pugh scale.
3070677|NCT02089659|Active Comparator|Part 1: Healthy Control Participants|A single doravirine tablet administered orally with approximately 240 mL water on the morning of Day 1 after an overnight fast
3070678|NCT02089659|Experimental|Part 2: Participants with Mild Hepatic Insufficiency|A single doravirine tablet administered orally with approximately 240 mL water on the morning of Day 1 after an overnight fast. All participants in this arm will have mild hepatic insufficiency based on the Child-Pugh scale, and at least 4 participants will have a score >=2 on the laboratory parameters of the Child-Pugh scale. This arm will be enrolled and investigated only if a clinically meaningful increase in doravirine exposure is observed in participants with moderate hepatic insufficiency in Part 1.
3070679|NCT02089633|Experimental|PACOX|Pegylated human arginase (PA) in combination with Capecitabine (C) and Oxaliplatin (OX)
3070680|NCT02089620|Active Comparator|Yasmin|Yasmin is an oral contraceptive pill containing (Disperinone 3mg+Ethinylestradiol 0.3mg) will be administered once daily orally by the woman from day 2 of the cycle for 21 days each month for 3 months in addition to a daily placebo.
3070681|NCT02089620|Active Comparator|Calver|Calver is a calcium supplement drug containing (ca 1000mg+vit D400 I.U) given to the woman continuously for 3 months in addition to placebo for 21 days
3070682|NCT02089620|Placebo Comparator|Placebo|A daily oral placebo will be given to the patients daily for 3 months in addition to a placebo similar to COC for 21 days
3070683|NCT02089607|Experimental|Zenith Fenestrated-Branched System|"The Zenith Fenestrated-Branched System is a tubular graft made of polyester fabric sewn to stainless steel stents that keep the graft open. The graft will be inserted through arteries in the leg (called endovascular repair). This procedure uses catheters that go inside the blood vessel to place a stent graft above and below the aneurysm.~The upper portion of the graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches) that allow the graft to be located above the renal arteries without blocking blood flow to them. This is needed when there is not enough healthy aorta below the renal arteries. At least one artery may also be treated with an alignment stent to help keep the arteries open and aligned with the fenestrations or branches."
3070684|NCT02089594|Experimental|Hyperbaric Oxygen Therapy (HBOT)|Hyperbaric Oxygen Therapy at 1.5 ATA (atmospheres absolute). The subjects will receive 40 low pressure HBOT's on a once/day, 5d/week eight week schedule.
3070685|NCT02089594|Experimental|No Hyperbaric Oxygen Treatment (HBOT)|Subjects will receive eight weeks of no hyperbaric treatment while they continue any pre-study maintenance medication and/or pre-study counseling. Subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
3070686|NCT02089581|Active Comparator|Drug|MR2XXX
3070687|NCT02089581|Experimental|MRXXX|MRXXX capsule 12 hourly
3070688|NCT02089581|Experimental|MR1XXX|MR1XXX capsule, 12 hourly
3070689|NCT02089581|Experimental|Experimental|Experimental Fed
3070690|NCT02089568|Experimental|Drug: co-amoxiclav|experimental
3070691|NCT02089568|Placebo Comparator|Control|comparator
3070692|NCT02089555||African Americans|This group consists of African American (AA) individuals aged 65-80 who are part of the Emory Alzheimer's Disease Research Center (ADRC) (a multi-racial cohort of subjects with normal cognition, Mild Cognitive Impairment (MCI) or mild Alzheimer's Disease (AD)) or the Registry for Remembrance (RfR) (a community of AA individuals who are interested in studies of memory and aging). AA and Non-Hispanic White (NHW) participants will be frequency-matched for age, gender, and education within each cognitive category (35 with normal cognition, 30 with MCI, and 10 with mild AD for each race).
3070693|NCT02089555||Non-Hispanic Whites|This group consists of Non-Hispanic White (NHW) individuals aged 65-80 who are part of the Emory Alzheimer's Disease Research Center (ADRC) (a multi-racial cohort of subjects with normal cognition, Mild Cognitive Impairment (MCI) or mild Alzheimer's Disease (AD)). African American (AA) and Non-Hispanic White (NHW) participants will be frequency-matched for age, gender, and education within each cognitive category (35 with normal cognition, 30 with MCI, and 10 with mild AD for each race).
3070694|NCT02089542|Experimental|MB and fluorescent imaging|Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
3070695|NCT02089529|Active Comparator|Ibuprofen/Ibumetin|Ibumetin is administrated. Intervention: No information about the effect.
3070696|NCT02089529|Placebo Comparator|Placebo|Placebo is administrated. Intervention: No information about the effect.
3070697|NCT02089529|Active Comparator|Ibuprofen/Ibumetin+positive information|Ibumetin is administrated. Intervention: The patient receive written information that the capsule is Ibumetin.
3070698|NCT02089529|Placebo Comparator|Placebo+positive information|Placebo is administrated. Intervention:The patient receive written information that the capsule is Ibumetin.
3070699|NCT02089529|Active Comparator|Ibuprofen/Ibumetin+neutral information|Ibumetin is administrated. Intervention: The patient receive written information that the capsule is Ibumetin.
3070700|NCT02089529|Placebo Comparator|Placebo+neutral information|Placebo is administrated. Intervention:The patients receive information that the capsule is placebo.
3070701|NCT02089529|No Intervention|Control|Control condition
3070702|NCT02089516||Frail elderly|Measuring movement activity in frail elderly (GFI score ≥ 4) of 75 years and older using DynaPort.
3070703|NCT02089503||induction phase + intravitreal inj.|Group of patients who received Lucentis ® with induction phase
3070704|NCT02089503||intravitreal inj. without induction|Group of patients who received Lucentis ® without induction phase
3070705|NCT02089503||intravitreal inj. + monthly follow-up|group of patients who were monthly monitored (+/- 1 week)
3070706|NCT02089503||intravitreal inj. + follow-up :> 1 month|group of patients with Follow up visits intervals> 1 month (+/- 1 week)
3070707|NCT02089503||intravitreal inj +induction+ month. FU|Group of patients who received Lucentis with induction phase and who were monthly monitored (+/- 1 week)
3070708|NCT02089503||date Lucentis® 1st intravitreal Inj.|Group of patients selected in accordance with the date of Lucentis® treatment start.
3070709|NCT02089490|Experimental|NEVELIA®|NEVELIA® implantation according to the intended use in the leaflet, prior to autologous skin grafting planned 3 weeks after its application.
3070710|NCT02089477|Experimental|Support|"The participants in the intervention group receives the intervention and support consisting of:~Individual Goal Setting: 2-3 functional goals related to everyday life evaluated every 4th week.~SMS send every Sunday with 5 possible responses. depending on the answer of the participant it will cause a telephone call from a project about motivation and barriers for interval walking."
3070711|NCT02089477|No Intervention|Control group|Patient's in the control group receives the intervention with interval Walking and no other support.
3070712|NCT02089464|Active Comparator|NBS-rTMS + task-oriented rehabilitation|NBS-guided rTMS + task-oriented rehabilitation
3070713|NCT02089464|Sham Comparator|Sham rTMS + task-oriented rehabilitation|Sham rTMS + task-oriented rehabilitation
3070714|NCT02089451|Experimental|FIAsp|Each subject will be randomised to a treatment sequence consisting of 5 treatment periods
3070715|NCT02089438|Experimental|Saxagliptin|Ssaxagliptin is given before breakfast
3070716|NCT02089438|Experimental|´Sitagliptin|Sitagliptin is given before breakfast
3070717|NCT02089438|Experimental|Vildagliptin|Vildagliptin is given before breakfast
3070718|NCT02089425|Placebo Comparator|Placebo|Placebo patch: 0% indomethacin
3070719|NCT02089425|Experimental|K-103-IP|K-103-IP: 0.5% indomethacin
3070720|NCT02089412|Experimental|E2006: fed conditions|E2006 10-mg will be administered as a single dose under fed treatment conditions.
3070721|NCT02089412|Experimental|E2006: fasted conditions|E2006 10-mg will be administered as a single dose under fasted treatment conditions.
3070722|NCT02089399|Experimental|Treatment AB|S->S+C
3070723|NCT02089399|Experimental|Treatment C|C
3070724|NCT02089386|Experimental|Tamoxifen|Tamoxifen 20 mg daily for 12 weeks
3070725|NCT02089373|Experimental|Probe-based confocal laser endomicroscopy|
3070726|NCT02089373|Active Comparator|White light endoscopy|
3070727|NCT02089347|Experimental|SP306 Group|Participants randomized to receive SP306 vaccine intramuscularly
3070728|NCT02089347|Active Comparator|DT Group|Participants randomized to receive DT vaccine subcutaneously
3070729|NCT02089334|Experimental|RX-0201 plus everolimus (Stage 1 & 2)|RX-0201 and everolimus will be taken together as described in the Interventions description.
3070730|NCT02089321||Patients with Low Back Pain|"n= 19~Inclusion Criteria:~Between the ages of 18 and 70 years Currently seeking, but not yet initiated, treatment from a health care professional (PT, MD, DO, DC) for a chief complaint of pain between the level of the twelfth thoracic vertebrae and the coccyx Able to transition between standing, sitting, supine, prone and sidelying independently~Exclusion Criteria:~Signs of neurological impairment including diminished myotatic reflex, sensory impairment or strength deficits in a myotomal pattern No previous spine or hip surgery Serious spinal or systemic pathology Pregnancy within previous 12 months Inability to understand and follow verbal instructions in English"
3070731|NCT02089321||Healthy Controls|"n= 19~Inclusion Criteria:~Between the ages of 18 and 70 years No LBP episodes requiring clinical care by a health professional and/or greater than 3 days absence from work/school/recreation within the previous 5 years Able to transition between standing, sitting, supine, prone and sidelying independently~Exclusion Criteria:~No previous spine or hip surgery Serious spinal or systemic pathology Pregnancy within previous 12 months Inability to understand and follow verbal instructions in English"
3070732|NCT02089308|Other|Treatment-Sequence 1|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treament periods.~Treatment -Sequence 1 : Period 1 (test drug) + period 2 (reference)~The duration of each treatment period will be 3 days. Each patch will be applied for 24 hours."
3070733|NCT02089308|Other|Treatment-Sequence 2|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treament periods.~Treatment-sequence 2 : Period 1 (reference) + period 2 (test drug)~The duration of each treatment period will be 3 days. Each patch will be applied for 24 hours."
3070734|NCT02089295|Experimental|Treatment A|Single dose of 5 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3070735|NCT02089295|Experimental|Treatment B|Single dose of 20 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3070736|NCT02089295|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3070737|NCT02089282||Clavicle fractures|
3070738|NCT02089269||Cohort 1|1,550 patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention
3070739|NCT02089269||Cohort 2|100 patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention
3070740|NCT02089256|Experimental|Liraglutide|Liraglutide 0.6 mg/day subcutaneously.
3070741|NCT02089243|Experimental|Vagus nerve stimulation therapy|Surgical follow-up typically occurred 2 weeks postoperatively and, subsequently, on a variable schedule as indicated. The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes. Retrospective chart review was performed to collect follow-up and outcome data. At the time of last available clinical follow-up, the following data were collected: mean weekly seizure frequency (from seizure logs kept by caretakers or patient or caretaker report averaged of the last 3 months prior to ﬁnal follow-up), complications of VNS therapy, duration of VNS therapy, timing and all subsequent surgical procedures.
3070742|NCT02089243|Experimental|Resective surgery|The type of surgery performed consisted of standard anterior temporal lobectomy, electrocorticography tailored temporal lobectomy, anteromedial temporal lobectomy, transcortical or transsylvian or subtemporal selective amygdalohippocampectomy, temporal lobe disconnection and hippocampal transection.
3070743|NCT02089230|Experimental|MEK 162|"Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.~Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I."
3070744|NCT02089217|Active Comparator|Carotid Endarterectomy (CEA)|Carotid Endarterectomy
3070745|NCT02089217|Active Comparator|Carotid Stenting (CAS)|Carotid Stenting
3070746|NCT02089217|Experimental|Intensive Medical Management - no CEA|Intensive Medical Management alone - no CEA
3070747|NCT02089217|Experimental|Intensive Medical Management - no CAS|Intensive Medical Management alone - no CAS
3070748|NCT02089204||FMISO-PET/CT|18F-MISO PET/CT -guided dose escalation chemoradiotherapy. All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
3070749|NCT02089204||FDG-PET/CT|18F-FDG PET/CT -guided dose escalation chemoradiotherapy. All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
3070750|NCT02089204||contrast-enhanced CT|contrast-enhanced CT -guided dose escalation chemoradiotherapy . GTVs were delineated based on fusing diagnostic CT images with simulation CT images.All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
3070751|NCT02089191|Other|DACP/MyDay|Nelfilcon A contact lenses worn in Period 1, with stenfilcon A contact lenses in Period 2. Each product worn bilaterally for 12 hours over 1 day.
3070752|NCT02089191|Other|MyDay/DACP|Stenfilcon A contact lenses worn in Period 1, with nelfilcon A contact lenses in Period 2. Each product worn bilaterally for 12 hours over 1 day.
3070753|NCT02089178|Experimental|intravenous|the total intravenous anesthesia group
3070754|NCT02089178|Active Comparator|inhalation|the inhalation anesthesia group
3070755|NCT02089165|Experimental|Krill oil|The interventions are administered in the randomized order.
3070756|NCT02089165|Experimental|Krill meal|The interventions are administered in the randomized order.
3070757|NCT02089165|Active Comparator|Fish oil|The interventions are administered in the randomized order.
3070758|NCT02089152|Other|Cluster A|General education for prevention of diabetic complications in year 1, Melioidosis prevention education in years 2, 3 and 4.
3070759|NCT02089152|Other|Cluster B|General education for prevention of diabetic complications in year 1 and 2, Melioidosis prevention education in year 3 and 4.
3070760|NCT02089152|Other|Cluster C|General education for prevention of diabetic complications in year 1, 2 and 3, Melioidosis prevention education in year 4.
3070761|NCT02089139|Experimental|DISCOGEL|Percutaneous intradiscal injection of Discogel
3070762|NCT02089139|Active Comparator|conventional treatment|conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to: medications (analgesics, NSAIDs, muscle relaxants), physical therapy, manual techniques, transcutaneous electrical nerve stimulation (TENS), blocks
3070763|NCT02089126|Experimental|Gemigliptin/Glimepiride combination|Gemigliptin 50mg qd added to ongoing Glimepiride as fix-dose combination. The subjects will take a total of 2 tablets, Gemigliptin/Glimepiride combination & Placebo for Glimepiride.
3070764|NCT02089126|Placebo Comparator|Placebo|The subjects will take a total of 2 tablets, Placebo for Gemigliptin/Glimepiride combination & Glimepiride.
3070765|NCT02089113|Active Comparator|OTX-DP (Dexamethasone Punctum Plug)|Resorbable hydrogel drug delivery vehicle containing dexamethasone
3070766|NCT02089113|Placebo Comparator|PVPP (Placebo Punctum Plug)|Resorbable hydrogel drug delivery vehicle containing no drug
3070767|NCT02089100|Experimental|stereotactic body radiation therapy|The SBRT of all metastases should start in maximum 4 weeks after randomization. Beginning of systemic treatment will take place before 2 and 7 days after SBRT completion. All metastases lesions should be treated every 48h.
3070768|NCT02089100|Active Comparator|no specific treatment|no specific treatment to the oligometastatic sites except for palliation (pain, compression, hemorrhage)
3070769|NCT02089087|Experimental|CFZ533 in healthy volunteers|CFZ533 single dose in healthy volunteers
3070770|NCT02089087|Experimental|CFZ533 in rheumatoid arthritis patients|CFZ533 single dose in rheumatoid arthritis patients
3070771|NCT02089087|Placebo Comparator|Placebo|Placebo single dose
3070772|NCT02089074|Experimental|drug use counselling|Pharmacist conducting drug reconciliation, medication reviews and drug use counselling during hospitalisation. Follow up telephone calls 1 week, 1 month, 2 months and three months after discharge from hospital
3070773|NCT02089074|No Intervention|Control group|The patients in the control group receive no intervention just treatment and follow up according to national standards
3070774|NCT02089061|Experimental|Cohort 1: Rosuvastatin + BMS-919373|"Rosuvastatin 10 mg tablet orally once for Day 1 and 5~BMS-919373: 100 mg dose on Day 4 and 30 mg dose once daily on Days 5, 6 and 7 of Microcrystalline suspension"
3070775|NCT02089061|Experimental|Cohort 2: Atorvastatin + BMS-919373|"Atorvastatin 40 mg tablet once for Days 1 and 5~BMS-919373: 100 mg dose on Day 4 and 30 mg dose once daily on Days 5, 6 and 7 of Microcrystalline suspension"
3070776|NCT02089048|Experimental|Cohort 1|15 subjects receive 6mg of auranofin once every 24 hours for 7 days
3070777|NCT02089035|Experimental|MUFA-rich dairy products|"Subjects are asked to exchange habitual dairy products for modified MUFA-rich experimental dairy products for a 12 week period.~Participants will provided with standardised quantities of pasteurised UHT milk, cheese and butter that they will be asked to consume on a daily basis."
3070778|NCT02089035|Experimental|Conventional dairy products|"Subjects are asked to consume habitual non-modified dairy products for a period of 12 weeks.~Participants will provided with standardised quantities of pasteurised UHT milk, cheese and butter that they will be asked to consume on a daily basis."
3070779|NCT02089022|Experimental|Physiotherapy resources|The goal of applying ice and shortwave diathermy to the calf, ankle and sole of the foot was to verify the effect of this resources at the neuromuscular response of the lower limb and postural balance
3070780|NCT02089009|Other|Group 1 Standard Population|Retinal Imaging, vessel measurements, vessel changes of a population of a female health hospital
3070781|NCT02089009|Other|Group 2 Pregnant Population|Change in vessel diameter at perinatal visits with retinal imaging (Retinal Imaging, vessel measurements, vessel changes)
3070782|NCT02088996|Active Comparator|IT and LWD on high power|IT and LWD on high power
3070783|NCT02088996|Placebo Comparator|LWD on low power|LWD on low power
3070784|NCT02088983|Experimental|CDP-Choline|Single dose of 500 mg, 1000 mg, or 2000 mg given in one of 4 test sessions
3070785|NCT02088983|Placebo Comparator|Placebo (cellulose)|Given randomly in one of the 4 testing sessions as a comparison
3070786|NCT02088970|Active Comparator|antibiotic treatment alone|
3070787|NCT02088970|Experimental|Crosslinking + Antibiotic|"The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.~Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation."
3070788|NCT02088957|Experimental|Brivaracetam|"Subjects will receive an acute intravenous (iv) dose of Brivaracetam (BRV) 200 mg as a bolus on Day 1. If seizures recur, a second iv bolus of BRV 100 mg can be given no sooner than 15 minutes after the first bolus. If the second acute bolus is not needed within12 hours after first iv bolus, BRV will be continued as 100 mg iv dose every 12 hours (bid). The total dose for the first 24 hours of treatment should not exceed a maximum dose of 400 mg. The rate of bolus administration is 50 mg (5 mL) undiluted BRV/min. On study Day 5 (or earlier), subjects will transition from iv to oral formulation, at comparable dosing for a maximum of 6 months.~Subjects should transition to oral medication as soon as they are able to swallow tablets."
3070789|NCT02088957|Active Comparator|Phenytoin|"Subjects will receive an acute intravenous (iv) dose of Phenytoin (PHT) 20 mg/kg at a rate of 50 mg/min on Day 1. If seizures recur, a second acute dose of PHT iv will be given no sooner than 15 minutes after the first dose. Treatment with PHT iv will be continued with at least 2 daily divided doses according to site practice. Daily PHT dose can be adapted according to investigator's clinical judgment. On study Day 5 (or earlier), subjects will transition from iv to oral formulation at comparable dosing for a maximum of 6 months.~Subjects should transition to oral medication as soon as they are able to swallow tablets."
3070790|NCT02088944||exposed to IFX|
3070863|NCT02088437|Experimental|Intensive physiotherapy|additional once daily physiotherapy and once daily allied health assistant intervention
3070791|NCT02088931|Experimental|Single infusion polyclonal Treg|"3 subjects with inflammation on their 6-month surveillance biopsy following renal transplantation will receive a single infusion of a target of 320 million ex vivo selected and expanded autologous polyclonal Tregs.~After the therapy visit the patient will return for a total of nine (9) more visits for the main part of the study: 1 and 4 days after therapy, then once a week for 4 weeks, and then 3, 6, and 12 months after you get the therapy."
3070792|NCT02088918|Active Comparator|Nateglinide+Metformin|coadministration of nateglinide and metformin
3070793|NCT02088918|Experimental|Nateglinide/Metformin|Nateglinide/Metformin tablet
3070794|NCT02088905|Experimental|Parent Child Interaction Therapy|Families will either recieve Parent Child Interaction Therapy or be placed on a wait-list control group
3070795|NCT02088905|No Intervention|Wait list control|Familes will wait 16 weeks for treatment, serving as controls.
3070796|NCT02088892|Experimental|Group A|10 BCG-naïve subjects receiving intradermal BCG SSI at standard dose (2-8 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
3070797|NCT02088892|Experimental|Group B|10 BCG-naïve subjects receiving BCG Tice at standard dose (2-8 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
3070798|NCT02088892|Experimental|Group C|10 BCG-naïve subjects receiving intradermal BCG SSI at high dose (6-24 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
3070799|NCT02088892|Experimental|Group D|10 BCG-naïve subjects receiving intradermal BCG Tice at high dose (6-24 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
3070800|NCT02088892|Experimental|Group E|8-12 BCG-naïve subjects receiving the optimal strain and dose of intradermal BCG identified from preliminary results obtained from Group A, B, C and D, followed by a punch biopsy at the challenge site 14 days later.
3070801|NCT02088879|Experimental|Group1|"first : chest compression with kneeling position~second : chst compression with standing position"
3070802|NCT02088879|Experimental|Group2|"first : chest compression with standing position~second : chst compression with kneeling position"
3070803|NCT02088866|Experimental|Transdermal Lidocaine|All patients will be in this arm. This arm will be the transdermal lidocaine group.
3070804|NCT02088853|Experimental|high fat diet|
3070805|NCT02088853|Active Comparator|high carb diet|
3070806|NCT02088840||stem cell tranplant|All patients undergoing autologous or allogeneic stem cell tranplant for any underlying disease
3070807|NCT02088827|Other|Activity|During a 4 hour Meal Test subjects will cycle for 2 minutes every 20 minutes
3070808|NCT02088827|Other|Inactivity|During a 4 hour Meal Test study subjects will remain inactive (remain lying on a bed)
3070809|NCT02088814|Experimental|'EPICAP'|Secondary preventive psychological intervention with parents of children ages 1-4 with acute burn injuries, consisting of psychoeducation, trauma narrative, storybook, provision of coping skills
3070810|NCT02088814|No Intervention|Medical treatment as usual|Medical treatment of burn injuries as usual
3070811|NCT02088801|Experimental|Airtraq, blade without channel for tracheal tube|intubation
3070812|NCT02088801|Experimental|KingVision , blade without channel for tracheal tube|intubation
3070813|NCT02088801|Experimental|A.P. Advance, blade without channel for tracheal tube|intubation
3070814|NCT02088801|Experimental|Macintosh|intubation
3070815|NCT02088788|Experimental|"Board (Rad Board)"|Radial artery catheterization is performed using radio-opaque armboard
3070816|NCT02088788|Active Comparator|No Board|Regular radio-penetrating armboard is used (the one normally used during non-study procedures) with a radio-opaque pelvic shield
3070817|NCT02088775|Experimental|Diagnostic: PET scan - CT scan|Patients undergo PET-CT scan before and after standard radioembolization on day 0. A subset of patients undergo PET-CT scan on day 1, 24 hours after the day 0 post-treatment PET-CT.
3070818|NCT02088762||1 cm safety margin|1 cm safety margin
3070819|NCT02088762||2 cm safety margin|2 cm safety margin
3070820|NCT02088749|Experimental|small group treatment|lifestyle intervention for obesity delivered to small groups of approximately 12 participants/group
3070821|NCT02088749|Active Comparator|large group treatment|lifestyle intervention for obesity delivered to a large group of approximately 30 participants
3070822|NCT02088736|Active Comparator|Intravenous and Intraosseous|'IV + IO' Intravenous fluids or medications needed and a peripheral IV given 2 attempts or 90 seconds. If IV is unsuccessful, IO will attempt at the Primary site (proximal tibia). If IO is unsuccessful at scene, 2nd attempt can be done in the ambulance. Adrenaline will be delivered as according to protocol.
3070823|NCT02088736|Experimental|Intravenous|Intravenous fluids or medications needed and a peripheral IV given 2 attempts or 90 seconds. If 1st IV is unsuccessful at scene, 2nd IV attempt can be done in the ambulance. Adrenaline will be delivered according to protocol.
3070824|NCT02088723|Experimental|head of bed elevation|Compare the apnea hypopnea index with the patient in standard polysomnography and in elevated polysomnography (head of bed elevation)
3070825|NCT02088697|Experimental|ASC-01 placebo|A single oral dose of ASC-01 Placebo (sertraline 100 mg)
3070826|NCT02088697|Active Comparator|Sertraline tablet|A single oral dose of sertraline tablets (sertraline 100 mg)
3070827|NCT02088684|Experimental|LEE011 + BKM120 + fulvestrant|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating) BKM120 - daily (dose escalating) fulvestrant - i.m. - 500 mg given on day 1 and day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
3070828|NCT02088684|Experimental|LEE011 + BYL719 + fulvestrant|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating) BYL719 - daily (dose escalating) fulvestrant - i.m. - 500 mg given on day 1 and day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
3070829|NCT02088684|Experimental|LEE011 + fulvestrant|LEE011 - 28 day cycles (3 weeks on, 1 week off) or (continuous daily dosing - dose escalating) fulvestrant - 500 mg i.m. given on Day 1 and Day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
3070830|NCT02088671|Other|Anesthesia|"Drug: Propofol induction followed by randomized doses of desflurane - See intervention descriptions.~Device: Recording of EEG using NeuroSENSE - See intervention descriptions. Other: Data Collection - See intervention descriptions."
3070864|NCT02088424||group A|cases with recurrent abortion with insulin resisance
3070865|NCT02088424||GROUP B|cases that are pregnant with no history of recurrent abortion with no insulin resistance
3070831|NCT02088658|Experimental|Techonology Intensified|Subjects randomized to this group will receive: 1) the FORA system for self-monitoring; 2) weekly telephone-delivered diabetes education/skills training; 3) patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions); and 4) patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools). The intervention will be delivered by telephone once a week for 12 weeks with each session lasting ~30 minutes.
3070832|NCT02088658|No Intervention|Usual Care|Apart from study visits, patients will be followed by their primary care providers. The provider will be responsible for determining treatment parameters, making changes in the treatment regimen, and determining the timing of follow up visits. Between scheduled office encounters, contact between patient and provider will be patient initiated. The provider may use clinic nurses to follow up on problematic patients or patients with abnormal results. In essence, this group will receive the current standard of care at the study clinics.
3070833|NCT02088645|Experimental|Phase 0: One arm; Phase I: One arm|"Phase 0: 6 patients, intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without Physiogel (crossover)~Phase I: expected 12 - 18 patients, intravenous application of 3 x max. 15 GBq 177Lu-PP-F11N (increasing activity in 1 GBq steps in groups of three patients). All patients with or without Physiogel, depending on the results of the phase 0 study."
3070834|NCT02088632|Active Comparator|Incobotulinumtoxina|Xeomin 25-100 units injected to chosen area one time.
3070835|NCT02088632|Placebo Comparator|Placebo Comparator|Placebo Comparator is 1-2 ml normal saline solution injected to chosen area one time.
3070836|NCT02088619|Experimental|Quality of Life Therapy (QOLT)|Positive emotion-focused cognitive behavioral psychotherapy
3070837|NCT02088619|Active Comparator|Heart Healthy Education (HHE)|Heart healthy education program
3070838|NCT02088606|Experimental|TactiCath Quartz|TactiCath Quartz treatment
3070839|NCT02088593|Experimental|DAWN simulation|Simulated Dawn Light box
3070840|NCT02088593|Active Comparator|Sleep hygiene instructions read aloud|Standard sleep hygiene instructions were read aloud.
3070841|NCT02088580|Experimental|Triple Chronotherapy|Total sleep deprivation, Sleep phase advance, and Bright light therapy.
3070842|NCT02088567|Experimental|dHACM|Total knee arthroplasty, per the usual practice of the physician with application of dHACM between the underlying fascia and the overlying skin layers to reduce scar formation
3070843|NCT02088567|Other|Control|Total knee arthroplasty, per the usual practice of the physician without application of dHACM.
3070844|NCT02088554|Experimental|Model 400 aortic valve bioprosthesis|
3070845|NCT02088541|Experimental|Selinexor (KPT-330)|"60 mg twice weekly (Protocol Versions ≥ 5.0);~~55 mg/m² dose, based on patient's BSA, twice weekly (Protocol Versions < 5.0)."
3070846|NCT02088541|Active Comparator|Physician's Choice|"One of the following 3 conventional care regimens will be selected by the physician:~Best supportive care (BSC) including blood product transfusions, antimicrobials, growth factors as needed, and hydroxyurea;~BSC + low dose Ara-C, 20 mg bid by subcutaneous (sc) injection daily on Days 1-10/14 days (20/28 doses) to be repeated at 28 to 42 day intervals;~BSC + hypomethylating agent: azacitidine 75 mg/m² by sc injection daily on Days 1-7, (or Days 1-5 and 8-9 under Protocol Versions ≥ 5.0), for a total of 7 doses, to be repeated at ≥ 28 day intervals; or decitabine (20 mg/m² IV over 1 hour daily on Days 1-5 (or Days 1-10 under Protocol Versions ≥ 5.0), to be repeated at ≥ 28 day intervals)."
3070847|NCT02088528|Active Comparator|Aurolab glaucoma drainage device|
3070848|NCT02088528|Active Comparator|Trabeculectomy with mitomycin-c|
3070849|NCT02088515|Experimental|experimental group|experimental group: Nedaplatin(（80 mg/m2, i.v Day1）in combination with Docetaxel（75 mg/m2, i.v Day1）for each cycle, 4 cycles in total.
3070850|NCT02088515|Active Comparator|comparative group|comparative group:Cisplatin (（75 mg/m2, i.v Day1 or 25 mg/m2 Day1-3）in combination with Docetaxel（75 mg/m2, i.v Day1）for each cycle, 4 cycles in total
3070851|NCT02088502|Active Comparator|N-acetylcysteine|Patients in the N-acetylcysteine group receive 600 mg non-effervescent N-acetylcysteine tablet plus placebo twice daily from 24 hours before to 48 hours after administration of contrast material.
3070852|NCT02088502|Active Comparator|Theophylline|Patients in the Theophylline group receive 200 mg Theophylline slow-release tablet plus placebo twice daily from 24 hours before to 48 hours after administration of contrast material.
3070853|NCT02088502|Active Comparator|Theophylline plus N-acetylcysteine|Patients in the Theophylline plus N-acetylcysteine group receive Theophylline slow-release 200 mg tablet plus non-effervescent N-acetylcysteine 600 mg tablet twice daily from 24 hours before to 48 hours after administration of contrast material.
3070854|NCT02088489|Active Comparator|Atrial flutter, irrigated catheter|Patients with isthmus dependent atrial flutter, undergone to catheter ablation with Thermocool® (Biosense Webster, Diamond Bar, CA) irrigated catheter
3070855|NCT02088489|Experimental|Atrial flutter, porous tip catheter|Patients with isthmus dependent atrial flutter, undergone to catheter ablation with Thermocool® SF(Biosense Webster, Diamond Bar, CA) irrigated catheter
3070856|NCT02088476||Candidemia|Candidemia is defined as the presence of growth of any candida species in at least one blood culture obtained by either peripheral venipuncture or through an indwelling central venous catheter.
3070857|NCT02088463|Experimental|Mobilization (manual therapy)|Mobilization (manual therapy) posterior- anterior at the L3 for 2 minutes in addition to the traditional treatment in the form of infra-red and ultrasound. The treatment duration for the three groups was 3 times/week for 4 weeks.
3070858|NCT02088463|Placebo Comparator|placebo mobilization|placebo mobilization applied without force application. The treatment duration for the three groups was 3 times/week for 4 weeks
3070859|NCT02088463|Other|Ultrasound and infrared therapy|ultrasound and infrared are a traditional treatment for low back painThe treatment duration for the three groups was 3 times/week for 4 weeks.
3070860|NCT02088450|Active Comparator|Active treatment|Active treatment with nitrendipine (10-40 mg/day). If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
3070861|NCT02088450|Placebo Comparator|Placebo|Placebo tablets were identical to the study drugs with a similar schedule.
3070862|NCT02088437|Active Comparator|Usual care|usual care physiotherapy - once daily treatment whilst inpatient in acute hospital
3070866|NCT02088411|Active Comparator|Diclofenac|Subjects assigned to receive 1 tablet of Diclofenac Sodium (50 mg) and two tablets of an indistinguishable placebo three times daily for a duration of 12 weeks.
3070867|NCT02088411|Active Comparator|Wobenzym|Subjects assigned to receive 2 tablets of Wobenzym(R) and 1 tablet of an indistinguishable placebo three times daily for a duration of 12 weeks.
3070868|NCT02088411|Placebo Comparator|Placebo|Subjects assigned to receive three tablets of an indistinguishable placebo three times daily for a duration of 12 weeks.
3070869|NCT02088398|Experimental|160 mg ACY-1215 CLF (20 mg/mL) fed|• Treatment A: a single dose of 160 mg ACY-1215 CLF (20 mg/mL) in the fed state
3070870|NCT02088398|Experimental|120 mg ACY-1215 ALF (10 mg/mL) fed|• Treatment B: a single dose of 120 mg ACY-1215 ALF (10 mg/mL) in the fed state
3070871|NCT02088398|Experimental|120 mg ACY-1215 ALF (10 mg/mL) fasted|• Treatment C: a single dose of 120 mg ACY-1215 ALF (10 mg/mL)
3070872|NCT02088385|Experimental|Hemospray|Hemospray (TC-325, Cook Medical Inc, Winston-Salem, NC, USA), an adsorptive nanopowder hemostatic agent
3070873|NCT02088385|Active Comparator|Combined Conventional Technique|Standard dual therapy with saline adrenaline injection and hemoclip / heater probe application
3070874|NCT02088372||Vanguard with E1 PS Bearing|"E1™ Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty.~Vanguard Total Knee System™ The Vanguard™ Knee System was designed to incorporate features from prior designs, including: ACG, Maxim, & Ascent."
3070875|NCT02088359||Cycled light|Approximately 12 hours of light on and 12 hours of light off.
3070876|NCT02088359||Near darkness|Continue near darkness
3070877|NCT02088346||Teleconsultation|Intravenous thrombolysis guided by telemedicine consultation system based on portable hardwares
3070878|NCT02088346||Historical control|Usual stroke care without the guidance from hub hospital
3070879|NCT02088333|Experimental|mCRC intervention|intervention arm
3070880|NCT02088333|Placebo Comparator|Healthy lifestyles education|tablet-based patient education about healthy lifestyles
3070881|NCT02088307|No Intervention|Control|Subjects in the control arm will not receive an intervention.
3070882|NCT02088307|Experimental|CardioLife|The main ingredients in the CardioLife supplements are as follows: garlic, co-enzyme Q10, arjuna, hawthorn, guggul, red yeast rice, policosanol, nattokinase, tumeric/curcumin, ashwangandha, L-carnitine, grape seed extract and vitamin B12.
3070883|NCT02088294|No Intervention|Non-intervention control|No intervention will be delivered.
3070884|NCT02088294|Experimental|Lifestyle Education (LS)|"The lifestyle curriculum will be taught in twice weekly after-school sessions of ~1.25 hours, one physical activity and one nutrition-related, delivered over 12-weeks during the course of a single academic semester. The lifestyle program will utilize the Shape Up curriculum of SOSMentor, a community non-profit collaborator, modified to seamlessly integrate key concepts of the non-diet philosophy of Intuitive Eating. The curriculum fully encompasses health-promoting nutrition and physical activity practices consistent with consensus recommendations ."
3070885|NCT02088294|Experimental|LS + Stress Reduction Guided Imagery|"In addition to the after school lifestyle classes, participants will receive group Interactive Guided Imagery (IGI) consisting of standard stress reduction imagery practices, delivered once weekly for 12 weeks as an after school class of ~1.25 hours. The group IGI will be delivered by certified facilitators in the context of the facilitated group process known as Council, a group communication process used by many indigenous and other cultures."
3070886|NCT02088294|Experimental|LS + Activity/Eating Guided Imagery|"In addition to the after school lifestyle classes, participants will receive group Interactive Guided ImagerySM (IGI) delivered once weekly for 12 weeks as an after school class of ~1.25 hours. The group IGI will be delivered by certified facilitators in the context of the facilitated group process known as Council, a group communication process used by many indigenous and other cultures. Participants in this arm will receive stress reduction IGI for 4 wks, plus 8 weekly sessions with IGI content designed to promote physical activity and healthy eating."
3070887|NCT02088281|Experimental|Indigo naturalis extract in oil ointment|Indigo naturalis extract in oil ointment: each gram of ointment contains 200 μg±20 μg of indirubin.
3070888|NCT02088268|Experimental|platelet-rich plasma|wound healing
3070889|NCT02088255|Active Comparator|Static surface|The subjects will do the walking training with partial body weight support on static surface. The will be submitted to three weekly training sessions of approximately 45 minutes each , for six weeks , totaling 18 sessions
3070890|NCT02088255|Active Comparator|dynamic surface|The subjects will do the walking training with partial body weight support on dynamic surface. The will be submitted to three weekly training sessions of approximately 45 minutes each , for six weeks , totaling 18 sessions
3070891|NCT02088242|Placebo Comparator|Placebo|Subjects receiving placebo will be asked to ingest 3 capsules identical in shape, colour and size to the Astaxanthin capsules, and will contain only the inactive ingredients of the same formulation.
3070892|NCT02088242|Experimental|Astaxanthin|Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
3070893|NCT02088216|Active Comparator|N-Acetylcysteine|Participants received 600 mg of oral N-acetylcysteine BID for 12 months.
3070894|NCT02088216|Placebo Comparator|Placebo|Placebo was administered oral tablet BID for 12 months.
3070895|NCT02088203|Experimental|Single Dose Sequence 1|Dose 1, Dose 2, Dose 0: Each subject will receive a single dose during each of three separate test periods.
3070896|NCT02088203|Experimental|Single Dose Sequence 2|Dose 1, Dose 0, Dose 2: Each subject will receive a single dose during each of three separate test periods.
3070897|NCT02088203|Experimental|Single Dose Sequence 3|Dose 0, Dose 1, Dose 2: Each subject will receive a single dose during each of three separate test periods.
3070898|NCT02088203|Experimental|Single Dose Sequence 4|Dose 3, Dose 4, Dose 0: Each subject will receive a single dose during each of three separate test periods.
3070899|NCT02088203|Experimental|Single Dose Sequence 5|Dose 3, Dose 0, Dose 4: Each subject will receive a single dose during each of three separate test periods.
3070900|NCT02088203|Experimental|Single Dose Sequence 6|Dose 0, Dose 3, Dose 4: Each subject will receive a single dose during each of three separate test periods.
3071411|NCT02084719|Experimental|Group A|Patients will be tests with both the standard algorithm and the Oraquick HCV Rapid Antibody Test
3070901|NCT02088203|Experimental|Single Dose Sequence 7|Dose 5, Dose 6, Dose 0: Each subject will receive a single dose during each of three separate test periods.
3070902|NCT02088203|Experimental|Single Dose Sequence 8|Dose 5, Dose 0, Dose 6: Each subject will receive a single dose during each of three separate test periods.
3070903|NCT02088203|Experimental|Single Dose Sequence 9|Dose 0, Dose 5, Dose 6: Each subject will receive a single dose during each of three separate test periods.
3070904|NCT02088203|Experimental|Multiple Dose Sequence 1|Dose 1, Dose 0, Dose 2: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3070905|NCT02088203|Experimental|Multiple Dose Sequence 2|Dose 1, Dose 2, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3070906|NCT02088203|Experimental|Multiple Dose Sequence 3|Dose 0, Dose 1, Dose 2: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3070907|NCT02088203|Experimental|Multiple Dose Sequence 4|Dose 2, Dose 0, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3070908|NCT02088203|Experimental|Multiple Dose Sequence 5|Dose 2, Dose 6, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3070909|NCT02088203|Experimental|Multiple Dose Sequence 6|Dose 0, Dose 2, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3070910|NCT02088203|Experimental|Multiple Dose Sequence 7|Dose 1, Dose 0, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3070911|NCT02088203|Experimental|Multiple Dose Sequence 8|Dose 1, Dose 6, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3070912|NCT02088203|Experimental|Multiple Dose Sequence 9|Dose 0, Dose 1, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3070913|NCT02088190||Age group 1|Age > 60 years old
3070914|NCT02088190||Age group 2|Age < 60 years old
3070915|NCT02088177|Experimental|Long-acting injectable naltrexone|Two doses of long-acting injectable naltrexone, 380 mg by intramuscular injection in the gluteal muscle at study day 1 and again between study days 28-30.
3070916|NCT02088164||Healthy men|Healthy men who received PSA screening
3070917|NCT02088151|Experimental|Treatment|Patients receive selective retinal pigment epithelium laser treatment
3070918|NCT02088138|Experimental|Functional Electrical Stimulation|"Functional Electrical Stimulation~In the intervention group the FES was applied in the medial and lateral vastus of both thighs targeting the movement of knee extension. The application frequency was 15 Hz, lasting 40 minutes, pulse width of 0.5 ms, time ON 5s, time OFF 10s, ramp-up of 0 or 1s, descent ramp 2s and intensity as tolerance patient."
3070919|NCT02088138|Experimental|FES placebo|"Functional Electrical Stimulation placebo~The placebo group received functional electrical stimulation with the same parameters in the intervention group, except that the intensity of stimulation did not lead to visible or palpable contraction."
3070920|NCT02088125|Active Comparator|Incentive Spirometry|The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
3070921|NCT02088125|Active Comparator|Breath Stacking|Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.
3070922|NCT02088112|Experimental|Escalation|MEDI4736 will be combined with gefitinib to assess safety and tolerability
3070923|NCT02088112|Experimental|Expansion Arm|MEDI4736 will be combined with gefitinib
3070924|NCT02088099|Experimental|Complex clinical intervention|
3070925|NCT02088099|Active Comparator|Treatment as usual|
3070926|NCT02088086|Experimental|BMI screening and reporting (Group 1)|For three school years, 3rd-8th grade students will have their heights and weights measured once annually. Additionally, 5th-8th grade students will participate in five fitness assessments. Schools will send BMI reports home to parents.
3070927|NCT02088086|Active Comparator|BMI screening only (Group 2)|For three school years, 3rd-8th grade students will have their heights and weights measured once annually. Additionally, 5th-8th grade students will participate in five fitness assessments. Schools will NOT send BMI reports home to parents.
3070928|NCT02088086|No Intervention|No BMI screening or reporting (Group 3)|For two school years, 3rd-8th grade students will NOT have their heights and weights measured at school.
3070929|NCT02088073|Experimental|Zirconium silicate (acute phase)|Open label oral administration of zirconium silicate 10g three times a day for 48 hours.
3070930|NCT02088073|Experimental|Zirconium silicate (maintenance phase)|Randomized oral doses (5g, 10g, and 15g) of microporous, fractionated, protonated zirconium silicate administered once daily with breakfast for 28 days.
3070931|NCT02088073|Placebo Comparator|Silicified microcrystaline cellulose (maintenance phase)|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days.
3070932|NCT02088060|Experimental|Cannabidiol|Cannabidiol capsules 2x200 mg twice a day and placebo olanzapine capsule once a day over 4 weeks
3070933|NCT02088060|Active Comparator|Olanzapine|Olanzapine capsule 15mg once a day and placebo cannabidiol capsules twice a day over 4 weeks
3070934|NCT02088060|Placebo Comparator|Placebo|Placebo cannabidiol capsules twice a day and placebo olanzapine capsule once a day over 4 weeks
3070935|NCT02088047|Experimental|Profoveate|The experimental group will receive the ProFoveate™ intervention along with pre (baseline) and post (end line)intervention assessment. Steel pellets (1.2 mm) will be placed strategically on ears following instructions on how to use the ProFoveate™ pellets. Parents will be provided with a Patient Diary Sheet and will be instructed to perform and document daily checks for placement of the pellets. Parents will be given a one month supply of stainless steel pellets at the initial study visit. Child participants will wear the stainless steel ProFoveate™ pellets for four weeks.
3070936|NCT02088047|No Intervention|NonProFoveate|Participants in the control group will have no intervention. They will receive the initial pre testing (baseline) followed by post testing after 4 weeks.
3070937|NCT02088034|Experimental|Promotora-led Intervention|The PLI consists of a core curriculum or 12 group sessions of 90 minute duration over a 12-week period and will be followed by a maintenance phase of 10 biweekly and then monthly 90-minute sessions during months 4 through 12. One promotora will lead each session in Spanish, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
3070938|NCT02088034|Active Comparator|Usual care|One physician visit at Puentes de Salud or Congreso Health Center to discuss healthy lifestyle behaviors that promote weight loss and diabetes prevention. During that visit, UC participants will also receive standard educational materials in Spanish from the NIDDK Weight-control Information Network covering the same topics. UC participants will receive another physician visit upon completion of 1-year follow-up to review laboratory assessments.
3070939|NCT02088034|Experimental|Metformin Therapy|Participants randomized to the metformin arm of the study will receive this medication from months 1 through 12 after randomization. Subjects will receive 850 mg daily for 1 month and increase to 850 mg twice daily thereafter if no side effects are experienced.
3070940|NCT02088021|Experimental|Portico Transcatheter Aortic Valve Implantation|Placement of the SJM Portico aortic valve with a ALC delivery system
3070941|NCT02088008|Experimental|cilnidipine/valsartan|cilnidipine/valsartan tablet
3070942|NCT02088008|Active Comparator|cilnidipine+valsartan|coadministration of cilnidipine and valsartan
3070943|NCT02087995|Experimental|Continuous Glucose Monitoring System|Single-Arm, CGM Device Glucose challenge performed during a clinic session to obtain accuracy data for the CGM system compared to a venous reference measurement
3070944|NCT02087982||Seniors|"The study will be based on a 6-months assessment period, with two consecutive monitoring visits on enrollment.~Patient follow-up after 3 months will be conducted by telephone and monitoring after 6 months will be carried out as part of a routine consultation.~Each subject will have a BGA (Brief Geriatric assesment)."
3070945|NCT02087969|Experimental|Dry Needling|Dry Needling to Triceps Surae
3070946|NCT02087969|Experimental|Stretching|Subjects will be given a home exercise program of stretches which are commonly prescribed to improve ankle dorsiflexion.
3070947|NCT02087956|Active Comparator|Personalized Support for Progress (PSP)|In Personalized Support for Progress (PSP), patients meet with a navigator to prioritize their concerns using a decision aid, develop a plan based on their identified priorities, and execute the plan.
3070948|NCT02087956|Active Comparator|Enhanced Screening and Referral (ESR)|(ESR)- participant will receive personal report of their current needs and list of resources available in the community.
3070949|NCT02087943|Experimental|Apremilast 40 mg|Apremilast 40 mg administered orally twice daily (BID) for 12 weeks (following dose titration) during the placebo controlled phase followed by 40 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
3070950|NCT02087943|Experimental|Apremilast 30 mg|Apremilast 30 mg administered orally BID for 12 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
3070951|NCT02087943|Experimental|Placebo + Apremilast 40 mg|Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 40 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
3070952|NCT02087943|Experimental|Placebo + Apremilast 30 mg|Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 30 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
3070953|NCT02087943|Placebo Comparator|Placebo|Oral Placebo tablets administered twice daily (BID) for 12 weeks during the placebo-controlled phase.
3070954|NCT02087930||Cow milk allergy children|Children affected by Immunoglobulin E medited cow milk allergy
3070955|NCT02087930||healthy control|healthy infants
3070956|NCT02087917|Placebo Comparator|Placebo|
3070957|NCT02087917|Active Comparator|HS-25 5 MG|
3070958|NCT02087917|Active Comparator|HS-25 10 MG|
3070959|NCT02087917|Active Comparator|HS-25 20 MG|
3070960|NCT02087917|Active Comparator|HS-25 30 MG|
3070961|NCT02087904|Active Comparator|ABT-981 low dose|Low dose
3070962|NCT02087904|Active Comparator|ABT-981 medium dose|Medium dose
3070963|NCT02087904|Active Comparator|ABT-981 high dose|High dose
3070964|NCT02087904|Placebo Comparator|Placebo|Placebo
3070965|NCT02087891|No Intervention|CTL|Wait-list control, no intervention. Intervention offered after week 16 and outcomes are collected.
3070966|NCT02087891|Experimental|Web-based stress management (WSM)|Subjects randomized to this group will receive access to the WSM program to complete on their own time.
3070967|NCT02087891|Experimental|WSMg1|Subjects randomized to this group will receive access to WSM with group support. They will meet once per week for 1 hour. Meeting will be led by one of their peers who is a non-expert facilitator.
3070968|NCT02087891|Experimental|WSMg2|Subjects randomized to this group will receive access to WSM and group support and clinical expert support. They will attend 4 weekly support groups led by a peer non-expert facilitator and 4 weekly support groups led by a clinical psychologist.
3070969|NCT02087878||Group 1|To collect and store blood and biopsy samples obtained from CD or UC patients exposed to adalimumab and diagnosed with HSTCL for the purpose of identifying potential biomarkers and genetic mutations in patients who develop HSTCL.
3070970|NCT02087865|Active Comparator|Donepezil HCL|Participants will receive 5mg of donepezil HCL for 4 weeks and then 10mg of donepezil HCL for 20 weeks.
3070971|NCT02087865|Placebo Comparator|Placebo|Participants will receive placebo for 24 weeks.
3070972|NCT02087865|No Intervention|Control Group|Participants without a family history of AD will undergo the study evaluations but will not receive any study drug
3070973|NCT02087852||kidney cancer patients receiving care at MSKCC|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
3071012|NCT02087579|Experimental|Cohort D: Quetiapine|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
3071013|NCT02087579|Experimental|Cohort E: Risperidone|Administration of oral formulation or LAI will continue at a participant's usual dose and dosing schedule.
3070974|NCT02087852||relatives of patients with kidney cancer|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
3070975|NCT02087852||healthy controls who are unrelated & do not have hx of cancer|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
3070976|NCT02087839|Experimental|Radiation Therapy + ZD6474|"Radiation Therapy - Phase I: 45 Gy at 3 Gy per fractions once a day.~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day.~ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth."
3070977|NCT02087826|Active Comparator|Carriers of the SLC16A11 risk allele|"Day 1: Mixed Meal Tolerance Test~Day 3-7: 500mg metformin, twice daily~Day 8: Mixed Meal Tolerance Test in presence of Metformin"
3070978|NCT02087826|Placebo Comparator|Non-carriers of the SLC16A11 risk allele|"Day 1: Mixed Meal Tolerance Test~Day 3-7: 500mg metformin, twice daily~Day 8: Mixed Meal Tolerance Test in presence of Metformin"
3070979|NCT02087813|Experimental|A1AT|Alpha1-antitrypsin 120mg/kg once weekly for a total of 4 doses, to be given intravenously. This will be given in addition to standard of care 3-5 days of 1000mg IV methylprednisolone.
3070980|NCT02087813|Active Comparator|Standard of care|Patients that do not wish to receive study treatment but agree to otherwise follow study protocol will also be enrolled in an observational cohort. They will receive the standard of care 3-5 days 1000mg IV methylprednisolone.
3070981|NCT02087800||F Phase Lab session|Potential participants will complete an interview over the phone, followed by an in clinic office visit, to assess eligibility. Those who meet eligibility criteria will be invited to attend two four-hour lab sessions. Lab sessions will occur in the F (F phase lab session) and L phases (L phase lab session) of menses. In this arm, the F phase lab session will be first. Followed by the L phase lab session.
3070982|NCT02087800||L Phase Lab Session|Potential participants will complete an interview over the phone, followed by an in clinic office visit, to assess eligibility. Those who meet eligibility criteria will be invited to attend two four-hour lab sessions. Lab sessions will occur in the F (F phase lab session) and L phases (L phase lab session) of menses. In this arm, the L phase lab session will be first. Followed by the F phase lab session.
3070983|NCT02087787|No Intervention|Control|The control group will be provided the standard method, which is providing the Cancer Legal Line (CALL) brochure with a short explanation of the resource.
3070984|NCT02087787|Experimental|Intervention|The intervention group will be provided with a 2 hour consultation with an attorney in the BMT Legal Clinic with potential follow-up as needed.
3070985|NCT02087774|No Intervention|Control School|Control School received no intervention.
3070986|NCT02087774|Experimental|6 minutes activity|Implementation of 6 minutes of physical activity daily into the school day routine. Children can jog in place, do jumping jacks or dance.
3070987|NCT02087748|Active Comparator|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
3070988|NCT02087748|Placebo Comparator|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
3070989|NCT02087735|Experimental|cranberry extract 1|One capsule with a proanthocyanidin standardized cranberry extract of 36 mg and one capsule of placebo cranberry extract.
3070990|NCT02087735|Experimental|cranberry extract 2.|Two capsules with a proanthocyanidin standardized cranberry extract of 36 mg.
3070991|NCT02087735|Placebo Comparator|cranberry extract 3.|Two capsules with a proanthocyanidin standardized cranberry extract of 2 mg.
3070992|NCT02087722|Experimental|KI1001|
3070993|NCT02087722|Placebo Comparator|Placebo|
3070994|NCT02087709|Experimental|Low-calorie diet|The subjects were prescribed a daily energy intake 500 kcal lower than the estimated energy requirement.
3070995|NCT02087696|Other|Naive biological treatment|"Rheumatoid arthritis patients with intolerance or poor compliance or contraindication to methotrexate and who have not received previous biological treatment.~Tocilizumab dose 8mg/kg administered every 4 weeks for 24 weeks"
3070996|NCT02087696|Other|Previous Biological treatment|"Rheumatoid arthritis patients with intolerance or poor compliance or contraindication to methotrexate and who have not received more than two previous biological treatments.~Tocilizumab dose 8mg/kg administered every 4 weeks for 24 weeks"
3070997|NCT02087683|Other|Vitamin D Supplementation|Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months.
3070998|NCT02087683|Placebo Comparator|Control Group (Placebo)|Participants in this group will receive a placebo containing gelatin and corn oil per day for 12 months
3070999|NCT02087670|Active Comparator|controlled, supervised exercise protocol|controlled, supervised exercise protocol within a cardiac rehabilitation program
3071000|NCT02087670|Placebo Comparator|community based exercise|educational program and not supervises exercise program
3071001|NCT02087657|Experimental|Hyperbaric Oxygen Treatment|Administration of hyperbaric oxygen on the morning of stem cell transplant (Day 0).
3071002|NCT02087644|Experimental|CYT003|Injections of CYT003
3071003|NCT02087644|Placebo Comparator|Placebo|Injections of placebo
3071004|NCT02087631|Experimental|Quetiapine|Extended-release quetiapine fumarate up to 300mg once daily for 4 weeks
3071005|NCT02087618|Active Comparator|Kodro+|Will begin Kodro program at baseline
3071006|NCT02087618|Placebo Comparator|Kodro+D|Will begin Kodro program 12-weeks post baseline
3071007|NCT02087592|No Intervention|Control|Usual standard of care
3071008|NCT02087592|Experimental|Intervention|Usual standard of care plus structured physical exercise training plus mediterranean-style diet
3071009|NCT02087579|Experimental|Cohort A: Aripiprazole|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
3071010|NCT02087579|Experimental|Cohort B: Olanzapine|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
3071011|NCT02087579|Experimental|Cohort C: Paliperidone|Administration of prolonged-release (extended-release) tablets or long-acting injectables (LAI) will continue at a participant's usual dose and dosing schedule.
3071014|NCT02087566|Other|Administration of linezolid to 6 healthy volunteers|Administration of linezolid to 6 healthy volunteers {six healthy subjects with normal renal function (CLcr ˃80 ml/min)}
3071015|NCT02087566|Other|Administration of linezolid to 6 acute renal failure patients|Administration of linezolid to 6 acute renal failure patients {(six patients with acute renal failure (RF) (30˂CLcr˂80 ml/mine)}
3071016|NCT02087566|Other|Administration of linezolid to 6 ESRD patients|Administration of linezolid to 6 end-stage renal disease (ESRD) patients during an intra-dialytic period (on-dialysis): 6 patients on long term HD (minimum period of dialysis was 40 month while maximum period were 130 month) with an ideal body weight of >60 kg (calculated as {height (cm) -100}×0.9) and a body mass index between 20 and 26 kg/m2 (calculated as {weight (kg)/height (m2)}).
3071017|NCT02087553||Transfused pediatric patients|Children who might receive packed red blood cell (PRBC) transfusion will be enrolled after obtaining consent from their parents/legal guardians and assent from the patient, if possible. Transfusion of red blood cells will be done according to standard of care.
3071018|NCT02087553||Saline/Albumin infusion|Children who might receive albumin or saline for volume resuscitation will be enrolled after obtaining consent from their parents/legal guardians and assent from the patient, if possible. Infusion will be done according to standard of care.
3071019|NCT02087540|Experimental|Telmisartan 80mg & Rosuvastatin 20mg|PO, Once Daily, 8 weeks
3071020|NCT02087540|Experimental|Telmisartan 80mg & Rosuvastatin 10mg|PO, Once Daily, 8weeks
3071021|NCT02087540|Active Comparator|Telmisartan placebo & Rosuvastatin 20mg|PO, Once Daily, 8 weeks
3071022|NCT02087540|Active Comparator|Telmisartan Placebo & Rosuvastatin 10mg|PO, Once Daily, 8 weeks
3071023|NCT02087540|Active Comparator|Telmisartan 80mg & Rosuvastatin placebo|PO, Once Daily, 8 weeks
3071024|NCT02087540|Placebo Comparator|Telmisartan placebo & Rosuvastatin placebo|PO, Once Daily, 8 weeks
3071025|NCT02087527|Experimental|CORTICOSTEROID|In addition to standard care for cellulitis, subject will receive intravenous Dexamethasone (8mg/2ml) 0.15 mg/kg/dose every 6 hours for the first 48 hours
3071026|NCT02087527|Placebo Comparator|NORMAL SALINE|In addition to standard care for cellulitis, subject will receive normal saline solution administered intravenously using the same volume as the active drug group every 6 hours for the first 48 hours
3071027|NCT02087514|Active Comparator|Transfusion of PRBC stored for 1 week|Subjects will receive blood transfusion with packed red blood cells stored for 1 week.
3071028|NCT02087514|Experimental|Transfusion of PRBC stored for 2 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 2 weeks.
3071029|NCT02087514|Experimental|Transfusion of PRBC stored for 3 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 3 weeks.
3071030|NCT02087514|Experimental|Transfusion of PRBC stored for 4 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 4 weeks.
3071031|NCT02087514|Experimental|Transfusion of PRBC stored for 5 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 5 weeks.
3071032|NCT02087514|Experimental|Transfusion of PRBC stored for 6 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 6 weeks.
3071033|NCT02087501|Other|HORIZON AAA Stent Graft|All patients will received the HORIZON AAA Stent Graft
3071034|NCT02087488|Experimental|auricular acupuncture(AA) & Eszopiclone|The disposable Seirin Pyonex Needle will be chosen as AA material to attach every 3 days for 4 weeks, meanwhile, oral Eszopiclone 1 piece (3mg) will be applied 15 minutes before going to sleep everyday for 4 weeks. The manufacturer of disposable Seirin Pyonex Needles is Seirin Corporation, a Japanese company.
3071035|NCT02087488|Placebo Comparator|placebo AA & Eszopiclone|The disposable Pyonex Zero Needle, a non-invasive material will be chosen as placebo AA, with auricular acupoints have no certain effect on PI. Additionally, 1 piece (3mg) Eszopiclone will be administrated to participants 15 minutes before going to sleep everyday for 4 weeks.
3071036|NCT02087475|Experimental|Neoadjuvant therapy arm|FOLFIRI * 6 cycles +/- radiotherapy -> surgery -> FOLFIRI * 6 cycles
3071037|NCT02087475|Active Comparator|Adjuvant therapy arm|Surgery -> FOLFIRI * 12 cycles +/- radiotherapy
3071038|NCT02087462|Experimental|Electroacupuncture (EA)|Use Electroacupuncture only
3071039|NCT02087462|Other|EA + Traction|Use electroacupuncture and traction together
3071040|NCT02087462|Other|EA + Traction + Oral Medication|Combine electroacupuncture, traction and oral medication (Voltaren and Vitamin B1) together for treatment
3071041|NCT02087449||E1-Hip Bearing|E1-Hip Bearing, Evaluate E1 Wear, Clinical Performance of E1 Liner in THA in Korean Patient Population
3071042|NCT02087436|Active Comparator|Taperloc Complete Standard|Group one will receive a total hip replacement with Taperloc Complete Standard. Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
3071043|NCT02087436|Active Comparator|Taperloc Complete Microplasty|Group one will receive a total hip replacement with Taperloc Complete Microplasty.Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.
3071044|NCT02087423|Experimental|MEDI4736|see below
3071045|NCT02087410||study|patients with polycystic ovary syndrome
3071046|NCT02087410||control|healthy patients serves as control group
3071047|NCT02087397|Experimental|AD-SVF Cell Injection|
3071048|NCT02087384|Experimental|Gardasil|Gardasil
3071049|NCT02087384|Placebo Comparator|Placebo|Intramuscular Saline 0.9% vaccination at 0, 2 and 6 months
3071050|NCT02087371||Included patients|Patients with end-stage liver failure and registered on transplantation list.
3071051|NCT02087358||Stress and craving|This 3 weeks study examines the correlation between stress and alcohol using an ecological, prospective design. Participants will be given phone calls 4 times a day for 3 weeks, assessing perceived stress and alcohol related craving.
3071052|NCT02087345||Dental erosions|
3071091|NCT02087007|Experimental|group 1|Cilostazol 50mg, Cilostzaol 100mg
3071092|NCT02087007|Placebo Comparator|group 2|placebo
3071093|NCT02086994|Active Comparator|cabetocin|a single dose of carbetocin (100 μg in 1 mL ampoule, Pabal) given intravenously after delivery of anterior shoulder
3071053|NCT02087332|Experimental|Prolonged release Torasemide (Britomar)|"Prolonged release Torasemide (Britomar) - round, biconvex, white to off-white tablets debossed SN with one side. 1 tablet contains active substance - torasemide 5 or 10 mg and excipients - guar gum, maize starch, anhydrous colloidal silica, magnesium stearate, lactose.~Dosage scheme: per os, once a day, regardless of meals. The common starting dose in CHF - 10-20 mg once a day. If adequate diuretic effect is absent, the dose is increased approximately twofold up to adequate diuretic effect."
3071054|NCT02087332|Active Comparator|Torasemide (Diuver)|Torasemide (Diuver) - white to off-white, round, biconvex tablets. 1 tablet contain active substance - torasemide 5 or 10 mg and excipients - lactose monohydrate, maize starch, sodium glycolate starch, anhydrous colloidal silica, magnesium stearate. Dosage scheme: per os, once a day, after meals. Therapeutic dose - 5 mg a day. If necessary, a dose may be increased up to 20 mg a day, in some cases - up to 40 mg.
3071055|NCT02087319|Experimental|platelet-rich plasma|hair loss, baldness
3071056|NCT02087306|Experimental|CMX001|
3071057|NCT02087293|Experimental|Intervention group, IVR call, RPh counseling|Group receives interactive voice response automated call asking about side effects of newly prescribed medications; has opportunity to speak with study pharmacist via phone about medication
3071058|NCT02087293|No Intervention|Control|Intervention patients are matched with control patients; control patients have only chart review completed.
3071059|NCT02087280||Anorexia Nervosa|
3071060|NCT02087280||Healthy controls|
3071061|NCT02087267||1- or 2-level spinal fusion|Patients suffering from symptomatic degenerative disc disease or degenerative spondylolisthesis grade 1 or 2 with chronic low back pain, pain in the leg or buttock, muscle weakness, sensation abnormalities and/or neurogenic claudication requiring 1- or 2-level lumbar or lumbar-sacral spinal fusion.
3071062|NCT02087241|Experimental|AZD1775 + carboplatin + pemetrexed|Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.
3071063|NCT02087241|Experimental|Placebo + carboplatin + pemetrexed|Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.
3071064|NCT02087228|Experimental|Hydrothermal ablation|Uterine ablation performed with a device that circulates heated water inside the uterus
3071065|NCT02087228|Active Comparator|radiofrequency energy|ablation performed with a device that uses radiofrequency energy.
3071066|NCT02087215|Active Comparator|boron gel|diabetic foot ulcer care with formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v).
3071067|NCT02087215|Placebo Comparator|control gel|placebo gel containing polymer of carbopol ultrex (1%)
3071068|NCT02087202|Experimental|magnesium|magnesium is added perioperatively to those patients undergoing staged total knee arthroplasty and other surgeries.
3071069|NCT02087202|Experimental|ketamine|ketamine is administered to those patients undergoing stated TKA and other operations.
3071070|NCT02087202|Placebo Comparator|control|normal saline (placebo) is administered to the patients.
3071071|NCT02087189||ICD/ CRT-D therapy|
3071072|NCT02087176|Experimental|AZD 1775, antimitotic, pegfilgrastim|AZD 1775, antimitotic agent + pegfilgrastim 21 day Cycle, maximum of 4 cycles
3071073|NCT02087176|Placebo Comparator|Placebo + antimitotic + pegfilgrastim|Placebo + antimitotic+pegfilgrastim 21 day cycle, maximum of 4 cycles
3071074|NCT02087163|Experimental|Movement Enhancement Technique|Movement Enhancement Technique Clear Aligner
3071075|NCT02087150|No Intervention|Medical management|Medical management will consist of 6 weeks of daily intranasal steroid (triamcinolone acetonide)
3071076|NCT02087150|Experimental|Eustachian tube dilation|Eustachian tube dilation with medical management for Eustachian tube dysfunction. Eustachian tube dilation will be conducted using the Acclarent Eustachian Tube Balloon Catheter (ETBC). Medical management will consist of intranasal steroid.
3071077|NCT02087137|Active Comparator|Memory and Aging Program|The Memory and Aging Program intervention consists of five 2-hour sessions conducted over five consecutive weeks. The content of the program includes: (a) the provision of factual information (i.e., about memory, age-related memory changes, lifestyle factors affecting memory, and memory strategies) in an informal lecture format; and (b) memory intervention (i.e., practice and application of several evidence-based memory strategies) in a hands-on interactive format.
3071078|NCT02087137|No Intervention|Wait-list Control|Participants randomized to the wait-list control group will receive no intervention following randomization. They will be offered the intervention immediately following completion of the week 14 outcome testing session.
3071079|NCT02087124|Experimental|0g whey protein|0g whey protein dissolved in 200 milliliter (mL) water.
3071080|NCT02087124|Experimental|10g whey protein|10g whey protein dissolved in 200 milliliter (mL) water.
3071081|NCT02087124|Experimental|20g whey protein|20g whey protein dissolved in 200 milliliter (mL) water.
3071082|NCT02087111|Experimental|Treatment|All patients who are fulfil the entry criteria are treated for 24 weeks with 40 Kd Pegylated interferon alfa 2a, Ribavirin and 12 weeks with telaprevir.
3071083|NCT02087098||Patients with residual OAB symptoms|Urge urinary incontinence, urgency, and frequency after treatment with other antimuscarinics
3071084|NCT02087085|Experimental|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye on Day 1, and every 3 months through Month 21.
3071085|NCT02087085|Sham Comparator|Sham|Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.
3071086|NCT02087072||Recently discharged homebound patients|
3071087|NCT02087059|Experimental|Ruxolitinib|Ruxolitinib was administered orally twice daily at the starting dose of 5 mg, 15 mg or 20 mg bid based on Baseline platelet counts. The dosage was subsequently adjusted for safety and efficacy so that each patient was titrated to their most appropriate dose.
3071088|NCT02087046|Other|Stimulation|Deep Brain Stimulation with the Libra System
3071089|NCT02087033|Placebo Comparator|ritmonutra and placebo|ritmonutra 2 tablets/day by mouth for 4 weeks sugar pill manufatured to simulate ritmonutra: 2 tablets/day by mouth for 4 weeks
3071090|NCT02087020||Periprosthetic joint infection|Patient treated with 'Debridement, antibiotics and implant retention' for early postoperative periprosthetic joint infection at Danderyd Hospital between 2007-01-01 and 2012-12-01
3071094|NCT02086994|Active Comparator|misoprostol|misoprostol (600 μg, 3 tables) sublingually after the delivery of the anterior shoulder of the baby.
3071095|NCT02086968|Active Comparator|Injectafer|2 doses of Injectafer, at 15 mg/kg for a maximum single dose of 750 mg given on Days 0 and 7 for a total of up to 1500 mg
3071096|NCT02086968|Active Comparator|Ferrous Sulfate tablets|Oral Ferrous Sulfate at 325 mg (1 tablet) three times a day for 28 days
3071097|NCT02086955|No Intervention|Standard care|All participants receive three specially-developed brochures with information regarding the diabetic foot condition. The brochures containes explanations to a) the cause and warning signs of diabetic foot ulcers, b) the precautions patients can take in their daily life, and c) helpful foot gymnastics to be practiced at home.
3071098|NCT02086955|Experimental|Nursing counseling|The participants who are randomized in the intervention group receive standardized education regarding diabetic foot care. The nurse-led outpatient intervention go on for five weeks. During a period of five weeks, the participants are provided with weekly education, skill training, and counseling sessions on foot care.
3071099|NCT02086942|Experimental|modified VCD regimen1|"Induction therapy：modified VCD regimen1 for 4 cycles,28 Days per Cycle.Intensive therapy：modified VCD regimen1 for 5 cycles.~Maintenance treatment:CP for 12 cycles. Interval between every two cycles for one month.~Interventions:~Drug: Bortezomib 1.6mg/m2 SC,Days 1, 6, 11, 16; Drug:Cyclophosphamide 300mg/m2 VD,Days 1-3; Drug: Dexamethasone 40 mg/d VD,Days 1, 6, 11,16; We undertook a pharmacodynamic substudy at selected sites. Blood samples were collected in cycle 1 on day 1, 6,11,16 before the dose was given and at several time points after dosing. We analysed whole blood samples to measure 20S proteasome chymotryptic activity, with a standard method. Pharmacodynamic parameters were calculated by analysis of percentage inhibition of 20S proteasome activity-time data."
3071100|NCT02086942|Experimental|modified VCD regimen2|"Induction therapy：modified VCD regimen1 for 4 cycles,28 Days per Cycle.Intensive therapy：modified VCD regimen 2 for 5 cycles.~Maintenance treatment:CP for 12 cycles. Interval between every two cycles for one month.~Interventions:~Drug: Bortezomib 1.3mg/m2 SC,Days 1, 6, 11, 16; Drug:Cyclophosphamide 300mg/m2 VD,Days 1-3; Drug: Dexamethasone 40 mg/d VD,Days 1, 6, 11,16; We undertook a pharmacodynamic substudy at selected sites. Blood samples were collected in cycle 1 on day 1, 6,11,16 before the dose was given and at several time points after dosing. We analysed whole blood samples to measure 20S proteasome chymotryptic activity, with a standard method. Pharmacodynamic parameters were calculated by analysis of percentage inhibition of 20S proteasome activity-time data."
3071101|NCT02086929|Experimental|Trazodone|"300 mg/day for 8 weeks (including 1 week 150 mg/day of dose-titration). After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 450 mg/day.~Dosage form: capsule."
3071102|NCT02086929|Active Comparator|Venlafaxine XR|"75 mg/die for 8 weeks. After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 225 mg/day.~Dosage form: capsule."
3071103|NCT02086916||Inpatients who test positive for CDI|Observational study, hence no intervention will be administered
3071104|NCT02086903|Experimental|Ticagrelor 90 mg|The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
3071105|NCT02086903|Experimental|Clopidogrel 600 mg|The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
3071106|NCT02086890|Experimental|Electro-acupuncture|Electro-acupuncture applied to acupoints around the eye and traditional needle acupuncture applied to acupoints throughout the body at 10 half-hour sessions over 2 weeks
3071107|NCT02086890|Sham Comparator|Sham Electro-acupuncture|No electro-acupuncture applied to non-acupoints around the eye and traditional needle acupuncture applied to non-acupoints throughout the body; i.e., to locations not on the acupuncture meridians; at 10 half-hour sessions over 2 weeks
3071108|NCT02086890|Experimental|Laser acupuncture|Laser applied to acupoints throughout the body at 10 sessions each lasting 15 minutes over a 2 week period
3071109|NCT02086890|Sham Comparator|Sham Laser acupuncture|An inactive sham laser (red light only) applied to non-acupoints throughout the body; i.e., to locations not on the acupuncture meridians; at 10 sessions each lasting 15 minutes over a 2 week period
3071110|NCT02086890|Experimental|Transcorneal Electrical Stimulation|Transcorneal Electrical Stimulation at 150% individual phosphene threshold applied to both eyes using DTL electrodes at 6 weekly 30 minute sessions
3071111|NCT02086890|Sham Comparator|Sham Transcorneal Electrical Stimulation|Sham Transcorneal Electrical Stimulation at 0% individual phosphene threshold (no stimulation) applied to both eyes using DTL electrodes at 6 weekly 30 minute sessions
3071112|NCT02086877||ICU Survivors who required > 72 hrs mechanical ventilation|No intervention
3071113|NCT02086864|No Intervention|Usual care|
3071114|NCT02086864|Active Comparator|Individualized homeopathic medicine treatment|Participant will have a homeopathic consultation and be given a homeopathic medicine. Homeopathic medicines are chosen from those available for sale in Canada.
3071115|NCT02086864|Placebo Comparator|Unmedicated lactose/sucrose pill|Participant will receive a homeopathic consultation and receive an unmedicated lactose/sucrose pill.
3071116|NCT02086851|Experimental|Lifestyle Intervention plus Parent Motivational Interviewing|Lifestyle intervention + Parent MI
3071117|NCT02086851|Active Comparator|Lifestyle Intervention alone|lifestyle intervention alone
3071118|NCT02086838|Active Comparator|Theragran Hematinic, oral iron, 120 mg elemental iron/|pregnant women taking 60 mg elemental iron twice per day (120 mg/day) using iron tablets (Theragran Hematinic)® SmithKline Beecham, Egypt an affiliated co. to GlaxoSmithKline. Adherence to the treatment will be monitored by asking the women to bring back the empty packs and mark the consumption of tablets on calendar.
3071155|NCT02086539|Experimental|Amazon|This arm will receive a recruitment letter with the image of an Amazon gift card and told they will receive the $25 gift card if they enroll in the study.
3071156|NCT02086526|Experimental|Metformin|Metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.
3071412|NCT02084719|Active Comparator|Group B|Patients will be tested only with the standard algorithm
3071119|NCT02086838|Active Comparator|low molecular weight iron dextran, total dose infusion|Pregnant women taking elemental iron in the form of low molecular weight dextran complex intravenously as a total dose infusion (T.D.I) using iron dextran ampules (Cosmofer)R pharmacosmos Denmark (Inspire Pharma Egypt). Patients selected for parental iron will be admitted as day cases in the hospital in a single visit. The required dose has to be individually adapted according to the total iron deficit which is dependent on the patient's body weight and hemoglobin status. Total iron dose (mg) = weight (kg) X Hemoglobin deficit {target Hemoglobin (g/l)- Actual Hemoglobin (g/l)} X 0.24 + 500 mg.
3071120|NCT02086825|Experimental|Rifaximin|
3071121|NCT02086825|Experimental|Lactulose|
3071122|NCT02086799|Experimental|IV thyroxin|IV thyroxin
3071123|NCT02086799|Placebo Comparator|control IV saline|Placebo
3071124|NCT02086786|Experimental|Gluteus (Risperidone ISM)|Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
3071125|NCT02086786|Experimental|Deltoid (Risperdione ISM)|Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
3071126|NCT02086773|Experimental|Restrictive transfusion threshold|Patients receive blood transfusion with transfusion threshold of 7g/dL Hb
3071127|NCT02086773|Active Comparator|Standard transfusion threshold|Patients receive blood transfusion with transfusion threshold of 8g/dL Hb
3071128|NCT02086760|Experimental|Ultrasonography sensibilized by oral hydratation|Ultrasonography before, 30 min and 90 min following hydratation.
3071129|NCT02086747|Active Comparator|Acetaminophen|Postoperative 72 hours acetaminophen 1 g iv 4 times a day for 72 hours iv
3071130|NCT02086747|Placebo Comparator|isotonic|1 g intravenous %0.9 NaCl four times Daily for 72 hours
3071131|NCT02086734||mRCC patients assessed with Perfusion CT|Study population consists of patients with metastasized renal cancer eligible for AAT with either Sunitinib (Sutent®), Pazopanib (Votrient ®), Sorafenib (Nexavar®) evaluated with Perfusion-CT
3071132|NCT02086721|Experimental|Oligometastatic cancer patients; N=18|
3071133|NCT02086708|Experimental|Shear Wave Sonoelastography, Fibrosis stage|Shear Wave sonoelastography is performed on patients who are scheduled for a non-focal liver biopsy.
3071134|NCT02086695||Cancer Group|All subjects with cancer who will be treated with anyone of the following chemotherapy drugs; Pazopanib, Sutent or Bevacizumab
3071135|NCT02086682||Hospitalized patients|The group includes adult hospitalized patients requiring hemodialysis at the inpatient dialysis unit or the ICU. The study is observational, and no intervention is administered.
3071136|NCT02086669|Experimental|Pneumatic dilatation|Repetitive pneumatic dilatation as the initial treatment followed by repetitive dilatation in case of dysphagia recurrence.
3071137|NCT02086669|Active Comparator|Surgical myotomy|Laparoscopic myotomy and subsequent follow up.
3071138|NCT02086656|Experimental|open label|Single arm, open label
3071139|NCT02086643|Experimental|Retroclavicular block|Retroclavicular block
3071140|NCT02086630|Experimental|Intervention|The Heart to Heart (HTH) intervention was a flexible and individualized intervention with the following components: 3 intervention sessions with video-components; patient navigation lasting up to 24 weeks; treatment initiation support groups (up to 5); and inclusion of a Support Partner. This is a behavioral intervention. The intervention uses Motivational Interviewing.
3071141|NCT02086630|No Intervention|Control|Treatment as usual
3071142|NCT02086617|Other|ultrasound of aorta|
3071143|NCT02086604|Experimental|Starting Dose (brentuximab vedotin & lenalidomide)|"Brentuximab vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
3071144|NCT02086604|Experimental|Dose Level 1 (brentuximab vedotin & lenalidomide)|"Brentuximab Vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
3071145|NCT02086604|Experimental|Dose Level 2 (brentuximab vedotin & lenalidomide)|"Brentuximab Vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
3071146|NCT02086591|Experimental|Doxycycline|Doxycycline 200 mg twice daily
3071147|NCT02086578|Experimental|Group 1|Physical examination by MD, optional Breast MRI, Breast-Q© at baseline (after permanent implant exchange, physical exam and Breast-Q© may be done after the initiation of IMRT), 12 ± 2 months and 24 ± 2 months post- IMRT. Total length of the follow-up time will be 24 ± 2 months post-IMRT. A subset of 10 left-sided patients will receive 13N-NH3 PET scans within the radiation simulation session. A CT for coronary calcium scoring and a low-dose CT for attenuation correction will also be obtained at this time. Myocardial blood flow will be measured during rest and at peak stress with 13N-NH3 as a perfusion tracer. A follow-up 13N-NH3 PET study with low-dose CT for attenuation correction will be obtained 12-18 months (± 6 months) post-IMRT.
3071148|NCT02086578|Experimental|Group 2|Physical examination by MD, optional Breast MRI, Breast-Q © at baseline (after permanent implant exchange and after IMRT), 18 ± 2 months and 30 ± 2 months post-IMRT, as these patients will undergo exchange of the temporary expander for the permanent implant approximately 4-8 months following the completion of radiation (at the discretion of the treating plastic surgeon). Total length of the follow-up time will be 30 ± 2 months post-IMRT
3071149|NCT02086565|Experimental|Portal training and home visits|Portal training and home visits from a community health worker to promote care coordination and use of the patient portal
3071150|NCT02086565|Active Comparator|portal training|Participants are assured internet access and taught to use the patient portal
3071151|NCT02086552|Experimental|Treatment (sonidegib, lenalidomide)|Patients receive sonidegib PO QD on days 1-28 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve sCR, CR, VGPR, PR, MR, or SD (or usCR, uCR, uVGPR, uPR, uMR) continue treatment in the absence of disease progression or unacceptable toxicity.
3071152|NCT02086539|No Intervention|Normal Letter|This arm will receive the recruitment letter in a business sized envelope. The letter states the participant will receive a $25 check upon enrollment into the study.
3071153|NCT02086539|Experimental|Large Envelope|This arm will receive the recruitment letter in an 8.5 x 11 inch envelope. The letter states the participant will receive a $25 check upon enrollment into the study.
3071154|NCT02086539|Experimental|Priority Mail|Group 3 will receive a recruitment letter shipped via USPS priority mail. The letter states the participant will receive a $25 check upon enrollment into the study.
3071157|NCT02086526|Other|Delayed Start Metformin|After baseline study visit, this arm will return after three months without metformin for a repeat of the baseline study visit prior to initiating metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.
3071158|NCT02086513|Experimental|LDE225|LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose of 200 mg, 400 mg, 600 mg, or 800 mg depending on the specific cohort. Starting dose 200 mg daily for a 28 day cycle. The DLT period will be for the first 2 cycles of therapy. Each cycle is 28 days in length, making the DLT period of minimum of 56 days.
3071159|NCT02086500|Experimental|Prehospital Tranexamic Acid|1 gram of Tranexamic Acid will be given during air medical transport
3071160|NCT02086500|Placebo Comparator|Control|Identical volume of saline during air medical transport
3071161|NCT02086487|Experimental|Nilotinib 300 mg|"Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg but show sub-optimal response on Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg twice daily and will be assessed for timely.~In the absence of safety concerns, nilotinib could be escalated to 400 mg twice daily if patients had not obtained any of the following milestones:~BCR-ABL1 transcript level ≤ 10% at 3 months;~CCyR at 6 months,~BCR/ABL1 ≤ 1% at 6 months~MMR at 12 months, or~if they showed loss of cytogenetic or molecular response or disease progression at any time. Failure and thus, stopping nilotinib will be considered if any of above milestones happened while on the 400mg twice daily dose."
3071162|NCT02086474|Experimental|Hyaluronan|Hyaluronan acid Neovisc : one 6cc (viscosupplement) intra-articular injection
3071163|NCT02086474|Placebo Comparator|Bupivacaine|one Marcain extra-capsular injection
3071164|NCT02086461|Sham Comparator|15 mm Pyloric balloon dilatation.|During fluoroscopic control the pneumatic balloon is positioned of the pyloric sphincter and maintained there during the entire dilatation.
3071165|NCT02086461|Active Comparator|Pneumatic pyloric dilatation.|Endoscopy and 15 mm balloon dilatation is completed according to the same principle as active comparator arm.
3071166|NCT02086448|No Intervention|Obese, SDB negative|No intervention, observational comparison group
3071167|NCT02086448|Active Comparator|Obese, SDB postive, CPAP|Therapeutic CPAP
3071168|NCT02086448|Sham Comparator|Obese, SDB postive, sham-CPAP|Sham (non-therapeutic) CPAP
3071169|NCT02086448|Other|Obese, SDB postive, sleep hygiene|Sleep hygiene information and local sleep resources
3071170|NCT02086435|Experimental|Extracorporeal morcellation|"Extracorporeal morcellation in which patients are treated with protected removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself"
3071171|NCT02086435|Active Comparator|Intracorporeal morcellation|Intracorporeal morcellation patients treated with standard intracorporeal morcellation, using reusable electronic device
3071172|NCT02086422|Active Comparator|ivabradine|Exercise with ivabradine
3071173|NCT02086422|Placebo Comparator|Placebo|Exercise with placebo
3071174|NCT02086409|Experimental|Yogurt supplemented with vitamin D and calcium|20 participants take yogurt supplemented with vitamin D and calcium during 12 weeks
3071175|NCT02086409|Active Comparator|Yogurt not supplemented with vitamin D and calcium|20 participants take yogurt not supplemented with vitamin D and calcium during 12 weeks
3071176|NCT02086396|Experimental|pumpkin seed flour|The pumpkin seed flour group received 20g/day of pumpkin seed flour during 12 weeks
3071177|NCT02086396|Placebo Comparator|Cassava flavored flour|The placebo group (cassava flour flavored) received 20g/day of cassava flour flavored during 12 weeks.
3071178|NCT02086383||Patients with COPD|This is an observational study of patients with chronic obstructive pulmonary disease (COPD) who attend pulmonary rehabilitation, which is the routine standard of care in Guy's and St. Thomas' Hospital, London. It lasts for 14 sessions, twice a week and primarily consists of a supervised exercise program and educational sessions.
3071179|NCT02086370|Active Comparator|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx
3071180|NCT02086370|Experimental|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal
3071181|NCT02086357||SWUE|
3071182|NCT02086344|Experimental|TLH_plus_PBS|TLH plus PBS
3071183|NCT02086344|Active Comparator|TLH _adnexal preservation|Standard TLH without PBS
3071184|NCT02086331|Active Comparator|Healthy|Healthy volunteers, deemed to have normal metabolic and cardiovascular biology by trial criteria
3071185|NCT02086331|Active Comparator|PAD|Symptomatic peripheral arterial disease
3071186|NCT02086331|Active Comparator|DM|Symptomatic diabetic peripheral neuropathy
3071187|NCT02086318||OvAge assessment|Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle
3071188|NCT02086305|Experimental|Usual Care + Transitional Care Model|Transitional Care, Evidence-based symptom management, Protocol-driven home visit and telephone follow-up, Trained nurse case manager and volunteer partnership
3071189|NCT02086305|Active Comparator|Usual Care|Usual care
3071190|NCT02086292|Experimental|2 milliliter lidocaine|2 ml 1% Lidocaine in one ring finger, 1 ml 2% Lidocaine in the other ring finger
3071191|NCT02086292|Experimental|1 milliliter lidocaine|1 ml 1% Lidocaine in one ring finger, 2 ml 2% Lidocaine in the other ring finger
3071222|NCT02086071|Other|Re biopsies faisibility|the Interest of the study is to evaluate the feasibility of the re biopsy; the re biopsy is done if the patient agrees to perform it.
3071223|NCT02086045|Other|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold|DESolve Scaffold
3071224|NCT02086032|Experimental|micronized progesterone|1 mg 17 beta-estradiol plus 100 mg micronized progesterone taken orally once a day for 3 months.
3071225|NCT02086032|Experimental|dydrogesterone|1mg 17 beta-estradiol plus 10 mg dydrogesterone taken orally once a day for 3 months.
3071192|NCT02086279|No Intervention|GnRH analogue|"Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for surgery are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.~Patients enrolled will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between 1 and 4 days of the menstrual cycle will be measured at study entry and at 1, 3 and 6 months after the administration of the first vial of GnRH-a"
3071193|NCT02086266|Experimental|PILATES|Weekly Pilates sessions, guided by a specialized physiotherapist. The duration of the treatment was 10 weeks, and each session lasted 45 to 50 minutes. All subjects received instruction to perform specific daily home exercises.
3071194|NCT02086266|Active Comparator|PFMT and AES|For also 10 weeks, the participants went trough anal electrical stimulation associated with Pelvic Floor Muscle Training, supervised by a specialized physiotherapist. All subjects received orientation to perform the same pelvic floor exercises at home.
3071195|NCT02086253|Experimental|BQ-788|Effect of BQ-788 on the magnitude of sustained flow-mediated dilatation
3071196|NCT02086253|Experimental|BQ-123|Effect of BQ-123 on the magnitude of sustained flow-mediated dilatation
3071197|NCT02086253|Experimental|BQ-788 + BQ-123|Effect of BQ-788+BQ-123 on the magnitude of sustained flow-mediated dilatation
3071198|NCT02086240|Experimental|XBD173|XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity. In a previous study (approved by NRES Committee London-West London, REC ref No. 12/LO/0735), we administered an oral dose of XBD173 (up to 90mg) in 12 subjects. No adverse events due to XBD173 occurred and it was well tolerated.
3071199|NCT02086227|Experimental|A Glucagon for Injection, Fresenius Kabi USA|The subjects will be administered the test (A) (Glucagon for Injection, Fresenius Kabi USA)or reference (B) product (GlucaGen® for Injection, Bedford Laboratories) according to a two treatments, four periods replicate crossover, randomized design with two sequences (BABA and ABAB, the Left-Right site of injection for each period and treatment will be randomized.
3071200|NCT02086227|Active Comparator|B GlucaGen® (Bedford Laboratories)|The subjects will be administered the test (A) Glucagon for Injection, Fresenius Kabi USA; or reference (B) product, GlucaGen® (Bedford Laboratories) according to a two treatments, four periods replicate crossover, randomized design with two sequences (BABA and ABAB, the Left-Right site of injection for each period and treatment will be randomized.
3071201|NCT02086214|Experimental|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
3071202|NCT02086214|Placebo Comparator|Control|LYCRA® non-compressive sleeve initially used in burn therapy : < 5 mmHg.
3071203|NCT02086201|Active Comparator|Problem Solving Therapy|Problem solving therapy is an evidence based psychotherapy for depression, with 30 years of research supporting its efficacy. PST focuses on the patients themselves and helps them develop skills in identifying, prioritizing, and solving problems, and thereby creates a sense of empowerment.
3071204|NCT02086201|Experimental|Engage|"Engage utilizes reward exposure consisting of the reintroduction of activities that patients once found rewarding and enjoyed, but have abandoned after they developed depression. Engage uses basic problem solving through which patients learn how to form action plans for pursuing rewarding activities of their choice."
3071205|NCT02086188|Experimental|Mirabegron|Mirabegron - 25mg (one tablet) taken by mouth daily with option to up-titrate to 50mg daily (two tablets) taken by mouth daily
3071206|NCT02086188|Placebo Comparator|Placebo|Placebo - one tablet taken by mouth daily and two tablets taken by mouth daily if subject chooses up-titration
3071207|NCT02086175|Experimental|Imprime PGG and Rituximab|The study drug, Imprime PGG, will be administered intravenously at a dose of 4mg/kg weekly for 4 weeks. Rituximab will be administered intravenously by institutional standards concurrently at a dose of 375mg/m2 weekly for 4 weeks. Response will be assessed with CT scans 10 weeks +/- 3 days following the completion of treatment
3071208|NCT02086162|Experimental|Behavioral intervention|Web-based motivational decision support system
3071209|NCT02086162|Active Comparator|Educational intervention|Computerized version of the National Cancer Institute (NCI) Educational Pamphlet
3071210|NCT02086149|Experimental|Exercise|12-week moderate-intensity behavioral exercise intervention (AE)
3071211|NCT02086149|Active Comparator|Health Education|12-week health education control
3071212|NCT02086136||Suspected AD|Consecutive adult patients with suspected AD presenting to Emergency Departments will be enrolled at the time of initial medical evaluation and before the establishment of a final diagnosis.
3071213|NCT02086123|Active Comparator|Epidural Analgesia|Subjects randomized to this arm will receive Bupivacaine + Fentanyl Epidural Analgesia. Subjects on this group could be allowed to receive Toradol Intravenously (IV) + Acetaminophen Orally (PO) if needed.
3071214|NCT02086123|Active Comparator|Parenteral Analgesia (Intravenous)|Subjects randomized to this arm will receive Analgesia with Dilaudid 0.2 -0.4 mg Intravenously (IV) every 3 hours. Subjects on this group could be allowed to receive Toradol Intravenously (IV) + Acetaminophen Orally (PO) if needed.
3071215|NCT02086110|Active Comparator|Prebiotic first|This group will receive bovine milk oligosaccharides, administered orally twice per day for a daily total of 0.3 g per pound of body weight.
3071216|NCT02086110|Active Comparator|Synbiotic first|This group will receive Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally.
3071217|NCT02086097|Experimental|dexketoprofen trometamol|Administration of 25mg of Dexketoprofen Trometamol, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
3071218|NCT02086097|Active Comparator|IBUPROFEN|Administration of 600mg of Ibuprofen, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
3071219|NCT02086097|Placebo Comparator|PLACEBO|4 doses of sugar pills, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
3071220|NCT02086084|Active Comparator|NIV|Standard application of NIV in hypercapnic respiratory failure as per usual standard of care
3071221|NCT02086084|Experimental|ECCO2R|Addition of ECCO2R to NIV in AECOPD
3071226|NCT02086019|Other|Conservative Arm- Medical therapy|Medical therapy
3071227|NCT02086019|Other|Invasive Arm-angiogram with PCI or CABG|same medical drug therapy as conservative arm, and angiogram with PCI (percutaneous coronary intervention) or CABG (coronary artery bypass grafting) revascularisation if appropriate
3071228|NCT02086006|Other|DESolve scaffold|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold. test arm, intervention
3071229|NCT02085993||single arm|single arm study
3071230|NCT02085980|Experimental|Laser Treatment|Laser Treatment
3071231|NCT02085967|Experimental|E2006 Part A|E2006 10-mg tablets alone and in combination with rifampin 600 mg or itraconazole 200 mg
3071232|NCT02085967|Experimental|E2006 Part B|E2006 10-mg tablets alone and in combination with midazolam 2 mg plus bupropion 75 mg
3071233|NCT02085941|Experimental|Image-guided cryoablation +/- biopsy|"MRI/PET/CT imaging in the Advanced Multimodality Image Guided Operating (AMIGO) suite used to place cryoablation needle(s) into target lesion (Mean: 3 cryoprobes, Range: 1-10).~MR/PET/CT imaging in the AMIGO suite will monitor two 15-minute freeze cycles separated by a 10 minute thaw period."
3071234|NCT02085928||Lateral epicondylitis|Patients with lateral epicondylitis with persistent pain for at least 3 months
3071235|NCT02085915|Other|strip Peri Screen|
3071236|NCT02085902|No Intervention|standard anesthesia|
3071237|NCT02085902|Experimental|standard anesthesia with ropivacaine|ropivacaine
3071238|NCT02085889||food intolerance|lactose intolerance fructose intolerance neither intolerance
3071239|NCT02085876||Patients requiring a liver biopsy|
3071240|NCT02085863|Experimental|Laquinimod|once daily oral doses of laquinimod (with combination oral contraceptives)
3071241|NCT02085863|Placebo Comparator|Placebo|Matching placebo (with combination oral contraceptives)
3071242|NCT02085850||Subjects identified in the Tema Eye Survey|Subjects identified in the Tema Eye Survey
3071243|NCT02085837|Experimental|Healthy Transitions Group|"Additional nursing services will be provided to this group in addition to a usual care by Nephrologist.~Daily weight measurement and monitoring~Medication review~Universal dietary education~Focused advanced directive program~Countdown to fistula program"
3071244|NCT02085837|No Intervention|Usual Care Group|Usual care by nephrologist. No additional nursing support services will be provide to this group.
3071245|NCT02085824|Experimental|enoxaparin|enoxaparin 40mg 1x1 s.c. daily, once preoperatively and then daily for 28 days
3071246|NCT02085824|Experimental|rivaroxaban|rivaroxaban 10 mg 1x1 p.o. daily for 28 days after the surgery
3071247|NCT02085824|Experimental|dabigatran|dabigatran 110 mg 1x1 p.o. postoperatively and then 1x2 p.o. for 27 days after the surgery
3071248|NCT02085811||Patients|
3071249|NCT02085798||Group 1|Low or intermediate-1 risk MDS patients according to IPSS
3071250|NCT02085798||Group 2|Intermediate-2 risk MDS patients according to IPSS
3071251|NCT02085798||Group 3|Any risk CMML patients according to CPSS
3071252|NCT02085785|Experimental|Coached|Participants randomized to the coached arm will receive the same educational and self-monitoring materials as the self-directed group. In addition, participants in the coached arm will receive 11 calls from a health coach and a single visit to their home by an exercise specialist.
3071253|NCT02085785|Active Comparator|Self-directed|Participants randomized to the self-directed arm will receive the same educational and self-monitoring materials as the coached group, but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.
3071254|NCT02085785|Other|Screened|Individuals who were contacted to inform them about the study or who contacted study personnel to express an interest in participating. This group is presented in order to present statistics on feasibility regarding recruitment
3071255|NCT02085772|Experimental|Patients with pre-conceptional obesity|
3071256|NCT02085759||Normal BMI|Subjects with a BMI range of 18.5 to 24.9 which is defined by the CDC as within normal range.
3071257|NCT02085759||Overweight BMI|Subjects with a BMI of 25.0 to 29.9 are defined by the CDC as being overweight.
3071258|NCT02085759||Obese BMI|Subjects with a BMI of 30.0 and above are defined by the CDC as being obese.
3071259|NCT02085733||Possible Septic Arhtritis Patients|
3071260|NCT02085720|Experimental|Chinese elderly OSAS|Subjects will be recruited in the community elderly center with home sleep study done. Those with significant OSAS will be prescribed with CPAP therapy and subsequent compliance is monitored.
3071261|NCT02085707|Active Comparator|Total hip replacement arthroplasty|59 off 118 patients will be randomized to total hip replacement arthroplasty
3071262|NCT02085707|Active Comparator|Closed reduction and internal fixation|"59 off 118 patients will be randomized to closed reduction and internal fixation.~2 cancellous parallel hip pins"
3071263|NCT02085694|Experimental|Lactobacillus brevis CD2 lozenges|
3071264|NCT02085681|Experimental|Tele-medicine|Tele-medicine aided retinal imaging and referral to eye hospital
3071265|NCT02085681|Other|Conventional Referral|Patients will be counselled on the importance of eye examination and will be referred to the eye hospital in the conventional manner.
3071266|NCT02085668|Experimental|Treatment Group|Renal denervation and maintenance of heart failure medications
3071267|NCT02085668|No Intervention|Control Group|Maintenance of heart failure medications with option for cross-over renal denervation treatment after 6-months
3071268|NCT02085655|Experimental|PEG-ASP+Gemox regimen group|PEG-ASP 2000U/m2 im d1 Gemcitabine 800mg/m2 ivdrip 30min d1，8 Oxaliplatin 100mg/m2 ivdrip d1 Thalidomide 150-200mg po qn d8-21
3071269|NCT02085655|Active Comparator|AspaMetDex regimen group|Pegaspargase 2000U/m2 im， d1 methotrexate 3000m g/m2 civ 6-hour，d1, Calcium folinate 30mg iv q6h x6 Dexamethasone 40 mg ivdrip QD
3071270|NCT02085642|Experimental|Acupuncture|True acupuncture
3071271|NCT02085642|Sham Comparator|Sham needle|Retractable acupuncture needles will be used. No true transcutaneous needling through the skin
3071302|NCT02085447|Experimental|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
3071303|NCT02085434|Experimental|FITLINE practice-based referral program|
3071304|NCT02085434|No Intervention|Contemporaneous control|
3071272|NCT02085629|Experimental|M reg treatment|"Donor M reg (2.5-7.5 million cells/kg) IV infused (6-7d before Tx) into recipients of a LD renal Tx. Recipients also receive prednisolone, mycophenolate mofetil and tacrolimus, as detailed below:~Prednisolone~D 0: 500 mg IV~D 1: 125 mg IV~D 2 - 14: 20.0 mg/d (oral)~Wk 3 - 4: 15.0 mg/d~Wk 5 - 8: 10.0 mg/d~Wk 9 - 12: 5.0 mg/d~Wk 13 - 14: 2.5 mg/d~Wk 15 - End: Cessation~MMF (or biologic equiv.)~D -7 to -2: 500 mg/d (250mg 2x/d)~D -1 to 14: 2000 mg/d~Wk 3 - 36: 1000 mg/d~Wk 37 - 40: 750 mg/d~Wk 41 - 44: 500 mg/d~Wk 45 - 48: 250 mg/d~Wk 49 - End: Cessation NOTE: MMF tapering will only happen if a 36-Wk biopsy shows no signs of subclinical rejection or if there is no evidence of declining renal function or if the clinician has any other concern about dose reduction.~Tacrolimus (or biologic equiv.)~≤ 48 h pre-Tx to D 14: 3-12 ng/ml~Wk 3 - 12: 3-10 ng/ml~Wk 13 - 36: 3-8 ng/ml~Wk 37 - End: 3-6 ng/ml"
3071273|NCT02085616|Experimental|Proactive service|Intervention: Tobacco cessation by telephone support. The structured treatment protocol is a mixture of motivational interviewing (MI), cognitive behaviour therapy, and pharmacological consultation. In the proactive service the callers to the quitline are offered a number of callbacks.
3071274|NCT02085616|Active Comparator|Reactive service|Intervention: Tobacco cessation by telephone support. The structured treatment protocol is a mixture of motivational interviewing (MI), cognitive behaviour therapy, and pharmacological consultation. In the reactive service the callers to the quitline are informed that they can themselves call back whenever they like.
3071275|NCT02085603|Active Comparator|Saracatinib|Saracatinib at a dose of 125mg orally will be administered daily for four weeks.
3071276|NCT02085603|Placebo Comparator|Placebo|Placebo tablet to be orally administered daily for four weeks.
3071277|NCT02085590|Active Comparator|BCG vaccine|BCG vaccine SSI, 0.75mg/ml, injection 0.1 cc intradermal
3071278|NCT02085590|Placebo Comparator|NaCl 0.9%|injection 0.1 cc intradermal
3071279|NCT02085577|Experimental|Ketamine|"(S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/h terminated at last suture to the skin.~Morphine. Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 min before expected awakening.~Escape sufentanil. Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.~Morphine. PCA-morphine, bolus 2.5 mg, lock-out-time 5 min. Concentration : Morphine sulphate 1 mg/ml.~Escape morphine. Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.~Ondansetron 2 mg/ml, 4 mg iv in case of moderate to severe nausea, supplemented by 1 mg iv if needed~Paracetamol 1 g orally 1 h preoperatively and every 6 h after extubation time during the first 24 h.~The patients usual daily opioids"
3071280|NCT02085577|Placebo Comparator|Placebo|"Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/h terminated at last suture to the skin.~Morphine. Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 min before expected awakening.~Escape sufentanil. Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.~Morphine. PCA-morphine, bolus 2.5 mg, lock-out-time 5 min. Concentration : Morphine sulphate 1 mg/ml.~Escape morphine. Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.~Ondansetron 2 mg/ml, 4 mg iv in case of moderate to severe nausea, supplemented by 1 mg iv if needed~Paracetamol 1 g orally 1 h preoperatively and every 6 h after extubation time during the first 24 h.~The patients usual daily opioids"
3071281|NCT02085564||GEJ-cancer patients consideres resectable|All patients have biopsy verified GEJ-cancer, and has been considered for intend curative resection by a multidisciplinary panel of specialists.
3071282|NCT02085551|Experimental|Mechanical thrombectomy by the Indigo System|
3071283|NCT02085538|Experimental|Normal Renal Function|
3071284|NCT02085538|Experimental|Mild Renal Impairment|
3071285|NCT02085538|Experimental|Moderate Renal Impairment|
3071286|NCT02085538|Experimental|Severe Renal Impairment|
3071287|NCT02085525|Other|Weekly NP Visits|100 HNC (Head and Neck Cancer) patients seen weekly in a Nurse Practitioner (NP) led symptom management clinic for supportive care.
3071288|NCT02085525|Other|Every Other Week NP Visits|100 HNC (Head and Neck Cancer) patients seen every other week in a Nurse Practitioner (NP) led symptom management clinic for supportive care.
3071289|NCT02085512|Experimental|Neurocognitive retraining|"Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity."
3071290|NCT02085512|Placebo Comparator|Control, Web Based Tasks|Engaging daily, for 30 days in web-based video games or reading tasks that do not specifically engage or train neurocognitive functions.
3071291|NCT02085499|Other|NIMV followed by S-NIMV|During the study infants assigned to this arm will undergo a 2-hour period of non-synchronized NIMV followed by a 2-hour period of Synchronized-NIMV.
3071292|NCT02085499|Other|S-NIMV followed by NIMV|During the study infants assigned to this arm will undergo a 2-hour period of synchronized NIMV followed by a 2-hour period of non-synchronized NIMV.
3071293|NCT02085486|Experimental|Ultrasound-assisted puncture|Ultrasound-assisted puncture by the nursing staff of patients with difficult AV-shunts.
3071294|NCT02085486|Other|Standard|Classical method wtih inspection and palpation
3071295|NCT02085473|Experimental|Cohort 1|Two subcutaneous injections at flow rate 1
3071296|NCT02085473|Experimental|Cohort 2|Single subcutaneous injection at flow rate 2
3071297|NCT02085473|Experimental|Cohort 3|Single subcutaneous injection at flow rate 3
3071298|NCT02085473|Experimental|Cohort 4|Single subcutaneous injection at flow rate 4
3071299|NCT02085460|Placebo Comparator|Placebo|6 times daily
3071300|NCT02085460|Experimental|2% Rebamipide liquid|6 times daily
3071301|NCT02085460|Experimental|4% Rebamipide liquid|6 times daily
3071305|NCT02085421|Active Comparator|Active tDCS|The active tDCS will be applied at a current of 1-2mA via two saline soaked electrode sponges (3 cm x 4.5 cm) for the first 15 minutes of each CRT session in the active condition.
3096722|NCT01914341|No Intervention|control|no intervention
3071306|NCT02085421|Sham Comparator|Sham tDCS|In the sham condition, tDCS will be ramped up to 1-2 mA via two saline soaked electrode sponges (3 cm x 4.5 cm) over the first 30 seconds of each CRT session and then turned off.
3071307|NCT02085408|Active Comparator|Arm I (daunorubicin hydrochloride and cytarabine)|See Detailed Description
3071308|NCT02085408|Experimental|Arm II (clofarabine)|See Detailed Description
3071309|NCT02085395|Experimental|SR-T100 ® Gel|Topical gel containing 2.3% of solamargine in Solanum undatum extract is used once daily with occlusive dressing for 16 weeks.
3071310|NCT02085382|Other|Kangaroo Mother Care Group|"Mothers in the KMC group were oriented in detail about KMC procedure. The mothers provided skin to skin contact using a specially tailored kangaroo tube made of soft flannel cloth. The mothers were encouraged to keep the baby in KMC as long as possible during the day and night for an accumulated time of at least 6 hours per day. The duration of the kangaroo care by each of the mother were recorded and tallied accordingly."
3071311|NCT02085382|Other|Conventional Mother Care|Conventional method of care was the routine care offered in the neonatal unit to low birth weight infants.
3071312|NCT02085356|Experimental|Intervention women with partners|Women will enroll with male partners and both members of the couple will attend the Protect your Family intervention
3071313|NCT02085356|Experimental|Intervention women without partners|Women will enroll alone and will attend the Protect your Family Intervention without a partner
3071314|NCT02085356|No Intervention|Control women with partners|Women will enroll with male partners and both members of the couple will attend time-matched video sessions
3071315|NCT02085356|No Intervention|Control women alone|Women will enroll alone and will attend time-matched video sessions
3071316|NCT02085343|Experimental|EXP + SBF + AA|Exposure therapy (EXP) with safety behavior fading (SBF) and anti-phobic action (AA)
3071317|NCT02085343|Active Comparator|EXP + SBF|Exposure therapy (EXP) with safety behavior fading (SBF)
3071318|NCT02085343|Active Comparator|EXP|Standard therapist-guided in vivo exposure therapy (EXP)
3071319|NCT02085343|No Intervention|Wait-list control|Subjects assigned to this arm will undergo assessments at Weeks 0, Week 1, and Week 5, but will not receive any interventions.
3071320|NCT02085330|Experimental|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
3071321|NCT02085330|No Intervention|Standard follow up|
3071322|NCT02085317|Other|Lepromatous Patients|Composed of patients with lepromatous Leprosy acetylcholine Iontophoresis sodium nitroprusside Iontophoresis
3071323|NCT02085317|Other|Healthy Patients|Composed of patients without any disease acetylcholine Iontophoresis sodium nitroprusside Iontophoresis
3071324|NCT02085304|Experimental|GammaKnife(R) stereotactic radiosurgery|Following surgery for Gross total resection and Gliadel(R) wafers implanted , the patient will receive a one-day GammaKnife(R) stereotactic radiosurgery procedure and will also take temozolomide (Temodar(R)) chemotherapy daily for six weeks with a one month break before taking temodar for additional 12 monthly cycles.
3071325|NCT02085304|Active Comparator|Standard fractionated radiation therapy|Following surgery for Gross total resection and Gliadel(R) wafers implanted , the patient will receive six weeks of standard fractionated radiation therapy plus daily temozolomide (Temodar(R)) chemotherapy for six weeks. This is followed by a one month break before taking temodar for additional 12 monthly cycles.
3071326|NCT02085291|Experimental|Resp-FL|Patients received 500 ml crystalloid for fluid challenge within 20 minutes, then a PLR test was performed to predict fluid responsiveness. If the patient was fluid responsive, more 500 ml crystalloids were given until fluid nonresponsive. If the MAP still not achieved the target value, NE was increased to achieve the target one. The target MAP was maintain MAP within 10% of the reference value.
3071327|NCT02085291|Experimental|Resp-NE|In Resp-NE group, norepinephrine was increased to enhance MAP within 10% of the reference value.
3071328|NCT02085291|Experimental|Nonresp-NE|In Nonresp-NE group, norepinephrine was increased to enhance MAP within 10% of the reference value.
3071329|NCT02085278|Experimental|Apollo Group|Apollo Micro catheter device
3071330|NCT02085265|Experimental|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
3071331|NCT02085265|Active Comparator|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
3071332|NCT02085252|Experimental|Leuprorelin 11.25 mg|Leuprorelin 11.25 mg, as one subcutaneous injection. Bicalutamide 50 mg, tablet, orally, once daily, to prevent flare-up.
3071333|NCT02085252|No Intervention|Active surveillance|Active surveillance is close medical monitoring of prostate cancer for any changes.
3071334|NCT02085239|Active Comparator|Lidocaine alone|Lidocaine: 8-10 ml of Lidocaine by subcutaneous injection
3071335|NCT02085239|Experimental|Lidocaine Ropivacaine|"Lidocaine Ropivacaine~8-10 ml of Lidocaine given by subcutaneous injection~8-10 ml of Ropivacaine given by subcutaneous injection"
3071336|NCT02085226|Experimental|Creative Engagement Intervention|Creative Engagement Intervention participants will receive 4-8 art sessions over 3-5 weeks, depending on length of inpatient stay. Sessions will be delivered as 1:1 sessions with the artist lasting up to one hour (depending on patient fatigue levels) and group sessions, with up to 5 participants, lasting up to two hours (depending on patient fatigue levels). Participant with receive one group and one individual session per week of inpatient stay. The sessions will cover 5 activity stages of the intervention, taking the participant through a progressive artwork development process. Participants will explore basic visual art materials and processes and progress to creating artworks with a personal context that they have directed and controlled.
3071337|NCT02085226|Placebo Comparator|Portfolio Group|The Portfolio group will receive conventional rehabilitation activity at each site. In addition, to control for effects of art related attention received by the intervention group, after baseline assessment and randomisation, this group will receive from the research assistant, a portfolio of work produced by previous participants of the Tayside CEI, with details of community programmes that people with stroke can attend after hospital discharge. Participants will be invited to view the portfolio during their stay. Prior to outcome assessment, the research assistant will visit participants again to answer questions and to discuss options for community programmes, if the person is interested.
3071372|NCT02085018|Placebo Comparator|Matched placebo|Matched placebo twice a day taken for 90 days
3071409|NCT02084745|Active Comparator|Implantation at post-Kpro 6 months|Implantation of a glaucoma drainage device 6 months after Boston keratoprosthesis type 1 surgery
3071338|NCT02085213|Experimental|Glyceryl Trinitrate|"Nitrolingual Pump Spray [Coro-Nitro] A liquid within non-pressurised, red plastic-coated glass bottle fitted with a pump capable of delivering a metered dose containing 400μg of glyceryl trinitrate.~Excipients: The formulation contains fractionated coconut oil, absolute ethanol, medium chain partial glycerides and peppermint oil.~The treatment will be self administered (2 puffs) as a single intervention. No second intervention will be given."
3071339|NCT02085213|Placebo Comparator|Placebo|Matched placebo formulation (except for active ingredient of Glyceryl Trinitrate) with matched packaging and labelling.
3071340|NCT02085200|Other|Horizontal adduction stretch without scapular stabilization|Scapular stabilization is not provided during a manual horizontal adduction stretch of the shoulder. Each stretch is held for 25 seconds and repeated for a total of 3 times.
3071341|NCT02085200|Other|Horizontal adduction with scapular stabilization|Scapular stabilization is provided during a manual horizontal adduction stretch of the shoulder. Each stretch is held for 25 seconds and repeated for a total of 3 times.
3071342|NCT02085187|Experimental|Telemedicine training and counselling|
3071343|NCT02085161|Placebo Comparator|placebo|patient will receive placebo once daily, 2 puffs in the morning
3071344|NCT02085161|Experimental|tiotropium + olodaterol high dose with BM|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
3071345|NCT02085161|Active Comparator|tiotropium|patient will receive tiotropium 5 mcg once daily, 2 puffs in the morning
3071346|NCT02085161|Experimental|tiotropium + olodaterol with exercise training and BM|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
3071347|NCT02085148|Experimental|Sequential dosing schedule|Expansion phase: Schedule B - Sequential dosing schedule: Of a 21-day cycle, regorafenib will be dosed sequentially, following administration of VI: Vincristine：intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 8 to Day 21.
3071348|NCT02085148|Experimental|Concomitant dosing schedule|Expansion phase: Schedule A - Concomitant dosing schedule: Of a 21-day cycle, regorafenib will be concomitantly administered with vincristine and irinotecan (VI): Vincristine: intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50 mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 1 to Day 14.
3071349|NCT02085148|Experimental|Dose escalation|Dose escalation phase: This phase of the study has been completed
3071350|NCT02085135|Experimental|Titration Schedule 1|
3071351|NCT02085135|Experimental|Titration Schedule 2|
3071352|NCT02085122|Experimental|noninvasive ventilation|
3071353|NCT02085122|No Intervention|Control Group|
3071354|NCT02085109|Experimental|High fat meal|A high fat milkshake containing 60.6 grams of fat
3071355|NCT02085109|Placebo Comparator|Low fat meal|A Low fat milkshake containing 10.5 gram of fat
3071356|NCT02085109|Experimental|A Low fat meal containing theobromine|A low fat milkshake containing 10.5 grams of fat supplemented with 850 mg of theobromine
3071357|NCT02085096|Experimental|Problem-Solving Therapy|A problem-solving therapy training program will be provided to the spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
3071358|NCT02085096|Placebo Comparator|Standard Supportive Care|Participants who are randomized to this arm will be encouraged to use whatever supporting care is recommended to them by their health provider.
3071359|NCT02085083|Experimental|Regular telephone and email access to an IBD Nurse|The IBD pediatric-adult transition nurse will send an email to each individual randomized to the intervention arm each month. The email will include the following: Brief Questionnaire;The Option For Direct Nurse Contact; Educational modules; MyHealth Passport and a Comprehensive Study Questionnaire.
3071360|NCT02085083|Active Comparator|Minimal Intervention|The IBD pediatric-adult transition nurse will send an email to each individual randomized to the control arm every 3 months. The email will include the following: MyHealth Passport and Study Questionnaire. This intervention is not expected to significantly improve outcomes.
3071361|NCT02085070|Experimental|Melanoma patients|"After establishing eligibility criteria, for patients with melanoma the investigator will determine at least one lesion that requires local therapy (surgical resection or LITT) based on size, location, and/or risk of hemorrhage; this will be considered the surgical lesion. All other eligible brain lesions will be considered clinically evaluable lesions and will be followed by modified RECIST (mRECIST) criteria to determine best response."
3071362|NCT02085070|Other|Non-small cell lung cancer patients|"NSCLC patients are not required to have a surgical lesion but must have at least one clinically evaluable lesion in the central nervous system. Patients on NSCLC are required to have formalin-fixed, paraffin-embedded tumor tissue available for biomarker analysis."
3071363|NCT02085057||anorexia nervosa|Diagnosis of anorexia nervosa
3071364|NCT02085057||obsessive-compulsive disorder|Diagnosis of obsessive-compulsive disorder
3071365|NCT02085057||healthy control|No psychiatric diagnoses
3071366|NCT02085057||sisters|Sisters of those enrolled with a diagnosis of anorexia nervosa
3071367|NCT02085044|Experimental|12 months RUSF|Children between 6 to 24 months received ready-to-used supplementary food every months during the whole year.
3071368|NCT02085044|Active Comparator|4 months RUSF|children between 6 to 24 months of one zone received a ready-to-used supplement food during the 4 months of the hunger gap period (june to september)
3071369|NCT02085031|Experimental|Intracorporeal Roux-en-Y esophagojejunostomy|During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed for the patients assigned to this arm.
3071370|NCT02085031|Active Comparator|Extracorporeal Roux-en-Y esophagojejunostomy|During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed for the patients assigned to this arm.
3071371|NCT02085018|Experimental|Omeprazole|Omeprazole 20 milligrams twice a day taken for 90 days
3071410|NCT02084732|Experimental|Sorafenib|drug
3071373|NCT02085005|Experimental|Aflibercept|Intravenous (IV) infusion on Day 1 every 3 weeks, followed by CAPOX (capecitabine by oral administration on Day 1 to Day 14 and oxaliplatin intravenous (IV) infusion on Day 1 every 3 weeks) for the induction treatment period (6 cycles) after which the patient may enter the maintenance period during which the treatment is Aflibercept + Capecitabine
3071374|NCT02084992|Experimental|Expanded technology disease management|After an initial visit where the program is introduced and education regarding adherence, methods for self-monitoring and early reporting of changes in status are reviewed, patients randomized to this arm will be given tablet computers with a web-based heart failure disease management application. Patients will be asked to interact with the system daily with transmission of weight, heart rate, blood pressure and symptom reports to the nurse manager. A nurse manager will check the data daily and contact patients if any parameters exceed pre-specified parameters. Nurse managers will also touch base with the participants at regular intervals as in the control arm. In addition, educational modules will be placed onto individual tablet computers and given to each patient.
3071375|NCT02084992|Active Comparator|telephonic disease management|After an initial visit where the program is introduced and education regarding adherence, methods for self-monitoring and early reporting of changes in status are reviewed, the nurse manager will telephone participants weekly for the first month followed by either every two weeks or monthly calls depending on clinical status with the goal of transitioning all participants to monthly calls. During these phone calls the nurse manager will focus on identifying changes in clinical condition and education reinforcement. Participants will be instructed to check and record their weight, heart rate and blood pressure daily and will be encouraged to call if there are any changes in their clinical status.
3071376|NCT02084979|Experimental|Asynchronous telepsychiatry|Experimental Arm: Asynchronous telepsychiatry evaluation and consultation
3071377|NCT02084979|Active Comparator|Synchronous telepsychiatry|Control Arm: Synchronous telepsychiatry evaluation and consultation
3071378|NCT02084966|Experimental|OCT Imaging|OCT imaging of the kidneys prior to and following their transplant
3071379|NCT02084953|Experimental|ARM A: BMS-791325|BMS-791325 600 mg tablet orally on 1st and 2nd day, then 900 mg on the 3rd day once a day for 3 days
3071380|NCT02084953|Active Comparator|ARM B: Moxifloxacin|Moxifloxacin 400mg tablet orally once on third day
3071381|NCT02084953|Placebo Comparator|ARM C: Placebo matching BMS-791325|Placebo matching BMS-791325 0 mg tablet orally once daily for 3 days
3071382|NCT02084940||GnRH antagonist depot, Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
3071383|NCT02084927|Experimental|HBOT|Group will be treated with HBOT for 60 treatments in 3 months.
3071384|NCT02084927|Other|Control/Crossover|Control for 3 months without treatment, and then HBOT for 60 treatments in 3 months.
3071385|NCT02084914|Experimental|Group A|Endometrial scraching of uterine cavity by pipelle .
3071386|NCT02084914|Active Comparator|Group B|Uterine sound intoduced into uterine cavity without scratch .
3071387|NCT02084901|Experimental|Orsiro Arm|
3071388|NCT02084901|Active Comparator|BioMatrix or BioMatrix Flex Arm|
3071389|NCT02084875|Experimental|tofacitinib MR 11 mg Fed|tofacitinib modified release (MR) 11 mg tablet administered with food.
3071390|NCT02084875|Experimental|tofacitinib MR 11 mg Fasting|tofacitinib modified release (MR) 11 mg tablet administered without food.
3071391|NCT02084862|Experimental|Ultrasound|Ultrasound guided percutaneous tracheostomy
3071392|NCT02084862|Active Comparator|Bronchoscopy|Bronchoscopy guided percutaneous tracheostomy
3071393|NCT02084849||Group 1|Group 1 will consist of 300 ADPKD individuals who are early in the course of their disease and demonstrate risk factors for progression to ESRD.
3071394|NCT02084849||Group 2|Group 2 will consist of ADPKD subjects who have progressed to a more advanced stage of their renal disease. There is no limit with regard to the number of subjects to be recruited into this group.
3071395|NCT02084836||Lean adolescents|
3071396|NCT02084823|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3071397|NCT02084823|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3071398|NCT02084823|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3071399|NCT02084823|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3071400|NCT02084810|Active Comparator|NovoSeven®|
3071401|NCT02084810|Experimental|Eptacog alfa A 6 mg|
3071402|NCT02084797|Experimental|all study participants|All study participants received all interventions. V2R Antagonist: 30mg Tolvaptan tablet ingested 2 hours before exercise. V2R agonist: 0.2mg DDAVP tablet ingested 2 hours before exercise Placebo
3071403|NCT02084784|Experimental|Indocyanine green & methylene blue,|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1% Indocyanine green with 1ml of 0.5%
3071404|NCT02084771|Experimental|Oral Salt and Water|"Oral Salt and Water Loading:~Participants randomized to this arm of the trial will receive 0.1 g/kg of salt (NaCl) and 12 mL/kg of water. Patients weighing more than 110 kg will receive the same amount as per a 110 kg patient. One third of the oral salt and water will be given before the CT and 2/3 post-CT as in the intravenous saline arm. Specifically, 0.03 g/kg of NaCl and 4 mL/kg of water in the one hour before CT and 0.07 g/kg of NaCl and 8 mL/kg of water taken over 2 hours post-CT. The ingestion of the oral salt and water will be directly observed by the study nurse to ensure adherence to the protocol."
3071405|NCT02084771|Active Comparator|Intravenous Saline|Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg give in the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
3071406|NCT02084758|Active Comparator|Nitrate supplementation|Sodium nitrate solution
3071407|NCT02084758|Placebo Comparator|Placebo supplementation|Sodium chloride solution
3071408|NCT02084745|Active Comparator|Simultaneous implantation|Simultaneous implantation of a glaucoma drainage device at the time of Boston keratoprosthesis type 1 surgery
3071413|NCT02084706|Active Comparator|Triamcinolone (20 g) and 2% Lidocaine injection over A1 pulley|Group one subjects will receive an injection of 0.5mL (20 g) of Triamcinolone and 0.5 mL of 2% Lidocaine over the A1 pulley.
3071414|NCT02084706|Experimental|J-tip lidocaine administration, then steroid injection|"Group two subjects will receive a needle free J-tip administration of 0.5mL of 2% lidocaine prior (2-10 minutes) to needle injection of 0.5mL of Triamcinolone (20 g) over the A1 pulley."
3071415|NCT02084693||COMPREHENSIVE|Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.
3071416|NCT02084680|No Intervention|Control|Control group standard care
3071417|NCT02084680|Experimental|Community Health Workers|individual prenatal education
3071418|NCT02084654|Active Comparator|exenatide 5 and 10 mcg 2 times a day|Exenatide in addition to weight loss. Starting dose 5 mcg titrate to 10 mcg
3071419|NCT02084654|Placebo Comparator|placebo|placebo in addition to weight loss
3071420|NCT02084641|Experimental|Insulin resistant and insulin sensitive|Both groups will be given the same intervention and then outcomes compared between groups
3071421|NCT02084628|Experimental|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole [mmol]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent [%] solution) manually.
3071422|NCT02084615|Experimental|81mg aspirin|This arm will include perioperative 81 mg of aspirin.
3071423|NCT02084615|Experimental|325mg aspirin|Subjects will be taking 325mg of aspirin.
3071424|NCT02084602|Experimental|Artesunate/mefloquine|Orally administration of artesunate 4mg/Kg by three days Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
3071425|NCT02084589|Active Comparator|PCEA of continuous background infusion with demand dose|PCEA with background infusion of 5 ml/h and demand dose of 5 ml with lockout 10 minutes, using ropivacaine 0,15% and fentanyl 2μg/ml.
3071426|NCT02084589|Active Comparator|PCEA with demand dose only|PCEA with demand dose of 5 ml with lockout 10 minutes, using ropivacaine 0,15% and fentanyl 2μg/ml.
3071427|NCT02084576|Experimental|Nepafenac|One drop in the study eye 3 times daily for 30 days
3071428|NCT02084576|Active Comparator|Ketorolac|One drop in the study eye 4 times daily for 30 days
3071429|NCT02084563|Other|AML-Intensive Chemotherapy|"Patients with Acute Myeloid Leukemia fit for intensive chemotherapy Patients will receive Induction Chemotherapy, and CR will be evaluated after 28 days.~Patients who achieve CR post-induction chemotherapy will receive post-remission therapy according to risk:~Low risk patients: Consolidation chemotherapy or Autologous stem cell transplantation~Intermediate and high-risk patients: Allogeneic stem cell transplantation Patients who do not achieve CR may receive one second induction cycle, and if CR is achieved may proceed to post-remission therapy as per above. Patients who do not achieve CR after two cycles of induction will be deemed refractory and removed from the study."
3071430|NCT02084563|Other|AML-Non-intensive chemotherapy|"Patients with acute myeloid leukemia not fit for intensive chemotherapy Patients will receive induction chemotherapy with either low dose cytarabine or decitabine. Assignment to each drug will depend on drug availability and physician discretion. No randomization will be done between the drugs.~Cycles will be repeated every 28 days. Patients who achieve CR will continue to post-consolidation therapy with either cytarabine or decitabine, based on the induction therapy received. Patients will receive a maximum of 4 cycles until achieving CR, if no response is seen after 4 cycles patients will be deemed refractory."
3071431|NCT02084563|No Intervention|Chronic Myeloid Disorders|"Patients with Chronic Myeloid Disorders:~Myeloproliferative Neoplasms~Myelodysplastic Syndromes~Myeloproliferative/Myelodysplastic Neoplasms"
3071432|NCT02084550|Active Comparator|Vaminolac|Intravenous Vaminolac during 3 hours, with an infusion rate of 1,6ml/kilogram bodyweight/h.
3071433|NCT02084550|Placebo Comparator|Saline|Intravenous saline during 3 hours, with an infusion rate of 1,6ml/kilogram bodyweight/h.
3071434|NCT02084537|Active Comparator|Endoscopic treatment|Treated by single or multiple transmural cystogastrostomy tracts, 15mm balloon dilation, two 7 French (Fr) double pigtail plastic stents or lumen-apposing metal stents and nasocystic drainage catheter, with or without endoscopic necrosectomy as needed.
3071435|NCT02084537|Active Comparator|Minimally invasive surgical necrosectomy|Video-assisted retroperitoneal debridement (VARD) or laparoscopic approach. This includes laparoscopic cystogastrostomy with internal debridement.
3071436|NCT02084524|No Intervention|Nutritional evaluation|
3071437|NCT02084511|Experimental|BI 1026706 low dose|BI 1026706 low dose
3071438|NCT02084511|Experimental|BI 1026706 high dose|BI 1026706 high dose
3071439|NCT02084511|Experimental|Placebo reference|Placebo reference
3071440|NCT02084511|Experimental|Celecoxib reference|Celecoxib capsule
3071441|NCT02084498|Active Comparator|ACC|Training in advanced carbohydrate counting
3071442|NCT02084498|Experimental|ACC + ABC|Training in advanced carbohydrate counting plus the use of an automated bolus calculator.
3071443|NCT02084485|Experimental|Arm A|
3071444|NCT02084485|Placebo Comparator|Arm B|
3071445|NCT02084472|Active Comparator|study 1: aqueous cream and baby oil|enrolled patients in this arm use either aqueous cream or baby oil as a soap substitute
3071446|NCT02084472|Active Comparator|study 2: emulsifying ointment and cetomacrogol|patients in this study arm continue to use emulsifying ointment and cetomacrogol as a moisturiser, the current standard of care in our institution
3071447|NCT02084459|No Intervention|Control|Standard of care
3071448|NCT02084459|Experimental|Autonomy-supportive counselling (GSD)|GSD, an educational method, comprising 32 semi-structured reflection sheets inviting the patients in groups of 4 through 8 sessions of 150 minutes' duration to reflect on the patient's own situation and to be active in co-operation with the nurses.
3071449|NCT02084446|Active Comparator|Mycophenolate + Low Tacrolimus|"Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1. Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.~Steroids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.~Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg)."
3071644|NCT02083133||End Stage Renal Disease|GFR 15 ml/min or less or on Dialysis
3071645|NCT02083133||Chronic Kidney Disease Stage 4|GFR 15-30 ml/min
3071450|NCT02084446|Experimental|Everolimus + Very Low Tacrolimus|"Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.~Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.~Corticoids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.~Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg)."
3071451|NCT02084433|Active Comparator|conventional anasthesia|para-apical maxillary and locoregional mandibular (Articaine 1/100000) anaesthesia
3071452|NCT02084433|Experimental|intraosseous anaesthesia|"intraosseous anaesthesia using a computerized system (Quicksleeper) 1 / Anesthesia of periosteum (Articaine 1/100000) 2 / penetration of the needle rotated to the apex 3 / osteocentral injection "
3071453|NCT02084420|Experimental|Ilaprazole or Pantoprazole placebo|Ilaprazole 10mg, Pantoprazole 40mg, Amoxicillin 1000mg, Clarithromycin 500mg 2 times/day, PO
3071454|NCT02084420|Active Comparator|Ilaprazole placebo or Pantoprazole|Pantoprazole 40mg, Ilaprazole 10mg, Amoxicillin 1000mg, Clarithromycin 500mg 2 times/day,PO
3071455|NCT02084407|Active Comparator|DM1 subject with cardiopathy|Clinical examination, Skin biopsy, Blood and urine sampling
3071456|NCT02084407|Active Comparator|DM1 subject without cardiopathy|Clinical examination, Skin biopsy, Blood and urine sampling
3071457|NCT02084407|Active Comparator|Not DM1subject|Clinical examination, Skin biopsy, Blood and urine sampling
3071458|NCT02084394||no intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the concommittent ultrasound of the temporal artery. Deemed interventional by JHUIRB but no actual intervention done to subject.
3071459|NCT02084381|Experimental|MCO-Ci 400|MCO-Ci 400 is the investigational medical product applied in hemodialysis mode
3071460|NCT02084381|Active Comparator|Revaclear 400|the standard high flux dialyzer Revaclear 400 is used as an comparator in hemodialysis mode
3071461|NCT02084368|Experimental|Nerve block|Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block guided by PNS.
3071462|NCT02084368|Placebo Comparator|combined spinal and epidural anesthesia|Combined spinal and epidural anesthesia were performed in patients of this group.
3071463|NCT02084355|Experimental|opioid rotation|"Patients who are randomized to opioid rotation are treated with strong opioid other than currently used strong opioid (Reduce the dose by 25%-50% to allow for incomplete cross-tolerance between different opioids).~oral oxycodone : convert to oral hydromorphone or fentanyl patch~oral hydromorphone : convert to oral oxycodone or fentanyl patch~fentanyl patch : convert to oral oxycodone or oral hydromorphone"
3071464|NCT02084355|Active Comparator|opioid dose escalation|"Patients who are randomized to opioid dose escalation will be treated cancer pain by escalation dose of same strong opioid.~oral oxycodone : maintain oral oxycodone and titrate the dose~oral hydromorphone : maintain oral hydromorphone and titrate the dose~fentanyl patch : maintain fentanyl patch and titrate the dose"
3071465|NCT02084342|Placebo Comparator|Group TN|"Tranexamic acid and sodium chloride injection at 10mg/kg, IV (in the vein) for 30min, before incision.Then at 1mg/kg/h, IV pump, until the surgery is over.~Normal saline (NS) 100ml IV for 20min, before incision."
3071466|NCT02084342|Experimental|Group TD|"Tranexamic acid and sodium chloride injection at 10mg/kg, IV (in the vein) for 30min,before incision.Then at 1mg/kg/h,IV pump,until the surgery is over.~Desmopressin acetate injection at 0.3μg/kg dissolved in 100ml NS, IV for 20min, before incision."
3071467|NCT02084329|Experimental|Weighted Compression Vest|Weighted Compression Vest
3071468|NCT02084329|No Intervention|Control|
3071469|NCT02084316|Experimental|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
3071470|NCT02084316|Active Comparator|Standard of Care|"The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.~After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.~Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling."
3071471|NCT02084303|Other|Ferumoxytol MRI|Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI.
3071472|NCT02084290|Experimental|Shared Decision Making Program|Patients will have access to an educational decision making program and a risk prediction model, this web based program will be sent subjects in the intervention arm upon enrollment, they can access the program as many times as they wish.
3071473|NCT02084290|No Intervention|Control|Subjects enrolled at sites participating as control arms will access the same web-based surveys as the intervention group, and receive the same contacts from the study coordinator as the subjects enrolled at intervention sites.
3071474|NCT02084277|Experimental|Self-ligating brackets|Several self-ligating brackets are currently FDA-approved but have not been rigorously studied in this malocclusion patient population or in comparison to traditional brackets methods. Unlike conventional brackets, Self-ligating brackets (SLB) are bracket systems, without the wire ligature or elastic ligature, that have a tube-like device build into the bracket to close off the edgewise slot.
3071646|NCT02083133||Chronic Kidney Disease Stage -3|GFR 30-60 ml/min
3071475|NCT02084277|Placebo Comparator|Conventional brackets|"The conventional brackets (CB) (edgewise appliance) retain the basic principle design of a rectangular wire in a rectangular slot. Archwire are tied to the bracket once placed in the slot with either elastometric ligation ties (O-rings) or steel ligation."
3071476|NCT02084264||Arm 1: Robotic-guided, open approach|Robotic-guided, open approach
3071477|NCT02084264||Arm 2: control arm- non-robotic, open approach|control arm- non-robotic, open approach°
3071478|NCT02084251|Experimental|Exenatide analogue, Injection|PB-119 will be administered once weekly subcutaneously at dosage of 2μg、5μg、10μg、25μg、50μg、100μg、200μg or 400μg.
3071479|NCT02084238|Experimental|Interleukin-2|Interleukin-2 to treat activated SLE.
3071480|NCT02084225||Course participants|Physicians, nurses and orthopedic officers who staff the emergency intake and orthopedic procedure area of HEAL hospital, Goma DRC, Black Lion Hospital, Addis Ababa and Kindu General Hospital in Kindu DRC. These participants recorded their nerve block intervention over one year for pain management and assessed patient pain level after 10 cc lidocaine.
3071481|NCT02084212|Other|Patients about to undergo epiretinal membrane surgery|
3071482|NCT02084199|Experimental|Part 1 - Severe renal impairment|Part 1 - Group 1: subjects with severe renal impairment or end-stage renal disease (ESRD), not on dialysis: Estimated glomerular filtration rate (eGFR) between 15-29 mL/min/1.73 m2 or <15 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days
3071483|NCT02084199|Experimental|Part 1: Normal renal function|Part 1 - Group 2: subjects with normal renal function: eGFR ≥90 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days
3071484|NCT02084199|Experimental|Part 2 - Mild renal impairment|Part 2 - Group 3: subjects with mild renal impairment: eGFR between 60-89 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
3071485|NCT02084199|Experimental|Part 2 - Moderate renal impairment|Part 2 - Group 4:subjects with moderate renal impairment: eGFR between 30-59 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
3071486|NCT02084199|Experimental|Part 2 - Normal renal function|Part 2 - Group 5: subjects with normal renal function: eGFR ≥90 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
3071487|NCT02084186|Experimental|moxibustion group|herb-partitioned moxibustion on bilateral Tianshu (ST25) and Shangjuxu (ST37)
3071488|NCT02084186|Placebo Comparator|bran-partitioned moxibustion|bran-partitioned moxibustion on bilateral Tianshu (ST25) and Shangjuxu (ST37)
3071489|NCT02084173|Other|MET|Motivational Enhancement Therapy (MET)
3071490|NCT02084173|Other|MET + CRA|Motivational Enhancement Therapy (MET) with subsequent add-on The Community Reinforcement Approach (CRA)
3071491|NCT02084160||CLD from HIS-EX-408/PLT-BID-1108|"Chronic liver disease subjects from previous Exalenz trial HIS-EX-408 and PLT-BID1108"
3071492|NCT02084147|Experimental|PET-CT and PET-MRI|Patients undergo PET-CT over approximately 30 minutes and PET-MRI over approximately 45-90 minutes.
3071493|NCT02084134|Active Comparator|steroid treatment arm|Receives intravenous hydrocortisone 100mg and following surgery intravenous dexamethasone 0.5mg
3071494|NCT02084134|No Intervention|non-steroid treatment|Subjects will not receive any steroids at the time of surgery or after surgery unless symptoms of adrenal insufficiency develop (i.e. nausea, vomiting, dizziness, or low blood pressure).
3071495|NCT02084108|No Intervention|Control arm= usual care|Two clusters of patients over 60 years of age followed by a primary care physician and routinely evaluated by the home nursing service with the resident assessment instrument-home care (RAI-HC) and identified as frail by pre-defined clinical criteria.
3071496|NCT02084108|Other|Intervention arm|The intervention arm will consist of two clusters of patients over 60 years of age followed by a primary care physician and routinely evaluated by the home nursing service with the RAI-HC and identified as frail by predefined clinical criteria that will receive in addition an in-home multidimensional geriatric assessment, access 24 hours a day, 7 days a week to a call service provided by the Community Geriatrics Unit and coordinated long-term follow-up.
3071497|NCT02084082|Experimental|FDC first, fasted|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
3071498|NCT02084082|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
3071499|NCT02084082|Experimental|FDC first, fed|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
3071500|NCT02084082|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
3071501|NCT02084069|Active Comparator|Treatment|Atorvastatin 40 mg once daily from 3 days before surgery up to five days after surgery
3071502|NCT02084069|Placebo Comparator|Control|Placebo
3071503|NCT02084056|Experimental|FDC first, fasted|Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fasted
3071504|NCT02084056|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fasted
3071505|NCT02084056|Experimental|FDC first, fed|Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fed
3071506|NCT02084056|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fed
3071507|NCT02084043|Experimental|Breath-actuated vibrating mesh nebulizer|500 mg/4 mL of Amikacin solution delivered with an experimental breath-actuated vibrating mesh nebulizer associated with a single limb circuit ventilator.
3071508|NCT02084043|Experimental|Conventional vibrating mesh nebulizer|500 mg/4 mL of Amikacin solution delivered with a conventional vibrating mesh nebulizer (in continuous mode) associated with a single limb circuit ventilator.
3071509|NCT02084030||Experimental: Patient with POCD|Patients who suffer from POCD after surgery. The mini-mental state examination scale decline more than 1 SD of baseline after surgery.
3071510|NCT02084030||Sham Comparator: patient without POCD|Patients who don't suffer from POCD after surgery. There is no obvious difference between pre-operation and post-operation in mini-mental state examination scale
3071511|NCT02084017|Active Comparator|Current Standard|Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing applied under sterile conditions in the operating room following skin closure. Dressing changed post-operative day two and daily thereafter with daily inspection for infection by a physician.
3071512|NCT02084017|Experimental|Negative Pressure Wound Therapy|A negative pressure therapy (Kinetic Concepts, Inc, San Antionio, Tex) device will be applied under sterile conditions post-operatively and placed on suction (125-150 cm H2O). The device will be removed on post-operative day 4-7 depending on day of discharge.
3071513|NCT02084004|Experimental|Bifidobacterium viable pharmaceutics|Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks
3071514|NCT02084004|Experimental|Berberine Hydrochloride|Berberine Hydrochloride, 0.5g, 2/day, 12 weeks
3071515|NCT02084004|No Intervention|lifestyle counseling|
3071516|NCT02083991|Experimental|Steroid-free low TAC-arm|"Induction therapy: Thymoglobulin i.v. 2,5 mg/kg day 0 and 1, preceded by methylprednisolone i.v. 250 mg day 0 and 50 mg day 1.~Maintenance therapy: Advagraf(TAC) 0,2 mg/kg p.o. started day1 (target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml; MMF 1g x 2 p.o. (target Area Under Curve, AUC 40-60 mg.h/L); No steroids p.o."
3071517|NCT02083991|Active Comparator|Standard low-TAC arm|"Induction therapy: Simulect i.v. 20 mg day 0 and 4; Steroids i.v. according to local practice.~Maintenance therapy: Advagraf(TAC) p.o. 0,2 mg/(target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml); MMF 1g x 2 p.o. (target AUC 40-60 mg.h/L); Steroids p.o. according to hospital practice (but not less than 5mg daily after 6 months)."
3071518|NCT02083978||Bipolar Diagnosis|Individuals identified as having a Bipolar Diagnosis with a manic episode
3071519|NCT02083978||Control|Individuals identified as not having a major psychiatric diagnosis
3071520|NCT02083965|Experimental|rFVIIIFc 1000 / 3000 PK Assessment|"A single intravenous (IV) injection of rFVIIIFc 50 IU/kg at a strength of 1000 IU/vial followed by a single IV injection of rFVIIIFc 50 IU/kg at a strength of 3000 IU/vial.~Following the PK assessment, participants will receive either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Participants will be allowed to switch from one regimen to another if approved by the Investigator."
3071521|NCT02083965|Experimental|rFVIIIFc 3000 / 1000 PK Assessment|"A single IV injection of rFVIIIFc 50 IU/kg at a strength of 3000 IU/vial followed by a single IV injection of rFVIIIFc 50 IU/kg at a strength of 1000 IU/vial.~Following the PK assessment, participants will receive either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Participants will be allowed to switch from one regimen to another if approved by the Investigator."
3071522|NCT02083952|Experimental|swaddle blanket|
3071523|NCT02083939||Antibiotic Prophylaxis|This cohort will receive antibiotic prophylaxis prior to the hernia repair
3071524|NCT02083939||No Antibiotic Prophylaxis|This cohort will not receive antibiotic prophylaxis prior to the surgery
3071525|NCT02083926|Experimental|Ketamine|Ketamine will be given at a dose of 0.5mg/kg over 40 minutes. This dose is identical to that used in previous anti-depressant studies of Ketamine.
3071526|NCT02083926|Placebo Comparator|Saline|Saline will be given at a dose of 0.5 mg/kg over a 40 minute period.
3071527|NCT02083913|Experimental|Supervised physical activity|
3071528|NCT02083900|Experimental|Banana Leaf Dressing Group|The Banana Leaf Dressing site will receive a single layer of banana leaf dressing
3071529|NCT02083900|Active Comparator|Hydrocolloid Dressing Arm|The donor under Hydrocolloid dressing was covered with hydrocolloid (DuoDERM CGF).
3071530|NCT02083887|Active Comparator|Group 1: ChAd63 ME-TRAP / MVA ME-TRAP at 16/24 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 infants aged 16 weeks at time of first vaccination vaccinated with ChAd63 ME-TRAP 5 x 10^10 vp (virus particles) intramuscular (IM) at 16 weeks and MVA ME-TRAP 1 x 10^8 pfu (plaque forming units) IM at 24 weeks.
3071531|NCT02083887|Active Comparator|Group 2: ChAd63 ME-TRAP / MVA ME-TRAP at 8/16 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 healthy infants aged 8 weeks at the time of first vaccination vaccinated with ChAd63 ME-TRAP 5 x 10^10 vp IM at 8 weeks and MVA ME-TRAP 1 x 10^8 pfu IM at 16 weeks
3071532|NCT02083887|Active Comparator|Group 3: ChAd63 ME-TRAP / MVA ME-TRAP at 1/8 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 healthy infants aged 1 week will be vaccinated with ChAd63 ME-TRAP 5 x 10^10 vp IM at 1 week and MVA ME-TRAP 1 x 10^8 pfu IM at 8 weeks.
3071533|NCT02083887|No Intervention|Group 4: Control|20 healthy infants aged 16, 8 and 1 weeks will be enrolled into this group. (Five infants will be randomised to each of Groups 1 and 2 respectively while 10 infants aged 1 week will be randomised to Group 3). All twenty infants will receive EPI vaccinations only.
3071534|NCT02083874|Experimental|CBD|Open label CBD
3071535|NCT02083861|Experimental|Active ultrasound device|Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
3071536|NCT02083861|Placebo Comparator|Placebo ultrasound device|Patients wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
3071537|NCT02083848|Other|7T MRI|All subjects are entered into a single arm.
3071538|NCT02083835||post-surgical patients|post-surgical patients > 18 years
3071539|NCT02083835||pediatric patients post-op day 1|pediatric patients > 4 years on post-op day 1 (sub-project QUIPSI - PAIN OUTinfant)
3071540|NCT02083822|Experimental|MRI assessment|
3071541|NCT02083809|Placebo Comparator|Placebo|500ml saline or lactated ringer without oxytocin added
3071542|NCT02083809|Active Comparator|Treatment group|Intravenous oxytocin mixed with saline or lactated ringer
3071543|NCT02083796|Experimental|Shoulder impingement_TSM|For the manipulation intervention, the subjects were in a seated position and a thrust technique was performed. If no cavitation was detected with the manipulation, the thrust was repeated up to 3 times.
3071544|NCT02083796|Sham Comparator|Shoulder impingement_sham|For the sham intervention, the subjects were positioned in the same seated position with the therapist holding the patient in the same position as for the thrust manipulation. In this position, the therapist applied all the same forces as done for a thrust-manipulation and held that position for a few seconds, but a thrust was not used.
3071545|NCT02083796|Active Comparator|Asymptomatic_TSM|For the manipulation intervention, the subjects were in a seated position and a thrust technique was performed. If no cavitation was detected with the manipulation, the thrust was repeated up to 3 times
3072534|NCT02077166|Experimental|Phase 1: Dose Level 2|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
3071546|NCT02083796|Sham Comparator|Asymptomatic_sham|For the sham intervention, the subjects were positioned in the same seated position with the therapist holding the patient in the same position as for the thrust manipulation. In this position, the therapist applied all the same forces as done for a thrust-manipulation and held that position for a few seconds, but a thrust was not used.
3071547|NCT02083783|Experimental|TRI102|Active
3071548|NCT02083783|Placebo Comparator|Placebo|Placebo
3071549|NCT02083770|Experimental|Cancer Clinical Trials Education Program|Cancer Clinical Trials Education Program is offered to English- and Spanish-speaking Hispanics in the experimental arm. This program was designed to promote increased clinical trials literacy among Hispanic Americans. Increased clinical trials knowledge and a better understanding of clinical trials is anticipated to create more positive attitudes, and perceptions about clinical trials among Hispanic Americans.
3071550|NCT02083770|Placebo Comparator|Neighborhood Watch Education Program|The Neighborhood Watch Program created by the Bureau of Justice Assistance and the National Crime Prevention Council was selected for inclusion in the control arm of this study. It provided participants with a program of equivalent length and format, as well as an equivalent focus on improving the well-being of Hispanic Americans. It also provided an opportunity to evaluate the impact of the Neighborhood Watch Program.
3071551|NCT02083757||Resp|Fluid responsiveness is defined as a change of stroke volume stroke volume ≥ 10% after 250 ml rapid saline infusion in 10 minutes.
3071552|NCT02083757||Nonresp|Fluid responsiveness is defined as a change of stroke volume stroke volume < 10% after 250 ml rapid saline infusion in 10 minutes.
3071553|NCT02083744|Active Comparator|Control Group|Usual care group - patients will receive scales to take home and heart failure literature for self-monitoring of heart failure. Patients will complete final questionnaires
3071554|NCT02083744|Experimental|Psychoeducational Counseling|"1-on-1 psychoeducation session conducted by a bilingual research nurse at the clinic site or in the patient's home. Patients will receive a scale to measure weight, a diary to record weight and symptoms of heart failure, and telephone follow-up from the research nurse to reinforce the content of the education program every other week.~Focus-groups - Perception of the intervention will be assessed with two focus groups."
3071555|NCT02083731|Experimental|MSCs|MSCs will be used to treat refractory CMV infection or CMV-associated diseases. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg. If anticipates do not attain the complete remission standards within 14d, a second course of the same treatment will be given.
3071556|NCT02083718|Experimental|PBSC & MSCs|PBSC will be intravenously infused at a dose of 2×10^8/kg. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week. The vital signs of all patients will be closely monitored during and for 24h after administration.If the NEU and PLT levels do not attain the completely response(CR)standards within 28d, a second course of the same treatment will be given.
3071557|NCT02083705|Experimental|SI+CC|"Chest compression will be superimposed by sustained inflations during CPR:~CC+SI group Infants randomized in the SI group requiring CC, would receive CC at a rate of 90/min during an SI with a duration of 20sec (CC+SI). After 20 sec the SI will be interrupted for 1 sec and the next SI will be started for another 20sec13. Throughout this time CC is continued until ROSC. Every 45 sec (approximately 2 SIs) the clinical team would assess for changes in heart rate. CC+SI was continued until ROSC."
3071558|NCT02083705|Active Comparator|3:1 CPR|"CPR using 3:1 C:V ratio:~3:1 C:V group Infants randomized into the 3:1 group requiring CC, would received CC using the current 3:1 C:V ratio recommend in the neonatal resuscitation guidelines16. Every 45 sec the clinical team would assess heart rate. 3:1 C:V CPR was continued until ROSC."
3071559|NCT02083692|Experimental|Metformin|
3071560|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|
3071561|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|
3071562|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|
3071563|NCT02083679|Experimental|Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel|
3071564|NCT02083666|Experimental|SOBI002|Single and repeated administration of different doses of test product
3071565|NCT02083666|Placebo Comparator|placebo|Single and repeated administration of placebo comparator
3071566|NCT02083653|Experimental|Arm A: Sym004|Sym004 will be administered as an intravenous infusion at a dose of 12 milligrams per kilogram (mg/kg) weekly until unacceptable toxicity, disease progression, or consent withdrawal.
3071567|NCT02083653|Experimental|Arm B: Sym004|Sym004 will be administered as an intravenous infusion at a loading dose of 9 mg/kg followed by 6 mg/kg weekly until unacceptable toxicity, disease progression, or consent withdrawal.
3071568|NCT02083653|Active Comparator|Arm C: Investigator's choice|Best supportive care (BSC) or Fluorouracil (5-FU) or Capecitabine will be given as per Investigator's discretion.
3071569|NCT02083640|Other|Treatment A (Reference)|
3071570|NCT02083640|Other|Treatment B (Test)|
3071571|NCT02083640|Other|Treatment C (Test)|
3071572|NCT02083627|Experimental|1:Single rosuvastatin,multiple fidaxomicin,single rosuvastatin|
3071573|NCT02083627|Experimental|2:Multiple fidaxomicin,single rosuvastatin,single rosuvastatin|
3071574|NCT02083614|Experimental|clamping|to clamp or release the catheter for 2 days before removal
3071575|NCT02083614|No Intervention|no clamping|
3071576|NCT02083601|Experimental|Psychological Support|The intervention group will participate in the 2-day, in-person Parent Forum and receive monthly phone calls from a mental health professional for 12 months.
3071577|NCT02083601|Other|No Psychological Support|This comparison group will attend the 2-day, in-person Parent Forum but will not receive long-term psychological support.
3071578|NCT02083588|Experimental|open - single arm|All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
3071579|NCT02083575|Active Comparator|vitamin c|25 heavily iron-loaded thalassemia patients, receiving adjuvant vitamin c with iron chelator.
3071580|NCT02083575|Other|iron chelator|Included 25 heavily iron-loaded thalassemia patients, not receiving adjuvant vitamin c with iron chelator.
3071581|NCT02083549||Trauma 1 massively transfused|Trauma 1 massively transfused patients are identified as a Trauma level one patient by triage through guidelines from the Kessler Regional Trauma Center Trauma Triage Guidelines.
3071582|NCT02083536|Experimental|LDFWART + Docetaxel|"This study has 6 treatment cycles given at 3 weeks intervals ± 3 days. A cycle is defined as 1 treatment of morning Docetaxel and afternoon Low Dose Fractionated Whole Abdominal Radiation Therapy (LDFWART). The first day of the first treatment is designated study day 1."
3071583|NCT02083523|Active Comparator|Motivational Interview|The Motivational Interview, or MI, (15-30 minutes) was provided after initial substance use disorder assessments but prior to treatment admission. I twas facilitated by a computer generated report and included: an orientation to the session, discussion of the participants' strengths, an agenda setting procedure, a review of concerns, and a session summary. Therapists conveyed empathy, used reflective listening, tried to elicit and reinforce change talk elements, and elicited action steps from the participants.
3071584|NCT02083523|Active Comparator|MI with Normative Feedback|The Motivational Interview with Normative Feedback, or MI + NF, condition/intervention included all procedures described for the MI condition. Additionally, in the MI + NF condition/intervention, the participants' days of marijuana and alcohol use were compared to two sets of norms ( age specific or level of care specific) available for treatment attending youth. Therapists used whichever norm provided a greater contrast with participants' use.
3071585|NCT02083510|Experimental|Colchicine|Patients will be enrolled with either gout/pericarditis or hypertriglyceridemia, have VAP and Apolipoprotein CIII levels at baseline, administer Colchicine for 6 weeks with reassessment of Apolipoprotein CIII and VAP.
3071586|NCT02083497|Experimental|No banding|The volunteers who make up this group, held 18 kicks, 9 with the dominant leg and 9 with the non-dominant lower limb, without the intervention of any kind of bandage.
3071587|NCT02083497|Experimental|Group with Rigid Bandage|Volunteers carry out the same protocol described above, however, using rigid bandage. The bandage will be used for tape, Cremer brand and will be applied ankle support member of the individual, in order to limit the movement of the joint inversion.
3071588|NCT02083497|Experimental|Group with elastic bands|The protocol will be maintained, however, a brand elastic bandage Kinesio Sport applied to the lower support member of the individual, also in order to limit the movement of the joint inversion is used.
3071589|NCT02083471|Active Comparator|SOTI|Specific Oral Tolerance Induction with Egg or Cow's milk
3071590|NCT02083471|No Intervention|Food Allergy follow-up|
3071591|NCT02083458|Experimental|axillary vein catheterization|Catheterization of the axillary vein based on anatomical landmark.
3071592|NCT02083445|Placebo Comparator|Control group|Once a week there will be an attendance cognitive session (specific sessions designed to work on aspects related to body perception, movement, space) and the extraction of blood samples will be carried out to determine the progenitor cells on the same day of the active groups.
3071593|NCT02083445|Active Comparator|Exercise group|Patients with past history of TBI will perform exercise sessions two hours three days a week during 12 weeks. The sessions will consist of aerobic, strength, flexibility, proprioception and balance activities and muscle electro-stimulation sessions or cycling sessions.
3071594|NCT02083445|Active Comparator|Muscle electro-stimulation and IHH|Patients with past history of TBI will perform a 12 weeks program: intermittent hypobaric hypoxia (IHH) 2 hours at a simulated altitude of 4500 meters 3 days/week. Muscle electro-stimulation for two periods of 20 minutes during the stay in the hypobaric chamber.
3071595|NCT02083432|Active Comparator|5-weeks waiting list control|Half of the participants were randomly assigned to 5-weeks waiting list/Control group.The participants in the waiting list/Control Group are enrolled to the treatment Group (INtervention: 5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV).
3071596|NCT02083432|Experimental|5 session of CBT|Half of the participants were direct enrolled to 5 weeks(5 sessions) of cognitive behaviour therapy (CBT) performed by specially trained dentists. (Intervention: CBT)
3071597|NCT02083419||LVAD CRT|The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
3071598|NCT02083406|Experimental|Treatment A: OZ439 Prototype 1|800mg OZ439 prototype formulation 1 and 960mg PQP single doses
3071599|NCT02083406|Experimental|Treatment B: OZ439 Prototype 2|800mg OZ439 prototype formulation 2 and 960mg PQP single doses
3071600|NCT02083406|Experimental|Treatment C: OZ439 Prototype 3|800mg OZ439 prototype formulation 3 and 960mg PQP single doses
3071601|NCT02083393||Patients with acute lung injury|Patients with sepsis induced acute lung injury
3071602|NCT02083393||Postsurgery patients|Postsurgery patients without acute lung injury and sepsis
3071603|NCT02083380|Experimental|A) Artefenomel 800mg: piperaquine 640mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 640mg loose combination
3071604|NCT02083380|Experimental|B) Artefenomel 800mg: piperaquine 960mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 960mg loose combination
3071605|NCT02083380|Experimental|C) Artefenomel 800mg: piperaquine 1440mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination
3071606|NCT02083367||Hepatic Encephalopathy Group|Disease Group
3071607|NCT02083367||Control Group|Healthy Group
3071608|NCT02083354|Experimental|Arm 1|All subjects will receive the combination of dabrafenib (150 mg) and trametinib (2 mg) in the morning at approximately the same time every day. The second dose of dabrafenib (150 mg) alone will be administered approximately 12 hours after the morning dose. Subjects will continue study treatment until disease progression, death, unacceptable toxicity, withdrawal of consent, or study closure
3071609|NCT02083341|Experimental|Muscle tension dysphonia - treatment|external vibration device. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP.
3071647|NCT02083120|Experimental|nasal High Flow and Oxygen|overnight nasal High Flow (NHF) therapy+ individually titrated supplemental oxygen (2-6 L/min),total 35 L/min, 4 weeks at home
3071648|NCT02083120|Active Comparator|Long term Oxygen Therapy (LOT)|individually titrated supplemental oxygen (2-6 L/min), 4 weeks at home
3071687|NCT02082769|Experimental|Febuxostat 40 mg QD|Febuxostat 40 mg, orally, once daily for up to 24 weeks
3071610|NCT02083341|Sham Comparator|Muscle tension dysphonia - Sham|external vibration device - sham. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP. Lelo® Siri vibrator with vibration component removed.
3071611|NCT02083341|Experimental|Classically trained singers|external vibration device. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP.
3071612|NCT02083341|Sham Comparator|Classically trained singers - Sham|external vibration device - sham. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP. Lelo® Siri vibrator with vibration component removed.
3071613|NCT02083328|Active Comparator|Caffeine|Caffeine will be administrated at a dosage of 6mg/kg of body mass. It is ingested once, one hour before the exercise performance test.
3071614|NCT02083328|Placebo Comparator|Mannitol (Placebo)|Placebo capsules will be administrated one hour before the exercise performance test. The subject gets exactly the same number of capsules as for the caffeine dosage. Caffeine and placebo capsules look the same.
3071615|NCT02083315|Experimental|TRV130 1.5 mg|TRV130 1.5 mg IV x 1 dose
3071616|NCT02083315|Experimental|TRV130 3 mg|TRV130 3 mg IV x 1 dose
3071617|NCT02083315|Experimental|TRV130 4.5 mg|TRV130 4.5 mg IV x 1 dose
3071618|NCT02083315|Active Comparator|Morphine|Morphine 10 mg IV x 1 dose
3071619|NCT02083315|Placebo Comparator|Placebo|Dextrose 5% in water IV x 1 dose
3071620|NCT02083302|Experimental|Treatment1|The Treatment1 group received SCREAM Theater Dose 1, SCREAM Theater Dose 2 and SCREAM Theater Dose 3.
3071621|NCT02083302|Experimental|Treatment2|The Treatment2 group received SCREAM Theater Dose 1, SCREAM Theater Dose 2, SCREAM Theater Dose 3 and SCREAM Theater Dose 4.
3071622|NCT02083302|Other|Control|The control group received SCREAM Theater Dose 1.
3071623|NCT02083289|Experimental|Experimental Arm 1|ONO-9054 eye drop solution, 30 µg/mL (0.003%), once daily in both eyes, for 28 days.
3071624|NCT02083289|Active Comparator|Active Comparator Arm 2|Latanoprost eye drop solution, 0.005%, once daily in both eyes for 28 days.
3071625|NCT02083276|Experimental|Pivmecillinamhydrochlorid|Selexid 400 mg x 3 , 7 days
3071626|NCT02083263|Experimental|Bilevel|Bilevel, 3 months. The treatment was performed twice a day, 1 hour each treatment.
3071627|NCT02083263|Active Comparator|PEP mask|PEP mask, 3 months. The treatment was performed twice a day, 1 hour each treatment.
3071628|NCT02083250|Experimental|Fludarabine + Clofarabine + Busulfan + SAHA +SCT|Starting dose of SAHA: 200 mg by mouth daily within one hour prior to fludarabine administration for total 4 doses. Fludarabine 10 mg/m2 by vein on Days -6 through -3. Clofarabine 40 mg/m2 by vein on Days -6 through -3. Busulfan test dose, 32 mg/m2, can be administered within 10 days prior to admission as an outpatient or as an inpatient on Day -8. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-6. Busulfan adjusted dose determined to achieve a systemic exposure represented by an average daily AUC of 5500 µMol-min ± 5% for the entire 4-day treatment period. If pharmacokinetic analysis cannot be completed for any reason, Busulfan given in a dose of 130 mg/m2 daily. Participants who receive a graft from an unrelated donor receive Thymoglobulin; 0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.0 mg/kg on day -1. Stem cell infusion on Day 0.
3071629|NCT02083237|Active Comparator|Behavioural Intervention Program|People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
3071630|NCT02083237|No Intervention|Waitlist Control|Due to the heavy demand for this clinical program, there is a naturally-occurring waitlist of approximately 3 months. Control participants are assessed during this period.
3071631|NCT02083224||Cancer patients|
3071632|NCT02083211|Experimental|mAb Nimotuzumab + chemotherapy|
3071633|NCT02083211|Placebo Comparator|placebo + chemotherapy|
3071634|NCT02083198||High Chloride|Patients receiving .9% sodium choride for resuscitation
3071635|NCT02083198||Low chloride|Patients receiving Plasmalyte for resuscitation
3071636|NCT02083185|Experimental|Relugolix 80 mg|Relugolix 320 mg (loading dose), tablets, orally, on Day 1 followed by relugolix 80 mg, tablets, orally, once daily for 48 weeks plus an optional 48 week extension at the investigator's discretion.
3071637|NCT02083185|Experimental|Relugolix 120 mg|Relugolix 320 mg (loading dose), tablets, orally, on Day 1 followed by relugolix 120 mg, tablets, orally, once daily for 48 weeks plus an optional 48 week extension at the investigator's discretion.
3071638|NCT02083185|Active Comparator|Leuprorelin 22.5 mg|Leuprorelin 22.5 mg, subcutaneous, injection on Day 1 and every 12 Weeks for up to 4 injections (48 weeks).
3071639|NCT02083172||Hemodynamically stable patients|Hemodynamically stable patients will be defined as patients with normal hemodynamic profile as evidenced by normal age-determined vital signs and normal perfusion.
3071640|NCT02083172||Hemodynamically unstable patients|Hemodynamically unstable patients will be defined as patients who are admitted to the Pediatric Critical Care Unit (PCCU), in whom there is a clinical diagnosis of shock as evidenced by signs and symptoms of hypoperfusion, requiring fluid resuscitation and/or inotropic support.
3071641|NCT02083172||Mechanically ventilated patients|Patients requiring mechanical ventilation
3071642|NCT02083159||Patients with NAFLD|
3071643|NCT02083146||Patients with CAD|Acute coronary syndromoe (ACS) patients who were admitted to the coronary care unit.
3071649|NCT02083107|Experimental|sublingual misoprostol & rectal placebo|"will receive 400 microgram of misoprostol (Sigma) sublingual 2 tablets and rectal placebo2 tablets."
3071650|NCT02083107|Placebo Comparator|rectal & sublingual placebo|"will receive rectal placebo2 tablets and sublingual placebo2 tablets."
3071651|NCT02083107|Experimental|rectal misoprostol & sublingual placebo|"will receive 400 microgram of misoprostol (Sigma) rectal 2 tablets and sublingual placebo2 tablets."
3071652|NCT02083081|Experimental|community intervention|Community level intervention (Social marketing campaign delivered to entire village) plus individual peer counseling sessions for enrolled pregnant women
3071653|NCT02083081|No Intervention|usual care|Usual care provided by health aides to pregnant women
3071654|NCT02083068|Experimental|Experimental|10 individuals per sub- group to be immunized with the Vaccine PvCS N+C at month 0 and the Vaccine PvCS N+C+R at months 2 and 6
3071655|NCT02083068|Placebo Comparator|Control|six individuals for each sub- group to be immunized with placebo SSN Montanide ISA-51
3071656|NCT02083055|Experimental|dexmedetomidine|Intraoperative controlled hypotension by dexmedetomidine
3071657|NCT02083055|Active Comparator|nitroglycerin|Intraoperative controlled hypotension by nitroglycerin
3071658|NCT02083029|Experimental|Syncopal Asthmatic|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
3071659|NCT02083029|Experimental|Non Syncopal Asthmatic|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
3071660|NCT02083029|Experimental|Normal Volunteers|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
3071661|NCT02083016|Other|Conventional Mapping|Both pre and post-ablation mapping will be performed firstly by conventional point by point mapping using a Navistar Thermocool catheter, and secondly by multielectrode contact mapping using a Pentaray catheter. In this group, ablation will be guided by conventional mapping.
3071662|NCT02083016|Other|Multielectrode mapping.|Both pre and post-ablation mapping will be performed firstly by multielectrode contact mapping using a Pentaray catheter, and secondly by conventional point by point mapping using a Navistar Thermocool catheter. In this group ablation will be guided by multielectrode contact mapping.
3071663|NCT02083003|Experimental|Polyamine low-diet|Polyamines depleted diet during the week before surgery : 2 cans per day of Polydol (oral alimentation without polyamines), associated to predefined menus low in polyamines
3071664|NCT02083003|Active Comparator|Liberal alimentation|No specific alimentary diet
3071665|NCT02082990|Active Comparator|Face-to-Face Brief Intervention Group|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
3071666|NCT02082990|Experimental|Online Brief Intervention Group|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
3071667|NCT02082977|Experimental|Part 1|Subject will be administered with a 50 milligram (mg) starting dose of GSK2816126 intravenous infusion over 2 - 4 hours, initially twice-weekly 3 weeks on / 1 week off in each 28-day cycle. Dose escalation will continue until an RP2D is determined or until an maximum tolerated dose (MTD) or a dose of 3000 mg twice-weekly is reached [Maximum Feasible Dose (MFD)].
3071668|NCT02082977|Experimental|Part 2|After the RP2D (or MTD/MFD) has been determined in Part 1, Part 2 expansion cohorts will be opened. In Part 2, subjects will be assigned to one of five cohorts based on disease and EZH2 mutation status and cancer type.
3071669|NCT02082964|Experimental|SCIM|after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation
3071670|NCT02082964|Experimental|video|video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course.
3071671|NCT02082951|Experimental|Group 2: empathic behaviour by family.|Considered the empathic behaviour performed by family as a hospital visit with greater than 45 minutes duration, a person with whom the patient had a good relationship, he considered it to be important and welcome. It is emphasized that these families did not have any prior training and after the visit, patients were asked about how the visit had been seeking to detect the presence of any conversations that have been unpleasant for patients and, if present, the patients were excluded from the study.
3071672|NCT02082951|Experimental|Group 1: empathic behaviour by nurses.|The empathic behaviour in group 1 was performed by a trained nurse.
3071673|NCT02082938|Experimental|Bracing|Bracing: the patients began four weeks of training the gait with the brace, under the guidance and observation of the physiotherapist belonging to the group of authors of this study.
3071674|NCT02082925|Experimental|COPD patient|
3071675|NCT02082912|Experimental|D-cycloserine|Subjects will take D-cycloserine and use the HandMentor Pro for robotic therapy
3071676|NCT02082912|Active Comparator|Placebo|Subjects will take a placebo pill and use the HandMentor Pro for robotic therapy
3071677|NCT02082899|Active Comparator|Active Comparator EBI-005 5 mg/mL|Administered 3 times per day
3071678|NCT02082899|Placebo Comparator|Placebo Comparator|Administered 3 times per day
3071679|NCT02082860|Experimental|Cohort A|rAAV2/5-PBGD vector dosage 1
3071680|NCT02082860|Experimental|Cohort B|rAAV2/5-PBGD vector dosage 2
3071681|NCT02082860|Experimental|Cohort C|rAAV2/5-PBGD vector dosage 3
3071682|NCT02082860|Experimental|Cohort D|rAAV2/5-PBGD vector dosage 4
3071683|NCT02082834|Experimental|EVAR|
3071684|NCT02082808|Experimental|Sequence 1|Participants will receive the study Treatment A for 5 days (DTG 50mg q24h) in Period 1 followed by a washout period (>=7days) and Treatment B for 5 days (DCV 60mg q24h) in Period 2 and Treatment C (DCV 60mg q24h + DTG 50mg q24h) for 5 days in Period 3
3071685|NCT02082808|Experimental|Sequence 2|Participants will receive the study Treatment B for 5 days (DCV 60mg q24h) in Period 1 followed by a washout period (>=7days) and Treatment A for 5 days (DTG 50mg q24h) in Period 2 and Treatment C (DCV 60mg q24h + DTG 50mg q24h) for 5 days in Period 3
3071686|NCT02082782|Experimental|irreversible electroporation (IRE)|Single arm study: percutaneous or open irreversible electropration of CRLM
3071768|NCT02082236|Experimental|Treatment D|12 consecutive doses of SSM 30 mcg administered 1 hour apart
3071688|NCT02082769|Experimental|Febuxostat 80 mg QD|Febuxostat 80 mg, orally, once daily for up to 24 weeks
3071689|NCT02082769|Active Comparator|Allopurinol 100mg QD|Allopurinol 100mg, orally, three times daily for up to 24 weeks
3071690|NCT02082756|Experimental|Bifidobacterium viable pharmaceutics|Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks
3071691|NCT02082756|Experimental|Berberine Hydrochloride|Berberine Hydrochloride, 0.5g, 2/day, 12 weeks
3071692|NCT02082756|No Intervention|lifestyle counseling|
3071693|NCT02082743|Experimental|Outdoor activity|Outdoor activity in recess time
3071694|NCT02082743|No Intervention|Control|
3071695|NCT02082730|Active Comparator|Mid treatment Group|Patients who have completed 6 sessions at the Manchester CFS/ME Service for Children & Young People will be recruited. They would have had previous experience of using paper diaries.They will collect activity data using the ASARM system.
3071696|NCT02082730|Experimental|Start of Treatment Group|Newly presented patients, will collect activity data using the ASARM system.
3071697|NCT02082730|No Intervention|Audit group|"To provide comparative baseline data for general treatment response, we will audit pre-treatment and post-treatment clinical data on the regular gold standard clinical measures package, as these are the outcome measures routinely used in the clinic."
3071698|NCT02082717|Experimental|Neut (4%sodium bicarbonate additive)|4% sodium bicarbonate additive during intravenous potassium chloride replacement.
3071699|NCT02082717|Active Comparator|Control|standard of practice potassium chloride replacement (with no additive)
3071700|NCT02082704|Experimental|SE Game on DSME|The intervention cohort will participate in an online team-based game on diabetes self-management education (DSME) and will receive a paper documents on American history,
3071701|NCT02082704|Active Comparator|SE Game on American History|The 'attention control' cohort will participate in an online team-based game on American history and will receive a paper documents on DSME.
3071702|NCT02082678|Active Comparator|Ondansetron|Ondansetron will be given 0.5 mg/ BID. The dose may be increased from 0.5 mg/BID to 1.0 mg/BID at week 4 for participants with less than 30% reduction in HAMD and/or alcohol use. An additional dose increase to 2.0 mg/BID and 4.0 mg/BID is allowed at weeks 8 and 10, respectively, for participants with less than a 50% reduction in HAMD scores and/or alcohol use.
3071703|NCT02082678|Placebo Comparator|Placebo|Placebo will be given 0.5 mg/ BID. The dose may be increased from 0.5 mg/BID to 1.0 mg/BID at week 4 for participants with less than 30% reduction in HAMD and/or alcohol use. An additional dose increase to 2.0 mg/BID and 4.0 mg/BID is allowed at weeks 8 and 10, respectively, for participants with less than a 50% reduction in HAMD scores and/or alcohol use.
3071704|NCT02082665|Experimental|Arm 1|On Day 1 subjects will simultaneously receive single dose of Rosuvastatin 10 mg tablet and Midazolam 3 mg syrup administered orally in the morning.
3071705|NCT02082652|Active Comparator|Control group (No ART)|Etonogestrel implant in participants not yet receiving ART (control group)
3071706|NCT02082652|Active Comparator|Nevirapine-based ART group|Etonogestrel implant in participants receiving nevirapine (NVP)-based ART
3071707|NCT02082652|Active Comparator|Efavirenz-based ART group|Etonogestrel implant in participants receiving efavirenz (EFV)-based ART
3071708|NCT02082639|Experimental|HPV Group|Subjects will receive two doses of HPV vaccine intramuscularly
3071709|NCT02082639|Experimental|HAV Group|Subjects will receive two doses of HAV vaccine intramuscularly
3071710|NCT02082639|Experimental|HPV+HAV Group|Subjects will receive two doses of both HPV and HAV vaccines intramuscularly
3071711|NCT02082626|Experimental|Eribulin|All patients will receive the experimental agent eribulin. The dose will increase with subsequent cohorts of patients.
3071712|NCT02082613|Experimental|Lord´s procedure|Lord´s procedure for testicular hydrocele, under local anesthesia in a conventional operation room, under sterile conditions
3071713|NCT02082613|Active Comparator|Sclerotherapy|Sclerotherapy with 4 ml of polidocanol 30mg/ml after complete emptying of the hydrocele. With or without local anesthesia, not performed in an operation room.
3071714|NCT02082600|Experimental|Sleep deprivation|Exercise induced-muscle damage protocol followed by 60h of sleep deprivation (two nights) and one night of normal sleep (rebound).
3071715|NCT02082600|Experimental|Normal sleep|Exercise induced-muscle damage protocol followed by 3 nights of normal sleep
3071716|NCT02082587||QOL Assessment|
3071717|NCT02082574||patients|HIV infected for more than 5 years, aged over 50, treated with ARV
3071718|NCT02082574||control|non HIV (matched for age and gender)
3071719|NCT02082561|Experimental|Transdiagnostic Treatment (F-SET)|F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The F-SET protocol is consistent with current CBT protocols for anxiety disorders.
3071720|NCT02082561|No Intervention|Waitlist|The waitlist control condition was comprised of patients randomly assigned to the waitlist condition (WL). Individuals in this condition were reassessed after five weeks and were then offered treatment, but were no longer followed.
3071721|NCT02082548|Experimental|Intervention|educational intervention arm
3071722|NCT02082548|No Intervention|control|Standard of care
3071723|NCT02082522|Experimental|Photodynamic therapy-Photofrin plus SMC|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin followed by the illumination of the tumor using a fiber optic device. Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals. Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen.
3071724|NCT02082522|Active Comparator|Standard Medical Care (SMC)|Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen. The chemotherapy regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
3071725|NCT02082509||Traumatic Brain Injury (TBI)|Patient who have sustained a TBI over 1 month prior to enrollment, and endorse at least 1 post-concussive symptom at the time of enrollment.
3096788|NCT01913847|Experimental|Sildenafil|Sildenafil 20 mg
3071726|NCT02082509||Healthy Controls (no TBI)|Subjects who match the TBI group's demographic characteristics, except that they have not sustained a TBI and they are otherwise physically and mentally healthy.
3071727|NCT02082496|Experimental|Control Group|4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection
3071728|NCT02082496|Experimental|Case Group|4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection
3071729|NCT02082483|Experimental|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
3071730|NCT02082483|No Intervention|Regular Screening|Patients randomized to regular screening will be tested as per the current standard described in guidelines published by the National Kidney Foundation (e.g. annually while wait-listed for transplantation). If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
3071731|NCT02082470|Active Comparator|Arm I (standard post-treatment)|Participants receive standard post-treatment care consisting of regular cancer surveillance visits with treating oncologists.
3071732|NCT02082470|Experimental|Arm II (survivorship care planning)|Participants complete survivorship care planning in close collaboration with treating oncologists.
3071733|NCT02082457|Placebo Comparator|Placebo|Two tablets of YKP10811 placebo are administered orally once a day for 12 weeks.
3071734|NCT02082457|Experimental|YKP10811 10mg|Two tablets of YKP10811 5mg are administered orally once a day for 12 weeks.
3071735|NCT02082457|Experimental|YKP10811 20mg|One tablet of YKP10811 20mg and one tablet of placebo are administered orally once a day for 12 weeks.
3071736|NCT02082457|Experimental|YKP10811 40mg|Two tablets of YKP10811 20mg are administered orally once a day for 12 weeks.
3071737|NCT02082444|Experimental|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
3071738|NCT02082418|Experimental|Healthy|healthy control subjects
3071739|NCT02082418|Experimental|MCI|mild cognitive impariments
3071740|NCT02082418|Experimental|Dementia|established diagnosis of dementia
3071741|NCT02082405|Experimental|Treatment (bortezomib, cyclophosphamide, dexamethasone)|Patients receive bortezomib SC or IV over 3-5 seconds on days 1, 8, and 15; cyclophosphamide PO QD on days 1-21; and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3071742|NCT02082392|Placebo Comparator|Clinical Frequency Management|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4.
3071743|NCT02082392|Placebo Comparator|Research Frequency Management|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders.
3071744|NCT02082379|Active Comparator|Term newborns 1-6 week old|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The interfaces that will be used are: tight mask, the angled PediNeb, the B&B adapter, mask placed at 2 cm from the face, the PediNeb T-piece, and a capped corrugated tubing placed 2 cm away from the face.
3071745|NCT02082379|Active Comparator|Infants 6-8 month old|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The interfaces that will be used are: tight mask, the angled PediNeb, the B&B adapter, mask placed at 2 cm from the face, the PediNeb T-piece, and a capped corrugated tubing placed 2 cm away from the face.
3071746|NCT02082366|Active Comparator|conventional irrigated ablation catheter|"TCD testing during procedure from trans-septal puncture until completion using a conventional irrigated ablation catheter.~Intervention: TCD monitoring of microembolic signal during procedure"
3071747|NCT02082366|Active Comparator|nMARQ circumferential irrigated catheter|"TCD testing during procedure from trans-septal puncture until completion using the nMARQ circumferential irrigated catheter.~Intervention: TCD monitoring of microembolic signal during procedure"
3071748|NCT02082353||Retrospective CGD Cohort|Longitudinal analysis
3071749|NCT02082353||Prospective CGD Cohort|Longitudinal analysis
3071750|NCT02082353||HCT CGD Cohort|Cross-sectional analysis
3071751|NCT02082353||Conventional Non-Transplant CGD Cohort|Longitudinal analysis
3071752|NCT02082340|Experimental|Intervention arm|The intervention includes the following components: self-administered drug intake strategy, TB knowledge and socio-psychological counseling session, SMS text messages, phone calls, educational leaflet
3071753|NCT02082340|No Intervention|Control arm|patients included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by WHO
3071754|NCT02082327|Experimental|0.3 mg/kg|IV infusion of migalastat HCl or placebo
3071755|NCT02082327|Experimental|1 mg/kg|IV infusion of migalastat HCl or placebo
3071756|NCT02082327|Experimental|10 mg/kg|IV infusion of migalastat HCl or placebo
3071757|NCT02082327|Experimental|150 mg IV|150 mg single IV infusion
3071758|NCT02082327|Experimental|150 mg oral|150 mg single oral dose
3071759|NCT02082301||Gestational diabetes|Primary cohort is women with diagnosis of gestational diabetes without evidence of overt diabetes
3071760|NCT02082288|Experimental|Edessy ICSI Outcome Embryo Score|ICSI
3071761|NCT02082275|Experimental|OB Nest|OB Nest is designed to reduce the number of pre-planned visits with their OB provider and replace the in-clinic visits with a direct and constant support from an assigned nursing team. OB Nest will empower moms-to-be to take ownership of their prenatal care by providing a wealth of resources.
3071762|NCT02082275|No Intervention|Traditional Prenatal care|Traditional prenatal visits in clinic with OB providers.
3071763|NCT02082262|Experimental|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
3071764|NCT02082249|Experimental|ABT-SLV187|up to 9 years
3071765|NCT02082236|Active Comparator|Treatment A|Sufenta® IV (50 mcg/mL) 30 mcg infused over 1 minute
3071766|NCT02082236|Experimental|Treatment B|Single dose of SSM 30 mcg
3071767|NCT02082236|Experimental|Treatment C|2 consecutive doses of SSM 15 mcg administered 20 minute apart
3071769|NCT02082223|Experimental|Preoperative Rehabilitation|"Patient & caregiver input regarding 'single biggest concern right now' (modified BEACON buttons) will be elicited. Information gathered by the study team which includes a trained nursing coach and the patient/caregiver will together develop an individualized 'toolbox' of possible interventions to improve preoperative quality of life.~Candidate interventions include, but not limited to: Participation in SMART program, caregiver participation in Caregivers study protocol MC1295 (IRB 13-002943), nutritional recommendations (deficiencies, immuno-nutrition), low impact resistance training/tai chi, referral to financial or counseling services, establishment of information sources & plans for concerns not frequently covered in clinical practice such as sleeplessness, spiritual assistance."
3071770|NCT02082210|Experimental|LY2875358 + Ramucirumab (Part A)|Part A: Dose escalation of LY2875358 administered intravenously (IV), on days 1 and 15 every 28 day cycle in combination with a fixed dose of ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
3071771|NCT02082210|Experimental|LY2875358 + Ramucirumab (Part B)|Part B: Recommended LY2875358 dose from Part A to be administered IV, on days 1 and 15 every 28 day cycle in combination with a fixed dose of ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
3071772|NCT02082197|Experimental|ABT-SLV176|ABT-SLV176 administered daily
3071773|NCT02082184|Experimental|Sensor Based Glucose Monitoring System|Standard system use for 6 months. Followed by open access to the device for 6 months.
3071774|NCT02082184|Active Comparator|Standard Blood Glucose Monitoring|Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
3071775|NCT02082171|No Intervention|Control group|
3071776|NCT02082171|Experimental|Intervention group|Comprehensive geriatric assessment followed by multi-domain preventive intervention
3071777|NCT02082158|Active Comparator|Local Respirator Model|Subjects randomized to the local respirator model will wear that model while performing study procedures.
3071778|NCT02082158|Active Comparator|Non-Local Respirator Model|Subjects randomized to the non-local respirator design will wear that model while performing study procedures.
3071779|NCT02082158|Experimental|Prototype 1 Respirator Design|Subjects randomized to the prototype 1 respirator design will wear that model while performing study procedures.
3071780|NCT02082158|Experimental|Prototype 2 Respirator Design|Subjects randomized to the prototype 2 respirator design will wear that model while performing study procedures.
3071781|NCT02082158|Experimental|Prototype 3 Respirator Design|Subjects randomized to the prototype 3 respirator design will wear that model while performing study procedures.
3071782|NCT02082158|Experimental|Prototype 4 Respirator Design|Subjects randomized to the prototype 4 respirator design will wear that model while performing study procedures.
3071783|NCT02082145|No Intervention|Control|Treated according to local protocol for diabetic peripheral neuropathy
3071784|NCT02082145|Experimental|NMES|Treated with neuromuscular stimulation of both legs, for 10 weeks
3071785|NCT02082119|Experimental|High Grade Glioma|To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed High Grade Glioma after biopsy.total dose of 60 Gy/ 4 Gy fraction/15 fractions (BED10 84 Gy) will prescribed to the PTV1; a total dose of 42 Gy/2.8 Gy fraction/15 fractions (BED10 53.76 Gy) will prescribed to PTV2 with SIB.
3071786|NCT02082106||males/females|Participants should be capable of alpine skiing and cross country skiing.
3071787|NCT02082093|No Intervention|Traditional Care|
3071788|NCT02082093|Experimental|eNephro Application|"Telemedicine system which is a collaborative and expert system, consisting of:~A dynamic shared medical record for the collection of administrative , medical, biological and clinical data for each patient. All health professionals can access the folder and fill in the support. It is the same for patients treated at home.~A secure messaging for communication between health professionals and between patients and health professionals Expert systems analyzing data from each patient A management tool of therapeutic education~These patients have a chronic renal failure moderate to end up being treated by ambulatory dialysis or kidney transplantation. The patients of each population will be randomly assigned in group 1 ie traditional care or in group 2 ie traditional care added by telemedicine system"
3071789|NCT02082080|Active Comparator|Obese and overweight children, education|Overweight and obese school children in grades 5 and 6
3071790|NCT02082080|No Intervention|Obese and overweight children|
3071791|NCT02082067|Experimental|Adductor canal|All patients in the arm will receive continuous adductor canal block under ultrasound guidance. 10ml of Ropivacaine 0,75%, BBraun, Germany, will be injected to dilate adductor canal. After catheter insertion 10ml of Ropivacaine 0,75% will be injected.
3071792|NCT02082067|Active Comparator|Femoral|All patients in the arm will receive continuous femoral nerve block under ultrasound guidance. Correct position of catheter will be check with injection of 20ml Ropivacaine 0,75% BBraun, Germany medial to femoral nerve.
3071793|NCT02082067|Placebo Comparator|Controls|No patients of this arm receive continuous nerve block. Intravenous opioids analgesia will be administered.
3071794|NCT02082054|Experimental|PSE 120 mg, CM 8 mg, Atr 0.36 mg|Pseudoephedrine 120 mg,chlorpheniramine 8 mg, atropine 0.36 mg tablet dosed BID for 7.5 days
3071795|NCT02082054|Experimental|PSE 120 mg, CM 8 mg, Atr 0.24 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg tablets dosed BID for 7.5 days
3071796|NCT02082054|Experimental|PSE 120 mg, CM 8 mg, Atr 0.12 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 dosed BID for 7.5 days
3071797|NCT02082054|Active Comparator|PSE 120 mg, CM 8 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg white, scored, tablets with M27 on scored side and plain on the other side"
3071798|NCT02082054|Experimental|Atropine 0.24 mg|Atropine 0.24 mg tablets dosed BID for 7.5 days
3071799|NCT02082041||Wounds on leg|
3071800|NCT02082028|Experimental|A (BGStar)|Patients will be educated within the context of the SINERGIA educational program to understand how to manage their own diabetes on the basis of their Self Monitoring of Blood Glucose values obtained with BGStar. Patients will be requested two 6-points profiles monthly.
3071801|NCT02082028|Active Comparator|B (traditional approach)|Usual approach for the disease management. Patients in Group B will receive usual education and, at any time during the study duration, if needed, will be instructed on Self Monitoring of Blood Glucose, performed with any glucose meter.
3072535|NCT02077166|Experimental|2Phase 1: Dose Level 3|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
3071802|NCT02082015|Experimental|true coil|Use the true coil / Low frequency rTMS / Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp
3071803|NCT02082015|Sham Comparator|sham coil|Use the sham coil / Low frequency rTMS / Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: vertical to scalp
3071804|NCT02082002||MS-Group|MS-Group
3071805|NCT02082002||Healthy control|Healthy control
3071806|NCT02081989|Experimental|Denervation|Renal denervation
3071807|NCT02081989|No Intervention|No intervention|Control group - no intervention
3071808|NCT02081976|Active Comparator|Standard Care Group|Dental therapist providing standard periodontal treatment
3071809|NCT02081976|Experimental|Integrated Care Group|a combined treatment approach of Dental Therapist, Dental Hygienist, Cardiologist along with counselor
3071810|NCT02081963|Experimental|Nebulized amikacin|Participants receive nebulized amikacin BID for 14 days in combination with standard treatment.
3071811|NCT02081963|Other|Nebulized normal saline|Participants received nebulized normal saline BID for 14 days in combination with standard treatment.
3071812|NCT02081950|Experimental|Enoxaparin sodium|Enoxaparin sodium (80mg) is administered subcutaneously as a single dose, in 2 periods.
3071813|NCT02081937|Experimental|Anti-CD19 CAR T cells|Patients receive anti-CD19-CAR retroviral vector-transduced autologous or donor-derived T cells on d1-5 in the absence of disease progression or unacceptable toxicity.
3071814|NCT02081924|Active Comparator|Kisspeptin|Participants will receive kisspeptin hormone or placebo via a subcutaneous pump device for up to 3 months.
3071815|NCT02081924|Placebo Comparator|Saline|Participants will receive kisspeptin hormone or placebo via a subcutaneous pump device for up to 3 months.
3071816|NCT02081911|Experimental|High volume Adductor canal block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine
3071817|NCT02081911|Experimental|Low volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine
3071818|NCT02081911|Experimental|Femoral nerve block|Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
3071819|NCT02081898|No Intervention|control group|weight maintenance diet
3071820|NCT02081898|Experimental|low calorie diet (LCD) group|approximate 100 kcal/d calorie deficit
3071821|NCT02081885|Experimental|Tricalcium Phosphate / Chitosan|
3071822|NCT02081885|Active Comparator|Autologous Graft|
3071823|NCT02081859|Placebo Comparator|Conventional grading|Embryos will be scored based on conventional criteria.
3071824|NCT02081859|Active Comparator|Embryoscope data|Embryos will be scored based on both conventional rating and embryoscope data.
3071825|NCT02081846|Experimental|Home Nurse Visit|Families in this arm will receive a nurse home visit within 96 hours of discharge.
3071826|NCT02081846|Active Comparator|Control|This arm will receive standard of care.
3071827|NCT02081833||Reminder group|the reminder group receives every 2 weeks a reminder to fill out the symptom diary (postcard or SMS)
3071828|NCT02081820||aneurysmal subarachnoid hemorrhage|observational, no intervention
3071829|NCT02081807||Dabigatran|
3071830|NCT02081807||Warfarin|
3071831|NCT02081794|Experimental|Arm I (Tailored education intervention)|Participants receive a tailored educational intervention on the risk of falls comprising one of four two-minute videos determined by which educational group the participant is placed in: high risk/high perception, high risk/low perception, low risk/high perception, or low risk/low perception. Participants also receive tailored printed educational information concerning hospital falls based on the participants' answers given on the Perceived Risk Survey and are tailored to the participants' perception of falls risk. Participants also complete an investigator-constructed satisfaction survey at 24 and 72 hours post-intervention.
3071832|NCT02081794|Active Comparator|Arm II (standard fall care)|Participants receive standard care by nurses comprising a falls risk assessment and verbal education and receive an educational instruction sheet on falls prevention.
3071833|NCT02081781||Probing, topical anesthesia|Nasolacrimal duct obstruction (NLDO) is a quite common condition among the infants. An imperforate membrane at the distal end of the nasolacrimal duct is the main cause of occlusion. Children with the signs of NLDO presenting with epiphora and/or mucous discharge were included in this study. Intervention with probing under topical anesthesia was performed on the same surgeon. And success rate was evaluated.
3071834|NCT02081768|Experimental|90yttrium colloid|90 Yttrium colloid will be inserted into the cystic cavity. Based on clinical expertise, the treating neurosurgeon will determine the appropriate surgical procedure for each patient on an individual basis which will be reflected in the surgical consent the patient is presented and signs.
3071835|NCT02081755|Experimental|Everolimus and Tacrolimus|Everolimus Dosing: 1.5 mg BID (3.0 mg/day) Tacrolimus Dosing: 0.05 mg/kg BID
3071836|NCT02081755|Active Comparator|Tacrolimus and Myfortic or CellCept or Imuran|Myfortic: 360 mg to 1080 mg BID OR CellCept: 500 mg to 1500 mg BID OR Imuran: 0.5mk/kg to 2mg/kg QD AND Tacrolimus Dosing: 0.05 mg/kg BID
3071837|NCT02081729||high VZV ELISPOT results|high spot counts in ELISPOT
3071838|NCT02081729||low VZV ELISPOT results|low spot counts in ELISPOT
3071839|NCT02081716||high CMV ELISPOT results|high spot counts in ELISPOT
3071840|NCT02081716||low CMV ELISPOT results|low spot counts in ELISPOT
3071841|NCT02081703|Experimental|AYX1 Injection 660 mg / 6 mL|Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
3071842|NCT02081703|Placebo Comparator|Placebo Injection 6 mL|Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
3071843|NCT02081703|Experimental|AYX1 Injection 1100 mg / 10 mL|Single Intrathecal (spinal) administration of AYX1 Injection (1100 mg in 10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
3071844|NCT02081703|Placebo Comparator|Placebo Injection 10 mL|Single Intrathecal (spinal) administration of Placebo Injection (10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
3071845|NCT02081690|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily
3071846|NCT02081677|Active Comparator|etafilcon A|Marketed control soft contact lens
3071847|NCT02081677|Experimental|Prototype E1|Investigational soft contact lens
3071848|NCT02081677|Experimental|Prototype E2|Investigational soft contact lens
3071849|NCT02081677|Experimental|Prototype E3|Investigational soft contact lens
3071850|NCT02081664|Other|Lifestyle intervention|life-style oriented group program together with an individualized treatment program using therapies out of the spectrum of Complementary and Alternative Medicine (CAM)
3071851|NCT02081651|Experimental|Parmigiano Reggiano cheese|Children treated Parmigiano Reggiano cheese for 12 months
3071852|NCT02081651|No Intervention|Control subjects|Children with cow's milk allergy not assuming Parmigiano Reggiano cheese
3071853|NCT02081638|Active Comparator|Elite Controller|40 HIV positive elite controllers. Twenty will be randomized to aspirin and 20 will be randomized to atorvastatin.
3071854|NCT02081638|Active Comparator|Treated Progressors (ART)|40 HIV positive, treated progressors. Twenty will berandomized to Aspirin and 20 will be randomized toatorvastatin.
3071855|NCT02081625|Experimental|NS-065/NCNP-01|
3071856|NCT02081612|Active Comparator|Nutrition Education|Educational weight management group sessions alone
3071857|NCT02081612|Active Comparator|Nutrition Education Plus Acupuncture|Educational weight management group sessions in addition to weight loss acupuncture
3071858|NCT02081599|Experimental|Teneli (Teneligliptin) /Teneli + insulin|Teneligliptin for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
3071859|NCT02081599|Placebo Comparator|Placebo/Teneli (Teneligliptin) + insulin|Placebo for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
3071860|NCT02081586|Experimental|6 Weeks Phone CBT plus smartphone app|Following baseline, six 30-minute sessions of phone CBT to address any beliefs, assumptions, attitudes, or perceptions that are not constructive to diabetes self-management. CBT phone app will assist patients to practice skills related to improving self-management via more constructive ways of thinking.
3071861|NCT02081586|Experimental|8 Weeks Phone CBT plus smartphone app|Following baseline, patients will receive 8 weeks of phone CBT to address non-constructive beliefs, assumptions, attitudes or perceptions related to diabetes self-management. They will have a smartphone apps to practice CBT skills between sessions.
3071862|NCT02081586|Experimental|12 weeks phone CBT plus smartphone app|Following baseline, patients will receive 12 weeks of phone CBT to address non-constructive beliefs, assumptions, attitudes or perceptions related to diabetes self-management. They will have a smartphone apps to practice CBT skills between sessions.
3071863|NCT02081586|Active Comparator|Standard Diabetes Care at PCP|Patients will remain in usual care and not receive study intervention. This will include usual diabetes care at PCP.
3071864|NCT02081573|Experimental|Brief CBT|During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
3071865|NCT02081560|Other|colistin pharmacokinetics|Intravenous colistin 9 million units loading dose and 3 million units q8h maintenance dose as long as treatment of infection is required
3071866|NCT02081547||IPC status|presence of cancer cells.
3071867|NCT02081534|Experimental|1 mg bid|1 mg AZD1722 bid
3071868|NCT02081534|Experimental|3 mg bid|3 mg AZD1722 bid
3071869|NCT02081534|Experimental|10 mg bid|10 mg AZD1722 bid
3071870|NCT02081534|Experimental|30 mg bid|30 mg AZD1722 bid
3071871|NCT02081534|Experimental|3 mg od|3 mg AZD1722 od
3071872|NCT02081534|Experimental|30 mg od|30 mg AZD1722 od
3071873|NCT02081534|Placebo Comparator|Placebo|Placebo (double dummy technique)
3071874|NCT02081521|Experimental|Community behaviour change campaign|Participants will be exposed to the community behaviour change intervention.
3071875|NCT02081521|No Intervention|No community behaviour change campaign|No community intervention will take place in the control arm, although exposure to some intervention messaging (radio adverts) may take place.
3071876|NCT02081508|Experimental|Unfilled interference|Interference onset: delayed test at 540000 ms
3071877|NCT02081508|Experimental|Early interference|Interference onset: delayed test at 0 ms
3071878|NCT02081508|Experimental|Mid interference|Interference onset: delayed test at 360000 ms
3071879|NCT02081508|Experimental|Late interference|Interference onset: delayed test at 180000 ms
3071880|NCT02081495|Experimental|Sequence AB|Twenty-one participants will receive DOXIL/CAELYX reference product in Cycle 1 and DOXIL/CAELYX test product in Cycle 2. Each cycle will be separated by 28 days.
3071881|NCT02081495|Experimental|Sequence BA|Twenty-one participants will receive DOXIL/CAELYX test product in Cycle 1 and DOXIL/CAELYX reference product in Cycle 2. Each cycle will be separated by 28 days.
3071882|NCT02081482|Experimental|subjects with refractory chronic cluster headache|Adult subjects with refractory chronic cluster headache and ONS indication
3071883|NCT02081469|Other|Arm A:TDF for extend 24 weeks|Arm A:Continue TDF 300mg daily for extend 24 weeks after completion of chemotherapy
3071884|NCT02081469|Other|Arm B: TDF for extend 48 weeks|Arm B: Continue TDF 300mg daily for extend 48 weeks after completion of chemotherapy.
3071885|NCT02081456|Active Comparator|Therapeutic Ultrasound|Therapeutic ultrasound applied for a period of 5 minutes to the most painful region of the neck, then a second 5 minute dose at the most painful region of the upper extremity
3071886|NCT02081456|Experimental|Soft Tissue Mobilization|Passive soft tissue mobilization to the neck and upper extremity
3096789|NCT01913847|Placebo Comparator|Placebo|Placebo
3071887|NCT02081443|Experimental|Ticagrelor 180mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
3071888|NCT02081443|Active Comparator|Ticagrelor 90mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
3071889|NCT02081430|Experimental|CT Manipulation|Prone cervicothoracic manipulation
3071890|NCT02081430|Active Comparator|Upper trapezius stretch|Passive sustained stretch to upper trapezius muscle
3071891|NCT02081430|No Intervention|Control|8 Minute wait
3071892|NCT02081417|Other|Peer led|"## sessions of the intervention of an evidenced based practice called Seeking Safety led by a Peer (6 sessions will be used to define treatment completion)"
3071893|NCT02081417|Other|Clinician led|"# intervention groups of an evidence based practice called Seeking Safety led by a master's level Clinician (6 sessions will be used to define treatment completion)."
3071894|NCT02081404|Active Comparator|Esomeprazole|proton pump inhibitor
3071895|NCT02081404|Placebo Comparator|Placebo|placebo
3071896|NCT02081391|Experimental|Tapentadol IR|Tapentadol immediate release oral solution 1.25 mg/kg will be given every 4 hours to participants aged 6 months to less than 18 years. Participants 30 days to less than 6 months old will be dosed with 0.5 mg/kg every 4 hours (in the first 24 hours). Participants from birth to less than 30 days of age will be dosed with 0.1 mg/kg every 4 hours (in the first 24 hours).
3071897|NCT02081391|Other|Placebo|
3071898|NCT02081378|Experimental|ABL001 in CML patients|Dose escalation study to estimate the MTD and/or RDE of ABL001 in adult patients with CML
3071899|NCT02081378|Experimental|ABL001+Nilotinib in CML patients|Dose escalation study to estimate the MTD and/or RDE of ABL001 in combination with Nilotinib in adult CML patients
3071900|NCT02081378|Experimental|ABL001 in Ph+ ALL patients|Dose escalation study to estimate the MTD and/or RDE of ABL001 in adult patients with Ph positive ALL patients
3071901|NCT02081378|Experimental|ABL001+Imatinib in CML patients|Dose escalation study to estimate the MTD and/or RDE of ABL001 in combination with imatinib in adult CML patients
3071902|NCT02081378|Experimental|ABL001+dasatinib in CML patients|Dose escalation study to estimate the MTD and/or RDE of ABL001 in combination with dasatinib in adult CML patients
3071903|NCT02081365|Experimental|High Anxiety Computerized Dental Anxiety Treatment|Computer based CBT intervention before the scheduled dental appoinment (1.5 hours)
3071904|NCT02081365|No Intervention|High Anxiety Wailist Control|
3071905|NCT02081352|Active Comparator|DermaPure™|DermaPure™ in combination with standard care comprising surgical debridement, covered by a non-adherent silicone wound contact layer, a wound cavity filler (if required), a secondary foam wound dressing and appropriate off-loading footwear.
3071906|NCT02081352|Sham Comparator|Standard care|Standard care comprising surgical debridement, covered by a non-adherent silicone wound contact layer, a wound cavity filler (if required), a secondary foam wound dressing and appropriate off-loading footwear.
3071907|NCT02081339||Macular diseases|ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
3071908|NCT02081326|Experimental|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
3071909|NCT02081326|Placebo Comparator|Saline injection|2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
3071910|NCT02081313|Active Comparator|Netherton syndrome|Patients with Netherton syndrome
3071911|NCT02081313|Active Comparator|Healthy controls|healthy controls
3071912|NCT02081300|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate: Initial dose: 225 mg TU BID. Dose titrated up to 300 mg TU BID or down to 150 mg TU BID based on serum T at Week 3 and 7.
3071913|NCT02081300|Other|Topical testosterone gel 1.62 %|Topical testosterone gel 1.62%: Initial dose: 40.5 mg T once daily. Dose titrated down to 20.25 mg or up to 81 mg based on serum T on Days 14 and 28
3071914|NCT02081287|Active Comparator|Lamotrigine|As adjunct to lithium therapy
3071915|NCT02081287|Experimental|IP6|As adjunct to lithium therapy
3071916|NCT02081274||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease between 2009 and 2013 in Samsung Medical Center
3071917|NCT02081261||Coronary artery bypass surgery|patients who underwent coronary artery bypass surgery between 2010 and 2012 in Samsung Medical Center
3071918|NCT02081248|Active Comparator|Standard Consent|This arm will receive the Consent Form Specific Format 1 'standard consent'. The standard consents are already approved and used for the BMT CTN 0901, 1101, 1203, and 1301 trials.
3071919|NCT02081248|Experimental|Easy-to-Read Informed Consent|This arm will receive the Consent Form Specific Format 2 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent (ETRIC) is the newly approved consent.
3071920|NCT02081235||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease during 2012 in Samsung Medical Center
3071921|NCT02081222||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease in 2013 at Samsung Medical Center
3071922|NCT02081209|Experimental|Fat Reduction|
3071923|NCT02081196|Experimental|Fat Reduction|
3071924|NCT02081183|Experimental|MMF, Prednisone|"Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 to (-) 1 grams per square meter (g/m^2), intravenously (IV) pulse once per month. Participants also received prednisone, 1 milligram per kilogram per day (mg/kg/day), orally (PO); the dose was reduced by 5 mg/day to a final dose of 10 mg/day.~Maintenance Phase (Months 7 through 12): Participants received mycophenolate mofetil (MMF), 1 g/day, PO, twice daily (BID) for 2 weeks; 1.5 g/day, PO, three times daily (TID) for the next 2 weeks; 2 g/day, PO, BID for the remainder of the Maintenance Phase. Participants also received prednisone, as in the Induction Phase."
3072340|NCT02078453|Active Comparator|Visual inspection|Dental treatment performed according to the caries diagnosis obtained with visual inspection performed alone
3071925|NCT02081183|Active Comparator|Maintenance Cyclophosphamide, Prednisone|"Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 - 1 g/m^2, IV, pulse once per month. Participants also received prednisone, 1 mg/kg/day), PO; the dose was reduced by 5 mg/day to a final dose of 10 mg/day.~Maintenance Phase (Months 7 through 12): Participants received cyclophosphamide, 0.5-1 g/m^2, IV, pulse once every 3 months. Participants also received prednisone, as in the Induction Phase."
3071926|NCT02081170|Experimental|autologous platelet concentrate|
3071927|NCT02081157|Other|Breast Mastopexy &/or reduction using GalaFlex Mesh|
3071928|NCT02081144|No Intervention|Control Condition|Control or Standard Care condition. No intervention will be provided.
3071929|NCT02081144|Experimental|Texting + NRT Condition|Enrollment in NCI's Smokefree TXT Program 4 weeks of Nicotine Replacement Patches 4 weeks of Nicotine Replacement Gum Faxed Referral CT Smokers Quitline
3071930|NCT02081131|Active Comparator|Laparoscopic Surgery|patients will be randomized to laparoscopic pancreatoduodenectomy group
3071931|NCT02081131|Active Comparator|Open Surgery|Patients will be randomized to Open pancreatoduodenectomy
3071932|NCT02081118|Experimental|HM11260C (8 mg)|Monthly administration of 8 mg of HMC11260C by subcutaneous injection for 16 weeks
3071933|NCT02081118|Experimental|HM11260C (12 mg)|Monthly administration of 12 mg of HMC11260C by subcutaneous injection for 16 weeks
3071934|NCT02081118|Experimental|HM11260C (16 mg)|Monthly administration of 16 mg of HMC11260C by subcutaneous injection for 16 weeks
3071935|NCT02081118|Placebo Comparator|Placebo|Monthly administration of placebo by subcutaneous injection for 16 weeks
3071936|NCT02081105|Other|PEEP 5|level of PEEP of 5 cm H2O randomly applied to the patient
3071937|NCT02081105|Other|PEEP 15|level of PEEP of 15 cm H2O randomly applied to the patient
3071938|NCT02081092||Pulmonary Alveolar Proteinosis (PAP)|Patients diagnosis with Pulmonary Alveolar Proteinosis.
3071939|NCT02081079|Experimental|Genotype 4|LDV/SOF for up to 12 weeks in treatment-naive and treatment-experienced participants with genotype 4 hepatitis C virus (HCV) infection
3071940|NCT02081079|Experimental|Genotype 5|LDV/SOF for up to 12 weeks in treatment-naive and treatment-experienced participants with genotype 5 hepatitis C virus (HCV) infection
3071941|NCT02081066|Other|patients with cardiovascular risk factors|
3071942|NCT02081053|Other|RF Ablation and Vertebral Augmentation|
3071943|NCT02081040||Infratentorial dysphagia patients|Infratentorial brain lesion patients with confirmed evidence of dysphagia
3071944|NCT02081040||Supratentorial dysphagia patients|Supratentorial brain lesions\ patients with confirmed evidence of dysphagia
3071945|NCT02081040||Brain lesion patients without dysphagia|Brain lesion patients with no evidence of dysphagia
3071946|NCT02081027|Experimental|Riluzole|The maximum dose of riluzole to be used in this study is 200 mg per day divided BID
3071947|NCT02081027|Placebo Comparator|Placebo|Placebo will be administered in the same manner as the riluzole group, in order to maintain subject assignment throughout the study.
3071948|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 75 ug|G-Pen Mini™ (glucagon injection), two 75 microgram subcutaneous injections given approximately 4-5 hours apart
3071949|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 150 ug|G-Pen Mini™ (glucagon injection), two 150 microgram subcutaneous injections given approximately 4-5 hours apart
3071950|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 300 ug|G-Pen Mini™ (glucagon injection), two 300 microgram subcutaneous injections given approximately 4-5 hours apart
3071951|NCT02081001|Experimental|G-Pump™ (glucagon infusion)|G-Pump™ (glucagon infusion); single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
3071952|NCT02081001|Active Comparator|Novo Nordisk GlucaGen®|Novo Nordisk GlucaGen®; single subcutaneous infusion doses 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
3071953|NCT02080988||Silent aspirators|Stroke patients with dysphagia with severe aspiration
3071954|NCT02080988||Non aspirating, no dysphagia group|Stroke patients with no dysphagia and no evidence of aspiration
3071955|NCT02080975|Experimental|Data Collection During Atrial Flutter Ablation|
3071956|NCT02080962|Experimental|30 Gy in 5 fractions of 6 Gy|tumors ≤ 2 cm in diameter: 5 fractions of 600 cGy, once a day, five times a week - TDF: 89
3071957|NCT02080962|Experimental|40 Gy in 10 fractions of 4 Gy|tumors > 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
3071958|NCT02080949|Experimental|HSRT - 4fx x 5 Gy|It'll be recruited 3 patients to the initial regimen of four fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered that the study was initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with the next dose level.
3071959|NCT02080923|Experimental|Brief Motivational Interview|Health-related counseling that takes place in as little as one hour or up to a few sessions.
3071960|NCT02080923|No Intervention|Standard Care|Participant will receive information about dating abuse in a handout and referrals to a national domestic violence hotline.
3071961|NCT02080910|Experimental|Psychoeducational program|Psychoeducational program consisted of (1) two inpatient sessions of face-to-face education on stroke and its caregiving; (2) six biweekly problem-solving training via telephone contacts after the discharge of stroke survivors
3071962|NCT02080910|No Intervention|Usual care|
3071963|NCT02080897||Palliative Surgery Group|Patients who present to clinic with soft tissue sarcoma with metastatic lung disease who opt to proceed with palliative surgical treatment
3071964|NCT02080897||Non-surgical Group|Patients who present to clinic with soft tissue sarcoma with metastatic lung disease who opt not to pursue palliative surgery
3071965|NCT02080884||CLL patients on Mabthera (rituximab)|
3071966|NCT02080871|Experimental|Gore VIABAHN BX|Balloon expandable stenting of iliac occlusive disease
3071967|NCT02080858|Experimental|Ticagrelor + Apixaban + ASA|180 mg Ticagrelor loading dose + apixaban 2.5 mg bid + 300 mg ASA loading dose (day 1) followed by ticagrelor 90 mg bid + apixaban 2.5 mg + 100 mg ASA od to reach steady state conditions within 4.5 days
3071968|NCT02080858|Active Comparator|Ticagrelor + Apixaban|180mg ticagrelor loading dose + apixaban 2.5 mg bid (day 1) followed by ticagrelor 90 mg bid + apixaban 2.5 mg to reach steady state conditions within 4.5 days
3071969|NCT02080845|Placebo Comparator|no caffeine & no theobromine|Drink 1
3071970|NCT02080845|Experimental|no caffeine & low theobromine|Drink 2
3071971|NCT02080845|Experimental|no caffeine & high theobromine|Drink 3
3071972|NCT02080845|Experimental|high caffeine & no theobromine|Drink 4
3071973|NCT02080832|Experimental|Medication (Citalopram 20mg)|Citalopram (20mg dose)
3071974|NCT02080832|Placebo Comparator|Placebo|
3071975|NCT02080832|Experimental|Medication (Citalopram 40mg)|Citalopram 40mg dose
3071976|NCT02080819|No Intervention|Healthy Control|Non drug using healthy controls
3071977|NCT02080819|Placebo Comparator|Placebo|Placebo BID for 7 weeks
3071978|NCT02080819|Experimental|Medication|Levodopa/carbidopa 400/100 BID for 7 weeks
3071979|NCT02080806|Active Comparator|Mechanical insufflation exsufflation|Application of cough assist machine as part of the regular physiotherapy
3071980|NCT02080793|Other|Patients phase pilote|
3071981|NCT02080793|Other|Patients phase réelle|
3071982|NCT02080780|Experimental|2% Diltiazem & Clarithromycin XL|"3 parts:~- Single Dose, Diltiazem (Day 1)~- Multiple Dose, Clarithromycin XL (Days 4-9)~- Single Dose, Diltiazem (Day 8)"
3071983|NCT02080754|Placebo Comparator|sham arm|sham sellick maneuver
3071984|NCT02080754|Experimental|sellick arm|effective sellick maneuver
3071985|NCT02080741|Other|Type A behaviour profile|
3071986|NCT02080741|Other|Type B behaviour profile|
3071987|NCT02080728|Experimental|TAP-Bloc|
3071988|NCT02080728|Placebo Comparator|Control|
3071989|NCT02080715|Experimental|Tolcapone|Tasmar
3071990|NCT02080702||Monosyn|Construction of a gastrointestinal anastomoses
3071991|NCT02080689|Other|Salvage setting|The clinical utility of Decipher will be evaluated for patients meeting the inclusion criteria in the salvage setting: post-RP with evidence of PSA rise or BCR (defined as PSA detectable and rising on 2 or more subsequent determinations)
3071992|NCT02080689|Other|Adjuvant setting|The clinical utility of Decipher will be evaluated for patients in the adjuvant setting: within 12 months after surgery (in the absence of detectable PSA rise of BCR)
3071993|NCT02080663||Proximal row carpectomy|Proximal row carpectomy
3071994|NCT02080650|Other|Prostate cancer|Mesenchymal-marker based ferrofluid (c-MET)
3071995|NCT02080650|Other|Renal cell carcinoma|Mesenchymal-marker based ferrofluid (c-MET)
3071996|NCT02080650|Other|Bladder cancer|Mesenchymal-marker based ferrofluid (c-MET)
3071997|NCT02080650|Other|Gastric cancer|Mesenchymal-marker based ferrofluid (c-MET)
3071998|NCT02080650|Other|Colorectal cancer|Mesenchymal-marker based ferrofluid (c-MET)
3071999|NCT02080650|Other|Pancreatic cancer|Mesenchymal-marker based ferrofluid (c-MET)
3072000|NCT02080650|Other|Non-small cell lung cancer|Mesenchymal-marker based ferrofluid (c-MET)
3072001|NCT02080650|Other|Advanced MET amplified solid tumor|Mesenchymal-marker based ferrofluid (c-MET)
3072002|NCT02080637|Active Comparator|Ambrisentan|Oral ambrisentan 2.5 - 5 mg, single dose, once daily
3072003|NCT02080637|Placebo Comparator|Placebo|Oral placebo 2.5 - 5 mg, single dose, once daily
3072004|NCT02080624|Experimental|Rapamycin|Topical rapamycin applied once a day
3072005|NCT02080598|No Intervention|Controle|The volunteer do not smoke any cigarette during the study period
3072006|NCT02080598|Experimental|smoking|the volunteer smokes 2 cigarettes in 15 minutes
3072007|NCT02080585|No Intervention|Control group without advice|Control group receives no intervention or physical activity advice.
3072008|NCT02080585|Experimental|Computer-tailored physical activity advice|Subjects receive computer-tailored physical activity advice.
3072009|NCT02080572||Parkinson's Disease with DBS|Individuals with Parkinson's disease and deep brain stimulation will be recruited.
3072010|NCT02080559|Experimental|4CMenB - Test group|Administered at 2, 4 and 12 months of age
3072011|NCT02080559|Active Comparator|4CMenB - control group|Given at 5, 7 and 13 months of age
3072012|NCT02080546|Active Comparator|Cut/Coag|
3072013|NCT02080546|Experimental|V-mode|
3072014|NCT02080533|Experimental|Single|Slow-paced respiration therapy
3072015|NCT02080520|Active Comparator|Nattokinase|Oral nattokinase 2,000 fibrinolytic units daily
3072016|NCT02080520|Placebo Comparator|Placebo|Oral placebo matched nattokinase daily
3072017|NCT02080507|Active Comparator|Active Neuronetics rTMS stimulator|Device: Active Neuronetics Transcranial Magnetic Stimulator. The Neuronetics transcranial magnetic stimulator is an FDA approved device. In the active group, magnetic power output will be delivered to the subject through the coils.
3072018|NCT02080507|Sham Comparator|Inactive Neuronetics rTMS stimulator|Device: Inactive Neuronetics Transcranial Magnetic Stimulator. The Neuronetics transcranial magnetic stimulator is an FDA approved device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
3072019|NCT02080494|No Intervention|Control|No tranexamic acid given
3072020|NCT02080494|Experimental|Tranexamic Acid|15 mg/kg preoperative IV dose followed by another 15 mg/kg IV dose three hours after the initial dose
3072021|NCT02080481|Experimental|Infiniti Plus needle guidance system|ultrasound guidance with the InfinitiPlus (TM) needle guidance system
3072022|NCT02080481|Other|conventional block needle|ultrasound guidance with a conventional block needle
3072023|NCT02080468|Experimental|Lomitapide & EE/Norgestimate - Taken Together|"2 single oral doses of lomitapide (20 mg) (Day 1 & Day 22)~21 single oral doses of EE/Norgestimate(Day 8 through day 28)"
3072024|NCT02080468|Experimental|Lomitapide & EE/Norgestimate - Taken 12 hours apart|"2 single oral doses of lomitapide (20 mg) (Day 1 & Day 22)~21 single oral doses of EE/Norgestimate(Day 9 through day 29)"
3072025|NCT02080455|Experimental|Lomitapide & Atorvastatin - Taken Together|"2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)~11 single oral doses of atorvastatin (80 mg) (Day 11 through day 21)"
3072341|NCT02078453|Experimental|Radiographic examination|Dental treatment performed according to the caries diagnosis obtained with visual inspection and additional radiographic method.
3072026|NCT02080455|Experimental|Lomitapide & Atorvastatin - Approx. 12 hours between|"2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)~11 single oral doses of atorvastatin (80 mg) (Day 12 through day 22)"
3072027|NCT02080442||Chronic Obstructive Pulmonary Disease|
3072028|NCT02080429|Active Comparator|Immediate Pushing|Patient's will begin to push when they are determined to be completely dilated.
3072029|NCT02080429|Experimental|Passive Descent|Patient's will wait 90 minutes prior to begin pushing
3072030|NCT02080416|Experimental|Nelfinavir|Nelfinavir twice daily on days 1-14 of a 14-day cycle for 4 cycles
3072031|NCT02080403|Experimental|Treatment|Treatment, 2.5 mg Chlorhexidine Gluconate chip (PerioChip®) inserted every two weeks starting at Baseline for the first 3 months, plus mechanical Subgingival Debridement at Baseline and 3 months.
3072032|NCT02080403|No Intervention|Control|Mechanical Subgingival Debridement at Baseline and 3 months.
3072033|NCT02080390||Transthoracic echocardiogram (ultrasound)|Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
3072034|NCT02080377|Active Comparator|Current Standard Care|Insulin + Metformin
3072035|NCT02080377|Active Comparator|Treatment|Glibenclamide + Metformin
3072036|NCT02080364|Experimental|Azeliragon 5mg|Azeliragon (TTP488) 5mg orally once daily for 18 months
3072037|NCT02080364|Placebo Comparator|Placebo|Placebo orally once daily for 18 months
3072038|NCT02080351|Experimental|Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
3072039|NCT02080351|No Intervention|Usual care|Usual care in the emergency department
3072040|NCT02080338|Experimental|0.018 bracket slot system|Participants treated using 0.018-inch orthodontic bracket slot system
3072041|NCT02080338|Active Comparator|0.022 bracket slot system|Participants treated using 0.022-inch orthodontic bracket slot system
3072042|NCT02080325|Other|High Protein-Weight loss-Meat/High Protein-Weight loss Soy|After 3 Days - Normal Protein Maintenance diet (NP- MTD, 3 days), there is the first arm of the study, Days 14 days- randomised to High Protein-Weight loss-Meat with High Protein-Weight loss-Soy
3072043|NCT02080325|Other|High Protein-Weight loss-Soya/High Protein Weight loss-meat|After 3 Days - Normal Protein Maintenance diet (NP- MTD, 3 days), there is the first arm of the study, Days 14 days- randomised to High Protein-Weight loss-Soy with High Protein-Weight loss-Meat
3072044|NCT02080312|Experimental|intratympanic injection|Magnevist (gadopentetate dimeglumine, Bayer Health Care) will be diluted eightfold with sterile saline (1:7 v/v) in a 1 ml syringe and injected intra-tympanically with a 23-25g needle up to 0.4 ml or less if contrast reflux is noted under direct visualization. Anesthesia with topical phenol is available for this procedure.
3072045|NCT02080299|Active Comparator|Remote ischemic preconditioning (RIPC)|RIPC-protocol before TAVI: after induction of conscious sedation/anesthesia, but prior to TAVI procedure, remote ischemic preconditioning (RIPC) protocol is performed, consisting of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion, followed by a time interval between the end of the last deflation and local groin anaesthesia with subsequent skin puncture of 30 min.
3072046|NCT02080299|Placebo Comparator|Placebo|Placebo protocol before TAVI: After induction of conscious sedation/anesthesia and before TAVI, the cuff is left uninflated for 30 min, followed by a further time interval of 30 min until local groin anaesthesia with subsequent skin puncture.
3072047|NCT02080286|Active Comparator|Prism adaptation + anodal tDCS|"Participants will receive 1 milliamp (mA) anodal tDCS over the left primary motor cortex concurrent with a 20-minute session of prism adaptation.~They will undergo 5 consecutive daily sessions."
3072048|NCT02080286|Placebo Comparator|Prism Adaptation + Sham tDCS|"Participants will receive Sham tDCS over the left primary motor cortex concurrent with a 20-minute session of prism adaptation.~They will undergo 5 consecutive daily sessions."
3072049|NCT02080286|Placebo Comparator|Prism adaptation + no tDCS|"Participants will receive no tDCS at all but will undergo a 20-minute session of prism adaptation.~They will undergo 5 consecutive daily sessions."
3072050|NCT02080273|Placebo Comparator|Colgate Cavity Protection toothpaste|currently marketed toothpaste in Poland
3072051|NCT02080273|Active Comparator|Colgate Total toothpate|Currently marketed toothpaste in Poland
3072052|NCT02080273|Active Comparator|Parodontax|currently marketed toothpaste Germany
3072053|NCT02080260|Experimental|Single Arm|Oral Regorafenib
3072054|NCT02080247|Active Comparator|Intervention: Skin care regimen with Calmoseptine ointment|In this arm the patients with IAD will receive treatment with Calmoseptine Ointment for 6 days as a part of a structured skin regimen
3072055|NCT02080247|Active Comparator|Control: Skin care regimen with Destin ointment|In this arm , patient will receive treatment with Destin Maximum Strength 40% Zinc Oxide. Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
3072056|NCT02080234|Experimental|concurrent chemoradiotherapy with GELOX|"GELOX:~gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days~IFRT~IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.~the first cycle of chemotherapy was initiated on the same day of radiotherapy."
3072057|NCT02080221|Experimental|FOLFOXA|"1 cycle = 14 days Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
3072058|NCT02080208|Experimental|High Flow Oxygen|Patients receiving oxygen via high flow oxygen therapy (Optiflow)
3072059|NCT02080208|No Intervention|Conventionnal|patients receiving oxygen via conventional way (low flow)
3072060|NCT02080195|Experimental|Nonmyeloablative Conditioning and BMT|Nonmyeloablative Conditioning and Bone Marrow Transplant in Systemic Lupus Erythematosus patients
3072061|NCT02080182|Active Comparator|Acetylcysteine|Effervescent tablet of acetylcysteine 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily less than 8.5 kg: 70 mg/kg
3072342|NCT02078440|Other|Bromocriptine mesylate (Cycloset)|Bromocriptine mesylate (Cycloset)
3072062|NCT02080182|Placebo Comparator|Placebo|Placebo effervescent tablet of acetylcysteine 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily: more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily less than 8.5 kg: 70 mg/kg
3072063|NCT02080169|Experimental|midazolam|Initiative dosage of midazolam is 0.05 mg/kg given intravenously, the maintenance dosage is 0.01-0.05 mg/kg/h, drug dosage is adjusted by target sedation level.
3072064|NCT02080169|Experimental|Dexmedetomidine|The loading dose of dexmedetomidine is 0.5-0.8 μg/kg given intravenously more than 10 min, the maintenance dosage is 0.2-0.7 μg/kg/h,the drug dosage is adjusted by target sedation level.
3072065|NCT02080169|Experimental|midazolam & dexmedetomidine|"Initiative dosage of midazolam is 0.05 mg/kg given intravenously, The loading dose of dexmedetomidine is 0.5-0.8 μg/kg given intravenously more than 10 min(given or not according to patients' condition),.~The maintenance dosage of midazolam is 0.01-0.05 mg/kg/h, the maintenance dosage of dexmedetomidine is 0.2-0.7 μg/kg/h,the drug dosage is adjusted by target sedation level."
3072066|NCT02080156|No Intervention|no-CPAP|CPAP vs. no-CPAP in patients undergoing Coronary Revascularization follow-up for 3 years
3072067|NCT02080156|Experimental|CPAP|CPAP vs. no-CPAP in patients undergoing Coronary Revascularization follow-up for 3 years
3072068|NCT02080143|Experimental|Air Activated Heat Patch|The experimental air activated heat patch will be worn by the subjects for 8 hours.
3072069|NCT02080143|Active Comparator|Marketed ThermaCare Air Activated Heat Patch|The marketed air activated heat patch will be worn by the subjects for 8 hours.
3072070|NCT02080130|Experimental|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
3072071|NCT02080130|Experimental|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
3072072|NCT02080130|Placebo Comparator|Placebo|Placebo sachet. One sachet orally, BID, for 5 days.
3072073|NCT02080117||patients who underwent kidney transplantation|patients who underwent living or deceased donor kidney transplantation between 2008 and 2013
3072074|NCT02080104|Active Comparator|intravenous 10 ıu oxytocin|group which 2 ampul prophylactic oxytocin given for third stage of labour intravenously after vaginal delivery
3072075|NCT02080104|Experimental|intramusculer 10 ıu oxytocin|group which oxytocin administered intramusculary after vaginal delivery
3072076|NCT02080091||Chronic DME|Patients with vision impairment associated with chronic diabetic macular edema (DME)
3072077|NCT02080078|Experimental|Increasing dose of Theophylline|Patients will be put on the standard dose of 150 mg/day of erlotinib. Patients will be entered into the study on different dose levels of theophylline (100 mg/bid, 150 mg/bid, 200 mg/bid, or 200 mg/tid) for 28 days to find what is the lowest dose that effectively controls the diarrhea caused by erlotinib.
3072078|NCT02080078|Experimental|Increasing dose of erlotinib|Patients will be kept on a specified dose of theophylline while the dose of erlotinib increases in each group of patients enrolled (200 mg/qd, 225 mg/qd, or 250 mg/qd) for 28 days to determine what the maximum dose of erlotinib that can be given with theophylline and maintain a safety profile.
3072079|NCT02080065||liver transplantation|patients who underwent living donor liver transplantation during between 2007 and 2013
3072080|NCT02080052|Experimental|Robot-assisted prostate biopsy|
3072081|NCT02080039|Experimental|Electrical Stimulation|
3072082|NCT02080026|Experimental|CPS-immunization|"In this group a total of four CPS-immunizations will be performed, with bites from 15 Plasmodium infected mosquitoes per immunization, over a period of four months, during which volunteers will take chloroquine prophylaxis.~14 weeks after the last immunization, these volunteers will undergo Controlled Human Malaria Infection (CHMI) by exposure to bites from 5 Plasmodium falciparum sporozoite infected mosquitoes.~If a subject develops a malaria infection he/she will be treated with atovaquone/proguanil (Malarone). At the end of the study any subjects that did not develop a malaria infection will also be treated with atovaquone/proguanil (Malarone)."
3072083|NCT02080026|Other|Control|"This group will take chloroquine prophylaxis during the same period as the immunization group, but will not receive CPS-immunizations.~10 weeks after stopping chloroquine prophylaxis, these volunteers will undergo Controlled Human Malaria Infection (CHMI) by exposure to bites from 5 Plasmodium falciparum sporozoite infected mosquitoes.~If a subject develops a malaria infection he/she will be treated with atovaquone/proguanil (Malarone). At the end of the study any subjects that did not develop a malaria infection will also be treated with atovaquone/proguanil (Malarone)."
3072084|NCT02080013|Sham Comparator|ClosureFast group|Radiofrequency Ablation for the Treatment of Great Saphenous Vein Reflux
3072085|NCT02080013|Sham Comparator|group 1|EVL group Endovenous Laser Ablation for the Treatment of Great Saphenous Vein Reflux
3072086|NCT02080000|Experimental|Optimised V-V timing delay|V-V timing delay setting on biventricular pacemaker will be optimised guided by size of R-wave on surface ECG
3072087|NCT02080000|Active Comparator|Standard V-V timing delay|Standard settings
3072088|NCT02079987|Experimental|ED to home care transition|The ED to home care transition intervention is a 4-week program that uses a Area Agency on Aging coach to conduct a home visit and three follow up phone calls to help patients develop the skills needed for self-management and to communicate with healthcare providers.
3072089|NCT02079987|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
3072090|NCT02079974|Experimental|Pravastatin|Pravastatin sodium 20mg PO daily
3072091|NCT02079961|Experimental|Micronutrient-fortified yoghurt|"Micronutrient-fortified yoghurt + BCC~All eligible children within the intervention arm will receive one fortified yoghurt per day, every day of the week, if the household satisfied to the contract of reliability in milk supply during the previous week, during the one year duration of the intervention."
3072092|NCT02079961|Active Comparator|Control|"BCC~Children will not receive fortified yoghurt during the duration of the intervention"
3072128|NCT02079779|Active Comparator|Classical therapy|All patients will receive a similar classical rehabilitation as a basis. The 30 patients of this group will receive a supplement of classical rehabilitation.
3072093|NCT02079948|Active Comparator|Methotrexate + Folic Acid|Participants in the methotrexate condition will consume a dose of 15 mg/week of methotrexate during months 2 - 6. Participants will also consume 1 mg of folic acid/day for six days per week.
3072094|NCT02079948|Placebo Comparator|Placebo + Folic Acid|Participants in the placebo condition will consume microcrystalline cellulose once per week. The number of capsules consumed on this day will match the number of capsules consumed by participants in the methotrexate condition. There are no active ingredients in the placebo capsules.
3072095|NCT02079948|Experimental|Functional MRI Experimental Tasks|15 participants will be randomly assigned to complete the fMRI visits at the baseline and 6 month.
3072096|NCT02079948|Experimental|Muscle Biopsy|10 participants will be randomly assigned to complete the skeletal muscle tissue sample at the baseline and 6 month visits.
3072097|NCT02079935|Experimental|Cognitive Behaviour Therapy|Treatment with small groups following a modified protocol first described by Fairburn 2008
3072098|NCT02079935|Experimental|Physical activity and dietary therapy|Treatment with guided physical activity and dietary therapy in small groups
3072099|NCT02079922|Experimental|Cohort 1|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3072100|NCT02079922|Experimental|Cohort 2|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3072101|NCT02079922|Experimental|Cohort 3|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3072102|NCT02079922|Experimental|Cohort 4|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3072103|NCT02079922|Experimental|Cohort 5|Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3072104|NCT02079922|Experimental|Cohort 6|Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3072105|NCT02079909|Experimental|T-817MA-H|224 mg T-817MA once daily for first 4 weeks and 448 mg T-817MA once daily for the following weeks.
3072106|NCT02079909|Experimental|T-817MA-L|224 mg T-817MA once daily
3072107|NCT02079909|Placebo Comparator|Placebo|Placebo once daily
3072108|NCT02079896|Experimental|Single dose cross-over pilot|Single dose of lexaptepid pegol (NOX-H94) cross-over with single dose of placebo
3072109|NCT02079896|Placebo Comparator|Control|Twice weekly doses of placebo, 9 total
3072110|NCT02079896|Experimental|Lexaptepid pegol (NOX-H94)|Twice weekly doses of lexaptepid pegol (NOX-H94), 9 total
3072111|NCT02079883||ocriplasmin|
3072112|NCT02079870|Experimental|Sema|Two 12-week treatment periods separated by a wash-out period of 5-7 weeks. Finally, a follow-up visit is performed 5-7 weeks after last dosing
3072113|NCT02079870|Placebo Comparator|Placebo|
3072114|NCT02079857|Experimental|Standard|Fixed protocol
3072115|NCT02079857|Experimental|Individualized|Individualized protocol
3072116|NCT02079857|Sham Comparator|Control|Sham acupuncture/Placebo moxa
3072117|NCT02079844|Experimental|Placebo + Roflumilast 100 μg + Roflumilast 250 μg|Roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
3072118|NCT02079844|Experimental|Roflumilast 100 μg + Roflumilast 250 μg + Placebo|Roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
3072119|NCT02079844|Experimental|Roflumilast 250 μg + Placebo + Roflumilast 100 μg|Roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
3072120|NCT02079831|Experimental|Higher protein and energy restriction|Participants in this arm will consume 30% of energy as protein with 25% energy restriction.
3072121|NCT02079831|Experimental|Lower protein and energy restriction|Participants in this arm will consume 15% of energy as protein with 25% energy restriction.
3072122|NCT02079818|Experimental|Penumbra Ruby Coil System|
3072123|NCT02079805|Experimental|Azilsartan 20 mg|Participants will receive azilsartan 20 mg once daily in the morning before or after breakfast.
3072124|NCT02079805|Active Comparator|Telmisartan 40 mg|Participants will receive telmisartan 40 mg once daily in the morning before or after breakfast.
3072125|NCT02079792|Active Comparator|Lying Head Back Position|Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort. Subjects will be instructed to administer budesonide 1mg/2cc nebules daily for 12 weeks using the MAD syringe, in the head position to which they were randomized.
3072126|NCT02079792|Experimental|Head Down and Forward Position|Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards. Subjects will be instructed to administer budesonide 1mg/2cc nebules daily for 12 weeks using the MAD syringe, in the head position to which they were randomized.
3072127|NCT02079779|Experimental|Robotic-assisted therapy|All patients will receive a similar classical rehabilitation as a basis. The 30 patients of this group will receive a supplement of robotic-assisted therapy.
3072343|NCT02078414||Ulipristal acetate|Women choosing EllaOne as emergency contraception
3072129|NCT02079766|Experimental|High Risk of CTE|Subjects at high risk of developing CTE (former National Football League players) will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of florbetapir F 18 and a single IV injection, 370 MBq (10 mCi) of 18F-AV-1451.
3072130|NCT02079766|Experimental|Control|Control subjects (former non-contact athletes) will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of florbetapir F 18 and a single IV injection, 370 MBq (10 mCi) of 18F-AV-1451.
3072131|NCT02079753|Active Comparator|combined system|During the first visit, the technician installed a reservoir of liquid oxygen (Liberator 30, Caire) and a liquid Stroller oxygen pack (Caire) for patients using liquid oxygen, or a VisionAire5 (Airsep) stationary concentrator and an Inogen One G2 portable (Inogen) concentrator for patients using concentrators.
3072132|NCT02079753|Experimental|single system|Inogen One G2 portable concentrator (Inogen)
3072133|NCT02079740|Experimental|Treatment (trametinib, navitoclax)|Patients receive trametinib PO QD and navitoclax PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. If unacceptable toxicity is observed, patients may receive trametinib PO QD on days 1-14.
3072134|NCT02079727|Experimental|Condrosulf (Chondroitin 4&6 sulfate)|1 tablet of Condrosulf 800 mg and 1 capsule of placebo of Celebrex once a day for 182 days
3072135|NCT02079727|Placebo Comparator|Placebo (PBO) 800 mg tablet and Placebo (PBO) 200 mg capsule|1 tablet of PBO of Condrosulf and 1 capsule of PBO of Celebrex, once a day for 182 days
3072136|NCT02079727|Active Comparator|Celebrex 200 mg capsule|1 capsule of 200 mg of Celebrex and 1 tablet of 800 mg placebo of Condrosulf once a day for 182 days
3072137|NCT02079714||Questionnaire|All STREAM Study participants will be complete a series of computer adaptive testing (CAT) questions covering all core and exploratory domains, once written informed consent is obtained. Administration of these surveys will follow completion of all other follow-up activities related to the main METRC study in which they were originally enrolled. Identical surveys will be repeated at the 6 month study visit. At the final 12 month study visit, participants will complete the CAT survey for the six core domains, and will also complete a randomly assigned subset of items from the total item bank across these six core domains. At any visit, if the CAT cannot be administered, respondents will instead complete paper surveys of the short form for each domain.
3072138|NCT02079701|Experimental|23-valent pneumococcal vaccine|single dose, 23-valent pneumococcal vaccine, 0.5ml, intramuscular (IM)
3072139|NCT02079701|Placebo Comparator|placebo|0.5 ml injectible saline, IM
3072140|NCT02079688|Experimental|SB011, 2 % (Water/Oil/Water) emulsion of hgd40|"All patients will perform treatment with formulation SB011 containing 2 % hgd40 and the active ingredient-free vehicle. The comparison of the IMPs will be performed intraindividually.~Comparison and random assignment of treatments to two distinct treatment areas (area 1, area 2).~IMP SB011: Topical application of approximately 5 mg/cm2 (250 μl) per treatment area (50 cm2) twice daily on 14 consecutive days, one single last application at the site on Day 15 (29 treatments) daily dosage: Approximately 10 mg hgd40 total dosage: Approximately 145 mg hgd40"
3072141|NCT02079688|Placebo Comparator|Multiple W/O/W formulation, active ingredient-free vehicle|"All patients will perform treatment with formulation SB011 containing 2 % hgd40 and the active ingredient-free vehicle. The comparison of the IMPs will be performed intraindividually.~Comparison and random assignment of treatments to two distinct treatment areas (Area 1, Area 2).~Vehicle: Topical application of approximately 5 mg/cm2 (250 μl) per treatment area (50 cm2) twice daily on 14 consecutive days, one single last application at the site on Day 15 (29 treatments)"
3072142|NCT02079675|Experimental|SKI3246 Low Dose|Intervention: Drug: SKI3246 Low Dose
3072143|NCT02079675|Experimental|SKI3246 High Dose|Intervention: Drug: SKI3246 High Dose
3072144|NCT02079675|Placebo Comparator|Placebo|Intervention: Drug: Placebo
3072145|NCT02079662|Experimental|Integrative Oncology Group (IO)|Baseline measures collected prior to start of radiotherapy. Assessment includes battery of questionnaires. Saliva samples collected 4 times a day for 3 days in a row at baseline and in follow up. At baseline and follow ups, blood drawn to measure hormones and immune system responses. Accelerometer worn for 5 days. Within 2 weeks of consent date, participant contacted by telephone on 3 random days for a dietary recall. Participants have up to 7 different intervention sessions per week during course of radiotherapy for between 1 and 2 hours each session, up to 6 aerobic training sessions per week and one grocery store trip. Participants have a weekly meeting on the computer for 6 months, followed by a monthly meeting on computer from 6-12 months, and 2 hour meetings at all follow-up appointments during first year after radiotherapy. Follow-up assessments will take place during the last week of radiotherapy (+/- 2 weeks), and 2-4, 5-7, 11-13, 17-19, 23-25, 35-37, 47-49, and 59-61 months.
3072146|NCT02079662|Active Comparator|Standard of Care (SC)|Baseline measures from participants collected prior to the start of radiotherapy. Assessment includes 60 to 90 minute-long battery of questionnaires. Saliva samples collected 4 times a day for 3 days in a row at baseline and in follow up. Within 2 weeks of consent date, participant contacted by telephone on 3 random days for a dietary recall. Follow-up assessments take place during the last week of radiotherapy (+/- 2 weeks), and 2-4, 5-7, 11-13, 17-19, 23-25, 35-37, 47-49, and 59-61 months. At baseline and follow ups, blood drawn to measure hormones and immune system responses.
3072147|NCT02079649|Experimental|AL-53817|AL-53817 Ophthalmic Solution, 0.1%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
3072148|NCT02079649|Experimental|AL-78843|AL-78843 Ophthalmic Solution, 0.03%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
3072149|NCT02079649|Active Comparator|Maxidex|Dexamethasone Ophthalmic Suspension, 0.1%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
3072150|NCT02079649|Placebo Comparator|Vehicle|AL-53817 Vehicle, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
3072151|NCT02079636|Experimental|Abemaciclib + Pemetrexed|Abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 500 milligrams/square meter (mg/m^2) pemetrexed given intravenously (IV) over approximately 10 minutes on Day 1 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3072344|NCT02078414||Copper IUD|Women choosing copper IUD as emergency contraception
3072345|NCT02078401||Neurofibromatosis type 1 children|
3096893|NCT01913093||Case|Leukemia survivors with TRANCE trait
3072152|NCT02079636|Experimental|Abemaciclib + Gemcitabine|Abemacicilib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 1250 milligram/square meter (mg/m^2) gemcitabine given intravenously over approximately 30 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3072153|NCT02079636|Experimental|Abemaciclib + Ramucirumab|Abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Day 1 or 8 to 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3072154|NCT02079636|Experimental|Abemaciclib + LY3023414|Abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 100, 150, or 200mg LY3023414 given orally every 12 hours on Days 1 through 21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3072155|NCT02079636|Experimental|Abemaciclib + Pembrolizumab|Abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 200 mg pembrolizumab given intravenously over approximately 30 minutes on day 1 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3072156|NCT02079623|Other|Pancreatic cancer|Patients with locally advanced pancreatic cancer.
3072157|NCT02079610|Experimental|real-time fMRI neurofeedback: Amygdala|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
3072158|NCT02079610|Active Comparator|real-time fMRI neurofeedback: HIPS|HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
3072159|NCT02079597||Healthy|Healthy individuals no infection
3072160|NCT02079597||SIRS|SIRS patients no included in an interventional study no peroperative infection
3072161|NCT02079584||Warfarin|A study group taken from existing anticoagulant clinics treated with warfarin.
3072162|NCT02079584||Rivaroxaban|A group seen in the rivaroxaban clinic under study.
3072163|NCT02079571|Experimental|water+ Coconut water|forty subjects
3072164|NCT02079571|Experimental|ginger tea +water|
3072165|NCT02079558|Experimental|Oxytocin|A single 100 microgram IV dose of carbetocin after operation
3072166|NCT02079558|Experimental|Carbetocin|A standard 30 international units (IU) IV infusion of oxytocin during two hours
3072167|NCT02079545|Experimental|Group 1|18 participants will receive a single intravenous (IV) infusion of 100 mg sirukumab
3072168|NCT02079545|Experimental|Group 2|18 participants will receive a single subcutaneous (SC) injection of 50 mg sirukumab using a Pre-filled Syringe (PFS) fitted with the UltraSafe Passive™ Delivery System (PFS-U)
3072169|NCT02079545|Experimental|Group 3|18 participants will receive a single SC injection of 50 mg sirukumab using the SmartJect™ Autoinjector (PFS-AI)
3072170|NCT02079545|Experimental|Group 4|42 participants will receive a single SC injection of 100 mg sirukumab using a PFS-U
3072171|NCT02079545|Experimental|Group 5|42 participants will receive a single SC injection of 100 mg sirukumab using a PFS-AI
3072172|NCT02079532|Experimental|MabThera (Rituximab)|
3072173|NCT02079519|Experimental|Bevacizumab 5 mg/kg|Participants received bevacizumab 5 mg/kg intravenously every 2 weeks for 6 months until disease progression or termination of the study. Participants showing a continuous benefit of therapy could receive treatment for a maximum of 12 months.
3072174|NCT02079506|Experimental|Treatment A|
3072175|NCT02079506|Experimental|Treatment B|
3072176|NCT02079493||Total Knee Arthroplasty patients|
3072177|NCT02079480|Experimental|Panel 1: BMS-986090 (0.5 mg) or Placebo|"BMS-986090 0.5 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
3072178|NCT02079480|Experimental|Panel 2: BMS-986090 (3 mg) or Placebo|"BMS-986090 3 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
3072179|NCT02079480|Experimental|Panel 3: BMS-986090 (10 mg) or Placebo|"BMS-986090 10 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
3072180|NCT02079480|Experimental|Panel 4: BMS-986090 (30 mg) or Placebo + KLH (1 mg)|"BMS-986090 30 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once~And Keyhole limpet hemocyanin (KLH) 1 mg solution single intramuscular dose once"
3072181|NCT02079480|Experimental|Panel 5: BMS-986090 (100 mg) or Placebo + KLH (1 mg)|"BMS-986090 100 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once~And KLH 1 mg solution single intramuscular dose once"
3072182|NCT02079480|Experimental|Panel 6: BMS-986090 (100 mg) or Placebo|"BMS-986090 100 mg solution single dose intravenously once~OR~Placebo matching with BMS-986090 0 mg solution single dose intravenously once"
3072183|NCT02079480|Experimental|Panel 7: BMS-986090 (300 mg) or Placebo + KLH (1 mg)|"BMS-986090 300 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once~And KLH 1 mg solution single intramuscular dose once"
3072184|NCT02079480|Experimental|Panel 8: BMS-986090 (750 mg) or Placebo|"BMS-986090 750 mg solution single dose intravenously once~OR~Placebo matching with BMS-986090 0 mg solution single dose intravenously once"
3072185|NCT02079480|Experimental|Panel 9: BMS-986090 (150 mg) or Placebo|"BMS-986090 150 mg solution subcutaneously once weekly for 4 weeks~OR~Placebo matching with BMS-986090 0 mg solution subcutaneously once weekly for 4 weeks"
3072215|NCT02079246|Experimental|Idalopirdine (Lu AE58054) 60 mg|Idalopirdine 60 mg adjunct to 10 mg donepezil. The dose of idalopirdine could be decreased from 60 mg to 30 mg if 60 mg was not well tolerated. The dose of donepezil was to be maintained throughout the study.
3072413|NCT02077998|Experimental|Diagnostic (carbon C 14 oxaliplatin and oxaliplatin)|"PHASE 0: Patients receive carbon C 14 oxaliplatin IV over 2 minutes on day 1.~PHASE II: Patients receive oxaliplatin IV over 2 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity."
3072186|NCT02079467|Active Comparator|Standard rehabilitation|"Patients randomized to the control group will be managed with hip precautions immediately following surgery. They will weight bear on the operative joint as tolerated after surgery. They will be managed as per usual protocol post total hip arthroplasty. They will be transferred from the operative table with an abduction pillow between their legs and will be asked to keep this pillow between their legs while resting in bed and during sleep throughout their course in hospital. During physiotherapy treatments they will not flex the operative hip beyond 90 degrees, internally or externally rotate the operative hip more than 45 degrees, or actively adduct the operative hip past neutral."
3072187|NCT02079467|Experimental|Unrestricted rehabilitation|Patients randomized to the treatment group will have no restrictions in their post-operative rehabilitation. They will weight bear on the operative joint as tolerated after surgery. They will be asked to participate in activity as their level of comfort permits and will have no positional restrictions while in bed or completing activities of daily living.
3072188|NCT02079441||Infants, IBD mothers, anti TNF, pregnancy|Infants born to mother with IBD receiving ant- TNF medications during pregnancy
3072189|NCT02079441||infants, IBD mothers, pregnancy, medications|Infants born to mothers with IBD receiving non anti TNF medications during pregnancy
3072190|NCT02079428||Systolic heart failure, Diastolic heart failure|
3072191|NCT02079402|Active Comparator|Liberal (target-guided) fluid resuscitation|"Noradrenaline to MAP >= 65 mmHg.~Fluid boluses may be given as long as hemodynamic variables improve (dynamic or static variable(s) of choice). A fluid bolus is to be followed by evaluation of effect 30 minutes after the intervention at the latest.~'Variable(s) of choice' refers to the variable(s) used to assess hemodynamic improvement.~Only isotonic crystalloids are to be given as resuscitation fluid; the type of isotonic crystalloid is free of choice."
3072192|NCT02079402|Experimental|Conservative (trigger-guided) fluid resuscitation|"Noradrenaline to MAP >= 65 mmHg.~A fluid bolus of 250-500 ml may be given followed by evaluation of effect 30 minutes after the intervention at the latest if one of the following occurs:~Plasma lactate concentration ≥ 4 mmol/l at point-of-care testing.~Severe hypotension (MAP < 50mmHg).~Mottling beyond edge of kneecap.~Severe oliguria (only in the first 2 hours after randomisation). Severe oliguria defined as urine output ≤ 0.1 ml/kg/hour IBW last hour.~Only isotonic crystalloids are to be given as resuscitation fluid; the type of isotonic crystalloid is free of choice."
3072193|NCT02079389|Active Comparator|Lap+Lus|"The included patients randomly assigned either to the department's standard laparoscopic (Lap) surgery or standard laparoscopic surgery (lap) plus a LUS examination.~In the intervention arm the intra-abdominal conditions are also assessed by laparoscopy, but then supplemented with a LUS examination of the primary tumor, liver and retroperitoneum.~All the included patients are getting a CT scan of the abdomen after 3 months."
3072194|NCT02079389|No Intervention|laparoscopic examination (Lap)|"The included patients randomly assigned either to the department's standard laparoscopic (Lap) surgery or standard laparoscopic surgery (lap) plus a LUS examination.~In the standard arm (Lap) the conditions at the abdomen is only assessed by laparoscopy immediately prior to the resection.~All the included patients are getting a CT scan of the abdomen after 3 months."
3072195|NCT02079376|Experimental|Low blood TG patients|subjects with baseline blood triglyceride level ≤ 1.7 mmol/l will have intervention device (DIAMOND Implantable Pulse Generator (IPG)) programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period.
3072196|NCT02079376|Experimental|High blood TG patients treated with blood TG lowering therapy|subjects with baseline blood triglyceride level > 1.7 mmol/l will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period and will receive fenofibrate at the dose of 160mg per day
3072197|NCT02079376|Placebo Comparator|High blood TG patients|subjects with baseline blood triglyceride level > 1.7 mmol/l will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period and will receive placebo of fenofibrate administered in the same schedule as the drug.
3072198|NCT02079363||Patients with pancreatic adenocarcinoma|"Exclusion criteria:~No prior cancer. No anticoagulant treatment."
3072199|NCT02079363||Patients with chronic pancreatitis|"Exclusion criteria:~No prior cancer. No anticoagulant treatment."
3072200|NCT02079363||Patients with acute pancreatitis|"Exclusion criteria:~No prior cancer."
3072201|NCT02079363||Patients screened for but not having upper GI cancer|"Exclusion criteria:~No prior cancer."
3072202|NCT02079350||%4 Gelofusine|patients administered %4 Gelofusine during liver transplantation
3072203|NCT02079350||%6 HES|patients administered %6 HES during liver transplantation
3072204|NCT02079337|Active Comparator|Deep NMB|Videorecordings and subjective ratings of intraabdominal surgical conditions during deep neuromuscular blockade and without neuromuscular blockade
3072205|NCT02079337|Placebo Comparator|No NMB|Videorecordings and subjective ratings of intraabdominal surgical conditions during no neuromuscular blockade and during deep neuromuscular blockade.
3072206|NCT02079324|Experimental|GX-051|GX-051 intratumoral injection
3072207|NCT02079311|Experimental|Active self-warming blanket|Active warming with BARRIER® EasyWarm active self-warming blanket during the perioperative phase
3072208|NCT02079311|Active Comparator|Forced air warming device|Active warming with forced air warming (FAW) during the intraoperative phase.
3072209|NCT02079298|Active Comparator|1|Premature newborn infants with Gestational Age 23+0 to 26+6 weeks who are treated only with fluconazole.
3072210|NCT02079298|Active Comparator|2|Premature newborn infants with Gestational Age 23+0 to 26+6 weeks who are treated with both fluconazole and Ibuprofen.
3072211|NCT02079298|Active Comparator|3|Premature newborn infants with Gestational Age 27+0 to 36+6 who are treated only with ibuprofen.
3072212|NCT02079298|Placebo Comparator|4|Premature newborn infants with Gestational Age 27+0 to 36+6 and fullterm infants who are not treated either with fluconazole or ibuprofen.
3072213|NCT02079285||EUS-FNA|Any patients who will undergo EUS-FNA for pancreas lesion during the study period
3072214|NCT02079272|Other|Helical tomotherapy for breast cancer|"All women included in REBECCA cohort will be treated with helical tomotherapy for theur breast cancer.~Their cardiac follow-up will be based on echocardiography, CT coronary angiogram and blood samples"
3072251|NCT02079012|No Intervention|Control group|Only receives measurements.
3072536|NCT02077166|Experimental|Phase 2|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
3072216|NCT02079246|Experimental|Idalopirdine 60 mg + memantine|Idalopirdine 60 mg as adjunct to 10 mg donepezil and memantine (patient's individualised maintenance dose, either immediate-release (IR) 20 mg/day (recommended target dose) or extended release (XR) 28 mg/day (recommended target dose). Memantine was administered to approximately 100 patients included in the OLEX-MEM. The dose of idalopirdine could be decreased from 60 mg to 30 mg if 60 mg was not well tolerated. The dose of donepezil was to be maintained throughout the study. The dose of memantine could be changed at any time throughout the study.
3072217|NCT02079233|Experimental|CLP 15 g QD|Cross-Linked Polyelectrolyte (CLP) study medication delivered immediately before bedtime
3072218|NCT02079233|Experimental|CLP 7.5 g BID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered b.i.d. one hour before breakfast and dinner
3072219|NCT02079233|Experimental|CLP 5 g TID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered t.i.d. one hour before breakfast, lunch and dinner
3072220|NCT02079233|Experimental|CLP 3.75 g QID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d on hour before breakfast, lunch, dinner and immediately before bedtime
3072221|NCT02079220|Experimental|Arm A|"Arm A (every 2 week schedule) Dosage and dosage regimen for all study periods~Capecitabine: will be administered 1,000 mg/m2 orally twice a day on Days 1 - 7 of each cycle, repeating every 14 days.~Oxaliplatin: will be administered 85 mg/m2 IV on Day 1 of each cycle, repeating every 14 days.~Ziv-aflibercept: will be administered 4 mg/kg IV on Day 1 of each cycle, repeating every 14 days."
3072222|NCT02079220|Experimental|Arm B|"Arm B (every 3 week schedule):~Dosage and dosage regimen for all study periods~Capecitabine: will be administered 850 mg/m2 orally twice a day on Days 1 - 14 of each cycle, repeating every 21 days.~Oxaliplatin: will be administered 130 mg/m2 IV on Day 1 of each cycle, repeating every 21 days.~Ziv-aflibercept: will be administered 6 mg/kg IV on Day 1 of each cycle, repeating every 21 days."
3072223|NCT02079207|Experimental|NBP606|Participants aged over 50 years are given a 0.5mL dose of 13-valent peumococcal conjugate vaccine administered on day 0.
3072224|NCT02079207|Active Comparator|Prodiax-23|Participants aged over 50 years are given a 0.5mL dose of 23-valent pneumococcal polysaccharide vaccine administered on day 0.
3072225|NCT02079194|Experimental|P2Y12 antagonist monotherapy|P2Y12 antagonist monotherapy after 3-month DAPT
3072226|NCT02079194|Experimental|Aspirin + P2Y12 antagonist|Aspirin + P2Y12 antagonist after 3-month DAPT
3072227|NCT02079181|Experimental|Diagnostic (fluorine F 18 d-FMAU PET/CT scan)|Patients receive fluorine F 18 d-FMAU IV followed by PET/CT prior to start of cancer treatment. Patients may undergo 2 additional scans at one week prior to second course of chemotherapy and after completion of cancer treatment depending on cancer type.
3072228|NCT02079168|Experimental|Cohort 1|Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin at the time of surgery.
3072229|NCT02079168|Experimental|Cohort 2|Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin two weeks after surgery.
3072230|NCT02079155|Active Comparator|Arm I (RALP)|Patients undergo standard RALP.
3072231|NCT02079155|Experimental|Arm II (R-LESS RP)|Patients undergo R-LESS RP.
3072232|NCT02079142|Experimental|High Intensity Strategy: Train-the-trainer|One therapist from each counseling center randomized to this arm will be selected to become the trainer and will be trained to train their colleagues.
3072233|NCT02079142|Active Comparator|Low Intensity Strategy: Expert Consultation|The IPT expert from Washington University will travel to all counseling centers randomized to this condition and train all participating therapists on site and be available for monthly phone consultation for up to one year following training on site.
3072234|NCT02079116|Experimental|60 grams of fat plus water solution|"In the group with 10 volunteers with obesity, some of them are submitted first to the 60 grams of fat plus water solution (meal challenge) and in another time to only water.~Also, in the group with 10 volunteers without obesity, some of them are submitted first to the 60 grams of fat plus water solution (meal challenge) and in another time to only water."
3072235|NCT02079116|Placebo Comparator|Pure water.|"In the same group with 10 volunteers with obesity, some of them are submitted first to only water (control) and in another time to the 60 grams of fat plus water solution (meal challenge).~Also, in the same group with 10 volunteers without obesity, some of them are submitted first to only water (control) and in another time to the 60 grams of fat plus water solution (meal challenge)."
3072236|NCT02079103|Experimental|Virtual reality|Virtual reality training using the YouGrabber® for patients with impaired arm motor function after stroke. The YouGrabber exercises focus on intensity, repetitions and motivating tasks and are adapted to the patient's motor abilities.
3072237|NCT02079103|Active Comparator|Conventional arm training|The patients receive supervised self-training exercises with focus on functional tasks adapted to their motor abilities.
3072238|NCT02079090|Active Comparator|Ketofol|Patient will receive 0.5 mg/kg Ketamine, and 2 minutes later receive 1 mg/kg Propofol.
3072239|NCT02079090|Experimental|Fentofol|Patient will receive 1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol.
3072240|NCT02079077|Other|Acetylsalicylic Acid (ASA)|ASA 81 mg. p.o. daily for two months
3072241|NCT02079077|Other|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. o.d. p.o. for two months.
3072242|NCT02079064|Experimental|Desflurane|Desflurane at 1 MAC and
3072243|NCT02079064|Experimental|propofol|propofol TCI (target controlled infusion) infusion of to keep a target plasma concentration between 2 and 5 µg ml-1
3072244|NCT02079051|Experimental|High Intensity Weight Loss|High intensity medical weight loss
3072245|NCT02079051|Active Comparator|Moderate Intensity Weight Loss|Moderate intensity weight loss
3072246|NCT02079038|Active Comparator|Totalis™ Direct Decompression Procedure|Totalis
3072247|NCT02079038|Sham Comparator|Sham Surgical Procedure|Sham
3072248|NCT02079025|Active Comparator|LR-TRUS|Low-resolution transrectal ultrasound guided prostate biopsy (standard of care)
3072249|NCT02079025|Experimental|UHR-TRUS|Ultra-high resolution transrectal ultrasound guided prostate biopsy
3072250|NCT02079012|Experimental|Intervention group|"Receives:~An information session~A 10-week walking program (with documents, pedometer and three information sessions about motivation, a healthy diet and smoking cessation)~A physical activity diary (which also functions as a tool to check protocol-compliance)~Measurements"
3096894|NCT01913093||Control|Leukemia survivors without TRANCE trait
3072252|NCT02078999||Control Grup|"Daily clinical data collection~Quantitative tracheal aspirates (QTA) every 3 days~Deep freeze serum samples for posterior analysis every day (two aliquots).~In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
3072253|NCT02078999||Patients with pulmonary infection|"Daily clinical data collection~Quantitative tracheal aspirates (QTA) every 3 days~Deep freeze serum samples for posterior analysis every day (two aliquots).~In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
3072254|NCT02078999||Patients with extrapulmonary infection|"Daily clinical data collection~Quantitative tracheal aspirates (QTA) every 3 days~Deep freeze serum samples for posterior analysis every day (two aliquots).~In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
3072255|NCT02078986|Experimental|Whole Body Electromyostimulation|
3072256|NCT02078986|Experimental|High Intensity Resistance Exercise Training|Supervised High Intensity Resistance Exercise 2-3 session/week/14 weeks
3072257|NCT02078973|Active Comparator|15 mg tolvaptan|Oral administration of 15 mg tolvaptan on each examination day.
3072258|NCT02078973|Active Comparator|30 mg tolvaptan|Oral administration of 30 mg tolvaptan on each examination day.
3072259|NCT02078973|Active Comparator|45 mg tolvaptan|Oral administration of 45 mg tolvaptan on each examination day.
3072260|NCT02078973|Placebo Comparator|Placebo|Oral administration of a Unikalk tablet
3072261|NCT02078960|Experimental|Omacetaxine mepesuccinate.|The study will consist of up to a 7-day screening period, and treatment for up to 12 months, in Phase 1 and Phase 2 portions, depending on response and tolerability. Patients will also have an end-of-treatment follow-up visit approximately 28 days after the last dose of omacetaxine. Each patient will be monitored for progression and survival for at least 1 year after their last dose of omacetaxine, death, or lost to follow-up, whichever comes first, regardless of patients receiving other anticancer treatment.
3072262|NCT02078947|Experimental|High Intensity Exercise|Patients perform interval- type endurance exercise at high intensity
3072263|NCT02078947|Active Comparator|Moderate Continuous Exercise|Patients perform endurance exercise at moderate intensity
3072264|NCT02078947|Sham Comparator|Usual Care|Patients receive advice on being physically active as well as usual care
3072265|NCT02078934|Experimental|Weight Loss|Patients with complex incisional/ventral hernias who are too obese to undergo hernia repair.
3072266|NCT02078921|Experimental|Treatment|Inorganic Nitrate
3072267|NCT02078921|Placebo Comparator|placebo|Placebo
3072268|NCT02078908|Active Comparator|40 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour
3072269|NCT02078908|Active Comparator|120 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour
3072270|NCT02078908|Active Comparator|240 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour
3072271|NCT02078908|Placebo Comparator|Placebo|Continuous 2 hour infusion of sodium chloride, 25 ml/hour
3072272|NCT02078895|Experimental|Botox|The experimental group will include ureteral stent placement with three peri-ureteral injections of Botox A and fourteen site-specific intradetrusor injections of Botox A.
3072273|NCT02078895|No Intervention|Control|The control group will involve a ureteral stent placement with no injection.
3072274|NCT02078882|Experimental|Abatacept 125 mg weekly|Open label treatment with Abatacept
3072275|NCT02078869|Active Comparator|intramuscular Progesterone in oil|50mg of intramuscular Progesterone injection will be administered once daily for 6 days including the day of embryo transfer
3072276|NCT02078869|Active Comparator|vaginal progesterone suppositories|200mg of progesterone suppositories will be administered 3 times a day for 6 days including the day of embryo transfer
3072277|NCT02078856|Experimental|A3384 Low dose|Administered twice daily for the duration of the study
3072278|NCT02078856|Experimental|A3384 High dose|Administered twice daily for the duration of the study
3072279|NCT02078856|Placebo Comparator|Placebo|Administered twice daily for the duration of the study
3072280|NCT02078843|Other|All patients|Subsequent performance of index test and standard test
3072281|NCT02078830|Placebo Comparator|3M™ Tegaderm™ I.V. Advanced Dressing|Placebo Dressing with the same shape like the CHG-Dressing without CHG.
3072282|NCT02078830|Experimental|3M™ Tegaderm™ CHG Securement Dressing|- CHG activity at EVD entry site
3072283|NCT02078817|Experimental|ketamine|Intravenous ketamine 0.5 mg/kg over 40 minutes will be given 6 times over 2 weeks.
3072284|NCT02078804|Experimental|Colonoscopy|20 000 subjects will be invited to an once-only colonoscopy.
3072285|NCT02078804|Experimental|FIT for occult blood|60 000 persons will be invited to take a fecal test for hemoglobin year 1 and year 3. If test-positive, they will be referred to colonoscopy.
3072286|NCT02078804|No Intervention|Controls|120 000 matched persons will be identified in the Swedish Register of the total population and will be used as controls.
3072287|NCT02078791|Experimental|Botox infiltration|Botox infiltration in cervical region
3072288|NCT02078791|Experimental|Psychology therapy|Problem solving group therapy
3072289|NCT02078791|Experimental|Botox infiltration & psychology therapy|Botox infiltration in cervical region and problem solving group therapy.
3072290|NCT02078778|Experimental|Treatment|Patients with hypertension and moderate to severe OSA is treated with CPAP for 3 months.
3072291|NCT02078765||hypertension|75 patients with hypertension and chronic kidney disease (CKD stage I-II)
3072292|NCT02078765||healthy subjects|75 healthy subjects
3072293|NCT02078752|Experimental|Part 1|
3072294|NCT02078739|Experimental|Yoga Program|Yoga Program twice per week for 8 weeks
3072295|NCT02078739|Active Comparator|Education|Education once per week for 8 weeks
3072296|NCT02078726|Active Comparator|Glucagon|1 mg glucagon given during colonoscopy
3072297|NCT02078726|Placebo Comparator|Placebo|1 mL normal saline
3072648|NCT02076399|Placebo Comparator|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
3072298|NCT02078713|Experimental|Contraceptive Decision Support Tool|Patients whose contraceptive counseling visits are scheduled with providers randomized to this arm will use the intervention immediately before their visit and bring the generated printout to their visit. Providers randomized to this arm will be free to integrate the tool and printout into their contraceptive counseling however they see fit.
3072299|NCT02078713|No Intervention|Usual Care (Control)|Patients in this arm will receive usual family planning care.
3072300|NCT02078700|Experimental|early palliative care programme|Patients will be proposed to be followed by the Palliative Care Team
3072301|NCT02078687|Active Comparator|Group 1, HM|This group received breastfeeding (human milk, HM) solely throughout the 4 month of intervention. Randomisation for group 1 or group 2. Mothers own milk.
3072302|NCT02078687|Active Comparator|Group 2, HMF|This group received mothers own milk with fortification (human milk fortification, HMF) throughout the 4 month intervention period. Randomisation for group 1 og group 2. Enfamil HM fortifier, Mead Johnson.
3072303|NCT02078687|Active Comparator|Group 3, PF|This group received preterm formula (PF) throughout the intervention period of 4 month. This group was not randomised for ethical reasons. Enfalac Premature Formula, Mead Johnson Nutritionals
3072304|NCT02078674|Experimental|Group A|Placebo
3072305|NCT02078674|Experimental|Group B|High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 and Day 21
3072306|NCT02078674|Experimental|Group C|High dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
3072307|NCT02078674|Experimental|Group D|Intermediate dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
3072308|NCT02078674|Experimental|Group E|Low dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
3072309|NCT02078674|Experimental|Group F|High dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
3072310|NCT02078674|Experimental|Group G|Intermediate dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
3072311|NCT02078674|Experimental|Group H|Low dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
3072312|NCT02078661|Active Comparator|PG101 0.25%|Topical application of drug
3072313|NCT02078661|Active Comparator|PG101 1.0%|Topical application of drug
3072314|NCT02078661|Placebo Comparator|Placebo|Topical application of placebo
3072315|NCT02078648|Experimental|SL-701; poly-ICLC 1.6mg; bevacizumab|SL-701 emulsion and the adjuvant poly-ICLC will be administered twice weekly for the initial 2 weeks, every 7 days during the subsequent 3 doses, and subsequently every 14 days for the subsequent 9 doses (16 doses total) through Week 22, and every 4 weeks thereafter. Bevacizumab will be administered every 2 weeks, subsequent to the administration of SL-701/poly-ICLC
3072316|NCT02078635|Experimental|Portfolio Plus Diet|Participants will be advised to follow a low glycemic index dietary portfolio. Specifically, the advice will be to limit saturated fat (to <7% of total calories and cholesterol to <200 mg/d) plus inclusion of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat and selection of low glycemic index foods; emphasizing current recommendations for fruit and vegetable intakes (5-10 servings/d)
3072317|NCT02078635|Active Comparator|DASH-like (high fibre) diet|The DASH-like dietary advice will emphasize a diet of whole grains, low-fat dairy and current recommendations for fruit and vegetables (5-10 servings/day)
3072318|NCT02078622||COPD, Education and Case Management|Respiratory Therapist Education and Case Management
3072319|NCT02078609|Experimental|LGH447 monotherapy arm|LGH447 monotherapy in patients with AML or MDS
3072320|NCT02078609|Experimental|LGH447 + midostaurin combination arm|LGH447 + midostaurin in patients with AML
3072321|NCT02078596|Experimental|Divalproex|Divalproex at 10 mgs/lb
3072322|NCT02078596|Placebo Comparator|Sugar Pill|Equivalent 250 mg pills titrated to 10 mgs / lb over six weeks
3072323|NCT02078583|Experimental|Remifentanil，midazolam|Remifentanil 1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02~0.1mg/kg/h continuous intravenous pump for 7days or extubation
3072324|NCT02078583|Experimental|Fentanyl，midazolam|Fentanyl 1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02~0.1mg/kg/h continuous intravenous pump for 7days or extubation
3072325|NCT02078583|Placebo Comparator|Normal saline|Normal saline1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02~0.1mg/kg/h continuous intravenous pump for 7days or extubation
3072326|NCT02078570||Breast Cancer ACR BI-RAD Category 3 or 4 result|
3072327|NCT02078557|Experimental|MK-8892|Starting dose of 1 mg daily (oral); the dose may be titrated up on the 8th, 15th, and 22nd day of treatment to 2 mg, 3 mg, or 4 mg, respectively, for the duration of the study (28 days) as tolerated. For participants who reach one or more of the down-dosing criteria, there is an opportunity to decrease the dose back to a previously well-tolerated dose level, or to ½ of the starting dose.
3072328|NCT02078544||Gynaecological cancer|
3072329|NCT02078531||Breast cancer, Chemotherapy|"CANTAB test~Fill up questionnaires (HADS, PDQ, EORTC QLQ-C30, FACT-ES)~Optional blood draw (10mls; 2 teaspoons)~PET/MRI imaging scan (for 10 patients)"
3072330|NCT02078518||Multiple Myeloma|Questionnaires will be given to patients for completion.
3072331|NCT02078505|Experimental|PCOS after diet|Patients after 2 months of diet
3072332|NCT02078505|No Intervention|control|Ovulatory women
3072333|NCT02078492|Experimental|Group 1 - 10 mg of Ketorolac|Subjects will be administered 10 mg of Ketorolac for pain relief.
3072334|NCT02078492|Experimental|Group 2 - 15mg|Subjects will be administered 15mg of Ketorolac.
3072335|NCT02078492|Experimental|Group 3 - 30mg|Subject will receive 30mg of Ketorolac as a part of standard care.
3072336|NCT02078479|Active Comparator|Real rTMS|The active group received Real rTMS over the hand area of motor cortex (20 Hz, 10 second, 10 trains with inter-train interval 30 second with total pulses 2000, intensity 80% of motor threshold) every day for ten consecutive days (5 days/week).
3072337|NCT02078479|Sham Comparator|Sham rTMS|Sham-rTMS was applied using the same parameters but with the coil elevated and angled away from the head to reproduce the same of subjective sensation of rTMS
3072338|NCT02078466|No Intervention|Control group|Usual care
3072339|NCT02078466|Experimental|Assessment of functional ability|Assessment of functional ability and follow-up at home
3072346|NCT02078388||Breast cancer,Doxorubicin|Breast cancer patients who received at least one cycle of doxorubicin-containing adjuvant chemotherapy for treatment of early stage breast cancer at least 12 months ago and who had a pre-doxorubicin echocardiography done at NUHS will be enrolled. Study subjects will donate one sample of blood (20ml) for genetic and biomarker studies related to breast cancer and anthracyclines pharmacodynamics. An echocardiography will be performed to measure left ventricular ejection fraction, and compared with the subject's pre-doxorubicin echocardiography done at NUH. Correlative analysis will be performed between genetic variants and left ventricular ejection change.
3072347|NCT02078375|Placebo Comparator|Carbohydrate supplement|Participants will be enrolled in a twice weekly resistance exercise program. They will receive a carbohydrate supplement to take twice daily (once after exercise).
3072348|NCT02078375|Experimental|Protein Supplementation|Participants will be enrolled in a twice weekly resistance exercise program. They will receive a twice daily protein supplement (once after exercise).
3072349|NCT02078349|Experimental|Solid Tumors|"Patients will receive Selinexor once weekly (Schedule 1) or twice weekly (Schedule 2) or three times a week (Schedule 3) orally at a starting dose of 50 mg/m² (Schedule 1) and 40mg/m2 (Schedule 2) and 20mg/m2 (Schedule 3).~One cycle is 28 days for Schedule 1 and Schedule 3 and 21 days for Schedule 2. Treatment will continue until disease progression or the development of unacceptable toxicities."
3072350|NCT02078336|Experimental|Midazolam|Midazolam Mylan 5 mg/ml solution for injection 15mg Oral use Single dose 45 minutes before dental treatment
3072351|NCT02078336|Active Comparator|Lorazepam / Valium+Akineton+Dehydrobenzperidol+Atropine sulfat|"Lorazepam Mylan 2,5 mg tabletten 2.5mg Oral use Single dose 45 minutes before dental treatment~OR~Valium 10 mg/2 ml solution for injection 10mg Intramuscular use Single dose 45 minutes before dental treatment~+ Akineton 5 mg/ml solution for injection 5mg Intramuscular use Single dose 45 minutes before dental treatment~+ Dehydrobenzperidol 5 mg/2 ml solution for injection 0,000125 ml/cm2 Intramuscular use Single dose 45 minutes before dental treatment~+ Atropine sulfate Sterop 0,25mg/1ml solution for injection 0,25mg Intramuscular use Single dose 45 minutes before dental treatment"
3072352|NCT02078323|Active Comparator|Linaclotide|Linaclotide 290micrograms q day 30 min before meal for a 10 week period
3072353|NCT02078323|Placebo Comparator|placebo|Placebo q day 30 min before meal for a 10 week period
3072354|NCT02078310|Experimental|ITI-007 Part 1|Part 1: Healthy geriatric volunteers with multiple oral dose escalation up to and including 20 mg ITI-007
3072355|NCT02078310|Placebo Comparator|Placebo Part 1|Part 1: Healthy geriatric volunteers with placebo given
3072356|NCT02078310|Experimental|ITI-007 Part 2|Part 2: Geriatric patients with dementia with ITI-007 given
3072357|NCT02078310|Placebo Comparator|Placebo Part 2|Part 2: Geriatric patients with dementia with placebo given
3072358|NCT02078297||Scalp psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
3072359|NCT02078297||pustular palmo-plantar psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
3072360|NCT02078297||non-pustular palmo-plantar psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
3072361|NCT02078297||elbow psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
3072362|NCT02078297||leg psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
3072363|NCT02078297||Healthy subjects|
3072364|NCT02078284|Experimental|Cohort 1 with 0.5 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 0.5 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
3072365|NCT02078284|Active Comparator|Cohort 1 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
3072366|NCT02078284|Experimental|Cohort 2 with 1 unit of CPP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
3072367|NCT02078284|Active Comparator|Cohort 2 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
3072368|NCT02078284|Experimental|Cohort 3 with 2 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 2 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
3072369|NCT02078284|Active Comparator|Cohort 3 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
3072370|NCT02078284|Experimental|Cohort 4 with 3 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 3 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
3072371|NCT02078284|Active Comparator|Cohort 4 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP
3072372|NCT02078271|Experimental|FBDG group|The group received Food Based Dietary Guidelines for feeding recommendation. Monthly-session with group of mothers involving interactive activities e.g. cooking session, cooking competition and games.
3072373|NCT02078271|Experimental|Stimulation group|The children received psychosocial stimulation from the mothers. Mothers were taught on psychosocial module which was developed using locally existing resources and was directed at improving four aspects of child development, namely gross motoric, fine motor, language and socio-emotional developments.
3072374|NCT02078271|Experimental|Combined (FBDG and Stimulation)|The group received both FBDG and psychosocial stimulation
3072375|NCT02078271|Other|Control|The group received standard health education messages from existing health care system.
3072414|NCT02077985|No Intervention|Regular Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Regular dental environment no sensory characteristics of the dental environment are altered, the cleaning is conducted as per usual.
3072376|NCT02078258|Experimental|Attentional bias modification training|Participants complete 8 sessions of dot-probe task attention bias modification training (ABMT) during a two-week period. ABMT is a modified dot probe task, in which a probe always appears in the location of neutral stimulus after the two stimuli (i.e. one is the depressive cue and the other is neutral) were simultaneously presented. In the ABMT,the probability that a probe appears in the location of neutral is 90%, and correspondingly,in the location of depressive stimuli is 10%. Each session consists of 320 trials, and the time to complete a training session is approximately 20 minutes.
3072377|NCT02078258|Placebo Comparator|Placebo control|Participants complete 8 sessions of placebo training(PT) during a two-week period. Placebo training is a classic dot-probe task, in which a probe appears after either of the locations that the two stimuli (i.e. one is the depressive cue and the other is neutral) were presented, with the same frequencies. In the PT condition, each session also consists of 320 trials, and the time to complete a PT session is approximately 20 minutes as well.
3072378|NCT02078245||Familial pancreatic cancer patients|Individual with ten fold higher risk to develop pancreatic cancer.
3072379|NCT02078232|Experimental|19G flex needle puncture|puncture of head of pancreas
3072380|NCT02078232|Active Comparator|22G needle puncture|puncture of head of pancreas
3072381|NCT02078219|Experimental|RDEA3170 1|RDEA3170 5mg followed by RDEA3170 7.5mg
3072382|NCT02078219|Experimental|RDEA3170 2|RDEA3170 10mg followed by RDEA3170 12.5mg
3072383|NCT02078219|Experimental|RDEA3170 3|RDEA3170 12.5mg followed by RDEA3170 15mg
3072384|NCT02078219|Placebo Comparator|RDEA3170 4|RDEA3170 Placebo
3072385|NCT02078219|Other|Allopurinol|Allopurinol 200mg
3072386|NCT02078206|Experimental|Neurocognitive stimulation|Intervention of experimental group consists in a neurocognitive stimulation treatment. Using kinect technology, patient can interact with a virtual environment where different cognitive tasks have to be resolved.
3072387|NCT02078206|No Intervention|Treatment as usual|
3072388|NCT02078193|Experimental|Belatacept|Participants will be converted from their current MMF to once a month infusions of Belatacept
3072389|NCT02078180|Active Comparator|generic bupropion IR75|One oral dose of generic bupropion IR75
3072390|NCT02078180|Active Comparator|generic bupropion IR100|One oral dose of generic bupropion IR100
3072391|NCT02078180|Active Comparator|generic bupropion SR100|One oral dose of generic bupropion SR100
3072392|NCT02078180|Active Comparator|generic bupropion SR150|One oral dose of generic bupropion SR150
3072393|NCT02078180|Active Comparator|generic bupropion XL150|One oral dose of generic bupropion XL150
3072394|NCT02078180|Active Comparator|generic bupropion XL300|One oral dose of generic bupropion XL300
3072395|NCT02078154||Deep Venous Thrombosis (DVT)|DVT diagnosed by imaging technique with a low or moderate Wells score
3072396|NCT02078128|Experimental|oral beta-glucans|Daily give kg per day to 30 mg of β-glucan (30mg/kg/day), taking to the wound healed.
3072397|NCT02078128|Placebo Comparator|oral sugar powder|control group, daily give and the glucose powder 30 mg per kilogram of body weight (30mg/kg/day) a day, taking to the wound healed.
3072398|NCT02078115||chronic kidney disease, hypertension|20 <= age < 75 years 15 <= estimated glomerular filtration rate (GFR) < 90
3072399|NCT02078102|Other|Treatment|"Meloxicam and Filgrastim will be administered in fixed doses to each patient enrolled on this study. The treatments will be administered in a staggered dose schedule for a total treatment duration of 7 days prior to apheresis.~15 mg tablets of Meloxicam will be taken orally for 5 consecutive days.~10 µg/kg of Filgrastim will be subcutaneously injected for 5 consecutive days. Filgrastim may be subcutaneously injected for an additional 3 days if patients do not meet the primary endpoint for cell collection."
3072400|NCT02078089|Other|Oxcarbazepine and Morphine|"Patients must be on stable or increasing doses of greater than or equal to 180 mg of morphine sulfate per day. Morphine is taken orally for 42 days.~In addition to Morphine, patients will also receive oral Oxcarbazepine 150 mg, every 12 hours, for 2 weeks, then increase the dose to 300 mg, every 12 hours, for 2 weeks and then increase the dose to 450 mg, every 12 hours, for the final 2 weeks. Patients will take oral tablets of oxcarbazepine for a total of 42 days."
3072401|NCT02078076|Experimental|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
3072402|NCT02078063|Experimental|Mepivacaine|10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter
3072403|NCT02078063|Placebo Comparator|NaCL|10 ml NaCl 9mg/ml instilled into the uterus through a hydrosonography catheter
3072404|NCT02078050|Other|Phrenic nerves magnetic stimulations|
3072405|NCT02078037|Experimental|Arctic Sun cooling device|The Arctic Sun device pads will be placed on the patient as per manufacturer's instructions. Patients, who cannot tolerate placement of all the pads for any given reason, will still be included in the study if they can maintain normothermia (normal body temperature). The total normothermia time for the study is five days. After 5 days, the attending physician will make clinical decisions based on the patient needs.The temperature goal for this study is 36.5 degree Celsius, but normothermia for the purpose of this study will be defined as a temperature of 35.5 - 37.5 degree Celsius. A thermometer mounted urinary catheter will be used for temperature monitoring and feedback to the Arctic Sun.
3072406|NCT02078037|Active Comparator|Standard of Care|Patient will be given standard fever management (acetaminophen + cooling blanket at the discretion of the treating physician) initiated at a temperature of 38.5 degrees Celsius
3072407|NCT02078024|Active Comparator|Annual Ivermectin|Ivermectin 200 µg/kg body weight given orally at 0, 12 and 24 months
3072408|NCT02078024|Experimental|Biannual IVM 200 µg/kg plus ALB 800 mg|IVM 200 µg/kg plus ALB 800 mg (regardless of weight) given at 0, 6, 12, 18, and 24 months.
3072409|NCT02078024|Experimental|Annual IVM 200 µg/kg plus ALB 800 mg|IVM 200 µg/kg plus ALB 800 mg given at 0, 12 and 24 months; vitamin pills at given at 6 and 18 months.
3072410|NCT02078024|Experimental|Biannual IVM 200 µg/kg|IVM 200 µg/kg given 0, 6, 12, 18, and 24 months.
3072411|NCT02078024|Experimental|IVM 200 µg/kg plus ALB 400 mg|IVM 200 µg/kg plus ALB 400 mg given at 0, 6, 12, 18, and 24 months.
3072412|NCT02078011|Experimental|HIFU treatment|The high intensity focused ultrasound (HIFU) will be administered to the targeted site to create heat and cause the cells to die
3072453|NCT02077686|Experimental|Education - Diabetes and Travel|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Travel"
3072415|NCT02077985|Experimental|Sensory Adapted Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Sensory Adapted Dental Environment the sensory characteristics of the dental environment are altered (visual, auditory, tactile adaptations).
3072416|NCT02077972|Experimental|High intensity whole-body infrared heating|The participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
3072417|NCT02077959|Experimental|Treatment (lenalidomide, pidilizumab)|Patients receive lenalidomide PO daily on days 1-21 and pidilizumab IV over 1-2 hours on day 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3072418|NCT02077946||Liraglutide / Sitagliptin|
3072419|NCT02077933|Experimental|alpelisib and everolimus|alpelisib and everolimus administered once a day
3072420|NCT02077933|Experimental|alpelisib, everolimus and exemestane|alpelisib, everolimus and exemestane administered once a day
3072421|NCT02077933|Experimental|alpelisib and exemestane|alpelisib and exemestane administered once a day
3072422|NCT02077920|Experimental|Chlorhexidine before intubation|Group A: Oropharyngeal decontamination with chlorhexidine before intubation, n=48. Oral cleansing with chlorhexidine will be performed before endotracheal intubation, and every 6 hours after intubation.
3072423|NCT02077920|Experimental|Chlorhexidine after intubation|Group B: Oropharyngeal decontamination with chlorhexidine after intubation, n=48. Oral cleansing with chlorhexidine will be performed every 6 hours after endotracheal intubation.
3072424|NCT02077920|Experimental|Subglottic secretion drainage|"Group C: Suctioning of subglottic secretions, n=48. Oral cleansing with chlorhexidine will be performed before endotracheal intubation and every 6 hours after intubation, and fiberoptic bronchoscopy-guided suctioning of subglottic secretions will be performed at 10:00 a.m. every day. The procedure will be as follows:~Routine cleaning of the bronchoscope.~Oral or nasal insertion of the bronchoscope (according to the decision of the attending physician based on the patient's condition). Rinsing of the subglottic region with 5-20 mL of chlorhexidine solution followed by suctioning. The rinsing procedure will be repeated 3-5 times.~Routine cleaning of the bronchoscope. The patient will be monitored during all procedures."
3072425|NCT02077920|Experimental|0.9% sodium chloride injection|Group D: 0.9% sodium chloride injection, n=48. After endotracheal intubation, oral cleansing with normal saline will be performed every 6 hours.
3072426|NCT02077907|Active Comparator|Super Cereal Plus (SC+)|"800 kcal/d, 215 g/d~Current protocol for treating MAM is supplemental food distribution, often providing a fortified blended food (FBF) that requires cooking. In Sierra Leone, their FBF standard is Super Cereal Plus."
3072427|NCT02077907|Experimental|Super Cereal (SC) and oil and sugar|"200 g SC and 20 g fortified oil and 15 g sugar, per day~Fortified blended food (FBF) Fortified Oil with Vitamins A & D"
3072428|NCT02077907|Experimental|Corn Soy Blend 14 (CSB14) and fortified oil|"978 kcal/day - 150 g CSB14 and 45 g oil, per day~Fortified blended food (FBF) Fortified Oil with Vitamins A & D"
3072429|NCT02077907|Experimental|Plumpy'Sup|"500 kcal/d, 92 g/d~Ready-to-Use Supplementary Food (RUSF)"
3072430|NCT02077881|Experimental|Indoximod and Gemcitabine + Nab-paclitaxel|"Phase 1 portion:~Participants to receive indoximod (600mg, 100mg, or 1200mg according to their assigned dose cohort) PO BID for 28 days concurrently with IV Nab-paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 weekly for 3 weeks with one week rest. Each cycle is 28 days. Patients will continue until they experience disease progression or significant toxicity.~Phase 2 portion:~Once a RP2D is determined, treatment will commence with oral indoximod concurrent with the first backbone chemotherapy cycle.Patients will receive gemcitabine plus nab-paclitaxel on a standard 4 week cycle schedule. Oral indoximod will continue throughout."
3072431|NCT02077868|Other|Control Arm A|Patients in Control Arm A receive usual maintenance Treatment according to local investigator's decsision
3072432|NCT02077868|Experimental|Treatment Arm B|MGN1703 treatment as maintenance therapy
3072433|NCT02077855||Toddlers fractures|
3072434|NCT02077842|Experimental|Nasal CPAP|The experimental group will receive nasal continuous positive airway pressure at 10cmH20 for one hour in the Post Anesthetic Care Unit.
3072435|NCT02077842|Active Comparator|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
3072436|NCT02077829|Other|IMR therapists, IMR patients|"30 voluntary therapists from 9 mental health services will be trained and coached in IMR.~40 patients from the 9 mental health services will receive Illness Management and Recovery from the therapists in training."
3072437|NCT02077816||Central venous catheter|Inpatients with CVC for medical care.
3072438|NCT02077803|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 100 mg, and 4 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
3072439|NCT02077803|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
3072440|NCT02077803|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
3072441|NCT02077790|No Intervention|Substantial Equivalence|The CASIA Cornea/Anterior Segment OCT SS-1000 was used on all subjects for this study.
3072442|NCT02077777|Experimental|5-ASA|Mesalazine 800 mg orally t.i.d for 3 months
3072443|NCT02077777|No Intervention|No treatment|no treatment
3072444|NCT02077764||Controls, healthy individuals|controls
3072445|NCT02077764||Heart transplanted patients|Patients
3072446|NCT02077751|Experimental|Biotin labelled RBCs|Subjects receive biotin labelled autologous red blood cells.
3072447|NCT02077738|Experimental|HFCWO|HFCWO for 15 min twice a day
3072448|NCT02077738|Placebo Comparator|placebo|not to receive high-frequency chest wall oscillation (HFCWO)
3072449|NCT02077725||Interdisciplinary polypharmacy clinic|Patients will be seen in the interdisciplinary polypharmacy clinic for a complete comprehensive medication review
3072450|NCT02077712|Active Comparator|Dexmedetomidine 1 ug/kg|1 ug/kg of intranasal dexmedetomidine
3072451|NCT02077712|Active Comparator|Dexmedetomidine 2 ug/kg|2 ug/kg of intranasal dexmedetomidine
3072452|NCT02077699|Experimental|1|Treatment with Lactobacillus casei DG (24 billion of live cells per pill) 2 pills b.i.d. for 4 weeks
3097755|NCT01907269|No Intervention|Usual care|
3072454|NCT02077686|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
3072455|NCT02077673||open surgery|25 patients undergoing open gastroesophageal resection
3072456|NCT02077673||robotic-assissted surgery|25 patients under-going robotic-assisted gastroesophageal surgery
3072457|NCT02077660|Placebo Comparator|4 daily placebo tea bags for 12 weeks|"All subjects will undergo a 12 weeks supplemented with four daily placebo maltodextrin tea-bags. The subjects will be instructed than to brew the placebo sachets for five minute in 240 mL boiling water without stirring and to drink 4 cups per day for 12 weeks period (Placebo period)."
3072458|NCT02077660|Experimental|Four green tea bags per day for 12 weeks|After the placebo period, all subjects will undergo a 12 weeks supplemented with four daily green tea bags. The subjects will be instructed than to brew the green tea sachets for five minute in 240 mL boiling water without stirring and to drink 4 cups per day for 12 weeks period (Green tea period).
3072459|NCT02077647||Conservative|Conservative treatment of osteoarthritis of the knee
3072460|NCT02077634|Active Comparator|abiraterone acetate + prednisone + LHRH-therapy|Patients randomized to this group will continue their LHRH-therapy.
3072461|NCT02077634|Active Comparator|abiraterone acetate + prednisone|Patients randomized to this group will stop LHRH-therapy.
3072462|NCT02077621|Experimental|PG2|"Treatment Group:~PG2 (500 mg in 500 ml saline), 1 dose a day before surgery and 1 dose a day for 3 days after surgery"
3072463|NCT02077621|Placebo Comparator|Placebo|"Control group:~Placebo (500 ml saline), 1 dose a day before surgery and 1 dose a day for 3 days after surgery"
3072464|NCT02077608||Hyaluronan enriched transfer media|Embryos are incubated at least 10 minutes in hyaluronan enriched embryo transfer media before transfer
3072465|NCT02077608||Control group|Embryos are incubated in embryo transfer media containing low concentration of hyaluronan for at least 10 minutes before transfer
3072466|NCT02077595|Active Comparator|120Hz alternating current stimulation group|
3072467|NCT02077595|Active Comparator|5Hz alternating current stimulation group|
3072468|NCT02077595|Sham Comparator|sham alternating current stimulation group|
3072469|NCT02077569|Experimental|AZD5363 480mg|STAGE 1 ONLY AZD5363 480mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
3072470|NCT02077569|Placebo Comparator|Placebo|STAGE 1 ONLY Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
3072471|NCT02077569|Experimental|AZD360mg|STAGE 2 AZD5363 360mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
3072472|NCT02077569|Experimental|AZD5363 240mg|STAGE 2 AZD5363 240mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
3072473|NCT02077556|Experimental|Everolimus|Everolimus/Tacrolimus/Methylprednisolone & Prednisolone
3072474|NCT02077556|Active Comparator|Mycophenolate mofetil|Mycophenolate mofetil/Tacrolimus/ Methylprednisolone & Prednisolone
3072475|NCT02077543|Experimental|ProTool|Device: Molecular and cellular tumor print Medical Device (ProTool)
3072476|NCT02077517|Active Comparator|hand sewn anastomosis|Patients with hand sewn anastomosis during Roux en Y Gastric bypass performing
3072477|NCT02077517|Active Comparator|stapled anastomosis|Patients with stapled anastomosis during Roux en Y Gastric Bypass performing
3072478|NCT02077504|Experimental|CONDUCTOME|MEG and MRI
3072479|NCT02077491|Active Comparator|Intervention|High-protein diet and resistance training
3072480|NCT02077491|No Intervention|Control|The control group recieves standard care during the study.
3072481|NCT02077478|Experimental|MCI|manually controlled infusion will be used
3072482|NCT02077478|Experimental|TCI|Target Controlled Infusion will be used
3072483|NCT02077465|Experimental|GS-5745|Participants will receive GS-5745 every 2 weeks for a total of 3 infusions.
3072484|NCT02077465|Placebo Comparator|Placebo to match GS-5745|Participants will receive placebo to match GS-5745 every 2 weeks for a total of 3 infusions.
3072485|NCT02077452|Experimental|HMS5552 dose 1|HMS5552 25~400mg. Oral administration, twice per day.
3072486|NCT02077452|Experimental|HMS5552 dose 2|HMS5552 25~400mg. Oral administration, twice per day.
3072487|NCT02077452|Experimental|HMS5552 dose 3|HMS5552 25~400mg. Oral administration, twice per day.
3072488|NCT02077452|Experimental|HMS5552 dose 4|HMS5552 25~400mg. Oral administration, once per day.
3072489|NCT02077452|Experimental|HMS5552 dose 5|HMS5552 25~400mg. Oral administration, twice per day.
3072490|NCT02077439|Experimental|Hand Robotic Training|Hand Robotic Training
3072491|NCT02077439|Experimental|Hand and Arm Robotic Training|Hand and Arm Robotic Training
3072492|NCT02077439|Active Comparator|Conventional therapy|Conventional therapy
3072493|NCT02077426|Experimental|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises
3072494|NCT02077413|Active Comparator|Healthy Muscle Group|Six subjects will be enrolled in this group. MRI measures will be performed at baseline and 48 hours post-exercise, when the largest amount of muscle damage is typically observed. They will be tested for maximum strength of the dorsiflexors and then undergo an eccentric exercise protocol for both lower legs on the Biodex with varying loads. Approximately two days after the exercise protocol, the participants will have another MRI of the lower legs to assess any change in T2 relaxation time as a construct of muscle edema/damage.
3072495|NCT02077413|Experimental|Stretch-Contract Pre-rehabilitation Group|"All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors. They will also receive the stretch-contract protocol on one leg consisting of the following: a 5 second passive stretch of the dorsiflexors, followed immediately by a 5 second active isometric contraction of the dorsiflexors, and a 5 second rest/relaxation period. This cycle will continue for a duration of ~5 minutes."
3072532|NCT02077166|Experimental|Phase 1: Dose Level 1|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
3072533|NCT02077166|Experimental|Phase 1: Dose Level 1+|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
3072496|NCT02077413|Active Comparator|Stretch-Contract Control Group|All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors.
3072497|NCT02077413|Experimental|Muscle Atrophy|These subjects will undergo MRI and strength testing at baseline and will also be assessed for CK levels, pain report, and ROM. They will then receive an eccentric loading paradigm for the dorsiflexor muscles of the involved leg using an isokinetic dynamometer with varying loads. Approximately two days after the exercise protocol, follow-up assessment of MRI, CK levels, pain report, ROM, and strength will be done.
3072498|NCT02077400|No Intervention|no antibiotic|
3072499|NCT02077400|Active Comparator|Cephazolin|cefazoline
3072500|NCT02077387|Experimental|CHild Inhibitory Control Play (CHIC) Play|CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.
3072501|NCT02077387|Active Comparator|Attention control|Children will receive information regarding other healthy behaviors: brushing teeth, sunscreen use, being physically active
3072502|NCT02077374|Experimental|IDN-6556|IDN-6556 capsules, 25 mg BID
3072503|NCT02077374|Placebo Comparator|Placebo|Placebo BID
3072504|NCT02077361|Experimental|Open Label|"Patients will receive a subretinal injection of 0.10 ml of the rAAV2.REP1 vector drug substance. It is a colourless opalescent frozen liquid with no visible particles. Each patient will be given a one-time dose in one eye.~It is the same vector used in the United Kingdom Phase I/II trial logged at: http://clinicaltrials.gov/ct2/show/NCT01461213."
3072505|NCT02077348|No Intervention|Insulin|"good glycemic control: 50 % of the subject's basal insulin dosage will be given as a continuous IV administration of insuman rapid overnight (hospitalized and fasting from 10 p.m.) and on the study-day. Basal period from 7.00 am to 12.00pm. The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
3072506|NCT02077348|Experimental|Insulin withdrawal|"10 % of the individual subject's regular insulin dosage will be given as a continuous IV administration of insuman rapid overnight (hospitalized and fasting from 10 p.m.) Basal period from 7.00 am to 12.00 pm (without insulin). The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
3072507|NCT02077348|Experimental|Norditropin (Growth Hormone)|"Same amount of insulin administered on the control day (good glycemic control) overnight and on the study day (hospitalized and fasting from 10 p.m.). On the study day, a bolus injection of 0,4 mg of growth hormone (Norditropin) will be administered at 7.05 am. Basal period from 7.00 am to 12.00 pm (good glycemic control).The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
3072508|NCT02077335|Experimental|HDR brachytherapy monotherapy|Radiation therapy: Treatment with 2 separate HDR brachytherapy implants, each with one fraction of 13.5 Gray (Gy) with an interval of 7-14 days between treatments.
3072509|NCT02077322|Experimental|Silastic Spacer|This study arm receives the experimental treatment, a Silastic spacer.
3072510|NCT02077322|Active Comparator|Merocel Spacer|Merocel spacers are actively being used as the standard of care.
3072511|NCT02077309|Active Comparator|Linagliptin|Patients will receive 5 mg linagliptin once daily for a period of 6 months.
3072512|NCT02077309|Placebo Comparator|Placebo|Patients will take placebo tablets once daily for a period of 6 months.
3072513|NCT02077296||Preoperative chemoradiotherapy|The group consists of patients aged ≥18 with a pathohistological diagnosis of locally advanced rectal adenocarcinoma (<15 cm from the anal verge). They are found eligible for preoperative chemoradiotherapy (chemotherapy: oral capecitabine / radiotherapy: 45-50 Gy in total; fractions of 1.8-2 Gy) and surgery (stage 2 or 3 rectal cancer).
3072514|NCT02077283||Healthy people|This group contains healthy people only whose liver function and B ultrasound are normal.
3072515|NCT02077283||"group of liver depression and spleen deficiency pattern"|"In this group, patients are considered to be the pattern of liver depression and spleen deficiency. They mainly have the symptoms of loose stool, depression, fat tongue with white coating and teeth marks and soft or string pulse."
3072516|NCT02077283||"group of damp-heat in the interior pattern."|In this group ,NAFLD patients have symptoms with dry mouth, bitter mouth, heavy feeling in legs, yellow urine, reddish tongue with thick yellowish coating and slippery pulse.
3072517|NCT02077270|Experimental|electroacupuncture|patients in whom precolonoscopic electroacupuncture is preformed
3072518|NCT02077270|Placebo Comparator|Sham electroacupuncture|sham electroacupuncture
3072519|NCT02077270|Sham Comparator|No intervantion|no intervantion
3072520|NCT02077257|Other|Rosuvastatin 20mg|Rosuvastatin 20 mg/d
3072521|NCT02077257|Other|Rosuvastatin 10mg|Rosuvastatin 10 mg/d
3072522|NCT02077244|Experimental|Follow up talks|Nurse led follow up talks at the ward and one and two months later.
3072523|NCT02077244|No Intervention|No talks|Care as usual
3072524|NCT02077231|Experimental|vitamin A palmitate eye gel|0.1% vitamin A palmitate; Sinqi, Shenyang, China
3072525|NCT02077231|Experimental|carbomer eye gel|0.2% Carbomer 940; Bausch & Lomb, Aschheim, Germany
3072526|NCT02077218|Experimental|Diagnostic (CT and blood biomarkers)|Patients undergo cardiac CT and collection of blood samples for analysis of hs-CRP via quantitative immunoturbidimetry and Lp-PLA2 via ELISA.
3072527|NCT02077205|Experimental|Manualised Cognitive Behavioral Therapy|Manualised Cognitive Behavioral Therapy in a Routine Care Setting
3072528|NCT02077192|Experimental|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
3072529|NCT02077179|No Intervention|Standard of Care|Participants in this arm will receive care as per the usual standards from Kingston General Hospital and their primary care provider.
3072530|NCT02077179|Experimental|HIP Program|Participants in this arm will follow the HIP Program in addition to their usual care from Kingston General Hospital and their primary care provider.
3072531|NCT02077166|Experimental|Phase 1: Dose Level -1|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
3072537|NCT02077153|Experimental|Group Reminescence|In the experimental condition, everything begins ensuring the participants that all the memories shared will not be spread out of the group. Every session will deal with a theme, recalling specific autobiographic experiences; they will be suggested following a chronological order. Participants are encouraged to bring photos or objects related to past themes: at the end of each meeting the theme of the following is revealed. The researchers can also bring materials as cues for reminiscence.
3072538|NCT02077153|Active Comparator|Group discussion|In the control condition, every meeting will offer topics for discussion taken from newspaper and newscasts: personal opinions are promoted, and links with the daily life of participants are welcome (everyday activities, personal preferences). The main goal is to stimulate the social interaction and the communication, without dealing with personal events from the past nor private memories.
3072539|NCT02077140|Experimental|MDT-10013|Subjects will receive MDT-10013.
3072540|NCT02077140|Active Comparator|Standard of Care|Subjects will receive standard of care.
3072541|NCT02077114|Experimental|Ipilimumab|Patient who according to standard criteria are candidates to treatment with Ipilimumab
3072542|NCT02077114|Experimental|Vemurafenib|Patients who according to standard criteria are candidates to treatment with Vemurafenib
3072543|NCT02077101|Other|Quantitative study group|Patients complete questionnaires validated and published in the literature: Brief IPQ R and HIV PROQOL [28, 29]. The questionnaire RAVVIH therapeutic vaccine has been designed from the literature review and advice of the Scientific Council in particular Dr. Pierre Verger social scientist vaccination and experts on the perception of patients. It was tested on a sample of 15 PWLHA
3072544|NCT02077101|Other|Qualitative study group|"An interview guide was developed from the literature and expert community. Data will be collected through qualitative interviews with a psychologist trained to conduct interviews. Volunteers will be recruited according to the different categories of people representative of the HIV population in France.~These interviews will be conducted at the Foch Hospital. The physician investigator propose participation in the investigation and agree on a day appointment with the psychologist. Consent will be collected at that time after reading the prospectus . All interviews will be recorded orally with the agreement of the participants , and transcribed in full . They will be completely anonymous .~The average length of the interviews will be 45-60 minutes. Textual data from these interviews will be analysis."
3072545|NCT02077088|Experimental|Galactooligosaccharides|addition of 0,5g galactooligosaccharides to HA (hypoallergenic) starter formula
3072546|NCT02077088|No Intervention|Only HA formula|only standard HA starter formula
3072547|NCT02077075|Active Comparator|Web-based weight loss program|Subjects will have access to a web-based weight loss program for an 8-week period.
3072548|NCT02077075|Experimental|On-line health coaching in addition to web-based program|Subjects will have access to the web-based wellness program and will also receive weekly personalized health coaching emails.
3072549|NCT02077062||study (hepatectomy) group|patients undergoing hepatectomy for malignant neoplasm
3072550|NCT02077062||control (non hepatectomy) group|patients undergoing intestinal resections (not incluiding hepatectomy) for malignant neoplasm
3072551|NCT02077049|Experimental|serious games self-training program|Serious games are played, using Kinect® and Fit Bit®. This program is performed during the 10 days of the intervention on a self-training basis and 2 specific time-slot (2x30 min) per day are allocated for this program.
3072552|NCT02077049|Active Comparator|Conventional self-training program|conventional physical exercises are performed during the 10 days of the intervention, on a self-training basis and 2 specific time-slot (2x30 min) per day are allocated for this program.
3072553|NCT02077036|Experimental|Active medical device|
3072554|NCT02077036|Placebo Comparator|Inactive medical device|
3072555|NCT02077023||Asymptomatic Carotid Artery Disease, AF|
3072556|NCT02077010|Experimental|Inhaled nebulized milrinone|Inhaled nebulized milrinone 60mg/4ml every 8 hours using a vibrating mesh nebulizer
3072557|NCT02077010|Active Comparator|Intravenous milrinone|Continuously infused IV milrinone at 0.375mcg/kg/min
3072558|NCT02076997|Experimental|Individualized High Dose Methotrexate|Individualized high dose methotrexate given as a 24-hour infusion.
3072559|NCT02076984|Other|Group A|laparoscopic incisional or ventral hernia repair use of lightweight polypropylene mesh fixed by titanium tacks
3072560|NCT02076984|Other|Group B|laparoscopic incisional or ventral hernia repair use of lightweight polypropylene mesh fixed by U shaped absorbable tacks
3072561|NCT02076958|Active Comparator|Traditional/classroom|Community health advisors trained using traditional/classroom methods and provided with technical assistance/support as needed
3072562|NCT02076958|Experimental|Technology|Community health advisors trained using technology/online methods and provided minimal technical assistance/support
3072563|NCT02076945|Active Comparator|Healthy patients|Patients without diabetes and without peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus <19.01 mm2)
3072564|NCT02076945|Experimental|Diabetic patients without neuropathy|Patients with diabetes but without peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus <19.01 mm2)
3072565|NCT02076945|Experimental|Diabetic patients with neuropathy|Patients with diabetes and with peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus > 19.01 mm2)
3072566|NCT02076932|Active Comparator|Premenopausal women|The premenopausal women will be attending Spinning classes.
3072567|NCT02076932|Experimental|Postmenopausal Women|The postmenopausal women will be attending Spinning classes.
3072568|NCT02076919|Experimental|LHA510 Part 1|LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye as a single dose during Part 1
3072569|NCT02076919|Placebo Comparator|LHA510 Vehicle Part 1|Inactive ingredients, 1 drop instilled in the study eye as a single dose during Part 1
3072570|NCT02076919|Experimental|LHA510 Part 2|LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye once, twice, or three times daily for 7 days during Part 2
3072571|NCT02076919|Placebo Comparator|LHA510 Vehicle Part 2|Inactive ingredients, 1 drop instilled in the study eye once, twice, or 3 times daily for 7 days during Part 2
3072572|NCT02076906|Experimental|MR-HIFU|Magnetic Resonance High Intensity Focused Ultrasound (MR-HIFU) ablative therapy for children with recurrent or relapsed solid tumors.
3072573|NCT02076893|Active Comparator|Tramadol/gabapentin/ibuprofen|(A) Scheduled tramadol 1mg/kg Q6h [max. 50mg] for 5 days; plus tramadol 1mg/kg Q6h PRN [max. 50mg] for 5 days (B) Scheduled gabapentin 3 mg/kg [max 150 mg] Q6h for 5 days (C) PRN ibuprofen 10 mg/kg [max. 500 mg] Q6h PRN
3072574|NCT02076893|Placebo Comparator|Tramadol/placebo/ibuprofen|(A) Scheduled tramadol 1mg/kg Q6h [max. 50mg] for 5 days; plus tramadol 1mg/kg Q6h PRN [max. 50mg] for 5 days (B) Scheduled placebo of same volume Q6h for 5 days (C) PRN ibuprofen 10 mg/kg [max. 500 mg] Q6h PRN
3072575|NCT02076880|Experimental|Arm with caloric restriction|"Patients in this arm will have, during 7 days before surgery, a caloric restriction of 1000 kcal per day compared to the usual food intake. They will be hospitalized during this period.~Intervention: caloric restriction"
3072576|NCT02076880|Experimental|Arm without caloric restriction|"Patients in this arm will not have a caloric restriction before surgery.~Intervention: No caloric restriction"
3072577|NCT02076867|Experimental|Intensive Short Term Dynamic Psychotherapy (ISTDP)|
3072578|NCT02076867|Active Comparator|Medical Care As Usual (MCAU)|
3072579|NCT02076854|Experimental|Text-Message Intervention|Participants will undergo four weeks (in a randomized order) of receiving personalized motivational text-messages while receiving CBT for their eating disorder.
3072580|NCT02076854|No Intervention|No Text Message Phase|Participants will receive 4 randomized weeks of not receiving text messages while receiving CBT for their eating disorder.
3072581|NCT02076841||interferon beta-1a|30 μg intramuscularly once a week using an injection device (Avonex Pen).
3072582|NCT02076828|Experimental|Fe-OH-PM (Santafer® sp.)(Group II)|The patients in Group II were treated with Fe-OH-PM (Santafer® sp.), 6 mg/kg/day orally.
3072583|NCT02076828|Experimental|Fe-Zn (Ferro Zinc® sp.)(Group III)|The patients in Group III were treated with Fe-Zn (Ferro Zinc® sp.), 6 mg/kg/day orally
3072584|NCT02076828|Experimental|Fe-S (Ferro Sanol® sp.)(Group I)|The patients in Group I were treated with Ferro Sanol® sp., 6 mg/kg/day orally
3072585|NCT02076815|Experimental|Anagrelide retard|Anagrelide Retard prolonged-release formulation
3072586|NCT02076815|Active Comparator|Thromboreductin|Anagrelide immediate release formulation
3072587|NCT02076802||lifestyle counseling|physical exercises
3072588|NCT02076789||ICD generator replacement|Patients with standard indications to ICD generator replacement
3072589|NCT02076776|Active Comparator|Repetitive Task Practice (RTP)|This group focuses on RTP.
3072590|NCT02076776|Experimental|Voluntary cycling + RTP|This group involves one biking session and one RTP session three times per week for eight weeks.
3072591|NCT02076776|Experimental|Assisted cycling + RTP|This group involves one biking session and one RTP session three times per week for eight weeks.
3072592|NCT02076763||Acute intermittent porphyria|Patient diagnosed of AIP (by clinical, biochemical data and genetic confirmation of porphobilinogen deaminase (PBGD) gene mutation). The patient must have a severe AIP condition, with at least two hospitalizations during the previous year due to acute attacks (clinical manifestations of acute porphyria), or at least four hospitalizations during the previous year due to the requirement of hospital treatment administration (including day-hospital and home hospital program).
3072593|NCT02076750|Experimental|Vitamin D3 (cholecalciferol) 10,000 IU per 10 kg body weight|Vitamin D3 (cholecalciferol) will be administered orally at a dose of 10,000 IU per 10 kg body weight weekly for 6 consecutive weeks. The maximum dose will be 50,000 IU weekly for patients weighing 50 kg or greater.
3072594|NCT02076750|Active Comparator|Vitamin D3 (cholecalciferol) 5,000 IU per 10 kg body weight|Vitamin D3 (cholecalciferol) will be administered orally at a dose of 5,000 IU per 10 kg body weight weekly for 6 consecutive weeks. The maximum dose will be 25,000 IU weekly for patients weighing 50 kg or greater.
3072595|NCT02076737|Experimental|VEO|
3072596|NCT02076724|Experimental|Biological mesh (Strattice Firm)|Strattice Firm is inserted using inlay technique as reinforcement of the abdominal wall where the anterior rectus fascia has been excised.
3072597|NCT02076724|Experimental|Synthetic mesh (Prolene)|Prolene mesh is inserted using inlay technique as reinforcement of the abdominal wall where the anterior rectus fascia has been excised.
3072598|NCT02076711|Active Comparator|Active|Metoprololsuccinate
3072599|NCT02076711|Placebo Comparator|Placebo|Placebo
3072600|NCT02076698|Experimental|AN-DBS|Deep Brain Stimulation of the Anterior Nucleus of the thalamus
3072601|NCT02076698|Active Comparator|Usual treatment|Usual treatment of epilepsy including vagus nerve stimulation (VNS)
3072602|NCT02076685|Experimental|isoniazid rechalleng|When patients encountered hepatotoxicity during the anti-TB treatment, genotyping and pk study of INH would be performed and dose adjustment accordingly.
3072603|NCT02076672|Experimental|Artichoke WPC|Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
3072604|NCT02076659|Experimental|F8IL10 + MTX|"Ten cohorts of 3-6 RA patients will be treated at increasing doses per cohort of F8IL10 plus fixed doses of MTX and folic acid.~An additional 12 patients will be randomized (6+6) in a double blind, placebo controlled cohort with F8IL10 given at RD and placebo. In both arms, MTX will be administered as concomitant medication.~In all coohorts a stable dose of folic acid (5 mg) will be administered on Day 2."
3072605|NCT02076646|Experimental|Ph I: L19IL2 + DTIC|"Cohorts of 3-6 patients will receive escalating doses of L19-IL2 until MTD is reached.~L19-IL2 will be administered on days 1, 8 & 15 of each 21-day-cycle. Dacarbazine will be given at a fixed dose on day 1 of each 21-day cycle, 30 minutes after the end of the L19-IL2 infusion."
3072606|NCT02076646|Experimental|Ph II - ARM 1: L19IL2 at RD + DTIC|During the phase II part of this study, 60 patients with Stage IV M1a and M1b melanoma will be randomized in a 1:1 ratio: 30 patients assigned to Arm 1 will receive L19IL2 at the RD + DTIC at a fixed dose.
3072607|NCT02076646|Active Comparator|Ph II - ARM 2: DTIC monotherapy|During the phase II part of this study, 60 patients with Stage IV M1a and M1b melanoma will be randomized in a 1:1 ratio: 30 patients assigned to Arm 2 will receive DTIC at a fixed dose as monotherapy.
3072608|NCT02076633|Experimental|L19IL2 + L19TNF|One arm, intratumoral injections of 10 Mio IU of L19IL2 and 312 μg L19TNF. Weekly administration for all combined leasions
3072649|NCT02076399|Active Comparator|Fostamatinib Disodium 150mg|Fostamatinib Disodium tablet 150 mg PO bid (morning and evening) over the course of 24 weeks.
3097756|NCT01907256|Active Comparator|group A|stair step incisions
3072609|NCT02076620|Experimental|L19TNFα + doxorubicin|"Only one arm is specified. Patients will be treated in three cohorts with 3 different dosages of L19TNFα in combination with 60 mg/m2 of doxorubicin, according to the following study design:~cohort 1 --> 10.4 μg/kg L19TNFα + doxorubicin; cohort 2 --> 13 μg/kg L19TNFα + doxorubicin; cohort 3 --> 17 μg/kg L19TNFα + doxorubicin."
3072610|NCT02076607||Conservative Treatment|Eleven patients underwent conservative treatment with Brace.
3072611|NCT02076607||Surgical Treatment|Fourteen patients who underwent surgical treatment (arthrodesis).
3072612|NCT02076594|Experimental|Docetaxel & Oxaliplatin & Capecitabine|Patients will receive cycles every 3 weeks of Docetaxel (35 mg/ m2, intravenous at days 1 and 8 by 1-hour infusion)and Oxaliplatin (80 mg/ m2, intravenous at day 1 by 2-hour infusion) and Capecitabine (750 mg/ m2, oral tablets of 500 and 150 mg, x2 daily for 2 weeks)
3072613|NCT02076594|Experimental|Epirubicin & Oxaliplatin & Capecitabine|Patients will receive cycles every 3 weeks of Epirubicin (50 mg/ m2, intravenous on day 1 by 2-hour infusion)and Oxaliplatin (130 mg/ m2, intravenous on day 1 by 2-hour infusion) and Capecitabine (625 mg/ m2,oral tablets of 500 and 150 mg, x2 daily for 3 weeks)
3072614|NCT02076581||Stroke|Ten individuals with chronic stroke and limb spasticity will be recruited.
3072615|NCT02076581||Dystonia|Ten individuals with dystonic limbs and no spasticity will be recruited.
3072616|NCT02076581||Cerebral Palsy|Ten individuals with Cerebral palsy with the potential for a mix of dystonic and spastic abnormal tone in their affected limbs will be recruited.
3072617|NCT02076581||Neurologically normal|Thirty individuals without neurological injury that are age matched to the rest of the study population will be recruited.
3072618|NCT02076568|Experimental|Education - Diabetes and Partnership|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Partnership"
3072619|NCT02076568|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
3072620|NCT02076555|Experimental|Education - Diabetes and Social Issues|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Social Issues"
3072621|NCT02076555|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
3072622|NCT02076542|Experimental|Education - Diabetes and Sports|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Sports"
3072623|NCT02076542|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
3072624|NCT02076529|Experimental|Ramosetron 0.6mg|Ramosetron 0.6mg intravenous injection 30min before chemotherapy
3072625|NCT02076529|Experimental|Ramosetron 0.45mg|Ramosetron 0.45mg intravenous injection 30min before chemotherapy
3072626|NCT02076529|Active Comparator|Ramosetron 0.3mg|Ramosetron 0.3mg intravenous injection 30 min before chemotherapy
3072627|NCT02076516|Experimental|Drug-eluting stent: CORACTO®|Single arrm
3072628|NCT02076503|Experimental|PET-MR 18F-FACBC|
3072629|NCT02076490|Experimental|Software Supported Mirror Therapy|First experimental condition Physical/Occupational Therapy
3072630|NCT02076490|Experimental|Traditional mirror therapy|Second experimental condition Physical/Occupational Therapy
3072631|NCT02076490|Active Comparator|Sensomotor exercises without mirror|Control condition Physical/Occupational Therapy
3072632|NCT02076477|Experimental|Arm A|"Patients receive concurrent chemoradiotherapy at first。Patients also receive chemotherapy every 3-4 weeks for two cycles after concurrent chemoradiotherapy.~chemotherapy：（1） squamous cell carcinoma：Docetaxel 60mg/m2 d1+Cisplatin 25mg/m2 d1-3.（2）non squamous cell carcinoma： pemetrexed 500mg/m2 d1+Cisplatin 25mg/m2 d1-3."
3072633|NCT02076477|Active Comparator|Arm B|"Patients receive neoadjuvant chemotherapy every 3-4 weeks for two cycles at first.Patients then receive concurrent chemoradiotherapy after neoadjuvant chemotherapy.~chemotherapy：（1） squamous cell carcinoma：Docetaxel 60mg/m2 d1+Cisplatin 25mg/m2 d1-3.（2）non squamous cell carcinoma： pemetrexed 500mg/m2 d1+Cisplatin 25mg/m2 d1-3."
3072634|NCT02076464|Experimental|StudentBodies - Eating Disorders|Participants will participate in the StudentBodies - Eating Disorders program
3072635|NCT02076464|No Intervention|Usual Care|Participants will be referred to treatment per protocol at students' corresponding college's mental health services center
3072636|NCT02076451|Experimental|2 mg/kg DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
3072637|NCT02076451|Experimental|8 mg/kg DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
3072638|NCT02076451|Experimental|16 mg/kg of DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
3072639|NCT02076451|Experimental|24 mg/kg of DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
3072640|NCT02076438|Placebo Comparator|Placebo|Placebo capsules
3072641|NCT02076438|Experimental|Probiotics|Lactobacillus Rhamnosus GG 10 billion cfu BID
3072642|NCT02076425|Experimental|PCIT-ED|Parent-Child Interaction Therapy - Emotional Development (PCIT-ED) is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
3072643|NCT02076425|No Intervention|Wait List|No intervention while subjects wait for PCIT-ED in the second phase of the study.
3072644|NCT02076412|Active Comparator|Fostamatinib Disodium 100mg|Fostamatinib Disodium tablet 100 mg PO bid (morning and evening) over the course of 24 weeks
3072645|NCT02076412|Placebo Comparator|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
3072646|NCT02076412|Active Comparator|Fostamatinib Disodium 150mg|Fostamatinib Disodium tablet 150 mg PO bid (morning and evening) over the course of 24 weeks
3072647|NCT02076399|Active Comparator|Fostamatinib Disodium 100mg|Fostamatinib Disodium tablet 100 mg PO bid (morning and evening) over the course of 24 weeks.
3072650|NCT02076386||Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
3072651|NCT02076373|Experimental|recombinant human Erythropoietin (Epo)|"Epo 2000 U in normal saline per ml/kg of body weight 5 times intravenously, total dosage 10000 U per 5ml/kg.~In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication."
3072652|NCT02076373|Placebo Comparator|Control|"Placebo 1 ml normal saline/kg of body weight 5 times intravenously, total dosage 5 ml/kg.~In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication."
3072653|NCT02076360|Experimental|Preop Video|This arm will watch an instructional video in addition to their normal preoperative visit with the physician.
3072654|NCT02076360|No Intervention|No video|This arm will receive only the normal preoperative visit with the physician without the additional video
3072655|NCT02076347|Experimental|Office visit-based intervention|
3072656|NCT02076347|Experimental|Electronic message-based intervention|
3072657|NCT02076334|Active Comparator|Compression + normal garment|Far Infrared Fabric during exercise + Spandex at night
3072658|NCT02076334|Active Comparator|Normal Garment + Test garment at night|Spandex during exercise + Far Infrared Fabric at night
3072659|NCT02076334|Sham Comparator|Normal Garment + normal garment|Spandex during exercise + Spandex at night
3072660|NCT02076334|Active Comparator|Test garment + Test garment|Far Infrared Fabric during exercise + Far Infrared Fabric at night
3072661|NCT02076321|Other|Acetaminophen|control group
3072662|NCT02076321|Other|NSAID (Ibuprofen)|Study group
3072663|NCT02076308|Experimental|Electroacupuncture|Electroacupuncture and physical therapy
3072664|NCT02076308|Sham Comparator|Sham-electroacupuncture|Sham-electroacupuncture and physical therapy
3072665|NCT02076295||Parkinson's disease subjects|
3072666|NCT02076295||Normal control subjects|
3072667|NCT02076282||Healthy volunteers 1 MRI scan|"Healthy volunteers, recruited at the UMC Utrecht, older than 18, who do not meet the exclusion criteria of the department of Radiology.~Healthy volunteers will receive 1 MRI scan without contrast agent."
3072668|NCT02076282||Patients with stage III NSCLC, 1 MRI scan|"Patients with histopathologically or cytologically proven stage III NSCLC (excluding T4N0), older than 18, with a recent (≤ 21 days) GFR value available~Patients will receive 1 MRI scan with contrast agent."
3072669|NCT02076269|Other|Arm 1|Subjects will receive no treatment in this study. Each subject will attend the clinic on 2 occasions, initially for a screening visit and then for further assessments (Visit 1). Subjects will remain in the study for maximum 33 days from the screening visit to follow up.
3072670|NCT02076256|No Intervention|Control Group|
3072671|NCT02076256|Experimental|The helping relationships intervention program|The helping relationships intervention program will be implemented on the experimental group. And the control group will be provided with routine nursing care. Data will be collected at baseline, the sixth and the ninth month of the third year of study. Data will be analyzed using generalized estimating equation measures to evaluate the effect of the intervention program.
3072672|NCT02076243|Experimental|nab-paclitaxel|weekly dosed nab-paclitaxel chemotherapy (days 1, 8 , 15 of a 28 day cycle) administered as an I.V. infusion over approximately 30 minutes. Dosage is determined by weight and height of participant.
3072673|NCT02076230|Experimental|[14C] TH-302 (Label 1)|
3072674|NCT02076230|Experimental|[14C] TH-302 (Label 2)|
3072675|NCT02076217||unprotected intercourse 5-14 days prior to contraception|Women who initiate highly effective reversible contraception within 5-14 days of unprotected intercourse.
3072676|NCT02076204|Experimental|Home visiting|Home visiting group: Women will be randomized so that 60 percent can receive home visiting services and 40 percent are in the control group. Home visiting for low-income, pregnant women - whereby individualized in-home services (including direct education, assessments, and referrals to community resources) are provided to families - has been identified by the Strong Start initiative as one promising method for reaching women who are vulnerable to poor birth outcomes.
3072677|NCT02076204|No Intervention|Non-Home Visiting|Control group: As described above, women will be randomized so that 60 percent can receive home visiting services and 40 percent are in the control group.The home visiting program will provide control group families with referrals to other appropriate services in the community.
3072678|NCT02076191|Experimental|Myeloproliferative neoplasms|In phase I, increasing doses of ruxolitinib in combination with decitabine at a dose of 20 mg/m2 daily intravenously over 5 days. An initial dose of ruxolitinib of 10 mg orally twice daily is anticipated with planned, dose escalations of 15 mg orally twice daily, 25 mg orally twice daily and 50 mg orally twice daily. The dose can also be de-escalated to 5mg orally twice daily if dose limiting toxicities (DLTs) are observed at the initial 10mg dose. Patients will receive ruxolitinib as a single agent for the first 7 days followed by the administration of decitabine on day 8 for a total of 5 consecutive days. Patients will continue ruxolitinib at the assigned dose through the first cycle and may reduce the dose for specified toxicity beginning with the second cycle. Patients in Phase II will start at the recommended phase II dose (RPTD) of ruxolitinib in combination with decitabine at a dose of 20 mg/m2 daily intravenously over 5 days.
3072679|NCT02076178|Experimental|Arm 1|Participants will receive daily oral 744 (30 mg tablets) for 4 weeks, followed by a one week washout period followed by intra-muscular (IM) injections of 800 mg of 744 LA at three time points at 12 week intervals as: Week 5, Week 17, and Week 29
3072680|NCT02076178|Experimental|Arm 2|Participants will receive daily oral matching placebo for 4 weeks, followed by a one week washout period followed by intra-muscular (IM) injections of saline at three time points at 12 week intervals as: Week 5, Week 17, and Week 29
3072681|NCT02076165|Experimental|ABC-I|Participants will participate in 5 individual sessions with a trained instructor.
3072682|NCT02076165|Active Comparator|CBT-I|Participants will participate in 5 individual sessions with a trained instructor.
3072739|NCT02075788|Active Comparator|Corn based products (porridge etc.)|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
3072740|NCT02075775||MOON Shoulder Instability|Patients indicated for Shoulder Instability surgery
3072683|NCT02076152|Experimental|FMISO PET & MRI Group 1|"Bevacizumab:~-- Bevacizumab will be administered at a dose of 10 mg/kg i.v. every 14 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).~FMISO PET Scan~FMISO will be intravenously injected at a dose of 3.7 MBq/kg (0.1 mCi/kg) (maximum 260 MBq, 7 mCi) in < 15 mL. The IV will remain in place for injection of the gadolinium for the MRI scan. There will be one injection of FMISO in the PET protocol. Approximately 90 minutes after the injection, the PET scan will begin.~The PET scan will be approximately 60-75 minutes.~MRI -- Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
3072684|NCT02076152|Experimental|FMISO PET & MRI Group 2|"Bevacizumab + CCNU:~Bevacizumab will be administered at a dose of 10 mg/kg i.v. every 14 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).~CCNU will be administered at a dose of 110 mg/m2 every 42 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).~-FMISO PET Scan~FMISO will be intravenously injected at a dose of 3.7 MBq/kg (0.1 mCi/kg) (maximum 260 MBq, 7 mCi) in < 15 mL. The IV will remain in place for injection of the gadolinium for the MRI scan. There will be one injection of FMISO in the PET protocol. Approximately 90 minutes after the injection, the PET scan will begin.~The PET scan will be approximately 60-75 minutes.~- MRI~Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
3072685|NCT02076139|Experimental|Nyaditum resae® 10e4|The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e4 Colony-forming units (CFUs) of Nyaditum resae®.
3072686|NCT02076139|Experimental|Nyaditum resae® 10e5|The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e5 CFUs of Nyaditum resae®.
3072687|NCT02076139|Placebo Comparator|Placebo|The subjects will receive 1 drinkable vial (4mL) of distilled water per day during 14 days.
3072688|NCT02076126||Gastric aspirate|L/S ratio on the gastric aspirates are retrospectively compared with the possible development of RDS
3072689|NCT02076126||Hypopharyngeal secretion|L/S ratio on the hypopharyngeal secretions are retrospectively compared with the possible development of RDS
3072690|NCT02076113|Active Comparator|Ventral|Ventral Decompression with Fusion
3072691|NCT02076113|Active Comparator|Dorsal|Dorsal Decompression with Fusion or Dorsal Laminoplasty
3072692|NCT02076100|Experimental|Part I GT3 Participants|Participants receive ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
3072693|NCT02076100|Experimental|Part II GT1a Participants|Participants receive ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
3072694|NCT02076100|Experimental|Part III GT2b Participants|Participants receive ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
3072695|NCT02076087||Normal Weight (BMI: 18.5-24.9 kg/m²)|Liposuction/lipectomy
3072696|NCT02076087||Overweight (BMI: 25.0-29.9 kg/m²)|Liposuction/lipectomy
3072697|NCT02076087||Obese (BMI: >30.0kg/m²)|Liposuction/lipectomy
3072698|NCT02076074|Experimental|Treatment (HG-PBI)|Patients undergo single fraction high gradient-partial breast irradiation within 8 weeks after partial mastectomy.
3072699|NCT02076061||GOLD stage I|
3072700|NCT02076061||GOLD Stage II|
3072701|NCT02076061||GOLD Stage III|
3072702|NCT02076061||GOLD Stage IV|
3072703|NCT02076061||Smokers/ex-smokers w/o COPD|
3072704|NCT02076061||non-Smokers w/o COPD|
3072705|NCT02076048||Previous LCPUFA Supplementation|Children between the ages of 7 and 10 that were previously enrolled in a study of supplemented LCPUFA formula.
3072706|NCT02076022|Active Comparator|Standard fat grafting|Once harvested the aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
3072707|NCT02076022|Experimental|Enhanced Fat Grafting|"Approximately 60 cc of lipoaspirate will be collected from the subject to be processed with the Tissue Genesis Cell Isolation System™ (CIS) to yield approximately 35cc of Stromal Vascular Fraction (SVF).Once harvested the aspirated fat will then be divided into two portions: one portion will be processed as standard graft material (standard/control graft) while the other portion will be used in a processing step that concentrates the adipose stromal cells.~The aspirated fat processed as standard graft material will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and allowed to decant before separating the fluid and oil layers from the fat tissue fractions, and transferred into 50 ml syringes. This graft preparation will be performed in the operating room."
3072708|NCT02076009|Experimental|Daratumumab + lenalidomide + dexamethasone|During each 28-day treatment cycle, participants will receive daratumumab, lenalidomide, and dexamethasone.
3072709|NCT02076009|Active Comparator|Lenalidomide + dexamethasone|During each 28-day treatment cycle, participants will receive lenalidomide and dexamethasone.
3072710|NCT02076009|Active Comparator|Daratumumab monotherapy|During each 28-day treatment cycle, participants will receive daratumumab alone in daratumumab monotherapy group.
3072711|NCT02075996||Pomalidomide following lenalidomide|75 patients with pomalidomide directly following lenalidomide treatment
3072712|NCT02075996||Pomalidomide following other therapy|75 patients with pomalidomide following any other prior therapy. This includes lenalidomide in earlier lines than the most recent line.
3072713|NCT02075983|Experimental|Group 3 (IM+EP)|Group 3 will receive 12.0mg of vaccine over 12 weeks administered with EP using the Trigid Ichor device. We expect to see the greatest proportion of individuals making T cell and antigen specific antibody responses responses in this group. Depending on the magnitude of the effects, the differences between group 3 and the other groups may be statistically significant.
3072714|NCT02075983|Experimental|Group 2 (IM+TC)|Group 2 will also receive 13.2mg of vaccine over 12 weeks, with 12.0mg given IM and 1.2mg TC. We are interested in the impact of TC relative to ID vaccination on the ratio between HIV-specific T-cell responses, and whether or not CD8+ Tcells are favoured by this route.
3072741|NCT02075762|Active Comparator|Transbronchial biopsy|S-TBBx will be performed using standard biopsy forceps (Boston Scientific, Natick, MA) - 2.0mm diameter.
3072715|NCT02075983|Active Comparator|Group 1 (IM+ID)|"Group 1 will serve as the reference arm and this group will receive a total dose of 13.2mg vaccine over 12 weeks with 12.0mg given IM and 1.2mg ID. This is 7.2mg more than has been given previously to healthy individuals and 6.2 mg more than given to those HIV-infected but similar doses of HIV DNA vaccines have been given in other trials with no serious consequences."
3072716|NCT02075970|Experimental|Epoetin Alpha study 1|"Epoetin Alpha Tthe number of separate doses (per kg) to be given over 4 weeks by day of age will not exceed 10. These will be administered as follows: day of life (DOL) 2 (1200 U), DOL 4 (600 U), DOL 5 (600 U), DOL 6 (600U), DOL 7 (600 U), DOL 9 (600 U), DOL 14 (600 U), DOL 15 (600 U), DOL 16 (1200 U), and DOL 28 (600 U). The greatest dose in any 1 wk period is 3600 U.~Infant study 1 Drug Intervention: all infants will be treated with Epoetin Alpha during the first four weeks of life to provide data for determining: 1) the PK/PD model determined optimized Epoetin Alpha dosing schedule; and 2) clinical and laboratory covariates predictive of which infants are good and poor Epoetin Alpha responder."
3072717|NCT02075970|Placebo Comparator|Epoetin Alpha study 2|"Epoetin Alpha dosing schedule will be determined based on the results of Infant Study 1.~Infant Study 2 is a randomized, masked study to test the hypothesis that optimized Epoetin Alpha treatment of VLBW infants predicted to be good responders will result in the elimination of RBCTx relative to poor responders.~Infant Study 2 in Years 4 and 5 will make use of the knowledge acquired in Infant Study 1 to test the central hypothesis that RBCTX can be eliminated in the majority of good Epoetin Alpha responders by optimal administration of Epoetin Alpha, but only marginal reductions in RBCTx will occur in the poor Epoetin Alpha responders."
3072718|NCT02075970|Experimental|Biotinylated red blood cells|Individual fetal RBC lifespans will be determined by administering biotinylated red blood cells, both autologous and allogeneic, simultaneously. Left over red blood cells are examined to determine red cell survival.
3072719|NCT02075944|Experimental|High intensity aerobic exercise|30 minutes of high intensity aerobic exercise 3 times a weeks for 9 weeks - incorporation interval training
3072720|NCT02075944|Experimental|Low intensity aerobic exercise|30 minutes of low intensity aerobic exercise 3 times a weeks for 9 weeks
3072721|NCT02075944|No Intervention|Control|No intervention. Participants are told not to make any changes in their everyday life
3072722|NCT02075931|Experimental|Physical Activity Feedback|The physical activity feedback intervention will involve real-time physical activity monitoring using a device to provide activity feedback directly to patients in combination with patient group meetings held monthly during the 12 week intervention for the purposes of mutual support in attaining physical activity goals.
3072723|NCT02075931|Active Comparator|Control|The control represents the current standard of care post total knee arthroplasty.
3072724|NCT02075905||Barrett's Esophagus-Low Grade Dysplasia|Subjects enrolled who have Barrett's Esophagus with low grade dysplasia. No research intervention is administered.
3072725|NCT02075905||Barrett's Esophagus-no dysplasia|Subjects enrolled with Barrett's Esophagus and no dysplasia. No research intervention is administered.
3072726|NCT02075892|Active Comparator|Mushroom Blend|4 grams daily; oral; 7 and 21 days
3072727|NCT02075892|Placebo Comparator|Placebo|4 grams maltodextrin, oral, 7 and 21 days
3072728|NCT02075879|Experimental|Nurse-led interviewing|Participants in experimental arm received the in-center exercise training (20 minutes) before hemodialysis sessions weekly for 6 weeks and were instructed to perform exercise at home. They were additionally instructed to start walking or brisk walking at low duration and gradually progress to a maximum of 30 minutes daily per week. To facilitate exercise progression, the nurse case managers discussed exercise benefits, explored exercise barriers and developed mutual goals with patients. The nurse motivated them and checked the exercise behaviors to ensure adherence to the recommended exercise regime. The nurse case managers interviewed the patients weekly for six weeks and biweekly for another six weeks.
3072729|NCT02075879|Active Comparator|Brief group exercise|Participants received the in-center exercise training (20 minutes) before hemodialysis sessions weekly for 6 weeks and were instructed to perform exercise at home. The in-center training was conducted by the researcher with a group of four-to six participants focusing on flexibility and strengthening exercise only.
3072730|NCT02075853||Bovine Xenograft|Patients in this group received a bovine xenograft in their Evans calcaneal lengthening procedure. Up until April 2014, patients were randomized into receiving the bovine graft or allograft. However, the bovine xenograft will no longer be manufactured, so no future patients will receive the bovine xenograft during the procedure.
3072731|NCT02075853||Iliac Crest Allograft|Patients in this group received an iliac crest cadaver allograft (bicortical or tricortical) in their Evans calcaneal lengthening procedure. Up until April 2014, patients were randomized into receiving the bovine graft or allograft. However, the bovine xenograft will no longer be manufactured, so all future patients will receive the allograft during the procedure.
3072732|NCT02075840|Experimental|Alectinib|Participants will receive alectinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
3072733|NCT02075840|Active Comparator|Crizotinib|Participants will receive crizotinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
3072734|NCT02075827|Active Comparator|Problem-solving video game|Playing the video game 'Little Big Planet'
3072735|NCT02075827|Experimental|Competitive video game|Playing the video game 'Call of Duty'
3072736|NCT02075801||Defective amalgam restorations|"Treatment Groups:~A. Sealing of amalgam margin defects: Defective areas were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Sealant, 3MESPE)was applied over the defective area. The sealant was polymerized with a photo curing unit (Curing-Light 2500, 3MESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~B. Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr, Orange, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~C. Control Group: The defective restorations did not receive any treatment."
3072737|NCT02075788|Placebo Comparator|Commercial white bread|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
3072738|NCT02075788|Experimental|Millet based products (porridge etc.)|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
3072854|NCT02075047|Placebo Comparator|1|
3072855|NCT02075047|Experimental|ziprasidone|
3072742|NCT02075762|Active Comparator|Cryoprobe biopsy|C-TBBx will be performed using the cryoprobe (ERBE, Tubingen, Germany) -1.9 mm diameter, 78cm in length. This cryoprobe is routinely used in the bronchoscopy suite for carcinoma-TBBX; therefore it is a technique already employed by the interventional pulmonologists who are familiar with its use.
3072743|NCT02075762|Active Comparator|VATS biopsy|Once the biopsies are obtained by the interventional pulmonologist, the thoracic surgeon will perform VATS biopsy. Following their procedure, subjects will be monitored in the post-anesthesia care unit as per standard of care. As part of their ongoing follow-up care, all subjects will be monitored for any adverse events that may have resulted from either the surgical or bronchoscopic procedure, specifically bleeding or pneumothorax.
3072744|NCT02075749|Active Comparator|triamcinolone acetonide mucoadhesive|30 patients received triamcinolone acetonide mucoadhesive films
3072745|NCT02075749|Experimental|Licorice|30 patients received licorice mucoadhesive films
3072746|NCT02075749|Placebo Comparator|Mucoadhesive film|30 patients received mucoadhesive films without any drug ingredients
3072747|NCT02075736|Experimental|KTP laser|device
3072748|NCT02075736|Active Comparator|TUR-P|device
3072749|NCT02075723|Experimental|Overfeeding + sleep restriction|overfeeding condition (130 % of energy requirements ) + 6 days of sleep restriction (4 hours per night)
3072750|NCT02075723|Experimental|Overfeeding + normal sleep duration|overfeeding condition (130 % of energy requirements ) + 6 days of normal sleep duration (8 hours per night)
3072751|NCT02075710|Experimental|High sugar/meal feed|Diet high in simple sugar fed as two large meals daily
3072752|NCT02075710|Experimental|High sugar/nibble|Diet high in simple sugar fed as 8 small meals daily
3072753|NCT02075710|Experimental|High fat/meal feed|Diet high in fat fed as two large meals daily
3072754|NCT02075710|Experimental|High fat/nibble|Diet high in fat fed as 8 small meals daily
3072755|NCT02075710|Experimental|High sugar/3 meals a day|Diet high in simple sugar fed as 3 meals a day
3072756|NCT02075710|Experimental|High fat/ 3 meals a day|Diet high in fat fed as 3 meals a day
3072757|NCT02075697||Biologic drugs|Drug data include biologic therapy (including infliximab (INF), etanercept (ET), efalizumab (EFA), adalimumab (ADA), and ustekinumab (UTK).
3072758|NCT02075697||Classic systemic therapy|Non-biological systemic treatment (methotrexate, cyclosporine and acitretin) Phototherapy was accepted as systemic therapy only in the small group of patients retrospectively included(PUVA, UVB 311).
3072759|NCT02075684|Other|In-office, Percutaneous Renal Biopsy|
3072760|NCT02075671|Experimental|Levulan and Blu-U Light|Entire face treated with 20% Aminolevulinic Acid (Levulan) and Blu-U light
3072761|NCT02075671|Sham Comparator|Vehicle and Blu-U Light|Entire face treated with vehicle substance only and Blu-U light
3072762|NCT02075671|Placebo Comparator|Vehicle Only|Entire face treated with vehicle substance only
3072763|NCT02075658|Other|Conventional Insufflation and Trocars|Subjects enrolled in this study arm will have their procedure performed using either the conventional insufflator and trocars. This system have been cleared for use by the FDA's 510 (k)process and are currently employed in clinical practice, including at UC Irvine Medical Center.
3072764|NCT02075658|Active Comparator|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port).
3072765|NCT02075645|Other|team training|"Intervention: team training course. A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the pre-course team performance and simulation #4 will be the post-course performance."
3072766|NCT02075632|Experimental|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% will be applied by the participants topically on the affected areas per label instructions for 14 days.
3072767|NCT02075619|Experimental|Sequence 1|Four subjects (2 Chinese and 2 Caucasian) will receive one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 1; one GSK3074477 Fixed dose combination (FDC) formulation-1 tablet in Period 2 and one GSK3074477 FDC formulation-2 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
3072768|NCT02075619|Experimental|Sequence 2|Four subjects (2 Chinese and 2 Caucasian) will receive one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 1; one GSK3074477 FDC formulation-2 tablet in Period 2 and one GSK3074477 FDC formulation-1 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
3072769|NCT02075619|Experimental|Sequence 3|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-1 tablet in Period 1, one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 2; and one GSK3074477 FDC formulation-2 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
3072770|NCT02075619|Experimental|Sequence 4|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-1 tablet in Period 1; one GSK3074477 FDC formulation-2 tablet in Period 2; and one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
3072771|NCT02075619|Experimental|Sequence 5|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-2 tablet in Period 1; one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 2; and one GSK3074477 FDC formulation-1 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
3072772|NCT02075619|Experimental|Sequence 6|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-2 tablet in Period 1; one GSK3074477 FDC formulation-1 tablet in Period 2; and one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
3072773|NCT02075606|Experimental|Somatuline Autogel®|Somatuline Autogel® to treat Functioning Midgut NeuroEndocrine Tumours (NET)
3072774|NCT02075593|Experimental|DTG/ABC/3TC|All subjects will be administered DTG 50 milligrams (mg)/ABC 600 mg/3TC 300 mg FDC tablet once daily, with or without food.
3072948|NCT02074384|Other|Clinicians|Clinicians completing study visits.
3072775|NCT02075580|Experimental|psychological support|Arm A will undergo psychological support and standard care prior and post TIVAD (Totally Implantable Venous Access Devices) insertion Arm B will undergo standard care prior and post TIVAD insertion
3072776|NCT02075580|No Intervention|standard care|this arm does not receive psychological support before and after Totally Implantable Venous Access Devices positioning
3072777|NCT02075567|Experimental|Therapy adaption T1DM|
3072778|NCT02075554|Other|CALIBER|1 or 2 levels of DDD between L2 and S1, treated with transforaminal interbody fusion
3072779|NCT02075541|Experimental|10-AS01E group|Subjects in this group will receive the investigational NTHi vaccine.
3072780|NCT02075541|Placebo Comparator|Control group|Subjects in this group will receive placebo.
3072781|NCT02075528|Experimental|Paliperidone Extended Release (ER)|The participants were assigned to receive a fixed dosage of 9 mg/d of paliperidone ER for the first 2 weeks. The paliperidone ER dosage was adjusted flexibly after 2 weeks according to the clinical judgment of the physicians in charge.
3072782|NCT02075515|Experimental|HZ/su Lot A|Subjects will receive Lot A of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
3072783|NCT02075515|Experimental|HZ/su Lot B|Subjects will receive Lot B of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
3072784|NCT02075515|Experimental|HZ/su Lot C|Subjects will receive Lot C of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
3072785|NCT02075502|Experimental|Exercise therapy|Claudication, no peripheral revasc
3072786|NCT02075502|Placebo Comparator|Exercise advice|Claudication, no peripheral revasc
3072787|NCT02075502|Experimental|lower extremity ET, exercise therapy|
3072788|NCT02075502|Placebo Comparator|lower extremity ET, exercise advice|
3072789|NCT02075502|Experimental|Peripheral open intervention, exercise therapy|
3072790|NCT02075502|Placebo Comparator|Peripheral open intervention, exercise advice|
3072791|NCT02075489|Experimental|Acupressure|This group of patients will serve as the experimental group and receive acupressure treatment in addition to routine clinical care. Acupressure will be provided 40 mins/day, 2 days/week for 6 weeks (total of 12 sessions).
3072792|NCT02075489|Active Comparator|Reiki|This group of participants will serve as control group and receive Reiki treatment in addition to routine clinical care. Reiki will be provided 40 mins/day, 2 days/week for 6 weeks (total of 12 sessions).
3072793|NCT02075476|Active Comparator|Hemiarthroplasty Global Fx(DePuy)|in this technique the prosthesis is implanted in similar approach to shoulder anatomy
3072794|NCT02075476|Experimental|reverse arthroplasty Delta Xtent(DePuy)|In this technique the prosthesis is implanted in the inverse mode of shoulder anatomy
3072795|NCT02075463|Experimental|GSK1278863 Arm|Subjects will receive a fixed starting dose of 12 milligrams (mg) GSK1278863 once daily (QD) orally for first 4 weeks. From Week 4 the dose of GSK1278863 will be adjusted based on Hgb levels and evaluated every 4 weeks until Week 16. This starting dose may be changed during the study if there is an early indication of either lack of efficacy or the rate of rise in Hgb is too rapid
3072796|NCT02075450|No Intervention|Arm 1|Practice CPRcard lights not visible, Practice Just in Time Video - not provided to study participants, CPRcard lights not visible during study scenario
3072797|NCT02075450|Experimental|Arm 2|Practice CPRcard light- not visible, Practice CPR Just in Time Video- not provided, CPRcard light visible during study scenario.
3072798|NCT02075450|Experimental|Arm 3|Practice CPRcard light- visible, Practice Just in Time Video- watched by study participant, CPRcard light- not visible during study scenario.
3072799|NCT02075450|Experimental|Arm # 4|Practice CPRcard visible and the study participants watch the Just in Time Video,CPRcard light visible during study scenario
3072800|NCT02075437|Experimental|Functional Abdominal Pain (FAP)|To access (FAP) subjects will participate in: 10 therapy sessions; and the following treatments: 1) identify strategies with unique patterns of neural circuit maturation associated with early visceral pain on the gut-brain axis: 2) adapt acceptance-based behavioral strategies used to address psychopathology in older children to younger children; and 3) incorporate caregivers as role models and facilitators based on attachment research.
3072801|NCT02075424|Experimental|salivery sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.~Only one sampling will occur to doctors who are assigned to a single workstation.~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call For each participant, a serie of control-samples will be taken during a day off and during a security break."
3072802|NCT02075411|Active Comparator|Males Single shot peripheral nerve block|a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
3072803|NCT02075411|Active Comparator|Females Single shot peripheral nerve block|a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
3072804|NCT02075411|Active Comparator|Males Continuous peripheral neural infusion|The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
3072805|NCT02075411|Active Comparator|Females Continuous peripheral neural infusion|The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
3072806|NCT02075385|Experimental|Speech pathology therapy|Pre, during and pos-treatment swallowing exercises.
3072807|NCT02075385|No Intervention|Control group|These patients will not receive speech pathology therapy.
3072808|NCT02075372||Data registration of CTO-PCI patients|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will register data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry.
3072809|NCT02075359||Preschoolers|Preschoolers, ages 3 to 5
3072810|NCT02075333|Active Comparator|Sucrose (50g)|A 381g blackcurrant drink (cordial and water) providing 50g of sucrose
3072811|NCT02075333|Placebo Comparator|Sucralose (0.92 g sugars)|A 381g blackcurrant drink (cordial and water) providing 0.92g of natural sugars
3072812|NCT02075320|Experimental|Stationary Digital Chest Tomosynthesis|All patients will be included in the experimental group.
3072813|NCT02075307|Experimental|Blueberry Powder|The intervention group will receive the Blueberry freeze-dried powder equivalent to 1 cup of whole Blueberries twice a day for 8 weeks (i.e. 2 cups/day).
3072814|NCT02075307|Placebo Comparator|Placebo Powder|The placebo group will receive placebo powder in the same amounts for the same duration.
3072815|NCT02075294||youth|"＜45years~Adefovir dipivoxil or Entecavir~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.~Participants who received 0.5mg ETV more than 3 years will be recruited."
3072816|NCT02075294||middle age|"≥45years and＜65years~Adefovir dipivoxil or Entecavir~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.~Participants who received 0.5mg ETV more than 3 years will be recruited."
3072817|NCT02075294||elderly|"≥65 years~Adefovir dipivoxil or Entecavir~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.~Participants who received 0.5mg ETV more than 3 years will be recruited."
3072818|NCT02075281|Experimental|HM11260C|HM11260C 4 mg weekly sc injection
3072819|NCT02075281|Placebo Comparator|Placebo|Placebo weekly sc injection
3072820|NCT02075281|Experimental|HM11260C 6 mg/week|HM11260C 6 mg weekly sc injection
3072821|NCT02075281|Experimental|HM11260C 6 mg/biweekly|HM11260C 6 mg biweekly sc injection
3072822|NCT02075281|Experimental|HM11260C 8 mg/biweekly|HM11260C 8 mg biweekly sc injection
3072823|NCT02075268|Other|10 mg, 30 mg|To compare PKPD of prasugrel 10 or 30 mg, 4 subjects will be given 10 mg of prasugrel (one tablet of 10 mg of Effient) on day 1 as a single oral dose and another 4 subjects will be given 30 mg of prasugrel (3 tablets of 10 mg of Effient) on day 1 as a single oral dose.
3072824|NCT02075255|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously every 4 weeks
3072825|NCT02075255|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
3072826|NCT02075255|Placebo Comparator|Placebo|Placebo administered subcutaneously every 4 weeks
3072827|NCT02075242|Active Comparator|tacrolimus|Control group: Tacrolimus + Corticosteroid (dual oral therapy)
3072828|NCT02075242|Experimental|Mycophenolate Mofetil|Tacrolimus + Mycophenolate Mofetil+Corticosteroid (triple oral therapy)
3072829|NCT02075229||Group A|45 participants with AzBio baseline sentence scores between 41 - 50%
3072830|NCT02075229||Group B|45 participants with AzBio baseline sentence scores between 51 - 60%.
3072831|NCT02075216|Experimental|Myoblasts Preparation|"Myoblast Preparation, Myoblast Transplantation & Neonatal Cystourethroscope Injection~Approximately 8 to 10 gm muscle will be obtained from the rectus abdominis. Patient muscle fibers will be isolated using the fiber explant technique described by Rosenblatt et al, with some modifications. Culture conditions will be mainly adapted from Rando and Blau.~After 22 days of culture myoblasts will be harvested by trypsinization and incubated in serum-free medium during the last 2 hours before injection. Immediately before injection the cell pellet will be resuspended in autologous serum and/ or platelet rich plasma (PRP)."
3072832|NCT02075203|Experimental|AERAS-404 (15 mcgH4/500 nmol IC31)|2 doses on Study Days 0 and 56
3072833|NCT02075203|Active Comparator|Bacillus Calmette-Guérin (BCG)|1 Dose on Study Day 0
3072834|NCT02075203|Placebo Comparator|Placebo|2 Doses on Study Days 0 and 56
3072835|NCT02075190|Other|Computerized intervention|Computerized intervention delivered online
3072836|NCT02075164|Experimental|Fructose|Volunteers will be challenged with oral 150g Fructose per day for 56 days.
3072837|NCT02075164|Experimental|Glucose|Volunteers will be challenged with oral 167g Fructose per day for 56 days.
3072838|NCT02075164|No Intervention|NAFLD|Patients with confirmed simple fatty liver will be compared at baseline with other arms.
3072839|NCT02075164|No Intervention|NASH|Patients with confirmed non-alcoholic steatohepatitis will be compared at baseline with other arms.
3072840|NCT02075151|Other|Bronchial Thermoplasty|Bronchial thermoplasty
3072841|NCT02075138||Grass-Induced Rhinoconjunctivitis Subjects|
3072842|NCT02075125|Experimental|Prasugrel 60 mg|Prasugrel 60 mg as loading dose and followed by 10 mg/day as maintenance dose
3072843|NCT02075125|Experimental|Ticagrelor 180 mg|Ticagrelor 180 mg as loading dose and followed by 90 mg twice a day as maintenance dose
3072844|NCT02075112|Experimental|Soy isoflavone|Study treatment: Soy isoflavone in combination with radiation therapy & cisplatin
3072845|NCT02075099|Experimental|Isotonic drink|"Predonation hydratation with 500 ml of isotonic drink, to drinking in immediate predonation.~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
3072846|NCT02075099|Experimental|mineral water|"Predonation hydratation with 500 ml of mineral water to drinking in immediate predonation whole blood.~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
3072847|NCT02075099|Active Comparator|Advices|"Advices of drinking water or fruit juice glass(es) in immediate predonation whole blood.~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
3072848|NCT02075086|Experimental|Chemotherapy treatment|Chemotherapy treatment with Xelox or Xeliri and bevacizumab
3072849|NCT02075073|Experimental|SB3|SB3, single dose of 6 mg/kg via intravenous infusion (study drug)
3072850|NCT02075073|Active Comparator|EU sourced Herceptin®|EU sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
3072851|NCT02075073|Active Comparator|US sourced Herceptin®|US sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
3072852|NCT02075060|Experimental|IPOI|One arm with pre-operative instillation of mitomycine 1h before TURB (IPOI : Instillation pré-opératoire immédiate),
3072853|NCT02075060|Active Comparator|IPOP|One arm with early post-operative instillation of mitomycine within 24 hours (IPOP : Instillation Post Opératoire Précoce).
3072856|NCT02075034|Experimental|560 mg morning/280 mg afternoon|Two 280 mg capsules of rigosertib will be taken in the morning and one 280 mg capsule of rigosertib will be taken in the afternoon.
3072857|NCT02075034|Experimental|420 mg morning and afternon|One 280 mg capsule and two 70 mg capsules of rigosertib will be taken in the morning and one 280 mg capsule and two 70 mg capsules of rigosertib will be taken in the afternoon.
3072858|NCT02075034|Experimental|280 mg TID|One 280 mg capsule of rigosertib will be taken in the morning, one 280 mg capsule of rigosertib will be taken at mid-day, and one 280 mg capsule of rigosertib will be taken in the afternoon.
3072859|NCT02075021|Experimental|lenalidomide and nab-paclitaxel|100 mg/m^2 of Abraxane weekly for 3 weeks and 10 mg Revlimid daily for 21 days, with a dose escalation for Revlimid to 15 mg and to 25 mg. One cycle is 4 weeks. Dose de-escalations will also be performed for both drugs as necessary. Patients will be treated until disease progression.
3072860|NCT02075008|Experimental|QGE031 every 4 weeks (q4w)|QGE031 240 mg subcutaneously q4w
3072861|NCT02074995|Experimental|BVS857 Grp 1A open label|0.03 mg/kg of BVS857intravenously in open label manner
3072862|NCT02074995|Experimental|BVS857 Group 1B/1C, 2, 3, 4 Double Blind|
3072863|NCT02074995|Placebo Comparator|Placebo Group 1B/1C, 2, 3, 4|
3072864|NCT02074982|Experimental|AIN457 300 mg|patients received AIN457 (secukinumab) 300 mg (two secukinumab 150 mg injections) s.c. (subcutaneously) once every week at weeks 0, 1,2,3, followed by monthly dosing starting at week 4 to week 48 inclusive
3072865|NCT02074982|Active Comparator|Ustekinumab|patients received ustekinumab 45/90 mg (weight depended, according to label) s.c. (subcutaneously) and/or placebo secukinumab injections once every week at weeks 0,1,2, and 3 followed by monthly dosing starting at week 4 to week 48 inclusive
3072866|NCT02074969|Active Comparator|Gamma Nail 3|Gamma Nail 3 Stryker.
3072867|NCT02074969|Active Comparator|PFNA|PFNA Antirotation Synthes
3072868|NCT02074956|Experimental|Cohort 1 AERAS-404|"H4 Antigen at 5 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56"
3072869|NCT02074956|Experimental|Cohort 2 AERAS-404|"H4 Antigen at 15 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56"
3072870|NCT02074956|Experimental|Cohort 3 AERAS-404|"H4 Antigen at 50 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56"
3072871|NCT02074956|Experimental|Cohort 4 AERAS-404|"H4 Antigen at 150 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56"
3072872|NCT02074956|Experimental|Cohort 5 AERAS-404|"H4 Antigen at 5 ug or 15 ug IC31 Adjuvant 100 nmol Placebo - sterile buffer~2 doses at Study days 0 and 56"
3072873|NCT02074943|Experimental|PRP/Saline|Same patient will be injected with PRP and normal saline. Each one will be inject on half head.
3072874|NCT02074930|Other|Single Arm|
3072875|NCT02074917|Experimental|AM anatomical ACL reconstruction|Femoral and tibial tunnels performed in anteromedial footprint of ACL reconstruction
3072876|NCT02074917|Experimental|CENTRAL anatomical ACL reconstruction|Femoral and tibial tunnels performed in the center of ACL footprint
3072877|NCT02074904|Experimental|Topiramate|up to 200mg/day orally (over 8 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
3072878|NCT02074904|Placebo Comparator|Placebo|placebo
3072879|NCT02074891||Persons prescribed PrEP|adults prescribed daily oral antiretroviral preexposure prophylaxis (PrEP) with the coformulated TDF/FTC to reduce HIV acquisition.
3072880|NCT02074878|Experimental|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200mg, twice daily and Sunitinib 25.0mg once daily
3072881|NCT02074878|Experimental|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
3072882|NCT02074878|Experimental|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
3072883|NCT02074865||newborns|
3072884|NCT02074852||Immediate catheter removal|The catheter was removed immediately after the CS
3072885|NCT02074852||Delayed catheter removal|The catheter was removed 12 hours postoperatively
3072886|NCT02074839|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle.
3072887|NCT02074826||Atrial fibrillation|"Genotyping of the AF associated variants~Measurement of the amount of left atrial fibrosis"
3072888|NCT02074813|No Intervention|Standard|conventional pulmonary rehabilitation
3072889|NCT02074813|Experimental|Inspiratory muscle training|Inspiratory muscle training associated with a conventional pulmonary rehabilitation
3072890|NCT02074800|Experimental|Part 1|Participants will receive either 1.4 or 2.8 mg/kg of either Sp2/0-derived CNTO 328 or CHO-derived CNTO 328 or placebo.
3072891|NCT02074800|Experimental|Part 2|Participants will receive 1.4 mg/kg of either Sp2/0-derived or CHO-derived CNTO 328.
3072892|NCT02074787||Adult burn injuries|Adult patients with burns injuries attending the regional burns unit at Chelsea & Westminster hospital between 48 and 72 hours post burn will be invited to take part in the study at the time of presentation to the unit.
3072893|NCT02074774|Experimental|IntellO2|Automated control of FiO2
3072894|NCT02074774|Active Comparator|Manual|Manual control of FiO2
3072895|NCT02074761||SImmetry Implant|Subjects who are indicated for the SImmetry device and meet the inclusion/exclusion criteria will receive a SImmetry implant.
3072896|NCT02074748||Bunion|Patients being treated for foot bunion with surgery.
3072897|NCT02074748||Controls (normal foot)|Participants in this group will not undergo surgery.
3072898|NCT02074735|Placebo Comparator|Placebo|Placebo schedule will mimic the schedule of the active comparator citicoline. Placebo will be started at the randomization visit (week 0, mimicking 500 mg/day of citicoline), then increased at week 2 to mimic 1000 mg/day citicoline, then increased to mimic 1500 mg/day of citicoline at week 4, and then increased to mimic 2000 mg/day of citicoline at week 6 until the end of week 12.
3072899|NCT02074735|Active Comparator|Citicoline|Citicoline will be started at 500 mg/day at the randomization visit (week 0), then increased to 1000 mg/day at week 2, then 1500 mg/day at week 4, and then 2000 mg/day at week 6 until the end of week 12.
3072900|NCT02074722||Healthy Subjects|Healthy Subjects
3072901|NCT02074709|Active Comparator|TAP block|TAP block with plain bupivacaine
3072902|NCT02074709|Active Comparator|Wound infiltration|Wound infiltration with liposomal bupivacaine
3073262|NCT02072525|Experimental|Pneum1 Group|Subjects will receive a dose of Pneumovax 23.
3072903|NCT02074683|Active Comparator|YEAR A PATHWAY|"Operative Procedure will occur after screening visit.~Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. In brief, fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.~Follow-up visits:~Post op Visit 1 (2 weeks +/- 5 days)~Post op study visit 2 (1 month)~Post op study visit 3 (2 month)~Post op study visit 4 (6 month)~Post op study visit 5 (12 month) CROSSOVER to YEAR B PathWay~Post op study visit 6 (18 months)~Post op study visit 7 (24 months)"
3072904|NCT02074683|Active Comparator|Year B Pathway|"Observational visits at 6 and 12 months with fat grafting procedures during year 2.~Study visit 1 (month 6)~Study Visit 2 (month 12)~Collection of subject's medication profile, vital signs (Temp, HR, Resp, BP), and weight to calculate BMI,~Limited physical exam with a foot exam completed by the PI and /or the Coinvestigator~Adverse Event Reporting~Ultrasound~Pedobarograph~2D Photographs~Foot Pain Assessment Questionnaire~Medical chart review including review of records from SOC podiatrists~Operative Visit Followed by Post op study visits 2-5 as described in Year A Pathway"
3072905|NCT02074670|Experimental|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
3072906|NCT02074657|Experimental|Activated natural killer cells|
3072907|NCT02074644|Experimental|Prostatic Arterial Embolization|Selective catheterization of the prostatic arteries followed by slow injection of Bead Block 300-500 or PVA 100+200 micra particles under fluoroscopic control.
3072908|NCT02074644|Sham Comparator|Sham procedure|Selective catheterization of the prostatic arteries followed by removal of the catheter with no particles injected.
3072909|NCT02074631|Active Comparator|Control group|Subjects will receive a standard recommended dose of calcium and vitamin D.
3072910|NCT02074631|Experimental|Pamidronate Group|Subjects randomized to pamidronate treatment will receive infusions approximately 100, 180, and 270 days after HCT along with calcium and vitamin D.
3072911|NCT02074618|Experimental|Physical Exercise|The program of physical exercise was a resistance and aerobic training, initiated at low intensity and with a slow progressing according to the patient's tolerance. In aerobic exercise, for greater effectiveness of the training, the literature recommends moderate intensity, which corresponds with 50 to 70% of the maximum heart rate. Patients were instructed to keep the most constant as possible the speed during exercise on treadmill or cycle ergometer. For muscle strengthening exercises, the number of repetitions varied from 1 to 4 sets of 10 to 15 repetitions.
3072912|NCT02074605||Observation|Patients with melanoma who qualify for interferon treatment, but choose not to receive it.
3072913|NCT02074605||Interferon alpha|Patients who receive high dose interferon alpha for 4 weeks
3072914|NCT02074592|Experimental|1|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
3072915|NCT02074592|Active Comparator|2|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
3072916|NCT02074579|Experimental|TU-100|15g TU-100 (oral, daily) for 4 consecutive weeks (administered as 5g three times daily)
3072917|NCT02074579|Placebo Comparator|Matching placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
3072918|NCT02074566|Other|2 times 1|PVI will be performed using a cryoballoon ablation application time of 2 times 1 minute
3072919|NCT02074566|Other|2 times 2|PVI will be performed using a cryoballoon ablation application time of 2 times 2 minutes
3072920|NCT02074566|Other|2 times 3|PVI will be performed using a cryoballoon ablation application time of 2 times 3 minutes
3072921|NCT02074553|Experimental|Part 1 (Fasted): Treatment A then B then C then D|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation (four 150 mg capsules) orally in Part 1 of the study according to following treatment sequences. Treatment A (Reference Treatment: formulation containing 50% SLS) on Day 1 of the first intervention period; then Treatment B (Test Treatment: formulation containing 25% SLS) on Day 1 of second intervention period (Day 11); then Treatment C (Test Treatment: formulation containing 12.5% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment D (Test Treatment: formulation containing 3% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
3072922|NCT02074553|Experimental|Part 1 (Fasted): Treatment B then D then A then C|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation orally in Part 1 of the study according to following treatment sequences. Treatment B (formulation containing 25% SLS) on Day 1 of the first intervention period; then Treatment D (formulation containing 3% SLS) on Day 1 of second intervention period (Day 11); then Treatment A (formulation containing 50% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment C (formulation containing 12.5% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
3072923|NCT02074553|Experimental|Part 1 (Fasted): Treatment C then A then D then B|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation orally in Part 1 of the study according to following treatment sequences. Treatment C (formulation containing 12.5% SLS) on Day 1 of the first intervention period; then Treatment A (formulation containing 50% SLS) on Day 1 of second intervention period (Day 11); then Treatment D (formulation containing 3% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment B (formulation containing 25% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
3072949|NCT02074358|Experimental|Treatment A: Apixaban + Placebo (Saline solution)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by Saline solution (placebo) 0 IU/kg infusion for 30 min Intravenously
3072950|NCT02074358|Experimental|Treatment B: Apixaban + Cofact (4-Factor PCC)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by a Cofact (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously
3073263|NCT02072525|Experimental|Pneum2 Group|Subjects will receive a dose of Pneumovax 23.
3072924|NCT02074553|Experimental|Part 1 (Fasted): Treatment D then C then B then A|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation orally in Part 1 of the study according to following treatment sequences. Treatment D (formulation containing 3% SLS) on Day 1 of the first intervention period; then Treatment C (formulation containing 12.5% SLS) on Day 1 of second intervention period (Day 11); then Treatment B (formulation containing 25% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment A (formulation containing 50% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
3072925|NCT02074553|Experimental|Part 2 (Fed): Treatment A then B then C then D|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment A (formulation containing 50% SLS) on Day 1 of the first intervention period; then Treatment B (formulation containing 25% SLS) on Day 1 of second intervention period (Day 11); then Treatment C (formulation containing 12.5% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment D (formulation containing 3% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
3072926|NCT02074553|Experimental|Part 2 (Fed): Treatment B then D then A then C|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment B (formulation containing 25% SLS) on Day 1 of the first intervention period; then Treatment D (formulation containing 3% SLS) on Day 1 of second intervention period (Day 11); then Treatment A (formulation containing 50% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment C (formulation containing 12.5% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
3072927|NCT02074553|Experimental|Part 2 (Fed): Treatment C then A then D then B|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment C (formulation containing 12.5% SLS) on Day 1 of the first intervention period; then Treatment A (formulation containing 50% SLS) on Day 1 of second intervention period (Day 11); then Treatment D (formulation containing 3% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment B (formulation containing 25% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
3072928|NCT02074553|Experimental|Part 2 (Fed): Treatment D then C then B then A|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment D (formulation containing 3% SLS) on Day 1 of the first intervention period; then Treatment C (formulation containing 12.5% SLS) on Day 1 of second intervention period (Day 11); then Treatment B (formulation containing 25% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment A (formulation containing 50% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
3072929|NCT02074540||Diabetes Type II Patients|
3072930|NCT02074514|Experimental|Sofosbuvir+RBV 16 weeks|Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 16 weeks.
3072931|NCT02074514|Experimental|Sofosbuvir+RBV 24 weeks|Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 24 weeks.
3072932|NCT02074501|Other|training capacity in caregivers|"The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put hands on caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge; (iii) using telephone support, counselling caregivers on 3rd, 6th, 8th and 10th weeks post discharge. It aims at facilitating the caregivers 'adjustment to stroke demands, increasing knowledge and practical skills to support their decision-making."
3072933|NCT02074488|Experimental|Fall Prevention Exercises|Participant provided with Balancing Act exercise curriculum for completion at least fifteen minutes three times a week over a six month period.
3072934|NCT02074488|Other|Informational brochure|Participant receives an informational brochure and orientation to brochure contents.
3072935|NCT02074475||Control group|The control group of three sites for larger Adequacy of Anaesthesia study. Total 150 patients
3072936|NCT02074436|Experimental|Prophylactic EACA|Prophylactic EACA 1000 mg PO twice daily if platelets < 20 x 10⁹/L
3072937|NCT02074436|Active Comparator|Platelet transfusion|Platelet transfusion if platelet count is < 20 x 10⁹/L in the outpatient or < 10 x 10⁹/L in the inpatient setting
3072938|NCT02074423|Experimental|MealShape cinnamon extract|Intake of 2 capsules of 500 mg MealShape 30 minutes before consumption of a standard meal (white bread)
3072939|NCT02074423|Placebo Comparator|Placebo|Intake of 2 capsules of 500 mg placebo, composed of 20% microcrystalline cellulose and 80% dicalcium phosphate, 30 minutes before consumption of a standard meal (white bread)
3072940|NCT02074410|Experimental|OMS643762 Low Dose without food|Orally administering OMS643762 low dose daily without food for 28 days
3072941|NCT02074410|Experimental|OMS643762 Medium Dose without food|Orally administering OMS643762 medium dose daily without food for 28 days
3072942|NCT02074410|Experimental|OMS643762 Medium Dose with food|Orally administering OMS643762 Medium dose daily with food for 28 days
3072943|NCT02074410|Placebo Comparator|Placebo|Orally administering placebo daily for 28 days
3072944|NCT02074397|Experimental|Distant extrafascial injection|Injection away from the brachial plexus with the needle tip positioned in the middle scalene muscle
3072945|NCT02074397|Active Comparator|Subfascial injection|Injection within the brachial plexus, with the needle tip positioned between C5 and C6
3072946|NCT02074384|Other|Continuous Glucose Monitoring|Participants will wear Continuous Glucose Monitoring for two weeks.
3072947|NCT02074384|Other|Self Monitoring Blood Glucose|Participants will self test for two weeks.
3072951|NCT02074358|Experimental|Treatment C: Apixaban + Beriplex P/N (4-Factor PCC)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by a Beriplex P/N (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously
3072952|NCT02074345|Experimental|TAK-816 0.5 mL|Primary immunization: TAK-816 0.5 mL, intramuscular injection, once on Day 1 and every 28 days for 2 intervals (Days 29 and 57). Booster immunization: TAK-816 0.5 mL, intramuscular injection, once, 52 weeks after the third dose of primary immunization.
3072953|NCT02074332|Experimental|Intervention|Physical activity guidance Health education
3072954|NCT02074332|No Intervention|Control|Receive no intervention
3072955|NCT02074319|Placebo Comparator|Placebo|Matching placebo for methotrexate
3072956|NCT02074319|Experimental|Methotrexate|Methotrexate 10 mg once a week orally
3072957|NCT02074306|Experimental|UROSHIELD®|Randomly selected patients,(ratio 1:1) with newly begun mechanical ventilation, will be connected to a low energy acustic wave generator UROSHIELD® within 48 hours. Endotracheal secretions will be collected for culture and antibiotic sensitivity every 3 days for 15 consecutive days or until disconnection from the mechanical ventilation.
3072958|NCT02074306|Sham Comparator|SHAM UROSHIELD®|same as abouve but with Sham device.
3072959|NCT02074293|Experimental|Splenius|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3072960|NCT02074293|Experimental|Scalene|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3072961|NCT02074293|Experimental|Sterno-cleido-mastoid|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3072962|NCT02074293|Experimental|Levator Scapulae|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3072963|NCT02074293|Experimental|Semispinalis|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3072964|NCT02074293|Experimental|Trapezius|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3072965|NCT02074293|Experimental|Longissimus|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3072966|NCT02074293|Experimental|Change from Baseline in Pain Frequency|Change from Baseline in Pain Frequency as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
3072967|NCT02074293|Experimental|Change from Baseline in Pain Intensity|Change from Baseline in Pain Intensity as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The severity on scales of 0(no pain) to 4(constant or extremely severe intensity).
3072968|NCT02074293|Experimental|Change from Baseline in CDSS|Change from Baseline in CDSS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The CDSS or Cervical Dystonia Severity Scale quantifies the severity of abnormal head positioning and was newly devised for this study. CDSS allots 1 point for each 5 degrees (or part thereof) of head deviation in each of the three planes of head movement (range of scores up to theoretical maximum of 54).
3072969|NCT02074293|Experimental|Percent of Patients with Improved PGAS|Percent of Patients with Improved PGAS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The Physician Global Assessment Scale or PGAS is a 9 category scale scoring the physician's evaluation of the patients' status compared to baseline, ranging from -4 to +4 (very marked worsening to complete improvement), with 0 indicating no change from baseline and +1 slight improvement.
3072970|NCT02074293|Experimental|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3072971|NCT02074293|Experimental|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3072972|NCT02074293|Experimental|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3072973|NCT02074293|Experimental|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3072974|NCT02074293|Experimental|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3072975|NCT02074293|Experimental|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3072976|NCT02074293|Experimental|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3072977|NCT02074293|Experimental|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073187|NCT02073084|Other|Sequence D|Sequence D
3073389|NCT02071719||Sorafenib|
3072978|NCT02074293|Experimental|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3072979|NCT02074293|Experimental|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3072980|NCT02074293|Experimental|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3072981|NCT02074280|Experimental|high dose of rifaximin|rifaximin 600 mg, bid, orally, 2 weeks and conventional treatment
3072982|NCT02074280|Experimental|low dose of rifaximin|rifaximin 400 mg bid,orally, 2 weeks
3072983|NCT02074280|No Intervention|control|conventional treatment
3072984|NCT02074267|Experimental|Carbatin|Carbatin is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days
3072985|NCT02074267|Active Comparator|Neurontin|Neurontin is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days
3072986|NCT02074241||Positive Expression|Expression analysis:Positive expression of DNA repair-related genes(XPC, XPF, Brca1, Rad51,SNF5, etc) in bladder cancer specimens.
3072987|NCT02074241||Negative Expression|Expression analysis:Negative expression of DNA repair-related genes(XPC, XPF, Brca1, Rad51, SNF5,etc) in bladder cancer specimens.
3072988|NCT02074228|Experimental|Methylphenidate|Methylphenidate (Concerta) 18mg or 36mg 1# qd, 12 weeks
3072989|NCT02074215|Experimental|Aerobic exercises|90-minute exercise sessions per week for 12 weeks
3072990|NCT02074215|Active Comparator|Stretch exercise|90-minute exercise sessions per week for 12 weeks
3072991|NCT02074202|Experimental|FCH PET/CT scan results|PET/CT scan results with FCH intravenous injection
3072992|NCT02074202|Active Comparator|FDG PET/CT scan|PET/CT scan results with FDG intravenous injection
3072993|NCT02074189|Active Comparator|Adjuvant Chemotherapy|Adjuvant Chemotherapy(Gemcitabine, Cisplatin):Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)
3072994|NCT02074189|No Intervention|Control|No immediate post-surgery treatment. Patients undergo observation followed by cisplatin and gemcitabine as in arm I at local relapse, or receive intravenously chemotherapy with cisplatin and gemcitabine at multiple metastases
3072995|NCT02074163|Experimental|Glabella|"Glabella~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3072996|NCT02074163|Experimental|Frontal|"Frontal~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3072997|NCT02074163|Experimental|Temporal|"Temporal~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3072998|NCT02074163|Experimental|Occipital|"Occipital~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3072999|NCT02074163|Experimental|Paraspinal|"Paraspinal~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3073000|NCT02074163|Experimental|Trapezius|"Trapezius~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3073001|NCT02074163|Experimental|Change in frequency of headache days|Change in frequency of headache days as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
3073002|NCT02074163|Experimental|Change in hrs of HA on HA days|Change in hrs of HA on HA days as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
3073003|NCT02074163|Experimental|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073004|NCT02074163|Experimental|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073005|NCT02074163|Experimental|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073006|NCT02074163|Experimental|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073007|NCT02074163|Experimental|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073008|NCT02074163|Experimental|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073009|NCT02074163|Experimental|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073010|NCT02074163|Experimental|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073011|NCT02074163|Experimental|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073012|NCT02074163|Experimental|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073013|NCT02074163|Experimental|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073188|NCT02073071||Preterm/low birth weight infants|Preterm infant formula per standard of care
3073014|NCT02074150|Experimental|Biceps Brachii|"Biceps Brachii (elbow flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3073015|NCT02074150|Experimental|Flexor Carpi Radialis|"Flexor Carpi Radialis (wrist flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3073016|NCT02074150|Experimental|Flexor carpi ulnaris|"Flexor carpi ulnaris (wrist flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3073017|NCT02074150|Experimental|Flexor digitorum profundus|"Flexor digitorum profundus (finger flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3073018|NCT02074150|Experimental|Flexor digitorum sublimis|"Flexor digitorum sublimis (finger flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3073019|NCT02074150|Experimental|Adductor pollicis|"Adductor pollicis (thumb flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3073020|NCT02074150|Experimental|Flexor pollicis longus|"Flexor pollicis longus (thumb flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3073021|NCT02074150|Experimental|Change from Baseline in Elbow Ashworth|"Change from Baseline in Elbow Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):~0 = No increase in muscle tone (none)~= Slight increase~= Moderate increase~= Considerable increase~= Limb rigid (very severe)."
3073022|NCT02074150|Experimental|Change from Baseline in Wrist Ashworth|"Change from Baseline in Wrist Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.Ashworth score (the force required to move an extremity around a joint):~0 = No increase in muscle tone (none)~= Slight increase~= Moderate increase~= Considerable increase~= Limb rigid (very severe)."
3073023|NCT02074150|Experimental|Change from Baseline in Finger Ashworth|"Change from Baseline in Finger Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):~0 = No increase in muscle tone (none)~= Slight increase~= Moderate increase~= Considerable increase~= Limb rigid (very severe)."
3073024|NCT02074150|Experimental|Change from Baseline in Thumb Ashworth|"Change from Baseline in Thumb Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):~0 = No increase in muscle tone (none)~= Slight increase~= Moderate increase~= Considerable increase~= Limb rigid (very severe)."
3073025|NCT02074150|Experimental|Change from Baseline in PGAS|Change from Baseline in PGAS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The Physician Global Assessment Scale or PGAS is a 9 category scale scoring the physician's evaluation of the patients' status compared to baseline, ranging from -4 to +4 (very marked worsening to complete improvement), with 0 indicating no change from baseline and +1 slight improvement.
3073026|NCT02074150|Experimental|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30
3073027|NCT02074150|Experimental|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073028|NCT02074150|Experimental|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073029|NCT02074150|Experimental|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073030|NCT02074150|Experimental|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073031|NCT02074150|Experimental|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073032|NCT02074150|Experimental|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073033|NCT02074150|Experimental|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073034|NCT02074150|Experimental|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073035|NCT02074150|Experimental|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073036|NCT02074150|Experimental|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3073037|NCT02074137|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously every 3 weeks, in combination with oral prednisone or prednisolone 10 mg daily
3073038|NCT02074124||Adenosine Vasodilation test|Group scanned with CT perfusion during adenosine vasodilation test.
3073039|NCT02074124||Reference group|Group scanned twice without adenosine vasodilation test for a reference. No randomization.
3073040|NCT02074111||Intracranial atherosclerotic stroke|
3073041|NCT02074111||Moyamoya disease|
3073042|NCT02074111||Healthy controls|
3073043|NCT02074098|Experimental|a 65 cm bed height|1) Bed height : approximately 65cm (Lowest)
3073044|NCT02074098|Experimental|a 95cm bed height|2) Bed height : approximately 95cm (highest)
3073045|NCT02074072|Experimental|Direct laryngoscope|Macintosh laryngoscope
3073046|NCT02074072|Experimental|Videolaryngoscope-1|Glidescope
3073047|NCT02074072|Experimental|Videolaryngoscope-2|Airwayscope
3073048|NCT02074059|Experimental|Aerosolized lucinactant (25 mg/kg)|25 mg total phospholipids (TPL)/kg: Lucinactant for inhalation with nCPAP
3073049|NCT02074059|Experimental|Aerosolized lucinactant (50 mg/kg)|50 mg TPL/kg: Lucinactant for inhalation with nCPAP
3073050|NCT02074059|Experimental|Aerosolized lucinactant (75 mg/kg)|75 mg TPL/kg: Lucinactant for inhalation with nCPAP
3073051|NCT02074059|Experimental|Aerosolized lucinactant (100 mg/kg)|100 mg TPL/kg: Lucinactant for inhalation with nCPAP; repeat dosing possible if criteria met.
3073052|NCT02074059|Experimental|Aerosolized lucinactant (150 mg/kg)|150 mg TPL/kg: Lucinactant for inhalation with nCPAP; repeat dosing possible if criteria met.
3073053|NCT02074059|Active Comparator|nCPAP alone|nCPAP therapy alone
3073054|NCT02074046|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3073055|NCT02074046|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3073056|NCT02074046|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3073057|NCT02074046|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3073058|NCT02074033||antibiotics for pneumonia|We will be examined whether the antibiotic prescribed following the orientation of literature, considering the dose, interval between doses, dose adjustment for renal failure infusion time, treatment time and conduct after the culture results (deescalation, escalation or maintenance of antimicrobial initially prescribed )
3073059|NCT02074020|Experimental|Blisibimod|
3073060|NCT02074020|Placebo Comparator|Placebo|
3073061|NCT02074007|Active Comparator|AR01 - Topical Otic Solution|"Topical ear drops~The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period"
3073062|NCT02074007|Placebo Comparator|Placebo Comparator|"Topical ear drops~Glycerin ear drops-The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period."
3073063|NCT02073994|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or Investigator discretion.
3073064|NCT02073981||Parkinson Disease|
3073065|NCT02073968|Experimental|Treatment (PET-adjusted IMRT, carboplatin, paclitaxel)|"RADIOTHERAPY: Patients undergo PET-adjusted IMRT or proton beam radiation therapy five days a week for 5 weeks.~CONCURRENT CHEMOTHERAPY: Patients receive carboplatin IV over 3 hours and paclitaxel IV over 1 hour once weekly for 6 weeks beginning week 1 of thoracic radiotherapy.~CONSOLIDATION CHEMOTHERAPY: Beginning approximately 4-6 weeks after the completion of all radiation therapy and when esophagitis and chemotherapy-induced neuropathy are grade 1 or less, ANC > 1500, and platelet count > 100,000, patients may receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Treatment may repeat every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity at the discretion of the treating physicians."
3073066|NCT02073955||Pakistani adults|"Men and women aged 40 and above, residing in Ibrahim Hyderi (periurban Pakistani community)~Consenting to Interview about stroke symptoms"
3073067|NCT02073929|Active Comparator|Active|Liraglutide s.c. 1,8mg daily for 26 weeks
3073068|NCT02073929|Placebo Comparator|Placebo|Placebo s.c. 1,8mg daily for 26 weeks
3073069|NCT02073916|Experimental|T-DM1 + Lapatinib + Abraxane|T-DM1 with Laptinib followed by Abraxane
3073070|NCT02073903||LEP inpatients and their providers|This is a feasibility project with the goal of improving communication between limited English proficiency (LEP )inpatients and their providers. Quantitative data will be obtained via two surveys: a patient survey to assess patients' feedback on the effectiveness of the communication during their hospital stay and their understanding of their medical care, and a provider survey to assess the handset's impact on the effectiveness of the communication. From this data we will be able to assess patient and provider communication effectiveness with both the current various practices at MSKCC and the new intervention.
3073071|NCT02073890||traumatic subarachnoid haemorrhage|
3073072|NCT02073877||Controls - Holgers 0 & 1|
3073073|NCT02073877||Cases - Holgers >1 (active peri-implant dermatitis)|
3073074|NCT02073851|Experimental|TriGuard™HDH|Patients undergoing TAVR will be treated wIth experimental device TriGuard™HDH
3073075|NCT02073838|Experimental|Ribavirin, vismodegib, decitabine|Decitabine 20mg/m2 IV QD days -7 to -3 for cycle 1. Ribavirin 1400mg BID and vismodegib 150mg QD starting on day 1. On subsequent cycles, decitabine will be administered on days 1 to 5.
3073076|NCT02073838|Experimental|Ribavirin, vismodegib|Ribavirin 1400mg BID, vismodegib 150mg QD
3073077|NCT02073825|Experimental|Web Brief Intervention (WBI)|4-session WBI
3073078|NCT02073825|No Intervention|Delayed-WBI|4-session WBI after follow-up
3073079|NCT02073812|Experimental|Multiple dose of Carbavance (RPX7009/RPX2014)|Multiple dose of Carbavance
3073080|NCT02073799||Photoselective vaporization of the prostate|Patients who underwent photoselective vaporization of the prostate for prostatic hyperplasia and in whom 12-months follow-up data were available
3073081|NCT02073799||Holmium laser enucleation of the prostate|Patients who underwent holmium laser enucleation of the prostate for prostatic hyperplasia and in whom 12-months follow-up data were available
3073082|NCT02073786|Active Comparator|Lightwand|Conventional lightwand intubation will performe for intubation
3073083|NCT02073786|Experimental|Optiscope|Rigid video stylet, manufactural named Optiscope, will perform for intubation
3073084|NCT02073773|Experimental|Virtual Reality based therapy, levodopa|"The VR therapy session consists of the subject interacting with a computer-based program in which they guide an avatar to gather items by using flexion and extension gestures of the affected upper limb. VR therapy sessions will last for 15-30 minutes depending on the subject's tolerance and participation. For patients who are unable to overcome gravity fully, they can still participate in this therapy by resting their arm on a table.~Patients will receive a single dose of 100mg levodopa in combination with benserazide 2-3 hours before each additional Occupational therapy session or VR therapy session depending on the assigned group."
3073085|NCT02073773|Active Comparator|occupational therapy, levodopa|"The control group will receive and additional half an hour per working day of standard occupational therapy.~Patients will receive a single dose of 100mg levodopa in combination with benserazide 2-3 hours before each additional Occupational therapy session or VR therapy session depending on the assigned group."
3073086|NCT02073760||Infection Prevention Experts|Adult caregivers of cardiac surgery patients (e.g. surgeons, nurses, infection preventionists) and administrators
3073087|NCT02073747|Placebo Comparator|Normal Saline Control Group|Control group will be administered a one hour normal saline inhaled treatment.
3073088|NCT02073747|Active Comparator|Albuterol Trial Group|Trial group to be administered one hour treatment of ten milligrams of inhaled albuterol
3073089|NCT02073734|Experimental|Dexamethasone|Dexamethasone
3073090|NCT02073734|Placebo Comparator|Placebo|Sterile normal saline solution
3073091|NCT02073721|Experimental|electrostimulation with exercises MAPs|this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.
3073092|NCT02073721|Active Comparator|exercises MAPs|This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor
3073093|NCT02073695|Other|Neutral Rotation Brace|Neutral Rotation Brace
3073094|NCT02073695|Other|Standard polysling (Current practice)|Standard polysling (Current practice)
3073095|NCT02073682|Experimental|Edoxaban group|Edoxaban
3073096|NCT02073682|Active Comparator|Dalteparin group|Dalteparin
3073097|NCT02073669|Other|Second generation immigrants from high TB incidence countries|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA).
3073098|NCT02073669|Other|Native Israelis|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA).
3073099|NCT02073656|Experimental|LDV/SOF 12 Weeks|LDV/SOF for 12 weeks
3073100|NCT02073656|Experimental|Retreatment Substudy|LDV/SOF plus RBV for 24 weeks
3073101|NCT02073630|Other|Healthy subjects|healthy subjects will receive either sham or active cerebellar stimulation
3073102|NCT02073630|Other|Dystonia|dystonic patients will receive either sham or active cerebellar stimulation
3073103|NCT02073617|Experimental|Real-time 3-dimensional DynaCT|Patients will undergo the standard CTA protocol and invasive coronary angiography performed as part of the pre-operative assessment for TAVR. Patients in this study will also undergo DynaCT during coronary angiography, utilizing 1 acquisition sweep and 20 to 35cc more of contrast media. Measurements of the major aortic annulus diameter, orthogonal minor aortic annulus diameter, aortic annulus perimeter, maximum ascending aorta diameter at 40mm above the annulus, sinus of Valsalva diameters, sinus of Valsalva heights, and aortic root angulation will be made using both the CTA and DynaCT protocols by a radiologist blinded to patient identity. Based on these measurements, a trained interventional cardiologist will select the appropriate TAVR size for the patient.
3073104|NCT02073604|Other|Healthy volunteers|Healthy volunteers
3073105|NCT02073604|Other|Congenital mirror movements|Patients presenting with congenital mirror movements
3073106|NCT02073591||Ceradan Regimen|Ceradan Cream and Ceradan Wash
3073107|NCT02073578|Other|Treatment|Peroral Endoscopic Myotomy (POEM)
3073108|NCT02073565|Experimental|Combo|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
3073109|NCT02073565|Active Comparator|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
3073110|NCT02073552|Active Comparator|High volume|"Two 5 mg bisacodyl tablets It is a stimulant laxative with local action.~Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate."
3073111|NCT02073552|Experimental|Low volume|"Two 5 mg bisacodyl tablets, taken in the same way as for the high volume group.~Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid."
3073112|NCT02073539|Experimental|chest compression with 5cm feedback|We will feedback by one accelerometer (U-cpr). U-cpr is android based smartphone application.
3073113|NCT02073539|Experimental|chest compression with 6cm feedback|We will feedback by one accelerometer(U-cpr). U-cpr is android based smartphone application.
3073114|NCT02073539|Experimental|chest compression with 7cm feedback|We will feedback by one accelerometer(U-cpr). U-cpr is android based smartphone application.
3073115|NCT02073526||Anti-TNF|Inflammatory bowel patients age 18 and over treated with anti-TNF agents
3073116|NCT02073513|Experimental|kinesiotape plus thenar pressure (PPTG)|"In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied which controled the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.~The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions."
3073117|NCT02073513|Experimental|Taping Group (TG)|In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
3073118|NCT02073513|No Intervention|Control Group (CG)|No application.
3073119|NCT02073500||Observational study|Patients diagnosed with PSM undergoing CRS with HIPEC.
3073120|NCT02073487|Experimental|T-DM1 + Lapatinib + Abraxane|T-DM1 intravenously (IV) every three weeks plus L orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.
3073121|NCT02073487|Active Comparator|Trastuzumab + Pertuzumab + Paclitaxel|Trastuzumab IV weekly plus pertuzumab IV every 3 weeks for 6 weeks, followed by paclitaxel IV weekly for 12 weeks.
3073122|NCT02073474||Sativex® users|UK: All patients and who are prescribed Sativex®. Germany and Sweden: Patients who are prescribed Sativex® from selected specialist neurology centres.
3073123|NCT02073461|Experimental|CD1579 2.5%|Benzoyl Peroxide 2.5%
3073124|NCT02073461|Experimental|CD1579 5%|Benzoyl Peroxide 5%
3073125|NCT02073461|Placebo Comparator|Vehicle|Vehicle
3073126|NCT02073448|Experimental|GK530G|Fixed-dose combination gel of Adapalene and Benzoyl Peroxide
3073127|NCT02073448|Active Comparator|CD0271|Adapalene 01% Gel
3073128|NCT02073448|Active Comparator|CD1579|Benzoyl Peroxide 2.5% Gel
3073129|NCT02073435||Intervention Group|Living Donor Liver Transplant patients with evidence based donor pain management solution and Living Donor liver transplant patients after the Standardization and Optimization of the Pre-operative OR Set-up Process
3073130|NCT02073435||Control Group|"Living Donor Liver Transplant patients prior to the implementation of the evidence based donor pain management solution.~Living Donor liver transplant recipients prior the Standardization and Optimization of the Pre-operative OR Set-up Process"
3073131|NCT02073422||Non-ST elevation myocardial infarction|Natural history study of non-ST elevation myocardial infarction and coronary physiology
3073132|NCT02073409||CF patients|Male and female subjects with CF age 6 years and older who have a positive sputum culture for NTM.
3073133|NCT02073396||Patients|Patients diagnosed with coronary disease or atrial fibrillation. All the patients will undergo Global Thrombosis Test.
3073134|NCT02073383|Experimental|Around Artery|"Intervention Name: Axillary brachial plexus block~Group A: 30 ml of 0.375% bupivacaine will be injected around the artery . If this were a clock, would deposit 7,5 ml of anesthetic in positions 0, 3, 6 and 9 ."
3073135|NCT02073383|Experimental|Two injections|Group 2: 30 ml of bupivacaine 0.375 % below the artery will be injected in the 6 o'clock position .
3073136|NCT02073383|Active Comparator|Perineural|Group Perineural : 10 ml of bupivacaine 0.375 % will be injected around the median, ulnar and radial nerves .
3073137|NCT02073370||health subjects; outpatients aged over 65|The research subjects will be culled from outpatients aged over 65 at NTUH; 1000 Taiwanese subjects aged 20-40 equally divided in both genders will be recruited in order to establish the norm of Taiwanese's skeletal muscle index.
3073138|NCT02073357|Experimental|Light general anaesthesia (BIS = 50)|Light general anaesthesia
3073139|NCT02073357|Experimental|deep general anaesthesia (BIS = 35)|deep general anaesthesia
3073140|NCT02073344|Experimental|Intevention group|A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG 6 months after the beginning of a renal replacement therapy
3073141|NCT02073344|Experimental|Control group|No intervention A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG at 6 months if the patient is not already on renal replacement therapy
3073142|NCT02073331||CorMatrix ECM|Data collection for information on the use of CorMatrix ECM for pericardial reconstruction
3073143|NCT02073318|Experimental|Balance training|
3073144|NCT02073318|Active Comparator|Control|Control group received 4 weeks upper extremities exercise in sitting position
3073145|NCT02073305||No sleep apnea|Subjects with no or light sleep apnea (AHI < 15/h)
3073146|NCT02073305||Sleep Apnea - untreated|"Subjects with moderate to severe sleep apnea (AHI ≥15/h) and no specific treatment.~Decision to treat or not sleep apnea is left to the treating physician, independently of the study protocol."
3073147|NCT02073305||Sleep Apnea - treated|Subjects with treated moderate to severe sleep apnea (AHI ≥15/h). Decision to treat or not sleep apnea is left to the treating physician, independently of the study protocol.
3073148|NCT02073292|Experimental|c-RFA|cooled radiofrequency ablation
3073149|NCT02073292|Active Comparator|t-RFA|thermal radiofrequency ablation
3073150|NCT02073279|Experimental|satralizumab (SA237)|Subcutaneous satralizumab (SA237)
3073151|NCT02073279|Placebo Comparator|Placebo|Subcutaneous placebo
3073152|NCT02073266|Active Comparator|SF6 vitrectomy|The first group included 31 patients who had undergone MH surgery using SF6 gas and who were advised to stay in face-down position for 7 days postoperatively (SF6 group). Patients in both groups underwent 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8. The internal limiting membrane was coloured with trypan blue or indocyanine green in equal proportion in both groups.
3073153|NCT02073266|Active Comparator|C3F8 vitrectomy|The second group included 28 patients who had undergone MH surgery with C3F8 gas and who were advised to maintain a face-down position for 14 days. Patients in both groups underwent 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8. The internal limiting membrane was coloured with trypan blue or indocyanine green in equal proportion in both groups.
3073154|NCT02073253|No Intervention|Without performing any operation (Phase Control)|
3073155|NCT02073253|Experimental|With ventilatory support through NIV (NIV Phase)|
3073156|NCT02073240||Enhanced TB IC Package|"Facilities randomized to the intervention group will receive the following:~Skills-based training for TB IC focal points~Audits and Feedback of performance data~TB IC collaborative (including mentoring)~Checklists"
3073157|NCT02073240||Usual Care Group|Usual Care group will receive available TB IC training/education alone.
3073158|NCT02073227|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 300 mg, and 4 tablets of metformin extended release (MET XR), 500 mg each, administered together under fed conditions.
3073159|NCT02073227|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
3073160|NCT02073227|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
3073258|NCT02072538||Post-discharge stress testing|Stress-testing (e.g. treadmill exercise test, stress-echochardiography)
3073259|NCT02072525|Experimental|Mtdap1 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
3073390|NCT02071719||Everolimus|
3073161|NCT02073214|Experimental|Probiotic|"Single dose of probiotic, was administered enterally twice daily with food (in the morning and in the evening). The first dose of probiotic was administered within the first 48 hours after birth. The probiotic administration was continued for 6 weeks or until hospital discharge (whichever was earlier).~Discontinuation of the enteral nutrition was equivalent with discontinuation of the administration of the probiotic. If the probiotic was discontinued for more than 7 days, the patient was withdrawn from the study."
3073162|NCT02073214|Placebo Comparator|Placebo|"Single dose of placebo was administered enterally twice daily with food (in the morning and in the evening). The first dose of placebo was administered within the first 48 hours after birth. The placebo administration was continued for 6 weeks or until hospital discharge (whichever was earlier).~Discontinuation of the enteral nutrition was equivalent with discontinuation of the administration of the placebo. If the placebo was discontinued for more than 7 days, the patient was withdrawn from the study."
3073163|NCT02073201||High-functioning older adults|Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
3073164|NCT02073201||Lower-functioning older adults|Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
3073165|NCT02073201||Young adults|Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
3073166|NCT02073188|Experimental|iBGStar (Group A)|Self-Monitoring Blood Glucose will be managed with iBGStar and iBGStar Diabetes Manager Application (App) uploaded on iPhone for all duration of the study (6 months of experimental phase plus 6-months of observational phase). In the first 3 months, the patients in Group A will send their glycemic test values and notes by mail to the physician through Diabetes Manager App every 2 weeks. Afterwards until the visit V2 (six months), the patients in Group A will send their glycemic test values and notes by mail monthly. 9 reports in total.
3073167|NCT02073188|Active Comparator|Traditional Glucometer (Group B)|Self-Monitoring Blood Glucose will be managed with a traditional glucometer according to usual care for the first 6 months (experimental phase). In the 6 months post-trial follow-up (observational phase), Self-Monitoring Blood Glucose will be managed with iBGStar and iBGStar Diabetes Manager App.
3073168|NCT02073175|Experimental|Postpartum with crying spells-Full dose|"Healthy women who are within the first 18 months postpartum and have crying spells but do not have major depression. The effect of the dietary supplement in reducing sadness in this group will be assessed.~Intervention: Full dose dietary supplement Motherwell"
3073169|NCT02073175|Experimental|Day-5 postpartum - Full dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.~Intervention: Full dose dietary supplement Motherwell"
3073170|NCT02073175|Experimental|Day-5 postpartum - Half dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the proposed dietary supplement consumption, is being done after delivery and during postpartum.~Intervention: Half dose dietary supplement Motherwell"
3073171|NCT02073175|Experimental|Day-5 postpartum - Quarter dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the proposed dietary supplement consumption, is being done after delivery and during postpartum.~Intervention: Quarter dose dietary supplement Motherwell"
3073172|NCT02073175|Other|Day-5 postpartum - Control|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving a control supplement consumption, is being done after delivery and during postpartum.~Intervention: Control protein to compare with Motherwell"
3073173|NCT02073162|Active Comparator|Liberal group|At induction-Hartmanns 10 ml/kg During surgery-Hartmanns 8 ml/kg/h After surgery-IV fluids ≥1.5 ml/kg/h Continue IV fluids ≥24hrs
3073174|NCT02073162|Experimental|Restrictive group|At induction-Hartmanns ≤5 ml/kg During surgery-Hartmanns 5 ml/kg/h After surgery-IV fluids, ≤0.8 ml/kg/h Cease IV fluids ASAP,aim for early oral fluids
3073175|NCT02073149|Active Comparator|Low-dose iron as NaFeEDTA|Daily point-of-care fortification of (complementary) foods with 3 mg iron as NaFeEDTA.
3073176|NCT02073149|Active Comparator|Conventional dose iron as ferrous salt|Daily point-of-care fortification of (complementary) foods with 12.5 mg iron as encapsulated ferrous fumarate.
3073177|NCT02073149|Placebo Comparator|Placebo|Daily point-of-care fortification of (complementary) foods with placebo.
3073178|NCT02073136|Experimental|Phosphate modified diet|
3073179|NCT02073123|Experimental|Indoximod + Ipilimumab|"Indoximod will be administered at 1200mg BID by mouth.~Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.~Indoximod and ipilimumab will be dosed concurrently. Indoximod will be dosed twice daily on all days of each 21 day cycles (segment 1). Ipilimumab will be dosed on the 1st day of each 21 day cycle for the first 4 cycles. Indoximod dosing will continue after all 4 doses of ipilimumab are administered (segment 2, 28-day cycles).~Patients will continue until they experience disease progression or limiting toxicity."
3073180|NCT02073123|Experimental|Indoximod + Pembrolizumab|"Indoximod will be administered at 1200mg BID by mouth.~Pembrolizumab administered intravenously at 2 mg/kg every three weeks."
3073181|NCT02073123|Experimental|Indoximod + Nivolumab|"Indoximod will be administered at 1200mg BID by mouth.~Nivolumab administered intravenously at 240 mg every 2 weeks."
3073182|NCT02073110||≥ 18 years, solid enhancing renal mass suspected for RCC|
3073183|NCT02073097|Experimental|Treatment (rituximab, combination chemotherapy, carfilzomib)|Patients receive rituximab IV over at least 90 minutes, cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV over 3-5 minutes, vincristine sulfate IV over 1 minute on day 1, and prednisone PO on days 3-7. Patients also receive carfilzomib IV over 30 minutes on days 1, 2, 8 and 9. Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3073184|NCT02073084|Other|Sequence A|Sequence A
3073185|NCT02073084|Other|Sequence B|Sequence B
3073186|NCT02073084|Other|Sequence C|Sequence C
3073189|NCT02073045|Experimental|Supportive care (lymphedema education)|In an educational intervention, participants complete a five question lymphedema survey, designed by the Occupational Therapy staff, as an instrument to assess a patient's knowledge of lymphedema signs/symptoms before surgery. An OT, PT, and/or CLT provide written handouts to participants on the pathophysiology, signs, symptoms, and treatment of lymphedema. Participants repeat the survey at 3 months post-surgery. BUE circumferential measurements are also collected before surgery and at 3 months post-surgery.
3073190|NCT02073032||Head -Neck cancer patients, no intervention|
3073191|NCT02073019|Experimental|Cohort A|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
3073192|NCT02073019|Experimental|Cohort B|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
3073193|NCT02073019|Experimental|Cohort C|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
3073194|NCT02073006|Active Comparator|Natural Fibre Supplement|2 doses per day for 4 weeks
3073195|NCT02073006|Placebo Comparator|Placebo|2 doses per day for 4 weeks
3073196|NCT02072993|Experimental|AZD1979|Single ascending doses of oral solution AZD1979
3073197|NCT02072993|Placebo Comparator|Placebo|Placebo to match single ascending doses of oral solution AZD1979
3073198|NCT02072980|Other|16hrs/15mins|Delefilcon A contact lenses worn bilaterally (in both eyes) for 16 waking hours (1 day) in Period 1, followed by 15 minutes in Period 2. A fresh pair of lenses was dispensed for Period 2.
3073199|NCT02072980|Other|15mins/16hrs|Delefilcon A contact lenses worn bilaterally for 15 minutes in Period 1, followed by 16 waking hours (1 day) in Period 2. A fresh pair of lenses was dispensed for Period 2.
3073200|NCT02072967||Ribomustin and rituximab|
3073201|NCT02072954|Experimental|Asenapine Sublingual Tablets|Asenapine Sublingual Tablets, 10 mg. Twice daily for a period of 7 days
3073202|NCT02072954|Active Comparator|Saphris Subligual Tablets|Asenapine Sublingual Tablets, 10 mg. Twice daily for 2 periods of 7 days each.
3073203|NCT02072941|Experimental|PREPARE intervention|The PREPARE arm will review the PREPARE website plus the easy-to-read advance directive (AD). Participants will review PREPARE on their own for ≥20 minutes with staff present to answer questions. During PREPARE, participants answer preference questions and make an action plan (i.e., commitment to engage in advance care planning). To ensure home access to PREPARE content, participants will be given a website login and PREPARE content in digital video disc (DVD), booklet, and pamphlet format as well as the action plan and AD. One to three days before a primary care visit, the PREPARE arm will receive a reminder to come to their appointment and to bring their action plan.
3073204|NCT02072941|No Intervention|Control|The control arm will review an easy-to-read AD. Controls will review the AD for ≥15 minutes with study staff present to answer questions and will take the AD home to complete if desired. One to three days before a primary care visit, controls will receive a reminder to come to their appointment.
3073205|NCT02072928||BOTOX®|Patients with incontinence from NDO due to spinal injury or MS prescribed BOTOX® (Botulinum toxin Type A) as standard of care in clinical practice.
3073206|NCT02072915|Experimental|Suction|Suction will be applied to patients undergoing EUS-FNA
3073207|NCT02072915|No Intervention|Without suction|No suction will be applied to patients undergoing EUS-FNA
3073208|NCT02072902||diabetes free|No intervention
3073209|NCT02072902||Diabetes prevalent|The exposure is diabetes morbidity present at study entery
3073210|NCT02072902||Diabetes incidence|The exposure is diabetes incidence during study follow up
3073211|NCT02072889|Experimental|Neck Angle Measures|Subjects will position his/her neck in order to measure distance between the internal jugular and the carotid artery to determine if there is a maximal distance to target prior to cannulation
3073212|NCT02072876||Asymptomatic ICAD on MRI Absent|Those who test negative on QVSFS, Questionnaire to Verify Stroke Free Status, and do not have ICAD on MRI. They are clinically and biologically free of disease.
3073213|NCT02072876||Asymptomatic ICAD Present on MRI|Those who are negative for Stroke Symptoms on QVSFS, Questionnaire to Verify Stroke Free Status, yet have evidence of ICAD on MRI
3073214|NCT02072863|Experimental|Oprozomib with Melphalan and Prednisone (OMP)|"Subjects will receive oprozomib administered orally.~The combination of oprozomib, melphalan, and prednisone (OMP) will be administered until progression of disease, unacceptable toxicity, discontinuation of study treatment for reasons other than progression or toxicity, or a maximum of 9 cycles (54 weeks), whichever occurs first."
3073215|NCT02072850||Myocardial infarction|Patients presenting with acute-ST elevation myocardial infarction referred for emergency invasive management by primary or rescue percutaneous coronary intervention.
3073216|NCT02072824|Experimental|Study Drug Level 1|
3073217|NCT02072824|Experimental|Study Drug Level 2|
3073218|NCT02072824|Placebo Comparator|Placebo|
3073219|NCT02072811|Other|Induction, DAC|"The first stage of treatment.~First DAC induction cycle is common to all patients (regardless of risk group). After completion of induction I occurs early assessment of bone marrow on the +14 day after the start of treatment (+7 day after completion of chemotherapy)."
3073220|NCT02072811|Other|II early induction, CLAG|"Patients with blasts in the bone marrow in D14> 10% receive early second induction (CLAG) which start form +16 day.~Patients with blasts in the bone marrow in D14 ≤ 10% do not receive early second induction and are qualified to assess the response times on +28 day or after full morphology recovery (if it occurs before the +28 day"
3073221|NCT02072811|Other|Consolidation, I HAM cycle|"I induction cycle starts after complete remission (CR).~- After I consolidation, patients from Intermediate I an Intermediate II group (ELN prognostic system):~If compatible donor is present - allogeneic HSCT qualification after I or II consolidation. If compatible donor for allogeneic HSCT is not present - attempt to CD34+ mobilization for autologous SCT after II consolidation~- After I consolidation, patients from Adverse risk group (ELN prognostic system):~If compatible donor is present - immediate qualification for allogeneic HSCT.~- Finding a donor should be initiated in all patients, at the latest after the end of I induction. In the first place, it should be checked whether the patient has a donor family, if not - searching start for an unrelated donor. For patients with no compatible donor for allogeneic HSCT - need to start searching for an alternative donor"
3073260|NCT02072525|Experimental|Mtdap2 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
3073261|NCT02072525|Experimental|Mtdap3 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
3073222|NCT02072811|Other|II Consolidation HiDAraC|"Patients from all 5 risk group receive second after first consolidation [Ara-C] Patient from Very adverse risk receive Ara-C + CLA (Cladribine). If it is needed - more intensive consolidation treatment with 2-Cda.~Patients form Very adverse risk receive Maintenance treatment:~Decitabine 20 mg/m2 60 min infusion iv (Intravenous injection) for 5 days every 6 weeks.~Patients from Favorable, - Intermediate I an Intermediate II risk groups: CD34+ mobilization (HSCT qualification)."
3073223|NCT02072811|Other|Consolidation, III HiDAraC cycle|"Patients from Favorable, Intermediate I an Intermediate II risk groups receive III consolidation or autologous HSCT (depends on results of mobilization).~Patients from Adverse risk receive III Consolidation HiDAraC + Cladribina (CLA) If no CR: CLAG-M reinduction therapy and after CR - treatment according to protocol."
3073224|NCT02072798|Active Comparator|preoperative antibiotic|iv Cefuroxime 1,5g administered 15-60 minutes before incision
3073225|NCT02072798|Active Comparator|postoperative antibiotic|iv Cefuroxime 1,5g administered after umbilical cord clamping
3073226|NCT02072785|Experimental|Vincristine Sulfate Liposome|"Vincristine Sulfate For Injection simulation agent 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection: 1.4mg/m2, (2mg, maximum dose), iv, d1, d8, d15, d22.~Duration between these two agents should be more than 2.5h, and saline should be avoided for flushing before Vincristine Sulfate Liposome For Injection."
3073227|NCT02072785|Active Comparator|Vincristine Sulfate|"Vincristine Sulfate For Injection 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection simulation agent: 1.4mg/m2,(2mg, maximum dose), iv, d1, 8, 15, 22.~Duration between these two agents should be more than 2.5h, and saline should not be used for flushing before Vincristine Sulfate Liposome For Injection simulation agent."
3073228|NCT02072772|Experimental|Positively Smoke Free group treatment|"Eight 90 minute group sessions (6-8 HIV-infected smokers per group) led by a pair of trained group leaders: a professional with psychology or social work training and a peer HIV-infected ex-smoker with tobacco treatment training.~All subjects will be offered a 3 month supply of nicotine patches"
3073229|NCT02072772|Active Comparator|Standard care|Brief (<5 minutes) advice to quit Offer of nicotine patches Self-help brochure
3073230|NCT02072759|Experimental|Carnitine supplement|Carnitine supplement
3073231|NCT02072759|Placebo Comparator|Placebo|Placebo supplement
3073232|NCT02072759|No Intervention|Healthy control|Healthy control group
3073233|NCT02072746|Active Comparator|Zinc|zinc sulfate 220 mg daily
3073234|NCT02072746|Placebo Comparator|Placebo|Placebo study for comparison
3073235|NCT02072733|Other|geriatric assessment|"The intervention is individual and based on the Comprehensive Geriatric assessment (CGA) : collection of information on comorbidity, polypharmacy, physical, psychological and cognitive functions, nutrition as well as social status and support.~The results of the CGA, the eventual medical changes and recommendations regarding e.g. initiation of nutritional supplementation, home-care referral or referral to e.g. physiotherapist will be forwarded to the general practitioner and to the oncologist in charge of the treatment"
3073236|NCT02072720|No Intervention|on-treatment tumor biopsie|patients will undergo an pre-treatment and on-treatment tumor biopsy, to measure VEGF expression, and identify the time point of induction of VEGF expression.
3073237|NCT02072720|Experimental|bevacizumab|These patients will receive bevacizumab once a week during their chemoradiation, starting at the identified time point of enhanced VEGF expression. These patients will also undergo and pre-treatment tumor biopsy and 1 tumor biopsy 1 week after the start of bevacizumab treatment.
3073238|NCT02072707|Active Comparator|Epicardial VT ablation|Patients will underwent combined epicardial and endocardial mapping and ablation
3073239|NCT02072707|Active Comparator|Endocardial VT Ablation|Patients will underwent endocardial only VT mapping and ablation
3073240|NCT02072694|Experimental|75 grams of glucose plus water solution|"In the group with 10 volunteers with obesity, some of them are submitted first to the 75 grams of glucose plus water solution (meal challenge) and in another time to only water.~Also, in the group with 10 volunteers without obesity, some of them are submitted first to the 75 grams of glucose plus water solution (meal challenge) and in another time to only water."
3073241|NCT02072694|Placebo Comparator|Pure water.|"In the same group with 10 volunteers with obesity, some of them are submitted first to only water (control) and in another time to the 75 grams of glucose plus water solution (meal challenge).~Also, in the same group with 10 volunteers without obesity, some of them are submitted first to only water (control) and in another time to the 75 grams of glucose plus water solution (meal challenge)."
3073242|NCT02072681||Mild and Rapidly Improving Ischemic Stroke|
3073243|NCT02072668|Other|Rivaroxaban for 4 wks, Placebo for 4 wks|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
3073244|NCT02072668|Other|Placebo for 4 wks, rivaroxaban for 4 wks|Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
3073245|NCT02072655|No Intervention|without socio-asthetic care|
3073246|NCT02072655|Experimental|with socio-aesthetic cares|
3073247|NCT02072642|Active Comparator|Active light therapy (10,000 lux)|Light therapy: DayVia lamp 10000 lux
3073248|NCT02072642|Placebo Comparator|Placebo light therapy (70 lux)|Placebo light therapy
3073249|NCT02072629|Experimental|Training of VHVs in iCCM|In these villages VHVs will be provided with iCCM training and equipped to support iCCM in their villages
3073250|NCT02072616|Experimental|Sample for Circulating Tumoral Cells|Sampling of Circulating Tumoral Cells will be done after Pancreatic adenocarcinoma diagnosis
3073251|NCT02072603|Experimental|Intervention Hospitals|HITSystem implementation at hospital and its affiliated laboratory
3073252|NCT02072603|Active Comparator|Control Hospitals|Existing standard of EID care
3073253|NCT02072577|Experimental|Knowledge|Educational video.
3073254|NCT02072564||Couples with indication for IVF|Couples with primary or secondary infertility with indication of IVF
3073255|NCT02072551||Adult with neonatal diabetes|Adult with neonatal diabetes (before 1 year ) and need for insulin
3073256|NCT02072551||non diabetic adults with a relative with neonatal diabetes|
3073257|NCT02072538||Pre-discharge stress testing|Stress-testing (e.g. treadmill exercise test, stress-echochardiography)
3073264|NCT02072525|Experimental|Pneum 3 Group|Subjects will receive a dose of Pneumovax 23.
3073265|NCT02072525|Experimental|Prev1 Group|Subjects will receive a dose of Prevnar 13.
3073266|NCT02072525|Experimental|Prev2 Group|Subjects will receive a dose of Prevnar 13.
3073267|NCT02072525|Experimental|Prev3 Group|Subjects will receive a dose of Prevnar 13.
3073268|NCT02072512|Active Comparator|Fulvestrant|Goserelin plus High Dose Fulvestrant
3073269|NCT02072512|Active Comparator|Anastrozole|Goserelin plus Anastrozole
3073270|NCT02072499|Experimental|KTP Green Light Prostatectomy|Device
3073271|NCT02072499|Active Comparator|Open prostatectomy|Surgical procedure
3073272|NCT02072486|Experimental|Treatment (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
3073273|NCT02072473||Unsuccessful right-sided AVNRT ablation|Patients with unsuccessful right-sided slow pathway ablation attempt, will be candidates for Coronary sinus / left-sided slow pathway ablation.
3073274|NCT02072460|Experimental|vestibular signals determination|vestibular signals determination by electromyography and electroencephalography associated to approaches from psychophysics
3073275|NCT02072447|Experimental|Microdose|
3073276|NCT02072434|Experimental|edoxaban treatment|Factor Xa inhibitor anticoagulant, oral, edoxaban tablet, 60 or 30 mg QD,28-49 days dosing
3073277|NCT02072434|Active Comparator|enoxaparin / warfarin|Vitamin K antagonist, sq/oral, 100mg/kg or 1 or 2.5 mg tablet QD, 28-49 days
3073278|NCT02072421|Other|Non-SOS|
3073279|NCT02072408|Experimental|polypoidal choroidal vasculopathy without polyp|
3073280|NCT02072395|Experimental|Band/Plication|Treatment -- band/plication
3073281|NCT02072382|Experimental|Metformin|Metformin 850 mg twice a day for eight weeks versus Placebo
3073282|NCT02072369|Experimental|VAEDA Glove|Voice And EMG-Driven Actuated glove used during hand occupational therapy training
3073283|NCT02072369|Active Comparator|No-glove|hand occupational therapy sessions without assistive device
3073284|NCT02072356|Experimental|Treatment (yttrium Y 90 glass microspheres)|Patients receive yttrium Y 90 glass microspheres IA on day 0. Patients may receive additional treatment 4-12 weeks after initial treatment at the discretion of the study physician.
3073285|NCT02072343|Experimental|Mainstream capnometer|
3073286|NCT02072343|Experimental|Microstream capnograph|
3073287|NCT02072330|Active Comparator|TAK-536CCB 20 mg/5 mg ＋Placebo (dual therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide (HCTZ) placebo for 10 weeks
3073288|NCT02072330|Experimental|TAK-536CCB 20 mg/5 mg ＋HCTZ 6.25 mg (triple therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo (triple therapy) for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 6.25 mg for the remaining 8 weeks.
3073289|NCT02072330|Experimental|TAK-536CCB 20 mg/5 mg ＋HCTZ 12.5 mg (triple therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 12.5 mg (triple therapy) for the remaining 8 weeks.
3073290|NCT02072330|Active Comparator|Placebo ＋HCTZ 6.25 mg (HCTZ monotherapy)|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period.
3073291|NCT02072330|Active Comparator|Placebo ＋Hydrochlorothiazide 12.5 mg (HCTZ monotherapy)|TAK-536CCB placebo and Hydrochlorothiazide 12.5 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period.
3073292|NCT02072317|Experimental|Paclitaxel plus raltitrexed|taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle
3073293|NCT02072317|Active Comparator|taxol|taxol 135 mg/m2, every three weeks for a cycle
3073294|NCT02072304|Experimental|web-based CBT|Web-based CBT group : The intervention is made up of 8 internet modules based on behavioral activation, cognitive behavioral therapy
3073295|NCT02072304|Active Comparator|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks
3073296|NCT02072291|Experimental|Nifedipine|Nifedipine 5mg single dose
3073297|NCT02072291|Placebo Comparator|Placebo|
3073298|NCT02072278|Experimental|Vortioxetine 10 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
3073299|NCT02072278|Experimental|Vortioxetine 20 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
3073300|NCT02072278|Active Comparator|Escitalopram 15 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
3073301|NCT02072278|Placebo Comparator|Placebo|capsules; 3 daily doses in each treatment period; orally
3073302|NCT02072265||Port-A implantation and chemotherapy|Patients scheduled for Port-A implantation and subsequent chemotherapy
3073303|NCT02072265||Port-A infection|Patients receiving Port-A removal due to infection
3073304|NCT02072252|Experimental|App teaching cognitive behavioral skills|"App teaching cognitive behavioral skills. This mobile phone application (app) teaches cognitive behavioral techniques to help participants manage their mood, for example by providing information, interactive tools and tips, and a mood tracker. A coach will support participants as they use the app via phone calls and email contacts."
3073305|NCT02072252|No Intervention|Wait-list with referrals|10-week wait-list control condition in which participants will be provided with and encouraged to use mental health referrals to resources in the community. After the 10-week waiting period, control group participants will have the option to receive the mobile phone application and coaching.
3073306|NCT02072239|Experimental|Device Applied|All participants will be treated with the Angioshield
3073307|NCT02072226|Active Comparator|Alteplase Placebo + Aspirin|Participants will receive single dose of IV alteplase placebo and aspirin orally.
3073308|NCT02072226|Experimental|Alteplase + Aspirin Placebo|Participants will receive single dose of IV alteplase and aspirin placebo orally.
3073309|NCT02072213|Experimental|GL2702 GLARS-NF1 , fasted|Tamsulsoin 0.4mg
3073310|NCT02072213|Active Comparator|Omix Ocas® , fasted|Tamsulsoin 0.4mg
3073311|NCT02072213|Experimental|GL2702 GLARS-NF1, after meal|Tamsulsoin 0.4mg
3073312|NCT02072213|Active Comparator|Omix Ocas®, after meal|Tamsulsoin 0.4mg
3073313|NCT02072200|Experimental|Modified release prednisone|Single arm / Lodotra
3073391|NCT02071719||Pazopanib|
3073392|NCT02071719||Axitinib|
3097757|NCT01907256|Active Comparator|Group B|inverted V incision
3073314|NCT02072187|Experimental|Active|"The vitamin D formula that will be used is Bio-D Mulsion 1000, produced by Biotics Research Corporation. This formula contains: Vitamin D (cholecalciferol), water and acacia gum and sesame oil.~Participants will be provided with a dose of vitamin D at each visit beginning at the Baseline visit. The weekly dose of vitamin D will be 28 000IU (the equivalent of 4000IU daily) for a period of eight weeks. If baseline or week 4 serum vitamin D levels are measured as >100nmol/L, the dose will be reduced to 14 000IU (the equivalent of 2000IU daily). The dose will be dispensed, using the bottle dropper, onto a disposable plastic spoon which the participant will insert into their mouth."
3073315|NCT02072187|Placebo Comparator|Placebo|"The placebo formula, also produced by Biotics Research Corporation, will contain all of the non-medicinal ingredients but no vitamin D. It will be identical in appearance and taste.~Participants will be provided with a dose of the placebo at each visit beginning at the Baseline visit. The weekly dose will be 28 drops or 14 drops if serum Vitamin D levels are >100nmol/L. The dose will be dispensed, using the bottle dropper, onto a disposable plastic spoon which the participant will insert into their mouth."
3073316|NCT02072174|Active Comparator|Anaferon for Children (1 tablet 3 times a day)|
3073317|NCT02072174|Placebo Comparator|Placebo (1 tablet 3 times a day)|
3073318|NCT02072161|Experimental|ETC-1002 120 mg/day|Orally, once daily in morning as capsules
3073319|NCT02072161|Experimental|ETC-1002 180 mg/day|Orally, once daily in morning as capsules
3073320|NCT02072161|Placebo Comparator|Placebo|Orally, once daily in morning
3073321|NCT02072148|Experimental|Low Risk Group I|"Group I:~Complete resection (margins: tonsil >1mm, tongue >3mm, pT1-2, pN0-2B),~No LVI, no PNI, <3 positive nodes.~No ECS, No matted or Level >III,"
3073322|NCT02072148|Experimental|Intermediate Risk Group II|"Group II~Complete resection (margins: tonsil <1mm, tongue <1mm, pT1-2, pN0-2B),~+LVI, +PNI, <3 positive nodes. ≤1mm ECS."
3073323|NCT02072148|Experimental|High Risk Group IIIA|"3+ nodes, no ECS > 1mm~Contralateral or supraclavicular nodes"
3073324|NCT02072148|Experimental|High Risk Group IIIB|"Incomplete surgical resection with + surgical margins~≥ 1 mm ECS~Matted nodes"
3073325|NCT02072135|Experimental|Exparel|Exparel 266mg
3073326|NCT02072122||women during fertility treatment|
3073327|NCT02072109||Bolus feeding|Preterm infants born in Meir Medical Center and being treated in the Neonatal Intensive Care Unit
3073328|NCT02072109||Continuous feeding|Preterm infants born in Meir Medical Center and being treated in the Neonatal Intensive Care Unit
3073329|NCT02072096|Experimental|Strategy A (Glucose-Dependent)|Participants may receive oral and injectable (glucagon-like peptide-1 receptor agonists [GLP-1 RA]) therapies that exert a glucose-dependent mode of action. Medications allowed in this arm include: metformin, pioglitazone, acarbose, linagliptin, sitagliptin, liraglutide, exenatide once weekly (QW), and exenatide twice daily (BID). Choice of therapy is based on investigator's discretion. Treatment used in label. Treatment may last up to 72 weeks.
3073330|NCT02072096|Active Comparator|Strategy B (Reference)|Participants will receive glimepiride and may receive basal insulin glargine as a first line injectable therapy. Medications allowed in this arm include: glimepiride, metformin, pioglitazone, acarbose, linagliptin, sitagliptin and basal insulin glargine. Choice of therapy is based on investigator's discretion. Treatment used in label. Insulin glargine is titrated according treatment algorithm. Treatment may last up to 72 weeks.
3073331|NCT02072083|Active Comparator|dexmedetomidine|intranasal 1mcg/kg
3073332|NCT02072083|Active Comparator|ketamine|intranasal 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
3073333|NCT02072070|Experimental|TissueGene-C|Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10^7 cells
3073334|NCT02072070|Placebo Comparator|Placebo|Single intra-articular injection to the damaged knee joint
3073335|NCT02072057|Experimental|Ruxolitinib|Interventional arm
3073336|NCT02072044|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3073337|NCT02072031|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3073338|NCT02072031|Active Comparator|Sunitinib maleate|Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
3073339|NCT02072018|Active Comparator|H-100|H-100, gel, daily, 6 months
3073340|NCT02072018|Placebo Comparator|Placebo|Placebo gel, daily, three months then switch to H-100 for three months
3073341|NCT02072005||Regular cigarette smokers|
3073342|NCT02071979|Experimental|Autologous PRP Gel|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. The application of topical PRP gel may be used in chronic wounds possessing an open, moist wound bed according to following treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare the autologous PRP gel. For data analysis, the data from these patients will be classified as PRP Treatment Group (Topical application) data.
3073343|NCT02071979|Experimental|Autologous PRP Injections|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. Autologous PRP Injections may be used where chronic wounds possess a raised, hyperproliferative wound margin and/or plaque, according to following treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare Autologous PRP for injections. For data analysis, the data from these patients will be classified as PRP Treatment Group (Direct Injection) data.
3073344|NCT02071979|Experimental|Autologous PRP Gel plus PRP Injections|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. Some wounds may be suitable for both Autologous PRP Gel plus PRP Injections. Autologous PRP injections into, or to the periphery of, a moist wound bed in which no scarification or raised wound margin is apparent (where autologous PRP Gel can also be used) may further augment wound healing by addressing wound healing in multiple areas, following the treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare the autologous PRP gel. For data analysis, the data from these patients will be classified as PRP Treatment Group (Topical and Direct) data.
3073393|NCT02071706|Other|Single-Arm PET/MRI|Single-group evaluation of PET/MRI for diagnostic quality of image
3073345|NCT02071979|No Intervention|Standard Wound Care|Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices. For data analysis, the data from these patients will be classified as Control (Standard of Care) Group data
3073346|NCT02071966|Active Comparator|Ticagrelor|Ticagrelor: oral, 180 mg once for the first dose then 90 mg twice a day
3073347|NCT02071966|Active Comparator|Clopidogrel|Clopidogrel: oral, 300 or 600 mg once for the first dose, 75 mg once a day
3073348|NCT02071953|Experimental|Adhesive without acid pretreatment|Experimental adhesive w/out phosphoric acid in post. rest.
3073349|NCT02071953|Active Comparator|Adhesive with acid pretreatment|Experimental adhesive with phosphoric acid in post. rest.
3073350|NCT02071940|Experimental|PLX3397|Patients will be given PLX3397 1000mg/day as monotherapy. Patients will remain on treatment as long as they are deriving benefit. This is a single cohort study and so there is no comparator arm - all patients receive the same treatment.
3073351|NCT02071927|Experimental|CB-839|CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity
3073352|NCT02071927|Experimental|CB-Aza|CB-839 administered as oral capsules twice daily (BID) in combination with azacitidine in 28-day cycles until disease progression or unacceptable toxicity
3073353|NCT02071914|Experimental|CT-P27 10mg/kg|CT-P27 10mg/kg IV in 90 minutes
3073354|NCT02071914|Experimental|CT-P27 20mg/kg|CT-P27 20mg/kg IV in 90 minutes
3073355|NCT02071914|Placebo Comparator|Placebo|Placebo IV in 90 minutes
3073356|NCT02071901|Experimental|Supportive care (eltrombopag olamine)|Patients receive eltrombopag olamine PO QD until platelet counts reach >= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.
3073357|NCT02071888|Experimental|CB-839|CB-839 is administered as oral capsules three times daily (TID) or twice daily with food (BIDf) in 21-day cycles until disease progression or unacceptable toxicity
3073358|NCT02071888|Experimental|CB-839 and low dose dexamethasone|CB-839 is administered as oral capsules twice daily with food (BIDf) in 28 day cycles in combination with dexamethasone until disease progression or unacceptable toxicity
3073359|NCT02071888|Experimental|CB-839, pomalidomide, and low dose dexamethasone|CB-839 is administered as oral capsules twice daily with food (BIDf) in 28 day cycles in combination with pomalidomide and dexamethasone until disease progression or unacceptable toxicity
3073360|NCT02071875||Nautilus NeuroWaveTM recording|Nautilus NeuroWaveTM recording 15 minute recording
3073361|NCT02071862|Experimental|CB-839|CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity
3073362|NCT02071862|Experimental|Pac-CB|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose paclitaxel in 28-day cycles until disease progression or unacceptable toxicity
3073363|NCT02071862|Experimental|CBE|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose everolimus in 28-day cycles until disease progression or unacceptable toxicity
3073364|NCT02071862|Experimental|CB-Erl|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose erlotnib in 28-day cycles until disease progression or unacceptable toxicity
3073365|NCT02071862|Experimental|CBD|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose docetaxel in 21-day cycles until disease progression or unacceptable toxicity
3073366|NCT02071862|Experimental|CB-Cabo|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose cabozantinib in 28-day cycles until disease progression or unacceptable toxicity
3073367|NCT02071849|Experimental|Aortic Valve Repair|Implantation of HAART 200 Aortic Valve Annuloplasty Device for bicuspid aortic valve reconstruction
3073368|NCT02071836|Experimental|Right Turns web application|Right Turns web application
3073369|NCT02071836|Active Comparator|Treatment as usual|Treatment as usual
3073370|NCT02071823|Experimental|Group A Fed/Fasted|"A single 50 mg dose of BIA 9-1067 (2 x 25 mg capsules) was to be administered on:~Period 1: Fed Washout Period (7days) Period 2: Fasted"
3073371|NCT02071823|Experimental|Group B Fasted/Fed|"A single 50 mg dose of BIA 9-1067 (2 x 25 mg capsules) was to be administered on:~Period 1: Fasted Washout Period (7days) Period 2: Fed"
3073372|NCT02071810|Experimental|BIA 9-1067 5 mg|BIA 9-1067 (OPC, Opicapone) 5 mg
3073373|NCT02071810|Experimental|BIA 9-1067 10 mg|BIA 9-1067 (OPC, Opicapone) 10 mg
3073374|NCT02071810|Experimental|BIA 9-1067 20 mg|BIA 9-1067 (OPC, Opicapone) 20 mg
3073375|NCT02071810|Experimental|BIA 9-1067 30 mg|BIA 9-1067 (OPC, Opicapone) 30 mg
3073376|NCT02071810|Experimental|Placebo|Placebo, PLC
3073377|NCT02071797|Active Comparator|Arm A - Blanketroll lll|Cutaneous Cooling Blanket, Blanketroll lll, applied to cool patient to 32C. Standard care
3073378|NCT02071797|Active Comparator|Arm B - RhinoChill|Intra nasal cooling system, RhinoChill, to cool patient to 32C - Standard care
3073379|NCT02071771|Other|DACP T, Then 1DAM A|Nelfilcon A toric contact lenses worn first, with etafilcon A toric contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 10 days.
3073380|NCT02071771|Other|1DAM A, Then DACP T|Etafilcon A toric contact lenses worn first, with nelfilcon A toric contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 10 days.
3073381|NCT02071758|Experimental|20 mcg LEISH-F3 + 5 mcg SLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + SLA-SE at Days 0, 28, and 56. High dose of antigen and low dose of SLA-SE adjuvant.
3073382|NCT02071758|Experimental|20 mcg LEISH-F3 + 10 mcg GLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + GLA-SE at Days 0, 28, and 56. High dose of antigen and high dose of GLA-SE adjuvant.
3073383|NCT02071758|Experimental|5 mcg LEISH-F3 + 10 mcg GLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of GLA-SE adjuvant.
3073384|NCT02071758|Experimental|20 mcg LEISH-F3 + 10 mcg SLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + SLA-SE at Days 0, 28, and 56. High dose of antigen and high dose of SLA-SE adjuvant.
3073385|NCT02071745||Navigation|
3073386|NCT02071732|Active Comparator|Real rTMS|Real rTMS is real continuous theta burst stimulation.
3073387|NCT02071732|Sham Comparator|Sham rTMS|Sham rTMS is sham continuous theta burst stimulation.
3073388|NCT02071719||Sunitinib|
3073394|NCT02071680|Other|Iodine-123 Meta-iodobenzylguanidine|123I-mIBG administration followed by nuclear imaging pre-ablation and post-ablation
3073395|NCT02071667||Subjects who require sinus surgery|
3073396|NCT02071654|Experimental|Venus P-valve transcatheter implantation|Single arm of percutaneous implantation of Venus-P valve for treating RVOT stenosis
3073397|NCT02071641|Experimental|Sunitinib|Patients will be treated in repeated 6-week cycles with 50 mg sunitinib orally daily for 4 weeks followed by 2 weeks off.
3073398|NCT02071615|Experimental|Methylphenidate and placebo|Placebo or Methylphenidate 20 mg tablet given once by mouth
3073399|NCT02071615|Experimental|modafinil and placebo|placebo or modafinil 200mg tablet given once by mouth
3073400|NCT02071615|Experimental|caffein and placebo|placebo or caffein 200mg tablet given once by mouth
3073401|NCT02071602|Placebo Comparator|Placebo|Placebo infused for up to 72 hours IV
3073402|NCT02071602|Active Comparator|CD-NP 5 ng/kg/min|CD-NP 5 ng/kg/min infused for up to 72 hours IV
3073403|NCT02071602|Placebo Comparator|CD-NP 10 ng/kg/min|CD-NP 10 ng/kg/min infused for up to 72 hours IV
3073404|NCT02071589|Experimental|Nifedipine oral solution|Nifedipine 5 mg/mL oral solution, 6 mL (30 mg of Nifedipine) at single dose
3073405|NCT02071589|Active Comparator|Nifedipine soft gelatine capsules|Nifedipine soft gelatine capsules x3 (total 30 mg Nifedipine) at a single dose
3073406|NCT02071576|Experimental|Proscan|Ametropia Lasik treatment of virgin eyes
3073407|NCT02071563|Active Comparator|CSB14|Isocaloric amount and cost-effectiveness of CSB14 (with whey protein concentrate and enhanced micronutrient profile), prepared with fortified vegetable oil (FVO).
3073408|NCT02071563|Active Comparator|RUSF1|Isocaloric amount and cost-effectiveness of Ready-to Use Supplementary Food 1(RUSF1), USAID's Lipid-Based Nutrient Supplement (LNS) product
3073409|NCT02071563|Active Comparator|SC+|Isocaloric amount and cost-effectiveness of Supercereal Plus (SC+), the FBF used by WFP, which has an enhanced nutrient profile, dairy ingredient (non-fat dry milk), and oil already embedded into the flour
3073410|NCT02071563|No Intervention|CSB+|Isocaloric amount and cost-effectiveness of Supercereal/CSB+ prepared with FVO.
3073411|NCT02071550||zero PEEP|Patients undergoing laparoscopic cholecystectomy and monitorized with FORESIGHT,INVOS monitor
3073412|NCT02071550||10 CM H2O PEEP|Patients undergoing laparoscopic cholecystectomy and monitorized with FORESIGHT,INVOS monitor
3073413|NCT02071537|Experimental|Chloroquine with Carboplatin/Gemcitabine|Chloroquine administered orally daily to start one week prior to Carboplatin (AUC5)/Gemcitabine (1250mg/m2). Chloroquine dose is escalating.
3073414|NCT02071524|Active Comparator|Cristalloid|group cristalloid (ringer lactate)
3073415|NCT02071524|Active Comparator|colloids|colloid: cristalloid in according to cardiac output
3073416|NCT02071511|Active Comparator|control group|Ablation of ventricular arrhythmias
3073417|NCT02071511|Sham Comparator|intervention group|Ablation of ventricular arrhythmias + renal denervation
3073418|NCT02071498|Experimental|Pillbox app named ALICE|pillbox app for elderly patients taking multiple medications. App was used during three months
3073419|NCT02071498|Active Comparator|oral and written information|oral and written information regarding the main risks related to their medications and the most common errors of patients
3073420|NCT02071485||No treatment|Subjects in this study will receive no treatment and rather will only be trained in using the motor imagination-based BCI system
3073421|NCT02071472|Experimental|DP medication reconciliation|medication reconciliation by a pharmacist using an electronic pharmaceutical record associated to the anesthesiologist consultation for planned surgery patients.
3073422|NCT02071472|No Intervention|control|conventional anesthesiologist consultation for planned surgery patients
3073423|NCT02071459|Experimental|L-Threo DOPS|patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with L-Threo DOPS
3073424|NCT02071459|Placebo Comparator|placebo|patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with placebo
3073425|NCT02071433|Experimental|Saphenous nerve blockade|Experimental treatment 15 mL of levobupivacaine 0.5%
3073426|NCT02071433|Active Comparator|Femoral nerve blockade|Standard treatment 15 mL of levobupivacaine 0.5%
3073427|NCT02071420|Experimental|Experimental Group|This group will receive the seated active workstation intervention, the ergonomic intervention and the email intervention for 16 weeks.
3073428|NCT02071420|Active Comparator|Active Control|This group will receive the ergonomic intervention and email intervention only for 16 weeks. This group will not receive a seated active workstation.
3073429|NCT02071407|Placebo Comparator|N1(traditional treatment group)|Patients in group N1 are treated with basic therapeutic measures which include reducing intracranial pressure with mannitol, hemostasis, acid inhibition, anti-infection, nutrition support and control of blood glucose, blood pressure and body temprature.
3073430|NCT02071407|Experimental|N2(midazolam group)|Patients in group N2 was treated with intravenous infusion of midazolam on the basis of basic treatment measures which include reducing intracranial pressure with mannitol, hemostasis, acid inhibition, anti-infection, nutrition support and control of blood glucose, blood pressure and body temprature.
3073431|NCT02071394|Experimental|72h cooling + 18h xenon inhalation|Babies in poor condition at birth and referred to our neonatal unit for standard therapy of cooling to 33.5 degree C body temperature will be randomised to receive xenon gas at 50% concentration for 18 hours
3073432|NCT02071394|Active Comparator|Standard 72 h whole body cooling therapy|Whole body cooling therapy to rectal temperature of 33.5 degree Centigrade (standard therapy)
3073433|NCT02071381|Experimental|A|only DW330SR 45mg
3073434|NCT02071381|Experimental|B|only DW1030 75mg
3073435|NCT02071381|Experimental|C|DW330SR 45mg and DW1030 75mg
3073436|NCT02071368|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 300 mg, and 2 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
3073437|NCT02071368|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC (2 x [150 mg/500 mg]) formulation 1, under fed conditions.
3073438|NCT02071368|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC (2 x [150 mg/500 mg]), formulation 2, under fed conditions.
3073439|NCT02071355|Experimental|Group 1|Participants will receive 100 mg TMC435 once daily for 7 days.
3073440|NCT02071355|Experimental|Group 2|Participants will receive 150 mg TMC435 once daily for 7 days.
3073441|NCT02071342||acute coronary syndrome|patients with acute myocardial infarction who are undergoing coronary angioplasty. MACE at 30 days and 1 year will be assessed . The acute recoil after implantation of bioabsorbable stents will also be assessed
3073442|NCT02071329|Experimental|Vaccine FP-01.1|Vaccine FP-01.1
3073443|NCT02071329|Placebo Comparator|Placebo|Placebo
3073444|NCT02071316|Active Comparator|Treatment group, hexacapron , esomeprazole|Treatment group - receive I.V. esomeprazole 80 mg and 8mg/h continuously with concurrent hexacapron I.V. every 6 hours until 72 hours and then continue oral treatment 6 g /day for 7 days.
3073445|NCT02071316|Placebo Comparator|Standard of care group, esomeprazole|* Standard of care group - receive I.V. esomeprazole 80 mg once then 8mg/h continuously
3073446|NCT02071303|Active Comparator|Tramadol|Women will receive Tramadol 100mg 1 hour before the procedure.
3073447|NCT02071303|Active Comparator|Celecoxib|Women will receive Celecoxib 200mg 1 hour before the procedure.
3073448|NCT02071303|Placebo Comparator|Placebo|Women will receive a placebo 1 hour before the procedure.
3073449|NCT02071290|Sham Comparator|Sham Remote Ischemic Conditioning|Sham inflation of pneumatic tourniquet pressure cuff at 0 mmHg on the thigh for 5 minutes and release for 5 minutes (repeated for 4 cycles) applied to trauma patients on arrival to hospital
3073450|NCT02071290|Experimental|Remote Ischemic Conditioning|Inflation of pneumatic tourniquet pressure cuff at 250mmHg on the thigh for 5 minutes and release for 5 minutes (repeated for 4 cycles) applied to trauma patients on arrival to hospital
3073451|NCT02071277|Experimental|Pressure targeted modes|
3073452|NCT02071264|Other|HIV/STI intervention|This study implements a socio-behavioral intervention in Metro Manila, the Philippines, using a community-based participatory approach with 1-2 psychosocial and health education training workshops for the establishment managers and their workers, including street sex workers, focusing on HIV/AIDS risk reduction information, condom use, and condom negotiation skill-building. Participants participate in dream-building activities to explore personal goals and goals for their organization of peers. The interventions are directed at organizational behavior change and social influence modeling through training peers and managers. The participants receive information on STIs along with standard care, held on a day convenient to the participants and at a neutral location.
3073453|NCT02071251|Experimental|Prospective intervention|The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
3073454|NCT02071238|Experimental|Pamphlet|Patient group that will receive a written pamphlet outlining the risks of surgery as discussed in consultation.
3073455|NCT02071238|No Intervention|No pamphlet, individual|Patient group that will not receive a written pamphlet outlining the risks of surgery as discussed in consultation.
3073456|NCT02071238|Experimental|Group Consultation|Patient group that will receive informed consent discussion in a group-format.
3073457|NCT02071225|Experimental|obinutuzmab + bendamustine|Participants will receive obintuzumab and bendamustine in 28-days cycles for a maximum of 6 cycles
3073458|NCT02071212|Active Comparator|Clopidogrel|Loading dose 600 mg .Mainatinance dose 75 mg QD
3073459|NCT02071212|Experimental|Ticagrelor|Loading dose 180 mg . Maintenance 90 mg BID
3073460|NCT02071199|Experimental|Low dose 0.3X ACCS|20 microliters of 0.3X ACCS per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
3073461|NCT02071199|Experimental|High dose 1X ACCS|20 microliters of 1X ACCS per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
3073462|NCT02071199|Placebo Comparator|Normal saline|20 microliters of saline placebo per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
3073463|NCT02071186|Experimental|Virtual Reality training|Subjects will be asked to walk on a treadmill while negotiating virtual obstacles. The VR system includes a camera based motion capture and a computer generated simulation. The camera is used to capture the movement of the participant's feet. These images are then transferred to the computer simulation and projected to the patient on a screen. The speed, orientation, size, frequency of appearance and shape of the targets are manipulated to increase task difficulty. The Virtual environment imposes a cognitive load requiring attention and response selection as well as processing of rich visual stimuli involving several perceptual processes. The system provides visual and auditory feedback of task performance to enhance motor learning.
3073464|NCT02071186|Experimental|Computerized Cognitive Remediation|"The AttenGo program will be used for neuro-cognitive remediation aimed at enhancing attention, concentration, working memory, and executive function. The program has shown to be effective in improving attention and executive function in children with ADHD. The training is composed of cognitive exercises that challenge subjects with problem solving, information processing, response inhibition and dividing attention. The users receive immediate feedback from the system when losing focus. The program is adaptive and progresses according to the subjects abilities."
3073465|NCT02071186|Active Comparator|Control group|Subjects in this group will be assessed based on the study protocol but will receive no treatment other than their standard of care which could include pharmacological or/ and non-pharmacological treatment.
3073466|NCT02071160|No Intervention|Healthy Control|A group of healthy control without any history suggestive of perinatal asphyxia or other diseases, are enrolled to compare different laboratory measurements
3073467|NCT02071160|No Intervention|Hypothermia Group|HIE infants who will not receive melatonin and only receive routine cooling protocol.
3073468|NCT02071160|Experimental|Melatonin/ hypothermia group|HIE infants who will receive melatonin in addition to the routine cooling protocol
3073469|NCT02071147|Other|Standard clinical intervention|Patients reviewed at 6 weeks (+/- 1 week) as is our normal practice and recalled for a further evaluation if deemed appropriate. Patients will be instructed to visit their optometrist once their eye has fully recovered from the operation for provision of glasses.
3073470|NCT02071147|Other|No Clinical Follow up|No routine follow-up appointment is made. Patients will be instructed to visit their optometrist between 6-8 weeks post-operative for review of the patient's glasses.
3073471|NCT02071134||Parkinson's disease|Subjects with Parkinson's disease who will receive Vercise DBS for deep brain stimulation.
3073472|NCT02071121|Placebo Comparator|Placebo|Fasted participants will receive a single oral dose of placebo to BIIB061.
3073473|NCT02071121|Experimental|BIIB061 3 mg|Fasted participants will receive a single oral dose of BIIB061 3 mg.
3073474|NCT02071121|Experimental|BIIB061 10 mg|Fasted participants will receive a single oral dose of BIIB061 10 mg followed by a tracer amount of 14C-BIIB061 (at ≤ 500 nCi/participant; approximately 4 μg of BIIB061), administered by manual slow intravenous push injection at 4 hours postdose.
3073475|NCT02071121|Experimental|BIIB061 30 mg|Fasted participants will receive a single oral dose of BIIB061 30 mg. Following a washout period, participants will receive the same dose of BIIB061 after a high-fat, high-calorie meal (fed state).
3073476|NCT02071121|Experimental|BIIB061 60 mg|Fasted participants will receive a single oral dose of BIIB061 60 mg.
3073477|NCT02071121|Experimental|BIIB061 100 mg|Fasted participants will receive a single oral dose of BIIB061 100 mg.
3073478|NCT02071108|Experimental|Lithoplasty Treatment|Shockwave Lithoplasty System
3073479|NCT02071095|Experimental|Arm A: Poly-ICLC|Arm A (N=15): Patients will receive an injection of 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir) subcutaneously on day 1 and day 2.
3073480|NCT02071095|Placebo Comparator|Arm B: Normal Saline|Arm B: (N=5): Patients will receive an injection of normal saline subcutaneously on day 1 and day 2.
3073481|NCT02071082|Experimental|HIV treatment-naive and HBV treatment-naive|HIV/HBV coinfected participants who are HIV treatment-naive and HBV treatment-naive will receive E/C/F/TAF for 48 weeks.
3073482|NCT02071082|Experimental|HIV-suppressed|HIV/HBV coinfected participants who are HIV-suppressed will receive E/C/F/TAF for 48 weeks.
3073483|NCT02071069|Experimental|maintenance therapy|"Initially, all subjects received 8 cycles of Cetuximab (400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks)plus FOLFIRI (irinotecan 180 mg/m2 IV on day 1 , leucovorin 400mg/m2 on day 1 , fluorouracil 400mg/m2 on day 1 and fluorouracil 2400mg/m2 civ46h every 2 weeks) .~After 8 cycles or severe toxicity, patients received maintenance therapy comprising Cetuximab (250mg/m2 every week or 500mg/m2 every 2 weeks) and either irinotecan( 180 mg/m2 IV every 2 weeks) or fluorouracil arm( leucovorin 400mg/m2 on day 1 , fluorouracil 400mg/m2 on day 1 and fluorouracil 2400mg/m2 civ46h every 2 weeks ). In cases of unacceptable toxicity, only the related medication was stopped"
3073484|NCT02071056||history of visceral cancer|
3073485|NCT02071043|Experimental|XELOX|"XELOX: Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:~Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks"
3073486|NCT02071030|Other|CBCT|Cone Beam CT
3073487|NCT02071030|Other|Panoramic radiograph|
3073488|NCT02071004|Other|Aspirin|Dispersible tablet, 300mg & 75 mg, once daily for 5 days
3073489|NCT02071004|Experimental|DS-1040b|IV of 6 mg given once over 30 minutes
3073490|NCT02070991|Experimental|Macitentan|oral tablet, 10 mg once daily.
3073491|NCT02070991|Placebo Comparator|Placebo|Matching placebo, once daily.
3073492|NCT02070978|Experimental|Atacicept 75 mg|
3073493|NCT02070978|Experimental|Atacicept 150 mg|
3073494|NCT02070965|Experimental|DFD01 Spray Group 1|DFD01 Spray, bid, 28 days
3073495|NCT02070965|Active Comparator|Comp01 Lotion|Comp01 Lotion, bid, 14 days
3073496|NCT02070965|Experimental|DFD01 Spray Group 2|DFD01 Spray, bid, 14 days
3073497|NCT02070952|Experimental|CyberKnife|CyberKnife Stereotactic Ablative Body Radiation Therapy
3073498|NCT02070939|Experimental|SAD cohorts 1-7 Experimental Arm|
3073499|NCT02070939|Placebo Comparator|SAD Cohorts 1-7 Placebo Arm|
3073500|NCT02070939|Experimental|MAD cohorts 2-6 Experimental Arm|
3073501|NCT02070939|Placebo Comparator|MAD cohorts 2-6 Placebo Arm|
3073502|NCT02070939|Experimental|Japanese MAD cohort 7 Experimental arm|
3073503|NCT02070939|Placebo Comparator|Japanese MAD cohort 7 Placebo Arm|
3073504|NCT02070926||Perform coronary CT angiography|
3073505|NCT02070926||Do not perform coronary CT angiography|
3073506|NCT02070900|No Intervention|Standard of Care|Sites implementing Option B+ for pregnant and lactating women according to the standard of care prescribed by the Ministry of health and Child Care national guidelines
3073507|NCT02070900|Experimental|POC Plus|Sites implementing Option B+ according to the standard of care prescribed by the Ministry of Health and Child Care, as well as programmatic mentoring and POC CD4 machines
3073508|NCT02070887||Entacapone|
3073509|NCT02070887||No Entacapone|
3073510|NCT02070874|Experimental|telehealth enhanced pain management|video-case conferences for providers PainTracker for patients
3073511|NCT02070874|No Intervention|usual care|usual care
3073512|NCT02070861|Experimental|Comparing cardiac output changes|"Explore the relationship between changes in cardiac output measured with eosophagal Doppler, the volume-clamp-method and exhaled CO2 during ventricular pacing and passive leg raise.~Measurements with the volume-clamp-method were aborted due to technological difficulties."
3073513|NCT02070848||Concentric vs eccentric|One arm study in which each subject will act as his own control.
3073514|NCT02070835|Experimental|ReCell®|ReCell® with skin graft
3073515|NCT02070835|Active Comparator|skin graft|split-thickness skin graft as control group
3073516|NCT02070822||TACE patients, for HCC|unresectable HCC patients
3073517|NCT02070809|Experimental|tissue-engineered skin method|This method is composite of skin grafting over human acellular dermal matrix scaffold the investigators used before with skin basal cell as seed cells, moreover it was finished in the surgery without culturing the cells
3073518|NCT02070809|Active Comparator|split-thickness skin graft method|This method is traditional split-thickness skin graft
3073519|NCT02070796|Experimental|Treatment A - B|Single application of the test transdermal patch (Treatment A, Rotigotine PR2.2.1) for 24 hours, followed by a Wash-Out Period of 7 days and a single application of the reference transdermal patch (Treatment B, Rotigotine PR2.1.1) for 24 hours.
3073598|NCT02070289|Experimental|Group 1: Cohort 2|
3073520|NCT02070796|Active Comparator|Treatment B - A|Single application of the reference transdermal patch (Treatment B, Rotigotine PR2.1.1) for 24 hours, followed by a Wash-Out Period of 7 days and a single application of the test transdermal patch (Treatment A, Rotigotine PR2.2.1) for 24 hours.
3073521|NCT02070783|Experimental|ARA290|11-amino acid, linear peptide ARA290; intravenous injection with 2 mg ARA290 (single dosage).
3073522|NCT02070783|Placebo Comparator|Placebo|saline (NaCl 0.9%)
3073523|NCT02070770|Experimental|Very low calorie diet|
3073524|NCT02070770|Active Comparator|Standard weight loss diet|
3073525|NCT02070757|Experimental|Ceftolozane/tazobactam|ceftolozane/tazobactam IV 3000 mg (comprising 2000 mg ceftolozane and 1000 mg tazobactam) every 8 hours for 8-14 days, or 14 days for Pseudomonas aeruginosa.
3073526|NCT02070757|Active Comparator|meropenem|meropenem IV 1000 mg every 8 hours for 8-14 days, or 14 for Pseudomonas aeruginosa
3073527|NCT02070744|Experimental|PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h|Participants received VX-661 50 milligram (mg) tablet plus Ivacaftor (IVA) 150 mg tablet every 12 hours (q12h) for 12 weeks.
3073528|NCT02070744|Placebo Comparator|PC Phase: VX 661 placebo q12h + IVA placebo q12h|Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.
3073529|NCT02070744|Experimental|PC Phase: VX-661 100 mg qd + IVA 150 mg q12h|Participants received two VX-661 50 mg tablets once daily (qd) plus IVA 150 mg tablet q12h for 12 weeks.
3073530|NCT02070744|Placebo Comparator|PC Phase: VX -661 placebo qd + IVA placebo q12h|Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.
3073531|NCT02070744|Experimental|OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h|Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.
3073532|NCT02070731|No Intervention|unprotected TAVI|standard unprotected Transcatheter Aortic Valve Implantation
3073533|NCT02070731|Experimental|TAVI with the TriGuard HDH|TAVI with the TriGuard HDH embolic deflection device
3073534|NCT02070718|Placebo Comparator|Placebo|Cornstarch, National Formulary
3073535|NCT02070718|Experimental|Standard Dose Kappa Agonist|Pentazocine/Naloxone 50/0.5 mg
3073536|NCT02070718|Experimental|Half Dose Kappa Agonist|Pentazocine/Naloxone 25/0.25 mg
3073537|NCT02070705|Experimental|Arm I (High-risk for familial/hereditary pancreatic cancer)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) yearly for a minimum of 3 scans.
3073538|NCT02070705|Experimental|Arm II (IPMN)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) prior to surgery for resection of IPMN.
3073539|NCT02070705|Experimental|Arm III (Pancreatic cancer)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) before and after receiving neoadjuvant therapy for borderline or locally advanced pancreatic cancer.
3073540|NCT02070705|Active Comparator|Arm IV (Healthy volunteers)|Patients undergo a single DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) examination.
3073541|NCT02070692|Experimental|Tamoxifen|Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.
3073542|NCT02070692|Placebo Comparator|Placebo|Placebo tablets twice daily for seven days, to be started on the third day of a bleeding episode.
3073543|NCT02070679|Placebo Comparator|Placebo|
3073544|NCT02070679|Active Comparator|Vit-E|600 IU on 12 hours before angiography and 400 IU on 2 hours before angiography
3073545|NCT02070666|Experimental|Protective ventilation arm|"Low tidal volumes (from 4 to 6 milliliters(mL)/kilogram (kg) of predicted body weight (PBW)~Plateau pressure less than 25 centimeter of water (cmH2O)~Minimum PEEP of 5 cmH2O."
3073546|NCT02070666|Active Comparator|Control group|"Traditional-sized tidal volumes (from 8 to 10 mL/kg PBW)~Plateau pressure less than 25 cmH2O~Minimum PEEP of 5 cmH2O."
3073547|NCT02070653|Active Comparator|Ticagrelor|Ticagrelor 90 mg tablets twice daily for 12 months.
3073548|NCT02070653|Placebo Comparator|Placebo|Ticagrelor-placebo tablets twice daily for 12 months.
3073549|NCT02070640|Experimental|NIRF-C|Each subject enrolled in this study will undergo near-infrared cholangiography fluorescence (NIRF-C) and standard of care intraoperative cholangiography. 2.5 mg of indocyanine green is injected 30-60 minutes prior to surgery. Visualization of the biliary tree during surgery is achieved with a near-infrared light source and camera.
3073550|NCT02070627|Experimental|NIRF-C and IOC|Each enrolled subject will undergo injection with indocyanine green (ICG), intraoperative near infrared fluorescence cholangiography (NIRF-C) and standard of care intraoperative cholangiography.
3073551|NCT02070614||rs2242480 wild-type homozygote|*1/*1 Grouped by rs2242480 polymorphism genotyping
3073552|NCT02070614||rs2242480 mutant heterozygote|*1/*1G Grouped by rs2242480 polymorphism genotyping
3073553|NCT02070614||rs2242480 mutant homozygote|*1G/*1G Grouped by rs2242480 polymorphism genotyping
3073554|NCT02070588|Active Comparator|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
3073555|NCT02070588|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
3073556|NCT02070575||Pts with prostate cancer|This study is planned to determine the kallikrein panel of 200 patients presenting with biochemical recurrence (PSA ≥ 0.05ng/ml) after radical prostatectomy prior to any additional therapy or minimum post 1 year additional therapy.
3073557|NCT02070562||Community Group|Chinese lactating mothers from community maternal & child healthcare centre
3073558|NCT02070562||VIP Group|Chinese lactating mothers from VIP clinics (maternal care center)
3073559|NCT02070549|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3073560|NCT02070536||ARDS (Acute Respiratory Distress Syndrome)|
3073561|NCT02070523|Experimental|PLD-contained VDCLD regimen|PLD 36 mg/m2 ivdrip over 60 minutes( d1、15),VCR 1.4mg/m iv(d1，8，15，22), CTX 800 mg/m2 ivdrip( d1), L-asp 6000u/m2 ivdrip(d19～28),Dex10mg ivdrip (d1～28).
3073599|NCT02070289|Experimental|Group 1: Cohort 3|
3073600|NCT02070289|Experimental|Group 2: Cohort 4|
3073562|NCT02070523|Active Comparator|DNR-contained VDCLD regimen|DNR 45 mg/m2 ivdrip over 60 minutes(d1～3),VCR 1.4mg/m2 iv(d1，d8，d15，d22), CTX 800 mg/m2 ivdrip(d1), L-asp 6000u/m2 ivdrip(d19～28),Dex10mg ivdrip(d1～28).
3073563|NCT02070510|Experimental|Victim and perpetrator compounds|Subjects receive two different victim compounds (lisinopril and warfarin) and two different perpetrator compounds (placebo semaglutide with carrier and oral semaglutide). Each dosing occasion is separated by a 7-day wash-out period.
3073564|NCT02070497|Experimental|case management_new|The patients with new-diagnosed lung cancer and accepting case management
3073565|NCT02070497|Experimental|case management_old|the patients with non-new-diagnosed lung cancer and with accepting case management
3073566|NCT02070497|No Intervention|control group|The patients with new-diagnosed lung cancer in the period of one year ago and without accepting case management
3073567|NCT02070484|Experimental|NuCel|Stemcell allograft
3073568|NCT02070484|Active Comparator|Demineralized Bone Matrix (DBM)|Demineralized Bone Matrix (DBM) bone graft substitute
3073569|NCT02070471|Experimental|LC28-0126 Dose A|LC28-0126 Dose A
3073570|NCT02070471|Experimental|LC28-0126 Dose B|LC28-0126 Dose B
3073571|NCT02070471|Experimental|LC28-0126 Dose C|LC28-0126 Dose C
3073572|NCT02070471|Placebo Comparator|Placebo|Placebo
3073573|NCT02070458|Experimental|Treatment (ixazomib, MEC)|Patients receive ixazomib PO on days 1, 4, 8, and 11; they receive mitoxantrone hydrochloride IV, etoposide IV over 1 hour; the receive intermediate-dose cytarabine IV over 6 hours on days 1-6.
3073574|NCT02070445||Patients undergoing CABG|Patients will have no ventilation during CABG. There will be non-invasive assessments of the lung using ultrasound at different times during the perioperative period.The first assessment will be conducted before anesthesia induction (i.e. patients will be awake). A second assessment will be conducted after anesthesiology induction, but before the beginning of surgery. A third assessment will be conducted at the end of the surgery in the operating room. And two subsequent assessments will be conducted in ICU before and after extubation.
3073575|NCT02070432|Experimental|LUZ11 PDT|"Study consists of two phases, in each participant:~Dose-finding phase with sequential periods in which single-ascending doses of LUZ11 will be titrated up to a dose that shows to be effective following photoirradiation of small spots of tumor surface.~Final PDT session with the previously identified individual effective dose."
3073576|NCT02070419|Active Comparator|Arm I (TACE)|Patients undergo (transarterial chemoembolization) TACE according to institutional standard with doxorubicin-eluting beads.
3073577|NCT02070419|Experimental|Arm II (TACE+SBRT)|Patients undergo transarterial chemoembolization (TACE) as in Arm I and 3 or 5 fractions of stereotactic radiosurgery (SBRT) given at least 48 hours apart over 14 days.
3073578|NCT02070406|Experimental|Treatment (gene-modified T-cells, vaccine therapy, ipilimumab)|"CONDITIONING CHEMOTHERAPY REGIMEN: Patients receive cyclophosphamide IV on days -5 and -4 and fludarabine phosphate IV over 30 minutes daily on days -4 to -1.~NY-ESO-1 TCR PBMC INFUSION: Patients receive NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV on day 0.~IPILIMUMAB ADMINISTRATION: Patients receive ipilimumab IV over 90 minutes before the NY-ESO-1 TCR PBMC infusion on day 0 or after the infusion on day 1. Treatment repeats every 3 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity.~NY-ESO-1(157-165) PEPTIDE PULSED DC ADMINISTRATION: Patients receive NY-ESO-1(157-165) peptide pulsed DC vaccine ID on days 1, 14, and 30.~LOW DOSE IL-2 ADMINISTRATION: Patients receive aldesleukin (IL-2) SC BID on days 1-14."
3073579|NCT02070393|Experimental|Radiation Treatment using Protons|14 -24 Radiation Treatments (typically 1.5 - 1.8 cobalt-Gray equivalent per fraction for 14-24 treatments).
3073580|NCT02070380|Experimental|MultiHance 0.1 then Dotarem 0.1 mmol/kg|MultiHance 0.1 mmol/kg Then Dotarem 0.1 mmol/kg
3073581|NCT02070380|Experimental|MultiHance 0.05 then Dotarem 0.1 mmol/kg|MultiHance 0.05 mmol/kg Then Dotarem 0.1 mmol/kg
3073582|NCT02070380|Active Comparator|Dotarem 0.1 then MultiHance 0.1 mmol/kg|Dotarem 0.1 mmol/kg Then MultiHance 0.1 mmol/kg
3073583|NCT02070380|Active Comparator|Dotarem 0.1 then MultiHance 0.05 mmol/kg|Dotarem 0.1 mmol/kg Then MultiHance 0.05 mmol/kg
3073584|NCT02070367|Experimental|Somatosensory rehabilitation|Weekly sessions with a certified (RSDC) somatosensory therapist using distal vibro-tactile counter-stimulation to anatomically related territories of the area of allodynia. Participants will also be provided with a structured home exercise program.
3073585|NCT02070367|Active Comparator|Usual treatment|Treatment as usual for condition Physiotherapy sessions
3073586|NCT02070354||Group 1|New clinic visit in GI Nutrition (prior to bariatric surgery).
3073587|NCT02070354||Group 2|1 month prior to bariatric surgery
3073588|NCT02070354||Group 3|6 months after bariatric surgery
3073589|NCT02070354||Group 4|12 months after bariatric surgery
3073590|NCT02070354||Group 5|24 months after bariatric surgery
3073591|NCT02070354||Group 6|≥ 36 months after bariatric surgery
3073592|NCT02070341|Experimental|Split dose PEG|Patients randomized to the Polyethylene Glycol (PEG) group will be instructed to ingest 2L of bowel preparation the night before their colonoscopy (starting at 7PM), as well as 1.5-2L of carbohydrate-electrolyte rehydration solution. The following day they will be instructed to ingest the remaining 2L of bowel preparation and must finish ingesting the entire preparation at least 4 hours prior to the scheduled colonoscopy.
3073593|NCT02070341|Experimental|Split dose Picosalax|Patients randomized to the Picosalax (P/MC) group will be instructed to mix one sachet in 150mL of water and ingest the entire mixture at 7PM the night before their colonoscopy. In addition, they will be instructed to ingest 1.5-2L of carbohydrate-electrolyte rehydration solution after they consume the P/MC sachet. The following day they will mix the second sachet in 150mL of water and must finish ingesting the entire preparation at least 4 hours prior to the scheduled colonoscopy. They will also be instructed to drink additional carbohydrate-electrolyte rehydration solution after they ingest the P/MC sachet.
3073594|NCT02070328||Radiation therapy Registry|Cancer patients who have received proton therapy
3073595|NCT02070302|Active Comparator|Botulinum Toxin Type A|After appropriate consent, each patient will receive 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
3073596|NCT02070302|Placebo Comparator|Placebo|.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
3073597|NCT02070289|Experimental|Group 1: Cohort 1|
3073603|NCT02070276|No Intervention|Arm A|"This arm is considered the current clinical standard for spinal anesthesia; its used as a control sample and statistical reference. During the induction phase the patient is fitted with a non-invasive blood pressure monitoring, three-lead ECG, pulse oximetry and peripheral intravenous device. The pressure control is set as the standard every 5 minutes until the procedure under spinal anesthesia, the cuff pressure is placed on the arm that is going to be on top during spinal anesthesia.~Data is recorded and vital signs of the patient and is put an infusion of crystalloid (0.9% NaCl or Ringer's acetate) with administration of 500 ml during the entire procedure until the beginning of the operation."
3073604|NCT02070276|Experimental|Arm B|"In addition to the current clinical standard (arm A of the study) a trans-thoracic echocardiography is performed with the aim of assessing patient's volume status, identifying if he is responsive to fluid and could benefit from their administration. The echocardiography is performed with the subcostal projection to assess the size of the abdominal inferior vena cava and its collapsing during breathing.~According to different pre-established parameters, the patient is defined as unresponsive to fluids or responsive. If it's not responsive, he proceed to spinal anesthesia. Otherwise investigators proceed to the administration of crystalloid (NaCl 0.9% or Hartmann's solution second clinical evaluation) and at the end he's rerun an echocardiographic assessment."
3073605|NCT02070276|Experimental|Arm C|"In addition to the arm A of the study, is performed a measurement of systemic pressure with a patient positioned in semi-recumbent position. After, investigators run the Passive Leg Raising Test (PLRT): the position of the bed is changed in such manner to bring the trunk from 45° to 0° and accordingly the legs from 0° to 45°. Measurements are performed before and during the maneuver (at one minute): an increase of 5% of the systolic blood pressure is interpreted as a responsiveness to liquids.~If the patient is not responsive to fluids, the patient is moving to the spinal anesthesia. If the patient is responsive investigators proceed to bolus administration, the patient returns to the initial PLRT position and is run again the PLRT until the patient is no longer responsive to fluids."
3073606|NCT02070250|Experimental|From Cancer to Health (C2H-D)|Individuals participating in the From Cancer to Health (C2H-D) Stress Management Psychological Intervention
3073607|NCT02070237|Active Comparator|Enoxaparin Once Daily|This arm will have patients randomized to receive 40 mg sub-cutaneous injection of Lovenox (enoxaparin) once daily.
3073608|NCT02070237|Active Comparator|Enoxaparin Twice Daily|This arm will have patients randomized to receive weight based (0.5 mg/kg) sub-cutaneous injection of Lovenox (enoxaparin) twice daily.
3073609|NCT02070224|Other|Knee osteoarthritis|
3073610|NCT02070211|Experimental|omega-3 PUFAs in add on to standard care|omega-3 PUFA supplementation as an adjunct to non-neuroleptic, standard therapy in individuals with 22q11DS and UHR criteria for psychosis
3073611|NCT02070211|Placebo Comparator|Placebo in add on to standard care|Placebo made by paraffin oil (not absorbed by the gastrointestinal tract) as an adjunct to non-neuroleptic, standard therapy in individuals with 22q11DS and UHR criteria for psychosis
3073612|NCT02070198|Experimental|Long acting FSH and GnrH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
3073613|NCT02070198|Experimental|daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
3073614|NCT02070198|Experimental|Triptorelin and recombinant FSH|Women in triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day until the day of HCG administration.
3073615|NCT02070185|Experimental|2 exposures|During the conditioning period, the children of this group was exposed only twice to the beverages
3073616|NCT02070185|Experimental|7 exposures|During the conditioning period, children of this group were exposed exposed 7 times to the beverages
3073617|NCT02070172||Cervicogenic Headache Group|This group of subjects is considered the symptomatic group. No intervention was provided in this study so there are no intervention groups.
3073618|NCT02070172||Healthy, Asymptomatic Group|Subjects in this group had no headache symptoms. Their neck motion was compared to subjects in the headache group. No intervention was provided to subjects in either group for this study.
3073619|NCT02070159|Active Comparator|Clopidogrel 600 mg|Patients administer conventional loading dose of clopidogrel 600 mg as active comparators.
3073620|NCT02070159|Experimental|Prasugrel 30 mg|Patients administer lower loading dose of prasugrel 30 mg.
3073621|NCT02070159|Active Comparator|Prasugrel 60 mg|Patients administer conventional loading dose of prasugrel 60 mg as active comparators.
3073622|NCT02070133|Experimental|Simvastatin|Patients with COPD will receive simvastatin 40 mg once a day for 12 weeks
3073623|NCT02070133|Placebo Comparator|Placebo|Patients with COPD will receive placebo once a day during 12 weeks
3073624|NCT02070120|Experimental|Chemoresection|4 once weekly outpatient intravesical instillations 40mg Mitomycin C
3073625|NCT02070120|Other|Surgical Management|Surgical management according to local practice
3073626|NCT02070107|Other|no arms|no arms, sponsor withdrew
3073627|NCT02070081|Experimental|Surgery|
3073628|NCT02070068|Experimental|Group 1|ICG administered 10 minutes prior to time of visualization
3073629|NCT02070068|Experimental|Group 2|ICG administered 45 min prior to time of visualization
3073630|NCT02070055||No treatment|No treatment
3073631|NCT02070042|Experimental|Omega- 3 Fatty Acid|The patient will receive oxybutynin 5 mg twice daily (BID). The patients in the study group will receive a 0.9 gm capsule of Omega-3 BID. The amount of medication was chosen based on dosage used in prior studies and the current FDA recommendations to not exceed 2gm/day of omega-3 in dietary supplementation.
3073632|NCT02070042|Placebo Comparator|Placebo|Seagate® Extra Virgin Olive oil capsules
3073633|NCT02070029|Experimental|Acupuncture|"Acupuncture Therapy~- twice weekly sessions for 5 weeks: 1st session 60 minutes with remaining 9 session approximately 45 minutes each. Physical exam at 1st session includes evaluation of peripheral pulses, head, neck, throat/tongue. No pelvic exam required."
3073634|NCT02070016|Experimental|TMS Parameter Condition 1 first|Application of Transcranial Magnetic Stimulation
3073635|NCT02070016|Experimental|TMS Parameter Condition 2 First|Application of Transcranial Magnetic Stimulation
3073636|NCT02070003|Experimental|Motivational Interviewing and Physician Guided Opioid Weaning|Patients will go through motivational interviewing with the study physician via phone once a week for 7 weeks, and once a month up to a year as applicable, until patient completes the protocol.
3073637|NCT02070003|No Intervention|Usual Care|
3073638|NCT02069990|Active Comparator|30000 IU cholecalcipherol once a week|30000 IU cholecalcipherol once a week oral
3073639|NCT02069990|Experimental|7000 IU cholecalcipherol once a week|7000 IU cholecalcipherol once a week oral
3073640|NCT02069990|Experimental|30000IU cholecalcipherol once a month|30000IU cholecalcipherol once a month oral
3073641|NCT02069990|Active Comparator|1000 IU cholecalciferol once a day|1000 IU cholecalciferol once a day
3073642|NCT02069977|Experimental|Aripiprazole|"Dose level: 2, 5, 10, 15 mg/day~Starting dose: 2 mg/day~Dose increment: The dose should be gradually increased according to the investigator's judgment of subject's response.~Target dose: 5-15 mg/day~Maximum dose: 15 mg/day~Flexibly dosed (2 to 15 mg/day) aripiprazole (oral tablet or solution) is taken once in a day at the same time without regarding to meals"
3073643|NCT02069964||Prospective hemi-neck RT|
3073644|NCT02069951|Experimental|Practice two procedures on a simulator|"All participants start by practicing a series of six basic skills modules until they reach a predefined proficiency level for each module. For all of the basic skills exercises proficiency is reached when the participants have passed the proficiency level for all exercises.~Participants randomised to the intervention group will practice two procedures on a simulator. First a procedural module A (a laparoscopic appendectomy) to a predefined proficiency level. Upon reaching proficiency for procedural module A the participants will practice procedural module B (a laparoscopic salpingectomy) to a predefined proficiency level."
3073645|NCT02069951|No Intervention|Practice one procedure on a simulator|"All participants start by practicing a series of six basic skills modules until they reach a predefined proficiency level for each module. For all of the basic skills exercises proficiency is reached when the participants have passed the proficiency level for all exercises. Each exercise has to be passed twice within five consecutive attempts.~Participants randomised to the control group will practice procedural module B (a laparoscopic salpingectomy) to a predefined proficiency level."
3073646|NCT02069938||Healthy Subjects|Noninvasive Brain Computer Interface Control
3073647|NCT02069925|Experimental|Early Detection (ED)|This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
3073648|NCT02069925|Active Comparator|Usual Detection|This intervention will provide equivalent best practice care without the benefit of an early detection campaign
3073649|NCT02069912|Experimental|Collaborative depression care|All enrolled patients will receive collaborative depression care management.
3073650|NCT02069899|Other|NI-0501 only in case is requested|NI-0501, in the event that, upon request of the treating physician, NI-0501 treatment needs to be prolonged beyond Week 8 foreseen in the previous protocol, patients will continue receiving NI-0501 in the context of this study.
3073651|NCT02069886|Experimental|deferasirox|single arm. all patients will receive deferasirox
3073652|NCT02069873|Experimental|16-Week Group Treatment|The 16-week treatment group will contain 3 blocks of treatment (exposure, cognitive, skills) with order randomized within the treatment. The first and last group session are considered inactive treatment sessions. The group treatment will be provided weekly.
3073653|NCT02069873|No Intervention|Wait List Control|The Wait List Control group will receive minimal attention, as they will meet bi-monthly for supportive sessions with the study psychologist. The study psychologist will not introduce any active treatment in the individual sessions.
3073654|NCT02069860|Experimental|Access for heamodialysis treatment|The Bone Anchored Port System (BAP) will be implanted in the mastoid bone behind the ear, connected with a double lumen central venous catheter inserted in the jugular vein, and will be used in conjunction with an adapter as a permanent vascular access for hemodialysis treatment
3073655|NCT02069847|Experimental|Esophageal stricture, Budesonide|Budesonide 1mg twice a day for a total of 8 weeks following endoscopic submucosal dissection or endoscopic mucosal resection
3073656|NCT02069834|Experimental|Arm 1 (intervention)|Dolutegravir 50 mg/d + Rilpivirine 25 mg/d qd orally (intake during a meal)
3073657|NCT02069834|Active Comparator|Arm 2 (control)|Continuation of existing HAART at the time of randomization
3073658|NCT02069821|Experimental|Group A|single administration : amlodipine/valsartan 10/160mg, qd, 10days(oral)
3073659|NCT02069821|Experimental|Group B|single administration : atorvastatin 40mg, qd, 7days(oral)
3073660|NCT02069808|Experimental|Group B: Follistim and Menopur|"Group B: N=25 subjects~Cycle day 2 start Follistim 200 U/day up to 11 days duration.~Cycle day 2 start Menopur (menotropins) 75 U/day up to 11 days duration.~Add GnRH antagonist Ganirelix 250 µg/day starting 5 days before GnRH agonist trigger.~GnRH agonist Leuprolide Acetate (Lupron) 1 mg subcutaneous injection 36 hours prior to egg collection.~Transvaginal ultrasound guided needle aspiration of oocytes 36 hours after Lupron trigger."
3073661|NCT02069808|Active Comparator|Group A: Follistim only|"Group A: N=25 subjects~Cycle day 2 start Follistim 250 U/day up to 11 days duration.~Add GnRH antagonist Ganirelix 250 µg/day starting 5 days before GnRH agonist trigger.~GnRH agonist Leuprolide Acetate (Lupron) 1 mg subcutaneous injection 36 hours prior to egg collection.~Transvaginal ultrasound guided needle aspiration of oocytes 36 hours after Lupron trigger."
3073662|NCT02069795|Experimental|Voice recording|Subjects voices were recorded as they spoke specific words
3073706|NCT02069418|Experimental|Experimental arm|All patients will be in the same arm. Patients are going to have two 18F-FLT-TEP and two 18F-FDG-TEP : the first ones during the two weeks before the beginning of erlotinib and the second ones will occur during the second week after the initiation of erlotinib. The order of TEP is not definite : 18F-FLT-TEP may be planned first or reciprocally. A period of 48 hours must separate two TEP.
3073707|NCT02069405|Experimental|Music Group plus normal standard of care|Patients will listen to music prior and during the scan
3073663|NCT02069782|Experimental|Home visiting|Home visiting programs in the United States grew from three major approaches that first became prominent in the 1960s: visits by public health nurses to promote infant and child health in disadvantaged families, Head Start home visiting to promote school readiness in hard-to-reach families, and home-based family support to promote positive parenting and prevent child abuse in high-risk families. All of these approaches sought to foster early childhood health and development by intervening in the home to support and improve socialization, health, and education practices.Today, home visiting is seen as a particularly important strategy for high-risk families who may be difficult to engage in other services.
3073664|NCT02069769|Experimental|communication with oncology team|oncology team will be prompted to contact family caregiver and/or patient twice weekly while the patient is receiving hospice care.
3073665|NCT02069756||Duchenne and Becker Muscular Dystrophy|Patients with Duchenne or Becker Muscular Dystrophy, as well as carrier females.
3073666|NCT02069743|Experimental|Intervention|The intervention group will use the study's mobile application during the 8-week study.
3073667|NCT02069743|No Intervention|Control|The control group will not use the study's mobile application during the study.
3073668|NCT02069730|Experimental|Unmatched Treatment (Selinexor)|Selinexor, 30mg/m2, by mouth, twice weekly, every 28 day cycles.
3073669|NCT02069730|Experimental|Unmatched Therapy|If the matched therapy is given through a clinical trial, the dosing schedule will be determined by that particular trial protocol. For matched treatments administered outside of a clinical trial, the dosing schedule will be the recommended dose by the expertise of the treating investigator.
3073670|NCT02069717||Not applicable-observational study|Not applicable-observational study
3073671|NCT02069704|Experimental|Bevacizumab biosimilar (BEVZ92)|Bevacizumab 25 mg/mL (strength: 100 mg/4 mL).
3073672|NCT02069704|Active Comparator|Avastin® (bevacizumab, ref. product)|Bevacizumab 25mg/ml (strength: 100mg/4ml)
3073673|NCT02069691|Experimental|virtual reality-cycling training system|
3073674|NCT02069665|Experimental|Injection, medications and application|"Intravenous injection: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co., Ltd;~Medications: according to TCM syndrome differentiations;~Wind-heat blocking lungs pattern (feng re bi fei zheng): Xiaoer Qingfei Heji (mixture), and Zhi Ke San (herbal powder to relieve cough)~Phlegm-heat blocking lungs pattern (tan re bi fei zheng): Xiaoer Qingfei Heji (mixture), and Hua Tan San (herbal powder to remove phlegm)~External application: Fuxiong San"
3073675|NCT02069665|Active Comparator|Injection and medications|"Intravenous injection: Ribavirin Injection;~Medications: symptomatic therapies~Guaifenesin Syrup, for removing phlegm, relieving gasp-cough;~Ibuprofen Suspension, and salbutamol in case of different symptoms"
3073676|NCT02069639||no treatment|
3073677|NCT02069626|Active Comparator|No wait|Usage of linear stapler without waiting of compression time
3073678|NCT02069626|Active Comparator|20 second wait|Usage of linear stapler with 20 second compression time
3073679|NCT02069626|Active Comparator|60 second wait|Usage of linear stapler with 60 second compression time
3073680|NCT02069613||Mild traumatic brain injury (mTBI)|Patients admitted to Huntington Memorial Hospital (HMH), Pasadena CA, Emergency Department (ED) diagnosed with mTBI by history (alteration of consciousness, post-traumatic amnesia, loss of consciousness) and normal brain computed tomography (CT).
3073681|NCT02069613||Control|Patients admitted to HMH ED for minor extremity trauma (sprains) and no evidence of mTBI
3073682|NCT02069600|Active Comparator|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure is a device that apply a positive pressure in the airway to avoid its collapse during sleep during three months in this study
3073683|NCT02069600|No Intervention|No intervention|No intervention. No placebo is used. Control group without CPAP treatment during three months
3073684|NCT02069587|Experimental|Pomegranate|The women in this group will drink pomegranate juice
3073685|NCT02069574|Experimental|severe periodontitis group|non-surgical periodontal therapy
3073686|NCT02069574|Experimental|Moderate periodontitis group|non-surgical periodontal therapy
3073687|NCT02069574|No Intervention|healthy control|No treatment
3073688|NCT02069561|Experimental|Eicosapentaenoic Acid|Subjects with long-standing ulcerative colitis and meeting the inclusion criteria will receive 2 g/day of Eicosapentaenoic Acid as a supplement for 90 days
3073689|NCT02069561|No Intervention|Normal controls|Five patients undergoing screening colonoscopy and polypectomy using biopsy forceps. Six biopsies of healthy mucosa will be collected at the time of colonoscopy. Faeces, urine and blood samples will be collected prior to performing colonoscopy. The samples will serve as healthy reference for the basic studies.
3073690|NCT02069548||Cervical dystonia|
3073691|NCT02069548||matched controlled subjects|matched in age (+/- 5 years) and gender
3073692|NCT02069535|Experimental|AVANZ Cupressus|AVANZ Cupressus
3073693|NCT02069522|Active Comparator|Standard Milk-based Formula Containing Carotenoid|milk-based ready to feed infant formula
3073694|NCT02069522|Experimental|Investigational Milk-based Formula Containing Carotenoid|investigational milk-based ready to feed infant formula
3073695|NCT02069509||Control research participants|diagnosis of FRDA genetically excluded
3073696|NCT02069509||FRDA patients|with genetically confirmed diagnosis of FRDA
3073697|NCT02069496||Subjects who receive Arepanrix®|Subjects who receive Arepanrix® as per routine practice
3073698|NCT02069483|Active Comparator|Motivational Interviewing|Subjects will engage in motivational interviewing and come up with messages to motivate quitting during the activity.
3073699|NCT02069483|Active Comparator|Tailored Feedback|Subjects will use reasons for quitting that they provided during the phone baseline for the text messages and audio recordings.
3073700|NCT02069470|Experimental|Continuing Medical Education|Continuing Medical Education
3073701|NCT02069470|No Intervention|Usual care|Usual care
3073702|NCT02069444||Truview EVO2 laryngoscope|patients intubated withTruview EVO2 laryngoscope
3073703|NCT02069444||Macintosh laryngoscope|patients intubated with Macintosh laryngoscope
3073704|NCT02069431|Experimental|Intranasal Oxytocin spray|Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.
3073705|NCT02069431|Placebo Comparator|Intranasal Placebo spray|placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
3073709|NCT02069392|Active Comparator|Cognitive remediation training with nicotine|Participants will complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
3073710|NCT02069392|Placebo Comparator|Cognitive remediation training without nicotine|Participants will complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a placebo lozenge prior to the training.
3073711|NCT02069379|No Intervention|Controls|metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.
3073712|NCT02069379|Experimental|Metformin|16 weeks treatment with metformin (insulin sensitizing treatment)
3073713|NCT02069379|Placebo Comparator|Placebo|Placebo comparator to metformin treatment
3073714|NCT02069366|Placebo Comparator|Placebo|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to fMRI scanning and task performance in 40 patients with PTSD, 40 trauma-exposed controls without PTSD (TEC), and 40 non-exposed healthy controls (HC).~Within each of the three groups half of the participants will receive dronabinol and the other half will received placebo to create the following 6 groups:~PTSD-dronabinol (20)~PTSD-placebo (20)~TEC-dronabinol (20)~TEC-placebo (20)~HC-dronabinol (20)~HC-placebo (20)"
3073715|NCT02069366|Active Comparator|Dronabinol|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to fMRI scanning and task performance in 40 patients with PTSD, 40 trauma-exposed controls without PTSD (TEC), and 40 non-exposed healthy controls (HC).~Within each of the three groups half of the participants will receive dronabinol and the other half will received placebo to create the following 6 groups:~PTSD-dronabinol (20)~PTSD-placebo (20)~TEC-dronabinol (20)~TEC-placebo (20)~HC-dronabinol (20)~HC-placebo (20)"
3073716|NCT02069353|Experimental|Cardiac arrest|Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
3073717|NCT02069340|Experimental|Arm I (zoledronic acid over 15 minutes)|Patients receive zoledronic acid IV over 15 minutes on day 1.
3073718|NCT02069340|Experimental|Arm II (zoledronic acid over 30 minutes)|Patients receive zoledronic acid IV over 30 minutes on day 1.
3073719|NCT02069314|Experimental|Whey protein supplementation|50 grams of whey blended into frozen drink
3073720|NCT02069314|Experimental|Carbohydrate supplementation|50 grams of polycose blended into frozen drink
3073721|NCT02069301|Experimental|Integrated Depression/Microfinance Group|LIFE-DM is a Depression and Microfinance integrated program using behavior activation and problem solving therapy applied to both depression and livelihood. Livelihood support include microfinance loans, personal finance, and income-generation skills.
3073722|NCT02069301|Other|Treatment as Usual|Currently treatment as usual in this province includes national guidelines for antidepressant care for depression and referral for microfinance/livelihood programs
3073723|NCT02069288|Experimental|1|Fludrocortisone
3073724|NCT02069288|Placebo Comparator|2|Placebo
3073725|NCT02069275|Experimental|Immediate mobilization|Immediate mobilization after coronary angiography or percutaneous coronary intervention
3073726|NCT02069275|Active Comparator|Two hours bedrest|Bedrest two hours after coronary angiography or percutaneous coronary intervention
3073727|NCT02069262|Experimental|angiography combination laparoscopy|All patients were randomized to receive either mesenteric angiography alone or angiography combination laparoscopy in a 1:1 ratio. Randomization was performed computer-generated list using a randomly permuted block design. To ensure concealed randomization, the randomization code was put in opaque envelope and kept by researchers not performing angiography or angiography combination laparoscopy. Both patients and investigators were unaware of the randomization sequence. Those who developed rebleeding during the observation would be crossed over to the other investigation modality. Patients with negative findings on the initial assigned investigation but who developed rebleeding would undergo further investigation to localize the site of bleeding.
3073728|NCT02069262|Placebo Comparator|angiography alone|All patients were randomized to receive either mesenteric angiography alone or angiography combination laparoscopy in a 1:1 ratio. Randomization was performed computer-generated list using a randomly permuted block design. To ensure concealed randomization, the randomization code was put in opaque envelope and kept by researchers not performing angiography or angiography combination laparoscopy. Both patients and investigators were unaware of the randomization sequence.
3073729|NCT02069249|Experimental|Healthy Nutrition Intervention|Healthy Nutrition Intervention (HNI)
3073730|NCT02069249|Experimental|Healthy Sleep Intervention|Healthy Sleep Intervention (HSI)
3073731|NCT02069249|No Intervention|Waiting list control|Waiting list control group
3073732|NCT02069236|No Intervention|G6PD Testing|All subjects receive G6PD test
3073733|NCT02069223|Active Comparator|Gastrectomy|Subjects in this group will undergo a gastrectomy as their first surgery with a BPD-DS 1-year later.
3073734|NCT02069223|Active Comparator|BPD-DS|Subjects in this group will undergo a BPD-DS as their first surgery with a gastrectomy 1-year later.
3073735|NCT02069223|Active Comparator|Gastrectomy+BPD-DS|Subjects in this group will undergo a gastrectomy AND a BPD-DS concomitantly. They will then be closely monitored for the remainder of the study.
3073736|NCT02069210||Blood transfusion|Patients receive blood transfusion during operation
3073737|NCT02069197|Active Comparator|Ketogenic diet, lifestyle counseling|ketogenic diet consisted of 3:1[fat]:[protein+carbohydrate] weight ratio with 1600kcal restriction.
3073738|NCT02069197|Active Comparator|Orlistat, Lifestyle counseling|Orlistat 120 mg TID, standardized diet and lifestyle-modification counseling based on the LEARN (Life, Exercise, Attitudes, Relationships,and Nutrition) program with recommended caloric goal of 1600 kcal/day.
3073739|NCT02069197|Active Comparator|Standartized diet, Lifestyle counseling|Standardized diet and lifestyle-modification counseling based on the LEARN (Lifestyle, Exercise, Attitudes, Relationship, Nutrition) program with recommended caloric goal of 1600kcal/day.
3073740|NCT02069184|Experimental|IV Acetaminophen|IV form, total of 4 doses (each 1000 mg), each every 6th hourly to a maximum dose of 4000 mg in 24 hours.
3073741|NCT02069184|Experimental|Saline as placebo|IV form, total 4 units, each given every 6th hourly in 24 hours.
3073742|NCT02069171||early ovarian cancer group|
3073743|NCT02069171||locally advanced cervical cancer group|
3073744|NCT02069171||primary endometrial cancer group|
3073745|NCT02069158|Experimental|PF-05212384, Carboplatin, Paclitaxel|starting dose of PF-05212384: 95 mg iv weekly Dose of Carboplatin: 5 AUC every 28 days Dose of Paclitaxel: 80 mg/m2 on days 1, 8 and 15
3073746|NCT02069145|Experimental|Drug: OMP-54F28, with Sorafenib|
3073747|NCT02069132||Warfarin in elderly with comorbidity|Patients 65 years or older, candidate for therapy with warfarin for non valvular atrial fibrillation or heart valve replacement
3073748|NCT02069119|Experimental|OPC-108459|OPC-108459 solution will be intravenously administered by 30-minute infusion in the forearm.
3073749|NCT02069119|Placebo Comparator|Placebo|placebo solution will be intravenously administered by 30-minute infusion in the forearm.
3073750|NCT02069106|Experimental|Pro-Omega LDL|3 capsules 1000 mg BID for 8 weeks
3073751|NCT02069106|Placebo Comparator|Placebo|3 capsules BID for 8 weeks
3073752|NCT02069093|Experimental|Dexamethasone based mouthwash|Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks. Participants remained without food or drink (NPO) for one hour after administration of the mouthwash. Also, participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations.
3073753|NCT02069080|Experimental|1|All subjects are administered the study drug
3073754|NCT02069067||Advanced cancer patients with pain|
3073755|NCT02069054||Asthma|Patients with mild to moderate asthma diagnosed in accordance with GINA
3073756|NCT02069054||COPD|Patients with mild to moderate COPD diagnosed in accordance with GOLD
3073757|NCT02069054||Control|Healthy subjects
3073758|NCT02069041|Experimental|Ramucirumab + FOLFOX4|Ramucirumab given intravenously (IV) on Day 1 followed by FOLFOX4 (folinic acid + fluorouracil + oxaliplatin chemotherapy regimen) given IV on Day 1 of 2 week cycles. Participants may continue to receive treatment until discontinuation criteria are met.
3073759|NCT02069028||Low intensity intervention|human oriented interventions with less consideration to the system based act including, but not limited to, education, training, sepsis profile and posters with protocol algorithms.
3073760|NCT02069028||Intermediate intensity intervention|interventions that lie in between human oriented and system oriented Including, but not limited to, sepsis protocols, daily audits, feedback and clinical pathway
3073761|NCT02069028||High intensity intervention|system based interventions with less involvement of human effect including, but not limited to, electronic alert systems and sepsis response team.
3073762|NCT02069015|Experimental|Enhanced discharge|Patient education about hypertension delivered through a touch-screen kiosk at 4 time points in addition to standard discharge.
3073763|NCT02069015|No Intervention|Standard discharge|Standard discharge is patient instruction, instructions for follow-up to primary care and medication/prescription
3073764|NCT02069002|Experimental|Cognitive-Behavioral Therapy (CBT)|"There will be ten (10) manualized session, fist 90 minutes and nine (9) 45-minute individual sessions conducted at weekly intervals, last two sessions 2 weeks intervals. One booster session will be conducted three months after the treatment. Sessions include psychoeducation about indoor air related symptoms and personal health behavior factors integrated on patients individual symptomatology, cognitive restructuring, behavioral experiments of patients health promoting behavior, imagery rescripting and relapse prevention.~Intervention: Behavioral: Psychotherapy (CBT)"
3073765|NCT02069002|Experimental|Applied relaxation group therapy|"There will be seven (7) manualized session, first 120 minutes and six (6) 90-minute group sessions conducted at weekly intervals, last two sessions 2 weeks intervals. One booster session will be conducted three months after treatment. Sessions include information about indoor air related symptoms, behavioral training and experiments focusing on applied relaxation technique and relapse prevention.~Intervention: Behavioral: group therapy (ART)~NB: The Applied Relaxation group Therapy won´t be carried out due to slow and prolonged recruiting process (A steering group agreement 4/2015 and the Ethics Committee approval 5/2015 for the change of the study plan)."
3073766|NCT02069002|Experimental|Information session (psychoeducation)|"There will be one (1) manualized 90-minute individual session. The session includes information about indoor air related symptoms and factors affecting individual health behavior.~Intervention: Information session (psychoeducation)"
3073767|NCT02068989||Stress Hyperglycemic Group|Repeat HbA1C in 1 year
3073768|NCT02068989||Euglycemic Group|Repeat HbA1C in 1 year
3073769|NCT02068976||Women with Primary Ovarian Insufficiency|
3073770|NCT02068963||Study Population|
3073771|NCT02068950|Other|Progressive resistance training|12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand).
3073772|NCT02068937|Active Comparator|Control Group|In the control group, patients just diuretic adjusted (Furosemide 40 milligrams) by the doctor on the baseline. The patients do not receive phone calls neither advising on non-pharmacological treatment; The medication is adjusted by the doctor during the initial evaluation of study baseline.
3073773|NCT02068937|Experimental|Furosemide and Phone contact|The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day.
3073774|NCT02068924|Experimental|slow freezing|Therefore, the aim of our study is to analyze whether extended culture of Day-2 top embryos to blastocyst-stage may improve the cumulative delivery rate in an in vitro fertilization program with Single Embryo Transfer policy in a prospective and randomized study integrating the transfer of fresh and frozen/thawed embryos using a slow freezing versus vitrification procedure.
3073853|NCT02068339|Placebo Comparator|Placebo|Placebo Comparator / Tid (total 0mg)
3073854|NCT02068339|Experimental|Oltipraz 1|Total 90mg, by mouth, tid
3073855|NCT02068339|Experimental|Oltipraz 2|Total 120mg, by mouth, tid
3073775|NCT02068924|Other|vitrification|Therefore, the aim of our study is to analyze whether extended culture of Day-2 top embryos to blastocyst-stage may improve the cumulative delivery rate in an in vitro fertilization program with Single Embryo Transfer policy in a prospective and randomized study integrating the transfer of fresh and frozen/thawed embryos using a slow freezing versus vitrification procedure.
3073776|NCT02068911||Monitoring of ETCO2 and PTCO2|All neuromuscular patients
3073777|NCT02068898|Experimental|XS003 Dose-level 1|Capsule formulation
3073778|NCT02068898|Experimental|XS003 Dose-level 2|Capsule formulation
3073779|NCT02068898|Experimental|XS003 Dose-level 3|Capsule formulation
3073780|NCT02068898|Experimental|Tasigna|Marketed capsule
3073781|NCT02068885|Experimental|Low carbohydrate diet|Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
3073782|NCT02068885|Experimental|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
3073783|NCT02068885|Active Comparator|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
3073784|NCT02068872|Experimental|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of > 40 or > 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
3073785|NCT02068859|Experimental|Diclofenac Cream 8%|Diclofenac Cream 8% applied 3-4 times daily for 6 weeks.
3073786|NCT02068859|Active Comparator|Control|Diclofenac Gel 1% applied 3-4 times daily fr 6 weeks
3073787|NCT02068846|Active Comparator|Ciprofloxacin|over encapsulated, 500mg bid, 28 days
3073788|NCT02068846|Placebo Comparator|Placebo|Over encapsulated to match active comparator, bid, 28 days
3073789|NCT02068833||Gastrectomy|Subjects in this group will undergo a gastrectomy only.
3073790|NCT02068833||BPD-DS|Subjects in this group will undergo a BPD-DS surgery.
3073791|NCT02068820|Active Comparator|ISB dye, standard white light|SLN mapping utilizing da Vinci surgical system with Isosulfan Blue (ISB) dye and standard white light imaging.
3073792|NCT02068820|Experimental|ICG dye, FireFly fluorescence imaging|SLN mapping utilizing da Vinci surgical system with ISB dye and standard white light first, and then additionally, Indocyanine Green (ICG) dye and FireFly fluorescence imaging.
3073793|NCT02068807|Active Comparator|Lutein drops|oral administration of 0.28 mg of lutein in two doses: within 6 hours (hrs) after birth and at 36 hrs of life
3073794|NCT02068807|Placebo Comparator|Glucose drops|oral administration of 0.28 mg of vehicle (0.5 mL of 5% glucose solution) in two doses: within 6 hours (hrs) after birth and at 36 hrs of life
3073795|NCT02068794|Experimental|Treatment (MV-NIS infected mesenchymal stem cells)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IP over 30 minutes on day 1 of course 1 and MV-NIS infected mesenchymal stem cells IP over 30 minutes of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3073796|NCT02068781|Active Comparator|Start with low-sodium diet|One week of low-sodium diet, followed by a two-week wash-out period and subsequently, another week of high-sodium diet
3073797|NCT02068781|Active Comparator|Start with high-sodium diet|One week of high-sodium diet, followed by a two-week wash-out period and subsequently, another week of low-sodium diet
3073798|NCT02068768||Operated Subjects|Subjects scheduled to receive an Avenue® L Interbody Fusion System (LDR Spine) for fusion of the lumbar spine from L2-S1
3073799|NCT02068755||Cardiac surgery|Patients who have undergone cardiac surgery
3073800|NCT02068742|Experimental|General Anesthesia patients battery neuropsychological tests|Mini Mental State Examination, Geriatric Index of Comorbidity, Geriatric Depression Scale, Trail Making Test B-A, Digit Span, Digit Symbol Substitution Test Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
3073801|NCT02068742|Active Comparator|Regular recovery patients|Mini Mental State Examination, Geriatric Index of Comorbidity, Geriatric Depression Scale, Trail Making Test B-A, Digit Span, Digit Symbol Substitution Test Application of the scores will be on the day 0 (the day after the hospital admission), day 2 and day 4 (days after the hospital admission).
3073802|NCT02068716||Adults with HAIs|"Adult cardiac surgery patients who develop infections in hospitals within 30 days post surgery.~We will exclude patients presenting with endocarditis."
3073803|NCT02068703|Active Comparator|Intervention|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools (face mask, ear plugs and white noise machine) to improve sleep.
3073804|NCT02068703|Placebo Comparator|Inert Control|Same 10 min time exposure and tool delivery to subjects in this arm WITHOUT demonstration.
3073805|NCT02068690|Experimental|BI 425809 single rising dose|BI 425809 powder for oral solution (PfOS) in single rising doses
3073806|NCT02068690|Experimental|BI 425809 Crossover|Bioavailability of BI 425809 PfOS
3073807|NCT02068677|Other|sympathetic response|This group will be composed of subjects who experience a heart rate and/or Blood Pressure change during injection.
3073808|NCT02068677|Other|no sympathetic response|This group will be made up of subjects that do not experience a vital sign change with injection for CPN.
3073809|NCT02068664||Observational|prism adaptation treatment
3073810|NCT02068651|Experimental|Advance care planning programme|Participants in the experimental group will receive a structured advance care planning programme, namely Let Me Talk, delivered by a trained nurse facilitator. The programme will be conducted on individual basis through three one-hour home visits, once weekly. Family carers of the participants will be invited to all sessions.
3073811|NCT02068651|No Intervention|Usual care|Participants in the control group will receive three weekly home visits with basic health assessment and education provided by the trained nurse facilitator. If they request advance care planning information or assistance, an advance directive form, which is available on the Internet for public access, will be provided to them for their information.
3073812|NCT02068638|Experimental|IHE first, CONT second, CSII and MDI therapy|IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
3073813|NCT02068638|Experimental|CONT first, IHE second,CSII and MDI therapy|CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
3073814|NCT02068638|Experimental|GLU first, GLUFRU second, CSII and MDI therapy|GLU: ingestion of a 6% carbohydrate solution (consisting of 100 g glucose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 20% carbohydrate solution (consisting of 100 g glucose + 100 g fructose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. CSII = continuous subcutaneous insulin infusion. MDI=multiple daily injections.
3073815|NCT02068638|Experimental|GLU-FRU first, GLU second, CSII therapy|GLU-FRU : ingestion of a 20% carbohydrate solution (consisting of 100 g glucose + 100 g fructose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): ingestion of a 10% carbohydrate solution (consisting of 100 g glucose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. CSII = continuous subcutaneous insulin infusion. MDI=multiple daily injections.
3073816|NCT02068625|Experimental|Treatment|Patients getting perioperative oral treatment with rasagiline (1mg daily) for 7 days
3073817|NCT02068625|Placebo Comparator|Control|Patients getting perioperative oral treatment with placebo for 7 days
3073818|NCT02068612|Experimental|MICT + IT|Moderate Intensity Continuous Training+Interval Training
3073819|NCT02068612|Active Comparator|LICT|Low Intensity Continuous Training
3073820|NCT02068599|Experimental|TV-45070 4%|Frequency is twice a day
3073821|NCT02068599|Experimental|TV-45070 8%|Frequency is twice a day
3073822|NCT02068599|Placebo Comparator|Placebo|Frequency is twice a day
3073823|NCT02068586|Experimental|Sunitinib|Patients receive sunitinib malate PO daily for 6 months in the absence of disease progression or unacceptable toxicity
3073824|NCT02068586|Experimental|Valproic acid|Patients receive valproic acid PO daily for 6 months in the absence of disease progression or unacceptable toxicity
3073825|NCT02068573|Active Comparator|Ventilation|Increased ventilation in the childs bedroom to at least 2-3 air changes pr hour.
3073826|NCT02068573|Placebo Comparator|Placebo ventilation|Ventilation system that recirculates the air in the childs bedroom
3073827|NCT02068560|Experimental|dDAVP infusion|During the 9 hour study period, the subjects will receive three doses of dDAVP infusion (0.0003micrg/kg, 0.0005micrg/kg, 0.004micrg/kg).
3073828|NCT02068547|Active Comparator|Group 1 - Surigical Best Practice|Group 1 will receive current best practice for posterior instrumented fusion (locally harvested autograft, demineralized bone matrix, and cadaveric allograft)
3073829|NCT02068547|Experimental|Group 2 - autograft/BMAC|Group II, will receive locally harvested autograft and 20 cc of bone marrow aspirate concentration.
3073830|NCT02068534||survivors from charcoal-burning suicide|survivors from charcoal-burning suicide and at least above 20 years old.
3073831|NCT02068521|Experimental|Treatment naive subjects with GHD|Up to 100 new treatment naïve subjects with GHD will receive somavaratan 3.5mg/kg twice monthly.
3073832|NCT02068521|Experimental|Subjects who have completed a somavaratan study|All subjects after participation in (12VR2) or participation in the 14VR4 protocols have the option to receive somavaratan 3.5mg/kg twice monthly.
3073833|NCT02068508||Pioglitazone 15 mg to 30 mg, orally, once daily|
3073834|NCT02068495||Candesartan cilexetil/Amlodipine besilate|8 milligram (mg)/2.5 mg or 8 mg/5 mg, orally, once daily
3073835|NCT02068482|Active Comparator|1a USDD|Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
3073836|NCT02068482|No Intervention|1b USDD|Patients control, no drug
3073837|NCT02068482|No Intervention|Control group|Control Group, no disease, no drug
3073838|NCT02068456||Roflumilast|Roflumilast will be administered according to the prescribing information of the approved Korean label.
3073839|NCT02068443|Active Comparator|Alogliptin Alone|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride placebo-matching, tablets, orally, 2 tablets after breakfast and 1 tablet after dinner for 24 weeks.
3073840|NCT02068443|Experimental|Alogliptin + Metformin Hydrochloride QD|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 500 mg QD (250 mg x 2 tablets, once daily), tablets, orally, once, daily, after breakfast and 1 metformin hydrochloride placebo-matching, tablet, orally, once, daily, after dinner for 24 weeks.
3073841|NCT02068443|Active Comparator|Alogliptin + Metformin Hydrochloride BID|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 250 mg BID (twice daily), tablets, orally, 1 tablet after breakfast and 1 tablet after dinner and 1 metformin hydrochloride placebo-matching, tablet, orally, once, daily, after breakfast for 24 weeks.
3073842|NCT02068430|Experimental|Riboflavin 0.1% & UV-X™ Illumination System|UV-X Cross linking: After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber. When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture.
3073843|NCT02068417|Active Comparator|Shock wave treatment|Shock waves are applied extracorporeally with 0.1 millijoule per square millimeter (mJ/mm2)
3073844|NCT02068417|Placebo Comparator|Placebo Shock wave treatment|Shock waves are prohibited to enter the body by placebo stand-off.
3073845|NCT02068404|Other|Nifedipine|
3073846|NCT02068391|Experimental|Exercise|This group will perform the 'Exercise Program' for months 0 to 6, and will be unsupervised for months 7 to 12.
3073847|NCT02068391|Active Comparator|Stretching|This group will perform the 'Stretching Program' for months 0 to 6, and the 'Exercise Program' for months 7 to 12.
3073848|NCT02068378|Experimental|CMPE Optical Sensor Device|Single arm study
3073849|NCT02068365|Other|Pegyinterferon-alfa-2a|Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks
3073850|NCT02068352|Experimental|0.3% OPA-15406|BID 0.3% OPA-15406 Ointment, N = 40
3073851|NCT02068352|Experimental|1% OPA-15406|BID 1% OPA-15406 Ointment, N = 40
3073852|NCT02068352|Placebo Comparator|Placebo|BID 0% Vehicle Ointment, N = 40
3073856|NCT02068326|Experimental|Mentalization Based Treatment|"the experimental intervention is a year-long manualized program that comprises four components:~Five individual case-formulation sessions,~MBT-I, an introductory pedagogical program for patients (three weekly sessions)~MBT-G, MBT-program in groups (37 weekly sessions)~MBT-P, a psychoeducation program for the patients' parents or parents substitutes (six sessions)."
3073857|NCT02068326|Active Comparator|Treatment As Usual|Participants randomized to the control group will receive Treatment As Usual (TAU). TAU is defined as comprising at least 12 monthly individual supportive sessions provided by non-MBT trained mental health professionals in the Department of Child and Adolescent Psychiatry in Region Zealand. Additional supportive sessions or other types of intervention may be offered to the patients according to the needs of the patients as evaluated by mental health professionals responsible for his/hers treatment. Hence, TAU may vary considerably in number and type of intervention across clinics and patients. All mental health services delivered during the treatment period to patients in the TAU group will be monitored and registered.
3073858|NCT02068313||Single cohort|
3073859|NCT02068287|Experimental|ESMOLOL|Resuscitated, hyperkinetic septic shock patients are treated with esmolol in order to reduce heart rate of 20% during 6 hours. During the intervention period, multimodal macro and micro hemodynamic data are recorded.
3073860|NCT02068274||chronic pain|CO2 monitoring in chronic pain patients who treated with opioids.
3073861|NCT02068261|Experimental|Cogmed working memory training|30-40 minutes of Cogmed computerized working memory training 3-5 days a week for 5-8 weeks. Every training session consists of a set of visual- and verbal working memory tasks that are trained on during the session.
3073862|NCT02068261|Active Comparator|Treatment as usual|Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment. After a 8 week period participants in this arm well be offered Cogmed working memory training.
3073863|NCT02068235|Experimental|Pilot Phase|Subjects will receive a single intravenous (i.v.) dose of 5 mg ponesimod dissolved in 50 mL sterile 0.9% sodium chloride (NaCl) solution as a 3-hour infusion in the fasted state in the morning (infusion rate: 0.028 mg/min).
3073864|NCT02068235|Experimental|Treatment A/Treatment B|"Subjects will receive Treatment A followed by Treatment B.~Treatment A: a single i.v. dose of ponesimod administered in the fasted state in the morning.~Treatment B: a single oral dose of ponesimod (10 mg) administered as 1 tablet in the fasted state in the morning.~There will be a washout period between doses of 12-15 days."
3073865|NCT02068235|Experimental|Treatment B/Treatment A|"Subjects will receive Treatment B followed by Treatment A.~Treatment A: a single i.v. dose of ponesimod administered in the fasted state in the morning.~Treatment B: a single oral dose of ponesimod (10 mg) administered as 1 tablet in the fasted state in the morning.~There will be a washout period between doses of 12-15 days."
3073866|NCT02068222|Experimental|ABT-450/r and ABT-530 plus RBV|ABT-450/r (150 mg/100 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
3073867|NCT02068209|Active Comparator|Tramadol|Patients will receive Tramadol 50mg 1 hour before outpatient hysteroscopy
3073868|NCT02068209|Placebo Comparator|Placebo|Patients will receive a placebo 1 hour before the procedure.
3073869|NCT02068196|Experimental|Ipilimumab|Ipilimumab 3mg/kg
3073870|NCT02068183||World Trade Center exposed group|After informed consent, anthropometric and blood pressure/brachial artery distensibility assessments; physical examination and environmental and respiratory history questionnaire completion; heart rate variability measurement; and spirometry/IOS will be performed on the World Trade Center exposed group. A research assistant well trained in pediatric phlebotomy will collect 23 mL of fasting blood. Spirometry and IOS, diet diary collection, lung volumes by plethysmography, and arterial wall stiffness.
3073871|NCT02068183||Unexposed comparison group|After informed consent, anthropometric and blood pressure/brachial artery distensibility assessments; physical examination and environmental and respiratory history questionnaire completion; heart rate variability measurement; and spirometry/IOS will be performed on the unexposed comparison group. A research assistant well trained in pediatric phlebotomy will collect 23 mL of fasting blood. Spirometry and IOS, diet diary collection, lung volumes by plethysmography, and arterial wall stiffness.
3073872|NCT02068170||patients treated with a potentional QT-prolonging drug|
3073873|NCT02068157|Experimental|Treatment (porfimer sodium, image-guided I-PDT)|Patients receive porfimer sodium IV over 3-5 minutes on day 0. Patients then undergo image-guided I-PDT on day 2.
3073874|NCT02068144|Experimental|Cranberry Extract|Cranberry Extract in a 15.2oz beverage daily for 8 weeks
3073875|NCT02068144|Placebo Comparator|Placebo|Placebo 15.2oz beverage daily for 8 weeks
3073876|NCT02068131|Experimental|Novaferon+ xeloda|"Capecitabine for 2 weeks straight (Days 1-14) followed by 1 week without capecitabine (Days 15-21).~Recombinant anti-tumor and anti-virus protein for injection(Novaferon), three times per week."
3073877|NCT02068118|No Intervention|reference group|usual follow
3073878|NCT02068118|Experimental|telecardiology group|Telecardiology program
3073879|NCT02068105|Experimental|ALKS 5461-A|
3073880|NCT02068105|Experimental|ALKS 5461-B|
3073881|NCT02068105|Experimental|ALKS 5461 Dose 1|
3073882|NCT02068105|Experimental|ALKS 5461 Dose 2|
3073883|NCT02068105|Experimental|ALKS 5461 Dose 3|
3073884|NCT02068105|Placebo Comparator|Placebo|
3073885|NCT02068092|Experimental|Hydroxytyrosol|Hydroxytyrosol 25 mg orally once daily for 1 year.
3073886|NCT02068079|Other|Vemurafenib and Trientine|
3073887|NCT02068053|Experimental|Arm A - BMS-986020|600 mg (approximately 80 micro Curie) of [14C] BMS-986020 Single Dose for 1 Day (Day 1) orally
3073888|NCT02068040|Experimental|CocoaVia capsules|From baseline to 3 months, patients will consume 2 capsules containing pure epicatechin
3073889|NCT02068027|Experimental|Clonidine Gel 0.1%|Clonidine hydrochloride topical gel, 0.1%
3073890|NCT02068027|Placebo Comparator|Placebo|Placebo gel of identical appearance as active treatment
3073891|NCT02068001||RYGB|Food preference assessment in 100 patients at different timepoints, in a subset of 30 participants, also brain reward response to food cues will be assessed.
3073892|NCT02067988|Experimental|Treatment arm|Holmium-166 microspheres hepatic radioembolization, adjuvant to systemic 177Lu-dotatate.
3073893|NCT02067975|Active Comparator|tryptophan|6gm of tryptophan at least two weeks apart at time zero of 7 hour visits 2 and 3
3073894|NCT02067975|Placebo Comparator|Placebo|Placebo will be a liquid drink without tryptophan. 6mg at least two weeks apart at time zero of the 7 hour visits 2 and 3.
3073895|NCT02067962|No Intervention|Juvenile idiopathic arthritis.|Blood sample
3073896|NCT02067949|No Intervention|broad spectrum AB +fluids|Control group :50 patients will be treated according to SURVIVING SEPSIS CAMPAIGN BUNDLES
3073897|NCT02067949|Active Comparator|simvastatin|50 patients will be treated according SSCG plus simvastatin as single oral tablet 40 mg / day begin with inclusion in the study and continue until hospital discharge .If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube. (White R, Bradnam V, 2013)
3073898|NCT02067936|Active Comparator|Group A propofol + remifentanil|Propofol highest dose, remifentanil lowest dose, TOL 90% according to Bouillon model
3073899|NCT02067936|Active Comparator|Group B propofol + remifentanil|Propofol intermediate high, remifentanil intermediate low, TOL90% according to the Bouillon Model
3073900|NCT02067936|Active Comparator|Group C propofol + remifentanil|propofol intermediate low+ remifentanil intermediate high: TOL 90% according to the Bouillon interaction model
3073901|NCT02067936|Active Comparator|group D propofol + remifentanil|propofol lowest dose+ remifentanil highest dose: TOL 90% according to the Bouillon model
3073902|NCT02067923||Anti-CD3 mAb Plus Diabetes Standard of Care Group|This group of individuals received treatment in the original AbATE study.
3073903|NCT02067923||Diabetes Standard of Care Group|During the original AbATE study these individuals received standard care.
3073904|NCT02067910|Active Comparator|Abatacept SC|Weekly subcutaneous administration of 125 mg Abatacept during 48 weeks
3073905|NCT02067910|Placebo Comparator|Placebo|First phase: Weekly subcutaneous administration of placebo during 24 weeks. Second phase: Weekly subcutaneous administration of 125 mg Abatacept during 24 weeks.
3073906|NCT02067897||Vandenbos procedure (skinfold excision)|Participants in this cohort will undergo with Vandenbos procedure (skinfold excision) for one or more ingrown toenails. This surgery will be formed as an day procedure under general anesthetic.
3073907|NCT02067884|Experimental|Diagnostic (CEUS, SWE)|Patients undergo dynamic contrast-enhanced ultrasound imaging and shear wave elastography at baseline, 2-3 weeks after initiation of chemotherapy, and before surgery.
3073908|NCT02067871|Experimental|Electrical stimulation|"18-32 min of pulsed current.~stimulation frequency of 80Hz (hertz).~pulse duration of 200μs (microseconds).~stimulation intensity fixed near to maximal tolerated."
3073909|NCT02067871|Experimental|Laser Therapy|"λ = 810 nm (nanometers)~continuous wave~200 mW (milliwatts) output power~low-level laser therapy dose of 4-6J (Joules) per point~six points at the knee joint"
3073910|NCT02067871|Experimental|Combined Treatment|"Electrical Stimulation:~18-32 min of pulsed current,~stimulation frequency of 80Hz (hertz).~pulse duration of 200μs (microseconds).~stimulation intensity fixed near to maximal tolerated.~and~Laser Therapy:~λ = 810 nm (nanometers)~continuous wave~200 mW (milliwatts) output power~low-level laser therapy dose of 4-6J (Joules) per point.~six points at the knee joint."
3073911|NCT02067858|Other|Stereotactic Radiosurgery|"3 fractions x 20 Gy 4 fractions x 12 Gy~Lesion dependent"
3073912|NCT02067845|Other|Pre-post test design|
3073913|NCT02067819|Experimental|Active Oral Orthotic Treatment|Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
3073914|NCT02067819|Placebo Comparator|Placebo Oral Orthotic Treatment|Control participants will receive an identical sham splint to the active condition, but not adjusted to the recommended height for the given participant. Participants will be asked to wear the orthotic 24/7 for the duration of the study.
3073915|NCT02067793|Placebo Comparator|Placebo|Placebo
3073916|NCT02067793|Experimental|NRX-1074 1 mg|NRX-1074 1 mg, intravenous
3073917|NCT02067793|Experimental|NRX-1074 5 mg|NRX-1074 5 mg, intravenous
3073918|NCT02067793|Experimental|NRX-1074 10 mg|NRX-1074 10 mg, intravenous
3073919|NCT02067780|Experimental|Guided Treatment Group|Levofloxacin 500mg prescribed for 7 days ; the duration of antibiotic therapy guided by decrease in inflammation markers level.
3073920|NCT02067780|Experimental|Standard Treatment Group|Levofloxacin 500mg prescribed for 7days
3073921|NCT02067780|Experimental|Short Treatment Group|1 tablet Levofloxacin 500mg / day for two days completed by 1 tablet Placebo Levofloxacin 500mg / day for 5 days.
3073922|NCT02067767|Experimental|Abacavir/Lamivudine/Dolutegravir|Patients switched from their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG.
3073923|NCT02067754||metastatic Cancer|metastatic gastrointestinal cancer, genitourinary cancer , rare cancer with treated any anti-cancer therapy
3073924|NCT02067741|Experimental|Stratum A - HER2neg BC RD - CR1447|Stratum A - patients with endocrine responsive-HER2neg BC
3073925|NCT02067741|Experimental|Stratum B - ARpos B - CR1447|Stratum B - patients with triple-negative and confirmed ARpos BC
3073926|NCT02067728|Active Comparator|Usual Care|Usual care is provided to patients in practice groups not undergoing intervention of FNPA tool
3073927|NCT02067728|Experimental|FNPA tool intervention|FNPA tool practice intervention comprising of two components: 1) FNPA assessment which screens for obesigenic behaviors; 2) Brief Action Planning conversation designed to assist the family develop a health behavior change goal based on obesigenic risks on the assessment tool.
3073928|NCT02067715|Experimental|Sealed bleaching Protocol|The 35% hydrogen peroxide gel will be mixed and applied over the buccal surfaces of teeth. The bleaching agent will remain for 45-min application without replacement of peroxide. However, a customized tray will be placed over the bleaching agent during entire permanence of peroxide (45 minutes).
3073929|NCT02067715|Active Comparator|Conventional Bleaching Protocol|The 35% hydrogen peroxide gel will be mixed and applied over the buccal surfaces of teeth. The bleaching agent will remain for 45-min application without replacement of peroxide.
3073930|NCT02067702||Limb Cooling Assessment of ET Control|Healthy, volunteers with no known dermatological lesions, sensitivity to cold, or peripheral vascular disease.
3073931|NCT02067702||Limb Cooling Assessment of ET Experimental|Patients with known essential tremor for at least a year, and +2 or worse action or kinetic tremor of one or both upper limbs involving at least the forearm and/or hand.
3098087|NCT01904968||Colon cancers in patients living the Cote D'or area|
3073932|NCT02067689||Hemisphere Stimulation|Participants will receive 1mA vs. 2mA transcranial direct current stimulation of a) right and b) left brain structures (1x1 stimulation), and sham/placebo stimulation. A subset of participants will undergo right and left brain stimulation, but all will undergo sham stimulation.
3073933|NCT02067689||Temporal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the temporal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left structures using 4x1 stimulation (e.g., 1mA left temporal, 1mA right temporal, sham; 2mA left temporal, 2mA right temporal, sham).
3073934|NCT02067689||Frontal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the frontal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left frontal structures using 4x1 stimulation (e.g., 1mA left frontal, 1mA right frontal, sham; 2mA left frontal, 2mA right frontal, sham).
3073935|NCT02067689||Parietal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the parietal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left parietal lobes using 4x1 stimulation (e.g., 1mA left parietal lobes, 1mA right parietal lobes, sham; 2mA parietal lobes, 2mA right parietal lobes, sham).
3073936|NCT02067689||Supplementary Motor Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the Supplementary Motor Area at 1mA vs. 2mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left Supplementary Motor Area using 4x1 stimulation (e.g., 1mA left Supplementary Motor Area, 1mA right Supplementary Motor Area, sham; 2mA left Supplementary Motor Area, 2mA right Supplementary Motor Area, sham).
3073937|NCT02067689||Brain Structure Interactions Group|This cohort will evaluate the interaction between frontal, parietal, temporal, and SMA regions in cognitive function. To accomplish this goal will require evaluation of change in cognitive and neurocognitive performance following transcranial direct current stimulation of different brain regions within the same subjects. For example, we will evaluate the contribution of frontal, SMA, and parietal regions by asking participants to undergo stimulation sessions at each of these sites, in addition to a sham session.
3073938|NCT02067676|Experimental|CJCV1 2 μg / Alum 0 μg (1A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 2 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
3073939|NCT02067676|Experimental|CJCV1 2 μg / Alum 125 μg (1B)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 2 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
3073940|NCT02067676|Experimental|CJCV1 5 μg / Alum 0 μg (2A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 5 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
3073941|NCT02067676|Experimental|CJCV1 5 μg / Alum 125 μg (2B)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 5 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
3073942|NCT02067676|Experimental|CJCV1 10 μg / Alum 0 μg (3A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 10 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
3073943|NCT02067676|Experimental|CJCV1 10 μg / Alum 125 μg (1A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 10 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
3073944|NCT02067663||Mirena Group|Women who have a postplacental Mirena IUD placed. (LNG-IUS)
3073945|NCT02067663||Paragard Group|Women who have a postplacental Paragard IUD placed. (Copper IUD - T380A)
3073946|NCT02067637||Exposed|Individuals with one of the following cancer diagnoses: breast, leukemia, lymphoma, and/or any gynecologic cancer.
3073947|NCT02067637||Unexposed|Healthy controls
3073948|NCT02067624|Experimental|Thai massage|The participants will receive a thirty minutes session of Thai massage onto the wrist extensor groups muscle for 9 sessions
3073949|NCT02067624|Sham Comparator|Sham Ultrasound therapy|The participants will receive a thirty minutes session of sham ultrasound therapy onto the wrist extensor groups muscle for 9 sessions
3073950|NCT02067611|Experimental|X0002|low dose, BID;middle dose, BID, or high dose, BID.
3073951|NCT02067611|Placebo Comparator|Placebo|low dose, BID; middle dose, BID, or high dose, BID.
3073952|NCT02067598|Experimental|Scapular exercise|The participants will receive thirty minutes session of scapular exercise for 12 sessions
3073953|NCT02067598|No Intervention|Control|
3073954|NCT02067585|Experimental|LAGB|Standardized Lipid meals will be served to Laparoscopic adjustable gastric banding patients.
3073955|NCT02067585|Experimental|LRYGB|Standardized Lipid meals will be served to the Laparoscopic Rou-en-Y gastric bypass patients.
3073956|NCT02067585|Experimental|Non-surgical|Standardized Lipid meals will be served to the non-surgical obese patients
3073957|NCT02067572|Experimental|Salvia|Salvia mouthwash used 4 times per day for 4 days
3073958|NCT02067572|Active Comparator|Saline|Saline mouthwash used 4 times per day for 4 days.
3073959|NCT02067559|Experimental|ICU Diaries|A bound empty journal will be stored at the patient's bedside near the nurse charting area. All family members and ICU staff are invited to write in the ICU diary at any time. Instructions will be provided to the patient's family at the time of randomization and will be available at the bedside for reference. Staff instructions will be posted at charting area for staff. During the patient's stay in ICU, the diary will never leave the unit. Under no circumstances will any part of an ICU diary be duplicated. Research staff will take a photograph of the patient after consent is obtained and the photograph will be mounted on the first page of the diary. Photographs will be taken with a Polaroid camera; therefore there will be no other record of the photograph.
3074030|NCT02067065|Experimental|Non-anesthesiologist propofol sedation|Bolus propofol sedation by non-anesthesiologist
3074031|NCT02067065|Active Comparator|Anesthesiologist administered propofol|Propofol sedation administered by an anesthesiologist
3073960|NCT02067559|Experimental|Psychoeducation|The research nurse will provide a psychoeducational brochure to study participants at ICU discharge (if cognitive capacity is established) or 30 days after ICU discharge. If participants are not well enough 30 days post-discharge, they will be assessed every two weeks by research staff until the brochure is given to them. The brochure will describe procedures in the ICU (sedation, ventilation), and the delirium, hallucinations, and trauma that may result; as well as symptoms of PTSD post-ICU. It will provide instructions for follow-up, information, and emergency care. The brochure will instruct participants to contact their follow-up healthcare provider if they have any questions. The document will also be mailed to the participant's follow-up physician.
3073961|NCT02067559|Experimental|ICU Diary plus Psychoeducation|Participants will receive both ICU diary and psychoeducation interventions, with both documents provided at ICU-discharge, or 30 days post-discharge as above.
3073962|NCT02067559|No Intervention|Treatment as Usual|No additional intervention to usual ICU care will be given.
3073963|NCT02067546|Experimental|Experimental toilet seat|Experimental toilet seat for 1 month
3073964|NCT02067546|Sham Comparator|Standard toilet seat|Standard toilet seat for 1 month
3073965|NCT02067533|Experimental|flexion position|
3073966|NCT02067533|Experimental|extension position|
3073967|NCT02067520|Other|IT hydromorphone dose|dose response study
3073968|NCT02067507|No Intervention|Control|"LACDPH Site: CDC-developed small media in preferred language~AltaMed Health Services Corporation Site: Usual care - Standing order for the HPV vaccine; required web-based training module for medical assistants and nurses containing basic information on HPV, the HPV vaccine, and standing order implementation~Northeast Valley Health Corporation Site: Usual care"
3073969|NCT02067507|Experimental|Tailored education and referral|LACDPH Site: Tailored education and referral intervention administered at LACDPH Site
3073970|NCT02067507|Experimental|Staff training and patient reminders|Staff training and patient reminders administered at AltaMed Health Services Corporation Site
3073971|NCT02067507|Experimental|Clinic-level reminder systems|Clinic-level reminders administered at Northeast Valley Health Corporation Site
3073972|NCT02067494|Experimental|Myofascial Soft Tissue Release|"Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.~Myofascial release assisted the paravertebral fascia."
3073973|NCT02067494|Active Comparator|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
3073974|NCT02067481|Experimental|Single-arm weight loss intervention|This single-arm pre-post study, that involved one-hourly weekly diet sessions delivered by a dietician and 75-minute bi-weekly Physical Activity (AP) sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment.
3073975|NCT02067468|Experimental|HPV test|Women with ASC-US cytology are HPV tested and those HPV positive are refer to Colposcopy
3073976|NCT02067468|Active Comparator|COLPOSCOPY|Women with ASC-US cytology are immediately refer to colposcopy
3073977|NCT02067468|Active Comparator|CYTOLOGY|Women with ASC-US Cytology are follow-up with cytology at 6 and/or 12 months and be referred to colposcopy if any of these cytologies is ASC-US or higher
3073978|NCT02067455|Other|LVAD patients|
3073979|NCT02067442|Active Comparator|oral acetaminophen|Patients in this arm of the study will receive oral acetaminophen and an IV placebo
3073980|NCT02067442|Active Comparator|intravenous acetaminophen|Patients in this arm of the study will receive IV acetaminophen and an oral placebo
3073981|NCT02067429|Experimental|Toric Intraocular lens|Toric intraocular lens implantation during standard cataract surgery
3073982|NCT02067429|Experimental|Limbal Relaxing Incisions|Limbal relaxing incisions during standard cataract surgery
3073983|NCT02067416|Active Comparator|taxane-based chemotherapy|physician choice: taxane-based chemotherapy to include Paclitaxel, Docetaxel, Abraxane or Ixabepilone given as standard of care
3073984|NCT02067416|Active Comparator|anthacycline based chemotherapy|Physician choice: anthracycline based chemotherapy including Adriamycin, Epirubicin give as standard of care
3073985|NCT02067403|Experimental|Eadi optimized pressure-support|
3073986|NCT02067390||Vancomycin|Vancomycin
3073987|NCT02067390||Linezolid|Linezolid
3073988|NCT02067377|Placebo Comparator|inactive powder substance|inactive powder substance by mouth twice a day for 6 months
3073989|NCT02067377|Experimental|serum bovine immunoglobulin (SBI) medical food|SBI medical food 5 gr powder substance by mouth twice a day for 6 months
3073990|NCT02067377|Experimental|serum bovine immunoglobulin (SBI) medicalfood|SBI medical food 10 gr powder substance by mouth twice a day for 6 months
3073991|NCT02067364|Other|Fit & function test|CRT ShuntCheck sensors will be applied over the shunts of asymptomatic hydrocephalus patients. The device will be activated, cooling the skin under the sensor. Patients will change positions during the one hour procedure and data will be recorded. Data will be analyzed offline to identify product performance issues due to motion.
3073992|NCT02067351|Experimental|Mindfulness Intervention|Mindfulness intervention
3073993|NCT02067338|Placebo Comparator|normal saline|During posterior lumbar spinal surgery,one group of patient received normal saline soaked collagen sponge.
3073994|NCT02067338|Active Comparator|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery ,Another group of patients received 1 mg morphine-soaked in epidural oxidized cellulose.
3073995|NCT02067325|Experimental|Thai massage|The participants will receive thirty minutes session of Thai massage onto the trapezius muscle for 1 sessions
3073996|NCT02067325|Sham Comparator|Sham Microwave diathermy|The participants will receive thirty minutes session of Sham Microwave diathermy onto the trapezius muscle for 1 sessions
3073997|NCT02067312|Experimental|Thai massage|The participants will receive a thirty minutes session of Thai massage onto the trapezius muscle
3073998|NCT02067312|Sham Comparator|Sham Microwave diathermy|The participants will receive a thirty minutes session of Sham microwave diathermy onto the trapezius muscle
3074032|NCT02067052||Advanced vulvar cancer|Patients with advanced-stage tumors.
3074033|NCT02067052||Early-stage vulvar cancer|Patients with early-stage tumors
3073999|NCT02067299|Experimental|Cohort A|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of placebo (Period 1), JNJ-42847922 10 mg (Period 2), JNJ-42847922 20 mg (Period 3), and JNJ-42847922 40 mg (Period 4). Each treatment period and each subsequent treatment period will be separated by 1 week.
3074000|NCT02067299|Experimental|Cohort B|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 10 mg (Period 1), JNJ-42847922 40 mg (Period 2), placebo (Period 3), and JNJ-42847922 20 mg (Period 4). Each subsequent treatment period will be separated by 1 week.
3074001|NCT02067299|Experimental|Cohort C|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 20 mg (Period 1), placebo (Period 2), JNJ-42847922 40 mg (Period 3), and JNJ-42847922 10 mg (Period 4). Each subsequent treatment period will be separated by 1 week.
3074002|NCT02067299|Experimental|Cohort D|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 40 mg (Period 1), JNJ-42847922 20 mg (Period 2), JNJ-42847922 10 mg (Period 3), and placebo (Period 4). Each subsequent treatment period will be separated by 1 week.
3074003|NCT02067273|Experimental|TMS Intervention for 5 days|Application of Transcranial Magnetic Stimulation (TMS) for up to 5 days
3074004|NCT02067273|Experimental|TMS Intervention for 1 day|Application of Transcranial Magnetic Stimulation (TMS) for 1 day
3074005|NCT02067260|Active Comparator|X5 HairLaser|
3074006|NCT02067260|Sham Comparator|X5 HairLaser Sham Device|
3074007|NCT02067247|Experimental|SOS forearm test|BeamMed Speed-of-Sound bone strength test at forearm
3074008|NCT02067234|Active Comparator|Routine Care/Education|Patient will be assessed by MD and provided education by nurse
3074009|NCT02067234|Experimental|Psychoeducation/Coping Prevention|Patient will be assessed by MD and will meet with psychologist to obtain psychoeducation about coping, behavioral strategies, and sleep hygiene
3074010|NCT02067221|Active Comparator|RIRS (retrograde intrarenal surgery)|Use of flexible ureteroscopy to access and remove renal stones without percutaneous nephrostomy tract
3074011|NCT02067221|Experimental|MPCNL (mini-perc)|"A new technique that reduced the size of percutaneous tract to make renal stone into small pieces.~Patients will be randomized and assigned to each group at the ratio 1:1"
3074012|NCT02067208|No Intervention|Waitlist Control|A waitlist control condition, where the participant receives no insole for 3 months. During this 3 month period, the participant will continue to be monitored for outcome variables.
3074013|NCT02067208|Experimental|Experimental wedged insole|Either a medially wedged or laterally wedged footwear insole (whichever reduces knee joint mechanical loading more, as determined from subject-specific biomechanical tests), constructed using a 3D printer will be inserted into each participant's shoe. The participant will be asked to utilize this insole as much as possible throughout the day over the course of 3 months.
3074014|NCT02067195|Active Comparator|Guideline Hydration|No hydration for patients without chronic kidney disease(CrCl<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
3074015|NCT02067195|Active Comparator|Adequate Hydration|Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP <13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and >1.5 ml/kg/hr for LVEDP >18 mmHg, whereas,0.5 ml/kg/hr for LVEDP >20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
3074016|NCT02067182|Experimental|Oral Anticoagulation with Dabigatran|"The recommended daily dose of Pradaxa is 300 mg taken as one 150 mg capsule twice daily.~For the following patients the recommended daily dose of Pradaxa is 220 mg taken as one 110 mg capsule twice daily:~Patients aged 75 years or above~Cr-Cl 30-50 ml/min~Patients who receive concomitant verapamil~For the following groups, the daily dose of Pradaxa of 300 mg or 220 mg should be selected based on an individual assessment of the thromboembolic risk and the risk of bleeding:~Patients with moderate renal impairment~Patients with gastritis, esophagitis or gastroesophageal reflux~Other patients at increased risk of bleeding"
3074017|NCT02067182|No Intervention|No Oral Anticoagulation|
3074018|NCT02067169||CMV infection|allograft recipient with active CMV infection
3074019|NCT02067156|Experimental|G-202 (Mipsagargin)|G-202 (Mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
3074020|NCT02067143|Experimental|Study population|In this phase II multicentric trial, eligible patients with Ph- ALL/LL will receive homogeneous supportive care and chemotherapy and will be homogeneously analyzed for response at prefixed timepoints from induction day 1. For risk-/MRD-oriented therapy, CR patients will be stratified by risk class according to diagnostic characteristics, MRD study and CT/PET (LL only) results during early consolidation.
3074021|NCT02067130|Other|Fibroscan|Subjects enrolled will undergo Fibroscan. It is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Fibroscan reading will be collected at the Gastroenterologist's (Dr. Ko) outpatient clinic (Pacific Gastroenterology Associates) where a qualified research nurse/assistant will perform the scan under supervision of the physician. Anticipated timing of this procedure will be October to December 2013
3074022|NCT02067117|Experimental|influenza split vaccine|
3074023|NCT02067104|Placebo Comparator|Placebo|receive 150 mg of oral placebo daily for a period of 2 months
3074024|NCT02067104|Experimental|Vismodegib|receive 150 mg of vismodegib daily for a period of 2 months
3074025|NCT02067091|Active Comparator|BVS|Implantation of bioresorbable vascular scaffold in coronary artery by direct stenting after thrombus aspiration by percutaneous coronary intervention
3074026|NCT02067091|Active Comparator|DES|Implantation of drug eluting stent in coronary artery by direct stenting after thrombus aspiration by percutaneous coronary intervention
3074027|NCT02067078|Experimental|Combined saphenous nerve and obturator nerve block|
3074028|NCT02067078|Experimental|Saphenous nerve block|
3074029|NCT02067078|Active Comparator|Local infiltration analgesia|
3074034|NCT02067039|Experimental|OraQuick in home & Sure Check HIV tests|The intervention group of MSM (HIV negative or unaware of HIV status) will receive 4 rapid HIV test kits - 2 oral fluid tests (OraQuick), and 2 finger-stick blood tests (Sure Check). Men in the randomized controlled trial will complete short follow-up surveys at 3-month intervals during the 12-month follow-up period, and men in the intervention arm will be allowed to order additional test kits to replenish the ones they use or give away. At month 12, all HIV-negative or those who are unaware of their HIV status participants will be sent 1 oral fluid test (OraQuick), 1 finger-stick blood test (Sure Check), and a dried blood spot (DBS) specimen collection kit to be mailed to Emory University after collecting a blood sample for laboratory testing.
3074035|NCT02067039|No Intervention|Information only|All comparison group of MSM (HIV negative or unaware of HIV status) will take a baseline survey. Men in the randomized controlled trial will complete short follow-up surveys at 3-month intervals during the 12-month follow-up period. At month 12, all HIV-negative and unaware of their HIV status comparison arm participants will be sent 1 oral fluid test (OraQuick), 1 finger-stick blood test (Sure Check), and a DBS specimen collection kit to be mailed to Emory University after collecting a blood sample for laboratory testing.
3074036|NCT02067026|Experimental|Aleurone supplementation|The study supplementation will be introduced in the daily diet according to the participant preference to a total of 27g of Aleurone/day. One bread bun (35 g) contains 4.8 g Aleurone; one biscuit (15 g) contains 4 g Aleurone; 36 g of RTE cereals contain 9 g Aleurone.
3074037|NCT02067026|Placebo Comparator|Hemicellulose supplementation|The study supplementation will be introduced in the daily diet according to the participant preference to a total of 27g of Hemicellulose/day. One bread bun (35 g) contains 4.8 g Hemicellulose; one biscuit (15 g) contains 4 g Hemicellulose; 36 g of RTE cereals contain 9 g Hemicellulose. Placebo products contain the same levels of cellulose in place of aleurone's dietary fiber content.
3074038|NCT02067013|Active Comparator|Ranibizumab|Subjects undergoing surgery for neovascular glaucoma, diabetic retinopathy, or tractional Retinal Detachment due to AMD will receive one intravitreal injection of ranibizumab within 2 weeks of their surgery. Vitreous and aqueous humor samples will be collected during the surgery. Serum samples may be collected before, during, or after surgery.
3074039|NCT02067013|Placebo Comparator|Control|Subjects undergoing surgery for ERM or macular hole will NOT receive an injection of ranibizumab, but will have vitreous, and aqueous humor samples collected during surgery (no serum collection).
3074040|NCT02067000||Obstructive Sleep Apnea|
3074041|NCT02066987|Experimental|Implementation intention|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth! If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth!"
3074042|NCT02066987|Experimental|Action planning|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY).~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY)."
3074043|NCT02066987|Active Comparator|active control group|Participants in the active control group will receive an educational pamphlet containing what it is dental brushing, why it is done, and how it is done.
3074044|NCT02066974||Hepatoma, Circulating tumor genome|Hepatoma requiring radiotherapy
3074045|NCT02066961||Cohort 1|Subjects with biochemical failure experience after primary treatment and have high-risk disease
3074046|NCT02066961||Cohort 2|Subjects with a medical diagnosis of castration-resistant prostate cancer
3074047|NCT02066961||Cohort 3|Subjects with an initial diagnosis of metastatic prostate cancer
3074048|NCT02066948|Active Comparator|Skew meal pattern w/ wt loss&exercise|Skew meal pattern w/ wt loss&exercise e
3074049|NCT02066948|Active Comparator|even meal pattern w/ wt loss&exercise|even meal pattern w/ wt loss&exercise
3074050|NCT02066935||kidney transplant patient|Kidney transplanted patients for at least one year
3074051|NCT02066922|Experimental|DAILIES TOTAL1|Delefilcon A contact lens randomly assigned to one eye, with narafilcon A contact lens in the fellow eye for contralateral wear. Both products worn in a daily wear, daily disposable mode approximately 8 hours a day for approximately 1 week, with spectacles worn over contact lenses if needed to provide acceptable vision.
3074052|NCT02066922|Active Comparator|TRUEYE|Narafilcon A contact lens randomly assigned to one eye, with delefilcon A contact lens in the fellow eye for contralateral wear. Both products worn in a daily wear, daily disposable mode approximately 8 hours a day for approximately 1 week, with spectacles worn over contact lenses if needed to provide acceptable vision.
3074053|NCT02066909|Experimental|Cohort 1|Dosing in healthy Western subjects.
3074054|NCT02066909|Experimental|Cohort 2|Dosing in healthy Western subjects.
3074055|NCT02066909|Experimental|Cohort 3|Dosing in healthy Western subjects.
3074056|NCT02066909|Experimental|Cohort 4|Dosing in healthy Western subjects.
3074057|NCT02066909|Experimental|Cohort 5|Dosing in healthy Western subjects.
3074058|NCT02066909|Experimental|Cohort 6|Dosing in healthy Western subjects.
3074059|NCT02066909|Experimental|Cohort 7|Dosing in healthy Western subjects.
3074060|NCT02066909|Experimental|Optional Cohort 8|Dosing in healthy Western subjects. Cohort may not be conducted.
3074061|NCT02066909|Experimental|Cohort 9|Dosing in healthy Japanese subjects.
3074062|NCT02066896|Sham Comparator|Sham Comparator: Sham Lasertherapy|Sham lasertherapy in parotid, submandibular and sublingual glands for six weeks.
3074063|NCT02066896|Active Comparator|Active Comparator: Lasertherapy|Low level lasertherapy in parotid, submandibular and sublingual glands for six weeks.
3074093|NCT02066662|Experimental|Rivaroxaban|Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing
3074064|NCT02066870|Experimental|Icotinib and arsenic trioxide|"Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.~Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
3074065|NCT02066857|Active Comparator|Generic plaster or fiberglass cast group|Patients will be randomized to receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture for 6 weeks.
3074066|NCT02066857|Active Comparator|"Generic off the shelf removable splint group"|"Subjects will be randomized and receive a generic off the shelf removable splint for treatment of non-displaced distal radius fracture for 6 weeks."
3074067|NCT02066844|Active Comparator|Standard Manual Needle Injection|2cc of Celestone and 5cc of Lidocaine will be administered by the nurse or surgeon
3074068|NCT02066844|Experimental|Navigator Injection|2cc of Celestone and 5cc of Lidocaine will be administered using the Navigator by the nurse or surgeon
3074069|NCT02066831|Experimental|Telemedical Coaching|Patients will receive telemedical devices i.e. for the measurement of blood glucose, weight and physical activity. These devices will transfer the data to a data collector with a SIM card which sends the data to a data portal, which can be monitored by the participant and the coach. Health coaches which will have close phone contact to patients, supporting them to reduce weight and increase physical activity. In the first 12 weeks, patients will follow a formula diet (Almased) to achieve an initial weight reduction.
3074070|NCT02066831|Active Comparator|Telemedicine|Patients will receive telemedical devices i.e. for the measurement of blood glucose, weight and physical activity. These devices will transfer the data to a data collector with a SIM card which sends the data to a data portal which can be monitored by the participant.
3074071|NCT02066818|Active Comparator|Lidocaine Injection|Incision and drainage performed after patient received placebo patch with injection of 1% lidocaine into the site of the abscess.
3074072|NCT02066818|Experimental|Lidocaine/tetracaine patch|Incision and drainage performed after patient received active lidocaine/tetracaine patch and injection of 10cc of saline into site of abscess
3074073|NCT02066805||Cohort 1|
3074074|NCT02066792|Experimental|Tailored Post-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs/placebo after the session). The type of pill (i.e. dcs vs. placebo) will be determined after the session.
3074075|NCT02066792|Active Comparator|Pre-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one dcs before and one placebo after the session).
3074076|NCT02066792|Placebo Comparator|Placebo|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one placebo after the session).
3074077|NCT02066792|Active Comparator|Non-Tailored Post-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs after the session).
3074078|NCT02066766||Subjects with diabetes mellitus (type 2)|
3074079|NCT02066753|Active Comparator|24 hours mild therapeutic hypothermia|The patient will be treated with mild therapeutic hypothermia for 24 hours after reaching the target temperature between 32-34°C.
3074080|NCT02066753|Experimental|48 hours mild therapeutic hypothermia|The patient will be treated with mild therapeutic hypothermia for 48 hours after reaching the target temperature between 32-34°C.
3074081|NCT02066740|Experimental|EverFlex™ stent with Entrust™ delivery system|
3074082|NCT02066727|Active Comparator|Dexmedetomidine|Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
3074083|NCT02066727|Placebo Comparator|Normal Saline|Normal Saline is administrated as an adjuvant of lidocaine.
3074084|NCT02066714||Healthy Cohort|These children will be recruited from district 8, Ho Chi Minh City where most HFMD admissions to the Hospital for Tropical Diseases occur. We wil recruit healthy children from three kindergartens and ask for volunteers from participants enrolled in an Oxford University Clinical Research Unit Dengue birth cohort study (OXTREC approval 02-09) in District 8, HCMC. This birth cohort is an observational study.
3074085|NCT02066714||Hand Foot and Mouth Disease|The Vietnamese Ministry of Health has a clinical grading system. Grade 1 disease is uncomplicated and are not admitted to hospital. Grade 2 and above are admitted to hospital with clinical features of neurological or systemic involvement. Grade 2 is split into Grade 2a and 2b depending if neurological manifestations such as myoclonus have been witnessed by the parents or by a health professional. In total, it is anticipated that 125 Grade 2a and 125 Grade 2b and 100 more severe Grade 3 and 4 will be recruited over one year. A subset who agree for brain magnetic resonance imaging (MRI) will also have a scan done during their hospital admission.
3074086|NCT02066701||Endoscopy Barrett's|Patients undergoing clinically indicated upper endoscopy will be invited to participate. Patients who are known to have Barrett's Esophagus as well as patient who do not will be approached for enrollment
3074087|NCT02066701||Endoscopy control|Patients undergoing clinically indicated upper endoscopy will be invited to participate. Patients who are known to have Barrett's Esophagus as well as patient who do not will be approached for enrollment
3074088|NCT02066688|Experimental|FA|Patients receive oral folic acid pill 1 mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects (FA Arm).
3074089|NCT02066688|Experimental|FA+Ca|Patients receive oral folic acid pill 1 mg+ calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects(FA+Ca arm).
3074090|NCT02066688|Experimental|Ca|Patients receive oral calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects (Ca Arm).
3074091|NCT02066688|Placebo Comparator|blank control group|Patients receive oral placebo once daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
3074092|NCT02066675|Experimental|Trabectedin|Trabectedin administered at the dose of 1.5 mg/mq-1.3 mg/mq a 24-hour continuous infusion via a central venous access, every 3 weeks
3074094|NCT02066662|Active Comparator|Marcumar|Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0.
3074095|NCT02066649|Active Comparator|Carvedilol|Initiating patient on carvedilol after diagnosis of varices made on endoscopy
3074096|NCT02066649|Active Comparator|Variceal Band Ligation|performing variceal band ligation during endoscopy on patient after diagnosis of esophageal varices made on endoscopy
3074097|NCT02066649|Active Comparator|Combination Group (Carvedilol + Variceal band ligation)|once patient has confirmed large esophageal varices on endoscopy, he/she will be started on carvedilol (post-procedure) in addition to having variceal band ligation performed during endoscopy
3074098|NCT02066636|Experimental|Cohort A: Nivolumab|Nivolumab 3 mg/kg solution intravenous infusion over 60 minutes every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent
3074099|NCT02066636|Experimental|Cohort B: Nivolumab|"Nivolumab 3 mg/kg solution intravenous infusion over 60 minutes every two weeks until 1 year (52 weeks).~Discontinue treatment and at progression, retreatment allowed"
3074100|NCT02066623||Implantation of ABSORB Scaffold|Patients suffering from coronary artery stenosis with an indication for implantation of ABSORB scaffold
3074101|NCT02066610|Experimental|PN selenium and formula sodium selenate|Parenteral nutrition (PN) with selenium and sodium selenate supplementation of infant formula
3074102|NCT02066610|Experimental|PN selenium and formula sodium selenite|Parenteral nutrition (PN) with selenium and sodium selenite supplementation of infant formula
3074103|NCT02066610|Experimental|PN without selenium and formula sodium selenate|Parenteral nutrition (PN) without selenium and sodium selenate supplementation of infant formula
3074104|NCT02066610|Experimental|PN without selenium and formula sodium selenite|Parenteral nutrition (PN) without selenium and sodium selenite supplementation of infant formula
3074105|NCT02066597|Experimental|Intervention|
3074106|NCT02066584||Universal IVF Medium|An oocyte culture medium containing 5.55 Mm glucose (Origio, Medi-Cult)
3074107|NCT02066584||ISM1 Medium|An oocyte culture medium containing 1mM glucose ((Origio, MediCult)
3074108|NCT02066584||P1 Medium|An oocyte culture medium containing no glucose (Irvine)
3074109|NCT02066584||ECM Medium|An oocyte culture medium containing 0.5mM glucose (Irvine)
3074110|NCT02066571|Other|droxidopa, then sugar pill|Droxidopa will be titrated over a 2-week period up to 300 mg twice daily (600 mg total daily dose). Subjects will be titrated to highest tolerated dose and will continue on that dose for two weeks. Then, the subject will start sugar pills.
3074111|NCT02066571|Other|sugar pill, then droxidopa|Subject will be be on sugar pill for 5 weeks (4 weeks of placebo treatment and one week of wash-out or sugar pills). Then, droxidopa will be titrated over 2 week period up to 300 mg twice daily (600 mg total daily dose). Subjects will be titrated to highest tolerated dose and will continue on that dose for two weeks.
3074112|NCT02066558|Active Comparator|carbon monoxide|Inhalation of carbon monoxide up to a carboxyhemoglobin concentration of 12% and 22%.
3074113|NCT02066558|Placebo Comparator|placebo|Atmospheric air
3074114|NCT02066545|Placebo Comparator|Vehicle Gel|
3074115|NCT02066545|Experimental|CLS001 topical gel 1%|Topical application once daily
3074116|NCT02066545|Experimental|CLS001 topical gel 1.75%|Topical application once daily
3074117|NCT02066545|Experimental|CLS001 topical gel 2.5%|Topical application once daily
3074118|NCT02066532|Experimental|Ruxolitinib/Trastuzumab|Jakafi (Ruxolitinib) and Trastuzumab (Herceptin) - 21 day cycle until disease progression
3074119|NCT02066519|Experimental|Physical exercise arm|Arm with physical exercise on rowing machine between M3 and M6
3074120|NCT02066519|No Intervention|Control arm|Arm with standard medical care without additional physical exercise
3074121|NCT02066506|Sham Comparator|asymptomatic group|patients with systemic right ventricle who are asymptomatic,
3074122|NCT02066506|Sham Comparator|symptomatic group|symptomatic group : patients with systemic right ventricle and heart failure signs and/or decrease exercise performance
3074123|NCT02066506|Sham Comparator|control|healthy subject matched with patients of asymptomatic group
3074124|NCT02066493||conservative management|neither surgical nor endovascular management
3074125|NCT02066493||endovascular management|endovascular management
3074126|NCT02066493||surgical management|surgical management
3074127|NCT02066480||women between 50 and 80 years hospitalized in CHD Vendée|
3074128|NCT02066467||Heart failure patients|"Subjects with art failure who receive stable optimal pharmacologic therapy~Moderate to severe heart failure (NYHA Class III-IV) with ejection fraction (EF) ≤ 35% and QRS duration ≥ 120 ms~Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure.~The study is collecting observational data on regular CRT-D device implants with special focus on the left ventricular ACUITY X4® Lead Family' ."
3074129|NCT02066454|Experimental|Apixaban|oral direct anti-Xa anticoagulant
3074130|NCT02066441|Experimental|Bio-D-Mulsion Forte®|Bio-D-Mulsion Forte® at a dosage level of 2 drops (4,000 IU) once daily for the 6-month treatment period.
3074131|NCT02066441|Placebo Comparator|Placebo|Placebo a dosage level of 2 drops once daily for the 6-month treatment period.
3074132|NCT02066428|Experimental|AERAS-404(50mcg H4/0nmol IC31) or Placebo|1 dose
3074133|NCT02066428|Experimental|AERAS404 (50mcgH4/100nmol IC31) or Placebo|1 dose
3074134|NCT02066428|Experimental|AERAS404 (50mcgH4/0nmol IC31) or Placebo|2 dose
3074135|NCT02066428|Experimental|AERAS404 (150mcgH4/0nmol IC31) or Placebo|1 dose
3074136|NCT02066428|Experimental|AERAS404 (50mcgH4/5000nmol IC31) or Placebo|1 dose
3074137|NCT02066428|Experimental|AERAS404 (50mcgH4/500nmol IC31) or Placebo|2 dose
3074138|NCT02066428|Experimental|AERAS404|2 dose placebo
3074139|NCT02066428|Experimental|AERAS404 (50mcg H4/100nmol IC31) or Placebo|2 dose
3074140|NCT02066415|Placebo Comparator|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection.
3074141|NCT02066415|Experimental|Erenumab 70 mg|Participants received 70 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
3074142|NCT02066415|Placebo Comparator|Erenumab 140 mg|Participants received 140 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
3074143|NCT02066402|Experimental|Tedizolid Phosphate (Sivextro, BAY119-2631)|Participants received 200 mg Tedizolid Phosphate once daily intravenous (I.V.) infusion to oral for 6 days, followed by 4 days of placebo.
3074144|NCT02066402|Active Comparator|Linezolid|Participants received 600 mg Linezolid twice daily I.V. infusion to oral for 10 days.
3074145|NCT02066389|Experimental|Group 1|ABT-494 orally twice daily, low dose
3074146|NCT02066389|Experimental|Group 2|ABT-494 orally twice daily, mid-low dose
3074147|NCT02066389|Experimental|Group 3|ABT-494 orally twice daily, mid-high dose
3074148|NCT02066389|Experimental|Group 4|ABT-494 orally twice daily, high dose
3074149|NCT02066389|Experimental|Group 5|ABT-494 once daily
3074150|NCT02066389|Placebo Comparator|Group 6|Placebo, twice daily
3074151|NCT02066363|Active Comparator|Best nutritional Care|Best supportive nutritional care and dietician advise
3074152|NCT02066363|Experimental|Parenteral nutrition|Supplemental Parenteral Nutrition and dietician advise. Supplemental parenteral Nutrition 30% of estimated needs. Parenteral nutrition given at home, administered by a nurse. The patient will be seen at the Outpatient Clinic every 6th week, talk to dietician and a doctor.
3074153|NCT02066350|Experimental|Single pancreas transplantation|This is an explorative analysis to assess the impact of establishing normoglycemia in previously hyperglycemic patients, without using antidiabetic drugs, by investigating patients before and after single pancreas transplantation. Active patients on the waiting list for single pancreas transplantation will be investigated while on the waiting list and subsequently 8 weeks and 1 year after transplantation if they have a functioning pancreas graft. A control group of healthy volunteers (non-diabetic, non-transplanted), frequency-matched for age and gender with regards to the pancreas transplanted patients, will be investigated once.
3074154|NCT02066337|Placebo Comparator|placebo gel|scaling and root planing with placebo gel
3074155|NCT02066337|Active Comparator|Ozonated olive oil gel|scaling and root planing with Ozonated olive oil gel
3074156|NCT02066311|Experimental|nelfinavir|Nelfinavir tablets will be taken by oral administration, 750mg (three 250 mg tablets) three times a day
3074157|NCT02066298|Experimental|Crossover sequence 1|Mometasone 220mcg BID, followed by Titropium Respimat 5mcg QD, followed by Placebo
3074158|NCT02066298|Experimental|Crossover sequence 2|Mometasone 220mcg BID, followed by Placebo, followed by Tiotropium Respimat 5mcg QD
3074159|NCT02066298|Experimental|Crossover sequence 3|Placebo, followed by Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD
3074160|NCT02066298|Experimental|Crossover sequence 4|Placebo, followed by Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID
3074161|NCT02066298|Experimental|Crossover sequence 5|Tiotropium Respimat 5mcg QD, followed by Placebo, followed by Mometasone 220mcg BID
3074162|NCT02066298|Experimental|Crossover sequence 6|Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID, followed by Placebo
3074163|NCT02066285|Experimental|Pazopanib|Single arm of pazopanib 800 mg (2x400 mg or 4x200 mg) given as a single agent once daily continuously.
3074164|NCT02066272||IBD patients|IBD patients who start or re-start anti-TNF therapy
3074165|NCT02066259||healthy_0|healthy, people with normal (negative) colonoscopy results.
3074166|NCT02066259||patient_1|people with biopsy/surgery verified carcinoma of the colon, either an Adenocarcinoma, or carcinoma in situ
3074167|NCT02066259||benign_2|people with biopsy verified benign polyps of the colon one of the following - Villus adenoma, Tubular adenoma, Low grade dysplasia, Intermediate grade dysplasia, High grade dysplasia, Severe dysplasia
3074168|NCT02066246|Sham Comparator|Olympus UHI-3|patients are treated with the Olympus UHI-3-CO2-insufflation and trocar system
3074169|NCT02066246|Active Comparator|AirSeal|patients are treated with the AirSeal-CO2-insufflator and trocar-system
3074170|NCT02066233|Active Comparator|Subjects with Barrett's Esophagus|All subjects will receive transnasal endoscopy (EG Scan II) followed by standard endoscopy.
3074171|NCT02066233|Active Comparator|Subjects with Reflux and/or Heartburn|All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.
3074172|NCT02066220|Experimental|PNET 5 MB-LR (low-risk)|Radiotherapy and reduced-intensity maintenance chemotherapy. Total treatment duration is 39 weeks.
3074173|NCT02066220|Experimental|PNET 5 MB-SR (standard-risk)|"Radiotherapy with carboplatin or radiotherapy without carboplatin and maintenance chemotherapy.~Total treatment duration is 48 weeks."
3074174|NCT02066207|Experimental|Fenofibrate|Subjects received Fenofibrate
3074175|NCT02066207|Experimental|Atorvastatin|Subjects received Atorvastatin
3074176|NCT02066207|Experimental|Fenofibrate and Atorvastatin|Subjects received Fenofibrate and Atorvastatin
3074177|NCT02066194|Active Comparator|Electroacupuncture|Patients randomized to the experimental group will receive EA at acupoints relevant to the treatment of abdominal pain and anxiety. Selection of these acupoints is based on a consensus between the acupuncturist of the study (Leung WW) and several professors of the Diploma Course of Clinical Acupuncture of the School of Professional and Continuing Education, University of Hong Kong.
3074178|NCT02066194|Placebo Comparator|Sham Acupuncture|Patients randomized to the control group will receive Sham acupuncture with sterile blunt-tip needles
3074179|NCT02066181|Experimental|Arm I (sorafenib tosylate)|Patients receive sorafenib tosylate PO QD on days 1-28.
3074180|NCT02066181|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Patients may crossover to Arm I upon disease progression.
3074181|NCT02066155|Experimental|Parish nurse|On-going support provided by parish nurse
3074182|NCT02066155|Experimental|Peer support|On-going support provided by a person with diabetes
3074183|NCT02066155|No Intervention|Control group|No on-going support provided
3074184|NCT02066142|Active Comparator|Tomosynthesis|Tomosynthesis will be compared to Ultrasound
3074185|NCT02066142|Other|Ultrasound|Ultrasound (sensitivity and specificity) will be compared to Tomosynthesis
3074186|NCT02066129|Active Comparator|Fluticasone 44 mcg|"Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of yellow zone symptoms."
3074187|NCT02066129|Active Comparator|Fluticasone 220 mcg|"Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of yellow zone symptoms."
3074188|NCT02066116|Experimental|Kinect-based Rehabilitation|
3074189|NCT02066116|Active Comparator|Self-exercises education|
3074190|NCT02066103|Experimental|Treatment|
3074191|NCT02066090|Experimental|Real acupuncture|manual acupuncture + electroacupuncture, twice a week, for 6 weeks
3074192|NCT02066090|Sham Comparator|Sham acupuncture|sham acupuncture + placebo acupuncture without electrical stimulation, twice a week, for 6 weeks
3074193|NCT02066077|Experimental|Bilateral temporal and propofol|During the MECT treatment, electrodes are placed at bilateral temporal, with propofol 2mg/kg to Induce anesthesia.
3074194|NCT02066077|Experimental|Bilateral temporal and etomidate|During the MECT treatment, electrodes are placed at bilateral temporal, with etomidate 0.3mg/kg to Induce anesthesia.
3074195|NCT02066077|Experimental|The right temporal and propofol|During the MECT treatment, electrodes are placed at the right temporal, with propofol 2mg/kg to Induce anesthesia.
3074196|NCT02066077|Experimental|The right temporal and etomidate|During the MECT treatment, electrodes are placed at the right temporal, with etomidate 0.3mg/kg to Induce anesthesia.
3074197|NCT02066077|Experimental|Bilateral frontal and propofol|During the MECT treatment, electrodes are placed at bilateral frontal, with propofol 2mg/kg to Induce anesthesia.
3074198|NCT02066077|Experimental|Bilateral frontal and etomidate|During the MECT treatment, electrodes are placed at bilateral frontal, with etomidate 0.3mg/kg to Induce anesthesia.
3074199|NCT02066077|Active Comparator|Standard-therapy Group|During the MECT treatment, electrodes are placed at bilateral temporal, with etomidate 0.3mg/kg to Induce anesthesia.
3074200|NCT02066064|Experimental|Group A|Subjects will undergo complete standard colonoscopy, followed by G-EYE(TM) Colonoscopy
3074201|NCT02066064|Active Comparator|Group B|Subject will undergo G-EYE(TM) colonoscopy followed by standard colonoscopy
3074202|NCT02066051|Experimental|IPL Treatment|Subjects who had inactive chronic graft versus host disease (GVHD) after allogeneic bone marrow transplantation and severe dry eye symptoms related to ocular rosacea unresponsive to conventional management were recruited. Subjects were treated with 4 monthly sessions of intense pulsed light (IPL) and meibomian gland expression.
3074203|NCT02066038|Experimental|A|Pemetrexed 500mg/m2+Carboplatin area under curve(AUC)=5, every 3 weeks, maximum 4 cycles, Erlotinib 150mg/d every cycle d2-15, and Erlotinib 150mg/d from the last cycle until disease progression
3074204|NCT02066025||group_0|Women with negative mammography (BIRADS 1-2), as negative controls.
3074205|NCT02066025||group_1|Women with positive biopsy for (ID, IL, DCIS) as patients.
3074206|NCT02066025||group_2|Women with positive mammography (BIRADS 3-4-5-6), and a negative biopsy diagnosis for breast cancer (ID, IL, DCIS) will be enrolled as benign (ADH, ALH, LCIS, fibroadenoma, fibrocystic changes (including sclerosing adenosis), Benign papillaoma, normal breast) as benigns.
3074207|NCT02066012||group DIOS|group DIOS composed of subjects with dysmetabolic hepatosiderosis
3074208|NCT02066012||group M|group M composed of subjects with metabolic syndrom without iron overload
3074209|NCT02066012||group T|group T composed of lean subjects
3074210|NCT02065986|Experimental|Arm A: Immediate offer of Truvada-PrEP|Immediate offer of Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)
3074211|NCT02065986|Other|Arm B: Deferred (12m) offer of Truvada-PrEP|Access to Truvada from 12 months after enrolment
3074212|NCT02065973|Active Comparator|Cohort 1 (Low Dose)|The group will receive the lowest dose of the vaccine
3074213|NCT02065973|Active Comparator|Cohort 2 (Mid Dose)|The Group will receive the middle dose of the vaccine
3074214|NCT02065973|Active Comparator|Cohort 3 (High Dose)|The Group will receive the highest dose of vaccine to be tested
3074215|NCT02065960|Experimental|Stereotactic body radiotherapy (SBRT)|Radiotherapy with SBRT to a dose of 40 Gy in 5 fractions delivered every other day over a period of 10-12 days, followed by breast conserving surgery.
3074216|NCT02065947|Active Comparator|general anesthesia|fentanyl 0,05 - 0.1 mg/h, propofol 150 - 200 mg, atracurium
3074217|NCT02065947|Experimental|paravertebral block|a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
3074218|NCT02065921||COPD patients|establishing COPD cohort database to allow high quality research on diagnosis, treatment, complication and progression of COPD on long-term course.
3074219|NCT02065895|Experimental|HIGH error, LOW error, NO error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control higher than blood glucose (HIGH error), then second with glucose-value-used-for-control lower than blood glucose (LOW error), then third with glucose-value-used-for-control equal blood glucose (NO error).
3074220|NCT02065895|Experimental|HIGH error, NO error, LOW error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control higher than blood glucose (HIGH error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third with glucose-value-used-for-control lower than blood glucose (LOW error).
3074221|NCT02065895|Experimental|NO error, HIGH error, LOW error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control equal blood glucose (NO error), then second with glucose-values-used-for-control higher than blood glucose (HIGH error), then third with glucose-value-used-for-control lower than blood glucose (LOW error).
3074222|NCT02065895|Experimental|NO error, LOW error, HIGH error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control equal blood glucose (NO error), then second with glucose-value-used-for-control lower than blood glucose (LOW error), then third with glucose-value-used-for-control higher than blood glucose (HIGH error).
3074223|NCT02065895|Experimental|LOW error, NO error, HIGH error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with with glucose-value-used-for-control lower than blood glucose (LOW error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third with glucose-value-used-for-control higher than blood glucose (HIGH error).
3074224|NCT02065895|Experimental|LOW error, HIGH error, NO error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control lower than blood glucose (LOW error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third glucose-value-used-for-control higher than blood glucose (HIGH error),
3098088|NCT01904929|Experimental|Reconditioning in the effort|
3074225|NCT02065882|Experimental|BT524|Single intravenous infusion of a fixed dose of 70 mg BT524 per kilogram body weight (BW)
3074226|NCT02065869|Experimental|BPX-501 T cells and AP1903|"TCR alpha beta depleted graft infusion with addback of BPX-501 T cells.~AP1903: Dimerizer drug administered to subjects who develop Grade III-IV acute GVHD, Grade II gut/liver acute GVDH or Grade I/II skin-only acute GvHD which is non-responsive after 7 days of standard of care treatment"
3074227|NCT02065856|Experimental|AVANZ Salsola kali|Subcutaneous immunotherapy
3074228|NCT02065843|Active Comparator|Mulungu|500 mg Mulungu Matusa® (Erytrina mulungu, 2 capsules of 250 mg) to be administered v.o., one hour before the surgical procedure.
3074229|NCT02065843|Placebo Comparator|placebo|500 mg of starch (2 capsules of 250 mg) to be administered v.o., one hour before the surgical procedure.
3074230|NCT02065843|Active Comparator|Passiflora incarnata|100 mg Passiflora incarnata (2 capsules of 50 mg) to be administered v.o., one hour before the surgical procedure.
3074231|NCT02065843|Active Comparator|midazolam|15 mg midazolam (2 capsules of 7.5 mg) to be administered v.o., one hour before the surgical procedure.
3074232|NCT02065830|Experimental|Robot Safety and Efficacy|"The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training."
3074233|NCT02065817|Experimental|Tracer|
3074234|NCT02065804|Experimental|Active drug|10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
3074235|NCT02065804|Placebo Comparator|Placebo|10 ml of normal saline deposited by ultra-sound guidance around the spermatic cord
3074236|NCT02065791|Experimental|Canagliflozin 100 mg|Each participant will receive 100 mg of canagliflozin once daily
3074237|NCT02065791|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily
3074238|NCT02065778|Experimental|Stem Cells|autologous bone marrow mononuclear cell transplantation
3074239|NCT02065752|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 100 mg, and 2 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
3074240|NCT02065752|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
3074241|NCT02065752|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
3074242|NCT02065739|Experimental|Period 1|Participants will receive a single 30-mg dose of JNJ-42165279 on Day 1.
3074243|NCT02065739|Experimental|Period 2|Participants will receive itraconazole 200 mg once a day from Day 4 to Day 10. A single oral 30-mg dose of JNJ-42165279 will be administered on Day 8 along with the dose of 200 mg itraconazole.
3074244|NCT02065726|Experimental|Whey protein|Nutritional counseling + 20 g (2 x 10 g) of whey proteins (Prother® - Spepharm Italy)
3074245|NCT02065726|Active Comparator|Nutritional counseling|Nutritional counseling
3074246|NCT02065713|Experimental|Golimumab in combination with methotrexate|"Golimumab 50mg, subcutaneous, once monthly, for 24 weeks, in combination with MTX.~MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity"
3074247|NCT02065713|Active Comparator|Placebo in combination with methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity.
3074248|NCT02065700|Experimental|Filgotinib 200 mg once daily|Filgotinib 200 mg (2 x 100 mg) once daily (morning)
3074249|NCT02065700|Experimental|Filgotinib 100 mg twice daily|Filgotinib 100 mg twice daily (morning and evening)
3074250|NCT02065687|Experimental|Arm I (paclitaxel, carboplatin, metformin hydrochloride)|"Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator."
3074251|NCT02065687|Active Comparator|Arm II (paclitaxel, carboplatin, placebo)|"Patients receive paclitaxel IV and carboplatin IV as in Arm I. Patients also receive placebo PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator."
3074252|NCT02065648||Syngo NATIVE MRA|All consenting participants will receive an additional non-contrast Syngo NATIVE MRA sequence prior to contrast injection their standard of care MRA.
3074253|NCT02065635|Experimental|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
3074254|NCT02065635|Active Comparator|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
3074255|NCT02065622|Experimental|Experimental Maintenance Dose|Experimental Maintenance Dose
3074256|NCT02065622|Experimental|Higher Induction Dose|Higher Induction Dose
3074257|NCT02065622|Active Comparator|Standard Induction Dose|Standard Induction Dose
3074258|NCT02065622|Active Comparator|Standard Maintenance Dose|Standard Maintenance Dose
3074259|NCT02065622|Experimental|Higher Maintenance Dose|Higher Maintenance Dose
3074260|NCT02065609|Experimental|Cohort 1|89Zr-Trastuzumab Human Dosimetry and Safety
3074261|NCT02065609|Experimental|Cohort 2: Lesion Detection and Safety|HER2 Positive Lesion Detection and Safety
3074262|NCT02065596|Experimental|Immunomodulation with Fludarabine prior to HSCT|Fludarabine given beginning at 25mgm/m2 three times per day. Patients may be escalated up to 25mgm/m2 five times per day depending on dose-limiting toxicity
3074263|NCT02065583||GI abdominal surgery patients|Patients recovering from gastrointestinal abdominal surgery.
3074264|NCT02065570|Other|Arm 2 - Induction|Subjects are randomized to receive a standard induction regimen of adalimumab. After the induction regimen is provided, subjects in this arm will receive blinded adalimumab until Week 12. No placebo arm is planned.
3074265|NCT02065570|Other|Arm 2 Maintenance|Subjects are re-randomized at Week 14 to the therapeutic drug monitoring regimen.
3074266|NCT02065570|Other|Arm 1 - Induction|Subjects are randomized to receive a higher induction regimen of adalimumab. After the induction regimen is provided, subjects in this arm will receive blinded adalimumab until Week 12. No placebo arm is planned.
3074267|NCT02065570|Other|Arm 1 Maintenance|Subjects are re-randomized at Week 14 to a clinically adjusted regimen.
3074268|NCT02065557|Experimental|Adalimumab Dose A|0.6 mg/kg every other week (maximum of 40 mg every other week)
3074269|NCT02065557|Experimental|Adalimumab Dose B|0.6 mg/kg every other week (maximum of 40 mg every other week)
3074270|NCT02065544|Experimental|behavioral weight loss and exercise|weight loss and exercise lifestyle intervention over a 6 month period
3074271|NCT02065531|Experimental|Myofascial Soft Tissue Release|Protocol: Transverse Plane-Level Clavicular Release. Diaphragmatic Transverse Plane Release. Square the Lumbar Fascia Release. Gluteal Fascia Release. Hint Of Pubic Region Release. Fascia Psoas Release. Lumbo-sacral Decompression. Pelvic Floor Release.
3074272|NCT02065531|Active Comparator|Mobilization with impulse technique|Subject in lateral decubitus with extension and lower limb traction contact the couch with contralateral lower limb was performed triple flexion and left trunk rotation. This technique reduces the slack (tension joints) of the ventral pelvis, head and into the contralateral side of the sacrum support (base) with the forearm.
3074273|NCT02065518|Active Comparator|Standard Rehabilitation Protocol (SRP)|All participants will receive the current standard of care, the physical therapy rehabilitation protocol for knee injuries at the WRNMMC and MGMCSC sites. This program includes treatment with a physical therapist at the physical therapy clinics.
3074274|NCT02065518|Experimental|NMES w/ SRP|In addition to the standard rehabilitation protocol, two treatment groups will receive a portable lightweight device (300PV unit) that provides clearly defined electrical stimuli. NMES training will consist of performing four 30-minute stimulation sessions per week for 12 weeks; each 30-minute session will entail 15 minutes/leg with 15 contractions per leg. Each contraction will be elicited by an electrical impulse (300PV) generated by a battery-operated device (EMPI, St. Paul, MN).
3074275|NCT02065518|Experimental|Strength Walking w/ SRP|The Strength Walking groups will participate in a Home-Based Pedometer-Driven Walking Program. All participants in this group will be given a pedometer to monitor their daily steps and, at week 7, a weighted exercise vest to begin the strengthening component. In addition to the standard WRNMMC rehabilitation protocol, a series of 10-minute lessons focused on increasing physical activity through lifestyle education and the use of a pedometer as a motivational tool and personal fitness tracker will be incorporated into their testing sessions for the first 6 weeks. At week 7, participants will be given a vest to begin the strengthening component.
3074276|NCT02065518|Experimental|NMES/Strength Walking w/ SRP|In addition to the standard rehabilitation protocol, one group will receive NMES training and will participate in a Home-Based Pedometer-Driven Walking Program. This group will follow the protocol for both the NMES training and Strength Walking.
3074277|NCT02065505|Experimental|Pilates Group Solo|participate in this group 30 individuals who will be treated with the Pilates Method performing the exercises on the ground, using the Swiss ball and elastic bands. The exercises will aim to lengthen the musculature that are shortened due to the characteristic postural pattern of pathology (major and minor pectoral, shoulder adductors, biceps, wrist flexors, trunk side chain); strengthen the musculature that provide postural support (abdominal, middle trapezius, rhomboids, gluteus maximus, erector spinae and latissimus dorsi) and the upper limb musculature important for activities of daily living (triceps, biceps, internal rotators, external rotators and abductors of the shoulder).
3074278|NCT02065505|Experimental|Water Pilates Group|participate in this group 30 individuals who will be treated with the Pilates method, but doing the exercises in the therapy pool, with the aid of floats and weights. The protocol of stretches and exercises will work the same muscle groups than the G1, keeping the same decubitus whenever possible. The adaptations to the exercises are justified by the physical principles of water, which at one point may act for or against the activity being performed.
3074279|NCT02065492|Experimental|Standard Chelation & Amlodipine|"This arm will receive both chelation and amlodipine.~Amlodipine will be administered as a single daily dose. It will be administered at a dose of 0.1 mg/kg/day or maximum of 2.5 mg/day.~Standard Chelation therapy will be administered either by subcutaneous infusion of Deferoxamine (3-5 days a week) or oral Deferasirox (daily) or combination of Deferoxamine and Deferiprone.~The dosage will depend on individual requirement, as determined by the treating hematologist."
3074280|NCT02065492|Active Comparator|Standard Chelation|"Deferasirox or Deferoxamine or Deferiprone. Patients in this arm will be administered only standard chelation therapy,either by subcutaneous infusion of Chelation therapy of Deferoxamine (3-5 days a week) or oral Deferasirox (daily) or combination of Deferoxamine and Deferiprone.~The dosage will depend on individual requirement, as determined by the treating hematologist.~This will serve as the control arm of the study without any additional intervention."
3074281|NCT02065479|Active Comparator|Ticagrelor|The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.
3074282|NCT02065479|Experimental|Prasugrel|The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.
3074283|NCT02065466|Experimental|Combination|nab-paclitaxel and temozolomide combined with full dose of bevacizumab
3074284|NCT02065453|Other|Disposable Device - Left & Reusable Devices - Right|One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien).
3074285|NCT02065453|Other|Disposable Device - Right & Reusable Devices - Left|One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic
3074286|NCT02065440|Active Comparator|Ebastine/Pseudoephedrine|administration of ebastine/pseudoephedrine 1cap/day for 1 week.
3074287|NCT02065440|Placebo Comparator|placebo|administration of placebo pill 1 cap/day for 1week
3074288|NCT02065427|Experimental|Social support|"Social support intervention~Intervention is performed by the health professionals working at the primary health care team responsible for the patient, and consisits of the following components:~a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support."
3074289|NCT02065427|No Intervention|Usual home health care|Caregivers and dependent patients: usual home health care, consisting of bimonthly scheduled visits, follow-up as needed, and additional attention upon request
3074290|NCT02065414|Placebo Comparator|Neg Control Mouth Rinse W002194-0221-P|"Mouth rinse containing 5% Hydroalcohol~Twice each day, brush in usual manner with a fluoride-containing dentifrice, rinse mouth with water, and then rinse with 20 ml of mouth rinse W002194-0221-P for 30 seconds and spit it out."
3074291|NCT02065414|Experimental|Experimental: Mouth Rinse 19668-012|Listerine Advance Gum Defense Twice each day, brush in usual manner with a fluoride-containing dentifrice, rinse mouth with water, and then rinse with 20 ml of mouth rinse 19668-012 for 30 seconds and spit it out - do not swallow.
3074292|NCT02065414|Active Comparator|Active Comparator Mouth Rinse 5000347078873|"Mouth rinse containing Chlorhexidine Corsodyl ®Mouthwash~Twice each day, brush in usual manner with a fluoride-containing dentifrice, in the usual manner, rinse mouth with water, wait 5 minutes after brushing and then rinse with 10 ml of mouth rinse 5000347078873for 60 seconds and spit it out - do not swallow."
3074293|NCT02065401|Experimental|Deferitazole (disodium salt, granule)|
3074294|NCT02065401|Experimental|Deferitazole (disodium salt, tablet)|
3074295|NCT02065401|Experimental|Deferitazole (magnesium hydroxide salt)|
3074296|NCT02065388|Active Comparator|Standard of care dosing for warfarin|Loading dose (5mg) of warfarin for the first 3 days of treatment. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
3074297|NCT02065388|Experimental|Genotype-guided dosingTaiwan algorithm for warfarin|Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the Taiwan algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
3074298|NCT02065388|Experimental|Genotype-guided dosing IWPC algorithm for warfarin|Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the IWPC algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
3074299|NCT02065375|Experimental|RTA 408 0.5% Ophthalmic Suspension or Placebo|Patients will be randomized to twice-daily dosing of ophthalmic suspension (RTA 408 0.5% or Placebo) in the study eye for 14 days
3074300|NCT02065375|Experimental|RTA 408 1.0% Ophthalmic Suspension or Placebo|Patients will be randomized to twice-daily dosing of ophthalmic suspension (RTA 408 1.0% or Placebo) in the study eye for 14 days
3074301|NCT02065362|Experimental|DNR.NPC-specific T cells or DNR.NPC-specific T cells + c/f|
3074302|NCT02065349|Placebo Comparator|Placebo|oral
3074303|NCT02065349|Active Comparator|ASP8477|oral
3074304|NCT02065336|Experimental|ARC-520 Cohorts 1-5|Single dose, IV ARC-520, 1.0, 2.0, 3.0 or 4.0 mg/kg
3074305|NCT02065336|Placebo Comparator|Placebo Normal Saline Cohorts 1-5|Single dose, IV normal saline
3074306|NCT02065336|Experimental|ARC-520 Cohort 6|Two doses, IV ARC-520, 2.0 mg/kg
3074307|NCT02065336|Experimental|ARC-520 Cohort 7|Single dose, IV ARC-520, 4.0 mg/kg
3074308|NCT02065336|Experimental|ARC-520 Cohort 8|IV ARC-520, 4.0 mg/kg Q4 weeks
3074309|NCT02065336|Experimental|ARC-520 Cohort 9|IV ARC-520, 4.0 mg/kg Q6 weeks or Q8 weeks
3074310|NCT02065336|Experimental|ARC-520 Cohort 10, tx naive|IV ARC-520, 4.0 mg/kg Q4 weeks
3074311|NCT02065336|Experimental|ARC-520 Cohort 11|Single dose, IV ARC-520, 5.0 mg/kg
3074312|NCT02065336|Experimental|ARC-520 Cohort 12|Single dose, IV ARC-520, 6.0 mg/kg
3074313|NCT02065323|Active Comparator|ADT alone|Standard androgen deprivation therapy (LHRH analogue or orchiectomy)
3074314|NCT02065323|Experimental|ADT plus Dovitinib|"Standard androgen deprivation therapy (LHRH analogue or orchiectomy)~Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons."
3074315|NCT02065310|No Intervention|Diabetes, Non-diabetes|
3074316|NCT02065297||Horton's disease|
3074317|NCT02065297||Infectious disease|
3074318|NCT02065297||Neoplasia|
3074319|NCT02065297||Control|
3074320|NCT02065284|Active Comparator|Walking-Rhythmic Auditory Stimulation|Walking daily with Rhythmic Auditory Stimulation (RAS) based music for 4 weeks
3074321|NCT02065284|Active Comparator|Walking- only|Walking daily with no Rhythmic Auditory Stimulation (RAS) based music for 4 weeks
3074322|NCT02065284|Active Comparator|Rhythmic Auditory Stimulation (RAS)only|Listening to based music only daily for 4 weeks
3074323|NCT02065271|Experimental|herbal supplements|500mg, 3 per day, 4weeks
3074324|NCT02065271|Placebo Comparator|placebo|500mg, 3 per day, 4 weeks
3074325|NCT02065258|Active Comparator|Breathing Exercise|It will be based on Yoga´s breathing technique (Eliade, 1996) and will be focus on to stimulate nasal and diaphragmatic breathings, to increase expiratory time, to slow respiratory flow and to regulate the breathing rhythm. Breathing exercises will be divided into 3 phases (lasting one month each) with progressive intensity every 8 sessions and will be part of the routine of breathing exercises the following exercises: I) Kapalabhati ; II) Uddhiyana ;III) Surya Bedhana
3074326|NCT02065258|Active Comparator|Aerobic Exercise|Exercise will be performed on a treadmill, with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957).Aerobic training sessions that will consist in 40 minutes divided in 5 minutes of warm-up, 35 minutes of aerobic training and 5 minutes of cool down. Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. The program will be performed twice a week, for 3 months.
3074503|NCT02064244||Acute renal failure in ICU|Ultrasound for measurement of Inferior Vena Cava size
3074327|NCT02065245|Experimental|Pilot phase - Group 1|Group 1 (5 subjects) - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 20 million cells/ml delivered via peripheral intravenous infusion.
3074328|NCT02065245|Experimental|Pilot Phase - Group 2|Group 2 (5 subjects) - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million cells/ml delivered via peripheral intravenous infusion.
3074329|NCT02065245|Experimental|Pilot Phase - Group 3|Group 3 (5 subjects) - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million cells/ml delivered via peripheral intravenous infusion.
3074330|NCT02065245|Experimental|Randomized Phase - Group A|Group A (10 subjects) - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million cells/ml delivered via peripheral intravenous infusion.
3074331|NCT02065245|Experimental|Randomized phase - Group B|Group B (10 subjects) - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million cells/ml delivered via peripheral intravenous infusion.
3074332|NCT02065245|Placebo Comparator|Randomized Phase - Group C|Group C (10 subjects) - Placebo delivered via peripheral intravenous infusion.
3074333|NCT02065245|Experimental|Addendum A - Pilot Phase 2nd Infusion|The pilot phase subjects will be able to receive one additional Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million cells/ml delivered via peripheral intravenous infusion.
3074334|NCT02065245|Experimental|Addendum B - Antibiotic free cell Group|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million cells/ml delivered via peripheral intravenous infusion.
3074335|NCT02065245|Experimental|Addendum C - Optional Follow-on Phase|"up to 2 additional doses for those that participated in Addendum A and up to 3 additional doses for subjects that took part in Addendum B.~Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million cells/ml delivered via peripheral intravenous infusion."
3074336|NCT02065245|Experimental|Addendum D - Optional for Randomized Placebo|Randomized phase subjects that received Placebo will be able to receive one additional Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million cells/ml delivered via peripheral intravenous infusion.
3074337|NCT02065232|Active Comparator|Tilmanocept|Patients will receive technetium-labeled tilmanocept, which is FDA approved for sentinel lymph node mapping in breast cancer.
3074338|NCT02065232|Active Comparator|Sulfur Colloid|Patients will receive technetium-labeled sulfur colloid, which is FDA approved for sentinel lymph node mapping in breast cancer.
3074339|NCT02065219|Experimental|Bupivacaine|injection, 25 mg, once, 5 min
3074340|NCT02065219|Placebo Comparator|Placebo|injection, 10 ml 0.9% sodium chloride, once, 5 min
3074341|NCT02065193||Beijing group|
3074342|NCT02065193||Guangdong group|
3074343|NCT02065193||Shenzhen group|
3074344|NCT02065193||Shanxi group|
3074345|NCT02065193||Liaoning group|
3074346|NCT02065193||Jilin group|
3074347|NCT02065193||Heilongjiang group|
3074348|NCT02065193||Jiangsu group|
3074349|NCT02065193||Zhejiang group|
3074350|NCT02065193||Fujian group|
3074351|NCT02065193||Henan group|
3074352|NCT02065193||Hubei group|
3074353|NCT02065193||Hunan group|
3074354|NCT02065193||'Shanxi group|
3074355|NCT02065180|Experimental|commercially available nutrition supplement|this group receives a commercially available nutritional supplement for a period of 2 months
3074356|NCT02065180|Placebo Comparator|control group|this group receives a placebo for a period of 2 months
3074357|NCT02065167|Experimental|Cultured autologous Mesenchymal Cells|"Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.~20x106 cells per cc in a single administration of 7cc"
3074358|NCT02065154|Experimental|Treatment|Cyclophosphamide (Cytoxan)
3074359|NCT02065141|Other|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day: stable isotope infusions with blood draws, sip feed"
3074360|NCT02065141|Other|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical information about them that will help determine study eligibility or can be used for later coding.~study day: stable isotope infusions with blood draws, sip feed"
3074361|NCT02065141|Other|Chronic Heart Failure|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical information about them that will help determine study eligibility or can be used for later coding.~study day: stable isotope infusions with blood draws, sip feed"
3074362|NCT02065128||Healthy Volunteers|Capsaicin cough challenge test. The ILS participants will be asked to attend two study visits at the pulmonary function laboratory at SMH; one before behavioural therapy and one after. The healthy volunteers will be asked to attend one study visit. At each of these study visits, the ILS participants will complete the Leicester Cough Questionnaire (LCQ) (Appendix B) and the Dyspnea Index (DI) Questionnaire (Appendix C). The LCQ is a valid assessment tool for evaluating the impact of cough on QoL.19 The DI is a short, validated questionnaire used to quantify a patient's symptoms of dyspnea.20 Following completion of the questionnaires, participants will complete a capsaicin cough challenge test, which is discussed in the following section.
3074363|NCT02065128||Irritable Larynx Syndrome Patients|Capsaicin cough challenge test. The ILS participants will be asked to attend two study visits at the pulmonary function laboratory at SMH; one before behavioural therapy and one after. The healthy volunteers will be asked to attend one study visit. At each of these study visits, the ILS participants will complete the Leicester Cough Questionnaire (LCQ) (Appendix B) and the Dyspnea Index (DI) Questionnaire (Appendix C). The LCQ is a valid assessment tool for evaluating the impact of cough on QoL.19 The DI is a short, validated questionnaire used to quantify a patient's symptoms of dyspnea.20 Following completion of the questionnaires, participants will complete a capsaicin cough challenge test, which is discussed in the following section.
3074364|NCT02065115|Experimental|Cryotherapy|Cryotherapy: 12 ounces of crushed ice place in a plastic bag applied to the radial artery puncture area for 3 minutes
3074365|NCT02065115|No Intervention|Control|Cryotherapy is not applied to the radial artery puncture area
3074366|NCT02065089|Experimental|playing the ipad quiz game|There will only be one arm--any patient who consents to participate in the intervention (playing the ipad quiz game)
3075004|NCT02060864|Experimental|AN-PEP 160.000 PPI|2 pills AN-PEP 80.000 PPI
3074367|NCT02065076|Active Comparator|Sodium Polystyrene Sulfonate|30 g sodium polystyrene sulfonate powder, mixed with water qs ad 150 ml, taken PO once daily for seven days
3074368|NCT02065076|Placebo Comparator|Lactose with carob gum|30 g placebo powder, mixed with water qs ad 150 ml, taken PO once daily for seven days
3074369|NCT02065063|Experimental|Part 1|Part 1 is a dose finding phase in which subjects will be initially administered 75 milligram (mg) of palbociclib (21 days on/7 days off) and 1.5 mg of trametinib (once daily continuous dosing) in each 28-day cycle. Dose escalations will continue based on predefined parameters until the RCR is identified. The RCR will not exceed the maximum tolerated dose (MTD).
3074370|NCT02065063|Experimental|Part 2|Once the MTD and schedule have been determined, two expansion cohorts of up to 20 subjects each will be enrolled. The cohorts will enroll subjects with BRAF-WT (wild type) cutaneous melanoma that are either NRAS-WT or NRAS-MUT (mutated). Subjects will be dosed at or below the RCR to determine the inhibition of selected tumor biomarkers at each dose level.
3074371|NCT02065063|Experimental|Part 3|Part 3 will be a randomized Phase II study in which subjects will be administered the RCR as previously identified. Part 3 will be initiated only if an RCR is identified, and sufficient anticancer activity is observed in Parts 1 and 2.
3074372|NCT02065050|No Intervention|Usual Care|Individuals in the usual care arm will not receive frequent contact by the study team. Individuals will be seen by a study team clinician 1 year after discharge to review diabetes management and obtain pertinent study related data.
3074373|NCT02065050|Experimental|Continued care|team-based care: Individuals in the continued care arm will be frequently contacted by the study team (consisting of endocrinologists, nurse practitioners, and health coaches) over the course of one year post-discharge. The team will monitor blood sugars and other health data, altering management as needed.
3074374|NCT02065037|Experimental|Warmed Carbon Dioxide Insufflation|warmed carbon dioxide insufflation used in colonoscopy
3074375|NCT02065037|Active Comparator|Room Temperature Air Insufflation|room temperature air insufflation used in colonoscopy
3074376|NCT02065024|Active Comparator|b-cryptoxanthin plus phytosterols|Fruit and milk based beverage enriched with b-cryptoxanthin and phytosterols
3074377|NCT02065024|Placebo Comparator|control|Fruit and milk based beverage not enriched
3074378|NCT02065011|Other|Long-term follow up|Long-term follow up of patients who received UshStat in a previous study
3074379|NCT02064998|Experimental|Promillekoll|Smartphone app monitoring alcohol use with feedback on eBAC level.
3074380|NCT02064998|Experimental|PartyPlanner|Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
3074381|NCT02064998|No Intervention|Control Study 1|Waitlist control group that is given access to the Promillekoll and PartyPlanner apps after a 12-week wait.
3074382|NCT02064998|Experimental|Crossover group 1: TeleCoach - Control|Six-week access to the TeleCoach app, with exercises and vignettes for reducing or abstaining from alcohol consumption, followed by a 6-week period with no access to the app.
3074383|NCT02064998|Experimental|Crossover group 2: Control - TeleCoach|Initially a 6 week no-app control period, followed by 6-week access to the TeleCoach app, offering exercises and vignettes for reducing or abstaining from alcohol consumption.
3074384|NCT02064985|Experimental|Ticagrelor 45mg|A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.
3074385|NCT02064985|Experimental|Ticagrelor 60mg|A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.
3074386|NCT02064985|Experimental|Ticagrelor 90mg|A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.
3074387|NCT02064972||Patients undergoing allo-HSCT, who manifest GvHD.|Patients undergoing allo-HSCT, that manifest GvHD. Patients undergoing allo-HSCT will have CEC count performed at the following timepoints: T1 (baseline), T2 (pre-transplant), T3 (engraftment), T4 (GvHD onset) and T5 (post-GvHD). All patients will also be checked for CEC at day + 28.
3074388|NCT02064959|Experimental|Hypothermia|Hypothermia to 33°C
3074389|NCT02064959|No Intervention|Normothermia|standard care - normothermia (37°C)
3074390|NCT02064946|Active Comparator|Vitamin D3|Vitamin D3 50,000 IU: Patients will be assigned to receive weekly high-dose vitamin D (50,000 IU/week) along with a daily multivitamin (600 IU/day vitamin D + 210 mg/day calcium) and calcium supplements (1,000 mg/day calcium) for a period of 24 weeks.
3074391|NCT02064946|Placebo Comparator|Control|Control: Patients will be assigned to receive a weekly vitamin D placebo along with a daily multivitamin (600 IU/day vitamin D + 210 mg/day calcium)and calcium supplements (1,000 mg/day calcium) for a period of 24 weeks.
3074392|NCT02064933||Retrospective Cohort (Longitudinal Analysis)|Participants with WAS treated at consortium centers since 1990 who have received transplant (Stratum A) or gene therapy (Stratum B)
3074393|NCT02064933||Prospective Cohort (Longitudinal Analysis)|Participants treated at consortium centers since 1990 who will receive transplant (Stratum A) or gene therapy (Stratum B)
3074394|NCT02064933||Cross-Sectional Cohort (Cross-sectional Analysis)|Living participants with WAS who have received transplant (Stratum A) or gene therapy (Stratum B) at Consortium Centers 1990-Present And >= 2 Years Post-Transplant
3074395|NCT02064920|Placebo Comparator|Placebo|Placebo for donepezil hydrochloride capsule administered orally once a day for 16 weeks.
3074396|NCT02064920|Experimental|Donepezil|During the first 4 weeks, participants received placebo for donepezil. Over the following 2 weeks, participants were treated with donepezil at 5 mg per day. Then, over the remaining 10 weeks were titrated to up to 10 mg per day donepezil based on tolerability.
3074397|NCT02064907|Experimental|Dexlansoprazole OD Tablets + Dexlansoprazole Capsules|Two Dexlansoprazole 30 mg, delayed-release orally disintegrating tablets, orally, once daily for 5 days in Period 1, followed by a 7 day washout period, followed by one dexlansoprazole 60 mg, capsule, orally, once daily for 5 days in Period 2.
3074398|NCT02064907|Experimental|Dexlansoprazole Capsules + Dexlansoprazole OD|Dexlansoprazole 60 mg, capsules, orally, once daily for 5 days in Period 1, followed by a 7 day washout period, followed by two dexlansoprazole 30 mg, delayed-release orally disintegrating tablets, orally, once daily for 5 days in Period 2.
3074845|NCT02061917|Experimental|Tobacco-Heating Cigarette|A group of 44 subjects who smoke and are switched to a tobacco-heating cigarette
3074399|NCT02064894|Experimental|oral morphine and oral ibuprofen|Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame
3074400|NCT02064894|Experimental|morphine and placebo of ibuprofen|Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study
3074401|NCT02064894|Active Comparator|ibuprofen and placebo of morphine|Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study
3074402|NCT02064881|Experimental|metformin glycinate|"620mg tablets of metformin glycinate: 1 tablet by mouth at night for 3 days, 1 tablet in the morning and evening for 3 days, 1 tablet in the morning and 2 tablets in the evening for 3 days and 2 tablets in the evening and 2 tablets in the morning until the end of the study.~Total study dose: 1240mg every 12 hours."
3074403|NCT02064881|Active Comparator|metformin hydrochloride|"500mg tablets of metformin hydrochloride:1 tablet by mouth at night for 3 days, 1 tablet in the morning and evening for 3 days, 1 tablet in the morning and 2 tablets in the evening for 3 days and 2 tablets in the evening and 2 tablets in the morning until the end of the study.~Total study dose: 1000mg every 12 hours."
3074404|NCT02064868|Experimental|Serelaxin + Standard of Care|Serelaxin (30 µg/kg/day) as continuous 48 hour intravenous infusion plus standard of care.
3074405|NCT02064868|Other|Standard of Care (SOC)|All patients will be required to receive standard of care background heart failure (HF) management during the study, according to local guidelines/international standards. This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, blockers and aldosterone receptor antagonists, etc.
3074406|NCT02064842|Experimental|TMC647055 150 mg or placebo + ritonavir (RTV)|Participants in Part 1 will receive a single oral dose of 150 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
3074407|NCT02064842|Experimental|TMC647055 450 mg or placebo + RTV|Participants in Part 1 will receive a single oral dose of 450 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
3074408|NCT02064842|Experimental|TMC647055 600 mg or placebo + RTV|Participants in Part 1 will receive a single oral dose of 600 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
3074409|NCT02064842|Experimental|Sequence 1 (Treatment A-B-C)|Participants in Part 2 will receive Treatment ABC in the following sequence - Treatment A: TMC435 150 mg once daily on Days 1 to 7; Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
3074410|NCT02064842|Experimental|Sequence 2 (Treatment B-C-A)|Participants in Part 2 will receive Treatment BCA in the following sequence - Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment A: TMC435 150 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
3074411|NCT02064842|Experimental|Sequence 3 (Treatment C-A-B)|Participants in Part 2 will receive Treatment CAB in the following sequence - Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment A: TMC435 150 mg once daily on Days 1 to 7; and Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
3074412|NCT02064842|Experimental|Sequence 4 (Treatment A-C-B)|Participants in Part 2 will receive Treatment ACB in the following sequence - Treatment A: TMC435 150 mg once daily on Days 1 to 7; Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
3074413|NCT02064842|Experimental|Sequence 5 (Treatment B-A-C)|Participants in Part 2 will receive Treatment BAC in the following sequence - Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment A: TMC435 150 mg once daily on Days 1 to 7; and Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
3074414|NCT02064842|Experimental|Sequence 6 (Treatment C-B-A)|Participants in Part 2 will receive Treatment CBA in the following sequence - Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment A: TMC435 150 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
3074415|NCT02064829|Active Comparator|Reference Drug - Nab-paclitaxel|260 mg/m2 administered intravenously over 30 minutes on Day 1
3074416|NCT02064829|Experimental|Test Drug - IG-001|260 mg/m2 administered intravenously over 30 minutes on Day 1
3074417|NCT02064816|Experimental|Rebif® Morning Administration|
3074418|NCT02064816|Experimental|Rebif® Evening Administration|
3074419|NCT02064803|Active Comparator|Control group: A|Gastro-entero anastomosis only
3074420|NCT02064803|Experimental|Experimental: B|Gastric partitioning Plus Gastro-entero anastomosis
3074421|NCT02064790||Group G - receiving gabapentin|Receiving gabapentin as standard of care. No intervention
3074422|NCT02064790||Group P - receiving pregabalin|Receiving pregabalin as standard of care No intervention
3074423|NCT02064790||Group Z - no neuropathic agent|Receiving only conservative treatment No drug treatment No intervention
3074424|NCT02064777|Experimental|Tacrolimus|
3074425|NCT02064764|Active Comparator|Cryoablation only|Pulmonary vein isolation
3074426|NCT02064764|Experimental|Cryoablation and renal nerve denervation|Pulmonary vein isolation plus renal nerve denervation
3074427|NCT02064751|Experimental|MultiPoint Pacing|CRT with MultiPoint Pacing
3074428|NCT02064738|No Intervention|Normal diet|Two weeks of unaltered diet
3074846|NCT02061917|Experimental|Snus (Smokeless Tobacco)|A group of 43 subjects who smoke and are switched to snus (smokeless tobacco)
3074429|NCT02064738|Experimental|Low omega-6/high omega-3 diet|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams
3074430|NCT02064725|Experimental|Sodium cridanimod|Sodium cridanimod in combination with megestrol acetate or medroxyprogesterone acetate. Treatment period is 12 months; patients will be followed for another 12 month period or to disease progression whichever occurs first.
3074431|NCT02064712|Active Comparator|Low CPAP Wean|NCPAP weaned to 5cm H2O for minimum of 24h, and if the neonate remains clinically stable as defined, wean in 1cm increments to 3cm H2O for minimum of 24h, at which time move to room air or 1L/min nasal cannula if supplemental O2 is required.
3074432|NCT02064712|Active Comparator|High CPAP Wean|NCPAP weaned to 5cm H2O for a minimum of 24h, and if the neonate remains clinically stable, move to room air or 1L/min nasal cannula if supplemental O2 is required.
3074433|NCT02064699||CMV infection|Renal transplant recipient immunized against the Cytomegalovirus
3074434|NCT02064686|No Intervention|TAE|
3074435|NCT02064673|Active Comparator|Curcumin|Curcumin 500 mg orally twice a day
3074436|NCT02064673|Placebo Comparator|sugar pill|placebo orally twice a day
3074437|NCT02064660|Experimental|single arm|A series of acupressure sessions within six months from the baseline
3074438|NCT02064647|Experimental|Trend Arrow Adjustment Tool|The Trend Arrow Adjustment Tool, uses a formula based on the patients Insulin Sensitivity Factor (ISF) to allow adjustments to meal time insulin boluses, based on CGM trend arrows.
3074439|NCT02064647|Active Comparator|10/20% bolus adjustment|10-20% increase/decrease of the total original recommended bolus dose (10% for one arrow up or down, and 20% for two arrows up or down), with the original bolus dose calculated by the pump calculator (i.e. Bolus Wizard).
3074440|NCT02064647|No Intervention|No adjustment/ignore trend arrows|Subjects will ignore the CGM trend arrows, meal time bolus insulin as per Bolus Wizard
3074441|NCT02064634||Shinbaro (only)|
3074442|NCT02064634||Celecoxib (only)|
3074443|NCT02064634||Shinbaro + NSAIDs|
3074444|NCT02064634||Shinbaro + Celecoxib|
3074445|NCT02064621|Experimental|C(Candesartan 32mg)|Candesartan 32mg 1T, PO, QD for 9days
3074446|NCT02064621|Experimental|B(Candesartan 32mg/Amlodipine 10mg)|Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days
3074447|NCT02064608|Experimental|AZD2014|This is a single arm study whereby a cohort of 20 patients with early high risk prostate cancer will be treated with a 15-day course of AZD2014 (mTOR inhibitor) treatment prior to radical prostatectomy.
3074448|NCT02064595|Other|Intramedullary nail|Fractures treated with intramedullary reamed nail
3074449|NCT02064595|Active Comparator|External fixator|Tibial fractures treated with biplanar external fixation
3074450|NCT02064582|Other|Enzalutamide, Leuprolide, radiation|Single arm Enzalutamide 160 mg daily for 6 months Leuprolide acetate 22.5mg every 3 months or 45mg every 6 months Radiation therapy as standard of care
3074451|NCT02064569|Experimental|GS010|
3074452|NCT02064556|Experimental|A(Amlodipine 10mg)|Amlodipine 10mg 1T, PO, QD for 9days
3074453|NCT02064556|Experimental|B(Amlodipine 10mg/Candesartan 32mg)|Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days
3074454|NCT02064543||ADPM and GAITRite|mobility assessments (ADPM, GAITRite) measuring gait parameters
3074455|NCT02064530|Active Comparator|bupivacaine|0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on TAP block
3074456|NCT02064530|Active Comparator|dexmedetomidine|100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on TAP block
3074457|NCT02064530|Sham Comparator|serum phsyologic|0,9% 21 ml serum physiologic
3074458|NCT02064517|Placebo Comparator|Conventional technique|Apical MTA barrier
3074459|NCT02064517|Experimental|Revascularisation pulpaire|hydroxide of calcium
3074460|NCT02064504|Experimental|Sequence 1|Participants will receive the study treatment in the following order: ABFCED in each period (one per period). Where A=GSK961081 administered from DISKUS, B=GSK961081 Single strip (SS) administered from DPI, C=GSK961081 Dual Strip (DS) administered from DPI with a filled (lactose) second strip (DS configuration), D=GSK961081/fluticasone furoate (GSK961081/FF) administered from DPI (GSK961081 higher dose), E=FF DS administered from DPI with a filled (lactose) second strip (dual strip configuration), F=GSK961081/FF administered from DPI (GSK961081 lower dose).
3074461|NCT02064504|Experimental|Sequence 2|Participants will receive the study treatment in the following order: BCADFE in each period (one per period)
3074462|NCT02064504|Experimental|Sequence 3|Participants will receive the study treatment in the following order: CDBEAF in each period (one per period)
3074463|NCT02064504|Experimental|Sequence 4|Participants will receive the study treatment in the following order: DECFBA in each period (one per period)
3074464|NCT02064504|Experimental|Sequence 5|Participants will receive the study treatment in the following order: EFDACB in each period (one per period)
3074465|NCT02064504|Experimental|Sequence 6|Participants will receive the study treatment in the following order: FAEBDC in each period (one per period)
3074466|NCT02064491|Experimental|Erlotinib and Chemotherapy|Intercalated erlotinib in combination with chemotherapy for four to six cycles followed by continuous erlotinib maintenance
3074467|NCT02064491|Active Comparator|Chemotherapy|Chemotherapy for four to six cycles
3074468|NCT02064478||Tissue preservation|Ponto implant installed using a tissue preservation surgical technique
3074469|NCT02064478||Tissue reduction|Ponto implant installed using a classical technique with skin thinning
3074470|NCT02064465|Experimental|Lamotrigine Dispersable/Chewable|lamotrigine dispersible/chewable tablet 100mg
3074471|NCT02064465|Experimental|Lamotrigine Compressed|lamotrigine compressed tablet 100mg
3074472|NCT02064452|Experimental|Triple P Online System|The Triple P Online System (TPOS) is an interactive, video-driven online parenting support website, delivered with 3 different levels of intensity, depending on severity of children's behavior problems. In this arm, pediatric clinics are randomized to receive training in child disruptive behavior disorders, Triple P principles and target parenting strategies, the Triple P Online System, effectively referring eligible families to TPOS, and supporting their use of the program. Referred parents in this condition receive access to TPOS immediately.
3074504|NCT02064231|Experimental|Coloplast Test A, Coloplast Test B, Own product|The subjects first test Coloplast Test A and thereafter Coloplast Test B and finally their own product for 14 days
3074473|NCT02064452|Placebo Comparator|Enhanced Usual Community Care-Waitlist|In this arm, pediatric clinics are randomized to receive access for their parents and practitioners to a referral website designed to assist parents of children with disruptive behavior disorders in accessing appropriate community resources; on the website, community resources for treatment of child disruptive behavior disorders (mental health services, parenting services) are described and can be searched by location, cost, and acceptance of Medicare. Parents in this condition receive access to the Triple P Online System (TPOS) after completion of their 1-year follow-up assessment. Pediatricians receive free training in TPOS at the end of their waiting period.
3074474|NCT02064439|Experimental|Arm 1|Rivaroxaban 10 mg once daily for 12 months
3074475|NCT02064439|Experimental|Arm 2|Rivaroxaban 20 mg once daily for 12 months
3074476|NCT02064439|Active Comparator|Arm 3|ASA (Acetylsalicylic Acid) 100 mg once daily for 12 months
3074477|NCT02064426|Experimental|Molidustat (BAY85-3934)|
3074478|NCT02064426|Active Comparator|Epoetin alfa/beta|
3074479|NCT02064413|Experimental|ESS310|All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.
3074480|NCT02064400||Observational study group|Musculoskeletal ultrasound (all patients) and semi-structured patient interview (anticipated maximum 15 patients)
3074481|NCT02064387|Experimental|Schedule 1 Part 1|Participants will receive GSK2857916 intravenously over 60 minutes (one dose) every 3 weeks (21 day cycle) for a maximum of 16 cycles.
3074482|NCT02064387|Experimental|Schedule 2 Part 1|Participants may receive GSK2857916 intravenously over 60 minutes (one dose) once weekly for three consecutive weeks followed by 1 week of rest (28 day cycle) for a maximum of 16 cycles.
3074483|NCT02064387|Experimental|Schedule 1 Part 2|Participants will receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for up to 16 cycles.
3074484|NCT02064387|Experimental|Schedule 2 Part 2|Participants may receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for a maximum of 16 cycles.
3074485|NCT02064374|Experimental|Cohort 1|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive Metformin immediate release (IR) 500 mg q12h following a moderate fat meal for 5 days (Period 1), followed by Metformin IR 500 mg q12h plus DTG 50 mg q24h following a moderate fat meal for 7 days (Days 1-7 of Period 2), followed by Metformin IR 500 mg q12h following a moderate fat meal (Days 1-10 of period 3).
3074486|NCT02064374|Experimental|Cohort 2|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive Metformin IR 500 mg q12h following a moderate fat meal (Day 1-5 of Period 1), followed by Metformin IR 500 mg q12h plus DTG 50 mg q12h following a moderate fat meal for 7 days (Days 1-7 of Period 2), followed by Metformin IR 500 mg q12h following a moderate fat meal (Days 1-10 of period 3).
3074487|NCT02064361|Experimental|High intensity exercise|A dive to 18 meters sea water for a duration of 41 minutes preceded by high intensity cycling
3074488|NCT02064348|Experimental|Arm 1: semaglutide + moxifloxacin placebo|Subjects will receive a single dose of moxifloxacin placebo both before the start of semaglutide treatment and at the end of the semaglutide treatment.
3074489|NCT02064348|Active Comparator|Arm 2A:|"Semaglutide placebo + moxifloxacin/moxifloxacin placebo:~Subjects will receive moxifloxacin before the start of semaglutide placebo treatment and moxifloxacin placebo at the end of the semaglutide placebo treatment."
3074490|NCT02064348|Experimental|Arm 2B:|"Semaglutide placebo + moxifloxacin placebo/moxifloxacin:~Subjects will receive moxifloxacin placebo before the start of semaglutide placebo treatment and moxifloxacin at the end of the semaglutide placebo treatment."
3074491|NCT02064335|Experimental|Intervention group|"Physical activity coaching: Participants will be coached by a professional physical activity coach through individual and group sessions.~Intake: This talk (1 hour) is the start of the coaching. A physical activity plan will be set up, according to the needs and possibilities of the participant. Activities in leisure time and daily physical activity will be included.~Group sessions: During 5 weeks and one time a week, the subjects will take part in the exercise lessons. About 5 subjects will be in one group and all sessions are supervised by a professional physical activity coach. Activities are walking, Nordic walking and conditional fitness.~Evaluation: After the 5 weeks of group sessions, an evaluation moment will take place between each participant and the physical activity coach. The physical activity plan will be refined."
3074492|NCT02064335|No Intervention|Control group|The control group will operate as a waiting group. It means that in the first 6 months of the project, the subjects of the control group will only be measured and will not receive any intervention.
3074493|NCT02064322||SImmetry Implant|Subjects who are indicated for the SImmetry Device according to the approved product labeling and inclusion/exclusion criteria will receive a SImmetry implant.
3074494|NCT02064309|Experimental|Human islets in Beta-Air device|
3074495|NCT02064296|No Intervention|Controls|Healthy pain free controls will be recruited for comparison with fibromyalgia patients.
3074496|NCT02064296|Active Comparator|Non-Traditional Acupuncture|40 fibromyalgia patients will be randomized to non-traditional laser acupuncture (Vita Laser 650, Lhasa OMS). They will receive 2 treatments per week for 4 weeks.
3074497|NCT02064296|Active Comparator|Traditional Acupuncture|40 fibromyalgia patients will be randomized to receive electro acupuncture (AS Super 4 digital needle stimulator, Harmony Medical Co) . They will receive 2 treatments per week for 4 weeks.
3074498|NCT02064283|Experimental|Diffusion MRI Assessment|Men with newly diagnosed metastatic disease initiating therapy with androgen deprivation, or men with hormone refractory prostate cancer initiating treatment with chemotherapy, will be assessed by diffusion MRI (Magnetic Resonance Imaging) at baseline, 2 weeks and again at 9-12 weeks.
3074499|NCT02064270|Active Comparator|Negative Pressure Wound Therapy|Single-Use Negative Pressure Wound Therapy (NPWT)
3074500|NCT02064270|Active Comparator|Standard dressings|Standard postsurgical dressings
3074501|NCT02064257|Experimental|Intervention group|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention. The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
3074502|NCT02064257|No Intervention|Assessment-only group|The assessment-only group will participate in all pre- and post-intervention assessments, but will not receive the Listening Project Protocol.
3074549|NCT02063893||giving middle vaccine|
3074505|NCT02064231|Experimental|Coloplast Test C , Coloplast Test D, Own product|The subjects first test Coloplast Test C and thereafter Coloplast Test D and finally their own product for 14 days
3074506|NCT02064218||Hypertensive patients|Hypertensive patients naive to hypertensive treatment
3074507|NCT02064218||healthy subjects|healthy subjects
3074508|NCT02064205|Active Comparator|polydextrose or glucose syrup at breakfast|Breakfast with pre-load four hours before lunch
3074509|NCT02064205|Placebo Comparator|Pre-load with yogurt and polydextrose or glucose later|Breakfast without pre-load. Pre-load with yogurt provided 1.5h before lunch.
3074510|NCT02064192||ICD Group (n=1500)|First ICD device implantation (after baseline assessments) is not part of this observational study and is carried out in the responsibility of the treating physician, all ICD-devices will undergo unique standard programming to ensure comparability of ICD shock events between patients.
3074511|NCT02064192||Control Group (n=750)|Patients who fulfill inclusion criteria but do not receive an ICD device will be followed as part of the Control Group
3074512|NCT02064166|Experimental|Insulin|40 IU of intranasal insulin daily
3074513|NCT02064166|Placebo Comparator|Placebo|Placebo arm using intranasal normal saline
3074514|NCT02064153|Active Comparator|Cool dialysate|Recruited study subject undergoes cool dialysate (35.5ºC) session.
3074515|NCT02064153|Active Comparator|Warm dialysate|Recruited study subject undergoes warm dialysate (37ºC) session.
3074516|NCT02064140|Experimental|Neuromuscular blocking agent|
3074517|NCT02064127||Patients with abdominal pain|Adult patients admitted to the Emergency Department with a main complaint of abdominal pain
3074518|NCT02064114|Active Comparator|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
3074519|NCT02064114|Active Comparator|control group|conventional treatment, followed for a period of 3,6 and 12 months after the procedure.
3074520|NCT02064101||Adolescent idiopathic scoliosis|Patients with adolescent idiopathic scoliosis undergoing spinal fusion
3074521|NCT02064088|Experimental|Small volume|Local analgesia by one injection of 0,2 ml/kg of 0,2% lévobupivacaine
3074522|NCT02064088|Experimental|High volume|Local analgesia by one injection of 0,4 ml/kg of 0,1% lévobupivacaine
3074523|NCT02064075|Active Comparator|Hydroxyethyl starch|15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day.
3074524|NCT02064075|Active Comparator|Lactated Ringer's solution|15-50 ml/kg Lactated-Ringer's solution was given intravenously every day.
3074525|NCT02064062|Experimental|Autologous Mesenchymal Stem Cells|
3074526|NCT02064049|Experimental|Hepatitis C treatment|All prisoners (in participating correctional centres) with hepatitis c, as identified during the hepatitis C surveillance phase of the study will be offered treatment for hepatitis C. The treatment course is sofosbuvir/velpatasvir 400/100mg for 12 weeks (1 tablet once daily).
3074527|NCT02064036|Experimental|Single|Neoadjuvant Androgen Blockade (Casodex) Followed by: Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade (Casodex and Leuprolide) to Whole Pelvis, Prostate, and Seminal VesiclesFollowed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance Followed by: Adjuvant Androgen Blockade (Casodex)
3074528|NCT02064023|Experimental|insulin pump|subjects will use an insulin pump for the duration of the pregnancy. The intervention is that they will control their diabetes using an insulin pump
3074529|NCT02064023|Active Comparator|Multiple Daily Insulin injections|subjects will continue their usual insulin treatment with multiple daily injections of sc insulin
3074530|NCT02064010|Experimental|SNC-102, low dose|SNC-102 (Acamprosate calcium) tablet 4 week duration dosing
3074531|NCT02064010|Experimental|SNC-102, high dose|SNC-102 (Acamprosate calcium) tablet 4 week duration dosing
3074532|NCT02064010|Placebo Comparator|Placebo|Placebo tablet 4 week duration dosing
3074533|NCT02063997|Experimental|Arhalofenate 600 mg|
3074534|NCT02063997|Experimental|Arhalofenate 800 mg|
3074535|NCT02063997|Active Comparator|Allopurinol 300 mg; colchicine 0.6 mg|
3074536|NCT02063997|Active Comparator|Allopurinol 300 mg|
3074537|NCT02063997|Placebo Comparator|Placebo|
3074538|NCT02063984|Experimental|Behavior Therapy + Hard Working Memory Training|Intensive Outpatient Treatment + Contingency Management, Hard (Adaptive) Working Memory Training (IOP + CM + HWMT)
3074539|NCT02063984|Active Comparator|Behavior Therapy|Intensive Outpatient Treatment + Contingency Management (IOP + CM)
3074540|NCT02063971|Experimental|Skin aging|Anti-age product will be applied once a day, in the evening, on half face and neck for an uninterrupted period of 12 weeks and the placebo cream in the morning with the same modalities. On the contralateral face side (right or left side according to a previous randomisation list), the volunteers will apply the placebo cream twice a day
3074541|NCT02063958|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules dosed in the morning once every other day (qod) for 21 days (11 doses), followed by a 7 day drug free period. Dose escalation will be based on safety defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level. Dose escalation will not exceed a dose of 100 mg/m2 SNX-5422 qod even if the MTD has not been identified. Subjects will receive daily oral everolimus in the PM about the same time every day for 28 days.
3074542|NCT02063945|Active Comparator|Methylphenidate|"Participants in this arm will be given either Concerta - a long acting (12 hours) Methylphenidate pill - once daily, in the morning (starting dose 1 mg/kg, max dose 2 mg/kg), or Ritalin LA - a long acting (10 hours) Methylphenidate pill - once daily, in the morning (starting dose 0.6 mg/kg, max dose 1.5 mg/kg) for children who can not swallow pills."
3074543|NCT02063945|Active Comparator|Risperidone|Participants in this arm will be given a low dose of Risperidone. Starting dose will be 0.5 mg/d, max dose will be 2 mg/d.
3074544|NCT02063932||endomicroscopy|
3074545|NCT02063919||endomicroscopy|
3074546|NCT02063906||Breast cancer stage I-III|who received curative surgery for stage I-III breast cancer and had available data on immunohistochemistry profiles including hormone receptor status (HR) status, human epidermal growth factor receptor 2 (HER2) status, and Ki 67 staining at Samsung Medical Center from January 2004 to September 2008.
3074547|NCT02063893||non-vaccine|
3074548|NCT02063893||giving low vaccine|
3074551|NCT02063880|Experimental|Urgent ART|"Initiation of highly active antiretroviral therapy (HAART) within 48 hours of enrollment.~Antiretroviral therapy will include regimens recommended by the Kenyan Ministry of Health."
3074552|NCT02063880|Active Comparator|Early ART|Initiation of HAART 7-14 days after enrollment.
3074553|NCT02063867|No Intervention|Arm 1: Usual Care|Routine policy for showering or bathing non-critical care patients
3074554|NCT02063867|Active Comparator|Arm 2: Decolonization|"Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen."
3074555|NCT02063854|Active Comparator|NE-58095 IR 2.5 mg Once Daily on Awakening|NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
3074556|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly on Awakening|NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
3074557|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly Following Breakfast|NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
3074558|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast|NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
3074559|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly on Awakening|NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
3074560|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly Following Breakfast|NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
3074561|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast|NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
3074562|NCT02063841|Active Comparator|sterile identical sham drape|Sham drape and conventional protection (wearing a lead apron and thyroid shield as well as suspension of a standard lead skirt over the X-ray source).
3074563|NCT02063841|Experimental|lead-free protective drape containing bismuth and antimony|lead-free protective drape containing bismuth and antimony (RADPAD®) hung around the fluoroscopy image intensifier to prevent scatter radiation, and conventional protection (wearing a lead apron and thyroid shield as well as suspension of a standard lead skirt over the X-ray source).
3074564|NCT02063828|Experimental|Group A|Group A - Device Guided Breathing Low Dose
3074565|NCT02063828|Active Comparator|Group B|Group B - Device guided breathing high dose
3074566|NCT02063828|Active Comparator|Group C|Group C - Usual Breathing Control Group
3074567|NCT02063815|Active Comparator|glass ionomer based fissure sealant|fissure sealant application
3074568|NCT02063815|Active Comparator|resin based fissure sealant|fissure sealant application
3074569|NCT02063802|Active Comparator|metformin and healthy habits program|1 gr per day. (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
3074570|NCT02063802|Experimental|Conjugated Linoleic Acid and healthy habits|Total dose: 3gr per day (500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner by mouth for four months.
3074571|NCT02063802|Placebo Comparator|Placebo and healthy habits program|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months.
3074572|NCT02063789|Experimental|Human immunoglobulin intravenous|Human immunoglobulin intravenous; GC5107A (IV-Globulin SN Inj. 10%); Day 1: GC5107A, 1g/kg, intravenous Day 2: GC5107A, 1g/kg, intravenous; Starting infusion rate: 0.01mg/kg/min (1mg/kg/min) for first 15 minutes, and then 2-fold increase every 30 minutes by maximum 0.08ml/kg/min (8mg/kg/min). Dosing modification is allowed due to tolerance.
3074573|NCT02063776||Children on HDF|
3074574|NCT02063776||Children on conventional HD|
3074575|NCT02063750|Experimental|Strengthening group|This group perform muscle strengthening exercises using a Swiss ball of 65 cm diameter.
3074576|NCT02063750|Active Comparator|Stretching group|Performed stretching exercises
3074577|NCT02063737|Sham Comparator|Control Group|The control group will receive text-message assessments only at the start, during, and end of shift. These queries will attempt to capture the worker's self-reported sleepiness, fatigue, and occurrence of work-related injury during shift work.
3074915|NCT02061475|Active Comparator|Lidocaine Patches|
3074578|NCT02063737|Experimental|Intervention Group|The intervention group will receive the same text-message assessments as the control group. In addition, these subjects will receive text-message interventions for high level fatigue for reducing fatigue and sleepiness during shift work if they report a high-level of fatigue or sleepiness at the start or during their shift. These subjects will then receive additional text message queries at the end of their shifts to determine if they adopted a strategy for reducing perceived sleepiness or fatigue.
3074579|NCT02063724|Experimental|HER-2 Pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
3074580|NCT02063711|Experimental|Yoga Intervention|A 1-hour yoga session will take place with guided instruction provided by a registered yoga instructor. The class includes a warm up period of 5 minutes, which includes sitting with the eyes closed and slowly breathing through the nose. After which the participant will perform a series of yoga postures in coordination with her breathing for approximately 45 minutes. The last 10 minutes of class will encompass a semi-recumbent relaxation period. This is a one time intervention.
3074581|NCT02063711|No Intervention|Control group|In order to control for 1 hour worth of time, the participants in the control group will be given a 1 hour Power Point presentation on the benefits of exercise and yoga during pregnancy.
3074582|NCT02063698|Experimental|Arm I (auranofin)|Patients receive auranofin PO on day 2.
3074583|NCT02063698|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on day 2.
3074584|NCT02063685|Other|GROUP 1 - STANDARD|R-CHOP or R-bendamustine + Standard Maintenance
3074585|NCT02063685|Experimental|GROUP 2|FDG-PET POSITIVE (score 4-5) patients (High risk) R-CHOP or R-bendamustine + Ibritumomab Tiuxetan + Maintenance
3074586|NCT02063685|Experimental|GROUP 1a|FDG-PET NEGATIVE (score 1-3) AND MRD NEGATIVE R-CHOP or R-bendamustine + Observation
3074587|NCT02063685|Experimental|GROUP 1b|FDG-PET NEGATIVE (score 1-3) AND MRD POSITIVE R-CHOP or R-bendamustine + Maintenance weekly x4
3074588|NCT02063672|Experimental|Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
3074589|NCT02063672|Active Comparator|PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter
3074590|NCT02063659|Experimental|250 mg Telotristat Etiprate|Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
3074591|NCT02063659|Experimental|500 mg Telotristat Etiprate|Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for one week, followed by two 250 mg telotristat etiprate tablets administered three times daily for 11 weeks in the 12 week double-blind treatment period, followed by a 36 week open-label extension period.
3074592|NCT02063659|Placebo Comparator|Placebo|Following a 3 to 4-week run-in period, participants were randomized to receive two placebo-matching telotristat etiprate tablets administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
3074593|NCT02063646|Placebo Comparator|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.~Dose: 2 capsules per day, one capsule at least 1 hour after breakfast and one capsule at least one hour after dinner, with a glass of water."
3074594|NCT02063646|Experimental|Polyphenol-rich extract|"The test product is a food supplement named Neurophenol. It is presented as a hard-shell capsule containing polyphenol-rich extracts.~Dose: 2 capsules per day, one capsule at least 1 hour after breakfast and one capsule at least one hour after dinner, with a glass of water."
3074595|NCT02063620|Active Comparator|ketamine HCL|%0.5 Lidocaine+Ketamine HCL 0.8 mg/kg, total 40ml, single dose administration, 30 minute duration, total 200mg lidocaine
3074596|NCT02063620|Placebo Comparator|lidocaine+ serum physiologic|% 0.5 lidocaine, 35 ml serum physiologic, 200 mg lidokaine, 30 minute single dose
3074597|NCT02063607|Active Comparator|Peginterferon alfa 2a|Peginterferon alfa 2a 180 mcg
3074598|NCT02063607|Experimental|Peginterferon Lambda|Peginterferon Lambda 60,120,180 and 240 mcg
3074599|NCT02063594|Placebo Comparator|Saline Placebo|2 of 8 subjects in each dose cohort will receive normal saline as a single intravenous infusion
3074600|NCT02063594|Experimental|NCTX|6 of 8 subjects in each dose cohort will receive NCTX (PEGylated Liposomal Iodixanol Injection) as a single intravenous infusion
3074601|NCT02063581|Experimental|Sequence 1: Tablet followed by Capsule|
3074602|NCT02063581|Experimental|Sequence 2: Capsule followed by Tablet|
3074603|NCT02063568|Active Comparator|Low dose oxytocin infusion|oxytocin will be administered as an intravenous infusion at a rate of 0.33 units/min starting after fetal delivery upon umbilical cord clamping and continuing for a total of 30 minutes
3074604|NCT02063568|Active Comparator|High dose oxytocin infusion|oxytocin will be administered as an intravenous infusion at a rate of 1.33 units/min starting after fetal delivery upon umbilical cord clamping and continuing for a total of 30 minutes
3074605|NCT02063555|Experimental|DAR-901|"Intradermal administration at 0, 2 and 4 months~Three dose groups in dose escalation: 0.1 mg, 0.3 mg and 1.0 mg, all constituted in 0.1 mL"
3074606|NCT02063555|Active Comparator|BCG|Intradermal injection of 0.1 mL saline at 0 mos, 2 mos, intradermal injection of 0.1 mL BCG at 4 mos
3074607|NCT02063555|Placebo Comparator|Sterile saline|Intradermal injection of 0.1 mL sterile saline at 0, 2 and 4 mos
3074608|NCT02063529|Experimental|A (FOLFOXIRI + Cetuximab)|FOLFOXIRI + Cetuximab
3074609|NCT02063529|Active Comparator|B (FOLFOXIRI)|FOLFOXIRI
3074610|NCT02063516|Experimental|Guardian|Device: Guardian Laryngeal Mask
3074611|NCT02063516|Experimental|Proseal|Device:Proseal Laryngeal Mask Airway
3074612|NCT02063503|Experimental|Motor control therapy|physiotherapy
3074613|NCT02063503|Experimental|Isometric training therapy|physiotherapy
3074614|NCT02063503|Experimental|Combination therapy|physiotherapy
3074615|NCT02063490|Experimental|Adherence support|"One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)~+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions"
3074616|NCT02063490|No Intervention|Control arm|Standard care
3074617|NCT02063477|Placebo Comparator|Product one|150 mg (maltodextrin)/day (75 mg maltodextrin included in 280 mg/gelule; 2 times/day: morning and evening) of Placebo plus Dietary Approaches to Stop Hypertension (DASH)
3074618|NCT02063477|Active Comparator|Product two|150 mg Oligopin/day (75mg Oligopin included in 280mg/gelule; 2 times/day: morning and evening) of Oligopin® plus Dietary Approaches to Stop Hypertension (DASH)
3074619|NCT02063451|Other|Obese, Weight Loss, Very Low Calorie Diet|Obese individuals will a Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA) for 3-6 months until individually targeted weight loss determined by a clinician is reached. Typically, individuals consume 850-1000 kilocalories per day.
3074620|NCT02063451|No Intervention|Lean, baseline measure|MOR binding will be observed in lean individuals at one timepoint. Lean individuals will not receive any intervention.
3074621|NCT02063438|Active Comparator|Pericostal Suture Technique|A #2 Vicryl suture is placed along the superior aspect of the rib above the specific thoracic interspace. This suture is then passed below the inferior rib along the superior aspect of the next rib below. These sutures are then tied to approximate the ribs leaving enough room for the tip of a finger.
3074622|NCT02063438|Active Comparator|Intracostal Suture Technique|A handheld drill is used to drill holes in the rib below the specific thoracic interspace. A #2 Vicryl suture is passed through each of the holes and then passed along the superior aspect of the rib above the specific thoracic interspace. These sutures are then tied to approximate the ribs leaving enough room for the tip of a finger.
3074623|NCT02063425|Active Comparator|Fluoxetine|
3074624|NCT02063425|Placebo Comparator|Placebo|
3074625|NCT02063412||XELOX|Capecitabine (Xeloda) 1000mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130mg/m2 iv over 2 hrs d1 Q3w x 8 cycles
3074626|NCT02063412||XP|Cisplatin (CDDP) 80 mg/m2 iv over 3 hrs d1 Capecitabine (Xeloda) 1000 mg/m2 po bid d1-14, Q3w
3074627|NCT02063412||FOLFOX|Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and d2 5-FU 400mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d1 and d2 Q2w
3074628|NCT02063412||FP|Cisplatin (CDDP) 100 mg/m2 iv d1 5-FU 1000 mg/m2/d civi d1-5, Q4w
3074629|NCT02063386|Experimental|AZD1722|Single oral dose 15 mg of [14C]AZD1722
3074630|NCT02063373|Experimental|biomechanis knee OA and HA injection|Weekly intra- articular Hyaluronic acid injection (20 MG/ 2 ML) into both knees for five weeks
3074631|NCT02063360|Experimental|Cohort 1: BMS-663068+DRV/RTV|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg orally orally twice daily on days 7-16
3074632|NCT02063360|Experimental|Cohort 2: BMS-663068+ETR|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet ETR 200mg orally orally twice daily on days 7-16
3074633|NCT02063360|Experimental|Cohort 3: BMS-663068+DRV/RTV+ETR|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg and ETR 200mg orally orally twice daily on days 7-16
3074634|NCT02063347||Coronary artery disease|With coronary artery disease
3074635|NCT02063347||No coronary artery disease|Without coronary artery disease
3074636|NCT02063334|Active Comparator|Vitamin D3|2000 micrograms of vitamin D3 in two doses during one day
3074637|NCT02063334|Placebo Comparator|Placebo|Placebo in two doses during one day
3074638|NCT02063308|Experimental|Oxaloacetate (OAA)|100 mg OAA to be taken twice daily over the course of a month
3074639|NCT02063295|Placebo Comparator|ZGN-440 sterile diluent|Subjects will receive placebo twice weekly subcutaneous injections for 4 weeks.
3074640|NCT02063295|Experimental|ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
3074641|NCT02063282||Clostridium difficile carriers|
3074642|NCT02063282||Clostridium difficile non carriers|
3074643|NCT02063269|Experimental|Rivastigmine|Rivastigmine
3074644|NCT02063256|Active Comparator|7 NUTS a day|the patients allocated to this arm will be instructed to supplement their diet with 7 nuts a day (whole shelled weight around 75 grams)
3074645|NCT02063256|Experimental|Diet modification|the patients allocated to this arm will be instructed to modify their diet allowing more intake of PUFA rich food avoiding saturated fat rich food
3074646|NCT02063243|Other|keloid or hypertrophic scars|All patient including all skin types with keloid or hypertrophic disease receiving Intralesional Cryotherapy
3074647|NCT02063230|Experimental|Selumetinib HV|Healthy volunteers (HV)
3074648|NCT02063230|Experimental|Selumetinib mild impairment|Mild (Child Pugh A) hepatic impaired patients
3074649|NCT02063230|Experimental|Selumetinib moderate impairment|Moderate (Child Pugh B) hepatic impaired patients
3074650|NCT02063230|Experimental|Selumetinib severe impairment|Severe (Child Pugh C) hepatic impairment patients
3074651|NCT02063217|Experimental|Sleep Induction|7.5 grams of sodium oxybate
3074652|NCT02063217|Experimental|Sleep Deprivation|Sleep deprivation for up to 36 hours with no naps or other sleep periods
3074653|NCT02063217|No Intervention|Control|Participant will sleep as normal under the same controlled conditions in a clinical research unit
3074654|NCT02063204|Experimental|HV selumetinib Stage 1|Healthy volunteer (HV)group to receive selumetinib 50mg (2x25mg) orally
3074655|NCT02063204|Experimental|ESRD selumetinib Stage 1|End stage renal disease (ESRD)patients to recieve selumetinib 50mg (2x25mg) orally
3074656|NCT02063204|Experimental|Selumetinib stage 2|If deemed necessary patients with mild and/or moderate and/or severe renal impairment will recieve selumetinib 50mg(2x25mg) orally
3074657|NCT02063191||Atrial Fibrillation|Patients with atrial fibrillation during the EP study
3074658|NCT02063191||Bundle Branch Block|Patient with bundle branch block during the course of the EP study
3074691|NCT02062944|Experimental|Single-arm study Sirolimus Withdrawal|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
3074916|NCT02061475|Placebo Comparator|Placebo Patches|
3074659|NCT02063178|Experimental|Counselor-Initiated|Participants will receive 28 telephone sessions over a 12 month period by interventionists trained in behavior change skills and motivational interviewing techniques. Participants will be asked to monitor food intake and physical activity using the LoseIt website/app and weight daily using a Body Trace e-scale. Participants will receive feedback on self-monitoring through e-mail. Dietary goals will be based on weight and participants' weight-loss progress. Participants will be encouraged to replace 2 meals and a snack with meal replacements (provided). Participants will be asked to gradually increase their moderate to vigorous exercise to 225-250 minutes per week. The Toolbox includes additional treatment options (e.g., food scales, exercise videos, cookbooks) for those who wish to take advantage of them. There will be several challenges that will provide a specific goal (e.g. increase self-monitoring), with a small award for completion.
3074660|NCT02063178|Active Comparator|Self-Paced|The Self-paced group uses a less intense approach, where the participants can receive the same telephone counseling sessions as the counselor-initiated group, only if they call the counselor. Participants will be asked to monitor food intake and physical activity using the LoseIt website/app and weight daily using a Body Trace e-scale. Participants will receive feedback on self-monitoring through e-mail only upon request. Dietary goals will be based on weight and participants' weight-loss progress. Participants will be asked to gradually increase their moderate to vigorous exercise to 225-250 minutes per week.
3074661|NCT02063152||Entire Taiwan women|
3074662|NCT02063139|Experimental|Flutiform 50/5 ug (2 puffs bid) pMDI|Flutiform 50/5 ug (2 puffs bid) pMDI
3074663|NCT02063139|Active Comparator|Fluticasone 50 ug (2puffs bid) pMDI|Fluticasone 50 ug (2puffs bid) pMDI
3074664|NCT02063139|Other|Beclometasone Autohaler 50 ug (2 puffs bid)|Active control
3074665|NCT02063126|Active Comparator|ReConnect|CFS patients who were randomized to measure the effect of oral ReConnect supplementation (NADH: 20 mg/day, Coenzyme Q10: 200 mg/day; 4 tablets/day) on the maximum HR during 8-weeks in term.
3074666|NCT02063126|Placebo Comparator|Placebo|CFS patients who were randomized to measure the effect of oral Placebo supplementation ( phosphoserine and vitamin C, 4 tablets/day) on the maximum HR during 8-weeks in term.
3074667|NCT02063113|No Intervention|NA/NA|
3074668|NCT02063100|Experimental|Shenyankangfu tablets and Losartan potassium 100mg|
3074669|NCT02063100|Experimental|Shenyankangfu tablets and Losartan potassium 50mg|
3074670|NCT02063100|Experimental|Losartan potassium 50mg|
3074671|NCT02063100|Experimental|Shenyankangfu tablets|
3074672|NCT02063100|Experimental|Losartan potassium 100mg|
3074673|NCT02063087|Active Comparator|Decision Aid|Head CT Decision Aid
3074674|NCT02063087|No Intervention|Usual Care|Clinicians and patients do not have access to the Head CT Decision Aid
3074675|NCT02063061|Sham Comparator|Sham treatment|Subject will answer standardized questionnaires. Sham treatment arm will receive initially 5 sham series and after they answer standardized questionnaires they will receive 5 series of active treatment. Afterwards patients will answer standardized questionnaires again.
3074676|NCT02063061|Active Comparator|ESWT treatment|Subject will answer standardized questionnaires. Subjects will receive 10 treatments with ESWT. Afterwards patients will answer standardized questionnaires again.
3074677|NCT02063048|No Intervention|Usual Care for Weight Loss|Patients randomized to this arm will not receive text messages or any other weight-loss support besides usual care provided at Denver Health. They will receive a weight loss educational packet and be asked to follow up with their primary care provider to further discuss their efforts at weight loss with additional follow-up as directed by their provider. They will be contacted periodically to be weighed. Providers will not be made aware that their patients are participating in the study's control arm.
3074678|NCT02063048|Experimental|Text Message Based Weight Loss Support|Patients will receive the same weight loss educational packet as those randomized to usual care. Patients will be assisted in choosing a self-management goal related to exercise and to eating behaviors. They will receive text messages at a frequency up to 1x daily; input from focus groups will guide text message frequency.
3074679|NCT02063035|Experimental|Tranexamic acid|Participants undergoing spinal surgery will receive a single, topical dose of tranexamic acid. The surgeon will irrigate the study medication in the wound prior to closure, and aspirate it after five minutes. Drains will be placed after the study drug has been aspirated.
3074680|NCT02063035|Placebo Comparator|Placebo|Participants undergoing spinal surgery will receive a single, topical dose of matching placebo. The surgeon will irrigate the study medication in the wound prior to closure, and aspirate it after five minutes. Drains will be placed after the study drug has been aspirated.
3074681|NCT02063022|Active Comparator|Standard treatment (as per ISG SSG III protocol)|"Standard treatment for non metastatic Ewing's Sarcoma (as defined by the ISG/SSG III protocol).~It is based on a 6 drugs pre-local treatment (Vincristin, dactinomycin, cyclophosphamide,ifosfamide,etoposide and doxorubicin) followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response"
3074682|NCT02063022|Experimental|Intensified treatment|Dose intense treatment for non metastatic Ewing's Sarcoma It is based on a 3 drug pre-local treatment (Vincristin, ifosfamide and doxorubicin)followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response
3074683|NCT02063009||patients scheduled for oncologic high-risk surgery|
3074684|NCT02062996|Experimental|ENT - full strength|Full strength oxymetazoline pledgets packed in the nose (total volume 20 ml).
3074685|NCT02062996|Experimental|ENT - 1/2 strength|½ strength oxymetazoline pledgets packed in the nose (total volume 20 ml).
3074686|NCT02062996|Experimental|DENTAL - Full strength 1.0 mL|Full strength oxymetazoline 1.0 mL to each naris (total =1000 mcg).
3074687|NCT02062996|Experimental|DENTAL - Full strength 0.5 mL|Full strength oxymetazoline 0.5 mL to each naris (total = 500 mcg).
3074688|NCT02062996|Experimental|DENTAL - ½ strength 0.5 mL|½ strength oxymetazoline 0.5 mL to each naris (total = 250 mcg).
3074689|NCT02062983||Herceptin|The study will be carried in prospective manner enrolling all patients diagnosed with breast cancer and over expressed human epidermal growth factor receptor 2 (HER2) and they are requiring Trastuzumab Neu adjuvant/ adjuvant /metastatic therapy as per standard care.
3074690|NCT02062970|Experimental|septic shock patients suffering|blood sample done in a population whom suffer of septic shock
3074917|NCT02061462|No Intervention|Standard Group|Recipients of lungs procured from brain dead donors.
3074692|NCT02062931|Experimental|Stem Cell Preparation and Injection|"Stem Cell Preparation and Injection:~Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared and suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .~Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue."
3074693|NCT02062918|No Intervention|Control group|Patients in the control group did not use an abdominal belt.
3074694|NCT02062918|Experimental|Experimental group|Patients were instructed in how to use the abdominal belt for activities of physical effort that exacerbated lumbar pain as well as during moments of pain, and not to use it during rest. They should record the number of hours of belt use per day on spreadsheets distributed for this purpose.
3074695|NCT02062905|Experimental|OTX-DP treatment|OTX-DP (sustained release dexamethasone, 0.4 mg)
3074696|NCT02062905|Placebo Comparator|Placebo Plug Delivery Vehicle|Placebo Plug with no drug
3074697|NCT02062892|Experimental|Everolimus / Tacrolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
3074698|NCT02062892|Active Comparator|Sirolimus / Tacrolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
3074699|NCT02062879|Experimental|Ketamine|Ketamine 90mg/30 mL PCA (3 mg/mL)
3074700|NCT02062879|Active Comparator|Hydromorphone|Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)
3074701|NCT02062866|Active Comparator|Purse-String|Surgical wounds are healed via suturing.
3074702|NCT02062866|Active Comparator|Second Intent|Surgical wounds are allowed to heal without sutures.
3074703|NCT02062853|Experimental|Video Group|Subjects view educational video on the use of cream medication for the treatment of actinic keratoses.
3074704|NCT02062853|Active Comparator|Verbal Group|Subjects are given verbal instructions on the use of cream medication for the treatment of actinic keratoses.
3074705|NCT02062840|Experimental|High intensity whole-body infrared heating and Neuroimaging|Subjects will have an fMRI the morning of their WBH session and and fill out study questionnaires. Following the fMRI session, the participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
3074706|NCT02062840|Sham Comparator|Low intensity whole-body infrared heating and|Subjects will have an fMRI the morning of their WBH session and and fill out study questionnaires. Following the fMRI session, the participant will undergo the WBH-control intervention where subjects will be induced to levels of heat that causes only a minor increase in body temperature.
3074707|NCT02062827|Experimental|Group A single dose of HSV-1 (M032)|single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
3074708|NCT02062801|Active Comparator|Prophylactic ephedrine|Ephedrine 10mg iv once at time of combined spinal epidural insertion
3074709|NCT02062801|Placebo Comparator|Normal saline (placebo) control group|1ml normal saline intravenously once at time of combined spinal epidural insertion
3074710|NCT02062788|Experimental|ORS group|Oral rehydration solution (ORS) treated group
3074711|NCT02062788|No Intervention|Non-ORS group|Oral rehydration solution (ORS) untreated group
3074712|NCT02062775|Active Comparator|Self-Fixating Hernia Mesh|Self-fixating polyester mesh will be used for laparoscopic inguinal hernia repair.
3074713|NCT02062775|Placebo Comparator|Non-Fixating Hernia Mesh|Non-fixating polyester mesh will be used for laparoscopic hernia repair.
3074714|NCT02062762|Experimental|Online-MBSR|8 week mindfulness based stress reduction online
3074715|NCT02062762|Active Comparator|Expressive Writing Online|Online distributed expressive writing intervention as active control
3074716|NCT02062749|Experimental|Hyperthermic Intraperitoneal Chemotherapy|After cytoreductive surgery and lysis of adhesions, two large bore catheters are placed in the peritoneal cavity through the incision. Thirty minutes before HIPEC is begun, body temperature is cooled to 35°C. ). The catheters are connected to a perfusion circuit. Heated Oxaliplatin is added to the perfusate administered over 90 minutes. The starting dose of Oxaliplatin is 175 mg/m2.
3074717|NCT02062736||pts addicted to heroin in MMT|patients addicted to heroin who have undertaken methadone maintenance treatment
3074718|NCT02062723||pts addicted to heroin in MMT|patients addicted to heroin who have undertaken methadone maintenance treatment
3074719|NCT02062710|Experimental|A, B, then C|"Subjects received the following: Period 1: single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg, in naturally-flavored cocoa syrup (treatment A). Period 2: dextromethorphan syrup 30 mg (treatment B); Period 3: placebo liquid, dextrose in water, 20 mL (treatment C).~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.Each dosing period separated by 1-2 day washout period."
3074720|NCT02062710|Experimental|A, C, then B|"Subjects received the following: Period 1: single oral doce of diphenhydramine 25 mg and phenylephrine 10 mg, in naturally-flavored cocoa syrup (treatment A); Period 2: placebo liquid, dextrose in watwer, 20 mL (treatment C); Period 3: dextromethorphan syrup 30 mg (treatment B).~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.Each dosing period separated by 1-2 day washout period."
3074721|NCT02062710|Experimental|B, A, then C|Subjects received the following: Period 1: dextromethorphan syrup 30 mg (treatment B); Period 2: single dose of oral diphenhydramine 25 mg and phenylephrine 10 mg, in a naturally-flavored cocoa syrup (treatment A); Period 3: placebo liquid, dextrose in water, 20 mL (treatment C). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
3074759|NCT02062437||Total hip replacement using a ceramic friction pair|Patients treated with total hip replacement using a ceramic friction pair Biolox® Delta, with Meije Duo® stem associated with Dynacup® cup
3074722|NCT02062710|Experimental|B, C, then A|"Subjects received the following: Period 1: dextromethorphan 30 mg syrup (treatment B); Period 2: placebo liquid, dextrose in water, 20 mL (treatment C); Period 3: single dose of oral diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A).~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period."
3074723|NCT02062710|Experimental|C, A, then B|Subjects received the following: Period 1: placebo liquid, dextrose in water, 20 mL (treatment C); Period 2: a single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A); Period 3: dextromethorphan 30 mg syrup (treatment B). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
3074724|NCT02062710|Experimental|C, B, then A|Subjects received the following: Period 1: placebo liquid, dextrose in water, 20 mL (treatment C); Period 2: dextromethorphan 30 mg syrup (treatment B); Period 3: a single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
3074725|NCT02062697|Other|Ovarian Epithelial Cancer|"Lavage of the Cavum uteri and proximal fallopian tubes~Liquid-PAP (Papanicolaou) smear"
3074726|NCT02062684|Experimental|Blisibimod|Blisibimod administered subcutaneously
3074727|NCT02062684|Placebo Comparator|Placebo|Placebo administered subcutaneously
3074728|NCT02062671|Experimental|immediate renal denervation|immediate renal denervation
3074729|NCT02062671|Active Comparator|delayed renal denervation|delayed renal denervation
3074730|NCT02062658|Experimental|Ketamine, Exposure & Response Prevention|0.5mg/kg IV Ketamine infusion followed by condensed course of Exposure and Response Prevention (EX/RP)
3074731|NCT02062645|Experimental|amlodipine/valsartan|All patients will receive amlodipine/valsartan 5/160 mg daily in screening and up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (day 30) if their hypertension can not be controlled. The duration of treatment period is 8 weeks.
3074732|NCT02062632|Experimental|Group I (doxepin hydrochloride)|Patients receive doxepin hydrochloride oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1. Patients then crossover to Arm II on day 3.
3074733|NCT02062632|Placebo Comparator|Group II (placebo)|Patients receive placebo oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1. Patients then crossover to Arm I on day 3.
3074734|NCT02062619|Experimental|Real tDCS|"Transcranial direct current stimulation (tDCS) administered concurrently with computer-based behavioural word reading therapy.~2mA anodal direct current stimulation applied to the left inferior frontal gyrus (IFG) for first 20 minutes of therapy."
3074735|NCT02062619|Sham Comparator|Sham tDCS|"Transcranial direct current stimulation (tDCS) administered concurrently with computer-based behavioural word reading therapy.~Sham tDCS (periodical fade-in and fade-out stimulation routine) applied to the left inferior frontal gyrus (IFG) for first 20 minutes of therapy."
3074736|NCT02062606||AIS|Surgical implantation of the K2M MESA Rail™ Deformity System in the treatment of Adolescent Idiopathic Scoliosis (AIS).
3074737|NCT02062593|Active Comparator|Coronary angioplasty and optimum medical therapy|Percutaneous coronary intervention and optimal medical therapy
3074738|NCT02062593|Placebo Comparator|Sham procedure and optimum medical therapy|Placebo percutaneous coronary intervention and optimal medical therapy with risk factor modification and anti-anginal therapy
3074739|NCT02062580|Active Comparator|Delayed BCG|BCG delayed to 8 weeks of age
3074740|NCT02062580|Other|Early BCG|BCG at birth; standard of care
3074741|NCT02062567||Acute Achilles tendon rupture|
3074742|NCT02062541|Experimental|Funct. assessment+fast rehabilitation|Funct. assessment+fast rehabilitation
3074743|NCT02062541|Experimental|Funct. assessment+usual rehabilitation|Funct. assessment+usual rehabilitation
3074744|NCT02062541|Experimental|usual assessment+fast rehabilitation|usual assessment+fast rehabilitation
3074745|NCT02062541|No Intervention|usual assessment+usual rehabilitation|usual assessment+usual rehabilitation
3074746|NCT02062528|Experimental|omega-3 fatty acids|3 capsules each day during 8 weeks
3074747|NCT02062528|Placebo Comparator|placebo|3 capsules each day during 8 weeks
3074748|NCT02062515|Experimental|Icotinib|Icotinib is administered orally 125 mg three times per day continuously for four weeks
3074749|NCT02062502|Experimental|VARIVAX™ NSP + M-M-R II™|VARIVAX™ New Seed Process 0.5 mL administered in the left arm and M-M-R II™ vaccine 0.5 mL administered in the right arm by subcutaneous injection on Day 1 and Day 91
3074750|NCT02062502|Active Comparator|VARIVAX™ 2007 Process + M-M-R II™|VARIVAX™ 2007 Process 0.5 mL administered in the left arm and M-M-R II™ vaccine 0.5 mL administered in the right arm by subcutaneous injection on Day 1 and Day 91
3074751|NCT02062489|Active Comparator|Tamoxifen|20mg(2#)/day, PO, daily, five years
3074752|NCT02062489|Placebo Comparator|Placebo|2#/day, PO, daily, five years
3074753|NCT02062476|Experimental|Treatment with Lactobacillus GG|extensively hydrolyzed casein formula containing LGG
3074754|NCT02062476|No Intervention|Children at diagnosis|
3074755|NCT02062463|Active Comparator|SPIROMAX|"Period 1 of this study will comprise a single visit wherein mastery of inhaler technique will be assessed. Empty training devices will be utilized for this period. Period 2 dosage will be equivalent to that received via the participants current device at baseline.~Participants receiving 800 mcg to 1000 mcg budesonide diphosphate (BDP)-equivalent inhaled corticosteroids at study entry will receive budesonide and formoterol at daily doses of 640 mcg and 18 mcg, respectively."
3074756|NCT02062463|Active Comparator|TURBOHALER|"Period 1 of this study will comprise a single visit wherein mastery of inhaler technique will be assessed. Empty training devices will be utilized for this period. Period 2 dosage will be equivalent to that received via the participants current device at baseline.~Participants receiving 1600 mcg to 2000 mcg budesonide diphosphate (BDP)-equivalent inhaled corticosteroids at study entry will receive budesonide and formoterol at daily doses of 1280 mcg and 36 mcg, respectively."
3074757|NCT02062450||Primary surgery with Dual Mobility Cup|Patients having a Primary Hip acetabular replacement, using a Dual Mobility Cup.
3074758|NCT02062450||Revision surgery with Dual Mobility Cup|Patients having a Revision Hip acetabular replacement, using a Dual Mobility Cup.
3075005|NCT02060851|Experimental|group 3|intravenous iron and EPO
3074760|NCT02062424|Active Comparator|DIPI: Danish national dietary guidelines|The subjects will receive dietary advice according to the current national dietary guidelines
3074761|NCT02062424|Active Comparator|DIPI: Specific IHD dietary guideline|The subjects will receive dietary advice, according to the specific ischemic heart disease dietary guidelines.
3074762|NCT02062424|No Intervention|Normal dietary habits|The Subjects will be instructed to follow their normal dietary habits
3074763|NCT02062411|Experimental|CBT with booster sessions|Participants will receive 12 cognitive-behavioral therapy sessions weekly and 3 booster sessions monthly following our protocol.
3074764|NCT02062411|Active Comparator|CBT only|Participants will only receive 12 cognitive-behavioral therapy sessions weekly.
3074765|NCT02062411|No Intervention|waiting|Participations will not be treated with CBT and keep waiting for 12 weeks for comparison.
3074766|NCT02062398|Experimental|The Reprieve system implantation|The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations.
3074767|NCT02062385|Experimental|V260 with staggered EPI|V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered China Expanded Program on Immunizations (EPI) as follows: Oral poliovirus vaccine (OPV) administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and diphtheria, tetanus, acellular pertussis vaccine (DTaP) administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months
3074768|NCT02062385|Placebo Comparator|Placebo with staggered EPI|Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months
3074769|NCT02062385|Experimental|V260 with concomitant EPI|V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months
3074770|NCT02062385|Placebo Comparator|Placebo with concomitant EPI|Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months
3074771|NCT02062372|Experimental|Biopsy|Subjects will receive a 7 T MRI and one additional biopsy to their standard diagnostic biopsies
3074772|NCT02062359|Experimental|All Participants|Patients will receive the standard National Cancer Institute (NCI) Surgery Branch non-myeloablative, lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of the anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ engineered peripheral blood lymphocyte (PBL) and aldesleukin
3074773|NCT02062346|Placebo Comparator|Placebo|Saline placebo
3074774|NCT02062346|Experimental|BQ123|BQ123 1000nmol/min for 15min
3074775|NCT02062346|Experimental|BQ123/788|BQ123 1000nmol/min; BQ788 300nmol/min
3074776|NCT02062346|No Intervention|Assessment of forearm vascular function|Response of forearm blood flow to endothelium-dependent and endothelium-independent vasodilators
3074777|NCT02062333|Active Comparator|dexmedetomidine|0,4-0,8 µg./kg./h dexmedetomidine
3074778|NCT02062333|Active Comparator|esmolol|100- 300 µg./kg./min esmolol
3074779|NCT02062320||PRE-PCAPS|Parturients who underwent delivery by Caesarean Section in the period October 2009 - September 2010
3074780|NCT02062320||POST-PCAPS|Parturients who underwent delivery by Caesarean Section in the period November 2010 - October 2011.
3074781|NCT02062307||control patients|BMI and age matched healthy male subjects
3074782|NCT02062307||hypogonadism patients|unconfounded group of patients with hypogonadism
3074783|NCT02062294||Cohort|
3074784|NCT02062281|Active Comparator|23-valent Pneumococcal Polysaccharide vaccine|"0.5ml 23-valent pneumococcal Polysaccharide vaccine made by Chengdu Institute of Biological Products Co.,Ltd.~lot number: 20130106-1, duration:JAN,17,2015."
3074785|NCT02062281|Active Comparator|Trivalent Influenza Vaccine|"0.5ml trivalent influenza vaccine made by Shanghai Institute of Biological Products Co.,Ltd.~lot number:20130713, duration:Jul,1,2014."
3074786|NCT02062281|Experimental|23vPPV+TIV|
3074787|NCT02062268||Urban area in South Jiangsu Province|health education & law enforcement
3074788|NCT02062268||urban area in Middle Jiangsu Province|health education & law enforcement
3074789|NCT02062268||urban area in North Jiangsu Province|health education & law enforcement
3074790|NCT02062268||rural area in South Jiangsu Province|health education & law enforcement
3074791|NCT02062268||rural area in North Jiangsu Province|health education & law enforcement
3074792|NCT02062255|Active Comparator|Aspirin|Twenty eight enteric coated 81mg Aspirin tablets will be dispensed for daily oral dosing, to be taken with a meal at the same time of day.
3074793|NCT02062255|Active Comparator|Omega-3 Free Fatty Acids|Three hundred thirty-six gelatin coated 450 mg capsules containing approximately 180 mg of EPA and 135 mg of DHA will be dispensed. Patients are to take 12 capsules daily with meals, either once daily (12 capsules with one meal) or divided twice daily (e.g., six with breakfast and six with dinner).
3074794|NCT02062255|Active Comparator|Aspirin & Omega-3 FFAs|Aspirin (81 mg po daily) to be taken simultaneously with Omega-3 Free Fatty Acids (1500mg of docosahexaoic acid (DHA) and 2500mg eicosapentanoic acid (EPA) given daily.
3074795|NCT02062242|Experimental|Transvaginal electrical stimulation|Patients treated with transvaginal electrical stimulation.
3074796|NCT02062242|Experimental|Palpation|Patients treated with vaginal palpation.
3074797|NCT02062242|Experimental|Palpation with posterior pelvic tilt|Patients treated with vaginal palpation associated with posterior pelvic tilt and contraction of accessory muscles.
3074798|NCT02062242|Experimental|Control group|Patients receive verbal instructions related to the pelvic floor and its contraction.
3074799|NCT02062229||Halthy controls|Subjects not affected by any disease and with normal seminal fluid characteristics
3074800|NCT02062229||Oligospermia|Infertile subjects with oligospermia
3074801|NCT02062229||Varicocele|Infertile subjects with varicocele
3074802|NCT02062229||Asthenospermia|Infertile subjects with asthenospermia
3074803|NCT02062216||STEMI|Patients with ST-elevation myocardial infarction (STEMI) with angiographic evidence of massive thrombosis in the culprit artery undergoing primary percutaneous coronary intervention (PCI)
3074804|NCT02062216||STABLE ANGINA|Patients with coronary artery disease in stable conditions scheduled to undergo elective percutaneous coronary intervention and patients with Class I indication to elective percutaneous coronary intervention
3074805|NCT02062203|Experimental|AKB-6548 (therapeutic dose)|
3074806|NCT02062203|Experimental|AKB-6548 (supratherapeutic dose)|
3074807|NCT02062203|Placebo Comparator|Placebo|
3074808|NCT02062203|Active Comparator|Moxifloxacin|
3074809|NCT02062190|Active Comparator|resveratrol|
3074810|NCT02062190|Placebo Comparator|corn starch|"(10 patients) 100mg 2x/day~1 month"
3074811|NCT02062177|Experimental|propofol group|70 patients (35 upper endoscopy - 35 colonoscopy)
3074812|NCT02062177|Active Comparator|midazolam group|70 patients (35 upper endoscopy - 35 colonoscopy)
3074813|NCT02062164||bariatric surgery group|subjects who participate in the overall project and undergo bariatric surgery
3074814|NCT02062164||conservative care group|subjects who participate in the overall project and do not undergo bariatric surgery
3074815|NCT02062151|Active Comparator|NAS babies|
3074816|NCT02062138|Active Comparator|continuous passive motion (CPM)|
3074817|NCT02062138|Experimental|controlled active motion (CAM I)|
3074818|NCT02062138|Experimental|controlled active motion (CAM II)|
3074819|NCT02062112|No Intervention|Unflavored group|The patient will mix 1 gallon of polyethylene glycol with water and drink as directed by his/her endoscopist. No flavoring will be added.
3074820|NCT02062112|Active Comparator|Flavored group|The patient will mix 1 gallon of polyethylene glycol with water, add flavoring to the entire solution and drink at the time specified by his/her endoscopist.
3074821|NCT02062112|Active Comparator|Liberal group|The patient will mix 1 gallon of polyethylene glycol with water. Fill 2 cups with the solution. The patient will add flavoring to one cup and drink both the flavored and unflavored solutions in the cups. The patient will then determine how he/she wants to drink the rest of the bowel preparation laxatives based on their taste preference and drink at the time specified by his/her endoscopist.
3074822|NCT02062099|Experimental|Memory complaint /MCI/ mild to moderate MA|Memory complaint (without cognitive decline): 12 patients/ Mild Cognitive Impairment: 12 patients/ Mild to moderate Alzheimer Disease: 12 patients
3074823|NCT02062086|Other|Population 1|"(Community-dwelling older adults) will participate in the study for approximately 65 days.~Population 1 will absorb deuterated creatine 30 mg, a non-radioactive, stable isotope of creatine, for the estimation of muscle mass in humans.~The estimation of muscle mass will be made on 2 separate occasions in the community-dwelling elderly population in order to assess reproducibility of the method when tested approximately 60 days apart."
3074824|NCT02062086|Other|Population 2|"(Hip-fracture patients) will participate in the study for approximately 35 days during their in-hospital period, followed by 30 during their post-discharge period, so for a total period of at least 65 days.~Population 2 will absorb deuterated creatine 30 mg, a non-radioactive, stable isotope of creatine, for the estimation of muscle mass in humans.~In the hip fracture population, estimation of muscle mass by the D3 creatine method will be performed on up to 3 separate occasions to assess whether the method is sensitive enough to detect decreases in muscle mass that may occur during the recovery period after hip fracture."
3074825|NCT02062073|Active Comparator|Abametapir Lotion 0.74%|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
3074826|NCT02062073|Placebo Comparator|Vehicle Lotion|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
3074827|NCT02062073|Other|0.1% sodium lauryl sulfate|Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
3074828|NCT02062073|Other|Saline 0.9%|Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
3074829|NCT02062060|Active Comparator|Abametapir Lotion 0.74% w/w|Single topical treatment administered to scalp and hair for 10 minutes. Applied at home by subject/caregiver.
3074830|NCT02062060|Placebo Comparator|Vehicle Lotion|Single topical treatment administered to scalp and hair for 10 minutes. Applied at home by subject/caregiver.
3074831|NCT02062047|Experimental|FMSRP+CLX|Full-mouth scaling and root planing in a maximum of 24 hours, application and irrigation of chlorhexidine 2% gel, rinsing chlorhexidine 0.12% solution during 60 days
3074832|NCT02062047|Placebo Comparator|FMSRP + placebo group|Full-mouth scaling and root planing in a maximum of 24 hours, application and irrigation of placebo, rinsing placebo solution during 60 days
3074833|NCT02062047|Active Comparator|PMSRP group|Partial-mouth scaling and root planing in 4-6 sessions in a maximum of 2 weeks
3074834|NCT02062034|Experimental|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
3074835|NCT02062034|Experimental|Combined antioxidant therapy|(1mg copper + 20mg zinc + 180mg vitamin C + 30mg vitamin E + 1mg zeaxanthin + 4mg astaxanthin + 10mg lutein) daily of oral antioxidant combined therapy for 24 weeks
3074836|NCT02062034|Placebo Comparator|Placebo|Placebo. 100mg daily oral intake for 24 weeks
3074837|NCT02062008|Other|Cardiac patients receiving PET/MR|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
3074838|NCT02061995|Experimental|PREOB® Intravenous Infusion|
3074839|NCT02061982|Experimental|Caffeine|Instant coffee with or without caffeine will be provided
3074840|NCT02061982|Placebo Comparator|Coffee without caffeine|Coffee without caffeine
3074841|NCT02061969|Active Comparator|Insulin glargine|Insulin glargine starting at 0.1 unit/kg/day added to ongoing metformin if the patient is already on it. The duration will be for a 6-month period.
3074842|NCT02061969|Experimental|linagliptin|Oral linagliptin 5mg once daily added to ongoing metformin if the patient is already on it. The duration will be for a 6-month period.
3074843|NCT02061956||HCC received TACE|Patients with HCC in cancer center, Sun Yat-sen University received TACE between 2011.01-2011.12
3074844|NCT02061930||single crowns supported by implants|single crowns supported by implants placed in the anterior maxilla region, periodontally healthy
3075006|NCT02060851|Placebo Comparator|group 1|no intravenous iron or EPO
3074847|NCT02061917|Experimental|Tobacco-Burning Cigarette|A group of 44 subjects who smoke and are switched to a tobacco-burning ultra-low machine yield cigarette
3074848|NCT02061904|Other|Bone Mineral Density|"Bone mineral density measurement with intervention DEXA at the bone impaction graft site:~DEXA: dual energy X-ray absorptiometry"
3074849|NCT02061904|Other|Hip function|"Hip Function/mobility development:~Harris Hip Score"
3074850|NCT02061904|Other|pain experience|Pain experiences after surgery in the hip joint VAS-pain
3074851|NCT02061904|Other|General Patients Health condition|"Patients health condition monitoring: intervention SF12:~Short Form Health Survey 12"
3074852|NCT02061904|Other|Intervention Satisfaction|Patients satisfaction development after the intervention VAS-satisfaction
3074853|NCT02061891|Active Comparator|Deferred invasive evaluation|Deferred invasive coronary evaluation and revascularization (PCI/CABG) within 72 hours from time of clinical diagnosis (CONTROL group)
3074854|NCT02061891|Experimental|Very early invasive evaluation|Acute invasive coronary evaluation within 12 hours from time of diagnosis - INTERVENTION group
3074855|NCT02061878|Experimental|Bexarotene|The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days
3074856|NCT02061878|Placebo Comparator|Placebo|The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
3074857|NCT02061865|Experimental|Cohorts 1 - 4|Participants in cohort 1 will receive REGN2176-3 dosing regimen 1. Participants in cohort 2 will receive REGN2176-3 dosing regimen 2. Participants in cohort 3 will receive REGN2176-3 dosing regimen 3. Participants in cohort 4 will receive REGN2176-3 dosing regimen 4.
3074858|NCT02061852|Active Comparator|Physiotherapy|Traditional techniques
3074859|NCT02061852|Experimental|simeox|Medical device
3074860|NCT02061839|Experimental|Teinted sunscream|UVA, UVB and visible light protection (exactly the same UVA and UVB protection as the comparator)
3074861|NCT02061839|Active Comparator|Regular sunscream|UVA and UVB protection
3074862|NCT02061813|Experimental|Abametapir lotion 0.74% w/w|Applied 0.2 mL topically under occlusive condition
3074863|NCT02061813|Placebo Comparator|Vehicle lotion|Applied 0.2 mL topically under occlusive condition
3074864|NCT02061813|Other|Sodium Lauryl Sulfate|Positive control applied 0.2 mL topically under occlusive condition
3074865|NCT02061813|Other|Saline 0.9%|Negative control applied 0.2 mL topically under occlusive condition
3074866|NCT02061800|Active Comparator|Full intensity with TBI|Patients will start their pre-conditioning regimen on 8 days before scheduled transplant. Fractionated total body irradiation (TBI) will be administered twice daily on the 6th, 7th, and 8th before transplant. Patients will receive Thiotepa on the 4th and 5th day before transplant, Cyclophosphamide on the 2nd and 3rd day before transplant, and Alemtuzumab on the 1st-5th day(s) before transplant. Then the stem cell infusion will be performed (allogeneic family member or ≥ 8/10 HLA matched adult unrelated donor peripheral blood stem cell transplantation with CD34 Selection using CliniMACS CD34+ Reagent System). GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after transplant, and methylprednisolone will start on day -5.
3074867|NCT02061800|Experimental|Full intensity without TBI|Patients will start their pre-conditioning regimen 9 days before their scheduled transplant. Patients will receive busulfan twice daily on the 5th-8th day before transplant, and Melphalan on the 2nd-4th days before transplant and Alemtuzumab on the 1st-5th day before transplant. Subjects will then undergo with their stem cell infusion (allogeneic family member or ≥ 8/10 HLA matched adult unrelated donor peripheral blood stem cell transplantation with CD34 Selection using CliniMACS CD34+ Reagent System) and GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after their transplant, and methylprednisolone will start on day -5.
3074868|NCT02061800|Experimental|Reduced intensity|Patients will begin tacrolimus 8 days pre-transplant, and then will receive alemtuzumab on the 3rd-7th day pre-transplant; busulfan twice daily on the 5th-8th day pre-transplant; and fludarabine on the 2nd-7th day pre-transplant. Methylprednisolone will start on day -7.The stem cell infusion will be performed (with CD34 Selection using CliniMACS CD34+ Reagent System). GVHD prophylaxis will consist of tacrolimus or sirolimus. For patients with a history of hepatic toxicity and/or high-risk for veno-occlusive disease or other liver toxicity post stem cell transplant, melphalan at 70 mg/m2 will be substituted for Busulfan, followed by fludarabine on the 2nd-7th day before transplant and alemtuzumab on the 3rd-7th day before transplant.
3074869|NCT02061787||cardiopulmonary exercise testing|cardiopulmonary exercise testing
3074870|NCT02061774|Active Comparator|acetaminophen|1g intravenous acetaminophen over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours; maximum dose of 4 grams in 24 hours
3074871|NCT02061774|Placebo Comparator|PlaceboComparator|Placebo Comparator 0.9% NaCl 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
3074872|NCT02061761|Experimental|BMS-986016|BMS-986016 specified dose on specified days
3074873|NCT02061761|Experimental|BMS-986016 + BMS-936558|BMS-986-016 + BMS-936558 specified dose on specified days
3074874|NCT02061748||dabigatran|
3074875|NCT02061748||warfarin|
3074876|NCT02061735||oral propranolol|Dosage of 1 mg/kg per day divided 2 times daily. Blood pressure, heart rate and oxygen saturation are monitored after propranolol initiation. Treatment is continued with a gradual increase to 2 mg/kg per day divided 2 times daily. Treatment is continued until the hemangioma no longer changes in the characteristics judged by the physicians, including, color, size, temperature and deformability.
3074877|NCT02061735||timolol maleate 0.5% gel|One drop of of timolol maleate 0.5% gel is topically applied and massaged into the hemangioma twice per day . This dosage provides an estimated 0.5 mg of timolol per day. The treatment is continued until it is considered to be no longer effective as judged by the physicians.
3074878|NCT02061735||No treatment, observation only|No oral or topical treatment will be given as recommended by the treating physicians and elected by the parents. Patients will be evaluated periodically to determine what changes in treatment are warranted. If this occurs, the patients will be included in the appropriate study group.
3074918|NCT02061462|Active Comparator|EVLP-DCD Group|Recipients of lungs procured from DCD donors, reconditioned/evaluated by EVLP
3074879|NCT02061722|Experimental|PET Imaging with [18F]MNI-659|"All subjects (both HDGECs and HCs) will receive single intravenous doses of the radioligands [11C]raclopride (non-investigational medicinal product [NIMP]) and [18F]MNI-659 (investigational medicinal product [IMP]).~The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
3074880|NCT02061709|Experimental|Ragweed-SPIRE 1|Ragweed SPIRE regimen 1 given 2 weeks apart
3074881|NCT02061709|Experimental|Ragweed-SPIRE 2|Ragweed-SPIRE regimen 2 given 2 weeks apart
3074882|NCT02061709|Experimental|Ragweed-SPIRE 3|Ragweed-SPIRE regimen 3 given 2 weeks apart
3074883|NCT02061709|Placebo Comparator|Placebo|Placebo given 2 weeks apart
3074884|NCT02061696|Active Comparator|Standard Manual Compression|Standard manual compression at the access site applied as per standard of care protocol for sheath removal.
3074885|NCT02061696|Active Comparator|AXERA 2 Access System|The Vascular Access device used is the AXERA 2 Access System for patients randomized to this arm.
3074886|NCT02061683|Experimental|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
3074887|NCT02061670|Experimental|Ragweed-SPIRE 1|Ragweed-SPIRE regimen 1 given 2 weeks apart
3074888|NCT02061670|Experimental|Ragweed-SPIRE 2|Ragweed-SPIRE regimen 2 given 2 weeks apart
3074889|NCT02061670|Placebo Comparator|Placebo|Placebo given 2 weeks apart
3074890|NCT02061657|Experimental|Myomectomy, rectal Misoprostol|25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation.
3074891|NCT02061657|Active Comparator|Myomectomy, Placebo|Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
3074892|NCT02061644|Experimental|Spinal|Spinal anesthesia for surgical procedure will be applied to the patients. Intraocular pressures will be measured before and after the procedure.
3074893|NCT02061631|Experimental|Docetaxel, Cisplatin|"Induction:One-hour intravenous infusion of docetaxel at 75 mg/m2 followed by a 30 minute intravenous infusion of cisplatin at 75 mg/m2. All patients to be pre-medicated with oral dexamethasone at 8 mg twice daily for 3 days, commencing one day before docetaxel infusion. All patients will be premedicated with intravenous dexamethasone 20 mg to be administered before cisplatin infusion. Docetaxel and cisplatin treatments to be repeated every 21 days for three cycles.~Chemoradiotherapy (CRT): Cisplatin to be administered by 30 minutes intravenous infusion at a dose of 30 mg/m2 weekly starting concomitantly with conventional radiotherapy for a period of 6 weeks. Intravenous cisplatin to be continued for four weeks.~Radiotherapy: Gross disease dose will be 60 Gy/30 fractions and sub clinical dose 45-50 Gy/30 fractions."
3074894|NCT02061618|No Intervention|Usual Care|
3074895|NCT02061618|Experimental|Bollywood Dance Exercise|Participants in the Bollywood Dance Exercise group will take part in an 8-week dance intervention. The dance classes will take place 2 times per week, approximately 60 minutes per class, for 8 weeks total.
3074896|NCT02061605|Experimental|Laser Tissue Welding Device|"The laser tissue welding device is intended for use in patients requiring laparoscopic surgery requiring hemostasis and sealing of the resected kidney after partial nephrectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure.~The device's intended use is to seal the kidney surface using a laser to weld human albumin based biomaterials after surgical removal of kidney tumors during a laparoscopic partial nephrectomy."
3074897|NCT02061592|Active Comparator|Etafilcon A Control Lens|etafilcon A
3074898|NCT02061592|Experimental|Etafilcon A Test Lens|etafilcon A
3074899|NCT02061579|Experimental|Once-Weekly Structured Contact|Participants in the Once Weekly Structured Contact group will take part in an 6-month exercise intervention and attend one structured group exercise session per week. They will engage in aerobic and resistance training for approximately 80 minutes per exercise session. Additionally, they will attend three exercise evaluations and six study visits.
3074900|NCT02061579|Experimental|Thrice-Weekly Structured Contact|Participants in the Thrice-Weekly Structured Contact group will take part in an 6-month exercise intervention and attend three structured group exercise sessions per week. In total, they will engage in aerobic and resistance training sessions for approximately 200 minutes per week. Additionally, they will attend three exercise evaluations and six study visits.
3074901|NCT02061579|No Intervention|Usual Care|Participants in the Usual Care group will not take part in an 6-month exercise intervention. They will continue to seek regular care from their primary care providers and attend six study visits.
3074902|NCT02061566||Acute kidney injury|Acute kidney injury in ICU
3074903|NCT02061566||Non acute kidney injury|Non acute kidney injury
3074904|NCT02061553|Experimental|Intention|SMS messages containing self-statements in the form of BA- based implementation intentions.
3074905|NCT02061553|Active Comparator|Motivation|SMS messages with self-selected motivational statements.
3074906|NCT02061540|Experimental|LUM001|LUM001 administered orally once each day
3074907|NCT02061527|Experimental|Breast reconstruction with ADM|Implant based Breast Reconstruction with ADM. Both arms will undergo skin or nipple sparing mastectomy and immediate breast reconstruction with implants. Patients in group B with ADM and partial submuscular coverage.
3074908|NCT02061527|Active Comparator|Breast reconstruction without ADM|Breast reconstruction without ADM. Both arms will undergo skin or nipple sparing mastectomy and immediate breast reconstruction with implant. Patients in group B will be reconstructed with implant and total submuscular coverage.
3074909|NCT02061514|Experimental|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
3074910|NCT02061514|Active Comparator|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
3074911|NCT02061501|Active Comparator|Speech therapy|Speech therapy (30 min per week) alone for the 6 first months. Then speech therapy (30 min per week) and optometric therapy (30 min per week) for the 6 last months.
3074912|NCT02061501|Experimental|Speech therapy and optometric therapy|Speech therapy (30 min per week) and optometric therapy (30 min per week) for 12 months.
3074913|NCT02061488|Active Comparator|open-loop night|
3074914|NCT02061488|Experimental|closed-loop night|
3074919|NCT02061449|Experimental|Initiating therapy with Romidepsin (Arm A)|Patients who are starting therapy with Romidepsin (intravenously on days 1, 8, and 15 of every 21-day cycle or alternate schedule per treating physician) also receive focal lesional radiation on days 1,3, and 5 without (level 1) or with (level 2) Poly ICLC (subcutaneously on days 1, 3, and 5) on the first cycle.
3074920|NCT02061449|Experimental|treatment with Romidepsin with SD or PR (Arm B)|Patients with stable disease on the treatment with Romidepsin (intravenously on days 1, 8, and 15 of every 21-day cycle or alternate schedule per treating physician) also receive focal lesional radiation on days 1,3, and 5 without (level 1) or with (level 2) Poly ICLC (subcutaneously on days 1, 3, and 5) on the first cycle.
3074921|NCT02061423|Experimental|HER-2 Pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months.
3074922|NCT02061410|Experimental|Neuromuscular Electrical Stimulation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
3074923|NCT02061397|Experimental|single simvastatin treatment arm|Simvastatin 20 mg oral daily for 2 months; if tolerated, followed by simvastatin 40 mg oral daily for 2 months
3074924|NCT02061384|Experimental|13-cis retinoic acid|20mg 13-cis retinoic acid twice daily (BID) with meals for 20 weeks
3074925|NCT02061384|Experimental|Calcitriol 0.25 mcg|oral calcitriol 025 mcg BID subjects 11-20 for 20 weeks
3074926|NCT02061371|Experimental|virtual therapy|Group 1 (G1) included 20 patients who will carry out the virtual therapy.
3074927|NCT02061371|Experimental|conventional physiotherapy|Group 2 (G2) included 20 patients who hold conventional physiotherapy.
3074928|NCT02061358|Experimental|Cohort 1 - 3 mg UV-4B|Subjects receiving UV-4B 3 mg oral solution or placebo
3074929|NCT02061358|Experimental|Cohort 2 - 10 mg UV-4B|Subjects receiving UV-4B 10 mg oral solution or placebo
3074930|NCT02061358|Experimental|Cohort 3- 30 mg UV-4B|Subjects receiving UV-4B 30 mg oral solution or placebo
3074931|NCT02061358|Experimental|Cohort 4 - 90 mg UV-4B|Subjects receiving UV-4B 90 mg oral solution or placebo
3074932|NCT02061358|Experimental|Cohort 5 - 180 mg UV-4B|Subjects receiving UV-4B 180 mg oral solution or placebo
3074933|NCT02061358|Experimental|Cohort 6 - 360 mg UV-4B|Subjects receiving UV-4B 360 mg oral solution or placebo
3074934|NCT02061358|Experimental|Cohort 7 - 720 mg UV-4B|Subjects receiving UV-4B 720 mg oral solution or placebo
3074935|NCT02061358|Experimental|Cohort 8 - 1000 mg UV-4B|Subjects receiving UV-4B 1000 mg oral solution or placebo
3074936|NCT02061345||MCI|Prostate cancer patients having mild cognitive impairment (MCI) attributable to ADT with LHRHa
3074937|NCT02061345||Control|Prostate cancer patients on ADT with LHRHa not having mild cognitive impairment
3074938|NCT02061332|Experimental|Intranodal Vaccine|An ultrasound device (probe) will be placed over the area of the groin or armpit. The vaccine needle will then be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes per visit. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into 1-2 different groin lymph nodes or axillary nodes.
3074939|NCT02061332|Experimental|Intralesional Vaccine|The HER-2 pulsed dendritic cell vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into the quadrant of the breast affected with DCIS.
3074940|NCT02061332|Experimental|Intranodal + Intralesional Vaccine|You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes and the quadrant of the breast affected with DCIS. An ultrasound device (probe) will be placed over the groin or armpit. The vaccine needle will be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. The intralesional vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells. Approximately half of the dose will be injected into 1-2 different groin lymph nodes or axillary nodes. The remaining half will be injected into the quadrant of the breast affected with DCIS.
3074941|NCT02061319|Experimental|Nordic Walking Group|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
3074942|NCT02061319|No Intervention|Standard Exercise Therapy|Individuals assigned to standard exercise therapy will attend on-site exercise classes twice weekly for 12 weeks. Each on-site class will be one hour in duration and consist of: a 15-minute chair-based warm-up that includes 6-8 upper and lower body resistance training exercises using either hand-held weights or therabands at an intensity of 50-60% of 1- RM with the patient completing one set of 10-12 repetitions progressing to 15 repetitions before increasing the intensity by 5-10%; 10-15 minutes of walking for the first 3 weeks, progressing to 30 minutes of continuous walking for the remaining 9 weeks; and 15 minutes of cool down exercises. A strength training program will be provided to participants and they will be encouraged to do one additional strength training session at home. Participants will also be instructed to complete additional walking sessions at home so that they can accumulate a total of 200-400 minutes of exercise per week.
3074943|NCT02061306||Infants with a first-degree relative with celiac disease|Infants who have a first-degree relative diagnosed with celiac disease.
3074944|NCT02061293|Experimental|Psilocybin|Psilocybin 25 mg/70 kg PO administered at week 4, 25-40 mg/70 kg PO administered at week 8. Psilocybin 25-40 mg/70 kg administered at 38 weeks.
3074945|NCT02061293|Active Comparator|Diphenhydramine|Diphenhydramine 50 mg PO administered at week 4, 50-100 mg PO administered at week 8. Psilocybin 25 mg/70 kg administered at 38 weeks.
3075003|NCT02060864|Experimental|AN-PEP 80.000 PPI|1 pill AN-PEP 80.000 PPI and 1 pill Placebo.
3074946|NCT02061280|Experimental|MICT Trial Design|"Participants randomized to MICT will complete study procedures using an iPad for data entry and FaceTime visits rather than coming into the study site for onsite visits. Participants will perform spirometry at home using a handheld spirometer, EasyOne Plus.~Randomized to one of 3 study treatments:~fluticasone/salmeterol 250/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone/salmeterol 100/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone 100mcg Dry Powder Inhaler one inhalation twice daily"
3074947|NCT02061280|Active Comparator|LASST Trial Design|"Participants randomized to LASST will complete study procedures in the traditional format in which all study visits are conducted at the study site, all questionnaires are completed by pen/paper, and all spirometry is performed at the clinic site.~Randomized to one of 3 study treatments:~fluticasone/salmeterol 250/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone/salmeterol 100/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone 100mcg Dry Powder Inhaler one inhalation twice daily."
3074948|NCT02061267|Experimental|Niacin Control|The subjects will receive a vitamin B3 supplement (2 g)
3074949|NCT02061267|Experimental|Niacin + SAT|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
3074950|NCT02061267|Experimental|Niacin + ROO|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
3074951|NCT02061267|Experimental|Niacin + O3|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
3074952|NCT02061254|Experimental|3 groups of subjects|"3 groups:~group of 48 healthy volunteers (matched with venous insufficiency patients)~group of 48 patients with venous insufficiency (16 with stage 1/2, 16 with stage 3/4, 16 with stage 5/6)~group of 40 patients with unilateral lymphedema (20 on upper limb (10 early stage, 10 severe stage), and 20 on lower limb (10 early stage, 10 severe stage))~Each group have the same interventions: physical examination, measures by cutometer, high resolution ultrasonography, elastography 30 persons will have a skin biopsy (15 healthy volunteers and 15 patients with venous insufficiency) For patients with lymphedema, all measures will be performed on lymphedema limb and on controlateral healthy limb"
3074953|NCT02061241||Patients|All included patients, having CRT implant procedure Will have both Pacing in vein at site of latest mechanical activation and Pacing in other suitable vein.
3074954|NCT02061228|No Intervention|Control arm|Women undergoing exogenous gonadotropin ovarian stimulation for ART in an antagonist downregulated cycle.
3074955|NCT02061228|Experimental|Induced endometrial injury arm|Women undergoing exogenous gonadotropin ovarian stimulation for ART in an antagonist downregulated cycle. Additionally, they will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France).
3074956|NCT02061215||recipients aged 20-40|CMV viral load
3074957|NCT02061215||recipients older than 60|CMV viral load
3074958|NCT02061202|Experimental|Mometasone Furoate|1 puff daily (220mcg) for 16 weeks
3074959|NCT02061202|Placebo Comparator|Placebo|1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo).
3074960|NCT02061189|Experimental|Swimming pool training group|"10 patients will be selected to perform a 6 months training in a swimming pool, from M12 to M18, in defined and reproducible conditions.~M0, M6, M12 and M18 assessments: Medical examination + MFM + Hammersmith scale + Non-invasive motor capacity analysis.~M12 to M18 (26 weeks): Physical exercise in a swimming pool (3 times per week).~M24: Medical examination + MFM + Hammersmith scale + Non-invasive motor capacity analysis."
3074961|NCT02061189|No Intervention|Control group|"20 patients with same assessments at M0, M6, M12 and M18, but:~without swimming pool training.~without M24 assessment."
3074962|NCT02061176|Experimental|Transanal Haemorrhoidal Dearterialization|Patients randomised to Transanal Haemorrhoidal Dearterialization.
3074963|NCT02061176|Active Comparator|Open Haemorrhoidectomy|Patients randomised to Open Haemorrhoidectomy
3074964|NCT02061163|Experimental|Subjects with Crohn's disease|Contrast Enhanced Ultrasound Optison
3074965|NCT02061150||Asymptomatic newborns that had sepsis workup|Evaluation of medical records of asymptomatic newborns that had sepsis workup in the first 48 hours of life.
3074966|NCT02061137|Experimental|Rett syndrome, fingolimod (FTY720)|0.5 or 0.25mg Fingolimod daily
3074967|NCT02061124|Active Comparator|T2DM, sevelamer|Patients with type 2 diabetes treated with sevelamer
3074968|NCT02061124|Placebo Comparator|T2DM, placebo|Patients with type 2 diabetes treated with placebo
3074969|NCT02061124|Active Comparator|Healthy subjects, sevelamer|Healthy subjects treated with sevelamer
3074970|NCT02061124|Placebo Comparator|Healthy subjects, placebo|Healthy subjects treated with placebo
3074971|NCT02061111||Subclinical thyroid disease|26 pregnant women with subclinical hypothyroidism and/orTPO-antibodies, and their offspring.
3074972|NCT02061111||Healthy controls|51 pregnant women without thyroid disease or any other metabolic disorders, and their offspring.
3074973|NCT02061098|Experimental|Pomegranate extract|"Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.~Group A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks."
3074974|NCT02061098|Placebo Comparator|Placebo|"Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.~Group A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks."
3074975|NCT02061085|Experimental|monotherapy treatment with Eribulin|Eribulin Dosage: 1.4 mg/m2 Route of administration: IV bolus Schedule of cycle: D1 and D8 every 21 days
3074976|NCT02061072||Population pharmacokinetic estimation|Patients with severe or moderate hemophilia A or B, providing sparse data for population PK estimation
3074977|NCT02061059|Other|group 1|"group is assigned to block 1: shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements.~group is assigned to standard: wears shoes produced with standard procedure"
3074978|NCT02061059|Other|group 2|"group is assigned to block 1: shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements~group is assigned to with measurements: wears shoes produced with plantar pressure measurements"
3074979|NCT02061059|Other|group 3|"group is assigned to block 2: shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements~group is assigned to standard: wears shoes produced with standard procedure"
3074980|NCT02061059|Other|group 4|"group assigned to block 2: shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements~group is assigned to with measurements: wears shoes produced with plantar pressure measurements"
3074981|NCT02061046||On CPAP therapy|OSA patients assessed before and after 8 weeks of CPAP therapy
3074982|NCT02061020|Experimental|Sequence 1|"THC containing cigarettes 10mg~THC containing cigarettes 30mg~Placebo"
3074983|NCT02061020|Experimental|Sequence 2|"THC containing cigarettes 30mg~Placebo~THC containing cigarettes 10mg"
3074984|NCT02061020|Experimental|Sequence 3|"Placebo~THC containing cigarettes 10mg~THC containing cigarettes 30mg"
3074985|NCT02061007|Experimental|Scans, Surgery and Follow-up|Pre-surgery scans, surgical resection and post-surgery follow-up. All patients will receive a fluorodeoxyglucose (FDG)-PET scan as part of standard of care. This scan must be completed within 28 days of surgery for the patient to be eligible. All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered. Prior to surgery, patients will be administered a single dose of 0.5 g/m^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
3074986|NCT02060994||37-38 weeks|"Children who were born by elective Cesarean section after 37-38 gestational weeks.~Intervention: No intervention."
3074987|NCT02060994||39 week or more|Children who were born by elective Cesarean section after 39 gestational weeks or more Intervention: No intervention.
3074988|NCT02060981|Active Comparator|Interview only|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension.
3074989|NCT02060981|Placebo Comparator|Control|Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey. These patients will be asked to review the brochure, complete the survey, and mail it back to the research team using a self-addressed stamped envelope.
3074990|NCT02060981|Experimental|Interview plus decision support tool|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension, and to provide feedback regarding a new tool for helping patients learn more about their medications. Interview plus patients' index date for follow-up is the date of the scheduled interview.
3074991|NCT02060968||IRIS PREMIER Cohort|Promus PREMIER
3074992|NCT02060955|Experimental|Alecsat|"The experimental product is an autologous product based on the individual patients blood. Blood donation are performed in study weeks 0, 6, 11, 23 and 43.~The patient receives treatment as bolus injection at study weeks 4, 9, 14, 26 and 46."
3074993|NCT02060955|Active Comparator|bevacizumab/irinotecan|Patients allocated to the comparator arm will be treated in accordance with standard practice in Denmark for relapsed glioblastoma multiforme, up to 16 treatment cycles with 4 weeks duration
3074994|NCT02060942||Coronary artery bypass grafting|Post Anaesthetic Care Unit (PACU) patients treated with coronary artery bypass grafting (CABG) are highly eligible for this study. These are patients with an indication for fast track treatment (PACU) post-cardiac surgery with a good left ventricular ejection fraction without significant co-morbidity. The final decision for PACU-classification is taken by the responsible anaesthesiologist and intensivist in close collaboration with the cardiothoracic surgeon performing the operation, as well as the cardiologist.
3074995|NCT02060929|Experimental|Sequence 1|Participants will self administer 1 spray of esketamine solution to each nostril using a intranasal (through nose) device with a nasal guide on Day 1 of period 1 as treatment regimen A at time 0 and repeated twice every 5 minutes (total dose: 84 mg). There will be a washout period of 5-10 days between the treatment regimens. On Day 1 of period 2, participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device without a nasal guide as treatment regimen B at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
3074996|NCT02060929|Experimental|Sequence 2|Participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device without a nasal guide on Day 1 of period 1 as treatment regimen B at time 0 and repeated twice every 5 minutes (total dose: 84 mg). There will be a washout period of 5-10 days between the treatment regimens. On Day 1 of period 2, participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device with a nasal guide as treatment regimen A at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
3074997|NCT02060916|Experimental|PAZ320|Patients will all take part in the control arm of the study and then be crossed over into treatment with PAZ320 at two different dosages.
3074998|NCT02060903|Active Comparator|Abametapir Lotion 0.74% w/w|Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.
3074999|NCT02060903|Placebo Comparator|Vehicle Lotion|Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.
3075000|NCT02060890||Group A|Patients will undergo collection of tumor at the time of tumor resection and after confirmation of tumor progression and will have blood samples drawn pre-surgery and during standard of care follow-up visits. Patients will then be provided with a specialized tumor board recommendations for personalized treatment options for up to 4 medications based on the specimen analysis results within 35 days of surgery. Patients may then elect to initiate recommended therapy within 42 days of surgery.
3075001|NCT02060877||patients suspected of having lung cancer|observational study, there is no study intervention, only patient questionnaires
3075002|NCT02060864|Placebo Comparator|Placebo|2 Placebo pills
3075008|NCT02060838||Acute normovolemic hemodilution (ANH)|Patients undergoing acute normovolemic hemodilution (ANH) as part of their cardiac surgery.
3075009|NCT02060825||Regional saturation monitor|Patients undergoing surgical repair of hypoplastic left heart syndrome.
3075010|NCT02060812|Experimental|Group I, SSNB & ANB|21 patients were randomly allocated into group I, and received suprascapular nerve block (SSNB) and axillary nerve block (ANB) both with 10mL ropivacaine.
3075011|NCT02060812|Placebo Comparator|Group II, SSNB alone|The other 21 patients were allocated into group II, and received suprascapular nerve block (SSNB) with 10mL ropivacaine and axillary nerve block (ANB) with placebo (10mL normal saline).
3075012|NCT02060786|Active Comparator|original Clopidogrel Bisulfate (Plavix®)|original Clopidogrel Bisulfate (Plavix®) 600mg loading
3075013|NCT02060786|Experimental|generic Clopidogrel Bisulfate (Plavitor®)|generic Clopidogrel Bisulfate (Plavitor®) 600mg loading
3075014|NCT02060760||UTROPIA study cohort|At least two cTnI data points available (including baseline) with blood samples available for hs-cTnI testing. No intervention.
3075015|NCT02060747|Experimental|Coordinator-based post fracture program|The intervention arm deals with the intervention of a nurse trained in the management of osteoporosis fractures assisted by a clinical research technician who will manage the logistics and reglementary aspects of the study (patient enrollment, quality and study proceedings).
3075016|NCT02060747|No Intervention|standard care|
3075017|NCT02060734|Experimental|lidocaine|The treatment group will receive a 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point. Three to five points injection.
3075018|NCT02060734|Active Comparator|Saline|The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
3075019|NCT02060721|Experimental|Macitentan|Macitentan 10mg, oral tablet, once daily
3075020|NCT02060708|Other|Real HD-tDCS first, Sham HD-tDCS second|Real HD-tDCS will be applied in the first session Sham HD-tDCS will be applied in the second session (at least one week after the first session)
3075021|NCT02060708|Other|Sham HD-tDCS first, Real HD-tDCS second|Sham HD-tDCS will be applied in the first session Real HD-tDCS will be applied in the second session (at least one week after the first session)
3075022|NCT02060682||Navvus Catheter FFR|The Navvus Catheter is a rapid exchange microcatheter with a pressure sensor at the distal tip that measures Fractional Flow Reserve measurements to guide PCI treatment strategy.
3075023|NCT02060669|Experimental|Arm 1|xeloda maintaenance
3075024|NCT02060669|No Intervention|Arm 2|best supprotive care
3075025|NCT02060656|Active Comparator|Control: R-GEM-P|Rituximab,Gemcitabine, Methylprednisolone,Cisplatin.
3075026|NCT02060656|Experimental|Experimental: LR-GEM|Lenalidomide, Rituximab, Gemcitabine, Methylprednisolone
3075027|NCT02060643||Cross-sectional hemi-neck RT|
3075028|NCT02060630|Other|Available vein, open surg. revasc.|Subjects with an available SSGSV cohort randomized to open surgical revascularization
3075029|NCT02060630|Other|Available vein, endovasc. revasc.|Subjects with an available SSGSV cohort randomized to endovascular revascularization
3075030|NCT02060630|Other|Alternative conduit, open surg. revasc.|Subjects with an alternative conduit cohort randomized to open surgical revascularization
3075031|NCT02060630|Other|Alternative conduit, endovasc. revasc.|Subjects with an alternative conduit cohort randomized to endovascular revascularization
3075032|NCT02060617|Experimental|Impairment-Based Group|The impairment-based intervention will be a multi-modal treatment approach utilizing manual therapy of the thoracolumbosacral spine and hips as well as motor control exercises. Patient education will also be provided.
3075033|NCT02060617|Active Comparator|Classification-Based Group|Patients in this group will be categorized into subgroups according to the Treatment-Based Classification (TBC) Algorithm and treated accordingly. Patient education will also be provided.
3075034|NCT02060604|Experimental|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed plus ketorolac eyedrops TID
3075035|NCT02060604|Active Comparator|Ranibizumab Alone|3 monthly ranibizumab, then as needed
3075036|NCT02060591|Active Comparator|Exparel|
3075037|NCT02060591|Active Comparator|Marcaine|
3075038|NCT02060578|Other|Intervention|Questionnaire completed by the parents Interview with the parents and the psychologist (University Rennes 2)
3075039|NCT02060565||Chronic liver disease|all patients with chronic liver disease followed using non-invasive methods
3075040|NCT02060552|Placebo Comparator|Febuxostat|Febuxostat 40mg once a day
3075041|NCT02060552|Experimental|Febuxostat plus diacerein|Febuxostat 40mg once a day plus diacerein 50mg twice a day
3075042|NCT02060552|Experimental|Febuxostat plus Colchicine|Febuxostat 40mg once a day plus Colchicine 0.5mg twice a day
3075043|NCT02060539|Experimental|Biofinity XR|Participants dispensed Biofinity XR lenses over two weeks of lens wear
3075044|NCT02060526|Active Comparator|45 mg Q2W|rhHNS 45 mg administered intrathecally Q2W (once every 2 weeks ie, every 14 days), for 48 weeks via the surgically implanted IDDD (or LP)
3075045|NCT02060526|Active Comparator|45 mg Q4W|rhHNS 45 mg administered intrathecally Q4W (once every 4 weeks ie, every 28 days), for 48 weeks via the surgically implanted IDDD (or LP)
3075046|NCT02060526|Placebo Comparator|Placebo|The comparator group will receive no treatment with rhHNS.
3075047|NCT02060500|Experimental|Cardiaplication|
3075048|NCT02060487|Experimental|Low dose|
3075049|NCT02060487|Experimental|Medium dose|
3075050|NCT02060487|Experimental|High dose|
3075051|NCT02060474|Experimental|AHDS patients|all AHDS recruited for this study will be located in the experimental arm and will receive the investigational medicinal product Triac. The Triac dose will be individually titrated to the optimal dose level.
3075052|NCT02060461|Experimental|FS200 femtosecond laser LASIK|LASIK flap created with an FS200 femtosecond laser system
3075053|NCT02060461|Experimental|IntraLase femtosecond laser LASIK|LASIK flap created with an IntraLase femtosecond laser system
3075081|NCT02060240|Experimental|High Activity Group|Subject randomized to High Activity group will have 36, one hour training sessions over 12 weeks.
3075082|NCT02060240|No Intervention|Standard of Care Group|The standard of care group will maintain their baseline level of activity for 12 weeks
3075378|NCT02058459|Sham Comparator|Sham-Control|non-active targeted lung denervation
3075054|NCT02060448|Experimental|2wk baseline + awareness (+ reappraisal)|"Participants in this arm will first undergo a two-week baseline phase. Participants who evidence a significant decrease in non-suicidal self-injurious thoughts and behaviors, or SITBs, (i.e., responders) after emotion awareness training will go straight to a four-week follow-up, and not receive cognitive reappraisal. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after emotion awareness training will return to a two-week baseline phase before receiving cognitive reappraisal, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after emotion awareness training will immediately receive cognitive reappraisal and then enter a four-week follow-up."
3075055|NCT02060448|Experimental|2wk baseline + reappraisal (+ awareness)|"Participants will first undergo a two-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after cognitive reappraisal will go straight to a four-week follow-up, and not receive emotion awareness training. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after cognitive reappraisal will return to a two-week baseline phase before receiving emotion awareness training, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs and behaviors (i.e., non-responders) after cognitive reappraisal will immediately receive emotion awareness training and then enter a four-week follow-up."
3075056|NCT02060448|Experimental|4wk baseline + awareness (+ reappraisal)|"Participants in this arm will first undergo a four-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after emotion awareness training will go straight to a four-week follow-up, and not receive cognitive reappraisal. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after emotion awareness training will return to a two-week baseline phase before receiving cognitive reappraisal, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after emotion awareness training will immediately receive cognitive reappraisal and then enter a four-week follow-up."
3075057|NCT02060448|Experimental|4wk baseline + reappraisal + (awareness)|"Participants in this arm will first undergo a four-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after cognitive reappraisal will go straight to a four-week follow-up, and not receive emotion awareness training. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after cognitive reappraisal will return to a two-week baseline phase before receiving emotion awareness training, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after cognitive reappraisal will immediately receive emotion awareness training and then enter a four-week follow-up."
3075058|NCT02060435||EBER+ AMC|EBV+DLBCL patients in Asan Medical Center
3075059|NCT02060435||EBER+ SMC|EBV+DLBCL patients in Samsung Medical Center
3075060|NCT02060435||EBER- SMC|EBV-DLBCL patients in Samsung Medical Center
3075061|NCT02060422|Placebo Comparator|Social support group|Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
3075062|NCT02060422|Experimental|Mindfulness-based therapy|Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
3075063|NCT02060409||spliceosome|patient who have available data for spliceosome mutation status
3075064|NCT02060396|Experimental|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
3075065|NCT02060383|Other|Incretin based therapy|Patients randomized to the incretin based arm will start with sitagliptin once daily. If sitagliptin does not control the patient's hyperglycemia, sitagliptin will be stopped and patients will be switched to liraglutide once daily.
3075066|NCT02060383|Other|Insulin|Patients randomized to the insulin arm may start with once daily dose of basal insulin. The dose may be up or down titrated at the discretion of the investigator. If blood glucose levels remain uncontrolled on basal insulin, patient may be switched to basal insulin plus prandial insulin.
3075067|NCT02060370|Experimental|Sunitinib|"Sunitinib starting dose 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks."
3075068|NCT02060357|Active Comparator|Resolute Integrity Stent|Patients will be randomised in a 1:1 ratio to receive two different types of DES
3075069|NCT02060357|Active Comparator|Promus Stent|Patients will be randomised in a 1:1 ratio to receive two different types of DES
3075070|NCT02060344||Hispanic/Latinos residing in the US|The cohort consists of over 16,400 persons of Hispanic/Latino origin, ages 18-74, specifically Cuban, Puerto Rican, Mexican, and Central/South American, to be recruited through four Field Centers affiliated with San Diego State University, Northwestern University in Chicago, Albert Einstein College of Medicine in the Bronx area of New York, and the University of Miami.
3075071|NCT02060331||Pelvic Organ Prolapse with Nocturia|Pelvic Organ Prolapse with Nocturia
3075072|NCT02060318||Infliximab|35 Crohn patients about to start Infliximab treatment, gives as i.v. injection of 5 mg/kg at baseline, after 2 weeks, 6 weeks, and then every 8th week.
3075073|NCT02060318||Healthy controls|12 healthy controls without Crohn's Disease.
3075074|NCT02060305|Experimental|Bevacizumab|Bevacizumab intra-articular injection; dose 20mg~40mg every month for 2~4 cycles
3075075|NCT02060292||COPD|Stable, Non hypoxaemic, without history of vascular disease
3075076|NCT02060292||Healthy smokers|Age matched, smokers without COPD
3075077|NCT02060279|Experimental|Lifestyle intervention and carotenoid supplement|
3075078|NCT02060279|Experimental|Lifestyle intervention and placebo|
3075079|NCT02060266|Experimental|Semaglutide|
3075080|NCT02060253|Experimental|ganetespib, paclitaxel, and trastuzumab with pertuzumab|Patients receive trastuzumab intravenously (IV) over 30 minutes on days 1, 8, 15, and 22, pertuzumab IV over 30 minutes every 3 weeks (only in Part II of the study, starting day 1), paclitaxel IV over 1 hour on days 1, 8, 15, and 22, and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. The MTD for ganetespib in combination with paclitaxel and trastuzumab is 150 mg/m2.
3075083|NCT02060227|Active Comparator|Arthroscopic Bankart repair|After the diagnostic arthroscopy is completed, any other pathology is documented. At least 3 anchors will be used for the bankart repair for repair of the labrum with an inferior to superior capsular shift. The suture anchors used will be at the discretion of the surgeon but will be of the screw-in variety. The sutures are passed through the labrum, and the labrum is tied to the glenoid rim after the bone is prepared in the standard fashion. The surgical times will be recorded on standardized forms.
3075084|NCT02060227|Active Comparator|Open Latarjet procedure|A deltopectoral approach is used. The coracoacromial ligament (CAL) is exposed and incised 1 cm from its coracoid attachment. Harvesting of a 2.5- to 3-cm coracoid graft allows use of 2 screws for fixation to the glenoid neck through a subscapularis-splitting approach. The stump of the CAL is repaired to the capsule with the arm positioned in neutral. The graft is placed in a extra-articular fashion with capsular closure to the native glenoid rim.
3075085|NCT02060201|Other|Treatment A: Saxagliptin 2.5mg+Dapagliflozin 5mg; Fasting|Saxagliptin 2.5 mg tablet and Dapagliflozin 5 mg tablet single dose orally on Day 1 in one of 3 periods
3075086|NCT02060201|Other|Treatment B: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fasting|Saxagliptin 2.5 mg/Dapagliflozin 5 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
3075087|NCT02060201|Other|Treatment C: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fed|Saxagliptin 2.5 mg/Dapagliflozin 5 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
3075088|NCT02060201|Other|Treatment D: Saxagliptin 5mg+Dapagliflozin 10mg; Fasting|Saxagliptin 5 mg tablet and Dapagliflozin 10 mg tablet single dose orally for on Day 1 in one of 3 periods
3075089|NCT02060201|Other|Treatment E: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fasting|Saxagliptin 5 mg/Dapagliflozin 10 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
3075090|NCT02060201|Other|Treatment F: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fed|Saxagliptin 5 mg/Dapagliflozin 10 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
3075091|NCT02060188|Experimental|Nivolumab Monotherapy|Nivolumab administered as IV infusion at a dose of 3mg/kg every 2 weeks until disease progression
3075092|NCT02060188|Experimental|Nivolumab (Nivo) + Ipilimumab (Ipi)|"Nivo 3mg/Kg IV with Ipi 1 mg/Kg IV every 3 week (wk) for 4 doses followed by Nivo 3mg/Kg IV every 2wk until progression~Dose Escalation Phase: (Complete)~Dose Level (DL) 1: Nivo 0.3mg/Kg with Ipi 1 mg/Kg IV every 3wk for 4 doses followed by Nivo 3mg/Kg IV every 2wk until progression~DL 1: Nivo 1mg/Kg IV with Ipi 1 mg/Kg IV every 3 wk for 4 doses followed by Nivo 3mg/Kg IV every 2wk until progression~DL 2a: Nivo 1mg/Kg IV with Ipi 3 mg/Kg IV every 3wk for 4 doses followed by Nivo 3mg/Kg IV every 2 wk until progression~DL 2b: Nivo 3mg/Kg IV with Ipi 1 mg/Kg IV every 3wk for 4 doses followed by Nivo 3mg/Kg IV every 2 wk until progression"
3075093|NCT02060188|Experimental|Nivolumab (Nivo) + Ipilimumab (Ipi) Cohort C3|Nivo IV dosed every 2wk with Ipi IV dosed every 6wk.
3075094|NCT02060188|Experimental|Nivolumab (Nivo) + Ipilimumab (Ipi) + Cobimetinib Cohort C4|Nivo IV dosed every 2wk, with Ipi IV dosed every 6wk, combined with Cobimetinib dosed orally once daily 21 days on/7 days off.
3075095|NCT02060188|Experimental|Nivolumab (Nivo) + BMS-986016 Cohort C5|Nivo IV dosed every 2wk with BMS-986016 dosed every 2 wk
3075096|NCT02060188|Experimental|Nivolumab (Nivo) + Daratumumab Cohort C6|Daratumumab IV dosed weekly for week 1-8; then every 2 wks from Week 9-24; then every 4 wks on week 25; with Nivo dosed every 2 wks starting at week 3 and every 4 wks starting at week 25
3075097|NCT02060175|Experimental|1 CILOTAX arm|Cilotax drug-eluting stents implantation
3075098|NCT02060175|Active Comparator|2 DESyne arm|DESyne drug-eluting stents implantation
3075099|NCT02060162||HIV/HBV co-infected|150-200 patients in Zambia and 250-300 across all sites
3075100|NCT02060162||HIV mono-infected|700-750 patients in Zambia and 1600-1700 across all sites
3075101|NCT02060149|Sham Comparator|no nebulization|Antibiotics protocol is C/S plus minocycline. That is Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral,q12h).No nebulization will given to these patients.
3075102|NCT02060149|Active Comparator|nebulization with pH 7.4 solution|Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.4 solution(Each time the volume of aerosol solution is 5ml, q8h).
3075103|NCT02060149|Experimental|nebulization with pH 7.8 solution|Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.8 solution(Each time the volume of aerosol solution is 5ml, q8h).
3075104|NCT02060136||Study group|Men presenting to the urology clinic with lower urinary tract symptoms
3075105|NCT02060123|Experimental|Qigong training|"a total of 103 hours over a period of 5.5 months, consisting of:~Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),~Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and~Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours)."
3075106|NCT02060123|Other|Wait-list control- Health talks|Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
3075107|NCT02060110||MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study
3075108|NCT02060110||MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study
3075109|NCT02060097|Active Comparator|Cocoa flavanol beverage|flavanol 320mg/day
3075110|NCT02060097|Placebo Comparator|Placebo beverage|no flavanol
3075111|NCT02060084|Experimental|a control group|a control group : the same dose of luke warm water
3075112|NCT02060084|Experimental|treatment group|treatment group: viable Bifidobacterium 0.5 bid po
3075113|NCT02060071|Other|Aortic setnsosi|blood test
3075114|NCT02060071|Other|controls|blood test
3075145|NCT02059837||Pterygium,recurrent|Consecutively recorded photographs of recurrent pterygium excision and following grafting were analyzed.
3075146|NCT02059824|Experimental|Eyelid|The selection of the laterality of the eyelid will be randomized
3075115|NCT02060058|Experimental|Patients with 32 week therapy|"For non-cirrhotic patients whose response of previous HCV therapy with PEG-IFN/RBV were relapse or partial response, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 (boceprevir+ PEG-IFN/RBV). If HCV RNA is undetectable during 8-24 weeks, boceprevir+PEG-IFN/RBV triple therapy will be administered from week 5 to week 32.~Dosage of drugs: Boceprevir 800mg tid po, PegIntron 1.5 mcg/kg im QW, and Ribavirin 800 to 1400 mg/day PO divided BID Regimen adjusted according to body weight.~Stop trial intervention for patients with 32 week therapy: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm A)."
3075116|NCT02060058|Experimental|Patients with 48 weeks therapy|"For non-cirrhotic patients whose response of previous HCV therapy with PEG-IFN/RBV were relapse or partial response, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 (boceprevir+ PEG-IFN/RBV). If HCV RNA is detectable at week 8 and undetectable at week 24, boceprevir+ PEG-IFN/RBV triple therapy will be administered from week 5 to week 32, followed by additional 12 weeks of PEG-IFN/RBV therapy.~Dosage of drugs: as Patients with 32 week therapy Stop trial intervention for patients with 48 weeks therapy: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm B)."
3075117|NCT02060058|Experimental|Null responder or cirrhotic patients|"For null responder or cirrhotic patients, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 to 48.~Dosage of drugs: as Patients with 32 week therapy Stop trial intervention for for null responder or cirrhotic patients: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm C)."
3075118|NCT02060045|Experimental|bundle implementation|The measures were a specific training program, aspiration of subglottic secretions (ASS), introduction of an inclinometer to improve the semirecumbent position, and reinforcement of oral care with chlorhexidine.
3075119|NCT02060032|Active Comparator|Atorvastatin|1.2% atorvastatin local drug delivery
3075120|NCT02060032|Sham Comparator|Simvastatin|1.2% simvastatin local drug delivery
3075121|NCT02060032|Placebo Comparator|Placebo|Placebo local drug delivery
3075122|NCT02060019|Experimental|exforge 10/160mg(amlodipine 10mg, valsartan160mg)|1 tablet daily for 10days
3075123|NCT02060019|Experimental|crestor 20mg(rosuvastatin 20mg)|1 tablet daily for 7days
3075124|NCT02060006|Placebo Comparator|Placebo 7.5 mg daily for 8 weeks|Placebo 7.5 mg once-daily First 8 weeks of ART Only Control arm
3075125|NCT02060006|Experimental|Meloxicam 7.5 mg once-daily|Meloxicam 7.5mg once-daily for 8 weeks
3075126|NCT02059993|Other|continuous positive airway pressure|mean continuous positive airway pressure use was at least 4 hours per night; continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
3075127|NCT02059993|No Intervention|Control|The control subjects received standardised anti-hypertension medications according to the current guildline.
3075128|NCT02059980|Experimental|Response inhibition training|Eight 45-minute sessions of computerized training on response inhibition over a 4 week period
3075129|NCT02059980|Placebo Comparator|Placebo Control Training|Eight 45-minute sessions of computerized placebo control training over a 4 week period
3075130|NCT02059967|Experimental|Treatment (IGART using ABC, SIVAB, paclitaxel, carboplatin)|Patients undergo IGART using ABC 5 days a week for 7 weeks, for a total of 33 fractions with SIVAB during fractions 26-33. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once a week for 6 weeks.
3075131|NCT02059954|Active Comparator|Vaginal hysterectomy|Vaginal hysterectomy
3075132|NCT02059954|Active Comparator|Total laparoscopic hysterectomy|Laparoscopic hysterectomy
3075133|NCT02059928|Experimental|Intraosseous device placement|Intraosseous device
3075134|NCT02059915|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3075135|NCT02059915|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3075136|NCT02059915|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3075137|NCT02059915|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3075138|NCT02059902|Placebo Comparator|Normal pain management|Normal saline (bolus followed by continuous infusion)
3075139|NCT02059902|Experimental|Lidocaine|Lidocaine (Pre-operative = 1.5kg/mg over a minimum of 30 minutes; peri-operative = 2.0mg/kg/hour; Post-operative = 1.5kg/mg/hour)
3075140|NCT02059889|Experimental|Diagnostic (diffusion-weighted MRI, 4D CT, FDG-PET)|Patients undergo 15 imaging studies: 5 chest CT scans, 5 chest MRI scans, 5 PET scans. Each scan will be obtained before treatment begins, weeks 2 and 4 during radiation therapy, 3 months and 1 year following radiation therapy. THe chest CT obtained pre-treatment, at 3 months post treatment and 1 year post treatment are considered routine and would be obtained regardless of study participation. The pre-treatment PET scan is also considered routine. All other scans are being done for the purposes of this research.
3075141|NCT02059876|Experimental|carboplatin and paclitaxel ± trastuzumab|dose-dense(biweekly) carboplatin and paclitaxel and or without trastuzumab as neoadjuvant treatment in early breast cancer.
3075142|NCT02059863|Experimental|SPRING intervention clusters|"SPRING package: Home visits by community based agents carried out from pregnancy to 2 years of age to encourage key behaviours to promote child growth, survival and development together with regular supervision~PLUS access to routine maternal and child health services"
3075143|NCT02059863|No Intervention|Control clusters|access to routine maternal and child health services
3075144|NCT02059850|Experimental|Treatment (cyclophosphamide, NY-ESO-1 specific T cells)|Patients receive cyclophosphamide IV on days -3 and -2 and NY-ESO-1 specific T cells IV over 60 minutes on day 0. Patients may receive additional infusions at the discretion of the PI.
3075379|NCT02058446|Experimental|Study group|Amlodipine/Valsartan Single-Pill Combination
3075147|NCT02059811|Experimental|DASH Diet|"All participants will be provided a control diet for a 7-day run-in period followed by the DASH dietary intervention for a 14-day intervention period. Participants will consume the largest meal of the day in a supervised setting at the study center and all other meals and snacks will be provided in to-go packages. Weight will be held constant by measuring participant weight daily and adjusting caloric content of meals. Adherence will be monitor by review of daily food diaries."
3075148|NCT02059798||Decompression of cervical myelopathy|JOA (Japanese Orthopaedic Association) Scores for cervical myelopathy Compliance Rigidity activity unit
3075149|NCT02059785|Experimental|Pinocembrin for Injection|40mg /60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day
3075150|NCT02059785|Placebo Comparator|placebo|60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day
3075151|NCT02059772|Experimental|Control Group|Standard therapy of diabetic macular edema with Lucentis (ranibizumab) according to SmPC
3075152|NCT02059772|Experimental|Treatment Group|Combination of standard therapy of Lucentis (ranibizumab) according to SmPC and micropulse diode laser treatment
3075153|NCT02059759|Placebo Comparator|Placebo|"Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).~Intervention: Placebo"
3075154|NCT02059759|Experimental|1.0 IL-2|"Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).~Intervention: 1.0 MIU IL-2 per day"
3075155|NCT02059759|Experimental|2.0 IL-2|"Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).~Intervention: 2.0 MIU IL-2 per day"
3075156|NCT02059746||Vaginal birth|"Patients in the group give birth vaginally.~Intervention: Questionnaires sent by mail"
3075157|NCT02059746||Cesaren section|"Patients in this group give birth via cesarean section.~Intervention: Questionnaires sent by mail"
3075158|NCT02059733|Experimental|18F-DTBZ for Parkinson's Disease and parkinsonism|"This study will compare the brain uptake of 18F- DTBZ in 20 patients with PD, 20 patients with MSA, 20 patients with PSP, 20 patients with CBS, and 20 patients with VaP, 20 patients with ET, and 10 patients with DT.~Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
3075159|NCT02059720|Active Comparator|auto|patients receive autologous SCT
3075160|NCT02059720|Active Comparator|haplo|patients receive haplo-SCT
3075161|NCT02059707|Experimental|LAA exclusion procedure|LAA exclusion with the LARIAT RS Suture Delivery Device
3075162|NCT02059694|Experimental|Hyaluronidase|"Dilutions (Blocks):~0.5 mL of lidocaine 2% with epinephrine 1:100,000 and 0.5 mL of marcaine 0.75% and 1 mL (150 U) of rHuPH20 for a total of 75 U/ml"
3075163|NCT02059694|Other|Comparitor|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20
3075164|NCT02059681|Experimental|Autologous bone marrow derived-CD133+ cells|CD133+ cells (1-12x10^6) suspended in 10 ml physiological saline supplemented with 5% human albumin solution will be injected into the myocardium via the endocardial route; the whole 10 ml solution will be divided into 15-20 injections.
3075165|NCT02059668||Biomarker analyses head & neck cancer tissue, blood specimen|Validation of prognostic biomarkers for local tumor control in definitive and adjuvant treatment of head and neck cancer.
3075166|NCT02059655|Placebo Comparator|Eye drop solution|Patients will receive 1 dose daily over 3 month period followed by 2 months washout period. Subsequently patient will cross over to the opposite treatment and continue further treatment for 3 month period.
3075167|NCT02059655|Active Comparator|Bimatoprost|1 drop daily of Bimatoprost 0.03%. Patients will receive 1 dose daily over 3 month period followed by 2 months washout period. Subsequently patient will cross over to the opposite treatment and continue further treatment for 3 month period.
3075168|NCT02059642|Placebo Comparator|Placebo|Placebo tablet identical in appearance to study investigational product Route, frequency: Administered orally once daily
3075169|NCT02059642|Experimental|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) Dose, route, and frequency: 1400 mg administered orally once daily
3075170|NCT02059629||Group A: Eluna pacemaker family|Patients with standard indication for pacemaker therapy or Cardiac Resynchronization Therapy (CRT), who will be implanted with a pacemaker or CRT device of the Eluna pacemaker family. Single-, Dual- and Tripple-chamber pacemakers are applicable.
3075171|NCT02059629||Group B: Sentus BP lead|Heart failure patients with indication for Cardiac Resynchronization Therapy (CRT) therapy, who will be implanted with the left ventricular Sentus BP lead. Patients can receive either CRT pacemaker or CRT-D (CRT with defibrillator function).
3075172|NCT02059616|Experimental|AML 5mg|Amlodipine 5 mg, once a day for 8 weeks
3075173|NCT02059616|Experimental|AML 10mg|Amlodipine 10 mg, once a day for 8 weeks
3075174|NCT02059616|Experimental|CC 8mg|Candesartan Cilexetil 8 mg, once a day for 8 weeks
3075175|NCT02059616|Experimental|CC 16mg|Candesartan Cilexetil 16 mg, once a day for 8 weeks
3075176|NCT02059616|Experimental|AML 5mg/CC 8mg|Amlodipine 5 mg and Candesartan 8 mg, once a day for 8 weeks
3075177|NCT02059616|Experimental|AML 5mg/CC16mg|Amlodipine 5 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks
3075178|NCT02059616|Experimental|AML 10mg/CC 8mg|Amlodipine 10 mg and Candesartan Cilexetil 8 mg, once a day for 8 weeks
3075179|NCT02059616|Experimental|AML 10mg/CC 16mg|Amlodipine 10 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks
3075180|NCT02059603|Experimental|Electroacupuncture|Bilateral acupoints relevant to the treatment of abdominal pain, abdominal distension, and constipation, including Zusanli (stomach meridian ST-36), Sanyinjiao (spleen meridian SP-6), Hegu (large intestine meridian LI-4), and Zhigou (triple energizer meridian TE-6), will be used. Electric stimulation at a frequency of 50 Hz will be employed to the acupuncture needles.
3075279|NCT02059096|Other|Theta-Burst Stimulation (pcTBS)|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation.
3075181|NCT02059603|Active Comparator|Fast-track program|The design of this program is based on the consensus between our surgeons, anesthetists, physiotherapists, dietitians, and nurses, who have reviewed the relevant literature and made appropriate adjustments to suit the local situation.
3075182|NCT02059590|Experimental|Pyridinylmethyl-14C-labeled isavuconazonium sulfate|single dose
3075183|NCT02059577|Experimental|Treatment Group|This group received a combination of nutritional treatments, added sequentially, including vitamins/minerals, essential fatty acids, Epsom salt baths, carnitine, digestive enzymes, and healthy, gluten-free, casein-free diets.
3075184|NCT02059577|No Intervention|Non-Treatment Group|This group did not have any significant changes in their treatments for 12 months
3075185|NCT02059564|Experimental|Cohort A|The weekly treatment of the 6 mg HM11260C or placebo will be maintained
3075186|NCT02059564|Experimental|Cohort B|The monthly treatment with 4 mg HM11260C or placebo will be up titrated to 16 mg
3075187|NCT02059564|Experimental|Cohort C|The daily treatment with 0.6 mg Victoza will be up titrated to 1.2 mg
3075188|NCT02059551|Experimental|Intervention|"In case of positive D-dimer testing or in patients with a high clinical probability of PE, these patients have MRI protocol combined with venous ultrasonography of the legs. MRI includes 2 different sequences: Unenhanced steady-state-free precession sequences (SSFP) sequences and angiography sequences. (please see \\\intervention section\\\ for more details). MRI readings will be performed centrally by two independent readers blinded to the results of diagnostic reference standard. Venous ultrasonography of the legs will be interpreted locally."
3075189|NCT02059538|Other|Group 1|Metabolic syndrome
3075190|NCT02059538|Other|Group 2|Severly obese patients
3075191|NCT02059538|Other|Group 3|Type-2 diabetics patients
3075192|NCT02059538|Other|Group 4|Patients with first recent (< 2 weeks) acute coronary syndrome (ACS)
3075193|NCT02059538|Other|Group 5|Patients with stable chronic coronary artery disease without heart failure
3075194|NCT02059538|Other|Group 6|Patients with ischemic systolic heart failure (CHF)
3075195|NCT02059538|Other|Group 7|Patients with non-ischemic chronic heart failure
3075196|NCT02059538|Other|Group 8|Healthy volunteers
3075197|NCT02059525||syphilis infected|all patients with a new diagnosis of syphilis, receiving treatment at the Institute of Tropical Medicine
3075198|NCT02059512|Active Comparator|cell Therapy 1|intramyocardial administration of autologous bone marrow mononuclear cells during the operation coronary artery bypass grafting
3075199|NCT02059512|Placebo Comparator|non cell therapy|intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml
3075200|NCT02059512|Active Comparator|cell therapy 2|intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells during coronary artery bypass grafting
3075201|NCT02059499|Experimental|Arm A (imiquimod)|Patients apply imiquimod intra-anally QD for 16 weeks.
3075202|NCT02059499|Experimental|Arm B (fluorouracil)|Patients apply fluorouracil intra-anally BID on days 1-5. Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
3075203|NCT02059499|No Intervention|Arm C (observation)|Patients receive no treatment. Patients who still have HSIL at week 20 and who agree to randomization may cross-over to Arm A or B.
3075204|NCT02059486|Experimental|Teen Choice|The curriculum provides comprehensive sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress. The curriculum can be delivered in different formats that range in length from 6 to 12 weeks.
3075205|NCT02059486|No Intervention|Control|Business as usual school health curriuclum
3075206|NCT02059473|Experimental|Physiotherapy & Surgery|Mini-open rotator cuff repair
3075207|NCT02059473|Active Comparator|Physiotherapy|Structured physiotherapy
3075208|NCT02059460|Experimental|Terlipressin group|Terlipressin group, Terlipressin (Glypressin®, Rentschler biotechnology Gmbh, Erwin, Germany) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
3075209|NCT02059460|Placebo Comparator|Control group|
3075210|NCT02059447|Experimental|Mindfulness Based Cognitive Therapy|An 8 week course of Mindfulness Based Cognitive therapy
3075211|NCT02059447|Active Comparator|Relaxation Therapy|An 8 week course of Relaxation Therapy.
3075212|NCT02059434|Experimental|LAS190792 Dose 1 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3075213|NCT02059434|Experimental|LAS190792 Dose 2 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3075214|NCT02059434|Experimental|LAS190792 Dose 3 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3075215|NCT02059434|Experimental|LAS190792 Dose 4 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3075216|NCT02059434|Experimental|LAS190792 Dose 5 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3075217|NCT02059434|Experimental|LAS190792 Dose 6 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3075218|NCT02059434|Placebo Comparator|Placebo (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3075219|NCT02059434|Experimental|LAS190792 Dose 1 (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3075220|NCT02059434|Experimental|LAS190792 Dose 2 (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3075221|NCT02059434|Active Comparator|Tiotropium 18 μg|Single dose, oral inhalation by HandiHaler® single-dose DPI
3075222|NCT02059434|Active Comparator|Indacaterol 150 μg|Single dose, oral inhalation by Breezhaler® single-dose DPI
3075223|NCT02059434|Placebo Comparator|Placebo (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3075224|NCT02059421|Experimental|Johrei Therapy|"3 sessions per week lasting 30 minutes.~Daily report of bedtime and wake time.~Baseline:~Polysomnography~Actigraphy~Questionnaires~Blood draw~Urine collection~2 weeks:~Questionnaires~Actigraphy download~Sleep log reconciliation~6 weeks:~Polysomnography~Actigraphy download~sleep log reconciliation~Questionnaires~Blood draw~Urine collection"
3075314|NCT02058849|Experimental|Beetroot|Beetroot 10 grams concentrated organic beetroot crystals
3075225|NCT02059421|Active Comparator|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"1 session per week for a total of 6 weeks with the option of 2 additional sessions.~Daily report of bedtime and wake time.~Baseline:~Polysomnography~Actigraphy~Questionnaires~Blood draw~Urine collection~2 weeks:~Questionnaires~Actigraphy download~Sleep log reconciliation~6 weeks:~Polysomnography~Actigraphy download~sleep log reconciliation~Questionnaires~Blood draw~Urine collection"
3075226|NCT02059408|No Intervention|Usual Care|The patients in this arm will receive normal care.
3075227|NCT02059408|Active Comparator|Screen-Educate|Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate CDSS arm will recommend using creatinine, cystatin C and albuminuria for risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage.
3075228|NCT02059408|Active Comparator|Screen-Educate and Intensify Treatment|Education and treatment program to improve blood pressure control among hypertensive non-diabetic persons. The Screen-Educate and Intensify Treatment is the CDSS plus a pharmacist-led CKD management program (CDSS PLUS) will attempt to improve BP management and patient-centered outcomes among persons with newly stratified higher risk CKD based on creatinine, cystatin c and albuminuria.
3075229|NCT02059395|Active Comparator|Time based|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course
3075230|NCT02059395|Experimental|Mastery based|Participants do follow the content of the Canadian Heart and Stroke Foundation Heartsaver Course content based on their own pace (timeframe)
3075231|NCT02059382|Active Comparator|Control|ChiRunning training Weekly training log Blinded accelerometer
3075232|NCT02059382|Experimental|Technology support for behavior change|ChiRunning training unblinded accelerometer tracking structured exercise using mobile app participation in online social network participation in study website
3075233|NCT02059369|Active Comparator|CFAE ablation|Intervention: Complex fractionated atrial electrograms (CFAE) Ablation
3075234|NCT02059369|Active Comparator|CFAE + Lines|CFAE Ablation followed by linear lesions (anterior and Roof line)
3075235|NCT02059356||Non-cirrhotic patients with cognitive impairment|
3075236|NCT02059343||age less than or equal to 2 years|
3075237|NCT02059330|Experimental|Healthy Subjects of Japanese Descent|Enrolled Japanese subjects will receive four palbociclib single doses of differing dose amounts in fixed sequence over four treatment periods.
3075238|NCT02059330|Experimental|Healthy Non-Asian Subjects|Enrolled healthy non-Asian subjects will receive a single 125mg oral dose of palbociclib in a single treatment period.
3075239|NCT02059317||Group 1|"Six groups are created in order to randomized the order of interventions. In group 1, the order of interventions is as follows:~Flexion-extension in the sagittal plane~Rotation in a transverse plane~Complex movement in three dimensions~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
3075240|NCT02059317||Group 2|"Six groups are created in order to randomized the order of interventions. In group 2, the order of interventions is as follows:~Flexion-extension in the sagittal plane~Complex movement in three dimensions~Rotation in a transverse plane~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
3075241|NCT02059317||Group 3|"Six groups are created in order to randomized the order of interventions. In group 3, the order of interventions is as follows:~Rotation in a transverse plane~Flexion-extension in the sagittal plane~Complex movement in three dimensions~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
3075242|NCT02059317||Group 4|"Six groups are created in order to randomized the order of interventions. In group 4, the order of interventions is as follows:~Rotation in a transverse plane~Complex movement in three dimensions~Flexion-extension in the sagittal plane~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
3075243|NCT02059317||Group 5|"Six groups are created in order to randomized the order of interventions. In group 5, the order of interventions is as follows:~Complex movement in three dimensions~Flexion-extension in the sagittal plane~Rotation in a transverse plane~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
3075244|NCT02059317||Group 6|"Six groups are created in order to randomized the order of interventions. In group 6, the order of interventions is as follows:~Complex movement in three dimensions~Rotation in a transverse plane~Flexion-extension in the sagittal plane~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
3075245|NCT02059304|Other|Preterm Delivery|Preterm Delivery: Births before the completion of 37 weeks' of gestation.
3075246|NCT02059304|Other|Term Delivery|Term Delivery: Births after the completion of 37 weeks' of gestation.
3075247|NCT02059291|Experimental|crFMF: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration.
3075248|NCT02059291|Placebo Comparator|crCMF: placebo|"During epoch 2, participants received matching placebo to canakinumab 150 mg Participants who required blinded escape,they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab.~150mg, participants were uptitrated to open-label canakinumab 300 mg."
3075278|NCT02059096|Experimental|Repetitive transcranial magnetic stimulation (rTMS)|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation
3075315|NCT02058849|Placebo Comparator|Placebo|Placebo
3075249|NCT02059291|Experimental|HIDS/MKD: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration.
3075250|NCT02059291|Placebo Comparator|HIDS/MKD: placebo|During epoch 2, participants received matching placebo to canakinumab 150 mg qw4. Participants who required blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28 and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab 150mg, participants were uptitrated to open-label canakinumab 300 mg.
3075251|NCT02059291|Experimental|TRAPS: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration
3075252|NCT02059291|Placebo Comparator|TRAPS: placebo|During epoch 2, participants received matching placebo to canakinumab 150 mg qw4. Participants who required blinded escape,they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between Day 8 and 28 and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab 150mg, participants were uptitrated to open-label canakinumab 300 mg.
3075253|NCT02059278|Experimental|T-2345|T-2345 Ophthalmic Solution dosed 1 drop QD in the eye(s) in the evening (8 pm +/- 30 minutes)
3075254|NCT02059278|Experimental|Xalatan|Xalatan (Latanoprost 0.005% Ophthalmic Solution) dosed 1 drop QD in the eye(s) in the evening (8 pm +/- 30 minutes)
3075255|NCT02059265|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3075256|NCT02059252|Experimental|SmartMatrix scaffold|SmartMatrix dermal replacement scaffold
3075257|NCT02059239|Experimental|Chemo plus Autologous Transplantation|Bendamustine 200 mg/ m2/ day on Days - 24 and Day - 23 followed by a short break of 10 - 14 days, followed by Melphalan, Carmustine, Etoposide, Cytarabine (BEAM) and alemtuzumab, plus rituximab for all b-cell malignancies, followed by autologous transplant
3075258|NCT02059239|Experimental|Chemo plus Allogeneic Transplantation|Bendamustine 200 mg/ m2/ day on Days - 24 and Day - 23 followed by a short break of 10 - 14 days, followed by Melphalan, Carmustine, Etoposide, Cytarabine (BEAM) and alemtuzumab, plus rituximab for all b-cell malignancies, followed by allogeneic transplant
3075259|NCT02059226|Experimental|Internet-based CBT|Internet-based cognitive behavioural therapy
3075260|NCT02059226|Active Comparator|Internet-based resource page|Static webpage
3075261|NCT02059213|Active Comparator|ADT Alone|Androgen Deprivation Therapy (ADT): Bicalutamide (an active non-steroidal antiandrogen; 50mg taken daily by mouth) and Zoladex (LHRH agonist administered by injection), or Lupron Depot (LHRH agonist, administered by injection).
3075262|NCT02059213|Experimental|ADT + Ibrance®|Ibrance® (125mg taken daily by mouth days 1-21 of a 28 day cycle) in addition to Androgen Deprivation Therapy (ADT): Bicalutamide (an active non-steroidal antiandrogen; 50mg taken daily by mouth) and Zoladex (LHRH agonist administered by injection), or Lupron Depot (LHRH agonist, administered by injection).
3075263|NCT02059200|Experimental|MBCL + TAU|This cohort receives the Mindfulness Based Compassionate Living program in addition to treatment as usual.
3075264|NCT02059200|No Intervention|TAU|This cohort receives treatment as usual of any nature, e.g. psychotherapy, antidepressant medication etc.
3075265|NCT02059187|Experimental|MK-1293|MK-1293 administered subcutaneously once daily in the evening.
3075266|NCT02059187|Active Comparator|Lantus™|Lantus™ administered subcutaneously once daily in the evening.
3075267|NCT02059174|Experimental|MK-1293 / EU-Lantus™ / MK-1293 / EU-Lantus™|MK-1293 or EU-Lantus™ 0.4 units/kg administered subcutaneously on Day 1 in 2 out of 4 study periods in a replicate crossover design with a minimum of 7 days between each treatment period
3075268|NCT02059174|Experimental|EU-Lantus™ / MK-1293 / EU-Lantus™ / MK-1293|MK-1293 or EU-Lantus™ 0.4 units/kg administered subcutaneously on Day 1 in 2 out of 4 study periods in a replicate crossover design with a minimum of 7 days between each treatment period
3075269|NCT02059161|Experimental|MK-1293|MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post randomization to the suggested target for fasting fingerstick glucose levels of >70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).
3075270|NCT02059161|Active Comparator|Lantus|Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of >70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).
3075271|NCT02059148|Experimental|LY2835219 Standard|Single oral dose of LY2835219 given with a standard meal in one of three study periods.
3075272|NCT02059148|Experimental|LY2835219 Fasted|Single oral dose of LY2835219 given with no food in one of three periods.
3075273|NCT02059148|Experimental|LY2835219 High-Fat|Single oral dose of LY2835219 given with a high fat meal in one of three periods.
3075274|NCT02059135|Active Comparator|Recombinant Human Antithrombin (ATryn)|ATryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
3075275|NCT02059135|Placebo Comparator|Normal Saline 0.9%|Placebo (Normal Saline 0.9%, matched for volume of active treatment) consisting of a loading dose over 15 minutes followed by continuous infusion.
3075276|NCT02059109|Experimental|Single|Staff will work alone to assemble the Belmont Rapid Infuser
3075277|NCT02059109|Experimental|Pair|Staff will work in pairs to assemble the Belmont Rapid Infuser
3075374|NCT02058485|Sham Comparator|Group NM|Midazolam was administered 0.025 mg. kg-1 in normotensive patient.
3075280|NCT02059096|Other|repetitive Transcranial Magnetic Stimulation (rTMS)placebo|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation.
3075281|NCT02059083|Active Comparator|Cognitive behavioral therapy (CBT) alone|
3075282|NCT02059083|Experimental|Cognitive behavioral therapy plus HRV biofeedback|
3075283|NCT02059070|Experimental|0.125% Bupivacaine|Group 1) Post-operative 0.125% Bupivacaine Interscalene brachial plexus block, 6ml/hr, continuous.
3075284|NCT02059070|Experimental|0.2% Ropivacaine|Group 2) Post-operative 0.2% Ropivacaine Interscalene brachial plexus block, 6ml/hr, continuous.
3075285|NCT02059057|Experimental|LVRC System|
3075286|NCT02059044|Experimental|ISTOP-ADE|Interactive Voice Response System + Pharmacist
3075287|NCT02059044|No Intervention|Routine care|Routine care
3075288|NCT02059031|Experimental|Part A|In Part A, subjects will be randomized to receive two new formulations of GSK1265744 30 mg (New formulation 1 -micronized [B], New formulation 2un-micronized [C]) and the sodium salt reference formulation 30 mg (Reference formulation [A]) in one of six sequences; ABC, BCA, CAB, BAC, ACB, CBA in three treatment periods under fasting condition.
3075289|NCT02059031|Experimental|Part B|Fifteen eligible subjects completing the Part A of the study will enter in to Part B where they will receive either formulation B or C. The selected drug (B or C) will be administered under fed (moderate fat meal) condition in the fourth treatment period.
3075290|NCT02059018|Experimental|Hypoxia|Inhaling hypoxic gas mixture to induce hypoxemia during recordings of diameter changes of retinal vessels. Recording are performed during hypoxia alone and in combination with the associated interventions over two examination days
3075291|NCT02059018|Experimental|Normoxia|Breathing atmospheric air during recordings of diameter changes of retinal vessels. Recording are performed during normoxia alone and in combination with the associated interventions over two examination days
3075292|NCT02059005|Experimental|Specialized Community Disease Management|Specialized Community Disease Management
3075293|NCT02059005|Active Comparator|Treatment As Usual|Treatment as Usual: standard post-hospital discharge with medical monitoring.
3075294|NCT02058992||Ramelteon 8 mg administered orally once daily|
3075295|NCT02058979|Active Comparator|BOLUS INFUSION|Bolus infusion of antibiotics
3075296|NCT02058979|Experimental|CONTINUOUS INFUSION|Continuous infusion of antibiotics by way of infusion pump
3075297|NCT02058966|Placebo Comparator|Placebo followed by Placebo|Subjects will receive placebo, then one hour later, placebo
3075298|NCT02058966|Experimental|Placebo followed by Methamphetamine|Subjects will receive placebo, then one hour later, methamphetamine
3075299|NCT02058966|Experimental|Entacapone followed by Placebo|Subjects will receive entacapone, then one hour later, placebo
3075300|NCT02058966|Experimental|Entacapone followed by Methamphetamine|Subjects will receive entacapone, then one hour later, methamphetamine
3075301|NCT02058953||Craniotomy scheduled|"Patients who have scheduled craniotomy with melanoma brain metastases will have the following specimens collected:~CNS tumor specimens, specifically the remaining portion from the resected melanoma CNS metastasis~the remaining portion from the adjacent normal CNS tissue. No additional normal brain tissue will be collected for research purposes only, however the routinely collect peritumoral tissue will be retained.~melanoma specimens from other extracranial, clinically palpable metastatic sites.~CSF taken at around the time of the craniotomy procedure~peripheral blood prior to craniotomy."
3075302|NCT02058953||Collection for non-craniotomy|"For those eligible patients who are not having a craniotomy:~collection of CSF will be performed by lumbar puncture or from the patient's Ommaya reservoir, if present.~collection of peripheral blood.~NOTE: Only patients who have no absolute contraindications or up to two relative contraindications will be considered for lumbar puncture"
3075303|NCT02058940|Experimental|Exenatide|
3075304|NCT02058927||HIV-1 infected children|HIV-1-infected children initiating ART
3075305|NCT02058927||HIV-1 uninfected children|control group of HIV-1 uninfected children matched by age
3075306|NCT02058927||HIV-1 infected children revaccinated|nested study of revaccination against measles virus of HIV-1-infected children receiving ART who lack protective antibody titers
3075307|NCT02058914|Experimental|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage (sweetened with 50 g fructose and 15 g glucose)
3075308|NCT02058914|Active Comparator|High Glucose sweetened beverage|HG-sweetened beverage (sweetened with 50 g glucose and 15 g fructose)
3075309|NCT02058901|Experimental|Sunitinib high dose, weekly schedule|Initial dose of sunitinib is set at 200 mg once weekly. Three patients are treated at the current dose level. If at least 2 patients are observed to have Dose Limiting Toxicity (DLT), the prior dose level is defined as the Maximum Tolerated Dose (MTD) (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 patients are observed to have DLT, the dose level is escalated one step for the next cohort of 3 patients. If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level. If none of these show DLT, the dose level is escalated for the next cohort of 3 patients; otherwise, the prior dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). A tentative MTD becomes final when a total of 6 patients are treated with less than 2 showing DLT
3075310|NCT02058901|Experimental|Sunitinib high dose, biweekly schedule|When the final MTD is reached for the cohort of patients treated once weekly and depending on the toxicities developed and defining MTD, enrollment of patients in the once every 2 weeks escalation cohort will begin, with the initial dose set at the MTD dose of the once weekly schedule, escalating again at 100 mg increments per dose level.
3075311|NCT02058875|Experimental|Treatment Group|Maximization of mycophenolicacid (MPA) derivative (to a total daily dosage of 1440mg of Myfortic®) and reduction of cyclosporine dosage (as defined by C2 monitoring) in 50 stable renal transplant patients previously on immunosuppressive therapy with cyclosporine, an MPA derivative and prednisone.
3075312|NCT02058875|Active Comparator|Control Group|25 patients continued on an mycophenolicacid (MPA) derivative, cyclosporine and prednisone.
3075313|NCT02058875|No Intervention|Observation Group|25 patients continued on an mycophenolic acid (MPA) derivative, tacrolimus, and prednisone will be followed during the same recruitment period as an additional comparison, as this is the other Calcineurin Inhibitor (CNI), which is used in kidney transplantation.
3075316|NCT02058836|Experimental|Botox Injection|The participant will be given an injection of Botox along the spermatic cord under ultrasound guidance. Before drug administration, a nerve block using bupivacaine will be completed to numb the area for treatment. This will be a 10 mL injection done one time at the initial patient visit.
3075317|NCT02058836|Placebo Comparator|Saline Injection|The patient will receive an inactive injection of normal saline along the spermatic cord under ultrasound guidance. This will be a 10 ml injection done once at the initial visit. Before the injection of saline, a spermatic cord block using bupivacaine will be completed to numb the area for treatment.
3075318|NCT02058823|Placebo Comparator|Arm 1: Real hypoxia and ¨Placebo|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the placebo during the first two weeks and, after the wash-out, receive the treatment of the arm 2.
3075319|NCT02058823|Placebo Comparator|Arm 2: Hypoxia placebo and Placebo|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the hypoxia placebo and the placebo during the first two weeks and, after the wash-out, receive the treatment of the arm 1.
3075320|NCT02058823|Active Comparator|Arm 3: Hypoxia and Valsartan|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the Valsartan during the first two weeks and, after the wash-out, receive the treatment of the arm 4.
3075321|NCT02058823|Active Comparator|Arm 4: Hypoxia and Amlodipine|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the amlodipine during the first two weeks and, after the wash-out, receive the treatment of the arm 3.
3075322|NCT02058810|Other|Conventional nasal Oxygen|Conventional nasal Oxygen as needed
3075323|NCT02058810|Other|Nasal high flow|Nasal high flow therapy with FiO2 40% and flow of 40l/min for at least 48h
3075324|NCT02058797|Experimental|Coherence Therapy|Individual treatment with Coherence Therapy: three one-hour sessions + one booster session.
3075325|NCT02058797|Active Comparator|Cognitive Behavioral Therapy|Individual treatment with Cognitive Behavioral Therapy: three one-hour sessions + one booster session.
3075326|NCT02058784|Experimental|Single-dose food effect in nonsmokers|Randomized, two-treatment design in nonsmoking healthy subjects. Single-dose pracinostat to be given under fasted and fed conditions followed by PK sampling for up to 48 hour post dose.
3075327|NCT02058784|Experimental|Single-dose food effect in smokers|Single-dose parallel treatment design in moderate to heavy smoking healthy subjects. Single-dose pracinostat will be given under fasted conditions followed by PK blood sampling up to 48 hours.
3075328|NCT02058771||Ischaemic cardiomyopathy|Patients with ischaemic cardiomyopathy attending for ICD implantation
3075329|NCT02058758||Healthy Volunteers|Device: Magnetic Resonance Imaging
3075330|NCT02058758||Breast Cancer Patients|Device: Magnetic Resonance Imaging
3075331|NCT02058745|Active Comparator|CAU+ (Enhanced Care as Usual)|CAU+ (Enhanced Care as Usual) is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page for the 10 month duration of the study.
3075332|NCT02058745|Experimental|CAU+ and SmartCare|CAU+ (Enhanced Care as Usual) for eight weeks, followed by eight weeks of SmartCare. SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management.
3075333|NCT02058745|Experimental|CAU+ and Beating the Blues and SmartCare|CAU+ (Enhanced Care as Usual) and Beating the Blues concurrently for eight weeks, followed by SmartCare for eight weeks. Beating the Blues is an established, web-based, self-directed, cognitive behavioral therapy for managing depressive symptoms.
3075334|NCT02058732|Active Comparator|ALS patients receivng stem cells|Amyotrophic lateral sclerosis(ALS)subjects, who will be receiving stem cells, will undergo a brief clinical evaluation and questionnaire that will last approximately 20 to 30 min. Subjects will be asked to undergo magnetic resonance imaging(MRI)scans of the cervical spine and brain that will last approximately 60 minutes.
3075335|NCT02058732|Active Comparator|ALS patients not receiving stem cells|Amyotrophic lateral sclerosis(ALS)patient who will not be receiving stem cells, will have an MRI that lasts approximately 60 minutes. This MRI will be repeated at three different time points. Subjects will have an initial MRI, then another at both 6 and 12 months after the initial magnetic resonance imaging(MRI)scan. Subjects will also complete a clinical examination which will take approximately 30 minutes for each MRI. The follow-up magnetic resonance imaging(MRI)scans done for ALS patients who do not receive stem cells are part of routine clinical studies and therefore subjects will not be billed.
3075336|NCT02058719||Cohort A1|HIV positive smokers
3075337|NCT02058719||Cohort A2|HIV positive non-smokers
3075338|NCT02058719||Cohort A3|HIV negative smokers
3075339|NCT02058719||Cohort A4|HIV negative non-smokers
3075340|NCT02058719||Cohort B1|HIV positive with COPD
3075341|NCT02058719||Cohort B2|HIV positive without COPD (non-COPD)
3075342|NCT02058719||Cohort B3|HIV negative with COPD
3075343|NCT02058706|Experimental|Arm A (enzalutamide and LHRH analogue therapy)|Patients receive enzalutamide orally PO QD and undergo orchiectomy or receive LHRH analogue therapy (leuprolide acetate, goserelin acetate, or any other FDA approved preparation). Treatment continues in the absence of disease progression or unacceptable toxicity.
3075344|NCT02058706|Active Comparator|Arm B (bicalutamide and LHRH analogue therapy)|Patients receive bicalutamide PO QD and undergo orchiectomy or receive LHRH analogue therapy as in Arm A. Treatment continues in the absence of disease progression or unacceptable toxicity.
3075345|NCT02058693|Placebo Comparator|Placebo Group|"Phase I (3 weeks) placebo adjunctive to Anti-Depressant Therapy (ADT). The total daily dosing of the concurrent ADT will be as follow: escitalopram 10-40 mg; Fluoxetine 20-80 mg; paroxetine CR 25-100 mg (paroxetine 20-80 mg may be substituted if paroxetine CR is not available); sertraline 100-400 mg; venlaflaxine XR 150-600 mg; desvenlafaxine 50-200 mg; citalopram 20-80 mg; or duloxetine 60-180 mg; buproprion 150-450 mg; mirtazapine 15-45 mg, tricyclics (standard dosing, individually per label instructions).~Phase II (3 weeks) mixed salts amphetamine adjunctive to ADT"
3075375|NCT02058472|Experimental|G3041|Amlodipine orotate 10mg/Olmesartan medoxomil 40mg
3075376|NCT02058472|Active Comparator|SEVIKAR®|Amlodipine besylate 10mg/Olmesartan medoxomil 40mg
3075377|NCT02058459|Active Comparator|Targeted Lung Denervation|active targeted lung denervation
3075346|NCT02058693|Active Comparator|MSA group|"mixed salts amphetamine, adjunctive to Anti-Depressant Therapy (ADT). The total daily dosing of the concurrent ADT will be as follow: escitalopram 10-40 mg; Fluoxetine 20-80 mg; paroxetine CR 25-100 mg (paroxetine 20-80 mg may be substituted if paroxetine CR is not available); sertraline 100-400 mg; venlaflaxine XR 150-600 mg; desvenlafaxine 50-200 mg; citalopram 20-80 mg; or duloxetine 60-180 mg; buproprion 150-450 mg; mirtazapine 15-45 mg, tricyclics (standard dosing, individually per label instructions).~Phase II (3 weeks) mixed salts amphetamine adjunctive to ADT"
3075347|NCT02058680|Experimental|PSA/IL-2/GM-CSF vaccine|"In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43."
3075348|NCT02058667|Experimental|Paclitaxel+Initial Radiation+Boost|Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
3075349|NCT02058654|Experimental|Creatine Group|Whey protein (30 g) and creatine supplement (5 g) shaken with 250-300 ml water in a blender bottle, and the full shake to be taken twice a day for 14 days.
3075350|NCT02058654|Placebo Comparator|Placebo Group|Whey protein (30 g) and bulking agent powder (5 g) shaken with 250-300 ml water in a blender bottle, and the full shake to be taken twice a day for 14 days.
3075351|NCT02058641|Experimental|Part A|Part A will consist of 2 sessions. In Session 1, 3 blisters will be induced by a challenging agent (cantharidin solution 0.2 %, with 5 microliter administered topically) in T2DM subjects on Day 1. Blisters will be harvested 48 (+/-2) hour (hr) post induction. In Session 2, the same subjects will be administered darapladib EC tablet 160 mg orally, once daily for 11 days. On Day 10, 3 blisters will be induced by cantharidin. Blisters will be harvested 48 (+/-2) hr post induction.
3075352|NCT02058641|Experimental|Part B|In Part B, healthy subjects will be enrolled and will follow the same dosing procedure as in Part A. The decision to initiate Part B will be made by the GSK study team based on an evaluation of data from Part A.
3075353|NCT02058628|Experimental|Arm 1|A total of 110 subjects will receive clindamycin + BPO once daily in the evening for 12 weeks as per the randomization schedule.
3075354|NCT02058628|Experimental|Arm 2|A total of 110 subjects will receive azelaic acid twice daily (1 in the morning and 1 in the evening) for 12 weeks as per the randomization schedule.
3075355|NCT02058615|Experimental|Male Spouse Transition Toolkit|All participants in this group will be given access to the Male Spouse Transition Toolkit (MaTT). MaTT is a website based application that is designed to help male spouses of women with breast cancer to increase their awareness of the transitions and experiences they have as a husband and caregiver as well as to stay organized and seek help and resources as needed. To do so it consists of six sections: about me; common changes to expect; frequently asked questions; resources; calendar; and, important health information. These sections contain activities and exercises, as well as fillable templates (i.e., resources, calendar) that users can download at their convenience, from their home computer, tablet, or smart phone. They will be asked to use the MaTT for one month.
3075356|NCT02058615|No Intervention|Usual Care|Participants in this group will not receive access to the Male Spouse Transition Toolkit, and thus will not receive an intervention. Data collection for outcome variables will be the same as the participants in the experimental arm.
3075357|NCT02058602|Experimental|Arm 1|This is a clinical study to characterise the lung function, airway morphometry, pharyngometry and inhalation profiles in patients with mild to severe Idiopathic Pulmonary Fibrosis (IPF) over a period of up to 6 months. Approximately 30 subjects will be enrolled so that at least 20 subjects complete all critical assessments.
3075358|NCT02058589|Experimental|GSK1437173A Group|Subjects, aged 18 years or older, received 2 doses of the GSK 1437173A vaccine, adjuvanted with AS01B at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
3075359|NCT02058589|Placebo Comparator|Placebo Group|Subjects, aged 18 years or older, received 2 doses of Placebo (lyophilised sucrose reconstituted with saline [NaCl] solution) at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
3075360|NCT02058576|Experimental|Sequence AB|Subjects will receive Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 1 and Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination) in period 2 orally once daily under fed condition.
3075361|NCT02058576|Experimental|Sequence BA|Subjects will be randomized to receive Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 1 and Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 2 orally once daily under fed condition.
3075362|NCT02058563|Experimental|INV_MMR Group|Subjects will receive 1 dose of GSK Biologicals' trivalent Measles, Mumps, and Rubella Virus Vaccine (Priorix®).
3075363|NCT02058563|Active Comparator|COM_MMR Group|Subjects will receive 1 dose of Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine.
3075364|NCT02058550|No Intervention|Arm I (no intervention)|Patients receive no additional reminders.
3075365|NCT02058550|Experimental|Arm II (email survey)|Patients receive a reminder email survey every 2 weeks for 1 year after completing radiation.
3075366|NCT02058550|Experimental|Arm III (email surveys and phone calls)|Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.
3075367|NCT02058537|Experimental|Bethanechol|Oral administration of 25 milligrams of bethanechol taken twice daily for a minimum of 7 days. Total dose taken daily for a minimum of 7 days is 50 mg.
3075368|NCT02058524|Experimental|fecal microbiota transplantation|
3075369|NCT02058511|Experimental|Intervention Group|"all enrolled patients undergo the same protocol/ treatment:~Anesthesia Premedication, Induction and Maintenance Pupillometry after administration of anesthetic drugs"
3075370|NCT02058498|Experimental|Liver Transplant Patients|Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log.
3075371|NCT02058485|Active Comparator|Group HD|Dexmedetomidine was administered 0.5 µg.kg-1 in hypertensive patient
3075372|NCT02058485|Sham Comparator|Group ND|Dexmedetomidine was administered 0.5 µg.kg-1 in normotensive patient
3075373|NCT02058485|Active Comparator|Group HM|Midazolam was administered 0.025 mg. kg-1 in hypertensive patient.
3075380|NCT02058433|Experimental|pharmacokinetics group|Based on pharmacokinetics. Observe safety and efficacy. In first cycle a fixed Paclitaxel dose depends on BSA. In subsequent cycles the dosage of Paclitaxel will be adjusted depending on pharmacokinetics follow up .
3075381|NCT02058433|Active Comparator|Body surface area(BSA) group|Based on body surface area. The dosage of Paclitaxel is based on the BSA of the patient. Paclitaxel/carboplatin up to 4 cycles or disease progression or intolerable toxicity.
3075382|NCT02058420|No Intervention|Placebo group|No active dose of tocotrienols
3075383|NCT02058420|Active Comparator|Low tocotrienols group|Low dose of tocotrienols
3075384|NCT02058420|Active Comparator|High tocotrienols group|High dose of tocotrienol
3075385|NCT02058407|Experimental|Cohort 1- Part A|This cohort will follow an interlocking design with Cohort 2 - Part A. Out of the 9 healthy subjects in this cohort, 3 subjects will receive placebo and 6 subjects will receive GSK2793660 according to randomization schedule in three single-dose study periods. Drug administration will be staggered over 2 days in each period. On Day 1, only 1 subject will receive GSK2793660 and 1 subject will receive placebo. The remaining subjects will be dosed on Day 2 of each treatment period assuming adequate safety from Day 1. Placebo administration and an escalation of GSK2793660 from 0.5 mg, to 3 mg, and 20 mg in the subsequent periods, will be done with a minimum washout period of 13 days between doses. If the target clinical dose is determined as being one of the doses administered to this cohort, they will have an additional study period for the administration of target clinical dose GSK2793660 following the standard Food and drug administration (FDA) high fat/high calorie meal.
3075386|NCT02058407|Experimental|Cohort 2- Part A|This cohort will follow an interlocking design with Cohort 1 - Part A. Out of the 9 healthy subjects in this cohort, 3 subjects will receive placebo and 6 subjects will receive GSK2793660 according to randomization schedule in three single-dose study periods. Drug administration will be staggered over 2 days in each period. On Day 1, only 1 subject will receive GSK2793660 and 1 subject will receive placebo. The remaining subjects will be dosed on Day 2 of each treatment period assuming adequate safety from Day 1. Placebo administration and an escalation of GSK2793660 from 1 mg, to 10 mg, and 50 mg in the subsequent periods, will be done with a minimum washout period of 13 days between doses. If the target clinical dose is determined as being one of the doses administered to this cohort, they will have an additional study period for the administration of target clinical dose GSK2793660 following the standard FDA high fat/high calorie meal.
3075387|NCT02058407|Experimental|Cohort 3- Part B|It is planned that up to two doses evaluated in Part A will be taken through to Part B. In this cohort, the lower dose (which will be the likely clinically efficacious dose) will be given for 14 days. The dosing frequency (once a day or twice daily) will be based on a review of the safety, tolerability, PK and PD data from Part A. It is planned that 10 subjects will receive GSK2793660 and 5 subjects will receive placebo. Subjects will be dosed on Day 1 and then on Days 3-15 (assuming once-daily dosing). If dosing is twice-daily, doses will be administered in the morning and evening from Day 1-14.
3075388|NCT02058407|Experimental|Cohort 4- Part B|It is planned that up to two doses evaluated in Part A will be taken through to Part B. In this cohort, the higher dose (maximum tolerated or safe dose) will be given for 14 days. The dosing frequency (once a day or twice daily) will be based on a review of the safety, tolerability, PK and PD data from Part A. It is planned that 10 subjects will receive GSK2793660 and 5 subjects will receive placebo. Subjects will be dosed on Day 1 and then on Days 3-15 (assuming once-daily dosing). If dosing is twice-daily, doses will be administered in the morning and evening from Day 1-14. Cohort 4 will commence only after Cohort 3 is completed and data is reviewed. Also there will be no Cohort 4, if only one dose is to be evaluated in Part B.
3075389|NCT02058394||Cataract Phacoemulsification|Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
3075390|NCT02058381|Experimental|Group 1 (alpelisib)|Alpelisib plus Tamoxifen and Goserelin (Group 1)
3075391|NCT02058381|Experimental|Group 2 (buparlisib)|Buparlisib plus Tamoxifen and Goserelin (Group 2)
3075392|NCT02058368|Experimental|Arm 1|Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatin placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet once daily (OD) (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 dutasteride 0.5 milligram (mg) capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.
3075393|NCT02058368|Experimental|Arm 2|Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatine placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet OD (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 placebo dutasteride 0.5mg capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.
3075394|NCT02058355|Experimental|Personalized Normative Feedback|This group receive the complete Personalized Normative Feedback (with normative information and a list of consequences)
3075395|NCT02058355|Experimental|Normative Feedback|This group receive a feedback only with normative informations (without a list of consequences)
3075396|NCT02058355|Experimental|Consequences List Feedback|This group receive a list of consequences without normative informations
3075397|NCT02058342|Experimental|Active Play at Home Intervention|Participant parents in the intervention arm will receive: 1) Active Play at Home curriculum and equipment, 2) Training session on Active Play at Home curriculum, 3) counseling on physical activity scheduling, identification of barriers, motivational strategies, 4) phone calls to check on compliance and issues with doing the program at home
3075398|NCT02058342|No Intervention|Wait-listed control|Participants will attend the baseline visit to do baseline measurements but will not receive any materials related to the Active Play at Home curriculum and will also not be contacted by phone during the control 24 weeks. After they serve as control group, they will be provided with the opportunity to receive the intervention.
3075399|NCT02058329|No Intervention|No intervention|Standard of care with no home visit
3075512|NCT02057575|Active Comparator|Netarsudil (AR-13324) Ophthalmic Solution|Netarsudil (AR-13324) Ophthalmic Solution
3098933|NCT01898845|Experimental|LEE011|LEE011
3075400|NCT02058329|Experimental|Home Visit|After the post hip-fracture patient is discharged to home, there will be home visits by a geriatric fellow assess overall function and response to treatment/s by depression screen, FIM scores, and environmental risk assessment
3075401|NCT02058316||Patients at risk for IPA|
3075402|NCT02058303|Experimental|Exparel forearm block|Under ultrasound guidance, 3-5 mL Exparel will be injected around the 3 nerves of the forearm prior to surgery. 20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
3075403|NCT02058303|Active Comparator|Bupivacaine supraclavicular block|Under ultrasound guidance, 20-30 mL 0.5% Bupivacaine will be used for the supraclavicular block.
3075404|NCT02058290|Active Comparator|IV Morphine Sulfate or Sponsor-approved Equivalent|Standard of Care (SOC)
3075405|NCT02058290|Experimental|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
3075406|NCT02058277|Other|Healthy volunteers|Healthy volunteers taking a single dose of bosutinib and a single dose of bosutinib plus aprepitant in random order
3075407|NCT02058264|Experimental|Low Strength BBI-4000 and Vehicle|
3075408|NCT02058264|Experimental|High Strength BBI-4000 and Vehicle|
3075409|NCT02058251|Experimental|Oxytocin|Each participant will self-administer a 40 IU dose of intranasal oxytocin.
3075410|NCT02058251|Placebo Comparator|Control|Each participant will self-administer a 40 IU dose of intranasal saline.
3075411|NCT02058238||Arm 1: Robotic-guided, Open approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
3075412|NCT02058238||Arm 2: control-arm - non-robotic, open approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
3075413|NCT02058238||Arm 3: robotic-guided, MIS approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
3075414|NCT02058238||Arm 4: control-arm - freehand, MIS approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
3075415|NCT02058225||Infant Group 1|This group consist of healthy, full-term babies whose mothers have no known medical conditions or complications during pregnancy.
3075416|NCT02058212|Placebo Comparator|no antioxidant , ROS , pregnancy outcome|no anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) will be given to endometriotic women undergoing IVF
3075417|NCT02058212|Active Comparator|antioxidant , ROS , pregnancy outcome|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium)
3075418|NCT02058199|Experimental|normal subjects|A single dose of 10 mg of rivaroxaban will be administered
3075419|NCT02058199|Experimental|Obese non bypassed|A single dose of rivaroxaban will be administered
3075420|NCT02058199|Experimental|obese bypassed|A single dose of rivaroxaban will be administered
3075421|NCT02058199|Experimental|pre and post bypassed subject|A single dose of rivaroxaban will be administered prior to gastric bypass. Subjects will be restudied 12 to 24 weeks following bypass
3075422|NCT02058186|Active Comparator|Atopic dermatitis patients: Active|Atopic dermatitis patients: age 1-18 years old
3075423|NCT02058186|Placebo Comparator|Atopic dermatitis patients: Placebo|Atopic dermatitis patients: age 1-18 years old
3075424|NCT02058173|Experimental|chloroquine|150 mg chloroquine and lacebo , one tablet daily for 2 month
3075425|NCT02058173|Experimental|placebo|150 mg chloroquine and lacebo , one tablet daily for 2 month
3075426|NCT02058160|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC once daily (QD) for 30 weeks. Dose individually adjusted.
3075427|NCT02058160|Active Comparator|Insulin glargine|Insulin glargine 100 U/mL QD for 30 weeks. Dose individually adjusted.
3075428|NCT02058147|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC once daily (QD) for 30 weeks. Dose individually adjusted.
3075429|NCT02058147|Active Comparator|Insulin Glargine|Insulin glargine QD for 30 weeks. Dose individually adjusted.
3075430|NCT02058147|Active Comparator|Lixisenatide|Lixisenatide 10 mcg QD for 2 weeks, then 20 mcg QD (maintenance dose).
3075431|NCT02058134|No Intervention|Control group|
3075432|NCT02058134|Experimental|Interventional group|For patients in the interventional group we use a CardioPAT cell saver intra- and postoperatively.
3075433|NCT02058121|Experimental|Acceptance and Commitment Therapy|
3075434|NCT02058121|Active Comparator|Treatment as usual|
3075435|NCT02058108|Experimental|Telbivudine|Patients of any age and weight< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
3075436|NCT02058108|Placebo Comparator|Placebo|Patients of any age and weight < 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
3075437|NCT02058095|Active Comparator|tadalafil|"Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is >95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil.~At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil.~At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil."
3075480|NCT02057796|Experimental|Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|"Arm1 Extensive TB screening:~In this arm, point-of-care tests for TB will be used at randomization (in all patients) and at each scheduled or unscheduled follow-up visit (in patients with signs or symptoms suggestive of TB and no clear alternative diagnosis); TB treatment will only be prescribed to patients with a diagnosis of TB"
3075438|NCT02058095|Placebo Comparator|Placebo|"Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is >95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo.~At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo.~At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo."
3075439|NCT02058082|Active Comparator|ejaculated sperm|Intracytoplasmic sperm injection (ICSI) cycles using ejaculated sperm
3075440|NCT02058082|Active Comparator|testicular extracted sperm|Intracytoplasmic sperm injection (ICSI) cycles using testicular extracted sperm
3075441|NCT02058069|Experimental|Robotic Assisted Total Knee Arthroplasty|
3075442|NCT02058056|Experimental|Experimental: HA-PCI treatment|Irradiation HA-PCI concomitant to the second cycle of CHT and to tRT for patients with LD SCLC
3075443|NCT02058030|Other|3cm head elevation|Insertion of ProSeal laryngeal mask airway
3075444|NCT02058030|Active Comparator|6cm head elevation|Insertion of ProSeal laryngeal mask airway
3075445|NCT02058017|Experimental|Part I & Part II|"Part I - This is a lead-in dose-finding, open-label, non-randomised arm of the study: Using a starting dose of 10mg per week, an accelerated dose titration escalation followed by a 3+3 design will be employed until MTD and recommended weekly dose are determined.~Part II - This is a single-centre, open-label non-randomised phase II study evaluating OPB-51602 in stage III-IVB NPC conducted in the window period prior to definitive chemoradiotherapy. Eligible patients will receive OPB-51602 on a weekly basis (Day 1, 8, 15) at the recommended dose determined in part I for a total of 15 days prior to definitive chemoradiotherapy."
3075446|NCT02058004|Experimental|Cricoid pressure|Patients randomized to receive cricoid pressure during endotracheal intubation.
3075447|NCT02058004|No Intervention|No cricoid pressure|Patients randomized to receive no cricoid pressure during endotracheal intubation.
3075448|NCT02057991|No Intervention|Group I (standard of care)|Patients and caregivers receive standard of care.
3075449|NCT02057991|Experimental|Group II (educational video)|Patients and caregivers receive a 20-minute self-playing interactive educational video brochure.
3075450|NCT02057991|Experimental|Group III (educational video, mindfulness exercise video)|Patients and caregivers receive a 20-minute self-playing interactive educational video brochure and watch a 20-minute interactive mindfulness exercise video.
3075451|NCT02057978||EXCEL DES|Use EXCEL DES implatationas as control group,Implant DES for CAD cases
3075452|NCT02057978||EXCEL-II DES|EXCEL-II DES implantation as control group,Implant DES for CAD cases
3075453|NCT02057965|Active Comparator|Mesenchymal Stromal Cells + Everolimus|"Intervention: two doses of autologous bone marrow (BM) derived Mesenchymal Stromal Cells IV, 7 days apart, 6 and 7 weeks after transplantation in combination with Certican® (1.5mg/day). Doses of MSCs will be 1-2x10^6 million MSCs per/kg body weight.~At the time of the second MSC infusion tacrolimus will be withdrawn in 2 weeks (after 1 week dose of tacrolimus wil be halved, after 2 weeks stopped)"
3075454|NCT02057965|No Intervention|Everolimus + Tacrolimus|Patients in the control group will receive Certican® (1.5 mg b.i.d.) and standard dose tacrolimus (through levels 6-8 ng/ml after 6 weeks).
3075455|NCT02057952|No Intervention|Usual Care Control|No intervention.
3075456|NCT02057952|Active Comparator|In Person Weight Management|Education and exercise in a community health center environment.
3075457|NCT02057952|Experimental|Video Conference Weight Management|Education and exercise delivered through video conference.
3075458|NCT02057939|Experimental|Enzalutamide|Enzalutamide, Androgen Deprivation, and Radiation Therapy
3075459|NCT02057926|Experimental|Tetracycline, Without Tetracycline|The study consist in two groups: test group (membrane treated with tetracycline) and control group (membrane no treated with tetracycline).
3075460|NCT02057913|Experimental|Vinflunine|All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
3075461|NCT02057900|Experimental|Human embryonic stem cell|Patients with ischemic heart failure receiving a fibrin gel embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors in addition to coronary artery bypass grafting and/or a mitral valve procedure.
3075462|NCT02057887|Experimental|Cohort1|HM10660A SC once weekly
3075463|NCT02057887|Experimental|Cohort2|HM10660A SC once every 2 weeks
3075464|NCT02057887|Experimental|Cohort3|HM10660A SC once every 4 weeks
3075465|NCT02057887|Active Comparator|Cohort4|180 mcg Pegasys SC once weekly
3075466|NCT02057874|Experimental|Diagnostic (3T MRI)|Patients undergo 3T MRI at baseline (=< 2 weeks before TACE) and at 2-4 weeks, 4-8 weeks, and 12 weeks after TACE. Each 3T MRI session will utilize a sequence of the following modalities: CEST-MRI, MT-MRI, DW-MRI, and DCE-MRI.
3075467|NCT02057861||non-diabetic|non-diabetic group; 2 mg/kg sugammadex iv, postoperatively Extubation times were recorded.
3075468|NCT02057861||diabetic|Diabetic group; 2 mg/kg sugammadex iv, postoperatively Extubation times were recorded
3075469|NCT02057848|Active Comparator|low amount of carbohydrates|2 x 10 g carbohydrates (muesli bars)
3075470|NCT02057848|Active Comparator|high amount of carbohydrates|2 x 20 g carbohydrates (muesli bars)
3075471|NCT02057848|Other|Rapid-acting carbohydrates|30 g rapidly absorbable carboh. + 20 g muesli bar
3075472|NCT02057835|Experimental|BI 691751 low dose 1|BI 691751 low dose 1
3075473|NCT02057835|Experimental|BI 691751 low dose 2|BI 691751 low dose 2
3075474|NCT02057835|Experimental|BI 691751 middle dose|BI 691751 middle dose
3075475|NCT02057835|Experimental|BI 691751 high dose|BI 691751 high dose
3075476|NCT02057822||vernal keratoconjunctivitis|The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjonctivitis and in control subjects
3075477|NCT02057822||healthy children|The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjunctivitis and in control subjects
3075478|NCT02057809||Parent-child dyad|Children with Developmental Disabilities and their parents
3075479|NCT02057809||Therapits|Therapists experienced in serving children with developmental disabilities
3075511|NCT02057575|Experimental|PG324 Ophthalmic Solution 0.02%|PG324 Ophthalmic Solution 0.02%
3075481|NCT02057796|Experimental|Rifampin, isoniazid, pyrazinamide, ethambutol|"Arm 2: Systematic Empiric treatment (Rifampicin,isoniazid, pyrazinamide, ethambutol) ART~In this arm, all patients will start a systematic 6-month TB treatment at randomization. TB screening tests will not systematically be used neither at randomization nor while patients are on TB treatment."
3075482|NCT02057783|Experimental|Physical activity|Obstructive sleep apnea and resistant hypertension controlled + physical activity
3075483|NCT02057783|No Intervention|Control Group|Obstructive sleep apnea and resistant hypertension controlled
3075484|NCT02057770|Experimental|Treatment (preparative regimen, transplant, cyclophosphamide)|"BUSULFAN AND FLUDARABINE BASED PREPARATIVE REGIMEN: Patients receive busulfan IV over 3 hours on days -7 to -4, fludarabine phosphate IV over 30-60 minutes on days -6 to -2, and cyclophosphamide IV over 60 minutes on days -3 and -2.~OR~FLUDARABINE AND TBI BASED PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -4 and undergo TBI twice daily on days -3 to 0.~AND~DONOR CELL INFUSION: Patients undergo HLA-matched sibling stem cell transplant, HLA-matched unrelated, or HLA-haploidentical transplant on day 0.~AND~POST-TRANSPLANT CYCLOPHOSPHAMIDE: Patients receive cyclophosphamide IV over 90 minutes on days 3 and 4."
3075485|NCT02057770|Experimental|CRS preventive regimen|The final ~15 people enrolled who will be recipients of haploidentical transplants will receive tocilizumab IV over 60 minutes 6-12 hours prior to the start of the donor cell infusion.
3075486|NCT02057757|Experimental|Nitazoxanide (NTZ)|Participants will receive NTZ for 5 days. Participants younger than 12 years will receive an oral suspension formulation of NTZ; participants 12 years and older will receive NTZ tablets.
3075487|NCT02057757|Placebo Comparator|Placebo|Participants will receive placebo for 5 days. Participants younger than 12 years will receive an oral suspension formulation of placebo; participants 12 years and older will receive placebo tablets.
3075488|NCT02057744||Robotic-guided|Adult patients (21 years or older) undergoing short (4 or less consecutive vertebrae) thoracic, lumbar or lumbosacral percutaneous/minimally invasive robotic-guided spinal fixation surgery.
3075489|NCT02057744||Freehand image-guided|Adult patients (21 years or older) undergoing short (4 or less consecutive vertebrae) thoracic, lumbar or lumbosacral percutaneous/minimally invasive image-guided freehand or navigated spinal fixation surgery.
3075490|NCT02057731||Ia carriers|Carriers of GSD type Ia will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
3075491|NCT02057731||Ib carriers|Carriers of GSD type Ib will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
3075492|NCT02057731||III carriers|Carriers of GSD type III will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
3075493|NCT02057731||0, VI, IX carriers|Carriers of GSD types 0, VI, and IX will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
3075494|NCT02057731||Noncarriers|Noncarriers of any type of GSD will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to ensure their noncarrier status. A questionnaire will also be filled out.
3075495|NCT02057718|Experimental|LUM001|Participants will receive LUM001 twice a day (BID).
3075496|NCT02057692|Experimental|LUM001|LUM001 for oral administration
3075497|NCT02057692|Placebo Comparator|Placebo|Placebo administered orally once each day
3075498|NCT02057679|Active Comparator|Group A (Amoxicillin Clavulanic)|Intake of active drug (Amoxicillin Clavulanic). 3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.
3075499|NCT02057679|Placebo Comparator|Placebo|Intake of placebo (Lactose). 1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
3075500|NCT02057666|Experimental|Tasquinimod|Main study: 1 capsule (0.25, 0.50 or 1 mg) daily, taken orally once a day with water and food (preferably the main evening meal).
3075501|NCT02057666|Placebo Comparator|Placebo|1 capsule daily, taken orally once a day with water and food (preferably the main evening meal).
3075502|NCT02057653||Before GDFM Training|Approximate 300 patients' medical record information will be extracted from the UC Irvine Medical Center electronic medical record prior to the start of the training curriculum.
3075503|NCT02057653||After GDFM Training|Approximate 300 patients' medical record information will be extracted from the UC Irvine Medical Center electronic medical record after the training program took place
3075504|NCT02057640|Experimental|Combination therapy: Panobinostat, dexamethasone, MLN9708|Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 4mg on day 1, 8, 15, 28
3075505|NCT02057627|Experimental|Perinatal Dyadic Psychotherapy|The Perinatal Dyadic Psychotherapy intervention consists of 8 home-based, nurse-delivered mother-infant sessions consisting of (a) a supportive, relationship-based, mother-infant psychotherapeutic component, and (b) a developmentally based infant-oriented component focused on promoting positive mother-infant interactions. The 8 sessions take place over three months with weekly 4 sessions (weeks 1 through 4) followed by 4 every other week sessions (weeks 5 through 8)
3075506|NCT02057627|Placebo Comparator|Standard care plus depression monitoring|Standard care plus depression monitoring by phone on a schedule comparable to the intervention groups' home visits. Eight phone calls will take place over three months with weekly 4 calls (weeks 1 through 4) followed by 4 every other week calls (weeks 5 through 8). Phone monitoring will include administration of the Edinburgh Postnatal Depression Scale.
3075507|NCT02057601|Experimental|Infiltration group|The patients in this group will receive spinal anaesthesia with intrathecal bupivacaine 0.5% 2.0ml and will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
3075508|NCT02057601|No Intervention|Non infiltration group|The patients in this group will receive spinal anaesthesia with intrathecal bupivacaine 0.5% 2.0 ml.
3075509|NCT02057588|Other|LV Paced sites|LV pacing sites : Patients will be paced from various left ventricular origin, defined by their 3D localization.
3075510|NCT02057575|Experimental|PG324 Ophthalmic Solution 0.01%|PG324 Ophthalmic Solution 0.01%
3075513|NCT02057575|Active Comparator|Latanoprost Ophthalmic Solution|Latanoprost Ophthalmic Solution
3075514|NCT02057562||Routine colonoscopy|Patients receiving routine colonoscopy (for a multitude of indications) at the study centers are eligible for participation
3075515|NCT02057549|Experimental|Haloperidol plus Conventional Therapy|Intravenous dose of haloperidol 5 mg in addition to conventional therapy. Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
3075516|NCT02057549|Active Comparator|Conventional Therapy alone|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
3075517|NCT02057536|Experimental|Arm A|8 week directed exercise program
3075518|NCT02057536|Active Comparator|Arm B|No directed exercise other than patients normal level of activity
3075519|NCT02057523|Experimental|Acthar|Acthar 80 units twice weekly for 6 months. If endpoint is not reached, duration may be increased to 12 months.
3075520|NCT02057510||Patients receiving head and neck RT|No intervention
3075521|NCT02057497||Healthy volunteers|Considered generally healthy based on medical history and physical examination as per discretion of the investigator
3075522|NCT02057497||Type 1 Diabetes|T1DM diagnosed clinically prior to start of trial examinations
3075523|NCT02057497||Type 2 Diabetes|T2DM diagnosis prior to the start of trial examinations
3075524|NCT02057484||Organ transplant patients treated with Advagraf|To evaluate long-term graft survival in patients treated with Advagraf
3075525|NCT02057471|Experimental|Intravenous Ferric Carboxymaltose|All recruited patients will be allocated to this treatment. 1 gram of Ferric carboxymaltose (FERINJECT) to be given at recruitment
3075526|NCT02057458|Experimental|Acute (1 hour) Sildenafil & Placebo|In randomized order, on two separate days, exercise capacity and endothelial function will be determined 1 hour following a single dose of either sildenafil (50 mg) or placebo.
3075527|NCT02057458|Experimental|Sub Chronic (4 weeks) Sildenafil|Following the acute study, patients will be instructed to take 20 mg of sildenafil, three times a day, for 4 weeks. Exercise capacity and endothelial function will be determined within 48 hours following the last dose.
3075528|NCT02057445|Experimental|Recipient|EBV+ patients will receive 3rd party LMP-CTLs for treatment of EBV infection and/or disease
3075529|NCT02057445|Other|Donor|Healthy donors who are EBV+ will be asked to donate 60-120 ml of peripheral blood for development of cell lines to be stored for cell line bank.
3075530|NCT02057432|Experimental|Intra-operative MRI|Images will be obtained both before and after intravenous bolus injection with subsequent dynamic imaging. Dynamic contrast enhancement maps will be created for evaluation of residual tumor. Images will be reformatted into three orthogonal planes as well as into a 3D model for surgical orientation. All imaging protocols using contrast, contrast enhancement maps and reformatting, as described above, which will be applied to the intra-operative MRI performed in the AMIGO suite are consistent with the standard MRI breast imaging at Brigham and Women's Hospital.
3075531|NCT02057419||Contraceptive Method|"Protocol 1: 3-month use period for each of 3 contraceptive methods, randomly ordered. intravaginal ring, oral contraceptive pill, spermicide+condom; dosage and frequency as instructed...~Protocol 2: 3-month use period for 1st randomly assigned contraceptive method. At end of use period, user chooses to continue on 1st method or to switch to 2nd randomly assigned method for remaining 3-month use-period."
3075532|NCT02057419||Sexual Lubricant Method|3-month use period for each of 3 sexual lubricant methods, randomly ordered. gel formulation, film formulation, insert formulation; dosage and frequency as instructed
3075533|NCT02057406|Active Comparator|2:1 EPA/DHA|400/200 EPA/DHA fish oil 2 grams
3075534|NCT02057406|Active Comparator|High EPA|Almost pure EPA 2 grams
3075535|NCT02057406|Placebo Comparator|Placebo|Matched placebo corn oil capsules
3075536|NCT02057393|Experimental|Indocyanine Green|Single arm study, each subject receives 0.9ml ICG, methylene blue and technetium 99.
3075537|NCT02057380|Experimental|Arm A: High dose linsitinib twice daily monotherapy|Arm A includes subjects from Protocol OSI-906-301
3075538|NCT02057380|Experimental|Arm B: High dose linsitinib BID plus high dose erlotinib QD|Arm B includes subjects from Protocol OSI-906-205
3075539|NCT02057380|Experimental|Arm C: High dose erlotinib monotherapy once daily|Arm C includes subjects from Protocol OSI-906-205 and OSI-906-207
3075540|NCT02057380|Experimental|Arm D: High dose linsitinib BID plus weekly paclitaxel|Arm D includes subjects from Protocol OSI-906-202
3075541|NCT02057380|Experimental|Arm E: Highest dose linsitinib intermittent once daily|Arm E includes subjects from Protocol OSI-906-202, linsitinib on Days 1-3 of each week plus weekly paclitaxel
3075542|NCT02057380|Experimental|Arm F: Paclitaxel alone weekly|Arm F includes subjects from Protocol OSI-906-202
3075543|NCT02057380|Experimental|Arm G: Lowest dose linsitinib twice daily + low dose erlotinib|Arm G includes subjects from Protocol OSI-906-103
3075544|NCT02057380|Experimental|Arm H: high dose linsitinib twice daily|includes subjects from protocols SARC 022/CTEP 8945, linsitinib x28 days (each cycle)
3075545|NCT02057380|Experimental|Arm I: highest dose linsitinib once daily|includes subjects from EuroSARC protocol, linsitinib on Days 1-3; Days 8-10 and Days 15-17
3075546|NCT02057380|Experimental|Arm J: Low dose linsitinib 2x daily+bortezomib & dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
3075547|NCT02057380|Experimental|Arm K: med. dose linsitinib 2x daily+bortezomib&dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
3075548|NCT02057380|Experimental|Arm L: high dose linsitinib 2x daily+bortezomib&dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
3075549|NCT02057367|Experimental|Scalp block with 0.5% plain marcaine|Anterior scalp block with 0.5% plain Marcaine 20 ml.
3075550|NCT02057367|Placebo Comparator|Scalp block with 0.9% normal saline|Anterior scalp block with 0.9% normal saline 20 ml.
3075920|NCT02054910|Experimental|Celiac Plexus Block|Celiac Plexus Block will be administered following EUS
3075551|NCT02057354|Active Comparator|Healthy Sedentary Young Adults|Participants 18-35 years of age will be randomized to either aerobic or non-aerobic exercise training.
3075552|NCT02057354|Experimental|Healthy Sedentary Older Adults|Participants 55-85 years of age will be randomized to either aerobic or non-aerobic exercise training.
3075553|NCT02057341|Experimental|ARRY-371797 (Dose 1)|
3075554|NCT02057341|Experimental|ARRY-371797 (Dose 2)|
3075555|NCT02057328|Active Comparator|NEBIVOLOL|Patients of the group of nebivolol will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM (24h SBP/DBP < 130/80 mm Hg) will continue on the same medication scheme. Patients still classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range 12,5 mg hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
3075556|NCT02057328|Active Comparator|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisarta daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM (24h SBP/DBP < 130/80 mm Hg) will continue on the same medication scheme. Patients classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. The same procedure will be repeated at the end of the 6th month from the beginning of the study. Patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
3075557|NCT02057315|Experimental|ELS-M11|Topical 5% ELS-M11 (3 g)
3075558|NCT02057315|Placebo Comparator|Placebo|A matching formulation with no active ingredient
3075559|NCT02057302|Placebo Comparator|Group B|There are 538 patients recruited in this group. Patients in this group will take 2 capsules of placebo every time, twice every day, respectively after breakfast and supper.
3075560|NCT02057302|Experimental|Group A|There are 1614 patients recruited in this group. Patients in this group will take 2 capsules of Xuezhikang every time, twice every day, respectively after breakfast and supper.
3075561|NCT02057289|Experimental|Micafungin|"Subjects will be administered 5 mg/kg of micafungin intravenously as a ONE TIME dose.~For patients undergoing Hematopoietic Stem Cell Transplant (HSCT), Micafungin will be given on during rest days (i.e. days when no chemotherapy is administered) and blood for pharmacokinetic measurements will be drawn over next 96 hours.~Following this, further anti-fungal coverage will be at the discretion of the patient's attending physician. (I.e. other antifungal agent(s) or Micafungin at a standard clinical dose; repeat doses of 5mg/kg will NOT be administered.)"
3075562|NCT02057276|Active Comparator|Active rTMS|Participants will receive daily active rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
3075563|NCT02057276|Sham Comparator|Sham rTMS|Participants will receive daily sham rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
3075564|NCT02057263|Experimental|Alendronate and Hepatitis B Vaccine|Participants in the experimental arm will receive 4 alendronate doses during their Hepatitis B vaccination course.
3075565|NCT02057263|Experimental|Sugar Pill and Hepatitis B Vaccine|Participants in the experimental arm will receive placebo doses during their Hepatitis B vaccination course.
3075566|NCT02057250|Experimental|Sarilumab 150 mg by AID|Sarilumab 150 mg subcutaneous (SC) injection every 2 weeks (q2w) administered by AID with one or a combination of non-biologic disease-modifying anti-rheumatic drug (DMARD) (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
3075567|NCT02057250|Experimental|Sarilumab 150 mg by PFS|Sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
3075568|NCT02057250|Experimental|Sarilumab 200 mg by AID|Sarilumab 200 mg SC injection q2w administered by AID with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
3075569|NCT02057250|Experimental|Sarilumab 200 mg by PFS|Sarilumab 200 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
3075570|NCT02057237|Experimental|single arm|Mitotane will be administered on an outpatient or inpatient basis.
3075571|NCT02057224|Experimental|Single arm|15 clinical patients undergoing renal denervation
3075572|NCT02057211|Placebo Comparator|sham transplantation of mesenchymal stem cells|control arm with sham transplantation
3075573|NCT02057211|Active Comparator|autologous mesenchymal stem cell transplantation|Active arm with transplantation of cells
3075574|NCT02057198||Fidaxomicin|200 mg. 2 times a day for 10 days
3075575|NCT02057198||Metronidazole|500 mg.orally 3 times daily for 10 days
3075576|NCT02057198||Vancomycin|125 mg. orally 4 times a day for 10 days
3075658|NCT02056678|No Intervention|OSA, laparoscopic cholecystectomy, narcotics|No IV acetaminophen in obese patients at risk of obstructive sleep apnea intraoperatively during laparoscopic cholecystectomy; patients will receive other modalities for pain control primarily including IV narcotics
3075577|NCT02057185||Study population|"Patients diagnosed with Chronic Myeloid Leukaemia, Chronic Lymphocytic Leukaemia, Myelodysplastic Syndromes (low risk), Chronic Thrombocytopenia or Hodgkin Disease in complete remission, who have signed written informed consent according to ICH/EU/GCP and Italian laws, aged between 15 and 74 years old.~The study excludes non Italian speaking patients or unable to fully understand the study's forms."
3075578|NCT02057172|Experimental|HM11260C (0.3 mg)|Weekly administration of 0.3 mg of HMC11260C by subcutaneous injection for 12 weeks
3075579|NCT02057172|Experimental|HM11260C (1 mg)|Weekly administration of 1 mg of HM11260C by subcutaneous injection for 12 weeks
3075580|NCT02057172|Experimental|HM11260C (2 mg)|Weekly administration of 2 mg of HM11260C by subcutaneous injection for 12 weeks
3075581|NCT02057172|Experimental|HM11260C (3 mg)|Weekly administration of 3 mg of HM11260C by subcutaneous injection for 12 weeks
3075582|NCT02057172|Experimental|HM11260C (4 mg)|Weekly administration of 4 mg of HM11260C by subcutaneous injection for 12 weeks
3075583|NCT02057172|Placebo Comparator|Placebo|Weekly administration of placebo by subcutaneous injection for 12 weeks
3075584|NCT02057172|Active Comparator|Liraglutide|Liraglutide will be administered daily, at doses of 0.6 mg to 1.8 mg.
3075585|NCT02057159|Experimental|NeuroVax|NeuroVax
3075586|NCT02057159|Placebo Comparator|IFA Placebo|IFA Placebo
3075587|NCT02057146|Experimental|Mother-baby endoscopy|Spyglass mother-baby endoscopy in conjunction with ERCP
3075588|NCT02057133|Experimental|LY2835219 + Letrozole|LY2835219 administered orally. Letrozole administered orally. This arm is closed to enrollment.
3075589|NCT02057133|Experimental|LY2835219 + Anastrozole|LY2835219 administered orally. Anastrozole administered orally. This arm is closed to enrollment.
3075590|NCT02057133|Experimental|LY2835219 + Tamoxifen|LY2835219 administered orally. Tamoxifen administered orally. This arm is closed to enrollment.
3075591|NCT02057133|Experimental|LY2835219 + Exemestane|LY2835219 administered orally. Exemestane administered orally. This arm is closed to enrollment.
3075592|NCT02057133|Experimental|LY2835219 + Exemestane + Everolimus Dose Escalation|LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.
3075593|NCT02057133|Experimental|LY2835219 + Exemestane + Everolimus Dose Expansion|LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.
3075594|NCT02057133|Experimental|LY2835219+ Trastuzumab Dose Escalation|LY2835219 administered orally. Trastuzumab administered intravenously (IV) infusion. This arm is closed to enrollment.
3075595|NCT02057133|Experimental|LY2835219+ Trastuzumab Dose Expansion|LY2835219 administered orally. Trastuzumab administered IV infusion. This arm is closed to enrollment.
3075596|NCT02057133|Experimental|LY3023414 + LY2835219 + Fulvestrant Dose Escalation|LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered intramuscularly (IM).
3075597|NCT02057133|Experimental|LY3023414 + LY2835219 + Fulvestrant Dose Expansion|LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered IM.
3075598|NCT02057133|Experimental|LY2835219 +Trastuzumab +Pertuzumab +Loperamide Dose Escalation|LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.
3075599|NCT02057133|Experimental|LY2835219 +Trastuzumab + Pertuzumab +Loperamide Dose Expansion|"Hormone Receptor Negative (HR-): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.~Hormone Receptor Positive (HR+): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion. Endocrine therapy administered orally."
3075600|NCT02057133|Experimental|LY2835219 + Endocrine Therapy|LY2835219 administered orally. Ongoing endocrine therapy administered orally.
3075601|NCT02057120|Active Comparator|Grupo A (Kinesio Taping)|Will be held the application of Kinesio Taping (Tex Gold) in the region of the rectus femoris dominant lower limb by a physical therapist trained in the technique (KT1 KT2 and) and with experience in this type of application to be designed without knowing in which group fits this patient. In the sequence, the athlete will be oriented to remain at rest for 30 min to get a better grip on the tape and one of the first tests and rest, only after this period will conduct a new evaluation of jump tests (single leg Hop test and Triple Hop Test) and, finally, a new test of strength in the isokinetic dinamomêtro in conjunction with the electromyographic assessment.
3075602|NCT02057120|Placebo Comparator|Placebo Taping|The volunteer will receive a Placebo application tape, being in this case the physical therapist will apply a strip of Kinesio Taping perpendicular to the muscle fibers of the rectus femoris of the dominant member of the individual.
3075603|NCT02057107|Other|SBRT + Cetuximab + Docetaxel followed by Cetuximab + Docetaxel|Previously Treated With Cetuximab - Group A No Previous Cetuximab - Group C
3075604|NCT02057107|Other|SBRT + Cetuximab followed by Cetuximab|Previously Treated with Cetuximab - Group B No Previous Cetuximab - Group D
3075605|NCT02057094|Placebo Comparator|Control|Dining facility recovery feeding only, no supplemental protein consumed (an isoenergetic, carbohydrate supplement will be consumed by those assigned to the Control group)
3075606|NCT02057094|Active Comparator|Protein|"Consume dining facility food with:~2, 20 g whey protein supplements daily (for ~27 days)~1, 40 g casein protein supplement daily (for ~27 days)"
3075607|NCT02057094|Active Comparator|High-Protein|"Consume dining facility food with:~2, 40 g whey protein supplements daily (~27 days)~1, 50 g casein protein supplement daily (~27 days)"
3075608|NCT02057081|Experimental|Treatment|Intensive 12-session psychoeducational rehabilitation and skills-building intervention for couples.
3075609|NCT02057081|Active Comparator|Control|Didactic 14-session educational group intervention for families.
3075610|NCT02057081|No Intervention|Epigenetic|Optional blood draw at Bronx site only to investigate epigenetic biomarkers of treatment.
3075659|NCT02056665|Experimental|MINOCYCLINE 8 weeks|"Duration of treatment: 8 weeks~Patients <35 kg. 100 mg / day. Administered at a dose of one capsule of 50 mg breakfast and dinner.~Patients 35 - 50 kg. 150 mg / day. Administered at a dose of 2 capsules of 50 mg breakfast and 1 capsule of 50mg dinner.~Patients > 50 kg. 200 mg / day. Administered at a dose of two capsules of 50 mg of breakfast and dinner."
3075660|NCT02056665|Placebo Comparator|PLACEBO 8 weeks|Pill manufactured to mimic Minocycline 50 mg capsule
3075974|NCT02054559|Active Comparator|Total 6 cycles of R-CHOP|
3075611|NCT02057068|Experimental|SLEEP-E Dyads Intervention|"SLEEP-E Dyads Six-Week Tele-Health Intervention~. Daily core video modules on sleep education, sleep hygiene and behavioral and environmental factors influencing sleep.~. Daily and on-demand video modules designed to promote and provide guided instruction for daily Move Out time consisting of activity enhancement and exercise.~. Daily and on-demand video modules designed to promote and provide guided instruction for daily Stand Down time (meditation, therapeutic breathing and self-care).~. SLEEP-E Dyads book~. Two tele-video conferences to discuss evaluation results, obtain buy-in for the prescribed intervention and address dysfunctional beliefs and attitudes about sleep. The second call involves checking-in, encouragement, reinforcement and coaching"
3075612|NCT02057068|No Intervention|Usual Care Group|During the intervention period there is no data collection or contact with research staff other than for scheduling outcomes visits.
3075613|NCT02057055|Experimental|Soap 300000027003|Subjects will apply this soap to one of their arms daily in the shower for 3 weeks
3075614|NCT02057055|Experimental|Soap 300000029240|Subjects will apply this soap to one of their arms daily in the shower for 3 weeks
3075615|NCT02057042|Experimental|PS-cCBT|peer-assisted computerized CBT
3075616|NCT02057042|Active Comparator|EUC|Enhanced usual care
3075617|NCT02057029|Other|BCI Assay Results|The Breast Cancer Index (BCI) is a novel gene expression-based prognostic predictor for ER positive cancers and is provided through a CLIA certified commercial laboratory. It is an RT-PCR assay that can be performed on formalin fixed paraffin embedded sections of archived tissues. Participants will work in concert with a physician to determine future treatment options based on BCI results.
3075618|NCT02057003||DAA-based therapy against HCV|HIV/HCV-coinfected patients who start therapy against HCV including one or more DAA
3075619|NCT02056990||training advise|
3075620|NCT02056977|Experimental|Titration|Individualized PEEP titration by EIT
3075621|NCT02056977|Active Comparator|Control|PEEP stablished according to the routines at the institution (PEEP table according to the P/F ratio)
3075622|NCT02056964||Post-HEART Pathway Implementation|Data will be collected on patients presenting to the Emergency Department (ED) with chest pain after implementation of the HEART Pathway decision aid.
3075623|NCT02056964||Pre-HEART Pathway Implementation|Data will be collected on patients presenting to the Emergency Department (ED) with chest pain prior to Implementation of the HEART Pathway decision aid.
3075624|NCT02056951|Active Comparator|Multidisciplinary rehabilitation|The central objective of inpatient multidisciplinary orthopedic rehabilitation (MOR) is to improve functional health with the main focus on restoring and improving work ability. A MOR lasts on average 23 days with a total extent of therapy of 48 hours on average. MOR is provided by a multiprofessional team consisting of physicians, psychologists, sport therapists, physiotherapists, occupational therapists, masseurs, social workers, dieticians and nurses. The interventions are carried out mainly in open groups.
3075625|NCT02056951|Experimental|Interprofessional rehabilitation|The central objective of the interprofessional rehabilitation (PASTOR) is the development of active self-management of chronic non-specific low back pain. PASTOR is matched to the MOR with respect to the total duration and total extent of therapy, the included professions and the interventions dimensions (physical, psychological). The differences between PASTOR and MOR are characterized by, a) an integrative combination of profession related modules within a comprehensive and consistent treatment approach, b) an interprofessional and collaborative teamwork based on profession related modules, c) the use of standardized methods, media and materials by all professions in the therapeutic team d) a highly structured and detailed manual for the entire treatment process. The interventions are carried in fixed groups with eight to twelve participants.
3075626|NCT02056938|Experimental|ATG|"The first infusion of Thymoglobuline® begins before the kidney reperfusion. In case of a patient with a functional arteriovenous fistula or a high-flow venous catheter, the infusion of Thymoglobuline® can begin just after the randomization pre operatively. When the patient has no available arteriovenous fistula for the Thymoglobuline® infusion, it is necessary to install a high-flow vein (central vein) by the anesthesiologist, and to begin the perfusion as soon as possible intra-operatively before the reperfusion of the kidney. The dose of Thymoglobuline® per infusion is 1.5mg/kg. The duration of each infusion is between 6 to 24 hours.~The total duration of the Thymoglobuline® administration is 4 days (starting at and including the first day of the surgery)."
3075627|NCT02056938|Active Comparator|Basiliximab|The first infusion of Simulect® begins within the two hours before the surgery. There is no need of central venous catheter or arteriovenous fistula to infuse the Simulect®. The duration of the infusion is 30 minutes. Each dose of Simulect® is 20 mg. The first infusion of Simulect® is displayed on Day 0 (within the two hours before the surgery) and the second infusion 3 days afterward (Day 4).
3075628|NCT02056925|Experimental|Experimental|
3075629|NCT02056912|Other|Lipodystrophie Héréditaire|
3075630|NCT02056899|Experimental|Gabapentin|
3075631|NCT02056886|Experimental|OSNA|"Intra operative sentinel lymph-node sampling. In this experimental arm, the molecular biology technique is only used through the OSNA technique (One Step Nuclear Acid analysis), and no other classical pathology's diagnosis method such as formalin fixation, then parraffin embedding before slices cutting, hematoxylin-eosin-safran staining or any other immunohistochemical stainings.~According to the results of the staging procedure, the treatment in this arm is decided in conformity with local and national guidelines in breast cancer treatments.~SLN detection +/- complementary axillary lymphadenectomy is immediately decided if a tumor invasion is detected within the sentinel LN material."
3075632|NCT02056886|Other|PATHOLOGICAL ANALYSIS|"No intra operative examination is performed in this arm, but the final pathological examination:~In this arm, the classical pathology's diagnosis method is starting with a formalin fixation of suspected invaded lymph-nodes sampling at least 24Hrs; then parraffin embedding before slices cutting; then hematoxylin-eosin-safran staining or any other immunohistochemical stainings.~According to the results of the staging procedure, the treatment in this arm is decided in conformity with local and national updated guidelines in breast cancer treatments.~SLN detection +/- complementary axillary lymphadenectomy: is decided in a second surgical step when the pathologic analysis has detected a tumor invasion"
3075704|NCT02056366|Active Comparator|α-lipoic acid|α-lipoic acid PO medication, 600mg per day, for 6weeks α-lipoic acid PO medication, 1200mg per day, for 6weeks
3075705|NCT02056366|No Intervention|No treatment group|No Intervention
3075706|NCT02056353|Active Comparator|Nurse-directed|Blood glucose control guided by paper protocol
3075633|NCT02056886|Other|EXTEMPORANEOUS|"Intra-operative pathological frozen sections of sentinel LN samples are coloured and examined immediately by the pathologist, allowing an immediate result at the disposal of the surgeon who can decide to complete by an axillary LN dissection or not.~Then the remaining material will be prepared similarly as in the pathological classical method (Arm B), ie formalin fixation, then parraffin embedding, then slices cutting, then HES staining or ImmunoHistochemistry for a final diagnosis.~SLN detection +/- complementary axillary lymphadenectomy: is decided immediately when the tumor invasion is detected in the sentinel LN material."
3075634|NCT02056873|Experimental|Deep Brain Stimulation (DBS)|"Subjects' DBS surgical intervention requires implantation of a DBS system: two CM thalamic leads (one in each brain hemisphere), two ECOG strip leads (one in each brain hemisphere), and two neurostimulators implanted in the chest.~The ECOG strip lead is implanted into the brain to provide an interface through which stimulation can be delivered or activity of the brain can be monitored by the device, or observed by a clinician using a programmer.~Neurostimulator and leads system includes a programmer, which includes a wand and telemetry interface, and a patient remote control to check battery status and whether the device is on or off. The programmer is used to set up the device, including setup of stimulation and recording, as well as to retrieve data for subsequent review."
3075635|NCT02056860||Group 1 will receive 15 Hz|Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
3075636|NCT02056860||Group 2 will receive 30 Hz|Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
3075637|NCT02056860||Group 3 will receive 60 Hz|Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz 2 .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
3075638|NCT02056860||Group 4 will receive 100 Hz|Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
3075639|NCT02056860||Phase II Optimal Frequency|Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
3075640|NCT02056847|Active Comparator|Pitavastatin calcium 4mg|Pitavastatin calcium (LIVALO®) 4mg, once a day
3075641|NCT02056847|Active Comparator|Pitavastatin calcium 2mg|Pitavastatin calcium (LIVALO®) 2mg, once a day
3075642|NCT02056834||chronOS Inject|Closed proximal tibial fractures of type Schatzker I - VI, AO-OTA 41, AO-OTA 42 with bone defect
3075643|NCT02056808|Experimental|SMT C1100|Patients will be studied in 3 groups (Groups A to C), with each group consisting of 4 patients aged between 5 to 11 years. It is planned that doses for Groups A to C will be administered in an escalating manner after safety review for each dose group.
3075644|NCT02056795|Experimental|Electroacupuncture|Subjects will do balance assessment in lab. In treatment room, practitioner will clean insertion area with alcohol swab, allow adequate time to dry, and insert 2 Asia-Med Special No 16 (0.30x30mm) needles: one at proximal insertion of fibularis longus anterior to fibular neck, in proximity to common fibular nerve (GB-34); one over sinus tarsi and lateral ligaments of ankle mortise (GB-40). Needles will be inserted approximately 1-2cm, connected for 10 min at 2Hz to electrical stimulation (ITO ES-130, 500 ohm test load, 1 to 500Hz). Needles will disposed of in sharps container. Area will be wiped with long handled cotton swab, pressure will be applied for 2 seconds. Subjects will be asked to slowly get up from table and return to lab for second balance assessment.
3075645|NCT02056795|Sham Comparator|Control|As with experimental group, controls will do balance assessment pre- and post-intervention. Streitberger placebo needles (Asia-Med, 0.03 x 30 mm), blunted with a telescoping mechanism, will be used. Subjects will feel slight prick, and shaft will telescope into handle, creating illusion of skin penetration. Needles will be held in place by plastic ring covered by a bandage. They are validated for blinding. They will be placed over non-traditional acupuncture points on medial aspect of leg, in direct opposition to treatment group needles. Needle placement is not intended to produce therapeutic outcome. The needles will be connected to a wire, which will be turned on for 10 minutes but no stimulation will be felt.
3075646|NCT02056782|Experimental|PGX-ODSH-2013-AML-1|See Intervention Description
3075647|NCT02056769|Experimental|CT Perfusion|All patients enrolled in the study
3075648|NCT02056756|Experimental|CBD|
3075649|NCT02056743|Experimental|Fermented-red ginseng|"At period 1, the fermented-red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the first day. At second day, they administered Fexofenadine 30mg under fasting conditions.~During 4~17th days they administered fermented-red ginseng. At period 2, the fermented-red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the 15th day. At 16th day, they administered Fexofenadine 30mg under fasting conditions."
3075650|NCT02056743|Experimental|Red ginseng|"At period 1, the red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the first day. At second day, they administered Fexofenadine 30mg under fasting conditions.~During 4~17th days they administered red ginseng. At period 2, the red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the 15th day. At 16th day, they administered Fexofenadine 30mg under fasting conditions."
3075651|NCT02056730|Experimental|Regpara|calcium sensing receptor agonist
3075652|NCT02056717|Experimental|Dexamethasone group|
3075653|NCT02056717|Placebo Comparator|Control group|
3075654|NCT02056704|No Intervention|Angiography|Evaluation by angiography only.
3075655|NCT02056704|Experimental|Angiography with IVUS|Evaluation with angiography and intravascular ultrasound.
3075656|NCT02056691|Experimental|Exercise programme|Exercise programme Muscle biopsies
3075657|NCT02056678|Active Comparator|IV acetaminophen, OSA, laparoscopic cholecystectomy|IV acetaminophen 1000mg to be administered to obese patients at risk of obstructive sleep apnea intraoperatively during laparoscopic cholecystectomy
3075707|NCT02056353|Experimental|LOGIC-Insulin|Blood glucose control guided by the LOGIC-Insulin algorithm
3075661|NCT02056665|Experimental|MINOCYCLINE 16 weeks|"Duration of treatment: 16 weeks~Patients <35 kg. 100 mg / day. Administered at a dose of one capsule of 50 mg breakfast and dinner.~Patients 35 - 50 kg. 150 mg / day. Administered at a dose of 2 capsules of 50 mg breakfast and 1 capsule of 50mg dinner.~Patients > 50 kg. 200 mg / day. Administered at a dose of two capsules of 50 mg of breakfast and dinner."
3075662|NCT02056652|Experimental|Pessary|Use of the Bioteque cup pessary. Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
3075663|NCT02056652|No Intervention|No pessary|No pessary will be used. Subjects will receive standard obstetrical management
3075664|NCT02056639|Experimental|Pessary|Use of the Bioteque cup pessary. Pessary will be placed between 18 and 27 6/7 weeks gestation, and will be removed during the 36th week of pregnancy (or earlier if indicated)
3075665|NCT02056639|No Intervention|No pessary|No pessary will be used. Subjects will receive standard obstetrical management
3075666|NCT02056626|Active Comparator|arm 2|partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)
3075667|NCT02056626|Active Comparator|arm 3|controlled dosing schedule 6.25 mg twice daily (15 days)
3075668|NCT02056626|Active Comparator|arm 4|controlled dosing schedule 6.25 mg twice daily, every other day (15 days)
3075669|NCT02056626|Active Comparator|arm 1|standard therapy, 25 mg twice daily (15 days)
3075670|NCT02056600|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
3075671|NCT02056600|Experimental|C|Combination of gemigliptin50mg/metformin HCl sustained release 1000mg
3075672|NCT02056587|Experimental|Everolimus|All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
3075673|NCT02056574|Experimental|NA-1|20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and an 11 amino acid domain that enables the peptide to cross the blood-brain barrier. Single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion.
3075674|NCT02056574|Placebo Comparator|Placebo|Single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion.
3075675|NCT02056561||TIVA (group T n: 15)|Group T were given propofol infusions of 12 mg/kg/hr for the first 10 minutes, 9 mg/kg/hr for the second 10 minutes and 6 mg/kg/hr after that. Patients were ventilated with 50% air and 50% O2 mix at 6 L/min flow.
3075676|NCT02056561||Sevoflurane (group S n: 15)|Group S were ventilated with 2% sevoflurane, 50% air and 50% O2 mix at 6 L/min flow.
3075677|NCT02056561||Desflurane (group D n: 15)|Group D cases were given 6% desflurane 50% air and 50% O2 mix at 6 L/min flow.
3075678|NCT02056535|No Intervention|Screened Only|Screened only and met criteria for eligibility for study
3075679|NCT02056535|No Intervention|Screened and Assessed|Screened as eligible for the study and received baseline assessment
3075680|NCT02056535|Active Comparator|Intervention|Screened eligible, received baseline assessment and intervention
3075681|NCT02056522||Suspicious skin lesions.|No intervention is administered.
3075682|NCT02056509||Out of hospital cardiac arrest|Out of hospital cardiac arrest of non-traumatic cause
3075683|NCT02056509||Unexpected in-hospital cardiac arrest|Unexpected cardiac arrest during emergency department stay
3075684|NCT02056496|Experimental|Pomegranate extract|The same group will consume the two types of pomegranate extract (crossover study).
3075685|NCT02056483|Experimental|Screening-based nurse navigation|Based on systematic screening for psychological and physical symptoms as well as health behavior a nurse navigator will refer to and monitor use of appropriate rehabilitation programs
3075686|NCT02056483|No Intervention|Usual care|Usual care
3075687|NCT02056470|Experimental|Freedom Total Knee Replacement|Freedom Total Knee
3075688|NCT02056457|Experimental|Responsible fatherhood or healthy marriage|
3075689|NCT02056457|Experimental|Control|
3075690|NCT02056444|Experimental|Topical tranexamic acid (TXA)|Single dose 1.5 grams topical TXA infiltrated into the surgical field at time of arthrotomy closure.
3075691|NCT02056444|Active Comparator|Intravenous TXA|Single 20 mg/kg dose of intravenous TXA administered prior to skin incision.
3075692|NCT02056431|Experimental|IVR Intervention Group|Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
3075693|NCT02056431|No Intervention|IVR Control Group|Participants will receive 3 non-interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) containing general messages regarding diabetic education.
3075694|NCT02056418|Experimental|enteral nutrition|The patients receive treatment of enteral nutrition only.
3075695|NCT02056418|Experimental|Corticosteroid|The patients receive treatment of corticosteroid only.
3075696|NCT02056418|No Intervention|Healthy control|healthy people applied with normal diet.
3075697|NCT02056405|Placebo Comparator|Placebo|Placebo arm: intake of placebo (Lactose). 1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
3075698|NCT02056405|Active Comparator|Mosapride|Mosapride arm: intake of active drug (Mosapride). 15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
3075699|NCT02056392|Experimental|Selumetinib 75mg|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule
3075700|NCT02056392|Active Comparator|Moxifloxacin 400 mg|Volunteers will receive moxifloxacin 400mg administered by mouth, as a capsule
3075701|NCT02056392|Placebo Comparator|Selumetinib 75mg placebo|Volunteers will receive selumetinib 75mg placebo, administered by mouth, as a capsule.
3075702|NCT02056379|Active Comparator|Budesonide|2 mg of nebulized budesonide at 12/12 hours and 8 cc of intravenous normal saline.
3075703|NCT02056379|Active Comparator|Dexamethasone|This group will receive 0,15 mg/kg/dose of intravenous dexamethasone at 6/6 hours and 8 cc of nebulized normal saline at 12/12 hours.
3075801|NCT02055716|Experimental|Sulforadex|100mg or 300mg size 00 acid resistant HPMC capsules
3075708|NCT02056340|Active Comparator|Atorvastatin|Patients will be administered study medication (atorvastatin 40 mg) orally once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.
3075709|NCT02056340|Placebo Comparator|Placebo|Patients will be administered study medication (matched placebo) orally once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.
3075710|NCT02056327||Oral appliance with monitoring suite|Subjects will sleep with a standard oral appliance with the newly developed monitoring suite embedded within it for 1-2 nights while being monitored with standard in lab polysomnography or home sleep testing.
3075711|NCT02056314|Active Comparator|brochure|The participants will be given a brochure that describes problem gambling and recommends methods of staying in control of gambling such as coping skills.
3075712|NCT02056314|Experimental|electronic tutorial|The participants will be given an electronic tutorial that will explain how to stay in control of their gambling including information about coping skills, warning signs, and information about myths related to gambling.
3075713|NCT02056301|Active Comparator|Patient Controlled Analgesia|One group will have a patient controlled device connected to an intravenous patient controlled analgesia (IV PCA). This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes.
3075714|NCT02056301|Active Comparator|epidural Catheter|The other group will have an epidural catheter inserted under sterile conditions in the thoracic epidural space after anesthesia has been induced. This will be connected to a patient controlled epidural analgesia (PCEA) device for postoperative pain control that works in a similar manner except the medication (a combination of local anesthetics and hydromorphone) will be administered in the thoracic epidural space.
3075715|NCT02056288|Active Comparator|Ultrasound guided supraclavicular block|Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml), using the technique described by Marhofer et al. In order to decrease variance in success rates, the ultrasound guided nerve block will be performed by 1 of the 4 anesthesiology co-investigators, each of whom have successfully performed over 100 ultrasound guided blocks in the past. Supraclavicular blocks were performed using the higher frequency of the probe and placing it in a coronal-oblique-plane in the supraclavicular fossa.
3075716|NCT02056288|Active Comparator|IV Opiods|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
3075717|NCT02056275|Experimental|ONS + dietary counseling|ONS/day + dietary counseling
3075718|NCT02056275|Active Comparator|Dietary counseling|Dietary counseling
3075719|NCT02056262||3 to 16 years of age|"Volunteers of 3 to 16 years of age, coming in to the hospital for a dental consultation. See inclusion/exclusion criteria.~Intervention: Dental cavity evaluation Intervention: Saliva sampling Intervention: Plaque sampling"
3075720|NCT02056262||17 - 45 years of age|"Volunteers of 17 to 45 years of age, coming in to the hospital for a dental consultation. See inclusion/exclusion criteria.~Intervention: Dental cavity evaluation Intervention: Saliva sampling Intervention: Plaque sampling"
3075721|NCT02056249||Healthy, lean subjects|Volunteers without anemia (hematocrit), diabetes (A1c), use of illicit drugs and antidepressants, or any other major health issues.
3075722|NCT02056236|Experimental|Anti-epileptic drugs|"Step 1. Lorazepam 4 mg iv (initial dosage) titrated up to a maximum of 12 mg/24 hours OR midazolam 10 mg (initial dosage) up to 60 mg/24 hours (in steps of 5 mg/5 minutes) PLUS Fenytoine bolus i.v. 15-20 mg/kg in 30 minutes, followed by 150 mg 2 dd 1, adapted based on serum levels.~Step 2. Propofol infusion with a maximum of 8 mg/kg/hour PLUS A second anti-epileptic drug in addition to fenytoin: Option 1: levetiracetam bolus 1500 mg, followed by 1000 mg 2 dd 1 intravenously or Option 2: valproic acid bolus 10-20 mg/kg in 30 min, followed by15 mg/kg/day in 2 dosages intravenously.~Step 3. Thiopental, initial dosage 12,5 mg/kg/hr for the first 6 hours followed by 5 mg/kg/hr for 6 hours. After these loading dosages treatment should be guided by the EEG pattern."
3075723|NCT02056236|Active Comparator|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma in both treatment arms. Reasons for withdrawal of treatment will be documented."
3075724|NCT02056223|Experimental|paracetamol|Boluses of intravenous paracetamol at 15 mg/Kg four time a day for three consecutive days.
3075725|NCT02056223|Active Comparator|Intravenous ibuprofen|Standard boluses of ibuprofen at 10-5-5-mg/Kg/dose once a day for three consecutive days.
3075726|NCT02056210|Experimental|Stem cell mobilization in diabetic patients|Injection of Mozobil (Plerixafor / AMD3100) in diabetic patients
3075727|NCT02056210|Experimental|Stem cell mobilization in non diabetic subjects|Injection of Mozobil (Plerixafor / AMD3100) in non diabetic subjects
3075728|NCT02056197|Placebo Comparator|Placebo|Shortwave 30 minutes.
3075729|NCT02056197|Active Comparator|Stable|Stable surface exercises
3075730|NCT02056197|Experimental|Unstable|Unstable surface exercises
3075731|NCT02056184|Active Comparator|Adalimumab, masked ultrasound|Adalimumab and blinded ultrasound.
3075732|NCT02056184|Experimental|Adalimumab, unmasked ultrasound|Adalimumab and open ultrasound.
3075733|NCT02056171|Experimental|Quetiapine|A randomized group will receive quetiapine as treatment for delirium.
3075734|NCT02056171|Placebo Comparator|Placebo|A randomized group will receive placebo, and not quetiapine.
3075735|NCT02056158||HIV Negative Early COPD Smokers|HIV Negative Early COPD Smokers
3075736|NCT02056158||HIV Negative COPD Smokers|HIV Negative COPD Smokers
3075737|NCT02056158||HIV Negative Nonsmokers|HIV Negative Nonsmokers
3075738|NCT02056158||HIV Negative Smokers|HIV Negative Smokers
3075739|NCT02056158||HIV Positive Smokers|HIV Positive Smokers
3075740|NCT02056158||HIV Positive Nonsmokers|HIV Positive Nonsmokers
3075741|NCT02056158||HIV Positive COPD Smokers|HIV Positive COPD Smokers
3075742|NCT02056158||HIV Positive Early COPD Smokers|HIV Positive Early COPD Smokers
3075802|NCT02055703|Experimental|E2609|Experimental drug for Parts A, B, and C
3075803|NCT02055703|Active Comparator|itraconazole|Comparator drug for Part A1
3075804|NCT02055703|Active Comparator|rifampin|Comparator drug for Part A2
3075743|NCT02056145|Placebo Comparator|Group 1|Group 1 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.9% saline solution for the femoral block and 10 cc of 0.9% saline solution for lateral femoral cutaneous block, for a total of 30 ml saline solution 0.9%.
3075744|NCT02056145|Active Comparator|Group 2|Group 2 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.25% bupivacaine solution for the femoral block and 10 cc of 0.9% saline solution for lateral femoral cutaneous block, for a total of 20 cc 0.25% bupivacaine solution en 10 cc saline solution 0.9%.
3075745|NCT02056145|Active Comparator|Group 3|Group 3 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.25% bupivacaine solution for the femoral block and 10 cc of 0.25% bupivacaine solution for lateral femoral cutaneous block, for a total of 30 cc of 0.25% bupivacaine solution.
3075746|NCT02056132||Cystic Fibrosis patients.|Patients with Cystic Fibrosis. Results of Exhaled Breath Condensate lab.
3075747|NCT02056132||Control Subjects|Individuals without Cystic Fibrosis or signs of current respiratory infection. Results of Exhaled Breath Condensate lab.
3075748|NCT02056119|Active Comparator|Jet Nebulizer Arm|"The Jet Nebulizer Protocol:~Physician order received for subject, randomization to jet nebulizer occurred.~Jet nebulizer, Misty Max 10™ (Carefusion, CA), placed into spring loaded t-piece between the humidifier and the ventilator (approximately 15 cm from the gas outlet).~Aerosol treatment delivered per physician order at flow rates of 8-10 L/min.~Jet nebulizer to be replaced every 3 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
3075749|NCT02056119|Experimental|Vibrating Mesh Nebulizer Arm|"Physician order received for subject, randomization to vibrating mesh nebulizer occurred.~Aeroneb® Solo (Aerogen, Galway, Ireland) vibrating mesh nebulizer to be placed before the heater on the dry side of the heater water chamber on the inspiratory ventilator circuit.~Aerosol treatment delivered per physician order.~Mesh nebulizer to be replaced every 30 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
3075750|NCT02056106|Active Comparator|Clinical acumen|Depression diagnosis and antidepressant treatment provided based on clinical acumen of primary care providers trained to provide depression care.
3075751|NCT02056106|Active Comparator|Protocolized Arm|Structured, algorithm-based protocol that guides depression diagnosis and antidepressant treatment
3075752|NCT02056093|Experimental|Intubated patients|Intubated patients: The three modes (PSV, PAV, NAVA) will be applied in random order to each mechanically ventilated patient included in the study.
3075753|NCT02056067|Experimental|Exercise|The exercise intervention group will receive social, behavioral support and research staff contact time to encourage them to increase their activity level to include twice weekly strength-training sessions and 150 min of walking/week (e.g., three 50-min walking sessions or five 30-min walking sessions) over 12 months.
3075754|NCT02056067|Active Comparator|Attention Control (Health Education)|The Attention Control Group will be provided written information that emphasizes the importance of a healthy lifestyle. Participants will be encouraged to follow the NCI and ACS physical activity guidelines. This procedure was followed in our exercise trials, with no increase in physical activity levels observed at follow-up among women in the usual care group. Attention Control participants will also receive frequent contacts throughout the 12 month intervention. Each month, women randomized to attention control will be contacted by phone to discuss a health education topic of interest
3075755|NCT02056054||Subjects with d-AIH|Pediatric transplant patients with de novo autoimmune hepatitis (d-AIH) will be enrolled at an outside center.
3075756|NCT02056054||Subjects with Acute Rejection|Pediatric transplant patients with acute rejection will be enrolled at an outside center.
3075757|NCT02056054||Subjects with Chronic Rejection|Pediatric transplant patients with chronic rejection will be enrolled at an outside center.
3075758|NCT02056054||Control Subjects|Healthy pediatric patients will be enrolled at the coordinating center (Yale).
3075759|NCT02056054||Subjects with Auto-immune Hepatitis|Adult non-transplant patients with auto-immune hepatitis will be enrolled at the coordinating center (Yale).
3075760|NCT02056054||Subjects with Chronic Hepatitis C Virus|Adult non-transplant patients with chronic hepatitis C will be enrolled at the coordinating center (Yale).
3075761|NCT02056054||Adult Subjects with d-AIH|Adult transplanted patients with de novo autoimmune hepatitis will be enrolled at the coordinating center (Yale).
3075762|NCT02056041||Hepatectomy for HCC|Patients submitted to surgery for HCC
3075763|NCT02056028||Bile leak after hepatic resection|
3075764|NCT02056015|Experimental|[68Ga]MLN6907|
3075765|NCT02056002|Active Comparator|Usual Care|"Standard CPAP educational training~Educational Brochures~Educational DVD videos mailed to participant"
3075766|NCT02056002|Experimental|Peer-Buddy System|"Two 30-minute in person sessions with Peer Buddy~Standard CPAP training~Eight phone conversations with Peer Buddy over 3 months~Subsequent 3 months use of phone system to contact Peer Buddy as needed~One Month Visit:~-Home visit to collect CPAP information~Three Month Visit:~Questionnaires~Psycho Motor Vigilance Test (PVT) Video Game~Collect CPAP information~Measure weight~Measure blood pressure~Six Month Visit:~Questionnaires~PVT (Video game)~Collect CPAP information~Measure Weight~Measure Blood Pressure~Evaluate the program and Peer Buddy"
3075767|NCT02055989|Experimental|Dose-escalated radiotherapy level 1|
3075768|NCT02055989|Experimental|Sequential dose-escalated radiotherapy level 2|
3075769|NCT02055976|Experimental|Population A|A total of 9 groups in two population. Population A comprises hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a stable dose of atorvastatin. A subject who is receiving a stable dose of atorvastatin will be randomized into one out of 5 dose groups.
3075770|NCT02055976|Experimental|Population B|A total of 9 groups in two population. Population B comprises hypercholesterolemic Japanese subjects who are naïve for a treatment by lipid lowering drug and whose fasting LDL-cholesterol is not controlled. A subject who is treatment naïve will be randomized into one out of 4 dose groups.
3075805|NCT02055703|Active Comparator|digoxin|Comparator drug for Part B
3075806|NCT02055703|Active Comparator|donepezil|Comparator drug for Part C
3075771|NCT02055963|Experimental|Minocycline|"Participants take study medication twice daily, starting 2 days prior to surgery, and continue for 3 weeks postsurgery. The final day of study medication will be the 21st day after surgery.~Minocycline100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.~Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21."
3075772|NCT02055963|Placebo Comparator|Placebo|"Participants take study medication twice daily, starting 2 days prior to surgery, and continue for 3 weeks postsurgery. The final day of study medication will be the 21st day after surgery.~Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery).~Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21."
3075773|NCT02055950||Kidney perfused by pulsatile machine|
3075774|NCT02055950||Kidney stored in refrigerated solution|
3075775|NCT02055937|Experimental|immediate implant breast reconstruction|immediate implant breast reconstruction
3075776|NCT02055924|Experimental|Ibrutinib and immunochemotherapies|Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
3075777|NCT02055911|Experimental|Ranibizumab|monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).
3075778|NCT02055898|Other|All subjects|All subjects will receive both sodium oxybate and placebo comparator in a crossover design
3075779|NCT02055885||Positive responders|Positive responders (R+): patients exhibiting an increase in the 6WT distance ≥ 10% and/or a decrease in dyspnea ≥ 10% (i.e., ≥ 1 point on the visual analogue scale).
3075780|NCT02055885||negative responders|Negative responders(R-): patients exhibiting a decrease in the distance ≥ 10% and/or an increase in dyspnea ≥ 10%.
3075781|NCT02055872|Experimental|Intravenous albumin|Administration of 25% albumin by intravenous infusion, twice daily for a total of 72 hours (6 treatments)
3075782|NCT02055872|Placebo Comparator|Normal saline|Administration of 100 mL normal saline by intravenous infusion, twice daily, for 72 hours (6 treatments)
3075783|NCT02055859|Other|single session radiosurgery|single session radiosurgery (gold standard)
3075784|NCT02055859|Experimental|multisession radiosurgery|multisession radiosurgery (3 fraction)
3075785|NCT02055846|Experimental|prostate cancer|Realisation of blood sample, urinary sample and tumor biopsy
3075786|NCT02055833|Experimental|Intensive nutritional counseling|Nutritional counseling (follow-up visits once a week for 6 weeks [during radiotherapy] and at 1 month and at 3 months since the end of radiotherapy) + n-3 polyunsaturated fatty acids-enriched oral nutritional supplements (1-2 bottles/day)
3075787|NCT02055833|Active Comparator|Nutritional counseling|Nutritional counseling (follow-up visits once a week for 6 weeks [during radiotherapy] and at 1 month and at 3 months since the end of radiotherapy)
3075788|NCT02055820|Experimental|Venetoclax + G-CHOP Arm|Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + obinutuzumab. Each cycle will consist of 21 days.
3075789|NCT02055820|Experimental|Venetoclax + R-CHOP Arm|"Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle will consist of 21 days.~Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + rituximab. Each cycle will consist of 21 days."
3075790|NCT02055807|Experimental|PEEP and recruitment maneuvers|A PEEP of 7 cm H2O will be applied starting after intubation until the end of surgery. Recruitment maneuvers (continuous positive pressure of 30 cm H20 for 30 seconds) will be initiated following intubation and repeated every 30 minutes during surgery and immediately prior to extubation. Lung ultrasound examinations will be performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis.
3075791|NCT02055807|Active Comparator|ZEEP (Zero end-expiratory pressure)|No PEEP nor recruitment maneuvers will be used during surgery. Lung ultrasound examinations will be performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis.
3075792|NCT02055794|Active Comparator|Suturing of the perineal skin|Suturing of the perineal skin after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
3075793|NCT02055794|Active Comparator|No suturing of the perineal skin|No suturing of the perineal skin after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
3075794|NCT02055794|Active Comparator|Closing perineal skin with surgical glue|Closure of the perineal skin with n-Butyl 2-cyanoacrylate (Indermil®) surgical glue after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
3075795|NCT02055781|Experimental|Pacritinib, Once Daily|Pacritinib 400 mg taken orally, once daily
3075796|NCT02055781|Experimental|Pacritinib, Twice Daily|Pacritinib 200 mg taken orally, twice daily
3075797|NCT02055781|Active Comparator|Best Available Therapy|Best Available Therapy includes any physician-selected treatment for primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis, such as approved JAK2 inhibitors, and may include any treatment received before study entry. Best Available Therapy may include ruxolitinib, other approved JAK2 inhibitors, hydroxyurea, glucocorticoids, erythropoietic agents, immunomodulatory agents, mercaptopurine, danazol, interferons, cytarabine, melphalan, or other agents and may also include no treatment and symptom-directed treatment without myelofibrosis-specific treatment.
3075798|NCT02055742||Specimen Collection|
3075799|NCT02055729||The study population|"The proposed study is a prospective, single-center pilot study lasting 28 days. Our goal is to study the temporal evolution of the bacterial communities present in the skin and digestive flora (stool) of spinal cord injured persons having one or more sacral bedsores. The study timespan can include treatment initiation, notably of antibiotics. Urinalysis for studying urinary flora will simultaneously occur.~For a description of the study population, see the inclusion/exclusion criteria.~Intervention: Superficial bedsore sample Intervention: 3mm tissue punch biopsy Intervention: Stool sample Intervention: Urine sample"
3075800|NCT02055716|Placebo Comparator|alpha-cyclodextrin|A placebo comparator composed of the same acid resistant HPMC capsules filled with 300mg of alpha cyclodextrin
3075807|NCT02055690|Experimental|Phase Ib/II: Fosbretabulin & Pazopanib|"Phase Ib:~Fosbretabulin and Pazopanib in combination. Fosbreatabulin dose will be in the range of 45mg/m2- 60 mg/m2 delivered by infusion every week for 3 weeks of a 4 week cycle until disease progression. Pazopanib will be either 600 mg or 800mg taken orally each day of 28 day cycle until disease progression.~The phase II dose of both drugs will be determined by the Phase Ib component which is a dose finding exercise.~Phase II:~Fosbretabulin and Pazopanib in combination. Fosbretabulin 54mg/m2 delivered by infusion every week for 3 weeks of a 4 week for 28 day cycle until disease progression. Pazopanib 600mg taken orally each day for 28 day cycle until disease progression"
3075808|NCT02055690|Active Comparator|Phase II: Pazopanib|Pazopanib 800mg taken orally each day of 28 day cycle until disease progression
3075809|NCT02055664|Experimental|treatment|
3075810|NCT02055664|Placebo Comparator|control|
3075811|NCT02055651||Bayer Sao Paulo employees|Workers from Bayer in site Socorro who participate in the trial
3075812|NCT02055638|Experimental|SRX246|SRX246 capsules, 120mg bid for 4 weeks followed by 160mg bid for 4 weeks
3075813|NCT02055638|Placebo Comparator|Placebo|Placebo capsules to match the amount of SRX246 capsules for 8 weeks
3075814|NCT02055625|Experimental|Mesenchymal stromal cell treatment|Biological: Mesenchymal stromal cells
3075815|NCT02055586|Experimental|Diagnostic (FLT-PET/MRI)|Patients undergo FLT-PET/MRI twice at baseline and once within 4 weeks after start of treatment.
3075816|NCT02055573|Experimental|Ready To Learn|1) The Ready to Learn (RTL) arm will receive a DVD in both Spanish and English and a bilingual booklet (both produced by Parents' action for Children) addressing the benefits of reading, talking and playing with young children, as well as a new children's board book.
3075817|NCT02055573|Experimental|All Babies Cry|2) The All Babies Cry (ABC) arm will receive a DVD in both, Spanish and English and a bilingual booklet (both produced by VIDA Health Communications, INC) explaining crying as part of normal infant behavior, highlighting signs of parental distress and providing strategies to sooth parents and their children
3075818|NCT02055560||PK-Guided Cohort|CRC patients who were treated with 5-FU containing therapy regimen where 5-FU dosing was monitored and optimized using PK-guided dose adjustment.
3075819|NCT02055560||BSA Cohort|CRC patients who were treated with 5-FU containing therapy regimen where 5-FU dosing was done according to body surface area (BSA) and no PK monitoring was performed.
3075820|NCT02055547|Experimental|100 - PBO (Part1)|Participants received a single dose of 100 micrograms (mcg) subcutaneous (sc) MK-8521 in the first treatment period, and Placebo (PBO) in the second period, with a 7-day washout between each period
3075821|NCT02055547|Experimental|PBO - 300 (Part 1)|Participants received a single dose sc PBO in the first treatment period, and 300 mcg MK-8521 in the second period, with a 7-day washout between each period
3075822|NCT02055547|Experimental|100 - 300 (Part 1)|Participants received a single dose sc 100 mcg MK-8521 in the first treatment period, and 300 mcg MK-8521 in the second period, with a 7-day washout between each period
3075823|NCT02055547|Experimental|150 - PBO - 175 (Part 1)|Participants received a single dose sc 150 mcg MK-8521 in the first treatment period, PBO in the second period, and 175 mcg MK-8521 in the third period, with a 7-day washout between each period
3075824|NCT02055547|Experimental|150 - 200 - 175 (Part 1)|Participants received a single dose sc 150 mcg MK-8521 in the first treatment period, 200 mcg MK-8521 in the second period, and 175 mcg MK-8521 in the third period, with a 7-day washout between each period
3075825|NCT02055547|Experimental|150 - 200 - PBO (Part 1)|Participants received a single dose sc 150 mcg MK-8521 in the first treatment period, 200 mcg MK-8521 in the second period, and PBO in the third period, with a 7-day washout between each period
3075826|NCT02055547|Experimental|PBO - 200 - 175 (Part 1)|Participants received a single dose sc PBO in the first treatment period, 200 mcg MK-8521 in the second period, and 175 mcg MK-8521 in the third period, with a 7-day washout between each period
3075827|NCT02055547|Experimental|50 - 74 (10 Days) (Part 2)|Once daily dose of sc MK-8521 over 10 days: 50 mcg Days 1-5, 74 mcg Days 6-10
3075828|NCT02055547|Experimental|100 - 150 (10 Days) (Part 2)|Once daily dose of sc MK-8521 over 10 days: 100 mcg Days 1-5, 150 mcg Days 6-10
3075829|NCT02055547|Experimental|125 - 150 (10 Days) (Part 2)|Once daily dose of sc MK-8521 over 10 days: 125 mcg Days 1-5, 150 mcg Days 6-10
3075830|NCT02055547|Experimental|72 - 125 (14 Days) (Part 2)|Once daily dose of sc MK-8521 over 14 days in older and obese participants: 72 mcg Days 1-7, 125 mcg Days 8-14
3075831|NCT02055547|Placebo Comparator|PBO (10 Days) (Part 2)|Placebo for sc MK-8521 once daily over 10 days
3075832|NCT02055547|Placebo Comparator|PBO (14 Days) (Part 2)|Placebo for sc MK-8521 once daily over 14 days
3075833|NCT02055547|Experimental|High-PBO-Low (Part 3)|Participants received a single dose sc high dose MK-8521 in the first treatment period, PBO in the second period, and low dose MK-8521 in the third period, with a 7-day washout between each period
3075834|NCT02055547|Experimental|Low-High-PBO (Part 3)|Participants received a single dose sc low dose MK-8521 in the first treatment period, high dose MK-8521 in the second period, and PBO in the third period, with a 7-day washout between each period
3075835|NCT02055547|Experimental|Low-PBO-High (Part 3)|Participants received a single dose sc low dose MK-8521 in the first treatment period, PBO in the second period, and high dose MK-8521 in the third period, with a 7-day washout between each period
3075836|NCT02055547|Experimental|PBO-High-Low (Part 3)|Participants received a single dose sc PBO in the first treatment period, high dose MK-8521 in the second period, and low dose MK-8521 in the third period, with a 7-day washout between each period
3075837|NCT02055547|Experimental|PBO-Low-High (Part 3)|Participants received a single dose sc PBO in the first treatment period, low dose MK-8521 in the second period, and high dose MK-8521 in the third period, with a 7-day washout between each period
3075838|NCT02055547|Experimental|High-Low-PBO (Part 3)|Participants received a single dose sc high dose MK-8521 in the first treatment period, low dose MK-8521 in the second period, and PBO in the third period, with a 7-day washout between each period
3075839|NCT02055534|Experimental|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the Amyloidosis Center
3075840|NCT02055534|Other|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the Amyloidosis Center
3075841|NCT02055508|Experimental|Exercise Intervention Program (EIP)|"Inpatient periods: The combined resistance and endurance program consist of free weight and rubber band training for major upper and lower body muscle groups respectively of cycling/walking on an ergometer/treadmill 3x/week.~Outpatient periods (3x/week at least two/one supervised training sessions): Supervised training sessions in the local outpatient training center will comprise of resistance exercise on machines and endurance training on an ergometer/treadmill. For non-supervised training session during the outpatient period participants will receive an exercise manual for individualized home-based exercising.~In weekly phone calls, the advanced practice nurse will review adherence to the intervention and identify problems. Furthermore, the patients will also be asked the same questions as in the CMPC group."
3075842|NCT02055508|Active Comparator|Care-Management-Phone-Calls (CMPC)|"Patients in this arm will receive a weekly care-management-phone-call (CMPC), performed by an advanced practice nurse (APN). The CMPCs are based on a structured questionnaire, reflecting pain, shortness of breath, disturbed sleep, exhaustion and distress and potentially treatment related side effects (e.g. infections, polyneuropathy, etc.). In case of demanding management of symptoms or complaints (e.g. uncontrolled pain or breathlessness) the treating physician is contacted by the APN to facilitate improvement."
3075843|NCT02055482|Experimental|BAY85-3934|
3075844|NCT02055482|Active Comparator|Darbepoetin|
3075845|NCT02055456|Experimental|Nandrolone Decanoate|Nandrolone Decanoate intramuscularly administered, every two weeks, 5 mg/kg/dose
3075846|NCT02055443||Holter monitor group|12-lead holter monitor application
3075847|NCT02055430|Active Comparator|percutaneous nephrostomy|percutaneous nephrostomy insertion (6-8 Fr in size) for initial urinary drainage followed by definitive stone management.
3075848|NCT02055430|Active Comparator|Bilateral double J ureteric stents|double J ureteric stent insertion (4.8-6 Fr JJ in size) for initial urinary drainage followed by definitive stone management.
3075849|NCT02055417|Experimental|Personal Approaches to Treatment Choices for HIV|PATCH is a brief intervention designed to support participants' decision-making processes and enhance intrinsic motivation to initiate ART.
3075850|NCT02055417|Active Comparator|Stress Reduction Skills Program|SRSP includes training in stress reduction skills such as relaxation, problem solving, and expressing negative feelings.
3075851|NCT02055404|Experimental|Delefilcon A|Delefilcon A spherical contact lens with molded marks randomly assigned to one eye, with etafilcon A toric contact lens in the fellow eye for contralateral wear approximately 2 hours in duration
3075852|NCT02055404|Other|Etafilcon A|Etafilcon A toric contact lens randomly assigned to one eye, with delefilcon A spherical contact lens with molded marks in the fellow eye for contralateral wear approximately 2 hours in duration
3075853|NCT02055391|Active Comparator|Behavioral Weight Loss|State of the art behavioral weight loss treatment
3075854|NCT02055391|Experimental|Enhanced Behavioral Weight Loss|Combines behavioral weight loss skills with skills specifically targeting emotional eating.
3075855|NCT02055378|Experimental|auricular acupoint stimulation|Five auricular acupoints were selected for taping stimulation by using a 1-mm alloy ball by fingers three times a day, each time for five minutes over the five selected acupoints. Topical 0.125% atropine was given nightly.
3075856|NCT02055378|Active Comparator|Atropine|topical 0.125% atropine was given nightly during the study period.
3075857|NCT02055365|Experimental|Hepatitis B vaccination|All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).
3075858|NCT02055352|Experimental|Budesonide/indacaterol|Participants will receive a fixed combination of fluticasone and salmeterol during 4 weeks followed by a free combination of budesonide and indacaterol for the remainig of study.
3075859|NCT02055352|Active Comparator|Fluticasone / salmeterol|Fixed combination of fluticasone and salmeterol
3075860|NCT02055339|Experimental|Fisher & Paykel heated humidified high flow nasal cannula|For neonates randomized to HHHFNC, they will be placed on a flow rate equivalent to the pressures of nCPAP they were originally receiving based on a published chart, or stay on the same flow rate prior to randomization. When it is time for oral feeds, the Registered Nurse (RN) will turn the dial of the high flow circuit down to 2 lpm. The baby will then proceed to feed for up to one hour, and afterwards, will be turned back up to the flow rate they were on prior to feeds.
3075861|NCT02055339|Active Comparator|InfantFlow/RAM nasal continuous positive airway pressure|Neonates randomized to the nCPAP arm will remain on the nCPAP pressures they were on before recruitment into the study or match the flow rate they were receiving on high flow based on a published chart. The nCPAP circuit will only be removed when it is time for oral feeds. The respiratory therapist (RT) will exchange the circuit for a low flow nasal cannula which will be set at the flow that is optimal for the baby's gestational age saturations. The baby will then proceed to feed for up to one hour, and afterwards, will be changed back to the nCPAP circuit.
3075862|NCT02055326|Experimental|Yoga|One-hour sessions of twice weekly yoga for 8 weeks.
3075863|NCT02055326|Active Comparator|Health & Wellness|8 week program of health & wellness classes, materials and handouts. Topics included healthy eating, cancer prevention and cardiovascular disease prevention.
3075864|NCT02055300|Experimental|LY03005 - 20|LY03005 Dose Strength 20mg
3075865|NCT02055300|Experimental|LY03005 - 40|LY03005 Dose Strength 40mg
3075866|NCT02055300|Experimental|LY03005- 80|LY03005 Dose Strength 80mg
3075867|NCT02055300|Experimental|LY03005 - 120|LY03005 Dose Strength 120mg
3075868|NCT02055300|Experimental|LY03005 - 160|LY03005 Dose Strength 160 mg
3075869|NCT02055300|Experimental|LY03005 - 200|LY03005 Dose Strength 200mg
3075870|NCT02055300|Experimental|LY03005 - 120 - Fed|LY03005 120mg under Fed Conditions
3075871|NCT02055300|Active Comparator|Pristiq|Pristiq - 50mg
3075872|NCT02055300|Placebo Comparator|Placebo|Placebo
3075873|NCT02055287|Experimental|LY03004- 12.5|LY03004 dosage strength at 12.5mg
3075874|NCT02055287|Experimental|LY03004 - 25|LY03004 Dose Strength 25mg
3075875|NCT02055287|Experimental|LY03004- 37.5|LY03004 Dose Strength 37.5mg
3075876|NCT02055287|Experimental|LY03004 - 50|LY03004 Dose Strength 50mg
3075877|NCT02055274|Experimental|LY03003|4 Stable doses of LY03003 14, 28, 42 and 56 mg
3075878|NCT02055274|Active Comparator|Neupro|Neupro patch 2 mg/24 hours in the first week, and then be titrated to 4, 6 and 8 mg/24 hours at weekly intervals
3099126|NCT01897545|Active Comparator|PV isolation+renal denervation|
3075879|NCT02055274|Active Comparator|Neupro PK|Neupro patch 2 mg/24hr in the first week then titrated to 4 and 6mg/24hr
3075880|NCT02055261|Other|OFF PPN DBS-ON PPN DBS|Patients randomly allocated to the order OFF Low frequency DBS of the pedunculopontine nucleus then ON Low frequency DBS of the pedunculopontine nucleus
3075881|NCT02055261|Other|ON PPN DBS - OFF PPN DBS|Patients randomly allocated to the order ON Low frequency DBS of the pedunculopontine nucleus then OFF Low frequency DBS of the pedunculopontine nucleus
3075882|NCT02055196|Experimental|Treatment (neuronal stem cells, irinotecan hydrochloride)|Patients receive carboxylesterase-expressing allogeneic neural stem cells via intracerebral catheter on day 1 of week 1; weeks 1 and 3, weeks 1, 2, and 3; or weeks 1, 2, 3, and 4. Patients also receive irinotecan hydrochloride IV over 90 minutes on day 3 of week 1; weeks 1 and 3, weeks 1, 2, and 3; or weeks 1, 2, 3, and 4. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3075883|NCT02055183||Participants treated with BAT®|Any patient of any age [age category: pediatric—newborn infants (0 to 27 days), infants and toddlers (28 days to 23 months), children (2 to 11-years), and adolescents (12 to <17-years); adult (17-64-years); and geriatric (≥65-years)] with a confirmed or suspected exposure to botulinum toxin who were treated with BAT® deployed from the national or state stockpiles.
3075884|NCT02055170|Experimental|finasteride|finasteride 5mg po od from study entry to date of surgery
3075885|NCT02055157|Experimental|BMN 111 - Subcutaneous Injection|"111-202 is an open-label sequential cohort dose-escalation study. BMN 111 will be administered as a morning dose in one of the following daily dosing regimens:~• Cohort 1: 2.5 microgram/kg, Cohort 2: 7.5 microgram/kg, Cohort 3: 15.0 microgram/kg, Cohort 4: 30.0 microgram/kg"
3075886|NCT02055144||Non squamous histology|patients with advanced, non-squamous non-small cell lung cancer treated with cisplatin (or carboplatin) and pemetrexed. Maintenance with pemetrexed is allowed.
3075887|NCT02055144||Squamous histology|patients with advanced squamous non-small cell lung cancer treated with cisplatin (or carboplatin) and gemcitabine
3075888|NCT02055131|Placebo Comparator|aspirn fixed dose|patients of this arm will receive 100 mg of aspirin daily.over the period of follow up we will detect all thromboembolic events.
3075889|NCT02055131|Placebo Comparator|aspirin dose titrated with PFA-100|patients of this arm will receive 100 mg of aspirin daily.this dose will be multiplied whenever the PFA-100 is not suitable.once the time of occlusion is correct ,we will keep the same dose of aspirin and continue monitoring the PFA-100 durin the follow up period.
3075890|NCT02055131|No Intervention|placebo arm|in this group of patients we will just supervise thromboembolic events of the vascular access.
3075891|NCT02055118|Experimental|idursulfase-IT|10 mg administered via IT using IDDD (intrathecal drug delivery device) once a month for 52 weeks.
3075892|NCT02055118|Other|Nontreatment control|Patients will receive weekly standard of care treatment with IV Elaprase only.
3075893|NCT02055105|Other|miRNA|
3075894|NCT02055092||YOD-FTD|Young onset dementia - frontotemporal dementia, 75 persons with their respective family members.
3075895|NCT02055092||YOD-AD|Young onset dementia - Alzheimer's disease, 75 persons with their respective family members.
3075896|NCT02055092||LOD|Late onset dementia >= 70 years of age; Control group of 100 persons with dementia (mostly AD and AD/vascular) and their respective family members. Data already collected in a previous study.
3075897|NCT02055079|Experimental|Sirolimus|Fixed oral dose of 3 mg Sirolimus (blinded) once weekly for 24 months.
3075898|NCT02055079|Placebo Comparator|Placebo|Fixed oral dose of placebo (blinded) once weekly for 24 months.
3075899|NCT02055066|Experimental|Arm 1|ARGX-111 0.3 mg/kg
3075900|NCT02055066|Experimental|Arm 2|ARGX-111 1.0 mg/kg
3075901|NCT02055066|Experimental|Arm 3|ARGX-111 3.0 mg/kg
3075902|NCT02055066|Experimental|Arm 4|ARGX-111 10 mg/kg
3075903|NCT02055053|Experimental|anesthetic intervention|After deployment of therapeutic mesh in the preperitoneal space of the abdomen wall during the procedure, the treatment group will receive infusion of 15 cc 0.5% Bupivicaine.
3075904|NCT02055053|Placebo Comparator|Saline intervention|After deployment of therapeutic mesh in the preperitoneal space of the abdomen wall during the procedure, the placebo group will receive the infusion of 15 cc 0.9% Saline.
3075905|NCT02055027||Adherent Patients|Comparison between groups
3075906|NCT02055027||Non-adherent patients|Comparison between groups
3075907|NCT02055014|Active Comparator|Liraglutide alone|Liraglutide 1.8mg once daily subcutaneous injection
3075908|NCT02055014|Experimental|Endobarrier alone|Duodenal-jejunal bypass liner (Endobarrier) device implantation without additional GLP-1RA therapy
3075909|NCT02055014|Experimental|Endobarrier and Liraglutide|Duodenal-jejunal bypass liner (Endobarrier) device with combined liraglutide 1.2mg once daily subcutaneous injection
3075910|NCT02054988|Experimental|caffeine|"three cups of coffee will be administered for 10 days (on chronic phase) and two cups of coffee will be consecutively administered for acute evaluation."
3075911|NCT02054988|Active Comparator|not caffeine|not caffeine will be administered for the duration of the study
3075912|NCT02054975|Experimental|vitamin D2 + vitamin D3|Vitamin D2 50,000 IU each week x 4 + vitamin D3 4,000 IU each day for 3 months
3075913|NCT02054975|Active Comparator|Vitamin D lower dose|800 IU vitamin D3 by mouth each day for 3 months
3075914|NCT02054962||Elderly|The investigators intend to asses the effect of fear of movement, PTSD symptoms, and physical activity on persistent pain and functional decline.
3075915|NCT02054949|Experimental|N-Acetyl Cysteine (NAC)|NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
3075916|NCT02054936|Active Comparator|Rivaroxaban (Xarelto)|Rivaroxaban dosing will be 10mg once daily beginning on postoperative day 1 for a duration of 30 days.
3075917|NCT02054936|Active Comparator|Warfarin (Coumadin)|Warfarin dosing will be titrated to achieve an INR of 2-3 and dosing will begin on postoperative day 1 for a duration of 30 days.
3075918|NCT02054923|Experimental|Routine video recording group|Intervention: Procedure: Implementation of routine videorecording of colonoscopy withdrawal
3075919|NCT02054923|Active Comparator|Control group|Intervention: Behavioral: No routine videorecording (on demand videorecording possible)
3099127|NCT01897532|Experimental|Linagliptin|
3075921|NCT02054910|Sham Comparator|Sham|A celiac plexus block will not be administered for pain management
3075922|NCT02054897|Experimental|Semaglutide 1.0 mg|
3075923|NCT02054897|Experimental|Semaglutide 0.5 mg|
3075924|NCT02054897|Placebo Comparator|Semaglutide placebo 1.0 mg|
3075925|NCT02054897|Placebo Comparator|Semaglutide placebo 0.5 mg|
3075926|NCT02054884|Experimental|Arm A: F16IL2 in combination with paclitaxel|
3075927|NCT02054884|Experimental|Arm B: Paclitaxel|
3075928|NCT02054871|Experimental|EGFR 30-60|"Experimental: RIPC Remote preconditioning Calculated EGFR based on MDRD. Patients receive intravenous fluids preprocedure as additional renal protection.~Preconditioning will be performed in the same manner as several previous trials. Immediately prior to angiography a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles."
3075929|NCT02054871|Experimental|EGFR 60-90|Experimental: RIPC Remote preconditioning. EGFR calculated using MDRD equation. Oral hydration pre-procedural as reno-protective measure. Preconditioning will be performed in the same manner as several previous trials. Immediately prior to angiography a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
3075930|NCT02054871|No Intervention|EGRF 30-60|"No Intervention: Remote preconditioning control Calculated EGFR based on MDRD. Patients receive intravenous fluids preprocedure as additional renal protection.~Patients randomised to this group will receive routine care."
3075931|NCT02054871|No Intervention|EGRF 60-90|No Intervention: Remote preconditioning control EGFR calculated using MDRD equation. Oral hydration pre-procedural as reno-protective measure. Patients randomised to this group will receive routine care.
3075932|NCT02054858|Experimental|RIPC|Preconditioning will be performed in the same manner as several previous trials. Immediately prior to having the CT scan a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
3075933|NCT02054858|No Intervention|Control|Patients randomised to this group will receive routine care associated with undergoing a CT scan.
3075934|NCT02054845|Experimental|Body awareness therapy|The experimental treatment: BEWARE
3075935|NCT02054845|Active Comparator|Treatment as Usual|The new treatment is compared to this arm: Physical therapy
3075936|NCT02054832||Glycosade|A prospective cohort design will be used to assess the impact on sleep and continue to monitor safety of Glycosade.
3075937|NCT02054819|Other|Single arm study|"Induction chemotherapy and concurrent radiation to primary tumor Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions~Consolidation Radiation: therapy to metastatic sites At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites."
3075938|NCT02054806|Experimental|Pembrolizumab|Participants receive pembrolizumab 10 mg/kg, intravenously (IV), on Day 1 of every 2-week dosing cycle for up to 24 months
3075939|NCT02054780|Active Comparator|Psychosocial Counseling|"The curriculum Psychosocial Care and Counseling (PC) was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH. PC is considered an enhanced model of a Psychosocial Support program for OVC."
3075940|NCT02054780|Experimental|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for more overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Recent trials have provided direct evidence that CBT may be effective in HIV prevention. TF-CBT has eight components including: Psychoeducation, Relaxation, Affective Modulation, Cognitive Coping, Trauma Narrative, In-vivo Exposure (if needed), Conjoint parent-child session, and Enhancing Safety Skills. This cognitive behavioral therapy teaches skills such as how to think about situations differently in order to feel better. It also includes helping a child face the fear and anxiety of the traumatic situations, rather than avoid them. Based on earlier pilot projects, the MoH has endorsed TF-CBT in Zambia.
3075941|NCT02054767|Experimental|lidocaine|injections of 3.6 mL of 2% lidocaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
3075942|NCT02054767|Experimental|mepivacaine|injections of 3.6 mL of 2% mepivacaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
3075943|NCT02054767|Experimental|articaine|injections of 3.6 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
3075944|NCT02054754|Experimental|Dexanabinol Dose Level 1|Single oral dose of dexanabinol
3075945|NCT02054754|Experimental|Dexanabinol Dose Level 2|Single oral dose of dexanabinol
3075946|NCT02054754|Experimental|Dexanabinol Dose Level 3|Single oral dose of dexanabinol
3075947|NCT02054754|Experimental|Dexanabinol Dose Level 4|Single oral dose of dexanabinol
3075948|NCT02054754|Experimental|Dexanabinol Dose Level 5|Single oral dose of dexanabinol
3075949|NCT02054754|Placebo Comparator|Placebo|Single oral dose of matching placebo
3075950|NCT02054741|Experimental|Arm I (GA intervention)|Patients complete a geriatric assessment. Patients and physicians are provided with the geriatric assessment information and recommendations.
3075951|NCT02054741|No Intervention|Arm II (usual care)|Patients complete a geriatric assessment, but information other than clinically significant cognitive impairment and depression is not provided to the oncology teams.
3075952|NCT02054728|Experimental|RHC and IMT|
3075953|NCT02054715|Experimental|Arm I (print educational)|Participants undergo a print educational intervention during which they meet with a site coordinator and are instructed to read the NCI booklet titled Taking Part in Cancer Treatment Studies, comprised primarily of information about the nature and conduct of cancer clinical trials.
3075954|NCT02054715|Experimental|Arm II (multimedia psychoeducational)|Participants undergo a multimedia psychoeducational intervention during which they meet with a site coordinator and are instructed to view a DVD and read a booklet titled Clinical Trials: Are They Right For You? Participants are encouraged to watch the DVD and read the booklet again at home.
3075955|NCT02054702|Experimental|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
3075956|NCT02054702|Experimental|Aripiprazole|Aripiprazole - Up to 20 mg/day, once daily dose, tablets, orally
3075957|NCT02054689|Other|Fractionated Stereotactic Radiosurgery|24 to 36 Gy in 3 fractions (8-12 Gy/fx).
3075958|NCT02054676|Experimental|Classification assessment.|Random group of the partially edentulous individuals will be assessed according to prepared classification evaluation protocol during dental implant treatment period. Cone-beam computed tomography preoperative evaluation will be made during preoperative stage. Intraoperative edentulous jaw segment parameters evaluation, endosseous dental implant placement parameters assessment during intraoperative stage will be made. Dental implant position evaluation during early postoperative stage will be made. Medications will be prescribed. Late postoperative soft tissue evaluation of edentulous jaw segment will be made during final crown placement. Cone-beam computed tomography analysis results will be compared with subsequent stages assessment results to evaluate reliability of the classification.
3075959|NCT02054663|Experimental|Bolus|Patients randomized to this arm will receive a 600mg bolus dose of clopidogrel at the time of switching from ticagrelor to clopidogrel, followed by 75mg daily.
3075960|NCT02054663|Experimental|no bolus|Individuals randomized to this arm will receive 75mg of clopidogrel at the time of the transition followed by a daily dose of 75mg orally.
3075961|NCT02054650|Experimental|Osteopathic Manual Treatment (OMT)|The OMT protocol will be delivered following an examination for somatic dysfunction at each treatment session. The protocol will target the thoracic, lumbosacral, iliac, and pubic regions using the following techniques: high-velocity, low-amplitude thrusts; moderate-velocity, moderate-amplitude thrusts; soft tissue including stretching, kneading, and pressure; myofascial stretching and release; counterstrain; muscle energy; and other optional techniques as time permits and indicated. The intervention will be delivered at weeks 0, 1, 2, 4, 6 and 8. Week 12 is a data collection visit with no intervention.
3075962|NCT02054650|Sham Comparator|Sham OMT|Sham OMT will involve hand contact, active and passive range of motion, and sham techniques that simulate OMT (including optional OMT techniques), but that utilize such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished provider force. Sham OMT will be delivered at weeks 0, 1, 2, 4, 6 and 8. Week 12 is a data collection visit with no intervention.
3075963|NCT02054637|Experimental|Lanreotide|Lanreotide autogel 120mg injection every 4 weeks (every patient will receive 3 injections)
3075964|NCT02054624|Active Comparator|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by one-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 you will receive two phone calls per month from your group leader for the first 6 months, and one phone call per month for the next 6 months."
3075965|NCT02054624|Active Comparator|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by conference telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 you will receive two phone calls per month from your group leader for the first 6 months, and one phone call per month for the next 6 months."
3075966|NCT02054624|Active Comparator|Health Education Control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 you will receive you will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help you maintain lost weight."
3075967|NCT02054611|Active Comparator|Educational Module First|Respondents will complete the online educational module first, followed by the evaluation
3075968|NCT02054611|Placebo Comparator|Evaluation First|Respondents will complete the the evaluation first, followed by the online educational module
3075969|NCT02054598|No Intervention|Control group|Usual care.
3075970|NCT02054598|Experimental|Intervention group|Decision aid and navigation
3075971|NCT02054585|Active Comparator|NaCl %0.9|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
3075972|NCT02054585|Experimental|NaCl 0.9% +5% dextrose|"Children will be included in each group in a randomized way using SAS program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% + 5% glucose. The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
3075973|NCT02054572|Experimental|[¹⁴C]Etelcalcetide|Participants received a single dose of 10 mg radiolabelled etelcalcetide administered by intravenous (IV) bolus injection at the end of hemodialysis on day 1.
3075975|NCT02054559|Experimental|Total 3 cycles of R-CHOP + RT|Total 3 cycles of R-CHOP followed by radiotherapy (involved field or involved site radiotherapy, 30-50 Gy/ 15-25 fractions)
3075976|NCT02054533||IBD patients|patients with IBD undergoing intra-abdominal surgery
3075977|NCT02054520|Experimental|HyperAcute®-Melanoma (HAM) Immunotherapy + Ipilimumab|Arm 1A will receive ipilimumab at 3 mg/kg given every 3 weeks for 4 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
3075978|NCT02054520|Active Comparator|Ipilimumab Alone|Arm 2A will receive ipilimumab alone at 3 mg/kg every 3 weeks for a total of four doses.
3075979|NCT02054520|Active Comparator|Nivolumab Alone|Arm 2B will receive nivolumab alone at 3 mg/kg given every 2 weeks
3075980|NCT02054520|Active Comparator|Pembrolizumab Alone|Arm 2C will receive pembrolizumab at 2 mg/kg given every 3 weeks
3075981|NCT02054520|Experimental|HyperAcute®-Melanoma (HAM) Immunotherapy + nivolumab|Arm 1B will receive nivolumab alone at 3 mg/kg given every 2 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
3075982|NCT02054520|Experimental|HyperAcute®-Melanoma (HAM) Immunotherapy + pembrolizumab|Arm 2C will receive pembrolizumab at 2 mg/kg given every 3 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
3075983|NCT02054507|No Intervention|Former premature infants|Cognitive and executive evaluation by Wechsler IV tests
3075984|NCT02054494||HIV patients with high CD4+ cell counts|HIV Infection, Chronic high CD4+ cell counts (>500 /μl), No known cardiac disease
3075985|NCT02054494||HIV patients with low CD4+ cell counts|HIV Infection, Chronic low CD4+ cell counts (<200 /μl), No known cardiac disease
3075986|NCT02054494||Control Group|No known cardiac disease.
3075987|NCT02054481|Experimental|Arm 1|BI 655066 s.c.
3075988|NCT02054481|Experimental|Arm 2|BI 655066 s.c.
3075989|NCT02054481|Experimental|Arm 3|BI 655066 s.c.
3075990|NCT02054481|Active Comparator|Arm 4|Ustekinumab s.c.
3075991|NCT02054468|Active Comparator|Single-shot-Propofol & Remifentanil|Induction group: A single-shot propofol induction dose with remifentanil infusion followed by injection of rocuronium (for doses, please see interventions). Airway: tracheal intubation
3075992|NCT02054468|Experimental|30min infusion Propofol & Remifentanil|Maintenance group: 30min of total intravenous anesthesia (TIVA) with propofol and remifentanil before rocuronium (for doses, please see interventions) is administered. Airway: tracheal intubation/laryngeal mask
3075993|NCT02054455|Placebo Comparator|PPI and placebo|Patients will receive PPI and placebo for 3 days/week for 6 months
3075994|NCT02054455|Active Comparator|PPI and Lactobacillus paracasei F19|Patients will receive Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for 6 months
3075995|NCT02054455|Active Comparator|PPI and Lactobacillus paracasei F19 cross-over 1|Patients will receive placebo 3 days/week for the first three months and Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for the following three months
3075996|NCT02054455|Active Comparator|PPI and Lactobacillus paracasei F19 cross-over 2|Patients will receive Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for the first three months and placebo 3 days/week for the following three months
3075997|NCT02054442|Experimental|Arm A: MTX in combination with cetuximab|"The dosage of cetuximab will be i.v. 400 mg/m2 over a period of 2h for the first infusion, followed by infusions of 250 mg/m2 over 1 hour once weekly. Cetuximab will be dissolved in 500 ml NaCl 0.9%.~Premedication: H1-receptor antagonist and dexamethasone.~The dosage of MTX (Methotrexate) will be i.v. 40 mg/m2 once weekly, administered within 5-10 minutes. MTX will be dissolved in 50 ml NaCl 0.9%.~Premedication: ondansetron 8 mg.~Treatment will be continued until progressive disease, unacceptable toxicity or refusal by patient."
3075998|NCT02054442|Active Comparator|Arm B: MTX|"The dosage of MTX (Methotrexate) will be i.v. 40 mg/m2 once weekly, administered within 5-10 minutes. MTX will be dissolved in 50 ml NaCl 0.9%.~Premedication: ondansetron 8 mg.~Treatment will be continued until progressive disease, unacceptable toxicity or refusal by patient."
3075999|NCT02054429|Experimental|Insulin|IIT arm subjects will receive an insulin aspart infusion at a minimal rate of 2 units/hr while maintaining blood glucose between 90-120mg/dl for 48 hrs
3076000|NCT02054429|No Intervention|Standard glycemic control|standard of care if not randomized to Insulin
3076001|NCT02054416|Active Comparator|Art Assist Device|The ArtAssist© (model AA1000) device is made by ACI Medical located in San Marcos, CA (http://acimedical.com/) and is cleared per FDA under K942530.The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
3076002|NCT02054416|Sham Comparator|Sham Device|"Sham devices look identical to the actual ArtAssist© devices, but provide low-pressure and differ only in number-coded tubing. The study sham intervention will consist of one hour of IPC with the sham ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the sham device has an internal device that stores the usage data) to evaluate subject compliance."
3076003|NCT02054403||angle closure|
3076004|NCT02054377|Experimental|Group A (face to face tai chi)|"8 x 1 hour taught individual classes of Tai Chi over 3 months provided by a Tai Chi instructor at the participant's home/convenient location. These focus on 8 core postures. This is in addition to participant's usual routine care. A DVD and booklet to aid home practise will be provided.~Daily home Tai Chi practise for 6 months (home practice encouraged for 5 to 10mins 5 times a week).~At the end of the 9 months, local Tai Chi classes can be recommended if requested."
3076005|NCT02054377|Active Comparator|Group 2 (online tai chi)|"3 months usual routine care.~8 x 1 hour taught individual classes of Tai Chi over 3 months provided over the internet by a Tai Chi instructor. A DVD and booklet to aid home practise will be provided.~Daily Tai Chi home practise for 6 months (home practice encouraged for 5 to 10mins 5 times a week).~At the end of the 9 months, local Tai Chi classes can be recommended if requested."
3099128|NCT01897532|Placebo Comparator|Placebo|
3076006|NCT02054364|Experimental|FBT and CRT|Family-Based Treatment combined with Cognitive Remediation Therapy (15 sessions of each)
3076007|NCT02054364|Experimental|FBT and art therapy|Family-Based Treatment combined with art therapy (15 sessions of each)
3076008|NCT02054351|Experimental|IMAB027 administration|Monotherapy - different dose Levels.
3076009|NCT02054338|Experimental|vinflunine plus gemcitabine|vinflunine 320 mg/m² D1 plus gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks
3076010|NCT02054338|Active Comparator|paclitaxel plus gemcitabine|paclitaxel 175 mg/m² D1 followed by Gemcitabine 1250 mg/m² D1 and D8 every 3 weeks
3076011|NCT02054325|Active Comparator|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml.
3076012|NCT02054325|Active Comparator|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5ml.
3076013|NCT02054312|Experimental|Family Based Interpersonal Psychotherapy (FB-IPT)|Family Based Interpersonal Psychotherapy for Depressed Preadolescents (FB-IPT) is a promising psychosocial treatment for preadolescent depression. It is conceptually rooted in an interpersonal model of depression that focuses on how stress in interpersonal relationships is often related to the onset or maintenance of depressive symptoms. In keeping with adult and adolescent models of IPT, FB-IPT focuses on improving the interpersonal functioning of individuals as a means to improve their depressive symptoms. FB-IPT addresses two domains of interpersonal impairment in depressed preadolescents, parent-child conflict and interpersonal avoidance, and focuses on family relationships, the primary context for children's social and emotional development.
3076014|NCT02054312|Active Comparator|Client Centered Therapy (CCT)|Child Centered Therapy (CCT), a supportive and nondirective treatment that closely approximates the standard of care for pediatric depression in community mental health. CCT is a manualized treatment for children between the ages of 8-14 based on a Rogerian counseling model. In that model, changes in children's mood and behavior are initiated through their experience of a therapeutic relationship marked by unconditional positive regard, empathic understanding, and therapeutic genuineness.
3076015|NCT02054299|Experimental|Drug application|6 treatment periods. On each period one of the following interventions
3076016|NCT02054286|Experimental|Group 1: THV01 (5.10E+6 TU) or Placebo|5.10E+6 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+6 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
3076017|NCT02054286|Experimental|Group 2: THV01 (5.10E+7 TU) or Placebo|5.10E+7 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+7 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
3076018|NCT02054286|Experimental|Group 3: THV01 (5.10E+8 TU) or Placebo|5.10E+8 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+8 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
3076019|NCT02054260|Experimental|Surgicel add therapy|
3076020|NCT02054247|Experimental|ultrasound|ultrasound : a frequency of 1 megahertz and with an intensity of 1 W/cm2
3076021|NCT02054247|Experimental|pulsed ultrasound|pulsed ultrasound : a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4
3076022|NCT02054247|Placebo Comparator|placebo ultrasound|placebo ultrasound : same ultrasound device as described above seemed to be working but without delivering any output
3076023|NCT02054221|Other|extended myectomy + MVreplacement|"Procedure: extended myoectomy, mitral valve surgery~Will be included in a group of 41 patients with obstructive hypertrophic cardiomyopathy and severe mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy with full isscheniem subvalvular apparatus and mitral valve replacement.~Evaluation results will be made myoectomy as TEE and direct tensiometer."
3076024|NCT02054221|Other|extended myectomy + MVrepair|"Procedure: extended myoectomy, mitral valve surgery~Will be included in a group of 41 patients with obstructive hypertrophic cardiomyopathy and severe mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy which supplemented resection and release of the papillary muscles and the mitral valve repair. Results of mitral valve repair will be more appreciated intraoperatively. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. There after, patients will be moved to the first group.~Evaluation results will be made myoectomy as TEE and direct tensiometer ."
3076025|NCT02054208|Experimental|NEUROSTEM (hUCB-MSCs)- low dose|human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
3076026|NCT02054208|Experimental|NEUROSTEM (hUCB-MSCs) - high dose|human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
3076027|NCT02054208|Placebo Comparator|Placebo|normal saline 2mL, doses separated by 4 weeks for a total of 3 doses
3076028|NCT02054195|Experimental|IUD new technique|Training
3076029|NCT02054195|Experimental|No Training|No Training
3076030|NCT02054182|Active Comparator|Vitamin D|Vitamin D 2 500 IU daily from enrolment until hospital discharge
3076031|NCT02054182|Placebo Comparator|Placebo|Placebo
3076032|NCT02054169||pre-test group|All patients aged 65 or older presenting to the ED during the pre-test period
3076033|NCT02054169||post-test period|All patients aged 65 or older presenting to the ED in the post-test period
3076034|NCT02054156|Active Comparator|azithromycin and TIS|azithromycin and tobramycin solution for inhalation (TIS) Azithromycin 3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months Tobramycin solution for inhalation (TIS), 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
3076035|NCT02054156|Placebo Comparator|placebo and TIS|placebo and tobramycin solution for inhalation (TIS) Placebo 3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months Tobramycin solution for inhalation (TIS), 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
3076036|NCT02054143|Experimental|Sevoflurane|Sevoflurane was administered to all patients at 1 minimal alveolar concentration (MAC) after the intubation occured until the patient was extubated.
3076037|NCT02054130|Placebo Comparator|Placebo|Placebo Comparator
3076038|NCT02054130|Experimental|MEDI9929 - Low Dose|MEDI9929 (Investigational Product)
3076039|NCT02054130|Experimental|MEDI9929 - Medium Dose|MEDI9929 (Investigational Product)
3076040|NCT02054130|Experimental|MEDI9929 - High Dose|MEDI9929 (Investigational Product)
3076041|NCT02054117||Intracerebral Hemorrhage|Spontaneous intracranial or intraparenchymal hemorrhage that occurred in a supratentorial location.
3076042|NCT02054104|Experimental|1/Vaccine plus chemotherapy|H1299 cell lysate vaccine with metronomic chemotherapy
3076043|NCT02054104|Experimental|2/Vaccine alone|H1299 cell lysate vaccine
3076044|NCT02054091|No Intervention|Control group|Infants are fed according to the standard feeding practices at each hospital. At FWCH & SBMCH babies are fed infant formula supplemented to mother's own milk (if avaible), and at RH, babies are fed donor milk supplemented to Mother'w own milk (if avaible).
3076045|NCT02054091|Experimental|Colostrum group|Infants are fed bovine colostrum supplemented to mother's own milk (if avaible) for max. 10 days at RH and 14 days at FWCH & SBMCH.
3076046|NCT02054078|Experimental|Bevacizumab|Bevacizumab200mg by intrapleural administration
3076047|NCT02054078|Active Comparator|Pulvis talci|Pulvis talci 4g by intrapleural administration
3076048|NCT02054065|No Intervention|Control|Normal care conditions, no computer-based physician alert.
3076049|NCT02054065|Experimental|CAUTI Decision Support|Decision support aimed at preventing Catheter Associated Urinary Tract Infections (CAUTIs)
3076050|NCT02054052|Experimental|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating maliganant pleural or percardial effusion
3076051|NCT02054039|Experimental|Incentive spirometry (IS)|Group I
3076052|NCT02054039|Active Comparator|Breath stacking (BS)|Group II
3076053|NCT02054026|Experimental|Reducing the Risk|An eight-lesson (approximately eight-hour) version of Reducing the Risk
3076054|NCT02054026|No Intervention|Control|
3076055|NCT02054013|Experimental|Prostatic artery embolization|Prostatic artery embolization (PAE) has been suggested as a minimal invasive alternative procedure with rapid recovery and low morbidity
3076056|NCT02054013|Other|Conventional monopolar transurethral prostatectomy|Standard treatment
3076057|NCT02054000|Active Comparator|Tirofiban group|If thrombolysis in myocardial infarction flow <3 in spite of performed treatments, patients were considered as no-reflow and randomized to tirofiban or placebo group. Intracoronary tirofiban (25 µgr/kg) was administered via the guiding catheter to the infarct related artery
3076058|NCT02054000|Placebo Comparator|Placebo group|If thrombolysis in myocardial infarction flow <3 in spite of performed treatments, patients were considered as no-reflow and randomized to tirofiban or placebo group. Intracoronary serum physiologic as placebo was administered via the guiding catheter to the infarct related artery
3076059|NCT02053987|Experimental|Stroke rehabilitation|
3076060|NCT02053987|No Intervention|Control Group|This group will undergo rehabilitation as per the current stroke rehabilitation pathway.
3076061|NCT02053974|Active Comparator|Spironolactone|patients who randomized to spironolactone administered arm
3076062|NCT02053974|Placebo Comparator|Placebo|Patients who randomized to placebo administered arm
3076063|NCT02053961|Active Comparator|1Hz dTMS Real|This group will receive dTMS real treatment of 1Hz
3076064|NCT02053961|Sham Comparator|1HZ dTMS SHAM|This group will receive 1HZ dTMS SHAM treatment
3076065|NCT02053948|Experimental|Pursestring Wound Closure group|use Pursestring Wound Closure technique to close the stoma
3076066|NCT02053948|Experimental|Gunsight Skin Incision and Closure group|use Gunsight Skin Incision and Closure Technique to close the stoma
3076067|NCT02053935|Other|Dopamine|All patients will receive the same intervention.
3076068|NCT02053922|Active Comparator|Syntocinon|Drug is given just after delivery of the neonate during cesarean section.
3076069|NCT02053922|Active Comparator|Carbetocin|Drug is given just after delivery of the neonate during cesarean section.
3076070|NCT02053922|Active Comparator|Misoprostol|Drug is given just after delivery of the neonate during cesarean section.
3076071|NCT02053909|Active Comparator|Aspirin|One aspirin 81 mg capsule 2 times per day
3076072|NCT02053909|Active Comparator|Ticagrelor|One ticagrelor 90 mg capsule 2 times per day
3076073|NCT02053896||ISU302|15~60U/kg (once every 2 weeks for 6 months)
3076074|NCT02053883|Placebo Comparator|Placebo|Fibrin sealant only.
3076075|NCT02053883|Experimental|Cethrin (BA-210) - Low Dose|Low dose of Cethrin in a fibrin sealant.
3076076|NCT02053883|Experimental|Cethrin (BA-210) - High Dose|High dose of Cethrin in a fibrin sealant.
3076077|NCT02053870|Experimental|Physiotherapy+conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.
3076078|NCT02053870|Active Comparator|Conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
3076079|NCT02053857|Active Comparator|RUTF|Standard RUTF at a dose of 175 kcal/kg/d
3076080|NCT02053857|Experimental|RUTF-P|RUTF fortified with polyunsaturated fatty acids (PUFA) at a dose of 175 kcal/kg/d
3076081|NCT02053844|Experimental|lottery and enhanced promotion of tool|tool users in the intervention arm will be eligible to enter a monthly lottery to win one of two monthly drawings of a $500 gift card, and will receive enhanced promotion of the tool (mailed promotion, promotional message on the member web portal, and promotion through employers to employees)
3076082|NCT02053844|No Intervention|usual promotion of the tool|Routine promotion of the tool through newsletter and on health plan web site
3076083|NCT02053818|Active Comparator|Remifentanil|Remifentanil the basic opioid drug in anesthesia
3076084|NCT02053818|Active Comparator|Sufentanil|Sufentanil the basic opioid drug in anesthesia
3076085|NCT02053805|Other|screening tests|The screening will include: DRE, PSA , a multiparametric prostate MRI and a trans-rectal ultra-sound guided prostate biopsy/ MRI-US fusion , IPSS questionnaire, trans-rectal US assessment of prostate size, urine flow and residual.
3076146|NCT02053272|Active Comparator|5 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 5 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
3076086|NCT02053792|Experimental|rIX-FP|"Subjects will administer rIX-FP by intravenous infusion as routine prophylaxis, prevention, and on-demand treatment during a treatment period of approximately 3 years.~The routine prophylaxis treatment interval for previously treated patients may be changed at each scheduled 6-month follow-up assessment. On-demand treatment with rIX-FP will be used for all bleeding episodes requiring treatment. Subjects (other than those in France) may participate in a surgical 'substudy' in which rIX-FP may be administered before, during and after surgery. An additional substudy will examine the safety and PK of subcutaneous administration of rIX-FP.~For previously untreated patients, subjects will administer rIX-FP intravenously as weekly prophylaxis and/or on-demand treatment during the first 12 months, and as weekly routine prophylaxis thereafter.~The dose of rIX-FP administered will be based on the subject's previous rIX-FP use and/or pharmacokinetic data."
3076087|NCT02053779|Experimental|GnRH-agonist|Experimental Arm: Triptorelin 0.1 mg
3076088|NCT02053779|No Intervention|Control Arm|Control Arm: No intervention
3076089|NCT02053766|Active Comparator|Sevoflurane|In the Operating Room (OR) after applying routine monitors, anesthesia will be induced with a mask using Sevoflurane up to 8%. Sevoflurane will be used for maintenance for the rest of the procedure with dosage between 1.5% and 4%. Vitals will be monitored. Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Sevoflurane will be turned off at the end of procedure.
3076090|NCT02053766|Active Comparator|Dexmedetomidine (Precedex®)|These subjects will receive Dexmedetomidine intravenously. In the OR routine monitors will be placed. Vitals will be monitored. A loading dose of Precedex 1mcg/ kg will be given over 10 minutes. Infusion will be started using Precedex 1mcg/ kg/ hr and can be increased or decreased as needed. Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Precedex infusion will be stopped at the end of the procedure.
3076091|NCT02053766|Active Comparator|Propofol|These subjects will receive propofol for anesthesia maintenance. In the OR routine monitors will be placed. Vitals will be monitored. A loading dose of Propofol 2mg/ kg will be given over 2 minutes. Infusion will be started using Propofol 50 mcg/ kg/min and can be increased or decreased as needed (range 50-300mcg/kg/min). Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Propofol infusion will be stopped at the end of the procedure.
3076092|NCT02053753|Experimental|Drug Product CP4|Participants received a single dose of 120 mg denosumab manufactured using the new CP4 process subcutaneously on day 1.
3076093|NCT02053753|Experimental|Drug Product CP2|Participants received a single dose of 120 mg denosumab manufactured using the current CP2 process subcutaneously on day 1.
3076094|NCT02053740|Experimental|R-S-Y-R-T|We added R-S-Y-R-T (500 mg 3 times per day) for 6 months
3076095|NCT02053740|Other|Routine western medicine|We kept routine western medicine only (as control group)
3076096|NCT02053727|Active Comparator|Abatacept Arm|This arm of study subjects will receive 125 mg subcutaneous abatacept during the 24 week double blind period.
3076097|NCT02053727|Placebo Comparator|Placebo Arm|This arm of study patients will receive matching placebo injections during the 24 week double blind period.
3076098|NCT02053714|Other|Self-management and education group|Self-management and education group - 8 weeks of group-based information and activities designed to improve diabetes self-management
3076099|NCT02053688|Active Comparator|Astigmatic Correction Lens|Nexis ACCL lenses vs commercial Toric Lenses
3076100|NCT02053688|Active Comparator|Toric Soft Contact Lenses|commercial toric soft contact lenses
3076101|NCT02053675|Other|Vasopressin|
3076102|NCT02053662||Bladder Cancer Patients|Patients with muscle invasive bladder cancer. A sample collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
3076103|NCT02053649|Active Comparator|Usual Care|Usual Care will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
3076104|NCT02053649|Experimental|Triple Chronotherapy + Usual Care|triple chronotherapy (TC) will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
3076105|NCT02053636|Experimental|lucitanib|"Hard gelatine capsules of 2,5, 5 and 10 mg or film coated tablets of 5 and 7,5 mg.~5 to 10 mg orally on a daily basis until unacceptable toxicity according to the investigator, disease progression or withdrawal of consent"
3076106|NCT02053610|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
3076107|NCT02053610|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
3076108|NCT02053610|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
3076109|NCT02053597|Experimental|doxorubicin and paclitaxel|All patients will receive four cycles of doxorubicin (A) (50 mg/m2) and paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
3076110|NCT02053584|Experimental|Dario BGMS|
3076111|NCT02053571|Experimental|TIPS with 3D overlay|
3076112|NCT02053558|Placebo Comparator|Systemic lidocaine|Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
3076113|NCT02053558|Active Comparator|TAP BLOCK with ropivacaine|TAP block will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
3076193|NCT02052934|Experimental|Cohort 3|Three SL doses of dMLT, 25 mcg, on Days 1, 15 and 29, 11 subjects
3099129|NCT01897519|Experimental|Arm 1 lower dose ABT-719|
3076114|NCT02053545|Experimental|Conditioning Regimen & GVHD Prophylaxis|"Stratum 1 (Refractory disease, relapse after previous transplant): Clofarabine, Melphalan,Thiotepa, Cyclophosphamide, Mesna, Tacrolimus and mycophenolate mofetil (MMF)~Stratum 2 (Myeloid in remission): Busulfan, Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Tacrolimus, MMF~Stratum 3 (Lymphoid in remission): Fractionated total body irradiation (fTBI), Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Tacrolimus, MMF"
3076115|NCT02053532||Positron emission tomography/magnetic resonance imaging|
3076116|NCT02053519|Active Comparator|Vigantol Oil, (Vitamin D3)|Oral Vigantol Oil 5 mls, (100 000 iu of Vitamin D). First dose at randomisation, 7 -28 days prior to commencing standard Hepatitis C treatment for Hepatitis C Genotypes 1 or 3 . Thereafter monthly with concurrent Hepatitis C treatment.
3076117|NCT02053519|Placebo Comparator|MyGliol Oil|Matched placebo. Subjects randomised to this arm will take 5 mls of active Placebo, (Mygliol oil), 7 - 28 days prior to commencing active Hepatitis C treatment and thereafter 5 mls monthly concurrent with Hepatitis C treatment for the duration of the study
3076118|NCT02053506|Experimental|Immune-enhancing nutritional beverage|This group will consume an immune-enhancing beverage and additional protein (1.2-1.5 grams•kg-1 body weight•day-1 versus the RDA of 0.8 grams•kg-1 body weight•day-1) during and after the period of sleep restriction to determine if this nutritional approach attenuate the loss of immune responsiveness.
3076119|NCT02053506|Experimental|Probiotics (BB-12)|This group will consume probiotics (BBB12) during and after the period of sleep restriction to determine if nutritional approaches attenuate the loss of immune responsiveness. Consistent with the control group, this group will consume the RDA for protein (0.8 grams•kg-1 body weight•day-1) and placebo beverage (no immune-enhancing vitamins/minerals).
3076120|NCT02053493|Active Comparator|Isosorbide Mononitrate|Isosorbide Mononitrate with dose up-titration (30 to 120 mg/day over 4 weeks)
3076121|NCT02053493|Placebo Comparator|Isosorbide Mononitate Placebo|Isosorbide Mononitrate placebo with dose up-titration (30 to 120 mg/day over 4 weeks)
3076122|NCT02053480||Pyruvate Kinase Deficiency|Patients of all ages with Pyruvate Kinase Deficiency
3076123|NCT02053467|Experimental|Group 1|Group 1 physicians randomized to the intervention will have access to the Champlain BASE eConsult service in Years One and Two
3076124|NCT02053467|Active Comparator|Control|Group 2 physicians randomized to the control group will conduct their consultation processes as normal during Year One, and will then be granted access to the Champlain BASE eConsult service in Year Two
3076125|NCT02053454|Active Comparator|patisiran (ALN-TTR02)|
3076126|NCT02053454|Active Comparator|Sterile Normal Saline (0.9% NaCl)|
3076127|NCT02053428|Active Comparator|Gastrostomy - pull technique|Percutaneous image-guided gastrostomy using large-bore mushroom-retained catheters via the pull technique
3076128|NCT02053428|Active Comparator|Gastrostomy - push technique|Percutaneous image-guided gastrostomy using small-bore cope loop catheters via the push technique
3076129|NCT02053415|Experimental|Krill oil low dose|3 capsules krill oil per day, for 28 days
3076130|NCT02053415|Experimental|Krill oil high dose|9 capsules krill oil per day, for 28 days
3076131|NCT02053402|Placebo Comparator|Placebo|Placebo to be given daily for six months
3076132|NCT02053402|Active Comparator|Vitamin D|1200 IU of vitamin D, daily for six months
3076133|NCT02053389|Experimental|DVD Decision Aid|"Eligible participants receive the written decision aid (Making the Choice: Deciding What to Do About Early Stage Prostate Cancer) AND the DVD decision aid (Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer), which provides instruction and recommendations on how to participate in shared decision making with one's physician."
3076134|NCT02053389|Active Comparator|Written Decision Aid|"Eligible participants receive the written decision aid (Making the Choice: Deciding What to Do About Early Stage Prostate Cancer) alone."
3076135|NCT02053376|Experimental|regorafenib|Patients with advanced and metastatic biliary tract adenocarcinoma (cholangiocarcinoma) who had been treated with and failed first-line chemotherapy will be treated with regorafenib (160 mg) orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle
3076136|NCT02053363|Experimental|High Dose/Study Group|Tranexamic Acid (Cyklokapron) Loading Dose 50mg/kg given over 15 minutes, followed by 5mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.
3076137|NCT02053363|Active Comparator|Standard of Care/Control|Tranexamic Acid (Cyklokapron) Loading Dose 10mg/kg given over 15 minutes, followed by 1mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.
3076138|NCT02053350|Experimental|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days.
3076139|NCT02053337|Experimental|Self adhesive foam dressing|Sponsor manufactured self adhesive foam dressing. Use of CE marked dressing according to instructions for use and study protocol.
3076140|NCT02053337|Active Comparator|Comparator self adhesive foam dressing|Non Sponsor manufactured self adhesive foam dressing. Use of CE marked dressing according to instructions for use and study protocol.
3076141|NCT02053324|Experimental|AvidinOX/ST2210|AvidinOX/ST2210 - vial containing 22.5 mg AvidinOX + vials containing 10 ml of water for injection (WFI) for the reconstitution in a clear solution with an AvidinOX concentration of 3 mg/ml. One Intralesion administration of a volume of reconstituted AvidinOX equal to 15 % of the lesion volume followed by intravenous infusion of 177Lu-ST2210 Diagnostic dose : 10 ml, 250 MBq±10%177Lu, approximately 1 mg ST2210, 100 mg/mL ascorbic acid, followed by intravenous infusion of a therapeutic dose: 25 ml, escalating 177Lu dose starting at 5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210, 100 mg/ml ascorbic acid
3076142|NCT02053311|Active Comparator|Arm A: Orteronel|300mg orteronel twice daily and best supportive care until disease progression
3076143|NCT02053311|Active Comparator|Arm B: Placebo|Placebo twice daily and best supportive care until disease progression
3076144|NCT02053298|Experimental|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
3076145|NCT02053272|Active Comparator|2 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 2 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
3099130|NCT01897519|Experimental|Arm 2 intermediate dose ABT-719|
3076147|NCT02053272|Active Comparator|15 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 15 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
3076148|NCT02053272|Placebo Comparator|Placebo|Licaps® size double zero (Size 00) hard gelatin capsules containing excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
3076149|NCT02053259|Experimental|Arm 1|Adaptive Goals, Reinforcement
3076150|NCT02053259|Experimental|Arm 2|Adaptive Goals, No Reinforcement
3076151|NCT02053259|Experimental|Arm 3|Static Goals, Reinforcement
3076152|NCT02053259|Active Comparator|Arm 4|Static Goals, No reinforcement
3076153|NCT02053246|Experimental|Nebivolol|Participants will be started at 2.5 mg of nebivolol by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
3076154|NCT02053233|Experimental|Walkbot group|The Walkbot group received conventional physical therapy (session I for 40 min/day) companied with Walkbot training (session II for 30 min/day) 5 days a week for 4 weeks, 40 session in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks.
3076155|NCT02053233|Placebo Comparator|control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
3076156|NCT02053220|Experimental|Intra-tumoural cohort|
3076157|NCT02053220|Experimental|Intra-venous cohort|
3076158|NCT02053207|Experimental|Cog-Train Intervention|
3076159|NCT02053194|Experimental|Pharmacist-led educational intervention|Participants will receive an educational brochure on an inappropriate prescription they are currently taking from their pharmacists. Participants' physicians will receive an evidence-based pharmaceutical opinion for the same medication.
3076160|NCT02053194|No Intervention|Control|Participants in the control group will be wait-listed and observed for 6 months prior to receiving the intervention.
3076161|NCT02053181|Experimental|Cadazolid|Single oral dose of 3000 mg.
3076162|NCT02053168|Other|Resorbable Mesh|Phasix Mesh
3076163|NCT02053155|Experimental|computer based patient education|The patients will complete a pre module and post module set of questions to determine whether their knowledge about peri operative smoking cessation increase smoking has changed. According to their willingness and eligibility, pharmacotherapy will be given.
3076164|NCT02053142|Experimental|Part 1 PK|400mg dose of acyclovir taken orally, followed by 2 ml blood plasma collection at 1,2,4,6 and 8 hours.
3076165|NCT02053142|Active Comparator|Acyclovir|400 mg Acyclovir three times daily for 5 days
3076166|NCT02053142|Placebo Comparator|Placebo|Placebo three times daily for 5 days
3076167|NCT02053129|Other|HIV negative pregnant women|Pregnant women who are HIV negative attending their first ANC visit
3076168|NCT02053129|Other|HIV positive pregnant women|Pregnant women who are HIV positive accessing antenatal care.
3076169|NCT02053116|Experimental|PF-05175157|
3076170|NCT02053116|Placebo Comparator|Placebo|
3076171|NCT02053103|Experimental|PF-05175157|
3076172|NCT02053103|Placebo Comparator|Placebo|
3076173|NCT02053090|Active Comparator|Group Education with Stretching|"Group Education with Stretching will receive 10 small group educational classes at the Oregon Health & Science University (OHSU), based on the book Fibromyalgia (Biographies of Disease). Each chapter of Fibromyalgia covers different aspects of the disease and its treatment including global, economic, and risk statistics; a timeline of key events in the study of fibromyalgia; common symptoms and diagnostic indicators; natural history of fibromyalgia; pharmacologic and non-pharmacologic treatments; associated disorders and syndromes; and impact of fibromyalgia at home, in the workplace and in society at large. Participants will be informed that they should not start additional treatments until the end of the study and complementary and alternative treatments won't be covered until the last session. Participants will also receive a digital video disk (DVD) covering stretching appropriate for fibromyalgia patients and will be asked to incorporate the DVD over the next 10 weeks."
3076174|NCT02053090|Experimental|Group Acupuncture|20 treatments in 10 weeks will include individualized acupuncture in a group setting, dietary and lifestyle recommendations each based on the Traditional Chinese Medicine diagnosis (zhang fu) at the time of the visit.
3076175|NCT02053064|Experimental|SAF-301|
3076176|NCT02053051|Experimental|MDI of insulin & ABC4D|Advanced Bolus Calculator for Type Diabetes (ABC4D)
3076177|NCT02053051|Active Comparator|MDI of insulin|Multiple daily injections(MDI) of insulin
3076178|NCT02053038|Experimental|iFR|Treatment guided by iFR
3076179|NCT02053038|Active Comparator|FFR|Treatment guided by FFR
3076180|NCT02053025|Active Comparator|mycoprotein|3 levels of mycoprotein will be consumed
3076181|NCT02053025|Active Comparator|control protein|3 levels of a control protein will be consumed
3076182|NCT02053012||PVT-192|
3076183|NCT02052999|Experimental|PAC-14028 cream 1%|PAC-14028 cream 1%, twice daily for 8 weeks
3076184|NCT02052999|Active Comparator|Rozex gel 0.75%|Rozex gel 0.75%, twice daily for 8 weeks
3076185|NCT02052999|Placebo Comparator|Vehicle|Vehicle, twice daily for 8 weeks
3076186|NCT02052986|Experimental|Vascazen|Enrolled patients will receive four capsules daily of VASCAZEN (a 3.0 gram daily dose of EPA+DHA) for a total of 12 weeks.
3076187|NCT02052973|Experimental|Propolis varnish|Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
3076188|NCT02052960|Experimental|Tomuzotuximab plus chemotherapy|60 mg/day 0, 930 mg/day 1, followed by 720 mg weekly administration
3076189|NCT02052960|Active Comparator|Cetuximab plus chemotherapy|400 mg/m2 on day 1, followed by 250 mg/m2 weekly administration
3076190|NCT02052947|Other|SPEC-DaTscan|SPEC-DaTscan
3076191|NCT02052934|Experimental|Cohort 1|Three sublingual (SL) doses of dMLT, 1 microgram (mcg), on Days 1, 15 and 29, 8 subjects
3076192|NCT02052934|Experimental|Cohort 2|Three SL doses of dMLT, 5 mcg, on Days 1, 15 and 29, 8 subjects
3076194|NCT02052934|Experimental|Cohort 4|Three SL doses of dMLT, 50 mcg, on Days 1, 15 and 29, 11 subjects
3076195|NCT02052934|Experimental|Cohort 5a|Three SL doses of dMLT,25 mcg on Days 1, 15 and 29, 13 subjects.
3076196|NCT02052934|Experimental|Cohort 5b|Three oral doses of dMLT, 25 mcg on Days 1, 15and 29, 13 subjects
3076197|NCT02052921|Active Comparator|Rectal resection|Surgical rectal resection
3076198|NCT02052921|Experimental|Observation|Conservative approach
3076199|NCT02052908|Experimental|Arm I (high-dose naproxen)|Patients receive high-dose naproxen PO QD for 6 months.
3076200|NCT02052908|Experimental|Arm II (low-dose naproxen, placebo)|Patients receive low-dose naproxen PO QD and placebo PO QD for 6 months.
3076201|NCT02052908|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO QD for 6 months.
3076202|NCT02052895||Sepsis/SIRS|Patients with sepsis or SIRS
3076203|NCT02052895||Control|Patients without SIRS, sepsis, or end stage renal disease
3076204|NCT02052895||End Stage Renal Disease|Patients with end stage renal disease, without SIRS or sepsis
3076205|NCT02052882|Experimental|Romiplostim|"All patients will begin weekly romiplostim at 2 mcg/kg, subcutaneously. The romiplostim dose will be titrated on weekly CBC/platelet counts. For titration purposes, the target platelet count is 150,000-200,000/mcL. Treatment can be held up to 16 days if a patient develops an intercurrent medical illness or symptom that is unrelated to study drug therapy.~Treatment may be held up to 20 days if the patient unavailable for non- medical reasons, such as vacation or travel."
3076206|NCT02052869|Other|esophagus intubation|all patients will be intubated in the trachea first, with subsequent intubation in the esophagus. measurements will be performed on both tubes in a blinded manner.
3076207|NCT02052856||ACL Surgery|All English speaking patients 16 years and older having anterior cruciate ligament (ACL) surgery without any other surgery to knee or contralateral knee.
3076208|NCT02052843|Experimental|Steps to Success|Steps to Success enhanced home visits—including instruction for both young mothers and fathers on contraception, comprehensive sex education, and the importance of adequate birth spacing, and accompanied by group sessions on adulthood preparation topics.
3076209|NCT02052843|Active Comparator|Traditional Healthy Families|Traditional Healthy Families home visits which cover topics of parenting and child development
3076210|NCT02052830|Experimental|Wise Guys|A sexual health and male responsibility program for adolescent males
3076211|NCT02052830|No Intervention|Control|Business as usual sexual education in schools
3076212|NCT02052817|Active Comparator|Control|Debridement and standard of care in off-loading on control patients
3076213|NCT02052817|Experimental|Toad Brace|Debridement and fitting of Toad Brace
3076214|NCT02052791|Experimental|nusinersen|
3076215|NCT02052778|Experimental|TAS-120|"TAS-120 tablets, oral; 21-day cycle~Dose escalation portion of the study was completed.~Dose expansion- patients with tumors harboring specific FGFR aberrations, specifically in CCA, Brain Tumor , Urotherial carcinoma and any other tumors with FGFR fusion, activating mutation and amplification.~Phase 2- intra-hepatic CCA patients with tumors harboring FGFR2 gene fusions"
3076216|NCT02052765|Experimental|ajmaline test|All patients underwent ajmaline test for ST shift recording
3076217|NCT02052752|Experimental|Test Product|Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
3076218|NCT02052752|Active Comparator|Vehicle gel|The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
3076219|NCT02052752|Placebo Comparator|Positive control|A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
3076220|NCT02052739|Experimental|active drug|SAGE-547
3076221|NCT02052726|Experimental|Arm Label: Month 0, 1 and 3 Schedule|
3076222|NCT02052726|Experimental|Day 1, 8, and 30 Schedule|
3076223|NCT02052713|Experimental|Sequence AB|Subjects will receive Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 1 and Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 2 orally once daily under fasted condition.
3076224|NCT02052713|Experimental|Sequence BA|Subjects will be randomized to receive Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 1 and Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 2 orally once daily under fasted condition.[dutasteride 0.5 mg and tamsulosin HCl 0.4 mg) in period 2 orally once daily under fasted condition.
3076225|NCT02052687|Experimental|Part 1: LFX453/placebo|once daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2
3076226|NCT02052687|Experimental|Part 2 groupA: LFX453/placebo|once daily: LFX453 cream 1 / Placebo 1
3076227|NCT02052687|Experimental|Part 2 groupB: LFX453/placebo|once daily: LFX453 cream 2 / Placebo 2
3076228|NCT02052687|Experimental|Part 2 groupC: LFX453/LFX453|once daily: LFX453 cream 1 / LFX453 cream 2
3076229|NCT02052687|Other|Part 2 groupD: Imiquimod|once daily: imiquimod cream
3076230|NCT02052687|Experimental|Part 3: LFX453/placebo|twice daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2
3076231|NCT02052674|Experimental|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
3076232|NCT02052674|Active Comparator|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
3076268|NCT02052479|Other|Polycystic Ovary Synrome, PCOS, African-American, No treatment|Frequently Sampled Intravenous Glucose Tolerance Test with minimal model analysis (MINMOD FSIVGTT)
3099131|NCT01897519|Experimental|Arm 3 high dose ABT-719|
3076233|NCT02052661|Experimental|Engerix-B Kinder Group|Subjects who were previously primed and boosted with four doses of Infanrix™ hexa in the first two years of life, received a single dose of Engerix™-B Kinder vaccine. The vaccine was administered intramuscularly into the deltoid of the non-dominant arm.
3076234|NCT02052648|Experimental|Phase 1b Cohort 1|"Phase 1B patients will receive Indoximod given in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth. The medication should be taken twice daily for 28 days each cycle.~Temozolomide will also be given by mouth at 150 mg/m^2 x 5 days at all dosing levels of indoximod. Each cycle is 28 days. Patients will continue until they experience disease progression or toxicity."
3076235|NCT02052648|Experimental|Cohort 2a|Bevacizumab naïve phase II patients who will receive indoximod with temozolomide. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2.
3076236|NCT02052648|Experimental|Cohort 2b|"Phase II patients who will receive indoximod with temozolomide and bevacizumab who have previously been treated with bevacizumab.~Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Bevacizumab will be dosed at 10mg/kg."
3076237|NCT02052648|Experimental|Cohort 2c|Phase II patients who will receive indoximod with temozolomide and stereotactic radiosurgery. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Single fraction SRS dose will be 16 or 20 Gy depending on target volume. The total 5-fraction SRT dose will be 27.5 Gy.
3076238|NCT02052635|Experimental|Ticagrelor|90 mg oral tablet
3076239|NCT02052635|Active Comparator|Clopidogrel|300 mg oral tablet
3076240|NCT02052622|Experimental|ATX-101 [5mg/ml]|Subjects treated with ATX-101 5 mg/mL in previous studies ATX-101-10-16 and ATX-101-10-17, respectively
3076241|NCT02052622|Experimental|ATX-101 [10mg/ml]|Subjects treated with ATX-101 10 mg/mL in previous studies ATX-101-10-16 and ATX-101-10-17, respectively
3076242|NCT02052622|Experimental|Placebo|Subjects treated with placebo in previous studies ATX-101-10-16 and ATX-101-10-17, respectively
3076243|NCT02052609|Experimental|KHK4827 140mg SC|
3076244|NCT02052609|Experimental|KHK4827 210mg SC|
3076245|NCT02052596|Experimental|GSK1437173A Group|Subjects received one injection of Boostrix vaccine and one injection of the GSK1437173A vaccine during the first visit and a second injection of the GSK1437173A vaccine during the third visit, two months later.
3076246|NCT02052596|Active Comparator|Control Group|Subjects received all vaccines separately i.e. one injection of Boostrix vaccine at the first visit, one injection of the GSK1437173A vaccine at the third visit and a second injection of the GSK1437173A vaccine at the fourth visit, all two months apart.
3076247|NCT02052583|Experimental|34°C|therapeutic hypothermia at 34 ° C
3076248|NCT02052583|Experimental|32°C|therapeutic hypothermia at 32 ° C
3076249|NCT02052570||Children post-HSCT|Children post-HSCT age 10-16 yrs of age who had allogeneic transplant who are within 5 years of transplant and returned to school in past 12-24 months after previously attending school pre-transplant
3076250|NCT02052570||Parents of children post-HSCT|Parents of children post-HSCT (children in focus group) will participate in focus group with other parents to discuss the challenges and successes of their child returning to school following HSCT.
3076251|NCT02052570||Teachers of children post-HSCT|Teachers of children post- HSCT (children in focus group) will participate in focus group with other teachers to discuss the challenges and successes of children returning to school post HSCT
3076252|NCT02052570||PBMT provider of child post-HSCT|PBMT provider of child-post HSCT (child in focus group) will participate in in focus group with other PBMT providers to discuss the successes and challenges of coordinating school reentry in child post-HSCT
3076253|NCT02052557|Active Comparator|Bupivacaine|30 milliliters (ml) of 0.5% marcaine with epinephrine
3076254|NCT02052557|Active Comparator|Bupivacaine liposome suspension|exparel 20ml, diluted with 10ml sterile saline for total of 30ml
3076255|NCT02052544||Study patients|Patients receiving unfractionated heparin (UFH)
3076256|NCT02052531|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, twice daily for 28 days
3076257|NCT02052531|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, twice daily for 28days
3076258|NCT02052531|Placebo Comparator|Vehicle|Vehicle, twice daily for 28days
3076259|NCT02052518|Experimental|Enhanced NFN Home Program|Education and Skill set training with materials to implement the behaviors recommended. Using a motivational interviewing framework, intervention participants will receive dietary and activity counseling, develop a Family Wellness Plan and will be linked to community resources.
3076260|NCT02052518|Placebo Comparator|Nurturing Family Network Home Visitation|Mothers will receive the standard of care from the Nurturing Families Network Home Visitation program
3076261|NCT02052505|No Intervention|Usual care|The patients will receive the usual care when admitted. This includes an examination by a physician, a medication review and the physician will prescribe medications for the patients as well as other necessary interventions.
3076262|NCT02052505|Experimental|Medication review|The patients will receive the usual care when admitted. This includes an examination by a physician, a medication review and the physician will prescribe medications for the patients as well as other necessary interventions. Following this (usual care) a trained nurse will perform a medication review and discuss the observations with a physician.
3076263|NCT02052492|Experimental|Cohort A: EF-022 100 ng once weekly|Intra-Muscular injections of EF-022 100 ng once weekly for a period of 8 weeks
3076264|NCT02052492|Experimental|Cohort B: EF-022 500 ng once weekly|Intra-Muscular injections of EF-022 500 ng once weekly for a period of 8 weeks
3076265|NCT02052492|Experimental|Cohort C: EF-022 1000 ng once weekly|Intra-Muscular injections of EF-022 1000 ng once weekly for a period of 8 weeks
3076266|NCT02052492|Experimental|Expanded Cohort|the expanded cohort, 24 Patients will be allocated to receive either 100ng, 500ng or 1000ng weekly treatment as detailed below: The first 18 patients will be assigned to alternating doses of either 100ng or 500ng in a sequential manner (each patient will be assigned to a single dose). A decision regarding adding a 1000ng dose cohort vs. continuing with the 100ng and 500ng doses will be based on a discussion of the interim analysis results.
3076267|NCT02052479|Other|Polycystic Ovary Synrome, PCOS, Caucasian, No treatment|Frequently Sampled Intravenous Glucose Tolerance Test with minimal model analysis (MINMOD FSIVGTT)
3076313|NCT02052154|Experimental|Prime-boost pneumococcal immunization|
3076269|NCT02052466||Reverse TSA patients|Patients having undergone reverse TSA at the Cleveland Clinic with a high quality preoperative CT of the operative shoulder and who are at least 24 months post surgery.
3076270|NCT02052440|Experimental|Baclofen 10mg three times daily|Baclofen 10mg by mouth three times daily
3076271|NCT02052440|Placebo Comparator|Sugar Pill given three times daily|Placebo sugar bill
3076272|NCT02052427|Experimental|ADRCs|"Adipose-Derived Regenerative Cells (ADRCs) processed by the Celution System:~0.8 x 10^6 cells/kg body weight (not to exceed 80.0 x 10^6 cells)~Delivered via the MYOSTAR™ Injection Catheter in 15 intramyocardial injections"
3076273|NCT02052427|Placebo Comparator|Placebo|"Placebo - Physiological Solution~Inactive substance (Lactated Ringers + autologous blood)~Delivered via the MYOSTAR™ Injection Catheter in 15 intramyocardial injections"
3076274|NCT02052414|Experimental|Gralise (Gabapentin ER)|"All patients will be treated with Gralise. Patients who are on pregabalin or gabapentin (lyrica or neurontin) will need to wash off the medication before starting Gralise.~Patients who are ready to take Gralise will start with starter pack, and will gradually titrate the dose up to 1800mg per day. After that, patient will take 1800mg per day out of the bottle.~Patient will be seen in clinic at 4weeks intervals for first 4 visits, and then there will be end of the study visit on week 15. On visit 4, week 12 of treatment, patients will be taught to taper off the study medication."
3076275|NCT02052401|Experimental|Occupational Therapy Intervention|Post Discharge Domiciliary Intervention by Occupational Therapy (OT)
3076276|NCT02052401|No Intervention|Usual follow-up|Usual follow-up of post discharge elderly patients, including pharmacological, and non-pharmacological care.
3076277|NCT02052388|Experimental|Low Single Dose Brilacidin|0.6mg/kg Brilacidin IV (single dose) on Day 1, followed by placebo Daily Days 2-7
3076278|NCT02052388|Experimental|High Single Dose Brilacidin|0.8mg/kg Brilacidin IV (single dose)
3076279|NCT02052388|Experimental|3-Day Regimen Brilacidin|0.6mg/kg Brilacidin IV on Day 1, followed by 0.3mg/kg Brilacidin IV on Days 2 & 3
3076280|NCT02052388|Active Comparator|Standard dosing regimen Daptomycin|4mg/kg Daptomycin IV daily for 7 Days
3076281|NCT02052375|Experimental|ASP2408 low dosing frequency|
3076282|NCT02052375|Experimental|ASP2408 high dosing frequency|
3076283|NCT02052375|Experimental|Placebo low dosing frequency|
3076284|NCT02052375|Experimental|Placebo high dosing frequency|
3076285|NCT02052362|Experimental|Group 1 - Regimen A|8 Subjects in Group I - Regimen A: ABT-450/r/ABT-267
3076286|NCT02052362|Experimental|Group 2 - Regimen B|8 Subjects in Group II - Regimen B: ABT-450/r/ABT-267
3076287|NCT02052349|Experimental|Arm 1: ABT-333|A single centre, open-label, 4-treatment, 3-period, 4-sequence incomplete randomised, single dose crossover study in healthy subjects.
3076288|NCT02052336|Experimental|CJ-12420 200 mg + Clarithromycin 500mg|CJ-12420 200mg QD for 5 days + Clarithromycin 500mg BID for 5 days
3076289|NCT02052336|Active Comparator|CJ-12420 200mg|CJ-12420 200mg QD for 5 days
3076290|NCT02052336|Active Comparator|Clarithromycin 500mg|Clarithromycin 500mg BID for 5 days
3076291|NCT02052323|Experimental|artesunate/mefloquine (AS/MQ)|The antimalarial drug regimen being evaluated is: artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours; plus mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours; plus primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours
3076292|NCT02052310|Experimental|FG-4592 (roxadustat)|FG-4592 (roxadustat) will be dosed orally three times a week.
3076293|NCT02052310|Active Comparator|Epoetin alfa|Epoetin alfa will be dispensed per the package insert or the country-specific product labeling.
3076294|NCT02052297|Other|Part A|In Part A, up to 6 healthy subjects will be enrolled in order to determine the human radiodosimetry following administration of the PET radioligand.
3076295|NCT02052297|Other|Part B|In Part B, up to 8 healthy subjects will be recruited to provide sufficient PET data to quantify the uptake and distribution of GSK2634673F in healthy subjects.
3076296|NCT02052297|Other|Part C|In Part C, up to 20 IPF subjects will be recruited to provide sufficient PET data to quantify the uptake and distribution of GSK2634673F in IPF subjects and, if appropriate, potentially quantify the test/re-test variability.
3076297|NCT02052284|No Intervention|Control|The control group will receive standard skin care of the NICU, which does not include specific measures to modulate skin-barrier function.The current practice at GWUH NICU is that nurses clean the bodies of newborns less than 1000 grams using a piece of damp cloth with warm water. This is performed at birth and consequently every other days.
3076298|NCT02052284|Experimental|Water wash|The study group will undergo a protocol of sterile water application in addition to routine skin care of the NICU. The study group will receive more frequent and standardized applications. A commercially sterile water bottle (Enfamil® Water) will be kept inside the isolette, to be maintained at isolette temperature, and will be changed on a daily basis. Nurses use sterile gloves as a routine for care of ELBW infants. A 2 inches x 2 inches sterile gauze will be soaked in sterile water and gently applied to all skin of the baby excluding umbilical cord and IV lines sites. This procedure will be repeated every 4 hours with routine patient care for the first 1 week of life.
3076299|NCT02052271|Experimental|Essential tremor|30 patients with essential tremor
3076300|NCT02052258|Experimental|oxytocin|
3076301|NCT02052245||Subject delivering preterm baby|
3076302|NCT02052245||Subject delivering term baby|
3076303|NCT02052232|Active Comparator|Control|Control protein powder sachet
3076304|NCT02052232|Experimental|Experimental|Experimental protein powder sachet
3076305|NCT02052219|Experimental|Blisibimod|
3076306|NCT02052219|Placebo Comparator|Placebo|
3076307|NCT02052206|Experimental|Computer-assisted 3D planning|Realization of the fracture reconstruction according to the computer-assisted 3D preoperative plan
3076308|NCT02052193|Experimental|Dabrafenib|Dabrafenib 150mg BID orally
3076309|NCT02052193|Active Comparator|Vemurafenib|Vemurafenib 960mg orally BID
3076310|NCT02052180|Experimental|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
3076311|NCT02052180|Active Comparator|Control|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
3076312|NCT02052167|Experimental|Methotrexate|
3076314|NCT02052141|Experimental|500/1000|500 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks
3076315|NCT02052141|Experimental|1000/500|1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 500 Units of CINRYZE administered by IV injection twice per week for 12 weeks
3076316|NCT02052128|Experimental|onapristone 10 mg BID mg|onapristone 10 mg BID extended-release tablets
3076317|NCT02052128|Experimental|onapristone 20 mg BID|onapristone 20 mg BID extended-release tablets
3076318|NCT02052128|Experimental|onapristone 30 mg BID|onapristone 30 mg BID extended-release tablets
3076319|NCT02052128|Experimental|onapristone 40 mg BID mg|onapristone 40 mg BID mg extended-release tablets
3076320|NCT02052128|Experimental|onapristone 50 mg BID|onapristone 50 mg BID extended-release tablets
3076321|NCT02052128|Experimental|onapristone 100 mg QD|onapristone 100 mg QD immediate-release tablets
3076322|NCT02052115|Other|Exercise and weight loss|12 month exercise and weight loss intervention
3076323|NCT02052102|Active Comparator|No prior therapy, DIBH irradiation|Cohort 1 - No prior anthracycline-based chemotherapy or herceptin, deep inspiration breath hold breast radiation therapy
3076324|NCT02052102|Active Comparator|No prior therapy, FB technique|Cohort II - no prior Anthracycline based chemotherapy or Herceptin and (ii) to receive FB RT (not able to hold breath for at least 20 seconds or does not have a minimum of 1.0 cm of heart on at least 3 slices (3mm slices) on the FB scan)
3076325|NCT02052102|Active Comparator|Prior therapy, DIBH irradiation|Cohort III - Prior Anthracycline-based chemotherapy or Herceptin, and (ii) eligible to receive DIBH RT. (Patient has a minimum of 1.0 cm of heart on at least 3 slices (3mm slices) on the FB scan)
3076326|NCT02052089|Active Comparator|Physiotherapy|patients were educated to do stretching and eccentric strengthening exercise of wrist extensor muscles
3076327|NCT02052089|Experimental|extracorporeal shockwave therapy|patients were treated with 3 sessions of high-energy shock wave therapy ESWT (Evotron, Switech medical, Kreuzlingen, CH) in 2 weeks interval. Total energy flux density ranged from 0.1 to 0.14 mJ/mm2 (1500 impulses). Shockwave was targeted over lateral epicondyle where maximum tenderness was located.
3076328|NCT02052089|Experimental|Prolotherapy|injection of 20% dextrose (3cc mixed with 0.3cc of lidocaine) to ECRB tendon was done under ultrasound guidance
3076329|NCT02052089|Experimental|Platelet-rich plasma|3 cc of PRP (Harvest SmartPReP 2 APC 30 Process Kit, Harvest Technologies, Plymouth, MA) was injected into ECRB tendon under ultrasound guidance
3076330|NCT02052076|Experimental|Irregular meal pattern|Participants will be asked to consume a standard diet, spread over a different number of meals/snacks per day, for a 2week intervention period. Number of meals will range from 3 to 9 per day.
3076331|NCT02052076|Placebo Comparator|Regular Meal Pattern|Participants will be asked to consume a standard diet, spread over 6 of meals/snacks every day, for a 2week intervention period.
3076332|NCT02052063|Experimental|Surgery|Patient who undergone stapled transanal rectal resection for rectocele. Anal compliance will be evaluated before and starting the surgery using endoflip system
3076333|NCT02052050|Experimental|core stability|Stabilized muscle program will consist of two months of individual physical training that it will be conducted 3 times/week for 90 min each. A correct progression to improve stabilization of deep abdominal muscles will be made.
3076334|NCT02052050|No Intervention|control group|usual care
3076335|NCT02052037|Experimental|Egg inclusion|Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week) in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions.
3076336|NCT02052037|Experimental|Egg exclusion|"Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products.~During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained."
3076337|NCT02052024|Active Comparator|Botox|Treatment group will receive 100 units of BOTOX and will receive 1-3 injections per muscle at each visit.
3076338|NCT02052024|Active Comparator|MYOBLOC|Treatment group will receive 5,000 units of MYOBLOC and will receive 1-3 injections per muscle at each visit.
3076339|NCT02052011|Experimental|Intervention Group|Subjects will take extended release Ranolazine for 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
3076340|NCT02052011|Placebo Comparator|Placebo Control|Subjects will take placebo pill twice daily for 4 weeks.
3076341|NCT02051985|Experimental|Aerobic exercise training|
3076342|NCT02051985|Active Comparator|Standard physical therapy|
3076343|NCT02051972||Indicated for a VVI(R) pacemaker|
3076344|NCT02051959|Active Comparator|Crossover 1a: anodal stimulation of M1 + sham|"6 amputees will undergo 8 active treatments of 20 min 2mA anodal stimulation of M1 localized to the contralateral amputation area followed by 8 sham treatments.~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.~Each session will last approximately one hour which will consist of:~EEG and pain measurements~20 minutes of stimulation~EEG and pain measurements after completion of stimulation"
3076345|NCT02051959|Active Comparator|Crossover 1b: sham + anodal stimulation of M1|"6 amputees will undergo 8 sham treatments followed by 8 active treatments of 20 min 2mA anodal stimulation of M1 localized to the contralateral amputation area.~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.~Each session will last approximately one hour which will consist of:~EEG and pain measurements~20 minutes of stimulation~EEG and pain measurements after completion of stimulation"
3076346|NCT02051959|Active Comparator|Crossover 2a: cathodal stimulation of M1 + sham|"6 amputees will undergo 8 active treatments of 20 min 2mA cathodal stimulation of M1 localized to the contralateral amputation area followed by 8 sham treatments.~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.~Each session will last approximately one hour which will consist of:~EEG and pain measurements~20 minutes of stimulation~EEG and pain measurements after completion of stimulation"
3076347|NCT02051959|Active Comparator|Crossover 2b: sham + cathodal stimulation of M1|"6 amputees will undergo 8 sham treatments followed by 8 active treatments of 20 min 2mA cathodal stimulation of M1 localized to the contralateral amputation area.~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.~Each session will last approximately one hour which will consist of:~EEG and pain measurements~20 minutes of stimulation~EEG and pain measurements after completion of stimulation"
3076348|NCT02051946|Active Comparator|Retroject device only|The first 5 patients enrolled will serve as controls and will have the device alone placed on the eye (without an injection of ethacrynic acid).
3076349|NCT02051946|Experimental|Retroject injection with ethacrynic acid injection|The next 3 patients, after the first 5 controls, will have the device placed on the eye with a subsequent injection of ethacrynic acid into the episcleral vein.
3076350|NCT02051946|Experimental|randomization to ethacrynic acid or balanced salt solution|The last 12 patients will all have the device placed on their eye. They will then be randomized in a 2:1 ratio to receive either an injection of ethacrynic acid or balanced salt solution.
3076351|NCT02051933|Experimental|Botox|See Botox intervention description
3076352|NCT02051933|Placebo Comparator|Placebo|See Placebo Intervention Description
3076353|NCT02051907|Experimental|KAM1403 Gel|A group treated with KAM1403 for the study period.
3076354|NCT02051907|Sham Comparator|Aloevera Gel|A group treated with Aloevera Gel for the study period
3076355|NCT02051894||HIE Group|
3076356|NCT02051881|Other|Biopsies|Intestinal biopsies were taken in patients who underwent endoscopy.
3076357|NCT02051868|Active Comparator|Arm A|Cisplatin and 5-Fluorouracil
3076358|NCT02051868|Experimental|Arm B|Carboplatin plus Paclitaxel
3076359|NCT02051842|Experimental|Metadoxine|Metadoxine 500 mg tablets by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months
3076360|NCT02051842|Placebo Comparator|Placebo tablet|Placebo tablet (for Metadoxine) by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months
3076361|NCT02051829||All patients|Comparison of the four screening score
3076362|NCT02051816|Active Comparator|VL and AO|Video laryngoscopy and apneic oxygenation
3076363|NCT02051816|Active Comparator|DL and AO|Direct Laryngoscopy and apneic oxygenation
3076364|NCT02051816|Active Comparator|VL and no AO|Video Laryngoscopy and no apneic oxygenation
3076365|NCT02051816|Active Comparator|DL and no AO|Direct Laryngoscopy and no apneic oxygenation
3076366|NCT02051803|Experimental|Distress Tolerance Treatment for Weight Concern (DT-W)|DT-W is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes distress tolerance intervention for weight concern plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
3076367|NCT02051803|Active Comparator|Health Education (HE)|HE is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes smoking health education program plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
3076368|NCT02051790|Experimental|Clinical Practice Scans|Approximately 250 florbetapir F 18 scans and final scan reports interpreted in a clinical setting will be collected from physicians across the country. These results will then be compared to expert panel interpretations for the same scans.
3076369|NCT02051777|Other|ONS 1 and DA|Oral Nutritional Supplement 1 and Dietary Advice
3076370|NCT02051777|Other|ONS 2 and DA|Oral Nutritional Supplement 2 and Dietary Advice
3076371|NCT02051777|Other|DA Alone|Dietary Advice Alone
3076372|NCT02051764|Experimental|Previous 18F-AV-1451 Scan|Subjects with a previous 18F-AV-1451 scan will receive an IV injection, 370 megabecquerel (MBq) (10 millicurie [mCi]), single dose of 18F-AV-1451. Subjects with an unknown amyloid status will receive an IV injection, 370 megabecquerel (MBq) (10 millicurie [mCi]), single dose of florbetapir F 18.
3076373|NCT02051751|Experimental|BYL719 and paclitaxel|All patients enrolled in the study will receive BYL719 once daily plus weekly paclitaxel
3076374|NCT02051738|Experimental|Treatment Sequence AB|A single 500 mg dose of mebendazole fast-disintegrating chewable tablet will be administrated under fasted condition (Treatment A) in Treatment Period 1; In Treatment Period 2, the same medication will be administrated under fed condition (Treatment B).
3076375|NCT02051738|Experimental|Treatment Sequence BA|A single 500 mg dose of mebendazole fast-disintegrating chewable tablet will be administrated under fed condition (Treatment B) in Treatment Period 1; In Treatment Period 2, the same medication will be administrated under fasted condition (Treatment A).
3076376|NCT02051725|Experimental|Active life-style intervention|"The active life-style intervention is designed as 12-week structured and progressive heavy-resistance power training combined with recommended everyday physical activity."
3076377|NCT02051725|No Intervention|Control|The control group is offered to enroll in the same active life-style intervention after the end of the 12-week control period. During the control period this group is asked to maintain the habitual life style.
3076378|NCT02051712|No Intervention|Usual care|Usual car accruing to guidelines
3076379|NCT02051712|Experimental|Individualized training|Individualized exercise training program in addition to usual care
3076380|NCT02051712|Experimental|Individualized training plus adherence measures|Individualized exercise training plus measures to increase adherence
3076381|NCT02051699||One-leg standing view|
3076382|NCT02051699||both-leg standing view|
3076383|NCT02051686|Active Comparator|Tranexamic Acid|Group I will receive 10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
3076384|NCT02051686|Placebo Comparator|Placebo|The control group will receive a similar volume load of normal saline and maintenance doses.
3076385|NCT02051660|Experimental|Manualized CALM Intervention|
3076386|NCT02051660|Active Comparator|Non-manualized supportive intervention|
3076494|NCT02050893|Experimental|Propofol|Propofol infuse at a loading dose of 0.5mg/kg，and 0.5-2.0mg/kg.h maintenance dose to achieve Ramsay score of 4
3076495|NCT02050880||Normal eyes|Eyes without pathology.
3076496|NCT02050880||Glaucoma|Eyes with Glaucoma.
3076387|NCT02051634|Active Comparator|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
3076388|NCT02051634|Placebo Comparator|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
3076389|NCT02051621|Active Comparator|Cavo-tricuspid-isthmus-ablation|Ablation of atrial flutter
3076390|NCT02051621|Active Comparator|Pulmonary vein isolation|pulmonary vein isolation
3076391|NCT02051621|Active Comparator|Antiarrhythmic drug|"Medical treatment of atrial flutter with either class I antiarrhythmics (flecainide (Tambocor ®) 100 mg twice daily or propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily~cardioversion as needed"
3076392|NCT02051608|Experimental|Gantenerumab|Participants will receive gantenerumab as subcutaneous (SC) injection every 4 weeks (Q4W)
3076393|NCT02051608|Placebo Comparator|Placebo|Participants will receive placebo as SC injection Q4W
3076394|NCT02051595|Other|Vancomycin concentrations|Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
3076395|NCT02051582||Surgeons using fluoroscopy with laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
3076396|NCT02051582||Surgeons using fluoroscopy without laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
3076397|NCT02051569|Experimental|Tryptophan first|Tryptophan is given for the first 14 days, 6 times 500mg per day. Placebo is given 6 times per day for the second 14 days.
3076398|NCT02051569|Experimental|Tryptophan second|Placebo is given 6 times per day for the first 14 days. Tryptophan is given for the second 14 days, 6 times 500mg per day.
3076399|NCT02051556|Experimental|Best Side Improvement|Physical Therapy BSI (Best Side Improvement), aimed to potentiate the less affected body side.
3076400|NCT02051556|Experimental|Worse side improvement|Physical Therapy WSI (Worst Side Improvement), aimed to potentiate the most affected body side.
3076401|NCT02051556|Active Comparator|Standard treatment|Physical Therapy ST (Standard Treatment), aimed to potentiate both sides equally.
3076402|NCT02051543|Experimental|Brief Behavioral Treatment of Insomnia-Military Version|
3076403|NCT02051530|Experimental|tryptophan depletion first day|tryptophan depletion on the first day. on the other day participants receive placebo.
3076404|NCT02051530|Experimental|tryptophan depletion on day 2|tryptophan depletion on the second day. on the first day participants receive placebo.
3076405|NCT02051517||Vitrectomy|Subjects expected to have normal vitreous, undergoing vitrectomy surgery for medically indicated reasons.
3076406|NCT02051504||Type 1 diabetes, HbA1c <7%|"Patients with Type 1 diabetes and adequate glycemic control: HbA1c <7% at the entrance in the study.~Intervention:~Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
3076407|NCT02051504||Type 1 diabetes, HbA1c >8%|"Patients with Type 1 diabetes and inadequate glycemic control: HbA1c >8% at the entrance in the study.~Intervention:~Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
3076408|NCT02051504||Healthy controls, Groupe 1|"Healthy controls for patients with Type 1 diabetes and adequate glycemic control matched on age, sex, body composition and physical activity level.~Intervention:~Oral Glucose Tolerance Test Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
3076409|NCT02051504||Healthy controls, Group 2|"Healthy controls for patients with Type 1 diabetes and inadequate glycemic control matched on age, sex, body composition and physical activity level.~Intervention:~Oral Glucose Tolerance Test Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
3076497|NCT02050880||Retinal|Eyes with Retinal Disease.
3076498|NCT02050880||Corneal|Eyes with corneal disease including a kerato-refractive group.
3076499|NCT02050854||Observation|Subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal adherence and are currently on treatment with oral aripiprazole
3076500|NCT02050841|Experimental|Octaplas|Qualified patients will receive Octaplas as per protocol.
3076410|NCT02051491|Active Comparator|BP-NCPAP|Nasal BP-NCPAP will be delivered using the Infant Flow® SiPAP™ and either nasal prongs or mask interface. A blood gas (arterial if an arterial line exists, or a capillary sample) will be drawn at the time of NCPAP failure (time 0) unless one was done within 1 hour preceding the randomization. The blood gas will then be repeated at 1 hour and recorded along with transcutaneous carbon dioxide (TcCO2) monitor data (if available). Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm water (H2O) and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on fraction of inspired oxygen (FiO2) requirements.
3076411|NCT02051491|Experimental|NIHFV|NIHFV will be provided using the Drager VN500, using either nasal prong or mask interfaces.A blood gas (arterial if an arterial line exists, or a capillary sample) will be drawn at the time of NCPAP failure (time 0) unless one was done within 1 hour preceding the randomization. The blood gas will then be repeated at 1 hour and recorded along with TcCO2 monitor data (if available). Initial settings for NIHFV arm will be MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
3076412|NCT02051478|Experimental|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied.
3076413|NCT02051478|Active Comparator|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
3076414|NCT02051465|Experimental|LumenR Retractor|Endoscopic removal of polyp using modified overtube LumenR Retractor
3076415|NCT02051465|Active Comparator|Removal without overtube|Endoscopic removal of polyp without overtube
3076416|NCT02051452|Experimental|Methylphenidate|Methylphenidate
3076417|NCT02051452|Placebo Comparator|placebo|Saline
3076418|NCT02051439|Other|Valsava|The patients were randomized to 2 groups. The first group performed conventional Valsava before balloon assisted Valsava. The second group performed balloon assisted Valsava before conventional Valsava for venous reflux examination by duplex scan.
3076419|NCT02051426|Experimental|D-serine|single P.O. administration of D-serine (2.1g)
3076420|NCT02051426|Placebo Comparator|Placebo|single P.O. administration of corn starch
3076421|NCT02051413|Other|Venlafaxine extended release|Venlafaxine extended-release, flexible dose
3076422|NCT02051400|Experimental|Intubation with the McGrath® MAC video laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
3076423|NCT02051400|Experimental|Intubation with the GlidesScope® Ranger video laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
3076424|NCT02051400|Experimental|Intubation with Macintosh laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
3076425|NCT02051387|Active Comparator|Cannabidiol|Cannabidiol capsule, 200 mg single dose
3076426|NCT02051387|Experimental|Cannabidiol CR|Cannabidiol tablet, various dosages
3076427|NCT02051387|Experimental|Amisulpride and Cannabidiol CR|Interaction between Amisulpride and Cannabidiol CR
3076428|NCT02051387|Experimental|Olanzapine and Cannabidiol CR|Interaction between Olanzapine and Cannabidiol CR
3076429|NCT02051387|Experimental|Quetiapine and Cannabidiol CR|Interaction between Quetiapine and Cannabidiol CR
3076430|NCT02051387|Experimental|Risperidone and Cannabidiol CR|Interaction between Risperidone and Cannabidiol CR
3076431|NCT02051387|Placebo Comparator|Cannabidiol CR and Placebo|Cannabidiol CR levels without interaction with antipsychotics
3076432|NCT02051374|Active Comparator|Decompression alone|Posterior approach with decompression will be performed. The decompression will be done after microsurgical principles, and the midline structures will be preserved. The surgeons will either use microscope or magnifying glasses.
3076433|NCT02051374|Active Comparator|Decompression followed by fusion with instrumentation|Posterior approach with decompression will be performed, followed by posterolateral pedicle screw fixation with or without an additional cage. The surgeons will either use microscope or magnifying glasses.
3076434|NCT02051361||Clopidogrel treated patients|Patients pre and post operatively following stent implantation treated with clopidogrel and aspirin
3076435|NCT02051348|Placebo Comparator|Placebo|Placebo - 2 doses per day for 4 weeks
3076436|NCT02051348|Active Comparator|Pylopass|Probiotic - 2 doses per day for 4 weeks
3076437|NCT02051335|Experimental|Sequence 1 (ABDC)|Roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
3076501|NCT02050828|Experimental|AKB-9778 15 mg BID monotherapy|Subcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus monthly sham intravitreal injection for 3 months.
3076502|NCT02050828|Experimental|AKB-9778 15 mg BID + ranibizumab 0.3 mg|Subcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
3076503|NCT02050828|Active Comparator|ranibizumab 0.3 mg monotherapy|Placebo subcutaneous injection (BID) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
3076718|NCT02049229|Experimental|OPTIMAX stent|Patients randomised to receive titanium-nitride-oxide coated OPTIMAX-stent
3076438|NCT02051335|Experimental|Sequence 2 (BCAD)|Roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
3076439|NCT02051335|Experimental|Sequence 3 (CDBA)|Roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
3076440|NCT02051335|Experimental|Sequence 4 (DACB)|Roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
3076441|NCT02051322|Experimental|Jet Nebulizer|Nebulization with a jet nebulizer and a classic mask
3076442|NCT02051322|Experimental|Trunk Mask Nebulizer|Nebulization with a je nebulizer and a trunk mask
3076443|NCT02051322|Experimental|Aerobika Nebulizer|Nebulization with an Aerobika
3076444|NCT02051309|Experimental|Guanfacine 6mg/day ER|Guanfacine 6mg/day extended release
3076445|NCT02051309|Placebo Comparator|Placebo|Placebo matching capsule
3076446|NCT02051296|Experimental|minocycline|perioperative minocycline for 5 days, starting 2 hours prior to surgery then 100mg BID
3076447|NCT02051296|Placebo Comparator|Placebo|PLacebo
3076448|NCT02051283||patients with HCC eligible for RFA|patients with HCC eligible for RFA
3076449|NCT02051270||Elders|Older people living in nursing homes will undergo a descriptive study.
3076450|NCT02051257|Experimental|Arm 1 (autologous TCM-enriched T cells)|Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TCM-enriched T cells IV over 10 minutes on day 2 or 3 following HSCT.
3076451|NCT02051257|Experimental|Arm 2 (autologous TN/MEM-enriched T cells)|Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TN/MEM-enriched T cells IV over 10 minutes on day 2 or 3 following HSCT.
3076452|NCT02051244||Subjective memory loss|Subjects who report memory loss, that may or may not be confirmed by an informant, but have normal cognitive tests ( MMSE scores of 27 or above out of 30. SLUMS scores of 20-30 for subjects with less than 8 years of education or 27-30 for those who have 12 or more years of education).
3076453|NCT02051244||Mild Cognitive Impairment|Subjects with Mild Cognitive Impairment - defined as being problems with memory, language or another essential cognitive ability that are severe enough to show up on cognitive tests but not to interfere with daily life. MMSE score of 23-27 out of 30. SLUMS score of 16-19 for subjects with less than 8 years of education or 20-26 for those who have 12 or more years of education.
3076454|NCT02051244||Control|Subject who do not report memory loss and have normal cognitive tests. MMSE of 27 or above out of 30. SLUMS score of 20-30 for subjects with less than 8 years of education or 27-30 for those who have 12 or more years of education.
3076455|NCT02051231|No Intervention|Control|A control sample from each patient (no oxytocin applied) will be measured concurrently with samples treated with oxytocin.
3076456|NCT02051231|Experimental|Oxytocin|Samples from each patient will be exposed to oxytocin and then allowed to rest for 30, 60 or 90 minutes.
3076457|NCT02051218|Active Comparator|Arm A (standard arm)|Denosumab 120mg (XGEVA®) sc. q4w
3076458|NCT02051218|Experimental|Arm B (reduced arm)|Denosumab 120mg (XGEVA®) sc. q4w [weeks 1, 5, 9] followed by Denosumab 120mg (XGEVA®) sc. q12w [weeks 13, 25, …]
3076459|NCT02051192|Experimental|Parent-Led Exposure Therapy (PLET)|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
3076460|NCT02051192|Active Comparator|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice.
3076461|NCT02051179||Replacement amalgam|Replacement The clinicians totally removed and replaced the defective restorations. After completing the cavity preparations, the tooth was restored with a new AM (Original D). Bonding agents and/or liners underneath the amalgam restorations were not used in this trial. Rubber dam isolation was used for all restorative treatments. .
3076521|NCT02050724|Experimental|CT guided labelling|CT guided radioactive labelling of pulmonary nodules followed by handheld-SPECT guided thoracoscopic surgery.
3076522|NCT02050724|Experimental|Electromagnetic bronchoscopic labelling|Electromagnetic guided bronchoscopic labeling of pulmonary nodules followed by handheld-SPECT guided thoracoscopic surgery.
3076523|NCT02050711|Other|Usual care|Patients will receive usual care from their general practitioners/pulmonologists.
3076524|NCT02050711|Experimental|Pulmonary rehabilitation|Patients will enrol in a 12-week PR program consisting on exercise training (3 times a week) and psychoeducation (once a week).
3076462|NCT02051179||Repair Amalgam|The clinicians (PV and CM) used Carbide burs (330-010 Komet, Brasseler GmbH Co. Postfach 160.32631, Lemgo, Germany) to explore the defective margin, carious lesion or anatomic form of the restorations. Part of the restorative material adjacent to the defect was removed as an exploratory proceedure thus allowing a proper evaluation and subsequent diagnosis of the extent of the defect. Provided that the defect was limited and localized, the clinician then removed any defective tooth tissue. Mechanical retention was employed inside the existing AM restoration. Rubber dam isolation was used for this procedure. Repair of the restorations was carried out with a dispersed-phased amalgam (Original D, Wyckle Research Inc, Carson City, NV, USA).
3076463|NCT02051153|Experimental|Placebo|"Placebo: study participants received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.~Other Names: Placebo."
3076464|NCT02051153|Experimental|Modafinil|"Study participants received, in a double blind fashion, either a single dose (200 mg) of modafinil or a placebo pill identical to the drug.~Other Names:~Provigil"
3076465|NCT02051140|Experimental|Strawberry|Participants randomized into this arm of the study consume freeze-dried strawberry.
3076466|NCT02051140|Placebo Comparator|Placebo|Participants randomized into this arm of the study consume a strawberry placebo.
3076467|NCT02051127|Experimental|Exercise|Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate > 75% of maximum heart rate determined by exercise test before start of the intervention
3076468|NCT02051127|No Intervention|Control|Instructed to continue with their sedentary behavior for another 6 months.
3076469|NCT02051101|Other|Port Wine Stain Birthmark|Biopsy sample from Port Wine Stain Birthmark
3076470|NCT02051088|Experimental|Revascularization with drug eluting technology|Revascularization with drug eluting technology
3076471|NCT02051088|Active Comparator|Revascularization without drug elution|Revascularization without drug elution technology
3076472|NCT02051075|Active Comparator|PXN only|Sperm activation with PXN before ICSI
3076473|NCT02051075|Experimental|PXN activation and oocyte activation|Sperm activation with PXN and oocyte activation
3076474|NCT02051062|Experimental|One 5 mL blood sample will be collected|A single 5 mL blood sample will be collected from pediatric patients treated with BAT®. The blood sample should be collected no later than 24 hours post BAT® administration. To ensure sufficient detectable circulating levels of BAT® for pharmacokinetic analysis the target window of time for collection should be between 6 and 24 hours post-BAT® administration.
3076475|NCT02051049||Inborn errors of liver metabolism|
3076476|NCT02051036|Experimental|Moxibustion|A series of moxibustion sessions within four weeks from the baseline with concurrent conventional medications for BPH.
3076477|NCT02051036|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no moxibustion treatments throughout the 4 weeks while receiving other conventional managements for BPH. After 4 weeks, if participants choose to try the moxibustion treatment, the active acupuncture treatment will be provided for 4 weeks (2 sessions/week).
3076478|NCT02051023|Experimental|FML 0.1% eyedrops|FML (fluorometholone) 0.1% eyedrops 4 times a day in both eyes for 22 days
3076479|NCT02051023|Active Comparator|Liquifilm artificial tears eyedrops|Topical application 4 times a day in both eyes for 22 days
3076480|NCT02051010||Metastatic Breast Cancer|
3076481|NCT02050997||B|Unresectable or metastatic PDAC patients who will receive standard treatment of CT +/- radiotherapy
3076482|NCT02050997||A|Resectable PDAC patients who will receive standard treatment of CT +/- radiotherapy
3076483|NCT02050971|Active Comparator|Autologous cord blood transfusion|Treatment Group 1 Interventions: collected autologous whole cord blood at birth will be transfused for the preterm neonate
3076484|NCT02050971|Sham Comparator|Standard treatment for neonatal anemia|Treatment Group 2 Interventions: transfusion of allogeneic whole peripheral blood or any of its components at a time of anemia of prematurity development
3076485|NCT02050958|Experimental|OXP001|OXP001
3076486|NCT02050958|Active Comparator|Ibuprofen|Brufen
3076487|NCT02050945|Experimental|Patients with COPD|Patients with COPD are to be trained 3 times a week for 8 weeks
3076488|NCT02050945|Active Comparator|Control patients with COPD|Control patients with COPD are to be trained 3 times a week for 8 weeks
3076489|NCT02050932|Experimental|Iron absorption assessement|"60 mg Fe as FeSO4 with stable isotopic labels participants will receive at different times of the day (total of three dosages) and follow a standardized diet scheme.~Subjects will act as their own controls during the study"
3076490|NCT02050919|Experimental|Treatment (sorafenib, chemotherapy, radiation, surgery)|Patients receive sorafenib tosylate PO QD on days 1-71 and 85-155, epirubicin hydrochloride IV over 3-5 minutes, and ifosfamide IV over 90 minutes on days 15-17, 36-38 (ifosfamide only), 57-59, 99-101, 120-122, and 141-143. Patients undergo EBRT on days 36-45 and surgical resection on day 78. Patients with positive margins, undergo EBRT boost on days 91-98.
3076491|NCT02050906|Experimental|Arm I (diet and exercise intervention)|"EXERCISE COMPONENT: Patients undergo 1 hour of monitored intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12. All patients will complete a comprehensive exercise and quality-of-life assessment at baseline, month 2 and month 3.~BEHAVIORAL ACTIVITY COUNSELING: Patients undergo behavioral activity counseling in small group sessions over 20 minutes once weekly during months 1-2 and individualized activity counseling via telephone calls over 20 minutes every 2 weeks for 3 months. Counseling will include questionnaire administration.~BEHAVIORAL DIETARY INTERVENTION: Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3."
3076492|NCT02050906|Active Comparator|Arm II (standard of care)|TELEPHONE BASED COUNSELING: Patients receive standard care and educational literature describing the American Institute of Cancer Research dietary and physical activity guidelines. Patients also receive phone calls over 20 minutes every 2 weeks for 3 months focusing on routine prostate cancer self-management. After 3 months, patients have the option to undergo 2 supervised exercise training and dietary counseling sessions. All patients will complete a comprehensive exercise and quality-of-life assessment at baseline, month 2 and month 3.
3076493|NCT02050893|Experimental|Midazolam|Midazolam infused at a 0.03mg/kg loading dose ,and 0.02-0.1mg/kg.h maintenance dose to achieve Ramsay score of 4
3099132|NCT01897519|Placebo Comparator|Arm 4 Placebo|
3076504|NCT02050815|Experimental|MEK162|A minimum of 24 subjects (6 subjects per group) will be enrolled. Enrollment into Group 1 (control group with normal hepatic function) should be similar to the enrollment into Group 2, 3 and 4 with respect to age, gender, and body weight. Enrollment into Group 1 will remain open until the enrollment into the mild, moderate, and severe impairment groups are complete with matching controls for comparison. Serum level of total bilirubin and AST will be used to determine which group the hepatic impaired patient will be allocated l. Dosing of the different treatment groups will be staggered. Initially, 6 subjects in Group 1 (normal hepatic function) and 6 subjects in Group 2 will receive a single oral dose of MEK162 on Day 1.
3076505|NCT02050802|Experimental|Treatment sequence BCAD|Subjects received study medication in the sequence BCAD. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
3076506|NCT02050802|Experimental|Treatment sequence ABDC|Subjects received study medication in the sequence ABDC. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
3076507|NCT02050802|Experimental|Treatment sequence DACB|Subjects received study medication in the sequence DACB. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
3076508|NCT02050802|Experimental|Treatment sequence CDBA|Subjects received study medication in the sequence CDBA. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
3076509|NCT02050802|Experimental|Treatment sequence DBAC|Subjects received study medication in the sequence DBAC. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
3076510|NCT02050802|Experimental|Treatment sequence ADCB|Subjects received study medication in the sequence ADCB. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
3076511|NCT02050802|Experimental|Treatment sequence CABD|Subjects received study medication in the sequence CABD . Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
3076512|NCT02050802|Experimental|Treatment sequence BCDA|Subjects received study medication in the sequence BCDA. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
3076513|NCT02050789|No Intervention|Usual Care Arm|Programs will continue adhering to current ACGME requirements.
3076514|NCT02050789|Experimental|Intervention Arm|The intent of the intervention arm is to allow flexibility in surgical resident duty hours and improve continuity of care.
3076515|NCT02050776|Experimental|Stem Cells|autologous bone marrow mononuclear cell transplantation
3076516|NCT02050763|Experimental|Intervention arm|Intervention arm clusters (n=4) received an IPV prevention intervention (the Safe Homes and Respect for Everyone (SHARE) Project), enhanced HIV testing and treatment and routine HIV services.
3076517|NCT02050763|No Intervention|Control arm|Control arm clusters (n=7) received standard of care HIV services alone.
3076518|NCT02050750||TAILORx ICORG 06-31|Patients must have participated in TAILORx ICORG 06-31, participated in trial arms, and have adequate tumour tissue available
3076519|NCT02050737||A - due for adjuvant chemotherapy|Stage II/III colorectal cancer resectable disease due for adjuvant chemotherapy
3076520|NCT02050737||B - for observation only|Stage II colorectal cancer with resectable disease for observation only
3076525|NCT02050698|Active Comparator|short leg walking cast|After 1 weeks of immobilization in a short leg posterior splint, patient is allowed protected weightbearing in a short leg walking cast
3076526|NCT02050698|Experimental|hard-soled shoe|After 1 weeks of immobilization in a short leg posterior splint, patient is allowed tolerable weightbearing in a hard-soled shoe
3076527|NCT02050685||All patients for PSG at SLBO|All patients incoming in the sleep study centre for a PSG. At the arrival the screening score will be recorder. AHI will be recorded next morning after analysis of the PSG.
3076528|NCT02050672|Active Comparator|untreated|Semen was prepared with routinely used media
3076529|NCT02050672|Experimental|myo-inositol|"routinely used semen preparation media have been enriched with myo-inositol 2mg/ml.~in particular the stock solution was prepared in order to add 15microliters per ml of medium"
3076530|NCT02050646|Experimental|Low salt/ Liberal salt Diet|Cross-over trial of liberal salt and low salt diet.
3076531|NCT02050646|Experimental|Liberal salt/Low salt diet|Cross-over trial of low salt and liberal salt diet
3076532|NCT02050633||Severe cranial trauma|This is a cohort of adult patients who have suffered a severe TBI between 1 July 2005 and 1 May 2007.
3076533|NCT02050607|No Intervention|Control group|Control group
3076534|NCT02050607|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation from healthy lean donors
3076535|NCT02050594||Melanoma patients on Ipilimumab|All unresectable, recurrent or metastatic melanoma patients
3076536|NCT02050568||Anterior genital prolapse|Women with anterior genital prolapse ≥ grade 2, who are awaiting genital prolapse surgery.
3076537|NCT02050568||Posterior genital prolapse|Women with posterior genital prolapse ≥ grade 2, who are awaiting genital prolapse surgery.
3076538|NCT02050555|Placebo Comparator|Koji-extracted beverage|100ml/day for 12 weeks
3076539|NCT02050555|Experimental|Koji-extracted beverage fermented with LP28|100ml/day for 12 weeks. 1x10^11 cells (LP28)/day
3076540|NCT02050542|Other|Targeted biopsies guided by a fusion of MRI and ultrasound|After the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
3076541|NCT02050542|Other|Systematic biopsies|The patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
3076542|NCT02050529|Experimental|Labetalol|This group (Group A; Labetalol) will receive intravenous(IV) labetalol manufactured by Zafa pharmaceutical, 50mg/10 ml ampoule) bolus doses administered over 2 minutes, at 10 minutes interval. Initially dose of 20mg will be administered, and if required repeated in increments of 40 mg,80 mg,80mg,80mg every 10 minutes till SBP becomes <160 and DBP <110 mm Hg, upto a maximum total dose of 300mg(total 5 bolus doses).During this time pulse and blood pressure will be checked every 10 minutes.
3076543|NCT02050529|Active Comparator|Hydralazine|This group (Hydralazine;Group B) will receive intravenous Hydralazine and will serve as control. Bolus doses of 5 mg administered over 2 minutes, at 20 minutes interval. Pulse and blood pressure will be checked every 10 minutes interval. If SBP threshold of 160 mm Hg or DBP 110 mm Hg is still reached after 20 minutes, then second bolus will be repeated. Similarly if after 20 minutes SBP is still ≥160 or DBP ≥110 mm Hg, then third dose will be given. If SBP or DBP thresholds are still exceeded after 20 minutes then similarly 4th dose of 5 mg will be given. Failure to reduce SBP<160 or DBP<110 after consecutive maximum 4 boluses(total 20 mg) will be labeled as severe persistent hypertension.
3076544|NCT02050516|Active Comparator|single embryo culture|single embryo culture in single drops inside micro-well group culture dish
3076545|NCT02050516|Experimental|group embryo culture|group embryo culture in a single drop inside micro-well group culture dish
3076546|NCT02050503||intranasal transmucosal fentanyl pectin|intranasal transmucosal fentanyl in pectin (100, 200, 400 or 800 microg) intranasal route titration phase 7 days treatment phase until completing treatment of 12 consecutive episodes of breakthrough pain
3076547|NCT02050490||Before group, no diary|
3076548|NCT02050490||After group, with symptom diary|
3076549|NCT02050477|Experimental|Laparoscopic Vertical Gastroplasty|
3076550|NCT02050464||Healthy controls|Healthy controls
3076551|NCT02050464||Alzheimer's disease|Patients with mild Alzheimer's disease
3076552|NCT02050464||Vascular dementia|Patients with vascular dementia
3076553|NCT02050464||Fronto-temporal dementia|Patients with fronto-temporal dementia
3076554|NCT02050464||Mild cognitive impairment|Patients with mild cognitive impairment
3076555|NCT02050451|Experimental|Nutrition Intervention|Ensure Plus®, consumed orally twice daily for 2 weeks before and 4 weeks after surgery
3076556|NCT02050451|Active Comparator|Control|Over the counter daily multivitamin for 2 weeks before and 4 weeks after surgery
3076557|NCT02050438||Knee Osteoarthritis patients with prostesis treatment|Patients operated previously of Knee Osteoarthritis with different prostesis designs according the Hospital guide
3076558|NCT02050425|Active Comparator|Therapeutic CPAP|Patients continue therapeutic continuous positive airway pressure (CPAP).
3076559|NCT02050425|Placebo Comparator|Subtherapeutic CPAP|Placebo-CPAP device delivering subtherapeutic pressure for two weeks.
3076560|NCT02050412|Other|Cat fur scratch test|
3076561|NCT02050399|Active Comparator|Healthy subjects|15 men, 45 and 65 years old. After initial evaluation, clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood) and isometric exercise protocol will be performed.
3076562|NCT02050399|Experimental|Coronary disease with Type 2 Diabetes|15 men, 45-65 years old, with coronary artery disease and type 2 diabetes will perform clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood), clinical autonomic tests and isometric exercise protocol will be performed.
3076563|NCT02050399|Experimental|Coronary disease without Type 2 Diabetes|15 men, 45-65 years old, with coronary artery disease will perform clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood) and isometric exercise will be performed.
3076564|NCT02050386||Cold pressor stimulation|Immersion of the foot in 0-2 degrees C water for 50 seconds.
3076565|NCT02050386||Sham Stimulation|Immersion of the foot in room temperature water for 50 seconds.
3076671|NCT02049619|No Intervention|Control|Following endotracheal intubation, no pharyngeal pack was inserted into the hypopharynx.
3076566|NCT02050373|Active Comparator|Low-Level laser (660nm, 40mW, 0.16 J, 4 J/cm2)|In the laser group, an indium phosphide, galium and aluminum (InGaAIP) diode laser was used to irradiate oral mucosa. Subjects received the LLLT from the first day of the conditioning regimen and continued until D+7. Laser therapy was applied by a single dentist expertise in laser irradiation. The tip touched the mucosa of the lips, right and left buccal mucosa, right and left lateral tongue, ventral tongue and buccal floor, giving a total of 10 points per region.
3076567|NCT02050373|No Intervention|Allocated not to receive intervention|
3076568|NCT02050360|Experimental|Sildenafil 80 mg|Sildenafil 80 mg
3076569|NCT02050360|Experimental|Sildenafil 40 mg|Sildenafil 40 mg
3076570|NCT02050360|Placebo Comparator|Placebo|placebo
3076571|NCT02050347|Experimental|Subgroup A1|Patients with residual or relapsed B-cell ALL and with an HLA-matched related donor will receive CD19.CAR-CD28Z T Cells - dose escalation 1
3076572|NCT02050347|Experimental|Subgroup B1|Patients with other B-cell malignancies and with an HLA-matched related donor will receive CD19.CAR-CD28Z T Cells - dose escalation 1
3076573|NCT02050347|Experimental|Subgroup A2|Patients with residual or relapsed B-cell ALL and with an unrelated or HLA-mismatched donor will receive CD19.CAR-CD28Z T Cells - dose escalation 2
3076574|NCT02050347|Experimental|Subgroup B2|Patients with other B cell malignancies and with an unrelated or HLA-mismatched donor will receive CD19.CAR-CD28Z T Cells - dose escalation 2
3076575|NCT02050334|Experimental|CC100 (3 single doses)|CC100 (3 single increasing doses by mouth). Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose.
3076576|NCT02050334|Experimental|CC100 (2 single doses) & placebo(1 dose)|CC100 (2 single increasing doses by mouth) and placebo (1 single dose by mouth). Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose.
3076577|NCT02050321|Experimental|Acitretin and Vemurafenib|Vemurafenib is self-administered at a dose of 960 mg (four 240 mg tablets) twice daily. The first dose should be taken in the morning and the second dose should be taken in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Acitretin will initially be dosed at 25 mg orally per day with dosing altered every two weeks with a 50 mg dose.
3076578|NCT02050308|Experimental|Internet-All Nations Breath of Life (I-ANBL)|"The culturally-tailored program includes 9 individual Internet-based sessions across a 12 week period and an additional individual Internet-based session at 6 months. Web sessions will last about half-an-hour (30 minutes) and will discuss topics that are important to quitting smoking (like: preparing to quit, dealing with cravings, and support systems, etc.) and topics relevant to American Indian culture (like traditional use of tobacco).~We plan to give participants in our cessation program a choice of varenicline, bupropion, nicotine replacement therapy or no pharmacotherapy. We choose to give our participants a choice because our experience shows that we would be unlikely to recruit AI participants into a trial that requires pharmacotherapy use."
3076579|NCT02050308|Active Comparator|Honoring the Gift of Heart Health|"The culturally-tailored program includes 9 individual Internet-based sessions across a 12 week period and an additional individual Internet-based session at 6 months. Web sessions will last about half-an-hour (30 minutes) and will discuss topics that are important to heart health (like: Assessing risk for heart disease, increasing fruit and vegetable consumption, physical activity, etc.).~We plan to give participants in our cessation program a choice of varenicline, bupropion, nicotine replacement therapy or no pharmacotherapy. We choose to give our participants a choice because our experience shows that we would be unlikely to recruit AI participants into a trial that requires pharmacotherapy use."
3076580|NCT02050295|Experimental|Nerve block washout|Patients will receive a washout infusion of saline through their perineural catheter to reverse their motor block while maintaining the sensory block.
3076581|NCT02050295|Sham Comparator|Sham washout|Patients will receive an infusion of saline run just enough to maintain catheter patency.
3076582|NCT02050282|No Intervention|Business as usual|Triage and treatment based on routine clinical assessment as usual
3076583|NCT02050282|Experimental|Supplementary NT-proBNP measurement|Triage and treatment based on routine clinical assessment supplemented with measurement of NT-proBNP
3076584|NCT02050269|Experimental|Iohexol|injection of 5 ml of iohexol
3076585|NCT02050256|Other|general practioner|
3076586|NCT02050243|Experimental|5ALA|All included patients will receive 20mg/kg of 5ALA (oral suspension) about 3 hours prior to surgery
3076587|NCT02050230|Active Comparator|Fresh blood transfusion|One unit of blood stored for less than 14 days
3076588|NCT02050230|Experimental|Standard issue blood transfusion|One unit of blood stored under standard conditions
3076589|NCT02050217|Experimental|Noninvasive ventilation|Neurally Adjusted Ventilatory Assist versus Pressure Support flow triggered delivered by helmet
3076590|NCT02050204|Experimental|LEEF Industry only: Intervention|"Customized to the Leef (alias) workplace: A 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors."
3076591|NCT02050204|No Intervention|LEEF Industry only: Usual Practice|"Continued work conditions and practice as Usual Practice in that workplace"
3076592|NCT02050204|Experimental|TOMO Industry only: Intervention|"Customized to the Tomo (alias) workplace: A 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors."
3076593|NCT02050204|No Intervention|TOMO Industry only: Usual Practice|"Continued work conditions and practice as Usual Practice in that workplace"
3076594|NCT02050191|No Intervention|program feasibility|
3076595|NCT02050178|Experimental|Drug: OMP-54F28, Nab-Paclitaxel and Gemcitabine|
3076596|NCT02050165|Experimental|KIND Bar|Daily inclusion of KIND Bars with almonds as a primary ingredient as part of the participant's usual diet, with diet counseling to adjust for the calories from the KIND Bars. KIND Bars that we will use in the study will include: Dark Chocolate Chili Almond; Cranberry Almond; Almond Walnut Macadamia; Pomegranate Blueberry Pistachio; Nut Delight; Fruit and Nut Delight; Almond and Apricot; Blueberry Pecan and Fiber.
3076672|NCT02049619|Experimental|pharyngeal pack|Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
3076673|NCT02049606|Experimental|LAYLA|Drug : LAYLA tablet/bid
3076597|NCT02050165|Experimental|Typical American Snack|Daily inclusion of conventional snacks (as part of the participant's usual diet, with diet counseling to adjust for the calories from the snacks. The snacks will consist of cookies considered to be conventional snack foods that are nutrient-dilute (i.e. relatively low in nutrients) and energy-dense (i.e., relatively high in kcal). Examples of conventional snack foods will include: Nabisco Snackwell Creme Sandwich 1.7 oz pack, Nabisco Newtons Fig 2 oz pack, Nabisco Cips Ahoy! Chocolate Chip 1.4 oz pack, and Nabisco Oreo Double Stuff Chocolate 1.3 oz pack.
3076598|NCT02050152|Placebo Comparator|0% nitrous oxide|Explicit and implicit memory will be tested in 0% nitrous oxide
3076599|NCT02050152|Active Comparator|30% nitrous oxide|Explicit and Implicit memory in 30% nitrous oxide
3076600|NCT02050152|Active Comparator|60% nitrous oxide|Explicit and Implicit memory with 60% nitrous oxide
3076601|NCT02050139|Experimental|L-cysteine (Biocysan®)|Study subjects will take one tablet of L-cysteine or placebo every morning four times a week and two tablets of L-cysteine or placebo three times a week during the whole study period
3076602|NCT02050139|Placebo Comparator|Placebo|Study subjects will take one tablet of L-cysteine or placebo every morning four times a week and two tablets of L-cysteine or placebo three times a week during the whole study period
3076603|NCT02050126|Experimental|Scar Revision|Caesarean Scar Revision using Lumenis UltraPulse Encore.
3076604|NCT02050113|Experimental|Endovascular repair|Endovascular repair of Complex Aortic Aneurysm using a physician modified stent graft
3076605|NCT02050100||Lung Cancer|Early-late stage primary lung cancer
3076606|NCT02050100||Lung Neoplasm|Benign non-calcified pulmonary nodules
3076607|NCT02050087|Active Comparator|3 weeks with simple sling|Early motion after arthroscopic rotator cuff repair.
3076608|NCT02050087|Active Comparator|6 weeks with neutral brace|Delayed motion after arthroscopic rotator cuff repair.
3076609|NCT02050074|Experimental|Colesevelam|
3076610|NCT02050074|Experimental|Metformin|
3076611|NCT02050074|Experimental|Placebo|
3076612|NCT02050074|Experimental|Colesevelam + exendin (9-39)|
3076613|NCT02050074|Experimental|Metformin + exendin (9-39)|
3076614|NCT02050074|Experimental|Placebo + + exendin (9-39)|
3076615|NCT02050061|Experimental|compression stocking|compression stocking (SIGVARISTM), daily for 3 months
3076616|NCT02050061|No Intervention|standard medical therapy|Usual care
3076617|NCT02050048|Experimental|High Volume Group (Intervention Arm)|"Patients will be randomized to receive intravenous Lactated Ringer's solution. In the high volume group (intervention arm), patients will receive fluids prior to, during, and after the completion of the procedure. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~LR fluid infusion during the procedure at 5 cc/kg/hr~Post-procedure bolus of 20 cc/kg over 90 minutes"
3076618|NCT02050048|Active Comparator|Low Volume Group (Control Arm)|Patients will be randomized to receive intravenous Lactated Ringer's solution. In the low volume group (control arm), patients will receive fluids at the start of the ERCP. The fluids will be administered via infusion at a rate of 1.5 cc/kg/hr. Fluids may be continued through the 90 minute post-procedure observation period.
3076619|NCT02050035|Experimental|CKD Aerobic Exercise Training|Chronic Kidney Disease participants randomly allocated to the CKD Exercise arm will receive 12 weeks of Aerobic Exercise Training three times per week.
3076620|NCT02050035|No Intervention|CKD Control|Chronic Kidney Disease participants allocated to the the CKD Control arm will receive their standard routine care over a 12 week period.
3076621|NCT02050035|No Intervention|Healthy Control|Healthy participants will act as comparators, they will undergo baseline testing only and will not receive an intervention.
3076622|NCT02050022||Exacerbation|Patients experiencing acute exacerbation of COPD.
3076623|NCT02050022||Non-Exacerbation|COPD patients not experiencing acute exacerbation of COPD.
3076624|NCT02050009|Experimental|Treatment (metformin hydrochloride, carboplatin, paclitaxel)|Patients receive metformin hydrochloride BID on days 1-21, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3076625|NCT02049996||Robotic-assisted prolapse repair|Subjects already scheduled for robotic-assisted prolapse repair in conjunction with vaginal hysterectomy
3076626|NCT02049996||Vaginal prolapse repair|Subjects already scheduled for vaginal prolapse repair in conjunction with vaginal hysterectomy.
3076627|NCT02049983|Experimental|Use of Levita Magnetics Grasper|
3076628|NCT02049970|Experimental|dexmedetomidine and bupivacaine|Bupivacaine 50 mg and dexmedetomidine 1 microgram/kg
3076629|NCT02049970|Experimental|Bupivacaine and placebo|Bupivacaine 100 mg and SF 10 ml
3076630|NCT02049957|Experimental|MLN0128 + Exemestane|
3076631|NCT02049957|Experimental|MLN0128 + Fulvestrant|
3076632|NCT02049944|Experimental|Cefazolin|All subjects undergoing elective term cesarean delivery will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision.
3076633|NCT02049931|Experimental|No brace group|Patients in the no brace treatment group were allowed to ambulate without any braces as long as it would be tolerable.
3076634|NCT02049931|Active Comparator|Rigid brace group|Patients in the rigid brace immobilization group were strictly maintained on bed rest until fitted a thoraco-lumbo-sacral orthosis. Brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
3076635|NCT02049931|Active Comparator|Soft brace group|Because soft back brace was a custom-made, it began to be worn when enrollment for the study. Brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
3076636|NCT02049905|Experimental|Aldoxorubicin|Aldoxorubicin is administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously on Day 1 every 21-day cycles until tumor progression or unacceptable toxicity occurs.
3076674|NCT02049606|Active Comparator|CENATONE|Drug : CENATONE tablet/qd
3076675|NCT02049593|Experimental|Arm A (PARP inhibitor BMN-673, temozolomide)|Patients receive PARP inhibitor BMN-673 PO QD on days 1-28 and temozolomide PO daily on days1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3078266|NCT02038673|Experimental|Expansion part Hepatocellular Carcinoma|Oral
3076637|NCT02049905|Active Comparator|Investigator's Choice of Treatment|"These treatments include:~Dacarbazine administered at 1000 mg/m2 by intravenous infusion (IVI), over 90±15 minutes on Day 1 every 21 days until tumor progression or unacceptable toxicity occurs;~Pazopanib, 800 mg orally each day until tumor progression or unacceptable toxicity occurs;~Gemcitabine, 900 mg/m2 by IVI over 90 minutes on Days 1 and 8, plus docetaxel, 100 mg/m2 by IVI over 1 hour on Day 8 of a 28 day cycle until tumor progression or unacceptable toxicity occurs;~Doxorubicin, 75 mg/m2 by IVI over 5 to 30 minutes every 21 days for a maximum cumulative dose of 550 mg/m2 or unacceptable toxicity occurs; or~Ifosfamide 2.0 g/m2 administered over 2 to 4 hours on Days 1-4 of a 21 day cycle + mesna per standard site administration regimen until tumor progression or unacceptable toxicity occurs."
3076638|NCT02049892||Metal Ion|
3076639|NCT02049879|Experimental|Injection|Corticosteroids injection
3076640|NCT02049866|Experimental|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months.
3076641|NCT02049853|No Intervention|default group|"Patients with the randomization result default group receive standard diagnostics"
3076642|NCT02049853|Active Comparator|POCT group|"patients with the randomization result POCT group receive a NTproBNP measurement with point of care device Cobash232 in the ambulance vehicle"
3076643|NCT02049840|Experimental|Altis Single Incision Sling System|Altis Single Incision Sling System
3076644|NCT02049827|Experimental|Renal transplant|
3076645|NCT02049814|Experimental|Metformin + Voglibose|Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12.
3076646|NCT02049814|Active Comparator|Metformin + Acarbose|Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12.
3076647|NCT02049801|Experimental|Treatment (MEK inhibitor, MEK162, idarubicin, cytarabine)|"INDUCTION THERAPY: Patients receive MEK inhibitor MEK162 PO BID on days -4 to -1 and days 5-18, cytarabine IV continuously over 24 hours on days 1-4, and idarubicin IV over 1 hour on days 1-3. Patients may receive a second course of induction at the discretion of the principal investigator.~POST-REMISSION THERAPY: Patients receive cytarabine IV continuously over 24 hours on days 1-3, idarubicin IV over 1 hour on days 1 and 2, and MEK inhibitor MEK 162 PO BID on days 4-17. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3076648|NCT02049788|Active Comparator|low calorie/fat diet|The low calorie/fat diet group, obese children aged 9-16, received conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
3076649|NCT02049788|Experimental|Low glycaemic index diet|Low glycaemic index diet group, obese children of both sexes aged 9-16, received experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
3076650|NCT02049775|Experimental|NBI|
3076651|NCT02049762|Active Comparator|P2Y12 inhibitors and aspirin|ACS patients on novel P2Y12 inhibitors and aspirin
3076652|NCT02049762|Placebo Comparator|P2Y12 inhibitors and placebo|ACS patients on novel P2Y12 inhibitors and placebo
3076653|NCT02049749|No Intervention|Delayed CARE|40 child-caregiver pairs will be randomized to usual treatment plus delayed CARE (control). Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment and/or provided with a 1-2 page informational handout on child behavior problems from the CHOP patient care manual. Following the final interview (3-4 months after enrollment for each subject) all participants randomized to the control arm (usual treatment plus delayed CARE) will receive the CARE training, if desired.
3076654|NCT02049749|Experimental|Immediate CARE|40 child-caregiver pairs will be randomized to usual treatment plus immediate CARE. The trainings are administered to groups of 4-10 caregivers at a time and are led by two mental health providers trained in the CARE curriculum. The children do not attend the training; however, caregivers are expected to practice the skills that they learn in CARE with their child between sessions. The curriculum involves 6 sessions over 6-8 weeks. Each session will be 1-2 hours.
3076655|NCT02049736|Experimental|Telbivudine|
3076656|NCT02049723||Patients with GERD|The knowledge level on GERD among Korean patients with gastroesophageal disease was evaluated by the method of multicenter survey
3076657|NCT02049710|Active Comparator|Sexual Behavior Intervention|
3076658|NCT02049710|Active Comparator|Driving behavior intervention|
3076659|NCT02049697|Experimental|14C-JNJ-39823277|
3076660|NCT02049684||Surgery|
3076661|NCT02049684||Physiotherapy|
3076662|NCT02049671||Growth Hormone Therapy|
3076663|NCT02049671||Control Group|
3076664|NCT02049658||Healthy volunteers|Healthy volunteers measured by currently used healthy screening procedures
3076665|NCT02049658||Suspected breast cancer subjects|Suspected breast cancer subjects without pathological examination yet but will have it soon
3076666|NCT02049658||Suspected lung cancer subjects|Suspected lung cancer subjects without pathological examination yet but will have it soon
3076667|NCT02049658||Suspected neurological tumor subjects|Suspected neurological tumor subjects without pathological examination yet but will have it soon
3076668|NCT02049658||Suspected patients with gynecological tumor|Suspected subjects with gynecological tumors without pathological examination yet but will have it soon
3076669|NCT02049645||faculty staff and their adult family members|faculties and their adult family members of the Third Xiang-Ya Hospital
3076670|NCT02049632|Experimental|Omission of axillary clearance|No axillary lymph node dissection after sentinel node biopsy and sentinel node micrometastases
3076717|NCT02049242|Active Comparator|Single tourniquet|
3076676|NCT02049593|Experimental|Arm B (PARP inhibitor BMN-673, irinotecan hydrochloride)|Patients receive PARP inhibitor BNM-673 as in Arm A and irinotecan hydrochloride IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3076677|NCT02049580|Experimental|RIC regimen|Thiotepa, Fludarabine, Cyclophosphamide pre- and post- transplantation.
3076678|NCT02049567|Experimental|Intraocular Lens Implantation|Single arm implantation of an accomodating intraocular lens
3076679|NCT02049554|No Intervention|Usual Care|
3076680|NCT02049554|Experimental|Preconception Care Screener Group|Women's Health Screener and Clinician discussion
3076681|NCT02049541|Experimental|Treatment (PI3K inhibitor BKM120, rituximab)|Patients receive BKM120 PO daily and rituximab IV. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with asymptomatic progression may continue treatment for up to 12 months. Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline. Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission.
3076682|NCT02049528|Experimental|3 mg CC-122 reference capsule formulation|3 mg CC-122 reference capsule given by mouth with 240 mL of room temp tap water
3076683|NCT02049528|Experimental|3 mg CC-122 test capsule formulation|3 mg CC-122 test capsule give by mouth with 240 mL of room temp tap water
3076684|NCT02049528|Experimental|3 mg CC-122 test capsule + high fat meal|3 mg CC-122 test capsule given by mouth with 240 mL of room temp tap water approximately 5 minutes after eating a high-fat meal
3076685|NCT02049515|Experimental|IPI-145|IPI-145 is administered orally and supplied as 5 mg and 25 mg formulated capsules.
3076686|NCT02049515|Active Comparator|Ofatumumab|Ofatumumab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg/5mL and 1000 mg/50 mL
3076687|NCT02049502|Experimental|fecal microbiota transplant|fecal microbiota transplant
3076688|NCT02049489|Experimental|ICT-121 DC vaccine|Autologous dendritic cells pulsed with peptide antigens
3076689|NCT02049476|Experimental|Dexamethasone Pellet|This is a proof of concept study; therefore all enrolled patients will receive the intervention according to its FDA-approved indication.
3076690|NCT02049450|Experimental|INC424 (ruxolitinib) - Study Treatment|Regularly transfused adult patients with thalassemia and spleen enlargement.
3076691|NCT02049437|Active Comparator|Arm A: TCZ|ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.
3076692|NCT02049437|Placebo Comparator|Arm B: Placebo|ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.
3076693|NCT02049424||transplanted patients|T-repleted haploidentical transplanted patients in Italy
3076694|NCT02049411|Experimental|Ketamine group|Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
3076695|NCT02049411|Sham Comparator|physiological solution|Control group: only physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
3076696|NCT02049385|Experimental|Diazoxide|Subjects received 200-400 mg daily of diazoxide orally for three weeks; the dose was, adjusted depending on side effects and response.
3076697|NCT02049385|Experimental|Placebo|Subjects received a matched placebo for three weeks
3076698|NCT02049359|No Intervention|Control group|Care as usual; no bidirectional texting
3076699|NCT02049359|Experimental|Texting|Bidirectional texting weekly for 12 weeks
3076700|NCT02049346|Active Comparator|Epoetin alpha or beta (Epoetin group)|Patients in that arm were continued on the previous same dose and route of administration of Epoetin alpha/ beta (Epoetin group).
3076701|NCT02049346|Active Comparator|Darbepoetin alpha|subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol.
3076702|NCT02049346|Experimental|Methoxy polyethylene glycol-epoetin beta|Patients in that arm received Intravenous Methoxy polyethylene glycol-epoetin beta monthly.
3076703|NCT02049333|Active Comparator|Phacoemulsification|Cataract extraction alone
3076704|NCT02049333|Experimental|Phacoemulsification with Endoscopic Cycloplasty (ECPL)|Cataract extraction combined with endoscopic cycloplasty
3076705|NCT02049320||Remifentanil|Patients sedated using Remifentanil
3076706|NCT02049307|Active Comparator|Treatment|Losartan 100mg daily
3076707|NCT02049307|Placebo Comparator|Placebo|Matching placebo
3076708|NCT02049294|Active Comparator|Omalizumab (Xolair)|Dosage/frequency is dependent on body weight (kg) and baseline blood IgE level.
3076709|NCT02049294|Placebo Comparator|Placebo (Normal Saline)|0.9% normal saline equivalent to the dosage/frequency/duration of Omalizumab
3076710|NCT02049281|Experimental|Vintafolide|Participants receive vintafolide intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
3076711|NCT02049268|Experimental|Nicotine + Alcohol|A nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (nicotine only) measurements will be made, then participants will drink an alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
3076712|NCT02049268|Experimental|Placebo Nicotine + Alcohol|A placebo nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (placebo nicotine) measurements will be made, then participants will drink an alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
3076713|NCT02049268|Experimental|Nicotine + Placebo Alcohol|A nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (nicotine only) measurements will be made, then participants will drink a placebo alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
3076714|NCT02049255|Placebo Comparator|Marcaine|Rachianesthesia with marcaine or chloroprocaine
3076715|NCT02049255|Active Comparator|Chloroprocaine|Rachianesthesia with marcaine or chloroprocaine
3076716|NCT02049242|Active Comparator|Triple tourniquet|
3076719|NCT02049229|Active Comparator|SYNERGY stent|Patients randomised to receive everolimus-eluting, biabsorabble polymer coated stent
3076720|NCT02049216|Sham Comparator|Sham tape|"Fixomull tape only~Single piece of 10cm wide, 32cm long applied from inferior to tibial tuberosity, over patella and onto quadriceps muscle. Corners rounded. Tape to be applied with the knee in 90 degrees flexion.~Participants in both groups will also be prescribed an individualised home exercise program by a physiotherapist."
3076721|NCT02049216|Experimental|Flexible tape|"Flexible tape (rocktape brand) applied as follows:~First piece of tape 10 cm wide and 32cm long (length of a standard goniometer). Split down centre 18cm from 1 end. Second piece of tape 5cm wide and 14cm long.~Tape applied in 90 degrees knee flexion Applied with no tension in proximal and distal ends. 30% tension to un-split portion placed over quads. 50% tension to split portion placed either side of patella and crossing over at tibial tuberosity Additional piece of 5cm wide flexible tape applied with 80% tension over patella tendon, with no tension in 3cm from ends All tape corners rounded~Participants in both groups will also be prescribed an individualised home exercise program by a physiotherapist."
3076722|NCT02049203|Placebo Comparator|Placebo|Placebo gel capsule, dosage matches number of Ataciguat capsules for each respective dose, capsules taken once daily with breakfast for 14 consecutive days.
3076723|NCT02049203|Active Comparator|Ataciguat|Ataciguat, orally administered gel capsule, 50, 100, or 200 mg, once per day with breakfast for 14 consecutive days
3076724|NCT02049190|Experimental|onapristone 10 mg BID|onapristone 10 mg BID extended-release tablets
3076725|NCT02049190|Experimental|onapristone 20 mg BID|onapristone 20 mg BID extended-release tablets
3076726|NCT02049190|Experimental|onapristone 30 mg BID|onapristone 30 mg BID extended-release tablets
3076727|NCT02049190|Experimental|onapristone 40 mg BID|onapristone 40 mg BID extended-release tablets
3076728|NCT02049190|Experimental|onapristone 50 mg BID|onapristone 50 mg BID extended-release
3076729|NCT02049190|Experimental|onapristone 30 mg BID + abiraterone 1000 mg|Expansion cohort: onapristone 30 mg BID + abiraterone 1000 mg
3076730|NCT02049190|Experimental|onapristone 50 mg BID + abiraterone 1000 mg|Expansion cohort: onapristone 50 mg BID + abiraterone 1000 mg
3076731|NCT02049190|Experimental|Expansion cohort: onapristone 50 mg BID|Expansion cohort: onapristone 50 mg BID
3076732|NCT02049177||Head and Neck Cancer Cases|Cases of Head and Neck Cancer identified in North West England in 2002/2003. Observational study - no intervention other than usual care.
3076733|NCT02049164|Experimental|AR08 0.5 mg/day|AR08 QD oral dosing for 14 weeks
3076734|NCT02049164|Experimental|AR08 1.0 mg/day|AR08 QD oral dosing for 14 weeks
3076735|NCT02049164|Experimental|AR08 2.0 mg/day|AR08 QD oral dosing for 14 weeks
3076736|NCT02049164|Placebo Comparator|Placebo|Placebo QD oral dosing for 14 weeks
3076737|NCT02049151|Experimental|Tecemotide|
3076738|NCT02049151|Placebo Comparator|Placebo|
3076739|NCT02049138|Experimental|Open-label extension|All subjects will start treatment with ABT-494.
3076740|NCT02049125||No AKI|Patients with cirrhosis admitted to hospital with bacterial infection with initial serum creatinine below 1.5mg/dL.
3076741|NCT02049125||AKI and Infection|Patients with cirrhosis admitted to hospital with bacterial infection and initial serum creatinine above 1.5mg/dL.
3076742|NCT02049125||AKI with No Infection|Patients with cirrhosis admitted to hospital with initial serum creatinine above 1.5mg/dL without bacterial infection.
3076743|NCT02049112|Experimental|Salivary equivalent|Single dose stick without any active substance
3076744|NCT02049112|Sham Comparator|Aequasyal|Multidose moisturizing oral spray without any active substance
3076745|NCT02049112|Sham Comparator|Biotene|Multidose moisturizing oral spray without any active substance
3076746|NCT02049086|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
3076747|NCT02049086|Active Comparator|Pain Module Only|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
3076748|NCT02049086|No Intervention|No Additional Referral|No intervention.
3076749|NCT02049073|Experimental|Zonisamide|Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
3076750|NCT02049073|Experimental|Methylprednisolone|Methylprednisolone 32 mg or 64 mg pill administered orally once
3076751|NCT02049073|No Intervention|Control|no medication
3076752|NCT02049060|Experimental|Tivantinib+carboplatino+pemetrexed|"•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks"
3076753|NCT02049047|Experimental|Everolimus|oral everolimus
3076754|NCT02049034|Placebo Comparator|Placebo|Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
3076755|NCT02049034|Experimental|Lixisenatide|"Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days."
3076756|NCT02049021|Experimental|Electroconvulsive Therapy|Patients in use of clozapine randomized to receive ECT treatment
3076757|NCT02049021|Sham Comparator|SHAM ECT|Patients receiving clozapine randomized to sham ECT (placebo)
3076758|NCT02049008|Experimental|Photodynamic Therapy|
3076759|NCT02049008|Sham Comparator|Sham Photodynamic Therapy|
3076760|NCT02048995||Bipolar Depressed|Bipolar Depressed - are participants with Bipolar Disorder Type I or II and a current episode of major depression which is confirmed on the SCID interview
3076761|NCT02048995||Healthy Comparator|Healthy Comparator - are participants without mental disorders, alcohol or substance disorders confirmed by the SCID-interview
3076762|NCT02048982|Experimental|Guideline and Cost|The Choosing Wisely guideline and the cost of the test at our institution: $60.35 for a basic metabolic panel.
3076763|NCT02048982|Placebo Comparator|Guideline|"The Choosing Wisely guideline: Don't perform blood chemistry panels in asymptomatic, healthy adults."
3076764|NCT02048982|Active Comparator|Guideline and Victim|The Choosing Wisely Guideline and a clinical scenario with a patient as an identifiable victim who suffered harm from having an unnecessary test done
3076765|NCT02048982|Experimental|Guideline, Cost, and Victim|The Choosing Wisely guideline and a clinical scenario with a physician as an identifiable victim who suffered harm when he ordered an unnecessary test.
3076766|NCT02048969|Experimental|Flumazenil|A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of flumazenil will be administered to the patient at a rate of 0.1 mg flumazenil per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
3076767|NCT02048969|Placebo Comparator|Saline|A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
3076768|NCT02048956|Experimental|Hydrotherapy intervention|30 people will be recruited in order to the inclusion criteria for the study and they will receive an hydrotherapy intervention.
3076769|NCT02048956|Active Comparator|Control group|30 people will be recruited and included in this control group. The are not going to receive hydrotherapy treatment, only the treatment they receive as usual.
3076770|NCT02048943|Experimental|Treatment (dovitinib, gemcitabine, nab-paclitaxel)|Patients receive dovitinib lactate PO QD 5 days per week, paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3076771|NCT02048930||Initiation cohort|Receive their first prescription for ICS therapy as one of the study drugs
3076772|NCT02048930||Step-up cohort|Receive a prescription for one of the study drugs at a dose ≥50% that of their prescribed ICS dose during baseline.
3076773|NCT02048930||Switch cohort|switch from BUD DPI (other) to BUD EH or continue on BUD DPI (other) with no change in ICS dose
3076774|NCT02048917|Experimental|High Intensity Counseling + Long Acting NRT + PRN NRT|High Intensity Counseling + Long Acting NRT + PRN NRT
3076775|NCT02048917|Experimental|High Intensity Counseling + bupropion + PRN NRT|High Intensity Counseling + bupropion + PRN NRT
3076776|NCT02048917|Experimental|High Intensity Counseling + varenicline + PRN NRT|High Intensity Counseling + varenicline + PRN NRT
3076777|NCT02048917|Experimental|High Intensity Counseling + Long Acting NRT|High Intensity Counseling + Long Acting NRT
3076778|NCT02048917|Experimental|High Intensity Counseling + bupropion|High Intensity Counseling + bupropion
3076779|NCT02048917|Experimental|High Intensity Counseling + varenicline|High Intensity Counseling + varenicline
3076780|NCT02048917|Experimental|Low Intensity Counseling + Long Acting NRT + PRN NRT|Low Intensity Counseling + Long Acting NRT + PRN NRT
3076781|NCT02048917|Experimental|Low Intensity Counseling + bupropion + PRN NRT|Low Intensity Counseling + bupropion + PRN NRT
3076782|NCT02048917|Experimental|Low Intensity Counseling + varenicline + PRN NRT|Low Intensity Counseling + varenicline + PRN NRT
3076783|NCT02048917|Experimental|Low Intensity Counseling + Long Acting NRT|Low Intensity Counseling + Long Acting NRT
3076784|NCT02048917|Experimental|Low Intensity Counseling + bupropion|Low Intensity Counseling + bupropion
3076785|NCT02048917|Experimental|Low Intensity Counseling + varenicline|Low Intensity Counseling + varenicline
3076786|NCT02048904|Active Comparator|Sitagliptin|100 mg/day for 3 months
3076787|NCT02048904|Placebo Comparator|Placebo|1 pill/day for 3 months
3076788|NCT02048891|Active Comparator|hCG trigger|Ovulation trigger with Ovitrelle 250 microgram, luteal support with vaginal progesterone: gel Crinone 8% daily.
3076789|NCT02048891|Experimental|GnRH agonist trigger|ovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG.
3076790|NCT02048878||Insomnia group|"Assessment of physiologic hyper-arousal across the two following domains:~Sympathetic neural activity: recording at the level of the muscle by microneurography and at the level of the heart by spectral analysis of heart rate variability from the ECG signal obtained during sleep and wakefulness.~Neurophysiologic arousal: recording of multiple sleep latency test (MSLT), recording of wake electroencephalography (EEG), and quantitative sleep EEG recording and analysis."
3076791|NCT02048878||Matched Control Group|"Assessment of physiologic hyper-arousal across the two following domains:~Sympathetic neural activity: recording at the level of the muscle by microneurography and at the level of the heart by spectral analysis of heart rate variability from the ECG signal obtained during sleep and wakefulness.~Neurophysiologic arousal: recording of multiple sleep latency test (MSLT), recording of wake electroencephalography (EEG), and quantitative sleep EEG recording and analysis."
3076792|NCT02048865|Active Comparator|Apixaban|2.5 mg BID for 6 months
3076793|NCT02048865|Placebo Comparator|Placebo drug|2.5 mg BID for 6 months
3076794|NCT02048852|Experimental|Reduced Nicotine Content -Non Menthol|Switch from own brand of cigarette to SPECTRUM research cigarettes (NRC 200-Reduced Nicotine Content cigarette) which contain 0.07mg nicotine yield without menthol.
3076795|NCT02048852|Experimental|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced Nicotine Research Cigarettes which contain 0.07mg nicotine yield with Menthol
3076796|NCT02048852|Active Comparator|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette. No research cigarettes used.
3076797|NCT02048852|Experimental|Conventional Nicotine Content- Non Menthol|Switch from own brand of cigarette to SPECTRUM research cigarette (NRC-600 Conventional Nicotine )which contains conventional nicotine yield.
3076798|NCT02048839||Radiel Intervention group and their children|Participated the Radiel- intervention study (2008-2011) in the Intervention group: Lifestyle counselling during and after pregnancy (up to 1 year post partum)
3076799|NCT02048839||Radiel Control Group with their children|Control group in the Radiel- intervention study.
3076800|NCT02048826|Experimental|FINGER I|Subjects participate in 3 weeks of exercising with the experimental device: FINGER robot with first setting at a minimum of 3 days per week, 1 hour per day with the exercise program
3076979|NCT02047604|Experimental|Cohort E - SAN-300 4.0 mg/kg|SAN-300 4.0 mg/kg subcutaneous every other week for six weeks or placebo
3076980|NCT02047591||Relaxing-touch method|
3076801|NCT02048826|Experimental|FINGER II|Subjects participate in 3 weeks of exercising with the experimental device: FINGER robot with a second setting at a minimum of 3 days per week, 1 hour per day with the exercise program
3076802|NCT02048826|Experimental|FINGER III|Subjects participate in 3 weeks of exercising with the experimental device: FINGER robot with third setting at a minimum of 3 days per week, 1 hour per day with the exercise program
3076803|NCT02048813|Experimental|Arm A (ibrutinib, rituximab)|Patients receive ibrutinib PO QD on days 1-28. Beginning course 2, patients also receive rituximab IV over 4 hours on day 1 (days 1 and 2 of course 2 only). Treatment repeats every 28 days for 7 courses. In the absence of disease progression, patients may continue ibrutinib PO QD.
3076804|NCT02048813|Experimental|Arm B (rituximab, fludarabine phosphate, cyclophosphamide)|Patients receive rituximab as seen in Arm A and fludarabine phosphate IV over 30 minutes and cyclophosphamide IV over 30 minutes on days 1-3. Treatment repeats every 28 days for 6 courses.
3076805|NCT02048800||Treosulfan PK|Children with indication to HSCT receiving Treosulfan
3076806|NCT02048787|Experimental|Moderate renal impairment group|Subjects with moderate renal impairment defined as eGFR of 30-59 mL/min/1.73m2 at screening can be enrolled in this group
3076807|NCT02048787|Experimental|Severe renal impairment group|Subjects with severe renal impairment defined as eGFR of 15-29 mL/min/1.73m2 at screening can be enrolled in this group
3076808|NCT02048787|Experimental|Matching healthy control group|Subjects with normal renal function defined as eGFR ≥ 90 mL/min/1.73m2 at screening and matching to the renal impaired subject based on gender, race, age, and weight can be enrolled in this group.
3076809|NCT02048774|Active Comparator|High Social Position|The investigators will randomly assign a participant to a higher social position.
3076810|NCT02048774|Experimental|Low Social Position|The investigators will randomly assign a participant to a lower social position.
3076811|NCT02048761|Placebo Comparator|Placebo Group|After debridement, placebo gel was applied into the periodontal pockets with a syringe and a blunt canula.
3076812|NCT02048761|Active Comparator|1% Metformin|After debridement, 1% Metformin gel was applied into the periodontal pockets with a syringe and a blunt canula.
3076813|NCT02048748|Experimental|Telemonitoring|Device: Weight and blood pressure device Device: Home telemonitoring device
3076814|NCT02048748|No Intervention|Control|Usual care
3076815|NCT02048722|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3076816|NCT02048709|Experimental|GDC-0919 Dose Escalation|GDC-0919 to be given on an outpatient basis as a single agent. Starting dose of GDC-0919 will be 50 mg by mouth every 12 hour. Patients will receive the study drug daily for 21 days followed by 7 days off for a cycle length of 28 days; or on 28 consecutive days of a 28-day cycle
3076817|NCT02048696|Experimental|Exercise training|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
3076818|NCT02048696|No Intervention|control|Individuals in this group are offered current ACC/AHA recommendations on physical activity in patients post-myocardial infarction.
3076819|NCT02048683|Experimental|burn ICU patients|Determination of plasmatic concentrations of sevoflurane at different times of a short term sedation of sevoflurane in burn versus non burn ICU patients
3076820|NCT02048683|Other|non burn ICU patients|Determination of plasmatic concentrations of sevoflurane at different times of a short term sedation of sevoflurane in burn versus non burn ICU patients
3076821|NCT02048670|Experimental|Vestibular Habituation Therapy|"3-5 repetitions for each of the sensitive head movements~3-5 repetitions for each of the sensitive visual motion~Balance belt is not turned on"
3076822|NCT02048657|Experimental|Foley group|The Foley Airway Stylet Tool was used to guide ProSeal LMA insertion
3076823|NCT02048657|Experimental|I-Tool group|the ProSeal LMA was inserted with a standard introducer-tool
3076824|NCT02048644|Placebo Comparator|placebo inhaler|matched placebo inhaler, to be taken 2 puffs, twice a day for 28 days
3076825|NCT02048644|Experimental|fostair|fostair 100mcg/6mcg 2pufss, twice a day.
3076826|NCT02048631||Oral Cancer Patients underwent Free Flap Reconstruction|
3076827|NCT02048618|Experimental|GLPG0634 200 mg QD|2 tablets of 100 mg GLPG0634 in the morning
3076828|NCT02048618|Experimental|GLPG0634 100 mg QD|1 tablet of 100 mg GLPG0634 and 1 placebo tablet in the morning
3076829|NCT02048618|Placebo Comparator|Placebo QD|2 placebo tablets in the morning
3076830|NCT02048605|Experimental|Psycho-social (CBT) based training|Psycho-social Training in Neurological Diseases - Parkinson`s Disease ( Training according to Ellgring et al., 2006)
3076831|NCT02048605|Placebo Comparator|Unspecific group training|"Health Enhancement Program~The validation of an active control intervention for Mindfulness Based Stress Reduction (MBSR) (MacCoon et al., 2012)"
3076832|NCT02048592|Active Comparator|Impact-Nutridrink|The first arm will be given immunonutrition -Impact- for 8 weeks, afterwards the patients will return to their previous nutrition support for another 8 weeks. We expect the improvement of oxidative stress parameters after 8 weeks of immunonutriton and return to baseline values when immunonutrition is stopped
3076833|NCT02048592|Active Comparator|Nutridrink-Impact|The second group will be given their previous nutrition support (Nutridrink) for 8 weeks, afterwards the patients will be switched to immunonutrition- Impact- for another 8 weeks. In this group of patients we do not expect any change of oxidative stress parameters after the first 8 weeks. The improvement is expected at the end of the second half of study.
3076834|NCT02048579|No Intervention|Treatment as Usual|
3076835|NCT02048579|Experimental|Behavior Therap + Motivational Interviewing|Supporting Teens' Academic Needs Daily Therapy program delivered to parents and teens
3076836|NCT02048566|Experimental|hTEEPM|Group hTEE protocolled monitoring (hTEEPM) will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, at the time of occurrence of defined new organ system deterioration (see below) and/or at least every 4 hours during the first 72h after study inclusion or until one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
3076981|NCT02047591||Usual care|
3076982|NCT02047578|Experimental|Busulfan|Drug: Busulfan First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
3076837|NCT02048566|Experimental|hTEESM|Group hTEE standard monitoring (hTEESM) will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, follow-up assessment intervals are at the discretion of the treating physician for the first 72h after study inclusion. A follow up assessment is defined as any assessment that leads to significant changes in hemodynamic management in which case an hTEE assessment has to be performed. hTEE monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
3076838|NCT02048566|Active Comparator|ControlPM|Group Control protocolized monitoring (ControlPM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, at the time of occurrence of defined new organ system deterioration or at least every 4 hours for the first 72h after study inclusion. Protocolized monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
3076839|NCT02048566|Active Comparator|ControlSM|Group Control standard monitoring (ControlSM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, follow-up measurement intervals are at the discretion of the treating physician for the first 72h after study inclusion. A follow up assessment is defined as any assessment that leads to significant changes in hemodynamic management. Data collection from standard monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
3076840|NCT02048553|Experimental|Tablet-guided|Guide-assisted ventriculostomy.
3076841|NCT02048553|Experimental|Freehand|standard ventriculostomy.
3076842|NCT02048540|Experimental|bevacizumab plus DOF|patients receive bev +DOF pre and post surgery up to total 6 cycles
3076843|NCT02048540|Active Comparator|DOF|patients receive DOF pre and post surgery up to total 6 cycles
3076844|NCT02048527|Active Comparator|Global|In vitro embryo culture in single-step medium (Global)
3076845|NCT02048527|Active Comparator|Origio|In vitro embryo culture in sequential media (Origio)
3076846|NCT02048514|Experimental|Nellix Aneurysm Sealing|The Nellix® EndoVascular Aneurysm Sealing System
3076847|NCT02048501|Other|Weight Regain|The weight regain group will include 20 subjects who underwent Roux-en-Y gastric bypass (RYGB) with a follow up of at least 2 years and have experienced excess weight loss (EWL) of at least 50% at 12 (+ 2) months post-operatively and regained at least 15% of the post-operative nadir weight.
3076848|NCT02048501|Other|Sustained Weight Loss (SWL)|The sustained weight loss group will include 20 subjects who underwent Roux-en-Y gastric bypass (RYGB) with a follow up of at least 2 years and have experienced excess weight loss (EWL) of at least 50% at 12 (+ 2) months post-operatively and have regained less than 15% of the post-operative nadir weight.
3076849|NCT02048488|Experimental|Experimental Drug TSR-011|Experimental Drug TSR-011
3076850|NCT02048475|No Intervention|desflurane|inhalation concentration
3076851|NCT02048462||Cyclists|
3076852|NCT02048436||male female 18-45 years range of body types|18 male female subject mix that are 18-45 years of age and selected to represent a range of body types of varying physiques and body mass indexes
3076853|NCT02048423|Experimental|Ketamine|Drug
3076854|NCT02048410|Active Comparator|diet plus Lactobacillus paracasei B21060|low saturated fats diet plus the symbiotic (2.5×109cfu, bid)
3076855|NCT02048410|Placebo Comparator|low saturated fats diet|low saturated fats diet
3076856|NCT02048397|Other|Pulmonary Rehabilitation (PRP)|Pulmonary Rehabilitation (PRP)
3076857|NCT02048397|Other|Pulmonary Rehabilitation plus oral nutritional supplement|Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB)
3076858|NCT02048384|Experimental|A - metformin alone|metformin alone Arm A patients will receive metformin 850mg orally twice a day on a 28 day cycle.
3076859|NCT02048384|Active Comparator|B - metformin + rapamycin|metformin + rapamycin Arm B patients will receive 850mg orally twice a day and rapamycin 4mg orally once a day on a 28 day cycle.
3076860|NCT02048371|Active Comparator|Regorafenib|160 mg daily; 21 days on and 7 days off
3076861|NCT02048371|Placebo Comparator|Placebo|21 days on and 7 days off
3076862|NCT02048358|Experimental|2B3-201 150mg|2B3-201 150mg, once, IV infusion in 1000ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 1000ml 5% dextrose/ Placebo, once, IV infusion 1000ml 5% dextrose
3076863|NCT02048358|Experimental|2B3-201 300mg|2B3-201 300mg, once, IV infusion in 1500ml 5% dextrose/ Methylprednisolone hemisuccinate 300mg, once, IV infusion in 1500ml 5% dextrose/ Placebo, once, IV infusion 1500ml 5% dextrose
3076864|NCT02048358|Experimental|2B3-201 450mg|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 2500ml 5% dextrose/ Placebo, once, IV infusion 2500ml 5% dextrose
3076865|NCT02048358|Experimental|450mg 2B3-201|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose
3076866|NCT02048358|Experimental|300mg 2B3-201|2B3-201 300mg, once, IV infusion in 1500ml 5% dextrose
3076867|NCT02048358|Experimental|2B3-201 450mg male volunteers|2B3-201 450mg, once, IV infusion in 1500ml 5% dextrose
3076868|NCT02048358|Experimental|2B3-201 300mg or 450mg female volunteers|2B3-201 300mg or 450mg, once, IV infusion in 1500 or 2500ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 1500 or 2500ml 5% dextrose
3076869|NCT02048358|Experimental|Relapsing MS patients; 2B3-201 450 mg|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose
3076870|NCT02048358|Experimental|Relapsing MS patients; 2B3-201 dose tbd|2B3-201 (dose to be determined), once, IV infusion in 5% dextrose
3076871|NCT02048345|Experimental|Suspension, fasted state|Suspension Noxafil will be administered in the fasted state to the volunteers.
3076872|NCT02048345|Experimental|Suspension, with sugar (delay gastric emptying)|Suspension will be co-administered with glucose to delay the gastric emptying time
3076873|NCT02048345|Experimental|Solution, fasted state|A solution (by acidifying the suspension in water to pH 1.2) will be administered to healthy volunteers in a fasted state.
3076874|NCT02048345|Experimental|Solution, with sugar (delaying gastric emptying)|A solution of posaconazol (by acidifying the suspension in water to pH 1.2) will be administered together with sugar to delay the gastric emptying.
3076875|NCT02048332|Experimental|Viral Specific CTL Infusion|Viral reactivation or infection. CTL Reinfusion required.
3076876|NCT02048319|Experimental|Experimental: Pasireotide LAR 60 mg|The subjects will be randomized (1:1) into two groups. Both groups will undergo aspiration sclerotherapy following the standard procedure. The intervention group will additionally receive two injections of 60 mg pasireotide long-acting release (LAR) intramuscularly: the first injection 14 days before and the second injection 14 days after the intervention.
3076877|NCT02048319|Placebo Comparator|Placebo|Patients in the placebo arm will receive two injections of saline solution corresponding to the scheme of the intervention group.
3076878|NCT02048306|Experimental|Family-based PR group|
3076879|NCT02048306|Active Comparator|Conventional PR group|
3076880|NCT02048293|Active Comparator|Group O|Remifentanyl innovative molecule = Ultiva®
3076881|NCT02048293|Active Comparator|Group A|Remifentanyl comparator A = Remifentanil Laboratorios Chalver de Colombia S.A.
3076882|NCT02048293|Active Comparator|Group B|Remifentanyl comparator B = Fada Remifentanilo
3076883|NCT02048280|Experimental|Intubated|NAVA level from 0.1 to 3
3076884|NCT02048267||Alcoholic|
3076885|NCT02048267||Non alcoholic|
3076886|NCT02048254|Experimental|brachytherapy|Iodine-125 radioactive seeds permanent interstitial implantation brachytherapy
3076887|NCT02048254|Active Comparator|IMRT|IMRT (intensity-modulated radiation therapy), 6 Millivolt (MV)-x fractionated irradiation, 1 time/day, 5 times a week, till the end. Add up to 33 times.
3076888|NCT02048241|Other|Placebo plus Parent Management Training|Pills matching Intuniv Tablets without active medication combined with weekly Parent Management Training
3076889|NCT02048241|Experimental|Intuniv plus Parent Management Training|Administration of Intuniv in increasing doses from 1 mg to 2 mgs to 3 mgs to 4 mgs as tolerated over a period of 4-6 weeks, combined with weekly Parent Management Training
3076890|NCT02048228|Experimental|genotyping guided therapy|Patients randomized to the genotyping guided therapy arm will have their CYP2C19*2 carrier status determined at the time before antiplatelet therapy with subsequent alteration in antiplatelet therapy for *2 carriers.CYP2C19*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers will be given 75 mg clopidogrel daily.
3076891|NCT02048228|Active Comparator|Standard Therapy|Patients randomized to the Standard Therapy arm will not undergo genotyping. All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
3076892|NCT02048215|Active Comparator|Ephedrine + Caffeine + diet|Ephedrine 20 mg + Caffeine 200 mg capsule t.i.d. for one month plus hypocaloric diet
3076893|NCT02048215|Placebo Comparator|Placebo + diet|Similarly-looking placebo capsule t.i.d. for one month plus hypocaloric diet
3076894|NCT02048202||premature neonate|premature neonate
3076895|NCT02048189|Other|Intensified multiple injections|
3076896|NCT02048189|Other|Pumps|
3076897|NCT02048176||Posterior Fossa Mutism|Patients with Posterior Fossa Mutism
3076898|NCT02048176||Non Posterior Fossa Mutism|Patients that did not develop Mutism
3076899|NCT02048163||Short infusion meropenem|Meropenem 20 mg/ml IV will be administered at a dose of 40 mg/kg (maximum 2,000 mg) every eight hours for 12 doses and will be infused over a 30 minute period. An equal volume of normal saline will be infused at the same time over four hours.
3076900|NCT02048163||Prolonged infusion meropenem|Meropenem 20 mg/ml IV will be administered at a dose of 40 mg/kg (maximum 2,000 mg) every eight hours for 12 doses and will be infused over a four hour period. An equal volume of normal saline will be infused at the same time over 30 minutes.
3076901|NCT02048150|Experimental|Diagnostic (MDX1201-A488, IOOI, RALP)|Patients receive anti-PSMA monoclonal antibody MDX1201-A488 IV over 30 minutes on day 1 and undergo IOOI during RALP on day 3.
3076902|NCT02048137|Active Comparator|Active transcranial direct current stimulation|
3076903|NCT02048137|Sham Comparator|Sham transcranial direct current stimulation|
3076904|NCT02048124|Active Comparator|25g standard needle|"EUS-FNA passes will be performed without stylet. One needle pass is defined as 5 strokes in 4 different areas of the lesion. The material from the needle passes will be expressed into formalin to look for core samples. Material from the next needle passes will be expressed onto slides for cytological analysis. Ease of puncture will be scored qualitatively as poor (scored 1), good (scored 2) or excellent (scored 3)."
3076905|NCT02048124|Experimental|25d ProCor needle|"EUS-FNA passes will be performed without stylet. One needle pass is defined as 5 strokes in 4 different areas of the lesion. The material from the needle passes will be expressed into formalin to look for core samples. Material from the next needle passes will be expressed onto slides for cytological analysis. Ease of puncture will be scored qualitatively as poor (scored 1), good (scored 2) or excellent (scored 3)."
3076906|NCT02048111|Experimental|IB1001|
3076907|NCT02048098|Active Comparator|Buccal misoprostol|400 µg buccal misoprostol per 3 hours
3076908|NCT02048098|Active Comparator|vaginal misoprostol|400 µg vaginal misoprostol per 3 hours
3076909|NCT02048085|Experimental|Ticagrelor|Ticagrelor Arm will be dosed with a loading dose of 180 mg followed by maintenance dose of 90 mg BID until discharge or up to 8 days.
3076910|NCT02048085|Active Comparator|Clopidogrel|Clopidogrel arm will be dose with a loading dose of 300 mg followed by maintenance dose of 75 mg everyday until discharge or up to 8 days.
3076911|NCT02048072|Experimental|Gilenya|Autonomic testing during first dose adminstration of Gilenya.
3076912|NCT02048059|Experimental|ANG1005|
3076913|NCT02048046||ECMO|
3076914|NCT02048033|Active Comparator|Arm with Apollo Endosurgery OverStitch technical|
3076915|NCT02048033|Placebo Comparator|Arm without Apollo Endosurgery OverStitch technical|
3076916|NCT02048020|Experimental|Treatment (paclitaxel, carboplatin, IMRT)|"INDUCTION: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~CHEMORADIOTHERAPY: At least 2 weeks after completion of induction chemotherapy, patients receive paclitaxel IV over 1 hour weekly and undergo IMRT daily 5 days a week for 5.5 weeks in the absence of disease progression or unacceptable toxicity."
3076974|NCT02047617|Experimental|standing table group|The same program as standard physiotherapy group is applied, with daily sessions of standing table in supplement. Standing table was performed on a motorized tilt table (ref: table de verticalisation, Franco&fils). The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform, at 10° intervals from 30° to 80°.
3076917|NCT02048007|Active Comparator|Biannual mass oral azithromycin|"Comparison of childhood infectious and nutritional morbidity in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years~Morbidity monitoring:~Collect swabs (nasopharyngeal, nasal, conjunctival), blood samples, (thick/thin blood smears, hemoglobin, dried blood spots), and stool samples from 40 randomly selected children aged 1 month to 60 months per community; collect swabs (nasopharyngeal) from 40 randomly selected children aged 7-12 years per community.~Anthropometry for all children aged 1 to 60 months per community.~Collect nasopharyngeal swabs from all children aged 1-60 months who are seen at a local health clinic and have a respiratory complaint."
3076918|NCT02048007|Placebo Comparator|Biannual mass oral placebo|"Comparison of childhood infectious and nutritional morbidity in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years~Collect swabs (nasopharyngeal, nasal, conjunctival), blood samples, (thick/thin blood smears, hemoglobin, dried blood spots), and stool samples from 40 randomly selected children aged 1 month to 60 months per community; collect swabs (nasopharyngeal) from 40 randomly selected children aged 7-12 years per community~Anthropometry for all children aged 1 to 60 months per community~Collect nasopharyngeal swabs from all children aged 1-60 months who are seen at a local health clinic and have a respiratory complaint"
3076919|NCT02047994|Experimental|Group 1:Triple therapy|Among those assigned to Group 1, participants who are Helicobacter pylori positive will receive Triple therapy and/or upper endoscopy. Participants with serological evidence of atrophic gastritis will undergo upper endoscopy and further endoscopic follow-up. H. pylori positive individuals will be offered Helicobacter pylori eradication as appropriate, independently of the pepsinogen results. From subjects in this group, breath samples will also be collected for volatile markers study. In addition, fecal occult blood test (FOBT) will be offered to this group as a benefit to participate in the study.
3076920|NCT02047994|No Intervention|Group 2:No intervention|Those who assigned to Group 2 will receive no intervention and will be offered FOBT as a benefit of study participation. Any participants who show positive FOBT will be referred to colonoscopy. This will be the benefit to this group together with initial medical evaluation at the time of inclusion. During the follow-up period this group will be offered to consult a specialist when required due to clinical symptoms.
3076921|NCT02047981|Active Comparator|Biannual mass oral azithromycin|"Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years"
3076922|NCT02047981|Placebo Comparator|Biannual mass oral placebo|"Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years"
3076923|NCT02047968|Experimental|wake therapy, light therapy and sleep time stabilisation|Wake therapy/sleep deprivation: Patients are awake for 36 hours three times in one week with a normal night of sleep between. Light therapy for 30 minutes daily in the entire study period. Sleep time stabilisation which involves psychoeducation regarding sleep hygiene and keeping the day-night cycle constant.
3076924|NCT02047968|No Intervention|treatment as usual|
3076925|NCT02047942|Active Comparator|Center-based cardiac rehabilitation|Patients randomized to the center-based training group will continue their training sessions at the outpatient clinics of UZ Leuven under direct supervision of physical therapists
3076926|NCT02047942|Experimental|Home-based training with telemonitoring guidance|Patients will receive an patient-tailored exercise prescription and will be asked to perform the exercise sessions in their home environment wearing heart rate monitors. Training data will be accessed by the research group on weekly basis in order to keep a record of frequency; duration and intensity of the sessions. Feedback will be given weekly to every patient.
3076927|NCT02047942|No Intervention|Control|
3076928|NCT02047929|Active Comparator|Facilitator-Led Participant Owned (FLOW) Dissemination|This approach to dissemination allows clinics some freedom to tailor the SDM Toolkit and training process for their specific environment and patient population while maintaining fidelity of certain key elements that are felt to be essential for success. The expertise of the trained Practice Facilitator will help guide the process of implementation at the practice level.
3076929|NCT02047929|Active Comparator|Traditional Dissemination (Active Diffusion)|"The most commonly used dissemination technique is active diffusion, which includes didactic presentations, academic detailing, exposure to journal publications and subject matter experts, and educational material distribution. We have defined this type of dissemination, traditional dissemination. For the purpose of this study, practices randomized to traditional dissemination will receive a lunchtime presentation by a physician champion / subject matter expert on shared decision making. The presentation will gives an overview of the Asthma SDM Toolkit, access to the internet link with additional information, and a copy of all printed materials associated with the Toolkit."
3076930|NCT02047929|No Intervention|Control|A third group will be randomized into an arm with no formal dissemination. This arm will receive information only through passive exposure to the concepts of shared decision making. This would include introduction to the SDM concepts through the media, conferences, or social networks. Having this control in place will allow the research team to isolate the effect of both the FLOW approach and the traditional approach to dissemination.
3076931|NCT02047916||Normal Neonates > 33 weeks gestation|"Neonates >33 weeks gestational age~Postnatal age <72 hours;~Parental informed consent;~Inpatient at the Royal Sussex County Hospital (RCSH): either receiving special care on the Trevor Mann Baby Unit (TMBU) or normal care on the postnatal ward"
3076932|NCT02047903||Afatinib|
3076933|NCT02047890|Experimental|BAY1000394|Approximately 12 subjects will be included: 3 to 6 evaluable subjects for each cohort. The cycle length will be 3 weeks (21 days).
3076975|NCT02047604|Experimental|Cohort A - SAN-300 0.5 mg/kg|SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks or placebo.
3076976|NCT02047604|Experimental|Cohort B - SAN-300 1.0 mg/kg|SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks or placebo
3076977|NCT02047604|Experimental|Cohort C - SAN-300 2.0 mg/kg|SAN-300 2.0 mg/kg subcutaneous every other week for six weeks or placebo
3077020|NCT02047292|Active Comparator|THA36|THA Corail DeltaMotion36
3076934|NCT02047877||Respiratory Illness|Previously healthy patients admitted with acute respiratory illness who are then intubated requiring mechanical ventilator support. Endotracheally intubated patients of age 37 weeks gestation through 17 years with an acute respiratory illness in the absence of existing cardiopulmonary disease, tracheostomy, or immunocompromised condition. Tracheal aspirates (TA), bronchial fluid (nb-BALF), and blood are collected within 48-hours following endotracheal intubation. All three samples are collected again at two additional time points following intubation: between days 3-4 and between days 5-7, so long as the patient remains endotracheally intubated.
3076935|NCT02047864|Experimental|Creatine monohydrate|Creatine monohydrate to be given during a resistance training program
3076936|NCT02047864|Placebo Comparator|Sugar pill|Placebo to be given during a resistance training program
3076937|NCT02047851|Active Comparator|Acupuncture in active points|Patients in this group will receive real acupuncture
3076938|NCT02047851|Sham Comparator|Acupuncture in non-active points|Patients in this group will receive acupuncture, but in non-active points
3076939|NCT02047851|No Intervention|No treatment, just observation|Patients in this group will receive no treatment and will only be observed.
3076940|NCT02047838||Cases.|Patients with recurrent unilateral endometrioma who were previously operated for the same condition.
3076941|NCT02047838||Controls.|Patients previously operated for unilateral endometrioma without recurrence.
3076942|NCT02047825|Experimental|Experimental group|The patients included in this group will receive an intensive intervention based on upper limbs intervention with exercises added to the usual treatment they receive.
3076943|NCT02047825|Active Comparator|Control group|Patients with multiple sclerosis not included in the intensive intervention. They receive the usual treatment of occupational and physical therapy.
3076944|NCT02047812||High volume hospitals|The hospitals in the upper tertile for procedural volume
3076945|NCT02047812||Medium volume hospitals|The hospitals in the middle tertile for procedural volume
3076946|NCT02047812||Low volume hospitals|The hospitals in the lowest tertile for procedural volume.
3076947|NCT02047799|Active Comparator|Calcitriol|A daily dose of 1000 IU of cholecalciferol (administered as 1 capsule of 25 μg each)
3076948|NCT02047799|Placebo Comparator|Control|A daily dose of placebo (administered as 1 capsule )
3076949|NCT02047786||General Hospital Patients|Those patients undergoing appendicectomy in a general (non-specialised) surgical centre.
3076950|NCT02047786||Paediatric Hospital Patients|Those patients undergoing appendicectomy in specialised paediatric centres.
3076951|NCT02047773|Placebo Comparator|14 days Duration|14 days of antibiotics regardless of bacterial load.
3076952|NCT02047773|Active Comparator|Bacterial load guided duration|Antibiotics stopped early on day 8 or day 11 if the bacterial load when checked on day 7 and day 10 is less than 10^6cfu/ml.
3076953|NCT02047760||MS patients|All MS sub-types
3076954|NCT02047760||Controls|sex- and age-matched controls
3076955|NCT02047747|Experimental|dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
3076956|NCT02047734|Experimental|RPC1063 0.5 mg|RPC1063 0.5 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
3076957|NCT02047734|Experimental|RPC1063 1 mg|RPC1063 1 mg oral capsules daily and an intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
3076958|NCT02047734|Active Comparator|Interferon β (IFN)|IFN β-1a 30 µg intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to RPC 1063) orally daily for 24 months
3076959|NCT02047721|Experimental|Physical Intervention|A supervised exercise program
3076960|NCT02047721|Experimental|Nutritional Intervention|A supervised diet program
3076961|NCT02047695||Migraine with aura|Participants with migraine with aura (cases), their co-twins, and unrelated migraine-free twins (controls)
3076962|NCT02047682|Experimental|Biopsychosocial|Biopsychosocial intervention with Individually tailored physical exercises and stress management
3076963|NCT02047682|Active Comparator|Reference|"Reference group receiving usual care in terms of standard workplace ergonomics and physical exercises"
3076964|NCT02047669|Experimental|Biopsychosocial|Biopsychosocial intervention with Individually tailored physical exercises and stress management
3076965|NCT02047669|Active Comparator|Reference|"Reference group receiving usual care in terms of standard workplace ergonomics and physical exercises"
3076966|NCT02047656|Placebo Comparator|Placebo to LFF269 (Part 1)|Placebo to LFF269 twice daily (b.i.d) for 10 days in healthy volunteers
3076967|NCT02047656|Experimental|LFF269 (Part 1)|LFF269 twice daily (b.i.d) for 10 days in healthy volunteers
3076968|NCT02047656|Experimental|LFF269 (Part 2)|LFF269 twice daily (b.i.d) for 5 days in patients with hypertension
3076969|NCT02047643|Experimental|Algorithm ON|During the period of exercise, accelerometer and continuous glucose monitor (CGM) data will be communicated electronically in real-time to the University of Virginia Diabetes Assistant (DiAs), available on a secure Android-based cell phone. During the day in which the pump shutoff algorithm is in effect, if the computer algorithm senses impending risk for hypoglycemia, an alarm will sound to recommend a manual suspension of the subject's insulin pump by the on-site physician. The on-site physician will then decide whether or not to proceed with manual shutoff of the insulin pump at that time. If the pump is suspended, it will be manually re-started when advised by the computer algorithm, as long as the physician agrees.
3076970|NCT02047643|No Intervention|Algorithm OFF|When participating in this arm of the study, no intervention to subjects' usual insulin pump settings will be made during exercise (i.e. the insulin pump suspension algorithm will not be active).
3076971|NCT02047630|Experimental|Generic latanoprost|1 eye drop hs
3076972|NCT02047630|Active Comparator|Brand-name latanoprost|1 eye drop hs
3076973|NCT02047617|Active Comparator|the standard physiotherapy group|Physiotherapy rehabilitation techniques used in the management of this group include passive range of motion, active range of motion/bed exercises, sitting at edge of bed, sitting in armchair, active transfer from the bed to chair. Mobilization and rehabilitation program is progressively introduced after clinical stabilization with a goal of progressing to ambulation and pulmonary rehabilitation.
3076978|NCT02047604|Experimental|Cohort D - SAN-300 2.0 mg/kg|SAN-300 2.0 mg/kg subcutaneous once weekly for six weeks or placebo
3076983|NCT02047565|Experimental|Part 1 - 60mg edoxaban|Treatment A: single oral dose of 60 mg edoxaban (1 × 60 mg tablet)
3076984|NCT02047565|Experimental|Part 1 - 180mg edoxaban|Treatment B: single oral dose of 180 mg edoxaban (3 × 60 mg tablet)
3076985|NCT02047565|Experimental|Part 2 - 60mg edoxaban and 50 IU/kg Beriplex P/N|Dose cohort 1: 60 mg edoxaban + 50 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
3076986|NCT02047565|Experimental|Part 2 - 60mg edoxaban and 20 IU/kg Beriplex P/N|Dose cohort 2: 60 mg edoxaban + 25 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
3076987|NCT02047565|Experimental|Part 2 - 60mg edoxaban and 10 IU/kg Beriplex P/N|Dose cohort 3: 60 mg edoxaban + 10 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
3076988|NCT02047552|Active Comparator|Iron sucrose|Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT < 25%, (2) Serum iron concentration < 150 ug/mL, and (3) Serum ferritin concentration < 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
3076989|NCT02047552|Active Comparator|Oxandrolone|Oxandrolone 10 mg PO q12 hours will be dosed for seven days.
3076990|NCT02047552|Experimental|Iron sucrose + oxandrolone|Combination goal-directed iron sucrose (as described in the iron sucrose only arm) and oxandrolone (as described in the oxandrolone only arm) for seven days.
3076991|NCT02047552|Placebo Comparator|IV iron placebo and Oxandrolone placebo|100 mL normal saline in place of iron and similar color and size sugar pill for Oxandrolone placebo
3076992|NCT02047539|Experimental|1000 mg/day aspirin|1000 mg/day aspirin
3076993|NCT02047539|Placebo Comparator|sugar pill|sugar pill
3076994|NCT02047526||1|
3076995|NCT02047513|Experimental|perioperative nab-paclitaxel/gemcitabine|neoadjuvant chemotherapy (8 weeks) preceding surgery (3 weeks after completion of chemotherapy) followed by adjuvant chemotherapy (16 weeks, begin within 12 weeks after surgery)
3076996|NCT02047513|Experimental|adjuvant nab-paclitaxel/gemcitabine|Surgery followed by adjuvant chemotherapy (24 weeks, begin within 12 weeks after surgery), follow-up per patient: Until end of study or death
3076997|NCT02047500|Experimental|TH-302 plus Nab-paclitaxel plus Gemcitabine|
3076998|NCT02047474|Experimental|Treatment (mFOLFIRINOX)|"NEOADJUVANT THERAPY: Patients receive mFOLFIRINOX comprising oxaliplatin IV over 2 hours, levoleucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously for 46 hours on day 1. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Beginning 3-8 weeks after completion of neoadjuvant therapy patients undergo surgical resection.~ADJUVANT THERARPY: Beginning within 12 weeks after surgery, patients receive mFOLFIRINOX as in neoadjuvant therapy. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3076999|NCT02047461|Experimental|ALXN1101|daily IV infusions
3077000|NCT02047448|No Intervention|Control Group|The control group will receive the current standard of care including medication reconciliation during hospitalization performed by a nurse or physician and education about discharge medications provided by the inpatient nurse. There will not be a pharmacist discharge care plan developed for this group. The patients will not be required to choose a participating community pharmacist and no counseling and education appointments will be scheduled. Any medication-related problems identified by the pharmacists and will be communicated as appropriate and resolved as is the standard of care. Any other interaction between the patient and their pharmacist will be according to the current standard of care.
3077001|NCT02047448|Experimental|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
3077002|NCT02047435|Experimental|Information, event and workshops at a cartoon museum|
3077003|NCT02047435|Active Comparator|Information and event at a cartoon museum|
3077004|NCT02047422|Experimental|Add furosemide/no spironolactone|
3077005|NCT02047422|Experimental|Add metolazone/no spironolactone|
3077006|NCT02047422|Experimental|Add furosemid/spironolactone|
3077007|NCT02047422|Experimental|Add metolazone/spironolactone|
3077008|NCT02047396||Myocardial Infarction subjects|Subjects with first Myocardial Infarction presenting to one of the Mayo Clinic Hospitals in Rochester, Minnesota.
3077009|NCT02047383||respiratory infection|Hospitalized patients with a respiratory infection
3077010|NCT02047370|Experimental|Diaphragm stretching|30 Patients with asthma are included in this group. They will receive a diaphragm stretching technique
3077011|NCT02047370|Placebo Comparator|Placebo group|Ultrasound disconnected in same position and with the same duration.
3077012|NCT02047357|Experimental|Intervention Arm|Learning Through Play Plus
3077013|NCT02047357|No Intervention|Control|This arm will receive no intervention
3077014|NCT02047344|Experimental|Antroquinonol (Hocena)|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
3077015|NCT02047331|Active Comparator|group PI|group PI were performed periarticular drug injection during surgery.
3077016|NCT02047331|Active Comparator|group FI|group FI were performed fascia iliaca block before surgery
3077017|NCT02047318|Experimental|LUM001|LUM001 administered orally once each day
3077018|NCT02047305|Experimental|Radiofrequency ablation|To study the safety and effectiveness of radiofrequency ablation (RFA) using the HALO ablation system in completely eradicating the diseased epithelium in patients with ESCN
3077019|NCT02047292|Active Comparator|THA28|THA Corail PinnacleCoC28
3077022|NCT02047279|Active Comparator|MVS + maze|"Procedure: Maze procedure, mitral valve surgery~The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp.~The left atrial appendage was excluded in all cases. For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed."
3077023|NCT02047279|Experimental|MVS + maze + LA reduction|"Procedure: maze procedure, mitral valve surgery, left atrial reduction~The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp.~The left atrial appendage was excluded in all cases. For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.~The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape."
3077024|NCT02047266|Experimental|MICS CABG|"Minimally invasive cardiac surgery coronary artery bypass grafting (complete multivessel minimally invasive off-pump revascularization via left minithoracotomy), which is performed with a help of Octopus® Nuvo, Starfish® Non-Sternotomy, ThoraTrak®, Starfish®, Octopus®, Clearview® blower, ClearView® Shunt.~(MICS CABG group, n=50)"
3077025|NCT02047266|Active Comparator|OPCABG|"Off-pump coronary artery bypass grafting treatment which is performed with a help of Starfish®, Octopus®, Clearview® blower, ClearView® Shunt.~(OPCABG group, n=50)"
3077026|NCT02047266|Active Comparator|ONCABG|On-pump coronary artery bypass grafting treatment (ONCABG group, n=50)
3077027|NCT02047253|Experimental|Carfilzomib|Carfilzomib is administered twice-weekly on consecutive days (days 1, 2, 8, 9, 15, 16) as a 30-minute intravenous infusion for 3 weeks every 4 weeks (1 cycle) with dexamethasone given as pre-medication. The dose of carfilzomib is 20 mg/m2 on days 1 and 2 of cycle 1 and is then escalated in succeeding weeks and cycles to 56 mg/m2 if no dose limiting toxicities occur. Acyclovir is given orally at 400 mg twice daily during therapy but may be discontinued at some point. Therapy will continue until side effects become unacceptable, the disease progresses, or the doctor withdraws the patient.
3077028|NCT02047227|Experimental|Pergoveris®|
3077029|NCT02047227|Active Comparator|GONAL-f®|
3077030|NCT02047214|Experimental|TPI 287 + bevacizumab|All subjects will be administered TPI 287 as an IV infusion (1-hour target duration) once every 3 weeks (Days 1 and 22) and bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29) of a 42-day cycle. The dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6 subjects, while the dose of bevacizumab remains constant (10 mg/kg). The planned dose escalation levels are 140, 160, 170, and 180 mg/m2; subsequent dose levels will be increased in increments of 10 mg/m2. If dose de-escalation below the starting dose level of 140 mg/m2 is required, dose levels of 130 and 120 mg/m2 will be used. Once the MTD is identified, 6 additional subjects will be enrolled at the MTD to better characterize the toxicity profile at this level. Subjects may continue on treatment unless they meet one or more of the discontinuation criteria outlined in the protocol.
3077031|NCT02047201|Experimental|Experimental|Induction chemotherapy (Docetaxel, Cisplatin and Fluorouracil) following radiochemotherapy (IMRT using PET/CT images after IC for treatment planning + cisplatin iv 40 mg/m2 weekly).
3077032|NCT02047175|Experimental|A(Telmisartan/S-Amlodipine)|"A(Telmisartan/S-Amlodipine)~: Telmisartan/S-Amlodipine 40/2.5mg 2T for 9days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 5days"
3077033|NCT02047175|Experimental|B(Rosuvastatin)|"B(Rosuvastatin)~: Rosuvastatin 20mg 1T for 5days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 9days"
3077034|NCT02047162|Experimental|Bismuth subsalicylate|Bismuth subsalicylate, 262 mg/chewable tablet, 2 tablets every hour as needed up to 16 tablets per 24 hours, for up to 48 hours.
3077035|NCT02047162|Placebo Comparator|Placebo|Placebo chewable tablets, 2 every hour as needed up to 16 tablets per 24 h, for up to 48 h.
3077036|NCT02047149|Experimental|Zileuton/Dasatinib|zileuton/dasatinib: This is a traditional phase I design. Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
3077037|NCT02047136|Experimental|Treatment group (on low histamine diet)|78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
3077038|NCT02047136|Active Comparator|Well-balanced diet|Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
3077039|NCT02047123|Experimental|Raw Flaxseed|For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of raw flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.The energy intake of the designed diet was similar into the three groups (ranging 1900-2000 Kcal per day).
3077040|NCT02047110|Placebo Comparator|Arm 4|s.c. injections placebo
3077041|NCT02047110|Experimental|Arm 1|BI 655066 s.c.
3077042|NCT02047110|Experimental|Arm 2|BI 655066 s.c.
3077043|NCT02047110|Experimental|Arm 3|BI 655066 s.c.
3077044|NCT02047097||dimethyl fumarate (DMF)|Patients with multiple sclerosis receiving dimethyl fumarate (DMF) under routine clinical care
3077045|NCT02047084||Theraskin, Apligraf|Theraskin used every other week x 4 Apligraf used weekly x 8
3077046|NCT02047084||Venous leg ulcers|Theraskin and Apligraft
3077047|NCT02047071|No Intervention|Standard Care|Conservative treatment. This group will be receive standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
3077048|NCT02047071|Experimental|Continuous positive airways pressure|Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
3077049|NCT02047058||high-risk|high-risk is determined by the evaluation of the biomarkers of Q cell.
3077164|NCT02046252|Active Comparator|ON Oral Naltrexone|ON (oral) naltrexone maintenance 48 weeks plus psychotherapy N=100
3077050|NCT02047045|Experimental|Electro-acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 min, 5 times/week for the first 2 weeks, and 3 times/week for the next 6 weeks.
3077051|NCT02047045|Active Comparator|Prucalopride|Prucalopride Succinate taken orally, 2mg/day in the morning before breakfast
3077052|NCT02047032|Experimental|acupuncture|BL33 and BL35 of both sides are used. Every session will last for 30 minuets and will be given every other day. There are 36 sessions for each participant in all (3 session per week, 12 weeks).
3077053|NCT02047032|Active Comparator|Solifenacin plus PFMT|Both PFMT and solifenacin will be given for 36 weeks. Solifenacin will be taken 5mg once daily, before or after meal. PFMT includes intensive exercises conducted in hospital and home exercises. Intensive exercises will be done once every week for the first 12 weeks and once every four weeks for the 13th to 36th week. Home exercises will be done three times daily for 36 weeks.
3077054|NCT02047019|Active Comparator|Candesartan|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan 16 mg, Placebo combination A, Placebo combination B)
3077055|NCT02047019|Experimental|Nifedipine/Candesartan-30/16|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan placebo, Placebo combination A, Combination nifedipine / candesartan 30/16 mg)
3077056|NCT02047019|Experimental|Nifedipine/Candesartan-60/16|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan placebo, Placebo combination B, Combination nifedipine / candesartan 60/16 mg)
3077057|NCT02047006|Experimental|Rivaroxaban 10 mg|"Measurement of AUC of rivaroxaban and effect on coagulation assays:~Rivaroxaban is given as a single oral dose of 10 mg immediately after three subsequent dialysis sessions. Patients remain in the hospital from the intake of the first dose until 48 hours after the intake of the third dose.~Effect of dialysis on levels of rivaroxaban:~Rivaroxaban is given as a single oral dose of 10 mg in the morning when dialysis is scheduled in the afternoon, or the previous evening when dialysis is scheduled in the morning. The interval between the two doses was at least 48 hours. Dialysis is scheduled 6 to 8 hours after the intake of rivaroxaban."
3077058|NCT02046993|Experimental|Smart phone based telemonitoring of HBP|". Patients do HBP monitoring~. record their BP readings into the smart phone with downloaded application."
3077059|NCT02046993|Active Comparator|Enhanced usual care|". Patients to do HBP measurement~. Record BP readings in their diary"
3077060|NCT02046980|Experimental|Gufoni|Gufoni maneuver for apogeotropic horizontal BPPV at the first day
3077061|NCT02046980|Experimental|Vibration|Vibration maneuver for apogeotropic horizontal BPPV at the first day
3077062|NCT02046980|Sham Comparator|Sham|Sham maneuver for apogeotropic horizontal BPPV at the first day
3077063|NCT02046967|Active Comparator|Endovenous laser ablation|Endovenous laser ablation with 940 nm bare fiber.
3077064|NCT02046967|Active Comparator|Endovenous steam ablation|Endovenous steam ablation with steam vein sclerosis system.
3077065|NCT02046954||Study group|Patients monitored with hemodynamically focussed transesophageal echocardiography (placement within 12 hours of ICU admission)
3077066|NCT02046954||Control Group|Patients receiving conventional monitoring (e.g. transpulmonary thermodilution)
3077067|NCT02046941|Experimental|Speech Production Treatment|This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction. The investigators chose this treatment for the following reasons: 1) rigor of development demonstrated across multiple studies, 2) large and predictable effects with published, quantified effect sizes, 3) a demonstrated pattern of generalization to untrained items, illustrating experimental control, 4) an established multi-modal stimulation protocol, and 5) use of repeated practice, which is associated with neural plasticity.
3077068|NCT02046928|Experimental|A6|A6 is administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
3077069|NCT02046915|Experimental|Pomalidomide, Dexamethasone, Cyclophosphamide|"Pomalidomide administered orally at the starting dose of 4 mg/day on Days 1-21 of a 28-day cycle~Low-dose Dexamethasone administered orally at the starting dose of 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle~Cyclophosphamide administered intravenously 500 mg/m² on Days 1 and 15 of a 28-day cycle"
3077070|NCT02046902||Heart disease|Adults with a diagnosis of coronary artery disease and may have had a percutaneous coronary intervention.
3077071|NCT02046902||Healthy adults|Adults without a diagnosis of coronary artery disease. Focus groups will be held.
3077072|NCT02046889|Experimental|Intervention group|The intervention group or experimental group will receive the bicycle training intervention during the first year of the study. The intervention is a 5 day/75 minutes per day bicycle training intervention which used specialized instruction and adapted equipment to teach independent bicycle riding skills to youth aged 9-18 years with autism spectrum disorder and Down syndrome.
3077073|NCT02046889|No Intervention|Control group|The control group will not receive the intervention during the first year of the study. Instead, this group will receive a delayed intervention during the second year of the study, after pre-post effects have been evaluated.
3077074|NCT02046876|Experimental|Multimodal Physiotherapy Program for Chronic Neck Pain Suffers|
3077075|NCT02046863|Experimental|Automated Programming|Subjects will have DBS settings changed as guided by prototype DBS-Expert software. Tremor, bradykinesia, and dyskinesia will be assessed at each DBS setting.
3077076|NCT02046850|Experimental|selumetinib 75mg.|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule
3077077|NCT02046850|Other|rifampicin 600mg.|Volunteers will receive rifampicin 600mg administered by mouth, as a capsule
3077078|NCT02046850|Experimental|selumetinib 75mg and rifampicin 600mg|Volunteers will receive selumetinib 75mg and rifampicin 600mg, by mouth, as a capsule
3077079|NCT02046837|Experimental|Supervised 1:1 exercise|This intervention arm will include 3 one-on-one, supervised sessions per week for 6 months with a certified exercise specialist. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
3077162|NCT02046265|Active Comparator|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
3077080|NCT02046837|Experimental|Supervised group exercise|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
3077081|NCT02046837|Experimental|Home-based exercise|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as supervised groups). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
3077082|NCT02046824|Experimental|Xtra®, Sorin cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the Xtra Sorin cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
3077083|NCT02046824|Experimental|C.A.T.S.®, Fresenius cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the C.A.T.S. cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
3077084|NCT02046824|Experimental|CardioPAT®, Haemonetics, cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the CardioPAT cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
3077085|NCT02046824|Other|no use of cell saver|When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
3077086|NCT02046811|Experimental|Patient activation and education|Patient activation and education (PAE)
3077087|NCT02046811|Experimental|PAE plus physician activation|PAE plus physician activation (PAE + MD)
3077088|NCT02046811|Experimental|PAE, MD, plus teledermoscopy|PAE physician activation, plus teledermoscopy (PAE +MD +TD)
3077089|NCT02046798|Experimental|14C labeled ASP3652|
3077090|NCT02046785|Other|0.9% saline solution|comparing values obtained before and after administration of 500 ml of 0.9% saline
3077091|NCT02046772|Experimental|Bupivacaine + Morphine Chloride|People in this arm will receive treatment with morphine chloride in addition to a low dose solution of the local intradural anaesthetic bupivacaine.
3077092|NCT02046772|Active Comparator|Bupivacaine standard dose|People in this arm will receive treatment with the standard dose of the local intradural anaesthetic bupivacaine
3077093|NCT02046759|Experimental|Pharmacist-Intervention|
3077094|NCT02046759|Active Comparator|Routine Care|
3077095|NCT02046746|Experimental|Oral Nutritional Supplement (ONS)|1-2 serving per day of a renal specific oral nutritional supplement
3077096|NCT02046733|Experimental|Nivolumab + Ipilimumab|"- Induction: Nivolumab at a dose of 1 mg/kg i.v. followed (on the same day) by Ipilimumab at a dose of 3 mg/kg i.v. once every 3 weeks, 4 cycles~- Maintenance: Nivolumab 240 mg i.v. once every 2 weeks, for a maximum of 12 months from start of maintenance"
3077097|NCT02046733|No Intervention|Observation|no further treatment; tumour assessment, follow-up documentation and collection of biological material will be done according to the same schedule as Arm 1.
3077098|NCT02046720|Experimental|propofol induced sedation|Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.
3077099|NCT02046707|Experimental|Patients with chronic heart failure|
3077100|NCT02046707|Other|Controls|
3077101|NCT02046694|Experimental|Allopurinol|Patients will stop taking their 6-MP and methotrexate at week 0. One week later (week 1), patients will begin allopurinol daily (100 mg for weight >30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks). Dose adjustments of 6-MP and methotrexate will be directed by the guidelines outlined in the study protocol.
3077102|NCT02046681||Acetam, acetam + codeine, Ibuprofen, Oxycodone|monitoring side effects of pain medication prescribed in patients over 65 acetaminophen 1000 mg tabs po q6h acetaminophen + codeine 500 mg tabs po q6h ibuprofen 200 mg tabs po q8h oxycodone 5 mg tabs po bid
3077103|NCT02046668|Active Comparator|spironolactone|25mg spironolactone daily
3077104|NCT02046668|Placebo Comparator|Placebo|Matched Placebo
3077105|NCT02046655|Experimental|Corifollitropin alfa group|"On day 2 of the cycle, a single subcutaneous (SC) dose of 150 μg Corifollitropin alfa (Elonva) will be administered.~GnRH antagonist (Orgalutran) 0.25 mg/day flexible initiation by a follicle of 14mm.~A daily dose of recFSH (450 IU/day) will be used from day 8 of stimulation until the day of hCG, if necessary.~Triggering of final oocyte maturation will be performed using 250 μg of rechCG."
3077106|NCT02046655|Active Comparator|rec FSH group|"On day 2 of the cycle, daily SC dose of min 450 IU recFSH (Puregon) will be administered.~GnRH antagonist (Orgalutran) 0.25 mg/day , flexible initiation by a follicle of 14mm.~Triggering of final oocyte maturation will be performed using 250 μg of rechCG."
3077107|NCT02046642|Active Comparator|Maternal rest in left lateral position|"women in maternal rest in left lateral position group rested in the left lateral position for 15 minutes and then rested in the right lateral position for another 15 minutes."
3077163|NCT02046252|Active Comparator|Naltrexone Implant + ART|Naltrexone implant maintenance 48 weeks plus psychotherapy N=100
3077108|NCT02046642|Active Comparator|Maternal rest in right lateral position|"Women in maternal rest in right lateral position group started resting in the right lateral position for 15 minutes and then rested in the left lateral position for another 15 minutes."
3077109|NCT02046629|Experimental|teriflunomide dose 1|Teriflunomide 14mg tablet, oral single dose, fast condition Cholestyramine power, 8 gram,oral three times a day for 4 days, fed condition
3077110|NCT02046616|Experimental|Tocilizumab Alone or Combined with Methotrexate or Other DMARD|All participants will receive tocilizumab as a single fixed dose (monotherapy) or in combination with methotrexate or other non-biologic DMARDs, irrespective of body weight, for 24 weeks.
3077111|NCT02046603|Experimental|RoActemra/Actemra|
3077112|NCT02046590|Active Comparator|Deep Sedation|"Remifentanil 1ng/ml throughout the procedure. Propofol administration starts at an initial (estimated plasma) target concentration of 1,5 microg/ml.~Propofol administration is adjusted to level 1 or 2 on the modified observer's assessment of alertness/sedation scale. The propofol infusion will be increased stepwise by 0,5 microg/ml every 1 minute until loss of consciousness. Propofol is continued while maintaining spontaneous ventilation without assistance and systolic blood pressure ≥ 60 % of baseline systolic blood pressure."
3077113|NCT02046590|Active Comparator|General Anaesthesia|"General anesthesia will be induced with target controlled infusion (TCI) of propofol and remifentanil as in the group deep sedation.~Suxamethonium (succinylcholine) will be used to facilitate intubation. Endotracheal tube balloon pressure will be controlled during the procedure. Ventilation will be assisted using 40% oxygen in air mixture and mechanically controlled using an anaesthetic ventilator."
3077114|NCT02046577|Experimental|5600 IU Vitamin D3|Oral 5600 IU Vitamin D3 in liquid weekly during 6 months
3077115|NCT02046577|Experimental|Oral 11200 IU Vitamin D3 weekly|Oral 11200 IU Vitamin D3 in liquid weekly during 6 months
3077116|NCT02046577|Placebo Comparator|Placebo|Oral placebo in liquid weekly during 6 months
3077117|NCT02046564|Experimental|ASC-01|The dose of 3-12mg/100mg(Aripiprazole/Sertraline Combination)will be orally administered once daily
3077118|NCT02046564|Placebo Comparator|Placebo|The dose of 0mg/100mg (Placebo/Sertraline Combination ）will be orally administered once daily
3077119|NCT02046551|Placebo Comparator|Placebo|placebo
3077120|NCT02046551|Experimental|Atomoxetine|atomoxetine (40 mg/day)
3077121|NCT02046538|Experimental|Postoperative Chemo WITH Zaltrap|"Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer). Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.~Following resection, patients will receive chemotherapy with zaltrap for 3 additional months. Patients may continue zaltrap (without chemotherapy) until disease recurrence or up to an additional 15 months."
3077122|NCT02046538|Active Comparator|Postoperative chemo WITHOUT zaltrap|"Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer). Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.~Following resection, patients will receive chemotherapy (without zaltrap) for 3 additional months."
3077123|NCT02046525|Experimental|Auto fecal microbitoa therapy|autologous fecal microbiota therapy
3077124|NCT02046525|Placebo Comparator|Saline enema|Saline enema
3077125|NCT02046512|Experimental|Probiotic|Patients randomized to probiotic therapy will receive 1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
3077126|NCT02046512|Placebo Comparator|Sugar Pill|Patients randomized to placebo therapy will receive an identical appearing placebo capsule on a twice-daily basis
3077127|NCT02046499|Active Comparator|Oxytocin arm|Oxytocin alone administered which is current standard of care
3077128|NCT02046499|Experimental|Oxytocin + syntometrine|Oxytocin plus syntometrine administered
3077129|NCT02046486|Active Comparator|Ticagrelor 180mg whole tablets|Ticagrelor 180mg loading dose, in the form of 2 whole tablets administered per os in the supine position (standard administration)
3077130|NCT02046486|Experimental|Ticagrelor 180mg crushed and dispersed|Ticagrelor 180mg in the form of 2 tablets crushed and dispersed in purified water administered per os with 1-minute-stay in a 60-70 degrees semi-upright sitting position
3077131|NCT02046473|Other|Volumetric Flow in TIPS|Subjects who have TIPS (transjugular intrahepatic porto-systemic shunts) have measurements taken to determine if someone has increased blood pressure in the portal vein of the liver (portal hypertension). Subjects who have a TIPS receive clinical ultrasounds every 3 months to determine if the TIPS is working properly.
3077132|NCT02046460|Active Comparator|antithrombotic treatment|acetylsalicylic acid, 300mg o.p.d.
3077133|NCT02046460|Experimental|oral anticoagulation|vitamin K-antagonist, dosage according to INR 2.0-3.0
3077134|NCT02046447||Primary Cervical Dystonia (Trihexyphenidyl)|"These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.~After the above baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional fMRI scan. The subjects will be done with the study after the second MRI scan has been completed."
3077135|NCT02046447||DYT 1 Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
3077136|NCT02046447||Primary Cervical Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
3077137|NCT02046447||DYT 1 Dystonia|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed; and 6) Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) to assess dystonia severity.
3077138|NCT02046434|Experimental|Parkinson's Diesase|Participant will take Glycerol Phenylbutyrate, participant has Parkinson's Disease
3077139|NCT02046434|Experimental|Control|Participant does not have Parkinson's Disease, Participant will be taking glycerol phenylbutyrate
3077140|NCT02046421|Experimental|Treatment (mifepristone, carboplatin, gemcitabine)|Patients receive mifepristone PO QD on days 0, 1, 7, and 8, and carboplatin IV over 30 minutes and gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3077141|NCT02046408|Experimental|Tablet Intervention|Primary care providers will be randomized into intervention or control conditions. The patients of intervention providers will be given a computer tablet that provides 5A's for smoking cessation counseling. Patients of control providers will not receive a tablet intervention.
3077142|NCT02046408|No Intervention|Control|Primary care providers will be randomized into intervention or control conditions. The patients of intervention providers will be given a computer tablet that provides 5A's for smoking cessation counseling. Patients of control providers will not receive a tablet intervention.
3077143|NCT02046395|Other|Washout Period for 30 days|In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure. The goal for their blood pressure will be set at < 140/90 mm/Hg. The washout period will last for four weeks at the end of which the patient will enter the test period.
3077144|NCT02046382|Experimental|IV Acetaminophen|Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
3077145|NCT02046382|Placebo Comparator|Normal Saline|Subjects will receive a 100mL dose of saline every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
3077146|NCT02046369|Experimental|Luradisone|Luradisone 20- 80 mg administered once daily
3077147|NCT02046369|Placebo Comparator|Placebo|Placebo administered once daily
3077148|NCT02046356||non-recurrence of Early-Stage HCC|those without recurrence of Early-Stage hepatocellular carcinoma after RFA in two years
3077149|NCT02046356||recurrence of Early-Stage HCC|those with recurrence of Early-Stage hepatocellular carcinoma after RFA in two years
3077150|NCT02046343|Experimental|Physical Activity|Weekly promotora-led group sessions on physical activity (16 weeks) and followed by monthly telephone counseling and newsletters during the 24 week maintenance period. Promotoras will also implement environmental change strategies to increase the number of PA program offerings available to study participants.
3077151|NCT02046343|Placebo Comparator|Community Health and Safety|Weekly promotora-led group sessions on home safety/first aid (16 weeks) followed by and monthly generic health education materials and informational telephone calls during the 24 week maintenance period.
3077152|NCT02046330|Experimental|Deep Brain Stimulation|Device implantation (Deep Brain Stimulation Model 3387 Model 3389)
3077153|NCT02046317|Experimental|Echogenic needle|The experimental arm will receive femoral nerve block using echogenic needles
3077154|NCT02046317|Active Comparator|Standard of care needle|The control group will receive femoral nerve block using standard of care needles
3077155|NCT02046304|Experimental|Gemcitabine + Radiation Therapy|Patients receive concurrent chemoradiation (days 1 - 33) consisting of external beam radiotherapy (EBRT) plus gemcitabine, administered in a phase I dose escalation format until MTD is reached. EBRT delivered preoperatively (for patients with measurable disease) or postoperatively (for patients who have undergone pre-referral excisional biopsy) to a dose of 50 Gy in 25 fractions at 2.0 Gy per fraction. Radiotherapy given once daily (Monday through Friday) for 5 weeks. Surgical resection of the post-treatment tumor mass performed 4 to 8 weeks after the final dose of gemcitabine. Gemcitabine administered intravenously (IV) on days 1, 8, 22, 29, 43, and 50, concurrently with radiotherapy. Starting dose of gemcitabine 400 mg/m2 by vein once a week.
3077156|NCT02046291|Experimental|Romiplostim treatment|Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks (i.e. 6 doses) unless platelet count exceeds 100 x 10^9/L and at least 4 doses of therapy were given.After the initial dose, subsequent doses will be administered within a window of +/- 3 days.
3077157|NCT02046278|No Intervention|Control arm - Standard of Care|The anastomosis will be created using Standard of Care only
3077158|NCT02046278|Experimental|Device arm - Standard of Care + LifeSeal™ Kit|The anastomosis will be created using SOC + LifeSeal™ Kit
3077159|NCT02046265|Experimental|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
3077160|NCT02046265|Experimental|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
3077161|NCT02046265|Experimental|Step up to Prevention|Participant receives both the knowledge session and the tailored belief sessions and the participant is offered the HPV vaccine only by their nurse practitioner in clinic. This combined intervention is call Step Up to Prevention.
3077165|NCT02046239|Other|Staple Group|Staple Group: At the end of the operation, the skin will be closed using stainless steel staples, which is standard clinical practice at St. James's University Hospital. Approximately ten days after the operation, the staples will be manually removed; this is normally performed by the patients GP.
3077166|NCT02046239|Experimental|Suture Group|Suture Group: At the end of the operation, the skin will be closed using absorbable surgical suture. Manual removal of this suture is not required because the thread is self-absorbable.
3077167|NCT02046226|Experimental|OxyGenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
3077168|NCT02046226|No Intervention|Standard Wound Care|Standard wound care using gauze dressings per institutional standard of care.
3077169|NCT02046213|Experimental|E2006|Single oral 10mg dose of 100 uCi [14C]E2006
3077170|NCT02046200|Experimental|Ivermectin|Ivermectin 30 mg single dose
3077171|NCT02046200|Placebo Comparator|Sugar pill|Matched placebo, single dose
3077172|NCT02046187|Experimental|Ketogenic Diet|Subjects will adhere to a ketogenic diet prior to the start of and through radiation therapy course until the time of first scan after radiation ends. During radiation course, patients also take temozolomide daily.
3077173|NCT02046174|Experimental|Macrobead Implantation Arm|patients who will undergo up to 4 implantations of RENCA macrobeads, at an amount of 8 RENCA macrobeads /kg body weight
3077174|NCT02046174|No Intervention|Best Supportive Care Arm|patients who will receive, or are receiving, best supportive care, defined as management of symptoms aimed at maintaining or improving quality of life, but not including approved therapies targeting the patient's malignancy
3077175|NCT02046161|Experimental|colon cleansing room group|All patients in colon cleansing room group drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
3077176|NCT02046161|Placebo Comparator|standard colon preparation group|All patients in the standard colon preparation groupinitiate the standard colon preparation with PEG-ELS made from two sachets of PEG (Klean-PrepTM, Norgine Ltd. Harefield, Middlesex, United Kingdom) dissolved in 2 L of water at 8:00 AM on the day of colonoscopy.
3077177|NCT02046148|Experimental|GBS Group|Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Group B Streptococcus (GBS) trivalent vaccine, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).
3077178|NCT02046148|Active Comparator|Placebo Group|Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Placebo, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).
3077179|NCT02046135|Experimental|Sodium bicarbonate|At the start of the surgery, the patient will receive NaHCO3 as a continuous infusion of D5% 1/3NS + 100 meq/L NaHCO3 + 20 meq/L KCl at maintenance IVF (solution contains ~154 meq of sodium which is equivalent to normal saline). The NaHCO3 infusion will continue for the first 24 hours after the discontinuation of CPB. After 24 hours of receiving the NaHCO3 infusion, the IVF administered to the patient will be the standard solutions used in the PICU at CCMC.
3077180|NCT02046135|Active Comparator|Sodium Chloride|At the start of surgery, patients in the control arm will receive D5% Normal Saline + 20 meq/L KCl at maintenance IVF. After 24 hours, standard IVF, not containing NaHCO3 or Na acetate will be administered for the duration of the PICU stay as required, determined by the clinicians primarily caring for the patient postoperatively.
3077181|NCT02046122|Experimental|Idarubicin + Cytarabine + DLI|Chemotherapy combined with adoptive transfer of HLA-haploidentical donor lymphocyte infusion (DLI)
3077182|NCT02046109|Experimental|Repair|Subjects in the Repair group will be given a local anesthetic only if required (i.e. for restorations extending gingivally or on exposed dentin surface) as per usual clinical protocol. The existing restoration will not be removed. The surface of the existing restoration will be roughened with a Brasseler 8856 bur without extending to the surrounding enamel (except is the defect being repaired is adjacent to enamel). No accessory groves/pits for retention will be prepared. To repair the restoration, the surface will be etched using 35% phosphoric acid, and then 3M ESPE Scotchbond Universal Adhesive System followed by 3M ESPE Filtek Supreme Ultra Universal Restorative composite will be used as per the manufacturer's instructions.
3077183|NCT02046109|Active Comparator|Replace|Subjects in the Replace group will be given local anesthetic (an injection of 2% lidocaine with 1:100 000 epinephrine). The type of injection and dosage of anesthetics will be dependent on the tooth being treated, and will follow the usual protocol used in the Dalhousie Dentistry undergraduate clinics. The existing composite restoration will then be removed and the peripheral enamel beveled if not already beveled. To restore the tooth, the surface will be etched using 35% phosphoric acid, and then 3M ESPE Scotchbond Universal Adhesive System followed by 3M ESPE Filtek Supreme Ultra Universal Restorative composite will be used as per the manufacturer's instructions.
3077184|NCT02046096|Experimental|Günther Tulip® Vena Cava Filter|Günther Tulip® Vena Cava Filter
3077185|NCT02046096|Experimental|Cook Celect® Vena Cava Filter|Cook Celect® Vena Cava Filter
3077186|NCT02046083|Experimental|treatment|Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance
3077187|NCT02046083|Placebo Comparator|placebo|Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance
3077188|NCT02046070|Experimental|Ixazomib (MLN9708) + 300mg/m^2 Cyclophosphamide_ NDMM|Ixazomib (MLN9708) 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until progressive disease (PD)/death or unacceptable toxicity [13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months] and cyclophosphamide 300 mg/m^2, tablets, orally, Days 1, 8 and 15 of a 28-day cycle for 13 cycles or PD/death or unacceptable toxicity and dexamethasone 40 mg, tablets, orally, Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle for 13 cycles or PD/death or unacceptable toxicity in participants with NDMM.
3077217|NCT02045927|Other|Control Group|sedation monitoring with RASS score
3077218|NCT02045914|No Intervention|control group|the patients who have no intervention with calcium ionophore during ICSI cycle
3077219|NCT02045914|Experimental|calcium ionophore|the patients whose oocytes are incubated with calcium ionophore solution during ICSI cycle
3077189|NCT02046070|Experimental|Ixazomib (MLN9708) + 400 mg/m^2 Cyclophosphamide_NDMM|Ixazomib (MLN9708) 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until progressive disease (PD)/death or unacceptable toxicity [13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months] and cyclophosphamide 400 mg/m^2, tablets, orally, Days 1, 8 and 15 of a 28-day cycle for 13 cycles or PD/death or unacceptable toxicity and dexamethasone 40 mg, tablets, orally, Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle for 13 cycles or PD/death or unacceptable toxicity in participants with NDMM.
3077190|NCT02046070|Experimental|Ixazomib (MLN9708) + 300 mg/m^2 Cyclophosphamide_RRMM|Ixazomib (MLN9708) 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle and cyclophosphamide 300 mg/m^2, tablets, orally, Days 1, 8 and 15 of a 28-day cycle and dexamethasone 40 mg, tablets, orally, Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle until PD/death or unacceptable toxicity in participants with RRMM.
3077191|NCT02046057|Experimental|PNB of SLN|Percutaneous core biopsy of sentinel node prior to standard sentinel node dissection
3077192|NCT02046044|Experimental|Ivabradine|Ivabradine: initial dose of 5 mg b.id. dose up-titration to 7,5 mg b.id. in 2 weeks due to the heart rate and maintaining the last dose during 6 months.
3077193|NCT02046044|Experimental|Digoxin|Digoxin: Digoxin 0,25 mg once a day 5 days per week during 6 months.
3077194|NCT02046031|Experimental|Ginkgolides Meglumine Injection|Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using Ginkgolides Meglumine Injection, dripping speed should be controlled for 10 ~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.
3077195|NCT02046018|Active Comparator|ICCM delivered by VHT|Health Outcomes in Communities where VHT's were trained in ICCM and given drugs.
3077196|NCT02046018|Active Comparator|ICCM delivered by VHT with cell phone|Health Outcomes in communities with VHT's who were trained in ICCM and given cell phones
3077197|NCT02046018|Active Comparator|Health outcomes in communities with no ICCM|Health outcomes in communities with VHT's who were not trained in ICCM
3077198|NCT02046005|Active Comparator|General Rheumatoid Arthritis Education|Arm 1 participants will receive general information about RA.
3077199|NCT02046005|Experimental|PRE-RA|Arm 2 participants will receive personalized RA risk education by the PRE-RA risk tool.
3077200|NCT02046005|Experimental|PRE-RA Plus|Arm 3 participants will receive personalized RA risk education by the PRE-RA risk tool and health educator.
3077201|NCT02045992|Experimental|Caffeine|Caffeine 500mg
3077202|NCT02045992|Placebo Comparator|Placebo|Lactose 500mg
3077203|NCT02045979|Experimental|BI 695501|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
3077204|NCT02045979|Active Comparator|adalimumab-EU source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-EU source
3077205|NCT02045979|Active Comparator|adalimumab-US source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-US source
3077206|NCT02045966|Experimental|Arm 1: Cocktail + DCV 3DAA FDC + BMS-791325|"Treatment A: Cocktail of CYP and transporter probe substrates orally as a single dose on Day 1~Treatment B: DCV 3DAA FDC tablet administered orally BID on Days 6 to 15~Treatment C: DCV 3DAA FDC tablet administered orally BID on Days 16 to 20, plus the cocktail of CYP and transporter probe substrates administered orally as a single dose on Day 16 only~Treatment D: DCV 3DAA FDC tablet plus BMS-791325 75-mg single-agent tablet administered orally BID on Days 21 to 30~Treatment E: DCV 3DAA FDC tablet plus BMS-791325 75-mg single-agent tablet administered orally BID on Days 31 to 35, plus the cocktail of CYP and transporter probe substrates administered orally as a single dose on Day 31 only"
3077207|NCT02045953|Experimental|Sequence 1|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): ABCD, where A= FLIXOTIDE 250 Hydrofluoroalkane (HFA) with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
3077208|NCT02045953|Experimental|Sequence 2|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): BDAC, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
3077209|NCT02045953|Experimental|Sequence 3|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): CADB, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
3077210|NCT02045953|Experimental|Sequence 4|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): DCBA, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
3077211|NCT02045940|Experimental|Cohort 1|Participants will receive one of the following four treatment sequences in four study period (one treatment per period). Sequence 1=Placebo, dose level (DL) 2, DL3, and DL4. Sequence 2=DL1, placebo, DL2, and DL4. Sequence 3=DL1, DL2, placebo, and DL4. Sequence 4=DL1, DL2, DL3, and placebo
3077212|NCT02045940|Experimental|Cohort 2|Participants will receive one of the following four treatment sequences in four study period (one treatment per period). Sequence 5=Placebo, DL5, DL6, and DL7. Sequence 6=DL4, placebo, DL6, and DL7. Sequence 7=DL4, DL5, placebo, and DL7. Sequence 8=DL4, DL5, DL6, and placebo
3077213|NCT02045940|Experimental|Cohort 3|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A
3077214|NCT02045940|Experimental|Cohort 4|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A and preceding repeat dose Cohort
3077215|NCT02045940|Experimental|Cohort 5|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A and preceding repeat dose Cohorts
3077216|NCT02045927|Active Comparator|Intevention Group|sedation monitoring with RASS score plus sedation monitoring with BIS-Guided monitoring
3077220|NCT02045901|Active Comparator|Diclegis|Participants will be randomized to receive Diclegis or placebo. On Day 1, all participants will take 2 tablets of study drug at bedtime. On Days 2 to 14, participants will take 2 tablets of study drug at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
3077221|NCT02045901|Placebo Comparator|Placebo|Participants will be randomized to receive Diclegis or placebo. On Day 1, all participants will take 2 tablets of study drug at bedtime. On Days 2 to 14, participants will take 2 tablets of study drug at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
3077222|NCT02045888|Experimental|Low Dose ADRC|ADRCs prepared by investigational Celution Device
3077223|NCT02045888|Experimental|High Dose ADRC|ADRCs prepared by investigational Celution Device
3077224|NCT02045888|Placebo Comparator|Placebo|Placebo
3077225|NCT02045875|Experimental|Dulera adherence monitoring|Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence
3077226|NCT02045875|Active Comparator|Dulera Standard of Asthma Care|Dulera standard of asthma care
3077227|NCT02045862|Active Comparator|Mirabegron 50 mg|Participants received mirabegron 50 mg once a day for 52 weeks.
3077228|NCT02045862|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg once a day for 52 weeks.
3077229|NCT02045862|Experimental|Solifenacin 5 mg + Mirabegron 50 mg|Participants received solifenacin 5 mg and mirabegron 50 mg once a day for 52 weeks.
3077230|NCT02045849|Experimental|Part 1|Subjects will receive either GSK2140944 1500 mg (500 mg x 3) capsules under fasted conditions or GSK2140944 1500 mg (750 mg x 2) tablets under fasted conditions or GSK2140944 1500 mg (750 mg x 2) tablets under fed conditions as per the randomization schedule in each of the three periods with a washout period of at least 3 days between the doses. There will also be a follow-up visit within 5-7 days after the last dose of study drug.
3077231|NCT02045849|Experimental|Part 2|Subjects will receive a single dose of GSK2140944 1500 mg (tablet or capsule) on Day 1 followed by a repeat dose of Itraconazole 200 mg once daily for 6 days from Day 4 to Day 9. On Day 7, subjects will receive a single dose of GSK2140944 1500 mg (tablet or capsule) one hour after the dose of Itraconazole. There will also be a follow-up visit within 5-7 days after the last dose of study drug.
3077232|NCT02045849|Experimental|Part 3|Subjects in Group 1 will receive GSK2140944 1500 mg (750 mg x 2) tablets twice daily from Day 1 to Day 5 under fasting and fed conditions in Period I and Period II, respectively. Subjects in Group 2 will receive GSK2140944 1500 mg (750 mg x 2) tablets twice daily from Day 1 to Day 5 under fed and fasting conditions in Period I and Period II, respectively. There will be a washout of at least 7 days between the periods. Subjects will have a follow up visit 5-7 days after the last dose of study drug in both the groups.
3077233|NCT02045836|Experimental|Co-Ad Group|Subjects received one dose of the GSK1437173A study vaccine and one dose of the Pneumovax™ 23 vaccine at Day 0 and a second dose of GSK1437173A study vaccine at Month 2. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.
3077234|NCT02045836|Active Comparator|Control Group|Subjects received one dose of the Pneumovax™ 23 vaccine at Day 0, one dose of the GSK1437173A study vaccine at Month 2 and a second dose of the GSK1437173A study vaccine at Month 4. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.
3077235|NCT02045823||Normal|Normal results from clinical exam and free of ocular pathology
3077236|NCT02045823||Glaucoma|Clinical exam with results consistent with glaucoma and visual field defects consistent with glaucoma
3077237|NCT02045823||Retina|clinical exam with results consistent with retina pathology
3077238|NCT02045810|Active Comparator|Treatment|Patients in group receive Ileoinguinal block before the start of surgery, and an injection of plasebo saline after surgery. Injectate is blinded from caregiver.
3077239|NCT02045810|Placebo Comparator|Control group|Patients receive a plasebo saline injetion at the site of ileoinguinal block prior to surgery and an injectio with local anesthetics after surgery. The treatment group is blinded for caregiver.
3077240|NCT02045797|Experimental|Treatment Group A|Subject will receive GSK2140944 750mg IV every 12 hours (q12h; twice daily [BID]) on Day 1 and Day 2. Subject may switch to GSK2140944 1500mg orally (PO) q12h (BID) at investigator's decision or will continue to receive GSK2140944 750mg IV q12h (BID) from Day 3 to Day 10.
3077241|NCT02045797|Experimental|Treatment Group B|Subject will receive GSK2140944 1000mg IV q12h (BID) on Day 1 and Day 2 . Subject may switch to GSK2140944 2000mg PO q12h (BID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q12h (BID) from Day 3 to Day 10.
3077242|NCT02045797|Experimental|Treatment Group C|Subject will receive GSK2140944 1000mg IV q8h (TID) on Day 1 and Day 2. Subject may switch to GSK2140944 2000mg PO q8h (TID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q8h (TID) from Day 3 to Day 10.
3077243|NCT02045784|Experimental|Infant formula milk 60 µg iodine/day|Infant formula containing 57 µg/100 g powder, providing approximately 60 µg iodine/day (i.e. 55% of the current AI). Unrestricted consumption during 11 days.
3077244|NCT02045784|Experimental|Infant formula milk 110 µg iodine/day|Infant formula containing 92 µg/100 g powder, providing approximately 110 µg iodine/day (i.e. 100% of the current AI). Unrestricted consumption during 11 days.
3077245|NCT02045784|Experimental|Infant formula 220 µg iodine/day|Infant formula containing 217 µg/100 g powder, providing approximately 220 µg iodine/day (i.e. 200% of the current AI). Unrestricted consumption during 11 days.
3077246|NCT02045784|Other|Breast milk|Unrestricted consumption during 4 days
3077247|NCT02045771|Other|Support Group (Control Group)|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
3077331|NCT02045134|Placebo Comparator|Placebo|Soluble corn flour not rich in anthocyanins
3077332|NCT02045134|Active Comparator|High-anthocyanin rich corn flour|Soluble corn flour at high content in anthocyanins
3077248|NCT02045771|Experimental|Behavioral Activation|Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
3077249|NCT02045758|Experimental|TAP20-C|TAP20-C
3077250|NCT02045758|Active Comparator|Fingerstick|Fingerstick
3077251|NCT02045745|Experimental|Prolonged postoperative air leaks in risk patients.|Patients with prolonged postoperative air leaks
3077252|NCT02045732|Experimental|Cohort 1|
3077253|NCT02045732|Experimental|PF-06342674 1.5 mg/kg|
3077254|NCT02045732|Experimental|PF-06342674 6.0 mg/kg (q2 Weeks)|
3077255|NCT02045732|Experimental|PF-06342674 6.0 mg/kg (q1 Week)|
3077256|NCT02045719|Experimental|cat's claw|100 mg dose of a dry extract of U. tomentosa three times per day
3077257|NCT02045706|Experimental|Community Health Worker Trainings|Trained community health workers (CHW) (one per 25 households), conducted a focus group and four quarterly meetings. CHWs were then responsible for 25 households where they would teach preventive health, track health data for the Ministry, and refer sick cases (700 households total). Staff and volunteers also conducted home visits and handed out printed summaries. We also worked with the local villagers and community health workers to construct 3 protected water sources in the Intervention areas.
3077258|NCT02045706|No Intervention|Control Group|The Control Group was comprised of similar households to the Intervention Group (n = 700). In these villages, however, we did not instill the community health worker program until after the trial was completed.
3077259|NCT02045693|Experimental|Part 1: Methadone + DCV 3DAA FDC + BMS-791325|"Methadone 40-120 mg tablet or solution orally once on Day 1~Methadone 40-120 mg tablet or solution orally once daily + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3 direct-acting antiviral (3DAA) fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12"
3077260|NCT02045693|Active Comparator|Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325|"Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once on Day 1~Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3DAA fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12"
3077261|NCT02045680||deep block|deep block
3077262|NCT02045680||non deep block (historical control)|non deep block (historical control)
3077263|NCT02045667|Placebo Comparator|Placebo|Placebo tablets three times daily orally
3077264|NCT02045667|Active Comparator|Mexiletine|Mexiletine 200mg three times daily orally
3077265|NCT02045654||MDS patients|MDS patients who were treated with decitabine
3077266|NCT02045641|No Intervention|current postoperative regimen|The group will follow the current postoperative regimen at the surgical ward; screening for pleural effusions with x-ray and further diagnostic procedures in case of symptoms. Treatment will be entirely in the hands of the clinical personnel.
3077267|NCT02045641|Experimental|pleuracentesis|The group will follow the current postoperative regimen. In addition they will be followed with ultrasound examination, clinical examination, spirometry examination and 6 minute walk test. In case of either a) pleural effusion > 400ml OR b) pleural effusion< 400ml with symptoms in rest or during the walk test, the effusion will be drained and examinations will be repeated. In case of pericardial effusion of predefined size and location, either the surgeon on call or a cardiologist will be consulted.
3077268|NCT02045628|Experimental|Investment intervention|Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
3077269|NCT02045628|No Intervention|Control|Those in the control group will receive usual care.
3077270|NCT02045615||Conventional|Conventional technique for Wichita nail extraction
3077271|NCT02045615||New|Proposed technique for Wichita nail extraction
3077272|NCT02045602|Experimental|Part I: Dose Escalation, Single Agent|Single intravenous injection of VCN-01 oncolytic adenovirus
3077273|NCT02045602|Experimental|Part II: Dose Escalation, Combination|Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine
3077274|NCT02045602|Experimental|"Part III: Dose Escalation, Combination, delayed schedule"|Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine
3077275|NCT02045589|Experimental|Dose Escalation, Combination|Three intratumoral administrations of VCN-01 oncolytic adenovirus every 28 days in combination with Abraxane® and Gemcitabine.
3077276|NCT02045576|Experimental|Sleep position trainer|Nightbalance
3077277|NCT02045576|Active Comparator|Oral Appliance Therapy|Somnodent
3077278|NCT02045563||Patients with type-1 diabetes|
3077279|NCT02045563||Patients with type-2 diabetes|
3077280|NCT02045563||Volontaires sains|
3077281|NCT02045550|Placebo Comparator|Placebo Syrup|Placebo Syrup 2.5 ml twice daily for 4 weeks
3077282|NCT02045550|Active Comparator|Prospan Syrup|Prospan Syrup 2.5 ml twice daily for 4 weeks
3077283|NCT02045537||Fractures|Patients in follow up from 1st Jan 1997 to 1st Jan 2012 with any fracture (pathologic)
3077284|NCT02045524|Experimental|Injection location1|Single dose IM injection
3077285|NCT02045524|Experimental|Injection location 2|Single dose IM Injection
3077286|NCT02045511|Experimental|Immediate Treatment Group|Immediate treatment with Baltimore HEARS intervention
3077287|NCT02045511|Placebo Comparator|Delayed Treatment Group|3-month delayed treatment with Baltimore HEARS intervention
3077288|NCT02045498|Experimental|capnography, feedback, quality of cpr|capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
3077289|NCT02045498|No Intervention|conventional cpr|conventional cpr
3077290|NCT02045472|Experimental|VIS410|VIS410 administered as a single infusion with ascending dose-escalation ranging from 2 to 50 mg/kg
3077291|NCT02045472|Placebo Comparator|Placebo|Placebo administered as a single infusion
3077333|NCT02045121|Experimental|Indwelling Pleural Catheter|Day-case IPC insertion. Attendance d10 for drainage, stitch removal and education in catheter care.
3077292|NCT02045459|Experimental|Exercise Program and Medical Therapy|All subjects randomized to this arm will be given intensive medical therapy including - Isosorbide mononitrate, Lisinopril, Carvedilol, and Simvastatin. After 8 weeks of ONLY medication therapy, the subjects will begin a intensive exercise program. This will be supervised on site at UVA. Also, on days that the subject is not being supervised, they will be required to keep a journal of their exercise at home.
3077293|NCT02045446|Active Comparator|Maintenance chemotherapy|FDA approved drugs for the study population: Bevacizumab, Docetaxel, Erlotinib, Gemcitabine, Pemetrexed
3077294|NCT02045446|Experimental|Stereotactic Body Radiation Therapy|consolidative Stereotactic Body Radiation Therapy (SBRT) plus maintenance chemotherapy
3077295|NCT02045433|Experimental|SABR Boost Therapy|
3077296|NCT02045420||Normal Participants|"The investigators will use normal age-matched volunteers to compare against the Idiopathic Parkinson's Disease Patients"
3077297|NCT02045420||Idiopathic Parkinson's Disease Patients|The investigators will observe the MR scans to determine the vascular flow, brain lesions and brain iron levels in this group.
3077298|NCT02045394||Patients presenting with haemoptysis|
3077299|NCT02045381|Other|MRI group|Patient receives one research MRI prior to radiation treatment.
3077300|NCT02045368|Experimental|Subject Treatment with IGF-Methotrexate conjugate|IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle.
3077301|NCT02045355|Experimental|Fish intervention|The patients will receive one portion of salmon (150 g), one portion of cod (150 g), and two portions of sild (50g each) per week.
3077302|NCT02045355|No Intervention|Meat control group|The control food will be pork and chicken (150 g each) and two portions of cooked ham / liver pate for use in cold meals (50 g each).
3077303|NCT02045342|Experimental|Carbohydrate drink|Ingest 500ml (1g/kg) prior to metabolic measures.
3077304|NCT02045342|Placebo Comparator|Placebo|Ingest 500ml of placebo prior to metabolic measures.
3077305|NCT02045329||Staphylococcus aureus nasal carriers|Patients who are treated with mupirocin to clear nasal colonization with Staphylococcus aureus
3077306|NCT02045316||Preeclamptic pregnants|pregnants with preeclampsia
3077307|NCT02045316||Normal pregnants|pregnants without obstetric complications
3077308|NCT02045303|Experimental|Ambulatory Wound Clinic|Intervention with contact ultrasound therapy and noncontact ultrasound therapy following the study protocol on subjects receiving care at the wound clinic.
3077309|NCT02045290|Placebo Comparator|Oral Placebo|"A central pharmacy will compound a placebo to match the metformin tablets.~The placebo product will contain the following components:~Micosolle™, silica based excipient~Silicified Micro Crystalline Cellulose, National Formulary~Safflower Oil, United States Pharmacopeia~K-30 Povidone Powder~Magnesium Stearate, National Formulary (Vegetable source)~Fumed Silica, National Formulary"
3077310|NCT02045290|Experimental|Metformin|Metformin 2000 mg per day
3077311|NCT02045277|Experimental|IDP-118 Lotion|halobetasol propionate [HP], tazarotene [Taz]
3077312|NCT02045277|Active Comparator|IDP-118 Monad HP Lotion|HP
3077313|NCT02045277|Active Comparator|IDP-118 Monad Taz Lotion|Taz
3077314|NCT02045277|Active Comparator|IDP-118 Vehicle Lotion|Vehicle
3077315|NCT02045264|Experimental|Icatibant (30 mg)|30mg dose of icatibant is administered as a single subcutaneous injection in the abdominal area
3077316|NCT02045251|Experimental|Interventional Arm|This arm will have 100 patients receiving the proposed Pylera based regimen for 10 days.
3077317|NCT02045238|Placebo Comparator|Normal Saline|Patients will receive inhaled normal saline, initially with a 2 hour interval, and clinical evaluation prior to each inhalation. When they attain sat>94% AND respiratory rate <60 AND RDAI score <4, the interval between inhalations will be changed to 4 hours. If they maintain these criteria for a whole 4 hour interval, they are discharged. If they do not improve enough to be discharged in 24 hours from the first inhalation, they are considered as admitted to hospital.
3077318|NCT02045238|Experimental|Hypertonic Saline|Patients will receive inhaled Hypertonic Saline 3%, initially with a 2 hour interval, and clinical evaluation prior to each inhalation. When they attain sat>94% AND respiratory rate <60 AND RDAI score <4, the interval between inhalations will be changed to 4 hours. If they maintain these criteria for a whole 4 hour interval, they are discharged. If they do not improve enough to be discharged in 24 hours from the first inhalation, they are considered as admitted to hospital.
3077319|NCT02045225|Experimental|Cognitive behavioural therapy|Reduction of social anxiety & substance use in gay/bi men
3077320|NCT02045212|Experimental|RPh201|3/6 month treatment schedule, consisting of bi-weekly SC administration of the RPh201
3077321|NCT02045212|Placebo Comparator|Placebo|3/6 month treatment schedule, consisting of bi-weekly SC administration of the Placebo
3077322|NCT02045199|Experimental|V0111|
3077323|NCT02045199|Placebo Comparator|Placebo|
3077324|NCT02045186|Other|Assessment of Oral HPV Infection|Oral HPV infection will be assessed 14 times, once prior to starting CRT, weekly during CRT, and then serially post-treatment: 4-8 weeks, 3 months, 6 months, 12 months, 18 months, 24 months. Patients will provide samples of their saliva and exfoliated epithelial cells at these timepoints. Samples will be collected with supplies provided by and analyzed by OralDNA Labs.
3077325|NCT02045173|Other|Apneascan TM|autoscoring algorithms of the Apneascan TM compared to the polysomnography or polygraphy
3077326|NCT02045160||Sulfamethoxazole-trimethoprim treatment|
3077327|NCT02045147|Experimental|Grp 1 Low Cognition, Low Activation|Group 1: Subjects will receive an 8 week care transition intervention with an Advanced Practice Registered Nurse-Nurse Practitioner (APRN-NP) and Certified Nursing Assistant (CNA). The APRN-NP will guide the care transition intervention. This group will receive the most intense intervention.
3077328|NCT02045147|Experimental|Grp 2 Low Cognition, High Activation|Group 2: Subjects will receive an 8 week care transition intervention with an APRN-NP and CNA. The APRN-NP will guide the care transition intervention. This group will receive an intense intervention.
3077329|NCT02045147|Experimental|Grp 3 Normal Cognition, Low Activation|Group 3: Subjects will receive an 4 week care transition intervention with a Registered Nurse (RN) Coach. This group will be evaluated at four weeks, if the patient activation levels are still low, they will be referred to the 4 week APRN-NP and CNA.
3077330|NCT02045147|Experimental|Grp 4 Normal Cognition, High Activation|Group 4: Subjects will receive the least intensive intervention delivered by a RN coach.
3077334|NCT02045121|Active Comparator|Talc Pleurodesis|Hospital admission for chest drain insertion and suction if needed, plus talc pleurodesis by slurry or poudrage if >75% of visceral and parietal pleura in direct contact on chest x-ray.
3077335|NCT02045108|Experimental|Active TDCS + Active Retraining|2.0 milliamps (mA) of TDCS applied during active alcohol avoidance retraining
3077336|NCT02045108|Experimental|Sham TDCS + Active Retraining|.1 mA of TDCS applied during active alcohol avoidance retraining
3077337|NCT02045108|Experimental|Active TDCS + Sham retraining|2.0 mA of TDCS applied during sham alcohol avoidance retraining
3077338|NCT02045108|Sham Comparator|Sham TDCS + Sham Retraining|0.1 mA of TDCS applied during sham alcohol avoidance retraining
3077339|NCT02045095|Experimental|MLN7243|
3077340|NCT02045082|Experimental|Flocked swab (Copan 519CS01)|Sampling of the cornea by the flocked swab
3077341|NCT02045082|Experimental|Traditionnal fiber swab (Copan 164KS01)|Sampling of the cornea by the traditional finer swab
3077342|NCT02045069|Experimental|2 days Ivermectin|Ivermectin 200 - 400 µg/kg once daily for 2 days
3077343|NCT02045069|Experimental|3 days Ivermectin|Ivermectin 200-400 µg/kg once daily for 3 days
3077344|NCT02045069|Placebo Comparator|Placebo|Placebo
3077345|NCT02045056|Experimental|Gemfibrozil|Gemfibrozil 600 mg by mouth twice daily for 48 weeks
3077346|NCT02045056|Placebo Comparator|Sugar pill|Matching placebo capsule by mouth twice daily for 48 weeks
3077347|NCT02045043||Cardiomyopathy patients with ICDs|
3077348|NCT02045030|Experimental|aflibercept and FOLFIRI|aflibercept and FOLFIRI
3077349|NCT02045017|Experimental|Pomalidomide and low dose Dexamethasone|Pomalidomide 4mg, and low dose Dexamethasone, starting at 40mgs(≤ 75 years old) or 20 mg/day (> 75 years old)
3077350|NCT02045004||Surgery Group Sevoflurane|Patients aged ≥ 65 years undergoing major surgical procedures.
3077351|NCT02045004||Control Group|Healthy study participants aged ≥ 65 years (no surgical intervention).
3077352|NCT02044991|Active Comparator|Treatment|Participants randomized to this arm will receive a corticosteroid. This is 40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
3077353|NCT02044991|Placebo Comparator|Placebo|Participant's randomized to this condition will receive a placebo injection once weekly
3077354|NCT02044978|Active Comparator|Bisphosphonate implant|Dental implant coated with zoledronate Note: Both arms in each patient (2 implants)
3077355|NCT02044978|Placebo Comparator|control|Dental implant without coating Note: Both arms in each patient (2 implants)
3077356|NCT02044965|No Intervention|Antibiotic|This group will be prescribed a dose of antibiotics (Septra 2mg/kg)
3077357|NCT02044965|Placebo Comparator|Probiotic plus placebo|Receive probiotic plus an antibiotic placebo
3077358|NCT02044965|Active Comparator|probiotics plus antibiotic|This group will be on a dose of probiotics (2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule) plus a antibiotic (Septra)
3077359|NCT02044952|Experimental|Mesalazine, Tripterygium glycosides|Mesalazine 4g/d and Tripterygium glycosides 2mg/kg/d for 12 weeks
3077360|NCT02044939|Experimental|Pulmonary rehabilitation|Sarcoidosis patients will realize a pulmonary rehabilitation program
3077361|NCT02044939|No Intervention|Controls|Sarcoidosis patients who do not achieve a respiratory rehabilitation program but will have physical activity counseling.
3077362|NCT02044913|Experimental|Phone-based Aftercare-Coordination|After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention aims at supporting the patients in coordinating their aftercare treatment which can help to maintain or even improve longterm treatment outcome.
3077363|NCT02044913|No Intervention|Treatment as usual|After inpatient treatment patients receive treatment as usual within routine care.
3077364|NCT02044887|Experimental|INTERVENTION|Participants will receive instructions to do physical activity with an adapted physical activity program. This program will be designed and applied by Primary Health Care professionals in patients with dementia and caregivers.
3077365|NCT02044887|No Intervention|Control|The control group will receive regular care.
3077366|NCT02044874|Experimental|APD356 10 mg b.i.d.|
3077367|NCT02044874|Experimental|APD356 10 mg q.d.|
3077368|NCT02044874|Placebo Comparator|Placebo 10 mg b.i.d|
3077369|NCT02044861|Experimental|ACT-PFK-158|dose escalation
3077370|NCT02044848|Experimental|Secukinumab|Secukinumab will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year
3077371|NCT02044848|Placebo Comparator|Placebo|Placebo will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year
3077372|NCT02044835|Placebo Comparator|OMT controll|placebo 20 ml every time, three times a day, combined with optimal medical therapy of internal medicine, including anti-platelet therapy and other protocol-driven medical therapies to control blood pressure and glucose and lipid levels in accordance with guidelines.
3077373|NCT02044835|Experimental|herbal treatment|Fu-zheng-qu-zhuo oral liquid ( herbal medicine) 20 ml every time, three times a day,combined with optimal medical therapy of internal medicine, including anti-platelet therapy and other protocol-driven medical therapies to control blood pressure and glucose and lipid levels in accordance with guidelines.
3077374|NCT02044822|Experimental|Idelalisib + rituximab|Participants will receive rituximab for 8 weeks and Idelalisib continuously throughout the study (up to 10 years).
3077375|NCT02044809|Placebo Comparator|Placebo|
3077376|NCT02044809|Experimental|Cannabidiol 200mg Oral|
3077377|NCT02044809|Experimental|Cannabidiol 400mg Oral|
3077378|NCT02044809|Experimental|Cannabidiol 800mg Oral|
3077420|NCT02044510|Experimental|Mirabegron|Patients randomised to this arm start with mirabegron 25mg PO daily for two weeks, and then at 2 weeks titrate to 50mg PO daily, and maintain that dose for the duration of the study (8 additional weeks).
3077421|NCT02044510|Placebo Comparator|Placebo|Inert placebo pill, matching active treatment pill.
3077580|NCT02043353||Primary snoring|All children that were diagosed with primary snoring at the Tel Aviv Medical center between 2005-2010
3077581|NCT02043353||Adenotonsillectomy Vs. Adenoidectomy|All children that underwent adenotonsillectomy or tonsillectomy at the Tel Aviv Medical center between 2005-2008
3077379|NCT02044796|Experimental|Treatment (filgrastim, mitoxantrone, cladribine, cytarabine)|"INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5, mitoxantrone hydrochloride IV over 60 minutes on days 1-3, cladribine IV over 2 hours daily on days 1-5, and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi, partial remission, or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.~CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi, patients receive G-CLA comprising filgrastim SC on days 0-5, cladribine IV over 2 hours daily on days 1-5, and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3077380|NCT02044783|Experimental|Behavioral Intervention|Behavioral Counseling Intervention: 6 telephone calls that include physical activity goal-setting, tracking,and problem-solving of barriers
3077381|NCT02044783|No Intervention|Usual Care|Monthly mailed print materials on aging topics (that would generally be administered by subjects' primary care clinic). No behavioral counseling.
3077382|NCT02044757|Experimental|SSB withdrawal|
3077383|NCT02044744|Experimental|Referral|Physical activity referral
3077384|NCT02044744|No Intervention|Wait-list control|Wait-list controls receive no intervention until after they provide follow-up measurements.
3077385|NCT02044731|Experimental|Family group sessions|Active and Healthy Families
3077386|NCT02044705|Experimental|Family group sessions|Active and Healthy Families
3077387|NCT02044705|No Intervention|Wait-list control|Controls may participate in Active and Healthy Families after the study
3077388|NCT02044679|Experimental|A = Increase water intake 1|+ 1,5 to 2,0 L/day of water
3077389|NCT02044679|Experimental|B = Increase water intake 2|+ 1,0 to 1,5 L/day of water
3077390|NCT02044679|Other|C = no change|No change
3077391|NCT02044666|Experimental|Treatment|
3077392|NCT02044653|Experimental|Group A (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 3ug/kg
3077393|NCT02044653|Experimental|Group B (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg
3077394|NCT02044653|Experimental|Group C (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg
3077395|NCT02044653|Experimental|Group D (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 3ug/kg
3077396|NCT02044653|Experimental|Group E (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 5ug/kg
3077397|NCT02044653|Experimental|Group F (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 8ug/kg
3077398|NCT02044653|Experimental|Group G (Part B)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg
3077399|NCT02044653|Experimental|Group H (Part B)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg
3077400|NCT02044653|Active Comparator|Group I (Part B)|MIRCERA : Subcutaneously injection every 2 weeks (Q2W) at dose 0.6ug/kg
3077401|NCT02044653|Experimental|Group J (Part B)|GX-E2 : Intravenously injection every week (Q1W) at dose 5ug/kg
3077402|NCT02044653|Experimental|Group K (Part B)|GX-E2 : Intravenously injection every week (Q1W) at dose 8ug/kg
3077403|NCT02044653|Experimental|Group L (Part B)|GX-E2 : Intravenously injection every 2 weeks (Q2W) at dose 8ug/kg
3077404|NCT02044653|Active Comparator|Group M (Part B)|NESP : Intravenously injection every week (Q1W) at dose 30ug
3077405|NCT02044640||Appendectomy|Patients undergoing a laporascopic appendectomy
3077406|NCT02044627|Experimental|1 dose of [14C-ETC-1002]|
3077407|NCT02044614|Other|icodextrin-based peritoneal dialysis to hemodialysis|12-week course of adjuvant low-frequency icodextrin-based peritoneal dialysis to ongoing thrice-weekly maintenance hemodialysis
3077408|NCT02044601|Experimental|Chemoradiation + Onartuzumab|"Participants with wild-type EGFR mutation to be randomized, and may receive this regimen.~Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle. Paclitaxel 45 mg/m2 by vein once a week throughout radiation for 7 weeks. Carboplatin AUC 2 by vein once a week throughout radiation for 7 weeks. Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.~Phase II: Same regimen as in Phase I, but starting dose of Onartuzumab is maximum tolerated dose from Phase I."
3077409|NCT02044601|Experimental|Chemoradiation + Erlotinib + Onartuzumab|"Participants with EGFR mutation to receive this regimen. Participants with wild-type EGFR mutation to be randomized, and may receive this regimen.~Phase I: Erlotinib 150 mg by mouth every day throughout radiation, except for chemotherapy day. Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle. Paclitaxel 45 mg/m2 by vein once a week throughout radiation for 7 weeks. Carboplatin AUC 2 by vein once a week throughout radiation for 7 weeks. Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.~Phase II: Same regimen as in Phase I, but starting dose of Onartuzumab is maximum tolerated dose from Phase I."
3077410|NCT02044588||HBsAg negative kidney allograft donor|
3077411|NCT02044588||HBsAg positive kidney allograft donor|HBsAg positive kidney allograft donor
3077412|NCT02044575||Critically ill patients|Intensive care unit patients with refractory septic shock
3077413|NCT02044562|Experimental|nitrate supplementation|Patients will receive 7-day nitrate supplementation at the end of the radiotherapy.
3077414|NCT02044562|Placebo Comparator|Placebo|Patients will receive 7-day placebo supplementation at the end of the radiotherapy
3077415|NCT02044549|Active Comparator|carbetocin|single 100 μg IV dose of carbetocin (150 women) after fetal extraction and before placental removal.
3077416|NCT02044549|Active Comparator|Syntometrine|Intravenous combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal.
3077417|NCT02044536||Faculty doctors|Experienced endoscopists (> 6000 cases). no intervention
3077418|NCT02044536||Trainees|Doctors on fellowship who are inexperienced endoscopists (< 4 months of endoscopy training) no intervention
3077419|NCT02044523||Hepatis C, Hepatitis B, NAFLD|"All patients enrolled will undergo:~Transient Elastography (Fibroscan)~Acoustic Radiation Force Impulse (ARFI)~Magnetic Resonance Elastography (MRE)"
3078267|NCT02038673|Experimental|Expansion part Squamous Cell Lung Carcinoma|Oral
3077422|NCT02044497|Experimental|oral oxycodone|An orogastric tube will be placed in the stomach (placement verified by routine accepted clinical guidelines) under anesthesia as is part of standard routine clinical care to remove gastric contents. The same orogastric tube will be used for intragastric liquid oxycodone administration in a dose of 0.1 mg/kg before the surgical incision. This weight-adjusted dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines at Boston Children's Hospital.
3077423|NCT02044484|Experimental|Multi-component intervention|"Computer-based intervention (CBI) completed twice (separated by 2-4 months) among patients whose viral load exceeds 1000 copies/mL at time of enrollment.~One-on-one counseling from a project Health Coach (three 1-hour sessions at the clinic and two follow-up phone calls at 1 and 3 months after last session). The counseling is offered to patients who do not show a 1-log reduction in their viral load after the first CBI or whose viral load remains above 200 copies/mL after two administrations of the CBI.~Behavioral screening of patients at HIV primary care visits.~Dissemination of palm cards with empowering messages at HIV primary care visits."
3077424|NCT02044484|No Intervention|Standard of care control|HIV patients will continue to receive existing standard of care practices at the clinic without receiving the multi-component intervention.
3077425|NCT02044471|Experimental|Intervention|"Our intervention will be ischemic conditioning (IC) remotely applied using a sphygmomanometer. We will use the standard, validated protocol, which is inflation of the sphygmomanometer to 200 mmHg for 5 minutes, then deflation with 5 minutes of reperfusion, repeated for 3 cycles (total 30 minutes). This will be done in the dominant arm, twice daily.~Once patients are discharged home on a stable pharmacotherapy regimen, they will be expected to follow the above intervention for 6 weeks, followed by another 6 weeks in the control (no intervention) phase. Patients will be randomized as to which phase they begin the study."
3077426|NCT02044471|No Intervention|Control|standard care
3077427|NCT02044458|Active Comparator|Stylette|Stylette: a thin wire inserted into a catheter to maintain rigidity, used to guide the insertion of the Foley catheter.
3077428|NCT02044458|No Intervention|No Stylette|No Stylette: 22 French Foley catheter placed without stylette or guide.
3077429|NCT02044445|Active Comparator|36 h group|Oocyte retrieval will be performed 36 hours after hCG administration
3077430|NCT02044445|Active Comparator|38 h group|Oocyte retrieval will be performed 38 hours after hCG administration
3077431|NCT02044432|Experimental|Ginger compress|
3077432|NCT02044432|No Intervention|Wait list|
3077433|NCT02044419|Experimental|lomitapide sprinkled in applesauce|Contents of single 20 mg capsule of lomitapide sprinkled in applesauce
3077434|NCT02044419|Experimental|lomitapide sprinkled in mashed banana|Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana
3077435|NCT02044419|Experimental|lomitapide (intact)|Intact capsule of 20 mg lomitapide
3077436|NCT02044406|Experimental|1 BI 1181181 single rising dose part|single rising doses of BI 1181181
3077437|NCT02044406|Experimental|2 BI 1181181 bioavailability part|bioavailability, food effect part of BI 11881181
3077438|NCT02044393|Experimental|Reference|single dose BI 691751
3077439|NCT02044393|Experimental|Test|multiple doses of itraconazole + single dose BI 691751
3077440|NCT02044380|Experimental|Afatinib|patient to receive a tablet containing 40 mg afatinib once a day, with the option to reduce the dose to 30 or 20 mg/day, based on individual tolerability
3077441|NCT02044367|Experimental|Test 1 (Treatment A)|multiple dose of dabigatran
3077442|NCT02044367|Experimental|Test 2 (Treatment B)|multiple dose of dabigatran
3077443|NCT02044367|Experimental|Reference|multiple dose of dabigatran
3077444|NCT02044354|Other|Do/Ca|Arm Do/Ca : Taxotere 75mg/m2/3w x 4 cycles, followed by Jevtana 25mg/m2/3w x 4 cycles
3077445|NCT02044354|Other|Ca/Do|Arm Ca/Do : Jevtana 25mg/m2/3w x 4 cycles, followed by Taxotere 75mg/m2/3w x 4 cycles
3077446|NCT02044341|Active Comparator|AR01 - Topical Otic Solution|"Topical ear drops~The dosing regimen is every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period~Children 2 Months to 12 Years: dispense five drops of study drug into the affected ear canal(s) each hour, as needed for ear pain, or Children 12 years to <19 years: dispense 10 drops of study drug into the affected ear canal(s) each hour, as needed for ear pain."
3077447|NCT02044341|Placebo Comparator|Glycerin ear drops|"Topical ear drops~The dosing regimen is every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period~Children 2 Months to 12 Years: dispense five drops of study drug into the affected ear canal(s) each hour, as needed for ear pain, or Children 12 years to <19 years: dispense 10 drops of study drug into the affected ear canal(s) each hour, as needed for ear pain."
3077448|NCT02044328|Experimental|Icotinib|Patients receive icotinib 125 mg three times daily as adjuvant chemotherapy with for 18 months after surgery.
3077449|NCT02044315|Sham Comparator|Conventional|Conventional ICD programming
3077450|NCT02044315|Experimental|High-zone|High-zone ICD programming
3077451|NCT02044302|Active Comparator|standard analgesics|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Placebo application during surgery will be made to establish perfection in the study design in terms of randomization and blinding. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
3077452|NCT02044302|Experimental|standard analgesics and bupivacaine|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into the chest 10 ml (about 2 teaspoons) of 0.5% bupivacaine during surgery. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
3077453|NCT02044302|Experimental|standard analgesics and botulinum toxins|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during your operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
3077582|NCT02043353||repeated PSG|All children that underwent Adenoidectomy / Adenotonsillectomy and two PSG evaluations at the Tel Aviv Medical center between 2005-2012
3077454|NCT02044302|Experimental|standard analgesics, bupivacaine and botulinum toxins|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 10 ml (about 2 teaspoons) of 0.5% bupivacaine and 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during the operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
3077455|NCT02044276|Experimental|lipegfilgrastim.|subcutaneous (SC) injection of 6 mg lipegfilgrastim
3077456|NCT02044276|Active Comparator|pegfilgrastim|SC injection of 6 mg pegfilgrastim
3077457|NCT02044263|Experimental|Internet CBT-i|Participants will be instructed on the use of the internet CBT-i (SHUTi) intervention site, then use the program for six weeks.
3077458|NCT02044263|Active Comparator|face-to-face CBT-i|4 to 8 sessions of face-to-face CBT-i treatment with one of three clinicians (experienced CBT-i psychiatrists)
3077459|NCT02044250|Active Comparator|Clopidogrel|Antiplatelet monotherapy : Clopidogrel 75mg P.O. daily
3077460|NCT02044250|Placebo Comparator|Aspirin|Antiplatelet monotherapy : Aspirin 100~200mg P.O. daily
3077461|NCT02044237|Experimental|Decoupling|specific technic to reduce hair pulling
3077462|NCT02044237|Active Comparator|progressive muscle relaxation|Progressive relaxation relaxation technic
3077463|NCT02044224|Experimental|Dexmedetomidine|Dexmedetomidine infusion during anaesthesia for IRE procedure
3077464|NCT02044211|Active Comparator|Collaborative Care for Heart Failure + Depression|"Collaborative care program for heart failure and depression involving a nurse care manager providing counseling and treatment advice via telephone~Interventions:~Behavioral:~Counseling for heart failure self-care Counseling for depression~Drug:~Pharmacotherapy for heart failure Pharmacotherapy for depression"
3077465|NCT02044211|Active Comparator|Collaborative Care for Heart Failure Only|"Collaborative care program for heart failure and depression involving a nurse care manager providing counseling and treatment advice via telephone~Interventions:~Behavioral:~Counseling for heart failure self-care Usual care for depression~Drug:~Pharmacotherapy for heart failure~Usual Care for depression"
3077466|NCT02044211|No Intervention|Usual Care for Heart Failure and Depression|Control group will receive their doctors' usual care for heart failure and depression
3077467|NCT02044211|No Intervention|Non-Depressed Comparison Cohort|Control group will receive their doctors' usual care for heart failure
3077468|NCT02044198|Active Comparator|Group 1 - FMP2.1/AS01B vaccine|"FMP2.1/AS01B vaccine administered at days 0, 28 and 56.~Blood-stage controlled human malaria infection (CHMI) at day 70."
3077469|NCT02044198|No Intervention|Group 2 - control|"Group 2 is an infectivity-control group for the malaria infection challenge procedures; these volunteers will not be vaccinated.~Blood-stage controlled human malaria infection (CHMI) at day 70."
3077470|NCT02044185||high dose chemotherapy|group of using myeloablation regimen, autologous stell cell transplantation
3077471|NCT02044185||control group|normal population with health screening
3077472|NCT02044172|Active Comparator|Radical prostatectomy|Radical prostatectomy
3077473|NCT02044172|Active Comparator|Conformal radiation therapy|Conformal radiation therapy External beam radiation therapy
3077474|NCT02044172|Active Comparator|Active monitoring|Active monitoring of prostate specific antigen levels and disease surveillance
3077475|NCT02044159|Experimental|Hydrocortisone|Patients randomized to the hydrocortisone arm will receive a 2 mg/kg hydrocortisone IV bolus on enrolment followed by 1 mg/kg of hydrocortisone IV q6h until the patient has not had an escalation in therapy for at least 12 hours. If the patient meets these criteria their hydrocortisone will be weaned to 1 mg/kg every 8 hours which will be continued until they are off all vasoactive infusions for 12 hours. If following the initial hydrocortisone wean, the patient requires fluid boluses and/or an increase in their vasoactive infusion(s), their hydrocortisone will be increased back to 1 mg/kg of hydrocortisone IV q6h until they meet stability criteria again. Duration of treatment will range from a minimum of 20 hours to a maximum of 7 days of study drug.
3077476|NCT02044159|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive a placebo solution consisting of normal saline equivalent in volume to the appropriate dose of hydrocortisone. Hydrocortisone and placebo will be identical in appearance, volume and smell as hydrocortisone is made up in normal saline and dissolves completely with no visible precipitate. The dosing regimen will be identical to the hydrocortisone arm.
3077477|NCT02044146|Experimental|Personalized Therapy|"A point-of-care bedside genetic test for CYP2C19*2 and CYP2C19*3 using a buccal swab will be conducted.2 P2Y12 inhibitory drug therapy will be then be directed based on a risk algorithm (integrating genotyping and clinical variables). Patients with high ischemic risk are defined as having (*2 or *3) and/or diabetes and/or (having age>65 AND BMI>=28). High-risk patients will be switched to prasugrel at 10mg daily, while low ischemic risk patients be kept on clopidogrel 75 daily. For patients >age 75 or wt < 60 kg, prasugrel will be reduced to 5mg daily."
3077478|NCT02044146|Active Comparator|Ticagrelor|Patients will be treated with a 90mg twice daily regimen of Ticagrelor
3077479|NCT02044146|Other|Clopidogrel registry arm|A concurrent registry of patients (not randomized) who are receiving clopidogrel only (as decided by treating physician) will be followed as a comparator group.
3077480|NCT02044133|Other|Dosage of vitamine D : inclusion and 6 month|Participant will have one dosage of vitamine D to entrance of prison and one dosage of vitamine D 6 month after entry
3077481|NCT02044133|Other|Dosage of Vitamine D 6 month|Participant will have one dosage of vitamine D 6 month after entry to prison
3077482|NCT02044120|Experimental|niraparib and temozolomide|Niraparib and temozolomide will be taken together
3077483|NCT02044120|Experimental|niraparib and irinotecan|Niraparib will be taken orally and Irinotecan intravenously
3077484|NCT02044107|Experimental|Co-packaging and counseling messages|"Current standard care at public health center ( zinc ORS for treatment of diarrhea and antibiotics for treatment of of pneumonia).~The intervention consists of health center level co-packaging and visual counseling messages (zinc & ORS packaged at health center for diarrhea, and zinc & antibiotics co-packaged at health center for pneumonia) Co-packaging is done in a plastic bag, which is covered with pre-tested zinc treatment messages - a distinct packaging has been designed for diarrhea and for pneumonia"
3077485|NCT02044107|No Intervention|Control group|Current standard care at public health center (zinc & ORS for treatment of diarrhea and zinc & antibiotics for treatment of of pneumonia).
3077486|NCT02044094|Experimental|depot buprenorphine|Participants were treated with RBP-6000 300-mg in a single subcutaneous injection on Days 1 and 29 following a prior 14 day stabilization period (day -14 to day -1) of buprenorphine and naloxone (SUBOXONE) . Challenges consist of participants receiving on three consecutive days intramuscular (IM) injections of hydromorphone 0 mg (placebo), 6 mg and 18 mg doses during weeks 1-12 in randomized sequential order.
3077487|NCT02044081|Other|Mouth Rinse Administration|Day 0, three consecutive C16G2 or placebo rinse administrations followed by three single C16G2 or placebo rinse administrations. Days 1 to 6 two additional C16G2 or placebo rinse administrations.
3077488|NCT02044081|Other|Dental Tray Gel Administration|Day 0, two C16G2 or placebo gel dental tray applications and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo dental tray applications and two C16G2 or placebo rinse administrations.
3077489|NCT02044081|Other|Electric Toothbrush Gel Application|Day 0, four C16G2 or placebo gel administrations applied with an electric toothbrush and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo gel administrations applied with a electric toothbrush and two C16G2 or placebo rinse administrations.
3077490|NCT02044081|Other|Manual Toothbrush Gel Application|Day 0, four C16G2 or Placebo gel administrations applied with a manual toothbrush and four C16G2 or Placebo rinse administrations. Days 1 to 6, two C16G2 or Placebo gel administrations applied with a electric toothbrush and two C16G2 or Placebo rinse administrations.
3077491|NCT02044068||children born from HIV-HBV women|Studying retrospectively their status for HBs Ag and HBc Ab
3077492|NCT02044055||Children born to HBV-HDV women|"Children born to HBV-HDV co-infected women will be checked for:~HDV antibodies~if positive, HDV RNA"
3077493|NCT02044042||HCV pregnant women|HCV chronically infected pregnant women, with a positive HCV RNA during pregnancy
3077494|NCT02044029||Age- and gender-matched controls|
3077495|NCT02044029||Patients with spinal muscular atrophy|
3077496|NCT02044016||Observational study|To compare results of the ATLM with goniometry and Ultrasound measures of the achilles tendon.
3077497|NCT02044003|Experimental|Post Angioplasty Dissection Repair|Implant of Innovasc Tack Intravascular Staple System (Tack) to repair post angioplasty dissections
3077498|NCT02043990|Experimental|Noninvasive NAVA Ventilation|Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
3077499|NCT02043977|Experimental|propofol infusion|Induction of sleep is accomplished with a bolus of propofol (up to 0.5mg/kg over one minute, concurrently with a constant infusion of propofol starting at 25 ug/kg/min titrated to a maximum of 100ug/kg/min, to maintain the subject at a Modified Ramsay Score of 3-4 for a total of 120 minutes. An additional bolus may be given by the investigator in order to maintain the level of sleep. This procedure will be conducted over 5 consecutive nights.
3077500|NCT02043964|Experimental|tears and cerebro-spinal fluid sampling|
3077501|NCT02043951||Single Arm: Lutonix Drug Coated Balloon|
3077502|NCT02043938|Experimental|Healthy Volunteers|All healthy volunteers will receive four sessions of anesthesia with different common drug combinations while having SedLine EEG sensors placed on their forehead during these sessions to study the effects of these drugs on the brain. The sessions were: propofol (P), sevoflurane (S), propofol with remifentanil (PR), and sevoflurane with remifentanil (SR).
3077503|NCT02043925||psychiatric patients treated with QT-prolonging drugs|
3077504|NCT02043912||patients treated with haloperidol|
3077505|NCT02043886|Active Comparator|Acarbose|Acarbose 50mg by mouth at minute 0 of the Meal Test.
3077506|NCT02043886|Placebo Comparator|Placebo|Placebo 1 tablet at 0 minutes of Meal Test.
3077507|NCT02043873||25 composite restorations replaced|25 composite replaced with clinically diagnosed secondary caries (Charlie) or undercontoured anatomical form defects (Bravo)
3077508|NCT02043873||25 composite repaired|25 composite repaired with clinically diagnosed secondary caries (Charlie) or undercontoured anatomical form defects (Bravo)
3077509|NCT02043860|Experimental|Total Marrow Irradiation|Escalating doses of total marrow irradiation (3Gy, 6Gy, 9Gy, or 12Gy) with standard high dose melphalan prior to autologous stem cell rescue.
3077510|NCT02043847|Experimental|Total Marrow Irradiation|Escalating doses of total marrow irradiation (3Gy, 6Gy, or 9Gy) with standard high dose melphalan prior to autologous stem cell rescue.
3077511|NCT02043834|Experimental|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
3077512|NCT02043834|No Intervention|Control|The control group will keep their normal activity without receiving any intervention.
3077513|NCT02043821|Other|Placebo|Placebo 1250mg/m2 tablet by mouth every 12 hours for 14 days
3077514|NCT02043821|Experimental|Capecitabine|Capecitabine 1250mg/m2 tablet by mouth every 12 hours for 14 days
3077515|NCT02043808||Dabigatran|
3077516|NCT02043808||Warfarin|
3077517|NCT02043795|Other|Treated with BVS|Symptomatic patients would be screened with a duplex ultrasound as per clinical practice prior to intervention. After informed consent for a standard angiography/intervention, the patient will undergo a planned intervention under general or local anaesthesia in an angiographic facility.
3077518|NCT02043782|Experimental|First Coloplast Test|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.~First subjects are allocated to Coloplast Test; Secondly to either~Own product (baseline)~Competitor soft convex"
3077519|NCT02043782|Experimental|First Competitor soft convex|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.~First subjects are allocated to Competitor soft convex; Secondly to either~Own product (baseline)~Coloplast Test"
3077520|NCT02043782|Experimental|First Own product|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.~First subjects are allocated to Own product; Secondly to either~Coloplast Test~Competitor soft convex"
3077577|NCT02043366|Active Comparator|Butorphanol-Flurbiprofen axetil|A dose of 10μg/ kg butorphanol and a dose of 0.5mg/ kg flurbiprofen axetil are intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
3077904|NCT02040844|Other|Cat-PAD Treatment 1|Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762].No further treatment received in CP007A
3077521|NCT02043769||Prospective Cohort|"The prospective cohort surveillance will be built upon and support the routine clinical care, visit schedule and monitoring system at each study site. Eligible HIV-infected ART naïve children who are accessing care at study sites will be recruited sequentially for study enrollment. Children enrolled in the surveillance study will attend study visits co-scheduled to coincide with routine clinical visits. Study nurses will:~review routinely collected information;~conduct questionnaires with caregiver and child;~conduct additional assessments of child;~contact the caregiver by phone or through home visits for active follow-up for up to 24 months; and~conduct active follow-up including appointment reminders by means of phone calls and defaulter tracking."
3077522|NCT02043756|Experimental|Mitoxantrone Hydrochloride Liposome|Dose escalation will begin at 6mg/m2 to 16mg/m2,4 weeks apart
3077523|NCT02043756|Active Comparator|Mitoxantrone ,injection|When the dose of experiment drup up 10mg/m2,10mg/m2 of Mitoxantrone as active comparator
3077524|NCT02043743|Experimental|Laboratory and Clinical|"Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.~Stem Cell Dose:~•3-5 Million Autologous MSCs Injected into Ovarian tissue."
3077525|NCT02043730|Experimental|nab-paclitaxel and gemcitabine|ARM A: nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
3077526|NCT02043730|Active Comparator|Gemcitabine|ARM B: Gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
3077527|NCT02043717||CF patients|Both children and adults, with or without vitamin D deficiency.
3077528|NCT02043704|Experimental|IV Acetaminophen|Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
3077529|NCT02043704|Placebo Comparator|Saline|Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
3077530|NCT02043691|Experimental|Cook Custom Aortic Endograft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Cook Custom Aortic Endograft. The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
3077531|NCT02043691|Experimental|Zenith t-Branch Endovascular Graft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the sizing of the the Zenith t-Branch Endovascular Graft. The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
3077532|NCT02043691|Experimental|Surgeon-Modified Endograft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Surgeon-Modified Endografts. These will be created in the operating room by modifying a commercially-available Cook Zenith or Cook TX2 device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
3077533|NCT02043678|Experimental|Radium-223 dichloride|Radium-223 dichloride +abiraterone+prednisone/prednisolone All study subjects will receive treatment with oral abiraterone acetate (1000 mg once daily), oral prednisone/prednisolone (5 mg twice daily), with best supportive care
3077534|NCT02043678|Placebo Comparator|Placebo|Placebo+abiraterone+prednisone/prednisolone All study subjects will receive treatment with oral abiraterone acetate (1000 mg once daily), oral prednisone/prednisolone (5 mg twice daily), with best supportive care
3077535|NCT02043665|Experimental|CVA21/pembrolizumab|CVA21/pembrolizumab
3077536|NCT02043652|Experimental|Chloroquine and primaquine|Patients will receive 3-day treatment with chloroquine and 7-day treatment with primaquine in accordance to treatment guidelines in Brazil for P vivax malaria. All patients will receive the same treatment as there is no comparison arm.
3077537|NCT02043626|Experimental|Physical Activity Only|Students in 3 designated study schools will receive educational intervention and increased opportunities for physical activity.
3077538|NCT02043626|No Intervention|Delayed Interventions Only|Students in 3 designated schools will receive educational interventions on health topics not related to nutrition or physical activity (i.e. peer relations, sleep, dental care, etc.)
3077539|NCT02043626|Experimental|Nutrition and Physical Activity|Students in 3 designated schools will receive nutrition education, nutrition standards for foods sold, and opportunities for physical activity.
3077540|NCT02043626|Experimental|Nutrition Only Interventions|Students in 3 designated study schools will receive multiple interventions regarding nutrition education and nutrition standards for foods sold.
3077541|NCT02043613|Active Comparator|Exercise in standard room|"Intervention: Exercise~Patients exercise in standard physical surroundings. The room is marked by years of use. The room is placed in the basement, has artificial lighting, poor acoustics and bare concrete walls."
3077542|NCT02043613|Experimental|Exercise in a contexually enhanced room|"Intervention: Exercise + contextually enhanced physical surroundings~Patients exercise in a contextually enhanced room. The room has both artificial lighting and daylight, view of a recreational park, better acoustics, decorations among other factors, which may cause or enhance the context effect."
3077543|NCT02043613|No Intervention|Waiting list|Patients on waiting list are included, baseline tested and placed on a waiting-list for a 8 week period and tested at 8 weeks follow-up. The group is representative of the natural cause of disease.
3077544|NCT02043600|Experimental|Yoga|
3077545|NCT02043600|Active Comparator|Self-care|
3077578|NCT02043366|Sham Comparator|Sufentanil|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with sufentanil
3077579|NCT02043353||Winter Vs. Summer|All children that underwent PSG evaluation at the Tel Aviv Medical center between 2005-2010
3077546|NCT02043587|Experimental|Chemotherapy for ALL|"Course 1A: DNR 60 mg/m2 IV d1,2,3; VCR 1.4 mg/m2 d1,8,15,22 (cap 2 mg age >50); PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3750 IU/m2; CTX 750 mg/m2 d1,15 age < 40; Prednisone 60 mg/m2 PO d1-28; Liposomal AraC 25 mg IT d1, 15~1B: MTX 220 mg/m2 IV then 60 mg/m2/h for 36h d2-3,d16-17; LCV 50 mg/m2 IV q6h x3 then 10 mg/m2 PO/IV q6h til MTX <0.1 uM; 6-MP 60 mg/m2 PO d2-8, d16-22; PEG-asp 2000 IU/m2 IV d18, age >50 1000 IU/m2, cap 3750 IU/m2~1C: AraC 2 g/m2 IV d1-4; Etoposide 500 mg/m2 IV d1-4~1A-C repeat x1(2A-C) then 3rd Course B (3B)~Maintenance (monthly, 24 mo): Prednisone 60 mg/m2 PO d1-5; VCR 1.4 mg/m2 IV d1 (cap 2 mg age >50); MTX 20 mg/m2 PO wkly; 6-MP 60 mg/m2 PO qd PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3,750 IU/m2 (Mo. 1)~Maintenance mo. 1-4: Liposomal AraC 50 mg IT d1~Dasatinib 140 mg PO qd if Ph/BCR-ABL+; Rituximab 375 mg/m2 IV d1,15 of 1A-C, 2A (Pre-B)~1:1 randomization: hydrocortisone v. placebo before PEG-asp 1B, 2B, & Maint."
3077547|NCT02043574|Other|Stretching (Control)|Six months of stretching
3077548|NCT02043574|Experimental|Treadmill Exercise|Six months of treadmill training
3077549|NCT02043561|Sham Comparator|no urge|rectal balloon deflated
3077550|NCT02043561|Experimental|moderate urge|moderate urge induced by rectal balloon
3077551|NCT02043561|Experimental|high urge|high urge induced by rectal balloon
3077552|NCT02043548|Active Comparator|Group A: Tocilizumab|Tocilizumab will be given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
3077553|NCT02043548|Placebo Comparator|Group B: Placebo|Placebo arm - no active drug
3077554|NCT02043535|Other|Myocardial blood flow quantification|"RespirAct ™ Gen4 Sequential gas delivery breathing circuit: delivery of CO2 in increasing levels.~Rubidium Elution System: delivery of Rb-82 through an automated pump system for myocardial PET perfusion imaging.~Adenosine stress myocardial PET perfusion imaging: as a standard for comparison."
3077555|NCT02043522|Experimental|Nuclear Imaging|Planar, conventional SPECT imaging and CZT SPECT imaging will be done. Imaging will begin immediately following radioisotope injection with CZT SPECT imaging for 15 minutes, followed by 1) planar anterior view imaging for 10 minutes, 2) conventional SPECT imaging for 12.5 minutes and 3) CZT SPECT imaging for 12 minutes. A low dose CT transmission scan will be acquired for attenuation correction (GE Infinia Hawkeye) with the initial conventional SPECT imaging and not repeated with subsequent imaging. Participants will undergo repeat imaging at 1, 2, 3 and 4 hours after radiotracer injection with each imaging session to include 1) planar anterior, 2) conventional SPECT and 3) CZT SPECT imaging.
3077556|NCT02043509|Experimental|MiQuit|12 weeks of MiQuit text support plus a standard NHS leaflet giving information and advice on stopping smoking in addition to usual care
3077557|NCT02043509|No Intervention|Control|Usual care plus the same standard NHS leaflet giving information and advice on stopping smoking
3077558|NCT02043496|Experimental|CBT-Guided Self Help|Integrative Cognitive-Affective Therapy CBT-Guided Self Help
3077559|NCT02043496|Experimental|Integrative Cognitive-Affective Therapy|Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships
3077560|NCT02043483||CPAP|Patients with moderate/severe OSAS will be treated with CPAP
3077561|NCT02043483||Control|Patients with snoring will not be subject to treatment with CPAP
3077562|NCT02043457||Lifestyle intervention|Opt-in intervention to include the following procedures, called 'phenotyping' performed at baseline, after 10-15% weight loss from baseline weight or 6 months (whichever comes first) and at end of 2 years while in weight maintenance: oral glucose tolerance test, mixed meal tolerance test, with fasting leptin, biased and unbiased metabolomic profiling, DNA, RNA, muscle and adipose tissue biopsies: measurement of resting energy expenditure by indirect calorimetry; oxidative capacity (V02 peak/max); inventories of depression and health related quality of life instruments, measures of impulsivity, measures of hunger and appetite, work performance (including presenteeism and absenteeism), measurements of posture allocation, physical activity and sleep using Sensewear Body Media at pre-specificied time intervals during weight loss and maintenance of weight loss
3077563|NCT02043444|Experimental|secretory azoospermia|110 men with secretory azoospermia will have FDG PET-CT
3077564|NCT02043444|Active Comparator|excretory azoospermia|30 men with secretory azoospermia will have FDG PET-CT
3077565|NCT02043444|Placebo Comparator|normospermia|20 men with secretory azoospermia will have FDG PET-CT
3077566|NCT02043418||children VIH+|children infected with HIV
3077567|NCT02043418||Chlidren VIH-|uninfected children born from HIV-positive or HIV-negative mothers
3077568|NCT02043405|Experimental|Exercise Training and Weight Loss Intervention|Combination weight loss/exercise training, on insulin sensitivity, muscle lipid composition and localization in skeletal muscle.
3077569|NCT02043405|Active Comparator|4 Month Weight Loss Only Intervention|Use exercise training and weight loss as separate interventions in obese subjects with and without pre-diabetes.
3077570|NCT02043392|Experimental|Magnamosis|Create an intestinal anastomosis using the Magnamosis Magnetic Compression Anastomosis (Magnamosis) device to re-establish intestinal continuity that would otherwise be performed using sutures or stapling devices
3077571|NCT02043379|Experimental|IVIG|Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose and will be administered per hospital standards for IVIG administration.
3077572|NCT02043379|Placebo Comparator|Normal Saline|Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug. This infusion will be administered as if the subject is receiving IVIG according to hospital policy.
3077573|NCT02043366|Placebo Comparator|Normal Saline|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
3077574|NCT02043366|Active Comparator|Butorphanol|Butorphanol is intravenously administrated at a dose of 20μg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
3077575|NCT02043366|Active Comparator|Flurbiprofen axetilⅠ|Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
3077576|NCT02043366|Active Comparator|Flurbiprofen axetilⅡ|Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before the skin closure and intraoperative pain management was with remifentanil
3077583|NCT02043340|Experimental|Indocyanine green (ICG)|The study included 30 patients diagnosed with chronic periodontitis. Three sites from three different quadrants were selected and assigned to three groups namely, SRP group - scaling and root planing, LASER group - scaling and root planing with application of 810 nm diode laser and ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
3077584|NCT02043327||Experienced in Colonoscopy|two tests on two different modalities of colonoscopy simulators
3077585|NCT02043327||Novices in colonoscopy|Two tests on each of trw colonoscopy simulators
3077586|NCT02043314|Active Comparator|Isoniazida-LAQFA®|3 coated tablet of 100mg
3077587|NCT02043314|Experimental|Isoniazida|coated tablet of 300mg
3077588|NCT02043301|Active Comparator|Single 150 mg PF-04950615 dose administered to the abdomen|
3077589|NCT02043301|Experimental|Single 150 mg PF-04950615 dose administered to the upper arm|
3077590|NCT02043301|Experimental|Single 150 mg PF-04950615 dose administered to the thigh|
3077591|NCT02043288|Experimental|NC-6004 and Gemcitabine combination|90mg/m2 i.v. on Day 1 and 1000mg/m2 i.v. on Day 1, 8 and 15 respectively
3077592|NCT02043288|Active Comparator|Gemcitabine monotherapy|1000mg/m2 i.v. on Day 1 ,8 and 15
3077593|NCT02043275|Experimental|Leg training|Lower body resistance training only
3077594|NCT02043275|Active Comparator|Arm training|Upper body resistance training only
3077595|NCT02043262|Experimental|Reablement|Reablement is an intensive, multidisciplinary, client-centered, home-based type of rehabilitation, where ordinary activities of daily living are used for rehabilitative purposes. It is a rehabilitation alternative that may be offered to older adults, although there is no lower age limit. An occupational therapist and physical therapist, or nurse, constitutes the key personal, while home helpers, assistants and others with lower education, are the ones who work rehabilitative with the older person on a daily basis focusing on self-help.
3077596|NCT02043262|Active Comparator|Standard treatment|This arm consists of the standard treatment home-dwelling elderly persons receive when applying for home-based help. Some elderly may receive home-based nursing or home help services assisting them in daily activities, while others may receive occupational therapy or physical therapy measures for rehabilitative purposes.
3077597|NCT02043249|No Intervention|CORD MILKING|WITHOUT MILKING
3077598|NCT02043236|Active Comparator|Healthy bones pamphlet, letter to GP|Strategy 1: Written educational material to patient and GP
3077599|NCT02043236|Active Comparator|Healthy bones pamphlet, Bone Health Care Coordinator|Strategy 2: Written educational material to patient and counseling from a Bone Health Care Coordinator
3077600|NCT02043236|No Intervention|Usual care|Control group gets usual care from their oncologist.
3077601|NCT02043223|Experimental|Early postpartum vitamin A suppl.|Single dose 200,000 IU vitamin A supplementation at <3-day and placebo supplementation at 6-wk postpartum.
3077602|NCT02043223|Experimental|Late postpartum vitamin A suppl.|Placebo supplementation at <3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.
3077603|NCT02043223|Experimental|Early & late postpartum vitamin A suppl|200,000 IU vitamin A supplementation, both at <3-day and 6-wk postpartum
3077604|NCT02043223|Experimental|No postpartum vitamin A suppl.|Placebo supplementation, both at <3-day and 6-wk postpartum.
3077605|NCT02043210|Active Comparator|Standard Treatment as Usual|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on substance abuse.
3077606|NCT02043210|Experimental|CBT4CBT plus Standard treatment as usual|A computerized program that teaches skills for stopping substance use by increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc. plus standard treatment as usual.
3077607|NCT02043197||Outpatients with neurological disorders and depression.|Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.
3077608|NCT02043184|Active Comparator|Standard Care 12 weeks|Standard care. Standard supportive care and Toolkit given at 12 weeks.
3077609|NCT02043184|Experimental|Standard Care 8 wks, Daily IVR 4 wks|Interactive Voice Response (IVR) Reminders Daily delivery for the last 4 weeks of the study.
3077610|NCT02043184|Experimental|Daily IVR 8 weeks|Interactive Voice Response (IVR) Reminders daily for the first 8 weeks of the study.
3077611|NCT02043184|Experimental|Daily IVR 4 wk, Every other day IVR 4 wk|Interactive Voice Response (IVR) Reminders daily for the first 4 weeks of the study and every other day for weeks 4-8.
3077612|NCT02043171|Placebo Comparator|Placebo Exercise|Placebo supplementation group with 3 days per week of exercise
3077613|NCT02043171|Placebo Comparator|Placebo Non-exercise|Placebo supplementation group without exercise
3077614|NCT02043171|Active Comparator|HMB plus Vitamin D Exercise|HMB plus Vitamin D supplementation group with 3 days per week of exercise
3077615|NCT02043171|Active Comparator|HMB plus Vitamin D Non-exercise|HMB plus Vitamin D supplementation group without exercise
3077616|NCT02043158||Ovarian Cancer Survivors|Short-term and long-term ovarian cancer survivors
3077617|NCT02043145||Axillary Hyperhidrosis|Patients with Axillary Hyperhidrosis who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
3077618|NCT02043145||Focal Spasticity|Patients with Focal Spasticity who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
3077619|NCT02043145||Glabellar Lines|Patients with moderate or severe Glabellar Lines who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
3077620|NCT02043132|Active Comparator|Tranexamic acid|Infusion Tranexamic acid on study subjects. They will be randomized to receive an infusion of the standard dose of Tranexamic acid (10mg/kg) One dose will be given by the bedside nurse within 60 minutes prior to surgery and a second dose will be given at wound closure. Infusion will be given along with standard preoperative and operative infusion; no additional infusion will be necessary.
3077905|NCT02040844|Other|Cat-PAD Treatment 2|Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762].No further treatment received in CP007A.
3077621|NCT02043132|Placebo Comparator|Normal Saline|Infusion of placebo on study subjects. They will be randomized to receive an infusion of placebo (an equivalent volume of normal saline). One dose will be given by the bedside nurse within 60 minutes prior to surgery and a second dose will be given at wound closure. Infusion will be given along with standard preoperative and operative infusion; no additional infusion will be necessary.
3077622|NCT02043119|Active Comparator|Breastfeeding Clinic|A breastfeeding clinic that mothers can attend with their infants up to one month post delivery.
3077623|NCT02043119|No Intervention|Standard of Care|
3077624|NCT02043106|Experimental|spinal cord injury|Individuals who have sustained an incomplete spinal cord injury
3077625|NCT02043106|Active Comparator|non-spinal cord injury|Individuals who have not sustained a spinal cord injury
3077626|NCT02043093|No Intervention|Waiting|Surveys are administered to school students and staff, but Sources of Strength program is not implemented until the school year following two years of survey participation
3077627|NCT02043093|Experimental|Intervention|School receives Sources of Strength Peer Leader training and implementation for two school years, beginning in fall of enrollment year. Peer leaders are actively implementing program across two school years. Students and school staff participate in surveys across the two implementing school years.
3077628|NCT02043080|No Intervention|SOC: sputum smear and Chest x-ray|HIV-infected adult and pediatric TB suspects screened for TB according to current standard of care
3077629|NCT02043080|Experimental|Xpert MTB/RIF, sputum, chest xray &TB culture|HIV-infected adult and pediatric TB suspects screened for TB using the Xpert MTB/RIF Tuberculosis diagnostic tool (algorithm) which include chest x-ray, sputum TB culture
3077630|NCT02043067||new HIV clinic enrollees|All new enrollees to a Lusaka HIV clinic will receive a full TB work-up.
3077631|NCT02043054|Experimental|Liraglutide|Liraglutide doses will be self-administered by the participant through daily subcutaneous injections. Liraglutide doses will be initiated at 0.6 mg and then increased to 1.2 mg in week two and 1.8mg in week three. The dose will then be maintained at 1.8 mg. Where 1.8 mg doses are not tolerated by the patient, the dose will be lowered to the maximum tolerated dose at the investigators discretion.
3077632|NCT02043054|Active Comparator|Sitagliptin|Sitagliptin doses will be self-administered by the participant orally at 100mg/day throughout the 26 week period of the study. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea)
3077633|NCT02043041||1 Dried Blood Spot (DBS)|Number of DBS Spots Participants will be asked to fill one spot on a dried blood spot collection card.
3077634|NCT02043041||3 DBS Spots|Number of DBS Spots Participants will be asked to fill three spots on a dried blood spot collection card.
3077635|NCT02043041||5 DBS Sports|Number of DBS Spots Participants will be asked to fill five spots on a dried blood spot collection card.
3077636|NCT02043028|Experimental|Group 1|"Participants compress the chest of a manikin with kneeling posture using a kneeling stool for chest compression posture during 5 minutes~2 weeks later, They perform the chest compression with standing posture using a step stool during 5 minutes"
3077637|NCT02043028|Experimental|Group 2|"Participants compress the chest of a manikin with a standing posture using a step stool for chest compression posture during 5 minutes~2 weeks later, They perform the chest compression with a kneeling posture using a kneeling stool stool and bed height adjustment during 5 minutes"
3077638|NCT02043015|Other|Comprehensive HIV prevention services|A comprehensive package of HIV prevention services, including condom choices, Condom-compatible lubricant choices, Couples HIV counseling and testing (CVCT), Staff and provider MSM and LGBT sensitization training, HIV Testing and Risk-reduction counseling, Linkage to care, Pre-exposure prophylaxis with FTC/TDF
3077639|NCT02043002|Experimental|18F-FDG-PET scan|An early evaluation 18F-FDG-PET scan after 7-10 days
3077640|NCT02042989|Experimental|MLN9708 and Vorinostat|"Dose Escalation Phase: Starting Dose of MLN9708 3 mg by mouth on day 1, 8 and 15. Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.~Dose Expansion Phase Starting Doses of MLN9708 and Vorinostat: Maximum tolerated dose from Dose Escalation Phase."
3077641|NCT02042976|Experimental|Mindfulness-based cognitive therapy + pulmonary rehabilitation|An 8-week manual-based programme developed by Segal, Williams and Teasdale (2013) adjusted to the COPD population. The programme is delivered as an add-on to an 8-week standardised rehabilitation programme consisting of physical exercise and COPD-specific patient education.
3077642|NCT02042976|Active Comparator|Pulmonary rehabilitation only|An 8-week standardised rehabilitation programme consisting of physical exercise and COPD-specific patient education.
3077643|NCT02042963||KNOW-KT|1000 Kidney transplant recipients in Korea
3077644|NCT02042950|Experimental|Carfilzomib|Carfilzomib given at a dose of 20*/56 mg/m^2 (* CFZ 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
3077645|NCT02042937|No Intervention|Control|No intervention
3077646|NCT02042937|Experimental|Exercise|Exercise to improve gluteus maximus recruitment
3077647|NCT02042924|Experimental|Imaging studies|Subjects will have a FLT PET/CT and a MRI prior to starting the preparative regimen for transplant and another of each scan 100 days after transplant.
3077648|NCT02042911|Experimental|SyB L-0501|
3077649|NCT02042898|Active Comparator|Restrictive transfusion strategy|Restrictive transfusion strategy: patients will receive a red cell transfusion if their hemoglobin is <75 g/L (<7.5 g/dL;<4.7mmol/L) intraoperatively and/or postoperatively
3077650|NCT02042898|Active Comparator|Liberal transfusion strategy|Liberal transfusion strategy: patients will receive a red cell transfusion if their hemoglobin concentration is <95 g/L (<9.5 g/dL<5.9mmol/L) intraoperatively, or postoperatively in the intensive care unit; and/or <85 g/L (< 8.5 g/dL;<5.3mmol/L) on the ward.
3077651|NCT02042885|Experimental|1: Regimen A Escalation|1: OPB-111001, orally, once weekly
3077652|NCT02042885|Experimental|2: Regimen A Extension|2: OPB-111001, orally, once weekly
3077653|NCT02042885|Experimental|3: Regimen B Escalation|3: OPB-111001, orally, 2 - 3 times per week
3077654|NCT02042885|Experimental|4: Regimen B Extension|4: OPB-111001, orally, 2 - 3 times per week
3077747|NCT02042092|Active Comparator|Magnetic resonance angiography (MRA)|The aorta, supraaortic large vessels and the temporal arteries of the sLVV patients will be evaluated by Magnetic resonance angiography
3077655|NCT02042872|Experimental|Zoledronic acid|At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
3077656|NCT02042872|No Intervention|No Intervention|Participants will receive no therapy and serve as a control group and have the same outcome measures completed at parallel time points.
3077657|NCT02042846|Experimental|SportWelding Fiji Anchor|
3077658|NCT02042833||Cohort|
3077659|NCT02042820||Dry Eye Disease|"Confocal Imaging - In vivo confocal microscopy (IVCM)~Ophthalmic Examination:~Tear Break Up Time (TBUT)~Ocular Surface Disease Index (OSDI)~Schirmer's II test~Conjunctival staining with lissamine green~Corneal staining with fluorescein~Conjunctival redness assessment"
3077660|NCT02042820||Control|"Confocal Imaging - In vivo confocal microscopy (IVCM)~Ophthalmic Examination:~TBUT~OSDI~Schirmer's II test~Conjunctival staining with lissamine green~Corneal staining with fluorescein~Conjunctival redness assessment"
3077661|NCT02042807|Placebo Comparator|Placebo|placebo arm
3077662|NCT02042807|Active Comparator|MCS® 15 mg/day|MCS® soft capsule
3077663|NCT02042807|Active Comparator|MCS® 30 mg/day|MCS® soft capsule
3077664|NCT02042781|Experimental|PG545|Once weekly, one hour IV infusion of PG545.
3077665|NCT02042742|Experimental|Antioxidant supplement|Treatment consist of consuming 65g of punicalagin and 3,3g of hydroxytyrosol (plus 331,7g of maltodextrin) three times daily, during 8 weeks.
3077666|NCT02042742|Placebo Comparator|Control supplement|Treatment consist of consuming 400g of maltodextrin three times daily, during 8 weeks.
3077667|NCT02042729|Experimental|E2022- Tape Formulation|
3077668|NCT02042729|Placebo Comparator|Matching Placebo E2022|Matching Placebo
3077669|NCT02042729|Active Comparator|E2022- New Formulation|
3077670|NCT02042729|Placebo Comparator|Placebo E2022- New Formulation|Matching Placebo
3077671|NCT02042716|Experimental|diagnosis of white matter damage|Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
3077672|NCT02042703||exfoliation syndrome|patients with exfoliation syndrome
3077673|NCT02042703||POAG|patients with primary open angle glaucoma (POAG)
3077674|NCT02042703||cataracts|patients with cataracts
3077675|NCT02042690|Active Comparator|chemotherapy|"Drugs:~Drug:Methotrexate 1g/m2 d1,IV (in the vein) , used in cycle 1,3,5 Drug:arabinoside 2-3g/m2,q12h, d2-3, IV, used in cycle 1,3,5 Drug:cyclophosphamide:300mg/m2 q12h, d1-3, IV,used in cycle 2,4,6 Drug:Epirubicin 60mg/m2.d，d4,used in cycle 2,4,6 Drug:Vindesin 4mg/d，d4，d11, IV,in cycle 2,4,6 Drug:dexamethasone 40mg/d，d1-4，d11-14, IV, in cycle 2,4,6 Drug:Methotrexate 20 mg/m2/w,po, during maintenance treatment for 2 years Drug:6-mercaptopurine 60 mg/m2/d，po，d1-d28,during maintenance treatment for 2 years Drug:Vindesin 4mg/d，Predisone:1mg/kg, d1-7, every month during maintenance treatment for 2 years"
3077676|NCT02042690|Experimental|Haplo-identical HSCT|Haplo-identical HSCT Protocol:G, donor treatment with recombinant granulocyte colony-stimulating factor (rhG-CSF); I, intensified immunologic suppression; A, antihuman thymocyte immunoglobulin (ATG) for the prevention of GVHD; C, combination of peripheral blood stem cell transplantation (PBSCT), and bone marrow transplantation (BMT)，named GIAC regimen. Graft versus-host disease(GVHD) prevention regimen: CSA/MMF/MTX, cyclosporine A(CSA) 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HSCt and then gradually tapered. Every 12h, 0.5g mycophenolate mofetil (MMF)(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. Methotrexate (MTX) was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
3077677|NCT02042664|Experimental|treatment BYETTA|
3077678|NCT02042664|Active Comparator|metformine|
3077679|NCT02042651|Experimental|Low intensity extracorporeal shockwave therapy|Active treatment with low intensity extracorporeal shockwave therapy applied to the perineum.
3077680|NCT02042651|Sham Comparator|Sham low intensity extracorporeal shockwave therapy|Sham treatment with low intensity extracorporeal shockwave therapy applied to the perineum.
3077681|NCT02042638||16 treatment naive Hypogonadotropic hypogonadism patients|Treatment naive 16 patients with idiopathic hypogonadotrophic hypogonadism
3077682|NCT02042625|Other|nasopharyngeal|The nasopharyngeal probe will be inserted into the nostril. The nasopharyngeal temperature will initially be recorded 45 minutes after anesthetic induction. The nasopharyngeal probe will then be withdrawn 2 cm and after a 3-minute equilibration period, nasopharyngeal temperatures will again be recorded. The nasopharyngeal probe withdrawal sequence will be repeated, 2 cm at a time, until only 2 cm remains in the nostril. There will be a total of 10 sets of nasopharyngeal temperatures obtained.
3077683|NCT02042612|Experimental|sevoflurane|Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in obese ICU patients
3077684|NCT02042599|Experimental|sevoflurane|Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in ICU patients with acute kidney injury
3077685|NCT02042586||Patients|
3077686|NCT02042586||Controls|
3077687|NCT02042573|Other|Depressive patients treated with rTMS|
3077688|NCT02042573|Other|Depressive patients treated with SSRI|
3077689|NCT02042573|Other|Controls|
3077690|NCT02042560||Patients with ITP|
3077691|NCT02042560||Controls|
3077692|NCT02042547||Patients about to undergo heart surgery|
3077693|NCT02042534|Experimental|Rivaroxaban|Rivaroxaban group for 1 month : initial 5 days after randomization rivaroxaban 10mg QD will be administered. Rivaroxaban 20mg QD, but 15mg in case of Cr CL will be administered for remaining 25 days.
3077694|NCT02042534|Active Comparator|Warfarin|Patients allocated to warfarin receive warfarin plus aspirin 100mg until INR value exceed 1.7 followed by warfarin monotherapy with target INR value of 2.5 [2.0 - 3.0].
3077695|NCT02042521|Experimental|Healthy Smokers (Active then Placebo)|"Healthy individuals who smokes at least 20 cigarettes per day~Interventions: Dietary Supplement, Lactose Placebo"
3077696|NCT02042521|Experimental|Healthy Smokers (Placebo then Active)|"Healthy individuals who smokes at least 20 cigarettes per day~Interventions: Dietary Supplement, Lactose Placebo"
3077697|NCT02042508|Experimental|Paraplegic patients|
3077748|NCT02042079|Experimental|EFTR with LA|(Endoscopic full-thickness resection with laparoscopic assistance)
3077698|NCT02042495|Experimental|Metformin|"Metformin 500 mg PO TID from time of entry to study until scheduled surgical staging operation.~In cases of unresolving side effects, the metformin will be dose reduced to metformin 500 mg PO BID with evaluation after 1 week followed by withdrawal from the study if side effects persist."
3077699|NCT02042482|Experimental|Coenzyme Q10U, L-carnitine|Patients receive combination of coenzyme Q10U 180 milligram and L-carnitine 2000 milligram
3077700|NCT02042469||Survey|Cross-sectional survey will be carried out using an interview questionnaire composed of close-ended questions to be completed by trained research coordinator.
3077701|NCT02042456||Main Cohort|Subjects enrolled in this group will receive a full field digital mammogram, digital breast tomosynthesis exam and an automated whole breast ultrasound exam as part of their visit.
3077702|NCT02042443|Experimental|Trametinib|Patients receive trametinib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3077703|NCT02042443|Experimental|Chemotherapy|Patients receive either A) leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46-48 hours on days 1 and 15 (courses repeat every 28 days); or B) capecitabine PO BID on days 1-14 (courses repeat every 21 days). Patients treated until disease progression or unacceptable toxicity.
3077704|NCT02042430|Experimental|Treatment (IDO1 inhibitor INCB024360)|Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-14 and undergo surgery on day 15. Treatment continues in the absence of disease progression or unacceptable toxicity. In circumstances where there are medical or administrative reasons for delaying surgery, treatment with IDO1 inhibitor INCB024360 may continue for up to 3 weeks.
3077705|NCT02042417|Experimental|INRatio2 and CoaguChek|one measuring per tool, in case of error: one repetiton
3077706|NCT02042404|Experimental|Mild to severe hearing impairment|Sound amplification provided via the EarLens System assistive hearing device.
3077707|NCT02042391|Experimental|Low-risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered low-risk if they reached a complete remission with the first 4 applications of rituximab monotherapy or if they reached a partial remission and had a baseline IPI of 0, 1 or 2. Patients considered low-risk will receive rituximab sc consolidation.
3077708|NCT02042391|Experimental|High risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered high-risk, if the reached a partial remission and were IPI 3, 4 or 5 at time of diagnosis of PTLD, if they show stable disease or if they had progressive disease but are not recipients of heart or lung transplants. Patients considered high-risk will receive four more applications of rituximab sc combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113.
3077709|NCT02042391|Experimental|Very high-risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, heart and lung transplant recipients and patients with a combination of organs transplanted including a heart or lung transplant who show disease progression during rituximab monotherapy or at interim staging will be considered very high-risk. Patients considered very high-risk will receive six more applications of rituximab sc combined with alternating chemotherapy with CHOP and DHAOx.
3077710|NCT02042378|Experimental|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
3077711|NCT02042365||ERAS (Enhanced recovery after surgery)|This observational study evaluates the feasibility of ERAS pathway in six French departments of surgery located at Clermont-Ferrand, Bordeaux, Montpellier, Amiens, Strasbourg and Aurillac
3077712|NCT02042352||pH test|VpH test gloves
3077713|NCT02042339|Experimental|Hyperbaric oxygen|Problem-wound schedule: 2.4 atmospheres, 100% oxygen for 90 minutes, two 10 - minute breaks (patients breathing pressurized air from the chamber atmosphere)
3077714|NCT02042339|Placebo Comparator|Sham Hyperbaric oxygen|The patients will be transferred into the chamber like the treatment group. Instead of 100% oxygen they will breathe normal air through the tight fitting masks, at an ambient pressure of 1.1 bar. During the two 10 - minute breaks patients will breathe pressurized air from the chamber atmosphere.
3077715|NCT02042326|Experimental|Sirolimus treatment|"Patients will receive sirolimus (Rapamune). The dose should be adjusted to obtain a residual plasma rate of 8 to 12 ng/ml in 4 weeks. This serum level will be maintained throughout the duration of the study in the absence of side effects. In case of intolerance that do not justify the discontinuation of treatment, the dose may be reduced by maintaining a serum level greater than 3 ng/ml.~The starting dose will be 2 mg per day, and will be adapted every week for one month.~The preferred dosage form is tablet form. To prevent common side effects in early treatment, corticosteroids based prednisolone (SOLUPRED) will be established at a dose of 0.5 mg/ kg/day for the first week of treatment."
3077716|NCT02042313|Active Comparator|Epidural|Epidural catheters will be applied at the T6-8 level prior to the induction. 6 ml of 2% xylocaine with 1 in 200,000 epinephrine administered before surgery. During the surgery, 2% xylocaine with 1 in 200,000 epinephrine infusion will be administered at a rate of 2-10 ml/hour adjusted according to patient's blood pressure. After surgery, 0.125% levobupivacaine with 2.5μg fentanyl and 1 in 400,000 epinephrine will be given at a rate of 0.10-0.15 ml kg-1 h-1 (0.5 h lock and 2 ml bolus) through a patient-controlled infusion pump.
3077717|NCT02042313|Experimental|combined PVB TAP|"Paravertebral catheterization into the paravertebral region ipsilateral to the VATS incision as described by Murata at the level of T7-8 will be performed. 10 ml of 2% xylocaine with 1 in 200,000 epinephrine to initiate analgesia. During the surgery, 2% xylocaine with 1 in 200,000 epinephrine infusion will be administered at a rate of 2-10 ml/hour adjusted according to patient's blood pressure. After the surgery, 0.125% levobupivacaine with 2.5μg fentanyl and 1 in 400,000 epinephrine will be administered at the rate of 0.10-0.15 ml kg-1 h-1 (0.5 h lock and 2 ml bolus) through a patient-controlled infusion pump.~Ultrasound-guided (USG) subcostal TAP block will be performed at the end of surgery. Fifteen milliliters of 0.5% levobupivacaine with 1 in 400,000 epinephrine will be injected in incremental doses on each side of the abdomen."
3077718|NCT02042300||IRIS-Xpedition/Alpine Cohort|XIENCE Xpedition/Alpine
3077719|NCT02042287|Experimental|1: Gynofit®|Vaginal lactic acid gel
3077720|NCT02042287|Active Comparator|2: metronidazole|Oral antibiotic
3077721|NCT02042274|Experimental|Fish oil supplement|Fish oil supplements providing up to 3g per day of EPA and DHA
3077722|NCT02042248|Experimental|Arm A: ART initiated during AHI|Arm A will enroll approximately 6 participants who initiated ART during AHI (acute HIV infection). The target dose of AGS -004 is delivered in three ID (intradermal) injections of 0.2 mL of AGS-004 (0.6 mL total volume) for a total of 1.2 x 107 viable cells. AGS-004 is administered every 4 weeks at weeks 0, 4, 8, and 12 for a total of 4 doses.
3077723|NCT02042248|Experimental|Arm B: ART initiated during CHI|Arm B will enroll approximately 6 participants who initiated ART during CHI (chronic HIV infection). The target dose of AGS -004 is delivered in three ID (intradermal) injections of 0.2 mL of AGS-004 (0.6 mL total volume) for a total of 1.2 x 107 viable cells. AGS-004 is administered every 4 weeks at weeks 0, 4, 8, and 12 for a total of 4 doses.
3077724|NCT02042235|Experimental|Parent-implemented language intervention|In the intervention group, the techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
3077725|NCT02042235|No Intervention|Control group|The control group will benefit from the actual routine care for children with language delay before the age of 3 years. In order to provide them the best routine care, the psychologist will provide some advice to the parents to enhance their child's language (e.g.: using life situations to talk with the child and encourage him/her to talk …).
3077726|NCT02042222|Active Comparator|Standard Arm|Half of the subjects initiating hydroxyurea will be randomly assigned to the standard treatment arm, consisting of escalation to the maximum tolerated dose (MTD) of hydroxyurea utilizing a previously published algorithm. Hydroxyurea dosing will commence at 20+/-2.5 mg/kg/day, given as a single daily oral dose. All patients will be offered the choice of a liquid formulation of hydroxyurea or hydroxyurea tablets, with the exact dose rounded up or down to the closest practical dose based on the chosen formulation but not differing from the intended dose by more than 2.5 mg/kg. It should take approximately 6 to 12 months for subjects to reach the MTD on this arm.
3077727|NCT02042222|Active Comparator|Alternative Treatment Arm|"Half of the subjects initiating hydroxyurea therapy will be assigned to the alternative treatment arm of the study. In this arm, the predicted hydroxyurea MTD will be calculated for each subject.~As in the dose-escalation arm, the exact dose will be rounded up or down to the closest practical dose based on the chosen formulation of hydroxyurea. Since the most common toxicity associated with hydroxyurea use is excessive myelosuppression, the maximum dose at which a subject in the dose-prediction arm will be started will be 30 mg/kg/day or 2000 mg/day. Patients with a higher predicted MTD will subsequently be escalated to this higher dose after four weeks on therapy if there is no evidence of toxicity."
3077728|NCT02042196|Experimental|Pre or Early perimenopausal 1|"Baseline experiment: Subjects randomized to either 1) KUVAN (10mg/kg body weight) crossover to placebo OR 2) placebo crossover to KUVAN~Hormone modification: GnRH antagonist with Cetrotide (0.25mg/d) + placebo transdermal patch, then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN"
3077729|NCT02042196|Experimental|Pre or Early Perimenopausal 2|"Baseline experiment: Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN~Hormone modification: Estrogen add-back with Cetrotide + Climara (0.075mg/d), then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN"
3077730|NCT02042196|Experimental|Late Perimenopausal and Postmenopausal|"Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN~No hormone modification."
3077731|NCT02042183|Experimental|Lubiprostone|12 or 24 mcg capsules twice daily (BID)
3077732|NCT02042183|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
3077733|NCT02042170|Experimental|Sr-hGH 0.5 mg/kg/wk|Patients inject Eutropin plus (Sr-hGH) 0.5 mg/kg/wk every week himself/herself.
3077734|NCT02042170|Experimental|Sr-hGH 0.7 mg/kg/wk|Patients inject Eutropin plus (Sr-hGH) 0.7 mg/kg/wk every week himself/herself.
3077735|NCT02042170|Active Comparator|Daily hGH 0.37 mg/kg/wk|Patients inject Eutropin (daily hGH) 0.37 mg/kg/wk everyday for the first 6days a week himself/herself.
3077736|NCT02042157|Experimental|Bidet use|This arm will have a bidet installed in their home bathroom and be instructed how to use it. This arm will use the bidet for usual toileting for a period of two years.
3077737|NCT02042157|Placebo Comparator|Usual Toileting|This group will toilet as usual.
3077738|NCT02042157|Experimental|Caregivers of PT in Arm 1 (bidet use)|"Participants with functional impairment will be randomized into one of two arms (bidet use or usual toileting). Their caregivers will be enrolled and their randomization is bundled with the study participant who they care for. This arm will care for participants who have been randomized to bidet."
3077739|NCT02042157|Placebo Comparator|Caregivers of PT in Arm 2 (usual toileting)|"Participants with functional impairment will be randomized into one of two arms (bidet use or usual toileting). Their caregivers will be enrolled and their randomization is bundled with the study participant who they care for. This arm will care for participants who have been randomized to usual toileting."
3077740|NCT02042144||Group 1|
3077741|NCT02042131|Active Comparator|Treatment As Usual (TAU)|"TAU includes the following intervention components:~suicide risk assessment~supportive listening~provision of professional and crisis contact information~referral to mental health treatment and community resources~verbal contract for safety"
3077742|NCT02042131|Experimental|Standard Crisis Response Plan (S-CRP)|"CRP includes the following intervention components:~suicide risk assessment~supportive listening~identify personal warning signs~identify self-management skills~identify social support contacts~provision of professional and crisis contact information~referral to mental health treatment and community resources"
3077743|NCT02042131|Experimental|Enhanced Crisis Response Plan (E-CRP)|"The E-CRP includes the following intervention components:~suicide risk assessment~supportive listening~identify personal warning signs~identify self-management skills~identify reasons for living~identify social support contacts~provision of professional and crisis contact information~referral to mental health treatment and community resources"
3077744|NCT02042118|Experimental|Laryngeal Mask Airway|Laryngeal mask airway (LMA) ventilation will be provided for newborns in this arm during the first 2.5 minutes.
3077745|NCT02042118|Active Comparator|Face mask ventilation|Face-mask ventilation (FMV) will be provided for newborns in this arm during the first 2.5 minutes.
3077746|NCT02042092|Active Comparator|Color Doppler Ultrasound (CDUS)|The aorta, supraaortic large vessels and the temporal arteries of the sLVV patients will be evaluated by color Doppler ultrasound
3077749|NCT02042066|Experimental|Treated Group|This group will receive actual shockwave treatment
3077750|NCT02042053|Experimental|PET/MR|Patients treated with SipT (standard of care) undergo FDG-PET/MRI, NaF-PET/CT and blood drawing at 3 time points: baseline, Day 7 after the last SipT infusion, Week 10 after the last SipT infusion.
3077751|NCT02042027|Active Comparator|Group A|Gamunex-C 50 mg subconjunctival injections, in addition to standard of care treatment (steroids and cyclosporine). One dose of Gamunex-C injection delivered four weeks prior to corneal transplant surgery and one dose at the time of corneal transplantation. Dose to be repeated if recurrence of corneal neovascularization
3077752|NCT02042027|Active Comparator|Group B|Gamunex-C 50 mg subconjunctival injections, one dose injected for patients with active disease from corneal melts (peripheral ulcerative keratitis; Mooren's ulcer), ocular cicatricial pemphigoid, or anterior uveitis refractory to conventional therapy.
3077753|NCT02042014|Experimental|QTI571|Participants will receive QTI571 during 3 years.
3077754|NCT02042001|Experimental|Immediate Switch|Immediate switch to TDF/FTC/RPV
3077755|NCT02042001|Active Comparator|Deferred Switch|Switch to TDF/FTC/RPV after 24 weeks
3077756|NCT02041988||0,2 mg/kg oral morphine|Patients have been assigned to two groups of 20 individuals, they have been premedicated with oral morphine sulfate, 0,2 mg/kg group A, 0,4mg/kg group B.During surgery analgesic administration will be monitored
3077757|NCT02041988||0,4 mg/ kg oral morphine|morphine and analgesic consumption throughout surgery will be monitored
3077758|NCT02041975|Experimental|Prebiotic|Nutriose FB06 14g/day
3077759|NCT02041975|Placebo Comparator|Placebo|Maltodextrin
3077760|NCT02041962|Active Comparator|Educational Control|Patients will receive their usual care from providers at their clinic. They will also receive in the mail a self-guided workbook.
3077761|NCT02041962|Experimental|Chronic Care Model for Mood Disorders|Life Goals Collaborative Care
3077762|NCT02041936|Experimental|NanoKnife IRE System|
3077763|NCT02041923|Placebo Comparator|Attention Control|Mothers received equal amount of attention from the team
3077764|NCT02041923|Experimental|H-HOPE Intervention|H-HOPE was administered twice daily by the mother.
3077765|NCT02041910|Experimental|Stem Cells|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
3077766|NCT02041910|Experimental|Stem Cells Injection|Stem Cell Dose 3-5 Million Autologous MSCs Injected into testis.
3077767|NCT02041897|Other|EUS-FNA, Rate of chang on diagnosis|It is a single arm study. We will conclude by calculating the rate of change of diagnosis before and after getting the results of EUS-FNA.
3077768|NCT02041884|Experimental|iCBT|A skill training internet-based treatment program based on CBT and DBT interventions .
3077769|NCT02041884|Active Comparator|Internet stress-reduction|Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
3077770|NCT02041884|Other|Treatment as usual (TAU)/waiting list|Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
3077771|NCT02041871|Experimental|Impact control|ORAL IMPACT Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
3077772|NCT02041871|Placebo Comparator|Placebo|Placebo
3077773|NCT02041858|No Intervention|Control|Control arm with organizational-based alarm parameter settings
3077774|NCT02041858|Experimental|Altered Alarm Settings|Altered set of alarm parameter settings.
3077775|NCT02041845|Active Comparator|A|3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week
3077776|NCT02041845|Experimental|B|3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week
3077777|NCT02041832|Other|Holter monitoring|Screening of patients with older age, arterial hypertension and diabetes for paroxysmal atrial fibrillation by using conventional Holter monitoring
3077778|NCT02041832|Other|Implantable loop recorder|Screening of patients with older age, arterial hypertension and diabetes mellitus for paroxysmal atrial fibrillation by using an implantable loop recorder
3077779|NCT02041819|Experimental|Nimotuzumab nab-paclitaxel cisplatin|"Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22.~Nab-paclitaxel: 125mg/m2,IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
3077780|NCT02041793|Active Comparator|Laparoscopic cystogastrostomy|Laparoscopic cystogastrostomy will be performed by using a stapled cystogastrostomy
3077781|NCT02041793|Active Comparator|Endoscopic cystogastrostomy|Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance.
3077782|NCT02041780|Experimental|Shearwave electrography|"Two experimental interventions will be realized in each patient in this population : Shearwave electrography (new diagnostic test of fibrosis) and Fibrotest .~Moreover, liver biopsies, the gold standard for the fibrosis diagnosis is also realized in each patient within usual cares."
3077783|NCT02041767|Experimental|group A|One single perfusion of 1g of ertapenem 1 hour prior to prostate surgical resection
3077784|NCT02041767|Experimental|group B|One single perfusion of 1g of ertapenem 12 hour prior to prostate surgical resection
3077785|NCT02041754|Active Comparator|IQP-AK-102|2 capsules per dose, 3 times daily, 30-60 mins before each main meal with a full glass (250 mL) of water
3077786|NCT02041754|Placebo Comparator|Placebo|2 capsules per dose, 3 times daily, 30-60 mins before each main meal with a full glass (250 mL) of water
3077787|NCT02041741|Active Comparator|Weekly tips|Daily small and concrete happiness tips
3077788|NCT02041741|Active Comparator|Daily Tips|Weekly more in-depth happiness tips involving an active (doing and experiencing) task
3077789|NCT02041741|No Intervention|Wait-List Control|No intervention
3077790|NCT02041715|Experimental|TKM-100802 for Injection|
3077791|NCT02041715|Placebo Comparator|Placebo|
3077792|NCT02041702|Experimental|Cardiac MRI Scan|Patients receiving the SJM MRI conditional pacing system implant who are randomized into the experimental group will undergo a Cardiac MRI scan .
3077793|NCT02041702|Active Comparator|MRI Control|Patients receiving the SJM MRI conditional pacing system implant who are randomized into this group will not undergo Cardiac MRI group
3077869|NCT02041156|Active Comparator|aerobic with balance training|Regular aerobic activity combined with 3 sessions/week of balance training totalling 150 minutes per week of physical activity
3077794|NCT02041689||Participants|"Patients at St. Jude Children's Research Hospital between the ages of 7 and 11 years who have a working diagnosis or initial diagnosis of a bone or soft tissue sarcoma.~Interventions: two unstructured life-story interview sessions, observations, and guided activities."
3077795|NCT02041676|Experimental|1: chest physiotherapy technique|Chest physiotherapy technique increasing inspiratory flow (IIF) 3 times per day
3077796|NCT02041676|Active Comparator|2: Usual surveillance|Usual surveillance of the non invasive ventilation
3077797|NCT02041663|Experimental|Population|Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
3077798|NCT02041650|Other|Patients with ACS treated medically|
3077799|NCT02041624||allergic rhino-conjunctivitis|Patient with proven allergic rhino-conjunctivitis due to grass pollen
3077800|NCT02041611|Other|Standard Care Pts Eval of T-Cell Immune Status|Pts undergoing standard radiation/TMZ and adjuvant TMZ will have blood collections at 6 different time points throughtout their treatment to evaluate T Cell changes
3077801|NCT02041598|Experimental|Full CHW Intervention|5 monthly group educational sessions, 2 1v1 Visits with CHW, Phone Calls as Needed
3077802|NCT02041598|No Intervention|Control: Intro to Diabetes Session Only|One-time, Introduction to Diabetes educational session only
3077803|NCT02041585||Elder discharge cohort|There will be no intervention in this observational survey research.
3077804|NCT02041572|Other|Attentional Bias Retraining|Each participant receives 12 sessions. The first three sessions are baseline (assessment only) sessions. The last four sessions must be treatment sessions. The attentional bias intervention starts randomly on sessions 4 - 8, and continues until the end of the 12 sessions.
3077805|NCT02041559||robot assisted prostatectomy|robot assisted prostatectomy
3077806|NCT02041546|Active Comparator|Bolus surfactant|Bolus surfactant 100 mg/kg proctant alfa
3077807|NCT02041546|Active Comparator|Lung lavage with surfactant|Lung lavage with surfactant
3077808|NCT02041533|Experimental|Arm A: Nivolumab subjects|Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
3077809|NCT02041533|Active Comparator|Arm B: Investigator's Choice Chemotherapy|"Investigator's Choice Chemotherapy administered in 3-week cycles up to a maximum of 6 cycles of Intravenous injection until disease progression, unacceptable toxicity or completion of the 6 cycles, whichever comes first~Squamous subjects:~Gemcitabine 1250 mg/mg(2) administered on Day 1 and Day 8 with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle; or~Gemcitabine 1000 mg/mg(2) administered on Day 1 and Day 8 with Carboplatin (AUC 5) administered on Day 1 of each cycle; or~Paclitaxel 200 mg/m(2) with Carboplatin (AUC 6) administered on Day 1 of each cycle~Non-Squamous subjects:~Pemetrexed 500 mg/m(2) with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle~Pemetrexed 500 mg/m(2) Carboplatin (AUC 6) administered on Day 1 of each cycle~Optional crossover:~Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent or study closure"
3077810|NCT02041520|Experimental|Omega 3 fatty acids|omega 3 fatty acids, 2.4 g per day, requiring intake 2 capsules (600mg each one) in the morning and two at night (Zonelabs, Marblehead MA) for 6 months.
3077811|NCT02041520|Placebo Comparator|Placebo|Placebo (olive oil gelcaps) in similar presentation as omega 3 fatty acids, requiring intake 2 capsules in the morning and two at night (Perfect Source, Fullerton CA, product code number PER 1016, lot number 8A0019/1600-1)
3077812|NCT02041507|Active Comparator|Air insufflation method.|Colonoscopy performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
3077813|NCT02041507|Experimental|Water Immersion method.|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using air insufflation.
3077814|NCT02041507|Experimental|Water Exchange method.|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using air insufflation.
3077815|NCT02041494|Active Comparator|Synthetic|Patients in this arm will have their ventral hernia repaired utilizing Ventralight, a synthetic prosthetic mesh made of polypropylene.
3077816|NCT02041494|Active Comparator|Biologic|Patients in this arm will have their ventral hernia repaired utilizing Strattice, a biologic prosthetic mesh derived from porcine dermis.
3077817|NCT02041481|Experimental|Arm I (continuous MEK inhibitor MEK162, FOLFOX)|Patients receive MEK inhibitor MEK162 PO BID on days 1-14, and leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3077818|NCT02041481|Experimental|Arm II (intermittent MEK inhibitor MEK162, FOLFOX)|Patients receive MEK inhibitor MEK162 PO BID on days 1-5, and leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 6 and 7. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3077819|NCT02041468||Pharmacoeconomic main study|Patients from Quebec and Ontario (first or second line treatment)
3077820|NCT02041468||Biomarker sub-study|Patients from Quebec only (first or second line treatment)
3077821|NCT02041455|Experimental|Melatonin and Placebo|Melatonin 10mg and placebo, once in the evening, for 6 weeks.
3077822|NCT02041455|Experimental|Amitriptyline and placebo|Amitriptyline 25mg and placebo, once in the evening, for 6 weeks.
3077823|NCT02041455|Active Comparator|Melatonin and Amitriptylin|Melatonin 10mg and Amitriptylin 25mg, once in the evening, for 6 weeks.
3077824|NCT02041442|Experimental|All subjects|Electrical mapping of the urinary bladder
3077870|NCT02041143|Experimental|Milk protein|Study product will provide 25 g of protein to subjects. One single supplement will be taken.
3077825|NCT02041429|Experimental|Ruxolitinib|Ruxolitinib 10 mg bid for 21 days Paclitaxel is administered at a dose of 80 mg/m2 IV weekly (3 Weeks) Pre-medicate with dexamethasone 10 mg po or IV; diphenhydramine 12.5-50 mg po or IV; famotidine 20 mg IV all administered 30-60 min prior to paclitaxel.
3077826|NCT02041416||Group 1|REDCap and paper pencil
3077827|NCT02041416||Group 2|REDCap twice
3077828|NCT02041416||Group 3|Support Screen and paper pencil
3077829|NCT02041416||Group 4|Support Screen twice
3077830|NCT02041403||Renal resistive Index|
3077831|NCT02041390|Experimental|SMS group|Patients in SMS group will receive reminding by additional SMS messages monthly after stent implantation.
3077832|NCT02041390|Active Comparator|Conventional reminder group|Patients in control group will not receive additional SMS reminder monthly after stent implantation.
3077833|NCT02041377|Experimental|Intended Users of the Monitoring System|"Subjects with diabetes used the Karajishi TS Investigational Blood Glucose Monitoring System with no training. The criteria for the intended use population:~At least 60% of subjects will be younger than age 65~At least 10% of subjects will have type 1 diabetes"
3077834|NCT02041364||Control: patients without fatigue|Patients whose scores on the brief fatigue inventory (BFI) (15) won't increase after having received the first cycle of chemotherapy will be considered as controls
3077835|NCT02041364||Patients with fatighe|Patients whose scores on the brief fatigue inventory (BFI) (15) increase after having received the first cycle of chemotherapy will be considered as having manifested fatigue
3077836|NCT02041351|Experimental|docetaxel|measurement evaluation every 2 months tomography of all measurable lesions in millimeters, to assess response rate, partial and complete responses.
3077837|NCT02041338|Experimental|Luminal subtype test|Paclitaxel 175mg/m2, every 2 weeks as a cycle for 4-6 cycles
3077838|NCT02041338|Active Comparator|Luminal subtype control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles
3077839|NCT02041338|Experimental|Her2 positive subtype test|Paclitaxel 175mg/m2 plus carboplatin AUC 4 with or without trastuzumab every 2 weeks as a cycle for 4-6 cycles
3077840|NCT02041338|Active Comparator|Her2 positive subtype control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 with or without trastuzumab every 3 weeks as a cycle for 4-6 cycles
3077841|NCT02041338|Experimental|Triple negative subtype test|Paclitaxel 175mg/m2 plus carboplatin AUC 4 every 2 weeks as a cycle for 4-6 cycles
3077842|NCT02041338|Active Comparator|Triple negative subypte control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles
3077843|NCT02041325|Experimental|Lenalidomide|Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
3077844|NCT02041325|Placebo Comparator|Placebo|Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
3077845|NCT02041312||Gastric cancer|No intervention
3077846|NCT02041299|Experimental|Deferiprone|Patients randomized to the deferiprone arm will be prescribed either tablets or liquid medication.
3077847|NCT02041299|Active Comparator|Deferoxamine|Patients randomized to the deferoxamine arm will be prescribed the drug as per the approved US prescribing information.
3077848|NCT02041286|Experimental|Intended Users of the Monitoring System|"Subjects with diabetes use the Karajishi Contour Investigational BG Monitoring System with no training. The criteria for the intended use population:~At least 60% of subjects will be younger than age 65~At least 10% of subjects will have type 1 diabetes"
3077849|NCT02041273|Experimental|Palbociclib given to healthy volunteers|
3077850|NCT02041247|Active Comparator|VAC-3S 16µg/administration|VAC-3S 16µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
3077851|NCT02041247|Placebo Comparator|VAC-3S Placebo|VAC-3S placebo administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
3077852|NCT02041247|Active Comparator|VAC-3S 32 µg/administration|VAC-3S 32µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
3077853|NCT02041247|Active Comparator|VAC-3S 64 µg/administration|VAC-3S 64µg/ml administered every 4 weeks for 3 months without maintenance vaccination.
3077854|NCT02041234|Active Comparator|Roux-en-Y Gastric Bypass (RYGB)|Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
3077855|NCT02041234|Active Comparator|Best Medical Treatment|"Anti-diabetic medications provided (Mono- or Combination- therapy):~Incretin analogues: Liraglutide up to 3 mg daily Or DPP-4 Inhibitors: Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily Xenical: Up to 120 mg tds SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily Participants will also take lipids & BP medications according to standard of care."
3077856|NCT02041221|Experimental|SPARC1316 Dose 1|Subjects will be administered with SPARC1316 dose 1
3077857|NCT02041221|Placebo Comparator|Placebo|The subjects will receive placebo.
3077858|NCT02041221|Experimental|SPARC1316 Dose 2|Subjects will be administered with SPARC1316 dose 2
3077859|NCT02041221|Experimental|SPARC1316 Dose 3|Subjects will be administered with SPARC1316 dose 3
3077860|NCT02041221|Experimental|SPARC1316 Dose 4|Subjects will be administered with SPARC1316 dose 4
3077861|NCT02041221|Experimental|SPARC1316 Dose 5|Subjects will be administered with SPARC1316 dose 5
3077862|NCT02041195|Active Comparator|RM-493 Once Daily|Once daily in the morning, equivalent PBO in evening.
3077863|NCT02041195|Active Comparator|RM-493 Split Dose|Split dose, one half in the morning and one half in the evening.
3077864|NCT02041195|Placebo Comparator|Placebo|Placebo in the morning, placebo in the evening.
3077865|NCT02041182|Experimental|Intervention Pre-visit Questionnaire|Adolescents receive PVQ that includes questions about youth violence/bullying
3077866|NCT02041182|Active Comparator|Control Pre-visit Questionnaire|Adolescents received PVQ without youth violence/bullying items
3077867|NCT02041169|Experimental|Subsequent walking performance|Subsequent walking performance
3077868|NCT02041156|Experimental|aerobic with resistance training|Regular aerobic activity combined with 3 sessions/week of resistance training totalling 150 minutes per week of physical activity
3077871|NCT02041143|Placebo Comparator|Placebo|Placebo (no protein)
3077872|NCT02041130|Experimental|Renal Denervation and standard medical management|"Renal Denervation (RDN) is a simple catheter procedure removing excess nerve signals to and from the kidneys. The renal denervation system consists of a small steerable treatment catheter and an automatically-controlled treatment delivery generator.~A guiding catheter is inserted through a tiny incision in the groin into the femoral artery to direct the treatment catheter to the renal arteries. The treatment catheter delivers high -frequency radio waves, called radiofrequency wavees, to 4-6 locations within each of the two renal arteries. the energy delivered is about 8 watts and aims to disrupt the nerves and lower blood pressure over a period of months. The procedure takes 40-60 minutes."
3077873|NCT02041130|No Intervention|Contorl and Standard Medical Management|Continued medical management will comprise management of all cardiovascular risk factors (hypertension, diabetes, dyslipidaemia) in accord with international guidelines. Lifestyle and dietary counselling will also be part of the patient management. As there is no established evidence-based pharmacotherapy for HFPEF per se, therapy aimed at HF specifically will adopt treatments recommended for HFREF with prescription of diuretic, ACE inhibitor/ARB, beta blocker and mineralocorticoid antagonist accordingly.
3077874|NCT02041117|Other|Rosuvastatin|
3077875|NCT02041104|Experimental|Bread with added beta-glucans|Experimental food is bread with high amount of barley beta-glucans. Experimental bread contains approximately 3,4 % (w/w) beta-glucans. Participants will consume 6 g of beta-glucans daily (approximately 200 g of bread per day). Beta-glucans are natural polysaccharides found in grain endosperm and are mostly represented in oat and barley. Beta-glucans are linear homopolymers of D- glycopyranosyl residues with mixed linkage (1-4, 1-3)-β-D-glucans. Their molecular structure enable beta-glucans their functional action that mostly depends of their viscosity and solubility (1). Testing bread has integrated flour with high amount of barley beta-glucans (ReducholTM). Beta-glucans are concentrated in flour up to 15 % with dry milling, sieving and air classification of barley flour.
3077876|NCT02041104|Placebo Comparator|Bread without added beta-glucans|Placebo bread without added barley beta-glucans in testing product.
3077877|NCT02041091|Experimental|Tabalumab Auto-Injector|Tabalumab given Week 0 as a loading dose of 240 milligram (mg) given as two subcutaneous (SC) injections each of 120 mg followed by 120 mg SC injection every two weeks for 12 weeks. Participants may continue on this treatment regimen for 52 weeks.
3077878|NCT02041091|Experimental|Tabalumab Prefilled Syringe|Tabalumab given Week 0 as a loading dose of 240 mg given as two SC injections each of 120 mg followed by 120 mg SC injections every two weeks for 12 weeks. Participants may continue to on this treatment regimen for 52 weeks.
3077879|NCT02041078|Placebo Comparator|Extrahepatic vein division|Conventional right sided hemihepatectomy with division of the liver parenchyma with CUSA.
3077880|NCT02041078|Experimental|Intrahepatic vein division|Conventional right sided hemihepatectomy with division of the liver parenchyma with CUSA and intrahepatic division of the right hepatic vein.
3077881|NCT02041065|Experimental|Waterjet induced dissection|Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
3077882|NCT02041065|Active Comparator|CUSA induced dissection|CUSA transection of the liver. Ultrasound based destruction of the liver parenchyma to allow separate ligation of the bile duct and intrahepatic vessels.
3077883|NCT02041052|Active Comparator|Conventional Whipple procedure|Conventional Whipple procedure
3077884|NCT02041052|Experimental|Subtotal gastrectomy added to whipple procedure.|Subtotal gastrectomy added to Whipple procedure.
3077885|NCT02041039||normal weight|non-smoking, right handed women age 18-40 years BMI between 18-25 kg/m2
3077886|NCT02041039||overweight/obese|non-smoking, right-handed women age 18-40 year BMI 30-50 kg/m2 (maximum weight 350 pounds, shoulder width no greater than 23/5 inches)
3077887|NCT02041026|Experimental|probiotic yoghurt|the subject will be given 200ml of yogurt daily for 28 days
3077888|NCT02041013|No Intervention|No Talking Card|Usual care of asthma by study clinician, including evaluation of asthma using C-ACT and clinical history, treatment using asthma action planning
3077889|NCT02041013|Experimental|Taking Card|Usual care, as in comparison group, plus recordable Talking Card at each visit
3077890|NCT02040987|Experimental|AZD3293 dose A|AZD3293 therapeutic dose oral solution (low dose)
3077891|NCT02040987|Experimental|AZD3293 dose B|AZD3293 supratherapeutic dose oral solution (high dose)
3077892|NCT02040987|Placebo Comparator|Placebo|Placebo oral solution
3077893|NCT02040987|Active Comparator|Moxifloxacin|Moxifloxacin tablet
3077894|NCT02040961|Experimental|EtView|Use of ETVew double-lumen tube
3077895|NCT02040948|Experimental|Surgical patients|"Nexfin (Pulse Pressure Variation)~Radical 7 (Pleth Variability Index)~CardioQ (stroke volume)"
3077896|NCT02040935|Experimental|Trastuzumab|Participants will receive 600 milligrams (mg) trastuzumab SC by SID every 3 weeks (Q3W) for up to a total of 1 year, unless disease recurrence, unacceptable toxicity or participant withdrawal occurs. The first 3 administrations will be done at hospital, after that participants will be permitted to self-administer under the supervision of a healthcare professional (HCP).
3077897|NCT02040922||Post-Campylobacter|Adults with symptoms of intestinal infection who submit a stool sample from which Campylobacter jejuni or coli is cultured
3077898|NCT02040909|Experimental|Propofol|A predetermined propofol dose is used in every 5 consecutive patients per age group. Starting dose is 1.0 mg/kg. Dose is increased or decreased with 0.5 mg/kg
3077899|NCT02040896||Group 1|All consecutive emergency department patients undergoing CT during study hours will be prospectively enrolled, except for those meeting pre-specified exclusion criteria.
3077900|NCT02040883|Active Comparator|Control Group|Treated with a stable dose of an AAPD for at least three months before enrollment; Atypical antipsychotic drugs(AAPDs): Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
3077901|NCT02040883|Experimental|Study Group|Atypical antipsychotic drugs(AAPDs) and Tandospirone ; Atypical antipsychotic drugs(AAPDs) ,treated with a stable dose of an AAPD for at least three months before enrollment; AAPD: Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole; Tandospirone, 30mg per day;
3077902|NCT02040870|Experimental|LDK378|750 mg once daily
3077903|NCT02040857|Experimental|Palbociclib, Aromatase Inhibitor|"Palbociclib 125 mg PO qd 21 days on, 7 days off~Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd"
3078268|NCT02038660||Patients with coronary artery disease|
3077906|NCT02040844|Other|Cat-PAD Treatment 3|Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]. No further treatment received in CP007A.
3077907|NCT02040831|Experimental|RSV LID ΔM2-2 Vaccine|Participants will receive one dose of the RSV LID ΔM2-2 vaccine at study entry, delivered as nose drops.
3077908|NCT02040831|Placebo Comparator|Placebo Vaccine|Participants will receive one dose of placebo at study entry, delivered as nose drops.
3077909|NCT02040818|Experimental|Antibiotic Lock Solution|
3077910|NCT02040818|Active Comparator|Guide-wire Exchange|
3077911|NCT02040805|Experimental|Group Cognitive-Behavioral Thearapy|Sixteen sessions of group therapy facilitated by a psychologist.
3077912|NCT02040805|Experimental|Peer Facilitated Manualized Support Group|Sixteen sessions of peer-facilitated group support.
3077913|NCT02040792|Placebo Comparator|Placebo|Placebo
3077914|NCT02040792|Experimental|44 mcg|TD-4208
3077915|NCT02040792|Experimental|88 mcg|TD-4208
3077916|NCT02040792|Experimental|175 mcg|TD-4208
3077917|NCT02040792|Experimental|350 mcg|TD-4208
3077918|NCT02040779|Experimental|BDP 80 mcg BAI|40 mcg beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily for a total of 80 mcg/day.
3077919|NCT02040779|Experimental|BDP 160 mcg BAI|80 mcg beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily for a total of 160 mcg/day.
3077920|NCT02040779|Placebo Comparator|Placebo BAI|Placebo breath-actuated inhaler (BAI) twice daily.
3077921|NCT02040766|Experimental|BDP 80 mcg BAI|"Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (40 mcg twice a day).~Placebo MDI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
3077922|NCT02040766|Experimental|BDP 160 mcg BAI|"Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (80 mcg twice a day).~Placebo MDI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
3077923|NCT02040766|Active Comparator|BDP 80 mcg MDI|"Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (40 mcg twice a day).~Placebo BAI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
3077924|NCT02040766|Active Comparator|BDP 160 mcg MDI|"Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (80 mcg twice a day).~Placebo BAI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
3077925|NCT02040766|Placebo Comparator|Placebo BAI and MDI|"Placebo was administered via breath-actuated inhaler (BAI) twice daily. Additionally placebo was administered via metered-dose inhaler (MDI) twice daily.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
3077926|NCT02040753||Intensive Lifestyle Intervention|Former participants of intensive lifestyle intervention at Ubberup Folk High School.
3077927|NCT02040740||Observation|Healthy early pubertal boys
3077928|NCT02040727|Active Comparator|Non-Resistance Trained|No Participation in Resistance Training
3077929|NCT02040727|Experimental|Resistance Trained|Participation in Resistance Training
3077930|NCT02040714||Nonoperative management between ages 6-8|The choice of non-osteotomy management without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
3077931|NCT02040714||Operative containment between age 6-8 in early stage|Operative containment treatment (femoral or pelvic osteotomy or Shelf acetabuloplasty) rendered in the early stage of the disease process (stage I)
3077932|NCT02040714||Operative containment between age 6-8 in the late stages|This arm examines operative containment treatment (femoral or pelvic osteotomy or Shelf acetabuloplasty) rendered in the later stage of the disease process (stage II)
3077933|NCT02040714||Nonoperative management between age 8-11|Patients who do not undergo some form of containment surgery because of medical, social, or other reasons will receive no surgical treatment.
3077934|NCT02040714||Operative containment with short-term non-weightbearing|"As per the current standard practice for patients between age 8-11 in developed countries, all patients will undergo some form of containment surgery (pelvic or femoral osteotomy) in order to better contain the femoral head underneath the acetabulum. Post-operative treatment will include 6 weeks of non-weight bearing on the operated leg."
3077935|NCT02040714||Operative containment with prolonged non-weightbearing|"As per the current standard practice for patients between age 8-11, all patients will undergo some form of containment surgery (pelvic or femoral osteotomy) in order to better contain the femoral head underneath the acetabulum. Post-operative treatment will include 6 months of non-weight bearing on the operated leg."
3077936|NCT02040714||Multiple epiphyseal drilling for patients over age 11|Patients will receive Multiple drilling and be non weight bearing for 6 months according to the treating physician's preference
3077937|NCT02040714||Multiple epiphyseal drilling and arthrodiastasis|Patients will undergo multiple epiphyseal drilling with application of fixator for 3-4 months followed by 8-12 weeks of non-weight bearing after fixator removal.
3077938|NCT02040714||Non-surgical management in over 11 age group|Patients will be non-weight bearing and receive physical therapy according to the physician preferences.
3077939|NCT02040714||Non-surgical management in 1-6 age group|The choice of non-osteotomy management without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
3077940|NCT02040714||Surgical management in 1-6 age group|The choice of osteotomy management with containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
3077980|NCT02040441|Placebo Comparator|Placebo|High-risk pattern: One placebo tablet once daily + Standard care
3077981|NCT02040441|Other|Observational|Low-risk pattern: Standard care
3077941|NCT02040714||Late Stage Bracing group|Patients presenting with <= 20 degrees of abduction on a maximum abduction x-ray treated with bracing who also present in the late stages of the disease (Waldenstrom Stage IIb or IIIa).The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
3077942|NCT02040714||Late Stage Symptomatic treatment group|Patients presenting in the late stages of the disease (defined as Waldenstrom stage IIb or IIIa) who are treated symptomatically. The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
3077943|NCT02040714||Late Stage Surgical Containment group|Patients presenting in the late stages of the disease (defined as Waldenstrom stage IIb or IIIa) who are treated with surgical containment. The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
3077944|NCT02040701||SDB group|
3077945|NCT02040701||Control group|
3077946|NCT02040688||Sleep Disorders|7-36 months old children with behavioral insomnia of childhood based on the International Classification of Sleep Disorders (ICSD) criteria will be recruited from the Pediatric Sleep Center at Dana Children's hospital
3077947|NCT02040688||Control|7-36 months old chidren of age who attend well-care clinics in the metropolitan of Tel Aviv for routine periodic medical examination.
3077948|NCT02040688||Feeding disorder|7-36 monthsold children with feeding disorders based on Chatoor criteria will be recruited from the clinic of feeding disorders at Dana Children's Hospital.
3077949|NCT02040662|Experimental|Continuous Thoracic Paravertebral Block|"continuous thoracic paravertebral blockade 0,08 ml/kg/h with bupivacaine 0,25% + epinephrine 1:200.000~patient-controlled analgesia (morphine), bolus dose 2 mg, lockout time 10 min"
3077950|NCT02040662|Experimental|Continuous Thoracic Epidural Analgesia|"continuous thoracic epidural block 0,06 ml/kg/h with bupivacaine 0,25% + epinephrine 1:200.000~patient-controlled analgesia (morphine), bolus dose 2 mg, lockout time 10 min"
3077951|NCT02040649|Experimental|Non-sedation|Non-sedation supplemented with pain management during mechanical ventilation.
3077952|NCT02040649|Active Comparator|Sedation|Current gold standard: Sedation with a daily wake-up trial.
3077953|NCT02040636|Experimental|Study Group 1|Participants randomized to receive Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) at month 0, Hepatitis B at months 1, 2 and 7.
3077954|NCT02040636|Active Comparator|Study Group 2|Participants randomized to receive Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) + Hepatitis B at month 0, Hepatitis B at months 1 and 6.
3077955|NCT02040623|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
3077956|NCT02040623|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
3077957|NCT02040623|Placebo Comparator|Placebo|Placebo Ophthalmic Solution 2 drops per eye twice a day
3077958|NCT02040610|Active Comparator|Low Risk Prostate Cancer|Hypofractionated Proton Therapy 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks
3077959|NCT02040610|Active Comparator|Intermediate Risk Prostate Cancer|Hypofractionated Proton Therapy 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks
3077960|NCT02040597|Experimental|CHF5993 pMDI|CHF 5993 pMDI (Beclometasone/Formoterol/Glycopyrrolate 100/6/25 mcg) 4 inhalations
3077961|NCT02040584|Experimental|Minimisation of TAC|Treatment with rTAC+EVR+corticosteroids
3077962|NCT02040584|Active Comparator|TAC + MMF + corticosteroids|Treatment with TAC + MMF + corticosteroids
3077963|NCT02040571|Experimental|Closed Loop|
3077964|NCT02040571|Active Comparator|Open Loop|
3077965|NCT02040558|Experimental|MNK-010|Subjects will receive 1 dose of MNK-010 followed by a 7-day post dose assessment period per treatment cycle. Dose levels will be based upon the amount of active delivered per square meter of body surface area (mg/m2). Cycles will repeat every 3 weeks (21 days) based on toxicity and response, as determined by a Safety Review Committee (SRC). Subjects will continue treatment with MNK-010 until unacceptable toxicity, documented progression of disease, another criterion for discontinuation is met, or until 4 treatment cycles have been completed.
3077966|NCT02040545||Infertility|Patients undergoing ovulation induction and controlled ovarian hyperstimulation at a participating infertility center
3077967|NCT02040532|Experimental|Open-label gabapentin|Dose titration of 100mg for 1 week, 300mg for 3 weeks, and 600mg for 3 weeks.
3077968|NCT02040519|Experimental|Evaluation by voiding diaries|
3077969|NCT02040506|Experimental|IGN523|IGN523
3077970|NCT02040493|Experimental|Intra-operative radiation therapy (IORT)|IORT
3077971|NCT02040480|Experimental|Sequence 1|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ABC
3077972|NCT02040480|Experimental|Sequence 2|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ACB
3077973|NCT02040480|Experimental|Sequence 3|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BAC
3077974|NCT02040480|Experimental|Sequence 4|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BCA
3077975|NCT02040480|Experimental|Sequence 5|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CAB
3077976|NCT02040480|Experimental|Sequence 6|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CBA
3077977|NCT02040454|Active Comparator|Standard Therapy Plus Paclitaxel|"Standard Therapy - heparin, angioplasty, stent~Paclitaxel - single intravascular dose up to 20 mg"
3077978|NCT02040454|Sham Comparator|Standard Therapy Alone|heparin, angioplasty, stent
3077979|NCT02040441|Active Comparator|Spironolactone|High-risk pattern: Spironolactone 25 mg once daily + Standard care
3078180|NCT02039063|Experimental|4|E6011 15 mg/kg
3077982|NCT02040428|Experimental|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
3077983|NCT02040428|Active Comparator|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
3077984|NCT02040415|Experimental|DW-1030(eperisone HCl)|DW-1030(eperisone HCl) 75mg BID
3077985|NCT02040415|Active Comparator|Myonal Tab.(eperisone HCl)|Myonal Tab.(eperisone HCl) 50mg TID
3077986|NCT02040402|Active Comparator|4-Dose Regimen|"3+1 schedule of 7-valent pneumococcal conjugated vaccine:~Infants who are randomized for 3+1 schedule will be administrated one dose of PCV7 at the age of 2 months old, 4months old and 6 months old. A booster dose will be administrated at the age of 12 months old.~Infants will be followed up for 12-16 months starting from vaccination of first dose. There is no restriction on the use of other medications before or during the follow-up period."
3077987|NCT02040402|Active Comparator|3-Dose Regimen|"2+1 schedule of 7-valent pneumococcal conjugated vaccine:~Infants who are randomized for 2+1 schedule will be administrated with one dose of PCV7 at the age of 2 months old and 4months old. A booster dose will be administrated at the age of 12 months old.~Infants will be followed up for 12-16 months starting from vaccination of first dose. There is no restriction on the use of other medications before or during the follow-up period."
3077988|NCT02040389|Active Comparator|pictures book + standard education|arm with children undergoing urological procedures and their parents will receive standard preoperative education + pictures book with pictures of surgical wound in different stages of healing
3077989|NCT02040389|Active Comparator|Standard preoperative education|Arm with children undergoing urological procedures and their parents will receive only standard preoperative education
3077990|NCT02040376|Experimental|Group A (Crossover Group 1)|Subjects assigned to this arm will receive metformin first, followed by a washout period and then placebo.
3077991|NCT02040376|Experimental|Group B (Crossover Group 2)|Subjects assigned to this arm will receive placebo first, followed by a washout period and then metformin.
3077992|NCT02040363|Active Comparator|COPD Patients ~90% VO2max|COPD Patients ~90% VO2max
3077993|NCT02040363|Active Comparator|COPD patients ~60-65% VO2max|COPD patients ~60-65% VO2max
3077994|NCT02040363|Placebo Comparator|healthy volunteers|healthy volunteers
3077995|NCT02040350|Placebo Comparator|Placebo|Placebo was given to compare the effects
3077996|NCT02040350|Active Comparator|Pralidoxime|Pralidoxime for treating organophosphorous poisoning patients
3077997|NCT02040324|Active Comparator|Endotracheal Intubation|Clinical routine for longer lasting procedures
3077998|NCT02040324|Experimental|Laryngeal Mask|Laryngeal mask with gastric access and drainage as airway management instead of endotracheal intubation
3077999|NCT02040311|Experimental|Topiramate 96 mg daily|
3078000|NCT02040311|Experimental|Topiramate 192 mg daily|
3078001|NCT02040311|Placebo Comparator|placebo|
3078002|NCT02040298|Active Comparator|3 months Clemastine, 2 months Placebo|4mg clemastine twice daily for first 3 months -- crossover -- equivalent quantity/frequncy of placebo for last 2 months
3078003|NCT02040298|Active Comparator|3 months Placebo , 2 months Clemastine|Placebo for first 3 months -- crossover -- 4mg clemastine twice daily for last 2 months.
3078004|NCT02040285|Active Comparator|Free laxative CTC|
3078005|NCT02040285|Experimental|Low-dose laxative bowel preparation for CTC|
3078006|NCT02040272|Experimental|Surgery|(Extended) pleurectomy decortication
3078007|NCT02040272|No Intervention|no surgery|no surgery
3078008|NCT02040259||Mechanical thrombectomy, Trevo Retriever|Mechanical thrombectomy, Trevo Retriever
3078009|NCT02040246|Experimental|Repaglinide|Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
3078010|NCT02040246|Active Comparator|Metformin|Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
3078011|NCT02040233|Active Comparator|BAY1067197 (10 mg)|
3078012|NCT02040233|Active Comparator|BAY1067197|
3078013|NCT02040233|Placebo Comparator|Placebo (10 mg)|
3078014|NCT02040233|Placebo Comparator|Placebo|
3078015|NCT02040220||Group 1|Eylea treatment goup
3078016|NCT02040207|Experimental|AM-101 injection|AM-101 gel for intratympanic injection
3078017|NCT02040194|Experimental|AM-101 injection|AM-101
3078018|NCT02040194|Placebo Comparator|Placebo injection|Placebo
3078019|NCT02040168||28 days - 18 yo|Children requiring mechanical ventilation for at least 24h from 28 days to 18 yo
3078020|NCT02040168||18 months - 18 yo|Post traumatic stress disorder evaluation in children requiring mechanical ventilation for at least 24h from 18 month to 18 Years old
3078021|NCT02040155|Experimental|Real time dosimetric monitoring of brachytherapy.|
3078022|NCT02040142|Experimental|HIPEC + Mitomycin C|HIPEC + 40mg of Mitomycin C. Mitomycin C, 30 mg, will be administered into the inflow line of the perfusion circuit once target temperature is reached. At the 60 minute time point of the perfusion, Mitomycin C, 10 mg, will be administered into the inflow line of the perfusion circuit. Once the 90-minute perfusion period has elapsed, the perfusate will be drained into the waste reservoir. The peritoneal cavity will be rinsed/washed-out.
3078023|NCT02040129|Experimental|Acrysof toric IOL|Acrysof Toric intraocular lens in congenital cataract
3078024|NCT02040116|Other|rituximab infusion|Every patient is getting the same therapy of rituximab. If day 1 is tolerated at standard infusion then day 14 and beyond will be given as rapid infusion over 90 minutes
3078025|NCT02040103|Experimental|Intermittent Pneumatic Compression(IPC)|The intervention group will be receiving Intermittent Pneumatic Compression(IPC)
3078026|NCT02040103|No Intervention|No Intermittent Pneumatic Compression|patients will not receive Intermittent Pneumatic Compression
3078027|NCT02040090|Experimental|KamRAB|KamRAB 20 IU/kg body weight via IM injection, once on Day 0
3078028|NCT02040090|Active Comparator|FDA approved commercially available HRIG product|Comparator product: IM injection once on Day 0 in the same manner and at the same dosage as KamRAB.
3078029|NCT02040077|Experimental|Computer + Fluency|Will receive computerized intervention and will be required to periodically demonstrate mastery of information before proceeding to the next module in the computerized intervention.
3078030|NCT02040077|Active Comparator|Computer Only|Will receive computerized intervention but will not be required to demonstrate mastery of information as part of the intervention.
3078031|NCT02040077|Active Comparator|Treatment as Usual|Will receive publicly available pamphlets that contain same information as the computerized intervention. Will not have access to computerized intervention and will not be required to demonstrate mastery of information as part of the intervention.
3078032|NCT02040064|Experimental|Treatment|"Cohort 1: Tremelimumab 3 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 3 mg/kg is the MTD)~Cohort 2: Tremelimumab 6 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 6 mg/kg is the MTD)~Cohort 3: Tremelimumab 10 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 10 mg/kg is the MTD)"
3078033|NCT02040051|Active Comparator|GROUP A: Sound isolation / Music therapy|"PREINTERVENTION: First hour. The patient will remain under the usual conditions of intensive care unit~INTERVENTION: Second hour. Sound isolation~INTERVENTION: Third hour. Music therapy~POSTINTERVENTION: Fourth hour. The patient will remain under the usual conditions of intensive care unit"
3078034|NCT02040051|Active Comparator|GROUP B: Music therapy / Sound isolation|"PREINTERVENTION: First hour. The patient will remain under the usual conditions of intensive care unit~INTERVENTION: Second hour. Music therapy~INTERVENTION: Third hour. Sound isolation~POSTINTERVENTION: Fourth hour. The patient will remain under the usual conditions of intensive care unit"
3078035|NCT02040038|Experimental|LIVE Arm|Participation in 3D virtual environment for DSMT/S for a period of 12 months.
3078036|NCT02040038|Active Comparator|Website|Participation in 2D website for DSMT/S for a period of 12 months.
3078037|NCT02040012|Active Comparator|AZP-531|subcut administration once or twice daily
3078038|NCT02040012|Placebo Comparator|Mannitol|subcut administration once or twice daily
3078039|NCT02039999|Experimental|Chronic cough|"Cough challenges to be administered include:~Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions"
3078040|NCT02039999|Active Comparator|Normal volunteer|"Cough challenges to be administered include:~Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions"
3078041|NCT02039986||all subjects|all subjects enrolled in same cohort
3078042|NCT02039973|Experimental|Task-sharing approach to group therapy|The intervention will consist of problem-solving therapy as well as cognitive behavioral components. Core problem-solving therapy components will involve lay CBHW facilitated discussions to explore symptoms of depression and how problems are related to depression. Core cognitive behavioral components will include lay CBHW facilitated discussions to explain the purpose of the sessions, as well as effect a number of behavioral changes in participants.
3078043|NCT02039973|Active Comparator|Enhanced standard of care|The control condition will promote an enhanced standard of care. Clinicians and nurses at MCH clinics included in the study will receive a structured one day re-orientation training consistent with the World Health Organization (WHO) mh-GAP guidelines for assessment as well as basic psychosocial and drug treatment of moderate to severe depression in primary care settings. The training will be consistent with the standard of care for mental health among HIV-positive populations as outlined in Tanzanian health policy. In addition, clinical staff will be trained to encourage women to invite their male partners to accompany them at clinic visits, where psycho-education on perinatal depression for couples will be offered for those opting to participate.
3078044|NCT02039960||DAWN cases including all prescription drugs|This group will consist of all DAWN cases where prescription drugs are mentioned.
3078045|NCT02039960||All bupropion cases (including use of other drugs)|This group will consist of all DAWN cases where bupropion is mentioned and is a subset of Group 1.
3078046|NCT02039960||Burpropion Only Cases|This group will consist of all DAWN cases where burpropion is specifically the only drug mentioned within the case report, and is a subset of Group 2.
3078047|NCT02039947|Experimental|Cohort A|Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.
3078048|NCT02039947|Experimental|Cohort B|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
3078049|NCT02039947|Experimental|Cohort C|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
3078050|NCT02039947|Experimental|Cohort D|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
3078051|NCT02039934|Experimental|high intensity interval training|
3078052|NCT02039908|Active Comparator|Methylphenidate 7-day dosing|During the school year, children in this arm will receive 7-day dosing of medication.
3078053|NCT02039908|Active Comparator|Methylphenidate 5-day dosing|During the school year phase, these children will receive 5-day dosing with weekend holidays.
3078054|NCT02039895|Experimental|HITS for CTCL|Cutaneous T-cell lymphoma treats by helical irradiation of the total skin (HITS) using helical tomotherapy
3078055|NCT02039882||Controls/Normals|control subjects without known cardiac disease, age ± 5 years and sex matched
3078056|NCT02039882||Acute Coronary Syndrome requiring Percutaneous Intervention|Subjects presenting to ER with Acute chest pain requiring cardiac catheterization
3078057|NCT02039882||Acute Coronary Syndrome, no intervention|Acute Coronary Syndrome, not requiring Percutaneous intervention
3078058|NCT02039869|Experimental|Proton Pump Inhibitor|Patients will receive proton pump inhibitor therapy with omeprazole twice daily while we observe for improvement in reflux symptoms. We will compare the confocal endomicroscopy images in the responders to non-responders at the end of 8 weeks to determine if confocal endomicroscopy can select patient that would benefit most from proton pump inhibitor therapy.
3078059|NCT02039869|Experimental|Sucralfate|Patients will receive sucralfate therapy four times a day while we observe for improvement in reflux symptoms. We will compare the confocal endomicroscopy images in the responders to non-responders at the end of 8 weeks to determine if confocal endomicroscopy can select patient that would benefit most from sucralfate therapy.
3078060|NCT02039856|Experimental|Evidence Based Quality Improvement|Intervention at eight of 12 study sites consisting of VISN/facility-level stakeholder panel meetings designed to set evidence-based priorities for quality improvement (QI) in the context of local data and needs; local practice quality improvement team design meetings; QI training and education; iterative formative data feedback; across intervention-practice QI collaboration calls; and practice facilitation. Local leadership, QI champions and frontline staff will develop and implement innovation projects aimed at improving aspects of WH PACT implementation based on site-level and VISN priorities in the context of national PACT and WH guidelines.
3078061|NCT02039856|Active Comparator|Routine PACT Implementation|PACT implementation is a nationally mandated initiative in VA primary care and women's health clinic settings, with audit-and-feedback of PACT-related performance measures, incentives for achievement of PACT attributes and continual guidance on PACT and WH policy and procedures from VA primary care and women's health leaders.
3078062|NCT02039843|Active Comparator|1|Emotional Support Dogs
3078063|NCT02039843|Active Comparator|2|Service Dogs
3078064|NCT02039830|Experimental|Group physiotherapy|12 weekly treatment visit + daily home exercise program
3078065|NCT02039830|Active Comparator|Individual one-on-one physiotherapy|12 weekly treatment visit + daily home exercise program
3078066|NCT02039817|Experimental|Healthy Volunteers|All subjects receive a single 50 mg oral dose of IDN-6556
3078067|NCT02039817|Experimental|Severe Renal Impairment|All subjects receive a single 50 mg oral dose of IDN-6556
3078068|NCT02039804|Experimental|Hyaluronic acid|Injectable hyaluronic acid.
3078069|NCT02039804|Active Comparator|Corticosteroids|Injectable corticosteroids.
3078070|NCT02039791|Experimental|Nimotuzumab plus chemoradiotherapy|
3078071|NCT02039778|Experimental|Stem Cell Radiotherapy and Temozolomide|"One treatment of 2.0 Gy will be given daily 5 days per week for a total of 60.0 Gy over 6 weeks.~Intensity Modulated Radiation Therapy (IMRT) Is Mandated; Proton therapy (Intensity-modulated proton therapy [IMPT] preferred) is an acceptable treatment modality.~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays)."
3078072|NCT02039765|Experimental|Brimonidine tartrate|One drop of brimonidine tartrate ophthalmic solution 0.025% in each eye once at Visit 2 (Day 1) then four times daily (QID) approximately 4 hours apart at Visit 3 (Day 2) through day 6, and then once at Visit 4 (Day 7).
3078073|NCT02039752||Multivessel|from 1995
3078074|NCT02039739||Orsiro™ Drug Eluting Stent|
3078075|NCT02039726|Experimental|Quizartinib|20 or 30 mg quizartinib tablets
3078076|NCT02039726|Active Comparator|Salvage chemotherapy|Low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA)
3078077|NCT02039713||IRIS DeSyne|DeSyne drug eluting stent group
3078078|NCT02039700|Experimental|Lesinurad and [14C]lesinurad|Single oral dose of lesinurad and single infusion of [14C]lesinurad
3078079|NCT02039687|Experimental|1 mg per day ARA 290|1 mg ARA 290 administered subcutaneously for 28 consecutive days
3078080|NCT02039687|Experimental|4 mg per day ARA 290|4 mg ARA 290 administered subcutaneously for 28 consecutive days
3078081|NCT02039687|Experimental|8 mg per day ARA 290|8 mg ARA 290 administered subcutaneously for 28 consecutive days
3078082|NCT02039687|Placebo Comparator|placebo|1 mL placebo administered subcutaneously for 28 consecutive days
3078083|NCT02039674|Experimental|Part 1 Cohort A (Pembro+Paclitaxel [Pa]+Carboplatin [C])|Cohort A participants receive pembrolizumab (2 or 10 mg/kg) via intravenous (IV) infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (6 mg/mL/min) via IV infusion on Day 1 of each 3-week cycle.
3078084|NCT02039674|Experimental|Part 1 Cohort B (Pembro+Pa+C+Bevacizumab [B])|Cohort B participants receive pembrolizumab (2 or 10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (6 mg/mL/min) via IV infusion on Day 1 of each 3-week cycle PLUS bevacizumab (15 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
3078085|NCT02039674|Experimental|Part 1 Cohort C (Pembro+Pemetrexed [Pe]+C)|Cohort C participants receive pembrolizumab (2 or 10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin Area Under the Curve (AUC) 5 (5 mg/mL/min) via IV infusion on Day 1 of each 3-week cycle.
3078086|NCT02039674|Experimental|Part 1 Cohort D (Pembro+Ipilimumab [I])|Cohort D participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (0.3, 1, or 3 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
3078087|NCT02039674|Experimental|Part 1 Cohort E (Pembro+Erlotinib)|Cohort E participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS erlotinib (150 mg) via oral (PO) tablet once a day (QD) on every day of each 3-week cycle.
3078088|NCT02039674|Experimental|Part 1 Cohort F (Pembro+Gefitinib)|Cohort F participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS gefitinib (250 mg) via PO tablet QD on every day of each 3-week cycle.
3078089|NCT02039674|Experimental|Part 2 Cohort G (C+Pe With/without Pembro)|Cohort G+ and G- participants receive carboplatin AUC 5 (5 mg/mL/min) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS pembrolizumab (200 mg) via IV infusion on Day 1 of each 3-week cycle OR carboplatin AUC 5 (5 mg/mL/min) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle.
3078090|NCT02039674|Experimental|Part 2 Cohort H (Pembro+I)|Cohort H participants receive pembrolizumab via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab via IV infusion on Day 1 of each 3-week cycle at the recommended Phase II dose determined in Cohort D.
3078091|NCT02039661|Active Comparator|Lidocaine Spray|
3078092|NCT02039661|Placebo Comparator|Placebo|These patients received placebo spray.
3078093|NCT02039648|Active Comparator|Rumex acetosa L. extract|Rumex acetosa L. extract mouthrinse, 10 ml, tid, 3 min, 7 days
3078094|NCT02039648|Placebo Comparator|Placebo|Placebo mouthrinse, 10 ml, tid, 3 min, 7 days
3078095|NCT02039635|Experimental|Korean Red Ginseng|"Patients receive oral Korean Red Ginseng twice daily for 16 weeks. Treatment repeats every 4 weeks for 4 courses.~Intervention: Dietary Supplement: Korean Red Ginseng"
3078096|NCT02039635|Placebo Comparator|Placebo|"Patients receive oral placebo twice daily for 16 weeks. Treatment repeats every 4 weeks for 4 courses.~Intervention: Other: Placebo"
3078097|NCT02039622||Patient under study condition|Patient under study condition
3078098|NCT02039609||Omnivores|No intervention, habitual diet
3078099|NCT02039609||Vegetarians|No intervention, habitual diet
3078100|NCT02039609||Vegans|No intervention, habitual diet
3078101|NCT02039609||Vegetarians consuming fish|No intervention, habitual diet
3078102|NCT02039596|Experimental|vegetarian breakfast|Diet: Vegetarian food items
3078103|NCT02039596|Experimental|Swedish Breakfast|Diet: Swedish food items
3078104|NCT02039596|Experimental|English breakfast|Diet: English food items
3078105|NCT02039596|Experimental|Lacto-vegetarian breakfast|Diet: Lacto-vegetarian food items
3078106|NCT02039596|Experimental|Swedish omnivore breakfast|Diet: Swedish breakfast with meat items
3078107|NCT02039583||full cohort|All singleton births in England. See 'statistical analysis' for denominator specification for individual outcomes.
3078108|NCT02039570||haemorrhoids|The cohort contains only patients with symptomatic haemorrhoids - these patients will receive a transvaginal scan to examine their ovarian and internal iliac veins to ascertain whether there is any reflux
3078109|NCT02039557||NiCord®/CordIn™ transplanted|Anyone who signed the consent for this study received a NiCord®/CordIn™ infusion as part of a GC clinical interventional study, and completed the interventional study Day 365 status assessment.
3078110|NCT02039544|Experimental|Xuebi formula|Xuebi formula , one dosage ,every day, treat 6 months.
3078111|NCT02039544|Placebo Comparator|Placebo|placebo,has the same taste and color as Xuebi formula one dosage ,every day, treat 6 months.
3078112|NCT02039531|Experimental|Plasma rich in growth factors (PRGF)|"Patients in this group will receive one cycle of three intra-articular injections of PRGF every 15 days.~Procedure for the application of the treatment:~1. Study Group or PRGF group~Blood sample :~Taken minimum after 4 hours of fasting and drinking only water in order to maintain low levels of glucose.~20 cc of peripheral blood will be taken by sterile systems with Sodium Citrate buffer to avoid hemolysis.~Spinning of the sample:~8 minutes at 1800 rpm .~getting the blood fraction containing the PRGF~activation of PRGF with 50 ul of 10% CaCl2 per ml of plasma.~the application of PRGF should not exceed 90 minutes after the blood sample extraction in order to avoid risk of contamination."
3078113|NCT02039531|Active Comparator|Hyaluronic acid (Durolane®)|Patients in this group will receive a single intra-articular injection at visit 1.
3078114|NCT02039518|Experimental|gemcitabine|gemcitabine 1000mg/m2，d1，d8，Q3W
3078115|NCT02039518|Other|observation group|observation
3078116|NCT02039505|Experimental|Vedolizumab 300mg|Intravenous Vedolizumab (300 mg) administered at Weeks 0, 2, and 6 and every 8 weeks thereafter.
3078117|NCT02039505|Placebo Comparator|Placebo|Vedolizumab Placebo. Intravenous infusion at Weeks 0, 2, and 6 and every 8 weeks thereafter
3078118|NCT02039492|Experimental|A|Denervation
3078119|NCT02039492|Active Comparator|B|Treatment with aldactone
3078120|NCT02039479|Placebo Comparator|TAU + Placebo|Treatment as Usual + Placebo
3078121|NCT02039479|Active Comparator|TAU + Lithium|Treatment as Usual + Lithium
3078122|NCT02039466|Active Comparator|volume controlled ventilation|volume controlled ventilation as a tidal volume of 8 ml/kg (ideal body weight)
3078123|NCT02039466|Active Comparator|pressure controlled ventilation|pressure controlled ventilation as a tidal volume of 8 ml/kg (ideal body weight)
3078124|NCT02039453|Experimental|Fentanyl arm|The subjects of this arm will consist of the patients who undergo colonoscopy with sedative agents, propofol and fentanyl.
3078125|NCT02039453|Active Comparator|Pethidine arm|The subjects of this arm will consist of the patients who undergo colonoscopy with sedative agents, propofol and pethidine.
3078126|NCT02039440|Other|Single arm|1 blood draw
3078127|NCT02039427|Placebo Comparator|Placebo|Normal saline(Placebo) 2 ml 5 min before induction Normal saline 2 ml 10 min before end of surgery
3078128|NCT02039427|Active Comparator|Preketorolac|Ketorolac 30 mg 5 min before induction Normal saline 2 ml 10 min before end of surgery
3078129|NCT02039427|Active Comparator|Postketorolac|Normal saline 2 ml 5 min before induction Ketorolac 30 mg 10 min before end of surgery
3078130|NCT02039427|Active Comparator|Dexamethasone|Dexamethasone 10 mg (total volume 2 ml) 5 min before induction Normal saline 2 ml 10 min before end of surgery
3078131|NCT02039414||Obese, Inactive|Pregnant women with a BMI≥30kg/m2 and sedentary lifestyle
3078132|NCT02039414||Obese, Active|Pregnant women with a BMI≥30kg/m2 and exercising >150min/week
3078133|NCT02039401|Experimental|VM202|Total dose of 64 mg of VM202 It will be administered over the course of four visits: Day 0, Day 7, Day 14, and Day 21. As in all previous VM202 studies, final dose of VM202 for each target muscle group is divided and administered 2 weeks apart.
3078134|NCT02039388|Other|High risk patients for breast and/or ovarian cancer|
3078135|NCT02039375|Experimental|"Hopkins post tPA monitoring protocol"|"Patients treated with IV tPA for acute stroke will be monitored in a non-ICU setting following the Hopkins post tPA monitoring protocol, a new schedule for vital signs and neurochecks. These patients will have vital signs and neurochecks every 15 minutes for two hours, then once upon admission to the stroke unit and after one hour, then every two hours for 8 hours and then every four hours until 24 hours post tPA."
3078136|NCT02039362|Other|tenofovir|tenofovir DF one pill (245 mg) per day from week 28 of pregnancy to week 12 after birth
3078137|NCT02039336|Experimental|Dacomitinib + PD-0325901|Dacomitinib: oral tablets PD-0325901: oral capsules
3078138|NCT02039323|Experimental|All Participants|Maraviroc 600 mg + Tenofovir 600 mg
3078139|NCT02039310||≥ 65 years / opts for radical cystectomy|
3078140|NCT02039297|Other|No Intervention: Baseline arm|Pre and post design (same arm)
3078141|NCT02039284|Experimental|SES group|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
3078255|NCT02038686|Active Comparator|Long PFN-A|Patients with unstable proximal femoral fractures treated with PFN-A long nail (300-420mm)
3078142|NCT02039284|Experimental|VCT group|VCT group received the VCT training in addition to traditional rehabilitation.Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise.
3078143|NCT02039284|Experimental|VRCIT group|VRCIT group received the VRCIT training in addition to traditional rehabilitation.Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day.
3078144|NCT02039284|Active Comparator|traditional rehabilitation group|Shame control group received the shame SES and traditional rehabilitation programs.
3078145|NCT02039271|No Intervention|Standard of Care|Subjects will receive standard post-operative care after total knee replacment surgery
3078146|NCT02039271|Experimental|Music Therapy|Subjects will receive music therapy in addition to standard post-operative therapy.
3078147|NCT02039258|Experimental|Sequence AB|A single dose of CANA/MET XR FDC tablet of 150 mg/1,000 mg under fasted conditions (treatment A) followed by the same single dose under fed conditions (treatment B).
3078148|NCT02039258|Experimental|Sequence BA|A single dose of CANA/MET XR FDC tablet of 150 mg/1,000 mg under fed conditions (treatment B) followed by the same single dose under fasted conditions (treatment A).
3078149|NCT02039245|Experimental|Canagliflozin/Metformin XR|Each patient will receive 2 tablets of CANA/MET XR combination of total dose 300/2000 mg
3078150|NCT02039232|Experimental|CarboFix Pedicle Screw System|
3078151|NCT02039219|Placebo Comparator|Placebo|Placebo
3078152|NCT02039219|Experimental|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 6 weeks.
3078153|NCT02039206|Experimental|Treatment|Deep TMS
3078154|NCT02039193|Experimental|adherence priming|"To investigate various types of how to conduct a standardized CBT-protocol, all therapists are tutored in peer dyads (tandem peer tutoring). Immediate before sessions 1 to 5, the therapists are required to contact the tandem-partner face-to-face or via self-phone to deliberate the forthcoming session by a 5 to 10 minute brief communication (primings; comparable to Flückiger & Grosse-Holtforth, 2008).~Adherence priming: Immediately before sessions 1 to 5, therapists have a five-minute conversation about how to implement the disorderspecific interventions that are described in the treatment protocol. These communications are focused on therapists' understanding of patients GAD and the related comorbidities and how these issues can be addressed in the prescriptive treatment protocol."
3078155|NCT02039193|Experimental|resource priming|Resource priming: Immediately before sessions 1 to 5, therapists have a five-minute conversation about how to implement strengths-based micro-interventions in the forthcoming session. Strengths-based micro-interventions addresses therapists explicit focus on patients' preexisting strengths and abilities, subtle changes and improvements during therapy (potential recources) as well as motivational preparedness, readiness and goals (motivational resources; Grawe, 2006; Flückiger, et al., 2010).
3078156|NCT02039193|Experimental|supportive resource priming|Supportive resource priming: The supportive resource priming condition has the very same protocol as the resource priming condition (5 brief tandem peer tutorings). The only difference in the procedure is that the therapists are allowed to integrate a helpful significant person of the patients (such as the partners or the best friends) around session 1 and 7 to encourage and support the patient to realize their treatment plans (active integration of interpersonal resources). However, the integration of a significant other person does not touch the CBT-treatment protocol.
3078157|NCT02039180|Experimental|AZD3293 oral solution|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
3078158|NCT02039180|Experimental|AZD3293 tablet formulation A|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
3078159|NCT02039180|Experimental|AZD3293 tablet formulation B|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
3078160|NCT02039167|Active Comparator|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
3078161|NCT02039167|No Intervention|OAC with a vitamin K antagonist|Oral anticoagulants (OAC) as Standard of Care (SOC) provided by primary care physician
3078162|NCT02039154|Experimental|Aerobic and strength training group|
3078163|NCT02039154|Active Comparator|Balance and flexibility group|
3078164|NCT02039141|Experimental|Every Little Step Counts Intervention|Exercise classes (3/week) Lifestyle sessions (1/week)
3078165|NCT02039141|No Intervention|Delayed ELSC Intervention Group|Control group (delayed intervention group)
3078166|NCT02039128|Experimental|Krill oil|1 gram per day in 12 weeks
3078167|NCT02039128|Active Comparator|Fish oil|1 gram per day in 12 weeks
3078168|NCT02039128|Placebo Comparator|Placebo|1 gram per day in 12 weeks
3078169|NCT02039115|Experimental|prednisone|Daily oral prednisone is taken for 6 weeks, at a dose of 40mg/day in week 1, 30mg/day in week 2, 20mg/day week 3 and 4, 10mg/day in week 5, and 5mg/day in week 6. Prednisone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage complete Barretts excision.
3078170|NCT02039115|Placebo Comparator|placebo|Placebo tablets will be taken in the same manner as the prednisone arm.
3078171|NCT02039102||Non-users of hormonal contraceptives|
3078172|NCT02039102||Users of hormonal contraceptives|
3078173|NCT02039089|Experimental|1|Part A: dose escalation of E2006 in Japanese subjects from 2.5 mg (1 x 2.5-mg tablet) up to 10 mg (1 x 10-mg tablet) then to 25 mg (2 x 10-mg tablet, 1 x 5-mg tablet).
3078174|NCT02039089|Experimental|2|Part B: E2006 10 mg for White subjects that will be group matched to the Japanese subjects in the 10 mg period in Part A.
3078175|NCT02039089|Placebo Comparator|3|E2006-matched placebo tablets
3078176|NCT02039076|Experimental|avatrombopag|Each subject will receive a single administration during each of the 5 treatment periods as follows: 40 and 60 mg in the fed and fasted state, and 20 mg in the fed state. Subjects will be randomized to one of four dosing sequences.
3078177|NCT02039063|Experimental|1|E6011 2 mg/kg
3078178|NCT02039063|Experimental|2|E6011 5 mg/kg
3078179|NCT02039063|Experimental|3|E6011 10 mg/kg
3078181|NCT02039050|Active Comparator|Tiotropium|Participants receive tiotropium for 2 to 3 weeks.Participants then enter a washout period and after the washout period receive the alternative treatment arm.
3078182|NCT02039050|Experimental|Aclidinium|Participants receive tiotropium for 2 to 3 weeks.Participants then enter a washout period and after the washout period receive the alternative treatment arm.
3078183|NCT02039037|Active Comparator|Acupuncture group|This group perform acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
3078184|NCT02039037|Active Comparator|Electroacupuncture group|Electro Group, will be added through the use of electrical stimulation of electroacupuncture using the apparatus Accurate pulse 585 at the same points.
3078185|NCT02039024|Experimental|18F- DTBZ for Parkinson's Disease|"This study will compare the amyloid deposition of brain by florbetapir F-18 PET imaging and monoaminergic function by18F- DTBZ PET in 10 NC group, 30 PD group, 30 PDD group, 20 AD group. We will also analyze monoaminergic function by18F- DTBZ PET in 30 PDI group.~Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, healthy subjects, PD, PDD, and AD patients will have 4 visits in this study. PDI patients will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
3078186|NCT02039011|Active Comparator|Indacaterol|
3078187|NCT02039011|Experimental|Indacaterol & tiotropium|
3078188|NCT02038998|Sham Comparator|Static group|Control group. They will receive the standard care provided by the protocols of the ictus unit. They will lay on the Exer-Rest® TL device but the acceleration will NOT be connected.
3078189|NCT02038998|Experimental|Single pGz intervention|In addition to the standard care established in the ictus unit, these patients will receive a single exposure to pGz on the Exer-Rest® TL, for 3 hours, during the first day of their stay in the hospital.
3078190|NCT02038998|Experimental|Multiple pGz interventions|In addition to the standard care, these patients will be exposed to 45 minutes of pGz, on the Exer-Rest® TL, every day during their first week in the Hospital.
3078191|NCT02038985|Other|+ ICG Dye (Firefly)|Participants will receive ICG Dye
3078192|NCT02038972|Experimental|Autologous Stem Cells|A single dose of intravenously administered autologous hUCB will be done. The minimum acceptable dose will be 6x10 6th mononuclear cells/kilogram body weight. The hUCB reanimation, cell processing and product infusion will occur at Florida Hospital for Children and the Florida Hospital Center for Cellular Therapy.
3078193|NCT02038959|No Intervention|Usual Care and Educational Materials|Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.
3078194|NCT02038959|Experimental|Virtual Visits and Educational Materials|Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.
3078195|NCT02038946|Experimental|Arm 1: Nivolumab|Nivolumab 3 mg/kg injection by Intravenous for every 2 weeks until disease progression or discontinuation due to toxicity
3078196|NCT02038933|Experimental|Nivolumab (3 mg/kg)|Nivolumab 3 mg/kg solution intravenously every 2 weeks until progression or unacceptable toxicity
3078197|NCT02038920|Experimental|Vedolizumab 300mg|Intravenous Vedolizumab (300 mg) administered at Weeks 0, 2, and 6 and every 8 weeks thereafter
3078198|NCT02038920|Placebo Comparator|Placebo|Vedolizumab Placebo. Intravenous infusion at Weeks 0, 2, and 6 and every 8 weeks thereafter
3078199|NCT02038907|Experimental|GI.1/GII.4 (15/15) - MPL (50)|Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MLP) and 500 µg aluminum hydroxide, IM on Day 28.
3078200|NCT02038907|Experimental|GI.1/GII.4 (15/50) - MPL (50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
3078201|NCT02038907|Experimental|GI.1/GII.4 (50/50) - MPL (50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
3078202|NCT02038907|Experimental|GI.1/GII.4 (15/15) - MPL (15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
3078203|NCT02038907|Experimental|GI.1/GII.4 (15/50) - MPL (15)|IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, on Day 28.
3078204|NCT02038907|Experimental|GI.1/GII.4 (50/50) - MPL (15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
3078205|NCT02038907|Experimental|GI.1/GII.4 (15/15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
3078206|NCT02038907|Experimental|GI.1/GII.4 (15/50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
3078207|NCT02038907|Experimental|GI.1/GII.4 (50/50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
3078256|NCT02038673|Experimental|Dose escalation part 0.5 mg QD|Oral
3078257|NCT02038673|Experimental|Dose escalation part 1.0 mg QD|Oral
3078208|NCT02038907|Experimental|GI.1/GII.4 (50/150)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
3078209|NCT02038907|Experimental|GI.1/GII.4 (15/50) - Al(OH)3 (167)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 28.
3078210|NCT02038907|Experimental|GI.1/GII.4 (15/50) x2|Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.
3078211|NCT02038907|Experimental|GI.1/GII.4 (50/150) x2|Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.
3078212|NCT02038907|Experimental|GI.1/GII.4 (15/50) - Al(OH)3 (167) x2|Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 1 and Day 28.
3078213|NCT02038894|Active Comparator|Intubated with Sevoflurane (IS)|Anesthetic technique during (EGD)
3078214|NCT02038894|Active Comparator|Intubated with Propofol (IP)|Anesthetic technique during (EGD)
3078215|NCT02038894|Active Comparator|Native Airway - no intubation|Anesthetic technique during (EGD)
3078216|NCT02038881|Experimental|Group 1 (standard regimen)|One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
3078217|NCT02038881|Experimental|Group 2 (double dose regimen)|Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
3078218|NCT02038881|Experimental|Group 3 (booster regimen)|One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
3078219|NCT02038868|Experimental|ASP4901 group|
3078220|NCT02038868|Placebo Comparator|Placebo group|
3078221|NCT02038868|Active Comparator|Tamsulosin group|
3078222|NCT02038855|Active Comparator|IIDEA|Patients in the Integrated Intervention for Dual Problems and Early Action (IIDEA) arm will receive the 10 session intervention administered in person and via telephone.
3078223|NCT02038855|No Intervention|Usual Care|Patients in this arm receive usual care for dual-diagnosis symptoms of mental health and substance use. They receive 5 check-in calls from a care manager to assess safety.
3078224|NCT02038842|Experimental|MVA HIV-B and LIPO-5 vaccines|MVA HIV-B primes 0,5 milliliter (mL) Intramuscular at Week 0 and Week 8 LIPO-5 1mL Intramuscular boosts at Week 20 and Week 28
3078225|NCT02038842|Experimental|LIPO-5 and MVA HIV-B vaccines|LIPO-5 primes 1mL intramuscular at Week 0 and Week 8 and MVA HIV-B 0,5mL intramuscular boosts at Week 20 and Week 28
3078226|NCT02038842|Experimental|GTU-MultiHIV B and LIPO-5 vaccines|GTU-MultiHIV B 0,5mL intramuscular via Biojector 2000 and 0,5mL intradermic primes at Week 0, Week 4 and Week 12 and LIPO-5 1mL intramuscular boosts at Week 20 and Week 28
3078227|NCT02038842|Experimental|GTU-MultiHIV B and MVA HIV-B vaccines|GTU-MultiHIV B 0,5mL intramuscular via Biojector 2000 and 0,5mL intradermic primes at Week 0, Week 4 and Week 12 and MVA HIV-B 0,5mL intramuscular boosts at Week 20 and Week 28
3078228|NCT02038829|Placebo Comparator|Placebo|Placebo bid
3078229|NCT02038829|Experimental|SUN-101 3 mcg|SUN-101 3 mcg bid
3078230|NCT02038829|Experimental|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
3078231|NCT02038829|Experimental|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
3078232|NCT02038829|Experimental|SUN-101 50 mcg|SUN-101 50 mcg bid
3078233|NCT02038829|Active Comparator|Aclidinium 400 mcg|Aclidinium 400 mcg bid
3078234|NCT02038816|Experimental|Deferasirox + Azacitidine|Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles + Deferasirox 10-30 mg/kg/d depending on transfusion needs
3078235|NCT02038816|Active Comparator|Azacitidine|Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles
3078236|NCT02038790|Experimental|Suboxone sublingual film 8/2|Participants took a single dose of Suboxone sublingual film 8/2 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study.
3078237|NCT02038790|Active Comparator|Zubsolv sublingual tablets 5.7/1.4|Participants took a single dose of Zubsolv sublingual tablets 5.7/1.4 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study.
3078238|NCT02038777|Experimental|Monotherapy Cohort|PF-04449913 Monotherapy
3078239|NCT02038777|Experimental|Combination Cohort 1|PF-04449913 in combination with low dose ARA-C (LDAC)
3078240|NCT02038777|Experimental|Combination Cohort 2|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
3078241|NCT02038777|Experimental|Azacitidine Combination Cohort|PF-04449913 in combination with azacitidine
3078242|NCT02038777|Experimental|Continuation Cohort|PF-04449913 Monotherapy for one patient rolled-over from another trial in the same project.
3078243|NCT02038764|Placebo Comparator|Placebo|Placebo
3078244|NCT02038764|Experimental|PF-06342674|
3078245|NCT02038751||Index proband|moderate to severe OSA (AHI>30 or AHI>15 needing CPAP intervention) age 20-99 y/o
3078246|NCT02038751||Index family|first-degree, second-degree, or spouse of index proband age >20 y/o
3078247|NCT02038751||Control proband|friends of index proband, living in the same environment as index proband age > 20 y/o
3078248|NCT02038751||Control family|first-degree, second-degree, or spouse of control proband age >20 y/o
3078249|NCT02038738|Experimental|Scan|We will perform 68Ga-DOTATATE PET scans on subjects.
3078250|NCT02038725||TIA in last 2 weeks|
3078251|NCT02038712|Experimental|Binge eating disorder (BED)|Blood samples, subjective appetite ratings and fMRI scan will be collected in subjects who meet the current criteria for binge eating disorder (BED) in the fed condition and fasted condition.
3078252|NCT02038712|Experimental|Control|Blood samples, subjective appetite ratings and fMRI scan will be collected in subjects who do not meet the current criteria for BED (Controls) in the fed condition and fasted condition.
3078253|NCT02038699|Experimental|ONC201|Oral ONC201 will be administered once every three weeks at various doses.
3078254|NCT02038686|Active Comparator|Standard PFN-A|Patients with unstable proximal femoral fractures treated with PFN-A short nail (170-240mm)
3078269|NCT02038647|Experimental|Alisertib (MLN8237) + Paclitaxel|Alisertib 40 mg, tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 60 mg/m^2 intravenously (IV) once a week for 3 weeks on Days 1, 8, and 15 in a 28-day cycle up to 11 cycles.
3078270|NCT02038647|Placebo Comparator|Placebo + Paclitaxel|Alisertib placebo-matching tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 80 mg/m^2 IV once a week for 3 weeks on Days 1, 8, and 15 in a 28-day cycle up to 11 cycles.
3078271|NCT02038634|Active Comparator|Unguided injections|Corticosteroid injection (betamethasone) without ultrasound guidance.
3078272|NCT02038634|Active Comparator|Ultrasound-guided injections|Corticosteroid injections (betamethasone) under ultrasound guidance.
3078273|NCT02038621|Experimental|A|Capecitabine: 1000mg/m^2 bid, days 1-14, every 3 weeks until progression/intolerance.
3078274|NCT02038621|Placebo Comparator|B|Observation until progression
3078275|NCT02038608|Experimental|PET|
3078276|NCT02038595|Experimental|Healthy subjects|Healthy subjects (male, female)
3078277|NCT02038582|Active Comparator|POC CD4 & Clinic Accompaniment|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and follow up with clinic accompaniment
3078278|NCT02038582|Active Comparator|POC CD4 & Lay Counselor|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and lay counselor follow up
3078279|NCT02038582|Active Comparator|POC CD4 & Clinic Referral|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and referral to clinic
3078280|NCT02038582|Active Comparator|CD4 Referral & Clinic Accompaniment|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and follow up with clinic accompaniment
3078281|NCT02038582|Active Comparator|CD4 Referral & Lay Counselor|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and lay counselor follow up
3078282|NCT02038582|Active Comparator|CD4 Referral & Clinic Referral|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and referral to clinic
3078283|NCT02038582|Active Comparator|Circumcision - SMS Reminder|HIV negative uncircumcised males, randomized to SMS reminder for male circumcision
3078284|NCT02038582|Active Comparator|Circumcision - Lay Counselor|HIV negative uncircumcised males, randomized to lay counselor follow-up for male circumcision
3078285|NCT02038582|Active Comparator|Circumcision - Promotion|HIV negative uncircumcised males, randomized to promotion of male circumcision at the time of HIV testing
3078286|NCT02038582|Active Comparator|POC VL|HIV positive persons on ART, randomized to POC viral load testing
3078287|NCT02038582|Active Comparator|Laboratory based VL assay|HIV positive persons on ART, randomized to laboratory based viral load testing
3078288|NCT02038569|Experimental|LEO 80185|
3078289|NCT02038556|Experimental|cognitive behaviorial therapy for insomnia group program|Behavioral
3078290|NCT02038543|Experimental|Primary hyperoxaluria patients|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the Clinical Research and Trials Unit (CRTU). The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
3078291|NCT02038530||No Ultrasound|Low Clinical Pretest Probability and D-dimer < 1000 ug/L; Moderate Clinical Pretest Probability and D-dimer < 500 ug/L
3078292|NCT02038530||Ultrasound Required|Low Clinical Pretest Probability and D-dimer 1000 - 3000 ug/L; Moderate Clinical Pretest Probability and D-dimer 500 - 3000 ug/L; High Clinical Pretest Probability
3078293|NCT02038504||gastrointestinal fistula|
3078294|NCT02038491||regional anesthesia|patients undergoing regional anesthesia procedures
3078295|NCT02038478|Experimental|Transplantation Arm|"Transplantation~One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects."
3078296|NCT02038465|Other|patient|Complete questionary remembering the day
3078297|NCT02038465|Other|healthy volunteers|- Complete questionary, remembering the day
3078298|NCT02038452|Active Comparator|Steroid Injection|Single steroid injection into Carpal Tunnel (as Depo-medrone 20mg)
3078299|NCT02038452|Active Comparator|Wrist Splint|Wrist splint to be worn at night
3078300|NCT02038439|Experimental|Interventions: A + B + C|"See Interventions Description. In this arm, clinicians will be offered all 3 online interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention B - Online Evidence Retrieval Coach~Intervention C - Online Audit and Feedback"
3078301|NCT02038439|Experimental|Interventions A + B|"See Interventions Description. In this arm, clinicians will be offered the 2 following interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention B - Online Evidence Retrieval Coach"
3078302|NCT02038439|Experimental|Interventions A + C|"See Interventions Description. In this arm, clinicians will be offered the 2 following online interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention C - Online Audit and Feedback"
3078303|NCT02038439|Experimental|Interventions B + C|"See Interventions Description. In this arm, clinicians will be offered the 2 following online interventions combined:~Intervention B - Online Evidence Retrieval Coach~Intervention C - Online Audit and Feedback"
3078304|NCT02038439|Experimental|Intervention A alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:~* Intervention A - Online Clinical Questions Recorder"
3078305|NCT02038439|Experimental|Intervention B alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:~* Intervention B - Online Evidence Retrieval Coach"
3078306|NCT02038439|Experimental|Intervention C alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:~* Intervention C - Online Audit and Feedback"
3078307|NCT02038439|No Intervention|No intervention|In this arm, clinicians will be offered non of the 3 online interventions, but will just be using the usual features of the search engine available to all users.
3078308|NCT02038426|Experimental|the patients with SpA|
3078311|NCT02038413||NSCLC stage I|Consecutive patients were identified from October 2009 onwards in MAASTRO clinic, Maastricht. All patients received respiratory gated CT (4DCT) scans. All were patients referred for primary radiotherapy or chemo radiation.
3078312|NCT02038400|Experimental|group A|KINETUBE medical Device
3078313|NCT02038400|Active Comparator|group B|insertion of tympanic ventilation tubes (tympanostomy)
3078314|NCT02038387|Experimental|Diet|
3078315|NCT02038374|Experimental|severe asthma atopic|
3078316|NCT02038374|Experimental|asthma non atopic|
3078317|NCT02038361|Experimental|blood sample|
3078318|NCT02038348|Other|PET with 18F-FDOPA|
3078319|NCT02038335||DMPA|Depot medroxyprogesterone acetate
3078320|NCT02038335||NET-EN|Norethisterone enantate
3078321|NCT02038335||MPA/E2|Medroxyprogesterone acetate and estradiol cypionate
3078322|NCT02038335||LNG-I|Levonorgestrel subdermal implant
3078323|NCT02038335||ENG-I|Etonogestrel subdermal implant
3078324|NCT02038335||Cu-IUD|Copper IUD
3078325|NCT02038322|No Intervention|The Stork|Device - The Stork - complete kit (Conceptacle and Applicator)
3078326|NCT02038296|Experimental|Group 1|Group 1 received single-drug (doxorubicin)transarterial chemoembolization.
3078327|NCT02038296|Experimental|Group 2|Group 2 received double-drug (doxorubicin and mitomycin C)transarterial chemoembolization
3078328|NCT02038296|Experimental|Group 3|Group 3 were treated with triple-drug (doxorubicin, mitomycin C and gemcitabine)transarterial chemoembolization.
3078329|NCT02038283||Low-risk Colorectal Polyps|≤2 adenomas or 3-4 adenomas all of which are <1cm
3078330|NCT02038283||High-risk Colorectal Polyps|≥5 adenomas or ≥3 adenomas at least one of which is ≥1cm
3078331|NCT02038283||Stage I CRC|at least six months since diagnosis of Stage I CRC
3078332|NCT02038283||Stage II CRC|at least six months since diagnosis of Stage II CRC
3078333|NCT02038283||Stage III CRC|at least six months since diagnosis of Stage III CRC
3078334|NCT02038283||Stage IV CRC|at least six months since diagnosis of Stage IV CRC
3078335|NCT02038270||surgical patients|120 Adult patients, that are having a routine surgical procedure.
3078336|NCT02038257|Active Comparator|MKTP with CO2 Laser/Collagen Dressing|Each Subject will have a depigmented patch of skin treated with MKTP using the carbon dioxide laser for de-epithelialization and a collagen dressing for the wound dressing.
3078337|NCT02038257|Active Comparator|MKTP with CO2 laser/vaseline gauze|Each subject will have a depigmented patch of skin treated with MKTP using the carbon dioxide laser for de-epithelialization and vaseline impregnated gauze as the wound dressing.
3078338|NCT02038257|Active Comparator|MKTP with dermabrasion/collagen dressing|Each subject will have a depigmented patch of skin treated with MKTP using dermabrasion for de-epithelialization and a collagen dressing for the wound dressing.
3078339|NCT02038257|Active Comparator|MKTP with dermabrasion/vaseline gauze|Each subject will have a depigmented patch of skin treated with MKTP using dermabrasion for de-epithelialization and vaseline impregnated gauze as a wound dressing.
3078340|NCT02038244|Experimental|Integrative Medicine|
3078341|NCT02038231|Experimental|Parenting Mindfully Program|Mindfulness program for parents of adolescents provided for 2 hours once per week for 8 weeks.
3078342|NCT02038231|Active Comparator|Parent Education Program|Group for parents of adolescents providing handouts and brief education to parents on topics of adolescence, family relations, and risk behaviors. Group meets 3 times over the course of 8 weeks for about 15 minutes per meeting.
3078343|NCT02038218|Experimental|DM-CHOC-PEN|"Two Cohorts of patients will be treated every once every 21 days with a single infusion of DM-CHOC-PEN as an out-patient. Patients will be divided into:~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
3078344|NCT02038192|Experimental|Living with Hope Program|"All participants in this group will receive the Living with Hope Program. It consists of viewing a 15 minute film on hope. Then for 5 minutes at the end of each day to write Stories of the Presentto work on over one month. Stories of the present is a directed journaling activity which includes writing challenges of the day, what was their hope that day and what would be their hope tomorrow."
3078345|NCT02038192|Experimental|Stories of the Present|Participants in this group will write Stories of the Present and not see the film.
3078346|NCT02038192|No Intervention|Usual Care|Participants in this group will not receive an intervention. Data collection for outcome variables will be the same as the participants in the other arms.
3078347|NCT02038179|Active Comparator|Allopurinol arm|Participants will be asked to take 4 weeks of allopurinol or placebo, then will crossover to the other drug (after 4 week washout period) and take either allopurinol or placebo for an additional 4 weeks.
3078348|NCT02038179|Placebo Comparator|Placebo Arm|Participants will be asked to take 4 weeks of allopurinol or placebo, then will crossover to the other drug (after 4 week washout period) and take either allopurinol or placebo for an additional 4 weeks.
3078349|NCT02038153|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Courses repeat 4 weeks in the absence of disease progression or unacceptable toxicity.
3078350|NCT02038140|Other|Zimmer TM Total Ankle System|Primary or revision total ankle arthroplasty subjects that receive the Zimmer Trabecular Metal Total Ankle System
3078351|NCT02038114|Experimental|Instructed to read pamphlets|This group will be instructed to read patient education pamphlets.
3078352|NCT02038101|Experimental|Education and Feedback Intervention|"This intervention includes the following components:~Formal Rounds on AUC for TTE:~Appropriate Use for TTE Application for Smartphone~Individualized Feedback Reports provided by email"
3078353|NCT02038101|No Intervention|Control|Usual echocardiography ordering pratice.
3078354|NCT02038088||A|intravenous inhalational anesthesia
3078355|NCT02038088||B|intravenous anesthesia
3078390|NCT02037893|Placebo Comparator|Placebo|Placebo otic solution will be glycerin that is dehydrated . Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
3079046|NCT02033486|Experimental|TOBI + DBT|TOBI + DBT of women presenting for breast imaging.
3078356|NCT02038075|Experimental|Brief Cognitive Behavioral Therapy (BCBT)|In addition to TAU, participants in BCBT receive 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. BCBT was is delivered in three sequential phases. In phase I (5 sessions), the therapist identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
3078357|NCT02038075|Active Comparator|Treatment As Usual (TAU)|Participants in TAU receive usual care from military clinicians as well as non-military clinicians from the local community, as determined by participants' primary mental health care provider. All mental health, substance abuse, and medical treatment are provided within the military health care system at no cost to participants.
3078358|NCT02038062|Experimental|Sevoflurane|Sevoflurane Preconditioning
3078359|NCT02038062|No Intervention|No Sevoflurane|No Sevoflurane Preconditioning
3078360|NCT02038049|Experimental|VAY736|Intravenous infusion of VAY736
3078361|NCT02038049|Placebo Comparator|Placebo to VAY736|Matching placebo (infusion bag) administered intravenously. Placebo randomized patients will be offered optional VAY736 administration after week 16
3078362|NCT02038036|Experimental|Ruxolitinib|52 patients- at a starting dose of 10 mg bid. Dose may be adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
3078363|NCT02038036|Active Comparator|Best Available Therapy|52 patients - as selected by the investigator from: Hydroxyurea, IFN/PEG-IFN, popobroman, anagrelide, IMIDs, or observation
3078364|NCT02038023|Other|IV iron|Intravaneous iron(1000 mg low molecular weight iron dextran over 60 minutes) for moderate to severe iron deficient anemia of pregnancy in women intolerant of or unresponsive to oral iron.
3078365|NCT02038010|Experimental|Treatment (PI3K inhibitor BYL719, ado-trastuzumab emtansine)|Patients receive PI3K inhibitor BYL719 PO daily on days 1-21 and ado-trastuzumab emtansine IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3078366|NCT02037997|Experimental|combination with Erlotinib|Erlotinib 150mg qd combination with docetaxel 75mg/m2 or pemetrexed 500mg/m2
3078367|NCT02037997|Active Comparator|sequential chemotherapy for Erlotinib|docetaxel 75mg/m2 or pemetrexed 500mg/m2，after PD，Erlotinib 150mg qd
3078368|NCT02037984|Experimental|Adult- V114 medium dose|Single vaccination on day 1.
3078369|NCT02037984|Experimental|Adult-V114 maximum dose|Single vaccination on day 1.
3078370|NCT02037984|Experimental|Infant-V114 medium dose|A 4-dose series at 2, 4, 6, and 12 to 15 months of age.
3078371|NCT02037984|Experimental|Infant-V114 high dose|A 4-dose series at 2, 4, 6, and 12 to 15 months of age.
3078372|NCT02037984|Experimental|Infant-V114 maximum dose|A 4-dose series at 2, 4, 6, and 12 to 15 months of age.
3078373|NCT02037984|Experimental|Infant-V114 low dose|A 4-dose series at 2, 4, 6, and 12 to 15 months of age.
3078374|NCT02037984|Experimental|Infant-V114 medium/high dose|A 4-dose series at 2, 4, 6, and 12 to 15 months of age.
3078375|NCT02037984|Active Comparator|Infant-Prevnar 13|A 4-dose series at 2, 4, 6, and 12 to 15 months of age.
3078376|NCT02037971|Experimental|Aerobic Exercise|Subjects will follow one defined exercise process, according their cardiopulmonary exercise test, during 16 weeks, two times per a week.
3078377|NCT02037971|Experimental|Control Group|A non-exercise group will receive regular educational information relating to their condition.
3078378|NCT02037958|Experimental|Laryngeal Mask Airway-Supreme|Patients who are randomly assigned to receive the LMA-Supreme
3078379|NCT02037958|Active Comparator|Endotracheal Tube|Patients who are randomly assigned to receive endotracheal intubation
3078380|NCT02037945|Experimental|pts with brain mets going for surgery|"This study will enroll patients with brain metastases that are evolving after SRS who are scheduled to undergo surgical resection. Eligible patients will undergo an 18F-FCH PET study 1-to-7 days pre-operatively. Although no toxicity has been previously reported following 18F-FCH administration, patients will be contacted 1-3 days after their scan and asked whether they experienced any adverse effects. The patients who have a positive 18F-FCH PET study (in which there is visible focal hot spots (a focus of lesion/normal white matter ratio >1.4) of 18F-FCH) will undergo further evaluation and be administered a second administration oflower activity 18F-FCH at the time of surgery. The purpose of the second 18F-FCH administration in the operating room is to further elucidate the tissue distribution of 18F-FCH radioactivity with respect to the histopathology of the surgically resected tissue."
3078381|NCT02037932|Experimental|Balloon Assisted Coiling|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
3078382|NCT02037919|Experimental|Immediate Nexplanon Insertion|An etonogestrel rod will be placed within 15 minutes following the abortion procedure.
3078383|NCT02037919|Active Comparator|Post-op Nexplanon Insertion|"Participants in the delayed placement group will be asked to return to Magee-Womens Hospital for a post-abortion visit 2-4 weeks following the procedure. Participants in the delayed group will be offered a method of contraception to use in the interim between their procedure and their insertion appointment. At this time an etonogestrel rod will be placed in her arm using standard procedure."
3078384|NCT02037906|Experimental|Escalating Energy SWL|50 Patients
3078385|NCT02037906|Experimental|Constant Energy SWL|50 Patients
3078386|NCT02037906|Experimental|Reduction Energy SWL|50 Patients
3078387|NCT02037893|Experimental|Antipyrine and Benzocaine Otic solution|antipyrine 54 mg and benzocaine 14 mg. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
3078388|NCT02037893|Active Comparator|Antipyrine Otic Solution|Antipyrine 54 mg and glycerine dehydrated to 1.0 mL. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
3078389|NCT02037893|Active Comparator|Benzocaine Otic Solution|benzocaine 14 mg and glycerine dehydrated to 1.0 ml. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
3078391|NCT02037880||MPS IIIA/B Subjects|Cohort will be followed for one year to assess natural history of the disease.
3078392|NCT02037867||Patients|"Patients identified with one of the below chronic liver disease risk factors and undergoing community liver disease stratification using fibrosis biomarkers:~Hazardous alcohol use (>14 units per week in females, >21 units per week in males, alcohol AUDIT score >=8 or read code relevant to alcohol abuse on GP system)~Type 2 Diabetes~Obesity~Persistently raised serum ALT level, negative liver serology, and absence of above 2 risk factors"
3078393|NCT02037854|Placebo Comparator|Placebo|A nutrient formulation without the active ingredient
3078394|NCT02037854|Experimental|Nutrient formulation|Nutrient formulations with variable amounts of active ingredients.
3078395|NCT02037841|Experimental|Nursing-driven Asthma protocol|Children randomized to the intervention group will have their β2-agonist medication weaned by the nurse, according to the steps outlined in the clinical pathway. The nurse will ensure that the patient's family is booked for asthma teaching, and will also remind the physicians to fill out an asthma action plan on discharge. Detailed information as to when to contact physicians in the event of an acute deterioration of the patient is included in the clinical pathway.
3078396|NCT02037841|No Intervention|Physician-driven asthma management|Patients in the control group will continue receiving the current standard of care, which consists of physicians weaning the β2-agonist medication when called to the bedside by the nurse or when deemed necessary by a physician
3078397|NCT02037828||Stable COPD in STEP1|no intervention
3078398|NCT02037828||Control in STEP 1|no intervention
3078399|NCT02037828||Case group in STEP 2|no intervention
3078400|NCT02037828||Control group in STEP2|no intervention
3078401|NCT02037815|Experimental|Mannitol|20% mannitol solution, 125 ml, IV infusion in 15 min
3078402|NCT02037815|Experimental|Hypertonic saline|3.1% sodium chloride solution, 125 ml, IV infusion in 15 min
3078403|NCT02037802|Active Comparator|caudal epidural catheterization group|30 patients received continuous intra and post-operative caudal epidural infusion of bupivacaine 0.125% with fentanyl (2 microgram/ml) over 24 hours
3078404|NCT02037802|Sham Comparator|control group|30 patients didn't receive caudal epidural analgesia
3078405|NCT02037776|Placebo Comparator|Rikkunshito Placebo|
3078406|NCT02037776|Active Comparator|Rikkunshito|
3078407|NCT02037750|Experimental|LINKS|
3078408|NCT02037750|No Intervention|Services as Usual|
3078409|NCT02037737||RA patients on Abatacept IV|Rheumatoid Arthritis (RA) patients with inadequate response to one or more conventional DMARDs including Methotrexate and treated with Abatacept IV according to routine clinical practice in France
3078410|NCT02037724|Other|supplement containing 60 mg iron sulfate|nutrient supplement containing 60 mg of iron as ferous sulfate
3078411|NCT02037724|Experimental|iron rich food supplement (60 mg iron)|contains 60 mg Iron
3078412|NCT02037724|Experimental|iron rich food supplement (10 mg iron)|contains 10 mg of iron
3078413|NCT02037724|Other|supplement containing 10 mg iron sulfate|nutrient supplement containing 10 mg of iron as ferous sulfate
3078414|NCT02037711|Active Comparator|Chirocaine group (levobupivacaine )|
3078415|NCT02037711|Sham Comparator|Control group|
3078416|NCT02037698|Experimental|Pre-PCI CT scan group|Pre-PCI CT scan
3078417|NCT02037698|No Intervention|Control group|Control
3078418|NCT02037685|Active Comparator|Usual care|Subjects randomized to usual care will receive a brochure once a year on the importance and impact of controlling cardiovascular risk factors, tips to improve statin adherence and smoking cessation strategies and public services. Subjects will also receive a letter every 6 months to remind about study participation along with educational material.
3078419|NCT02037685|Experimental|Motivational Interviewing (MINT)|"The MINT intervention will consist of 6 to 9 telephone encounters between a counselor trained in Motivational interviewing. All subjects in the MINT arm will be contacted every 3 months; however subjects who are not filling medication appropriately will receive additional calls.~Each telephone encounter will last from 20 to 30 minutes and have a patient centered approach having the following basic structure and goals:~Establishing a connection and reinforcing autonomy: .~Empathizing with ambivalence and rolling with resistance.~Coach the subject towards expressions of commitment."
3078420|NCT02037672|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
3078421|NCT02037672|Active Comparator|metformin and roflumilast|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time roflumilast was initiated at a dose of 500 mg BID per os.
3078422|NCT02037659||Gastric Varices treatment|DermaBond (glue) treatment of Gastric Varices.
3078423|NCT02037646|Other|Qualitative fecal immunochemical test|"Stool samples will be tested with the qualitative fecal immunochemical test (qFIT), and will be stratified for colonoscopy as follows:~>200 ng/dL - colonoscopy with one month 100-200 ng/dL - colonoscopy as per waiting list <100 ng/dL - no colonoscopy~Cost analysis, anxiety scores and patient satisfaction scores will be calculated for all patients."
3078424|NCT02037646|Other|Quantitative fecal immunochemical test|"Stool samples will be tested with the quantitative fecal immunochemical test (FIT), and will be scheduled for colonoscopy as follows:~Positive - colonoscopy as per waiting list Negative - no colonoscopy~Cost analysis, anxiety scores and patient satisfaction scores will be calculated for all patients."
3078425|NCT02037633|Active Comparator|Fascia iliaca compartment block|
3078426|NCT02037633|Active Comparator|Fentanyl|
3078427|NCT02037620|Experimental|Epidural Stimulation|80 sessions each of epidural spinal cord stimulation for 1) cardiovascular function; 2) voluntary movement; and 3) standing.
3078428|NCT02037594|Experimental|Counseling + SOC Adherence|Sexual Health Counseling followed by Standard of Care Adherence Support
3078429|NCT02037594|Experimental|Counseling + Enhanced Adherence|Sexual Health Counseling followed by Enhanced Adherence Intervention
3078430|NCT02037594|Experimental|Information + SOC Adherence|PrEP Information followed by Standard of Care Adherence Support
3078431|NCT02037594|Experimental|Information + Enhanced Adherence|PrEP Information followed by Enhanced Adherence Intervention
3078464|NCT02037373||Octaplas™|Patients treated with Octaplas™ infusion solution for IV administration as prescribed by their treating physician.
3078697|NCT02035839|Other|Target Temperature Management of 32°C|In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
3078432|NCT02037581|Experimental|Early detection and Integrated Care|"The intervention condition consisted of measures to improve early detection and treatment quality (Integrated Care).~Interventions for the improvement of early detection. The measures for improved early detection aiming at reducing the duration of untreated psychosis included 4-year measures to improve mental health literacy, reduce stigma and improve service utilization.~Measures to improve treatment quality should be achieved through extending the Hamburg model to a cross-age and interdisciplinary Integrated Care model for adolescent and young adult patients with psychotic disorders aged 12-29 years."
3078433|NCT02037581|Other|Standard Care|Historical control group with standard care parallelized regarding age, diagnosis and illness stage, which was treated in the period before the implementation of the intervention conditions. The control group consisted of n=105 patients with early psychosis between the ages of 12 and 29, who had been treated between January 2005 and December 2008. The central differences in comparison with the intervention conditions lie in the lack of measures for the improvement of early detection, the absence of the TACT team, as well as the regular referral to an established psychiatrist with in most cases regular contact frequency.
3078434|NCT02037568|No Intervention|Caregiver Self-Directed|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care; caregiver workbook.
3078435|NCT02037568|Experimental|Caregiver Intervention|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation and Relaxation (fPER), which included one-on-one psychoeducation, and stress management intervention.
3078436|NCT02037555|Experimental|AT-III (Human)|"Single intravenous dose of AT-III (Human) sufficient to achieve an absolute increase of 20% (percentage points) above pretreatment AT levels according the following formula:~AT-III (Human) dose (IU) required = (20) × (subject weight in kg) / 1.4"
3078437|NCT02037555|Placebo Comparator|Placebo|Single intravenous administration of placebo at a volume equivalent to the volume for the calculated AT-III (Human) dose.
3078438|NCT02037542|Experimental|Diet and Exercise|Prospective, observational, cohort study, with a proposed start date of May 2013 and proposed end date of June 2018. Our goal is to gather data on a total of 200 patients: 100 patients (study group) will be prospectively enrolled, while data on another 100 patients (control) will be accessed through retrospective data collection. Number of patients to be analyzed will depend on enrollment and patient compliance. We would like to enroll the proposed 100 patients in the first 1-3 years of the study (approximately 30 per year).
3078439|NCT02037529|Experimental|Arm A (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3078440|NCT02037529|Experimental|Arm B (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3078441|NCT02037516|Active Comparator|Control Group|qualitative monitoring of neuromuscular paralysis, standard treatment at this facility
3078442|NCT02037516|Active Comparator|Study Group|quantitative monitoring of neuromuscular paralysis as described in (Brull Murphy Anesth Analg 2010;111:129-40) Acceleromyography
3078443|NCT02037503|Placebo Comparator|Placebo for drug resistant depression|Patients will be treated for 21 days with daily oral placebo
3078444|NCT02037503|Experimental|Ketamine for suicidal ideation|Patients will be treated for 21 days with daily oral Ketamine
3078445|NCT02037503|Experimental|Ketamine for drug resistant depression|Patients will be treated for 21 days with daily oral Ketamine
3078446|NCT02037503|Placebo Comparator|Placebo in suicidal ideation|Patients will be treated for 21 days with daily oral placebo
3078447|NCT02037490|Experimental|Grow2Gether Intervention|"Participants in the intervention group will:~Participate in the Grow2Gether intervention~Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network."
3078448|NCT02037490|No Intervention|Control|"Participants in the control group will:~Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network."
3078449|NCT02037477|Experimental|Sequence A (Cohort 1): Vonoprazan + Esomeprazole|Vonoprazan (TAK-438) 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then esomeprazole 20 mg, orally, once daily for 7 days.
3078450|NCT02037477|Experimental|Sequence B (Cohort 1): Esomeprazole + Vonoprazan|Esomeprazole 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.
3078451|NCT02037477|Experimental|Sequence C (Cohort 2): Vonoprazan + Rabeprazole Sodium|Vonoprazan 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then Rabeprazole sodium 10 mg, orally, once daily for 7 days.
3078452|NCT02037477|Experimental|Sequence D (Cohort 2): Rabeprazole Sodium + Vonoprazan|Rabeprazole sodium 10 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.
3078453|NCT02037464|Experimental|Capsaicin Supplement|
3078454|NCT02037451|Experimental|intervention group|intervention group which receive auditory cueing while performing movement
3078455|NCT02037451|No Intervention|Control group|control group which performing movement after listen to required movement rhythm.
3078456|NCT02037438|Active Comparator|CONV|Conventional (CONV) care for the diagnosis and treatment of sleep disorders
3078457|NCT02037438|Experimental|PCCM|Patient-Centered Outcomes and Coordinated Care Management (PCCM) for the diagnosis and treatment of sleep disorders
3078458|NCT02037425|Other|onabotulinumtoxinA|At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
3078459|NCT02037412|Experimental|Ticagrelor Arm|Ticagrelor Arm
3078460|NCT02037412|Active Comparator|Clopidogrel Arm|Clopidogrel Arm
3078461|NCT02037399|Experimental|intravenous dexamethasone|To receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD
3078462|NCT02037399|Placebo Comparator|intravenous normal saline|To receive normal saline as placebo intravenous immediately after ESD
3078463|NCT02037386|Experimental|H-side branch stent|H-side branch stent group
3078465|NCT02037373||Plasma|Patients treated with regular plasma (e.g., fresh frozen plasma (FFP) and other FDA and American Association of Blood Banks (AABB) approved plasma products).
3078466|NCT02037360|Active Comparator|Active Comparator App/Training|This is a standard smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. Subjects will be encouraged to set a quit date of 3 weeks, to allow comparison to experimental arm quit date.
3078467|NCT02037360|Experimental|Experimental App/Training|This is a 3-week smartphone-based training program that trains mindfulness for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
3078468|NCT02037347|Experimental|Palifermin|Palifermin 60 micrograms/kg/day IV for 3 consecutive days
3078469|NCT02037334||Pregnancy|
3078470|NCT02037308|Placebo Comparator|Control white bread|
3078471|NCT02037308|Experimental|Beetroot bread|
3078472|NCT02037269||All participants|Female patients ≥30 years of age with known breast cancer scheduled for breast-conserving surgery (BCS) +/- sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND)
3078473|NCT02037256|Experimental|Treatment (bortezomib and filgrastim)|"GROUP A: Patients receive filgrastim SC on days 1-9 and begin apheresis on day 5. Patients undergo apheresis for up to 2 days, and receive bortezomib intravenously (IV) over 3-5 seconds after target collection is obtained with filgrastim alone or on the first day of collection with the Bortezomib plus filgrastim mobilization, prior to receiving the administration of filgrastim. Second apheresis will continue until target stem cell dose is reached or for maximum 4 days. Patients undergo autologous hematopoietic stem cell transplantation after receiving high dose chemotherapy and peripheral blood stem cell (PBSC) infusion following standard of care procedures.~GROUP B: Patients receive filgrastim SC on days 1-8 and receive bortezomib IV over 3-5 seconds on days 4 and day 7, before administration of filgrastim. Patients undergo apheresis on days 5-8. (See Detailed Description)"
3078474|NCT02037243|Experimental|Water Treatment|Chlorine dispenser promotion and provision
3078475|NCT02037243|Experimental|Hand washing|Hand washing with soapy water promotion
3078476|NCT02037243|Experimental|Standard public health intervention|Health promotion using information about germs and disease
3078477|NCT02037243|Experimental|Disgust and shame intervention|Health promotion using disgust shame
3078478|NCT02037230|Experimental|MK-1775/ Gemcitabine/ Radiation Therapy|
3078479|NCT02037217|Experimental|ExAblate Treatment|
3078480|NCT02037204|Experimental|Cartilage repair surgery|Single-stage cartilage repair surgery using autologous chondrons and allogeneic MSCs in a fibrin glue carrier.
3078481|NCT02037191|Placebo Comparator|ARM A : METHOTREXATE|"Arm A: methotrexate 20 to 25 mg / week for 6 months. Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).~Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or~methotrexate associated with prednisone 0.3 mg/Kg/day"
3078482|NCT02037191|Placebo Comparator|ARM B : PLACEBO|"Arm B placebo Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).~Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or~methotrexate associated with prednisone 0.3 mg/Kg/day"
3078483|NCT02037178||The study population|"See inclusion/exclusion criteria.~Intervention: First ultrasound reading~Intervention: Second ultrasound interpretation"
3078484|NCT02037165|Experimental|Test Treatment 1: BI 1026706|BI 1026706 plus matching placebo to BI 1026706 Powder for Oral Solution (PfOS) and placebo tablet
3078485|NCT02037165|Experimental|Test Treatment 2: BI 1026706|BI 1026706 and placebo tablet
3078486|NCT02037165|Experimental|Reference Treatment 1: BI 1026706|Matching placebo to BI 1026706 PfOS and placebo tablet
3078487|NCT02037165|Experimental|Reference Treatment 2: Celecoxib|Celecoxib hard capsule as active comparator plus matching placebo to BI 1026706 PfOS
3078488|NCT02037165|Experimental|Reference Treatment 3: Pregabalin|Pregabalin hard capsule as active comparator plus matching placebo to BI 1026706 PfOS
3078489|NCT02037152|No Intervention|Waitlist|Participants randomized to this arm are instructed that they will have access to the study intervention after four weeks. Waitlist group participants are prompted to answer weekly questionnaires.
3078490|NCT02037152|Experimental|Active treatment|"The active treatment group will be instructed to use the app-guided body scan exercise daily for six days per week over a period of four weeks. The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. Before and after each use of the body scan, users complete a single-item scale measuring pain intensity/distress. Users are prompted to complete all other questionnaires at weekly or four-week intervals. The app includes access to a graphical display showing changes in average pain level. Subjects also have access to a section of frequently asked questions about the practice."
3078491|NCT02037139|Active Comparator|Control (screening)|screening only (standard care control)
3078492|NCT02037139|Active Comparator|Educational brochure|Screening + illustrated educational brochure
3078493|NCT02037139|Experimental|Education|Screening + illustrated educational brochure + an in-person educational intervention
3078494|NCT02037126|Experimental|Psilocybin administration|Psilocybin will be administered in pill form at a dose of .36 mg/kg. Psilocybin will be administered in one session over the course of 8 hours.
3078495|NCT02037126|Active Comparator|Diphenhydramine administration|Diphenhydramine will be administered in pill form at a dose of 100 mg. Diphenhydramine will be administered in one session over the course of 8 hours.
3078496|NCT02037113||Patient underwent PAD-Stent|Patient who underwent angioplasty and/or atherectomy with stent placement for Femoro-popliteal disease and Intravascular ultrasound was performed after stent deployment.
3078497|NCT02037100||T2DM|Children 6-20 years old diagnosed with T2DM
3078498|NCT02037100||Obesity|
3078499|NCT02037087|Experimental|Good household prenatal practice (GHPP)|The GHPP arm receives SMS messages regarding knowledge on nutrition, labor, non-medical pain management, breastfeeding, and depression. This arm also receives messages delivered to the control group.
3078500|NCT02037087|Experimental|Care seeking (CS)|The CS arm receives SMS messages which include danger-sign recognition and reminders for government-subsidized projects. This arm also receives messages delivered to the control group.
3078501|NCT02037087|Experimental|Full bank of SMS|This arm receives the SMS messages delivered to the GHPP, CS and control group.
3078502|NCT02037087|No Intervention|Control|"Control group receives SMS messages regarding:~Reminders of prenatal visits and certified skilled attendance of labor (status quo);~Fetal development in different gestational stages.~The three experimental groups receive the control messages as well."
3078503|NCT02037074|Experimental|Experimental: EVP-6308; Arm 1|low dose, Capsule, Twice Daily, Day 1 through Day 14
3078504|NCT02037074|Experimental|Experimental: EVP-6308; Arm 2|intermediate dose, Capsule, Once Daily, Day 1 through Day 14
3078505|NCT02037074|Experimental|Experimental: EVP-6308; Arm 3|high dose, Capsule, Once Daily, Day 1 through Day 14
3078506|NCT02037074|Placebo Comparator|Placebo Comparator; Arm 4|Placebo, Capsule, Once Daily, Day 1 through Day 14
3078507|NCT02037061|Placebo Comparator|normal saline|Intraoperatively the patient will receive 10ml of normal saline injected into the sacrospinous ligament.
3078508|NCT02037061|Active Comparator|bupivacaine|Intraoperatively the patient will receive 10 ml of bupivacaine injected into the sacrospinous ligament.
3078509|NCT02037048|Active Comparator|Positive Pathologic Response|Patients with ≤50% viable tumor cells remaining in the surgical specimen will receive postoperative chemo-radiotherapy with the mFOLFOX6 regimen
3078510|NCT02037048|Experimental|Negative Pathologic Response|Patients with >50% viable tumor cells remaining in the surgical specimen, will receive postoperative chemo-radiotherapy with weekly carboplatin and paclitaxel.
3078511|NCT02037035|Experimental|Healthy|Healthy participants will receive ketamine in the scan
3078512|NCT02037035|Experimental|Depressed|Depressed participants will receive ketamine in the scan
3078513|NCT02037022|Experimental|Pivotal Response Treatment Package|Pivotal Response Treatment Package (PRT-P)
3078514|NCT02037022|No Intervention|Delayed Treatment Group|Delayed Treatment Group (DTG)
3078515|NCT02037009|No Intervention|Usual surveillance|surveillance performed by a qualified nurse, present in the operating room during the whole anesthesia.
3078516|NCT02037009|Experimental|centralised monitoring surveillance|1 anesthetic nurse is posted at a centralised monitoring station outside of the 3 operating rooms, while another one can intervene inside the 3 operating rooms whenever needed. Interphones allow communication between the monitoring station and the operating rooms.
3078517|NCT02036983|Active Comparator|Ultrasound guided bilateral TAP block|Ultrasound guided TAP Block with local anesthetic and dexamethasone.
3078518|NCT02036983|Active Comparator|Instillation of surgical site with local anesthestic.|Instillation of surgical site under direct visualization with local anesthetics and dexamethasone.
3078519|NCT02036983|Placebo Comparator|Control Group|Standard anesthetic technique
3078520|NCT02036970|Experimental|Dose-Ranging Phase: Dose 1|Bardoxolone methyl [Dose 1] mg capsules or placebo by mouth once daily x 16 weeks
3078521|NCT02036970|Experimental|Dose-Ranging Phase: Dose 2|Bardoxolone methyl [Dose 2] mg capsules or placebo by mouth once daily x 16 weeks
3078522|NCT02036970|Experimental|Dose-Ranging Phase: Dose 3|Bardoxolone methyl [Dose 3] mg capsules or placebo by mouth once daily x 16 weeks
3078523|NCT02036970|Experimental|Dose-Ranging Phase: Dose 4|Bardoxolone methyl [Dose 4] mg capsules or placebo by mouth once daily x 16 weeks
3078524|NCT02036970|Experimental|Dose-Titration Phase|"Bardoxolone methyl [Dose 2] mg capsules or placebo by mouth once daily x 3 weeks, escalating to [Dose 3] mg or placebo by mouth once daily at Week 4 for 13 weeks~If a patient experiences a dose-limiting toxicity, the investigator may de-escalate the dose."
3078525|NCT02036957|Experimental|BALM ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. Will be applied twice a day (after showering and at night), massaging the area until completely absorption.
3078526|NCT02036957|Placebo Comparator|PLACEBO ARM|It be applicated in like manner that balm arm
3078527|NCT02036931||Metal on Polyethylene articulation|G7 cup with Metal on Polyethylene articulation (MOP)
3078528|NCT02036931||Ceramic on Polyethylene articulation|G7 cup with Ceramic on Polyethylene articulation (COP)
3078529|NCT02036931||Ceramic on Ceramic articulation|G7 cup with Ceramic on Ceramic articulation (COC)
3078530|NCT02036918|Active Comparator|Arm A|Pre-treatment control group will be randomized to immediate lymph node biopsy followed by sipuleucel-T immunotherapy.
3078531|NCT02036918|Experimental|Arm B|Post-treatment experimental group will be randomized to immediate sipuleucel-T immunotherapy followed by lymph node biopsy.
3078532|NCT02036905|Experimental|Cervical and thoracic mobilization|Cervical and thoracic mobilization: described as a repetitive low-velocity oscillatory movement applied to a joint segment. It is graded 1-4 based on the size of the amplitude and where in range it is being applied. The mobilization technique chosen will be based on the examination and clinical reasoning process of the therapist. The cervical and thoracic mobilization will be applied to the most provocative level.
3078533|NCT02036905|Experimental|Cervical and thoracic manipulation|Cervical and thoracic manipulation: is defined as high-velocity low-amplitude thrust at end range of a particular spinal segment. The therapist performs this technique by taking up all available slack at a particular segment and applying a high-velocity thrust through the end-range restriction. The manipulation technique will be chosen based on the examination and clinical reasoning process of the therapist.
3078534|NCT02036892|Experimental|Lifestyle counseling with smartphones|Lifestyle counseling assisted by smartphones
3078535|NCT02036892|Active Comparator|Lifestyle counseling|Lifestyle counseling
3078536|NCT02036879|No Intervention|Main study|"The main study is an observational study.~All women will be followed for one menstrual cycle (or approximately one month) observationally off of any hormone supplementation. They will have 3 study visits corresponding to their menstrual cycle phases (menses, ovulation, and luteal).~Women participating in the main study may participate in the optional interventional sub-study.~Men participating in this study will be followed for 1 month observationally. They will have 3 study visits that correlate with the female arm of this study."
3078600|NCT02036515|Placebo Comparator|Placebo|Matching placebo to ertuglifozin, oral, once daily for 52 weeks
3078776|NCT02035254|Experimental|Intervention group|Web-based wellness program
3078537|NCT02036879|Experimental|Loestrin Optional Substudy|Women participating in the main study may participate in the optional sub-study. Following a negative urine pregnancy test, women will be started on once daily oral Loestrin (1.5 mg norethindrone + 0.03 mg ethyl estradiol). They will be followed for two months on this agent and have 2 additional study visits.
3078538|NCT02036866|Experimental|Physical Therapy Positive Expectation|The physical therapist will read a script indicating that the intervention is an effective treatment for knee osteoarthritis and is expected to reduce pain and improve strength. Patients are then instructed on the home exercise program and how to operate the TENS (transcutaneous electrical nerve stimulation) unit. The duration of intervention is 1 week during which patients will wear then wear the TENS unit for 8 hours per day and perform no more than 3 sets of 10 repetitions of the physical therapy exercises daily.
3078539|NCT02036866|Experimental|Physical Therapy Neutral Expectation|The physical therapist will read a script indicating that the intervention may or may not be an effective treatment for knee osteoarthritis and may nor may not reduce pain and improve strength. Patients are then instructed on the home exercise program and how to operate the TENS unit. The duration of intervention is 1 week during which patients will wear then wear the TENS unit for 8 hours per day and perform no more than 3 sets of 10 repetitions of the physical therapy exercises daily.
3078540|NCT02036866|Experimental|Control- No Intervention|The patients in the control group will be reminded of their appointment in 1 week and instructed to maintain their usual activity level during that time.
3078541|NCT02036853|Experimental|Schedule A|Subjects previously treated with triheptanoin
3078542|NCT02036853|Experimental|Schedule B|Naïve to triheptanoin
3078543|NCT02036840||Penicillin allergy|
3078544|NCT02036827|Active Comparator|moderate NMB + standard pressure|Investigators will administrate rocuronium until moderate neuromuscular blockade (Train of Four >=1, Post-tetanic count>=8) is established. And pneumoperitoneum will be maintained with standard-pressure 14 mmHg.
3078545|NCT02036827|Active Comparator|deep NMB + standard pressure|Investigators will administrate rocuronium until deep neuromuscular blockade (Train of Four=0, Post-tetanic count<=3) is established. And pneumoperitoneum will be maintained with standard-pressure 14 mmHg.
3078546|NCT02036827|Active Comparator|deep NMB + low pressure|Investigators will administrate rocuronium until deep neuromuscular blockade (Train of Four=0, Post-tetanic count<=3) is established. And pneumoperitoneum will be maintained with standard-pressure 8 mmHg.
3078547|NCT02036814|Experimental|Group A who underwent to an inter-relational strategy|Group A who underwent to a health educational orientation program (inter-relational strategy)
3078548|NCT02036814|Experimental|Group B who underwent group orientation by the nurse|
3078549|NCT02036801||ARDS|Patients with ARDS (according to the Berlin Definition criteria) in mechanical ventilation
3078550|NCT02036801||Healthy control|Patients with healthy lung supported with mechanical ventilation for clinical purposes
3078551|NCT02036788||Postsurgical patients sedated and paralized|Patients admitted to ICU after surgery, treated with mechanical ventilation, sedated and paralized
3078552|NCT02036788||Postsurgical patients intubated and breathing spontaneously|
3078553|NCT02036775|Experimental|Treatment sequence 1|Treatment 1, Washout 6 days, Reference product, Washout 6 days, Treatment 2
3078554|NCT02036775|Experimental|Treatment sequence 2|Treatment 2, Washout period 6 days, Treatment 1, Washout 6 days, Reference product
3078555|NCT02036775|Experimental|Treatment sequence 3|Reference product, Washout 6 days, Treatment 2, Washout 6 days, Treatment 1
3078556|NCT02036775|Experimental|Treatment Sequence 4|Treatment 2, Washout 6 days, Reference product, Washout 6 days, Treatment 1
3078557|NCT02036775|Experimental|Treatment sequence 5|Reference product, Washout 6 days, Treatment 1, Washout 6 days, Treatment 2
3078558|NCT02036775|Experimental|Treatment Sequence 6|Treatment 1, Washout 6 days, Treatment 2, Washout 6 days, Reference product
3078559|NCT02036762|Active Comparator|Treatment Group|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
3078560|NCT02036762|Sham Comparator|Control Group|The control group received stretching exercises in the fist and ankle muscles and treadmill exercises
3078561|NCT02036749|Active Comparator|quadratus lumborum block (nerve block)|quadratus lumborum block with ropivacaine
3078562|NCT02036749|Placebo Comparator|sham block|QL block with saline
3078563|NCT02036736|Experimental|Propofol|Intraoperative anesthetic strategy by Propofol versus Desflurane
3078564|NCT02036736|Experimental|Desflurane|Intraoperative anesthetic strategy by Desflurane versus Propofol
3078565|NCT02036723|Experimental|BCD-021|"BCD-021 is a product code for bevacizumab biosimilar manufactured by CJSC BIOCAD, Russia.~In this arm 72 patients will receive BCD-021 at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months."
3078566|NCT02036723|Active Comparator|Lucentis®|Lucentis® is ranibizumab drug produced by Novartis Pharmaceuticals Canada Inc. In this arm 36 patients will receive Lucentis® at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
3078567|NCT02036710||Cecum|Food hydrolysate instilled into terminal cecum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin.
3078568|NCT02036710||Ileum|Food hydrolysate instilled into terminal ileum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin.
3078569|NCT02036697|Experimental|Low Dose Spinal|"Hyperbaric bupivacaine 4.5mg with fentanyl 15mcg and preservative free morphine 150mcg.~The patient will be positioned right side down and head down 20-30 degrees for the dural puncture and then positioned supine in the left lateral tilt position after the anesthetic solution has been given. The OR table will be kept in 20-30 degrees head down for the cesarean section."
3078570|NCT02036697|Active Comparator|Control Spinal Group|"Hyperbaric bupivacaine 1.2cc (9mg) with fentanyl 15mcg and preservative free morphine 150mcg.~The patient will be in the sitting position for the dural puncture and then positioned supine, in the left lateral tilt position after the anesthetic solution has been given. Once block height has been established the patient will be placed in 20-30 degrees trendelenberg for the cesarean section."
3078777|NCT02035254|Other|Wait control group|Web-based wellness program after 3 month wait.
3078571|NCT02036684|No Intervention|Healthy Lifestyle Booklet|Standard care for radical prostatectomy (RP) patients includes the provision of preoperative information from a urology nurse educator. Usual care (UC) participants will be given generic instructions by the research coordinator about pelvic floor muscle exercises (PFMX), mobilization and general timeframes for a return to normal activities. The UC group will receive the same PFMX prescription as the PREHAB (Experimental) group and will receive weekly communication from the research coordinator regarding compliance with the PFMX prescription to provide an attentional-control. These instructions are provided in a healthy lifestyle booklet for men with prostate cancer.
3078572|NCT02036684|Experimental|Prehabilitation (PREHAB)|The prehabilitation (PREHAB) program focuses on total-body physical exercises and pelvic floor muscle exercises (PFMX). The total-body exercise prescription will consist of 60 minutes of home-based, unsupervised exercise on 3-4 days per week, alternating between aerobic and resistance training. Each session will include: a 5-minute warm-up, 25 minutes of aerobic exercise, 25 minutes of resistance training (5 exercises targeting major muscle groups), and a 5-minute cool-down. Training intensity progression will occur throughout the intervention. Participants will be provided with resistance bands, a stability ball, and an exercise mat. The PFMX prescription will include a gradual increase in PFMX exercises from 60 per day during weeks 1-2, 120 per day during weeks 3-4, and 180 per day during weeks 5-6 until the surgery date. The total number of repetitions of the PFMXs will be divided equally between the rhythmic and sustained contractions.
3078573|NCT02036671|Experimental|EndoAVF|The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access
3078574|NCT02036658|Active Comparator|Cognitive Behavioral Group Therapy|Cognitive behavioral group therapy (CBGT) will be delivered by two Ph.D. clinical psychologists trained by Dr. Richard Heimberg to implement his CBGT for SAD (Heimberg & Becker, 2002). Groups of six individuals will meet for 12 sessions of 2.5 hours each. The participants will also use selected portions of the client workbook developed by (Hope, Heimberg, & Turk, 2010) to supplement relevant portions of the protocol. The treatment will be comprised of four major components: (1) psychoeducation and orientation to CBGT; (2) cognitive restructuring skills; (3) graduated exposure to feared social situations, within session and as homework; and (4) relapse prevention and termination. Further details of the treatment are available elsewhere (Heimberg & Becker, 2002).
3078575|NCT02036658|Active Comparator|Mindfulness-Based Stress Reduction|MBSR will follow the standard curriculum outline compiled in 1993 by Jon Kabat-Zinn except that the one-day meditation retreat will be converted to four additional weekly group sessions between the standard class 6 and 7 so that there will be 12 weekly 2.5 hour sessions. This will be done to match the CBGT protocol in duration and time. The MBSR intervention will be delivered by a University of Massachusetts Center for Mindfulness certified MBSR instructor with more than 30 years of teaching experience. To support the practice, each participant will be given A Mindfulness-Based Stress Reduction Workbook (Stahl & Goldstein, 2010), which includes descriptions of mindfulness exercises together with pre-recorded audio files to support ongoing practice.
3078576|NCT02036658|No Intervention|Waitlist Control|This will be a delayed treatment arm. Participants randomized to the waitlist control group will be re-randomized after completing the no treatment period of 12 weeks to CBGT or MBSR with equal probability.
3078577|NCT02036645|Experimental|MEDI1814 IV|Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.
3078578|NCT02036645|Placebo Comparator|IV Placebo|Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.
3078579|NCT02036645|Experimental|MEDI1814 Sub Cutaneous Injection|2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort
3078580|NCT02036645|Placebo Comparator|Subcutaneous Placebo|2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort
3078581|NCT02036632|Other|Eye Patching|Intervention
3078582|NCT02036619||pregnant women without known diabetes|
3078583|NCT02036606||mood disorders|Questionary and neuropsychological tasks will be administered
3078584|NCT02036606||control|Questionary and neuropsychological tasks will be administered
3078585|NCT02036593|Experimental|Walk Your Heart to Health intervention|"Participants were randomized into one of two groups: intervention and lagged intervention. The intervention group completed the 8 week Walk Your Heart to Health intervention, followed by a second wave of data collection for both initial and lagged intevention groups. The lagged intervention group then completed the 8 week Walk Your Heart to Health intervention. Both groups continued walking for another 24 weeks.~Walking group sessions conducted 3 times per week for 32 weeks."
3078586|NCT02036593|Other|Walk Your Heart to Health lagged|"Participants were randomized into one of two groups: intervention and lagged intervention. The intervention group completed the 8 week Walk Your Heart to Health intervention, followed by a second wave of data collection for both initial and lagged intevention groups. The lagged intervention group then completed the 8 week Walk Your Heart to Health intervention. Both groups continued walking for another 24 weeks.~Walking group sessions conducted 3 times per week for 32 weeks."
3078587|NCT02036580|Experimental|Low Dose|Investigational product Tralokinumab
3078588|NCT02036580|Experimental|High Dose|Investigational product Tralokinumab
3078589|NCT02036580|Placebo Comparator|Placebo|Placebo
3078590|NCT02036567||surgical patients|no interventions, observational study
3078591|NCT02036567||laboring women|no interventions, observational study
3078592|NCT02036567||volunteers|pain induction by noxious heat stimulation, measurement of pain by device and documentation of pain reported by subjects
3078593|NCT02036554|Experimental|Tacrolimus plus Everolimus|Low dose Tacrolimus + Everolimus
3078594|NCT02036554|Active Comparator|Tacrolimus plus Mycophenolic acid|standard dose Tacrolimus + Mycophenolic acid
3078595|NCT02036541|Experimental|AqueSys XEN 45 Glaucoma Implant|
3078596|NCT02036528|Experimental|AppliGel-G with oral Ciprofloxacin and Doxycycline|AppliGel-G (Gentamicin Topical Gel) in conjunction with oral Ciprofloxacin and Doxycycline
3078597|NCT02036528|Active Comparator|Oral Ciprofloxacin and Doxycycline only|Ciprofloxacin and Doxycycline
3078598|NCT02036515|Experimental|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily for 52 weeks
3078599|NCT02036515|Experimental|Ertugliflozin 15 mg|Ertugliflozin, 15 mg, oral, once daily for 52 weeks
3078601|NCT02036502|Experimental|Dose Determination Arm|Participants receive pembrolizumab 2 mg/kg every 2 weeks (Q2W, Days 1 and 15) in combination with lenalidomide 10 mg or 25 mg (Days 1-21) and dexamethasone 40 mg weekly during each 28-day cycle.
3078602|NCT02036502|Experimental|Dose Confirmation Arm|Participants receive pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 10 mg or 25 mg (Days 1-21) and dexamethasone 40 mg weekly during each 28-day cycle.
3078603|NCT02036502|Experimental|Cohort 1: rrMM|Cohort 1 is closed. All participants must stop study treatment and move into long term safety and survival follow up. Participants previously received pembrolizumab 200 mg once every 2 weeks (Q2W; Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg once weekly (Q1W) during each 28-day cycle.
3078604|NCT02036502|Experimental|Cohort 2: rMM|Cohort 2 is closed to enrollment. Participants who are enrolled and not deriving clinical benefit must stop study treatment and move into the long term safety and survival follow up. Participants who are already enrolled and deriving clinical benefit from study treatment may continue in the study until protocol-specific end of treatment, and then progress into long term safety and survival follow up. Participants receive pembrolizumab 200 mg once every 3 weeks (Q3W) in combination with carfilzomib 56 mg/m^2 (Days 1, 2, 8, 9, 15, 16) and dexamethasone 20 mg (Days 1, 2, 8, 9, 15, 16, 22, 23) during each 28-day cycle.
3078605|NCT02036489|Experimental|Induction and consolidation treatment|
3078606|NCT02036476|Experimental|Cabozantinib|Cabozantinib 60 mg Oral Daily 28 days (4 weeks)
3078607|NCT02036463|Active Comparator|Immediate Release Prednisone|During the entire 18 months of the protocol, these subjects will receive immediate release prednisone as a morning dose. All observations and measurements are performed the same as the other study groups.
3078608|NCT02036463|Experimental|Delayed Release Prednisone|During the entire 18 months of the protocol, these subjects will receive delayed release prednisone as an evening dose. All observations and measurements are performed the same as the other study groups.
3078609|NCT02036463|Placebo Comparator|Placebo-Delayed Release Prednisone|During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the delayed release prednisone medication. All observations and measurements are performed the same as the other study groups.
3078610|NCT02036463|Placebo Comparator|Placebo-Immediate Release Prednisone|During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the immediate release corticosteroid medication. All observations and measurements are performed the same as the other study groups.
3078611|NCT02036450|Experimental|ILR group|A LOOP recorder will be implanted. The device sampled arrhythmia information is transmitted to a core facility and evaluated. Data are sent automatically. When AF with a duration of 6 min or more is detected the participant will be advised to start oral anticoagulation therapy according to local preference.
3078612|NCT02036450|No Intervention|Control group|Control group will be followed according to standard care, i.e. in principal by their own GP. The control group will receive an annual phone call for clinical information and a mailed QOL form.
3078613|NCT02036437|Experimental|Cases|A dose of 20ug is required obtained by dissolving the 200ug tablet (Misotac® Sigma Pharmaceutical Industries) in 200 ml water (1ug per ml), the solution is shaked well before each administration. The solution will be orally administrated every two hours (max. 12 hrs) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy.
3078614|NCT02036437|Active Comparator|Control|Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
3078615|NCT02036424|Active Comparator|Bevacizumab|1.25 mg intravitreal injection given monthly during a 6 month period
3078616|NCT02036424|Active Comparator|Ozurdex|Dexamethasone intravitreal implant, 0.7 mg given every 3 months over 6 month period with a maximum of 3 injections
3078617|NCT02036398|Active Comparator|Nephrostomy tube + double J stent|Standard therapy group with nephrostomy tube and double J stent left at the end of the PCNL
3078618|NCT02036398|Experimental|Double J stent without nephrostomy|Double J stent only left at the end of the procedure
3078619|NCT02036372|Experimental|BR (bolus regimen)|"Day before surgery: half evening dose long acting insulin~Day of surgery:~patients using mealtime and longacting insulin/NPH: withhold mealtime morning dose, stop glucose lowering tablets~patients using only long acting insulin/NPH: half dose of long-acting or NPH insulin, stop glucose lowering tablets~Measure blood glucose every 60 minutes, start 30 min prior to surgery~Give bolus of insulin according to treatment algorithm"
3078620|NCT02036372|Experimental|LG (Liraglutide)|"Day before surgery: half dose of long acting and mealtime insulin from start liraglutide~Day of surgery: withhold own insulin, stop oral glucose lowering tablets~Start with 0.6 mg liraglutide subcutaneously (s.c.) the day prior to surgery at 17.00hr.~In case of nausea graded higher than minimal, the patient will be excluded from the study~Otherwise, treatment will be continued with 1.2 mg liraglutide s.c. per day on the day of surgery at 07.00hr.~Measure glucose every 60 minutes, start 30 min prior to surgery~Adjust according to bolus algorithm of BR group"
3078621|NCT02036372|Active Comparator|GIK (glucose -insulin - potassium) infusion|"Day before surgery: half evening dose long acting insulin~Day of surgery: stop oral glucose lowering tablets and withhold own insulin.~GIK infusion: 500 cc glucose 5% with insulin and 10 mmol KCL per 500 cc. Start at 83 ml/hr.~Calculate the insulin amount in the GIK infusion according to the formula:~I= (PG-7)/(200/W)+8 I=Insulin amount, PG=glucose 30 minutes preoperative, W= body weight in kg~Measure blood glucose every 60 minutes, start 30 min prior to surgery~Adjust glucose > 8 mmol/l according to treatment algorithm"
3078622|NCT02036359|Active Comparator|erlotinib|Patients in erlotinib arm will take erlotinib 150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.
3078696|NCT02035839|Other|Target Temperature Management of 34°C|In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
3078778|NCT02035241|Experimental|Spices 1|220 ml test drink containing spices 1, acute study / one time administration
3078623|NCT02036359|Active Comparator|Chemotherapy|"Patients in chemotherapy arm will then receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.~Treatment failure will include patients who fail to complete 3 cycles (9 weeks) of study treatments due to disease progression or unacceptable toxicity.~Patients with no disease progression after terminating study treatment will undergo surgical resection and be followed until disease progression is noted, or study end. Survival will be recorded and analyzed.~If progressive disease or unacceptable toxicity occurs during study treatments, patients will be treated at discretion of investigator according to local protocol."
3078624|NCT02036346|Experimental|Oral rehydration solution|Patients who have undergone colorectal resection surgery resulting in an ileostomy creation
3078625|NCT02036346|Experimental|No intervention|Patients who have undergone colorectal resection surgery resulting in an ileostomy creation
3078626|NCT02036346|Active Comparator|Colorectal resection without an ileostomy|Patients who have undergone colorectal resection surgery without an ileostomy creation
3078627|NCT02036333||Concussion Group|
3078628|NCT02036333||Control Group|
3078629|NCT02036320|Experimental|etafilcon A with additive printed limbal ring|Each subject will insert the trial lens while being observed by a technician prior to assessment by the study investigator.
3078630|NCT02036320|Active Comparator|etafilcon A|Each subject will insert the trial lens while being observed by a technician prior to assessment by the study investigator.
3078631|NCT02036307|Experimental|DHA-enriched|DHA-enriched supplement (DHA 3g + 600 mg EPA in 6 g of fish oil/day)
3078632|NCT02036307|Experimental|EPA-enriched|EPA-enriched supplement (EPA 2.4 g + DHA 600mg in 6 g of fish oil/day)
3078633|NCT02036294|Other|Usual Care|Usual Care: Standard healthcare services will be received. Study participants in this arm will not receive any additional study interventions.
3078634|NCT02036294|Experimental|BREATHE program|Study participants randomized to this arm will be offered the BREATHE program an integrated multifaceted intervention that includes comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
3078635|NCT02036281|Experimental|SP-SAP ARM|The first subject will be enrolled in the 1-mcg SP-SAP cohort. A percutaneous intraspinal catheter will be placed at the L5-S1 interspace and the catheter advanced 4-5 cm into the intrathecal space under fluoroscopic guidance. To confirm location, CSF will be aspirated and radioopaque contrast dye injected. 1-mL study drug will be mixed with 1-mL patient CSF fluid and administered intrathecally via the catheter. The catheter will be flushed with 1 mL bolus of saline. Four hours after injection (+15 min), the catheter will be removed and the exit site treated with Neosporin ointment and sterilely dressed. Subjects will be monitored in the recovery room for 4 hours and in the hospital for 24 hours and discharged home. Patients only receive a single IT dose.
3078636|NCT02036268|Active Comparator|Standard|Subjects will receive standard ostomy education.
3078637|NCT02036268|Experimental|Pre-Operative Education|In addition to standard ostomy education, subjects will receive additional education pre-operatively.
3078638|NCT02036268|Experimental|Two-week Post Operative Education|In addition to standard ostomy education, subjects will receive additional education two weeks following surgery.
3078639|NCT02036255|Experimental|Taurolidine Urokinase|Taurolock Urokinase is used weekly in this arm substituting the classic Taurolock HEP500
3078640|NCT02036255|Active Comparator|Taurolidine Heparin|Taurolock HEP 500 is used as locking solution after each dialysis session
3078641|NCT02036242|Experimental|Sole local anesthetic|Epidural analgesia will be given with sole local anesthetic (0.125% ropivacaine) intermittently
3078642|NCT02036242|Active Comparator|Opioid plus local anesthetic|Epidural analgesia will be given with opioid (sufentanil) combined with local anesthetic (0.125% ropivacaine) intermittently
3078643|NCT02036229|Experimental|0.5% ivermectin cream|Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
3078644|NCT02036229|Placebo Comparator|vehicle cream|Each participant will be treated with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
3078645|NCT02036216||Hepatocellular Carcinoma|The mutation will be found in the DNA samples from the plasma and solid tumor tissues in the patients with HCC.
3078646|NCT02036203|Experimental|SCu300A IUB|
3078647|NCT02036203|Active Comparator|TCu380A|
3078648|NCT02036190||Control group|Former or current smokers without emphysema
3078649|NCT02036190||Emphysema|Current or former smokers with emphysema
3078650|NCT02036177|Experimental|SCu300A IUB|
3078651|NCT02036177|Active Comparator|T380A copper IUD|
3078652|NCT02036164|Active Comparator|Concurrent chemoradiation|"Radiation: Radiation Therapy~External beam pelvic radiotherapy (45-50.4 Gy in 1.8 Gy fractions) delivered by Linear accelerator machine~Vaginal brachytherapy for 4-5 fractions~Chemotherapy: Cisplatin~- Cisplatin 40 mg/m2 i.v., q wk, 6 cycles during radiotherapy"
3078653|NCT02036164|Experimental|Concurretn chemoradiation plus adjuvant chemotherapy|"Radiation: Radiation Therapy~External beam pelvic radiotherapy (45-50.4 Gy in 1.8 Gy fractions) delivered by Linear accelerator machine~Vaginal brachytherapy for 4-5 fractions~Chemotherapy: Cisplatin, paclitaxel, carboplatin~Cisplatin 40 mg/m2 i.v., q wk, 6 cycles during radiotherapy~Paclitaxel 175 mg/m2 i.v. q 4 wks, 3 cycles starting 4 week after completion of CCRT~Carboplatin AUC 5 i.v. q 4 wks, 3 cycles given together with paclitaxel"
3078654|NCT02036151|Experimental|Experimental, control|Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
3078655|NCT02036151|Active Comparator|fluoride varnish application|The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
3079105|NCT02033096||stannsoporfin 4.5 mg/kg|stannsoporfin 4.5 mg/kg
3078656|NCT02036138|Active Comparator|Advanced Medical Therapy Patients.|Advanced medical therapy is deﬁned as the use of the latest lifestyle guidelines set forth by the American Diabetes Association to optimize weight loss and glycaemic management, frequent home monitoring/titration strategies, use of latest FDA approved drug therapy (incretin analogues, insulin sensitizers, etc.)
3078657|NCT02036138|Experimental|Bariatric Surgery Patients - Roux-en-Y gastric by- pass|
3078658|NCT02036138|Experimental|Bariatric Surgery Patients -Laparoscopic sleeve gastrectomy|
3078659|NCT02036125|Experimental|Ultrasound guided injection|Ultrasound guided injection of 40 mg of methylprednisolone
3078660|NCT02036125|Active Comparator|Blind injection|Blind injection of 40 mg of methylprednisolone
3078661|NCT02036112|Experimental|Individual ELAPE|Patients will receive Individual ELAPE technique
3078662|NCT02036112|Experimental|Conventional ELAPE|Patients with advanced lower rectal cancer will receive conventional EALPE technique
3078663|NCT02036099|Experimental|Driving in Mild Dementia Decision Tool|Participants in this arm will be assessing patients using the Driving in Mild Dementia Decision Tool
3078664|NCT02036099|No Intervention|Control|Participants will assess patients using their usual care strategies.
3078665|NCT02036086|Experimental|Vemurafenib, pill, twice daily|Vemurafenib, 960 mg, oral, twice daily plus Cobimetinib, 60 mg, oral, four times daily
3078666|NCT02036073|Experimental|EPO|In EPO group, the EPO was given by 500IU/kg every other day intravenously for 2 weeks. Recombinant human erythropoietin was configured by the hospital pharmacy intravenous Center Configuration, melted configured with saline to 1ml/kg solution. For severe patients, they were started to treat with EPO when their vital signs, blood pressure were stable.
3078667|NCT02036060|Experimental|Arm A|docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d
3078668|NCT02036060|Active Comparator|Arm B|docetaxel 75 mg/m2 + prednisone 10 mg/d
3078669|NCT02036047|Experimental|Exclusive cold polypectomy snare|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed using an exclusive cold polypectomy snare (Exacto cold snare). The technique is cold snare resection of the polyp without tenting without electrocautery and then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is not performed after cold snare polypectomy.
3078670|NCT02036047|Active Comparator|regular polypectomy snare|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed using a regular polypectomy snare. The technique is cold snare resection of the polyp without tenting without electrocautery and then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is not performed after cold snare polypectomy.
3078671|NCT02036034|Active Comparator|drape with forced air warmer|forced air warmer placed under the chin before draping, inflated after draping completed.
3078672|NCT02036034|Placebo Comparator|drape with warming blanket|warming blanket placed on torso of patient under the drape.
3078673|NCT02036021||PRE/non-PRE|children who develop or did not perioperative respiratory events between November 2012 and December 2013
3078674|NCT02036008|Other|Liver MRI with EcGd and with Gdfos|All participants will receive two contrast-enhanced MRI studies of the liver: one with gadofosveset trisodium (Gdfos) and one with gadobutrol (EcGd) at a dose of 0.1 mL/kg body mass up to 10 mL.
3078675|NCT02035995||Healthy volunteers|This group consisted of age matched non-pregnant healthy volunteers
3078676|NCT02035995||Healthy pregnant volunteers|This group consisted of age matched healthy pregnant volunteers
3078677|NCT02035982|Active Comparator|Cholinesterase Inhibitor|Participants randomized into the cholinesterase inhibitor arm will continue receiving their cholinesterase inhibitor at the same dosage.
3078678|NCT02035982|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be tapered off their cholinesterase inhibitor for the first 2 weeks. For the remaining 6 weeks of their study they will be receiving only placebo, and no cholinesterase inhibitor.
3078679|NCT02035969|No Intervention|Conventional treatment (CT)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling and clinical follow up every three months. The caretaker of the child is responsible that the child will take the drugs and is provided with a pre-packed dosage form for easy remembering
3078680|NCT02035969|Experimental|Enhanced Treatment Support (ETS)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counselling and clinical follow up every three months. In addition adherence support is provided according to the description under intervention.
3078681|NCT02035956|Experimental|IVAC MUTANOME RBL001/RBL002|All participants will be treated with the personalized IVAC MUTANOME vaccine with or without prior treatment with RBL001/RBL002 vaccine depending on expression of these two antigens. Vaccines will be administered intra-nodally.
3078682|NCT02035943|Active Comparator|Insulin separated|Seprated infusion of insulin
3078683|NCT02035943|Active Comparator|Insulin added to parenteral nutrition|Insulin added to parenteral nutrition
3078684|NCT02035930|Other|menstrual cycle,dexmedetomidine|
3078685|NCT02035917|Experimental|Locking plate|
3078686|NCT02035917|Active Comparator|Non-Locking plate|
3078687|NCT02035904|Experimental|Levobupivacaine|Levobupivacaine Patient Controlled Infusion 5 ml 0,25%, lock out 2 hours
3078688|NCT02035904|Placebo Comparator|Saline|patient controlled infusion 5 ml bolus, lock out 2 hours
3078689|NCT02035891|Active Comparator|colchicine|0.5mg/d colchicine
3078690|NCT02035891|Placebo Comparator|placebo|appearance is same as colchicine
3078691|NCT02035878|Active Comparator|Probiotics|400mg probiotic capsule taken once daily for ten weeks
3078692|NCT02035878|Placebo Comparator|Placebo (rice flour)|400mg placebo capsule containing rice flour taken once daily for ten weeks
3078693|NCT02035865||Participants from former study 1|Surviving participants from a former study called 'Psykosomale faktorer hos pasienter med hjertesvikt og hos hjertetransplanterte'
3078694|NCT02035865||Participants from former study 2|Surviving participants, included at the Norwegian centre, from a study called 'Scandinavian Heart Transplant Everolimus De Novo Study with Early Calcineurin Inhibitor Avoidance (SCHEDULE)' (NCT01266148)
3078695|NCT02035852||Adult Gilomas|
3078779|NCT02035241|Experimental|Spices 2|220 ml test drink containing spices 2, acute study / one time administration
3078698|NCT02035839|Other|Target Temperature Management of 33°C|In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
3078699|NCT02035826|Active Comparator|Arm 1|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 1 ($2.80) $100 $10 $10
3078700|NCT02035826|Active Comparator|Arm 2|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 2 ($1.40) $50 $5 $5
3078701|NCT02035826|Active Comparator|Arm 3|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 3 ($0.70) $25 $5 $0
3078702|NCT02035826|No Intervention|Arm 4|Control Arm
3078703|NCT02035813|Experimental|Everolimus in combination with standard endocrine therapy|Postmenopausal female patients with hormone-receptor positive, HER2-negative metastatic breast cancer with HER2-negative circulating tumor cells (CTCs) and indication for standard endocrine therapy.
3078704|NCT02035813|Experimental|Eriubulin|Patients with hormone-receptor positive, HER2-negative metastatic breast cancer and indication to chemother-apy or patients with triple-negative metastatic breast cancer, both with HER2-negative circulating tumor cells (CTCs).
3078705|NCT02035800|Experimental|Adalimumab (humira)|As standard of care.
3078706|NCT02035787|Experimental|Metformin|Metformin, 850 mg. twice daily.
3078707|NCT02035774|Active Comparator|LSIB +SSNB|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml)
3078708|NCT02035774|Placebo Comparator|LSIB + placebo|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml) + SSNB (4 ml saline)
3078709|NCT02035761||MSA Case|The screening evaluation will take less than 1 to 2 hours, and is usually conducted over the telephone. The visit for testing will take approximately 3 days, consisting (usually) of a day for clinical examinations and questionnaires and one day each for PET and MRI brain imaging and the third day for PET imaging of the heart and autonomic testing. If some checklists and questionnaires could not be completed conveniently in the time available, they may be finished over the telephone on a later day. At the completion of the 3-day evaluation, subjects are asked to return home and keep a log of their MSA symptoms and medication responses for 2 days. This will complete the active participation of MSA subjects in all aspects of the entire research program. The average time the subjects will be followed could be up to 1 week during which time the subjects are undergoing research related procedures.
3078710|NCT02035748|Experimental|Ocriplasmin|Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal injection
3078711|NCT02035735|Experimental|Videoendoscopy with WL and NBI|The day before the laryngoscopy under general anesthesia (LGA), two endoscopies by two different physicians were performed for each patients and recorded: the first one with white light (WL) and the second one with NBI (NBI).
3078712|NCT02035722|No Intervention|Control group|AMD-related information is not given to patients randomized to the control group.
3078713|NCT02035722|Active Comparator|Video materials|Educational materials are presented in through a video (audio and visual)
3078714|NCT02035722|Active Comparator|Print materials|Educational materials are presented in the format of printed brochure (visual)
3078715|NCT02035709|Active Comparator|TCI-PCA|Intravenous Patient-Controlled Analgesia with Target-Controlled Infusion
3078716|NCT02035709|Active Comparator|PCA|Intravenous Patient-Controlled Analgesia
3078717|NCT02035696|Experimental|TIVc-High Dose|Subjects (6 to <48 months old) received two doses of 0.75 mL of TIVc vaccine
3078718|NCT02035696|Experimental|TIVc-Full Dose|Subjects(6 to <48 months old) received two doses of 0.50 mL of TIVc vaccine
3078719|NCT02035696|Experimental|TIVc- Half Dose|Subjects (6 to <48 months old)received two doses of 0.25 mL of TIVc vaccine
3078720|NCT02035696|Active Comparator|TIVe|Subjects (6 to <48 months old) received two doses of TIVe vaccine(IM/0.25mL -for ages 6 to <36 months and IM/ 0.5 mL -for ages 36 to <48 months)
3078721|NCT02035683|Other|Advanced NSCLC patients undergoing first-line chemotherapy|single cohort
3078722|NCT02035670||tradition diagnostic strategy|According to the current diagnistic procedures of FUO
3078723|NCT02035670||two-step diagnostic strategy|"First step is to differentiate FUO according to the onset of disease and invasive pathogens.~Second step is to further differentiate FUO according to trends of disease and inflammation scores."
3078724|NCT02035657|Experimental|GLA-SE|Glucopyranosyl Lipid A in Stable Emulsion
3078725|NCT02035644|Experimental|Jinlida granules|Jinlida granules, a traditional Chinese medicine, was a herbal formula which was developed under cognition of the theory in the onset of diabetes
3078726|NCT02035644|Placebo Comparator|placebo granules|placebo prepared in indistinguishable granules
3078727|NCT02035631|Experimental|Intervention|Lifestyle intervention combining weight control, diet and physical activity
3078728|NCT02035631|Sham Comparator|Minimal intervention|Minimal diet intervention and minimal physical activity intervention
3078729|NCT02035618|Experimental|Exercises and manual therapy|
3078730|NCT02035618|Active Comparator|Exercises|
3078731|NCT02035605|Active Comparator|ALN-AT3SC|
3078732|NCT02035605|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3078733|NCT02035592|Active Comparator|Full dose blueberry|"26g of freeze dried blueberry powder; equivalent to 2 portions of fresh blueberries per day.~Frequency: 26g per day.~Total duration: 6-month."
3078734|NCT02035592|Active Comparator|Half dose blueberry|"26g of freeze dried powder; containing 13g of freeze dried blueberry powder and 13g of placebo comparator material; equivalent to 1 portion of fresh blueberries per day.~Frequency: 26g per day.~Total duration: 6-month."
3078735|NCT02035592|Placebo Comparator|Control|"Matched control powder; matched for appearance, taste and sugar content.~Frequency: 26g per day.~Total duration: 6-month."
3078736|NCT02035579|Experimental|Aerobic Training Intervention|Children with PCS who are eligible for the study will be randomized to a progressive, sub-symptom exacerbation, cycling aerobic training intervention or stretching comparison intervention. Children with PCS that meet criteria for the intervention trial will complete a baseline evaluation followed by a one week run-in-period (week 0-1) prior to their first intervention visit. After the initial intervention visit, weekly visits will be completed for at least 6 additional weeks (i.e., at least 6 weeks of aerobic training). An individualized home exercise program 5-6 days per week will also be developed. Children will be provided with a home stationary cycle to complete the home program.
3078780|NCT02035241|Experimental|Spices 3|220 ml test drink containing spices 3, acute study / one time administration
3078737|NCT02035579|Experimental|Stretching Intervention|Children in the stretching intervention will complete a series of full body stretches of the shoulders, arms, chest, back, legs, and feet 5-6 days per week and will return weekly to review the stretching program. The minimum duration of the stretching intervention will also be 6 weeks
3078738|NCT02035566|Experimental|Telehome Care Monitoring + Usual Care|
3078739|NCT02035566|No Intervention|Usual Care|
3078740|NCT02035553|Placebo Comparator|Placebo|Placebo, two tablets, once daily by mouth
3078741|NCT02035553|Experimental|Pimavanserin 40 mg|Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
3078742|NCT02035540||Decellularized human valves|Pulmonary heart valve replacement
3078743|NCT02035527|Experimental|Treatment (sorafenib tosylate, docetaxel, and cisplatin)|Patients receive sorafenib tosylate PO BID on days 1-14 of course 0. Beginning in course 1, patients receive sorafenib tosylate PO BID on days 1-21, docetaxel IV over 1 hour on day 1, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity.Correlative studies will be performed and a total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
3078744|NCT02035514|Experimental|Arm 1|A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on day 0 and placebo on month 6.
3078745|NCT02035514|Experimental|Arm 2|A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on month 6 and placebo on day 0.
3078746|NCT02035501|Active Comparator|L-Tyrosine|
3078747|NCT02035501|Placebo Comparator|Placebo|
3078748|NCT02035488|Experimental|Tobramycin|Patients with bronchiectasis
3078749|NCT02035475|Active Comparator|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
3078750|NCT02035475|Active Comparator|Maryland Bipolar Cautery|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
3078751|NCT02035449||McGrath MAC|McGrath MAC is a videolaryngscope
3078752|NCT02035436|Experimental|Non-sedation|Non-sedation supplemented with pain management during mechanical ventilation.
3078753|NCT02035436|Active Comparator|Sedation|Current gold standard: Sedation with a daily wake-up trial.
3078754|NCT02035423|Active Comparator|Male Guidance School|Non-Fortified Milk 120IU Milk 200IU Milk
3078755|NCT02035423|Active Comparator|Female Guidance|Non-fortified Milk 120IU Milk 200IU Milk
3078756|NCT02035423|Active Comparator|Male Highschool|Non-Fortified Milk 120IU Milk 200IU Milk
3078757|NCT02035423|Active Comparator|Female Highschool|Non-Fortified Milk 120IU Milk 200IU Milk
3078758|NCT02035410|Active Comparator|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
3078759|NCT02035410|No Intervention|Control group|No intervention group
3078760|NCT02035397|Experimental|Botulinum toxin A|Botulinum toxin type A injection in muscles of stomach wall
3078761|NCT02035397|Placebo Comparator|Saline solution|Placebo (saline solution) injection first 6 months, then active treatment
3078762|NCT02035384||All patients|
3078763|NCT02035371|Experimental|FIAsp|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
3078764|NCT02035371|Active Comparator|NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
3078765|NCT02035358|Experimental|HyperAcute®-Renal Immunotherapy|Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization. Once the first three months of immunizations are completed, patients may receive other systemic treatment (non-investigational) while continuing to receive the remaining 6 immunizations.
3078766|NCT02035345|Experimental|Carboplatin|"Carboplatin will be prepared as a single 500ml infusion. Potentially 6 cycles Carboplatin (Amount of total dose) will be administered intravenously by the treating nurse according to the following schedule:~First hour - Administer 1 percent of total dose (5ml with tubing primed)~Second hour - Administer 9 percent (45 mL)~Third hour - Administer 90 percent (450 mL)"
3078767|NCT02035332|Experimental|Aurora Treatment Arm|Endometrial Ablation
3078768|NCT02035319||capillary malformation treated by laser|capillary malformation treated by laser
3078769|NCT02035306|Experimental|non-invasive Haemaglobin|Measuring haemaglobin using non-invasive co-oximetry device
3078770|NCT02035293|Other|PEP|No drug and no placebo were used in this study. For all the patients who participated at the study PEP, only following exams must be performed: a clinical probability score (revised Geneva score), plasma D-dimer assay and if necessary, a chest multidetector-row CT angiography and venous ultrasound of the lower limbs
3078771|NCT02035280||Elderly suffering of spine deformity|Spinal deformity patients over the age of 60 years undergoing elective surgery and requiring fusion of at least 5 levels.
3078772|NCT02035267|Placebo Comparator|Placebo - Grade 1|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3078773|NCT02035267|Experimental|ATX-101 - Grade 1|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3078774|NCT02035267|Placebo Comparator|Placebo - Grade 4|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3078775|NCT02035267|Experimental|ATX-101 - Grade 4|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3078781|NCT02035241|Experimental|Herbs 1|220 ml test drink containing herbs 1, acute study / one time administration
3078782|NCT02035241|Experimental|Herbs 2|220 ml test drink containing herbs 2, acute study / one time administration
3078783|NCT02035241|Placebo Comparator|Placebo|220 ml control drink, acute study / one time administration
3078784|NCT02035228|Experimental|Seated|"Patients breathing will be compared across a series of 9 trials in which unassisted breathing is compared to abdominal stimulation (SecondBreath) assisted breathing at various intensities. Each breathing trial will last for 2 minutes and will be conducted while the patient is seated. The following abdominal stimulation trials were included:~Abdominal Stimulation - low / early Abdominal stimulation - low/late Abdominal Stimulation - low/full Abdominal stimulation - med/early Abdominal stimulation - med/late Abdominal Stimulation - med/full Abdominal Stimulation - high/early Abdominal Stimulation - high/late Abdominal Stimulation - high/full"
3078785|NCT02035228|Experimental|6 minute step test|"Patients will complete a 6 minute step test with and without abdominal stimulation (SecondBreath).~Abdominal Stimulation - high/full"
3078786|NCT02035215|Experimental|Atorvastatin 20mg, Omega-3-acids ethylesters 90 4g|Atorvastatin calcium 20mg, Omega-3-acids ethylesters 90 4g: po, q.d
3078787|NCT02035215|Placebo Comparator|Atorvastatin 20mg, Placebo|Atorvastatin calcium 20mg, Placebo for Omega-3-acids ethylesters 90 4g: po, q.d
3078788|NCT02035202|Experimental|CBT2go|Participants assigned to this condition will attend one session with a therapist to identify cognitive and behavioral strategies around four areas: 1) mood/psychotic symptoms, 2) medication adherence, 3) socialization, and 4) relapse prevention. Subsequently they will answer questions on a mobile device (smartphone) 3 times per day for 12 weeks, and they will receive personalized cognitive and behavioral strategies linked to their momentary responses with bi-monthly telephone support.
3078789|NCT02035202|Active Comparator|EMA-only|Participants assigned to this condition will answer questions on a mobile device (smartphone) 3 times per day for 12 weeks but will not receive personalized cognitive and behavioral strategies.
3078790|NCT02035202|No Intervention|Standard Care|Participants assigned to this condition will only participate in the assessments.
3078791|NCT02035176||Autistic children ages 6-11|Autistic children ages 6-11
3078792|NCT02035176||ADHD children ages 6-11|ADHD children ages 6-11
3078793|NCT02035176||Typical children ages 6-11|Typical children ages 6-11
3078794|NCT02035163|Active Comparator|Two sites cryoablation group|Two ganglionic plexi around atrium was performed with 90-second cryoablation.
3078795|NCT02035163|No Intervention|Control group|No Intervention group
3078796|NCT02035150|Experimental|Oatmeal Breakfast|Participants will consume oatmeal breakfast daily for 4 weeks
3078797|NCT02035150|Experimental|Frosted Flakes|Participants will consume a frosted flakes breakfast daily for 4-weeks
3078798|NCT02035150|Placebo Comparator|No Breakfast|Participants will consume no breakfast for a 4-week period
3078799|NCT02035137|Active Comparator|Single-Agent 131I-MIBG|Single-agent 131I-MIBG (Arm A) 18 mCi/kg 131I-MIBG on Day 1 and autologous stem cell infusion on Day 15.
3078800|NCT02035137|Active Comparator|131I-MIBG with Vincristine/Irinotecan|Vincristine / irinotecan / 131I-MIBG (Arm B): vincristine 2 mg/m2 (maximum dose 2 mg) intravenously on Day 0; irinotecan 50 mg/m2 (maximum dose 100 mg) intravenously on Days 0 to 4. Patients will also receive diarrhea prophylaxis with cefixime 8 mg/kg/day orally on Days -1 to +6. 31I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15.
3078801|NCT02035137|Active Comparator|131I-MIBG with Vorinostat|Vorinostat / 131I-MIBG (Arm C); vorinostat 180 mg/m2 (maximum dose 400 mg) orally once daily on Days -1 to +12 (14 total doses). 131I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15.
3078802|NCT02035124|Experimental|BKM120 and Cabazitaxel|"BKM 120 orally once daily;~Cabazitaxel 25 mg/m2 IV every 3 weeks"
3078803|NCT02035111|Experimental|Tianshu capsule|Four Tianshu capsules (0.34 g per capsule) by oral three times a day for 12 weeks.
3078804|NCT02035111|Placebo Comparator|Sugar pill|Four sugar pills (0.34 g per capsule) by oral three times a day for 12 weeks.
3078805|NCT02035098|Experimental|The Pac-IFicO programme|The Pac-IFicO programme is a complex interventions aimed at improving the quality of pain managementi in hospitalized patients.
3078806|NCT02035085|Experimental|CS-1000|Breast cancer patients with RIF will undergo liposuction, the autologous SVF cell fraction will be isolated and labeled with CS-1000 in the operating room without entering cell culture, which will then be returned to the patient at the site of breast grafting.
3078807|NCT02035072|Experimental|Hypofractionated RT + Gem + Oxali|Hypofractionated radiotherapy + Gemcitabine + Oxaliplatin
3078808|NCT02035059||Women with/without gestational diabetes|Women with/without gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
3078809|NCT02035046|Other|study's population|
3078810|NCT02035033||low calcium supplement|low calcium supplement
3078811|NCT02035033||Calcium intake 500-1000 mg per day|Calcium intake 500-1000 mg per day
3078812|NCT02035033||Calcium intake above 1000 mg per day|Calcium intake above 1000 mg per day
3078813|NCT02035020|Experimental|Gamma interferon|IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
3078814|NCT02035007|Experimental|LV-EF > 50%|PiCCO catheter analysis of patients with coronary heart disease without impaired left ventricular function [LV-EF > 50%]
3078815|NCT02034994|Experimental|Intervention group|Reduction of sugar sweetened beverages. cookies, sedentary activities and increasing physical activity
3078816|NCT02034994|No Intervention|Control group|No intervention
3078817|NCT02034981|Experimental|CRIZOTINIB|All eligible patients entering the study will receive oral crizotinib as monotherapy
3078818|NCT02034968|Experimental|Nimotuzumab & nab-paclitaxel & cisplatin|"Nimotuzumab: 200mg,IV once a week during chemotherapy.~Nab-paclitaxel: 125mg/m2,(IV over 30 min) (days 1 and 8) on 21 day cycle~Cisplatin: 75mg/m2,IV on 21 day cycle"
3078819|NCT02034955|Experimental|Post-Operative adaptive radiotherapy|All Patients enrolled in this study will have additional scans (Cone-Beam CT, MRI) daily during their treatment. This extra imaging will help us see any changes that might have occurred during radiation treatment and update the treatment plan to include these changes before patient treatment is continued.
3078906|NCT02034448||Acute Kidney Injury|CRRT intervention with adult patients with Acute Kidney Injury
3078820|NCT02034942|Experimental|Non-sedation|"The experimental group will not receive sedatives. Patients are thoroughly and repeatedly informed by the staff of where they are, what have happened, and what type of treatment they are going to receive.~Participants will be awake and have a natural sleep rhythm. In case these patients develop and outward delirium, it is necessary to have a nurse or other caregiver at the bedside in order to calm the patient. Patients with delirium will be treated with haloperidol."
3078821|NCT02034942|Active Comparator|Sedation with daily wake-up|"The control group will be sedated to Ramsay score 3-4. The first 48 hours the patients will be sedated with propofol, after 48 hours midazolam will be used. During daytime, the patient will be awakened as the intravenous infusion of sedatives will be discontinued. The patient will be considered to be awake when he/she can perform at least three of the following four tasks:~Open the eyes to verbal commands.~Follow the examiner's instructions with the eyes.~Squeeze hands on request.~Stick out the tongue on request.~After a successful wake-up, the infusion of sedative will be resumed, starting on half of the pre-wake-up dose and adjusted to Ramsey score 3-4."
3078822|NCT02034929|Active Comparator|Endocuff-assisted colonoscopy|Endocuff-assisted colonoscopy
3078823|NCT02034929|Active Comparator|Standard colonoscopy|Standard Colonoscopy
3078824|NCT02034916|Experimental|talazoparib|"Cohort 1) Subjects with a documented PR or CR to a prior platinum-containing regimen for metastatic disease with disease progression > 8 weeks following the last dose of platinum~Cohort 2) Subjects who have received > 2 prior chemotherapy regimens for metastatic disease and who have had no prior platinum therapy for metastatic disease"
3078825|NCT02034903|No Intervention|Standard warming|Feeding warmed in water bath
3078826|NCT02034903|Experimental|Commercial warmer|Feedings warmed with a commercial warmer
3078827|NCT02034890|Experimental|hyaluronic acid|intravesical instillation of 40 mg of hyaluronic acid at 6 specific time points: 1,2,3 and 4 weeks postoperatively 2 and 3 months postoperatively
3078828|NCT02034890|No Intervention|retrospective control patients|retrospective control patients
3078829|NCT02034877|Experimental|1|
3078830|NCT02034864|Experimental|Osteopathic manipulative treatment|6 sessions of standardized manipulative treatment
3078831|NCT02034864|Sham Comparator|Placebo of osteopathic manipulative treatment|6 sessions of standardized placebo of manipulative treatment
3078832|NCT02034851||Dexamethasone|Intervention group
3078833|NCT02034851||Control|Placebo group (physiological saline)
3078834|NCT02034838|Experimental|atazanavir 300mg boosted with ritonavir 100mg|"Two period drug interaction. Period one: atazanavir 300mg boosted with ritonavir 100 mg once daily as part of current treatment standard of care.~Period two: atazanavir 300 mg boosted with ritonavir 50 mg once daily for study days 2-8 inclusive"
3078835|NCT02034825||Practicing urologic surgeons|"US board-certified~Practicing urologic surgeons~Performing at least 40 radical prostate surgeries annually~Urologists will be excluded from participating in the study if:~They are unable to identify a the required number of eligible patient cases with available clinical data and tissue specimens;~They have spent less than 3 years in practice or perform less than 40 RP's per year~All participants will be asked to complete a questionnaire based on a random selection of retroactively selected cases."
3078836|NCT02034812||Radiation Oncologists|"Radiation oncologists targeted for recruitment into the study must meet the following criteria:~Practicing, board-certified radiation oncologists~Perform consultations on at least 80 patients with prostate cancer annually~Each participant is asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant's opinion is collected based on a random selection of cases."
3078837|NCT02034799|Other|Standard of Care (SoC)|Standard of Care (SoC) include any active or inactive adjunctive treatment to hemostasis methods currently used based on each surgeons surgical practice except for the use of other fibrin sealants.
3078838|NCT02034799|Experimental|Bioseal Fibrin Sealant|A porcine-derived fibrin sealant consisting of thrombin and fibrinogen
3078839|NCT02034786|Experimental|Test|Adipose tissue collection and Transdermal injection of the filler agent, composed of mesenchymal stem cells derived from the autologous adipose tissue, associated with hyaluronic acid.
3078840|NCT02034786|Active Comparator|Control|Transdermal injection of hyaluronic acid only.
3078841|NCT02034773|Experimental|CC-220 0.3mg x 14 days|
3078842|NCT02034773|Experimental|CC-220 1mg x 28 days|
3078843|NCT02034773|Experimental|CC-220 0.3mg x 28 days|
3078844|NCT02034773|Experimental|CC-220 1mg x a total of 14 days|
3078845|NCT02034773|Experimental|Placebo|
3078846|NCT02034773|Experimental|CC-220 0.3mg (once every 3 days for 14 days)|
3078847|NCT02034773|Experimental|CC-220 1mg (once every 7 days for 28 days)|
3078848|NCT02034773|Experimental|CC-220 1mg (formulated and reference capsules)|
3078849|NCT02034760|Active Comparator|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
3078850|NCT02034760|Experimental|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
3078851|NCT02034760|Active Comparator|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
3078852|NCT02034760|Active Comparator|Protein Collagen|Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.
3078853|NCT02034760|Placebo Comparator|Carbohydrate|Two daily 30g carbohydrate supplementations for 52 weeks.
3078854|NCT02034747|Experimental|Corticosteroid with the 50% reduced dose|
3078855|NCT02034747|Active Comparator|Corticosteroid with the maintained dose|
3078856|NCT02034734|Experimental|1: ASP3652|Multiple doses of ASP3652
3078857|NCT02034721|Experimental|Protein supplementation|60 grams protein before, during, after eccentric exercise
3078858|NCT02034721|Placebo Comparator|Placebo|60 grams placebo before, during, after eccentric exercise
3078859|NCT02034708|Experimental|Dotarem®/Gadovist®|Dotarem®-enhanced MRI, then Gadovist®/Gadavist®-enhanced MRI
3078860|NCT02034708|Experimental|Gadovist®/Dotarem®|Gadovist®/Gadavist®-enhanced MRI then Dotarem® enhanced MRI
3078861|NCT02034695||RAMP and Non-RAMP|
3078862|NCT02034682|Experimental|Volulyte 6%|"- Volulyte 6% (HES 130/0.4 in an isotonic composition). In 1000 ml:~Maize starch 60 gr. Molar substitution 0.38-0.45. 130000 Da~Na acetate trihydrate 4.63 gr~Sodium Chloride 6.02 gr~Potassium Chloride 0.3 gr~MgCl 0.3 gr~Sodium hydroxide-hydrochloric acid & H2O"
3078863|NCT02034682|Active Comparator|Geloplasma|"In 1000 ml:~Modified fluid gelatin 30 gr~Sodium Chloride 5.4 gr~Potassium Chloride 0.37 gr~MgCl 0.14 gr~Sodium lactate 3.36 gr"
3078864|NCT02034669|Experimental|Treatment with ADSCs transplantation|4 Intervention: laminectomy, intradural space at damage site, intrathecal at lumbar puncture, intravenous
3078865|NCT02034669|No Intervention|Treatment without ADSCs transplantation|Only intervention: laminectomy
3078866|NCT02034656||imatinib resistance|All mutation data from CML and Ph positive ALL patients who developed imatinib resistance during the year 2001-2009
3078867|NCT02034643|Other|patients with single-lumen tube|Patients who required intraoperative TEE and single-lumen tube; balloon pressure adjustment before TEE probe insertion
3078868|NCT02034643|Other|patients with double-lumen tube|Patients who required intraoperative TEE and double-lumen tube; balloon pressure adjustment before TEE probe insertion
3078869|NCT02034630|Experimental|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
3078870|NCT02034617|No Intervention|Standard care|The family receive standard care when enrolled in the Neonatal intensive care unit
3078871|NCT02034617|Experimental|Observation|The family receive standard care when enrolled in the Neonatal intensive care unit and are also included in an observational program called LiMoNid.
3078872|NCT02034604|Experimental|Naftopidil Group|Naftopidil medication patients
3078873|NCT02034604|Active Comparator|Tamsulosin Goup|Tamsulosin medication patients
3078874|NCT02034591|Experimental|Arm A-Apixaban|Solution Apixaban 5 mg ( 0.4 mg/ml oral solution x 12.5 ml) through mouth or oral syringe
3078875|NCT02034591|Experimental|Arm B-Apixaban|Oral Solution Apixaban 5 mg single dose (0.4 mg/mL oral solution x 12.5 mL) after 180 mL of Boost Plus®, followed by 60 mL of Boost Plus® via same NGT
3078876|NCT02034591|Experimental|Arm C-Apixaban|Single dose crushed Apixaban tablet 5 mg (5 mg tablet crushed and suspended in 60 mL Dextrose 5% in water (D5W)) through NGT
3078877|NCT02034578|Experimental|Arm A: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via oral syringe
3078878|NCT02034578|Experimental|Arm B: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via nasogastric tube (NGT) immediately followed by 60 mL of D5W via NGT
3078879|NCT02034578|Experimental|Arm C: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via NGT immediately followed by 60 mL of infant formula via NGT
3078880|NCT02034565|Experimental|Treatment A: Apixaban tablet|Apixaban Film coated Tablet Single dose 10 mg orally
3078881|NCT02034565|Experimental|Treatment B: Apixaban oral solution|Apixaban Solution Single dose 10 mg orally
3078882|NCT02034552|Experimental|Radium-223 dichloride(Xofigo, BAY88-8223)|
3078883|NCT02034552|Experimental|Radium-223 with abiraterone&prednisone|
3078884|NCT02034552|Experimental|Radium-223 with enzalutamide|
3078885|NCT02034539|Experimental|VADOplex treatment|best medical treatment in combination with intermittent pneumatic foot compression by the VADOplex system for 4 - 6 hours/day until total wound closure of the target lesion is achieved with a maximum treatment of 24 weeks
3078886|NCT02034539|No Intervention|conservative treatment|best medical treatment of the target lesion alone
3078887|NCT02034526|Placebo Comparator|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
3078888|NCT02034526|Experimental|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
3078889|NCT02034513|Experimental|IDeg OD + IAsp followed by IGlar OD + IAsp|Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period
3078890|NCT02034513|Active Comparator|IGlar OD + IAsp followed by IDeg OD + IAsp|Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period
3078891|NCT02034500|Experimental|S. sonnei 1790GAHB - 0.1 mcg - ID|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 0.1 mcg intradermally (ID)
3078892|NCT02034500|Experimental|S. sonnei 1790GAHB - 1 mcg - ID|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 1 mcg intradermally (ID)
3078893|NCT02034500|Experimental|S. sonnei 1790GAHB - 10 mcg - ID|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 10 mcg intradermally (ID)
3078894|NCT02034500|Experimental|S. sonnei 1790GAHB - 5 mcg - IN|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 5 mcg intranasally (IN)
3078895|NCT02034500|Experimental|S. sonnei 1790GAHB - 20 mcg - IN|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 20 mcg intranasally (IN)
3078896|NCT02034500|Experimental|S. sonnei 1790GAHB - 80 mcg - IN|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 80 mcg intranasally (IN)
3078897|NCT02034500|Experimental|S. sonnei 1790GAHB - 5 mcg - IM|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 5 mcg intramuscularly (IM)
3078898|NCT02034500|Placebo Comparator|Placebo - ID|2 subjects enrolled in each COHORT A, B and C receiving 3 injections of Placebo intradermally (ID). These were pooled in one Placebo group in the analyses
3078899|NCT02034500|Placebo Comparator|Placebo - IN|2 subjects enrolled in each COHORT A, B and C receiving 3 injections of Placebo intranasally (IN). These were pooled in one Placebo group in the analyses
3078900|NCT02034500|Placebo Comparator|Placebo - IM|2 subjects enrolled in COHORT C receiving 3 injections of Placebo intramuscularly (IM)
3078901|NCT02034487||Boys with delayed puberty|Boys with no signs of puberty by an age that is -2 standard deviation below the population mean.
3078902|NCT02034474|Experimental|tocilizumab|Tocilizumab will be administered at day 0, week 4 and week 8 via an iv drip over 60 min. Dose is 8mg/kg but may be reduced to 4mg/kg if intolerable. Maximum dose will be 800mg.
3078903|NCT02034474|Placebo Comparator|Placebo|Placebo will be administered intravenously via an iv drip over 60 min
3078904|NCT02034461|Experimental|Acute surgical implantation|
3078905|NCT02034461|Experimental|Implantation of a Utah Electrode Array|Arm which has been amputated or has peripheral nerve trauma. Interventions include insertion of the Utah Slanted Electrode Arrays which will interact with nerve endings in order to gain knowledge about nerve stimulation.
3078907|NCT02034435|Active Comparator|Aim1-Low salt diet|Subjects will be provided with a diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.
3078908|NCT02034435|Active Comparator|Aim 1-high salt diet|Subjects will be provided with a diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.
3078909|NCT02034435|Active Comparator|Aim2- low salt diet and epleronone-amlodipine|Subjects on a low salt diet will receive epleronone 50mg for 8 days and assessments will be made, then cross over to a low salt diet with amlodipine 5mg for 8days and assessments will be made.
3078910|NCT02034435|Active Comparator|aim2- lowsaltdiet and amlodipine-epleronone|Subjects on a low salt diet will receive amlodipine 5mg for 8 days and assessments will be made, then cross over to a low salt diet with epleronone 50mg for 8days and assessments will be made.
3078911|NCT02034422|Experimental|Specific Aim #1|Specific Aim 1: Determine the consequences of oxidative stress on skeletal muscle afferent feedback and muscle blood flow during exercise in hypertension. Hypothesis: Afferent feedback sensitivity, determined by passive leg movement (isolation of mechanoreceptor sensitivity) and post exercise circulatory occlusion (isolation of metaboreceptor sensitivity) will be greater in hypertension leading to the exaggerated EPR. Muscle blood flow, assessed by Doppler ultrasound during multiple exercise intensities, will be impaired in hypertension leading to exercise intolerance. Reductions in oxidative stress, achieved by an oral antioxidant treatment (Vitamins C, E and alpha lipoic acid), will reduce afferent fiber sensitivity and improve muscle blood flow in hypertension. Additionally, venous endothelial cells will express elevated markers of oxidative stress providing novel evidence that the vascular endothelium contributes to the greater oxidative stress in hypertension.
3078912|NCT02034422|Experimental|Specific Aim #2|Specific Aim 2: Determine the remediable effect of combined antioxidant treatment and exercise rehabilitation in the treatment of hypertension. Hypothesis: Acute antioxidant treatment administered prior to exercise in hypertensive patients will ameliorate the exaggerated EPR resulting in a normal and safe blood pressure response to exercise-based rehabilitation. This two-pronged approach (antioxidants and exercise training) will result in a safely achieved reduction in skeletal muscle afferent feedback facilitating improved exercise tolerance, improved muscle blood flow and ultimately reduced cardiovascular risk in this population.
3078913|NCT02034409|Sham Comparator|Sham|Treatment to index knee with sham device for 48 weeks
3078914|NCT02034409|Experimental|PLIUS|Treatment to index knee with PLIUS device for 48 weeks
3078915|NCT02034396|Other|Blood draw|One blood draw at enrollment
3078916|NCT02034383|Experimental|Control|Diet will consist of a controlled diet without almonds for 3 weeks.
3078917|NCT02034383|Experimental|Whole Almonds|Diet will consist of a controlled diet with whole almonds for 3 weeks.
3078918|NCT02034383|Experimental|Roasted Whole Almonds|Diet will consist of a controlled diet with roasted whole almonds for 3 weeks.
3078919|NCT02034383|Experimental|Diced Almonds|Diet will consist of a controlled diet with diced almonds for 3 weeks.
3078920|NCT02034383|Experimental|Almond Butter|Diet will consist of a controlled diet with almond butter for 3 weeks.
3078921|NCT02034370||Included patients|All ten patients included in this cohort. Shoulder surgery patients that are getting a nerve block and are at high risk for OSA. They will receive a Lung-function spirometry test and an overnight sleep test.
3078922|NCT02034357|Other|Neurocognitive function|Neurocognitive function assessment (verbal learning and memory) as measured by CVLT and sleep evaluations in Parkinson's disease patients at baseline, and after 4 months and 1 year of CPAP treatment
3078923|NCT02034344||Group 1: Healthy participants|20 healthy participants will be enrolled.
3078924|NCT02034344||Group 2: DLE/SCLE without SLE|30 participants with Discoid Lupus Erythematosus/Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) without Systemic Lupus Erythematosus (SLE) will be enrolled.
3078925|NCT02034344||Group 3: DLE/SCLE with SLE|30 participants with DLE/SCLE with SLE will be enrolled.
3078926|NCT02034331|Active Comparator|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
3078927|NCT02034331|Active Comparator|Heat Application|For the provocation with heat, an insulated thermal heat pack (~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
3078928|NCT02034331|Experimental|Insulin Iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
3078929|NCT02034331|Placebo Comparator|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
3078930|NCT02034292|Experimental|10mg MD|APD791 10mg Multiple dose and
3078931|NCT02034292|Experimental|20mg MD|APD791 20mg Multiple dose
3078932|NCT02034292|Experimental|40mg MD|APD791 40mg Multiple dose
3078933|NCT02034292|Experimental|60mg MD|APD791 60mg Multiple dose
3078934|NCT02034292|Placebo Comparator|Placebo MD|Placebo for Multiple dose group
3078935|NCT02034292|Experimental|120mg SD|APD791 120mg Single dose
3078936|NCT02034292|Experimental|240mg SD|APD791 240mg Single dose
3078937|NCT02034292|Experimental|320mg SD|APD791 320mg Single dose
3078938|NCT02034292|Placebo Comparator|Placebo SD|Placebo for Single dose
3078939|NCT02034279|Experimental|Intravenous infusion of albumin|Treatment arm will receive intravenous albumin on days 1 and 3 plus antibiotics
3078941|NCT02034266|Experimental|Omega-3 supplementation|Participants will take an oral 5 mL serving (1 tbsp) of mammalian omega-3 seal oil (375 mg EPA, 280 mg DPA and 510 mg DHA) (Auum Inc., Timmons, On) twice daily. Total daily essential fatty acid load - 2330 mg.
3078942|NCT02034253||first episode psychosis|Unmedicated first episode psychosis patients that wish to enroll in a 16 week treatment regimen with the drug Risperidone.
3078943|NCT02034253||healthy demographic-matched controls|healthy controls will be matched to patients one to one based on: age, smoking status, parental socio-economic status, and gender. Healthy controls must be free from current or past Axis I mental disorders, 1st degree relative current or past Axis I mental disorders, and any other neurological conditions.
3078944|NCT02034227|Experimental|SG2000 - 15 µg/m2/day|Cohort 1 - will commence at 15 µg/m2/day intravenous doses of SG2000 until Maximum Tolerated Dose is determined.
3078945|NCT02034227|Experimental|SG2000 - 30 µg/m2/day|Cohort 2 - will commence at 30 µg/m2/day intravenous doses of SG2000 until Maximum Tolerated Dose is determined.
3078946|NCT02034214|Experimental|Full Intervention|Life skills education vocational counseling Economic livelihoods reproductive health services social support
3078947|NCT02034214|Active Comparator|Education and health services alone|Life skills education Reproductive health services
3078948|NCT02034201|Active Comparator|Lisdexamfetamine|Lisdexamfetamine will be admistered at 140 mg orally daily through week 6 of the protocol.
3078949|NCT02034201|Placebo Comparator|Placebo|Placebo will be administered orally daily through week 6 of the protocol.
3078950|NCT02034188|Experimental|Umbilical cord mesenchymal stem cells|
3078951|NCT02034175||group 1|
3078952|NCT02034162|Active Comparator|Mebendazole|Mebendazole will be administered as a single 500-mg chewable tablet in a double-blind manner at the baseline visit (Day 1) and in an open-label manner at Visit 4 (Day 21).
3078953|NCT02034162|Placebo Comparator|Placebo|Matching placebo will be administered as a single-dose chewable tablet in a double-blind manner at the baseline visit (Day 1).
3078954|NCT02034149|Other|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.We collected information on baseline and follow-up data on biochemical and physiological check-ups, health promotion behavior, dietary intake status, self-efficacy and cost etc. The effectiveness assessments have been set for the baseline, 3rd, 6th, 12th and 18th months.
3078955|NCT02034149|Experimental|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with digital video disc (DVD) courses. We negotiated their behavior change set goals for them etc.With one year of intervention period, the 3 groups will be assessed at the 18th months of follow-up next year.
3078956|NCT02034149|Experimental|peer-assisted management|The peer-assisted management group received the peer oriented group activities followed, including group discussions to share experience and sports map etc. With one year of intervention period, the 3 groups will be assessed at the 18th months of follow-up next year.
3078957|NCT02034136|Experimental|Ginsenoside|"Ginsenoside :~Intervention : ginsenoside, 3 gram / day, for 28 days in intervention group"
3078958|NCT02034136|Placebo Comparator|Dietary fiber fill|Dietary fiber fill manufactured to mimic Ginsenoside tablet
3078959|NCT02034123|Experimental|Dose Escalation Cohort|The safety and PK/PD data will be reviewed prior to the dose decision, and the dose escalation will be guided by the Neuenschwander -continuous reassessment method (N-CRM).The dose escalation will complete when RP2D is determined. The RP2D will be the MTD or a lower dose that provides adequate PK exposure and biologic activity with superior tolerability.
3078960|NCT02034123|Experimental|Dose Expansion Cohort|Once the RP2D has been determined, an expansion cohort of up to 30 subjects will be enrolled in order to better characterize the clinical activity and safety profile of the RP2D
3078961|NCT02034110|Experimental|Dabrafenib + Trametinib|Subjects will receive Dabrafenib 150 mg twice daily orally plus Trametinib 2 mg once daily orally on a continuous basis. Dabrafenib will be administered under fasted conditions, either 1 hour (hr) before or 2 hours (hrs) after a meal with approximately 200 mL of water with an interval of 12 hours. Trametinib will be administered under fasted conditions, either 1 hr before or 2 hrs after a meal with approximately 200 mL of water. Subjects will take their dose of Trametinib concurrently with the morning dose of Dabrafenib. A treatment cycle is 28 days in duration. Subjects will continue treatment until an unacceptable toxicity, disease progression, or death occurs.
3078962|NCT02034097|Experimental|Cohort 1|Subjects with EGFRm NSCLC who have received clinical benefit (CR, PR, SD) for at least 4 months and then progressed on an EGFR-TKI within the last 30 days will receive 150 milligram (mg) erlotinib once daily (OD) and 45 mg foretinib OD as a combination therapy until disease progression
3078963|NCT02034097|Experimental|Cohort 2|Subjects with EGFR/WT NSCLC who have received clinical benefit (CR, PR, SD) for at least 2 months and then progressed on an EGFR-TKI within the last 30 days will receive 150 mg erlotinib OD and 45 mg foretinib OD as a combination therapy until disease progression.
3078964|NCT02034097|Experimental|Cohort 3|Subjects with NSCLC who are predicted to be sensitive to foretinib based on biomarkers identified with preclinical or clinical data will receive 60 mg foretinib OD as a monotherapy until disease progression
3078965|NCT02034084|Experimental|Right radial approach|Coronary diagnostic procedures performed through right radial approach
3078966|NCT02034084|Experimental|Left radial approach|Coronary diagnostic procedures performed through left radial approach
3078967|NCT02034071|Experimental|DCCR Open Label - DCCR Double Blind|Patients are initiated on a DCCR dose of about 1.5 mg/kg (maximum starting dose of 145 mg) and are titrated every 14 days through 4 dose levels of DCCR. Patients will be up-titrated at each visit at the discretion of the investigator. Randomized to continue DCCR, at the same dose as they received on Day 69, in the Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension
3078968|NCT02034071|Experimental|DCCR Open Label - Placebo Double Blind|Patients are initiated on a DCCR dose of about 1.5 mg/kg (maximum starting dose of 145 mg) and are titrated every 14 days through 4 dose levels of DCCR. Patients will be up-titrated at each visit at the discretion of the investigator. Randomized to receive placebo equivalent to the DCCR dose received on Day 69 in the Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension
3078969|NCT02034058|Other|Wingspan Stent System|Placement of the Wingspan Stent
3078970|NCT02034045|Active Comparator|Usual Care|Patients randomized to the control group will continue to receive usual care from their Family Health Care Team. Usual care includes physician assessment and treatment and periodic augmentation of care in the community (CCAC or case manager, nurse practitioner) at the discretion of the treating physician.
3078971|NCT02034045|Experimental|Community Paramedicine|The intervention will consist of an initial visit and 3 follow-up visits at 3 month intervals over one year by a paramedic who has received additional training in chronic disease management, in addition to routine usual care and any additional visits prompted by the patient, the paramedic or the Family Health Care Team.
3078972|NCT02034032|Active Comparator|Regenexx SD|Regenexx-SD (Same Day) is a bone marrow based injection procedure.
3078973|NCT02034032|Active Comparator|Exercise Therapy|Subjects in the Exercise Therapy group will attend an initial session with a trained Physical Therapist. During that session the physical therapist will instruct the subject in a home exercise program and instructions about activity limitations. The subject's progress will also be followed by the Physical Therapist during the 6 week follow-up visit with further instructions provided.
3078974|NCT02034019|Active Comparator|OTX-DP (Dexamethasone Punctum Plug)|Resorbable hydrogel drug delivery vehicle containing dexamethasone
3078975|NCT02034019|Placebo Comparator|PVPP (Placebo Punctum Plug)|Resorbable hydrogel drug delivery vehicle containing no drug
3078976|NCT02034006|Experimental|Ranibizumab|patients treated with ranibizumab 0,5 mg/0,05ml intravitreal injection
3078977|NCT02033993|Active Comparator|Arm 1|Nab-Paclitaxel - 260mg/m2: q21 days
3078978|NCT02033993|Active Comparator|Arm 2|Paclitaxel - 175mg/m2: q21 days
3078979|NCT02033980|Other|colorectal lesions|All lesions will be observed with NBI and removed endoscopically or surgically for histological diagnosis.
3078980|NCT02033967|Active Comparator|CVP|Central venous pressure-guided vasodilator-induced hypovolemia
3078981|NCT02033967|Experimental|SVV|stroke volume variation-guided vasodilator-induced hypovolemia
3078982|NCT02033941|Active Comparator|Meganatural-Az Grapeseed Extract|Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
3078983|NCT02033941|Placebo Comparator|Placebo|Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
3078984|NCT02033928||Arm I: Transplant patients|
3078985|NCT02033928||Arm II: Plasma cell dyscrasia patients|
3078986|NCT02033915|Experimental|Interactive Discussion Group|The interactive discussion groups were held for six times (8-10 persons for each group). During the 50-60 minutes' discussion, the facilitators guided the participants to discuss a case vignette, focusing on the key issues of hospital suicide prevention, and to enhance their abilities of suicide risk identification and evaluation. Two research team members who served as facilitators led the group in a standardized manner.
3078987|NCT02033902||Perampanel|Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment
3078988|NCT02033889|Experimental|Ertuglifozin 5 mg|Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Participants will receive 1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet per day. Participants requiring glycemic rescue during the 26-week initial treatment period (Phase A) will receive open-label glimepiride. This rescue will continue through the 78-week, double-blind, extension period (Phase B). If not rescued during Phase A, participants will receive placebo to glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) during Phase B. All participants will also receive metformin at a dose >=1500 mg/day in Phase A and B.
3078989|NCT02033889|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Participants will receive 1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet per day. Participants requiring glycemic rescue during the 26-week initial treatment period (Phase A) will receive open-label glimepiride. This rescue will continue through the 78-week, double-blind, extension period (Phase B). If not rescued during Phase A, participants will receive placebo to glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) during Phase B. All participants will also receive metformin at a dose >=1500 mg/day in Phase A and B.
3078990|NCT02033889|Placebo Comparator|Placebo to Ertugliflozin|Placebo to ertuglioflozin, orally once daily from Day 1 to Week 104. Participants will receive 1 placebo ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet per day. Participants requiring glycemic rescue during the 26-week initial treatment period (Phase A) will receive open-label glimepiride. This rescue will continue through the 78-week, double-blind, extension period (Phase B). If not rescued during Phase A, participants will receive blinded glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) during Phase B. All participants will also receive metformin at a dose >=1500 mg/day in Phase A and B.
3078991|NCT02033876|Experimental|Ursodiol|Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
3078992|NCT02033876|Placebo Comparator|Placebo|matching placebo capsules to be taken twice daily
3078993|NCT02033863||Cohort A|Varicocele arising from the spermatic vein(s) and pampiniform plexus, with or without concomitant diagnosis of infertility or subfertility
3078994|NCT02033863||Cohort B|Pelvic varices in females for the treatment of pelvic congestion syndrome (e.g., pelvic venous incompetence).
3078995|NCT02033850|Experimental|APT-II group|"Intervention: rehabilitation of attention using the Attention Process Training-II.~Participants in the APT-II group will receive overall up to 40 hours of individual attention process training. Therapy will be administered in one two-hour session each week over a total of 20 weeks."
3078996|NCT02033850|No Intervention|standard care group|Participants in the standard care group will not receive cognitive training or rehabilitation interventions, will be instructed to have an usual lifestyle, and will be conventionally provided of medication and clinic consultations
3078997|NCT02033824|Other|Group 1 Control|Will receive only traditional craniectomy
3078998|NCT02033824|Experimental|Group 2 Treatment dHACM|Will receive craniectomy, but with the addition of a piece of dHACM placed over any dural defect or dural closure.
3078999|NCT02033798|Experimental|Tamsulosin|The dosage form of Tamsulosin is tablet, dosage is 0.2mg, frequency is once daily and duration is 6 months.
3079000|NCT02033772||Thoracoscopic surgery|Infants undergoing thoracoscopic surgery.
3079001|NCT02033759|Active Comparator|Traditional circumferential measurements|Traditional screening with volumetric analysis Patient Anxiety Questionnaire
3079002|NCT02033759|Experimental|Bio-Impedance Testing|Traditional Screening with Volumetric Analysis and Bio-Impedance Analysis Patient Anxiety Questionnaire
3079003|NCT02033746|Experimental|Transdermal Electroacupuncture - Arm A|week 1-2 real treatment, week 3-6 sham treatment with Han's Acupoint Nerve Stimulator while receiving concurrent buprenorphine-naloxone as prescribed
3079004|NCT02033746|Experimental|Transdermal Electroacupuncture - Arm B|week 1-2 real treatment, week 3-6 sham treatment with Han's Acupoint Nerve Stimulator treatment while receiving concurrent buprenorphine-naloxone as prescribed
3079005|NCT02033733||Adequate cooling time|"Patients that reached target temperature within 4 hours of initiation of the hypothermia protocol will be in the adequate cooling time group."
3079006|NCT02033733||Inadequate cooling time|"Patients that did not reach target temperature within 4 hours of initiation of the hypothermia protocol will be in the inadequate cooling time group."
3079007|NCT02033720||Shockable arrest|Initial arrest rhythm shockable. This is either pulseless ventricular tachycardia (pulseless VT) or ventricular fibrillation (VF).
3079008|NCT02033720||Pulseless electrical activity|Initial arrest rhythm is pulseless electrical activity.
3079009|NCT02033720||Asystole|Initial arrest rhythm is asystole.
3079010|NCT02033707|Experimental|Male volunteers|Hallucinogens and psychoactive substances will be administered via capsule. Results will be compared between male and female participants.
3079011|NCT02033707|Experimental|Female volunteers|Hallucinogens and psychoactive substances will be administered via capsule. Results will be compared between male and female participants.
3079012|NCT02033694||Group A: Large LRP with 2 year follow up|TVC (NIRS-IVUS) diagnostic imaging used to identify Large LRP
3079013|NCT02033694||Group B: Small/No LRP with 2 year follow up|TVC (NIRS-IVUS) diagnostic imaging used to identify Small/No LRP
3079014|NCT02033694||Group B: Small or NO LRP without follow up|TVC (NIRS-IVUS) diagnostic imaging used to identify Small/No LRP
3079015|NCT02033681|Experimental|"One-per-mil Tumescent Solution"|
3079016|NCT02033681|Placebo Comparator|Saline Solution|
3079017|NCT02033668|Active Comparator|Arm A|Participants in this arm will receive single 200 milligram (mg) dose of GSK933776 administered by IV infusion
3079018|NCT02033668|Experimental|Arm B|Participants in this arm will receive single 200 mg dose of GSK933776 administered SQ
3079019|NCT02033668|Experimental|Arm C|Participants in this arm will receive 50 mg dose of GSK933776 administered SQ once weekly for 4 weeks (total dose = 200 mg).
3079020|NCT02033668|Experimental|Arm D|Participants in this arm will receive single 200 mg dose of GSK933776 administered IM
3079021|NCT02033655|Experimental|Weight loss high protein|Protein supplementation. Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of protein, including substantial amounts of supplemental protein provided as lean beef. Intakes of > 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60% of animal protein from pork.
3079022|NCT02033655|Active Comparator|Weight loss control|Diet counseling and group education lessons. Subjects follow a calorie-reduction diet for a weight loss of ≥10%.
3079023|NCT02033642|Experimental|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to train parents or family members of adolescent/young adult participants with intellectual disability to monitor diet and physical activity behavior, set goals, provide support and reinforcement, and assess and make changes to the home environment.
3079024|NCT02033642|Experimental|Maintenance|The Maintenance condition in this study is a 12-session intervention for parent/family member of adolescents with intellectual disability, designed to teach families to continue lifestyle behaviors, generalize healthful behaviors to new environments, find additional social and community supports and prevent relapse.
3079025|NCT02033629|Active Comparator|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
3079026|NCT02033629|Active Comparator|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
3079027|NCT02033629|Placebo Comparator|Ce 3 ng/ml|Remifentanil Ce 3 ng/ml
3079028|NCT02033616|Experimental|AVOVA-1|Autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells. AVOVA-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
3079029|NCT02033616|Placebo Comparator|MC|Autologous monocytes will serve as the control arm. MC is admixed with GM-CSF as an adjuvant, prior to injection.
3079030|NCT02033603|Active Comparator|Femoral Nerve Block|Femoral Nerve block performed with 0.5% Ropivacaine 30mls (150mg)
3079031|NCT02033603|Active Comparator|Adductor Canal block|Adductor Canal block performed with 0.5% Ropivacaine 30mls (150mg)
3079032|NCT02033590|Experimental|SERI® Surgical Scaffold|
3079033|NCT02033577|Experimental|Distal gastrojejunal bypass|RYGB with 200 cm BP limb and 150 cm common limb
3079034|NCT02033577|Active Comparator|RYGB|RYGB with 60 cm BP limb and 150 cm alimentary limb
3079035|NCT02033564|Active Comparator|Macintosh/Miller Laryngoscope|Macintosh or Miller laryngoscopy blade, preference left up to practitioner conducting intubation. These are the gold standards currently used in laryngoscopy.
3079036|NCT02033564|Active Comparator|Glidescope Laryngoscope|Glidescope video-guided laryngoscopy blade
3079037|NCT02033551|Experimental|Arm A - Veliparib Monotherapy|Subjects in this arm will be dosed with Veliparib continuous dosing.
3079038|NCT02033551|Experimental|Arm B - Veliparib in Combination with Carboplatin & Paclitaxel|Subjects enrolled will receive Veliparib in combination with Carboplatin and Paclitaxel and have an option to move to Veliparib monotherapy.
3079039|NCT02033551|Experimental|Arm C Veliparib in Combination with Modified FOLFIRI|Subjects will be given Veliparib in combination with modified FOLFIRI. The subject will have the opportunity to receive Veliparib as monotherapy.
3079040|NCT02033538|Experimental|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
3079041|NCT02033525|Experimental|XCEL-M-ALPHA and standard rehabilitation|Intraarticular administration of XCEL-M-ALPHA followed by standard rehabilitation program
3079042|NCT02033525|Active Comparator|standard rehabilitation|Standard rehabilitation program
3079043|NCT02033499|No Intervention|No testing|No testing
3079044|NCT02033499|Other|standard messaging|SMBG standard messaging
3079047|NCT02033473|Experimental|Apelin|An apelin clamp in which an apelin infusion will be administered prior to reference clamp
3079048|NCT02033473|Placebo Comparator|Placebo|A clamp reference during which a placebo solution (saline solution) will be administered prior to apelin clamp
3079049|NCT02033460|Experimental|Manual therapy, education and Exercise|"The protocol for this group is identical to the previous group with the sole difference that is added an exercise protocol :~In the fifth session we explained the patients to perform :~Five sets of isometric contraction of the deep neck flexors for 8-10 seconds.~Five sets of isometric contraction of the neck extensors for 6-8 seconds~Neural self-mobilization and stretching held for 10 - 12 seconds for the levator scapulae and the trapezius muscle.~In the sixth session the patient repeat all the exercises from the previous session and also with the help of a theraband made :~• Isotonic contraction of the head, performing 3-4 sets of 8-10 repetitions."
3079050|NCT02033460|Active Comparator|Manual Therapy and Education|"The protocol used for therapeutic education consisted of two approaches:~Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective."
3079051|NCT02033460|Active Comparator|Manual Therapy|Manual therapy will consist on Traction oscillatory, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
3079052|NCT02033447|Experimental|Magnetic Nanoparticle Injection|Patients undergoing radical cystoprostatectomy or prostatectomy
3079053|NCT02033434|Experimental|Intranasal Ketamine|All patients
3079054|NCT02033421||Pharmacokinetics Beta-lactam antibiotics|Patients with infective endocarditis treated with Beta-lactam antibiotics
3079055|NCT02033408|Experimental|Antibiotics in addition to steroids|"methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses and in addition the following antibiotics:~PO Vancomycin 250mg 4 times a day for 3 weeks (children under age 8 125mgX4/d for 3 weeks)~PO Amoxycillin 50mg per Kg divided by 3 (up to 500mg 3 times a day) - for 3 weeks~PO Metronidazole 5mg per Kg 3 times a day (up to 250mg 3 times a day) - for 3 weeks~PO Doxycycline 2mg per kg twice a day (up to 100mg twice a day) - for 3 weeks; OR- For children younger than 7 years: PO Ciprofloxacin 10mg per Kg twice a day (up to 250mg twice a day) for 3 weeks"
3079056|NCT02033408|Active Comparator|Steroids only|methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses
3079057|NCT02033408|Other|Open arm|either the antibiotics and/or FMT (fecal microbiome transplant) may be administered in a non-randomized, uncontrolled open-label arm to any resistant IBD patients
3079058|NCT02033395||Participants exposed to tramautic event|
3079059|NCT02033382||Healthy Controls|Age and gender matched healthy controls
3079060|NCT02033382||Patients|Participants diagnosed with Schizophrenia, schizophreniform disorder, or schizoaffective disorder, depressed type that are naive to anti-psychotic treatment.
3079061|NCT02033369|Experimental|Pramipexole|Six weeks of treatment with oral pramipexole, initiated at 0.25 mg/day and titrated to a maximum daily dose of 2.5 mg.
3079062|NCT02033369|No Intervention|Healthy Control|Healthy volunteers were matched to MDD group subjects by age, gender, and ethnicity, and will have no lifetime psychiatric disorders.
3079063|NCT02033356|Experimental|ACB with 30 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
3079064|NCT02033356|Experimental|ACB with 25 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
3079065|NCT02033356|Experimental|ACB with 20 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
3079066|NCT02033356|Experimental|ACB with 15 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
3079067|NCT02033356|Experimental|ACB with 10 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
3079068|NCT02033356|Experimental|ACB with 5 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
3079069|NCT02033343|Experimental|Real-time tracking & beam adjustment|Prostate cancer radiotherapy using real-time tracking
3079070|NCT02033330|Active Comparator|phenolics form orange peel, type 1|1 dose of 500 mg of phenolics from orange peel, orally ingested
3079071|NCT02033330|Active Comparator|phenolics from orange peel, type 2|1 dose of 500 mg of phenolics from orange peel, orally ingested
3079072|NCT02033330|Experimental|phenolics from orange peel, type 3|1 dose of 500 mg of phenolics from orange peel, orally ingested
3079073|NCT02033317|Experimental|patiromer|
3079074|NCT02033291||Cortical stroke or primary intracerebral hemorrhage patients:|patients who have a clear clinical presentation of either cortical stroke or primary intracerebral hemorrhage confirmed on brain CT. The patients are eligible when the DCE-MRI scans can be performed within 0-6 weeks of the vascular event and on two subsequent days as the vascular permeability may change significantly on the timescale of weeks.
3079075|NCT02033291||cSVD patients|patients who present with a transient ischemic attack (TIA) and cSVD related abnormalities on brain MRI. TIA patients are defined as patients with stroke like symptoms that last no longer than 24 hours. MRI abnormalities include extended white matter lesions, (asymptomatic) lacunar infarcts, microbleeds and enlarged Virchow-Robin spaces. The patients are eligible when the first DCE-MRI scan can be performed 8-12 weeks after the TIA to avoid the acute phase, and the second MRI-scan within four weeks after the first.
3099821|NCT01892995|Placebo Comparator|Saline|placebo
3079076|NCT02033278|Experimental|Infusion of autologous mononuclear bone marrow cells|Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)
3079077|NCT02033278|Placebo Comparator|Placebo infusion|Placebo infusion plus conventional medical treatment (as indicated by clinician)
3079078|NCT02033265||Patients with BMI less than 30 kg/m2|Patients with BMI less than 30 kg/m2 undergoing surgical procedures on upper limb (elbow, forearm and hand) scheduled to receive ultrasound-guided axillary brachial plexus block as their primary anesthetic modality at SJHC.
3079079|NCT02033265||Patients with BMI 30 or above|Patients with BMI 30 kg/m2 undergoing surgical procedures on upper limb (elbow, forearm and hand) scheduled to receive ultrasound-guided axillary brachial plexus block as their primary anesthetic modality at SJHC
3079080|NCT02033252|Experimental|Acupuncture|A series of acupuncture sessions within four weeks from the baseline with concurrent conventional medications for asthma
3079081|NCT02033252|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no acupuncture treatments throughout the 4 weeks while receiving other conventional managements for asthma. After 4 weeks, if participants choose to try the acupuncture treatment, the active acupuncture treatment will be provided for 4 weeks (3 sessions/week).
3079082|NCT02033239|Experimental|FIAsp|Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
3079083|NCT02033239|Active Comparator|NovoRapid®|Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
3079084|NCT02033226|Experimental|Amniotic Membrane|The test site was treated as follows; After placement and proper condensation of natural Hydroxyapatite graft in the defect, AM was cut based on defect anatomy of surgical site and then adapted over the bone graft and alveolar bone extending from base of the flap reflection to the tooth surface.
3079085|NCT02033226|Placebo Comparator|Control group (Hydroxyapatite only)|The control site was treated by graft placement (Hydroxyapatite) only
3079086|NCT02033213|Active Comparator|Restrictive group|Patients who received ≤ 8ml/kg/h of intraoperative fluid. A fluid administered during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
3079087|NCT02033213|Active Comparator|Liberal group|Patients who received > 8 ml/kg/h of fluid. A fluid used during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
3079088|NCT02033200|Experimental|Active|Stendra 200 mg
3079089|NCT02033200|Placebo Comparator|Placebo|placebo
3079090|NCT02033187|Experimental|Chlorhexidine bathing|Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.
3079091|NCT02033187|Active Comparator|Non-chlorhexidine bathing|Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
3079092|NCT02033174|Other|Sugar water first, then alcohol|8 participants have received oral fat diet plus water with sugar (equivalent caloric intakes as sugar with water in the control group). Then they receive the same oral fat-enriched diet (1486 kcal/m2) with 654 kcal/m2 (44%) as fat and a daily total amount of 16 g/m2 of alcohol, of different beverages (red wine, vodka, brandy or rum)
3079093|NCT02033174|Other|Alcohol first then sugar water|8 participants have received oral fat diet plus alcoholic beverages (a daily total amount of 16 g/m2 of alcohol, of different beverages : red wine, vodka, brandy or rum). Then they receive the same oral fat-enriched diet (1486 kcal/m2) with 654 kcal/m2 (44%) as fat and water with sugar (equivalent caloric intakes as sugar with water in the control group).
3079094|NCT02033161|Experimental|Internet-delivered CBT|
3079095|NCT02033148|Experimental|Treatment (icotinib hydrochloride)|Patients receive icotinib hydrochloride PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3079096|NCT02033135|Experimental|Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX) plus unsupervised exercise therapy, smoking cessation advice and best medical therapy.
3079097|NCT02033135|Active Comparator|Best medical treatment|Unsupervised exercise therapy, smoking cessation advice and best medical therapy.
3079098|NCT02033122|Active Comparator|Aerobic training|the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.
3079099|NCT02033122|Sham Comparator|Breathing exercise|Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
3079100|NCT02033109|Experimental|PC-1005|"4.00 g dosed once daily for 3 days (safety run-in)~4.00 g dosed once daily for 14 days (main study)"
3079101|NCT02033109|Placebo Comparator|HEC gel|4.00 g dosed once daily for 14 days (main study only)
3079102|NCT02033096||Placebo|placebo
3079103|NCT02033096||stannsoporfin 1.5 mg/kg|received 1.5 mg/kg in study 202
3079104|NCT02033096||stannsoporfin3.0 mg/kg|received 1.5 mg/kg in study 202
3079106|NCT02033083|Active Comparator|Laminaria|Patients in this arm will receive laminaria cervical dilators one day before D&E procedure.
3079107|NCT02033083|Active Comparator|Dilapan-S|Patients in this arm will receive Dilapan-S cervical dilators one day before D&E procedure.
3079108|NCT02033070||Non-Dysplastic IM, LGD, HGD|
3079109|NCT02033057|Experimental|Muscular electrostimulation.|The interventions is muscular electrostimulation.
3079110|NCT02033044|Experimental|cognitive remediation|Cognitive remediation programme in order to improve several cognitive domains.
3079111|NCT02033044|Active Comparator|Psychoeducation|Psychoeducation group in order to improve psychosocial functioning of patients.
3079112|NCT02033031|Active Comparator|Lucentis|PRN intravitreal injection of Lucentis
3079113|NCT02033031|Active Comparator|Avastin|PRN intravitreal injection of Lucentis
3079114|NCT02033018|Experimental|Aflibercept injection|Myopic eyes with retinal neovascularization submitted a aflibercept intravitreal injection
3079115|NCT02033005||Breastfed infants|>80% of feeds consisting of breast milk at both scanning points
3079116|NCT02033005||Formula-fed infants|>80% of feeds consisting of formula milk at both scanning points
3079117|NCT02033005||Mixed-fed infants|20%-80% of feeds consisting of breast milk.
3079118|NCT02032979|Experimental|FSHD patient|
3079119|NCT02032966|Experimental|Nonsurgical|"Randomized to nonsurgical: patient will receive surgical treatment of the inside portion (medial malleolus) of the tibia fracture only; the fibula fracture (and posterior malleolus fracture, if present) will be closed reduced (not repaired surgically)."
3079120|NCT02032966|Active Comparator|Surgical|"Randomized to surgical: patient will receive surgical treatment of both the inside portion (medial malleolus) of the tibia fracture, as well as the fibula fracture (lateral malleolus). Fixation of the posterior side of the tibia (posterior malleolus) may or may not be performed based upon intraoperative x-rays."
3079121|NCT02032966|Other|syndesmotic injury|"Non-randomized / syndesmotic injury: patients who have a positive ligament stress test (signifying a syndesmotic injury) during surgery will require surgical treatment of both the tibia and the fibula and cannot be randomized to either arm (nonsurgical versus surgical). Patients in this arm will still be included in the study for the collection of clinical and functional outcomes."
3079122|NCT02032953|Experimental|Insulin, Travasol (35%) postop|Insulin (hyperinsulinemic-normoglycemic clamp) with Travasol (amino acid supplementation) given from start of surgery to 6 hours after, at an amount of 35% of patient's energy expenditure as measured before surgery, .
3079123|NCT02032953|Experimental|Insulin, Travasol (20%) postop|Insulin (hyperinsulinemic-normoglycemic clamp) with Travasol (amino acid infusion), given from start of surgery to 6 hours after, at an amount of 20% of patient's energy expenditure as measured before surgery.
3079124|NCT02032953|Placebo Comparator|Insulin, no protein after surgery|Insulin (hyperinsulinemic-normoglycemic clamp, an insulin infusion between 2 and 5 microunits/kg with glucose at a variable rated titrated to maintain normoglycemia, blood glucose 4-6 mmol/L) with no protein supplementation from start of surgery to 6 hours after.
3079125|NCT02032940||Standard Sequence Imaging MRI|Patients requiring MRI. All Comers accepting study participation.
3079126|NCT02032940||Additional Pulse Sequence Increased|Patients requiring MRI. All comers accepting study participation and the run of additional pulse sequences during MRI procedure.
3079127|NCT02032927|Active Comparator|Codeine/paracetamol|"The combination codeine/paracetamol,30 mg/500 mg,1 tablet every 8 hours, paracetamol 500 mg if NRS> 4, repeatable up to 3 times per day.~At any stage of the study, patients treated with combination codeine/paracetamol in case of ineffectiveness (NRS> 4) despite maximal dosage (2 tablets every 8 hours) and/or side effect, will be subject to the opioid switch and will start equianalgesic therapy with oxycodone/naloxone combination."
3079128|NCT02032927|Active Comparator|Oxycodone/Naloxone|Combination oxycodone /naloxone, 5 mg/2.5 mg, 1 tablet/day, paracetamol 500 mg if NRS> 4, repeatable up to 3 times per day.
3079129|NCT02032914||Colonoscopic examination group|The patients diagnosed with cryptogenic pyogenic liver abscess
3079130|NCT02032901|Experimental|A1:Daclatasvir + Sofosbuvir in treatment-naive subjects|Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks
3079131|NCT02032901|Experimental|A2:Daclatasvir + Sofosbuvir in treatment-experienced subjects|Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks
3079132|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks|Treatment-naïve participants received daclatasvir 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 12 weeks
3079133|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks|Treatment-naïve participants received daclatasvir, 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 8 weeks
3079134|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks|Treatment-experienced participants received daclatasvir, 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 12 weeks
3079135|NCT02032875|Experimental|Post-liver Transplant Cohort|Participants with liver transplant received daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (based on baseline hemoglobin and creatinine clearance and tolerated dose) tablets daily for 12 weeks and were followed for 24 weeks post treatment.
3079136|NCT02032875|Experimental|Cirrhotic Cohort|Cirrhotic participants received daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (based on baseline hemoglobin and creatinine clearance and tolerated dose) tablets orally for 12 weeks and were followed for 24 weeks post-treatment. Cirrhotic participants who received a liver transplant while on study treatment were eligible (>3 months post transplant) for a treatment extension of daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (dose based on hemoglobin level) tablets orally for an additional 12 weeks
3079137|NCT02032862|Experimental|Sage tablets|Sage extract, 3400 mg , DER 1:17, in once daily application over 12 weeks treatment phase
3079138|NCT02032862|Placebo Comparator|Placebo|Placebo, matching the verum in size and appearance, in once daily application over 12 weeks treatment phase
3079139|NCT02032849|Active Comparator|subglottic secretion drainage|The conventional method with a special tube to drainage subglottic secretion
3079140|NCT02032849|Experimental|Manual air-impingement operation|A method which we invented to clear subglottic secretion
3079205|NCT02032368|Experimental|TACE group|Patients in TACE group receive transarterial chemoembolization (TACE) one month after resection.
3079206|NCT02032368|No Intervention|Control group|Patients in Control group receive no management.
3079141|NCT02032836|Other|lloprost(Ventavis,BAYQ6252, 20 µg/mL)|Cross over design: First single inhalation of 5 µg iloprost using 20 µg/ml iloprost nebuliser solution with the FOX nebulizer. Then single inhalation of 5 µg iloprost using 10 µg/mL iloprost nebuliser solution with the I-Neb nebulizer. Subsequent 6 to 9 inhalations of 5 µg iloprost per day using FOX over 2 weeks, followed by 6-9 inhalations of 5 µg iloprost per day using I-Neb over 2 weeks
3079142|NCT02032836|Other|lloprost(Ventavis,BAYQ6252, 10 µg/mL)|Cross over design: First single inhalation of 5 µg iloprost using 10 µg/ml iloprost nebuliser solution with the I-Neb nebulizer. Then single inhalation of 5 µg iloprost using 20 µg/mL iloprost nebuliser solution with the FOX nebulizer. Subsequent 6 to 9 inhalations of 5 µg iloprost per day using I-Neb over 2 weeks, followed by 6-9 inhalations of 5 µg iloprost per day using Fox over 2 weeks
3079143|NCT02032823|Experimental|Olaparib|Olaparib tablets 300mg b.i.d. p.o.
3079144|NCT02032823|Placebo Comparator|Placebo|Placebo tablets b.i.d. p.o.
3079145|NCT02032810|Experimental|Dose Escalation of Panobinostat, Plus Ipilimumab|Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg) along with a dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
3079146|NCT02032797|Experimental|A: 7 days of progesterone|"Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B.~Group A receives 7 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 5 days of micronized progesterone vaginally. On the 7th (group A) or 5th (group B) day of progesterone supplementation, the cryopreserved-thawed day 5 embryo is transferred."
3079147|NCT02032797|Placebo Comparator|B: 5 days of progesterone|"Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B.~Group A receives 7 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 5 days of micronized progesterone vaginally. On the 7th (group A) or 5th (group B) day of progesterone supplementation, the cryopreserved-thawed day 5 embryo is transferred."
3079148|NCT02032784|Experimental|Octreotide|Octreotide 100mcg subcutaneous every 8 hours for 5 days
3079149|NCT02032784|Other|no octreotide|No Octreotide
3079150|NCT02032771|Experimental|M22 IPL and ResurFX|The procedure will include an intense pulse light (IPL) treatment followed by fractional non-ablative (FNA) treatment.
3079151|NCT02032758|Experimental|Golfers With Golfer's Cramp|Subjects in this arm will be tested with the Opal device, the Science and Motion PuttLab (SAM), and the Surface Electromyography (EMG) to collect movement parameters while putting before and after a single dose of 10 mg Propranolol.
3079152|NCT02032758|Other|Golf Pros|Subjects in this arm will be tested with the Opal device, the Science and Motion PuttLab (SAM), and the Surface Electromyography (EMG) to collect movement parameters while putting. The subjects in this arm will not receive any study drug.
3079153|NCT02032745||Chemo-insensitive|Non-responders to chemotherapy (Probability for pathological negative nodal status)
3079154|NCT02032745||Chemo-sensitive|Responders to chemotherapy (Probability for pathological negative nodal status)
3079155|NCT02032732||suspected infection|leukocyte esterase test on fluid removed by intra-articular aspiration for suspected infection
3079156|NCT02032732||no suspected infection|leukocyte esterase test on fluid removed by intra-articular aspiration for reason other than suspected infection
3079157|NCT02032719|Experimental|smartphone assisted lifestyle coaching|6 months of smartphone assisted lifestyle coaching
3079158|NCT02032719|Active Comparator|Lifestyle health coaching|6 months of lifestyle health coaching
3079159|NCT02032706|Experimental|Positional feedback|Deliver therapy when the supine position is detected
3079160|NCT02032693|Experimental|Everycell™|Patient will take 1 tablet two times daily of Everycell™ (double-blind) for the 4-week treatment period.
3079161|NCT02032693|Placebo Comparator|Placebo|Patient will take 1 tablet two times daily of the placebo (double-blind) for the 4-week treatment period.
3079162|NCT02032680|Experimental|Web-based family psycho-education treatment|The e-health/web-based intervention provides: three therapist facilitated group forums; a function to send facilitators questions; a library of previously answered questions; and a library of educational materials.
3079163|NCT02032680|Active Comparator|In-persons multi-family psycho-educational treatment|This arm provides the evidence based multi-family psychoeducational treatment, termed Multi-Family Group (MFG) that is the standard of care in the VA.
3079164|NCT02032680|Other|Treatment as Usual|The Treatment as usual (TAU) group provides a benchmark against which to measure the impact of the two individual interventions (MFG & DSW) independent from each other. Through enhancements of TAU, such as regular monitoring which will be done in the assessment process and by the provision of information to VA psychiatrist when there are concerns or problems with the psychiatric status of their patients, we will be taking reasonable steps to ensure the safety of the participants who are assigned to TAU.
3079165|NCT02032667|Experimental|Multi-player condition|The multi-player condition examines the aspect of online gaming and social interaction with adherence to the exergame.
3079166|NCT02032667|No Intervention|Single-player condition|This arm will look at whether those who play an exergame by themselves or with a computer generated player have the same adherence and use when compared to a multi-player condition.
3079167|NCT02032654|Active Comparator|Standard course|Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Flucloxacillin 500mg capsules, every 6 hours, for 6 days
3079168|NCT02032654|Experimental|Short course|Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Placebo (for flucloxacillin 500mg) 500mg capsules, every 6 hours, for 6 days
3079207|NCT02032355||hypotension|
3079208|NCT02032342|Active Comparator|Fuji Uni-blocker|Fuji Uni-blocker for selective lobar deflation
3099942|NCT01892111|No Intervention|no intervention|IVF/ICSI procedure.
3079169|NCT02032641|Experimental|Laser Treatment Side|"Each patient was randomized to have one of two scars treated with Laser Genesis. The treatment was administered by manually scanning the rapidly pulsed laser in an even, painting motion throughout the entire treatment zone. The eyebrow hairs were covered with white tape to prevent inadvertent alopecia. The laser handpiece was oriented perpendicular to the skin at all times, at a distance of 1-2 cm. Patients were instructed throughout to give verbal feedback regarding if the area was too hot as an additional safeguard against epidermal damage."
3079170|NCT02032641|No Intervention|Control side|Each patient had a scar which was randomized to not undergo treatments with Laser Genesis, and was used as a control. Patients were not allowed to undergo laser or any other scar treatments with the exception of sun protection for the control scar for the duration of the study.
3079171|NCT02032628|Experimental|High Intensity/Longer Duration|Exercise at higher intensity (~75% of VO2max) for 40 minute bouts 4 times per week
3079172|NCT02032628|Experimental|High Intensity/Lower Duration|Exercise at high intensity (~75% of VO2max) for 20 minute bouts 4 times per week
3079173|NCT02032628|Experimental|Lower Intensity/Higher Duration|Exercise at lower intensity (~55% of VO2max) for 40 minute bouts 4 times per week
3079174|NCT02032628|Experimental|Low Intensity/Low Duration|Exercise at lower intensity (~55% of VO2max) for 20 minute bouts 4 times per week
3079175|NCT02032615|Active Comparator|Education plus Gudness Nutritional Bar|Subjects will receive education about anemia and will consume Gudness Nutrition bars for 3 months
3079176|NCT02032615|Placebo Comparator|Education with no nutrition bar|Subjects will receive education about anemia but will not receive nutrition bar
3079177|NCT02032602|Active Comparator|1, CG: Active MTrP|a single session of physical therapy intervention which will be consisted on Deep Dry Needling of the active MTrP most hyperalgesic to palpation of the infraspinatus muscle homolateral to painful shoulder
3079178|NCT02032602|Experimental|2, EG: Active+Latent MTrPs|The same treatment described above for the Control Group, combined with the Deep Dry Needling of the most hyperalgesic latent MTrP, both located in the infraspinatus muscle homolateral to the painful shoulder.
3079179|NCT02032589|Experimental|Self-generation treatment|self-generation strategy treatment, embedded within practice of various activities
3079180|NCT02032589|Placebo Comparator|memory training|Treatment consists on traditional memory training
3079181|NCT02032576|Experimental|ECT for depressed patients|electroconvulsive therapy with a bipolar brief pulse square wave
3079182|NCT02032563|Experimental|Indocyanine Green|intravenous injection of 0.25mg/kg Indocyanine Green just before surgery
3079183|NCT02032550|Experimental|Preference Based Decision Aid|The experimental arm of preference based decision aid intervention will complete a web-based conjoint analysis instrument for preference assessment.
3079184|NCT02032550|No Intervention|Usual Care|Participants randomized into this group will have usual care from their doctors without any intervention
3079185|NCT02032537|Active Comparator|Callmax cream|
3079186|NCT02032537|Placebo Comparator|Placebo|
3079187|NCT02032524|Experimental|neoGAA|administered intravenously every 2 weeks
3079188|NCT02032511||RAM Cannula Nasal Continuous Positive Airway Pressure|
3079189|NCT02032511||Infant Flow Nasal Continuous Positive Airway Pressure (NCPAP)|
3079190|NCT02032498|Experimental|Indocyanine Green|superficial injections of Indocyanine Green in the breast
3079191|NCT02032485|Experimental|Indocyanine Green|Intravenous injection of 0.25 mg/kg Indocyanine Green in patients with peritoneal carcinomatosis from colorectal cancer before the surgery
3079192|NCT02032472|No Intervention|Health Center (usual practice)|Controlling arterial pressure in the health center (a common practice is carried out)
3079193|NCT02032472|Experimental|Collaboration of pharmacies|Pharmacies cooperate in Measurement of Arterial Pressure of patients
3079194|NCT02032459||Minority Women|Study data pulled from already collected data (N=1141 from the Camden Study of low income gravidae and minority gravidae (White, African-American and Hispanic) living in the northeastern United States (New Jersey).
3079195|NCT02032446|Experimental|Umbilical Cord Mesenchymal stromal cells (UC-MSC)|"Pentostatin will be given by intravenous infusion at a dose of 1 mg/m2 for 3 consecutive days. Thereafter, three Umbilical Cord Mesenchymal stromal cells (UC-MSC) infusions will be given at weekly interval starting from day 5. We will follow a dose escalating programme with progressively increasing doses of cells until the maximally tolerated dose (MTD) is achieved.~The dose escalating design will be characterised by the administration of 1x106 /kg UC-MSC per dose per three doses for the first three patients (total up to 3x106/kg). The second three patients will receive 2x106/kg UC-MSC per dose per three doses (total up to 6x106/kg). The third three patients will receive 3x106/kg UC-MSC per dose per three doses (total up to 9x106 cells/kg).~Since three dosages of cells are programmed for each group of 3 patients, a minimum of 9 patients should be studied, unless unacceptable acute infusion related toxicity is observed."
3079196|NCT02032433|Active Comparator|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol)
3079197|NCT02032433|Active Comparator|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone)
3079198|NCT02032420|Experimental|STAR|Introductory training by video depicting 4 sequential maneuvers for reacquisition of needle image in ultrasound: see, tilt, align, rotate.
3079199|NCT02032420|Active Comparator|ART|Introductory training with a video depicting 3 probe position aspects for reacquisition of needle image by ultrasound: alignment, rotation, tilt.
3079200|NCT02032407|Experimental|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
3079201|NCT02032394|Experimental|Chlorhexidine|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Chlorhexidine 0.2%, 3 times a day for 10 days.
3079202|NCT02032394|Experimental|Povidone-Iodine|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Povidone-iodine 10%, 3 times a day for 10 days.
3079203|NCT02032394|Active Comparator|Normal saline|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Normal saline 0.9%, 3 times a day for 10 days.
3079204|NCT02032381|Other|allogeneic hematopoietic stem cell|The eligible population for this study will consist of all children under 18 years who received allogeneic hematopoietic stem cell and evaluate of late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.
3079209|NCT02032342|Active Comparator|Cohen blocker|Cohen blocker for selective lobar deflation
3079210|NCT02032342|Active Comparator|Arndt® blocker|Arndt® blocker for selective lobar deflation
3079211|NCT02032342|Placebo Comparator|Endobronchial double lumen tube|Endobronchial double lumen tube for one lung ventilation
3079212|NCT02032329|Experimental|FastFES|Single Group Study - see Intervention Description
3079213|NCT02032316|Experimental|Interventional|Placement of ureteral stent following post-ureteroscopy
3079214|NCT02032303|Active Comparator|Ticagrelor|Patient randomized to Ticagrelor
3079215|NCT02032303|Active Comparator|Prasugrel|Patient randomized to Prasugrel
3079216|NCT02032290|Active Comparator|ticagrelor|ticagrelor: loading dose of 180 mg and maintaining dose of 90 mg twice daily in NSTEMI and STEMI (Class I B) patients;
3079217|NCT02032290|Active Comparator|clopidogrel|clopidogrel: loading dose of 600 mg and maintaining dose of 75 mg daily in NSTEMI (Class I B) and STEMI (Class I C) patients.
3079218|NCT02032277|Active Comparator|Arm A|Veliparib + carboplatin + paclitaxel followed by doxorubicin/cyclophosphamide (AC)
3079219|NCT02032277|Placebo Comparator|Arm C|Placebo + placebo + paclitaxel followed by AC.
3079220|NCT02032277|Placebo Comparator|Arm B|Placebo + carboplatin + paclitaxel followed by AC
3079221|NCT02032264|Experimental|Comprehensive Chromosome Screening|Trophectoderm biopsy will be performed on all blastocysts and CCS via next generation sequencing screening performed on biopsy samples. Patients will proceed with a single or double embryo transfer of the one or two morphologically best euploid embryos
3079222|NCT02032264|Placebo Comparator|No Comprehensive Chromosome Screening|The patients in this group will proceed with a single or double embryo transfer of the one or two morphologically best embryos.
3079223|NCT02032251|Experimental|ginger|The patients with infertility that underwent oral administration of ginger.
3079224|NCT02032251|Placebo Comparator|Placebo|The patients with infertility that receive placebo.
3079225|NCT02032238|Experimental|laser photocoagulation with bevacizumab|Combining laser photocoagulation and Anti-VEGF Injections in a pre-defined manner
3079226|NCT02032238|No Intervention|Bevacizumab, no laser photocoagulation|patients receive Anti-VEGF injections (Bevacizumab) only
3079227|NCT02032225||CADASIL|patients with CADASIL
3079228|NCT02032212|Experimental|Sequence 1|Subjects use the unflavoured EVP on Day 1, the flavoured EVP on Day 2, the nicotine inhalator on Day 3 and the conventional cigarette on Day 4.
3079229|NCT02032212|Experimental|Sequence 2|Subjects use the flavoured EVP on Day 1, the unflavoured EVP on Day 2, the conventional cigarette on Day 3 and the nicotine inhalator on Day 4.
3079230|NCT02032212|Experimental|Sequence 3|Subjects use the nicotine inhalator on Day 1, the conventional cigarette on Day 2, the unflavoured EVP on Day 3 and the flavoured EVP on Day 4.
3079231|NCT02032212|Experimental|Sequence 4|Subjects use the conventional cigarette on Day 1, the nicotine inhalator on Day 2, the flavoured EVP on Day 3 and the unflavoured EVP on Day 4.
3079232|NCT02032186|Experimental|Mg++|Magnesium Citrate oral supplementation from early pregnancy; 160 mg twice per day.
3079233|NCT02032186|Placebo Comparator|Placebo|Placebo pills twice per day.
3079234|NCT02032173|Experimental|Main group|All patients enrolled in the study (155 patients) will start in this main group. They will receive 6 ranibizumab injections (one per month from baseline to month 5, 0.5 mg of ranibizumab per injection). After this intensive follow up phase, injection will be done every 3 months until month 24. If a patient does not meet the criteria to stay in the main group, he/she will be directed to the rescue group, where monitoring and treatment is recommended to be performed according to the SmPC of Lucentis® (ranibizumab) (PRN with monthly follow up)
3079235|NCT02032160|Experimental|Engerix B|Engerix B IM injection - 20ug At 0, 1 and 6 months
3079236|NCT02032160|Experimental|Fendrix|Fendrix IM injection - 20ug At 0, 1 and 6 months
3079237|NCT02032147||NGF group|This group will be treated with NGF 18u daily for 60 days.
3079238|NCT02032147||control group|"this group will receive conservative therapy such as hyperbaric therapy or corticosteroids therapy or wait and see policy"
3079239|NCT02032134|Other|Patients with severe thrombocytopenia|Intervention Patients with severe thrombocytopenia with an active bleeding, in preparation for surgery, or after chemotherapy (prophylaxis of bleeding),will receive transfusion of Pooled Platelets Cryopreserved In DMSO With a New System
3079240|NCT02032121|Experimental|Intervention procedures|All the procedures will be completed for every subject
3079241|NCT02032108|Experimental|lifestyle counselling|"A 45-min lifestyle educational session will be delivered to the subjects randomized to the intervention group every month for one year.~Lifestyle intervention will consist in group counselling on dietary habits, effects of regular physical activity, importance of adherence to medications, diabetes complications, actions to control blood sugar and ways of coping with stress."
3079242|NCT02032095|Experimental|GB-0998|
3079243|NCT02032082|No Intervention|Ex vivo without CO|
3079244|NCT02032082|Experimental|EX Vivo with carbone monoxide|During the Ex Vivo Lung Perfusion reconditioning,the lungs will be ventilated wit h Oxygen (21%) and Carbon Monoxide (250ppm).
3079245|NCT02032069||NHBD|Non Heart Beating Donors
3079246|NCT02032069||BDD|Brain death donors
3079247|NCT02032056|Experimental|probiotic (10^9 cfu/day)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12), 10^9 cfu/day, provided as powder in a sachet which can be added to food or drink.
3079248|NCT02032056|Experimental|probiotic (10^8 cfu/day)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12), 10^8 cfu/day, provided as powder in a sachet which can be added to food or drink.
3079249|NCT02032056|Placebo Comparator|Placebo|provided as powder in a sachet which can be added to food or drink.
3079250|NCT02032043||Annual MDA treated Group|This group will receive annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Ivorian Ministry of Health.
3079251|NCT02032043||Semiannual Mass Drug Administration|This group will receive semi-annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Ivorian Ministry of Health.
3079290|NCT02031731|Experimental|4 mg/kg Onartuzumab (MetMAb)|
3079291|NCT02031731|Experimental|15 mg/kg Onartuzumab (MetMAb)|
3079292|NCT02031731|Experimental|30 mg/kg Onartuzumab (MetMAb)|
3079293|NCT02031718|No Intervention|Online Education|
3079294|NCT02031718|Experimental|Online Education & Virtual Counseling|Online virtual counseling
3079252|NCT02032017|Experimental|Percutaneous assisted approach|In this technique, a second small incision (1 cm) at the anterior border of the femur is made. A canulla is placed underneath the muscle and used to pass the reamers in the direction of the acetabulum. There's no need to enlarge the skin incision or to release more muscle insertion to achieve good working access to the acetabulum. Two advantages can be defined: sparing of the gluteus medius muscle and safe access to the acetabulum to obtain perfect positioning of the implants.
3079253|NCT02032017|Active Comparator|Anterolateral approach|A standard transgluteal approach is used. This means a large part of the gluteus medius muscle is released to obtain good access to the acetabulum.
3079254|NCT02032004|Experimental|Allogeneic Mesenchymal Precursor Cells|Participants randomly assigned to treatment will undergo a single index cardiac catheterization involving transendocardial delivery of rexlemestrocel-L into the myocardium at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.
3079255|NCT02032004|Sham Comparator|Control Treatment|Participants randomly assigned to control treatment will undergo a single cardiac catheterization involving a scripted sham cardiac mapping and cell delivery procedure at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.
3079256|NCT02031991|Experimental|A = PF-06439535|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
3079257|NCT02031991|Active Comparator|B = Bevacizumab-EU|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
3079258|NCT02031991|Active Comparator|C = Bevacizumab-US|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
3079259|NCT02031978||WIC Program Participants|The cohort is made up of infants. Pregnant women enrolling in WIC for the first time for that pregnancy and mothers/caregivers of infants younger than 2.5 months of age enrolling in WIC for the first time are recruited to participate.
3079260|NCT02031965|Experimental|Treatment (oncolytic HSV-1716)|Patients receive oncolytic HSV-1716 IT and peritumorally after undergoing surgical tumor resection. Patients also receive dexamethasone IV prior to and 6 and 12 hours after surgery.
3079261|NCT02031952|Experimental|hepatectomy combined lymphadenectomy|hepatectomy combined lymphadenectomy
3079262|NCT02031952|Active Comparator|hepatectomy|hepatectomy alone
3079263|NCT02031939|Active Comparator|Standard chemoradiotherapy|Standard chemoradiotherapy (Capecitabine 825mg/m2 combined with radiotherapy )
3079264|NCT02031939|Experimental|induction and gap chemotherapy|induction chemotherapy (Capecitabine 2000mg/m2 +oxaliplatine 130mg/m2) + standard chemoradiotherapy (Capecitabine 2000mg/m2 combined with radiotherapy) + gap chemotherapy (Capecitabine 2000mg/m2 + oxaliplatine 130mg/m2)
3079265|NCT02031926|Experimental|Positive expiratory pressure|
3079266|NCT02031913||HBV without FL|Chronic hepatitis B without steatosis
3079267|NCT02031913||HBV with FL|Chronic hepatitis B patients with steatosis
3079268|NCT02031900||Undergoing EGD|
3079269|NCT02031887|Experimental|Infant starter formula with synbiotics|Infant starter formula with synbiotics
3079270|NCT02031887|Active Comparator|Infant formula without synbiotics|Infant formula without synbiotics
3079271|NCT02031874||Miami Cohort|Measured vaccine response to H1N1 in HIV perinatally infected children
3079272|NCT02031861|Experimental|nifedipine CR tablets (Xin Ran)|Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 12-week treatment period.
3079273|NCT02031861|Active Comparator|nifedipine CR tablets (Adalat)|Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 12-week treatment period.
3079274|NCT02031848|Active Comparator|Healthy Weight Control Group|Subjects will complete the Assessments, Diet Intake, and MRI portions of the study
3079275|NCT02031848|Active Comparator|Dieting Group|Subjects will complete the Assessments, Diet Intake, and MRI portions of the study and will be given the weight loss and weight maintenance diets, and will attend weekly behavioral meetings
3079276|NCT02031835|Other|BWSTT (3 days a week for maximum of 20 minutes session)|BWSTT (20 minutes of treadmill training (velocity (≥0.1km/h) and body weight support (≤40% of patients weight) according to patients capability and comfort
3079277|NCT02031822|Active Comparator|US-guided Distal GON Block (Group D)|Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the superior nuchal line lateral to the external occipital protuberance, close to the occipital artery.
3079278|NCT02031822|Active Comparator|US-guided Proximal GON Block (Group P)|Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the bifid C2 spinous process laterally, between the inferior obliquus capitis and semispinalis capitis muscles.
3079279|NCT02031809||No additional unplanned major surgery|uneventfull intra-operative and postoperative course
3079280|NCT02031809||Additional unplanned major surgery|"Additional per-operative or post-operative unplanned major surgery such as unforeseen pneumonectomy, bilobectomy, lobectomy or additional segmentectomy, repair of major vessels or bronchi, bronchopleural fistula, unplanned surgery to other organs, within 30 days after the primary surgery.~These do not include:~Conversions without additional unplanned major surgery or suddne blood loss less than 500cc~Conversions or additional resection for unforeseen oncologic reasons.~Plasty, repair or sleeve resection of vessels after deliberate resection or transection for oncologic reasons"
3079281|NCT02031796|Experimental|CAVAREC images|CAVAREC images from x-ray angiography
3079282|NCT02031783|Experimental|mixture of glucose and fructose|mixture of glucose and fructose
3079283|NCT02031783|Active Comparator|Glucose|Single glucose
3079284|NCT02031770|Other|A: Treatment/Control|Patients will start with sodium bicarbonate treatment then switch to control (no treatment)
3079285|NCT02031770|Other|B: Control/Treatment|Patients will start with control (no treatment) then switch to sodium bicarbonate treatment
3079286|NCT02031757|Experimental|perturbation training|Standard physiotherapy augmented with perturbation training (BaMPer system).
3079287|NCT02031757|Active Comparator|balance exercise|standard physiotherapy augmented with balance exercises.
3079288|NCT02031744|Placebo Comparator|erlotinib [Tarceva] + placebo|
3079289|NCT02031744|Experimental|erlotinib [Tarceva] + onartuzumab [MetMAb]|
3079295|NCT02031705|Active Comparator|cavotricuspid isthmus ablation|Isthmus ablation was performed in paroxysmal atrial fibrillation patients.
3079296|NCT02031705|Placebo Comparator|control group|Control group was performed no additional cavotricuspid isthmus ablation.
3079297|NCT02031692|Active Comparator|Vitamin D and calcium supplement|
3079298|NCT02031692|No Intervention|Control|
3079299|NCT02031679|Experimental|AZD1981|"AZD1981 for oral administration will be available in tablet form. AZD1981 tablets will be provided in 10 mg strengths.~The drug will be self-administered by the subject. Subjects will take 4 tablets in the morning, 4 tablets in the afternoon, and 4 tablets in the evening.~The tablets should be swallowed whole with a glass of water."
3079300|NCT02031679|Placebo Comparator|Placebo|"The placebo will be available in tablet form. The placebo contains the same ingredients as the AZD1981 with the exception of the active compound.~The placebo will be self-administered by the subject. Subjects will take 4 tablets in the morning, 4 tablets in the afternoon, and 4 tablets in the evening.~The tablets should be swallowed whole with a glass of water."
3079301|NCT02031666|Active Comparator|Treatment A|15 participants will receive 240-mg dose as Softgel Capsule Formulation of JNJ-56021927.
3079302|NCT02031666|Experimental|Treatment B|15 participants will receive 240-mg dose as Tablet Formulation number 1 of JNJ-56021927.
3079303|NCT02031666|Experimental|Treatment C|15 participants will receive 240-mg dose as Tablet Formulation number 2 of JNJ-56021927.
3079304|NCT02031666|Experimental|Treatment D|15 participants will receive 240-mg dose as Tablet Formulation number 3 of JNJ-56021927.
3079305|NCT02031666|Experimental|Treatment E|15 participants will receive 240-mg dose as Tablet Formulation number 4 of JNJ-56021927.
3079306|NCT02031666|Experimental|Treatment F|15 participants will receive 240-mg dose as Tablet Formulation number 5 of JNJ-56021927.
3079307|NCT02031666|Experimental|Treatment G|15 participants will receive 240-mg dose as Tablet Formulation number 6 of JNJ-56021927.
3079308|NCT02031666|Experimental|Treatment H|15 participants will receive 240-mg dose as Tablet Formulation number 7 of JNJ-56021927.
3079309|NCT02031653||Study Group|
3079310|NCT02031640|Experimental|BDP 320 mcg BAI|Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.
3079311|NCT02031640|Experimental|BDP 640 mcg BAI|Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.
3079312|NCT02031640|Active Comparator|BDP 320 mcg MDI|Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.
3079313|NCT02031640|Active Comparator|BDP 640 mcg MDI|Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.
3079314|NCT02031640|Placebo Comparator|Placebo BAI and MDI|Placebo breath-actuated inhaler (BAI), twice daily. Plus placebo metered dose inhaler (MDI), twice daily.
3079315|NCT02031627|Experimental|pneumatic compression - 1 hour per day|Pneumatic compression device - 12 consecutive days undergoing a 1 hour treatment regimen.
3079316|NCT02031627|Experimental|pneumatic compression - 2 hours per day|Pneumatic compression device - 5 consecutive days undergoing 1 hour treatment in the am and 1 hour of treatment in the pm.
3079317|NCT02031627|Experimental|pneumatic compression - 4 hours per day|Pneumatic compression device - 5 consecutive days undergoing treatment twice per day consisting of 2 consecutive 1 hour treatments in the am and the pm (4 hours total)
3079318|NCT02031614|Experimental|Phlebotomy|Subjects in this arm will undergo phlebotomy of 500 mL of blood.
3079319|NCT02031601|Experimental|Combination therapy|"Interventions:~Drug: Erlotinib [Tarceva] or Gefitinib [Iressa] or Icotinib [Conmana] plus Drug: Docetaxel for patients of lung squamous cell carcinoma; Pemetrexed for patients of lung adenocarcinoma plus Drug: Platinum (cisplatin or carboplatin)"
3079320|NCT02031601|Other|TKI alone therapy|"Interventions:~Drug: Erlotinib [Tarceva] or Gefitinib [Iressa] or Icotinib [Conmana]"
3079321|NCT02031588||Ceftriaxone|Patients receiving a C3G (ceftriaxone) during the hospitalization.
3079322|NCT02031588||Ceftriaxone + Fluoroquinolone|ceftriaxone followed by fluoroquinolone (which is a common situation in clinical practice, Fluoroquinolone being prescribed after obtaining antibiogram).
3079323|NCT02031588||Fluoroquinolones|fluoroquinolones (levofloxacin, ofloxacin, moxifloxacin or ciprofloxacin).
3079324|NCT02031588||Reference|"A third reference group will consist of patients hospitalized in the same services as the case patients but did not receive antibiotics (60 patients). They will have an idea of possible changes in flora during hospitalization without any antibiotics, for example due to horizontal transfer of resistant strains. This group will be composed of 60 patients who had not received antibiotics within 3 months before and not receiving for the duration of their participation."
3079325|NCT02031575|Experimental|Basic Treatment|Sends messages to participants about reproductive health.
3079326|NCT02031575|Experimental|Interactive Treatment|Sends multiple choice questions and receives texts message responses from participants with incentive for responding correctly
3079327|NCT02031575|Placebo Comparator|Control|Sends messages to students about malaria prevention and control.
3079328|NCT02031562|Active Comparator|Chiropractic|Chiropractic
3079329|NCT02031562|Active Comparator|Physical therapy|Physical therapy
3079330|NCT02031549||SpermComet Assay|All study subjects will have their surplus sperm analyzed for DNA fragmentation with the SpermComet assay.
3079331|NCT02031536|Experimental|Arm A (everolimus)|Patients receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3079332|NCT02031536|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD on days on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3079333|NCT02031523|Active Comparator|Sanjie analgesic capsule|every 4 capsules , 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.
3079334|NCT02031523|Placebo Comparator|placebo|every 4 capsules, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.
3079335|NCT02031510|Active Comparator|bupivacaine-dexmedetomidine|transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
3079336|NCT02031510|Active Comparator|bupivacaine|transversus abdominis plane block with bupivacaine 0.25%
3079337|NCT02031510|Placebo Comparator|placebo|Transversus abdominis block with saline 0.9%
3079338|NCT02031497|Experimental|Drink with sweeteners|
3079340|NCT02031471|Experimental|Tocilizumab|Adults with rheumatoid arthritis received a fixed dose of tocilizumab during the 24-week open-label core study and those entering the long term extension (LTE) period further received a fixed dose up to a maximum of 28 weeks or until tocilizumab was commercially available and/or reimbursed whichever came first. A fixed dose of 162 mg tocilizumab was administered subcutaneously once weekly.
3079341|NCT02031458|Experimental|Atezolizumab|
3079342|NCT02031445|Placebo Comparator|Placebo|BID
3079343|NCT02031445|Experimental|MRX-6|BID
3079344|NCT02031432|Experimental|cebranopadol|
3079345|NCT02031419|Experimental|CC-122 + CC-223 +/- rituximab|CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days
3079346|NCT02031419|Experimental|CC-122 + CC-292 +/- rituximab|CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-292 administered orally twice daily at 500 mg with or without Rituximab administered by IV once every 28 days
3079347|NCT02031419|Experimental|CC-292 + CC-223 +/- rituximab|CC-292 administered twice daily at 500 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days
3079348|NCT02031419|Experimental|CC-122 + rituximab|CC-122 administered orally once daily in combination with Rituximab.
3079349|NCT02031406|No Intervention|Usual care|No extra post-discharge pharmacist counseling is explicitly provided to patients, although some patients may receive it depending on their care setting
3079350|NCT02031406|Experimental|Post-discharge pharmacist counseling|Patients will receive post-discharge telephonic pharmacist counseling at around 72 hours after hospital discharge.
3079351|NCT02031393||singelton pregnancy|will be followed 11-14 weeks and 19-28 weeks of gestation and after birth
3079352|NCT02031393||twin pregnancy|will be followed 11-14 weeks and 19-28 weeks of gestation and after birth
3079353|NCT02031380|Experimental|Open angle glaucoma - iDropper device|Device
3079354|NCT02031367|Active Comparator|Corticosteroid|
3079355|NCT02031367|Experimental|Platelet Rich Plasma|
3079356|NCT02031354|Experimental|Lysine Chloride|
3079357|NCT02031341||Patients with type 2 diabetes mellitus|
3079358|NCT02031341||Normoglycemic individuals|Control group
3079359|NCT02031328|Experimental|Stereotactic Ablative Radiation|Stereotactic Ablative Radiation 26 Gy in 2 fractions, once weekly to prostate
3079360|NCT02031315||Resident of health areas of interest|Residents of 4 health areas will be monitored for sudden unexpected death within 72 months of follow up. Circumstances and past medical conditions will be checked.
3079361|NCT02031302||Lotus Valve|All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed the Informed Consent Form (ICF) and are selected to receive a Lotus Valve.
3079362|NCT02031302||Lotus with Depth Guard|All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed the Informed Consent Form (ICF) and are selected to receive a Lotus with Depth Guard.
3079363|NCT02031289|Active Comparator|Anemia|Hb < 120 g/L in women, Hb < 130 g/L in men Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
3079364|NCT02031289|Active Comparator|Iron deficiency|ferritin < 100 µg/l Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
3079365|NCT02031289|No Intervention|Natural comparison group|Patients without anemia or iron deficiency will be observed and the same postoperative measurements performed
3079366|NCT02031276|Experimental|ABBV-066 Low Dose IV (Double Blind Period 1)|Multiple, low doses of ABBV-066 by intravenous infusion
3079367|NCT02031276|Experimental|ABBV-066 High Dose IV (Double Blind Period 1)|Multiple, high doses of ABBV-066 by intravenous infusion
3079368|NCT02031276|Placebo Comparator|Placebo (Double Blind Period 1)|Multiple doses of placebo for ABBV-066 by intravenous infusion
3079369|NCT02031276|Experimental|ABBV-066 IV (Open-label Period 2)|Multiple, high doses of ABBV-066 by intravenous infusion
3079370|NCT02031276|Experimental|ABBV-066 SC (Open-label Period 3)|Multiple, low doses of ABBV-066 by subcutaneous injection
3079371|NCT02031263|Experimental|thermoplasty group|Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
3079372|NCT02031250|Active Comparator|Control Arm|Standard chemotherapy (Cisplatin or Carboplatin) and IMRT (Intensity-Modulated Radiation Therapy)
3079373|NCT02031250|Experimental|Boost Arm|Boost radiation to hypoperfused volumes in addition to standard chemotherapy (Cisplatin or Carboplatin) and IMRT (Intensity-Modulated Radiation Therapy)
3079374|NCT02031237|Other|Stereotactic Radiosurgery (SRS)|"Patients with brain metastases receiving single fraction Stereotactic Radiosurgery (SRS). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.~MRI scans will be performed approximately 1-2 weeks prior to SRS, and 1-2 weeks and 1 month after SRS. The MRI scan will include a routine clinical MRI series."
3079375|NCT02031237|Other|Whole Brain Radiation Therapy|"Patients with brain metastases receiving fractionated (spread out over time) Whole Brain Radiation Therapy (WBRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.~MRI scans will be performed approximately 1-2 weeks prior to RT, at the end of RT and 1 month after RT. The MRI scan will include a routine clinical MRI series."
3079376|NCT02031237|Other|Stereotactic Radiation Therapy|"Patients with brain metastases receiving fractionated (spread out over time) Stereotactic Radiation Therapy (FSRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.~MRI scans will be performed approximately 1-2 weeks prior to FSRT, during the last week of RT but before the last fraction and 1 month after RT. The MRI scan will include a routine clinical MRI series."
3079377|NCT02031224|Experimental|Keto-diet (KD)|Patients in the intervention arm (KD group) will receive a vegetarian very low protein diet (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.
3079378|NCT02031224|Active Comparator|Low Protein Diet group (LPD)|"The patients in the control arm (LPD group) will continue their conventional low protein diet, with 0.6 g/kg per day (including high biological value proteins).~The total recommended energy intake is of 30 kcal/kg of ideal dry body weight per day in both arms."
3079379|NCT02031211|Placebo Comparator|Placebo|0.4 ml/kg of normal saline will be administered subcutaneously.
3079380|NCT02031211|Experimental|Etanercept|Patient will receive 0.4 mg/kg of Etanercept subcutaneously twice weekly.
3079381|NCT02031198|Experimental|AADvac1|"Patients who have received 6 doses in the previous trial will be administered 1-2 booster doses of AADvac1 (2 if their antibody titers decline below those achieved in the previous trial).~Patients who have received 3 doses in the previous trial will be administered another 3 doses, then vaccinated with booster doses as above."
3079382|NCT02031185|No Intervention|Wait-list control|No intervention
3079383|NCT02031185|Experimental|FitBit only|Participants will use the FitBit device
3079384|NCT02031185|Experimental|FitBit and Text Messages|Participants will use the FitBit device and receive daily affective text messages
3079385|NCT02031172||Subjects with Dry Eye Disease|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
3079386|NCT02031172||Subjects with Sjogren's Syndrome|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
3079387|NCT02031172||Healthy Controls|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
3079388|NCT02031146|Other|LP|Participants undergo lumbar puncture for CSF evaluation
3079389|NCT02031146|No Intervention|No LP|Participants do not undergo lumbar puncture and CSF is not examined.
3079390|NCT02031107|Active Comparator|cTBS|A transcranial magnetic stimulator (MagPro X100, Medtronic Functional Diagnostics, Skovlunde, Denmark) will deliver continuous bursts of bipolar magnetic pulses exerting an inhibition on the underlying brain tissue (cTBS). The stimulation coil will be placed over the unaffected primary motor cortex. The stimulation protocol implies 200 bursts, each consisting of three pulses applied at 30 Hz, repeated at inter-burst intervals of 167 ms. Two stimulation trains of 30 s, separated by 15 min, will be applied 3 times per week for 3 weeks and will be immediately followed by physical therapy.
3079391|NCT02031107|Active Comparator|cathodal tDCS|A stimulator (NeuroConn GmbH, Illmenau, Germany) will deliver cathodal transcranial direct current stimulation (tDCS) of the unaffected motor cortex. The anode will be placed over the contralateral supraorbital region. Stimulation will be performed for 25 min, 3 times per week for 3 weeks during upper extremity treatment sessions.
3079392|NCT02031107|Sham Comparator|sham stimulation|This group will receive the same stimulation protocol as used for the active groups except that sham stimuli will be applied. Half of the patients receive sham cTBS, the other half sham tDCS.
3079393|NCT02031094||Major resection|Patients undergoing resection of >3 segments (resting energy expenditure measured by Sense Wear Armband and indirect calorimetry)
3079394|NCT02031094||Minor resection|Patients undergoing resection of </= 3 segments (resting energy expenditure measured by Sense Wear Armband and indirect calorimetry)
3079395|NCT02031081|Experimental|Treatment Period 1|A randomized assignment of prucalopride or placebo for a period of 28 days, crossover design
3079396|NCT02031081|Experimental|Treatment Period 2|A randomized assignment of either prucalopride or placebo for a period of 28 days, crossover design. Subjects who received active drug in Treatment Arm 1 will receive placebo and vice versa.
3079397|NCT02031068|Active Comparator|Treatment-as-usual (TAU)|"The TAU program will be implemented after the initial assessment. It will consist of 2 components:~An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms~A school consultation to provide teacher education, recommend accommodations, and facilitate return to school"
3079398|NCT02031068|Experimental|Behavioral:Active Rehabilitation Program|"The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:~Sub-maximal aerobic training for up to 15 minutes~Light coordination and sport-specific exercises for up to 10 minutes~Visualization and imagery techniques~Home program.~A physiotherapist will supervise the rehabilitation."
3079399|NCT02031055|Experimental|TAS-102 with light tracer dose of [14C]FTD|
3079400|NCT02031055|Experimental|TAS-102 with light tracer dose of [14C]TPI|
3079401|NCT02031016|Active Comparator|Fentanyl|"fentanyl bolus injections on an as needed base, next to the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium."
3079402|NCT02031016|Active Comparator|Remifentanil|remifentanil, starting with 0.15 ug/Ideal Body Weight(IBW)(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
3079403|NCT02031003|Other|Control|Standard infant formula
3079404|NCT02031003|Experimental|Experimental 1|Standard infant formula containing a new fat blend
3079405|NCT02031003|Experimental|Experimental 2|Standard infant formula containing a new fat blend and fiber
3079406|NCT02031003|No Intervention|Human Milk (HM)|Non-randomized Human Milk group
3079407|NCT02030990|Experimental|Mitomycin-C; 3 week FML steroid taper|Mitomycin-C 0.01% will be administered intraoperatively during PRK for 15 seconds. The patient will take a 3 week fluorometholone 1% topical steroid taper.
3079408|NCT02030990|Experimental|Mitomycin-C; 1 week FML steroid taper|Mitomycin-C 0.01% will be administered intraoperatively during PRK for 15 seconds. The patient will take a 1 week of fluorometholone 1% topical steroid.
3079584|NCT02029833|Active Comparator|Western Type Diet - Common Dietary Oils|Ghee, Safflower oil, Coconut oil, & flax oil
3079409|NCT02030990|Active Comparator|No mitomycin-C; 8 week FML steroid taper|No mitomycin-C will be administered during the procedure. Instead a sham application of salt solution will be given for 15 seconds. The patient will take 8 weeks of topical fluorometholone 1% topical steroid drop taper.
3079410|NCT02030977|Active Comparator|Resveratrol|"Active Comparator: Resveratrol~1 Resveratrol capsules for 12 weeks"
3079411|NCT02030977|Placebo Comparator|Placebo|one capsule per day
3079412|NCT02030964|Experimental|DFMO, Celecoxib, Cyclophosphamide & Topotecan|Reconstituted DFMO powder by mouth for 14 days and celecoxib capsule by mouth daily in each cycle. Cyclophosphamide and Topotecan IV on days 8-12 in cycle 1 and days 1-5 of cycles 2-17. Patients may continue for up to 17 cycles as long as therapy is tolerated (no DLT) and disease progression does not occur (SD or better). *Cycle 1 will include a 7 day lead-in with DFMO and celecoxib to deplete tumor polyamines.
3079413|NCT02030938|Experimental|SERI® scaffold implanted breasts|
3079414|NCT02030925|Experimental|IW-3718|Twice a day
3079415|NCT02030925|Placebo Comparator|Matching Placebo|Twice a day
3079416|NCT02030912|Active Comparator|3 doses of amoxicillin daily for 7 days|Cohort A: 3 doses of amoxicillin daily for 7 days (n=14). Follow up 12 months.
3079417|NCT02030912|Active Comparator|2 doses of minocycline daily for 5 days|Cohort B: 2 doses of minocycline daily for five days (n=14). Follow up 12 months.
3079418|NCT02030912|Placebo Comparator|2 doses of placebo daily for 5 days|Cohort C: 2 doses of placebo daily for five days (n=14). Follow up 12 months.
3079419|NCT02030899|Active Comparator|Cage|Cage filled with autologous bone
3079420|NCT02030899|Other|Plate|Plate augmentation after iliac bone graft
3079421|NCT02030886|Other|Ocular hypertension subjects|All subjects will be monitored by Sensimed Triggerfish for 24 hours.
3079422|NCT02030873|Experimental|Virtual simulation training first|Participants in this arm receive virtual simulation training before dissection training.
3079423|NCT02030873|No Intervention|Dissection training first|Participants in this arm receive dissection training first and then virtual simulation training.
3079424|NCT02030847|Experimental|Arm1|
3079425|NCT02030834|Experimental|Cohort A|murine CART19
3079426|NCT02030834|Experimental|Cohort B|T cell/histiocyte-rich Diffuse Large B Cell Lymphoma (DLBCL) treated with murine CART19
3079427|NCT02030834|Experimental|Cohort C|Diffuse Large B Cell Lymphoma (DLBCL) treated with humanized CART19
3079428|NCT02030821|Active Comparator|TXA|"TXA will be administered as a 1 gm dose IV prior to the procedure then as a repeat dose of 1 gram at the time of wound closure. These doses are currently used at Duke for TKAs and THAs per standard of care by the orthopaedic team.~All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization."
3079429|NCT02030821|Active Comparator|Amicar|"Administered 5g in 250mL of IV normal saline over 15 minutes prior to the procedure and then an infusion of 5g at the time of wound closure. These doses are currently used at Duke for TKAs and THAs per standard of care by the orthopaedic team.~All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization."
3079430|NCT02030808|Placebo Comparator|Muscle Relaxants (MR) group|Cisatracurium will be administered
3079431|NCT02030808|Active Comparator|Non- Muscle Relaxants (NMR) group|No cisatracurium will be administered
3079432|NCT02030795|Active Comparator|Disconnection group|The single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse.
3079433|NCT02030795|Active Comparator|Bronchial Suction group|The suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
3079434|NCT02030782|Active Comparator|Usual Care|Patients received usual care through primary care, enhanced by provider education regarding depression evaluation and management (1-2 hour training, plus study manual)
3079435|NCT02030782|Experimental|Quality Improvement for Depression|Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.
3079436|NCT02030769|Experimental|Pronase|Add pronase 20000 U in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.
3079437|NCT02030769|Sham Comparator|control|No pronase in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.
3079438|NCT02030756|Active Comparator|Vibrating capsule|patients will receive vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
3079439|NCT02030756|Sham Comparator|sham non-vibrating capsule|patients will receive sham non-vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
3079440|NCT02030743|Active Comparator|Visual training|Training in visual attention
3079441|NCT02030743|Placebo Comparator|Usual activity|Usual activity
3079442|NCT02030730|Experimental|Triple P Seminar Series|Intervention parents received the Seminar Series (Selected TripleP); three 90-minute seminars ('The Power of Positive Parenting', 'Raising Confident, Competent Children', and 'Raising Resilient Children'), including 60 minutes of scripted presentation material and 30 minutes question time for discussion. Parents received tip sheets with the material presented at the end of each seminar. The seminars were free of charge. The delivery of each seminar was 2 to 4 weeks apart.
3079443|NCT02030730|No Intervention|Leaflets on child health and development|An attention control group received leaflet information on child health and development provided by the Greek National Health Services of the Ministry of Health. They cover topics such as vaccinations, common childhood illnesses, first aid guide on severe injuries and cuts, and nutrition. The topics did not overlap with the topics of the Seminar Series or the general purpose of the study. Control families received the seminar tip sheets after 6-month follow-up.
3079444|NCT02030717|Experimental|Spinal anesthesia|The drugs used in the spinal injection are: 12 mg bupivacain, 160 ug morfin och klonidin( < 60 years 75 ug, 60 - 85 years old 60 ug and older than 85 years 45 ug)
3079445|NCT02030717|Active Comparator|Epidural anesthesia|Epidural anesthesia patients group gets an epidural catheter at level Th 8- 10 with per- and postoperative infusion with a routine mixture of: bupivacain 1 mg/ml, fentanyl 1 ug/ml, and adrenalin 1 ug/ml) until termination.
3079446|NCT02030704||Atherosclerotic Plaque|
3079447|NCT02030691|Experimental|nCPAP - nHFPV|Eligible patient received after randomization nCPAP or nHFPV for 15 minutes then after the 15 minutes, they received the seconde non invasive device for 15 minutes. Study end 30 minutes after randomization or before if mechanical ventilation is required.
3079448|NCT02030691|Experimental|nHFPV - nCPAP|Eligible patient received after randomization nCPAP or nHFPV for 15 minutes then after the 15 minutes, they received the seconde non invasive device for 15 minutes. Study end 30 minutes after randomization or before if mechanical ventilation is required.
3079449|NCT02030678|Experimental|irinotecan Hydrochloride|irinotecan , 100mg/m2, day1,day8, 3 cycles or till Progressive Disease or death
3079450|NCT02030665|Active Comparator|Standardized MET plus CB (SMET-CB)|Motivational Enhancement plus Cognitive-Behavioral treatment
3079451|NCT02030665|Experimental|SMET+ CM (SMET-CB-CM)|Motivational Enhancement plus CB treatment plus contingency management
3079452|NCT02030665|Experimental|Individualized Assessment & Treatment (IATP)|Individualized Assessment and Treatment Program; Cognitive-Behavioral Treatment based on in-depth field monitoring of patient behavior
3079453|NCT02030665|Experimental|IATP + CM (IATP-CM).|Individualized Assessment and Treatment plus Contingency Management
3079454|NCT02030652|Experimental|SNIPPV Group|Synchronized nasal intermittent positive pressure using NAVA ( Intermittent nasal positive pressure positive ventilation.)
3079455|NCT02030652|Active Comparator|CPAP Group|Nasal CPAP group without intermittent ventilation.
3079456|NCT02030639|Experimental|[14C]-rigosertib|A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib ([14C]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
3079457|NCT02030626|Experimental|active rTMS or active tDCS or placebo|Active rTMS (10 Hz) of the motor cortex followed by active tDCS (2 mA) of the motor cortex or conversely
3079458|NCT02030626|Placebo Comparator|Sham rTMS followed by tDCS (or conversely)|Placebo rTMD followed by placebo tDCS or conversely
3079459|NCT02030613|Other|Single arm: etanercept|Patients treated with etanercept for JIA
3079460|NCT02030600|Experimental|IDeg OD ± OADs followed by IGlar OD ± OADs|The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
3079461|NCT02030600|Active Comparator|IGlar OD ± OADs followed by IDeg OD ± OADs|The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
3079462|NCT02030587|Experimental|Radiofrequency Ablation|Radiofrequency Ablation
3079463|NCT02030587|Active Comparator|Laparoscopic Adrenalectomy|Laparoscopic Adrenalectomy
3079464|NCT02030574|Experimental|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
3079465|NCT02030561|Experimental|Trastuzumab + NK cells|"During cycle 1, Day 1 patient will receive intravenous trastuzumab and subcutaneous IL-2 on day 1, followed by NK cell infusion on day 2, followed by subcutaneous IL-2 for an additional 5 doses three times a week to support NK cell viability and expansion in vivo.~From cycles 2-4, patient will receive trastuzumab monotherapy alone every 21 days, except for patients who achieve objective tumor response after 2 cycles of therapy, who will then receive an additional infusion of NK cells along with trastuzumab during cycle 4 therapy at the same dose and schedule as in cycle 1.~Patients will be taken off study after cycle 4, unless the patient has objective tumor response after 4 cycles of therapy with only stable disease after cycle 2, in which case the patient will be given another 2 cycles of trastuzumab with an additional NK cell infusion during cycle 6 therapy at the same dose and schedule as in cycle 1."
3079466|NCT02030548||acute CABG|patients undergoing acute CABG with or without valve replacement during dual antiplatelet therapy
3079467|NCT02030535|Experimental|Tiotropium/Olodaterol FDC|patient will receive tiotropium and olodaterol in a fixed dose combination
3079468|NCT02030535|Experimental|Tiotropium and Olodaterol FC|patient will receive tiotropium and olodaterol in a free combination
3079469|NCT02030535|Placebo Comparator|Placebo|patient will receive placebo
3079470|NCT02030522|Experimental|Prospective Treatment Cohort of ART|The target population (n=200) of persons treated with the intervention, Accelerated Resolution Therapy, will consist of U.S. service members and veterans who have symptoms indicative of a current diagnosis of PTSD. No age limit or duration of symptoms of PTSD will be imposed for study eligibility, and it is anticipated that most, if not all, of eligible and enrolled participants will have had prior deployments to conflicts dating back to the 1970s, including the Vietnam War, Persian Gulf conflict, and wars in Iraq and Afghanistan. No person will be excluded on the basis of race, ethnicity, gender, or disability.
3079471|NCT02030509||New diagnosed patients of head and neck cancer|New diagnosed patients of head and neck cancer
3079472|NCT02030509||Old diagnosed head and neck cancer patients|
3079473|NCT02030496|Active Comparator|Closed reduction and plaster|Closed reduction will be performed and after adequate reduction has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks.
3079474|NCT02030496|Active Comparator|open reduction and internal fixation|The intervention group will be treated with open reduction and internal fixation with a volar locking plate.
3079475|NCT02030483|Experimental|All Subjects|Palbociclib (PD 0332991) will be given at a prespecified dose by cohort orally on days 1-14 of a 28-day cycle. For cycle 1 only, PD 0332991 will start on Day 0. Lenalidomide (Revlimid®) will be given at a prespecified dose by cohort orally on days 8-21 of a 28-day cycle (or days 1-21 as defined by dose cohort level). Dexamethasone (Decadron®) will be given orally at a dose of 20 mg on days 1, 8, 15, and 22 of a 28-day cycle. For cycle 1 only, the dexamethasone will be omitted on Day 1.
3079476|NCT02030470|Other|fotosan|
3079477|NCT02030457|Experimental|Treatment A|Treatment A: beclomethasone dipropionate BAI, 160 mcg - a single administration of 4 inhalations (40 mcg/inhalation)
3079478|NCT02030457|Experimental|Treatment B|Treatment B: beclomethasone dipropionate BAI, 320 mcg - a single administration of 4 inhalations (80 mcg/inhalation)
3079479|NCT02030457|Experimental|Treatment C|Treatment C: beclomethasone dipropionate MDI, 320 mcg - a single administration of 4 inhalations (80 mcg/inhalation)
3079480|NCT02030444|No Intervention|Standard diagnostic work-up|All patients will undergo todays' standard work-up (examination for diagnosing and staging) of lung cancer. This will be individualized for each patient according to current guidelines.
3079481|NCT02030444|Experimental|Extensive diagnostic work-up|All patients will in addition to standard diagnostic work-up undergo PET-MRI and systematic mediastinal and hilar lymph node mapping using EBUS-TBNA (endobronchial ultrasound transbronchial needle aspiration of lymph nodes).
3079482|NCT02030431|Active Comparator|Cancellous screws|Patients in this group are having osteosynthesis with three screws
3079483|NCT02030431|Active Comparator|Dynaloc|Patients in this group are having osteosynthesis with Dynaloc (three screws fixed in a small plate)
3079484|NCT02030418|Experimental|Leadless Pacemaker|VVIR pacing
3079485|NCT02030405|Experimental|Ixazomib (MLN9708)|Patients receive ixazomib PO on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3079486|NCT02030392|Experimental|Intervention group|"IG participation in the cognitive-behavioral program Stop the pain with Happy Pingu. The program compromises six weekly sessions for the children in small groups (90 min each) and 2 sessions for the parents (90 min each)."
3079487|NCT02030392|Active Comparator|Active control group|CG participation in an information and education control group (physical well-being, health and gastrointestinal tract). The program of the control group compromises six weekly sessions for the children in small groups (90 min each) and 2 sessions for the parents (90 min each).
3079488|NCT02030379|Experimental|Online QPL-CT to Oncologist|Use the online QPL-CT to prioritize their questions and the prioritized list will be conveyed to their oncologist
3079489|NCT02030379|Experimental|Online QPL-CT|Use the online QPL-CT to prioritize their questions.
3079490|NCT02030379|Experimental|Pencil and Paper QPL-CT|Use pencil and paper QPL-CT to prioritize their questions
3079491|NCT02030366||TBI patients|
3079492|NCT02030366||Healthy Volunteers|
3079493|NCT02030353|Experimental|Self-regulation plus activity monitoring|Participants will receive an individual in-person session, digital smart scale, access to a website to view tracking information, weekly lessons, tailored feedback, and activity monitoring.
3079494|NCT02030353|Experimental|Self-regulation|Participants will receive an individual in-person session, digital smart scale, access to a website to view tracking information, weekly lessons, and tailored feedback.
3079495|NCT02030353|No Intervention|Delayed intervention control|Participants will receive an individual in-person session and a digital smart scale, and a modified version of the self-regulation intervention after the 6-month assessment.
3079496|NCT02030340||Testing Lower urinary tract dysfunction|All patients with lower urinary tract dysfunction where urodynamic diagnosis is required according to standards and (international) practice guidelines will have a synchronous double system (combination of air-charged and water filled) urodynamic test.
3079497|NCT02030327||No trauma|n=5 patients
3079498|NCT02030327||trauma without organ dysfunction|n=40 patients
3079499|NCT02030327||trauma with organ dysfunction|n=40 patients
3079500|NCT02030314|Experimental|chlorthalidone, resistant high blood pressure|if Furosemide dose is 40 mg per day, start Chlorthalidone 12.5 mg per day if Furosemide dose is 80 mg per day, start Chlorthalidone 25 mg per day
3079501|NCT02030301|Experimental|VCL-HB01, 0.25-mL dose|VCL-HB01, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses
3079502|NCT02030301|Placebo Comparator|PBS, 0.25-mL dose|PBS, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses
3079503|NCT02030301|Experimental|VCL-HB01, 0.5-mL dose|VCL-HB01, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses
3079504|NCT02030301|Placebo Comparator|PBS, 0.5-mL dose|PBS, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses
3079505|NCT02030301|Experimental|VCL-HB01, 1-mL dose|VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 3 doses
3079506|NCT02030301|Experimental|VCL-HM01, 1-mL dose|VCL-HM01, 1-mL dose by intramuscular injection once every 28 days for 3 doses
3079507|NCT02030301|Placebo Comparator|PBS, 1-mL dose|PBS, 1-mL dose by intramuscular injection once every 28 days for 3 doses
3079508|NCT02030288|Experimental|Relational Agent|Relational Agent Intervention
3079509|NCT02030288|No Intervention|Treatment as Usual|Treatment as Usual
3079510|NCT02030275|Experimental|RXI-109|Treatment with RXI-109 on one side of revised scar and a placebo comparator on the other side. Treatment to begin either immediately or 2 weeks following the scar revision surgery.
3079511|NCT02030275|Placebo Comparator|Placebo|Treatment with RXI-109 on one side of revised scar and a placebo comparator on the other side. Treatment to begin either immediately or 2 weeks following the scar revision surgery.
3079512|NCT02030262|Experimental|Air|The participant will undergo epiretinal membrane peeling with fluid-air exchange. The remaining of the surgery is the same in all arms.
3079513|NCT02030262|Active Comparator|Sulfur hexafluoride (SF6)|The participant will undergo epiretinal membrane peeling with fluid-SF6 exchange. The remaining of the surgery will stay the same.
3079514|NCT02030249|Experimental|High Protein / Low Glycaemic Index|A 10-month weight maintenance diet, administered from the 2-month to the 12-month time point, where protein intake is 25% of energy intake, carbohydrate intake is 45% of energy intake, dietary glycaemic index is < 55. Please see parent study for further Arm details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview&rank=1
3079515|NCT02030249|Active Comparator|Moderate Protein / High Glycaemic Index|A 10-month weight maintenance diet, administered from the 2-month to the 12-month time point, where protein intake is 15% of energy intake, carbohydrate intake is 55% of energy intake, dietary glycaemic index is > 65. Please see parent study for further Arm details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview&rank=1
3079516|NCT02030236|Experimental|Cooling|
3079517|NCT02030223|Active Comparator|Transversus abdominis plane block with 20 ml ropivacaine 0,75%|Transversus abdominis plane block with 20 ml ropivacaine 0,75%
3079518|NCT02030223|Placebo Comparator|Transversus abdominis plane block with 20 ml saline|Transversus abdominis plane block with 20 ml saline
3079519|NCT02030210||cardiologists|
3079520|NCT02030210||study coordinators|
3079521|NCT02030210||registred nurses|
3079522|NCT02030197|Active Comparator|CRISP program|educational and socialization program
3079523|NCT02030197|Placebo Comparator|Control Group|no treatment control group
3079585|NCT02029820|Active Comparator|RenalGuard|Hydration with the device renalguard
3079586|NCT02029820|No Intervention|Saline|Hydration with saline 1ml/Kg/h for 12h
3079524|NCT02030184|Experimental|Topotecan and Rhenium Re 188 P2045|In the phase II portion of this study, patients will be screened using Technicium Tc99m. Eligible, consented patients will receive Topotecan treatment for three days, at doses of either 1.0 mg/m2 or 1.5 mg/m2. They will then receive a single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
3079525|NCT02030171|Active Comparator|PLURIHOC|-Functionnal reeducation : in hospital, intensive, multidisciplinary.
3079526|NCT02030171|Active Comparator|KIPLURI|-Functionnal reeducation : ambulatory, no intensive multidisciplinary.
3079527|NCT02030171|Active Comparator|KIMONO|-Functionnal reeducation : ambulatory, low-intensity
3079528|NCT02030158||Early Goal-Directed Therapy (EGDT)|Protocolised resuscitation (termed Early Goal-Directed Therapy - EGDT)
3079529|NCT02030158||Usual resuscitation|Usual resuscitation
3079530|NCT02030145|Active Comparator|Classic Thoracic Lymphatic Pump|Subjects begin with Classic Thoracic Lymphatic Pump, then crossover to Compressive Thoracic Lymphatic Pump after 4-week washout period.
3079531|NCT02030145|Experimental|Compressive Thoracic Lymphatic Pump|Subjects begin with Compressive Thoracic Lymphatic Pump, then crossover to Classic Thoracic Lymphatic Pump after 4-week washout period.
3079532|NCT02030132|Active Comparator|Feedback 50th Percentile|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on all 7 days. They will also be told the average for the 50th percentile in their arm. If the team's average daily step count is ≥ 7000 steps, the team will be eligible for the weekly lottery.
3079533|NCT02030132|Experimental|Feedback 75th Percentile|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on all 7 days. They will also be told the average for the 75th percentile in their arm. If the team's average daily step count is ≥ 7000 steps, the team will be eligible for the weekly lottery.
3079534|NCT02030132|Experimental|Feedback 50th Percentile + Forgiveness|At the end of each week, participants will be told (by email or text, based on the participant's preference) the average team's average daily step count for the previous week based on the best 5 of 7 days. They will also be told the average for the 50th percentile in their arm. If the team's average daily step count (best 5 of 7 days) is ≥ 7000 steps, the team will be eligible for the weekly lottery.
3079535|NCT02030132|Experimental|Feedback 75th Percentile + Forgiveness|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on the best 5 of 7 days. They will also be told the average for the 75th percentile in their arm. If the team's average daily step count (best 5 of 7 days) is ≥ 7000 steps, the team will be eligible for the weekly lottery.
3079536|NCT02030119|Active Comparator|Control|The participant will receive either an email or text message (based on the participant's preference) stating whether the participant achieved their goal for the prior day.
3079537|NCT02030119|Experimental|Gain Framing|Participants will be told that they will earn money for each day they walk at least 7000 steps. Each participant will receive either an email or text message (based on the participant's preference) stating whether or not he/she achieved the goal for the prior day and can collect the earnings. Non-adherent participants will receive messages about how much they would have earned had they met their target step goal.
3079538|NCT02030119|Experimental|Loss Framing|The participants will be told that their account has been credited a certain amount of money for the upcoming 30 days. However, for each day they do not meet their goal of at least 7000 steps, they will lose a small portion of that money. The participant will receive either an email or text message (based on the participant's preference) stating whether the participant achieved the goal for the prior day. Non-adherent participants will receive messages about how much the participant would have kept had they met the target step goal.
3079539|NCT02030119|Experimental|Daily Lottery|Each participant will be entered into a lottery daily, but participants will only be eligible to collect their winnings if they walked at least 7000 steps the day before. Participants will receive either an email or text message (based on the participant's preference) stating whether or not they won the lottery and if they met their target step goal. If both occur, the participant will be told how much money he or she won. Non-adherent participants will receive messages about how much they would have won had they met the target step goal.
3079540|NCT02030106||Prior Preterm Birth Patients|All obstetrical patients eligible for the study that have had a prior preterm birth.
3079541|NCT02030106||Term Birth Patients|All obstetrical patients eligible for the study that have not had a prior preterm birth.
3079542|NCT02030093||High-frequency telephone-based continuing care|High-frequency telephone-based continuing care
3079543|NCT02030093||Low-frequency telephone-based continuing care|Low-frequency telephone-based continuing care
3079544|NCT02030093||SMS group|SMS group
3079545|NCT02030093||Control group|Control group
3079546|NCT02030080|Active Comparator|Feedback 50th Percentile|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 50th percentile in their arm.
3079547|NCT02030080|Experimental|Feedback 75th Percentile|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 75th percentile in their arm.
3079548|NCT02030080|Experimental|Feedback 50th Percentile + Lottery|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 50th percentile in their arm. If their team's average daily step count is ≥ 7000 steps, they'll be eligible to collect winnings from a weekly lottery. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
3079549|NCT02030080|Experimental|Feedback 75th Percentile + Lottery|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 75th percentile in their arm. If their team's average daily step count is ≥ 7000 steps, they'll be eligible to collect winnings from a weekly lottery. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
3079550|NCT02030067|Experimental|RX-3117|All subjects will receive RX-3117.
3079551|NCT02030054|Active Comparator|atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) or rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
3079552|NCT02030054|Active Comparator|rosuvastatin|Patients were randomly assigned to atorvastatin (40 mg day) or rosuvastatin(20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
3079553|NCT02030041|Experimental|Simvastatin and placebo|"Eleven participants will be vitamin D deficient with LDL-C between 100 to 130mg/dl.~This arm will receive Simvastatin 40 mg once daily and placebo once weekly, and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week"
3079554|NCT02030041|Active Comparator|Simvastatin and vitamin D|"Eleven participants will be vitaminD deficient with LDL-C between 100 to 130mg/dl.~This arm will receive simvastatin 40 mg once daily and vitaminD 60,000 units once weekly , and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week"
3079555|NCT02030041|Active Comparator|Vitamin D and placebo|Eleven participants will be vitamin D deficient with LDL-C between 100 to 130mg/dl This arm will receive vitamin D 60,000 units once weekly and placebo once daily, and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week
3079556|NCT02030028|Other|ACTHAR Gel|Open label Adrenocorticotropic Hormone (ACTH) Gel for 12 weeks, 80u (1mL), given subcutaneously twice each week.
3079557|NCT02030015|Experimental|Syner-G Therapy Regimen|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet, and daily treatment with orally-administered miglustat, for the duration of the 60-month study.
3079558|NCT02030002|Experimental|APC Flash-Free Adhesive Coated Appliance System|APC Flash-Free Adhesive Coated Appliance System
3079559|NCT02030002|Active Comparator|APC II Adhesive Coated Appliance System|APC II Adhesive Coated Appliance System
3079560|NCT02029989|Experimental|Extended Treatment Group|Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference and Comprehensive Medication Management
3079561|NCT02029989|Active Comparator|Usual Treatment Group|Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference
3079562|NCT02029976|Active Comparator|attention control condition|Child and parent participants randomized to the attention control condition will receive a Newsletter Program or mailed monthly newsletter with general family-focused health information.
3079563|NCT02029976|Experimental|after school weight management program|The 9-month after school weight management program called SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together), with a focus on healthy food and activity practices will be directed by a school nurse and will include: 1) quarterly parent/child coaching sessions with the school nurse held in the participant's home; 2) 14 child group sessions led by the school nurse, held in a school setting 1-2 times a month; 3) 5 parent group sessions led by a school nurse held in a school setting; and 4) collaboration with health care providers and community-based organizations that provide families opportunities for healthy eating and activity. Mailed monthly newsletters
3079564|NCT02029963|Experimental|Cluster rTMS|Two weeks of daily repetitive Transcranial Magnetic Stimulation (total of 10 rTMS sessions), six months following completion of regular six-week rTMS treatment.
3079565|NCT02029963|Experimental|Taper rTMS|Immediately following completion of regular six-week repetitive Transcranial Magnetic Stimulation treatment, patients in this group will receive three sessions of rTMS a week for two weeks followed by two sessions of rTMS a week for two weeks (total of 10 rTMS sessions tapered in 4 weeks)
3079566|NCT02029963|Experimental|Treatment as Usual|Following their last session of regular six-week rTMS treatment, patients in this group will follow an individually-tailored maintenance plan as determined by their own psychiatrist or primary care provider
3079567|NCT02029950|Experimental|Treatment (combination chemotherapy, pomalidomide)|See Detailed Description
3079568|NCT02029937|Experimental|Proflavine, high resolution imaging|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
3079569|NCT02029937|No Intervention|Standard of care|No invention
3079570|NCT02029924|Experimental|BioChaperone insulin lispro|BioChaperone insulin lispro
3079571|NCT02029924|Active Comparator|Humalog®|Humalog®
3079572|NCT02029911|Experimental|Aurora Treatment Arm|Endometrial Ablation
3079573|NCT02029898|Active Comparator|Remifentanil|injectable solution, 0.5 microgramme/Kg for 30 seconds following by a continuous dose of 0.1 microgramme/kg/minute
3079574|NCT02029898|Placebo Comparator|Placebo|injectable solution 0.9% for the end of surgery
3079575|NCT02029885|Experimental|Investigational Therapy (Surround Sound)|Investigational Therapy using external focused ultrasound
3079576|NCT02029885|Sham Comparator|Sham Control|Blinded Sham Control Arm
3079577|NCT02029872|Active Comparator|Individual plus household|Standard decolonization regimen for individual plus household: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
3079578|NCT02029872|Active Comparator|Individual alone|Standard decolonization regimen for the individual alone: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily, plus a 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
3079579|NCT02029859|Experimental|Prevalence of obstructive sleep apnea syndrome|"Determine the prevalence of obstructive sleep apnea syndrome (OSA) in late pregnancy in a population of obese patients .~Polygraphic examination between 30 and 36 weeks of amenorhea"
3079580|NCT02029846|Active Comparator|Standard Treatment|A regimen with traditional drugs only
3079581|NCT02029846|Experimental|Incretin-based Treatment|A regimen including incretin-based drugs
3079588|NCT02029794|Experimental|HPV Self-collection|Subjects will self-collect a cervical-vaginal sample. One time use.
3079589|NCT02029794|Active Comparator|VIA arm|Standard of care in Uganda is visual inspection with acetic acid (VIA). Women randomized to this arm will undergo the following: Cervix examined by clinician using speculum and light source. Cervix then sprayed with 3-5% acetic acid, and then lesions described one minute after application of acetic acid. VIA negative no acetowhite lesions detected; positive is when dense aceto-white lesions are seen touching squamocolumnar junction
3079590|NCT02029781|Other|LAPP score|Use of the LAPP score during a diagnostic laparoscopy.
3079591|NCT02029768||Women with burn injury|
3079592|NCT02029768||Men with burn injury|
3079593|NCT02029755|Experimental|TAP block|postoperative analgesia with sono-guided transversus abdominis plane block and intravenous patient controlled analgesia (IV-PCA). Bilateral sono-guided TAP block will be performed after the induction of general anesthesia. 20 ml of 0.25% ropivacaine will be injected to the transversus abdominis plane under ultrasound guidance at each side (total 40 ml). IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
3079594|NCT02029755|Active Comparator|Local infiltration|postoperative analgesia with local anesthetics infiltration at surgical wound and intravenous patient controlled analgesia (IV-PCA). 20 ml of 0.5% ropivacaine will be injected at the surgical wound by the surgeon before the closure of wound. IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
3079595|NCT02029755|Active Comparator|PCA only|postoperative analgesia with intravenous patient controlled analgesia. IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
3079596|NCT02029742|Experimental|Community Health Worker Intervention|Community Health Workers will have scheduled interactions with subjects and will customize text messaging jointly with each youth and parent and initiate text message reminders to both parent and youth for months 4-6.
3079597|NCT02029742|Active Comparator|Education|Those randomized to the Education group will continue usual care, and will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
3079598|NCT02029729|Experimental|RTA 408 Capsules|RTA 408 capsules, beginning dose 2.5 mg once daily, 28-day cycle, up to 12 cycles. Doses will increase by 100% of previous dose (e.g., 5 mg, 10 mg, 20 mg, etc.) until such time the Protocol Safety Review Committee decreases the escalation rate to 50% of the previous dose (e.g., 20 mg, 30 mg, 45 mg, etc). Dose escalation will continue until Maximum Tolerated Dose is identified.
3079599|NCT02029716|Placebo Comparator|Part A|RTA 408 lotion 0.5%, 1%, and 3% and lotion vehicle applied to skin twice daily for 14 days
3079600|NCT02029716|Experimental|Part B|Up to 3% RTA 408 lotion applied to skin twice daily for 14 days (% concentration to be determined, based on results from Part A, ~100 cm2 surface area)
3079601|NCT02029716|Experimental|Part C|3% RTA 408 lotion applied to skin twice daily for 28 days (~500 cm2 surface area)
3079602|NCT02029703|Sham Comparator|Sham injection|Subjects randomized into this group will receive, under sterile conditions, a sham injection of lidocaine 1% (10 mg/ml) 1-2 ml. Sterile preparation of the affected knee (treatment site) and the sham injection procedure will take place after sterile preparation into subcutaneous tissue without involving treatment to the intra-articular joint. The sham procedure will be performed by the unblinded treating physician ONLY. This procedure will include an 22-25 gauge needle stick through the skin into the subcutaneous tissue without violating the joint capsule or performing arthrocentesis.
3079603|NCT02029703|Active Comparator|Synvisc-One Injection|Subjects randomized into the Synvisc-One group will receive a single 6 mL intra-articular injection of Synvisc-One under sterile conditions. The unblinded treating physician will prepare the treatment site according to his/her standard practice guidelines (i.e. after cutaneous numbing with a vasocoolant spray and / or local lidocaine injection), an 18 gauge needle will be advanced into one of three compartments of the knee using the injectors' technique of choice. Subjects will be monitored for a minimum 5 minutes post injection to evaluate for adverse events.
3079604|NCT02029690|Experimental|ADI-PEG 20|Arginine deiminase formulated with polyethylene glycol
3079605|NCT02029664|Experimental|Visual feedback distortion|Visual distortion increment based on the gait pattern
3079606|NCT02029651|Experimental|E-glove system|E-glove rehabilitation system for upper extremity
3079607|NCT02029651|Active Comparator|Conventional occupational therapy|conventional occupational therapy
3079608|NCT02029638|Experimental|Kidney Transplantation|
3079609|NCT02029625|Experimental|NVP-1205|administration of NVP-1205(rosuvastatin+ezetimibe)
3079610|NCT02029625|Active Comparator|rosuvastatin and ezetimibe|coadministration of rosuvastatin and ezetimibe
3079611|NCT02029612|Other|Group 1 - Phone Call Support|Smoking cessation telephone hotline phone number provided to participants, along with a 10 week supply of nicotine patches. Each participant counseled on quitting smoking at baseline. Questionnaires completed at baseline, 3 months, and at 6 months. Participant receives 11 phone calls from study staff over a 6-month period. Breath test performed at 3 month and 6 month visit.
3079612|NCT02029612|Other|Group 2 - Text Messaging Support|Participants receive 10 week supply of nicotine patches. Each participant counseled on quitting smoking at baseline. Questionnaires completed at baseline, 3 months, and at 6 months. Participants receive text messages for support about quitting smoking over a 6 month period. Breath test performed at 3 month and 6 month visit.
3079613|NCT02029599|Experimental|High dose group|Fang yi qing feng shi granule, Oral,10g, 3 times a day, Oral,for 3 months Methotrexate,Oral,7.5-15mg per week Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10.
3079614|NCT02029599|Experimental|Low dose group|"Fang yi qing feng shi granule,Oral,10g, 2 time a day, taking morning and evening,for 3 months.~placebo,Oral,10g, 1 time a day, taking noon ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10."
3079615|NCT02029599|Placebo Comparator|The placebo group|placebo,Oral,10g, 3 time a day ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10.
3079616|NCT02029586|Experimental|MB12066|
3079617|NCT02029586|Placebo Comparator|Placebo|
3079618|NCT02029573|Experimental|Atorvastatin in Combination With Radiotherapy and Temozolomide|
3079619|NCT02029547|Experimental|Physician Readers|Physician readers will interpret 60 Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to florbetapir (18F) as part of this study.
3079620|NCT02029534|Active Comparator|Atorvastatin 20 mg|atorvastatin 20 mg daily 2 to 7 days prior to surgery and up to 7 post surgery
3079621|NCT02029534|Experimental|Atorvastatin 80 mg|atorvastatin 80 mg daily 2 to 7 days prior to surgery and up to7 days post surgery
3079622|NCT02029521|Experimental|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg.
3079623|NCT02029521|Placebo Comparator|Placebo Calcium Citrate|The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
3079624|NCT02029508|Active Comparator|Epley maneuver|The group using modified Epley maneuver for PSCC BPPV
3079625|NCT02029508|Active Comparator|Semont maneuver|The group using Semont maneuver for PSCC BPPV
3079626|NCT02029508|Sham Comparator|Sham|The group using Reverse Epley maneuver for PSCC BPPV
3079627|NCT02029495|Experimental|210 mg brodalumab|Administered via subcutaneous injections
3079628|NCT02029495|Experimental|140 mg brodalumab|Administered via subcutaneous injection
3079629|NCT02029495|Placebo Comparator|Placebo|Administered via subcutaneous injection until week 24.
3079630|NCT02029482|Experimental|ACT-128800|ACT-128800 tablets, once daily for 3 days at each dose level: 10 mg, 20 mg, 40 mg, 60 mg, 80 mg, and 100 mg.
3079631|NCT02029482|Placebo Comparator|Placebo|Matching placebo tablets, once daily, for 18 days
3079632|NCT02029469|Experimental|HRA Device|Patients who will be treated with Ascension HRA device.
3079633|NCT02029456|Experimental|Low dose prolonged infusion arm|Low dose prolonged infusion of tPA arm (25mg Actilyse in 6 hours)
3079634|NCT02029443|Experimental|acalabrutinib|
3079635|NCT02029430|Experimental|aldoxorubicin|Subjects will receive either 100 or 150 mg/m2 (75, and 110 mg/m2 doxorubicin equivalents) by intravenous infusion (IVI) to 10 subjects in each group.
3079636|NCT02029417|Experimental|Treatment (cytarabine, omacetaxine mepesuccinate, decitabine)|"INDUCTION CHEMOTHERAPY: Patients receive cytarabine SC BID and omacetaxine mepesuccinate SC BID on days 1-14. Treatment for induction therapy repeats every 28 days for up to 4 courses or until patients achieve CR in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Patients alternate courses between decitabine and OAG. Patients receive decitabine IV on days 1-5. Patients alternate with OAG courses, comprising cytarabine SC BID on days 1-7 and omacetaxine mepesuccinate SC BID on days 1-7. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
3079637|NCT02029404|Active Comparator|Tibial nerve group|In the TN (tibial nerve ) group probe will be placed in popliteal cave to identify the popliteal artery and laterally the tibial nerve. Identified the tibial nerve we will proceed , previous local anaesthesia, to insert a catheter medially to tibial branch of the sciatic nerve according to in plane approach.
3079638|NCT02029404|Active Comparator|Tibial peroneal nerve group|"In the TPN (tibial -peroneal nerve) group the probe will be placed in popliteal cave to identify the popliteal artery and laterally the tibial nerve. Afterwards, proceeding cranially with the probe according to in plane approach, we will identify the confluence of tibial with peroneal branch and in this point, previous local anaesthesia, we will position the catheter within the confluence of peroneal and tibial nerve."
3079639|NCT02029391|Active Comparator|Myofascial pain syndrome patients|Manual pressure release only
3079640|NCT02029391|Experimental|Myofascial pain syndrome|One session of manual pressure release and kinesio tape
3079641|NCT02029378|Experimental|Eculizumab|Eculizumab, 900 mg intravenously once a week
3079642|NCT02029378|Placebo Comparator|Placebo|Matched placebo, intravenously once a week
3079643|NCT02029365|Other|Without eating disorders|Women consulting for infertility but without diagnosis of eating disorder.
3079644|NCT02029365|Other|With Eating disorders|Womenconsulting for infertility for which eating disorder is diagnosed.
3079645|NCT02029352|Experimental|Sinecatechins 10%|Patients are instructed to apply a thin layer of the sinecatechins 10% ointment twice daily (morning and evening) in a thin layer to the tumour including 5mm of the surrounding skin. Before applying a new layer patients are advised to wipe off the remnants. Sinecatechins 10% ointment has to be applied for six weeks. Patients are advised to wash their hands after each application to prevent spreading of the ointment.
3079646|NCT02029352|Placebo Comparator|Placebo|Patients are instructed to apply a thin layer of the placebo ointment twice daily (morning and evening) in a thin layer to the tumour including 5mm of the surrounding skin. Before applying a new layer patients are advised to wipe off the remnants. Sinecatechins 10% ointment has to be applied for six weeks. Patients are advised to wash their hands after each application to prevent spreading of the ointment.
3079647|NCT02029339|Experimental|triple-tube group|The patients were treated with continuous topical triple-tube irrigation and suction
3079648|NCT02029339|Active Comparator|SOC group|The patients were treated with standard of care (SOC) without topical irrigation
3079649|NCT02029313|Experimental|MKT-N2|Montelukast
3079650|NCT02029313|Active Comparator|Singulair|Montelukast sodium
3079651|NCT02029300|Other|Nasal Route|The nasal route will be when the airway is acquired and secured with a fiberoptic bronchoscope through one of the nares.
3079652|NCT02029300|Other|Oral Route|The oral route will be when the airway is acquired and secured with a fiberoptic bronchoscope through the patient's mouth.
3079653|NCT02029287||Subjects with CHF follow-up|Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up.
3079654|NCT02029274|Experimental|BAF312 0.5mg|BAF312 0.5 mg/day
3079655|NCT02029274|Experimental|BAF312 2mg|BAF312 2 mg/day
3079656|NCT02029274|Experimental|BAF312 10 mg|BAF312 10 mg/day
3079657|NCT02029274|Placebo Comparator|Placebo|placebo
3079658|NCT02029248||Children 6-7|Patients who are between 6 and 7 years old
3079659|NCT02029248||Children 8-11|Patients who are between 8 and 11 years old
3079660|NCT02029248||Children 12-16|Patients who are between 12 and 16 years old
3079661|NCT02029248||Patients 17-30|Patients who are between 17 and 30 years old
3079662|NCT02029235|Active Comparator|Acetaminophen/Ibuprofen (AIGU) Group|Acetaminophen 325 mg and Hydrocodone 5 mg
3079663|NCT02029235|Active Comparator|Acetaminophen/Hydrocodone (AH) Group|Acetaminophen 500 mg and Ibuprofen 400 mg
3080666|NCT02022241|Experimental|Repeated GnRHa|Patients were triggered with repeated GnRHa
3079664|NCT02029222||25 NSCLC patients|25 NSCLC patients who received curative radiotherapy. Re-irradiation can either be indicated for primary or secondary cancers in the lung. All patients referred for primary radiotherapy or chemoradiation after curative radiation therapy more or equal to one year ago with overlapping CTV will be included. The organs at risk of the primary tumor are the same organs at risk at the secondary treatment.
3079665|NCT02029209|Experimental|Anlotinib|Anlotinib QD orally and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3079666|NCT02029209|Placebo Comparator|Placebo Capsule|Placebo capsule QD orally and it should be continued until disease progression or patients withdrawal of consent
3079667|NCT02029196|Experimental|e-vapour product (EVP)|Subjects who switch from using conventional cigarettes to using an e-vapour product (EVP).
3079668|NCT02029196|Active Comparator|Conventional cigarette (CC)|Subjects who continue smoking their usual conventional cigarette (CC) brand.
3079669|NCT02029183|Experimental|bi-level positive airway pressure|bi-level positive airway pressure for 6 hour per night，total 7 days
3079670|NCT02029170|Experimental|Early weightbearing|After operative reduction and fixation of the fractures, patients allocated to the early weightbearing group start weightbearing after stitch out at 2 weeks and the application of a walking cast.
3079671|NCT02029170|Active Comparator|Non-weightbearing|Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
3079672|NCT02029157|Experimental|ARQ 197|Daily oral dose
3079673|NCT02029157|Placebo Comparator|Placebo|Daily oral dose
3079674|NCT02029131|Experimental|Exercise|
3079675|NCT02029131|No Intervention|Controls|
3079676|NCT02029118|Experimental|Herbal application on acupoint group|Containing the herbal medicine application on the specific acupoints plus foundation treatment
3079677|NCT02029118|Placebo Comparator|Placebo application on acupoint|Not containing herbal medicine application on the specific acupoints plus foundation treatment
3079678|NCT02029118|Placebo Comparator|Herbal application on non-acupoint group|Containing the herbal medicine application on the non-acupoints plus foundation treatment
3079679|NCT02029118|Sham Comparator|Placebo application on non-acupoint|Not containing herbal medicine application on the non-acupoints plus foundation treatment
3079680|NCT02029105||Mesothelin, hyaluronan, osteopontin, syndecan|The patients with pleural diseases
3079681|NCT02029092||Orsiro|
3079682|NCT02029079|Experimental|E+ drink, enriched with energy and nutrients.|The intervention consists of 300 ml E+ per day for 35 days in addition to a normal food intake. This means 525 kcal, and 22.5 gram protein extra per day for five weeks.
3079683|NCT02029079|No Intervention|Control|Subjects in the control group will be assessed in the same way and same time as the intervention group.
3079684|NCT02029066|Experimental|SR-T100 gel|dosage form: topical gel dosage: 2g of 2.3% SR-T100 frequency: once duration: 24 hours
3079685|NCT02029053|Other|Single Arm Study|Vaginal Lubrication Ring for Vaginal Dryness
3079686|NCT02029040|Experimental|3% hypertonic saline group|Once consented, the study drug (in this arm: 3% Hypertonic Saline) will be ordered by a physician at the request of a study team member. Once the drug order set is received by a pharmacist, he/she will obtain the study drug from an Omnicell and prepare the medication to a volume of 3 mL in a syringe with a blinded study label prepared in advance by the IDS pharmacy. The pharmacist will then give the study drug to the patient's respiratory therapist or the bedside nurse. The respiratory therapist or the nurse will pour the drug from a syringe to an inhaler cup and the study drug will be given by the standard nebulizer over the course of 15 minutes.
3079687|NCT02029040|Placebo Comparator|0.9% normal saline group|Once consented, the study drug (in this arm: 0.9% normal saline) will be ordered by a physician at the request of a study team member. Once the drug order set is received by a pharmacist, he/she will obtain the study drug from an Omnicell and prepare the medication to a volume of 3 mL in a syringe with a blinded study label prepared in advance by the IDS pharmacy. The pharmacist will then give the study drug to the patient's respiratory therapist or the bedside nurse. The respiratory therapist or the nurse will pour the drug from a syringe to an inhaler cup and the study drug will be given by the standard nebulizer over the course of 15 minutes.
3079688|NCT02029027|Experimental|GYNEFFIK(R)|30 min-session of vaginal electro-stimulation by GYNEFFIK thrice a week for 6 months (except during menstrual periods)
3079689|NCT02029027|Other|Usual Care|Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
3079690|NCT02029014|Experimental|LAmbre closure system|
3079691|NCT02029001|Experimental|Arm A: Maintenance treatment|"Patients will continue targeted treatment matching the molecular alterations identified in their tumor for a maximum of 136 weeks starting from the date of patient's first study drug intake following inclusion. In case of on-treatment disease progression, the patient will permanently discontinue treatment and will be withdrawn from study.~Targeted treatments available in the study are: nilotinib, everolimus, sorafenib, lapatinib, pazopanib, olaparib, durvalumab + tremelimumab"
3079692|NCT02029001|No Intervention|Arm B:Interruption of targeted treatment|Targeted treatment received during induction period will be discontinued until a first documented off-treatment disease progression occurs. At progression, treatment reintroduction may be proposed to the patient (left at the investigator's appreciation, and upon patient approval) and treatment may be continued until on-treatment disease progression, unacceptable toxicity or for a maximum of 136 weeks from the date of patient's first study drug intake following inclusion. If the investigator considers that the treatment cannot be safely reintroduced (regarding patient's condition and/or laboratory results), the patient will be withdrawn from study.
3079693|NCT02028988|Experimental|Enzalutamide with External Beam Radiation|On this study patients will be treated with 6 months of Xtandi (enzalutamide). Approximately one-third of the way through this treatment they will receive EBRT. Starting on Day 1, all patients will ingest enzalutamide 160 mg/day at the same time each day without breaks (except as outlined for toxicity), with or without food, for 6 (28 day +/-3 days) cycles. Dose reduction of enzalutamide to 120 mg/day is allowed with the approval of the Medical Monitor. Patients will be instructed to return all unused capsules at each study visit to assess compliance and will receive study drug every 28 days (+/-3 days) for 6 cycles (24 weeks).
3079694|NCT02028975|Other|Patients with type 2 diabetes|
3079695|NCT02028975|Other|Obese patients without diabetes|
3079697|NCT02028962|Experimental|Lifestyle counseling|The experimental group will receive three letters with advices for smoking cessation-the first letter after the enrolment in the study, the second one one month after the first letter, the third one three months after the first letter
3079698|NCT02028962|No Intervention|Control|
3079699|NCT02028949|Experimental|Chemo-lipiodol|
3079700|NCT02028936|Experimental|Grape juice rich in polyphenols|
3079701|NCT02028936|Active Comparator|grape juice not enriched with polyphenols|
3079702|NCT02028923|Experimental|Morphine gel|morphine 30 mg, quantity of gel per application: 15mg (15ml)
3079703|NCT02028923|Placebo Comparator|Neutral gel|water for injection, quantity of gel per application: 15mg (15ml)
3079704|NCT02028910|Experimental|Ondansetron|"The treatments in the form of cases numbered 1 vial of 50 ml of ondansetron 0.8 mg / ml oral solution + 5 ml syringe for oral administration.~No special storage conditions ondansetron syrup.The treatment is administered orally as a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed a maximum dose of 10mg. A second outlet, at the same dose, is restored if the child vomits within 15 minutes after the first administration."
3079705|NCT02028910|Placebo Comparator|placebo|"The treatments in the form of cases numbered 1 vial of 50 ml of placebo 0.8 mg / ml oral solution + 5 ml syringe for oral administration.~No special storage conditions placebo syrup.The treatment is administered orally as a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed a maximum dose of 10mg. A second outlet, at the same dose, is restored if the child vomits within 15 minutes after the first administration."
3079706|NCT02028897|Active Comparator|Conventional embryo culture|Conventional embryo culture in dishes, in droplets under oil.
3079707|NCT02028897|Experimental|Alternative embryo culture|Embryo culture in system using small enclosed containers
3079708|NCT02028884|Experimental|satralizumab (SA237)|Subcutaneous satralizumab (SA237)
3079709|NCT02028884|Placebo Comparator|Placebo|Subcutaneous placebo
3079710|NCT02028871|Experimental|Intranasal Insulin|Intranasal Insulin
3079711|NCT02028871|Placebo Comparator|Placebo|Placebo
3079712|NCT02028845|Active Comparator|Loop guidewire|This study has two arms. We will compare the performance of a loop-tipped guidewire with a straight-tipped guidewire in achieving successful deep biliary cannulation with loop guidewire.
3079713|NCT02028845|Active Comparator|Straight guidewire|This study has two arms. We will compare the performance of a loop-tipped guidewire with a straight-tipped guidewire in achieving successful deep biliary cannulation with straight guidewire.
3079714|NCT02028832|Active Comparator|Usual care|Usual care provided to pediatric inpatients
3079715|NCT02028832|Experimental|PIM consult and service provision|Pediatric integrative medicine service (PIM) through which pediatric inpatients will have the option of supplementing their usual care with acupuncture/acupressure, massage, and/or reiki
3079716|NCT02028806|Experimental|FOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
3079717|NCT02028793||Pharmacists provide pharmaceutical care|The group is the community pharmacists who attend the protocol to provide home visit to the patients with heavy health expenditure, through pharmaceutical care approach.
3079718|NCT02028780|Experimental|Idarucizumab single doses|different infusion durations
3079719|NCT02028780|Experimental|Idarucizumab with dabigatran|short infusion with 2 capsules dabigatran
3079720|NCT02028767|Experimental|Fixed Dose Combination (FDC)|12.5 mg Empagliflozin / 500mg metformin fixed dose combination
3079721|NCT02028767|Active Comparator|Separate tablets|Empagliflozin and Metformin tablets
3079722|NCT02028754|Experimental|Sodium Carboxymethylcellulose and Conventional Therapy|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days plus conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
3079723|NCT02028754|Active Comparator|Conventional Therapy|Conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
3079724|NCT02028741|Experimental|symptomatic intervention group|Paitients with mechanical neck pain were treated with transverse vertebral pressures
3079725|NCT02028741|Sham Comparator|aymptomatic non-intervention group|Sham treatment to aymptomatic subjects
3079726|NCT02028728||Orsiro|
3079727|NCT02028715|Placebo Comparator|Control|Morphine patient-controlled-anesthesia (PCA) for the initial 24 hours post-operation with a low-dose basal rate (0.5mg/hr) and patient administered boluses prn. Oral oxycodone from 24-48 hours post-operation will be used prn for pain and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay. Normal saline 100cc IV will be infused as placebo every 6 hours for a total of eight doses with the first dose being given at time of anesthesia induction.
3079728|NCT02028715|Active Comparator|Experimental (IV Acetaminophen)|Morphine PCA for the initial 24 hours post-operation with low-dose basal rate (0.5mg/hr) with patient administered boluses prn. IV acetaminophen 1,000mg will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction. Oral oxycodone from 24-48 hours post-operation will be used prn and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay.
3079729|NCT02028702|Active Comparator|Red Clover extract|150 ml/d Red Clover extract
3079730|NCT02028702|Placebo Comparator|Placebo|150 ml/d sweetened and coloured water
3079731|NCT02028689|Experimental|Lesinurad and Metformin|"Sequence A- Day 1: Metformin 850 mg; Day 5: Lesinurad 400 mg with metformin 850 mg~Sequence B- Day 1: Lesinurad 400 mg with metformin 850 mg; Day 5: Metformin 850 mg"
3079732|NCT02028689|Experimental|Lesinurad and Furosemide|"Sequence C - Day 1: Furosemide 40 mg; Day 5: Lesinurad 400 mg with furosemide 40 mg~Sequence D - Day 1: Lesinurad 400 mg with furosemide 40 mg; Day 5: Furosemide 40 mg"
3079733|NCT02028676|Experimental|Clinically Driven Monitoring (CDM)|
3079734|NCT02028676|Active Comparator|Laboratory plus Clinical Monitoring (LCM)|
3079958|NCT02027194|Placebo Comparator|Placebo group|In syrup form (wheat powder with ginger and flavors), 20 ml once daily for 4 weeks
3079959|NCT02027181|Experimental|device FreeO2|Automatic adjustment of oxygen
3079735|NCT02028676|Active Comparator|Arm A: abacavir (ABC)+lamivudine (3TC)+NNRTI|ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO non-nucleoside reverse transcriptase inhibitor (NNRTI): either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
3079736|NCT02028676|Experimental|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|ZDV [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO NNRTI: either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
3079737|NCT02028676|Experimental|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|ZDV [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO NNRTI: either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
3079738|NCT02028676|Experimental|Once-daily ABC+3TC|ABC [abacavir]: syrup or tablet, dosed once-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed once-daily according to weight-bands following WHO
3079739|NCT02028676|Active Comparator|Twice-daily ABC+3TC|ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO
3079740|NCT02028676|Active Comparator|Continued cotrimoxazole prophylaxis|Once-daily doses 5-<15 kg: 200 mg of trimethoprim + 40 mg sulfamethoxazole 15-<30 kg: 400 mg trimethoprim + 80 mg sulfamethoxazole >=30 kg: 800 mg trimethoprim + 160 mg sulfamethoxazole
3079741|NCT02028676|Experimental|Stopped cotrimoxazole prophylaxis|Children had been taking once-daily cotrimoxazole prophylaxis since at least ART initiation. Children randomised to this experimental arm stopped taking cotrimoxazole prophylaxis.
3079742|NCT02028663|Experimental|CJ-12420 Amg|50 volunteers will be administered CJ-12420 Amg
3079743|NCT02028663|Experimental|CJ-12420 Bmg|50 volunteers will be administered CJ-12420 Bmg
3079744|NCT02028663|Experimental|CJ-12420 Cmg|50 volunteers will be administered CJ-12420 Cmg
3079745|NCT02028663|Active Comparator|Esomeprazole 40mg|50 volunteers will be administered Esomeprazole 40mg
3079746|NCT02028650||the first donor|the original donor applicable patients were assigned to receive the first donor's stem cell treatment after G-CSF mobilization or combination chemotherapy
3079747|NCT02028650||the second donor|HLA-mismatched, the second donor's stem cell infusion
3079748|NCT02028637|Experimental|toll like receptor (TLRs)|TLRs are a family of proteins responsible for the recognition of Pathogen-Associated Molecular Patters
3079749|NCT02028624|Experimental|Face-to-face|Patients received face-to-face nutrition counseling.
3079750|NCT02028624|Experimental|Telephone|Patients received telephone nutrition counseling.
3079751|NCT02028624|No Intervention|Minimum Intervention|Patients in this group received no further lifestyle-related counseling and contact until the 6-month evaluation.
3079752|NCT02028598|Experimental|Sequence A|Treatment 1 - Treatment 2 - Treatment 3
3079753|NCT02028598|Experimental|Sequence B|Treatment 1 - Treatment 3 - Treatment 2
3079754|NCT02028598|Experimental|Sequence C|Treatment 2 - Treatment 1 - Treatment 3
3079755|NCT02028598|Experimental|Sequence D|Treatment 2 - Treatment 3 - Treatment 1
3079756|NCT02028598|Experimental|Sequence E|Treatment 3 - Treatment 1 - Treatment 2
3079757|NCT02028598|Experimental|Sequence F|Treatment 3 - Treatment 2 - Treatment 1
3079758|NCT02028585|Active Comparator|Low-fat milk group|The low-fat milk group was instructed to consume 2 packs of low-fat milk per day (200 mL twice daily) for 6 weeks.
3079759|NCT02028585|No Intervention|Control group|Control group maintained their usual diet without low-fat milk supplement.
3079760|NCT02028572||Primary open angle glaucoma|Subjects diagnosed to have primary open angle glaucoma with intraocular pressure > 21 mm Hg and characteristic glaucomatous damage to the optic nerve.
3079761|NCT02028559|Experimental|Treatment|Subjects receive treatment with study device.
3079762|NCT02028546|Experimental|Water|The patients in water group were soaking an arm for 10 minutes with tap water before application of moisturizer. (Excepted the 4th regimen included no bathing, waited for 10 minutes and followed by moisturizer application.)
3079763|NCT02028546|Experimental|mild cleanser|The patients in mild cleanser group were soaking an arm for 10 minutes with mild cleanser before application of moisturizer. (Excepted the 4th regimen included no bathing, waited for 10 minutes and followed by moisturizer application.) Non soap base cleanser contained Sodium Cocoyl Isethionate was used in this mild cleanser arm.
3079764|NCT02028533|Active Comparator|Patients|Participants will receive intranasal oxytocin 40 International Units (IU) or inactive placebo twice daily for two weeks
3079765|NCT02028507|Experimental|Palbociclib plus Exemestane or Fulvestrant|"Palbociclib 125 mg orally once daily on Day 1 to Day 21 followed by 7 days off treatment on every 28 days cycles in combination with~Cohort 1: Exemestane 25 mg orally once daily.~Cohort 2: Fulvestrant 500 mg on Days 1 and 15 of Cycle 1, and Day 1 of each subsequent 28 days Cycle."
3079766|NCT02028507|Active Comparator|Capecitabine|Capecitabine, 1,250 mg/m2 twice daily for 2 weeks followed by a 1 week rest period, given as 3 weeks cycles. Capecitabine must be administered at a dose of 1,000 mg/m2 twice daily for 2 weeks followed by a 1 week of rest period, given as 3 weeks cycles, in patients over 70 years of age.
3079767|NCT02028494|Experimental|Arm A: Capecitabine 2,000 mg (flat dose)|Arm A: Capecitabine 2,000 mg (flat dose), orally, twice daily for 7 days followed by a 7 day rest (7-7) (4-week cycle length ).
3079806|NCT02028247|Experimental|Personalized Cognitive-behavioral therapy|Personalized Cognitive-behavioral therapy involves 16 weekly individual therapy sessions, up to 90 minutes each, based on a treatment protocol that has been designed specifically for youth with high-functioning autism spectrum disorders.
3079768|NCT02028494|Active Comparator|Arm B: Capecitabine 1,000 mg/m2 twice daily for 14 day|Arm B: Capecitabine 1,000 mg/m2, orally, twice daily for 14 days followed by a 7 day rest (14-7) (3-week cycle length ). The control arm dose of capecitabine has been reduced from the US Food and Drug Administration approved dose of 1,250 mg/m2, orally, twice daily due to common clinical practice.
3079769|NCT02028481|Experimental|Postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
3079770|NCT02028468|Active Comparator|Anterolateral Approach|Patient Operated with Watson Jones Approach
3079771|NCT02028468|Active Comparator|Trans-gluteal Approach|Patient operated with Trans-gluteal Hardinge Approach
3079772|NCT02028455|Experimental|Cohort 1|This cohort will determine the maximum tolerated dose of the Patient Derived CD19 specific CAR T cells also expressing an EGFRt and is restricted to patients with a prior history of allo-HCT
3079773|NCT02028455|Experimental|Cohort 2A|This cohort is for patient who have a history of allo-HCT with recurrence of disease post HCT and they will receive the MTD of Patient Derived CD19 specific CAR T cells also expressing an EGFRt determined in cohort 1.
3079774|NCT02028455|Experimental|Cohort 2B|This cohort is restricted to patients wtih no prior history of allo-HCT and they will receive the MTD of Patient Derived CD19 specific CAR T cells also expressing an EGFRt determined in cohort 1
3079775|NCT02028442|Experimental|Enadenotucirev|
3079776|NCT02028429|Experimental|Intervention 'Sildenafil'.|MHE patient receiving Sildenafil. Intervention: Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
3079777|NCT02028429|No Intervention|'No sildenafil'|Control Arm: MHE patients not receiving SIldenafil Intervention.Followed up for 4 weeks.
3079778|NCT02028416|Active Comparator|ATG-Fresenius 3 Days|In one group Injection ATG-Fresenius will be given @ 10mg/kg will be given for 3 days along with Capsule Cyclosporin 5mg/kg for 6 months followed by very slow tapering of dose
3079779|NCT02028416|Experimental|ATG-Fresenius 5 Days|In other arm injection ATG will be given @10mg/Kg for 5 days (different dose regimen, according to the randomization) with capsule Cyclosporin@5mg/Kg (same dose) for 6 months followed by very slow tapering. There is a difference of days of treatment received i-e 5 days.
3079780|NCT02028403|Experimental|Cohort 1A: single dose 0.3 mg/kg BMS-936559|Participants will receive 0.3 mg/kg of BMS-936559, administered as a single infusion once at study entry.
3079781|NCT02028403|Placebo Comparator|Cohort 1B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
3079782|NCT02028403|Experimental|Cohort 2A: single dose 1 mg/kg BMS-936559|Participants will receive 1 mg/kg of BMS-936559, administered as a single infusion once at study entry.
3079783|NCT02028403|Placebo Comparator|Cohort 2B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
3079784|NCT02028403|Experimental|Cohort 3A: single dose 3 mg/kg BMS-936559|Participants will receive 3 mg/kg of BMS-936559, administered as a single infusion once at study entry.
3079785|NCT02028403|Placebo Comparator|Cohort 3B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
3079786|NCT02028403|Experimental|Cohort 4A: single dose 10 mg/kg BMS-936559|Participants will receive 10 mg/kg of BMS-936559, administered as a single infusion once at study entry.
3079787|NCT02028403|Placebo Comparator|Cohort 4B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
3079788|NCT02028390|Experimental|subjects with external wounds|Subjects with external wounds or body surface areas of interest are imaged visually and thermally with the Scout to trace the wound's perimeter visually and measure thermal variation data as described in the primary outcomes, using the ImageReview software.
3079789|NCT02028377|Experimental|Imaging|PET/MRI
3079790|NCT02028364|Experimental|Everolimus given in conjunction with exemestane|Everolimus 10mg orally daily given in conjunction with exemestane 25mg orally daily until disease progression or treatment discontinuation for any other reasons.
3079791|NCT02028351||Normal|No Intervention
3079792|NCT02028351||Cataract|No intervention
3079793|NCT02028351||Maculopathy|No Intervention
3079794|NCT02028338|Experimental|Dapivirine ring|dapivirine vaginal ring (25 mg)
3079795|NCT02028338|Placebo Comparator|Placebo ring|silicone vaginal ring
3079796|NCT02028325|Experimental|Fluorescein Sodium|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
3079797|NCT02028312|Active Comparator|Loteprednol etabonate + Restasis|Loteprednol Etabonate Ophthalmic Gel 0.5%, BID 30 days Restasis, BID 45 days
3079798|NCT02028312|Placebo Comparator|Artificial Tears + Restasis|Artificial Tears, BID 30 days Restasis, BID 45 days
3079799|NCT02028299|Experimental|2D doppler echo with Definity solution|Study subjects will already be scheduled for right heart catheterization to diagnose pulmonary hypertension. Prior to the catheterization, each subject will have a 2D doppler echocardiogram with Definity solution as well.
3079800|NCT02028286|Experimental|CLS001|CLS001
3079801|NCT02028273||Control|Healthy control group. No history of substance abuse or dependence.
3079802|NCT02028273||Actively using patients|Participants actively using cocaine.
3079803|NCT02028273||Abstinent Patients|Participants who have been abstinent from cocaine use for 3-6 months.
3079804|NCT02028260|Active Comparator|Modafinil|Modafinil 200 mg qAM enterally for the duration the patient is confirmed to be in a hypoactive delirium to a maximum of 14 days.
3079805|NCT02028260|Placebo Comparator|Placebo|normal saline
3079951|NCT02027246|Experimental|Stem cell|Autologous bone marrow mononuclear cell transplantation
3079807|NCT02028247|Active Comparator|Standard Practice Cognitive-behavioral therapy|Standard Practice Cognitive-behavioral therapy involves 16 weekly individual therapy sessions, up to 60 minutes each, based on a treatment protocol that represent the standard practice psychotherapy for anxiety that has been found to be effective in multiple trials in youngsters without autism spectrum disorders.
3079808|NCT02028247|No Intervention|Waitlist condition|Participants randomized to the Waitlist condition will be asked to refrain from seeking out psychotherapy for anxiety as well as making psychiatric medication changes (if applicable) for a 16-week period.
3079809|NCT02028234|Active Comparator|pantoprazole|Patients were randomly assigned to omeprazole (20 mg day) or pantoprazole (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
3079810|NCT02028234|Active Comparator|Omeprazole|Patients were randomly assigned to omeprazole (20 mg day) or pantoprazole (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
3079811|NCT02028221|Placebo Comparator|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
3079812|NCT02028221|Experimental|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the remaining duration of he intervention period.
3079813|NCT02028208|Experimental|Mercury, Aluminum or Palladium Subjects|Subjects will be patch tested with ascending doses of mercury, aluminum or palladium and a negative control and a second panel containing the marketed reference allergen. The panels will be worn for approximately 48 hours. Skin reactions will be assessed at 3, 4 and 21 days following application.
3079814|NCT02028195|Experimental|Health check|The intervention consists of invitation for a behavioural and clinical examination followed by either (I) referral to a health promoting consultation in general practice (II) targeted behavioural programmes at the local Health Centre or (III ) no need for follow-up.
3079815|NCT02028195|No Intervention|No invitation|The persons randomised to the control arm does not get invitation to a health care examination before time for follow up in the intervention group.
3079816|NCT02028182|Experimental|Lyral® Sensitive Subjects|Subjects were patch tested with one experimental T.R.U.E. Test allergen panel containing 0.40 mg/cm^2, 0.20 mg/cm^2, and 0.10 mg/cm^2 of Lyral® and a negative control and a second panel containing the marketed reference allergen (20 mg of Lyral® 5%, in petrolatum). The panels were worn for approximately 48 hours. Skin reactions were assessed at 3, 4 and 21 days following application.
3079817|NCT02028169||Participants Receiving Anti-TNF for PsA|Participants who are actively working (full-time or part-time) with rheumatologist-confirmed PsA for which the physician has initiated treatment with an anti-TNF.
3079818|NCT02028156|Experimental|Partially Hydrolyzed Infant Formula|Fed ad lib.
3079819|NCT02028143|Experimental|Study arm|The study arm group will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
3079820|NCT02028143|Active Comparator|Control arm|The control arm group will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
3079821|NCT02028130|Experimental|LAA electrical isolation + occlusion|Standard persistent AF ablation protocol + LAA electrical isolation + Watchman device implantation to occlude LAA
3079822|NCT02028117|Experimental|Enadenotucirev|
3079823|NCT02028104|Experimental|stem cells|autologous bone marrow mononuclear cell transplantation
3079824|NCT02028091||Diabetes mellitus|All patients over 18 years with diagnosed diabetes mellitus type II.
3079825|NCT02028091||Non Diabetic|Patients over 18 years with no known diabetes mellitus or other known/diagnosed vascular diseases.
3079826|NCT02028078|Experimental|Insulin human (Actrapid)|At 22:00 subject will receive insulin human (Actrapid) intravenously in order to obtain a steady state of a PG level of 5.5 mmol/L overnight until approximately 08:00 in the morning of day 2. At 8:00 am, in the morning at day 2, human insulin infusion will be increased to 1.5 mU/kg/min for each subject until approx. 12 pm for hypoglycaemia induction.
3079827|NCT02028065|Experimental|Sugammadex 4 mg/kg|Administration of 3 single IV doses of sugammadex 4 mg/kg, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
3079828|NCT02028065|Experimental|Sugammadex 16 mg/kg|Administration of 3 single IV doses of sugammadex 16 mg/kg, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
3079829|NCT02028065|Placebo Comparator|Placebo|Administration of 3 single IV doses of placebo, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
3079830|NCT02028052|Other|ROSE|In the case of ROSE, sampling frequency will occur similarly, but no additional samples will be taken in the case of provision of a preliminary diagnosis.
3079831|NCT02028052|Other|NO ROSE|In the case of no ROSE, sampling frequency will be predetermined at 4 needle aspirations per site
3079832|NCT02028039|Experimental|IPI-145|IPI-145 given at dose of 75 mg orally twice daily for 4 weeks. Courses repeated about every 4 weeks (range 4-6 weeks).
3079833|NCT02028026|Experimental|Vilazodone|10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
3079834|NCT02028026|Active Comparator|Citalopram|20 mg/day for 2 weeks and then 40 mg/day for 6 weeks.
3079835|NCT02028000|Active Comparator|INSORB staples skin closure|Women undergoing cesarean section delivery will have skin closure with INSORB staples.
3079836|NCT02028000|Active Comparator|Monocryl skin closure|Women undergoing cesarean section delivery will have skin closure with Monocryl.
3079837|NCT02028000|Active Comparator|Vicryl skin closure|Women undergoing cesarean section delivery will have Vicryl skin closure
3079952|NCT02027233|Experimental|Nasopharyngeal sample|Rapid completion of nasopharyngeal within 24 hours after hospitalization without exceeding 7 days after the onset
3079838|NCT02027987|Experimental|valproate acid|The patients began receiving treatment at a dose of 400 mg VPA twice daily on the day after randomization by intravenous drip, with this dose continued for 14 days.The dose was increased to 500 mg twice daily at week 3 and to 400 mg three times daily at week 4 if the DRS score had not improved by at least 2 points from baseline. After the week 4 assessment, the study drug was tapered over a period of 2 to 3 days, with assessment of the patients continued through week 6. Additional procedural details are provided in the study protocol.
3079839|NCT02027987|Placebo Comparator|placebo|
3079840|NCT02027974|Active Comparator|Iconacy Hip System|Iconacy hip system prosthesis components
3079841|NCT02027974|Active Comparator|Stryker Accolade Hip System|Stryker Accolade hip system prosthesis components
3079842|NCT02027961|Experimental|Cohort A|Dabrafenib/Trametinib/MEDI4736
3079843|NCT02027961|Experimental|Cohort B|Trametinib/MEDI4736
3079844|NCT02027961|Experimental|Cohort C|Trametinib/MEDI4736
3079845|NCT02027948|Experimental|nutritional management|The proposed study will be a prospective feasibility study of a nutritional management algorithm with risk-based guidelines in older adults (n=50) with newly diagnosed locally advanced esophageal cancer receiving preoperative or definitive chemoradiotherapy with an induction chemotherapy approach. Eligible patients must be age ≥ 65 years old. While all patients with esophageal cancer may benefit from this intervention, we wish to target the most vulnerable population (older patients who are at highest risk of malnutrition) in this pilot study.
3079846|NCT02027935|Experimental|CD8+ T Cells + Cyclophosphamide + Interleukin-2 + Ipilimumab|Leukapheresis procedure performed to collect blood cells so they can be separated and grown as CD8+T cells. Cyclophosphamide administered at 300 mg/m2 by vein 2 days prior to T cell infusion. T cells administered at a dose of 10^10 cells/m2 by vein on Day 0. IL-2 250,000 U/m2 administered subcutaneously every 12 hours begins within 6 hours of T cell infusion and continues for a total of 14 days On Day 0 to Day +14. Ipilimumab administered 24 hours after T cell infusion at a dose of 3 mg/kg by vein. Subsequent infusions administered on Days +22, +43 and +64.
3079847|NCT02027922|Experimental|Fluoride varnish Fluor Protector S|Fluoride varnish Fluor Protector S (Ivoclar Vivadent) with 1.5% ammonium fluoride was not scored. The emergence of a new varnish implies the necessity to compare the effectiveness of both agents in preventing caries in deciduous teeth. All of the elements of a clinical trial and the varnish applications will be performed four times at three-month intervals: examination - 0 (initial score), follow-ups to the initial examination and intervention: 1 - after 3 months, 2 - after 6 months, 3 - after 9 months. Changes in OHI-S, spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs, and their components will be scored at follow-up examinations.
3079848|NCT02027922|Active Comparator|Duraphat|5% Sodium fluoride varnish Duraphat Colgate implies the necessity to compare the effectiveness with Fluor Protector S in preventing caries in deciduous teeth. All of the elements of a clinical trial and the varnish applications will be performed four times at three-month intervals: examination - 0 (initial score), follow-ups to the initial examination and intervention: 1 - after 3 months, 2 - after 6 months, 3 - after 9 months. Changes in OHI-S, spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs, and their components will be scored at follow-up examinations.
3079849|NCT02027922|No Intervention|an oral hygiene tutorial|an oral hygiene tutorial
3079850|NCT02027909||Therapy group one|Lower rate of 60 bpm and out of the box rate response settings of an ADL Rate of 95 bpm and rate profile optimization on with the only change being adjusting the activity threshold from med/low to low.
3079851|NCT02027909||Therapy group two|Rate response programming will be determined by an exercise test consisting of a 2 minute hall walk will be performed at the 2 week follow up and set points will be manually adjusted to achieve an ADL rate of 95 bpm. Rate Profile Optimization will be turned off. Activity threshold is programmed to low.
3079852|NCT02027909||Therapy group three|Lower rate of 60 bpm and the ADL rate based upon 220- age x 55%. Activity threshold is programmed to low. Rate Profile Optimization will be turned ON.
3079853|NCT02027896|Experimental|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
3079854|NCT02027896|No Intervention|Standard surgical care|Surgical hip fracture repair according to the standard timing.
3079855|NCT02027883|Active Comparator|Nominal Parameter|Nominal T shock setting
3079856|NCT02027883|Experimental|Experimental Parameter|Educated T shock setting
3079857|NCT02027870||EXCEL-II DES|Using EXCEL-II biodegradable polymer sirolimus-eluting stent treating CAD
3079858|NCT02027857|No Intervention|mannitol empirical therapy|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the empirical therapy by doctors.
3079859|NCT02027857|Experimental|EIT monitoring|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the results of Electrical impedance tomography monitoring.
3079860|NCT02027857|Other|non-invasive ICP monitoring|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the results of non-invasive intracranial pressure monitoring.
3079861|NCT02027844|Experimental|Cartoon|cartoon watching by children during inhalational induction of anesthesia in the operating room
3079862|NCT02027844|Active Comparator|Paretnal presence|parental presence with their children during inhalational induction of anesthesia in the operating room
3079863|NCT02027844|Experimental|Combined|parental presence and cartoon watching by children during inhalational induction of anesthesia in the operating room
3079864|NCT02027831|Experimental|Indocyanine Green|Intravenous injection of 0,25 mg/kg Indocyanine Green
3079865|NCT02027818|Experimental|Indocyanine Green|study of the correlation between fluorescence and margins of the tumours after iv injection of Indocyanine Green
3079866|NCT02027805|Experimental|T-Guard|Four doses of T-Guard (4 mg/m2), administered at 48-hour intervals as 4 hour infusions.
3079867|NCT02027792|Experimental|Cabbage leaf wraps|Daily application of cabbage leaf wraps over night, 4 weeks application
3079868|NCT02027792|Active Comparator|Diclofenac gel|daily application of diclofenac gel 4 weeks application
3079869|NCT02027792|No Intervention|Usual care|no specific intervention
3079960|NCT02027181|Active Comparator|Manual oxygenation|Manual adjustment of oxygen
3079870|NCT02027779|Experimental|Prophylaxis safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over ≥ 50 additional exposure days.
3079871|NCT02027779|Experimental|On-demand safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during additional 50 exposure days.
3079872|NCT02027766|Experimental|Stretching|Daily stretching of the calf (dominant side; defined as leg used to kick a ball). 2 stretching exercises are performed daily: 1) stretching of the soleus muscle; 2) stretching of the gastrocnemius muscle.
3079873|NCT02027766|No Intervention|Control|
3079874|NCT02027753|Experimental|Insulin glargine and Oral anti diabetic treatment(s)|"Insulin glargine: Lantus~Add basal insulin: starting with 0.2 U/kg/day or 10 U/day~Adjust insulin glargine dose according to Fasting blood glucose~Oral Anti Diabetic treatment(s): DPP-4 inhibitors and Metformin plus or minus Sulphonylurea - Only Sulphonylurea can either be omitted or reduced at the physician's discretion."
3079875|NCT02027740|Experimental|almond|almonds are substituted for visible fat and carbohydrates
3079876|NCT02027727||No intervention|No intervention- this is an observational study of patients receiving Infliximab.
3079877|NCT02027714||Women's Quantitative Survey|"Quantitative surveys will be administered to 200 pregnant and recently postpartum women. Surveys will be conducted in either English or Sesotho depending on the participant's preference. Surveys will be administered by a study-staff member. Survey activities will be conducted in a private space either within or around the clinic building. All study activities will take approximately 1 hour to complete.~The survey is comprised of 62 close-ended questions. Included in this survey are questions related to demographics, sexual behaviors, HIV and various HIV testing services."
3079878|NCT02027714||Women's Focus Group Discussions|"6-8 focus groups of approximately 6-12 pregnant or recently postpartum women will be conducted. Focus group discussions will be organized according to HIV serostatus to allow for open dialogue and participant comfort. All group discussions will be conducted in Sesotho. Each group discussion will be facilitated, preferably, by a female study-staff member. All group discussions will be held in a private space either within a study site or another speciﬁed location within the community. All study activities will take approximately two hours to complete.~Topics that will be discussed during these interviews include relationship dynamics between Basotho men and women, knowledge of HIV and various related issues, including HIV testing, HIV treatment and discordancy in HIV status. Additionally, questions about knowledge and attitudes regarding male circumcision will be asked."
3079879|NCT02027714||Male Interviews|"30 in-depth individual interviews with men. In-depth semi structured interviews consisting of open-ended questions will be conducted in either English or Sesotho depending on the participant's preference will be conducted. Interview activities will be conducted in a private space either within or around the clinic building.~Topics that will be discussed during these interviews include relationship dynamics between Basotho men and women, knowledge of HIV and various related issues, including HIV testing, HIV treatment and discordancy in HIV status. Additionally, questions about knowledge and attitudes regarding traditional and medical male circumcision will be asked.~Following the completion of the interview, the same facilitator will administer a brief survey to the study participant."
3079880|NCT02027701|Experimental|IgPro20|20% liquid formulation (200 mg/mL) of human normal immunoglobulin for SC use administered SC weekly: 0.2 g/kg bw (low-dose IgPro20) for up to 48 weeks. Subjects who experience CIDP relapse on 0.2 g/kg IgPro20 will have an increase to 0.4 g/kg IgPro20 immediately and will continue on high-dose until they have completed a total of 48 weeks of IgPro20 treatment.
3079881|NCT02027688|Active Comparator|Every 6 hour Feeding Schedule|Infants in this arm will be offered oral feedings every 6 hours if they are safe and ready to feed by mouth.
3079882|NCT02027688|Active Comparator|Every 3 Hour Oral Feeding|Infants in this arm will be offered oral feedings every 3 hours if they are safe and ready to feed by mouth.
3079883|NCT02027675|Experimental|Meal Exercise Challenge- Order 2|Two different meals,an high fat micronutrient poor meal and Mediterranean Meal will be followed by an exercise challenge and performed at different orders accordingly to the cross over design.
3079884|NCT02027675|Experimental|Meal Exercise Challenge- Order 1|"Two different meals,an high fat micronutrient poor meal and Mediterranean Meal will be followed by an exercise challenge and performed at different orders accordingly to the cross over design.~Each arm corresponds to a different intervention order."
3079885|NCT02027662|Experimental|Osvaren Granules|Osvaren Granules
3079886|NCT02027662|Active Comparator|Osvaren film-coated tablets|Osvaren film-coated tablets
3079887|NCT02027649||Bladder cancer|Patients who suffered a bladder cancer
3079888|NCT02027649||Control group|Patients with urologic diseases of non tumoral origin
3079889|NCT02027636|Active Comparator|Engagement and Counseling for Latinos (ECLA-F)|Patients in this arm (ECLA-F) receive the 6-8 session CBT plus care-management intervention, administered in person.
3079890|NCT02027636|Active Comparator|Engagement and Counseling for Latinos (ECLA-T)|Patients in this arm received the 6-8 session CBT intervention via telephone.
3079891|NCT02027636|No Intervention|Usual Care|Patients in this arm receive usual care for depression from their primary care providers, which could include antidepressant prescription or referral to specialty mental health care.
3079892|NCT02027623|Experimental|Motor skill training|The motor skill training condition involves supervised, massed practice of novel, challenging functional activities that are difficult or painful for the participant to perform due to his low back pain.
3079893|NCT02027623|Active Comparator|Strength and flexibility exercise|The strength and flexibility exercise condition involves performance of 1) strengthening exercises that target all trunk muscles, and 2) flexibility exercises that target all trunk and lower extremity motions.
3079894|NCT02027597|Experimental|Video Game Treatment|This group received the AOTSM game experience followed by additional oral health information. They did not receive any follow-up treatment after the exhibit.
3079895|NCT02027597|Active Comparator|Control|Instead of playing Attack of the S. Mutans!, children in the control group attended a 90 minute classroom session about virtual reality applications for relieving pain and for therapy. This content was unrelated to oral health.
3079961|NCT02027168||CPA treatment|CPA treatment group receives 20 hours of patient centered manual physical therapy
3079896|NCT02027597|Experimental|Video Game Treatment Plus Follow-Up|Children assigned to the Treatment-Plus conditions not only had the Attack of the S. Mutans video game experience, but also gained access to an educational website that reinforced the exhibit's teachings two months later. These students received a special login and password in the mail and were instructed to visit the site before completing their next questionnaire.
3079897|NCT02027584||parturient|mother who had given birth within 48 hours of clinically indicated blood sampling
3079898|NCT02027584||healthy, non-pregnant, female volunteers|healthy, non-pregnant, female volunteers
3079899|NCT02027584||preterm infant|gestational age at birth < 37 weeks
3079900|NCT02027584||term infant|gestational age at birth >36 weeks
3079901|NCT02027571|Experimental|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( > 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
3079902|NCT02027558|Experimental|Behavioral Education Intervention|Manual-based education program focusing on sleep and sleep apnea provided by allied health personnel in individual sessions.
3079903|NCT02027558|Experimental|Behavioral Education Intervention II|Manual-based education program focusing on sleep and sleep apnea provided by allied health personnel in individual sessions.
3079904|NCT02027545|Experimental|Decision Aid|One half of the eligible patients will be randomly assigned the Veteran-centered intervention (VC) that includes an individualized decision aid, provider education, and modified performance measure/reminder).
3079905|NCT02027545|Other|No Decision Aid|One half of the eligible patients will be randomly assigned to the pragmatic control (PC) (provider education and modified performance measure/reminder, but no decision aid).
3079906|NCT02027532|Active Comparator|Cefazolin|intravenous, weight-based dose (1gm<80kg, 2gm>80kg), perioperatively
3079907|NCT02027532|Active Comparator|Vancomycin|intravenous, weight-based dose (1gm<80kg, 2gm>80kg), perioperatively
3079908|NCT02027519||Home-based Self-testing|"Index participants who have tested positive for HIV will be provided with information regarding the importance of HIV testing for their partners and other household members and the role of home-based self-testing in potentially increasing the number of partners and household members tested for HIV. In addition, index participants will be counseled about ways in which to talk to partners and household members about HIV testing and provided with information sheets that can be distributed within the household. Lastly, index participants will be introduced to a member of the testing team that will present at their home and offer the study intervention."
3079909|NCT02027493|Active Comparator|Reiferon R weekly plus ribavirin|patients who continued treatment on weekly basis (7-day schedule). This group included patients who were HCV-RNA negative at week 12 and those who had < 1 log decrease in HCV-RNA viremia
3079910|NCT02027493|Active Comparator|Reiferon R (every 5-day) plus ribavirin|patients who continued treatment on a 5-day schedule. This group included patients who had ≥ 1 log decrease in viremia (compared to pre-treatment level) at week 12
3079911|NCT02027480||Prospective Cohort|"The study will be a prospective cohort study of HIV-infected adults initiating ART at 4-8 health facilities in Nyanza Province, Kenya. Participants will be asked to take part in four visits over a 12 month period.~At each study visit, participants will be asked questions related to demographic characteristics, medical history, including history of/recent medical conditions, family medical history, TB history and smoking status. Participants will also have their height (at baseline visit only) and weight measured for calculation of BMI and blood pressure reading. Blood and urine specimens will be collected and stored at each study visit for future testing."
3079912|NCT02027467|Experimental|StemAlive®|Stem Alive® includes ingredients like green tea, ashwagandha. Dose: 3 capsules twice daily to be taken orally for 14 days.
3079913|NCT02027467|Placebo Comparator|Placebo|Matching placebo capsules (for StemAlive®) containing polyethylene glycol, rice powder and magnesium stearate. Dose: 3 capsules twice daily to be taken orally for 14 days.
3079914|NCT02027454|Experimental|Sequence 1|Participants in this arm will receive treatment A in period 1, treatment B in period 2 and treatment C in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
3079915|NCT02027454|Experimental|Sequence 2|Participants in this arm will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
3079916|NCT02027454|Experimental|Sequence 3|Participants in this arm will receive treatment B in period 1, treatment A in period 2 and treatment C in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
3079917|NCT02027454|Experimental|Sequence 4|Participants in this arm will receive treatment B in period 1, treatment C in period 2 and treatment A in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
3079918|NCT02027454|Experimental|Sequence 5|Participants in this arm will receive treatment C in period 1, treatment A in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
3079919|NCT02027454|Experimental|Sequence 6|Participants in this arm will receive treatment C in period 1, treatment B in period 2 and treatment A in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
3079953|NCT02027220|Experimental|G-CSF/Bortez/Cyc/Dex|G-CSF IC on days 0, 1, 7, 8, 14, 15, 21 and 22. Bortezomib IV on days 1, 8, 15 and 22. Cyclophosphamide CIV on days 1, 8, 15 and 22. Dexamethasone IV on days 1, 2, 8, 9, 15, 16, 22 and 23.
3079954|NCT02027207|Experimental|Shanchol|
3079955|NCT02027207|Placebo Comparator|Placebo|
3079956|NCT02027194|Experimental|Cure-Allergic Rhinitis Syrup|In syrup form, 20 ml once daily for 4 weeks
3079957|NCT02027194|Active Comparator|Yu-ping-fung San|In syrup form, 20ml once daily for 4 weeks
3079920|NCT02027441||Home-based Testing|"At enrollment, consenting index participants will provide the study staff with locator information and a complete list of individuals currently living in his/her home who may be eligible for home-based HIV testing intervention (Household Composition form).~The study staff and index participant will schedule a date/time for the study staffto visit the index participant's home. Study staff will also provide the index participant with an information sheet to give to household members.~A study testing team comprised of trained counselors and interviewers will visit the index participant's home on the pre-determined date/time and offer home-based HIV testing to those household members who are present."
3079921|NCT02027428|Experimental|Abraxane + Best Supportive Care (BSC)|Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes Abraxane plus best supportive care.
3079922|NCT02027428|Other|Best Supportive Care (BSC)|Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes best supportive care only.
3079923|NCT02027415|Experimental|Beet Orange|Beet juice will be given prior to the first car ride and orange juice will be given prior to the second car ride.
3079924|NCT02027415|Experimental|Orange Beet|Orange juice will be given before the first car ride and beet juice will be given before the second car ride.
3079925|NCT02027402|Experimental|Drain insertion|Laparoscopic cholecystectomy with drain insertion is performed in this arm.
3079926|NCT02027402|No Intervention|no drain insertion|In this arm, investigators perform only laparoscopic cholecystectomy, and not insert a drain
3079927|NCT02027389||control|Patients with growth of S. aureus from sterile site cultures between Sept 15, 2012 - Dec 31, 2012. No rapid testing was performed, and standard bacterial culture and susceptibility testing was done.
3079928|NCT02027389||intervention|Patients with growth of S. aureus from sterile site cultures between Sept 15, 2013 - Dec 31, 2013. Rapid PBP2a testing was performed along with pharmacist notification of service if modification to therapy needed based on rapid test results.
3079929|NCT02027376|Experimental|LDE225 in combination with docetaxel|Eligible patients will be included and treated with docetaxel intravenously (75mg/m2)in every three weeks cycles and LDE225 will be administered orally at three dose levels 400, 600 and 800mg QD. Treatment will be repeated on day 1 of a 21-day cycle until radiographic or symptomatic progression, unacceptable toxicity or withdraws informed consent.
3079930|NCT02027363|Experimental|Observation group|Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation.
3079931|NCT02027363|Experimental|Capecitabine group|"Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy could continue to receive oral capecitabine as maintenance therapy, capecitabine, 1000mg/m2 bid d1-14, every 3 week.~The maintenance treatment was continued until progression, unacceptable toxicity, or patient withdrawal."
3079932|NCT02027350|Experimental|Pressure-volume relationship|Changes in pressure-volume relationships will be compared to changes in LV and RV systolic pressure during respiration.
3079933|NCT02027337|No Intervention|Control group|Healthy women that no use combined oral contraceptives
3079934|NCT02027337|Experimental|20 mcg EE/3 mg drospirenone|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz)
3079935|NCT02027337|Experimental|20 mcg EE/3 mg drospirenone and Selmevit|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz) and antioxidant complex Selmevit
3079936|NCT02027337|Experimental|30 mcg EE/3 mg drospirenone|Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin)
3079937|NCT02027337|Experimental|30 mcg EE/3 mg drospirenone and Selmevit|Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin) and antioxidant complex Selmevit
3079938|NCT02027337|Experimental|35 mcg EE/2mg cyproterone|Women that use combined oral contraceptives containing 35 mcg ethinylestradiol/2 mg cyproterone
3079939|NCT02027337|Experimental|35 mcg EE/2 mg cyproterone and Selmevit|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/2 mg cyproterone and Selmevit
3079940|NCT02027324|Experimental|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
3079941|NCT02027324|Experimental|Povidone-Iodine group|10% Povidone-iodine applied topically according to manufacturer's instructions
3079942|NCT02027311|Experimental|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
3079943|NCT02027311|Experimental|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
3079944|NCT02027298|Experimental|Abatacept|Abatacept by SC injection of 125 mg weekly for 6 months
3079945|NCT02027285|Experimental|fortified milk|The subjects assumed daily 250 ml of fortified milk for 12 weeks. Then, after a period of wash-out of 12-14 weeks they start to assume placebo milk for 12 weeks.
3079946|NCT02027285|Placebo Comparator|placebo milk|The subjects assumed daily 250 ml of placebo milk. Then, after a period of wash-out of 12-14 weeks they start to assume fortified milk for 12 weeks.
3079947|NCT02027272|Active Comparator|Dexamethasone|Dexamethasone 12 mg, 2 doses, 12 hours apart.
3079948|NCT02027272|Placebo Comparator|Placebo|Placebo, 2 doses, 12 hours apart
3079949|NCT02027259|Experimental|Group visits with behavioral activation|Group visits with behavioral activation (BA) will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
3079950|NCT02027259|No Intervention|Standard group visits|Standard group visits will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
3079962|NCT02027155|Active Comparator|AR09 solution|AR09, Randomized, Double-blind, Placebo-controlled, Rising-dose Study to Assess the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single IV Doses of AR09 in Healthy Subjects
3079963|NCT02027155|Placebo Comparator|Placebo (for AR09 solution)|Placebo; normal saline
3079964|NCT02027142||Cases|Women referred to two academic centres for the diagnosis and treatment of endometriosis.
3079965|NCT02027142||Controls|Women referred to our Institutions because of routine gynaecologic consultations.
3079966|NCT02027129|Other|Low frequency HFO/HFO-TGI vs high frequency HFO|Total study population for the testing of the ventilatory strategies
3079967|NCT02027116|Experimental|Experimental: 1mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 1mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
3079968|NCT02027116|Experimental|Experimental: 3mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 3mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
3079969|NCT02027116|Experimental|Experimental: 6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
3079970|NCT02027103|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
3079971|NCT02027103|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
3079972|NCT02027090|Experimental|Higher dose icotinib|Patients with stable disease after 8-week routine dose icotinib treatment, are randomly assigned to higher dose icotinib group to receive icotinib with a dose of 375 mg three times per day, till progressive disease or unaccepted toxicity.
3079973|NCT02027090|Active Comparator|Routine dose icotinib|Patients with stable disease after 8-week routine dose icotinib treatment, are administered with icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity.
3079974|NCT02027077|Active Comparator|Control group|Control group
3079975|NCT02027077|Active Comparator|Lifestyle counseling|Behavioral intervention group
3079976|NCT02027064|Experimental|interferon|
3079977|NCT02027038|Experimental|Patients with sacroiliac joint pain|Patients suffering from sacroiliac joint pain
3079978|NCT02027038|Active Comparator|Controls|healthy controls
3079979|NCT02027025|Active Comparator|SPARC1103 I|The subjects will receive SPARC1103 I
3079980|NCT02027025|Active Comparator|SPARC1103 II|The subjects will receive SPARC1103 II
3079981|NCT02027025|Placebo Comparator|SPARC Placebo|The subjects will receive SPARC Placebo
3079982|NCT02027012|Experimental|Renal denervation with Vessix system|
3079983|NCT02026986|Experimental|sleep deprivation|Ten subjects in the SD group were examined after a SD experiment in which they did not sleep for 24 h.
3079984|NCT02026986|No Intervention|control|The 10 subjects in the control group were not sleep deprived (had 8 h of sleep).
3079985|NCT02026973|Experimental|IM Placebo/Oral Placebo|IM placebo given once on Day 1; Oral placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
3079986|NCT02026973|Experimental|IM Placebo/PO Anastrozole|IM placebo given once on Day 1; Oral Anastrozole 2.0mg pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
3079987|NCT02026973|Experimental|IM Fulvestrant/PO Placebo|IM Fulvestrant 250mg given once on Day 1; Oral Placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
3079988|NCT02026973|Experimental|IM Fulvestrant/IM Anastrozole|IM Fulvestrant 250mg given once on Day 1; Oral Anastrozole pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
3079989|NCT02026960|Experimental|Renal Cell Carcinoma Tumor Tissue|
3079990|NCT02026960|Experimental|Genitourinary tumor tissue (Expansion cohort)|Bladder, prostate or testicular cancer
3079991|NCT02026947|Placebo Comparator|Placebo|In both arms, one capsule at the morning for the first week. One capsule at the morning and one at the evening for the weeks 2-12.
3079992|NCT02026947|Experimental|Sodium benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
3079993|NCT02026921|Experimental|Carboplatin and docetaxel|Intravenous infusion every 3 weeks Carboplatin plus docetaxel
3079994|NCT02026908|Experimental|Prostate Artery Embolization|There is only one arm of this study where patients receive Prostate Artery Embolization
3079995|NCT02026895|Experimental|Patient with infection by Staphylococcus lugdunensis|
3079996|NCT02026882|Other|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway with gastric tube. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
3079997|NCT02026869|Active Comparator|Oral metformin|Metformin 850 mg tablets taken by mouth every 12 hours for 6 months
3079998|NCT02026869|Active Comparator|Vaginal metformin|Metformin 850 mg tablets taken vaginally every 12 hours for 6 months
3079999|NCT02026856||Se-OI> 200|patients who received form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was higher than 200
3080000|NCT02026856||Se-OI <200|patients who received form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was lower than 200
3080001|NCT02026856||Placebo-OI> 200|patients who received continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was higher than 200
3080002|NCT02026856||Placebo-OI <200|patients who who received continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was lower than 200
3080114|NCT02025998|Experimental|Ibudilast|Ibudilast will be administered for 7 days at the target dose of 50 mg/bid
3080003|NCT02026843||Diabetic retinopathy,humor,angiogenic|Samples of aqueous humor was taken before injection and before surgery. The injection include bevacizumab or triamcinolone.
3080004|NCT02026843||Nondiabetic,angiogenic,humor|Aqueous humor was taken before surgery. Surgery include pars plana vitrectomy of macular hole, epiretinal membrane, cataract surgery.
3080005|NCT02026830||Diabetic foot infection|Patients with DM (Diabetes Mellitus) presenting with a diabetic foot infection will be enrolled in the current trial to determine the causative microorganisms and their antibiotic sensitivity patterns in diabetic patients with a foot infection in Turkey.
3080006|NCT02026817|Experimental|HCP1201|Participants received a single oral dose of the HCP1201 750/10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3080007|NCT02026817|Active Comparator|Metformin and Rosuvastatin|Participants received a single oral dose of coadministration of Metformin SR 750 mg and Rosuvastatin 10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3080008|NCT02026804||Prenatal mental disorders|
3080009|NCT02026791|Experimental|The clinical efficacy of the I-gel|The clinical efficacy of the I-gel
3080010|NCT02026791|Active Comparator|The clinical efficacy Supreme-LMA|The clinical efficacy Supreme-LMA
3080011|NCT02026778|Experimental|ondansetron-betahistine|ondansetron-betahistine group
3080012|NCT02026778|Placebo Comparator|ondansetron|ondansetron group
3080013|NCT02026765|Other|Heparin Surface Modified Aspheric Lens|Heparin Surface Modified Aspheric Lens
3080014|NCT02026765|Other|traditional lens|traditional Aspheric lens
3080015|NCT02026752||Study Population|
3080016|NCT02026739|Experimental|low supplemental oxygen concentration|The group in which low supplemental oxygen concentration of 40% will be performed during minimally invasive esophagectomy.
3080017|NCT02026739|Active Comparator|high supplemental oxygen concentration (conventional)|The group in which high supplemental oxygen concentration (onventional) of 80% will be performed during minimally invasive esophagectomy.
3080018|NCT02026713|Experimental|smokers on dual antiplatelet therapy with ASA and Prasugrel or|All patients quit smoking for a 2 weeks period
3080019|NCT02026713|Experimental|smokers on dual antiplatelet therapy with ASA and ticagrelor|All patients on chronic dual antiplatelet therapy (>1 month) quit smoking for a 2 weeks period
3080020|NCT02026713|Active Comparator|smokers on dual antiplatelet therapy with ASA and Clopidogrel|All patients on chronic dual antiplatelet therapy (>1 month) quit smoking for a 2 weeks period
3080021|NCT02026700|Experimental|bariederm, barrier cream|one arm study: use of bariederm cream on hands twice daily for 21 days
3080022|NCT02026687|Active Comparator|Epidural analgesia|The epidural anesthesia is applied at a low thoracic level, primarily Th10-Th11. A bolus dose of fentanyl together with a continuous infusion of bupivacain 2.5 mg/ml, fentanyl 1.8 µg/ml and epinephrine 2.5 µg/ml is used during surgery. Infusion rate is chosen by the attending anesthetist. Postoperatively the epidural anesthesia is continued until the morning of the third postoperative day using bupivacain 1 mg/ml, fentanyl 2 µg/ml and epinephrine 2µg/ml. Infusion rate is set by the responsible physician, maximum rate is 10 ml/hour.
3080023|NCT02026687|Active Comparator|Intrathecal analgesia|The patient is given one intrathecal dose of plain bupivacaine (Marcain® spinal) 5 mg/ml, 15 mg together with morphine (Morphine Special®) 0,4 mg/ml, 0.2 mg and clonidine (Catapresan®) 150 µg/ml, 75 µg. The intrathecal mixture is given through a lumbal puncture at level L2/3, L3/4 or L4/5 before the induction of general anesthesia.
3080024|NCT02026674|Experimental|FloRite|LUTS patients that used FloRite for home urine flow diagnostics.
3080025|NCT02026661||those that did not receive ICSI or LAH|
3080026|NCT02026661||those that received ICSI only|
3080027|NCT02026661||those that received LAH only|
3080028|NCT02026661||those that received both ICSI and LAH|
3080029|NCT02026648||cases with cervical cancer|
3080030|NCT02026635||Optivol® Device in CareLink|A single cohort group of heart failure patients with already implanted Optivol® capable devices who are discharged home from the hospital
3080031|NCT02026622|Other|3 groups of subjects|"3 groups: depressive subjects, subjects remitted from depression and control subjects, with the same interventions.~psychometric tests, MRI, transcranial doppler and TPI, explicitative interview"
3080032|NCT02026609||TIPS|Patients 18-75 year old with refractory ascites or hepatic hydrothorax and cirrhosis, eligible for TIPS placement. All patients will have a baseline oral glutamine challenge and psychometric tests.
3080033|NCT02026596||aSAH patients|Patients suffering from aneurysmal subarachnoid haemorrhage
3080034|NCT02026583|Experimental|Simvastatin|
3080035|NCT02026570|No Intervention|Control|Persons with unilateral transtibial amputation receiving standard physical therapy.
3080036|NCT02026570|Experimental|Motor Control Internal Focus|Persons with unilateral transtibial amputation receiving standard physical therapy and additional training with motor control internal focus of attention instructions.
3080037|NCT02026570|Experimental|Motor Control External Focus|Persons with unilateral transtibial amputation receiving standard physical therapy and additional training with external focus of attention instructions.
3080038|NCT02026544|Experimental|Low Frequency Therapeutic Ultrasound|Low Frequency Therapeutic Ultrasound (LOTUS) applied transcutaneously
3080039|NCT02026531|Experimental|3-Helium inhalation gas|This is a pilot study. The aim is to recruit 20 patients who will all receive the product under investigation.
3080040|NCT02026518|Experimental|Soy|Group Soy receiving placebo similar to 50000 IU cholecalciferol (includes MCT oil) biweekly for 6 weeks in addition to 40 milligram (2 capsules per day) soy isoflavones capsules for 6 weeks
3080041|NCT02026518|Experimental|Soy- Cholecalciferol|Group Soy- Cholecalciferol receiving Supplement in form of 40 milligrams soy isoflavones (diadzein, genistein, glycitin) per day (2 capsules of 20 milligrams) for 6 weeks in addition to supplement of cholecalciferol (vitamin D3) biweekly for 6 weeks
3080042|NCT02026518|Placebo Comparator|Placebo|Group Placebo receiving Placebo in similar form of cholecalciferol supplement biweekly for 6 weeks in addition to 40 milligrams placebo in similar form of soy isoflavones including starch for 6 weeks
3080115|NCT02025998|Placebo Comparator|Sugar pill|Placebo pills will be administered for 7 days and taken twice daily
3080043|NCT02026518|Experimental|Cholecalciferol|Group Cholecalciferol receiving oral Placebo in similar form to soy isoflavones (diadzein, genistein, glycitin) supplement including starch (2 capsules per day) for 6 weeks in addition to 50000 IU cholecalciferol supplement biweekly for 6 weeks
3080044|NCT02026505||Multiple Myeloma, Bortezomib|
3080045|NCT02026492|Other|40 patients aged 6-18 years|All 40 patients with a diagnosis of asthma are recruited from the outpatients clinic of the department of Pediatric Pneumology and Allergology of the University Hospital Frankfurt. Patients undergo a methacholine challenge and two exercise challenges in a cold chamber and one exercise challenge in room temperature.
3080046|NCT02026492|Other|40 subjects aged 18-45 years|All subjects show bronchial hyperresponsiveness e.g. dyspnea when exercising in cold environment, in their medical history. Subjects undergo a methacholine challenge and exercise challenge in a cold chamber and one exercise challenge in room temperature.
3080047|NCT02026479|Experimental|regular treatment comparator|Ginaton
3080048|NCT02026479|Experimental|Dexamethasone Phosphate low dose|5mg
3080049|NCT02026479|Experimental|Dexamethasone Phosphate high dose|10mg
3080050|NCT02026466||CAD with CTO|Subjects will have Coronary Artery Disease with a diagnosed Chronic Total Occlusion: a coronary artery with TIMI flow of zero(no flow) for at least three months.
3080051|NCT02026453|No Intervention|Usual care|Physicians and nurses obtain admission medication history.
3080052|NCT02026453|Experimental|Pharmacist obtains home med hx|Pharmacist obtains admission medication history, although usual care practices may also continue.
3080053|NCT02026453|Experimental|Pharm tech obtains home med hx|Pharmacy technician obtains admission medication history, although usual care practices may also continue.
3080054|NCT02026440||Smokers|Those who smoke at least one cigarette a day.
3080055|NCT02026440||Non smokers|Those who have not smoked for at least one week when the sample is collected.
3080056|NCT02026427||Drotaverine|40 mg of drotaverine hydrochloride administered intramuscularly just after the proper level of spinal anesthesia was achieved.
3080057|NCT02026427||Control|Without intramuscular administration of drotaverine hydrochloride.
3080058|NCT02026414|Experimental|PrimaVie Exercise|Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
3080059|NCT02026401|Experimental|NGM282 Dose 1|NGM282 Dose 1
3080060|NCT02026401|Experimental|NGM282 Dose 2|NGM282 Dose 2
3080061|NCT02026401|Placebo Comparator|Placebo|Placebo
3080062|NCT02026388||Primary Hyperoxaluria|Diagnosis of Primary Hyperoxaluria, or a family member of someone with this diagnosis.
3080063|NCT02026388||Dent Disease|Diagnosis of Dent Disease, or a family member of someone with this diagnosis.
3080064|NCT02026388||Cystinuria|Diagnosis of Cystinuria, or a family member of someone with this diagnosis.
3080065|NCT02026388||APRT deficiency|Diagnosis of APRT Deficiency, or a family member of someone with this diagnosis.
3080066|NCT02026362|Other|The foundation treatment after radical operation or RFA|The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
3080067|NCT02026362|Experimental|MASCT:Multiple Antigens Specific Cellular Therapy|autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens
3080068|NCT02026349|Active Comparator|favipiravir|
3080069|NCT02026349|Placebo Comparator|placebo|
3080070|NCT02026336|No Intervention|enose|Electronic nose can discriminate the inflammatory asthma phenotypes, supporting their potential as a non-invasive alternative tool to induced sputum.
3080071|NCT02026323|Experimental|acupuncture|"Normal weight group,the PCOS women with insulin resistance who are normal weight( BMI=18.5-23Kg/m2).The acupuncture treatment will last for six months, 3 times per week, 30 minutes per treatment."
3080072|NCT02026323|Experimental|acupuncture 2|"Over weight or obese group ,the PCOS women with insulin resistance who are overweight or obese: BMI >23 Kg/m2.The acupuncture treatment will last for six months, 3 times per week, 30 minutes per treatment."
3080073|NCT02026310|Experimental|glimepiride|on the basis of metformin and glargine, the initial dose of glimepiride is 2 mg,qd (before breakfast), and adjust the dosage for fasting plasma glucose, dosage-adding indicator is the FPG≥7.2, maximum dose of glimepiride is 4 mg/d per day.
3080074|NCT02026310|Active Comparator|Metformin and glargine|on the basis of Metformin and glargine,no glempiride addition. dose of glargine was adjust according to the FPG, with the target less than 7.2mmol/l
3080075|NCT02026297|Placebo Comparator|Control, low risk PPH|Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care NOT including tranexamic acid.
3080076|NCT02026297|Experimental|Treated, low risk PPH|Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care AND tranexamic acid.
3080077|NCT02026284||Gravid women|A questionnaire was performed to gravid women
3080078|NCT02026271|Experimental|Ad-RTS-hIL-12+veledimex|varying doses of intratumoral Ad-RTS-hIL-12 (INXN-2001) and oral veledimex (activator ligand).
3080079|NCT02026258|Active Comparator|Orthodontics no piezocision|Subjects will have orthodontic treatment without corticision with piezotome. Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment. The time taken to reach complete alignment for each patient and the rate of tooth alignment will be calculated.
3080110|NCT02026050|Placebo Comparator|serum phsyologic|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
3080111|NCT02026037|Experimental|Experimental|Brief Treatment for Acutely Burned Patients (BTBP)
3080080|NCT02026258|Experimental|Orthodontics with piezotome corticision|Subjects receiving orthodontic treatment in conjunction with piezotome-corticision. Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment. The time taken to reach complete alignment for each patient and the rate of tooth alignment will be calculated.
3080081|NCT02026245|Experimental|5DT electronic data glove|"Using the electronic data gloves to perform a set routine of movements.~Intervention: Data gloves to perform movements"
3080082|NCT02026245|Experimental|Tyndall/UU electronic data glove|"Using the electronic data gloves to perform a set routine of movements~Intervention: Data gloves to perform movements"
3080083|NCT02026232|Active Comparator|hydroxychloroquine|hydroxychloroquine twice daily for 4 weeks
3080084|NCT02026232|Placebo Comparator|Placebo|hydroxychloroquine placebo twice daily for 4 weeks
3080085|NCT02026219|Experimental|Clopidogrel|Clopidogrel 600mg loading
3080086|NCT02026219|Experimental|Ticagrelor|Ticagrelor 180mg loading
3080087|NCT02026206|Experimental|LLLT group|low-level light therapy (LLLT) was self-performed for 20 min/day over 5 days prior to the expected onset of menstruation during three menstrual cycles.
3080088|NCT02026206|Placebo Comparator|Placebo-controlled group|Placebo low-level light therapy (LLLT) was self-performed for 20 min/day over 5 days prior to the expected onset of menstruation during three menstrual cycles. The placebo LLLT device was identical to the active device but did not radiate light as the hole was blocked.
3080089|NCT02026193|Experimental|oocyte vitrification|All retrieved mature oocytes will be vitrified.
3080090|NCT02026193|Active Comparator|embryo freezing|All retrieved oocytes will be fertilized, and resulting embryos will be frozen.
3080091|NCT02026180|Active Comparator|Micropuncture Access|Vascular access using micropuncture needle kit
3080092|NCT02026180|Active Comparator|Standard 18G vascular access needle|Vascular access using standard 18G needle
3080093|NCT02026167|No Intervention|Usual Care|No intervention, usual care
3080094|NCT02026167|Experimental|Invervention|Collaborative care with Health Care Assistant
3080095|NCT02026154||A, B, C|Group A- 15 patients without symptoms of heart failure - control group Group B- 30 patients with exertional dyspnoea Group C - 40 patients with overt heart failure
3080096|NCT02026141|Experimental|Dexmedetomidine arm|"Standardized pre-op meds and spinal anesthetic.~Once the patient's spinal is performed, patient will receive the following:~Start with bolus of 0.5micrgram/kg over 10 minutes, and then infusion of 0.5 microgram/kg/hr~Infusion will be stopped after the last staple or suture is performed on the incision.~Both groups will have a midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation as defined by ASA."
3080097|NCT02026141|Placebo Comparator|Saline Placebo|"Patients will receive the standardized pre-op meds and spinal anesthetic. Once the spinal anesthetic is performed,~Patient will receive the same infusion rates as in the Dexmedetomidine arm, however with Normal Saline as a Placebo.~midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation."
3080098|NCT02026128||Active Uveitis|Physician-confirmed diagnosis of uveitis of any origin.
3080099|NCT02026115|Active Comparator|usual hospice care|The usual care group will receive the typical hospice care and interact with PAINReportIt to provide data necessary for the analysis of study aims. They will use the tablet computer at baseline and at the study end and daily between. They also will have access to what looks like PAINUCope, but is really computer games so that they have similar attention with the computer as the experimental group. For ethical purposes, we will provide a PAINReportIt Summary to their hospice nurses to have access to their pain assessment information, something we did not do in previous studies focused on efficacy of the interventions.
3080100|NCT02026115|Experimental|PAINRelieveIt (experimental group)|We will use Nursing Consult LLC's PAINRelieveIt software that includes: (1) PAINReportIt that has screens to collect pain, medications, and misconception data; (2) the intervention for the nurse clinicians, PAINConsultN; and (3) the intervention for the patients and lay caregiver, PAINUCope. This innovative, new program is the first computerized, multi-dimensional, self-report measure of pain with clinician decision support for analgesic prescriptions and multimedia patient education tailored to the patient's misconceptions and pain. Prototype versions of PAINConsultN and PAINUCope were tested in recently completed studies among outpatients with cancer and patients with sickle cell disease in outpatient, emergency and hospital settings.
3080101|NCT02026102|No Intervention|Usual Care|Patients will receive no additional ICD specific information other than what is offered by the clinic consistent with usual care. The control group will be asked where they went for information in the follow-up interviews.
3080102|NCT02026102|Experimental|ICD Decision Aid Toolkit|In the intervention arm, research assistants will provide the patients with the toolkit of decision aids. At that time, participants will have the option of using all of the decision aids or just some of the decision aids. Participants who do not have access to the internet, will be offered a DVD (digital video disc) version of the video and they will be asked if they would like to arrange a visit where they can review the website with the research assistant.
3080103|NCT02026089|No Intervention|Sero-positive for varicella at least 5 years prior|No treatment
3080104|NCT02026089|Active Comparator|Varicella vaccine|One dose varicella vaccine (Varivax).
3080105|NCT02026076|Experimental|manual unloading|All subjects will first undergo a manual unloading test, followed by a single application of mechanical lumbar traction to determine predictive effect
3080106|NCT02026063|Experimental|250 mg telotristat etiprate|One telotristat etiprate (250 mg) tablet administered three times daily
3080107|NCT02026063|Experimental|500 mg telotristat etiprate|Two telotristat etiprate (250 mg) tablets administered three times daily
3080108|NCT02026050|Active Comparator|intraarticular dexamethasone|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2 ml serum phsyologic and after surgery 2 ml 8 mg dexamethasone+ 8 ml serum phsyologic administration for intraarticular
3080109|NCT02026050|Active Comparator|interscalene dexamethasone|interscalene brachial plexus was preoperative performed 30 ml 0.5 % bupivacaine added 2 ml 8mg dexamethasone and after surgery 10 ml serum phsyologic administration for intraarticular
3080112|NCT02026011|Experimental|Naltrexone|Naltrexone 50 mg/day
3080113|NCT02026011|Placebo Comparator|Sugar pill|Matched placebo
3080116|NCT02025985|Experimental|Part 1, Selinexor 50mg/m2 twice weekly|3 Cohorts of patients with ovarian, endometrial, or cervical carcinoma will receive oral Selinexor 50 mg/m2 twice weekly.
3080117|NCT02025985|Experimental|Part 2, Schedule 1, Selinexor 35 mg/m2 twice weekly|Ongoing ovarian carcinoma cohort will receive oral Selinexor 35 mg/m2 twice weekly.
3080118|NCT02025985|Experimental|Part 2, Schedule 2, Selinexor 50 mg/m2 once weekly|Ongoing ovarian carcinoma cohort will receive oral Selinexor 50 mg/m2 once weekly.
3080119|NCT02025985|Experimental|Part 3, Selinexor 60 mg twice weekly|Breast cancer cohorts will receive oral Selinexor 60 mg twice weekly.
3080120|NCT02025972|Experimental|Allogeneic umbilical cord blood therapy|Allogeneic umbilical cord blood therapy
3080121|NCT02025959|Experimental|Educational Intervention|Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders
3080122|NCT02025946||Total Ankle Arthroplasty|
3080123|NCT02025946||Tibiotalar Arthrodesis|
3080124|NCT02025933||Salmon Group|Participants will eat 75 - 150 grams of salmon for dinner, three times a week for 12 weeks.
3080125|NCT02025933||Cod Group|Participants will eat 75-150 grams of cod for dinner, three times a week for 12 weeks.
3080126|NCT02025933||Meat Group|Participants will eat 75-150 grams of mixed meat for dinner, three times a week for 12 weeks.
3080127|NCT02025920||Salmon Group|Participants will eat 150g salmon for dinner, 3 times per week for 12 weeks
3080128|NCT02025920||Cod Group|Participants will eat 150g cod for dinner, 3 times per week for 12 weeks
3080129|NCT02025920||Meat Group|Participants will eat 150g mixed meat for dinner, 3 times per week for 12 weeks
3080130|NCT02025907|Experimental|Canagliflozin (JNJ-28431754)|Each participant will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 6 weeks, then the dose may be increased to 300 mg once daily.
3080131|NCT02025907|Placebo Comparator|Placebo|Each participant will receive placebo (inactive medication) once daily for 28 weeks.
3080132|NCT02025894||PCVCs|Cohort of cancer patients with indication PCVC under the usual practice
3080133|NCT02025881|Experimental|Treatment|carboplatin + etoposide then thiotepa then Cyclophosphamide + Busilvex
3080134|NCT02025868|Experimental|Adherence reinforcement before switch to 3rd-line ART|
3080135|NCT02025855|Experimental|Methadone|Methadone will be administered at a dose calculated from the subjects total daily opioid requirements, with a maximum methadone dose of 60 mg per day. The methadone will be administered every 8 hours as 5 mg capsules that will be given via an enteral feeding tube.
3080136|NCT02025855|Placebo Comparator|Placebo|This will be a capsule containing only lactose and will be given every 8 hours via an enteral feeding tube. The number of placebo capsules will be calculated based on the subjects opioid requirements. This will ensure the same number of capsules will be given despite which arm the patient is enrolled in.
3080137|NCT02025842||Chronic hepatitis B patients|Chronic hepatitis B patients treated with nucleoside/nucleotide
3080138|NCT02025842||Compensated cirrhosis patients|Compensated cirrhosis patients treated with nucleoside/nucleotide
3080139|NCT02025829||Clinically Stable|Patients with cystic fibrosis and are clinically stable, 10 subjects with one copy of F508del and 4 subjects with at least one copy of G551D
3080140|NCT02025829||Exacerbation|Patients with cystic fibrosis admitted for treatment of a pulmonary exacerbation with IV antibiotics, 10 subjects with one copy of F508del
3080141|NCT02025803|Experimental|TAS-114/capecitabine|See intervention description
3080142|NCT02025790|Experimental|Group A - POEM|Per Oral Endoscopic Myotomy for treatment of achalasia
3080143|NCT02025790|Active Comparator|Group B - Dilatation|- Pneumatic dilatation using a balloon for treatment of achalasia.
3080144|NCT02025777|Experimental|capsule endoscopy and colonoscopy|
3080145|NCT02025751|Experimental|Metoclopramide Nasal Spray|Metoclopramide Nasal Spray 10 mg, 30 minutes before meals and at bedtime (QID) for 4 weeks
3080146|NCT02025751|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 30 minutes before meals and at bedtime (QID) for 4 weeks
3080147|NCT02025738|Active Comparator|MAGNET|magnet application over cardiac device
3080148|NCT02025738|Active Comparator|REPROGRAMING|reprograming of cardiac device by trained technician/electrophysiologist
3080149|NCT02025738|Active Comparator|NO ACTION|no action is performed if patient meets inclusion criteria
3080150|NCT02025725|Experimental|10 mg Metoclopramide Nasal Spray|Metoclopramide Nasal Spray 10 mg, 30 minutes before meals and at bedtime (QID) for 4 weeks
3080151|NCT02025725|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 30 minutes before meals and at bedtime (QID) for 4 weeks
3080152|NCT02025712|Experimental|Exemestane plus Everolimus|Exemestane 25 mg daily in combination with Everolimus 10 mg daily until disease progression or intolerable toxicity
3080153|NCT02025699||LRTI|
3080154|NCT02025699||Sepsis|
3080155|NCT02025699||Non-Infectious disease group|
3080156|NCT02025686|Experimental|Hyperbaric Oxygen|Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min
3080157|NCT02025673||Healthy Controls|Healthy subjects as control group.
3080158|NCT02025673||Type 2 diabetes|Patients with type 2 diabetes.
3080159|NCT02025673||Gestational diabetes mellitus|Patients with gestational diabetes mellitus.
3080160|NCT02025660|Experimental|Mw|
3080161|NCT02025660|Placebo Comparator|Saline; 0.3 ml x three days sc|
3080162|NCT02025647||Innerview MHCDS|Innerview, Mental Health Clinical Decision Support tool
3080163|NCT02025634|Experimental|Intravenous acetaminophen|Infusion of Intravenous acetaminophen (Ofirmev)
3080164|NCT02025634|Placebo Comparator|Placebo (0.9% Normal Saline Infusion)|Infusion of 100 ml of 0.9 NS Normal Saline
3080165|NCT02025621|Experimental|Levosimendan|levosimendan 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
3080166|NCT02025621|Placebo Comparator|Placebo|placebo 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
3080167|NCT02025608|Experimental|Pramipexole|Pramipexole, 0.25 mg, daily for 4 weeks
3080168|NCT02025608|Placebo Comparator|Placebo|Placebo, daily for 4 weeks
3080169|NCT02025595||Monozygotic twin pairs|15 monozygotic twin pairs discordant for obesity
3080228|NCT02025218|Experimental|Re-administration gefitinib|
3080170|NCT02025595||Genetic predisposition for obesity|15 obese and 15 non-obese individuals with a high genotype obesity risk score and 15 obese and 15 non-obese individuals with a low genotype obesity risk score. Genotype obesity risk score will be based on genome wide association single-nucleotide polymorphisms (SNP's) associated with obesity.
3080171|NCT02025582|Experimental|Kinesio tape|
3080172|NCT02025569|Experimental|Experimental group|Strain counterstrain intervention
3080173|NCT02025569|Sham Comparator|Control Group|Sham Strain Counterstrain intervention
3080174|NCT02025556|Experimental|LBR-101 High Dose|Subcutaneous High Dose LBR-101 Administered Monthly x 3
3080175|NCT02025556|Experimental|LBR-101 Low Dose|Subcutaneous Low Dose LBR-101 Administered Monthly x 3
3080176|NCT02025556|Placebo Comparator|Placebo|Subcutaneous Placebo Administered Monthly x 3
3080177|NCT02025543||Patient|Subjects with known or suspected iron overload will undergo serum ferritin measurement and an MRI scan.
3080178|NCT02025543||Control|Subjects with no known history of iron overload or liver disease will undergo an MRI scan.
3080179|NCT02025530||Cases|A structured questionnaire will be administered to women who have experienced a late ≥ 28 weeks gestation stillbirth, who have a singleton pregnancy with no congenital abnormality.
3080180|NCT02025530||Controls|A structured questionnaire will be administered to controls. These are women matched to the case group by gestation and unit of birth, who have a normal ongoing singleton pregnancy with no congenital abnormality.
3080181|NCT02025517|No Intervention|Without Cognitive Tasks|Gait training on treadmill during 20 minutes.
3080182|NCT02025517|Experimental|Cognitive Tasks|Treadmill training plus cognitive verbal fluency, memory and spatial planning tasks, during 20 minutes.
3080183|NCT02025504|Experimental|ColoWrap Intervention Group|Patients randomized to ColoWrap Intervention Group will have the ColoWrap abdominal binder secured firmly around their lower abdomen just prior to colonoscopy.
3080184|NCT02025504|Sham Comparator|Sham Group|Sham Group will also have a ColoWrap binder placed around their lower abdomen, but it will be placed loosely so no appreciable lower abdominal pressure is generated by the device.
3080185|NCT02025491|Experimental|Liposomal Amphotericin|Liposomal Amphotericin by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment.
3080186|NCT02025478|Experimental|Enteral Donor Breastmilk|"Donor breast milk will be pasteurized prior to use.~Given orally or by nasogastric (NG) or nasojejunal (NJ) tube.~Feeding will be supervised and will be advanced as quickly as tolerated with a goal of providing 40-50% of nutritional needs from the donor milk.~It is recognized that the volume of enteral feeds will need to be adjusted per patient tolerance."
3080187|NCT02025465|Experimental|Metoprolol|"Metoprolol 2.5 to 5.0 mg IV bolus over two minutes~Repeat every five minutes up to a total dose of 15 mg as long as tolerated (Blood pressure is over 100 mm /Hg systolic (or BP is 90 to 100 mm\Hg systolic and the patient is not dizzy))~If rate inadequate the physician has option of:~Further doses of metoprolol IV or PO~Intravenous amiodarone~IV diltiazem~Observation"
3080188|NCT02025465|Active Comparator|Diltiazem|"Bolus 0.25 Mg/Kg over two minutes (average adult dose 20 mg).~If after 15 minutes~The first dose is tolerated, and~Ventricular rate is over 100 beats a minute AND~Blood pressure is over 100 mm /Hg systolic (or BP is 90 to 100 mm\Hg systolic and the patient is not dizzy)~Give diltiazem 0.35 Mg/Kg over two minutes (average adult dose 25 mg).~After initial bolus', start infusion 5 to 15 Mg/hour to maintain rate control as long as:~1. BP over 100 mm/Hg or between 90 and 100 mm/Hg and the patient is not dizzy.~If rate inadequate the physician has an option of:~Metoprolol PO (by mouth) or IV (intravenous)~Digoxin PO or IV~Intravenous amiodarone~Observation"
3080189|NCT02025452|Active Comparator|Rapid diagnostics and probiotic|
3080190|NCT02025452|Placebo Comparator|Rapid diagnostics and placebo|
3080191|NCT02025452|Experimental|Delayed diagnostics and probiotic|
3080192|NCT02025452|Placebo Comparator|Delayed diagnostics and placebo|
3080193|NCT02025439|Active Comparator|rTMS Alone|Subjects assigned to rTMS Alone will receive 30 sessions of rTMS. Two rTMS sessions will be provided per day, four days per week.
3080194|NCT02025439|Active Comparator|Amantadine Alone|Subjects who are assigned to the Amantadine Alone group will receive 28 doses of Amantadine (100mg BID) every day for 28 days.
3080195|NCT02025439|Active Comparator|rTMS plus Amantadine|All subjects, after first completing Amantadine Alone arm or rTMS Alone arm, will receive rTMS plus Amantadine. A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.
3080196|NCT02025426|Active Comparator|Phenylephrine|Phenylephrine for maintaining blood pressure within 10 % of baseline
3080197|NCT02025426|Active Comparator|Ephedrine|Ephedrine for maintaining blood pressure within 10 % of baseline
3080198|NCT02025413|Other|Metastatic progressive castration-resistant prostate cancer|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
3080199|NCT02025413|Other|Metastatic progressive breast cancer|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
3080200|NCT02025400|Active Comparator|Physical Therapy|This arm will receive the standard of care for orthopedic patients receiving a diagnosis and then a recommendation for outpatient physical therapy referral. They will follow through on the referral and attend physical therapy.
3080201|NCT02025400|Experimental|eRehab|This group will not go to formal therapy but receive Internet delivered patient education and exercise instruction. This group will then perform those exercises at home.
3080202|NCT02025387|Experimental|Experimental|Patients will receive physical activity feedback and be encouraged to achieve the daily goals of physical activity
3080203|NCT02025387|Sham Comparator|Control|Physical activity will be measured but not be informed to patients. She will receive usual care.
3080204|NCT02025374|Experimental|Hyperbaric levobupivacaine|Group 2 Hyperbaric levobupivacaine % 0.5 plus fentanyl; 2 ml total intrathecally
3080205|NCT02025374|Active Comparator|Hyperbaric bupivacaine|Group 1 Hyperbaric bupivacaine % 0.5 plus fentanyl 2 ml intrathecally
3080206|NCT02025361|Experimental|intrarectal lidocaine gel|transrectal ultrasound guided prostate biopsy was performed with intrarectal lidocaine gel anesthesia: 10 minutes before the procedure % 2 lidocaine hydrochloride gel instilated into the rectum for local anesthesia
3080229|NCT02025205|Experimental|ELVR with Endobronchial Valves|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
3081214|NCT02018510|Experimental|Group 1D|HIV-uninfected individuals 10 mg/kg, two doses IV of 3BNC117
3080207|NCT02025361|Experimental|periprostatic nerve blockade|transrectal ultrasound guided prostate biopsy was performed with intrarectal lidocaine gel anesthesia: 10 minutes before the procedure transrectal ultrasound guided 10 ml prilocaine and serum physiologic blend (5ml %2 prilocaine and 5 ml serum physiologic) injected separetly 5ml right and 5ml left junction between the prostate base and seminal vesicle.
3080208|NCT02025348|Experimental|Treatment A metoprolol 50mg|IntelliCap® capsule Release profile 1 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
3080209|NCT02025348|Experimental|Treatment B metoprolol 50mg|IntelliCap® capsule Release profile 2 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
3080210|NCT02025348|Experimental|Treatment C metoprolol 50mg|IntelliCap® capsule Release profile 3 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
3080211|NCT02025348|Experimental|Treatment D metorpolol 50mg|metoprolol oral solution 1 mg/mL (dose 50 mg).
3080212|NCT02025335||high CMV ELISPOT results|high spot counts in ELISPOT
3080213|NCT02025335||low CMV ELISPOT results|low spot counts in ELISPOT
3080214|NCT02025322|No Intervention|Standard of Care|Between baseline and 4-month follow-up, control group patients will receive current standard of care which includes: (a) two or more HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (b) resource referrals from a Patient Navigator based on the participant's needs (e.g., mental health, substance abuse, social support groups, etc.); and (c) automated medical appointment reminders via phone.
3080215|NCT02025322|Experimental|Peer Mentoring|Between baseline and 4-month follow-up, experiment group patients will be receiving (a) Weekly contacts with their Peer Mentor, with the option of receiving more frequent contact, if needed; and (b) 4 monthly, 1-hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness. In addition, experiment group participants will also be provided with all standard practice services given to control group participants, including: (c) Two more or HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (d) resource referrals from a Patient Navigator based on the participant's needs; and (e) automated medical appointment reminders via phone.
3080216|NCT02025309|Active Comparator|Group Methylprednisolone|Patient in this group received general anaesthesia for surgical procedures. During the anesthesia management methylprednisolone was administered intravenously (1mg/kg) to the patients in this group. Also neuromuscular monitorisation was performed to assess the train of four ratio at the end of the procedure, after the reversal of neuromuscular block. All patients were followed during the recovery period from general anaesthesia and the time needed to regain a full neuromuscular recovery was noted. For that, the train of four ratio was followed up and the ratio of 0.9 was recorded.
3080217|NCT02025309|Placebo Comparator|Group Control|Patients who received general anaesthesia and endothracheal entubation but who did not recieved methyprednisone during general anaesthesia were enrolled in the study as control group. Neuromuscular monitorisation was performed to assess the train of four ratio at the end of the procedure, after the reversal of neuromuscular block. All patients were followed during the recovery period from general anaesthesia and the time needed to regain a full neuromuscular recovery was noted. For that, the train of four ratio was followed up and the ratio of 0.9 was recorded.
3080218|NCT02025296|No Intervention|Self-Monitoring of Blood Glucose|measurement of their blood glucose level using a glucometer at least eight times a week
3080219|NCT02025296|Experimental|U-healthcare|individualized multidisciplinary u-healthcare service combined with exercise monitoring and dietary feedback on glucose control
3080220|NCT02025283||Group Decompression|Group Decompression: Patients assigned to Group Decompression. After determination of the appropriate space for the approach under fluoroscopy guidance, a 17 gauge trochar needle was advanced posterolaterally up to the center of the disc. Then site verification was done again with water soluble contrast material under floroscopy guidance. Then flexible intradiscal decompression catheter (SpineCATH®, Smith & Nephew, Memphis, TN) were advanced inside the trochar needle towards the disc and decompression was performed. After being sure of achieving sufficient decompression inside the disc, the decompression device were removed under fluoroscopy guidance and the incision site was closed and the patients were recommended to have bedrest for 2 hours.
3080221|NCT02025283||Group Nucleoplasty|Group Nucleoplasty : Patients assigned to Group Nucleoplasty. After determination of the appropriate space for the approach under fluoroscopy guidance, a 17 gauge trochar needle was advanced posterolaterally up to the center of the disc. Then site verification was done again with water soluble contrast material under floroscopy guidance. Then radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM [ArthroCare Spine, Sunnyvale, CA] were advanced inside the trochar needle towards the disc and nucleoplasty was performed. After being sure of achieving sufficient decompression inside the disc, the nucleoplasty probe was removed under fluoroscopy guidance and the incision site was closed and the patients were recommended to have bedrest for 2 hours.
3080222|NCT02025270|Other|Laboratory and Clinical|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into rete testis.
3080223|NCT02025257|Experimental|Exercise|Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
3080224|NCT02025257|No Intervention|Control|Patients are asked to live as usual.
3080225|NCT02025244|Active Comparator|Key Hole Biopsy|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
3080226|NCT02025244|Active Comparator|EUS-FNA|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
3080227|NCT02025231|Experimental|External beam radiotherapy|Hypofractionated external beam radiation delivered in 4 different sequential dose/fractionation groups.
3080230|NCT02025205|No Intervention|Standard of Care|Patients will receive optimal drug therapy and medical management according to clinical practice.
3080231|NCT02025192|Experimental|Tucatinib (ONT-380) in combination with capecitabine|
3080232|NCT02025192|Experimental|Tucatinib (ONT-380) in combination with trastuzumab|
3080233|NCT02025192|Experimental|Tucatinib (ONT-380) combined with capecitabine and trastuzumab|
3080234|NCT02025179|Experimental|Teriparatide and vibration|"Experimental: Teriparatide and vibration~Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months~Device: Vibration 10 min/day for 12 months"
3080235|NCT02025166|Active Comparator|Paracetamol|Pain treatment, aniline analgesics
3080236|NCT02025166|Active Comparator|lornoxicam|Pain treatment, nonsteroidal anti-inflammatory (NSAID)
3080237|NCT02025153|Other|Cohort|pain testing. All 444 subjects enrolled in the study. Subjects will receive preoperative physical (tonic heat stimulation, mechanical temporal summation and wound hyperalgesia), psychological (State Trait Anxiety Inventory, Pain Catastrophizing Scale), and genetics test; postoperative pain score assessment at 24, 48 hours; postoperative wound hyperalgesia in open abdominal hysterectomy at 72 hours; and phone survey for CPSP at 4 months.
3080238|NCT02025153|Other|Chronic Post-surgical Pain|pain testing. physical testing, psychological testing, genetics testing and functional brain imaging
3080239|NCT02025153|Other|No Chronic Post-surgical Pain|pain testing. physical testing, psychological testing, genetics testing and functional brain imaging
3080240|NCT02025140|Active Comparator|: This group consisted of 30 patients.|The traditional IANB injection was given according to the standard technique (Evers and Haegerstam 1981). From everyday practice, it is known that the present operator takes approximately 60 to 90 seconds to give a mandibular block
3080241|NCT02025140|Experimental|30 IANB with Computer controlled|The IANB injection was given by a computer- regulated device performed with the STA system. The IANB injection was given according to the manufacturer's instruction (the model was used is the STA Single Tooth Anesthesia System produced by Milestone Scientific, Livingston, NJ).
3080242|NCT02025140|Experimental|consisted of 30 periodontal anesthesia|The interligamental injection was given by computer- regulated device performed with the STA system.
3080243|NCT02025127|Experimental|Trophic feeding|Mechanically ventilated patients with septic shock > 18 years old randomized to this group will receive more than 50 but less than 600 kilocalories of enteral nutrition per day while on vasopressors. This will be started within 24 hours of intensive care unit admission.
3080244|NCT02025127|No Intervention|No Enteral Nutrition|Mechanically ventilated patients with septic shock randomized to this group will receive no enteral nutrition while on vasopressor support.
3080245|NCT02025114|Experimental|Capsule|The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
3080246|NCT02025101||Slow Coronary Flow|Patients who were hospitalized with anginal pain and with laboratory markers or pathological ECG for ischemia.
3080247|NCT02025088|Active Comparator|Laser|In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
3080248|NCT02025088|Active Comparator|Microneedling|"In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction."
3080249|NCT02025075|Experimental|Deep Neuromuscular Block (NMB)|Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (neuromuscular function monitor).
3080250|NCT02025075|Active Comparator|Moderate Neuromuscular block (NMB)|Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 twitches in the train-on-four (neuromuscular function monitor).
3080251|NCT02025062|No Intervention|Control|In the control arm, patients are followed-up by the head-and-neck physician, oncologist and radiotherapists and did not benefit of Comprehensive Geriatric Assessment.
3080252|NCT02025062|Experimental|Comprehensive Geriatric Assessment|The CGA (Comprehensive Geriatric Assessment) is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up.
3080253|NCT02025049|Experimental|DP-b99|Intravenous DP-b99, 1.0 mg/kg twice daily for 2 consecutive days
3080254|NCT02025049|Placebo Comparator|Placebo|Intravenous placebo (mannitol based, DP-b99 look-alike) twice daily for 2 consecutive days
3080255|NCT02025036|Experimental|Capecitabine-oxaliplatin-radiotherapy|"oxaliplatin：65mg/m2，d1，8，22, 29,I.V.or d1, 8, 22, 29, 43, 50, 64, 71,I.V.plus,capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks or 12 weeks in total.~radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w."
3080256|NCT02025036|Active Comparator|cisplatin with 5-FU and radiotherapy|"cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85, 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.~radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w."
3080257|NCT02025036|Experimental|Capecitabine and radiotherapy|capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks or 12 weeks in total, radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
3080258|NCT02025023|Active Comparator|Incision and Curettage|A vertical incision over the area of chalazion will be done. Inflammatory material will be removed and the chalazion capsule will be excised.
3080259|NCT02025023|Active Comparator|Injection of Triamcinolone Acetonide|0.1 ml of triamcinolone is injected directly in the chalazion.
3080260|NCT02025023|Active Comparator|Injection of 5-fluorouracil|0.1 ml of 5-fluorouracil is injected directly in the lesion transconjunctivally.
3080261|NCT02025023|Active Comparator|Injection of triamcinolone/5FU mixture|0.1 ml of a 4:1 mixture of 4 parts 5-FU and 1 part triamcinolone is injected in the lesion.
3080292|NCT02024828|Experimental|Late/Fast|Infants were offered oral feedings beginning at 34 weeks PMA. They were offered 8 oral feedings every day, at each of 8 scheduled daily feedings.
3080293|NCT02024815|Experimental|External Beam radiotherapy|Single 8 Gy fraction
3080294|NCT02024815|Active Comparator|3 Gy x 10 fractions|External Beam radiotherapy - total dose 30 Gy, 3 Gy per fraction.
3080295|NCT02024789|Placebo Comparator|Placebo|
3080296|NCT02024789|Experimental|RG1662 120 mg bid|
3080297|NCT02024789|Experimental|RG1662 240 mg bid|
3080262|NCT02025010|Experimental|abiraterone acetate|"Pre-treatment and progression tumor biopsies.~Four 250 mg tablets (1,000 mg) of abiraterone acetate (AA) taken orally on 28 day cycles.~For participants who experience symptoms of persistent or severe hypertension or hypokalemia, prednisone 5 mg by mouth twice daily.~For participations who tolerate AA monotherapy without the addition of prednisone to manage symptoms of persistent or severe mineralocorticoid excess, prednisone 5 mg by mouth twice daily will be added at PSA progression.~Participants will undergo assessment of serum corticosteroid intermediates and ACTH at baseline and subsequent treatment visits for correlation with symptoms of mineralocorticoid excess."
3080263|NCT02024997|Experimental|Abdominal MRI|Subjects will undergo magnetic resonance imaging (MRI) with contrast. Magnetic resonance (MR)_freebreathing scan will be acquired. MR_inspiration scan will be acquired. MR_expiration scan will be acquired.
3080264|NCT02024984|Experimental|Group A|Luteal Phase Administration of Clomiphene (50mg twice per day for 5 days)
3080265|NCT02024984|Active Comparator|Group B|Follicular Phase Administration of Clomiphene Citrate in PCOS(50mg twice per day for 5 days)
3080266|NCT02024971||Pioglitazone/Metformin Hydrochloride|Pioglitazone/metformin hydrochloride combination tablets, orally, for 12 months as prescribed by the standard of care.
3080267|NCT02024958||indirect calorimetry measurement|Measurement of energy expenditure in made by indirect calorimetry in patients laying down in a supine position on a bed during ongoing measure by connecting the calorimeter to the endotracheal tube (invasive mechanical ventilation) or to the facemask (non-invasive mechanical ventilation), or by using a transparent canopy in plexiglas to cover the head while room-air flows through and is mixed with the expirate (spontaneous breathing). This mixture of patient breath and room air is finally collected and analyzed by the IC device for O2 and CO2 concentrations, and used to calculate EE. EE is calculated using the modified Weir equation.
3080268|NCT02024945||Propiverine|Participants with symptoms of OAB, prescribed propiverine in accordance with the summary of product characteristics (SPC).
3080269|NCT02024932|Experimental|BVS857 Part A Open label (Cohort 1)|Participants received single doses of 0.01 mg/kg BVS857 intravenously (i.v.) on day 1, 0.01 mg/kg BVS857 subcutaneously (s.c.) on day 15, 0.03 mg/kg BVS857 s.c. on day 29, 0.06 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57.
3080270|NCT02024932|Experimental|BVS857 Part A double blind (Cohort 2)|Participants received single doses of 0.03 mg/kg BVS857 i.v on day 1, 0.03 mg/kg BVS857 s.c. on day 15, 0.06 mg/kg BVS857 s.c. on day 29, 0.10 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57. (BVS857 concentrations differed on days 43 and 57.)
3080271|NCT02024932|Placebo Comparator|Placebo Part A double blind (Cohort 2)|Participants received single doses of matching placebo i.v. on day 1 and matching placebo s.c. on days 15, 29, 43 and 57.
3080272|NCT02024932|Experimental|BVS857 Part B open-label (Cohort 4)|Participants received 0.1 mg/kg BVS857 i.v. weekly for 12 weeks.
3080273|NCT02024932|Experimental|BVS857 Part B double blind (Cohort 5)|Participants received 0.06 mg/kg (maximum 6 mg) BVS857 i.v. weekly for 12 weeks.
3080274|NCT02024932|Placebo Comparator|Placebo Part B double blind (Cohort 5)|Participants received matching placebo i.v. to BVS857 weekly for 12 weeks.
3080275|NCT02024919|Active Comparator|Diltiazem|intracoronary diltiazem 5 milligrams which is diluted with 5 mL of saline
3080276|NCT02024919|Placebo Comparator|Saline|intracoronary saline 5 mL
3080277|NCT02024906|Experimental|soy protein isolate (SPI)|25 grams soy protein isolate (SPI) containing approximately 30 mg/d isoflavones
3080278|NCT02024906|Active Comparator|milk protein isolate (MPI)|milk protein isolate (MPI) containing 0 mg/d isoflavones
3080279|NCT02024893||National womens water- polo team|Observational study-members of the national womens waterpolo team participating in formal team training and tournaments for the 2014-2015 season.
3080280|NCT02024893||National mens handball team|Observational study-Twenty men , members of the national , over 18 years old handball team preparing for the european championships for summer 2014
3080281|NCT02024893||National womens volleyball team|20 players who are part of the women's national olympic volleyball team
3080282|NCT02024880|Experimental|Protective catheter group|Protective catheter group uses Guardia™ Pro Protective ET catheter from Cook.
3080283|NCT02024880|Active Comparator|Conventional catheter group|Conventional catheter group uses Sydney IVF catheter from Cook.
3080284|NCT02024867|Active Comparator|10 days of Trimethoprim-Sulfamethoxazole|Oral Trimethoprim-Sulfamethoxazole dosed at 10 mg Trimethoprim/kg/day divided twice a day, to a maximum of 640 mg Trimethoprim/day
3080285|NCT02024867|Experimental|3 days of Trimethoprim-Sulfamethoxazole|Oral Trimethoprim-Sulfamethoxazole dosed at 10 mg Trimethoprim/kg/day divided twice a day, to a maximum of 640 mg Trimethoprim/day
3080286|NCT02024854|Experimental|skin-to-skin|immediately after birth the baby is laid on mother's chest for as long as justifiable medically to max 2 hours.
3080287|NCT02024854|Active Comparator|standard care|after birth the baby is transferred to the neonatal intensive care unit
3080288|NCT02024841|Experimental|Intraperitoneal docetaxel|"Intraperitoneal docetaxel in 1litre normal saline infused over 1 hour on day 1 every 3 weeks:~- Level I: 40mg/m2; Level II: 50mg/m2; Level III: 60mg/m2~Intravenous cisplatin: 60mg/m2 on day 1 every 3 weeks~Oral TS-ONE: 40-60mg twice daily on day 1 -14 every 3 weeks"
3080289|NCT02024828|Experimental|Early/Slow|Infants were offered oral feedings beginning at 32 weeks PMA. They were offered 2 oral feedings per day for 3 days (Days 1-3). The number of oral feedings offered per day increased by 1 feeding every other day until day 14 when they were offered 8 oral feedings each day (Days 4-5, 3 oral feeds offered; Days 6-7, 4 oral feeds offered; Days 8-9, 5 oral feeds offered; Days 10-11, 6 oral feeds offered; Days 12-13, 7 oral feeds offered; Day14, 8 oral feeds offered). Any feedings not offered orally were provided by gavage.
3080290|NCT02024828|Experimental|Early/Fast|Infants were first offered oral feedings beginning at 32 weeks PMA. They were offered 8 oral feedings every day, at each of 8 scheduled daily feedings.
3080291|NCT02024828|Experimental|Late/Slow|Infants were offered oral feedings beginning at 34 weeks PMA. They were offered 2 oral feedings per day for 3 days (Days 1-3). The number of oral feedings offered per day increased by 1 feeding every other day until day 14 when they were offered 8 oral feedings each day (Days 4-5, 3 oral feeds offered; Days 6-7, 4 oral feeds offered; Days 8-9, 5 oral feeds offered; Days 10-11, 6 oral feeds offered; Days 12-13, 7 oral feeds offered; Day14, 8 oral feeds offered). Any feedings not offered orally were provided by gavage.
3081316|NCT02017938|Experimental|Stage 2: Health group|Stage 2 controlled group
3080298|NCT02024776|Active Comparator|Prehabilitation|Prehabilitation program is defined as a tailored physical exercise program to be carried out to a patient on the basis of his/her health condition, social circumstances and adherence profile. The intervention consisted of a standard 4-6 week supervised outpatient program including global endurance exercise training, or educational sessions followed by a self-management program supported by ICT during the follow-up period, or a combination of both.
3080299|NCT02024776|No Intervention|No-intervention|Standard counseling and conventional pre-surgical measures
3080300|NCT02024763|Experimental|Educational Intervention|Intervention was applied to classroom teachers by the RRIDA Project team. Training lasted six weeks, 12 hours devoted to physical activity and 18 hours to nutritional content. Modules of educational activities were taught in order to be replicated at PE classes to 1st and 2nd grades' children of three exposed schools. Physical activity module was based on a theoretical approach of physical activity benefits and risks for health, children's physical fitness and activity patterns, physical education and change behavior models. In each meeting the PE professionals, performed PE classes with the classroom teachers as students, focusing in strategies to keep them in movement for the most of PE class time to stimulate students' joint participation instead of individual participation or games.
3080301|NCT02024763|No Intervention|No Intervention|No educational intervention was taken place in the control schools while the project was running. Afterwards, control schools received training.
3080302|NCT02024750|Experimental|Tailored Resources|Use of PRISM screening tool to identify self-management needs and to provide tailored group session resources over 1 year
3080303|NCT02024750|No Intervention|Control|Patients and families obtain routine multidisciplinary diabetes care
3080304|NCT02024737||Moderate-Severe COPD|"Patients with moderate to severe COPD, as defined by GOLD 2-3 (The GOLD classifications are the main method doctors use to describe the severity of COPD.~GOLD is short for the Global Initiative for Chronic Obstructive Lung Disease, a collaboration between the National Institutes of Health and the World Health Organization)"
3080305|NCT02024724|Active Comparator|Dexamethasone|4 mg of Dexamethasone and 4 mL of 0.25% bupivacaine
3080306|NCT02024724|Active Comparator|Triamcinolone|40 mg of Triamcinolone and 4 mL of 0.25% bupivacaine
3080307|NCT02024711|Experimental|EYEFILL® C.-US Viscoelastic|EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
3080308|NCT02024711|Active Comparator|Healon® Viscoelastic (CONTROL)|Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
3080309|NCT02024698|Active Comparator|omafilcon A|Study participants are randomized to wear omafilcon A lenses.
3080310|NCT02024698|Active Comparator|etafilcon A|Study participants are randomized to wear etafilcon A lenses.
3080311|NCT02024685|Active Comparator|Standard patient-physician counseling interaction|The control arm will receive counseling regarding treatment options using standard patient-physician interactions and nomogram-predicted probabilities of treatment outcome for the various treatment options and they will be unaware of the decision analysis recommendation.
3080312|NCT02024685|Experimental|Personalized treatment recommendations|The treatment arm would be provided with a personalized treatment recommendations based on the decision analysis model prior to treatment selection.
3080313|NCT02024672||Immediate postpartum placement of IUD|Women who plan to have an IUD placed at the time of cesarean section or vaginal delivery, or women who have had an IUD placed at the time of cesarean section or vaginal delivery.
3080314|NCT02024659|Experimental|budesonide|
3080315|NCT02024659|Placebo Comparator|placebo|
3080316|NCT02024646|Experimental|210 mg brodalumab|Administered via subcutaneous injections.
3080317|NCT02024646|Experimental|140 mg brodalumab|Administered via subcutaneous injection.
3080318|NCT02024646|Placebo Comparator|Placebo|Administered via subcutaneous injection until week 24.
3080319|NCT02024633|Experimental|icotinib plus gemcitabine|"Three dose of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.~Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks."
3080320|NCT02024620|Experimental|Behavioral activation plus mobile app|Standard behavioral activation protocol with the addition of the Mood Coach mobile app to replace the paper and pencil forms used in the standard protocol.
3080321|NCT02024620|Active Comparator|Standard behavioral activation|Standard behavioral activation protocol using paper and pencil forms for treatment delivery and homework completion.
3080322|NCT02024607|Experimental|ARM A- BBI608 in combination with FOLFOX6|BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2 over 46-48 hours) continuous intravenous infusion This regimen will be repeated every 14 days thereafter.
3080323|NCT02024607|Experimental|ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab|BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2 over 46-48 hours) continuous intravenous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.
3080324|NCT02024607|Experimental|ARM C- BBI608 in combination with CAPOX|BBI608 is administered orally twice daily, continuously. CAPOX regimen will be administered orally (capecitabine) and IV (oxaliplatin). Capecitabine 850 mg/m^2 will be administered orally twice-daily for 14 consecutive days and be repeated every 21 days. Oxaliplatin will be administered IV and be repeated every 21 days thereafter. If capecitabine is tolerated at the 850 mg/m^2 twice daily dose, dosage may be increased to 1000 mg/m^2 twice daily as tolerated after the first cycle.
3080511|NCT02023294|Active Comparator|Lap|Patients candidate to bariatric surgery undergoing Conventional laparoscopic Sleeve Gastrectomy
3080325|NCT02024607|Experimental|ARM D- BBI608 in combination with FOLFIRI|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated every 14 days thereafter.
3080326|NCT02024607|Experimental|ARM E- BBI608 in combination with FOLFIRI and Bevacizumab|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.
3080327|NCT02024607|Experimental|ARM F- BBI608 in combination with Regorafenib|BBI608 is administered orally twice daily, continuously. Regorafenib 120 mg will be administered orally once daily, with a low-fat meal and be continued for 21 consecutive days of every 28 days thereafter. If regorafenib is tolerated in the first cycle, dosage may be increased to 160 mg once daily as tolerated after the first cycle.
3080328|NCT02024607|Experimental|Arm G- BBI608 in combination with Irinotecan|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 will be administered intravenously. This regimen will be repeated every 14 days thereafter.
3080329|NCT02024594|Experimental|Nitrous Oxide-Oxygen|Children in this group were sedated by rapid induction method by means of Nitrous Oxide-Oxygen gas.
3080330|NCT02024594|Experimental|cognitive-behavioral therapy|Children in this group were asked to come to playroom before entering operation room. Modeling , Benson relaxation and positive self-talking were instructed to them.
3080331|NCT02024594|No Intervention|control|No intervention
3080332|NCT02024581|Active Comparator|10% East Indian sandalwood oil cream|East Indian sandalwood oil in a cream formulation administered twice a day for ninety (90) days
3080333|NCT02024581|Placebo Comparator|Placebo cream|A scented cream formulation administered twice a day for ninety (90) days
3080334|NCT02024568|Active Comparator|Pregabalin|"Includes 19 out of 38 subjects reporting athralgia-myalgia in the wake of paclitaxel infusion in the course of breast cancer treatment.~Pregabalin started on the evening before receiving infusion of paclitaxel and 5 day thereafter. Initial dosing of 75mg twice daily (morning + evening). Option for dose increase with additional 75mg in case of inadequate pain control. A minimal interval of 2 hours is required between doses.~In case of poorly tolerated side effects a reduction to 50mg doses is available.~Access to additional analgesic interventions is open as required for patient wellbeing."
3080335|NCT02024568|Placebo Comparator|Placebo|"Includes 19 out of 38 subjects reporting athralgia-myalgia in the wake of paclitaxel infusion in the course of breast cancer treatment.~Placebo externally identical to the pregabalin 75mg capsules will be started on the evening before receiving infusion of paclitaxel and 5 day thereafter. Initial dosing of 1 capsule twice daily (morning + evening). Option for dose increase with additional capsule in case of inadequate pain control. A minimal interval of 2 hours is required between doses.~In case of poorly tolerated side effects a reduction to capsules with the appearance of 50mg pregabalin capsules is available.~Access to additional analgesic interventions is open as required for patient wellbeing."
3080336|NCT02024555|Active Comparator|Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin|Levofloxacin 500mg po QD; Ethambutol 1200mg po QD; Azithromycin 250 mg po QD; Rifampin 600mg po QD or Rifabutin 300mg po QD
3080337|NCT02024555|Placebo Comparator|Placebo|"Riboflavin will be used for rifampin; encapsulated microcrystalline cellulose will be used to replace the levofloxacin, ethambutol and azithromycin.~The pill count will be the same as the comparator regimen."
3080338|NCT02024542||Weight Loss Surgery - Healthy|Patients consented to participate have met the NIH criteria for Bariatric Surgery and have completed the normal pre-operative work up including nutritional counseling, psychological evaluation, and all necessary studies to rule out other co-morbid conditions prior to surgery. Patients do not have metabolic syndrome.
3080339|NCT02024542||Weight Loss Surgery - Metabolic Syndrome|Patients consented to participate have met the NIH criteria for Bariatric Surgery and have completed the normal pre-operative work up including nutritional counseling, psychological evaluation, and all necessary studies to rule out other co-morbid conditions prior to surgery. Patients have metabolic syndrome.
3080340|NCT02024529|Experimental|Ampion < 5 kDa ultrafiltrate of 5% HSA|4 mL Intra-articular injection of Ampion
3080341|NCT02024529|Placebo Comparator|Placebo solution|4 mL placebo intra-articular injection
3080342|NCT02024516|Experimental|50 gr concentrated pomegranate juice|
3080343|NCT02024503||Experimental group|Hospitalized patients with acute stroke.
3080344|NCT02024503||Control group|Healthy Volunteers.
3080345|NCT02024490||RDS group, non-RDS group|RDS group; infants with clinical, radiological and laboratory findings of RDS non-RDS group; infants without clinical, radiological and laboratory findings of RDS
3080346|NCT02024477|Placebo Comparator|Placebo|Matching placebo 1 pill daily for 12 weeks
3080347|NCT02024477|Active Comparator|saxagliptin|Saxagliptin 5mg once daily for 12 weeks
3080348|NCT02024464|Experimental|Hydrus Microstent|Patients randomized to the Hydrus Microstent
3080349|NCT02024464|Active Comparator|iStent Trabecular Micro Bypass|Patients randomized to the iStent Trabecular Micro Bypass
3080350|NCT02024451|Active Comparator|Radial shock wave, Acupuncture|"Radial shock wave: 2 Hz with 2000 shock waves, and the energy level of 0.056mJ/mm2 in the trapezius muscle. It will be done once per week for 3 weeks.~Acupuncture: performed at Fenfchi (GB20) point over upper back. It will be performed once per week for 3 weeks ."
3080351|NCT02024451|No Intervention|radial shock wave& no treatment|No treatment: patients recieved no intervention.
3080352|NCT02024438|Other|placebo|arm B: equal saline as placebo ,one hour before chemotherapy(mFOLFOX6) every two weeks until tumor progress or intolerant
3080353|NCT02024438|Experimental|monosialotetrahexosylganglioside Sodium|arm A: monosialotetrahexosylganglioside Sodium Injection, 40mg,one hour before chemotherapy(mFOLFOX6), every two weeks until tumor progress or patients become intolerant
3080354|NCT02024425|Active Comparator|Functional bioactive supplement|The functional bioactive supplement is composed of antioxidant extracted from rosemary, oligosaccharides derived from lactulose and bioactive peptides. It will be used for obese and overweight treatment
3080355|NCT02024425|Placebo Comparator|Maltodextrin and saccharose|The control supplement is composed of maltodextrin and saccharose . It has no effect for obese and overweight treatment
3080356|NCT02024412|Experimental|monosialotetrahexosylganglioside Sodium|arm A: monosialotetrahexosylganglioside Sodium Injection, 40mg,one hour before chemotherapy(mFOLFOX6), every two weeks until tumor progress or patients become intolerant
3080357|NCT02024412|Placebo Comparator|placebo|arm B: equal saline as placebo ,one hour before chemotherapy(mFOLFOX6) every two weeks until tumor progress or intolerant
3080358|NCT02024399|Other|Exercise|Strength training x 20 sessions (10 weeks) Aerobic exercise core strengthening Running
3080359|NCT02024386|Experimental|Riociguat 0.5 mg|Riociguat 0.5 mg tablets, one-time oral dose of 0.5 mg
3080360|NCT02024386|Experimental|Riociguat 1.0 mg|Riociguat 0.5 mg tablets, one-time oral dose of 1.0 mg
3080361|NCT02024386|No Intervention|Control arm|No drug
3080362|NCT02024373|Experimental|Atorvastatin|atorvastatin：20 mg (every evening orally) for 8 weeks
3080363|NCT02024373|Placebo Comparator|placebo|placebo:20 mg (every evening orally) for 8 weeks
3080364|NCT02024360|Experimental|patient navigation|Patient navigator visits home to encourage health eating, active living and parental skill building
3080365|NCT02024347||LSSM arm|Intervention: upper endoscopy only performed to patients with high LSM (≥12.0kPa) or SSM (≥41.3kPa) values
3080366|NCT02024347||Control arm|Intervention: upper endoscopy performed to all patients in this group.
3080367|NCT02024334|Active Comparator|leflunomide|leflunomide tablet: for patients less than 20 kg: 10 mg every 2 day, for patients 20 - 40 kg: 10 mg daily, for patients more than 40 kg: 20 mg daily.
3080368|NCT02024334|Placebo Comparator|placebo|placebo tablet for patients less than 20 kg: 10 mg every 2 day, for patients 20 - 40 kg: 10 mg daily, for patients more than 40 kg: 20 mg daily.
3080369|NCT02024321||Tumor patients, TPN, surgery|This work involved prospective study of surgical patients receiving TPN during the calendar year of 2013 at Cancer Hospital.
3080370|NCT02024308|Experimental|Fludarabine|The patients in experimental arm should receive the consolidation chemotherapy regimen with fludarabine and cytarabine. The dosage of fludarabine is 30mg/m2/d for 5 days intravenously and cytarabine is 1.4g/m2/d for 5 days intravenously.
3080371|NCT02024308|Active Comparator|HD-Arac|The patients in control arm should receive the consolidation chemotherapy regimen with high-dose cytarabine. The dosage of cytarabine is 2000mg/m2/12h for 3 days (1,3,5) intravenously.
3080372|NCT02024295|Experimental|Ademethionine|ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
3080373|NCT02024295|Active Comparator|Polyene Phosphatidyl choline|Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
3080374|NCT02024282|Other|usual care|
3080375|NCT02024282|Active Comparator|Use of C-reactive protein point of care (CRP POC) test|"CRP analysis will be performed during the consultation in accordance with the manufacturer's instructions.~The CRP point of care test will be performed in case of a positive decision tree (irrespective of the intervention group) and also in case of a negative decision tree by clinicians of intervention group 1 and 2. Because no reliable cut-off points for CRP are known currently (as this is the aim of this study) for acute infections in children in primary care (nor for referral, nor for prescription of antibiotics), clinicians will not be given guidance on the interpretation of the CRP results.~We will not impose restrictions on the clinicians about treatment, other technical investigations nor referrals.~The device distributor will provide technical assistance. All clinicians will be trained in the use of the CRP device prior to the start of the study."
3080376|NCT02024282|Active Comparator|Brief intervention and parent leaflet|
3080377|NCT02024282|Active Comparator|CRP POC test and brief intervention & parent leaflet|Combination of CRP POC test and the brief intervention & parent information leaflet intervention groups (factorial design)
3080378|NCT02024269|Experimental|Adipose Stem Cells|
3080379|NCT02024256|Active Comparator|Magnesium sulfate|Pads soaked in cold magnesium sulfate solution
3080380|NCT02024256|Sham Comparator|Water|Pads soaked with cold water
3080381|NCT02024243||miR210 and Punch Tissue Biopsy|Patients visiting the OSU Wexner Medical Center Comprehensive Wound Center, with a choronic venous leg ulcer(s), who qualify based on the study inclusion and exclusion criteria, will be involved in a 14-week (98 days) longitudinal observational study. All subjects in this arm will have wound measurements, photographs for digital planimetry to measure wound area, and two 3 mm punch tissue biopsies of the same wound/ulcer (for OCT & infection) on days day 0, 14, and 28. Biopsies will not be taken if the wound has closed by day 14 or 28. Patient charts will be reviewed 98 days (14 weeks) after enrollment to determine the final status of the wound as healed or not-healed.
3080382|NCT02024230|Experimental|Warfarin|The dose of warfarin can be controlled so that the PT-INR value will be 2.0-3.0 in those aged under 70 years and 1.6-2.6 in those aged 70 years or more.
3080383|NCT02024230|Active Comparator|Rivaroxaban|A dose of 15 mg of rivaroxaban is orally administered to adults once a day. The dose can be reduced to 10 mg in patients with renal insufficiency (creatinine clearance: 30-49 mL/minute), patients at a high risk of hemorrhage (HAS-BLED score), old patients aged 75 years or more, and low body weight patients.
3080384|NCT02024217|Experimental|chemoradiotherapy, S1, oxaliplatin|chemoradiotherapy is given before surgical therapy,S1(Tegafur，Gimeracil and Oteracil Potassium Capsules) is given during radiation therapy and neoadjuvant chemotherapy, oxaliplatin is given during neoadjuvant chemotherapy.
3080385|NCT02024204|Active Comparator|Visit 1 Uncontrolled LRS|Patients who have uncontrolled LRS (ACT < 20) at time of Visit 1 will be provided with study Advair (Fluticasone propionate 230mcg/salmeterol 21mcg) for a total of 3 months and receive medication adherence counseling Patients who have uncontrolled LRS at V1, but do not fit criteria for Step 3,4 or 5 asthma therapy according to NIH EPR III asthma guidelines will be deferred from the study until they have been seen by their physician and tried on ICS therapy.
3080386|NCT02024204|Other|Visit 1 Controlled LRS|Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
3080387|NCT02024191|Experimental|Glutamine|The patient group had 3x10 gr daily glutamine during first 4 cycles of mFOLFOX6 regimen.
3080388|NCT02024191|No Intervention|Observation|The group who had only mFOLFOX6 regimen, no additional intervention for neuropathy prophylaxis..
3080389|NCT02024178|Experimental|Ultrasound Imaging|Men already electing to undergo radical prostatectomy will undergo transrectal ultrasound procedure at induction of anesthesia prior to their surgery procedure.
3080390|NCT02024165||Electrode Sensor, FSE|Pregnant women between the ages of 18-50 with a single viable fetus in cephalic presentation monitored with Electrode Sensor, and/or FSE
3080391|NCT02024165||Electrode Sensor, Ultrasound|Pregnant women between the ages of 18-50 with a single viable fetus in cephalic presentation monitored with Electrode Sensor, and/or Ultrasound
3080392|NCT02024152|Experimental|JDP-205 IV high dose|
3080393|NCT02024152|Experimental|JDP-205 IV low dose|
3080394|NCT02024152|Experimental|JDP-205 IM high dose|
3080395|NCT02024152|Active Comparator|Control|
3080396|NCT02024139|Experimental|Chewing Sugarless Gum and Mouthwash|Patients are asked to chew sugarless gum 3 times per day in addition to using a fluoridated mouthwash 3 times per day
3080397|NCT02024139|Placebo Comparator|Using fluoridated mouthwash|Using Mouthwash: Patients are asked to use a fluoridated mouthwash 3 times per day as a placebo
3080398|NCT02024126|Experimental|High dosage exercise therapy|The high-dosage exercise treatment will be conducted under supervision of experienced physiotherapists, and it follows an exercise protocol previously described as Medical Exercise Therapy, MET. The regimen contains different semi-global and local exercises for the knee. To be able to reach a high number of repetitions despite ongoing pain, the principle of de-loading (reducing weight) will be applied. The use of de-loading allows high number of repetitions nearly or entirely pain free. Later, as the patient improves and tolerates increased loading, the exercises are adapted to be more functional, using closed chain exercises without de-loading the body. Each of the exercises will be performed in 3 sets of 30 repetitions with 30-60s rest in between. Global exercises using a stationary bike will be performed three times during one treatment-session; first 20 minutes as global pain modulation, ten minutes in the middle of the treatment, and then ten minutes at the end of the treatment.
3080399|NCT02024126|Active Comparator|Lower dosage exercise therapy|Patients in the comparison-/control group will perform six exercises, of which, five will be in 2 sets of 10 repetitions combining local and semi-global exercises, again using the principle of de-loading. The five semi-global and local exercises are the same as performed in the MET-group, and the regimen will be supervised in the same manner as for the MET-group. The therapy starts with 10 minutes using a stationary bike, and the same principles will be applied as for the MET-group regarding grading and follow-up with exercises and adjusting the exercises so that they are performed close to pain-free.
3080400|NCT02024113||Lung cancer|"Subjects with lung cancer detected by a computed tomography (CT)-scan and referred to a positron emission tomography (PET)/CT-scan are included. The diagnosis of lung cancer is confirmed by means of an pathological biopsy or by a medical doctor specialized in oncology with respect to radiological or clinical data.~Intervention: a fasted venous blood sample is taken before PET-scan"
3080401|NCT02024113||Control subjects|"The control group consists of subjects who were referred to the department Nuclear Medicine for an examination of the heart. This control group represents the average population, consists of healthy subjects and patients with non-cancer diseases and who did not undergo a PET/CT-scan.~Intervention: fasted venous blood sample"
3080402|NCT02024087|Experimental|Dalantercept plus sorafenib|
3080403|NCT02024074|Other|Sestamibi(Tc- MBI) scan of the breast|
3080404|NCT02024061|Experimental|Peer support|"The intervention will be similar with the exception that in the experimental group during the interventions (Interactive Sessions, Physical activity sessions and holiday camps), the presence of peers is predominant, indispensable and motivational in the context and the dynamics of development of activities.~A team composed by a paediatrician and five exercise physiologists will conduct the delivery of the intervention. They all have previous training in adolescent obesity, resulting from their involvement in the adolescent obesity consult at the Hospital of Santa Maria."
3080405|NCT02024061|Active Comparator|Regular treatment|"The intervention will be similar with the exception that in the experimental group during the interventions (IS, PA sessions and holiday camps), the presence of peers is predominant, indispensible and motivational in the context and the dynamics of development of activities.~A team composed by a paediatrician and five exercise physiologists will conduct the delivery of the intervention. They all have previous training in adolescent obesity, resulting from their involvement in the adolescent obesity consult at the Hospital of Santa Maria."
3080406|NCT02024048||Pregnant|OCT
3080407|NCT02024048||Control|OCT
3080408|NCT02024035||Tomotherapy|
3080409|NCT02024035||Arc'therapy Vmat|
3080410|NCT02024035||Arctherapy Rapid'Arc|
3080411|NCT02024022|Active Comparator|Standard approach|"patients will be randomized to one of the 2 currently used bowel preparation regimens in our clinic:~4L split polyethylene glycol solution~split magnesium citrate/sodium picosulphate preparation regimen"
3080412|NCT02024022|Experimental|Individualized approach|patients will receive either the 4L split polyethylene glycol bowel prep regimen or the sodium picosulphate/magnesium citrate split prep regimen according to personal characteristics assessed using a self-administered questionnaire (including bowel habits, the preference for large-volume preparation and education level)
3080413|NCT02024009|Experimental|Arm A|"12 weeks (3 cycles) of induction Gemcitabine and Nab-paclitaxel (GEMABX) chemotherapy then 1 cycle of GEMABX* whilst radiotherapy (RT) planned then capecitabine (830mg/m2 oral bd) + Nelfinavir** + 50.4 Grays (Gy) in 28#~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
3080414|NCT02024009|Experimental|Arm B|"12 weeks (3 cycles) of induction GEMABX chemotherapy then 1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + 50.4Gy in 28#~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
3080415|NCT02024009|Experimental|Arm C|"12 weeks (3 cycles) of induction GEMABX chemotherapy then~1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + Nelfinavir** + 60Gy in 30#~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15"
3080416|NCT02024009|Experimental|Arm D|"12 weeks (3 cycles) of induction GEMABX chemotherapy then~1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + 60Gy in 30#~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
3080512|NCT02023294|Experimental|SILS|Patients candidate to bariatric surgery undergoing Single Incision Laparoscopic Sleeve Gastrectomy supported by Endograb
3080417|NCT02024009|Experimental|Arm E|"6 cycles of GEMABX*~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
3080418|NCT02023996|Experimental|PET Imaging With 89Zr-DFO-Trastuzumab|Patients will receive 5 mCi + 0.5 mCi of 89Zr-DFO-trastuzumab given IV over 5-10 min. Injection of cold trastuzumab will be mixed with 89Zr-DFO-trastuzumab so that total mass is equal to 50 mg [1]. In the first ten patients we wish to obtain normal organ dosimetry, pharmacokinetics & determine optimal imaging time, therefore these patients will undergo imaging at 4 time points post injection, whole body counts & blood draws. Subsequent patients will receive the antibody & will only undergo imaging at a single time point (based on the first 10 patients) & will not have whole body counts or serial bloods for pharmacokinetics. The administration of 89Zr-DFO-trastuzumab to patients undergoing a second study will be identical as for their baseline study. Patients undergoing a second injection will only have one scan that will be performed within 1 day before or 2 days after their optimum imaging time point, determined from their baseline imaging study.
3080419|NCT02023983|Experimental|Early discharge|
3080420|NCT02023983|Active Comparator|Standard discharge|
3080421|NCT02023970|Other|Phase A: Diagnostic Study|Objective: to assess the differential immune response in patients with or without SVD (given the low rate of SVD) a matched cases-controls study allows a powerful statistical analysis avoiding main confounding factors for a first discovery of a SVD-specific immune response. Results will be validated in prospective Phase B.
3080422|NCT02023970|Other|Phase B1 (Prospective Study): Cohort of prevalent patients|This cohort is specifically designed to study the kinetics of the immune response before and after implantation of an aortic BHV. Eight of the most frequently implanted BHV worldwide will be assessed:
3080423|NCT02023970|Other|Phase B2 (Prospective Study): Cohort of incident patients|Due to the low incidence of SVD during the first 4 post-operative years, a second cohort will be constituted by patients undergone biological aortic valve replacement at least 5 years before. The objective of this second cohort is to cover a period of time where risk of SVD occurrence is potentially high.
3080424|NCT02023957|Experimental|Interactive computer-assisted screening|Eligible patients completed the interactive computer-assisted screening (iCAS) tool in English or Spanish before seeing the consenting clinician. Participating patients then received the iCAS generated tailored recommendation sheet. Participating clinicians received the iCAS generated risk report.
3080425|NCT02023957|No Intervention|Usual Care|Eligible patients randomized to the control group completed their standard visit to the participating clinician. There was no pre-visit health risk screening. There were no tailored reports for the patients or clinicians.
3080426|NCT02023944|Experimental|Intervention|12-week course on aging
3080427|NCT02023944|No Intervention|Control, No Intervention|No Intervention
3080428|NCT02023931|Experimental|Broccoli Sprout Extract Drink|Three different regimens of BSE delivery will be evaluated in each participant, with participants serving as their own controls. Each regimen will involve a 3 day exposure, with daily collection of buccal cell scrapings. Between regimens, a minimum 3 day (72 hour) washout period will occur.
3080429|NCT02023918|Experimental|Pegvisomant arm|Pegvisomant 20 mg subcutaneously Qday x 28 days will be administered by the study subject.
3080430|NCT02023905|Experimental|Arm 1|If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If activation is present, patients will be treated in Arm 1 with single-agent everolimus at 10 mg daily continuously. In all arms, treatment with everolimus will continue for up to 24 cycles, after which patients will be followed with interval MRIs until progression.
3080431|NCT02023905|Experimental|Arm 2|If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If activation is not present, patients will be treated in Arm 2 with combined everolimus and Temozolomide. Everolimus will be given at 10 mg daily continuously, and Temozolomide will be dosed initially at 150 mg/m2/day for 5 days out of a 28-day cycle. In all arms, treatment with everolimus will continue for up to 24 cycles, after which patients will be followed with interval MRIs until progression. In Arm 2, TMZ will be stopped after 12 cycles.
3080432|NCT02023905|Experimental|Arm 3|If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If 1p/19q co-deletion is present, patients will be treated in Arm 3 with single-agent everolimus at 10 mg daily continuously. In all arms, treatment with everolimus will continue for up to 24 cycles, after which patients will be followed with interval MRIs until progression.
3080433|NCT02023892|Experimental|atorvastatin|atorvastatin 20mg tablet, single dose of 80mg by mouth
3080434|NCT02023892|Placebo Comparator|placebo|placebo 20mg tablet, single dose of 80mg by mouth
3080435|NCT02023879|Placebo Comparator|Placebo Q2W|"Period 1: Placebo (for Alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable non-statin lipid modifying therapy (LMT) or diet alone for 24 weeks.~Period 2: Alirocumab 150 mg SC injection every 4 weeks (Q4W) from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and low-density lipoprotein cholesterol (LDL-C) values. Subsequent down titration to 150 mg Q4W was allowed."
3080436|NCT02023879|Other|Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)|"Period 1: Alirocumab 75 mg SC injection Q2W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline.~Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed."
3080513|NCT02023281|No Intervention|Control Group|Control group will serve as a wait list and not be exposed to the intervention.
3080514|NCT02023281|Experimental|Experimental Group|The experimental group will engage in a mild-moderate level of structured and clinically supervised exercise program for approx. 30-45 mins 2-3 days per week for 12 weeks
3080515|NCT02023268|Experimental|T2762|
3080516|NCT02023268|Active Comparator|Vismed®|
3081382|NCT02017444|Active Comparator|AZD4017 (11b-HSD1 inhibitor)|AZD4017 400mg tablet B.D. for 12 weeks
3080437|NCT02023879|Experimental|Alirocumab 150 mg Q4W/Up to 150 mg Q2W|"Period 1: Alirocumab 150 mg SC injection Q4W alternating with placebo (for alirocumab) Q4W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline.~Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed."
3080438|NCT02023866|Experimental|Cysteamine Bitartrate Delayed-release|Cysteamine bitartrate delayed-release capsules were administered twice daily following a dose-escalation design with a progressive weekly dose increase over the first 6 weeks. The starting dose was 0.2 g/m²/day, up to a maximum dose of 1.3 g/m²/day. Participants remained on their highest tolerated dose until Week 24.
3080439|NCT02023853|Experimental|ultrasonic, erythritol, metronidazole gel|
3080440|NCT02023840|Active Comparator|ultrasonics and erythritol, metronidazole gel|Scaling and root planing with ultrasonics and erythritol air powder will be followed by application of metronidazole gel
3080441|NCT02023840|Placebo Comparator|ultrasonics and erythritol, placebo|Scaling and root planing with ultrasonics and erythritol air powder will be followed by application of placebo
3080442|NCT02023827|Experimental|RAYS intervention|In addition to standard care, participants receive three monthly online RAYS sessions, each followed by a one-on-one discussion with the probation officer
3080443|NCT02023827|No Intervention|Standard care|Participants receive standard care from the probation officer
3080444|NCT02023814||Study group|All patients who underwent stem cell mobilization after chemotherapy and G-CSF at our institution between 2002 and 2013
3080445|NCT02023801|Experimental|Aurora Treatment Arm|Endometrial Ablation
3080446|NCT02023788||Pneumostem®|"Low Dose Group (3 subjects): 1.0 x 10^7 cells/kg, High Dose Group (6 subjects): 2.0 x 10^7 cells/kg~Intervention: Biological: Pneumostem®"
3080447|NCT02023775||Patients implanted with Medtronic Melody valve|
3080448|NCT02023749|Active Comparator|Nut group|Subjects were supplemented with 30 g of mixed nuts including walnuts, peanuts, and pine nuts for 6 weeks
3080449|NCT02023749|No Intervention|Control group|Control group maintained their usual diet without nut supplement
3080450|NCT02023736|Active Comparator|Treatment as Usual|Patients in the Treatment as Usual condition receive the same psychotherapy treatment as they would were they not enrolled in the study.
3080451|NCT02023736|Experimental|Treatment as Usual with the STIC (TAU + STIC)|Patients in the TAU + STIC condition receive the treatment that they normally would from their therapist, but with the addition of the STIC measurement and feedback system.
3080452|NCT02023723|Experimental|Monster Energy Drink|16oz Monster Energy Original Flavor consume 2 -16oz Monster Energy drinks within 60 minutes
3080453|NCT02023723|Active Comparator|Active Control|16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
3080454|NCT02023710|Experimental|BEV plus Chemotherapy|Paclitaxel 175mg/m2, d1; Carboplatin AUC=5, d1; Bevacizumab 5mg/kg, d1、15; 28 days a cycle
3080455|NCT02023710|Active Comparator|Chemotherapy alone|Paclitaxel 175mg/m2, d1; Carboplatin AUC=5, d1; 28 days a cycle
3080456|NCT02023697|Experimental|Radium-223 dichloride (Standard dose)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update).
3080457|NCT02023697|Experimental|Radium-223 dichloride (High dose)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 80 kBq/kg body weight (88 kBq/kg after implementation of NIST update).
3080458|NCT02023697|Experimental|Radium-223 dichloride (Extended standard dose)|One injection to be administered every 4 weeks up to 12 injections. The dose per injection is 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update).
3080459|NCT02023684|Placebo Comparator|control|Irrigation will be carried out with saline
3080460|NCT02023684|Active Comparator|Lidocaine|Irrigation will be carried out with Lidocaine
3080461|NCT02023684|Active Comparator|Ropivacaine|Irrigation will be carried out with Ropivacaine
3080462|NCT02023658|Experimental|Systems analysis and improvement|pMTCT systems analysis and improvement
3080463|NCT02023658|No Intervention|Control|No systems analysis and improvement intervention for prevention of mother to child HIV transmission services in place.
3080464|NCT02023645|Experimental|Active supplement|10 mg lutein + 2 mg zeaxanthin
3080465|NCT02023645|Placebo Comparator|inert placebo|placebo for comparison
3080466|NCT02023632|Experimental|Similar-Age-Same-Gender (SASG)|Participants in this trial arm will be of similar age (65+) and of the same gender (i.e., separate groups for male older adults and female older adults).
3080467|NCT02023632|Active Comparator|Similar-Age-Mixed-Gender (SAMG)|This group will include participants of both genders who are similar aged (65+).
3080468|NCT02023632|Sham Comparator|Mixed-Age-Mixed-Gender (MASG)|This group is used as the 'standard' group based exercise course; including those of mixed age and mixed gender.
3080469|NCT02023619||Keratoconus|Eyes with confirmed keratoconus diagnosis
3080470|NCT02023619||Astigmatism >2.0 D|Healthy eyes with astigmatism >2.0 D
3080471|NCT02023606|Experimental|SPN-810M|Single dose of 20 mL solution containing 50 mg of SPN-810M and no less than 8.5 MBq (225 µCi) carbon-14 (14C)-SPN-810M, and no more than 11.3 MBq (305 µCi) [14C] SPN-810M.
3080472|NCT02023593|Experimental|FOLFIRI|Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
3080473|NCT02023580|Experimental|Intervention|The Video Treatment arm will complete baseline, 3-, 6-, 9-, and 12-month online survey assessments. Between baseline and 3-month follow-up, men will view 6 video vignettes (participants will receive a link to view a video vignette once a week for 6 weeks). Based on our team's experience of attenuated intervention effects at 6 months, men will receive 4 video boosters, spaced 1 week apart, after the 6-month assessment survey. Spacing the dose over time can improve critical thinking. The additional videos will be a continuation of the dramatic series plus additional video scenes on disclosure and serodiscordant partnerships.
3080474|NCT02023580|Active Comparator|Control|The video control arm will complete baseline, 3-, 6-, 9-, and 12-month online survey assessments. The control arm will receive the same number (and timing of) video clips as the intervention arm, but from a non-theoretically driven gay-oriented show with videos that are similar in length in order to preserve dosing equality across both arms. As the video treatment arm will be provided efficacious theory-driven videos, investigators expect to find a significant decrease in sexual risk behaviors in the intervention arm, compared to the control arm. Should this occur by month 6, with agreement from the data safety monitoring board (DSMB), investigators will provide the control arm with the video treatments.
3080475|NCT02023567|Experimental|MDD group|Drugs: SSRIs fluoxertine hydrochloride (20- 60m/day),paroxetine hydrochloride (20- 60m/day),sertraline hydrochloride (50- 200m/day),citalopram (20-60m/day), escitalopram (10-20mg/day),fluvoxamine (50-300mg/day)
3080476|NCT02023567|No Intervention|Healthy controls|This group just receive baseline evaluation and did not receive any intervention.
3080477|NCT02023554|Experimental|Theophylline with azithromycin|steady-state plasma concentration of theophylline in the presence of azithromycin
3080478|NCT02023554|Active Comparator|Theophylline alone|steady-state plasma concentration of theophylline alone
3080479|NCT02023541|Other|Resectable disease|Patients with resectable disease will undergo treatment with proton beam therapy.
3080480|NCT02023541|Other|Unresectable disease|Patients with unresectable disease will undergo treatment with proton beam therapy.
3080481|NCT02023515|Experimental|Stress Management|Approximately half of the participants will be randomized to a stress management arm. Participants will undergo Emotional Brain Training during a 90 minute session once per week for ten weeks in order to rewire the brain and improve stress management techniques.
3080482|NCT02023515|Active Comparator|standard behavioral weight loss|Half of participants will receive a standard behavioral weight loss program in 90 minute sessions once per week for 10 weeks
3080483|NCT02023502||stress urinary incontinence|Patients presenting with stress urinary incontinence according to the inclusion and exclusion criteria
3080484|NCT02023502||healthy controls|healthy women with the same inclusion and exclusion criteria as the case group, except for stress urinary incontinence
3080485|NCT02023489|Other|Type 2 Diabetes Mellitus|
3080486|NCT02023489|Other|Insulin sensitive volunteers|
3080487|NCT02023489|Other|prediabetic subjects|
3080488|NCT02023489|Other|familiar hypocalciuric hypercalcemic patients|
3080489|NCT02023489|Other|Type 1 diabetes mellitus|
3080490|NCT02023476|Experimental|wide tourniquet|(Zimmer A.T.S.®3000 ) wide tourniquet MRI intervention
3080491|NCT02023476|Active Comparator|narrow tourniquet|HemaClear ™ tourniquet MRI intervention
3080492|NCT02023463|Experimental|Treatment (enzalutamide, radiation therapy, hormone therapy)|Patients receive enzalutamide PO QD for 6 months. Beginning 2 weeks after start of enzalutamide, patients receive LHRH agonist therapy with goserelin acetate SC or leuprolide acetate IM or SC for 6 months (intermediate risk patients) or 24 months (high risk patients) post-radiation therapy. Beginning 8 weeks after the start of LHRH therapy, patients undergo either IMRT or VMAT daily five days a week for 8 weeks.
3080493|NCT02023450|Experimental|micro/low dose saquinavir and ritonavir|To determine if micro dose and low dose SQV+RIT mediates parameters of chronic inflammation in patients with IPAH.
3080494|NCT02023450|Experimental|standard dose saquinavir and ritonavir|To determine if short-term use of SQV+RIT reduces parameters of chronic inflammation and PA pressure of IPAH based on echocardiographic parameters. Safety issue also evaluated at the same time.
3080495|NCT02023437|Experimental|Experimental: Femtosecond laser cataract surgery|"Laser group: a pre-fragmentation of the ocular lens will be performed by VICTUS femtosecond laser lens fragmentation procedure."
3080496|NCT02023437|Active Comparator|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are performed manually without femtosecond laser assisted lens fragmentation"
3080497|NCT02023424|Experimental|Copaxone|Glatiramer Acetate (Copaxone® , Teva Pharmaceutical Industries Ltd.) 20 mg daily or in an interval determined in the Dose Setting period. Administration will be subcutaneous to various areas on the body: back of the upper arms (2 areas), front and outside of thighs (2 areas), upper buttocks/rear hips (2 areas), and stomach (the abdomen).
3080498|NCT02023411|Active Comparator|teriparatide|10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive 20 microgram of teriparatide , subcutaneously between 8-9 p.m., daily.
3080499|NCT02023411|Placebo Comparator|placebo|10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive placebo , subcutaneously between 8-9 p.m. , daily.
3080500|NCT02023398|Experimental|HFT group|Subjects in the High Frequency Therapy (HFT) group will be treated with the BTL-9000 HFT
3080501|NCT02023398|Placebo Comparator|Placebo group|Subjects in the Placebo group with be treated with the sham BTL-9000 HFT
3080502|NCT02023385|Experimental|LLLT group|Subjects in the Low Level Laser Therapy (LLLT) group will be treated with the BTL-9000 LLLT
3080503|NCT02023385|Placebo Comparator|Placebo group|Subjects in the Placebo group with be treated with the sham BTL-9000 LLLT
3080504|NCT02023372|Experimental|NuCel with Autograft|NuCel will be used with local autograft during surgical treatment of one, two or three level degenerative disease of the lumbar spine
3080505|NCT02023359||Treatment|Everolimus and exemestane
3080506|NCT02023346||Malignant Glioma patients|This is a cross-sectional study of patients with MG who are admitted to the inpatient Neurology service at MSKCC. We anticipate that participants will be accrued over approximately 18-24 months. All patients with MG admitted to Neurology, will be screened for eligibility and willingness to participate in the study.
3080507|NCT02023333|Experimental|Regorafenib|This is an open-label, phase II study of regorafenib for patients with metastatic colorectal carcinoma. The treatment will be repeated every week for three weeks on and one week off. Patients will be evaluated for response after every 2 cycles (8 weeks).
3080508|NCT02023320|Experimental|Low dose of blueberry dry powder|0.5 g blueberry dry powder, twice a day for 12 weeks
3080509|NCT02023320|Experimental|High dose of blueberry dry powder|5.0 g blueberry dry powder, twice a day for 12 weeks
3080510|NCT02023307|Experimental|Rhytidectomy with Covidien|25 patients receiving a mid-face lift in short-flap rhytidectomy
3080664|NCT02022267||control group|healthy children of employees of our hospital
3080517|NCT02023255|Experimental|Part A: Cohort 1|8 participants will be included in this cohort. 6 participants will receive a single dose of 50 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
3080518|NCT02023255|Experimental|Part A: Cohort 2|8 participants will be included in this cohort. 6 participants will receive a single dose of 150 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
3080519|NCT02023255|Experimental|Part A: Cohort 3|8 participants will be included in this cohort. 6 participants will receive a single dose of 450 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
3080520|NCT02023255|Experimental|Part A: Cohort 4|8 participants will be included in this cohort. 6 participants will receive a single dose of 1,350 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
3080521|NCT02023255|Experimental|Part A: Cohort 5|8 participants will be included in this cohort. 6 participants will receive a single dose of 2,700 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
3080522|NCT02023255|Experimental|Part B: Cohort A|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the pharmacokinetic (PK) data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
3080523|NCT02023255|Experimental|Part B: Cohort B|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the PK data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
3080524|NCT02023255|Experimental|Part B: Cohort C|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the PK data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
3080525|NCT02023242|Experimental|Hydrus Microstent|Patients randomized to the Hydrus Microstent .
3080526|NCT02023242|Active Comparator|iStent Trabecular Micro Bypass|Patients randomized to the iStent Trabecular Micro Bypass
3080527|NCT02023229|Experimental|Diet plus branched chain aminoacids|High-fiber high-protein diet Oral supplement : branched chain aminoacids
3080528|NCT02023229|Active Comparator|Diet|High-fiber high-protein diet
3080529|NCT02023203|Experimental|LP PTFE|Placement of Large Pore PTFE mesh for inguinal hernia treatment
3080530|NCT02023203|Active Comparator|SP-PPL|Placement of Small Pore polypropylene mesh for inguinal hernia treatment
3080531|NCT02023190||Nutritional assessment|Nutritional assessment will be performed by bioelectrical impedance vector analysis
3080532|NCT02023177||Phase angle|Phase angle obtained from bioelectrical impedance
3080533|NCT02023164|Experimental|Test Drug|10 mg/mL, 1 mL
3080534|NCT02023164|Active Comparator|Control|50 mg/mL, 1 mL
3080535|NCT02023151|Other|Omalizumab|Active
3080536|NCT02023138|Active Comparator|Focus group|
3080537|NCT02023138|Experimental|Wiki|
3080538|NCT02023125|Experimental|Group 1: Treatment A first, then Treatment B|Treatment A (Fasted Treatment): Following an overnight fast of at least 10 hours, a single 600-mg oral dose of alectinib will be administered. Treatment B (Fed Treatment): Following an overnight fast of at least 10 hours, participants will start a high-fat, high-calorie meal 30 minutes prior to study drug administration; study participants should eat this meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal. Each period will be separated by at least 10 days.
3080539|NCT02023125|Experimental|Group 1: Treatment B first, then Treatment A|Treatment B (Fed Treatment): Following an overnight fast of at least 10 hours, participants will start a high-fat, high-calorie meal 30 minutes prior to study drug administration; study participants should eat this meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal. Treatment A (Fasted Treatment): Following an overnight fast of at least 10 hours, a single 600-mg oral dose of alectinib will be administered. Each period will be separated by at least 10 days.
3080540|NCT02023125|Experimental|Group 2: Alectinib Alone, Alectinib + Esomeprazole|Period 1 (Days 1 to 10): Following an overnight fast of at least 10 hours, participants will start a standardized meal and should consume the meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal on Day 1 of Period 1. Period 2 (Days 11 to 20): Participants will receive oral esomeprazole 40 mg once daily for 6 days (Days 11-16) in the morning after an overnight fast of at least 10 hours, and at least 1 hour before a regular breakfast; On Day 16, following an overnight fast of at least 10 hours, a single oral dose of 40 mg esomeprazole will be administered 1.5 hours prior to the start of a standardized meal. Following a standardized meal, a single oral 600 mg dose of alectinib will then be administered.
3080541|NCT02023112|Experimental|ABT-450/r/ABT-267 plus RBV for 12 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based ribavirin (RBV; 400 to 1,000 mg/day, divided twice daily) for 12 weeks
3080542|NCT02023112|Experimental|ABT-450/r/ABT-267 plus RBV for 16 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based RBV (400 to 1,000 mg/day, divided twice daily) for 16 weeks
3080543|NCT02023099|Experimental|Substudy 1, Arm A: DB 2-DAA|Double-blind (DB) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2 direct-acting antiviral agents [2-DAA]) once daily (QD) for 12 weeks in participants without cirrhosis
3080544|NCT02023099|Placebo Comparator|Substudy 1, Arm B: DB Placebo, Followed by OL 2-DAA|DB placebo QD for 12 weeks followed by open-label (OL) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants without cirrhosis
3080545|NCT02023099|Experimental|Substudy 2, Arm C: OL 2-DAA|OL 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants with compensated cirrhosis
3080546|NCT02023086||FABRY group|"contrast sensitivity measurement~slit lamp assessment and intra-ocular pressure measurement~ocular coherence tomography at the optic nerve head~visual field testing~OSOME (oxygen flow at the optic nerve head measurement)~Tropicamide"
3080547|NCT02023086||CONTROL group|"contrast sensitivity measurement~slit lamp assessment and intra-ocular pressure measurement~ocular coherence tomography at the optic nerve head~visual field testing~oxygen flow at the optic nerve head measurement (OSOME)~Under tropicamide"
3080548|NCT02023073||Healthy volunteers|
3080549|NCT02023047|Experimental|Once daily|Nifedipine 12 mg Once daily
3080550|NCT02023047|Experimental|Twice Daily|Nifedipine 12 mg twice daily
3080665|NCT02022254|Experimental|Semaglutide administrations|
3080551|NCT02023034|Experimental|Virtual exercises|"All patients underwent 12 sessions, twice a week for a period of 06 weeks. The exercises were performed in the on dopaminergic medication, supervised by the researchers, the period instrument used was the video game with the Nintendo ® Wii Balance Board ® platform."
3080552|NCT02023034|Sham Comparator|Control|"Traditional exercises. All patients underwent 12 sessions, twice a week for a period of 06 weeks. The exercises were performed in the on dopaminergic medication, supervised by the researchers."
3080553|NCT02023021|Experimental|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
3080554|NCT02023008|Experimental|Supportive care (internet-based integral yoga intervention)|Participants undergo 12 sessions of cancer-adapted integral yoga classes using an internet-based videoconferencing platform. Integral yoga includes postures, deep relaxation, breathing practices and meditation to create a profound experience of peace and well-being. Participants take part in study classes from home (or other location that is convenient for the participant and that allows them to access the internet-based classes) with two-way interaction with group instructors and members alike over 75 minutes twice weekly for 6 weeks during radiation therapy. Participants are encouraged to complete additional yoga practice sessions outside of the twice weekly study sessions.
3080555|NCT02022995||Patients with cetuximab treatment|Patients with cetuximab treatment
3080556|NCT02022995||Patients without cetuximab treatment|Patients without cetuximab treatment
3080557|NCT02022982|Experimental|Palbociclib and PD-0325901|"Palbociclib by mouth once a day, every day for 3 weeks every 4 in each cycle.~PD-0325901 by mouth twice a day, every day for 3 weeks every 4 in each cycle. ."
3080558|NCT02022956|Experimental|Open-Label Lorcaserin (BELVIQ)|
3080559|NCT02022930|Experimental|Hydros|Hydros Joint Therapy
3080560|NCT02022930|Experimental|Hydros-TA|Hydros-TA Joint Therapy
3080561|NCT02022930|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide
3080562|NCT02022917|Experimental|Epithelial Ovarian Cancer|Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab Three 21 day cycles of carboplatin, paclitaxel, and bevacizumab
3080563|NCT02022904|Experimental|Metastatic prostate cancer|Near infrared (NIR) emissive nanotechnology
3080564|NCT02022891||systematic psychological care|Systematic psychological treatment plan added to medical care for children with SCD. Bio-psychosocial paradigm applied at pediatric consultations.
3080565|NCT02022891||Control|medical care only at routine pediatric consultations for SCD. Psychological support provided only when the pediatrician consider it appropriate.
3080566|NCT02022878||Attempted PCI of CTO|Attempted PCI of CTO with preprocedural coronary CTA scan
3080567|NCT02022865||periodontitis patients|according to american academy of periodontology classification of periodontal diagnosis.
3080568|NCT02022865||healthy periodontium|according to american academy of periodontology classification of periodontal diagnosis.
3080569|NCT02022852|Active Comparator|Concurrent chemoradiotherapy|Capecitabine neoadjuvant concurrent radiochemotherapy and XELOX adjuvant therapy
3080570|NCT02022852|Experimental|Sequential therapy|XELOX/capecitabine/XELOX neoadjuvant chemo-chemoradio-chemo sequential therapy and XELOX adjuvant therapy
3080571|NCT02022826|Experimental|SmartPill Monitoring System|patients with symptoms of Gastroparesis will undergo the SmartPill monitoring system test
3080572|NCT02022813|No Intervention|Enteral nutrition only|Enteral nutrition to be progressed as soon as possible to energy target measured on day 3, and verified on day 4, using the usual facilitators (prokinetics)
3080573|NCT02022813|Experimental|Supplemental parenteral nutrition|"Addition of supplemental parenteral nutrition to complete the gap between energy delivered by enteral feeding and energy target measured on day 4.~Aim: 100% of this target, and not exceeding it, no catch up for energy deficit accumulated before day 4."
3080574|NCT02022800|Other|PET 18FDOPA|PET 18FDOPA
3080575|NCT02022787||Renal cell carcinoma|Patients with renal cell carcinoma scheduled for partial or radical nephrectomy
3080576|NCT02022761|Experimental|40 mg Laninamivir octanoate|Dry Powder Inhaler
3080577|NCT02022761|Experimental|80 mg Laninamivir octanoate|Dry Powder Inhaler
3080578|NCT02022761|Placebo Comparator|Matching placebo|Dry Powder Inhaler
3080579|NCT02022748|Experimental|Sequence 1|hemodialysis patients: subjects will receive treatment A (ticagrelor oral 90 mg 1 day following the dialysis session but 2 days before the next dialysis session) in period 1 and treatment B (ticagrelor oral 90 mg just prior to dialysis session) in period 2.
3080580|NCT02022748|Experimental|Sequence 2|hemodialysis patients: subjects will receive treatment B (ticagrelor oral 90 mg just prior to dialysis session) in period 1 and treatment A (ticagrelor oral 90 mg 1 day following the dialysis session but 2 days before the next dialysis session) in period 2.
3080581|NCT02022748|Experimental|Treatment H|Healthy subjects: ticagrelor oral 90 mg on 1 day of treatment
3080582|NCT02022735|Experimental|Bilateral stimulation|Deep Brain Stimulation Bilaterally
3080583|NCT02022735|Experimental|Left stimulation|Deep Brain Stimulation Left side only
3080584|NCT02022735|Experimental|Right stimulation|Deep Brain Stimulation Right side only
3080585|NCT02022735|No Intervention|OFF stimulation|No stimulation
3080586|NCT02022722|Active Comparator|Pelvic Rehabilitation|Pelvic Rehabilitation will be conduction on weekly basis for a total of 6 weeks
3080587|NCT02022722|Active Comparator|Trigger Point Injections|Trigger point injections will be administered on weekly basis for a total of 6 weeks
3080588|NCT02022709|Active Comparator|Selective Serotonin Reuptake Inhibitor|In this group,routine treatment strategies will be used for patients. Any one of the SSRIs including fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine ,which are approved in the treatment of OCD by SFDA,, may be used for patients who are randomized to this treatment arm. The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
3080589|NCT02022709|Active Comparator|Exposure and Response Prevention|Exposure and Response Prevention Structured protocol described by Foa et al., 2012 Patients will attend eight 1-h sessions,once a week. Benzodiazepine will be used when necessary.
3080590|NCT02022683|Experimental|Endoscopic Lung Volume Reduction|Patients are implanted Zephyr EBV
3080591|NCT02022683|No Intervention|Standard of Care|Patients are given Standard of Care treatment
3080592|NCT02022670|Placebo Comparator|Placebo|inert oral capsules (0 mg sodium nitrite morning; 0 mg sodium nitrite in evening) for 10 weeks
3080593|NCT02022670|Experimental|Sodium Nitrite 80 mg/d|80 mg/day (40 mg in morning; 40 mg in evening) oral capsules for 10 weeks
3080594|NCT02022670|Experimental|Sodium Nitrite 160 mg/d|160 mg/day (80 mg in morning; 80 mg in evening) oral capsules for 10 weeks
3080595|NCT02022657|Active Comparator|33%/67%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
3080596|NCT02022657|Active Comparator|33%/100%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
3080597|NCT02022657|Active Comparator|67%/33%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
3080598|NCT02022657|Active Comparator|67%/100%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
3080599|NCT02022657|Active Comparator|100%/33%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
3080600|NCT02022657|Active Comparator|100%/67%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
3080601|NCT02022644|Experimental|Group 1 - 20 mg|Tumor diameter: 1 cm, Tumor volume: ~0.5cm3, Infusion Volume: 2-3 ml, Irinotecan conc.: 20 mg/ml, Infusion time: 6-24 hours, no more than 48
3080602|NCT02022644|Experimental|Group 2 - 40 mg|Tumor diameter: 2 cm,Tumor volume: ~4.1cm3, Infusion Volume: 3-4 ml, Irinotecan conc.: 40 mg/ml, Infusion Time: 6-24 hours, no more than 48
3080603|NCT02022644|Experimental|Group 3 - 140 mg|Tumor diameter: 3 cm, Tumor volume: ~14cm3, Infusion Volume: 6-7 ml, Irinotecan conc.: 140 mg/ml, Infusion Time: 6-24 hours, no more than 48
3080604|NCT02022644|Experimental|Group 4 - 340 mg|Tumor diameter: 4 cm, Tumor volume: ~34cm3, Infusion Volume: ≤17 ml, Irinotecan conc.: 340 mg/ml, Infusion Time: 6-24 hours, no more than 48
3080605|NCT02022644|Experimental|Group 5 - 40 mg|Tumor diameter: 1 cm, Tumor volume: ~0.5cm3, Infusion Volume: 2-3 ml, Irinotecan conc.: 40 mg/ml, Infusion Time: 6-24 hours, no more than 48
3080606|NCT02022644|Experimental|Group 6 - 80 mg|Tumor diameter: 2 cm, Tumor volume: ~4.1cm3, Infusion Volume: 3-4 ml, Irinotecan conc.: 80 mg/ml, Infusion Time: 6-24 hours, no more than 48
3080607|NCT02022644|Experimental|Group 7 - 280 mg|Tumor diameter: 3 cm, Tumor volume: ~14cm3, Infusion Volume: 6-7 ml, Irinotecan conc.: 280 mg/ml, Infusion Time: 6-24 hours, no more than 48
3080608|NCT02022644|Experimental|Group 8 - 680 mg|Tumor diameter: 4 cm, Tumor volume: ~34cm3, Infusion Volume: ≤17 ml, Irinotecan conc.: 680 mg/ml, Infusion Time: 6-24 hours, no more than 48
3080609|NCT02022631|Experimental|Alternative SoF|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
3080610|NCT02022631|Active Comparator|Current SoF|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
3080611|NCT02022605|Experimental|Hands-on EMS training group|
3080612|NCT02022605|Active Comparator|Standard training group|
3080613|NCT02022592|Experimental|Lormetazepam|The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Sedalam®).
3080614|NCT02022592|Active Comparator|Midazolam|The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Midazolam-ratiopharm®, Midazolam-hameln®).
3080615|NCT02022579|Experimental|DCE-MRI and DWI|Single arm study, diagnosis defined as BIRADS 3, 4, or 5 lesion(s) based on DCE-MRI only with DWI collected in tandem as standard practice.
3080616|NCT02022566||Supported self-management of osteoarthrits program|
3080617|NCT02022553|Experimental|rectal cancer, surgery|
3080618|NCT02022553|Active Comparator|rectal cancer, RACHEL, surgery|
3080619|NCT02022540|Experimental|Stage 1 - Group 1|Patients randomized to Group 1 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
3080620|NCT02022540|Experimental|Stage 1 - Group 2|Patients randomized to Group 2 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
3080621|NCT02022540|Experimental|Stage 1- Group 3|Patients randomized to Group 3 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
3080622|NCT02022540|Experimental|Stage 1- Group 4|Patients randomized to Group 4 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
3080623|NCT02022540|Experimental|Stage 1 - Group 5|Patients randomized to Group 5 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
3080624|NCT02022540|Experimental|Stage 2|Patients enrolled in Stage 2 will receive an intravitreal injection of ranibizumab and then 7-9 days later begin daily dosing with PAN-90806 Ophthalmic Solution for 12 weeks
3080625|NCT02022527|Experimental|Combination|Warfarin tablets adjusted according to international normalized ratio (INR) (2 for Aortic Valve Replacement & 2.5-3 for Mitral Valve Replacement, 2.5-3.5 for Double Valve Replacement) and oral 75 mg Acetyl Salicylic Acid tablets daily long life.
3080626|NCT02022527|Active Comparator|Warfarin|Warfarin tablets adjusted according to INR (2 for Aortic Valve Replacement & 2.5-3 for Mitral Valve Replacement, 2.5-3.5 for Double Valve Replacement) and placebo long life.
3080627|NCT02022514|Experimental|Mononuclear cells from autologous bone marrow|Mononuclear bone marrow cells autologous intracoronary
3080628|NCT02022514|Active Comparator|Conventional medical treatment|Conventional medical treatment
3080629|NCT02022501|Experimental|Low Dose DE-120|Single 20 µL intravitreal injection of Low Dose DE-120 injectable solution
3080630|NCT02022501|Experimental|Medium Dose DE-120|Single 20 µL intravitreal injection of Medium Dose DE-120 injectable solution
3080631|NCT02022501|Experimental|High Dose DE-120|Single 20 µL intravitreal injection of High Dose DE-120 injectable solution
3080632|NCT02022488|Active Comparator|midazolam and alfentanil|Midazolam 0.5mg/kg (oral) Alfentanil 10 microgram/kg (oral)
3080633|NCT02022488|Active Comparator|midazolam and ketamine|Midazolam 0.5mg/kg (oral) Ketamine 2mg/kg (intranasal)
3080634|NCT02022488|Placebo Comparator|midazolam|Midazolam 0.5mg/kg
3080635|NCT02022475|Active Comparator|Cholecalciferol|100 000 units vitamin D3 single dose
3080636|NCT02022475|Placebo Comparator|Placebo|similar appearance
3080637|NCT02022462|Experimental|Health Navigation|Up to 151 participants with SMI in the El Camino clinic, operated by Pacific Clinics, will be recruited to participate in a 12 month study of Bridge navigation. Participants will be randomly assigned to either waitlist control (6 month waitlist with treatment as usual) or immediate intervention with the Bridge. Participants in the immediate treatment group will complete three assessments (baseline, 6 months, and 12 months) and, after 6 months, one interview about their health, healthcare, and navigation experiences. Participants in the waitlist control group will complete three assessments (baseline, 6 month, 12 months) and one interview about their health, health care, and their experiences using health navigation after 12 months.
3080638|NCT02022462|Other|Waitlist Control|Up to 146 participants with SMI in the El Camino clinic, operated by Pacific Clinics, will be recruited to participate in a 12 month study of Bridge navigation. Participants will be randomly assigned to either waitlist control (n = 73, 6 month waitlist with treatment as usual then they will receive the intervention) or immediate intervention with the Bridge (n = 73). Participants in the immediate treatment group will complete three assessments (baseline, 6 months, and 12 months) and, after 6 months, one interview about their health, healthcare, and navigation experiences. Participants in the waitlist control group will complete three assessments (baseline, 6 month, 12 months) and one interview about their health, health care, and their experiences using health navigation after 12 months.
3080639|NCT02022449|No Intervention|Control|participants only complete assessments
3080640|NCT02022449|Experimental|Stress management|Cognitive Behavioral Stress management Coping enhancement strategies Progressive muscle relaxation Guided imagery relaxation skills Deep breathing relaxation skills Social support
3080641|NCT02022436|Active Comparator|contrast ultrasound for patients with AAA|Contrast ultrasound
3080642|NCT02022436|Active Comparator|contrast ultrasound for patients without arterial disease|contrast enhanced ultrasound
3080643|NCT02022423|Active Comparator|Telephone Counseling|Weekly telephone calls to assess compliance to exercise prescription and discuss various topics related to adoption and adherence to walking programs
3080644|NCT02022423|Experimental|Internet-based walking program|Weekly automated goals are delivered via email to subject; goals are based on previous week's step count accumulation. Subjects have access to group-specific forums in which they may communicate with other PAD patients in the study
3080645|NCT02022423|Experimental|Telephone counseling and Internet-based walking program|Combination of previous two arms
3080646|NCT02022423|No Intervention|Usual Care|Subjects will continue with their health care as usual and will receive access to the study website (for arm 2) at the end of their participation
3080647|NCT02022410||CAS after primary and revision TKA|CAS and RAPT
3080648|NCT02022397||difficult intubation|general population necessitating tracheal intubation for general anesthesia
3080649|NCT02022384||study patients|Blood sample and life quality questionnaires
3080650|NCT02022371|Experimental|Targeted biopsy|Snap frozen targeted biopsies of the prostate for genomic analysis
3080651|NCT02022358|Active Comparator|M|"Methotrexate (12 g/m2 x 1, intravenously) with standard folinic acid rescue~In arm A patients will receive cycle M first followed by cycle GluM. Cycle M starts with course M1 on day 1 followed by course M2 planned for day 8. Cycle GluM starts with course GluM1 on day 1 followed by GluM2 planned for day 8. Cycle GluM will not start for a minimum of 14 days from the beginning of course M2, or until bone marrow, renal and hepatic functions have completely recovered and the patient is clinically ready to receive further chemotherapy ."
3080652|NCT02022358|Experimental|GluM|"Methotrexate (12 g/m2 x 1, intravenously) with folinic acid and glucarpidase rescue (50 units/kg x 1, intravenously).~In arm B, patients will receive cycle GluM first followed by cycle M. Cycle GluM starts with course GluM1 on day 1 followed by GluM2 planned for day 8.Cycle M starts with course M1 on day 1 followed by course M2 planned for day 8. Cycle M will not start for a minimum of 14 days from the beginning of course GluM2, or until bone marrow, renal and hepatic function have completely recovered and the patient is clinically ready to receive further chemotherapy"
3080653|NCT02022345|Active Comparator|PCI at pilot hospitals|Percutaneous Coronary Interventions performed at pilot hospitals which do not have onsite cardiac surgery.
3080654|NCT02022345|Active Comparator|PCI at non-pilot hospitals|Percutaneous Coronary Intervention performed at non-pilot hospitals which have onsite cardiac surgery or perform only primary PCIs for STEMI patients.
3080655|NCT02022319|Other|Shear Wave Elastography|All included patients undergo a supplementary Shear Wave Elastographic scan
3080656|NCT02022306|Placebo Comparator|SAD TD-6450|Single ascending dose (Part A)
3080657|NCT02022306|Placebo Comparator|MAD TD-6450|Multiple ascending dose (Part B)
3080658|NCT02022306|Active Comparator|Food effect of TD-6450|Food effect will be assessed in Part A (SAD) of this study.
3080659|NCT02022293|Active Comparator|Atorvastatin|Patients will take atorvastatin 20mg per night, totally 2 years.
3080660|NCT02022293|Placebo Comparator|Placebo|Patients will take placebo once per night for 2 years. The appearance and dosage of placebo will be the same as atorvastatin.
3080661|NCT02022280|Experimental|Proton Pump Inhibitor|Lansoprazole (Prevacid)
3080662|NCT02022280|Placebo Comparator|Vitamin pill|
3080663|NCT02022267||study group|Patients with a minimum age of three years from our prospective, consecutive database of patients with clubfoot treated with the Ponseti method beginning in 2002 are considered for this study. Patients with unilateral or bilateral idiopathic clubfoot are included. Patients with clubfoot associated with syndromes or neurological diseases, with mild clubfoot that required fewer than three casts for initial correction, who first presented at an age older than three months, who were living outside of the country, and who were initially treated elsewhere with more than three casts are excluded.
3080667|NCT02022228|Experimental|0.2mg triptorelin and 500 IU hCG|Patients were triggered with 0.2mg triptorelin and 500 IU hCG
3080668|NCT02022228|Experimental|0.2mg triptorelin and 1000 IU hCG|Patients were triggered with 0.2mg triptorelin and 1000 IU hCG
3080669|NCT02022215|Experimental|ME1111 Solution, Low strength|
3080670|NCT02022215|Experimental|ME1111 Solution, High strength|
3080671|NCT02022215|Placebo Comparator|Matching Vehicle Solution|
3080672|NCT02022189||Dent Disease patients|Patients with diagnosed Dent Disease
3080673|NCT02022176|Active Comparator|Sodium nitrate|0.1 mmol NaNO3 / kg bodyweight / day for three days.
3080674|NCT02022176|Placebo Comparator|Sodium Chloride|0.1 mmol NaCl / kg bodyweight / day for three days.
3080675|NCT02022176|Active Comparator|Sodium nitrite infusion|Sodium nitrite (NaNO2) at a rate of 1, 10 and 100 nmol kg-1 min-1 (10 minutes per dose) was infused intravenously.
3080676|NCT02022176|Placebo Comparator|Saline infusion|Saline at a rate corresponding to 1, 10 and 100 nmol NaCl kg-1 min-1 (10 minutes per dose) was infused intravenously.
3080677|NCT02022163|Experimental|Low dose of H7 VLP vaccine + Alhydrogel|Biological: Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
3080678|NCT02022163|Experimental|Med dose of H7 VLP vaccine + Alhydrogel|Biological: Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
3080679|NCT02022163|Experimental|High dose of H7 VLP vaccine + Alhydrogel|Biological: High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
3080680|NCT02022163|Experimental|High dose of H7 VLP vaccine|Biological: High dose of H7 VLP vaccine, 2 doses given 21 days apart
3080681|NCT02022163|Placebo Comparator|Placebo|Placebo, 2 doses given 21 days apart
3080682|NCT02022150||Body composition in paracentesis|Taking blood samples and bioelectrical impedance, Psychometric Hepatic Encephalopathy Score (PHES) and Critical Flicker Frequency (CFF) before and after paracentesis.
3080683|NCT02022137|Experimental|Red cereal bar|It includes the intervention of the red cereal bar for the designation of the group.
3080684|NCT02022137|Placebo Comparator|Green cereal bar|It includes the intervention of the green cereal bar for the designation of the group.
3080685|NCT02022137|Active Comparator|White cereal bar|It includes the intervention of the white cereal bar for the designation of the group.
3080686|NCT02022124|Experimental|microcrystalline cellulose (open-label inert substance)|3-week course of non-deceptive placebo using placebo pills plus the usual regime that the patients had been prescribed at the time of intake.
3080687|NCT02022124|No Intervention|Usual care treatment|This arm will entail a 3-week course of the stable treatment the patient is following at time of intake.
3080688|NCT02022111|Active Comparator|Intervention Program of Care|"Patient Education and Behavioral Activation by a Care Coordinator;~Supporting Self-Care;~Psychiatrist and Diabetologist Reviews; and~Decision-support Electronic Health Record System"
3080689|NCT02022111|Placebo Comparator|Control Arm|Participants randomized to the control arm will receive the existing standard of care and treatment for their diabetes that is provided routinely at each Clinic Site and their care provider will be notified regarding their depressive symptoms. The physicians treating the control arm will also be provided with trainings regarding identification and care for people with depression. The control participants will have no contact with care coordinators and will only be contacted at 6-monthly intervals for assessment by the blinded outcomes assessor.
3080690|NCT02022098|Experimental|Debio 1143|In addition to Cisplatin and Radiotherapy, Debio 1143 in solution form will be administered orally or by feeding tube (while fasting) daily for 14 days every three weeks (on days 1-14, 22-35 and 43-56).
3080691|NCT02022098|Placebo Comparator|Placebo|In addition to Cisplatin and Radiotherapy, matching placebo in solution form will be administered orally or by feeding tube (while fasting) daily for 14 days every three weeks (on days 1-14, 22-35 and 43-56).
3080692|NCT02022085|Experimental|Baha Attract System|"This transcutaneous solution is based on a magnet coupling using magnets on both side of the skin;~One implant magnet~One external magnet on which a sound processor is attached, i.e. the Sound Processor magnet (SP magnet)"
3080693|NCT02022072|Other|measure of assisted vital capacity by mechanical insufflation|measure of assisted vital capacity by a mechanical insufflation/exsufflation
3080694|NCT02022059|Experimental|Lidocaine|patient nécessitant une SNG pour nutrition entérale bénéficiant d'une pré-médication par vaporisateur de lidocaïne lors de l'insertion (group A = lidcoaine)
3080695|NCT02022059|Placebo Comparator|Placebo|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion (group B)
3080696|NCT02022046||2/study, control|Study group: children aged<18 years with chronic kidney disease Control group: children aged<18 years without chronic kidney disease Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
3080697|NCT02022033|Experimental|FOLFOXA|"Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
3080698|NCT02022020||Group 1|
3080699|NCT02022007|Active Comparator|Metformin XR|Metformin 2000 mg daily (QD) for 16 weeks
3080700|NCT02022007|Active Comparator|Saxagliptin|Saxagliptin 5 mg QD for 16 weeks
3080701|NCT02022007|Experimental|Saxagliptin-Metformin XR|"Saxagliptin-Metformin XR (combination pill)~5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks"
3080702|NCT02021994||Arm Automatic Electronic BPM|
3080703|NCT02021994||mercury sphygmomanometer|
3080704|NCT02021981||Observational Group 1|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3080705|NCT02021981||Observation Group 2|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3080742|NCT02021799|No Intervention|Overweight/obese Pregnant women|Pregnant women who are classified as obese or overweight
3080706|NCT02021981||Observation Group 3|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3080707|NCT02021981||Observation Group 4|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3080708|NCT02021981||Observation Group 5|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3080709|NCT02021981||Observation Group 6|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3080710|NCT02021981||Observation Group 7|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3080711|NCT02021981||Observation Group 8|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3080712|NCT02021981||Observation Group 9|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3080713|NCT02021981||Observation Group 10|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3080714|NCT02021968|Experimental|TetraVax-DV-TV003 vaccine|Participants in this arm will receive a single injection of the TetraVax-DV-TV003 vaccine on Day 0 (study entry). On Day 180, participants will receive a single injection of the attenuated rDEN2∆30-7169 virus.
3080715|NCT02021968|Placebo Comparator|Placebo|Participants in this arm will receive a single injection of placebo on Day 0 (study entry). On Day 180, participants will receive a single injection of the attenuated rDEN2∆30-7169 virus.
3080716|NCT02021955|No Intervention|usual care|Primary care providers treat their patients discharged from hospital for a COPD exacerbation as usual.
3080717|NCT02021955|Experimental|guideline treatment recommendations|Primary care clinicians receive treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
3080718|NCT02021942|Experimental|SOM230 LAR|SOM230 LAR in a dosage of 60 mg i.m. once every 4 weeks
3080719|NCT02021929|Experimental|Sorafenib|400 mg (2 capsules) taken by mouth once a day
3080720|NCT02021929|Placebo Comparator|Placebo|2 capsules taken by mouth once a day
3080721|NCT02021903|Experimental|HGPO + Placebo|V1: HGPO 75 mg + meal and V2: Placebo 75 mg + meal
3080722|NCT02021903|Placebo Comparator|Placebo + HGPO|V1: Placebo 75 mg + meal and V2: HGPO 75 mg + meal
3080723|NCT02021890|Experimental|ballroom and Latin dance program|two-hour dancing session twice a week
3080724|NCT02021890|Active Comparator|Self-selected physical activity|self-selected program of physical activity
3080725|NCT02021877||TBI subjects|Unselected adult patients with acute TBI from the Emergency Departments of the recruiting hospitals
3080726|NCT02021877||Control subjects|Acute orthopaedic non-trivial trauma that needs either surgery or conservative measures and clinical follow-up (including mere superficial soft tissue injuries)
3080727|NCT02021864|Experimental|vitamin D3, prenatal multivitamin|vitamin D3 50,000 unit/week for 8 weeks, daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
3080728|NCT02021864|Active Comparator|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
3080729|NCT02021851|Active Comparator|Group DA: Dexamethasone and aprepitant|Group DA: Dexamethasone: 8 mg (intravenous), Aprepitant: 40 mg (oral)
3080730|NCT02021851|Placebo Comparator|Group DO: Dexamethasone and ondansetron|Group DO: Dexamethasone: 8 mg (intravenous), Ondansetron: 4 mg (intravenous)
3080731|NCT02021838||Contra Costa County, California|Lethality Assessment Program
3080732|NCT02021838||Pitt County, North Carolina|Lethality Assessment Program
3080733|NCT02021838||Cuyahoga County, Ohio|Domestic Violence High Risk Team
3080734|NCT02021838||Winnebago County, IL|Lethality Assessment Program
3080735|NCT02021838||Miami Dade County, FL|Lethality Assessment Program
3080736|NCT02021838||Battle Creek, MI|Lethality Assessment Program
3080737|NCT02021838||Nashville, TN|Lethality Assessment Program
3080738|NCT02021825|Other|MITO, annual relapse rate, safety|For refractory NMO patients aged 18-55, the initial dose 12 mg/m2 mitoxantrone was administered over a five day course every 3 months for 2 years (a total of eight courses). The initial dose was reduced to 9 mg/m2 if the preinfusion white-blood-cell count was 3.0-3.99 ×109/L,and to 6 mg/m2 if the white-blood-cell count was 2.0-2.99 ×109/L. No infusion if the white-blood-cell count was less than 2.0×109/L. The initial dose was reduced to 10 mg/m2 for nonhaematological toxic effects of WHO grade 2-3. Subsequent dose after 3 month was reduced to 10 mg/m2 for infections that occurred within 3 weeks of a previous infusion accompanied by a white-blood-cell count below 2×109/L, or to 8 mg/m2 for infections accompanied by white-blood-cell count of less than 1×109/L.
3080739|NCT02021812|Experimental|Branched TAG® Device|Treatment with the GORE® TAG® Thoracic Branch Endoprosthesis
3080740|NCT02021799|No Intervention|Undernourished Pregnant Women|Pregnant women who are classified as undernourished
3080741|NCT02021799|No Intervention|Nourished Pregnant Women|Pregnant women who are classified as healthy
3080743|NCT02021799|Experimental|Undernourished + Yogurt Pregnant Women|Pregnant women who are undernourished and selected to receive Moringa and Lactobacillus rhamnosus GR-1 probiotic yogurt. Yogurt contained 4.3 grams of Moringa and 10^8 CFU/mL of Lactobacillus rhamnosus GR-1 as well as Streptococcus thermophilus and Lactobacillus bulgaricus starter cultures.
3080744|NCT02021799|Experimental|Nourished + Yogurt Pregnant Women|Pregnant women who are healthy and selected to receive Moringa and Lactobacillus rhamnosus GR-1 probiotic yogurt. Yogurt contained 4.3 grams of Moringa and 10^8 CFU/mL of Lactobacillus rhamnosus GR-1 as well as Streptococcus thermophilus and Lactobacillus bulgaricus starter cultures.
3080745|NCT02021786|Experimental|Mobile phone based intervention|The intervention in the present study is a web- and mobile phone based intervention aiming to develop healthy lifestyle behaviors regarding physical activity and dietary habits in 4-year-olds. The intervention will be delivered to the parents and it is available to the parents during six months.
3080746|NCT02021786|No Intervention|Control|The control group receive a pamphlet on healthy eating and physical activity in pre-school children based on the existing guidelines. The information is similar to what parents receive from the Swedish child healthcare system
3080747|NCT02021773|Experimental|LBR-101 High Dose|Subcutaneous High Dose LBR-101 Administered Monthly x 3
3080748|NCT02021773|Experimental|LBR-101 Low Dose|Subcutaneous Low Dose LBR-101 Administered Monthly x 3
3080749|NCT02021773|Placebo Comparator|Placebo|Subcutaneous Placebo Administered Monthly x 3
3080750|NCT02021760|Active Comparator|Remote Ischemic per-postconditioning|Remote conditioning is induced by inflation of a blood pressure cuff around the left thigh to 200 mmHg or 20 mmHg above systolic blood pressure (if >180 mmHg) for 5 min followed by deflation for 5 min. At least one of these conditioning cycles is performed before PCI is initiated. If time allows, cycles of remote conditioning (5 min leg ischemia and 5 min reperfusion) are repeated until PCI is performed. Following reperfusion, defined as first balloon inflation, four additional cycles of remote conditioning will be performed.
3080751|NCT02021760|Sham Comparator|Sham|"The sham procedures include application of the cuff around the thigh but it is not inflated.~Otheriwize normal primary PCI."
3080752|NCT02021747||Individuals with TB|"Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~Symptoms consistent with TB~Chest X-rays and or chest CT consistent with TB~Positive PPD test~Positive sputum test"
3080753|NCT02021747||Smokers|"Active smoker as evidenced by self report and urine nicotine >30 ng/mL and urine cotinine >50 ng/mL~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~Symptoms consistent with TB~Chest X-rays and or chest CT consistent with TB~Positive PPD test~Positive sputum test"
3080754|NCT02021747||Non-smokers|"Never smokers is defined as someone who has smoked < 100 cigarettes per lifetime and whose urine nicotine <2 ng/mL and urine cotinine <5 ng/mL, at entry into the study~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~Symptoms consistent with TB~Chest X-rays and or chest CT consistent with TB~Positive PPD test~Positive sputum test"
3080755|NCT02021747||Individuals with COPD|"All study subjects should meet the Lung Disease protocol criteria for having COPD may be of any stage (GOLD I - IV), be ambulatory and have no evidence of respiratory failure~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~Symptoms consistent with TB~Chest X-rays and or chest CT consistent with TB~Positive PPD test~Positive sputum test"
3080756|NCT02021721||Cohort|Subjects who fulfill the inclusion criteria will be pre-identified by consultation with their attending physicians and by thorough review of the literature to establish that the disease is indeed genetic and unsolved.
3080757|NCT02021708||Non-smoker|This group will include individuals without any history of lung disease, including asthma, and without recurrent or acute pulmonary disease. Individuals must also have smoked less than 100 cigarettes and/or less than 10 shisha pipes in their lifetime.
3080758|NCT02021708||Shisha smoker|This group will include individuals who have a shisha smoking history of more than 5 pipe-years and must currently smoke more than 5 pipes per week. Individuals must not show any signs of acute lung infection or have medical history of significant illness or other significant medical issues.
3080759|NCT02021708||Cigarette smoker|This group will include individuals who have a cigarette smoking history that will be confirmed by urine testing. Individuals must not show any signs of acute lung infection or have medical history of significant illness or other significant medical issues.
3080760|NCT02021695||Diabetics|Subjects minimum age :30 years; must hold Qatari passport; have diabetes with no concomitant diseases except micro- and macrovascular complications of diabetes or symptoms of metabolic syndrome; and not taking any chronic medications
3080761|NCT02021682||Amyloid positive (Amyloidosis)|Amyloidosis defined by positive Positive emission tomography (PET)/Pittsburg Compound B (PIB) score, or low CSF Aβ42 concentration.
3080762|NCT02021682||Amyloid negative (Control)|Amyloid negative defined by negative Positive emission tomography (PET)/Pittsburg Compound B (PIB) score or high/normal CSF Aβ42 concentration .
3080763|NCT02021669|Experimental|Omega-3 supplement|Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks
3080764|NCT02021669|Placebo Comparator|Placebo|Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
3080765|NCT02021656|Experimental|LDV/SOF|Treatment-experienced and treatment-naive participants will receive LDV/SOF for 12 weeks.
3080766|NCT02021643|Experimental|Sofosbuvir+RBV+PEG 12 weeks|Participants with genotype 1 or 6 will receive sofosbuvir+RBV+Peg-IFNα-2a for 12 weeks.
3080767|NCT02021643|Experimental|Sofosbuvir+RBV 12 weeks|Participants with genotype 1, 2 or 6 will receive sofosbuvir+RBV for 12 weeks.
3080768|NCT02021643|Experimental|Sofosbuvir+RBV 16 weeks|Participants with genotype 1, 6 will receive sofosbuvir+RBV for 16 weeks.
3080769|NCT02021643|Experimental|Sofosbuvir+RBV 24 Weeks|Participants with genotype 1, 3, or 6 will receive sofosbuvir+RBV for 24 weeks.
3080770|NCT02021630||Patient|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
3080771|NCT02021630||Spouse/Partner|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
3080772|NCT02021630||Child(ren)|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
3080896|NCT02020746|Placebo Comparator|Gel Vehicle|Control arm
3080773|NCT02021617|No Intervention|Intraosseous Access|This study will evaluate the proximal humerus and proximal tibia IO infusion sites for infusion flow rates attainable at specified infusion pressures. We will evaluate the IO infusion pathway to determine the mean time from IO contrast injection at the proximal humerus and proximal tibia sites to delivery to central circulation. This study will provide additional data regarding the relationship between IO and IV blood when used for routine laboratory analysis, adding to the current sample size. Lastly, this study will provide data to determine the average time from IO needle insertion to access of the IO space for immediate drug administration, and the average time from IO needle insertion to the ability to infuse fluids in the conscious subject. Intraosseous access.
3080774|NCT02021604|Experimental|Pancreatic Imaging with Fluorodopa F 18|
3080775|NCT02021591|No Intervention|Control|Control Arm: Study participants attending one of the 4 control arm centers will receive usual diabetes education provided by staff at the site; be provided with free test strips for their blood glucose meters during the 4-week intervention period; given access to the MODD application at the end of the study. Instructions on how to use the MODD will be provided by site staff.
3080776|NCT02021591|Experimental|Intervention|Intervention: Mobile Diabetes Detective (MoDD) Study participants attending one of the 4 Intervention sites will receive usual diabetes education provided by staff at the site and be given access to the MODD application and instructions for use for 4 weeks at the beginning of the study. After the initial 4 weeks of access to the MODD application, participants will be offered an option to continue using MODD for the duration of the study.
3080777|NCT02021578|Experimental|Family Cognitive Behavioral Prevention|A family cognitive behavioral program for parents and children. Parents learn parenting skills and cognitive behavioral techniques for managing depression. Children learn coping skills.
3080778|NCT02021578|Active Comparator|Written Information|Families receive written materials about depression and the effects of parental depression on children.
3080779|NCT02021565|Experimental|Immediate Intervention Group|"Receives the in-home training intervention immediately after completing the baseline assessment.~The intervention includes three home visits from an AT Specialist (Occupational or Physical Therapist) who observes the dyad perform three ADL transfers, provides recommendations, equipment, home modifications, training, and follow-up training as needed."
3080780|NCT02021565|Other|Delayed Intervention Control Group|Receives the in-home training intervention six weeks after completing the initial baseline assessment. This allows for a control comparison group while still providing the intervention to all participants.
3080781|NCT02021552||trauma patients|trauma patients 18 years or older requiring treatment in the ICU >24 hours. All subjects will undergo blood sampling.
3080782|NCT02021539||The study population|"The study population consists of pregnant women presenting between the 24th and 34th week of pregnancy, with uterine contractions associated with cervical changes objectified by ultrasound examination of the cervix (5-25mm) who consult for obstetric emergencies (both single or multiple pregnancies can be included).~Intervention : Cervical ultrasound +elastography 1 Intervention : Vaginal fibronectin measurement Intervention : Tocolytic treatment for 2 hours Intervention : Cervical ultrasound +elastography 2"
3080783|NCT02021526|Experimental|No Dietary Therapy|Patients currently on no dietary therapy will receive triheptanoin (C7 oil), dosed at 1 g/kg body weight and divided into 4 doses daily, administered for 6 months
3080784|NCT02021526|Experimental|Ketogenic Diet|Patients on ketogenic diet will receive triheptanoin (C7 oil) in place of their usual fat intake, at a dose sufficient to maintain their ketogenic diet ratio (based on patient weight and current ratio). Patients will receive triheptanoin for 6 months.
3080785|NCT02021513|Experimental|Fish Oil|Fish Oil (2.25gm EPA and 2.25gm DHA total)
3080786|NCT02021513|Placebo Comparator|Placebo|Olive Oil
3080787|NCT02021500||Patients previously enrolled in study CA046|No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
3080788|NCT02021474|Experimental|Histamine Dihydrochloride|Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis.
3080789|NCT02021474|Placebo Comparator|Evan's solution = phenol 0.4%, isotonic sodium chloride|Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis.
3080790|NCT02021461|Experimental|ESL Banana taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
3080791|NCT02021461|Experimental|ESL Grape taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
3080792|NCT02021461|Experimental|ESL Tutti-Frutti taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
3080793|NCT02021448|Other|Obesity: BMI > 30 kg/m2|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS) Polygraphy/Polysomnography, Blood sampling, EKG, Lung function testing, Arterial blood gases, Thoracic radiography, Six-minute walk test, Respiratory questionnaires
3080794|NCT02021435|Experimental|Salt Substitute|salt substitute
3080795|NCT02021435|No Intervention|Control|Participants continue to buy salt at their own expense
3080796|NCT02021422|Other|Anakinra with Modified Folfirinox|"8-weeks of anakinra and modified FOLFIRINOX regimen (refer to Appendix 9 for regimen) as follows~Kineret (anakinra) Dosage Route Administration 100 mg SC Every Other Day~Modified FOLFIRINOX Drug Dose Administration Oxaliplatin 85 mg/m2 2-4 hours Irinotecan 180 mg/m2 90 minutes fluorouracil 2400 mg/m2 48 hours"
3080797|NCT02021409|Experimental|BAY85-3934 (25mg)|Fixed starting dose of 25 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's hemoglobin (Hb) response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
3080897|NCT02020733|Other|balloon catheter|
3080898|NCT02020733|Other|metal cannula|
3080798|NCT02021409|Experimental|BAY85-3934 (50mg)|Fixed starting dose of 50 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
3080799|NCT02021409|Experimental|BAY85-3934 (75mg)|Fixed starting doses of 75 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
3080800|NCT02021409|Active Comparator|Darbepoetin alfa|Darbepoetin (intravenous or subcutaneous) will be administered according to the local label and titrated at the scheduled dose control visits. Titration will be based on the subject's Hb response and tolerability of the prior dose.
3080801|NCT02021396|Experimental|Embolization|this arm of the study was interventional (embolization) with CT scans at inclusion (D0, to validate the inclusion criteria), at one month (D30-validating the primary endpoint) and at 6 months (D180) read by 2 expert radiologists blinded to the study arm
3080802|NCT02021396|No Intervention|Surveillance|this arm of the study was non-interventional (surveillance), with CT scans at inclusion (D0, to validate the inclusion criteria), at one month (D30-validating the primary endpoint) and at 6 months (D180 ) read by 2 expert radiologists blinded to the study arm
3080803|NCT02021383|Experimental|Contest Plus|The Contest Plus group were eligible to receive the financial incentives for weight loss maintenance at three monthly follow ups; weeks 16, 20 and 24. Eligible participants completed online surveys and in person weigh ins verifying weight maintenance. In addition to the financial incentives, participants in this group had bi-weekly in person meetings with a Registered Dietician during phase 2 (week 16-24) of the trial. They also received an in home scale to monitor weight daily.
3080804|NCT02021383|No Intervention|Control|The Control condition did not receive any intervention and were not eligible to win the lottery based incentive. Participants completed follow surveys (weeks 16, 20 and 24) and received remuneration for completing surveys and in person weigh in.
3080805|NCT02021383|Experimental|Contest Only|The Contest only group were eligible to receive the financial incentives for weight loss maintenance for maintaining weight lost at three monthly follow ups; weeks 16, 20 and 24. Eligible participants completed online surveys and in person weigh ins verifying weight maintenance.
3080806|NCT02021370|Experimental|BAY85-3934 (25mg OD)|25 mg once daily (OD) of BAY85-3934 Morning: 1 tablet BAY85-3934 25 mg and 2 tablets matching placebo Evening: 3 tablets matching placebo
3080807|NCT02021370|Experimental|BAY85-3934 (50mg OD)|50 mg OD of BAY85-3934 Morning: 2 tablets BAY85-3934 25 mg and 1 tablet matching placebo Evening: 3 tablets matching placebo
3080808|NCT02021370|Experimental|BAY85-3934 (75mg OD)|75 mg OD of BAY85-3934 Morning: 3 tablets BAY85-3934 25 mg Evening: 3 tablets matching placebo
3080809|NCT02021370|Experimental|BAY85-3934 (25mg BID)|25 mg twice daily (BID) of BAY85-3934 Morning and evening: 1 tablet BAY85-3934 25 mg and 2 tablets matching placebo
3080810|NCT02021370|Experimental|BAY85-3934 (50mg BID)|50 mg BID of BAY85-3934 Morning and evening: 2 tablets BAY85-3934 25 mg and 1 tablet matching placebo
3080811|NCT02021370|Placebo Comparator|Placebo BID|Placebo BID Morning and evening: 3 tablets of placebo matching BAY85-3934 25 mg
3080812|NCT02021357|Experimental|Hyperboloid associated with the exercise of proprioceptive|The proprioceptive treatment protocol if run in the use of exercises with hyperboloid based on studies of Biasotto-Gonzalez (2005), for each exercise will be held 6 sets of 6 reps. Between exercises, 1 minute will be established for rest of the volunteer, in order to avoid muscle fatigue and possible exacerbation of pain, and after that period you will be asked to volunteer the proprioceptive exercise of ´ ´ tongue on the hard palate ´ ´ Biasotto-Gonzalez-based (2005), which consists of the language supported in the hard palate, you must open and close the mouth, having as the principle language as a physical reference.
3080813|NCT02021357|Active Comparator|Hyperboloid|"The proprioceptive treatment protocol if run in the use of the hyperboloid, based on studies of Biasotto-Gonzalez (2005), but without the proprioceptive exercise of language in ´ ´ hard palate ´ ´.~For each exercise will be held 6 series of 6 repetitions, and between exercises, 1 minute will be established for rest of the volunteer, in order to avoid muscle fatigue and possible exacerbation of pain."
3080814|NCT02021344|No Intervention|Pure control|Practice as usual (no MHFA) in all residences on these campuses.
3080815|NCT02021344|Experimental|Intervention residence on mixed campus|Mental Health First Aid delivered to these residences, but not all other residences at the same campus.
3080816|NCT02021344|Experimental|Pure intervention residence|Mental Health First Aid delivered to this residence and all other residences at the same campus
3080817|NCT02021344|No Intervention|Control at mixed campus|Practice as usual (no MHFA) at this residence, but some other residences at same campus are in experimental condition (MHFA).
3080818|NCT02021331|Active Comparator|immediate implant placement without provisionalization|The subject will have the tooth removed and an implant placed right away. In this arm the subject will have no temporary crown on the implant.
3080819|NCT02021331|Experimental|immediate implant placement with immediate provisionalization|The subject will have the tooth removed and an implant placed right away. In this arm the subject will get a temporary crown on the implant.
3080820|NCT02021318|Experimental|Roxadustat|Study drug Roxadustat will be dosed three times weekly (TIW) during correction period, and TIW during the maintenance period. Dose adjustments are allowed during the study
3080821|NCT02021318|Active Comparator|darbepoetin alfa|darbepoetin alfa will be dosed per European Summary of Product Characteristics (SmPC)
3080822|NCT02021305||Patients|60 children with a recorded episode of acute Urinary Track infection who attended 4th Department of Pediatrics of Medical School of Aristotle University of Thessaloniki.
3080823|NCT02021305||Controls|100 children with no history of Urinary Track Infection who attended 4th Department of Pediatrics of Medical School of Aristotle University of Thessaloniki.
3080824|NCT02021292|Experimental|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
3080825|NCT02021292|Placebo Comparator|Placebo|Matching placebo oral tablet, to be taken once daily.
3080826|NCT02021279|Experimental|MatriStem Pelvic Floor Matrix|surgical mesh device
3080827|NCT02021279|Active Comparator|Native Tissue Repair|suture repair
3080828|NCT02021253|Placebo Comparator|Placebo of Probiotics|"Placebo: Composition: Each capsule contains 560 mg:~459 mg of corn starch~6 mg of magnesium stearate~Dosage: 2 capsules / day, in the morning at sunrise, one at bedtime.~Methods of administration: Oral.~Duration of treatment: 14 days"
3080829|NCT02021253|Active Comparator|Probiotics- Lactibiane Tolerance|"Active substance mixture of lactic 10% Bifidobacterium lactis LA 303, 10% Lactobacillus acidophilus LA 201, LA 40% Lactobacillus plantarum 301, 20% Lactobacillus salivarius LA 302, LA 20% Bifidobacterium lactis 304 Dosage: 10 X 10^9 probiotic / capsule~Composition: One capsule of 560 mg contains Lactibiane tolerance:~345 mg of corn starch~114 mg premix lactic~6 mg of magnesium stearate Excipients: magnesium stearate~Method of administration: Oral~Dosage: 2 capsules per day for 14 days in two doses: one capsule at sunrise, one capsule at bedtime;"
3080830|NCT02021240|Active Comparator|Ketamine|Single dose of intravenous ketamine 0.5mg/kg before incision
3080831|NCT02021240|Active Comparator|Dexamethasone|Single dose of intravenous dexamethasone 8mg before incision
3080832|NCT02021240|Placebo Comparator|Normal saline|Single dose of intravenous normal saline before incision
3080833|NCT02021227|No Intervention|Standard group|
3080834|NCT02021227|Other|Chair sitting group|
3080835|NCT02021214|Experimental|Methylphenidate/Placebo|40 mg Methylphenidate, per os, single dose or Placebo
3080836|NCT02021201|Experimental|1|Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound
3080837|NCT02021188||Carotid artery disease|Participants with symptomatic or asymptomatic carotid artery plaques
3080838|NCT02021188||Coronary artery disease|Participants with stable coronary artery disease or recent acute coronary syndrome
3080839|NCT02021175|Experimental|Tailored CBME Therapy via Technology|6 weeks of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones
3080840|NCT02021175|Other|Standard of Care|Referral to currently available resources for 6 weeks of a standard smoking cessation approach
3080841|NCT02021162||Gilenya|MS patients taking Gilenya
3080842|NCT02021162||Healthy Controls|Healthy controls age and gender matched to MS patients taking Gilenya
3080843|NCT02021149|Other|Psychotherapy and Questionnaire Group|Participants in this arm will have their regular psychotherapy sessions with their psychotherapist and will, prior to each session, fill out study related questionnaires.
3080844|NCT02021149|Experimental|High intensity whole-body infrared heating and Psychotherapy.|Subjects will have weekly psychotherapy sessions and fill out study questionnaires. The participant's 4th psychotherapy session will be conducted while the patient undergoes the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
3080845|NCT02021149|Sham Comparator|Low intensity whole-body infrared heating and Psychotherapy|Subjects will have weekly psychotherapy sessions and fill out study questionnaires. The participant's 4th psychotherapy session will be conducted while the patient undergoes WBH-control where subjects will be induced to levels of heat that causes only a minor increase in body temperature.
3080846|NCT02021136|Experimental|Rebel reliever|Rebel Reliever(R) knee brace + usual antalgic treatment + physical exercises recommendations.
3080847|NCT02021136|Active Comparator|Control|usual antalgic treatment + physical exercises recommendations.
3080848|NCT02021123|Experimental|Anidulafungin 100 mg single dose|100 mg single dose anidulafungin pre-surgery (gastric bypass)
3080849|NCT02021110|No Intervention|Control group|This group will receive standard care (no treatment)
3080850|NCT02021110|Experimental|Ursodeoxycholic Acid|The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
3080851|NCT02021097|Experimental|LNG100 mcg/EE20 mcg|
3080852|NCT02021097|Active Comparator|LNG 150mcg/ EE 30mcg|
3080853|NCT02021084|Placebo Comparator|placebo, response, adverse effect|children (5-17 years old) with FMF that are currently followed in the pediatric rheumatology clinic at Mayer children hospital Israel Haifa that are being treated with colchicine and suffering from either gastrointestinal adverse effect or partial response to colchicine.in the first 3 month patients will be followed with no interventions and will be required to record all there FMF episodes and their GIT adverse effect, in the second period the patients will be randomly divided into two groups patients that will received placebo arm one and patients that will receive probiotics arm two.
3080854|NCT02021084|Active Comparator|probiotic, response, adverse effect|children (5-17 years old) with FMF that are currently followed in the pediatric rheumatology clinic at Mayer children hospital Israel Haifa that are being treated with colchicine and suffering from either gastrointestinal adverse effect or partial response to colchicine.in the first 3 month patients will be followed with no interventions and will be required to record all there FMF episodes and their GIT adverse effect, in the second period the patients will be randomly divided into two groups patients that will received placebo arm one and patients that will receive probiotics arm two.
3080855|NCT02021071||XperGuide|Image-guided needle procedures with XperGuide performed prior to this study within institution (retrospective data).
3080856|NCT02021071||XperGuide with virtual path planning|Image-guided needle procedures with XperGuide with virtual path planning
3080857|NCT02021058|Experimental|Experimental Formula|Experimental Formula
3080858|NCT02021058|Other|Standard Formula|Standard Control formula
3080859|NCT02021045||Patient on Hemodialysis|Renal hemodialysis
3080860|NCT02021045||Patient in a hemodialysis-free interval|No Renal hemodialysis
3080861|NCT02021032|Experimental|Prolieve|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
3080862|NCT02021019|Experimental|Renal Denervation|Renal denervation using a catheter-based Radio-frequency approach
3080863|NCT02021019|No Intervention|Usual Care|Usual care
3080899|NCT02020720|Experimental|Diagnostic (18F-DOPA-PET)|Within 1 week of biopsy or resection, patients undergo 18F-DOPA PET/CT scan and pMRI and DTI at baseline. Patients then undergo stereotactic craniotomy or image-guided biopsy.
3081112|NCT02019160|Active Comparator|Silver diamine fluoride|Biannual application of 38% SDF solution followed by placebo varnish.
3080864|NCT02021006|Active Comparator|ANTIBIOTIC PROPHYLAXIS|"Children in this arm will take antibiotic prophylaxis for 2 years. Patients in this arm will do clinical/instrumental follow-up for 5 years.~The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~nitrofurantoin 1.5-2 mg/kg per day~Amoxicillin-Potassium Clavulanate Combination 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~cefixime 2 mg/kg per day~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
3080865|NCT02021006|Experimental|NO PROPHYLAXIS|Children in this arm will not take antibiotic prophylaxis. Patients in this arm will do clinical/instrumental follow-up for 5 years
3080866|NCT02020993||Respiratory distress group|Newborns with respiratory distress will constitute the study group. All patients will be evaluated by Urine NT-proBNP and echocardiography on postnatal days 1-2 and 5-7.
3080867|NCT02020993||Control Group|Newborns without any respiratory and cardiac diseases will constitute the control group, and will be evaluated by urine Nt-proBNP and echocardiography on postnatal days 1-2 and 5-7.
3080868|NCT02020980||Post-stroke lower limb spasticity patients|
3080869|NCT02020967||Acromegaly patients|
3080870|NCT02020954||Dystrophinopathy|Patients with mutations in the DMD gene and Becker muscular dystrophy and/or dilated cardiomyopathy
3080871|NCT02020941|Experimental|Treatment (carfilzomib, dexamethasone)|"TREATMENT PHASE (COURSES 1-8): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than PR also receive dexamethasone PO or IV weekly in courses 4-8.~MAINTENANCE PHASE (COURSES 9-14): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Patients who received dexamethasone in the Treatment Phase continue to receive dexamethasone PO or IV weekly. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity."
3080872|NCT02020928|Experimental|Low level laser therapy|The Low level laser therapy application is performed from the first day of conditioning of the patient until the second day after bone marrow transplantation (D + 2). The patients are divided into two groups. The first will contain the patients who will receive the red laser light, whereas the second will cover patients who receive sham or placebo controlled - the device is triggered, but not deliver the laser light.
3080873|NCT02020928|Sham Comparator|sham|patients will receive sham Low level laser therapy - the device is triggered, but not deliver the laser light
3080874|NCT02020915||Patients with chronic anal fissure|Patients are included who had previous treatment with diltiazem or glycerol-nitrate and botox injections
3080875|NCT02020889|Experimental|Mepolizumab 300 mg|Each subject will receive mepolizumab 300 mg subcutaneous (SC) injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections (100 mg each- total dose 300 mg); individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.
3080876|NCT02020889|Placebo Comparator|Placebo|Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections; individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.
3080877|NCT02020876||Practicing urologic surgeons|Performing at least 60 radical prostate surgeries annually
3080878|NCT02020863|Experimental|Closed Loop|Study patients will receive a baseline crystalloid infusion of 3 cc/kg/hr and all additional fluid management will be performed via a closed loop (automated) system that will determine rate, amount, and timing of fluid administration.
3080879|NCT02020850||Toe-Brachial and Ankle-Brachial Index|toe systolic blood pressure, ankle systolic blood pressure, brachial systolic blood pressure test
3080880|NCT02020837|Experimental|Lymphaticovenous Micro-Anastomosis|
3080881|NCT02020824|Active Comparator|Exposure without control|"Exposure to anxiogenous environments: 20 acrophobic patients will be exposed during 8 sessions to anxiogenous environments without control.~Imagery with functional MRI initial. Imagery with functional MRI final. Imagery with PET-scanner initial. Imagery with PET-scanner final."
3080882|NCT02020824|Experimental|Exposure with control|"Exposure to anxiogenous environments: 20 acrophobic patients will be exposed during 8 sessions to anxiogenous environments with the ability to control and secure these.~Imagery with functional MRI initial. Imagery with functional MRI final. Imagery with PET-scanner initial. Imagery with PET-scanner final."
3080883|NCT02020824|Other|Healthy volunteers|"20 healthy volunteers will be submitted to the same initial measurements in order to explore potential differences between them and the patients.~Imagery with functional MRI initial. Imagery with PET-scanner initial."
3080884|NCT02020811|Experimental|sentinel arm|all patients will be recieving Iv therapy by using the sentinel controller, a device that is mounted on the IV administration set.
3080885|NCT02020798|Placebo Comparator|Nutrient formulations without active ingredient|4 nutrient formulations without active ingredient and variable level of available placebo ingredient
3080886|NCT02020798|Experimental|Nutrient formulation with active ingredien|4 nutrient formulations with increasing amount of active ingredient
3080887|NCT02020785|Active Comparator|Higher phosphorus period|Commercially-available unaltered food/beverage products containing phosphorus additives (~1gm/d of phosphorus) will be given for 3 weeks
3080888|NCT02020785|Placebo Comparator|Lower phosphorus period|Commercially-available unaltered food/beverage products without phosphorus additives (<10mg/d of phosphorus) will be given for 3 weeks
3080889|NCT02020772|Experimental|coordinating primary health care 1|musculoskeletal pain care by a coordinating team of one general practitioner and two physical therapists
3080890|NCT02020772|Active Comparator|usual primary health care 1|usual care of musculoskeletal pain in general practice
3080891|NCT02020772|Experimental|coordinating primary health care 2|musculoskeletal pain care by a coordinating team of one general practitioner and two physical therapists
3080892|NCT02020772|Active Comparator|usual primary health care 2|usual care of musculoskeletal pain in general practice
3080893|NCT02020759||Patient on ECMO|Neurological monitoring with transcranial Doppler ultrasound
3080894|NCT02020759||Healthy subjects|Neurological monitoring with transcranial Doppler ultrasound
3080895|NCT02020746|Active Comparator|EscharEx|Enzymatic debridement
3080900|NCT02020707|Experimental|Treatment (AB-complex)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation/bevacizumab-complex IV over 30-60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3080901|NCT02020694|Experimental|Vitamin D and Diet|"Cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL oral solution. 25,000 I.U. (one bottle) per week.~Hypocaloric diet"
3080902|NCT02020694|Placebo Comparator|Placebo & Diet|"Oral solution mimicking cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL. One bottle per week.~Hypocaloric diet"
3080903|NCT02020681|Experimental|Curodont Repair|Single application of Curodont Repair on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.
3080904|NCT02020681|Placebo Comparator|Placebo|Single application of Placebo on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.
3080905|NCT02020668|Experimental|Physiotherapy|Physiotherapy included joint protection strategies, performance of therapeutic exercises and patient education.
3080906|NCT02020668|Other|Wait list control|Wait list control received standard care and were invited to join the physiotherapy once intervention period is finished.
3080907|NCT02020655||10 healthy volunteers|Shear- force model
3080908|NCT02020642|Experimental|Intervention Group|A baseline polysomnography (PSG) is performed at inclusion (before renal transplantation, Tx), followed by a post-Tx PSG 6 months after transplantation
3080909|NCT02020642|No Intervention|Control Group|A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG at 6 months if the patient is not already transplanted
3080910|NCT02020629|Experimental|Lixisenatide|Lixisenatide 20µg daily
3080911|NCT02020616|Experimental|LY3053102|Stage 1: Escalating dose (7 milligrams [mg] up to 200 mg) of LY3053102 administered once a week by subcutaneous (SC) injection for 12 weeks. Stage 2: LY3053102 administered once a week by SC injection for 12 weeks
3080912|NCT02020616|Placebo Comparator|Placebo|Stage 1 and Stage 2: Placebo to match LY3053102 administered by SC injection once a week for 12 weeks
3080913|NCT02020616|Active Comparator|Exenatide Extended-Release (ER)|Stage 1 and Stage 2: Exenatide ER 2 mg given by SC injection once a week for 12 weeks
3080914|NCT02020616|Experimental|LY3053102 + Exenatide ER|Stage 2: LY3053102 administered by SC injection once a week for 12 weeks and exenatide ER 2 mg administered by SC injection once a week for 12 weeks
3080915|NCT02020603|Active Comparator|APC group|epinephrine injection plus argon plasma coagulation
3080916|NCT02020603|Active Comparator|Forceps group|epinephrine injection plus soft coagulation using hemostatic forceps
3080917|NCT02020590|Experimental|ALLOB® Implantation|One arm: ALLOB® Implantation
3080918|NCT02020577|Experimental|combination arm|Patients to receive afatinib once daily plus weekly cetuximab infusion
3080919|NCT02020564|Experimental|Computerized Tests|
3080920|NCT02020551|Placebo Comparator|saline spray application|Placebo group
3080921|NCT02020551|Experimental|lidocaine spray application|2 puff lidocaine spray applicated before IUD insertion
3080922|NCT02020538|Placebo Comparator|Chloride-rich IV fluid|The chloride-rich strategy will include 0.9% saline as the perioperative crystalloid of choice with 4% albumin as the perioperative colloid of choice.
3080923|NCT02020538|Active Comparator|Chloride-poor IV fluid|A low-chloride strategy of perioperative IV fluid will include PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice with 20% albumin as the colloid of choice.
3080924|NCT02020525|Experimental|restrictive transfusion strategy|Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.
3080925|NCT02020525|Active Comparator|liberal transfusion strategy|Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
3080926|NCT02020512|Experimental|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
3080927|NCT02020499||Acromegalic patients|Acromegalic subjects treated with Somatuline Autogel® (Lanreotide)
3080928|NCT02020486|Experimental|Group A|Experimental
3080929|NCT02020486|Experimental|Group B|Days 1-14: Multiple oral dose of 2 mg perampanel (one 2 mg tablet) Days 15-28: Multiple oral dose of 4 mg perampanel (two 2 mg tablets) Days 29-42: Multiple oral dose of 6 mg perampanel (three 2 mg tablets)
3080930|NCT02020473||WLS group|patients with informed consents for withholding/withdrawing life support
3080931|NCT02020473||non-WLS group|patients without informed consents for withholding/withdrawing life support
3080932|NCT02020460|Active Comparator|Subdural trial lead|SCS trial lead in the subdural space.
3080933|NCT02020460|Active Comparator|Epidural trial lead|SCS trial lead in the epidural space.
3080934|NCT02020434|Experimental|Single dose of RPX7009 and RPX2014|Single dose of combination RPX7009 and RPX2014
3080935|NCT02020421|Experimental|rTMS|Participants will receive real rTMS and sham tDCS
3080936|NCT02020421|Experimental|tDCS|Participants will receive real tDCS and sham rTMS
3080937|NCT02020421|Sham Comparator|Sham|Participants will receive both sham rTMS and sham tDCS
3080938|NCT02020408|Experimental|[11C]raclopride, [11C]DASB, amphetamine|One time administration of oral amphetamine based on subject's weight (0.5 mg/kg). One PET scan using [11C]DASB. Two PET scans using [11C]raclopride.
3080939|NCT02020395|Placebo Comparator|Test meal (500 kcal)_normal weight|ham sandwich chocolate cream orange juice
3080940|NCT02020395|Active Comparator|Test meal (500 kcal)_obese weight|ham sandwich chocolate cream orange juice
3080941|NCT02020382|Other|Crohn adult colic|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
3080942|NCT02020382|Other|RCH adults|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
3080943|NCT02020382|Other|Witnesses healthy adults|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
3080944|NCT02020382|Other|Witnesses adults with non-IBD inflammation|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
3080945|NCT02020382|Other|Children with colitis|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
3080946|NCT02020382|Other|Witnesses healthy children|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
3080947|NCT02020369|Experimental|FVIIa: 75 µg/kg first, then 225 µg/kg|Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.
3080948|NCT02020369|Experimental|FVIIa: 225 µg/kg first, then 75 µg/kg|Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.
3080949|NCT02020356|Experimental|Music therapy|"U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase."
3080950|NCT02020356|Placebo Comparator|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
3080951|NCT02020343||Healthy|Not insulin resistant
3080952|NCT02020343||Insulin resistant|Insulin resistant by IVGTT
3080953|NCT02020343||Type 2 diabetics|Type 2 diabetics
3080954|NCT02020330|Active Comparator|AL3days|Artemether-lumefantrine 3 days
3080955|NCT02020330|Experimental|AL5days|Artemether-lumefantrine 5 days
3080956|NCT02020317|Active Comparator|computer-based reminders and alerts|Behavioral: display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts (decision support in potassium-inc. drug-drug-interactions)
3080957|NCT02020317|No Intervention|no computer-based reminders or alerts|Behavioral: no display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
3080958|NCT02020304|Experimental|Room temperature|room temperature combined spinal epidural dose (60-75 degrees F)
3080959|NCT02020304|Active Comparator|refrigerated temperature|refrigerated temperature combined spinal epidural dose (~<43 degrees F)
3080960|NCT02020291|Experimental|Foxy-5|Slow infusion of lyophilised and reconstituted Foxy-5 three times weekly on Monday, Wednesday and Friday for three weeks.
3080961|NCT02020278|Experimental|Follow-up|"Subjects enrolled in this trial may be eligible to receive open-label tolvaptan if they have a clinical need as determined by the investigator and meet the eligibility criteria for optional tolvaptan treatment.~Tolvaptan will initially be supplied as 3.75-, 7.5-, 15-, and 30-mg spray-dried tablets. Initial dose administration is dependent on age and weight with subsequent changes dependent on serum sodium levels. Daily dose levels include 3.75 mg, 7.5 mg, 15 mg, 30 mg, and 60 mg."
3080962|NCT02020265|Experimental|NF group|This group will train modulation of the amygdala EEG fingerprint by EEG neurofeedback.
3080963|NCT02020265|Sham Comparator|Sham NF|This group preform the same procedure as the NF group only reviving sham feedback
3080964|NCT02020265|Active Comparator|A\T NF|This group will train modulation of A\T ratio by EEG neurofeedback
3080965|NCT02020252||Touchscreen Participants|
3080966|NCT02020239|Experimental|Prescribed exercise|Participants will be asked to choose one activity and stick to it for the duration of the intervention. Participants will be able to choose between brisk walking/slow jogging or cycling. The intervention will require the completion of 30 minutes of chosen activity on 5 days of the week, which will be recorded in a physical activity diary.
3080967|NCT02020239|Experimental|Points-based physical activity|Participants will be asked to achieve a pre-set, individualised points target for physical activity each week. Points are acquired through the completion of a minimum 10 minutes of activity, choosing from the extensive list of activities provided; for example, 10 minutes of jogging achieves 4.5 points, whereas 10 minutes of washing a car achieves 1.5 points. The target will be 35-40 points per week, which equates to approximately 6 points per day. Any combination of activity, duration and frequency can be selected.
3080968|NCT02020239|No Intervention|Waiting list control|Participants will be asked to maintain their normal activities and diet. They will be added to a waiting list to receive either exercise intervention after completing the 24-week trial period, so that they do not miss out on the opportunity to receive the exercise intervention.
3080969|NCT02020226|Experimental|TH-302|480 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle
3080970|NCT02020213|Other|Posaconazole, salvage|Posaconazole, per oral , 400 mg, bid , 8 weeks.
3080971|NCT02020200|Experimental|MPH or Placebo|MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight<40 kg; 30 mg in case weight>90 kg; otherwise 20 mg. Both participants and investigators will be blinded to when participant receives MPH or Placebo.
3080972|NCT02020187|Experimental|Exercise|10 weeks of home training on a cycle-ergometer. Exercise 30 minutes every other day or at least three times a week.
3080973|NCT02020187|No Intervention|Controls|Controls with diagnosed congenital myopathy. Subjects are tested two times on a cycle ergometer. There will be ten weeks between the tests. In between tests the subjects are living life as usual without any interventions.
3080974|NCT02020161|Experimental|ATRA-Idarubicin|
3080975|NCT02020135|Experimental|Arm 1: PSMA ADC|Subjects started the extension study at the same dose received upon completion of the core PSMA ADC 2301 study. Each Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) dose was administered as an IV infusion over approximately 60 minutes once every three weeks (Q3W) for up to eight doses, unless a dose delay or dose reduction was required.
3080976|NCT02020122|Active Comparator|Duloxetine|DUL 60mg x once a day x 2 days. This arm will also take 2 non-active placebo x once a day x 2 days
3080977|NCT02020122|Active Comparator|Pregabalin|PGB 150mg x twice a day x 2 days
3080978|NCT02020122|Placebo Comparator|Placebo|Non active placebo x twice a day x 2 days
3080979|NCT02020109||Patients with Chronic Lymphatic Leukemia|Patients with Chronic Lymphatic Leukemia treated with splenic irradiation
3080980|NCT02020096|Experimental|U+N group|Ultrasound and nerve stimulator guided lumbar plexus block combined with nerve stimulator guided sciatic block
3080981|NCT02020096|Active Comparator|N group|Nerve stimulator guided lumbar plexus block combined with nerve stimulator guided sciatic nerve block
3081018|NCT02019875|Active Comparator|Clarithromycin Plus Rifampin|Clarithromycin 250 mg twice a day for 14 days plus rifampin 600 mg once a day for 14 days
3081019|NCT02019862||TRJ®|
3081020|NCT02019849||Plasmafit® Total Hip Arthroplasty|
3081021|NCT02019836||sepsis group, control group|Sepsis group; infants with the diagnosis of high probable sepsis Control group; infants without sepsis
3081113|NCT02019147||Term Hypoxic Ischaemic Encephalopathy|Term Hypoxic Ischaemic Encephalopathy (HIE)
3080982|NCT02020070|Experimental|Ipilimumab & Degarelix With Radical Prostatectomy|"Week 1: Degarelix SQ injection (except patients who have already received hormonal therapy per standard of care and are not yet due for their next dose) and Ipilimumab at 3 mg/kg intravenously (IV). Surgery Radical prostatectomy (RP)will be performed during week 3 ± 1 week or after recovery to grade ≤ 1 adverse events experienced during the induction period related to treatment. Continued Androgen Depletion and Ipilimumab Weeks 5, 9, 13, 17, 21, 25, and 29: Degarelix 80 mg SQ (except patients who have already received hormonal therapy per standard of care and are not yet due for their next dose)~Week 11, 14, 17 or after sufficient wound healing and recovery post RP:~Ipilimumab 3 mg/kg IV Follow-up Twelve week intervals until Week 87."
3080983|NCT02020070|Experimental|Ipilimumab & Degarelix With Prior With Radical Prostatectomy|Week 1: Degarelix 240 mg SQ injection and Ipilimumab at 3 mg/kg intravenously (IV) Continued Androgen Depletion and Ipilimumab Weeks 5, 9, 13, 17, 21, 25, and 29: Degarelix 80 mg SQ Week 4,7,10: Ipilimumab 3mg/kg IV Follow-up Twelve week intervals until Week 81, with MD visits at weeks 52 and 84 (12 and 20 months).
3080984|NCT02020057|Active Comparator|Conventional|knee receiving Total knee arthroplasty with conventional polyethylene inserts
3080985|NCT02020057|Experimental|Prolong|knee receiving total knee arthroplasty with highly cross linked polyethylene insert
3080986|NCT02020044|Other|Endothelial Keratoplasty|Descemet membrane endothelial keratoplasty DMEK Ultra-thin Descemet stripping automated endothelial keratoplasty Ultra-thin DSAEK
3080987|NCT02020031|Experimental|Vancomycin 500mg intraosseous|Vancomycin 500mg is given via intraosseous regional administration (IORA) into a proximal tibial cannula, after tourniquet inflation and immediately prior to skin incision.
3080988|NCT02020031|Active Comparator|Vancomycin 1g IV|Vancomycin 1g is administered via forearm vein, given over a one-hour infusion, timed to finish approximately 30 minutes prior to tourniquet inflation.
3080989|NCT02020018|Experimental|prospective group|This will be the high risk group that will have the wound VAC device (prevena) applied immediately postoperatively
3080990|NCT02020018|Active Comparator|Retrospective arm|standard wound management group
3080991|NCT02020005|Experimental|Smoking replacement|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
3080992|NCT02019992||sepsis|sepsis defined as suspected infection and systemic inflammatory response
3080993|NCT02019992||severe sepsis|sepsis with organ dysfunction or septic shock defined as sepsis plus hypotension
3080994|NCT02019992||control group|control defined as non-infected patients without systemic inflammatory response.
3080995|NCT02019979|Experimental|metformin /carbohydrate restricted diet|metformin and carbohydrate restricted diet added to platinum based chemotherapy regimen
3080996|NCT02019966||TDF monotherapy|"TDF monotherapy - treated by tenofovir alone~patients with CHB receiving rescue TDF (300mg once daily) monotherapy"
3080997|NCT02019966||TDF-based combination therapy|"TDF-based combination therapy - treated by tenofovir based combination therapy.~patients with CHB receiving rescue TDF-based combination therapy (TDF 300mg once daily with any other nucleoside analogue such as lamivudine 100mg, telbivudine 600mg, or entecavir 1.0 mg once daily)."
3080998|NCT02019953|Other|Yoga 3 times per week|Yoga participation 3 x per week for 24 weeks; 48 week follow-up.
3080999|NCT02019953|Other|Yoga 2 times per week|Yoga participation 2 x per week for 24 weeks; 48 week follow-up
3081000|NCT02019953|Other|Yoga 1 time per week|Yoga participation 1 x per week for 24 weeks; 48 week follow-up
3081001|NCT02019953|Other|Walking 3 times per week|Walking 3x per week for 24 weeks; 48 week follow-up
3081002|NCT02019953|Other|Healthy Lifestyles Education|Healthy Lifestyles Education Participation 1 x per week for 24 weeks; 48 week follow-up
3081003|NCT02019940|Experimental|Riluzole|Riluzole 50 mg orally twice per day
3081004|NCT02019927|Active Comparator|Non-arteritic ischemic optic neuropathy|Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
3081005|NCT02019927|Active Comparator|Multiple Sclerosis|Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
3081006|NCT02019927|Active Comparator|Ocular Trauma|Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
3081007|NCT02019914||PTSD and OSA|Veterans diagnosed with Post Traumatic Stress Disorder (PTSD) and Obstructive Sleep Apnea (OSA), interested in a trial of CPAP therapy.
3081008|NCT02019901|No Intervention|Regular care|"The control-group is treated according to care as usual with visits to physician every 6th month."
3081009|NCT02019901|Experimental|Nurse-led clinic|Nurse-led visits every 6th week, with structured person-centered care and evaluation of disease activity. If disease remission is not reached, pharmacological treatment including both short-term (intra-articular and oral steroids) and long-term alterations (DMARDs and biologics) is modified according to a predefined algorithm.
3081010|NCT02019888||Normal hearing adults|Adults between 20 and 79 years old with hearing at all audiometric frequencies between 250 and 8000 Hz at less than or equal to 25 dB HL
3081011|NCT02019888||Adults with sensory neural hearing loss|Adults between 20 and 79 years old with sensory neural hearing at one or more audiometric frequencies between 250 and 8000 Hz.
3081012|NCT02019888||Adults with middle ear disorders|Adults between 20 and 89 years old with middle ear disorders: tympanic membrane perforation, serous otitis media, cholesteatoma, otosclerosis, and unspecified middle ear disorders.
3081013|NCT02019875|Placebo Comparator|Water|200 mL of water once a day for 14 days
3081014|NCT02019875|Active Comparator|Rifampin|Rifampin 600 mg once a day for 14 days
3081015|NCT02019875|Active Comparator|Grapefruit Juice|200 mL of grapefruit juice once a day for 14 days
3081016|NCT02019875|Active Comparator|Grapefruit Juice Plus Rifampin|200 mL of grapefruit juice once a day for 8 days plus rifampin 600 mg once a day for 14 days
3081017|NCT02019875|Active Comparator|Clarithromycin|Clarithromycin 250 mg twice a day for 14 days
3081022|NCT02019823|Active Comparator|Enhanced usual care|"In addition to usual care participants will receive the pre-randomisation Welcome to the *StAR Study SMS-text, post-randomisation they will received a Happy Birthday SMS-text on their date of birth and up to six additional SMS-text messages containing study specific information and thanking the participant for taking part in the study. Participants in the Enhanced Usual Care group will receive no more than one study specific SMS-text every two months."
3081023|NCT02019823|Experimental|Informational SMS-text|"In addition to enhanced usual care, participants allocated to the informational SMS-text support group will receive a series of text-messages covering the following areas:~I. Medication pick-up reminders send 48 hours before scheduled medication pick-up date a) Participants who fail to pick-up medication within 3 days of scheduled pick-up date will be sent one further reminder SMS-text~II. III. Clinic appointment reminder 48 hours before scheduled follow-up appointment~a) Participants who fail to attend clinic appointment will be sent an additional SMS-text checking they are alright and inviting them to rebook their appointment via the clinic IV. Messages which support medication adherence (focused on organisation, memory, and habit) or provide hypertension related health information"
3081024|NCT02019823|Experimental|Interactive SMS-text|"In addition to enhanced usual care and informational SMS-text messages, SMS-text messages sent to participants in the interactive SMS-text group will contain a prompt to respond which will guide participants to additional SMS-text based resources."
3081025|NCT02019810|Active Comparator|Noradrenaline alone|Treatment for 30 minutes with noradrenaline alone
3081026|NCT02019810|Experimental|Noradrenaline + dobutamine|Treatment with noradrenaline and dobutamine for 30 minutes
3081027|NCT02019797|Experimental|Desflurane|Desflurane inhalation at 1-2 MAC during surgery.
3081028|NCT02019797|Active Comparator|Propofol|5-8 mg/kg/hr infusion during surgery.
3081029|NCT02019784|Active Comparator|Rifaximin-α|Rifaximin-α (TARGAXAN TM, manufactured by Alfa-Wasserman, Bologna, Italy) tablets - 550mg twice daily for 90 days
3081030|NCT02019784|Placebo Comparator|Placebo|Placebo tablets - 550mg twice daily for 90 days
3081031|NCT02019758|Active Comparator|Oral Viscous Budesonide (OVB)|Subjects will be treated with OVB at a dose of 1 mg twice daily, and they will also be instructed to use a placebo inhaler identical to the fluticasone MDI, with instructions to swallow 4 puffs twice daily.
3081032|NCT02019758|Active Comparator|Active Fluticasone MDI|Subjects will be treated with fluticasone MDI at a dose of 880 mcg twice daily (4 puffs of a 220 mcg inhaler twice daily), and they will also be instructed to take 4 mL twice daily of a placebo slurry of sucralose identical in consistency and taste to the OVB.
3081033|NCT02019745||LAIV (FluMist)|All subjects will receive a 0.2 mL dose of LAIV (FluMist) once during the study.
3081034|NCT02019732||Study Group|Applicable subjects less than 65 years of age identified in the Marketscan Commercial database during the period from July 2000 through April 2009, and October 2010 to May 2011 and subjects 65 years of age and older identified in MarketScan Medicare Supplemental database during the period from July 2006 through April 2009, and October 2010 to May 2011.
3081035|NCT02019719|Experimental|GSK1278863 4 milligrams (mg)|Subjects will receive GSK1278863 4 mg once daily for 4 weeks
3081036|NCT02019719|Experimental|GSK1278863 6 mg|Subjects will receive GSK1278863 6 mg once daily for 4 weeks
3081037|NCT02019719|Experimental|GSK1278863 8 mg|Subjects will receive GSK1278863 8 mg once daily for 4 weeks
3081038|NCT02019719|Experimental|GSK1278863 10 mg|Subjects will receive GSK1278863 10 mg once daily for 4 weeks
3081039|NCT02019719|Placebo Comparator|Placebo|Subjects will receive placebo once daily for 4 weeks
3081040|NCT02019693|Experimental|1-Single Cohort|INC280 400 mg twice every day by mouth, continuously
3081041|NCT02019667|Experimental|phase II|study drug or placebo (blinded)
3081042|NCT02019667|Experimental|phase I for 6 months|Study drug or placebo (blinded) for 6 months
3081043|NCT02019667|Experimental|phase I|study drug or placebo (blinded)
3081044|NCT02019667|Experimental|phase II crossover|crossover study drug or placebo blinded
3081045|NCT02019641|Experimental|AET|AET will consist of a 10-week regimen of supervised treadmill walking three times a week. The duration of the exercise sessions will progress from 30 minutes to 45 minutes per session over the 10 weeks as tolerated. The intensity of the exercise will be between 70 and 80% of the patient's heart rate reserve.
3081046|NCT02019641|Active Comparator|No AET|control will not engage in AET.
3081047|NCT02019628|Experimental|BRM4 at a dosage level of 1 gram/day|60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 1 gram/day.
3081048|NCT02019628|Experimental|BRM4 at a dosage level of 3 grams/day|60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 3 grams/day.
3081049|NCT02019615|Active Comparator|anodal stimulation|Patients received anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 5 days (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed one week after the end of the session to assess the potential long term effects of the tDCS.
3081050|NCT02019615|Sham Comparator|sham stimulation|Patients received sham tDCS (5 secondes of stimulation) every day for 5 days. A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed one week after the end of the session.
3081051|NCT02019602|Experimental|Pharmacokinetic samples|"Pharmacokinetic (PK) samples will be taken from the mother at Day 0 within 24 hours before/after delivery, from the infant within 24 hours after birth, at Week 4 and Week 8 and from the umbilical cord within one hour after delivery.~Included are mothers who decided to continue on, or to start treatment with certolizumab pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
3081052|NCT02019589|Active Comparator|Progesterone 225 mg/day|Progesterone + Placebo
3081053|NCT02019589|Active Comparator|Progesterone, 300 mg/ day|Progesterone + Placebo
3081054|NCT02019589|Placebo Comparator|Placebo|Placebo
3081055|NCT02019576|Other|Stereotactic radiotherapy (SRT)|Stereotactic radiotherapy will be administered for up to five areas of metastatic sites showing oligo-progression within the same time period. During the Sunitinib break period, stereotactic radiotherapy will be delivered in a single fraction or up to a maximum of eight fractions. The number of fractions will depend on how many sites are being irradiated.
3081056|NCT02019563|Experimental|MTA/FS pulpotomy Group|Children randomized to this arm will undergo a mineral trioxide aggregate (MTA) pulpotomy after hemostasis is achieved using ferric sulfate (FS).
3081057|NCT02019563|Active Comparator|RCT Group|Children randomized to this group will undergo the root canal therapy (RCT) technique.
3081058|NCT02019550|Experimental|First Rebif Rebidose, Then Rebiject II|Subjects will self-inject Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using Rebif Rebidose self-injector device in Treatment Period 1 for 4 weeks followed by self-injecting Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebiject II self-injector device in Treatment Period 2 (4 weeks) for the next 4 weeks.
3081059|NCT02019550|Experimental|First Rebiject II, Then Rebif Rebidose|Subjects will self-inject Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebiject II self-injector device in Treatment Period 1 for 4 weeks followed by self-injecting Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebif Rebidose self-injector device in Treatment Period 2 for the next 4 weeks.
3081060|NCT02019537|Active Comparator|Steroid group|Triamcinolone injection group
3081061|NCT02019537|Experimental|PRP group|Allogeneic PRP injection group
3081062|NCT02019524|Experimental|E39 peptide vaccine|Patients receive 6 monthly injections of E39 peptide + GM-CSF. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
3081063|NCT02019524|Experimental|E39 vaccine then J65 vaccine|Patients receive 3 inoculations with the E39 vaccine followed by 3 inoculations with the J65 vaccine. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
3081064|NCT02019524|Experimental|J65 vaccine then E39 vaccine|Patients receive 3 inoculations with the J65 vaccine followed by 3 inoculations with the E39 vaccine. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
3081065|NCT02019511||High dose Steroid|"Patients scheduled for primary unilateral elective TKA Age >17 years~none of the following contraindications for Methylprednisolone:~Allergy against Methylprednisolone.~Currently in systemic treatment with glucocorticoid~Current gastric ulcer~Insulin dependent diabetes mellitus~Citizens without Danish social security number are not eligible for this study as follow-up is not possible."
3081066|NCT02019511||Historical cohort|"Patients having primary unilateral elective TKA before initiation of Methylprednisolone as standard treatment~age >17 years, Danish social security number~and none of the following at time of surgery:~systemic treatment with glucocorticoid defined as: regular prescriptions on glucocorticoid within 2 months prior to surgery.~gastric ulcer defined as: prescriptions on drugs used in triple therapy for Helicobacter Pylori infection or prescriptions on antiacids/proton pump inhibitors beginning 1 month before surgery~Insulin dependent diabetes mellitus defined as: any prescriptions on insulin within 6 months prior to surgery"
3081067|NCT02019511||Procedures without Steroid|Patients scheduled for primary unilateral elective TKA and age >17 years but who did not receive high dose Methylprednisolone regardless of reason.
3081068|NCT02019498|Experimental|relaxation|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
3081069|NCT02019498|Active Comparator|Usual care waiting list|Patients allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
3081070|NCT02019485|Experimental|Treatment Sequence AB|Participants will receive single dose of new tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF) tablet and later, participants will receive single dose of current tapentadol prolonged-release formulation 2 (PR2) tablet without food. Administration of the study medications will be separated by a washout period (no treatment) of 7 to 14 days.
3081071|NCT02019485|Experimental|Treatment Sequence BA|Participants will receive single dose of current tapentadol PR2 tablet and later, participants will receive single dose of new tapentadol ER TRF tablet without food. Administration of the study medication will be separated by a washout period of 7 to 14 days.
3081072|NCT02019472|Experimental|Group 1 (adalimumab 40 mg)|Adalimumab 40 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. At Week 16, subjects who have < 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive adalimumab 40 mg every week through Week 52.
3081073|NCT02019472|Experimental|Group 2 (sirukumab 100 mg)|Sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. Subjects may meet the early escape criteria at Week 16 (< 20% improvement from baseline in both swollen and tender joint counts) but no sirukumab dose adjustments will made for these subjects. However, these subjects will receive placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
3081111|NCT02019160|Experimental|Silver nitrate|Biannual application of 25% AgNO3 solution followed by 5% NaF varnish.
3081074|NCT02019472|Experimental|Group 3 (sirukumab 50 mg)|Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks through Week 50. At Week 16, subjects who have < 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive sirukumab 100 mg every 2 weeks through Week 52 and placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
3081075|NCT02019459|Active Comparator|0.8 mg nicotine with 10.5 mg tar|SPECTRUM Cigarette: 0.8 (±0.15) mg nicotine yield with 9 (±1.5) mg tar (standard nicotine and tar yields of commercially-available cigarettes; control condition)
3081076|NCT02019459|Experimental|0.03 mg nicotine with 9 mg tar|SPECTRUM Cigarette: 0.03 mg (± 0.02) nicotine yield with 9 mg (± 1.5) tar
3081077|NCT02019446|Experimental|Laser Treatment|Participants randomized to laser group will undergo laser treatment at baseline and be asked to return for 2 subsequent visits six weeks apart (at weeks 6 and 12) to undergo further laser treatment of the hallux. Each visit will last approximately 45 minutes. Laser energy (1064 nm Nd:YAG) will be delivered via an optical fibre (300 μm core/320 μm clad) secured in a hand piece. Laser energy will be delivered by maintaining the tip of the optical fibre 3 mm from the treatment area to achieve around 1-1.5 mm diameter spot size (25.5 J/cm2 fluence per pulse; 10-pulse pulse-train to each spot in 0.5 seconds). Multiple treatment spots will be delivered to cover the entire area of involvement.
3081078|NCT02019446|Active Comparator|Standard Treatment (control group)|Control group volunteers will be asked to dedicate the same amount of time to the project with the same number of visits. However, they will receive conventional terbinafine therapy instead of laser treatments. Therefore, each of the 3 treatment visits would last only about 20 minutes.
3081079|NCT02019433||Structan®|
3081080|NCT02019420|Experimental|Tedizolid phosphate IV|Tedizolid phosphate 200 mg IV once daily for 7 days, or 14 days for bacteremia
3081081|NCT02019420|Active Comparator|Linezolid IV|Linezolid 600 mg IV every 12 hours for 10 days, or 14 days for bacteremia
3081082|NCT02019407|Experimental|CTI group|CTI(Cavo-Tricuspid Isthmus)
3081083|NCT02019407|Placebo Comparator|Non CTI group|Non CTI (Cavo-Tricuspid Isthmus)
3081084|NCT02019394|Experimental|Lu AE58054|
3081085|NCT02019381|Other|Endocrine Society UL Dosage Vitamin D|Participants will be randomly assigned vitamin D + calcium dose based on Endocrine Society Upper limit guidelines. And given 10,000IU Vitamin D + 1200mg Calcium (600IU Placebo Vitamin D, in addition to two calcium tablets of 600mg) each to be taken per day.
3081086|NCT02019381|Other|Institute of Medicine Dosage Vitamin D|Participants will be randomly assigned Vitamin D dose based on IOM guidelines; calcium dose will be as per IOM upper limits. And will receive 600 IU Vitamin D + 1,200 mg of calcium tablets to be taken per day.
3081087|NCT02019368|Placebo Comparator|Placebo|Smoker subjects take 6 capsules once a day for 4 weeks.
3081088|NCT02019368|Experimental|Aged garlic extract|Smoker subjects take 1.5 g of aged garlic extract in 6 capsules once a day for 4 weeks.
3081089|NCT02019368|No Intervention|Non-smoker|Oxidative status in non-smoker
3081090|NCT02019355|Experimental|calcipotriol plus 5-fluorouracil|calcipotriol 0.005% ointment and 5-fluorouracil 5% cream are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.
3081091|NCT02019355|Active Comparator|5-fluorouracil plus vaseline|5-fluorouracil 5% cream and vaseline are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.
3081092|NCT02019342||Post-quality improvement cohort|Patient cohort after FACE quality improvement initiative is implemented
3081093|NCT02019342||Pre-quality improvement cohort|Patient cohort prior to implementation of FACE quality improvement initiative
3081094|NCT02019329|Placebo Comparator|Placebo + risperidone|
3081095|NCT02019329|Experimental|RO5545965 + risperidone|
3081096|NCT02019316|Experimental|BioSteel Sports Drink|Participants will ingest 500ml of BioSteel Sports Drink 3 times during an exercise session.
3081097|NCT02019316|Placebo Comparator|Isoenergetic Control|Participants will orally ingest 500ml of Isoenergetic Control (0.18 calories/kg body weight) 2 times separated by 60 minutes.
3081098|NCT02019303|Other|Abnormal lymph nodes|There is only one arm to this study and includes all eligible and consented patients with abnormal axillary lymph node on ultrasound.
3081099|NCT02019290|Experimental|bitopertin-Midazolam|
3081100|NCT02019277|Experimental|Trastuzumab SC, Pertuzumab, and Taxane|Participants will receive pertuzumab, trastuzumab and a taxane (docetaxel, paclitaxel or nab-paclitaxel) once every 3 weeks (21-day cycles). Choice of taxane will be at the discretion of the investigator and administered per routine clinical practices and local prescribing instructions.
3081101|NCT02019264|Experimental|APD356 10 mg|APD356 10 mg twice daily
3081102|NCT02019264|Placebo Comparator|Placebo|Placebo twice daily
3081103|NCT02019251|Experimental|Post single or double lung transplant|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using Disposable Face mask and a standard Douglas Bag system.
3081104|NCT02019238|Placebo Comparator|Group 1-Standard PVI ablation|Pulmonary Vein Isolation procedure combined with ablation of documented non-PV triggers of AF
3081105|NCT02019238|Active Comparator|Group 2-PVI with empiric ablation|Pulmonary Vein Isolation procedure combined with empiric ablation of common sites of non-PV triggers of AF and locations that may sustain AF sources on long term arrhythmia control
3081106|NCT02019225|Experimental|Dialysis session of at least 4.25 hours|Dialysis facilities randomized to the Intervention arm will adopt an approach of recommending that all patients who are initiating treatment with maintenance hemodialysis have a treatment session duration of at least 4.25 hours.
3081107|NCT02019225|No Intervention|Usual care|There will be no trial-driven approach to dialysis session duration in the Usual Care arm.
3081108|NCT02019212||MPI Perfusion Imaging|Clinical patients who have undergone myocardial perfusion imaging with 99mTc
3081109|NCT02019186|Experimental|Vitamin C and E|6 weeks of daily treatment with Vitamin C and E
3081110|NCT02019173|Experimental|Boot camp balance training|Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
3081114|NCT02019147||Healthy Term Neonates|Controls
3081115|NCT02019134|Active Comparator|usual care waiting list|Patients allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
3081116|NCT02019134|Experimental|relaxation exercise|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
3081117|NCT02019108|Experimental|Gait Modification Group|Participants will complete 4 months of a home-based progressive walking program with toe-out gait modification aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with a study therapist and will be instructed to perform a toe-out gait, with the aid of a mirror during walking. Focus will also be on increasing the time and distance of walking. These goals will be emphasized for the home-based portion of the intervention as well.
3081118|NCT02019108|Active Comparator|Walking Only Group|Participants will complete 4 months of a home-based progressive walking program aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with the study therapist with focus on increasing the time and distance of walking. This goal will be emphasized for the home-based portion of the intervention as well.
3081119|NCT02019095||Acute Respiratory Failure - Bronchoalveolar lavage|Intensive care unit patients with acute respiratory failure due to ventilator-associated pneumonia or the acute respiratory distress syndrome. Bronchoalveolar lavage (BAL) fluid will be obtained on days 1 and 5 post-enrollment for the determination of biochemical markers, and microbiological studies.
3081120|NCT02019082|Active Comparator|electrical stimulation|electrical stimulation group, group who received direct current ES at sensory threshold intensity for 1 h/day, 3 days/week, for 4 weeks (12 sessions)
3081121|NCT02019082|Placebo Comparator|placebo|In the placebo group, the treatment procedure was the same as that the ES group, but the current intensity was zero.
3081122|NCT02019069|Experimental|Treatment (liposomal cytarabine-daunorubicin CPX-351)|"INDUCTION: Patients receive liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients achieving a complete remission (CR) or a CR with incomplete blood count recovery (CRi) at day 14 proceed to consolidation therapy. Patients with reduced blast count not achieving a morphological leukemia free state (< 5% blasts) receive a second course of induction therapy liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1 and 3. Patients achieving a CR or a CRi at day 14 or after a second course of induction therapy proceed to consolidation therapy.~SECOND INDUCTION: Patients receive liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1 and 3.~CONSOLIDATION: Beginning on day 28, patients receive liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1 and 3. Treatment may repeat after 28-75 days in the absence of disease progression or unacceptable toxicity."
3081123|NCT02019056|Placebo Comparator|Placebo|enteric coated capsule
3081124|NCT02019056|Experimental|MG 500mg|Metadoxine + garlic oil
3081125|NCT02019056|Experimental|MG 1000mg|Metadoxine + garlic oil
3081126|NCT02019056|Sham Comparator|Metadoxine 500mg|enteric coated capsule
3081127|NCT02019043|Experimental|Syphilis testing with routine HIV bloodwork|The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count.
3081128|NCT02019043|No Intervention|Current care practice|The control condition will remain the current care practice, which is generally opportunistic screening or diagnostic testing for those presenting with signs/symptoms or who report sexual risk behaviour.
3081129|NCT02019030||BPH on anticoagulation|Patients with Benign Prostatic Hyperplasia (BPH) undergoing Transurethral Vaporization of Prostate and are on anticoagulant medication
3081130|NCT02019017|Experimental|Botulinum Toxin Type A 25 IU|The first five patients will be injected 25 IU of Botulinum Toxin Type A
3081131|NCT02019017|Experimental|Botulinum Toxin Type A 50 IU|the next five patients will receive 50 IU of Botulinum Toxin Type A
3081132|NCT02019004|Active Comparator|Onabotulinum Toxin A|One side of the face will be randomized to receive Onabotulinum Toxin A injections in the forehead and glabellar region of the face.
3081133|NCT02019004|Active Comparator|Incobotulinum Toxin A|The other side of the face will be randomized to receive Incobotulinum Toxin A injections in the glabellar and forehead region of the face.
3081134|NCT02018991|Active Comparator|Everolimus-Eluting-Stent (EES)|Patients treated with EES
3081135|NCT02018991|Active Comparator|Zotarolimus-Eluting-Stent (ZES)|Patients treated with ZES
3081136|NCT02018991|Active Comparator|Biolimus-Eluting-Stent (BES)|Patients treated with BES
3081137|NCT02018978|Experimental|CTHP|"HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.~Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.~Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.~Incentives & Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential."
3081138|NCT02018978|No Intervention|Standard of Care|This arm will receive standard of care HIV-related services, including clinic-based voluntary counseling and testing and referrals to HIV care and treatment government-run facilities.
3081139|NCT02018965|Other|ER niacin followed by ART alone|For Arm 1, ER niacin administration begins Week 0 and ends Week 24 (defined as 'immediate use' arm).
3081140|NCT02018965|Other|ART alone followed by ER niacin|For Arm 2, ER niacin administration begins after the Week 24 Visit and ends Week 48 (defined as 'deferred use' arm).
3081141|NCT02018952|Other|Ultrasonography assessment|
3081142|NCT02018939|Experimental|Pharmacokinetic profiling in Hemodialysis|Patients with chronic intermittent hemodialysis receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
3081213|NCT02018510|Experimental|Group 1C|HIV-uninfected individuals 10 mg/kg, single dose IV administration of 3BNC117
3081143|NCT02018939|Experimental|Pharmacokinetic profiling in CVVH|Patients receiving continuous venovenous renal replacement therapy in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
3081144|NCT02018939|Experimental|Pharmacokinetic profiling in MARS|Patients receiving liver replacement therapy (MARS) in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
3081145|NCT02018926|Experimental|Mocetinostat and azacitidine|"Drug: Mocetinostat (MGCD0103) Mocetinostat (a histone deacetylase [HDAC] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5 for 10 doses in each 28 day cycle~Drug: Azacitidine (Vidaza) Azacitidine (a hypomethylating agent [HMA]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle"
3081146|NCT02018900|Placebo Comparator|Placebo|Placebo
3081147|NCT02018900|Experimental|Ecologic 825/scFOS|Ecologic 825/scFOS
3081148|NCT02018887|Experimental|LY2969822 (Part A)|Single dose of LY2969822 administered orally in 2 of 3 study periods.
3081149|NCT02018887|Placebo Comparator|Placebo (Part A)|Single dose of placebo administered orally in 1 of 3 study periods.
3081150|NCT02018887|Experimental|LY2969822 (Part B)|LY2969822 administered orally for 14 days.
3081151|NCT02018887|Placebo Comparator|Placebo (Part B)|Placebo administered orally for 14 days.
3081152|NCT02018887|Experimental|LY2969822 (Part C)|LY2969822 administered orally for 14 days.
3081153|NCT02018887|Placebo Comparator|Placebo (Part C)|Placebo administered orally for 14 days.
3081154|NCT02018874|Experimental|LY2780301|
3081155|NCT02018861|Experimental|INCB050465|escalating doses given every day (QD)
3081156|NCT02018861|Experimental|INCB050465 in combination with itacitinib (INCB039110)|Starting dose of INCB050465 determined in Part 1 of the study in combination with itacitinib (INCB039110)given QD
3081157|NCT02018861|Experimental|INCB050465 rituximab, ifosfamide, carboplatin, and etoposide|Starting dose of INCB050465 determined in Part 1 given in combination with: rituximab on Days 1 and 2 of Cycle 1, and Day 1 of Cycles 2 and 3; ifosfamide and carboplatin given on Day 3 of each Cycle; and etoposide given on Days 3 to 5 of each Cycle.
3081158|NCT02018848|Placebo Comparator|Attention Training Placebo|"Same procedure, stimulus material, frequency and duration as in experimental group.~The only difference: In the placebo group the probe randomly appears at one of the two locations on the screen so as not to train attention in any direction.~Thus, the placebo training sessions are identical to the bias assessment sessions."
3081159|NCT02018848|Experimental|Attention Training Program|"The Attention Training consists of a modified dot-probe task. In this task pairs of pictures (OCD-relevant/neutral) are presented for 500 ms on a computer screen. Next, a probe appears on one of the two former picture locations. Participants have to react to that probe by pressing the corresponding button on the keyboard. One training session takes approximately 10 minutes in which 160 stimulus pairs are shown.~In the experimental group the probe always appears at the location of the neutral picture so as to train attention away from OCD-relevant stimuli.~Participants are asked to complete at least 2 training sessions per week over a period of 5 weeks. The first and last session are bias assessment sessions (see outcome measures), but participants stay blind to this."
3081160|NCT02018835|Other|patients of an insufficiency organic severe surgical mitrale|
3081161|NCT02018835|Other|insufficiency organic mitrale moderated in severe asymptomatic|
3081162|NCT02018835|Other|patients of an aortic bicuspidie|
3081163|NCT02018835|Other|patients of a syndrome of Marfan|
3081164|NCT02018835|Other|Healthy volunteers|
3081165|NCT02018822|Experimental|All Participants|Participants who needed at least two tooth restorations
3081166|NCT02018809|Experimental|MAP Daily Notification|The subject's MAP receives daily notification about whether subject took statin.
3081167|NCT02018809|Experimental|MAP Weekly Notification|The subject's MAP receives weekly about how often the subject took statin during previous week.
3081168|NCT02018809|Experimental|MAP Missed Doses|The subject's MAP receives notification if the subject missed >2 consecutive daily doses of statin.
3081169|NCT02018809|Other|Usual Care|Usual care with GlowCap.
3081170|NCT02018796||Women seeking medical abortion|Women with pregnancies less than 71 days gestation seeking medical abortion. Women who choose to participate in the study will be administered 200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol.
3081171|NCT02018783|Experimental|Sensodyne|Digital application for 60 seconds.
3081172|NCT02018783|Experimental|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
3081173|NCT02018783|Experimental|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
3081174|NCT02018783|Placebo Comparator|Cocorico|Digital application for 60 seconds
3081175|NCT02018770|Experimental|Phototherapy|Three groups will receive different fototerapia of light sources, and group 1 will not receive dose: Group A (0, 65Joules), Group B (1.30 Joules) and Group C (1.95 Joules) .
3081176|NCT02018770|Placebo Comparator|Placebo phototherapy|The volunteers will be subjected to the same Groups intervention Phototherapy . The but researcher will receive placebo pen. It is the caveat that, after completed the voluntary participation, will be held with the active pen treatment.
3081177|NCT02018757|Experimental|As2O3|Subjects will be treated with TACE containing As2O3
3081178|NCT02018757|Placebo Comparator|placebo|Subjects will be treated with TACE containing placebo which mimics the arsenic trioxide
3081179|NCT02018731|Experimental|Metformin and Metformin & L-Citrulline|1500 mg/d metformin for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
3081180|NCT02018731|Experimental|L-Citrulline and Metformin & L-Citrulline|15 g/d L-citrulline for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
3081181|NCT02018718|Other|Marathoners|
3081182|NCT02018705||POEM|group of Achalasia patients treated with POEM (peroral endoscopic myotomy)
3081183|NCT02018705||LHM|group of Achalasia patients treated with LHM (laparoscopic Heller myotomy)(+ fundoplication)
3081184|NCT02018692|Experimental|Alga Dunaliella Bardawil 9-cis beta Carotene Rich Powder|15 patients will first receive the capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder (5mg/Kg) for 24 weeks. After 24 weeks of washout period they will receive capsule containing placebo (Starch) for 24 weeks.
3100009|NCT01891565|No Intervention|No Feedback|
3081185|NCT02018692|Placebo Comparator|Placebo (Starch)|The other 15 Patients will receive first the placebo (Starch) capsules for 24 weeks. After 24 weeks of washout period they will receive capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder .
3081186|NCT02018679|Experimental|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
3081187|NCT02018679|Active Comparator|MAL-PDT|Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
3081188|NCT02018666|Experimental|spontaneous NAVA mode|
3081189|NCT02018666|Active Comparator|Inspiratory pressure support (IPS)|
3081190|NCT02018653|Experimental|Calcium Alumina-Silicate (CASAD)|CASAD 1 gram orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.
3081191|NCT02018653|Placebo Comparator|Placebo|Placebo orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.
3081192|NCT02018627|Experimental|Xeris glucagon|Xeris glucagon 50 micrograms, subcutaneous injection
3081193|NCT02018627|Active Comparator|Lilly glucagon|Lilly glucagon 30 micrograms, subcutaneous injection
3081194|NCT02018614||testretest relaibility|Data from a sample of 50 patients will be used to explore the test-retest reliability of the scale administered by the same trained clinician, on two occasions four hours apart, without any treatment in between. The ALGOPLUS® scores obtained from the patients at a time t will be compared with their (t + 4 hours) scores to assess test-retest reliability
3081195|NCT02018614||statistical test|For a sample of at least 50 patients, two physicians trained for the use of ALGOPLUS, will assess pain independently. A statistical test will be used to compare the results for the inter-rater reliability
3081196|NCT02018601|Experimental|BRILMA&dexketoprofen&paracetamol|dexketoprofen: 50 mg/8h paracetamol: 1gr/6h
3081197|NCT02018601|Active Comparator|paravertebral block&dexketoprofen&paracetamol|dexketoprofen: 50 mg/8h paracetamol: 1g/6h
3081198|NCT02018588|Experimental|tryptophan intake|Graded levels of tryptophan will be given to each subject on different study days around the anticipated breakpoint.
3081199|NCT02018575|Experimental|levels of lysine intake.|Randomly selected levels of lysine intake which are lower than the lysine requirement (previously derived).
3081200|NCT02018562|Experimental|Intervention|"The talking tracheostomy trial involves placement of a talking tracheostomy tube (Portex Blueline Ultra Suctionaid Tracheostomy Tube) by respiratory therapist after obtaining an order from an authorized prescriber (Physician or Nurse Practitioner). The Speech-Language Pathologist (SLP) sets up the tracheostomy tube for speech and then determines the optimal air flow required for voicing. This amount of air flow is communicated to the ICU staff for further use.~We will ensure that the SLP meets with the patient for a minimum of 3 sessions within a week to optimize the use of a talking tracheostomy tube.~i. SLP will also assess the duration of successful speech during each session~ii. Sentence intelligibility will also be assessed during the 3rd session. This session will be audio-taped and reviewed by a second rater for sentence intelligibility.~iii. SLP will determine the level of independence with talking tracheostomy during the 3rd session."
3081201|NCT02018562|No Intervention|Control|This group will also receive talking tracheostomy tube trial as standard of care but a week later after the pre and post assessments have been completed
3081202|NCT02018549|Experimental|Placebo|Inhalation through Chiesi NEXThaler DPI containing Placebo Dry Powder. Each patient will perform at least two inhalations using the Chiesi NEXThaler DPI device containing placebo dry powder. There is no comparator and all patients will receive the same study treatment.
3081203|NCT02018536|Experimental|Part 1, Cohort A|8 participants to receive a single oral dose of 30 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
3081204|NCT02018536|Experimental|Part 1, Cohort B|8 participants to receive a single oral dose of 60 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
3081205|NCT02018536|Experimental|Part 1, Cohort C|8 participants to receive a single oral dose of 120 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
3081206|NCT02018536|Experimental|Part 2, Sequence 1|6 participants to receive Treatment A (TMC435 150 mg), D (TMC435 150 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), and C (TMC435 100 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
3081207|NCT02018536|Experimental|Part 2, Sequence 2|6 participants to receive Treatment B (GSK2336805 60 mg), A (TMC435 150 mg), C (TMC435 100 mg+GSK2336805 60 mg), and D (TMC435 150 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
3081208|NCT02018536|Experimental|Part 2, Sequence 3|6 participants to receive Treatment C (TMC435 100 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), D (TMC435 150 mg+GSK2336805 60 mg), and A (TMC435 150 mg) in a sequence with a 7 days washout period between each treatment sessions.
3081209|NCT02018536|Experimental|Part 2, Sequence 4|6 participants to receive Treatment D (TMC435 150 mg+GSK2336805 60 mg), C (TMC435 100 mg+GSK2336805 60 mg), A (TMC435 150 mg) and B (GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
3081210|NCT02018523|Experimental|Lenalidomide|Oral lenalidomide 10 mg daily until disease progression
3081211|NCT02018510|Experimental|Group 1A|"HIV-uninfected individuals~1 mg/kg, single dose IV administration of 3BNC117"
3081212|NCT02018510|Experimental|Groups 1B|HIV-uninfected individuals 3 mg/kg, single dose IV administration of 3BNC117
3081215|NCT02018510|Experimental|Group 1E|HIV-uninfected individuals 30 mg/kg, single dose IV administration of 3BNC117
3081216|NCT02018510|Experimental|Group 1F|HIV-uninfected individuals 30 mg/kg, two doses IV of 3BNC117
3081217|NCT02018510|Experimental|Group 2A|"HIV-infected individuals on or off ART~1 mg/kg, single dose IV administration of 3BNC117"
3081218|NCT02018510|Experimental|Group 2B|HIV-infected individuals on or off ART 3 mg/kg, single dose IV administration of 3BNC117
3081219|NCT02018510|Experimental|Group 2C|HIV-infected individuals on or off ART 10 mg/kg, single dose IV administration of 3BNC117
3081220|NCT02018510|Experimental|Group 2D|HIV-infected individuals on or off ART 30 mg/kg, single dose IV administration of 3BNC117
3081221|NCT02018510|Experimental|Group 2E|HIV-infected individuals off ART, VL 2,000-100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
3081222|NCT02018510|Experimental|Group 3|HIV-infected individuals off ART, VL < 2,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
3081223|NCT02018510|Experimental|Group 4|HIV-infected individuals on ART, VL < 100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
3081224|NCT02018510|Experimental|Group 5A|HIV-infected individuals on ART, VL < 20 copies/ml 10 mg/kg, single dose IV administration of 3BNC117
3081225|NCT02018510|Experimental|Group 5B|HIV-infected individuals on ART, VL < 20 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
3081226|NCT02018497||Consecutive patients who consult a cardiologist|"Consecutive patients who consult a cardiologist - electrophysiologist since June 2006, regardless of the age or gender in the city of Medellin, Colombia. They could have consulted previously (considered as the enrollment date) if they had, at least, one measurement of their BP in supine position, and an immediate measurement of their BP in standing position that allows diagnosing their group of blood pressure. All patients have a record in paper and/or magnetic file and in OpenClinica.~No interventions."
3081227|NCT02018484|Experimental|Patient specific cutting guides|Unicompartmental knee replacement with patient specific cutting guides
3081228|NCT02018471|Experimental|Pilot group|Forty-three patients who had to undergo one or more diagnostic tests (PET, TAC, fMRI, Mammography, Endoscopy, Colonoscopy) took part in the study. Most of the 43 patients had to undergo only one diagnostic test, and only 6 patients had more than one. They have attended a psychoeducative training.
3081229|NCT02018458|Experimental|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
3081230|NCT02018458|Experimental|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
3081231|NCT02018445|Experimental|Accell Evo3 Demineralized Bone Matrix|
3081232|NCT02018432|Experimental|Roflumilast escalation dosage|Roflumilast 250 μg qd (4 weeks) →500 μg qd
3081233|NCT02018432|Experimental|Roflumilast conventional dosage|Roflumilast 500 μg qd
3081234|NCT02018419|Experimental|Dosing Schedule A|"the priming step with ID injection of AlloStim on Days 0, 7, and 14;~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 21;~the activation step with an IV infusion of AlloStim on Day 28;~the booster step with intravenous booster infusion of AlloStim on Days 56 and 84;~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
3081235|NCT02018419|Experimental|Dosing Schedule B|"the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14;~the activation step with an IV infusion of AlloStim on Day 21;~the booster step with intravenous booster infusion of AlloStim on Days 49 and 77.~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
3081236|NCT02018419|Experimental|Dosing Schedule C|"the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14, and intra-tumor injection of AlloStim again into the same cryoablated lesion on Day 17;~the activation step with an IV infusion of AlloStim on Day 21;~the booster step with intravenous infusion of AlloStim on days 49 and 77.~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
3081237|NCT02018406|Experimental|Intervention|Intervention Group
3081238|NCT02018406|Placebo Comparator|Control|Control Group
3081239|NCT02018393||Prophylaxis group|Prophylaxis with FEIBA is defined in this study as the regular infusion of FEIBA for the prevention of bleeding at a dose of ≥50 UF/kg on at least three non-consecutive days a week. Patients must have been on this modality for at least 6 months prior to the study visit
3081240|NCT02018393||On demand group|On-demand Treatment is defined as the administration of FEIBA only to control bleeding. Patients must have been on this modality for at least 6 months prior to the study visit.
3081241|NCT02018380|Experimental|Shock Absorbing Insoles vs. Athletic shoes|
3081311|NCT02017951||Urban-Rural Classification 7: Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 10,000 or more.
3081242|NCT02018367|Experimental|Proflavine, high resolution imaging|Proflavine hemisulfate will be used as a topical contrast agent in conjunction with the high resolution imaging device to visualize and image areas suspicious for neoplasia. Biopsies will be taken per Seattle biopsy protocol for Barrett's Esophagus surveillance.
3081243|NCT02018367|No Intervention|Standard of care|Standard of care examination of the upper GI tract using the standard high resolution endoscope with bipsies taken per Seattle biopsy protocol for Barrett's Esophagus surveillance.
3081244|NCT02018354|Active Comparator|ACL Reconstruction|Standard ACL reconstruction only.
3081245|NCT02018354|Experimental|ACL + LET|Anatomic ACL reconstruction following the same procedure as the active comparator group with an added lateral extra-articular tenodesis (LET).
3081246|NCT02018341|Experimental|homeopathic remedy in 30C potency|5 lactose globules containing a commonly used homeopathic remedy in the potency of 30C will be administered twice daily for 3 days
3081247|NCT02018341|Placebo Comparator|placebo|5 lactose globules without any homeopathic remedy will be administered twice daily for 3 days
3081248|NCT02018328|No Intervention|Triple therapy, helicobacter pylori|
3081249|NCT02018328|Experimental|triple therapy+curcumin helicobacter pylori|Curcumin will be added to the regular triple therapy
3081250|NCT02018315|Experimental|Triheptanoin|Triheptanoin (C7 oil, liquid) dosed at 1 g/kg body weight divided and administered 4 times per day via mouth or g-tube for 3 months.
3081251|NCT02018289|Experimental|Triclosan|Suture of the abdominal wall with triclosan coated suture
3081252|NCT02018289|Sham Comparator|No triclosan|Suture of the abdominal wall with the same suture, but without triclosan
3081253|NCT02018276|Experimental|The effect of perioperative lidocaine infusion|
3081254|NCT02018276|Active Comparator|The effect of perioperative magnesium infusion|
3081255|NCT02018263|Experimental|Cocaine Administration|Subjects self administer cocaine hydrochloride in both laboratory and outpatient settings
3081256|NCT02018263|Active Comparator|Nicotine Administation|Subjects self administer nicotine in both laboratory and outpatient settings
3081257|NCT02018263|Active Comparator|Exercise|Subjects complete a cardiovascular exercise session in both laboratory and outpatient settings
3081258|NCT02018250|Experimental|0.6 mg/kg MMB4 DMS|0.6 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
3081259|NCT02018250|Placebo Comparator|Placebo|5 mg benzyl alcohol USP/NF and 5 mg methanesulfonic acid adjusted to a pH 2.3 administered intramuscular (i.m.) to the anterior thigh.
3081260|NCT02018250|Experimental|0.9 mg/kg MMB4 DMS|0.9 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
3081261|NCT02018250|Experimental|1.2 mg/kg MMB4 DMS|1.2 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
3081262|NCT02018250|Experimental|1.5 mg/kg MMB4 DMS|1.5 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
3081263|NCT02018250|Experimental|2.0 mg/kg MMB4 DMS|2.0 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
3081264|NCT02018250|Experimental|3.0 mg/kg MMB4 DMS|3.0 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
3081265|NCT02018237|Active Comparator|NAFLD|Subjects with nonalcoholic fatty liver disease (NAFLD) will complete baseline testing and then be assigned to either the high fructose corn syrup diet or the standard diet (low in high fructose corn syrup) for 4 weeks. Post intervention testing will be completed after the subjects have completed the 4 week diet intervention.
3081266|NCT02018237|Active Comparator|Non-NAFLD|Subjects without nonalcoholic fatty liver disease (Non-NAFLD) will complete baseline testing and then be fed a high fructose corn syrup diet for 4 weeks. Post intervention testing will be completed after the subjects have completed the 4 week diet intervention.
3081267|NCT02018224|Experimental|End-to-end suturation without augmentation|
3081268|NCT02018224|Experimental|End-to-end suturation with augmentation|
3081269|NCT02018211|Experimental|experimental group|All participants performed a modified version of the Loughborough Intermittent Shuttle Test (LIST; Nicholas et al, 2000), an exercise protocol designed to simulate the activity pattern characteristics of intermittent sports such as soccer. The LIST was performed on three occasions, at the same time of day, each separated by approximately four weeks. Following each exercise trial, one of three recovery interventions were applied, the order of which were randomly allocated.
3081270|NCT02018185|Active Comparator|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
3081271|NCT02018185|Sham Comparator|Sham rTMS|Sham Transcranial Magnetic Stimulation
3081272|NCT02018172||Zomacton® treatment with Zomajet® Vision X device|
3081273|NCT02018159||Women treated with Menopur|Women treated with Menopur can participate with more than one cycle. 700 cycles will be enrolled.
3081274|NCT02018146|Other|Nasopharyngeal then mask|Patients will be randomized to nasopharyngeal airway placement and ventilation followed by mask ventilation
3081275|NCT02018146|Other|Mask then nasopharyngeal|Patients will be randomized to mask ventilation followed by nasopharyngeal airway placement and ventilation
3081276|NCT02018133|Experimental|Vitamin D or Placebo|Take vitamin D for 2 weeks. 2mg daily before meal
3081277|NCT02018120|Active Comparator|connective tissue graft|connective tissue graft harvested from palatum of subjects and placed under modified coronally advanced flap
3081278|NCT02018120|Experimental|Platelet rich fibrin|Autogenous platelet rich fibrin was obtained from subjects own blood samples after centrifugation. Platelet rich fibrin membranes were placed under modified coronally advanced flaps.
3081312|NCT02017951||Urban-Rural Classification 8: Very Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 60 minutes to a settlement of 10,000 or more.
3081313|NCT02017951||Travel Time - see below|Travel time will be analysed as both a continuous and discrete variable.
3081314|NCT02017938|No Intervention|Stage 1: Health group|To establish non-invasive fatigue monitoring method via testing healthy individuals.
3081315|NCT02017938|Experimental|Stage 2: PD group|To find the optimal feedback variables for anti-fatigue training on individuals with PD.
3081279|NCT02018107|Experimental|N-13 ammonia to image liver PET perfusion|This single-arm study involves the non-therapeutic administration of a radiopharmaceutical, N-13 ammonia or F-18 fluorodeoxyglucose, one to two doses, during the tumor ablation procedure. The N-13 ammonia perfusion PET scan is a diagnostic imaging test. The tumor ablation procedure is performed according to our standard clinical practice and is not itself a research activity. The use of N-13 ammonia to image liver perfusion with a PET scanner is the research portion of the procedure. The participant will receive one or two IV doses of N-13 ammonia (10 mCi/dose) for intraprocedural assessment of ablation results. Not more than two doses will be administered and one or both doses will be administered on the day of the tumor ablation procedure only
3081280|NCT02018094|Active Comparator|24 hour antibiotic course|24 hours of the stated antibiotics administered intravenously (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function)
3081281|NCT02018094|Active Comparator|5 day antibiotic Course|24 hours of IV antibiotics followed by 4 days of oral antibiotics (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function. Clindamycin will be used as a an oral replacement for penicillin allergic patients)
3081282|NCT02018094|Active Comparator|Iodine|Skin Preparation used pre-operatively: Alcoholic Povidone
3081283|NCT02018094|Active Comparator|Chlorhexidine|Skin preparation to be used preoperatively: Alcoholic chlorhexidine
3081284|NCT02018081|Experimental|Levofloxacin|Population having a community-acquired pneumonia of which the indication of the treatment is administration of Levofloxacin
3081285|NCT02018068|Experimental|Remote control|"For patient randomized in arm Remote Control, the communication with anesthesiologist will be done by teletransmission. The intervention Remote control is assigned to this arm. When evaluated pain values, sensory or motricity blockades are over the selected threshold then, the patient enters the data in the PCA (Patient Control Analgesia) pump, the physician in charge of the patient for the protocol is alerted by SMS on a specific smart phone and makes the necessary settings changes by Remote Control on the Micrel CareTM site."
3081286|NCT02018068|Active Comparator|At bedside care|"For patient randomized in arm At bedside care, the communication with the anesthesiologist in charge of the patient will be done via the nurses and referent physician of the medical unit, as a routine procedures. The necessary changes of pump settings are doing by the anesthesiologist. The intervention at beside care is assigned to arm at bedside care."
3081287|NCT02018055||Ticagrelor|A Group which treated with Ticagrelor
3081288|NCT02018055||Clopidogrel|A Group which treated with Clopidogrel
3081289|NCT02018042|Experimental|Abatacept|Patients will be treated with abatacept 125mg subcutaneous (SC) self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse.
3081290|NCT02018029||cardiac resynchronisation therapy|
3081291|NCT02018016||High volume hospitals|The hospitals in the upper tertile for procedural volume
3081292|NCT02018016||Medium volume hospitals|The hospitals in the middle tertile for procedural volume
3081293|NCT02018016||Low volume hospitals|The hospitals in the lowest tertile for procedural volume.
3081294|NCT02017990||Renal transplant recipients|No intervention. Measurements of plasma marine n-3 polyunsaturated fatty acids levels, indicating intake of fish and seafood.
3081295|NCT02017977||Urban-Rural Classification 1: Large Urban Areas|Settlements of over 125,000 people
3081296|NCT02017977||Urban-Rural Classification 2: Other Urban Areas|Settlements of 10,000 to 125,000 people
3081297|NCT02017977||Urban-Rural Classification 3: Accessible Small Towns|Settlements of between 3,000 and 10,000 people and within 30 minutes drive of a settlement of 10,000 or more.
3081298|NCT02017977||Urban-Rural Classification 4: Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more.
3081299|NCT02017977||Urban-Rural Classification 5: Very Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more
3081300|NCT02017977||Urban-Rural Classification 6: Accessible Rural|Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 or more
3081301|NCT02017977||Urban-Rural Classification 7: Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 10,000 or more
3081302|NCT02017977||Urban-Rural Classification 8: Very Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 60 minutes to a settlement of 10,000 or more
3081303|NCT02017977||Travel Time - see below|Travel time will be analysed as a continuous and discrete variable.
3081304|NCT02017964|Experimental|Treatment (combination chemotherapy)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV over 1 minute or infused via minibag on days 1, 15, and 29; cyclophosphamide IV over 1 hour on days 1-3; methotrexate IV over 24 hours on days 15 and 29; etoposide IV over 60-120 minutes on days 43-45; and carboplatin IV over 1 hour on days 43-45. Treatment repeats every 63 days for 3 courses in the absence of disease progression or unacceptable toxicity.~CONTINUATION THERAPY: Patients receive vincristine sulfate IV over 1 minute or infused via minibag on day 1, cyclophosphamide IV over 1 hour on days 1-3, etoposide IV over 60-120 minutes on days 21-23, and carboplatin IV over 1 hour on days 21-23. Treatment repeats every 42 days for 2 courses in the absence of disease progression or unacceptable toxicity."
3081305|NCT02017951||Urban-Rural Classification 1: Large Urban Areas|Settlements of over 125,000 people.
3081306|NCT02017951||Urban-Rural Classification 2: Other Urban Areas|Settlements of 10,000 to 125,000 people.
3081307|NCT02017951||Urban-Rural Classification 3: Accessible Small Towns|Settlements of between 3,000 and 10,000 people and within 30 minutes drive of a settlement of 10,000 or more.
3081308|NCT02017951||Urban-Rural Classification 4: Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more.
3081309|NCT02017951||Urban-Rural Classification 5: Very Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more.
3081310|NCT02017951||Urban-Rural Classification 6: Accessible Rural|Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 or more.
3081317|NCT02017938|Experimental|Stage 3: PD group|To evaluate the effect of four weeks of VR anti-fatigue ergo cycling training on various fatigue components and functional abilities in individuals with PD.
3081318|NCT02017938|No Intervention|Stage 3: PD controlled group|Stage 3 controlled group
3081319|NCT02017925|Experimental|Arm I (early intervention)|Beginning within 2 weeks of starting chemoradiation, patients undergo an individualized rehabilitation program comprising aerobic exercise and strength training, including treadmill walking, stationary bicycle, NU-Step, upper body resistance training and breathing retraining, 3 times per week for 8 weeks (36 sessions).
3081320|NCT02017925|Experimental|Arm II (late intervention)|Beginning 1 month after completion of chemoradiation, patients undergo an individualized exercise rehabilitation program as in Arm I.
3081321|NCT02017912|Active Comparator|Autologous MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
3081322|NCT02017912|Placebo Comparator|Excipient|Combined intramuscular and intrathecal placebo administration
3081323|NCT02017899|Experimental|S. sonnei 1790GAHB - 1 mcg|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 1 mcg
3081324|NCT02017899|Experimental|S. sonnei 1790GAHB - 5 mcg|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 5 mcg
3081325|NCT02017899|Experimental|S. sonnei 1790GAHB - 25 mcg|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 25 mcg
3081326|NCT02017899|Experimental|S. sonnei 1790GAHB - 50 mcg|Subjects enrolled in COHORT D receiving 3 injections of S. sonnei 1790GAHB - 50 mcg
3081327|NCT02017899|Experimental|S. sonnei 1790GAHB - 100 mcg|Subjects enrolled in COHORT E receiving 3 injections of S. sonnei 1790GAHB - 100 mcg
3081328|NCT02017899|Placebo Comparator|Placebo|2 subjects enrolled in each COHORT A, B, C, D, E receiving 3 injections of Placebo. These were pooled in one Placebo group in the analyses
3081329|NCT02017886|Active Comparator|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks.
3081330|NCT02017886|Placebo Comparator|Placebo|Placebo tablet twice daily for three weeks
3081331|NCT02017873|Active Comparator|healthy patients bleaching|Healthy patients Peroxide Carbamide 10% - Dental bleaching treatment
3081332|NCT02017873|Experimental|Smokers bleaching|smokers patients Peroxide Carbamide 10% - Dental bleaching treatment
3081333|NCT02017860|Experimental|Everolimus|Patients who are receiving everolimus in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study that has reached its study objectives, are not progressing on the current study treatment as defined by the parent protocol and are unable to access everolimus treatment outside of a clinical trial will be allowed to enroll.
3081334|NCT02017847||Gen100|150 participants in the Generation 100 study with anticipated 3000 participants aged 70-75
3081335|NCT02017834|Experimental|harmonic scalpel|
3081336|NCT02017834|Active Comparator|standard technique|
3081337|NCT02017821|Experimental|training group|high intensity aerobic training 3 weekly sessions for 8 weeks
3081338|NCT02017821|No Intervention|care as usual|
3081339|NCT02017808||Copaxone|Patients with multiple sclerosis who are currently prescribed glatiramer acitate (Copaxone)
3081340|NCT02017808||OCT|Healthy controls
3081341|NCT02017795|Experimental|SMS-Web eAAP group|electronic asthma action plan (eAAP) group
3081342|NCT02017795|Active Comparator|regular-care group|written asthma action plan (WAAP) group
3081343|NCT02017782|Experimental|Dust, Ozone, Interaction Dust & Ozone|Dust (250-300µg/m3), Ozone (0,1ppm ozone),Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (<20µg/m3). with at least 2 weeks between each exposure session
3081344|NCT02017782|Active Comparator|Interaction Dust & Ozone and placebo Filtered air|Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (<20µg/m3) with at least 2 weeks between each exposure session.
3081345|NCT02017769||CIDP - treated|Patients diagnosed with CIDP and fulfilling the criteria by EFNS and PNS and in maintenance treatment with subcutaneous immunoglobulin
3081346|NCT02017769||Healthy controls|Healthy, gender and age matched controls
3081347|NCT02017769||CIDP - untreated|Patients newly diagnosed with CIDP and untreated are treated with immunoglobulin and re-examined after 4 months of treatment
3081348|NCT02017730|Experimental|Part 1: [11C]BMT-136088 (Safety Study)|Single PET SCAN with single bolus injection of [11C]BMT-136088
3081349|NCT02017730|Experimental|Part 2: [11C]BMT-136088 (Test/Retest study)|Single PET SCAN with Intravenous (IV) bolus plus infusion of [11C]BMT-136088 followed by a re-test PET scan (approximately 6 hours apart) with IV bolus plus infusion of [11C]BMT-136088
3081350|NCT02017730|Experimental|Part 3: BMS-986020+[11C]BMT-136088 (Receptor Occupancy study)|BMS-986020 Tablets or Oral Solution of 4 dose levels from from the 6 dose levels of (50 mg, 150 mg, 300 mg, 600 mg, 1200 mg and 1500 mg) and 3 PET SCANS (Pre-Dose, Post-Dose1, Post-Dose2) with bolus plus infusion of [11C]BMT-136088
3081351|NCT02017730|Experimental|Part 4: [11C]BMT-136088 (Tissue Distribution study)|Single PET SCAN with [11C]BMT-136088 to evaluate additional tracer uptake sites in humans other than the lung, such as heart, kidney, liver, gallbladder, etc.
3081352|NCT02017717|Experimental|Arm N:Nivolumab|Cohort 1, 1c, 1d and 2: Nivolumab 3mg/kg intravenously once every 2 weeks until disease progression or unacceptable toxicity
3081353|NCT02017717|Experimental|Arm N + I:Nivolumab + Ipilimumab|"Cohort 1: Nivolumab 1mg/kg + Ipilimumab 3mg/kg intravenously every 3 weeks x 4 doses, then Nivolumab 3mg/kg every 2 weeks until disease progression or unacceptable toxicity~Cohort 1b: Nivolumab 3mg/kg + Ipilimumab 1mg/kg intravenously every 3 weeks for 4 doses, then Nivolumab 3mg/kg every 2 weeks thereafter until disease progression or unacceptable toxicity"
3081354|NCT02017717|Active Comparator|Arm B: Bevacizumab|Cohort 2: Bevacizumab 10 mg/kg intravenously once every 2 weeks until disease progression or unacceptable toxicity
3081355|NCT02017704|Active Comparator|IMRT and Capecitabine (potentially randomized to this arm)|"Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications~Followed by:~Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions~5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus~Cycle length: 14 days (2 weeks)~Duration of treatment: 12 cycles~Then: Surgical Resection"
3081624|NCT02015884||All patients admitted to the ophthalmologic emergency unit.|
3081356|NCT02017704|Experimental|Endo-HDR (potentially randomized to this arm)|"Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy~Followed by:~Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions~5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus~Cycle length: 14 days (2 weeks)~Duration of treatment: 12 cycles~Then: Surgical Resection"
3081357|NCT02017691|Experimental|Near Infrared Spectroscopy|crSO2 measurements in addition SpO2 measurements will be visible to guide supplemental oxygen support and respiratory support according predefined interventions depending on the infants breathing efforts and the heart rate during the first 15 minutes after birth
3081358|NCT02017691|Other|Pulse-oximetry|Only SpO2 measurements will be visible to guide supplemental oxygen support and respiratory support according predefined interventions depending on the infants breathing efforts and the heart rate during the first 15 minutes after birth
3081359|NCT02017678|Experimental|JX-594 IV Infusion|Patients with peritoneal carcinomatosis of ovarian origin that are not eligible for curative treatments will receive 5 weekly IV infusions of JX-594
3081360|NCT02017652||Preterm Infants|Preterm infants 32 to 36 weeks will be eligible for this study
3081361|NCT02017639|Experimental|Sarilumab SAR153191 (REGN88)|Single dose of simvastatin before and after sarilumab administration
3081362|NCT02017626|Experimental|group 1|5 patients will receive 10 single rising doses of mCyp c 1 (modified allergen)from 0.6 ng to 6 ug and two maintenance doses, and 2 patients will receive placebo
3081363|NCT02017626|Experimental|Group 2|6 patients will receive 10 single rising doses of mCyp c 1 from 6 ng to 60 ug and two maintenance doses, and two patients will receive placebo.
3081364|NCT02017613|Experimental|Single arm|RP6530 administered orally
3081365|NCT02017600|Experimental|Induction Chemotherapy DCF followed by Surgery|All eligible patients will receive ND-420, Cisplatin and fluorouracil every 3 weeks for 2 cycles. After induction chemotherapy, patients will be planned to receive Surgery.
3081366|NCT02017587||Chronic HBV|chronic HBV strata: HBV tolerant, Chronic active HBe+ or HBe-, suppressed with antiviral therapy
3081367|NCT02017574|Experimental|Implicit Group|Receives little feedback about task performance during learning
3081368|NCT02017574|Active Comparator|Control|Receives detailed feedback about task performance during learning
3081369|NCT02017561|Active Comparator|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of regular moderate-intensity physical activity and healthy diet.
3081370|NCT02017561|Experimental|Metformin + Lifestyle Counseling|Metformin: maximum dose of 1000mg twice daily. Lifestyle counseling: Written and individualized information during the interview in all clinic visits, emphasizing the importance of regular moderate-intensity physical activity and healthy diet.
3081371|NCT02017548|Experimental|Life-extension default|Subjects in this group will receive an advance directive form that defaults to an overall goal of care directed towards life extension (vs. comfort oriented care) unless the subject specifies otherwise. The form also states 4 specific life extending interventions (cardiopulmonary resuscitation, mechanical ventilation, hemodialysis, and feeding tube insertion) will be provided unless patients specifically opt-out from such selections. It also will state that upon discharge from the hospital, long-term care (vs. hospice care) will be provided unless the patient chooses otherwise.
3081372|NCT02017548|Experimental|Comfort default|Subjects in this group will receive an advance directive form that defaults to an overall goal of care directed towards comfort and relief of pain and suffering (vs. life extension) unless the subject specifies otherwise. The form also states 4 specific life extending interventions (cardiopulmonary resuscitation, mechanical ventilation, hemodialysis, and feeding tube insertion) will be not provided unless patients specifically opts into such selections. It also will state that upon discharge from the hospital, hospice care (vs. long-term care) will be provided unless the patient chooses otherwise.
3081373|NCT02017548|No Intervention|Standard advance directive|Subjects in the standard advance directive (AD) group will receive an AD that will have no options pre-selected.
3081374|NCT02017535|Experimental|Interpersonal Psychotherapy|Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.
3081375|NCT02017535|Other|Fluoxetine|The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. The medication will be taken as a daily pill.
3081376|NCT02017522|Experimental|11C-PBR PET|"Subjects will have a blood sample drawn to evaluate the presence of a specific genetic variation which would prevent the new type of imaging test we are evaluating from working and we will test the inflammatory cells in the blood for the same purpose.~All participants who proceed will have to return on at least one additional day to undergo a positron emission tomography (PET) scan similar to the scan your doctor ordered. we will use 11C-PBR28 as the radiotracer. This study will evaluate whether 11C-PBR28 can show areas of inflammation due to cardiac sarcoidosis. On either the same day or a different day, you will also undergo a cardiac MRI."
3081377|NCT02017509||Rectal Cancer Patients|Patients with a diagnosis adenocarcinoma of the rectum will provide a tumor sample from their diagnostic biopsy and surgical procedure for research purposes, including RNA gene expression analysis. In addition to a standard MRI, patients will have an Intravoxel Incoherent Motion MRI (IVIM) and a Dynamic Contrast Enhanced MRI (DCE-MRI) for research purposes.
3081378|NCT02017470|Experimental|Gender-tailored women's heart health outpatient programme|The programme consists of general cardiologist, advanced practice nurse, dietician, physiotherapist and occupational therapist. The participant will be asked to participate in one-on-one interviewing, focus group discussions, and the forthcoming health promotion strategies that are developed based on the data collected
3081379|NCT02017470|No Intervention|Conventional general cardiology outpatient programme|
3081380|NCT02017457|Experimental|Azacytidine + Donor lymphocyte infusion|"Azacytidine will be administered subcutaneously for 5 days. During the first cycle, a dose of 100mg/m2/day will be used and for the following cycles a dose of 35mg/m2/day will be administered. Each cycle will consist in 28 days. All patients will receive at least 6 cycles of Azacytidine and the total number of cycles will depend on the response to treatment.~Donor lymphocyte infusion will be performed on day 1 of cycle 2, 4 and 6 of Azacytidine. The amount of cells infused will depend on donor origin."
3081381|NCT02017444|Placebo Comparator|Placebo|Matched placebo tablet B.D for 12 weeks
3081383|NCT02017431|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by subject specific inhaled allergen challenge
3081384|NCT02017431|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by subject specific inhaled allergen challenge
3081385|NCT02017431|Active Comparator|Filtered air control|Exposure for 2 hours to filtered air followed by inhaled saline challenge
3081386|NCT02017431|Experimental|Particle depleted diesel exhaust|Exposure for 2 hours to particle depletion diesel exhaust followed by inhaled allergen challenge
3081387|NCT02017418|Experimental|zeaxanthin|placebo zeaxanthin
3081388|NCT02017418|Active Comparator|combinatory supplement|placebo combinatory supplement
3081389|NCT02017405|Other|5g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 5.0 g total daily dose of SBI on Day 1 followed by 5.0 g Placebo on Day 2 or a 5.0 g total daily dose of Placebo on Day 1 followed by 5.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 2.5g SBI will be taken two times a day for 14 days during the open-label phase."
3081390|NCT02017405|Other|10g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 10.0 g total daily dose of SBI on Day 1 followed by 10.0 g Placebo on Day 2 or a 10.0 g total daily dose of Placebo on Day 1 followed by 10.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 5.0 g SBI will taken two times a day for 14 days during the open-label phase."
3081391|NCT02017405|Other|20g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 20.0 g total daily dose of SBI on Day 1 followed by 20.0 g Placebo on Day 2 or a 20.0 g total daily dose of Placebo on Day 1 followed by 20.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 20.0 g SBI will be taken two times a day for 14 days during the open-label phase."
3081392|NCT02017405|Other|Matching Placebo|Placebo will be taken either on Day 1 or on Day 2 based on the randomization during the double-blind, crossover phase.
3081393|NCT02017392|Experimental|Compound Lidocaine Cream|The cuff of endotracheal tube is covered by 1-2g compound lidocaine cream before the general anesthesia.
3081394|NCT02017392|No Intervention|blank control|No intervention.
3081395|NCT02017379|Experimental|Erythromycin|Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure
3081396|NCT02017379|Experimental|Metoclopromide|Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy
3081397|NCT02017379|No Intervention|Control|no medications will be given prior to endoscopy
3081398|NCT02017366|No Intervention|Control|Control group = standard of Care regimen: 1000ml = 1000 kCal TPN postop from day 1 until day 7. Oral feeds are started from day 5 onwards if no arguments for clinical leak (cervical anastomosis) or barium swallow is normal. Oral intake consists of regular post gastrectomy diet (building up from fluids over semi-solids to solids) with eventually added high nitrogen energy drinks.
3081399|NCT02017366|Active Comparator|Enteral feeding|Treatment group: start jejunostomy feeds from day 1, with target of 1000ml = 1000kCal (= 40cc/hour). To equilibrate energy intake during build up fase, Glucose 20% is given at a total cumulative dose taking into account the dose of j-drip, cumulative not exceeding 40cc/hr. Oral feeds are started at the same time as in the control group (reg. day 5) Jejunostomy feeds are then continued for 6 weeks together with oral intake with a continuous energy administration of 1000kCal, and then stopped. After this time, patients should be on regular full diet in both groups. If failure and step-back needed, temporary switch to Glc 20% is done to maintain fluid and calory administration.
3081400|NCT02017353|Experimental|Curcuphyt|Intake of Curcuphyt capsules, 2 g per day during 2 weeks
3081401|NCT02017340|Placebo Comparator|Placebo|250 patients will receive the placebo
3081402|NCT02017340|Active Comparator|Nilvadipine|250 patient will receive the active drug Nilvadipine 8mg
3081403|NCT02017327|Experimental|Monoprost|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
3081404|NCT02017327|Active Comparator|Lumigan 0.01%|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
3081405|NCT02017327|Active Comparator|Lumigan 0.03% Unit Dose|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
3081406|NCT02017314|Active Comparator|Group 5|Patients with BMI > 50
3081407|NCT02017314|Active Comparator|Group IV|Patients with BMI between 40 and 49.9
3081408|NCT02017314|Active Comparator|Group III|Patients with BMI between 35 and 39.9
3081409|NCT02017314|Active Comparator|Group II|patients with BMI between 30 and 34.9
3081410|NCT02017314|Active Comparator|Group I|Patients with BMI <30
3081411|NCT02017275|Experimental|BuMA group|Implant BuMA stent only
3081412|NCT02017275|Active Comparator|EXCEL group|Implant EXCEL stent
3081413|NCT02017262|Experimental|Self-management group|8 weekly sessions of group self-management
3081414|NCT02017262|Active Comparator|Enhanced usual care|Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
3081415|NCT02017249|Experimental|Arginine|24.15g of arginine supplement in powder form will be administered orally 3 times per day for 7 days before surgery and 7 days after surgery.
3081416|NCT02017249|Placebo Comparator|Silica and cellulose placebo powder|3.5 teaspoons of placebo powder will be mixed with a sweet beverage and given orally 3 times per day for 7 days prior to surgery and 7 days after surgery.
3081417|NCT02017236|Experimental|Volitinib ,after high fat meal intake|A:single oral Volitinib after high fat meal intake
3081418|NCT02017236|Experimental|Volitinib,after general diet|B:single oral Volitinib, after general diet
3081419|NCT02017223|Experimental|Knowme Device Wear|
3081420|NCT02017210|Experimental|Longitudinal follow up|Participant's metabolic parameters are followed up after approximately 6 years.
3081421|NCT02017197|Other|Sequence A|"Phase 1 (run-in): Marevan®~Phase 2: Marevan®~Phase 3: generic warfarin #1~Phase 4: generic warfarin #2"
3081422|NCT02017197|Other|Sequence B|"Phase 1 (run-in): generic warfarin #1~Phase 2: generic warfarin #1~Phase 3: Marevan®~Phase 4: generic warfarin #2"
3081423|NCT02017197|Other|Sequence C|"Phase 1 (run-in): generic warfarin #1~Phase 2: generic warfarin #1~Phase 3: generic warfarin #2~Phase 4: Marevan®"
3081424|NCT02017197|Other|Sequence D|"Phase 1 (run-in): Marevan®~Phase 2: Marevan®~Phase 3: generic warfarin #2~Phase 4: generic warfarin #1"
3081625|NCT02015871|Experimental|Degarelix|
3081425|NCT02017197|Other|Sequence E|"Phase 1 (run-in): generic warfarin #2~Phase 2: generic warfarin #2~Phase 3: Marevan®~Phase 4: generic warfarin #1"
3081426|NCT02017197|Other|Sequence F|"Phase 1 (run-in): generic warfarin #2~Phase 2: generic warfarin #2~Phase 3: generic warfarin #1~Phase 4: Marevan®"
3081427|NCT02017184|Experimental|Research arm|This trial contains one group which will undergo the described protocol while connected to both sensors: a rectal thermistor and a non invasive thermistor.
3081428|NCT02017171|Experimental|Allopurinol|Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function
3081429|NCT02017171|Placebo Comparator|Placebo|Oral placebo tablets
3081430|NCT02017158|Experimental|Virtual Sprouts|The Virtual Sprouts intervention arm will play Virtual Sprouts in a school-based implementation of the game.
3081431|NCT02017158|No Intervention|Control group|The control group will consist of students who will not play the Virtual Sprouts game at school.
3081432|NCT02017145|No Intervention|no reapplication|This group will not have chloraprep reapplied after their surgery and prior to dressing application.
3081433|NCT02017145|Experimental|reapplication|This group will have chloraprep reapplied following their lower extremity surgical procedure and prior to dressing application.
3081434|NCT02017132|Active Comparator|Pomegranate extract|1.1g pomegranate extract capsule administered daily to each participant for 8 weeks
3081435|NCT02017132|Placebo Comparator|Placebo capsule|1.1g placebo capsule taken daily by each participant for 8 weeks
3081436|NCT02017119|Experimental|Lactulose|Lactulose 15ml oral intake 8hrs daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
3081437|NCT02017119|Experimental|Lactulose-paraffin|Paraffin 15g daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
3081438|NCT02017106|Experimental|Concomitant phlebectomies|Removal of varicose tributaries during Endovenous laser ablation
3081439|NCT02017106|Active Comparator|Sequential Phlebectomies|Endovenous laser ablation only
3081440|NCT02017093|Experimental|Error Enhancement|Training of the upper extremity, using a robotic devise with error enhanced forces and traditional therapy.
3081441|NCT02017093|Experimental|Control treatment|Training of the upper extremity, using a robotic devise without forces applied and traditional therapy.
3081442|NCT02017080||Hyperthyroid pregnant women|Autoimmune hyperthyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound clinical examination
3081443|NCT02017080||Hypothyroid pregnant women|Autoimmune hypothyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination
3081444|NCT02017080||Healthy pregnant women|Euthyroid women with uncomplicated pregnancies, with antithyroid antibodies within reference ranges
3081445|NCT02017067|No Intervention|control|Maintain regular physical activity as usual, and received health education material about their disease, importance of nutrition and risks factors.
3081446|NCT02017067|Experimental|hydraulic resistance circuit training|12 weeks resistance training
3081447|NCT02017054||Cath patients|Patients with previous cardiac cath via the radial access who are planned for additional radial access cardiac cath
3081448|NCT02017041||buprenorphine/naloxone|Opioid substitution therapy patient taking buprenorphine/naloxone, MedSignals and smartphone app.
3081449|NCT02017015|Experimental|nab-paclitaxel with gemcitabine|nab-paclitaxel at 125 mg/m^2, intravenous (IV) infusion over 30 to 40 minutes followed by gemcitabine at 1000 mg/ m^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
3081450|NCT02017002|Active Comparator|Tri-incision|a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
3081451|NCT02017002|Placebo Comparator|Ivor Lewis|for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound
3081452|NCT02016989|Other|Physiological salt solution|The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
3081453|NCT02016989|Experimental|CACICOL20|The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
3081454|NCT02016976|Active Comparator|EMLA analgesic cream|Patients who have had EMLA analgesic cream applied to area before pacemaker implantation
3081455|NCT02016976|Active Comparator|Routine treatment|Patients who have received routine treatment (Dormicum 2.5 mg and Pethidine 25 mg) before and during pacemaker implantation
3081456|NCT02016963|Experimental|Raxibacumab arm|A maximum of 25 subjects (to include 3 evaluable female subjects) will receive a second dose of raxibacumab equal to that of the previous dose >= 4 months following the first dose.
3081457|NCT02016950||Permanent pacemaker|Pre-existing permanent pacemakers
3081458|NCT02016937||group g|general anesthesia, n: 21
3081459|NCT02016937||group S|spinal anesthesia, n: 21
3081460|NCT02016937||group E|epidural anesthesia, n: 21
3081461|NCT02016937||group V|vaginal birth, without anesthesia, n: 21
3081462|NCT02016924|Experimental|Part A, Cohort 1|Participants ages 12 to <18 years old will receive cobicistat 150 mg with either ATV or DRV plus BR.
3081463|NCT02016924|Experimental|Part A, Cohort 2|Participants ages 6 to <12 years old will receive cobicistat 150 mg (150 mg if ≥ 25 kg) or cobicistat 90 mg (if ≥ 15 kg and < 25 kg) with either ATV or DRV plus BR.
3081464|NCT02016924|Experimental|Part A, Cohort 3|Participants ages 3 to <6 years old will receive cobicistat (dose to be determined) with either ATV or DRV plus BR.
3081465|NCT02016924|Experimental|Part A, Cohort 4|Participants ages 3 months to <3 years old will receive cobicistat (dose to be determined) with ATV plus BR.
3081466|NCT02016924|Experimental|Part B, Cohort 1|Participants ages 12 to <18 years old will receive cobicistat 150 mg with either ATV or DRV plus BR.
3081508|NCT02016716|Placebo Comparator|Placebo 70 mg/mL|Participants received matching placebo administered as 3 subcutaneous injections of 1.0 mL every month for 6 months.
3081467|NCT02016924|Experimental|Part B, Cohort 2|Participants ages 6 to <12 years old will receive cobicistat 150 mg (150 mg if ≥ 25 kg) or cobicistat 90 mg (if ≥ 15 kg and < 25 kg) with either ATV or DRV plus BR.
3081468|NCT02016924|Experimental|Part B, Cohort 3|Participants ages 3 to <6 years old will receive cobicistat (dose to be determined) with either ATV or DRV plus BR.
3081469|NCT02016924|Experimental|Part B, Cohort 4|Participants ages 3 months to <3 years old will receive cobicistat (dose to be determined) with ATV plus BR.
3081470|NCT02016911|Experimental|Subjects with hepatic impairment|
3081471|NCT02016911|Active Comparator|Subjects with normal hepatic function|
3081472|NCT02016898|Experimental|Sponge placement of Mitomycin-C|Randomization will be stratified by age (age ≥65 or age < 65), baseline IOP (IOP ≥ 28 mmHg or IOP < 28 mmHg), and concurrent cataract surgery.
3081473|NCT02016898|Experimental|Irrigation placement of Mitomycin-C|Randomization will be stratified by age (age ≥65 or age < 65), baseline IOP (IOP ≥ 28 mmHg or IOP < 28 mmHg), and concurrent cataract surgery.
3081474|NCT02016885|Experimental|DRM04B, 1.0%|DRM04B, 1.0%
3081475|NCT02016885|Experimental|DRM04B, 2.0%|DRM04B, 2.0%
3081476|NCT02016885|Experimental|DRM04B, 3.0%|DRM04B, 3.0%
3081477|NCT02016885|Experimental|DRM04B, 4.0%|DRM04B, 4.0%
3081478|NCT02016885|Placebo Comparator|Vehicle|Vehicle
3081479|NCT02016872|Experimental|18F-FMISO PET/CT|All enrolled patients will undergo a baseline 18F-FDG PET scan as part of their standard clinical treatment for NSCLC. Dynamic 18F-FMISO PET scans will be performed on one of the GE PET/CT scanners in 3D mode, at least one day after the baseline 18F-FDG PET scan. The dynamic baseline 18F-FMISO studies may precede the 18F-FDG study if the patient had a CT or PET/CT scan within the last 30 days that would permit the investigators to localize the tumor of interest during the 18F-FMISO study. In a group of 5 patients, the feasibility of simultaneous imaging of 18F-FMISO and 18F-FDG will be assessed. The patient will have an IV line placed for radiotracer injection and for venous blood sampling. All dynamic PET scans will be performed over one PET FOV centered at the lesion position. The 18F-FDG mid-treatment PET/CT scan will be performed over only one bed position.
3081480|NCT02016859||Critically ill patients admitted to ICU|those patients who are admitted to ICU with multiorgan failure/injury
3081481|NCT02016859||Neutropinc Fever patients|admitted to ER, haemato-oncology or oncology
3081482|NCT02016859||Patients of Hip's Fracture|admitted to orthopedic departement
3081483|NCT02016846|Placebo Comparator|Placebo|
3081484|NCT02016846|Active Comparator|Intervention|Liraglutide, tapered from 0.6 mg/day to 1.8 mg/day.
3081485|NCT02016833||Cancer patients|Patient with histologically confirmed diagnosis of cervical cancer or cervical intraepithelial neoplasia (grade 3) or of high-grade serous (or undifferentiated) ovarian cancer or patients with AML or CML confirmed by bone marrow biopsy or peripheral blood Not treated - prior standard of care therapy acceptable one blood sampling performed on the visit day
3081486|NCT02016820|Experimental|Omeprazole (suspension)|Open-label, with all subjects receiving omeprazole
3081487|NCT02016820|Other|Lifestyle Modification|Treated with lifestyle modification (upright feeding, smaller meals, elevation of the head of the bed, etc.)
3081488|NCT02016807||1-Treat OroEsophageal Mucositis|Prothelial: Arm 1 Patients with oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
3081489|NCT02016807||2-Treat Upper Alimentary Mucositis|Prothelial: Arm 2 Patients with gastric/small intestinal mucositis (delayed nausea, vomiting as prominent symptom/sign) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
3081490|NCT02016807||3-Treat Lower Alimentary Mucositis|ProThelial: Arm 3 Patients with lower GI mucositis develop chemoradiation diarrhea as their \ prominent symptom/sign[n=30]. Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
3081491|NCT02016807||4-Prevent Oral Mucositis|ProThelial: Arm 4 Patients anticipated to develop oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and spit. (Phase IV)
3081492|NCT02016807||5- Prevent Upper Alimentary Mucositis|ProThelial: Arm 5 Patients anticipated to develop gastric/small intestinal mucositis (delayed nausea vomiting as prominent symptom/sign) [n=30]. Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
3081493|NCT02016807||6- Prevent Lower Alimentary Mucositis|ProThelial: Arm 6 Patients anticipated to develop chemoradiation diarrhea as their prominent symptom/sign [n=30]. Intervention: ProThelial 1.5 gram taken tid x 2 days then bid swish and swallow. (Phase I)
3081494|NCT02016794||Patients|Patients suffering from degenerative cervical condition that requires anterior decompression and fusion in a single or multiple levels
3081495|NCT02016781|Active Comparator|Transplant|Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT)
3081496|NCT02016781|Active Comparator|Non-Transplant|Hypomethylating Therapy / Best Supportive Care
3081497|NCT02016768||operation|To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
3081498|NCT02016755|Experimental|AMG0001|Hepatocyte Growth Factor (HGF) Plasmid
3081499|NCT02016742|Experimental|RDC5 dose level 1|Single dose of RDC5
3081500|NCT02016742|Experimental|RDC5 dose level 2|Single dose of RDC5
3081501|NCT02016742|Experimental|RDC5 dose level 3|Single dose of RDC5
3081502|NCT02016742|Experimental|RDC5 dose level 4|Single dose of RDC5
3081503|NCT02016729|Experimental|AMG 232|AMG 232 is an anti-cancer agent
3081504|NCT02016729|Experimental|AMG 232 & Trametinib|AMG 232 and Trametinib are anti cancer agents
3081505|NCT02016716|Experimental|Romosozumab 90 mg/mL|Participants received 210 mg romosozumab monthly, administered as 2 subcutaneous (SC) 1.17 mL injections of a 90 mg/mL solution, for 6 months.
3081506|NCT02016716|Experimental|Placebo 90 mg/mL|Participants received matching placebo administered as 2 subcutaneous injections of 1.17 mL every month for 6 months.
3081507|NCT02016716|Experimental|Romosozumab 70 mg/mL|Participants received 210 mg romosozumab monthly, administered as 3 subcutaneous 1.0 mL injections of a 70 mg/mL solution, for 6 months.
3100010|NCT01891552||Tacetux|DEBIRI+ CETUXIMAB ADMINISTRATION
3081509|NCT02016703|Experimental|5 g group|5g erythritol dissolved in 250 ml (2% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
3081510|NCT02016703|Experimental|15 g group|15g erythritol dissolved in 250 ml (6% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
3081511|NCT02016703|Experimental|25 g group|25g erythritol dissolved in 250 ml (10% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
3081512|NCT02016703|Experimental|20 g group|20g erythritol dissolved in 250 ml (8% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
3081513|NCT02016690||Immunocompromised children|Children with immunocompromised conditions or Down syndrome at high-risk of serious RSV disease who received palivizumab during the RSV season
3081514|NCT02016677||observation|no specific treatment. Long term observation the results of any breast lifting or reduction surgeries
3081515|NCT02016664|Experimental|Chronic pain patients on oral ketamine|"Days 1-7:~Subjects will be given a 7 day supply of 10 mg ketamine tablets three times per day for seven days and to return to clinic on Day 7. They will be instructed not to take their morning dose of ketamine and to eat a light breakfast on Day 7. Upon arrival, the patient will have a 20 gauge (saline locked) IV started in the antecubital fossa to allow for five blood samples: Time Zero,30, 60,90 and 120 minutes. The first blood sample at Time 0 will be obtained just before the patient takes his/her oral dose of ketamine.~Days 8-14:~The subjects will be given a supply of 20 mg ketamine capsules and instructed to take them three times per day, at specified times, and to return to clinic on Day 14. The instructions and procedures at the second clinic visit will be the same as on Day 7."
3081516|NCT02016651|Experimental|Right side position|Premature infants on mechanical ventilation are kept on their right side
3081517|NCT02016651|No Intervention|Supine position|Premature infants on mechanical ventilation are kept on their back
3081518|NCT02016638|Experimental|polysomnography and AMBP on pregnant females|"Consecutive patients undergoing antenatal check up at the Antenatal Clinic at AIIMS hospital and obstetrics wards will be recruited and followed.Using Somnomedic systems, GmbH polysomnography machine by trained staff nurses and technicians at:~Obstetrics ward, AIIMS hospital"
3081519|NCT02016625|Experimental|1 Cyclosporine + Faldaprevir|
3081520|NCT02016625|Experimental|2 Tacrolimus + Faldaprevir|
3081521|NCT02016612|Active Comparator|Reduction, Mastopexy No Implant, No Seri|Patients undergoing reduction or mastopexy but no implant is used and no Seri Surgical Scaffold support is used
3081522|NCT02016612|Active Comparator|Mastopexy, Implant no Seri Scaffold|Mastopexy with implant, No Seri Surgical Scaffold support is used
3081523|NCT02016612|Active Comparator|Breast Reduction with Seri Support|Patients undergoing breast reduction with the use of Seri Surgical scaffold support
3081524|NCT02016612|Active Comparator|Augmentation Mastopexy, Implant and Seri|Augmentation Mastopexy patients where Seri Surgical scaffold is used
3081525|NCT02016599||Initial cohort|Initial cohort used to develop a series of multivariate clinical deterioration indices using monitoring modalities and biospecimen collection
3081526|NCT02016599||Validation cohort|Separate cohort of infants used to validate the clinical deterioration indices using monitoring modalities and biospecimen collection
3081527|NCT02016586|No Intervention|Control Group|Subjects in the control group will continue to take the prenatal supplement primarily consisting of folic acid (400 mcg), elemental iron (60 mg) and will receive breastfeeding advice during prenatal visits.
3081528|NCT02016586|Experimental|Intervention|Lactation support in conjunction with a maternal nutritional supplement S348S0
3081529|NCT02016573|No Intervention|Usual care|participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
3081530|NCT02016573|Experimental|Renal Denervation Group|participants randomised to undergo the renal denervation procedure
3081531|NCT02016560|Experimental|Exploratory Cognitively Healthy Subjects|Subjects will receive an IV injection, 370 megabecquerel (MBq) (10 millicurie [mCi]), single dose of florbetapir F 18 at baseline. Cross-sectional and longitudinal subjects will receive an IV injection, 370 MBq (10 mCi), single dose of 18F-AV-1451 at baseline. Longitudinal subjects only will receive an IV injection, 370 MBq (10 mCi) of 18F-AV-1451 at 9 and 18 months.
3081532|NCT02016560|Experimental|Exploratory MCI Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of 18F-AV-1451 at baseline, 9 months and 18 months.
3081533|NCT02016560|Experimental|Exploratory AD Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of 18F-AV-1451 at baseline, 9 months and 18 months.
3081534|NCT02016560|Experimental|Confirmatory Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 and 18F-AV-1451 at baseline.
3081535|NCT02016547|Experimental|abciximab IV and thrombectomy|abciximab IV (0.25mg/kg by IV bolus, following by 0.125μg/kg by 12 hours IV drip) and thrombectomy
3081536|NCT02016547|Active Comparator|alteplase|alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)
3081537|NCT02016534|Experimental|Single arm|AMG 337 Monotherapy
3081538|NCT02016521|Experimental|Cooling Fabric|Garment made of 100% nylon fabric consisting of long sleeved shirt and full trouser.
3081539|NCT02016521|Placebo Comparator|Placebo Garment|Garment made of 100% polyester consisting of long sleeved shirt and full trouser.
3081540|NCT02016508|Experimental|autologous bone marrow stem cells|use of autologous bone marrow derived stem cells as intravitreal injection in AMD patients
3081541|NCT02016495|Active Comparator|Magnesium + Lipoic Acid|
3081542|NCT02016495|Placebo Comparator|Placebo|
3081543|NCT02016482|Active Comparator|Adalimumab (ADA)|Period A: ADA 40 mg subcutaneous every other week (sc eow) for 25 weeks starting 1 week after initial loading dose of 80 mg. Period B: Placebo at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
3081544|NCT02016482|Placebo Comparator|Placebo|Period A: Placebo sc eow for 25 weeks. Period B: ADA 80 mg sc at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
3081620|NCT02015910|Experimental|Januvia (Sitagliptin)|Sitagliptin 100 mg a day for 12 weeks
3081545|NCT02016469|Experimental|co-transplantation of FMT and pectin|300ml Bacterial suspension (from 60g fresh stool )given for the first day and 20g pectin given from the second to the sixth day for total five days
3081546|NCT02016469|Active Comparator|single fecal microbiota transplantation|300ml Bacterial suspension (from 60g fresh stool )given for the first day
3081547|NCT02016469|Active Comparator|give pectin 20g/d|pure give pectin 20g/d for five days
3081548|NCT02016456|Experimental|Theta-Burst Stimulation|Theta-Burst protocol for transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
3081549|NCT02016456|Active Comparator|High Frequency stimulation|High frequency Transcranial Magnetic Stimulation using the standard protocol for depression, on left dorsolateral prefrontal cortex.
3081550|NCT02016443|Experimental|Tizanidine|Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
3081551|NCT02016443|Placebo Comparator|Placebo|Group Placebo (Group P) will receive placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
3081552|NCT02016430|Experimental|MeLT Dietary intervention|Mediterranean Low-TMAO (MeLT) diet
3081553|NCT02016430|Experimental|TLC Dietary intervention|Therapeutic Lifestyle Changes (TLC) diet
3081554|NCT02016430|Experimental|MeLT dietary intervention with TMAO|Mediterranean Low TMAO diet with TMAO levels reported
3081555|NCT02016417|Experimental|A combination of Gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
3081556|NCT02016417|Active Comparator|A combination of Docetaxel, cisplatin and 5-Fluorouracil|The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
3081557|NCT02016404|Active Comparator|Low-sodium, high-potassium salt|Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, mono sodium glutamate (MSG), sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation
3081558|NCT02016404|Placebo Comparator|Regular salt|Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
3081559|NCT02016391|Experimental|Dexmedetomidine|
3081560|NCT02016378|Sham Comparator|sham retraining|Participants in this condition will participate in a computerized task wherein the size of pictures of drug and non-drug related stimuli are increased or decreased based on the tilt (left or right) of the pictures, but without regard to the content (i.e., drug or non-drug).
3081561|NCT02016378|Active Comparator|Bias retraining|Participants in this condition will participate in 6 sessions of a computerized bias retraining.
3081562|NCT02016365|Experimental|Doxycycline and UDCA|Doxycycline (200 mg/day intermittently) and UDCA (750 mg/day continuously)
3081563|NCT02016352|Experimental|patient|patient CSF extraction with hydrocephalus
3081564|NCT02016352|Other|witness|patient without hydrocephalus but with peridural catheter for anesthetic. Witness CSF extraction has realized on catheter.
3081565|NCT02016339|Active Comparator|Standard Care|24 hour consultation telephone line to the sleep nurses will be open for the patients. Patients were reviewed at 1 month and at 3 month intervals during the first year and every 6 months thereafter in the CPAP clinic. Additional visits or phone calls by sleep specialist if doubts about a patient's compliance or willingness to continue with the therapy
3081566|NCT02016339|Active Comparator|Intensive care|"Standard group care plus:~Involvement of the patient's partner or family. Extra education on sleep apnea syndrome and CPAP by sleep specialists via a 15-min videotape. 10- to 15-min lecture from the sleep clinic's nurses. Phone calls by nurses at 2 and 7 days. Early review of patients by sleep specialists at 15 and 30 days. Home visits by sleep nurses, if there doubts about a patients adherence."
3081567|NCT02016326|Experimental|HD Colon|High Definition White Light modality will be used by the endoscopist for the entire procedure.
3081568|NCT02016326|Experimental|I-Scan 1|I-scan 1 modality will be used by the endoscopist for the entire procedure.
3081569|NCT02016326|Experimental|I-Scan 2|I-Scan 2 modality will be used by the endoscopist through out the procedure.
3081570|NCT02016313|Experimental|Immediate therapy|Physiotherapy protocol
3081571|NCT02016313|Placebo Comparator|waiting list|Physiotherapy protocol
3081572|NCT02016300|Experimental|Unloader Bracing|This group will be randomly selected and assigned to wear an unloader brace post-operatively during the study period.
3081573|NCT02016300|Active Comparator|Non-Bracing Arm|This group will be randomly selected and assigned to wear no brace post-operatively.
3081574|NCT02016287|Experimental|sequential treatment|paclitaxel treatment and radiotherapy
3081575|NCT02016274|Experimental|sequential treatment|paclitaxel/cisplatin treatment and radiotherapy
3081576|NCT02016261|Experimental|Remitted Depression Outpatients|Adults 18-65 years old, males and females with the diagnosis of recurrent depressive disorder and who had at least two severe depressive episodes (with or without psychotic symptoms) of the disorder and who currently in remission
3081577|NCT02016248|Experimental|Low Risk Cohort|"The low risk cohort will receive:~Stereotactic Ablative Body Radiotherapy as Monotherapy on the CyberKnife System"
3081578|NCT02016248|Experimental|High Risk Cohort|"The high risk cohort will receive:~28 treatments of external beam radiation therapy followed by Stereotactic Ablative Body Radiotherapy as a Boost on the CyberKnife System and hormonal therapy as indicated."
3081579|NCT02016235|Experimental|Dent Disease patients|A. 1. LMWP (at least 5 times above the upper limit of normal) and at least 1 of the following criteria: 1. Hypercalriuria, 2. Kidney Stones, 3. Nephrocalcinosis, 4. Hypophosphatemia, 5. Renal phosphate leak, 6. Aminoaciduria, 7. Glucosuria without diabetes mellitus, 8. Hematuria, 9. Renal insufficiency, 10. Family history with X-linked inheritance or B. 1 of the above criteria (1-9) and confirmed genetic mutation of CLCN5 or OCRL1.
3081621|NCT02015910|Placebo Comparator|Placebo|Placebo
3081580|NCT02016235|Experimental|hypercalciuria w/ phosphate leak|A. Male patients >18 years old will be recruited from the stone clinics at Mayo Clinic and NY Harbor VA Medical Center B. Eligibility Criteria include: 1) History of a symptomatic calcium oxalate or calcium phosphate stone; 2) hypercalciuria (>250 mg/24 hrs); 3) renal phosphate leak (TMP/GFR <2.07 mg/dl)
3081581|NCT02016235|Experimental|hypercalciuria w/out phosphate leak|A. Male patients >18 years old will be recruited from the stone clinics at Mayo Clinic and NY Harbor VA Medical Center B. Eligibility Criteria include: 1) History of a symptomatic calcium oxalate or calcium phosphate stone; 2) hypercalciuria (>250 mg/24 hrs); 3) (TMP/GFR <2.07 mg/dl)
3081582|NCT02016222|Experimental|Tears sampling|
3081583|NCT02016209|Experimental|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of platinum-based nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
3081584|NCT02016196|Experimental|rifaximin|6 rifaximin caps of 200 mg per day morning and night, during 15 days before TIPS, and after TIPS during 6 months.
3081585|NCT02016196|Placebo Comparator|placebo|6 caps placebo morning and night, 15 days before and 6 months after TIPS
3081586|NCT02016183||Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil / hydrochlorothiazide combination tablets LD&HD
3081587|NCT02016170|Experimental|Ticagrelor 180mg|Patients on prasugrel will switch to ticagrelor with a 180mg loading dose
3081588|NCT02016170|Experimental|Ticagrelor 90mg|Patients on prasugrel will switch to ticagrelor with a 90mg maintenance dose
3081589|NCT02016170|Active Comparator|Prasugrel 10mg|Patients already on prasugrel, will maintain prasugrel
3081590|NCT02016157|Experimental|Moxifloxacin, Chronic periodontitis|50 micrograms Moxifloxacin
3081591|NCT02016131||none endoleak events|Patients who have no further endoleaks related adverse events including aneurysm enlargement and rupture or persistent endoleaks.
3081592|NCT02016131||Endoleak events|Patients who undergo endoleaks related adverse events or persistent endoleaks during follow up.
3081593|NCT02016118||Ialuril|Intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
3081594|NCT02016118||Standard of care|Antimicrobial prophylaxis (continuous or postcoital), as described in the Guidelines on Urological Infections of the European Association of Urology or Immunoactive prophylaxis or Prophylaxis with probiotics or Prophylaxis with cranberry, or combination of these.
3081595|NCT02016105|Experimental|GP2017 Adalimumab|Study arm with intervention being studied in the protocol. Adalimumab Solution for subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
3081596|NCT02016105|Active Comparator|Humira ® Adalimumab|Humira® Adalimumab as a subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
3081597|NCT02016092||Patients with Parkinson's disease|
3081598|NCT02016092||Healthy Controls|
3081599|NCT02016079|Experimental|Omega-3|a fruit drink containing omega-3
3081600|NCT02016079|Placebo Comparator|Fruit drink|the same fruit drink given in the experimental arm, but not containing omega-3
3081601|NCT02016066|Experimental|CR6261|
3081602|NCT02016066|Placebo Comparator|Placebo|
3081603|NCT02016053||cirrhosis with baseline renal function|500 patients of cirrhosis with normal baseline renal function will be enrolled.
3081604|NCT02016053||Cirrhosis with Acute Kidney Injury (AKI).|Cirrhotics patients who present with AKI (Acute Kidney Injury) will be enrolled.
3081605|NCT02016040|Active Comparator|HIFU hemi-ablation|Focal Therapy Using High Intensity Focused Ultrasound (Ablatherm)
3081606|NCT02016027|Experimental|Carica folia Arm|
3081607|NCT02016014|Experimental|Intervention group|Lifestyle counseling in physical activity and alimentation and add for three months a smartphopne with a app (EVIDENT) to improve alimentation and physical activity
3081608|NCT02016014|Active Comparator|Lifestyle counseling|Lifestyle counseling in physical activity and alimentation
3081609|NCT02016001|Experimental|toothpaste 1|tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
3081610|NCT02016001|Experimental|toothpaste 2|toothpaste 2 will be the intervention with 1000 ppm of fluoride, which will be used by control group. They will brush the teeth twice daily for 2 minutes
3081611|NCT02015988|Experimental|Simvastatin and Fenofibrate|Simvastatin 40 mg once daily and fenofibrate 145 mg once daily orally for 52 weeks (1 year)
3081612|NCT02015988|Active Comparator|Simvastatin|Simvastatin 40 mg once daily orally for 52 weeks (1 year)
3081613|NCT02015962|Experimental|Intravenous potassium|Patients in this arm will be administered intravenous potassium if they develop hypokalemia. As per CICU protocol 1-ml blood sample from already placed art-line or central venous line is sent for analysis of serum potassium concentration in all the immediate post operative patients. In the IVPR group, potassium will be given according to the hospital protocol through a central line. As per a previously established protocol and bioavailability data, repeat serum potassium will be sent 1 hour after replacement in the IVPR group.
3081614|NCT02015962|Experimental|Enteral potassium (ERP)|Once included in the study, patients in this arm will be given oral potassium if they develop an episode of hypokalemia. As per CICU protocol 1-ml blood sample from already placed art-line or central venous line is sent for analysis of serum potassium concentration in all the immediate post operative patients. As per a previously established protocol and bioavailability data, repeat serum potassium will be sent 2 hours after replacement in the EPR group. Replacement and serum level monitoring will be done till the episode of hypokalemia is resolved
3081615|NCT02015949|Active Comparator|Methylphenidate|2 weeks of 0.3mg/kg twice daily of methylphenidate to the nearest 5mg
3081616|NCT02015949|Placebo Comparator|Sugar pill|2 weeks of twice daily placebo
3081617|NCT02015936|Experimental|Prescriped Physical Activity|Physical fitness evaluation followed by prescribed physical activity and progress reporting.
3081618|NCT02015923|Experimental|colonic resection|Arm A (experimental): surgery (complete tumoral resection; R0) followed by chemotherapy, regimen according to each center.
3081619|NCT02015923|Active Comparator|Chemotherapy|Arm B (control): chemotherapy alone, regimen according to each center
3081626|NCT02015858||Epidural analgesia|Postoperative patients with epidural analgesia
3081627|NCT02015858||Oral analgesics|Postoperative patients with oral analgesics
3081628|NCT02015845|Experimental|Accuvein|Use of Accuvein to facilitate placement of peripheral intravenous catheters in obese patients
3081629|NCT02015845|Active Comparator|Routine technique|Routine technique used to insert a peripheral intravenous catheters in obese patients.
3081630|NCT02015832||Percutaneous Coronary Intervention|All patients (single arm study) will be receiving the SYNERGY™ Everolimus eluting stent (EES)
3081631|NCT02015819|Experimental|Treatment (neural stem cells, flucytosine, leucovorin)|Patients receive CD-expressing neural stem cells intracranially on days 1 and 15. Flucytosine is taken orally every 6 hours on days 4-10 and 18-24. Depending on when a subject enters the study, s/he may also be given leucovorin orally every 6 hours on days 4-10 and 18-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3081632|NCT02015806|Experimental|All meds but depression, 1x daily use, RxTimerCap|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a RxTimerCap.
3081633|NCT02015806|Experimental|All meds but depression, 1x daily use, Take-N-Slide|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a Take-N-Slide.
3081634|NCT02015806|Experimental|All meds but depression, 1x daily use, pillbox|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a standard pillbox.
3081635|NCT02015806|No Intervention|All meds but depression, 1x daily use, control|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to continue with usual care.
3081636|NCT02015806|Experimental|All meds but depression, ≥1 med >1 daily use, RxTimerCap|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a RxTimerCap.
3081637|NCT02015806|Experimental|All meds but depression, ≥1 med >1 daily use, pillbox|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a standard pillbox.
3081638|NCT02015806|No Intervention|All meds but depression, ≥1 med >1 daily use, control|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to continue with usual care.
3081639|NCT02015806|Experimental|Only depression meds, 1x daily use, RxTimerCap|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a RxTimerCap.
3081640|NCT02015806|Experimental|Only depression meds, 1x daily use, Take-N-Slide|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a Take-N-Slide.
3081641|NCT02015806|Experimental|Only depression meds, 1x daily use, pillbox|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a standard pillbox.
3081642|NCT02015806|No Intervention|Only depression meds, 1x daily use, control|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to continue with usual care.
3081643|NCT02015806|Experimental|Only depression meds, ≥1 med >1 daily use, RxTimerCap|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a RxTimerCap.
3081644|NCT02015806|Experimental|Only depression meds, ≥1 med >1 daily use, pillbox|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a standard pillbox.
3081645|NCT02015806|No Intervention|Only depression meds, ≥1 med >1 daily use, control|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to continue with usual care.
3081646|NCT02015793|Experimental|Low Induction Dose|Participants received the low loading dose of adalimumab (80 mg at Week 0) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 2, 4, and 6.
3081647|NCT02015793|Experimental|Standard Induction Dose|Participants received the standard loading dose of adalimumab (160 mg at Week 0 and 80 mg at Week 2) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 4 and 6.
3081648|NCT02015780|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, once daily, and stable antihyperglycemic therapy for up to 16 weeks. Then Fasiglifam placebo-matching tablets, once daily and antihyperglycemic therapy, adjusted as necessary per the Investigator's discretion, for up to 36 weeks.
3081649|NCT02015780|Experimental|Fasiglifam|Fasiglifam 50 mg tablets, once daily and stable antihyperglycemic therapy for up to 16 weeks. Then Fasiglifam 50 mg tablets, once daily and antihyperglycemic therapy, adjusted as necessary per the Investigator's discretion, for up to 36 weeks.
3081650|NCT02015767||Roflumilast|Participants prescribed roflumilast (Daxas®) according to local guidelines and marketing authorization.
3081651|NCT02015754|Experimental|DEBIRI|
3081652|NCT02015741||Aged patients|EEG monitoring with Bispectral Index and NeuroSENSE
3081682|NCT02015559|Experimental|Arm I (mucoadhesive oral wound rinse)|Patients receive mucoadhesive oral wound rinse PO as a gentle swish for 30-60 seconds 3-6 times daily beginning on day 1 of everolimus therapy and continuing for up to 6 months in the absence of unacceptable toxicity.
3081653|NCT02015728|Experimental|Regimen B|"Depending on tumor biology testing, subjects assigned to Regimen B will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Everolimus 3 mg/m2/dose daily PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
3081654|NCT02015728|Experimental|Regimen C|"Depending on tumor biology testing, subjects assigned to Regimen C will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Erlotinib 85 mg/m2/dose daily PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
3081655|NCT02015728|Experimental|Regimen D|"Depending on tumor biology testing, subjects assigned to Regimen D will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Dasatinib 60 mg/m2/dose BID PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
3081656|NCT02015728|Experimental|Regimen A|"Depending on tumor biology testing, subjects assigned to Regimen A will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Sorafenib 150 mg/m2/dose BID PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
3081657|NCT02015715|Experimental|RO6864018|Asian participants will receive a single oral dose of RO6864018 capsule on Day 1. The first dose escalation cohort will receive a single 400 mg oral dose. Dose will be escalated in subsequent cohorts (up to Cohort 4) up to a maximum of 1600 mg, based on safety, pharmacokinetic, and pharmacodynamic data available from lower dose cohorts. The Cohort 5 will include Caucasian participants who will receive a single 1200 mg (or the highest dose well-tolerated by Asian participants, if lower than 1200 mg) oral dose of RO6864018 capsules on Day 1.
3081658|NCT02015715|Placebo Comparator|Placebo|Participants will receive a single oral dose of placebo matching to RO6864018.
3081659|NCT02015702|Experimental|One-on-one physician training|One-on-one physician training Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
3081660|NCT02015702|Active Comparator|Usual training|Usual training. This group will get the usual specified training for learning to use our electronic health record. Both groups received 12 hours of EPIC classroom training, exposure to the EPIC e-learning modules, user acceptability testing classes, and unlimited time on the EPIC 'playground', a site to practice on virtual patients. All had 90 days of elbow support with an EPIC-training non-physician technician, who were visible and available on all inpatient wards, as well as access to a physician-only support line available at all hours.
3081661|NCT02015689|Experimental|Benefits to Child|CDC VIS + message emphasizing benefits of MMR vaccine to child
3081662|NCT02015689|Active Comparator|CDC VIS|CDC Vaccine Information Statement (VIS)
3081663|NCT02015689|Experimental|Benefits to Society|CDC VIS + message emphasizing benefits of MMR vaccine to society
3081664|NCT02015689|Experimental|Benefits to Child and Society|CDC VIS + message emphasizing benefits of MMR vaccine to both child and to society
3081665|NCT02015676|Experimental|Trastuzumab, Myocet, Paclitaxel; Phase I|Participants received an initial loading dose of trastuzumab 4 milligrams per kilogram (mg/kg), intravenously (IV), over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 40 mg/ square meter (m^2), IV, every 3 weeks, from Week 1; if no dose limiting toxicity (DLT) was observed in greater than or equal to (≥) two-thirds (2/3) of cohort for 2 treatment cycles, the dose was increased to 50 mg/m^2, IV, and continued for 6 cycles. Participants also received paclitaxel 60 mg/ m^2, IV, once per week, from Week 19; if no DLT was observed in ≥ 2/3 of cohort for 2 treatment cycles, the dose was increased to 70 mg/m^2, IV, and subsequently 80 mg/m^2, IV, and continued until disease progression.
3081666|NCT02015676|Experimental|Trastuzumab, Myocet, Paclitaxel; Phase II|Participants received an initial loading dose of trastuzumab 4 mg/kg, IV, over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 50 mg/m^2, IV, every 3 weeks, from Week 1 for 6 cycles. Participants also received paclitaxel 80 mg/m^2, IV, once per week, from Week 19 until disease progression.
3081667|NCT02015663|Experimental|Arm 1|Tobramycin Inhalation Powder (112 mg) once daily during 168 days
3081668|NCT02015663|Active Comparator|Arm 2|Tobramycin Inhalation Powder (112 mg) twice daily on days 1-28, days 57-84 and days 113-140
3081669|NCT02015650|Active Comparator|Cetuximab|Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
3081670|NCT02015650|Active Comparator|Mitomycin-C / 5-Fluorouracil|Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
3081671|NCT02015637|Experimental|Delafloxacin|900mg orally (2 x 450 mg tablets) administered once
3081672|NCT02015637|Active Comparator|ceftriaxone|Ceftriaxone 250 mg intramuscular injection administered once
3081673|NCT02015611|Placebo Comparator|Placebo|Matched bottle/pill placebo
3081674|NCT02015611|Experimental|Vitamin D|2,000 IU Vitamin D3 per day
3081675|NCT02015598|Experimental|Carbocysteine|Carbocysteine , tablet ,250mg per one tablet , patients oral intake with 500mg .tid.(1500mg/day)
3081676|NCT02015598|Active Comparator|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure(CPAP),auto-CPAP(USA,Philips), patients use Nasal CPAP overnight.
3081677|NCT02015585|Experimental|Interocclusal appliance|Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
3081678|NCT02015585|Experimental|Relining complete denture base|Patients will be submitted to a procedure of relining their old dentures 30 days before the replacement of the complete dentures.
3081679|NCT02015585|Active Comparator|Only Rehabilitation|Patients will be treated with a complete denture without any kind of previous intervention
3081680|NCT02015572|Experimental|Occupational intervention|Early coordinated occupational intervention. Supervision in physically activities by a physiotherapist.
3081681|NCT02015572|Active Comparator|Usual care|Intervention from the patient's general physician.
3081683|NCT02015559|No Intervention|Arm II (no intervention)|Patients receive no intervention.
3081684|NCT02015546|Experimental|Vilazodone 10mg|Vilazodone 10 mg/d arm (10mg/d initiation dose, titrated to 40 mg/d in 2 weeks, continued for 8 week trial)
3081685|NCT02015546|Experimental|Vilazodone 20mg|vilazodone 20 mg arm (20mg/d initiation dose, titrated to 40 mg/d in 1 week, continued for 8-week trial)
3081686|NCT02015546|Experimental|Vilazodone 40mg|vilazodone 40 mg/d arm (40 mg/d initiation and continuation dose for 8-week trial.
3081687|NCT02015533|Experimental|CR8020|
3081688|NCT02015533|Placebo Comparator|Placebo|
3081689|NCT02015520|Experimental|Arm 1: Clazakizumab (Dose # A) (Double-Blind)|Clazakizumab Dose # A injection by subcutaneous for 12 weeks + background Methotrexate
3081690|NCT02015520|Experimental|Arm 2: Clazakizumab (Dose # B) (Double-Blind)|Clazakizumab Dose # B injection by subcutaneous for 12 weeks + background Methotrexate
3081691|NCT02015520|Experimental|Arm 3: Clazakizumab (Dose # C) (Double-Blind)|Clazakizumab Dose # C injection by subcutaneous for 12 weeks + background Methotrexate
3081692|NCT02015520|Experimental|Arm 4: Placebo matching with Clazakizumab (Double-Blind)|Clazakizumab Dose # D injection by subcutaneous for 12 weeks + background Methotrexate
3081693|NCT02015520|Experimental|Arm 5: Clazakizumab (Dose# A) (Open Label)|Any subject who completes Double-Blind will receive Clazakizumab Dose # A injection by subcutaneous + background Methotrexate for 96 weeks
3081694|NCT02015507|Active Comparator|Cohort 1|participants in Cohort 1 will be administered ivacaftor alone followed by ivacaftor with concomitant ciprofloxacin.
3081695|NCT02015507|Experimental|Cohort 2|Participants in Cohort 2 will be administered VX-661 in combination with ivacaftor followed by VX-661 in combination with ivacaftor and concomitant ciprofloxacin
3081696|NCT02015494|Experimental|4 mcg VAX2012Q|4 mcg VAX2012Q
3081697|NCT02015494|Experimental|8 mcg VAX2012Q|8 mcg VAX2012Q
3081698|NCT02015494|Experimental|14 mcg VAX2012Q|14 mcg VAX2012Q
3081699|NCT02015494|Experimental|18 mcg VAX2012Q|18 mcg VAX2012Q
3081700|NCT02015494|Experimental|12 mcg VAX2012Q|12 mcg VAX2012Q
3081701|NCT02015494|Experimental|8 mcg VAX2012Q repeated|8 mcg VAX2012Q
3081702|NCT02015494|Experimental|12 mcg VAX2012Q repeated|12 mcg VAX2012Q
3081703|NCT02015481|Experimental|Cabaletta 30gr.|weekly IV of Cabaletta 30gr.
3081704|NCT02015468|Experimental|Early mobilization|
3081705|NCT02015468|Experimental|Late mobilization|
3081706|NCT02015455|Experimental|Intervention Arm|Epidemiologic benchmarks included in lumbar imaging reports
3081707|NCT02015455|No Intervention|Usual Care Arm|Clinics with typical lumbar imaging reports (no epidemiologic benchmarks included)
3081708|NCT02015442|Experimental|High sucrose diet|High sucrose diet for 7 days
3081709|NCT02015442|Experimental|Low sucrose diet|Low sucrose diet for 7 days
3081710|NCT02015429|Active Comparator|Control|Pasta meal with added fractions or control with no fractions Pasta meal with no pea fractions
3081711|NCT02015429|Experimental|10 g protein|Pasta meal with added fractions or control with no fractions 10 g net yellow pea protein added to pasta meal
3081712|NCT02015429|Experimental|7 g yellow pea fibre|Pasta meal with added fractions or control with no fractions 7 g net yellow pea fibre added to pasta meal
3081713|NCT02015429|Experimental|Yellow pea fibre & protein|Pasta meal with added fractions or control with no fractions 10 g net yellow pea protein plus 7 g net yellow pea fibre added to pasta meal
3081714|NCT02015416|Experimental|IDC-G305|NY-ESO-1 recombinant protein together with GLA-SE
3081715|NCT02015403|Experimental|Standard Care + NAC (N-ACETYLCYSTEINE) infusion|
3081716|NCT02015403|Active Comparator|Standard Care|
3081717|NCT02015390|Active Comparator|Masquelet defect reconstruction|The Masquelet defect reconstruction is a two-stage technique for the treatment of large segmental bone defects that involves the induction of a biomembrane about a poly(methylmethacrylate)(PMMA) cement spacer within the defect and, following cement removal, autogenous bone grafting (harvested using Reamer-Irrigator-Aspirator) or allogeneic bone graft is used to pack the defect while preserving the biomembrane. The typical time interval between the two stages is 6-8 weeks. The biomembrane not only assists in retaining the bone graft, but serves as a rich source of vascular supply and growth factors which constitute an excellent biological milieu for the graft to consolidate and heal the defect.
3081718|NCT02015390|Active Comparator|Titanium cage reconstruction|The cylindrical titanium mesh cage technique is a single-stage surgical procedure that immediately restores limb anatomy and alignment, and provides limb stability sufficient enough for early, unrestricted mobilization while permitting bone and soft tissue healing. It involves the implantation of a fenestrated cylindrical titanium mesh cage packed with autogenous bone graft (harvested using Reamer-Irrigator-Aspirator) or with allogeneic bone graft.
3081719|NCT02015377|Experimental|High Sugar/Low Fiber (HSLF) meals|Comparing the impact of High sugar/Low fiber (HSLF) meal versus Low Sugar/High Fiber meals (LSHF) on insulin and glucose profiles, gut hormones (ghrelin, amylin, leptin) free fatty acids, cortisol, mood (MOOD), meaning of physical activity (MEANPA), and physical activity engagement (PA) in overweight African American and Hispanic youth
3081720|NCT02015377|Experimental|Low Sugar/High Fiber (LSHF) meals|Comparing the impact of High sugar/Low fiber (HSLF) meal versus Low Sugar/High Fiber meals (LSHF) on insulin and glucose profiles, gut hormones (ghrelin, amylin, leptin) free fatty acids, cortisol, mood (MOOD), meaning of physical activity (MEANPA), and physical activity engagement (PA) in overweight African American and Hispanic youth
3081721|NCT02015364|Experimental|Controlled early mobilization|The intervention group: Must perform controlled mobilization-exercises from the beginning of week 3 to 8
3081722|NCT02015364|No Intervention|Immobilization|The control group: In line with the current treatment regimen the patients must keep the boot on at all times and they are not allowed to move the ankle.
3081723|NCT02015351|Experimental|Anti-VEGF and Immunosuppression|"Bevacizumab: Dosage 1.25mg/0.05ml; Frequency monthly injections; Duration at least 3 months.~Immunosuppression: cyclosporine and/or azathioprine"
3081724|NCT02015338||Typically Developing Children|Normal developing children
3081725|NCT02015338||Children with Hemiparesis|Children diagnosed with Hemiparesis
3081726|NCT02015325|No Intervention|Control|Control schools were included if they did not have any ongoing water and sanitation hygiene initiative.
3081845|NCT02014506|Experimental|HAPLO|
3081727|NCT02015325|Experimental|Planet Water Program Intervention|School were included that were receiving the Planet Water Foundation's Program (PWP) providing a school-based program focusing on three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. Children will have access to safe water in the schools provided through the use of an AquaTower, and a 4 week educational program.
3081728|NCT02015312|Experimental|Epigallocatechin-3-gallate (EGCG)|EGCG 400 mg/d p.o. for 3 months; 800 mg/d p.o. for 3 months, 1200 mg/d p.o. for 6 months
3081729|NCT02015312|Placebo Comparator|Placebo|"capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
3081730|NCT02015299|Experimental|Linagliptin|Linagliptin 5 mg/day + lifestyle advise
3081731|NCT02015299|Placebo Comparator|Placebo|Matching placebo + lifestyle advise
3081732|NCT02015286||Growth Disorders|
3081733|NCT02015273||Growth Disorders|
3081734|NCT02015260|Placebo Comparator|placebo|placebo 0% nitrite cream and placebo 0% citric acid cream
3081735|NCT02015260|Active Comparator|Topical NO Dose A|3% sodium nitrite + 4.5% citric acid twice daily
3081736|NCT02015260|Active Comparator|Topical NO Dose B|6% sodium nitrite + 9% citric acid once daily
3081737|NCT02015260|Active Comparator|Topical NO Dose C|6% sodium nitrite + 9% citric acid twice daily
3081738|NCT02015247|Other|computer-assisted surgery|use of computer-assisted navigation during periacetabular osteotomy
3081739|NCT02015234|Experimental|TNX-102 SL|1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 12 months
3081740|NCT02015221|Experimental|ACTitouch|ACTitouch in sustained gradient compression mode during all waking hours (at least 10 hours per day) and intermittent pneumatic compression mode for 2 hours each day.
3081741|NCT02015221|Active Comparator|Standard Compression Garments|Standard Compression Garments of compression levels 30mmHg to 40mmHg during all waking hours each day.
3081742|NCT02015208|Experimental|Ruxolitinib|Ruxolitinib will be administered over a 28-day cycle, which will be repeated 6 more times in the absence of intolerable toxicity, disease progression, patient withdrawal of consent, or investigator decision to end therapy. The dose and schedule have been adapted from the product monograph for myelofibrosis. The starting dose will be 20 mg orally twice a day with normal .platelet and absolute neutrophil counts and no hepatic and renal impairment.
3081743|NCT02015195|Experimental|Acetic Acid 5%|Acetic Acid (5%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
3081744|NCT02015195|Experimental|Sodium Bicarbonate Slurry (50%)|Sodium Bicarbonate Slurry (50%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
3081745|NCT02015195|Experimental|Papain Slurry (70%)|Papain Slurry (70%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
3081746|NCT02015195|Experimental|Household ammonia (10%)|Ammonia (10%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
3081747|NCT02015195|Experimental|Lidocaine (4%)|Lidocaine (4%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
3081748|NCT02015195|Experimental|Isopropyl Alcohol (70%)|Isopropyl Alcohol (70%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
3081749|NCT02015195|Experimental|Hot Water (40 degrees Celsius)|Hot Tap Water (40 degrees Celsius) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
3081750|NCT02015182||Blood sample for bupivicaine pharmacokinetics|Children undergoing TAP block will have blood sampled for bupivacaine pharmacokinetics
3081751|NCT02015169|Experimental|XELOX+lapatinib|"D1 Oxaliplatin130mg/m2 + D5W 500ml MIV over 2hrs~D1-D14 Capecitabine 850mg/m2 p.o bid~D1 ~ Lapatinib 1250 mg qd dailiy"
3081752|NCT02015156|Experimental|PF-05280014|
3081753|NCT02015156|Active Comparator|Trastuzumab-US|
3081754|NCT02015143||Bipolar Disorder|
3081755|NCT02015143||Unipolar Disorder|
3081756|NCT02015130|Experimental|individual treatment|Individualized treatment
3081757|NCT02015130|No Intervention|control group|treatment according to current national guidelines
3081758|NCT02015117|Experimental|Cohort A (trametinib, whole-brain radiation therapy)|Patients receive trametinib PO QD for 4 weeks. Beginning in week 2, patients undergo whole brain radiation therapy five days a week for 3 weeks. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
3081759|NCT02015117|Experimental|Cohort B (trametinib, surgery)|Patients receive trametinib PO QD on days 1-14 followed by surgical resection of the tumor.
3081760|NCT02015104|Experimental|B|Intravesical TICE BCG (50mg) once weekly starting in week 3 for a total of 6 weeks. PANVAC-V 2 x 108 pfu SQ at week 0 only; PANVAC-F 1 x 109 pfu SQ at weeks 3, 7, 11, and 15
3081761|NCT02015104|Experimental|A|Intravesical TICE BCG (50mg) once weekly starting in week 3 for a total of 6 weeks
3081762|NCT02015091|Experimental|1, 4, 5, 6, 7|Vaccination schedules with 3 to 4 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
3081763|NCT02015091|Experimental|2|Vaccination schedules 4 IM vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
3081764|NCT02015091|Experimental|3|Vaccination schedules 5 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
3081765|NCT02015091|No Intervention|8|Participation in controlled human malari infection (CHMI) without prior vaccinations to serve as controls.
3081766|NCT02015065|Experimental|1|Adults and children with measurable localized or metastatic wt-GIST
3081767|NCT02015039|Active Comparator|Botulinum Toxin Therapy Only|
3081768|NCT02015039|Experimental|Botulinum Toxin Therapy plus Occupational Therapy|Intervention
3081769|NCT02015000|Experimental|pterygium recurrence|Surgical Result of Primary and Recurrent Pterygium by Using Pterygium Extended Removal followed by Fibrin Glue Assisted Amniotic Membrane Transplantation (P.E.R.F.A.M.T)
3081770|NCT02014987|Experimental|Running training programmes|"Runners with a high body mass index are going to follow a training programme of 3 kilometres per week compared to a training programme of 6 kilometres per week.~The amount of running will be increased with 10 % per week."
3081771|NCT02014974||Public Hospitals|Patients presenting and treated in public trauma centers in India.
3081772|NCT02014974||Private Hospitals|Patients presenting and treated in private trauma centers in India.
3081773|NCT02014961|Active Comparator|Mutation Carriers|Whole-exome sequencing (WES) Dermal biopsy Gastro-intestinal questionnaire
3081774|NCT02014961|Placebo Comparator|Non-Mutation Carriers|Whole-exome sequencing (WES) Gastro-intestinal questionnaire
3081775|NCT02014961|Other|Spouse|Whole-exome sequencing (WES) 12-Lead ECG
3081776|NCT02014948|Experimental|Exercises|This group will consist of 20 individuals, 10 with lumbar disc herniation and 10 with chronic low back pain who underwent treatment with exerxises.
3081777|NCT02014935|Experimental|Low intensity laser|"So that this research recrutarou 30 subjects with spastic hemiparesis sequel, post stroke who have gone through three phases, with three evaluations. If this conformation is necessary, therefore, it is a search for intergroup analysis, and the values found in Phase I were faced with the values found in Phases II and III.~The phases comprise:~Phase I (1st Cycle): Individuals treated with LLLT not only performed the evaluation of muscle activity, torque and lactic acid level.~Phase II (2nd Cycle): Individuals undergoing the application of LLLT, with the same off, and assessment of muscle activity, torque and lactic acid level.~Phase III (3rd Cycle): Individuals undergoing the application of LILT and evaluation of muscle activity, torque and lactic acid level."
3081778|NCT02014922|No Intervention|Control|Participants randomized to the control group will be allowed to continue using their habitual artificial tears, and / or additional habitual concurrent dry eye treatments.
3081779|NCT02014922|Experimental|Treatment|"Participants in the study treatment group will receive all four products:~TheraTears® Lubricant Eye Drop (15mL) - Dosage: Ophthalmic, 1 or 2 drops, prn~TheraTears® preservative-free single-use containers (32-pack, 0.6mL each) - Dosage: Ophthalmic, 1 or 2 drops, prn~TheraTears® Nutrition (90 pack) - Dosage: Oral, 3 capsules QD~TheraTears® TheraLid® Eyelid Cleanser (48mL) - Dosage: Ophthalmic, 1 or 2 application OU, QD"
3081780|NCT02014909|Experimental|KTN3379|KTN3379
3081781|NCT02014909|Experimental|Part II, Arm A|Combination of KTN3379 and cetuximab
3081782|NCT02014909|Experimental|Part II, Arm B|Combination of KTN3379 and erlotinib
3081783|NCT02014909|Experimental|Part II, Arm C|Combination of KTN3379 and vemurafenib
3081784|NCT02014909|Experimental|Part II, Arm D|Combination of KTN3379 and trastuzumab
3081785|NCT02014896||Ischemic Stroke|"Ischemic stroke subjects presenting within 24 hours from symptom onset will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department (if available) or hospital; 24 hours +/- 6 hours from symptom onset (if available) and 48 hours+/- 6 hours from symptom onset (if available).~Biomarker blood draw"
3081786|NCT02014896||TIA (Transient Ischemic Attack)|"TIA subjects presenting within 24 hours from symptom onset will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department (if available) or hospital; 24 hours +/- 6 hours from symptom onset (if available) and 48 hours+/- 6 hours from symptom onset (if available).~Biomarker blood draw"
3081787|NCT02014896||Non-Ischemic TNE|"Non-Ischemic Transient Neurological Event (TNE) subjects will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department or hospital.~Biomarker blood draw"
3081788|NCT02014896||Control|"Control group subjects will have PAX Gene Blood RNA tubes drawn within 8 hours of arrival to the Emergency Department or hospital. Control group matched with ischemic stroke and TIA subjects for age, race, gender, smoking history with at least one of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidemia.~Biomarker blood draw"
3081789|NCT02014883|Experimental|GLUT1 DS|
3081790|NCT02014870|Experimental|Cohort 1|1:1000 dilution of neat virus
3081791|NCT02014870|Experimental|Cohort 2|1:100 dilution of neat virus
3081792|NCT02014870|Experimental|Cohort 3|1:10 dilution of neat virus
3081793|NCT02014857||Periodonatlly healthy smokers|Gingival crevicular fluid sampling
3081794|NCT02014857||Periodontally healhty non-smokers|Gingival crevicular fluid sampling
3081795|NCT02014844|Experimental|aldoxorubicin|Subjects will receive either 250 mg/m2 or 350 mg/m2 aldoxorubicin IV.
3081796|NCT02014831|Active Comparator|TIP|"Reference arm; Patients will be treated with 6 cycles of Paclitaxel + Ifosfamide + Cisplatin (TIP treatment)"
3081797|NCT02014831|Experimental|Cetuximab + TIP|"Experimental arm: Patients will be treated with 6 cycles of Paclitaxel + Ifosfamide + Cisplatin (TIP treatment) and weekly infusion of Cetuximab."
3081798|NCT02014818|Experimental|3 month OCT follow-up, CoCr-EES|Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 3 months after the index procedure.
3081799|NCT02014818|Experimental|1 month OCT follow-up, CoCr-EES|Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 1 months after the index procedure.
3081800|NCT02014805|Experimental|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
3081801|NCT02014805|No Intervention|observation|no treatment after radical resection for thymoma
3081802|NCT02014792||Chronic kidney disease, stage 5|Patients with stage 5 chronic kidney disease who have recently commenced haemodialysis treatment (within 6-10 weeks of starting treatment)
3081803|NCT02014779|Experimental|eChange web-based relapse prevention|A relapse intervention program consisting of 14 modules. Patients will have access to therapist support through an internal secure messaging system.
3081804|NCT02014779|Active Comparator|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be vary for different therapists, but all have an evidence-based approach to therapy
3081805|NCT02014766|Active Comparator|Interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.375% ropivacaine is injected.
3081806|NCT02014766|Experimental|Supraclavicular block|Supraclavicular block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral supraclavicular fossa visualizing the brachial plexus located lateral to the subclavian artery. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.375% ropivacaine is injected.
3081886|NCT02014233|Placebo Comparator|Olive oil|Participants will consume 5 mL of olive oil with 1000 IU vitamin D3 for 21 days.
3081807|NCT02014753||CoCr-EES, 2-week OCT follow-up|Undergo primary PCI with cobalt-chromium everolimus-eluting stent (CoCr-EES) for AMI culprit lesion and perform OCT observation at 2-week after PCI.
3081808|NCT02014753||CoCr-EES, 3-month OCT follow-up|Undergo primary PCI with cobalt-chromium everolimus-eluting stent (CoCr-EES) for AMI culprit lesion and perform OCT observation at 3-month after PCI.
3081809|NCT02014740|Experimental|Liraglutide|• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued.
3081810|NCT02014740|Active Comparator|Metformin|M-group will be treated with Metformin for the duration of the study. Metformin (from 500 mg twice daily to a maximum of 1000 mg twice daily) regimen will be continued to achieve fasting glucose between 80 and 140 mg/dl
3081811|NCT02014727|Experimental|AMA1-DiCo + Alhydrogel|AMA1-DiCo: 50µg Alhydrogel® : 0.85 mg Al3+ per dose Route : Intramuscular Vaccination schedule : Do, W4, W26
3081812|NCT02014727|Experimental|AMA1-DiCo+ GLA-SE|"Group A2 (15) : European volunteer : AMA1-DiCo + GLA-SE~AMA1-DiCo: 50µg~GLA-SE 2.5 µg GLA per dose~Route : Intramuscular Vaccination schedule : Do, W4, W26"
3081813|NCT02014727|Experimental|AMA1-DiCo + GLA-SE|"Group B1 (18) : African volunteer : AMA1-DiCo + GLA-SE~AMA1-DiCo: 50µg~GLA-SE 2.5 µg GLA per dose~Route : Intramuscular Vaccination schedule : Do, W4, W26"
3081814|NCT02014727|Placebo Comparator|Placebo|"Group B2 (18) : African volunteer : Placebo~Placebo : isotonic saline solution~Route : Intramuscular Vaccination schedule : Do, W4, W26"
3081815|NCT02014714|Active Comparator|Morphine|Intrathecal Morphine 0.1mg
3081816|NCT02014714|Active Comparator|Fentanyl|Intrathecal Fentanyl 40mcg
3081817|NCT02014701|Other|Echocardiogram|Patients presenting with NSTEMI who are scheduled to undergo elective cardiac catheterization and coronary angiography with primary PCI will be selected for participation in the study. The patients will undergo a clinically indicated resting non-contrast echocardiogram to assess LV function and regional wall motion. They will then undergo contrast echocardiography with bolus injection of Optison™ contrast to reassess LV ejection fraction, improve LV opacification and assess regional wall motion abnormalities. Finally, they will be given a continuous infusion of Optison™ and will have assessment of myocardial perfusion of each of the 17 myocardial segments using low mechanical index continuous imaging of the myocardium and blood pool.
3081818|NCT02014688||American Indian or Alaskan Native Descent|
3081819|NCT02014688||Black or African American Descent|
3081820|NCT02014688||Asian Descent|
3081821|NCT02014688||Hispanic Descent|
3081822|NCT02014675||SD01 ICD lead|
3081823|NCT02014662|Other|Arm 1|Healthy subjects aged 18 to 35 years
3081824|NCT02014649|Experimental|20mg Laninamivir Octanoate|Dry Powder plus placebo
3081825|NCT02014649|Experimental|40mg Laninamivir Octanoate|Dry Powder
3081826|NCT02014636|Experimental|Part 1|Part 1 is a dose escalation phase in which subjects will receive pazopanib orally and the MK 3475 intravenously. Subjects will be evaluated for a minimum of 8 weeks before the next dose level cohort is enrolled.
3081827|NCT02014636|Experimental|Part 2|"Part 2 is a randomized phase in which subjects will be enrolled in each treatment arm:~Pazopanib monotherapy Pazopanib+MK-3475 MK-3475 monotherapy"
3081828|NCT02014623|Active Comparator|Grass pollen sublingual immunotherapy tablet|A sublingual allergen immunotherapy tablet (Oralair) containing: 300 index of reactivity (IR) of 5 grass pollen allergen extracts:perennial ryegrass (Lolium perenne), meadow grass (Poa pratensis), timothy grass (Phleum pratense), cocksfoot (Dactylis glomerata) and sweet vernal grass (Anthoxanthum odoratum) in an open label fashion administered for 4 months prior to the pollen season.
3081829|NCT02014623|Other|Control|Standard medical therapy: oral antihistamines AND/OR nasal steroids AND/OR nasal antihistamines
3081830|NCT02014597|Experimental|Normal - No glaucoma|HOCD
3081831|NCT02014597|Experimental|Glaucoma|HOCD
3081832|NCT02014584|Experimental|Dutasteride Arm|Subjects will receive dutasteride 0.5 milligrams (mg) administered orally once daily for 24 Weeks
3081833|NCT02014584|Placebo Comparator|Placebo Arm|Subjects will receive placebo administered orally once daily for 24 Weeks
3081834|NCT02014571|Experimental|Cohort A|Eight subjects will be randomized to receive either 10 mg of GSK2878175 active treatment (4 HCV genotype 1a [GT1a] and 2 HCV genotype 1b [GT1b]) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
3081835|NCT02014571|Experimental|Cohort B|Eight subjects will be randomized to receive either 30 mg of GSK2878175 active treatment (4 GT1a and 2 GT1b) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
3081836|NCT02014571|Experimental|Cohort C|Eight subjects will be randomized to receive either GSK2878175 active treatment (4 GT1a and 2 GT1b) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
3081837|NCT02014571|Experimental|Cohort D|Twenty subjects will be randomized to receive either 60 mg of GSK2878175 active treatment (6 GT2, 6 GT3, 3 GT4) or matching placebo (2 GT2, 2 GT3, 1 GT4).
3081838|NCT02014558|Experimental|Dose Escalation Cohort|oral
3081839|NCT02014558|Experimental|Dose Expansion Cohort|oral
3081840|NCT02014545|Active Comparator|WBRT + Lucanthone|Treatment will consist of WBRT given in a dose of 30 Gy in ten fractions with lucanthone given as an adjunct. Lucanthone will be administered as 25 mg and 100 mg tablets to be swallowed. Dosage will be one of the following: 250 mg bid, 250 tid, or 375 mg tid.
3081841|NCT02014545|Placebo Comparator|WBRT + Placebo|Patients will receive prophylactic cranial irradiation at 3 Gy per fraction, 5 days per week, for 2 weeks to a total dose of 30 Gy.
3081842|NCT02014532|Active Comparator|Montelukast|Patients in Test Group were given Leukotriene receptor antagonist, Montelukast 1 tablet twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
3081843|NCT02014532|Placebo Comparator|Placebo|Patients in Control Group were given placebo drug 1 tablet twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
3081844|NCT02014519|Other|Study Group|Subjects, male and female, aged 18 years and above who had agreed to collection of blood sample.
3081846|NCT02014493|Active Comparator|HFNC first|4 hours with High Flow Nasal Cannulae (HFNC) 6 l/pr.min, then 4 hours with Continuous Positive Airway Pressure (CPAP) 6l/pr.min.
3081847|NCT02014493|Active Comparator|CPAP first|4 hours Continuous Positive Airway Pressure (CPAP) 6 l/pr.min, then 4 hours High Flow Nasal Cannulae (HFNC) 6 l/pr.min.
3081848|NCT02014480|Experimental|Umeclidinium|All subjects will receive UMEC in the dose of 62.5 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
3081849|NCT02014480|Experimental|Vilanterol|All subjects will receive VI in the dose of 25 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
3081850|NCT02014480|Experimental|Umeclidinium/Vilanterol|All subjects will receive UMEC/VI in the dose of 62.5/25 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
3081851|NCT02014467|Experimental|Denosumab 60mg|injection
3081852|NCT02014467|Placebo Comparator|Placebo|injection
3081853|NCT02014454|Experimental|Propranolol eye drops|"All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularization, but no more than 60 days.~The propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP Cooperative Group."
3081854|NCT02014441|Experimental|Talimogene Laherparepvec|"Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL followed by a dose of 10⁸ PFU/mL 21 days after the initial dose and every 14 days thereafter.~Participants were treated with talimogene laherparepvec until they achieved a complete response (CR), all injectable tumors had disappeared, clinically relevant (resulting in clinical deterioration or requiring change of therapy) disease progression per modified World Health Organization (WHO) response criteria beyond 6 months of therapy, or intolerance of study treatment, whichever occurred first."
3081855|NCT02014428|Experimental|Hyaluronic acid|220 mg hyaluronic acid per tablet (two tablets/day for 10 days, and subsequently one tablet/day for three months)
3081856|NCT02014428|Placebo Comparator|Placebo|two tablets/day for 10 days, and subsequently one tablet/day for three months
3081857|NCT02014415||Liver Biopsy|Participants will provide liver tissue specimens collected at the time of liver biopsy, to determine the rate of progression of liver injury in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
3081858|NCT02014415||Known Severe Liver Disease|Participants will provide samples of serum, plasma, and DNA at defined time points to determine what genetic and environmental modifiers and biomarkers are associated with severe clinical liver disease, such cirrhosis, portal hypertension and liver failure in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
3081859|NCT02014415||Post Liver Transplant|Participants will provide a DNA sample to determine what genetic and environmental modifiers are associated with the need for liver transplantation in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
3081860|NCT02014402|Experimental|IG1202-A (Vascular)|
3081861|NCT02014402|Experimental|IG1202-B (Hepatic)|
3081862|NCT02014402|Experimental|IG1202-C (Soft Tissue)|
3081863|NCT02014402|Experimental|IG1202-D (Spinal)|
3081864|NCT02014389||Healthy subjects|Healthy subjects will be used as control group
3081865|NCT02014389||Patients|Patients with Glaucoma , Patients with retinal dystrophy
3081866|NCT02014376|Experimental|SD-101 dermal cream (6%)|6% SD-101 dermal cream applied topically once daily for 90 days
3081867|NCT02014376|Experimental|SD-101 dermal cream (3%)|3% SD-101 dermal cream applied topically once daily for 90 days
3081868|NCT02014376|Placebo Comparator|Vehicle|Vehicle dermal cream (0% SD-101) applied topically once daily for 90 days
3081869|NCT02014363|Experimental|ETS6103 (low dose)|ETS6103 (low dose) extended release tablets (encapsulated) taken once daily orally for the duration of randomised phase of the study (8 weeks).
3081870|NCT02014363|Experimental|ETS6103 (high dose)|ETS6103 (high dose) extended release tablets (encapsulated) taken once daily orally for the duration of randomised phase of the study (8 weeks).
3081871|NCT02014363|Active Comparator|Amitriptyline|Amitriptyline tablets (encapsulated) Standard dosing regime
3081872|NCT02014363|No Intervention|Lead-in phase|"Citalopram tablets:~Standard dosing regime"
3081873|NCT02014350||DePuy Delta Xtend RTSA|
3081874|NCT02014337|Experimental|Mifepristone and Eribulin in combination|Single Arm
3081875|NCT02014324||(suspected) NSCLC, mediastinal staging, endosonography|Patients with potentially medically operable and resectable NSCLC are eligible if there is an indication for pathological evaluation of mediastinal lymph nodes.
3081876|NCT02014311|Experimental|CTA+CTP guided treatment strategy|Patients with adenosine stress induced regional myocardial hypoperfusion (CT perfusion imaging) in combination with a corresponding epicardial coronary vessel with >50% stenosis (Coronary CT angiography) will be referred for invasive investigation within 30 days after study inclusion - CTP-INTERVENTION
3081877|NCT02014311|Active Comparator|CTA guided treatment strategy|Patients with at least one epicardial coronary artery stenosis >50% (Coronary CT angiography) will be referred for invasive investigation within 30 days after initial discharge from the hospital - CONTROL
3081878|NCT02014298|Other|Control|One area assessed as a control area, compared to the laser-treated area
3081879|NCT02014298|Active Comparator|Non-ablative Laser treatment|3 Non-ablative fractional laser treatments of one area
3081880|NCT02014285||Muscle Ultrasound/Sample|30 subjects enrolled from Wake Forest Baptist Health Intensive Care Units. Each study subject will undergo an ultrasound to examine the size and echogenicity of their muscles and a muscle biopsy from the rectus femoris. The muscles studied will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior.
3081881|NCT02014272|Experimental|Test|RIN 150 contains 150 rifampicin and 75 mg isoniazid
3081882|NCT02014272|Active Comparator|Reference|Individual references of rifampicin and isoniazid
3081883|NCT02014259|Experimental|Subjects with renal impairment|
3081884|NCT02014259|Active Comparator|Subjects with normal renal function|
3081885|NCT02014233|Experimental|Omega-3|Participants will consume 5 mL of omega-3 (2333 mg essential fatty acids) with 1000 IU vitamin D3 for 21 days.
3081887|NCT02014220|Experimental|Atlantic Western chips|deep fried potato chips
3081888|NCT02014220|Experimental|Dakota Pearl chips|deep fried potato chips
3081889|NCT02014220|Experimental|Andover Ontario chips|deep fried potato chips
3081890|NCT02014220|Experimental|white bread with margarine|energy control
3081891|NCT02014220|Experimental|white bread|control
3081892|NCT02014207|Experimental|golden crinkle|
3081893|NCT02014207|Experimental|high blanch|
3081894|NCT02014207|Experimental|low blanche|
3081895|NCT02014207|Experimental|high chill|
3081896|NCT02014207|Experimental|low chill|
3081897|NCT02014194|Placebo Comparator|attentional bias modification, placebo|Measure of attentional bias modification treatment after 10 sessions of attentional bias modification (two arms). There are two arms with 15 OCD patients each one.
3081898|NCT02014194|Active Comparator|attentional bias modification, active group|Measure of attentional bias modification treatment after 10 sessions of attentional bias modification (two arms).
3081899|NCT02014181|Experimental|Flaxseed|40 grams finely ground flaxseed powder daily for one month in patient with cystic fibrosis
3081900|NCT02014168|Experimental|Viroflu® and MVA-NP+M1|1 dose (0.5ml) of Viroflu® and 1 dose of 1.5 x10^8 pfu MVA-NP+M1 intramuscularly into the vastus lateralis muscle on day 0. The vaccines will be given side by side, with MVA NP+M1 being given immediately after the seasonal influenza vaccine.
3081901|NCT02014168|Placebo Comparator|Viroflu® and saline placebo|1 dose (0.5ml) of Viroflu® and 1 dose of a 0.9% saline placebo injected intramuscularly into the vastus lateralis muscle on day 0. The placebo will be administered immediately after the seasonal influenza vaccine.
3081902|NCT02014155|Experimental|Group Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard desinsuflativo (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
3081903|NCT02014155|Experimental|Group TMI + Pulmonary Rehabilitation|Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects. Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
3081904|NCT02014155|Experimental|Control Group|Inspiratory muscle training will be held three times a week for eight weeks
3081905|NCT02014155|Experimental|COPD group not rehabilitation|
3081906|NCT02014142|Experimental|Group A. L-PPDS single occlusion|Latanoprost Punctal Plug Delivery System (L-PPDS) continuous single occlusion; L-PPDS will be inserted in the lower punctum and no plug will be inserted in the upper punctum of each eye; L-PPDS will remain for a period of 14 weeks.
3081907|NCT02014142|Experimental|Group B. L-PPDS double occlusion|Latanoprost Punctal Plug Delivery System (L-PPDS) continuous double occlusion; L-PPDS will be inserted in the lower punctum and non-therapeutic (NT) plug will be inserted in the upper punctum of each eye and both will remain for a period of 14 weeks.
3081908|NCT02014129|Experimental|LY2835219|Oral LY2835219 will be administered in escalating dose cohorts twice daily in 28-day cycles (Cycle 1: 32-days). Treatment with LY2835219 may continue until disease progression, unacceptable toxicity, or other discontinuation criteria are met.
3081909|NCT02014116|Experimental|LY3009120|LY3009120 in escalating dose cohorts given orally BID (twice daily) every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
3081910|NCT02014103|Other|Sequence 1|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 1: Formulation 3, 5, 6, 4, 2, 1.
3081911|NCT02014103|Other|Sequence 2|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 2: Formulation 3, 4, 6, 5, 1, 2.
3081912|NCT02014103|Other|Sequence 3|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 3: Formulation 4, 3, 5, 1, 6, 2.
3081913|NCT02014090|Active Comparator|half supine bicycle Exercise|60 minutes of half supine bicycle exercise with submaximal workload
3081914|NCT02014090|Active Comparator|ECP|90 minutes of ECP
3081915|NCT02014077|Active Comparator|Thoracostomy Tube|patients selected for thoracostomy tube reinsertion after failure of drainage with first thoracostomy tube for traumatic haemothorax
3081916|NCT02014077|Active Comparator|VATS|patients selected for VATS after failure of first thoracostomy tube drainage of traumatic haemothorax will undergo a Video-Assisted Thoracoscopic clearance of the persistent/retained haemothorax
3081917|NCT02014064|Experimental|Atomoxetine|Double-blind, Placebo controlled, 2-phase study the safety & efficacy of Atomoxetine
3081918|NCT02014064|Placebo Comparator|Placebo|"Control Group Schedule:~Day 1: 40mg @ 8:00am Day 2: 40mg @ 8:00am Day 3: 40mg @ 8:00am, 40mg @ 8:00pm Day 4: 40mg @ 8:00am, 40mg @ 8:00pm Day 5: 40mg @ 8:00am, 40mg @ 8:00pm Day 6: 40mg @ 8:00am = Testing day (fMRI scan & cognitive testing session)"
3081919|NCT02014051|Experimental|SyB C-1101|
3081920|NCT02014025|Experimental|laparoscope hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery E district is Group B ,they will accept laparoscopic hepatectomy: tumors are totally resected through laparoscopic.
3081921|NCT02014025|Experimental|open hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery A and D district is Group A ,they will accept Open Hepatectomy: tumors are totally resected by conventional laparotomy.
3081922|NCT02013999|Experimental|Virtual reality program|mobile device for virtual reality program
3081923|NCT02013999|Active Comparator|Control|standard occupuational therapy
3081924|NCT02013986|Experimental|etomidate & midazolam|a bolus of midazolam(Jiangsu Enhua Pharmaceutical Ltd.) 0.1mg/kg then a bolus of etomidate(Etomidate Fat Emulsion Injection, Jiangsu Enhua Pharmaceutical Ltd.)0.3 mg/kg and intravenously, during induction period, the other steps as usual.
3081925|NCT02013986|Active Comparator|midazolam & propofol|During induction period,use a bolus of midazolam injection 0.1mg/kg(Jiangsu Enhua Pharmaceutical Ltd.) and then a bolus of propofol injection 2mg/kg(Astrazeneca PLC.)intravenously, the other steps are as usual.
3081926|NCT02013973|Experimental|AMH-group|The patients randomized to the AMH-group calculation of gonadotropin starting dose will be made from an algorithm including age, BMI, AFC and AMH-analysis.
3081927|NCT02013973|No Intervention|Non-AMH-group|The patients randomized to the non-AMH-group, calculation of gonadotropin starting dose will be made from an algorithm including only age, BMI and AFC
3081928|NCT02013960|Experimental|Laminaria|cytotec and laminaria
3081929|NCT02013960|Active Comparator|Cytotec|Cytotec only
3081930|NCT02013947|Other|Moderate altitude group|2 weeks of exercise at 1900 meters sea level
3081931|NCT02013947|Other|low altitude group|2 weeks of exercise at 400 meters sea level
3081932|NCT02013934|Active Comparator|Probiotics|Dietary supplement
3081933|NCT02013934|Placebo Comparator|Placebo|Dietary supplement
3081934|NCT02013921||Physical Activity|Patients with a breast cancer and are completing treatment
3081935|NCT02013908|Active Comparator|Standard ED management alone|Radiographic and physical examinations to exclude fractures or other serious conditions will be performed for all patients before considering eligibility in the study. After completion of the examination, patients who have pain of at least a level 4, as measured by the Wong-Baker scale (ranges 0 to 10), will receive intravenous or intramuscular injections of non-steroidal anti-inflammatory drugs (NSAIDs) for immediate pain control. All patients will be observed 30 minutes after the administration of the NSAIDs. In patients with primary headaches who respond poorly to the initial NSAID injection, an intravenous injection of opioid analgesics will be provided. After these initial standard ED management interventions, patients who are still suffering from acute pain will be asked to participate in the trial. During the study, rescue medication for immediate pain control will be allowed for patients allocated to both groups.
3081936|NCT02013908|Experimental|Acupuncture plus standard ED management|The patients in this group will receive a single session of individualized acupuncture treatment delivered by a certified Korean Medicine Doctor (KMD) specialized (or in-training) in acupuncture and moxibustion medicine and with at least 3 years of clinical experience. The acupuncture formulas will be composed based on the individual patient's symptoms and at the KMD's discretion. Acupuncture treatments will be provided in line with standard ED management, the same as in the control group.
3081937|NCT02013882||1-1-12 wash-in|wash-in using O2:N2O 1:1 L/min with desflurane 12%
3081938|NCT02013869|Experimental|Flow-I|Wash in of desflurane in an anaesthesia machine without below
3081939|NCT02013869|Active Comparator|Asys|Wash in of desflurane in conventional anaesthesia machine Asys
3081940|NCT02013856|Experimental|Low Epicatechin and procyanidin|Low epicatechin and procyanidin doses
3081941|NCT02013856|Experimental|High Epicatechin and procyanidin|High epicatechin and procyanidin doses
3081942|NCT02013856|Experimental|High Procyanidin|High procyanidin only
3081943|NCT02013856|Placebo Comparator|Placebo|No epicatechin and procyanidin
3081944|NCT02013843|Other|Community-based treatment|"Overweight and obese children are seen on a regular basis by health care professionals in the 8 communities included in the project. The care providers are all trained thoroughly in using the Holbaek-method for treatment of pediatric obesity."
3081945|NCT02013830|Experimental|Avastin + Xeloda|
3081946|NCT02013817|Experimental|MabThera/Rituxan|
3081947|NCT02013804|Experimental|Dose arms|Dose Escalation
3081948|NCT02013791|Other|Stage 1 Cohort 1|Vehicle administered to study eye and Sham administered to non-study eye on Day 1.
3081949|NCT02013791|Experimental|Stage 1 Cohort 2|Cyclosporine New Ophthalmic Formulation Dose A administered to study eye and Vehicle administered to non-study eye on Day 1.
3081950|NCT02013791|Experimental|Stage 1 Cohort 3|Cyclosporine New Ophthalmic Formulation Dose B administered to study eye and Vehicle administered to non-study eye on Day 1.
3081951|NCT02013791|Experimental|Stage 1 Cohort 4|Cyclosporine New Ophthalmic Formulation Dose C administered to study eye and Vehicle administered to non-study eye on Day 1.
3081952|NCT02013791|Experimental|Stage 1 Cohort 5A|Cyclosporine New Ophthalmic Formulation Dose D administered to the study eye and vehicle administered to the non-study eye on Day 1.
3081953|NCT02013791|Experimental|Stage 1 Cohort 6A|Cyclosporine New Ophthalmic Formulation Dose E administered to study eye and Vehicle administered to non-study eye on Day 1.
3081954|NCT02013791|Experimental|Stage 1 Cohort 6B|Cyclosporine New Ophthalmic Formulation Dose F administered to study eye and Vehicle administered to non-study eye on Day 1.
3081955|NCT02013791|Experimental|Stage 1 Cohort 6C|Cyclosporine New Ophthalmic Formulation Dose C administered to study eye and Vehicle administered to non-study eye on Day 1 and retreatment at Week 12 if applicable.
3081956|NCT02013791|Experimental|Stage 1 Cohort 6D|Cyclosporine New Ophthalmic Formulation Dose F administered to study eye and Vehicle administered to non-study eye on Day 1 and retreatment at Week 12 if applicable.
3081957|NCT02013765|Experimental|Trastuzumab Monotherapy|Participants received an initial dose of trastuzumab 4 milligrams per kilogram (mg/kg) intravenously (IV) on Day 1, followed by weekly doses of 2 mg/kg IV beginning on Day 8 and continuing for up to 37 weeks.
3081958|NCT02013752|Active Comparator|Perineal device during delivery|"Delivery should be managed by using the perineal protection device when the head was crowning and 5-6 cm of it was visible. One part the tongue was inserted between the head and the posterior vaginal wall and the two wings were held against the perineum and kept in place by the delivery attendant's hand."
3081959|NCT02013752|Other|Standard care|Standard care at delivery: Manual support of the perineum
3081960|NCT02013739||Patients with chronic heart failure|other
3081961|NCT02013739||Healthy volontiers|other
3081962|NCT02013726|Experimental|MBI Scan & Tomosynthesis Scan|Patients will receive both scans.
3081963|NCT02013713||Family Hypercholesterolemia in cardiology|
3081964|NCT02013700|Experimental|20 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 2 x10^6 (20 million) cells delivered via peripheral intravenous infusion
3081965|NCT02013700|Placebo Comparator|Placebo|Patients will receive a matched placebo delivered via peripheral intravenous infusion
3081966|NCT02013700|Experimental|100 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 100 x10^6 (20 million) cells delivered via peripheral intravenous infusion
3081967|NCT02013700|Experimental|200 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 200 x10^6 (200 million) cells delivered via peripheral intravenous infusion
3081968|NCT02013687|Experimental|2 µg + Alhydrogel|vaccine
3081972|NCT02013674|Experimental|Group 1: 20 million Allogeneic hMSCs|Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
3081973|NCT02013674|Experimental|Group 2: 100 million Allogeneic hMSCs|Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
3081974|NCT02013661||Suture in Periodontal resective surgery|Four types of suture including silk, polypropylene, PGA, and PTFE
3081975|NCT02013648|Active Comparator|Standard arm|"Induction therapy:~Patients will receive induction therapy (one or two cycles) with daunorubicin 60 mg/m2/day administered on days 1-3 and cytarabine 200 mg/m2/day administered by continuous IV infusion on days 1-7. No dose reduction is planned in elderly (>60 years) patients.~Optional second induction cycle:~Patients achieving PR only at the end of cycle 1 will receive a second induction cycle with daunorubicin 50 mg/m2/day administered on days 1-3 and cytarabine 200 mg/m2/day administered by cont. IV infusion daily on days 1-5.~Consolidation therapy:~Patients will receive 4 cycles of consolidation therapy. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, days 1-3 administered intravenously over three hours.~Follow-up period:~There is no maintenance therapy in the standard arm. Patients will be closely followed, in particular for molecular disease persistence or molecular relapse."
3081976|NCT02013648|Experimental|Investigational arm|"Induction therapy:~Patients will receive induction therapy (one or two cycles) with daunorubicin 60 mg/m2/day administered on days 1-3 and cytarabine 200 mg/m2/day administered by continuous IV infusion on days 1-7. Patients will receive dasatinib 100 mg once daily (QD) on days 8-21.~Opt. 2nd induction cycle:~Patients achieving PR only at the end of cycle 1 will receive a 2nd induction cycle with daunorubicin 50 mg/m2/day administered on days 1-3 and cytarabine 200 mg/m2/day administered by cont. IV infusion on days 1-5. Patients will receive dasatinib 100 mg QD on days 6-21.~Consolidation therapy:~Patients will receive 4 consolidation cycles. Treatment consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, days 1-3 administered IV over 3 hours. Patients will receive dasatinib 100 mg QD on days 4-21.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
3081977|NCT02013635||Cerebral Venous Thrombosis|patients over 16 years old with acute cerebral venous thrombosis
3081978|NCT02013622|Experimental|Brexpiprazole|Up to 4 mg/day, once daily dose, tablets, orally
3081979|NCT02013609|Experimental|Brexpiprazole|Up to 3mg/day, once daily dose, tablets, orally
3081980|NCT02013596|No Intervention|Control|Patients were given no TEAS
3081981|NCT02013596|Experimental|TEAS Pretreatment|Patients were given 30min of TEAS before pneumoperitoneum
3081982|NCT02013596|Experimental|TEAS Treatment|Patients were given 30min of TEAS during pneumoperitoneum
3081983|NCT02013583||Glucose Transporter Type I Deficiency|No interventions
3081984|NCT02013570|Active Comparator|Dexmedetomidine|Group S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration.
3081985|NCT02013570|Placebo Comparator|Normal saline, postoperative pain|Group S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration.
3081986|NCT02013557|Experimental|Intervention Group|Women in the intervention group will receive a test text-message reminder at the time of enrollment. They will then receive a text-reminder to schedule their oral glucose tolerance test at 6 weeks postpartum, with further reminders at 3 months and 6 months if they have not completed their testing.
3081987|NCT02013557|No Intervention|Control group|This arm will only receive the test text-message reminder at the time of enrollment. Otherwise they will receive usual postpartum care.
3081988|NCT02013544|Placebo Comparator|Placebo|Placebo vaginal ovule daily for 12 weeks
3081989|NCT02013544|Experimental|Prasterone|Prasterone (DHEA) vaginal ovule daily for 12 weeks
3081990|NCT02013531|Experimental|Brexpiprazole|Up to 3 mg/day, once daily dose, tablets, orally
3081991|NCT02013518|Experimental|Cognitive behavioural therapy|11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
3081992|NCT02013518|Other|Control group|Treatment as usual at the participating memory clinics
3081993|NCT02013505|No Intervention|Instructions printed on a paper.|There will be no intervention.
3081994|NCT02013505|Experimental|Paper and video instructions|.Instructions printed on paper and a educational video.
3081995|NCT02013492|Experimental|Treatment (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO BID for 4 months in the absence of disease progression or unacceptable toxicity. Propranolol will be administered on an out-patient basis. Blood for correlative studies (30 ml - green top tube) will be drawn at baseline and at each clinic visit. Tumor tissue for analysis will be obtained via core needle biopsy (or other appropriate modality) pre-study and at approximately the two month time point.
3081996|NCT02013479|Experimental|SelenoPRECISE|SelenoPRECISE
3081997|NCT02013479|Placebo Comparator|Placebo|Placebo
3081998|NCT02013466|Other|Bolus ONS intake|Bolus ONS A Bolus ONS B Bolus ONS C Bolus ONS D ONS = oral nutritional supplement 4-way cross-over design: Determination of the product order is based on a Latin square design. 3 Latin squares (4x4) are used, resulting in 12 unique product orders. Subjects receive a randomisation number corresponding with 1 of the 12 product orders. Study product labels will contain randomisation number and appropriate visit number.
3081999|NCT02013453|Active Comparator|Observational|Patients on the Observational arm are currently being treated with a proton pump inhibitor (PPIs) such as Omeprazole. They will receive standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
3082000|NCT02013453|Active Comparator|Standard Chemo + Placebo|Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI). They will be randomized to receive placebo along with standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
3082001|NCT02013453|Experimental|Standard Chemo + Omeprazole|Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI). They will be randomized to receive Omeprazole along with standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
3082002|NCT02013427|No Intervention|Observational|Subjects randomized to this arm will be asked to discontinue their current pain medications for the length of the study. This arm is not blinded, as both study staff and participants will be aware that they are not receiving a study treatment.
3082003|NCT02013427|Active Comparator|Naproxen & Omeprazole|Subjects randomized to this arm will be asked to discontinue their current pain medications and take one 500mg naproxen capsule and one 40mg omeprazole capsule twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
3082004|NCT02013427|Placebo Comparator|Placebo Only|Subjects randomized to this arm will be asked to discontinue their current pain medications and take two placebo capsules twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
3082005|NCT02013414|Experimental|Biopsy|
3082006|NCT02013388|Experimental|10 mg|single oral daily dose of 10 mg N91115 for 14 days
3082007|NCT02013388|Placebo Comparator|Placebo|single oral daily dose of placebo for 14 days
3082008|NCT02013388|Experimental|50 mg|single oral daily dose of 50 mg N91115 for 14 days
3082009|NCT02013388|Experimental|50 mg (single dose)|single oral dose of 50 mg N91115
3082010|NCT02013388|Experimental|250 mg|single oral daily dose of 250 mg N91115 for 14 days (fasted)
3082011|NCT02013388|Experimental|250 mg (Fed)|single oral daily dose of 250 mg N91115 for 1 day (fed fat meal)
3082012|NCT02013388|Experimental|500 mg|single oral daily dose of 500 mg N91115 for 14 days
3082013|NCT02013388|Placebo Comparator|Placebo-Day 1 only|Single oral dose of placebo (Day 1 only)
3082014|NCT02013375|Experimental|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
3082015|NCT02013362|Experimental|Pralatrexate injection|Dietary Supplement: Vitamin B12, Folic Acid
3082016|NCT02013349|Other|DESyne Novolimus Eluting CSS|approved device continued access
3082017|NCT02013336|Experimental|MM-398 + cyclophosphamide|
3082018|NCT02013323|Active Comparator|Septilin Group|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing
3082019|NCT02013323|Placebo Comparator|Placebo Group|Subjects in placebo group received Placebo tablets thrice daily for 7 days after Scaling and root planing
3082020|NCT02013310|Experimental|HT-0712 (50mg)|HT-0712 capsules administered once daily.
3082021|NCT02013310|Placebo Comparator|Placebo|Placebo capsules administered once daily.
3082022|NCT02013297|Experimental|SBRT treatment|According to the site to irradiate and to local constraints, SBRT consist in 1 to 8 fractions of 5 to 18 Gy
3082023|NCT02013271||Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
3082024|NCT02013258|Active Comparator|Intranasal oxytocin|Intranasal oxytocin. 16 IU intranasal oxytocin x 5 days. One month interval between arms of treatment.
3082025|NCT02013258|Placebo Comparator|Placebo|Placebo will be administered via nasal spray - 1 spray in each nostril x5 days.
3082026|NCT02013245|Experimental|MTBVAC group 1|Intervention: MTBVAC live vaccine (low dose 5 x 10E03 CFU/0.1mL)
3082027|NCT02013245|Experimental|MTBVAC Group 2|Intervention: MTBVAC live vaccine (middle dose 5 x 10E04 CFU/0.1mL)
3082028|NCT02013245|Experimental|MTBVAC Group 3|Intervention: MTBVAC live vaccine (high dose 5 x 10E05 CFU/0.1mL)
3082029|NCT02013245|Active Comparator|BCG Control Group|Intervention: Commercially available BCG live vaccine (dose 5 x 10E05 CFU/0.1mL)
3082030|NCT02013232|Placebo Comparator|placebo|risperidone plus placebo
3082031|NCT02013232|Experimental|aripiprazole 5mg|risperidone treatment plus aripiprazole 5mg/day
3082032|NCT02013232|Experimental|aripiprazole 10mg|risperidone plus aripiprazole 10mg/day
3082033|NCT02013232|Experimental|aripiprazole 20mg|risperidone plus aripiprazole 20mg/day
3082034|NCT02013219|Experimental|Stage 1: Alectinib and Atezolizumab|In Stage 1, starting dose of atezolizumab will be 1200 mg IV q3w administered on Day 8 of Cycle 1 and on Day 1 (21-day cycle) of each cycle thereafter along with alectinib at a starting dose of 600 mg PO BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter; unless maximum tolerable dose (MTD) is exceeded. The combination will be given to treatment-naive participants with ALK-positive, locally advanced or metastatic NSCLC.
3082035|NCT02013219|Experimental|Stage 1: Erlotinib and Atezolizumab|In Stage 1, starting dose of atezolizumab will be 1200 mg IV q3w administered on Day 8 of Cycle 1 and on Day 1 (21-day cycles) of each cycle thereafter along with erlotinib at a starting dose of 150 mg PO QD, for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter; unless MTD is exceeded. The combination will be given to participants with EGFR TKI treatment-naive, locally advanced or metastatic NSCLC.
3082036|NCT02013219|Experimental|Stage 2: Alectinib and Atezolizumab|In Stage 2, participants received the RP2D on the basis of the MTD or maximum allowed dose (MAD) of the combination treatment established in Stage 1. Treatment-naive participants with ALK-positive, locally advanced or metastatic NSCLC will be included.
3082037|NCT02013219|Experimental|Stage 2: Erlotinib and Atezolizumab|In Stage 2, participants received the RP2D on the basis of the MTD or MAD of the combination treatment established in Stage 1. Previously untreated (or with one prior treatment that was not an EGFR TKI), EGFR mutation positive, locally advanced or metastatic NSCLC participants will be included.
3082038|NCT02013206|Experimental|Never Smokers|Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib [Tarceva] 150 mg orally daily until disease progression or unacceptable toxicity.
3082072|NCT02013011|Active Comparator|recruitment maneuver and PEEP|apply recruitment maneuver and positive end expiratory pressure (PEEP) 5 centimeter of water (cmH2O) after induction of anesthesia
3082039|NCT02013206|Experimental|Current/Former Smokers|Current Smokers (participants who smoked > 100 cigarettes in entire lifetime and either quit smoking < 1 year ago or were currently smoking) or Former Smokers (participants who smoked > 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib [Tarceva] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity.
3082040|NCT02013193|Experimental|Ranger(TM) Paclitaxel-coated balloon|Index lesion treated with Ranger(TM) Paclitaxel-coated PTA balloon catheter (Ranger DCB)
3082041|NCT02013193|Active Comparator|uncoated PTA balloon|Index lesion treated with an uncoated standard PTA dilatation balloon catheter selected upon investigator´s discretion
3082042|NCT02013180||prostate cancer|prostate adenocarcinoma in pathologic evaluation
3082043|NCT02013180||control|benign prostatic diseases in pathologic evaluation
3082044|NCT02013167|Experimental|Blinatumomab|"Participants received blinatumomab by continuous intravenous infusion (CIVI) over 4 weeks followed by a 2 week treatment-free interval for 2 induction cycles. Participants who achieved a bone marrow response, complete remission, or complete remission with partial or incomplete hematologic recovery (CR/CRh*/CRi) within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.~Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive blinatumomab for an additional 12 months (4 cycles), where 1 cycle consisted of 4 weeks of CIVI followed by an 8-week treatment-free period.~The initial dose of blinatumomab was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 through day 29 and for all subsequent cycles."
3082045|NCT02013167|Active Comparator|Standard of Care Chemotherapy|"Participants received one of four prespecified, investigator-chosen chemotherapy regimens for 2 induction cycles. Participants who achieved a bone marrow response, CR/CRh*/CRi within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of SOC chemotherapy.~Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive SOC therapy for an additional 12 months."
3082046|NCT02013154|Experimental|Part A: DKN-01 (Dose Escalation)|Escalating dose of 150 milligrams (mg) up to 300 mg of DKN-01 administered on days 1 and 15 and 80 milligrams per meter squared of body surface area (mg/m2) of paclitaxel administered on days 1,8,15, and 22
3082047|NCT02013154|Experimental|Part B: DKN-01 (Dose Confirmation)|Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
3082048|NCT02013154|Experimental|Part C: DKN-01 (Cohort Expansion)|Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction adenocarcinoma patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
3082049|NCT02013154|Experimental|Part D: DKN-01 (Cohort Expansion)|Dose of DKN-01 determined in Part A will be administered to esophageal squamous cell cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
3082050|NCT02013154|Experimental|DKN-01 Monotherapy Substudy|Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction cancer patients on Days 1 and 15
3082051|NCT02013154|Experimental|Part E: DKN-01 (Cohort Expansion)|Dose of DKN-01 determined in Part A will be administered to gastric adenocarcinoma with Wnt signaling alteration cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
3082052|NCT02013154|Experimental|Part F DKN-01 (Dose Escalation+Expansion)|Escalating dose on 150mg up to 300 mg of DKN-01 administered to patients with recurrent or metastatic esophageal cancer, gastroesophageal junction cancer or gastric adenocarcinoma with Wnt signaling alterations on days 1 and 15 and 200 mg of pembrolizumab administered on day 1 of a 21 day cycle
3082053|NCT02013141|Experimental|Telavancin|Telavancin 10 mg/kg IV administered over one hour one time.
3082054|NCT02013128|Experimental|Ublituximab + ibrutinib|Ublituximab: IV infusion dose Days 1, 8 and 15 followed by maintenance infusions Ibrutinib: Fixed oral daily dose
3082055|NCT02013115|No Intervention|Cursurf|The baby with respiratory distress syndrome was given Cursurf through intubation.
3082056|NCT02013115|Experimental|Cursurf and Budesonide|The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation.
3082057|NCT02013102|Experimental|Arm Ⅰ|Decitabine Injection 20mg/m2/d*5d, IV> 1h, one cycles per 4 weeks.
3082058|NCT02013102|Experimental|Arm Ⅱ|Decitabine Injection 12mg/m2/d*8d, IV> 1h, one cycles per 4 weeks.
3082059|NCT02013089|Experimental|Erlotinib or Gefitinib|Erlotinib 150 mg tablet or Gefitinib 250 mg tablet by mouth every day
3082060|NCT02013089|Experimental|Everolimus|Everolimus 10 mg orally once daily every day
3082061|NCT02013089|Experimental|Imatinib|Imatinib 400 mg tablet orally per day
3082062|NCT02013089|Experimental|Sorafenib or Sunitinib|Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day
3082063|NCT02013089|Experimental|Vandetanib|Vandetanib 300 mg orally once daily
3082064|NCT02013089|No Intervention|Control|No intervention was performed for patients without any gene alternation or without any available target agents
3082065|NCT02013076||Oral corticosteroids (OCS)|"All patients receive:~Prednisone or Prednisolone at 1 mg/kg (in 1 site) or 2 mg/kg (in all other sites) (max. 50 mg); if vomiting prednisone/prednisolone: they receive dexamethasone (0.3 mg/kg, max. 10 mg)~2 to 3 doses of salbutamol within the first hour of therapy according to severity Those with severe exacerbations receive 3 treatments with salbutamol and ipratropium bromide within the initial hour of therapy."
3082066|NCT02013050|Placebo Comparator|Placebo|Control
3082067|NCT02013050|Experimental|SGX942|Investigational Drug i) 1.5 mg/kg ii) 3.0 mg/kg iii) 6.0 mg/kg
3082068|NCT02013037|Experimental|Eculizumab|Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.
3082069|NCT02013037|No Intervention|Historical Cohort|A historical cohort of heart transplant recipients at Cedars-Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, who have not received Eculizumab intervention.
3082070|NCT02013024|Active Comparator|cryopreservation technique|slow freezing cryopreservation technique
3082071|NCT02013024|Active Comparator|vitrification cryopreservation technique|vitrification cryopreservation technique
3082073|NCT02013011|Active Comparator|PEEP|apply positive end expiratory pressure (PEEP) 5 cmH2O after induction of anesthesia
3082074|NCT02012998|Experimental|HBVAXPRO Challenge dose|HBVAXPRO 5µg
3082075|NCT02012985|Experimental|Oxabact OC5 capsules|The active study drug consists of Oxalobacter formigenes OC5 in enteric-coated size-4 capsules. The dose (not less than (NLT) 1E+09 colony forming units (CFU)) will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks.
3082076|NCT02012985|Placebo Comparator|Placebo capsules|The placebo study drug consists of microcrystalline cellulose in enteric-coated size-4 capsules. It has been manufactured to mimic the OC5 capsule. The dose will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks.
3082077|NCT02012972||NCD Risks|Study subjects with NCD risks or disease at enrollment. Each of these subjects will have a Referral for NCD care
3082078|NCT02012972||No NCD Risks|Study subjects without NCD risks or disease at enrollment.
3082079|NCT02012959|Experimental|Tolvaptan Early Withdrawal|"All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment.~At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 millimoles/liter [mmol/L]) were randomized to either the Early or Late Withdrawal Group. Non-responders could continue treatment with tolvaptan for an additional 2 days.~Discontinued tolvaptan treatment immediately after randomization.~All participants were observed up to 14 days post randomization."
3082080|NCT02012959|Experimental|Tolvaptan Late Withdrawal|"All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment.~At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 mmol/L) were randomized to either the Early or Late Withdrawal Group in Treatment Phase B. Non-responders could continue treatment with tolvaptan for an additional 2 days.~Continued treatment for 2 additional days.~All participants were observed up to 14 days post randomization."
3082081|NCT02012946|Active Comparator|dobutamine|patient receiving dobutamine
3082082|NCT02012946|Active Comparator|Levosimendan|patient receiving levosimendan
3082083|NCT02012920|Experimental|Single Failure of Abiraterone or Enzalutamide|Seviteronel: given orally once daily in 28 day cycles
3082084|NCT02012920|Experimental|Double Failure of Abiraterone and Enzalutimide|Seviteronel: given orally once daily in 28 day cycles
3082085|NCT02012894||Obese patients with preoperative GER|Obese patients selected for laparoscopic sleeve gastrectomy with preoperative GER at 24 H pH-monitoring (Group A)
3082086|NCT02012894||Obese patients without preoperative GER|Obese patients selected for laparoscopic sleeve gastrectomy without preoperative GER at 24 H pH-monitoring (Group B)
3082087|NCT02012881|Experimental|Physical activity intervention|60 minutes of physical activity on every school day
3082088|NCT02012881|Active Comparator|Control|Usual practice
3082089|NCT02012868||bariatric surgery, obstructive sleep apnoea|bariatric surgery
3082090|NCT02012855|Experimental|Exercise only|90 minutes of exercise
3082091|NCT02012855|Experimental|Exercise and high glycemic index meal|90 minutes of exercise followed by a high glycemic index meal matched for calories expended during the exercise
3082092|NCT02012855|Experimental|Exercise and low glycemic index meal|90 minutes of exercise followed by a low glycemic index meal matched for calories expended during the exercise
3082093|NCT02012855|No Intervention|No exercise and no meal|No exercise and no meal
3082094|NCT02012842|Active Comparator|Immediate periodontal treatment|Strict supragingival plaque control and non surgical periodontal treatment immediately after the baseline examination(test group).
3082095|NCT02012842|Other|Delayed periodontal treatment|Strict plaque control and non surgical periodontal treatment 6 months after the baseline examination (control group).
3082096|NCT02012829|No Intervention|control group|GPs from practices in the control group are asked to continue their usual care, as if they were not participating in this trial. They had to send their patients list to the research team to calculate their eligible population. They were also asked to list all the gaiac Fecal occult blood test ( gFOBT) delivered during the six months period of the study.
3082097|NCT02012829|Active Comparator|intervention|GPs communication skills and CRC screening :the intervention was a four hours educational training for GPs of the intervention group focused on communication skills with a patients' centered care approach to improve patients participation at CRC screening
3082098|NCT02012816|Other|Uncircumcised men|The program allows each man coming for circumcision to refer up to 5 uncircumcised men in their social network for VMMC services and receive a monetary reward for each successful referral.
3082099|NCT02012803|Experimental|Operative treatment|
3082100|NCT02012803|Active Comparator|conservative treatment|
3082101|NCT02012790|Experimental|Diet A|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
3082102|NCT02012790|Experimental|Diet B|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
3082103|NCT02012790|Active Comparator|Diet C|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
3082104|NCT02012777|Active Comparator|cohort 1 10mg propranolol|"first study arm will consist of 5 subjects who will be administered a dose of 10mg propanolol and followed 1-4 weeks.~Data safety and monitoring committee has reviewed the data for safety and instructed the study to continue based on the findings."
3082105|NCT02012777|Active Comparator|cohort 2 20mg propranolol|This cohort will involve the administration of 5 subjects with 20mg propanolol. The data safety and monitoring committee will review the data for safety when the 5 subjects are recruited and instruct the study to continue depending on the findings.
3082106|NCT02012777|Active Comparator|cohort 3 40mg propranolol|This cohort will involve the administration of 10 subjects with 40mg propanolol. The data safety and monitoring committee will review the data for safety when the 10 subjects are recruited and instruct the study to continue depending on the findings.
3082107|NCT02012764||Musculoskeletal symptoms - Pre diagnosis|Patients presenting with non-specific musculoskeletal complaints at risk of development of RA.
3082108|NCT02012751|Experimental|Nevus doctor program|Use of Nevus doctor program to assess the diagnostic category of pigmented skin lesions
3082109|NCT02012738|Active Comparator|Assignment to FORNET|17 participants were randomly assigned to FORNET
3082110|NCT02012738|Active Comparator|Assignment to CBT|14 participants were randomly assigned to CBT
3082111|NCT02012738|Other|Waiting List Control Group (camp)|7 participants were randomly assigned to the Waiting List Control Group (camp)
3082112|NCT02012738|Other|Waiting List Control Group (no camp)|36 participants were assigned to the Waiting List Control Group (no camp)
3082113|NCT02012725||Arm 1 Mycardial Fibrosis|MRI with Intravenous administration of gadolinium
3082114|NCT02012725||Arm 2 Chronic Kidney Disease|MRI with no gadolinium administration
3082115|NCT02012712|Experimental|Personal Health Record (PHR)|Subjects were sent an invitation to use an online Personal Health Record (PHR)
3082116|NCT02012712|No Intervention|Usual care|Subjects received usual care (no invitation or access to the study PHR)
3082117|NCT02012686|Placebo Comparator|Control group|numerical rating scale of TENS non-applied group
3082118|NCT02012686|Active Comparator|TENS group|numerical rating scale of TENS applied group
3082119|NCT02012673|Experimental|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system
3082120|NCT02012660||Hyponatremia, seasonality|Summer months = June, July, August Winter months = December, January, February
3082121|NCT02012647|Active Comparator|People with Parkinsons Disease|Participants have been diagnosed with Parkinson's Disease, and as recommended by their physicians, have undergone DBS surgery for both sides of the brain. These participants will undergo TMS and motor physiology testing, and results will be compared to participants without Parkinson's Disease.
3082122|NCT02012647|Placebo Comparator|Healthy Controls|These participants do not have Parkinson's Disease, nor have they had DBS surgery, and are a healthy controls. These participants will undergo TMS and motor physiology testing, and results will be compared to participants with Parkinson's Disease.
3082123|NCT02012608|Active Comparator|Glutamine|Powdered Glutamine, 10.0 grams by mouth three times a day (TID) for 30 days, so that daily dose is 30 grams per day
3082124|NCT02012608|Placebo Comparator|Placebo|Powdered Dextrose, 8.33 grams by mouth TID for 30 days, so that daily dose is 25 grams per day
3082125|NCT02012595||Parkinson's patients|Participants with Parkinson's Disease
3082126|NCT02012595||Healthy Controls|Healthy participants
3082127|NCT02012582|Experimental|VAS203 15 mg/kg|Three 5 mg/kg/12-hours infusion with 12 hours break after each infusion. Total dose: 15 mg/kg
3082128|NCT02012582|Experimental|VAS203 20 mg/kg|10 mg/kg/24 hours, 48 hour continuous infusion. Total dose: 20 mg/kg
3082129|NCT02012582|Experimental|VAS203 30 mg/kg|10 mg/kg/24 hours, 72 hour continuous infusion. Total dose: 30 mg/kg
3082130|NCT02012582|Placebo Comparator|Saline|0.9 % Sodium chloride infusion
3082131|NCT02012569|Experimental|TT.173|It is applied directly to the bleeding of the donor site
3082132|NCT02012569|Placebo Comparator|placebo|It is applied directly to the bleeding of the donor site
3082133|NCT02012556|Experimental|Tesamorelin|
3082134|NCT02012543|Experimental|Agar jelly, constipation|Subjects eat a cap of agar jelly (180g) shortly before eating dinner every day for 4 weeks.
3082135|NCT02012530|Active Comparator|HA|Patients in this arm will have hyaluronic acid (HA) injected into their knee along with 3 ml local anaesthetic. The HA injection is in the form of 2 ml aqueous sodium hyaluronate. The exact constituents of the HA change in a proprietary manner. All HA injections used will have the CE marking on them.
3082136|NCT02012530|Active Comparator|PRP|Patients in this arm will have platelet rich plasma (PRP) injected into their knee. The PRP sample will be produced at the time of the injection. 30 ml of blood is drawn fro the patient a few minutes before the injection. Using a CE marked differential centrifugation device, the platelets are isolated. This concentrated sample of platelets is injected into the knee after the skin around the injection site is anaesthetised with local anaesthetic.
3082137|NCT02012517|Active Comparator|short antibiotic course|Intravenous 2 gram cefazolin every 8 hours for 24 hours beginning at surgery
3082138|NCT02012517|Experimental|Prolonged antobiotic treatment|Intravenous 2 gram cefazolin every 8 hours for 48 hours starting at surgery followed by oral cefalexin 500 mg every 6 hours until removal of drains
3082139|NCT02012504||Western medicine|venlafaxine or escitalopram
3082140|NCT02012504||Chinese medcine|Shuganjieyu capsule
3082141|NCT02012491|Active Comparator|misoprostol plus mifepristone|800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior
3082142|NCT02012491|Active Comparator|misoprostol|800 micrograms of vaginal misoprostol alone
3082143|NCT02012478|No Intervention|No intervention|baseline session - with surveys and HbA1C only
3082144|NCT02012478|Experimental|MI-informed SMS intervention|Baseline session with surveys & HbA1C MI baseline session Technology tutorial Intervention x 3 months
3082145|NCT02012465|Experimental|Insulin protocol|"For diabetic patients, as part of the initial chemotherapy orders on admission, the following will be calculated by the primary oncologist to determine the amount of neutral protamine Hagedorn (NPH) insulin needed to cover steroid use in prednisone equivalents (all insulin in this study is to be administered subcutaneously):~Use 0.1 (mg of prednisone equivalent - 20)/20 x weight (kg) to estimate total insulin in 24 hours (Total daily dose (TDD))~Total daily NPH dose will be divided equally based on the frequency of steroid administration, and given with each steroid dose.~For nondiabetic participants with hyperglycemia recruited during admission, the inpatient oncology team will consult the endocrine team within 24 hours of eligibility for NPH dosing as above."
3082146|NCT02012452|Experimental|tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
3082147|NCT02012452|Sham Comparator|health education treatment|Participants will be provided education on a variety of health topics and will set health goals around each topic
3082148|NCT02012439|Active Comparator|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
3082149|NCT02012439|Active Comparator|Cognitive therapy|Cognitive Therapy
3082150|NCT02012426|Experimental|Intervention Group|Participants enrolled in commercial weight management program
3082151|NCT02012426|Active Comparator|Control group|Participants enrolled in standard care weight management provision
3082191|NCT02012205|Experimental|wet cupping|patient will receive wet cupping
3082152|NCT02012413|Active Comparator|PST group|roughly 20 patients will be treated with PST protocol, outcomes will be Kujala score improvement at 3, 6 and 12 months.
3082153|NCT02012413|Placebo Comparator|Control group|roughly 20 patients will be submitted to a placebo PST protocol, outcomes will be Kujala score improvement at 3, 6 and 12 months.
3082154|NCT02012400|Experimental|Intervention group|
3082155|NCT02012400|No Intervention|Control group|
3082156|NCT02012387|Active Comparator|Active|Omalizumab 300 mg Subcutaneous route 300 mg dose (independent from total IgE, weight or high)
3082157|NCT02012387|Placebo Comparator|Placebo|Placebo Saline serum Subcutaneous route 0.6 ml saline serum with same volume as an active treatment
3082158|NCT02012387|Active Comparator|Open labeled|After the double blinded period, all patients from both arms will receive the active drug for 8 more months.
3082159|NCT02012374|Experimental|"Intensive Language Action Therapy (constrained)"|Following a phase of baseline pre-treatment testing, speech therapy sessions take place 5 days/week for 3 hours per session during two consecutive weeks. Spoken responses are explicitly modeled and encouraged during therapy. Following the intensive 2-week treatment, participants are trained in using individualized home practice programs on iPads. They practice approximately daily for six months, checking in weekly with an SLP via videoconferencing software and return for probes monthly. Six months post-treatment testing will take place following completion of the home practice phase and again at 12 months post-treatment.
3082160|NCT02012374|Experimental|Unconstrained Intensive Language Action Therapy|Following a phase of baseline pre-treatment testing, speech therapy sessions take place 5 days/week for 3 hours per session during two consecutive weeks. All communicative responses are encouraged during therapy. Following the intensive 2-week treatment, participants are trained in using individualized home practice programs on iPads. They practice approximately daily for six months, checking in weekly with an SLP via videoconferencing software and return for probes monthly. Six months post-treatment testing will take place following completion of the home practice phase and again at 12 months post-treatment.
3082161|NCT02012361|Active Comparator|Control Group|This group will be treated as any other patient would. Their anesthesia will be conducted as per routine with a target Fraction of inspired oxygen concentration (FiO2) of 0.25. During the course of the operation a small muscle biopsy will be collected.
3082162|NCT02012361|Active Comparator|Single-Dose Heliox Group|This group will be treated with a single dose of inspired 75/25 heliox (75% helium 25% oxygen) breathed continuously for 15 minutes prior to the inflation of the surgical tourniquet. During the course of the operation a small muscle biopsy will be collected.
3082163|NCT02012348|Placebo Comparator|Control soap|Forearms of subjects in this arm will be washed with control (non-antibacterial) soap
3082164|NCT02012348|Experimental|Antibacterial soap with triclocarban|The forearms of subjects in this group will be washed with antibacterial soap containing triclocarban
3082165|NCT02012348|Active Comparator|Antibacterial soap + benzalkonium chloride|The forearms of subjects in this group will be washed with antibacterial soap containing benzalkonium chloride
3082166|NCT02012335|Placebo Comparator|ECT + saline|Brief pulse ECT with saline as placebo in each session
3082167|NCT02012335|Experimental|ECT + Ketamine|Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
3082168|NCT02012322|Other|Placebo vs. Q10 100mg vs. Q10 300mg|
3082169|NCT02012322|Other|Placebo vs. Q10 300mg vs. Q10 100mg|
3082170|NCT02012322|Other|Q10 100mg vs. Placebo vs. Q10 300mg|
3082171|NCT02012322|Other|Q10 100mg vs. Q10 300mg vs. Placebo|
3082172|NCT02012322|Other|Q10 300mg vs. Placebo vs. Q10 100mg|
3082173|NCT02012322|Other|Q10 300mg vs. Q10 100mg vs. Placebo|
3082174|NCT02012309|Experimental|HIV-seronegative|HIV-seronegative subjects will receive Prevnar (PCV-13) at week 0.
3082175|NCT02012309|Experimental|HIV-infected|HIV-infected subjects will receive Prevnar (PCV-13) at week 0, and Pneumovax (PPSV-23) at week 8 per Advisory Committee on Immunization Practices (ACIP) guidelines.
3082176|NCT02012296|Active Comparator|Treatment (enzalutamide)|Patients receive enzalutamide PO per standard of care.
3082177|NCT02012296|Experimental|Treatment (enzalutamide, mifepristone)|Patients receive enzalutamide PO and mifepristone PO.
3082178|NCT02012283|Experimental|High restraint male eaters|Since degree of restrained eating can affect food consumption, the Three Factor Eating Questionnaire version R21 (Cappeleri, 2009) will be completed to assess the degree of restrained eating characteristic of the subjects studied.
3082179|NCT02012283|Experimental|High restraint female eaters|Since degree of restrained eating can affect food consumption, the Three Factor Eating Questionnaire version R21 (Cappeleri, 2009) will be completed to assess the degree of restrained eating characteristic of the subjects studied.
3082180|NCT02012283|Experimental|Low restraint male eater|Since degree of restrained eating can affect food consumption, the Three Factor Eating Questionnaire version R21 (Cappeleri, 2009) will be completed to assess the degree of restrained eating characteristic of the subjects studied.
3082181|NCT02012283|Experimental|Low restraint female eater|Since degree of restrained eating can affect food consumption, the Three Factor Eating Questionnaire version R21 (Cappeleri, 2009) will be completed to assess the degree of restrained eating characteristic of the subjects studied.
3082182|NCT02012270||Conventional Group|Group of patients in whom after open AAA repair abdominal wall will be closed by conventional technique by the operating surgeons. There will be a great variation in sutures and techniques used
3082183|NCT02012270||PRINCIPLES Group|Group of patients in whom after open AAA repair abdominal wall will be closed by PRINCIPLES technique by the operating surgeons.
3082184|NCT02012257|Experimental|Anterior Site|AMSA nerve block injection
3082185|NCT02012257|Experimental|Common Site|AMSA nerve block injection
3082186|NCT02012257|Experimental|Posterior Site|AMSA nerve block injection
3082187|NCT02012244|Experimental|fentanyl-based analgesia|fentanyl intravenous patient-controlled analgesia + additional pethidine
3082188|NCT02012244|Experimental|local anesthetic wound infiltration-based anlagesia|continuous wound inflitration with ropivacaine + tramadol intravenous patient-controlled analgesia + additional ketorolac or propacetamol
3082189|NCT02012231|Experimental|Dose Escalation|Cohort 1/Day -7 = 300 mg/day PLX8394; Cohort 1/Day 1 = 900 mg/day PLX8394
3082190|NCT02012218|Experimental|ADT and Brexpiprazole|ADT and Brexpiprazole
3082193|NCT02012192|Experimental|Ganetespib + Paclitaxel|Drug: ganetespib, dose will depend on phase I results, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle); Drug: paclitaxel, 80 mg/m2, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle), until progression.
3082194|NCT02012192|Active Comparator|Paclitaxel|Drug: paclitaxel: 80 mg/m2, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle), until progression
3082195|NCT02012179|Experimental|Low sodium diet|Low sodium diet (65 mmol or 1500 mg/day)
3082196|NCT02012179|No Intervention|Usual Care|General advice to limit dietary sodium as it is provided during routine clinic practice
3082197|NCT02012166|Experimental|MK-0893 40 mg→MK-0893 200 mg→placebo|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
3082198|NCT02012166|Experimental|MK-0893 200 mg→placebo→MK-0893 10 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
3082199|NCT02012166|Experimental|Placebo→MK-0893 10 mg→MK-0893 40 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
3082200|NCT02012166|Experimental|MK-0893 10 mg→MK-0893 40 mg→MK-0893 200 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
3082201|NCT02012166|Experimental|Placebo→MK-0893 1000 mg→MK-0893 200 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
3082202|NCT02012166|Experimental|MK-0893 200 mg→placebo→MK-0893 1000 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
3082203|NCT02012166|Experimental|MK-0893 1000 mg→MK-0893 200 mg→placebo|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
3082204|NCT02012153|Experimental|Mesenchymal Stromal Cells|"A single intravenous infusion of ex-vivo expanded autologous MSCs will be performed in patients in addition to the living-donor kidney transplantation.~2x10 elevated to sxth power MSCs per kilogram body weight previously isolated from the same recipient will be infused intravenously the day before the kidney transplant procedure."
3082205|NCT02012140|Experimental|Ticagrelor|As per ACC/AHA and ESC guidelines 180 mg is the recommended LD. The ticagrelor 90 mg BID dose, following the loading dose, has been selected for the clopidogrel naïve patients with stable angina, NSTEMI and STEMI patients undergoing PCI as the maintenance dose for this study since it is the FDA recommended dose.
3082206|NCT02012127||Acromegalic patients|
3082207|NCT02012114|No Intervention|Cysteamine Bitartrate|Single arm study. Subjects receive their current oral form of cysteamine bitartrate treatment : Cystagon® or RP103
3082208|NCT02012101|Experimental|niv plus oxygen therapy|oxygen therapy is given during the whole experimental process, niv is given at peak exercise until the borg scale reaches it's baseline point
3082209|NCT02012101|Active Comparator|oxygen therapy|oxygen therapy is given during the whole experimental process
3082210|NCT02012088|Experimental|RCOMP|"R-COMP Regimen:~Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles"
3082211|NCT02012088|Active Comparator|RCHOP|"R-CHOP Regimen:~Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles"
3082212|NCT02012075|Experimental|Extended-Release Carvedilol Sulfate|18-72mg/d,po
3082213|NCT02012075|Active Comparator|Sustained-release Metoprolol Succinate|11.875-190mg/d,po
3082214|NCT02012062|Active Comparator|Arm Cisplatin|Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by cisplatin 40 mg/m2/week in concurrent with IMRT
3082215|NCT02012062|Experimental|Arm Nimotuzumab|Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by weekly nimotuzumab 200mg in concurrent with IMRT
3082216|NCT02012049|Experimental|Risperdal OD / Risperdal Quicklet|Risperdal OD (investigational drug) + Risperdal Quicklet (control drug)
3082217|NCT02012049|Experimental|Risperdal Quicklet / Risperdal OD|Risperdal Quicklet (control drug) + Risperdal OD (investigational drug)
3082218|NCT02012036||TUR-B|TUR-B in patients suspected to have non-muscle-invasive bladder cancer (NMIBC).
3082219|NCT02012023|Experimental|Controllable tube ileostomy|After LAR, the experimental group accepted controllable tube ileostomy.
3082220|NCT02012023|Active Comparator|Loop ileostomy|After LAR, the experimental group accepted loop ileostomy.
3082221|NCT02012010|Experimental|Manual syringe infusion method|Infuse the distension medium of hysteroscopy by manual syringe infusion method
3082222|NCT02012010|Active Comparator|Pump infusion method|Infuse the distension medium of hysteroscopy by pump infusion method
3082223|NCT02011997|Experimental|segmentectomy|Patients undergo cVATS (complete Video-assisted Thoracoscopic Surgery) segmentectomy
3082224|NCT02011997|Active Comparator|Lobectomy|Patients undergo cVATS lobectomy
3082225|NCT02011984||peripheral artery disease|de novo stenotic lesions in superficial femoral artery
3082226|NCT02011971|Active Comparator|Low dose|Vinpocetine 10 mg Healthy subjects
3082227|NCT02011971|Active Comparator|Mid-dose 1|Vinpocetine 20mg Healthy subjects
3082228|NCT02011971|Placebo Comparator|Placebo|0 dose of vinpocetine Healthy and Epilepsy subjects
3082229|NCT02011971|Active Comparator|High Dose|Vinpocetine 60 mg single dose Healthy Subjects & 20mg tid Epilepsy Subjects
3082230|NCT02011958|Experimental|Liposomal Amphotericin B / Miltefosine|"Liposomal Amphotericin B : 30mg/kg total dose: IV infusion 5mg/kg per day on day 1, 3, 5, 7, 9, 11~Miltefosine: orally taken every day during 28 days~1 x 50 mg capsule per day if patient weights less or equal to 25 kg~2 x 50 mg capsules per day if the patient weights more than 25 kg"
3082231|NCT02011958|Experimental|Liposomal Amphotericin B|Liposomal Amphotericin B: 40 mg/kg total dose : IV infusion of 5mg/kg per day on day 1 to 5, 10, 17, 24
3082232|NCT02011945|Experimental|Arm 1: Dasatinib + Nivolumab|"Dose Escalation Phase:~Dasatinib [100 mg Chronic Phase (CP) OR 140 mg Accelerated Phase (AP)] Tablet orally, once daily (QD), maximum 2 years of administration of the combination Dasatinib plus Nivolumab and up to maximum 1 year of single agent Dasatinib after last dose of Nivolumab~Nivolumab (Dose level -1: 0.3 mg/kg, Dose level 1: 1 mg/kg, Dose level 2: 3 mg/kg) Intravenous (IV) Injection every 2 weeks (q 2 weeks) maximum 2 years of administration of the combination Dasatinib plus Nivolumab and up to maximum 1 year of single agent Dasatinib after last dose of Nivolumab~Expansion Phase:~Dasatinib: Same as in Dose Escalation phase~Nivolumab: Dose selected on the basis of safety determination Dose Escalation Phase"
3082233|NCT02011932||Healthy volunteers|
3082234|NCT02011932||Chronic hepatitis C|
3082235|NCT02011919|Other|Echopulse|Echopulse HIFU
3082236|NCT02011906|Active Comparator|CAD, OMEGA 3|patients with CAD who receive 4 gr/day omega 3 in the form of 4 softgels each of them contains 1000 mg omega 3 and a softgel contains placebo of vitamin E
3082237|NCT02011906|Active Comparator|CAD, omega 3 and vitamin E|patients with CAD who receive 4 gr/day omega 3 in the form of 4 softgels each of them contains 1000 mg omega 3 and a softgel contains 400 IU vitamin E
3082238|NCT02011906|Placebo Comparator|CAD, placebo|patients with CAD who receive 4 softgels/day each of them contains placebo of omega 3 and a softgel/day contains placebo of vitamin E
3082239|NCT02011893|Experimental|Burst Stimulation|Burst Stimulation using the Prodigy system
3082240|NCT02011893|Active Comparator|Tonic Stimulation|Tonic Stimulation using the Prodigy system
3082241|NCT02011867|Experimental|Cork Electrode|Using Cork Electrode for CSF leak prevention for inner ear malformations.
3082242|NCT02011854|Experimental|Acupuncture with rehabilitation|Electric acupuncture,Chinese medicine,Chinese medicine cupping,rehabilitation,To treat five times a week,Total course is eight weeks
3082243|NCT02011854|Other|rehabilitation|rehabilitation,To treat five times a week,Total course is eight weeks
3082244|NCT02011841|Experimental|Rifaximin group|Rifaximin 1200 mg/day orally for 6 months
3082245|NCT02011841|Active Comparator|Control group|Ciprofloxacin 500 mg/day orally for 6 months
3082246|NCT02011828|Experimental|Ergocalciferol, then Placebo|Participants first receive Ergocalciferol 50,000 international units (IU)/week for the first 12 weeks. After a 4 week wash-out period, they then receive matching placebo treatment for 12 weeks.
3082247|NCT02011828|Experimental|Placebo, then Ergocalciferol|Participants first receive placebo treatment (matching ergocalciferol 50,000 IU/week) for the first 12 weeks. After a 4 week wash-out period, they then receive ergocalciferol 50,000 IU/week treatment for 12 weeks.
3082248|NCT02011815||Breast cancer|Diagnosed breast cancer patients who are getting chemotherapy for the first time.
3082249|NCT02011802|Active Comparator|Algosteril TM|Calcium alginate dressings are made from seaweed. Calcium alginate dressings form a natural gel of the exudates against the healing tissue that keeps it moist and supple, aiding in healing and tissue growth. In addition, this gel material forms a natural barrier to bacteria that may complicate healing with secondary infections of the wound. Alginates are the reference of dressing after sinus pilonidal excision.
3082250|NCT02011802|Experimental|Sorbact TM|DACC (dialkylcarbamoyle chloride) is a main component of the bacterial binding wound dressing: Sorbact. DACC is a hydrophobic fatty acid derivative that can be used to coat dressing materials, resulting in a dressing with highly hydrophobic pathogen binding properties. This is a primary wound interface dressing and is effective when in close contact with the wound bed in a moist environment.
3082251|NCT02011789|Experimental|Group1|Group 1 consumes Placebo beverage for 56 days followed by Citrus Limonoid Beverage for 56 days.
3082252|NCT02011789|Active Comparator|Group 2|Group 2 consumes Citrus Limonoid Beverage for 56 days followed by Placebo beverages for 56 days
3082253|NCT02011776||Group 1|using the 0.1% fluorometholone eye drops combined with the 0.1% sodium hyaluronate eye drops
3082254|NCT02011776||Group 2|using the 0.5% cyclosporin A eye drops combined with 0.1% sodium hyaluronate eye drops
3082255|NCT02011763|Experimental|Study Group|Toddlers, children and adolescents aged 12 months to 15 years
3082256|NCT02011750|Experimental|Sodium Valproate treatment|Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment grou, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
3082257|NCT02011750|Placebo Comparator|Placebo|Placebo Comparator: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
3082258|NCT02011737|Active Comparator|Naftopidil|Naftopidil 75mg once daily
3082259|NCT02011737|Placebo Comparator|Placebo|Placebo once daily
3082260|NCT02011724|Experimental|Apligraf|
3082261|NCT02011711||Mirena|Women interested in beginning use of Mirena
3082262|NCT02011711||Depot-medroxyprogesterone acetate|Women interested in beginning use of depot-medroxyprogesterone acetate
3082263|NCT02011711||Oral Contraception|Women interested in beginning use of oral contraception
3082264|NCT02011698|Experimental|absorbable sutures|mesh fixation with absorbable sutures in lichtenstein anterior inguinal herniorrhaphy
3082265|NCT02011698|Active Comparator|non absorbable sutures|mesh fixation with non absorbable sutures in lichtenstein anterior inguinal herniorrhaphy. This is the method to be considered the standard of care thus far.
3082266|NCT02011698|Experimental|fibrin biological glue|mesh fixation with fibrin biological glue in lichtenstein anterior inguinal herniorrhaphy
3082267|NCT02011685|Active Comparator|Home BP Telemonitoring (HBPTM)|Participants will take home BP readings 3 days per week (morning and evening) for one week out of each month during the 12-month intervention.
3082268|NCT02011685|Experimental|HBPTM + Nurse Case Management (NCM)|Participants will complete the same Home BP Telemonitoring protocol and will also complete 20 counseling phone calls with a nurse case manager during the 12-month intervention.
3082269|NCT02011672|Experimental|nutrient-enriched milk|consumption of 250 ml three times per day
3082270|NCT02011672|Placebo Comparator|regular milk|consumption of 250 ml three times per day
3082271|NCT02011659|Active Comparator|Ramosetron|
3082272|NCT02011646|Experimental|Healthy Weight|intervention four times per week and consist of approximately 10 participants.
3082273|NCT02011646|Active Comparator|Controlled Intervention|Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web.
3082274|NCT02011633|Experimental|HCP1201, Part 1|Participants received a single oral dose of the HCP1201 500/10 mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3082275|NCT02011633|Active Comparator|Metformin and Rosuvastatin, Part1|Participants received a single oral dose of coadministration of Metformin SR 500 mg and Rosuvastatin 10 mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3082276|NCT02011633|Experimental|HCP1201, Part 2|Participants received a single oral dose of the HCP1201 500/10mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3082277|NCT02011633|Active Comparator|Metformin and Rosuvastatin, Part 2|Participants received a single oral dose of coadministration of Metformin SR 500mg and Rosuvastatin 10mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3082278|NCT02011620|Active Comparator|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
3082279|NCT02011620|No Intervention|Standard care|Standard care - no intervention with nitrates
3082280|NCT02011594|Experimental|Arm A|Nimotuzumab
3082281|NCT02011594|Placebo Comparator|Arm B|Placebo (normal saline)
3082282|NCT02011568|Other|Moderate hypothermia|Therapeutic hypothermia at 31 degrees celsius
3082283|NCT02011568|Active Comparator|Mild Hypothermia|Therapeutic Hypothermia at 34 degrees Celsius
3082284|NCT02011542|Placebo Comparator|Placebo|Placebo (not an active drug/ Inactive component) is given to this group
3082285|NCT02011542|Active Comparator|VSL #3|VSL #3 (probiotic mixture) is given to this group
3082286|NCT02011529|Active Comparator|TEAMcare treatment of diabetes|
3082287|NCT02011529|No Intervention|Treatment as usual|Participants randomized to treatment as usual will receive their usual mental health treatment and primary care treatment
3082288|NCT02011516|Placebo Comparator|Sugar pill, psychosocial intervention|twice weekly appointments with a certified clinician
3082289|NCT02011516|Active Comparator|Baclofen, psychosocial intervention|20 mg. q.i.d. twice weekly appointments with a certified clinician
3082290|NCT02011503|Experimental|dHACM|Application of multi-layer compression therapy with application of dHACM.
3082291|NCT02011503|Other|Control|Application of multi-layer compression therapy without application of dHACM.
3082292|NCT02011490|Experimental|Severe Renal Insufficiency Participants: Part 1|Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
3082293|NCT02011490|Experimental|Moderate Renal Insufficiency Participants: Part 1|Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
3082294|NCT02011490|Experimental|Healthy Control Participants: Part 1|Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
3082295|NCT02011490|Experimental|Severe Renal Insufficiency Participants: Part 2|Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
3082332|NCT02011243||Junior players, women|This group includes junior, female, handball players meeting study inclusion criteria.
3082540|NCT02009826||Schizophrenia patients|Young schizophrenia patients 18-40y
3082296|NCT02011490|Experimental|Moderate Renal Insufficiency Participants: Part 2|Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
3082297|NCT02011490|Experimental|Healthy Control Participants: Part 2|Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
3082298|NCT02011477|Experimental|Neural glide|This technique involves two movements, initial and final. It consists of going from one to the other constantly. The therapist took the subject's head by putting his hands on the suboccipital and front region. In the initial movement, the therapist perform craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject perform dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as perform plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject. The session lasted 7 minutes.
3082299|NCT02011477|Placebo Comparator|Placebo|The model of the ultrasound (ENRAF-NONIUS, P.O. Box 12080, 3004 GB Rotterdam, The Netherlands). The subject was placed in a prone position, with arms along the body and the head in the hole of the examining couch. The therapist applied a non-therapeutic dose of ultrasound for 7 minutes with no break all over the cervical area and trapezius, in circles.
3082300|NCT02011477|Active Comparator|Neural Stretching|In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject . In the final position, the therapist made the subject execute a craniocervical flexion while he pushed the subject's hands against the chest, in order to increase thoracic kyphosis. At the same time, the subject had to raise the elevated leg without separating the popliteal zone in the other knee, while maintaining dorsiflexion of the ankle and a maximum knee extension. The session lasted 7 minutes.
3082301|NCT02011464|Experimental|Exparel infiltration|Exparel infiltrated into the posterior compartment of the knee
3082302|NCT02011464|Placebo Comparator|Control|Saline infiltrated into posterior compartment
3082303|NCT02011451|Experimental|95% Pure ECGC capsules 200mg|95% Pure ECGC capsules 200mg three times a day with food for 6 months
3082304|NCT02011451|Placebo Comparator|Sugar pill|Matched placebo capsules
3082305|NCT02011438|Experimental|UTalk Intervention|Active preventative intervention condition.
3082306|NCT02011438|No Intervention|Control|Education/Support Condition
3082307|NCT02011425|Experimental|mandibular advancement appliance|mandibular advancement appliance (SomnoDent by SomnoMed)
3082308|NCT02011425|No Intervention|without mandibular advancement appliance|no therapy
3082309|NCT02011412||Intermountain Risk Score known|
3082310|NCT02011412||Intermountain Risk Score Unknown|
3082311|NCT02011386||Treatment|Treatment: Injection Golimumab 50 mg every month on the same date
3082312|NCT02011373|Experimental|IFABOND|
3082313|NCT02011360|Other|Low carbohydrate diet|Low carbohydrate diet: 15%carb; 65%fat; 20% protein. This will be administered over 72 hour hospital stay.
3082314|NCT02011360|Other|Low Fat diet|Low fat diet: 65%carb; 15%fat; 20% protein. This will be administered over a 72 hour hospital stay.
3082315|NCT02011347|Experimental|Ketamine|Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Ketamine (bolus dose of Ketamine (0.15 mg.kg-1) followed by an infusion of Ketamine (0.15 mg.kg-1 h-1) until the end of anesthesia)
3082316|NCT02011347|Experimental|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo (NaCl 9/00 (same volume as in the Ketamine group)
3082317|NCT02011334|Experimental|RoActemra/Actemra|
3082318|NCT02011321|Experimental|clevidipine|Four-hour infusion of low-dose intravenous clevidipine in patients with moderate vasospasm after aneurysmal subarachnoid hemorrhage
3082319|NCT02011308|Active Comparator|Green Light Laser|
3082320|NCT02011308|Active Comparator|TURP|Transurethral Resection of the Prostate
3082321|NCT02011295|Other|Microfracture|Procedure/Surgery: ankle arthroscopy with debridement and microfracture of the OLT
3082322|NCT02011295|Other|microfracture + injection of autologous BMAC|Procedure/Surgery: ankle arthroscopy with debridement and microfracture of the OLT plus injection of autologous Bone Marrow Aspirate Concentration
3082323|NCT02011282|Experimental|Electro-Neuro-Muscular Stimulation|Patients will receive daily sessions of electrostimulation with a commercially available device (En-Stimulation 4, Netherlands) in the quadriceps muscle for 10 days
3082324|NCT02011282|No Intervention|Control|Patients in this arm will receive the usual standard treatment
3082325|NCT02011269|Active Comparator|7500 TSO|7500 active Trichuris suis ova will be provided in a15 mL of aqueous suspension (supplied in 30 mL glass containers) administered orally, once every 2 weeks for 10 weeks
3082326|NCT02011269|Active Comparator|15000 TSO|15000 active Trichuris suis ova will be provided in two 15 mL of aqueous suspension (supplied in 30 mL glass containers) administered orally, once every 2 weeks for 10 weeks
3082327|NCT02011269|Placebo Comparator|Non-active treatment|The TSO placebo drug product is a non-sterile, 15 mL aqueous solution containing phosphate buffer, pH 5 and 0.05% potassium sorbate as antimicrobial preservative. The TSO placebo is supplied in two 30 mL glass containers that is identical to the container/closure described above for the active drug product.
3082328|NCT02011256|Experimental|Implantable loop-recorder|
3082329|NCT02011243||Professional players, men|This group includes professional, male, handball players meeting study inclusion criteria.
3082330|NCT02011243||Professional players, women|This group includes professional, female, handball players meeting study inclusion criteria.
3082331|NCT02011243||Junior players, men|This group includes junior, male, handball players meeting study inclusion criteria.
3082610|NCT02009410|Experimental|Creon|
3082333|NCT02011230|No Intervention|Control|Patients in the control group will not be given any special fluids to take after surgery Patients will use their discretion to drink as needed following surgery
3082334|NCT02011230|Experimental|Hoist|Patients in the Hoist group will be given a 10 day supply of Hoist that they will self administer
3082335|NCT02011217|Experimental|Rye crisp bread A|
3082336|NCT02011217|Experimental|Rye crisp bread B|
3082337|NCT02011217|Experimental|Wheat crisp bread C|
3082338|NCT02011204||People with ALS|"People diagnosed with early ALS (possible, probable, probable-laboratory supported or definite ALS according to El Escorial criteria)~Intervention: Electrical Impedance Myography (EIM)."
3082339|NCT02011204||Other Neurological Diseases|People with a diagnosis of a disease that mimics ALS
3082340|NCT02011204||Healthy Controls|Healthy Volunteers that do not have ALS or another neurological disease that mimics ALS.
3082341|NCT02011191|Active Comparator|Biotin|10,000 micrograms biotin daily for 8 weeks
3082342|NCT02011191|Placebo Comparator|Sugar pill|
3082343|NCT02011178|Active Comparator|Optimal medical treatment and surgery|In the study 50 obese patients with CKD 3 andT2DM will be treated using the European Association for Study of Diabetes protocol in combination with RYGB surgery.
3082344|NCT02011178|Other|Optimal medical treatment|In the study 50 obese patients with CKD 3 andT2DM will be treated using the European Association for Study of Diabetes protocol
3082345|NCT02011165||Tennis ball|Night with tennis ball fastened in the back of the night shirt. A positioning measuring device mounted.
3082346|NCT02011165||No tennis ball|Night without tennis ball fastened in the back of the night shirt. A positioning measure device mounted.
3082347|NCT02011139|Active Comparator|Group A|12 sessions of Cognitive-behavioral group therapy in the first 12 weeks
3082348|NCT02011139|Active Comparator|Group B|12 sessions of Cognitive-behavioral group therapy in the second 12 weeks
3082349|NCT02011126|Experimental|Treatment (imetelstat sodium)|Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for up to 36 courses in the absence of disease progression or unacceptable toxicity.
3082350|NCT02011113|Experimental|Pomalidomide plus dexamethasone|
3082351|NCT02011100|Experimental|CARNOSINE|3 months oral carnosine administration in a dose of 2 gram per day, twice a day 1 gram dose (1-0-1)
3082352|NCT02011100|Placebo Comparator|placebo|3 months placebo intake - taken twice a day (1-0-1)
3082353|NCT02011087|Experimental|Diagnostic (bioelectric impedance analysis)|Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment.
3082354|NCT02011048||Giant ventral incisional hernia|Patient with a giant ventral incisional hernia (> 10 cm fascial defect) scheduled to undergo endoscopic components separation.
3082355|NCT02011048||Control group|Patients scheduled to undergo surgery on other indications.
3082356|NCT02011022|Experimental|3g group|The dose of MTX is 3 g/m2
3082357|NCT02011022|Experimental|5g group|The dose of MTX is 5g/m2
3082358|NCT02011009|Experimental|BLSE|The main objective of this study is to measure the carriage of antibiotic-resistant bacteria (enterobacteria ESBLs) in HIV seropositive patients looking for potential factors associated with sexual transmission. As a matter of fact, there is currently a worldwide community epidemic outbreak of enteric bacteria resistant to antibiotics for which the modes of transmission are still not fully known. There are many open questions about the possibility of sexual transmission and this study aims to find an answer.
3082359|NCT02010996|Experimental|Vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
3082360|NCT02010996|Active Comparator|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
3082361|NCT02010983|Experimental|longstanding achalasia|
3082362|NCT02010970|Experimental|Group 1 AZD3293-itraconazole|Subjects from Group 1 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 1, itraconazole will be administered orally twice daily starting on Day 5 for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the morning dose of itraconazole. Group 1 subjects will be discharged on Day 14.
3082363|NCT02010970|Experimental|Group 2 AZD3293-diltiazem|Subjects from Group 2 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 2, diltiazem will be administered orally once daily starting on Day 5, for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the diltiazem dose. Group 2 subjects will be discharged on Day 14.
3082364|NCT02010970|Experimental|Group 3 AZD3293-midazolam|Subjects from Group 3 will receive a single dose of midazolam on Day 1 . AZD3293 will be administered as an oral solution once daily starting on Day 2 for 9 consecutive days (Days 2 to 10) followed by a 7 day wash-out period. On Day 8 and Day 17 a single dose of midazolam will be administered. Group 3 subjects will be discharged on Day 18
3082365|NCT02010957|Experimental|FDG positron emission tomography and Iodometomidate imaging|Combined FDG PET and Iodometomidate imaging prior adrenal surgery of uncertain adrenal neoplasms
3082366|NCT02010944|Experimental|1: FDC-SET-SET|Fixed Dose Combination followed by two periods of the Single Entity Tablets
3082367|NCT02010944|Experimental|2: SET-FDC-FDC|Single Entity Tablets followed by two periods of Fixed Dose Combination
3082368|NCT02010931||primary|subjects who are 18 years or older, who have minimal residual disease detected by PCR at a level of 1/10-3 or higher, who are free form allogeneic stem cell transplantation until hematological relapse or until 18 months after minimal residual disease detection (whichever comes first)
3082369|NCT02010918|Experimental|glucosamine sulfate /chondroitin sulfate capsule|500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
3082370|NCT02010918|Experimental|glucosamine sulfate /chondroitin sulfate - sachet|1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
3082371|NCT02010918|Active Comparator|Cosamin DS®|500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
3082611|NCT02009410|Placebo Comparator|Placebo|
3082372|NCT02010905|Active Comparator|Losartan 150mg daily|Losartan: white film-coated biconvex tablet (50mg) with a diameter of 8mm. One time daily three tablets.
3082373|NCT02010905|Placebo Comparator|Placebo 150mg daily|Placebo: white film-coated biconvex tablet (50mg) with a diameter of 8mm. One time daily three tablets.
3082374|NCT02010892||Watchful Waiting|Patients with aneurysms considered to be at low risk of rupture will remain under surveillance with annual CT / MRI scans and multi-disciplinary team review (as per local practice). These patients' data will contribute to the natural history component of the study.
3082375|NCT02010892||Best Medical Therapy|This refers to lifestyle modification (smoking cessation and dietary management) as well as medical management of hypercholesterolaemia and hypertension for patients who are considered unsuitable for, or who refuse, OSR / ESG.
3082376|NCT02010892||Open Surgery (OSR)|Replacement of the aneurysmal aorta with prosthetic conduit via a sternotomy or thoracotomy with circulatory support.
3082377|NCT02010892||Stenting (ESR)|Endovascular repair of the aneurysm via transluminal introduction of a stent-graft under X-ray guidance. Hybrid procedures that comprise a combination of a conventional surgical component and a transluminal repair are to be included in this group.
3082378|NCT02010866|Other|Counseling|in-person counseling through RFWP to distressed respondents on the ISP
3082379|NCT02010853|Experimental|patient|"each patient TGA will receive an evaluation in resting state IRMf during three successive visits:~During the acute phase within 24 hours~In 72 hours~In 3 months"
3082380|NCT02010853|Other|control|"each control will receive an evaluation in resting state IRMf during three successive visits:~During the acute phase within 24 hours~In 72 hours~In 3 months"
3082381|NCT02010840|Experimental|Psychodeucation program|Both couples receive the father inclusive psychoeducation program which consists of a single 3-hour session during pregnancy and two telephone follow up at postpartum.
3082382|NCT02010840|Active Comparator|Mother only|Only the women receives the psychoeducation program.
3082383|NCT02010840|No Intervention|Control group|Receives usual perinatal care services only
3082384|NCT02010827||Patients|Patients
3082385|NCT02010827||healthy controls|healthy controls
3082386|NCT02010814||PCOS|"Women fulfilling at least two of the three Rotterdam criteria for PCOS, including~Irregular menstrual cycle~Clinical/biochemical hyperandrogenemia~Polycystic ovaries"
3082387|NCT02010801|Experimental|IRE for tumor before tumor resection|
3082388|NCT02010788||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
3082389|NCT02010775|Active Comparator|BOTOX® 24U|Botulinum Toxin Type A (BOTOX®) 24U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
3082390|NCT02010775|Active Comparator|BOTOX® 48U|Botulinum Toxin Type A (BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
3082391|NCT02010775|Active Comparator|BOTOX® 72U|Botulinum Toxin Type A (BOTOX®) 72U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
3082392|NCT02010775|Active Comparator|BOTOX® 96U|Botulinum Toxin Type A (BOTOX®) 96U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
3082393|NCT02010775|Placebo Comparator|Placebo|Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
3082394|NCT02010762|Active Comparator|Vitamin D|Weekly Vitamin D3 drops 25.000 IU for 6 months following ileocoecal resection
3082395|NCT02010762|Placebo Comparator|Placebo|Weekly placebo drops for 6 months following ileocoecal resection
3082396|NCT02010749||Control|Control: Children who had received Standard formula (SF) as infants
3082397|NCT02010749||Experimental|Experimental: Children who had received lower protein formula as infants
3082398|NCT02010736|Experimental|Spastic Hemiparetic Cerebral Palsy|Single treadmill gait training with additional loading
3082399|NCT02010723|Active Comparator|surgery|crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia
3082400|NCT02010723|Experimental|sclerotherapy|foam sclerotherapy with aethoxysclerol foam
3082401|NCT02010710|Experimental|Decison support|"Decision-support - CTGs with the decision support software running that will alert clinicians to the presence of abnormalities in the CTG in real time."
3082402|NCT02010710|No Intervention|No Decision Support|"No decision-support - CTGs with no additional interpretation (UK standard care),"
3082403|NCT02010697|Experimental|Messages targeting nonsmokers|Messages targeting nonsmokers include 10 mailings for nonsmokers sent over 10 weeks. The mailed materials include postcards, informational materials, CDs, DVDs, coupons for cessation-related incentives such as nicotine patches, and links to secured websites. The mail campaign is augmented with brief phone calls to ensure receipt of mailings and to reinforce targeted messages.
3082404|NCT02010697|Experimental|Messages targeting smokers|Messages targeting smokers include 10 mailings for smokers sent over 10 weeks. The mailed materials include postcards, informational materials, CDs, DVDs, coupons for cessation-related incentives such as nicotine patches, and links to secured websites. The mail campaign is augmented with brief phone calls to ensure receipt of mailings and to reinforce targeted messages.
3082405|NCT02010697|No Intervention|Usual care|one time mailing with a self-help quit kit
3082406|NCT02010684|No Intervention|Wait-listed Control Group|Participants in the Wait-listed Control Group will receive augmented access and communication with a primary care provider. The augmentation would consist of providing the participant with a letter to be shared with their primary care doctor indicating their Hb A1c level and depression score at the time of eligibility screening. The research team will also attach a list of local mental health service providers to the letter. The participants randomized to the wait-listed control group will also be offered access to the intervention after the trial is completed in the event that the randomized controlled trial (RCT) has significant results.
3082471|NCT02010255|Experimental|Cohort A, Group 1 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
3100011|NCT01891552||DEBIRI|only DEBIRI treatment
3082407|NCT02010684|Experimental|Empowerment and CBT Classes|"Participants will attend weekly 2-hour group Empowerment and CBT classes for 12 weeks led by two trained health educators. Participants will learn cognitive behavioral therapy (CBT) techniques to manage their mood. After CBT, participants will learn a diabetes education format that is grounded in empowerment theory that employs group problem solving, individualized goal setting, and personal behavioral change experiments designed to help patients set priorities and to become better self-managers of both diabetes and their mood. As part of the intervention activities, group members will be advised to monitor their blood sugar levels, blood pressure, and mood on a daily basis."
3082408|NCT02010671||Women with a prior cesarean section|Survey of women who had a cesarean section with their last pregnancy and no other prior cesarean section deliveries
3082409|NCT02010658|No Intervention|Memory|
3082410|NCT02010658|Experimental|Cognitive Aid|
3082411|NCT02010645|Experimental|Eltrombopag + Decitabine|"Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.~Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle."
3082412|NCT02010632|Experimental|Generic clopidogrel product|Apolets® 75 mg tablet
3082413|NCT02010632|Active Comparator|Original clopidogrel product|Plavix® 75mg tablet
3082414|NCT02010619|Experimental|Cognitive behavior therapy|
3082415|NCT02010619|Active Comparator|Supportive therapy|
3082416|NCT02010606|Experimental|Cohort A: Patients with newly diagnosed glioblastoma|Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy
3082417|NCT02010606|Experimental|Cohort B: Patients with recurrent glioblastoma|Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
3082418|NCT02010593|Experimental|Dapivirine vaginal ring|Safety Study of a Virginal Ring Containing Dapivitine in a postmenopausal Femal population
3082419|NCT02010593|Placebo Comparator|Placebo|The placebo VR is a felxible, platinum-catalyzed-cured matrix ring, identical to dapivirine ring-004, containing no active-drug
3082420|NCT02010580||Osphena|Subjects will be randomized in a ratio of 1:1 to receive either 60 mg of ospemifene (Osphena, Shionogi, Florham, NJ) or placebo tablet.
3082421|NCT02010567|Experimental|CLRX101 MTD/RP2D|During Phase Ib, we will evaluate the safety and determine the MTD/RP2D of CRLX101 + capecitabine (Cape) and radiation therapy (XRT) in patients with rectal cancer using the traditional 3+3 dose escalation design. Adverse events (AEs) will be evaluated via the CTCAE version 4.0. Patients in Phase Ib will also be followed for pathological response if they have resectable disease.
3082422|NCT02010567|Experimental|Chemoradiotherapy + Surgery|In Phase II, CRLX101 will be administered at the RP2D in combination with capecitabine and radiation in patients with locally advanced rectal cancer for a total of 5-6 weeks, depending on the total radiation dose. A total of 3 doses of CRLX101 will be administered every other week. Surgery will take place at least 6 weeks after the completion of chemoradiotherapy.
3082423|NCT02010554|Active Comparator|Brief Education|Patients receive a brief educational packet along with treatment as usual
3082424|NCT02010554|Experimental|MI-CBT Treatment|Patients receive five 20 minute phone sessions of motivational interviewing/cognitive behavioral therapy weekly along with a brief educational packet.
3082425|NCT02010541||insulin pump group|20 children below the age of 7 years who use an insulin pump for at least 6 months, more than 6 months of duration of type 1 diabetes, complete remission, no associated disease (normal blood pressure for age, only therapy insulin).
3082426|NCT02010541||RT (real time) -CGMS group|20 children below the age of 7 years who use an insulin pump and RT-CGMS on regular basis for at least 6 months, more than 6 months of duration of type 1 diabetes, complete remission, no associated disease (normal blood pressure for age, only therapy insulin). pump for at least 6 months, and children below the age of 7 years who use RT-CGMS on regular
3082427|NCT02010528||Type 1 diabetes|Parents or caregivers of children and adolescents with type 1 diabetes
3082428|NCT02010528||Controls|Parents or caregivers of children and adolescents without diabetes
3082429|NCT02010515||Sinus rhythm, first ICD implantation|
3082430|NCT02010502|Active Comparator|Concentrated Beet Root Juice|500ml per day for 6 days
3082431|NCT02010502|Active Comparator|Beet root powder|500ml per day for 6 days
3082432|NCT02010502|Placebo Comparator|Placebo juice|Negligible nitrate
3082433|NCT02010489|No Intervention|Control|Following randomization, the control group will receive usual preoperative care consisting of two to four multidisciplinary visits over six months. During this time, patients will be provided with exercise counseling through the team kinesiologist. They will complete a behavior modification program called Craving ChangeTM and must achieve usual goals of lifestyle and dietary modification, along with modest weight loss of approximately 5%, in order to be scheduled for surgery. Patients will also complete a liquid diet consisting of 900 calories per day for two weeks prior to their procedure in order to reduce intra-abdominal obesity and facilitate the procedure.
3082434|NCT02010489|Other|12 Week Exercise Program|The intervention group will undergo standard pre-operative care and will also be enrolled in a 12-week exercise program at the Reh-Fit Centre in Winnipeg. The Reh-Fit Centre is a non-profit organization with the mission to enhance the health and wellbeing of its members and the community by providing innovative health and fitness services. The intervention will be offered at no cost to the patient. It will involve regular supervised exercise sessions at the Reh-fit centre three times per week. Most patients will complete the intervention prior to commencing the liquid diet but will otherwise discontinue the program while on the diet two weeks prior to surgery.
3082435|NCT02010476||Normal insulin sensitivity|cognitively normal men without insulin resistance
3082436|NCT02010476||Insulin resistance|cognitively normal men with insulin resistance
3082437|NCT02010463|Other|Exercise Intervention|9-month exercise program involving four exercise education sessions
3082438|NCT02010450|Experimental|Wearable Blanket|subjects randomized to this group will receive a wearable blanket (sleep sack) that contains a safe sleep message.
3082439|NCT02010450|Active Comparator|Control Group|subjects randomized to this group will receive an incentive item (such as a University of Kansas Pediatrics water Bottle) that does not contain the safe sleep message.
3082612|NCT02009397|Experimental|Ipilimumab and GM-CSF|IV ipilimumab followed by subcutaneous GM-CSF, for up to 4 cycles
3082613|NCT02009384|Experimental|Ipilimumab|IV ipilimumab
3082440|NCT02010437|Active Comparator|Foam Sclerotherapy Group|"The axial vein will be cannulated under local anaesthesia and ultrasound guidance with the patient reclined in a supine position for GSV or ASV treatment, prone position if SSV or GV treatment.~The foam is then prepared by the Tessari technique by the surgeon. Two 2-ml syringes will be connected via a three way stop-cock tap and a 5 micron filter in series (Braun Medical, Sheffield, UK). The syringes will contain 1 part Sodium Tetradecyl Sulphate 3% and 3 parts air. In practice 0.5ml of 3% STS will be drawn up against 2 ml of air. The foam will be produced by at least 20 passages from syringe to syringe through the filter.~Up to 2ml of foam will be injected into each cannula under ultrasound control to observe venous spasm, followed by gentle massaging of the skin to propagate the foam through the segment of vein treated."
3082441|NCT02010437|Active Comparator|Catheter Directed Foam Sclerotherapy (CDS) Group|The straight segment of axial vein will be cannulated under local anaesthesia at the lowest point of demonstrable reflux and a guide-wire inserted to facilitate the placement of the catheter system.The appropriate Unifuse® catheter will be selected and deployed through the introducer sheath and advanced to within 2cm of the junction or perforator at the upper limit of incompetence or the top of the incompetent segment in the case of segmental reflux. A 1:3 foam of 3% STD will be produced as described for FS. At this point the patient will be repositioned into a Trendelenburg position (head up)
3082442|NCT02010437|Active Comparator|ClariVein Group (CV) Treatment|The straight segment of axial vein will be cannulated under local anaesthesia at the lowest point of demonstrable reflux and the ClariVein device 4-F micro sheath will be introduced up the vein via a guide wire as per manufacturer's instructions. Concentration of STD will depend on axial vein to be treated; if treating GSV or ASV 1.5% STD liquid will be used, if SSV or GV 1.0% STD liquid will be used. Volume of STD to be prepared for the CV treatment will be calculated using a dosage chart provided by the manufacturer
3082443|NCT02010424|Experimental|Individual culture|standard IVF protocol: half of the fertilized oocytes of the patient will be cultured individually in drops of 25 µl Cook cleavage medium till day 3 after fertilization and subsequently in drops of 25 µl Cook blastocyst medium till day 5 after fertilization
3082444|NCT02010424|Experimental|WOW|Half of the fertilized oocytes of the patient will be cultured in group in a WOW dish, each in a separate microwell but covered with one drop of 30 µl of Cook cleavage medium till day 3 after fertilization and subsequently all the embryos will be transferred to a new WOW dish (in the exactly the same position) covered with 30 µl of Cook blastocyst medium till day 5 after fertilization
3082445|NCT02010411|Active Comparator|Prolastin|Prolastin 250 mg nebulized BID, 10 days
3082446|NCT02010398|Active Comparator|Cross-Training healthy subjects|A cohort of healthy subjects (N=15) will undergo a phase of intervention consisting of cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
3082447|NCT02010398|Active Comparator|Standard-Training multiple sclerosis|A cohort of patients with multiple sclerosis (N=15), presenting with a marked asymmetry in limb strength, will undergo a standard-training of the more-impaired limb employing an isokinetic contraction regimen at maximal intensity.
3082448|NCT02010398|Experimental|Cross-Training multiple sclerosis|A cohort of patients with multiple sclerosis (N=15), presenting with a marked asymmetry in limb strength, will undergo a cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
3082449|NCT02010398|No Intervention|Healthy Control|A cohort of healthy subjects (N=15) will undergo baseline assessment and a second evaluation after one month of no-intervention
3082450|NCT02010385|Active Comparator|Octreotide|One subcutaneous injection - 1 mL
3082451|NCT02010385|Placebo Comparator|Saline|One subcutaneous injection - 1 mL
3082452|NCT02010372|Experimental|Reminder Recall Reports|Training in how to use reminder-recall reports in the Immunization registry will be given to administrators who will then be asked to regularly run these reports for a period of one year.
3082453|NCT02010372|Experimental|Audit-Feedback/Immunization Forecasting Reports|Training in how to use audit-feedback/immunization forecasting reports in the Immunization registry will be given to administrators who will then be asked to regularly run these reports for a period of one year.
3082454|NCT02010372|No Intervention|Control|No intervention will be administered to this group.
3082455|NCT02010359|Experimental|Lovaza|Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks
3082456|NCT02010359|Placebo Comparator|Placebo|An inactive Placebo (2 pills twice daily) will be given for 8 weeks
3082457|NCT02010346|Experimental|Early headgear treatment|Headgear treatment is initiated at the age of 7-8 years and continued as long as Class I occlusion is achieved
3082458|NCT02010346|No Intervention|Later headgear treatment|Headgear treatment is initiated in the beginning of the growth spurt.
3082459|NCT02010333|Experimental|Ha44 Gel 0.74% w/w|Open label, one arm
3082460|NCT02010320|Experimental|Computer dosed|Patients for which the computer model will calculate the individual doses
3082461|NCT02010320|Active Comparator|Control|Patients which will get their tacrolimus doses determined by experience transplant physicians
3082462|NCT02010307|Experimental|aggressive periodontitis|25 patients with aggressive periodontitis blood extraction
3082463|NCT02010307|Experimental|chronic periodontitis|25 patients with chronic periodontitis blood extraction
3082464|NCT02010307|Experimental|healthy|25 healthy periodontal patients blood extraction
3082465|NCT02010294||Children hospitalized for invasive GAS infection|Children hospitalized for invasive GAS infection
3082466|NCT02010294||Children with non-invasive infection|Children with non-invasive infection such as pharyngitis, tonsillitis, proctitis or skin infection diagnosed by a positive test for rapid diagnosis of GAS performed at the site of infection with a positive GAS culture
3082467|NCT02010281|Experimental|rTMS of the motor cortex (Magventure)|experimental : rTMS of the motor cortex : repetitive magnetic stimulation targeting the motor cortex assisted by neuronavigation
3082468|NCT02010281|Placebo Comparator|rTMS placebo (magventure)|sham stimulation of the motor or prefrontal cortex with the placebo face of the device
3082469|NCT02010281|Experimental|rTMS prefrontal cortex (magventure)|Experimental : repetitive transcranial stimulation targeting the prefrontal cortex as indicated by neuronavigation
3082470|NCT02010268|Experimental|preterm neonates|Preterm neonates (birth before 33 weeks of gestation)
3082657|NCT02009059||Non-invasive temperature in hypothermia|Adult patients undergoing elective thoracic surgery in deep hypothermia
3082472|NCT02010255|Experimental|Cohort A, Group 1 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
3082473|NCT02010255|Experimental|Cohort A, Group 2 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
3082474|NCT02010255|Experimental|Cohort A, Group 2 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
3082475|NCT02010255|Experimental|Cohort B, Group 3 (12 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3
3082476|NCT02010255|Experimental|Cohort B, Group 3 (24 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3
3082477|NCT02010255|Experimental|Cohort B, Group 4 (12 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)
3082478|NCT02010255|Experimental|Cohort B, Group 4 (24 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)
3082479|NCT02010255|Experimental|Cohort B, Group 5 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
3082480|NCT02010255|Experimental|Cohort B, Group 5 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
3082481|NCT02010255|Experimental|Cohort B, Group 6 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
3082482|NCT02010255|Experimental|Cohort B, Group 6 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
3082483|NCT02010255|Experimental|Cohort B, Group 7 (12 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with FCH
3082484|NCT02010255|Experimental|Cohort B, Group 7 (24 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH
3082485|NCT02010242|Experimental|GKT137831|GKT137831 100 mg capsules twice a day
3082486|NCT02010242|Placebo Comparator|Placebo|Placebo capsule twice a day
3082487|NCT02010229||women at high risk of placenta accreta|Parturient women with placenta praevia and at least one previous caesarean delivery
3082488|NCT02010216|Experimental|tocilizumab [RoActemra/Actemra]|Participants received tocilizumab 8 mg/kg by intravenous infusion every 4 weeks for 12 weeks (3 cycles).
3082489|NCT02010203|Experimental|Phase I: HS-410 Low Dose|In the open label Phase 1 portion, HS-410 is given as 1*10^6 cells per dose for 12 weekly injections followed by 3 monthly injections.
3082490|NCT02010203|Experimental|Phase II: HS-410 Low-Dose Plus BCG|In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
3082491|NCT02010203|Experimental|Phase II: High-Dose HS-410 Plus BCG|In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
3082492|NCT02010203|Placebo Comparator|Phase II: Placebo Plus BCG|In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.
3082493|NCT02010203|Experimental|Phase II: High-Dose HS-410|In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.
3082494|NCT02010190||Cancer Survivors|Participants will be survivors of a childhood cancer.
3082495|NCT02010190||Control Group|Control participants will consist of age- and gender-matched individuals who are non-first-degree relatives of the survivor group.
3082496|NCT02010164|Experimental|Old-CoQ10|
3082497|NCT02010164|No Intervention|Old|
3082498|NCT02010164|No Intervention|Young|Young less than 33 years old participants
3082499|NCT02010151|Experimental|NAD-CPR|When dispatcher detects a patient with OHCA, the dispatcher activates trained neighborhoods by informing events nearby using short message service via cellular phone. The neighborhood within geographically accessible area who could perform effective CPR and defibrillation would be alerted with event of OHCA and the nearest AED.
3082500|NCT02010151|No Intervention|Conventional dispatcher assisted CPR|When dispatcher detects OHCA, they instruct the caller with CPR instructions. This is conventional dispatcher assisted CPR performed in Seoul.
3082501|NCT02010138|Active Comparator|Small Extent Group (SG)|Patients who were scheduled for surgery for idiopathic macular hole were randomly assigned to the SG. The small-extent peeling was performed in SG.
3082502|NCT02010138|Active Comparator|Large Extent Group (LG)|Patients who were scheduled for surgery for idiopathic macular hole were randomly assigned to the LG. The large-extent peeling was performed in LG.
3082536|NCT02009852||Oral cancer|"Subjects who suffer from oral cancer.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
3083063|NCT02006329|No Intervention|Control group - dietary consultation - Mediterranean diet|
3082503|NCT02010125||Acute ACL injury|"Subjects with acute ACL injury will be recruited and enrolled within 28 days of injury Serum, urine, and synovial fluid will be collected at baseline, 6wks post-injury or post-surgery, 6 months, and 1 year Patients will have a quantitative MRI on both knees 7 days after initial visit, then at 6 months and 1 year.~Patients may or may not opt for ACL reconstruction Patients will have functional testing (One-legged hop tests and Star excursion balance test) at 6 months and 1 year Patients will fill out questionnaires (Knee Osteoarthritis Outcome Survey, Veteran Rand-12, Lysholm, International Knee Documentation Committee, Marx Questionnaire) at baseline, 6 weeks, 6 months, and 1 year"
3082504|NCT02010112|Experimental|Initial Diagnosis Cohort|Subjects with clinical indication of H.pylori infection will undergo breath test compared to routine clinical standard of care- endoscopy
3082505|NCT02010099|Experimental|PP110 Gel|PP110 Gel
3082506|NCT02010099|Experimental|PP110 medicated wipes|PP110 Medicated wipes
3082507|NCT02010099|Active Comparator|Preparation-H cream|Preparation-H cream
3082508|NCT02010086|Experimental|Individual Cognitive Behavioral Therapy|
3082509|NCT02010086|Active Comparator|Standard Community Treatment|
3082510|NCT02010073||One Group|This is a prospective observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
3082511|NCT02010060|No Intervention|Control|The goal of this group is to maintain their current lifestyle habits during the intervention. participants are asked to make no conscious changes to their physical activity or dietary habits.
3082512|NCT02010060|Experimental|Aerobic Exercise Training|The Aerobic training group will participate in 6 months of aerobic training and asked to make no conscious alterations in their physical activity outside of exercise session, or dietary habits
3082513|NCT02010060|Experimental|Aerobic Exercise+ Physical Activity|The goal of this group is to perform 6 months of aerobic exercise and increase the amount of physical activity outside of their training sessions. They will be asked to make no conscious changes to their dietary habits
3082514|NCT02010047|Experimental|IHC, FISH and qPCR ALK assays|ALK testing by IHC and FISH will be compared to ALK qPCR testing on NSCLC FFPE tissue.
3082515|NCT02010034|Other|Compassionate use|This lipid preparation is only being used for compassionate use.
3082516|NCT02010021|No Intervention|No drug treatment|Post-menopausal women with stage I-III breast cancer will have surgical resection of tumor and tumor tissue will be used to study cell growth signaling pathways ex-vivo.
3082517|NCT02010021|Active Comparator|Letrozole-presurgical|Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
3082518|NCT02010008|Experimental|Motivational Interviewing Intervention|Motivational Interviewing (MI) Intervention includes in -person home visit that elicits behavior change by helping participants explore and resolve ambivalence. A telephone follow-up call also uses MI technique.
3082519|NCT02010008|No Intervention|Comparison|Usual care
3082520|NCT02009995|Active Comparator|Aerobic Training (AT) only|All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.
3082521|NCT02009995|Experimental|AT plus Primarily Home-Based Resistance Band Training|"Both of the bands + AT groups will engage in RBT 3 times per week, progressing to 3 sets of 8-12 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.~Participants in this group will attend supervised group sessions weekly in weeks 1-4, every 2 weeks in weeks 5-8, and every 4 weeks thereafter to ensure proper form and appropriate progression. Participants in this group will be responsible to complete all remaining sessions (a total of 3 per week, including supervised sessions) at home on their own time."
3082522|NCT02009982|Experimental|Cardioneuroablation|Patients in this group will receive the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
3082523|NCT02009982|No Intervention|Standard Medical Thearpy|Patients in this group will not receive the cardioneuroablation and will continue to be managed using standard medical therapy
3082524|NCT02009956|Other|DESyne Novolimus Eluting CSS|Enrollment of up to 50 patients with up to two de novo native coronary artery lesions measuring between 2.5 and 4.0 mm in diameter and </= 34 mm in length receiving the DESyne Novolimus Eluting CSS.
3082525|NCT02009943|Experimental|Ferric carboxymaltose (FDA IND pending)|15 mg/kg, up to 750 mg IV x 1 on the day of study enrollment.
3082526|NCT02009943|Active Comparator|Iron sucrose (FDA IND 109,877)|"Iron sucrose 100 mg IV will be dosed daily using goal-direction up to a total of 700 mg over a 7-day period. Specifically, iron sucrose will be dosed daily if:~TSAT < 25%~Serum iron concentration < 150 ug/mL~Serum ferritin concentration < 1,500 ng/mL"
3082527|NCT02009943|No Intervention|Control|No iron supplementation
3082528|NCT02009904||Phenylketonuria (PKU); Healthy Controls|Children with PKU (5-18y); Age and Gender matched healthy subjects for comparison
3082529|NCT02009891||Control|Control couples who will not use predictive model
3082530|NCT02009891||Predictive model|Couples who will use predictive model
3082531|NCT02009878|Other|tolvaptan 3.75 mg|tolvaptan 3.75 mg
3082532|NCT02009878|Other|tolvaptan 7.5 mg|tolvaptan 7.5 mg
3082533|NCT02009878|Other|tolvaptan 15 mg|tolvaptan 15 mg
3082534|NCT02009865|Experimental|Epanova 2 g/day|Arm 1
3082535|NCT02009865|Placebo Comparator|Olive Oil 2 g/day|Arm 2
3082537|NCT02009839|Experimental|Meeky Mouse program|"14-week Meeky Mouse program consists of 8 training sessions (psychoeducation and anxiety management) followed by 6 practice sessions (exposure using social skills training)"
3082538|NCT02009839|Placebo Comparator|Computer Games|14 weeks of interactive session with the therapist while playing computer games
3082539|NCT02009826||Healthy controls|Healthy age- and sex-matched controls
3082541|NCT02009800|No Intervention|2 dose of quadrivalent HPV vaccine|The participants who have already received 2 doses of the quadrivalent HPV vaccine (0, 6 months schedule) 5 years before recruitment will not receive an additional dose.
3082542|NCT02009800|Experimental|3 doses of quadrivalent HPV vaccine|The participants will receive a 3rd dose of quadrivalent HPV vaccine at recruitment visit, which is 5 years after having received two doses of vaccine given 6 months apart in grade 4 (0, 6, 60 months Schedule)
3082543|NCT02009787|Experimental|Vitamin D supplementation group|drug: vitamin D3 tablets (Vigantoletten; Merck Pharma, Germany); the frequency: 2000 IU vitamin D3 tablets were taken daily; duration: 6 months.
3082544|NCT02009787|Placebo Comparator|Control group|drug: placebo tablets; the frequency: 2000 IU placebo tablets were taken daily; duration: 6 months.
3082545|NCT02009774||Controll group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITHOUT using the NBI function of the scope.
3082546|NCT02009774||Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITH THE HELP OF the NBI function of the scope.
3082547|NCT02009761|Experimental|BI 655064 subcutaneous|Escalating single dose as subcutaneous injection
3082548|NCT02009748|Active Comparator|Vitamin D supplementation|Colecalciferol 2.800 IU/day
3082549|NCT02009748|Placebo Comparator|Placebo|Vehicle (coconut oil)
3082550|NCT02009735|Experimental|virosensor|virus detection
3082551|NCT02009722|Active Comparator|Intrathecal hydromorphone|Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
3082552|NCT02009722|Active Comparator|Intrathecal morphine|Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
3082553|NCT02009709|Active Comparator|9 mW/cm2|CCL-VARIO UV lamp Riboflavin 0.1% ophthalmic solution
3082554|NCT02009709|Active Comparator|18 mW/cm2|CCL-VARIO at 18 mW/cm2 Riboflavin 0.1% ophthalmic solution
3082555|NCT02009696||Pacemaker Therapy|Patients with a ProMRI Pacemaker System
3082556|NCT02009670|Experimental|13C inulin|13C inulin combined with an inulin load are administered orally
3082557|NCT02009670|Placebo Comparator|Placebo|A placebo is administered orally
3082558|NCT02009644|Experimental|Treovance|Subjects who receive the Treovance stent-graft
3082559|NCT02009631|Experimental|Sequence Group A|200 mg Veliparib
3082560|NCT02009631|Experimental|Sequence Group B|400 mg Veliparib
3082561|NCT02009631|Placebo Comparator|Sequence Group C|Placebo
3082562|NCT02009618|Placebo Comparator|Irritable bowel syndrome patients|placebo tablet was given to another group in same doses for 10 days
3082563|NCT02009618|Experimental|Rifaximin|"Irritable bowel syndrome patients~Rifaximin is given to patients 200 mg tablets, 3x2/daily, for 10 days"
3082564|NCT02009605|Experimental|one arm|Icotinib of routine dose Icotinib: 125mg, oral administration, three times per day.
3082565|NCT02009592|Active Comparator|Hepatosteatosis|Rifaximin was given to patients with hepatosteatosis in the doses of 3x2 daily, 200 mg tablets for 4 weeks.
3082566|NCT02009592|Active Comparator|Steatohepatitis|Rifaximin was given to patients with steatohepatitis patients in the doses of 3x2 daily, 200 mg tablets for 4 weeks.
3082567|NCT02009579|Active Comparator|Experimental arm|Nintedanib/vargatef
3082568|NCT02009579|Placebo Comparator|Comparator arm|Placebo
3082569|NCT02009566|Experimental|Abdominal radiographs with microfabricated tags|
3082570|NCT02009553||Information sheet, Applied|In this group, all patients will receive the information sheet one month before the procedure
3082571|NCT02009553||Information sheet, not applied|In this group, patients will not receive a pre-procedural information sheet
3082572|NCT02009540|Placebo Comparator|Botulinum toxin injected to bladder body|arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor.
3082573|NCT02009540|Active Comparator|Botulinum toxin injected into trigone|Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml).
3082574|NCT02009527|Experimental|N-hydroxy-nor-arginine|N-hydroxy-nor-arginine 0.1 mg/ min i.a. for 20 min
3082575|NCT02009527|Placebo Comparator|NaCl|NaCl 0.9%, 6 ml/min i.a. for 20 min
3082576|NCT02009501|Active Comparator|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins .125% instillation will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4.
3082577|NCT02009501|Active Comparator|VAC Ulta Therapy|VAC ULTA Therapy will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4.
3082578|NCT02009488|Experimental|Canagliflozin (JNJ-28431754)|Each patient will receive canagliflozin 100 mg once daily during the first 4 weeks of the 25 weeks double-blind period, then the dose may be increased to 300 mg once daily, till the end of the period.
3082579|NCT02009488|Placebo Comparator|Placebo|One placebo capsule taken orally (by mouth) once daily for approximately 28 days during the Pre-Treatment Run-In and the Baseline Periods, then during double-blind study for 178 days (approximately 24-25 weeks).
3082580|NCT02009475|Active Comparator|Continues aerobic training|Treadmill or exercise bike training with target heart rate of 50-70% of the heart rate reserve (or 50-60% of the peak VO2 reserve). Overall 45 minutes of exercise (including the 5-10 minute warm-up period).
3082614|NCT02009371|Experimental|Light therapy|In this group, participants will be exposed to the LED treatment device (light box) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
3082581|NCT02009475|Experimental|Interval Exercse Training|Bouts of high intensity interval treadmill or exercise bike training, comprising of 85-95% of the heart rate reserve (or 80-90% of the peak VO2 reserve), for the duration of 4 minutes, separated by periods of low intensity activity until the heart rate reaches 50% of the peak heart rate. This set will be repeated 3 times.
3082582|NCT02009462|Experimental|Artefill|Four treatment visits using Artefill dermal filler
3082583|NCT02009449|Experimental|Part A: Dose Escalation Cohort 1|AM0010 (1 ug/kg) - Daily subcutaneous (SC) injections of AM0010 for up to 22 months
3082584|NCT02009449|Experimental|Part A: Dose Escalation Cohort 2|AM0010 (2.5 ug/kg) - Daily subcutaneous injections of AM0010 for up to 22 months
3082585|NCT02009449|Experimental|Part A: Dose Escalation Cohort 3|AM0010 (5 ug/kg) - Daily subcutaneous injections of AM0010 for up to 22 months
3082586|NCT02009449|Experimental|Part A: Dose Escalation Cohort 4|AM0010 (10 ug/kg) - Daily subcutaneous injections of AM0010 for up to 22 months
3082587|NCT02009449|Experimental|Part A: Dose Escalation Cohort 5|AM0010 (20 ug/kg) - Daily subcutaneous injections of AM0010 for up to 22 months
3082588|NCT02009449|Experimental|Part A: Dose Escalation Cohort 6|AM0010 (40 ug/kg) - Daily subcutaneous injections of AM0010 for up to 22 months
3082589|NCT02009449|Experimental|Part A: Dose Expansion Cohort 1|at least 15 RCC patients will be dosed with AM0010 for up to 22 months
3082590|NCT02009449|Experimental|Part B: Dose Escalation Cohort 1|"AM0010 (2.5 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.~Day 1~Paclitaxel 200/175 mg/m2 IV, or~Docetaxel 75/65 mg/m2 IV And~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or~Cisplatin 75mg/m2 IV"
3082591|NCT02009449|Experimental|Part B: Dose Escalation Cohort 2|"AM0010 (5 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.~Day 1~Paclitaxel 200/175 mg/m2 IV, or~Docetaxel 75/65 mg/m2 IV And~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or~Cisplatin 75mg/m2 IV"
3082592|NCT02009449|Experimental|Part B: Dose Escalation Cohort 3|"AM0010 (10 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.~Day 1~Paclitaxel 200/175 mg/m2 IV, or~Docetaxel 75/65 mg/m2 IV And~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or~Cisplatin 75mg/m2 IV"
3082593|NCT02009449|Experimental|Part B: Dose Expansion Cohort|"Daily SC injection with AM0010 with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.~Day 1~Paclitaxel 200/175 mg/m2 IV, or~Docetaxel 75/65 mg/m2 IV And~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or~Cisplatin 75mg/m2 IV"
3082594|NCT02009449|Experimental|Part C: Dose Escalation Cohort 1|"AM0010 (2.5 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;~Day 1~Oxaliplatin 85 mg/m2 IV over 2 hours~Leucovorin 200 mg/m2 IV over 2 hours followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours"
3082595|NCT02009449|Experimental|Part C: Dose Escalation Cohort 2|"AM0010 (5 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;~Day 1~Oxaliplatin 85 mg/m2 IV over 2 hours~Leucovorin 200 mg/m2 IV over 2 hours followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours"
3082596|NCT02009449|Experimental|Part C: Dose Escalation Cohort 3|"AM0010 (10 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;~Day 1~Oxaliplatin 85 mg/m2 IV over 2 hours~Leucovorin 200 mg/m2 IV over 2 hours followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours"
3082597|NCT02009449|Experimental|Part C: Dose Expansion Cohort 1|"Daily SC injection with AM0010 with FOLFOX4 Every 14 days FOLFOX4; (14 days = 1 cycle) ;~Day 1~Oxaliplatin 85 mg/m2 IV over 2 hours~Leucovorin 200 mg/m2 IV over 2 hours followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours"
3082598|NCT02009449|Experimental|Part D: Dose Escalation Cohort 1|"AM0010 (5 ug/kg) daily subcutaneous injections with Gemcitabine and nab-paclitaxel on Days 1, 8, 15 of each cycle (28 days = 1 cycle).~Nab-paclitaxel 125 mg/m2 IV over 30 minutes followed by~• Gemcitabine 1000 mg/m2 IV."
3082599|NCT02009449|Experimental|Part E: Dose Escalation Cohort 1|"AM0010 (10 ug/kg) daily subcutaneous injections with capecitabine BID daily for 14 days of each cycle (21 days= 1 cycle).~• Capecitabine 1000 mg/m2 po BID"
3082600|NCT02009449|Experimental|Part F: Dose Escalation Cohort 1|"AM0010 (10 ug/kg) daily subcutaneous injections with paclitaxel on Days 1, 8, 15 of each cycle (28 days= 1 cycle)~• Paclitaxel 80 mg/ m2 IV"
3082601|NCT02009449|Experimental|Part G: Dose Escalation Cohort 1|"AM0010 (10 ug/kg) daily subcutaneous injections with pazopanib orally given daily for 14 days of each cycle (21 days= 1 cycle)~• Pazopanib 800 mg po QD"
3082602|NCT02009449|Experimental|Part H: Dose Escalation Cohort 1|"AM0010 (10 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).~• Pembrolizumab 2 mg/kg IV over 30 min"
3082603|NCT02009449|Experimental|Part I: Dose Escalation Cohort 1|"AM0010 (20 ug/kg) daily subcutaneous injections with nivolumab on Day 1 of each cycle (14 days= 1 cycle).~• Nivolumab 3 mg/kg IV over 60 min"
3082604|NCT02009449|Experimental|Part H: Dose Escalation Cohort 2|"AM0010 (20 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).~• Pembrolizumab 2 mg/kg IV over 30 min"
3082605|NCT02009449|Experimental|Part H: Dose Escalation Cohort 3|"AM0010 (40 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).~• Pembrolizumab 2 mg/kg IV over 30 min"
3082606|NCT02009449|Experimental|Part J: Dose Escalation Cohort 1|AM0010 (10 ug/kg) daily subcutaneous injections with gemcitabine and carbolplatin on Days 1,8 of each cycle (21 days=1 cycle) until disease progression gemcitabine 1000mg/m2 IV over 30 minutes followed by carboplatin AUC2 over 60 minutes
3082607|NCT02009436|Experimental|Treatment (azacitidine)|Patients receive azacitidine via nebulizer over 20 minutes QD on days 1-5 and 15-19. Treatment repeats every 28 days for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients may continue treatment on a case-by-case basis at the discretion of principal investigator and Institutional Review Board.
3082608|NCT02009423|Experimental|Masitinib|masitinib-treatment arm
3082609|NCT02009423|Placebo Comparator|Placebo|placebo-treatment arm
3082615|NCT02009371|Placebo Comparator|Control group|In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
3082616|NCT02009358|Experimental|Mental health promotion group|
3082617|NCT02009332|Experimental|ABI-009|
3082618|NCT02009306|Experimental|PecFent and Epistatus|Medication administered by family / carer for symptoms
3082619|NCT02009306|Active Comparator|Standard subcutaneous medication|Standard subcutaneous medication - diamophine and / or midazolam administered by nursing staff
3082620|NCT02009306|Experimental|Epistatus Alone|"From 28/11/17 following approval from sponsor, ethics committee and MHRA a 3rd observational arm was introduced:~Epistatus administered PRN by family / carer for symptoms"
3082621|NCT02009293||Cough IPF|Male and female with idiopathic pulmonary fibrosis and cough and about to start on Pirfenidone according to regular practice will be asked to wear a cough monitor 24 hours before starting Pirfenidone and twice 24 hours while using Pirfenidone. Patients will also be asked to fill in questionnaires about quality of life and cough.
3082622|NCT02009280|Experimental|Propofol group|Propofol group
3082623|NCT02009280|Active Comparator|Sevoflurane group|Sevoflurane group
3082624|NCT02009267||Patient controlled analgesia|Use of patient controlled analgesia (PCA) for the management of postoperative pain after the Nuss procedure.
3082625|NCT02009267||Continuous thoracic epidural infusion|Continuous thoracic epidural infusions (TE) for the management of postoperative pain after the Nuss procedure.
3082626|NCT02009267||Continuous paravertebral blockade|Continuous paravertebral blockade (PVB) for the management of postoperative pain after the Nuss procedure.
3082627|NCT02009254|Experimental|Mashed Potatoes (as produced)|
3082628|NCT02009254|Experimental|Mashed Potatoes (with no added butter during production)|
3082629|NCT02009254|Experimental|glucose control (50 g)|
3082630|NCT02009241|Active Comparator|Pulmonary Rehabilitation|The intervention group will perform a 12 week pulmonary rehabilitation program consisting of 30 minutes of treadmill aerobic exercise training and 30 minutes of muscle strength training.
3082631|NCT02009241|No Intervention|Control|
3082632|NCT02009228|Active Comparator|Single-port laparoscopy|The three-channel single-port: a 1.5-cm horizontal intraumbilical skin incision, a 1.5-cm to 2-cm rectus fasciotomy to open the peritoneal cavity, and the insertion of an Alexis small wound retractor (Applied Medical, Rancho Santa Margarita, CA). The wrist portion of a size 6.5 surgical glove was fixed to the outer ring of the wound retractor. A 12-mm trocar was inserted through a small hole made in one of the fingertips of the glove and advanced into the abdominal cavity. Two additional holes for the accessory channels were made in another fingertip of the glove, and two conventional 5-mm trocars were inserted through the holes.
3082633|NCT02009228|Active Comparator|Conventional laparoscopy|The 12-mm main troca was inserted via subumbilical incision after fully insufflation by verness needle and other 3 working 5-mm trocas were inserted under vision at right middle abdominal, left middle abdominal and suprapubic incisions.
3082634|NCT02009215|Experimental|Intermittent preventive treatment (IPT)|Dihydroartemisinin-piperaquine (DP)
3082635|NCT02009215|No Intervention|Control|No intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be given.
3082636|NCT02009202|Active Comparator|picosulphate|Picosulphate is given orally
3082637|NCT02009202|Active Comparator|polyethylene glycol|Polyethylene glycol is given orally
3082638|NCT02009189|Placebo Comparator|Control|Saline flush
3082639|NCT02009189|Active Comparator|2% Taurolidine lock|Catheter lock with 2% Taurolidine
3082640|NCT02009189|Active Comparator|1.35% Taurolidine with citrate|Catheter lock with 1.35% Taurolidine + citrate
3082641|NCT02009176|Experimental|Laparoscop Anatomical Hepatectomy|Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy when necessary. The intraoperative ultrasound, hepatic segmental staining were used selectively.
3082642|NCT02009176|Active Comparator|Laparoscope Aon-anatomical Hepatectomy|Total laparoscopic aon-anatomical hepatectomy were performed, combined with cholecystectomy when necessary. The intraoperative ultrasound or hepatic segmental staining will be used to ensure the tumour was completely resected.
3082643|NCT02009163|Experimental|Lisdexamfetamine dimesylate|Administer one capsule (50 or 70 mg) orally daily at approximately 7:00 AM.
3082644|NCT02009163|Placebo Comparator|Placebo|Administer one capsule orally daily at approximately 7:00 AM.
3082645|NCT02009150||Women at high risk for breast cancer|Proven carriers of deleterious BRCA1 or BRCA2 mutations Or Women that were found to have a lifetime risk of developing breast cancer greater or equal to 20% based on Tyrer-Cuzick, Gail or Clause risk models.
3082646|NCT02009137|Experimental|EVERA|EVERA- korean ESTES system, apply for 12 weeks
3082647|NCT02009137|Active Comparator|ESTES|ESTES apply for 12 weeks
3082648|NCT02009124|Experimental|Stem cell|autologous bone marrow mononuclear cell transplantation
3082649|NCT02009124|No Intervention|Control|Stem cell therapy is not done for this group of spinal cord injury patients
3082650|NCT02009111|Experimental|Couple CARE for Parents|Couple CARE for Parents is a couple-focused intervention that addresses interpersonal processes within relationships and promotes healthy relationship and parenting skills among couples with a newborn. Couple CARE for Parents uses a highly disseminable model (i.e., home-visitation and video- and telephone-assisted skills training) developed in Australia.
3082651|NCT02009111|Other|Wait-list control|The control group will be wait-listed until after the 24-month assessment, at which point they are eligible to receive Couple CARE for Parents (tailored for their children's ages).
3082652|NCT02009098|Active Comparator|præoperativ antibiotic|iv Cefuroxime 1,5g administered 15-60 minutes before incision
3082653|NCT02009098|Active Comparator|postoperativ antibiotic|iv Cefuroxime 1,5g administered after umbilical cord clamping
3082654|NCT02009085||Individuals undergoing skin excision.|Skin lesions are under suspicion for skin cancer.
3082655|NCT02009072|Experimental|Sutured limbal conjunctival autograft|Sutured limbal conjunctival autograft was done for patients of group 2 after pterygium excision
3082656|NCT02009072|Experimental|Suturless and glue free Limbal conjuctival autograft|Sutureless and glue free Limbal conjunctival autograft was done for patients of group 1 after pterygium excision
3082658|NCT02009046|Experimental|SEI Classroom Curriculum|Participants receive the SEI classroom curriculum.
3082659|NCT02009046|Active Comparator|Control Classroom Curriculum|Participants receive the control classroom curriculum.
3082660|NCT02009046|Experimental|3 School Wide Components|Participants receive three school wide components (peer advocacy and education, parent education, clinical services linkages).
3082661|NCT02009046|Active Comparator|1 School Wide Component|Participants receive one of the three school wide components (clinical services linkages).
3082662|NCT02009033|Experimental|Ringer`s lactate|Fluid therapy during operation
3082663|NCT02009007|Experimental|dopamine|dopamine is administered to maintain systolic blood pressure in the range of 80-120% of baseline during operation
3082664|NCT02009007|Experimental|phenylephrine|Phenylephrine is administered to maintain systolic blood pressure in the range of 80-120% of baseline during operation
3082665|NCT02008994|Experimental|Genomic and Proteomic Profiling|"Reverse Phase Protein Microarray will be used to determine how often there are specific proteins that could make your tumor susceptible or resistant to treatment.~Immunohistochemistry will look for specific markers of disease in your DNA.~RNA sequencing will be used to help doctors and scientists understand how your genes are working.~Low pass whole genome and exome sequencing will be used to help identify variants in your DNA."
3082666|NCT02008981|Active Comparator|Angelica sinensis|Angelica sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
3082667|NCT02008981|Active Comparator|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
3082668|NCT02008981|Active Comparator|Siwu Tang|"TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after."
3082669|NCT02008968|Active Comparator|Uric acid ≥7 mg/dL|This arm will receive allopurinol treatment. 50 subjects will be recruited.
3082670|NCT02008968|Active Comparator|Uric acid ≥6 and <7|This arm will not receive allopurinol. 50 subjects will be recruited.
3082671|NCT02008968|Placebo Comparator|Normouricemic|This arm is healthy controls. 30 subjects will be recruited.
3082672|NCT02008955|Experimental|lysine intake at different levels of intake|
3082673|NCT02008942|Experimental|PL2200 Aspirin Capsules|PL2200 Aspirin Capsules
3082674|NCT02008942|Active Comparator|Enteric-coated aspirin caplets|Enteric-coated aspirin caplets
3082675|NCT02008929|Other|MG4101|Ex vivo expanded allogeneic NK cell
3082676|NCT02008916|Experimental|Secukinumab 10 mg/kg i.v. / 300 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
3082677|NCT02008916|Experimental|Secukinumab 10 mg/kg i.v. / 150 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
3082678|NCT02008916|Placebo Comparator|Placebo i.v. and s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection at weeks 8 and 12. At week 16, patients are re-randomised to one of the active treatment arms, to receive secukinumab s.c. Q4W until the end of the study.
3082679|NCT02008903||EoE active disease|Inflammation as defined by >15 eos / HPF
3082680|NCT02008903||EoE remission|No inflammation in EoE patients after treatment
3082681|NCT02008903||normal control|No inflammation
3082682|NCT02008890|Experimental|Secucinumab 300mg|70 patients with moderate to severe chronic palmoplantar pustular psoriasis will be treated with Secukinumab 300 mg subcutanous (s.c.) until Week 16. From Week 16 until Week 52 all patients and in addition half of the patients in the placebo arm that are non-responders to the placebo treatment are treated with Secucinumab 300 mg s.c. Efficacy and patient's safety will be compared separately in each group.
3082683|NCT02008890|Experimental|Secucinumab 150mg|70 patients with moderate to severe chronic palmoplantar pustular psoriasis will be treated with Secukinumab 150 mg subcutanous (s.c.) until Week 16. From Week 16 until Week 52 all patients and in addition half of the patients in the placebo arm that are non-responders to the placebo treatment are treated with Secucinumab 150 mg s.c. Efficacy and patient's safety will be compared separately in each group.
3082684|NCT02008890|Placebo Comparator|Placebo|70 patients with moderate to severe chronic palmoplantar pustular psoriasis will be treated with matching placebo subcutanous (s.c.) until Week 16. At week 16 non-responders to placebo treatment will be re-randomized 1:1 to both secukinumab treatment arms.
3082685|NCT02008877|Experimental|ganetespib / sirolimus|28-day cycles of ganetespib + sirolimus
3082686|NCT02008864|Placebo Comparator|Placebo|Wheat
3082687|NCT02008864|Active Comparator|Senna|Senna
3082688|NCT02008851|Experimental|Implantation of Neo-kidney Augment|Patients receiving one dose (implant) of NKA into the left kidney
3082689|NCT02008838|Active Comparator|Synbiotic|Each synbiotic capsule (Protexin, UK) contained 2 × 108 CFU of seven strains of friendly bacteria (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, Lactobacillus bulgaricus), prebiotics (FOS [Fructooligosaccharide]), and probiotics culture (Magnesium stearate [source: mineral and vegetable], and vegetable capsule [hydroxypropyl methyl cellulose])
3082690|NCT02008838|Placebo Comparator|Placebo|250 mg Maltodexterin
3082691|NCT02008825|Experimental|ViSiGi|Utilization of ViSiGi calibration tube
3082692|NCT02008825|Active Comparator|Usual standard of care|Usual non suction Bougie
3082693|NCT02008812|Experimental|Ad sensor|virus detection
3082694|NCT02008799|Experimental|Bone marrow stem cell injection|through special butterfly inject stem cell in testicular artery and inside tubules
3082695|NCT02008786|Experimental|Rosuvastatin, placebo|rosuvastatin 10-20mg daily or placebo (suggested dose of 10mg for Asians, and 20mg for others)
3082696|NCT02008786|Experimental|Ramipril, placebo|ramipril (starting dose of ramipril at 5mg daily titrating up to 10mg daily at 1 week if tolerated) versus placebo
3082697|NCT02008773|Active Comparator|valacyclovir|3000mg daily oral 16 weeks
3082698|NCT02008773|Placebo Comparator|placebo|placebo 6 capsules daily oral 16 weeks
3100087|NCT01891032||VAMS|the adult patients with VAMS partial nephrectomy
3082699|NCT02008760|Placebo Comparator|vegetable oil with betacarotene|4 capsules vegetable oil with betacarotene
3082700|NCT02008760|Active Comparator|krill and vitamin D3|krill and vitamin D3. (72 mg), four capsules daily
3082701|NCT02008747|Active Comparator|Magnesium sulphate|"The patients in this group underwent general anaesthesia with total intravenous anesthesia containing Remifentanyl (0,3 mg/kg ideal body weight/h), Propofol (4 mg/kg ideal body weight/h) and Atracurium.~They also received 40mg/kg ideal body weight magnesium sulphate by bolus injection before the operation started, followed by a continuous application of 10mg/kg ideal body weight/hour for 24 hours."
3082702|NCT02008747|No Intervention|No treatment|The patients in this group underwent general anaesthesia with total intravenous anesthesia containing Remifentanyl (0,3 mg/kg ideal body weight/h), Propofol (4 mg/kg ideal body weight/h) and Atracurium. They received no additional medication.
3082703|NCT02008734|No Intervention|Control|
3082704|NCT02008734|Experimental|PD0332991|Patients will be randomized 3:1 to be treated with PD0332991 125mg/day orally for a total duration of 14 days (or 100 mg/day for a total duration of 21 days depending on results of interim analysis) with last treatment taken the day previous to the surgical procedure.
3082705|NCT02008721|Active Comparator|EGCG as putative neuroprotective agent|Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
3082706|NCT02008721|Placebo Comparator|Placebo|Placebo
3082707|NCT02008708|Experimental|Livestock microfinance|Participants randomized to the microfinance intervention receive a female pig loan with ongoing support to manage health and care of the pig by trained agents.
3082708|NCT02008708|Active Comparator|Delayed Control Group|Participants randomized to delayed control group receives pig loan 12 months after the intervention group
3082709|NCT02008695|Active Comparator|Youth microfinance only|Youth receive loan
3082710|NCT02008695|Active Comparator|youth and adult micro finance|youth and adult receive loan
3082711|NCT02008695|Active Comparator|adult microfinance|adults receive loan
3082712|NCT02008682|Experimental|Liraglutide 1.8 mg + metformin|2-week screening period, 26-week treatment duration, and a 1-week follow-up period
3082713|NCT02008682|Active Comparator|Sitagliptin 100 mg + metformin|2-week screening period, 26-week treatment duration, and a 1-week follow-up period
3082714|NCT02008669||Multiple Sclerosis cases|"All patients will undergo the following interventions~Gustatory sensitivity test using Taste strips~Blood sampling~Questionnaires"
3082715|NCT02008656|Experimental|INCT|Arm 1 will receive chemotherapy before chemoradiation. This is called induction neoadjuvant chemotherapy arm (INCT). The neoadjuvant chemotherapy regimen is prescribed specifically as 8 cycles of FOLFOX or 5 cycles of CapeOX over a period of approximately 15-16 weeks. Endoscopic exam (2-4 wks) after chemotherapy. If stable or response then pt will have radiation with either 5-FU or capecitabine.
3082716|NCT02008656|Experimental|CNCT|Arm 2 will receive chemoradiation before chemotherapy This is called the consolidation neoadjuvant chemotherapy arm (CNCT). Pt will have 6 weeks of chemoradiation therapy. Along with the radiation the pt will receive either 5-FU or capecitabine. 2-4 weeks after pt will have endoscopic exam and if stable or response pt will have will have 8 cycles of FOLFOX or 6 cycles of CapeOX.
3082717|NCT02008643|Experimental|children with food allergy|Chidren aged 8-18 year with food allergy
3082718|NCT02008643|Active Comparator|children with chronic diseases|
3082719|NCT02008643|Active Comparator|witnesses|"Inclusion criteria Age between 8-18 year old Children attending schools of Nice City Signed informed consent of the two parents Signed informed consent of the child Health insurance recipient~Non inclusion criteria Association with another medical or psychiatric chronic disease No signed consent"
3082720|NCT02008630|Experimental|Animal-assisted activity|30 minutes group session with animal-assisted activity twice a week for 12 weeks in groups of 4-6 participants.
3082721|NCT02008630|Experimental|Animal-assisted therapy|30 minutes group session with animal-assisted therapy twice a week for 12 weeks in groups of 4-6 participants
3082722|NCT02008630|No Intervention|Control|Control group with treatment as usual
3082723|NCT02008617|Active Comparator|Study Drug|Ultrasound guided posterior genicular nerve infiltration with 30mL of Bupivicaine 0.20% with epinephrine 1:300,000 (Study Drug)
3082724|NCT02008617|Sham Comparator|Preservative free normal saline|Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
3082725|NCT02008604||Stroke patients|
3082726|NCT02008604||TIA patients|patients with a transient ischemic attack (control group)
3082727|NCT02008591|Active Comparator|Epidural Technique|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 15 mL load over 5 min
3082728|NCT02008591|Active Comparator|Combined Spinal Epidural Technique|Bupivacaine 2.5 mg with Fentanyl 25 mcg
3082729|NCT02008591|Active Comparator|Dural Puncture Epidural Technique|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 15 mL load over 5 min
3082730|NCT02008578|Experimental|Intravenous hyperimmune immunoglobulin (Flu-IVIG)|Adults with confirmed Influenza A or B and evidence of ongoing viral replication (as demonstrated by positive rapid Ag or PCR preferably within 24 hours and no later than 6 days from symptom onset) will receive 0.25g Flu-IVIG/kg of actual body weight, to a maximum dose of 25g Flu-IVIG.
3082731|NCT02008578|Placebo Comparator|Placebo|Adults with Influenza A or B and evidence of ongoing viral replication (as demonstrated by positive rapid Ag or PCR preferably within 24 hours and no later than 6 days from symptom onset) will receive placebo for Flu-IVIG (a comparable volume of saline).
3082732|NCT02008565|Placebo Comparator|Placebo|Placebo doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.
3082733|NCT02008565|Experimental|Anal exercises with biofeedback|Six sessions with trained personnel will occur every 2 weeks over a 12-week period. Sessions will be held at the following study visits: baseline, 2, 4, 6, 9, and 12 week visits.
3082734|NCT02008565|Placebo Comparator|Usual care|Participants will receive education and a NIDDK Bowel Control Educational pamphlet
3082735|NCT02008565|Experimental|Loperamide|Loperamide doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.
3082736|NCT02008552|Other|Mediagene|Sampling blood
3082737|NCT02008539|Experimental|treatment arm|
3082930|NCT02007278|Active Comparator|vildagliptin and metformin|Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks
3082738|NCT02008526|Experimental|TXT-PHE|"Gay-specific, Theory-based Text Messages Transmitted by Peer Health Educators (TXT-PHE)~This condition is interactive and tailored to the needs of the individual participant. PHEs initiate (i.e., push) text messages to participants and also respond to participant-initiated queries and participant responses to the PHE messages (i.e., pull).~Participants receive five pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE.~During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
3082739|NCT02008526|Experimental|TXT-Auto|"Group 2: Gay-specific, Theory-based Text Messages Transmitted by Automation (TXT-Auto)~Participants assigned to this group receive automatic text-messages.~Following the initial welcome message, participants receive five pre-written messages per day sent on a predetermined schedule.~During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
3082740|NCT02008526|No Intervention|Assessment Only (AO)|During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
3082741|NCT02008513|Active Comparator|Group 1|AFF006 Placebo groups receive 6 AFFITOPE® AD02 vaccinations
3082742|NCT02008513|Active Comparator|Group 2|AFF006 verum groups receive 3 Placebo injections then followed by 3 AFFITOPE® AD02 vaccinations
3082743|NCT02008500|Placebo Comparator|Placebo Mouthwash Group|Group 1 (placebo mouthwash group) contained 51 individuals
3082744|NCT02008500|Active Comparator|Herbal Mouthwash Group|Group 2 ( Herbal mouthwash) contained 52 individual
3082745|NCT02008500|Sham Comparator|Non Herbal Mouthwash Group|Group 3 (Non Herbal mouthwash) contained 50 individuals
3082746|NCT02008487|Other|Wound powder|In both hospice settings, a registered nurse establishes the wound protocol per principles of wound care and agency guidelines. The cover dressing will be removed and the wound cleansed according to agency protocol (usual care) or as needed. The RGN107 powder, contained in a small squirt bottle, will be squeezed/sprinkled on the wound at each dressing change after cleansing or until a crust is formed. Once formed, the powder will be applied only minimally to reinforce crust integrity. The peri-wound skin will receive care and the cover dressing will be applied. Minimal manipulation of the crusted area will ensue once it has formed. Frequency of dressing changes depends on wound characteristics such as exudate.
3082747|NCT02008474|Active Comparator|Online weight loss + Incentives for behavior 3 months|
3082748|NCT02008474|Active Comparator|Online weight loss + Incentives for weight loss 3 months|
3082749|NCT02008474|Active Comparator|Online weight loss + Incentives for behavior 12 months|
3082750|NCT02008474|Active Comparator|Online weight loss + Incentives for weight loss 12 months|
3082751|NCT02008461|Active Comparator|RFA|Mapping and radiofrequency ablation are performed by using standard methods.
3082752|NCT02008461|Active Comparator|RFA+BT injection|"Mapping and radiofrequency ablation are performed by using standard methods.~Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster)."
3082753|NCT02008448|Active Comparator|PVI+LL|Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.
3082754|NCT02008448|Active Comparator|PVI+LL+BT injection|"Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.~Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster)."
3082755|NCT02008435|Experimental|Enriched GLB|This arm aims to increase the effectiveness of the Group Lifestyle Balance (GLB) program by integrating habit formation techniques, namely if-then plans and their mental practice, into the program.
3082756|NCT02008435|Active Comparator|Standard GLB|This arm is the standard Group Lifestyle Balance (GLB) program, which is the group version of the Diabetes Prevention Program developed by the NIH.
3082757|NCT02008422|Experimental|Oxaliplatin & Endostar injection|Oxaliplatin, 130 mg/m2 , iv, 3-4h, d1; Gimeracil and Oteracil Potassium Capsules, 40 mg/m2, po., Bid., d1-14; Endostar injection, 7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10; 21 d as a cycle.
3082758|NCT02008422|Active Comparator|Oxaliplatin|Oxaliplatin, 130 mg/m2 , iv, 3-4h, d1; Gimeracil and Oteracil Potassium Capsules, 40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
3082759|NCT02008409|Experimental|EndoLift Liver Retractor|"During surgery, the surgeon will use the new internal liver retractor device. The device will retract the subject's liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends."
3082760|NCT02008396|Placebo Comparator|Placebo|Subjects will receive inactive placebo in two sessions
3082761|NCT02008396|Experimental|MDMA|Participants will receive 75 to 125 mg during two sessions; first session dose lower than second session dose.
3082762|NCT02008383|Experimental|Cabozantinib and Panitumumab|60 mg Cabozantinib PO daily and 6 mg/kg Panitumumab IV every 2 weeks.
3082763|NCT02008383|Experimental|Cabozantinib|60 mg Cabozantinib PO daily.
3082764|NCT02008370|Experimental|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
3082765|NCT02008357|Experimental|Solanezumab|Solanezumab (400-1600 milligrams) intravenously (IV) every 4 weeks for 240 weeks.
3082766|NCT02008357|Placebo Comparator|Placebo|Placebo IV every 4 weeks for 240 weeks.
3082767|NCT02008344|Active Comparator|favipiravir|Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
3082768|NCT02008344|Placebo Comparator|placebo|Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
3082769|NCT02008331|Experimental|SYNBIOTIC|Patients of this group assumed Probinul-Neutro® po 5g three times a day for 30 days
3082770|NCT02008331|Placebo Comparator|PLACEBO|patients of this group received 5g of placebo 3 times a day for 30 days
3082771|NCT02008318|Experimental|Ph 2: LY2157299 + BSC|Phase (ph) 2. 150 milligrams LY2157299 given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
3082772|NCT02008318|Placebo Comparator|Placebo + BSC|Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive BSC according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
3082773|NCT02008318|Experimental|Ph 3: LY2157299 + BSC|150 milligrams LY2157299 given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
3082774|NCT02008305|Experimental|protocol of optimization ALARA|protocol of optimization ALARA protocol of optimization of doses
3082775|NCT02008305|Active Comparator|protocol of opimization Philips|protocol of optimization Philips usual protocol of optimization of doses
3082776|NCT02008292|Experimental|physostigmine and amphetamine|There is only one arm to the study. All subjects will receive physostigmine and amphetamine.
3082777|NCT02008279|Experimental|Group 1A|100 mg CNTO 3157 or placebo in healthy male Japanese participants
3082778|NCT02008279|Experimental|Group 1B|100 mg CNTO 3157 or placebo in healthy male Caucasian participants
3082779|NCT02008279|Experimental|Group 2A|300 mg CNTO 3157 or placebo in healthy male Japanese participants
3082780|NCT02008279|Experimental|Group 2B|300 mg CNTO 3157 or placebo in healthy male Caucasian participants
3082781|NCT02008279|Experimental|Group 3A|600 mg CNTO 3157 or placebo in healthy male Japanese participants
3082782|NCT02008279|Experimental|Group 3B|600 mg CNTO 3157 or placebo in healthy male Caucasian participants
3082783|NCT02008279|Experimental|Group 4|300 mg CNTO 3157 in healthy male Caucasian participants
3082784|NCT02008266||Patients with Rheumatoid Arthritis|
3082785|NCT02008253||INTRASTROMAL CORNEAL RING SEGMENT|Forty-two eyes of 26 patients, 14 men and 12 women, with ectasia after refractive surgery were studied in a nonrandomized, retrospective, observational case series.
3082786|NCT02008240|Experimental|Needle aspiration of hydrosalpinx|Aspiration of hydrosalpingeal fluid under ultrasound guidance
3082787|NCT02008240|Active Comparator|salpingectomy|Surgical removal of hydrosalpinx
3082788|NCT02008227|Experimental|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab 1200 milligrams (mg) will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
3082789|NCT02008227|Active Comparator|Docetaxel|Docetaxel 75 milligrams per meter square (mg/m^2) will be administered via IV infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
3082790|NCT02008214|Experimental|PTX|IFN 180 micrograms subcutaneous weekly RBV 400 mg each 12 h, oral PTX 400 mg each 12 h, oral
3082791|NCT02008214|Placebo Comparator|Placebo|IFN 180 micrograms subcutaneous weekly RBV 400 mg each 12 h, oral Placebo oral daily
3082792|NCT02008201|Experimental|Vitamin D dose 1|Vitamin D dose 1
3082793|NCT02008201|Experimental|Vitamin D dose 2|Vitamin D dose 2
3082794|NCT02008201|Experimental|Vitamin D dose 3|Vitamin D dose 3
3082795|NCT02008201|No Intervention|observational|No dose
3082796|NCT02008188|Experimental|Five consecutive nights|The subjects will begin wearing two CGMs 24-48 hours prior to the start of the experimental week. This Diabetes Assistant (DiAs) system will be initiated at 23:00 and will be discontinued at 7:00 before breakfast. This will be repeated for 5 consecutive nights.
3082797|NCT02008188|Placebo Comparator|Subjects will be at home using their home insulin pump and CGM|"During the outpatient data collection period, subjects will be equipped with a DexCom Gen4 CGM. Subjects will be provided with instructions on how to upload CGM data through the DexCom software and how to download insulin pump data to record insulin pump information.~Data collection will include:~CGM Data~Self-Monitoring Blood Glucose (SMBG) readings~Meal times and Carbohydrate Administration~Insulin administration"
3082798|NCT02008175|Experimental|Conventional CXL|Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/sq.cm with riboflavin and distilled water alternated every 2 minutes was used for the procedure.
3082799|NCT02008162||Bronchodilators|"Patients with severe heterogeneous emphysema selected as potential candidtes for lung volume reduction surgery.~Bronchodilators employed for the study include albuterol 200µg and tiotropium bromide 18 µg administered by puffs following a first spirometry and plethysmography performed after a washout period of 48h from all bronchodilators and subsequently repeated within 30 min after bronchodilators administration."
3082800|NCT02008149|No Intervention|Standard of care group|SCI individuals receiving conventional rehab
3082801|NCT02008149|Experimental|FES-rowing group|Individuals with SCI participating in an FES-rowing program
3082802|NCT02008136|Experimental|botulinum toxin injected|Because this is an open label study, all subjects will receive one of two botulinum toxins based on their symptoms. Those will cervicalgia will receive Botox (botulinum toxin A) and those with lumbago or low back pain will receive Myobloc (botulinum toxin B)
3082803|NCT02008123|Experimental|Primidone|Participants will receive primidone in addition to their clopidogrel regimen. For the first 3 days of the study, participants will take 125 mg of primidone (one-half tablet). After 3 days of 125 mg, the primidone dose will be increased to 250 mg (1 tablet) taken at bedtime for the next 17-25 days. The participant will then be asked to return and be retested.
3082804|NCT02008110|Experimental|CA125 guided strategy|In this group, physician will be encouraged to maximize all treatment measures aimed to keep CA125≤35 U/ml (normal values).
3082805|NCT02008110|Active Comparator|Standard treatment strategy|Therapy is based on established european current guidelines
3083454|NCT02003755|Experimental|Spastic CP|continuous passive motion training
3082806|NCT02008097|Experimental|Liver transplant without a stent|Liver Transplant patients without a stent who are referred for liver ultrasound will have will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System .
3082807|NCT02008097|Experimental|Liver transplant with a stent|Liver transplant patients who are referred for angioplasty and stenting, or who have had angioplasty and stenting and are referred for liver ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
3082808|NCT02008097|Experimental|Renal artery disease without a stent|Patients with hypertension or impaired renal function who are referred for renal ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
3082809|NCT02008097|Experimental|Renal artery disease with a stent|Patients who are referred for angioplasty and stenting, or who have had angioplasty and stenting and are referred for renal ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
3082810|NCT02008097|Experimental|Pregnancy, Normal|Pregnant women referred for an obstetrical ultrasound to evaluate a normal pregnancy; for example, to determine gestation or gestational age will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
3082811|NCT02008097|Experimental|Pregnancy, High Risk|Pregnant women referred for an obstetrical ultrasound to evaluate a high risk pregnancy due to a medical condition present before or during pregnancy for either the mother or the baby will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System. Examples of risk factors include placenta previa, vaginal bleeding, suspected multiple gestation, suspected uterine abnormality, suspected fetal growth abnormality, advanced maternal age, a prior C-section, prior low birth weight baby, and prior preterm birth.
3082812|NCT02008084|Sham Comparator|TRIA-662 single-blind baseline|Baseline, 6 to 8-week, dietary lead-in period
3082813|NCT02008084|Experimental|TRIA-662|Following successful completion of the Baseline randomized to active drug
3082814|NCT02008084|Placebo Comparator|Placebo|Following successful completion of the Baseline randomized to placebo drug
3082815|NCT02008071|Experimental|Daily step goal financial incentive|
3082816|NCT02008071|Active Comparator|Control, Standard of Care|
3082817|NCT02008058||Single Arm|Surveys, diaries, clinical assessments of men with metastatic castrate-resistant prostate cancer
3082818|NCT02008045||Neonates at Risk for Brian Injury|Magnetic Resonance Imaging Neurodevelopmental Testing - 18 Month
3082819|NCT02008045||Term Neonates|Magnetic Resonance Imaging Neurodevelopmental Testing - 18 Month
3082820|NCT02008032|Experimental|All patients|Stationary Breast Tomosynthesis
3082821|NCT02008019|No Intervention|No treatment|No Everolimus treatment before surgery
3082822|NCT02008019|Experimental|Everolimus 2,5 mg/day|Everolimus treatment at 2,5 mg/day for 30 days
3082823|NCT02008019|Experimental|Everolimus 10 mg/day|Everolimus treatment at 10 mg/day for 30 days
3082824|NCT02008006|Experimental|BeEAM|"High Dose Chemotherapy (HDT) containing :~Bendamustine~Etoposide~Cytarabine~Melphalan~HDT will be followed by an Autologous Stem Cell Transplantation"
3082825|NCT02007993|Active Comparator|Group 1|Treatment with a tongue scraper
3082826|NCT02007993|Experimental|Group 2|PDT wavelength = 660 nm Fluency = 320 J/cm2 Power = 100 milliwatt Energy = 9 J Time = 90 s
3082827|NCT02007993|Experimental|Group 4|Tongue scraper + PDT wavelength = 660 nm Fluency = 320 J/cm2 Power = 100 milliwatt Energy = 9 J Time = 90 s
3082828|NCT02007993|Experimental|Group 3|PDT wavelength = 660 nm Fluency = 428 J/cm2 Power = 100 milliwatt Energy = 12 J Time = 120 s
3082829|NCT02007993|Experimental|Group 5|Tongue scraper + PDT wavelength = 660 nm Fluency = 428 J/cm2 Power = 100 milliwatt Energy = 12 J Time = 120 s
3082830|NCT02007980||Patients with indwelling ureteral stent|Patients with existing indwelling ureteral stent, no additional treatment
3082831|NCT02007954|Experimental|DEBDOX|
3082832|NCT02007941|Experimental|End Stage Renal Disease(ESRD)|"CKD-501 will be administered to patients who have required dialysis and non-dialysis eGFR(estimate glomerular filtration rate ) is Less than 15.~First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress"
3082833|NCT02007941|Active Comparator|normal renal function|"CKD-501 will be administered to normal renal function subject who have eGFR(estimate glomerular filtration rate ) of 90 or more.~First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress"
3082834|NCT02007941|Experimental|Mild renal impairment|CKD-501 will be administered to patients who have eGFR(estimate glomerular filtration rate ) is 60 to 89 that.
3082835|NCT02007928|Other|rispéridone, aripiprazole, olanzapine...|"Study:~We propose a prospective, interventional multicenter study.~Method:~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
3082836|NCT02007915|Experimental|Pamidronate Disodium|
3082837|NCT02007902||Very preterm babies|Observational model: cohort
3082838|NCT02007889|Active Comparator|L-carnitine|50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
3082839|NCT02007889|No Intervention|Control|control group received just antibiotic regimens without L-carnitine
3082840|NCT02007876|Experimental|Mobility and Activity Training|"Pre-operative: Participants will receive weekly sessions of higher level, task-specific transfer training. All MAT participants will learn the GCS set of exercises chosen to activate core muscles and lessen decline in core strength. These sessions will be supplemented by a home-based walking and physical activity enhancement program of the participants' choosing, focusing on attaining a safe community-based rate of perceived exertion. A pedometer and home exercise log will be used to encourage compliance and advance activities.~Post-operative: Participants will be screened by physical therapy for standard physical therapy with focus on early mobilization. The GCS exercises taught pre-operatively will be reinstituted.~Post-discharge/home: Participants will continue the GCS program and begin to return to elements of their pre-operative home-based MAT program. The program physical therapist will call weekly to review progress."
3082841|NCT02007876|No Intervention|Normal activity|"Pre-operative: Participants will be given the National Institute on Aging guide to home-based exercise but no further instruction or incentive for walking or physical activity enhancement.~Post-operative: Participants will be screened by in-hospital physical therapy for standard physical therapy with focus on early mobilization. Those who do not receive physical therapy will not be given any additional training, as is standard for reimbursed hospital services.~Post-discharge: Program nurse will call weekly to provide health education but no instruction or incentives for mobility or physical activity enhancement."
3082842|NCT02007863|Experimental|Umbilical Cord Blood + Chemotherapy|Umbilical Cord Blood transfusion + Chemotherapy (Fludarabine + Busulfan + Melphalan)
3082843|NCT02007850|Placebo Comparator|ropivacaine continuous mode|0.2% ropivacaine 8 ml/hr through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
3082844|NCT02007850|Active Comparator|ropivacaine patient controlled mode|0.2% ropivacaine patient controlled mode, basal rate 4 ml/hr, bolus 4 ml, lockout 60 minutes through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
3082845|NCT02007837|Experimental|Combined aspirin and multinutrient supplement|In a single capsule, the following will be combined: 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12
3082846|NCT02007837|Placebo Comparator|Placebo|5mg folic acid, cellulose filler
3082847|NCT02007824|Experimental|ULSD-12D|ultrasound surgical device made by Ultech.
3082848|NCT02007824|Active Comparator|SONOCA-180|ultrasound surgical device made by Soering
3082849|NCT02007811|Experimental|allogeneic donor derived B-lymphocytes|
3082850|NCT02007798|Experimental|low-dose group|S group : dexmedetomidine is infused intravenously at a dose of 0.4 ug/kg
3082851|NCT02007798|Experimental|middle-dose group|M group: dexmedetomidine is infused intravenously at a dose of 0.8 ug/kg
3082852|NCT02007798|Experimental|control group|P group: normal saline is infused intravenously
3082853|NCT02007785|Experimental|CO-OP treatment protocol|Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
3082854|NCT02007772|Active Comparator|BiPAP breathing support|BiPAP is used over a period of 6 weeks (outpatient)
3082855|NCT02007772|Experimental|nHF / TNI breathing support|nasal high-flow is used over a period of 6 weeks (outpatient)
3082856|NCT02007759|Experimental|VitalStim|This group will be assigned to the active VitalStim unit.
3082857|NCT02007759|Sham Comparator|Sham VitalStim|This group will be assigned to the sham VitalStim unit.
3082858|NCT02007746||Subjects with sickle cell disease and iron overload|Patients will have blood tests done to evaluate liver function and general health, then have FibroScan and Ferriscan. A blinded (no access to laboratory parameters or available data) radiologist will interpret the Ferriscan. Liver biopsy will be also obtained (if not done within the previous year). Otherwise, the results of the recent liver biopsy will be collected.
3082859|NCT02007746||control patients with sickle cell disease|Patients 10 years and older with sickle cell disease without history of chronic transfusions (less than 4 transfusions in a lifetime) and without obvious liver disease. Will have liver function blood tests and general health check ups. Then will have FibroScan performed. No liver biopsy will be performed in control patients.
3082860|NCT02007733|Other|Single Arm|All children enrolled in this study will receive the same interventions, which include collection of regular weights to establish percent weight change with rehydration, clinical assessment of dehydration status, and ultrasound of the IVC and aorta.
3082861|NCT02007720|Placebo Comparator|Placebo|Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.
3082862|NCT02007720|Experimental|Serelaxin|Patients will receive continuous intravenous infusion of serelaxin for 48 hours.
3082863|NCT02007707|Experimental|Tobacco LHW|Quit Smoking For a Healthy Family - family-based psycho-education intervention using lay health worker (LHW) outreach.
3082864|NCT02007707|Active Comparator|Healthy Eating|Eating Healthy and Physically Active for You and Your Family - This is a attention-control comparison group using a family-based psycho-education intervention delivered through lay health worker (LHW) outreach.
3082865|NCT02007694|Active Comparator|VRET plus Yohimbine|Virtual Reality Exposure Therapy combined with the administration of yohimbine.
3082866|NCT02007694|Active Comparator|VRET plus propranolol|Virtual Reality Exposure Therapy combined with the administration of propranolol
3082867|NCT02007694|Placebo Comparator|VRET plus placebo|Virtual Reality Exposure Therapy combined with the administration of a non-active placebo pill
3082868|NCT02007681|Experimental|Lifestyle change|One 5-10 minute break per hour during the work day using a software that alert the participant, and perform 6000 steps above the baseline number of steps/day (previously evaluated), by adopting several domain specific strategies, during 7 days.
3082869|NCT02007681|No Intervention|Control|Regular free week with no changes performed
3082870|NCT02007668|Experimental|Kinesio Taping|Patients will receive an application of Kinesio taping in their lumbar spine.
3082871|NCT02007668|Placebo Comparator|Kinesio Taping Placebo|Patients will receive an application of medical adhesive tape in their lumbar spine.
3082872|NCT02007668|No Intervention|Control|This participants will not receive intervention
3082873|NCT02007655||Eliquis on Nonvalvular Atrial Fibrilliation patients|Patients who are beginning to receive the treatment with Eliquis under the approved indications, dosage, and administration will be included in this study
3082874|NCT02007642||No study treatment|
3082907|NCT02007434|Placebo Comparator|Paradigm 2 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.
3100341|NCT01889602|Active Comparator|Lorazepam|Lorazepam: 2mg, po,1x
3082875|NCT02007629|Experimental|Riociguat|Subjects received riociguat film coated immediate-release (IR) tablet 3 times a day (tid) with or without food at a starting dose of 1.0 milligram (mg) and increased by 0.5 mg increments at 2-weekly intervals to a maximum of 2.5 mg tid, until Week 8 (titration phase). An optimal dose was determined based on systolic blood pressure (SBP) and well-being. Thereafter, riociguat continued at the optimal individual dose until Week 24 (Main phase). Dose reductions or stop of study medication for safety reasons were allowed at any time. Increases or re-increases in 0.5 mg steps (maximum dose 2.5 mg) were possible at the investigator's discretion weighing the benefit with potential risks implied. Subjects were offered participation in EDSP and received riociguat 2.5 mg film coated IR tablet 3 tid with or without food for 18 months or until reimbursement.
3082876|NCT02007616|Experimental|Non-action video game training|20 1-hour sessions of non-action video game training
3082877|NCT02007616|No Intervention|Control|Participants in the control group did not receive non-action video game training
3082878|NCT02007603|Experimental|Ampicillin / sulbactam|Patients are randomized to the ampicillin / sulbactam arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions.
3082879|NCT02007603|Experimental|Amoxicillin / clavulanic acid|Patients are randomized to the amoxicillin / clavulanic acid arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions.
3082880|NCT02007590|Experimental|Aerosure 25 Hz|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
3082881|NCT02007590|Sham Comparator|Aerosure sham|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
3082882|NCT02007590|No Intervention|No device|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
3082883|NCT02007577|Active Comparator|salsalate 3500mg in 2 divided doses a day|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
3082884|NCT02007577|Placebo Comparator|placebo|Participants will take 3 placebo tablets with breakfast and 4 placebo tablets with dinner
3082885|NCT02007564|Experimental|LIFE Intervention|RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
3082886|NCT02007564|No Intervention|Supportive Telephone Contact Control|Patients and caregivers each received three separate, structured emotional support telephone calls with research staff (M duration = 13 minutes; SD = 6.5 minutes) to minimize differential drop-out with the RSV intervention group. Control callers asked questions of participants and then engaged in supportive conversations using empathic listening and reflection. Topics discussed included family, intergenerational ties, and important aspects of the patient's life, but structured reminiscence and the creative and therapeutic nature of legacy activities were not discussed.
3082887|NCT02007551|Experimental|Mealtime Intervention|The mealtime intervention group will receive a trained peer volunteer to their home once weekly for 8 weeks to prepare and share a meal with them.
3082888|NCT02007538||Thin Prep|Samples obtained from this group will be tested with thin prep
3082889|NCT02007538||Control Group|Samples obtained from this group will be tested with conventional procedure.
3082890|NCT02007525|Experimental|Yoga intervention|
3082891|NCT02007525|No Intervention|Wait list control|
3082892|NCT02007512|Experimental|Enzalutamide & exemestane|Enzalutamide 160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food and exemestane 50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) once daily after food.
3082893|NCT02007512|Active Comparator|Placebo & exemestane|Placebo and exemestane 25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet after unblinding) once daily after food.
3082894|NCT02007499||Cardiac Arrest, Out of hospital|Pre-arrival Cardiopulmonary Resuscitation (CPR) instruction for bystander.
3082895|NCT02007486||Heart Failure: NYHA functional class I|Ambulatory and clinically-stable patients with New York Heart Association Functional Class I heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
3082896|NCT02007486||Heart Failure: NYHA functional class II|Ambulatory and clinically-stable patients with New York Heart Association Functional Class II heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
3082897|NCT02007486||Heart Failure: NYHA functional class III|Ambulatory and clinically-stable patients with New York Heart Association Functional Class III heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
3082898|NCT02007486||Healthy Control Subjects|Healthy, sedentary, non-smoking, age- and sex-matched control subjects.
3082899|NCT02007473||Patients requiring transfusion with plasma|Recipients, who have received a transfusion with Methylene Blue plasma produced using the THERAFLEX MB-Plasma procedure from MacoPharma.
3082900|NCT02007460|Experimental|Exercise leg|
3082901|NCT02007460|No Intervention|Control leg|
3082902|NCT02007447|Active Comparator|OCYTOCINA - SPRAY NASAL|OCYTOCINA - SPRAY NASAL - 24Ui twice per day for 8 weeks
3082903|NCT02007447|Placebo Comparator|Placebo|Placebo - twice per day for 8 weeks
3082904|NCT02007434|Experimental|Paradigm 1 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL (based on Baseline CR-SMFRS grade 2 or 3, respectively) on Day 0 and a cold compress applied to the treatment area.
3082905|NCT02007434|Placebo Comparator|Paradigm 1/ Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.
3082906|NCT02007434|Experimental|Paradigm 2 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.
3082908|NCT02007434|Experimental|Paradigm 3 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.
3082909|NCT02007434|Placebo Comparator|Paradigm 3 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
3082910|NCT02007434|Experimental|Paradigm 4 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
3082911|NCT02007434|Placebo Comparator|Paradigm 4 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
3082912|NCT02007421|Other|HIV positive homosexual men|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
3082913|NCT02007421|Other|HIV negative homosexual men|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
3082914|NCT02007408|Placebo Comparator|Placebo group|
3082915|NCT02007408|Active Comparator|Paracervical block plus lidocaine spray|Lidocaine injection+Lidocaine spray received PCB with 2 ampoules of lidocaine solution plus 2 pumps (20 mg=2 pumps) of 10% lidocaine spray
3082916|NCT02007408|Active Comparator|paracervical block plus isotonic saline spray|2 ampoules of lidocaine solution (20 mg Lidocaine HCl+0.0125 mg epinephrine/ml) plus isotonic spray
3082917|NCT02007408|Active Comparator|only lidocaine spray|paracervical block with saline solution plus 10% lidocaine spray
3082918|NCT02007395||colonoscopy population|
3082919|NCT02007369|Experimental|WhatsApp|Provide peer support and deliver relapse prevention messages through WhatsApp for 8 weeks and telephone follow ups
3082920|NCT02007369|Experimental|Facebook|Provide peer support and deliver relapse prevention messages through Facebook for 8 weeks and telephone follow ups
3082921|NCT02007369|No Intervention|Control|Telephone follow ups and received a self-help book only
3082922|NCT02007356|Experimental|allogeneic HSCT|"The present study will evaluate and validate in a single-center, open-label, single arm fashion the safety and feasibility of direct infusions of donor-derived pathogen-specific IFN-γ positive T-cells in recipients of HSCT with post-transplant viral infection according to the previously clinically certified CCS® [3-6]. The Investigator will first generate and apply IFN-γ positive selected T-cells to recipients of HSCT with CMV, EBV or adenovirus as previously published. The Investigator aim is to include 6 patients from the University Hospital of Basel.~With confirmed safety the investigator will in the future perform an efficacy study and extend this treat-ment for other clinically relevant pathogens including human herpesvirus (HHV)-6, HHV-8, polyomaviruses JC and BK and fungi including Aspergillus fumigatus and Candida albicans, to other immunosuppressed patients such as solid organ transplant (SOT) recipients."
3082923|NCT02007343||Patients with gram-negative infections|"Sample (5/week/hospital) of all patients in a hospital that meet all of the following:~meeting the criteria of at least one infection entity based on (modified) definitions of the Center for Disease Control and Infection Prevention (CDC; Am J Infect Control 2008;36:309-32) (restricted to infections that have septic potential);~a culture with a gram-negative isolate (Enterobacteriaceae / Pseudomonas aeruginosa / Acinetobacter spp. / Stenotrophomonas maltophilia) with minimal inhibitory concentration (MIC) results from an automated system available that can be used to identify such an infection entity according to these criteria;~receipt of antibiotics (oral, intravenous or intramuscular) for this infection, the choice of which is determined by the culture with the gram-negative (i.e. this isolate is seen as the causative pathogen);~were admitted to the hospital during (part of) the infection episode.~Date of entry into cohort: date of index culture of infection episode"
3082924|NCT02007343||Non-infected patients|"Matched sample of all patients that (1) were admitted to the hospital and (2) did not have a gram-negative infection according to the 4 criteria set out in the other group on the date used for matching. Selected by matching 1:1 to patients with gram-negative infections on (1) hospital, (2) length of hospital stay on the date the index culture for the infected patient was obtained, and (3) age.~Date of cohort entry: date of index culture of matched infected patient"
3082925|NCT02007330|Experimental|Group L|Intravenous lidocaine infusion group
3082926|NCT02007330|Placebo Comparator|Group C|Intravenous normal saline infusion - control group
3082927|NCT02007317|Experimental|Oshadi D and Oshadi R|Anti tumor agents
3082928|NCT02007304|Experimental|Herbs|participants assigned to experimental arm will take 300mg panax ginseng and 300mg salvia miltiorrhiza extracts in capsules for 12 weeks along with eccentric exercise training
3082929|NCT02007304|Placebo Comparator|Placebo|parcipants in this group will take placebo capsule containing microcrystalline cellulose
3082931|NCT02007278|Active Comparator|glimepiride and metformin|Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin
3082932|NCT02007265||TIA and SPC outpatients|All consecutive patients attending outpatient TIA and Stroke Prevention Clinics at three regional stroke centres will be eligible to be screened.
3082933|NCT02007252|Experimental|ACZ885|Participants received ACZ885 150 mg subcutaneously (s.c.) once per month for 12 months.
3082934|NCT02007252|Placebo Comparator|Placebo|Participants received matching placebo to ACZ885 s.c. once per month for 12 months.
3082935|NCT02007239|Experimental|treatment|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
3082936|NCT02007226||Spinal Cord Injury|Chronic SCI (Duration of Injury >5 years)
3082937|NCT02007200|Experimental|Treatment (soy isoflavones)|Patients receive soy isoflavones PO for approximately 14 days before undergoing surgery.
3082938|NCT02007187|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.
3082939|NCT02007187|Placebo Comparator|Placebo|Based on the standard medical care, placebo was 40ml of 0.9% saline, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.
3082940|NCT02007174||Bevacizumab injection|Three subconjunctival intralesional injections of bevacizumab. Bevacizumab injections were 2.5 mg/0.05 ml, subconjunctivally applied near to the pterygium recurrence. Application of bevacizumab was performed three times: basal, 2 and 4 weeks.
3082941|NCT02007174||Medical Treatment|In order to reduce the patient bias, the control eye received a sham laser treatment, under slit lamp, topical anesthesia using 0.5% tetracaine hydrochloride eye drops (Ponti-Ofteno, Laboratorios Sophia, Jalisco, Mexico) and topical 1 mg fluorescein Sodium staining (Bio-Glo, Hub Pharmaceuticals, Rancho Cucamonga CA). Post sham laser care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
3082942|NCT02007174||Argon Laser Treatment|Argon laser therapies were performed on an outpatient basis only by one ophthalmologist. Under slit lamp, topical anesthesia using 0.5% tetracaine hydrochloride eye drops (Ponti-Ofteno, Laboratorios Sophia, Jalisco, Mex) and topical 1 mg fluorescein Sodium staining (Bio-Glo, Hub Pharmaceuticals, Rancho Cucamonga CA) was applied. Argon laser was applied along the vessels of the pterygium apex with power between 450mW to 780 mW, spot size of 100 u with 10 milliseconds duration. Additional grill pattern treatment was given to pterygium body using a 200 microns spot size. Treatments were given in one only session. Post laser care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, CA, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
3082943|NCT02007161|Active Comparator|Nutritional State|"Fed vs. Fasted State~Diclofenac potassium 50 mg"
3082944|NCT02007161|Active Comparator|Use of a PPI|"Nexiam (esomeprazole) 40 mg~Diclofenac potassium 50 mg"
3082945|NCT02007148|Experimental|micado|CAPECITABINE 500 mg twice a day, orally, continuously DOCETAXEL 60 mg/sqm i.v. over 1 hr on day 1 cycles repeated every 3 weeks Duration of treatment: Chemotherapy should be continued until: progressive disease; unacceptable toxicities; patients' refusal; or upon investigator's judgement is in the best interest for the patient.
3082946|NCT02007135||Healthy|Healthy persons, without non-specific low back pain
3082947|NCT02007122|Experimental|IRRT|Ceftaroline levels are measured in patients receiving intermittent renal replacement therapy
3082948|NCT02007122|Experimental|CRRT|Ceftaroline levels are measured in patients receiving continuous renal replacement therapy
3082949|NCT02007109||Nausea measurement by VAS and BARF|"All patients will be asked to rate their nausea on both the VAS and the BARF scales. For the nausea scales, the script would be: Have you thrown up or felt like you were going to throw up before? How did your tummy feel then? We call that feeling of being sick to the stomach as nausea.~For the BARF scale:These faces show children who feel no nausea at all, who feel a little bit nauseated, who feel even more nauseated, and these are children who have the most nausea it is possible to feel. (Point to the each face at the appropriate time). Which face is more like you feel right now? For the VAS scale: On this line the far left indicates No nausea and the far right Worst nausea ever. Can you show me on this line how much nausea you have right now?"
3082950|NCT02007096|Experimental|Transabdominal Plane Block|Receiving Transabdominal Plane Block with 0.25% bupivacaine
3082951|NCT02007096|Placebo Comparator|Non Transabdominal Plane Block|Receiving placebo saline injection
3082952|NCT02007083|Active Comparator|Bilateral laminotomy (BL)|The multifidus muscles is detached from the spinous process bilaterally.The decompression of the spinal canal is performed by first doing a flavectomy. Thereby performing a laminotomy (about 1/3) of the the lower part of the superior lamina, and a laminotomy of the upper part (about 1/4) of the inferior lamina. This is performed bilaterally.
3082953|NCT02007083|Active Comparator|Unilateral laminotomy with crossover (UL)|The multifidus muscles is detached from the spinous process unilaterally. The laminotomy is first performed ipsilaterally. The decompression of the spinal canal is performed by first doing a flavectomy. Then, performing a laminotomy (about 1/3) of the the lower part of the superior lamina, and a laminotomy of the upper part (about 1/4) of the inferior lamina. Dura is then retracted, and the decompression is performed contralaterally.
3082954|NCT02007083|Active Comparator|Spinous process osteotomy (SPO)|The multifidus muscles is detached from the spinous process unilaterally. An osteotomy of the superior spinous process is performed at the basis, in the actual level. The spinous process with intact interspinal and supraspinal ligaments is then retracted to the contralateral side. The decompression is first performed in the midline. Then one goes laterally on both sides too perform the decompression. About 1/3 of the lower part of the superior lamina is removed, and about 1/4 of the upper part of the inferior lamina is removed.
3082955|NCT02007070|Experimental|Pembrolizumab 10 mg/kg|Participants receive pembrolizumab 10 mg/kg intravenously over 30 minutes on Day 1 of each 21-day cycle for up to 2 years.
3082987|NCT02006849|Other|Acthar 40 units|Acthar 40 units subcutaneously three times a week for patients with sub-nephrotic proteinuria.
3083524|NCT02003222|Experimental|Arm I (blinatumomab, chemotherapy)|See Detailed Description
3082956|NCT02007057|Active Comparator|Interscalene nerve block|"Interscalene block is performed preoperatively with ultrasound guidance and neurostimulation 0.8 milliampere. The block is performed using in-plane approach with a needle of 50 mm for a neurostimulation. During the injection, it is verified that the diffusion extends to the anterior and posterior space. If the posterior distribution is limited, the needle is remobilized to obtain an overall diffusion: a bolus of 20 mL of ropivacaine 0.75% is made by the anesthetist. The effectiveness of the nerve block is checked before the start of surgery."
3082957|NCT02007057|Experimental|Suprascapular nerve block|The suprascapular block is performed at the end of surgery when the incisions are closed but before the removal of the surgical drapes. The material used is a compound of a 10 cc syringe sterile equipment, a green intramuscular needle (14 gauge) and a bulb 10 cc of 0.75% Ropivacaine. The injection of 10 cc is realized by the technical princeps
3082958|NCT02007044|Experimental|Ibrutinib (Subgroup 1)|Ibrutinib started on Day 1 of cycle 1 at dose of 420 mg (3 x 140-mg capsules) orally once daily in each 28 day cycle. Patients in the iR group alternatingly assigned to subgroups 1 and 2, the purpose is to compare rituximab infusion reactions.
3082959|NCT02007044|Experimental|Ibrutinib (Subgroup 2)|Ibrutinib started on Day 2 of cycle 1 at dose of 420 mg (3 x 140-mg capsules) orally once daily in each 28 day cycle. Patients in the iR group alternatingly assigned to subgroups 1 and 2, the purpose is to compare rituximab infusion reactions.
3082960|NCT02007044|Experimental|Ibrutinib (Subgroup 1) + Rituximab|"Ibrutinib 420 mg (3 x 140-mg capsules) given orally on Day 1 of cycle 1 for each 28 day cycle. Patients in the iR group alternatingly assigned to subgroups 1 and 2, the purpose is to compare rituximab infusion reactions.~Rituximab 375 mg/m2 given intravenously on Day 1, Day 8, Day 15, and Day 22 , and then continued once every 4 weeks only on Days 1 during cycles 2 - 6. Patients in the iR group alternatingly assigned to subgroups 1 and 2, the purpose is to compare rituximab infusion reactions."
3082961|NCT02007044|Experimental|Ibrutinib (Subgroup 2) + Rituximab|"Ibrutinib 420 mg (3 x 140-mg capsules) given orally on Day 2 of cycle 1 for each 28 day cycle. Patients in the iR group alternatingly assigned to subgroups 1 and 2, the purpose is to compare rituximab infusion reactions.~Rituximab 375 mg/m2 given intravenously on Day 1, Day 8, Day 15, and Day 22 , and then continued once every 4 weeks only on Days 1 during cycles 2 - 6. Patients in the iR group alternatingly assigned to subgroups 1 and 2, the purpose is to compare rituximab infusion reactions."
3082962|NCT02007031||Hypertensive subjects|Hypertensive subjects are exposed to brief cold exposure (-15 C for 15 min) mainly subjected to their facial region during which their cardiovascular responses are registered.
3082963|NCT02007031||Normotensive subjects|Normotensive subjects are exposed to brief cold exposure (-15 C for 15 min) mainly subjected to their facial region during which their cardiovascular responses are registered.
3082964|NCT02007018|Experimental|Negative Pressure Wound Therapy|This group will receive the usual care of surgical wound AND Negative Pressure Wound Therapy (NPWT). The Prevena™ Incision Management System (PIMS) is placed in a sterile fashion over the closed surgical site prior to leaving the operating room. The PIMS is to remain in place until the completion of therapy at five days.
3082965|NCT02007018|Active Comparator|Usual Care of Surgical Wound|This group will receive the usual care of a surgical wound.
3082966|NCT02007005|Experimental|Dose escalation|intravesical instillation of abnobaVISCUM Fraxini
3082967|NCT02006992|Active Comparator|RTF Infant Formula 1|a ready to feed (RTF) extensively hydrolyzed infant formula fed ad lib.
3082968|NCT02006992|Experimental|Powder Infant Formula 2|a powdered extensively hydrolyzed infant formula fed ad lib.
3082969|NCT02006979|Experimental|Exercise|an acute bout of exercise performed ≤24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post
3082970|NCT02006979|No Intervention|No exercise|no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines
3082971|NCT02006966|Experimental|Group L|Intravenous lidocaine infusion group
3082972|NCT02006966|Active Comparator|Group C|Intravenous normal saline infusion - control group
3082973|NCT02006953|Active Comparator|Bolus|"Bolus: Total volume of feedings is determined by the amount of formula required to meet calorie and protein needs, which is determined by a Registered Dietitian. Volume of each bolus is determined by dividing the total volume of feeding by the desired number of feedings per day:~If child is less than 6 months: 8 feeds/day If child is 6-12 months 6 feeds/day If child is 12 months or greater: 5 feedings/day Rate of feeds is determine by the rate needed to infuse each bolus over 1 hour. Patient to remain NPO. Once at goal, if able to take PO, may offer orally first with remainder of goal volume over the remainder of the hour."
3082974|NCT02006953|Active Comparator|Continuous|Continuous: Total volume of feedings is determined by the amount of formula required to meet calorie and protein needs, which is determined by a Registered Dietitian. Rate of feeds is determined by dividing total volume of feedings by 24 hours. Patient is to remain NPO. Once at goal, if able to take PO, may offer hourly amount orally, but only 2x per day.
3082975|NCT02006940|Experimental|Alveoflex, in vivo imaging miniprobe|All the patients will be examined using confocal laser endomicroscopy during bronchoscopy with a special minirobe Alveoflex before and after the treatment. Records will be done and analyzed prospectively with the included software for endomicroscopic system.
3082976|NCT02006927|Experimental|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
3082977|NCT02006914||Chromium Picolinate|Subjects who are HIV+ and insulin resistant
3082978|NCT02006914||Placebo|HIV+ and insulin resistant
3082979|NCT02006901||microdecompression|surgical microdecompression using a bilateral or unilateral approach depending on the surgeon's preference and the individual patient's anatomy and symptoms.
3082980|NCT02006901||laminectomy|the spinous process and the laminae of the involved level(s) as well as the medial aspects of the facet joints are resected
3082981|NCT02006888|Experimental|IBI-10090 low dose|IBI-10090 low dose
3082982|NCT02006888|Experimental|IBI-10090 med dose|IBI-10090 med dose
3082983|NCT02006888|Placebo Comparator|Placebo|Placebo
3082984|NCT02006875|Experimental|real rTMS|Experimental included the a daily real rTMS session for 15 mins followed by a physical therapy for 45 mins.
3082985|NCT02006875|Sham Comparator|sham rTMS|the control interventions included a daily sham rTMS session for 15 minutes followed by a physical therapy for 45 minutes.
3082986|NCT02006862||olanzapine, schizophrenia|
3083023|NCT02006615|Sham Comparator|Sham rTMS|Sham stimulation
3082988|NCT02006849|Other|Acthar 80 units|Acthar 80 units subcutaneously twice a week for patients with nephrotic proteinuria.
3082989|NCT02006836|Other|Diabetic|Diabetic patients use metformin or only on diet control(met or diet).18 of the patients were on metformin treatment and 2 patients were on diet control due to the early stage of this disease. On the first test day we utilized 50 g of glucose dissolved in 200 ml water. The second day was washout day. On the third day we used 922 g of Majia pomelos which contained 50 g carbohydrate.This group of diabetic patients enrolled for the case control period.
3082990|NCT02006836|Other|Healthy|On the first test day we utilized 50 g of glucose dissolved in 200 ml water. The second day was washout day. On the third day we used 922 g of Majia pomelos which contained 50 g carbohydrate.This group of volunteers enrolled for the case control period.
3082991|NCT02006836|Other|Diabetic 2 - without pomelo|Patients of Diabetic 2 group were on CSII treatment with insulin subcutaneous pump.The scheme and dose of CSII for each patients were adjusted on the first 3 test days to optimize glucose control, followed by 3-day CSII treatment without change of insulin dose. On the 7th test day, patients consumed 100g Majia pomelos after meals (breakfast, lunch and dinner) for 3 test days. This arm refers to the group on the 4th to 6th day with a constant dose of insulin and did not consumed Majia pomelos after meals, and this intervention was defined as blank.
3082992|NCT02006836|Other|Diabetic 2 - with pomelo|Patients of Diabetic 2 group were on CSII treatment with insulin subcutaneous pump.The scheme and dose of CSII for each patients were adjusted on the first 3 test days to optimize glucose control, followed by 3-day CSII treatment without change of insulin dose. On the 7th test day, patients consumed 100g Majia pomelos after meals (breakfast, lunch and dinner) for 3 test days. This arm refers to the group on the 7th to 9th day with a constant dose of insulin and consumed 100g Majia pomelos after meals (breakfast, lunch and dinner).
3082993|NCT02006810|Experimental|lipids|The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome).
3082994|NCT02006810|Other|flavonoids|The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome).
3082995|NCT02006797|Experimental|intervention|patients with reconciliation procedure at discharge and included in the exchange process
3082996|NCT02006797|No Intervention|control|usual care
3082997|NCT02006771|Experimental|Southern Chinese meal|White rice (1 bowl), stir fried Choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil
3082998|NCT02006771|Experimental|Northern Chinese meal|Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil
3082999|NCT02006771|Experimental|American meal|Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil plus Coca-cola classic (21 fluid ounces)
3083000|NCT02006771|Experimental|South Indian meal|Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
3083001|NCT02006758||Uncontrolled hypertension patients|The study will enroll 500 patients planned to undergo a renal denervation procedure (with the 'EnligHTN™ Renal Denervation System') for the treatment of their uncontrolled hypertension.
3083002|NCT02006745|Other|Ribavirin|ARM 1: PEG-IFN and weight-based ribavirin (RBV)
3083003|NCT02006745|Other|Telaprevir|ARM 2: PEG-IFN and weight-based RBV plus telaprevir (TPV)
3083004|NCT02006732|Experimental|tiotropium + olodaterol low dose|Once daily 2 puffs solution for inhalation Respimat
3083005|NCT02006732|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
3083006|NCT02006732|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
3083007|NCT02006732|Placebo Comparator|placebo|Once daily 2 puffs solution for inhalation Respimat
3083008|NCT02006719|Experimental|Collagenase Clostridium Histolyticum|Up to 3 injections of .58 mg/1 mL of collagenase clostridium histolyticum (CCH), minimum of 21 days apart and home shoulder exercise.
3083009|NCT02006719|Placebo Comparator|Placebo|Up to 3 1-mL injections of placebo, minimum of 21 days apart and home shoulder exercise.
3083010|NCT02006706|Experimental|MabThera/Rituxan|
3083011|NCT02006693|Other|XEN Gel Stent|The XEN Gel Stent will be placed as a standalone procedure.
3083012|NCT02006693|Other|XEN Gel Stent with cataract surgery|The XEN Gel Stent with cataract surgery, only will occur if the patient is diagnosed with a cataract..
3083013|NCT02006680||Children with Central Precocious Puberty|Children with Central Precocious Puberty will have hormonal testing of markers of puberty up to 30 days prior to placement of a Supprelin LA insert and 28-97 days after placement of the Supprelin LA insert.
3083014|NCT02006667|Experimental|Trastuzumab, Gemcitabine, Cisplatin|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v until disease progression; 1200 mg per square meter (m2) gemcitabine i.v. on Days 1, 8, and 15 of Cycles 1 through 6; and 70 mg/m2 cisplatin i.v. on Day 2 of Cycles 1 through 6.
3083015|NCT02006654|Placebo Comparator|Placebo|Placebo adjunct to base treatment with an AChEI
3083016|NCT02006654|Experimental|Idalopirdine 60 mg (or 30 mg)|Idalopirdine adjunct to base treatment with an AChEI
3083017|NCT02006641|Placebo Comparator|Placebo|Placebo adjunct to 10 mg Donepezil
3083018|NCT02006641|Experimental|Idalopirdine 10 mg|Idalopirdine adjunct to 10 mg Donepezil
3083019|NCT02006641|Experimental|Idalopirdine 30 mg|Idalopirdine adjunct to 10 mg Donepezil
3083020|NCT02006628|Placebo Comparator|Placebo|"Placebo oral solution is presented as an oily solution containing excipients, sesame oil, ethanol, sucralose and strawberry flavouring.~Dose: 5 mL Placebo oral solution to be taken twice daily for 6 weeks.~The total dose administered within any 24-hour interval will be 10 mL of oral solution."
3083021|NCT02006628|Active Comparator|GWP42003|"GWP42003 oral solution is presented as an oily solution containing 100 mg/mL of cannabidiol (CBD) dissolved in excipients, sesame oil, ethanol, sucralose and strawberry flavouring.~Dose: 5 mL GWP42003 (500 mg CBD) oral solution to be taken twice daily for 6 weeks.~The total dose administered within any 24-hour interval will be 10 mL of oral solution (1 g CBD)."
3083022|NCT02006615|Experimental|5Hz rTMS|rTMS group
3083024|NCT02006602|Experimental|Arm 1 reference then test|Subjects will be randomized and receive the following two treatments administered orally in a fasting state: A=Single dose of candesartan cilexetil (Reference treatment) 16mg; B= Single dose of candesartan cilexetil (Test formulation) 16mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
3083025|NCT02006602|Experimental|Arm 2 test then reference|Subjects will receive the following two treatments administered orally in a fasting state: A= Single dose of candesartan cilexetil (Test formulation) 16mg. B=Single dose of candesartan cilexetil (Reference treatment) 16mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
3083026|NCT02006589|Experimental|Arm 1 Test then Reference|Subjects will be randomized and receive the following two treatments administered orally in a fasting state A= Single dose of candesartan cilexetil (Test formulation) 8mg; B = Single dose of candesartan cilexetil (Reference treatment) 8mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
3083027|NCT02006589|Experimental|Arm 2 Reference then Test|Subjects will be randomized and receive the following two treatments administered orally in a fasting state: A=Single dose of candesartan cilexetil (Reference treatment) 8mg; B= Single dose of candesartan cilexetil (Test formulation) 8mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
3083028|NCT02006576|Placebo Comparator|COPD, Placebo|Placebo three times daily
3083029|NCT02006576|No Intervention|Control subject|Control subjects, no intervention
3083030|NCT02006576|Experimental|COPD, ibuprofen|600 mg ibuprofen three times daily for 48 weeks
3083031|NCT02006537|Experimental|Cohort 1|Cohort 1 will enrol 8 healthy male volunteers, who will receive a single 10 mg dose of GSK225694 in the fasted state.
3083032|NCT02006537|Experimental|Cohort 2|Cohort 2 will enrol 20 healthy elderly male and female volunteers (10 males and 10 females), who will receive a single 10 mg dose of GSK225694 in the fasted or fed state according to the randomization schedule.
3083033|NCT02006524|Active Comparator|Screening with MyDiagnostick|All patients eligible for influenza vaccination are screened for atrial fibrillation with the MyDiagnostick, an easy to use and patient friendly device.
3083034|NCT02006511|Experimental|Incisional Neg Pressure Wound Therapy|Incisional negative pressure wound therapy dressings applied to the surgical site
3083035|NCT02006511|Active Comparator|Standard of care wound dressing|Standard of care wound dressing of gauze and tape or the equivalent applied to the surgical site
3083036|NCT02006498|Experimental|Sillymarin|Active component study medication
3083037|NCT02006498|Placebo Comparator|Placebo|Placebo capsules
3083038|NCT02006485|Experimental|Ublituximab + TGR-1202|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose
3083039|NCT02006485|Experimental|Ublituximab + TGR-1202 + ibrutinib|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose ibrutinib oral daily dose
3083040|NCT02006485|Experimental|Ublituximab + TGR-1202 + bendamustine|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Bendamustine at a fixed IV infusion on Days 1 & 2
3083041|NCT02006472|Experimental|Pridopidine 45 mg|Twice daily
3083042|NCT02006472|Experimental|Pridopidine 67.5 mg|Twice daily
3083043|NCT02006472|Experimental|Pridopidine 90 mg|Twice daily
3083044|NCT02006472|Experimental|Pridopidine 112.5 mg|Twice daily
3083045|NCT02006472|Placebo Comparator|Placebo|Twice daily
3083046|NCT02006446||VATES|men with altered spermograms (isolated teratozoospermia or oligo-astheno-teratozoospermia)
3083047|NCT02006433|Experimental|Deep Brain Stimulation|Deep brain stimulation (DBS) for the alleviation of chronic neuropathic pain in patients with spinal cord injury (SCI). The stimulation will be applied bilaterally or unilaterally in the midbrain periaqueductal/periventricular gray region (PAG/PVG).
3083048|NCT02006433|No Intervention|Extension|Extended participation in the study, which will last approximately 2 more years, precisely 104 weeks.The purpose of this extended portion of the study is to obtain long-term follow-up information on safety and efficacy, in subjects that have opted to receive continuing brain stimulation. Investigators label weeks in terms of original enrollment. Thus the surgery occurs in weeks 7 and 8 and the original study finishes in week 52, with the extension lasting from week 53 to week 156.
3083049|NCT02006420|Experimental|ARFI-SVI Ultrasound|Ultrasound imaging of forearm and thigh, lasting approximately 5-10 minutes.
3083050|NCT02006420|Experimental|Healthy Volunteers: AFRI/SVI Ultrasound|Ultrasound imaging of forearm and thigh, lasting approximately 5-10 minutes.
3083051|NCT02006407|Other|Primary Brain Tumor|Patients receiving standard cranial radiotherapy will undergo (1) Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI) and (2) Neuro-cognitive testing (CogState-a computerized software testing system that offers various cognitive assessments based on traditional expansive neurocognitive tests) at four timepoints (Baseline, 3 weeks, 6 weeks and 6 months).
3083052|NCT02006394|Experimental|Active Diet|Reduced glycemic index bread products, fish oil capsules, and polyphenol capsules.
3083053|NCT02006394|Placebo Comparator|Placebo Diet|Market variety bread products, corn oil capsules, and corn starch capsules.
3083054|NCT02006381||Age 3-6|This will include 10 typically developing boys age 3-6
3083055|NCT02006381||Age 7-12|This will include 10 typically developing boys age 7-12
3083056|NCT02006381||Age 13-17|This will include 10 typically developing boys age 13-17
3083057|NCT02006368|Experimental|Storage Age|
3083058|NCT02006355|Active Comparator|Continuous femoral nerve bloc|Continuous femoral nerve bloc
3083059|NCT02006355|Experimental|Continuous local anesthesia|Continuous local infiltration of local anesthetic in the operated knee.
3083060|NCT02006342|Experimental|Insulin Glargine plus Regular Insulin|Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring, with the addition of subcutaneous Insulin Glargine within 2 hours of diagnosis.
3083061|NCT02006342|Active Comparator|Control - Regular Insulin|Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring.
3083062|NCT02006329|Experimental|Intervention group - dietary consultation - Medit|
3100342|NCT01889602|Placebo Comparator|Placebo|Placebo: one tablet, po,1x
3083064|NCT02006316||varicoceles|men with clinical varicoceles underwent microsurgical varicocelectomy due to causes other than infertility such as testicular pain, discomfort or scrotal mass
3083065|NCT02006303|Active Comparator|Green light PVP|The KTP:YAG laser is based on the principle of passing Nd:YAG laser light through a KTP crystal. This halves the wavelength of the emitted laser to 532 nm and doubles its frequency. The emitted light is a visible green light, which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. Prostate tissue is vaporized leaving an appropriate cavity for voiding.
3083066|NCT02006303|Active Comparator|Prostatic Artery Embolization|Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
3083067|NCT02006290|Experimental|1|
3083068|NCT02006290|Placebo Comparator|2|
3083069|NCT02006277|Experimental|Cohort 1|Cohort 1 will be an open label, randomized, 4 period, 4 treatment, 4 sequence, cross over sensory evaluation of three new prototype formulations (75 mg dose of crizotinib as prototypes 0.529 mg/mg, 0.470 mg/mg and 0.420 mg/mg Microspheres) and OS (75 mg dose of crizotinib)via use of a Crizotinib Taste Assessment - Questionnaire for Cohort 1 in healthy adults.
3083070|NCT02006277|Experimental|Cohort 2|This cohort will be an open label, randomized, 5 period, 5 treatment, 4 sequence, cross over single dose bioavailability study employing administration of four crizotinib formulations Treatments E, F, G and H (Crizotinib 250 mg dose Formulated Capsule and 250 mg dose crizotinib as prototypes 0.529 mg/mg, 0.470 mg/mg and 0.420 mg/mg Microspheres, respectively) in the fasted state to healthy adult subjects (Periods 1-4). In addition, Treatment I (250 mg dose of crizotinib OS) will be administered at Period 5, for a taste evaluation only (no pharmacokinetic (PK) sample collection after the dose), in the period immediately following the completion of Period 4 of Cohort 2. A Crizotinib Taste Assessment - Questionnaire for Cohort 2 will be filled by all subjects.
3083071|NCT02006264|Active Comparator|TDF Intravaginal Ring|Tenofovir Disoproxil Fumarate intravaginal ring (TDF-IVR) is a white (with clear segment), flexible torus-shaped device with an inner core compartment comprised of TDF (86 wt% of formulation) and Sodium Chloride (NaCl) (14 wt% of formulation). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
3083072|NCT02006264|Placebo Comparator|Placebo Intravaginal Ring|The placebo intravaginal ring (IVR) is a clear, flexible torus-shaped device with an inner core which contains sodium chloride (NaCl). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
3083073|NCT02006238|Experimental|Farabloc|The participants will sleep on Farabloc fabric nightly for a week.
3083074|NCT02006238|Placebo Comparator|Nylon Fabric|The participants will sleep on Nylon fabric nightly for week.
3083075|NCT02006225|Experimental|Plerixafor|The use of plerixafor as additive measurment for the conventional stem cell collection protocol.
3083076|NCT02006212|Other|cadiac surgical patient; One arm|All patients undergoing first or redo cardiac surgery with or without cardiopulmonary bypass necessitating general and/or local anesthesia. If they present any EEG abnormality intraoperatively an immediate cerebral CT scan will be performed and the necessary measures will be taken to reduce the neurologic damage.
3083077|NCT02006199|Experimental|relaxation with psychoeducation|after 8 weeks of relaxation with psychoeducation. subject take part in 8 weeks of the mindfulness meditation program
3083078|NCT02006199|Experimental|meditation|8 weeks of mindfulness meditation
3083079|NCT02006186|Experimental|Bicycle Train Intervention|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants. All participants, regardless of group assignment, each receive a bicycle, safety equipment, and take a bicycle safety course.
3083080|NCT02006186|No Intervention|Control|The control arm does not receive any intervention. All participants, regardless of group assignment, each receive a bicycle, safety equipment, and take a bicycle safety course.
3083081|NCT02006173|Placebo Comparator|Normal saline|Participants will be randomly assigned to nasolabial or nasolabial&cheekbone group and receive control treatment (20mg/ml hyaluronic acid mixed with 0.175 ml normal saline) in one side of the face.
3083082|NCT02006173|Active Comparator|Lidocaine|Participants will be randomly assigned to nasolabial or nasolabial&cheekbone group and receive experiment treatment (20mg/ml hyaluronic acid mixed with 0.175 ml 2% lidocaine) in one side of the face.
3083083|NCT02006160|Active Comparator|treatment|dalfampridine
3083084|NCT02006160|Placebo Comparator|control|placebo
3083085|NCT02006147|Experimental|TLC399- Group R1|0.24 mg DSP with 100 mM PL (20 µL)
3083086|NCT02006147|Experimental|TLC399- Group 1|0.36 mg DSP with 100 mM PL (30 µL)
3083087|NCT02006147|Experimental|TLC399- Group 2|0.6 mg DSP with 100 mM PL (50 µL)
3083088|NCT02006147|Experimental|TLC399- Group 3|0.6 mg DSP with 50 mM PL (50 µL)
3083089|NCT02006134||PEDIATRIC VASCULITIS/PROSPECTIVE|Pediatric patients in this cohort are those diagnosed with vasculitis within 12 months from study entry. Clinical data, blood (RNA, plasma, serum), urine, and saliva (DNA) will be collected at 3 to 5 timepoints: time-of-diagnosis, post-induction, 12-month post diagnosis, disease flare, and remission/post-flare.
3083090|NCT02006134||PEDIATRIC VASCULITIS/RETROSPECTIVE|Patients in this cohort are those diagnosed with vasculitis more than 12 months from study entry and/or were previously enrolled in the ARChiVe or Brainworks registries. Clinical outcome data will be collected retrospectively. Blood (RNA & serum), urine, and saliva (DNA) will be collected at 2 timepoints: disease flare, and remission/post-flare.
3083091|NCT02006134||ADULT VASCULITIS/ COHORT 1|Adult patients in this cohort are those at or near the time of diagnosis of GPA, MPA, EGPA or unclassified vasculitis that are participants in DCVAS. Clinical data and blood (RNA, DNA) will be collected at the time-of-diagnosis only.
3083092|NCT02006134||ADULT VASCULITIS / COHORT 2|Adult patients in this cohort are those individuals that are participants in DCVAS and have any form of vasculitis. Clinical data and blood (DNA) collected at the time-of-diagnosis will be used for study.
3100343|NCT01889589||NYC adults|
3083093|NCT02006134||HEALTHY CHILDREN / PEDIATRIC CONTROL|Participants in this cohort are otherwise healthy children with no history of inflammatory disease. Children will provide a one time donation of blood (RNA, serum) and urine.
3083094|NCT02006134||HEALTHY ADULTS / ADULT CONTROL|Participants in this cohort are otherwise healthy adults with no history of inflammatory disease. Adults will provide a one time donation urine and will provide blood (RNA, serum) as many as 4 times.
3083095|NCT02006121|Active Comparator|Apomorphine hydrochloride|Apo-go® Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
3083096|NCT02006121|Placebo Comparator|Placebo|Placebo: saline infusion
3083097|NCT02006108|Experimental|Feraheme|"Intravenous injection of Feraheme, 5 mg Fe/kg~Interventions:~Drug: Feraheme Procedure: MR Scan"
3083098|NCT02006095||Neuroimaging Correlates|
3083099|NCT02006082||COPD patients followed after TVC|All COPD patients living in the southern part of Rogaland county in Western Norway, with a habitual value of FEV1 < 50%, who were monitored at home by TVC following discharge after emergency hospitalization for COPD exacerbation at Stavanger University Hospital, or who had tele-monitoring at home under outpatient treatment for acute COPD deterioration during the pilot project period (16th April 2010 - 31st December 2011). The telemedicine equipment consisted of a computer with a web camera with a microphone, through which the patient at home and the specially trained nurse in hospital were able to communicate, and also comprised requisites to measure the patient's oxygen saturation and heart rate, and to perform a spirometry.
3083100|NCT02006069|Experimental|MPP ON|MPP ON: feature is enabled
3083101|NCT02006069|No Intervention|MPP OFF|MPP OFF: feature not enabled
3083102|NCT02006056|Experimental|Secondary prophylaxis|Patients already experiencing mild nausea/vomiting within 24 hours before radiotherapy. Intervention is 8mg of ondansetron (Ondissolve) on the day of radiation treatment at least 1 hour prior to treatment and repeated approx. 608 hours later in the day (bid). For patients who are treated with 20Gy/5 fractions, or 30Gy/10 fractions, they will take ondansetron twice (bid) on each day of treatment, at least 1 hour prior to treatment, and also on weekends or holidays in between treatment.
3083103|NCT02006056|Experimental|Primary prophylaxis|Patients experiencing no nausea and vomiting 24 hours before commencement of radiotherapy. Intervention is 8mg of ondansetron (Ondissolve) on the day of radiation treatment at least 1 hour prior to treatment and repeated approx. 608 hours later in the day (bid). For patients who are treated with 20Gy/5 fractions, or 30Gy/10 fractions, they will take ondansetron twice (bid) on each day of treatment, at least 1 hour prior to treatment, and also on weekends or holidays in between treatment.
3083104|NCT02006043|Experimental|Erlotinib 150mg/day taken orally|Erlotinib 150mg/day taken orally until disease progression or intolerable toxicities
3083105|NCT02006030|Experimental|ADI-PEG 20 + TACE|ADI-PEG 20 plus concurrent transarterial chemoembolization
3083106|NCT02006030|Active Comparator|Transarterial chemoembolization (TACE)|transarterial chemoembolization alone
3083107|NCT02006017|Experimental|Group A|We will present to participants two general clinical scenarios. The first scenario will be accompanied by an evidence summary plus a recommendation and a second scenario will be accompanied by an evidence summary alone
3083108|NCT02006017|Experimental|Group B|We will present to participants two general clinical scenarios. The first scenario will be accompanied by an evidence summary alone and a second scenario will be accompanied by an evidence summary plus a recommendation
3083109|NCT02005991|Experimental|PF-05212377 70 mg|
3083110|NCT02005991|Experimental|PF-05212377 20 mg|
3083111|NCT02005991|Experimental|PF-05212377 10 mg|
3083112|NCT02005978||Acromegaly1|Acromegalic patients treated with radiation therapy
3083113|NCT02005978||Healthy controls|Health controls matched for age, gender and BMI to the patients
3083114|NCT02005978||Acromegaly 2|Acromegalic patients treated with pituitary surgery
3083115|NCT02005965||Staging and outcomes for patients with Low Rectal Cancer|Low Rectal Cancer defined on MRI as a cancer within 6cm of the anal verge
3083116|NCT02005952||Spirometry, quality control, Pulmonary Function Laboratory|Performing spirometry, with control over the quality of the same, made from the pulmonary function laboratory of the Hospital de la Santa Creu i Sant Pau.
3083117|NCT02005952||Spirometry, quality control, software|Performing spirometry, with the support of software self-management quality of spirometry maneuvers incorporated therein
3083118|NCT02005952||Spirometry, quality control, control group|Performing spirometry in the way that is currently working in primary care (control group without any support).
3083119|NCT02005939|Experimental|Pomegranate extract capsule|All participants receive 1.1 g pomegranate extract capsule daily for 4 weeks
3083120|NCT02005939|Placebo Comparator|Placebo capsule|All participants receive a 1.1g placebo capsule daily for 4 weeks
3083121|NCT02005926|Experimental|negative FNA result of abnormal node|Axillary ultrasound examination was undergone for all breast cancer patients before sentinel lymph node biopsy (SLNB). If abnormal axillary lymph node was found, ultrasound-guided FNA cytology of these nodes were performed. The abnormal nodes were defined as completely hypoechoic node, asymmetric focal hypoechoic node, cortical lobulation and cortical thickness >3mm. Patients with negative results of FNA would undergo SLNB. Technetium-99m-labeled Rituximab was used for lymphatic mapping. Before the SLNB operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
3083122|NCT02005900|Experimental|DHA|Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART
3083123|NCT02005900|Placebo Comparator|PLACEBO|
3083124|NCT02005887|Experimental|triptorelin +letrozol|Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles
3083125|NCT02005887|Experimental|degarelix + letrozol|Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles
3083126|NCT02005874||Dry eye|
3083127|NCT02005874||Non-dry eye|
3083193|NCT02005458|Active Comparator|PEG-rhG-CSF 100μg/kg|100μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
3083194|NCT02005445|Experimental|CPAP|Continuous positive airway pressure
3083195|NCT02005445|Sham Comparator|HLSE|Healthy living and sleep education
3083525|NCT02003222|Active Comparator|Arm II (chemotherapy)|See Detailed Description
3083128|NCT02005861|Experimental|bone marrow cells transplantation|"surgical procedure :the day before the surgery: platelet gel production. The day of the surgery: bone marrow aspiration from the posterior iliac crest of the patient and concentration. After the bone marrow harvesting, ankle arthroscopy will be performed. The lesion will be detected and cleaned.~An equine collagen type 1 scaffold (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) will be loaded with 2 ml of bone marrow concentrate and implanted.~After that platelet gel will be loaded on the top of implant"
3083129|NCT02005848|Experimental|Alpha1 Antitrypsin (Glassia)|60 mg/kg body weight
3083130|NCT02005848|Experimental|Alpha-1 Antitrypsin (Glassia)|120 mg/kg body weight
3083131|NCT02005848|Placebo Comparator|Placebo|Placebo
3083132|NCT02005835|Other|Facility-based Peer Support|"Facility-based Peer Support to provide the following at the clinic~Routine standard clinical care based on the MoH guidelines~Mentor mothers provide education and psychosocial support at facility~Weekly support groups provided in clinic~Phone call, SMS, or home visit for each missed appointment"
3083133|NCT02005835|Other|Community-based Peer Support|"Community-based Support from Peer Mothers (Expert mothers):~Routine standard clinical care based on the MoH guidelines~Mentor mothers provide education and psychosocial support in community prior to each visit~Monthly support groups in community~Home visits for each missed appointment"
3083134|NCT02005835|No Intervention|Standard of Care|The Standard of care as outlined in the Malawi HIV integrated Care Guidelines
3083135|NCT02005822|Experimental|Valganciclovir|Valganciclovir 32 mg/kg per day in two doses (16 mg/kg per dose) during 6 weeks in an oral solution.
3083136|NCT02005822|No Intervention|Control|"Refusal control group:~Infants in the control group receive no antiviral therapy. Counseling and treatment assigned by an audiological center remain unchanged.~Historical control group:~Infants with birth date 1-11-2011 till 1-07-2012 with sensorineural hearing loss and congenital CMV."
3083137|NCT02005809|Active Comparator|Second look endoscopy|This group is performed second look endoscopy about 24 hours later from endoscopic submucosal dissection.
3083138|NCT02005809|No Intervention|without second look endoscopy|This group is not performed second look endoscopy after ESD
3083139|NCT02005796|Experimental|Blue-fleshed potato tubers|Intervention: Steam cooked mashed potato tubers
3083140|NCT02005796|Experimental|Yellow-fleshed potato tubers|Intervention: Steam cooked mashed potato tubers
3083141|NCT02005796|Experimental|Bilberries and potato starch|Intervention: A gel boiled with bilberries and potato starch
3083142|NCT02005783|Experimental|DBD arm|Epirubicin: 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 DBD: one dose of medicine twice per day, orally OR; Docetaxel: 75mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 DBD: one dose of medicine twice per day, orally
3083143|NCT02005783|Other|EC/TC|Epirubicin: 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 OR; Docetaxel: 75mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4
3083144|NCT02005770|Experimental|Sevoflurane|General anesthesia using Sevoflurane
3083145|NCT02005770|Active Comparator|Propofol|General anesthesia using propofol TCI
3083146|NCT02005757|Experimental|Bredinin tablet 150mg|dosage form: Tablet, dosage: 150mg qd, Duration: for 6months
3083147|NCT02005757|Active Comparator|Bredinin tablet 50mg|dosage form: Tablet, dosage: 50mg tid, Duration: for 6months
3083148|NCT02005744|Experimental|Child Pugh A|CKD-501 will be administered to patients who are included Child Pugh A
3083149|NCT02005744|Experimental|Child Pugh B|CKD-501 will be administered to patients who are included Child Pugh B
3083150|NCT02005744|Experimental|Subject who are matched Child Pugh A|CKD-501 will be administered to the Subjects who are matched Child Pugh A
3083151|NCT02005744|Experimental|Subject who are matched Child Pugh B|CKD-501 will be administered to the subjects who are matched Child Pugh B
3083152|NCT02005731||Shockwaves|Low intensity linear focused shockwave device ('Renova')
3083153|NCT02005718|Experimental|Vitamin D|Cholecalciferol 300,000 twice
3083154|NCT02005705|Active Comparator|Outpatient|
3083155|NCT02005705|Active Comparator|Inpatient|
3083156|NCT02005692|Experimental|DynaSense sensor|
3083157|NCT02005679|Experimental|deaf persons with potential dementia|
3083158|NCT02005666|Experimental|Test-Cadila healthcare limited|Drug:-Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
3083159|NCT02005666|Active Comparator|Reference|Drug:-DUAC® Gel (of Stiefel Laboratories, USA) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
3083160|NCT02005666|Placebo Comparator|Placebo|Drug:-Placebo (Vehicle Gel) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
3083161|NCT02005653|Experimental|DEC + ALB sequential|Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet at 30 days post treatment sequentially
3083162|NCT02005653|Experimental|DEC + ALB co-admin|Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet per day given orally as single dose for 12 days
3083163|NCT02005653|Experimental|DEC + DOXY co-admin|Diethylcarbamazine 300 mg tablet and Doxycycline 100 mg per day given orally as single dose for 12 days
3083164|NCT02005653|Active Comparator|Diethylcarbamazine (DEC)|Diethylcarbamazine 300 mg tablet as single dose orally per day for 12 days
3083165|NCT02005640||MSCT-based prothesis sizing|
3083166|NCT02005640||Echocardiographic-based prothesis sizing|
3083167|NCT02005627|Active Comparator|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 standardised quality units tablet (SQ-T) once daily.
3083168|NCT02005627|Placebo Comparator|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
3083189|NCT02005471|Experimental|Venetoclax + Rituximab|Participants will be initially placed on a venetoclax 5 weeks ramp-up period, and will receive an initial dose of 20 milligrams (mg) via tablet orally once daily (QD). Then the dose will be incremented weekly up to a maximum dose of 400 mg. Participants will then continue receiving venetoclax 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards, as directed by the investigator, in combination with rituximab 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m^2 on Day 1 of Cycles 2-6.
3083169|NCT02005614|Experimental|Gamma Knife Radiosurgery|"Rational dose selection is a concept wherein doses used for stereotactic radiosurgery is selected based on tumor volume, prior irradiation with whole brain radiotherapy, and the relative radioresistance of the tumor (radioresistant = melanoma, renal cell carcinoma, sarcoma; radiosensitive = breast cancer, lung cancer, colorectal cancer, gastrointestinal cancers).~Dose may be altered for lesions in the brainstem, adjacent to the optic nerve, optic chiasm, or motor cortex, or other clinical scenarios as defined by the treating physician. Reason for dose alteration will be recorded at the time of treatment.~For patients with 10+ brain metastases with multimorbidity or difficulty in tolerating a supine position, doses may be modified by the treating physicians for patient comfort."
3083170|NCT02005601|Experimental|Duloxetine|Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken preoperatively. Starting on postoperative day (POD) 1, patients will take one capsule once a day until end of POD14.
3083171|NCT02005601|Placebo Comparator|Control|Patients will receive 0mg of duloxetine
3083172|NCT02005588|Active Comparator|amino acid chelated iron arm|this arm will contain 150 pregnant women with proved iron deficiency anemia and pregnant 14-18 weeks. these pregnant women will be given amino acid chelated iron capsules (15 mg iron/capsule) 1-2 capsules daily according to hemoglobin level (hemoglobin 7-9 g/dl will receive 2 capsules, and hemoglobin 9.1-11 g/dl will receive 1 capsule). complete blood picture and serum ferritin will be assessed at 22-23 weeks, 29-30 weeks and 36-37 weeks. possible side effects (colicky abdominal pains, constipation and metallic taste) will be asked about in each follow up visit.
3083173|NCT02005588|Active Comparator|iron salt arm|this arm will contain 150 pregnant women with proved iron deficiency anemia and 14-18 weeks gestation. these women will be given oral iron salt ferrous fumarate capsules (350 mg iron/ capsule containing about 70 mg elemental iron/ capsule) 1-2 capsules daily according to hemoglobin level (hemoglobin 7-9 g/dl will receive 2 capsules daily and hemoglobin 9.1-11 g/dl will receive 1 capsule daily. women will be followed up with complete blood picture and serum ferritin at 22-23 weeks, 29-30 weeks and 36-37 weeks. women will be asked about possible side effects (colicky abdominal pains, constipation, and metallic taste) in each visit.
3083174|NCT02005575|Placebo Comparator|Group 1|an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml normal saline)
3083175|NCT02005575|Active Comparator|Group 2|an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml .4% dexamethasone)
3083176|NCT02005562|Experimental|Mycophenolate Mofetil, Adapted Dose|Participants received 3 grams (g) mycophenolate mofetil (MMF) tablets per os (p.o.) in divided doses (every 12 hours [q12h]) adapted to mycophenolic acid (MPA) by area under the curve (AUC) beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by interleukin-2R (IL-2R) was administered at Day 0 per standard of care at the site at the investigator's discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 nanograms (ng) per (/) milliliter (mL) from Day 0 to (-) Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg intravenously (i.v.) was administered before or after the transplantation, and 0.5 milligrams (mg) per kilogram (kg) p.o. daily from Day 1 - Day 7.
3083177|NCT02005562|Active Comparator|Mycophenolate Mofetil, Fixed Dose|Participants received 2 g MMF tablets p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 ng/mL from Day 0 - Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg i.v. was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 - Day 7.
3083178|NCT02005549|Experimental|Neoadjuvant Therapy|
3083179|NCT02005536|Experimental|Study Group|Participants will receive one booster dose of SP059 (IMOVAX POLIO®)
3083180|NCT02005523|Experimental|RNS60|
3083181|NCT02005523|Placebo Comparator|Saline|
3083182|NCT02005510|Experimental|In-home HPV Screening|"Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). Usual care consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women."
3083183|NCT02005510|Placebo Comparator|Usual Care|"Usual care. Usual care consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women."
3083184|NCT02005497|Experimental|HealthLinks|Worksites in this arm will receive the standard HealthLinks intervention protocol, which includes on-site consulting, toolkits, and support via telephone and email to implement a worksite wellness program and adopt evidence-based practices.
3083185|NCT02005497|Active Comparator|HealthLinks+|Worksites in this arm will receive the standard HealthLinks intervention protocol, which includes on-site consulting, toolkits, and support via telephone and email plus support to form a worker wellness committee to implement a worksite wellness program and adopt evidence-based practices.
3083186|NCT02005497|No Intervention|Delayed Control|Worksites in this arm will not receive an intervention during the study. After they have provided their final follow-up data, they will receive the HealthLinks intervention.
3083187|NCT02005484|Experimental|Trastuzumab Monotherapy|Initial dose of 4 milligrams (mg) per (/) kilogram (kg) by body weight (BW), followed by 2 mg/kg BW at each subsequent visit
3083188|NCT02005471|Active Comparator|Bendamustine + Rituximab|Participants will receive bendamustine 70 milligrams per meter squared (mg/m^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m^2 on Day 1 of Cycles 2-6.
3083190|NCT02005458|Experimental|YPEG-rhG-CSF 20μg/kg|20μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
3083191|NCT02005458|Experimental|YPEG-rhG-CSF 30μg/kg|30μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
3083192|NCT02005458|Experimental|YPEG-rhG-CSF 45μg/kg|45μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
3100376|NCT01889329|Experimental|RUTF-1|Made from local food ingredients
3083196|NCT02005432|Active Comparator|SS-PRP arm|panfotocoagulation (PRP) single shoot (ETDRS) + 0,05ml intravitreal injection anti-VEGF (ranibizumabe)
3083197|NCT02005432|Experimental|MS-PRP arm|Multiple shoot panfotocoagulation (PASCAL) plus IVR
3083198|NCT02005432|Other|IVR arm|only IVR (intravitreal Ranibizumabe)
3083199|NCT02005419|Placebo Comparator|gemcitabine + placebo|gemcitabine at 1000 mg/m^2 on days 1, 8, and 15; placebo at 2 g on days 1-28
3083200|NCT02005419|Experimental|gemcitabine + metformin|gemcitabine at 1000 mg/m^2 on days 1, 8, and 15; metformin at 2 g on days 1-28
3083201|NCT02005406||wei group and control group|wei group(n=25) and control group(n=24)
3083202|NCT02005393|Other|FICE Imaging System followed by NBI|Images Captured with FICE Image Acquisition System (experimental) followed by NBI Image Acquisition System (standard of care); always in that order. Imaging took place in esophagus, gastric, duodenum and/or colon.
3083203|NCT02005380||Text-based Task|This group is required to do the text-based task
3083204|NCT02005380||Graphic-based Task|This group is required to do the graphic-based task
3083205|NCT02005367|No Intervention|DAP-CP|512 patients who elected to participate in the Drug Abuse Core Program alone (DAP-CP).
3083206|NCT02005367|Experimental|Natural Recovery-Horticulture|Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using one module per week with a staff facilitator and also pursued four hours of their hobby on each weekend day for up to 14 weeks.
3083207|NCT02005367|Experimental|Natural Recovery-Art/Music|Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using one module per week with a staff facilitator and also pursued four hours of their hobby on each weekend day for up to 14 weeks.
3083208|NCT02005354|Active Comparator|Trans-cutaneous Electrical Nerve Stimulation (TENS)|"The Intervention-TENS group will have 2 electrodes applied proximal to the painful area along neuro-anatomical distribution (electrode-one placed 5cm superior and 2cm medial to the posterior superior iliac spine and electrode-two placed 5cm medial to the posterior superior iliac spine) in the same way as the control-TENS group.~The concealed electrical parameter in this group will be within the therapeutic window, that is, well above the sensory detection threshold but below the pain threshold giving a strong but comfortable sensation. From previous studies, this is likely to be 50-110Hz.~The device will be activated prior to entry into the treatment room and 2 minutes before administration of local anaesthetic and for 2 minutes after removal of the biopsy needle. This will cover the expected duration of pain as assessed in the pilot study.~All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)"
3083209|NCT02005354|Placebo Comparator|Trans-cutaneous Electric Nerve Stimulation (TENS)|"Patients in the CT group will have 2 gel-electrodes applied proximal to the sampling area (usually the right posterior superior iliac crest).~The Control-TENS device will be identical in appearance to the Intervention-TENS device with a functioning display panel. The concealed electrical parameter in this group will be titrated to and set at the sensory detection.~All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)"
3083210|NCT02005341|Active Comparator|Autograft bone|
3083211|NCT02005341|Experimental|nanOss with bone marrow aspirate|
3083212|NCT02005328|Experimental|cross-over|Four periods separated by a wash out lasting up to 3 days at maximum. At each period, application of one product (twice). Duration of treatment period: From 4 to 13 days.
3083213|NCT02005315|Experimental|Vanctictumab (OMP-18R5)|Vantictumab will be administered by intravenous (IV) infusion.
3083214|NCT02005315|Experimental|Nab-Paclitaxel|Nab-Paclitaxel will be administered by intravenous (IV) infusion.
3083215|NCT02005315|Experimental|Gemcitabine|Gemcitabine will be administered by intravenous (IV) infusion.
3083216|NCT02005302|Experimental|Vitamin D2 Treatment|
3083217|NCT02005302|Active Comparator|1,25(OH)2 Vitamin D3|
3083218|NCT02005302|Experimental|low protein diet|
3083219|NCT02005302|Active Comparator|normal protein diet|
3083220|NCT02005289|Experimental|Cohorts 1-3Treatment (MOR00208, lenalidomide)|Patients receive anti-CD19 monoclonal antibody MOR00208 IV over 2 hours on day 1 (days 1, 2, 8, 15, and 22 of course 1 only) and lenalidomide PO daily on days 1-28 (days 9-28 of course 1 only). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Correlative studies will be collected for this trial and will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.
3083221|NCT02005289|Experimental|Cohort 4 Treatment (MOR00208, ibrutinib)|Patients receive anti-CD19 monoclonal antibody MOR00208 IV over 2 hours on day 1 (days 1, 2, 8, 15, and 22 of course 1 only) and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Correlative studies will be collected for this trial and will focus on the effects of MOR00208 alone and in combination with ibrutinib on immune effector cell number and function.
3083222|NCT02005276|No Intervention|Control|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day.
3083223|NCT02005276|Experimental|Basic Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:~About a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day."
3083224|NCT02005276|Experimental|Combined Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:~About a 1 in 5 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day."
3083269|NCT02005029|Experimental|Erythromycin|One time IV dose of 100 mg Erythromycin
3083270|NCT02005016|Experimental|Intervention|All study participants will be assigned to this arm of this single-arm study. Participants will receive intensive behavioral therapy intended to improve their naming (word production) ability.
3083225|NCT02005276|Experimental|Jackpot Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:~About a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day."
3083226|NCT02005263|Experimental|Salpingography|Infusion of air bubbles through Fallopian tubes with hysteroscopic visualization; typically 1-2 mL is infused. This is less than that typically used in the established technique of sonosalpingography.
3083227|NCT02005250||Graves' disease - premeno|30 premenopausal women with Graves' disease
3083228|NCT02005250||Graves' disease - postmeno|30 postmenopausal women with Graves' disease
3083229|NCT02005250||toxic nodular goiter - premeno|30 premenopausal women with toxic nodular goiter
3083230|NCT02005250||toxic nodular goiter - postmeno|30 postmenopausal women with toxic nodular goiter
3083231|NCT02005250||subclinical hyperthyroidism - premeno|30 premenopausal women with subclinical hyperthyroidism
3083232|NCT02005250||subclinical hyperthyroidism - postmeno|30 postmenopausal women with subclinical hyperthyroidism
3083233|NCT02005250||hypothyroidism - premeno|30 premenopausal women with hypothyroidism
3083234|NCT02005250||hypothyroidism - postmeno|30 postmenopausal women with hypothyroidism
3083235|NCT02005250||subclinical hypothyroidism - premeno|30 premenopausal women with subclinical hypothyroidism
3083236|NCT02005250||subclinical hypothyroidism - postmeno|30 postmenopausal women with subclinical hypothyroidism
3083237|NCT02005237|Experimental|Aerobic Exercise (12 Weeks)|Aerobic exercise on a bicycle ergometer, tailored to the individual's level of fitness. Duration: 12 weeks with 2-3 sessions per week.
3083238|NCT02005237|No Intervention|Waitlist Control Group|No intervention (patients randomized to this group will be offered access to the training program after completion of the trial)
3083239|NCT02005224|Other|LCHF diet and a bout of exercise|LCHF diet for 3 weeks, where E% 70 fat, E% 20-25 proteins and 20g or less carbohydrates. Oral glucose tolerance test on the morning of day 21 followed by a bout of exercise in the afternoon (indoor bicycle, 60min at 75% HFpeak). The following morning (day 22) a new oral glucose tolerance test. Oral glucose tolerance test results from pre-tests used to determine the effect of LCHF and a bout of exercise on insulin sensitivity.
3083240|NCT02005211|Experimental|AZD3293|AZD3293 will be administered as single dose of an oral solution in Part 1 and single and multiple doses of an oral solution in Part 2. The ascending doses are planned to be 15, 50 and 150 mg for young subjects in Part 1 and 15 and 50 mg for elderly subjects in Part 2. Before proceeding to next dose level, safety, tolerability and pharmacokinetic data from the previous cohort(s) will be evaluated by a Safety Review Committee. Part 2 will start after confirming safety and tolerability in Part 1.
3083241|NCT02005211|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
3083242|NCT02005198||Survey|
3083243|NCT02005185||6-11y/o anesthetized at 0-2y/o for >2hrs|6-11yr olds anesthetized for more than120 minutes before the age of 2.
3083244|NCT02005185||6-11y/o anesthetized @ 0-2y/o for <30min|6-11 year olds anesthetized for < 30min before the age of 2.
3083245|NCT02005185||6-11y/o anesthetized at 4-7y/o for >2hrs|6-11 year olds anesthetized for more than 120 min between the ages of 4-7.
3083246|NCT02005185||6-11 y/o healthy control|6-11 year olds that have never received general anesthesia.
3083247|NCT02005172|Other|Alivecor device and event monitor|Both the Alivecor device (experimental) and the standard of care (event monitor) will be provided to all patients for the duration of the study
3083248|NCT02005159||Positive blood-culture to bacteremia by enterobacteria|Patients with positive blood-culture to bacteremia by enterobacteria
3083249|NCT02005146||Patients with chronic hepatitis B treated with nRTI|Patients with chronic hepatitis B with HBsAg loss treated with nucleoside/nucleotide analogues (Lamivudine, Adefovir, Tenofovir, Telbivudine, Entecavir, Emtricitabine)
3083250|NCT02005133||VEGF inhibitor naïve|
3083251|NCT02005133||VEGF inhibitor prior treated|
3083252|NCT02005120|Experimental|Arm A|Bevacizumab
3083253|NCT02005120|Experimental|Arm B|recombinant human endostatin
3083254|NCT02005107|Experimental|venlafaxine|Venlafaxine IR and XR, single dosages of each separated by a wash-out period
3083255|NCT02005107|Other|Venlafaxine XR and Venlafaxine IR|Each participant (3 groups of participants) will receive one dose of venlafaxine IR and one dose of venlafaxine XR seperated by a wash-out period.
3083256|NCT02005094||Healthy group|patients without MAC/MAB lung disease and colonization
3083257|NCT02005094||MAC/MAB colonization group|patients with pulmonary MAC/MAB colonization
3083258|NCT02005094||MAC/MAB lung disease group|Patient with MAC/MAB lung disease
3083259|NCT02005081|Other|Actifuse SHAPE|Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
3083260|NCT02005081|Other|Autograft with Demineralized Bone Matrix|autograft mixed with demineralized bone matrix in cervical spine fusion.
3083261|NCT02005068|Experimental|Acute Osteomyelitis - Non MRSA|For treatment of Acute osteomyelitis (< 6 months duration) Non MRSA isolate- Ceftaroline 600 MG (milligram) IV (intra-venous) every 8 hours for 6 weeks.
3083262|NCT02005068|Experimental|Acute osteomyelitis MRSA isolate|For treatment of Acute osteomyelitis (< 6 months duration) MRSA isolate- Ceftaroline 600 MG IV every 8 hours for 8 weeks.
3083263|NCT02005068|Experimental|Prosthetic joint infection|For treatment of prosthetic joint infection Ceftaroline 600 mg IV every 8 hours for 6 weeks.
3083264|NCT02005055||Patients with recalcitrant keloid scars|All patients with keloids insensitive to other treatments
3083265|NCT02005042|No Intervention|Accelerometer only|Wear accelerometer only to measure activity levels (steps)
3083266|NCT02005042|No Intervention|Accelerometer plus EMA|Wear accelerometer and complete Ecological Momentary Assessment (EMA) surveys on smartphone 5 times daily
3083267|NCT02005042|Experimental|Feedback on smartphone|Wear accelerometer, complete EMA surveys on smartphone 5 times daily, receive intervention
3083268|NCT02005029|Placebo Comparator|Placebo|One time IV dose of placebo
3083408|NCT02004093|Experimental|Chemotherapy + Pertuzumab|
3083271|NCT02005003|Active Comparator|Probiotic|Probiotic pills given for 2 weeks, during one of the interventions that the participants is either randomized to as the first or second intervention period. At day 0 and following each intervention period (at week 2 and week 6), participants will be tested using Inhibitory task, Blood samples, Feces collection, Caloric preload, Food selection task, Memory task and Food consumption task.
3083272|NCT02005003|Placebo Comparator|Placebo|Placebo pills given for 2 weeks, during one of the interventions that the participants is either randomized to as the first or second intervention period. At day 0 and following each intervention period (at week 2 and week 6), participants will be tested using Inhibitory task, Blood samples, Feces collection, Caloric preload, Food selection task, Memory task and Food consumption task.
3083273|NCT02004990|Experimental|Single cleansing procedure of 10% povidone iodine cleansing|10% povidone iodine cleansing
3083274|NCT02004977|Experimental|Intervention arm|The role of the intervention arm (schools) is to improve access to the school breakfast program
3083275|NCT02004977|No Intervention|Comparison arm|the role of the comparison arm (schools) is to maintain usual breakfast program at school
3083276|NCT02004951|Other|Misago RX (Misago RX, Terumo Corp., Tokyo|The Misago RX is a peripheral stent (Misago RX, Terumo Corp., Tokyo, Japan) indicated to treat iliac and femoropopliteal arteries. The Misago RX is a flexible self-expanding nitinol stent that is delivered via a RX monorail delivery catheter.
3083277|NCT02004951|Other|Zilver PTX (Cook Medical, Bloomington, IN, USA)|Zilver PTX (Cook Medical, Bloomington, IN, USA) is a nitinol stent with a polymer-free paclitaxel coating designed to treat the above- the-knee femoropopliteal arteries. The anti-proliferative drug is the paclitaxel, a cytotoxic drug. The Zilver PTX stent is delivered via a over-the-wire system.
3083278|NCT02004938||normal respiratory function|This will include the 40 subjects enrolled in the study
3083279|NCT02004925||Pneumoperitoneum|Patients with a diagnosis of pneumoperitoneum by CT or surgery
3083280|NCT02004925||no pneumoperitoneum|patients with acute abdominal pain with a diagnosis other than pneumoperitoneum in whom pneumoperitoneum was excluded by CT or surgery
3083281|NCT02004912|Experimental|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
3083282|NCT02004912|No Intervention|No mentoring intervention|The no mentoring intervention arm does not have supportive visits and education to health center staff by nurse mentors.
3083283|NCT02004899|Active Comparator|F20|Patients randomized to this arm of the study receive 20 mcg fentanyl and 8 mg bupivacaine as their epidural loading dose
3083284|NCT02004899|Experimental|F50|Patients randomized to this arm of the study receive 50 mcg fentanyl with 8 mg bupivacaine as their epidural loading dose
3083285|NCT02004899|Experimental|F100|Patients randomized to this arm of the study receive 100 mcg fentanyl and 8 mg bupivacaine as their epidural loading dose
3083286|NCT02004886|Experimental|MK-0893 (40 mg)|MK-0893 40-mg q.d. (quaque die, once daily) group will receive MK-0893 40-mg tablets (after loading dose with 160 mg) and matching placebo to metformin and matching placebo to MK-0893.
3083287|NCT02004886|Experimental|MK-0893 (120 mg)|MK-0893 at 120 mg q.d. group will receive MK-0893 120 mg q.d. tablets (after loading dose of 500 mg on Day 1) and matching placebo tablets to metformin and matching placebo to MK-0893
3083288|NCT02004886|Active Comparator|Metformin (2000 mg)|Metformin taken orally, 500 mg tablets, Day 1 to Day 6: 500 mg b.i.d. (bis in die, twice daily), Day 7 to Day 13: 1000 mg in the morning and 500 mg in the evening, and Day 14 to Day 28: 1000 mg. b.i.d. and matching placebo to MK-0893.
3083289|NCT02004886|Placebo Comparator|Placebo|Placebo tablets matching the MK-0893 and placebo tablets matching metformin.
3083290|NCT02004873|Experimental|Micra Pacemaker Implant|
3083291|NCT02004860|Experimental|Protopic Arm|Protopic® 0.1% ointment - 2 applications per week for 6 months
3083292|NCT02004860|Active Comparator|Mycoster Arm|2 applications per week for 6 months
3083293|NCT02004847|Experimental|High Intensity (HI) vs control|PSO-CT02 device: Light wavelength 453nm, high intensity, compared to contralateral untreated control plaque on the same patient.
3083294|NCT02004847|Experimental|Low Intensity (LI) vs control|PSO-CT02 device: Light wavelength 453nm, low intensity, compared to contralateral untreated control plaque on the same patient.
3083295|NCT02004834|Active Comparator|0,5% levobupivacaine with 2% lidocaine|7,0 ml.of mixture 0,5% levobupivacaine with 2% lidocaine are given per level Th2,Th3,Th4 for ultrasound guided paravertebral blocks in breast surgery
3083296|NCT02004834|Active Comparator|0,5% levobupivacine|7,0 ml. 0,5% levobupivacaine are given per level Th2,Th3,Th4, given for ultrasound guided paravertebral blocks in breast surgery
3083297|NCT02004821|Experimental|Renutryl® Booster|Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat).
3083298|NCT02004795|Experimental|BNCT+ IG-IMRT|single arm
3083299|NCT02004782|Active Comparator|Prenisolone|Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
3083300|NCT02004782|Placebo Comparator|Placebo|Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
3083301|NCT02004769|Experimental|Trastuzumab, Capecitabine, Docetaxel|Trastuzumab(8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) Capecitabine(2000mg/m2d, d1-14,every 3 weeks) Docetaxel (60mg/m2 every 3 weeks for 6 cycles).All patients will continue to receive trastuzumab and Capecitabine until either disease progression, occurrence of unacceptable toxicity or withdrawal from the study for another reason.
3083302|NCT02004756|Experimental|Fontan Patients|Fontan patients who are monitored at the Hospital for Sick Children (SickKids) will undergo an exercise program
3083303|NCT02004756|No Intervention|Healthy Controls|Healthy age-matched adolescents
3083304|NCT02004743|Other|Control|Treatment as Usual
3083305|NCT02004743|Other|Intervention|Psychological management guidelines + patient education
3083306|NCT02004730|Experimental|long single vessel disease|ABSORB implantation for long single vessel disease
3083307|NCT02004730|Experimental|multivessel disease ABSORB only|multivessel disease treated with ABSORB implantation only
3083308|NCT02004730|Experimental|"multivessel disease hybrid"|multivessel disease treated with ABSORB implantation and other devices such as drug eluting stents
3083309|NCT02004717|Experimental|dose escalation then expansion|"Dose escalation of this study will follow a 3+3 study design with a starting intravenous (IV) dose of 0.1 mg/kg. Six dose levels are planned: level 1,0.1 mg/kg; level 2,0.3 mg/kg; level 3, 1.0 mg/kg; level 4,3.0 mg/kg; level 5,10 mg/kg; level 6,20 mg/kg.~Dose Expansion - Up to 20 subjects will be enrolled and treated at the dose determined in Dose Escalation arm."
3083310|NCT02004704|Experimental|GZ402665|GZ402665 administered intravenously once every 2 weeks for up to 9 years at the dose each patient was receiving at the end of their previous olipudase alfa study.
3083311|NCT02004691|Experimental|GZ402665|Olipudase alfa dose (3 mg/kg body weight) in saline administered intravenously once every 2 weeks during the 52 weeks of the primary analysis period for patients randomized to olipudase alfa, and during the extension treatment period for all patients.
3083312|NCT02004691|Placebo Comparator|Placebo|Placebo (saline) administered intravenously once every 2 weeks during the 52 weeks of the primary analysis period for patients randomized to placebo.
3083313|NCT02004678|Other|Cohort 1, 7.5 mg DS-1150b|"Dosing will occur over two periods. Subjects will receive either~a dose of placebo in Period 1 followed by a single dose of 7.5 mg DS-1150b in Period 2; or~a single dose of 7.5 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2."
3083314|NCT02004678|Other|Cohort 2, 15 mg DS-1150b|"Dosing will occur over two periods. Subjects will receive either~a dose of placebo in Period 1 followed by a single dose of 15 mg DS-1150b in Period 2; or~a single dose of 15 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2."
3083315|NCT02004665||acute coronary syndrome and delirium|patients with acute coronary syndrome and delirium
3083316|NCT02004652|Experimental|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
3083317|NCT02004652|Placebo Comparator|Placebo|Vitamin C, 50mg, tablet
3083318|NCT02004639|Active Comparator|Mastictors sparing group|Using IMRT or HT to do masticators sparing techniques and physical therapy to prevent trismus.
3083319|NCT02004639|No Intervention|Masticators not sparing group|The patients do not receive masticators sparing technique as traditional techniques but still receive physical therapy after radiotherapy to prevent trismus.
3083320|NCT02004639|Active Comparator|EA group|Using masticators sparing techniques and electro-acupunture stimulation to prevent trismus
3083321|NCT02004639|Sham Comparator|Sham-EA group|Using masticators sparing techniques but with sham EA stimulation.
3083322|NCT02004626|Active Comparator|Collagenase|"Each gram of ointment contains :~Collagenase ...0.6 U~Vehicle qs ... 1 g~Presentation:~Topic use. 5 g tube of ointment containing smooth, lump-free , pale white to slightly brown with faint characteristic odor .~Dosage The ointment should have full contact with the entire injured area, and uniformly applied twice a day."
3083323|NCT02004626|Active Comparator|Kollagenase|"Each gram of ointment contains :~Collagenase ... 0.6 U~Vehicle qs ... 1 g~Presentation~Topic use. 5 g tube of ointment containing brownish clear, fat and weak characteristic odor.~Dosage The ointment should have full contact with all the injured area, being uniformly applied twice a day."
3083324|NCT02004613|Active Comparator|Dexmedetomidine|Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 kg/hr; at the end of bypass, the dose will be increased to 0.2 kg/hr.
3083325|NCT02004613|Placebo Comparator|Placebo|Placebo
3083326|NCT02004600|Experimental|patient receiving one PDT session|patient receiving one photodynamic therapy (PDT) session
3083327|NCT02004587|Experimental|Mild hepatic impairment group|Mild hepatic impairment group by Child-Pugh scores
3083328|NCT02004587|Experimental|Moderate hepatic impairment group|Moderate hepatic impairment group by Child-Pugh scores
3083329|NCT02004587|Active Comparator|Healthy volunteers|Gemigliptin dosing in Healthy subjects
3083330|NCT02004574|Experimental|PRN treatment|Group 1: PRN treatment Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel) once daily as needed (PRN)
3083331|NCT02004574|Experimental|Continuous treatment|Group 2: Continuous treatment Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel)once daily
3083332|NCT02004574|Experimental|Weekends treatment|Group 3: Weekends treatment (twice weekly) Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel) once daily at weekends (on Saturdays and Sundays)
3083333|NCT02004561||Gastric Banding|Patients chose Gastric banding
3083334|NCT02004561||Gastric Bypass|Patients chose gastric bypass surgical operation
3083335|NCT02004548|Experimental|Metatinib Tromethamine|"Dose escalation is in accordance with the traditional 3 +3 design, and dose groups are subsequently set as: 25, 50, 100, 200, 300, 450, 600, 800 mg/d."
3083336|NCT02004535|Experimental|Cochlear implantation|Cochlear implantation of the ear with severe to profound hearing loss
3083337|NCT02004522|Experimental|IPI-145|IPI-145 is administered orally and supplied as 5 mg and 25 mg formulated capsules
3083338|NCT02004522|Active Comparator|Ofatumumab|Ofatumumab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg/5mL and 1000 mg/50 mL
3083339|NCT02004509|Active Comparator|anticoagulant by physician criteria|
3083340|NCT02004509|No Intervention|Control|
3083341|NCT02004496|No Intervention|Group A: no app|no use of an mobile application while treatment
3083342|NCT02004496|Active Comparator|Group B: only app|Patients, who use independently the mobile application named Consilium without involvement of the physician.
3083343|NCT02004496|Active Comparator|Group C: app and physician|Patients use the mobile application named Consilium in collaboration with the physician.
3083344|NCT02004483|Experimental|Percutaneous Coronary Intervention|Each patient will get elective percutaneous coronary angioplasty with balloon inflation(PCI). During and after PCI 2D-echography (strain) will be performed.
3083345|NCT02004470|No Intervention|Passive exsufflation|Will not actively suction carbon dioxide from abdomen. Open laparoscopic trocars and allow C02 to passively empty from abdomen.
3083409|NCT02004093|Active Comparator|Chemotherapy|
3083410|NCT02004080||TBI admitted to ICU|Intensive Care treatment
3083346|NCT02004470|Experimental|Active lavage and suction|This step is already employed in many ongoing surgeries where normal saline will be used to lavage the right upper quadrant and then will be suctioned out to remove as much Carbon dioxide from the patient's abdomen and to therefore decrease postoperative pain.
3083347|NCT02004457|Experimental|Acceptance-based behavior therapy (ABBT)|ABBT will consist of 2 sessions. The first session will be used to introduce the concept of acceptance and its possible benefits in the context of life values and patient-identified barriers to care engagement. Following a discussion of life values will be a discussion of which, if any, of these values are currently misaligned with the participant's HIV self-care. At the second session, acceptance-based coping skills will be practiced and a behavioral plan will be developed to targets barriers identified in the first session. These discussions will help the participant clarify how best to align their values with decisions on how to manage his/her HIV (e.g. when and how to disclose, what to expect at appointments).
3083348|NCT02004457|Placebo Comparator|Treatment-as-usual (TAU)|TAU will consist of the standard sessions all individuals receive as they enter HIV care and attend their first follow-up visit to review lab results. TAU includes identification of environmental barriers to care, assessment of needs for additional care and corresponding referrals (i.e., for depression, substance abuse), and recommendations to attend HIV support groups.
3083349|NCT02004444||Natalizumab 18 months|10 patients on continuous natalizumab monotherapy for 18 months
3083350|NCT02004444||Natalizumab 24 months|10 patients on continuous natalizumab monotherapy for 24 months
3083351|NCT02004444||Natalizumab 36 months|10 patients on continuous natalizumab monotherapy for 36 months
3083352|NCT02004444||IFN-beta 36 months|10 patients on continuous interferon-beta monotherapy for 36 months
3083353|NCT02004444||Untreated|10 untreated patients
3083354|NCT02004431||Pain (experimental)|The cases are patients with significant pain on day one after surgery
3083355|NCT02004431||No pain (control)|The controls are sex, age and operation matched individuals without pain.
3083356|NCT02004418|Experimental|C-Choline PET Scans|Radioactive doses of 11C-Choline: 400 MBq ± 10% per injection, pre-radiation treatment and following treatment at 3 and 6 months
3083357|NCT02004405|Experimental|strengthening exercise|"The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks."
3083358|NCT02004405|Active Comparator|Flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
3083359|NCT02004392|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
3083360|NCT02004392|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
3083361|NCT02004379||Patients with hepatitis C, genotype 1|Patients with hepatitis C, genotype 1, treated with telaprevir or boceprevir
3083362|NCT02004366|Experimental|Linagliptin In-hospital|Linagliptin once daily+ correction doses of aspart or lispro if needed
3083363|NCT02004366|Active Comparator|Basal Bolus In-hospital|Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
3083364|NCT02004366|Experimental|Linagliptin on discharge|Patients with admission A1C < 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
3083365|NCT02004366|Experimental|Linagliptin+50%Glargine dose on d/c|Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
3083366|NCT02004366|Experimental|Linagliptin+80%Glargine dose on d/c|Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
3083367|NCT02004353||Cochlear® Hearing Implants, hearing loss|Implanted Adolescents and Adults with permanent hearing loss
3083368|NCT02004340|Active Comparator|Transcutaneous auricular vagal stimulation|Transcutaneous stimulation at auricular concha
3083369|NCT02004340|Sham Comparator|Transcutaneous auricular non-vagal stimulation|Transcutaneous stimulation at auricular edge
3083370|NCT02004340|No Intervention|control|No transcutaneous stimulation is given
3083371|NCT02004327|Experimental|A Group|"1st administration - DW1029M300mg PO Once~2nd administration - DW1029M600mg PO Once~3rd administration - DW1029M1200mg PO Once"
3083372|NCT02004327|Experimental|B Group|"1st administration - DW1029M600mg PO Once~2nd administration - DW1029M1200mg PO Once~3rd administration - DW1029M300mg PO Once"
3083373|NCT02004327|Experimental|C Group|"1st administration - DW1029M1200mg PO Once~2nd administration - DW1029M300mg PO Once~3rd administration - DW1029M600mg PO Once"
3083374|NCT02004314|Other|Chloroquine|This will be a single arm, pilot study with each subject as his/her own control. The study will last 44 weeks, with 8 weeks observation period on ART alone to assess stability of activated CD8CD38 T cells, followed by 24 weeks chloroquine treatment with ART and a 12-week follow-up period on ART alone. Twenty ART treated patients will be recruited. To maximize chances of demonstrating a treatment effect, the chloroquine will be administrated for 24 weeks.
3083375|NCT02004301|Experimental|Radiolabelled T4 Tablet|Single dose of delayed release diclofenac potassium (25 mg) tablet with time delay of 4 h radiolabelled with 4 MBq 99mTc
3083376|NCT02004301|Experimental|Radiolabelled T6 Tablet|Single dose of delayed release diclofenac potassium (25 mg) tablet with time delay of 6 h radiolabelled with 4 MBq 99mTc
3083377|NCT02004288|Experimental|Lactobacillus reuteri Protectis DSM17938|One chewable tablet per day with L reuteri Protectis DSM 17938, 1x108 CFU/tablet (colony forming unit)
3083378|NCT02004288|Placebo Comparator|Placebo|One chewable tablet with placebo per day
3083411|NCT02004067|Active Comparator|Refresh Endura|Topical lubricant containing (glycerin; polysorbate 80; castor oil; carbomer, boric acid, sodium hydroxide, purified water), one drop 2 times a day, for 3 months.
3083379|NCT02004275|Experimental|Arm I (pomalidomide, dexamethasone)|Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.
3083380|NCT02004275|Experimental|Arm II (pomalidomide, dexamethasone, ixazomib)|Patients receive pomalidomide, dexamethasone, and ixazomib as in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3083381|NCT02004262|Experimental|Primary Cohort: Cy/GVAX + CRS-207|"200 mg per square meter (mg/m^2) cyclophosphamide (Cy) administered by intravenous (IV) infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (GVAX, 5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 colony forming units [CFU]) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
3083382|NCT02004262|Experimental|Primary Cohort: CRS-207|"CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16.~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
3083383|NCT02004262|Active Comparator|Primary Cohort: Chemotherapy|"Investigator's choice of one of the following: gemcitabine (1000 mg/m^2) administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle; capecitabine (1000 mg/m^2) administered orally twice a day on Days 1 through 14 of a 21-day cycle; fluorouracil with or without leucovorin (2400 mg^m2) administered by IV infusion over 46 hours on Days 1 and 15 of a 28-day cycle; irinotecan (150 mg/m^2) administered by IV infusion on Days 1 and 15 of a 28-day cycle; or erlotinib (100 mg) administered orally once a day for a 21-day cycle.~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
3083384|NCT02004262|Experimental|2nd-line Cohort: Cy/GVAX + CRS-207|"200 mg/m^2 Cy administered by IV infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
3083385|NCT02004262|Experimental|2nd-line Cohort: CRS-207|"CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16.~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
3083386|NCT02004262|Active Comparator|2nd-line Cohort: Chemotherapy|"Investigator's choice of one of the following: gemcitabine (1000 mg/m^2) administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle; capecitabine (1000 mg/m^2) administered orally twice a day on Days 1 through 14 of a 21-day cycle; fluorouracil with or without leucovorin (2400 mg^m2) administered by IV infusion over 46 hours on Days 1 and 15 of a 28-day cycle; irinotecan (150 mg/m^2) administered by IV infusion on Days 1 and 15 of a 28-day cycle; or erlotinib (100 mg) administered orally once a day for a 21-day cycle.~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
3083387|NCT02004236|Experimental|tRNS Fronto-temporal cortex|This group receive 35 sessions of tRNS over fronto-temporal cortex
3083388|NCT02004236|Experimental|tRNS over fusiform temporal cortex|This group receive 35 sessions of tRNS over fusiform temporal cortex
3083389|NCT02004236|Placebo Comparator|tRNS with sham|This group receive 35 sessions with sham
3083390|NCT02004223|Experimental|Dose escalation using stereotactic boost|Dose level allocation - Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level
3083391|NCT02004210|Experimental|The TARE group|transarterial radioembolization group
3083392|NCT02004210|Experimental|The TACE group|Transarterial chemoembolization group
3083393|NCT02004197|Experimental|Pylorex plus|Pylorex plus consisting of medicinal plants.
3083394|NCT02004197|Active Comparator|Quadruple therapy|Omeprazole, Amoxicillin, Metronodazole and TRITEC (ranitidine bismuth citrate)
3083395|NCT02004184|Experimental|maintenance pemetrexed|maintenance pemetrexed immediately after induction chemotherapy
3083396|NCT02004184|Active Comparator|pemetrexed at progression|observation and pemetrexed therapy at disease progression
3083397|NCT02004171|Experimental|electronic cigarette|electronic cigarette 24mg cartridges; 1-2 cartridges daily
3083398|NCT02004171|Active Comparator|nicotine inhaler|nicotine inhaler 10mg cartridge; max 16 cartridges daily
3083399|NCT02004158|Experimental|Positive psychology|Positive psychology intervention
3083400|NCT02004145|Experimental|Positive Psychology|"The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.~Exercises:~Gratitude for positive events~Gratitude letter~Performing acts of kindness~Using personal strengths~Enjoyable and meaningful activities:~Repeating one of the previous exercises."
3083401|NCT02004145|Sham Comparator|Organizational Skills|"The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.~Exercises:~Daily Events~Health Events~Morning and Evening Events~Interactions with Others~Leisure Time Activities~Repeating one of the previous exercises."
3083402|NCT02004132|Experimental|Axiron|Axiron administered topically via metered dose pump to each underarm on Day 1
3083403|NCT02004119|Placebo Comparator|Placebo|
3083404|NCT02004119|Experimental|KHK4577|
3083405|NCT02004106|Experimental|Part 1: RO6895882 Single Ascending Dose|Participants will receive RO6895882 at ascending doses (</= 6 mg) as a single intravenous (IV) infusion.
3083406|NCT02004106|Experimental|Part 2: RO6895882 Dose Escalation Monotherapy|Participants in different cohorts will receive RO6895882 at ascending doses as IV infusion qw, q2w or q3w. After completion of Part 2 all participants have the option to receive the recommended RO6895882 dose once defined in Part 2 at the discretion of investigator.
3083407|NCT02004106|Experimental|Part 3: RO6895882 MTD Expansion|Participants will receive RO6895882 at MTD determined in Part 2 as IV infusion qw, q2w or q3w.
3083412|NCT02004067|Experimental|Restasis|Topical immunomodulatory lubricant (Ophthalmic emulsion containing cyclosporine 0.5 mg/mL, i.e., 0.05%), one drop 2 times a day, for 3 months
3083413|NCT02004054||optic neurotis|measure of pupil diameter
3083414|NCT02004041|Experimental|VLY-686 x mg|Single dose, X mg VLY-686, administered as X 50 mg VLY-686 oral capsule(s)
3083415|NCT02004041|Placebo Comparator|Placebo|Single dose, placebo, administered as X 50 mg oral capsule(s)
3083416|NCT02004028|Experimental|VS-6063 (defactinib)|Administered orally (BID) for 12, 21 or 35 days (+/- 2 days)
3083417|NCT02004015|Experimental|Atracurium|injection of NMBA 0.5 mg/kg milligram(s)/kilogram in Intravenous bolus use
3083418|NCT02004015|Experimental|ROCURONIUM|injection of NMBA 0.6 mg/kg milligram(s)/kilogram in Intravenous bolus
3083419|NCT02004015|Placebo Comparator|placebo|injection of placebo Injection in Intravenous bolus use
3083420|NCT02004002|Active Comparator|Weight maintenance with normal protein intake|Control group will consume 1.4 g protein/kg body wt/d; consistent with the average protein intake in the US population.
3083421|NCT02004002|Experimental|Weight maintenance with protein restriction|Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
3083422|NCT02003989||patients|HIV patients infected for more than ten years with undetectable viral load, undergoing ophthalmologic examination and MRI
3083423|NCT02003989||control|non HIV patients (same gender and age) undergoing ophthalmologic examination and MRI
3083424|NCT02003976|Experimental|Non-Surgical Treatment plus HTO|The optimized non-surgical treatment program consists of medications, physiotherapy and nutritional seminars. The 12-week program will include an assessment by a primary care physician, physiotherapist and orthopaedic surgeon, one supervised physiotherapy session per week, one body recomposition session per week, and a home program. After the 12-week program is completed, patients randomized to this group will undergo a medial opening wedge high tibial osteotomy (HTO). They will continue with their home program and will be followed up for 2 years after baseline.
3083425|NCT02003976|Active Comparator|Non-Surgical Treatment|The optimized non-surgical treatment program consists of medications, physiotherapy and nutritional seminars. The 12-week program will include an assessment by a primary care physician, physiotherapist and orthopaedic surgeon, one supervised physiotherapy session per week, one body recomposition session per week, and a home program. After the 12-week program is completed, patients randomized to this group will continue with their home program and will be followed up for 2 years after baseline.
3083426|NCT02003963|Experimental|Exergame Intervention|"Participants randomly assigned to the exergame condition will participate in the intervention condition of Klub Kinect. Klub Kinect is a 12-week intervention occurring for 90-minute sessions, 3 times per week. During each 90-minute intervention session, adolescents will engage in 60-minute bouts of aerobic gaming. Adolescents attending an exergaming session will attend concurrently."
3083427|NCT02003963|No Intervention|Control (Self-Directed Care)|The control condition will receive no contact or intervention other than telephone reminders of their final clinic visit.
3083428|NCT02003950|Other|Chocolate pre-restriction|
3083429|NCT02003950|Other|Chocolate Baseline|
3083430|NCT02003950|Other|Chocolate post-restriction|
3083431|NCT02003950|Other|Salty Snacks|
3083432|NCT02003950|Other|Sweet Non-Chocolate Snacks|
3083433|NCT02003950|Other|Dried Fruit|
3083434|NCT02003937|Experimental|12 weeks of aerobic conditioning|12 weeks of aerobic conditioning, a total 42 sessions of 30min exercise on a stationary cycle ergometer
3083435|NCT02003924|Sham Comparator|Placebo|Sugar pill manufactured to mimic enzalutamide 40 mg capsule
3083436|NCT02003924|Experimental|Enzalutamide|160 mg by mouth once daily
3083437|NCT02003911|Experimental|Azithromycin suspension|"Azithromycin suspension at 10mg/kg/dose (max 500mg)~Once daily for 3 days"
3083438|NCT02003911|Placebo Comparator|Placebo suspension|"Same volume as active drug~Once daily for 3 days"
3083439|NCT02003898|Experimental|Medtronic MiniMed 530G Insulin Pump|All subjects received diabetes treatment using the Medtronic MiniMed 530G insulin pump.
3083440|NCT02003885|Experimental|Desflurane increment|increment of desflurane 0.5-1.5 MAC in remifentanil anesthesia for cardiac surgery
3083441|NCT02003872|Experimental|Spattz 3 intragastric balloon|obese patients, . BMI ≥ 35 kg/m² or BMI ≥ 30 kg/m² and hypertension or diabetes mellitus. All will have the intragastric balloon
3083442|NCT02003846||Premature infant|Each premature infant will be on bubble nasal CPAP for 2 hours and on ventilator nasal CPAP for 2 hours
3083443|NCT02003833|Experimental|Poly-L-lactic acid|Subjects in the treatment arm will receive three injections of 5 cc of poly-L-lactic acid (PLLA) into both sides of the face.
3083444|NCT02003833|Placebo Comparator|Placebo|Subjects in the placebo arm will receive three injections of 5 cc of saline into both sides of the face. After the completion of the study, subjects in the placebo arm will receive free injections with Sculptra Aesthetic same as the treatment arm.
3083445|NCT02003820|Experimental|Group 1|Group 1 will receive plaque index exam and immediately start their three week intervention of watching a dental hygiene video immediately before brushing twice per day. Plaque index exams will be completed at start, t-10 days, and t-21 days. Parental surveys will be completed at each plaque index exam and 6 weeks after start.
3083446|NCT02003820|Experimental|Group 2|Group 2 will receive plaque index exam and immediately start their three week intervention of watching a control video immediately before brushing twice per day. Plaque index exams will be completed at start, t-10 days, and t-21 days. Parental surveys will be completed at each plaque index exam and 6 weeks after start.
3083447|NCT02003807||Diverticulitis patients (case)|Cases were the patients who admitted to hospital because of acute diverticulitis attack.
3083448|NCT02003807||Non-diverticulitis patients (control)|Controls were the patients who admitted to hospital due to non-gastrointestinal disorder.
3083449|NCT02003794|Experimental|IV Fluid|0.9% NaCl solution infusion: 100 ml/hr for three days.
3083450|NCT02003794|No Intervention|No IV Fluid|Not receive any intravenous fluid but can consume oral fluid normally for three days.
3083451|NCT02003781||cardiovascular disease|high risk cardiovascular disease patients and their relatives
3083452|NCT02003768|Experimental|TIVA|2% Propofol (Fresofol®), Remifentanil 20mcg/cc (Ultiva®)
3083453|NCT02003768|Active Comparator|Des|Desflurane (Suprane®), Remifentanil continuous infusion (20mcg/cc)
3083455|NCT02003742|Experimental|NX-1207|Subjects randomised to the NX-1207 group will receive a single NX-1207 (2.5 mg) TRUS-guided intraprostatic injection (under antibiotic prophylaxis), followed by a placebo QD oral treatment for 12 months.
3083456|NCT02003742|Active Comparator|Comparator|Subjects randomised to the comparative arm will undergo TRUS only (under placebo prophylaxis) and will continue the tamsulosin 0.4 mg QD oral treatment for 12 months
3083457|NCT02003729|Active Comparator|Portable Sleep Monitor|The clinical diagnosis of OSA will be done according to the American Academy of Sleep Medicine criteria, a combination of data from clinical examination, presenting symptoms, risk factors and results from portable monitor sleep studies.
3083458|NCT02003729|No Intervention|Polysomnography|The clinical diagnosis of OSA will be done according to the American Academy of Sleep Medicine criteria, a combination of data from clinical examination, presenting symptoms, risk factors and results from polysomnography from the sleep clinic.
3083459|NCT02003716||No treatment|
3083460|NCT02003703|Experimental|Recombinant Hepatitis B Virus Vaccine (High Dose)|Patients allocated to this arm will receive three doses of 40mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
3083461|NCT02003703|Active Comparator|Recombinant Hepatitis B Virus Vaccine (Standard Dose)|Patients allocated to this arm will receive three doses of 20mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
3083462|NCT02003690|Experimental|Dialectical Behavior Therapy + Pharmacotherapy|Dialectical Behavior Therapy + Pharmacotherapy
3083463|NCT02003690|Active Comparator|Standard of Care Psychotherapy + Pharmacotherapy|Standard of Care Psychotherapy + Pharmacotherapy
3083464|NCT02003677|Experimental|FIAsp followed by NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
3083465|NCT02003677|Active Comparator|NovoRapid® followed by Insulin aspart|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
3083466|NCT02003664|Active Comparator|Baclofen ER versus Placebo|Baclofen ER versus Placebo (sugar pill)
3083467|NCT02003664|Placebo Comparator|Placebo versus Baclofen ER|Participants will receive either placebo (sugar pill) or Baclofen ER
3083468|NCT02003651|Experimental|Quick Defense|250 mg E. purpurea root and 83 mg E.angustifolia root standardized to 10 mg alkylamides, and 210 mg of a proprietary synergistic extract blend containing andrographis paniculata leaf, black elderberry berries, sambucus nigra, ginger root, and zingiber officinale
3083469|NCT02003651|Placebo Comparator|Placebo|Placebo will contain the excipients vegetable glycerin and olive oil. Placebo and echinacea capsules will be colored green and contain the same proportions of inert ingredients.
3083470|NCT02003638|Experimental|Niacin|Niacin titrated up to 6 grams taken orally every day for 12 weeks
3083471|NCT02003638|Placebo Comparator|Placebo|Placebo taken orally every day for 12 weeks
3083472|NCT02003625|Placebo Comparator|A. GCSF + Placebo|GCSF + Placebo Patients in this group will receive GCSF 10 ug/kg s.c. daily, beginning 4 days prior to the 1st apheresis [days -4, -3, -2, -1] and continued on daily GCSF for a total of 4 apheresis or until ≥ 5 x 10^6 CD34+ cells/kg are collected. They will also receive oral placebo for 5 days on days -6 through -2. Patients will undergo apheresis for 300 minutes to achieve approximately 3 to 4 whole blood volumes processed. This is a standard institutional protocol for autologous HSPC collection at the MGH.
3083473|NCT02003625|Experimental|B. GCSF + meloxicam|"B. GCSF + meloxicam:~Patients in this group will be treated with meloxicam and GCSF in an approximate two-day staggered dose schedule as described in our preclinical studies. Meloxicam will be given orally at a dose of 15 mg/day for 5 days (days -6 through -2). GCSF at 10 ug/kg/day subcutaneously will be started on day -4 and continued daily for a total of 4 apheresis or until ≥ 5 x 10^6 CD34+ cells/kg are collected."
3083474|NCT02003612||All subjects|All subjects
3083475|NCT02003599|Placebo Comparator|Placebo|"In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .~Both arm will use institutional skin care protocol."
3083476|NCT02003599|Experimental|Laser therapy|"In the intervention group, 26 patients will be submitted a laser therapy .The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2. It will be administrated five days a week before radiotherapy.~Both arm will use institutional skin care protocol."
3083477|NCT02003586|Other|Plant-based ingredient to a starchy meal|Plant-based ingredient
3083478|NCT02003586|Other|Starchy meal alone|No plant-based ingredient
3083479|NCT02003573|Experimental|volasertib + decitabine|dose escalation and MTD (Maximum Tolerated Dose) Extension (Note: Decitabine is a Backbone Treatment and Volasertib is Investigational Medicinal Product (IMP))
3083480|NCT02003560|Experimental|Accelerated partial breast irradiation|Accelerated partial breast irradiation delivered by 3 dimensional conformal radiotherapy or intensity modulated radiotherapy
3083481|NCT02003547|Experimental|AMA0076 Formulation A|Topical Ocular Drop BID X 1 wk
3083482|NCT02003547|Experimental|AMA0076 Formulation B|Topical Ocular Drop BID X 1wk
3083483|NCT02003547|Experimental|AMA0076 Formulation C|Topical Ocular Drop BID X 1 wk
3083484|NCT02003547|Placebo Comparator|Placebo|Topical Ocular Drop BID X 1 wk
3083485|NCT02003534|Experimental|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
3083486|NCT02003521||Intervension|Lung Flute
3083487|NCT02003495|Experimental|MCV-ACYW135 Vaccine Group|"Participants at age 2 to 6 years of enrollment will receive 1 dose on Meningococcal ( A, C, Y and W 135) conjugate vaccine.~Participants at age 6 to 23 months of enrollment will receive 2 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 3 months apart.~Participants at age 3 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 1 month apart.~Participants at age 2 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 2 months apart."
3083488|NCT02003495|Active Comparator|MPV-ACYW135 Vaccine Group|Participants at age 2 to 6 years of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
3083489|NCT02003495|Active Comparator|MPV-A Vaccine Group|Participants at age 6 to 23 months of enrollment will receive 2 doses on Group A Meningococcal Polysaccharide vaccine at 3 months apart.
3083490|NCT02003495|Active Comparator|MCV-AC Vaccine Group|Participants at age 3 to 5 months of enrollment will receive 3 doses on Group A and C Meningococcal conjugate vaccine at 1 month apart.
3083491|NCT02003495|Placebo Comparator|Hib Vaccine Group|Participants at age 2 to 5 months of enrollment will receive 3 doses on Haemophilus Influenzae Type b Conjugate Vaccine at 2 months apart.
3083492|NCT02003482||Postop IMRT for Head/Neck cancer|CT for Radiation Treatment Planning
3083493|NCT02003482||Chemo/IMRT for bulky Head/Neck cancer|CT for Radiation Treatment Planning
3083494|NCT02003469|Experimental|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
3083495|NCT02003456|Experimental|Cardiac PET scan|To evaluate methods that could allow the use of two radiotracers(rubidium-82/18F-fluorodeoxyglucose(FDG)and rubidium-82, that are used in cardiac positron emission tomography(PET)imaging scans to be performed at one time instead of the current method which involves being imaged at separate times, several hours apart.
3083496|NCT02003443|Placebo Comparator|Sham Acupressure|Participants assigned to sham acupressure will receive similar instruction as those assigned to pain-relief acupressure, except that they will be taught to apply pressure to 10 acupoints that are unrelated to pain. That is, they will conduct self-administered acupressure 5 days/week for 8 weeks, as the pain-relief acupressure group does, but on 'sham' acupoints.
3083497|NCT02003443|No Intervention|Usual Care|Participants assigned to the UC group will receive no intervention.
3083498|NCT02003443|Experimental|Pain-Relief Acupressure|Participants assigned to pain-relief acupressure will be taught to apply physical pressure, using a wooden hand-held device designed for acupressure, to 10 acupoints on their body.That is, they will conduct self-administered acupressure 5 days/week for 8 weeks,on acupoints that are relevant to pain reduction.
3083499|NCT02003430||≥65 years old|20 patients greater than or equal to 65 years of age
3083500|NCT02003430||<65 years old|20 patients less than 65 years of age
3083501|NCT02003417||Non-metastatic prostate cancer patients|Histologically-confirmed, non-metastatic prostate cancer patients who received external beam radiation treatment with androgen deprivation therapy (total ADT duration > 3 months) for definitive treatment.
3083502|NCT02003404||Control Abdominal Skin|Apply SoftFlex (standard wear commercial skin barrier), FlexWear (standard wear commercial skin barrier), and FlexTend (extended wear commercial skin barrier), material to non-peristomal abdominal skin.
3083503|NCT02003404||Peristomal Abdominal Skin|Apply SoftFlex, FlexWear and FlexTend barrier material to peristomal abdominal skin.
3083504|NCT02003391|Experimental|DuoTrav|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 8 weeks.
3083505|NCT02003391|Active Comparator|Beta-blocker|Participant's current beta-blocker monotherapy, 1 drop instilled in the study eye twice daily (morning and evening) for 4 weeks, followed by travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 4 additional weeks.
3083506|NCT02003378|Active Comparator|Minute Ventilation (MV)|Pacemaker sensor set to MV (Cross over study)
3083507|NCT02003378|Active Comparator|Accelerometer (XL)|Pacemaker sensor set to XL (Cross over study)
3083508|NCT02003365|Experimental|FX006 10 mg|Single 3 mL intra-articular (IA) injection
3083509|NCT02003365|Experimental|FX006 40 mg|Single 3 mL intra-articular (IA) injection
3083510|NCT02003365|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection
3083511|NCT02003352|Experimental|Functional Neurological Rehabilitation|Functional Neurological and physical/vestibular rehabilitation strategies
3083512|NCT02003339|Experimental|RMIs|
3083513|NCT02003326|Other|Inflammatory markers|All patients with inclusion criteria (ARDS moderate and severe: Berlin definition) and absence of non inclusion criteria will have a broncho alveolar wash at day 0 and blood sample every three day to measure inflammatory markers. All patients will receive protective ventilation with low tidal volume and pressures limited (Pplat <30cmH2O). End-Expiratory Lung Volume and strain will be measured every 6 hours from the inclusion to the extubation.
3083514|NCT02003313|Experimental|Group T|Participants of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine.
3083515|NCT02003313|Active Comparator|Group C|Participants of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine.
3083516|NCT02003287|Experimental|FEES|Swallowing evaluation with the Fiberoptic Endoscopic Evaluation of Swallowing
3083517|NCT02003287|Active Comparator|VFSS|Swallowing evaluation with the Videofluoroscopic Swallowing Study
3083518|NCT02003274|Other|Clamp-Mixed Meal Arm|Twenty adult patients with type 1 diabetes, regularly attending the Division of Endocrinology and Metabolic Diseases of University of Verona School of Medicine, using continuous subcutaneous fast insulin analogue infusion (CSII) through a permanent pump and on subcutaneous glucose sensing will be enrolled.
3083519|NCT02003274|Other|IVGTT-Mixed Meal Arm|Twenty healthy adult volunteers will be recruited.
3083520|NCT02003261|Experimental|Unified Protocol with Treatment As Usual|Unified Protocol is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. During this treatment period, the participants continue the Treatment As Usual.
3083521|NCT02003261|Other|Waitlist Control with Treatment As Usual|Waitlist participants will not receive treatment during a 20-week waitlist period, but will receive the unified protocol immediately following the 20 week waiting period. During the waitlist period, the waitlist participants continue the treatment as usual.
3083522|NCT02003248|Experimental|dyskinesia of PD|The proposed study is to evaluate the safety and initial effectiveness of the ExAblate Transcranial MRI-guided focused ultrasound (MRgFUS) treatment of patients with dyskinesia of Parkinson's Disease (PD)
3083523|NCT02003235|Experimental|Single Arm|Daily watching videos using Reviview™, a dichoptic video display device
3083526|NCT02003209|Active Comparator|Arm I (combination chemotherapy, surgery, radiation)|"NEOADJUVANT: Patients receive docetaxel IV over 60 minutes, carboplatin IV over 30-60 minutes, trastuzumab IV over 30-90 minutes, and pertuzumab IV over 30-60 on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients enrolled after Amendment #4 undergo 2 core biopsies prior to course 3 of treatment.~SURGERY: Patients undergo lumpectomy or mastectomy.~RADIATION: Patients undergo whole breast irradiation within 8 weeks following surgery.~ADJUVANT: Patients receive trastuzumab IV over 30-60 minutes every 21 days for up to 1 year."
3083527|NCT02003209|Experimental|Arm II (chemo, estrogen deprivation, surgery, radiation)|"NEOADJUVANT: All patients receive docetaxel, carboplatin, trastuzumab, and pertuzumab as in arm I. Premenopausal patients also receive goserelin acetate SC every 28 days until surgery and aromatase inhibition therapy at the investigator's discretion daily until 1 day before surgery. Postmenopausal patients receive aromatase inhibition therapy at the investigator's discretion daily until 1 day before surgery. Patients enrolled after Amendment #4 undergo 2 core biopsies prior to course 3 of treatment.~SURGERY: Patients undergo lumpectomy or mastectomy.~RADIATION: Patients undergo whole breast irradiation within 8 weeks following surgery.~ADJUVANT: Patients receive trastuzumab IV over 30-60 minutes every 21 days for up to 1 year."
3083528|NCT02003183|Experimental|[F-18]FDDNP|
3083529|NCT02003170||Neurodevelopmental Disorders|Children who present to various Arkansas Children's Hospital clinics for standard care related to neurodevelopmental disorders.
3083530|NCT02003157|Active Comparator|hypnosis|embryo transfer procedure with hypnosis
3083531|NCT02003157|Active Comparator|usual|embryo transfer usual procedure
3083532|NCT02003144|Experimental|Eculizumab|Eculizumab intravenous infusion every two weeks.
3083533|NCT02003131|Other|Intra-articular knee injection of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered intra-articularly.
3083534|NCT02003131|Other|Subcutaneous injection of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered subcutaneously once per week for 12 weeks.
3083535|NCT02003118|Experimental|AKR 202|
3083536|NCT02003118|Placebo Comparator|Placebo|
3083537|NCT02003092|Experimental|RX-5902|RX-5902 will be taken daily for 4 weeks in each 4 week cycle. Subjects will be fasting for 8 hours before and food may be ingested approximately 3 hours after the dose has been administered.
3083538|NCT02003079||Diagnosed with or without Chronic Rhinosinusitis|
3083539|NCT02003066|Experimental|Standard|
3083540|NCT02003066|Active Comparator|Conservative|
3083541|NCT02003053|Experimental|IMT|In the IMT group, inspiratory muscle training will start with 30% of MIP, for five minutes twice a day with increments of 10 % (absolute) everyday. Supplemental oxygen will be given as needed. The exercise will be done seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge.
3083542|NCT02003053|Sham Comparator|Sham|In the SHAM group, sham device will be used to train subjects 5 minutes twice a day, seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge.
3083543|NCT02003040||St. Michael's Hospital Patients|Patients admitted to the Cardiology ward at St Michael's Hospital with a main diagnosis of acute decompensated heart failure
3083544|NCT02003027|Experimental|BT injection|
3083545|NCT02003014||Pioglitazone 15 mg to 30 mg|administered orally once daily
3083546|NCT02003001|Experimental|BT injection|
3083547|NCT02002988|Experimental|BT injection|
3083548|NCT02002975||Pioglitazone 15 to 30 mg|administered orally once daily before or after breakfast for 3 years.
3083549|NCT02002962|Active Comparator|RFA+BT injection|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
3083550|NCT02002962|Active Comparator|RFA|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
3083551|NCT02002949|Experimental|Short daily hemodialsysis|Short Daily Hemodialysis (SDHD) - 5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
3083552|NCT02002949|Active Comparator|Conventional hemodialysis|Conventional Hemodialysis (CHD) - 3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
3083553|NCT02002936|Experimental|SyB C-1101|
3083554|NCT02002923|Active Comparator|PVI only|
3083555|NCT02002923|Active Comparator|PVI+BT injection|
3083556|NCT02002897|Experimental|Fractional carbon dioxide laser|Single session of fractional laser is done using DEKA machine , for 3 months .
3083557|NCT02002897|Active Comparator|Ultraviolet A1 phototherapy (UVA1)|24 sessions of UVA 1 phototherapy are give at a rate of 3 sessions per week , at a dose of 30 joules using a Waldman targeted machine.
3083558|NCT02002884|Experimental|8 Units per kg body weight incobotulinumtoxinA (Xeomin)|8 Units per kg body weight (maximum of 200 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 300 Units per injection cycle. Overall maximum dose per injection cycle: 500 Units.
3083559|NCT02002884|Experimental|6 Units per kg body weight incobotulinumtoxinA (Xeomin)|6 Units per kg body weight (maximum of 150 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 225 Units per injection cycle. Overall maximum dose per injection cycle: 375 Units.
3083560|NCT02002884|Experimental|2 Units per kg body weight incobotulinumtoxinA (Xeomin)|2 Units per kg body weight (maximum of 50 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 75 Units per injection cycle. Overall maximum dose per injection cycle: 125 Units.
3083561|NCT02002871|Experimental|Blue light|Irradiation with PSOCT02 device emitting blue light at a wavelength of 453nm
3083562|NCT02002871|No Intervention|Control|contralateral untreated control plaque on the same patient.
3083563|NCT02002858|Experimental|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
3083564|NCT02002858|Active Comparator|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
3083565|NCT02002845||Robotic arm|Patient who have undergone benign non-tumor TORS procedures using the da Vinci Surgical System
3083566|NCT02002832||Lurasidone group|Lurasidone tablets: oral,40 or 80mg/day,once after the meal for 6 weeks Risperidone placebo tablets: oral ,2~6mg/day,once after the meal for 6 weeks
3083567|NCT02002832||Risperidone group|Risperidone tablets:oral,2-6mg/day,once after the meal for 6 weeks Lurasidone placebo tablets: oral,40 or 80mg/day,once after the meal for 6 weeks
3083568|NCT02002819|Experimental|Levetiracetam-Placebo|This group receives levetiracetam for 4 weeks twice daily, then has a break where no treatment is given for 4 weeks, and then receives placebo for 4 weeks.
3083569|NCT02002819|Experimental|Placebo-Levetiracetam|This group receives placebo for 4 weeks twice daily, then has a break where no treatment is given for 4 weeks, and then receives levetiracetam for 4 weeks.
3083570|NCT02002806|Experimental|Alcohol Injection|Celiac plexus neurolysis by alcohol injection One time administration during surgery 20 ml of alcohol injection on each side of aorta at level of celiac axis
3083571|NCT02002806|Placebo Comparator|Placebo Injection|Celiac plexus injection - placebo injection
3083572|NCT02002793|Other|Early stage abdominal drainage|SAP patients who matches one of the following criteria:1．Intravesical pressure≥20cmH2O or 2.CT images:acute peripancreatic liquid collection should have early stage abdominal drainage immediately;
3083573|NCT02002793|Other|Late stage abdominal drainage|Despite that it matches one of the cirteria as the study group:1．Intravesical pressure≥20cmH2O or 2．CT images:acute peripancreatic liquid collection, the patients continue acquire prearranged integrative treatment and will not accept early stage abdominal drainage until any of the followings emerge:1.Intra-abdominal apartment syndrome; 2. Pancreatic pseudocyst;3. Pancreatic or peripancreatic necrosis;
3083574|NCT02002780|Experimental|Subjects|"Children identified during the screening phase of the project as having elevated, but not clinically defined, levels of psychosocial stress will be invited to participate in the intervention phase of this research if they are between 8 and 11 years of age.~Screening will identify 6 girls and 6 boys eligible and willing to participate in the intervention phase of the project."
3083575|NCT02002780|No Intervention|Control|All families that were screened during the screening phase of this study will complete the final screening instrument assessment, whether or not the child participated in the day camp intervention. The control group will be comprised of those families that did not participate in the intervention.
3083576|NCT02002767|Experimental|Participants with renal impairment|Participants with severe renal impairment will receive a single dose of GS-5816.
3083577|NCT02002767|Active Comparator|Participants with normal renal function|Participants with normal renal function will receive a single dose of GS-5816.
3083578|NCT02002754|Active Comparator|Eosinophilic bronchitis|Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
3083579|NCT02002754|Active Comparator|cough variant asthma|Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
3083580|NCT02002741|Active Comparator|Ibuprofen + Paracetamol|"Ibuprofen 10mg/kg once --> 5mg/kg twice, q 24h for total of 3 doses~+ Intravenous Paracetamol : Loading dose 20mg/kg --> 10 mg/kg q6h for total of 12 doses"
3083581|NCT02002741|Placebo Comparator|Ibuprofen + Placebo|"Ibuprofen 10mg/kg once --> 5mg/kg twice, q 24h for total of 3 doses~+ Placebo (NaCl 0.9%) , Intravenous , at equal volume to the paracetamol in the paracetamol arm, total of 12 doses given q 6h."
3083582|NCT02002715|Active Comparator|Inhaled budesonide for 4 weeks|inhaled Budesonide 100µg , 2puff Q12h for 4 weeks
3083583|NCT02002715|Active Comparator|Inhaled budesonide for 8 weeks|inhaled Budesonide 100µg , 2puff Q12h for 8 weeks
3083584|NCT02002715|Active Comparator|Inhaled budesonide for 16 weeks|inhaled Budesonide 100µg , 2puff Q12h for 8 weeks
3083585|NCT02002702|Experimental|Serelaxin 10 mcg/kg/Day|Participants received 10 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.
3083586|NCT02002702|Experimental|Serelaxin 30 mcg/kg/Day|Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.
3083587|NCT02002702|Placebo Comparator|Placebo|Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.
3083588|NCT02002689|Experimental|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule.
3083589|NCT02002663|Experimental|ropivacaine + methylprednisolone|Continuous infusion of Ropivacaine 0.2% and methylprednisolone 1mg/kg 10ml/h through intralesional catheter for 24 hours
3083590|NCT02002663|Placebo Comparator|saline|Continuous infusion of saline through intralesional catheter for 24 hs
3083591|NCT02002650|Experimental|Pre-ERCP group|Pre-ERCP rectal Indomethacin in all patients.
3083592|NCT02002650|Active Comparator|Post-ERCP group|Post-ERCP rectal Indomethacin in high-risk patients.
3083593|NCT02002637|Experimental|Latella Knee Implant System|
3083594|NCT02002624|Active Comparator|Conventional|Conventional instrumentation
3083595|NCT02002624|Experimental|PSI|Patient specific instrumentation
3083596|NCT02002611|Experimental|Lobeglitazone|Subjects received Lobeglitazone 0.5 mg daily for 12 days in one period and in the other period, Subjects don't receive Lobeglitazone.
3083597|NCT02002611|Experimental|Warfarin|Subjects received Warfarin 25 mg once at period 1 and 2.
3083598|NCT02002598|Experimental|CFZ with bendamustine and dexamethasone|Subjects will receive Carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days with dose escalation from 27, 36, 45 to 56 mg/ m2 . No matter what target dose the subject will receive, days 1 and 2 doses in the first cycle will always be 20 mg/m2, followed by target dose for all subsequent dates and cycles. Bendamustine will be given IV on days 1 and 2 with dose escalation up to 90 mg/m2 and dexamethasone 20 mg orally or intravenously on 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle. Study treatment will be given until 8 cycles of treatment are completed or until disease progression, whichever comes first.
3083739|NCT02001610|Experimental|Acidophilus pearls|"Encapsulated using patented process~One capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
3083599|NCT02002585|Experimental|RDN and optimal medical therapy|Renal denervation will be performed using the available denervation device with a european approval according to current guidelines. The same device will be used for all patients in this arm to avoid efficacy bias.
3083600|NCT02002585|No Intervention|optimal medical therapy alone|Group of patients who will be treated only with optimal medical therapy and will not be denervated. Subsequently, the patients will be followed in our cardiology and nephrology department according to the study flowchart for 3 years according to the standard of care in our institution for patients with chronic renal insufficiency.
3083601|NCT02002572|Experimental|Mimic facial muscle from 3T MRI data|
3083602|NCT02002559||NBI Magnify Endoscopy|
3083603|NCT02002559||Lugol Chromoendoscopy|
3083604|NCT02002546||ED chest pain presenting patients|
3083605|NCT02002533|Experimental|Arm I (BBT intervention)|Patients undergo BBT intervention, comprising insomnia education, stimulus control, discouragement of napping and encouragement of exercise, and sleep compression over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6.
3083606|NCT02002533|Active Comparator|Arm II (control)|Patients undergo HEAL comprising nutritional education and suggestions for symptom management over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6.
3083607|NCT02002520||case group|patients undergo third molar surgery
3083608|NCT02002520||control group|subjects do not require surgery
3083609|NCT02002507||park bench position|Comparing jugular venous flow in supine and park bench position in neurosurgical patients requiring their surgery in park bench position
3083610|NCT02002507||prone position|Comparing the jugular venous flow in the supine and prone position in patients requiring their surgery to be done in the prone position.
3083611|NCT02002494||volunteers in different positions|"The following will be compared in the same volunteer:~Bilateral internal jugular venous flow in supine and prone position~Bilateral internal jugular venous flow in supine and park bench position~Bilateral internal jugular venous flow in prone and park bench"
3083612|NCT02002481|No Intervention|Control|10 minutes ALS-CPR in a normal environment
3083613|NCT02002481|Experimental|Transport|10 minutes ALS-CPR during a transport
3083614|NCT02002468|Experimental|Test result sent by letter|The pap-smear test result is sent by letter directly to the women. Women in need of follow up are in the letter recommended to contact their general practitioner.
3083615|NCT02002468|Active Comparator|Test result conveyed by general practitioners|In Denmark it is a standard procedure that general practitioners convey the pap-smear test results to the women.
3083616|NCT02002455|Experimental|Multimodality imaging|PET/CT, PET/MRI, mpMRI
3083617|NCT02002442|Active Comparator|0.12% Chlorhexidine|Alcohol-free Chlorhexidine Gluconate Oral Rinse USP, 0.12% from GUM®
3083618|NCT02002442|Active Comparator|Essential oil|LISTERINE® ZERO™ Mouthwash
3083619|NCT02002442|Active Comparator|0.07% Cetylpyridinium Chloride|Crest Pro-Health Multi-Protection Rinse - Refreshing Clean Mint (Procter and Gamble)
3083620|NCT02002442|Placebo Comparator|Saline|
3083621|NCT02002429|Experimental|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine
3083622|NCT02002429|Active Comparator|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine
3083623|NCT02002429|Sham Comparator|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline
3083624|NCT02002416||Metastatic gastric cancer patients|Selecte 100 cases of eligible metastatic gastric cancer patients with primary and metastatic lesion (1:1). Use the immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH) to detect the status of C-met.
3083625|NCT02002416||Early stage gastric cancer|Selected 100 cases of eligible gastric cancer patients with previously early stage gastric cancer
3083626|NCT02002403|Placebo Comparator|Placebo|
3083627|NCT02002403|Experimental|Optina Low Dose|Optina, 15 mg orally, twice daily
3083628|NCT02002403|Experimental|Optina - High Dose|Optina, 45 mg orally, twice daily
3083629|NCT02002390|Experimental|Fingolimod (FTY720) group|Drug: Fingolimod capsules will be administered as 0.5mg/day over a course of 3 consecutive days after stroke onset.
3083630|NCT02002390|Placebo Comparator|Control group|Patients will receive usual care and drug use in hospital.
3083631|NCT02002377|Experimental|Aflibercept|Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
3083632|NCT02002364|Active Comparator|Single use flexible optical scope|Single use flexible optical scope , Ambu aScope
3083633|NCT02002364|Active Comparator|Multiple use flexible optical scope|Multiple use flexible optical scope
3083634|NCT02002351||Pulmonary disease|
3083635|NCT02002338||Pterygium|Patients who were operated of pterygium
3083636|NCT02002325|Experimental|Alteplase|Intravenous tissue-type plasminogen activator (alteplase)
3083637|NCT02002325|Other|Standard Care|Standard treatment for acute stroke
3083638|NCT02002312|Experimental|Lu-177-DOTA-girentuximab|Patients in receive 10 mg of girentuximab coupled to DOTA and labeled with 65 mCi/m2 of Lu-177 if targeting of In-111-DOTA-girentuximab is observed in at least 1 lesion. Patients may be retreated no sooner than 12 weeks after the prior treatment with a dose of no more than 75% of the previous dose, for a total of not more than three treatments.
3083639|NCT02002286|Experimental|TwHF extract + cART|Use Tripterygium Wilfordii Hook F extract (TwHF extract) and continue current cART regimen
3083640|NCT02002286|Other|cART control|Continue current cART regimen
3083641|NCT02002273|Experimental|Patients with regulated suction mode|On the morning of each postoperative day (starting with POD#1) patients of group 1 are switched for 4 hours to -8 cm H2O After this period of 4 hours both groups are switched back to their original pressure levels, with the effect on air leak and fluid leak measured. Pts are then left on their original pressure level until the next day, when the switch to -8 or - 20 cm H2O is again made.
3083740|NCT02001597||Surgery patients|
3083741|NCT02001584|Experimental|Healthy Volunteers|
3083642|NCT02002273|Experimental|regulated seal mode (-8 cmH2O).|On the morning of each postoperative day (starting with POD#1) patients of group 1 are switched for 4 hours to -8 cm H2O and patients of group 2 are switched to -20 cm H2O. After this period of 4 hours both groups are switched back to their original pressure levels, with the effect on air leak and fluid leak measured. Pts are then left on their original pressure level until the next day, when the switch to -8 or - 20 cm H2O is again made.
3083643|NCT02002260|Active Comparator|Levonorgestrel intrauterine system|levonorgestrel intrauterine system with 52 mg of levonorgestrel, levonorgestrel is released at a rate of approximately 20 μg/day. Inserted once, duration 5 years.
3083644|NCT02002260|Active Comparator|Combined oral contraceptives|A combined ethinyl estradiol (ee) and progestin oral contraceptive pill chosen by the participants' primary gynecologic care provider. Monophasic with 30 or 35 mcg ee administered according to pill pack instructions (21 days active pills, 7 placebo pills)
3083645|NCT02002247|Placebo Comparator|Placebo|Normal saline will be administered to subjects intravenously pre-operatively, upon admission to the ICU, then daily up to post-operative day 10 or ICU discharge, whichever occurs first.
3083646|NCT02002247|Active Comparator|sodium selenite|"High-dose sodium-selenite will be administered to subjects intravenously:~1) pre-operatively (2000 ug); 2) upon admission to the ICU (2000 ug), 3) then daily (1000 ug) up to post-operative day 10 or ICU discharge, whichever occurs first."
3083647|NCT02002234|Other|Medical Treatment Arm|Received standardized medical therapy in an intensive care unit (ICU), which included elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L. Hyperglycemia, hyperthermia and hypotension were avoided or corrected when present.
3083648|NCT02002234|Other|Surgery with Medical Treatment Arm|Aside from receiving standardized medical therapy, decompressive hemicraniectomy was performed by removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank. Cranioplasty was performed during a separate admission on an elective basis not earlier than 6 months from the initial surgery.
3083649|NCT02002221|Experimental|Vildagliptin (LAF237)|Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study
3083650|NCT02002221|Placebo Comparator|Placebo|In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study
3083651|NCT02002208|Experimental|OC000459 Tablets|50 mg orally once a day
3083652|NCT02002208|Placebo Comparator|Placebo Tablets|Orally once a day
3083653|NCT02002195||modified folfox|Oxaliplatin 85 mg/m2 in 2 hours intravenous infusion, + S-leucovorin 200 mg/m2, + 5-FU 2,400 mg/m2 as a 46 hours continuous infusion. The cycles are repeated every 2 weeks for a total of 8 cycle, if tumor response is stable disease, partial or complete response, then maintenance with Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
3083654|NCT02002182|Experimental|Treatment-Vaccine Group|Two vaccinations with ADXS11-001 (ADXS-HPV) will be given at a dose of 1x10^9 cfu intravenously. The drug will be given as a 500ml infusion over 60 minutes.
3083655|NCT02002182|No Intervention|Control Group|Observational control group treated with standard of care therapy only
3083656|NCT02002169|Experimental|Shower Technique Protocol (STP)|Participants will be given a minimum 30 minute personalized educational session by the study coordinator. They will be taught safe and clean techniques for showering with their CVC. If the participant passes the Shower Technique Test, they will be provided a pamphlet on the STP, not to be shared with other participants, to be kept as a reference and placed in their bathroom/household. They will also be given the necessary supplies for the STP.
3083657|NCT02002169|Active Comparator|Standard CVC care|Standard CVC Care consists of cleansing with chlorhexidine 2% or povidone (if allergic to chlorhexidine) at the CVC exit site by trained HD nurses followed by placement of a dry gauze dressing by the HD nurse 1x/week or when clinically indicated. In order to participate in the standard CVC care arm, participating sites must have in their policy that it is trained HD nurses who will apply the Polysporin Triple Ointment after standard cleansing with chlorhexidine 2% or povidone during HD, according to guideline recommendations or as per hospital patient care standards and nursing regulations.
3083658|NCT02002156|Experimental|BCG at birth and routine vaccines|BCG, NeisVac‐C®, Pediacel®, Infanrix™, Prevenar‐13®, Menitorix®, Priorix®, Rotarix®
3083659|NCT02002156|Experimental|BCG at 3 months old and routine vaccines|BCG, NeisVac‐C®, Pediacel®, Infanrix™, Prevenar‐13®, Menitorix®, Priorix®, Rotarix®
3083660|NCT02002156|Experimental|Routine vaccines|NeisVac‐C®, Pediacel®, Infanrix™, Prevenar‐13®, Menitorix®, Priorix®, Rotarix®
3083661|NCT02002143|Active Comparator|Individual Appointments (IAs)|"Participants randomly assigned to the IAs group will receive eight traditional 1-to-1 appointments, seeing their physician quarterly as per standard care in BC. They will be referred to ancillary services such as nutrition advice, counseling, and physical activity promotion according to 'usual care' practice. In addition, we will organize 4 1-hour social events for these participants annually. The 4 social events will be 1) a potluck lunch; 2) a movie night; 3) an event chosen by participants; and 4) a talent show. From our experience, these events enhance compliance to reporting and minimize dropouts. These events also serve to minimize 'socialization bias' that may otherwise potentially influence health measures including quality of life."
3083697|NCT02001883|Active Comparator|Association low-dose statin and nutraceuticals|Patients will receive the association between low-dose statin (10 to 20 mg/day of simvastatin or 5 to 10 mg/day atorvastatin) and a commercially available nutraceutical combined pill (1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg).
3083698|NCT02001883|Active Comparator|Low-dose statin|Patients will receive low-dose statin (10 to 20 mg/day of simvastatin or 5 to 10 mg/day atorvastatin)
3083699|NCT02001870|Experimental|In Vitro Fecundation (IVF)|Couples will be treated by In Vitro Fecundation (IVF)
3083742|NCT02001584|Experimental|Obese, Otherwise Healthy Volunteers|
3083662|NCT02002143|Experimental|Group Appointments (GAs)|"Participants randomly assigned to the intervention group will participate in GAs of 8 patients for 1.5 hours, every 3 months for 2 years. The 3-member Care Team (MD, nurse, behaviorist) will attend each session. The nurse facilitates the session and curriculum. The MD responds to specific health questions. Patients may schedule time before or after to review their clinical results with the MD/nurse (e.g. HbAIC).~Key elements include 1) completed pre-appt questionnaires used to identify a patient's educational needs; 2) patients use goal setting and action plans to initiate and maintain healthy behaviors; 3) each class has a designated purpose and learning objectives; 4) sessional feedback, which is used to adapt the next class (3 months later) based on patient needs."
3083663|NCT02002130|Placebo Comparator|Placebo GABA and Placebo GAD-alum|"Placebo formulation, Maltodextrin, for Gamma-Amino Butyric Acid (GABA) capsule-identical in appearance and taste, but no active medication will be taken with meals.Number of pills based on body surface area.~Placebo GAD-alum(Glutamic Acid Decarboxylase in alum) injection- identical in appearance but no active medication will be received at baseline and 1 month."
3083664|NCT02002130|Active Comparator|GABA and placebo GAD-alum|"Patients will receive the Active GABA (Gamma-Amino Butyric Acid) capsules. Each capsule 250mg. Dosage will be calculated according to body surface area of the child and divided between 2 meals/day. Larger dose taken with larger meal.~Patients will receive the GAD-alum( Glutamic Acid Decarboxylase in alum) placebo at baseline and 1 month."
3083665|NCT02002130|Active Comparator|Active Oral GABA and Active GAD-alum Injection|"Patients will receive Oral GABA(Gamma-Amino Butyric Acid) 250mg capsules. Dosage (# of capsules) based on body surface area and divided between 2 meals/day.~Patients will receive a primary (at baseline)injection of recombinant human GAD(Glutamic Acid Decarboxylase) in a standard vaccine formulation with alum, and a booster injection of the same at 1 month after baseline."
3083666|NCT02002117||DNA mass spectrometry|DNA mass spectrometry
3083667|NCT02002104||EPCs|No proliferation and no differentiation on the ePTFEs
3083668|NCT02002104||Modified ePTFE|EPCs adherence, proliferation and differentiation on the ePTFEs.
3083669|NCT02002091||Complications,no specific treatment|After screening for complications, a non specific multi interventional treatment is applied to patients. After one year of follow up, we will compare two groups: with and without chronic kidney disease, on the advent of cardiovascular events. An adjustment is done for age and major risk factors.
3083670|NCT02002078|No Intervention|Methylprednisolone, caustic burns|
3083671|NCT02002065||Inactivated HAV vaccine|Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
3083672|NCT02002065||Attenuated alive HAV vaccine|Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
3083673|NCT02002052|Active Comparator|Standard Arm|Standard platinum-based chemoradiotherapy, total radiation dose 60 Gy in 30 fractions
3083674|NCT02002052|Experimental|Experimental Arm|Functional-lung avoidance radiotherapy, total dose 60 Gy in 30 fractions, with concurrent platinum-based chemotherapy
3083675|NCT02002039|Active Comparator|erythropoietin, perinatal asphyxia,|Treatment group
3083676|NCT02002039|Placebo Comparator|Normal saline, perinatal asphyxia|Normal saline on alternate days for 5 doses starting from first 6 hours of life
3083677|NCT02002026|Active Comparator|Ligation group|Uterine artery ligation will be done for patients in this group
3083678|NCT02002026|Placebo Comparator|Control group|Conventional CS
3083679|NCT02002013||Adult ICU patient receiving Fluid resus|Adult patients present in the ICU at the start of the study day or admitted during the 24-hour study period will be included in the study sample.
3083680|NCT02002000|Experimental|vitamin D|Patients receiving 3 doses of vitamin D (cholecalciferol)
3083681|NCT02002000|Experimental|Placebo|Patients receiving 3 doses of placebo according to the same schedule as experimental arm
3083682|NCT02001987|Experimental|RoActemra/Actemra (tocilizumab)|
3083683|NCT02001974|Experimental|Paclitaxel 80 mg/m2 i.v.+Reparixin oral 400 mg t.i.d.|Paclitaxel+reparixin three weeks on one week off (three to six patients)
3083684|NCT02001974|Experimental|Paclitaxel 80 mg/m2 i.v.+Reparixin oral 800 mg t.i.d.|Paclitaxel+reparixin three weeks on one week off (three to six patients)
3083685|NCT02001974|Experimental|Paclitaxel 80 mg/m2 i.v.+Reparixin oral 1200 mg t.i.d.|Paclitaxel+reparixin oral three weeks on one week off (three to six patients).
3083686|NCT02001961||Heart failure|Patients will be recruited from the heart failure clinic by their consultant. These will include patients who are due to have a MRI scan for clinical reasons and those who volunteer to participate. Voluntary subjects will be over 8 years.
3083687|NCT02001961||Control|Control subjects will be identified after being referred for an MRI scan and being allocated to a non-cardiac MRI with gadolinium contrast.
3083688|NCT02001948|Active Comparator|intrathecal morphine 0.1 mg|After routine monitorisation, intravenous cannulation and premedication, patients in this group will receive a spinal anaesthesia with 0.1 mg morphine combined with 7.5 mg heavy bupivacaine
3083689|NCT02001948|Active Comparator|0.4 mg of intrathecal morphine|After routine monitorisation, intravenous cannulation and premedication, patients in this group will receive spinal anesthesia with 0.4 mg of morphine combined with 7.5 mg of heavy bupivacaine.
3083690|NCT02001935|Other|theophylline|
3083691|NCT02001922|Experimental|COPD integrated care|The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
3083692|NCT02001922|No Intervention|Usual care|Usual COPD care
3083693|NCT02001909|Experimental|Regorafenib|
3083694|NCT02001909|Experimental|Neomycin|
3083695|NCT02001896|Experimental|erlotinib combine with chemotherapy|Drug: gemcitabine 1000mg/m2 iv on days 1 of each 4 week cycle for 6 cycles Drug: Platinum chemotherapy (cisplatin or carboplatin) cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles Drug: Erlotinib[Tarceva] po on days 15-28 of each 4 week cycle until disease progression
3083696|NCT02001896|Active Comparator|erlotinib along|Drug: erlotinib [Tarceva] 150mg/day po until disease progression
3083700|NCT02001870|Active Comparator|Intra Uterine Insemination (IUI)|Couples will be treated by Intra Uterine Insemination (IUI)
3083703|NCT02001844|Placebo Comparator|Control|"The control FOs, or placebo FOs was supplied to patients who were randomly included in the control group. The control FOs was made of leather board (1mm), grey Poron (1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any sort of biomechanical support, nor had it any effect on the distribution of pressure, as it was completely flat. In addition, the placebo FOs did not present with any intrinsic or extrinsic correction underneath the sub-talar-joint (STJ).~The use of black EVA as the covering material and the leather-board as a base, allowed for gathering of a dynamic impression over the 6 months of the trial."
3083704|NCT02001844|Experimental|Trial Group|"Trial Group:~children who were randomly introduced into this group received the pre-formed semi-rigid FOs. The FOs were used as an off the-shelf device and subsequently customised with chair side modifications. In order to reproduce the exact same aesthetical appearance as the control FOs, grey poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs.~Furthermore, depending on the type of correction applied to the trial patient, the black EVA also allowed the correction applied on the surface of the device to be masked."
3083705|NCT02001831|Experimental|Supplement|"Liquid nutrient support (quantity 200 mL per day; energy 200 kcal per day):~Carbohydrate 28.5 g~Protein 8 g as Whey Protein Isolate~ω-3 PUFA 3000 mg, as DHA 1500mg, as EPA 1500mg~Vitamin D3 10 μg~Resveratrol 150 mg"
3083706|NCT02001831|Placebo Comparator|Control|"Placebo control~Liquid nutrient support~Quantity 200 mL per day - fruit juice only i,e. in absence of bioactives present in the supplement (whey protein, omega 3, vitamin D and resveratrol)."
3083707|NCT02001818|Experimental|Nilotinib or Imatinib with Peginterferon|"Nilotinib 300mg twice daily for 24 months. Pegylated interferon alpha-2b 30-50 micrograms subcutaneously once weekly for maxium 21 months (3 months after trial registration).~Patients intolerant of nilotinib may be switched to appropriate doses of imatinib"
3083708|NCT02001805||Marathon runners|Very active runners that have been running > 10 marathons, 2 within the last year, or an amount of 50 km/week for the last 5 years
3083709|NCT02001805||Control subjects|Healthy normal weight control subjects, with a low activity level < 1 hour phsyical activity pr. week. They are matched with runners on age, BMI and gender
3083710|NCT02001792|Sham Comparator|Controll group|Patients lying in a supine position during colonoscopy
3083711|NCT02001792|Active Comparator|Intervention|Patients lying in a left lateral position during colonoscopy
3083712|NCT02001779|Experimental|Biliary SEMS loaded with 125I seeds|A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
3083713|NCT02001779|Active Comparator|Conventional biliary SEMS|A self-expandable metallic biliary stent is inserted in patients with inoperable malignant biliary obstruction.
3083714|NCT02001766|Experimental|High intensity exercise|3 times per week in a total of 12 weeks
3083715|NCT02001766|Experimental|Low intensity exercise|3 times per week in a total of 12 weeks
3083716|NCT02001766|Experimental|Control|Normal lifestyle for 12 weeks
3083717|NCT02001753|Experimental|CMR group|Endothelial function, oxidative stress and inflammation were measured before and after CMR.
3083718|NCT02001753|Placebo Comparator|Placebo group|"The subjects keep supine position the MR machine as same time as experimental group when the MR machine is power off. The endothelial function, oxidative stress and inflammation were measured before and after this procedure. This group is called the non-CMR group or sham CMR group."
3083719|NCT02001753|No Intervention|health subject group|Healthy subjects (30) will be enrolled as controls at baseline.
3083720|NCT02001740|Placebo Comparator|lidocaine|frequency = once
3083721|NCT02001740|Experimental|Triamcinalone (steroid) and lidocaine|frequency = once
3083722|NCT02001727|Active Comparator|Hp-screened group|Screened for Helicobacter Pylori and eradication therapy (1998-99)
3083723|NCT02001727|Other|Control group|primarily unscreened group
3083724|NCT02001714|Experimental|Group Behavioral Treatment|Participants will attend a group behavioral treatment class and follow-up visits.
3083725|NCT02001714|No Intervention|No Treatment|Subjects will not attend group behavioral treatment class.
3083726|NCT02001701|Experimental|Intravitreal Gas|Intravitreal injection of sulfahexafluoride gas
3083727|NCT02001688|Experimental|Active, group A|Kamada-API for Inhalation, 80mg
3083728|NCT02001688|Placebo Comparator|Placebo|Placebo administered by inhalation daily
3083729|NCT02001688|Experimental|Active, group B|Kamada-API for Inhalation, 160mg
3083730|NCT02001675|Experimental|Volunteer healthy|
3083731|NCT02001662|Experimental|Intervention group, block no. 1 - Ropivacain|"Adductor-Canal-Block no.1: 30mL ropivacaine (7.5 mg/ml) when postoperative VAS-score is > 40mm (on a 0-100 mm VAS-scale) during a 45 degree active flexion of the knee.~Adductor-Canal-Block no.2: after 45 min (t45) - 30mL isotonic saline."
3083732|NCT02001662|Sham Comparator|Control group, block no. 1 - saline|"Adductor-Canal-Block no.1: 30mL isotonic saline when postoperative VAS-score is above 40mm (on a 0-100 mm VAS-scale) during a 45 degree active flexion of the knee.~Adductor-Canal-Block no.2: after 45 min (t45) - 30mL ropivacaine (7.5 mg/ml)"
3083733|NCT02001649|Other|Inpatient group SNP Genotyping|"Patients will be recruited from pediatric departments in which 13 -17 y old adolescents are hospitalized for a suicide attempt. Data will be collected through self-administered questionnaires and face to face interview. DNA will be extracted from saliva sample.~Individuals will be genotyped at a total of 96 SNPs"
3083734|NCT02001649|Other|Control group SNP Genotyping|Control subjects are young adults without suicide attempt and without mental disorders
3083735|NCT02001636|Experimental|Protein group|"Patient group which takes daily protein supplements after bariatric surgery over 6 months.~Protein product: Resource Instant Protein 88, Nestlé Health Nutrition"
3083736|NCT02001636|Placebo Comparator|Control group|"Patient group which takes daily isocaloric placebo after bariatric surgery over 6 months and thus can be compared to the protein group.~Placebo product: Resource Maltodextrin, Nestlé Health Nutrition"
3083737|NCT02001623|Experimental|Tisotumab Vedotin (HuMax-TF-ADC)|All arms of the trial (borh in escalation and expansion phase) will be administered tisotumab vedotin (HuMax-TF-ADC)
3083738|NCT02001610|Active Comparator|Hard shell gelatin capsules|"Comparison delivery vehicle in the form of gelatin capsule~One capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
3083743|NCT02001571|Experimental|Cohort 1|Mild Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
3083744|NCT02001571|Experimental|Cohort 2|Moderate Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
3083745|NCT02001571|Experimental|Cohort 3|Normal Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
3083746|NCT02001558|Experimental|Microcyn|
3083747|NCT02001558|Active Comparator|Sterile saline|
3083748|NCT02001545||Patients with STEMI and NSTEMI|Patients aged 18 years or older, hospitalized and diagnosed with STEMI (ST-segment elevation myocardial infarction) or NSTEMI (non-ST-segment elevation myocardial infarction) within 24 hours of symptom onset.
3083749|NCT02001532||Diabetes type 2|Patients diagnosed with type 2 diabetes within 5 years from baseline (i.e. 10 years at follow-up)
3083750|NCT02001532||Healthy controls|Sex and age-matched healthy controls
3083751|NCT02001519|Experimental|adriamycin,cytoxan, cisplatin|4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks followed by 4 cycles of cisplatin 75 mg/m2 every 3 weeks
3083752|NCT02001506|Active Comparator|FEC3-D3|"3 cycles of FEC followed by 3 cycles of Docetaxel~Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
3083753|NCT02001506|No Intervention|AC4-D4|"4 cycles of Adriamycin plus Cyclophosphamide (AC) followed by 4 cycles of Docetaxel~Adriamycin 60 mg/m2, every 3 weeks Cyclophosphamide 600 mg/m2, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
3083754|NCT02001480|Other|Echocardiography|"12 lead holter for 7 days~CGM = continuous Glucose Monitoring"
3083755|NCT02001467|Active Comparator|Simulation-based training|Simulation-based training to an expert criterion followed by clinical training until proficiency and certification.
3083756|NCT02001467|No Intervention|Control|No training is provided the control group participants.
3083757|NCT02001454||Patients in pain|There is no intervention, only questionnaires for the patient
3083758|NCT02001454||Attending Physicians and Nurses|The staff physicians and nurses will also fill out a questionnaire
3083759|NCT02001441||No treatment|
3083760|NCT02001428|Experimental|Intermittent Screening and Treatment|Infants enrolled at Village health posts will be randomly allocated to receive intermittent screening and treatment (IST) on every scheduled immunization visit at 2, 3, 4 and 9 months of age. Infants in this group will be screened for malaria by Rapid Diagnostic Test (RDT), and if positive, treated with dihydroartemisinin-piperaquine (DHP). Infants will also receive follow up home visits at 6 and 12 months.
3083761|NCT02001428|No Intervention|Passive Case Detection|Infants in the control arm will only be checked for malaria if they have fever, or history of fever in the 24 hours prior to the scheduled immunization visit at 2,3,4 and 9 months of age, or at a follow up home visit at 6 and 12 months. Infants with malaria will be treated with DHP once daily for 3 days according to local treatment guidelines.
3083762|NCT02001415|Active Comparator|Spectacles|Spectacles are the most common lens treatment to correct myopia. This arm is set to be as a control group for the other two arms. Myopia patients who enter in this group will wear a normal pair of glasses after the baseline examinations (axial length, refraction...).
3083763|NCT02001415|Active Comparator|Myovison|Myovision is a kind of specially designed, commercially available spectacle lenses that could control the peripheral refraction of myopia patients. Latest studies have changed the understanding of myopia--correcting both central and peripheral vision during lens treatment is indicating to be an effective way of slowing down eye growth. Patients who entered this group will wear a pair of Myovision after baseline examinations.
3083764|NCT02001415|Active Comparator|Ortho-K|Orthokeratology has recently been reported as an effective way to control eye growth for myopia adolescents. Patents who enter this group will wear ortho-K lenses during sleep after baseline examinations.
3083765|NCT02001389|Experimental|EVP-6308; Arm 1|low dose, Capsule, Twice Daily, Day 1 through Day 3
3083766|NCT02001389|Experimental|EVP-6308; Arm 2|low intermediate dose, Capsule, Twice Daily, Day 1 through Day 3
3083767|NCT02001389|Experimental|EVP-6308; Arm 3|high intermediate dose, Capsule, Once Daily, Day 1 through Day 3
3083768|NCT02001389|Experimental|EVP-6308; Arm 4|high dose, Capsule, Once Daily, Day 1 through Day 3
3083769|NCT02001376|Experimental|Intensive exercise & home exercise|Intensive exercise group Home exercise group
3083770|NCT02001376|Experimental|Intensive exercise & control|Intensive exercise group Control group
3083771|NCT02001376|Experimental|Home exercise & control group|Home exercise Control group
3083772|NCT02001363|Experimental|liraglutide|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
3083773|NCT02001363|Placebo Comparator|liraglutide placebo|drug:liraglutide placebo (Novo Nordisk) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
3083774|NCT02001350||Resistant hypertension|
3083775|NCT02001324|Active Comparator|Paper-based data collection|Paper-based data collection
3083776|NCT02001324|Active Comparator|Web-based data collection|Web-based data collection
3083777|NCT02001311|Experimental|chlorhexidine gel|anti microbial agent that prevents the formation of plaque and reduces caries risk
3083778|NCT02001298|Experimental|nitroprusside|After induction of anesthesia, controlled hypotension was induced with continuous infusion of nitroprusside. Cardiac index, stroke volume index, and total peripheral resistance index were continuously measured using noninvasive cardiac output monitor (Cheetah NICOM, Cheetah Medical Inc, UK).
3083779|NCT02001298|Experimental|remifentanil|After induction of anesthesia, controlled hypotension was induced with continuous infusion of remifentanil. Cardiac index, stroke volume index, and total peripheral resistance index were continuously measured using noninvasive cardiac output monitor (Cheetah NICOM, Cheetah Medical Inc, UK).
3083808|NCT02001129|Experimental|Automated Telephone System|In addition to a standardized reminder letter, participants also received a telephone call from an automated system to remind them of a recommended follow-up appointment.
3084008|NCT01999816|Experimental|Lifestyle Redesign|Occupational therapist led lifestyle redesign program to prevent pressure ulcers
3083780|NCT02001285|Experimental|Double lumen tube|This arm contains patients who are needed endobronchial intubation with double lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.
3083781|NCT02001285|Active Comparator|single lumen tube|This arm contains patients who are needed endotracheal intubation with single lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.
3083782|NCT02001272|Experimental|A:Paclitaxel + Carboplatin every 3 weeks|Patients randomized to the arm A receive 6 courses the following regimen: Paclitaxel 175 mg/m²/3 hours, I.V. and carboplatin AUC 5, I.V. every 3 weeks (1 cycle = 21 days).
3083783|NCT02001272|Experimental|B:Carboplatin monotherapy every 3 weeks|Patients randomized to the arm B receive 6 courses the following regimen: Carboplatin monotherapy AUC 5 or 6 every 3 weeks (1 cycle = 21 days).
3083784|NCT02001272|Experimental|C:Weekly Paclitaxel and Carboplatin|Patients randomized to the arm C receive 6 courses the following regimen: weekly paclitaxel 60 mg/m²/1 hour and weekly carboplatin AUC 2 (d1, d8, d15 ; d1=d29) (1 cycle = 28 days).
3083785|NCT02001259|Active Comparator|Epidural lidocaine|epidural lidocaine: 3 mL of 1% lidocaine with adrenaline and 3 mL of 1% lidocaine without adrenaline into epidural catheter at 48 hr after surgery
3083786|NCT02001259|Experimental|epidural triamsinolone|epidural triamsinolone: 40 mg of triamsinolone (1 mL), 2.5 mL of 1% lidocaine with adrenaline and 2.5 mL of 1% lidocaine without adrenaline into epidural catheter at 48 hr after surgery
3083787|NCT02001246|Active Comparator|Real Deal program for Anger Management|"The Real Deal Anger Management Program is a structured, video-based intervention, which is an easy-to-implement, plug and play program that engages students in: (a) cognitive exercises for learning to recognize and correct thinking errors that lead to anger, (b) active practice of social-behavioral skills through role-playing, and (c) participation in progressive muscle relaxation exercises. The program features three training videos that focus on specific skills for controlling conflict."
3083788|NCT02001246|Experimental|Mind-body Bridging program|The Mind-Body Bridging program for anger management, includes experiential awareness activities, in which individuals learn to become aware of their thoughts, feelings, emotions, and bodily sensations, to help them identify and deal with ruminative and negative thoughts that might be associated with their anger. MBB helps participants use their senses to listen to sounds, and experience visual or tactile input, to calm their minds and relax their bodies. Written 'mapping' exercises enable them to recognize and defuse requirements, which are expectations of how they or the world should be. For the MBB anger management program, participants will be provided with a variety of mapping exercises to identify the source of their anger, and how they can effectively control it.
3083789|NCT02001233||EV71 Vaccine|Inactivated vaccine (vero cell) against EV71 of 400U /0.5ml in 5000 infants aged 6-35 months old on day0,28
3083790|NCT02001233||Placebo|placebo in 5000 infants aged 6-35 months old on day0,28
3083791|NCT02001220|Active Comparator|Once daily screening|Patients will undergo assessments to determine readiness to undergo an SBT once daily.
3083792|NCT02001220|Experimental|At least twice daily screening|Patients will undergo assessments to determine readiness to undergo an SBT at least twice daily.
3083793|NCT02001207||MICU patients|
3083794|NCT02001194|No Intervention|Control|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Control Arm will receive no financial incentive.
3083795|NCT02001194|Experimental|Individual|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $50 if that participant met the step goal during the prior day.
3083796|NCT02001194|Experimental|Team|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $50 only if all four team members met the step goal during the prior day.
3083797|NCT02001194|Experimental|Individual Plus Team|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $20 if the participant met the step goal during the prior day the participants met their own goal. Each participant will also receive an additional $10 for every one of the other three team members that also met the goal.
3083798|NCT02001181|Experimental|Treatment group A|
3083799|NCT02001181|Placebo Comparator|Treatment B|
3083800|NCT02001168|Experimental|Pemetrexed &Cis-platinum|Pemetrexed d1＋Cis-platinum , d1, 21 d as a cycle.
3083801|NCT02001168|Experimental|Pemetrexed & Cis-platinum & rh-Endostatin|Pemetrexed d1＋Cis-platinum , d1； rh-Endostatin d1-14; 21 d as a cycle.
3083802|NCT02001168|Experimental|Docetaxel & Cis-platinum|Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
3083803|NCT02001168|Experimental|Docetaxel & Cis-platinum & rh-Endostatin|Docetaxel ＋ Cis-platinum ＋ rh-Endostatin，21 d as a cycle.
3083804|NCT02001155||Trabeculectomy|Individuals in this group will have undergone a trabeculectomy for the treatment of glaucoma.
3083805|NCT02001155||Tube Shunt|Individuals in this group will have undergone a tube shunt for the treatment of glaucoma.
3083806|NCT02001142|Experimental|Exercise|
3083807|NCT02001142|No Intervention|Sedentary Control|
3084009|NCT01999816|No Intervention|Control|Usual care
3083809|NCT02001129|Experimental|Personalized Telephone Call|In addition to the usual care letter, a staff member called participants one month prior of recommended follow-up appointment. During this call, participants were given the option to schedule an appointment.
3083810|NCT02001129|Active Comparator|Usual Care|"Participants randomized to this arm receive a usual care letter which is a standard reminder letter from the primary eye care office. This is usual practice in many primary eye care facilities."
3083811|NCT02001116|Experimental|Pilot Hospitals|
3083812|NCT02001116|No Intervention|Control Hospitals|
3083813|NCT02001103|Active Comparator|Memantine 10 mg/day|Dosing titration with 5 mg incremental each week Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
3083814|NCT02001103|Active Comparator|Memantine 20 mg/day|Dosing titration with 5 mg incremental each week Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
3083815|NCT02001103|Placebo Comparator|Placebo|Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
3083816|NCT02001090||CABG patients|Patients undergoing cardiac surgery for coronary artery disease with the use of heart-lung machine in St Olavs Hospital Trondheim University Hospital.
3083817|NCT02001077|Active Comparator|CBT-I|Participants will complete 8 weekly therapy sessions focused on improving sleep. A multicomponent CBT-I (Cognitive Behavioral Therapy for Insomnia) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, and cognitive restructuring.
3083818|NCT02001077|Active Comparator|CBT-P|Participants will complete 8 weekly therapy sessions focused on improving pain. A multicomponent CBT-P (Cognitive Behavioral Therapy for Pain) protocol will involve: pain education, relaxation, activity pacing, and cognitive restructuring.
3083819|NCT02001077|No Intervention|Waitlist Control (WLC)|Participants in the WLC group will not receive any treatment between the baseline and post-treatment assessments. After the final follow-up assessment, they will be offered the opportunity to receive therapy which combines aspects of both CBT-I and CBT-P.
3083820|NCT02001064|Experimental|Application + Standard of care|Participants in the experimental application arm will use the Care4Today v2.0 mobile application for antiretroviral medication adherence support. Alert messages generated via the app will be targeted to the specific schedule and needs of the individual.
3083821|NCT02001064|No Intervention|Standard of care|Participants will receive standard of care while on study.
3083822|NCT02001051|Other|Operative Arm|operative arm
3083823|NCT02001051|Other|Delayed Operative Arm|delayed operative arm
3083824|NCT02001038||Orthopaedic surgeons|Orthopaedic surgeons who perform surgical procedures for foot deformities in CMT patients at participants centres.
3083825|NCT02001025||Absorb scaffold|Bioresorbable vascular scaffold implanted in coronary arteries, which are completely resorbed over a period of approximately two years
3083826|NCT02001025||Xience stent|Second generation drug-eluting stent to treat coronary artery lesions
3083827|NCT02001012|Active Comparator|Artemether-lumefantrine|"Artemether-lumefantrine.~1 tablet = 20mg arthemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; >35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, >10-15kg = 1 tablet."
3083828|NCT02001012|Active Comparator|Chloroquine|"Chloroquine.~1 tablet contains 155mg chloroquine base. Adult dose (>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.~Child dose (>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours."
3083829|NCT02000999||Patients with bile duct strictures|
3083830|NCT02000986|Experimental|Specimen Collection/Risk Factor Assessment -> Diet/Exercise ->|Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy
3083831|NCT02000973|Placebo Comparator|Normal saline|General anesthesia combined with thoracic epidural 0.9% normal saline 8ml
3083832|NCT02000973|Experimental|Lidocaine|General anesthesia combined with thoracic epidural 1% lidocaine 8ml
3083833|NCT02000973|Experimental|Bupivacaine|General anesthesia combined with thoracic epidural 0.25% bupivacaine 8ml
3083834|NCT02000973|Experimental|Ropivacaine|General anesthesia combined with thoracic epidural 0.3% ropivacaine 8ml
3083835|NCT02000960|Experimental|Triheptanoin|All subjects will receive the study treatment which includes adding triheptanoin to the ketogenic diet with a goal intake of 35% total calories provided by triheptanoin (max 100 ml oil/day.
3083836|NCT02000947|Experimental|Dose Escalation|MEDI4736 and tremelimumab received by intravenous infusion.
3083837|NCT02000947|Experimental|Arm A|Medi4736 and tremelimumab received by intravenous infusion
3083838|NCT02000947|Experimental|Arm B|MEDI4736 and tremelimumab received by intravenous infusion
3083839|NCT02000947|Experimental|Arm C|MEDI4736 and tremelimumab received by intravenous infursion
3083840|NCT02000934|Experimental|TAK-659|Given orally in a once daily schedule.
3083841|NCT02000921|Experimental|CN + combusted & non-combusted products|Subjects will be asked to smoke the assigned conventional nicotine content (CN) cigarettes, instead of their normal brand, for 8 weeks and will also be given access to use other combusted and non-combusted tobacco and medicinal nicotine products during that time.
3083842|NCT02000921|Experimental|VLNC + combusted & non-combusted products|Subjects will be asked to smoke the assigned very low nicotine content (VLNC) cigarettes, instead of their normal brand, for 8 weeks and will also be given access to use other combusted and non-combusted tobacco and medicinal nicotine products during that time.
3083843|NCT02000921|Experimental|VLNC with non-combusted products|Subjects will be asked to smoke very low nicotine content (VLNC) cigarettes instead of their usual cigarettes for an 8 week period and will be given the opportunity to use non-combusted types of tobacco and medicinal tobacco products.
3083844|NCT02000908|Experimental|Realief Therapy|Each patient will be given 15-18 treatments depending on response of 30-minute duration of photobiomodulation with the Realief Therapy system, scheduled every three times weekly for 5-6 weeks. The treatments will include laser exposure of any or all of 27 differentiated areas of the legs, feet, cervical spine region and lumbar spine region, for durations of 3 to 30 minutes, based on the symptom presentation at the time. Power densities will vary from 5 to 12 watts, based on the symptom presentations through the course of therapy.
3083914|NCT02000388|Other|Standard of care|The intervention used will be standard of care
3084010|NCT01999803|Experimental|sNN0029 (VEGF)|4 µg/d of sNN0029 administered by continuous intracerebral infusion during12 weeks
3083845|NCT02000908|Sham Comparator|Sham Treatment|"The placebo group will receive sham treatment, during which a heat probe will be guided over both lower extremities over a period of 30 minutes, consistent with the treatment arm. The laser device will be activated during the treatment so that the visual and auditory environment prior to therapy will be the same for both treatment and sham control.~After 8 weeks of sham treatment the subjects in this arm will be offered the photobiomodulation combined with physiotherapy."
3083846|NCT02000895||Preterm infants|>24 weeks <37 weeks gestational age
3083847|NCT02000895||Term infants|>37 weeks' gestational age
3083848|NCT02000895||Follow-up at 6 Years|Children enrolled from the birth cohort(s) to be followed at 6 to 10 years of age.
3083849|NCT02000882|Experimental|BKM120 plus Capecitabine|"BKM120 will be administered at a dose of 100 mg orally (PO) daily. Capecitabine will be administered at a dose of 1000 mg/m2 orally (PO) twice a day (rounded down to the nearest 500 mg pill) 14 days on and 7 days off.~For patients with HER2+ MBC only, standard every 3-weekly trastuzumab (6 mg/kg IV) will be added to the capecitabine/BKM120."
3083850|NCT02000869||wait-listed kidney transplant candidates|
3083851|NCT02000856|Active Comparator|Nitrate rich beetroot juice|Eligible subjects will be randomised, in a double-blind crossover design, to receive treatment with either nitrate rich beetroot juice (70 ml containing approximately 8 mmol nitrate - active comparator) or nitrate depleted beetroot juice (70 ml - placebo) twice daily for 7 days (treatment period 1) followed by a 7 day washout period followed by treatment twice daily with the active comparator or placebo depending on initial treatment for another 7 days (treatment period 2) .
3083852|NCT02000856|Placebo Comparator|Nitrate depleted beetroot juice|Eligible subjects will be randomised, in a double-blind crossover design, to receive treatment with either nitrate rich beetroot juice (70 ml containing approximately 8 mmol nitrate - active comparator) or nitrate depleted beetroot juice (70 ml - placebo)twice daily for 7 days (treatment period 1) followed by a 7 day washout period followed by treatment twice daily with the active comparator or placebo depending on initial treatment for another 7 days (treatment period 2) .
3083853|NCT02000843|Other|perichondrium graft perforation|tympanoplasty -- conchal cavum approach is used.
3083854|NCT02000830||Placebo|
3083855|NCT02000830||stannsoporfin 3.0 mg/kg|
3083856|NCT02000830||stannsoporfin 4.5 mg/kg|
3083857|NCT02000817|Experimental|Otelixizumab 9 mg|Each subject will receive otelixizumab 1.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-9 mg)
3083858|NCT02000817|Experimental|Otelixizumab 18 mg|Each subject will receive otelixizumab 3 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-18 mg)
3083859|NCT02000817|Experimental|Otelixizumab 27 mg|Each subject will receive otelixizumab 4.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-27 mg)
3083860|NCT02000817|Experimental|Otelixizumab 36 mg|Each subject will receive otelixizumab 1.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-36 mg)
3083861|NCT02000817|Placebo Comparator|Placebo|Each subject will receive otelixizumab matching placebo diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days
3083862|NCT02000804|Experimental|darapladib 160mg|drug
3083863|NCT02000791|Experimental|cLMA insertion via laryngoscopic technique|Comparison of cLMA insertion via laryngoscope view by fiberscope
3083864|NCT02000791|Active Comparator|cLMA insertion via standart technique|Comparison of cLMA insertion via standart technique view by fiberscope
3083865|NCT02000778|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
3083866|NCT02000765|Experimental|GSK2140944 for Injection and Capsule|Each subject will receive a single 1000 milligram (mg) IV dose of GSK2140944 containing [14C]-GSK2140944 of approximately 22.5 microcurie [μCi] (approximately 0.8 megabecquerel [MBq]) of radioactivity given as a 2 hour infusion on Day 1 of treatment period 1 and 2000 mg oral dose of GSK2140944 containing [14C]-GSK2140944 of approximately 45 μCi (approximately 1.7 MBq) of radioactivity on Day 1 of treatment period 2. Each treatment period will be followed with washout of atleast 8 Days.
3083867|NCT02000752|Experimental|Acupuncture|In the intervention group with real acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the point Ren Mai 6. This point is located on the anterior midline, between the umbilicus and the upper part of the pubic symphysis, at a distance of 0.3d from the umbilicus, being d the distance from the umbilicus to the upper part of the pubic symphysis. A sterilized steel needle of 0.25x40 mm is inserted in this point at 15-30 mm, depending on the adipose tissue of the woman.
3083868|NCT02000752|Sham Comparator|Sham acupuncture|Regarding to the control group with sham acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the placebo point with a sterilized 0.25x40 mm steel needle. The control point is located at the same horizontal level than the Ren Mai 6 point, but at 0.6d to the left of the anterior midline of the mother. In this case, the sterilized steel needle of 0.25x25 mm is inserted 15 mm into the tissue.
3083869|NCT02000739|Other|Genetically Informed Therapy|"The treatment participants get will depend on the results of the DNA sequencing and the availability of targeted therapies that match the genetic profile of the tumor identified by the DNA sequencing.~If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant."
3083870|NCT02000726|Experimental|Placebo and Citalopram|4 weeks of 1 placebo pill/day and 12 weeks of citalopram 20-40 mg/day
3083871|NCT02000713|Experimental|Amyotrophic Lateral Sclerosis|All subjects will be interviewed and administered a brief questionnaire to determine current disease severity. A brief neurological examination will be given to determine reflexes. Subjects will also have magnetic resonance imaging(MRI)scans of the cervical spine (neck). Women of child-bearing potential will need to have a urine pregnancy test immediately prior to the MRI scan. Mri scan will take approximately 60 minutes to complete. The clinical examinations will take approximately 30 minutes to complete. Subject participation in this study will be complete following the MRI and clinical examinations.
3083974|NCT02000011|Experimental|experimental strategy|
3083872|NCT02000713|Active Comparator|Healthy controls (MRI)|Subjects will also have magnetic resonance imaging (MRI) scans of the cervical spine(neck). Women of child-bearing potential will need to have a urine pregnancy test immediately prior to the MRI scan. Mri scan will take approximately 60 minutes to complete. Subject participation in this study will be complete following the MRI.
3083873|NCT02000700|Experimental|Canagliflozin (Dose Group 1)|Participants will receive 100 mg (as 1 x 100-mg tablet) of canagliflozin daily for 14 days.
3083874|NCT02000700|Experimental|Canagliflozin (Dose Group 2)|Participants will be enrolled into Dose Group 2 to receive either 50 mg (as 1 x 50-mg tablet) or 300 mg (as 1 x 300-mg tablet) of canagliflozin daily for 14 days.
3083875|NCT02000674|Active Comparator|Administration of Succinylcholine|Intubation after IV administration of Succinylcholine 1mg/kg
3083876|NCT02000674|Experimental|Administration of Rocuronium|Intubation after IV administration of Rocuronium 1.2 mg/kg
3083877|NCT02000661|Experimental|Routine use of FFR|Fractional Flow Reserve (FFR) used in most cases to guide PCI
3083878|NCT02000661|Active Comparator|Selective use of FFR|Fractional Flow Reserve (FFR) used at investigator discretion (Current practice)
3083879|NCT02000648||Patients diagnosed with chronic rhinitis or chronic urticaria|Patients diagnosed with chronic rhinitis/urticaria and followed-up at Allergy Clinics, Chulalongkorn University
3083880|NCT02000635||Leptospirosis|Patient with a diagnosis of leptospirosis confirmed by PCR in the five first day
3083881|NCT02000622|Experimental|Olaparib|Olaparib tablet 300mg bd po
3083882|NCT02000622|Active Comparator|Physician's choice chemotherapy|Capecitabine 2500 mg/m2 d1-14 q 21, or Vinorelbine 30 mg/m2 d1,8 q 21, or Eribulin 1.4 mg/m2 d1,8 q 21
3083883|NCT02000609|Active Comparator|CHF 1535 NEXThaler 800/48 ug|single dose administration of CHF 1535 100/6 NEXThaler DPI, total dose: 800ug BDP, 48 ug Formoterol Fumarate
3083884|NCT02000609|Placebo Comparator|CHF 1535 NEXThaler PLACEBO|single dose administration of placebo via NEXThaler DPI
3083885|NCT02000609|Active Comparator|CHF 1535 pMDI 200/12|single dose administration of CHF 1535 100/6 pMDI , total dose: 200 ug BDP, 12 ug Formoterol Fumarate
3083886|NCT02000609|Active Comparator|CHF 1535 100/6 pMDI 800/48|single dose administration of CHF 1535 100/6 pMDI total dose: 800ug BDP, 48 ug Formoterol Fumarate
3083887|NCT02000609|Active Comparator|CHF 1535 NEXThaler 200/12|single dose administration of CHF 1535 100/6 pMDI, total dose: 200 ug BDP, 12 ug Formoterol Fumarate
3083888|NCT02000596|Experimental|Cohort 1: T+P|Trastuzumab plus Pertuzumab as first line treatment for HER2 overexpressed Metastatic Breast Cancer (without hormonal therapy or chemotherapy)
3083889|NCT02000596|Experimental|Cohort 2 - Arm A|Hormonal Therapy with Anastrozole and Fulvestrant in addition Trastuzumab plus Pertuzumab for women who progressed on T+P alone, and who are ER/PR +
3083890|NCT02000596|Experimental|Cohort 2 - Arm B|Chemotherapy with Eribulin in addition to Trastuzumab plus Pertuzumab for women who progressed on T+P alone and who are ER/PR -
3083891|NCT02000583|Experimental|Aerobic Exercise Group|Exercise 150 minutes per week (over 3 to 5 days) for 52 weeks
3083892|NCT02000583|Other|Control Group|Standard of Care exercise recommendations
3083893|NCT02000570|Experimental|sitting position|
3083894|NCT02000557||Class II Malocclusion|
3083895|NCT02000544|Active Comparator|Modular Cardiopulmonary Bypass Circuit|Patients undergoing open heart surgery with a modular hybrid extracorporeal circulation circuit.
3083896|NCT02000531|Experimental|Erlotinib-Chemotherapy|Erlotinib in first-line treatment, followed by chemotherapy in the second-line treatment
3083897|NCT02000531|Active Comparator|Chemotherapy-Erlotinib|Chemotherapy in first-line treatment, followed by erlotinib in the second-line treatment
3083898|NCT02000518||external beam radiotherapy|emergency radiotherapy within 12 hours after neurological deficit due to MSCC
3083899|NCT02000505|No Intervention|Control|5 minutes chest-compression-only CPR, without any support
3083900|NCT02000505|Experimental|PocketCPR|5 minutes chest-compression-only CPR, with support
3083901|NCT02000505|Experimental|Metronome|5 minutes chest-compression-only CPR, with support
3083902|NCT02000505|Experimental|110bpm Song|5 minutes chest-compression-only CPR, with support
3083903|NCT02000492|Experimental|Training|Football, circuit training or running 5x12 minutes or 3x 40 minutes
3083904|NCT02000492|No Intervention|Control|
3083905|NCT02000479|Experimental|training|12 weeks (2 x 6 weeks) of combined exercise training programme (supervised)
3083906|NCT02000479|No Intervention|Control|Continued usual care, habitual lifestyle
3083907|NCT02000466||Exposed cohort|
3083908|NCT02000453|Experimental|GSK2586184|A total of 15 subjects to be administered 400 mg GSK2586184 Tablet (200 mg X 2) twice daily for up to 56 days
3083909|NCT02000440|Experimental|Losmapimod (GW856553X)|The subjects will be administered with 7.5 mg (1 tablet) of losmapimod following the completion of the Baseline (time zero) assessments. Subjects will continue to take one tablet in the morning and one tablet in the evening for approximately 2 weeks. After all the pre-dose assessments are completed at the Week 2 visit, subjects will be administered the first 15 mg (2 tablets) dose. Subjects will continue to take two tablets in the morning and two tablets in the evening every day for approximately 22 weeks. Doses of study treatment will be separated by at least 6 hours
3083910|NCT02000427|Experimental|Blinatumomab|"Participants will receive blinatumomab by continuous intravenous (CIVI) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieve a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.~The initial dose will be 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 for all subsequent cycles of treatment."
3083911|NCT02000414|Experimental|intraperitoneal daptomycin|3 first patients : 200mg/day 3 following patients : 300mg/day
3083912|NCT02000401|Other|Ketorolac Tromethamine|Ketorolac Tromethamine one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs. as needed for pain with a maximum daily dose of 126 mg. The treatment may be continued for up to 5 days.
3083913|NCT02000388|Other|Ketorolac tromethamine (SPRIX)|A SPRIX dose will be one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs as needed for post vasectomy pain with a maximum daily dose of 126 mg to be continued for up to 5 days.
3083915|NCT02000375|Experimental|DHEA|Daily oral administration of DHEA at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
3083916|NCT02000362|Experimental|Treatment|"cohort 1. 5.0 x 10^7 stem cells after registration~cohort 2. 1.0 x 10^8 stem cells after registration"
3083917|NCT02000349|Experimental|Frozen Embryo Transfer with PGD|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5 or day 6, embryos will then be vitrified, analyzed by NGS, and will have one or two euploid embryo(s) thawed and transferred on a FET cycle, before noon. If more than two euploid blastocysts are available the one(s) to be transferred will be selected based on morphology (*).
3083918|NCT02000349|Experimental|Fresh Embryo Transfer with PGD|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5, analyzed by NGS, and will have one or two euploid embryo transferred on day 6, in the am. If more than two euploid blastocysts are available the one(s) to be transferred will be selected based on morphology (*). Any morulas developing to hatching blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle.
3083919|NCT02000336|Experimental|Prednisolone 10|Prednihexal (Prednisolon), daily oral tablet, 10 mg during week one to four, 7,5 mg during week five to eight. Finally 5 mg for four weeks.
3083920|NCT02000336|Experimental|Prednisolone 60|Prednihexal (Prednisolon), daily oral tablet, 60 mg during the first week, weekly tapering: 40 mg, 20mg, 15mg, 10mg, 7,5mg. 7,5mg continued for one more week. Finally 5 mg for four weeks
3083921|NCT02000336|Placebo Comparator|Placebo|daily oral tablet
3083922|NCT02000323|Active Comparator|early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~After catharsis, Standard enteral nutrition liquid regimen （Peptisorb Liquid）will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day."
3083923|NCT02000323|Active Comparator|modified early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~After catharsis, Only Normal Saline were given through Naso-gastro-Jejunal tube until 2 or more followed requirements were met mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure <20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day."
3083924|NCT02000297|Active Comparator|Allogenic bone graft group|Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
3083925|NCT02000297|Experimental|Synthetic bone substitute (geneX®) group|Patients in this arm is treated with synthetic bone substitute(geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
3083926|NCT02000284||General ASD|150 general ASD children
3083927|NCT02000284||ASD/MD|50 children Diagnosed with an Autism Spectrum Disorder and a Mitochondrial Disorder
3083928|NCT02000284||ASD/noMD|50 children with ASD that have been r/o as having a mitochondrial disorder
3083929|NCT02000284||MD/noASD|50 children with a mitochondrial disorder and without an ASD
3083930|NCT02000284||Developmental Delay|50 children without a mitochondrial disorder or autism spectrum disorder, but with general developmental delays
3083931|NCT02000284||Typically Developing|100 children with no history of medical, behavioral, or immunological disorders
3083932|NCT02000271|Other|Vaginal packing|Vaginal packing will be placed as is typical following vaginal reconstructive surgery.
3083933|NCT02000271|Experimental|No vaginal packing|No vaginal packing will be used following vaginal reconstructive surgery.
3083934|NCT02000258|Other|Double-bundle ACL reconstruction|Double-bundle ACL reconstruction
3083935|NCT02000258|Other|Magnetic resonance imaging (MRI)|MRI of the ACL double-bundle reconstructed knee was done at 2 years after surgery.
3083936|NCT02000245|Active Comparator|verbal expression for compassion|verbal expression for compassion
3083937|NCT02000245|Active Comparator|verbal expression and touch|verbal expression and touch
3083938|NCT02000245|No Intervention|control|control
3083939|NCT02000232||Diagnosis with Gout and use of colchicine|Observational study age 18+
3083940|NCT02000219|Experimental|Oxabact OC5 capsule|"This is an open-label study so all patients will receive the active drug product, Oxalobacter formigenes, OC5. This will be administered as an enteric-coated capsules twice daily for 6 weeks of treatment.~In Germany, the protocol has been amended such that patients can receive OC5 for a further 3 year of continued treatment after the initial part of the study."
3083941|NCT02000206|Active Comparator|propofol + alfentanil|"Patients from the Propofol / Alfentanil group will receive in addition:~A loading dose of 10-15 mcg/kg Alfentanil + 0.4 mg/kg Propofol, 2 minutes prior to the beginning of the procedure.~Additional boluses of Propofol (aliquots of 10-50 mg) throughout the procedure if required"
3083942|NCT02000206|Active Comparator|propofol + ketamine|"Patients from the Propofol / Ketamine group will receive in addition:~A loading dose of 0.2-0.3 mg/kg Ketamine + 0.4 mg/kg Propofol, 2 minutes prior to the beginning of the procedure.~Additional boluses of Propofol (aliquots of 10-50 mg) and/or Ketamine (aliquots of 5-25 mg) throughout the procedure if required."
3083943|NCT02000193|Experimental|1|"drug: Fulvestrant treatment : Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, 29, then every 28 days.~The treatment will continue until disease progression or intolerable adverse event"
3083944|NCT02000180|Experimental|Progressive Group|The progressive learning group will undertake 6 hours of interactive small-group didactic sessions, interlaced with up to 6 hours of self-directed instruction initially on the low-fidelity box simulator, with feedback provided one-on-one by an expert academic endoscopist. Participants in the progressive learning group can switch to the high-fidelity simulator at their discretion, but cannot return to the low-fidelity simulator. On the high fidelity VR simulator they can progress through six modules each in colonoscopy and endoscopic polypectomy in a self-directed fashion, with one-on-one feedback by an expert academic endoscopist. The endoscopy instructor will demonstrate techniques, answer questions and provide feedback. The entirety of this will be delivered over two days.
3083975|NCT01999998|Experimental|Pilot|
3084011|NCT01999803|Placebo Comparator|Placebo|Placebo administered by continuous intracerebral infusion during12 weeks
3083945|NCT02000180|No Intervention|High-Fidelity Group|The high-fidelity group will undertake 6 hours of interactive small-group didactic and hands-on sessions on the theory of colonoscopy, led by an expert academic gastroenterologist. The sessions will be interlaced with up to six hours of self-directed instruction on the high-fidelity VR simulator. Six task-specific modules of increasing difficulty in colonoscopy and colonoscopic polypectomy will be taught solely on the VR simulator with one-on-one feedback from an expert academic endoscopist. The endoscopy instructor will demonstrate techniques, answer questions and provide feedback as necessary. The entirety of this will be delivered over two days.
3083946|NCT02000167||Phelan-McDermid Syndrome only|Diagnosed with Phelan-McDermid Syndrome; 50 subjects to be recruited. 1-21 years of age
3083947|NCT02000167||Co-morbid Phelan-McDermid Syndrome & Mitochodrial Disorder|1-21 years of age; Diagnosed with Phelan-McDermid Syndrome AND diagnosed with Mitochondrial Disorder; 50 subjects to be recruited.
3083948|NCT02000154|Experimental|SyB L-1101|
3083949|NCT02000141||Endoscopic Mucosal Resection|Endoscopic Mucosal Resection of Colonic Advanced Mucosal Lesions
3083950|NCT02000128|Experimental|bioimpedance monitoring group|patients whose fluid status will be monitored and guided by bioimpedance analysis
3083951|NCT02000128|Other|clinical monitoring group|patients whose fluid status will be monitored and guided by clinical experience
3083952|NCT02000115|Experimental|Portico|Portico transcatheter aortic valve
3083953|NCT02000115|Active Comparator|Commercially Available Valve|Commercially available transcatheter aortic valve
3083954|NCT02000115|Experimental|Portico Continued Access Protocol (CAP)|The PORTICO IDE CAP is a prospective, multicenter, single-arm, continued access arm designed to collect additional safety and clinical effectiveness data on the Portico Transcatheter Heart Valve and Delivery System (Portico) upon completion of enrollment in the pivotal cohort and while the pre-market approval (PMA) application for the Portico Transcatheter Heart Valve and the Portico Delivery System is under FDA review.
3083955|NCT02000102||Diabetic Macular Edema Patients Switched to Aflibercept|
3083956|NCT02000089||Familial pancreas cancer relatives|"High Risk Group 2 (familial pancreatic cancer relatives):~> 55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and~come from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and~have a first-degree relationship with at least one of the relatives with pancreatic cancer.~If there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened"
3083957|NCT02000089||Group 1 germline mutation carrier|"High Risk Group 3 (Group 1 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~10% or higher):~a. > 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and b. The Patient is a carrier of a confirmed FAMMM (p16/CDKN2A), BRCA2, or PALB2 mutation, and there is 1 or more pancreatic cancer diagnoses in the family, one of whom is a first- or second-degree relative of the subject to be screened."
3083958|NCT02000089||Group 2 germline mutation carrier|"High Risk Group 4 (Group 2 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~5%):~> 55 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and~The patient is a carrier of a confirmed BRCA1, ATM or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is > 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened."
3083959|NCT02000089||Hereditary pancreatitis|High risk group 5 (hereditary pancreatitis) with confirmed gene mutations that predispose to chronic pancreatitis, such as PRSS1, PRSS2, CTRC) and age 50 years or older (these patients have an estimated lifetime risk for pancreatic cancer of 40%) or twenty-years since their first attack of pancreatitis, whichever age is younger.
3083960|NCT02000089||Peutz-Jeghers Syndrome|"At least 30 years old, and~at least 2 of 3 criteria diagnostic of Peutz-Jeghers syndrome (characteristic intestinal hamartomatous polyps, mucocutaneous melanin deposition, or family history of Peutz-Jeghers syndrome), or,~known STK11 gene mutation carrier"
3083961|NCT02000089||Negative control|"are undergoing Endoscopic Ultrasound (EUS) and/or Endoscopic Retrograde Cholangiopancreatography (ERCP) for non-pancreatic indications as part of their standard medical care, and~have no clinical or radiologic suspicion of pancreatic disease (chronic pancreatitis or pancreatic cancer)"
3083962|NCT02000089||Chronic Pancreatitis|"are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven chronic pancreatitis as part of their standard medical care, and,~have no clinical or radiologic suspicion of pancreatic cancer"
3083963|NCT02000089||Pancreas cancer|a. are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic ductal adenocarcinoma (based on clinical and radiologic evidence)
3083964|NCT02000089||Pancreas cyst, IPMN evaluation|are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic cancer precursor, intraductal papillary mucinous neoplasm (based on clinical presentation and radiologic or prior EUS or radiologic evidence of a dilated main pancreatic duct and/or pancreatic cystic lesion communicating with the pancreatic ductal system).
3083965|NCT02000076|Experimental|Sleep deprivation|Partial sleep deprivation allowing 3 h sleep at night
3083966|NCT02000076|Experimental|Full sleep|Sleep with no restriction
3083967|NCT02000050|Experimental|Single Arm|"Neoadjuvant therapy: FOLFOX4 2 cycles + Tomotherapy + FOLFOX4 2 cycles~Surgery~Adjuvant therapy: FOLFOX4 8 cycles~TME (Total Mesorectal Excision)"
3083968|NCT02000037|Active Comparator|Dietary care|Treatment is composed of a dietary care (with advices on physical activity) given by a professional (dietician of the Nutrition Department of the Institut Pasteur de Lille).
3083969|NCT02000037|Experimental|IR reflexotherapy + dietary care|"Treatment is composed of :~IR reflexotherapy sessions given by a trained professional ;~dietary care (with advices on physical activity) given by a professional (dietician of the Nutrition Department of the Institut Pasteur de Lille)."
3083970|NCT02000037|Experimental|IR Reflexotherapy|Treatment is composed of IR reflexotherapy sessions given by a trained professional.
3083971|NCT02000024|Experimental|Lifestyle coaching|The existing Weight Watchers lifestyle modification program including the online support tools.
3083972|NCT02000024|Active Comparator|Lifestyle counseling|Brief advice regarding risk factors and strategies to reduce them by lifestyle modification guided by National Diabetes Education Program (NDEP) materials.
3083973|NCT02000011|Other|standard strategy|
3083976|NCT01999985|Experimental|1A - Dose Escalation Group|Dose escalation: Afatinib and Dasatinib. This study is divided into two parts. The first 8 - 18 people will be entered in the first part, called Phase 1A. Then this part will end.
3083977|NCT01999985|Experimental|1B - Extension Group|Extension: Afatinib and Dasatinib. The next 20 people will enter into the second part, called Phase 1B.
3083978|NCT01999972|Experimental|Axitinib in combination with crizotinib, escalation phase|Dose Escalation Advanced solid tumor that is resistant to standard therapy or for which no standard therapy is available
3083979|NCT01999972|Experimental|Expansion Phase Cohort 1|Dose Expansion, Cohort 1: axitinib in combination with crizotinib Advanced renal cell cancer [RCC] with no prior systemic therapy
3083980|NCT01999972|Experimental|Expansion Phase Cohort 2|Dose Expansion, Cohort 2: axitinib in combination with crizotinib Advanced renal cell cancer with at least one but no more than two prior systemic treatment regimens directed at advanced RCC
3083981|NCT01999959|Experimental|Pertubation performed|Study group had pertubation and insemination
3083982|NCT01999959|No Intervention|Pertubation not performed|Study group had insemination only
3083983|NCT01999946|Experimental|Extended-Release Naltrexone (XR-NTX)|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
3083984|NCT01999946|No Intervention|Enhanced Treatment As Usual (ETAU)|Enhanced Treatment As Usual arm will not receive any study medication, but will receive enhancement counseling centered on post-release treatment involvement and a patient-drug educational handout with direct referrals to re-entry community treatment, including agonist maintenance (methadone and buprenorphine programs), drug-free outpatient and 12-step resources, and residential treatment including supportive housing programs will be provided. These counseling and referral efforts are designed to exceed standard, out-of-treatment experiences, and will ensure both arms are offered tangible health benefits above and beyond that of the usual jail incarceration period in accordance with DHS prisoner research standards.
3083985|NCT01999946|No Intervention|Methadone Treatment Program (MTP)|Quasi-Experimental cohort, will be participants recruited from NYC Rikers Island jail's Key Extended Entry Program (KEEP)'s jail methadone maintenance program, they will not receive any intervention from study, but will receive enhancement counseling centered on post-release treatment involvement and a patient-drug educational handout with direct referrals to re-entry community treatment.These counseling and referral efforts are designed to exceed standard, out-of-treatment experiences, and will ensure both arms are offered tangible health benefits above and beyond that of the usual jail incarceration period in accordance with DHS prisoner research standards. MTP participants are new KEEP methadone participants not enrolled in community methadone at the time of arrest.
3083986|NCT01999933|Active Comparator|CCRT with cisplatin(DDP) weekly|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation
3083987|NCT01999933|Experimental|CCRT with TP|concurrent TP tri-weekly, docetaxel plus cisplatin tri-weekly (75mg/m2), begin with radiation
3083988|NCT01999933|Experimental|concurrent and adjuvant TP|2 cycles of concurrent TP, docetaxel plus cisplatin tri-weekly (75mg/m2),begin with radiation; and 4 cycles of adjuvant TP, the same regimen, after radiation
3083989|NCT01999920|Experimental|Vilazodone|Vilazodone treatment. Dosage will begin at 10mg/day and will be increased to 20mg/day after 1 week, and 40mg/day after two weeks (optional). Dosage can be held steady or lowered at any time during the study as clinically indicated in the event of adverse effects. Twelve weeks of treatment, total.
3083990|NCT01999920|Placebo Comparator|Placebo|Pill placebo.
3083991|NCT01999907|Placebo Comparator|Placebo|bolus placebo given in a 2ml dose by mouth at baseline. This group receives daily vitamin D supplement by mouth for the 6 month study (400IU cholecalciferol per day).
3083992|NCT01999907|Active Comparator|Vitamin D|Vitamin D (100,000IU) bolus in a 2ml dose by mouth given at baseline. This group receives a daily vitamin D supplement by mouth for 6 months (400IU cholecalciferol per day).
3083993|NCT01999894|Experimental|Memantine|Once daily oral administration of memantine for 48 weeks: 6-week double-blind dose-titration period followed by a 42-week maintenance period.
3083994|NCT01999881|Experimental|Arm A (aerobic and exercise training)|Patients and their support persons undergo a supervised combined aerobic exercise comprising walking, cycling, or video-based aerobics and strength training using resistance bands for 40 minutes 2 days a week at the UWHC and 3 days a week at home over 8 weeks.
3083995|NCT01999881|Active Comparator|Arm II (usual care)|Patients and their support persons undergo the usual care over 8 weeks.
3083996|NCT01999868|Experimental|Abatacept After Removal of Ustekinumab|Subjects in this arm receive abatacept subcutaneous injections of 125 mg, from week 12 to week 39. The abatacept treatment group will also receive subcutaneous ustekinumab placebo at week 16 and week 28, corresponding to the ustekinumab dosing regimen.
3083997|NCT01999868|Active Comparator|Continued Ustekinumab|The continued ustekinumab treatment group will receive subcutaneous injections of 45 mg ustekinumab (<= 100 kg) or 90 mg ustekinumab (> 100 kg) at week 16 and week 28. The ustekinumab treatment group will also receive weekly subcutaneous injections of abatacept placebo from week 12 to week 39, corresponding to the abatacept dosing regimen.
3083998|NCT01999855|Active Comparator|control group|"the Phonatory Maximum Time~Vocal Handicap Index~Scale GRBAS of Hirano~Videolaryngoscopy"
3083999|NCT01999855|Experimental|Asthmatic patients|"The Phonatory Maximum Time~Vocal Handicap Index~Scale GRBAS of Hirano~Videolaryngoscopy"
3084000|NCT01999842|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 1 at a 21 day interval
3084001|NCT01999842|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 2 at a 21 day interval
3084002|NCT01999842|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 3 at a 21 day interval
3084003|NCT01999842|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 4 at a 21 day interval
3084004|NCT01999842|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK3206640A H7N9 vaccine formulation 5 at a 21 day interval
3084005|NCT01999842|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
3084006|NCT01999829|Experimental|citrate of caffeine|
3084007|NCT01999829|Placebo Comparator|placebo|
3084124|NCT01999075|Placebo Comparator|Conventional Treatment|Conventional Treatment
3084012|NCT01999790|Experimental|Blepharothomy|Patients treated with blepharotomy to correct upper lid retraction secondary to Grave's orbitopathy
3084013|NCT01999790|Experimental|posterior approach|Patients treated with a posterior approach to correct upper lid retraction secondary to Grave's orbitopathy
3084014|NCT01999777|Experimental|USL261|5 mg intranasal midazolam
3084015|NCT01999777|Placebo Comparator|Placebo|intranasal placebo
3084016|NCT01999764|Placebo Comparator|Placebo (for QLT091001)|Placebo is supplied to mimic QLT091001 oral solution.
3084017|NCT01999764|Experimental|QLT091001 - first oral dose|Subjects will receive an oral dose of 10mg/m2 of QLT091001.
3084018|NCT01999764|Experimental|QLT091001 - second oral dose|Subjects will receive an oral dose of 40 mg/m2 of QLT091001.
3084019|NCT01999751||MRI Scan|Patients with implantable cardioverter-defibrillator or pacemaker who undergo an MRI scan
3084020|NCT01999738|Experimental|Part A - MTD (Treatment 1)|"Treatment 1 is BIW on Days 1, 4, 8, and 11 of a 3-week schedule (BIW).~Intervention: EC1456 and EC20"
3084021|NCT01999738|Experimental|Part A - MTD (Treatment 2)|"Treatment 2 is EC1456 QW on Days 1 and 8 of a 3-week schedule (QW).~Intervention: EC1456 and EC20"
3084022|NCT01999738|Experimental|Part A - MTD (Treatment 3)|"Treatment 3 is EC1456 QW on Days 1, 8, and 15 of a 3-week schedule (CWD).~Intervention: EC1456 and EC20"
3084023|NCT01999738|Experimental|Part A - MTD (Treatment 4)|"Treatment 4 is EC1456 QIW on Days 1, 2, 3, 4, 8, 9, 10, and 11 of a 3-week schedule (QIW).~Intervention: EC1456 and EC20"
3084024|NCT01999738|Experimental|Part B - Efficacy (Treatment 5)|"Treatment 5 is EC1456 BIW. Once a dose is determined in Part A, Part B will begin with 3-6 subjects who will receive consecutive day dosing on Days 1, 2, 8, and 9 of a 3-week schedule. If this is not tolerated, the BIW cohort will continue with dosing on Days 1, 4, 8, and 11 of a 3-week schedule.~Intervention: EC1456 and EC20"
3084025|NCT01999738|Experimental|Part B - Efficacy (Treatment 6)|"Treatment 6 is EC1456 QW on Days 1 and 8 of a 3-week schedule or CWD on Days 1, 8 and 15 of a 3-week schedule.~Intervention: EC1456 and EC20"
3084026|NCT01999738|Experimental|Part B - Efficacy (Treatment 7)|"Treatment 7 is EC1456 QIW on Days 1, 2, 3, 4, 8, 9, 10, and 11 of a 3-week schedule for at least two cycles. If the patient is eligible to continue treatment (based upon treatment response and tolerability), he/she may opt to continue on the QIW schedule or change to the Treatment 6 regimen schedule (once its MTD and schedule have been determined).~Intervention: EC1456 and EC20"
3084027|NCT01999725|Experimental|EDP-788|Single doses with dose escalation to continue in successive cohorts
3084028|NCT01999725|Placebo Comparator|Placebo|Single dose with matching placebo
3084029|NCT01999712||LVAD recipients|Patients who are scheduled for LVAD implantation will undergo preoperative echocardiography
3084030|NCT01999699|Experimental|HEPLISAV|
3084031|NCT01999686|Experimental|Treatment I : DLBS3233|DLBS3233 100 mg capsule once daily, and Placebo metformin caplet twice daily; orally, for 6 months
3084032|NCT01999686|Active Comparator|Treatment II : Metformin|Metformin XR 750 mg caplet twice daily, and Placebo DLBS3233 once daily; orally, for 6 months
3084033|NCT01999686|Experimental|Treatment III : Combination DLBS3233 and Metformin|DLBS3233 100 mg capsule once daily, and Metformin XR 750 mg caplet twice daily; orally, for 6 months.
3084034|NCT01999673|Experimental|bavituximab plus docetaxel|Six 21-day cycles of docetaxel plus weekly bavituximab. Patients who have not experienced disease progression will continue to receive bavituximab weekly until progression.
3084035|NCT01999673|Placebo Comparator|placebo plus docetaxel|Six 21-day cycles of docetaxel plus weekly placebo. Patients who have not experienced disease progression will continue to receive placebo weekly until progression.
3084036|NCT01999660||SpaceOAR™|prostate cancer patient prophetically treated by SpaceOAR™
3084037|NCT01999647|Active Comparator|Perineural|Patients in this group will receive a perineural injection for subgluteal sciatic nerve block under real-time, short-axis, in-plane ultrasound guidance, in addition to a femoral nerve block and patient-controlled postoperative analgesia. Ropivacaine will be used for the sciatic nerve block, whereas the choice of agent for the femoral nerve block is left to the attending anesthesiologist.
3084038|NCT01999647|Experimental|Intraneural|Patients in this group will receive an intraneural injection for subgluteal sciatic nerve block under real-time, short-axis, in-plane ultrasound guidance, in addition to a femoral nerve block and patient-controlled postoperative analgesia. Ropivacaine will be used for the sciatic nerve block, whereas the choice of agent for the femoral nerve block is left to the attending anesthesiologist.
3084039|NCT01999634|Experimental|cma microdialysis catheter placement|At the end of the surgery the cma microdialysis catheter is placed near the anastomosis
3084040|NCT01999621||lung cancer|Each lung cancer patient with organ failure, admitted in emergency, thoracic oncology or directly in ICU
3084041|NCT01999608||Vitamin D deficient patients|Serum 25-OH Vitamin D levels <20ng/L
3084042|NCT01999608||Vitamin D sufficient patients|Serum 25-OH Vitamin D levels ≥20ng/L
3084043|NCT01999595|No Intervention|Control|"Control TENS applied via 2 standardized pads ( 5cm x 5cm each) for 30 minutes~TENS= transcutaneous electrical nerve stimulation~Dosage: No current"
3084044|NCT01999595|Sham Comparator|Sham|"Sham TENS applied via 2 standardized pads (5cm x 5cm each) for 30 minutes~Dosage= No current and the participant was told TENS is at a turn-on level whether or not you feel it"
3084045|NCT01999595|Experimental|High frequency (80 Hz) TENS with large pads|"High frequency TENS applied via two large pads (5cm x10cm each)~Dosage: the pre-determined intensity with same current density using the standardized pad size (5cm x 5cm) for comfortable intensity"
3084046|NCT01999595|Experimental|Low frequency (3 Hz) TENS with large pads|"Low frequency TENS applied via two large pads (5cm x10cm each)~Dosage: the pre-determined intensity with same current density using the standardized pad size (5cm x 5cm) for comfortable intensity."
3084047|NCT01999595|Experimental|High frequency TENS with small pads|"High frequency TENS applied via two small pads (2.5cm x2.5cm each)~Dosage: the pre-determined intensity with same current density using the standardized pad size (5cm x 5cm) for comfortable intensity."
3084048|NCT01999595|Experimental|Low frequency TENS with small pads|"Low frequency TENS applied via two small pads (2.5cm x2.5cm each)~Dosage: the pre-determined intensity with same current density using the standardized pad size (5cm x 5cm) for comfortable intensity."
3084125|NCT01999075|Active Comparator|Lung Volume Recruitment|Conventional treatment plus the use of Lung Volume Recruitment (LVR) twice per day
3084049|NCT01999582|Experimental|Intravenous Dose Group 1, 2, and 3|Intravenous Dose Group 1 starting at 0.1 mg/kg and escalated in Dose Groups 2 (0.2 mg/kg) and Dose Group 3 (0.1, 0.2, 0.3, 0.4 mg/kg, titrated based on titration rules, administered every 14 days)
3084050|NCT01999582|Experimental|Subcutaneous Dose Group 1, 2, and 3|Subcutaneous Dose Group 1 starting at 0.13 mg/kg and escalated in Dose Groups 2 (0.26 mg/kg) and Dose Group 3 (0.4 to 0.5 mg/kg, titrated based on titration rules, administered every14 days)
3084051|NCT01999569|No Intervention|Control|Control cycle. No intervention.
3084052|NCT01999569|Experimental|Letrozole|5mg daily
3084053|NCT01999556||Patient|Specimen Collection
3084054|NCT01999556||Relative|Specimen Collection
3084055|NCT01999543|Other|Reference food format|reference food format with and without plant-based ingredient added
3084056|NCT01999543|Experimental|Food format one|Food format one with and without plant-based ingredient added
3084057|NCT01999543|Experimental|Food format two|Food format two with and without plant-based ingredient added
3084058|NCT01999543|Experimental|Food format three|Food format three with and without plant-based ingredient added
3084059|NCT01999530|Experimental|Prazosin Hydrochloride|Gradual upward titration to 15mg/day (or highest dose tolerated) for approximately three weeks.
3084060|NCT01999517|Active Comparator|Intravenous Nitroglycerin|IV Nitroglycerin with IV Fluids
3084061|NCT01999517|Placebo Comparator|Placebo|IV Fluids
3084062|NCT01999504|Experimental|PAL-2|Based on WHO dietary guidelines for protein, fat and carbohydrate but made with ingredients that would have been available in palaeolithic times (e.g. no cereals, no dairy).
3084063|NCT01999504|Experimental|TFH-1|Based on WHO dietary guidelines for protein, fat and carbohydrate but made with ingredients that would have been available in palaeolithic times, (e.g. no cereals, no dairy).
3084064|NCT01999504|Placebo Comparator|Reference|Meal based on WHO dietary guidelines for protein, fat and carbohydrate.
3084065|NCT01999478||Patients undergoing colonoscopy|Patients undergoing colonoscopy per standard of care.
3084066|NCT01999465|Active Comparator|Standard NMES cohort|Patients who will apply standard NMES device.
3084067|NCT01999465|Sham Comparator|Sham NMES cohort|Patients who will apply sham NMES device.
3084068|NCT01999452|Experimental|Paleolithic diet first|Starting with Paleolithic diet and then switching to Diabetes diet
3084069|NCT01999452|Experimental|Diabetes diet first|Starting with Diabetes diet and then switching to Paleolithic diet
3084070|NCT01999439|Experimental|Eosinophilic Esophagitis with Dysphagia|To assess quantitative magnetic resonance imaging(MRI)as a potential diagnostic tool for evaluating esophageal wall thickness and stiffness and response to treatment in children and adolescents with a diagnosis of eosinophilic esophagitis (EoE) presenting with difficulty swallowing(dysphagia)and food impaction.
3084071|NCT01999426|Experimental|Airway clearance intervention|Non-respiratory on-call physiotherapy treatment using airway clearance techniques
3084072|NCT01999426|Active Comparator|Airway clearance intervention 2|Specialist respiratory physiotherapy intervention using airway clearance techniques
3084073|NCT01999413|Experimental|OMEGAVEN - Daunorubicin - Cytarabine|"If WBC ≥ 30 G/L, chemotherapy the induction cycle :~Daunorubicin 60 mg/m²/day IV on D1, D2, and D3~Cytarabine 200 mg/m²/day D1 to D7~OMEGAVEN® 2 ml/kg D1 to D9,~If WBC ≤ 30 G/L, OMEGAVEN during 48 hours~Induction cycle :~OMEGAVEN® 2 ml/kg D-2 to D7 Daunorubicin 60 mg/m²/day IV on D1, D2, and D3~- Cytarabine 200 mg/m²/day IV D1 to D7~bone marrow aspirate at D15: If BM blasts are > 5% or if second induction course :~Daunorubicin 35 mg/m²/day IV D17 and D18~OMEGAVEN® 2 ml/kg~Cytarabine 1000 mg/m²/12h IV on D17, D18, and D19~For all patients: G-CSF 5 µg/kg/day subcutaneously from D21 to hematopoietic recovery (PMN > 1 G/L or > 0.5 G/L during 3 days).~Consolidation will be administered at investigator's discretion"
3084074|NCT01999400|Experimental|Arm 1: Pentasa then Delzicol then Apriso then Lialda|"Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Apriso 375 mg capsule x 3 with 240 mL water, single dose.~Washout period of 10 days.~Lialda 1200 mg tablet x 1 with 240 mL water, single dose."
3084075|NCT01999400|Experimental|Arm 2: Pentasa then Delzicol then Lialda then Apriso|"Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~Washout period of 10 days.~Apriso 375 mg capsule x 3 with 240 mL water, single dose."
3084076|NCT01999400|Experimental|Arm 3: Apriso then Delzicol then Pentasa then Lialda|"Apriso 375 mg capsule x 3 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~Washout period of 10 days.~Lialda 1200 mg tablet x 1 with 240 mL water, single dose."
3084077|NCT01999400|Experimental|Arm 4: Apriso then Delzicol then Lialda then Pentasa|"Apriso 375 mg capsule x 3 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~Washout period of 10 days.~Pentasa 500 mg capsule x 2 with 240 mL water, single dose."
3084078|NCT01999400|Experimental|Arm 5: Lialda then Delzicol then Pentasa then Apriso|"Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~Washout period of 10 days.~Apriso 375 mg capsule x 3 with 240 mL water, single dose."
3084079|NCT01999400|Experimental|Arm 6: Lialda then Delzicol then Apriso then Pentasa|"Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Apriso 375 mg capsule x 3 with 240 mL water, single dose.~Washout period of 10 days.~Pentasa 500 mg capsule x 2 with 240 mL water, single dose."
3084080|NCT01999387||Completed OIT|Patients who completed OIT >6 months prior to enrollment
3084081|NCT01999361|Experimental|Myfortic treatment|Treatment with Myfortic
3084082|NCT01999348||Patients with POAG or OHT|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
3084126|NCT01999062|Experimental|IMRT + CT + MR scan|
3084127|NCT01999036||Resuscitation of OHCA|Resuscitation of out-of-hospital cardiac arrest
3084083|NCT01999335|Experimental|Oprozomib with Pomalidomide and Dexamethasone (OPomd)|"Phase 1b:~Oprozomib doses will be escalated in sequential groups of at least 3 subjects. Study subjects will receive oprozomib in combination with pomalidomide and dexamethasone. Assuming no dose de-escalation is needed, pomalidomide and dexamethasone doses will remain fixed, while the dose of oprozomib for subsequent cohorts will be escalated until the MTD is reached.~Phase 3:~Study subjects will receive oprozomib in combination with pomalidomide and dexamethasone."
3084084|NCT01999335|Placebo Comparator|Placebo with Pomalidomide and Dexamethasone (Pomd)|"Phase 3:~Study subjects will receive placebo in combination with pomalidomide and dexamethasone."
3084085|NCT01999322|Experimental|FIAsp|The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period
3084086|NCT01999322|Active Comparator|Insulin Aspart|The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period
3084087|NCT01999309|Experimental|Simvastatin|The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
3084088|NCT01999309|Placebo Comparator|Placebo|Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
3084089|NCT01999296||Patients undergoing laparoscopic surgery|
3084090|NCT01999283|Active Comparator|Yoga Group Exercise|Yoga group exercise will be taught by a licensed Physical Therapist. Groups consist of 4-8 individuals with 12 sessions once weekly over 12 weeks.
3084091|NCT01999283|Active Comparator|Pilates Group Mat Exercise|Pilates mat exercise will be taught by a licensed Physical Therapist with additional Rehabilitation Pilates certification.
3084092|NCT01999283|No Intervention|Control|Wait Listed control group. Participants complete the same testing and were offered the option of attending the exercise classes on completion. The controls were not included in the exercise groups after completion.
3084093|NCT01999270|Experimental|Irinotecan, Bevacizumab and FDOPA-PET/MRI imaging|Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider.
3084094|NCT01999257|No Intervention|In-person counselling|Similar to standard of care, wherein Ashkenazi Jewish individuals seeking carrier genetic screening meet a genetic counsellor for an in-person education and counselling session.
3084095|NCT01999257|Active Comparator|Online pre-test genetic education tool|Use of a web-based pre-test education program, wherein the information from a typical genetic counselling session for carrier screening in Ashkenazi Jewish individuals is presented.
3084096|NCT01999244|Experimental|SC|Self-guided self-monitoring condition. Participants will receive standard self-monitoring tools and information on weight regulation.
3084097|NCT01999244|Experimental|TECH|Technology condition. Participants will receive self-monitoring technology and information regarding weight regulation.
3084098|NCT01999244|Experimental|TECH+INT|Technology plus interventionist contact arm. Participants will receive self-monitoring technology, information regarding weight regulation, and interventionist contact via telephone.
3084099|NCT01999231|Experimental|1μg/ml ESAT6-CFP10|The 1μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
3084100|NCT01999231|Experimental|5μg/ml ESAT6-CFP10|The 5μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
3084101|NCT01999231|Experimental|10μg/ml ESAT6-CFP10|The 10μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
3084102|NCT01999231|Experimental|20μg/ml ESAT6-CFP10|The 20μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
3084103|NCT01999218|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104
3084104|NCT01999218|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg QD from Day 1 to Week 104
3084105|NCT01999218|Active Comparator|Glimepiride up to 8 mg|Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104
3084106|NCT01999205|Experimental|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees
3084107|NCT01999192|Experimental|Dose Level 1 Tregalizumab|25mg Tregalizumab s.c. weekly
3084108|NCT01999192|Experimental|Dose Level 2 Tregalizumab|100mg Tregalizumab s.c. weekly
3084109|NCT01999192|Experimental|Dose Level 3 Tregalizumab|200mg Tregalizumab s.c. weekly
3084110|NCT01999192|Placebo Comparator|Placebo|Placebo s.c. weekly
3084111|NCT01999179|Other|low-molecular-weight heparin or direct oral anticoagulant|"Enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing that was obtained by clinical team.~Apixaban, rivaroxaban, dabigatran, or edoxaban at standard dosing per FDA package insert for direct oral anticoagulants."
3084112|NCT01999166||Osteoarthritis|
3084113|NCT01999153|Experimental|DRUG : ROPIVACAINE|20 mL topically used during alginate dressing
3084114|NCT01999153|Placebo Comparator|PLACEBO : NaCl 0.9 %|20 mL topically used during alginate dressing
3084115|NCT01999140||Primary prevention|
3084116|NCT01999114|Experimental|BTDS|Buprenorphine transdermal patches 10, 40 (2 x 20) and 80 (4 x 20) mcg/hr
3084117|NCT01999114|Experimental|BTDS with naltrexone|Buprenorphine transdermal patches 10, 40 (2 x 20) and 80 (4 x 20) mcg/hr and naltrexone 50 mg tablets
3084118|NCT01999114|Active Comparator|Naltrexone|Naltrexone 50 mg tablets
3084119|NCT01999114|Placebo Comparator|Placebo|Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets
3084120|NCT01999114|Active Comparator|Moxifloxacin|Moxifloxacin 400-mg tablets
3084121|NCT01999101|Experimental|Px-104|Px-104 capsules, 5 mg
3084122|NCT01999088|Experimental|Functional meat|During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
3084123|NCT01999088|Placebo Comparator|Control Meat|During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
3084128|NCT01999023|No Intervention|Observational group|No intervention
3084129|NCT01999023|Experimental|Dietary supplement|Low protein formula formula (28.5 g) twice a day
3084130|NCT01999010|No Intervention|"Treatment as usual (A Stage)"|The treatment as usual (TAU) group will continue to receive their usual treatment from their current treatment team - i.e. MHT will not be introduced during this phase.
3084131|NCT01999010|Experimental|"MHT (B Stage)"|Patients will be given software for Mental Health Telemetry (MHT), which allows them to record symptom intensity, hospital / ER visits, life events, etc., and to visualize their MHT data. Patients will be encouraged to make MHT entries once daily at a pre-determined time while in this arm, and will be prompted via text message by the MHT software to do so.
3084132|NCT01999010|Experimental|"Choice (A'  Stage)"|Patients exiting the MHT arm will be given the choice to continue with MHT for a further two months or whether to resume TAU (i.e., no further use of MHT) for the remaining two months.
3084133|NCT01998997|Active Comparator|Family educational intervention|A family educational, non-pharmacologic intervention will be administered to educate family members on how to prevent delirium. Family members will be encouraged to actively participate in this non-pharmacologic intervention.
3084134|NCT01998997|Placebo Comparator|general health education|The placebo group will be given a brochure on good health habits
3084135|NCT01998984|Experimental|2 days placebo and 2 days drug|Placebo and drug
3084136|NCT01998984|Experimental|1 day placebo and 3 days drug|Placebo and drug
3084137|NCT01998984|Placebo Comparator|4 days placebo|Placebo
3084138|NCT01998984|Experimental|4 days drug|Drug
3084139|NCT01998971|Experimental|Daratumumab + VD|Daratumumab will be administered with Velcade-dexamethasone (VD).
3084140|NCT01998971|Experimental|Daratumumab + VMP|Daratumumab will be administered with Velcade-melphalan-prednisone (VMP).
3084141|NCT01998971|Experimental|Daratumumab + VTD|Daratumumab will be administered with Velcade-thalidomide-dexamethasone (VTD).
3084142|NCT01998971|Experimental|Daratumumab + Pom-dex|Daratumumab will be administered with pomalidomide-dexamethasone (Pom-dex).
3084143|NCT01998971|Experimental|Daratumumab + CFZ-dex|Daratumumab will be administered with carfilzomib (CFZ)-dexamethasone (CFZ-dex) regimen.
3084144|NCT01998971|Experimental|Daratumumab + KRd|Daratumumab will be administered with carfilzomib- lenalidomide-dexamethasone (KRd) regimen.
3084145|NCT01998958|Experimental|Esketamine 14 mg|Participants in Panel B will self-administer intranasal esketamine 14 milligram or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, and 25 during the optional open-label phase. During the optional open-label phase, participants will start with treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
3084146|NCT01998958|Experimental|Esketamine 28 mg|Participants in Panel A will self-administer intranasal esketamine 28 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
3084147|NCT01998958|Experimental|Esketamine 56 mg|Participants in Panel A and Panel B will self-administer intranasal esketamine 56 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase. During the optional open-label phase, participants in Panel A will self-administer intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 and participants in Panel B will self-administer intranasal esketamine on Days 15, 18, 22, and 25. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
3084148|NCT01998958|Experimental|Esketamine 84 mg|Participants in Panel A will self-administer intranasal esketamine 84 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
3084149|NCT01998958|Placebo Comparator|Placebo|Participants in Panel A and B will self-administer intranasal placebo on Days 1 and 4 during the double-blind phase. Depending on response on Day 8, participants will receive intranasal placebo on Days 8 and 11 or be re-randomized to receive intranasal placebo or esketamine at a dose of 28 mg, 56 mg, or 84 mg (Panel A) or 14 mg or 56 mg (Panel B) on Day 8 and Day 11.
3084150|NCT01998945|Experimental|Exposure-based Cognitive Behavioral Therapy (ET)|Participants will receive exposure-based cognitive behavioral therapy
3084151|NCT01998945|Active Comparator|Relaxation Training (RT)|Participants will receive relaxation training
3084152|NCT01998932||Chronic Venous Ulcer|Patients with a chronic venous ulcer defined as a wound of greater than four weeks in duration between the foot and the ankle with an Ankle Brachial Pressure Index greater than 0.85 and a colour venous duplex evidence of chronic venous insufficiency showing either reflux or obstruction.
3084153|NCT01998919|Experimental|Tarceva + gemcitabine/platinum|
3084154|NCT01998919|Placebo Comparator|Placebo + gemcitabine/platinum|
3084155|NCT01998906|Experimental|HER-2+ Trastuzumab, Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene positive breast cancer (HER2+) were treated with trastuzumab 8 milligrams per kilogram (mg/kg), intravenous (IV), on Day 1 of Cycle 1, followed by 6 mg/kg, IV, on Day 1 of Cycle 2 to up a maximum of Cycle 17. Participants also received doxorubicin 60 mg/ square meter (m^2), IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF: cyclophosphamide 600 mg/m^2, IV; methotrexate 40 mg/m^2, IV; and 5-fluorouracil 600 mg/m^2, IV, on Day 1 of Cycles 8 through 10.
3084156|NCT01998906|Active Comparator|HER-2+ Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene positive breast cancer were treated with doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
3084199|NCT01998633|Experimental|Hematopoietic Stem Cell Transplant|Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
3084157|NCT01998906|Active Comparator|HER-2- Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene negative breast cancer were treated with doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
3084158|NCT01998893|Experimental|MabThera/Rituxan|
3084159|NCT01998880|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
3084160|NCT01998880|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
3084161|NCT01998880|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
3084162|NCT01998854||VizAblate treatment|VizAblate System with subject serving as her own control
3084163|NCT01998841|Experimental|Mutation Carriers: Crenezumab|Participants will receive crenezumab subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.
3084164|NCT01998841|Placebo Comparator|Mutation Carriers: Placebo|Participants will receive placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.
3084165|NCT01998841|Placebo Comparator|Non-carriers of Mutation: Placebo|Participants will receive placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.
3084166|NCT01998828|Experimental|Momelotinib 100 mg PV|Participants with polycythemia vera will receive 100 mg of momelotinib.
3084167|NCT01998828|Experimental|Momelotinib 200 mg PV|Participants with polycythemia vera will receive 200 mg of momelotinib.
3084168|NCT01998828|Experimental|Momelotinib 100 mg ET|Participants with essential thrombocythemia will receive 100 mg of momelotinib.
3084169|NCT01998828|Experimental|Momelotinib 200 mg ET|Participants with essential thrombocythemia will receive 200 mg of momelotinib.
3084170|NCT01998815||Obese patients|Laparoscopic Roux-en-Y gastric bypass
3084171|NCT01998802|Active Comparator|Active Comparator: EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day.
3084172|NCT01998802|Placebo Comparator|Placebo Comparator|One of two study arms: placebo topical administered 3 times per day.
3084173|NCT01998789|Experimental|Everolimus Conversion Arm|"Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day). Therapeutic Drug Monitoring will be performed throughout the study. Tacrolimus should be eliminated when the everolimus target range has been reached. Complete tacrolimus elimination will not occur earlier than 90 days post transplant and no later than 120 days post transplant. Enteric coated mycopenolic acid will be maintained for the duration of the study. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Everolimus doses will be adjusted based on local lab results of everolimus trough levels."
3084174|NCT01998789|Active Comparator|Standard Tacrolimus Immunosuppresion Arm|"Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels."
3084175|NCT01998776|Active Comparator|Misoprostol|ASA 100 mg daily + misoprostol 200 four times daily (misoprostol group)
3084176|NCT01998776|Placebo Comparator|Placebo misoprostol|ASA 100 mg daily + placebo misoprostol four times daily (placebo group)
3084177|NCT01998763|Placebo Comparator|Placebo|5 placebo pills per day, 20 weeks
3084178|NCT01998763|Experimental|2000 IU/d Vitamin D3|5 vitamin D3 pills per day, 20 weeks
3084179|NCT01998750||Early-onset severe obesity|The study will enroll children and young adults up to 21 years of age with early onset severe obesity (BMI > 99th percentile noted at an age < 6 years of age).
3084180|NCT01998737||Women under osteoporosis suspicion|
3084181|NCT01998737||Healthy women|
3084182|NCT01998724|No Intervention|Standard Care|No intervention
3084183|NCT01998724|Experimental|Tai Chi Exercise|24 week Tai Chi intervention designed for individuals with COPD
3084184|NCT01998724|Experimental|Group Walking Exercise|24 week group walking intervention
3084185|NCT01998711|Experimental|Memory group|Memory training
3084186|NCT01998711|No Intervention|Control|Standard care
3084187|NCT01998698|Active Comparator|Monovision Group|Phacoemulsification surgery with intraocular lens implantation (monovision correction)
3084188|NCT01998698|Active Comparator|Multifocal Group|Phacoemulsification surgery with intraocular lens implantation (multifocal lens insertion)
3084189|NCT01998685|Experimental|Balanced (BAL) anaesthesia|In the BAL group anaesthesia is induced with midazolam 0.1mg kg-1 and fentanyl 1.5 μg kg- 1 Anaesthesia is maintained with sevoflurane 2.0% , oxygen 40% and air 70% with positive pressure ventilation in a circle system, in order to achieve normocapnia.
3084190|NCT01998685|Active Comparator|Totally Intravenous Anesthesia (TIVA-TCI)|In the TIVA-TCI group anaesthesia is induced with propofol 6 microg ml-1 and remifentanyl 0.4-1 microg kg-1 min, simultaneously administered using two separate modules of a continuous computer-assisted TCI system. Anaesthesia is maintained with propofol 4 microg ml-1 and remifentanil 0.25 microg Kg-1 min. This infusion is modified by 0.05 microg kg-1 min steps according to analgesic needs.
3084191|NCT01998672|Active Comparator|Px-102|Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
3084192|NCT01998672|Placebo Comparator|Placebo|Oral drinking solution
3084193|NCT01998659|Active Comparator|Px-102|Px-102 drinking solution, single dose
3084194|NCT01998659|Placebo Comparator|Placebo|Placebo drinking solution, single dose
3084195|NCT01998646|Experimental|ASP4058 Tablet Dose Escalation Cohort|
3084196|NCT01998646|Experimental|ASP4058 Tablet - Fasting conditions|
3084197|NCT01998646|Experimental|ASP4058 Tablet - Fed conditions|
3084198|NCT01998646|Placebo Comparator|Placebo|
3084202|NCT01998620|Active Comparator|Ademetionine 3|no treatment in first 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
3084203|NCT01998607||Round 1|Survey of 210 oncologists 12 - 18 months after commercial availability of XGEVA® in the respective country
3084204|NCT01998607||Round 2|Survey of 210 oncologists 24 - 30 months after commercial availability of XGEVA® in the respective country
3084205|NCT01998594|Active Comparator|Arthroplasty without HADM|Three - five (3 - 5) subjects with Eaton stage III-IV thumb CMC osteoarthritis undergo the basilar joint arthroplasty procedure without using a spacer constructed from human acellular matrix (HADM). Their postoperative DASH scores, grip strength, pinch strength, pain scale scores and quality of life questionnaires are compared to their preoperative scores. These subjects will be compared with a group of twenty-five (25) similar subjects who received the arthroplasty procedure with the use of the HADM spacer.
3084206|NCT01998594|Experimental|Arthroplasty with HADM|Twent-five (25) subjects with Eaton stage III-IV thumb CMC osteoarthritis undergo the basilar joint arthroplasty procedure with an interposition arthroplasty technique using a spacer constructed from human acellular matrix (HADM). Their postoperative DASH scores, grip strength, pinch strength, pain scale scores and quality of life questionnaires are compared to their preoperative scores. These subjects will be compared with a group of three - five (3 - 5) similar subjects who received the arthroplasty procedure without the use of the HADM spacer.
3084207|NCT01998581|Experimental|JUVEDERM VOLBELLA® XC|Lips injected with JUVEDERM VOLBELLA® XC
3084208|NCT01998581|Active Comparator|Restylane-L®|Lips injected with Restylane-L®
3084209|NCT01998568||Corneal edema|Intraocular pressure measurement
3084210|NCT01998555|Other|CAD-CBT group therapy|CAD receive web-based CBT group therapy
3084211|NCT01998555|Other|CAD-CBT group therapy waiting list|CAD waiting list will receive web-based CBT group therapy later
3084212|NCT01998542|Experimental|AlloVax|AlloVax(TM) - the intradermal injection of AlloSim(TM) followed immediately by the intradermal injection of CRCL weekly for 3 weeks followed by intravenous infusion of AlloStim(TM) in week 4 (cycle 1 = 4 weeks. Total 4 cycles).
3084213|NCT01998542|Placebo Comparator|Placebo Arm|AlloVax(TM) placebo (the intradermal placebo injection followed immediately by the intradermal placebo injection weekly for 3 weeks followed by intravenous infusion of AlloStim(TM) placebo in week 4. (Cycle 1 = 4 weeks. Total 4 cycles).
3084214|NCT01998529|Experimental|Cisplatin|After cytoreductive surgery, possible pneumonectomy, and possible diaphragm resection, the chest cavity will be closed in layers, leaving inflow and outflow chest tubes in place. Catheters connected to an extracorporeal perfusion circuit. Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C). In order to limit the systemic toxicity of cisplatin, amifostine administered intravenously over 15 minutes beginning 30 minutes after cisplatin perfusion. Patient response to amifostine continuously monitored by anesthesiologist. Infusion may be stopped and/or restarted based on blood pressure.
3084215|NCT01998516||Schizophrenia Patients|
3084216|NCT01998516||Bipolar I Patients|
3084217|NCT01998516||Siblings of Schizophrenia Patients|
3084218|NCT01998516||Siblings of Bipolar I Patients|
3084219|NCT01998516||Healthy Controls|
3084220|NCT01998503|Active Comparator|BD induction followed by ASCT|The BD regimen included bortezomib 1.3 mg/m2 i.v. and dexamethasone 40 mg p.o. on days 1, 4, 8 and 11 of the 21 day cycle. This process was repeated for 2 cycles. After two cycles of BD therapy, the collection of peripheral blood stem cells (PBSC) should be completed within 4 weeks. Patients receive filgrastim (G-CSF) on days 1 to 5 and undergo autologous hematopoietic stem cell (HSC) collection. Patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day 0), while melphalan (day -2) with a dose of 140 or 200 mg/m2 (choosing a dose according to the degree of risk for patients). Melphalan will be administered by central venous catheter.
3084221|NCT01998503|Experimental|ASCT alone|the patients who assigned to this arm will receive ASCT alone as an initial treatment. At first, patients receive the collection of peripheral blood stem cells (PBSC), Patients receive filgrastim (G-CSF) on days 1 to 5 and undergo autologous hematopoietic stem cell (HSC) collection. After then patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day 0), while melphalan (day -2) with a dose of 140 or 200 mg/m2 (choosing a dose according to the degree of risk for patients). Melphalan will be administered by central venous catheter.
3084222|NCT01998490|Experimental|Animal-assisted activity|30 minutes group session with animal-assisted activity twice a week for 12 weeks in groups of 4-6 participants.
3084223|NCT01998490|Experimental|Robot-assisted activity|30 minutes group session with robot-assisted activity with the robot seal Paro twice a week for 12 weeks in groups of 4-6 participants
3084224|NCT01998490|No Intervention|Control|Control group with treatment as usual
3084225|NCT01998477|Experimental|TIVc|flu vaccine
3084226|NCT01998477|Active Comparator|TIV|flu vaccine
3084227|NCT01998464||Retinal Vasculitis Group|Up to 35 patients diagnosed with retinal vasculitis will be considered and evaluated for enrollment in this study.
3084228|NCT01998451|Experimental|Double sphincter group|patients from double sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
3084229|NCT01998451|Other|general gallbladder sphincter group|patients from general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
3084230|NCT01998438|Experimental|small dose|10mg/kg tranexamic acid add in priming fluid, 10mg/kg single shot slowly when incision, followed by 2mg/(kg·h) infusion until the end of surgery
3084231|NCT01998438|Experimental|medium dose|20mg/kg tranexamic acid add in priming fluid, 20mg/kg single shot slowly when incision, followed by 4mg/(kg·h) infusion until the end of surgery
3084232|NCT01998438|Experimental|large dose|30mg/kg tranexamic acid add in priming fluid, 30mg/kg single shot slowly when incision, followed by 6mg/(kg·h) infusion until the end of surgery
3084233|NCT01998425||Non-small cell lung cancer|The cohort data of patients with NSCLC will follow up from diagnosis, treatment response and final survival. Fibrocytes will be checked on the date of diagnsis (before treatment), re-staing (3months after treatment) and disease progression.
3084234|NCT01998399|Experimental|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
3084235|NCT01998399|Placebo Comparator|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
3100377|NCT01889329|Experimental|RUTF-2|Made from local food ingredients
3084236|NCT01998386|Placebo Comparator|Placebo gel without hydrogen peroxide|The volunteers of this group will receive a placebo gel without hydrogen peroxide for whitening treatment.
3084237|NCT01998386|Experimental|6.0% hydrogen peroxide - White Class|Volunteers of this group will receive a gel with 6.0% hydrogen peroxide - White Class with calcium for whitening treatment.
3084238|NCT01998386|Experimental|7.5% hydrogen peroxide - White Class|The volunteers of this group will receive a gel with 7.5% hydrogen peroxide -White Class with calcium for whitening treatment.
3084239|NCT01998386|Experimental|7.5% hydrogen peroxide - Oral-B 3D White|The participants in this group will receive disposable whitening strips - Oral-B 3D White for whitening treatment.
3084240|NCT01998373|Experimental|patient training and patient without training|Experimental group 1: patient education intervention group (PIGE) Experimental group 2: patient without intervention group (PWIG)
3084241|NCT01998373|No Intervention|control without education|this group did not receive an education
3084242|NCT01998360|Experimental|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and sealing wound with tissue adhesive
3084243|NCT01998360|Active Comparator|Surgical control|Surgical circumcision using forceps guided, dorsal slit, or sleeve method
3084244|NCT01998347|Experimental|Paclitaxel liposome and Cisplatin|"Drug: paclitaxel liposome 175mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles:up to 6 cycles.~Drug: cisplatin 37.5 mg/m2, IV (in the vein) on day 1~2 of each 21 day cycle. Number of Cycles: up to 6 cycles."
3084245|NCT01998347|Active Comparator|Cisplatin plus 5-fluorouracil|"Cisplatin:~37.5 mg/m2, IV (in the vein) on day 1-2 of each 21 day cycle. Number of Cycles: up to 6 cycles.~5-fluorouracil: 200mg/m2, CIV (continuous intravenous infusion) on day 1~5 of each 21 day cycle. Number of Cycles: up to 6 cycles."
3084246|NCT01998334|Experimental|CVVH 6h|CVVH 6h for first three days
3084247|NCT01998334|Experimental|CVVH 10h|CVVH 10h for first three days
3084248|NCT01998334|Experimental|CVVHDF|CVVHDF 6h for first three days
3084249|NCT01998321|Experimental|TKA using PSI|Total Knee Arthroplasty using Patient Specific Instrument
3084250|NCT01998321|Experimental|2 TKA using conditional technique.|Total Knee Arthroplasty using conditional technique.
3084251|NCT01998308||Group 1|50 Knees will have single injection of Crespine gel
3084252|NCT01998308||Group 2|50 Knees will have single injection of 2 ampules of intragel
3084253|NCT01998308||Group 3|50 knees will have single injection of crespine plus gel
3084254|NCT01998308||Group 4|50 knees will have single injection of Monovisc
3084255|NCT01998295|Active Comparator|Artemether/lumefantrine|"Artemether/lumefantrine tablets, 6 doses, for 3 days~Dosage:~tablet for body weight between 5-14.9 Kilograms.~tablets for body weight between 15-24.9 Kilograms.~tablets for body weight between 25-34.9 Kilograms."
3084256|NCT01998282||Household water filter and improved cook stove|Vestergaard-Frandsen LifeStraw Family 2.0 filter and Ecozoom stove
3084257|NCT01998282||Control|Traditional water management practices and cooking stoves
3084258|NCT01998269||Adult patients with diabetes and hypertension|
3084259|NCT01998256|Sham Comparator|Group I|All patients were programmed in the same nominal AV delay settings (sensed AV delay 120ms, paced AV delay 150 ms) before randomization. Patients in group I received a sham AV optimization; patients in group II received a real AV optimization. Baseline echocardiography measurements were repeated after (sham)optimization. At 4 weeks cross-over was done by AV optimization in group I and resetting pacemaker settings to nominal values in group II. At 8 weeks patients were evaluated with the same investigations as at week 4; every pacemaker was programmed in the most optimal AV setting. All optimizations were performed by 2 unblinded echocardiographists with experience in the field.
3084260|NCT01998256|Active Comparator|Group II|All patients were programmed in the same nominal AV delay settings before randomization. Patients in group I received a sham AV optimization; patients in group II received a real AV optimization. Baseline echocardiography measurements were repeated after (sham)optimization. At 4 weeks cross-over was done by AV optimization in group I and resetting pacemaker settings to nominal values in group II. At 8 weeks patients were evaluated with the same investigations as at week 4; every pacemaker was programmed in the most optimal AV setting. All optimizations were performed by 2 unblinded echocardiographists with experience in the field.
3084261|NCT01998243|No Intervention|group B|patients were followed during at least 6 months before surgery by the same group of nutritionist that followed the group A and with the same type of diet and diet recommendations
3084262|NCT01998243|Active Comparator|IGB-BIB® group A|patients included have a preoperative intragastric balloon during a period of 6 months before operation
3084263|NCT01998230|Experimental|Early oral feeding group|In this goup patients with esophagectomy are encouraged to begin the oral intake carefully and adjust according to tolerance on post operative day 1.
3084264|NCT01998230|No Intervention|Delayed oral feeding group|In delayed oral feeding group the patients receive isotonic saline by the nasoenteral feeding tube at 20 mL/h until the morning of post operative day1. Nutrition was then commenced at 20 mL/h. The rate was increased by 20 mL/h each day if tolerated, up to 80 mL/h.Esophagography was performed on postoperative day 7. Sip of water were allowed after confirming the absence of anastomosis leakage, and a full liquid diet was implemented on the following day and enteral infusion halted.
3084265|NCT01998217|Active Comparator|Rem group|Patients in this group receive single infusion of remifentanil with target concentration infusion.
3084266|NCT01998217|Experimental|Flur group|Patients in this group receive both infusion of flurbiprofen and remifentanil
3084267|NCT01998204||PD group|Patients with Parkinson's disease undergoing deep brain stimulator implantation and pulse generator placement
3084268|NCT01998204||non-PD group|Patients without Parkinson's disease undergoing intracranial surgery
3084269|NCT01998191|Active Comparator|Implicit Case note review (nurse)|"Notes to be reviewed using the implicit method by a nurse~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
3084270|NCT01998191|Active Comparator|Implicit Case note review (MDT)|"Notes to be reviewed using the implicit method by an expert physician and nurse team.~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
3100378|NCT01889329|Active Comparator|Plumpynut|Made from peanut
3084271|NCT01998191|Active Comparator|Implicit Case note review (physician)|"Notes to be reviewed using the implicit method by an expert physician~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
3084272|NCT01998165|Experimental|Remifentanil (0.25 µg/kg/min)|
3084273|NCT01998152|Experimental|Nutritional counseling|Individualized nutritional counselling by a registered dietitian
3084274|NCT01998152|No Intervention|No intervention|Usual nutritional care by the oncologist. A dietitian is only involved when serious nutritional problems occur.
3084275|NCT01998139||Test Cohort|EMP levels will be measured at ICU admission in subjects with physician-suspected sepsis. For each subject, the final diagnosis of sepsis or non-sepsis critical illness will be adjudicated using standard criteria. The subjects without sepsis will form the Test Cohort.
3084276|NCT01998139||Validation Cohort|EMP levels will be measured at ICU admission in subjects with physician-suspected sepsis. For each subject, the final diagnosis of sepsis or non-sepsis critical illness will be adjudicated using standard criteria.The subjects determined to have sepsis will serve as the Validation Cohort .
3084277|NCT01998126|Experimental|EGFR patients with ipilimumab|ipilimumab and erlotinib in EGFR mutated patients
3084278|NCT01998126|Experimental|ALK patients plus ipilimumab|ipilimumab and crizotinib in ALK mutated patients
3084279|NCT01998126|Experimental|EGFR patients with nivolumab|nivolumab and erlotinib in EGFR mutated patients
3084280|NCT01998126|Experimental|ALK patients plus nivolumab|nivolumab and crizotinib in ALK mutated patients
3084281|NCT01998113||Glyburide (Glyburide vs Insulin)|Glyburide vs Insulin trials
3084282|NCT01998113||Insulin (Glyburide vs Insulin)|Glyburide vs Insulin trials
3084283|NCT01998113||Metformin (Metformin vs Insulin)|Metformin vs Insulin trials
3084284|NCT01998113||Insulin (Metformin vs Insulin)|Metformin vs Insulin trials
3084285|NCT01998113||Metformin (Metformin vs Glyburide)|Metformin vs Glyburide trials
3084286|NCT01998113||Glyburide (Metformin vs Glyburide)|Metformin vs Glyburide trials
3084287|NCT01998100|Experimental|Prolonged Exposure + Exercise|
3084288|NCT01998100|Active Comparator|Prolonged Exposure Alone|
3084289|NCT01998087|Experimental|Breastfeeding support|A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three standardized phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following birth of the baby.
3084290|NCT01998087|Active Comparator|General Support|The active control group of mothers will receive a brochure in pregnancy covering general pregnancy and parenting issues and follow-up phone calls but breastfeeding issues will not be specifically addressed. If a mother raises any breastfeeding issue she will be referred to appropriate support.
3084291|NCT01998087|No Intervention|Standard Care|This group will receive standard antenatal care provided by their chosen gynaecologist and obstetrician, consisting of regular antenatal visits. No written materials or telephone calls are routinely provided to pregnant women in Croatia.
3084292|NCT01998074|Experimental|Study formula|
3084293|NCT01998061|Experimental|Arm A|TKI alone until rapid progression
3084294|NCT01998061|Experimental|Arm B|TKI combined with investigator's choice of chemotherapy regimen and subsequent line of treatment until rapid progression.
3084295|NCT01998048|Active Comparator|Latarjet|60 patients treated with open Latarjet operation
3084296|NCT01998048|Active Comparator|Bankart|60 patients treated with arthroscopic Bankart operation
3084297|NCT01998035|Experimental|R/O: Level -1|Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Day 8), cycle length (28 days)
3084298|NCT01998035|Experimental|R/O: Level 1|Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
3084299|NCT01998035|Experimental|R/O: Level 2|Oral 5-Azacitidine 200 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
3084300|NCT01998035|Experimental|R/O: Level 3|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
3084301|NCT01998035|Experimental|R/O: Level 4|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
3084302|NCT01998035|Experimental|R/O: Level 5|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8, 15 and 22), cycle length (35 days)
3084303|NCT01998035|Experimental|R/O: Level 6|Oral 5-Azacitidine 300 mg (Days 1-21) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8, 15 and 22), cycle length (35 days)
3084304|NCT01998009|Other|Fecal occult blood tests|Each patient will perform one guaiac and two immunochemical fecal occult blood tests at home.
3084305|NCT01997996||PROLIFT+M|Patients that undergo surgery due to prolapse POP ≥ stage II with PROLIFT+M device having had ≥ 2x/4 weeks sexual intercourse before surgery.
3084306|NCT01997983|Experimental|TC-3 Gel with Botox|open label observational study
3084307|NCT01997970|Experimental|Treadmill workstation|Will receive a health talk with recommendations about diet and physical activity habits and will also receive a treadmill workstation at regular office site for 12 months.
3084308|NCT01997970|Experimental|Control group|Will receive a health talk with recommendations about diet and physical activity habits. Will continue to work with conventional office work at their regular desk.
3084309|NCT01997957|Experimental|TACE+HAIC-OXA+S-1|
3084310|NCT01997957|No Intervention|TACE+HAIC-OXA|
3084311|NCT01997944|Experimental|Human Serum Albumin/interferon alpha2a|Human Serum Albumin/interferon alpha2a 600,750 or 900 mcg multiple dose S.C.
3084312|NCT01997944|Active Comparator|Pegasys|Peginteferon 180 mcg multiple dose S.C.
3084313|NCT01997905|Experimental|AtriClip LAA Exclusion Device|AtriClip delivered via minimally invasive surgical procedure
3084314|NCT01997892||Chronic Kidney Disease (CKD)|Participants with CKD on dialysis and treated with PEG epoetin beta for a minimum of 14 weeks immediately prior to being switched to darbepoetin alfa.
3084315|NCT01997879|Experimental|AR-13324 Ophthalmic Solution, 0.02%|Eyedrop
3084316|NCT01997866|Other|Patients with Congestive Heart Failure|"STOP-BANG Scoring Model~Polysomnogram Sleep Study"
3084317|NCT01997853|Active Comparator|Test Group|Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks
3084318|NCT01997853|Placebo Comparator|Control Group|Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks
3084319|NCT01997840|Experimental|ACY-1215 in combination with pomalidomide and dexamethasone|ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
3084320|NCT01997827|Active Comparator|metal-ceramic RBFDP|Treatment with a metal-ceramic RBFDP
3084321|NCT01997827|Experimental|all-ceramic RBFDP|Treatment with an all-ceramic RBFDP
3084322|NCT01997814|Active Comparator|Test Group|Patients in Test Group were given Herbal Immunomodulators (SeptilinTM) 2 tablets twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
3084323|NCT01997814|Placebo Comparator|Control Group|Patients in Control Group were given placebo drug 2 tablets twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
3084324|NCT01997801|Placebo Comparator|C group|In C group, NS infusion will be done intraoperatively.
3084325|NCT01997801|Experimental|KET group|In KET group, ketamine infusion will be done intraoperatively(0.25 mg/kg bolus injection following 100 mcg/kg/hr till the end of surgery).
3084326|NCT01997788|Experimental|The ITM group|The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
3084327|NCT01997788|Placebo Comparator|The IV-PCA group|The postoperative pain management includes only the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
3084328|NCT01997775|Experimental|METFORMIN|For patients with stage IV lung adenocarcinoma and IL-6 level higher than 2.0 pg/ml after 2 cycles of standard treatment, metformin 500mg tid orally will be given.
3084329|NCT01997762|Placebo Comparator|Placebo|Corn starch capsules, 1 capsule twice a day for 3 months
3084330|NCT01997762|Experimental|Resveratrol|Resveratrol capsules, 250 mg twice a day for 3 months
3084331|NCT01997749|Experimental|Ketogenic diet|Acute stroke patients will receive a ketogenic diet (Ketocal 4:1 and ketogenic meals) for the first week after inclusion
3084332|NCT01997749|Active Comparator|Control diet|Acute stroke patients will receive a control diet (the regular diet, enteral or oral, offered at the hospitals) for the first week after inclusion.
3084333|NCT01997736|Experimental|Ablation|
3084334|NCT01997723|Experimental|OSA testing|Cross-over design, single group/arm Interventions: polysomnography with simultaneous portable monitoring and home portable monitoring administered to each participant in random order.
3084335|NCT01997710|Experimental|all-ceramic inlay-retained RBFDP|Treatment with an all-ceramic inlay-retained RBFDP
3084336|NCT01997710|Active Comparator|all-ceramic RBFDP|Treatment with an all-ceramic RBFDP
3084337|NCT01997697|Experimental|Patients with obesity|behavior change program among patients with obesity
3084338|NCT01997684|Experimental|Colonic Stenting with Elective Surgery|"In the experimental group, the patients will undergo colonic stenting within 24 h of inclusion. For this study, the WallFlex ™ Colonic Stent (Boston Scientific, Natick, MA) will be employed.~Candidates for elective surgery, after clinical success of colonic stenting, will be preferably operated on 5-14 days after inclusion, and no later than 4 weeks. Type and extent of the elective surgery will be selected by the surgeon.~In this group, unplanned emergency surgery will be indicated in case of technical failure of colonic stenting, iatrogenic morbidity, or clinical failure.~In case of a primary colostomy, restoration of bowel continuity was attempted within 3-6 months."
3084339|NCT01997684|Active Comparator|Emergency Surgery|"In the comparator group, patients will be undergo emergency surgery. Surgical options including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.~In case of a primary colostomy, restoration of bowel continuity was attempted within 3-6 months."
3084340|NCT01997671|Experimental|Information Support System|Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering.
3084341|NCT01997671|No Intervention|Control group|Routine clinical practice
3084342|NCT01997658|Experimental|Methylprednisolone|Injection, 500 mg, single use, over 15 to 20 minutes.
3084343|NCT01997658|Placebo Comparator|Control|In Control arm, patients will receive the standardized surgical treatment without receiving methylprednisolone preoperatively (placebo).
3084344|NCT01997645|Active Comparator|Rectal advanced mucosal flap|"Procedure will be performed in general anesthesia without mechanical bowel preparation. Antibiotic prophylaxis (Metronidazole 1g) will be applied intravenously 60 minutes prior the surgery.~In RAF procedure, internal opening will identified and after infiltration with saline-adrenalin solution (1/100000) the mucosal flap will be mobilized proximally. The external tract and internal opening will be excised and the defect will be sutured. After that, the flap will be advanced from both sides with absorbable suture and overlapped over the internal opening. External openings will be left open."
3084345|NCT01997645|Active Comparator|Ligation of intersphincteric fistula tract|"Procedure will be performed in general anesthesia without mechanical bowel preparation. Antibiotic prophylaxis (Metronidazole 1g) will be applied intravenously 60 minutes prior the surgery.~Before LIFT procedure the fistula tract will be identified with small probe. The intersphincteric space will be reached by dissection from small (2-4cm) incision. The fistula tract will be divided and ligated on both sides with Polydioxanone (PDS) suture. The external and internal openings will be left open to drain."
3084346|NCT01997632|Active Comparator|control vaccine: Imovax Polio®|
3084347|NCT01997632|Experimental|investigational vaccine|
3084348|NCT01997606|Experimental|Purotex|use of Purotex treated bedding covers
3084349|NCT01997606|Placebo Comparator|Placebo|no use of Purotex treated bedding covers
3084350|NCT01997593|Experimental|ropivacaine|Preincisional wound intraperitoneal infiltration of 1% ropivacaine 0.3ml/kg was performed in group I patients before surgery.
3084351|NCT01997580|Experimental|Escitalopram|depressed patients receiving escitalopram treatment
3084352|NCT01997580|No Intervention|Control|healthy controls matched for age, gender, and BMI
3084486|NCT01996644|Experimental|Setraline|250 mg DCS (setraline) versus placebo plus exposure
3084353|NCT01997567|Active Comparator|Grp 1 Ropivacaine Block|Group 1 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
3084354|NCT01997567|Placebo Comparator|Grp 2 Placebo Block|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
3084355|NCT01997554|Experimental|less than 60 years old with clinical symptom of hypothyroidism|Group of patients less than 60 years old, with at least one clinical symptom of hypothyroidism
3084356|NCT01997554|Experimental|less than 60 years old without clinical symptoms|Group of patients less than 60 years old, without clinical symptoms of hypothyroidism
3084357|NCT01997554|Experimental|more than 60 years old|Group of patients more than 60 years old at recruitment.
3084358|NCT01997541||plain tube|
3084359|NCT01997541||reinforced tube|
3084360|NCT01997528|Experimental|Extracorporeal CO2 elimination by ILA Activve(R)|
3084361|NCT01997515|Active Comparator|Group K (Ketamine)|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
3084362|NCT01997515|Placebo Comparator|Group P (placebo)|Group P (placebo) will receive the same amount of saline.
3084363|NCT01997489|Experimental|Fabry patients during treatment|39 patients with Fabry disease having had baseline examinations of the eyes were assessed also at follow-up 10 years after enzyme replacement therapy
3084364|NCT01997476|Experimental|Combined EUS, e-PFT and sEUS Testing|"Establish the advantage of combined EUS, ePFT & sEUS testing to provide a more definitive diagnostic assessment, rather than each test alone.~Establish the advantage of reduced time and cost of combining EUS and ePFT, rather than when done separately."
3084365|NCT01997463|No Intervention|Regular Therapy|Regular Asthma Therapy
3084366|NCT01997463|Experimental|Supervised Therapy|Supervised asthma therapy in schools
3084367|NCT01997450||Q/LAIV|FluMist Quadrivalent
3084368|NCT01997450||Inactivated Influenza Vaccine|Inactivated Influenza Vaccine
3084369|NCT01997437|Other|Tissue-engineered airway transplantation|Stem-cell seeded bioartificial tracheal scaffold
3084370|NCT01997411|Experimental|Nasal Glucagon (NG)|Nasal glucagon (NG) doses of 2.0 mg and 3.0 mg for participants 4 to less than 12 years of age and 3.0 mg for those 12 to less than 17 years of age were administered in a nostril with a prefilled delivery device that delivered a single dose upon activation.
3084371|NCT01997411|Active Comparator|Intramuscular (IM) Glucagon|Participants who weighed at least 25 kilograms (kg)/55 pounds (lbs) were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 lbs, IM glucagon dosed with 0.5 mg
3084372|NCT01997385|Active Comparator|KAPD-C|KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
3084373|NCT01997385|Experimental|KAPD-A|KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
3084374|NCT01997372|Experimental|high dose ATG,low dose ATG|
3084375|NCT01997359||Key Informant Interviews|Eligible patients will undergo a one hour structured interview about barriers and facilitators to early ART initiation.
3084376|NCT01997359||Prospective Cohort|The prospective cohort will include all patients initiating ART at one of the six study sites, estimated at 1,200 patients. Cases will be adults initiating ART with either: CD4 count <150 cells/µL. Controls will be adults who initiate ART with CD4≥200 . Individuals initiating ART with CD4 counts of 150-199 cells per µL and at WHO Stage I-III will be excluded from the case-control analysis in order to ensure meaningful distinction between the two groups. We will enroll 720 patients for the case control study nested in the prospective cohort, which will include 360 cases and 360 controls, who will be frequency matched by sex, month of ART initiation, and clinic.
3084377|NCT01997346||Key Informant Interviews|We will conduct interviews with 4 clinic personnel (16 across the 4 sites) to learn about practices and provider perspectives in the HIV clinic or ancillary clinics such as VCT. The 4 clinic personnel in each site will include: the physician-in-charge, a nurse, one peer educator, and a nurse or community counselor from the VCT clinic. A semi-structured interview guide will be used to query respondents about: procedures for enrolling new clients, conducting active testing, identifying and initiating patients on ART, CD4 monitoring, tracking clients who have missed appointments, support programs, and peer education. We will also aim to understand how each respondent views her/his role, how s/he counsels patients on pre-ART care, and the challenges faced from each one's perspective.
3084378|NCT01997333|Active Comparator|Capecitabine|Capecitabine will be administered on Days 1 through 14 of each 21 day cycle.
3084379|NCT01997333|Experimental|Drug: CDX-011|CDX-011 administered as an intravenous infusion on Day 1 of each 21 day cycle.
3084380|NCT01997320|Experimental|Heavy resistance exercise and nutrition|Heavy resistance exercise of the lower extremities three times weekly for 12 weeks combined with nutrient supplementation twice daily each containing 20g of milk protein.
3084381|NCT01997320|Active Comparator|Nutrition supplement|Nutrient supplementation twice daily for 12 weeks. Each supplement contains 20g of milk protein.
3084382|NCT01997307||Stratification by gender and age, including 4 age categories|>=55-64 years
3084383|NCT01997307||Age >=65 to 74|
3084384|NCT01997307||Age >=75 to 84|
3084385|NCT01997307||Age >=85|
3084386|NCT01997294|Active Comparator|sequential therapy group|80mg atorvastatin before primary PCI (PPCI) followed by 40mg/d for 7 days after PPCI followed by 20mg/d for 1 year
3084387|NCT01997294|Placebo Comparator|Usual Therapy of atorvastatin|20mg/d before and after PPCI for 1 year
3084388|NCT01997281|Experimental|DF-cereal|"dietary fiber-enriched cereal is provided with milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~amount of cereal: 79 g (285.7 kcal) for dinner and breakfast, 38.5g (142.9 kcal) for night snack (10 p.m.)~one serving (40g) of steamed egg is added for dinner and breakfast"
3084389|NCT01997281|Other|conventional cereal|"conventional cereal is provided with milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~amount of cereal: 80g (285.7 kcal) for dinner and breakfast, 40g (142.9 kcal) for night snack (10 p.m.)~one serving (40g) of steamed egg is added for dinner and breakfast"
3084390|NCT01997268|Placebo Comparator|Placebo|Placebo 6 capsules (1.24 g each) daily for 12 weeks
3084391|NCT01997268|Experimental|SC401B 2 capsules|SC401B 2 capsules (1.24 g each) + 4 placebo capsules daily for 12 weeks
3084392|NCT01997268|Experimental|SC401B 4 capsules|SC401B 4 capsules (1.24 g each) + 2 placebo capsules daily for 12 weeks
3084393|NCT01997268|Experimental|SC401B 6 capsules|SC401B 6 capsules (1.24 g each) daily for 12 weeks
3084394|NCT01997255|Experimental|Everolimus|Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
3084395|NCT01997242||stenting undergoing surgery|Patients with prior coronary stenting undergoing urgent or elective surgical/endoscopic procedures
3084396|NCT01997229|Experimental|Eculizumab|Biological/Vaccine: Eculizumab; Induction phase: 3 vials of study drug (equivalent to 900 mg of eculizumab) weekly for 4 doses (every 7 days ± 2 days) followed by 4 vials of study drug (equivalent to 1200 mg of eculizumab) 1 week later for the fifth dose (Week 4); Maintenance phase: 4 vials of study drug (equivalent to 1200 mg of eculizumab) every 2 weeks (14 days ± 2 days) from the fifth dose onwards (Week 6 through Week 26).
3084397|NCT01997229|Placebo Comparator|Placebo|Placebo contains the same buffer components without the active ingredient; Induction phase: 3 vials of study drug (placebo) weekly for 4 doses (every 7 days ± 2 days) followed by 4 vials of study drug (placebo) 1 week later for the fifth dose (Week 4); Maintenance phase: 4 vials of study drug (placebo) every 2 weeks (14 days ± 2 days) from the fifth dose onwards (Week 6 through Week 26).
3084398|NCT01997216|Other|Delefilcon A MF, then AOAMF|Delefilcon A multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
3084399|NCT01997216|Other|AOAMF, then Delefilcon A MF|Lotrafilcon B multifocal contact lenses, followed by delefilcon A multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
3084400|NCT01997203|Experimental|HCV patients under treatment|"Fifty patients study group administered vitamin D were compared with 50 patients control group without vitamin D.~Dose of vitamin D 15,000 IU/week"
3084401|NCT01997203|No Intervention|HCV without Vit D|
3084402|NCT01997190|Experimental|Study Arm|AdV-tk + valacyclovir
3084403|NCT01997177||novices|novice endoscopists, fellows of gastroenterology
3084404|NCT01997177||experienced endoscopist|consultant doctors of gastroenterology
3084405|NCT01997164|Experimental|Cohorts 1 through 4|Participants in cohorts 1 through 4 will receive IVT REGN910-3 and IAI
3084406|NCT01997164|Experimental|Cohort 5|Participants in cohort 5 will receive IVT REGN910 and IAI
3084407|NCT01997151|Experimental|Healthy Pregnancy: Step by Step|Pregnant women interacted with a multiple behavior change iPad- delivered program at federally funded health centers. The 20-30 minute program offered onscreen assessments of Transtheoretical Model strategies of change, and then provided individually tailored feedback messages matched to their readiness to change for relevant target behaviors. The program addressed smoking cessation and relapse prevention, stress management, and fruit and vegetable consumption. The feedback screens were interactive and engaging. The messages were written at a 4th-5th grade level and were reviewed for multicultural relevancy. Participants in the treatment group interacted with the program up to 3 times during pregnancy. A printed multiple behavior change guide also was distributed. All program components are available in English and Spanish.
3084408|NCT01997151|No Intervention|Usual Care|Pregnant women received regular prenatal care as delivered by the health care center from where they were receiving care. Standard informational March of Dimes brochures related to the target behaviors were distributed to usual care participants.
3084409|NCT01997138|Experimental|Anakinra|Anakinra 100 mg in 2 ml saline IA
3084410|NCT01997138|Placebo Comparator|Placebo|Saline 2 ml IA
3084411|NCT01997125|Experimental|Open Label|Neural bridge system implant and external stimulator
3084412|NCT01997112|Active Comparator|Paracetamol|paracetamol 1g (500mg x2) four times daily for 14 day period
3084413|NCT01997112|Placebo Comparator|Placebo|Matched placebo control: hard gelatin placebo capsules containing Lactose Ph Eur. Taken for 14 days
3084414|NCT01997099||Library Creation|Individuals responsible for creating the drug library
3084415|NCT01997099||Pump Programming|Individuals responsible for programming ambulatory infusion pumps
3084416|NCT01997099||Home Implementation|Individuals responsible for implementing ambulatory infusion pumps in patients' homes
3084417|NCT01997099||Workflow|Individual at the facility responsible for describing the workflow of processing and implementing an ambulatory infusion pump prior to and after introducing the CADD®-Solis VIP System.
3084418|NCT01997099||Ambulatory Infusion Pump Patients|Patients that receive a prescription requiring use of the CADD®-Solis VIP pump
3084419|NCT01997086|Active Comparator|Transforaminal discectomy|patients diagnosed as lumbar disc herniation undergoing percutaneous transforaminal endoscopic discectomy (PTED).
3084420|NCT01997086|Active Comparator|Microendoscopic discectomy|Patients diagnosed as lumbar disc herniation undergoing microendoscopic discectomy (MED).
3084421|NCT01997060|Experimental|Intensive Lifestyle Intervention|Intensive Lifestyle Intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction (~-700KCal/day). Education within nutrition, exercise and healthy living in general.
3084422|NCT01997047||Tachypneic children|All tachypneic children under 5 yrs age presenting to study centres. No exclusions.
3084423|NCT01997034||Intensive Lifestyle Intervention|Former participants of Ubberup Folk High Schools intensive lifestyle intervention programme.
3084424|NCT01997021|Experimental|US/IW/CW|This is a 3 arm crossover design. Arm US/IW/CW corresponds to the group of participants randomized to uninterrupted sitting (US) first, then Intermittent Walking (IW) and then continuous walk (CW).
3084487|NCT01996644|Placebo Comparator|placebo|Placebo group plus exposure
3084425|NCT01997021|Experimental|IW/US/CW|This is a 3 arm crossover design. Arm IW/US/CW corresponds to the group of participants randomized to Intermittent Walking (IW) first, then uninterrupted sitting (US), and then continuous walk (CW).
3084426|NCT01997021|Experimental|IW/CW/US|This is a 3 arm crossover design. Arm IW/CW/US corresponds to the group of participants randomized to Intermittent Walking (IW) first, then Continuous Walk (CW) and then Uninterrupted Sitting (US).
3084427|NCT01997021|Experimental|CW/IW/US|This is a 3 arm crossover design. Arm CW/IW/US corresponds to the group of participants randomized to Continuous Walk (CW) first, then Intermittent Walking (IW) and then Uninterrupted Sitting (US).
3084428|NCT01997021|Experimental|CW/US/IW|This is a 3 arm crossover design. Arm CW/IW/US corresponds to the group of participants randomized to Continuous Walk (CW) first, then Uninterrupted Sitting (US), and then Intermittent Walking (IW).
3084429|NCT01997021|Experimental|US/CW/IW|This is a 3 arm crossover design. Arm US/CW/IW corresponds to the group of participants randomized to Uninterrupted Sitting (US) first, then Continuous Walk (CW), and then Intermittent Walking (IW).
3084430|NCT01997008|Experimental|Intervention|"Participants receive a five week intervention providing the following activities:~EMA:~Ecological Momentary Assessment (EMA) of Emotion throughout the day.~Intervention:~Positive Events: Participants identify a positive event and then describe how they capitalized on this event.~Gratitude: Participants identify one more more things that make them feel grateful.~Mindfulness: Participants participate in a 30 minute guided mindfulness/meditation practice.~Positive Reappraisal: Participants identify how they reappraised a negative event making it into a positive event.~Personal Strengths: Participants identify one more more personal strengths. Attainable goals: Participants identify a short-term attainable goal. Participants will outline what they did that day to work toward attaining their week's goal.~Acts of Kindness: Participants will identify one more more acts of kindness that they engaged in and how it made them feel."
3084431|NCT01997008|No Intervention|Emotion reporting and EMA notification|"Participants report emotions and receive EMA (ecological momentary assessment) text messages on the same regular basis as intervention participants, but receive no interventions.~EMA detail:~Ecological Momentary Assessment (EMA) of Emotion throughout the day. We will assess current emotions via email or text message 4 times per day, 2 days per week (one randomly selected week/work day and one randomly selected weekend/non-work day) during the 8 week study period, for a total of 16 days of EMA reporting. Participants will be asked to rate how much they are currently feeling several positive and negative emotions that have been associated with mortality and health: happy, excited, content, appreciative, sad, worried, and fearful."
3084432|NCT01996995|Experimental|Nd:YAG laser pulse therapy|Nd:YAG laser pulse therapy Patients are treated with laser session in week 0, 2, 4, and 12. The settings are; 1064 nm, spot size 3 mm, 20 J /cm2, 5 Hz, power 10 W, pulse duration 132 millisecond. A maximum of two sequential sessions (one session on the horizontal and one the vertical passing) will be applied to eliminate potential safety issues in those patients with a lack protective sensibility.
3084433|NCT01996995|Sham Comparator|Sham|Sham treatment Patients are treated with a sham session in week 0, 2, 4, and 12. The study settings are similar to the laser except the laser beam. Because the patient is also blinded, they can't see the procedure. The sound and the beeps are audible similar to the laser treatment.
3084434|NCT01996982|Experimental|Device|CCS Device application
3084435|NCT01996969|Other|Regorafenib|This study is a single arm study with biomarker analysis
3084436|NCT01996956|Other|Volume loading|
3084437|NCT01996943|Placebo Comparator|Placebo|The placebo will be administered to participants after the baseline electrophysiologic measurements are recorded.
3084438|NCT01996943|Active Comparator|Ethanol|Ethanol (alcohol) will be administered to participants after the baseline electrophysiologic measurements are recorded.
3084439|NCT01996930|Active Comparator|Haelan tape (steroid impregnated tape)|"Haelan tape, medicated tape for cutaneous use, containing 4mcg Fludroxycortide per centimetre squared.~Maximum daily dosage of 0.1mg = 25cm squared per day. Application = once daily and left in situ for 24 hours Maximum duration of treatment = 28 days"
3084440|NCT01996930|Active Comparator|Silver nitrate|Avoca caustic applicator 95% w/w cutaneous stick Cautery with silver nitrate cutaneous stick undertaken twice weekly Maximum duration of treatment = 28 days
3084441|NCT01996917|Active Comparator|Prineo closure|One breast will have skin closure with Prineo.
3084442|NCT01996917|No Intervention|Standard Suture|One breast will be closed in the standard fashion with suture.
3084443|NCT01996904|Experimental|arthroscopic repair|"Lateral-anterosuperior portal (Miracle Portal) was used to repair subscapularis tendon. Bursa anterior to the subscapularis tendon was usually removed for the accurate positioning of the suture-hook. Subscapularis tendon was released, pulled and sutured with suture-hook. One or two suture anchors of Modified Mason-Allen technique was used to secure the tendon."
3084444|NCT01996904|Active Comparator|arthroscopic debridement|Open and arthroscopic cuff debridement procedures have been described in the literatures for management of massive rotator cuff tears; these generally result in decreased pain and overall improvement in patient's function.
3084445|NCT01996891|Other|Anti-Inflammatory Diet First|For the first 6 weeks, subjects will receive the anti-inflammatory diet. For the second 6 weeks, subjects will consume their habitual diet.
3084446|NCT01996891|Other|Anti-Inflammatory Diet Second|For the first 6 weeks, subjects will consume their habitual diet. For the second 6 weeks, subjects will receive the anti-inflammatory diet.
3084447|NCT01996878||Case (Parkinson's disease patients)|Clinical diagnosis of Parkinson's disease (cases are diagnosed by the presence of at least three of the five following primary signs: rest tremor, bradykinesia, rigidity, impaired postural refluxes, and the presence of a sustained L-dopa response.)
3084448|NCT01996878||Control (Healthy volunteers)|Healthy volunteers without Parkinson's disease
3084483|NCT01996657||Standard intensity of anticoagulation|After mechanical valve replacement，patients should be gave oral anticoagulants，such as warfarin.and The intensity of anticoagulation for this group was standard intensity (INR:2.5-3.5).
3084484|NCT01996657||Low intensity and adjusted by elevated D-dimer|The intensity of anticoagulation maintained at low level initiatively, D-dimer testing were analyzed at 3 month later. In case of D-dimer level elevated, adjusted the intensity to standard level.
3084485|NCT01996657||Low intensity without adjustment|The intensity of anticoagulation for this group was kept at low intensity without adjustment (INR:1.8-2.6),
3100899|NCT01886053|Active Comparator|Ertapenem|
3084449|NCT01996865|Experimental|Arm A: Lenalidomide + rituximab followed by lenalidomide|Induction Period (12 cycles): Lenalidomide 20mg (10 mg if creatinine clearance ≥ 30 mL/min but < 60mL/min) by mouth (PO) daily (QD) on Days 1 to 21 of every 28-day cycle during cycles 1 through 12 and rituximab 375mg/m^2 intraveneously (IV) every week in Cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period (lasting 18 Cycles) that includes Lenalidomide 10 mg PO QD on Days 1 to 21 of every 28-day cycle during cycles 13 to 30 and rituximab 375 mg/m^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29 followed by a Maintenance Period (up to Progressive Disease) receiving Lenalidomide 10mg PO QD on Days 1 through 21 of every 28 day cycle until the disease progresses
3084450|NCT01996865|Active Comparator|Arm B: Lenalidomide + rituximab followed by rituximab|Induction Period (12 Cycles): Lenalidomide 20 mg PO QD (10 mg if creatinine clearance ≥ 30 mL/min but < 60 mL/min) on Days 1 to 21 of every 28-day cycle during cycles 1 to 12 and rituximab 375 mg/m^2 IV every week in cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period for 18 Cycles that includes: Rituximab 375 mg/m^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29
3084451|NCT01996852|Active Comparator|Standard ED Care|Standard medical treatment of erectile dysfunction (ED) including administration of sildenafil citrate (Viagra) and/or vacuum constriction devices (pump)
3084452|NCT01996852|Experimental|Standard ED Care + Cognitive-Behavioral Intervention|standard medical treatment of ED (administration of sildenafil citrate (Viagra) and/or vacuum constriction devices (pump)) in addition to cognitive-behavioral meetings
3084453|NCT01996839|Experimental|Loteprednol Etabonate Gel (BID)|Loteprednol Etabonate Gel 0.38% administered two times daily (BID).
3084454|NCT01996839|Active Comparator|Vehicle (BID)|Vehicle of Loteprednol Etabonate Gel 0.38% administered two times daily (BID).
3084455|NCT01996839|Experimental|Loteprednol Etabonate Gel (TID)|Loteprednol Gel 0.38% administered three times daily (TID).
3084456|NCT01996839|Active Comparator|Vehicle (TID)|Vehicle of Loteprednol Etabonate Gel 0.38% administered three times daily (TID).
3084457|NCT01996826|Active Comparator|Avastin® (bevacizumab)|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
3084458|NCT01996826|Placebo Comparator|0.9% NaCl & Refresh Liquigel|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% NaCl. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
3084459|NCT01996813|Experimental|Prospective Case|Patients with a BMI of 30 kg/m^2 or greater who underwent shoulder arthroscopy in the beach chair position and were monitored intraoperatively using near-infrared spectroscopy while wearing thigh-high compression stockings.
3084460|NCT01996813|No Intervention|Historical Control|Patients with a BMI of 30 kg/m^2 or greater who underwent elective shoulder arthroscopy in the beach-chair position and were monitored intraoperatively using near-infrared spectroscopy but without wearing compression stockings.
3084461|NCT01996800|Experimental|Spinal Manipulative Therapy (SMT)|Patients will receive 12 weeks of chiropractic SMT
3084462|NCT01996800|Active Comparator|SMT and Neuromuscular Reeducation|"Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.~A neuromuscular re-education program will consist of repetitive movements, posturing, and stimulation designed to reinforce nerve signals for functional movements. It is theorized that when the nerve signals are retrained and appropriate muscle movements are repeated, movement patterns become automatic again. Neuromuscular re-education is usually done along with other types of treatment to promote functional muscle movement."
3084463|NCT01996787|Active Comparator|Air Optix Aqua|Compare safety and efficacy of the lens using OptiFree Replenish solution
3084464|NCT01996787|Active Comparator|Clariti with Handling Tint|Compare safety and efficacy of the lens using OptiFree Replenish solution
3084465|NCT01996774||Child, peanut/ nut allergy, no treatment|
3084466|NCT01996774||Child, peanut/nut allergy, tolerance|
3084467|NCT01996774||Non allergic child, without atopia|
3084468|NCT01996761|Experimental|Study Group 1|Study Group 1: 30ml Cerebrolysin
3084469|NCT01996761|Placebo Comparator|Study Group 2|Study Group 2: Placebo (0.9% NaCl)
3084470|NCT01996748|Experimental|DF277|Two administrations daily for 7 days
3084471|NCT01996748|Placebo Comparator|Placebo|Two administrations daily for 7 days
3084472|NCT01996735|Active Comparator|Ticagrelor 180 mg single dose|Ticagrelor 180 mg single dose
3084473|NCT01996735|Placebo Comparator|Placebo|Placebo single dose
3084474|NCT01996709|Experimental|Clear Care|Hydrogen peroxide-based contact lens solution used with habitual contact lenses for 90 days
3084475|NCT01996709|Active Comparator|Habitual MPS|Habitual contact lens solution used with habitual contact lenses for 90 days
3084476|NCT01996696|Experimental|Metformin|Metformin 500 mg PO TID x 30-36 months
3084477|NCT01996696|Placebo Comparator|Placebo|Identical placebo TID x 30-36 months
3084478|NCT01996683|Active Comparator|iron chelation|Included 25 thalassemia patients with low serum ferritin (< 500) or downward ferritin trend inspite of reduction of chelation dose over the last 6 months. They will continue their chelation therapy.
3084479|NCT01996683|Placebo Comparator|blood transfusion only|Included 25 thalassemia patients with low serum ferritin (< 500) or downward ferritin trend inspite of reduction of chelation dose over the last 6 months. They will be subjected to discontinuation of their chelation therapy.
3084480|NCT01996670||<2h group|
3084481|NCT01996670||2-4h group|
3084482|NCT01996670||>4h group|
3084488|NCT01996618|Experimental|Ranolazine|Subjects will be consented by the study investigator and then randomly assigned in an allocation-concealed fashion to double blinded treatment with either titrated doses of ranolazine or matched placebo. After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily or matching placebo) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days. When the subject returns the monitor, subjects will enter the washout period (cessation of the study medication) for 6 days and have electrocardiographic monitoring prior to return to the subject's referring provider for care.
3084489|NCT01996618|Placebo Comparator|Placebo|Subjects will be consented by the study investigator and then randomly assigned in an allocation-concealed fashion to double-blinded treatment with either titrated doses of ranolazine or matched placebo. After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily or matching placebo) with the plan to then undergo a repeat 24-hour ambulatory electrocardiographic monitoring in 6 days. When the subject returns the monitor, subjects will enter the washout period (cessation of the study medication) for 6 days and have electrocardiographic monitoring prior to return to the subject's referring provider for care.
3084490|NCT01996605|Experimental|Oxytocin 15 mcg|Oxytocin 15 mcg injected spinally
3084491|NCT01996605|Experimental|Oxytocin 150 mcg|Oxytocin 150 mcg injected spinally
3084492|NCT01996605|Active Comparator|Placebo|Preservative free normal saline injected spinally
3084493|NCT01996592||cesarean section deliveries|those subjects having an elective cesarean section will complete an informed consent form, complete the preoperative questionnaire, and then be contacted for 60 days postoperatively
3084494|NCT01996579|Experimental|Lactoferrin|Patients randomized to the Lactoferrin arm will receive Lactoferrin delivered to the oral cavity as a mouth swab and Lactoferrin down a nasogastric tube; a total of 2 grams administered in 4 divided doses per day.
3084495|NCT01996579|Placebo Comparator|Placebo (sterile water)|Placebo (sterile water) will also be delivered down the nasogastric tube; administered in 4 divided doses per day.
3084496|NCT01996553||Transradial cardiac catheterization|Patients undergoing cardiac catheterization through the radial artery.
3084497|NCT01996540|Experimental|Interventional arm|Interventional arm
3084498|NCT01996540|No Intervention|Standard arm|Standard arm
3084499|NCT01996527|Experimental|3-Tesla magnetic resonance imaging|Patients undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and blood flow (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent) no more than 2 weeks before, and 2 and 4 weeks after, the initiation of treatment.
3084500|NCT01996514|Experimental|Sweetener, non-food advertisements|non-caloric sweetener with water followed by TV program with non-food advertisements while feeding at 30 min
3084501|NCT01996514|Experimental|Glucose, non-food advertisements|Glucose with water followed by TV program with non-food advertisements while feeding at 30 min
3084502|NCT01996514|Experimental|Sweetener, food advertisements|non-caloric sweetener with water followed by TV program with food advertisements while feeding at 30 min
3084503|NCT01996514|Experimental|Glucose, food advertisements|Glucose with water followed by TV program with food advertisements while feeding at 30 min
3084504|NCT01996501|Experimental|Torrent's Olanzapine Orally Disintegrating Tablets 5mg|
3084505|NCT01996488|Experimental|Torrent's Olanzapine Orally Disintegrating Tablets 5mg|
3084506|NCT01996475|Experimental|Torrent's of Escitalopram Oxalate Tablet 20 mg|
3084507|NCT01996462|Experimental|Torrent's of Escitalopram Oxalate Tablet 20 mg|
3084508|NCT01996449|Active Comparator|Initial treatment with Amlodipine|The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 8 weeks. Following the 8 week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
3084509|NCT01996449|Active Comparator|Initial treatment with Eplerenone|The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 8 weeks. Following the 8 week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
3084510|NCT01996436|Active Comparator|Nicardipine|Group 1 : Nicardipine 5mg per circulation intra-arterial injection, Pharmacological angioplasty
3084511|NCT01996436|Active Comparator|Verapamil|Group 3: Verapamil 10mg per circulation intra-arterial injection, Pharmacological angioplasty
3084512|NCT01996436|Active Comparator|Nicardipine + Verapamil + Nitroglycerin|Group 4 : Nicardipine 5mg + Verapamil 10mg + Nitroglycerin 200mcg in 4cc 5 % dextrose in water , intra-arterial injection, Pharmacological angioplasty
3084513|NCT01996423|Experimental|Vitamin D3 supplementation|Subjects in the experimental arm will receive weekly vitamin D3 doses in oral suspension during 6 weeks. Weekly dose varies according to age group: VD3 8000 IU between ages 2-5.9 years, VD3 12000 IU between ages 6-11.9 years, VD3 16000 IU between ages 12-17.9 years.
3084514|NCT01996423|Placebo Comparator|Placebo|Subjects in the placebo arm will receive weekly placebo oral suspension during 6 weeks.
3084515|NCT01996410|Active Comparator|Chemotherapy 1 Acupuncture|"Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms."
3084535|NCT01996319|Active Comparator|Treatment sequence I|QVA149 once a day during 21 days cross-over to placebo once a day for up to 21 days
3084516|NCT01996410|Active Comparator|Chemotherapy 2 Acupuncture|"Chemotherapy 2: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) on day 1 every 2 weeks for 4 cycles followed by Taxol (80mg/m2) on day 1 weekly for 12 cycles. Patients who randomize to the experimental (acupuncture) group will undergo acupuncture the morning of every treatment day of the adriamycin/cytoxan cycles; they will receive acupuncture for every third Taxol treatment, beginning with the first treatment. They will receive a total of 8 acupuncture sessions: 4 with the adriamycin/cytoxan cycles and 4 with the Taxol cycles. Both groups will fill out MDASI on day 3 (+/- 1 days) of each Adriamycin/Cytoxan cycle; they will also fill out the MDASI on day 3 (+/- 1 days) of every third Taxol treatment for a total of 8 MDASI forms."
3084517|NCT01996410|Active Comparator|Chemotherapy 3 Acupuncture|"Chemotherapy 3: In the adjuvant setting- This group will receive Taxotere (75mg/m2) and Cytoxan (600 mg/m2) on day 1 every 3 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Cytoxan for a total of 4 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 4 MDASI forms."
3084518|NCT01996410|Active Comparator|Chemotherapy 4 Acupuncture|"Chemotherapy 4: In the neoadjuvant setting- This group will receive Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose) day 1 every 3 weeks for 6 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Carboplatin/Perjeta treatment for a total of 6 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 6 MDASI forms."
3084519|NCT01996410|No Intervention|Chemotherapy 1 No Acupuncture|"Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms."
3084520|NCT01996410|No Intervention|Chemotherapy 2 No Acupuncture|"Chemotherapy 2: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) on day 1 every 2 weeks for 4 cycles followed by Taxol (80mg/m2) on day 1 weekly for 12 cycles. Patients who randomize to the experimental (acupuncture) group will undergo acupuncture the morning of every treatment day of the adriamycin/cytoxan cycles; they will receive acupuncture for every third Taxol treatment, beginning with the first treatment. They will receive a total of 8 acupuncture sessions: 4 with the adriamycin/cytoxan cycles and 4 with the Taxol cycles. Both groups will fill out MDASI on day 3 (+/- 1 days) of each Adriamycin/Cytoxan cycle; they will also fill out the MDASI on day 3 (+/- 1 days) of every third Taxol treatment for a total of 8 MDASI forms."
3084521|NCT01996410|No Intervention|Chemotherapy 3 No Acupuncture|"Chemotherapy 3: In the adjuvant setting- This group will receive Taxotere (75mg/m2) and Cytoxan (600 mg/m2) on day 1 every 3 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Cytoxan for a total of 4 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 4 MDASI forms."
3084522|NCT01996410|No Intervention|Chemotherapy 4 No Acupuncture|"Chemotherapy 4: In the neoadjuvant setting- This group will receive Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose) day 1 every 3 weeks for 6 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Carboplatin/Perjeta treatment for a total of 6 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 6 MDASI forms."
3084523|NCT01996397|Other|CRT implantation|Standard CRT indication. Assessment of acute response to CRT.
3084524|NCT01996384|Experimental|Classical Acupuncture + Lidocaine|Study participants will attend 18 classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area based on up to three Traditional Chinese Medicine Diagnosis categories. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).
3084525|NCT01996384|Active Comparator|Non-classical acupuncture + lidocaine|Study participants will attend 18 non-classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with non-classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).
3084526|NCT01996371|Other|Group 1|Unilateral pedicle screws
3084527|NCT01996371|Other|Group 2|Ipsilateral pedicle screws, contralateral facet screw
3084528|NCT01996371|Other|Group 3|Bilateral pedicle screws
3084529|NCT01996358|Active Comparator|Succinylcholine|Succinylcholine 0,5mg/kg as muscle relaxant during induction of anaesthesia for rigid bronchoscopy
3084530|NCT01996358|Active Comparator|Rocuronium 0,3|Rocuronium 0,3 mg/kg during induction of anaesthesia for rigid bronchoscopy. At the end of procedure 2mg/kg sugammadex for reversal of neuromuscular block are applied.
3084531|NCT01996358|Active Comparator|Rocuronium 0,6|Rocuronium 0,6 mg/kg during induction of anaesthesia for rigid bronchoscopy. At the end of procedure 2mg/kg sugammadex for reversal of neuromuscular block are applied.
3084532|NCT01996345|Experimental|Cervical Pessary Placement|For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
3084533|NCT01996345|No Intervention|Expectant Managment|Each participant will have standard care for placenta previa. This is the same care that a patient with a placenta previa would ordinarily receive even if she were not participating in the trial. The trial's participating investigators agree that the management outlined in this section is standard management for placenta previa.
3084534|NCT01996332|Experimental|Tarceva Arm|
3084536|NCT01996319|Active Comparator|Treatment sequence II|Placebo once a day during 21 days cross-over to QVA149 once a day for 21 days
3084537|NCT01996306|Active Comparator|FOLFIRI +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1 CPT-11 180 mg/m2 (150 mg/m2) IV 90 min Day 1 l-LV (dl-LV) 200 mg/m2 (400 mg/m2) IV 120 min Day 1 5-FU - bolus 400 mg/m2 IV bolus Day 1 5-FU - infusional 2400 mg/m2 IV continuous (46 hours) Day 1 - 3
3084538|NCT01996306|Experimental|XELIRI +/- Bevacizumab|Bevacizumab 7.5 mg/kg IV 90-30 min Day 1 CPT-11 200 mg/m2 (150 mg/m2) IV 90 min Day 1 Capecitabine 800 mg/m2 p.o. twice daily 14 Days consecutively
3084539|NCT01996293||Lamotrigine for Bipolar|antepartum and peripartum women taking lamotrigine for Bipolar Disorder
3084540|NCT01996280|Placebo Comparator|Motivational Interviewing|The MI is a single brief motivational intervention lasting 1.5 hours that includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan. The MI is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.
3084541|NCT01996280|Experimental|Culturally Tailored MI|The CTMI is a single brief motivational interview lasting 1.5 hours. It follows the same sequence of structured strategies as the MI, but the focus of the components is different. CTMI has augmented some of the components with culturally relevant material, including discussion about acculturation stress. The CTMI components are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback elements in the CTMI, such as ethnic normative feedback about drinking. To control for time across conditions, interventionists are instructed to select CTMI components based on participant interests, not the entire array of components.
3084542|NCT01996267|Active Comparator|FEC-T +Pertuzumab|Fluorouracil; 500 mg/m2; day 1 Epirubicine; 90 mg/m2; day 1 Cyclophosphamide; 500 mg/m2; day 1 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg) Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle is repeated every 21 days
3084543|NCT01996267|Active Comparator|PTC+Pertuzumab|Paclitaxel; 80 mg/m2; day 1,8 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1 Carboplatin; AUC=6; day 1 Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle repeated every 21 days
3084544|NCT01996254|Experimental|SPRINT Group 1|Subjects in Group 1 will have a Lead placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
3084545|NCT01996254|Sham Comparator|SPRINT Group 2|Subjects in Group 2 will have a Lead placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System for a total of 8 weeks. They will receive 4 weeks of stimulation and 4 weeks with no stimulation.
3084546|NCT01996241|Experimental|Educational enhancement intervention|Receive educational enhancement intervention
3084547|NCT01996241|No Intervention|No eduational enhancement intervention|No educational enhancement intervention
3084548|NCT01996228|Experimental|Cord Blood-derived multipotent stem cells|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations in patients.
3084549|NCT01996215||AMD controls|
3084550|NCT01996215||AMD cases|
3084551|NCT01996202|Other|Resected Melanoma|Subjects with resected melanoma.
3084552|NCT01996202|Other|Unresected Melanoma|Subjects with unresected melanoma.
3084553|NCT01996189|Experimental|Insulin|Arterial puncture with an insulin syringe followed by arterial puncture with standard needle.
3084554|NCT01996189|Active Comparator|Standard|Arterial puncture with standard needle followed by arterial puncture with insulin syringe.
3084555|NCT01996176|Experimental|Intervention group|Intervention group
3084556|NCT01996176|Placebo Comparator|Intervention control|Control group
3084557|NCT01996163||Male|
3084558|NCT01996163||Female|
3084559|NCT01996150|Experimental|Dilute bleach bath|Subjects will take a diluted bleach bath (0.005% Sodium hypochlorite) for 5-10 minutes twice a week for 12 weeks.
3084560|NCT01996137|Experimental|VASST II|Stroke patients selected to undergo VASST II treadmill training for 60 minutes
3084561|NCT01996124|Experimental|Indacaterol|Indacaterol Fumarate 150 mcg Breezehaler,Onbrez Novartis International AG, Basel Switzerland. Once daily.
3084562|NCT01996124|Placebo Comparator|Placebo|Placebo Breezehaler
3084563|NCT01996111|Experimental|• Group 2:|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension
3084564|NCT01996111|Experimental|• Group 3:|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension
3084565|NCT01996111|Experimental|• Group 4:|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension
3084566|NCT01996111|Placebo Comparator|• Group 1|• Injection of 1.0 cc of 0.9% Saline
3084567|NCT01996098|Experimental|6-month icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 6 months
3084568|NCT01996098|Experimental|12-month icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months
3084569|NCT01996098|No Intervention|Chemotherapy alone|No intervention
3084570|NCT01996085|Experimental|Hemodynamic group|"The treatment choice based on hemodynamic parameters established with ICG method.~Monotherapy or combined therapy in case of 1/ complex hemodynamic disturbances and/or 2/ office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg"
3084571|NCT01996085|Active Comparator|Empiric Group|"The treatment choice based on current guidelines (blinded to ICG).~Monotherapy or combined therapy in case of office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg"
3084572|NCT01996072|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
3084573|NCT01996059|Experimental|Functional Jejunal Interposition|First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
3100900|NCT01886053|Experimental|Faropenem（low-dose group)|
3084574|NCT01996059|Active Comparator|Roux-en-Y|The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
3084575|NCT01996046||Bone mets|Patients will undergo an [18F] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
3084576|NCT01996007||Children|Pneumococcal nasopharyngeal carriage and immunogenicity in children aged 13-48 months who have previously received PCV13
3084577|NCT01996007||Parents|Pneumococcal nasopharyngeal carriage and immunogenicity in parents of children also participating in the study
3084578|NCT01995994||RT-CGM|
3084579|NCT01995981||Advanced soft tissue sarcoma patients|Advanced soft tissue sarcoma patients, who have an indication for pazopanib treatment.
3084580|NCT01995968||SGA stillbirths (Cases)|Stillbirths, SGA births (below the 10th percentile of French customised birthweight curves), born in 2012-13, at or after 24 completed weeks of gestational age, without lethal congenital anomalies, to mothers residents in Isère, Savoie or Haute-Savoie
3084581|NCT01995968||SGA livebirths (Controls)|Livebirths, SGA births (below the 10th percentile of French customised birthweight curves), born in 2013, at or after 24 completed weeks of gestational age, without lethal congenital anomalies, to mothers residents in Isère, Savoie or Haute-Savoie
3084582|NCT01995955|Experimental|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
3084583|NCT01995942||Group 1|Patients with mrEMVI positive rectal cancer
3084584|NCT01995942||Group 2|Patients with mrEMVI negative rectal cancer
3084585|NCT01995929||neurogenic dysphagia|Patients suffering from neurogenic dysphagia due to several reasons (e.g. Parkinson´s disease).
3084586|NCT01995916|Experimental|Mindfulness Intervention|Mindfulness Based Stress Reduction Intervention
3084587|NCT01995916|Active Comparator|Social Support Group|Social Support Group Intervention
3084588|NCT01995903|Experimental|Amyotrophic lateral sclerosis|Clinical examination for ALS(amyotrophic lateral sclerosis) and subjects with lower motor neuron signs will be completed. These subjects will undergo MRI (magnetic resonance imaging) scans of the brain to assess neurological conditions.
3084589|NCT01995903|Active Comparator|Healthy controls (MRI)|These subjects will undergo MRI (magnetic resonance imaging) scans of the brain to compare against diseased subjects.
3084590|NCT01995890|Experimental|nepafenac|Nepafenac 0.1% eye drops, 3 times a day
3084591|NCT01995890|No Intervention|control|No intervention in the control arm
3084592|NCT01995877||Subjects scheduled for IVC filter placement|A filter may be needed to be placed in the IVC (inferior vena cava) to prevent blood clots from traveling from legs to lungs. Patients who have had a pelvic fracture, or have blood clots in the leg(s) may need an IVC. Filter placement may be ordered when a patient is scheduled for major surgery and extensive bed rest.
3084593|NCT01995864|Experimental|CTI-TS|CTI-TS is a time-limited, 9-month long intervention, provided at the critical time when a person is first offered services at a mental health clinic, or, at the similarly critical time when a person first seeks to reconnect with a mental health clinic after a long lapse.
3084594|NCT01995864|No Intervention|Usual Care|The Usual Care group will receive mental health services as provided by the local mental health services clinic.
3084595|NCT01995851||Intervention (LAIV)|Healthy children and adolescents between Junior Kindergarten (JK) and Grade 8 in the intervention schools will be immunized with LAIV (FluMist influenza vaccine) recommended for the 2013-14 the influenza season.
3084596|NCT01995851||Control (TIV)|Healthy children and adolescents between JK and Grade 8 in schools assigned to TIV will be immunized with inactivated influenza vaccine (Vaxigrip vaccine) recommended for the 2013-14 influenza season.
3084597|NCT01995838|Experimental|E2006|E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
3084598|NCT01995838|Placebo Comparator|Placebo|E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
3084599|NCT01995825|Active Comparator|brand tablet: initial exposure|brand name lamotrigine tablet
3084600|NCT01995825|Experimental|generic: initial exposure|generic lamotrigine tablet
3084601|NCT01995825|Active Comparator|brand tablet: second exposure|brand name lamotrigine tablet
3084602|NCT01995825|Experimental|generic: second exposure|generic lamotrigine tablet
3084603|NCT01995812|Experimental|Hula and heart health education|12 weeks of hula classes, 2 times a week for one hour. An additional 3 hours of heart health education was given to participants
3084604|NCT01995812|No Intervention|Control group|
3084605|NCT01995799|Experimental|USPIO timepoint 2-4 days|USPIO given 2-4 days post MI Ferumoxytol enhanced MRI
3084606|NCT01995799|Experimental|USPIO timepoint 5-7 days|USPIO given 5-7 days post MI Ferumoxytol enhanced MRI
3084607|NCT01995799|Experimental|USPIO tiempoint 11-21 days|USPIO given 11-21 days post MI Ferumoxytol enhanced MRI
3084608|NCT01995786|No Intervention|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour
3084609|NCT01995786|Experimental|GDT|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 2,5 ml/kg/h and boluses of crystalloids for values of stroke volume (SV) < SV TRIGGER. Every additional infusion of colloids, blood derivates, drugs must be recorded
3084610|NCT01995773||Healthy Controls|Healthy control women
3084611|NCT01995721|Experimental|4-valent HPV vaccine|4-valent HPV vaccine administered in months 0., 2., 6.
3084612|NCT01995708|Experimental|Arm 1 Vaccine|This is a prospective, two-arm phase I randomized trial. Patients will be accrued only from and treated at MSKCCand The Rockefeller University/Center for Clinical & Translational Science . The study will assess autologous LCs presenting CT7, MAGE-A3, and WT1 after electroporation with CT7, MAGE-A3, and WT1 mRNA. Twenty patients will accrue to the study and ten will receive vaccines at 9x10^6 LCs per dose (i.e., combination of 3x10^6 CT7 mRNA-electroporated LCs + 3x10^6 MAGE-A3 mRNA-electroporated LCs + 3x10^6 WT1 mRNA-electroporated LCs) and another ten who will not receive any LC vaccines but will otherwise undergo identical cytoreduction, ASCT, and standard supportive care. At approximately 3 months after ASCT and as deemed clinically appropriate, patients will start lenalidomide maintenance therapy, which is now standard to delay disease progression.
3084613|NCT01995708|Active Comparator|Arm 2 control|Patients receive standard of care treatment after autologous stem cell transplant
3084614|NCT01995695|Experimental|Group 1: One Vaccine Dose and One Booster Vaccine Dose|Participants will receive one dose of live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine at study entry. They will then receive one dose of inactivated subvirion H7N9 influenza vaccine on Day 98.
3084615|NCT01995695|Experimental|Group 2: Two Vaccine Doses and One Booster Vaccine Dose|Participants will receive two doses of live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine: one dose at study entry and one dose on Day 28. They will then receive one dose of inactivated subvirion H7N9 influenza vaccine on Day 98.
3084616|NCT01995669|Experimental|Relapsed/Refractory Indolent Lymphoma Group|"Phase I: Lenalidomide starting dose of 10 mg taken orally in the morning each day on days 2 - 22, followed by 6 days of no therapy of each 28-day cycle.~Phase I: Obinutuzumab (GA101) 1000 mg given by vein on day 1, 2, 8, and 15 of cycle one and on day 1 of each subsequent cycle up to 6 cycles. Obinutuzumab given in divided doses on cycle 1; 100 mg by vein on day 1, and 900 mg by vein on day 2, subsequent doses given over 1 day."
3084617|NCT01995669|Experimental|Cohort B - Non-Follicular Indolent Lymphoma|"Phase II: Lenalidomide capsules taken orally daily each day on days 2 - 22, followed by 6 days of no therapy of each 28-day cycle at the MTD tolerated in Phase I.~Phase II: Participants with diagnosis of small lymphocytic lymphoma (SLL) begin cycle #1 at a maximum dose of Lenalidomide 10 mg total on days 2 to 22 of a 28 day cycle. Dose escalated by 5 mg each cycle up to MTD if no toxicity is encountered.~Phase II: Obinutuzumab (GA101) 1000 mg given by vein on day 1 every 2 months for 2 years."
3084618|NCT01995669|Experimental|Cohort A - Relapsed/Refractory Follicular Lymphoma|"Phase II: Lenalidomide capsules taken orally daily each day on days 2 - 22, followed by 6 days of no therapy of each 28-day cycle at the MTD tolerated in Phase I.~Phase II: Obinutuzumab (GA101) 1000 mg given by vein on day 1 every 2 months for 2 years."
3084619|NCT01995656|Placebo Comparator|Placebo - Healthy|Part A. Healthy participants will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.
3084620|NCT01995656|Experimental|LY3108743 - Healthy|Part A. Healthy participants will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
3084621|NCT01995656|Placebo Comparator|Placebo - Diabetes|Part B. Participants with diabetes mellitus will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.
3084622|NCT01995656|Experimental|LY3108743 - Diabetes|Part B. Participants with diabetes mellitus will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
3084623|NCT01995656|Placebo Comparator|Placebo - Solution|Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of placebo matching LY3108743 in 1 of 2 study periods.
3084624|NCT01995656|Experimental|LY3108743 - Solution|Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of LY3108743 in 1 of 2 study periods.
3084625|NCT01995643|Active Comparator|Active Capsule|Grape Seed Extract Capsule: 300 mg
3084626|NCT01995643|Placebo Comparator|Placebo Capsule|Placebo Capsule: Maltodextrin
3084627|NCT01995630|Experimental|Hypermetropic, spherical IOL|AMO Sensar AR40e
3084628|NCT01995630|Experimental|Hypermetropic, aspheric IOL|AMO Tecnis ZA9003
3084629|NCT01995630|Active Comparator|Emmetropic, spherical IOL|AMO Sensar AR40e
3084630|NCT01995630|Active Comparator|Emmetropic, aspheric IOL|AMO Tecnis ZA9003
3084631|NCT01995617|Experimental|Low Dose (Cohort 1)|
3084632|NCT01995617|Experimental|Mid Dose (Cohort 2)|
3084633|NCT01995617|Experimental|High Dose (Cohort 3)|
3084634|NCT01995604|Experimental|dHACM|UltraPulse laser therapy with application of dHACM
3084635|NCT01995604|Placebo Comparator|Sterile 0.9% Saline Solution|UltraPulse laser therapy with application of Sterile 0.9% Saline Solution
3084636|NCT01995578|Experimental|low dose 5'-azacitidine|This is a single arm phase II trial to assess the efficacy and confirm the safety of maintenance therapy with 5'-azacitadine compared to historical control after TCD allogeneic hematopoietic stem cell transplant for patients with MDS and AML who are at high risk of relapse.
3084637|NCT01995552|Other|External Loop Recorder|This is a non-randomized study. All the patients will be enrolled will received the ELR system.
3084638|NCT01995539|Other|iPro2 Use|
3084639|NCT01995526|Experimental|Insulin Peglispro|Insulin peglispro is given subcutaneously once.
3084640|NCT01995513|Experimental|Enzalutamide & Abiraterone/prednisone|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily
3084641|NCT01995513|Active Comparator|Enzalutamide placebo & Abiraterone/prednisone|Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily.
3084642|NCT01995500|Experimental|BioNIR|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~Ridaforolimus drug - CAS Registry Number: 572924-54-0 The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
3084643|NCT01995500|Active Comparator|Resolute|"The Endeavor Resolute Zotarolimus-Eluting Coronary Stent System consists of four subsystems:~Endeavor Resolute Stent - a premounted cobalt alloy based stent~Delivery system - Rapid Exchange (RX) Coronary System~Polymer system~Zotarolimus - drug The Resolute has a nominal drug dose of 1.6 µg zotarolimus per mm2 of the stent surface area."
3084644|NCT01995487|Experimental|BioNIR|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~Ridaforolimus drug - CAS Registry Number: 572924-54-0~The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
3084813|NCT01994434|Other|Decompression of the ulnar nerve|Surgical decompression of the Guyon's canal and ganglion excision
3084645|NCT01995487|Active Comparator|Resolute|"The Endeavor Resolute Zotarolimus-Eluting Stent System consists of four subsystems:~Endeavor Resolute Stent- a pre-mounted cobalt alloy based stent~Delivery system (Rapid Exchange [RX] Coronary System)~Polymer system~Zotarolimus - drug The Resolute has a nominal drug dose of 1.6µg Zotarolimus per mm2 of the stent surface area."
3084646|NCT01995474|Experimental|Twisted Syringe|briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
3084647|NCT01995474|Active Comparator|Conventional Technique|syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
3084648|NCT01995461|Experimental|BTESI|a prospective, non-randomized, case series investigating bilateral transforaminal epidural steroid injections (BTESI)
3084649|NCT01995448||SEPSIS Blood test|Patient with two criteria of systemic inflammatory response syndrome and a progressive infection which is clinically or microbiologically documented.
3084650|NCT01995435|Experimental|Telemedicine refraction before traditional refraction|We will first refract an individual using telemedicine refraction, and then refract them using a traditional refraction method.
3084651|NCT01995435|Experimental|Traditional refraction before telemedicine refraction|We will first refract an individual using a traditional refraction, and then refract them using a telemedicine refraction method.
3084652|NCT01995422|Experimental|Physical activity program|A 5-month follow-up including a 3-month period of supervised physical activity
3084653|NCT01995396|Active Comparator|APE with intersphincteric dissection|Abdominoperineal excision with intersphincteric dissection and a stoma is performed in patients with rectal cancer and fecal incontinence and/or severe co-morbidity
3084654|NCT01995396|Active Comparator|Hartmann´s procedure|Hartmann´s operation and stoma is performed in patients with rectal cancer and fecal incontinence and/or severe co-morbidity
3084655|NCT01995383|Placebo Comparator|Part 1: Placebo (PL)|
3084656|NCT01995383|Experimental|Part 1: Single Ascending Doses (SAD) of RO6836191|
3084657|NCT01995383|Placebo Comparator|Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet|
3084658|NCT01995383|Placebo Comparator|Part 2: PL: NS followed by LS diet|
3084659|NCT01995383|Experimental|Part 2: RO6836191: LS followed by NS diet|
3084660|NCT01995383|Experimental|Part 2: RO6836191: NS followed by LS diet|
3084661|NCT01995370|Active Comparator|Monotherapy group|"Aspirin (81mg or 100mg) or clopidogrel (50mg or 75mg) will be orally administered once daily.~The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject."
3084662|NCT01995370|Experimental|DAPT group|"Cilostazol (100mg twice daily) will be orally administered in combination with aspirin (81 or 100mg once daily) or clopidogrel (50 or 75mg once daily).~The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject."
3084663|NCT01995357|Experimental|First Coloplast Teast A; then Coloplast Test B|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test A; Coloplast Test B; Standard product; Training + Coloplast Test A; Training + Coloplast Test B"
3084664|NCT01995357|Experimental|First Coloplast Test A; Then Standard product|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test A; Standard product; Coloplast Test B; ; Training + Coloplast Test A; Training + Coloplast Test B"
3084665|NCT01995357|Experimental|First Coloplast Test B; Then Colopast Test A|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test B; Coloplast Test A; Standard product; Training + Coloplast Test B; Training + Coloplast Test A"
3084666|NCT01995357|Experimental|First Coloplast Test B; Then Standard product|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test b; Standard product; Coloplast Test A; Training + Coloplast Test B; Training + Coloplast Test A"
3084667|NCT01995357|Experimental|First Standard product; Then Coloplast Test A|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Standard product; Coloplast Test A; Coloplast Test B; ; Training + Coloplast Test A; Training + Coloplast Test B"
3084668|NCT01995357|Experimental|First Standard Product, Then Coloplast test B|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Standard product; Coloplast Test B; Coloplast Test A; ; Training + Coloplast Test B; Training + Coloplast Test A"
3084669|NCT01995344|Active Comparator|ARM A: High Dose Interleukin-2 (HD IL2)|Eligible participants will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Participants will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused on day 0 and the patients will receive up to 12 doses of intravenous HD IL2
3084670|NCT01995344|Active Comparator|ARM B: Low Dose Interleukin-2 (LD IL2)|Eligible participants will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Participants will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused on day 0 and the patients will receive up to 12 doses of intravenous LD-IL2
3084671|NCT01995331|Other|moderate-dose cyclophosphomide|
3084672|NCT01995318|Placebo Comparator|Elastic bandage|Elastic bandage application as one of routine treatment choice of acute ankle sprains.
3084673|NCT01995318|Other|Kinesiotaping|Application of anti-edema kinesiotaping
3084674|NCT01995292|Experimental|bronchoscope|Patients will receive local anaesthetics via the working channel of the bronchoscope.
3084675|NCT01995292|Experimental|Enk Fiberoptic Atomizer|Patients will receive local anaesthetics for the awake fiberoptic intubation via the Enk Fiberoptic Atomizer.
3084676|NCT01995279|Experimental|French ear acupuncture|Application of single session of French ear acupuncture at specific points used to reduce low back pain.
3084677|NCT01995279|Placebo Comparator|Sham Ultrasound|Sham ultrasound will be applied at lumbar spine.
3084678|NCT01995266|Experimental|Asunaprevir + Daclatasvir|"Asunaprevir 100mg soft capsule by mouth twice daily for 24 weeks and~Daclatasvir 60mg tablet by mouth once daily for 24 weeks"
3084679|NCT01995253|Experimental|Controlled conditions|
3084680|NCT01995253|Experimental|Free-living conditions|
3084681|NCT01995240|Experimental|Optimization|For optimization of the protocol patients will undergo one DCE-MRI (Gadobutrol), T2* MRI and DWI MRI scan.
3084682|NCT01995240|Experimental|Reproducibility|For determination of the reproducibility patients will undergo two DCE-MRI (Gadobutrol), T2* MRI and DWI MRI scans within one week.
3084683|NCT01995227|Experimental|AlloVax Treatment|Intradermal injection (ID) of AlloStim(TM) (1ml) on day 4 and 7. AlloVax Treatment: ID injection of AlloSim(TM) (1 ml) followed immediately by the ID injection of CRCL (1ml) on day 11 and 14 in same location on the left arm and on day 18 and 21 in the same location on the right arm. Intravenous infusion of AlloStim(TM)(5ml) and a CRCL alone Intradermal injection on Day 27.
3084684|NCT01995214|Experimental|P|Anesthesia maintenance with propofol+remifentanil
3084685|NCT01995214|Experimental|S|Anesthesia maintenance with sevoflurane+remifentanil
3084686|NCT01995201|Experimental|Part 1: All patients|
3084687|NCT01995201|Experimental|Part 2 A: Sustained clinical remission|
3084688|NCT01995201|Experimental|Part 2 B: Low disease activity|
3084689|NCT01995188|Experimental|Dose Escalation Cohort: DNIB0600A+Carboplatin|DNIB0600A at an initial dose of 1.2 milligrams per kilogram (mg/kg) will be administered via intravenous (IV) infusion further following a dose-escalation until DLT under consultation of the investigator in combination with Carboplatin fixed dose of area under the curve (AUC)=6 mg/milliliter(mL)*minute (min) administered by IV infusion on Day 1 of a 21-day cycle.
3084690|NCT01995188|Experimental|NSCLC Dose Expansion Cohort: DNIB0600A+Carboplatin|Recommended phase 2 dose (RP2D) of DNIB0600A administered via IV infusion in combination with Carboplatin, AUC=6 mg/mL*min administered via IV infusion on Day 1 of each 21-day cycle in participants with NSCLC until disease progression or death, whichever occurs first.
3084691|NCT01995188|Experimental|PSOC Dose Expansion Cohort: DNIB0600A+Carboplatin|RP2D of DNIB0600A administered via IV infusion in combination with AUC=6 mg/mL*min administered via IV infusion on Day 1 of each 21-day cycle in participants with PSOC until disease progression or death, whichever occurs first.
3084692|NCT01995188|Experimental|PSOC Dose Expansion Cohort: DNIB0600A+Carboplatin+Bevacizumab|RP2D of DNIB0600A administered via IV infusion in combination with Carboplatin, AUC=6 mg/mL*min and Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle in participants with PSOC until disease progression or death, whichever occurs first.
3084693|NCT01995175|Other|Prospective Cohort|Newborn subjects followed up for LRTI symptoms from birth until they are 2 years of age and for incidence of wheeze and asthma up to 6 years of age.
3084694|NCT01995162|Experimental|Free-living conditions|
3084695|NCT01995149|Experimental|Weight loss and dietary intervention|The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
3084696|NCT01995136|Experimental|TRAVATAN Z|Travoprost Ophthalmic Solution 0.004%, 1 drop instilled in each eye once daily at 9PM for 3 months.
3084697|NCT01995123|Experimental|Behavioral Activation Therapy|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding. In addition, this arm will receive standard smoking cessation therapy, nicotine patch, and either nicotine gum or nicotine lozenge.
3084698|NCT01995123|Active Comparator|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health. In addition, this arm will receive standard smoking cessation therapy, nicotine patch, and either nicotine gum or nicotine lozenge.
3084699|NCT01995110|Experimental|normal weight subjects|
3084700|NCT01995110|Experimental|obese subjects|
3084701|NCT01995097|Experimental|SGR + Support Messages|scheduled gradual reduction text messages for first 3-5 weeks of participation; support text messages through 35th week of pregnancy
3084702|NCT01995097|Active Comparator|Support Messages Only|support text messages through 35th week of pregnancy
3084703|NCT01995084|Experimental|Optimization|Patients undergo a [F-18]HX4 PET/CT scan 2,3 and 4h after [F-18]HX4 injection.
3084704|NCT01995084|Experimental|Reproducibility|Patients undergo two [F-18]HX4 PET/CT scans 3.5h after [F-18]HX4 injection within a 10-day time frame.
3084705|NCT01995071|Experimental|Arm 1 Non-cirrhotic|ABT-493 Dose A (100 mg once daily [QD]) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3084706|NCT01995071|Experimental|Arm 2 Non-cirrhotic|ABT-493 Dose B (400 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3084707|NCT01995071|Experimental|Arm 3 Non-cirrhotic|ABT-493 Dose C (700 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3084810|NCT01994460|Experimental|Arm 3 (experimental arm 2)|Isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and linezolid (600 mg/day, 4 weeks)
3084708|NCT01995071|Experimental|Arm 4 Non-cirrhotic|ABT-493 Dose D (200 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3084709|NCT01995071|Experimental|Arm 5 Compensated cirrhotic|ABT-493 Dose E (200 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3084710|NCT01995071|Experimental|Arm 6 Non-cirrhotic|ABT-530 Dose A (15 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3084711|NCT01995071|Experimental|Arm 7 Non-cirrhotic|ABT-530 Dose B (120 mg QD) for 3 days,followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3084712|NCT01995071|Experimental|Arm 8 Non-cirrhotic|ABT-530 Dose C (400 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3084713|NCT01995071|Experimental|Arm 9 Non-cirrhotic|ABT-530 Dose D (40 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3084714|NCT01995071|Experimental|Arm 10 Compensated cirrhotic|ABT-530 Dose E (120 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3084715|NCT01995071|Experimental|Arm 11 Non-cirrhotic|ABT-493 Dose F (300 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3084716|NCT01995071|Experimental|Arm 12 Non-cirrhotic|ABT-530 Dose F (≤ 400 mg) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3084717|NCT01995058|Experimental|Cabozantinib arm 1|Subjects randomized to this arm will receive cabozantinb 40 mg daily with abiratarone and prednisone
3084718|NCT01995058|Experimental|Cabozantinib arm 2|Subjects randomized to this arm will receive cabozantinib 20 mg daily with abiraterone and prednisone
3084719|NCT01995058|Experimental|Cabozantinib arm 3|Subjects randomized to this arm will receive cabozantinb 20 mg every other day with abiraterone and prednisone
3084720|NCT01995058|Active Comparator|Abiraterone only arm (4)|Subjects randomized to this arm will receive abiraterone with prednisone only
3084721|NCT01995045|Experimental|Bupivicaine & Triamcinolone|Retrobulbar anesthesia with Bupivicaine Hydrochloride and Triamcinolone Acetonide
3084722|NCT01995045|Active Comparator|Bupivicaine|Retrobulbar anesthesia with Bupivicaine Hydrochloride
3084723|NCT01995032|Experimental|750 mg metformin and 7.5 g L-citrulline daily p.o.|7.5 g L-citrulline p.o. and 750 mg metformin daily p.o. (3x 2.5 g, respectively 3x 250 mg) for 26 weeks
3084724|NCT01995032|Placebo Comparator|Placebo|metformin placebo and L-citrulline placebo 3 times daily p.o. for 26 weeks
3084725|NCT01995019|Placebo Comparator|Physiologic saline|Sodium chloride 9 mg/ml liquid for parental use
3084726|NCT01995019|Experimental|Methylprednisolone|Depo-Medrol 40 mg/ml, single dose, injection, intra-articular
3084727|NCT01995006|Experimental|Metamizole|Metamizole 1000mg TID Day 1 till Day 7
3084728|NCT01995006|Active Comparator|Naproxen|Naproxen 500 mg BID Day 1 till Day 7
3084729|NCT01994993|Active Comparator|Group 1 (ampicillin +gentamycin +metronidazole)|Ampicillin and gentamycin and metronidazole
3084730|NCT01994993|Active Comparator|Group 2 (ampicillin +gentamicin+clindamycin)|ampicillin and gentamicin and clindamycin
3084731|NCT01994993|Active Comparator|Group 3 (piperacillin-tazobactam and gentamicin)|piperacillin-tazobactam and gentamicin
3084732|NCT01994993|Active Comparator|Group 4 (metronidazole)|Per standard of care antibiotics, and Metronidazole
3084733|NCT01994993|Active Comparator|Group 5 (metronidazole/clindamycin/piperacillin-tazobactam)|metronidazole, clindamycin, or piperacillin-tazobactam
3084734|NCT01994980|Active Comparator|Default 4 days antibiotic therapy|Default 4 days antibiotic therapy
3084735|NCT01994980|No Intervention|Default 8 days antibiotic therapy|Default 8 days antibiotic therapy
3084736|NCT01994967|Experimental|Levobupivacaine|"Presentation: injectable solution - ampoule of Levobupivacaine Hydrochloride~Indication: production of subarachnoid block (spinal/ spinal anesthesia)."
3084737|NCT01994967|Active Comparator|Bupivacaine|"Presentation: injectable solution - ampoule of Bupivacaine Hydrochloride~Indication: production of subarachnoid block (spinal/ spinal anesthesia)."
3084738|NCT01994954|No Intervention|Arm A:Standard therapy|Infants' oxygen will be increased, decreased, or maintained based on brief structured assessments during monthly clinic visits. Polysomnograms will be utilized prior to final discontinuation of oxygen. RHO will only be utilized on the night prior to and during the polysomnogram to compare these two modalities.
3084739|NCT01994954|Experimental|Arm B:RHO|"Infants will have the same monthly clinic assessments as in Arm A, but also will utilize RHO to potentially increase, decrease or maintain oxygen between monthly visits.~Parents will transmit a minimum of 4 days of stored RHO data (min 8 hrs per day) every 4-7 days. Changes in oxygen needs will be made based on standardized objective criteria. To determine discontinuation of oxygen, RHO will be utilized instead of polysomnography."
3084768|NCT01994733|Experimental|Intensive phosphate control|Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of < 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice.
3084811|NCT01994447|No Intervention|Traditional Nurse Enrollment|Research nurses will obtain verbal consent from patient/caregiver.
3084812|NCT01994447|Experimental|Student Enrollment|Trained research students will use digital video discs (DVD's) of primary investigators explaining study information to obtain informed consent
3084814|NCT01994421|Sham Comparator|Kinesiotape|
3084740|NCT01994941|Experimental|Genotype guided group|"Patients are given standard doses of clopidogrel (either 300mg or 600mg according to clinical protocol). Blood will be drawn for rapid genetic testing (Verigene) and results will be expected in 2-4 hours. If patients are intermediate or poor clopidogrel metabolisers, loading dose of ticagrelor 180mg are given to enhance the antiplatelet response.~Apart from the approach in guiding the use of P2Y12 receptor blocker, all patients will be treated according to usual clinical care including medications and coronary intervention. Blood will also be sent to standard laboratory for CYP2C19 genotyping using conventional polymerase chain reaction (PCR) method so as to confirm the accuracy of rapid genetic test. 24 hours after initial clopidogrel loading, blood will be taken to measure platelet reactivity by verifyNow P2Y12 assay (Accumetrics). In case glycoprotein IIbIIIa inhibitor (Integrilin) is used, verifyNow P2Y12 assay will be performed 48 hours after cessation of Integrilin."
3084741|NCT01994941|Active Comparator|Clinical guided group|"Patients are given standard doses of clopidogrel (either 300mg or 600mg according to clinical protocol).~Apart from the approach in guiding the use of P2Y12 receptor blocker, all patients will be treated according to usual clinical care including medications and coronary intervention. Blood will also be sent to standard laboratory for CYP2C19 genotyping using conventional polymerase chain reaction (PCR) method so as to confirm the accuracy of rapid genetic test. 24 hours after initial clopidogrel loading, blood will be taken to measure platelet reactivity by verifyNow P2Y12 assay (Accumetrics) which is an FDA approved, point-of-care device using light-transmission based optical detection which measures platelet aggregation. In case glycoprotein IIbIIIa inhibitor (Integrilin) is used, verifyNow P2Y12 assay will be performed 48 hours after cessation of Integrilin."
3084742|NCT01994928|Active Comparator|Nose-mouth mask|Performance of intubation after preoxygenation using a nose-mouth mask.
3084743|NCT01994928|Experimental|High flow nasal cannula oxygen|Performance of intubation after preoxygenation using high flow nasal cannula oxygen.
3084744|NCT01994915|Experimental|Occupational therapy group|35 patients diagnosed with chronic obstructive pulmonary disease attending to the Hospital because of an exacerbation are going to be included in this group.
3084745|NCT01994915|No Intervention|Control group|35 patients diagnosed with chronic obstructive pulmonary disease are going to be included in this group. They are not going to receive other than standard care (medical and physical therapy intervention).
3084746|NCT01994902|Experimental|First Coloplast test product|"The subjects test:~test period 1: Coloplast test product test period 2: SenSura Convex Light"
3084747|NCT01994902|Experimental|First SenSura Convex Light|"The subjects test:~test period 1: SenSura Convex Light test period 2: Coloplast test product"
3084748|NCT01994889|Experimental|Tafamidis - 20 mg|Active Treatment-Low dose
3084749|NCT01994889|Experimental|Tafamidis - 80 mg|Active Treatment-High Dose
3084750|NCT01994889|Placebo Comparator|Placebo|Placebo control
3084751|NCT01994876|Experimental|First Coloplast Test 1|"The subjects first test their own product to collect a baseline measurement~The subjects are randomised to first test Coloplast Test 1 and thereafter Coloplast Test 2"
3084752|NCT01994876|Experimental|First Coloplast Test 2|"The subjects first test their own product to collect baseline measurements~The subjects are randomised to first test Coloplast Test 2 and thereafter Coloplast Test 1"
3084753|NCT01994863|Experimental|First Coloplast Test product; then Standard Care (see below)|"The subjects are randomised to test Coloplast Test product first and thereafter test Standard Care.~Standard Care is a collection of three different already marketed 1-piece flat ostomy appliances. These are Coloplast Sensura 1-piece; Hollister: Moderma 1-piece and B.Braun Flexima 1-piece.~The three Standard Care products were tested in a 1:1:1 randomisation."
3084754|NCT01994863|Experimental|First Standard Care (see below); Then coloplast test product|"The subjects are randomised to test Standard care first and thereafter test Coloplast test product.~Standard Care is a collection of three different already marketed 1-piece flat ostomy appliances. These are Coloplast Sensura 1-piece; Hollister: Moderma 1-piece and B.Braun Flexima 1-piece.~The three Standard Care products were tested in a 1:1:1 randomisation."
3084755|NCT01994837|Experimental|ABT-199|Continuous dosing of venetoclax (ABT-199) QD (once daily) beginning with dose-escalation on Week 1 Day 1. Participants received a dose of 20 mg of ABT-199 on Week 1 Day 1, 50 mg on Day 2, 100 mg on Day 3, 200 mg on Day 4, 400 mg on Day 5, 800 mg on Day 6 and QD thereafter.
3084756|NCT01994824|Experimental|Intervention arm|"Transplant recipients will have IL15 and IL2Ra measured on day 7. If at risk for significant GVHD, the patient will get rabbit antithymocyte globulin, 3 mg/kg on day 8.~Patients from this intervention/experimental arm will be compared to historical and concurrent controls (no ATG on day 8)."
3084757|NCT01994785|Active Comparator|EGD capnography open|Capnographic monitoring during EGD - Data made available to study staff throughout procedure
3084758|NCT01994785|Active Comparator|EGD capnography blinded|Capnographic monitoring during EGD - Data made available to study staff only if necessary for safety reasons
3084759|NCT01994785|Active Comparator|Colonoscopy capnography open|Capnographic monitoring during Colonoscopy - Data made available to study staff throughout procedure
3084760|NCT01994785|Active Comparator|Colonoscopy capnography blinded|Capnographic monitoring during Colonoscopy - Data made available to study staff only if necessary for safety reasons
3084761|NCT01994772|Active Comparator|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5 ° C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5 ° C for 24 hours.
3084762|NCT01994772|Placebo Comparator|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5 ° C for 48 hours.
3084763|NCT01994759|Active Comparator|Training|strengthening and stretching exercises.
3084764|NCT01994759|Active Comparator|Glucocorticosteroid injection|Injection of 40 mg methylprednisolone.
3084765|NCT01994759|Active Comparator|Training and Glucocorticosteroid injections|A combination treatment of the two above.
3084766|NCT01994746|Experimental|Nasal Glucagon|At one visit, a glucagon dose of 3 mg was administered in a nostril with a prefilled delivery device that delivers a single dose upon activation.
3084767|NCT01994746|Active Comparator|Intramuscular Glucagon|At a separate visit, 1 mg of glucagon was administered into the deltoid muscle of the non-dominant arm (intramuscular [IM]).
3084809|NCT01994460|Experimental|Arm 2 (experimental arm 1)|Isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and linezolid (600 mg/day, 2 weeks)
3084769|NCT01994733|Active Comparator|Liberalized phosphate control|"Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). Rescue P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L."
3084770|NCT01994720|Experimental|ticagrelor|
3084771|NCT01994720|Active Comparator|Acetylsalicylic acid (ASA)|
3084772|NCT01994707|Active Comparator|Remote ischemic preconditioning|Left arm blood pressure cuff inflation for 5 min then deflation of cuff for 5 min- cycle repeated 3 times before coronary artery bypass grafting.
3084773|NCT01994707|Placebo Comparator|Placebo|Deflated cuff on arm for 30 minutes.
3084774|NCT01994694||adults with ADHD|adults with ADHD, without neurological and psychiatric comorbidities
3084775|NCT01994694||controls|people without ADHD, with no neurological and psychiatric disorders
3084776|NCT01994681||Pancreatic Cancer|
3084777|NCT01994681||Healthy|
3084778|NCT01994668|Experimental|Lorazepam|
3084779|NCT01994668|Placebo Comparator|Placebo|
3084780|NCT01994655|Experimental|Doing exercise|We want to use Kupperman Index to assess the severity of climacteric symptoms,and assess the effect of doing exercise fof the climacteric symptoms
3084781|NCT01994642|Active Comparator|Reference|CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)
3084782|NCT01994642|Placebo Comparator|Placebo|Placebo Sterile Otic Suspension
3084783|NCT01994642|Experimental|Test|Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension
3084784|NCT01994629|Experimental|MenACWY-CRM|MenACWY-CRM
3084785|NCT01994629|Active Comparator|MenACWY-TT|MenACWY-TT
3084786|NCT01994616||keloid or hypertrophic scars|All patient including all skin types with keloid or hypertrophic disease receiving Intralesional Cryotherapy
3084787|NCT01994603|Experimental|Opt-in testing|"Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group. Opt-in: Common barriers to HIV screening testing will be removed as much as possible (i.e., providing rapid testing, results shortly available, testing on-site, confidentiality). There is voluntary HIV testing available to all study participants if you wish to do it. "
3084788|NCT01994603|Experimental|Opt-out testing|Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group. Opt-out multicomponent testing. Participants will be informed that a bundled routine health test is available on a voluntary basis to study participants, and the participant may elect to decline all or part of the testing.
3084789|NCT01994590|Experimental|Dovitinib + Abiraterone Acetate + Prednisone|"Participants receive a single daily oral dose of Dovitinib for 5 consecutive days, on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle. Starting dose will be 400 mg daily.~Participant to take 4 tablets (250 mg each) orally (PO) daily of Abiraterone acetate.~Participant to take 5 mg oral prednisone, twice daily."
3084790|NCT01994577||Adults (18+) presenting to the ED with symptoms of ACS|
3084791|NCT01994538|Active Comparator|Longer (14 day) duration antimicrobial treatment|14 days of ciprofloxacin or trimethoprim/sulfamethoxazole
3084792|NCT01994538|Placebo Comparator|Shorter (7 day) duration antimicrobial treatment|7 days of ciprofloxacin or trimethoprim/sulfamethoxazole, followed by 7 days of placebo
3084793|NCT01994525|Experimental|Cohort 1: PfRAS-infected|"5 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is 960 infectious bites.~Challenge occurs 3 weeks after final immunization."
3084794|NCT01994525|Placebo Comparator|Cohort 1: Noninfected|"Placebo immunization. 5 doses of approximately 200 noninfected bites (200-400 bites total) from irradiated uninfected mosquitoes (mock-immunization). The target dose is 960 noninfected bites.~Challenge occurs 3 weeks after final immunization."
3084795|NCT01994525|Other|Cohort 1: Nonimmunized|"No protective intervention given.~Challenge occurs directly after screening."
3084796|NCT01994525|Experimental|Cohort 2: PfRAS-infected|"3 to 7 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.~Challenge occurs 3 weeks after final immunization."
3084797|NCT01994525|Placebo Comparator|Cohort 2: Noninfected|"Placebo. 3 to 7 doses of approximately 200 noninfected bites (200-400 bites total) from irradiated, uninfected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.~Challenge occurs 3 weeks after final immunization."
3084798|NCT01994525|Other|Cohort 2: Nonimmunized|"No protective intervention given.~Challenge occurs directly after screening."
3084799|NCT01994525|Experimental|Hyperimmunity PfRAS-infected|"Cohort 1 sub-cohort~3 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes. This arm will receive the first 3 immunizations of Cohort 2.~Challenge occurs at the same time as Cohort 2 (3-20 weeks after the final immunization)"
3084800|NCT01994512|Experimental|Decompression without fusion|Surgery of the stenotic spinal segments with decompression of the neural elements without concommitant fusion.
3084801|NCT01994512|Experimental|Decompression with fusion|Surgery of the stenotic spinal segments with decompression of the neural elements with concommitant fusion.
3084802|NCT01994499|Experimental|videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
3084803|NCT01994499|Active Comparator|Medical pleural drainage|Medical drainage
3084804|NCT01994486|Experimental|Telaprevir and Sofosbuvir|All subjects will receive Telaprevir twice a day, 1125mg capsule and Sofosbuvir 400 mg capsule once daily. Both will be given for 12 weeks.
3084805|NCT01994473|Experimental|SEP-363856|Dosing will be initiated at 10 mg SEP-363856 as a single oral dose. Subsequent cohorts will be dosed at 25, 50, and 100 of SEP-363856.
3084806|NCT01994473|Placebo Comparator|Placebo|An oral of matched placebo
3084807|NCT01994473|Experimental|SEP-363856 Open Label|75 mg SEP-363856 given once-daily
3084808|NCT01994460|Active Comparator|Arm 1 (control arm)|Standard treatment for drug-sensitive pulmonary TB using isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and ethambutol (2 months)
3084815|NCT01994408|Experimental|default intensification arm (all)|all subjects will receive blister packs with weekly increasing blood pressure medications. There is no control arm for this study
3084816|NCT01994395|Experimental|Stride Management Assist (SMA) System|Participants will be randomized into either the SMA group or impairment based (IPT) group. The SMA group (task specific training) will be trained to simulate the demands of overground walking using the Stride Management Assist Device in outpatient physical therapy.
3084817|NCT01994395|Active Comparator|Impairment based therapy|Impairment based therapy will include traditional functional mobility training physical therapy. It will match the SMA group in intensity but will be focused on balance and other functional goals rather than explicitly on walking in outpatient physical therapy.
3084818|NCT01994382|Experimental|cerdulatinib (PRT062070)|Intervention: Drug: cerdulatinib (PRT062070) or cerdulatinib (PRT062070) plus rituximab
3084819|NCT01994369|Experimental|EC17 Injection group|This group with receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, they will be imaged with a camera and an imaging probe the investigators have developed.
3084820|NCT01994356|Active Comparator|Usual contraceptive counseling|subjects received usual contraceptive counseling
3084821|NCT01994356|Experimental|Physician self-disclosure of IUC use|subjects received usual contraceptive counseling plus intervention which was Physician self-disclosure of personal IUC use during the counseling
3084822|NCT01994343|Experimental|Experimental group|Adult women aged over 18 years old with pain during more than six months are included in the study. These patients will receive a global posture reeducation.
3084823|NCT01994343|No Intervention|Control group|Adult women aged over 18 years old without chronic pain. will receive no intervention.
3084824|NCT01994330|Experimental|Desmopressin|"0,3 mcg per kilogram of desmopressin in 100 ml of saline, labeled as study drug and administered in 30 minutes a half hour before surgical incision"
3084825|NCT01994330|Placebo Comparator|placebo|"100 of saline labeled as study drug administered in 30 minutes a half hour before surgical incision"
3084826|NCT01994317|Active Comparator|Standard sedation dose|IV sedation dose calculated using current standard of care
3084827|NCT01994317|Experimental|Algorithm|IV sedation dose calculated by study algorithm
3084828|NCT01994304|No Intervention|No safe childbirth checklist|The selected control districts include Bharatpur, Pali, Jhunjhunu, and Nagaur
3084829|NCT01994304|Active Comparator|Safe Childbirth Checklist|The selected districts for SCC intervention include Alwar, Jalore, Sirohi, Sikar, Dausa, and Churu
3084830|NCT01994291|Active Comparator|Arm 1|Intravitreal administration of ranibizumab (either 0.3 or 0.5 mg, given monthly, as detailed in the prescribing information and label content approved for the country governing the study site) plus an oral placebo.
3084831|NCT01994291|Experimental|Arm 2|Oral PF-04634817 200 mg, once daily plus a masked sham therapy (given monthly).
3084832|NCT01994278|Experimental|Tooth brush|Periclean is a soft rubber gentle toothbrush
3084833|NCT01994265|Active Comparator|Warfarin|Treatment with Warfarin once daily, taken at fast, to maintain INR between 2 and 3.
3084834|NCT01994265|Active Comparator|Dabigatran|Dabigatran 150 mg twice daily
3084835|NCT01994252|Active Comparator|Optimal Medical therapy plus ICD|Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter only group will receive an ICD + optimal medical therapy
3084836|NCT01994252|Active Comparator|Optimal Medical therapy plus CRT/ICD|Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter plus cardiac resynchronisation therapy (CRT) group will receive an ICD + CRT and optimal medical therapy
3084837|NCT01994239|Active Comparator|Radiation|"Pelvic radiotherapy~46 Gy in 23 fractions of 2 Gy.~prostate only-boost up to 66 Gy"
3084838|NCT01994239|Experimental|Radiation and Degarelix|"Radiotherapy:~46 Gy in 23 fractions of 2 Gy.~prostate only-boost up to 66 Gy~Associated with hormonal therapy by degarelix:~beginning in parallel to radiotherapy for 6 months~First dose of 240 mg~Maintenance dose of 80 mg"
3084839|NCT01994226|Active Comparator|Low-dose colchicine|500 mcg every eight hours for four days
3084840|NCT01994226|Active Comparator|Naproxen|Single initial dose of 750 mg followed by 250 mg every eight hours for up to seven days
3084841|NCT01994213|Experimental|Famitinib|Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
3084842|NCT01994200|Experimental|Interdisciplinary Team-Based Approach|The delivered intervention will be to provide patients with an interdisciplinary team-based approach defined as care provided by a variety of professionals, each having their own domain of expertise, defined roles and responsibilities, who work together and meet to discuss patient needs and develop comprehensive treatment plans. Team composition will include physicians, a dedicated nurse, and allied professionals (e.g., dieticians, social workers, psychologists). The dedicated nurse will have a central integrative role in this interdisciplinary team and will provide patients with information about their illness and treatment, symptom management, emotional support, and reference to other resources when needed
3084843|NCT01994200|Other|Usual Care Control Group|Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
3084844|NCT01994187||CAS or CEA|CAS:the patient who accepted carotid angioplasty due to catotid artery stenosis CEA:the patient who accepted carotid endarterectomy due to catotid artery stenosis
3084845|NCT01994161||Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
3084846|NCT01994148|Experimental|Laparoscopy|Laparoscopy has been increasingly applied in patients with abdominal trauma , as an diagnostic and therapeutic modality. In this arm, we will include 100 Hemodynamically stable patients with gastrointestinal trauma, all of them will receive laparoscopic exploration,laparoscopic repair of the gastrointestinal injury will be attempted.
3084847|NCT01994135|Active Comparator|Reference food|The reference food is white bread
3084848|NCT01994135|Experimental|Test food dose 1|Test food dose 1 response will be compared to reference test food
3084849|NCT01994135|Experimental|Test food dose 2|Test food dose 2 response will be compared to reference test food as well as to test food dose 1
3084850|NCT01994122||People who have dropped out of school|
3084851|NCT01994122||College students (control group)|
3084852|NCT01994109|Active Comparator|MYOBLOC Dose 1|Subjects will receive specified dose of MYOBLOC
3084853|NCT01994109|Active Comparator|MYOBLOC Dose 2|Subjects will receive specified dose of MYOBLOC
3084854|NCT01994109|Placebo Comparator|Placebo|Subjects will receive volume matched Placebo
3084855|NCT01994096|Experimental|Caspofungin|1 arm, dose adjustment of caspofungin when exposure is inadequate
3084856|NCT01994083|Placebo Comparator|Placebo|Placebo
3084857|NCT01994083|Experimental|IX-01|Up to 4 different dose groups within 50 to 1,200 mg of IX-01 oral aqueous dispersion, administered once daily for 10 days
3084858|NCT01994070|Active Comparator|Electrical-first|"Patients in atrial fibrillation for less than 48 hours will be administered procedural sedation and analgesia and an electrical current applied across their chest (cardioversion) to attempt conversion to normal sinus rhythm. If this does not succeed, they will be given intravenous procainamide (chemical cardioversion). If procainamide is required, physicians will be informed as follows: 50% of patients convert to normal sinus rhythm within one hour and 90% of patients convert within two hours. Physicians can then proceed at their discretion."
3084859|NCT01994070|Active Comparator|Chemical-first|"Patients in atrial fibrillation for less than 48 hours will be administered intravenous procainamide (chemical cardioversion) to attempt conversion to normal sinus rhythm. If procainamide is required, physicians will be informed as follows: 50% of patients convert to normal sinus rhythm within one hour and 90% of patients convert within two hours. Physicians can then proceed at their discretion. If this does not succeed, patients will be administered procedural sedation and analgesia and an electrical current applied across their chest (electrical cardioversion) to attempt conversion to normal sinus rhythm."
3084860|NCT01994057||sensitive group; resistant group|"sensitive patients were defined as patients reached CR or PR after first month administration,SD after first three months administration.~resistant patients were defined as patients reached PD after first month administration and first three months administration"
3084861|NCT01994044|Active Comparator|Multimodal rehabilitation|
3084862|NCT01994044|Active Comparator|Cervical fusion|
3084863|NCT01994031|Experimental|Dose level A|Paclitaxel liposome injection 135mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
3084864|NCT01994031|Experimental|Dose level B|Paclitaxel liposome injection 175mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
3084865|NCT01994031|Experimental|Dose level C|Paclitaxel liposome injection 210mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
3084866|NCT01994031|Experimental|Dose level D|Paclitaxel liposome injection 250mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
3084867|NCT01994031|Experimental|Dose level E|Paclitaxel liposome injection 300mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
3084868|NCT01994031|Active Comparator|Comparator|Paclitaxel injection 175mg/m2 on day 1, each 21 days
3084869|NCT01994018||Control Group (Vitamin D level)|Twenty (20) healthy individuals not on vitamin D supplementation will be used as controls to get a baseline vitamin D level.
3084870|NCT01994018||MS Group|RR-MS patients treated with a FDA approved immuno-modulatory drug with and without vitamin D supplementation for at least 2 years.
3084871|NCT01994005|Placebo Comparator|Standard + Pamphlet|Subjects receiving standard counseling + ACOG pamphlets
3084872|NCT01994005|Active Comparator|Group 2: standard + facebook|Subjects receiving standard counseling + facebook education Intervention is 30 mins of use of facebook page
3084873|NCT01993979|Other|Surveillance|Patients allocated to surveillance will be seen at 4, 7, 10 and 13 weeks post randomisation - equivalent to the end of cycle in patients receiving chemotherapy - in order to collect details of early treatment failure in this group and comparative data relating to toxicity and quality of life. Patients on surveillance will then be followed up for signs of recurrence at the same intervals as those who received chemotherapy
3084874|NCT01993979|Experimental|Chemotherapy|Patients allocated adjuvant chemotherapy will receive 4 x 21 day cycles of gemcitabine-cisplatin. Patients who have a sub-optimal renal function (GFR 30-49ml/min) will receive carboplatin instead of cisplatin.
3084875|NCT01993966||drug-resistant|specimens com from drug-resistant bladder urothelial carcinoma patients
3084876|NCT01993966||normal|specimens come from normal bladder urothelial carcinoma patients
3084877|NCT01993966||non-tumoral|specimens come from non-tumoral patients
3084878|NCT01993953|Active Comparator|BodyPump|Resistance training in group, with one instructor. This pre-choreographed class contains 10 to 12 exercises with a barbell, weights and a step. Number of repetitions throughout the class varies between muscle groups, but is generally high (20-100).
3084879|NCT01993953|Active Comparator|Personal training|The PT will instruct proper technique to their clients, correct the training and technique, control the intensity and serve as a motivator at each training session.
3084880|NCT01993953|Active Comparator|Resistance training with instructor|Participants in this group are aimed to perform resistance training individually, based on two sessions with an instructor and a standarized training program given prior to the intervention. After six weeks, all participants in this group received a second instruction, as well as evaluation of the training protocol.
3084881|NCT01993953|No Intervention|Controlgroup|Control group - This group will be instructed to continue their activity and diet patterns. After the intervention period, they will be offered free exercise with BP at a fitness centre (12 weeks) and resistance training with a instructor at the Norwegian School of Sport Science.
3084882|NCT01993940|Experimental|Naldemedine|Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
3084883|NCT01993940|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 12 weeks.
3084884|NCT01993927||Voglibose 0.2 mg or OD Tablets 0.2 mg|Voglibose 0.2 mg or OD Tablets 0.2 mg will be administered orally three times daily immediately before each meal.
3084885|NCT01993901|Experimental|CSRT led telephone follow up|Patients in the experimental arm will be telephoned by the CSRT 4-6 weeks after completion of their treatment to assess any symptoms.
3084926|NCT01993615|Active Comparator|Arthroscopic Surgery|Arthroscopic surgery at the femoroacetbular joint, followed by a standardized post-operative rehabilitation protocol in physical therapy.
3084927|NCT01993615|Active Comparator|Physical Therapy|An impairment-based supervised in-clinic physical therapy program.
3085698|NCT01988298|Experimental|Ibuprofen|Experimental: Ibuprofen 400 mg each 8 hours for 2-3 days.
3084886|NCT01993901|No Intervention|Standard Follow up|"Patients in the control group will have the standard follow up (CT of the chest, abdomen and pelvis prior to follow-up with the radiation oncologist 4 months after the completion of their treatment). In order to control for an attention effect that may be seen in the intervention group, patients in the control group will get a placebo or sham telephone call initiated by a research assistant 4-6 weeks after completion of their treatment. This telephone call will simply confirm their follow up appointment."
3084887|NCT01993888|Experimental|EVARREST® Fibrin Sealant Patch|EVARREST® Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts — a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
3084888|NCT01993888|Other|Standard of Care (SoC)|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical. For this study, SoC will be initiated with continuous firm manual compression with or without gauze or sponge and with or without a topical absorbable hemostat (example SURGICEL).
3084889|NCT01993875|Experimental|Lubiprostone|
3084890|NCT01993875|Placebo Comparator|Placebo|
3084891|NCT01993862|No Intervention|Next Day Discharge|The patient will have a 23 hour standard of care observational stay in the hospital after an implantable cardioverter defibrillator implant procedure.
3084892|NCT01993862|Active Comparator|Same Day Discharge|The patient will be discharged from the hospital the same evening after an implantable cardioverter defibrillator implant procedure. Follow up after surgery will be done via remote device follow up (1) on the day of discharge and (2) 24 hours after surgery.
3084893|NCT01993849|Active Comparator|NAC|Twice daily dosing for 8 weeks
3084894|NCT01993849|Placebo Comparator|Placebo|Twice daily dosing for 8 weeks
3084895|NCT01993836|Active Comparator|Total Intravenous Anesthesia with Propofol|Patients in this arm will receive general anesthesia with propofol as the primary amnestic agent.
3084896|NCT01993836|Active Comparator|General anesthesia with Isoflurane|Patients in this arm will undergo general anesthesia with isoflurane as the primary amnestic agent.
3084897|NCT01993823|Experimental|G238|Five drops into the ear canal twice daily for 14 days
3084898|NCT01993823|Active Comparator|Clotrimazole|Five drops into the ear canal twice daily for 14 days
3084899|NCT01993810|Active Comparator|Arm I (photon beam radiation therapy and chemotherapy)|"Patients undergo photon beam radiation therapy 5 days per week for a total of 35 fractions and receive either paclitaxel* IV over 1 hour and carboplatin* IV weekly during radiation therapy or etoposide IV on days 1-5 and 29-33 and cisplatin IV on days 1, 8, 29, and 36.~*In both arms, patients who receive paclitaxel and carboplatin must complete consolidation therapy.~CONSOLIDATION THERAPY: Patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity."
3084900|NCT01993810|Experimental|Arm II (proton beam radiation therapy and chemotherapy)|"Patients undergo proton beam radiation therapy 5 days per week for a total of 35 fractions and receive either paclitaxel* and carboplatin* or etoposide and cisplatin as in Arm I.~*In both arms, patients who receive paclitaxel and carboplatin must complete consolidation therapy.~CONSOLIDATION THERAPY: Patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity."
3084901|NCT01993797||Bronchiolitis|children presented with signs suggestive of bronchiolitis
3084902|NCT01993784|Experimental|Nimotuzumab|the nimotuzumab treatment: 2 levels (400 mg/w, 600 mg/w, weekly, until disease progression)
3084903|NCT01993771||Males and females with alopecia|Males and females with alopecia scheduled for general anaesthesia.
3084904|NCT01993758|Active Comparator|Conventional tourniquet pressure|The patients in this group will undertake total knee arthroplasty under conventional tourniquet pressure, which will be set as the pressure added by 150mmHg on the last systolic blood pressure just before tourniquet inflation.
3084905|NCT01993758|Experimental|Low tourniquet pressure|The patients in this group will undertake total knee arthroplasty under low tourniquet pressure, which will be set as the pressure added by 120mmHg on the last systolic blood pressure just before tourniquet inflation.
3084906|NCT01993745||Study group|ECMO Patients survived
3084907|NCT01993745||Control|ECMO Patient died
3084908|NCT01993732|Experimental|Retrieval and Cryopreservation|Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
3084909|NCT01993719|Experimental|1/High-Dose Chemotherapy|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin
3084910|NCT01993719|Experimental|2/Low-Dose Chemotherapy (CLOSED)|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin (CLOSED)
3084911|NCT01993719|Experimental|3/Retreatment|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin + pembrolizumab
3084912|NCT01993693|Experimental|Ultrasonic Diathermy Device|Therapeutic ultrasound used daily.
3084913|NCT01993693|Placebo Comparator|Sham Ultrasonic Diathermy Device|Sham device that does not deliver ultrasound
3084914|NCT01993680|Experimental|Pyridostigmine bromide|14 days of active treatment followed by 21 days wash out
3084915|NCT01993680|Active Comparator|fludrocortisone|14 days of fludrocortisone treatment; 21 days wash out
3084916|NCT01993667|Experimental|Acetazolamide normal dose|Experimental : Acetazolamide 125 mg twice daily
3084917|NCT01993667|Experimental|Acetazolamide low dose|Experimental: Acetazolamide 62.5 mg twice daily
3084918|NCT01993654||Nevus|
3084919|NCT01993654||Racial Melanosis|
3084920|NCT01993654||Primary Acquired Melanosis|
3084921|NCT01993654||Malignant Melanoma|
3084922|NCT01993654||Normal|
3084923|NCT01993641|Experimental|Pracinostat added to HMA|Pracinostat in combination with HMA treatment (either azacitidine or decitabine) used in initial single agent treatment for that patient
3084924|NCT01993628|Experimental|Alzheimer's disease (AD)|Rey figure test and MRI
3084925|NCT01993628|Experimental|Lewy body's dementia (LBD)|Rey figure test and MRI
3084928|NCT01993602|No Intervention|Control group|no intervention was performed in this group during postoperative period,
3084929|NCT01993602|Active Comparator|volumetric incentive spirometry|patients performed breathing exercises using volumetric incentive spirometer during five postoperative days
3084930|NCT01993602|Active Comparator|Flow oriented incentive spirometry|patients performed breathing exercises using flow oriented incentive spirometer during five postoperative days
3084931|NCT01993602|Active Comparator|Deep breathing group|patients performed deep breathing exercises without any device during five postoperative days
3084932|NCT01993602|Active Comparator|Continuous positive airway pressure group|patients performed breathing exercises using continuous positive airway pressure group during five postoperative days
3084933|NCT01993589|No Intervention|Control group|Control group
3084934|NCT01993589|Active Comparator|Pain reliever|1000 mg paracetamol (Parol 1 g Atabay ilaç Turkey)
3084935|NCT01993589|Active Comparator|Dexketoprofen trometamol|25 mg oral Dexofen Atabay ilaç Turkey
3084936|NCT01993589|Active Comparator|Lidocaine spray|2 puff on cervical mucosa (Xylocain Pump 100 Mg 50 Ml Sprey Astra Zeneca)
3084937|NCT01993589|Active Comparator|pethidine|Aldolan 100 mg Liba Laboratuarı İstanbul Turkey
3084938|NCT01993589|Active Comparator|diclofenac sodium|Dicloron amp 75 mg Deva İlaç Levent İstanbul/Turkey
3084939|NCT01993576|Experimental|indocyanine green|Indocyanine green is injected intravenously.
3084940|NCT01993563|Experimental|Graded Motor Imagery|
3084941|NCT01993563|Active Comparator|Standard treatment|
3084942|NCT01993550|Experimental|Telephone counseling|Telephone counseling to enhance symptom management and reduce distress
3084943|NCT01993550|Active Comparator|Education|Overview of resources for psychosocial support and health information
3084944|NCT01993537|No Intervention|Sufficeint|In this arm the participants have a Vitamin D level of greater than 75 ng/ml. They will continue to be monitored throughout the study but will not receive any intervention.
3084945|NCT01993537|No Intervention|Mild Insufficiency|In this arm the participants have a Vitamin D level between 37.5 - 75 ng/ml. The participants will be monitored throughout the study but will receive no intervention.
3084946|NCT01993537|No Intervention|Severe Deficiency no treatment|In this arm the participants have a low Vitamin D level of less than 37.5 ng/ml. The participants will be monitored but will receive no intervention.
3084947|NCT01993537|Experimental|Severe Deficiency - Treatment|In this arm the participants will be treated with Vitamin D. The participants will be prescribed a dose of 1000 IU a day (1 pill a day). At 6 weeks the dosage will increase to 2000 IU a day (2 pills a day).
3084948|NCT01993524|Experimental|probiotic|At I visit standard treatment(500mg oral metronidazole twice daily for 7 days) and probiotic twice daily for 10 days. At II visit, participants were checked for signs of vaginal infection; if they were still present they were given a targeted antibiotic according to the microbiological analysis. Antibiotic was taken together with probiotic twice daily for 10 days. Participants showing positive response to metronidazole treatment on the II visit were given only the probiotic once daily for 10 days in the peri-menstrual period for the next 3 months. Participants with targeted antibiotic were to come to the visit IIbis, and if treatment was successful they were to proceed for the next 3 months in the same manner as those successfully treated with metronidazole, as described above.
3084949|NCT01993524|Placebo Comparator|placebo|At I visit standard treatment (500mg oral metronidazole twice daily for 7 days) and placebo twice daily for 10 days. At the II visit, participants were checked for signs of vaginal infection; if they were present they were given a targeted antibiotic according to the microbiological analysis. Antibiotic was taken together with placebo twice daily for 10 days. Participants showing positive responses to metronidazole on the II visit were given only placebo once daily for 10 days in the peri-menstrual period for the next 3 months. Participants with targeted antibiotic were to come to the visit IIbis, and if treatment was successful they were to proceed for the next 3 months in the same manner as those successfully treated with metronidazole, as described above.
3084950|NCT01993511||RYGB patients with type 2 diabetes|Preoperative oral glucose tolerance test with 2 h P-glucose >11.1 mmol/L
3084951|NCT01993511||RYGB patients with IGT|Preoperative oral glucose tolerance test with 2 h p-glucose >7.8 and <11.1 mmol/L
3084952|NCT01993511||RYGB patients with NGT|Preoperative oral glucose tolerance test with 2 h p-Glucose <7.8 mmol/L
3084953|NCT01993498|Other|breast cancer treatment + blood sampling|Standard treatment of breast cancer with intervention : samples collection
3084954|NCT01993472|Experimental|Andrographolides with Capecitabine|Capecitabine1250mg/m2 , bid，d1-14，q3w, Andrographolides 500mg，qd，d1-14，q3w;
3084955|NCT01993472|Active Comparator|Capecitabin alone|Capecitabine1250mg/m2 , bid，d1-14，q3w,
3084956|NCT01993459|Experimental|Midazolam intravenous|3mg/ml midazolam given intravenously
3084957|NCT01993459|Placebo Comparator|NaCl (sodium chloride) 0,9%|NaCl (sodium chloride) 0,9% given intravenously 3ml.
3084958|NCT01993446|Experimental|DRM02|DRM02 Topical Gel, 0.25%
3084959|NCT01993446|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
3084960|NCT01993433|Experimental|DRM02|DRM02 Topical Gel, 0.25%
3084961|NCT01993433|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
3084962|NCT01993420|Experimental|DRM02|DRM02 Topical Gel, 0.25%
3084963|NCT01993420|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
3084964|NCT01993407|Experimental|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
3084965|NCT01993407|Placebo Comparator|Pure Task Training|Participants will complete four, one-hour training sessions in which they will perform a single task each session, alternating tasks between but not within sessions.
3084966|NCT01993394|Experimental|ventilation|hypergravity gas mixture
3084967|NCT01993381||CINV of FOLFOX, FOLFIRI|moderate emetogenic chemotherapy
3084968|NCT01993368|Other|chronic periodontitis|biopsy of periodontal granulation tissue (surgical waste)
3084969|NCT01993368|Other|aggressive periodontitis (AP)|biopsy of periodontal granulation tissue (surgical waste)
3084970|NCT01993368|Other|controls|necessitating an extraction of wisdom teeth
3084971|NCT01993355|Active Comparator|TAU|Control group. Treatment as usual (TAU): Physiotherapy program for CLBP.
3084972|NCT01993355|Experimental|Intervention 1 Relaxation techniques-sophrology|Intervention group 1: TAU + relaxation techniques-sophrology program.
3084973|NCT01993355|Experimental|Intervention 2 Cognitive-behavioral therapy|Intervention group 2: TAU + cognitive-behavioral therapy.
3084974|NCT01993342||Inflammatory knee osteoarthritis|We recruited patients with osteoarthritis and synovial effusion to diagnostic the effusion and to confirm that this this synovial fluid had mechanical characteristics. Now we are going to determine the adipocytokines and traditional parameters of inflammation in this synovial fluid to correlate it, and we will associate it with the ultrasound explanation of the knee that we have in our database.
3084975|NCT01993329|Experimental|Gefapixant and placebo|Gefapixant 50 mg tablet and placebo (for gefapixant) tablet by mouth twice daily for 3.5 days
3084976|NCT01993329|Placebo Comparator|Placebo|Placebo (for gefapixant) tablets by mouth twice daily for 3.5 days
3084977|NCT01993329|Experimental|Gefapixant 300 mg and placebo|Gefapixant 300 mg tablet and placebo (for gefapixant) tablet by mouth twice daily for 3.5 days
3084978|NCT01993316|Experimental|neurofeedback training|Subjects will undergo neurofeedback training to either the right primary motor cortex or the right superior parietal gyrus. The EEG measurements will be analyzed using LORETA.
3084979|NCT01993303||Single Cohort|Population: 19 subjects, mean age 65 years, mean BMI 30 kg/m2, 79% male. Radionuclide Dosage: Rb-82 doses were rest 53+/-5 mCi and stress 53+/-6 mCi All were stress with Dipyridamole.
3084980|NCT01993290|Active Comparator|USG Supraclavicular block|20 ml of ropivacaine 0,75% is administered to brachial plexus at supraclavicular level.
3084981|NCT01993290|Active Comparator|Lateral infraclavicular block|20 ml of ropivacaine 0,75 % is administered to brachialis plexus at lateral infraclavicular level
3084982|NCT01993290|Active Comparator|USG Axillaris block|20 ml of ropivacaine 0,75% is administered to plexus brachialis at axillaris level
3084983|NCT01993277|Active Comparator|Fischer Wallace Stimulator|30 20-minute sessions of the Fischer Wallace Stimulator administered twice-per-day within a 3-week time-frame;
3084984|NCT01993277|Active Comparator|Nexalin Brain Stimulator|15 40-minute sessions of Nexalin Brain Stimulator adminsitered once-per-day within a 3-week time-frame
3084985|NCT01993277|Active Comparator|DAVID Delight Stimulator|15 40-minute sessions of the DAVID Delight administered once-per-day within a 3-week time-frame
3084986|NCT01993277|Active Comparator|Relaxation Therapy|15 40-minute relaxation therapy sessions once-per-day within a 3-week time-frame
3084987|NCT01993251|Active Comparator|melatonin 0.5mg|
3084988|NCT01993251|Active Comparator|melatonin 2mg|
3084989|NCT01993251|Active Comparator|melatonin 6mg|
3084990|NCT01993251|Placebo Comparator|placebo|
3084991|NCT01993238|Experimental|Liposonix with pre-treatment analgesia|Liposonix System (Model 2) treatment of subcutaneous adipose tissue with pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
3084992|NCT01993225|Placebo Comparator|Placebo|Placebo Gel and Placebo capsules
3084993|NCT01993225|Experimental|Androxal Treatment|Androxal 12.5mg/25 mg and Placebo gel
3084994|NCT01993225|Active Comparator|AndroGel Treatment|AndroGel 1.62% and Placebo Capsules
3084995|NCT01993212|Placebo Comparator|Placebo|Androxal Placebo and Gel Placebo
3084996|NCT01993212|Active Comparator|AndroGel Treatment|AndroGel 1.62% and Placebo Capsules
3084997|NCT01993212|Experimental|Androxal Treatment|Androxal 12.5 mg or 25mg and Placebo Gel
3084998|NCT01993199|Active Comparator|deep biopsy|
3084999|NCT01993186|Experimental|UX007 (triheptanoin)|Oral liquid administered with food 4 times a day to make up to 35% of total caloric intake. 52 weeks.
3085000|NCT01993186|Placebo Comparator|Placebo Oil|Placebo oil matching color and appearance of UX007.
3085001|NCT01993173|Experimental|ADACEL Vaccine Group|Children, adolescents and adults randomized to receive a single booster dose of ADACEL (Tdap vaccine)
3085002|NCT01993173|Active Comparator|Local DT/Td Vaccine Group|Participants randomized to receive either a single booster dose of local DT vaccine (children aged 4 through 11 years) or local Td vaccine (adolescents and adults aged 12 through 64 years)
3085003|NCT01993160|Experimental|18F-FCH PET MR|Integrated whole body PET-MR or PET-CT and separate whole body MRI with use of 18F-FCH as the molecular probe
3085004|NCT01993147|Placebo Comparator|Sugar Pill|Healthy adult participants to be given either 20mgs of Methylphenidate or a placebo one hour before fMRI and task performance.
3085005|NCT01993147|Active Comparator|Methylphenidate|Healthy adult participants to be given either 20mgs of Methylphenidate or a placebo one hour before fMRI and task performance.
3085006|NCT01993147|No Intervention|Dual Task Paradigm|This arm does not involve any drug intervention, it is an experimental type consisting of 80 subjects to study the dual task paradigm implemented during the fMRI scanning session. 80 subjects will perform the fMRI scan but will not undergo any drug intervention.
3085007|NCT01993134|Experimental|Cefazolin|2g of Cefazolin, 20minutes before sugery. After surgery, 1g of cefazolin 06/06h.
3085008|NCT01993134|Active Comparator|Cefazolin Single Dose|2g of Cefazolin, 20minutes before sugery. After surgery, no drugs.
3085009|NCT01993121|Experimental|Three-month exercise training program|All subjects will perform three months of supervised exercise training.
3085010|NCT01993108|Experimental|Healthy Controls|Healthy individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
3085011|NCT01993108|Experimental|Adult Attention-Deficit/Hyperactivity Disorder|ADHD individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
3085012|NCT01993095|Experimental|Experimental: FlexToBa physical activity DVD|Participants in this arm will receive a physical activity program delivered by DVD that focuses on exercises targeting flexibility, toning and balance. These exercises will be progressive in nature throughout the six months and will also focus on modifications for all ability levels. Participants will be provided with three DVDs including: an Introduction to physical activity, Sessions 1-3, and Sessions 4-6, which they will be asked to watch and participate in over the course of six months.
3085013|NCT01993095|Active Comparator|Usual care-Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
3085014|NCT01993082|Experimental|Aerobic Training Intervention|"For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.~A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage."
3085015|NCT01993082|No Intervention|Activity Maintenance Group|Participants randomized into the waitlist control group receive no aerobic training. Wait-list control participants will receive monthly check-in phone calls to establish that they have not significantly increased activity engagement. Participants in this group will receive a free gym membership at the end of the study, monthly phone calls with a fitness coach support provider for 6 months, and 2 coaching text messages per week.
3085016|NCT01993069|Experimental|Iyengar-based Yoga Training|6 weekly Iyengar-based yoga classes
3085017|NCT01993056|Experimental|warm-up with 11+|"The FIFA 11+ is a complete warm up program aiming on reduce common soccer injuries"
3085018|NCT01993056|Placebo Comparator|control|the control group follows its regular training routine
3085019|NCT01993030|Experimental|HQ® Matrix Medical Wound Dressing|After harvesting the graft, the donor site wounds were treated with the dressing material. Dressing changes if needed. An operative removal of the HQ® Matrix Medical Wound Dressing is not required as it becomes spontaneously detached from the regenerated skin areas.
3085020|NCT01993030|Active Comparator|Sidaiyi® wound dressing|After harvesting the graft, the donor site wounds were treated with the dressing material. Dressing changes if needed.
3085021|NCT01993017|Experimental|AHA Depression Screen & Treat|"Participants randomized to this arm will complete the Depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (>=10) will be offered treatment. Treatment will be delivered according to participant preference, and will be managed according to stepped care. Stepped care includes, a) participant preference for either brief, cognitive behavioral therapy (CBT), delivered centrally by telephone, or antidepressant medication managed at the local site, or both, or neither, and b) review of progress at approximately 2-month intervals, with stepping up of care if sufficient progress is not being realized."
3085022|NCT01993017|Active Comparator|Depression Screen & Notify Arm Type :|Participants randomized to this arm will complete the depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (>=10) will have a letter sent to their primary care provider about their positive screen for depressive symptoms, with subsequent actions at the provider's discretion.
3085023|NCT01993017|Placebo Comparator|No Depression Screen|Participants randomized to this arm will not complete a PHQ-8 assessment at randomization, and so will not be screened for depressive symptoms.
3085024|NCT01993004||Healthy subjects|Self-explanatory
3085025|NCT01993004||Untreated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are not on any disease-modifying treatment approved for MS
3085026|NCT01993004||Treated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who were prescribed Glatiramer acetate prior to enrollment
3085027|NCT01992991|Experimental|Transcranial direct current stimulation|Anodal stimulation
3085028|NCT01992991|Sham Comparator|Sham stimulation|30 sek of Transcranial direct current stimulation
3085029|NCT01992978|Experimental|radiofrequency-assisted resection group（RF-R)|Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
3085030|NCT01992978|Active Comparator|conventional liver resection group（CLR-R）|Conventional liver resection group: hepatectomy only without RF assisted during parenchymal transection.Separating and dissecting the tumor with the routine clamp-crushing technical.
3085031|NCT01992965|Experimental|Continuous Glucose Monitoring Group|"Continuous Glucose Monitoring Group:~Different methods of blood glucose monitoring between groups, and this group will use real-time continuous glucose monitoring system with alarm limits（high and low limit is 10 mmol/L and 8 mmil/L , respectively ) up to five days for glucose control, the target mean glucose level is between 8 and 10 mmol/L."
3085032|NCT01992965|Active Comparator|Conventional Group|"Conventional Group：~Different methods of blood glucose monitoring between groups, and this group will use finger prick blood glucose measurements for glucose control with the same target mean glucose level of 8 -10 mmol/L. Patients also wear real-time continuous glucose monitoring system to collect glucose measurements. The values of real-time continuous glucose monitoring system are blinded to investigator and patients."
3085033|NCT01992952|Experimental|AZD5363 plus fulvestrant|Fulvestrant 500mg and AZD5363 4 days on 3 days off at dose determined in safety run in (maximum 480mg and minimum 320mg bd)
3085034|NCT01992952|Active Comparator|Placebo plus fulvestrant|Fulvestrant 500mg D1, D15 (cycle 1) and D1 of a 28 cycle thereafter. AZD5363 placebo 4 days on 3 days off
3085035|NCT01992939|Active Comparator|Non-Healthy Subjects arm|Subjects in this arm will have peripheral vascular disease (PVD), vasoconstriction, or hypothermic extremities and they will receive two pulse oximetry probes. One probe will be a standard of care pulse oximetry probe and the second probe is the specialized pulse oximetry probe with external heat pack
3085036|NCT01992939|Active Comparator|Healthy Subjects Arm|Subjects who do not have peripheral vascular disease (PVD), vasoconstriction, or hypothermic extremities will be considered healthy subjects and they will receive two pulse oximetry probes. One probe will be a standard of care pulse oximetry probe and the second probe is the specialized pulse oximetry probe with external heat pack.
3085037|NCT01992926|Active Comparator|interactive educational intervention|Physicians will use an interactive educational worksheet during the standard-of-care clinic visit.
3085038|NCT01992926|No Intervention|control group|Physicians will conduct the standard-of-care clinic visit as usual.
3085039|NCT01992913|Experimental|iCBT|integrated CBT with computerized cognitive remediation
3085040|NCT01992913|Other|UC|usual care
3085041|NCT01992900|Experimental|Eurartesim dispersible oral tablets|Each patient will receive a specific amount of drug according to his/her body weight, once a day for three consecutive days (from 5 to <7 kg: 1 tablet containing 80 mg PQP and 10 mg DHA; from 7 to < 13 kg: 1 tablet containing 160 mg PQP and 20 mg DHA).
3085127|NCT01992276|Experimental|CR6261|Investigational monoclonal antibody against influenza A viruses
3085042|NCT01992900|Active Comparator|Eurartesim film coated tablet|Each patient will receive a specific amount of drug according to his/her body weight, once a day for three consecutive days (from 5 to <7 kg: half tablet equal to 80 mg PQP and 10 mg DHA; from 7 to < 13 kg: 1 tablet containing 160 mg PQP and 20 mg DHA).
3085043|NCT01992887||In-depth Interview|Up to 20 in-depth interviews will be conducted among adult ART naïve patients, balanced by gender, site and reason for ART naiveté (determined ineligible or eligibility not yet determined) as much as possible. Up to 4 in-depth interviews will be conducted with health care providers.
3085044|NCT01992887||Focus Group Participants|Up to 40 patients ineligible or not yet eligible for ART will be invited to join a focus group discussion. Patients will be eligible for selection for either in-depth interviews or focus group discussions if they have made at least one prior visit to the clinic. Selected patients will be balanced as much as possible by gender and by pre-ART status (e.g. roughly half pre-ART eligibility determined, and roughly half pre-ART eligibility indeterminate).
3085045|NCT01992887||Prospective Cohort|Based on historical patient data from the four study CTCs, we expect that approximately 1,000 patients will enroll in HIV care at these clinics during the study period and be determined not eligible for ART or of unknown eligibility. Assuming a 10% refusal rate, approximately 900 patients would then enroll in this study and complete baseline interviews. These 900 patients will be prospectively monitored using routinely collected patient care data for up to 24 months. Outreach workers will attempt to trace all of the enrolled patients who are observed to be LTF during the study period, and complete a defaulter tracing survey.
3085046|NCT01992874|Experimental|Pimasertib Capsule/Pimasertib Tablet|
3085047|NCT01992874|Experimental|Pimasertib Tablet/Pimasertib Capsule|
3085048|NCT01992861|Experimental|Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)|Patients undergo radiation therapy and receive chemotherapy per standard of care. Patients undergo DCE MRI, DW MRI, and MR spectroscopy at baseline, 2-2.5 weeks, 4-5 weeks, and 1 month following radiation therapy completion, and FDG PET/CT at baseline, 2-2.5 weeks, and 4-5 weeks.
3085049|NCT01992848|Experimental|All participants|"Venous blood sampling 4-day food diary~1 week UV Dosimeter Peripheral Quantitative Computed Tomography of the radius"
3085050|NCT01992835|Placebo Comparator|measurement of mediators in biological fluids|
3085051|NCT01992835|Experimental|Grass pollen allergen extract|
3085052|NCT01992822|Experimental|experimental pain induction|application of a pre-fixed pressure (160 kPa) on the forearm
3085053|NCT01992809|Active Comparator|Omega 3|Omega-3 group (n=30) received capsules containing 945 mg of Omega-3 PUFA [α linolenic acid/ 64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic acid (DHA)/21%], in 3 capsules/ day
3085054|NCT01992809|Placebo Comparator|placebo mineral oil|placebo mineral oil 3 ml/day
3085055|NCT01992796|Experimental|irbesartan|"Irbesartan (total dose of 75 mg) or placebo administered every 24 hrs for 15 days. Moreover, the sepsis management will follow standard international guidelines (Crit Care Med.2008 Jan;36(1):296-327. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock).~Duration of treatment: Irbesartan 75 mg daily for 15 days; only one cycle. Follow up will last 90 days both for treatment and control arm.~Route of administration : oral by nasogastric tube.~Medication permitted and not permitted during the trial:~all the therapeutic interventions for sepsis management as indicated by international guidelines are admitted. During the trial are not permitted: ACE inhibitors, ARBs different from Irbersartan, angiotensin I synthesis inhibitors"
3085056|NCT01992796|Placebo Comparator|Placebo|Packaging and labelling for blinding purposes: tablets of placebo looking like the study drug
3085057|NCT01992783|Experimental|Hi-maize resistant starch|13.5 g/day
3085058|NCT01992783|Placebo Comparator|Maltodextrin|13.5 g/day
3085059|NCT01992770|Experimental|Tailored behavioural medicine|After having received a minimal intervention (step 1) comprising 'stay-active advice', participants scoring >90 on the Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) are randomly allocated to an eight-week treatment in step 2, depending on risk profile. The experimental condition includes supervised physical exercises integrated with either (a) graded activity, or (b) hierarchical graded exposure depending on risk profile, i.e. absence or presence of pain catastrophizing and fear-avoidance beliefs.
3085060|NCT01992770|Active Comparator|Control group|"Participants will be scheduled for supervised, regular Physical exercises twice a week during eight weeks 8. Participants with a moderate to high disability risk profile will receive: Tailored graded activities training."
3085061|NCT01992757||Cardiac surgery with cardiopulmary bypass|
3085062|NCT01992744||Healthy Pregnant Women|Participants 8 to 12 weeks gestational age as determined by their physician.
3085063|NCT01992731|Active Comparator|IUI group|"Group 1: Patients undergo a standard treatment with 3 consecutive gonadotrophin stimulated IUI cycles Intervention: treatment choice and drug:(Follitropine Bèta, Puregon, MSD).~vs."
3085064|NCT01992731|Active Comparator|IVF/ICSI arm|"Group 2: 1 Patients start immediately with IVF/ICSI instead of IUI. A standard antagonist protocol with treatment with a recombinant FSH (Follitropine Bèta, Puregon, MSD) is used.~Intervention: treatment choice and drug: recombinant FSH (Follitropine Bèta, Puregon,"
3085065|NCT01992718|Active Comparator|Evaluation of MRI, US for pelvic conditions|MRI and ultrasound imaging will be used clinically to evaluate pelvic pain and abnormal uterine bleeding. The goal is to determine which exams are most helpful to the clinician in providing an accurate diagnosis as well as evaluating patient preference.
3085066|NCT01992718|Active Comparator|Patient preference MRI vs. US|We are asking subjects to evaluate patient preference between MRI (magnetic resonance imaging) and ultrasound to determine which they would rather undergo.
3085067|NCT01992705|Other|Chemotherapy+SBRT prior to surgery if applicable|"FOLFIRINOX Drugs:~Calcium Folinate (Folinic Acid) 400 mg IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles.~Stereotactic Body Radiotherapy (SBRT):~30 Gy in 5 fractions given to radiographically defined pancreatic mass alone"
3085068|NCT01992692||PD group|Parkinsonian patients undergoing deep brain stimulator insertion and pulse generator placement
3085069|NCT01992692||non-PD group|Non-Parkinsonian patients undergoing intracranial surgery
3085070|NCT01992679|No Intervention|Control|Participants in the control group will undergo the same assessments but receive no exercise stimulus and be asked to maintain current physical levels
3085128|NCT01992276|Placebo Comparator|Placebo|Dextrose: 5% in water
3085129|NCT01992263|Experimental|Vitamin D (600 IU)|
3085071|NCT01992679|Experimental|Exercise group|The exercise program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training.
3085072|NCT01992666|Experimental|Blood sampling|
3085073|NCT01992653|Experimental|Polatuzumab Vedotin + G-CHP|Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
3085074|NCT01992653|Experimental|Polatuzumab Vedotin + R-CHP|Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
3085075|NCT01992627|Experimental|High Intensity Laser Therapy|High Intensity Laser Therapy (HILTERAPIA HIRO 3.O)will be used among diagnosed patients with elbow epicondylosis. A five minutes duration of HILTERAPIA HIRO 3.0 along the epicondyle area in a targeted manner will be use on the initial treatment, one week after the initial treatment, two weeks after the initial treatment and four weeks after the initial treatment thereafter.
3085076|NCT01992614|Experimental|Cohort 1|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
3085077|NCT01992614|Experimental|Cohort 2|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
3085078|NCT01992614|Experimental|Cohort 3|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
3085079|NCT01992601|Experimental|1|This arm is consist of 12 subject. Crestor 20mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.
3085080|NCT01992601|Experimental|2|This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Crestor 20mg alone for 6 day during period 2.
3085081|NCT01992601|Experimental|3|This arm is consist of 12 subject. Micardis 80mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.
3085082|NCT01992601|Experimental|4|This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Micardis 80mg alone for 6 day during period 2.
3085083|NCT01992588|Experimental|FIAsp followed by NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
3085084|NCT01992588|Experimental|NovoRapid® followed by FIAsp|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
3085085|NCT01992575||Retinal Vein Occlusion Group|Up to 35 patients diagnosed with retinal vein occlusions will be considered and evaluated for enrollment in this study.
3085086|NCT01992562|Experimental|Treatment|5 mcg ziconotide in 1ml of normal saline bolus intrathecal injection
3085087|NCT01992562|Placebo Comparator|Placebo|1ml of normal saline bolus intrathecal injection
3085088|NCT01992549|Experimental|Human-cl rhFVIII|
3085089|NCT01992536|Experimental|Ia: MenABCWY+OMV|Investigational
3085090|NCT01992536|Placebo Comparator|Ib: Placebo|Saline
3085091|NCT01992536|Experimental|IIa: MenABCWY+¼OMV|Investigational
3085092|NCT01992536|Placebo Comparator|IIb: Placebo|Saline
3085093|NCT01992536|Experimental|IIIa: MenABCWY+OMV|Investigational
3085094|NCT01992536|Experimental|IIIb: MenABCWY+¼OMV|Investigational
3085095|NCT01992536|Experimental|IVa: MenABCWY+OMV|Investigational
3085096|NCT01992536|Experimental|IVb: MenABCWY+¼OMV|Investigational
3085097|NCT01992536|Placebo Comparator|IVc: Placebo|Saline
3085098|NCT01992523|Experimental|Ticagrelor mashed pills|Ticagrelor loading dose (LD) 180 mg as mashed pills
3085099|NCT01992523|Active Comparator|Ticagrelor integral pills|Ticagrelor loading dose (LD) 180 mg as integral pills
3085100|NCT01992510||silicone oil fiiled eye|those with a condition
3085101|NCT01992510||fellow eye|the contralateral eye in the same patient
3085102|NCT01992497|Placebo Comparator|Formula + placebo|
3085103|NCT01992497|Experimental|Formula + probiotic|Formula + probiotic
3085104|NCT01992497|Experimental|Breastfed + probiotic|Breastfed + probiotic
3085105|NCT01992497|Placebo Comparator|Breastfed + placebo|
3085106|NCT01992471||history of breast cancer who have undergone BRCA1/2 testing|This is a single-arm observational study. Subjects with a history of breast cancer who have undergone BRCA1/2 testing and have received uninformative findings will enroll in this study, and then receive pre-test counseling for multiplex testing.
3085107|NCT01992445||Suicidal|
3085108|NCT01992445||Other mental health|
3085109|NCT01992445||Control (non suicidal, non mental health)|
3085110|NCT01992432||Single-group study: chemotherapy|Single-group study: chemotherapy
3085111|NCT01992406||Transrectal hybrid-NOTES anterior resection|
3085112|NCT01992393|Experimental|TIME|This arm will receive the TIME intervention.
3085113|NCT01992393|No Intervention|Treatment as Usual (TAU)|This arm will receive treatment as usual.
3085114|NCT01992380|Experimental|Healthy Volunteer Subjects|Subjects will receive two i.v. bolus injections of approximately 370 Megabecquerels (MBq) of 18F-AV-1451 up to four weeks apart.
3085115|NCT01992380|Experimental|MCI subjects|Subjects will receive two i.v. bolus injections of approximately 370 MBq of 18F-AV-1451 up to four weeks apart.
3085116|NCT01992380|Experimental|Probable AD Subjects|Subjects will receive two i.v. bolus injections of approximately 370 MBq of 18F-AV-1451 up to four weeks apart.
3085117|NCT01992367|Placebo Comparator|Placebo|placebo arm
3085118|NCT01992367|Other|ASLAN003|Active drug
3085119|NCT01992354|Experimental|Single Arm|Evaluation of PET MR device for image assessment and device performance
3085120|NCT01992341|Experimental|AMG 386 15mg/kg and paclitaxel 80mg/m2|
3085121|NCT01992328|Experimental|Immune Globulin|Immunoglobulin G Deficiency Associated with persistent asthma subtypes
3085122|NCT01992315|Experimental|Adipose-Derived ECM|
3085123|NCT01992302||Rapid Cycling Group|Patients who develop a rapid cycling course during the follow-up period.
3085124|NCT01992302||Non Rapid Cycling Group|Patients who do not develop a rapid cycling course during the follow-up period.
3085125|NCT01992289||No treatment|This is a long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002.
3085126|NCT01992276|Experimental|CR8020|Investigational monoclonal antibody against influenza A viruses
3085133|NCT01992250|Other|Low Risk - Age 70+|Age 70+. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies
3085134|NCT01992250|Other|Moderate Risk - Age 50-69|Age between 50-69. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies
3085135|NCT01992237||ALI patients|Patients with ARDS by Berlin definition and with or without clinical indication for ECMO treatment.
3085136|NCT01992224|Experimental|early mechanical ventilation|"Fulfillment of three or more criteria below:~respiratory rate > 28 per minute serum lactate > 3 mmol/L PaO2/FiO2 Index <300 mmHg SvO2 < 65% lung infiltration or atelectasis, pleural exudation~Abbreivation: PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; SvO2, venous oxygen saturation"
3085137|NCT01992224|Experimental|conventional mechanical ventilation|other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate > 28 bpm dyspnea PaO2/FiO2 Index <200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
3085138|NCT01992211|Experimental|Treatment Sequence 1(ABC)|"Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 15Day."
3085139|NCT01992211|Experimental|Treatment Sequence 2(ACB)|"Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 15Day."
3085140|NCT01992211|Experimental|Treatment Sequence 3(BAC)|"Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 1Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 15Day."
3085141|NCT01992211|Experimental|Treatment Sequence 4(BCA)|"Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 8Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 15Day."
3085142|NCT01992211|Experimental|Treatment Sequence 5(CAB)|"Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 1Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 15Day."
3085143|NCT01992211|Experimental|Treatment Sequence 6(CBA)|"Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 8Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 15Day."
3085144|NCT01992198|Experimental|cefoperazone + metronidazole|cefoperaozone 2g q8h + MDZ 0.5g q8h Oral care Somatostatin 3-6mg per 24h enteral nutrition
3085145|NCT01992198|Active Comparator|meropenem|Meropenem 0.5g q6h or adapted with renal function. Oral care Somatostatin 3-6mg per 24h enteral nutrition
3085146|NCT01992185|Active Comparator|Photocil for Vitiligo|Active Drug - Photocil for Vitiligo
3085147|NCT01992185|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
3085148|NCT01992172|Active Comparator|Photocil for Atopic Dermatitis|Active Drug - Photocil for Atopic Dermatitis
3085149|NCT01992172|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
3085150|NCT01992159|Placebo Comparator|Placebo|Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.
3085151|NCT01992159|Experimental|Romosozumab 70 mg|Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.
3085152|NCT01992159|Experimental|Romosozumab 140 mg|Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.
3085153|NCT01992159|Experimental|Romosozumab 210 mg|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
3085154|NCT01992146|Placebo Comparator|Placebo|Change in Pain Ratings (NRS) at the surgical site and at the mirror-site in the contralateral groin six to eight weeks after unilateral herniotomy following administration of placebo.
3085155|NCT01992146|Experimental|Target-controlled naloxone-infusion (total dose: 3.25 mg/kg)|Change in Pain Ratings (NRS) at the surgical site and at the mirror-site in the contralateral groin six to eight weeks after unilateral herniotomy following administration of naloxone.
3085156|NCT01992133|Experimental|Vitamin D3|Vitamin D3 at 4000 iu per day for 6 months
3085157|NCT01992133|Placebo Comparator|Placebo|matching placebo- capsules containing soya oil at 4 capsules a day for 6 months
3085158|NCT01992120|Experimental|Debriefing of high-fidelity sepsis simulation scenarios|"First visit:~Subjects will fill out a self-assessment focusing on perceptions of their knowledge and ability in the recognition and management of sepsis in hospitalized patient~Subjects will be specifically exposed to high-fidelity simulated sepsis scenarios and be debriefed on their performance in these scenarios (intervention)~Subjects will take a written test focusing on early recognition and management of sepsis~Subjects will receive a didactic teaching session focusing on recognition and management of early sepsis in the hospitalized patient~In the second visit:~Subjects will be exposed to a number of high-fidelity simulated sepsis scenarios and be scored on their performance in management of these scenarios~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis~Subjects will then be debriefed specifically on their performance in the simulation scenarios"
3085192|NCT01991873|Experimental|Maintenance Chemotherapy + Panitumumab|"Maintenance therapy:~Panitumumab 6 mg/kg prior to administration of chemotherapy Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15~Re-induction upon progression:~Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.~mFOLFOX6: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15"
3085313|NCT01991106|Active Comparator|nutritional advice|10 individual nutrition consultations with an accredited dietitian over the 12 month period. Content of consultations will include healthy food choices, portion sizes and regular mealtimes.
3085159|NCT01992120|Placebo Comparator|Debriefing of high-fidelity non-sepsis simulation scenarios|"First visit:~Subjects will fill out a self-assessment survey of their perceptions of their knowledge and ability in the recognition and management of sepsis in the hospitalized patient~Subjects will be exposed to high-fidelity simulation scenarios (non-sepsis) and be debriefed in terms of their performance in these scenarios~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis~Subjects will receive a didactic teaching session focusing on recognition and management of early sepsis in the hospitalized patient~In the second visit:~Subjects will be exposed to a number of high-fidelity simulated sepsis scenarios and be scored on their performance in management of the scenarios~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis~Subjects will then be debriefed specifically on their performance in the simulation scenarios"
3085160|NCT01992107|Experimental|QIVc (≥4 to <18 years)|Subjects received one or two doses of QIVc-Quadrivalent Cell-based Influenza Vaccine recommended for 2013-2014 season
3085161|NCT01992107|Active Comparator|TIV1c (≥4 to <18 years)|"Subjects received one or two doses of TIV1c (Trivalent Inactivated Cell-based Influenza Vaccine containing one strain from B lineage (B1 strain) recommended for 2013-2014 season"
3085162|NCT01992107|Active Comparator|TIV2c (≥4 to <18 years)|"Subjects received one or two doses of TIV2c (Trivalent Inactivated Cell-based Influenza Vaccine containing B strain from the alternate lineage (B2 strain) recommended for 2013-2014"
3085163|NCT01992094|Experimental|QIVc|Influenza vaccine
3085164|NCT01992094|Active Comparator|TIV1c|Influenza vaccine
3085165|NCT01992094|Active Comparator|TIV2c|Influenza vaccine
3085166|NCT01992081|Experimental|Telecoaching|Participants will receive daily coaching by an automated telehealth system and coaching by the investigator during study visits, in addition to the usual care.
3085167|NCT01992081|Other|Control|Participants will receive the usual care but will NOT receive daily coaching by telehealth system.
3085168|NCT01992068||Lung cancer patients ≥ 18 years of age|"Lung cancer patients age ≥ 18 years or older who have:~Histologically confirmed lung cancer scheduled to undergo conventionally fractionated radiation treatment~Absence of any severe disorders of esophageal motility (patients with reflux and/or a hiatal hernia are eligible)"
3085169|NCT01992055|Experimental|Goal Management Training|The modified GMT intervention will consist of seven group sessions and, similar to van Hooren et al (2007), an individual session with a neuropsychologist on Session 5. Sessions will be held twice weekly. The manualized group sessions will include: (1) structured psychoeducation introducing participants to the brain and executive functioning, the relationship between stress and cognitive functioning, and relaxation training; (2) stepwise learning of GMT, including education regarding attentional lapses and goal neglect, as well as in-session practice targeting individual everyday functional deficits with the goal of maximizing generalization. Homework assignments targeting individual functional deficits will be assigned following each session.
3085170|NCT01992055|Active Comparator|Education & relaxation training|Education and relaxation training control group
3085171|NCT01992042|Experimental|Fluvastatin/Pimonidazole|Patients will take 40mg BID of fluvastatin. The day before surgery patients will take a single dose of pimonidazole that will be calculate based on body surface area.
3085172|NCT01992029||ALS Patients|
3085173|NCT01992029||Control patients suffering from neuropathy|
3085174|NCT01992029||Control patients suffering from myopathy|
3085175|NCT01992029||Control subjects|control patients without any neurological disease having an orthopedic surgery for shoulder disease
3085176|NCT01992016|Experimental|Arm I (localized prostate cancer)|Patients receive ranolazine PO BID for 1 day. Patients undergo FDG-PET/CT scan at baseline and after ranolazine treatment. Patients may then undergo robotic or open radical prostatectomy.
3085177|NCT01992016|Experimental|Arm II (metastatic prostate cancer)|Patients receive ranolazine PO BID for 1 day. Patients undergo FDG-PET/CT scan at baseline and after ranolazine treatment.
3085178|NCT01992003||Patients undergoing spine surgery|
3085179|NCT01991990|Placebo Comparator|Placebo|
3085180|NCT01991990|Experimental|RoActemra/Actemra|
3085181|NCT01991977|Experimental|Diagnostic (PET, pMRI, DTI, IMRT, temozolomide)|Patients undergo 18F DOPA-PET, pMRI and DTI within 14 days before radiation therapy, 3-6 weeks after radiation therapy, and during follow-up. Patients also undergo IMRT over 30 fractions and receive temozolomide.
3085182|NCT01991964|Experimental|laryngeal ultrasound stridor|During the study period, infants referred for FLB and bronchoscopy due to congenital stridor at the Department of Pediatric Pulmonology, Critical Care and Sleep Medicine at the Tel Aviv Sourasky Medical Centre will undergo an awake US of the larynx prior to performing the Flexible bronchoscopy.
3085183|NCT01991964|Other|laryngeal ultrasound -control|Infants matched for age referred for flexible bronchoscopy for reasons other than stridor will undergo an awake US of the larynx.
3085184|NCT01991951|Experimental|Short term warfarin group|taking warfarin for only 2 weeks after catheter ablation of atrial fibrillation
3085185|NCT01991951|Active Comparator|Conventional therapy arm|conventional warfarin therapy of 3 weeks before and 8 weeks after catheter ablation of AF
3085186|NCT01991938|Experimental|VS-5584|Oral VS-5584 administered once daily on Day 1, 3, 5, 8, 10, 12, 15, 17 and 19 of each cycle
3085187|NCT01991925||quality of life, quality of care|
3085188|NCT01991912|Experimental|irrigation endoscopic decompression|endoscopic decompression is performed for cases of lumbar spinal stenosis.Portals 0.5cm in size are used for the introduction of the instruments and the endoscope. Saline under pump pressure is used to open a potential working space. This is followed by performing an ipsilateral hemilaminotomy and contralateral decompression under the midline structure
3085189|NCT01991899|Experimental|MMR Bio-Manguinhos|Arm 1:1170 children will receive MMR Bio-Manguinhos, 3 diferents lots
3085190|NCT01991899|Active Comparator|MMR GlaxoSmithKline|Arm 2:390 children will receive MMR GlaxoSmithKline
3085191|NCT01991886|Experimental|nasal High Flow applied|Application of nasal High Flow 6-7l/min via nasal prongs after birth using a mobile Vapotherm Precision Flow device
3085309|NCT01991119|Active Comparator|Propafenone|Propafenone group
3085310|NCT01991119|Active Comparator|Dronedarone|Dronedarone group
3085314|NCT01991106|No Intervention|non-obese children|100 healthy non-obese children aged 7-16 (controls)
3085315|NCT01991080|Active Comparator|Wheatgerm juice|patients will drink Wheatgerm juice
3085193|NCT01991873|Experimental|Maintenance Chemotherapy w/o Panitumumab|"Maintenance therapy:~Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15~Re-induction upon progression:~Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.~mFOLFOX6 chemotherapy: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15"
3085194|NCT01991860|Experimental|APD421|Single dose of IV APD421
3085195|NCT01991860|Placebo Comparator|Placebo|Single dose of IV placebo
3085196|NCT01991847|Experimental|Physical activity|Physical activity
3085197|NCT01991834|Placebo Comparator|Placebo|Patients in this arm will receive intravenous sterile saline 30 minutes before the gynecologic laparoscopy.
3085198|NCT01991834|Active Comparator|Cefazolin|Patients in this arm will receive intravenous cephazolin 1g, 30 minutes before the gynecologic laparoscopy.
3085199|NCT01991821|Experimental|APD421|IV APD421 single dose
3085200|NCT01991821|Placebo Comparator|Placebo|IV placebo single dose
3085201|NCT01991795|Experimental|Ticagrelor 60 mg|Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.
3085202|NCT01991795|Placebo Comparator|Ticagrelor placebo|Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.
3085203|NCT01991782|No Intervention|Control|Control patients with all follow-up visits in person at the Vanderbilt Orthopaedic Trauma clinic (2 weeks, 6 weeks, 3 months, and 6 months post-operative).
3085204|NCT01991782|Experimental|Telemedicine|Experimental cohort with two follow-up visits (6 weeks and 6 months) occurring via telemedicine video calls and two follow-up visits (2 weeks and 3 months) occurring in person.
3085205|NCT01991769|Experimental|exercise diabetes type 2|4x4 min interval training, 47 min moderate intensity training, or no exercise preceding an 'unhealthy' meal.
3085206|NCT01991769|Active Comparator|exercise healthy volunteers|4x4 min interval training, 47 min moderate intensity training, or no exercise preceding an 'unhealthy' meal.
3085207|NCT01991756||AAA|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm will be treated with the Altura Endograft System.
3085208|NCT01991743|Active Comparator|Drug:Group 2.5|Administration of 2.5 mg bupivacaine
3085209|NCT01991743|Active Comparator|Group 5|Administration of 5 mg bupivacaine.
3085210|NCT01991743|Active Comparator|Group 7.5|Administration of 7.5mg bupivacaine.
3085211|NCT01991743|Active Comparator|Group 10|Administration of 10 mg bupivacaine.
3085212|NCT01991717|Experimental|Victus Group|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
3085213|NCT01991717|Other|Conventional Group|The Conventional Group acts as a control group where the capsulotomy as well as the lens fragmentation is performed manually
3085214|NCT01991691|Experimental|Tablet-based reported outcome|With the start of chemotherapy until the end of the last cycle of chemotherapy the study participants have to document all signs of discomfort or changes to their overall coenesthesia in the tablet-based questionnaire.
3085215|NCT01991678|Experimental|normal hepatic function|12 Patients will receive a 90-minute IV infusion
3085216|NCT01991678|Experimental|mild hepatic dysfunction|6 Patients will receive a 90-minute IV infusion
3085217|NCT01991678|Experimental|severe hepatic dysfunction|6 Patients will receive a 90-minute IV infusion
3085218|NCT01991665|Other|Group A|Digital examination before instrumental delivery to determine fetal head station and position
3085219|NCT01991665|Other|Group B|Digital examination before instrumental delivery to determine fetal head station and position + sonography evaluation of fetal head position
3085220|NCT01991652||Wilms tumour|"Children diagnosed with a Wilms tumour receive SIOP PODC Wilms tumour treatment; preoperative chemotherapy, surgery and postoperative chemotherapy (= standard care).~One group of patients."
3085221|NCT01991639|No Intervention|cognitive training|Participants are visited twice a week by buddies, but they do not specifically monitor the nutritional status or perform physical training in the first 10-12 weeks. Instead of that buddies are provided with a portfolio of possible activities, especially cognitive training, which they could perform together with the frail, malnourished subjects.
3085222|NCT01991639|Experimental|nutritional & physical activity|Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
3085223|NCT01991626|Other|LNS|Maize meal mixed with Lipid Nutrient Supplement (LNS) containing micronutrient powder
3085224|NCT01991626|Other|FePP-Emulsion mixed|Fat emulsion mixed to the meal containing FePP
3085225|NCT01991626|Other|FeSO4-Mixed|meals containing FeSO4 mixed with a fat emulsion
3085226|NCT01991626|Other|FePP-Emulsion before|Fat emulsion taken before a meal containing FePP
3085227|NCT01991626|Other|FeSO4- Emulsion before|Fat emulsion taken before a maize meal containing FeSO4
3085228|NCT01991626|Other|LNS-Phytase|Maize meal mixed with LNS containing micronutrient powder and phytase
3085229|NCT01991626|Other|phytase|Maize meal containing micronutrient powder and phytase
3085230|NCT01991626|Other|MNP-control|maize meal containing micronutrient powder (MNP)
3085231|NCT01991626|Other|FePP control|Maize meal containing FePP
3085232|NCT01991626|Other|FeSO4 control|Maize meal containing FeSO4
3085233|NCT01991613|Experimental|liquid protein supplement|Study subjects will receive standard of care nutrition with the addition of a liquid protein supplement when the baby is able to tolerate an enteral feeding volume of 40mL/kg/day.
3085234|NCT01991613|No Intervention|Control group|Study subjects will receive standard of care nutrition
3085235|NCT01991600|Active Comparator|Ferrous Sulphate|The active comparator was the standard-of-care therapy for iron deficiency anaemia (namely ferrous sulphate). Generic uncoated ferrous sulphate tablets BP 300 mg containing 60mg elemental iron were purchased from a local pharmacy. The route of administration was oral. Each participant ingested one ferrous sulphate tablet (60 mg Fe) on one of the study visits.
3085316|NCT01991080|Active Comparator|Biofeedback|The patients will undergo biofeedback relaxation therapy
3085357|NCT01990781|Active Comparator|Group L: Lidocaine|Group L: lidocaine 1.5 mg/kg iv prior to induction of anesthesia
3085236|NCT01991600|Experimental|ferric iron oxide-organic acid (Fe-OA)|Fifteen different ferric iron oxide-organic acid preparations were investigated. Most organic acids used were generally recognised as safe (GRAS) and all were used at dietary equivalent levels. The dosage was 58 ± 6 mg elemental iron equivalent (average of all compounds). The route of administration was oral using methyl-cellulose capsules. On one of the study visits, each participant ingested a single dose, equivalent to ca. 60 mg iron, of the Fe-OA preparation allocated to her.
3085237|NCT01991587|Experimental|Low dose of quadrivalent VLP vaccine|Biological: A single low dose of quadrivalent VLP vaccine
3085238|NCT01991587|Experimental|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
3085239|NCT01991587|Experimental|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
3085240|NCT01991587|Placebo Comparator|Placebo|A single dose of Placebo
3085241|NCT01991574|Placebo Comparator|Methylcellulose|On one of the study days: ingest one methylcellulose capsule with a test meal rich in phosphate.
3085242|NCT01991574|Active Comparator|Calcium Acetate|On one of the study days: ingest 667 mg calcium acetate, equivalent to 169 mg elemental calcium, with a test meal rich in phosphate.
3085243|NCT01991574|Experimental|Iron Hydroxide Adipate|On one of the study days: ingest 800 mg ferric hydroxide adipate, equivalent to 175 mg elemental iron, with a test meal rich in phosphate.
3085244|NCT01991561|Experimental|Low dose of H5 VLP vaccine + Alhydrogel|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
3085245|NCT01991561|Experimental|Med dose H5 VLP vaccine + Alhydrogel|Biological:Med dose of H5 VLP vaccine + Alhydrogel, 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
3085246|NCT01991561|Experimental|High dose of H5 VLP vaccine + Alhydrogel|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
3085247|NCT01991561|Experimental|Low dose of H5 VLP vaccine + GLA-SE|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
3085248|NCT01991561|Experimental|High dose of H5 VLP vaccine + GLA-SE|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
3085249|NCT01991561|Placebo Comparator|Placebo comparator: Placebo|Biological: Placebo 2 doses given 21 days apart of the placebo
3085250|NCT01991548|Other|Diabetic participants with study devices|
3085251|NCT01991522|Experimental|Curriculum Group|The curriculum group will undergo a comprehensive curriculum in colonoscopy utilizing a virtual reality (VR) colonoscopic simulator. This curriculum involves 6 hours of interactive, small-group didactic teaching on colonoscopy interlaced with 8 hours of supervised one-on-one endoscopy VR simulation training with experienced endoscopists.
3085252|NCT01991522|Active Comparator|Self-directed learning group|The self-directed group will receive 8 hours of colonoscopic virtual reality (VR) simulation practice with an experienced endoscopist present, but without structured training.
3085253|NCT01991509|Experimental|LBR-101 IV Dose 1|LBR-101 Dose 1 Administered Intravenously
3085254|NCT01991509|Experimental|LBR-101 SC Dose 1|LBR-101 Dose 1 Administered Subcutaneously
3085255|NCT01991509|Placebo Comparator|Placebo IV|Placebo Administered Intravenously
3085256|NCT01991509|Placebo Comparator|Placebo SC|Placebo Administered Subcutaneously
3085257|NCT01991509|Experimental|LBR-101 Dose 2 IV|LBR-101 Dose 2 Administered Intravenously
3085258|NCT01991509|Experimental|LBR-101 Dose 2 SC|LBR-101 Dose 2 Administered Subcutaneously
3085259|NCT01991483|Experimental|LY2928057 (No ESA)|Multiple doses of LY2928057 administered intravenously (IV) either once every 2 weeks (Q2W) or once per week (QW) for 6 weeks. Participants discontinued their personal physician-prescribed erythropoiesis stimulating agent (ESA) before treatment.
3085260|NCT01991483|Experimental|LY2928057 (Reduced ESA)|Multiple doses of LY2928057 administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.
3085261|NCT01991483|Placebo Comparator|Placebo (No ESA)|Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants discontinued their personal physician-prescribed ESA dose before treatment.
3085262|NCT01991483|Placebo Comparator|Placebo (Reduced ESA)|Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.
3085263|NCT01991470|Experimental|2-18 year olds with Insulin requiring diabetes.|Each subject will wear enlite and / or enlite 3 sensors and will undergo 1 or 2 frequent sample tests, in-clinic
3085264|NCT01991457|Other|Treatment|Fludarabine, Total Body Irradiation (TBI)
3085265|NCT01991444||TAVI patients of > 79 years|"All patients undergoing transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve in participating sites.~Routine data about the intervention (transcatheter valve Implantation) will be collected. In addition, data describing the geriatric status of the patient, including a patient questionnaire evaluating his/her Quality of life will be collected."
3085266|NCT01991431||TAVI|All Patients undergoing transaortic transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve with the Ascendra+ Delivery-System in participating sites
3085267|NCT01991418||early staged non-small cell lung cancer|patients diagnosed as early staged non-small cell lung cancer and received surgery in HunanPTH
3085268|NCT01991405|Sham Comparator|Computerized Working Memory Training.|The Working Memory Training, includes both auditive and visual tasks, administrated on a computer, under guidance. 5 x 45 minutes per week, for 5 weeks. The placebo group will train at an fixed level (non-adaptive), but with otherwise identical computer programs.
3085269|NCT01991392|Active Comparator|Maintaining tube|Maintain nasogastric tube after extubation following pancreaticoduodenectomy
3085270|NCT01991392|Experimental|Non-tube|Remove nasogastric tube after extubation following pancreaticoduodenectomy
3085311|NCT01991106|Experimental|High intensity interval training|10-minute warm up at 60-70% of maximal heart rate (HRmax). Then walking, running or cycling at 85-95% of maximal heart rate at intervals of 4 x 4 minutes, with 3 minute active breaks (50-70% of HRmax) between intervals. A 5-minute cool down period.
3085312|NCT01991106|Experimental|Moderate intensity continuous training|walking, running or cycling continuously at 60-70% HRmax for 44 minutes.
3100901|NCT01886053|Experimental|Faropenem（high dose group）|
3085271|NCT01991379|Experimental|MEK162 in Combination With Imatinib Mesylate|Pts will be treated with the combination therapy of MEK162 & imatinib. The phase Ib portion of the study, pts will receive imatinib at 400 mg once daily & MEK162 at the standard 3+3 escalation doses. Phase Ib expansion cohort, pts will receive the RP2D: imatinib 400 mg once daily (standard of care first line imatinib dose) & MEK162 at the RP2D twice daily. The phase II portion of the study, pts will receive imatinib at 400 mg once daily & MEK162 at the RP2D. The MEK162 RP2D was originally determined based on the phase Ib escalation data & it was established as 45 mg BID. After the completion of the phase Ib dose expansion & initiation of phase II, the MEK162 RP2D was reduced to 30 mg BID30 for better long term tolerability. Patient's will now begin MEK162 at the revised RP2D of 30 mg BID. 1 cycle is 28 days. If no progression of the tumor is seen, pts will continue on therapy. Pts who have progression of disease will proceed directly to second line therapy as per standard of care.
3085272|NCT01991366||Eptifibatide Pre PCI|Receive eptifibatide pre PCI
3085273|NCT01991366||Eptifibatide during PCI|Receive eptifibatide during PCI
3085274|NCT01991366||No Eptifibatide|Receive no eptifibatide
3085275|NCT01991353|Experimental|With PRP|Standardized meniscal repair with PRP (platelet rich plasma) in the meniscal healing bed.
3085276|NCT01991353|Active Comparator|Without PRP|Standardized meniscal repair without PRP (platelet rich plasma).
3085277|NCT01991340||Cohort|
3085278|NCT01991327|Experimental|Androxal|Androxal 25 mg capsules once a day for 7 days
3085279|NCT01991327|Active Comparator|Placebo Androxal|
3085280|NCT01991314|Experimental|Ferrous sulphate|Ferrous sulphate 200mg twice daily for 6 weeks
3085281|NCT01991301|Experimental|carfilzumib|Carfilzomib at a dose of 20mg/m2 I.V. will be administrated at day 1, 2 post infusion of the stem cell (SC) graft to the first 10 patients. If no > grade II toxicity* the next 10 patients will receive Carfilzomib (27 mg/m2) at day 1,2 and 8, 9, 15 and 16. If no > grade II toxicity* the next 10 patients will receive 2-3 cycles of Carfilzomib (27 mg/m2) administered at day 1,2 8,9,15 and 16 post SC graft infusion.
3085282|NCT01991288|Experimental|SNB Saphenous Nerve block|Patients received SNB preoperatively at mid thigh level with ultrasound guidance. 10 mls 0.5% bupivacaine was administered for nerve block by the anesthetist. All patients also received peri operative Local Infiltration Analgesia by the surgeon. All patients will receive preoperative oxycontin, peri operative paracetamol and diclofenac. Post operatively all patients received regular paracetamol 1g 6 hourly, Diclofenac sodium 12 hourly and oxycontin 10-20 mg 12 hourly. All patients received standardized spinal block by the same anesthetist, post nerve block for surgery.
3085283|NCT01991288|Active Comparator|NSNB Non Saphenous Nerve Block|Patients only received Local Infiltration Analgesia. As per protocol all patients received the same pre, peri and post operative analgesia as described in the experimental group. All patients had a standardized spinal block for surgery.
3085284|NCT01991275|Experimental|The ITM group|The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia.
3085285|NCT01991275|Placebo Comparator|The IV-PCA group|The postoperative pain management includes only the intravenous patient-controlled analgesia.
3085286|NCT01991262||Group 1 phone call and SMS reminder.|cloosed no one enrolled
3085287|NCT01991262||Group 2 phone call only.|cloosed no one enrolled
3085288|NCT01991262||Group 3 SMS reminder only .|cloosed no one enrolled
3085289|NCT01991262||Group 4 (Control) no support|cloosed no one enrolled
3085290|NCT01991249|Experimental|blood sample|
3085291|NCT01991236|Experimental|Video|An educational video discussing the benefits and risk associated with long term usage of systemic corticosteroids.
3085292|NCT01991236|Other|Standard script|Standard scripted discussion of risks and benefits of systemic corticosteroids read to participants.
3085293|NCT01991223|Placebo Comparator|Placebo group|NS infusion will be done during surgery.
3085294|NCT01991223|Experimental|Dex group|DEX infusion will be done during surgery.
3085295|NCT01991210|Experimental|DNIB0600A|DNIB0600A will be administered on Day 1 of each cycle (1 cycle = 21 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
3085296|NCT01991210|Active Comparator|PLD|PLD will be administered on Day 1 of each cycle (1 cycle = 28 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
3085297|NCT01991197|Experimental|Sitagliptin|"Double blind phase (week 0-16):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks.~Placebo Comparator: Gliclazide matched placebo One gliclazide matched placebo capsule daily for 4 weeks. If no severe hypoglycaemic episodes one gliclazide matched placebo capsule twice daily for 4 weeks. If no severe hypoglycaemic episodes two gliclazide matched placebo capsules twice daily for 8 weeks.~Open-label phase (week 16-32):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks."
3085298|NCT01991197|Active Comparator|Gliclazide|"Double-blind phase (week 0-16):~Gliclazide 80mg once daily for 4 weeks Then if no severe hypoglycaemic episodes increase to Gliclazide 80mg twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes increase to Gliclazide 160mg twice daily for 8 weeks Placebo Comparator: Sitagliptin matched placebo Two tablets (or one tablet in participants with moderate kidney disease) once daily for 16 weeks.~Open-label phase (week 16-32):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks."
3085299|NCT01991184|Experimental|Dose-escalation|
3085300|NCT01991171|Experimental|Kinesio Taping|Participant will receive application of Kinesiotaping in their thigh on quadriceps muscle
3085301|NCT01991171|Placebo Comparator|Kinesio Taping Placebo|Participant will receive application of placebo Kinesiotaping in their thigh on quadriceps muscle
3085302|NCT01991171|No Intervention|Control Group|This participants will not receive intervention
3085303|NCT01991158|Experimental|GAD-M regimen|GAD-M regimen means High dose of methotrexate combined with gemcitabine, pegaspargase and dexamethasone
3085304|NCT01991145|Experimental|UCB and EPO|UCB + EPO + Rehabilitation
3085305|NCT01991145|Active Comparator|UCB and placebo EPO|UCB + placebo EPO + Rehabilitation
3085306|NCT01991145|Active Comparator|placebo UCB and EPO|placebo UCB + EPO + Rehabilitation
3085307|NCT01991145|Placebo Comparator|placebo UCB and placebo EPO|placebo UCB + placebo EPO + Rehabilitation
3085308|NCT01991132|Other|MediView 2.0 software|
3085317|NCT01991067|Active Comparator|HSCT patients / TBE virus vaccine|Study population: patients who had undergone an allogeneic HSCT 11 to 13 months ago Eligible patients will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME-IMMUN®. Whenever possible, the patients will receive complete primary vaccination with a third dose of TBE vaccine (study visit 9 - 9 to 12 months after the first vaccination).
3085318|NCT01991067|Active Comparator|healthy volunteers / TBE virus vaccine|Clinical healthy volunteers will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME IMMUN®. Whenever possible, the volunteers will receive complete primary vaccination with a third dose of TBE vaccine FSME IMMUN® (study visit 9 - 12 months after the first vaccination).
3085319|NCT01991054|Experimental|vitamin D3 supplementation|The study group participants will receive vitamin D3 supplementation (120,000 I.U per month)for 6 months
3085320|NCT01991054|Placebo Comparator|placebo group|placebo group, 15 ml per month for 6 months
3085321|NCT01991041||Rufinamide|
3085322|NCT01991041||Anti-Epileptic Drugs|Includes those used off label as part of local clinical practice
3085323|NCT01991028|Experimental|Radiolabelled OligoG CF-5/20 DPI|Single dose OligoG CF-5/20 Dry Powder for Inhalation by 3 capsules of 32mg OligoG via Miat Monodose Inhaler, radiolabelled ca10MBq 99mTc.
3085324|NCT01991028|Active Comparator|Radiolabelled OligoG CF-5/20 6% Solution|Single dose of 1.5mL (90mg) aerosolised OligoG CF-5/20 6% solution via Sidestream Plus nebuliser, radiolabelled ca10MBq 99mTc.
3085325|NCT01991002|Other|14/21 diet|"Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.~The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group."
3085326|NCT01990989||Clopidogrel treated patients|A consecutive cohort with 500 cases treated with 75mg/day maintenance dose of clopidogrel.
3085327|NCT01990976||FSHD training|Only the patients who have participated to the FSHD1 study (NCT01116570) and the FSHD2 study (NCT01689480) can be included in this study.
3085328|NCT01990950|Experimental|Zenith® Fenestrated AAA Endovascular Graft|
3085329|NCT01990937|Active Comparator|Oral midazolam|Oral midazolam (5 mg) in 15 mL of apple juice was drunk 30 minutes before EGD
3085330|NCT01990937|Placebo Comparator|Apple juice|15 mL of apple juice was drunk 30 minutes before EGD
3085331|NCT01990924|Experimental|7.5 FPS|Low rate fluoroscopy at 7.5 frames per second (FPS)
3085332|NCT01990924|Active Comparator|15 FPS|Conventional rate fluoroscopy at 15 FPS
3085333|NCT01990911|Experimental|Renal denervation|Renal denervation: both renal arteries are denervated by applying radio-frequency energy at application points moving in a helical fashion starting in the distal renal artery and moving to the proximal junction with the abdominal aorta.
3085334|NCT01990911|Sham Comparator|Medical therapy|This group will not receive renal sympathetic denervation
3085335|NCT01990898|Experimental|Cyclosporine|Drug: Cyclosporine, Pill form, dosage calculated upon patient study visit, frequency - twice daily, duration - 3 months.
3085336|NCT01990885|Experimental|Cohort A|Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion
3085337|NCT01990885|Experimental|Cohort B|Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion
3085338|NCT01990885|Experimental|Cohort C|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from Cohorts A and B) in a randomized double-blind fashion
3085339|NCT01990885|Experimental|Cohort D|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion
3085340|NCT01990885|Experimental|Cohort E|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion
3085341|NCT01990872|Placebo Comparator|Placebo in high calcium group|Placebo + habitual dietary calcium intake (>1000 mg/d)
3085342|NCT01990872|Active Comparator|Vitamin D3 in low/moderate calcium group|Vitamin D3 (20 microgram/day) + habitual calcium intake <700 mg/d
3085343|NCT01990872|Placebo Comparator|Placebo in low/moderate calcium group|Placebo + habitual calcium intake <700 mg/d
3085344|NCT01990872|Active Comparator|Vitamin D3 in high calcium group|Vitamin D3 (20 microgram/day) + habitual calcium intake (>1000 mg/d)
3085345|NCT01990859|Experimental|Arm A: Ipilimumab|Ipilimumab Intravenous Injection 3 mg/kg for every 3 weeks upto 4 doses
3085346|NCT01990846|Experimental|Flufirvitide-3 dose level 1|Single dose administration for dose level 1
3085347|NCT01990846|Experimental|Flufirvitide 3-Dose level 2|Single dose administration for Dose Level 2
3085348|NCT01990846|Placebo Comparator|Placebo|Single Dose administration Placebo for Flufirvitide-3
3085349|NCT01990846|Experimental|Flufirvitide-3 Dose level 1- Repeat dose|Repeat dose administration for five days
3085350|NCT01990846|Experimental|Flufirvitide-3-Dose level 2 Repeat dose|Repeat dose administration for 5 days
3085351|NCT01990846|Placebo Comparator|Placebo for Flufirvitide-3 Repeat dose|Repeat dose administration for 5 days
3085352|NCT01990820|Active Comparator|Arm 1|Subjects will have Adenoidectomy + maxillary sinus irrigation, without balloon dilation.
3085353|NCT01990820|Experimental|Arm 2|Adenoidectomy + balloon dilation of maxillary sinus ostia using Acclarent Relieva Balloon Sinuplasty + irrigation
3085354|NCT01990807|Active Comparator|Idarubicin(IDA)|philadelphia negative high -risk ALL : Induction therapy: IDA(6mg/m2/time) one time for each week,altogether 3 times
3085355|NCT01990794||Study Volunteers|"Volunteers (males and females) were instructed to take the cobalt dietary supplement in the morning according to the manufacturer's label, which suggested a serving of 1 mg cobalt (~2 mL) daily in water or juice as maintenance. Dietary supplementation lasted for approximately three months."
3085356|NCT01990781|Experimental|Group LD: Lidocaine and Dexamethasone|lidocaine 1.5 mg/kg and dexamethasone (dexona) 8 mg iv prior to induction of anesthesia
3085358|NCT01990781|Active Comparator|D: Dexamethasone|Dexamethasone 8 mg iv prior to induction of anesthesia
3085359|NCT01990781|Placebo Comparator|N: normal saline|N: normal saline (placebo): 2 ml
3085360|NCT01990768|Experimental|1 gram Tranexamic Acid (TXA)|Loading dose of 1 gram TXA given prior to hospital arrival followed by a 1 gram TXA infusion over 8 hours after hospital arrival
3085361|NCT01990768|Experimental|2 grams TXA|Loading dose of 2 gram TXA given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival
3085362|NCT01990768|Placebo Comparator|0.9% Sodium Chloride injectable|Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival
3085363|NCT01990755|Active Comparator|CBT (Cognitive Behavioral Therapy)|"Investigates the effects of cognitive-behavioral therapy (CBT), on the secretion of brain dopamine (DA), noradrenalin (NE) and serotonin (5-HT) in a group of 50 female inpatients, 14 with AN restricter type (AN-R), 14 with the bingeing-purging type (AN-BP), and 22 with BN.~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation"
3085364|NCT01990755|Active Comparator|IBPP (IP brief psychotherapy )|"Investigates the effects in 15 AN and 17 BN patients of an individual psychology brief psychotherapy (IBPP) on psychological alterations and DA secretion measured as peripheral blood values of HVA before and after treatment.~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation."
3085365|NCT01990755|Active Comparator|CBT + OLANZAPINE (5 MG)|"The study evaluated in 18 AN-R and 12 AN-BP patients the effects of CBT and of CBT associated with orally administered 5 mg olanzapine on the psychopathological aspects of the disease and on the secretion of HVA.~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation"
3085366|NCT01990742|Experimental|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention homes.
3085367|NCT01990742|No Intervention|Standard care|Usual care will be provided to residents in the control homes.
3085368|NCT01990729||ARTRA|Patients with low back pain treated with ARTRA.
3085369|NCT01990716|Other|IBD patients|Patients (diagnosed with IBD) having a screening colonic biopsy
3085370|NCT01990716|Other|Control Group|individuals undergoing screening colonic biopsy for colon cancer or polyp detection, who have not been diagnosed with any intestinal pathology.
3085371|NCT01990703|Experimental|Early IUD Insertion Group|Immediate post-placental placement of the levonorgestrel IUD
3085372|NCT01990703|Active Comparator|Standard Postpartum Insertion Group|Placement of the levonorgestrel IUD 4-6 weeks postpartum
3085373|NCT01990690|Active Comparator|anti oxidant omega 3|The patients were randomized to receive either a daily dose of omega-3 plus as antioxidant once daily for two weeks or a daily placebo then stored in envelopes numbered from 1 to 140
3085374|NCT01990690|Placebo Comparator|placebo|"Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks.~Group 2 was given a placebo once daily for two weeks."
3085375|NCT01990677|Active Comparator|25mg Eplerenone- Chronic CSCR Diagnosis|Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 58 days. Throughout the 58 day treatment period dosage will be adjusted. The adjustment will be based on serum potassium and creatine levels from blood draws done at Day 12 and Day 33. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or reduced to placebo, one time, each day.
3085376|NCT01990677|Placebo Comparator|Placebo- Chronic CSCR Diagnosis|Dosing will begin with placebo and will stay as placebo throughout the study. The placebo pills will be taken orally, once daily, for 58 days. The placebo pills will be compounded to be of similar composition to the eplerenone tablets, without the active ingredient.
3085377|NCT01990677|Active Comparator|25mg Eplerenone- Acute CSCR Diagnosis|Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 28 days. Throughout the 28 day treatment period, dosage will be adjusted based on serum potassium and creatine levels from blood draws done on Day 12. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or reduced to placebo, one time, each day.
3085378|NCT01990677|Active Comparator|Placebo- Acute CSCR Diagnosis.|Dosing will begin with placebo and will stay as placebo throughout the study. The placebo pills will be taken orally, once daily, for 28 days. The placebo pills will be compounded to be of similar composition to the eplerenone tablets, without the active ingredient.
3085379|NCT01990664|Experimental|senofilcon A|Contact lenses to be worn in a daily wear modality
3085380|NCT01990664|Experimental|senofilcon A for Astigmatism|Contact lenses to be worn in a daily wear modality
3085381|NCT01990638||DM group|
3085382|NCT01990638||non-DM group|
3085383|NCT01990625|Experimental|Ultrasound scan|The group is pregnant women who reside in an intervention cluster who receive at least one antenatal ultrasound scan during antenatal care during the study time period.
3085384|NCT01990625|No Intervention|Routine antenatal care|The group is pregnant women that reside in the control clusters during the study time period. The group received routine antenatal care.
3085385|NCT01990612|No Intervention|Expectant Management|Expectant management (unless a medical indication arises) until at least 40 weeks 5 days.
3085386|NCT01990612|Other|Elective Induction of Labor|Elective induction of labor between 39 weeks 0 days and 39 weeks 4 days
3085387|NCT01990599|Other|Nasopharyngeal Tube|Every patient undergoing trigeminal thermal coagulation of the Gasserian ganglion will be ventilated by a nasopharyngeal placed ID 5mm tube during the whole neurosurgical intervention.
3085388|NCT01990573|Experimental|methadone HCl 0.3 mg/kg|0.3mg/kg IV methadone HCl
3085389|NCT01990573|Experimental|methadone HCl 0.5 mg/kg|0.5mg/kg IV methadon HCl
3085390|NCT01990573|Active Comparator|control group|control no methadone, standard of care opioids.
3085391|NCT01990560|Experimental|Mifepristone|Mifepristone 300mg tablets taken once daily with dose increase of no more than 300mg once monthly and to a maximum dose of 1200mg daily as indicated by symptom response
3085392|NCT01990547||Healthy Veterans|Healthy veterans, who have been deployed in support of OIF/OEF who do not have blast exposure or PTSD
3085393|NCT01990547||Veterans with history of blast exposure|OIF/OEF veterans with a history of blast exposure who do not meet criteria for PTSD
3100902|NCT01886040||cases with endometrial cancer|
3085394|NCT01990547||Veterans with PTSD receiving usual care|OIF/OEF veterans with PTSD (with or without blast exposure) only who receive usual care (i.e., pharmacotherapy and/or supportive or psychodynamic individual or group therapy, not involving exposure therapy)
3085395|NCT01990547||Veterans with PTSD receiving Virtual Reality Exposure Therapy|"OIF/OEF veterans with PTSD (with or without blast exposure) that will receive Virtual Reality Exposure Therapy through the WRNMMC IRB approved protocol entitled Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure with Cognitive Enhancer ClinicalTrials.gov Identifier: NCT01352637, which is also open to new enrollment"
3085396|NCT01990534|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 in every 3-week cycle, until there is evidence of disease progression or unacceptable toxicity occurs (Up to 16 cycles). The dose may be decreased or delayed or discontinued in participants who develop treatment-associated non-hematologic, hematologic toxicity or peripheral neuropathy to brentuximab vedotin.
3085397|NCT01990521|Experimental|MS3TMRI / TRUS Guided Biopsy|
3085398|NCT01990508|Experimental|Targeted beverage education and financial incentives|Study subjects receive monthly letters with beverage education and financial incentives for not purchasing sugar-sweetened beverages
3085399|NCT01990508|Sham Comparator|Control|Monthly letters with generic nutrition information only
3085400|NCT01990495|Active Comparator|Exercise vs. usual care|The study involves two arms randomized to exercise and usual care groups
3085401|NCT01990495|Active Comparator|Usual care|This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.
3085402|NCT01990482|Experimental|coffee|coffee
3085403|NCT01990482|Placebo Comparator|water group|water
3085404|NCT01990469|Experimental|Gemigliptin|Gemigliptin 50mg qd
3085405|NCT01990469|Placebo Comparator|Placebo|Gemigliptin placebo
3085406|NCT01990456|Experimental|PHASE 1: impact of tidal ventilation on VILI|In the first phase we will test whether administering a distending inspiratory pressure to produce tidal ventilation is superior to a strategy where only continuous positive airway pressure (CPAP) is applied for ventilation induced lung injury (VILI) mitigation, as assessed by its impact on biotrauma (serum cytokines) and physiologic measurements.
3085407|NCT01990456|Experimental|PHASE 2: impact of PEEP on VILI|In the second phase we will gain more insight as to whether a strategy that utilizes a PEEP level that correspond to best compliance is beneficial over Zero End-Expiratory Pressure (ZEEP). We will test the impact of both strategies on biotrauma (serum cytokines), physiologic parameters, and right ventricular function (transesophageal echocardiographic assessment).
3085408|NCT01990443|Experimental|Reslizumab IV|Reslizumab 220-mg administered Intravenously (IV)
3085409|NCT01990443|Experimental|Reslizumab SC|Reslizumab 220-mg administered Subcutaneously (SC)
3085410|NCT01990430|Experimental|Exercise Intervention|"The exercise program was designed and conducted by a qualified exercise physiologist with oncologic training. The exercise program consisted in a twice weekly supervised training program developed in a social framework. The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation.~The nutrition program consisted of three theoretical and practice classes, where specific terms of nutrition and diet were explained. Teachers did not promote avoiding any group of aliments and a Mediterranean diet was encouraged to be followed."
3085411|NCT01990430|No Intervention|Control|Patients will be asked to maintain their usual life style, without special changes
3085412|NCT01990417|Experimental|Passive stretching|After evaluation, the participants were randomly divided into four groups: A, B, C and D. Group A. stretched before and after workout ; group B stretched only before workout; group C stretched only after workout; and group D did not stretch at all.
3085413|NCT01990404|Active Comparator|Premixed 50% nitrous oxide and oxygen|The patient will be taken care by the physician SMUR or home emergency. Upon acceptance of participation in the study, the clock will be started at the time of the establishment of the face mask. Premixed 50% nitrous oxide and oxygen is administered for 30 minutes and an opioid titration is started 10 minutes after the introduction of gas, unless the patient expresses pain score EN <3/10.
3085414|NCT01990404|Placebo Comparator|Medical air|The patient will be taken care by the physician SMUR or home emergency. Upon acceptance of participation in the study, the clock will be started at the time of the establishment of the face mask. The medical air is administered for 30 minutes and an opioid titration is started 10 minutes after the introduction of gas, unless the patient expresses pain score EN <3/10.
3085415|NCT01990391|Placebo Comparator|Cassava flavored flour|The placebo group (cassava flour flavored) received 9g/day of cassava flour flavored during three months (12 weeks)
3085416|NCT01990391|Experimental|Brazil nut flour|The Brazil nut group received 13g/day of Brazil nut flour during three months (12 weeks)
3085417|NCT01990352|Experimental|Pegylated liposomal doxorubicin|
3085418|NCT01990339||Lansoprazole|Lansoprazole (Takepron), tablets, orally, once daily for up to 8 weeks. Reflux esophagitis: the usual adult dosage is 30 mg of lansoprazole. For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily. Nonerosive gastroesophageal reflux disease: the usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks.
3085419|NCT01990326|Experimental|XAF5 Gel|The patient will apply XAF5 Gel to the skin of the submental area once a night.
3085420|NCT01990326|Placebo Comparator|Placebo Gel|The patient will apply a Placebo Gel to the skin of the submental area once a night.
3085421|NCT01990313|Experimental|Activa PC+S|
3085422|NCT01990300||Alogliptin/pioglitazone (Liovel) combination tablets|Alogliptin/pioglitazone (Liovel) combination tablets, taken orally, once daily for up to 12 months
3085423|NCT01990287|Experimental|SCS and PNfS|Eon or Eon Mini IPG with epidural leads in the spinal column and subcutaneous leads in the peripheral field
3085424|NCT01990287|Active Comparator|SCS Alone|Eon or Eon Mini IPG with epidural leads in the spinal column
3085425|NCT01990274|Experimental|Novel|Patients in this arm will receive 3 sputum samples for GeneXpert MTB/RIF assay and MGIT liquid TB culture.
3085426|NCT01990274|Active Comparator|Standard|Patients in this arm will receive 2 sputum samples for fluorescence smear microscopy and MGIT liquid TB culture.
3103285|NCT01869881|Placebo Comparator|Placebo|
3085427|NCT01990261||Erlotinib|Participants diagnosed with locally advanced or metastatic non-small cell lung with known carcinoma epidermal growth factor receptor (EGFR) status received erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
3085428|NCT01990248||Cohort|
3085429|NCT01990235|Experimental|PREPARE intervention|The PREPARE arm will review the PREPARE website plus the easy-to-read advance directive (AD). Participants will review PREPARE on their own for ≥ 20 minutes with staff present to answer questions. During PREPARE, participants answer preference questions and make an action plan (i.e., commitment to engage in advance care planning). To ensure home access to PREPARE content, participants will be given a website login and PREPARE content in digital video disc (DVD), booklet, and pamphlet format as well as the action plan and AD. One to three days before a primary care visit, the PREPARE arm will receive a reminder to come to their appointment and to bring their action plan.
3085430|NCT01990235|No Intervention|Control|The Control arm will review an easy-to-read AD. Controls will review the AD for ≥ 15 minutes with study staff present to answer questions and will take the AD home to complete if desired. One to three days before a primary care visit, controls will receive a reminder to come to their appointment.
3085431|NCT01990209|Experimental|Orteronel|The planned dose of orteronel is 300mg orally (PO) twice daily (BID), for a total daily dose of 600mg.
3085432|NCT01990196|Active Comparator|AR inhibition only|"AR inhibition only Group 1: degarelix + enzalutamide~Endocrine therapy with degarelix and enzalutamide will continue for a minimum of 6 weeks and a maximum of 8 weeks in all groups prior to the planned prostatectomy."
3085433|NCT01990196|Active Comparator|AR inhibition plus MEK inhibition|"AR inhibition plus MEK inhibition Group 2: trametinib + degarelix + enzalutamide~In Group 2, treatment with trametinib will begin on Day 29 (i.e. four weeks after initiation of androgen deprivation). Thus, trametinib will be administered for no less than two weeks and no more than four weeks."
3085434|NCT01990196|Active Comparator|AR inhibition plus SRC inhibition|"AR inhibition plus SRC inhibition Group 3: dasatinib + degarelix + enzalutamide~In Group 3, treatment with dasatinib will begin on Day 29 (i.e. four weeks after initiation of androgen deprivation). Thus, dasatinib will be administered for no less than two weeks and no more than four weeks."
3085435|NCT01990183|Experimental|CareToy|CareToy intervention
3085436|NCT01990183|Other|Standard Care|Standard Care
3085437|NCT01990170||ultrasound-guided foam sclerotherapy|This project is ongoing from an original study conducted by our research group looking at short- and mid-term clinical outcomes after UGFS. The original patient cohort from the aforementioned study was made up of 132 patients who underwent UGFS between 1 March 2005 and 31 December 2009 for treatment of a chronic venous ulcer (CEAP classification C5 or C6 disease) with significant (>0.5s) SVR confirmed with duplex ultrasound.
3085438|NCT01990157|Experimental|TAB08|Multiple TAB08 administrations as intravenous infusions.
3085439|NCT01990144|Experimental|Bendamustine|Bendamustine is a novel chemotherapeutic agent, a hybrid of a purine analogue and an alkylator. It shows only partial in vitro cross-resistance with other alkylating agents and it is clinically well tolerated. In fact it has shown to be active in vitro against cell lines which are resistant to other alkylating agents. Preclinical data demonstrate that bendamustine acts in two distinct ways to kill cancer cells: it damages the DNA in cancer cells, which leads to cell death by a process known as apoptosis (programmed cell death) as well as by an alternate cell death pathway known as mitotic catastrophe (a disruption of normal cell division). This dual-effect may be attributable to its unique chemical structure.Bendamustine has demonstrated clinical activity in patients with chronic lymphocytic leukaemia, patients with relapsed indolent NHL, mantle cell lymphoma, multiple myeloma and several solid tumors.
3085440|NCT01990131|Experimental|Intervention|The anxiety risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
3085441|NCT01990131|Placebo Comparator|Control|The control condition will be a combination of information about general health and wellness (e.g. diet, exercise etc.) plus an inert Cognitive Bias Modification (CBM-I) task.
3085442|NCT01990118|Active Comparator|Neoral|Patients who continued to be treated with the drug Neoral.
3085443|NCT01990118|Experimental|Gengraf arm|Patients were randomly selected to be converted to 'Gengraf® capsule containing 25mg or 100mg cyclosporine'
3085444|NCT01990105||Patients with AF in the ER|All patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of arrhythmia or other cardiac diseases during the study period will be included.
3085445|NCT01990092|Experimental|Metanx|Subjects will take 2 Metanx tablets once daily for 48 weeks.
3085446|NCT01990092|Placebo Comparator|Placebo|Subjects will take 2 placebo tablets once daily for 48 weeks.
3085447|NCT01990079|Experimental|QUIT4Ever|QUIT4EVER is an intervention that combines 4 guideline-based smoking cessation counseling sessions, bupropion and nicotine replacement therapy, mobile contingency management, and the smart-phone application Stay Quit Coach.
3085448|NCT01990079|Active Comparator|Control Contact Condition|This intervention combines 4 guideline-based smoking cessation counseling sessions, bupropion and nicotine replacement therapy, and mobile contingency management.
3085449|NCT01990066|Experimental|Intervention|Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
3085450|NCT01990066|No Intervention|Observation|Subjects randomized to observation will only have physical therapy assessment using the Berg Balance Test and 6min Walk Test at baseline and end point. These subjects will not receive any exercise teaching.
3085451|NCT01990053|Experimental|Beating the Blues|Beating the Blues plus helper support.
3085452|NCT01990053|No Intervention|Waitlist Condition|Eight week waitlist condition group parallel to the immediate treatment condition with optional entrance into the Beating the Blues after the first eight weeks
3085453|NCT01990040||Teduglutide treated|SBS participants who have been treated with teduglutide.
3085454|NCT01990040||Non-teduglutide treated|SBS participants who have not been treated with teduglutide.
3085455|NCT01990027||SKSC Patients group|"A group a 1000 subjects affected by kidney stone as described in the eligibility criteria will be recruited in the period 2014-2024 and the same exams will be repeated for each participants for a period of 3 years.~No intervention will be undertaken."
3085456|NCT01990027||SKSC Control group|"A group of 250 stone-free participants will be recruited and analysed with the same protocol as the patients but in a single visit. This group will be used for comparison with the patients group in future studies.~No intervention will be undertaken."
3085457|NCT01990014||craniectomy|Adult subjects who experienced a cerebral infarction extended the sylvian area, and having received treatment by decompressive craniectomy.
3085458|NCT01990001|Experimental|Office enrollment in the online contraceptive reminder system|Members of this arm were enrolled in the reminder system during their visit.
3085459|NCT01990001|No Intervention|Control|Members in the control group were not enrolled in the reminder system
3085460|NCT01989988|Active Comparator|LRYGB|20 subjects Randomized will undergo LRYGB surgery
3085461|NCT01989988|Active Comparator|SADJB|20 subjects will undergo SADJB surgery
3085462|NCT01989988|Active Comparator|LMGB|20 subjects will undergo LMGB surgery
3085463|NCT01989962|Experimental|E4E Intervention Group|E4E Intervention Group is a group of family physicians who will participate in the first wave of E4E intervention.
3085464|NCT01989962|Sham Comparator|E4E Late Intervention Control Group|E4E Late Intervention Control Group is a group of family physicians who will participate in the second wave of E4E intervention 12 month later after the completion of the first wave of E4E intervention.
3085465|NCT01989949|Experimental|TP-434 (Eravacycline) via IV infusion|TP-434 (Eravacycline) reconstituted and administered via IV infusion at a dose of 1 mg/kg, every 12 hours, for 7 doses over 4 days.
3085466|NCT01989936|Placebo Comparator|Placebo|
3085467|NCT01989936|Experimental|Eletriptan 40 mg|
3085468|NCT01989936|Experimental|Eletriptan 80 mg|
3085469|NCT01989923|Active Comparator|Nicotine replacement therapy|"Women in this arm of the study will receive 24-hour Nicotine Patches - either 21 mg patches (for 1 pack per day smokers), or 14 mg patches (for 1/2 pack per day smokers) smokers). Patients will use one patch per day for 6 weeks for a total of 42 patches. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.~Women will also receive nicotine gum or lozenges (subject choice)- these will be 2 mg pieces of nicotine gum or lozenge (approximately 210 pieces). This will account for using 8-10 per day at the beginning of the study and tapering to 2-3 pieces per day by the end of the study."
3085470|NCT01989923|Active Comparator|Electronic Cigarettes|"Women in this arm of the study will receive one Blu Cig Electronic Nicotine Delivery Device (E-cigarette) along with 2 electronic cigarette batteries, 1 wall charger and 1 USB charger, cartridges/refills in menthol or regular (patient choice). The number of cartridges is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation."
3085471|NCT01989910|Active Comparator|Raltegravir|Raltegravir 400mg oral twice daily
3085472|NCT01989910|Active Comparator|Efavirenz|Efavirenz 600mg oral at bedtime
3085473|NCT01989897|Experimental|diluents|Negative control = diluent, saline with HSA--phenol Positive control = saline with 1mg/ml Histamine base
3085474|NCT01989884|Experimental|Ortataxel|75 on day 1 every 21 days mg/m2 milligram(s)/square meter (intravenous use)
3085475|NCT01989871|No Intervention|protocol feeding|Feeding of preterm infants according to current unit protocol: every 3 hours a prescribed amount
3085476|NCT01989871|Experimental|Adjusted individual feeding|Feeding every 2-4 hours, starting with que of hunger and finished upon infant signs.
3085477|NCT01989858|Experimental|peri-operative CHT (Arm A)|In peri-operative CHT arm CHT will be administered within 1 week (+3 days) after randomization, surgery will be performed after re-staging and 3+1 weeks after completion of the third cycle of CHT (approximately 13+1 weeks after randomization). Then CHT will be re-administered 5+1 weeks after surgery.
3085478|NCT01989858|Active Comparator|post-operative CHT (Arm B)|In post-operative CHT arm, surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).
3085479|NCT01989858|Experimental|peri-operative CHT + post-operative CHT-RTX (Arm C)|CHT 1 week (+3 days) after randomization surgery after re-staging and 3+1 weeks after completion of the third cycle of CHT CHT 5+1 weeks after surgery.
3085480|NCT01989858|Active Comparator|post-operative CHT + post-operative CHT-RTX (Arm D)|surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).
3085481|NCT01989845|Experimental|oral rivaroxaban in cancer-associated VTE|
3085482|NCT01989832||Biological and clinical Data collected|
3085483|NCT01989819||patients with Sjögren's syndrome|A skin biopsy will be performed in patients
3085484|NCT01989819||control group|A skin biopsy will be performed in control group
3085485|NCT01989819||non auto-immune small fiber neuropathies|
3085486|NCT01989806|Active Comparator|Robotic-assisted body weight supported treadmill training|Robotic assisted body weight supported treadmill training with conventional PT training
3085487|NCT01989806|Placebo Comparator|Passive lower limbs mobilization training|Passive lower limbs mobilization training with conventional PT training
3085488|NCT01989793|Active Comparator|Losartan|For those subjects randomized to the losartan group, they will receive losartan 25mg by mouth daily for 8 weeks, then increase to 50mg by mouth daily for another 8 weeks, then increase to 100mg by mouth daily for a final 8 weeks.
3085489|NCT01989793|Placebo Comparator|Placebo|For those subjects randomized to placebo, they will receive a placebo to take for 24 weeks total.
3085490|NCT01989780|Active Comparator|Arm A|weekly paclitaxel + bevacizumab
3085491|NCT01989780|Experimental|Arm B|"weekly paclitaxel + bevacizumab followed by hormone therapy(Treatment of physician's choice)* + bevacizumab then back to weekly paclitaxel + bevacizumab~* Letrozole, Anastrozole, Exemestane, Fulvestrant, Goserelin, leuprorelin or LHRH Analogs + Aromatase inhibitors."
3085492|NCT01989767|Active Comparator|control|Rehabilitation as usual
3085493|NCT01989767|Experimental|education|education of rehabilitation officers in psychiatric topics plus rehabilitation as usual
3085494|NCT01989754|Experimental|Canagliflozin (JNJ-28431754)|Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 13 weeks, then the dose may be increased to 300 mg once daily.
3085495|NCT01989754|Placebo Comparator|Placebo|Each patient will receive placebo (inactive medication) once daily.
3085496|NCT01989741|Other|sleep restriction|Longitudinal study of response to sleep restriction. Comparison between baseline values and sleep restriction values
3085497|NCT01989728|Active Comparator|care as usual|
3085498|NCT01989728|Experimental|psychiatric examination and feedback|
3085499|NCT01989715|Experimental|adult patients waiting for orthognathic surgery|
3085500|NCT01989702|Active Comparator|Fermented blueberry product|
3085501|NCT01989702|Placebo Comparator|Placebo|
3085502|NCT01989702|Active Comparator|Probiotic bacteria|
3085503|NCT01989689|Experimental|Etanercept/Placebo|The subjects will receive subcutaneous etanercept therapy at 50mg twice weekly for 3 months then will be switched to placebo therapy for an additional 3 months.
3085504|NCT01989689|Active Comparator|Placebo/Etanercept|The subjects will receive placebo injections for 3 months then will be switched to etanercept therapy for an additional 3 months.
3085505|NCT01989676|Experimental|PF-05280014|
3085506|NCT01989676|Active Comparator|Herceptin®|
3085507|NCT01989663|Experimental|1% vaginally applied tenofovir gel|1% vaginally applied tenofovir gel administered for 7 daily doses
3085508|NCT01989663|Placebo Comparator|HEC placebo vaginal gel|HEC placebo vaginal gel administered for 7 daily doses
3085509|NCT01989663|Experimental|Tenofovir film- 10mg|Tenofovir Film 10mg inserted vaginally, administered for 7 daily doses
3085510|NCT01989663|Experimental|Tenofovir Film-40 mg|Tenofovir Gel 40 mg inserted vaginally, administered for 7 daily doses
3085511|NCT01989663|Placebo Comparator|Placebo Film|Placebo Film inserted vaginally, administered for 7 daily doses
3085512|NCT01989650|Active Comparator|Break|A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
3085513|NCT01989650|No Intervention|No break|No break will be provided
3085514|NCT01989637|Experimental|Strawberry Meal|40 g freeze-dried strawberries included in test meal
3085515|NCT01989637|Placebo Comparator|Control Meal|Control consisting of matched test meal with strawberry flavoring instead of freeze-dried strawberry powder
3085516|NCT01989624||Pancreatic Adenocarcinoma|
3085517|NCT01989611|Other|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year.
3085518|NCT01989598|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease or who achieve less than PR after 4 courses may also receive Akt inhibitor GSK2141795 PO daily on days 1-28.
3085519|NCT01989585|Experimental|Arm I (dabrafenib, trametinib)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3085520|NCT01989585|Experimental|Arm II (dabrafenib, trametinib, and navitoclax)|Patients receive navitoclax PO QD days -7 to -1 of course 1 only. Patients also receive dabrafenib PO BID, trametinib PO QD, and navitoclax PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3085521|NCT01989572|Experimental|Arm I (GM-CSF, peptide vaccine)|Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
3085522|NCT01989572|Experimental|Arm II (GM-CSF placebo, peptide vaccine)|Patients receive GM-CSF (sargramostim) placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
3085523|NCT01989572|Experimental|Arm III (GM-CSF, peptide placebo)|Patients receive GM-CSF (sargramostim) SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
3085524|NCT01989572|Placebo Comparator|Arm IV (GM-CSF placebo, peptide placebo)|Patients receive GM-CSF placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
3085525|NCT01989572|Experimental|Arm V (GM-CSF)|Patients receive GM-CSF (sargramostim) SC on days 1-14.
3085526|NCT01989572|Placebo Comparator|Arm VI (GM-CSF placebo)|Patients receive GM-CSF (sargramostim) placebo SC on days 1-14.
3085527|NCT01989559|Experimental|Treatment (vaccine therapy)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine with Montanide ISA 51 VG or Montanide ISA 51 SC on day 1 and between days 25-30. After 6 months, patients free of disease receive booster injections every 6 months for 3 years in the absence of unacceptable toxicity or disease progression.
3085528|NCT01989546|Experimental|1|Single agent
3085529|NCT01989520|Experimental|Treatment A|Phase IIb formulation
3085530|NCT01989520|Experimental|Treatment B|Putative phase III formulation
3085531|NCT01989520|Experimental|Treatment C|Slow dissolution variant 1
3085532|NCT01989520|Experimental|Treatment D|Slow dissolution variant 2
3085533|NCT01989520|Experimental|Treatment E|Optional treatment that may use one of 3 45 mg (intermediate dissolution variant) of AZD5069
3085534|NCT01989507|Experimental|Very low nicotine content cigarettes|Cigarettes with Nicotine Yield 0.07 ± 0.02
3085535|NCT01989507|Active Comparator|Conventional nicotine content cigarettes|Cigarettes with Nicotine Yield 0.8 ± 0.15
3085536|NCT01989494||Attendings|Anesthesiology Attendings who will wear a pedometer for five days while at work
3085537|NCT01989494||CA1 Residents|Anesthesiology residents in their first year of anesthesiology residency who will wear a pedometer for five days while at work
3085538|NCT01989494||CA2 and CA3 Residents|Anesthesiology residents in their second year of anesthesiology residency who will wear a pedometer for five days while at work
3085699|NCT01988298|Active Comparator|Acetaminophen|Acetaminophen 1 g oral each 6 hours, 2-3 days.
3085539|NCT01989468|Experimental|Secukinumab (AIN457) 150 mg s.c.|Secukinumab 150 mg at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
3085540|NCT01989468|Experimental|Secukinumab (AIN457) 300 mg s.c.|Secukinumab 300 mg at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
3085541|NCT01989468|Placebo Comparator|Placebo|Placebo at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
3085542|NCT01989455|Experimental|Cohort 1|"Single dose of 500mg deferiprone or placebo administered via intravenous infusion.~First 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.~Next 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo."
3085543|NCT01989455|Experimental|Cohort 2|"Single dose of 1000mg deferiprone or placebo administered via intravenous infusion and oral solution.~Randomization will be done for all 16 subjects at the same time: 14 will be randomized to receive deferiprone and 2 to receive placebo.~Subjects enrolled to cohort 2 will receive an oral dose of deferiprone."
3085544|NCT01989455|Experimental|Cohort 3|"Single dose of 1500mg deferiprone or placebo administered via intravenous infusion.~Randomization will be done for all 16 subjects at the same time, 14 will be randomized to receive deferiprone and 2 to receive placebo."
3085545|NCT01989455|Experimental|Cohort 4|"Single dose of 2000mg deferiprone or placebo administered via intravenous infusion.~First 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.~Next 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo."
3085546|NCT01989442|Experimental|Nasal Mask|patients who receive NIV by nasal mask interface after randomization
3085547|NCT01989442|Active Comparator|nasal prong|patients who receive NIV by nasal prongs as interface after randomization
3085548|NCT01989429|Active Comparator|Daivonex|topical application
3085549|NCT01989429|Placebo Comparator|vehicle|topical application
3085550|NCT01989429|Experimental|M518101|topical application
3085551|NCT01989416|Placebo Comparator|Soap bathing|ICU patients will be bathing with soap at least once daily
3085552|NCT01989416|Experimental|2% chlorhexidine wipes|Use 2% chlorhexidine wipes to clean the patient at least once daily
3085553|NCT01989403||Lumbar disc herniation patients|LBP with sciatica, with a numeral rating scale (NRS) leg pain intensity of 5 or higher and onset within 1 year; (2) LDH confirmed by MRI
3085554|NCT01989351||VAS<4|
3085555|NCT01989351||VAS>4|
3085556|NCT01989338||Hallux valgus patients|Females patients with hallux valgus asses for pain, function, and quality of life
3085557|NCT01989325|Experimental|Carfilzomib + Filanesib|"Single agent + Carfilzomib arm.~Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information.~Filgrastim to be administered per the approved product prescribing information and institutional guidelines."
3085558|NCT01989325|Experimental|Carfilzomib|"Single agent arm.~Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information."
3085559|NCT01989312|Active Comparator|supraclavicular block|A supraclavicular block with 32 mL of lidocaine 1.5% + epinephrine 5µg/mL was performed for the anaesthetic management of the forearm and hand.
3085560|NCT01989312|Active Comparator|Supraclavicular and median, ulnar, radial blocks|Patients in this group received 20 mL of lidocaine 1.5% + epinephrine 5µg/mL for supraclavicular block and after the supraclavicular block they recieved a distal median, radial, and ulnar nerve blocks using 50:50 mixture of lidocaine 2% + levobupivacaine 0.5% (4 mL/nerve).
3085561|NCT01989286||Plagiocephaly group-Assessment|Children (3-5 years) who were diagnosed and treated because of positional plagiocephaly are included in this group. An asssessment of posture will be performed.
3085562|NCT01989273||IVC Collapsibility >50% or IVC < 12mm|Major Trauma Victims admitted at Level I Trauma Center with an inferior vena cava collapsibility >50% or IVC diameter less than or equal to 12mm
3085563|NCT01989273||IVC Collapsibility <50% or IVC >12mm|Major Trauma Victims admitted at Level I Trauma Center with an inferior vena cava collapsibility <50% or IVC diameter >12mm
3085564|NCT01989260|Other|Anti-adhesive gel|An anti-adhesive gel will be administered to one ovary (randomised at the time of laparoscopic surgery to severe endometriosis). The coated ovary will be compared to the non-coated ovary 3 months after surgery to assess for the presence of post-operative ovarian adhesions. Neither the patient nor the person performing the ultrasound scan assessing for the presence of ovarian adhesions will know which was the ovary coated in the anti-adhesive gel.
3085565|NCT01989247|Experimental|Self-management program|Seven weekly sessions of a group-based self-management programme for people with anxiety and depressive symptoms
3085566|NCT01989247|No Intervention|Control group|
3085567|NCT01989234|Placebo Comparator|Placebo Comparator|Placebo Comparator
3085568|NCT01989234|Experimental|YKP10811 High Dose|YKP10811 High Dose
3085569|NCT01989234|Experimental|YKP10811 Mid Dose|YKP10811 Mid Dose
3085570|NCT01989234|Experimental|YKP10811 Low Dose|YKP10811 Low Dose
3085571|NCT01989221|Placebo Comparator|Placebo|Placebo - Control
3085572|NCT01989221|Active Comparator|Sancuso®|Sancuso® (granisetron transdermal system) 3.1 mg/24 hours
3085573|NCT01989208|Placebo Comparator|Sugar capsule|One normal healthy subject and two heart failure subjects will be randomized and given placebo throughout the trial period.
3085574|NCT01989208|Experimental|SG1002|200 mg capsule of SG1002 (alpha sulfur/sodium sulfate)
3085575|NCT01989195|Experimental|CORONARY DISEASE SUBJECT|ALL SUBJECTS IN THIS STUDY HAVE PREVIOUSLY DOCUMENTED CORONARY ARTERY DISEASE BY ANGIOGRAPHY
3085576|NCT01989182|Experimental|Treatment with Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management.
3085577|NCT01989182|Active Comparator|Medical Management|The control group for this study will receive medical management. This medical management group will be evaluated and followed in the same manner as the treatment group, but without having a bronchoscopic procedure.
3085578|NCT01989169|Active Comparator|Midazolam|Administered as a single oral 6 mg dose on Day 1.
3085652|NCT01988649|Placebo Comparator|Placebo (saline)|Administration of 4 sprays intranasally of normal saline.
3085579|NCT01989169|Experimental|SSP-004184SS + Midazolam|Midazolam (6 mg) + SSP-004184SS (30 mg/kg) concomitantly administered as a single oral dose on Day 1.
3085580|NCT01989156|Experimental|THS 2.2 Menthol (mTHS 2.2)|Ad libitum use of THS 2.2 Menthol for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
3085581|NCT01989156|Active Comparator|Menthol Conventional Cigarette (mCC)|Ad libitum use of subject's own preferred brand of mCC for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
3085582|NCT01989156|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
3085583|NCT01989143|Experimental|SAD Cohorts 1-8 Experimental Arm|
3085584|NCT01989143|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
3085585|NCT01989143|Experimental|MAD Cohorts 9-11 Experimental Arm|
3085586|NCT01989143|Placebo Comparator|MAD Cohorts 9-11 Placebo Arm|
3085587|NCT01989143|Experimental|MAD Cohort 12 Experimental Arm|
3085588|NCT01989143|Placebo Comparator|MAD Cohort 12 Placebo Arm|
3085589|NCT01989130|Experimental|Real-time results with Cepheid Xpert CT/NG Test|Diagnosis of +/- CT/NG within 2 hours of specimen entering laboratory
3085590|NCT01989130|Active Comparator|Batched results with Roche AMPLICOR CT/NG test|Diagnosis of +/- CT/NG within 1 to 4 days of visit to the ED
3085591|NCT01989117||Osteopathy|
3085592|NCT01989117||No osteopathy|
3085593|NCT01989104||Children|6-12 years of age
3085594|NCT01989104||Adolescents|13-17 years of age
3085595|NCT01989104||Young adults|18-20 years of age
3085596|NCT01989091|Experimental|B-Lock (IMD)|Investigational Medical Device (IMD)
3085597|NCT01989091|Active Comparator|Heparin 5,000 U/mL (ACH)|Active Comparator Heparin (ACH)
3085598|NCT01989078|Experimental|Losartan|Participants taking losartan, in addition to taking hydroxyurea therapy, as prescribed per standard of care
3085599|NCT01989065|Active Comparator|Lifestyle counseling|The Duke Healthy Lifestyles program is a comprehensive childhood obesity treatment program. Standard of care is active engagement and Lifestyle Counseling of families by nutritionist, physician, mental health provider, and physical therapist. Monthly visits for 1 year are recommended.
3085600|NCT01989065|Experimental|Lifestyle counseling PLUS text messaging|Patients in this arm will receive full standard of care as described for the Active Comparison group. In addition, parents will be texted daily with a motivational message that provides information and support for healthy behaviors.
3085601|NCT01989052|Experimental|Phase 1: CTO and lomustine|The combination of CTO with the standard dosing of 100 mg/m2 of lomustine among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have not previously received bevacizumab as treatment for their disease
3085602|NCT01989052|Experimental|Phase 2: CTO alone|CTO alone at the MTD established in the Phase 1 portion of this study
3085603|NCT01989052|Experimental|Phase 2: CTO and lomustine|CTO at the same daily dose of as in the CTO alone arm in combination with 110 mg/m2 oral lomustine every 6 weeks
3085604|NCT01989052|Experimental|Phase 2: Lomustine alone|Oral lomustine alone at 110 mg/m2 every 6 weeks
3085605|NCT01989026|Active Comparator|BCG at admission to NICU|These children will receive the BCG (and OPV) vaccines at admission to the Neonatal Intensive Care Unit (NICU).
3085606|NCT01989026|No Intervention|BCG at discharge (as usual)|These children will only receive the BCG (and OPV) vaccines at discharge, as per current standard of care.
3085607|NCT01989013|Other|biweekly intervention|biweekly intervention
3085608|NCT01989000|Active Comparator|Neoadjuvant radiochemotherapy|Patients elected for neoadjuvant radiochemotherapy undergo DWI-MRI, DCE-MRI (Gadobutrol),T2*-MRI and [F-18]HX4 PET/CT imaging within two weeks before start of the chemoradiation and again after radiochemotherapy (Gemcitabine/Radiotherapy), within two weeks before surgery (Pancreaticoduodenectomy).
3085609|NCT01989000|Active Comparator|Primary Surgery|Patients elected for primary surgery undergo DWI-MRI, DCE-MRI (Gadobutrol),T2*-MRI and [F-18]HX4 PET/CT imaging within two weeks before surgery (Pancreaticoduodenectomy).
3085610|NCT01988987||Inpatient Postpartum GTT|Women with gestational diabetes will undergo a 75 gram, 2 hour, oral glucose tolerance test 2-4 days postpartum prior to hospital discharge, in addition to undergoing the standard of care, outpatient glucose tolerance test performed 6-12 weeks postpartum
3085611|NCT01988974|Experimental|Alert for AF Program|1) participation in the Alert for Atrial Fibrillation program ) .
3085612|NCT01988974|Active Comparator|Attention control condition|2) participation in the healthy sleep program
3085613|NCT01988961|Experimental|Golimumab|Participants will receive the approved induction subcutaneous (SC) dose regimen of 200 mg at Week 0 followed by 100 mg at Week 2. At Week 6 and thereafter through Week 50, participants will receive the SC maintenance dosage of golimumab that has been approved for UC in the country in which the study is being conducted. In countries where golimumab is not approved for UC, a maintenance dosage of 100 mg every 4 weeks will be used.
3085614|NCT01988948|Other|student cohort|"Various biological sampling~blood sampling,~oral, vulvar, vaginal and anal sampling for women,~oral and genital sampling for men"
3085615|NCT01988935|Experimental|Prolonged Exposure + Smoking Cessation|Prolonged Exposure therapy plus smoking cessation intervention
3085616|NCT01988935|Active Comparator|Smoking Cessation|Smoking cessation intervention
3085617|NCT01988922|Experimental|Ketamine arm- *1/*1|1.*1/*1- oral racemic ketamine 0.4 mg/kg
3085618|NCT01988922|Experimental|Ketamine arm - *1/*6|2. *1/*6- oral racemic ketamine 0.4 mg/kg
3085619|NCT01988922|Experimental|Ketamine arm - *6/*6|3. *6/*6- oral racemic ketamine 0.4 mg/kg
3085620|NCT01988909|Experimental|WR 279,396|All patients with the same Study drug: WR 279,396 (Topical Paromomycin and Gentamicin Cream)
3085621|NCT01988896|Experimental|Dose-Escalation: Cobimetinib, Atezolizumab|Participants will receive single dose of 800 milligrams (mg) of atezolizumab IV infusion on Day 1, 15 and 29 of Cycle 1 (cycle length=42 days [14-day run-in period + 28-day concomitant dosing period]), thereafter with atezolizumab IV dosing every 2 weeks (q2w) in all subsequent treatment cycles (28 days each). Combination with cobimetinib will begin on Cycle 1 Day 15 and will be given at increasing dose levels during Stage 1. During Stage 1, cobimetinib will be administered once daily (QD) orally for 21 consecutive days out of 28 days (21/7 dosing schedule) at a starting dose of 20 mg with escalation of 20 mg until the maximum tolerated dose (MTD; not more than 60 mg) for the two-drug combination.
3085622|NCT01988896|Experimental|Dose-Expansion: Cobimetinib, Atezolizumab|Participants will receive single dose of 800 mg of atezolizumab IV infusion q2w in all subsequent treatment cycles (28 days each). Participants will receive cobimetinib at the selected recommended RP2D on Days 1-14 of each 28-day cycle during Stage 2.
3085623|NCT01988883|Placebo Comparator|Placebo|Patients will receive two inactive placebo pills filled with microcrystalline cellulose on a randomized study day. Medications will be dummy blinded to the patient and investigators.
3085624|NCT01988883|Experimental|Modafinil|Patients will receive single doses of modafinil (200 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
3085625|NCT01988883|Experimental|Propranolol|Patients will receive single doses of propranolol (20 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
3085626|NCT01988883|Experimental|Modafinil plus Propranolol|Patients will receive single doses of modafinil (200 mg, oral) and propranolol (20 mg, oral) on a randomized study day. Medications will be dummy blinded to the patient and investigators.
3085627|NCT01988870|Experimental|Intra-operative Radiation Therapy (IORT)|Following breast conserving surgery, a CT-based plan will be prepared to deliver highly conformal IORT and the treatment will be administered.
3085628|NCT01988857|Experimental|dTpa Group|
3085629|NCT01988844||Children with cerebral palsy|Children diagnosed with cerebral palsy are included in this group. An assessment and an intervention will be carried out.
3085630|NCT01988831|Placebo Comparator|Placebo|"113 patients will be enrolled in the placebo group with respect to randomization.~Placebo group will be prescribed placebo pills in the same packaging as propranolol treated group.~The frequency and duration of the treatment is the same as propranolol arm. The placebo group will have the same cardiology consultation as propranolol treated group to ensure the respect of blindness."
3085631|NCT01988831|Experimental|Betablocker|"drug: 'Propranolol hydrochloride' 338 patients will be enrolled in the Propranolol Group and treated with propranolol.~The dosage will be determined by the cardiologist as the maximum tolerated dose to a maximum of 160mg/day.~One long acting pill a day until an evidence of disease progression or the end of the study."
3085632|NCT01988818|Active Comparator|Standard wound dressing|As comparator will be used a standard Cosmopor E®adhesive, island wound dressing (Paul Hartmann LTD)after hip or knee arthroplasty or spinal surgery
3085633|NCT01988818|Experimental|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
3085634|NCT01988805||Blood Draw|Normal healthy individuals will be consented and their blood drawn at the time of their visit.
3085635|NCT01988792|Active Comparator|Fortification at 20 ml/kg/day feeding volume|Human milk fortifiers will be added to the human milk when neonates reach to feeding volume of 20 ml/kg/day.
3085636|NCT01988792|Active Comparator|Fortification at 100 ml/kg/day feeding volume|human milk fortifiers will be added to the human milk when neonates reach to feeding volume of 100 ml/kg/day.
3085637|NCT01988779|Active Comparator|oral placebo with nebulized intranasal levofloxacin|Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days
3085638|NCT01988779|Active Comparator|oral antibiotics with nebulized intranasal placebo|Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.
3085639|NCT01988766||Thrombosis|incidence of thrombosis in subjects who had PICC line placement
3085640|NCT01988766||No Thrombosis|no incidence of thrombosis in subjects who had PICC line placement
3085641|NCT01988753||Subjects with Liver Fibrosis|"Shearwave elastography is a non-invasive procedure for assessing liver status. Measurements of liver tissue elasticity will be obtained in the right lobe of the liver by using a curvilinear transducer (C5-1, Philips Healthcare) through intercostal spaces.~Biomarker Analysis~A. Blood: Blood will be drawn at the same time the IV is placed for the liver biopsy for the purposes of the serum biomarker study. If subjects return for an additional liver biopsy in the future or a standard of care visit they may be asked to provide an additional sample for biomarker analysis. Blood will be processed, aliquoted and stored by pathology.~B. Tissue: Unstained slides from pathology will be prepared from leftover tissue taken during the liver biopsy to be stained for additional biomarker analysis."
3085642|NCT01988714|Experimental|(TCT) plus evidence-based SE|(TCT) plus evidence-based SE
3085643|NCT01988714|Placebo Comparator|(CG) plus evidence-based SE|(CG) plus evidence-based SE
3085644|NCT01988701||Allogeneic SCT Groups|Patients who have received stem cell transplantation at The Ohio State University are eligible and who are at or beyond day +75 following allogeneic SCT regardless of previous diagnosis of acute or chronic GVHD.
3085645|NCT01988701||Autologous SCT group|Patients who have received an autologous stem cell transplant at The Ohio State University and who have achieved platelet and neutrophil engraftment.
3085646|NCT01988688|Experimental|Bilateral DBS placement in area LC|Bilateral DBS placement in area LC. Devices include Medtronic Activa DBS model 3387 and 3389; Medtronic DBS extension; Medtronic Activa PC or Activa RC neurostimulator; Medtronic Patient Programmer; Medtronic Test Stimulator; Medtronic N/Vision Clinician Programmer
3085647|NCT01988675||Partial Brain Irradiation|Patients will receive partial brain irradiation for malignant or benign brain tumors as standard of care. Patients will also have MRI (Magnetic Resonance Imaging) scans and neuropsychological/QOL (Quality of Life Questionnaire) tests prior during and after RT (Radiation Therapy).
3085648|NCT01988675||Whole Brain Irradiation|Patients will receive whole brain irradiation for brain metastases as standard of care. Patients will also have MRI (Magnetic Resonance Imaging) scans and neuropsychological/QOL (Quality of Life Questionnaire) tests prior during and after RT (Radiation Therapy).
3085649|NCT01988662|Experimental|Ranibizumab|104 patients with an eligible study eye were randomized to be treated with Ranibizumab IVT. 0.5 mg of commercially available Ranibizumab were used for intravitreal injection adminstered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).
3085650|NCT01988662|Active Comparator|Aflibercept|101 patients with an eligible study eye were randomized to be treated with Aflibercept IVT. 2.0 mg of commercially available Aflibercept were used for intravitreal injection admistered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).
3085651|NCT01988649|Active Comparator|Intranasal Oxytocin|Administration of 32 units of Oxytocin administered intranasally
3085653|NCT01988636|Experimental|Group 1|Pilot Safety Group- 135000 PfSPZ + 270000 PfSPZ; staggered at Day 0 and 2 weeks
3085654|NCT01988636|Active Comparator|Group 4|Group to start at week 4 after Group 1 is deemed safe - 5 immunizations of 270000 PfSPZ at weeks 4, 8, 12, 16 and 24
3085655|NCT01988636|Placebo Comparator|Group 5|Group to receive placebo at same points as Group 4 - 5 immunizations of normal saline at weeks 4, 8, 12, 16 and 24
3085656|NCT01988623|Experimental|Pivotal Response Treatment (PRT)|
3085657|NCT01988610|Experimental|Intervention Group|Open-label trial to assess the effects of Mifepristone on mood and cognition in people with a history of depression.
3085658|NCT01988597||Dry Eyes|
3085659|NCT01988584|Active Comparator|Umbilical Cord Blood (UCB) Arm|Children who have banked UCB with CBR will receive an umbilical cord blood stem cell infusion at the baseline/treatment visit.
3085660|NCT01988584|Active Comparator|Bone Marrow Stem Cells (BMMNC's)|Children in the BMMNC group will undergo bone marrow harvest and stem cell infusion at the baseline/treatment visit.
3085661|NCT01988584|Placebo Comparator|Placebo (inactive substance) Group|Five children in each group will be randomly assigned to receive an inactive substance (placebo) at the baseline/treatment visit. Parents will be given the opportunity to cross-over to either the umbilical cord blood or bone marrow harvest group at the one year visit.
3085662|NCT01988571|Active Comparator|Arm 1 - Atorvastatin|One 40 mg Atorvastatin tablet each morning by mouth for 24 months
3085663|NCT01988571|Placebo Comparator|Arm 2 - Placebo|One placebo tablet each morning by mouth for 24 months.
3085664|NCT01988558|Experimental|Treated Group|Children diagnosed as suffering from recurrent Tonsillitis (at least 4 episodes per year) to receive DL-Lactic acid syrup twice a day for a month.
3085665|NCT01988558|Placebo Comparator|Placebo Group|
3085666|NCT01988545|Active Comparator|GLP-1|1,5 nmol/kg,GLP-1 sc injection
3085667|NCT01988545|Active Comparator|GLP-1 9-36amide|1,5 nmol/kg GLP-1 9-36amide, sc injection
3085668|NCT01988545|Active Comparator|Exendin-4|Exendin-4 ;10 ug,sc injection
3085669|NCT01988545|Placebo Comparator|isotonic saline|2 ml of isotonic saline, sc injection
3085670|NCT01988532||Adult PWH|
3085671|NCT01988519|Active Comparator|Closed suction drain|Two closed suctions drains will be placed near the pancreatic anastomosis or suture line. The drains will be removed on the 4th or 5th day if the amylase activity is not increased.
3085672|NCT01988519|Active Comparator|Closed gravity drain|Two closed gravity drains will be placed near the pancreatic anastomosis or suture line. The drains will be removed on the 4th or 5th day if the amylase activity is not increased.
3085673|NCT01988506|Experimental|Interleukin 2|Interleukin 2, 1MUI.= Proleukin®, RhIL-2
3085674|NCT01988493|Experimental|MSC2156119J|
3085675|NCT01988493|Active Comparator|Sorafenib|
3085676|NCT01988480|Experimental|Image-guided surgery|Image-guided implant placement
3085677|NCT01988480|Sham Comparator|sinus graft|Sinus lift surgery : Patients receive sinus graft before implant placement
3085678|NCT01988467|Experimental|nasal breathing|"At the time that the exposure took place with nasal breathing, the study was as follows:~Before the exposure: rhinomanometry, IOS , FeNO , spirometry, plethysmography, P.100.~Exposure to second hand smoking:Each volunteer was exposed to secondhand smoking twice, for 20 minutes, once with nasal breathing and once with oral breathing, with 3 days interval and in random sequence.~After the exposure: rhinomanometry, IOS , FeNO , spirometry,plethysmography , P.100."
3085679|NCT01988467|Experimental|oral breathing|"At the time that the exposure took place with oral breathing, the study was as follows:~Before the exposure: IOS, exhaled nitric oxide (FeNO), spirometry, plethysmography and P.100.~Exposure to second hand smoking: each volunteer was exposed to secondhand smoking twice, for 20 minutes, once with nasal breathing and once with oral breathing, with 3 days interval and in random sequence.~After the exposure: IOS, FeNO, spirometry,plethysmography and P.100."
3085680|NCT01988428|No Intervention|standard care|"standard care~training of ambulance personnel in recognizing sepsis and initiating pre-hospital treatment"
3085681|NCT01988428|Experimental|Antibiotics|"ceftriaxone 2000 mg (after taking bloodcultures)~training of ambulance personnel in recognizing sepsis and initiating pre-hospital treatment"
3085682|NCT01988415|Other|VSS-Rx1 OPM vs Commercial iDesign Treatment|Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile in one eye (active comparator [i.e., control]) and investigational software (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration) in the fellow eye (experimental).
3085683|NCT01988402|Active Comparator|Allopurinol|Patients in this arm receive allopurinol, 100 mg daily for 14 days and then 200 mg daily for 14 days
3085684|NCT01988402|Placebo Comparator|Sugar pill (Placebo)|Patients in this arm receive one placebo (sugar) pill per day for 14 days then 2 placebo pills for 14 days.
3085685|NCT01988389|Experimental|whole apples|Subjects are asked to consume 2 apples a day for 8 weeks in addition to their habitual diet
3085686|NCT01988389|Other|apple juice squash|Subjects are asked to consume 100 ml of apple juice squash (recommended dilution with water up to 500 ml) for 8 weeks in addition to their habitual diet. The apple juice is used as a sugar matched control.
3085687|NCT01988376|Experimental|Women with cervical cancer receive Surepath for screening|Women will receive Surepath as a tool for screening the recurrence of cervical cancer.
3085688|NCT01988376|Active Comparator|Women receive conventional Pap smear for screening|Women who will receive conventional Pap smear for screening
3085689|NCT01988363|Other|GON injection at C2 location|A 25 gauge, 2 inch spinal needle will be inserted into the symptomatic side after locating the GON via US at the level of C2. Subjects will receive an injection of 4 ml of injectate consisting of 1 ml of 2% Lidocaine, 3 mg betamethasone and 2.5 ml of 0.25% Bupivicaine to the greater occipital nerve at the novel, proximal C2 location.
3085690|NCT01988350||Non-smokers|
3085691|NCT01988350||Smokers|
3085692|NCT01988337|Experimental|Icon|Icon resin infiltration
3085693|NCT01988337|Sham Comparator|mock treatment|mock treatment without penetration of the lesion by resin
3085694|NCT01988324|Experimental|FES/FDHT-PET|
3085695|NCT01988311|Experimental|Drug Only|psilocybin dose manipulation as described in the protocol
3085696|NCT01988311|No Intervention|Cognitive/Behavioral Tasks Only|
3085697|NCT01988311|No Intervention|Imaging Only|
3085700|NCT01988285||Dysphagia and GERD controls|"The cross-sectional arm will consist of patients who are having a clinically indicated endoscopy for reflux and/or dysphagia.~Cross-sectional participants will have specimens collected and complete a questionnaire."
3085701|NCT01988285||Prospective Longitudinal EoE Cases|"The prospective longitudinal group will be subjects who have a positive EoE diagnosis during initial endoscopy. This prospective group will be followed up at their clinically indicated endoscopy after their standard of care clinical therapy of swallowed steroids.~Prospective longitudinal participants will have specimens collected and complete questionnaires s prior to their standard of care clinical therapy of swallowed steroids and at their clinically indicated follow up upper endoscopy."
3085702|NCT01988259|Active Comparator|Bilateral approach for laminoplasty|Open approach for laminoplasty
3085703|NCT01988259|Active Comparator|Unilateral approach for laminoplasty|Minimally invasive approach for laminoplasty
3085704|NCT01988259|Active Comparator|Subperiosteal approach for foraminotomy|Open approach for foraminotomy
3085705|NCT01988259|Active Comparator|Transmuscular approach for foraminotomy|Minimally invasive approach for foraminotomy
3085706|NCT01988246|Sham Comparator|Sham Injection|"Patients will be sequentially randomized to treatment with a sham injection at the time of surgery. The sham injection is accomplished by pressing an empty syringe against the eye wall without penetration. This will be administered post cataract excision by the Prinicipal Investigator. The patient will be masked as to which Arm they are assigned."
3085707|NCT01988246|Active Comparator|Intravitreal Aflibercept Injection|Patients will be sequentially randomized to treatment with Aflibercept 2 mg via intravitreal injection (0.05 mL or 50 microliters) at the time of surgery. This will be administered post cataract excision by the Principal Investigator. The patient will be masked as to which Arm they are assigned.
3085708|NCT01988233|Experimental|BAILAMOS© Dance Program|BAILAMOS© Dance Program + Maintenance Program: includes a 4-month twice-weekly adoption phase and a 4-month twice-weekly maintenance phase. Each month during adoption a new dance style is introduced by a professional dance instructor. During the 4-month maintenance phase an indigenous dance leader, trained by the professional dance instructor, will lead dance with participants twice per week
3085709|NCT01988233|Experimental|Health Education Control Group|Health Education Control Group: Sedentary older Latinos randomly assigned to the health education control group will participate in classes developed for older adults and offered by the University of Illinois Extension. All classes are conducted in Spanish by extension staff using Spanish-language materials. Classes will meet one day per week for two hours, to provide equitable social contact as the treatment group.
3085710|NCT01988220|Experimental|sensory retraining|sensory identification and discrimination training. using different attention and sensation modalities for sensory retraining
3085711|NCT01988220|Active Comparator|repeated exposure to sensory input|
3085712|NCT01988207|Experimental|12 Exercise Sessions|Patients will receive 12 treatment sessions with flow phonation exercises, as well as education on vocal hygiene.
3085713|NCT01988207|Active Comparator|6 Hygiene and 6 Exercise|Patients will receive 6 sessions of vocal hygiene training for initial comparison to patients in Arm 1. They will then receive 6 sessions of vocal exercise training and vocal hygiene training combined.
3085714|NCT01988194|No Intervention|Usual care|Participants will receive usual care in the hospital.
3085715|NCT01988194|Experimental|Usual care with acupuncture|Participants will receive usual care with acupuncture treatments up to four days per week for the duration of their hospital stay.
3085716|NCT01988181|Active Comparator|Best clinical practice HD|All study patients will be dialyzed with the Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany) using high flux dialyzers. For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
3085717|NCT01988181|Experimental|Best clinical practice plus BVM-guided UF biofeedback|Patients in the BVM-guided UF biofeedback (intervention) phase will have the same prescription as the control group but will also have the ultrafiltration rate automatically adjusted by the Fresenius 5008 HD machine based on the changes in the relative blood volume.
3085718|NCT01988168|Experimental|Suture closure|Closure of skin with a running subcuticular, absorbable monofilament suture.
3085719|NCT01988168|Active Comparator|Staples closure|Closure of skin with stainless-steel surgical staples.
3085720|NCT01988155|Active Comparator|Eccentric Exericse|
3085721|NCT01988155|Experimental|Astym|
3085722|NCT01988142|Experimental|SCI|
3085723|NCT01988129|Experimental|Intervention|Workplace-based fatigue risk management program consisting of sleep health education and sleep disorders screening. The 32 fire department stations were paired according to the previous calendar years' workload. One station from each pair was randomly assigned to receive the intervention program. Sleep education sessions were scheduled according to station. On the education day(s) assigned to that stations, all personnel present that day were instructed to attend, and 542/601 did so.
3085724|NCT01988129|No Intervention|Control|"Current practice. Firefighters in the Control Stations continued their normal role and were not invited to attend the sleep education and sleep disorders screening program. There was no formal contact with the control group.~As part of normal operational requirements, a small number of firefighters are reassigned to other stations each day and therefore 18/588 firefighters from control stations happened to be reassigned to an intervention station on the day of the education session and attended the session."
3085725|NCT01988116|Experimental|Oral Calcitriol|Oral Calcitriol 0.5 mcg once daily for 6 weeks
3085726|NCT01988116|Placebo Comparator|Placebo Arm|Placebo capsule 1 Capsule once daily for 6 weeks
3085727|NCT01988103|Experimental|Apremilast 20mg|Apremilast 20 mg tablets orally twice a day (BID)
3085728|NCT01988103|Experimental|Apremilast 30mg|Apremilast 30 mg tablets orally BID
3085729|NCT01988103|Placebo Comparator|Placebo|Identically-appearing placebo tablets BID for 16 weeks followed by participants being re-randomized in a blinded fasion to apremilast 20 mg or 30mg tablets BID for 52 weeks
3085730|NCT01988090|Experimental|High Dose Vitamin D ARM|50,000 IU Vitamin D supplement
3085731|NCT01988090|Active Comparator|800 IU Vitamin D Supplement|800 IU Vitamin D Supplement
3085732|NCT01988077|Other|Adoptive cell transfer combined with Ipilimumab|Adoptive cell transfer combined with Ipilimumab
3085733|NCT01988064|Experimental|Face-to-face training|One-to-one face-to-face training on calculating the pulse rate and detecting pulse abnormalities performed by the nurse.
3085734|NCT01988064|Experimental|Group training|Group training using a tutorial film on calculating the pulse rate and detecting pulse abnormalities.
3085735|NCT01988038||No treatment|
3085736|NCT01988012|Experimental|Tocilizumab|Adults with rheumatoid arthritis will be treated with tocilizumab for 24 weeks followed by an 8 week follow-up period without treatment.
3085737|NCT01987999|Experimental|Acetogenins|Acetogenins twice (BID) per day for 12 months
3085738|NCT01987986|Experimental|AA4500 0.06 mg (low dose)|"AA4500 (Collagenase Clostridium Histolyticum)~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
3085739|NCT01987986|Experimental|AA4500 0.48 mg (mid-dose)|"AA4500 (Collagenase Clostridium Histolyticum)~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
3085740|NCT01987986|Experimental|AA4500 0.84 mg (high dose)|"AA4500 (Collagenase Clostridium Histolyticum)~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
3085741|NCT01987986|Placebo Comparator|Placebo|"Placebo~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
3085742|NCT01987973|Active Comparator|Partial Repair / Debridement|"Subjects in this arm of the study will receive the intervention Partial Rotator Cuff Repair. This is the control group."
3085743|NCT01987973|Experimental|Allograft Reconstruction|"Subjects in this arm of the study will receive the intervention Partial Rotator Cuff Repair with Allograft Augmentation"
3085744|NCT01987960|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER)
3085745|NCT01987960|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER). Brexpiprazole dosing was 1mg/day for one week, followed by 2mg/day for 3 weeks. Thereafter the dose was flexible and could be adjusted from 1 to 3 mg/day.
3085746|NCT01987947|Placebo Comparator|Placebo|
3085747|NCT01987947|Active Comparator|Quilizumab|
3085748|NCT01987934||Normal or Control group|Those subjects with normal oral epithelium will be included in this group.
3085749|NCT01987934||Study Group|Those subjects with oral squamous cell carcinoma will be included in this group.
3085750|NCT01987921||Pediatric Intensive Care Unit Patients|All patients will be included in a single cohort initially (admission to the PICU) and then cohorted into groups based on development of severe AKI (Stage 2-3 KDIGO by either Cr or UOP criteria) within the first seven days, renal angina risk strata, medical admission diagnoses, and outcomes.
3085751|NCT01987908|Experimental|Cohort A (Drug)|Subjects randomized 3:1 to receive 4 times daily dosing of 1,000 mg of Aes 103 or placebo for 28 days
3085752|NCT01987908|Placebo Comparator|Cohort A (Placebo)|Subjects randomized 3:1 to receive 4 times daily dosing of 1,000 mg of Aes 103 or placebo
3085753|NCT01987908|Experimental|Cohort B (Drug)|In this adaptive design, the dose frequency and the total amount given per day to Cohort B will be adjusted depending on the tolerability, clinical pharmacology and clinical endpoint results of Cohort A. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
3085754|NCT01987908|Placebo Comparator|Cohort B (Placebo)|The dosing regiment of placebo will match that of the Aes-103 treatment in Cohort B. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
3085755|NCT01987895|Experimental|Cadazolid|Subjects receive oral cadazolid 250 mg twice daily (bid) and oral vancomycin-matching placebo 4 times per day (qid) for 10 days
3085756|NCT01987895|Active Comparator|Vancomycin|Subjects receive oral vancomycin 125 mg qid and oral cadazolid-matching placebo bid for 10 days
3085757|NCT01987882||"A. Natural History or Watchful Waiting"|
3085758|NCT01987882||B. Serial Botulinum Toxin Injections +/- Abduction Bracing|
3085759|NCT01987882||C. Adductor (+/- psoas) Muscle Releases Alone|
3085760|NCT01987882||D. Hip Reconstructive Surgery|
3085761|NCT01987882||E. Salvage Hip Surgery|
3085762|NCT01987856|Active Comparator|aCGH screen|aCGH screen; euploid blastocyst chosen on 23 plus XY chromosome screening plus blastocyst morphology
3085763|NCT01987856|Placebo Comparator|Blastocyst morphology|blastocysts chosen on morphological criteria only; scaled assessment of blastocyst expansion, inner cell mass and trophectoderm morphology
3085764|NCT01987843|Experimental|MT-1303-Low|MT-1303-Low Dose
3085765|NCT01987843|Experimental|MT-1303-Middle|MT-1303-Middle Dose
3085766|NCT01987843|Experimental|MT-1303-High|MT-1303-High Dose
3085767|NCT01987843|Placebo Comparator|Placebo|Placebo
3085768|NCT01987830|Other|TMZ-PET scans/ MRI-PET Scan|"The investigators plan to study patients with recurrent glioblastoma whose clinical care plan includes treatment with bevacizumab and temozolomide. Patients taking daily temozolomide 50 mg/m2/day will undergo a PET scan using radiolabeled temozolomide (TMZ-PET) at 3 time points: 7-13 days after initiation of temozolomide but before beginning bevacizumab (baseline- temozolomide steady-state scan), 1 day after initiation of bevacizumab (day 15) and 1 month after initiation of bevacizumab (day 45). Arterialized venous blood samples will be collected during the imaging in order to measure radioactivity, blood metabolites, and the relationship between radiotracer uptake and tumor features such as blood-brain barrier (BBB) breakdown and tumor blood flow.~In addition, we will explore the link between flow, permeability, and tumor temozolomide retention. These studies will be performed using our human simultaneous MRI-PET imaging camera."
3085769|NCT01987817|Experimental|AR101 powder provided in capsules|Study product provided in pull-apart peanut protein capsules
3085770|NCT01987817|Placebo Comparator|Placebo powder provided in capsules|Placebo formulation in pull-apart capsules containing only inactive ingredients
3085771|NCT01987804|Experimental|Oxytocin 100 i.u.|N=24 patients are administrated Oxytocin 100 i.u. vaginally
3085772|NCT01987804|Experimental|Oxytocin 400 i.u.|N=24 patients are administrated Oxytocin 400 i.u. vaginally
3085773|NCT01987804|Placebo Comparator|Placebo|N=16 patients are administrated placebo vaginally
3085774|NCT01987778|Experimental|Resistance training|The resistance training will be supervised and individualized by an experienced physiotherapist. First the relative load will be lighter during three weeks, thereafter the intensity and load will be increased over another 12 weeks.
3085775|NCT01987778|No Intervention|Control group|No intervention for 15 weeks but the same registrations, diaries and forms as the intervention group. The control group will however be omitted from muscle strength testing.
3085776|NCT01987765||Relestat Ophthalmic Solution 0.05%|Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.
3085777|NCT01987752||Combigan® Ophthalmic Solution|Patients treated with Combigan® Ophthalmic Solution as per local standard of care in clinical practice.
3085778|NCT01987739|Experimental|Arm 1|Subjects were randomized to receive single, oral doses of study medication in the sequence ABFCED, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
3085779|NCT01987739|Experimental|Arm 2|Subjects were randomized to receive single, oral doses of study medication in the sequence BCADFE, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
3085780|NCT01987739|Experimental|Arm 3|Subjects were randomized to receive single, oral doses of study medication in the sequence CDBEAF, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
3085781|NCT01987739|Experimental|Arm 4|Subjects were randomized to receive single, oral doses of study medication in the sequence DECFBA, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
3085782|NCT01987739|Experimental|Arm 5|Subjects were randomized to receive single, oral doses of study medication in the sequence EFDACB, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
3085783|NCT01987739|Experimental|Arm 6|Subjects were randomized to receive single, oral doses of study medication in the sequence FAEBDC, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
3085784|NCT01987726||Observational (NGS, FMI testing)|"PART I: Within 10 weeks of beginning a treatment regimen, tumor tissue samples, Blood Collection and CTCs(Circulating tumor cell)from patients are collected for NGS and FMI testing, respectively. Patients remain on current line of therapy until a change in treatment is warranted. The physician's treatment recommendation is documented prior to the release of the FMI results.~PART II: Physicians are furnished with FMI test results when patients become eligible for a change in therapy and new treatment recommendations are documented. Treatment is dependent on preferences of the physician, patient, and/or results of the FMI test."
3085785|NCT01987713|Experimental|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
3085786|NCT01987700|Active Comparator|FLEX-HD (underlay)|FLEX-HD human acellular dermal matrix applied using an underlay technique
3085787|NCT01987700|Active Comparator|FLEX-HD (overlay)|FLEX-HD human acellular dermal matrix applied using an overlay technique
3085788|NCT01987700|Active Comparator|Strattice (underlay)|Strattice porcine acellular dermal matrix applied using an underlay technique
3085789|NCT01987700|Active Comparator|Strattice (overlay)|Strattice porcine acellular dermal matrix applied using an overlay technique
3085790|NCT01987687|Active Comparator|Rest|Breakfast followed by a rest period prior to OGTT.
3085791|NCT01987687|Experimental|Exercise-immediate|Breakfast followed by exercise and an immediate OGTT
3085792|NCT01987687|Experimental|Exercise-delay|Breakfast followed by exercise and a delayed (1 h) OGTT.
3085793|NCT01987674|Experimental|Pre-meal protein drink|A dose of 100 ml is taken just before breakfast, lunch and dinner.
3085794|NCT01987674|Placebo Comparator|Water drink|A dose of 100 ml is taken just before breakfast, lunch and dinner.
3085795|NCT01987661|Active Comparator|bilevel ventilation BIPAP ST|one night, BIPAP ST ventilation with individually optimised pressure parameters and supplemental oxygen if necessary.
3085796|NCT01987661|Experimental|BIPAP ST plus Airtrap|"one night, BIPAP ST ventilation with Airtrap control, same pressure parameters and oxygen."
3085797|NCT01987648||All study participants|Included are all patients who 18 years or older, who get an elective craniotomy (no biopsy, no awake surgery, no re-operation) and who are treated at the Department of Neurosurgery
3085798|NCT01987635|Experimental|MEMO 3D anuloplasty ring|MEMO 3D anuloplasty ring
3085799|NCT01987635|Active Comparator|rigid ring|rigid ring
3085800|NCT01987622|Experimental|Acupuncture|A series of acupuncture sessions within six weeks from the baseline
3085887|NCT01987024|Experimental|groupB- actim partus|
3085888|NCT01987011|Experimental|MG1109|MG1109 0.5 mL Intramuscularly injection, twice at an interval of 21 days
3085801|NCT01987622|Active Comparator|Usual care|An intervention consisting of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed.
3085802|NCT01987609|Experimental|Hylenex|Psoriatic plaques in this arm will be injected with Hylenex every week for 4 weeks.
3085803|NCT01987609|Placebo Comparator|Normal Saline|Psoriatic plaques in this arm will be subcutaneously injected with sterile normal saline every week for four weeks
3085804|NCT01987596|Experimental|Arm I (fixed filgrastim)|Patients receive filgrastim SC QD started at 24 hours after completion of chemotherapy and stopped when ANC reaches at least 1,000/uL post nadir.
3085805|NCT01987596|Experimental|Arm II (flexible filgrastim)|Patients receive filgrastim SC QD started on the first day after chemotherapy when ANC falls below 1,000/uL and stopped when ANC reaches at least 1,000/uL post nadir.
3085806|NCT01987583|Experimental|Wet cupping and conventional treatment|"Wet cupping: Will be administered through 3 sessions every other day, on the 17th, 19th and 21st days of the lunar month.~Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department."
3085807|NCT01987583|Active Comparator|Conventional treatment|Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department
3085808|NCT01987570|Experimental|Allopurinol|One tablet of allopurinol is administrated orally at a dose of 300 mg/24 hours, during the time that the patient remains immobilized for 15 days.
3085809|NCT01987570|Placebo Comparator|Placebo|One tablet/24 hours of placebo orally, during the time that the patient remains immobilized for 15 days.
3085810|NCT01987557|Experimental|Treadmill Intervention 1: Rate Group|Participants in this condition will walk with a cadence (steps per minute) that is approximately 35% faster than comfortable walking pace. In this condition, participants will maintain a step length that is similar to that of their comfortable walking pace.
3085811|NCT01987557|Experimental|Magnitude treadmill group|In this condition participants will walk on a treadmill with weights on their ankles to elicit a greater magnitude of instrinsic feedback from force sensitive golgi tendon organs
3085812|NCT01987557|Placebo Comparator|regular treadmill walking|participants will walk at a comfortable self-selected pace on a treadmill
3085813|NCT01987544|Active Comparator|Self-Control|3 months of ergometer training under self control at home without any interventional motivation.
3085814|NCT01987544|Experimental|Motivation|3 months of ergometer training at home with telemonitoring and motivation phone calls once a week when training sessions drop below 20 minutes per day.
3085815|NCT01987531|Experimental|left ventricular epicardial pacing lead|Enrolled patients will have a temporary left ventricular epicardial pacing lead placed in addition to the standard right ventricular and right atrial temporary epicardial pacing leads after open cardiac chamber cardiac surgery.
3085816|NCT01987518||digestive polyposis|Family adenomatous polyposis (APC or MYH genes) Peutz Jeghers Disease Cowden Disease Festooned Polyposis Juvenile Polyposis Hyperplastic Polyposis
3085817|NCT01987505|Experimental|Subcutaneous Rituximab|Participants with CD20+ non-Hodgkin's follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), who had already received at least one full dose of intravenous (IV) rituximab will be treated with subcutaneous (SC) rituximab. Participants with FL will be administered 1400 mg rituximab during induction therapy (once monthly for 4-7 cycles) and maintenance therapy (once every 2 months for 6-12 cycles). Participants with DLBCL will be administered 1400 mg SC of rituximab once monthly for 4-7 cycles. Treatment duration is expected to last up to 7 months for participants with DLBCL and up to 32 months for participants with FL.
3085818|NCT01987492|Experimental|Lebrikizumab High Dose|Participants will receive lebrikizumab at high dose level as subcutaneous (SC) injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.
3085819|NCT01987492|Experimental|Lebrikizumab Low Dose|Participants will receive lebrikizumab at low dose level as SC injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.
3085820|NCT01987492|Placebo Comparator|Placebo|Participants will receive placebo matching to lebrikizumab SC injection every 4 weeks during the 44-week DBPC period. Participants will then be randomized to receive either high- or low-dose lebrikizumab every 4 weeks during the 32-week ATE period and will continue same treatment in the LTE period.
3085821|NCT01987479|Experimental|Tocilizumab Alone or in Combination with Methotrexate or DMARD|Participants will receive a weekly SC injection of tocilizumab 162 milligrams (mg) as monotherapy or in combination with methotrexate or other non-biologic DMARDs for 24 weeks.
3085822|NCT01987466||Post cardiac arrest patient|
3085823|NCT01987453|Experimental|LDV/SOF+RBV 12 weeks (Group 1)|Participants who failed a prior SOF+RBV ± pegylated interferon (Peg-IFN) regimen will receive LDV/SOF FDC plus RBV for 12 weeks.
3085824|NCT01987453|Experimental|LDV/SOF 24 weeks (Group 2)|Participants who failed a prior LDV/SOF ± RBV regimen will receive LDV/SOF FDC for 24 weeks.
3085825|NCT01987453|Experimental|LDV/SOF+RBV 24 weeks (Group 3)|Participants with advanced compensated or decompensated cirrhosis who failed a prior SOF+RBV regimen will receive LDV/SOF FDC plus RBV for 24 weeks.
3085826|NCT01987440|Experimental|Lubricating Gel|The speculum was warmed, and patients were informed about what was going to happen. The labia were spread from below to introduce the speculum, which was inserted at a 45-degree angle pointing downward then rotated horizontally as the insertion continued. A VAS score (insertion) was obtained at this point. Next, the bill of the speculum was opened up until the vaginal cuff could be seen, and the speculum was secured by turning the thumbnut. A second VAS score (dilation) was recorded. During speculum examination, cervical smear with cervical brush was obtained for pathologic assessment if necessary. The speculum was withdrawn slightly, which allowed the bill to close together, and at this stage (extraction) the final VAS score was obtained. In the gel group , a doctor placed 6,5 mL mL sterile lubricating gel on the top and bottom blades of the speculum. Length of the vagina was measured by the index finger.
3085889|NCT01987011|Placebo Comparator|Placebo|Placebo(for MG1109) 0.5 mL Intramuscularly injection, twice at an interval of 21 days
3085890|NCT01986998|Active Comparator|oMP 1250 mg: Group A|Methylprednisolone 1250 mg/24h x3 days
3085891|NCT01986998|Active Comparator|oMP 625 mg: Group B|Methylprednisolone oral 625 mg/24h x3 days
3085892|NCT01986985|Other|Single arm PET MRI|single group evaluation of PET/MRI system scan for diagnostic quality of image
3085827|NCT01987440|Placebo Comparator|water|A VAS score (insertion) was obtained at this point. Next, the bill of the speculum was opened up until the vaginal cuff could be seen, and the speculum was secured by turning the thumbnut. A second VAS score (dilation) was recorded. During speculum examination, cervical smear with cervical brush was obtained for pathologic assessment if necessary. The speculum was withdrawn slightly, which allowed the bill to close together, and at this stage (extraction) the final VAS score was obtained. In the water group the speculum's top and bottom blades were moistened with 6,5 mL tap water previously loaded into a syringe kept at room temperature.After the speculum examination, pelvic examination was performed and length of the vagina (defined as distance from vaginal cuff to vaginal apex) was measured by the index finger.
3085828|NCT01987427|Experimental|A|lorcaserin + phentermine placebo
3085829|NCT01987427|Experimental|B|lorcaserin + phentermine-HCl + phentermine placebo
3085830|NCT01987427|Experimental|C|lorcaserin + phentermine-HCl
3085831|NCT01987414|Experimental|Group A|Forearm rotation orthosis (6 weeks); Forearm rotation orthosis plus occupational therapy task-oriented approach (6 weeks)
3085832|NCT01987414|Active Comparator|Group B|no treatment (6 weeks); occupational therapy task-oriented approach (6 weeks)
3085833|NCT01987401||Iraq and Afghanistan Era Veterans|Veterans who served during the Iraq and Afghanistan Era
3085834|NCT01987388|Experimental|High Intensity Exercise, High Carbohydrate Beverage|Study participant consumes a high carbohydrate beverage as part of the day's meals, and performs high intensity exercise (85% of VO2 max), while in the calorimeter.
3085835|NCT01987388|Experimental|High Intensity Exercise, High Fat Beverage|Study participant consumes a high fat beverage as part of the day's meals, and performs high intensity exercise (85% of VO2 max), while in the calorimeter.
3085836|NCT01987388|Experimental|Low Intensity Exercise, High Carbohydrate Beverage|Study participant consumes a high carbohydrate beverage as part of the day's meals, and performs low intensity exercise (65% of VO2 max), while in the calorimeter.
3085837|NCT01987388|Experimental|Low Intensity Exercise, High Fat Beverage|Study participant consumes a high fat beverage as part of the day's meals, and performs low intensity exercise (65% of VO2 max), while in the calorimeter.
3085838|NCT01987375|Experimental|Cetuximab-IRDye800 Participants|Participants who received the study drug cetuximab-IRDye800, following a loading dose of unlabeled cetuximab
3085839|NCT01987362|Experimental|RO6870810 (Part 1)|Participants will receive escalated doses of RO67870810 SC. RO6870810 will be escalated at a starting dose of 0.03 milligrams per kilogram (mg/kg) to a maximum of 0.85 mg/kg. Treatment will be administered in treatment cycles of either 21 days or 28 days and continued until PD, adverse events which justify treatment withdrawal, non-adherence, non-compliance, investigator decision, lost to follow-up, enrollment in other clinical study, or unacceptable toxicity.
3085840|NCT01987362|Experimental|RO6870810 (Part 2)|Participants will receive RO6870810 at doses up to the MTD or up to the highest dose tested if the MTD is not defined. Treatment will be administered in treatment cycles of either 21 days or 28 days and continued until PD, adverse events which justify treatment withdrawal, non-adherence, non-compliance, investigator decision, lost to follow-up, enrollment in other clinical study, or unacceptable toxicity.
3085841|NCT01987349|Other|Group A: age 8-17 yo identical twins|Participants will be randomized to receive either Fluzone® (intramuscular) or FluMist® (intranasal)
3085842|NCT01987349|Other|Group B: 18-30 yo identical twins|Participants to receive FluMist® (intranasal)
3085843|NCT01987349|Other|Group C: 18-30 yo fraternal twins|Participants to receive FluMist® (intranasal)
3085844|NCT01987349|Other|Group D: 40-49 yo identical twins|Participants to receive FluMist® (intranasal)
3085845|NCT01987349|Other|Group E: 40-49 yo fraternal twins|Participants to receive FluMist® (intranasal)
3085846|NCT01987349|Other|Group F: 70-100 yo twins|Participants to receive Fluzone® (intramuscular)
3085847|NCT01987349|Other|Group G: 70-100 yo non-twins|Participants to receive Fluzone® (intramuscular)
3085848|NCT01987323|Experimental|Lipolat|Subconjunctival injection of Lipolat into the superior bulbar conjunctiva of all enrolled participants
3085849|NCT01987310|Active Comparator|Statin|statin therapy (atorvastatin 20 mg/d) for 6 months
3085850|NCT01987310|No Intervention|usual care|follow up group with no intervention
3085851|NCT01987310|Active Comparator|lifestyle counseling|lifestyle modification by dietician counseling and follow-up
3085852|NCT01987297|Experimental|ATRA+Arsenic|Patients received treatment with retinoic acid and arsenic trioxide
3085853|NCT01987297|Active Comparator|ATRA+chemo|patients recieved retinoic acid and chemotherapy with idarubicin or daunorubicin
3085854|NCT01987284|Experimental|SER100|SER100 10 mg s.c. twice daily
3085855|NCT01987284|Placebo Comparator|Placebo|Placebo administered s.c. twice daily
3085856|NCT01987271|Experimental|With noninvasive ventilation|When patients do the six minute walk test with the noninvasive ventilation.
3085857|NCT01987271|No Intervention|Without noninvasive ventilation|When patients do the six minute walk test without noninvasive ventilation.
3085858|NCT01987258|No Intervention|Control|No exercise (control experiment)
3085859|NCT01987258|Experimental|Interval Walking|A one hour interval walking exercise bout
3085860|NCT01987258|Experimental|Continuous walking|A one hour continuous walking exercise bout
3085861|NCT01987232|Experimental|Carfilzomib Combination|Participants received carfilzomib on days 2, 3, 9, and 10 of each 21-day cycle as per the dose escalation schema, carboplatin at a target area under the curve (AUC) of 5 on day 1 of each cycle, and etoposide 100 mg/m² on days 1, 2, 3 of each 21-day cycle for up to 6 cycles. Participants with stable disease or better continued to receive carfilzomib alone until progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death, whichever occurred earliest.
3085862|NCT01987219|Active Comparator|Albuterol-sulphate|Albuterol-sulphate (Proventil ®) Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
3085863|NCT01987219|Active Comparator|Ipratropium-bromide (Atrovent ®)|IpratroAnti-cholinergic(Atrovent ®) 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.pium-bromide
3085864|NCT01987219|Placebo Comparator|Placebo|Placebo Saline solution 3 cc NA
3085893|NCT01986972|Active Comparator|Toothbrushing With Dentifrice|After 72 hours of absence oral hygiene, patients performed toothbrushing with common dentifrice.
3103286|NCT01869868||Depression, ECT|
3085865|NCT01987206|Active Comparator|PID algorithm with HMS|"The control algorithm, at its core, is a Proportional-Integral-Derivative (PID)controller that incorporates an Internal Model Control (IMC) based tuning rule using an explicit model of human T1DM glucose-insulin dynamics. Parameters of the model are personalized based on a priori easily available subject parameters. This controller divides the control action into three components - the proportional distance between the current measurement and the target setpoint, the accumulated integral error as expressed by the area between the current state curve and the target set point over time, and the derivative rate of change of the current measurement.~The Health Monitoring System algorithm uses the same glucose monitoring (CGM) data as the PID control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device."
3085866|NCT01987206|Experimental|MPC algorithm with HMS|"The first control strategy is a flavor of Model Predictive Control (MPC) algorithm. MPC employs an explicit model of the process to be controlled when optimizing the input. Specifically, MPC controllers for glycemia control use a model of a human's T1DM insulin-glucose dynamics to predict the evolution of the blood glucose values over a so-called prediction horizon of controller steps, and optimize a predicted insulin input trajectory in order to optimize a specified cost objective that penalizes unsafe glycemic values, and also insulin usage.~The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device."
3085867|NCT01987180||Usual standard care|Parents will be provided with the usual standard of care in the NICU. Discharge information will be provided to parents as is typically done in the NICU for VLBW infants getting ready to go home. Typical handouts are given to parents that describe their child's care and needs specifically as well as general guidelines. The project coordinator for the research study will verify that parents received information prior to discharge from the NICU staff. Parents will determine how you use this information.
3085868|NCT01987180||NICU-2-Home mobile app user|Parents will receive smartphone and unique NICU-2-Home app for their use. A pair of parents will be given two smartphones and will be asked to use the devices in their preferred way. Within the given app there is a baby tracking tool (baby-connect.com) that enables parents to keep track of the baby's feeding, diapers, sleep, health, medicines, vaccines, photos, etc. The objective in doing this is not to monitor the growth and development of the child; rather, it is to observe what tools within the app parents use and how frequently they use them.
3085869|NCT01987167|Experimental|-ACHTHAR|Subcutaneous ACTHAR 5 days of 80 IU and 10 Days of 40 IU
3085870|NCT01987154|Active Comparator|Marketed cow milk-based premature infant formula|
3085871|NCT01987154|Experimental|Marketed extensively hydrolyzed casein infant formula|
3085872|NCT01987141|Experimental|EMR intervention|Patients will have an electronic medical record popup/highlight in their chart, displaying the recommended guidelines for weight gain in pregnancy.
3085873|NCT01987141|No Intervention|Control|The patient's medical record will be displayed as usual, with no flag or highlight for weight gain recommendations
3085874|NCT01987128|Experimental|Intraneural injection|All patients in the arm will receive a single intraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, in the sciatic nerve under echographic guidance.
3085875|NCT01987128|Active Comparator|extraneural injection|All patients in the arm will receive a single extraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, around the sciatic nerve under echographic guidance.
3085876|NCT01987115|Experimental|Fascial Manipulation|Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
3085877|NCT01987115|Active Comparator|Traditional physiotherapy|Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
3085878|NCT01987102|Other|Cohort 1|"1 MAP cycle (incl. 2 HDMTX Courses using SOC rescue 15mg/m2)~1 MAP cycle (incl. 2 HDMTX Courses using [6R] 5,10-methylenetetrahydrofolate rescue 15mg/m2)"
3085879|NCT01987102|Other|Cohort 2|"1 MAP cycle (incl. 2 HDMTX Courses using SOC rescue 15mg/m2)~1 MAP cycle (incl. 2 HDMTX Courses using [6R] 5,10-methylenetetrahydrofolate rescue 7,5 or 30mg/m2*~*Dose will depend on outcome from Cohort 1"
3085880|NCT01987089|Experimental|CBT-I|Eight Session CBT-I: Cognitive Behavioral therapy is conducted in 8 individual sessions with the study clinician. Session 1 serves as an orientation. No active treatment is delivered at this time. Sessions 2 & 3 are used to deliver the three main components of the intervention which are Sleep Restriction (SRT), Stimulus Control, and Sleep Hygiene. All but two of the remaining sessions are dedicated to the titration of total sleep time and to ensuring patient adherence. One session (session 5) entails the delivery of a specific form of cognitive therapy. The final session (session 8) is used to engage in a relapse-prevention didactic, i.e., to review first, how insomnia becomes chronic and second, the strategies that are likely to abort an extended episode of insomnia.
3085881|NCT01987089|Placebo Comparator|QDT|"This form of placebo therapy has been commonly used in prior studies investigating behavioral interventions for insomnia. The therapist presents the QDT as a means to eliminate conditioned arousal, occurring after nocturnal arousal using 8 sessions on a weekly basis. The therapist initially helps the subject to develop a chronological 12-item hierarchy of commonly practiced activities on awakening at night, like opening eyes and clock watching. As a next step, the subject develops 6 imaginable scenes of himself/herself engaged in neutral activities like reading a newspaper. The therapist then helps the subject pair the neutral scenes with the items from the 12-item hierarchy, which is then practiced by the subject 2 hours before bedtime."
3085882|NCT01987076|Active Comparator|Corticosteroids per os: Prednisone + Emollient|
3085883|NCT01987076|Experimental|Topical corticosteroid: Clobetasol + Emollient|
3085884|NCT01987063||pregnant woman with twins|pregnant woman with twins
3085885|NCT01987037||tests evaluation|children with autism spectrum disorder subjected to the NP-MOT tests
3085886|NCT01987024|Active Comparator|group A-usual procedure|
3085894|NCT01986972|Experimental|Toothbrushing Without Dentifrice|After 72 hours of absence oral hygiene, patients performed toothbrushing without dentifrice.
3085895|NCT01986959|Experimental|Surgery with Periodontal dressing|After the Surgical crown lengthening, the patients were randomly allocated to the periodontal dressing group (PDG) and control group (CG - non-placement of periodontal dressing).
3085896|NCT01986959|Other|Surgery without Periodontal dressing|After surgery, the patients were randomly allocated to the periodontal dressing group (PDG) and control group (CG - non-placement of periodontal dressing).
3085897|NCT01986946|Experimental|Intravenous opioids|This is the standard of care method for post-operative analgesia following lumbar spine fusion surgery. Participants randomly assigned to this arm will receive Intravenous Patient-Controlled Analgesia (IVPCA) with dilaudid (or other opioid) for post-operative pain control.
3085898|NCT01986946|Experimental|Epidural Catheter|The intervention to be tested in this study against standard intravenous opioids is infusion of local anesthetic and dilaudid via epidural catheter for post-operative pain control in patients undergoing lumbar spine fusion surgery.
3085899|NCT01986933|Experimental|Group1|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
3085900|NCT01986933|Experimental|Group2|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
3085901|NCT01986933|Experimental|Group3|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
3085902|NCT01986933|Experimental|Group4|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
3085903|NCT01986933|Experimental|Group5|Part A: Placebo Part B: nemolizumab (CIM331)
3085904|NCT01986920|Active Comparator|A-101 25%|Low dose group
3085905|NCT01986920|Active Comparator|A-101 32.5%|Mid Dose Group
3085906|NCT01986920|Active Comparator|A-101 40%|High Dose Group
3085907|NCT01986920|Placebo Comparator|A-101 Vehicle|Placebo group
3085908|NCT01986907|Experimental|Ranibizumab|patients treated with 0.5mg ranibizumab
3085909|NCT01986894|Placebo Comparator|Treatment 1 (placebo)|Five placebo capsules matching the appearance of the 4 mg pomalidomide capsule will be administered orally on the morning of Day 1
3085910|NCT01986894|Experimental|Treatment 2 (4 mg pomalidomide)|Five capsules (one 4 mg pomalidomide capsule and four placebo capsules matching the appearance of the 4 mg pomalidomide capsule) will be administered orally on the morning of Day 1
3085911|NCT01986894|Experimental|Treatment 3 (20 mg pomalidomide)|Five 4 mg pomalidomide capsules will be administered orally on the morning of Day 1
3085912|NCT01986894|Active Comparator|Treatment 4 (moxifloxacin)|One 400 mg moxifloxacin tablet (AVELOX®, moxifloxacin hydrochloride, Bayer Pharmaceuticals Corporation) will be administered orally on the morning of Day 1
3085913|NCT01986881|Experimental|Ertugliflozin, 15 mg|Ertugliflozin 15 mg administered orally once daily for up to 6.1 years
3085914|NCT01986881|Experimental|Ertugliflozin, 5 mg|Ertugliflozin 5 mg administered orally once daily for up to 6.1 years
3085915|NCT01986881|Placebo Comparator|Placebo|Matching placebo to ertugliflozin administered orally once daily for up to 6.1 years
3085916|NCT01986868|Other|Coronary MR Angiography (CMRA)|Coronary MR Angiography(CMRA). A gadolinium-based contrast (Optimark or MultiHance) will be administered as well as a beta blocker which will be assigned based upon heart rate.
3085917|NCT01986855|Experimental|Ertugliflozin (5 mg)|Ertugliflozin, 5 mg, oral, one 5 mg ertugliflozin tablet and one placebo tablet, once daily for 52 weeks
3085918|NCT01986855|Experimental|Ertugliflozin (15 mg)|Ertugliflozin, 15 mg, oral, one 5 mg and one 10 mg tablet, once daily for 52 weeks
3085919|NCT01986855|Placebo Comparator|Placebo|Matching placebo
3085920|NCT01986842|Experimental|Low protein|Subject will receive a low protein diet (0.7 g/kg BW/day) for 14 days prior to the experimental trial
3085921|NCT01986842|Experimental|High protein|Subjects will receive a high protein diet (1.5 g/kg BW/day) for 14 days prior to the experimental trial
3085922|NCT01986829|Experimental|Treatment (ablation)|"Patients undergo cryoablation, radiofrequency ablation, or microwave ablation of each lesion.~Patients complete pain survey (BPI-Short form) and quality of life questionnaires (FACT-G7)"
3085923|NCT01986803|Experimental|PCI with ABSORBTM bioresorbable vascular scaffold system (BVS)|All patients assigned to the experimental arm will be treated with a primary Percutaneous Coronary Intervention using the Abbott Vascular ABSORB TM everolimus eluting bioresorbable vascular scaffold system (BVS)
3085924|NCT01986803|Active Comparator|PCI with XIENCE Xpedition stent|All patients assigned to the experimental arm will be treated with a primary Percutaneous Coronary Intervention using the XIENCE Everolimus Eluting Coronary Stent System (XIENCE Xpedition) (commercial product)
3085925|NCT01986790|Experimental|Plain Language|This intervention group will receive a plain-language table describing the features and costs of health insurance plans, with definitions of health insurance terms incorporated into the table.
3085926|NCT01986790|Experimental|Plain Language + Visuals|This intervention group will receive the plain-language table plus visuals that focus on specific features of the plans. Participants will be able to view the information about each health insurance feature one feature at a time, in the order they prefer.
3085927|NCT01986790|Experimental|Plain Language + Narratives|This intervention group will receive the plain language table plus narratives about how others might use and rate the insurance plans.
3085928|NCT01986777|Active Comparator|lisdexamfetamine|Participants will have a 50% chance of receiving the active study medication. They will begin at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 10 weeks.
3085929|NCT01986777|Placebo Comparator|Placebo|Participants will have a 50% chance of receiving the placebo for this study. They will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 8-10 weeks.
3085930|NCT01986764|Active Comparator|lisdexamfetamine|lisdexamfetamine 20 mg/d to 60 mg/d for 12 weeks
3085931|NCT01986764|Active Comparator|Estradiol|Estradiol 1 mg/d to 3 mg/d for 12 weeks
3085932|NCT01986764|Placebo Comparator|Placebo|
3085933|NCT01986751|Experimental|Clonidine and Ropivacaine|A bolus of 20 mL of 0.5% ropivacaine mixed with clonidine 1mcg/kg will be injected through the stimulating needle with gentle aspiration between divided doses (5 mL per dose).
3085934|NCT01986751|Active Comparator|Ropivacaine|Standard saphenous nerve block (adductor canal approach) will be performed using 15ml of 0.5% ropivacaine
3085935|NCT01986738||Radiation Treatment|Patients undergoing standard of care radiation treatment with Active Breathing Control (ABC)
3085936|NCT01986725|Active Comparator|Standardized care|During treatment and routine follow-up consultations, patients randomized to standardized care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.
3085937|NCT01986725|Active Comparator|Standardized care + WOMAN-PRO II program|During treatment and routine follow-up consultations, patients randomized to standardized care + WOMAN-PRO II program will be provided with usual care and nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments.
3085938|NCT01986712||Intron A, HDI|High-dose interferon alfa (Intron A, HDI)
3085939|NCT01986712||Sylatron|Pegylated alfa-interferon 2b (Sylatron, PEG IFN)
3085940|NCT01986699||Standard Therapy|Patients are treated as per current standard of care
3085941|NCT01986699||Laparoscopic Assisted Polypectomy|Patients treated with Laparoscopic Assisted Colonoscopic Polypectomy
3085942|NCT01986686|No Intervention|Observational|The observation group will be followed clinically with no further intervention until the primary endpoint is reached.
3085943|NCT01986686|Active Comparator|Surgery|The surgery group will be offered colon resection.
3085944|NCT01986673|Experimental|5% Sildenafil Cream (SST-6006)|5% Sildenafil Cream
3085945|NCT01986673|Active Comparator|Oral Sildenafil 50 mg|Oral Sildenafil 50 mg
3085946|NCT01986660|Experimental|Ibuprofen Cream (SST-0225)|
3085947|NCT01986647|Experimental|On the Move Exercise group|On the Move group exercise - 2 times per week for 12 weeks. Each session lasts approximately 1 hour. Timing and coordination exercises to improve walking.
3085948|NCT01986647|Active Comparator|Standard group exercise program|Standard impairment based seated group exercise program. 2 times per week for 12 weeks, approximately 1 hour class.
3085949|NCT01986647|Experimental|Exercise leader|Exercise class will be led by a person who is trained in exercise such as exercise physiologist, physical therapist, physical therapist assistant
3085950|NCT01986647|Experimental|Activity Personnel|Exercise class will be led by a member of the facility who does not necessarily have formal exercise training. this person will be trained by the research staff to lead the class.
3085951|NCT01986634|Other|Laser Treatment|Patients enrolled will have split face laser treatment. Patients will serve as their own control.
3085952|NCT01986621||Patients undergoing elective PCI|
3085953|NCT01986608|Experimental|Lacosamide 30-minute iv|A 30-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial).
3085954|NCT01986608|Experimental|Lacosamide 60-minute iv|60-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial).
3085955|NCT01986608|Experimental|Lacosamide oral tablet|Oral administration of Lacosamide (LCM) 200 mg (2 x 100 mg film-coated tablet) with 200 mL of water.
3085956|NCT01986582|Active Comparator|Group A|One puff of oxymetazoline immediately followed by one puff of hydroxyl-propyl-methyl cellulose powder, morning & evening, for 8 days.
3085957|NCT01986582|Placebo Comparator|Group B|One puff of oxymetazoline immediately followed by one puff of placebo, morning & evening, for 8 days.
3085958|NCT01986569|Experimental|[18F]fluoroestradiol (FES)|The injectable radioactive dose of 111-222 megabecquerel. One single IV injection over 1-2 min. [18F]FES PET/CT for imaging.
3085959|NCT01986556|Experimental|Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot A)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)
3085960|NCT01986556|Experimental|Lesinurad 400 mg Fed (Site 1 and Site 2, Lot A)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)
3085961|NCT01986556|Experimental|Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot B)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)
3085962|NCT01986556|Experimental|Lesinurad 400 mg Fed (Site 1 and Site 2, Lot B)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)
3085963|NCT01986543|Experimental|Arm 1|8 weeks R20mg/Kg + HZE and efavirenz 600mg
3085964|NCT01986543|Experimental|Arm 2|8 weeks R20mg/Kg + HZE and efavirenz 800mg
3085965|NCT01986543|Active Comparator|Standard arm|8 weeks R10mg/Kg + HZE and efavirenz 600mg
3085966|NCT01986530||Healthy individuals|Participants will be healthy volunteers of both sexes recruited from the Greek Military Medical School personnel, Thessaloniki, Greece.
3085967|NCT01986530||Boost Subgroup|After an overnight fast, 40 participants will be provided a standardized mixed meal in two different quantities (125 ml, n=20 and 250 ml, n=20) and blood samples will be obtained before as well as 30 min after mixed meal ingestion
3085968|NCT01986530||Aerobic exercise|After an overnight fast, 20 participants will be subjected to aerobic exercise for 30 min and blood samples will be obtained at baseline and at 30 min
3085969|NCT01986530||Circadian variation Subgroup|20 of the participants will be hospitalized and closely monitored for 24 hours. A catheter will be inserted in a vein and blood samples will be obtained every 3 hours through the 24-hour period.
3085970|NCT01986530||Seasonal variation Subgroup|20 of the participants will be monitored for one year and blood samples will be obtained every 3 months (at the middle of month January - April - July - October). Subjects will be instructed to maintain their normal exercise routine and dietary habits.
3085971|NCT01986517|Experimental|Feedback|Therapists assigned to this group will receive standardized feedback on their psychotherapeutic competency after every fourth treatment session with a patient for a period of 20 therapy sessions. The feedback will be given by two experienced raters who are licensed as psychological psychotherapists.
3085972|NCT01986517|Experimental|No feedback|Therapists assigned to this group will receive no feedback
3085973|NCT01986491|Experimental|Part 1; Period 1|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks. 30 mg of solid X, 120 mg of solid Y, 30 mg of solid Y, and 120 mg of solid X.
3085974|NCT01986491|Experimental|Part 1; Period 2|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks. 30 mg of solid Y, 30 mg of solid X, 120 mg of solid X and 120 mg of solid Y.
3085975|NCT01986491|Experimental|Part 1; Period 3|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 120 mg of solid X, 30 mg of solid Y, 120 mg of solid Y, and 30 mg of solid X.
3085976|NCT01986491|Experimental|Part 1; Period 4|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 120 mg of solid Y, 120 mg of solid X, 30 mg of solid X, and 30 mg of solid Y.
3085977|NCT01986491|Experimental|Part 2; Period 1|Four participants will receive 30 mg of JNJ 39393406 of 2 different formulations (solid formulation selected from Part 1 and solution) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 30 mg of solid formulation, and 30 mg of solution.
3085978|NCT01986491|Experimental|Part 2; Period 2|Four participants will receive 30 mg of JNJ 39393406 of 2 different formulations (solid formulation selected from Part 1 and solution) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 30 mg of solution, and 30 mg of solid formulation.
3085979|NCT01986491|Experimental|Part 3|Eight participants (same participants from Part 2) will receive JNJ 39393406 (dose will likely be 30 mg, or another multiple of the 30 mg solid dose form selected in Part 1, but not higher than 210 mg) from Days 1 to 7.
3085980|NCT01986478||Normal|Normal results from clinical exam and free of ocular pathology
3085981|NCT01986465|Experimental|Depomedrol|The trial pharmacist prepares a series of similar vials containing either 4 mg of Depomedrol or Normal Saline and coded them either 1, 2, 3 or 4, the group assignments are not decoded until the end of the trial when the final analysis is due to take place. Patients take their envelopes to the trial pharmacist who give them a coded vial which they take to the orthopaedic surgeon who make the injection. After the injection the trial clerk take the patients to a technician who give patients in groups 1 and 3 long arm splints.
3085982|NCT01986465|Placebo Comparator|Placebo|The trial pharmacist prepares a series of similar vials containing either 4 mg of Depomedrol or Normal Saline and coded them either 1, 2, 3 or 4, the group assignments are not decoded until the end of the trial when the final analysis is due to take place. Patients take their envelopes to the trial pharmacist who give them a coded vial which they take to the orthopaedic surgeon who make the injection. After the injection the trial clerk take the patients to a technician who give patients in groups 1 and 3 long arm splints.
3085983|NCT01986452|Active Comparator|Unattended CPAP therapy|Therapy data will be examined by reading out the CPAP device after 6 months. Patients can obtain help on own request, corresponding to the standard CPAP prescription routine.
3085984|NCT01986452|Experimental|Telemonitoring and support|CPAP device therapy data will be downloaded by the study site via GSM modules once a week. In case of poor therapy adherence (defined by a minimum average usage of 3h/night over the week) a contact call will be initiated to motivate patients or solve problems identified by telemonitoring. If active home intervention is required, the study site will inform the healthcare provider to visit the patient in a timely manner.
3085985|NCT01986426|Experimental|Arm A: LTX-315 monotherapy singe lesion|"Cohort 1-3: First induction treatment (6 weeks): In week 1 the first index lesion will be injected Twice daily on 3 consecutive days. During week 2-6 the injection will be once a week.~Second induction treatment (6 weeks) and Maintenance treatment (20 weeks)- At week 7 the second index lesion will be injected with same dosing schedule as the first index lesion.~Cohort 4 and above: Once daily on 3 consecutive days week 1. Week 2-6 one injection per week. From week 8, one dosing days every 2 weeks."
3085986|NCT01986426|Experimental|Arm B: LTX-315 monotherapy in multiple concurrent lesions|"Patients with at least one injectable lesion and one bystander lesion will receive LTX-315 to one or more lesions:~Once daily on 2 consecutive days week 1-3."
3085987|NCT01986426|Experimental|Arm C|Patients with melanoma and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with ipilimumab given for 4 cycles every 3 weeks.
3085988|NCT01986426|Experimental|Arm D|Patients with TNBC and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with pembrolizumab given every 3 weeks.
3085989|NCT01986413|Active Comparator|BIPAP ST|one night, NIV with pressure controlled ventilation (BIPAP ST) with individually titrated pressure parameters.
3085990|NCT01986413|Experimental|IVAPS|one night, NIV with volume assured pressure support (IVAPS).The pressure parameters will be adjusted according to the BIPAP pressure levels.
3085991|NCT01986400|Experimental|Virtual Peer-to-Peer Support Mentoring|In addition to standard medical care, adolescents in the experimental group will receive the VP2P support program, a manualized peer-mentorship program that will provide modeling and reinforcement by peers (young adults with JIA aged 16-25 years who have learned to function successfully with their JIA to the mentored participants).
3085992|NCT01986400|No Intervention|Wait-list Control|The control group will receive usual care but without the mentorship intervention. They will be offered the VP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
3085993|NCT01986387|Experimental|Virtual Peer-to-Peer Support Mentoring|In addition to standard medical care, adolescents in the experimental group will receive the VP2P support program, a manualized peer-mentorship program that will provide modeling and reinforcement by peers (young adults with chronic pain aged 16-25 years who have learned to function successfully with their chronic pain to the mentored participants).
3085994|NCT01986387|No Intervention|Waitlist Control|The control group will receive usual care but without the mentorship intervention. They will be offered the VP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
3085995|NCT01986374|Experimental|HCG is introduced with small catheter.|phase 1 non randomized pilot
3085996|NCT01986361|Experimental|flurbiprofen 8.75 mg lozenge|A single flurbiprofen lozenge is sucked until fully dissolved.
3085997|NCT01986361|Placebo Comparator|Placebo lozenge|A single placebo lozenge is sucked until fully dissolved.
3085998|NCT01986348|Experimental|Arm A: Selinexor and surgery|Patients who require surgery will receive up to 3 doses of Selinexor, undergo surgery, and resume Selinexor after recovery. Selinexor will be given twice weekly.
3085999|NCT01986348|Experimental|Arm C: Selinexor only|Patients who were not eligible for surgery may be randomized to take Selinexor twice weekly.
3086000|NCT01986348|Experimental|Arm D: Selinexor only|Patients who were not eligible for surgery may be randomized to take Selinexor once weekly.
3086001|NCT01986335|Experimental|DTP/HB/Hib Vaccine (Batch: A)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
3086002|NCT01986335|Experimental|DTP/HB/Hib vaccine (Batch: B)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
3086003|NCT01986335|Experimental|DTP/HB/Hib vaccine (Batch: C)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
3086004|NCT01986322|Experimental|DTP/HB/Hib vaccine|"Group A will receive DTP/HB/Hib combination vaccine at 6-11, 10-15 and 14-19 weeks of age.~DTP/HB/Hib component:~Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal"
3086005|NCT01986322|Active Comparator|DTP/HB and Hib vaccine|"Group B will receive DTP/HB and Hib Vaccines separately at 6-11,10-15, 14-19 weeks of age~DTP/HB component:~Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis rHbsAg Aluminum phosphate Natrium Chloride Thimerosal~Hib component:~Purified Haemophilus influenzae type b polysaccharide 10 mcg"
3086006|NCT01986309|Active Comparator|Group L|Group L Lidocaine load dose 1.5 mg / kg over 5 minutes, followed by continuous infusion of 2 mg / kg / h, which is maintained until the end of surgical procedure
3086007|NCT01986309|Placebo Comparator|Group P|Normal saline solution administered under the same regimen
3086008|NCT01986296|Experimental|ExAblate Treatment|
3086009|NCT01986283|Placebo Comparator|Treatment A|Placebo solution +placebo capsule + placebo capsule chewed.
3086010|NCT01986283|Experimental|Treatment B|PF-00345439 taken whole + placebo solution + placebo chewed
3086011|NCT01986283|Experimental|Treatment C|PF-00345439 chewed + placebo solution + placebo taken whole
3086012|NCT01986283|Active Comparator|Treatment D|Oxycodone HCl immediate-release 40 mg tablets (eg, 2 x 5 mg + 1 x 30 mg) + placebo taken whole + placebo chewed
3086013|NCT01986270|Placebo Comparator|Placebo|
3086014|NCT01986270|Experimental|Eletriptan 40 mg|
3086015|NCT01986270|Experimental|Eletriptan 80 mg|
3086016|NCT01986270|Experimental|Sumatriptan 25 mg|
3086017|NCT01986270|Experimental|Sumatriptan 50 mg|
3086018|NCT01986257|Experimental|Emotion Regulation Group Therapy (ERGT).|
3086019|NCT01986244||STAR Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the STAR
3086020|NCT01986244||Salto Talaris Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the Salto Talaris
3086021|NCT01986244||In-Bone Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the In-Bone
3086022|NCT01986231|Experimental|Open-Label Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg.
3086023|NCT01986218|Experimental|Arm A: Dose Escalation (BMS-986115)|Continuous daily dosing until disease progression or unacceptable toxicity
3086024|NCT01986218|Experimental|Arm A: Dose Expansion (BMS-986115)|Continuous daily dosing until disease progression or unacceptable toxicity
3086025|NCT01986218|Experimental|Arm B: Dose Escalation (BMS-986115)|Twice weekly dosing until disease progression or unacceptable toxicity
3086026|NCT01986218|Experimental|Arm B: Dose Expansion (BMS-986115)|Twice weekly dosing until disease progression or unacceptable toxicity
3086027|NCT01986205|Experimental|Hyperbaric Oxygen|100% oxygen at 1.5 atmospheres absolute for 60 minutes, 40 sessions
3086028|NCT01986205|Placebo Comparator|Minimal pressure air|Regular air at minimal pressurization for 60 minutes, 40 sessions
3086029|NCT01986192|Experimental|rivaroxaban|Rivaroxaban 15mg bid for 3 weeks and 20mg qd for 6 months
3086030|NCT01986192|Active Comparator|warfarin|Enoxaparin 1mg/kg bid overlapping with warfarin (target PT INR 2.0-3.0) for 6 months
3086031|NCT01986179|Active Comparator|Telephone Interpretation|These families will be assigned to use telephone interpretation throughout the ED visit.
3086032|NCT01986179|Experimental|Video Interpretation|These families will be assigned to use video interpretation throughout the ED visit.
3086033|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 1|Patients will receive MEHD7945A 1100 milligrams (mg) intravenous (IV) infusion every 2 weeks (q2w) in combination with cobimetinib. Cobimetinib will be administered at a starting dose of 80 mg oral tablet q2w. Cobimetinib doses will be escalated to establish maximum tolerated dose (MTD) of MEHD7945A+cobimetinib combination for Stage 2.
3086034|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 2 (CRC)|CRC patients will receive MEHD7945A in combination with cobimetinib until disease progression or unacceptable toxicity. The doses and schedule of the combination treatment will be according to the MTD established in Stage 1.
3086035|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 2 (NSCLC)|NSCLC patients will receive MEHD7945A in combination with cobimetinib until disease progression or unacceptable toxicity. The doses and schedule of the combination treatment will be according to the MTD established in Stage 1.
3086036|NCT01986153||Home parenteral nutrition patients|Patients who receive home parenteral nutrition.
3086037|NCT01986153||Healthy controls|Those who don't receive home parenteral nutrition and consume a normal diet.
3086038|NCT01986140|Experimental|PAXMAN Orbis Scalp Cooler|Scalp Cooling
3086039|NCT01986140|Other|Control No treatment|Control
3086040|NCT01986127|Experimental|Adalimumab|single administration of Adalimumab 80mg diluted in 5ml saline
3086041|NCT01986127|Placebo Comparator|saline|5 ml of saline
3086042|NCT01986114|Experimental|SM-13496 20-120mg|once daily orally
3086043|NCT01986101|Placebo Comparator|Placebo|once daily orally
3086044|NCT01986101|Experimental|SM-13496 20 -60 mg|once daily orally
3086045|NCT01986101|Experimental|SM-13496 80-120 mg|once daily orally
3086046|NCT01986088|Placebo Comparator|Placebo|
3086047|NCT01986088|Experimental|Eletriptan 40 mg|
3086048|NCT01986088|Experimental|Eletriptan 80 mg|
3086049|NCT01986088|Experimental|Sumatriptan 50 mg|
3086050|NCT01986088|Experimental|Sumatriptan 100 mg|
3086126|NCT01985659||Early VATS|In a second cohort, (2010-2011) the experience with vats was early.
3086967|NCT01979744|Active Comparator|Resolute Integrity - Angio|Resolute Integrity - Angio arm
3086051|NCT01986075|Active Comparator|Computer-assisted Therapy alone|Computer-assisted behavior therapy based on the Community Reinforcement Approach (CRA) to treating cocaine dependence. CRA is skills based treatment program that incorporates coping skills development and contingency management. Participants will attend the clinic 3x per week and receive counseling 2x per week when receiving Behavioral: Computer assisted therapy alone.
3086052|NCT01986075|Experimental|Computer-assisted CBT + Adderall-XR|Patients who are randomized to the computer-assisted behavior therapy plus mixed amphetamine salts (extended release) arm will have their dose titrated to 80 mg or the maximum tolerated extended release mixed amphetamine salts daily. Participants will be asked to take the medication once per day in the morning or early afternoon and will be maintained on this schedule through week 14 of the trial.
3086053|NCT01986075|Placebo Comparator|Computer-assisted CBT plus placebo|Patients who are randomized to the Computer-assisted CBT plus placebo arm will have their medication dose titrated in a fix-flexible dose schedule matching the active medication arm. Participants will be asked to take the medication once per day in the morning or early afternoon and will be maintained on this schedule through week 14 of the trial.
3086054|NCT01986062|Experimental|AR11 (amphetamine sulfate) (1 week) - double blind|AR11, administered orally, BID, for one week (crossover to placebo administration week 2)
3086055|NCT01986062|Placebo Comparator|Placebo (1 week) - double blind|Placebo, administered orally, BID, for one week (crossover to AR11 administration week 2)
3086056|NCT01986049|Experimental|Bupivicaine 0.5%|Drug Bupavacaine 0.5%
3086057|NCT01986049|Experimental|Bupivicaine 0.25%|Drug Bupavacaine 0.25%
3086058|NCT01986049|Placebo Comparator|Normal Saline|Saline Normal
3086059|NCT01986036|Sham Comparator|CONTROL|Control breakfast low in protein and calcium. Porridge-based breakfast.
3086060|NCT01986036|Active Comparator|PROTEIN|High-protein breakfast.
3086061|NCT01986036|Active Comparator|CALCIUM|High-calcium breakfast.
3086062|NCT01986036|Experimental|PRO-CAL|High-protein and calcium breakfast.
3086063|NCT01986023|Experimental|SMS Short Message Service Arm plus Prescription|"Intervention is as follows: Drug reminder SMS will be sent to the participants in the intervention arm customised to their stroke prescription. These SMS will be interactive in a way that the participants will have to answer back if they have taken their medicine or not in a Yes/No format. Moreover behaviour change SMS will also be sent to the intervention arm twice weekly. In addition , Participants will be encouraged to take medication using a taxonomy of behavioral change intervention techniques."
3086064|NCT01986023|No Intervention|Standard Prescriptions and Counselling|The usual care arm will undergo standard treatment and counselling regarding their treatment and the education regarding their medication as per standard of care. They will receive a standard written prescription and no SMS
3086065|NCT01986010|Experimental|HCMV seropositive (+) V160 Low Dose Intramuscular (IM)|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
3086066|NCT01986010|Experimental|HCMV seronegative (-) V160 Low Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
3086067|NCT01986010|Experimental|HCMV+ V160 Medium Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
3086068|NCT01986010|Experimental|HCMV- V160 Medium Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
3086069|NCT01986010|Experimental|HCMV+ V160 High Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
3086070|NCT01986010|Experimental|HCMV- V160 Medium Dose plus MAPA 225 µg IM|Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
3086071|NCT01986010|Experimental|HCMV- V160 High Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
3086072|NCT01986010|Experimental|HCMV+ V160 High Dose plus MAPA 225 µg IM|Participants seropositive for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
3086073|NCT01986010|Experimental|HCMV+ V160 Maximum Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
3086074|NCT01986010|Experimental|HCMV- V160 High Dose plus MAPA 225 µg IM|Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
3086075|NCT01986010|Experimental|HCMV- V160 Maximum Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
3086076|NCT01986010|Placebo Comparator|HCMV+ Placebo IM|Participants seropositive for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
3086077|NCT01986010|Placebo Comparator|HCMV- Placebo IM|Participants seronegative for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
3086078|NCT01986010|Experimental|HCMV+ V160 Medium Dose Intradermal (ID)|Participants seropositive for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
3086079|NCT01986010|Experimental|HCMV- V160 Medium Dose ID|Participants seronegative for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
3086080|NCT01986010|Placebo Comparator|HCMV+ Placebo ID|Participants seropositive for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
3086081|NCT01986010|Placebo Comparator|HCMV- Placebo ID|Participants seronegative for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
3086082|NCT01985984||H&N cancer patients|"Patients with Head and Neck Cancer, treated with curative intent~Any tumor site~Stage I-IV, M0~Treated with radiotherapy alone or in combination with systemic therapy~Definitive radiotherapy or postoperative radiotherapy~Interventions:~Radiation alone~Radiation in combination with systemic therapy"
3086083|NCT01985945|Other|Yoga|
3086084|NCT01985945|No Intervention|Without Yoga|
3086085|NCT01985906|Experimental|Pararenal aortic aneurysm|"The aneurysm is adjacent to (proximal/distal landing zone < 15mm) or involving vital branches, including the celiac artery, superior mesenteric artery, or renal artery.~The intervention is endovascular management of the aneurysms with multiple overlapping uncovered stents"
3086086|NCT01985893|Other|Lapatinib plus trastuzumab|Drug intervention: Lapatinib IMP, Trastuzumab on prescription. Lapatinib 1000 mg p.o. once daily for 21 days. Trastuzumab i.v. infusion 8 mg/kg loading dose; 6 mg/kg on Day 1 of each subsequent 3 weekly cycle.
3086087|NCT01985893|Other|Lapatinib plus Capecitabine|Drug intervention: Lapatinib and Capecitabine on prescription. Lapatinib 1250 mg p.o. once daily. Capecitabine 2000 mg/m2 p.o. in two divided doses on days 1 to 14 of a 21 day cycle.
3086088|NCT01985880||Hunner's ulcer interstitial cystitis|Hunner's ulcer interstitial cystitis
3086089|NCT01985880||non-ulcer interstitial cystitis|non-ulcer interstitial cystitis
3086090|NCT01985880||Control|Control
3086091|NCT01985867|Experimental|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 8×10^8 colony forming units (CFU), twice daily, orally for 4 weeks
3086092|NCT01985867|Placebo Comparator|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
3086093|NCT01985854|Active Comparator|Propofol|Propofol target-controlled infusion will be kept 2-4μg /ml plasma concentration throughout procedure.
3086094|NCT01985854|Experimental|Desflurane|After taking off the electrophysiological monitoring from the patients, discontinue propofol and start desflurane from 6% (dialed concentration) at flow rate of 4L/min for 2 minutes in desflurane group. When achieve end tidal concentration of 4-5%, decrease the flow rate to 2L/min.
3086095|NCT01985841|Experimental|Bevacizumab/FEC/Docetaxel|Bevacizumab plus 5-Fluorouracil/Epirubicin/Cyclophosphamide (FEC) -> Bevacizumab plus Docetaxel
3086096|NCT01985828|Experimental|Intermediate Risk|"Short term (4-6 months) androgen deprivation therapy (ADT) per current standard of care + CyberKnife 21 Gy (7 Gy x 3) and Prostate/SV Intensity Modulated radiation therapy (IMRT) 45-50.4 Gy~OR~Short term (4-6 months)androgen deprivation therapy + CyberKnife 36.35 Gray (7.27 Gray x 5)"
3086097|NCT01985828|Experimental|High Risk|Short or Long term (6 months - 3 years) androgen deprivation therapy (ADT) + 45-50.4 Gy and Pelvis Intensity Modulated radiation therapy (IMRT) per current standard of care + 21 Gy (7 Gy x 3) CyberKnife boost
3086098|NCT01985815|Experimental|VC/VS stimulation ON followed by OFF|triple blind, randomised, two periods of three months
3086099|NCT01985815|Experimental|VC/VS stimulation OFF followed by ON|triple blind, randomised, two periods of three months
3086100|NCT01985802|Other|Pacing - Cross-over|Pacing will be conducted in 3 different ways (atrial, dual chamber and His-bundle pacing) at 2 different rates (basal and 100 bpm).
3086101|NCT01985789|Active Comparator|diphenhydramine|50mg dose given as two 25mg capsules
3086102|NCT01985789|Active Comparator|cetirizine|10mg dose given as 1 10mg capsule and 1 placebo capsule
3086103|NCT01985789|Active Comparator|desloratadine|5mg dose given as 1 5mg capsule and 1 placebo capsule
3086104|NCT01985789|Placebo Comparator|placebo|given as 2 placebo capsules
3086105|NCT01985776|Active Comparator|Exercise intervention|Patients will functional stabilisation exercise for the trunk.
3086106|NCT01985776|Active Comparator|Exercise and e-stim|Patients will receive exercise intervention and electrical stimulation simultaneously.
3086107|NCT01985776|No Intervention|Patients control|Patients will not receive any treatment but could use compression belt as per usual.
3086108|NCT01985776|No Intervention|Healthy control|Healthy asymptomatic participants who will not receive any treatment.
3086109|NCT01985763|Experimental|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin Genistein 60mg/day orally for 7 days every 2 weeks. Genistein will be administered beginning 4 days prior to FOLFOX or FOLFOX-Avastin and continuing the 3 days of chemotherapy.
3086110|NCT01985750|Placebo Comparator|Drug: d-cycloserine or placebo|"Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
3086111|NCT01985750|Active Comparator|D-cycloserine|"Placebo Comparator: Drug: d-cycloserine or placebo~Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
3086112|NCT01985737||Infants with infected PICC line|After informed consent the subjects that develop a PICC line infection in the NICU will serve as the cases.
3086113|NCT01985737||Infants without infected PICC line|After informed consent the subjects that do not develop a PICC line infection in the NICU will serve as the controls.
3086114|NCT01985724|Active Comparator|A|FEC -> TXT
3086115|NCT01985724|Experimental|B|Docetaxel/Cyclophosphamide (TC)
3086116|NCT01985711|Experimental|web-based,CBT,MI,TTM, outpatient|Participants in web-based collaborative care group will receive 24 weekly 40-minute web-based Cognitive Behavioral Therapy (CBT) sessions, undergo structured Transtheoretical Model of Behavior Change or Motivational interviewing to set up proper life-style and healthy behavior to improve their live quality，conducted on the web. Besides, they will receive usual diabetes outpatient care and web-based diabetes care.
3086117|NCT01985711|Other|waitlist, usual diabetes outpatient|Participants assigned to the wait-list group will be given usual diabetes outpatient service (diabetic medication guidance and appointment to see doctor as routine, without specific anti-depression therapy). After 6 months, they will receive web-based collaborative care for 6 months too.
3086118|NCT01985698|Experimental|Robotic-assisted resection|patients with low rectal cancer receiving robotic-assisted abdominoperineal resection.
3086119|NCT01985698|Experimental|Laparoscopic resection|patients with low rectal cancer receiving laparoscopic abdominoperineal resection.
3086120|NCT01985698|Active Comparator|Open Surgery|patients with low rectal cancer receiving open abdominoperineal resection.
3086121|NCT01985685|Experimental|Thiamine|200mg intravenous thiamine in 50ml 5% dextrose, single dose
3086122|NCT01985685|Placebo Comparator|Placebo|50ml intravenous 5% dextrose, single dose
3086123|NCT01985672||Vitamin D deficient patients|Serum 25-OH Vitamin D levels <20ng/L undergoing Frozen embryo transfer (vitamin D levels are measured on the day of embryo transfer)
3086124|NCT01985672||Vitamin D sufficient patients|Serum 25-OH Vitamin D levels >20ng/L undergoing Frozen embryo transfer (vitamin D levels are measured on the day of embryo transfer)
3086125|NCT01985659||open thoracotomy|In the first cohort(20007-2009) almost all patients where operated through a thoracotomy.
3086127|NCT01985659||Standardized VATS|In the third period (2012-2013), a standardized vats technique with extensive intrapulmonary and mediastinal lymphadenectomy was used.
3086128|NCT01985646|Experimental|surgery treatment|one stage pull through left-colectomy
3086129|NCT01985646|Experimental|conservative treatment|anal dilation, colonic lavage, oral probiotic
3086130|NCT01985633|Experimental|Mesenchymal stem cell, PRP|Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 10 ml of Mesenchymal stem cell suspension and 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle
3086131|NCT01985633|Active Comparator|platelet rich plasma|About 100 ml of venous blood would be drawn with aseptic technique from the antecubital vein with an 18g needle , in order to avoid irritation and trauma to the platelets which are in a resting state. The blood would be collected in a 100 ml paediatric bag with CPDA(citrate phosphate dextrose adenine) as anti coagulant. A leucocyte filter will be also used to filter off the leucocytes. The blood will be then centrifuged for 15 min at 1300 rpm. This separates blood in to RBC( packed red blood cells) and platelet rich plasma. Next the PRP will be passed through a leucocyte filter to obtain leucocyte poor platelet rich plasma. 10 ml of PRP will be dispensed in a sterile syringe. The PRP would be used for injection.
3086132|NCT01985620|Active Comparator|study group|Educational intervention with the parents
3086133|NCT01985620|No Intervention|control group|
3086134|NCT01985607|Experimental|Thickened|
3086135|NCT01985607|Active Comparator|Control|
3086136|NCT01985594|Active Comparator|Utrogestan|oral tablet Utrogestan 400mg daily for 2 days
3086137|NCT01985594|Placebo Comparator|Nifedipine|tablet Nifedipine 20 mg stat then 20 mg after 30 minutes then another 20 mg after 30 minutes followed by 10 mg three times daily for 2 days
3086138|NCT01985581|Experimental|Placebo first then GXR|patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine). In the first intervention period subject took placebo and second intervention period subject took GXR. GXR dose was optimized to between 1 and 4mg.
3086139|NCT01985581|Placebo Comparator|GXR first then Placebo|patient will continue to take stable dosage of usual stimulant(Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine). In the first intervention period subject took GXR and second intervention period subject took placebo. GXR dose was optimized to between 1 and 4mg.
3086140|NCT01985568|Active Comparator|Standard Behavioral Therapy (Standard BT)|Standard BT: This group will follow a traditional model of initiating exercise concurrently with a dietary intervention for weight loss within an 18 month behavioral weight loss program.
3086141|NCT01985568|Experimental|Sequential Behavioral Therapy (Sequential BT)|Sequential BT: This group will receive diet and exercise interventions delivered sequentially within an 18 month behavioral weight loss program.
3086142|NCT01985555|Experimental|Volitinib(HMPL-504)|There are 5 dose cohorts,including600 QD,800QD and 400BID mg,500BID in the dose escalation stage and HMPL-504 will be administered orally to patients once daily for each dose cohort., in the dose expansion stage 500BID will be administered orally to patients.
3086143|NCT01985542|Active Comparator|subcutaneous immunotherapy|Starts with birch pollen subcutaneous immunotherapy
3086144|NCT01985542|No Intervention|no immunotherapy|not starting with birch pollen subcutaneous immunotherapy
3086145|NCT01985529|Experimental|Exercise|Enrollment in pulmonary rehabilitation
3086146|NCT01985529|No Intervention|Control|
3086147|NCT01985516|Experimental|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
3086148|NCT01985516|Active Comparator|Pouring the gel on the tip of the catheter|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally)
3086149|NCT01985503||Phase 1 group|Subjects were studied in 2009 and their follow-up is in 2014.
3086150|NCT01985503||Phase 2 group|Subjects were studied in 2011 and their follow-up is in 2016.
3086151|NCT01985490|Experimental|epiretinal membrane|
3086152|NCT01985477|Experimental|Lenalidomide + Dexamethasone + All-Trans Retinoic Acid (ATRA)|"Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21. Dexamethasone starting dose 40 mg by mouth on Days 1,8,15,22. ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.~Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment. Dexamethasone starting dose: Dose previously on when progressing prior to study entry. ATRA starting dose: MTD from Phase I.~Maintenance Therapy Group A: Lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days, with ATRA at dose determined in Phase I for 14/28 days, and Dexamethasone at last tolerated dose on Days 1, 8, 15 and 22. After 3 months on therapy at MTD in Phase I study, patients must be switched to this dose schedule. Patients unable to tolerate either Dexamethasone during maintenance phase may dose reduce Dexamethasone as needed."
3086153|NCT01985477|Experimental|Lenalidomide + All-Trans Retinoic Acid (ATRA)|"Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent Lenalidomide prior to study enrollment. All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.~Maintenance Therapy: Maintenance therapy consists of lenalidomide at the dose level tolerated at the completion of cycle 3 for 21/28 days, with ATRA at the dose determined in the phase I portion of the trial for 14/28 days. Dexamethasone will not be administered. After 3 months on therapy at the MTD in the phase 1 study, patients must be switched to this dose schedule."
3086154|NCT01985464|Experimental|Umbilical cord mesenchymal stem cells|
3086155|NCT01985451|Experimental|Pemetrexed and Temozolomide|Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m2) and temozolomide (200mg/m² day 1-5, 28 day cycle).
3086156|NCT01985438|Active Comparator|percutaneous endoscopic gastrostomy tube|Percutaneous endoscopic gastrostomy tube placement - A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion
3086197|NCT01985152|Experimental|1.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 8.75mg,orally
3086968|NCT01979744|Active Comparator|Promus - Angio|Promus - Angio arm
3086157|NCT01985438|Active Comparator|nasogastric tube|Nasogastric tube placement - All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.
3086158|NCT01985425|Experimental|Active Colchicine|On the day of surgery, the intervention group will receive 2 doses of colchicine 0.6 mg orally. The first dose will be administered within 4 hours before surgery. The second dose will be given between 6:00PM and 11:59PM after surgery. All patients will receive colchicine 0.6 mg or placebo twice daily orally for 10 days.
3086159|NCT01985425|Placebo Comparator|Placebo Colchicine|On the day of surgery, the intervention group will receive 2 doses of colchicine placebo 0.6 mg orally. The first dose will be administered within 4 hours before surgery. The second dose will be given between 6:00PM and 11:59PM after surgery. All patients will receive colchicine 0.6 mg or placebo twice daily orally for 10 days.
3086160|NCT01985412||Adult Heart Transplant Recipients|Patients >18 yrs old that received a heart-only transplant and are followed at Stanford Hospital
3086161|NCT01985412||Pediatric Heart Transplant Recipients|Patients <18 yrs old that received a heart-only transplant and are followed at Lucile Packard Hospital
3086162|NCT01985412||Adult Lung Transplant Recipients|Patients >18 yrs old that received a lung-only transplant and are followed at Stanford Hospital
3086163|NCT01985412||Pediatric Lung Transplant Recipients|Patients <18 yrs old that received a lung-only transplant and are followed at Lucile Packard Hospital
3086164|NCT01985412||Kaiser Adult Heart Transplant Recipients|Patients >18 yrs old that received a heart-only transplant at Stanford Hospital but are followed at Kaiser Permanente in Santa Clara
3086165|NCT01985399||EFV containing ARV regimen|Pts on Efavirenz containing ARV regimen will have neuropsychological testing performed
3086166|NCT01985399||Non -EFV ontaning ARV regimen|Pts on a Non-Efavirenz containing ARVregimen will have neuropsychological testing measures performed
3086167|NCT01985386|Experimental|GDS (gastric delivery system), meal|GDS capsule with meal
3086168|NCT01985386|Active Comparator|Ferrous sulfate, meal|Ferrous sulfate with meal
3086169|NCT01985373|Experimental|Intravenous immunoglobulin infusion|One intravenous infusion with Nanogam 50 mg/ml and 4 with Nanogam 100 mg/ml (0.2-0.8 g/kg)
3086170|NCT01985360|Active Comparator|Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization (Percutaneous Coronary Intervention or Coronary Artery Bypass Graft Surgery) plus optimal medical therapy.
3086171|NCT01985360|Active Comparator|Conservative Strategy (CON)|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with OMT failure.
3086172|NCT01985347|Active Comparator|Obstructive Sleep Apnoea|Patients with newly diagnosed obstructive sleep apnoea and who have anxiety and depression would be given continuous positive airway pressure (CPAP) treatment.
3086173|NCT01985347|No Intervention|Chronic obstructive pulmonary disease and western population|(For this group no intervention needed).Patients with COPD, who have anxiety and depression & normal population in Western Adelaide who also have anxiety and depression their prevalence would be compare with patients of Obstructive sleep apnoea.
3086174|NCT01985334|Experimental|Group A|Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) during 90 days of treatment
3086175|NCT01985334|Experimental|Group B|Patients treated with any LABA OR LAMA (except glycopyrronium bromide (NVA237)) monotherapy and mMRC score =1 point will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) during 90 days of treatment
3086176|NCT01985334|Experimental|Group C|Patients treated with any LABA and ICS in free or fixed dose combination will be assigned to indacaterol maleate and glycopyrronium bromide or will remain in their baseline therapy (3:1) during 90 days of treatment
3086177|NCT01985334|Experimental|Group D|Patients treated with any LABA OR LAMA (except glycopyrronium bromide(NVA237)) monotherapy and mMRC score >1 point will be assigned to indacaterol maleate and glycopyrronium bromide fixed dose combination or will remain in their baseline therapy (3:1) during 90 days of treatment
3086178|NCT01985321|Experimental|Merlin - ethanol/glycolic acid solution|36 applications over a 96 hour period
3086179|NCT01985321|Placebo Comparator|Placebo/Ethanol|36 applications over a 96 hour period
3086180|NCT01985308|Experimental|MRT-Active|Magnetic Field, modulated as per EEG analysis, is active for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks.
3086181|NCT01985308|Sham Comparator|MRT-SHAM|Magnetic field is not active, but a sham coil is used, for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks.
3086182|NCT01985295|Other|cohort|"Dose level Dose of pazopanib orally, once daily, # patients -1 200 mg --~(starting) 400 mg 3~600 mg 3~(maximum) 800 mg 3"
3086183|NCT01985282||Nutrition Status and Physical Function|Nutrition questionnaire will be administered Physical functional status will be tested
3086184|NCT01985269|Active Comparator|Home visits|Minimal physical examination at home Drug adherence/pill counts
3086185|NCT01985269|No Intervention|Control|Normal standard of care
3086186|NCT01985256|Experimental|Single Arm|Toca 511 vector/Toca FC
3086187|NCT01985243|Experimental|Nutrition and agriculture|Intervention arm with integrated nutrition and agriculture education, skill building, and animal husbandry promotion
3086188|NCT01985243|Experimental|Iron-rich food & business literacy|Integrated business literacy and food supplementation program to promote school retention among female adolescents
3086189|NCT01985243|No Intervention|IYC Comparison|Comparison group of infants and young children for the nutrition-agriculture intervention
3086190|NCT01985243|No Intervention|Adolescent comparison|Comparison group for the adolescent business-food supplement intervention
3086191|NCT01985230|Experimental|ReActiv8 Implant|
3086192|NCT01985204|Placebo Comparator|Placebo|Placebo tablet
3086193|NCT01985204|Experimental|Intervention|Iodine tablet
3086194|NCT01985191|Experimental|Arm 1|SAR405838 and pimasertib in escalating doses
3086195|NCT01985178|Experimental|Omega-3 Fatty Acid Supplement|
3086196|NCT01985165|Experimental|Imrecoxib|0.1g,BID,po
3086969|NCT01979744|Active Comparator|Promus - IVUS|Promus - IVUS arm
3086198|NCT01985152|Experimental|2.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 17.5mg,orally
3086199|NCT01985152|Experimental|3.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 35mg,orally
3086200|NCT01985152|Experimental|4.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 70mg,orally
3086201|NCT01985152|Experimental|5.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 140mg,orally
3086202|NCT01985152|Experimental|6.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 210mg,orally
3086203|NCT01985152|Experimental|7.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 280mg,orally
3086204|NCT01985152|Placebo Comparator|Placebo|Placebo-matching tablets, orally
3086205|NCT01985139|Experimental|Obese patients|Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
3086206|NCT01985139|Experimental|Normal-weight healthy volunteers|Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
3086207|NCT01985126|Experimental|Part 1|During Stage 1 of Part 1, participants will be randomized to receive daratumumab treatment regimens in Group A and Group B. If in Stage 1, 1 or both of the treatment groups is considered to be ineffective and/or not well tolerated, then that treatment group will be terminated. Participants in Group B will be given the option to cross over to Group A if the investigator deems it in the best interest of the participants.
3086208|NCT01985126|Experimental|Part 2|Based on the Part 1 response rate, Group A or B daratumumab treatment will be selected as the treatment regimen for participants enrolled in Part 2.
3086209|NCT01985113||early staged non-small cell lung cancers|patients who diagnosed as early staged non-small cell lung cancer after surgery
3086210|NCT01985113||lung benign mass patients|patients who diagnosed as lung benign mass after surgery
3086211|NCT01985100|Experimental|single group|single group of 6 patients will be treated with hyperbaric oxygen at 2 atmospheres absolute (ATA) for 90 minutes 5 days per week for 4 weeks (20 treatments) to see if the previously reported increase in cell metabolism following such treatment can be better documented by the more sensitive and precise method for assessing this, i.e. PET/MRI, than the previously reported SPECT/CT method
3086212|NCT01985087|Experimental|Hypofractionated radiotherapy and temozolomide|All subjects will receive treatment as is a single arm study. Two weeks of combined hypofractionated radiotherapy with concurrent temozolomide followed by up to 6 cycles of adjuvant temozolomide treatment.
3086213|NCT01985074|Experimental|Case-management intervention|Receiving nurse-managed intervention
3086214|NCT01985074|No Intervention|Control arm|Control group not receiving any intervention
3086215|NCT01985061|Active Comparator|BX2|Fludarabine (Fludara®): 30 mg/m2 on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-4 and D-3 Thymoglobuline®: 2.5 mg/kg/d on D-3 and D-2
3086216|NCT01985061|Experimental|BX3|Fludarabine (Fludara®): 30 mg/m² on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-5, D-4 and D-3 Thymoglobuline® : 2.5 mg/kg/d on D-3 and D-2
3086217|NCT01985061|Active Comparator|BX4-Suspended|Fludarabine (Fludara®): 30 mg/m²on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-6, D-5, D-4 and D-3 Thymoglobuline® : 2.5 mg/kg/d on D-3 and D-2
3086218|NCT01985035|Experimental|Obese Apneic carbohydrate diet|Obese apneic individuals will be subject to a energy restriction diet rich in carbohydrates
3086219|NCT01985035|Experimental|Obese Apneic protein diet|Obese apneic individuals will be subject to a energy restricted diet rich in protein
3086220|NCT01985035|Experimental|Obese Non Apneic carbohydrate diet|Obese individuals without Obstructive sleep apnea will be subjected to a energy restricted diet rich in carbohydrates
3086221|NCT01985035|Experimental|Obese Non Apneic protein diet|Obese individuals without Obstructive Sleep Apnea will be subjected to a energy restricted diet rich in protein
3086222|NCT01985022|Experimental|PII with IES|The treatment condition that this group receives is PII with IES for 9 months.
3086223|NCT01985022|Experimental|IES|The treatment condition that this group receives is IES for 9 months.
3086224|NCT01985009|Other|Fibroscan®|Single arm study. See intervention item for détails..
3086225|NCT01984996|Experimental|Freedom ProFlor Inguinal Hernia Implant|
3086226|NCT01984983|Experimental|VEEV DNA Vaccine 0.5 mg/ml Intramuscular|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
3086227|NCT01984983|Experimental|VEEV DNA Vaccine 0.5 mg/ml Intradermal|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
3086228|NCT01984983|Experimental|VEEV DNA Vaccine 2.0 mg/ml Intramuscular|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
3086229|NCT01984983|Experimental|VEEV DNA Vaccine 2.0 mg/ml Intradermal|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
3086230|NCT01984983|Placebo Comparator|Placebo: 0.9% saline|0.9% saline
3086231|NCT01984970||videolaryngoscope|The patients received videolaryngoscope for double-lumen tube intubation
3086232|NCT01984957|Other|disease (ALS, SMA or SBMA)|muscle biopsy
3086233|NCT01984944|Other|Autistic Patient|"50 adults~25 childs"
3086234|NCT01984944|Other|Controls|"50 adults~25 childs"
3086235|NCT01984931|Experimental|Trimebutine Maleate 300 mg Tab|A single dose of NEWBUTIN SR 300 mg Tab will be given orally one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
3086236|NCT01984931|Active Comparator|Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A|Anti-emetic medication protocol of Chungmu Hospital includes MACPERAN (Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A)thru IV twice in a day
3086237|NCT01984918|Active Comparator|SMS|A SMS will be sent to remind subjects 7-10 days before his colonoscopy appointment
3086238|NCT01984918|No Intervention|Non-SMS|No SMS will be sent
3086239|NCT01984892|Experimental|IT and IM injections Poly-ICLC|Enrolled patients will receive two cycles of Poly-ICLC treatment. Each priming (intratumoral injections - IT) and boosting (intramuscular injections - IM) treatment course will constitute one cycle.
3086240|NCT01984879||Inflammatory bowel diseases|Patients who have inflammatory bowel diseases and who give consent to participate in the survey
3087410|NCT01976819|Experimental|TW speaking valve/HME|Use of the TW speaking valve/HME
3086241|NCT01984866||Breast tumors sensitive to neoadjuvant|"Treated patients as usual clinical practice with unicentered tumors in stages II or III and good response determined by MR after 6 cycles of treatment (less than 2 cm apparent residual injury) will be consecutively subjected to radiofrequency biopsy and the surgery previously established for each case (Tumorectomy or mastectomy). Before surgery, the sentinel node will be biopsied in order to define the surgical treatment on the axilla (none in case of negative sentinel node, axillary lymphadenectomy if positive).~The tumor samples obtained by percutaneous radiofrequency and mastectomy-Tumorectomy biopsy will be studied thoroughly to define the correlation between the two."
3086242|NCT01984853||OBSERVATIONAL REGISTRY|Individuals presenting with signs and/or symptoms of Acute Coronary Syndrome at the Henry Ford Hospital Emergency Department (ED).
3086243|NCT01984840|Active Comparator|Telemedicine|A tablet (a Samsung GALAXY TAB 2 (10.1)) that holds information on handling COPD in general and software that automatically instructs the patient in handling COPD during exacerbations. The device can also collect and transmit relevant disease-specific data, which are indicative of their current state of health, via an attached Fingertip Pulse Oximeter (Nonin, Onyx II % SpO2), a Digital Blood Pressure Monitor (Model UA-767, plus BT-C) and a scale. The device can measure four vital signs, which are transferred wirelessly: blood pressure, pulse, blood oxygen saturation and weight. The tablet can be activated and give a sound, when it is time for taking measurements again.
3086244|NCT01984840|No Intervention|Usual care|In Denmark, usual practice for treating, monitoring and caring for patients with COPD are the responsibility of the patient's general practitioner (treatment and monitoring) and the municipalities (practical help and nursing care). COPD patients can make appointments with their general practitioner or practice nurse free of charge in order to get help in managing COPD. Community based care and practical help varies. As a rule community care comes at regular intervals based on a clinically based estimate of the patients' needs, but the personnel are not necessarily certified nurses and often not fully educated in COPD and definitely not on call
3086245|NCT01984827|Experimental|hyper-glycaemic clamp:|hyper-glycaemic clamp: intra-venous Glucose as an initial bolus of 250mg/kg followed by a variable maintenance infusion for 4 hours
3086246|NCT01984827|Experimental|Moxifloxacin|Single oral dose of 400 mg Moxifloxacin
3086247|NCT01984827|Placebo Comparator|Placebo|Placebo
3086248|NCT01984814|Experimental|Stem cell|Autologous bone marrow mononuclear cells intrathecal and intramuscular transplantation
3086249|NCT01984814|No Intervention|Control|No cell transplantation was done
3086250|NCT01984801|Experimental|Part 1|Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.5% SLS in sterile distilled water, Each treatment will be applied using individual patches, daily for 2 days
3086251|NCT01984801|Experimental|Part 2|Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.1% SLS in sterile distilled water. Each treatment will be applied using individual patches, daily for 21 days
3086252|NCT01984801|Experimental|Part 3|Each acne patient will apply a thin coat of one or two concentration of GSK1940029 gel or vehicle to acne affected facial/neck skin by hand, once daily for 28 days
3086253|NCT01984788|Active Comparator|BCX4161|400 mg TID for 28 days
3086254|NCT01984788|Placebo Comparator|Placebo|TID for 28 days
3086255|NCT01984775|Experimental|GSK2894512 0.5%|Each subject will receive a topical application of GSK2894512 0.5% under semi-occlusive patch conditions once daily (OD) for 21 days.
3086256|NCT01984775|Experimental|GSK2894512 1%|Each subject will receive a topical application of GSK2894512 1% under semi- occlusive patch conditions OD for 21 days.
3086257|NCT01984775|Experimental|GSK2894512 2%|Each subject will receive a topical application of GSK2894512 2% under semi-occlusive patch conditions OD for 21 days.
3086258|NCT01984775|Placebo Comparator|Vehicle|Each subject will receive a topical application of Vehicle cream under semi-occlusive patch conditions OD for 21 days.
3086259|NCT01984775|Active Comparator|Sodium lauryl sulfate 0.1%|Each subject will receive a topical application of 0.2 milliliter (mL) of Sodium lauryl sulfate under semi-occlusive patch conditions OD for 21 days. This will serve as a positive control.
3086260|NCT01984775|Active Comparator|Petrolatum|Each subject will receive a topical application of 0.2 mL of Petrolatum under semi-occlusive patch conditions OD for 21 days. This will serve as a negative control.
3086261|NCT01984762|Active Comparator|RYGBP|Roux-en-Y gastric bypass
3086262|NCT01984762|Active Comparator|SG|sleeve gastrectomy
3086263|NCT01984749|Experimental|Febuxostat treatment group|Once daily after breakfast (generally within 30 minutes after eating)
3086264|NCT01984749|No Intervention|Non-febuxostat treatment group|No febuxostat treatment
3086265|NCT01984736|Experimental|EVP-6124, single dose|Single dose, Tablet, single administration, Day 1
3086266|NCT01984723|Experimental|EVP-6124, single dose|Single dose, Tablet, single administration, Day 1
3086267|NCT01984710|Experimental|DBS for Treatment Resistant Depression|"DBS for TRD: Exploration of LFP with the Medtronic Activa PC+S Brain Radio system"
3086268|NCT01984697|Experimental|Girls 9 to 14 Years V503 at Months 0 and 6|Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
3086269|NCT01984697|Experimental|Boys 9 to 14 Years V503 at Months 0 and 6|Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
3086270|NCT01984697|Experimental|Girls and Boys 9 to 14 Years V503 at Months 0 and 12|Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.
3086271|NCT01984697|Experimental|Girls 9 to 14 Years V503 at Months 0, 2, and 6|Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
3086272|NCT01984697|Active Comparator|Young Women 16 to 26 Years V503 at Months 0, 2, and 6|Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
3086273|NCT01984684|Experimental|Delafloxacin|Delafloxacin 300 mg IV Q12H for 6 doses, then Delafloxacin 450 mg oral tablet Q12H for a minimum of 10 up to a maximum of 28 doses total
3086274|NCT01984684|Active Comparator|Vancomycin plus Aztreonam|Vancomycin 15 mg/kg IV plus two grams Aztreonam every 12 hours for a minimum of 10 up to a maximum of 28 doses total (Aztreonam was discontinued as soon as possible if a gram-negative organism was not identified in baseline cultures)
3086275|NCT01984671|Experimental|Mobile Pain Coping Skills Training|Pain coping skills training
3086276|NCT01984671|No Intervention|Standard Care Control|
3086277|NCT01984658|Experimental|Alecsat|The ALECSAT CBMP will be administered as single dose at week 4, 7 and week 10 which is considered an appropriate time for ALECSAT CBMP to strengthen the immune system and thus have the ability to kill tumour cells. It is the aim that the patients will receive three doses during the study period however, if the patient wish and it is recommended by the investigator, patients may receive more than three doses, continuing until progression or as judged by the Investigator. Continued treatment after the 24 week study period is only possible under the condition that no safety issues have been discovered. The interval between injections for continued treatment will be decided based on e.g. tumour response and clinical examinations.
3086278|NCT01984645|Experimental|Notification|Providers in this arm will receive a secure online notification whenever their patients are visited in the emergency department or admitted as an inpatient.
3086279|NCT01984645|No Intervention|No intervention|Providers in this arm will not get a secure online notification about their patient's visit to the emergency department or inpatient admission.
3086280|NCT01984632|Experimental|Single-port laparoscopic myomectomy|We will use barbed suture (V-Loc) under intervention of single-port laparoscopic myomectomy
3086281|NCT01984632|Active Comparator|Multi-port laparoscopic myomectomy|We will use barbed suture(V-Loc) under intervention of multi-port laparoscopic myomectomy.
3086282|NCT01984619||Blunt Tip Cannula|
3086283|NCT01984606|Experimental|Empagliflozin|Empagliflozin once daily
3086284|NCT01984606|Active Comparator|Sitagliptin|Sitagliptin once daily
3086285|NCT01984593|No Intervention|Control|No changes will be made for the participants in the control group, but they will undergo the same measurements and evaluations as the intervention group.
3086286|NCT01984593|Active Comparator|yoga|Two yoga exercises to perform at home 15 minutes twice daily.
3086287|NCT01984580|Experimental|Zinc|
3086288|NCT01984580|Placebo Comparator|sodium|
3086289|NCT01984567|Experimental|Vitamin E|
3086290|NCT01984567|Experimental|Lipoic acid|
3086291|NCT01984567|Placebo Comparator|Control|
3086292|NCT01984554||Ferric Carboxymaltose (FCM)|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician.
3086293|NCT01984554||Iron Sucrose|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
3086294|NCT01984554||Iron Dextran|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
3086295|NCT01984554||Ferumoxytol|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
3086296|NCT01984541|Experimental|1|Artemisia vulgaris allergen extract(four concentrations 10, 1, 0,1 y 0,01 mg/ml) Positive Control Negative Control
3086297|NCT01984528|Experimental|Prick Test|Alternaria alternata allergen extract Positve control Negative control
3086298|NCT01984515|Experimental|Team Red Primary Care|Eligible patients will receive the Referral Management System in primary care
3086299|NCT01984502|Experimental|Radiation|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
3086300|NCT01984489|Placebo Comparator|Placebo/Metformin|patients are administered oral tablets of placebo once daily and 500mg TID for 4 weeks at the run-in period. After randomized ,patients administer the drugs too.
3086301|NCT01984489|Experimental|SHR117887 (50mg q.d)/Metformin|patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 50mg QD and metformin 500mg TID for 12 weeks.
3086302|NCT01984489|Experimental|SHR117887 (100mg q.d)/Metformin|patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 100mg QD and metformin 500mg TID for 12 weeks.
3086303|NCT01984476||Older Able-Bodied Controls|Subjects must be between the age of 55 and 65 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
3086304|NCT01984476||Spinal Cord Injured|Subjects must be between the age of 25 and 49 years old, be English-literate and able to provide informed consent. They must be injured between 5 to 10 years, level of injury between C1-T12, non-ambulatory (wheelchair dependent), and AIS grade of A or B. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
3086335|NCT01984255|Active Comparator|A- Bavituximab plus Ipilimumab|Arm A—Interventions Drug: Bavituximab Dose:3mg/kg IV over 90 minutes weekly x 2 followed by Bavituximab 3mg/kg IV over 90 minutes weekly Duration-x 12 weeks plus Drug :Ipilimumab 3mg/kg IV over 90 minutes every 3 weeks Duration-x 4.weeks
3086305|NCT01984476||Age-Matched Able-Bodied Controls|Subjects must be between the age of 25 and 49 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
3086306|NCT01984463|Active Comparator|Fentanyl|Patients will be randomized to receive by the epidural catheter a bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL.
3086307|NCT01984463|Experimental|Morphine|Patients will be randomized to receive by the epidural catheter a bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL.
3086308|NCT01984450|Active Comparator|ACIC|The patients in this group will be treated by the ACIC technique, which uses autologous collagen to regenerate articular cartilage. ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation.
3086309|NCT01984450|Active Comparator|MCIC|The patients in this group will be treated by the MCIC technique, which uses concentrated BMAC to regenerate articular cartilage. MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation.
3086310|NCT01984424|Other|Part A: Atorvastatin 20 mg => Placebo|Participants received atorvastatin 20 mg orally for 10 weeks (period 1) followed by placebo orally for 10 weeks (period 2), separated by a 2-week washout period.
3086311|NCT01984424|Other|Part A: Placebo => Atorvastatin 20 mg|Participants received placebo orally for 10 weeks (period 1) followed by atorvastatin 20 mg orally for 10 weeks (period 2), separated by a 2-week washout period.
3086312|NCT01984424|Active Comparator|Part B: Ezetimibe|Participants received 10 mg ezetimibe orally only a day and placebo to evolocumab by subcutaneous injection once a month for 24 weeks.
3086313|NCT01984424|Experimental|Part B: Evolocumab|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo to ezetimibe orally once a day for 24 weeks.
3086314|NCT01984424|Experimental|Part C: Open-label Evolocumab|Participants who completed part B and were eligible to proceed to open-label extension part C and could choose quarterly between evolocumab 420 mg once a month or evolocumab 140 mg every 2 weeks for up to 2 years.
3086315|NCT01984411|Experimental|Radial Technical|Radial technical is the procedure for catheterization
3086316|NCT01984411|Active Comparator|Femoral Technical|Vascular Access for cardiac catheterization
3086317|NCT01984398|Experimental|Androxal 12.5 mg Formulation A Crossover B|Androxal capsules, 12.5 mg, once a day for one day for each formulation
3086318|NCT01984398|Experimental|Androxal 25 mg Formulation A Crossover B|Androxal 25 mg, capsules, one a day for one day for each formulation
3086319|NCT01984385||Patients with a hip fracture|
3086320|NCT01984372||Tresiba® users|
3086321|NCT01984346|Experimental|Convergent Procedure|Convergent Procedure EPi-Sense-AF Guided Coagulation System
3086322|NCT01984346|Active Comparator|Standalone Endocardial Catheter Ablation|Endocardial Catheter Ablation Treatment
3086323|NCT01984333|Experimental|Online cognitive training|Online cognitive training will provides eight sessions of a computerized training game. Each session will last about 30-40 minutes, and participants will undergo 2 sessions each week over a 4-week period.
3086324|NCT01984333|No Intervention|Waitlist control|This is a 1-month waitlist control to be compared with the active online cognitive training intervention. This is a no intervention control group.
3086325|NCT01984320|Active Comparator|Coasting|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 to 3 days until drop of estradiol to a safe level to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
3086326|NCT01984320|Active Comparator|Cabergoline|In their ICSI cycle patients will take 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
3086327|NCT01984320|Active Comparator|Coasting and Cabergoline|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 day plus receiving 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
3086328|NCT01984294|Experimental|LDV/SOF+RBV|Participants will receive LDV/SOF plus RBV for 8 weeks.
3086329|NCT01984294|Experimental|LDV/SOF + GS-9669 250 mg|Participants will receive LDV/SOF plus GS-9669 250 mg for 8 weeks.
3086330|NCT01984294|Experimental|LDV/SOF + GS-9669 500 mg|Participants will receive LDV/SOF plus GS-9669 500 mg (2 x 250 mg) for 8 weeks.
3086331|NCT01984281|Experimental|Pedometer-based prescription|After baseline assessments, the control group will receive a educational session, regarding important aspects of asthma (symptoms, treatment, exacerbations, triggers, etc) plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes) and a pedometer-based physical activity prescription, consisting of targets to be achieved (in terms of steps per day).
3086332|NCT01984281|No Intervention|Control|After baseline assessments, the control group will receive a educational session, regarding important aspects of asthma (symptoms, treatment, exacerbations, triggers, etc) plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes).
3086333|NCT01984268|Experimental|Four week ACTHAR treatment|Rheumatoid arthritis subjects with inadequate response to methotrexate will be randomized to receive twice a week dosing of ACTHAR for a period of four weeks.
3086334|NCT01984268|Experimental|Twelve week ACTHAR treatment|Rheumatoid arthritis subjects with inadequate response to methotrexate will be randomized to receive twice a week dosing of ACTHAR for a period of twelve weeks.
3086377|NCT01984008|Active Comparator|polyethylene glycol, bisacodyl,|colonoscopy polyethylene glycol,powder bisacodyl,tablet
3086336|NCT01984255|Experimental|Arm B Ipilimumab|Arm B—Interventions Drug- I3mg/kg IV over 90 minutes day 1 followed three weeks later by Drug: Ipilimumab every 3 weeks x 3weeks. Total number of treated patients will be 8.
3086337|NCT01984242|Experimental|Atezolizumab and Bevacizumab|Atezolizumab 1200 milligrams (mg) and bevacizumab 15 milligrams per kilogram (mg/kg) will be administered as intravenous (IV) infusions every 3 weeks (q3w) on Day 1 and Day 22 of each 6-week cycle until disease progression.
3086338|NCT01984242|Experimental|Atezolizumab|Atezolizumab 1200 mg will be administered as IV infusion q3w on Day 1 and Day 22 of each 6-week cycle until disease progression. Upon disease progression, participants (except European Union [EU] participants) can crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.
3086339|NCT01984242|Active Comparator|Sunitinib|Sunitinib 50 mg will be administered orally once daily on Days 1 to 28 of each 6-week cycle until disease progression. Upon disease progression, participants can crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.
3086340|NCT01984229|Experimental|Cohort A|There will be 3 dosing periods in the study: Period 1 (Days 1 to 7), Period 2 (Days 8 to 14), and Period 3 (Days 15 to 18). Alectinib will be administered as a 40 milligrams (mg) single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants). On Days 8 to 14 (Period 2) and Days 15 to 18 (Period 3) posaconazole will be administered as a 400-mg twice daily (BID) oral dose after a high-fat meal. The follow-up assessments will occur within 10 to 14 days after the last dose of posaconazole.
3086341|NCT01984229|Experimental|Cohort B|There will be 3 dosing periods in the study: Period 1 (Days 1 to 7), Period 2 (Days 8 to 14), and Period 3 (Days 15 to 21). Alectinib will be administered as a single oral dose at the dose selected based on Cohort A data on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants). On Days 8 to 14 (Period 2) and Days 15 to 21 (Period 3) posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal. The follow-up assessments will occur within 10 to 14 days after the last dose of posaconazole.
3086342|NCT01984216|Experimental|Roux-en-Y|Roux-en-Y for the gastrojejunostomy reconstruction
3086343|NCT01984216|Active Comparator|Billroth II|Billroth II for the gastrojejunostomy reconstruction
3086344|NCT01984203|Experimental|Progressive Heavy Strength Exercises|"The Progressive Heavy Load Exercise group gradually increases the external load from 60%RM to 90%RM and correspondently decreases the number of performed repetitions pr. set for the two rotator cuff exercises. Furthermore 4 sets is performed.~A progressive exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction."
3086345|NCT01984203|Active Comparator|Low Load Exercises|"Active exercises comparator continuously training with 60%RM through 12 weeks.~An exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction."
3086346|NCT01984190||Lower Extremity Joint Arthroplasty|Postoperative venous thromboembolism incidence in lower extremity joint arthroplasty using only the mobile compression device with or without aspirin for venous thromboembolism prevention. Sub-analysis of Total Hip Arthroplasty and Total Knee Arthroplasty will be included.
3086347|NCT01984177||cocaine-dependent (CD)|cocaine-dependent individuals
3086348|NCT01984177||healthy control (HC)|healthy age and sex-matched individuals who do not use cocaine
3086349|NCT01984164|Active Comparator|Candesartan|To achieve blood pressure control, we will use a stepwise protocol as follows: candesartan (blinded) 8mg→ 16mg→ 32mg. Both groups will also receive (unblinded) , if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg →10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg. Antihypertensive medications will be increased every 2 weeks until control is achieved.
3086350|NCT01984164|Active Comparator|Lisinopril|To achieve blood pressure control we will use a stepwise protocol as follows: lisinopril (blinded) 10mg→ 20mg→ 40mg. Both groups will also receive (unblinded), if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg→ 10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg. Antihypertensive medications will be increased every 2 weeks until control is achieved.
3086351|NCT01984138|Experimental|Estring|ESTRING
3086352|NCT01984138|Active Comparator|REPLENS|Replens
3086353|NCT01984125|Experimental|Point-of-Care Prompt|A prompt, either electronically or by a nurse, will notify a provider if an adolescent is due for a vaccination. This prompt will appear at any type of visit where the patient is seen by a health provider.
3086354|NCT01984125|No Intervention|Control|
3086355|NCT01984112|Experimental|Intramedullary Locked Nail|
3086356|NCT01984112|Active Comparator|Locked Plate|
3086357|NCT01984099|Active Comparator|Chemoprohylaxis Group|Chemoprohylaxis Group: the treatment group, will be given a single course of methotrexate within fourteen days from molar evacuation. Methotrexate will be given at 0.4 mg/kg intramuscularly per day for 5 days. No chemotherapy will be administered if the hemoglobin is lower than 10 g/L, WBC is less than 3.0 x 10 g/L or more than 10.0 x 10 g/L, absolute neutrophil count is less than 1.5, platelet count is lower than 100,000/cu.cc., patient has elevated liver and renal function test and has concurrent infection.
3086358|NCT01984099|Placebo Comparator|Control Group|Control Group: will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
3086378|NCT01983995||Actigraphy|Postmenopausal women starting aromatase inhibitor therapy will undergo assessment with questionnaires and actigraphy before starting AI therapy and after 3 months of treatment.
3086379|NCT01983982||Adjuvant chemotherapy|Subjects will undergo pain testing, then receive standard of care chemotherapy, and then undergo pain testing.
3086413|NCT01983683|Experimental|Cadazolid|Subjects receive oral cadazolid 250 mg twice daily (bid) and oral vancomycin-matching placebo 4 times per day (qid) for 10 days
3086414|NCT01983683|Active Comparator|Vancomycin|Subjects receive oral vancomycin 125 mg qid and oral cadazolid-matching placebo bid for 10 days
3086359|NCT01984086|Experimental|Part A|Subjects will receive following six treatments each in six period, with a 3-days minimum wash-out period, between each treatment period: 1) Single dose (SD) salbutamol (200mcg per blister from 1.6% blend) delivered via the UD-DPI by inhalation of 3 Blisters (BTR) giving a total dose of 600mcg; 2) SD salbutamol sulphate (200mcg per BTR from a 1.0% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 600mcg; 3) SD salbutamol (150mcg per BTR from a 1.6% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 450mcg; 4) SD salbutamol (250mcg per BTR from a 1.6% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 750mcg; 5) SD of salbutamol (200mcg per BTR) delivered via the Diskus by inhalation of 3 BTR giving a total dose of 600mcg; 6) SD salbutamol (100mcg per actuation) delivered via the MDI giving a total dose of 600mcg
3086360|NCT01984086|Experimental|Part B|Prior to the start of Part B, a decision will be made regarding the UD-DPI products to be used in Part B. Subjects will receive following 6 treatments each in 6 period, with a 3-days minimum wash-out period, between each treatment period: 1) SD salbutamol (selected from Part A) delivered via the UD-DPI without activated charcoal (AC) by inhalation of 3 BTR (total dose dependant on UD-DPI formulation chosen); 2) SD salbutamol (selected from Part A) delivered via the UD-DPI with AC by inhalation of 3 BTR (total dose dependant on UD-DPI formulation chosen); 3) SD salbutamol by inhalation of 3 BTR (200mcg per BTR) delivered via the Diskus without AC (total dose 600mcg); 4) SD salbutamol by inhalation of 3 BTR (200mcg per BTR) delivered via the Diskus with AC (total dose 600mcg); 5) SD salbutamol 6 inhalations (100mcg) delivered via the MDI without AC (total dose 600mcg); 6) SD salbutamol 6 inhalations (100mcg) delivered via the MDI with AC (total dose 600mcg)
3086361|NCT01984073|Active Comparator|ER Niacin Oral Fat Challenge|ER Niacin (Niaspan) 2000mg one hour prior to Oral Fat Challenge using fresh cream at a dose of 50 g fat per square meter of body surface area. This is followed by frequent plasma and urine collections for next 12 hours to assess markers of fat metabolism and inflammation.
3086362|NCT01984073|Active Comparator|IR Niacin Oral Fat Challenge|Immediate-Release Niacin (Nialor) 500 mg one hour prior to Oral Fat Challenge and again 1, 3 and 5 hours after the oral fat load for a total dose of 2 grams.Subjects will undergo plasma and urine collections for 12 hours to assess markers of fat metabolism and inflammation.
3086363|NCT01984073|Placebo Comparator|Placebo Oral Fat Challenge|Placebo one hour before and 1,3, and 5 hours after oral fat load using heavy cream at 50 grams of fat per square meter of body surface area. Plasma and urine collections for 12 hours
3086364|NCT01984060|Other|HOME-EX|"Motivational Counseling: Six patient-centered motivational counseling sessions based on the self-determination theory (SDT) of behavior change will be conducted with the patients in the HOME-EX group over 12 weeks.~Exercise Intervention: an individually tailored home-based exercise program performed 5-7 days a week that consists of walking prescription, and individualized strength training exercise designed to provide moderately intense progressive resistance exercise. Subjects will be given a set of 3 color-coded therapeutic resistance bands representing varying levels of resistance and they will start with a number of sets which is customized for each individual and they will be encouraged to progressively increase from their individual baseline sets."
3086365|NCT01984060|No Intervention|Control|Subjects are instructed to maintain their usual activities during the study period. This group did not receive any PA counseling or recommendations.
3086366|NCT01984047|Experimental|GSK3050002 0.1 mg|Six subjects in this cohort will receive a single dose of GSK3050002 0.1 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects (i.e. 1 subject will be dosed with GSK3050002 and 1 with placebo before the remainder of the cohort is dosed) will be used in the cohort.
3086367|NCT01984047|Experimental|GSK3050002 0.5 mg|Six subjects in this cohort will receive a single dose of GSK3050002 0.5 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
3086368|NCT01984047|Experimental|GSK3050002 1 mg|Six subjects in this cohort will receive a single dose of GSK3050002 1 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort
3086369|NCT01984047|Experimental|GSK3050002 5 mg|Six subjects in this cohort will receive a single dose of GSK3050002 5 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
3086370|NCT01984047|Experimental|GSK3050002 10 mg|Six subjects in this cohort will receive a single dose of GSK3050002 10 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
3086371|NCT01984047|Experimental|GSK3050002 20 mg|Six subjects in this cohort will receive a single dose of GSK3050002 20 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
3086372|NCT01984034|Experimental|Educational Outreach Visits|The intervention is three educational outreach visits, one per prescription guideline. During each 15 to 20 minutes visit an academic detailer will promote one of the guidelines to a family doctor (up to three physicians may be present in each visit if they wish to, but one to one visits will be preferred and encouraged). The detailer will also distribute a point of care summary highlighting the main messages. The detailers will be mainly Family Physicians and family medicine residents.
3086373|NCT01984034|Active Comparator|Passive Dissemination|Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
3086374|NCT01984021|Experimental|traditional acupuncture (tACP)|In the upper trapezius muscle with the greatest area pain and lowest PPT score will be chosen for acupuncture. Sterile acupuncture needles measuring 0.25 x 13 mm (Suzhou Huanqiu Acupuncture Medical Appliance Co. Ltd.®) will be inserted in TE-5 (located on the dorsal face of the forearm between the radius and ulna 3 cm above the joint line of the wrist) and LI-11 (located at the outermost point of the skinfold of elbow flexion in the direction of the lateral epicondyle of the elbow).
3086375|NCT01984021|Placebo Comparator|sham acupuncture (sACP)|The needles will be inserted 1 cm to the side of TE-5 (located on the dorsal face of the forearm between the radius and ulna 3 cm above the joint line of the wrist) and 1 cm to the side of LI-11 (in the direction of the styloid process of the radius).The acupuncture needles are positioned at different acupoints.
3086376|NCT01984008|Experimental|picosulfate,MgO, citric acid, bowel preparation, powder|colonoscopy picosulfate,MgO, citric acid, bowel preparation, powder
3086380|NCT01983969|Experimental|Azacitidine + Vorinostat + Gemcitabine + Busulfan + Melphalan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1. Dexamethasone 8 mg by vein twice a day from Day -11 AM to Day -2 PM. Caphosol oral rinses 30 mL four times a day used from Day -9. Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9. Pyridoxine 100 mg by vein or mouth three times a day from Day -1. Vorinostat 1000 mg by vein on Day -11 through Day -2. Gemcitabine loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8. Melphalan 60 mg/m2 by vein on Days -3 and -2. Azacitidine starting dose 15 mg/ m2 by vein on Day -11. Stem cell transplant on Day 0. Patients with CD20+ tumors receive rituximab 375 mg/m2 by vein on Days -9.
3086381|NCT01983956|Experimental|Experimental arm|The structured approach intervention with the SENS model is based on the bio-psycho-social-spiritual model of care and the WHO definitions of palliative care as well as the NCCN Practice Guidelines for Palliative Care. It supports the assessment of areas and complexity of concerns from the patient perspective, determines the priority and structures the support needed. The intervention is performed by palliative care physicians and nurses collaboratively. It is utilized as baseline assessment and afterwards integrated in each routine oncology care out-patient and in-patient visit. Depending on the goals it may be applied between routine visits. In addition, patients will receive usual oncology care throughout the study period.
3086382|NCT01983956|No Intervention|Control arm|Patients in the usual care group will receive routine oncology care throughout the study. This incorporates a routine assessment according to the standard SAKK - protocol which assesses overall symptoms. Patients are not seen by nurses during a routine visit to the outpatient clinic unless they need a blood withdrawal or any intravenous or subcutaneous treatment. Only nursing staff of the palliative care unit is familiar with using the SENS-assessment instrument. Participants assigned to usual care may meet with the palliative care service on request according to established practice.
3086383|NCT01983943|Experimental|Hydroxytyrosol|Hydroxytyrosol, the major polyphenol in olive oil, 40mg will be taken once per day for 6 months.
3086384|NCT01983943|Placebo Comparator|Placebo|Placebo 40mg will be taken once per day for 6 months.
3086385|NCT01983930|Active Comparator|Memory Training|Group memory training will be administered for amnestic MCI
3086386|NCT01983930|Experimental|Kundalini yoga and meditation|PArticipants will engage in weekly yoga classes and daily 20 minute meditation
3086387|NCT01983917|Other|Use of the Diabetes Application|
3086388|NCT01983904|Experimental|Long Pulse Width|deep brain stimulation with short & long pulse width
3086389|NCT01983904|Experimental|Short Pulse Width|deep brain stimulation with short & long pulse width
3086390|NCT01983891|Experimental|Intervention|6-week nutrition education and cooking course
3086391|NCT01983878|Experimental|Ramucirumab|Ramucirumab 8 milligrams per kilogram (mg/kg) administered intravenously (IV) once every 2 weeks. Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance or withdrawal of consent.
3086392|NCT01983865|Other|Exposure to birch pollen|
3086393|NCT01983852||1|Children during End of Life Care
3086394|NCT01983839||Pharmacokinetics Moxifloxacin|Patients with community-acquired pneumonia treated with moxifloxacin
3086395|NCT01983826|Experimental|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
3086396|NCT01983826|Placebo Comparator|Placebo capsule|Microcrystalline cellulose (daily) for 8 weeks
3086397|NCT01983813|Experimental|PHCVRS intervention|Each participant will receive communication with a clinical pharmacist for 12 months to decrease risk of developing cardiovascular disease.
3086398|NCT01983813|Other|Usual care/Personal Health Record|Will receive usual medical care plus access to an online Personal Health Record, where the participant can document medications and diagnosed conditions.
3086399|NCT01983800|Active Comparator|intravenous propofol/midazolam|Sedation using intravenous propofol/midazolam, sedation will be titrated to a Riker Agitation Sedation Score
3086400|NCT01983800|Active Comparator|isoflurane|Sedation using inhaled isoflurane, sedation will be titrated to a Riker Agitation Sedation Score
3086401|NCT01983787||Pharmacokinetics Piperacillin|Patients with cystic fibrosis , treated with Piperacillin/Tazobactam, given as continuous infusion for a period of two weeks.
3086402|NCT01983774|Placebo Comparator|Placebo|A matching placebo (sugar pill) to esomeprazole 40mg twice daily
3086403|NCT01983774|Active Comparator|Esomeprazole|Esomeprazole 40mg twice daily
3086404|NCT01983761|Experimental|Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)|"Fludarabine, Clofarabine, Busulfan, Anti-thymocyte Globulin (ATG), Total Body Irradiation (TBI) (Myeloablative) Day Treatment~Day0 Admit, IV hydration, rituximab 375 mg/m2 (B cell malignancy)~Day 1 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000~Day2 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000~Day3 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000~Day4 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000, rabbit ATG 1.25 mg/kg~Day5 Low-dose TBI 2 Gy in AM, rabbit ATG 1.75 mg/kg~Day6 Rest~Day7 Rest~Day8 Cord blood infusions"
3086405|NCT01983761|Experimental|Fludarabine, Melphalan, ATG (Reduced Intensity)|"Day Treatment~Day0 Admit, hydration~Day1 Fludarabine 40 mg/m2 IV~Day2 Fludarabine 40 mg/m2 IV, rabbit ATG 1.25 mg/kg~Day3 Fludarabine 40 mg/m2 IV, rabbit ATG 1.75 mg/kg~Day4 Fludarabine 40 mg/m2 IV and Melphalan 140 mg/m2 IV~Day5 Rest Day6 Cord blood infusions"
3086406|NCT01983748|Experimental|A|Biological/Vaccine; Autologous Dendritic Cells loaded with autologous Tumor RNA
3086407|NCT01983748|No Intervention|B|Control, Standard of care, which is clinical control every 3 months
3086408|NCT01983735|Experimental|TELMINUVO Tab. (80/2.5mg, 80/5mg)|
3086409|NCT01983735|Active Comparator|S-Amlodipine 2.5, 5mg|
3086410|NCT01983709|Experimental|Allogeneic Human Mesenchymal Stem Cells|"This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10^6 cells/kg or a maximum dose of 1 x 10^8 total cells IV.~The remaining subjects will receive a single dose of 2 x 10^6 cells/kg or a maximum dose of 2 x 10^8 total cells IV."
3086411|NCT01983696|Experimental|5% oxygen|the oocytes and embryos are cultured in 5% oxygen concentration after oocytes retrieval until Day 6 (counting from fertilization)
3086412|NCT01983696|No Intervention|20% oxygen|the oocytes and embryos are cultured in 20% oxygen concentration (in atmosphere) after oocytes retrieval until Day 6(counting from fertilization)
3086415|NCT01983670|Experimental|health group 1|Health subjects received 30 mins delay antagonist activation temporal ES.
3086416|NCT01983670|Experimental|SCA group 1|SCA subjects received four weeks temporal ES assisted home training program.
3086417|NCT01983670|No Intervention|health group 2|health subjects controlled group
3086418|NCT01983670|No Intervention|SCA group 2|SCA subjects controlled group
3086419|NCT01983657|Experimental|D1|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~If the treatment is effective, participants may be entered into low-dose group(D1)(rhGM-CSF administration 1.25 ug/kg/d, qd, sc, for 2 months，then rhGM-CSF administration 1.25 ug/kg/d, qod, sc, for 3 months), when the chest CT absorption≥25% , and /or the PaO2 elevated by 5 mm Hg."
3086420|NCT01983657|Experimental|D2|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~When the treatment is ineffective, and anti-GM-CSF antibody titers level ≥1:1000，the dose will be increased to 2.5 ug/kg/d. After 2 months, if the clinical response was optimal, that dose is continued for 3 months, and defined as group 2(D2)."
3086421|NCT01983657|Experimental|D3|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~When the treatment is ineffective, and anti-GM-CSF antibody titers level ≥1:1000，the dose will be increased to 2.5 ug/kg/d. After 2 months, if the clinical response was not optimal, the patients will receive whole lung lavage(WLL), who are defined as group 3(D3)."
3086422|NCT01983657|Active Comparator|D4|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~When the treatment is ineffective, and anti-GM-CSF antibody titers level ＜1:1000，the patients will receive whole lung lavage(WLL), then give rhGM-CSF administration (1.25 ug/kg/d) for 3 months, which belong to group4(D4)."
3086423|NCT01983644|Experimental|RECO thrombectomy|IA thrombectomy is executed by RECO flow restoration device which is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
3086424|NCT01983644|Active Comparator|Solitaire FR thrombectomy|IA thrombectomy is executed by Solitaire FR flow restoration device
3086425|NCT01983631|Experimental|WBV group|Stage 1: Short-term Whole body vibration(3 minutes in half-squatting position)
3086426|NCT01983631|No Intervention|Non-WBV group|Stage 1 : Controlled group
3086427|NCT01983631|Experimental|training group|Stage 2: Long-term WBV training (3 sessions per week for 4 weeks)
3086428|NCT01983631|No Intervention|non-training group|Stage 2: Controlled group
3086429|NCT01983618|Placebo Comparator|Interscalene catheter|No block will be performed prior to surgery. An interscalene catheter will be inserted under ultrasound guidance by the anesthesiologist before the induction of anesthesia. Local anesthetics will only be administered once all TCD assessments are completed but prior to the end of surgery.
3086430|NCT01983618|Experimental|Interscalene nerve block and catheter|The anesthesiologist will perform the interscalene nerve block and insert an interscalene catheter under ultrasound guidance before induction of anesthesia. A standardized mixture of bupivacaine, lidocaine and epinephrine will be administered prior to surgery.
3086431|NCT01983605|Experimental|Treatment|LAA exclusion with the LARIAT Suture Delivery Device
3086432|NCT01983592|Active Comparator|Homeopathic medicine|The study medication will be administered in one of two forms: (1) 3.5 mm diameter lactose/sucrose globule to be administered sublingually; or (2) 3.5 mm diameter lactose/sucrose globule dissolved in 250 ml spring water and administered orally. The medication will be administered as either 1 globule sublingual or 5 mL oral remedy/water up to 3 times per day. The dosage regimen is varialble at the discretion of the study clinician.
3086433|NCT01983592|Placebo Comparator|Unmedicated lactose/sucrose globule|The placebo will be administered in one of two forms: (1) 3.5 mm diameter lactose/sucrose globule to be administered sublingually; or (2) 3.5 mm diameter lactose/sucrose globule dissolved in 250 ml spring water and administered orally. The medication will be administered as either 1 globule sublingual or 5 mL oral remedy/water up to 3 times per day. The dosage regimen is varialble at the discretion of the study clinician.
3086434|NCT01983579|Experimental|Anti-VEGF substance|At the first study visit patients receive anti-VEGF injection with the standard substance (comparator) and at the second visit with an alternative anti-VEGF substance.
3086435|NCT01983579|Experimental|Sclerotomy occlusion|In the first session patients receive anti-VEGF injection without occlusion of the injection hole, while in the second session no occlusion is done.
3086436|NCT01983579|Experimental|Injection volume|In the first session patients receive anti-VEGF injection with the standard injection volume, while in the second session they receive anti-VEGF injection with a modified injection volume.
3086437|NCT01983566|Active Comparator|BI 207127 fasted|patient to receive BI 207127 as a single dose in fasted state
3086438|NCT01983566|Experimental|BI 207127 high fat|patient to receive BI 207127 as a single dose after a high fat breakfast
3086439|NCT01983566|Experimental|BI 207127 low fat|patient to receive BI 207127 as a single dose after a low fat breakfast
3086440|NCT01983566|Experimental|BI 207127 with Omeprazole|patient to receive BI 207127 as a single dose after 4 days treatment with Omeprazole 40 mg once a day
3086441|NCT01983553||Study Group|Participants in study CYD23 (NCT00842530) with hospitalized dengue cases
3086442|NCT01983540|Experimental|Study Group 1|Participants who received 3 doses of DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of the same investigational vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
3086443|NCT01983540|Experimental|Study Group 2|Participants who received 3 doses of DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of Infanrix hexa vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
3086444|NCT01983540|Active Comparator|Study Group 3|Participants who received 3 doses of Infanrix hexa vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of DTaP-IPV-Hep B-PRP~T vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
3086485|NCT01983306|Placebo Comparator|Placebo|Placebo orally once daily for 4-week Treatment Period
3087825|NCT01973829|Other|Baseline arm|baseline data (50 patients or 3 months per center)
3086445|NCT01983527|Experimental|Arthrographic distention + intra-articular corticosteroid|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension), 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
3086446|NCT01983527|Active Comparator|Arthrographic distention|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
3086447|NCT01983527|Active Comparator|Intra-articular corticosteroid|Arthrographic pseudodistention of the glenohumeral joint with injection of 5 ml contrast and 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension).
3086448|NCT01983514|Active Comparator|1 international unit (IU) intravenous oxytocin|Using a double-dummy design participants will be administered 1 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) slow infusion with varying infusion rate over 20 minutes and placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device. Subject to pilot data this may be increased to 2 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) and the infusion time/rate may change to best match the pharmacokinetic profile of intranasally administered oxytocin.
3086449|NCT01983514|Placebo Comparator|Placebo|Using a double-dummy design participants will be administered Placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device and placebo delivered intravenously (0.9% sodium chloride 200 ml slow infusion for 20 minutes)
3086450|NCT01983514|Experimental|8IU intranasal oxytocin|Using a double-dummy design participants will be administered 8IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)
3086451|NCT01983514|Experimental|24IU intranasal oxytocin|Using a double-dummy design participants will be administered 24IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)
3086452|NCT01983501|Experimental|Tucatinib (ONT-380) in combination with T-DM1|Brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm.
3086453|NCT01983488||Uveitis|Patient with a clinical diagnosis of Uveitis.
3086454|NCT01983475|Placebo Comparator|Placebo|A group of participants will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
3086455|NCT01983475|Experimental|Denosumab|A group of participants will be randomized to the experimental group and will have Denosumab (Prolia, 60 mg SC) administered at baseline, 6 and 12 months.
3086456|NCT01983462|Experimental|Clonidine|Oral 0.2 mg/day (0.1 mg bid)for 4 weeks
3086457|NCT01983462|Active Comparator|Hydrochlorothiazide|Oral, 12.5 mg/day qd, 4 weeks
3086458|NCT01983462|Placebo Comparator|Placebo|Placebo
3086459|NCT01983449|Experimental|Adventitial Dexamethasone|In patients receiving either angioplasty or atherectomy-based revascularization (pre-stratified to each by 50% of the total study), dexamethasone will be delivered to the adventitia following revascularization.
3086460|NCT01983436|Experimental|Manual Lymphatic Drainage|"9 daily sessions of manual lymphatic drainage (except on Saturday/Sunday) starting at Day 1 after surgery.~4 more sessions (one every two days)."
3086461|NCT01983436|No Intervention|Control|No session of manual lymphatic drainage
3086462|NCT01983423|Experimental|Endometrial Biopsy|Endometrial biopsy performed within 5-10 days prior to starting controlled ovarian stimulation, as part of in vitro fertilization treatment.
3086463|NCT01983423|No Intervention|Without Biopsy|Those proceeding with in vitro fertilization routinely, without an endometrial biopsy.
3086464|NCT01983410||BRCAmut carrier relatives of a BRCAmut PDAC patient|Who themselves have no known prior or active personal history of non-PDAC malignancy (e.g. breast , ovarian cancer or prostate cancer)
3086465|NCT01983410||BRCAmut carrier relatives of a BRCA mutation PDAC|Patient who themselves have a known prior or active breast, ovarian cancer or prostate cancer
3086466|NCT01983410||BRCAmut carriers|who are not related to a BRCAmut PDAC patient
3086467|NCT01983410||AJ PDAC patients|who are proven non-BRCAmut carriers.
3086468|NCT01983397|Experimental|Resistance training|Resistance training
3086469|NCT01983397|Experimental|Multicomponent training|Multicomponent training
3086470|NCT01983397|No Intervention|Control Group|The Control Group did not realize any intervention.
3086471|NCT01983384|Placebo Comparator|Anesthesia depth: control|A cohort of older patients undergoing major non-cardiac surgery will be randomized to receive a control anesthetic not monitored by the processed electroencephalogram
3086472|NCT01983384|Experimental|Anesthetic depth: intervention|A cohort of older patients undergoing major non-cardiac surgery will be randomized to receive an anesthetic guided by the processed electroencephalogram
3086473|NCT01983371|Experimental|Ferumoxytol-enhanced MRI|This is a single-arm study. All enrolled patients will have a ferumoxytol-enhanced MRI scan.
3086474|NCT01983358|Experimental|JPI-289|Each cohort, volunteers will be infused JPI-289 through I.V for 30 min.(6 volunteers per each cohort, total 7 cohort)
3086475|NCT01983358|Placebo Comparator|Placebo|Each cohort, volunteer will be infused placebo through I.V for 30 min.(2 volunteers per each cohort, total 7 cohort)
3086476|NCT01983345|No Intervention|no surgery|
3086477|NCT01983345|Experimental|open surgical repair|open surgical repair of myelomeningocele before 26 SA
3086478|NCT01983332||occupational therapists|Occupational Therapists
3086479|NCT01983319|Experimental|CIMT + active anodal tDCS|Subjects in this group will be trained with constraint-induced movement therapy for the hand (10 consecutive sessions Monday- Friday) while concurrently receiving active anodal transcranial Direct Current Stimulation 1,5 mA for 30 min.
3086480|NCT01983319|Sham Comparator|CIMT + sham tDCS|Subjects in this group will be trained with constraint-induced movement therapy for the hand (10 consecutive sessions Monday- Friday) while concurrently receiving sham transcranial Direct Current Stimulation
3086481|NCT01983319|No Intervention|Healthy control subjects|20 healthy age-matched control subjects will undergo MRI spectroscopy of the brain.
3086482|NCT01983306|Experimental|SP-333 1 mg|1 mg SP-333 orally once daily for 4-week Treatment Period
3086483|NCT01983306|Experimental|SP-333 3 mg|3 mg SP-333 orally once daily for 4-week Treatment Period
3086484|NCT01983306|Experimental|SP-333 6 mg|6 mg SP-333 orally once daily for 4-week Treatment Period
3086486|NCT01983293|Experimental|QLV based implant strategy|QLV is the pacing site with the largest amount of dyssynchrony as measured by the LV electrical delay. The QLV based implant strategy is choosing the vein branch and the cathode with the longest QLV measurement and programming a vector based on that cathode.
3086487|NCT01983293|Placebo Comparator|Standard of care implant strategy|The placement of LV lead will be carried out according to the physician's standard of care implant approach
3086488|NCT01983280|Experimental|Healing Touch|
3086489|NCT01983267|Active Comparator|cannabis|Patient using cannabis during chemotherapy treatment
3086490|NCT01983267|No Intervention|control|Patients under chemotherapy treatment
3086491|NCT01983254|Experimental|Coping skills training|6 sessions of weekly telephone-based coping skills training delivered by trained interventionist
3086492|NCT01983254|Active Comparator|education program|6 week access to a web-based, critical illness-specific education program
3086493|NCT01983241|Experimental|Alpha-1 MP 60 mg/kg|Alpha-1 MP 60 mg/kg administered weekly by IV infusion for 156 weeks
3086494|NCT01983241|Experimental|Alpha-1 MP 120 mg/kg|Alpha-1 MP 120 mg/kg administered weekly by IV infusion for 156 weeks
3086495|NCT01983241|Placebo Comparator|Placebo|0.9% Sodium Chloride for Injection, USP, administered weekly by IV infusion for 156 weeks
3086496|NCT01983228|No Intervention|Arm 1: Usual Care|Participants randomized to the usual care control condition will receive pedometers and an informational brochure.
3086497|NCT01983228|Experimental|Arm 2: Intervention Group|Participants assigned to the intervention group will receive personalized recruitment materials, including a letter and brochure describing the program and the benefits of walking for pain. They will also receive pedometers. Participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
3086498|NCT01983215|Experimental|negative pressure dressing vs. standard of care|single arm study- randomized Prevena vac or standard of care
3086499|NCT01983202||Women with PCOS|208 women diagnosed with PCOS and giving birth after singleton pregnancies at Odense University Hospital during 2003-2011.
3086500|NCT01983202||Controls|1040 women giving birth after singleton pregnancies at Odense University Hospital during 2003-2011, matched 1:5 to women with PCOS according to date-of-childbirth.
3086501|NCT01983189|Experimental|Low frequency rTMS|low frequency, repetitive transcranial magnetic stimulation (rTMS) for 20 minutes daily, 5 times a week for 3 weeks
3086502|NCT01983163|Active Comparator|ketogenic diet|ketogenic diet (2.5 to 4:1)
3086503|NCT01983163|Active Comparator|Modifid Atkin's diet|Modified Atkin's Diet
3086504|NCT01983150|Experimental|Crush the Crave Application|Crush the Crave (CTC) intervention group will receive a quit smoking smartphone intervention via the internet that is based on scientific findings related to tobacco use among young adults. It is a multi-component intervention informed by evidence on quitting smoking. The app was developed with the input of key experts in the field of smoking cessation, was assessed against Fiore's practice guidelines for treating tobacco use and dependence, and was tested with eight focus groups of male and female young adult smokers (n=57) on functionality, look and feel and usability, as well as being piloted by over 300 smokers.
3086505|NCT01983150|Active Comparator|On the Road to Quitting - Self Help|"The control group will receive an evidence-based self-help guide known as On the Road to Quitting(45) that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide."
3086506|NCT01983124|Experimental|Fotemustine + Vemurafenib|Fotemustine 100 mg/m2 q21 + Vemurafenib gelatin capsules supplied as 240-mg strengths. Vemurafenib will be administered continuous oral dosing at 960 mg twice daily or dose administered at time of disease progression with Vemurafenib previous treatment.
3086507|NCT01983111|Experimental|buprenorphine|Patch
3086508|NCT01983111|Active Comparator|tramadol/acetaminophen|Oral tablet
3086509|NCT01983085|Other|SPT Burn Wound|Each wound will be divided into 2 with half the wound being treated with the NOx dressing and the other half with standard of care
3086510|NCT01983085|Other|SPT graft donor site|Each wound will be divided into 2 with half the wound being treated with the NOx dressing and the other half with standard of care
3086511|NCT01983072|Active Comparator|Infant starter formula|standard infant formula
3086512|NCT01983072|Experimental|Infant starter formula + prebiotics + probiotics|infant formula
3086513|NCT01983072|Other|Breastfeeding group|reference group
3086514|NCT01983059||Patients with Liver Venous Thrombosis|
3086515|NCT01983046|Placebo Comparator|placebo|placebo
3086516|NCT01983046|Active Comparator|high acetate ratio|high acetate ratio
3086517|NCT01983046|Active Comparator|high butyrate ratio|high butyrate ratio
3086518|NCT01983046|Active Comparator|high propionate ratio|high propionate ratio
3086519|NCT01983033|Experimental|active treatment condition (ATC)|training protocol 'drop it'
3086520|NCT01983033|Other|waiting list control|no treatment other than treatment as usual
3086521|NCT01983020|Experimental|Ketamine|Ketamine infused at 0.25 mg/kg/hour.
3086522|NCT01983020|Experimental|Lidocaine|Lidocaine infused at 0.5 mg/kg/hour.
3086523|NCT01983020|Experimental|Ketamine and Lidocaine|Ketamine infused at 0.25 mg/kg/hour along with lidocaine at 0.5 mg/kg/hour
3086524|NCT01983020|Placebo Comparator|Placebo|Placebo (saline) given to compare usual treatment against active agents in post operative pain management.
3086525|NCT01983007|Experimental|high-intensity exercise group|Patients undergoing high-intensity exercise group. Intervention: high-intensity exercise.
3086526|NCT01983007|Experimental|low-intensity exercise group|Patients undergoing low-intensity exercise group Intervention: low-intensity exercise
3086527|NCT01982994|Experimental|Education/Daily Planning|Physical Activity Education and Daily Planning Tool
3086528|NCT01982994|No Intervention|No Education/Daily Planning|No Physical Activity Education/ Daily Planning Tool
3086529|NCT01982981|No Intervention|control|The control group only be assessed
3086530|NCT01982981|Experimental|water provision|The experimental group get water every 15 days
3103603|NCT01867788||Parkinson's disease subjects|
3086531|NCT01982968|No Intervention|Control|Subjects to receive standard anti-reflux treatment per clinical discretion
3086532|NCT01982968|Active Comparator|Surgery|Subjects will receive laparoscopic fundoplication surgery
3086533|NCT01982955|Experimental|Tepotinib plus Gefitinib|
3086534|NCT01982955|Active Comparator|Pemetrexed plus Cisplatin/Carboplatin|Subjects will either receive Pemetrexed plus Cisplatin combination or Pemetrexed plus Carboplatin combination.
3086535|NCT01982942|Experimental|ibudilast|Subjects will receive up to 100 mg/d ibudilast for 96 weeks.
3086536|NCT01982942|Placebo Comparator|Placebo Oral Capsule|Subjects will receive placebo for 96 weeks.
3086537|NCT01982929|Sham Comparator|Sham block & Oral Meds: Paracetamol 1000 mg Q8H, diclofenac 50|
3086538|NCT01982916|Experimental|AGR & Placebo|AGR tablet by qd and Placebo by bid for 4 weeks
3086539|NCT01982916|Placebo Comparator|Placebo|Placebo by bid for 4 weeks
3086540|NCT01982916|Active Comparator|Active comparator|Active Comparator and Placebo by bid for 4 weeks
3086541|NCT01982903||Kidney transplant recipients|Adult recipients of a primary or secondary cadaveric or living donor single renal allograft at the University Hospitals Leuven between July 2014 and June 2016
3086542|NCT01982890||Normal human controls|"Observational study. Subjects are screened for the absence of severe illnesses and followed prospectively with sequential blood draws, noting the occurence of acute and chronic severe illnesses.~Subjects are matched by age groups and sex with patients of the prospective cohort EUPA including patients with recent-onset inflammatory polyarthritis."
3086543|NCT01982877|Experimental|Family Support Intervention|Multifaceted family support intervention as well as ICU educational component.
3086544|NCT01982877|Experimental|Educational Control|ICU educational component
3086545|NCT01982864|Experimental|hemodialysis patients|The administration of gentamicin at the beginning of the hemodialysis.
3086546|NCT01982851|Active Comparator|Group E|Epidural de novo technique
3086547|NCT01982851|Active Comparator|Group BF|Combined spinal epidural (CSE) technique with intrathecal 0.5% Bupivicaine 2.5mg + Fentanyl 15mcg
3086548|NCT01982851|Active Comparator|Group F|Combined spinal epidural (CSE) technique with intrathecal fentanyl 25mcg
3086549|NCT01982838|Active Comparator|Group E|Epidural de novo technique
3086550|NCT01982838|Active Comparator|Group BF|Combined spinal epidural (CSE) technique with intrathecal 0.5% Bupivicaine 2.5mg + Fentanyl 15mcg
3086551|NCT01982838|Active Comparator|Group F|Combined spinal epidural (CSE) technique with intrathecal fentanyl 25mcg
3086552|NCT01982825|Experimental|Online intervention arm|Bi-weekly (MTh) for 6 weeks, participants will receive an email asking them to report number of cigarettes smoked, alcoholic drinks, engagement in physical activity, and overall mood the two-three days before. Upon answering, they will be launched to the site which will contain health messaging focused on smoking and other health topics.
3086553|NCT01982825|Active Comparator|Online control arm|Control participants will receive bi-weekly emails (MTh) over 6 weeks but in the context of a standard smoking cessation website. Because we are primarily testing the check-ins, tailored feedback, and market research-based mini-drama and other web content, we feel that this control group will isolate the hypothesized active elements of our program.
3086554|NCT01982812|Experimental|Oral Levetiracetam|Oral Levetiracetam administered by NG tube.
3086555|NCT01982812|Active Comparator|Standard AED|Standard AED regimen
3086556|NCT01982799|Experimental|Endododontic Tx + Long acting local anesthetic|long acting local anesthetic
3086557|NCT01982799|Experimental|Endodontic Tx plus local anesthetic|local anesthetic
3086558|NCT01982786|Active Comparator|Arm 1|IGRT* 60 Gy in 20 fractions OR IGRT 78 Gy in 39 fractions
3086559|NCT01982786|Active Comparator|Arm 2|"IGRT 37.5 Gy in 15 fractions~+ HDR brachytherapy boost 15 Gy"
3086560|NCT01982773|Experimental|Virtual Hope Box Smartphone App|Use of the smartphone app, Virtual Hope Box on their personal smartphone
3086561|NCT01982773|Active Comparator|EnhancedTreatment As Usual|Subjects will be issued printed materials guiding them in coping with suicidal thoughts, which include information about coping strategies and emergency contact information.
3086562|NCT01982760|Experimental|DDAVP|Arm receiving DDAVP prior to the operation. Drug is administered intravenously at .3mcg per kg, over 30 minutes prior to the operation.
3086563|NCT01982760|No Intervention|No DDAVP|Patients Will not receive DDAVP prior to Rhinoplasty
3086564|NCT01982747|Other|MGN - Placebo|Subjects of the MGN-Placebo arm will receive 60mg MGN1703 as 2 s.c. injections of 2 ml each during period 1 and physiological saline solution as Placebo as 2 s.c. injections of 2 ml each during period 2
3086565|NCT01982747|Other|Placebo-MGN|Subjects of the Placebo-MGN arm will receive physiological saline solution as Placebo as 2 s.c. injections of 2 ml each during period 1 and 60mg MGN1703 as 2 s.c. injections of 2 ml each during period 2
3086566|NCT01982734|Active Comparator|Native curcumin|80 mg curcumin as native powder
3086567|NCT01982734|Experimental|Native curcumin plus phytochemicals|80 mg curcumin as native powder plus 80 mg sesamin, 40 mg naringenin, 40 mg ferulic acid and 40 mg xanthohumol
3086568|NCT01982734|Experimental|Curcumin micelles|80 mg curcumin incorporated into liquid micelles
3086569|NCT01982734|Experimental|Curcumin micelles plus phytochemicals|80 mg curcumin incorporated into liquid micelles plus 80 mg sesamin, 40 mg naringenin, 40 mg ferulic acid, 40 mg xanthohumol incorporated into micelles
3086570|NCT01982721|Experimental|Transfemoral amputees|Locking mechanism for prosthetic knee (no trade mark provided)
3086571|NCT01982721|No Intervention|Healthy volunteers|
3086572|NCT01982695|Active Comparator|Lisinopril|
3086573|NCT01982695|Active Comparator|Losartan|
3086574|NCT01982682|Experimental|Treatment (TBI, DLI, cyclophosphamide, CD34+ donor HSCT)|"CONDITIONING REGIMEN: Patients undergo TBI BID on days -10 to -8, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANT: Patients undergo CD34+ (cluster of differentiation 34+) selected allogeneic HSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning by day 42, and mycophenolate mofetil IV BID on days -1 to 28."
3086575|NCT01982669||Different degree of spicy food intake|
3086690|NCT01981798|Active Comparator|Training group|Physiotherapy and occupational therapy: Training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour.
3086576|NCT01982656|Experimental|Massage technique|In addition to standard medical care and pharmacologic interventions, massage technique for 20 minutes for 5 to 14 days while in the ICU will be provided to help alleviate pain and anxiety in the patient.
3086577|NCT01982656|Placebo Comparator|No intervention|Patients with an aneurysmal subarachnoid hemorrhage will receive standard medical care to include pharmacologic interventions prescribed by the primary physician and nonpharmacologic interventions provided by the bedside RN such as ice or heat to address their pain and anxiety needs.
3086578|NCT01982643|Experimental|naltrexone plus bupropion|extended-release depot naltrexone (XR-NTX; as Vivitrol®)plus extended-release bupropion tablets (BRP; as Wellbutrin XL®)
3086579|NCT01982630|Experimental|Part I - MK-8521 64/120 μg/day|Participants will receive once daily subcutaneous MK-8521 (starting dose 64 μg/day Days 1 to 7 escalated to 120 μg/day for Days 8 to 14).
3086580|NCT01982630|Experimental|Part I - MK-8521 34/72 μg/day|Participants will receive once daily subcutaneous MK-8521(starting dose 34 μg/day Days 1 to 7 escalated to 72 μg/day for Days 8 to 14).
3086581|NCT01982630|Active Comparator|Part I - Liraglutide 0.6/1.2/1.8 mg/day|Participants will receive once daily subcutaneous liraglutide (starting dose 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, escalated to 1.8 mg for Days 8 to 14).
3086582|NCT01982630|Placebo Comparator|Part I - Placebo|Participants receive a dose of placebo that will match the administration volume of MK-8521.
3086583|NCT01982630|Experimental|Part II - MK-8521 300 ug/day - T2DM Participants|For T2DM participants, MK-8521 titrated to 300 ug/day. Starting at 64 ug and increasing to 120 ug on Day 8 and to 180 ug on Day 15 and increasing to 240 ug on Day 20 and to 300 ug on Day 25. The total number of dosing days will be 29.
3086584|NCT01982630|Active Comparator|Part II - Liraglutide 1.8 mg/day - T2DM Participants|Liraglutide titrated to 1.8 mg/day for 29 days. Starting at 0.6 mg and increasing to 1.2 mg on Day 8 and to 1.8 mg on Day 15.
3086585|NCT01982630|Placebo Comparator|Part II - Placebo - T2DM Participants|Participants receive a dose of placebo that will match the administration volume of MK-8521 across the 29 days.
3086586|NCT01982630|Experimental|Part II - MK-8521 120 ug/day - Non-Diabetic Participants|For non-diabetic overweight/obese participants MK-8521 titrated to 120 ug/day. The total dosing days will be 14 days, starting at 64 ug and increasing to 120 ug on Day 8.
3086587|NCT01982617|Experimental|Motivational Interviewing|The Cognitive Behavioral Therapy/Motivational Interviewing group consisted of four group sessions focused on using motivational interviewing to enhance motivation to quit smoking and on presenting cognitive-behavioral techniques for preparing to cut down or quit smoking. The following four topics were covered in this program: 1) Positive and Negative Aspects of Smoking, 2) Concerns and Hopes about Cutting Down or Quitting, 3) Small Changes that Can Help You Get Motivated, and 4) Planning for the Future.
3086588|NCT01982617|Experimental|Psychoeducation|The education group also consisted of four group sessions that were co-led by a doctoral-level clinical psychologist and at bachelors-level research assistant. However, the focus of the education group was to present factual information about health risks of smoking, benefits of quitting, pharmacological smoking cessation aides, and smoking cessation programs in the area. The four group topics included: 1) Health Risks of Smoking, 2) Benefits of Quitting, 3) Nicotine Replacement Therapy and Bupropion (Zyban), and 4) Options for Treatment Programs.
3086589|NCT01982604|Experimental|Sequence (Group) 1|"Subjects randomized to Sequence 1 will receive TI in the following sequence:~TI-Inhalation Powder A TI-Inhalation Powder B~*30 units (10 units + 20 units)"
3086590|NCT01982604|Experimental|Sequence (Group) 2|"Subjects randomized to Sequence 2 will receive TI in the following sequence:~TI-Inhalation Powder B TI-Inhalation Powder A~*30 units (10 units + 20 units)"
3086591|NCT01982591||Ancillary-Correlative (heavy metal and neurotoxicity)|Patients undergo serum and urine sample collection for heavy metal analysis by ICP-MS at baseline and at the completion of treatment. Patients also complete neurotoxicity assessment questionnaire at baseline and at the completion of treatment.
3086592|NCT01982578|Experimental|Product: Genistein|60 mg of genistein BID for 180 days. Intervention: Product: Genistein
3086593|NCT01982578|Placebo Comparator|Product: Placebo|1 placebo capsule BID for 180 days. Intervention: Product: Placebo
3086594|NCT01982565|Experimental|Treatment Arm|NOx dressing applied and changed at least every 2 days for 12 weeks or until ulcer is healed.
3086595|NCT01982565|Active Comparator|Control Arm|Standard of Care
3086596|NCT01982539|Experimental|Zipsor® (Liquid filled capsules)|25mg/every 6hrs/up to 4 days treatment
3086597|NCT01982526||Endmetrioma surgery|
3086598|NCT01982513||Term pregnant patients|"ASA I-II term (36-40 weeks) non-laboring women with singleton pregnancies who are admitted at MSH for induction of labor, elective cesarean section or for observation for any medical reason.~These patients will be examined in 4 positions with the ultrasound."
3086599|NCT01982500||Avastin regimens|Patients who are going to receive chemotherapy plus Avastin (bevacizumab)
3086600|NCT01982487|No Intervention|Arm A (no treatment)|Patients receive no treatment.
3086601|NCT01982487|Experimental|Arm B (IDO1 inhibitor INCB024360)|Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-28.
3086602|NCT01982487|Experimental|Arm C (vaccine, IDO1 inhibitor INCB024360)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and IDO1 inhibitor INCB024360 PO BID on days 1-28.
3086603|NCT01982487|Experimental|Arm D (vaccine)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1.
3086604|NCT01982474|Experimental|Grass pollen extract injection|Grass pollen extract injected intralymphatically q 4 weeks x 3
3086605|NCT01982474|Placebo Comparator|Placebo injection|Normal saline injected intralymphatically q 4 weeks x 3
3086606|NCT01982474|No Intervention|Observational group|Subjects already receiving traditional subcutaneous allergy immunotherapy for grass pollen, being observed for safety of their subcutaneous injections. Not receiving active intervention during this study.
3086607|NCT01982461|Experimental|Rosuvastatin|One Rosuvastatin tablet 10mg taken once daily.
3086608|NCT01982461|Active Comparator|Crestor®|One Crestor® tablet 10mg taken once daily.
3086609|NCT01982448|Experimental|Paclitaxel|Paclitaxel will be given as an IV infusion at a dose of 80mg/m2 weekly x 12 weeks (4 cycles).
3086610|NCT01982448|Experimental|Cisplatin|Cisplatin will be given by IV at 75 mg/m2 every 3 weeks, 4 cycles.
3086691|NCT01981798|No Intervention|Control Group|Members of the control group were referred to their general practitioner or specialist for further care.
3086611|NCT01982435|Other|Group I - Monthly|Enrolled subjects will receive multiple open-label intravitreal injections of 0.3 mg ranibizumab administered every 28 days (+/- 7 days from the last treatment) for 12 months in the monthly group.
3086612|NCT01982435|Other|Group II - Treat-and-Extend|Enrolled subjects will initially receive 3 loading doses of open-label Ranibizumab 0.3 mg given via intravitreal injection every 28 days (+/- 7 days from the last treatment). After the third loading dose, the follow-up interval is determined by the Principal Investigator based on OCT results as stated in the protocol. The follow-up interval is increased by 2 weeks (+/- 7 days) at each visit up to a maximum interval of 12 weeks (+/- 7 days). There is criteria built into the protocol in case a reduction in the follow-up intervals becomes necessary based upon worsening OCT results.
3086613|NCT01982422|Experimental|Dietary Intervention|A whole food, nutrient-dense dietary intervention which restricts processed foods high in food additives and optimizes micronutrient intake.
3086614|NCT01982422|Placebo Comparator|Standard-of Care Group|This group will receive normal standard-of-care for pregnancy.
3086615|NCT01982409|Experimental|Live Attenuated Varicella Vaccine|use the arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
3086616|NCT01982396|Active Comparator|Twice daily|
3086617|NCT01982396|Experimental|Once daily|
3086618|NCT01982383|Experimental|Micropulse Laser Treatment|Patient's randomized to ML treatment would be treated with the following settings: 200 micron spot size, 0.2 second duration, 15% duty cycle, and 300 milliWatt power. Their eyes would be dilated prior to treatment with standard mydriatic medications, including Tropicamide and Phenylephrine
3086619|NCT01982383|Placebo Comparator|No Treatment|Patients randomized to this treatment arm, will not receive treatment for CSC. They will continue to be observed at month 1 and month 3. If any worsening of pathology is found during the follow up visits, the patient will be removed from the study and given appropriate standard of care by the attending
3086620|NCT01982357||premature infant|Laser Speckle Imaging and Diffuse Optical Spectroscopy
3086621|NCT01982344|Experimental|mini-exchange-room (G2)|the other group will utilize disposable mini-exchange-room group
3086622|NCT01982344|No Intervention|usual care (G1)|The one group perform traditional PD procedure (G1)
3086623|NCT01982331|Experimental|LAIV H2N2 vaccine|LAIV H2N2 vaccine A/17/California/66/395 (H2N2) live monovalent influenza vaccine delivered intranasally 2 doses 1 month apart
3086624|NCT01982331|Placebo Comparator|Placebo|Placebo is composed of a lyophilizate containing the same concentrations of stabilizers as LAIV vaccine. It is prepared onsite in an identical fashion to the vaccine and delivered intranasally.
3086625|NCT01982318|Active Comparator|VitroGro®ECM|A topical application of synthetic extracellular matrix (ECM) protein formulation to the wound bed) plus Standard Care (moisture retentive dressing and multi-layer compression therapy).
3086626|NCT01982318|Placebo Comparator|Dulbecco's Phosphate Buffered Saline|Dulbecco's Phosphate Buffered Saline plus Standard Care (moisture retentive dressing and multi-layer compression therapy).
3086627|NCT01982305|Experimental|Simulator|One training session with the simulator.
3086628|NCT01982305|Active Comparator|Cadaver|One training session with a cadaver.
3086629|NCT01982292|Experimental|RLX030 (serelaxin)|Randomized patients received an IV infusion of 30 μg/kg/day of serelaxin for 48 hours at randomization and at Weeks 4 and 8
3086630|NCT01982292|Placebo Comparator|Placebo|Randomized patients received an IV infusion of placebo of serelaxin for 48 hours at randomization and at Weeks 4 and 8
3086631|NCT01982266|Experimental|GRADION™ Hip Total Cartilage Replacement (TCR)™|
3086632|NCT01982253|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, orally, twice daily for up to 12 weeks.
3086633|NCT01982253|Experimental|Fasiglifam 25 mg BID|Fasiglifam 25 mg tablets, orally, twice daily (BID) for up to 12 weeks.
3086634|NCT01982253|Experimental|Fasiglifam 50 mg QD +Placebo QD|Fasiglifam 50 mg tablets, orally once daily (QD) and fasiglifam placebo-matching tablets, orally, once daily for up to 12 weeks.
3086635|NCT01982240|Experimental|Plecanatide 3.0 mg|Plecanatide tablets 3.0 mg QD for 12 weeks
3086636|NCT01982240|Experimental|Plecanatide 6.0 mg|Plecanatide tablets 6.0 mg QD for 12 weeks
3086637|NCT01982240|Placebo Comparator|Placebo|Matching placebo tablets QD for 12 weeks
3086638|NCT01982227||patients|Patients (Aged 18 to 70 inclusive) with progressive colorectal cancer in intra-abdominal surgery requiring resection +/- Chemotherapy Hyperthermic Intraperitoneal
3086639|NCT01982214|Sham Comparator|sedentary|No intervention
3086640|NCT01982214|Experimental|Vibration|Subjects in this group will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week while 12 months. The training included light squats at 35-50 Hz and ended up by stretching and relaxation exercises.
3086641|NCT01982201|Experimental|Lesinurad and Tums|Day 1: 240 mL water or 240 mL water and Tums Day 2: Lesinurad 400 mg or Lesinurad 400 mg and Tums; Day 6: 240 mL water and Tums or 240 mL water; Day 7: Lesinurad 400 mg and Tums or Lesinurad 400 mg
3086642|NCT01982201|Experimental|Lesinurad and MINTOX|Day 1: 240 mL water or 240 mL water and MINTOX ; Day 2: Lesinurad 400 mg or Lesinurad 400 mg and MINTOX; Day 6: 240 mL water and MINTOX or 240 mL water; Day 7: Lesinurad 400 mg and MINTOX or Lesinurad 400 mg
3086643|NCT01982188||Single incision sling|
3086644|NCT01982175|Experimental|Alemtuzumab|Patients receive Alemtuzumab escalated from initial dose of 3mg/day then 10mg/day and up to 30mg/day by intravenous infusion(if tolerated). when stable dose of 30mg/day is tolerated, Alemtuzumab is administrated at 30mg by IV infusion 3 times per week for up to 12 weeks (including escalation and stable dose period). After completion of 12 weeks treatment, or discontinuation of treatment within 12 weeks due to disease progression, patients will be visited every 3 months up to 1 year from enrollment or to death, whichever occurs first.
3086645|NCT01982162||Cohort A|severe school aged asthma cohort
3086646|NCT01982162||Cohort B|mild to moderate school aged asthma cohort
3086647|NCT01982162||Cohort C|Severe pre school wheeze cohort
3086648|NCT01982162||Cohort D|Mild to moderate pre school wheeze cohort
3086649|NCT01982149||Group 1|Non-smokers (n=20)
3086650|NCT01982149||Group 2|Non-smokers (n=20), Smokers (n=20) and Individuals with lung cancer (n=20)
3086651|NCT01982149||Group 3|Subjects with abnormalities (nodules) detected on CT (n=20)
3086652|NCT01982136||Urethral stricture|patients requiring surgery for urethral stricture
3086653|NCT01982123|Experimental|Diagnostic (99mTc-MAA and 99mTc-DTPA SPECT/CT)|Patients undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT at baseline, mid-radiation therapy (up to 1 week post-treatment), and at 3-6 months post-treatment. Patients also undergo a pre-treatment 18F FDG PET/CT scan per standard of care.
3086654|NCT01982110|Experimental|Mindfulness Based Therapy|Craving to Quit mobile application is provided for participants
3086655|NCT01982110|Active Comparator|Behavioral Smoking Cessation|NCI Quit Pal via a mobile phone application is provided for participants
3086656|NCT01982097||Group 1|
3086657|NCT01982071|Experimental|Treatment group|Intravenous (IV)
3086658|NCT01982058|Experimental|Intimacy-Enhancing Couples|Patients and their partners receive communication and intimacy-enhancing intervention (IEC) once a week comprising the following five 90-minute sessions: Orientation and Stories of the Cancer Experience; Communication and Listening to Partner's concerns; Communication and Coping with Cancer Issues as a Team; Being Supportive to Solve Concerns; and Reflecting on Changes and Future Adaptation.
3086659|NCT01982058|Active Comparator|General Health and Wellness|Patients and their partners receive a General Health and Wellness intervention focusing on nutrition and physical activity once a week comprising of five 90-minute sessions: Introduction and Nutrition Basics; Nutrition and Prevention of Recurrence; Nutritional Review and Introduction to Relaxation; Physical Activity Basics; Aerobics and Resistance Exercises and Wrap up.
3086660|NCT01982058|Other|Usual Care|Patients and their partners receive standard psychological and emotional care (usual care [UC]) (i.e., social work consultations and referral to a psychiatrist or psychologist, if requested or deemed necessary by the attending physician).
3086661|NCT01982045|Experimental|AttraX condition|8-10cc of AttraX® Putty per spinal level at the randomized allocation side of the spine (left or right).
3086662|NCT01982045|Active Comparator|Autograft condition|8-10cc autologous bone graft per spinal level at the control side of the spine. This can be a combination of local bone and iliac crest bone, but at least 50% of the volume has to be iliac crest bone graft.
3086663|NCT01982032|Active Comparator|Edwards SAPIEN bioprosthesis|Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
3086664|NCT01982032|Active Comparator|Medtronic CoreValve® system|Transcatheter aortic valve replacement with the Medtronic CoreValve system
3086665|NCT01982019|Other|Obese patients with type 2 diabetes|Meal test taking and hormones measure including 26RFa
3086666|NCT01982019|Other|Obese patients witout diabetes|Meal test taking and hormones measure including 26RFa
3086667|NCT01982019|Other|healthy volonteers|Meal test taking and hormones measure including 26RFa
3086668|NCT01982006|Active Comparator|Phaco|Cataract surgery by phacoemulsification
3086669|NCT01982006|Experimental|Femto|Corneal incision, anterior capsulorhexis and lens fragmentation by femtosecond laser
3086670|NCT01981993||patients at ICU with sepsis|
3086671|NCT01981980|Experimental|Carboxytherapy|It was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
3086672|NCT01981980|Experimental|Radiofrequency|The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
3086673|NCT01981967|Experimental|Primary Vaccination Group|Participants who never received a JE vaccine, or who received a single dose of inactivated JE vaccine, or whose JE vaccination history is unknown or not documented.
3086674|NCT01981967|Active Comparator|Booster Vaccination Group|Participants who received at least 2 doses of inactivated JE vaccine (at least 1 year earlier for the last dose), or received a single dose of IMOJEV®, THAIJEV®, or IMOJEV® MD as part of the routine vaccination schedule (i.e., outside of Study JEC17) at least 1 year earlier
3086675|NCT01981954|Experimental|Solifenacin succinate|Children aged 6 months to less than 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods.
3086676|NCT01981941|Experimental|Treatment group|Oral
3086677|NCT01981928|Experimental|ASP7962|Each dose level group will include 8 subjects, of which 6 will be randomized to receive active ASP7962
3086678|NCT01981928|Placebo Comparator|Placebo|Each dose level group will include 8 subjects, of which 2 will be randomized to receive placebo
3086679|NCT01981915|Experimental|Lung Insufflation Volume|Measurement of the lung volume after hyperinsufflation with positive pressure by IPPB or LIAM
3086680|NCT01981915|Experimental|Peak Cough Flow|Measurement of the peak cough flow after hyperinsufflation with positive pressure by IPPB or LIAM
3086681|NCT01981902||Dehydration|Non-Invasive Optical Spectroscopic monitoring method for dehydration
3086682|NCT01981889|Other|Prednisone|Participants who are started on Prednisone 40 mg per day for 2 weeks and then tapered.
3086683|NCT01981863|Experimental|Epsilonaminocaproic acid|One arm: Epsilonaminocaproic acid 10 gr IV, followed by 1 gr/hr infusion Second arm: placebo
3086684|NCT01981863|Placebo Comparator|Placebo, Antifibrinolytic activity|Placebo: same IV volume as experimental arm
3086685|NCT01981850|Experimental|Cohort 1 0.3mg/kg Every 4 Weeks|Subjects will be treated with single agent PRM-151 at a dose of 0.3 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
3086686|NCT01981850|Experimental|Cohort 2 3 mg/kg Every 4 Weeks|Subjects will be treated with single agent PRM-151 at a dose of 3.0 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles
3086687|NCT01981850|Experimental|Cohort 3 10mg /kg Every 4 Weeks|Subjects will be treated with single agent PRM-151 at a dose of 10 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles
3086688|NCT01981837|Experimental|ALN-TTRSC (revusiran)|
3086689|NCT01981811|Active Comparator|Aripiprazole and Ingestible Event Marker (IEM)|All subjects will continue to receive their previously prescribed dose of aripiprazole (10 mg, 15 mg, 20 mg, or 30 mg) through the trial. Subjects will discontinue dosing of the conventional oral aripiprazole tablet and will begin taking MIND1 (aripiprazole embedded with an Ingestible Event Marker) tablet once-daily for 12 weeks.
3086692|NCT01981785||Immune deficiencies/Immune disorders|Patients with abnormal immune responses or potential primary immune deficiencies or immune disorders (allergies, autoimmune diseases) will be enrolled as the study group.
3086693|NCT01981785||No prior immune abnormalities|Patients with no prior immune abnormalities will be enrolled as the control group.
3086694|NCT01981772|Experimental|buffered lidocaine|administration of 4% buffered lidocaine with 1:100,000 epinephrine
3086695|NCT01981772|Active Comparator|nonbuffered lidocaine|administration of 4% lidocaine with 1:100,000 epinephrine
3086696|NCT01981759|Placebo Comparator|Placebo|Participants receive a weekly dose of 50 mg placebo by mouth one hour before Cognitive Behavioral Therapy (CBT) sessions from week 1-12 (12 visits).
3086697|NCT01981759|Experimental|D-Cycloserine|Participants will receive a weekly dose of 50 mg placebo by mouth one hour before Cognitive Behavioral Therapy (CBT) sessions from weeks 1-2 (2 visits), then a weekly 50 mg dose of D-Cycloserine by mouth one hour before CBT sessions from weeks 3-12 (10 visits).
3086698|NCT01981746|Experimental|30 ml|30 ml ropivacaine 0.1%, single bolus
3086699|NCT01981746|Experimental|10 ml|10 ml 0.1% ropivacaine, single bolus
3086700|NCT01981733|Experimental|Device|
3086701|NCT01981720|Experimental|1.0 mg/kg|PRX-102 (pegunigalsidase alfa) 1.0 mg/kg IV every 2 weeks (+/- 3 days)
3086702|NCT01981707|Experimental|F-Choline PET|The F-Choline-PET will be performed before and at 6 weeks of the beginning of treatment by abiraterone acetate or enzalutamide.
3086703|NCT01981694|Experimental|Single ascending doses|
3086704|NCT01981694|Experimental|Measurement of eye blink rate|
3086705|NCT01981681|Experimental|Cohort 1 Experimental Arm|
3086706|NCT01981681|Experimental|Cohort 2 Experimental Arm|
3086707|NCT01981681|Experimental|Cohort 3 Experimental Arm|
3086708|NCT01981681|Placebo Comparator|Cohort 3 Placebo Arm|
3086709|NCT01981681|Experimental|Cohort 4 Experimental Arm|
3086710|NCT01981681|Placebo Comparator|Cohort 4 Placebo Arm|
3086711|NCT01981668|Experimental|Cabazitaxel, Eligard and Radiotherapy|This study utilizes a conventional phase I study design with a '3+3 cohort expansion' design(15), to determine the MTD of 1) Cabazitaxel, in Part A, and 2) Radiotherapy, in Part B. The determination of the MTD is given in Section 5.2, Definition of Dose - Limiting Toxicity. All patients who enter the study, and begin concurrent chemo-radiation are analyzable for the primary endpoint of the study.
3086712|NCT01981655|Experimental|0.5M Sodium lactate|A bolus of 0.5M Sodium lactate of 3 ml per kg body weight (BW) is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
3086713|NCT01981655|Active Comparator|Hartmann's solution|Hartmann's solution of 3 ml per kg BW is administered in 15 minutes. There is NO continuous infusion infused thereafter; i.e. in total 3 ml per kg over 24 hours
3086714|NCT01981642|Experimental|Patients with a LVAD implanted.|Recording of LVAD data during routine visits and daily life. Recording of daily activity using wristwatch accelerometers.
3086715|NCT01981629||Shock|Defined by systolic blood pressure less than 95 mmHg or shock index (heart rate/systolic blood pressure) greater than 0.9
3086716|NCT01981616|Experimental|Vedolizumab 750 mg|Vedolizumab 750 mg, intravenous (IV) infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
3086717|NCT01981616|Placebo Comparator|Placebo|Vedolizumab placebo-matching, IV infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
3086718|NCT01981603|Experimental|navigator|Kidney transplant recipients will serve as navigators to educate and assist other patients with the transplant process.
3086719|NCT01981603|No Intervention|usual care|usual care
3086720|NCT01981590|Experimental|phrenic nerve stimulation|intravenously stimulating the phrenic nerve
3086721|NCT01981577||Patients with Parkinson's Disease|
3086722|NCT01981577||Healthy volunteers|
3086723|NCT01981564|Experimental|Asthma Express Intervention|Clinic visit for asthma education + nurse home visits
3086724|NCT01981564|Active Comparator|Standard Asthma Education Control group|Standard asthma education during nurse home visits
3086725|NCT01981551|Experimental|1|PF-03084014 will be administered orally at 150 mg twice a day in 21-day cycles
3086726|NCT01981538||Healthy Volunteers|Informal caregivers to patients enrolled in cancer treatment study
3086727|NCT01981525|Experimental|Single Arm|Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose.
3086728|NCT01981499|Experimental|Arm A1|Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999
3086729|NCT01981499|Placebo Comparator|Arm A2|Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999 relative to placebo
3086730|NCT01981499|Experimental|Arm B1|Part B of study to assess effects of PF-05180999 on histamine-induced wheal
3086731|NCT01981499|Experimental|Arm B2|Part B of study to assess effects of PF-05180999 on histamine-induced wheal
3086732|NCT01981499|Experimental|Arm B3|Positive control to ensure histamine-induced wheal assay integrity
3086733|NCT01981499|Experimental|Arm B4|Placebo control
3086734|NCT01981486|Placebo Comparator|Placebo|Placebo tablets
3086735|NCT01981486|Experimental|PF-05180999|Modified-release tablets of PF-05180999
3086736|NCT01981473||etanercept|Participants currently receiving etanercept treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
3086737|NCT01981473||adalimumab|Participants currently receiving adalimumab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
3086738|NCT01981473||infliximab|Participants currently receiving infliximab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
3086739|NCT01981460|No Intervention|Chloroprep and biopatch|Both arms are cleaned with chloroprep and a biopatch is placed on each arm.
3086740|NCT01981460|Experimental|Methylene blue and light treatment|Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
3086919|NCT01980095|Placebo Comparator|Placebo|Capsules that look like the RHB-105 product but contain no active ingredient.
3086741|NCT01981447|Active Comparator|Group A|IV Lacosamide administered (intravenously) over 30 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1 mg/ kg and 2.9 mg/kg over 30 minutes.
3086742|NCT01981447|Active Comparator|Group B|IV Lacosamide to be administered (intravenously) over 15 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1mg/kg, 2,4 mg/kg
3086743|NCT01981434|Active Comparator|Video game based obesity education|This is the intervention group, 250 parent/child dyads will be enrolled over a 6 month period from the pediatric emergency department and the Family Learning Center at our institution. The comparison group consisting of 250 additional parent/child dyads will not be subject to video game intervention.
3086744|NCT01981434|No Intervention|No intervention|250 children will be randomized to this group, they will not undergo the video game based obesity intervention educational intervention but will be followed up similar to the intervention group.
3086745|NCT01981421||Liver fibrosis|patients who had chronic liver disease
3086746|NCT01981408|Experimental|[^14C]-LY2801653|Single oral dose of LY2801653 containing 100 micro curies of radioactivity
3086747|NCT01981395|Experimental|Treatment regimn 1|150 mg Fenobam Orally - once
3086748|NCT01981395|Placebo Comparator|Treatment Regimen 2|Placebo orally - once
3086749|NCT01981382||Incident cases|Persistent nonspecific low back pain
3086750|NCT01981382||Controls|Acute low back pain that resolves in <6 months
3086751|NCT01981369|Active Comparator|Propofol sedation.|This group will have infraclavicular block and sedation during surgery with intravenous Propofol. Patients will receive intravenous Propofol sedation 50-100 mcg/kg/min infusion. The infusion will be stopped 15 minutes before the end of surgery.
3086752|NCT01981369|Experimental|Dexmedetomidine sedation.|This group will have infraclavicular block and sedation with intravenous Dexmedetomidine. Patients will receive intravenous Dexmedetomidine sedation bolus 0.5mcg/kg in 10 minutes and then 0.2-0.5 mg/kg/hr infusion. The infusion will be stopped 15 minutes before the end of surgery.
3086753|NCT01981356|Experimental|Acceptance and Commitment Therapy (ACT)|Participants randomized to the ACT condition will be provided with the opportunity to attend 4 ACT sessions. The treatment protocol is adapted from and virtually identical to that presented in Gaudiano and Herbert (2006). Each ACT session will serve as a standalone session, with all essential elements of the treatment briefly presented. Participants in the ACT condition will also receive treatment as usual.
3086754|NCT01981356|Active Comparator|Treatment as Usual (TAU)|TAU consists of psychopharmacology, case management, and psychotherapy. Additionally, patients randomized to the TAU condition will meet with ACT facilitators for 15 minutes every other day to provide additional support and answer questions, while ensuring not to discuss or suggest the use of therapeutic techniques related to ACT.
3086755|NCT01981343|Experimental|A-F Betafood|Two A-F Betafood tablets taken with a meal, 3 times daily for 12 weeks
3086756|NCT01981343|Placebo Comparator|Placebo|2 Placebo tablets taken with a meal, 3 times daily for 12 weeks
3086757|NCT01981330|Experimental|aMSC with and without hyaluronan gel|autologous mesenchymal stem cells (aMSC) injected into the vocal folds in 8 patients and aMSC mixed with hyaluronan gel in 8 patients
3086758|NCT01981317|Experimental|Stepped Care CBT|"All participants in this arm receive Step One which includes 3-in-office sessions lasting 1 hour each over 6 weeks and 6 weekly phone calls lasting 15 minutes or less. The in-office sessions are devoted to psychoeducation, cognitive therapy, and hierarchy development. These sessions will include all procedures of the standard therapist-delivered CBT but will be parent-led, therapist guided; thus, the parent is delivering evidence-based strategies with clinician guidance.~Children are then stepped up to Step Two of SC-CBT if it is determined that more therapy is needed following the post assessment. Step Two is a continuation of therapy and will include 9 additional in-office weekly session lasting 1 hour each over 9 weeks. These sessions will be therapist-led and are devoted to exposure and response prevention."
3086759|NCT01981317|Active Comparator|Standard CBT|All patients in this arm will receive 12 sessions of therapy over 12 weeks using the evidence-based cognitive behavioral therapy protocol in POTS (2004). Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-12 involve exposure and response prevention exercises specific to each youth.
3086760|NCT01981304||DES with a biodegradable polymer coating|Patients receiving the first carbonized bio-absorbable coated rapamycin-eluting coronary stent at time of percutaneous coronary intervention
3086761|NCT01981291|Active Comparator|Perineural|Patients in this group will receive a perineural injection of mepivacaine for subgluteal sciatic nerve block, in addition to a femoral nerve block and patient-controlled postoperative analgesia.
3086762|NCT01981291|Experimental|Intraneural|Patients in this group will receive an intraneural injection of mepivacaine for subgluteal sciatic nerve block, in addition to a femoral nerve block and patient-controlled postoperative analgesia.
3086763|NCT01981278|Experimental|Treatment A|Tapentadol ER 250-mg tamper-resistant formulation (TRF) tablet will be administered as a single oral dose under fasted condition.
3086764|NCT01981278|Experimental|Treatment B|Tapentadol ER 250-mg prolonged-release formulation 2 (PR2) tablet will be administered as a single oral dose under fasted condition.
3086765|NCT01981265||Hand osteoarthritis|
3086766|NCT01981252|Experimental|Ulthera® System Treatment|Ulthera® System treatment of the peri-orbital and peri-oral regions.
3086767|NCT01981239|Experimental|LPC analysis group|Voice sampling is executed before and immediately after drinking of 20ml N/S and linear voice analyses using LPC method are performed to calculate LPC index, residual variance, coefficiency mean, coeffiency variance, and coeffiency skewness.
3086768|NCT01981239|Active Comparator|spectral analysis group|Voice sampling is executed before and immediately after drinking of 20ml N/S and spectral voice analyses using Dr. Speech program are performed to calculate HNR (dB), RAP (%: Jitter), Mean and SD Fundamental Frequency (Hz: Fo), Shimmer (%) and SNR (dB).
3086769|NCT01981226|Experimental|Extracoporeal shock wave|Extracoporeal shock wave, 3000 shots/time, once a week for 3 weeks, treatment duration:30 minutes/time, shock wave freqency：2-4Hz, energy level:0.8-1.0 mJ/mm2
3086770|NCT01981200|Experimental|Resistance training in AECOPD|The patients conduct daily training during admission with weight cuff 3 set of 10 rep.
3086771|NCT01981187|Experimental|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
3086772|NCT01981174|Active Comparator|30-gauge needle|Subjects will be screened, assessed, and randomized to be injected with onabotulinum toxin A using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the other side during their first clinic visit. All needles would be luer lock, ½ inch length, and attached to separate 1cc syringes. Injection depth would be 1-2mm, dermal, and the angle of incidence would be perpendicular.
3086773|NCT01981174|Active Comparator|32-gauge needle|Subjects will be screened, assessed, and randomized to be injected with onabotulinum toxin A using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the other side during their first clinic visit. All needles would be luer lock, ½ inch length, and attached to separate 1cc syringes. Injection depth would be 1-2mm, dermal, and the angle of incidence would be perpendicular.
3086774|NCT01981161||Fingolimod|patients treated by Fingolimod will have biological samples and clinical data
3086775|NCT01981161||Natalizumab|patients treated by Natalizumab will have biological samples and clinical data
3086776|NCT01981148||Healthy patients|Healthy patients
3086777|NCT01981148||Patients with various retinal diseases|Various retinal diseases (vascular, hereditary, degenerative)
3086778|NCT01981135|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
3086779|NCT01981135|Experimental|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
3086780|NCT01981122|Experimental|Concurrent Arm|Subjects will receive sipuleucel-T concurrently with enzalutamide (160 mg orally once daily). Enzalutamide treatment will start 2 weeks prior to the first leukapheresis and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first.
3086781|NCT01981122|Experimental|Sequential Arm|Subjects will receive sipuleucel-T followed by enzalutamide (160 mg orally once daily). Enzalutamide treatment will start approximately 10 weeks after the first infusion of sipuleucel-T and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first.
3086782|NCT01981096|Experimental|Fibromyalgia Integrative Training|8 week (16 sessions) combined intervention with cognitive-behavioral therapy and neuromuscular training
3086783|NCT01981096|Active Comparator|Cognitive Behavioral Therapy|8 week (16 session) cognitive-behavioral therapy treatment.
3086784|NCT01981083|Experimental|Egg albumin-based protein supplement|Powder form, dosage 30 g daily, duration 6 months
3086785|NCT01981083|Active Comparator|Renal-specific oral supplement|Liquid form, dosage 237 ml (one can) daily, duration 6 months
3086786|NCT01981070|Other|Mindfulness Intervention for Parents|"The mindfulness intervention program incorporates the same structure as the Support and Information for Parents intervention (orientation session, six 2-hour sessions over 6 weeks, co-facilitated by two leaders) but different content. Instead of presentations by experts and open-ended discussions and peer support, sessions will offer experiential training in meditation practice (sitting meditation, gentle yoga, and walking meditation), as outlined in the MBCT Program (Segal et al., 2012). Each week, parents will be required to practice a mindfulness skill, and also participate in a mindful parenting exercise as homework, such as joining their child in an activity of the child's choice."
3086787|NCT01981070|Active Comparator|Support and Information for Parents|This 6-week program includes orientation session, six 2-hour sessions, held weekly. Parents will be provided with information on existing services in the region, and strategies to be strong advocates and plan and access services for their child. Each session will include a presentation by an expert, with a question answer period, a break, and facilitated discussion with other parents. The sessions will be co-facilitated by clinicians from the Disability Services Ontario (DSO) and Centre for Addiction and Mental Health (CAMH).
3086788|NCT01981057||Numeta|parenteral receipt prescribed with Numeta
3086789|NCT01981057||Individual|individually prescribed parenteral receipt
3086790|NCT01981044|Experimental|SERI® Surgical Scaffold|It is a prospective, multicenter, single-arm, post-market on-label clinical study of a 510(k)-cleared device.
3086791|NCT01981031|Experimental|A|Drug: BioChaperone® Combo
3086792|NCT01981031|Active Comparator|B|Drug: Humalog® Mix25
3086793|NCT01981018|Experimental|Imagery-focused Cognitive Therapy|"10 sessions of imagery-focused Cognitive Therapy delivered approximately weekly by two co-therapists, divided in 4 assessment, 4 treatment and 4 consolidation sessions; additional 2 blip management sessions during therapy and 3 blip management and booster session during follow up can be delivered if necessary."
3086794|NCT01981005|Experimental|RO5424802|
3086795|NCT01980992|Active Comparator|Wheat OIT|Active treatment participants receive Vital Wheat Gluten, and have up to four oral food challenges as directed by the protocol.
3086796|NCT01980992|Placebo Comparator|Placebo|Placebo for Vital Wheat Gluten followed by crossover to open-label active therapy (Vital Wheat Gluten), and up to three oral food challenges as directed by the protocol.
3086797|NCT01980979|Experimental|Remodulin|Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
3086798|NCT01980966|Experimental|MHAA4549A|
3086799|NCT01980966|Placebo Comparator|Placebo|
3086800|NCT01980966|Active Comparator|Tamiflu|
3086801|NCT01980953|Experimental|Part 1: Food Effect|GDC-0032 will be administered orally over 3-Treatment Period (TP) in 6-sequence as one 3 milligrams (mg) capsule in TP-A after 10 hour fasting from food, one 3 mg Phase III tablet in TP-B after 10 hour fasting from food and one 3 mg Phase III tablet in TP-C following the start of standard Food and Drug Administration (FDA) high-fat breakfast. Washout period o 14 to 20 days will be given between each TP.
3086802|NCT01980953|Experimental|Part 2: Tablet Formulation Comparison|Different formulations of tablets (Tablet A and Tablet B) of GDC-0032 will be administered orally over 2-TP having 10 hour fasting from food. Participants will receive one 3 mg Tablet A in TP-A and one 3 mg Tablet B in TP-B after 14 to 20 days washout period.
3086803|NCT01980953|Experimental|Part 3: Capsule API Lot Comparison|Two different lots of GDC-0032 active pharmaceutical ingredient (API) capsule formulation will be administered orally in crossover fashion over 2-TP to 20 participants having 10 hour fasting from food. Participants will receive one 3 mg capsule in TP-A and one 3 mg capsule in TP-B after 14 to 20 days washout period.
3086804|NCT01980953|Experimental|Part 4: Tablet Relative Bioavailibity|GDC-0032 will be administered orally in crossover fashion over 2-TP to 20 participants having 10 hour fasting from food. Participants will receive one 3 mg capsule in TP-A and one 2 mg Phase III tablet in TP-B after 14 to 20 days washout period.
3086805|NCT01980940|Experimental|Pt 1: ETOR 75 DMSO/ETOR 150 PG/ETOR 75 PG/ETOR 150 DMSO|Single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel. All treatments were applied topically.
3086806|NCT01980940|Experimental|Pt 1: ETOR 75 PG/ETOR 75 DMSO/ETOR 150 DMSO/ETOR 150 PG|Single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel. All treatments were applied topically.
3086807|NCT01980940|Experimental|Pt 1: ETOR 150 DMSO/ETOR 75 PG/ETOR 150 PG/ETOR 75 DMSO|Single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel. All treatments were applied topically.
3086808|NCT01980940|Experimental|Pt 1: ETOR 150 PG/ETOR 150 DMSO/ETOR 75 PG/ETOR 75 DMSO|Single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
3086809|NCT01980940|Experimental|Pt 1: ETOR OD/ ETOR 150 DMSO/ ETOR 75 DMSO/ ETOR 75 PG|Single-dose etoricoxib 163 mg (4.30 mL) 4% DMSO gel (DMSO formulation administered in error/overdose [OD]), followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
3086810|NCT01980940|Other|Pt 1: Placebo (Deviation)|Participants randomized to a treatment sequence in Part 1 who received single dose placebo gel (1.97 or 3.94 mL) applied topically in error instead of active study drug and dropped out after the first treatment period in the sequence. Included in the safety assessments only.
3086811|NCT01980940|Experimental|Pt 2: ETOR 50 DMSO|Etoricoxib 50 mg (1.31 mL, 4% DMSO gel) applied topically twice daily to the affected knee for a period of 2 weeks.
3086812|NCT01980940|Placebo Comparator|Pt 2: Placebo|Matching placebo to etoricoxib 50 mg 1.31 mL 4% DMSO gel applied topically twice daily to the affected knee for a period of 2 weeks.
3086813|NCT01980927|Experimental|NUCCA atlas correction|NUCCA atlas correction for migraine patients
3086814|NCT01980901||Ovation™/Ovation Prime™ Abdominal Stent Graft System|Adult male and female patients.
3086815|NCT01980888|Experimental|Idelalisib+bendamustine+rituximab|Participants will receive idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
3086816|NCT01980888|Placebo Comparator|Placebo+bendamustine+rituximab|Participants will receive placebo to match idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
3086817|NCT01980875|Experimental|Safety Run-In: Idelalisib+obinutuzumab|Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks. Following 4 weeks of treatment, safety data will be reviewed by an independent data monitoring committee (DMC). If acceptable tolerability is observed, the randomized portion of the study will begin.
3086818|NCT01980875|Experimental|Randomized: Idelalisib+obinutuzumab|Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks.
3086819|NCT01980875|Active Comparator|Randomized: Obinutuzumab+chlorambucil|Participants will receive obinutuzumab over 21 weeks and chlorambucil over 23 weeks.
3086820|NCT01980862||Heart Failure patients|No interventions for this study. Blood draw provided by patients.
3086821|NCT01980849|Experimental|Long term prophylaxis|Nadroparin, 0.4mL, subcutaneously, qid, given by long-term
3086822|NCT01980849|Active Comparator|Short-term prophylaxis|Nadroparin, 0.4mL, subcutaneously, qid, given during hospitalization
3086823|NCT01980836|Active Comparator|Seasonal influenza vaccine in tocilizumab treated RA patients|RA patients treated with tocilizumab
3086824|NCT01980836|Active Comparator|Seasonal influenza vaccine to Healthy controls|Healthy controls will be vaccinated against seasonal influenza
3086825|NCT01980823|Experimental|Metformin-Atorvastatin combination|Patients will receive metformin and atorvastatin for approximately 2 weeks prior to breast surgery.
3086826|NCT01980810|Experimental|albumin-bounded paclitaxel plus S-1|arm 1:albumin-bounded paclitaxel 200mg iv d1 and S-1 80mg/m2/d po d1-10, repeated every 2 weeks,up to 9 cycles,then S-1 as single agent to treat to disease progression
3086827|NCT01980797||Bicuspid aortic valve disease|"Group/Cohort Label - Bicuspid aortic valve~Group/Cohort Description -~Patients diagnosed with bicuspid aortic valve~All ages ≥8 years~Able to provide fully informed consent"
3086828|NCT01980797||Tricuspid aortic valve control patients|"Group/Cohort Label - Tricuspid aortic valve control patients~Group/Cohort Description -Control patients will come from approximately matched patients without an identified bicuspid aortic valve who are trace, gender and geographically matched.~Patients not diagnosed with bicuspid aortic valve~All ages ≥8 years~Able to provide fully informed consent"
3086829|NCT01980771|Experimental|BTWB intervention|Barbershops are assigned to either experimental or active control condition. Men recruited from experimental barbershops receive a single-session group intervention focused on HIV prevention.
3086830|NCT01980771|Active Comparator|Cancer prevention and screening|Barbershops are assigned to either experimental or control condition. Men recruited from control barbershops receive information on cancer prevention and control.
3086831|NCT01980758|Experimental|Surgery|Laparoscopic Gastric Plication
3086832|NCT01980745|Active Comparator|Chloroquine diphosphate|chloroquine diphosphate 250mg/day
3086833|NCT01980745|Placebo Comparator|sugar pill|sugar pill
3086834|NCT01980719||Healthy, Age-Matched|
3086835|NCT01980719||Fatigued|
3086836|NCT01980719||Not Fatigued|
3086837|NCT01980706|Placebo Comparator|Placebo|Participants will take placebo for 107 days, 3 times per day. Placebo will be given in blister packs.
3086838|NCT01980706|Active Comparator|30 Mg Baclofen|Participants will take baclofen/placebo for 107 days, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
3103604|NCT01867788||Healthy Control subjects|
3086839|NCT01980706|Active Comparator|90 mg Baclofen|Participants will take baclofen/placebo for 107 days, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 101.
3086840|NCT01980693|Other|bone age assessment by ultrasound|The aim of this phase is to collect the ultrasound reading values of Speed of Sound (SOS) and Distance (DIS) of all participants by performing a one time measurement of the left hand by the SonicBone's BA device. Each measurement will be performed on three sites of the hand: the wrist the phalanx and the metacarpal bones.
3086841|NCT01980680|Experimental|Agonist trigger|Agonist trigger Buserelin 0,5 mg and Pregnyl (hCG)
3086842|NCT01980680|Active Comparator|hCG|hCG trigger Pregnyl (hCG) and Progesterone and Estradiol
3086843|NCT01980667|Experimental|lurbinectedin (PM01183) / cisplatin|Patients will receive cisplatin as a 90-min i.v. infusion. In addition, patients will receive PM01183 as an i.v. infusion over 1-hour.
3086844|NCT01980654|Experimental|Main Study Arm 1|Subjects enrolled into this arm will receive ibrutinib continuously until disease progression or unacceptable toxicity. In addition, subjects will receive rituximab once weekly for four doses for the first four weeks of study treatment.
3086845|NCT01980654|Experimental|Exploratory Study Arm 2|Subjects enrolled into this arm will receive ibrutinib continuously as a single agent for the first eight weeks, then ibrutinib concurrently with rituximab once weekly for four doses. After the rituximab treatment, subjects will receive ibrutinib continuously until disease progression or unacceptable toxicity.
3086846|NCT01980641|No Intervention|Control group|Assessment of each participant's home and his or her performance of ADL.
3086847|NCT01980641|Experimental|Experimental group|Educational intervention: Assessment of each participant's home and his or her performance of ADL and the therapist will provide to the participants of the experimental group a list of advice related to the HTAS items that are evaluated negatively.
3086848|NCT01980641|Experimental|Application smartphone-based group|Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
3086849|NCT01980641|No Intervention|Non Application smartphone-based group|Non Smartphone-based application group (NSG) sample won't have a reminder
3086850|NCT01980628|Experimental|ibrutinib|ibrutinib capsules: 560 mg once daily
3086851|NCT01980615|Experimental|BGF MDI (PT010) Dose 1|BGF MDI Dose 1 taken as 2 inhalations
3086852|NCT01980615|Experimental|BGF MDI (PT010) Dose 2|BGF MDI Dose 2 taken as 2 inhalations
3086853|NCT01980615|Experimental|BGF MDI (PT010) Dose 3|BGF MDI Dose 3 taken as 2 inhalations
3086854|NCT01980615|Active Comparator|GFF MDI (PT003)|GFF MDI (PT003) taken as 2 inhalations
3086855|NCT01980615|Active Comparator|Symbicort MDI Dose 1|Symbicort MDI taken as 2 inhalations
3086856|NCT01980615|Active Comparator|Symbicort MDI Dose 2|Symbicort MDI Dose 2 taken as 2 inhalations
3086857|NCT01980602|Experimental|Supervised Exercise Program|
3086858|NCT01980589|Experimental|Carfilzomib, Cyclophosphamide and Dexamethasone (CCd)|Participants received carfilzomib, cyclophosphamide and dexamethasone for up to eight 28-day cycles, or until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
3086859|NCT01980576||Pre-operative pain measurement|Patients with low back pain
3086860|NCT01980563|Active Comparator|ultrasound|
3086861|NCT01980563|Active Comparator|combined monitoring|
3086862|NCT01980550|Experimental|sublingual nicotine，placebo|sublingual nicotine：one or two tablets per hour, up to a maximum of 20 tablets per day Subjects were advised to use the full treatment dose for 4 weeks
3086863|NCT01980537|Experimental|Stereotaxis|Magnetic wire navigation
3086864|NCT01980537|Active Comparator|Conventional|Conventional wire navigation
3086865|NCT01980524|Experimental|acipimox+|250 mg at 0 and 180 minutes (one day)
3086866|NCT01980524|Placebo Comparator|Placebo|1 Tablet at 0 and 180 minutes (one day)
3086867|NCT01980498|Experimental|PecFent nasal spray|"Patients that have signed the ICF and met inclusion and exclusion criteria are randomly assigned 1:1 to receive one of the following IP-BTP treatments:~Fentanyl pectin nasal spray (FPNS)~Physician choice-Usual Care (PC-UC)"
3086868|NCT01980498|Active Comparator|Physician choice-Usual Care (PC-UC)|"Patients that have signed the ICF and met inclusion and exclusion criteria are randomly assigned 1:1 to receive one of the following IP-BTP treatments:~Fentanyl pectin nasal spray (FPNS)~Physician choice-Usual Care (PC-UC)"
3086869|NCT01980485|Active Comparator|Feedback on lung age and exhaled carbon monoxide|
3086870|NCT01980485|Sham Comparator|No lung age feedback|Those allocated to the control group will simply be informed of their scores on the spirometry.
3086871|NCT01980472|Experimental|bevacizumab, carboplatin and paclitaxel|bevacizumab, carboplatin and paclitaxel
3086872|NCT01980459|Experimental|Magnesium Lactate|Patients will receive 2 tablets twice a day of Magnesium Lactate for 3 months.
3086873|NCT01980446|Other|1:Mismatch negativity|Presence of the mismatch negativity during the cortical auditory-evoked potential would predict a favorable outcome in comatose survivors after cardiac arrest.
3086874|NCT01980433|Experimental|Active rTMS|Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
3086875|NCT01980433|Sham Comparator|Sham rTMS|Placebo Transcranial Magnetic stimulation delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
3086876|NCT01980420|Other|Sleeve gastrectomy|All patients will undergo sleeve gastrectomy
3086877|NCT01980407|Experimental|SOL, single arm|S-1 combined with leucovorin and oxaliplatin
3086878|NCT01980394|Other|prospective cohort study|
3086879|NCT01980381|Experimental|Tree Theme Method ® (TTM) intervention|The TTM involves storytelling and story making, in which the patient draws tree maps representing certain periods of his/her life.
3086880|NCT01980381|No Intervention|Control group|Treatment as usual, with focus on the present everyday occupations
3086881|NCT01980368|Experimental|Group I (Tai Chi Easy)|Patients attend Tai Chi Easy class for 60 minutes once a week for 6 weeks. Patients also receive a DVD and exercise manual of Tai Chi Easy exercises and are encouraged to practice at home for 30 minutes most days per week for 6 weeks.
3086966|NCT01979744|Experimental|Resolute Integrity - IVUS|Resolute Integrity - IVUS arm
3086882|NCT01980368|Active Comparator|Group II (educational control)|Patients receive readings each week and attend a book club to discuss the readings for 60 minutes once a week for 6 weeks.
3086883|NCT01980355|Experimental|Tranexamic Acid|1000mg tranexamic acid; given over 15 minutes into the vein once prior to surgery.
3086884|NCT01980355|Placebo Comparator|Placebo|Placebo given over 15 minutes into the vein once prior to surgery.
3086885|NCT01980342|Experimental|Efavirenz|Healthy, reproductive-age women using the etonogestrel contraceptive implant who will take a two-week course of efavirenz 400 mg orally each night.
3086886|NCT01980329|Experimental|Maraviroc|single oral administration of 300 mg maraviroc
3086887|NCT01980316|Experimental|Argatroban group|Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
3086888|NCT01980316|Experimental|non-argatroban treated group|Patients in control group will receive Unfractionated heparin treatment
3086889|NCT01980303|Experimental|Cohort 1: Treatment A|Japanese participants will receive 1 spray of esketamine solution in each nostril (total dose: 28 mg).
3086890|NCT01980303|Experimental|Cohort 1: Treatment B|Japanese participants will receive 1 spray of esketamine solution in each nostril at time 0 and 5 minutes (total dose: 56 mg).
3086891|NCT01980303|Experimental|Cohort 1: Treatment C|Japanese participants will receive 1 spray of esketamine solution in each nostril at time 0, 5, and 10 minutes (total dose: 84 mg).
3086892|NCT01980303|Experimental|Cohort 2: Treatment A|Caucasian participants will receive 1 spray of esketamine solution in each nostril (total dose: 28 mg).
3086893|NCT01980303|Experimental|Cohort 2: Treatment B|Caucasian participants will receive 1 spray of esketamine solution in each nostril at time 0 and 5 minutes (total dose: 56 mg).
3086894|NCT01980303|Experimental|Cohort 2: Treatment C|Caucasian participants will receive 1 spray of esketamine solution in each nostril at time 0, 5 and 10 minutes (total dose: 84 mg).
3086895|NCT01980277|Experimental|LY2780301 + paclitaxel|"The following dose-levels will be investigated:~Continuous daily PO LY2780301 400 mg QD + weekly paclitaxel 70 mg/m²/week~Continuous daily PO LY2780301 400 mg QD + weekly paclitaxel 80 mg/m²/week~Continuous daily PO LY2780301 500 mg QD + weekly paclitaxel 80 mg/m²/week~A dose reduction could be explored:~- Continuous daily PO LY2780301 300 mg QD + weekly paclitaxel 70 mg/m²/week"
3086896|NCT01980264|Experimental|Diagnostic imaging|Harmonic Generation Microscopy
3086897|NCT01980238|Experimental|cannula ileostomy|After LAR, experimental group will accept cannula ileostomy. Operation has described in the Detailed Description.
3086898|NCT01980238|Active Comparator|loop ileostomy|After LAR, active comparator group will accept loop ileostomy. This operation is well known by colorectal surgeons.
3086899|NCT01980225|Experimental|Collapse|This arm includes the patients where laser-induced collapse (=artificial shrinkage) of all blastocysts is performed before vitrification
3086900|NCT01980225|No Intervention|control|This control arm includes the patients of which the blastocysts are vitrified without performing collapse
3086901|NCT01980212||first line advanced non-small cell lung cancer|patients newly diagnosed advanced non-small cell lung cancer, and received platinum based chemotherapy in Hunan Province Tumor Hospital
3086902|NCT01980199|Experimental|Fexinidazole|"600mg tablets~3 tablets once a day for 4 days continued by 2 tablets once a day for 6 days"
3086903|NCT01980186||Individuals with autism|Both individuals with autism and their siblings will be evaluated with (TUS)transcranial 2D ultrasound.
3086904|NCT01980186||Siblings of individuals with autism|Non-autistic siblings with no other obvious health issues will be screened
3086905|NCT01980173|Experimental|With Bakri balloon|"Patients randomized to this arm will be treated using the Bakri balloon.~Intervention: Bakri balloon"
3086906|NCT01980173|Active Comparator|Without Bakri balloon|"Patients randomized to this arm will receive routine care not including the Bakri Balloon.~Intervention: Routine Care"
3086907|NCT01980160|Active Comparator|Activated Nometex Device|Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.
3086908|NCT01980160|Sham Comparator|Unactivated Nometex Device|The Nometex device will not be activated and therefore have no effect on the nausea/vomiting associated with chemotherapy.
3086909|NCT01980147|Experimental|maCBT|Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT). This integrated model focuses on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The model and techniques are adapted to an age range of 9 to 17 years, with more visual material and child friendly language options for the younger part of the age range (9-12) and more teen-relevant and interpersonal content options for the older part of the age range (13-17). The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
3086910|NCT01980147|No Intervention|Comparison|Naturalistic comparison arm: No intervention offered, no intervention prohibited.
3086911|NCT01980121||Term pregnant patients|Term pregnant patients for scheduled elective cesarean section will be examined using a portable ultrasound machine to evaluate gastric contents.
3086912|NCT01980108|No Intervention|empty stomach|No fluid will be given to the patient prior to scanning.
3086913|NCT01980108|Experimental|50mL|50mL of water will be given to the patient prior to scanning
3086914|NCT01980108|Experimental|100mL|100mL of water will be given to the patient prior to scanning
3086915|NCT01980108|Experimental|200mL|200mL of water will be given to the patient prior to scanning
3086916|NCT01980108|Experimental|300mL|300mL of water will be given to the patient prior to scanning
3086917|NCT01980108|Experimental|400mL|400mL of water will be given to the patient prior to scanning
3086918|NCT01980095|Experimental|RHB-105|RHB-105 is an 'all-in-one' combination oral capsule consisting of 2 different antibiotics and a proton pump inhibitor combined in a single capsule.
3086920|NCT01980082|Active Comparator|Cefazolin|"Cefazolin~1 gram/2 gram if body mass index > 40 - one time dose, 30-60 min prior to incision."
3086921|NCT01980082|Placebo Comparator|Placebo|1 dose of placebo - NaCl 0.9% with no drugs added to it.
3086922|NCT01980069|Experimental|Neostigmine arm|Neostigmine arm
3086923|NCT01980069|Active Comparator|Sugammadex arm|Sugammadex arm
3086924|NCT01980056|Experimental|Vosaroxin: All Patients|All patients will receive vosaroxin according to the dose cohort in which they are enrolled.
3086925|NCT01980043|Other|Rectal Prolapse|endoluminal rectal prolapse repair under sedation and local anesthesia using CO2 colonoscopy to fix the rectum with sutures to the abdominal wall under needlescopic control.
3086926|NCT01980030|Experimental|Romiplostim|Weekly Romiplostim for 12 weeks with intra-patient weekly dose escalation from 1µg/Kg to a maximum dose of 10 µg/Kg with a dose reduction schema in case of platelet overshoot
3086927|NCT01980017|No Intervention|Wait-Listed Control Group|Usual care for smoking cessation
3086928|NCT01980017|Experimental|Ottawa Model for Smoking Cessation|Ottawa Model for Smoking Cessation
3086929|NCT01980004|Experimental|Dietary Education|Participants in this treatment arm will undergo dietary counseling for the prevention of kidney stone formation.
3086930|NCT01980004|Experimental|Potassium Citrate and Dietary Education|Participants in this treatment arm will undergo potassium citrate supplementation and dietary counseling for the prevention of kidney stone formation.
3086931|NCT01979991|Experimental|CT Imaging and Reconstruction|To develop a MBIR (model-based image reconstruction) method that will improve X-ray CT lung imaging by improving image quality and reducing dose.
3086932|NCT01979978|Experimental|Healthy Buddies Curriculum|Healthy buddies curriculum delivered by older peers weekly covering three components of healthy living: Physical activity, healthy eating and a healthy body image.
3086933|NCT01979978|No Intervention|Control|This group received standard school curriculum.
3086934|NCT01979965|Active Comparator|Active drug|Ranolazine therapy for three months
3086935|NCT01979965|Placebo Comparator|Sugar Pill|sugar pill therapy for three months
3086936|NCT01979952|Experimental|Nintedanib|150 mg twice daily
3086937|NCT01979952|Placebo Comparator|Placebo|twice daily dosing
3086938|NCT01979939|Experimental|A 1: DCV/ASV/BMS-791325 in treatment-naive subjects|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
3086939|NCT01979939|Experimental|A 2: DCV/ASV/BMS-791325 in treatment-experienced subjects|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
3086940|NCT01979926|Experimental|N02RS1 200mg|Combination of Broussonetia spp and Lonicera spp
3086941|NCT01979926|Experimental|N02RS1 400mg|Combination of Broussonetia spp and Lonicera spp
3086942|NCT01979926|Placebo Comparator|Placebo|Sugar pill
3086943|NCT01979913|Experimental|Patients with POAG or OHT|Patients with primary open angle glaucoma or ocular hypertension
3086944|NCT01979900|Experimental|Vaccae|Experiment group:One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
3086945|NCT01979900|Placebo Comparator|Placebo|Placebo group:One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally
3086946|NCT01979887||Non-MGD Participants|Participants without MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
3086947|NCT01979887||Mild-Moderate MGD Participants|Participants with Mild-Moderate MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
3086948|NCT01979887||Severe MGD Participants|Participants with Severe MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
3086949|NCT01979874|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day x 3 months (Nordic Naturals, Watsonville, CA, USA)
3086950|NCT01979874|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
3086951|NCT01979861|Experimental|vapor endometrial ablation|endometrial ablation using the AEGEA Vapor System
3086952|NCT01979848||MRI Mapping Group|After Subjects arrive at the MRI facility, subjects will fill out a medical questionnaire that will be used to determine whether a MRI study can be performed. The investigators will determine whether there are any problems that make the subject not suitable for participating in this study.
3086953|NCT01979835|Experimental|GF|Women who have a GyneFix Viz inserted
3086954|NCT01979822||PH patients with LenusPro pump|"Patient Inclusion Criteria:~Patient aged ≥ 18 years;~diagnosed with Pulmonary Arterial Hypertension (WHO) Category Group 1~Patient is in stable clinical condition and~the previous specific PH medication has been retained unchanged during the past 3 weeks"
3086955|NCT01979809|Sham Comparator|Arm 1|Untailored control website designed to support increase in fruit and vegetables with no age targeting used in previously funded MENU Choices study
3086956|NCT01979809|Active Comparator|Arm 2|MENU GenY age-targeted and tailored interactive website including 8 information sessions over 4 months, and options to visit over 185 recipes, videos, 4 bloggers, and information articles on dietary change topics
3086957|NCT01979809|Active Comparator|Arm 3|"Web intervention that is age targeted and tailored, identical to Arm 2, with the addition of personalized e-coaching support via email."
3086958|NCT01979796|Experimental|Ecig 24 mg nicotine|Ecig 24 mg nicotine
3086959|NCT01979796|Sham Comparator|Ecig 0 mg nicotine|Ecig 0 mg nicotine
3086960|NCT01979796|Placebo Comparator|Nicotine free inhalator|Nicotine free inhalator
3086961|NCT01979783||LBP|group of subjects with low back pain
3086962|NCT01979783||nonLBP|group without low back pain
3086963|NCT01979770||Adolescents|Adolescents who participated in an intervention trial of iron and zinc supplementation and a follow-up study at 9 years of age in 3 rural districts in Khon Kaen province, northeast of Thailand.
3086964|NCT01979757|Active Comparator|Centrifugation|Patients recieved fatgraft processed by Centrifugation
3086965|NCT01979757|Active Comparator|Puregraft|Patients recieved fatgraft processed by Puregraft
3107587|NCT01840371|Active Comparator|Fentanyl based group|
3086970|NCT01979731|Experimental|Job rotation|The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.
3086971|NCT01979731|Active Comparator|Guidelines Ergonomics|Manual material handling Orientation posture Orientation furniture Orientation in general
3086972|NCT01979718|Experimental|Full term intervention|"random selection~composed of the daily standard physical treatment and 1 session per one day over two weeks with a break on Saturday and Sunday (1 session is consisted of 50 repetitions of voluntary simultaneous flexion and extension of the both knees, taking a look at the mirrored virtual reality simulating the surgeried knee."
3086973|NCT01979718|Active Comparator|Half term intervention|"random selection~composed of the daily standard physical treatment over two weeks and 1 session per one day over one weeks with a break on Saturday and Sunday (1 session is consisted of 50 repetitions of voluntary simultaneous flexion and extension of the both knees, taking a look at the mirrored virtual reality stimmulating the surgeried knee )"
3086974|NCT01979692|Experimental|One arm ; CLM use in TTNB|"to determine the feasibility of using the CLM in performing TTNB of thoracic and mediastinal lesions~to obtain imaging criteria for distinguishing viable from non viable (necrotic) tissue and normal versus abnormal (inflammatory/malignant) lesions. On site rapid cytological examination (ROSE) will be the standard of biopsy quality.~the results will be compared to historic data of standard biopsies as to yield and quality of sampling"
3086975|NCT01979679|Active Comparator|Lurasidone 80 mg per day|Lurasidone 80 mg per day
3086976|NCT01979679|Active Comparator|Lurasidone 120 mg per day|Lurasidone 120 mg per day
3086977|NCT01979679|Active Comparator|Lurasidone 160 mg per day|Lurasidone 160 mg per day
3086978|NCT01979666|Experimental|study group|the patients that will get a nitrate patch
3086979|NCT01979666|Placebo Comparator|control group|the patients that will get the placebo patch
3086980|NCT01979653|Experimental|dexmedetomidine alone|dexmedetomidine 0.5 mcg/kg for 10 min + normal saline (volume-matched) bolus + dexmedetomidine 0.2-0.4 mcg/kg/hr infusion
3086981|NCT01979653|Experimental|dexmedetomidine + midazolam|normal saline (volume-matched) for 10 min + midazolam 0.2 mg/kg bolus + dexmedetomidine 0.2-0.4 mcg/kg/hr infusion
3086982|NCT01979640|Experimental|39 Fr double lumen group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
3086983|NCT01979640|Experimental|37 Fr double lumen group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
3086984|NCT01979640|Experimental|35 Fr double lumen tube group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
3086985|NCT01979627|Experimental|transulnar approach group|Patients in transulnar group received interventional procedure through ulnar artery
3086986|NCT01979627|Other|transradial approach group|patients in transradial group received interventional procedure through radial artery
3086987|NCT01979614|Experimental|Serelaxin|Serelaxin will be administered at a dose of 30 μg/kg/24h by intravenous infusion for 48 hours
3086988|NCT01979614|Placebo Comparator|Placebo|Placebo will be administered by intravenous infusion for 48 hours
3086989|NCT01979601|Experimental|Patient: LGT209 0.3 mg/kg|0.3 mg/kg LGT209 intravenous administration in patients on stable doses of statins
3086990|NCT01979601|Experimental|Patient: LGT209 1 mg/kg|1 mg/kg LGT209 intravenous administration in patients on stable doses of statins
3086991|NCT01979601|Experimental|Patient: LGT209 3 mg/kg|3 mg/kg LGT209 intravenous administration in patients on stable doses of statins
3086992|NCT01979601|Experimental|Patient: LGT209 10 mg/kg|10 mg/kg LGT209 intravenous administration in patients on stable doses of statins
3086993|NCT01979601|Experimental|Patient: LGT209 20 mg/kg|20 mg/kg LGT209 intravenous administration in patients on stable doses of statins
3086994|NCT01979601|Experimental|Healthy Volunteers: LGT209 0.3 mg/kg|0.3 mg/kg LGT209 intravenous administration in healthy volunteers
3086995|NCT01979601|Experimental|Healthy Volunteers: LGT209 1 mg/kg|1 mg/kg LGT209 intravenous administration in healthy volunteers
3086996|NCT01979601|Experimental|Healthy Volunteers: LGT209 3 mg/kg|3 mg/kg LGT209 intravenous administration in healthy volunteers
3086997|NCT01979601|Experimental|Healthy Volunteers: LGT209 10 mg/kg|10 mg/kg LGT209 intravenous administration in healthy volunteers
3086998|NCT01979601|Experimental|Healthy Volunteers: 20 mg/kg|20 mg/kg LGT209 intravenous administration in healthy volunteers
3086999|NCT01979601|Placebo Comparator|Patient: Placebo|Matching intravenous placebo in patients on stable doses of statins
3087000|NCT01979601|Placebo Comparator|Healthy Volunteers: Placebo|Matching intravenous placebo in healthy volunteers
3087001|NCT01979588|Placebo Comparator|Control|Providers do not have access to What's Going Around Tool but receive an instructional video explaining tool
3087002|NCT01979588|Active Comparator|What's Going Around Tool|Provider has access to What's Going Around Tool. Provider also shown a video explaining how to use Tool
3087003|NCT01979562||100 runners|Male runners between 18-60 years.
3087004|NCT01979549||Sedation|patients underwent upper gastrointestinal endoscopy with sedation
3087005|NCT01979549||non-sedation|patients underwent upper gastrointestinal endoscopy without sedation
3087006|NCT01979536|Experimental|Arm BV (brentuximab vedotin, combination chemotherapy)|"COURSE A (COURSES 1, 3, AND 5): Patients receive brentuximab vedotin IV over 30 minutes on day 1, dexamethasone PO BID or IV on days 1-5, ifosfamide IV over 60 minutes on days 1-5, methotrexate IV over 3 hours on day 1, cytarabine IV over 1-30 minutes every 12 hours for 4 doses on days 4 and 5, and etoposide IV over 2 hours on days 4 and 5.~COURSE B (COURSES 2, 4, AND 6): Patients receive brentuximab vedotin, dexamethasone, and methotrexate as in Arm BV, Course A. Patients also receive cyclophosphamide IV over 15-30 minutes on days 1-5 and doxorubicin hydrochloride IV over 1-15 minutes on days 4 and 5."
3087049|NCT01979302|Experimental|Depression CAREPATH|Patients receiving care from Nurses trained in depression care management
3107588|NCT01840358|Other|Patients starting pump therapy|
3087007|NCT01979536|Experimental|Arm CZ (crizotinib, combination chemotherapy)|"COURSE A (COURSES 1, 3, AND 5): Patients receive crizotinib PO BID on days 1-21 and dexamethasone, ifosfamide, methotrexate, cytarabine, and etoposide as in Arm BV, Course A.~COURSE B (COURSES 2, 4, AND 6): Patients receive crizotinib as in Arm CZ, Course A and dexamethasone, cyclophosphamide, methotrexate, and doxorubicin hydrochloride as in Arm BV, Course B."
3087008|NCT01979523|Experimental|Arm A (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who experience objective disease progression may crossover to Arm B. (no patients will be enrolled to Arm B or Crossover therapy as of 11/6/2015)
3087009|NCT01979523|Experimental|Arm B (trametinib, Akt inhibitor GSK2141795)|Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3087010|NCT01979510|Experimental|MK-0663B|MK-0663B (etoricoxib 90 mg immediate release [IR]/tizanidine 6 mg modified release [MR]) capsules once daily for 8 days.
3087011|NCT01979510|Experimental|DOLOCAM PLUS®|DOLOCAM PLUS® (meloxicam 7.5mg/methocarbamol 215mg) capsules once daily for 8 days.
3087012|NCT01979497|Active Comparator|Suture with Adhesive Stripping|Buried dissolving subcuticular sutures are sued for both sides of the wound to approximate wound edges and then steri-strips for the adhesive stripped half of the scar is applied.
3087013|NCT01979497|Active Comparator|Suture without Adhesive Stripping|Buried dissolving subcuticular sutures are sued for both sides of the wound to approximate wound edges and then no closure material for the half of the scar is applied.
3087014|NCT01979484|Experimental|PPI-668 capsule followed by tablet|On day 1 two 100 mg PPI-668 capsules will be administered; on day 8 one 200 mg PPI-668 tablet will be administered
3087015|NCT01979484|Experimental|PPI-668 tablet followed by capsule|On day 1 one 200 mg PPI-668 tablet will be administered; on day 8 two 100 mg PPI-668 capsules will be administered
3087016|NCT01979471|Other|Advanced care|For all the patients randomized to the advanced care group the pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA)
3087017|NCT01979471|No Intervention|Usual Care|"Patients randomized to the usual care group will receive:~Usual pharmacy care with no specific interventions for 3 months~At the end of the 3 months of the usual care period, all patients will cross over to receive the advanced care outlined above for 3 months"
3087018|NCT01979458|Experimental|PSE|Patients whose distal colon is imaged using the PSE device. This is a pilot trial of 30 patients.
3087019|NCT01979445|Experimental|Prasugrel 30 Min After Cangrelor|Prasugrel 60 milligram (mg) administered orally 30 min after the discontinuation of cangrelor infusion on Day 1 (2.5 hours [hrs] after initiation of cangrelor infusion).
3087020|NCT01979445|Experimental|Clopidogrel Within 5 Min After Cangrelor|Clopidogrel 600 mg administered orally within 5 min after the discontinuation of the cangrelor infusion on Day 1 (2 hrs after initiation of cangrelor infusion).
3087021|NCT01979445|Experimental|Clopidogrel 1.5 Hrs During Cangrelor|Clopidogrel 600 mg administered orally 1.5 hrs after the initiation of cangrelor infusion on Day 1.
3087022|NCT01979445|Experimental|Clopidogrel 1 Hr During Cangrelor|Clopidogrel 600 mg administered orally 1 hr after the initiation of cangrelor infusion on Day 1.
3087023|NCT01979432|Other|Cardiovascular evaluation|Measure of the index of systolic pressure Echo doppler Echography Measure of the speed of the wave of pulse and the central pressure
3087024|NCT01979419||cognitively normal|MRI scans, PET scans, lumbar puncture
3087025|NCT01979419||mild cognitive impairment|MRI scans, PET scans, lumbar puncture
3087026|NCT01979419||Alzheimer's Disease|MRI scans, PET scans, lumbar puncture
3087027|NCT01979419||vascular MCI|MRI scans, PET scans, lumbar puncture
3087028|NCT01979419||subcortical ischemic vascular dementia|MRI scans, PET scans, lumbar puncture
3087029|NCT01979406|Active Comparator|AVA|Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
3087030|NCT01979406|Experimental|Ad4-PA-1|"Given at 10^9, 10^10 and 10^11 vp~Ad4-PA at Day 1 + oral placebo on Day 15 + AVA boost at Day 29"
3087031|NCT01979406|Experimental|Ad4-PA-2|"Given at 10^9, 10^10 and 10^11 vp~Ad4-PA at Days 1, 15 and 29"
3087032|NCT01979406|Experimental|Ad4-PA-3|"Ad4 given at 10^9, 10^10 and 10^11 vp~Ad4 PA-GPI at Day 1 + AVA boost at Day 15 + placebo on Day 29"
3087033|NCT01979406|Experimental|Ad4-PA-GPI-1|"Given at 10^9, 10^10 and 10^11 viral particles~Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15"
3087034|NCT01979406|Experimental|Ad4 PA-GPI-2|"Given at 10^9, 10^10 and 10^11 viral particles~Ad4 PA-GPI at Day 1 + placebo on Day 15 + AVA boost at Day 29"
3087035|NCT01979406|Experimental|Ad4-PA-GPI -3|"Given at 10^9, 10^10 and 10^11 viral particles~Ad4-PA-GPI at Days 1, 15 and 29"
3087036|NCT01979393|Experimental|Cabozantinib|Cabozantinib maintenance 60 mg daily for 2 years or until withdrawal criterion After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving cabozantinib shall be further treated at the investigator discretion.
3087037|NCT01979393|Experimental|Placebo|Placebo daily for 2 years or until withdrawal criterion. After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving placebo shall be offered the option of receiving cabozantinib up to further progression. This is not mandatory and treatment is at the investigator decision.
3087038|NCT01979380|Experimental|KD101|
3087039|NCT01979380|Placebo Comparator|placebo|
3087040|NCT01979367|Experimental|Anodyne|To evaluate the efficacy treatment of lower extremity pathologies from neurological ischemia disorders using the Monochromatic Infrared Photo Energy (MIRE)
3087041|NCT01979354|Active Comparator|Spinal morphine|0.15 mg spinal morphine
3087042|NCT01979354|No Intervention|Control|No spinal morphine
3087043|NCT01979341|Active Comparator|Dual trigger|final oocyte maturation trigger using 6500 IU Ovitrelle (hCG) plus 0.2mg triptorelin acetate (GnRH agonist)
3087044|NCT01979341|Active Comparator|hCG trigger|final oocyte maturation trigger using 6500 IU Ovitrelle (hCG)
3087045|NCT01979341|Active Comparator|agonist trigger|final oocyte maturation trigger using 0.2mg triptorelin acetate (GnRH agonist)
3087046|NCT01979328|Experimental|Study arm|geko neuromuscular electrostimulation
3087047|NCT01979315||patients with LBP|
3087048|NCT01979315||healthy individulas|
3087050|NCT01979302|Other|Usual Care|Patients under the care of nurses who were trained in depression assessment and usual care
3087051|NCT01979289|Experimental|Computer Treatment: Active|Computerized Cognitive Remediation: Targeted to underlying cerebral networks associated with remission.
3087052|NCT01979289|Active Comparator|Computer Treatment: Control|Computerized Cognitive Remediation: Non-targeted
3087053|NCT01979276|Experimental|Pomalidomide, Romidepsin, Dexamethasone|Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined Dexamethasone
3087054|NCT01979263|Active Comparator|Attention Bias Modification|Attention Bias Modification computer task
3087055|NCT01979263|Placebo Comparator|Placebo Computer Task|Placebo computer task
3087056|NCT01979250|No Intervention|Normal corneas|Normal corneas from patients that undergo cataract surgery.
3087057|NCT01979250|Other|DSAEK surgery|Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK).
3087058|NCT01979237|Experimental|SPASO method, FARES method|Reduction method: SPASO method, FARES method
3087059|NCT01979224|No Intervention|treatment and routine counseling|Parents attend regular consultation and receive regular medical guidance
3087060|NCT01979211|Experimental|Cetuximab and Radiation|Cetuximab 400 mg/m2 IV over 120 minutes loading dose > 4 days prior to initiation of radiation; Cetuximab 250 mg/m2 IV over 60 minutes weekly weeks 2-7 concurrent with Radiation therapy 60-66 Gy in 2 Gy daily fractions
3087061|NCT01979198||fusion group|close reduction with posterior short-segment transpedicular screw fixation with posterior fusion
3087062|NCT01979198||non-fusion group|close reduction with posterior short-segment transpedicular screw fixation without posterior fusion
3087063|NCT01979185|Active Comparator|Simvastatin|Administered as a single oral 20 mg dose on Day 1.
3087064|NCT01979185|Experimental|Simvastatin + SSP-004184SS|Simvastatin (20 mg) + SSP-004184SS (30 mg/kg) administered concomitantly as a single oral dose on Day 1.
3087065|NCT01979159|Experimental|Combined aphasia and apraxia of speech treatment (CAAST)|Administration of CAAST to 4 persons with aphasia and apraxia of speech in the context of single-subject designs
3087066|NCT01979146|Experimental|Provider Unrelieved Symptom Alert|Patients in the intervention arm called the automated monitoring system daily to report presence, severity and distress on a 1-10 scale for nine symptoms. The system immediately sent an emailed symptom alert report to their oncologist and oncology nurse if symptoms exceeded preset thresholds (moderate to severe levels). Two thresholds were set: a simple alert when severity or distress was 4 or greater on the 10 point scale and trend alerts based on a pattern of moderate severity over several days.
3087067|NCT01979146|No Intervention|Attentional Control Usual Care Group|Patients in the usual care group called the automated monitoring system daily to report presence, severity and distress (1-10 scale) on 9 symptoms and also measured symptom interference with daily activities, functional status, work attendance, and unscheduled provider visits, urgent care and emergency department visits, and unscheduled hospitalizations. The usual care group received equivalent contact time with the automated system including identical voice and assessment questions. Data were not available for clinical action and not reported to the oncology providers. On every call, usual care participants were reminded to call their oncology provider if they had symptom concerns, which is the usual practice in oncology settings to address unrelieved symptoms.
3087068|NCT01979133|Experimental|icariin|Icariin will be given 100 mg/day. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 for participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
3087069|NCT01979120||only 1 cohort!|All patients already got an ICD implanted which includes an algorithm for screening of sleep-disordered breathing and will be examined by an portable polygraphy monitor in order to compare the Apnea-Hypopnea-Index.
3087070|NCT01979107|Experimental|Proactive action by the general practitioner|Proactive action by the general practitioner inviting to preventive health check.
3087071|NCT01979107|No Intervention|Control group|The participants will be treated as usual by the general practitioner.
3087072|NCT01979094||spinal arthrodesis and/or arthroplasty procedures|
3087073|NCT01979081||People with chronic disease|Participants greater than or equal to 44 years of age with a chronic disease (diabetes, heart disease, stroke, hypertension, osteoporosis, osteoarthritis, rheumatoid arthritis, chronic obstructive pulmonary disease, back pain, Multiple Sclerosis, Parkinson's Disease).
3087074|NCT01979081||People without chronic disease|Participants greater than or equal to 65 years of age without a chronic disease.
3087075|NCT01979055|Experimental|Self-regulation intervention|6 session educational intervention (3 telephone, 3 In-person), led by a health educator
3087076|NCT01979055|Placebo Comparator|Control group|3 telephone calls to assess any additional questions regarding asthma
3087077|NCT01979042||patients with stones|80 men and women with a normal creatinine for the past year that present in the ER with renal colic and a stone in their ureter according to imaging
3087078|NCT01979042||patients without stones|20 men and women that presented in our department for elective surgery that is not related to stones or bladder outlet obstruction
3087079|NCT01979029|Experimental|preserving the left colic artery|We preserve the left colic artery and resect the No. 253 lymph node during the rectal surgery.
3087080|NCT01979029|Experimental|not preserving the left colic artery|We preserve the high ligation of the inferior mesenteric artery during the rectal surgery.
3087081|NCT01979016|Experimental|Group A|
3087082|NCT01979016|Placebo Comparator|Group B|
3087083|NCT01979003|Experimental|Fluorescein Injection|All research participants will receive fluorescein injection through existing intravenous line during the operative procedure. This will consist of one ampule (5 cc) injected intravenously 5- 10 minutes prior to ligation of the uterine arteries.
3087084|NCT01978990||Diabetes Management System , blood glucose|
3087085|NCT01978977||Avastin regimens|Patients who are going to receive chemotherapy plus Avastin (bevacizumab)
3087086|NCT01978964|Experimental|ONT-10 Vaccine|
3087239|NCT01978028|Active Comparator|ferric carboxymaltose|ferric carboxymaltose
3087087|NCT01978951|Experimental|Integrated Chronic Kidney Disease care|standard guidelines of CKD treatment + Integrated CKD care consisting of multidisciplinary team care and home visit by community care network
3087088|NCT01978951|Active Comparator|Conventional CKD care|standard guidelines of CKD treatment
3087089|NCT01978938|Experimental|Eravacycline IV and oral|Eravacycline 1.5 mg/kg IV q24h plus eravacycline 250 mg PO BID
3087090|NCT01978938|Active Comparator|Levofloxacin|Levofloxacin 750 mg PO QD + placebo PO QD
3087091|NCT01978938|Experimental|Eravacycline 1.5 mg/kg, plus eravacycline 200 mg PO|Eravacycline 1.5 mg/kg IV q24h plus eravacycline 200 mg PO BID
3087092|NCT01978925|Experimental|Pharmaceutical care|In the ED, immediately after discharge, participants randomized to the pharmaceutical care group will receive intervention coordinated by the study pharmacist.
3087093|NCT01978925|No Intervention|Usual care|In addition to counseling provided by a physician and by the nursing staff during their stay in the ED (usual care), patients randomized to the control group will receive the same printed material information on hypertension and/or diabetes medications and lifestyle interventions in order to keep patients masked.
3087094|NCT01978912|Experimental|KTP-001 (First Cohort; Low Dose)|
3087095|NCT01978912|Experimental|KTP-001 (Second Cohort; Lower Middle Dose)|
3087096|NCT01978912|Experimental|KTP-001 (Third Cohort; Higher Middle Dose)|
3087097|NCT01978912|Experimental|KTP-001 (Fourth Cohort; High Dose)|
3087098|NCT01978899|Active Comparator|Immediate Weight Loss Program Group|"Immediate Weight Loss Program Group~The weight loss Program Group will include weekly in-person sessions comprised of dietary counseling and increased physical activity. Patients will also be provided with exercise and dietary goals each week to implement at home.~Assessments will occur at baseline (pre-randomization), at the end of the 16-week intervention or control period and at 32 weeks."
3087099|NCT01978899|Active Comparator|Delayed Weight Loss Program Group|The Delayed Weight Loss Program Group will take part in the weight loss intervention after the 16-week control period. Assessments will occur at baseline (pre-randomization), at the end of the 16-week intervention or control period and at 32 weeks
3087100|NCT01978886||Patient with diabetes|Patients who have been diagnoses with diabetes.
3087101|NCT01978886||Patients without diabetes|Patients who have not previous been diagnosed with diabetes.
3087102|NCT01978873|Experimental|Arm A:|"Cabazitaxel 25 mg / m² / day on day 1 every 3 weeks continued if the patient has stable disease or responding to up to 10 cycles. Cabazitaxel will be administered in combination with oral prednisone or prednisolone (Prednisolon 10mg 1x1)~Hormones will be initiated in conjunction with the last cycle of chemotherapy. Consists of the administration of a luteinizing hormone-releasing hormone (LHRH) agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device. G-CSF treatment according to ASCO guidelines is recommended."
3087103|NCT01978873|Active Comparator|Arm B:|-Hormone: LHRH agonist antiandrogens for 30 days + OR surgical castration OR CAB complete androgen blockade by LHRH agonist + antiandrogen device.
3087104|NCT01978860|Experimental|NovaCross, CTO|assess the safety and technical feasibility, deployment and withdrawal characteristics of the NovaCross™ micro-catheter during an interventional coronary angioplasty procedure and evaluating the CTO penetration rate.
3087105|NCT01978821|Experimental|stem cell|autologous bone marrow mononuclear cell transplantation
3087106|NCT01978795|Experimental|Brain 101 website|Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. The website offers a school-wide approach to preventing and managing sports concussion, including a) training for educators, athletics staff, students, and parents; b) guidelines for creating a concussion management team; and c) information on strategies for supporting students in the classroom following concussion.
3087107|NCT01978795|Active Comparator|Control|
3087108|NCT01978782|Active Comparator|raltegravir alone|raltegravir 400 mg BID for 5 days
3087109|NCT01978782|Active Comparator|citalopram alone|citalopram 10 mg QD for 3 days, followed by citalopram 20 mg QD for 13-14 days
3087110|NCT01978782|Experimental|raltegravir + citalopram|raltegravir 500 mg BID and citalopram 20 mg QD for 5 days
3087111|NCT01978769||Preadolescents with ADHD|preadolescents with prior diagnosis of ADHD and without any other psychiatric or neurological diagnosis.
3087112|NCT01978769||Preadolescents with out any diagnosis|Preadolescents with out any diagnosis
3087113|NCT01978756||Outpatient clinic|All patients treated for breast cancer with curative intent in MAASTRO clinic in 2002-2003 who are still alive, who respond to our invitation letter and are willing to participate to visit the outpatient clinic. These patients will be sent a questionnaire with both basic and more detailed questions on their disease-status and on quality of life related outcome. In addition they will be asked to come to MAASTRO clinic for a more detailed evaluation of late side effects of the treatment. Patients are seen by a physician or a physician assistant at the outpatient clinic.
3087114|NCT01978743|Experimental|Raltegravir|Switch from Atripla (EFV/FTC/TDF) to raltegravir (RAL) + Truvada (FTC/TDF). Raltegravir will be administered 400mg twice-a-day with Truvada for 8 weeks.
3087115|NCT01978730|Experimental|high dose group of SaiLuoTong capsule|take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
3087116|NCT01978730|Experimental|low dose group of SaiLuoTong capsule|take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
3087117|NCT01978730|Placebo Comparator|the control group|The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
3087118|NCT01978717|Experimental|general anesthesia & epidural anesthesia|26 patients received general anesthesia combined with epidural anesthesia for surgery, and patient-controlled epidural analgesia for 2 days after surgery
3087119|NCT01978717|Experimental|general anesthesia|27 patients received general anesthesia for surgery, and patient-controlled intravenous analgesia for 2 days after surgery
3087120|NCT01978704|Experimental|Glycaemic load|
3087121|NCT01978704|Active Comparator|Carbohydrates content|
3087240|NCT01978028|Placebo Comparator|placebo|placebo
3087122|NCT01978691|Active Comparator|Probiotic|Bifidobacterium animalis ssp. lactis 420 (10^10 colony-forming units (CFU)/day in 12 g of microcrystalline cellulose), once per day for six months in a sachet mixed into a smoothie drink
3087123|NCT01978691|Active Comparator|Prebiotic|Polydextrose, 12 g once per day for six months in a sachet mixed into a smoothie drink
3087124|NCT01978691|Active Comparator|Synbiotic|B. lactis 420 (10^10 CFU/day) in 12 g of polydextrose, once per day for six months in a sachet to be mixed into a smoothie drink
3087125|NCT01978691|Placebo Comparator|Control|12 g of microcrystalline cellulose once per day for six months in a sachet to be mixed into a smoothie drink
3087126|NCT01978678||Pulmicort|
3087127|NCT01978665|Placebo Comparator|prednisone and Solumedrol|placebo arm versus prednisone
3087128|NCT01978665|Placebo Comparator|solumedrol|placebo versus solu medrol
3087129|NCT01978665|Placebo Comparator|placebo|
3087130|NCT01978652|Experimental|Peginterferon Beta-1a administered to Japanese participants|A single dose of Peginterferon Beta-1a 125 μg subcutaneous (SC) injection administered by pre-filled syringe
3087131|NCT01978652|Experimental|Peginterferon Beta-1a administered to Caucasian participants|A single dose of Peginterferon Beta-1a 125 μg subcutaneous (SC) injection administered by pre-filled syringe
3087132|NCT01978626|Experimental|Smart phone Apps|"1st year: Electronic sleep diary module: an app with electronic sleep diary and message reminder~2nd year: Social persuasion system module: an app of smart phone that encourages participants with each others~3rd year: Tai-chi module: a multi-media oriented app that helps participants practice Tai-Chi"
3087133|NCT01978626|Active Comparator|Control|"1st year: traditional paper-pencil diary~2nd year: no social persuasion is given beyond sessions~3rd year: Tai-chi teaching by Digital Video Disc only"
3087134|NCT01978613|Experimental|Oral B (DC)|Escalation design. Planned end dose level is 5 mg alternative dosing condition (fasting for 30 minutes post-dosing)
3087135|NCT01978613|Experimental|Oral D|Escalation design. Planned end dose level is 20 mg standard dosing condition (fasting for 120 minutes post-dosing)
3087136|NCT01978613|Experimental|Oral C|Escalation design. Planned end dose level is 10 mg standard dosing condition (fasting for 120 minutes post-dosing)
3087137|NCT01978613|Experimental|Oral B|Escalation design. Planned end dose level is 5 mg standard dosing condition (fasting for 120 minutes post-dosing)
3087138|NCT01978613|Experimental|Oral A|Escalation design. Planned end dose level is 2.5 mg standard dosing condition (fasting for 120 minutes post-dosing)
3087139|NCT01978600|Experimental|SIMBRINZA™|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension, 1 drop 3 times a day (8AM, 3PM, 10PM) in each eye for 4 weeks
3087140|NCT01978600|Active Comparator|Timolol Maleate 0.5%|Timolol Maleate 0.5%, 1 drop twice a day (8AM, 8PM) in each eye for 4 weeks
3087141|NCT01978587|Experimental|Dose 1 JTZ-951|Tablets, 1 dose on Day 1 before hemodialysis
3087142|NCT01978587|Experimental|Dose 2 JTZ-951|Tablets, 1 dose on Day 8 after hemodialysis
3087143|NCT01978574|Active Comparator|Documentary videos|In the placebo control condition, participants watch daily videos.
3087144|NCT01978574|Experimental|Intellectual Enrichment|Daily activities that encourage intellectual enrichment, including games, reading/writing, and hobby activities.
3087145|NCT01978561|Experimental|Follow-Up after dosing with NT100 Dose 1|Follow-Up after dosing with NT100 Dose 1
3087146|NCT01978561|Experimental|Follow-Up after dosing with NT100 Dose 2|Follow-Up after dosing with NT100 Dose 2
3087147|NCT01978561|Placebo Comparator|Follow-Up after dosing with Placebo|Follow-Up after dosing with Placebo
3087148|NCT01978548|Experimental|JNJ-54861911 10 mg|From Day 1 to Day 28 inclusive, patients will self-administer once daily study drug (JNJ-54861911 or placebo) with a glass of non-carbonated water (approximately 200 mL).
3087149|NCT01978548|Experimental|JNJ-54861911 50 mg|
3087150|NCT01978548|Placebo Comparator|Placebo|Patients will receive matching placebo.
3087151|NCT01978535|Experimental|Iron infusion|Iron Sucrose (Venofer (R))
3087152|NCT01978535|Placebo Comparator|Normal saline infusion|Equal volume to intervention of normal saline
3087153|NCT01978522|Experimental|NICOLA Participants|All participants enrolled in the NICOLA cohort
3087154|NCT01978509|Active Comparator|Low volume prep (Prepopik)|Low volume prep for colonscopy (Prepopik)
3087155|NCT01978509|Active Comparator|Moderate volume prep (Moviprep)|Moderate volume prep for colonscopy (Moviprep)
3087156|NCT01978509|Active Comparator|High volume prep (Golytely)|High volume prep for colonoscopy (Golytely)
3087157|NCT01978496|Placebo Comparator|Placebo|
3087158|NCT01978496|Experimental|Eletriptan 20 mg|
3087159|NCT01978496|Experimental|Eletriptan 40 mg|
3087160|NCT01978496|Experimental|Eletriptan 80 mg|
3087161|NCT01978483|Other|DPCP alone (Cohort 1)|Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
3087162|NCT01978483|Experimental|UVB and denosumab group (Cohort 2)|Denosumab 60mg subcutaneous injection once. Broadband UVB exposure once. Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
3087163|NCT01978483|Placebo Comparator|UVB and placebo group (Cohort 2)|Normal saline 1mL subcutaneous injection once. Broadband UVB exposure once. Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
3087164|NCT01978470|Experimental|Active|Trigeminal nerve stimulation
3087165|NCT01978457|Experimental|cocaine hydrochloride|cocaine hydrochloride
3087166|NCT01978457|Experimental|propranolol|propranolol
3087167|NCT01978457|Placebo Comparator|placebo|placebo
3087168|NCT01978444|Experimental|laparoscopic D2 lymphadenectomy plus CME|Laparoscopic D2 lymphadenectomy plus CME will be performed for the treatment of patients assigned to this group.
3087169|NCT01978444|Active Comparator|laparoscopic D2 lymphadenectomy|Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
3087170|NCT01978431|Experimental|Stimulant|Cocaine and Methylphenidate
3087171|NCT01978431|Placebo Comparator|Placebo|methylphenidate
3087172|NCT01978418|Placebo Comparator|Placebo|Placebo is administered once, at 30-60 minutes of age
3087173|NCT01978418|Active Comparator|Intervention|Salbutamol 0,4 mg inhalation, given once at 30-60 minutes of age
3087174|NCT01978405|Experimental|alpha-lipoic acid group|Alpha lipoic acid 600 mg in 0.9% sodium chloride 250 ml was given before and after contrast agent was administrated.
3087175|NCT01978405|Placebo Comparator|Placebo intervention group|Only 0.9% sodium chloride 250 ml was given for this group.
3087176|NCT01978392|Experimental|Self-management group workshops|Self-management group workshops: Participants randomized to the intervention arm will be asked to participate in group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months.
3087177|NCT01978392|No Intervention|No treament (wait-list control)|Wait-list control: Participants randomized to the control arm will receive no intervention during the one-year period of data collection, but they will be invited to attend a full-day Saturday workshop after all study data collection is complete). The intent of the full-day workshop will be to provide the same self-management information as in the intervention arm, but on a delayed basis and in a more condensed format.
3087178|NCT01978366|Experimental|Cohort 1: HT-100 tablet, Dose 1|• Multiple dose administration: Dose 1
3087179|NCT01978366|Experimental|Cohort 2: HT-100 tablet, Dose 2|• Multiple dose administration: Dose 2
3087180|NCT01978366|Experimental|Cohort 3: HT-100 tablet, Dose 3|• Multiple dose administration: Dose 3
3087181|NCT01978366|Experimental|Cohort 4: HT-100 tablet, Dose 4|• Multiple dose administration: Dose 4
3087182|NCT01978366|Experimental|Cohort 5: HT-100 tablet, Dose 5|• Multiple dose administration: Dose 5
3087183|NCT01978353|Experimental|Memory Training|Participants receive memory training to facilitate learning and memory of face-name associations
3087184|NCT01978353|Active Comparator|Psychoeducation|Participants receive information about memory functioning and aging
3087185|NCT01978340||sleeplab|Sleep Lab examined, usualy with some obesity or sleeping disorders.
3087186|NCT01978327|Experimental|GSK2647544|The planned repeat doses of GSK2647544 are 80 mg bid, 200 mg bid, and 350 mg bid
3087187|NCT01978327|Placebo Comparator|Placebo|Matching placebo
3087188|NCT01978327|Experimental|simvastatin|for drug-drug interaction
3087189|NCT01978327|Experimental|simvastatin co-dosed with GSK2647544|for drug-drug interaction
3087190|NCT01978314|Experimental|Cohort 1|eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
3087191|NCT01978314|Experimental|Cohort 2|eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
3087192|NCT01978314|Experimental|Cohort 3|eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
3087193|NCT01978314|Experimental|Cohort 4|a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol
3087194|NCT01978314|Experimental|Cohort 5|eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
3087195|NCT01978301|Active Comparator|Triamcinolone acetonide|Subjects will receive three intra-lesional injections of triamcinolone acetonide in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence
3087196|NCT01978301|Placebo Comparator|Placebo|Subjects will receive three intra-lesional injections of placebo in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence.
3087197|NCT01978301|No Intervention|No treatment|Keloid(s) assigned 'No Treatment' will not receive any treatment.
3087198|NCT01978288||Cohort 1 Newborns with asthmatic mothers|Infants born to mothers who have diagnosis of Asthma that were enrolled in study from 5/7/14 to 6/1/16.
3087199|NCT01978288||Cohort 2 Newborns with asthmatic mothers|Infants born to mothers who have a diagnosis of Asthma with enrollment from June 2, 2016 going forward.
3087200|NCT01978288||Cohort 3 Newborns with healthy parents|Infants born to healthy parents without atopy (asthma, eczema, seasonal allergies) from June 2, 2016 going forward.
3087201|NCT01978275|Experimental|stimulating catheters group|Lumbar plexus block performed through stimulating catheter
3087202|NCT01978275|Active Comparator|nonstimulating catheters|lumbar plexus block through nonstimulating catheters
3087203|NCT01978262|Other|healthy woman|All women are to receive the quadrivalent influenza vaccine
3087204|NCT01978249|Experimental|Chemotherapy first without primary tumor resection|Patients will receive chemotherapy first without primary tumor resection.
3087205|NCT01978249|Active Comparator|Primary tumor resection followed by chemotherapy|Patients will receive primary tumor resection followed by chemotherapy.
3087206|NCT01978236|Experimental|Cohort A|The first cohort of 15 subjects will receive oral dabrafenib 150 mg twice daily orally for 7 to 14 days prior to surgery in Cohort A; Subjects will be treated for at least 7 days prior to craniotomy, but not more than 14 days. Subjects in either cohort with intracranial and/or extracranial metastases remaining after surgery may resume treatment with the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily no earlier than 72 hours after surgery
3087207|NCT01978236|Experimental|Cohort B|The second cohort of 15 subjects will receive dabrafenib 150 mg twice daily combined with trametinib 2 mg once daily (Cohort B) orally for 7 to 14 days prior to surgery; Subjects will be treated for at least 7 days prior to craniotomy, but not more than 14 days. Subjects in either cohort with intracranial and/or extracranial metastases remaining after surgery may resume treatment with the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily no earlier than 72 hours after surgery
3087208|NCT01978223||Cases|Children hospitalised for SGE, aged 12 weeks to < 5 years at the time of hospital admission/ED stay and whose stool samples test positive for RV by enzyme linked immunosorbent assay (ELISA) at a GSK designated laboratory.
3087209|NCT01978223||Controls|Children hospitalised for SGE, aged 12 weeks to < 5 years at the time of hospital admission/ ED stay, whose stool samples test negative for RV by enzyme linked immunosorbent assay at a GSK designated laboratory and who will be matched to the cases by date of birth and the hospital of admission/ ED stay.
3087210|NCT01978210|Experimental|Wireless Moisture Pager|Parent(s) of subjects will participate in training and follow-up sessions in a manualized toilet training intervention for their child that incorporates use of a wireless moisture pager.
3087241|NCT01978015|Experimental|latanoprost and timolol maleate fixed combination|Latanoprost 0.005% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
3087572|NCT01975675|Experimental|LDV/SOF+RBV (treatment naive)|Treatment-naive participants will receive LDV/SOF plus RBV for 12 weeks.
3087211|NCT01978210|Active Comparator|Standard Behavioral Treatment|Parent(s) of subjects will participate in training and follow-up sessions in a toilet training intervention for their child that incorporates use of the Autism Treatment Network's Toilet Training Tool Kit. The Tool Kit is a publication widely available to parents and clinicians that is designed to serve as an aid in the toilet training of children with autism. In this study, it is being used as a standard treatment control.
3087212|NCT01978184|Experimental|gemcitabine and abraxane|Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
3087213|NCT01978184|Experimental|gemcitabine, abraxane and hydroxychloroquine|"Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.~Hydroxychloroquine is an oral drug (capsule) that subjects will take once or twice a day at home. The dose of hydroxychlorquien will be 1200mg. This is an experimental drug. Subjects will take their first dose of hydroxychloroquine on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and will continue to take it every day until the day before surgery."
3087214|NCT01978171||breast cancer patients|Postmenopausal women with estrogen receptor (ER) positive advanced breast cancer whose disease is refractory to non steroidal aromatase inhibitors, and are eligible for treatment with exemestane and everolimus.
3087215|NCT01978158|Experimental|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
3087216|NCT01978158|Experimental|Hyperoxia|Subjects will be breathing 100% of oxygen
3087217|NCT01978158|Active Comparator|Normoxia|Subjects wil be breathing room air (21%)
3087218|NCT01978145|Experimental|Regimen A|Placebo administered BID by multi-dose inhaler followed by FSC (250/50 mcg) administered BID by capsule-based inhaler.
3087219|NCT01978145|Experimental|Regimen B|FSC (250/50 mcg) administered BID by multi-dose inhaler followed by placebo administered BID by capsule-based inhaler.
3087220|NCT01978132|Active Comparator|Primary hyperaldosteronism|"patients with primary hyperaldosteronism will be subjected to the intervention forearm ischemia and reperfusion (20 minutes of forearm ischemia and 20 minutes of reperfusion).~Primary endpoint is the reduction in brachial FMD by forearm ischemia-reperfusion, as a measure of endothelial ischemia-reperfusion injury"
3087221|NCT01978132|Placebo Comparator|Primary hypertension|"Patients with primary hypertension (PHA excluded)will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.~Primary endpoint is the reduction in brachial FMD by forearm ischemia-reperfusion, as a measure of endothelial ischemia-reperfusion injury"
3087222|NCT01978119|Experimental|Sequence 1|Subjects in this Arm will receive Regimen A followed by Regimen B. Regimen A: Placebo administered BID by Multi-Dose Inhaler followed by FSC (250/50 mcg) administered BID by Capsule-Based Inhaler. Regimen B: FSC (250/50 mcg) administered BID by Multi-Dose Inhaler followed by Placebo administered BID by Capsule-Based Inhaler
3087223|NCT01978119|Experimental|Sequence 2|Subjects in this Arm will receive Regimen B followed by Regimen A. Regimen B: FSC (250/50 mcg) administered BID by Multi-Dose Inhaler followed by Placebo administered BID by Capsule-Based Inhaler. Regimen A: Placebo administered BID by Multi-Dose Inhaler followed by FSC (250/50 mcg) administered BID by Capsule-Based Inhaler
3087224|NCT01978106||a WTR corneal astigmatism group|Corneal astigmatism was defined as WTR when the steep corneal cylinder axis was within 30 degrees of the horizontal axis.
3087225|NCT01978106||an ATR corneal astigmatism group|Corneal astigmatism was defined as ATR when the cylinder axis was within 30 degrees of the vertical axis.
3087226|NCT01978093|Experimental|HibCY Group|Subjects received 4 doses of Hib-MenCY-TT (MenHibrix®) vaccine at Day 0, Month 2, Month 4 and Month 10-13 , 3 doses of Pediarix® vaccine at Day 0, Month 2 and Month 4, 2 doses of Rotarix® vaccine at Day 0 and Month 2, 4 doses of Prevnar 13® vaccine at Day 0 and Month 2, Month 4 and Month 10-13 and 2 doses of Havrix® vaccine at Month 10-13 and Month 16-19.
3087227|NCT01978093|Active Comparator|PedHIB Group|Subjects received 3 doses of PedvaxHIB® vaccine at Day 0, Month 2 and Month 10-13, 3 doses of Pediarix® vaccine at Day 0, Month 2 and Month 4, 2 doses of Rotarix® vaccine at Day 0 and Month 2, 4 doses of Prevnar 13® vaccine at Day 0 and Month 2, Month 4 and Month 10-13 and 2 doses of Havrix® vaccine at Month 10-13 and Month 16-19.
3087228|NCT01978080|Experimental|Tremor reports provided|Kinesia HomeView utilized to monitor tremor at home and reports provided to treating clinician
3087229|NCT01978080|Active Comparator|Tremor reports not provided|Kinesia HomeView utilized to monitor tremor at home and reports not provided to treating clinician
3087230|NCT01978067||transvaginal resection of Uterine Scar|transvaginal resection of Uterine Scar From Previous Cesarean Delivery
3087231|NCT01978054|Experimental|Dissemination|Dissemination of public health knowledge: Participating states will help develop and choose 3-5 dissemination strategies they prefer for their state health department chronic disease units to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, and information on ways to enhance organizational climates favorable to evidence-based chronic disease prevention.
3087232|NCT01978054|No Intervention|Comparison|Comparison state health department chronic disease units will be provided links to preexisting sources of public health evidence-based information such as the Community Guide, Cancer Control P.L.A.N.E.T. (Plan, Link, Act, Network, with Evidence-based Tools), and NCI Research to Reality.
3087233|NCT01978041|Experimental|Meal prepared with non fluoridated water (<0.1 ppm F)|
3087234|NCT01978041|Experimental|Meal prepared with fluoridated water (1 ppm F)|
3087235|NCT01978041|Experimental|Non fluoridated water (<0.1 ppm F)|
3087236|NCT01978041|Experimental|Fluoridated water (1 ppm F)|
3087237|NCT01978041|Experimental|Pilot study: Meal providing a fluoride dose of 60 ug F/kg|
3087238|NCT01978041|Experimental|Pilot study: Meal providing a fluoride dose of 120 ug F/kg|
3087242|NCT01978015|Experimental|bimatoprost and timolol maleate fixed combination|bimatoprost 0.03% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
3087243|NCT01978015|Placebo Comparator|dextran and hypromellose|A control group of patients with POAG and pseudophakic after trabeculectomy without medication. These patients received a lubricant drop twice daily at 8 a.m. and 8 p.m. for 6 months
3087244|NCT01978015|Experimental|travoprost and timolol maleate fixed combination|Travoprost 0.004% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
3087245|NCT01978002||Group 1 (Clinic Patients)|Women who have documented urinary status from surveys completed.
3087246|NCT01978002||Group 2 (Community Sample)|Women who have a clinical diagnosis of IC/BPS or OAB, and who have undergone urodynamic testing within the preceding 6 months as part of their routine clinical care.
3087247|NCT01977989|No Intervention|No Vancomycin Powder|Patients who only receive IV Vancomycion prior to surgery. No Vancomycin powder is administered.
3087248|NCT01977989|Active Comparator|Vancomycin Powder|Patients who receive Vancomycin powder in the surgical site following surgery.
3087249|NCT01977976|Experimental|Endometrial Aspirate (EA) group|Endometrial aspirate by pipelle
3087250|NCT01977976|No Intervention|Control group|No intervention prior to scheduled IVF
3087251|NCT01977963||Agranulocytosis|
3087252|NCT01977937|Experimental|Gabapentin|Gabapentin 15 milligrams per kilogram will be given orally one time pre-operatively. Gabapentin will be continued at a dose of 10 milligrams per kilogram every eight hours orally starting as soon as the patient is admitted to his or her floor bed in the hospital.
3087253|NCT01977937|Placebo Comparator|Simple Syrup|Simple syrup compounded by the Oregon Health and Science University research pharmacy will be administered in the same volume as if the patient were receiving the Gabapentin both pre-operatively and every eight hours after the patient is admitted to his or her floor bed in the hospital.
3087254|NCT01977924|Experimental|polyphenols|600 mg polyphenols (grape extract)
3087255|NCT01977924|Placebo Comparator|Placebo|microcrystalline cellulose
3087256|NCT01977911|Experimental|Tissue engineered airway construct|"Stem cell based tissue engineered partial laryngeal implants:~The final experimental product is a highly tested, recellularised, stem cells based tissue engineered product (airway construct) for operative partial laryngeal implantation into patients with severe laryngotracheal stenosis"
3087257|NCT01977898|Experimental|Morphine|Patients randomized to the treatment group (morphine) will receive preservative-free morphine 0.3 mL (150 mcg) intrathecally.
3087258|NCT01977898|Placebo Comparator|Saline|Patients randomized to the control group will receive normal saline 0.3 mL intrathecally.
3087259|NCT01977885|Experimental|High Protien Diet + Exercise|All participants will participate in both interventions (High Protein Diet and Exercise).
3087260|NCT01977872|Experimental|A worksite activity-diet intervention|A 12 month intensive program that includes individual sessions, interactive group sessions and online activities.
3087261|NCT01977872|No Intervention|Motiva Program|The Motiva Program is the internal corporate wellness program offered to all BCBSIL employees.
3087262|NCT01977859|Placebo Comparator|Saline|Saline infusion
3087263|NCT01977859|Active Comparator|Nesiritide 1.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 1.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
3087264|NCT01977859|Active Comparator|Nesiritide 2.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 2.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
3087265|NCT01977859|Active Comparator|Nesiritide 4.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 4.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
3087266|NCT01977859|Active Comparator|Nesiritide 8.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 8.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
3087267|NCT01977833|Experimental|High Calorie Breakfast (BTdiet)|High Calorie Breakfast (BTdiet): The subject will consume High caloric breakfast, average lunch and reduced in calories dinner (BTdiet)
3087268|NCT01977833|Active Comparator|High Calorie Dinner (DTdiet)|High Calorie Dinner (DTdiet): The subject will consume High caloric dinner, average lunch and reduced in calories breakfast (DTdiet)
3087269|NCT01977820|Experimental|Sapropterin|
3087270|NCT01977820|Placebo Comparator|Placebo|
3087271|NCT01977807|Experimental|Myopia|Myopia Lasik treatment of virgin eyes.
3087272|NCT01977807|Experimental|Hyperopia|Hyperopia Lasik treatment of virgin eyes.
3087273|NCT01977794|Experimental|Bisoprolol failed group|Subjects who failed monotherapy with bisoprolol 5 milligram (mg) before trial inclusion will be randomized to bisoprolol failed group to receive Bisoprolol/Amlodipine FDC tablet
3087274|NCT01977794|Experimental|Amlodipine failed group|Subjects who failed monotherapy with amlodipine 5 mg before trial inclusion will be randomized to amlodipine failed group to receive Bisoprolol/Amlodipine FDC tablet.
3087275|NCT01977781|Experimental|Tacrolimus|Topical tacrolimus suspension will be formulated and aseptically prepared from commercially available intravenous tacrolimus, PROGRAF® (Astellas Pharma US, Inc), and transferred into a sterile dropper container by the MEEI pharmacy. A formulation of 0.05% (5mg/10ml) concentration of tacrolimus with diluting solvent, LiquiTears Ophthalmic Solution (Major Pharmaceuticals, Inc.) will be used. Patients will be instructed to keep refrigerated each bottle after opening for 9 days and keep frozen the unopened bottles up to 45 days. They will also be instructed to shake the bottles at least 20 times before using it.
3087306|NCT01977547|Active Comparator|Short storage|Red blood cells storage duration of equal to or less than 7 days.
3087307|NCT01977547|Active Comparator|Standard issue|Red blood cells storage duration of 2 to 42 days with an expected average length of storage of about 17-21 days.
3087308|NCT01977534||Absorb BVS|Subjects receiving Absorb BVS
3087309|NCT01977521|Experimental|Treatment|transcranial direct current stimulation (2mA)
3087310|NCT01977521|Sham Comparator|Sham|Sham stimulation
3087276|NCT01977781|Active Comparator|Methylprednisolone Sodium Succinate|Topical methylprednisolone sodium succinate suspension will be formulated and aseptically prepared from commercially available sterile dry powder vial preservative-free for intravenous use, SOLU-MEDROL® (Pfizer, Inc.). A formulation of 0.5% (5mg/1ml) concentration of methylprednisolone with diluting solvents, LiquiTears Ophthalmic Solution (Major Pharmaceuticals, Inc.) will be used. Patients will be instructed to keep refrigerated each bottle after opening for 9 days and keep frozen the unopened bottles up to 45 days. They will also be instructed to shake the bottles at least 20 times before using it.
3087277|NCT01977768|Experimental|V7: Heat-inactivated M. vaccae pill|Daily pill of V7 together with standard tuberculosis therapy
3087278|NCT01977768|Placebo Comparator|Placebo pill|one pill of placebo pill once per day together with standard of care TB drugs
3087279|NCT01977755|Active Comparator|danegapetide high dose|7,5 mg bolus injection, followed by 22,5 mg infused over 6 hours
3087280|NCT01977755|Active Comparator|danegaptide low dose|2,5 mg bolus injection, followed by 7,5 mg infused over 6 hours
3087281|NCT01977755|Placebo Comparator|Placebo|bolus injection, followed by infused over 6 hours
3087282|NCT01977742|Active Comparator|Initiate with SEP but without RTTE|Initiate supervised exercise (SEP) program but without rest-exercise transition training (RTTE)to improve cardiac vagal tone at same time; will stop RTTE after 8 weeks.
3087283|NCT01977742|Active Comparator|Initiate with RETT and SEP|"Supervised exercise program (aerobic, strength and flexibility exercises) and a specific sudden rest-exercise training protocol, three times a week. After 8 weeks, the sudden rest-exercise training protocol will be discontinued.~The cardiac vagal index will be measured at every 8 weeks."
3087284|NCT01977729|Experimental|CBT with SRT|CBT (Cognitive Behavioral Therapy)+SRT (Sertraline) will be scheduled at weeks 9-12, 14, 16, 18, 20 with telephone visits at weeks 15, 17, and 19. The same therapist as in Phase I will deliver CBT in Phase II, which will occur in conjunction with the psychiatrist visits. Phase II CBT will emphasize continued therapist prescribed in-session and out-of-session exposure tasks (developed with patient) and continued patient cognitive-affective processing of exposure sessions with therapist, with no instruction on new skills or therapeutic strategies. Therapists will be encouraged to discuss clinical status with patients, psychiatrists, and PIs to allow for treatment integration (e.g., psychiatrist could increase the dose of SRT, or not, depending on whether the patient Is making sufficient progress in CBT).
3087285|NCT01977729|Experimental|Switch to SRT alone|Sertraline is a selective serotonin reuptake inhibitor. Sertraline is FDA approved for the treatment of major depressive disorder, obsessive compulsive disorder, posttraumatic stress disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder in adults. Sertraline is also approved for the treatment of obsessive compulsive disorder in children and adolescents. Pharmacotherapy visits will be scheduled at weeks 9-12, 14, 16, 18, 20 with phone visits at weeks 15, 17, and 19. The psychiatrist will meet for ~30 min. with the youth and parents. Efforts will be made to use the most effective and tolerated SRT dose.
3087286|NCT01977716||Incident peritoneal dialysis patients|Patients with chronic kidney disease incident to peritoneal dialysis treatment
3087287|NCT01977703|Active Comparator|Traditional ICD Programming|ICD will be set to pre-LVAD settings post LVAD implant.
3087288|NCT01977703|Experimental|Ultra Conservative ICD Programming|ICD will be set to ultra conservative settings post LVAD implant.
3087289|NCT01977690|No Intervention|Standard Management|Patients wore no brace.
3087290|NCT01977690|Experimental|Clavicle Brace Wearing|Patient has to wear clavicle brace for one month.
3087291|NCT01977677|Experimental|Treatment (radiation therapy, temozolomide, plerixafor)|Within 4 weeks of surgery, patients undergo radiation therapy and receive temozolomide PO over 42 days. Beginning 8 days prior to completion of chemoradiotherapy, patients receive plerixafor IV continuously for 2-4 weeks. Patients also receive temozolomide PO 5 days a month beginning 35 days after completion of radiation therapy.
3087292|NCT01977664||oocyte maturation failure|no intervention
3087293|NCT01977651|Experimental|enzalutamide|Subjects will receive one daily dosing of enzalutamide
3087294|NCT01977638|Experimental|CXD101|Dose escalation study of CXD101 administered orally twice daily for 5 consecutive days in every 21 day cycle. Starting dose 1mg twice daily (2mg/day).
3087295|NCT01977625|Active Comparator|Lisdexamfetamine|Lisdexamfetamine or Vyvanse
3087296|NCT01977625|Placebo Comparator|Sugar Pill|Placebo pill, capsules
3087297|NCT01977612|Active Comparator|Stainless Steel Staples|Skin closure with stainless steel staples
3087298|NCT01977612|Experimental|4-0 monofilament Sutures|Skin closure with 4-0 monofilament sutures
3087299|NCT01977599|No Intervention|No Text Message Reminder (Control) Arm|Control Arm, in which patients are invited to breast screening as per standard West of London Breast Screening Protocol (i.e. without a text message appointment reminder). Uptake of breast screening in this group will be compared with the text message reminder group to test for significant differences.
3087300|NCT01977599|Experimental|Text Message Reminder Arm|Patients randomly allocated to this arm of the study will be sent a text message reminding them of the time, date and venue of their breast screening appointment 48 hours in advance.
3087301|NCT01977586|Experimental|Metastatic renal cell carcinoma|Patients with clear cell renal cell carcinoma treated with anti-angiogenic therapies
3087302|NCT01977573|Experimental|GSK1278863|Subjects will be administered GSK1278863 QD. Starting dose will be based on data from previous studies with GSK1278863 and dose-response modelling, as well as Baseline Hgb concentration. After 4 Week of fixed dose period, dose may be adjusted to achieve Hgb 9.0 to 10.5 g/dL
3087303|NCT01977573|Other|Control|All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered.
3087304|NCT01977560|Other|Standard Care|This arm will receive standard care for Type 2 diabetes: exercise and diet counseling according to the American Diabetes Association recommendations.
3087305|NCT01977560|Experimental|Optimum Lifestyle intervention|This arm will be participate in weekly visits with a dietitian and 4 weekly supervised exercise sessions. They will be advised to follow a high-protein, low-carbohydrate diet.
3087311|NCT01977508||haemodialysis vascular access using ePTFE grafts|
3087312|NCT01977495|Active Comparator|Opt-in Enrollment|Opt-in enrollment: patient will be sent a recruitment letter, in which they must call the study team to take part in the study. During that call, the study team will schedule the participant for an intake visit.
3087313|NCT01977495|Active Comparator|Opt-out enrollment|Opt-out enrollment: patient will be sent a letter communicating to them that they have been enrolled into a research program at their doctor's office. After 10 days, the study team will contact the opt-out participants to schedule an intake visit.
3087314|NCT01977482|Experimental|GSK1278863 4 mg|Subjects will take GSK1278863 4 mg blinded once daily (OD) orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
3087315|NCT01977482|Experimental|GSK1278863 6 mg|Subjects will take GSK1278863 6 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
3087316|NCT01977482|Experimental|GSK1278863 8 mg|Subjects will take GSK1278863 8 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
3087317|NCT01977482|Experimental|GSK1278863 10 mg|Subjects will take GSK1278863 10 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
3087318|NCT01977482|Experimental|GSK1278863 12 mg|Subjects will take GSK1278863 12 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
3087319|NCT01977482|Active Comparator|Control|Subjects will take GSK1278863 matching placebo blinded OD orally for 4 weeks with a glass of water. From Week 4, rhEPO will be administered and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
3087320|NCT01977469|Experimental|Low strength training + aerobic training|The group LI-RT will be perform the aerobic training on a cycle ergometer with the intensity between 70-80 % of the maximum load achieved in ICPT, after this, they will begin resistance training for arms with 30% of 1RM with an increase of 5% of 1RM every 3 weeks, ending with 50% of 1 RM. The training for lower limbs will start with 30% of 1RM with increment of 7% every 2 weeks, reaching a maximum of 58% of 1RM. Will be performed 3 sets with 15 replicates each, with an interval of two minutes between them
3087321|NCT01977469|Experimental|High strength training + aerobic training|The group HI-RT will be perform the aerobic training on a cycle ergometer with the intensity between 70-80 % of the maximum load achieved in ICPT, after this, they will begin resistance training for arms with 60% of 1RM with increment of 5% of 1RM every 3 weeks, reaching 80% of 1RM. In exercise of the lower limbs, the initial charge will be 60% of 1RM with increment of 7% every 3 weeks, totaling 88% of 1RM after 8 weeks. These patients will perform 3 sets with 8 repetition each, remaining 2 minutes of rest between each set.
3087322|NCT01977456|Experimental|Eptifibatide|All subjects will receive the standard dose of IV rt-PA. All subjects will promptly receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours.
3087323|NCT01977443|Active Comparator|APD-209 Eye drops|APD-209 Eye drops
3087324|NCT01977443|Placebo Comparator|APD-209 Placebo Eye drops|APD-209 Placebo Eye drops
3087325|NCT01977430|Experimental|Diuretics arm|The diuretic arm's patients will receive combined thiazide-furosemide therapy for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
3087326|NCT01977430|No Intervention|Control Arm|
3087327|NCT01977417|Experimental|Salsalate|3.0 grams/day salsalate (1.5 g twice per day)
3087328|NCT01977417|Placebo Comparator|Placebo|Placebo capsule twice per day
3087329|NCT01977378|Experimental|Sustained-Release Desvenlafaxine Hydrochloride|50-100mg/d
3087330|NCT01977378|Active Comparator|Sustained-Release Venlafaxine Hydrochloride|75-225mg/d
3087331|NCT01977365|Experimental|Growth promotion based on child centered approach|
3087332|NCT01977365|No Intervention|Control|
3087333|NCT01977352|Active Comparator|Bupivacaine 0.25%|20 cc of bupivacaine 0.25%
3087334|NCT01977352|Experimental|Liposomal bupivacaine|liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
3087335|NCT01977339|Experimental|Liposome Bupivacaine|Single injection femoral nerve block of 10 cc of 266 mg liposome bupivacaine with 10 cc of normal saline
3087336|NCT01977339|Active Comparator|Bupivacaine|Single shot femoral nerve block with 20cc of 0.25% bupivacaine
3087337|NCT01977326|Experimental|counseling intervention|Each woman recruited into the intervention arm will undergo 6 sessions of basic counselling by lay-health workers
3087338|NCT01977326|Active Comparator|Enhanced usual care|usual antenatal care with additional 3 - 4 monthly phone calls.
3087339|NCT01977313||All study participants|All study participants
3087340|NCT01977300|Placebo Comparator|Mood stabilizer & Placebo|Patients will receive lithium or valproate plus placebo for 52 weeks (risperidone or olanzapine tapering will begin on the day of randomization with discontinuation of the drug within 2 weeks).
3087341|NCT01977300|Experimental|"'24 week  arm"|Continuation of the lithium or valproate plus risperidone or olanzapine for 24 weeks followed by mood stabilizer plus placebo for another 28 weeks. Dosages: 1 to 6 mg of risperidone, 5 to 20 mg olanzapine.
3087342|NCT01977300|Active Comparator|"52 week arm"|Continuation of the atypical antipsychotic, risperidone or olanzapine, plus lithium or valproate for 52 weeks.
3087343|NCT01977287||Functional Electrical Stimulation|The Functional Electrical Stimulation (FES) group will be asked to use their clinically prescribed FES unit (either ODFS III or Pace) to the dorsiflexors to treat foot drop for a period of 12 weeks.
3087344|NCT01977287||Ankle Foot Orthosis|The people in the Ankle Foot Orthosis group (AFO) will be asked to use their clinically prescribed AFO to treat drop foot for a period of 12 weeks.
3087345|NCT01977274|Experimental|gynecological cancer|blood and tumor samples
3087346|NCT01977261|Experimental|Opening-wedge HTO|Opening-wedge high tibial osteotomy fixated with a Puddu-plate
3087347|NCT01977261|Active Comparator|Closing-wedge HTO|Closing-wedge high tibial osteotomy fixated with 2 staples
3087570|NCT01975688|Experimental|Sativex: severe mucositis (Grade 3)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 3 (severe).
3087348|NCT01977248|Experimental|SMART therapy|The Sensorimotor Affect Relationship-based Therapy (SMART) program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
3087349|NCT01977235|Experimental|Arm A|Irinotecan 90mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.
3087350|NCT01977235|Active Comparator|Arm B|Irinotecan 65mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.
3087351|NCT01977222|Experimental|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|
3087352|NCT01977209|Experimental|Arm A|Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Gossypol 20mg from day 1 to day 14. repeat Q 3weeks. Four cycles.
3087353|NCT01977209|Placebo Comparator|Arm B|Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Placebo from day 1 to day 14. repeat Q 3weeks. Four cycles.
3087354|NCT01977196|Experimental|DTP/HepatitisB/Hib vaccine|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
3087355|NCT01977183|Experimental|Elderly adults with MSPrebiotic|30 g of MSPrebiotic (potato resistant starch) per day taken with 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi-solid food. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
3087356|NCT01977183|Placebo Comparator|Elderly adults with Placebo|30 g of corn starch per day taken with 1 glass (approximately 250 mL) of non-heated fluid or or non-heated semi-solid food. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
3087357|NCT01977183|Experimental|General adult population with MSPrebiotic|30 g of MSPrebiotic (potato resistant starch) per day taken with 1 glass (approximately 250 mL) of non-heated fluid. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
3087358|NCT01977183|Placebo Comparator|General adult population with Placebo|30 g of corn starch per day taken with 1 glass (approximately 250 mL) of non-heated fluid. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
3087359|NCT01977170|Experimental|Hib/PRP-T vaccine|"One dose, correspond to 0.5 ml, composed of:~PRP-T 10ug NaCl 0.85%~Frequency: 1 injection"
3087360|NCT01977157||bioimpedance measurements while trinking alcohol|Bioimpedance spectroscopy (BIS) measurements on 12 healthy subjects were performed while they were drinking alkohol until reaching a BAC of 0.8 ‰.
3087361|NCT01977144|Other|Embryo Transfer with CCS|Patients will have either a single or double embryo transfer with CCS tested embryos
3087362|NCT01977144|No Intervention|Embryo Transfer without CCS|Patients in this group will not have CCS performed on their embryo(s)
3087363|NCT01977131|Experimental|stromal cells modified HGF|
3087364|NCT01977118|Experimental|Group B [streptokinase]|50000U of injection streptokinase dissolved in 100ml of normal saline instilled in to the pancreatic and/or peripancreatic collections via the percutaneous catheters and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of normal saline. This procedure will be done thrice daily for five days
3087365|NCT01977118|Placebo Comparator|Group A [placebo]|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
3087366|NCT01977105|Experimental|Pilot Intervention Group|Mothers who are screened and determined to be eligible for this single-group pilot study will be enrolled along with their infants in the Grow Together peer group intervention.
3087367|NCT01977092|Experimental|Motivational interviewing case management|MICM intervention combines aspects of motivational interviewing along with case management to influence HIV risk and recovery from alcohol and drug problems. Participants assigned to the MICM condition will be contacted to receive 3 individual sessions within the first 4 weeks of entering the study. Thereafter they will have contact with the MICM therapist monthly throughout the duration of their enrollment in the study (12 months).
3087368|NCT01977092|Other|Resource referrals|Respondents will receive SLH services as usual along with a list of resources that can be used to address a variety of problems.
3087369|NCT01977079|Other|Premature birth|"At the end of the study patients will be divided into two groups: Premature delivery versus No premature delivery. Prematurity is defined as a birth before 37.~In each group, the procalcitonin rate be estimated with a confidence interval of 95% and compared from a logistic regression."
3087370|NCT01977079|Other|Not premature birth|"At the end of the study patients will be divided into two groups: Premature delivery versus No premature delivery. Prematurity is defined as a birth before 37.~In each group, the procalcitonin rate be estimated with a confidence interval of 95% and compared from a logistic regression."
3087371|NCT01977066|Experimental|Six months supervised exercise training|
3087372|NCT01977066|Experimental|Six months home-based exercise training|
3087373|NCT01977066|No Intervention|Control group|
3087374|NCT01977053|No Intervention|A: Standard medical care|Arm A: standard supervision and medical care during an adjuvant chemotherapy treatment in France
3087375|NCT01977053|Experimental|B: telephonic monitoring|Arm B: telephonic monitoring during inter-treatment intervals + personalized medical care.
3087376|NCT01977040||Vasa Previa|Women with the diagnosis of Vasa Previa made during the pregnancy or at time of delivery who delivered between January 1, 2000 and December 31, 2012.
3087408|NCT01976832|Experimental|Music with movement|Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-weeks music with movement (MWM) intervention protocol.
3087409|NCT01976832|Active Comparator|Social interaction|"The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.~The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period."
3087377|NCT01977027|Other|Stroke & age-matched Controls|"Alternate Hand Training or Affected Hand Training:~40 patients with stroke and 40 control subjects will participate over 7 visits. After completion of informed consent, subjects will undergo clinical assessments (Visit 1) which will involve testing for kinesthetic, visual, tactile and motor impairments and upper limb function. Visit 2, subjects will undergo no contrast MRI to identify lesion location. Healthy controls will not be imaged.~Visits 3-7 will involve psychophysical experiments to test adaptation with short-term Alternate Hand Training and Affected Hand Training. During 5 visits the subjects will grasp and lift an instrumented grip device of different weights, textures and shapes while data is being collected via surface electrodes from, upper arm and back muscles."
3087378|NCT01977027|Other|Phase 2 - Stroke ONLY|"Alternate Hand Training or Affected Hand Training:~Subjects will be randomized into two groups one receiving Alternate Hand Training and the other receiving Affected Hand Training. The groups will be matched by age, gender, handedness, side of lesion, extent of motor impairment and lesion location. They will complete 17 Study visits.~Visits 1 and 2 will involve clinical assessments and MRI. Visit 3. Pre-intervention assessments involving grasping and lifting objects of different weights, textures and shapes while fingertip forces, finger and arm movements. Muscle activity and performance is measured.~Visits 4-15. Subjects will participate in 12 training visits for 1 hour a day, twice a week for 6 weeks.~Visits 16-17. Recovery of hand function will be measured by repeating the pre-intervention clinical and grasping assessments (in 2 visits) immediately after 6-weeks of training, and another 6 weeks later."
3087379|NCT01977014||Patient with LenusPro pump|
3087380|NCT01977001||Primary Headache|Treatment with MigraineBoxTM
3087381|NCT01976988|Active Comparator|Post-op Heparin|Postoperative venous thromboprophylaxis (Control Arm/current standard practice: subcutaneous Heparin 5000 units started 23 hours after the end of surgery and continued every 8 hours for the remainder of the patients hospital course
3087382|NCT01976988|Experimental|Pre-op Heparin|Treatment arm: subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
3087383|NCT01976975||Mood disorder patients|Patients with depressive and/or manic or hypomanic symptoms
3087384|NCT01976975||Healthy controls|Participants with no lifetime history of psychiatric illness
3087385|NCT01976962|Experimental|Prostate stereotactic body RT with MR-guided boost|Patients will receive a dose of 36.25 Gy in 5 fractions to the entire prostate and proximal seminal vesicles with an additional boost to the dominant lesion for a total of 40 Gy in 5 fractions.
3087386|NCT01976949|Active Comparator|Social-networking intervention|Individuals interested in participating in the study will be randomized to receive access to a 12-week internet-based treatment group. Subjects assigned to the treatment group will have access to a group discussion board, a structured 12-week coping-skills training course, professional facilitation of the group, a real-time chat board, and personal profiles established by other group members. Subjects will be asked to complete online self-report measures of distress, mood disturbance, and quality of life at baseline and again after participation in the 12-week group.
3087387|NCT01976949|Active Comparator|Control group|12 week wait-list control subjects will be able to join a group after they complete the 12-week assessment and will be asked to complete a 24-week assessment in order to measure change over time. Subjects will have access to a group discussion board, a structured 12-week coping-skills training course, professional facilitation of the group, a real-time chat board, and personal profiles established by other group members. Subjects will be asked to complete online self-report measures of distress, mood disturbance, and quality of life at baseline and again after participation in the 12-week group.
3087388|NCT01976936|Experimental|High Dose Lovastatin|High dose lovastatin (640 mg daily for three days) will be administered orally
3087389|NCT01976936|Active Comparator|Low Dose Lovastatin|Lovastatin 80 mg daily for three days will be administered orally to patients who were taking statin therapy at the time of enrolment
3087390|NCT01976936|Placebo Comparator|Placebo|Placebo will be administered orally to patients who were NOT taking statin therapy at the time of enrolment
3087391|NCT01976923|Active Comparator|Study arm|Intravitreal bevacizumab Small-gauge pars plana vitrectomy
3087392|NCT01976923|Sham Comparator|Control arm|Small-gauge pars plana vitrectomy
3087393|NCT01976910|Experimental|4-DM-CHOC-PEN|"DM-CHOC-PEN is an intervention and will be dosed @ 39 mg/M2,escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
3087394|NCT01976897||The study population|"Only one group is included. See inclusion/exclusion criteria.~Intervention: Knee flexion measurement 1~Intervention: Knee flexion measurement 2~Intervention: Heel - interface pressure measurements"
3087395|NCT01976884||Severe sepsis|Patients with severe sepsis
3087396|NCT01976884||Infectious kidney stone|Patients with sepsis after PCNL for infectious kidney stone
3087397|NCT01976884||Tumor|Patients with pancreatic cancer
3087398|NCT01976884||Volunteer|
3087399|NCT01976871|Experimental|Oral Dopamine Agonist to Rotigotine|During the study, we will switch patients who are not satisfied with their current oral dopamine agonist to rotigotine. Cross-titration will allow determination of the lowest effective dose of rotigotine. We will use as initial guidance the equivalence determined from the Parkinson's Disease trials, in which 1 mg rotigotine was shown to be approximately equivalent to 1-1.5 mg ropinirole or 0.25 -0.375 mg pramipexole. Tolerability, adverse events, and RLS symptom control will be evaluated. These data will provide clinicians with practical guidance to optimize RLS treatment while minimizing adverse events.
3087400|NCT01976858|Experimental|PEX168 50 microgram|PEX168 50 microgram qw sc. and the medication continued for 8 weeks
3087401|NCT01976858|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 8 weeks
3087402|NCT01976858|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication continued for 8 weeks
3087403|NCT01976858|Experimental|PEX168 300 microgram|PEX168 300 microgram qw sc. and the medication continued for 8 weeks
3087404|NCT01976858|Placebo Comparator|Placebo|Placebo qw sc. and the medication continued for 12 weeks
3087405|NCT01976845|Experimental|Propofol|Propofol 20 mg IV (2 ml)
3087406|NCT01976845|Active Comparator|Midazolam|Midazolam 2 mg IV (2 ml)
3087407|NCT01976845|Placebo Comparator|Saline|Saline 2 ml
3108809|NCT01831466|Experimental|Treatment Group E|
3087411|NCT01976806|Experimental|Aspirin & Docosahexaenoic acid|Aspirin 81 mg 1 tablet by mouth daily and Docosahexanoic acid (DHA) 500 mg 4 capsules by mouth daily (total daily dose of 2 grams DHA) for 3 months
3087412|NCT01976806|Active Comparator|Aspirin & Placebo|Aspirin 81 mg by mouth daily and placebo (50% corn oil/50% soybean oil) 4 capsules by mouth daily for 3 months
3087413|NCT01976793||patients with major depression|Inpatients and outpatients diagnosed with an episode of major depression relating to RDD (ICD-10, Version 2010) during the period from January 1, 2012 till September 30, 2013. Initially treated with antidepressant monotherapy, using a flexible dosage regimen if required, for at least 2 week
3087414|NCT01976780|Active Comparator|AS/MQ|Treatment of P.falciparum mono-infection with 4 mg/kg of Artesunate daily for three days followed by 25mg/kg of Mefloquine split over two days.
3087415|NCT01976780|Active Comparator|AL|Treatment of P. falciparum mono-infection with Artemether Lumefantrine administered at the standard dosage according to pre-defined weight bands (5-14 kg: 1 tablet; 15-24 kg: 2 tablets; 25-34 kg: 3 tablets; and > 34 kg: 4 tablets) given twice a day for 3 days.
3087416|NCT01976767||Cohort A|Adults: severe asthmatics on high dose ICS and / or OCS
3087417|NCT01976767||Cohort B|Adults: current smokers or ex-smokers, severe asthmatics on high dose ICS and / or OCS
3087418|NCT01976767||Cohort C|Adults: non-smokers, mild to moderate asthmatics on regular inhaled corticosteroids (ICS)
3087419|NCT01976767||Cohort D|Adults: healthy volunteers, non-smokers, non-asthmatic with pre bronchodilator FEV1 > 80% predicted
3087420|NCT01976754|Other|dexmedetomidine,sepsis,ED50|Intervention Name: dexmedetomidine dosage form: intravenous injection dosage：0.2-0.7μg/kg/h frequency: 1 duration:12 hours
3087421|NCT01976741|Experimental|Rogaratinib (BAY1163877)|
3087422|NCT01976728|Experimental|LutrePulse 10µg/pulse|Gonadorelin acetate 10µg/pulse
3087423|NCT01976728|Experimental|LutrePulse 15µg/pulse|Gonadorelin acetate 15µg/pulse
3087424|NCT01976728|Experimental|LutrePulse 20µg/pulse|Gonadorelin acetate 20µg/pulse
3087425|NCT01976728|Placebo Comparator|Placebo|Placebo
3087426|NCT01976702|Experimental|Enhanced Behavioral Skills Training|The Enhanced Behavioral Skills Training (E-BST) will include four 90-minute group sessions and two 60-minute individual sessions regarding HIV prevention and diminishing risk behavior, enhancing communication skills, improving the use of support services, and enhancing the use of resources in their community.
3087427|NCT01976702|Active Comparator|Health Promotion Comparison|The Health Promotion Comparison (HPC)condition will receive one video-based HIV prevention session, 3 video-based 90-minute group sessions and an additional 2 60-minute sessions with discussions on relevant topics unrelated to HIV.
3087428|NCT01976689||Patients with New-onset Diabetes|New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.
3087429|NCT01976689||Patients without NODAT|New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.
3087430|NCT01976676|Experimental|5-methyltetrahydrofolate|1 mg 5-methyltetrahydrofolate per day
3087431|NCT01976676|Active Comparator|folic acid|1 mg Folic acid per day
3087432|NCT01976663|Experimental|VOLIFT® XC NLFs|Nasolabial folds treated with JUVEDERM VOLIFT® XC.
3087433|NCT01976663|Active Comparator|Control NLFs|Nasolabial folds treated with Control.
3087434|NCT01976650||OZURDEX®|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
3087435|NCT01976637|Experimental|no compression|no compression stockings worn during a 3 weeks period
3087436|NCT01976637|Active Comparator|compression stockings|compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
3087437|NCT01976624||Ganfort®|Patients who received treatment with bimatoprost/timolol (Ganfort®) for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
3087438|NCT01976611||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for chronic migraine as per local standard of care in clinical practice.
3087439|NCT01976598||Spinal Cord Stimulation: Sub-Sensory|Patients implanted with a Boston Scientific Spinal Cord Stimulation System for the treatment of chronic back and/or leg pain using Sub-Sensory Stimulation.
3087440|NCT01976585|Experimental|rhuFlt3L/CDX-301|intratumoral injections on days 1-5 and 8-11. and Poly-ICLC intratumoral injection weekly, weeks 2-8
3087441|NCT01976572|Placebo Comparator|Candesartan alone|Single dose of 16 mg candesartan was administered orally on Day 1.
3087442|NCT01976572|Active Comparator|T0hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T-0 of 3 dosing time-points means the single dose of candesartan was administered at the same time relative to the first daily dose of colestilan.
3087443|NCT01976572|Active Comparator|T-1hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T-1 of 3 dosing time-points means the single dose of candesartan was administered at 1 hour before relative to the first daily dose of colestilan.
3087444|NCT01976572|Active Comparator|T+3hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T+3 of 3 dosing time-points means the single dose of candesartan was administered at 3 hour after relative to the first daily dose of colestilan.
3087445|NCT01976559|Experimental|Hydrocephalus / Shunt Malfunction|Patients between the ages of 18-80 years with suspected hydrocephalus, shunt malfunction, or disorders of CSF circulation who are recommended by their doctor based on standard clinical criteria to undergo CSF infusion testing. The interventions include tympanic membrane displacement (TMD) and DPOAE.
3087446|NCT01976546||airway|Patients with one or more predictors of diffucult airway
3087447|NCT01976533||Advanced therapy, Heart-lung transplantation, dead|
3087448|NCT01976520|Experimental|Oncoquest-CLL vaccine treatment|Patients receive Oncoquest-CLL vaccine subcutaneously on Day 1 and 15, and then monthly for 3 months in the absence of disease progression or unacceptable toxicity.
3087449|NCT01976507|Experimental|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
3087450|NCT01976494|Experimental|domestic PCA equipment|Patient controlled analgesia by the domestic PCA equipment
3087451|NCT01976494|Active Comparator|imported PCA equipment|Patient controlled analgesia by imported PCA equipment
3087452|NCT01976481|Experimental|Sunbed|sunbed exposure
3087453|NCT01976481|No Intervention|Observation|only observation of subjects recruited after randomization
3087454|NCT01976468||SCC metastasis|organ transplant recipients
3087455|NCT01976455||20% calorie depletion|During each 11-day stays the volunteer will have 9 days of calorie depletion (20% one stay and 40% the other).
3087456|NCT01976455||40% calorie depletion|During each 11-day stays the volunteer will have 9 days of calorie depletion (20% one stay and 40% the other).
3087457|NCT01976429|Other|asymptomatic on flight/dive|individuals who experience no middle-ear problems on flying or diving
3087458|NCT01976429|Other|symptomatic on flying/diving|individuals who have experienced middle-ear problems on flying or diving
3087459|NCT01976416|Experimental|Hydroxyurea|Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
3087460|NCT01976416|Placebo Comparator|Placebo|Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
3087461|NCT01976403|Experimental|Pain booklet|
3087462|NCT01976403|No Intervention|standard care|
3087463|NCT01976390|Active Comparator|Zortress (Everolimus)|Zortress will be started on day of transplant and initially dosed at 0.75 mg twice a day (12 hours apart) dosed simultaneously with Neoral.
3087464|NCT01976390|Active Comparator|Rapamune (Sirolimus)|Rapamune will be dosed on day of transplant at 5 mg/d, decreasing to 3 mg/d.
3087465|NCT01976377||Stage I, II, III, IV HNSCC|Stage I, II, III, IV HNSCC reveive treatment in NTUH
3087466|NCT01976364|Experimental|Tofacitinib|
3087467|NCT01976351||Barrett's esophagus|Patients were eligible for the study if they were scheduled for endoscopic examination at the National Taiwan University Hospital and its Yun-Lin branch, because of a BE, with or without a previous history of dysplasia. Exclusion criteria included patients who are younger than 20 years of age or patients with esophageal or cardiac varices or pregnant women.
3087468|NCT01976338|Experimental|Ranibizumab 0.5 mg|PRN Intravitreal injection
3087469|NCT01976338|Sham Comparator|Sham injection|As of Month 6 ranibizumab 0.5 mg PRN intravitreal injection
3087470|NCT01976325|No Intervention|Standard Care|This arm will receive no intervention; only standard medical care.
3087471|NCT01976325|Experimental|Decision Aid + Standard Care|This group will receive the intervention (the Ottawa Malaria Decision Aid), in addition to standard medical care.
3087472|NCT01976312|Experimental|Ranibizumab 0.5 mg|PRN intravitreal injection
3087473|NCT01976312|Sham Comparator|Sham injection|As of Month 3, ranibizumab 0.5 mg PRN intravitreal injections
3087474|NCT01976299|Experimental|Active Treatment|Standard of Care with the AVERT system
3087475|NCT01976299|No Intervention|Standard of Care|
3087476|NCT01976286|Active Comparator|Salicylic Acid Peels|Salicylic Acid and Glycolic Acid Chemical Peels are skin treatments used to correct uneven texture and color by removing dead cells from the skin's top layer.
3087477|NCT01976286|Active Comparator|Glycolic Acid Peels|Salicylic Acid and Glycolic Acid Chemical Peels are skin treatments used to correct uneven texture and color by removing dead cells from the skin's top layer.
3087478|NCT01976273|Active Comparator|1064nm Q-switch Laser|The 1064 Q-Switch Laser is a medical device that uses a focused laser to remove dark pigment (color) from the skin.
3087479|NCT01976273|Active Comparator|Glycolic Acid Peels|A Glycolic Acid Chemical Peel is a mild skin treatment used to correct uneven texture and color by removing dead cells from the skin's outermost layer.
3087480|NCT01976260|Active Comparator|Fractional Radiofrequency|Subjects will be randomly assigned to receive fractional radiofrequency treatment to either the right or left side of the face and the contralateral side will receive 1550-nm fractional photothermolysis. Subjects will receive treatments at baseline, week 4, and week 8 for a total of three treatments. Follow up visits will take place at week 16, two months following the last treatment visit.
3087481|NCT01976260|Active Comparator|1550-nm Fractional Photothermolysis|Subjects will be randomly assigned to receive fractional radiofrequency treatment to either the right or left side of the face and the contralateral side will receive 1550-nm fractional photothermolysis. Subjects will receive treatments at baseline, week 4, and week 8 for a total of three treatments. Follow up visits will take place at week 16, two months following the last treatment visit.
3087482|NCT01976247|Active Comparator|Noninvasive Cryolipolysis Device|The Zeltiq System is a noninvasive (not breaking the skin) device that reduces fat by freezing fat cells until they break apart.
3087483|NCT01976247|Active Comparator|High Intensity Focused Ultrasound Device|The LipoSonix System is a noninvasive ultrasound device, which can be used to selectively target and destroy fat tissue located deep under the skin.
3087484|NCT01976234|Active Comparator|Fresh group|Fresh group will receive RBC stored for less than 14 days
3087485|NCT01976234|Active Comparator|Old group|Old group will receive RBC stored for 14 days or more
3087486|NCT01976221|Experimental|Prioritization|Team-based multifaceted interactive training
3087571|NCT01975675|Experimental|LDV/SOF (treatment naive)|Treatment-naive participants will receive LDV/SOF for 12 weeks.
3108810|NCT01831466|Placebo Comparator|Treatment Group F|
3087487|NCT01976208|Experimental|Omalizumab|During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the following treatment phase, patients continued to receive optimized BUD and Omalizumab for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks. The dosage of Omalizumab received was based on body weight and serum IgE.
3087488|NCT01976208|Placebo Comparator|placebo|During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the treatment phase, patients continued to receive placebo and optimized BUD for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks.
3087489|NCT01976195|Experimental|Thalidomide plus HD-Dexmamethasone|Thalidomide 150mg per day, 15 consecutive days Dexamethasone 40 mg per day, 4 consecutive days
3087490|NCT01976195|Active Comparator|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
3087491|NCT01976182|Active Comparator|METHOTREXATE|"In step 1, 55 patients will receive methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take~In step 2, responders at Month 4 (CR or PR) will be treated during 8 additional months with methotrexate at the same dosage.~Non responders at Month 4 will be randomized and treated either by:~Cyclophosphamide delivered at 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take between Month 5 and Month 8, decreased to 50 mg orally once daily beyond Month 8 for responders at Month 8;~Ciclosporine A delivered at 3 mg/kg per day (at split doses of 1.5 mg/kg in the morning and 1.5 mg/kg at night) orally administered."
3087492|NCT01976182|Active Comparator|CYCLOPHOSPHAMIDE|"In step 1, 55 patients will receive cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take.~In step 2, responders at Month 4 (CR or PR) will be treated during 8 additional months with cyclophosphamide (at 50 mg orally once daily);~Non responders at Month 4 will be randomized and treated either by:~Methotrexate administered at 10 mg/m2 orally once a week (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take;~Ciclosporine A delivered at 3 mg/kg per day (at split doses of 1.5 mg/kg in the morning and 1.5 mg/kg at night) orally administered."
3087493|NCT01976169|Experimental|PD-0332991 and T-DM1|"The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.~A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.~Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)"
3087494|NCT01976156|Experimental|Phopsholean dietary supplement|Subjects in the Phospholean group will receive six capsules of PhosphoLean orally daily (total of 180 mg of NOPE and 120 mg of EGCG), ); two capsules consumed one hour before lunch, two capsules one hour prior to dinner, and two capsules two hours after dinner.
3087495|NCT01976156|Placebo Comparator|Placebo (rice flour) group|The control (placebo) group will receive a placebo (identical in appearance, but containing 100 mg of rice flour per capsule).
3087496|NCT01976143|Experimental|NKTR-102|A single 90 minute IV infusion of 220 mg/m2 NKTR-102
3087497|NCT01976130|Experimental|bronchoscopy|Procedure
3087498|NCT01976117|Experimental|enose|
3087499|NCT01976104|Experimental|Group A (avatrombopag, lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
3087500|NCT01976104|Placebo Comparator|Group B (placebo, lower baseline platelet count)|placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5
3087501|NCT01976104|Experimental|Group C (avatrombopag, higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5
3087502|NCT01976104|Placebo Comparator|Group D (placebo, higher baseline platelet count)|placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
3087503|NCT01976091|Experimental|Cohort 1A|Two (n=2) adult LGMD2D wheelchair-dependent subjects will receive self-complementary scAAVrh74.tMCK.hSGCA via single-limb perfusion at the low dose. Subjects will receive a dose of 1 x 10 12th vg/kg in a single limb with delivery to the whole limb.
3087504|NCT01976091|Experimental|Cohort 1B|Three (n=3) LGMD2D subjects will receive self-complementary scAAVrh74.tMCK.hSGCA via bilateral whole limb perfusion at low dose of 1 x 10 12th vg/kg.
3087505|NCT01976091|Experimental|Cohort 2|Three (n=3) LGMD2D subjects will receive self-complementary scAAVrh74.tMCK.hSGCA bilateral whole limb perfusion at high dose.Subjects will receive a total dose of 3 x 10 12th vg/kg per limb delivered to both extremities
3087506|NCT01976078||Midazolam/Ranitidine/Esomeprazole|All enrolled subjects will have a study pharmacokinetic visit where they will be given the above cocktail of drugs along with their clinically indicated voriconazole dose, followed by blood sampling over the next 12 hours.
3087507|NCT01976065|Other|Mineral Trioxide Aggregate (MTA)|Standard Treatment group consisting of placement of Mineral Trioxide Aggregate (MTA), an FDA approved dental material at the end of an immature root followed by a composite restoration (crown).
3087508|NCT01976065|Experimental|Revascularization Treatment (REVASC)|Consists of standard treatment procedure PLUS disinfection of the canal space with Triple Antibiotic Paste study medication followed by placement of Collaplug, an FDA approved material to help promote clotting. A composite restoration in then placed.
3087509|NCT01976065|Experimental|Regeneration Treatment (REGENDO)|Consists of standard treatment procedure PLUS Triple Antibiotic Paste study medication PLUS use of Emdogain, an FDA approved medication used in an FDA approved manner, that is a growth factor to help surrounding tissues to grow together and heal.
3087510|NCT01976052||Obstructive sleep apnea patients|Patients with obstructive sleep apnea that has not received CPAP treatment
3087511|NCT01976052||Matched volunteers with non OSA|Matched volunteers without OSA. Matched in respect to age and BMI
3087512|NCT01976052||Matched normal controls with normal BMI|Volunteers that are matched according to age but has a normal BMI
3087513|NCT01976039|Other|RRC|rhinopharyngeal retrograde clearance (RRC) isolated: First patient sits in a chair. Second: patient inhales air deeply and exhales making noise and vibration in the upper airway to facilitate swalling. Third patients finishes with another deep inhalation. This technique is new, simple to use and with no cost. No need of any material or equipment.
3087514|NCT01976039|Experimental|RRC+S|retrograde rhinopharyngeal retrograde clearance combined with saline instillation (RRC+S): patient sits in a chair and inhaled air and make noise and vibrate the upper airway at the same instills saline into the nare to facilitate nose washing and swalling. This technique is new, simple to use and with low cost (only saline).
3087515|NCT01976026|Experimental|Endovascular treatment with flow diversion|"Endovascular treatment with flow diversion, including standard management of thrombo-embolic risk. The goal of the treatment procedure is (as usual) to prevent rebleeding, while keeping treatment-related risks as low as possible.~This trial permits the interventionist or surgeon to use any device, technique or drug judged important to the safety and success of the endovascular or surgical procedure, at his/her discretion at any time during the procedure. It is imperative that the allocated procedure is conducted in the safest possible manner. The interventionist or surgeon may switch to an alternative BST or cross-over to the alternative treatment group, if it is in the best interest of the patient."
3087516|NCT01976026|Active Comparator|Best standard therapy|"May be any of the following:~Conservative management when no surgical or endovascular treatment is considered possible or reasonable~Conventional endovascular options including coiling with or without high-porosity stenting, and stent-in stent techniques~Parent vessel occlusion, with or without bypass~Surgical clipping or clip-wrapping (including parent vessel occlusion as a salvage procedure).~Choice of best option is based on the location, anatomy, and particular circumstances, before randomization for this patient's aneurysm.~This trial permits the interventionist or surgeon to use any device, technique or drug judged important to the safety and success of the endovascular or surgical procedure, at his/her discretion at any time during the procedure. The interventionist or surgeon may switch to an alternative BST or cross-over to the alternative treatment group, if it is in the best interest of the patient."
3087517|NCT01976013|Other|Coaguchek|infants will receive sequential coagulation checks
3087518|NCT01976000||Group A|the surgeons were able to view 3D reconstructions before and during surgery
3087519|NCT01976000||Group B|the surgeons were only able to view 3D reconstructions after the surgery
3087520|NCT01975987|Experimental|Intubation with the Bonfils fiberscope|"Characteristics of patients will be assessed before induction of general anesthesia~Glottic visualization will be evaluated by direct laryngoscopy.~The endotracheal tube will be loaded onto the scope~Intubation will be performed with the Bonfils fiberscope with the patient in supine position with head and neck in neutral position~Bonfils fiberscope will be inserted from the right side of the patient's mouth, alongside the molars and advanced underneath the epiglottis. With the tip of the Bonfils in satisfactory position, the endotracheal tube will be advanced into the trachea using gentle rotary motions. The scope will then be removed.~Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation."
3087521|NCT01975974||Ultrasound|Ultrasound guided peripheral vascular access
3087522|NCT01975961|Experimental|FDC YH16410|"Drug: Test treatment: FDC YH16410 (Telmisartan 80mg/ Rosuvastatin 20mg).~Subjects will receive single oral dose of 1 tablet of FDC containing Telmisartan 80mg and Rosuvastatin 20mg in fasted state"
3087523|NCT01975961|Active Comparator|Co-administration|"Drug: Reference Treatment: Co-administration(Telmisartan 80mg and Rosuvastatin 20mg).~Subjects will receive 1 x Telmisartan 80mg with 1 x Rosuvastatin 20mg tablet administered orally in fasted state as a single dose"
3087524|NCT01975948|Experimental|Mental Health PSP: Physicians|Physicians training in Adult Mental Health Practice Support Program
3087525|NCT01975948|Active Comparator|Treatment as Usual: Physicians|Those administering treatment as usual for depression
3087526|NCT01975948|Experimental|Mental Health PSP: Patients|Those belonging to a physician who has completed the Adult Mental Health Practice Support Program training.
3087527|NCT01975948|Active Comparator|Treatment as Usual: Patients|Those receiving treatment as usual for depression
3087528|NCT01975935|Placebo Comparator|Placebo|Placebo tablet (TID) 2 weeks Placebo tablets (2 x TID) 10 weeks
3087529|NCT01975935|Experimental|Amlexanox|Solfa tablets (Amlexanox 25mg) TID for 2 weeks Solfa tablets (Amlexanox 25mg x 2) TID for 10 weeks
3087530|NCT01975922|Experimental|Enhanced Milieu Teaching|"Parents receive 28 intervention sessions in which they learn to use language support strategies with their children.~Children are assessed at baseline, 4 months after baseline, 10 months after baseline, and 16 months after baseline."
3087531|NCT01975922|No Intervention|Community Services|Children receive speech-language services in the community. Children are assessed at baseline, 4 months after baseline, 10 months after baseline, and 16 months after baseline.
3087532|NCT01975909|Active Comparator|Transcranial Magnetic Stimulation (TMS)|A Magstim 200 (Magstim, UK) and 14cm circular coil positioned tangential to the head will be used to deliver stimuli at 100% of maximum stimulator output. Transcranial Magnetic Stimulation will be applied to three regions: 1) 4cm lateral to the right of the inion, 2) centered on the inion, 3) 4cm lateral to the left of the inion. Five pulses separated by 6 seconds will be delivered with a counter-clockwise current, followed by the same five pulses delivered with a clockwise current, for a total of 10 pulses per region, and 30 pulses per session.
3087533|NCT01975909|Sham Comparator|Sham Transcranial Magnetic Stimulation|A sham condition of Transcranial Magnetic Stimulation will be used and follow the same protocol as the active stimulation; however no magnetic pulses will be delivered through the scalp.
3087534|NCT01975896|Experimental|Meditation|The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
3087567|NCT01975688|Experimental|Sativex: pre-treatment (Grade 0)|The PKs of a single dose of Sativex are investigated in subjects with mucositis of Radiation Therapy Oncology Group (RTOG) Grade 0 (i.e. at baseline, pre-induction of mucositis).
3087568|NCT01975688|Experimental|Sativex: mild mucositis (Grade 1)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 1 (mild).
3087569|NCT01975688|Experimental|Sativex: moderate mucositis (Grade 2)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 2 (moderate).
3087535|NCT01975896|No Intervention|Health Education|The health education curriculum will be informed by: 1) the dietary and PA didactic units and materials developed as part of our school based trial, adapted for adolescents from the Diabetes Prevention Program (DPP) and 2) the standard curricula for school-based health education programs with particular attention to the unique needs of adolescents:increasing fruits and vegetables, reducing sugar sweetened drinks, and decreasing foods high in fat, unhealthy carbohydrates, and calories. The PA component will be based on current recommendations of engaging in at least 1 hour of moderate-to-vigorous physical activity (MVPA) most days of the week, building PA into the teen's lifestyle,and reducing sedentary behavior.
3087536|NCT01975883||Spine surgical patients|Sequential patients scheduled for spine surgery, including degenerative, deformative, tumoral and traumatologic indications are eligible to participate. Exclusion criteria are the following : infection or history of infection of surgical site, past medical history of diabetes mellitus, defined as chronic glucose intolerance either insulin-dependent or non insulin-dependent at the time of operation, and patients with preoperative random BG levels greater than 126 mg/dl considering they could also represent undiagnosed diabetes
3087537|NCT01975870|Experimental|intervention group|use of application on smartphone for lifestyle counseling
3087538|NCT01975870|No Intervention|control group|no use of application on smartphone
3087539|NCT01975857|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP) to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
3087540|NCT01975857|Active Comparator|Supportive Education|Supportive Education program will provide educational lectures on disability, sleep hygiene, and current research on depression and non-directive, supportive discussions about these topics.
3087541|NCT01975844|Experimental|Individualized Anemia Mangement Protocol|"Single arm study, therefore all patients will participate in the following:~Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.~Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
3087542|NCT01975831|Experimental|MEDI4736 & Tremelimumab Treatment|MEDI4736 and Tremelimumab will be administered by IV infusion
3087543|NCT01975818|Experimental|Molidustat (BAY 85-3934)(25mg)|Starting dose of 25 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.
3087544|NCT01975818|Experimental|Molidustat (BAY 85-3934)(50mg)|Starting dose of 50 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.
3087545|NCT01975818|Experimental|Molidustat (BAY 85-3934) (75mg)|Starting dose of 75 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.,
3087546|NCT01975818|Experimental|Molidustat (BAY 85-3934) (150mg)|Starting dose of 150 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, 150 and 200 mg once daily
3087547|NCT01975818|Active Comparator|Epoetin alfa/beta|Starting dose at the subject's current weekly dose. Administered IV or SC 3 times per week. Doses will be titrated at the scheduled dose control visits according to the local label. Titration will be based on the subject's Hb response and tolerability of the prior dose. Epoetin alfa may be administered in either the United States (US) or Japan; epoetin beta will only be administered in Japan.
3087548|NCT01975805|Experimental|Chlorhexidine Gluconate|Use of Chlorhexidine Gluconate as skin disinfectant for cesarean section.
3087549|NCT01975805|Experimental|Povidone Iodine|Use of Povidone Iodine as skin disinfectant for cesarean section.
3087550|NCT01975792||Preterm Admits|Women who are admitted for preterm labor observation and management
3087551|NCT01975779|Experimental|Cohort A1: Lu AE58054 or placebo|
3087552|NCT01975779|Experimental|Cohort A2: Lu AE58054 or placebo|
3087553|NCT01975779|Experimental|Cohort B1: Lu AE58054|
3087554|NCT01975766|Experimental|Ketogenic diet|Ketogenic diet designed to sustain ketone levels through treatment.
3087555|NCT01975753|Active Comparator|Intravenous morphine|one bolus of intravenous morphine
3087556|NCT01975753|Experimental|nebulized morphine|"one nebulized bolus of morphine"
3087557|NCT01975753|Active Comparator|fentanyl|"one nebulized bolus of fentanyl"
3087558|NCT01975740|Experimental|Manual diaphragm release technique|
3087559|NCT01975740|Other|Sham manual diaphragm release technique|
3087560|NCT01975727|Placebo Comparator|Injection of Placebo|Intravenous Saline 0.9% 10 ml
3087561|NCT01975727|Active Comparator|Dexamethasone 3 mg|Intravenous Dexamethasone 3mg diluted in saline 0.9% up to 10 ml
3087562|NCT01975727|Active Comparator|Dexamethasone 6 mg|Intravenous Dexamethasone 6mg diluted in saline 0.9% up to 10 ml
3087563|NCT01975727|Active Comparator|Dexamethasone 12 mg|Intravenous Dexamethasone 12mg diluted in saline 0.9% up to 10 ml
3087564|NCT01975714|Experimental|Latanoprost (Period I) + Bimatoprost (Period II)|"Preservative-free latanoprost 0.005% Unit Dose (LUDPF) (Monoprost) eye drops will be administered every day at 21:00 for the first 3 months.~After the follow-up visit, patient will start Preservative-free bimatoprost 0.03% Unit Dose (BUDPF) eye drops every day at 21:00 for the last 3 months."
3087565|NCT01975714|Experimental|Bimatoprost (Period I) and Latanoprost (Period II)|"Preservative-free bimatoprost 0.03% Unit Dose (LUDPF) (Monoprost) eye drops will be administered every day at 21:00 for the first 3 months.~After the follow-up visit, patient will start Preservative-free latanoprost 0.005% Unit Dose (BUDPF) eye drops every day at 21:00 for the last 3 months."
3087566|NCT01975701|Experimental|BGJ398X|To estimate anti-tumor efficacy of BGJ398
3087573|NCT01975675|Experimental|LDV/SOF (treatment experienced)|Treatment-experienced participants will receive LDV/SOF for 12 weeks.
3087574|NCT01975675|Experimental|LDV/SOF+RBV (treatment experienced)|Treatment-experienced participants will receive LDV/SOF plus RBV for 12 weeks.
3087575|NCT01975662|Experimental|Daptomycin|"Daptomycin will be dosed intravenously at 6-8mg/kg every 24 hours.~Patients with uncomplicated bacteremia will receive a dose of 6mg/kg every 24 hours. Patients with suspected complicated bacteremia or endocarditis, or receipt of at least two doses of vancomycin in the last 90 days (apart from vancomycin received for their current MRSA bacteremia) will receive a dose of 8mg/kg every 24 hours.~In patients with a creatinine clearance less than 30ml/min, or on intermittent or continuous hemodialysis, daptomycin will be dosed at 6-8mg/kg every 48 hours. The same criteria as above applies as to whether they receive 6mg/kg or 8mg/kg every 48hours. Daptomycin will be administered after hemodialysis in patients undergoing intermittent hemodialysis."
3087576|NCT01975662|Active Comparator|Vancomycin|Vancomycin will be dosed at 15mg/kg every 12 hours with appropriate dose adjustments by a pharmacist in patients with a creatinine clearance less than 50 ml/min, so as to achieve a vancomycin trough level of 15-20ug/ml.
3087577|NCT01975649|Experimental|Tribulus Terrestris|patients will use Tribulus terrestris (750 mg/day) during 120 days
3087578|NCT01975649|Placebo Comparator|Placebo|patients will use placebo for 120 days
3087579|NCT01975636|Experimental|E2609|Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
3087580|NCT01975623|Experimental|Intervention Group|Pulmonary artery Energy Sealing with HARMONIC ACE+ Shears (HS) ex-vivo
3087581|NCT01975610|Experimental|CC-292 375mg|Treatment
3087582|NCT01975610|Placebo Comparator|Placebo|Control
3087583|NCT01975597|Experimental|Bone marrow aspirates and biopsy|
3087584|NCT01975584|Experimental|Trier Social Stress Test|Participants will participate in a standardized role play (Trier Social Stress Test ). A role play is pretending to be in a certain situation. A research staff member will describe the role play, during which teh participant will act out a scene. Participants will be asked to imagine that they are in a certain role with several other research team members who will also participate in the role play. Participants will also be asked to do some math problems without using paper or pencil.
3087585|NCT01975571|Experimental|Adult|"Population 1: 15 Adults who have a severe sensorineural hearing loss with a pure-tone average (PTA) between 60-90 dB HL between 125-1500 Hz and profound loss at higher frequencies.~Intervention: These patients will receive a Hybrid L24 cochlear implant."
3087586|NCT01975571|Experimental|Children and adolescents (L24)|"Children (ages 5-12 years) and adolescents (ages 13-15 years) who have a sensorineural hearing loss with a pure-tone average (PTA) between 70-90 dB HL between 125-1500 Hz, a hearing threshold >90 dB HL at 1500 Hz and profound loss at higher frequencies.~Intervention: These patients will receive a Hybrid L24 cochlear implant."
3087587|NCT01975571|Experimental|Children and adolescents S12|"Children (ages 5-12 years) and adolescents (ages 13-15 years) who have a sensorineural hearing loss with a pure-tone average (PTA) between 70-90 dB HL between 125-1500 Hz, a hearing threshold hearing threshold between 70-90 dB HL at 1500 Hz and profound loss at higher frequencies.~Intervention: These patients will receive a Hybrid S12 cochlear implant."
3087588|NCT01975558||Control group A|Control group. The group will undergo blood, urine, sebum, and saliva sampling.
3087589|NCT01975558||Breast cancer B|Breast cancer (60 Gy). The group will undergo blood, urine, sebum, and saliva sampling within the irradiation field.
3087590|NCT01975558||Breast cancer C|Breast cancer (60 Gy). The group will undergo blood, urine, sebum, and saliva sampling outside of the irradiation field, e.g. at the arm.
3087591|NCT01975545|Active Comparator|Fluor varnish|Fluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein)
3087592|NCT01975545|Experimental|Fluor varnish with nanoparticles|Fluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein) plus 25% 50 nm silver nanoparticles.
3087593|NCT01975519|Experimental|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose Pazopanib.
3087594|NCT01975506||head start practitioners|
3087595|NCT01975493||Amoxicillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
3087596|NCT01975493||Ampicillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months)"
3087597|NCT01975493||Benzylpenicillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
3087598|NCT01975493||Co-amoxiclav|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
3087599|NCT01975493||Flucloxacillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
3087600|NCT01975493||Piperacillin/tazobactam|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
3087601|NCT01975480|Experimental|Desvenlafaxine|At the screening visit those who are eligible will enter a randomized trial with Pristiq (desvenlafaxine) 50 to 100 mg. The study will begin with a single week of Pristiq (desvenlafaxine) 50mg. Subsequently, tablets will be administered in a flexible dose fashion and patients will be followed up weekly (biweekly after week 8) and at the investigators discretion. After the first week the patients' dosage will be increased up to a maximum of 100 mg daily. This dose will remain fixed after 8 weeks of treatment until week 16.
3087602|NCT01975467||Control Group - Nonoperative|Subjects that were treated with a sling for their displaced midshaft clavicle fracture.
3087603|NCT01975467||Test Group - Intramedullary Nail|Subjects that were treated with an intramedullary nail for their displaced midshaft clavicle fracture.
3087604|NCT01975454|Active Comparator|chemotherapy|Patients receive chemotherapy until disease progression or unacceptable toxicity
3087605|NCT01975454|Experimental|Herbal therapy plus chemotherapy|Patients receive herbal therapy plus chemotherapy until disease progression or unacceptable toxicity
3109263|NCT01828463|Experimental|Nitisinone 2mg|interventional
3087606|NCT01975441|Active Comparator|standard treatment|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg administered annually (at 0, 12, and 24 months).
3087607|NCT01975441|Experimental|DEC 6 mg/kg + Alb 400 mg x 1|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once
3087608|NCT01975441|Experimental|DEC + ALB + IVM|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg + Ivermectin 200 µg/kg administered once only at the beginning of the RCT (0 month)
3087609|NCT01975428|Other|Control|Disease Management program
3087610|NCT01975428|Active Comparator|DM Pgm + glucometer|iBGStar - iPhone enabled capillary blood glucose meter plus disease management program. Subjects test blood glucose up to 4 times per day, every day.
3087611|NCT01975428|Active Comparator|DM Pgm + Blood Pressure Monitor|Withings BP monitor - iPhone enabled home blood pressure monitor. Subjects test their blood pressure 2 times per day, up to 3 days per week.
3087612|NCT01975428|Active Comparator|DM pgm + Alive Cor ECG|Disease management program + iphone enabled Alive Cor ECG monitor. Participants take an ECG reading only when symptomatic
3087613|NCT01975415||Experienced Meditators|Self-identified participants who confirm to having a regular meditation practice for at least 3 months and practiced at least 70 minutes per week.
3087614|NCT01975415||Novice meditators|Self-identified participant who confirm to either having never seriously tried meditation, or who have not meditated more than once a week for at least 3 months
3087615|NCT01975389|Experimental|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous.
3087616|NCT01975389|Placebo Comparator|Placebo|Placebo comparator, every 2 weeks, subcutaneous.
3087617|NCT01975376|Experimental|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous
3087618|NCT01975376|Placebo Comparator|Placebo|Placebo comparator, every 2 weeks, subcutaneous.
3087619|NCT01975363|Experimental|Arm I (lower dose curcumin)|Participants receive 50 mg dose curcumin PO BID for 3 months. Biomarker analyses of breast adipose tissue and plasma samples will be obtained at baseline and 3 months. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin and also stored at -80°C for biomarker analysis. Assessment of dietary intake by food frequency questionnaires and 24 hour dietary recalls will be used to assess usual dietary habits. All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
3087620|NCT01975363|Experimental|Arm II (higher dose curcumin)|Participants receive 100 mg dose curcumin PO BID for 3 months. Biomarker analyses of breast adipose tissue and plasma samples will be obtained at baseline and 3 months. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin and also stored at -80°C for biomarker analysis. Asssessment of dietary intake by food frequency questionnaires and 24 hour dietary recalls will be used to assess usual dietary habits. All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
3087621|NCT01975350||Colistimethate sodium inhalation|"Colistimethate sodium inhalation for patients with ventilator-associated tracheobronchitis, pneumonia or lower respiratory tract colonization by multidrug resistant Gram-negative bacteria.~Additional intravenous colistimethate sodium for patients with ventilator-associated pneumonia"
3087622|NCT01975350||saline inhalation|saline inhalation for patients with ventilator-associated tracheobronchitis, pneumonia or lower respiratory tract colonization by multidrug resistant Gram-negative bacteria.
3087623|NCT01975337|Experimental|End stage renal disease participants|End stage renal disease (ESRD) participants received a single 400 mg (2 x 200 mg capsules) oral dose of alisporivir with food at any time during the 2 hours after completion of hemodialysis on Day 1.
3087624|NCT01975337|Active Comparator|Matched healthy participants|Healthy participants (matched to those with end stage renal disease by sex, age, weight, and smoking status), received a single 400 mg (2 x 200 mg capsules) oral dose of alisporivir with food on Day 1.
3087625|NCT01975324|Experimental|dalfampridine (ampyra)|Dalfampridine (ampyra) 10mgs twice a day (b.i.d.)for two weeks
3087626|NCT01975324|Placebo Comparator|Placebo|placebo (sugar Pill) twice a day (b.i.d.)for two weeks
3087627|NCT01975311|Experimental|Lumbopelvic Manipulation|Participants in this group will receive lumboplevic manipulation twice within a week.
3087628|NCT01975311|Placebo Comparator|Passive lumbar spine flexion and extension|Participants in this group will receive passive lumbar spine flexion and extension for 1 min twice within a week.
3087629|NCT01975298|Experimental|Laquinimod 0.6 mg|
3087630|NCT01975298|Experimental|Laquinimod 1.2 mg|
3087631|NCT01975298|Active Comparator|Avonex®|
3087632|NCT01975285|Active Comparator|Dexamethasone group|Dexamethasone 4mg(1 ml) per 20cc
3087633|NCT01975285|Placebo Comparator|Saline group|Saline 1 ml per 20cc
3087634|NCT01975272|Active Comparator|Ferinject|Once an infusion of Ferinject 1000 mg, 1 day after surgery
3087635|NCT01975272|Active Comparator|Ferrous fumarate|2 times a day 200 mg ferrous fumarate, starting 24-48 hours after surgery
3087636|NCT01975272|Placebo Comparator|Placebo infusion and tablets|Patient will get a once a placebo infusion (250 ml NaCl), one day after surgery, and 60 placebo tablets for 30 days (2 tablets a day), starting 24-48 hours after surgery
3087637|NCT01975259||Cystic Fibrosis|"Adult patients with confirmed cystic fibrosis who are clinically stable. Interventions:~Oral Glucose Tolerance test (75g 2-hour) Modified Oral Glucose Tolerance Test (50g 4-hours) Matched isoglycemic clamp Hyperglycemic clamp with concurrent GLP-1 infusion Hyperglycemic Clamp with concurrent GIP infusion Hyperglycemic clamp with placebo infusion Liquid Meal Test (Carbohydrate-rich) Continuous Glucose Monitoring"
3087638|NCT01975259||Controls|"Adult Non-CF subjects matched for age and body mass index with normal glucose tolerance.~Oral Glucose Tolerance test (75g 2-hour) Modified Oral Glucose Tolerance Test (50g 4-hours) Matched isoglycemic clamp Hyperglycemic clamp with concurrent GLP-1 infusion Hyperglycemic Clamp with concurrent GIP infusion Hyperglycemic clamp with placebo infusion Liquid Meal Test (Carbohydrate-rich)"
3087639|NCT01975246|Experimental|Telmisartan+amlodipine+HCTZ|telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet
3087640|NCT01975246|Active Comparator|Telmisartan+amlodipine|telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet
3087641|NCT01975233||WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 75 years requiring treatment for intracranial aneurysms.
3087642|NCT01975220|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs. 3 single tablets under fasted conditions
3087643|NCT01975220|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs. 3 single tablets under fed conditions
3087644|NCT01975220|Experimental|Low dose, fasted|2 fixed low dose combination (FDC) tablets vs. 4 single tablets under fed conditions
3087645|NCT01975207|No Intervention|Group 1|"Patients will have information collected on their quality of life (QOL) at baseline (EuroQual 5-item measure - EQ-5D). Patients will be followed up at week 12 for a repeated measure of QOL and a score on the depression rating scale being used in this study (Patient Health Questionnaire-9 item version - PHQ-9). Individuals will also be asked on their health care access frequency (HCAF) at baseline and follow up."
3087646|NCT01975207|Experimental|Group 2|"Group #2. Screening for depression followed by treatment as usual: Patients will complete baseline measurements of their score on the PHQ-9, self-reported HCAF and QOL (EQ-5D) score.~The PHQ-9 score will be given to the clinic staff who will then follow up with treatment as usual. Patients will be followed up at week 12 for self-reported HCAF,PHQ-9 and QOL scores."
3087647|NCT01975207|Experimental|Group 3|Group #3 is Internet intervention: At baseline patients will complete QOL (EQ-5D), PHQ-9 scores, and self-reported HCAF. Those who score 10 or more on the PHQ-9 will be offered a guided internet-based intervention for the treatment of depression by the study staff. Patients will be followed up at week 12 for self-reported HCAF, PHQ-9 and QOL scores.
3087648|NCT01975207|Experimental|Group 4|Depression Treatment Pathway: At baseline patients will complete PHQ-9, QOL (EQ-5D) scores, and self-reported HCAF. Those who score 10 or more on the PHQ-9 will be offered the specific treatment as determined by the Depression Pathway by the clinic physician. Whenever possible, this pathway will be integrated into the local clinic's electronic medical record system, for ease of administration by the clinic. Patients will be followed up at week 12 for self-reported HCAF, PHQ-9 and QOL (EQ-5D) scores.
3087649|NCT01975194|Experimental|Rosuvastatin|Patients that receive rosuvastatin
3087650|NCT01975168|Experimental|Group 1|arrange laser acupuncture intervention for 12 weeks, then cross over to sham laser acupuncture intervention for 12 weeks
3087651|NCT01975168|Sham Comparator|Group 2|arrange sham laser acupuncture for 12 weeks, then cross over to laser acupuncture for 12 weeks
3087652|NCT01975155||Celiac|patients with celiac disease filling the questionnaire and undergoing urinary test
3087653|NCT01975155||healthy controls|healthy patients filling the questionnaire and undergoing urinary test
3087654|NCT01975142|Experimental|TDM-1|
3087655|NCT01975129|Experimental|Vagitocin (Oxytocin)|
3087656|NCT01975116|Experimental|Treatment: p28|Pts receive azurin-derived cell-penetrating peptide p28 IV over 15 min 3x/week for 4 wks. Tx repeats every 6 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
3087657|NCT01975103|Experimental|Topcon Endpoint management|Active laser treatment
3087658|NCT01975103|Sham Comparator|Control|Powerless (sham) laser treatment
3087659|NCT01975090|Experimental|SENTRY IVC Filter|The SENTRY IVC Bioconvertible Filter
3087660|NCT01975077|Experimental|A- 4mg QD|arm A- fruquintinib 4mg once daily, p.o.,continuous;given in 28-days cycles until disease progress, intolerable toxicity or patients withdrawal of consent
3087661|NCT01975077|Experimental|B- 5mg once daily, 3wks on/1wk off|arm B-fruquintinb 5mg once daily,p.o.,3 weeks on/1 week off, given in 28-day cycles until disease progress,intolerable toxicity or patients withdrawal of consent
3087662|NCT01975064|Active Comparator|Propofol|Propofol for maintenance of anesthesia
3087663|NCT01975064|Active Comparator|Sevoflurane|Sevoflurane for maintenance of anesthesia
3087664|NCT01975051|Experimental|Miltefosine|Tablet Miltefosine 100 mg daily in two divided doses for 12 weeks.
3087665|NCT01975038||A convenience sample|The characteristics of the sample will be monitored to assure that each category of skin type (I- VI) is accrued in sufficient size to support analysis. In addition, the sample will have equal representation from 4 ethnic groups within each skin type category: African American, Asian, Hispanic, or non-Hispanic White. Participants will self-identify as being Asian, Black, Hispanic Black, Hispanic White, or non-Hispanic White.
3087666|NCT01975025|Experimental|All study participants|Short daily dialysis for 2 weeks
3087667|NCT01975012|Experimental|Cohort 1: 6 to less than 12 years of age|Participants in this arm will be at least 6 but younger than 12 years of age; they will receive the study drug RPV together with 2 other NRTIs.
3087668|NCT01975012|Experimental|Cohort 2: 2 to less than 6 years of age|Participants in this arm will be at least 2 but younger than 6 years of age; they will receive the study drug RPV together with 2 other NRTIs.
3087669|NCT01974986|Placebo Comparator|Placebo|Water with flavoring and non-nutritive sweetener.
3087670|NCT01974986|Experimental|High-Na low-CHO beverage|Beverage containing sodium concentration of 40 to 50 mEq/L and carbohydrate concentration between 310 and 350 mmol/L.
3087671|NCT01974986|Experimental|Low-Na high-CHO beverage|Beverage containing sodium concentration of 15 to 25 mEq/L and carbohydrate concentration between 120 and 160 mmol/L.
3087672|NCT01974973|Experimental|Stem cell|autologous bone marrow mononuclear cell transplantation
3087673|NCT01974947||Infertile men|Man partner of an infertile couple. Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
3087674|NCT01974934|Experimental|Desvenlafaxine Succinate|
3087675|NCT01974921|Experimental|Bronchial thermoplasty|ALAIR Catheter. Radiofrequency system.
3087676|NCT01974908|Experimental|Ventricular Tachycardia (VT)|Patients with VT will undergo a clinically indicated ablation of their VT
3087677|NCT01974895|Experimental|FluLaval Quadrivalent Group|Subjects received 1 or 2 doses of FluLaval® Quadrivalent vaccine at Day 0 or Days 0 and 28, depending on age and vaccine priming status.
3087678|NCT01974895|Active Comparator|Fluzone Group|Subjects received 1 or 2 doses of Fluzone® vaccine at Day 0 or Days 0 and 28, depending on age and priming status.
3087679|NCT01974882|Experimental|Cryotherapy|Patients in the cryotherapy study group will have ice packs placed on their abdominal wound for the first hour following surgery.
3087680|NCT01974882|No Intervention|Control|No adjunctive therapy following abdominal surgery.
3087681|NCT01974869||Inflammatory bowel diseases-1|Treatment with anti-tumor necrosis factor alpha agents
3087682|NCT01974869||Inflammatory bowel diseases-2|Controls
3087683|NCT01974843||Group BT|Bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg
3087684|NCT01974843||Group LT|Levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg, resulting in a total volume of 1 ml/kg.
3087685|NCT01974830||Adult Alpha-1 Patients|Adult Alpha-1 patients recieving augmentation therapy in the home through Coram
3087686|NCT01974817|Experimental|Vaccine|Patients will receive one dose of 0.5 ml 13-valent conjugate pneumococcal vaccine (Prevnar-13) intra-muscularly.
3087687|NCT01974804||Pts having an MRI|Patients will undergo a 20 minute pretreatment MRI scan and a 30 minute post treatment MRI scan with contrast agent administration. Ten patients with brain metastasis will be recruited in the study. All the patients will be undergoing SRS (Stereotactic Radiosurgery). Patients will have 1 pretreatment evaluation and 2 post treatment evaluations [1-72 hours post treatment and 8 weeks (+/- 2 weeks) post treatment] for early response. Patients are to be administered contrast prior to obtaining MRI scans. These research scans are estimated to take 20 minutes of scan time (+/- 10 minutes), which includes patient set up and conducting the research sequences..
3087688|NCT01974791|Experimental|GET Living Treatment|
3087689|NCT01974778|Experimental|Active|Meal
3087690|NCT01974778|Placebo Comparator|Control|Water
3087691|NCT01974765|Experimental|Enzalutamide|"After signing a screening consent, patients archival tissue will be evaluated for degree of AR positivity by AR staining. Patients with no archival tissue available will undergo a biopsy (using the modality deemed most appropriate by the patient's physician) for collection of tumor tissue for AR positivity by IHC. Only AR+ patients, defined as ≥5 % positivity by IHC, will be included. All IHC testing will be performed in the MSKCC Clinical CLIA approved laboratory.~All enrolled patients will be treated with enzalutamide 160 mg by mouth QD until progression of disease (POD), unacceptable toxicity or withdrawal from study. All treatments will be administered in the outpatient setting."
3087692|NCT01974752|Experimental|selumetinib 75mg twice daily|selumetinib 75mg twice daily in combination with dacarbazine.
3087693|NCT01974752|Placebo Comparator|placebo twice daily|placebo twice daily in combination with dacarbazine.
3087694|NCT01974739|Active Comparator|hydrochloorthiazide|once a day 25 mg
3087695|NCT01974739|Placebo Comparator|placebo|once a day placebo
3087696|NCT01974726|Other|affected, intact tympanic membranes|History of middle-ear disease, ears with no holes/perforations/patent tympanostomy tubes in eardrum
3087697|NCT01974726|Other|affected, non-intact tympanic membranes|History of middle-ear disease, ears with hole/perforation/patent tympanostomy tube in eardrum
3087698|NCT01974726|Other|controls, intact tympanic membranes|No history of middle-ear disease, ears with no hole/perforation/patent tympanostomy tube in eardrum
3087699|NCT01974726|Other|controls, non-intact tympanic membranes|No history of middle-ear disease, ears with hole/perforation/patent tympanostomy tube in eardrum
3087700|NCT01974700|Active Comparator|Levetiracetam|
3087701|NCT01974700|No Intervention|No anti-epileptic treatment|
3087702|NCT01974687|Experimental|Healthy (Group A)|Healthy participants will receive sequentially higher doses of uprifosbuvir (10 mg - 300 mg) capsules or matching placebo capsules once daily (QD) on Day 1 (Cohorts 1a-3a, 5a), Days 1 and 7 (Cohort 4a), or Day 1 - Day 7 (Cohort 6a). Dosing of next cohort will be based on review of available safety and PK data. Dosing will occur under fasted conditions with the exception of Cohort 4a, in which drug administration will occur under both fasted and fed conditions.
3087703|NCT01974687|Experimental|HCV GT1 on Day 1 (Group B)|HCV GT1 participants with no prior direct-acting antiviral (DAA) exposure will receive a single dose of uprifosbuvir (10 mg - 300 mg) for 1 day across sequential dose cohorts. Dosing will commence following review of available safety and PK data from respective dose cohorts in Group A. All dosing will occur under fasted conditions.
3087704|NCT01974687|Experimental|HCV GT1 for 7 days (Group C)|HCV GT1 participants will receive uprifosbuvir (50 mg - 400 mg in capsules or 300 mg or 450 mg in tablets) or matching placebo capsules QD for 7 days. Dosing will commence following review of available safety and PK data of Group A. Fed vs. fasted dosing will be dependent on food effect results from Group A.
3087705|NCT01974687|Experimental|HCV GT2 - HCV GT6 for 7 days (Group D)|HCV GT2 - GT6 participants will receive uprifosbuvir (50 mg - 300 mg) capsules QD for 7 days. Dosing will commence following review of available safety and PK data from Group A. Fed vs. fasted dosing will be dependent on food effect results from Group A.
3087706|NCT01974687|Experimental|HCV-GT1 for 1 or 7 days (Group E)|HCV GT1 participants with mildly impaired hepatic function will receive uprifosbuvir (150 mg - 450 mg) capsules QD for 1 or 7 days. Dosing of subsequent cohorts will be based on review of available safety and PK data. Fed vs. fasted dosing will be dependent on food effect results from Group A.
3087707|NCT01974687|Experimental|HCV GT1 Itraconazole + Uprifosbuvir (Group F)|HCV GT1 participants will receive itraconazole 200 mg twice daily (BID) on Day -5 and itraconazole 200 mg QD from Day -4 to Day 11. Participants will also be co-administered uprifosbuvir 300 mg from Day 1 to Day 7.
3087708|NCT01974674|Experimental|Allogeneic transplantation of intrahepatic islet|Allogeneic transplantation of intrahepatic islet number required for insulin independence of obtaining, with a threshold dose of 9,000 IEQ/kg body weight of the recipient and a maximum sequence number of 3 infusions. The patient will receive after transplantation immunosuppressive therapy with Thymoglobulin for induction, Prograf and Cellcept, both of which are given throughout the duration of the study
3087709|NCT01974661|Experimental|COMBIG-DC|COMBIG-DC (allogeneic dendritic cells) Cancer Vaccine 3 vaccinations: 5, 10 or 20 million cells per injection
3087710|NCT01974648|Active Comparator|propofol|In control group, propofol concentrations will start at 4 μg ml-1, with 0,5 μg ml-1 as the step size, with the coadministration of saline.
3087711|NCT01974648|Experimental|propofol and remifentanil|In propofol-remifentanil group, propofol + remifentanil at a target-controlled infusion 5 ng/mL will be coadministered.
3087712|NCT01974635|Experimental|AMES Therapy|During treatment, the AMES device rotates the hand, into flexion and extension, while the patient assists with this motion. At the same time, the AMES device provides sensory stimulation by vibrating the tendons of muscles stretched by the movement. The vibratory stimulus switches from one side of the limb to the other when the rotation reverses direction so that the sensory stimulation remains functionally related to the movement. This study provides for 25 AMES treatments over 8-13 weeks, at a rate of 2-3 sessions per week.
3109264|NCT01828463|Experimental|Nitisinone 4mg|interventional
3087713|NCT01974622|Experimental|Visudyne|Visudyne half fluence- 1 treatment with the possibility of a second treatment.
3087714|NCT01974609|Experimental|Narcotic|Hydrocodone + acetaminophen 4 times per day 1 week after surgery
3087715|NCT01974609|Active Comparator|non-narcotic|ibuprofen + acetaminophen 4 times per day 1 week after surgery
3087716|NCT01974596|Experimental|Probiotic Lactobacillus reuteri Vs Placebo|patients with full arch with dental implant received a tablet of Lactobacillus reuteri every day during 28 days, and after a wash-up, the same patients receive a tablet of placebo every day during 28 days
3087717|NCT01974583||the treatment group A|The people in treatment group were regrafted with thin split-thickness skin graft
3087718|NCT01974583||the control group B|The group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith & Nephew)
3087719|NCT01974583||the control group C|Group C were covered with paraffin gauze
3087720|NCT01974570|Experimental|Marealis refined peptide concentrate|Participants are provided in double blinded fashion to Marealis refined peptide concentrate
3087721|NCT01974570|Placebo Comparator|Placebo|Participants are provided in double blinded fashion to Placebo
3087722|NCT01974544|Experimental|Best medical treatment|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will will be treated using the American Diabetes Association protocol. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
3087723|NCT01974544|Experimental|gastric bypass surgery|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will undergo gastric bypass surgery, in the conventional procedure. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
3087724|NCT01974544|Experimental|sleeve gastrectomy|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will undergo sleeve gastrectomy surgery, in the conventional procedure. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
3087725|NCT01974531||Preterm birth/ Timely birth|
3087726|NCT01974531||Women/men|
3087727|NCT01974518|Active Comparator|Rituximab|Inj Rituximab 1 gram IV given on day 0 and day 15
3087728|NCT01974518|Active Comparator|Combination of Rituximab and Cyclophosphamide IV|IV Rituximab 1gram on day 0 and 15 750 mg IV cyclophosphamide in 250 ml of NS over 2-3 hr on day 1 and day 16
3087729|NCT01974505|Experimental|intubation using optiscope|The investigators are novice on optiscope. They will perform intubation using optiscope to patients scheduled elective surgery.
3087730|NCT01974492|Active Comparator|Upper leg vein|Upper leg vein harvesting
3087731|NCT01974492|Active Comparator|Lower leg vein|Lower leg vein harvesting
3087732|NCT01974479|Experimental|anti-CD19 redirected NK cells|This is a single arm study. Intravenous Infusion of activated NK cells bearing anti-CD19-BB-zeta receptors at cell dose of 0.5 - 5 x 10^7 CD56+ cells/kg, and up to 1 x 10^8 CD56+ cells/Kg
3087733|NCT01974466|Active Comparator|Goal A|"controled fluid therapy: 5~10ml/kg/hr fulfillment of two or more of four criteria:~heart rate <120 beats/min,~mean arterial blood pressure 65-85 mm Hg,~urine output ≥1 ml/kg /h~Hematocrit ≤35%."
3087734|NCT01974466|Other|Goal B|"controled fluid therapy: 5~10ml/kg/hr fulfillment of all of the following criteria:~1 central venous pressure8-12 mmHg , 2.mean arterial pressure 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%"
3087735|NCT01974453||Right transradial|Procedures performed through right transradial approach
3087736|NCT01974453||Left transradial|Procedures performed through left transradial approach
3087737|NCT01974453||Femoral|Procedures performed through transfemoral approach
3087738|NCT01974440|Placebo Comparator|Treatment Arm A|Treatment Arm A = background immune-chemotherapy (bendamustine and rituximab [BR] or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) for 6 cycles + placebo.
3087739|NCT01974440|Experimental|Treatment Arm B|Treatment Arm B = background immune-chemotherapy (BR or R-CHOP) for 6 cycles + PCI-32765 (Ibrutinib).
3087740|NCT01974414|Active Comparator|cedar honey|The two study groups were provided with standard treatment(dexamethasone and Fluconazole).The Case group(A) received cedar honey, 20 ml 3 times daily by swish and swallow technique, in addition to the standard treatment .
3087741|NCT01974414|No Intervention|control group|the control group (B) only received standard treatment(Dexametazone and Fluconazole).
3087742|NCT01974401|Active Comparator|water jet irrigator|patients used supra-gingival irrigators as an oral health measure
3087743|NCT01974401|No Intervention|control group|patients in this group received routine oral health care protocols.
3087744|NCT01974388|Active Comparator|LSG started 2 cm from the pylorus|laparoscopic sleeve gastrectomy starting 2 cm from the pylorus
3087745|NCT01974388|Active Comparator|LSG started 6 cm from pylorus|LSG started 6 cm from pylorus
3087746|NCT01974375|Experimental|micafungin|micafungin sodium IV (Mycamine®)
3087747|NCT01974375|Active Comparator|Fluconazole|Fluconazole IV (use same brand in each hospital)
3087748|NCT01974362||Cad/Cam Monolithic Zirconia|Patients that have a full-mouth (maxilla and mandible) dental implant supported rehabilitation restored with monolithic zirconia biomaterial
3087749|NCT01974362||Zirconia-Feldspathic|Patients that have a full-mouth (maxilla and mandible) implant supported rehabilitation restored with zirconia substructure and feldspathic veneered biomaterial
3087750|NCT01974349|Experimental|selumetinib 75mg (oral capsule fasted)|Volunteers will recieve selumetinib 75mg administered by mouth, as a capsule, in a fasted state.
3087751|NCT01974349|Experimental|selumetinib 75mg (oral capusle fed)|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule, in a fed state.
3087752|NCT01974336|Experimental|UDCA+placebo group|15-30mg/kg/d UDCA for 2 months + placebo for 2 months
3087753|NCT01974336|Experimental|placebo+UDCA|placebo for 2 months+15-30mg/kg/d UDCA for 2 months
3087754|NCT01974323|Experimental|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
3087755|NCT01974323|Placebo Comparator|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
3087756|NCT01974310|Active Comparator|Face-down positioning|Patients advised face-down positioning after surgery for macular hole.
3087757|NCT01974310|Experimental|Non-face-down positioning|Patients advised non-face-down positioning after surgery for macular hole.
3087758|NCT01974297|Active Comparator|Atorvastatin 20mg, monotherapy|Atorvastatin 20mg/day PO for 12weeks
3087759|NCT01974297|Experimental|Atorvastatin 10mg, Fenofibric acid 135mg|Atorvastatin 10mg, Fenofibric acid 135mg per day PO for 12weeks
3087760|NCT01974284|Experimental|percutaneous ethanol ablation|The experimental group of the study is comprised of patients that will undergo percutaneous ethanol ablation for the management of papillary thyroid microcarcinoma.
3087761|NCT01974271||Cohort|
3087762|NCT01974258|Experimental|Dose-expansion: onartuzumab + cobimetinib|
3087763|NCT01974258|Experimental|Dose-expansion: onartuzumab + vemurafenib|
3087764|NCT01974258|Experimental|Dose-expansion: onartuzumab + vemurafenib + cobimetinib|
3087765|NCT01974258|Experimental|Dose-finding: onartuzumab + vemurafenib + cobimetinib|
3087766|NCT01974245|Placebo Comparator|Placebo|100 drops/week for 12 weeks
3087767|NCT01974245|Active Comparator|Cholecalciferol|Drug: Cholecalciferol - 100,000 IU/week
3087768|NCT01974232||Romiplostim group|
3087769|NCT01974232||Eltrombopag group|
3087770|NCT01974219||Healthy nonsmokers|Healthy nonsmokers
3087771|NCT01974219||Healthy smokers|Healthy smokers
3087772|NCT01974219||COPD smokers|COPD smokers
3087773|NCT01974206|Experimental|ASP0113|One (1) mL of 5 mg/mL ASP0113 will be administered to the subjects at the clinical site via injection
3087774|NCT01974206|Placebo Comparator|Placebo|One (1) mL of 5 mg/mL placebo will be administered to the subjects at the clinical site via injection
3087775|NCT01974193|Experimental|Floseal|application of floseal to one side of pelvis after pelvic lymphadenectomy
3087776|NCT01974193|No Intervention|Control|counter-site of pelvis; no intervention after pelvic lymphadenectomy
3087777|NCT01974167|Experimental|Eldecalcitol group|Eldecalcitol 0.75 microgram once daily orally
3087778|NCT01974167|Active Comparator|Alfacalcidol group|Alfacalcidol 1 microgram once daily orally
3087779|NCT01974154||Cohort I|A. Healthy nonsmokers B. Healthy smokers C. Healthy smokers/quit smoking D. COPD smokers E. COPD smokers/ quit smoking
3087780|NCT01974154||Cohort II|A. Smokers with normal spirometry and normal DLCO B. Smokers, normal spirometry, low DLCO
3087781|NCT01974141|Experimental|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
3087782|NCT01974141|Placebo Comparator|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
3087783|NCT01974115|Active Comparator|Radial extracorporeal shock wave therapy|All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
3087784|NCT01974102|Experimental|lifestyle|Both active and control groups will receive counseling on nutrition and physical activity.
3087785|NCT01974102|Experimental|therapy|Active group will receive 8 weeks of mindfulness based stress reduction therapy
3087786|NCT01974089|Other|Modified diet|
3087787|NCT01974076|Active Comparator|Active tDCS|
3087788|NCT01974076|Sham Comparator|Sham tDCS|
3087789|NCT01974063||A. Nonsmokers|Subjects have smoked <100 cigarettes or <10 shisha pipes per lifetime and whose urine nicotine <2 ng/mL and/or urine cotinine <5 ng/mL, at entry into the study.
3087790|NCT01974063||B.Current cigarette smokers|Defined by self-report and urine nicotine >30 ng/mL and/or urine cotinine >50 ng/ml.
3087791|NCT01974063||C. Current shisha smokers|Defined by self-report of smoking >4 pipes/wk and carboxyhemoglobin >2.5.
3087792|NCT01974063||D. smokers willing to quit|Defined by self-report and urine nicotine >30 ng/ml and/or urine cotinine >50 ng/ml. Subjects must be a current smoker willing to stop smoking. Subjects will stop smoking after the baseline bronchoscopy, and switch to taking a smoking cessation medication called varenicline. We will provide subjects with the smoking cessation medication as part of this study. They will also receive phone calls to help with smoking cessation counseling.
3087793|NCT01974063||E. Smokers switching to E-cigarettes|Defined by self-report and urine nicotine >30 ng/ml and/or urine cotinine >50 ng/ml. Must be willing to switch from tobacco cigarettes to electronic cigarettes. The switch will occur after the baseline bronchoscopy. The nicotine dose that will be given to each subject will be determined by the study physician based on the urine smoking metabolite test. It will be adjusted depending on whether the subject is a light smoker or heavy smoker (Light smoker defined as having either a urine nicotine value from 2ng/ml-1000ng/ml or a urine cotinine value from 5ng/ml-1000ng/ml. Heavy smoker is defined as having either a urine nicotine or cotinine value of over 1000ng/ml.) We will provide the subjects with the electronic cigarettes to use as part of this study.
3087794|NCT01974050|Other|Text message monitoring|Use of text messaging to monitor post-vaccination
3087795|NCT01974037|Active Comparator|Capsaicin_effect subgroup 1|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of water with capsaicin.
3087796|NCT01974037|Experimental|Capsaicin_effect subgroup 2|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 100 mmol/L NaCl with capsaicin.
3087797|NCT01974037|Experimental|Capsaicin_effect subgroup 3|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 150 mmol/L NaCl with capsaicin.
3087798|NCT01974037|No Intervention|Capsaicin_effect subgroup 4|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 200 mmol/L NaCl.
3087799|NCT01974037|No Intervention|Salt_effect subgroup 1|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of water.
3087800|NCT01974037|Experimental|Salt_effect subgroup 2|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 100 mmol/L NaCl.
3087801|NCT01974037|Experimental|Salt_effect subgroup 3|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 150 mmol/L NaCl.
3087802|NCT01974037|Experimental|Salt_effect subgroup 4|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 200 mmol/L NaCl.
3087803|NCT01974024|Experimental|Methylprednisolone|Dexamethasone was replaced with methylprednisolone as an antiemetic.
3087804|NCT01974024|Active Comparator|Dexamethasone|Dexamethasone was re-administered in the cycle.
3087805|NCT01974011|Experimental|Dorsal penile nerve block according to Dalens' technique|Two injections at the dorsum penis according to Dalens' technique.
3087806|NCT01974011|Active Comparator|DPNB with additional infiltration of the ventromedial penis|"Modified procedure:~Two injections at the dorsum penis according to Dalens' technique plus on subcutaneous injection in the ventral midline of the penis at the transition between the penis and the scrotum."
3087807|NCT01973998|Experimental|Roflumilast|500 ug tablet daily for 180 days
3087808|NCT01973998|Placebo Comparator|Placebo|Placebo 1 tablet daily x 180 days
3087809|NCT01973972|Experimental|Weight management/shared medical appointment (WM/SMA)|Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
3087810|NCT01973972|Active Comparator|Shared medical appointments (SMA)|Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.
3087811|NCT01973946|No Intervention|Usual Care|Patients in the usual care group called the automated monitoring system daily to report presence, severity, and distress for 11 common symptoms. The attentional control group received equivalent contact time with the automated system including identical voice and assessment questions. Patients did not hear self-care messages during the call and the data were not available for clinical action by the study nurse practitioner. Patients were told on every phone call to call their oncology providers if they had concerns about their symptoms which is usual care for symptom follow up in oncology.
3087812|NCT01973946|Experimental|Symptom Alert and Coaching|"Patients in the Symptom Alert and Coaching arm called the automated monitoring system daily to report presence, severity, and distress on 11 symptoms. The system provided automated self care coaching based on the symptoms reported and automatically generated alerts to the study NP if symptoms exceeded preset thresholds. Two thresholds were set: a simple alert when severity or distress was 4 or greater on a 10 point scale and trend alerts based on a pattern of moderate severity over several days.~The alerts went into a case management site. The study NP logged into the system daily and responded to the alerts within 24 hours by calling patients to further assess the symptoms and to intensify symptom treatment using evidence based guidelines."
3087813|NCT01973933|Experimental|Metformin and Pyrimethamine|Metformin 750mg(D1), Metformin 500mg(D2)/Metformin 750mg+Pyrimethamine 50mg(D7), Metformin 500mg+Pyrimethamine 50mg(D8)
3087814|NCT01973920|Experimental|Oshadi Icp|Oshadi Icp oral insulin,
3087815|NCT01973907|No Intervention|Usual Care Resuscitation Strategy|Decisions regarding the IV/IO administration of isotonic fluid boluses and/or the initiation and escalation of vasoactive medication infusions are left to the discretion of the treating physician and medical team. We ask that vasoactive medications not be initiated until at least 60 mL/kg (3 litres for children ≥ 50 kg) of isotonic fluid bolus therapy has been administered. The treating physician and medical team are advised to follow ACCM guidelines for the resuscitation of neonatal and pediatric septic shock and to target ACCM recommended therapeutic endpoints.
3087816|NCT01973907|Experimental|Fluid Sparing Resuscitation Strategy|The treating physician and medical team are advised to follow the assigned Fluid Sparing Resuscitation Strategy to guide decisions regarding the IV/IO administration of further isotonic fluid boluses, and the timing of initiation and escalation of vasoactive medication infusions to target the therapeutic endpoints recommended in the ACCM guidelines for the resuscitation of neonatal and pediatric septic shock.
3087817|NCT01973894||Midazolam|"Patients will be enrolled within 24h from the beginning of continuous Midazolam perfusion.~Blood and urine sampling will follow this schedule:~24h: blood (3ml)~48h: blood (3ml) and urine~End of infusion: blood (3ml)~6h after end of infusion: blood (3ml) and urine.~Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.~Then all frozen samples will be analyzed to get Midazolam concentrations."
3087818|NCT01973881||T1 weighted MRI (magnetic resonance imaging)|For the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis. Quantitative MRI parameters for diffusion of water and/or fat content in bone marrow will determine extent of disease in patients with myelofibrosis, and changes in these parameters will predict response to therapy. To investigate this hypothesis, the researchers will perform this pilot clinical study of diffusion and fat content (T1 weighted imaging) in patients before and during treatment for myelofibrosis. The researchers expect to identify MRI parameters that determine the extent and severity of bone marrow disease in these patients and determine response to therapy at earlier time points than currently used clinical parameters.
3087819|NCT01973868|Experimental|Regorafenib|"Regorafenib will be administered once daily on Days 1-21 of each 28-day Cycle (3 weeks on / 1 week off). The starting dose of regorafenib is 120 mg q.d., if this is tolerable in combination with cetuximab the dose will be escalated to 160 mg q.d.; if it is not tolerated the dose will be de-escalated to 80 mg q.d.~Subjects will receive an initial i.v. infusion of cetuximab (loading dose of 400 mg/ m2 BSA) on Pre-cycle Day -7.~The treatment of regorafenib in combination with cetuximab maintenance dose (250 mg/m2 BSA) starts on Cycle 1 Day 1.~Cetuximab infusions will be given in a once-weekly dosing-regimen as approved."
3087820|NCT01973855|Experimental|TCM and Western Medicine|TCM and Western Medicine:First Infectious diseases soup recipe,every time a dose,Two times a day;Ribavirin 10-15mg per kg every time Western Medicine：Ribavirin 10-15mg per kg every time
3087821|NCT01973855|Placebo Comparator|Western Medicine|Western Medicine：Ribavirin 10-15mg per kg every time
3087822|NCT01973842|Active Comparator|0.2 mg triptorelin|0.2 mg triptorelin compared with 0.1 mg triptorelin and 0.4 mg triptorelin
3087823|NCT01973842|Active Comparator|0.1 mg triptorelin|0.1 mg triptorelin compared with 0.2 mg triptorelin and 0.4 mg triptorelin
3087824|NCT01973842|Active Comparator|0.4 mg triptorelin|0.4 mg triptorelin compared with 0.1 mg triptorelin and 0.2 mg triptorelin
3087826|NCT01973816|Experimental|Medical treatment|The patients received triptoreline and add back therapy by estradiol during 6 months, followed by daily intake of cyproterone acetate and add back therapy during 18 months.
3087827|NCT01973816|Active Comparator|Surgical|The patients are managed by rectal surgery (depending on the surgeon choice: rectal shaving, rectal disc excision or colorectal resection) followed by the prevention of recurrences by daily intake of cyproterone acetate and add back therapy during 18 months.
3087828|NCT01973790|Experimental|Z-338|100mg TID
3087829|NCT01973777|Experimental|IUB|There is one arm of women who will have IUBs inserted
3087830|NCT01973764|Other|Ultrasound guided arm|
3087831|NCT01973764|Other|Landmark-based arm|
3087832|NCT01973751|No Intervention|Healthy controls|Healthy controls who will be studied at baseline and serve as a control group for the bronchoscopy, induced sputum and peripheral blood collection.
3087833|NCT01973751|Active Comparator|Asthmatics (treatment)|Steroid-naïve asthma, randomized to inhaled budesonide, 2 puffs (200mcg) twice a day for 8 weeks. These subjects will undergo bronchoscopy and induced sputum collection at baseline, undergo pulmonary function testing and peripheral blood collection at baseline, 4 and 8 weeks after treatment with inhaled corticosteroids.
3087834|NCT01973751|No Intervention|Asthmatics (no treatment)|Steroid-naïve asthmatics randomized to no treatment for 8 weeks. These subjects will undergo bronchoscopy and induced sputum collection at baseline, undergo pulmonary function testing and peripheral blood collection at baseline, 4 and 8 weeks of no treatment.
3087835|NCT01973725|Experimental|Icotinib Hydrochloride|Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.
3087836|NCT01973712|Experimental|Locked Compression Plating|A direct lateral approach to the distal femur will be employed utilizing minimally invasive and indirect reduction techniques. After fracture reduction is achieved with the use of intra-operative fluoroscopy, a locking plate will be provisionally implanted. Following confirmation of placement, definitive fixation will follow with multiple locking screws in the distal fragment and bicortical screw fixation proximally. A standard layered closure will follow
3087837|NCT01973712|Experimental|Retrograde Intramedullary Nailing (RIMN)|The previous midline knee incision will be employed to access to the knee joint, allowing exposure of the femoral start point via the open box in the femoral component. Following reaming of the canal, an appropriately sized retrograde nail will be inserted. Intra-operative fluoroscopy will be used to confirm reduction. Both proximal and distal locking screws will be used to transfix the nail. A standard layered closure will follow.
3087838|NCT01973699|Placebo Comparator|With Epinephrine|Patients undergoing shoulder arthroscopy with epinephrine in their irrigation as standardly performed
3087839|NCT01973699|Experimental|Without Epinephrine|Patients undergoing shoulder arthroscopy without epinephrine in their irrigation fluid as typically done
3087840|NCT01973686|Experimental|Vigorous intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 70% of maximal oxygen uptake (VO2 max); Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
3087841|NCT01973686|Experimental|Moderate intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 50% VO2 max; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
3087842|NCT01973686|No Intervention|Control|Receives no intervention
3087843|NCT01973673|Active Comparator|Bone health educational materials|Bone health written educational materials, Bone health prescription,verbal counselling
3087844|NCT01973673|No Intervention|Usual care|Usual clinical care to be provided by oncologists.
3087845|NCT01973660|Experimental|Dual HER2 blockade|For a total of 18 weeks, HR-negative patients will be given dual blockade consisting of daily lapatinib at 1000 mg and trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks.
3087846|NCT01973660|Experimental|Dual HER2 blockade plus endocrine therapy|For a total of 18 weeks, HR-positive patients will be given letrozole (2.5 mg daily) or tamoxifen (20 mg daily) with concurrent dual blockade consisting of daily lapatinib at 1000 mg and trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks.
3087847|NCT01973647|Experimental|Cognitive Behavioral Therapy (CBT-I)|Six weekly sessions of Cognitive Behavioral Therapy for Insomnia
3087848|NCT01973647|Experimental|CBT-I + COPD-ED|Six weekly sessions of Cognitive Behavioral Therapy for Insomnia plus COPD Education
3087849|NCT01973647|Experimental|COPD Education (COPD-ED)|Six weekly sessions of COPD education
3087850|NCT01973647|Placebo Comparator|Attention Control (AC)|Six weekly sessions of non-sleep, non-COPD health education
3087851|NCT01973634|Active Comparator|Minimal surgical margin 1 mm, conventional arm: seq boost|Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost).
3087852|NCT01973634|Experimental|Minimal surgical margin of 1 mm, experimental arm with SIB|Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
3087853|NCT01973634|Active Comparator|Minimal surgical margin <1 mm, conventional arm: seq boost|Minimal surgical margin < 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
3087854|NCT01973634|Experimental|Minimal surgical margin < 1 mm, experimental arm with SIB.|Minimal surgical margin < 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
3087855|NCT01973608|Experimental|MSB0010445 Low Dose Cohort 0.3 mg/kg|
3087856|NCT01973608|Experimental|MSB0010445 Intermediate Dose Cohort 1.0 mg/kg|
3087857|NCT01973608|Experimental|MSB0010445 High Dose Cohort 1.8 mg/kg|
3087858|NCT01973608|Experimental|MSB0010445 High Dose Cohort 2.4 mg/kg|
3087859|NCT01973595|Experimental|Almonds then no almonds|Adults will consume 1.5 ounces of almonds or almond paste per day and children will consume 0.5 ounces of almonds or almond paste per day for 3 weeks.
3087860|NCT01973595|Other|No almonds then almonds|No almonds will be consumed by participants for 3 weeks.
3087861|NCT01973569|Experimental|Denosumab 6 months|denosumab administered subcutaneously every 6 months
3087862|NCT01973569|Experimental|Denosumab 3 months|denosumab administered subcutaneously every 3 months
3087863|NCT01973569|Placebo Comparator|placebo|placebo administered subcutaneously to match denosumab
3087864|NCT01973556|Experimental|Pharmacist-Physician Collaborative Medication Management|Pharmacist-Physician Collaborative Medication Management
3087865|NCT01973556|No Intervention|Usual Care|
3087866|NCT01973543|Experimental|VY-AADC01 Dose 1|7.5 x 10^11 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
3087867|NCT01973543|Experimental|VY-AADC01 Dose 2|1.5 x 10^12 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
3087868|NCT01973543|Experimental|VY-AADC01 Dose 3|4.7x 10^12 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
3087869|NCT01973530|Active Comparator|adductor canal block|Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
3087870|NCT01973530|Other|continuous femoral nerve block|Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
3087871|NCT01973517||Relapsing Remitting MS|Patients with relapsing remitting multiple sclerosis will be imaged under high-field (7T) MRI prior to and following administration of gadolinium-based contrast (0.1 mmol/kg IV). Afterwards, they will be administered Feraheme 5mg/kg IV via slow push, and they will return 24 hours or later after pharmaceutical administration for post-Feraheme MR imaging.
3087872|NCT01973504|Experimental|MP4OX 500-mL|500-mL dose of MP4OX
3087873|NCT01973504|Experimental|MP4OX 750-mL|750-mL dose of MP4OX
3087874|NCT01973504|Sham Comparator|Control|Standard crystalloid Keep Vein Open (KVO) infusion
3087875|NCT01973491|Experimental|ATX-MS-1467|
3087876|NCT01973478|Experimental|DBS|"The medical device includes:~Either a pacemaker ACTIVA PC (Ref 37601) two-channel (Medtronic USA) or two pacemakers Activa SC (Ref 37603) to a channel (Medtronic USA)~Two DBS electrodes with four contacts (type Medtronic DBS 3389). Patients will be operated with the usual stereotactic surgical procedure.~The target is the Accumbens nucleus.~The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery.~The DBS is on during 6 months (between Month 1 and Month 7). Stimulation will also be on after Month 7."
3087877|NCT01973478|Sham Comparator|SHAM|"The medical device includes:~Either a pacemaker ACTIVA PC (Ref 37601) two-channel (Medtronic USA) or two pacemakers Activa SC (Ref 37603) to a channel (Medtronic USA)~Two DBS electrodes with four contacts (type Medtronic DBS 3389). Patients will be operated with the usual stereotactic surgical procedure.~The target is the Accumbens nucleus.~The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery.~The DBS is off during 6 months (between Month 1 and Month 7). Possibility to active the stimulation after Month 7."
3087878|NCT01973465|Experimental|Fecal Microbiota Therapy|
3087879|NCT01973452|Experimental|Dexmedetomidine|continuous infusion of 0.4 mcg/kg/hr
3087880|NCT01973452|Placebo Comparator|Placebo|continuous infusion of 0.4 mcg/kg/hr
3087881|NCT01973439|Other|Abacavir Once versus Twice Daily|This is a single arm study. Intervention 1: PK assessment while on Twice Daily Abacavir (Week 0) Intervention 2: PK assessment while on Once Daily Abacavir (Week 4)
3087882|NCT01973426||Children with limited control of their thumb|Children afflicted by hemiplegic stroke or hemiplegic cerebral palsy who have lost the ability to actively (and accurately) control the thumb.
3087883|NCT01973413|Experimental|Closed-Loop Control with DiAs System|Subjects will use the Diabetes Assistant (DiAs) and will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. Subjects will be remotely monitored throughout the night in real time.
3087884|NCT01973413|Placebo Comparator|Control Group, Sensor-Augmented Pump Therapy|Subjects will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. They will not use the Diabetes Assistant (DiAs) nor have remote monitoring.
3087885|NCT01973400|Experimental|Tocotrienol|200 mg, twice a day, 12 months
3087886|NCT01973400|Placebo Comparator|Placebo|200 mg, twice a day, 12 months
3087887|NCT01973387|Experimental|Treatment Arm A|
3087888|NCT01973387|Experimental|Treatment Arm B|
3087889|NCT01973374|No Intervention|Routine Care|
3087890|NCT01973374|Experimental|Text Message Intervention|The text message intervention group receives usual prenatal and diabetic care in addition to two text messages per week throughout the pregnancy and a reminder text message prior to the postpartum visit. The text message intervention group also fills out a survey about the intervention after delivery.
3087891|NCT01973361|Experimental|Ultrasound debridement|Participants receiving ultrasound assisted debridement in addition to best practice wound care.
3087892|NCT01973361|Active Comparator|Best Practice wound care|Participants receiving best practice wound care alone
3087893|NCT01973348|Experimental|4-hour AmblyZ glasses|4-hour AmblyZ glasses for moderate amblyopia
3087894|NCT01973348|Active Comparator|2-hour eye patching|2-hour eye patching for moderate amblyopia
3087895|NCT01973348|Experimental|12-hour AmblyZ glasses|12-hour AmblyZ glasses for severe amblyopia
3087896|NCT01973348|Active Comparator|6-hour eye patching|6-hour eye patching for severe amblyopia
3087897|NCT01973335|Experimental|Acetazolamide/low-dose loop diuretics, upfront spironolactone|"2x2 factorial design: This group is the experimental group for both study interventions (acetazolamide and upfront spironolactone).~See interventions for more details."
3087898|NCT01973335|Experimental|High-dose loop diuretics, upfront spironolactone|"2x2 factorial design: This group is the experimental group for the study intervention with upfront spironolactone. This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide.~See interventions for more details."
3087899|NCT01973335|Experimental|Acetazolamide/low-dose loop diuretics, no spironolactone|"2x2 factorial design: This group is the experimental group for the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.~See interventions for more details."
3087900|NCT01973335|Active Comparator|High-dose loop diuretics, no spironolactone|"2x2 factorial design: This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.~See interventions for more details."
3109265|NCT01828463|Experimental|Nitisinone 8mg|interventional
3087901|NCT01973322|Experimental|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
3087902|NCT01973322|Experimental|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
3087903|NCT01973322|Experimental|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
3087904|NCT01973322|Experimental|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
3087905|NCT01973309|Experimental|Vantictumab combined with paclitaxel|Drug: vantictumab combined with paclitaxel - administered intravenously
3087906|NCT01973296|Experimental|ED to home care transition|The ED to home care transition intervention is a 4-week program that uses a Area Agency on Aging coach to conduct a home visit and three follow up phone calls to help patients develop the skills needed for self-management and to communicate with healthcare providers.
3087907|NCT01973296|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
3087908|NCT01973283|Experimental|Medication Treatment|Participants are treated with a flexible-dose antidepressant medication for a period of 8 weeks.
3087909|NCT01973270|Experimental|Targeted Cognitive Training - TCT|Neuroadaptive cognitive training
3087910|NCT01973270|Experimental|General Cognitive Exercises (GCE)|Neuroadaptive cognitive training
3087911|NCT01973270|No Intervention|Treatment as Usual|Treatment as Usual
3087912|NCT01973257|Experimental|select from the option menu|select from the option menu
3087913|NCT01973244|Experimental|NNC0195-0092 (somapacitan)|
3087914|NCT01973244|Active Comparator|Norditropin®|
3087915|NCT01973231|Experimental|Metformin + liraglutide 1.8 mg|
3087916|NCT01973231|Active Comparator|Metformin + lixisenatide 20 microg|
3087917|NCT01973218|Experimental|rMenB|Subjects received two doses of rMenB+OMV NZ vaccine (at Day 1 and Day 31) in the study.
3087918|NCT01973218|Active Comparator|Placebo/MenACWY|Subjects received one dose of saline placebo (Day 1) and one dose of MenACWY-CRM vaccine (Day 31) in the study.
3087919|NCT01973205|Placebo Comparator|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
3087920|NCT01973205|Experimental|Acetaminophen 250 mg and aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and aspirin 250 mg
3087921|NCT01973179||Radiation therapy|Radiotherapy with protons in patients with head and neck carcinoma
3087922|NCT01973166|Experimental|Picosecond Q-switched Laser Treatment|Picosecond Q-switched Nd:YAG (1064 nm and 532 nm) laser
3087923|NCT01973166|Active Comparator|Nanosecond Q-switched Laser Treatment|Nanosecond Q-switched Nd:YAG (1064 nm and 532 nm) laser
3087924|NCT01973153|Active Comparator|Brief Motivational Counseling (BMC)|
3087925|NCT01973153|Active Comparator|Brief Motivational Counseling Plus Phone Calls (BMC+Phone)|
3087926|NCT01973153|Active Comparator|Brief Motivational Counseling Plus Home Visits (BMC+Home)|
3087927|NCT01973140|Other|Tolvaptan and Hypertonic saline infusion|Tolvaptan 60 mg or 30 mg tablet by mouth for the first part of the study. A week later, infusion of hypertonic saline.
3087928|NCT01973127|Experimental|Verum rTMS|"n=15. After detoxification of alcohol (maximum 4 days) rTMS treatment will start : 20 sessions (5 times during 4 weeks)of verum rTMS on the right dorsolateral prefrontal cortex.~Measurements of all objectives at baseline and 2,4,8 and 12 weeks after start treatment."
3087929|NCT01973127|Sham Comparator|Sham TMS|"n=15. After detoxification of alcohol (maximum 4 days) rTMS treatment will start : 20 sessions (5 times during 4 weeks)of sham rTMS on the right dorsolateral prefrontal cortex.~Measurements of all objectives at basleine and 2,4,8 and 12 weeks after start treatment."
3087930|NCT01973114|Experimental|Group 1|One intratympanic injection of latanoprost (Day1)
3087931|NCT01973114|Placebo Comparator|Group 2|One intratympanic injection of placebo
3087932|NCT01973114|Experimental|Group 3|Three intratympanic injections of latanoprost (Day 1, 2 and 3)
3087933|NCT01973114|Placebo Comparator|Group 4|Three intratympanic injections of placebo (Day 1, 2 and 3)
3087934|NCT01973101|Experimental|Chemo-induction|Cisplatin plus Gemcitabine for 3 cycles followed by Cisplatin, radiotherapy and brachytherapy
3087935|NCT01973101|Active Comparator|Chemoradiotherapy|Cisplatin, radiotherapy and brachytherapy
3087936|NCT01973088||non-urate calculus|
3087937|NCT01973088||non-calculus|
3087938|NCT01973088||urate calculus|
3087939|NCT01973075||premature ovarian Insufficiency|4ml whole blood sample is going to collect from premature ovarian Insufficiency group for the assessment of genetic abnormalities
3087940|NCT01973075||healthy control group|4 ml of whole blood is going to taken from healthy control group
3087941|NCT01973062|Experimental|rituximab and yttrium Y 90 ibritumomab tiuxetan|Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.
3087942|NCT01973049|Experimental|A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Placebo matching Ribavirin 0mg tablet orally twice a day for 12 weeks"
3087943|NCT01973049|Experimental|A2: DCV/ASV/BMS-791325 + RBV (naive)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Ribavirin 200mg tablet orally twice a day for 12 weeks"
3087944|NCT01973049|Experimental|A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Placebo matching Ribavirin 0 mg tablet orally twice a day for 12 weeks"
3087980|NCT01972776|Experimental|QBM076 Part 1 Cohort 1|Participants received QBM076 25 mg twice daily (bid) for 14 days.
3087981|NCT01972776|Experimental|QBM076 Part 1 Cohort 2|Participants received QBM076 75 mg bid for 14 days.
3087982|NCT01972776|Experimental|QBM076 Part 1 Cohort 3|Participants received QBM076 150 mg bid for 14 days.
3087945|NCT01973049|Experimental|A4: DCV/ASV/BMS-791325 + RBV (experienced)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Ribavirin 200 mg tablet orally twice a day for 12 weeks, Weight based dosing: If < 75 kg, 1000 mg per day (two 200 mg tablets in AM and three 200 mg tablets in PM); if ≥ 75 kg, 1200 mg per day (three 200 mg tablets in AM and three 200 mg tablets in PM), AM=in the morning, PM=in the evening"
3087946|NCT01973036|Active Comparator|Oxytocin|This arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
3087947|NCT01973036|Experimental|Foley Catheter and Oxytocin|A 30cc/16 French (16F) foley catheter will be inserted by the provider under direct visualization or by palpation, ensuring that the catheter is appropriately and adequately positioned. Oxytocin will be administered concurrently at a rate of 2 milliunits/milliliter (as noted under oxytocin active comparator). If the catheter remains in place after 12 hours, it will be deflated and removed and oxytocin infusion will continue.
3087948|NCT01973023||Chronic spastic stroke patients|Chronic spastic stroke patients treated regularly with botulinum toxin injection in lower limb muscles
3087949|NCT01973010|Experimental|Massage|To treat low back pain with massage
3087950|NCT01973010|Active Comparator|Ibuprofen|Medicine control group
3087951|NCT01972997|Experimental|SENSIMED Triggerfish|There is only 1 arm in the study. SENSIMED Trigerfish lens sensors with different base curves are placed on subjects in random and double-blinded manner in sequential sessions.
3087952|NCT01972984|Experimental|Anastrozole|All qualifying women will receive anastrozole at the usual dose of 1mg daily for 2-6 weeks leading up to their surgery
3087953|NCT01972971|Other|pharmacist care|
3087954|NCT01972958|Experimental|comprehensive care|comprehensive assessment, physical activity training, community resources referral, health education, health promotion activity.
3087955|NCT01972958|No Intervention|usual care|control group with usual care
3087956|NCT01972945|Experimental|Vaginoscopy|Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.
3087957|NCT01972945|Active Comparator|Standard Hysteroscopy|Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
3087958|NCT01972932|Placebo Comparator|Placebo|Placebo 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
3087959|NCT01972932|Active Comparator|Bio K+®|Bio K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
3087960|NCT01972919|Experimental|Radiation therapy plus chemotherapy|MR guided dose escalated radiation therapy plus concurrent chemotherapy in unresectable non-metastatic pancreas cancer. Radiation therapy dose escalation to an MR-defined GTV of up to 69.75 Gy at 2.25 Gy per fraction and concurrent Gemcitabine or Capecitabine.
3087961|NCT01972906|Experimental|Moxibustion treatment group|Apply traditional acupuncture to prevent the dysmenorrhea according to traditional Chinese medicine theory
3087962|NCT01972906|Active Comparator|Medicine control group|Ibuprofen Sustained Release Capsules will be penetrated for dysmenorrhea
3087963|NCT01972893|Experimental|ZYD1|Tablet ZYD1 5 to 50 mg subcutaneously Once a day (OD) or BID depending upon the pharmacokinetic profile obtained in Plan I (Single dose study)
3087964|NCT01972893|Placebo Comparator|Placebo|Tablet Placebo 5 to 50 mg subcutaneously OD or BID depending upon the pharmacokinetic profile obtained in Plan I (Single dose study)
3087965|NCT01972880|Experimental|tablet-1|
3087966|NCT01972880|Active Comparator|tablet-2|
3087967|NCT01972867|Experimental|NanoKnife Procedure|The NanoKnife procedure will be performed on focal prostate tumors, under ultrasound guidance.
3087968|NCT01972854|Experimental|riboflavin solution and KXL System|The cornea will receive 5 drops of VibeX (0.12% riboflavin ophthalmic solution). Five additional VibeX drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
3087969|NCT01972854|Placebo Comparator|placebo solution and KXL System|The cornea will receive 5 drops of placebo (0.0% riboflavin ophthalmic solution. Five additional placebo drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
3087970|NCT01972841|Experimental|1: Solifenacin 5 mg + Mirabegron 25 mg|Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.
3087971|NCT01972841|Experimental|2: Solifenacin 5 mg + Mirabegron 50 mg|Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.
3087972|NCT01972841|Placebo Comparator|3: Placebo|Participants who received matching placebo once a day for 12 weeks.
3087973|NCT01972841|Active Comparator|4: Solifenacin 5 mg|Participants who received solifenacin 5 mg once a day for 12 weeks.
3087974|NCT01972841|Active Comparator|5:Mirabegron 25 mg|Participants who received mirabegron 25 mg once a day for 12 weeks.
3087975|NCT01972841|Active Comparator|6: Mirabegron 50 mg|Participants who received mirabegron 50 mg once a day for 12 weeks.
3087976|NCT01972828|Experimental|PRELOAD DEPENDENCE|in this arm, fluid loading is administered with an algorithm using preload dependence indexes (variation in cardiac output in response to passive leg raising).
3087977|NCT01972828|Active Comparator|CONTROL|
3087978|NCT01972789|Experimental|Intensive retinal fluid regimen|Ranibizumab 0.5mg is given monthly for the first 3 months followed by an individualised treatment regimen as determined by disease activity defined by a loss of ≥5 letters, new retinal haemorrhage, presence of any IRF or SRF on OCT.
3087979|NCT01972789|Experimental|Relaxed retinal fluid regimen|Ranibizumab 0.5mg is given monthly for the first 3 months followed by an individualised treatment regimen as determined by disease activity defined by a loss of ≥5 letters, new retinal haemorrhage, presence of IRF or SRF >200 um on OCT.
3087983|NCT01972776|Placebo Comparator|Placebo Part 1|Participants in each cohort received matching placebo for 14 days.
3087984|NCT01972776|Experimental|QBM076 Part 2|Participants received QBM076 150 mg bid for 8 weeks.
3087985|NCT01972776|Placebo Comparator|Placebo Part 2|Participants received matching placebo for 8 weeks.
3087986|NCT01972763|Active Comparator|Ranibizumab 1 mg|Subjects will receive Ranibizumab 0.5 mg for 3 doses and then be separated into 2 arms based on initial response. In this Arm (Arm 1), patients will receive 1 mg of Ranibizumab monthly for the remainder of the study, if persistent or worse subretinal fluid with or without intraretinal cysts on SD-OCT is present.
3087987|NCT01972763|Active Comparator|Ranibizumab 0.5 mg|Subjects will receive Ranibizumab 0.5 mg for 3 doses and then be separated into 2 arms based on initial response. In this Arm (Arm 2), patients will receive 0.5 mg of Ranibizumab monthly for the remainder of the study, if complete resolution of subretinal fluid on SD-OCT is present.
3087988|NCT01972750|Experimental|Dovitinib|IMP: Dovitinib (TKI258) Manufacturer: Novartis Dose: 500 mg/day Mode of application: orally Duration of treatment: 5 days / week (5 days on / 2 days off) of a 28-days cycle until progression of disease
3087989|NCT01972737|Experimental|Ad5-hGCC-PADRE Vaccine|Active vaccine
3087990|NCT01972724|Experimental|Pioglitazone 15 mg (Double-Blind)|Pioglitazone 15 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
3087991|NCT01972724|Experimental|Pioglitazone 30 mg (Double-Blind)|Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
3087992|NCT01972724|Experimental|Pioglitazone 30 mg (Open-Label)|Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
3087993|NCT01972711|Experimental|SEP-363856|Single-dose SEP-363856 50 mg
3087994|NCT01972711|Active Comparator|Amisulpride|Single-dose Amisulpride 400 mg.
3087995|NCT01972711|Placebo Comparator|Placebo|Matched placebo
3087996|NCT01972698|Experimental|Self-directed and simulation-assisted training|
3087997|NCT01972698|Active Comparator|Traditional apprenticeship training|
3087998|NCT01972685|Other|Cryo vs Transbronchial vs VATS biopsy|Each patient will be brought to the operating room and will undergo transbronchial, cryoprobe and VATS biopsy of the lung.
3087999|NCT01972672|Experimental|Icaritin|Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
3088000|NCT01972659|Active Comparator|sugammadex and placebo|sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 placebo: isotonic saline (%0.9 NaCl) 50 mg/kg iv bolus plus 15 mg/kg continuous infusion until the end of surgery
3088001|NCT01972659|Experimental|sugammadex and magnesium sulphate|sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 magnesium: 50 mg/kg iv bolus plus continuous infusion until the end of surgery
3088002|NCT01972646||Adult patients (≥ 18 years) with uncomplicated cellulitis|Adult patients (≥ 18 years) whose chief complaint was consistent with a skin or soft tissue infection (key words included cellulitis, abscess, infection, insect bite, ulcer, or rash) were screened for eligibility by ED staff or trained research assistants and invited to participate in this study once an emergency physician confirmed a cellulitis infection.
3088003|NCT01972633|Active Comparator|1470nm Laser|Patient with varicose vein treated with 1470nm Laser (Biolitec)
3088004|NCT01972633|Active Comparator|VNUS Closure Fast|Patient with varicose vein treated with VNUS Closure Fast (Radiofrequency System)
3088005|NCT01972620|Active Comparator|Multi-modal analgesia|Thirty-one patients were enrolled in this arm. Standard analgesia according to institutional standard and 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume = 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of ~ 2 cm. Following evacuation of the pneumoperitoneum, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the 4 laparoscopic port sites (2 ml per port site) prior sutured closure.
3088006|NCT01972620|No Intervention|Control|Thirty-two patients were enrolled in this arm. They received standard analgesia according to institutional standard of practice consisted of non-narcotic analgesia with narcotic analgesic rescue after laparoscopic cholecystectomy.
3088007|NCT01972607|No Intervention|CONTROL|This group will receive the same treatment of the experimental group after the test-retest measurements.
3088008|NCT01972607|Experimental|EXERCISE|This group will receive the treatment with aerobic exercise training
3088009|NCT01972594|No Intervention|Control group.|Natural progession based on Step count is recorded with a pedometer for 12 weeks.
3088010|NCT01972594|Experimental|Targeted protocol with Pedometer|A step based targeted protocol is given along with a pedometer for 12 weeks post surgery.
3088011|NCT01972581|Experimental|Reaction Time Training|
3088012|NCT01972581|No Intervention|Control|
3088013|NCT01972568|Experimental|Atacicept 75 mg|
3088014|NCT01972568|Experimental|Atacicept 150 mg|
3088015|NCT01972568|Placebo Comparator|Placebo|
3088016|NCT01972555|Experimental|Minimally invasive aortic valve replacement|Minimally invasive AVR with either ministernotomy or anterior right-sided minithoracotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.
3088017|NCT01972555|Active Comparator|Conventional aortic valve replacement|Conventional AVR through a standard median sternotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.
3088018|NCT01972542|Active Comparator|Type 2 DM|"Intervention : Oral fat tolerance test~well or moderately controlled type 2 diabetes mellitus (HbA1c < 10%) No dipeptidyl peptidase-4 -inhibitor, Glucagon-like peptide-1 agonist, thiazolidinediones"
3088019|NCT01972542|Active Comparator|Prediabetes|"Intervention : Oral fat tolerance test~Glucose 140-199 mg/dL after 75g oral glucose tolerance test HbA1c 5.7-6.4%"
3088020|NCT01972542|Sham Comparator|Normal glucose tolerance|"Intervention : Oral fat tolerance test~No impaired fasting glucose and impaired glucose tolerance"
3088021|NCT01972529|Experimental|Group A (avatrombopag, lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
3088022|NCT01972529|Placebo Comparator|Group B (placebo, lower baseline platelet count)|placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5
3088023|NCT01972529|Experimental|Group C (avatrombopag, higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5
3088024|NCT01972529|Placebo Comparator|Group D (placebo, higher baseline platelet count)|placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
3088025|NCT01972516|Experimental|Tivozanib|Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.
3088026|NCT01972516|No Intervention|Standard Care|Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.
3088027|NCT01972503|Experimental|ARM A|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In ARM A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg + curative resection+mFOLFOX6.
3088028|NCT01972503|Active Comparator|ARM B|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm B, patients accepted curative resection + mFOLFOX6 alone.
3088029|NCT01972490|Experimental|ARM A|patients received avastin in combination with chemotherapy
3088030|NCT01972490|Active Comparator|ARM B|Patients received chemotherapy (mFOLFOX6 or FOLFIRI) alone. mFOLFOX6 (day 1, oxaliplatin 85 mg/m², folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then 2400 mg/m² over 46 h continuous infusion) FOLFIRI (day 1, irinotecan 180mg/m2, folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then continuous infusion for 46 hours of 2400 mg/m2).
3088031|NCT01972477|Experimental|DLBS1449, 1x75 mg|DLBS1449 softcapsule 1x75 mg daily, taken every day along the study period.
3088032|NCT01972477|Experimental|DLBS1449, 1x150 mg|DLBS1449 softcapsule 1x150 mg (2 softcapsules 75 mg) daily, taken every day along the study period
3088033|NCT01972477|Placebo Comparator|Placebo|Placebo once daily, taken every day along the study period
3088034|NCT01972464|Placebo Comparator|placebo|In this group women will receive a placebo pill which will appear similar to progesterone and will be inert.
3088035|NCT01972464|Experimental|Progesterone|In this group women will receive oral micronized progesterone twice a day.
3088036|NCT01972451|Placebo Comparator|Colonoscopy without enhanced dye|no enhanced dye
3088037|NCT01972451|Active Comparator|Colonoscopy with enhanced dye|enhanced dye
3088038|NCT01972438|Experimental|ASEDs - Saline|Participants administer autologous serum eye drops (ASEDs) daily for the first three months, then crossover to administer control (normal saline) eye drops daily beginning at Month 3 through Month 6.
3088039|NCT01972438|Placebo Comparator|Saline - ASEDs|Participants administer control (normal saline) eye drops daily for the first three months, then crossover to administer autologous serum eye drops (ASEDs) daily beginning at Month 3 through Month 6.
3088040|NCT01972425|Experimental|Biomarker-based diagnostic|Analyse sample on arrival
3088041|NCT01972425|No Intervention|Routine use of antibiotics|Do not analyse the sample on arrival
3088042|NCT01972412|Other|Telephone support|Intervention type: Telephone support for four months.
3088043|NCT01972399|Experimental|Laser|A laser will be used to clean out the area around the diseased implant to try to regain bone.
3088044|NCT01972399|Active Comparator|Mechanical|Mechanical debridement will be used to clean out the area around the diseased implant to try to regain bone.
3088045|NCT01972386||Spectrum Image Analysis|
3088046|NCT01972373|Experimental|NIR endoscopy with Bevacizumab-IRDye800CW|In this non-randomized, non-blinded, prospective, feasibility study, bevacizumab-IRDye800CW will be administered to a total of 30 patients with proven locally advanced rectal cancer.
3088047|NCT01972360||Diagnosis|Group 3: 99mTCSPECT plus stress echocardiography
3088048|NCT01972360||group 1 : diagnosis|Group 1: 99mTcSPECT plus CMR
3088049|NCT01972360||Group 2: diagnosis|Group 2: 99mTcSPECT plus CT
3088050|NCT01972347|Experimental|Dabrafenib and Trametinib|Dabrafenib 150mg bid orally and Trametinib 2mg od orally for 52 weeks
3088051|NCT01972334|Experimental|FMT or fecal microbial transplant|intervention is fecal microbial transplant done through endoscopy, subjects will be randomized 1:1 to receive either FMT or placebo
3088052|NCT01972334|Placebo Comparator|placebo|1:1 randomization to FMT versus placebo (which is saline or salt water)
3088053|NCT01972321|Experimental|Technology supported supervision|The technology supported supervision intervention will support the CHWs in providing quality case management for the under-fives who suffer from diarrhea, pneumonia and malaria through unlimited communication with their health facility supervisors and colleagues through closed-user-groups. It will enhance timely reporting of patient data and targeted support supervision on the CHWs who need support from their supervisors. With the CHWs receiving the above support and feedback messages, this will potentially increase CHW motivation, performance and retention. Data reported by CHWs can be used by the district planners to forecasting of medicine procurements and react to drug stock-outs or unusual data trends (e.g. disease outbreaks).
3088054|NCT01972321|Experimental|Community supported supervision|The community supported supervision intervention will set up village health clubs with the aim to improve child health through a community led forum with the CHW as the main focus point. Village health club meetings will provide a forum where CHWs and community members who are part of the club can work together to identify child health and CHW challenges. They will use village networks, knowledge, creativity and other assets.
3088055|NCT01972321|Active Comparator|Control arm|The CHWs in the control arm will be receiving the standard Ministry of Health designed package to integrated community case management support and supervision.
3088101|NCT01972074|Placebo Comparator|Placebo|Subjects in the placebo control group will receive a matched placebo pill with no active ingredients. This will be administered twice daily for 12 weeks.
3088102|NCT01972074|Experimental|Memantine|Memantine administered in tablet form twice daily titrated to a maximum dose of 20 mg for 12 weeks
3088056|NCT01972308|Experimental|Patient advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to carrying out medical advice, and transfer of information between providers and patients.
3088057|NCT01972308|Other|usual care|Patient receives asthma care as usual from their asthma provider
3088058|NCT01972269|Active Comparator|bupivacaine-fentanyl 4|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 4mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3088059|NCT01972269|Active Comparator|bupivacaine-fentanyl 6|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 6mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3088060|NCT01972269|Active Comparator|bupivacaine-fentanyl 8|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 8mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3088061|NCT01972269|Active Comparator|bupivacaine-fentanyl 10|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 10mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3088062|NCT01972269|Active Comparator|bupivacaine-fentanyl 12|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 12mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3088063|NCT01972269|Active Comparator|bupivacaine-fentanyl 14|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 14mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3088064|NCT01972269|Active Comparator|bupivacaine-fentanyl 16|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 16mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3088065|NCT01972269|Active Comparator|lidocaine 4|Test dose: 3mL of 2% lidocaine. Loading dose: 4mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3088066|NCT01972269|Active Comparator|lidocaine 6|Test dose: 3mL of 2% lidocaine. Loading dose: 6mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3088067|NCT01972269|Active Comparator|lidocaine 8|Test dose: 3mL of 2% lidocaine. Loading dose: 8mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3088068|NCT01972269|Active Comparator|lidocaine 10|Test dose: 3mL of 2% lidocaine. Loading dose: 10mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3088069|NCT01972269|Active Comparator|lidocaine 12|Test dose: 3mL of 2% lidocaine. Loading dose: 12mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3088070|NCT01972269|Active Comparator|lidocaine 14|Test dose: 3mL of 2% lidocaine. Loading dose: 14mL of 0.125% bupivacaine-fentanyl 5mcg/mL
3088071|NCT01972269|Active Comparator|lidocaine 16|Test dose: 3mL of 2% lidocaine. Loading dose: 16mL of 0.125% bupivacaine-fentanyl 5mcg/mL
3088072|NCT01972256||Previous transsacral fusion|Subject candidates are those who had required a transsacral fusion at L4-L5-S1 where these were the only lumbar levels treated for pseudoarthrosis, spinal stenosis, spondylolisthesis, or degenerative disc disease (DDD).
3088073|NCT01972256||Previous transforaminal lumbar interbody fusion|Subject candidates are those who had required transforaminal lumbar interbody fusion at L4-L5-S1 where these were the only lumbar levels treated for pseudoarthrosis, spinal stenosis, spondylolisthesis, or degenerative disc disease (DDD).
3088074|NCT01972243||venous thromboembolism|
3088075|NCT01972230|Experimental|Bilanced group|"Sevofluorane adjusted to obtain an Et-Sevo of 1.8-2%, for all the time of the surgical procedure.~Remifentanyl TCI adjusted according to protocol to maintain the range of 1-3 ng / ml."
3088076|NCT01972230|Active Comparator|TCI group|Propofol 3-4 mg / ml and remifentanyl 1-3 ng / ml according to protocol TCI
3088077|NCT01972217|Active Comparator|Olaparib|200 mg or 300 mg bid
3088078|NCT01972217|Placebo Comparator|Placebo|placebo to match olaparib bid
3088079|NCT01972204|Experimental|Intensive adherence instruction|Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure
3088080|NCT01972204|Sham Comparator|Control|The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice.
3088081|NCT01972191||Group 1|Group 1 : Bare eye marking group
3088082|NCT01972191||Group 2|Group 2 : Pendulum attached marker group
3088083|NCT01972191||Group 3|Group 3 : Horizontal slit beam assisted marker group
3088084|NCT01972178|Experimental|PRC-4016|PRC-4016, oral administration once daily, capsule
3088085|NCT01972178|Placebo Comparator|Placebo|Placebo, oral administration once daily, capsule
3088086|NCT01972165|Experimental|Group I|Mini-incision carpal tunnel release group
3088087|NCT01972165|Active Comparator|Group II|Endoscopic carpal tunnel release group
3088088|NCT01972152|Experimental|G-Pen(TM) 1 mg|G-Pen(TM) (glucagon injection), single 1 mg subcutaneous (SC) injection
3088089|NCT01972152|Experimental|G-Pen(TM) 0.5 mg|G-Pen(TM) (glucagon injection), single 0.5 mg SC injection
3088090|NCT01972152|Active Comparator|Lilly Glucagon(TM) 1 mg|Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection
3088091|NCT01972139|Experimental|Renal Denervation|Subjects are treated with the renal denervation procedure after randomization.
3088092|NCT01972139|Other|Control|Subjects randomized prior to enrollment closure were treated with sham renal denervation (angiography only). Once enrollment was closed and the protocol revised, no control subjects crossed-over.
3088093|NCT01972126||AMI patients with LVEF 36% - 50%|Acute myocardial infarction patients with left ventricular ejection fraction between 36% and 50%
3088094|NCT01972113|Placebo Comparator|Placebo-Control|The placebo-control group will take one placebo softgel capsules every day for 8 weeks.
3088095|NCT01972113|Active Comparator|Low-Dose Vitamin K2 (45 mcg/d)|The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.
3088096|NCT01972113|Active Comparator|High-Dose Vitamin K2 (90 mcg/d)|The high-dose vitamin K2 group will take one 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
3088097|NCT01972100|Active Comparator|Low-level laser therapy (LLLT)|Use of low-level laser therapy (LLLT) to induce a muscle fatigue resistance in intense exercises
3088098|NCT01972100|Active Comparator|Placebo low-level laser therapy (Placebo)|Use of low-level laser therapy (LLLT) placebo to induce a muscle fatigue resistance
3088099|NCT01972087|No Intervention|Control|Participants randomized to the control arm receive no telephone simulation training.
3088100|NCT01972087|Experimental|Simulation Training|Participants randomized to the intervention arm receive telephone simulation training.
3088103|NCT01972074|No Intervention|Control Group|Healthy volunteers will be scanned twice (10-12 weeks apart) and will receive no intervention.
3088104|NCT01972061|Experimental|CMG group|Foot stimulation will be applied during a cystometrogram (CMG).
3088105|NCT01972061|Active Comparator|3 hours group|Foot stimulation will be applied daily for 3 hours in the evening.
3088106|NCT01972061|Active Comparator|1/2 hour group|Foot stimulation will be applied daily for 1/2 hour in the evening.
3088107|NCT01972061|Active Comparator|3 hour hand group|Hand stimulation will be applied daily for 3 hours in the evening.
3088108|NCT01972048|Active Comparator|Control group|Participants in the control group will receive the mailed print brochure about breast cancer screening and community resources.
3088109|NCT01972048|Experimental|Intervention group|Participants will receive the mMammogram intervention.
3088110|NCT01972035|Experimental|ValAcyclovir|Kidney recipients who give informed consent will be randomly assigned to receive ValA or ValG in a 1:1 ratio. Duration of therapy is 3-12 months depending on risk and age of recipient. Dosing is based on glomerular filtration rate.
3088111|NCT01972035|Active Comparator|ValGanciclovir|Kidney recipients who give informed consent will be randomly assigned to receive ValG or ValA in a 1:1 ratio. Duration of therapy is 3-12 months depending on risk and age of recipient. Dosing is based on glomerular filtration rate.
3088112|NCT01972022|Experimental|EES SYNERGY™|coronary artery lesions treated with Bioabsorbable Polymer EES
3088113|NCT01972022|Active Comparator|ZES, RESOLUTE Integrity™|coronary artery lesions treated with ZES, RESOLUTE Integrity™ stent system
3088114|NCT01972009||Subjects without pulmonary hypertension|Patients with normal pulmonary pressures will be recruited amongst patients who are on the waiting list awaiting routine cardiac catheterisation for the investigation of shortness of breath and chest pain.
3088115|NCT01972009||Subjects with pulmonary hypertension|Patients with pulmonary hypertension will be recruited from the National Pulmonary Hypertension Service who are awaiting right and left heart catheterisation studies as part of their routine diagnostic work-up.
3088116|NCT01971996||Lumbar spine surgical patients|Patients undergoing lumbar spine surgery in the prone position
3088117|NCT01971983|Experimental|HVLA|The subjects allocated to this group will receive a 'High-velocity, low-amplitude (HVLA) technique over the lumbar spine.
3088118|NCT01971983|Experimental|ME|Subjects allocated to this group will receive a muscle energy (ME) technique.
3088119|NCT01971983|Sham Comparator|Sham group|"The individuals allocated to this group received an intervention of the sham. The sample of this group will consist of subjects with history of dysfunctions of the lumbar spine."
3088120|NCT01971970||Pediatric IBD patients|Anti-TNF naive patients with either Crohn's disease or ulcerative colitis will be treated with either Infliximab or Adalimumab
3088121|NCT01971970||Adult IBD patients|Anti-TNF naive patients with either Crohn's disease or ulcerative colitis will be treated with either Infliximab or Adalimumab
3088122|NCT01971957||Sjogren-Larsson syndrome|There are no cohorts for this study.
3088123|NCT01971944||Patients achieving steady state concentrations of carvedilol|Patients achieving steady state concentrations of carvedilol who receive a trial of dobutamine followed by milrinone.
3088124|NCT01971944||Patients achieving steady state concentrations of metoprolol|Patients achieving steady state concentrations of metoprolol who receive a trial of dobutamine followed by milrinone.
3088125|NCT01971944||Patients not receiving beta blocker|Patients not receiving beta blocker who receive a trial of dobutamine followed by milrinone.
3088126|NCT01971931||Patients undergoing TKR.|
3088127|NCT01971918|Experimental|early switch|"early switch of monoclonal antibodies anti-TNF~anti drug antibodies dosage"
3088128|NCT01971918|Experimental|therapeutic intensification|"therapeutic intensification of monoclonal antibodies anti-TNF~anti drug antibodies dosage"
3088129|NCT01971905||Oben label|There is no intervention on this descriptive study
3088130|NCT01971892|Experimental|Non invasive ventilation (NIV)|Experimental arm = non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O) NIV will intermittently delivered to the patients for at least six hours (cumulative tme of all trials which lasted at least 30 min) during the first 24h after the initiation of treatment. Between each NIV period, the patient will received supplemental oxygen through facial mask to achieve an oxygen saturation level above 94%.
3088131|NCT01971892|Active Comparator|standard oxygen therapy with facial mask|Patients assigned to standard medical therapy will received supplemental oxygen via a facial Venturi mask at a rate of up to 15 liters per minute with in order to maintain peripheral oxygen saturation above 94%.
3088132|NCT01971879|Sham Comparator|Control|
3088133|NCT01971879|Active Comparator|Remote preconditioning|
3088134|NCT01971853|Placebo Comparator|oral placebo|an Ibuprofen and Acetaminophen Placebo will be added to a Demerol-Vistaril regimen
3088135|NCT01971853|Active Comparator|Oral Analgesics|5 mg/kg ibuprofen + 15 mg/kg acetaminophen will be added to a Demerol-Vistaril regimen
3088136|NCT01971840|Experimental|MOVI-KIDS Program|Intervention group
3088137|NCT01971840|No Intervention|Control|No intervention
3088138|NCT01971827|No Intervention|Control|No intervention
3088139|NCT01971827|Experimental|MOVI-KIDS Program|Intervention group
3088140|NCT01971814|Experimental|Early infliximab monitoring group.|A consecutive sample of patients hospitalized with severe ulcerative colitis who are eligible to receive infliximab at 10mg/kg IV.
3088141|NCT01971801|Active Comparator|Vitamin D|Vitamin D3, 50,000 IU, weekly
3088142|NCT01971801|Placebo Comparator|Placebo|Placebo comparator, weekly
3088143|NCT01971788|Experimental|Prolonged bivalirudin infusion|Bivalirudin infusion is prolonged after the end of primary PCI
3088144|NCT01971788|Active Comparator|Intra-procedural bivalirudin infusion|Bivalirudin infusion is stopped at the end of primary PCI
3088145|NCT01971775|Active Comparator|Ultrasonically Activated Shear|Dissection and lymphovascular sealing with Ultrasonically Activated Shears
3088146|NCT01971775|Active Comparator|Conventional Monopolar Electrocautery|Dissection and lymphovascular sealing with Conventional Monopolar Electrocautery
3088147|NCT01971762||Patients diagnosed bacteremia by S. aureus|
3088148|NCT01971749||Unprotected left main coronary artery stenosis patients|
3088149|NCT01971736||1064nm laser, laxity|split-face single-blind randomized placebo-controlled trial evaluating improvement in facial skin laxity of the side of the face with placebo versus laser
3088150|NCT01971723|Active Comparator|T+ Supplement|This arm requires the participants to take a prescribed dose of the T+ supplement for 4 weeks while completing an exercise regiment.
3088151|NCT01971723|Placebo Comparator|Placebo|This arm requires the participants to take a prescribed dose of a calorie matched placebo for 4 weeks while completing an exercise regiment.
3088152|NCT01971710|Other|Community Leader Engagement|Trained formal and informal community leaders conducting community dialogues and advocacy, and developing community action plans
3088153|NCT01971710|Other|Community Days|Community gatherings involving participatory dialogue, guided discussion, and the provision of education and selected health services.
3088154|NCT01971710|Other|Community Peer Groups|Pregnant women attend 4 weekly peer-led classes in community peer groups. Men attending 4 peer-led education sessions in community peer groups
3088155|NCT01971684||Refractory Pediatric ITP Patients|Pediatric ITP patients, ages 1-18, starting a new second line ITP therapy, defined as not IVIG, steroids, anti-D, or aminocaproic acid.
3088156|NCT01971671||Chinese lactating mother|no intervention.
3088157|NCT01971658|Active Comparator|VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD)|"Arm A:~Induction therapy 4 cycles of VTD (21 days) Thalidomide® 100 mg/day Per Os Day1 to Day21 Velcade® 1.3 mg/m²/day Subcutaneous Day1, 4, 8 and 11 Dexamethasone 40 mg/day Per Os Day 1 to 4 and Day 9 to 12~Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and one week after the last dose of Thalidomide, stem cells have to be harvested"
3088158|NCT01971658|Active Comparator|VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD)|"For arm B:~Induction therapy : 4 cycles of VCD (21 days)~Cyclophosphamide 500 mg/m²/day, Per Os Day 1, 8, 15~Velcade® and Dexamethasone identical treatment to Arm A~Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and two weeks after the last dose of Cyclophosphamide, stem cells have to be harvested"
3088159|NCT01971645|Experimental|Group D|Group D patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) with 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) perineurally for their femoral block. Group D will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml).
3088160|NCT01971645|Placebo Comparator|Group R|Group R patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally. Group R will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml).
3088161|NCT01971645|Active Comparator|Group M|Group M patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally. Group M will also receive a gluteal intramuscular injection of 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg).
3088162|NCT01971632|Active Comparator|Oxycodone/Naloxone|
3088163|NCT01971632|Placebo Comparator|Placebo oxycodone/naloxone|
3088164|NCT01971619||SACS cohort|patients with acute myocardial infarction at Severance hospital
3088165|NCT01971606|Experimental|Rosuvastatin group|Rosuvastatin group
3088166|NCT01971606|Placebo Comparator|Placebo group|Placebo group
3088167|NCT01971593|Other|Eplerenone after drug free period|Patients will be given eplerenone 50mg for 12 months after an initial 3 month drug free period
3088168|NCT01971593|Other|Eplerenone before drug free period|Patients will be given eplerenone 50mg for 12 months, followed by a 3 month drug free period
3088169|NCT01971580|Other|Ambrisentan first, Placebo second|These patients will be randomized to have ambrisentan during the first study period, and placebo during the second study period.
3088170|NCT01971580|Other|Placebo first, Ambrisentan second|These patients will be randomized to have placebo during the first study period, and ambrisentan during the second study period.
3088171|NCT01971567|Active Comparator|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, electroencephalic-based feedback technology to facilitate relaxation and auto-calibration of neural oscillations by using auditory tones to reflect brain frequencies in near real time.
3088172|NCT01971567|Placebo Comparator|Placebo|Subjects in this arm will receive a sham-HIRREM placebo, for which the scalp sensors have no active recording capability, and for which the auditory tonal feedback is randomly generated rather than based on current brain frequencies and amplitudes.
3088173|NCT01971554|Experimental|MK-8666 50 mg|MK-8666, 50 mg, oral, once a day (QD) for Days 1 to 14.
3088174|NCT01971554|Experimental|MK-8666 150 mg|MK-8666, 150 mg, oral, QD, for Days 1 to 14
3088175|NCT01971554|Experimental|MK-8666 500 mg|MK-8666, 500 mg, oral, QD for Days 1 to 14
3088176|NCT01971554|Placebo Comparator|Placebo|Placebo, oral, QD for Days 1 to 14
3088177|NCT01971541|Experimental|Mindfulness-Based Stress Reduction (MBSR)|An 8-week program designed to teach mindfulness skills
3088178|NCT01971541|Active Comparator|Cognitive Processing Therapy|A group-administered PTSD treatment program.
3088179|NCT01971528|No Intervention|Stage 1: Health control|pilot study: Establishing the central and peripheral contributing factors to the voluntary muscle strength loss during a fatiguing exercise in young and PD groups.
3088180|NCT01971528|No Intervention|Stage 1: PD subjects|pilot study: Establishing the central and peripheral contributing factors to the voluntary muscle strength loss during a fatiguing exercise in young and PD groups.
3088181|NCT01971528|No Intervention|Stage 2: Health subjects|pilot study: Finding optimal sensory stimulation parameters for PD individuals.
3088182|NCT01971528|No Intervention|Stage 2: PD subjects|pilot study: Finding optimal sensory stimulation parameters for PD individuals.
3088183|NCT01971528|Experimental|Stage 3: PD subjects|Investigating the long-term effects of combined sensory stimulating strengthening program on the activation level and central fatigue in PD individuals.
3088184|NCT01971528|No Intervention|Stage 3: PD subjects (Control Subjects)|Investigating the long-term effects of combined sensory stimulating strengthening program on the activation level and central fatigue in PD individuals.
3088185|NCT01971515|Experimental|MSC2363318A|
3088186|NCT01971515|Experimental|MSC2363318A plus Trastuzumab|
3088187|NCT01971515|Experimental|MSC2363318A plus Tamoxifen|
3088188|NCT01971502|Experimental|BI 1060469 single rising dose part|single rising doses given as tablet
3088189|NCT01971502|Experimental|BI 1060469 food effect part|given as tablet fasted and fed
3088190|NCT01971489|Experimental|Treatment (buparlisib, gemcitabine hydrochloride, cisplatin)|Patients receive buparlisib PO QD on days 1-21, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3088191|NCT01971476|Experimental|All patients|Volasertib will be administered as intravenous infusion
3088192|NCT01971463|Experimental|Normal Saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
3088193|NCT01971450||Iloprost|The patients with pulmonary hypertension with inhaled treatment with Ventavis according to routine practice meeting the criteria of inclusion.
3088194|NCT01971437|Experimental|Cystodistension & Cystoscopy Arm|This is the Arm receiving cystodistension and cystoscopy due to refractory OAB.
3088195|NCT01971437|Placebo Comparator|Cystoscopy Arm|This is the arm that receives cystoscopy only in women with refractory OAB.
3088196|NCT01971424|Experimental|Mg oxide|Participants were supplemented for 12-weeks with 300 mg of daily oral magnesium oxide.
3088197|NCT01971424|No Intervention|Controls|The control group was educated by a trained dietician to follow a healthy diet.
3088198|NCT01971411||Community dwelling elderly black females|
3088199|NCT01971398|Experimental|Positive Brochure|"Women receive a positive FASD education brochure with positive images and are asked to read this brochure in the presence of a data collector."
3088200|NCT01971398|Experimental|Negative Brochure|"Women receive a negative FASD education brochure with negative, vivid images and are asked to read this brochure in the presence of a data collector."
3088201|NCT01971398|Active Comparator|A general women's health brochure|Women receive a brochure on general aspects of women's health and pregnancy that is available in the Russian language and are asked to read this brochure in the presence of a data collector.
3088202|NCT01971385|Active Comparator|2% Squaric Acid Sensitization|2% Squaric Acid solution will be applied for sensitization to the inner arm.
3088203|NCT01971385|Placebo Comparator|Placebo Solution|Patients in placebo group will be given dimethyl sulfoxide.
3088204|NCT01971359||Retrospective|
3088205|NCT01971346|Other|Etanercept|100 mg Etanercept injections per week for 3 months.
3088206|NCT01971333||Liver transplantation|"Compare intraoperative change of dynamic parameters after fluid loading:~pulse pressure variation~stroke volume variation~plethysmographic variation index"
3088207|NCT01971320|Experimental|active stimulation|"sensitive electrical stimulation applied during meals with Urostim I for 6 weeks~Urostim I stimulation will be done during meals for 6 weeks"
3088208|NCT01971320|Placebo Comparator|fake stimulation|"Urostim I stimulation will be done during meals for 6 weeks~Fake sensitive electrical stimulation applied during meals with modified Urostim I who not deliver stimulation for 6 weeks"
3088209|NCT01971307|Experimental|SGE-PsyScan|The SGE-PsyScan is an internet application to which the General Practitioner (GP) refers the patient, which includes the distress screener, the 4-Dimensional Symptom Questionnaire (4DSQ) and a series of additional questions for differentiating between stress, depressive, anxious and somatization symptoms. Based on the 4DSQ patients and GPs receive advices for possible treatments.
3088210|NCT01971307|No Intervention|Usual care|Usual care for persons with psychosocial symptoms and disorders in Dutch primary care includes all usual care procedures; preventive, screening, diagnostic, (non-)pharmacological or therapeutic procedures which are routinely used in everyday care.
3088211|NCT01971294||Systemic sclerosis|Adult suffering from systemic sclerosis included in the EUSTAR network of Brescia (I), Geneva (CH), Padova (I) and Paris (F).
3088212|NCT01971281|Experimental|TTFilelds + gemcitabine|Patients will be treated continuously with the NovoTTF-100L device, in addition to Gemcitabine.
3088213|NCT01971281|Experimental|TTFields + gemcitabine+ nab-paclitaxel|Patients will be treated continuously with the NovoTTF-100L device, in addition to Gemcitabine plus nab-paclitaxel
3088214|NCT01971268||Platform-Switch Group|T3 dental implant, with platform-switch dental implant platform concept, measure marginal bone loss
3088215|NCT01971268||Platform-Matched Group|T3 dental implant, platform-matched dental implant platform concept, measure marginal bone loss
3088216|NCT01971255|Experimental|High Titer (HAI > or = 1:40)|Subjects with prechallenge hemagglutination inhibition (HAI) titers of ≥1:40 were assigned to this group. The human challenge virus, Ca/04/2009/H1N1r Challenge Virus, will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
3088217|NCT01971255|Experimental|Low Titer (HAI < 1:40)|Subjects with prechallenge hemagglutination inhibition (HAI) titers of <1:40 were assigned to this group. The human challenge virus, Ca/04/2009/H1N1r Challenge Virus, will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
3088218|NCT01971242|Active Comparator|Exenatide|Bydureon- 2mg administered subcutaneously once weekly
3088219|NCT01971242|Placebo Comparator|Placebo|Placebo, 2mg administered subcutaneously once weekly
3088220|NCT01971229|Sham Comparator|Carbohydrate|Patients in this arm will drink a 425 mL 100% clear apple juice (carbohydrate 50 g, 700 mOsmol). 1.5 g of acetaminophen will be dissolved in the beverage for determination of gastric emptying.
3088221|NCT01971229|Active Comparator|Whey Protein|Patients in this arm will drink a 330 mL Boost fruit flavoured clear beverage (whey protein 12.2 g, carbohydrate 50 g, 700 mOsmol).1.5 g of acetaminophen will be dissolved in the beverage for determination of gastric emptying.
3088222|NCT01971216|No Intervention|Control|Breastfeeding mothers who are not randomised to relaxation intervention
3088223|NCT01971216|Experimental|Relaxation|Breastfeeding mothers randomised to use relaxation tape at 2 weeks post-partum
3088224|NCT01971203|Experimental|seroquel xr|quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day 16 weeks of treatment including CBT
3088225|NCT01971203|Placebo Comparator|placebo plus CBT|treatment group receiving placebo pill plus CBT
3088226|NCT01971190|Sham Comparator|Sham injection|Sham injection at baseline, at 1 month, and at 2 month
3088227|NCT01971190|Active Comparator|Intravitreal Aflibercept injection|2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month
3088270|NCT01970878|Experimental|GFF MDI (PT003)|
3088228|NCT01971177|Experimental|Femtosecond laser cataract surgery|"Laser group: a pre-fragmentation of the ocular lens will be performed by VICTUS femtosecond laser lens fragmentation procedure."
3088229|NCT01971177|Active Comparator|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are performed manually without femtosecond laser assisted lens fragmentation"
3088230|NCT01971164|Experimental|Dose 1 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
3088231|NCT01971164|Experimental|Dose 2 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
3088232|NCT01971164|Experimental|Dose 3 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
3088233|NCT01971164|Experimental|Dose 4 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
3088234|NCT01971151|Experimental|Exposure with safety-seeking behavior|Patients receive exposure therapy. In the current condition, exposure is offered while patients are allowed to use their own safety-seeking behaviors (i.e., behavior believed to be necessary to prevent a feared catastrophe).
3088235|NCT01971151|Experimental|Exposure without safety-seeking behavior|Patients receive exposure therapy.In the current condition, exposure is offered while patients are instructed to omit their safety-seeking behavior.
3088236|NCT01971151|Active Comparator|Exposure therapy only|Patients receive exposure therapy. In the current condition, exposure is offered while patients do not receive any specific instructions about what to do with their safety-seeking behavior.
3088237|NCT01971138||Surgical site infection registration|Is there a routine for SSI registration
3088238|NCT01971125||No treatment|"Patients with:~diabetes mellitus type 2~absence of heart disease previously reported~age >45 years~Informed Consent~Patients without:~presence of heart disease previously reported~diabetes type 1~serious systemic disease, with an expected lifetime lower than 2 years~no willingness to participate to the screening~inadequate compliance to study procedure~participation to other study"
3088239|NCT01971112|Experimental|Multivitamins and minerals|Experimental: X: Multivitamins and minerals (MVM) Arm X: 1X US-RDA of vitamins A, D,E,B6,B12, folate, copper and iron plus 500 mg vitamin C, and 14 mg of Zinc
3088240|NCT01971112|Placebo Comparator|Placebo|
3088241|NCT01971099|Placebo Comparator|Placebo|patients will use placebo for 120 days
3088242|NCT01971099|Experimental|Tribulus Terrestris|patients will use Tribulus terrestris (750 mg/day) during 120 days
3088243|NCT01971086||acute rhinitis|
3088244|NCT01971073|Experimental|bilateral Anodal-L/R Cathodal-R/L tDCS|"bilateral Anodal-left and cathodal-right tDCS over DLPFC or bilateral Anodal-right and cathodal-left tDCS over DLPFC.~Intervention: Device: transcranial direct current stimulation"
3088245|NCT01971073|Sham Comparator|Sham tDCS|Sham tDCS
3088246|NCT01971060|Experimental|V-Loc suture|Laparoscopic surgery utilizing V-Loc suture
3088247|NCT01971047|Active Comparator|Group 1-Regular Insulin|Intravenous Regular Insulin will be administered for a preoperative Blood glucose of greater than 180.
3088248|NCT01971047|Active Comparator|Group 2-Humalog|Subcutaneous Humalog will be administered for a preoperative Blood glucose of greater than 180
3088249|NCT01971034|Experimental|Paclitaxel and Metformin|
3088250|NCT01971021|Active Comparator|PICC-line|PICC line insertion.
3088251|NCT01971021|Active Comparator|PORT|Subcutaneous venous port insertion
3088252|NCT01971008|Placebo Comparator|Placebo binder|"Patients in this arm will be invited to wear a placebo binder (Clima Care Body warmer, Bort Medical) for 2 hours"
3088253|NCT01971008|Active Comparator|Elastic abdominal binder|"Patients in this arm will be invited to wear an elastic abdominal binder (Abdosyncro Abdominalbandage, Syncro Med GmbH) for 2 hours"
3088254|NCT01970995|Experimental|THS 2.2 Menthol (mTHS 2.2)|Ad libitum use of THS 2.2 Menthol for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
3088255|NCT01970995|Active Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
3088256|NCT01970995|Active Comparator|Menthol Conventional Cigarette (mCC)|Ad libitum use of subject's own preferred brand of mCC for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
3088257|NCT01970982|Experimental|Tobacco Heating System (THS 2.2)|Ad libitum use of THS 2.2 for 5 days in confinement
3088258|NCT01970982|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 days in confinement
3088259|NCT01970982|Active Comparator|Conventional cigarette (CC)|Ad libitum use of Subject's own preferred brand of CC for 5 days in confinement
3088260|NCT01970969||Cardiac arrhythmia symptoms|All subjects enrolled in the study will have an iRhythm Zio patch placed and a blood sample obtained.
3088261|NCT01970943|No Intervention|No Intervention|PET-fMRI investigation on healthy subjects and patients with migraine. No drug condition.
3088262|NCT01970943|Placebo Comparator|Saline Injection (Placebo)|PET-fMRI investigation on healthy subjects and patients with migraine. Placebo condition.
3088263|NCT01970930||PV or ET|subject who has polycythemia vera or essential thrombocythemia
3088264|NCT01970917|Other|Healthy volunteers right eye|The medical device will be randomly assigned to the right or left eye on the study day (randomization 1:1) whereas the fellow eye will receive placebo.
3088265|NCT01970917|Other|Healthy volunteers left eye|The medical device will be randomly assigned to the right or left eye on the study day (randomization 1:1) whereas the fellow eye will receive placebo.
3088266|NCT01970904|Experimental|200 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 200 mg twice daily (BID) and Ribavirin (RBV) for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
3088267|NCT01970904|Experimental|300 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 300mg BID and RBV for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
3088268|NCT01970904|Experimental|400 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 400 mg BID and RBV for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
3088269|NCT01970891|Experimental|Freezing of Gait relief|Effect of neuromuscular stimulation device will be assessed on Freezing of Gait relief
3088273|NCT01970878|Active Comparator|Open-label tiotropium bromide inhalation powder|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
3088274|NCT01970865|Experimental|PF-06463922|
3088275|NCT01970865|Other|Crizotinib|ALK+ NSCLC patients who are treatment naïve may be eligible to receive crizotinib following PF-06463922 as a substudy to the main study.
3088276|NCT01970852|Experimental|Standard tablet computer|Patient will receive tablet computer within 18 hours of admission and will continue to have access to it for the rest of his/her stay. Tablet has typical applications including access to the internet and entertainment.
3088277|NCT01970852|No Intervention|Usual Care|Patients will receive usual care and will answer surveys during the usual time-frame specified.
3088278|NCT01970852|Experimental|Enhanced tablet computer|Patients will receive a tablet computer within 18 hours of admission. Tablet will give access to a personalized inpatient personal health record portal. Will also provide access to standard tablet applications (e.g. video calling, streaming movies, etc.)
3088279|NCT01970839|Other|Tourniquet, pain, nerve injury, sensory nerve function|
3088280|NCT01970826|Experimental|Sterilized Clean Full-Mouth|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~Full-mouth dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
3088281|NCT01970826|Active Comparator|Sterilized Aseptic Full-Mouth|"The operatory room will be prepared with sterilized aseptic clean instruments. Full-mouth dental implants placement will be performed and involves meticulous hand washing, use of a sterile field, use of sterile gloves for application of a sterile dressing, and use of sterile instruments and fluid only. Involves the use of only sterile instruments and materials in dressing.~There is no contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or products.~It will be evaluated the duration of surgery."
3088282|NCT01970826|Experimental|Sterilized Clean Single|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~Single dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or products.~It will be evaluated the duration of surgery."
3088283|NCT01970826|Active Comparator|Sterilized Aseptic Single|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~Single dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
3088284|NCT01970826|Experimental|Sterilized Clean - Partial|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~One or more dental implants will be made for partial rehabilitation, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
3088285|NCT01970826|Active Comparator|Sterilized Aseptic - Partial|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~One or more dental implants will be made for partial rehabilitation, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
3088286|NCT01970813|Active Comparator|Study group|acupuncture and bee venom acupuncture point injection
3088287|NCT01970813|Sham Comparator|Control group|sham acupuncture and normal saline injections
3088288|NCT01970813|No Intervention|Waiting group|no additional intervention
3088289|NCT01970800|Experimental|Growth hormone, injections|Growth hormone injection 0.3mg/kg/week dailY
3088290|NCT01970787|Experimental|RFA|Assess the feasibility, safety, and efficacy of RF to the anal canal using the HALO Ablation System to eradicate anal HSIL lesions
3088291|NCT01970774|Experimental|MTM and PGx|Participants attend two MTM sessions and have PGx testing
3088292|NCT01970761||scar, Fat Graft, Visual Analogue Scale|patients received autologous fat grafting in scar areas
3088293|NCT01970748|Placebo Comparator|Propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
3088294|NCT01970748|Active Comparator|Esophageal variceal ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy. After eradication, follow-up endoscopy every 3 months and variceal ligation again if recurrence.
3088295|NCT01970735|Experimental|FSHD patient|
3088296|NCT01970722|Experimental|Treatment (surgery, HIPEC cisplatin)|"Patients undergo surgery and receive hyperthermic cisplatin intraperitoneally (IP) over 60 minutes.~At least 3 weeks after surgery, patients may receive carboplatin, paclitaxel, pegylated liposomal doxorubicin hydrochloride, or gemcitabine hydrochloride IP or IV at the discretion of the medical and gynecologic oncologists."
3088297|NCT01970696||Ovarian Stromal Tumors|
3088298|NCT01970696||Testicular Stromal Tumors|
3088299|NCT01970696||Ovarian Small Cell Carcinoma|
3088300|NCT01970683|Experimental|VSL #3|probiotics given orally BID
3088301|NCT01970683|Other|placebo|Near-identically appearing placebo
3088302|NCT01970657||HP802-247 in prior study|Observational safety follow up study, no treatment specified
3088303|NCT01970657||Vehicle Control in prior study|Observational safety follow up study, no treatment specified
3088304|NCT01970644||Brain metastases (>= 4)|Patients with pathologically proven solid tumour malignancy who have >=4 brain metastases will be treated with gamma knife radiosurgery.
3088305|NCT01970631|No Intervention|Usual Care|Participants randomized to the Usual Care group will receive the current standard post-operative TKR care.
3088306|NCT01970631|Active Comparator|Motivational Interviewing (MI)|Participants randomized to the MI Intervention group will receive up to 14 telephone calls from a Health Educator for 9 months post-TKR.
3088307|NCT01970631|Active Comparator|Financial Incentives (FI)|Participants randomized to the FI Intervention group will receive financial incentives for completing physical activity logs weekly/bi-weekly and achieving pre-specified physical activity goals over the course of the study.
3088308|NCT01970631|Active Comparator|Motivational Inverterviewing (MI) + Financial Incentives (FI)|Participants randomized to the FI + MI Intervention group will receive financial incentives for completing physical activity logs weekly/bi-weekly and achieving pre-specified physical activity goals as well as receive up to 14 telephone calls from a Health Educator for 9 months post-TKR.
3088309|NCT01970618|Experimental|Part A: single dose escalation (healthy subjects)|
3088310|NCT01970618|Experimental|Part B: 7 day repeat dose (healthy subjects)|
3088311|NCT01970618|Experimental|Part C: 14 day repeat dose (COPD patients)|
3088312|NCT01970605||Patients with PAOD or aneurysms|"Patients~in Fontaine class > IIa,~in need of aneurysm repair,~with defined cardiovascular risk factors or~graft infections.~Surgical reconstruction with defined Silver Graft vascular prosthesis."
3088313|NCT01970592|Experimental|POWER|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be ~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking.
3088314|NCT01970579|Experimental|Paclitaxel coated balloon|
3088315|NCT01970579|Active Comparator|uncoated PTA catheter|
3088316|NCT01970566|Experimental|IE-MCR|Intense Exercise/Moderate Calorie Restriction
3088317|NCT01970566|Active Comparator|TP-CBT|Topiramate-Phentermine plus cognitive behavioral therapy
3088318|NCT01970566|Active Comparator|CBT|cognitive behavioral therapy
3088319|NCT01970553|Experimental|lurbinectedin (PM01183) / gemcitabine|"Patients will consecutively receive the following on Days 1 and 8 q3wk (three weeks = one treatment cycle):~- Gemcitabine: intravenous infusion of 800 mg/m2/day over 30 minutes,~immediately followed by:~- PM01183: intravenous infusion over one hour at a starting dose of 2.5 mg/day, flat dose (FD), both on Days 1 and 8 every 3 weeks"
3088320|NCT01970540|Experimental|lurbinectedin (PM01183) / doxorubicin|
3088321|NCT01970527|Experimental|Treatment (stereotactic body radiotherapy, ipilimumab)|Patients undergo a total of 3 fractions of stereotactic body radiotherapy between days 1-13. Patients then receive ipilimumab IV every 3 weeks. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
3088322|NCT01970514|Experimental|ARO Spinal System|ARO Spinal System
3088323|NCT01970501|Experimental|bucindolol hydrochloride|"bucindolol hydrochloride (bucindolol)~Capsules are available in the following dosage strengths to be taken twice daily (with or without food): 6.25mg, 12.5mg, 25mg, 50mg, and 100mg."
3088324|NCT01970501|Active Comparator|metoprolol succinate|"metoprolol succinate (Toprol-XL)~Capsules are available in the following dosage strengths to be taken twice daily (with or without food): 25mg, 50mg, 100mg, 200mg and/or matching placebo to maintain blinded dosing."
3088325|NCT01970488|Experimental|ABP 501|"Participants received 80 mg ABP 501 subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~Participants with a PASI 50 response at week 16 continued to receive 40 mg APB 501 until week 48."
3088326|NCT01970488|Active Comparator|Adalimumab|"Participants received 80 mg adalimumab subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~At week 16 participants with a PASI 50 response were re-randomized to treatment with adalimumab or were transitioned to ABP 501 until week 48."
3088327|NCT01970475|Experimental|ABP 501|Participants received ABP 501 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.
3088328|NCT01970475|Active Comparator|Adalimumab|Participants received adalimumab 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.
3088329|NCT01970462|Experimental|Sitagliptin|Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
3088330|NCT01970462|Placebo Comparator|Placebo|Patients will receive placebo prior to discharge and 6 weeks after discharge.
3088331|NCT01970449|Experimental|Group 1: study vaccines with Nat-B env insert|Participants in this arm will receive DNA Nat-B env vaccine injections on Day 0 and Day 28 followed by NYVAC Nat-B env vaccine injections on Day 84 and Day 164.
3088332|NCT01970449|Placebo Comparator|Group 1: placebo vaccines with Nat-B env insert|Participants in this arm will receive placebo injections of DNA Nat-B env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC Nat-B env vaccine on Day 84 and Day 164.
3088333|NCT01970449|Experimental|Group 2: study vaccines with CON-S env insert|Participants in this arm will receive DNA CON-S env vaccine injections on Day 0 and Day 28 followed by NYVAC CON-S env vaccine injections on Day 84 and Day 164.
3088334|NCT01970449|Placebo Comparator|Group 2: placebo vaccines with CON-S env insert|Participants in this arm will receive placebo injections of DNA CON-S env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC CON-S env vaccine on Day 84 and Day 164.
3088335|NCT01970449|Experimental|Group 3: study vaccines with Mosaic env insert|Participants in this arm will receive DNA Mosaic env vaccine injections on Day 0 and Day 28 followed by NYVAC Mosaic env vaccine injections on Day 84 and Day 164.
3088336|NCT01970449|Placebo Comparator|Group 3: placebo vaccines with Mosaic env insert|Participants in this arm will receive placebo injections of DNA Mosaic env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC Mosaic env vaccine on Day 84 and Day 164.
3088337|NCT01970436|Experimental|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
3088338|NCT01970436|No Intervention|Usual Prenatal Care|Usual, in-person prenatal care.
3088339|NCT01970423|Other|CRT|After randomization and polysomnography the CRT will get activated. After 3-5 months cross over to conventional right ventricular stimulation.
3088340|NCT01970423|Other|Right Ventricular Stimulation|After randomization and polysomnography the conventional right ventricular stimulation will get activated. After 3-5 months cross over to CRT activation.
3088341|NCT01970410|Experimental|Teriflunomide|Teriflunomide 14 mg oral teriflunomide daily
3088342|NCT01970397|Experimental|JUVEDERM® Ultra XC|Perioral lines treated with JUVEDERM® Ultra XC
3088343|NCT01970397|Experimental|Belotero Balance®|Perioral Lines treated with Belotero Balance®
3088344|NCT01970384|Experimental|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
3088345|NCT01970384|Sham Comparator|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
3088346|NCT01970371|Experimental|Plazomicin in Combination with Meropenem or Tigecycline|Cohort 1
3088347|NCT01970371|Active Comparator|Colistin in Combination with Meropenem or Tigecycline|Cohort 1
3088348|NCT01970371|Experimental|Plazomicin in Combination with Adjunctive Antibiotic|Cohort 2
3088349|NCT01970358|Experimental|Personalized NeoAntigen Cancer Vaccine|"- NeoVax (peptides + poly-ICLC)~Poly-ICLC: 4 x 0.5 mg (total dose 2 mg) given on days Days 1, 4, 8, 15, 22, 78, and 162~Peptides: 4 x 300 mcg per peptide given on days Days 1, 4, 8, 15, 22, 78, and 162"
3088350|NCT01970345|Experimental|IGF-1|"Randomized, placebo-controlled, crossover format with 12 weeks in each treatment arm (IGF-1 and placebo), separated by a four-week wash-out phase.~Dose titration will be initiated at 0.04 mg/kg twice daily by subcutaneous injection, and increased, as tolerated, every week by 0.04 mg/kg per dose to a maximum of 0.12 mg/kg twice daily. Doses may be decreased according to tolerability by 0.04 mg/kg per dose. Medication will be administered twice daily with meals, and preprandial glucose monitoring will be performed by parents at treatment initiation, prior to each injection, and until a well tolerated dose is established."
3088351|NCT01970345|Placebo Comparator|Placebo|Placebo
3088352|NCT01970332|No Intervention|No Exercise Therapy or Revascularization operation|The patient is evaluated but no intervention
3088353|NCT01970332|Experimental|Revascularization Surgery|The patient undergoes surgery to revascularize the ischemic, symptomatic limb(s)
3088354|NCT01970332|Experimental|Exercise Therapy|The patient undergoes supervised exercise therapy for 6 months
3088355|NCT01970319||Diabetic with nephropathy|
3088356|NCT01970319||Diabetics without nephropathy|
3088357|NCT01970306|Experimental|Surgical intervention|Patients will undergo standard resection and gastrointestinal anastomosis and will then have reinforcement of the anastomosis with MatriStem PSM. Patients undergoing esophagectomy, PG or TG will be evaluated with one routine postoperative contrast swallow study at post-operative day #4-10.
3088358|NCT01970293|Other|Introduction to AA volunteer|
3088359|NCT01970293|No Intervention|AA materials offered|
3088360|NCT01970280|Active Comparator|Enoxaparin|Following a first AV graft thrombosis and successful thrombolysis with angioplasty, patients on chronic hemodialysis will be randomized to s.c Enoxaparin (Clexane) 0.5 mg/1kg of body weight per day or control group (not on Clexane).
3088361|NCT01970280|No Intervention|Observation|
3088362|NCT01970267|Active Comparator|Laser Treated|Laser will direct the laser at vitreous opacities. The power of the laser will be adjusted from 0.3-12 millijoules (mJ) with the end point being laser induced optical breakdown and the production of a small gas bubble 50% of the time. The treatment will attempt to reduced or eliminate symptomatic floaters in the visual axis. Each treatment session will be limited to 300 laser applications. Participants will be retreated based on continued symptoms for up to 5 sessions
3088363|NCT01970267|Sham Comparator|Not Treated|
3088364|NCT01970254||Hepatitis B Screening|Testing for positive hepatitis B virus (HBV) infection before chemotherapy using three HBV screening tests (HBsAg,anti-HBc,and anti-HBs) and survey completion.
3088365|NCT01970241|Experimental|NPH|"Receive NPH with each corticosteroid dose during the study duration (2-5 days).~Low dose corticosteroids High dose corticosteroids Eating and 6a-8p 0.15 units NPH/kg 0.3 units NPH/kg NPO(nothing by mouth) or 8p-6a 0.1 units NPH/kg 0.2 units NPH/kg"
3088366|NCT01970241|Active Comparator|Control|Receive usual care with background insulin and correction factor for duration of study (2-5 days)
3088367|NCT01970228|Active Comparator|Adverse reaction to metal debris|68Ga-citrate and 19F-FDG PET/CT imaging of hip replacement patients with adverse tissue reactions to metal debris
3088368|NCT01970228|Active Comparator|Periprosthetic joint infection|68Ga-citrate and 19F-FDG PET/CT imaging of hip replacement patients with periprosthetic joint infection
3088369|NCT01970228|Active Comparator|Aseptic mechanical implant loosening|68Ga-citrate and 19F-FDG PET/CT imaging of patients with aseptic mechanical loosening of hip prosthesis
3088370|NCT01970215|Placebo Comparator|Group 1|TA-8995 0mg (placebo) & placebo statin
3088371|NCT01970215|Experimental|Group 2|TA-8995 1mg & placebo statin
3088372|NCT01970215|Experimental|Group 3|TA-8995 2.5mg & placebo statin
3088373|NCT01970215|Experimental|Group 4|TA-8995 5mg & placebo statin
3088374|NCT01970215|Experimental|Group 5|TA-8995 10mg & placebo statin
3088375|NCT01970215|Active Comparator|Group 6|TA-8995 0mg (placebo) & atorvastatin 20mg
3088376|NCT01970215|Active Comparator|Group 7|TA-8995 10mg & atorvastatin 20mg
3088377|NCT01970215|Active Comparator|Group 8|TA-8995 0mg (placebo) & rosuvastatin 10mg
3088378|NCT01970215|Active Comparator|Group 9|TA-8995 10mg & rosuvastatin 10mg
3088379|NCT01970202|Active Comparator|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
3088380|NCT01970202|Active Comparator|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
3088381|NCT01970202|Other|Control|no treatment
3088548|NCT01969136|Experimental|Experimental: EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
3088382|NCT01970189||Primary Immune Thrombocytopaenia|Recently-diagnosed (i.e. < 6 months) primary ITP adult patients (≥ 18 years) characterized by platelet counts less than 100x109/L as defined by the International Working Group.
3088383|NCT01970176|Active Comparator|tadalafil|"Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is >95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil.~At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil.~At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil."
3088384|NCT01970176|Placebo Comparator|Placebo|"Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is >95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo.~At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo.~At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo."
3088385|NCT01970163|Experimental|DermACELL|DermACELL acellular dermal matrix will be used to treat subjects diagnosed with an ulcer of the lower extremity (diabetic foot ulcer or venous stasis ulcer).
3088386|NCT01970163|Placebo Comparator|Conventional care dressings|Currently accepted standard of care wound management including Conventional care dressings will be utilized in subjects with a diagnosis of either diabetic foot ulcer or venous stasis ulcer.
3088387|NCT01970163|Active Comparator|GraftJacket|GraftJacket acellular dermal matrix will be used in those subjects diagnosed with a diabetic foot ulcer.
3088388|NCT01970150|Experimental|1|In this intervention patients receive 5 days a week for 4 weeks of rTMS treatment with real coil
3088389|NCT01970137|Experimental|KPS-0373|
3088390|NCT01970124|Experimental|KPS-0373|
3088391|NCT01970111|Experimental|KPS-0373|
3088392|NCT01970098|Experimental|KPS-0373|
3088393|NCT01970098|Placebo Comparator|Placebo|
3088394|NCT01970072|Experimental|1.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.01 mg/kg body weight
3088395|NCT01970072|Experimental|2.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.02 mg/kg body weight
3088396|NCT01970072|Experimental|3.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.05 mg/kg body weight
3088397|NCT01970072|Experimental|4.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.075 mg/kg body weight
3088398|NCT01970072|Experimental|5.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.1 mg/kg body weight
3088399|NCT01970072|Experimental|6.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.15 mg/kg body weight
3088400|NCT01970072|Experimental|7.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.2 mg/kg body weight
3088401|NCT01970072|Experimental|8.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.25 mg/kg body weight
3088402|NCT01970072|Experimental|9.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.3mg/kg body weight
3088403|NCT01970072|Experimental|10.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.35 mg/kg body weight
3088404|NCT01970072|Active Comparator|11.Midazolam|Single IV bolus of Midazolam over 1 minute at 0.075 mg/kg body weight
3088405|NCT01970059|Experimental|Extended-Release Carvedilol Sulfate|18-72mg/d,po
3088406|NCT01970059|Active Comparator|Sustained-release Metoprolol Succinate|47.5-190mg/d,po
3088407|NCT01970046|Placebo Comparator|Placebo/Metformin|
3088408|NCT01970046|Experimental|SP2086 (50mg b.i.d)/Metformin|
3088409|NCT01970046|Experimental|SP2086 (50mg q.d.)/Metformin|
3088410|NCT01970033|Placebo Comparator|Placebo|
3088411|NCT01970033|Experimental|SP2086 50 mg b.i.d|
3088412|NCT01970033|Experimental|SP2086 100 mg q.d.|
3088413|NCT01970020|Experimental|JNJ-38518168|
3088414|NCT01970007|Experimental|Zilver Vena Venous Stent|
3088415|NCT01969994|Experimental|Controlled dietary background & (−)-[2-14C]epicatechin intake|
3088416|NCT01969981||PICC placement|
3088417|NCT01969968|Other|sleeve bariatric surgery|morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing sleeve gastrectomy
3088418|NCT01969968|Other|morbidly obese adults with by pass surgery|morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing gastric bypass
3088419|NCT01969968|Other|non obese|non obese patients
3088420|NCT01969955|Experimental|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
3088421|NCT01969942|Experimental|allogeneic stem cell transplantation Plan A|Subjects will receive the vaccine, Busulfan and Melphalan.
3088422|NCT01969942|Experimental|allogeneic stem cell transplantation Plan B|If subject have already received a stem cell transplant using Busulfan and Melphalan, they will receive Clysophosohamide and Fludarabine.
3088423|NCT01969929|Active Comparator|20G|20G vitrectomy with scleral and conjunctival sutures for closure
3088424|NCT01969929|Active Comparator|23G|23G transconjunctival sutureless vitrectomy
3088425|NCT01969916|Other|Regadenoson|
3088426|NCT01969903|Experimental|No dexmedetomidine injected|Control group in which will be used only lidocaine for brachial plexus block
3088427|NCT01969903|Experimental|0.3 microgs/kg of dexmedetomidine|Experimental group, in which 0.3 microgs/kg dexmedetomidine will be added to lidocaine for brachial plexus block
3088428|NCT01969903|Experimental|0.6 microgs/kg of dexmedeomidine|Experimental group, in which 0.6 microgs/kg dexmedetomidine will be added to lidocaine for brachial plexus block
3088429|NCT01969890|Experimental|G-CSF administration|Granulocyte Colony-Stimulating Factor (G-CSF) administration - 5 microg/kg subcutaneous every 12 hours for 6 days
3088430|NCT01969890|No Intervention|standard therapy|Standard therapy
3088431|NCT01969877|Experimental|Arm 1|Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 1-4).
3088432|NCT01969877|Experimental|Arm 2|Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 3-4).
3088433|NCT01969877|Experimental|Arm 3|Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 1-4).
3088434|NCT01969877|Experimental|Arm 4|Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 3-4).
3088435|NCT01969864|Experimental|HRSA Video Intervention|5-minute video on organ donation from U.S. Department of Health and Human Services
3088436|NCT01969864|Experimental|PI Video Intervention|5-minute video on organ donation created in part by the principal investigator.
3088437|NCT01969864|Placebo Comparator|CDC Health Website Intervention|This control intervention will include text from the CDC website on health and wellness.
3088438|NCT01969851|Experimental|Lacosamide|
3088439|NCT01969838|Experimental|Momelotinib|Participants will receive momelotinib plus placebo to match ruxolitinib.
3088440|NCT01969838|Active Comparator|Ruxolitinib|Participants will receive ruxolitinib plus placebo to match momelotinib.
3088441|NCT01969825|Experimental|Massage|Professional Swedish massage less than 15 minutes prior to semen collection for intrauterine insemination.
3088442|NCT01969825|No Intervention|No massage|Normal protocol for semen collection prior to intrauterine insemination.
3088443|NCT01969812|Experimental|Evie Slow-Release Insemination Device|Preliminary studies in Europe have shown increased pregnancy rates using slow-release insemination. Evie slow-release insemination device is a device that is FDA approved. This device has been used in Europe, it has not yet been used at Carolinas Medical Center, by the Women's Institute. The technique for using this device involves loading a pump syringe with the prepared sperm, placing a balloon-secured catheter and syringe in the patient's sounded uterus, and connecting the insemination syringe to the catheter. The slow-release insemination occurs for 4 hours after the insertion of the catheter. The removal procedure, which can be performed by the patient if desired, involves deflating the catheter balloon and removing the catheter.
3088444|NCT01969812|Active Comparator|Traditional Intrauterine Insemination|Traditional IUI is one of the treatment modalities for infertility that allows sperm to bypass the cervix and shortens the distance to the fallopian tubes for fertilization. The pregnancy rates for IUI with clomiphene citrate for couples with relatively unexplained infertility have been found to be 7.6% (for women 21-39 years old with up to 3 cycles of IUI with clomiphene).
3088445|NCT01969799|Experimental|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System.
3088446|NCT01969799|Placebo Comparator|Aerosolized placebo|Aerosolized placebo twice daily for 10 days administered using the eFlow Inline System
3088447|NCT01969786|Experimental|Corneal ulcer prevention program|Female community health volunteers (FCHV) residing in Village Development Committees (VDC) randomized to the corneal ulcer prevention arm will be trained to diagnose and treat corneal abrasions with antifungal (itraconazole) and antibiotic (chloramphenicol) ointments. FCHVs will promote their new services to their communities and encourage villagers who experience ocular trauma to present to them within 24 hours.
3088448|NCT01969786|No Intervention|Control|Female community health volunteers (FCHV) residing in Village Development Committees (VDC) randomized to control (no intervention) will not receive additional training and will not undertake a promotional campaign in their communities.
3088449|NCT01969773|Experimental|Botulinum toxin A|Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
3088450|NCT01969773|Placebo Comparator|Control arm-Normal saline instillation|Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
3088451|NCT01969760|No Intervention|Wait-list control|Wait-list control. No intervention delivered until post follow-up assessment. Upon completion of the follow-up, the family was offered the full intervention.
3088452|NCT01969760|Experimental|Healthy Families DC Program|Healthy Families DC Program
3088453|NCT01969747|Experimental|Empagliflozin low|Empagliflozin low once daily
3088454|NCT01969747|Experimental|Empagliflozin medium|Empagliflozin medium once daily
3088455|NCT01969747|Experimental|Empagliflozin high|Empagliflozin high once daily
3088456|NCT01969747|Placebo Comparator|Placebo|Placebo once daily
3088457|NCT01969734|Experimental|Endobronchial valves|All subjects will have endobronchial valves inserted into the target lobe of the lung with the aim of complete lobar exclusion.
3088458|NCT01969721|Experimental|T+O FDC dosage 1|Low dose
3088459|NCT01969721|Experimental|T+O FDC dosage 2|High dose
3088460|NCT01969721|Active Comparator|ICS/LABA FDC Dosage 1|Low dose
3088461|NCT01969721|Active Comparator|ICS/LABA FDC Dosage 2|High dose
3088462|NCT01969708|Active Comparator|aflibercept|2.0 mg aflibercept every 4 weeks
3088463|NCT01969708|Active Comparator|bevacizumab|1.25 mg bevacizumab every 4 weeks
3088464|NCT01969695|Experimental|ABT-199|ABT-199 monotherapy
3088465|NCT01969682|Experimental|Arm A (ABT-199 and rifampin)|
3088466|NCT01969669|Experimental|Arm A (ABT-199 and ketoconazole)|
3088467|NCT01969656|Placebo Comparator|Placebo|
3088468|NCT01969656|Active Comparator|Calcitriol|
3088469|NCT01969656|Experimental|50 ng 2MD|
3088470|NCT01969656|Experimental|110 ng 2MD|
3088471|NCT01969656|Experimental|170 ng 2MD|
3088472|NCT01969656|Experimental|220 ng 2MD|
3088473|NCT01969656|Experimental|440 ng 2MD|
3088474|NCT01969643|Experimental|SGN-LIV1A Dose Escalation|
3088475|NCT01969643|Experimental|SGN-LIV1A + Trastuzumab|
3088476|NCT01969643|Experimental|SGN-LIV1A|SGN-LIV1A will be given at the recommended dose (at or below the monotherapy MTD determined in the SGN-LIV1A dose escalation arm).
3088477|NCT01969630|Active Comparator|PEB|PEB angioplasty plus provisional nitinol stent implantation
3088478|NCT01969630|Experimental|PES|Systematic PES angioplasty
3088479|NCT01969617|Experimental|Nalmefene 18 mg, then placebo|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
3088480|NCT01969617|Placebo Comparator|Placebo, then Nalmefene 18 mg|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
3088549|NCT01969136|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 182
3088481|NCT01969604|Experimental|Motivational lifestyle counselling|This arm will include 1) Three individual motivational counselling sessions including handouts of four key messages regarding reduction of daily sitting time in combination with 2) Individual Short Text Message (SMS) reminders.
3088482|NCT01969604|No Intervention|Control Group|A control group will be encouraged to maintain their usual lifestyle during the 16-week intervention period.
3088483|NCT01969591|Experimental|fast-track surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
3088484|NCT01969591|Other|convontional postoperative care|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
3088485|NCT01969578|Active Comparator|Chemotherapy|"Chemotherapy = either Cisplatin + Doxorubicin or Carboplatin + Paclitaxel~Patients from cohort A (chemonaïve) may be randomized in this arm to receive chemotherapy"
3088486|NCT01969578|Experimental|Androgen Deprivation Therapy (ADT)|"ADT = bicalutamide + triptorelin~Patients from cohort A (chemonaive) may be randomized to receive ADT, and patients from cohort B (pre-treated) will receive ADT without having been randomized."
3088487|NCT01969565|Experimental|Carfilzomib in combination with dexamethasone|Carfilzomib will be administered at a dose of 20 mg/m², with a dose escalation to 36 mg/m² after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m², with a dose escalation to 45 mg/m² after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment naïve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.
3088488|NCT01969552||Thyroid testing|Adult subjects presenting for thyroid testing or treatment
3088489|NCT01969539|Experimental|Combivent Respimat via tee adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
3088490|NCT01969539|Experimental|Combivent Respimat - ventilator adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation with /CVT-R via ventilator adapter
3088491|NCT01969526|Experimental|Multifactorial Intervention|Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy plus intake of hyperproteic shakes, memory workshop and review of the medication.
3088492|NCT01969526|No Intervention|No intervention|Usual care
3088493|NCT01969513|Experimental|INTERVENTION ARM|Patients meeting the inclusion criteria will be randomly assigned to the experimental group. They will receive Epley's manoeuvre plus betahistine 8mg three times a day until they no longer have symptoms. The Epley's manoeuvre will be performed only on the first visit.
3088494|NCT01969513|Sham Comparator|CONTROL GROUP|Patients meeting the inclusion criteria will be randomly assigned to the control group. These patients will receive sham manoeuvre (simulated Epley manoeuvre) plus betahistine 8mg three times a day until they no longer have symptoms. Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
3088495|NCT01969500|Active Comparator|Treatment as Usual|Treatment as usual includes outpatient case management, linkage to services and medication monitoring.
3088496|NCT01969500|Experimental|Mobile Application|Mobile Application system designed to improve coping with psychotic symptoms, social functioning, and medication adherence.
3088497|NCT01969487|Experimental|Preoperative warm-up on simulator|Trainees perform standard practice tasks programmed into a robotic surgical simulator immediately before the surgery.
3088498|NCT01969487|No Intervention|No preoperative warm-up|
3088499|NCT01969474|Experimental|Cannabis|Treatment with a Cannabis capsule
3088500|NCT01969474|Placebo Comparator|Placebo|Placebo
3088501|NCT01969461|Experimental|Healthy Choices: MET CHW Clinic|The 4-session Motivational Enhancement Therapy (MET) intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the CLINIC by a CHW (outreach worker, etc) already providing services in the clinic. The intervention is based on Motivational Interviewing (MI) techniques, building motivation for change by eliciting and reinforcing change talk.
3088502|NCT01969461|Active Comparator|Healthy Choices: MET CHW Home|The 4-session Motivational Enhancement Therapy (MET) intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the HOME by a CHW (outreach worker, etc) already providing services in the clinic. The intervention is based on Motivational Interviewing (MI) techniques, building motivation for change by eliciting and reinforcing change talk.
3088503|NCT01969448|Active Comparator|Inframammary Fold Incision Cohort|"Inframammary fold incision which is in the crease under the breast.~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)~Intraoperatively prior to mastectomy~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
3088504|NCT01969448|Active Comparator|Lateral Radial Incision Cohort|"Lateral radial incision~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)~Intraoperatively prior to mastectomy~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
3088546|NCT01969149|Active Comparator|Insulin group|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
3088547|NCT01969136|Experimental|Experimental: EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
3088505|NCT01969448|Other|Non-Randomized Cohort|"Patients in which the surgeon feels that for oncologic reasons must have a specific incision (either inframammary fold or lateral radial incision) and cannot be randomized due to concerns of compromising clinical care but otherwise meet the inclusion and exclusion criteria will be offered participation as part of a non-randomized cohort.~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)~Intraoperatively prior to mastectomy~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
3088506|NCT01969435|Experimental|Melphalan, carmustine, etoposide, cytarabine (BEAM)|"Day -7, carmustine intravenous (IV) infusion~Days -6, -5, -4, and -3, etoposide and cytarabine (IV) infusions twice a day~Day -2, melphalan HCl (propylene glycol-free)(IV) infusion~Day 0, stem cell transplant."
3088507|NCT01969422||observation group|observation
3088508|NCT01969409|Placebo Comparator|Placebo|These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.
3088509|NCT01969409|Experimental|Rituximab|Rituximab i.v. given on two occasions, with 14 days between doses.
3088510|NCT01969396|Experimental|SonoBiopsy Catheter|
3088511|NCT01969396|Active Comparator|Endometrial biopsy catheter|
3088512|NCT01969383|Experimental|heated pool|After selection, all volunteers will be asked to attend two exercise protocols performed on the ground and in the heated pool and the minimum interval of 24 hours between each protocol. Data collection will be performed only with the dominant member of each volunteer.
3088513|NCT01969370|Experimental|Experimental|Option to request non-medically actionable incidental information (after receiving education about them)
3088514|NCT01969370|No Intervention|Control|No option to request non-medically actionable incidental information
3088515|NCT01969357|Placebo Comparator|Placebo|
3088516|NCT01969357|Experimental|50 mg SP2086|
3088517|NCT01969357|Experimental|100 mg SP2086|
3088518|NCT01969357|Experimental|200 mg SP2086|
3088519|NCT01969357|Active Comparator|100 mg Sitagliptin|
3088520|NCT01969344||Smokers without COPD|Current or former smokers with at least a 20 pack-year history with normal lung function based on post-bronchodilator spirometry (n=944).
3088521|NCT01969344||Severe COPD|Current and former smokers with at least a 20 pack-year history with severe COPD based on post-bronchodilator spirometry (n=625).
3088522|NCT01969344||Mild/Moderate COPD|Current and former smokers with at least a 20 pack-year history with mild to moderate COPD based on post-bronchodilator spirometry (n=1210).
3088523|NCT01969344||Non-smokers|Never-smokers with normal lung function on spirometry without use of bronchodilators (n=201).
3088524|NCT01969331|Placebo Comparator|Placebo|"maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171) Placebo as an addition to standard H. Pylori eradication therapy 7 days of initial therapy (2 antibiotics + PPI), followed by 21 days of PPI only therapy.~Two weeks after the end of PPI therapy subjects are seen at the follow up visit."
3088525|NCT01969331|Active Comparator|Normia|Lactobacillus rhamnosus GG, LGG® and Bifidobacterium, BB-12® Normia® probiotic as an addition to standard H. Pylori eradication therapy 7 days of initial therapy (2 antibiotics + PPI), followed by 21 days of PPI only therapy. One capsule twice per day/14 days Two weeks after the end of PPI therapy subjects are seen at the follow up visit.
3088526|NCT01969318|Placebo Comparator|Placebo/Metformin|
3088527|NCT01969318|Experimental|SP2086 (50mg q.d)/Metformin|
3088528|NCT01969318|Experimental|SP2086 (100mg q.d.)/Metformin|
3088529|NCT01969305|Experimental|Kazakhstani Family Together (KFT)|Usual Care Plus KFT: Family-based multi-media HIV and drug abuse prevention intervention
3088530|NCT01969305|Experimental|Health education curriculum|Usual Care Alone: Health education curriculum on HIV and drug use prevention
3088531|NCT01969292|Experimental|Colometer|Colometer software will be engaged during the colonoscopy to provide real time feedback to the endoscopist.
3088532|NCT01969292|Sham Comparator|Sham Software|An identical set-up to the experimental arm but with a green band showing across the top for the duration of the colonoscopy.
3088533|NCT01969292|No Intervention|Control|Recordings of colonoscopies made without Colometer or sham feedback during the course of the colonoscopy will be evaluated retrospectively using the Colometer software.
3088534|NCT01969266|Experimental|PCI-32765|PCI-32765 840 mg will be administered as capsule (Treatment A in Period 1) and solution (Treatment B in Period 2) formulations. All participants will receive both treatments with a 7-day washout period between doses.
3088535|NCT01969240|Active Comparator|Chest Pain Choice Decision Aid|Patients randomized to the decision aid arm.
3088536|NCT01969240|No Intervention|Usual Care|Patients randomized to the usual care arm (no decision aid used)
3088537|NCT01969227|Other|subanesthetic ketamine|
3088538|NCT01969214|Experimental|IQP-MM-101|"Dissolve the effervescent tablets in half a glass of water,to be taken orally~1 tablet, 3 times a day"
3088539|NCT01969201|Experimental|Fostimon®|75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
3088540|NCT01969201|Active Comparator|Gonal-F®|75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
3088541|NCT01969188||SpA in RA|Patients with SpA with psoriatic arthritis (PsA), ankylosing spondylitis (AS), no biologic therapy for 3 months, over 18 yrs old.
3088542|NCT01969175|Experimental|Intervention Diet|
3088543|NCT01969175|Placebo Comparator|Control|
3088544|NCT01969162||All Participants|Adult volunteers without ocular disease who have tear samples collected as per protocol. No investigational drug is administered in this study.
3088545|NCT01969149|Experimental|Exenatide group|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
3088550|NCT01969123|Experimental|Experimental: EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
3088551|NCT01969123|Experimental|Experimental: EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
3088552|NCT01969123|Placebo Comparator|EVP-6124 Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 182
3088553|NCT01969110|Active Comparator|Perioperative|Oral IMPACT (1 L/day) for 5 days before surgery and by enteral feeding after surgery
3088554|NCT01969110|Active Comparator|Preoperative|Oral IMPACT 1000ml/day for 5 days (1 L/day) before surgery
3088555|NCT01969097|Experimental|Dual tDCS + motor training|Motor training of the affected upper extremity combined with dual transcranial direct current stimulation (tDCS).
3088556|NCT01969097|Active Comparator|Anodal tDCS + motor training|Motor training of the affected upper extremity combined with anodal tDCS.
3088557|NCT01969097|Sham Comparator|Sham tDCS + motor training|Motor training of the affected upper extremity combined with sham tDCS.
3088558|NCT01969084|Experimental|Linagliptin|Subjects given Linagliptin
3088559|NCT01969084|Placebo Comparator|Sugar pill|Subjects given sugar pill/placebo
3088560|NCT01969071|Active Comparator|Levosimendan, inotropic agent|In the levosimendan group, levosimendan will be used in addition to standard inotropic therapy (one or more agent including; dopamine, dobutamine, noradrenaline, adrenaline)for 24 hours.Levosimendan dosage; a loading dose of levosimendan (6 μg kg-1) will be administered after removal of the aortic cross-clamp, followed by an infusion of levosimendan at a dose of 0.1 μg kg-1 min-1.
3088561|NCT01969071|Active Comparator|Control|In the control group, only standard inotropic therapy (one or more agent including; dopamine, dobutamine, noradrenaline, adrenaline)will be administered
3088562|NCT01969058|Active Comparator|Isotretinoin Arm|Participants received Isotretinoin at approximately 0.5 mg/kg orally once daily for 4 weeks, then increased to approximately 1.0 mg/kg orally once daily for 12 weeks.
3088563|NCT01969058|No Intervention|No study treatment Arm|No Isotretinoin treatment
3088564|NCT01969045|Experimental|Working channel|Patients will receive local anaesthetics via the working channel of the bronchoscope.
3088565|NCT01969045|Experimental|Enk Fiberoptic Atomizer|Patients will receive the local anaesthetics for the flexible bronchoscopy via the nebulizer Enk Fiberoptic Atomizer.
3088566|NCT01969032|Experimental|2 consequent anthracycline-taxane based chemotherapy regimens|Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
3088567|NCT01969019|Active Comparator|methylprednisolone|intravenous MP: 0.5g weekly for six weeks followed by 0.25g weekly for six weeks
3088568|NCT01969019|Active Comparator|methylprednisolone plus prednisone|intravenous MP 0.5g daily for three days per week, twice, followed by 0.25g daily for three days per week, twice, and followed by tapering oral prednisone (starting with 60mg/d, then10 mg less/week than each previous week for the next 3 weeks, then20mg/week at the 5th week followed with 5mg less/week than each previous week for the next 3 weeks)
3088569|NCT01969006|Experimental|Injection of Marcaine ½ %|Injection of 40 ml of Marcaine ½ % 2 cm medial, 2 cm downwards from the Anterior Iliac Spine
3088570|NCT01969006|Placebo Comparator|Needle prick|Needle prick 2 cm medial and 2 cm downwards from the Anterior Iliac spine
3088571|NCT01968993|Experimental|nanOss Bioactive - posterolateral gutter|Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side. Autograft alone will be used in the opposite posterolateral gutter.
3088572|NCT01968980|Experimental|Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)
3088573|NCT01968980|Placebo Comparator|Placebo|
3088574|NCT01968967|Experimental|Bococizumab (PF-04950615; RN316)|
3088575|NCT01968967|Placebo Comparator|Placebo|
3088576|NCT01968954|Experimental|Bococizumab (PF-04950615;RN316)|
3088577|NCT01968954|Placebo Comparator|Placebo|
3088578|NCT01968941|Experimental|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy (SBRT)
3088579|NCT01968941|Active Comparator|Conventional Radiotherapy|Conventional Radiotherapy (CRT)
3088580|NCT01968928||drug-resistant|specimens com from drug-resistant bladder urothelial carcinoma patients.
3088581|NCT01968928||normal|specimens come from normal bladder urothelial carcinoma patients.
3088582|NCT01968928||non-tumoral|specimens come from non-tumoral patients.
3088583|NCT01968915|Experimental|LCL161|Dose escalation part: Eligible patients will start to receive oral LCL161 once a week and will receive weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour, in combination with LCL161 from cycle 2. Dose expansion part: Eligible patients will receive oral LCL161 at the maximum tolerated dose and/or recommended dose in combination with weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour from cycle 1.
3088584|NCT01968902|Active Comparator|incabotulinumtoxinA|intramuscular injection, 200 to 400 units, 1 injection visit only
3088585|NCT01968902|Placebo Comparator|Placebo|intramuscular injection, saline 200 - 400 units , 1 injection visit only
3088586|NCT01968889||Critical illness neuromyopthy|Non invasive phrenic nerve stimulation allowing to measure the twitch airway pressure during airway occlusion
3088587|NCT01968876|No Intervention|Standard Care|The control group will not use the medication adherence app
3088588|NCT01968876|Experimental|Medication Adherence Smartphone App|The experimental group will receive the medication adherence app on their smartphone and will have their entire outpatient medication list pushed to the application. Text message reminders will be sent to their phones at the appropriate times.
3088589|NCT01968850|No Intervention|no bone anti-resorptive therapy|(standard of care)
3088590|NCT01968850|Experimental|24-week tx of alendronate/vitamin D|Concomitant initiation of a 24 week course of co-formulated alendronate/vitamin D
3088591|NCT01968850|Experimental|Delayed 24-week tx of alendronate/vitamin D|a 24 week delay in initiation of a 24 week course of alendronate/vitamin D
3088592|NCT01968837|No Intervention|Cervical cancer screening|
3088593|NCT01968824|No Intervention|General Anesthesia|general anesthesia only
3088594|NCT01968824|Experimental|Brachial Plexus Nerve Block|brachial plexus nerve block
3088595|NCT01968811|Experimental|Avance foam, abdominal dressing kit|
3088598|NCT01968785|Active Comparator|Radiation dose 25 Gy|• 25 Gy: Subjects will be treated with beta radiation dosage of 25 Gy during renal denervation procedure. Subjects are to maintain baseline anti-hypertensive medications and will undergo follow-up for 24 months.
3088599|NCT01968785|Active Comparator|Radiation dose 50 Gy|• 50 Gy: Subjects will be treated with beta radiation dosage of 50 Gy during renal denervation procedure. Subjects are to maintain baseline anti-hypertensive medications and will undergo follow-up for 24 months.
3088600|NCT01968772|Other|Transdermal Magnesium Chloride|This is a clear, odorless liquid that dries rapidly on the skin and leaves no oily residue. Its ingredients are water, magnesium chloride, and a proprietary blend of less than two-tenths of 1% trace minerals (Boron, Selenium, and Manganese).
3088601|NCT01968759|Active Comparator|Ramipril and Irbesartan|Best available therapy including dual RAS blockade with Ramipril and Irbesartan
3088602|NCT01968759|Experimental|Sevelamer|Two tablets of Sevelamer carbonate 800 mg will be orally administered three times per day during the meals for 3 months.
3088603|NCT01968746||ED patients with suspected infection|
3088604|NCT01968733|Active Comparator|Moxifloxacin|Intravenous with the potential step-down to oral moxifloxacin
3088605|NCT01968733|Experimental|Solithromycin|Intravenous with potential step-down to oral solithromycin
3088606|NCT01968720|Experimental|CAT-2003 or Placebo|All patients will receive placebo for a 14 day treatment period and CAT-2003 for a 28 day treatment period.
3088607|NCT01968707|Active Comparator|ChloraPrep CHG/IPA Hi-Lite Orange Tint|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
3088608|NCT01968707|Placebo Comparator|Normal Saline|0.9% normal saline with applicator
3088609|NCT01968707|Experimental|3M CHG/IPA Prep Tint 10.5-mL|Chlorhexidine gluconate 2% / Isopropyl alcohol 70% 10.5 mL
3088610|NCT01968707|Experimental|3M CHG/IPA Prep Tint 26-mL|Chlorhexidine gluconate 2% / Isopropyl alcohol 70% 26 mL
3088611|NCT01968694|Experimental|IV Lidocaine|IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes
3088612|NCT01968694|Placebo Comparator|IV diphenhydramine|IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes
3088613|NCT01968681|Experimental|Alexandrite laser treatment|
3088614|NCT01968668|Experimental|BAY94-8862 (1.25 mg)|
3088615|NCT01968668|Experimental|BAY94-8862 (2.5 mg)|
3088616|NCT01968668|Experimental|BAY94-8862 (5 mg )|
3088617|NCT01968668|Experimental|BAY94-8862 (7.5 mg)|
3088618|NCT01968668|Experimental|BAY94-8862 (10 mg)|
3088619|NCT01968668|Placebo Comparator|Placebo|
3088620|NCT01968668|Experimental|BAY 94-8862 (15 mg)|
3088621|NCT01968668|Experimental|BAY 94-8862 (20 mg)|
3088622|NCT01968642|Experimental|Educational Intervention|"Attending physicians in the intervention arm will receive the following multi-faceted educational intervention on transthoracic echocardiogram appropriateness: 1) a lecture at the beginning of the study period, which describes Appropriate USe Criteria (AUC) and highlights common clinical scenarios for which outpatient echocardiograms are ordered, 2) an electronic pocket cared via email that provides tips on appropriate ordering of echocardiograms, and 3) an individualized monthly feedback report that categorizes echocardiograms ordered over the preceding month. The feedback report will contain the number of echocardiograms ordered during the month and how many are classified as appropriate, inappropriate, or uncertain based on the 2011 AUC."
3088623|NCT01968642|No Intervention|Control Group|Attending physicians in the control arm will have their echocardiogram orders tracked and classified, but will not receive any feedback on their ordering behavior.
3088624|NCT01968629|Experimental|Eovist at 24 Hour Delayed Imaging|This study will evaluate uptake of the hepatobiliary magnetic resonance imaging (MRI) contrast agent gadolinium ethoxybenzyl dimeglumine, or Eovist (Bayer Imaging, Wayne, NJ) within hepatocellular carcinomas (HCCs) at delayed, 24 hour imaging. The recommended dose of Eovist is 0.1 mL/kg, or 0.025 mmol/kg.
3088625|NCT01968616|Other|Intravitreal Lucentis 0.5mg|One arm
3088626|NCT01968590|Active Comparator|cholecalciferol 600 IU|cholecalciferol in Ddrops form at either 600 International units per day versus 4,000 IU per day
3088627|NCT01968590|Active Comparator|cholecalciferol 4,000 IU|Cholecalciferol at 4,000 IU per day in the form of liquid Ddrops
3088628|NCT01968577|Experimental|Rosuvastatin 40 mg|Administration of rosuvastatin 40 mg 2 to 6 hours before percutaneous coronary intervention
3088629|NCT01968577|No Intervention|Control group|The group of patients that do not receive rosuvastatin, 40 mg, before percutaneous coronary intervention.
3088630|NCT01968564|Experimental|High-dose curcumin pill|
3088631|NCT01968564|Experimental|Low-dose curcumin pill|
3088632|NCT01968564|Placebo Comparator|Placebo pill|
3088633|NCT01968551|Experimental|Cohort 1|"Participants will receive E/C/F/TAF FDC + DRV once daily with food for 48 weeks.~Based on safety and efficacy data from Cohort 1 at Week 4, the participants will be randomized into Cohort 2. The participants in Cohort 1 will continue receiving E/C/F/TAF FDC + DRV through 48 weeks."
3088634|NCT01968551|Experimental|Cohort 2, Treatment Group 1|Participants will be randomized to receive E/C/F/TAF FDC+DRV once daily with food for 48 weeks.
3088635|NCT01968551|Active Comparator|Cohort 2, Treatment Group 2|Participants will be randomized to continue on their baseline DRV-containing ARV regimen for 48 weeks.
3088636|NCT01968538||Prostate Cancer Patients|Prostate cancer patients who underwent radiation therapy
3088637|NCT01968538||Healthy control|age-matched male who has no known prostate cancer
3088638|NCT01968525|Experimental|Group A|the hemoglobin is >12g/L in patients from group A.
3088639|NCT01968525|Experimental|Group B|Hb 9-12g/L
3088640|NCT01968525|Experimental|Group C|Hb<9g/L
3088641|NCT01968512|Experimental|Transcranial Direct Current Stimulation|Subjects will undergo to Transcranial Direct Current Stimulation with anode in left dorsolateral prefrontal cortex and cathode in right supra orbicular region. The stimulus will be 1mA for 20 minutes.
3088642|NCT01968512|Sham Comparator|TDCS-Sham|Subjects will undergo to procedure similar to the Transcranial Direct Current Stimulation with anode in dorsolateral prefrontal cortex and left cathode region supraorbicular right. They will receive a stimulus of 1mA only in initial 30 seconds and it will change the electrical charge for 0mA after this time, however the electrodes will be kept for 20 minutes as the active arm.
3088643|NCT01968499||All recruited patients|Patients who receive stent implantation and aged >18 years.
3088644|NCT01968486|Experimental|PDT Standard Fluence, ranibizumab|verteporfin (6 mg/m2) SF (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 milliwatt(mW)/cm2 for 83 s) plus 0.5 mg intravitreal ranibizumab
3088645|NCT01968486|Experimental|PDT Reduced Fluence, ranibizumab|verteporfin (6 mg/m2) RF ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s) plus 0.5 mg intravitreal ranibizumab
3088646|NCT01968486|Experimental|ranibizumab|0.5 mg (10 mg/ml) intravitreal ranibizumab.
3088647|NCT01968473|Experimental|NMES Device comfort|NMES Device comfort, establishing Sensory, Motor and Pain thresholds. Max Pain tolerance is also established.
3088648|NCT01968460|Experimental|P2B001 Treatment A|Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily.
3088649|NCT01968460|Experimental|P2B001 Treatment B|Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
3088650|NCT01968460|Placebo Comparator|Placebo|Placebo once daily for 12 weeks.
3088651|NCT01968447|Experimental|hypocapnia|arterial pCO2 of 3.5 kPa or 26.3 mmHg
3088652|NCT01968447|Active Comparator|normocapnia|arterial PCO2 of 6.5-7.0 kPa or 48.8-52.5 mmHg
3088653|NCT01968434|Experimental|protective cough syrup|"syrup containing honey, plantago lanceolata, grindelia robusta, helichrysum italicum ina syrup form. The cough syrup is a CE marked medical device acting in a non pharmacological way to reduce cough.~Dosage: 20 ml divided in three doses per day for the duration of the study (4 nights, 3 days)"
3088654|NCT01968434|Active Comparator|carbocisteine cough syrup|Dosage 20-25 mg/kg/day three times a day (3 days/4 nights)
3088655|NCT01968421|Experimental|OM-85|The subjects will be randomly received two courses of 7mg of OM-85 to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
3088656|NCT01968421|Placebo Comparator|Placebo|The subjects will be randomly received two courses of 7mg of matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
3088657|NCT01968408|Active Comparator|L. reuteri DSM 17938|"Lactobacillus reuteri DSM 17938,10(9)CFU/daily (for the duration of hospitalization)~ARM I: Rotavirus vaccinated patients~ARM II: Non-rotavirus vaccinated patients"
3088658|NCT01968408|Placebo Comparator|Placebo|"Placebo consists of an identical formulation in all respects except that the live probiotic bacteria were excluded~for the duration of hospitalization"
3088659|NCT01968395|Other|Caspofungin 70 mg|Infusion of one dose of Caspofungin 70 mg
3088660|NCT01968382|Experimental|IMM 124-E 2400 mg/day|Imm-124-E (2400 mg/day) will be provided in two divided doses daily in the form of powder to be mixed with water. Subjects will get 1 active drug powder and 1 placebo powder with each dosing for a total of 4 sachets daily.
3088661|NCT01968382|Experimental|IMM 124-E 4800 mg/day|Imm-124-E (4800 mg/day) will be provided in two divided doses daily in the form of 2400 mg in the form of a powder to be mixed with water. The total number daily will be 4 sachets.
3088662|NCT01968382|Placebo Comparator|Placebo (High protein milk powder)|Subjects will receive 2 sachets of placebo powder to be mixed with water in the morning and 2 sachets of placebo powder (to be mixed with water) in the evening for a total of 4 sachets of placebo daily.
3088663|NCT01968369|Active Comparator|tomato sauce (+/- high fat meal)|80 gr for 7 days= total load 560 mg (+/- high fat meal)
3088664|NCT01968369|Placebo Comparator|diet without tomato (+/- high fat meal)|diet without tomato (+/- high fat meal)
3088665|NCT01968356|Experimental|3M CHG/IPA Prep Colorless|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70% 10.5 mL applicator
3088666|NCT01968356|Experimental|3M CHG/IPA Prep Tint|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70% 10.5 mL applicator
3088667|NCT01968356|Active Comparator|ChloraPrep CHG/IPA Hi-Lite Orange Tint|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70% 10.5 mL applicator
3088668|NCT01968356|Placebo Comparator|Normal Saline|0.9% normal saline with applicator
3088669|NCT01968343|Experimental|Group cognitive-behavioral therapy|22 subjects, all of whom met the criteria for a diagnosis of trichotillomania established in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Subjects receive 22 sessions of group cognitive-behavioral therapy.
3088670|NCT01968343|Active Comparator|Group supportive therapy (control)|22 subjects, all of whom met the criteria for a diagnosis of trichotillomania established in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Subjects receive 22 sessions of group supportive therapy (control).
3088671|NCT01968330|Experimental|Go!®to sleep|Patients in the sleep intervention arm will undergo a sleep wellness program entitled Go!®to sleep as part of their group prenatal visits. This intervention is a six-week online program developed by the Cleveland clinic for non-pregnant patients suffering from insomnia. In collaboration with the Cleveland clinic sleep disorders center researchers will modify the program to fit the specific needs of a pregnant population. Subjects will receive access to the program and instructed on its use at their initial group prenatal visit. In subsequent visits subjects will be able to discuss their experience with the program.
3088672|NCT01968330|No Intervention|Routine prenatal care|Patients in the routine prenatal care arm will complete prenatal care in a group setting and will not complete the sleep intervention.
3088673|NCT01968317|Experimental|Megestrol acetate and metformin|Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.Then an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
3088674|NCT01968317|Experimental|Megestrol acetate|Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.Then an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
3088675|NCT01968304|No Intervention|Iron status follow up|
3088676|NCT01968291|Experimental|Teach-back|Patients are prompted to state back in their own words their comprehension of the information given to them at discharge.
3088677|NCT01968291|No Intervention|Standard Discharge Instructions|Patient receives usual discharge instructions as administered by the nurse assigned to the patient.
3088678|NCT01968278|Experimental|Baked milk group|BM (baked milk)
3088679|NCT01968278|No Intervention|Control|IgE-cow's milk allergic patients not treated with OIT
3088680|NCT01968265|Placebo Comparator|Placebo|
3088681|NCT01968265|Active Comparator|ISIS-GCCRRx|
3109266|NCT01828437|Experimental|Pyridoxine plus prednisolone|
3088682|NCT01968252||Intraoperative Patient|All patients in the cohort will be scheduled to undergo a planned surgical procedure in which the subject will undergo general anesthesia and the procedure and/or the patient will require transesophageal echocardiographic monitoring for the procedure.
3088683|NCT01968239|Experimental|OCT guided group|Patients randomized to this group will get the intravitreal injection of 0.5 mg ranibizumab if the morphological macular changes for recurrence of macular edema (microcystic changes with or without increase of central retinal thickness) will be detected by OCT.
3088684|NCT01968239|Active Comparator|Standard treatment|Patients randomized to this group will get the intravitreal injection of 0.5 mg ranibizumab according to the in SmPC defined re-treatment criteria (re-injection if decrease of BCVA will be detected).
3088685|NCT01968226|Experimental|PET imaging with [F-18] RDG-K5|This is an observational study of a group of individuals who all have carotid artery stenosis. The observation will be the measurement of [F-18]RGD-K5 uptake by the carotid artery plaque after intravenous administration of this radiolabeled tracer using PET imaging.
3088686|NCT01968213|Experimental|Rucaparib|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
3088687|NCT01968213|Placebo Comparator|Placebo|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
3088688|NCT01968200|Experimental|Enalapril concomitant|Enalapril started concomitantly to AC-containing treatments
3088689|NCT01968200|Experimental|Enalapril after injury|Enalapril prescribed to selected patients showing laboratory evidences of injury after chemotherapy at follow-up visits.
3088690|NCT01968187|Experimental|FE 992097|
3088691|NCT01968187|Placebo Comparator|Placebo|
3088692|NCT01968174||eyelid displacement|patients suffering from eyelid disposition due to ptosis, blepharochalasis and are registered for eyelid surgeries will be assigned for the study
3088693|NCT01968161|Other|Asenapine|Open label switch to asenapine: asenapine will be introduced at the target dose (5 mg bid)
3088694|NCT01968135|Placebo Comparator|Sugar Pill|Placebo Sugar Pill
3088695|NCT01968135|Experimental|Combined Oral Contraceptive Pill|150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
3088696|NCT01968122||aggressive medical treatment|administer Aspirin (100mg/d) + Clopidogrel (75mg/d) for more than 5d before the operation (but Clopidogrel of loading dose 200mg in case of emergency operation for TIA); administer Aspirin (100mg/d) + Clopidogrel (75mg/d) for 90d and subsequent monoclonal antibody after the operation; control the primary risk factors (e.g. hypertension and high LDL); control the secondary risk factors (e.g. diabetes, blood lipid of not high LDL, smoking, obesity and hypomotility); and intervene the life style. Primary risk factors: target systolic pressure of <140mmHg (or <130mmHg in the diabetes patients); and LDL <70mg/dl (1.81mmol/L) or drop by 50%.
3088697|NCT01968109|Experimental|Relatlimab|Relatlimab (BMS-986016) specified dose on specified days
3088698|NCT01968109|Experimental|Relatlimab + Nivolumab|Relatlimab (BMS-986016) + Nivolumab (BMS-936558) specified dose on specified days
3088699|NCT01968109|Experimental|BMS-986213|Relatlimab (BMS-986016) + Nivolumab (BMS-936558)
3088700|NCT01968096|No Intervention|SCI subjects|Stage 1 subjects: pilot study:understand post activation depression with spinal cord injury to avoid the influence of the suprasegmental level.
3088701|NCT01968096|No Intervention|Incomplete SCI subjects|Stage 2 subjects: pilot study:The strength of depression will be evaluated in individuals with and without SCI.
3088702|NCT01968096|No Intervention|Health subjects|Stage 2 subjects: pilot study:The strength of depression will be evaluated in individuals with and without SCI.
3088703|NCT01968096|Experimental|SCI subjects with high muscle tone (High frequency)|Stage 3 subjects:A rehabilitation program of machine driven passive stretch(High frequency) will be executed .
3088704|NCT01968096|Experimental|SCI subjects with high muscle tone(low frequency)|Stage 3 subjects:A rehabilitation program of machine driven passive stretch(Low frequency) will be executed.
3088705|NCT01968096|No Intervention|SCI subjects with high muscle tone|Stage 3 subjects:Control subjects
3088706|NCT01968083|Experimental|RSV cps2 Vaccine|Participants will receive one dose of the RSV cps2 vaccine administered as nose drops at study entry.
3088707|NCT01968083|Placebo Comparator|Placebo|Participants will receive one dose of placebo administered as nose drops at study entry.
3088708|NCT01968070|Experimental|LY3127760 (Single)|Single oral dose of up to 900 milligram (mg) LY3127760 administered in up to 3 of 3 study periods.
3088709|NCT01968070|Placebo Comparator|Placebo (Single)|Single oral dose of placebo administered in up to 2 of 3 study periods. Placebo matches LY3127760 in appearance.
3088710|NCT01968070|Experimental|LY3127760 (Multiple)|Multiple ascending oral doses of up to 900 mg LY3127760 administered once or twice daily (QD or BID) for 28 days.
3088711|NCT01968070|Placebo Comparator|Placebo (Multiple)|Multiple oral doses of placebo administered QD or BID for 28 days. Placebo matches LY3127760 in appearance.
3088712|NCT01968070|Active Comparator|Celecoxib (Multiple)|Multiple oral doses of 400 mg celecoxib administered QD for 28 days.
3088713|NCT01968057|Experimental|Baricitinib|Single oral dose of 4 milligrams (mg) baricitinib on Day 1
3088714|NCT01968057|Experimental|Baricitinib + Ciclosporin|Single oral dose of 4 mg baricitinib co-administered with a single oral dose of 600 mg ciclosporin on Day 4
3088715|NCT01968044|Experimental|Gemigliptin|Participant will remain gemigliptin 50mg throughout entire study (52 weeks).
3088716|NCT01968044|Other|Placebo to linagliptin|Participant who is randomized to placebo will be switched to linagliptin after 12 week and administered linagliptin by week 52.
3088717|NCT01968031|Experimental|Istradefylline 20 mg/day|"Istradefylline 20 mg and placebo to match istradefylline 40 mg:~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
3088718|NCT01968031|Experimental|Istradefylline 40 mg/day|"Istradefylline 40 mg and placebo to match istradefylline 20 mg:~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
3088753|NCT01967810|Experimental|Arm 3|ANG1005 administered to recurrent WHO Grade III anaplastic glioma
3088719|NCT01968031|Placebo Comparator|Placebo|"Placebo to match istradefylline 20 mg and placebo to match istradefylline 40 mg:~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
3088720|NCT01968018|Experimental|Tramadol HCI + acetaminophen|
3088721|NCT01968005|Placebo Comparator|Placebo|Therapy with placebo
3088722|NCT01968005|Experimental|Etoreat®(Etodolac-Lidocaine Topical Patch)|Therapy with experimental drug
3088723|NCT01967992|Active Comparator|American Diabetes Association recommended diet|"Participants in the American Diabetes Association (ADA) diet group will receive standard ADA advice. The diet includes high-fiber foods (such as vegetables, fruits, whole grains, and legumes), low-fat dairy products, fresh fish, and foods low in saturated fat. They will be asked to use the plate method to guide their nutritional choices."
3088724|NCT01967992|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate, ketogenic diet: carbohydrate intake 20-35 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
3088725|NCT01967979|Experimental|Cohort 1 (Itraconazole DDI)|
3088726|NCT01967979|Experimental|Cohort 2 (Fluoxetine DDI)|
3088727|NCT01967966|Experimental|Bioavailability|
3088728|NCT01967966|Experimental|Elimination & PK|
3088729|NCT01967953|No Intervention|Standard Group|"Recipients of lungs procured from brain death donors deemed suitable for transplantation according to standard criteria.~Events: lung procurement, cold storage on ice, transplantation."
3088730|NCT01967953|Experimental|EVLP Group|"Recipients of marginal lungs procured from brain death donors and reconditioned with ex-vivo lung perfusion (EVLP).~Events: lung procurement, cold storage on ice, reconditioning by EVLP, cold storage on ice, transplantation."
3088731|NCT01967940|Experimental|Part 1 Sentinel Cohort (TAF)|TAF + their current failing ARV regimen for 10 days in Part 1
3088732|NCT01967940|Experimental|Part 1 Randomized Cohort (TAF)|Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive TAF + their current failing ARV regimen for 10 days in Part 1.
3088733|NCT01967940|Placebo Comparator|Part 1 Randomized Cohort (Placebo)|Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive placebo + their current failing ARV regimen for 10 days in Part 1.
3088734|NCT01967940|Experimental|Part 2 E/C/F/TAF+ATV|Following a 14-day period to confirm eligibility, participants in the Randomized Cohort TAF group with a > 0.5 log10 decline in HIV-1 RNA and all participants completing the Randomized Cohort Placebo group will receive E/C/F/TAF+ATV for 48 weeks in Part 2. After completion of Part 2, all participants will be eligible to continue to receive E/C/F/TAF plus ATV in the extension phase until E/C/F/TAF becomes commercially available, or until Gilead Sciences terminates development of E/C/F/TAF in the applicable country.
3088735|NCT01967927|Experimental|GRID 18F-MISO|
3088736|NCT01967914||Women undergoing cesarean delivery under spinal anesthesia|
3088737|NCT01967901|Active Comparator|Sequence: ABBA A=usual care, B=self-care|"The usual care consists of patients' follow up by their usual nephrologist and endocrinologist or general practitioner.~Self-care management consists of a the addition of a multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.~In this sequence, patients will receive the usual care for 3 months. Then, they will cross-over to receive a multidisciplinary self-management for the following 6 months and then cross-over to a 3 months of usual care."
3088738|NCT01967901|Active Comparator|Sequence BAAB|Patients will receive the multidisciplinary self-management program for 3 months. Then, they will cross-over to usual care for the following 6 months and then cross-over to 3 months of multidisciplinary self-management
3088739|NCT01967901|Active Comparator|Sequence AABB|Patients will receive the usual care for two periods of three months, then they will cross-over to a period of 6 months of a multidisciplinary self-management
3088740|NCT01967901|Active Comparator|Sequence BBAA|Patients will receive the multidisciplinary self-management for two periods of three months, then they will cross-over to a period of 6 months of usual care.
3088741|NCT01967888|Experimental|Reparixin|Solution for iv infusion with active compound
3088742|NCT01967888|Placebo Comparator|Placebo|Physiologic solution
3088743|NCT01967875|Active Comparator|H-A: ERCC1 High Expression Group A|XP：Capecitabine+Cisplatin
3088744|NCT01967875|Experimental|H-B: ERCC1 High Expression Group B|DX：Docetaxel+Capecitabine
3088745|NCT01967875|Active Comparator|L: ERCC1 Low Expression Group|XP：Capecitabine+Cisplatin
3088746|NCT01967862|Experimental|Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)|Patients first undergo CT scan and bone scan. Patients with negative results from the CT and bone scans then undergo WB MRI scan using diffusion-weighted MRI, axial MRI scan using 3-Tesla MRI, and fluorine F 18 sodium fluoride PET/CT scan.
3088747|NCT01967849|Other|Obese/overweight chldren/adolescents|Obese or overweight children and adolescents between ages 7-21 that are at risk for developing type 2 diabetes will undergo an Oral Glucose Tolerance test (OGTT) to asses glucose status.
3088748|NCT01967849|Other|Lean children/adolescents|Lean children/adolescents between the ages of 7-21. This cohort should have family members that have type 2 diabetes or was the result of a gestational diabetes pregnancy. They will undergo an Oral Glucose Tolerance Test to assess glucose status.
3088749|NCT01967836|Other|Glad Press 'n Seal|Cohort Subjects will use Glad Press 'n Seal product as a moisture barrier to an IV line
3088750|NCT01967823|Experimental|1/Experimental Therapy|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + anti-ESO murine TCR transduced PBL + high-dose aldesleukin
3088751|NCT01967810|Experimental|Arm 1|ANG1005 administered to bevacizumab-naive recurrent GBM patients
3088752|NCT01967810|Experimental|Arm 2|ANG1005 and possibly bevacizumab administered to bevacizumab-refractory recurrent GBM patients
3088754|NCT01967797|Experimental|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes & team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners & teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
3088755|NCT01967797|No Intervention|Control|Though the controls will have knowledge of the '5A's of Obesity Management', they will not be receiving 5As Team Intervention.
3088756|NCT01967784|Experimental|Study Group|Participants age 9 to 17 years will receive a dose of Quadrivalent Influenza Vaccine
3088757|NCT01967771|Experimental|DTG/CBZ|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive DTG 50 mg once daily (OD) for 5 days (Period 1), followed by CBZ 100 mg twice daily (BID) for 3 days (days 1-3 of Period 2), CBZ 200 mg BID for 3 days (days 4-6 of Period 2), CBZ 300mg BID for 10 days (days 7-16 of Period 2), followed by DTG 50 mg OD in combination with CBZ 300mg BID for 5 days (Period 3).
3088758|NCT01967758|Experimental|Cohort 1|Patients in Cohort 1 will receive ADU-623 at a dose of 3 x 10^7cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
3088759|NCT01967758|Experimental|Cohort 2|Patients in Cohort 2 will receive ADU-623 at a dose of 3 x 10^8cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
3088760|NCT01967758|Experimental|Cohort 3|Patients in Cohort 3 will receive ADU-623 at a dose of 3 x 10^9cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
3088761|NCT01967745||laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars, placed in the periumbilical area, right midabdomen, and forceps.
3088762|NCT01967745||open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
3088763|NCT01967732|Active Comparator|THS 2.2 then CC|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of THS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of CC)."
3088764|NCT01967732|Active Comparator|CC then THS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of CC)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of THS 2.2)."
3088765|NCT01967732|Active Comparator|THS 2.2 then NNS|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of THS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single administration of NNS)"
3088766|NCT01967732|Active Comparator|NNS then THS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single administration of NNS)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of THS 2.2)."
3088767|NCT01967719|Active Comparator|mTHS 2.2 then mCC|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mTHS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mCC)."
3088768|NCT01967719|Active Comparator|mCC then mTHS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mCC)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mTHS 2.2)."
3088769|NCT01967719|Active Comparator|mTHS 2.2 then NNS|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mTHS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single administration of NNS)"
3088770|NCT01967719|Active Comparator|NNS then mTHS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single administration of NNS)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mTHS 2.2)."
3088771|NCT01967706|Active Comparator|mTHS then mCC|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mTHS)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mCC)."
3088772|NCT01967706|Active Comparator|mCC then mTHS|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mCC)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mTHS)."
3088773|NCT01967706|Active Comparator|mTHS then NRT|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mTHS)~Day 2 = wash-out~Day 3 = 2nd intervention (single administration of NRT)"
3088774|NCT01967706|Active Comparator|NRT then mTHS|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single administration of NRT)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mTHS)."
3088775|NCT01967680|Active Comparator|Sedation with daily wake-up trial|The control group is sedated with continuous infusion to Ramsay score 3-4. During daytime, the patient is awakened as the intravenous infusion of sedatives is discontinued. After a successful wake-up, the infusion of sedative is resumed, starting on half of the pre-wake-up dose. If the patient becomes uncomfortable or agitated during the awakening, sedation is resumed, again starting with half the dosage. The infusion of sedatives is then adjusted to Ramsey score 3-4.
3088818|NCT01967368|Active Comparator|Vaxigrip|intramuscular injection (15ug hemagglutinin 2013/2014 trivalent influenza vaccine) delivered with the Vaxigrip, single dose injection
3088819|NCT01967355|Experimental|Lipid apheresis|Lipid apheresis: lipid removing therapy,frequency and duration depending on the symptoms of mother and fetus.
3088849|NCT01967212|Experimental|Game-based swallow biofeedback|swallowing training combined with game-based biofeedback in stroke dysphagia patient.
3088850|NCT01967212|Active Comparator|Swallow training without biofeedback|
3088776|NCT01967680|Experimental|Non-sedation|"This group will not receive sedatives. Patients are thoroughly and repeatedly informed by the staff of where they are, what have happened, and what type of treatment they are going to receive.~Participants in the non-sedated group are awake and have a natural sleep rhythm. In case these patients develop and outward delirium, it is necessary to have a nurse or other caregiver at the bedside in order to calm the patient. Patients with delirium are treated with haloperidol according to the U.S. guidelines, 2002 and the Danish national guidelines.~If, despite these measures, it is necessary to sedate an agitated patient more than twice, or where sedation might be necessary to ensure sufficient oxygenation or prone position, the patient is sedated and treated like the control-group. Every day during the wake-up trial it is evaluated whether the patient is able to continue the intervention of non-sedation."
3088777|NCT01967667|Experimental|Liposomal glutathione|dose steps
3088778|NCT01967667|Placebo Comparator|Placebo|dose steps
3088779|NCT01967654|Experimental|Technical assistance, training, plus clinical reminder system|To assess the contextual factors of the intervention settings (district level policies and organizational level characteristics) that may influence tobacco use treatment in CHCs and to inform additional modifications to the proposed implementation strategies.
3088780|NCT01967654|Experimental|TTC + referral to community health workers|To compare the effectiveness and cost effectiveness of two multi component implementation strategies.
3088781|NCT01967641|Experimental|buprenorphine/naloxone combination|Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be followed at the Substance Use Research Center (SURC) and maintained on 16/4 mg Bup/Nx.
3088782|NCT01967628|Experimental|Vitamin D3 (cholecalciferol)|Vitamin D3 (1000 international units) daily for 3 months.
3088783|NCT01967628|Placebo Comparator|Sugar capsule|Placebo comparator made of sugar in a capsule
3088784|NCT01967589|Experimental|DC (dosing condition)|Escalation design.
3088785|NCT01967589|Experimental|Oral A|Escalation design. Planned end-dose is 5 mg.
3088786|NCT01967589|Experimental|Oral B|Escalation design. Planned end-dose is 10 mg.
3088787|NCT01967589|Experimental|Oral C|Escalation design. Planned end-dose is 20 mg.
3088788|NCT01967576|Experimental|1/Arm 1|Axitinib 5 mg twice a day on a 28-day cycle
3088789|NCT01967550|Experimental|diclofenac diethylamine, DDEA 2.32% gel|diclofenac diethylamine, DDEA 2.32% gel
3088790|NCT01967550|Placebo Comparator|Placebo|Vehicle control
3088791|NCT01967537|Experimental|A|68Gallium DOTATATE imaging
3088792|NCT01967524|Experimental|botulinum toxin A + ropivacaïne|
3088793|NCT01967524|Active Comparator|Ropivacaïne|
3088794|NCT01967511||FMD subjects|patients who fulfill standard diagnostic criteria for FMD
3088795|NCT01967511||SCAD subjects|patients who fulfill standard diagnostic criteria for SCAD
3088796|NCT01967511||CvAD subjects|patients who fulfill standard diagnostic criteria for CvAD
3088797|NCT01967511||Healthy control subjects|
3088798|NCT01967498|Experimental|montelukast|this arm will receive montelukast as the active intervention of the study
3088799|NCT01967498|Placebo Comparator|placebo|
3088800|NCT01967485|Experimental|Text Messaging|Text messaging to the parents of children. Children will receive open treatment for Attention Deficit/Hyperactivity Disorder (ADHD) with stimulant medication.
3088801|NCT01967485|Active Comparator|No Text Messaging|Children will receive open treatment for ADHD with stimulant medication. This group will not get the text messaging intervention, but will receive treatment as usual.
3088802|NCT01967472|Active Comparator|co-formulated Amodiaquine-Artesunate|"Sanofi Coarsucam Infant dose (2-12 months/4.5-8kg), amodiaquine:67.5mg/artesunate 25mg; 1 tablet once a day for 3 days.~Sanofi Coarsucam Young Child (13-59 months/9-17kg), amodiaquine: 136mg/artesunate 50mg; 1 tablet once a day for 3 days."
3088803|NCT01967472|Active Comparator|artemether-lumefantrine|"Novartis coartem infant dose (2-11 months/5-14kg), artemether 20mg/lumefantrine 120mg; 1 tablet twice a day for 3 days.~Novartis coartem child dose (12-59 months/15-24kg), artemether 20mg/lumefantrine 120mg; 2 tablets twice a day for 3 days"
3088804|NCT01967459|Active Comparator|High dose vitamin D|Volunteers assigned to this arm will receive a single dose of oral cholecalciferol 300 000 IU, in the form of 3 ml D-cura drink 100 000 IU/ml
3088805|NCT01967459|Active Comparator|Low dose vitamin D|Volunteers assigned to this arm will receive a single dose of oral cholecalciferol 75000 IU, in the form of 3 ml D-cura drink 25 000 IU/ml
3088806|NCT01967433|Experimental|Diphenhydramine|Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives
3088807|NCT01967433|Placebo Comparator|Placebo|0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives
3088808|NCT01967420|Experimental|Cognitive remediation plus social cognition training|A combined intervention of 60 minutes of computerised cognitive remediation and 30 minutes of computerised social cognition training.
3088809|NCT01967420|Active Comparator|Cognitive remediation alone|An active control condition consisting of 60 minutes of computerised cognitive remediation and 30 minutes of free computer time.
3088810|NCT01967407|Experimental|renal tumor <4cm, suspected RCC|Intervention/ Time point: Irreversible Electroporation at day 0 of each patient.
3088811|NCT01967394|Experimental|Intervention County|Use of internet based social marketing intervention
3088812|NCT01967394|Placebo Comparator|Control County|No use of social media
3088813|NCT01967381|Placebo Comparator|Arm 1|Subjects will be maintained on oral placebo.
3088814|NCT01967381|Experimental|Arm 2|Subjects will be maintained on oral oxazepam (Serax®).
3088815|NCT01967381|Experimental|Arm 3|Subjects will be maintained on oral naltrexone (Revia®).
3088816|NCT01967381|Experimental|Arm 4|Subjects will be maintained on oral naltrexone (Revia®) and oral oxazepam (Serax®).
3088817|NCT01967368|Experimental|Intanza|intradermal injection (15ug hemagglutinin 2013/2014 trivalent influenza vaccine) delivered with the Intanza, single dose injection
3088820|NCT01967342|Experimental|Pain Ed|Pain Education: A psychosocial treatment group focusing on providing core pain education to low-income patients who may not have received this information due to existing barriers that often includes limited health literacy. This condition also included medical treatment as usual.
3088821|NCT01967342|Experimental|CBT for Pain|Cognitive-Behavioral Therapy for Pain: A psychosocial treatment group focusing on providing core pain education and cognitive-behavior skills to low-income patients who may not have received this information due to existing barriers that often includes limited health literacy. This condition also included medical treatment as usual.
3088822|NCT01967342|Active Comparator|Usual Care|Usual Care (Medical Treatment-as-Usual: A control/comparison condition in which patients receive on-going standard care at the federally qualified health center partnering in this research. Facets of care may include medication, surgery, chiropractic, and physical therapy, among others, which are available to all patients in all arms.
3088823|NCT01967329|Active Comparator|Standard Triple, treatment naive|"Standard Triple Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)~One of two treatments randomly assigned to treatment naive participants in Aklavik"
3088824|NCT01967329|Active Comparator|Sequential, treatment naive|"Sequential Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)~One of two treatments randomly assigned to treatment naive participants in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
3088825|NCT01967329|Active Comparator|Quadruple, treatment naive|"Quadruple Thearpy for H. pylori:~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily~One of two treatments randomly assigned to treatment naive participants in Old Crow, Tuktoyaktuk & Fort McPherson"
3088826|NCT01967329|Active Comparator|Sequential, previous failure(s)|"Sequential Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)~One of two treatments randomly assigned to participants who previously failed one or more treatments in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
3088827|NCT01967329|Active Comparator|Quadruple, previous failure(s)|"Quadruple Therapy for H. pylori:~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily~One of two treatments randomly assigned to participants who previously failed treatment in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
3088828|NCT01967329|Active Comparator|Sequential, clarithromycin-resistant|"Sequential Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)~One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik"
3088829|NCT01967329|Active Comparator|Quadruple, clarithromycin-resistant|"Quadruple Therapy for H. pylori:~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily~One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik"
3088830|NCT01967303||Patients with stroke or transient ischemic attack|Interview regarding restless legs syndrome
3088831|NCT01967303||Subjects without stroke or transient ischemic attack|Interview regarding restless legs syndrome
3088832|NCT01967290|Experimental|Hand-to-mouth task - vibratory feedback|Hand-to-mouth task under vibratory feedback and 3D movement analysis. The SWORD device is in place over the patient arm, performs continuous 3D movement analysis and provides vibratory feedback according to quality performance settings established by the clinician after patient assessment. If movement is of lower amplitude or slower than prescribed a vibratory stimulus is delivered at the wrist of the patient. The intervention is repeated on the hemiparetic and normal sides and the duration of the task is defined according to the patient cardiovascular status.
3088833|NCT01967290|Active Comparator|Hand-to-mouth task - no vibratory feedback|Hand-to-mouth task in the same conditions as the experimental arm but without vibratory feedback, only 3D movement analysis. The SWORD device is in place over the patient arm, performs continuous 3D movement analysis but does not provides vibratory feedback according to quality performance settings established by the clinician after patient assessment. If movement is of lower amplitude or slower than prescribed NO vibratory stimulus is delivered at the wrist of the patient. The intervention is repeated on the hemiparetic and normal sides and the duration of the task is defined according to the patient cardiovascular status.
3088834|NCT01967277|Placebo Comparator|Incandescent red light source|A red, incandescent light source replaces all laser output. The treatment sessions are self-administered at home, every other day, for 16 weeks.
3088835|NCT01967277|Active Comparator|Handi-Dome Laser|Study subjects self-administer actual laser treatments, at home, every other day, for 16 weeks.
3088836|NCT01967264|Experimental|Udenafil 150 mg + Udenafil 150 mg|Udenafil 150 mg, tablet, orally, once on Day 1, followed by udenafil 150 mg, tablet, orally, once on Day 3.
3088837|NCT01967264|Experimental|Udenafil 150 mg + Placebo|Udenafil 150 mg, tablet, orally, once on Day 1, followed by placebo, tablet, orally, once on Day 3.
3088838|NCT01967264|Experimental|Placebo + Udenafil 150 mg|Placebo, tablet, orally, once on Day 1, followed by udenafil 150 mg, tablet, orally, once on Day 3.
3088839|NCT01967264|Placebo Comparator|Placebo + Placebo|Placebo, tablet, orally, once on Day 1, followed by placebo, tablet, orally, once on Day 3.
3088840|NCT01967251|Experimental|Udenafil 25 mg|Udenafil 25 mg, tablets, orally, once daily for 12 weeks.
3088841|NCT01967251|Experimental|Udenafil 50 mg|Udenafil 50 mg, tablets, orally, once daily for 12 weeks.
3088842|NCT01967251|Experimental|Udenafil 75 mg|Udenafil 75 mg, tablets, orally, once daily for 12 weeks.
3088843|NCT01967251|Placebo Comparator|Placebo|Udenafil placebo-matching tablets, orally, once daily for 12 weeks.
3088844|NCT01967238|Active Comparator|Biologic/Vaccine, Age 18-64 cohort|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
3088845|NCT01967238|Active Comparator|Biologic/Vaccine, Age 65-80 cohort|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
3088846|NCT01967238|Active Comparator|Vaccine, healthy adults|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
3088847|NCT01967225|Experimental|Tedizolid|
3088851|NCT01967199|Active Comparator|Drug Eluting Stent|Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
3088852|NCT01967199|Experimental|paclitaxel eluting balloon|paclitaxel eluting balloon (SeQuent Please)
3088853|NCT01967186|Experimental|Intraportal islet transplantation|Subject randomized to the protocol with intraportal islet transplantation and kidney transplantation
3088854|NCT01967186|Experimental|Intramuscular islet transplantation|Subject randomized to the protocol with intramuscular islet transplantation and kidney transplantation
3088855|NCT01967186|Experimental|Intramuscular transpl with stemcells|Subject randomized to the protocol with intramuscular islet transplantation and where islets have been incubated autologous mesenchymal stemcells. Will also receive kidney transplant
3088856|NCT01967186|Active Comparator|Kidney transplantation only|Subject that only undergoes kidney transplantation
3088857|NCT01967173|Experimental|Crossover sequence 1|Flovent Diskus® 100 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 250/50 mcg
3088858|NCT01967173|Experimental|Crossover sequence 2|Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Flovent Diskus® 250 mcg
3088859|NCT01967173|Experimental|Crossover sequence 3|Flovent Diskus® 250 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg
3088860|NCT01967173|Experimental|Crossover sequence 4|Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 100 mcg
3088861|NCT01967173|Experimental|Crossover sequence 5|Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 500 mcg, followed by Advair Diskus® 250/50 mcg
3088862|NCT01967173|Experimental|Crossover sequence 6|Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Flovent Diskus® 500 mcg
3088863|NCT01967173|Experimental|Crossover sequence 7|Flovent Diskus® 500 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg
3088864|NCT01967173|Experimental|Crossover sequence 8|Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 500 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg
3088865|NCT01967160||XGEVA inception cohort|Patients with cancer who are naïve to oral or IV bisphosphonate treatment at the dose indicated for SRE prevention and who begin treatment with XGEVA at any time during the treatment cohort identification period
3088866|NCT01967160||Zoledronic acid inception cohort|Patients with cancer who are naïve to oral or IV bisphosphonate treatment at the dose indicated for SRE prevention and who begin treatment with IV zoledronic acid at any time during the treatment cohort identification period
3088867|NCT01967160||XGEVA-switch cohort|Patients with cancer who switch to XGEVA during treatment cohort identification period after having started antiresorptive therapy at the dose indicated for SRE prevention of no more than 2 years duration with bisphosphonates (<24 IV infusions or <24 monthly oral prescriptions)
3088868|NCT01967147|Experimental|Systane Balance|Propylene Glycol, 0.6% eye drops, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).
3088869|NCT01967147|Active Comparator|Saline|Preservative-Free 0.9% Saline solution, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).
3088870|NCT01967134|Experimental|Aeras-456 (50 ug H56/500 nmol IC31)|LTBI Negative 3 Doses
3088871|NCT01967134|Experimental|Aeras-456 (15 ug H56/500 nmol IC31)|LTBI Positive 3 Doses
3088872|NCT01967134|Experimental|Aeras-456 (50ug H56 / 500 nmol IC31)|LTBI Positive 3 Doses
3088873|NCT01967121|Experimental|'Compex unit's Active Recovery® program'|The Compex electrical stimulation system utilized in this study is intended for external application with electrodes to create a muscular contraction and help enhance recovery after eccentric muscular activity.
3088874|NCT01967121|Other|Ice application|A randomized pre and post-test research design will be used to compare three interventions (control, ice, compex) to alleviate the physical symptoms of delayed-onset muscle soreness (DOMS).
3088875|NCT01967121|No Intervention|Control|This is a control group where subjects will not perform an intervention.
3088876|NCT01967108|Experimental|chest physiotherapy|chest physiotherapy in patient's bed, including deep breathing, directed cough, arm movment and more.
3088877|NCT01967108|No Intervention|control group|This patients will not recive chest physiotherapy after extubation, unless developing respiratory deterioration
3088878|NCT01967095|Experimental|erlotinib|"This protocol is a phase 1, single arm, open label study of combination daily low dose erlotinib plus twice weekly high dose erlotinib in patients with EGFR-Mutant lung cancer who have not yet received erlotinib or gefitinib. Six dose levels are planned for escalation, with the pulse dose erlotinib increasing.~Expansion cohort A: Treat an additional 19 pts at the MTD with CNS involvement at diagnosis"
3088879|NCT01967082||Non-Smoking Student - University of Houston|Survey asking about health-related attitudes and behaviors completed at first visit. Smoking cessation and prevention smart phone application provided to participants at this visit. Telephone survey performed at 1 and 4 months after participant receives smart phone application.
3088880|NCT01967082||Smoking Student - University of Houston|Survey asking about health-related attitudes and behaviors completed at first visit. Smoking cessation and prevention smart phone application provided to participants at this visit. Telephone survey performed at 1 and 4 months after participant receives smart phone application.
3088881|NCT01967069|Active Comparator|DFD01 Spray|DFD01 Spray twice daily
3088882|NCT01967069|Placebo Comparator|Vehicle Spray|Vehicle Spray twice daily
3088883|NCT01967043|Experimental|Oraxol Arm 1|"HM30181AK-US tablet administered as a single oral dose of xmg on Days x, y, and z of each cycle~Paclitaxel administered as a fixed oral daily dose of xmg (nine xmg capsules) starting on Days x, y, and z of each cycle. Depending on the cohort, subjects will receive 2, 3, 4, or 5 consecutive days of paclitaxel per week."
3088884|NCT01967043|Experimental|Oraxol Arm 2|"HM30181AK-US tablet administered as a single oral dose of xmg daily with each dose of Paclitaxel~Paclitaxel administered as a fixed oral daily dose of xmg (nine xmg capsules) starting on Days x, y, and z of each cycle. Depending on the cohort, subjects will receive 2, 3, 4, or 5 consecutive days of paclitaxel per week."
3088885|NCT01967030||Women with recent GDM pregnancy|The study cohort includes women who had gestational diabetes mellitus (GDM) in their index pregnancy for study enrollment. There are two pre-defined groups: 1) women who breastfeed intensively during the first 4 months postpartum, and 2) women who mostly fed formula during the first 4 months postpartum. The study enrolled women into these pre-defined groups, but some women transitioned into mixed feeding groups after enrollment.
3088886|NCT01967017|Experimental|Lidocaine|Paracervical block using 15 mL of 1 % lidocaine
3088887|NCT01967017|Placebo Comparator|Placebo|paracervical block using 15 mL of bacteriostatic saline
3088888|NCT01967004|Experimental|Functional Assessment|Participant will be asked to perform a series of tasks involving their prosthesis. These tasks can involve switching grips as well as moving objects.
3088889|NCT01966991||Surveyed DNAFirst users|Women who opted for DNAFirst testing and who provided written permission (attested by signature and provision of telephone number)for DNAFirst Study staff to telephone them and conduct a brief telephone survey about their experiences.
3088890|NCT01966978|Active Comparator|Control: Metformin, Insulin Detemir, Insulin Aspart|Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
3088891|NCT01966978|Active Comparator|Metformin, insulin determir, Liraglutide|"Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)"
3088892|NCT01966965|Experimental|PIOLIN®|PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
3088893|NCT01966965|Active Comparator|NEDAX|FOLLOWING THE LEAFLET TREATMENT
3088894|NCT01966952||Resistant Hypertension|Resistant hypertension as described as; patients with uncontrolled hypertension on 3 or more antihypertensive medications with no secondary causes for hypertension (i.e. hyperaldosteronism, renal artery stenosis)
3088895|NCT01966939||Surgery|Craniotomy or Craniectomy
3088896|NCT01966939||Control|age, gender and teeth condition matched
3088897|NCT01966926|Experimental|Daily Weight Tracking|weighing frequency instructions and tips
3088898|NCT01966926|Experimental|Weekly Weight Tracking|weighing frequency instructions and tips
3088899|NCT01966913|Experimental|bevacizumab|"Two intensified treatments at 6-week intervals will start on D69 (max D76) and D111 (max J118) respectively, combining:~A bevacizumab treatment: 7.5 mg/kg every 3 weeks from D1 to the first intensified treatment for a total of 4 injections.~The ICE chemotherapy regimen:~Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals,~Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance,~Ifosfamide, 2400 mg/m²/d,~For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle"
3088900|NCT01966900|Active Comparator|Group A|"Biological/Vaccine: CN54gp140 mixed with GLA-AF~Vaccination at Months 0, 1, 2 and 6; each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF"
3088901|NCT01966900|Active Comparator|Group B|"Biological/Vaccine: CN54gp140 mixed with GLA-AF~Vaccination at Months 0, 1, 2 and 12; each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF"
3088902|NCT01966887|Experimental|MYDICAR-single intracoronary infusion|Genetic / AAV1 Serca2a (MYDICAR)
3088903|NCT01966887|Placebo Comparator|Placebo; single intracoronary infusion|Placebo comparator
3088904|NCT01966874||Study population|"All study participants will receive 200 mg of the mifepristone product Zacafemyl, followed 24-48 hours later by 800 mcg of misoprostol."
3088905|NCT01966861|No Intervention|usual care|Weaning as protcolised by the units' daily practice (SBT)
3088906|NCT01966861|Experimental|Weaning guided by lung ultrasound|Predictive early signs of respiratory distress are assessed by lung ultrasound and if found will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis)
3088907|NCT01966848|Active Comparator|Vanguard CR|Patients will receive the posterior cruciate retaining Vanguard CR prosthesis
3088908|NCT01966848|Active Comparator|Vanguard XP|Patients will receive the bi-cruciate retaining Vanguard xp prosthesis
3088909|NCT01966835|Experimental|High intensity aerobic interval training|The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
3088910|NCT01966835|No Intervention|control group|no exercise intervention
3088911|NCT01966822|Experimental|Dolutegravir 50mg|Dolutegravir 50mg every 24 hours + Kivexa (ABC+3TC)
3088912|NCT01966822|Active Comparator|Protease Inhibitor/ritonavir|Protease Inhibitor/ritonavir + Kivexa (ABC+3TC)
3088913|NCT01966809|Experimental|Photofrin photodynamic therapy.|Photofrin photodynamic therapy. Drug - 2.5 mg/kg, light - 240 mJ/cm2.
3088914|NCT01966796||PSI II|PSI less than 70 or equal to 70
3088915|NCT01966796||PSI III|PSI 70-90
3088916|NCT01966796||PSI IV|PSI 90-130
3088917|NCT01966796||PSI V|PSI more than 130
3088918|NCT01966783|Experimental|Budesonide dosage 1|Budesonide 2 mg suppository
3088919|NCT01966783|Experimental|Budesonide dosage 2|Budesonide 4 mg suppository
3088920|NCT01966783|Active Comparator|Mesalazine|Mesalazine 1g suppository
3088921|NCT01966783|Experimental|Combination|Budesonide 2 mg suppository/Mesalazine 1 g suppository
3088922|NCT01966770|Active Comparator|Pair 1 (ocufilcon D / ocufilcon D)|Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
3088923|NCT01966770|Active Comparator|Pair 2 (ocufilcon D / enfilcon A)|Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
3088924|NCT01966770|Active Comparator|Pair 3 (ocufilcon D / comfilcon A)|Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
3088925|NCT01966770|Active Comparator|Pair 4 (methafilcon A / methafilcon A)|Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
3089331|NCT01963858|Experimental|Functional relaxation|Functional relaxation
3088926|NCT01966770|Active Comparator|Pair 5 (methafilcon A / comfilcon A)|Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
3088927|NCT01966770|Active Comparator|Pair 6 (omafilcon A / comfilcon A)|Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
3088928|NCT01966757||Neuronal ceroid lipofuscinosis patients|Caregiver of patient with NCL to provide information regarding patient's sleep habits
3088929|NCT01966744||Clinicians/Nurses|Clinicians and nurses who treat patients diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
3088930|NCT01966744||Patients|Patients age 11-18 years diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
3088931|NCT01966744||Caregivers|Caregivers of patients diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
3088932|NCT01966731|Experimental|Hydroxyurea|After patient enrollment, a two-month pre-hydroxyurea evaluation phase will be used to perform baseline evaluations including nutritional and infectious assessments, and to provide supplements or treatments as deemed necessary. After the pre-hydroxyurea evaluation and supplementation phase, hydroxyurea dosing will be administered as a single daily dose, using capsules provided as a monthly supply in 200mg, 300mg, 400mg, or 500mg sizes.
3088933|NCT01966718|Experimental|Repository corticotropin injection|Repository corticotropin injection, 80 United States Pharmacopeia (USP) Units per mL, dosed as 1 mL (80 Units) subcutaneous injection every 72 hours for 12 weeks
3088934|NCT01966705|Experimental|Therapist-guided Internet-based Cognitive Behavior Therapy|Cognitive Behavior Therapy delivered via the Internet: 12 weeks, supported self-help
3088935|NCT01966705|Experimental|Unguided Internet-based Cognitive Behavior Therapy|Cognitive Behavior Therapy delivered via the Internet: 12 weeks, self-help only
3088936|NCT01966705|Experimental|Cognitive Behavior Therapy-based bibliotherapy|Cognitive Behavior Therapy delivered in book form: 12 weeks, self-help only
3088937|NCT01966705|No Intervention|Waiting-list condition|No intervention: 12 weeks
3088938|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 1|"Fluticasone Propionate Drug formulation 1 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.~See Formulation Development in Detailed Description for details regarding differences in formulations"
3088939|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 2|"Fluticasone Propionate Drug formulation 2 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.~See Formulation Development in Detailed Description for details regarding differences in formulations"
3088940|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 3|"Fluticasone Propionate Drug formulation 3 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.~See Formulation Development in Detailed Description for details regarding differences in formulations"
3088941|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 3*|Fluticasone Propionate Drug formulation 3 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose. * (The asterisk) A different batch of the formulation 3 is given to the patient to ensure that the study is sufficiently powered to show bioequivalence between two batches of the same formulation.
3088942|NCT01966679|Active Comparator|Double-blind (active versus placebo)|AZD7325 versus placebo
3088943|NCT01966679|Placebo Comparator|Placebo|
3088944|NCT01966666|Experimental|TPI-287 low dose|2 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
3088945|NCT01966666|Experimental|TPI-287 moderate dose|6.3 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
3088946|NCT01966666|Experimental|TPI-287 high dose|20 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
3088947|NCT01966666|Placebo Comparator|Placebo|
3088948|NCT01966653|Active Comparator|nitrofurantoin|Nitrofurantoin will be given orally at a dose of 100 mg three times daily for 5 days.
3088949|NCT01966653|Active Comparator|fosfomycin|A single 3g dose of oral fosfomycin will be given.
3088950|NCT01966640|Experimental|Child food allergy suspicion|Basophil Activation Test realized in case of Child food egg and peanut allergy suspicion
3088951|NCT01966627||Pediatric NAFLD Cohort|Overweight and obese children and adolescents at risk for non alcoholic fatty liver disease will undergo oral glucose tolerance testing (ogtt), genotyping, abdominal and liver magnetic resonance imaging (mri), and will provide a stool sample at baseline and at 2 year follow up. A small subset will undergo liver biopsy to test for hepatic steatosis and nonalcoholic steatohepatitis.
3088952|NCT01966614|Experimental|PRX302|PRX302 injection
3088953|NCT01966614|Placebo Comparator|Placebo|Placebo (Vehicle-only injection)
3088954|NCT01966601|Experimental|TRV027 dose #1|TRV027 dose #1 via continuous IV infusion
3088955|NCT01966601|Experimental|TRV027 dose #2|TRV027 dose #2 via continuous IV infusion
3088956|NCT01966601|Experimental|TRV027 dose #3|TRV027 dose #3 via continuous IV infusion
3088957|NCT01966601|Placebo Comparator|Placebo|Placebo via continuous IV infusion
3088958|NCT01966588||Metabolic Arm|Blood samples for whole genomic/transcriptomic sequencing; administration of the UKU Side Effect Rating Scale.
3088959|NCT01966588||Neutropenia/Immune System Arm|Blood samples for whole genomic/transcriptomic sequencing
3088960|NCT01966575|Experimental|No withdrawal bleed|No progestin prior to ovulation induction with clomiphene citrate
3088961|NCT01966575|No Intervention|Withdrawal Bleed|Progestin prior to beginning ovulation induction with clomiphene citrate (standard care)
3088962|NCT01966562|Experimental|WBV TRAINING|WHOLE-BODY VIBRATION TRAINING
3088963|NCT01966562|Active Comparator|MC TRAINING|MULTICOMPONENT TRAINING
3088964|NCT01966562|No Intervention|CG|Control group
3088965|NCT01966549|Experimental|CNTO 6785|
3088966|NCT01966549|Placebo Comparator|Placebo|
3088967|NCT01966536|Experimental|Poor ovarian reserve|Autologous transplantation of CD133+ cells into ovarian artery
3089080|NCT01965665|Experimental|Medihoney HCS dressing|weekly Medihoney pin site care until frame removal. Standard size dressings and application technique will be used at each pin site with prefabricated materials.
3089081|NCT01965652|Experimental|Naldemedine|Participants received 0.2 mg naldemedine tablets orally once daily for 52 weeks.
3088968|NCT01966523|Experimental|Intervention|Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
3088969|NCT01966523|Other|Usual Care|Residents will receive usual care for infections
3088970|NCT01966510|Experimental|Cord blood transplantation|Two cord blood units containing both together more than 3x10^7 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients.
3088971|NCT01966497||Core study therapy|"idarubicin for both induction and consolidation courses~if Cr, two cycles of IDAC alone (1.5g/m2 per infusion every 12hours, on D1, 3 and 5 of each cycle)"
3088972|NCT01966484|Active Comparator|Succinylcholine|Patient receive succinylcholine as a muscle relaxant (0,5mg/kg) after induction of general anaesthesia for rigid bronchoscopy.
3088973|NCT01966484|Active Comparator|Mivacurium|Patients receive mivacurium (0,08mg/kg) as a muscle relaxant after induction of general anaesthesia for rigid bronchoscopy. At the end of the procedure and a twitch of 25% mivacurium was reversed with neostigmine (50 microg/kg) and atropin (10 microg/kg)
3088974|NCT01966471|Active Comparator|Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane|Trastuzumab and pertuzumab will be administered concurrently for up to a total duration of 1 year (up to 18 cycles [1 Cycle = 21 days]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline [5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)] based chemotherapy.
3088975|NCT01966471|Experimental|Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab|Trastuzumab emtansine and pertuzumab will continue for up to a total duration of 1 year (up to 18 cycles [1 Cycle = 21 days]) following anthracycline [5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)] based chemotherapy.
3088976|NCT01966458|Experimental|HeartWare® VAS (HVAD)|Implant of HeartWare® Ventricular Assist System
3088977|NCT01966458|Active Comparator|Control LVAD|Implant of FDA-approved LVAD approved for destination therapy
3088978|NCT01966445|Experimental|GSK2849330 Part 1|1 hour infusion administered intravenously at intervals of one week or more (escalating doses).
3088979|NCT01966445|Experimental|GSK2849330 Part 2|Intravenous infusion administered at the dose and schedule established in Part 1
3088980|NCT01966432|Other|SBIRT|"This is a single arm, non-randomized study. However, based on participants' substance use status, participants will be categorized into three groups:~Screening group. Patients who screen for no use of cigarettes, alcohol, or other drugs. Patients are re-screened at followup visits.~Screening, Brief Intervention group. Patients who screen positive for cigarette, alcohol, or other drug use.~Screening, Brief Intervention, and Referral to Treatment group. Patients who screen positive for use and have a positive AUDIT-C and/or positive DAST-10 assessment for problematic alcohol or drug use."
3088981|NCT01966419|Active Comparator|ornithine phenylacetate|continuous intravenous infusion of ornithine phenylacetate for up to 5 days on top of standard of care
3088982|NCT01966419|Placebo Comparator|placebo intravenous infusion|continuous intravenous infusion of placebo up to 5 days on top of standard of care
3088983|NCT01966406|Experimental|No nasogastric tube insertion before pancreaticoduodenectomy|The patients receiving pancreaticoduodenectomy will not undergo NG tube insertion before operation
3088984|NCT01966406|Active Comparator|Pre-operative NG tube use|The patients receiving pancreaticoduodenectomy will undergo NG tube insertion before operation
3088985|NCT01966393|Active Comparator|Dual-hormone closed-loop strategy|In dual-hormone closed-loop strategy, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels
3088986|NCT01966393|Active Comparator|Single-hormone closed-loop strategy|In single-hormone closed-loop strategy, variable subcutaneous insulin infusion rate will be used to regulate glucose levels
3088987|NCT01966393|Active Comparator|Conventional insulin pump therapy|In control visit, subjects will use conventional pump therapy to regulate glucose levels.
3088988|NCT01966380|Experimental|Device, dressing|Intervention: Device, Leia dressing
3088989|NCT01966380|Active Comparator|Dressing , device|Intervention: Device: Hydroactive surgical dressing
3088990|NCT01966367|Experimental|CliniMacs PLUS followed by chemotherapy|"Patients will receive a pre-transplant conditioning regimen of Busulfan Fludarabine and Alemtuzumab. For patients with pre-transplant hepatic dysfunction, Melphalan will be substituted for the Busulfan. For patients receiving a second transplant or a boost, pre-transplant conditioning based on the clinical condition of the patient will be determined by the Principal Investigator and the patient's bone marrow transplantation (BMT) physician. The donor peripheral blood stem cells will undergo CD34+ selection (Biological/Vaccine: CD34 Stem Cell Selection Therapy). The CliniMacs (PLUS) Reagent System will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD)."
3088991|NCT01966354|Experimental|Long axis, in-plane needle|"Ultrasound-guided Internal jugular venous approach~Long axis, in-plane needle:~Jugular vein is ultrasonographically visualized in a longitudinal fashion (long axis) and the needle is inserted in the same ultrasound plane, aligned with the longitudinal axis of the transducer."
3088992|NCT01966354|Experimental|Short axis, out-of-plane needle|"Ultrasound-guided Internal jugular venous approach~Short axis, out-of-plane needle:~Jugular vein is ultrasonographically visualized in a transverse fashion (short axis) and the needle is inserted perpendicular to the longitudinal axis of the transducer (out-of-plane)."
3088993|NCT01966354|Experimental|Oblique axis, in-plane needle|"Ultrasound-guided Internal jugular venous approach~Oblique axis, in-plane needle:~Jugular vein is ultrasonographically visualized in an oblique axis (intermediate view between long and short axis) and the needle is inserted in the same ultrasound plane, aligned with the longitudinal axis of the transducer."
3089082|NCT01965652|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once daily for 52 weeks.
3088994|NCT01966341|Active Comparator|Routine Management|All patients will be given a prescription for the use of antispasmodics. If patients demonstrate symptoms consistent with constipation predominant IBS they will be treated with laxatives. If symptoms are more consistent with diarrhea predominant IBS they will be treated with bulking agents (fiber) +/- antibiotics. Patient will be called every week while enrolled in the study in order to titrate doses, and answer questions.
3088995|NCT01966341|Experimental|CBT/ Hypnotherapy|The CBT (cognitive behavior therapy) program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
3088996|NCT01966328|Experimental|36% Resolvine|Patients in this arm will be given one dose of 36% Resolvine intravitreal injection, with the possibility of a second dose at Day 30
3088997|NCT01966328|Active Comparator|9% Resolvine|Patients in this arm will be given one dose of 9% Resolvine intravitreal injection, with the possibility of a second dose at Day 30
3088998|NCT01966315||Dexmedetomidine group|"Dexmedetomidine group is the patients who sedated with dexmedetomidine in intensive care unit. We will randomly allocate using www.randomizer.org.~They will sedate at the level of RASS -2. The dose of dexmedetomidine will be 0.2-0.7ug/kg/hr."
3088999|NCT01966315||Midazolam group|"Midazolam group is the patients who sedated with midazolam in intensive care unit. We will randomly allocate using www.randomizer.org.~They will sedate at the level of RASS -2. The dose of midazolam will be 0.05-0.1 mg/kg/hr."
3089000|NCT01966302|Experimental|Beraprost open label|Compassionate use access to open label BPS-314d-MR
3089001|NCT01966289|Experimental|Cohort 1:CY/GVAX concurrently with SGI-110|During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2, the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells, and SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
3089002|NCT01966289|Experimental|Cohort 2: CY/GVAX after SGI-110|During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2, Cyclophosphamide (CY) is administered on Day 8 at 200 mg/m2, and the colon cancer tumor vaccine (GVAX) is administered on Day 9 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
3089003|NCT01966289|Experimental|Cohort 3: CY/GVAX|During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 and the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
3089004|NCT01966289|Experimental|Cohort 4: SGI-110|During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
3089005|NCT01966276|Experimental|Methyl-P plus Nutrient Formula|"Methylphenidate hydrochloride plus a CFS Nutrient Formula, both taken twice daily.~The CFS Nutrient Formula is a broad-spectrum CFS-specific dietary supplement that provides CFS patients with cellular fuel and cofactors (amino acids, antioxidants, and mitochondrial cofactors) while the low-dose CNS stimulant (methylphenidate hydrochloride) provides a metabolic catalyst to enhance cellular metabolism."
3089006|NCT01966276|Placebo Comparator|Methyl-P plus Nutrient matched placebos|Methylphenidate matched placebo + CFS Nutrient Formula matched placebo, both taken twice daily.
3089007|NCT01966263|Active Comparator|Local Infiltration Analgesia (LIA)|local infiltration analgesia is an anesthetic technique that consists of the infiltration of operated tissue with a long acting local anesthetic during surgery to achieve postoperative pain relieve. In this study LIA of the knee will exist of: 1. local infiltration analgesia (LIA) of the posterior capsule of the knee, 2. LIA of the anterior capsule of the knee and 3. LIA of the subcutaneous tissue of the knee
3089008|NCT01966263|Active Comparator|Femoral Nerve Block (FNB)|"a femoral nerve block is an anaesthetic technique that consists of anesthetizing the femoral nerve proximal of the operating area to achieve numbness distal of the block puncture site. A catheter can be placed, so the nerve can be anesthetized continuously or repeatedly for post-operative pain relieve.~In this study the FNB with catheter will be combined with local infiltration analgesia (LIA) of the posterior capsule of the knee"
3089009|NCT01966250|Experimental|Electroacupuncture and Usual care|15 minutes of electroacupuncture and usual care. Usual care contains 15 minutes ICT(Interferential Current Therapy), 10 minutes hot pack or ice pack and education of patients.
3089010|NCT01966250|Active Comparator|usual care|15 minutes ICT, 10 minutes hot pack or ice pack and education of patients
3089011|NCT01966237||Acute kidney injury|AKI defined by an elevation in urinary AKI biomarkers
3089012|NCT01966237||No acute kidney injury|No AKI defined by normal urinary AKI biomarkers
3089013|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 1|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 1, who were skin test negative at Day 0 and remained negative at Day 132.~Group 1: These subjects will be re-vaccinated with one dose of 2mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered by Intramuscular injection (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study. These subjects will receive the same batch vaccine used in Phase 1A."
3089014|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 2|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 2, who were skin test positive at Day 0 and remained positive or converted to negative for any JRC-related allergens at Day 132.~Group 2: These subjects will be re-vaccinated with one dose of 2mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered Intramuscularly (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study. These subjects will receive the same batch vaccine used in Phase 1A."
3089083|NCT01965639|Experimental|High Risk group|Extension of Care
3089084|NCT01965626|Active Comparator|Oseltamivir Combining HD-DXM|"Oseltamivir 75 mg twice per day, 10consecutive days~HD-DXM (orally at 40 mg daily for 4d as one cycle, If platelet count remained below 30 × 109/L or there were bleeding symptoms by day 10, an additional four-day cycle of dexamethasone was given.)"
3089015|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 3|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 3, who were skin test positive at Day 0 and remained positive or converted to negative for any JRC-related allergens at Day 132.~Group 3: These subjects will be re-vaccinated with one dose 2mg of Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered Intramuscularly (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study."
3089016|NCT01966198|Experimental|all patients|tilt
3089017|NCT01966185|No Intervention|Tutor function off|The tutor function will be off for 12 out of 12 repeat simulations.
3089018|NCT01966185|Experimental|Tutor function on|The group will have the tutor function on for the 5 first out of 12 repeat simulation sessions.
3089019|NCT01966172|Experimental|Multimodal|oral Ibuprofen 400mg 4 times daily oral Gabapentin 300mg twice daily oral Paracetamol 1000mg 4 times daily
3089020|NCT01966172|Active Comparator|Morphine|oral Morphine 10mg 4 times daily oral paracetamol 1000mg 4 times daily
3089021|NCT01966159|Experimental|SYNERGY Investigational Device|SYNERGY Stent System
3089022|NCT01966159|Active Comparator|PE Plus Investigational Device|PE Plus Stent System
3089023|NCT01966146|Experimental|TAVI|Echocardiography after TAVI
3089024|NCT01966146|Experimental|MitraClip|Echocardiography after MitraClip procedure
3089025|NCT01966133|No Intervention|Control|no interventions were assigned
3089026|NCT01966133|Active Comparator|TACE('Ethiodized Oil + Doxorubicin)|TACE using Ethiodized Oil + Doxorubicin mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4-6 weeks after surgery.
3089027|NCT01966120|Active Comparator|BF-200 ALA gel|Photodynamic therapy with BF-RhodoLED in combination with BF-200 ALA.
3089028|NCT01966120|Placebo Comparator|Placebo to BF-200 ALA gel|Photodynamic therapy with BF-RhodoLED in combination with a nanoemulsion gel formulation similar to BF-200 ALA, but without the active ingredient 5-aminolevulinic acid.
3089029|NCT01966107|Experimental|Aclidinium Bromide|Two-week washout/run-in period [for patients on a long-acting muscarinic antagonist (LAMA)] followed by a maximum of 36-month double-blind treatment period.
3089030|NCT01966107|Placebo Comparator|Placebo|Two-week washout/run-in period [for patients on a long-acting muscarinic antagonist (LAMA)] followed by a maximum of 36-month double-blind treatment period.
3089031|NCT01966094||HIV+ subjects with HAND|Human immunodeficiency virus (HIV) positive subjects with HIV-associated neurocognitive disorder (HAND) and either antiretroviral therapy (ART) naïve or ART-experienced off treatment for at least 6 months
3089032|NCT01966094||HIV+ subjects without HAND|Human immunodeficiency virus (HIV) positive subjects without HIV-associated neurocognitive disorder (HAND) and either antiretroviral therapy (ART) naïve or ART-experienced off treatment for at least 6 months
3089033|NCT01966081|Other|Cases|
3089034|NCT01966081|Other|controls|
3089035|NCT01966068|Experimental|MyAsthma Web Portal|The portal, MyAsthma, will provide asthma education, collect patient-reported outcomes, evaluate medication use and side effects, and track parents' concerns and goals. Parents will log into the web portal each month (for a total of 3 portal visits in 6 months), and the information entered by parents will be shared through the electronic health record with the child's primary care provider.
3089036|NCT01966055|Experimental|Solithromycin|
3089037|NCT01966042|Experimental|Stem Cell Therapy|"All subjects enrolled in the study underwent:~Local Sedation; Bone Marrow Aspiration; Minithoracotomy; Autologous bone marrow mononuclear cells infusion."
3089038|NCT01966029|Experimental|Treatment|All patients receive treatment with BMN 110
3089039|NCT01966016|Experimental|biventricular pacing|The first configuration will be biventricular pacing (RV and postero-lateral branch of CS for LV pacing), as accepted
3089040|NCT01966016|Experimental|triventricular pacing|The second configuration will be triventricular pacing (RV+ postero-lateral branch of CS for LV pacing+ antero-lateral branch of CS for LV pacing) i.e. multisite LV pacing
3089041|NCT01966003|Experimental|ABP 215|Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.
3089042|NCT01966003|Active Comparator|Bevacizumab|Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.
3089043|NCT01965990||NEP|Patients undergoing the administration of a homemade very low-calorie protein-based formula (2000 mL per day) by enteral route for 14 days
3089044|NCT01965977|Experimental|Bortezomib|bortezomib 1.3mg/m2 subcutaneous on day 1 and15
3089045|NCT01965951|Experimental|Experimental Treatment|Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, one hour each session.
3089046|NCT01965951|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, one hour each session.
3089047|NCT01965938|Active Comparator|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
3089048|NCT01965938|Other|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
3089049|NCT01965925|Experimental|Modafinil|Modafinil will be administered at baseline with a single dose of 100 mg/day QAM increased at week 1 to a single dose 200mg/day QAM. Patients will take drug upon waking with no adjustment in sleep schedule. Dosing will be flexible based on side effects with a maximum dose of 200 mg/day. Subjects will be discontinued if 100mg/day is not tolerated.
3089050|NCT01965925|Placebo Comparator|Placebo|Subjects will take placebo upon waking once per day.
3089051|NCT01965912|Experimental|Kuvan®|
3089052|NCT01965899|Experimental|Insertable Cardiac Monitor Implant|
3089053|NCT01965886|Active Comparator|Medial approach|Medial parapatellar approach (classic approach)
3089054|NCT01965886|Experimental|Keblish approach|Lateral parapatellar approach (Keblish approach)
3089332|NCT01963858|Active Comparator|No relaxation|No relaxation
3089055|NCT01965873|Experimental|Enteral nutrition|In the enteral nutrition group a nasojejunal feeding tube will be placed via esophagogastroduodenoscopy and the position confirmed radiographically. Nutritional support will be started within 24 hours of enrollment, supplying daily 105 kJ (25 kcal)/kg, and 1.5 g/kg of protein based on ideal body weight. An elemental product for enteral nutrition will be infused at a rate of 25 ml/h, and increased by 10 ml/h every 6 hours, until the target rate of 100 ml/h will be achieved within 24-48 hours.
3089056|NCT01965873|No Intervention|Nil-by-mouth treatment|The nil-by-mouth treatment consists intravenous fluid replacement according to assessed needs via peripheral veins. This will include crystalloid (0.9% saline and 5% glucose), and colloid (10% hydroxyethyl starch and 3.5% plasma expander - haemaccel) solutions.
3089057|NCT01965860|Experimental|PROSPECT|the trainee will study four modules of E-learning (basic endovascular skills module, iliac artery module, superficial femoral artery module and postoperative care module. After studying each module the trainee will complete a Multiple Choice Questionnaire and perform a simple and a complex exercise on the simulator.
3089058|NCT01965860|No Intervention|CONTROL|The trainee will continue clinical education without additional curriculum, but will be allowed to study independently.
3089059|NCT01965847|Active Comparator|AM dosing|The study student pharmacist will perform medication therapy management with a focus on antihypertensive medications and specifically on the once daily antihypertensive assigned to MORNING dosing. Medication therapy management will take place in the clinic or by phone. Medication therapy management will include review of antihypertensive medications, patient empowerment and education, and provision of a personal medication record to the participant with specific instructions regarding the once daily antihypertensive medication assigned to morning versus evening. If a patient is taking more than one antihypertensive medication, only one will be used for the current study.
3089060|NCT01965847|Experimental|PM dosing|The study student pharmacist will perform medication therapy management with a focus on antihypertensive medications and specifically on the once daily antihypertensive assigned to EVENING dosing. Medication therapy management will take place in the clinic or by phone. Medication therapy management will include review of antihypertensive medications, patient empowerment and education, and provision of a personal medication record to the participant with specific instructions regarding the once daily antihypertensive medication assigned to morning versus evening. If a patient is taking more than one antihypertensive medication, only one will be used for the current study.
3089061|NCT01965834|Experimental|Fenofibrate Therapy|Fenofibrate orally daily for each 28 day cycle, per study protocol.
3089062|NCT01965821|Other|Continuous control of Pcuff followed by manual control|Patients receive continuous control of cuff pressure with Mallinckrodt electronic device for 24h, followed by discontinuous control (every 8 hours) with a manual manometer for 24h.
3089063|NCT01965821|Other|Manual control of Pcuff followed by continuous control|Patients receive the reverse sequence (manual control followed by continuous control of Pcuff)
3089064|NCT01965808|Experimental|LY2157299 (Fasted)|Single dose of 150 mg LY2157299 administered orally in fasted state in one of two study periods.
3089065|NCT01965808|Experimental|LY2157299 (Fed)|Single dose of 150 mg LY2157299 administered orally in fed state in one of two study periods.
3089066|NCT01965795|Placebo Comparator|Nutrim|"Nutrim will be capsulated in size 1 gelatin capsules, white and blue, distributed in brown plastic bottles (28 caps/bottle: enough for 14 days of treatment). The first bottle will be provided at the time of randomization, and the second bottle will be provided on day 14 for dosing on days 15-28. The bottle will be labeled with the ABC logo and treatment code.~A dose of 100 mg will be administered twice daily (once before breakfast and again before dinner)."
3089067|NCT01965795|Experimental|Whole Coffee Fruit Concentrate (WCFC)|"WCFC is in powder form, and will be capsulated in size 1 gelatin capsules, white and blue, distributed in brown plastic bottles (28 caps/bottle: enough for 14 days of treatment). The first bottle will be provided at the time of randomization, and the second bottle will be provided on day 14 for dosing on days 15-28. The bottles will be labeled with the ABC logo and treatment code.~A dose of 100 mg will be administered twice daily (once before breakfast and again before dinner)."
3089068|NCT01965782|Experimental|[^14C]-LY3023703|Single oral dose of 15 mg LY3023703, containing approximately 100 µCi [^14C] labeled drug, administered as an oral solution.
3089069|NCT01965769|Experimental|no gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding
3089070|NCT01965769|No Intervention|gastric residual evaluation|Infants will receive routine gastric residual evaluation
3089071|NCT01965756|Experimental|Metformin, Then Placebo|Participants first received metformin for 8 weeks, according to the following dosing schedule: 500 mg by mouth daily for 1 week, then daily dose (in divided doses) increased by 500 mg per week until a maximum of 2000 mg/d (1000mg twice daily) was reached. After 8 weeks, subjects were switched to matching placebo for an additional 8 weeks.
3089072|NCT01965756|Experimental|Placebo, Then Metformin|Participants first received placebo for 8 weeks. After 8 weeks, subjects were switched to metformin, according to the following dosing schedule: 500 mg by mouth daily for 1 week, then daily dose (in divided doses) increased by 500 mg per week until a maximum of 2000 mg/d (1000mg twice daily) was reached.
3089073|NCT01965743|Other|Contraception Information Packet|Everyone in the study will receive the intervention, which is an information packet designed to facilitate conversations among peers about intrauterine contraception.
3089074|NCT01965730|Active Comparator|epsilon-aminocaproic acid (EACA)|75mg/kg loading dose with infusion 15mg/kg/hr
3089075|NCT01965730|Experimental|EACA|125mg/kg loading dose of EACA followed by an infusion of EACA at 25mg/kg/hr for length of cardiac surgery.
3089076|NCT01965704|Experimental|Ondansetron|Pregnant Women: ondansetron 8mg intravenously (IV) within 4 hours of delivery. Neonates: ondansetron 0.07 mg/kg given orally every 24 hours starting 4-8 hours after delivery, for up to 5 days (if IV line available in neonate, ondansetron 0.04 mg/kg IV every 24 hours for up to 5 days).
3089077|NCT01965704|Placebo Comparator|Placebo|"Pregnant Women: placebo given intravenously prior to delivery (volume to mimic the IV volume of the ondansetron group).~Neonates: placebo given orally every 24 hours, starting 4-8 hours after delivery, for up to 5 days with volume to mimic the oral volume of the ondansetron group (if IV line available, placebo may be given IV)."
3089078|NCT01965691|Experimental|Protein intake|Protein intake- Dietary supplement
3089079|NCT01965678|Experimental|OMT|
3089333|NCT01963845|Placebo Comparator|Placebo|Placebo
3089085|NCT01965626|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4d as one cycle, If platelet count remained below 30 × 109/L or there were bleeding symptoms by day 10, an additional four-day cycle of dexamethasone was given.)
3089086|NCT01965613|Experimental|open label-Xilonix|Open label-Xilonix
3089087|NCT01965600|Experimental|Cohort 1|
3089088|NCT01965600|Experimental|Cohort 2|
3089089|NCT01965587|Active Comparator|novasure mirena IUS combined|novasure mirena IUS combined therapy
3089090|NCT01965587|Active Comparator|novasure alone|Sole treatment with Novasure
3089091|NCT01965574|Experimental|Single arm|
3089092|NCT01965561|Experimental|CRoC|Use of Combat Ready Clamp (CRoC)
3089093|NCT01965561|Experimental|AAJT|Use of Abdominal Aortic and Junctional Tourniquet
3089094|NCT01965561|Experimental|JETT|Junctional Emergency Treatment Tool
3089095|NCT01965561|Experimental|SJT|SAM Junctional Tourniquet
3089096|NCT01965548||Splenic injury|All patients admitted at the University Hospital North Norway Tromsø with a splenic injury following trauma, are included in the study.
3089097|NCT01965535|Experimental|LDV/SOF|LDV/SOF FDC tablet plus placebo to match RBV for 24 weeks
3089098|NCT01965535|Experimental|LDV/SOF + RBV|Placebo to match SOF/LDV FDC plus placebo to match RBV for 12 weeks, followed by LDV/SOF FDC plus RBV for 12 weeks.
3089099|NCT01965522|Experimental|Melatonin and Vitamin D|
3089100|NCT01965522|Experimental|Placebo and Vitamin D|
3089101|NCT01965522|Experimental|Melatonin and Placebo|
3089102|NCT01965522|Placebo Comparator|Placebo and Placebo|
3089103|NCT01965509|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 12 weeks
3089104|NCT01965509|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication continued for 12 weeks
3089105|NCT01965509|Placebo Comparator|Placebo|Placebo qw sc. and the medication continued for 12 weeks
3089106|NCT01965496|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 14 weeks
3089107|NCT01965496|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication start form 100 microgram qw for 4 weeks and then increased to 200 microgram qw for the 10 weeks.
3089108|NCT01965496|Experimental|PEX168 300 microgram|PEX168 300 microgram qw sc. and the medication start form 100 microgram qw for 4 weeks and then increased to 300 microgram qw for the 10 weeks.
3089109|NCT01965483|Experimental|Weekly radiation|once-weekly breast irradiation
3089110|NCT01965470|Experimental|Combination Prevention|"Scale-up of HTC services during 2 annual HTC campaigns, with a target of >90% of adults having documentation of their HIV-infected status or documentation of an HIV-negative test in the preceding 12 months.~Scale-up of universal ART for all HIV-infected adults, with a target of >93% of HIV positive adults receiving ART.~Scale-up of retention in care and adherence interventions, with a target of ensuring that >95% of HIV-infected adults are virally suppressed with HIV-1 RNA <400 copies per ML..~Scale-up of linkage to MC services, with a target of ensuring >60% of HIV-negative men are circumcised.~Rapid strengthening of PMTCT services, with a target of >90% of women initiated on indefinite ART (Option B+) during pregnancy remaining in care and on treatment at 12 months post-delivery."
3089111|NCT01965470|Active Comparator|Enhanced Care|Enhanced Care Communities will receive guidance and improved technical support for quality management and data systems at all local clinics at which individuals receive HIV care and treatment.
3089112|NCT01965431|Experimental|BI 207127 + Faldaprevir|Tablets/capsules
3089113|NCT01965431|Active Comparator|Moxifloxacin (Avalox®)|Tablets
3089114|NCT01965431|Experimental|BI 207127 placebo + Faldaprevir placebo|Tablets/capsules
3089115|NCT01965418|Active Comparator|Fufang Biejia Ruangan Tablet|Fufang Biejia Ruangan Tablet will be administered to all of subjects in this arm.
3089116|NCT01965418|Placebo Comparator|placebo|placebo of Fufang Biejia Ruangan Tablet
3089117|NCT01965405|Experimental|Phase 1: Standard of Care (A)|Brief counseling and bupropion
3089118|NCT01965405|Experimental|Phase 1: Standard of Care (B)|Brief counseling, bupropion, and brief high-magnitude prize contingency management.
3089119|NCT01965405|Experimental|Phase 2a Non-Responders (A)|Bupropion, continued counseling, monitored support to quit smoking.
3089120|NCT01965405|Experimental|Phase 2a: Non-Responders (B)|Bupropion, monitored support to quit smoking, prize contingency management for abstinence.
3089121|NCT01965405|Experimental|Phase 2b: Responders (A)|Bupropion, no additional treatment.
3089122|NCT01965405|Experimental|Phase 2b: Responders (B)|Bupropion, continued monitoring and low intensity prize contingency management.
3089123|NCT01965392|Experimental|healtn education|one group received an educational program
3089124|NCT01965379|Active Comparator|Intervention|Restriction on food containing phosphorus additives.
3089125|NCT01965379|Placebo Comparator|Control|Standard care.
3089126|NCT01965366|Active Comparator|Dexamethasone + VRE|0.5 mg DEX + virtual reality exposure therapy
3089127|NCT01965366|Placebo Comparator|Placebo + VRE|Placebo + virtual reality exposure therapy
3089128|NCT01965353|Experimental|Panobinostat|"Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.~Bortezomib - subcutaneous injection twice a week during the first two weeks of each 21 day cycle.~Dexamethasone oral dose on the days of and after bortezomib administration during Cycles 1-8, and on days 1, 8 and 15 for Cycles 9 and beyond.~Lenalidomide - oral dose once daily on days 1-14 of each cycle. Accrual to the next higher dose level will not occur until the safety and tolerability of the prior dose level(s) has been determined at the end of the first cycle.~Each cycle of treatment will consist of 21 days. Accrual to the next higher dose level will not occur until the safety and tolerability of the prior dose level(s) has been determined at the end of the first cycle"
3089129|NCT01965340|Experimental|Patients with systematic TDM of anti-infective agents|Patients with systematic TDM of anti-infective agents and dosages adapted accordingly
3089130|NCT01965340|No Intervention|Patients treated as usual|
3089131|NCT01965327|Experimental|Interferon Gamma-1b (ACTIMMUNE)|All individuals in this study will be given active medication (interferon gamma-1b) for 12 weeks. This will be administered according to a dose-escalation schedule.
3089169|NCT01965054|Experimental|Fish Oil Supplement Group|Receive the daily DHA pill and given a validated Itching Survey to assess maternal symptoms on admission and then weekly thereafter
3089132|NCT01965314|Placebo Comparator|Traditional Training Group|These subjects will be offered multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
3089133|NCT01965314|Active Comparator|Simulation Training Group|In addition to traditional training the SG group will participate in a period of simulator based training. Following initial familiarization with the simulator these participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which these participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same simulator.
3089134|NCT01965301|Experimental|BP1.5375|Single oral administration ranging from 0.5 mg to 100 mg
3089135|NCT01965301|Active Comparator|Diphenhydramine|Single oral dose of diphenhydramine 50mg
3089136|NCT01965301|Placebo Comparator|Placebo|Single oral dose
3089137|NCT01965288|Experimental|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating the schedule for the second pair without a washout period.
3089138|NCT01965288|Active Comparator|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating the schedule for the second pair without a washout period.
3089139|NCT01965275|Experimental|Erlotinib or Gefitinib|Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
3089140|NCT01965262|Active Comparator|Hema-copolymer Lens|Participants were randomized to wear the Hema-copolymer lens pair for one week during the cross over study.
3089141|NCT01965262|Active Comparator|etafilcon A Lens|Participants were randomized to wear the etafilcon A lens pair for one week during the cross over study.
3089142|NCT01965249|Active Comparator|Long stitch group|Long stitch suture technique Stitch interval > 10mm; Lateral > 10mm
3089143|NCT01965249|Experimental|Short stitch group|Short stitch technique for AWC stitch interval < 5 mm; Lateral 5 - 8 mm
3089144|NCT01965236|Experimental|Group 1|Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
3089145|NCT01965236|Experimental|Group 2|Patients are given 5 placebo (microcrystalline cellulose) pills per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 pills (1 g per pill) of sodium chloride per day.
3089146|NCT01965223|Experimental|Multi-fraction SABR|Radiotherapy: 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
3089147|NCT01965223|Experimental|Single fraction SABR|Radiotherapy: 28Gy delivered in 1 fraction
3089148|NCT01965210|Experimental|Rye + high dose inulin + low dose gluten|Rye porridge supplemented with a high dose of the fermentable dietary fibre inulin and low dose of the plant protein gluten.
3089149|NCT01965210|Experimental|Rye + equal doses of inulin & gluten|Rye porridge supplemented with equal doses of the fermentable dietary fibre inulin and the plant protein gluten.
3089150|NCT01965210|Experimental|Rye + low dose inulin + high dose gluten|Rye porridge supplemented with a low dose of the fermentable dietary fibre inulin and a high dose of the plant protein gluten.
3089151|NCT01965210|Experimental|Large non-supplemented rye|Large portion of rye porridge without supplements.
3089152|NCT01965210|Experimental|Small non-supplemented rye|Small portion of rye porridge without supplements.
3089153|NCT01965210|Active Comparator|Refined wheat bread|Refined wheat bread.
3089154|NCT01965184|Experimental|Cognitive-Behavioral Therapy (CBT) for Aggressive Behavior|CBT is a behavioral intervention that consists of 12 one-hour long, weekly sessions. During CBT children are taught various skills for coping with frustration and parents are taught various strategies for managing situations that can be anger provoking for their child.
3089155|NCT01965184|Active Comparator|Supportive Psychotherapy (SPT)|SPT consists of 12 one-hour sessions that are focused on discussing peer relationships and family functioning with a goal of enhancing subjective well-being
3089156|NCT01965158|Experimental|Naldemedine|Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
3089157|NCT01965158|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 12 weeks.
3089158|NCT01965145|Experimental|Gevokizumab|Solution for subcutaneous injection, Dose 1
3089159|NCT01965145|Placebo Comparator|Placebo|Solution for subcutaneous injection, placebo
3089160|NCT01965132||Biologic DMARD|Korean patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis who will initiate, restart or switch to a biologic agent (etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab)
3089161|NCT01965119|Experimental|Ruxolitinib|20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
3089162|NCT01965106|Active Comparator|QPI-1007 Injection|single intravitreal (IVT) injection of QPI-1007
3089163|NCT01965106|Sham Comparator|Control|Placebo (Sham injection procedure)
3089164|NCT01965093||perioperative desaturation|children aged 0-5 years who received general anesthesia and developed perioperative desaturation
3089165|NCT01965093||no perioperative desaturation|children aged 0-5 years who received general anesthesia and did not developed perioperative desaturation
3089166|NCT01965080|Experimental|Exemestane|Exemestane 25 mg daily
3089167|NCT01965067|Active Comparator|C group|normal thermal condition with core temperatures between 36.5°C and 37°C
3089168|NCT01965067|Experimental|H group|mild hypothermia with core temperatures between 34.5°C and 35°C
3089334|NCT01963845|Experimental|Active drug|Sitagliptin 100 mg
3089170|NCT01965054|No Intervention|Control Group|Given a validated Itching Survey to assess maternal symptoms on admission and then weekly thereafter.
3089171|NCT01965041|Experimental|Eyelea, ophthalmic exam, photgraphy|2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaCl
3089172|NCT01965028|Experimental|Transcranial random noise stimulation (tRNS)|High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
3089173|NCT01965015|Experimental|V-Wave shunt implant|Implantation of the V-Wave inter-atrial shunt
3089174|NCT01965002|Experimental|MRgHIFU|The InSightec ExAblate 2000 magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system is a non-invasive device that is fully integrated with an MR imaging system and used for the ablation of soft tissue. The treatment process begins with the physician acquiring a set of MR images, identifying 1+ target volume(s) of fibroid tissue to be ablated, and drawing the treatment contours. The therapy planning software computes the type and number of sonications required to treat the defined volume while minimizing total treatment time. MR images taken during the sonication provide a diagnostic quality image of the target tissue and a quantitative, real-time temperature map overlay to confirm the therapeutic effect of the treatment. The transducer is then automatically moved to the succeeding treatment point and the process is repeated until the entire volume has been treated. About 100 individual sonications can be delivered over a 3-hour period to complete a treatment.
3089175|NCT01964989|Experimental|aQIV|flu vaccine
3089176|NCT01964989|Active Comparator|non-adjuvanted comparator|flu vaccine
3089177|NCT01964976||Alogliptin + Biguanides|All participants who received alogliptin 25 milligram (mg), tablets, orally, once daily for up to 12 months along with biguanide or without biguanide within 3 months from the start of administration of alogliptin and during the treatment period of alogliptin as per routine clinical practice were observed in this study.
3089178|NCT01964963||Aloglipin|Aloglipin 25 mg, tablets, orally, once daily for up to 12 months
3089179|NCT01964950||Alogliptin|All participants who received alogliptin 25 milligram (mg), tablets, orally, once daily for up to 12 months along with Sulfonylurea (SU) or without SU within 3 months from the start of administration of alogliptin and during the treatment period of alogliptin as per routine clinical practice were observed in this study.
3089180|NCT01964937|Experimental|Group 1|"At Months 0 and 1, participants in Group 1 will receive one injection of AIDSVAX B/E ® administered intramuscularly (IM) in the right deltoid and two injections of placebo vaccine administered IM in the left deltoid.~At Months 3 and 6, participants will receive two injections of NYVAC vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid."
3089181|NCT01964937|Experimental|Group 2|"At Months 0 and 1, participants in Group 2 will receive two injections of NYVAC vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid.~At Months 3 and 6, participants will receive the AIDSVAX ® B/E vaccine administered IM in the right deltoid and two injections of placebo vaccine administered IM in the left deltoid."
3089182|NCT01964937|Experimental|Group 3|"At Months 0 and 1, participants in Group 3 will one injection of the AIDSVAX B/E vaccine administered IM in the right deltoid and one injection of placebo vaccine administered IM the left deltoid.~At Months 3 and 6, participants will receive one injection of the DNA-HIV-PT123 vaccine administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid."
3089183|NCT01964937|Experimental|Group 4|"At Months 0 and 1, participants in Group 4 will receive one injection of the DNA-HIV-PT123 vaccine administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid.~At Months 3 and 6, participants will receive one injection of the AIDSVAX B/E ® vaccine administered IM in the right deltoid and one injection of placebo vaccine administered IM the left deltoid."
3089184|NCT01964937|Experimental|Group 5|At Months 0, 1, 3, and 6, participants in Group 5 will receive one injection of the DNA-HIV-PT123 vaccine administered in the left deltoid and one injection of the AIDSVAX B/E ® vaccine administered IM in the right deltoid.
3089185|NCT01964924|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|"PART 1: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression continue to Part 2.~PART 2: Patients receive trametinib as in Part 1 and also receive Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3089186|NCT01964911|Experimental|Ropivacaïne|
3089187|NCT01964898|Experimental|BA for cardiac patients who smoke|Behavioral Activation Treatment for cardiac patients who smoke (BAT-CS). Participant will receive (a) 1 hour of standard smoking cessation counseling in the hospital and (b) 5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management after they leave the hospital. BA sessions will occur over the 12 weeks after hospital discharge. An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
3089188|NCT01964898|Active Comparator|Standard Care|Participant will receive (a) 1 hour of standard smoking cessation counseling in the hospital and (b) 5 packets of printed self-help materials for smoking cessation mailed 1, 3, 6, 9, and 12 weeks after hospital discharge. An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
3089189|NCT01964885|Active Comparator|IQP-AS-105|One tablet daily
3089190|NCT01964885|Placebo Comparator|Placebo|One tablet daily
3089191|NCT01964872|Experimental|JNJ-38877618|
3089192|NCT01964872|Placebo Comparator|Placebo|
3089193|NCT01964859|Experimental|autologous skin fibroblasts|we are comparing 3 injection sites in the same individual
3089194|NCT01964846|Experimental|Resveratrol, curcumin|Subjects will take 2 capsules of resveratrol and curcumin. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
3089195|NCT01964846|Placebo Comparator|Placebo|Subjects will take 2 capsules of Placebo. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
3089516|NCT01962701||None-OCT-group|No OCT prior to C-section
3089196|NCT01964833|Sham Comparator|Periodontal treatment|Conventional periodontal treatment with hygiene orientation, calculus removal and root scaling and planing. Sham PDT.
3089197|NCT01964833|Experimental|Periodontal Treatment and PDT|Conventional periodontal treatment with hygiene orientation, calculus removal, root scaling and planing. Active PDT with diode laser and methylene blue photosensitizer
3089198|NCT01964820|Experimental|Positive affect skills intervention|Participants receive a 5-week intervention providing training in 8 skills for generating positive affect.
3089199|NCT01964820|No Intervention|Emotion reporting|Participants report emotions on the same regular basis as intervention participants, but receive no intervention.
3089200|NCT01964807|Experimental|Cigarette smokers|Will smoke 1 cigarette, NIDA test type with 16.6 mg nicotine; 1 cigarette, NIDA test type with <0.45 mg nicotine; perform sham smoking by puffing on a drinking straw. Each intervention will last 10 minutes, and each will take place one time, on one of 3 study visits, in random order.
3089201|NCT01964807|Experimental|Nonsmokers|Will undergo secondhand cigarette smoke (SHS) exposure and conditioned, filtered air exposure. Each intervention will last 180 minutes, and each will take place one time, on one of 2 study visits, in random order.
3089202|NCT01964807|Experimental|Smokeless tobacco users|Will use 1 pouch of commercially available moist oral snuff and will chew gum (sham moist snuff). Each intervention will last 30 minutes, and each will take place one time, on one of 2 study visits, in random order.
3089203|NCT01964807|Experimental|e-cigarette users|Will use one electronic cigarette with 18 mg/ml nicotine, one electronic cigarette with no nicotine, and will perform sham smoking by puffing on a drinking straw. Each intervention will last 10 minutes, and each will take place one time, on one of 3 study visits, in random order.
3089204|NCT01964781|Experimental|topical tranexamic acid|tranexamic acid to be smeared on surgical wounds before closure
3089205|NCT01964781|Experimental|topical adrenaline|adrenaline solution to be smeared on surgical wounds before closure
3089206|NCT01964781|Experimental|topical bupivacaine|bupivacaine to be smeared on surgical wounds before closure
3089207|NCT01964781|Experimental|topical adrenaline plus tranexamic acid|tranexamic acid and adrenaline to be smeared on surgical wounds before closure
3089208|NCT01964781|Placebo Comparator|placebo control|saline to be smeared on surgical wounds before closure
3089209|NCT01964781|Placebo Comparator|tranexamic acid and placebo control|tranexamic acid and saline to be smeared on surgical wounds before closure
3089210|NCT01964755|Experimental|Chemotherapy + Antiviral-Based Therapy|"Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy:~Chemotherapy: Up to 6 cycles, 21 days each:~Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1 per study protocol;~Rituximab: 375mg/m2 (optional) IV on Day 1 per study protocol;~Methotrexate: 3.5 gm/m2 IV on Day 2 per study protocol;~Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses per study protocol;~Antiviral-Based Therapy~Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses per study protocol;~Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses per study protocol."
3089211|NCT01964742|Experimental|HIV-HCV co-infected patients|
3089212|NCT01964729|Sham Comparator|Sham rTMS|Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
3089213|NCT01964729|Experimental|Transcranial Magnetic Stimulation|We will deliver high frequency rTMS at 10 Hz rate was over right M1 in sessions consisting of of 4 seconds of stimulation followed by 26 second intervals, with a total of 1600 pulses per session.
3089214|NCT01964716|Experimental|Multidose Vial Group|Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the multidose vial formulation. Each dose is 0.5 mL
3089215|NCT01964716|Active Comparator|Single-Dose Syringe Group|Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the single-dose syringe formulation. Each dose is 0.5 mL
3089216|NCT01964703|Placebo Comparator|control|
3089217|NCT01964703|Active Comparator|Rubus occidentalis extract 900mg|taking Rubus occidentalis extract 900mg/day for 12weeks
3089218|NCT01964703|Active Comparator|Rubus occidentalis extract 1800mg|taking Rubus occidentalis extract 1800mg/day for 12weeks
3089219|NCT01964677|Experimental|MR-HIFU of painful bone metastases|
3089220|NCT01964664|Experimental|Mindfulness meditation training|6-week, one-on-one, mindfulness meditation intervention based on Mindfulness-Based Cognitive Therapy program
3089221|NCT01964664|Active Comparator|Audio Group|6 weeks of listening to podcasts daily (same length as guided meditations), and discussing podcast content with research assistant during weekly study visits
3089222|NCT01964651|Experimental|Cohort A (Part 1)|Healthy male participants, 18 to 55 years of age.
3089223|NCT01964651|Experimental|Cohort B (Part 1)|Healthy male participants, 18 to 55 years of age.
3089224|NCT01964651|Experimental|Cohort C (Part 2)|Healthy female participants of nonchildbearing potential (surgically sterile or postmenopausal), 18 to 58 years of age.
3089225|NCT01964651|Experimental|Cohort D (Part 2)|Healthy elderly male or female participants, from 65 to 85 years of age.
3089226|NCT01964638|Other|Targeted Biopsy|Men being evaluated for prostate cancer based upon standard of care clinical parameters (e.g. elevated PSA levels, abnormal DRE, mpMRI) will be considered for enrollment. Men who have undergone prostate mpMRI that has revealed an area(s) of suspicion for prostate cancer are eligible for enrollment. All men enrolled in the study undergo fusion targeted biopsy, visual estimation biopsy, and systematic biopsy. As a result the study includes a single arm with direct comparison of biopsy techniques.
3089227|NCT01964625|Experimental|PET-CT|Patients who have a negative routine PET-CT evaluation followed by onset and confirmation in accordance with NIH guidelines, will receive another PET-CT scan prior to initiation of therapy for chronic GvHD.
3089228|NCT01964599|Other|PF-RS|14 days consuming the PF-RS containing 30 g fiber and then 14 days consuming the control containing no fiber
3089229|NCT01964599|Other|PF-RO1|14 days consuming the PF-RO1 containing 30 g fiber and then 14 days consuming the control containing no fiber
3089230|NCT01964599|Other|PF-RO2|14 days consuming the PF-RO2 containing 30 g fiber and then 14 days consuming the control containing no fiber
3089298|NCT01964105|Experimental|3D Imaging Simulation|Intervention Group: 3D Image Simulation + Standard Preoperative Evaluation Goal: 50 patients
3089231|NCT01964586|Active Comparator|Lidocaine plus Adrenaline|Lidocaine and adrenaline diluted to 10 ml with normal salin and infiltrated to both side of the nasal septum before 10 minutes from the surgery.
3089232|NCT01964586|Active Comparator|Dexmedetomidine|2 mcg/kg dexmedetomidine diluted to 10 ml with normal salin and infiltrated to both side of the nasal septum before 10 minutes the surgery.
3089233|NCT01964573|Experimental|Rotigotine group|
3089234|NCT01964573|Placebo Comparator|Placebo group|Placebo matched to rotigotine will be administered in the same way as within the Rotigotine group.
3089235|NCT01964560|Experimental|Lacosamide|"In the first week after enrollment into EP0034 subjects will be dosed according to their weight:~Lacosamide (LCM) 10 mg/kg/day (oral solution) for subjects weighing <30 kg~LCM 6 mg/kg/day (oral solution) for subjects weighing ≥30 kg to <50 kg~LCM 300 mg/day (tablets) for subjects weighing ≥50 kg~After 1 week the investigator may adjust the LCM dose during the Treatment Period based on clinical judgment within a range of 2 mg/kg/day to 12 mg/kg/day for the oral solution and 100 mg/day to 600 mg/day for the tablets."
3089236|NCT01964547|Active Comparator|Sativex|"Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.~Dose: 100 µL oromucosal spray to be administered up to a maximum of 12 sprays per day. There was an initial dose-titration period during which patients gradually increased their dose of study drug according to individual response and tolerability."
3089237|NCT01964547|Placebo Comparator|Placebo|Oromucosal spray, containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Dose: 100 µL oromucosal spray to be administered up to a maximum of 12 sprays per day. There was an initial dose-titration period during which patients gradually increased their dose of study drug according to individual response and tolerability.
3089238|NCT01964534|Active Comparator|ARM 1 ABI-007 + Gemcitabine|ABI-007 : 125mg/m² IV / 30min (day 1, day 8, day 15) Gemcitabine : 1000mg/m² IV /30 min (day 1, day 8, day 15) One cycle every four weeks treatment until progression or limiting toxicity
3089239|NCT01964534|Experimental|Arm 2 ABI-007 + simplified LV5FU2|ABI-007 : 125mg/m² IV /30 min (day 1, day 15) folinic acid : 400mg/m² IV /2h (day 1, day 15) Bolus 5-FU : 400mg/m² IV /15min 5-FU infusion : 2400mg/m² IV / 46h (day 1-2, day 15-16) One cycle every four weeks Treatment until progression or limiting toxicity
3089240|NCT01964521|Experimental|Mepilex Transfer Ag|Mepilex Transfer Ag is a transfer dressing designed for low to high exuding wounds and used to prevent microbial growth. It is worn for up to two weeks at a time.
3089241|NCT01964508||Thyroid nodule|Patients with thyroid nodules undergoing FNA.
3089242|NCT01964495|Active Comparator|Common clinical practice|Treatment according to current guidelines. Often a 7 day course of antibiotics. Initial treatment should be broad spectrum antibiotics and can be narrowed down if a specific pathogen is identified.
3089243|NCT01964495|Experimental|CRP-guided treatment|Treatment according to CRP levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.
3089244|NCT01964495|Experimental|PCT guided treatment|Treatment according to PCT levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.
3089245|NCT01964482|Experimental|Strength training|Supervised strength training daily during hospitalization and 3 times per week for 4 weeks after discharge in the participant's home
3089246|NCT01964482|No Intervention|Usual care|Usual care
3089247|NCT01964469|Placebo Comparator|Written self-management action plan|Usual Care: Evidence-based best practice within the primary care asthma program including written self-management action plan and regular clinical review.
3089248|NCT01964469|Experimental|mobile & web based action plan|Evidence-based best practice within the primary care asthma program, replacing the written action plan with the Breathe mobile health and web-based application.
3089249|NCT01964469|No Intervention|Administrative data set|Health services use will be evaluated comparatively against our intervention population and our control and we will include health services utilization data from one year prior randomization.
3089250|NCT01964456|Active Comparator|Patients|Patients suffering of anorexia
3089251|NCT01964456|Placebo Comparator|Control|Subjects controls (not suffering of anorexia)
3089252|NCT01964443||all included patients|Men and women, 18 years of age and older, who have had the onset of the first symptoms of plaque psoriasis less than 10 years before study entry, are naïve or experienced to topical treatment, and are eligible for phototherapy or systemic treatment
3089253|NCT01964430|Experimental|nab-Paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2|Treatment Arm A
3089254|NCT01964430|Active Comparator|Gemcitabine 1000 mg/m2|Treatment Arm B
3089255|NCT01964417|Active Comparator|4L-split Dose of PEG Solution|4L-split Dose of PEG Solution for bowel preparation
3089256|NCT01964417|Active Comparator|Low-volume PEG Plus Ascorbic Acid|Low-volume PEG Plus Ascorbic Acid for bowel preparation
3089257|NCT01964404|Experimental|Marijuana cigarette and placebo capsule|3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.
3089258|NCT01964404|Experimental|Dronabinol and placebo cigarette|Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI.
3089259|NCT01964404|Placebo Comparator|Placebo cigarette and placebo capsule|Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.
3089299|NCT01964105|No Intervention|Standard Preoperative Evaluation|"Control Group: Patients will receive standard preoperative evaluation (2D imaging).~Goal: 50 patients"
3089260|NCT01964391|Experimental|Trastuzumab|In adjuvant setting trastuzumab will be administered in the following treatment regimens: (a) trastuzumab following surgery, chemotherapy (neo-adjuvant or adjuvant) and radiotherapy (if applicable); (b) trastuzumab following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel; (c) trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. In neo-adjuvant setting, trastuzumab will be administered in combination with neo-adjuvant chemotherapy followed by adjuvant trastuzumab, for locally advanced (including inflammatory) breast cancer or tumors greater than (>) 2 centimeters (cm) in diameter.
3089261|NCT01964378|Experimental|Cebranopadol|Once daily oral administration. 200, 400 or 600 µg film coated tablets. Dosage 200 µg to 1000 µg per day.
3089262|NCT01964378|Active Comparator|Morphine Prolonged Release|Twice daily oral administration. 15, 30 or 45 mg morphine sulfate capsules. Dosage 30 to 150 mg per day.
3089263|NCT01964365|Experimental|Rosuvastatin|multiple dose of Rosuvastatin 20mg
3089264|NCT01964365|Experimental|Fenofibric acid|multiple dose of Fenofibric acid 135mg
3089265|NCT01964365|Experimental|Rosuvastatin + Fenofibric acid|multiple dose of the combination of Rosuvastatin 20mg and Fenofibric acid 135mg
3089266|NCT01964352|Experimental|tiotropium + olodaterol low dose|Once daily 2 puffs solution for inhalation Respimat
3089267|NCT01964352|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
3089268|NCT01964352|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
3089269|NCT01964352|Placebo Comparator|placebo|Once daily 2 puffs solution for inhalation Respimat
3089270|NCT01964339||BMI greater than or equal to 30kg/m2 -venous|BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.
3089271|NCT01964339||BMI greater than or equal to 30kg/m2 - arterial|BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.
3089272|NCT01964326|Experimental|Atorvastatin calcium 10 mg|
3089273|NCT01964313||ACS cohort|Patients diagnosed with acute coronary syndrome.
3089274|NCT01964300|Experimental|Treatment (peginterferon alfa-2b)|Patients receive peginterferon alfa-2b SC weekly for 6 weeks. Treatment may repeat every 6 weeks for up to 18 courses in the absence of disease progression or unacceptable toxicity.
3089275|NCT01964287|Experimental|Gembrax followed by Folfirinox|"Gembrax:~Albumin-bound paclitaxel followed by Gemcitabine Day 1,8,15 followed by 2 weeks of rest~Folfirinox:~Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous"
3089276|NCT01964274||Surgical patients|Adult male and female patients undergoing surgery
3089277|NCT01964261|Experimental|Neural Prosthetic System 2|The Neural Prosthetic System 2 consists of three Neuroport Arrays, which are described in detail in the intervention description. Two of the three Neuroport Arrays are inserted into the posterior parietal cortex, an area of the brain used in reach and grasp planning. The third Neuroport Array is inserted into somatosensory cortex, specifically S1 which represents sensory feedback for the hand and fingers. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to control an end effector by thought augmented with sensory feedback via intracortical microstimulation. They will then use the end effector to perform various reach and grasp tasks.
3089278|NCT01964248|Experimental|Lidocaïne/prilocaïne|"Lidocaine/prilocaine eutectic mixture 5% incorporated in a cream base~Single dose: 2 grams (one tube of cream)~Cream applied 2 hours before blood sample"
3089279|NCT01964248|Placebo Comparator|Placebo|"Single dose: 2 grams (one tube of cream)~Cream applied 2 hours before blood sample"
3089280|NCT01964235|Experimental|INC280 plus best supportive care|Approximately 46 patients will be treated with INC280 600 mg twice a day plus best supportive care.
3089281|NCT01964235|Placebo Comparator|Placebo plus best supportive care|Approximately 23 patients will be treated with matching placebo twice a day plus best supportive care.
3089282|NCT01964222|Experimental|Decision Aid (DA)|The decision aid (DA) will be provided to patients randomized to the experimental/intervention group.
3089283|NCT01964222|No Intervention|Control|Participants randomized to the control group will receive usual care and will be shown Siteman Cancer Center website about clinical trials.
3089284|NCT01964209||No treatment|This is a psychometric study of a screening tool for ADHD, so we will not be administering any treatments or interventions.
3089285|NCT01964196|Experimental|ASP1517 low dose group|
3089286|NCT01964196|Experimental|ASP1517 middle dose group|
3089287|NCT01964196|Experimental|ASP1517 high dose group|
3089288|NCT01964196|Placebo Comparator|Placebo group|
3089289|NCT01964183|Experimental|treatment group|
3089290|NCT01964170|Experimental|ASP3550 PART 1 and PART 2|Part 1 for 1 year treatment and Part 2 for an extended period of treatment
3089291|NCT01964170|Active Comparator|Goserelin|part 1 for 1 year treatment
3089292|NCT01964157|Experimental|LDK378 arm|
3089293|NCT01964144|Experimental|Dovitinib arm|
3089294|NCT01964131|Experimental|D961H sachet 20 mg|Pellets contains esomeprazole 20 mg (esomeprazole magnesium trihydrate 22.3 mg) and excipient granules filled into single-use aluminium sachets
3089295|NCT01964131|Other|D961H HPMC capsule 20 mg|Pellets contains esomeprazole 20 mg (esomeprazole magnesium trihydrate 22.3 mg) in HPMC capsule
3089296|NCT01964118|Other|Control group|The participants randomized to the crossover group begin study participation as a control group (no changes in food intake) for the first 6 months and switch to IF for the remaining 6 months of the study.
3089297|NCT01964118|Experimental|Intermittent Fasting group|Participant with a BMI between 28 and 35 kg/m2 will fast 3 non-consecutive days per week, whereas participant with a BMI between 24 and 27.9 kg/m2 will fast 2 non-consecutive days per week. Individuals following intermittent fasting (IF) will work with the study dietitian to design their weekly meal plans and menus for the non-fasting days. The subjects following IF will be asked to skip breakfast, lunch, dinner, snacks, and calorie-containing beverages on the fast days, but we will give them the option to consume at dinner a big salad (i.e. non-starchy raw and/or cooked vegetables dressed with 2 tablespoons of salad dressing prepared with vegetable oil, vinegar and seasonings).
3089300|NCT01964105|Other|Non-Randomized Cohort: 3D Imaging|"Patients who refuse the option of randomization but otherwise meet the inclusion and exclusion criteria will be offered participation in this study as part of a non-randomized cohort.~Goal: 50 Patients"
3089301|NCT01964092|Experimental|Individual Placement and Support|Individual Placement and Support (IPS) is a well-defined intervention aiming to help people with disabilities participate in the competitive labor market by working in jobs they prefer with the professional help that they need. IPS actively facilitates job acquisition and provides ongoing support once the client is employed.
3089302|NCT01964092|Active Comparator|Ordinary employment schemes|The control group will receive treatment as usual in terms of the ordinary employment schemes offered to this group, primarily Work with assistance and/or Traineeship in a sheltered business.
3089303|NCT01964079|Active Comparator|CCB (amlodipine)|For patients who fail to respond to 5 mg oral amlodipine daily, the dose will be titrated up to 10 mg amlodipineh. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
3089304|NCT01964079|Active Comparator|ARB (losartan)|For patients who fail to respond to 50 mg oral losartan daily, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
3089305|NCT01964066|Experimental|ERCP & Thoracic epidural analgesia|Used thoracic epidural analgesia (ropivacaine 0.5% -10ml) for pain relief ERCP.
3089306|NCT01964066|Active Comparator|ERCP & Premedication|Used Premedication (trimeperidine 2% -1ml intravenously) for pain control ERCP.
3089307|NCT01964053|Experimental|PATCH Intervention|The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
3089308|NCT01964053|Active Comparator|Usual Care|The usual care group will receive standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen. No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
3089309|NCT01964040|Placebo Comparator|group B: control bupivacaine group|Patient in this group will receive 25 ml bupivacaine 0.5% plus 0.5 ml normal saline peri-neurally and 0.5 ml subcutaneous normal saline.
3089310|NCT01964040|Experimental|Group B-peri-DEX: Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 0.5 ml (50 microgram) Dexmedetomidine peri-neurally and 0.5 ml subcutaneous normal saline
3089311|NCT01964040|Active Comparator|Group B-sys-DEX:Systemic Dexmedetomidine|Patients in this group will receive 25 ml bupivacaine plus 0.5 ml saline peri-neurally and 0.5 ml (50 microgram) subcutaneous Dexmedetomidine.
3089312|NCT01964027|Experimental|Irinotecan plus epirubicin|Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment * 6 cycles as the second line chemoregime for advanced gastric cancer
3089313|NCT01964014|Experimental|advagraf|The same capacity advagaf + sirolimus
3089314|NCT01964001|Placebo Comparator|Placebo|starch
3089315|NCT01964001|Experimental|Dietary supplements|Vitamin B-6/Coenzyme Q10/vitamin B6+Coenzyme Q10
3089316|NCT01963988||Transurethral Coagulation (TUC)|This cohort patients will be managed with Transurethral Coagulation (TUC) of IC ulcer lesion
3089317|NCT01963988||Transurethral Resection(TUR)|This cohort patients will be managed with transurethral resection(TUR) of IC ulcer lesion
3089318|NCT01963962||Copper IUD|Women selecting the copper IUD for emergency contraception and to use for contraception after
3089319|NCT01963962||Levonorgestrel IUD|Women who select oral levonorgestrel for emergency contraception and begin the levonorgestrel IUD for ongoing contraception at the same time.
3089320|NCT01963949||Primary Liver Cancer|Patients that have liver masses suspicious for primary liver cancer.
3089321|NCT01963936|Experimental|Supreme LMA|
3089322|NCT01963936|Active Comparator|Facial mask|
3089323|NCT01963923|Experimental|Rehabilitation Group|The rehabilitation group must complete at least 16 sessions of the Pulmonary Rehabilitation Program
3089324|NCT01963923|No Intervention|Control Group|The control group must complete only the outcome measures and continue with their clinical routine as specified by their physicians.
3089325|NCT01963910|Active Comparator|Mannitol in vehicle cream|Once the capsaicin has been removed, .2 mL of 30% mannitol in vehicle cream will be applied to one half of the upper lip and kept there for 10 minutes.
3089326|NCT01963910|Placebo Comparator|Vehicle Cream|Once the capsaicin has been removed, .2 mL of vehicle cream will be applied to the other half of the upper lip and kept there for 10 minutes.
3089327|NCT01963884||Alveolar Socket Below Basal Bone|Tooth and the alveolar socket are positioned below basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
3089328|NCT01963884||Alveolar Socket in Basal Bone (imbedded)|Tooth and alveolar socket are positioned in basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
3089329|NCT01963884||Alveolar Socket Buccal to Basal Bone|Tooth and alveolar socket are positioned buccally in relation to maxillary basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
3089330|NCT01963871|Experimental|Yoga in Chronic Low Back Pain|12 weeks of no yoga followed by 12 weeks of yoga, 2 times per week for individuals with chronic low back pain
3109267|NCT01828437|Active Comparator|Prednisolone|
3089335|NCT01963832|Experimental|eCMIT and Fluoxetine|expanded form of Constraint Induced Movement Therapy (eCIMT) combined with Fluoxetine (FLX)
3089336|NCT01963832|Experimental|eCIMT and placebo|expanded form of Constraint Induced Movement Therapy (eCIMT) combined with placebo
3089337|NCT01963832|Experimental|Usual care and fluoxetine|Ususal physical care combined with Fluoxetine (FLX)
3089338|NCT01963832|Experimental|Usual care and placebo|Usual physical care combined with placebo
3089339|NCT01963819|No Intervention|Control|Standard treatment
3089340|NCT01963819|Experimental|Intervention|Endometrial biopsy before standard treatment
3089341|NCT01963806|Experimental|Smartphone-supplemented iCBT with therapist support|n = 50
3089342|NCT01963806|Experimental|Smartphone-supplemented iCBT without therapist support|n = 50
3089343|NCT01963806|Active Comparator|Active waiting list control group with delayed treatment|n = 50
3089344|NCT01963793|Other|placebo (left) / aprepitant (right)|placebo (on defined treatment area on left side of the body) / aprepitant (on defined treatment area on right side of the body)
3089345|NCT01963793|Other|aprepitant (left) / placebo (right)|aprepitant (on a treatment area on the left side of the body) / placebo (on a treatment area on the right side of the body)
3089346|NCT01963780|Experimental|OCS Lung Tx.|
3089347|NCT01963767|Experimental|NT-020|Participants received two pills of NT-020 plus Biovin (900 mg proprietary formulation of blueberry, carnosine, green tea, plus 200 U Vitamin D3, 40 mg Biovin), with one to be taken in the morning and the other in the evening.
3089348|NCT01963767|Placebo Comparator|Placebo|Subjects took two pills, one in the morning and one in the evening, that were matched in size and shape to the active compound.
3089349|NCT01963754|Experimental|Subepriosteal Articaine|Administer Subperiosteal 1:100.000 Articaine 4% epinephrine, buccal and lingually, for Dental Implants in Posterior mandible
3089350|NCT01963754|Active Comparator|Loco-regional Articaine|Administer Loco-regional 1:100.000 articaine 4% epinephrine, for Dental Implants in Posterior Mandible
3089351|NCT01963741|Experimental|leukotriene D4|Nasal provocation test was induced by leukotriene D4 with a stepwisely concentration method (4 mcg/ml, 8 mcg/ml, 16 mcg/ml).
3089352|NCT01963741|Experimental|histamine|Nasal provocation test was induced by histamine with a stepwisely concentration method (0.4 mg/ml, 0.8 mg/ml, 1.6 mg/ml, 3.2mg/ml).
3089353|NCT01963728|Active Comparator|insulin isophane|daily dose will be titrated based on fasting morning glucose values
3089354|NCT01963728|Active Comparator|insulin glargine|daily dose will be titrated based on fasting morning glucose values
3089355|NCT01963715|Experimental|EGFR+ Solid Tumor|EGFR+ Solid Tumor
3089356|NCT01963702|Experimental|Docetaxol ＆Capecitabine (TX)|Docetaxol: 75 mg/m2 d1, (From MAY 15th 2013, the dose was reduced to 60mg/m2 for high incidence of G3/4 myelosuppression after approved by institute Ethics Committee) ; Capecitabine 1000 mg/m2 bid ×14d; Repeat every 3 weeks, until disease progression or intolerable toxicity or patients withdrawal of consent,or total 8 cycles
3089357|NCT01963702|Active Comparator|Oxaliplatin ＆Capecitabine (XELOX)|Oxaliplatin: 130 mg/m2 d1; Capecitabine 1000 mg/m2 bid ×14d; Repeat every 3 weeks, until disease progression or intolerable toxicity or patients withdrawal of consent,or total 8 cycles
3089358|NCT01963689|Placebo Comparator|Intervention Group 2|Individuals belonging to Group 2 received a bottle containing aromatic gel enriched with ylang ylang essence only in 2% concentration and used massage with essential oil 3 times a day: leaving home to go to work, leaving the shift and before bedtime. The points indicated were the two handles and the sternum. Gel was applied and massaged in a circular motion for 30 seconds.
3089359|NCT01963689|Experimental|Intervention Group 1|Individuals belonging to Group 1 received a bottle containing aromatic gel enriched with essential oil of ylang ylang in a concentration of 2% and used massage with essential oil 3 times a day: leaving home to go to work, leaving the shift and before bedtime. The points indicated were the two handles and the sternum. Gel was applied and massaged in a circular motion for 30 seconds.
3089360|NCT01963689|Experimental|Intervention Group 3|The subjects in Group 3 were responsible for before the beginning of their working, put a drop of essential oil of ylang ylang in cotton located within the freshener personal and should be used throughout your work shift
3089361|NCT01963676|Experimental|transcranial direct current stimulation (tDCS)|13 subjects total. 2mA stimulation for 20 minutes.
3089362|NCT01963676|Sham Comparator|Sham stimulation|13 subjects total. An initial 40sec of stimulation at 2mA followed by a small current pulse every 550msec for the remainder of the 20 minute period.
3089363|NCT01963663|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
3089364|NCT01963663|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
3089365|NCT01963650||No treatment|
3089366|NCT01963637|Experimental|Patients with morbid obesity|Patients with morbid obesity and who requires a gastric bypass or a Sleeve gastrectomy as a 1st bariatric procedure.
3089367|NCT01963624||Breast masses detected with screening US|Those assessed with conventional B-mode US alone and those assessed with combined elastography and color doppler ultrasonography along with B-mode US.
3089368|NCT01963611|Experimental|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
3089369|NCT01963611|Experimental|Plovamer acetate 3 mg|Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
3089370|NCT01963611|Experimental|Plovamer acetate 10 mg|Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
3089371|NCT01963611|Experimental|Plovamer acetate 20 mg|Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
3089372|NCT01963611|Active Comparator|Copaxone 20 mg|Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
3089373|NCT01963598|Experimental|Group 1|Dosing regimen 1
3089374|NCT01963598|Experimental|Group 2|Dosing regimen 2
3089375|NCT01963598|Experimental|Group 3|Dosing regimen 3
3089376|NCT01963598|Experimental|Group 4|Dosing regimen 4
3089377|NCT01963585||Negative metacholine|Healthy control
3089378|NCT01963585||Positive metacholine|Hyperreactive airway disease - study group
3089379|NCT01963572|Experimental|surveillance group (SG)|SG will have health education brochure and free class from the first visit post-operatively but CG will only have the brochure. Moreover, SG will be screened every time when they visit the clinics. If there is any early sign of impairment, professional advice and counseling will be given additionally.
3089380|NCT01963572|No Intervention|general care group (CG)|CG raises any health-related question, they can be answered.
3089381|NCT01963559|Other|Diabetic patients with MPP|
3089382|NCT01963559|Other|Diabetic patients without MPP|
3089383|NCT01963546|Other|Intravenous anesthesia|We use total intravenous anesthesia to assess the stress response.
3089384|NCT01963546|Other|Intravenous and Inhalation anesthesia|We use intravenous and inhalation anesthesia during the surgery.
3089385|NCT01963546|Other|Inhalation anesthesia|We use inhalation anesthesia during the surgery.
3089386|NCT01963546|Experimental|Dexmedetomidine|"the effect of dexmedetomidine on the stress responses generated by patients with diabetic given gastric-bypass surgery : Group A group given the best anesthetic technique from preliminary work + dexmedetomidine Dexmedetomidine as a inducer was given intravenous infusion loading dose 1.0μg/kg for 10min, maintained intravenous infusion by 0.4μg/kg/h.~Group B group given the best anesthesia method from preliminary work(not using dexmedetomidine)."
3089387|NCT01963507|Experimental|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
3089388|NCT01963507|No Intervention|Control|
3089389|NCT01963494|Experimental|Dyadic planning intervention|A general motivational treatment is provided to each participant. For randomly assigned couples, randomly selected target persons form action plans to increase daily physical activity together with their partners.
3089390|NCT01963494|Active Comparator|Individual planning intervention|A general motivational treatment is provided to each participant. For randomly assigned couples, target persons form action plans individually to increase daily physical activity and partners receive a distraction task.
3089391|NCT01963494|Active Comparator|No-planning control condition|A general motivational treatment is provided to each participant. For randomly assigned couples, target persons do not receive instructions for action planning, but perform a distraction task together with their partners.
3089392|NCT01963481|Experimental|Exemestane and cyclophosphamide|"A treatment cycle is defined as 4 weeks:~One tablet (25 mg) of exemestane and one tablet (50 mg) of cyclophosphamide given daily by mouth until disease progression or unacceptable adverse events."
3089393|NCT01963468|Experimental|Early language intervention|"Children will receive 6 months of weekly parent-implemented intervention sessions.~Children will be assessed monthly via audio recordings and language checklists to monitor language development more closely."
3089394|NCT01963468|No Intervention|Monthly language check-ups|Children will be assessed monthly via home observations and parents will complete a language checklist to monitor language development more closely.
3089395|NCT01963455|Experimental|MDCs transplant|The women who have stress urinary incontinency.
3089396|NCT01963442|Active Comparator|Amoxicillin/Clavulanic acid treatment|after 3 day treatment of β-lactams, the subjects receive 5-day treatment of Amoxicillin/clavulanic acid. Chest X-ray performed at admission and Day 30 and replapses. 'blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
3089397|NCT01963442|Placebo Comparator|placebo treatment|after 3-day treatment of β-lactams, the subjects receive 5-day treatment of placebo. Chest X-ray performed at admission and Day 30 and replapse. blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
3089398|NCT01963429|Experimental|A(radiofrequency ablation )|radiofrequency ablation
3089399|NCT01963429|Experimental|B(Proton)|hypofractionated proton beam therapy
3089400|NCT01963416|Placebo Comparator|Control|macro- and micro-nutrient matched control (240 ml)
3089401|NCT01963416|Experimental|Orange juice|commercial orange juice (240 ml)
3089402|NCT01963416|Experimental|whole orange|whole orange fruit (240 ml)
3089403|NCT01963416|Experimental|processed whole orange|processed whole orange (240 ml)
3089404|NCT01963403|Active Comparator|EE 30mcg/LNG 150mcg|combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)
3089405|NCT01963403|Placebo Comparator|Placebo|Placebo
3089406|NCT01963390||Testosterone therapy|The study population is a cohort of testosterone deficient men who are planning on undergoing testosterone therapy at an outpatient men's health clinic.
3089407|NCT01963377|Experimental|1. Nasal Cannulae / 2. Bronchoscope channel|Supplementation of O2 through will take place first through the aspiration channel of the bronchoscope, in second phase of the study O2-supplementation will be done through nasal cannulae.
3089408|NCT01963377|Experimental|1. Bronchoscope channel / 2. Nasal Cannulae|Supplementation of O2 through will take place first through nasal cannulae, in second phase of the study O2-supplementation will be done through the aspiration channel of the bronchoscope.
3089409|NCT01963364|Experimental|Intervention group|All healthy volunteers
3089410|NCT01963351||Locally advanced and metastatic nsclc|non squamous
3089411|NCT01963338|Experimental|Intradermal group|These group participants received two intradermal injections with the newly developed device, one in the forearm and one in the upper arm (deltoid region).
3089412|NCT01963338|Experimental|Intramuscular group|These group participants received one intramuscular injection in the upper arm(deltoid region) using needle and syringe and one intradermal injection in the forearm using the newly developed device.
3089413|NCT01963325|Experimental|S-1 plus Abraxane|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, <1.25 m2: 80mg/day, 1.25~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
3089414|NCT01963312|Experimental|Transarterial Supraselective Embolization|Transarterial supraselective embolization of prostatic arteria with Bead Block 300-500 μm
3089415|NCT01963312|Active Comparator|Transurethral Resection|Surgery to remove part of the prostate gland
3089416|NCT01963299|Active Comparator|Ropivacaine alone group|
3089417|NCT01963299|Experimental|Ropivacaine/Clonidine group|
3089778|NCT01960855|Experimental|ABT-494 12 mg BID|ABT-494 12 mg twice daily (BID) for 12 weeks.
3089418|NCT01963286|Other|Enhanced SVT discriminators|Patients with activated enhanced SVT discriminators (in accordance with predefined mandatory study settings)
3089419|NCT01963273|Experimental|pilonidal sinuses|All consecutive patients with diagnosis of chronic sacrococcygeal pilonidal sinus will be screened for the enrollment in our study.
3089420|NCT01963260|Experimental|Part 1: MK-8723 1 mg/kg in Healthy Participants|MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.
3089421|NCT01963260|Experimental|Part 1: MK-8723 3 mg/kg in Healthy Participants|MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.
3089422|NCT01963260|Experimental|Part 1: MK-8723 10 mg/kg in Healthy Participants|MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.
3089423|NCT01963260|Experimental|Part 1: MK-8723 30 mg/kg in Healthy Participants|MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.
3089424|NCT01963260|Experimental|Part 1: MK-8723 100 mg/kg in Healthy Participants|MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.
3089425|NCT01963260|Placebo Comparator|Part 1: Matching Placebo to MK-8723|Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.
3089426|NCT01963260|Experimental|Part 2: MK-8723 10 mg/kg in ITP Participants|MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
3089427|NCT01963260|Experimental|Part 2: MK-8723 30 mg/kg in ITP Participants|MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
3089428|NCT01963260|Placebo Comparator|Part 2: MK-8723 100 mg/kg in ITP Participants|MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
3089429|NCT01963260|Placebo Comparator|Part 2: Matching Placebo to MK-8723|Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.
3089430|NCT01963247||Healthy Athletes|
3089431|NCT01963247||Concussed Athletes|
3089432|NCT01963234|Experimental|Seva|Up to 100 patients in each of 3 intervention clinics will receive access to the Seva mobile health system for drug use disorders.
3089433|NCT01963221|Other|fluodeoxyglucose (18f)|
3089434|NCT01963208|Experimental|ganaxolone|active
3089435|NCT01963208|Placebo Comparator|Placebo|placebo, non-active
3089436|NCT01963195|Experimental|Icotinib|Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicity occurred. The overall study period takes about 24 months
3089437|NCT01963182|Experimental|irinotecan dose based on genetic polymorphism of UGT1A1|
3089438|NCT01963169|Experimental|TO-BoneHealth Group|The group will use the 8-week TO-BoneHealth program, which includes: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.
3089439|NCT01963169|Experimental|TO-BoneHealth Plus Group|The group will use the TO-BoneHealth Plus program intervention, which includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
3089440|NCT01963169|No Intervention|Control Group|No specific intervention will be provided to the control group participants. To keep in contact with participants, a monthly e-mail will be sent to inform them of upcoming follow-up surveys. At the end of the study (upon completion of all five surveys), the control group participants will receive a CD version of the TO-BoneHealth program via mail.
3089441|NCT01963156|Experimental|Prescription synchronization|
3089442|NCT01963156|No Intervention|Control|
3089443|NCT01963143|Experimental|Treatment Sequence 1 - Adults|Gammaplex 5% - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days, followed by Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
3089444|NCT01963143|Experimental|Treatment Sequence 2 - Adults|Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days, followed by Gammaplex 5% - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
3089445|NCT01963143|Experimental|Pediatrics|Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
3089446|NCT01963130||drug (metformin and gliclazide)|The first group (Group 1) consisted of patients that used metformin (1000 mg bid) and gliclazide (60 mg qd).
3089447|NCT01963130||drug (metformin, gliclazide and vildagliptin)|The second group (Group 2) consisted of patients that used vildagliptin (50 mg bid) in addition to the same amount of metformin and gliclazide since their HbA1c were detected 7 % or over.
3089448|NCT01963117|Experimental|Combined hypertermia and RT|
3089449|NCT01963104|Experimental|Automated hearing test|Subjects will take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.
3089450|NCT01963104|Experimental|Pure-tone Screener test|Subjects will take a pure-tone hearing screening test and then receive recommendations for hearing healthcare follow-up.
3089451|NCT01963104|Experimental|Digits-in-noise test|Subjects will take a digits-in-noise test and then receive recommendations for hearing healthcare follow-up.
3089452|NCT01963104|Experimental|No screening test|This group of subjects will not receive a screening test.
3089453|NCT01963104|Experimental|Automated hearing test/Motivation video|Subjects will take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up. They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
3089454|NCT01963104|Experimental|Pure-tone Screener/Motivation video|Subjects will take a pure-tone hearing screening test and then receive recommendations for hearing healthcare follow- up. They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
3089455|NCT01963104|Experimental|Digits-in-noise test/Motivational video|Subjects will take a digits-in-noise test and then receive recommendations for hearing healthcare follow-up.They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
3089779|NCT01960855|Experimental|ABT-494 18 mg BID|ABT-494 18 mg twice daily (BID) for 12 weeks.
3089456|NCT01963104|Experimental|No screening test/Motivational video|This group of subjects will not receive a screening test. They will watch a brief video that shows how hearing works and learn about the different types of hearing loss
3089457|NCT01963104|Experimental|Home Hearing Screening Test|Subjects will be taught the set-up for a home hearing screening test, take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.
3089458|NCT01963104|Experimental|Home Hearing Screening Test/Brief video|"Subjects will be taught the set-up for a home hearing screening test, take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.~They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss."
3089459|NCT01963091|Experimental|oxytocin|
3089460|NCT01963091|Placebo Comparator|placebo|
3089461|NCT01963078|Placebo Comparator|Saline|Participants will self-administer matching placebo (containing all ingredients except OT) at 10:30 a.m., approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
3089462|NCT01963078|Experimental|Oxytocin|Participants will self-administer 24 IUs of OT nasal spray at 10:30 a.m., approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
3089463|NCT01963065||Very low birth weight infant|All neonates born at Mount Sinai with birth weight < 1500g
3089464|NCT01963052|Experimental|Part A: AGS-15E Dose Escalation (Dose Levels 1-6)|Subjects will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks.
3089465|NCT01963052|Experimental|Part B: AGS-15E Cisplatin Therapy -ineligible Expansion|Urothelial subjects who have not received any prior lines of therapy an who are unfit for Cisplatin therapy (Cis-ineligible) will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Subjects will initially be dosed one dose level below the preliminary recommended phase 2 dose (RP2D).
3089466|NCT01963052|Experimental|Part C: AGS15E Immune Checkpoint Inhibitor Treated Expansion|Subjects previously treated with immune checkpoint inhibitors (CPI) in the metastatic setting will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Subjects will be dosed at the RP2D.
3089467|NCT01963039|Active Comparator|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement (PMMA) is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
3089468|NCT01963039|Sham Comparator|Sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the bone cement(PMMA) is prepared to simulate the odor associated with mixing of polymethacrylate , but the needle is not placed and cement is not injected.
3089469|NCT01963026|Experimental|ToCUEST (constant or variable practice)|After therapy as usual (intervention A), the Task-oriented Client-centred Upper Extremity Skill Training (ToCUEST) module (Spooren et al., 2011) will be given. In this program individual goals will be extracted using the COPM (Canadian Occupational Performance Measure) and the training program is based on a task-analysis and uses principles of training physiology and motor learning. Intervention B will consist of the ToCUEST program, including the component 'practice variability' (ToCUEST variability). Intervention C will consist of a modified ToCUEST program in which the component 'practice variability' will be replaced by 'constant practice' (ToCUEST constant) in order to evaluate the contribution of these components. Intervention A' will be therapy as usual.
3089470|NCT01963013|Experimental|Non-returning catheter valve|Non-returning catheter valve (UnometerTM SafetiTM Plus) was used in experimental group only.
3089471|NCT01963013|Active Comparator|Conventional urine bag|Conventional urine bag hasn't the non-returning catheter valve.
3089472|NCT01963000||CAP|A patient with CAP was identified by encoding pneumonia without severe immunosuppression (HIV infection, solid organ or bone marrow/stem cell transplants, severe neutropenia) as the main diagnosis (ICD 10 GM) of hospital admission.
3089473|NCT01962987|Experimental|Diclofenac Sodium 3% gel - Test|The diclofenac sodium 3% test gel is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Test Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
3089474|NCT01962987|Active Comparator|Diclofenac Sodium 3% gel - Reference|The Reference diclofenac sodium 3% gel (Solaraze®) is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Reference (Solaraze®) Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
3089475|NCT01962987|Placebo Comparator|Placebo gel|The placebo gel (contains no active ingredient) is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough placebo gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
3089476|NCT01962974|Experimental|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
3089477|NCT01962961|Experimental|PharmaNAC 1800 mg|PharmaNAC 900 mg orally twice daily for 8 weeks
3089478|NCT01962961|Experimental|PharmaNAC 3600 mg|PharmaNAC 1800 mg orally twice daily for 8 weeks
3089479|NCT01962961|Placebo Comparator|Placebo|Matching placebo pills given twice daily for 8 weeks
3089517|NCT01962688|Experimental|Handheld ultrasound - inpatient|Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy
3089480|NCT01962948|Experimental|Treatment (paclitaxel, ganetespib)|Patients receive paclitaxel IV over 1 hour and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3089481|NCT01962935|Experimental|Part A AZD4721|Part A of the study, multiple ascending doses of AZD4721 will be administrated once daily for 10 days
3089482|NCT01962935|Placebo Comparator|Placebo|Part A of the study, multiple ascending doses of matching Placebo will be administrated once a daily for 14 days
3089483|NCT01962935|Active Comparator|AZD5069, then AZD4721|Part B of the study, subject will participate in two treatment periods (one with AZD5069 administrated for 3 days and the second period with AZD4721 administrated for 14 days) separated by a wash-out period of 6-10 days between the two periods.
3089484|NCT01962922|Active Comparator|LCP-Tacro|Envarsus XR
3089485|NCT01962922|Active Comparator|Tacrolimus - IR|Tacrolimus
3089486|NCT01962909|Experimental|PTP-01|single IV bolus dose 24 hours prior to surgery
3089487|NCT01962896|Experimental|Erlotinib + sirolimus|
3089488|NCT01962883|No Intervention|Control group|Osteopathic evaluation Cognitive and Physical Rest
3089489|NCT01962883|Experimental|Osteopathic Treatment Group|4 osteopathic treatments following a set protocol to which only the osteopathic lesions found within the subjects assessment will be treated.
3089490|NCT01962870|Placebo Comparator|Placebo|Placebo Nasal Spray
3089491|NCT01962870|Active Comparator|Vasopressin|Vasopressin Nasal Spray
3089492|NCT01962857|Experimental|Exercise|4 week supervised high-intensity shuttle running intervention, with 3 sessions per week (12 sessions in total)
3089493|NCT01962857|No Intervention|Control|No intervention - participants maintain usual lifestyle
3089494|NCT01962844|Other|Nutritional treatment|All patients received an individualized diet plan and balanced. The diet was calculated according to the nutritional status and the protein 15-20% of total energy value, lipids 25-30% of daily energy intake and carbohydrate 50-60% of of total energy value
3089495|NCT01962844|Experimental|extra virgim coconut oil group|Oil from coconuts (cocos nucifera L.) contains a high proportion of medium chain fatty acids, principally the lauric acid (12:0), in proportions that range from 45 to 50%
3089496|NCT01962831|Experimental|dinoprostone|Group of women that will receive dinoprostone for induction of labour dinoprostone 10 mg in vagina to be reassessed every 24 hours
3089497|NCT01962831|Experimental|Single balloon foley catheter|Group of women that will have a single balloon foley catheter inserted for induction of labour
3089498|NCT01962818|Experimental|HFOV-sigh at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~Frequency 3 breaths/min Ti = 1s Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
3089499|NCT01962818|Experimental|HFOV-only at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~Frequency 3 breaths/min Ti = 1s Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
3089500|NCT01962805|Experimental|Proellex Schedule A|Proellex vaginal capsule, 12 mg, once a day for up to 7 days
3089501|NCT01962805|Experimental|Proellex Schedule B|Proellex vaginal capsule, 12 mg, once a day for up to 7 days
3089502|NCT01962792|Experimental|Phase 1 - Dose Finding|Ibrutinib PO + Carfilzomib IV + Dexamethasone PO
3089503|NCT01962792|Experimental|Phase 2b - Main Study|Ibrutinib PO + Carfilzomib IV + Dexamethasone PO
3089504|NCT01962792|Experimental|Phase 2b - Sub-study|Ibrutinib PO + Carfilzomib IV + Dexamethasone PO
3089505|NCT01962779|Experimental|Continuous positive airway pressure|Moderate to severe SDB subjects will be offered a 6-month therapy with continuous positive airway pressure (CPAP).
3089506|NCT01962779|No Intervention|No intervention|Subjects that refuse treatment with CPAP or that have a poor long-term compliance will be considered controls.
3089507|NCT01962766|Active Comparator|complete myofunctionnal therapy|complete therapy (at least 5 sessions) to correct their swallowing pattern and tongue position
3089508|NCT01962766|Experimental|instructions|instructions to modify their tongue position (1 session)
3089509|NCT01962753|Experimental|18FAV45|
3089510|NCT01962740|Active Comparator|Xience EES|This arm of patients will receive Xience Everolimus Eluting Stents(EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
3089511|NCT01962740|Active Comparator|Resolute Integrity ZES|This arm of patients will receive Resolute Integrity Zotaralimus Eluting Stents (ZES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
3089512|NCT01962740|Active Comparator|Promus Element EES|This arm of patients will receive Promus Element Everolimus Eluting Stents (EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
3089513|NCT01962714|Experimental|Loving-Kindness Meditation|A 12-week duration, 90-minute per session Loving-Kindness Meditation (LKM) course, taught in groups of 10 participants.
3089514|NCT01962714|Active Comparator|Cognitive Processing Therapy - Cognitive Only|A 12-week duration, 90-minute per session Cognitive Processing Therapy (CPT) course, taught in groups of 10 participants.
3089515|NCT01962701||OCT-group|OCT prior to C-section
3089518|NCT01962688|Sham Comparator|Sham ultrasound - inpatient|Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding
3089519|NCT01962688|Experimental|Handheld ultrasound - ambulatory|Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy in the ambulatory setting during normal clinic visits.
3089520|NCT01962688|Sham Comparator|Sham ultrasound - ambulatory|Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding in the ambulatory setting during normal clinic visits.
3089521|NCT01962675|Experimental|tDCS and skilled training|tDCS and skilled leg training. Transcranial direct current stimulation + step training TDCS will be delivered to the motor cortical area in conjunction with skilled locomotor training
3089522|NCT01962675|Sham Comparator|Sham tDCS and skilled leg training|Sham (Non active) tDCS and skilled leg training. 'Sham transcranial direct current stimulation + step training Sham tDCS will be delivered to the motor cortical area in conjunction with skilled locomotor training
3089523|NCT01962662|Experimental|variable practice|EMG biofeedback training on force control muscle the goal of force level control training is 25%, 50%, 75%, and 100% of maximal strength.
3089524|NCT01962662|Experimental|constant practice group|EMG biofeedback training on force control muscle the goal of force level control training is 100% of maximal strength.
3089525|NCT01962662|Other|control group|U/E exercise
3089526|NCT01962649|Experimental|ICG & Optical Molecular Imaging|All patients will receive a dose of ICG 0.5mg/kg, with a maximum dose of 40mg, one day prior to the scheduled procedure. The patients will then undergo a routine image-guided biopsy on the day of the procedure; immediately prior to obtaining the biopsy sample, fluorescence intensity within the target lesion will be measured by a handheld optical molecular imaging device, which will be passed through the biopsy needle. Once the core sample is obtained using a standard biopsy needle, the specimen will be imaged using an epifluorescence, point-of-care imaging system and will then be submitted for standard pathologic analysis.
3089527|NCT01962636|Experimental|Umbilical Cord Blood Transplant|The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI)followed by umbilical cord blood transplant. Immunosuppressive Cyclosporine and Mycophenylate Mofetil (MMF) will be administered pre- and post UCBT.
3089528|NCT01962623|Active Comparator|Treatment as Usual (TAU)|Participants who are not randomly assigned to the IPT-MBD group will continue with treatment at usual, which is considered routine care.
3089529|NCT01962623|Other|IPT-MBD|Weekly Interpersonal Therapy for SMD/DMDD (IPT-MBD) sessions, which emphasizes building skills in managing relationships, helping with problem solving, strengthening communication skills and other skills.
3089530|NCT01962610|Experimental|ePCA and Pain keycept intervention|Study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit
3089531|NCT01962610|No Intervention|Usual Care|No study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit
3089532|NCT01962597|Active Comparator|aerobic exercise|patients will undergo supervised exercise on a bike ergometer for 30 minutes three times per week during hemodialysis
3089533|NCT01962597|Active Comparator|resistance training|patients will undergo supervised lower extremity strength training three times per week pre-hemodialysis
3089534|NCT01962597|Experimental|aerobic exercise and resistance training|patients will undergo a combination of aerobic exercise and resistance training on an alternating schedule three time per week
3089535|NCT01962584||SAM|patients with suspected acute myocarditis
3089536|NCT01962584||HC|Healthy controls
3089537|NCT01962571|Experimental|Erythropoietin alfa|Recombinant human EPO (Epoetin alfa HEXAL®) will be given as an i.v. bolus injection on days 1, 2 and 3. The dosage per day will be 33.000 IU in accordance with previous trials.
3089538|NCT01962571|Placebo Comparator|Placebo|As matched placebo for this study, sterile normal saline (0.9% sodium chloride for i.v. administration) will be used. It will be given as a bolus injection in the same manner as EPO.
3089539|NCT01962558|Experimental|VNS Treatment|Vagus nerve stimulation and tones are used 2.5 hours per day for a 6-week period.
3089540|NCT01962558|Sham Comparator|VNS Control|Vagus nerve stimulation and tones are given daily over a 2.5 hour period, but not in the same way as the experimental group, and in such a way that it is believed to be ineffective but still provide both VNS and tones so that blinding is maintained.
3089541|NCT01962545|Experimental|OAC alone|OAC includes warfarin or NOAC. The dose of warfarin should be adjusted with the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years, which is recommended in the Japanese guidelines. NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice daily, and edoxaban 60mg daily with the reduced dose of 30mg daily.
3089542|NCT01962545|No Intervention|OAC plus single APT|"OAC includes warfarin or NOAC. The dose of warfarin should be adjusted with the target INR range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years, which is recommended in the Japanese guidelines. NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice daily, and edoxaban 60mg daily with the reduced dose of 30mg daily.~Single APT includes aspirin or clopidogrel. The dose of aspirin is 81-324mg/day and the dose of clopidogrel is 75mg/day."
3089543|NCT01962532|Experimental|Part 1: Dose Escalation (Daily Dosing)|Dose escalation of JNJ-42756493 is to occur until a dose at which <33 percent of participants experience a dose-limiting toxicity, the maximum concentration of JNJ-42756493 is less than the protocol-defined cardiovascular threshold, and JNJ-42756493 is biologically active. Participants will receive study drug once day on Day 1 of Cycle 1 followed by a 2-day drug-free period (Days 2 and 3 of Cycle 1) and continues throughout the 21 day cycle. For all subsequent cycles once a day for 21 days.
3089544|NCT01962532|Experimental|Part 1: Dose Escalation (Intermittent Dosing)|Intermitting dosing regimen will be 28 days (7 days on and 7 days off). Participants will receive JNJ-42756493 on Days 1 to 7 and Days 15 to 21 of each cycle; JNJ-42756493 will not be administered on Days 8 to 14 and Days 22 to 28 of each cycle.
3089579|NCT01962298|Active Comparator|Repeated rocuronium dose - sugammadex|The patients will receive multiple rocuronium doses and neostigmine 2mg/kg as a reversal agent
3089545|NCT01962532|Experimental|Part 2: Dose Expansion|Participants will receive the recommended Phase 2 JNJ-42756493 dose determined in Part 1 as Intermitting dosing regimen (28 days, 7 days on and 7 days off). Participants who are tolerating study drug treatment and achieve clinical responses or stable disease will continue to receive study drug at the same dose until disease progression, unacceptable toxicity, or withdrawal of consent.
3089546|NCT01962519|Experimental|Early oral feeding|Early oral feeding starting with liquids on postoperative day (POD) 1, followed by a soft diet on POD 2, and solid foods on day 3
3089547|NCT01962519|No Intervention|Delayed oral feeding|Delayed oral feeding starting with liquids on postoperative day (POD) 4, followed by a soft diet on POD 5, and solid foods on day 6
3089548|NCT01962493|Other|Sodium bicarbonate/ Sodium Fluoride toothpaste|Marketed Sodium bicarbonate toothpaste containing 1400 parts per million (ppm) fluoride as Sodium fluoride (NaF)
3089549|NCT01962493|Active Comparator|Sodium fluoride toothpaste|Non-sodium bicarbonate toothpaste containing 1450ppm fluoride as NaF
3089550|NCT01962493|Other|Chlorhexidine digluconate mouthwash|0.2% w/v Chlorhexidine digluconate mouthwash for rinsing post-brushing with study toothpastes
3089551|NCT01962480|Active Comparator|sutured closure of the hernia gap|The hernia gap is sutured intracorporally
3089552|NCT01962480|No Intervention|No closure of the hernia gap|Physiomesh is placed with at least 5 cm overlap of the gap and fixated with double crown technique
3089553|NCT01962467|Experimental|Arm 1|Each subject will receive 7 once daily doses of one of the 3 treatments (FF/LEV FDC or FF or LEV) administered as two 50 µL sprays per nostril in the morning, during each of the 3 treatment periods, as per one of the 6 possible randomization sequences. Each treatment period will be separated by a minimum washout period of 14 days
3089554|NCT01962454|Experimental|Arm 1|Run-in Phase: All participants will receive oral deuterated water (D2O) for 3 weeks prior to the Treatment Phase of the study. The participants will consume 50mL 70% D2O three times per day (TID) for 7 days, followed by a 50ml 70% D2O dose twice daily (BID) for the next 2 weeks. Treatment Phase: Subjects will receive testosterone matching placebo IM injection one per week and 50 mL 70% D2O dose BID for 3 weeks.
3089555|NCT01962454|Placebo Comparator|Arm 2|Run-in Phase: All participants will receive oral D2O for 3 weeks prior to the Treatment Phase of the study. The participants will consume 50 mL 70% D2O TID for 7 days, followed by a 50mL 70% D2O dose BID for the next 2 weeks. Treatment Phase: Subjects will receive testosterone IM injection one per week and 50 mL 70% D2O dose BID for 3 weeks
3089556|NCT01962441|Experimental|SOF+RBV 16 weeks|SOF+RBV for 16 weeks
3089557|NCT01962441|Experimental|SOF+RBV 24 weeks|SOF+RBV for 24 weeks
3089558|NCT01962441|Experimental|SOF+RBV+Peg-IFN 12 weeks|SOF+RBV+Peg-IFN for 12 weeks
3089559|NCT01962441|Experimental|Retreatment Substudy|Participants from the SOF+RBV arms (16 weeks or 24 weeks) who experienced virologic failure on treatment, or during the posttreatment period at or before Posttreatment Week 24 may be eligible to enroll into the Retreatment Substudy to receive SOF+RBV+Peg-IFN for 12 weeks.
3089560|NCT01962428|Experimental|high loading dose of ticagrelor|Patients will receive ticagrelor 360mg loading dose, then 90mg bid maintenance dose starting 12 hours after loading dose.
3089561|NCT01962428|Active Comparator|conventional loading dose of ticagrelor|Patients will receive ticagrelor 180mg loading dose, then 90mg bid maintenance dose starting 12 hours after loading dose.
3089562|NCT01962415|Experimental|UCBT:transfusion dependent anemias or increased rejection risk|Day -21 to -19: Alemtuzumab + Hydroxyurea; Day -18 to -10: Hydroxyurea; Day -9 to -5: Fludarabine + Hydroxyurea; Day -4 to -3: Melphalan; Day -2: Thiotepa; Day -1: Rest; Day 0: Transplant
3089563|NCT01962415|Experimental|BMT, PBSCT and not transfusion dependent UCBT|Start of conditioning to Day -15: Hydroxyurea; Day -14 to -13: Alemtuzumab + Hydroxyurea; Day -12 to -10: Hydroxyurea; Day -9 to -5: Fludarabine + Hydroxyurea; Day -4 to -3: Melphalan; Day -2: Thiotepa; Day -1: Rest; Day 0: Transplant
3089564|NCT01962402|Experimental|Lorcaserin with intensive diet counseling|Patients will be taking lorcaserin 10mg tablet by mouth twice daily. In addition, patients will be provided with intensive dietary counseling to promote weight loss.
3089565|NCT01962389|Experimental|Winsor Laser Catheter|
3089566|NCT01962376|Active Comparator|Bevacizumab,postoperative chemotherapy|"Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.~Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.~placebo:Physiological saline"
3089567|NCT01962376|Experimental|Preoperative Chemotherapy|"Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.~Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.placebo:Physiological saline"
3089568|NCT01962363|Experimental|EPI-743|EPI-743, oral, 400mg three times daily for 3 months
3089569|NCT01962350|Experimental|Active H1-Coil deep brain rTMS|"Deep Brain Transcranial Magnetic Stimulation~18Hz Active H1-Coil deep brain rTMS for 4-weeks over the cortex prefrontal. n=25"
3089570|NCT01962350|Experimental|Sham H1-Coil deep brain rTMS|"Deep Brain Transcranial Magnetic Stimulation~Sham H1-Coil deep brain rTMS for 4-weeks over the cortex prefrontal. n=25"
3089571|NCT01962337|Experimental|1-FPA008/Placebo Randomize DoseLevels1-4|Single infusion at 4 different dose levels
3089572|NCT01962337|Experimental|2-FPA008/Placebo Randomize DoseLevels1-2|Dual Infusions at 2 different dose levels
3089573|NCT01962337|Experimental|3-FPA008 Open-Label DoseLevels 1-3|Dual infusions at 1 dose level AND Dual/Triple infusions at 2 different dose levels
3089574|NCT01962324|Experimental|SIB Dose-Escalation radiotherapy|Simultaneous integrated boost to intraprostatatic tumor and lymph nodes
3089575|NCT01962311|Experimental|All patients|lumbar puncture
3089576|NCT01962298|Placebo Comparator|Single rocuronium dose - placebo|The patients will receive a single rocuronium dose, and no reversal agent.
3089577|NCT01962298|Active Comparator|Single rocuronium dose - sugammadex|The patients will receive a single rocuronium dose and sugammadex 2mg/kg as a reversal agent
3089578|NCT01962298|Active Comparator|Repeated rocuronium dose - neostigmine|The patients will receive multiple rocuronium doses and neostigmine 70 mcg/kg as a reversal agent
3089708|NCT01961388||Group 2|Metformin
3089580|NCT01962298|Active Comparator|Continuous rocuronium dose|The participants will receive a continuous rocuronium infusion and sugammadex 4 mg/kg as a reversal agent
3089581|NCT01962285|Experimental|propofol slow infusion|"(healthy volunteers, non invasive monitoring and O2 supply via nasal cannula) Target controlled infusion of propofol using Schnider´s pharmacokinetic parameters in a slow, stepped fashion. beginning at Cp 0.5 mcg/ml and increasing in 0.5 mcg/ml every 7 minutes until LOC occurred, then a prolonged step of 14 minutes (2 samples), increase 2 steps further and then decrease in 0.5 mcg/ml steps until ROC and a 7 minute registry after ROC.~Blood sampling for propofol plasma level every 7 minutes (at the end of each step, allowing for pseudo-equilibrium condition.~32 channel-EEg and BIS continuous monitoring"
3089582|NCT01962272|Experimental|Nutritional counseling and Forticare®|Weekly nutritional counseling and Forticare®. The goal being an intake that met the protein and energy requirements according to Harris-Benedict equation multiplied with an individual activity factor (1,1-1,5) and a stress factor (1,0-1,1). Daily protein requirements were estimated to 1,5 g/kg per day. In addition to the counseling, the patients in the intervention group were offered a high-protein nutrition supplement containing n-3 fatty acids (Forticare®, Nutricia). The recommended daily dose contained 2531 kJ, 33.8 g protein and 2.2 g EPA.
3089583|NCT01962272|Active Comparator|Control|"The control group was nutritionally instructed by the nurses with the possibility to call for a dietician not related to the study if needed. No fixed schemes.~Apart from the nutritional element the patients had the same care and therapy, including treatment of pain and side-effects to the treatment."
3089584|NCT01962259|Experimental|Vigorous intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 70% of maximal oxygen uptake (VO2 max); Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
3089585|NCT01962259|Experimental|Moderate intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 50% VO2 max; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
3089586|NCT01962259|Experimental|Active commuting|Bicycling to/from work/school/university. No requirements for exercise intensity; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week; Avg distance per day Females 9-15 km; Males 11-17 km
3089587|NCT01962259|No Intervention|Control|Receives no intervention.
3089588|NCT01962246|Active Comparator|postoperative chemotherapy,XELOX|
3089589|NCT01962246|Experimental|Preoperative Concurrent Chemoradiotherapy|
3089590|NCT01962233|Experimental|mesenchymal stem cells|Umbilical Cord Derived Mesenchymal Stem Cells at a dose of 100-800 million by intravenous infusion
3089591|NCT01962220|No Intervention|Standard of Care|"Routine ANC, Delivery and Postpartum Care: All consenting women will receive routine ANC/Delivery and Postpartum care offered to pregnant women in Kenya as per national guidelines at the MCH of the respective facility.~Routine PMTCT and HIV Care: All newly diagnosed HIV-infected pregnant women are enrolled into HIV care in the MCH and receive PMTCT/HIV care per Kenya national guidelines (Revised 2012 PMTCT Guidelines)."
3089592|NCT01962220|Experimental|Study Intervention for Retention (APFU)|Participants randomized to the experimental arm of the study will receive routine antenatal and HIV services as described above per Kenya national guidelines. In addition each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri), who will perform numerous tasks described in the intervention. In addition to the Mama Mshauri, this arm will receive phone/SMS appointment reminders, and default patient tracking if participants miss an appointment.
3089593|NCT01962207|Experimental|ACWY<2 Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with MenACWY-TT.
3089594|NCT01962207|Experimental|ACWY≥2 Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with MenACWY-TT.
3089595|NCT01962207|Experimental|MenCCRM Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with Meningitec.
3089596|NCT01962207|Experimental|MenPS Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with Mencevax ACWY.
3089597|NCT01962194|Experimental|PD and OCD paients for DBS intervention|Parkinson's disease (PD; n=5) and obsessive-compulsive disorder (OCD; n=5) patients that are candidates for treatment with STN DBS will be recruited over a period of two years.
3089598|NCT01962181|Active Comparator|Ritalin|Ritalin treatment at different doses
3089599|NCT01962181|Placebo Comparator|Placebo|Two meetings, one of which will be given a placebo and the other will be given a low dose of Ritalin, randomly.
3089600|NCT01962168||Evolution® Biliary Stent - Uncovered|
3089601|NCT01962155||chronic infected with hepatitis B virus|patients infected with hepatitis B virus for at least 6 months and agreed with liver biopsy
3089602|NCT01962142||Exacerbated asthma patients|
3089603|NCT01962129||Patients affected by a syndrome OFD|
3089604|NCT01962129||Patients AFFECTED BY A SEVERE MENTAL RETARDATION SYNDROMIQUE|
3089605|NCT01962116|Placebo Comparator|Heparin lock|
3089606|NCT01962116|Experimental|Citrate lock|
3089607|NCT01962103|Experimental|nab-paclitaxel|nab-paclitaxel 100-240 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle.
3089608|NCT01962090|Experimental|Thoracic Spine Thrust in Seated Position|Thoracic spine thrust manipulation will be applied two times at each of two treatment sessions while the participant is in a seated position.
3089609|NCT01962090|Experimental|Thoracic Spine Thrust in Supine Position|Thoracic spine thrust manipulation will be applied two times at each of two treatment sessions while the participant is in the supine position.
3089610|NCT01962077|Experimental|MedCem MTA pulpotomies|
3089611|NCT01962064|Experimental|Semantic demantia|cognitive assessment and Brain imaging examination MRI of patient with the semantic variant of primary progressive aphasia
3089612|NCT01962064|Experimental|Frontotemporal dementia|cognitive assessment and Brain imaging examination MRI of patients with the behavioral variant of frontotemporal lobar degeneration
3089613|NCT01962064|Experimental|Elderly|cognitive assessment and Brain imaging examination MRI of healthy elderly subjects
3089614|NCT01962064|Experimental|Young|cognitive assessment and Brain imaging examination MRI of young subjects
3089615|NCT01962051||Delivery system Entry|
3089616|NCT01962038|Active Comparator|Combined Aerobic and Resistance Exercise/Cognitive Training|
3089617|NCT01962038|Active Comparator|Stretching Exercises/Cognitive Training|
3089709|NCT01961375||Group 1|BAY 86-5028; Levonorgestrel- Intra Uterine System
3089618|NCT01962025|Active Comparator|Buttonhole needling technique|the intervention is the Buttonhole needling technique for home hemodialysis
3089619|NCT01962025|No Intervention|Step Ladder Group|Patients will use step ladder needling technique
3089620|NCT01962012|Experimental|AcceleDent Aura|AcceleDent Aura device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
3089621|NCT01962012|Sham Comparator|Sham Device|Sham devices will look identical to active devices but will not deliver vibration to the patient.
3089622|NCT01961999|Active Comparator|Early RRT|"In the early arm renal replacement therapy was started on the basis of refractory oliguria: urine output <0,5ml/Kg/h for > 6 hours"
3089623|NCT01961999|Active Comparator|Late RRT|"In the late arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:~persistent and refractory oliguria (<0,5 ml/Kg/h >12h), despite therapy~refractory extravascular fluid overload~azotemia > 40mmol/L or 240 mg/dL~metabolic acidosis (pH<7,2)~hyperkaliemia (k+>6 mmol/L)"
3089624|NCT01961986|Active Comparator|TSR: traditional subscap release|"TSR - traditional subscapularis release approach~Subscapularis tendon release technique TSR"
3089625|NCT01961986|Experimental|TSR: rotator cuff sparing|Rotator cuff sparing technique TSR
3089626|NCT01961973|Active Comparator|Cultured chondrocytes|"Cultured chondrocytes:~This method has two stages. In the first stage, a knee arthroscopy is done to harvest viable cartilage cells which are then sent to a lab to be cultured for 6 weeks. In the second stage, an arthrotomy is performed. The area of cartilage deficiency is prepared and the cultured cells are transplanted onto it. After discharge from the hospital, the patient is advised partial weight bearing on the operated leg for 6 weeks after the surgery."
3089627|NCT01961973|Active Comparator|Cultured BMAC|This method also has two major stages. The first stage involves harvesting BMAC from the patient's iliac crest (hip bone), which are then sent to the laboratory for culture for 3 weeks. Simultaneously, an arthroscopy is performed on the affected knee and the area of cartilage deficiency is debrided and microfractured. In the second stage, the cultured BMAC are injected into the affected knee and cells attach themselves to the microfractured area. The patient is then recalled at 4, 5 and 6 weeks from the first stage for an injection of Hyaluronic Acid into the operated knee.
3089628|NCT01961960|Experimental|ASP7374 group|
3089629|NCT01961947|Experimental|ASP7374 group|
3089630|NCT01961947|Active Comparator|TIV group|
3089631|NCT01961934|Experimental|Sodium Acetate C11 PET/CT Imaging|
3089632|NCT01961921|Experimental|ALN-TTR02 (patisiran)|
3089633|NCT01961908|Experimental|12 mg Proellex|12 mg capsules, orally, once daily for 8 months, including off-drug interval
3089634|NCT01961895|Active Comparator|Intravenous patient-controlled analgesia|Intravenous morphine solution 0.2 mg / ml in PCA mode without basal infusion, 1mg bolus demand and lockout of 8 minutes.
3089635|NCT01961895|Experimental|Continuous lumbar plexus (LP) block analgesia|"Continuous lumbar plexus (LP) block analgesia. Continuous infusion of a solution of 0.1% bupivacaine in PCA mode, programmed at 8 ml / h.~Rescue bolus 5 ml and 30 minutes lockout"
3089636|NCT01961882|Experimental|OCV-501 arm|
3089637|NCT01961882|Placebo Comparator|Placebo arm|
3089638|NCT01961869|Experimental|Arm I (Fast release BRB confection 4g)|Participants receive one fast release BRB confection (4g) PO 4-6 hours apart thrice daily (TID) for 2 weeks.
3089639|NCT01961869|Experimental|Arm II (Fast release BRB confection 8g)|Participants receive two fast release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
3089640|NCT01961869|Experimental|Arm III (Intermed release BRBconfection 4g)|Participants receive one intermediate release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
3089641|NCT01961869|Experimental|Arm IV (Intermed release BRBconfection 8g)|Participants receive two intermediate release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
3089642|NCT01961869|Experimental|Arm V (Prolong release BRB confection 4g)|Participants receive one prolonged release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
3089643|NCT01961869|Experimental|Arm VI (Prolong release BRB confection 8g)|Participants receive two prolonged release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
3089644|NCT01961856|Active Comparator|Ticagrelor|Ticagrelor 180mg loading dose
3089645|NCT01961856|Experimental|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by a Ticagrelor 180mg loading dose 2 hours later
3089646|NCT01961843|Experimental|Abiraterone acetate with Prednisone|1000 mg Abiraterone daily by mouth, 4 x 250 mg tablets Prednisone administered as 5 mg orally twice a day
3089647|NCT01961830|Experimental|ME1100|ME1100 inhalation solution 0.6 mL for 90 mg, Single Dose ME1100 inhalation solution 3.0 mL for 450 mg, Single Dose
3089648|NCT01961817|Other|Retromolar|"Patients in whom the vocal cord visualisation starts with the retromolar method, which has been randomized determined preoperatively.~The second visualization then will be performed with the conventional method."
3089649|NCT01961817|Other|Convenvtional|"Patients in whom the vocal cord visualisation starts with the conventional method, which has been randomized determined preoperatively.~The second visualization then will be performed with the retromolar method."
3089650|NCT01961804|Other|Actual recommendations|Current guidelines recommend to perform a CT scan and realise the anticoagulation reversion only in case of intracranial bleeding diagnosed.
3089651|NCT01961804|Experimental|Preventive reversion|Realise a preventive reversion before performing any CT scan.
3089652|NCT01961791||TNM 7th edition|staged by the current TNM 7th edition of AJCC/UICC
3089653|NCT01961791||new TNM stage|staged by new TNM stage with new lymph node staging concept
3089654|NCT01961778|Active Comparator|Radio-Frequency Ablation|Patients in this arm will receive treatment with radio-frequency ablation.
3089655|NCT01961778|Active Comparator|Cryothearpy|Patients in this arm will receive treatment with cryotherapy.
3089656|NCT01961765|Experimental|cabozantinib|Cabozantinib will be administered at a dose of 40mg daily by mouth in the first cohort. Dose escalation will occur in subsequent patient cohorts. We will evaluate 3-6 patients per dose level.
3089657|NCT01961752|Placebo Comparator|Control group|
3089658|NCT01961752|Experimental|Bupivacaine only group|
3089659|NCT01961752|Active Comparator|Bupivacaine with triamcinolone group|
3089660|NCT01961739|Experimental|2% lidocaine|topical application, two times per day for 15 consecutive days
3089661|NCT01961739|Placebo Comparator|placebo|vaseline base applied topically, two times per day for 15 consecutive days
3089662|NCT01961726|Placebo Comparator|Placebo|
3089663|NCT01961726|Experimental|30 mg dose of JVS-100|
3089664|NCT01961726|Experimental|45 mg dose of JVS-100|
3089665|NCT01961713||Prostatectomy|Subjects with prostate cancer diagnosed on prostate biopsy who undergo radical prostatectomy at Massachusetts General Hospital
3089666|NCT01961700|Experimental|Physiotherapy|Physiotherapy (breathing exercises, mobilisation, exercises for upper limbs, advice on physical activity and exercise) provided daily during hospitalization.
3089667|NCT01961700|No Intervention|Control group|No physiotherapy.
3089668|NCT01961687|Other|Resorbable Mesh|Phasix Mesh
3089669|NCT01961674|Experimental|Capsinoid arm|On capsinoids
3089670|NCT01961674|Placebo Comparator|Placebo arm|Placebo
3089671|NCT01961661|Experimental|probiotic|Lactobacillus rhamnosus GG 5x10^9 colony forming units (CFU)per day
3089672|NCT01961661|Placebo Comparator|placebo|maltodextrins
3089673|NCT01961648|Active Comparator|Dead space|Participant will sleep connected to a mask with added dead space half of the night
3089674|NCT01961648|Sham Comparator|room air|Participant will sleep connected to a mask open to rrom air, half of the night
3089675|NCT01961635|Experimental|Zirconia Abutments|Place zirconia one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
3089676|NCT01961635|Experimental|Titanium Abutments|Place titanium one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
3089677|NCT01961635|Experimental|Cad-Cam Acrylic abutments|Place cad-cam acrylic one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
3089678|NCT01961622|Experimental|Florence D2A Closed Loop Glucose control|Subjects glucose levels are controlled by Florence D2A or similar closed loop insulin delivery system
3089679|NCT01961622|Active Comparator|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (FreeStyle Navigator CGM)
3089680|NCT01961609|Active Comparator|Secukinumab 150 mg|Patients randomised to 150mg secukinumab will use one pre-filled syringe at each dosing.
3089681|NCT01961609|Active Comparator|Secukinumab 300 mg|Patient randomised to 300mg secukinumab will use two pre-filled syringes (150mg each) at each dosing.
3089682|NCT01961596|Experimental|cooling ice|"A bursts of the Cooling Ice Spray over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.~After 2 days the measurements will be repeated with the other application."
3089683|NCT01961596|Placebo Comparator|water|"A bursts of the water spray (room temperature over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.~After 2 days the measurements will be repeated with the other application."
3089684|NCT01961583|Experimental|Drug; 18F-Fluciclatide|18F-Fluciclatide, 0.14 mCi/kg (not to exceed 10 mCi), IV(in the vein) administration
3089685|NCT01961544|Experimental|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
3089686|NCT01961531|Experimental|Accuboost APBI|28Gy delivered in 5 daily fractions
3089687|NCT01961505|Experimental|Topical Tripterygium group|Patients were treated with topical compound tripterygium for 1 hour, twice per day. Area dosages were as followed that each 1st to 5th metacarpophalangeal joints (MCPJs), 1st to 5th proximal interphalangeal joints (PIPJs) and wrist was 3 ml, each elbow and ankle was 5 ml, each knee was 10 ml.
3089688|NCT01961505|Placebo Comparator|Topical Placebo group|Patients were treated with topical placebo for 1 hour, twice per day. The dosage was the same as the topical tripterygium group.
3089689|NCT01961492|Active Comparator|Fecal microbiota transplantation|A single fecal microbiota transplantation via colonoscope as an adjunct therapy to standard medical treatment
3089690|NCT01961492|No Intervention|Standard medical treatment|Standard medical treatment as recommended by the ECCO Guidelines of UC therapy.
3089691|NCT01961479|Experimental|Internet-based CBT for patients with PMS|The therapeutical intervention follows a treatment manual consisting of 14 modules. Patients work on up to two modules every week for eight weeks in a row. Modules comprise a) psychoeducation (e.g., information about PMS and its treatment); b) cognitive strategies (e.g., identifying and modifying dysfunctional cognitions, or coping with negative affects); and c) suggestions for lifestyle changes (e.g., sports, stress reduction, or balanced diet). Aim of the iCBT is to improve coping and thus to reduce the impairment due to premenstrual symptoms.
3089692|NCT01961479|Other|waiting list|During the waiting period, patients receive no treatment. After a waiting time of 2 months, patients of the waitlist receive the same iCBT treatment as the experimental group.
3089693|NCT01961466||Diabetic patients|
3089694|NCT01961453|Active Comparator|Isosorbide Mononitrate, sustained release|One tablet containing 60 mg (Titration Stage 1) OR 120 mg (Titration Stage 2) of sustained-release ISMN administered at 8 AM.
3089695|NCT01961453|Placebo Comparator|Placebo capsule|One capsule of placebo administered once daily at 8 AM
3089696|NCT01961427|Active Comparator|sodium Nitrate 12mmol|Ingestion of a solution of inorganic nitrate, dosage: 12mmol
3089697|NCT01961427|Active Comparator|sodium Nitrate (6mmol)|ingestion of inorganic nitrate (6mmol solution)
3089698|NCT01961427|Active Comparator|sodium nitrate 3mmol|ingestion of inorganic nitrate (3mmol solution)
3089699|NCT01961427|Active Comparator|sodium nitrate (0mmol)|Ingestion of water as a placebo
3089700|NCT01961427|Active Comparator|Beetroot juice (12mmol)|ingestion of 170ml of concentrated beetroot juice (12mmol)
3089701|NCT01961427|Active Comparator|beetroot juice (6mmol)|ingestion of 85ml concentrated beetroot juice (6mmol)
3089702|NCT01961427|Active Comparator|Beetroot juice (3mmol)|Ingestion of 42.5ml of concentrated beetroot juice (3mmol)
3089703|NCT01961414|Experimental|Aflibercept|All patients will receive aflibercept 2.0mg intravitreal injection
3089704|NCT01961401|Experimental|High intensity exercise|High intensity, short duration exercise on bike
3089705|NCT01961401|Experimental|Moderate exercise|Moderate intensity exercise training on bike
3089706|NCT01961401|No Intervention|No exercise|No exercise, resting in the lab
3089707|NCT01961388||Group 1|Acarbose_BAY G5421
3089710|NCT01961362||Pulmonary fibrosis patients|Patients with pulmonary fibrosis of any cause (idiopathic, connective tissue disease, chronic hypersensitivity pneumonitis)
3089711|NCT01961362||Primary supporter/caregiver of patient with pulmonary fibrosis|We will interview primary supporters/caregivers of people living with PF to learn from a different perspective of what it's like to use supplemental oxygen, both for the person living with PF and the primary supporter him/herself.
3089712|NCT01961362||Prescribers of supplemental oxygen|We will interview supplemental oxygen prescribers to better understand their practices around prescribing oxygen and their expectations for the patients to whom they prescribe supplemental oxygen.
3089713|NCT01961349|Placebo Comparator|Group 1|Group 1 (placebo group) is treated by Anaesthesiologist
3089714|NCT01961349|Active Comparator|Group 2|Group 2 (ICI35,868 without EES0000645/A) is treated by Anaesthesiologist
3089715|NCT01961349|Active Comparator|Group 3|Group 3 (ICI35,868 with EES0000645/A) is treated by Endoscopist
3089716|NCT01961336|Experimental|Testosterone|"Long depot follicular GnRH agonist protocol. On day 21 initiation of ovarian stimulation with recombinant FSH for ICSI. If necessary downregulation will be achieved with additional daily agonist s.c.~10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI."
3089717|NCT01961336|No Intervention|Control|Long depot follicular GnRH agonist protocol. On day 21 initiation of ovarian stimulation with recombinant FSH for ICSI. If necessary downregulation will be achieved with additional daily agonist s.c.
3089718|NCT01961323|Experimental|Nebivolol|Nebivolol 5 mg (titrated to a maximal dose of 10mg for optimal blood pressure) for 6 months
3089719|NCT01961310||RA patients|"This group is composed of 25 patients with RA. The diagnosis of RA is based upon the American College of Rheumatology criteria.~Intervention: Plasma analysis for bacterial translocation~Intervention: Stool analysis"
3089720|NCT01961310||Healthy voluteers|"This group is composed of 25 healthy volunteers.~Intervention: Plasma analysis for bacterial translocation~Intervention: Stool analysis"
3089721|NCT01961297|Experimental|Sodium oxybate|Oral administration of a single dose of sodium oxybate (0.75-2.0 gm)
3089722|NCT01961284|Active Comparator|Zygomatic Implants|2-4 zygomatic implants inserted into edentulous maxilla with no augmentation/grafting prior to providing patient with dental prosthesis
3089723|NCT01961284|Active Comparator|Bone Graft and Conventional implants|Edentulous maxilla which is deficient in bone is first grafted using bone grafting material derived from cows and then ordinary implants are placed into the augmented jaw bone approximately 6 monhts after grafting. Patients will be provided with a dental prosthesis following osseointegration.
3089724|NCT01961271|Experimental|Buprenorphine transdermal patch|Subjects will be on either 5mg, 10mg, 15mg, 20mg, 25mg, 30mg or 40mg doses for 17 weeks. Dose titration will occur every week for the first 6 weeks, and will be maintained for the next 11 weeks.
3089725|NCT01961258||Sever asthmatics in the comminity|Computerized data base analysis and sampling of patients for outpatient clinic evaluation.
3089726|NCT01961245|Active Comparator|nocturnal non-invasive ventilation|patients will undergo 12 nights of non-invasive ventilation during pulmonary rehabilitation
3089727|NCT01961245|No Intervention|no nocturnal non-invasive ventilation|patients will undergo pulmonary rehabilitation without nocturnal non-invasive ventilation
3089728|NCT01961232||Pulmonary Hypertension & WHO group I|Participants with Pulmonary Hypertension with a WHO classification group I and are scheduled to have a right heart catheterization.
3089729|NCT01961232||Pulmonary Hypertension & WHO group II|Participants with Pulmonary Hypertension with a WHO classification group II and are scheduled to have a right heart catheterization.
3089730|NCT01961232||Without Pulmonary Hypertension|Participants without Pulmonary Hypertension
3089731|NCT01961232||Connective Tissue Disease|Participants without PH, but with connective tissue disease
3089732|NCT01961219|Active Comparator|Adhesive Capsulitis with MUA|"Subjects with idiopathic adhesive capsulitis in the frozen or thawing phase who have failed pain management and failed improvement in range of motion after at least 3 months of supervised, regimented conservative treatment; or who after less than 3 months of conservative treatment demand a quicker return to function. Treatment closed manipulation under anesthesia."
3089733|NCT01961219|Active Comparator|Adhesive Capsulitis with Arthroscopy|"Subjects with idiopathic adhesive capsulitis in the frozen or thawing phase who have failed pain management and failed improvement in range of motion after at least 3 months of supervised, regimented conservative treatment; or who after less than 3 months of conservative treatment demand a quicker return to function. Treatment Arthroscopic Capsular Release"
3089734|NCT01961206||Case Patients|Case Patients with Community-Onset Bacteremia Due toESBL producing E.coli or K.pneumoniae
3089735|NCT01961206||control group|bacteremia caused by ESBL producing E.coli or K.pneumoniae
3089736|NCT01961193|Experimental|bandage contact lens|A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
3089737|NCT01961193|Experimental|punctal plug|A punctal plug (Painless Silicon Plugs),will be inserted into each eye. Lubricant drops will be instilled four times daily into each eye. The punctal plug will remain in- situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
3089738|NCT01961193|No Intervention|Control group|Hydroxyethylcellulose drops will be inserted into each eye four times a day and erythromycin ophthalmic ointment will be applied three times a day as well.
3089739|NCT01961180|Active Comparator|active comparator|Drug: Cipralex
3089740|NCT01961180|Placebo Comparator|placebo comparator|Drug: Placebo
3089741|NCT01961167|Experimental|PI 13-05|
3089742|NCT01961154|Other|Medication reduction|All participants undergo similar type of asthma medical reduction. Thus, there is only one arm.
3089743|NCT01961128|Experimental|Exercise Intervention|220 minutes of exercise per week, including 2-3 supervised sessions for 6 weeks
3089776|NCT01960855|Experimental|ABT-494 3 mg BID|ABT-494 3 mg twice daily (BID) for 12 weeks.
3089777|NCT01960855|Experimental|ABT-494 6 mg BID|ABT-494 6 mg twice daily (BID) for 12 weeks.
3089744|NCT01961115|Experimental|Treatment (epacadostat, MELITAC 12.1)|Patients receive epacadostat PO BID on days 1-98 and receive MELITAC 12.1 peptide vaccine ID/SC on days 21, 28, 35, 56, 77, and 98 for up to 3 additional courses in the absence of disease progression or unacceptable toxicity.
3089745|NCT01961089|Experimental|Normal|Arm: Normal eyes Interventions: Galilei Lens Professional, IOLMaster, Lenstar
3089746|NCT01961089|Active Comparator|Mild Cataract|Arm: Eyes with mild cataract Interventions: Galilei Lens Professional, IOLMaster, Lenstar
3089747|NCT01961089|Experimental|Severe cataract|Arm: Eyes with severe cataract Interventions: Galilei Lens Professional, IOLMaster, Lenstar
3089748|NCT01961076|Experimental|uncooked corn starch|Patients receive uncooked corn starch before bed-time
3089749|NCT01961076|Experimental|modified corn starch|Patients receive modified corn starch before bed-time
3089750|NCT01961076|Experimental|other carbohydrate (starch) containing meal|Patients receive a carbohydrate (starch) containing meal before bed-time
3089751|NCT01961063|Experimental|Treatment (gene therapy)|Patients receive busulfan IV over 3 hours on day -2 followed by lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells IV on day 0.
3089752|NCT01961050|Experimental|Intervention|Dual-Focused Brief Physician Intervention (DFBPI)
3089753|NCT01961050|Other|Standard care|Services as usual including standard OB/GYN clinic visits; no experimental intervention is provided.
3089754|NCT01961037|Experimental|Physical activity intervention|Tai Chi: Moving for Better Balance exercise program
3089755|NCT01961024||Type 2 diabetic men|
3089756|NCT01961024||Age- and weight-matched controls|
3089757|NCT01961011||Cohort #1: Bilateral carpal tunnel release|Cohort #1: Patients undergoing simultaneous bilateral carpal tunnel release for treatment of bilateral carpal tunnel syndrome. Inclusion criteria includes any adult patient indicated for bilateral carpal tunnel release. Exclusion criteria include age less than 18, pregnancy, any protected patient population, and the lack of assistance at home during the early postoperative period.
3089758|NCT01961011||Cohort #2: Unilateral carpal tunnel release|Cohort #2: Patients undergoing unilateral carpal tunnel release fir bilateral carpal tunnel syndrome. Patients will chose which hand they wish to have operated on. Patient will plan on undergoing carpal tunnel release on the unoperated side at a later date. Inclusion criteria include any adult patient indicated for unilateral carpal tunnel release. Exclusion criteria include age less than 18, pregnancy, and any protected patient population.
3089759|NCT01960998|Experimental|Telehealth with Pelvic Floor Muscle Training|Participants in this group will participate in an evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 1 month before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively. In addition to the pelvic floor muscle training, content will also include general perioperative care; wetness, odor and skin care management; and outcome measures.
3089760|NCT01960998|Active Comparator|Telehealth without Pelvic Floor Muscle Training|Participants in this group will receive a telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 3 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
3089761|NCT01960985|Experimental|Physicaltherapy|Exprerimental group I - motor training balance training Exprerimental group II - motor training associated with visual and auditory cues on the balance training Control group - recived general orientations.
3089762|NCT01960985|Experimental|physiotherapy|Exprerimental group I - motor training balance training Exprerimental group II - motor training associated with visual and auditory cues on the balance training Control group - recived general orientations.
3089763|NCT01960972|Experimental|Salt substitute|"As described by Brown, in a stepped wedge design, an intervention is rolled-out sequentially to the trial participants (either as individuals or clusters of individuals) over a number of time periods. The order in which the different individuals or clusters receive the intervention is determined at random and, by the end of the random allocation, all individuals or groups will have received the intervention. Stepped wedge designs incorporate data collection at each point where a new group (step) receives the intervention.~Thus, the salt substitute will be implemented in each cluster (village) in a randomized fashion. Not arms are needed since the 6 randomly-selected villages will be implemented in some moment of the protocol."
3089764|NCT01960946|Active Comparator|Modified Citrus Pectin (MCP)|Dietary Supplement: Modified Citrus Pectin (MCP, PectaSol-C), 5 grams by mouth three times a day
3089765|NCT01960946|Placebo Comparator|Placebo|Matched placebo 5 grams by mouth three times a day
3089766|NCT01960933|Active Comparator|Culprit lesion revascularization|Only the culprit lesion is treated whereas other study lesions are left un-treated.
3089767|NCT01960933|Active Comparator|Full revascularization|Culprit lesion is treated initially and all other lesions with diameter stenosis angiographically >50% and FFR <0.80 are treated in a separate procedure within the index hospitalization. Stenoses > 90% are treated without prior FFR.
3089768|NCT01960920|Active Comparator|Healthy Volunteers|Dilute diesel exhaust Filtered diesel exhaust Filtered air
3089769|NCT01960920|Experimental|Heart Failure patients|Dilute diesel exhaust Filtered diesel exhaust Filtered air
3089770|NCT01960907|No Intervention|Observational|"Subjects in the observational arm will receive monthly interviews for collecting informations about their status and level of utilization of healthcare resources.~They will follow their usual care path as provided by their local NHS"
3089771|NCT01960907|Experimental|Interventional|"Patients will receive a system form monitoring their health status.~The system is composed by:~a touch-screen pc for the administration of daily questionnaires~RESMONPRO DIARY for the measurement of lung mechanical impedance and breathing pattern~a Medic4all Wrist Clinic for the assessment of heart rate, blood pressure, saturation, 1 lead ECG, body temperature.~Subjects will receive medical treatment following the activation of alarms by the monitoring devices.~Monthly phone interviews will be performed to collect data about their level of utilization of the health care system."
3089772|NCT01960881||Prostate Cancer Patients|Prostate Cancer Patients
3089773|NCT01960868|Experimental|patients|
3089774|NCT01960868|Other|control group|
3089775|NCT01960855|Placebo Comparator|Placebo BID|Placebo twice daily (BID) for 12 weeks.
3089780|NCT01960842|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants received LCIG via the N-J tube during the nasojejunal (N-J) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.~The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the PEG-J Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour)."
3089781|NCT01960829|Experimental|Everolimus|
3089782|NCT01960816|Experimental|InFlux System|Intervention: Procedure: thermal coagulation of tissue in the nasal airway
3089783|NCT01960803|Experimental|IOERT arm|Intraoperative electron radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on a mobile self-shielded magnetron-driven X-band linear accelerator specifically developed for use in the operating room. This machine produces megavoltage electron beams of energy ranging between 4 and 12 MeV. The radiation is delivered from the device to the tumor bed through an attached applicator. A single dose of 21 Gy calculated to the 90% depth posterior to the tumor bed will be administered and will last approximately 2.5 minutes.
3089784|NCT01960790||Humira®|Humira® 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 160 mg and 2nd dosage of 80 mg in two weeks after the initial administration
3089785|NCT01960777|Experimental|Onstep|Participants in this group will have an inguinal hernia repair ad modum Onstep.
3089786|NCT01960777|Active Comparator|Laparoscopic repair|Participants in this group will receive an inguinal hernia repair by use of a laparoscopic approach.
3089787|NCT01960764|Experimental|Pre-Treatment|Prior to receiving the transplant, this arm will be washed with an antimicrobial regimen
3089788|NCT01960764|Placebo Comparator|Control|This arm will still be transplanted with the autologous microbiome transplant cream, however it will not be pre-treated with an antimicrobial regimen
3089789|NCT01960751|Other|neurocognitive tests|neurocognitive tests battery (MMSE, SDS, SF-36, HAD, BPRS, RAVLT, FACT-Cog, MoCA)
3089790|NCT01960738|Experimental|Intervention|The intervention group received a pre-dive checklist and a post-dive log
3089791|NCT01960738|No Intervention|Control|The control group received the post-dive log only.
3089792|NCT01960725|Active Comparator|Standard Dosing Group|Group will receive RV5 vaccine at 2, 4, and 6 months of age
3089793|NCT01960725|Experimental|Alternate Dosing Group|Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
3089794|NCT01960712|No Intervention|Continued external drainage|Continued external drainage alone.
3089795|NCT01960712|Active Comparator|Continued external drainage + transpapillary stent|External drainage + transpapillary plastic stent (7-10 Fr).
3089796|NCT01960699||CPC < 3|Good neurological outcome
3089797|NCT01960699||CPC >/= 3|Unvavourable neurologic outcome
3089798|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 1 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 1 of aluminum adjuvant Day 28: Placebo
3089799|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 2 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen content with Dose 2 of aluminum adjuvant Day 28: Low dose RSV F Antigen content with Dose 2 of aluminum adjuvant
3089800|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 3 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 3 of aluminum adjuvant Day 28: Low dose RSV F Antigen with Dose 3 of aluminum adjuvant
3089801|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 4 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 4 of aluminum adjuvant Day 28: Low dose RSV F Antigen with Dose 4 of aluminum adjuvant
3089802|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 2 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen with Dose 2 of aluminum adjuvant Day 28: Placebo
3089803|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 3 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen with Dose 3 of aluminum adjuvant Day 28: Placebo
3089804|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 4 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen content with Dose 4 of aluminum adjuvant Day 28: Placebo
3089805|NCT01960686|Placebo Comparator|Placebo|Day 0: Placebo Day 28: Placebo
3089806|NCT01960673|Experimental|LMA proseal|"The investigator will use proseal LMA in this study. The cuff of the proseal LMA could be inflation. It is thought to fix the larynx shape.~The investigator wants to test the efficacy during 30,45,60 degree of head and neck position."
3089807|NCT01960673|Experimental|igel LMA|"igel LMA did not have cuff. The shape, softness and contours accurately mirror the perilaryngeal anatomy.~The investigator want to test the efficacy of the igel at 30,45,60 degree of head and neck position."
3089808|NCT01960673|Experimental|air Q LMA|"The air-Q LMA should be used routinely as a classic passive airway. It is user-friendly, placement in patients is easy and air movement is outstanding. It has the added benefit of allowing for intubation using standard ET Tubes.~It also has the cuff and the contour of the mask is thought to mimic the the shape of the perilaryngeal region.~The investigator want to test the efficacy of the air Q LMA at 30,45,60 degree of the head and neck position."
3089809|NCT01960673|Experimental|ambu LMA|ambu LMA is also an cuff device LMA. The investigator wanted to test the efficacy about the leak pressure and the view at 30,45,60 degree of head and neck position.
3089810|NCT01960660|Experimental|Investigational Product|Omega-3 fatty acids in the form of triglycerides
3089811|NCT01960660|Active Comparator|Comparator Product 1|Omega-3 fatty acids in the form of ethyl esters.
3089812|NCT01960660|Active Comparator|Comparator Product 2|Omega-3 fatty acids in the form of phospholipids from krill oil.
3089813|NCT01960660|Active Comparator|Comparator Product 3|Omega-3 fatty acids from salmon oil.
3089814|NCT01960647|Other|Uncoated PTA balloon catheter|Dilatation with uncoated PTA balloon catheter
3089815|NCT01960647|Active Comparator|Freeway Paclitaxel balloon catheter|Dilatation with Freeway Paclitaxel (3 µg/mm2) coated balloon catheter
3089816|NCT01960621|Experimental|2|
3089817|NCT01960608||low sodium group|24_hours_urine_sodium < 100 mEq/L
3089818|NCT01960608||mid sodium group|24_hours_urine_sodium >= 100 mEq/L and < 200 mEq/L
3089819|NCT01960608||high sodium group|24_hours_urine_sodium >= 200 mEq/L
3089821|NCT01960608||low mid income group|the income 25% - 50% below the quartile
3089822|NCT01960608||mid income group|the income 50% - 75% below the quartile
3089823|NCT01960608||high income group|the income 75% over the quartile
3089824|NCT01960595|Experimental|IV fentanyl PCA|The patient receives post-OP IV fentanyl PCA
3089825|NCT01960595|Active Comparator|post-OP IV fentanyl PCA and local infiltration|pretreatment of local infiltration 0.25% bupivacaine 5 ml and post-OP IV fentanyl PCA
3089826|NCT01960595|Active Comparator|nerves block and post-OP IV fentanyl PCA|pretreatment of peroneal nerves 0.25% bupivacaine 10 ml and post-OP IV fentanyl PCA
3089827|NCT01960582|Experimental|New Practice Strategy|Structured strategy for assessment and evaluation before and after intervention
3089828|NCT01960582|No Intervention|Ordinary practice|Ordinary practice, not structured
3089829|NCT01960569|Active Comparator|Arm 1 : active product (Thrombexx)|100 patients will have the active product(Thrombexx), their visits on days 1,4,8 and 16 for target parameters assessment
3089830|NCT01960569|Placebo Comparator|Arm 2 : Placebo|100 patients will have placebo , their visits on days 1,4,8 and 16 for target parameters assessment
3089831|NCT01960556||Simulation|Simulation Training part of education
3089832|NCT01960556||Non-Simulation Based Education|Did not receive simulation based education
3089833|NCT01960543|Active Comparator|Bupivacaine|"Intrathecal administration of bupivacaine 0.5%~Doses:~Bupivacaine 7 mg plus fentanyl 15 ug for patients shorter than 160 cm. Bupivacaine 9 mg plus fentanyl 15 ug for patients equal or taller than 160 cm or hip replacement."
3089834|NCT01960543|Active Comparator|Levobupivacaine|"Intrathecal administration of levobupivacaine 0.5%:~Doses:~Levobupivacaine 7 mg plus fentanyl 15 ug for patients shorter than 160 cm. Levobupivacaine 9 mg plus fentanyl 15 ug for patients equal or taller than 160 cm or hip replacement."
3089835|NCT01960530|No Intervention|Endogenous Cortisol|No Study medication will be given during this study period, however various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
3089836|NCT01960530|Other|Dexamethasone|1mg Dexamethasone will be administered at 22:00 on Day 1 and at 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. Dexamethasone is considered a challenge agent and therefore a non-IMP
3089837|NCT01960530|Experimental|Infacort®|20mg Infacort® will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous adrenocorticotropic Hormone (ACTH) and cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
3089838|NCT01960530|Active Comparator|Hydrocortisone Tablet|20mg Hydrocortisone Tablet will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
3089839|NCT01960530|Active Comparator|i.v Hydrocortisone Injection|20mg i.v. Hydrocortisone Injection will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
3089840|NCT01960517|Experimental|Catheter placed|
3089841|NCT01960504|Experimental|Drug Eluting Absorbable Metal Scaffold|DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold
3089842|NCT01960491|Experimental|Device Closure of Atrial Septal Defect|
3089843|NCT01960478|Other|bood test|
3089844|NCT01960465|Experimental|African Americans|160 Self identified African American
3089845|NCT01960465|Active Comparator|non African Americans|and 60 Other race (non African Americans) Veterans will be enrolled.
3089846|NCT01960452||Primary insomnia|
3089847|NCT01960452||Healthy sleeping controls|
3089848|NCT01960439||Endoscopic evaluation|The study population contained a broad spectrum of endoscopic disease and clinical activity. At entry to the trial patients had active disease defined by the presence of a modified UCDAI score between 4 and 10.1 Only patients who had a MMCS endoscopy subscale score according to a single central reader (n= 194 of 281 participants) were eligible for assessment in the current study.
3089849|NCT01960426|Active Comparator|Empiric Dose Intensification|Intensify treatment with the existing drug
3089850|NCT01960426|Active Comparator|Testing based strategy|Measurement of drug (Adalimumab/Infliximab) Testing-based strategy for the management of secondary loss of response that is based on drug/ ADA measurement
3089851|NCT01960413|Experimental|Montelukast added to Hydroxyurea|Oral montelukast therapy taken daily for eight weeks with current hydroxyurea regiment
3089852|NCT01960413|Placebo Comparator|Placebo added to Hydroxyurea|Oral placebo taken daily for eight weeks with current hydroxyurea regiment
3089853|NCT01960400|Active Comparator|GMI + tDCS|Graded motor imagery (GMI) + tDCS
3089854|NCT01960400|Placebo Comparator|GMI + sham TDCS|Graded motor imagery (GMI) + sham tDCS
3089855|NCT01960387|Experimental|Clofarabine and Cytarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5. Cytarabine at a dose of 1g/m2 daily will then be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
3089856|NCT01960374|Experimental|Japanese Arm|3 cohorts of 9 subjects. Each cohort will receive oral 25 mg, 50 mg (anticipated) or 75 mg (anticipated) selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate).
3089857|NCT01960374|Experimental|Non-Japanese Asian Arm|3 cohorts of 9 subjects. Each cohort will receive oral 25 mg, 50 mg (anticipated) or 75 mg (anticipated) selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate).
3089858|NCT01960361|Experimental|ICE dental implant|Subjects implanted with ICE implant
3089859|NCT01960348|Active Comparator|patisiran (ALN-TTR02)|
3089860|NCT01960348|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3090130|NCT01958489|Experimental|Pravastatin|Single 40 milligram (mg) oral dose of pravastatin administered on Day 1.
3089861|NCT01960335|Active Comparator|Whey Protein Only|Ingestion of whey protein only (20 grams per serving) consumed 3X/day along with ad libitum diet for a total of 60 grams per day. One serving was consumed within 1 hour of waking in the morning; a second serving was consumed mid-afternoon; and a third serving was consumed within 2 hours of going to sleep at night.
3089862|NCT01960335|Experimental|Whey Protein and Resistance Exericse|Ingestion of whey protein (20 grams per serving) 3X/day: one serving within an hour of waking in morning; a second serving mid-afternoon or within 1 hour immediately following a resistance exercise bout on exercise days; and a third serving within 2 hours of going to bed at night.
3089863|NCT01960335|Experimental|Whey Protein and RISE exercise routine|Ingestion of whey protein (20 gram serving) 3X/day: one serving within an hour of waking in the morning; a second serving mid-afternoon or within 1 hour immediately following the RISE exercise bout; and a third serving within 2 hours of going to bed at night.
3089864|NCT01960322|Experimental|Telemetric|Enrolled patients will be followed for 12 months during which they will receive the study telemetry intervention.
3089865|NCT01960309|Experimental|1. TnI elevation|TnI 0.06-0.60ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
3089866|NCT01960309|Experimental|2. TnI elevation|TnI 0.61-6.00 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
3089867|NCT01960309|Experimental|3. TnI elevation|TnI>6.00 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
3089868|NCT01960309|Experimental|4. TnI elevation|TnI >6.00 ng/ml, ischemia on ECG and Hb<5.1. Intervention: minimal invasive cardiac imaging
3089869|NCT01960309|Experimental|5. TnI elevation|TnI >6.00 ng/ml, ischemia on ECG and Hb>5.0. Intervention: minimal invasive cardiac imaging
3089870|NCT01960309|Active Comparator|Control|TnI <0.06 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
3089871|NCT01960296|Experimental|Clopidogrel|Continue home dose of clopidogrel into surgery
3089872|NCT01960296|Active Comparator|Discontinue|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
3089873|NCT01960283|Active Comparator|Group I|"The group I will receive the intervention :~Methotrexate + anti-H1"
3089874|NCT01960283|Placebo Comparator|Group II|The intervention in group II will include : placebo + anti-H1
3089875|NCT01960270|Experimental|Alone controlateral stimulation|"Device: INTERSTIM II~Stimulator II activated~Stimulator I not activated~Measure of efficacy on bladder hyperactivity"
3089876|NCT01960270|Experimental|2 sides-stimulation|"Device: INTERSTIM II~Stimulator I and II activated~Measure of efficacy on bladder hyperactivity"
3089877|NCT01960257|Experimental|DHFS with IS-RM|Digital Health Feedback System (DHFS) Rifamate (combination of isoniazid 150 mg and rifampin 300 mg) over-encapsulated with ingestion sensor - 2 capsules orally daily (QD) administered orally preferably on an empty stomach first thing in the morning for 10-16 weeks, depending on time left to complete TB treatment.
3089878|NCT01960257|Active Comparator|SOC DOT|Isoniazid 300 mg -1 tablet orally QD plus rifampin 300 mg - 2 capsules orally QD, OR Rifamate (combination of isoniazid 150 mg and rifampin 300 mg) - 2 capsules orally QD preferably on an empty stomach first thing in the morning for 10-16 weeks, depending on time left to complete TB treatment.
3089879|NCT01960244||hypercholesterolemia|familial hypercholesterolemia
3089880|NCT01960231||pancreas specific MODY-2|
3089881|NCT01960218||acute decompensated heart failure|Adult subjects anticipating discharge from a hospitalization where the primary discharge diagnosis is acute decompensated heart failure and who are not excluded due to existing conditions.
3089882|NCT01960205|Experimental|Standarddose Saxagliptin|Saxagliptin 5 mg (tablet) ,5mg a day and lifestyle intervention for 6 months
3089883|NCT01960205|Active Comparator|Lifestyle intervention|Lifestyle intervention for 6 months
3089884|NCT01960205|Active Comparator|Metformin|Metformin 500 mg (tablet) ,500mg three times a day and lifestyle intervention for 6 months
3089885|NCT01960205|Experimental|low dose Saxagliptin|Saxagliptin 5 mg (tablet) ,2.5 mg a day and lifestyle intervention for 6 months
3089886|NCT01960192|Experimental|FVD regimen|FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
3089887|NCT01960192|Experimental|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
3089888|NCT01960179|Experimental|lixisenatide|lixisenatide monotherapy by group (Group 1: 52-week treatment; Group 2: 24-week treatment)
3089889|NCT01960166|Experimental|Active distraction|Child will use Ipad as active distraction
3089890|NCT01960166|Experimental|Passive Distraction|Child will watch movie as passive distraction (control)
3089891|NCT01960153|Experimental|Tadalafil|Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.
3089892|NCT01960153|Placebo Comparator|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
3089893|NCT01960140|Experimental|Simvastatin|Single oral dose of 40 milligrams (mg) simvastatin on Day 1.
3089894|NCT01960140|Experimental|Baricitinib + Simvastatin|Oral doses of 10 mg baricitinib once daily (QD) on Days 3 to 7, with a single oral dose of 40 mg simvastatin coadministered on Day 6.
3089895|NCT01960127|Experimental|Aerobic Exercise|Supervised aerobic training 3 times per week for 8 weeks (30-60 minute sessions)
3089896|NCT01960127|Placebo Comparator|Usual Care Group|These patients will continue with their normal daily activity ad will not be provided with supervised aerobic exercise training during the study period.
3089897|NCT01960114|Experimental|Acetaminophen ER|
3089898|NCT01960114|Placebo Comparator|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
3089899|NCT01960101|Experimental|Lactoxeros milk product|Patient will take the milk product orally for 14 days as many times as needed per day(but not more than 6 times daily).
3090528|NCT01955707|Experimental|natalizumab|300 mg single intravenous (IV) injection
3089900|NCT01960101|Other|Aequasyal|Patients will take the oral spray for 14 days. The Aequasyal ® Oral Spray is a solution of oxidized glycerol triesters. The oral spray is applied by spraying on the inside of each cheek, 3-4 times per day. After each administration, users are instructed to gently spread the product around the mouth with the tongue. The Aequasyal ® Oral Spray is a Class I medical device, and is CE-marked.
3089901|NCT01960088||Adolescents and their parents|Pharmacy demonstration project: HPV vaccine delivery
3089902|NCT01960075|Active Comparator|Fosphenytoin (FOS)|Administer 20 mg/Kg fosphenytoin intravenously up to a maximum dose of 1500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 1500 fosphenytoin over 10 minutes.
3089903|NCT01960075|Active Comparator|Valproic acid|Administer 40 mg/Kg valproic acid intravenously up to a maximum dose of 3000 mg (75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 3000 valproic acidover 10 minutes.
3089904|NCT01960075|Active Comparator|Levetiracetam|Administer 60 mg/Kg levetiracetam intravenously up to a maximum dose of 4500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 4500 levetiracetam over 10 minutes.
3089905|NCT01960062|No Intervention|Control|Diabetes care with primary care practitioner supplemented with clinical pharmacy specialist
3089906|NCT01960062|Experimental|Intervention|Diabetes care with primary care practitioner and clinical pharmacy specialist, with the aid of a diabetes software and device to upload glucometer results from home
3089907|NCT01960049|Placebo Comparator|MOTAP Catheter with Saline and IV PCA|Control group will have saline 20cc of 0.9% normal saline injected into the catheters and then run at 5ml/hr for 72 hours
3089908|NCT01960049|Active Comparator|MOTAP catheter with ropivocaine and IV PCA|20cc of 0.2% ropivacaine will be injected in two equal divided doses through the two catheters then run at 5ml/hr for 72 hours
3089909|NCT01960036|No Intervention|Treatment as usual (TAU)|Usual intensive outpatient treatment for substance use disorders
3089910|NCT01960036|Experimental|Mindful Awareness in Body-oriented Therapy (MABT)|A mind-body intervention to teach interoceptive skills for self-care.
3089911|NCT01960036|Active Comparator|Womens Health Education|A comparative arm to control for time and attention that involves education about the human body relevant to women's health.
3089912|NCT01960023|Experimental|Arm 1: Cetuximab and Neratinib|Cetuximab 400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV plus neratinib per oral daily until disease progression
3089913|NCT01960010|Active Comparator|1% MIM-D3|1% MIM-D3 Ophthalmic Solution
3089914|NCT01960010|Placebo Comparator|Vehicle|Vehicle
3089915|NCT01959997|Active Comparator|Redo PVI|Therapeutic anticoagulation will be required for at least 3 weeks prior to ablation. An MRA will be performed to define cardiac and PV anatomy. Standard ablation technique will be employed. After gaining venous access, double transseptal puncture will be performed to permit left atrial access, guided by intracardiac ultrasound. A circular mapping catheter will be placed in each PV and any reconnections will be ablated by delivery of RF energy. Confirmation of re-isolation of all PVs will be performed at the conclusion of the procedure.
3089916|NCT01959997|Active Comparator|PVI + RDN|"All patients who are randomized to Group II will undergo redo PVI exactly as described above.~At the conclusion of PVI, RDN will be performed. Real-time 3-dimensional aorta-renal artery maps will be constructed with the use of the same navigation system and catheter used for PVI after femoral artery access. Both mapping and ablation will performed under the same modified sedation. RF ablations of 8 to 10 watts will be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium, for 2 min, and up to 6 lesions (separated by ≥ 5 mm). Lesions will be made both longitudinally and rotationally within each renal artery. To confirm renal denervation, high-frequency stimulation (HFS) will be used before the initial and after each RF delivery within the renal artery. RDN will be considered to have been achieved when the sudden increase of blood pressure (≥ 15 mm Hg from invasive arterial monitoring) is absent."
3089917|NCT01959984|Experimental|100g Standard Noodles|100g Standard Noodles
3089918|NCT01959984|Experimental|75g Oral Glucose|75g Oral Glucose
3089919|NCT01959971|Experimental|Placebo - Alirocumab|Injection through subcutaneous (SC) administration, placebo for 4 weeks then, alirocumab for 10 weeks
3089920|NCT01959958||Sickle cell disease|In this study, children and adolescents with sickle cell disease ages 6-18 years and their parents/guardians will complete a questionnaire/interview.
3089921|NCT01959945|Experimental|Study Group 1, Flublok|Participants at 9 years to 17 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
3089922|NCT01959945|Active Comparator|Study Group 2, Fluarix|Participants at 9 years to 17 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
3089923|NCT01959945|Experimental|Study Group 3, Flublok|Participants at 6 years to 8 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
3089924|NCT01959945|Active Comparator|Study Group 4, Fluarix|Participants at 6 years to 8 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
3089925|NCT01959932|Experimental|Tobacco Heating System (THS 2.2)|Ad libitum use of THS 2.2 for 5 days in confinement
3089926|NCT01959932|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 days in confinement
3089927|NCT01959932|Active Comparator|Conventional cigarette (CC)|Ad libitum use of subject's own preferred brand of CC for 5 days in confinement
3089928|NCT01959919||Arm 1: Device|
3089929|NCT01959906||R0|Complete resection
3089930|NCT01959906||R1|Incomplete resection, microscopical tumor residu left behind
3089931|NCT01959906||CRM<1mm|complete resection (R0), however tumor spreads till less than 1 mm from the section pane.
3089932|NCT01959880|Other|Primary Augmentation|The Augmentation cohort will include patients who have post-lactational mammary involution or wish general breast enlargement.
3089933|NCT01959880|Other|Primary Reconstruction|"The Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity.~Congenital deformities will include deformities of the breast itself as well as skeletal abnormalities reflected in breast deformity or asymmetry."
3089934|NCT01959880|Other|Revison Augmentation|Patients in this cohort will have had previous breast augmentation with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast augmentation surgery.
3090529|NCT01955707|Placebo Comparator|Placebo|A single IV dose of placebo
3089935|NCT01959880|Other|Revision Reconstruction|Patients in this cohort will have had previous breast reconstruction with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast reconstruction surgery.
3089936|NCT01959867|Experimental|SurgiMend® PRS (ADM)|Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
3089937|NCT01959867|Other|No Intervention|Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
3089938|NCT01959854|Active Comparator|carboxymethylcellulose|1 drop in each eye four times a day for 30 days
3089939|NCT01959854|Experimental|xanthan gum|1 drop in each eye four times a day for 30 days
3089940|NCT01959841|Experimental|ASP2151(200 mg)|once daily
3089941|NCT01959841|Experimental|ASP2151(400mg)|once daily
3089942|NCT01959841|Experimental|valaciclovir|1000 mg three times daily
3089943|NCT01959828|Experimental|inhaled nitric oxide|"Adults: IK-3001 at start dose 20 ppm; may be increased to 40 ppm at the investigator's or subinvestigator's discretion (up to ~ 24 hrs).~Children: IK 3001 at start 10 dose ppm; may be increased to 20 ppm at the investigator's or subinvestigator's discretion (up to ~24 hrs).~Treatment with IK-3001 will continue until it is clinically indicated to begin the weaning process from IK-3001."
3089944|NCT01959815||Scleroderma and diagnosed PAH|
3089945|NCT01959815||"Low risk scleroderma"|
3089946|NCT01959815||Healthy volunteers|
3089947|NCT01959815||"High risk scleroderma"|
3089948|NCT01959802|Other|Vitrectomy|Vitrectomy for macular pseudo hole
3089949|NCT01959789||Control|Standard treatment
3089950|NCT01959789||2 days|bleaching treatments made in 2 days
3089951|NCT01959776|Other|Vitrectomy|
3089952|NCT01959763|Experimental|weight loss counseling|Cognitive behavioral therapy-based weight loss counseling program including 8 group visits
3089953|NCT01959763|Experimental|ELVIRA-based weight loss counseling|Weight loss counseling program based on 2 group visits of ELVIRA counseling method
3089954|NCT01959763|Experimental|ICT-based weight loss counseling|ICT-based weight loss counseling program with 52 weekly tasks and information packages.
3089955|NCT01959750|Experimental|Intervention Group|
3089956|NCT01959750|No Intervention|Control Group|
3089957|NCT01959737|No Intervention|visual contact|After initial assessment/stabilization of the VLBW infant, visual contact of mother and infant is permitted for 5 minutes.
3089958|NCT01959737|Experimental|skin-to-skin contact|After initial stabilization mother and preterm infant are cared for skin-to-skin for 60 minuter. SSC is supervised by the attending neonatologist.
3089959|NCT01959724|Other|Vitrectomy|Vitreous surgery to treat macular detachment
3089960|NCT01959711|Experimental|Posterior RA|Posterior retroperitoneoscopic adrenalectomy
3089961|NCT01959711|Active Comparator|Lateral transperitoneal LA|Lateral transperitoneal laparoscopic adrenalectomy
3089962|NCT01959698|Experimental|Treatment (carfilzomib, rituximab, chemotherapy)|Patients receive carfilzomib IV over 10-30 minutes on days 1, 2, 8, and 9; rituximab IV over 3-8 hours on day 3; etoposide IV over 1 hour on days 4-6; carboplatin IV over 1 hour on day 5; and ifosfamide IV over 24 hours on day 5. Treatment repeats every 21-28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3089963|NCT01959685|Experimental|Dose escalting|Placebo, 125 mg Androxal, 250 mg Androxal each given as a single dose
3089964|NCT01959672|Experimental|Treatment (chemotherapy, oregovomab, SBRT, surgery)|"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV, leucovorin calcium IV over 30 minutes, and fluorouracil IV over 24 hours on days 1 and 8. Treatment repeats every 3 weeks for 7 courses.~IMMUNOTHERAPY: Patients with CA125 level >= 10 receive oregovomab IV over 15-30 minutes on day 15. Treatment repeats every 3 weeks for 3 courses (weeks 1, 4, 7) and post- radiation therapy for 1 course (week 14). Patients may receive an additional 3 courses concurrently with chemotherapy upon recovery from surgery based on CA125 level. Patients also receive nelfinavir mesylate PO BID for 5 weeks beginning on day 15 of week 9.~STEREOTACTIC RADIATION THERAPY: Beginning in week 11, patients undergo SBRT in 5 fractions over 5 consecutive days. Upon completion of radiation therapy, patients resume nelfinavir mesylate for 14 days (week 12-13). Patients without metastasis and with resectable disease undergo surgery in week 17-18."
3089965|NCT01959659||Cohort|
3089966|NCT01959646|Placebo Comparator|Placebo|Placebo Group
3089967|NCT01959646|Experimental|Aged Garlic Extract Supplementation|Aged Garlic Extract Supplementation Group
3089968|NCT01959633|Experimental|vemurafenib+ Peg-interferon|Vemurafenib 960 mg b.i.d. + Peg-interferon 1/2/3 micrograms/Kg once weekly
3089969|NCT01959620|No Intervention|Assessment only|Participants will receive assessment only.
3089970|NCT01959620|Experimental|1-session exposure intervention|Participants will receive one session of exposure therapy.
3089971|NCT01959620|Experimental|3-session exposure intervention|Participants will receive three sessions of exposure therapy.
3089972|NCT01959607|Active Comparator|THS 2.2 then CC|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of THS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of CC)."
3089973|NCT01959607|Active Comparator|CC then THS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of CC)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of THS 2.2)."
3089974|NCT01959607|Active Comparator|THS 2.2 then NRT|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of THS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single administration of NRT gum [Nicorette® 2mg])."
3089975|NCT01959607|Active Comparator|NRT then THS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single administration of NRT gum [Nicorette® 2mg])~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of THS 2.2)."
3089976|NCT01959594|Experimental|Cohort 1|
3089977|NCT01959594|Experimental|Cohort 2|
3089978|NCT01959594|Experimental|Cohort 3|
3089979|NCT01959594|Experimental|Optional Cohort 4|
3089980|NCT01959594|Experimental|Optional Cohort 5|
3089981|NCT01959581|Other|Movement enhancing device|Guided play while wearing a movement assisting device
3089982|NCT01959568|Experimental|Double tamponade|Vitrectomy and tamponade: subtotal vitrectomy, epiretinal membrane removal, perfluorodecalin tamponade, retinal photocoagulation. After that the surgeon replaces ½ of perfluorodecalin volume by silicone oil.
3089983|NCT01959568|Active Comparator|Silicone oil tamponade|Vitrectomy and tamponade: subtotal vitrectomy, epiretinal membrane removal, perfluorodecalin tamponade, retinal photocoagulation and perfluorodecalin-silicone oil exchange.
3089984|NCT01959555||Retrospective collection of data|
3089985|NCT01959542|Experimental|MRIs and PSA Blood Test|"Visit 1 (8 weeks after starting ADT): PSA blood test and prostate MRI~Visit 2 (6 weeks after starting EBRT): PSA blood test and prostate MRI~Visit 3 (on last day of EBRT): PSA blood test~Visit 4 (6 months after starting ADT): PSA blood test and prostate MRI"
3089986|NCT01959529|Experimental|Insulin degludec (IDeg)|All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.
3089987|NCT01959529|Active Comparator|Insulin glargine (IGlar)|All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.
3089988|NCT01959516|Experimental|Sequence A ⇒ B|Participants will receive sequence A = glycopyrronium + placebo to tiotropium during 28 days, followed by a 14 day washout period, then sequence B= tiotropium + placebo to glycopyrronium for 28 days.
3089989|NCT01959516|Experimental|Sequence B ⇒ A|Participants will receive sequence B= tiotropium + placebo to glycopyrronium during 28 days, followed by a 14 day washout period, then sequence A= glycopyrronium + placebo to tiotropium for 28 days.
3089990|NCT01959503|Experimental|Progel Vascular Sealant|Progel Vascular Sealant after confirmation of anastomotic leakage during intra-procedure leak test.
3089991|NCT01959503|Active Comparator|Gelfoam Plus|Gelfoam Plus Sealant after confirmation of anastomotic leakage during intra-procedure leak test.
3089992|NCT01959490|Experimental|Cohort I (HER2 positive)|Patients receive trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
3089993|NCT01959490|Experimental|Cohort II (HER2 negative)|Patients receive bevacizumab IV over 30-60 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11; doxorubicin IV and cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.
3089994|NCT01959477|Experimental|Treatment (busulfan, etoposide, cyclophosphamide, transplant)|Patients receive busulfan IV over 3 hours on days -9 to -6, etoposide IV continuously over 24-36 hours on days -5 and -4, and cyclophosphamide IV over 4 hours on days -3 and -2. Patients then undergo autologous stem cell transplant on day 0.
3089995|NCT01959464|Experimental|Crinone vaginal progesterone gel|"Crinone is a bioadhesive vaginal gel containing micronized progesterone in an emulsion system containing a water swellable but insoluble polymer, polycarbophil. Crinone 8% is formulated to provide a long-acting vaginal retention, and is prescribed daily. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg of progesterone. The reported time to maximum progesterone concentration is 6.8 +/- 3.3 hours with use of a single dose of Crinone 8%. Absorption half-life is approximately 25-50 hours and an elimination half-life of 5-20 minutes.~On the evening of day 3, the female will insert the applicator into the vagina, administer the gel, and have intercourse within 1 hour of insertion of the cream."
3089996|NCT01959464|Placebo Comparator|Placebo vaginal gel|The couple will be given a prefilled applicator containing either Crinone gel (progesterone) or placebo vaginal gel, data collection sheets and laboratory requisitions. On the evening of day 3, the female will insert the applicator into the vagina, administer the gel, and have intercourse within 1 hour of insertion of the cream.
3089997|NCT01959451|Active Comparator|Prasugrel|Prasugrel 5 mg or 10mg daily for 12 months.
3089998|NCT01959451|Experimental|Prasugrel/Clopidogrel|Day 0 - 7 Prasugrel 5 or 10mg Day 8 - 14 Clopidogrel 75mg q/d. On Day 14 platelet function testing Patients with HPR will be switched to Prasugrel the others will remain on Clopidogrel for 11 1/2 months
3089999|NCT01959438|Experimental|Selenite treatment|In the first part of the study, cohorts of 3 patients receive sodium selenite iv, starting with a dose of 0.5 mg/m2. If no serious adverse event the next cohort is treated according to a dose escalation schedule and this part has been completed. In the modified protocol, a continuous infusion over 2 days will be administered.
3090000|NCT01959425|Experimental|Off OAT Group (Test)|Discontinuation of OAT Therapy
3090001|NCT01959425|Other|On OAT Group (Control)|Continuation of OAT Therapy
3090002|NCT01959412|Experimental|Treatment Period Sequence 1|Indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcgin the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening
3090003|NCT01959412|Experimental|Treatment Period Sequence 2|Indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later 37.5 in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening
3090004|NCT01959412|Experimental|Treatment Period Sequence 3|Indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later 55mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo n the evening, 14 days later placebo in the morning + matching placebo in the evening
3090005|NCT01959412|Experimental|Treatment Sequence Period 4|Indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening, 14 days later 75 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening
3090561|NCT01955538|Experimental|Mixed physical activity|Standard psychiatric treatment + Mixed physical activity for 20 weeks, 1 hour/week.
3090006|NCT01959412|Experimental|Treatment Period Sequence 5|Indacaterol 27.5 mcg in the morning + 27.5mcg in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later 150mcg in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening
3090007|NCT01959412|Experimental|Treatment Period Sequence 6|Placebo in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later 27.5 mcg in the morning + 27.5mcg in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later 75 mcg in the morning + matching placebo in the evening
3090008|NCT01959399|Experimental|ASP015K + rosuvastatin|
3090009|NCT01959386||HER2 Positive Breast Cancer Participants|Participants with HER2 positive tumors who are considered for treatment with trastuzumab SC according to the judgement of physician and according to the actual summary of product characteristics will be observed for a period of approximately 1 year and will be followed for an additional 2 years.
3090010|NCT01959373|Experimental|patients|
3090011|NCT01959373|Experimental|healthy volunteers|
3090012|NCT01959360|Active Comparator|direct lateral|
3090013|NCT01959360|Experimental|minimal invasive|
3090014|NCT01959360|Experimental|modified minimal invasive|
3090015|NCT01959347|Sham Comparator|Miduretheral Sling (Control)|Miduretheral Sling (Control)
3090016|NCT01959347|Experimental|MUS+BPTx|Miduretheral Sling with behavioral/pelvic floor therapy
3090017|NCT01959334|Active Comparator|Glucagon IM|GlucaGen® HypoKit (Glucagon) 1 mg Powder and solvent for solution for injection Novo Nordisk Canada
3090018|NCT01959334|Experimental|Glucagon IN|AMG504-1 Dry-Mist Nasal Glucagon Powder AMG Medical Inc. Canada
3090019|NCT01959308||Immunosuppressive therapy|Liver Transplant recipients who are receiving various doses and types of immunosuppressive therapy
3090020|NCT01959295|Experimental|ASP2151|
3090021|NCT01959295|Placebo Comparator|ASP2151 placebo|
3090022|NCT01959282|Placebo Comparator|Placebo|Participants will receive placebo once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive placebo through Week 32. Participants not in clinical response at Week 8 will receive treatment with 150 mg JNJ-54781532 orally once daily from Week 8 to Week 16. Participants who achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) at Week 16 can continue receiving 150 mg JNJ-54781532 orally once daily through Week 32
3090023|NCT01959282|Experimental|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 25 mg once daily through Week 32
3090024|NCT01959282|Experimental|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg once daily through Week 32
3090025|NCT01959282|Experimental|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 150 mg once daily through Week 32
3090026|NCT01959282|Experimental|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg twice daily through Week 32
3090027|NCT01959269||Regorafenib|Patients treated with Stivarga as 3rd or 4th line treatment, no intervention
3090028|NCT01959256|Experimental|Learning|Visual perceptual learning (VPL) group
3090029|NCT01959256|No Intervention|Control|Control group
3090030|NCT01959243|Experimental|Brimonidine Tartrate|Brimonidine tartrate ophthalmic solution 0.025%, one drop of drug into each eye, four times daily for up to four weeks.
3090031|NCT01959243|Placebo Comparator|Vehicle|Vehicle of brimonidine tartrate ophthalmic solution, one drop of vehicle into each eye, four times daily, for up to four weeks.
3090032|NCT01959230|Experimental|Brimonidine Tartrate|Brimonidine tartrate ophthalmic solution 0.025%, one drop of drug into each eye, four times daily for up to 30 days.
3090033|NCT01959230|Placebo Comparator|Vehicle|Vehicle of brimonidine tartrate ophthalmic solution, one drop of vehicle into each eye, four times daily for up to 30 days.
3090034|NCT01959217|Experimental|PM Component Text Reminders|There will be a a single face-to-face intervention followed by tailored text reminders. The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text message reminders will be determined by Phase 1.
3090035|NCT01959217|Active Comparator|Traditional Text Reminders|There will be a single face-to-face session followed by traditional text reminders.
3090036|NCT01959204|Other|Active|Open label pharmacokinetic study of oxycodone.
3090630|NCT01955070|Experimental|Intervention|Multimedia Presentation for Ketamine sedation
3090037|NCT01959191||Low platelet reactivity group|"Platelet reactivity will be measured after 7-days treatment of clopidogrel by VerifyNow system and the cohort will be divided by two group according to P2Y12 reactivity unit (PRU) cutoff value. Receiver operating characteristic (ROC) curves will be plotted to assess the optimal PRU cutoff value for differentiating between patients with and without subsequent MACEs after 1 year of follow-up. Low platelet reactivity indicates good response to clopidogrel and high platelet reactivity, resistance to clopidogrel. Groups will be Low platelet reactivity group and High platelet reactivity group"
3090038|NCT01959191||high platelet reactivity group|"Platelet reactivity will be measured after 7-days treatment of clopidogrel by VerifyNow system and the cohort will be divided by two group according to P2Y12 reactivity unit (PRU) cutoff value. Receiver operating characteristic (ROC) curves will be plotted to assess the optimal PRU cutoff value for differentiating between patients with and without subsequent MACEs after 1 year of follow-up. Low platelet reactivity indicates good response to clopidogrel and high platelet reactivity, resistance to clopidogrel. Groups will be Low platelet reactivity group and High platelet reactivity group"
3090039|NCT01959165|Experimental|MEDI7183 dose 1|Double blinded
3090040|NCT01959165|Experimental|MEDI7183 dose 2|Double blinded
3090041|NCT01959165|Experimental|MEDI7183 dose 3|Double blinded
3090042|NCT01959165|Placebo Comparator|Placebo|Double blinded
3090043|NCT01959152|Experimental|HiRes90K™ Advantage Cochlear Implant|HiRes90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with a moderate level of hearing loss in the low frequencies and severe-to-profound hearing loss in the mid-to-high frequencies.
3090044|NCT01959139|Active Comparator|Phase II: mFOLFIRINOX|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 1.5 hours on day 2, and 5-fluorouracil (5-FU) IV over 46 hours on days 2-4. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3090045|NCT01959139|Experimental|Phase II: mFOLFIRINOX + PEGPH20|Patients receive pegylated recombinant human hyaluronidase (PEGPH20) IV over 10 minutes on day 1 and oxaliplatin, leucovorin calcium, irinotecan hydrochloride, and 5-fluorouracil (5-FU) as in Arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3090046|NCT01959139|Experimental|Phase I|PEGPH20, 3 ug/kg on Day 1 and Day 3/4, IV over 15 minutes; Oxaliplatin, 85 mg/m^2, on Day 2, IV over 2 hours; Leucovorin, 400 mg/m^2, on Day 2, IV over 2 hours; Irinotecan, 180 mg/m^2, on Day 2, IV over 1.5 hours; 5-fluorouracil (5-FU), 2,400 mg/m^2, Days 2-4, IV over 46 hours
3090047|NCT01959126|Experimental|Stress-reduction class|Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment.
3090048|NCT01959113|Experimental|Autologous Microbiome Transplant|Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.
3090049|NCT01959113|Placebo Comparator|Placebo Arm|This arm will have a base moisturizer alone applied to it during the third visit.
3090050|NCT01959100|Experimental|Azithromycine|250 mg x 3/week during a meal for a period of 2 years
3090051|NCT01959100|Placebo Comparator|Placebo|250 mg x 3/week during a meal for a period of 2 years.
3090052|NCT01959087|Experimental|1: Single port surgery|Surgery with single port
3090053|NCT01959087|Active Comparator|2: Multiport surgery|Surgery with multiport
3090054|NCT01959074|Active Comparator|Naftopidil|This interventional group will receive analgesics and naftopidil 75mg po qd.
3090055|NCT01959074|Placebo Comparator|Control groups with only analgesics|Control groups will receive only analgesics
3090056|NCT01959061|Experimental|Raltitrexed and Oxaliplatin|Raltitrexed and Oxaliplatin were mixed with 10-15 ml lipiodol by arterial chemoembolization on day 1 and during each 28-day cycle.
3090057|NCT01959048|Experimental|fecal microbiota transplant|fecal microbiota transplantation
3090058|NCT01959035|Experimental|Aripiprazole once-monthly|
3090059|NCT01959022|Experimental|Doxazosin XL|Subjects will participate in a 2 week flexible-dose titration of doxazosin XL based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
3090060|NCT01959009|Experimental|HFOV-sigh at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~Frequency 3 breaths/min~Ti = 1s~Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
3090061|NCT01959009|Experimental|HFOV-only at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~Frequency 3 breaths/min~Ti = 1s~Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
3090062|NCT01958996|Experimental|idarubicin|
3090063|NCT01958983|Experimental|Music Therapy Group Session|Participants will receive 60-minute group session twice a week over 2 months of period. Each session will be led by a music therapist. The contents of the music therapy session include drumming, rhythm imitation, score reading, lyrics comprehension, singing, and song discussion.
3090790|NCT01954108|Other|ESWT (Extracorporal Shock Wave Therapy)|Three applications in weekly interval.
3090064|NCT01958983|No Intervention|No Music Therapy Session|Participants will receive pre- and post-assessments and evaluations at 0 and 2 months. No intervention will be provided. Music therapy sessions will be offered to participants in completion of their study participation.
3090065|NCT01958970|Experimental|PINTA 745|
3090066|NCT01958970|Placebo Comparator|Placebo|
3090067|NCT01958957|Experimental|Ginkgolides Meglumine Injection|Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using, dripping speed should be controlled for 10 ~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.
3090068|NCT01958944|Experimental|Nitric oxide + standard treatment|Inhalation of 160 ppm NO for 30 minutes, 3 times daily, for a duration of 10 working days with the exclusion of weekend days (Friday & Saturday) in which no treatment under this study will be provided.
3090069|NCT01958931||Patients Suspicious for Lung Cancer|Subjects are symptomatic of lung cancer and have one or more lung nodules or lung masses suspicious for lung cancer.
3090070|NCT01958918|Experimental|Ranibizumab|0.5 mg intravitreal injections of ranibizumab monthly until maximum stable BCVA with retreatment based on BCVA loss and/or SD-OCT signs of wet AMD disease activity.
3090071|NCT01958918|Active Comparator|Aflibercept|2 mg intravitreal injections of aflibercept monthly for the first 3 months, followed by 2 mg intravitreal injections once every 2 months (current EU SmPC label)
3090072|NCT01958905|Experimental|Artemether-Lumefantrine|All patients will receive Artemether-Lumefantrine and the endpoints will be compared between the two populations of severely malnourished and non-severely malnourished children
3090073|NCT01958892||TURP|
3090074|NCT01958892||TUERP|
3090075|NCT01958879|Experimental|ringer with corticosteroid|Intra-articular irrigation was performed under local anesthesia with subcutaneous injection of 1%lidocaine solution (0.6 to 0.9 mL anaesthetic solution )was injected to block the auriculotemporal nerve. Then the skin on the TMJ was penetrated with a 21-gauge needle at the articular fossa followed by the injection of 3 mL Ringer solution to distend the joint space, pumping it in and out repeatedly. Another 21-gauge needle was inserted into the distended compartment in the area of the articular eminence, and the superior joint space was irrigated with 200 mL Ringer solution, allowing a free flow through the first needle in the both groups .In this group patients received 1mg dexamethasone after finishing the irrigation .
3090076|NCT01958879|Placebo Comparator|Ringer with out corticosteroid|Intra-articular irrigation was performed under local anesthesia with subcutaneous injection of 1%lidocaine solution (0.6 to 0.9 mL anaesthetic solution )was injected to block the auriculotemporal nerve. Then the skin on the TMJ was penetrated with a 21-gauge needle at the articular fossa followed by the injection of 3 mL Ringer solution to distend the joint space, pumping it in and out repeatedly. Another 21-gauge needle was inserted into the distended compartment in the area of the articular eminence, and the superior joint space was irrigated with 200 mL Ringer solution, allowing a free flow through the first needle in the both groups
3090077|NCT01958866|Active Comparator|Acetaminophen|Acetaminophen administer 1000 mg every 4-6 hours when fever is presented
3090078|NCT01958866|Experimental|Tinospora Crispa-extract Product|Tinospora Crispa-extract tablet administer 500 mg every 4-6 hours when fever is presented
3090079|NCT01958866|Placebo Comparator|Placebo|Placebo 2 tablets will be administered every 4 hours when fever is presented
3090080|NCT01958853|Experimental|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from the NeuroPoint device
3090081|NCT01958840|Experimental|Behavioral Activation Treatment for Depression|Behavioral Activation Condition - 10 sessions
3090082|NCT01958840|Active Comparator|Supportive Counseling|Supportive Counseling Condition - 10 sessions
3090083|NCT01958827|Experimental|Adalimumab 80 mg|All participants were to receive subcutaneous injections of open-label adalimumab 80 mg every other week from Week 0 to Week 50.
3090084|NCT01958814|Experimental|Salbutamol - Placebo|salbutamol at M0 and M60 placebo administration
3090085|NCT01958814|Experimental|Placebo - Salbutamol|placebo at M0 and M60 salbutamol administration
3090086|NCT01958801|Active Comparator|Interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, nerve stimulation needle is advanced into the brachial plexus sheath, into which 25 ml of 1.5% mepivacaine is injected.
3090087|NCT01958801|Experimental|Supraclavicular block|Supraclavicular block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral supraclavicular fossa visualizing the brachial plexus located lateral to the subclavian artery. Using in-plane technique, nerve stimulation needle is advanced into the brachial plexus sheath, into which 25 ml of 1.5% mepivacaine is injected.
3090088|NCT01958788|Experimental|Cognitive-Behavioural Treatment|12 sessions of cognitive-behavioral treatment targeting negative beliefs about uncertainty
3090089|NCT01958775|Experimental|GLP=2|active treatment with a single dose of GLP-2 (1500mcg)
3090090|NCT01958775|Placebo Comparator|Placebo|placebo
3090091|NCT01958762|Other|Screening for cancers in the oral cavity|
3090092|NCT01958749|No Intervention|Fat graft without Platelet Rich Plasma|"Step 1. Under Local Anaesthetic (or General Anaesthetic if the patient is unable to tolerate this), a fat graft is taken from just behind the mastoid process, or more posteriorly just beneath the hairline if necessary. The graft is kept moist in 0.9% saline.The ear canal is injected with local anaesthetic and the edges of the perforation are freshened. Gelfoam is placed into the middle ear and the fat graft placed on top of this until it touches the underside of the TM and slightly bulges through. In an attempt to achieve standardisation of surgical technique between sites, surgeons will be provided with an operative video to watch beforehand.~Step 2. The fat graft will simply be covered with a piece of saline-soaked Gelfoam cut to completely cover the perforation and graft."
3090131|NCT01958489|Experimental|Evacetrapib + Pravastatin|Oral doses of 130 mg evacetrapib administered once daily on Days 2-11, with a single oral dose of 40 mg pravastatin coadministered on Day 11
3090164|NCT01958281|Experimental|SOF 200 mg + RBV 200 mg (Cohort 1)|Participants with genotype 1 or 3 HCV infection will receive SOF 200 mg (2 × 100 mg tablets) plus RBV once daily for 24 weeks.
3090821|NCT01953887|Experimental|2: solifenacin|
3090093|NCT01958749|Experimental|Fat graft with Platelet Rich Plasma|"Procedure as for as for Fat graft without PRP, but at Step 2 the Gelfoam will instead be soaked in PRP derived from the patient's own whole blood. The generation of PRP is descibed below: -~10-20 mL of autologous blood collected from an antecubital vein is placed in an adenosine citrate dextrose-acid (ACD-A) collection tube to prevent premature activation~Blood immediately placed in the centrifuge at 1100g for 10 minutes (once)~Supernatant removed and collected into syringe~Injected onto surface of fat graft~Rest added to piece of gelfoam~Place gelfoam + PRP on the TM perforation"
3090094|NCT01958736|Experimental|Experimental|Ballistic Strength Training
3090095|NCT01958736|Active Comparator|Control|Usual care Physiotherapy
3090096|NCT01958723||Hospitalists|Introduction of Problem Specific Templates
3090097|NCT01958710||Embolisation|(preoperative) embolisation of the bronchial circulation
3090098|NCT01958710||Surgery|Any surgically treated patient with a functional lung resection (at least wedge resection)
3090099|NCT01958697||AG-BMI < 10 pct|Patients who's peroperative BMI is less than the 10th centile
3090100|NCT01958697||AG-BMI >= 10th pct|Patients who's peroperative BMI equals or is greater than the 10th centile
3090101|NCT01958684||Group 1|The MIRENA intrauterine delivery system (initial release rate: 20 μg LNG /24 h)
3090102|NCT01958684||Group 2|Copper IUDs with different shape and with or without drugs
3090103|NCT01958671|Experimental|Ertugliflozin 5 mg/Ertugliflozin 5 mg|Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
3090104|NCT01958671|Experimental|Ertugliflozin 15 mg/Ertugliflozin 15 mg|Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
3090105|NCT01958671|Other|Placebo/Metformin|Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
3090106|NCT01958645|Experimental|A|MEDI8111
3090107|NCT01958645|Placebo Comparator|B|Placebo for MEDI8111
3090108|NCT01958632||N|nerve suture
3090109|NCT01958632||NT|nerve transplantation
3090110|NCT01958632||VM|vein-in-muscle conduit
3090111|NCT01958619|Experimental|Treatment A: 1440mg PQP tablets & 800mg OZ439 + TPGS|Piperaquine phosphate tablets (1440mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
3090112|NCT01958619|Experimental|Treatment B: 960mg PQP tablets & 800mg OZ439 + TPGS|Piperaquine phosphate tablets (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
3090113|NCT01958619|Experimental|Treatment C: 960mg PQP granules & 800mg OZ439 + TPGS|Piperaquine phosphate granules for oral solution (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
3090114|NCT01958619|Experimental|Treatment D: 800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
3090115|NCT01958606|Experimental|High-intensity interval training (HIT)|Treadmill exercise using bursts of concentrated effort alternated with recovery periods
3090116|NCT01958606|Active Comparator|Traditional aerobic training|Moderate intensity continuous aerobic exercise on a treadmill
3090117|NCT01958593|Placebo Comparator|Comparator|Participants will receive placebo during each of two experimental sessions.
3090118|NCT01958593|Experimental|3,4-methylenedioxymethamphetamine|Participants will receive full-dose MDMA during each of two experimental sessions.
3090119|NCT01958580|Experimental|Treatment (gemcitabine, docetaxel, brachytherapy/IMRT, EBRT)|"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV over 90 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~RADIATION THERAPY: Beginning week 10, patients undergo 3 fractions of brachytherapy or IMRT over 3 weeks. Patients then undergo EBRT QD 5 days a week for 5 weeks."
3090120|NCT01958567|Experimental|Patients with clinical signs of scleritis or episcleritis|Optical Coherence Tomography for patients with scleral inflammation
3090121|NCT01958567|Experimental|Normal subjects with normal sclera|Optical Coherence Tomography on eyes with normal scleral
3090122|NCT01958554|Experimental|Intervention Group|The integrated intervention consisted of 12 week of program and group support, based on the freedom program by pet craven. The former component was provided covering beliefs held and tactics used by the domestic violence abusers and took about 45 minutes. It included protection and enhanced choice-making and problem-solving skills.
3090123|NCT01958554|No Intervention|Wait list control group|The group was listed in wait list and were offered the same intervention and support on completion of study period.
3090124|NCT01958541|Experimental|Behavioral Intervention I|This non-medication group treatment (Sleep Intervention I) consists of four 90-minute sessions.
3090125|NCT01958541|Active Comparator|Behavioral Intervention II|This non-medication group treatment (Sleep Intervention II) consists of four 90-minute sessions.
3090126|NCT01958528||Cohort 1 Progressors|
3090127|NCT01958528||Cohort 2 - Non-Progressors|
3090128|NCT01958515||Chemoradiation with Research Samples|Standard of care chemoradiation therapy will be given as clinically indicated by the treating physicians. 4 research blood and tissue samples will be obtained. One before treatment starts, 2 while treatments are being received and finally one after treatments are completed.
3090129|NCT01958502|Experimental|mesenchymal stem cell|stem cells drived from iliac bone marrow with centrifuge and ficoll method then implant in collagenic 3-D scaffold with BMP-2 and put in non union site by surgical approach under general or spinal anesthesia as deemed appropriate by the anesthetist.
3090132|NCT01958476|Active Comparator|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
3090133|NCT01958476|Active Comparator|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
3090134|NCT01958463|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation during colonoscopy.
3090135|NCT01958450|Experimental|Er:YAG laser|acne scar treatment using Er:YAG laser
3090136|NCT01958450|Active Comparator|Bipolar radiofrequency with diode laser|Bipolar radiofrequency with diode laser
3090137|NCT01958437|Experimental|Cognitively intact older adults - ACTIVE tDCS|Group receives active brain stimulation
3090138|NCT01958437|Active Comparator|MCI ACTIVE tDCS|Group receives active brain stimulation
3090139|NCT01958437|Sham Comparator|Cognitively intact older adults - SHAM tDCS|Group receives sham brain stimulation
3090140|NCT01958437|Sham Comparator|MCI SHAM tDCS|Group receives sham brain stimulation
3090141|NCT01958424||women with metabolic syndrome|women undergoing ivf treatment who have BMI>25 and meet the criteria for metabolic syndrome
3090142|NCT01958424||women without metabolic syndrome|women undergoing ivf treatment who have BMI>25 and who do not meet the criteria for metabolic syndrome
3090143|NCT01958411||18FDG-PET/CT|
3090144|NCT01958398|Experimental|Promillekoll|Smartphone app monitoring alcohol use with feedback.
3090145|NCT01958398|Experimental|PartyPlanner|Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
3090146|NCT01958398|No Intervention|Control|Untreated control group
3090147|NCT01958385|Active Comparator|Treatment group|The treatment of obese patients with the placement of g-Cath EZ suture anchors along with Diet and Exercise
3090148|NCT01958385|Sham Comparator|Sham Group|The treatment of obese patients with the sham procedure along with Diet and Exercise
3090149|NCT01958372|Experimental|Group I (squamous cell histology)|Patients receive etoposide IV over 1 hour on days 1-5 and 29-33, cisplatin IV over 1 hour on days 1, 8, 29, and 36, and undergo RT 5 days a week for 6.6 weeks. Within 48 hours of initiating treatment, patients receive soy isoflavones PO daily on days 1-90.
3090150|NCT01958372|Experimental|Group II (non-squamous cell histology)|Patients receive pemetrexed disodium IV over 10 minutes on days 1, 22, and 43 and cisplatin IV over 1 hour on days 1, 22, and 43. Patients also undergo RT and receive soy isoflavones as in Group I.
3090151|NCT01958359|Experimental|Short IVR|IVR-based alcohol diary with feedback
3090152|NCT01958359|Experimental|Therapeutic IVR|IVR-based conversation offering a menu of exercises and vignettes.
3090153|NCT01958359|No Intervention|Control|Untreated control group
3090154|NCT01958346|Sham Comparator|Fiberoptic Intubation Alone|Intubation with fiberoptic scope assistance
3090155|NCT01958346|Experimental|Fiberoptic Intubation with lingual traction|Intubation with fiberoptic scope assistance and lingual traction maneuver provided by a second anesthesiologist
3090156|NCT01958333|Experimental|Exercise 1|Low-intensity, low-volume cardiorespiratory exercise and strength training
3090157|NCT01958333|Experimental|Exercise 2|Medium-intensity, medium-volume cardiorespiratory exercise and strength training
3090158|NCT01958333|Experimental|Exercise 3|High-intensity, High-volume cardiorespiratory exercise and strength training
3090159|NCT01958320|Experimental|Early treatment|"Infants randomized to the early treatment group will receive pharmacologic treatment of the PDA to produce PDA closure. Within 24-36 hr following the last treatment dose an echocardiogram will be obtained to document the degree of ductus closure or patency.~Echocardiograms will be obtained at 1) 10-14 days after study entry (if the PDA was open and of moderate size on the last echocardiogram), and 2) at the time of hospital discharge (if the PDA was open (any size) on the last echocardiogram). The echocardiogram obtained at discharge will be used to determine the need for outpatient follow-up."
3090160|NCT01958320|Active Comparator|Conservative Treatment|"Infants randomized to the Conservative Treatment approach will receive no pharmacologic treatment of the PDA but will be followed to determine if they meet criteria for later PDA rescue treatment (Infants will be eligible for rescue treatment of their persistent PDA if they meet the rescue treatment criteria.)~Echocardiograms will be obtained at 1) 10-14 days after study entry (if the PDA was open and of moderate size on the last echocardiogram), and 2) at the time of hospital discharge (if the PDA was open (any size) on the last echocardiogram). The echocardiogram obtained at discharge will be used to determine the need for outpatient follow-up."
3090161|NCT01958307|Experimental|Intervention|Lifestyle intervention
3090162|NCT01958307|No Intervention|No intervention|Standard prenatal care, short information leaflet about healthy lifestyle in pregnancy
3090163|NCT01958294|Other|MICHI Neuroprotection System|Subjects enrolled into this study will be male or female subjects who are candidates for carotid angioplasty and stenting, who, after meeting all of the eligibility criteria, undergo transcervical Carotid Artery Stenting with carotid flow reversal using the MICHI Neuroprotection System.
3090165|NCT01958281|Experimental|SOF 400 mg + RBV 200 mg (Cohort 2)|Participants with genotype 1 or 3 HCV infection will receive SOF 400 mg (4 × 100 mg tablets or 1 × 400 mg tablet) plus RBV once daily for 24 weeks.
3090166|NCT01958281|Experimental|LDV/SOF (Cohort 3)|Participants with genotype 1 or 4 HCV infection will receive LDV/SOF once daily for 12 weeks.
3090167|NCT01958255|Other|Tobacco cessation counseling|planned intervention for tobacco cessation counseling
3090168|NCT01958242|No Intervention|Preoperative blood harvesting|
3090169|NCT01958229||CHB patients without cirrhosis|
3090170|NCT01958216|Other|Trans-intestinal cholesterol excretion in vivo|Measuring trans-intestinal cholesterol excretion in vivo in bile diverted patients
3090171|NCT01958190|Active Comparator|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
3090172|NCT01958190|Experimental|combination Tacrolimus and Sirolimus|Patients receive combination of low-dose extended release Tacrolimus and low-dose Sirolimus
3090173|NCT01958177|Other|BMMNC|Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
3090174|NCT01958164|Experimental|Actilyse 2 mg/2 ml|First dose of Actilyse 2mg/2ml will be given at time 0. Second dose will be given at 120 if CVAD function has not been restored.
3090175|NCT01958164|Sham Comparator|Saline solution (NaCl 0.9%)|Saline solution will be given at time 0. First dose of Actilyse 2mg/2ml will be given to patients if CVAD function has not been restored.
3090176|NCT01958151||Sedated colonoscopy|"Planned colonoscopies for screening under propofol sedation titrated to reach a bispectal index value of 60.~Anxiety levels are assessed before the procedure with State-Trait Anxiety Inventory Scores."
3090177|NCT01958138|Experimental|propofol with Isoflurane|Propofol with Isoflurane, Group-P is the intervention arm with combination of two drugs such as low dose propofol and with reduced MAC of Isoflurane.
3090178|NCT01958138|Active Comparator|group-D|The group-D is the control arm of study by using the only Isoflurane 1.2 MAC
3090179|NCT01958125|Active Comparator|gammacore|gammacore active device to be used noninvasively to the vagal nerve in the neck.
3090180|NCT01958125|Placebo Comparator|inactive gammacore|same as the active treatment, but without the therapy treatment provided
3090181|NCT01958112|Experimental|GSK1120212 (trametinib) and GSK2141795|GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles
3090182|NCT01958099|Other|Injury Prevention Specialist|
3090183|NCT01958099|Experimental|Kiosk Intervention|
3090184|NCT01958086|Experimental|Neural Communication System|The Neural Communication System consists of two Neuroport Arrays, which are descried in detail in the intervention description. Both Neuroport Arrays are inserted into Brodmann's Area 5 in the posterior parietal cortex, an area of the brain used in reach planning. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to use thought to control a simple computer environment or a tablet computer.
3090185|NCT01958073|Experimental|Conjugated Estrogen Vaginal Cream|Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly
3090186|NCT01958073|Experimental|Estradiol Ring|Estradiol Ring per vagina every 3 months
3090187|NCT01958073|Placebo Comparator|Placebo|Per vagina
3090188|NCT01958060|Experimental|BI 1034020 intravenous part|single rising doses
3090189|NCT01958060|Experimental|BI 1034020 subcutaneous part|single rising doses
3090190|NCT01958047|Experimental|ASP3652|One single dose
3090191|NCT01958034|Experimental|Dietary supplement with bilberry extract|Billberry powder 3 times daily for 2 months.
3090192|NCT01958034|No Intervention|Control|No dietary supplement with bilberry extract
3090193|NCT01958021|Experimental|LEE011 + letrozole|LEE011 (Ribociclib) oral (3 weeks on/ 1 week off) in combination with oral once daily letrozole. 600mg LEE011 QD + 2.5 mg letrozole QD
3090194|NCT01958021|Placebo Comparator|Placebo + letrozole|Matching ribociclib placebo was the control drug and was administered orally once daily.
3090195|NCT01958008|Experimental|BI 113608 low dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
3090196|NCT01958008|Experimental|BI 113608 medium dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
3090197|NCT01958008|Experimental|BI 113608 high dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
3090198|NCT01957995|Experimental|Arm I (lowest dose NDLS)|Patients receive lowest dose nanosomal docetaxel lipid suspension IV over 1 hour.
3090199|NCT01957995|Experimental|Arm II (low dose NDLS)|Patients receive low dose nanosomal docetaxel lipid suspension IV over 1 hour.
3090200|NCT01957995|Experimental|Arm III (high dose NDLS)|Patients receive high dose nanosomal docetaxel lipid suspension IV over 1 hour.
3090201|NCT01957995|Experimental|Arm IV (highest dose NDLS)|Patients receive highest dose nanosomal docetaxel lipid suspension IV over 1 hour.
3090202|NCT01957969||Principal Population|Patients who undergo a definitive neuro-stimulator implantation.
3090203|NCT01957969||Annex Population|Patients who do not respond to the temporary test for the neurostimulator implantation
3090204|NCT01957956|Experimental|Treatment (vaccine therapy and temozolomide)|"COURSE 1: Patients receive temozolomide PO daily on days 1-5.~COURSES 2-3: Patients receive temozolomide PO daily on days 1-5 and malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 1, 3, and 5.~COURSES 4-6: Patients receive temozolomide PO daily on days 1-5 and malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on day 1.~COURSES 7-12: Patients receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on day 1.~Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3090205|NCT01957943|Placebo Comparator|Control|38 patients Will receive standard oral diet 3 days before the operation will receive similar volume of 10% glucose solution Will receive same solution for 5 days postoperatively
3090206|NCT01957943|Active Comparator|OMEGA_PRE|38 patients Will receive standard oral diet 3 days before the operation will receive lipid supplementation 2 days before the operation with omega 3 enriched lipid emulsion (SMOFlipid) Will receive omega 3 enriched lipid emulsion (SMOFlipid) supplementation for 5 days postoperatively
3090348|NCT01957007|Experimental|vantictumab|Drug: vantictumab - administered intravenously
3090822|NCT01953887|Experimental|3: tamsulosin|
3090207|NCT01957943|Active Comparator|OMEGA_POST|38 patients Will receive standard oral diet 3 days before the operation will receive glucose 10% solution 2 days before the operation Will receive omega 3 enriched lipid emulsion (SMOFlipid 20%) supplementation for 5 days postoperatively
3090208|NCT01957930||Intensified insulin treatment|
3090209|NCT01957930||Standard-treatment|Continuing with routine diabetes care
3090210|NCT01957917|Experimental|NAC + Food Assistance|Arm 1 participants will receive NAC (nutritional assessment and counseling), plus a food ration once a month for 6 months if they continue their regular HIV care.
3090211|NCT01957917|Experimental|NAC + Cash Transfer|Arm 2 participants will receive NAC (nutritional assessment and counseling), plus a cash transfer equivalent in value to the food transfer once a month for 6 months if they continue their regular HIV care.
3090212|NCT01957917|Active Comparator|NAC Only|Arm 3 participants will receive NAC (nutrition assessment and counseling) only, which is the standard of care at the selected health facilities.
3090213|NCT01957904|Other|ArterX Surgical Sealant|
3090214|NCT01957878|Experimental|HPV therapeutic vaccine|ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod
3090215|NCT01957878|Placebo Comparator|Placebo matching ProCervix|Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod
3090216|NCT01957865|Experimental|Fixed SMS, real-time monitoring|SMS will be sent daily for one month, then weekly for two months. Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
3090217|NCT01957865|Experimental|Triggered SMS, real-time monitoring|Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
3090218|NCT01957865|No Intervention|control|Real-time adherence monitoring only (no SMS)
3090219|NCT01957852||FloSeal +|Routine use of Floseal during cytoreductive and HIPEC surgery
3090220|NCT01957852||FloSeal -|FloSeal not used during CRS and HIPEC procedure
3090221|NCT01957839|No Intervention|pretreatment group|doppler evaluation at pretreatment period
3090222|NCT01957839|Experimental|posttreatment group|doppler evaluatıon in normoprolactinemia women who given cabergoline treatment
3090223|NCT01957826|Placebo Comparator|placebo comparator|transendocardial injection of placebo solution
3090224|NCT01957826|Experimental|bone marrow-derived MSCs injection|transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
3090225|NCT01957813|Other|Standard Health Services|Service currently being provided to FSW in Naivasha include peer education and health services delivered through a drop-in center (DIC) staff by a counselor and a nurse. For peer education, there are six modules that the peer educators walk all peers through with sessions being held once a week.
3090226|NCT01957813|Experimental|LifeStyle Counseling|A package of enhancements to the current package of services delivered to FSW will be implemented and evaluated.
3090227|NCT01957800|Experimental|Website|Group will be asked to complete a daily plan online for specific situations that tempt people to overeat. The website can be accessed online using a computer or smart phone and will allow participants to view others' plans. Participants will also be asked to enter their weight online every week.
3090228|NCT01957800|Active Comparator|Usual Care|Group will be given access to the online intervention after the 3-month study ends.
3090229|NCT01957787|Other|Cryoablation|Freezing of the tumor(s)
3090230|NCT01957774|Experimental|THR-18|
3090231|NCT01957774|Placebo Comparator|Placebo|matching placebo; look-alike with no active ingredients
3090232|NCT01957761||Clostridium difficile infection|
3090233|NCT01957748|No Intervention|Standard of Care (SoC)|Subjects randomized to the Standard of Care Arm will receive their HIV clinic's current standard of care retention services.
3090234|NCT01957748|Active Comparator|SoC + ALERT Intervention|Subjects randomized into the ALERT Enhanced Retention Intervention Arm will receive SoC at the HIV clinic where subjects are seen. In addition to SoC, the Intervention arm will receive aggressive engagement efforts by the ALERT specialist to ensure visit continuity and retention into care. The ALERT specialist will also administer an education intervention consisting of 5 retention modules designed to improve HIV knowledge and self-efficacy, and will also monitor health care visits and intervene via methods to track, find, and re-engage patients during the study.
3090235|NCT01957735|Experimental|BP31510 monotherapy|"Starting dose level of BPM31510 will be 66 mg/kg administered by IV infusion over 48 hours 2 times per week of each 28-day cycle.The 2 doses will be administered over 4 consecutive days.The study drug will be administered undiluted via a central venous access device and the infusion rate will be controlled by a programmable ambulatory infusion pump.~first dose of each week of the cycle a loading dose will be infused over 1 hour with the remainder of the dose volume infused over 47 hours.At each dose level of Arm 1 and Arm 2, patients will be treated for either 8 hours at minimum of outpatient monitoring or inpatient monitoring for the first 24-hrs of the first infusion of Cycle 1.~second dose of each week of the cycle, the total dose volume given over 48 hours with no loading dose."
3090236|NCT01957735|Active Comparator|BP31510 in combination with chemotherapy|"standard 3+3 design will be used for Arm 2 of the study. BPM31510 will be started at one dose level below the dose that has been studied and determined to be safe in the monotherapy portion of the trial. Arm 2 patients will be enrolled onto one of 3 chemotherapies, gemcitabine, 5-FU, or docetaxel according to the dose levels below:~Gemcitabine IV once weekly at a starting dose of 600 mg/m2 ;~5-Fluorouracil (5-FU) IV once weekly at a starting dose of 350 mg/m2 with leucovorin (LV) 100 mg/m2; OR~Docetaxel IV once weekly at a starting dose of 20 mg/m2.~Note:Both BPM31510 and the chemotherapy agent can escalate simultaneously in Cohorts 3 and 4 only if there are no DLTs observed in the previous cohorts. If one or more DLTs are observed, then intermediate dose levels will be added where one agent is escalated."
3090237|NCT01957722|Experimental|NOVOCART 3D|Scaffold assisted autologous chondrocyte Implant
3090238|NCT01957722|Active Comparator|Microfracture|considered a typical treatment for articular cartilage repair
3090239|NCT01957709|Experimental|Basic science (interferon gamma and MHC expression)|Patients receive recombinant interferon gamma SC every 7 days for 4 weeks before surgery or thrice weekly for 2 weeks before surgery.
3090240|NCT01957696||Pancreas-Tx recipients; single cohort|This is a prospective, single cohort observational study, aimed at using a historical control group as comparison. It will be conducted at our single, national centre for organ transplantation in Oslo. All pancreas recipients > 18 years of age, who fulfill the inclusion criteria, will prior to transplantation be asked for inclusion.
3090241|NCT01957683|Experimental|Single Arm|
3090242|NCT01957670|Experimental|Treatment with Lacrima medical device|
3090243|NCT01957657|Experimental|Healthy volunteers group 1|Healthy volunteers with normal renal function
3090244|NCT01957657|Experimental|Renal function group 2|Patients with mild renal impairment
3090245|NCT01957657|Experimental|Renal function group 3|Patients with moderate renal impairment
3090246|NCT01957657|Experimental|Renal function group 4|Patients with severe renal impairment
3090247|NCT01957644|Experimental|Schedule A|Volasertib (d1 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
3090248|NCT01957644|Experimental|Schedule B|Volasertib (d 7 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
3090249|NCT01957644|Experimental|Schedule C|Volasertib (d 1 and 7 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
3090250|NCT01957631|Active Comparator|Corticosteroid injection|
3090251|NCT01957631|Experimental|Platelet rich plasma injection|
3090252|NCT01957618||Treatment group|liver cirrhosis group who received indefinite anti-viral treatment
3090253|NCT01957618||Historical control group|Liver cirrhotic patients who were enrolled before 2004 and did not receive treatment during the follow-up
3090254|NCT01957605||prone position|Patient scheduled for surgery in the prone position
3090255|NCT01957592||Subjects with diabetes mellitus (type 2)|
3090256|NCT01957579|Experimental|MEDI-551|
3090257|NCT01957566|Experimental|APS|
3090258|NCT01957553|Experimental|Treatment sequence 1, First Coloplast Test product|Subjects first allocated to Coloplast Test product will after cross-over test SenSura
3090259|NCT01957553|Experimental|Treatment seqence 2; First SenSura|Subjects first allocated to SenSura will after cross-over test Coloplast Test product
3090260|NCT01957540|Experimental|Ticagrelor|Ticagrelor 90mg bid for 15 days
3090261|NCT01957540|Active Comparator|Prasugrel|Prasugrel 10mg od for 15 days
3090262|NCT01957527||Ticagrelor discontinuation|
3090263|NCT01957514||Ancillary-Correlative (sample collection)|Patients undergo collection of tissue biopsy, blood, buccal swab, saliva, and urine at baseline.
3090264|NCT01957501||Major Depressive Disorder Participants|
3090265|NCT01957501||Bipolar Disorder Participants:|
3090266|NCT01957501||Healthy Control Participants|
3090267|NCT01957488|Experimental|Treatment sequence 1; First Coloplast Test product 1|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first allocated to test Coloplast Test product 1 secondly test either:~Coloplast Test product 1 and thereafter Coloplast SenSura~Coloplast Sensura and thereafter Coloplast Test product 2"
3090268|NCT01957488|Experimental|Treatment seqence 2; First Coloplast Test product 2.|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first allocated to test Coloplast Test product 2 secondly test either:~Coloplast Test product 1 and thereafter Coloplast SenSura~Coloplast Sensura and thereafter Coloplast Test product 1"
3090269|NCT01957488|Experimental|Treatment sequence 3, First Coloplast SenSura|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first allocated to test Coloplast SenSura secondly test either:~Coloplast Test product 2 and thereafter Coloplast Test product 1~Coloplast Test product 1 and thereafter Coloplast Test product 2"
3090270|NCT01957475|Experimental|First Coloplast Test product Z; then Coloplast Test product Y|The subjects first test Coloplast Test product Z and after cross-over Coloplast Test product Y
3090271|NCT01957475|Experimental|First Coloplast Test product Y, Then Coloplast Test product Z|The subjects first test test product Y and after cross-over test product Z
3090272|NCT01957462|Experimental|FirstColplast Test V, Then Coloplast Test X|The subject tests two experimental coloplast products in a randomised order. Coloplast Test product V and after cross over ColoplastTest product X
3090273|NCT01957462|Experimental|First Coloplast Test X, Then Coloplast Test V|The subjects test the two experimental Coloplast products in a randomised order: Coloplast Test product X and after cross over Coloplast Test product V
3090274|NCT01957449|Active Comparator|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
3090275|NCT01957449|Placebo Comparator|Sugar Pill|Placebo by mouth given daily throughout hospitalization for up to 12 months
3090276|NCT01957436|Active Comparator|Arm A|androgen deprivation therapy + docetaxel
3090277|NCT01957436|Experimental|Arm B|androgen deprivation therapy + docetaxel + abiraterone acetate + prednisone
3090278|NCT01957436|Experimental|Arm C|Arm A + radiotherapy
3090279|NCT01957436|Experimental|Arm D|Arm B + radiotherapy
3090280|NCT01957423|Experimental|Whey protein|Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
3090281|NCT01957423|Active Comparator|Soy protein|Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
3090282|NCT01957410|Experimental|Ketamine Intravenous (IV)|Patients will receive a single IV dose of ketamine given as a continuous infusion.
3090283|NCT01957410|Placebo Comparator|Placebo Intravenous (IV)|Patients will receive a single IV dose of placebo given as a continuous infusion.
3090284|NCT01957397|Experimental|Coloplast Test 1|"The subjects are randomised to two arms~In both arms the subjects start measuring the performance of own product to collect baseline data.~In this arm the subjects are randomised to test Coloplast Test1 first and thereafter Coloplast Test 2~Finally the all subject test Coloplast Test 3"
3090349|NCT01956994|Experimental|Whey protein supplement|Subjects will be instructed to consume 40 g whey protein each day for 12 weeks.
3090285|NCT01957397|Experimental|Coloplast Test 2|"The subjects are randomised to two arms~In both arms the subjects start measuring the performance of own product to collect baseline data.~In this arm the subjects are randomised to test Coloplast Test 2 first and thereafter Coloplast Test 1~Finally the all subject test Coloplast Test 3"
3090286|NCT01957384|Experimental|Treatment 1; First Coloplast Test product 1|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first testing Coloplast Test product 1 are randomised to secondly test either:~Coloplast Test product 2 and thereafter Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)~Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)and thereafter Coloplast Test product 2"
3090287|NCT01957384|Experimental|Treatment 2; First Coloplast Test product 2.|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first testing Coloplast Test product 2 are randomised to secondly test either:~Coloplast Test product 1 and thereafter Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)~Standard Care Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)and thereafter Coloplast Test product 1"
3090288|NCT01957384|Experimental|Treatment 3,First Standard care (see below)|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first testing Standard Care Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active) are randomised to secondly test either:~Coloplast Test product 1 and thereafter Coloplast Test product 2~Coloplast Test product 2 and thereafter Coloplast Test product 1"
3090289|NCT01957371|Experimental|Mindful Yoga Therapy|12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
3090290|NCT01957358|Experimental|Lifestyle counselling using the Grief Recovery Method|Volunteers will participate in a series of weekly and twice-weekly sessions with a counselor who has obtained special training in the Grief Recovery Method.
3090291|NCT01957345|Other|bleeding disorder|"Blood punction at patients with bleeding disorder definitely other than of platelet origin (e.g. low von Willebrand)"
3090292|NCT01957345|Other|constitutional platelet disorder|Blood punction at patients with constitutional platelet disorder (e.g. Glanzmann thrombasthenia)
3090293|NCT01957345|Other|defect of platelet function|Blood punction at patients with defect of platelet function of unknown origin, potentially defective in signalling pathway.
3090294|NCT01957332|Experimental|Molecular imaging|All patients receive 18F-FES (~200MBq) injection followed by a FES-PET. On the same day or the day after 18F-FES injection 89Zr-trastuzumab (~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
3090295|NCT01957319|Active Comparator|Silybin - vitamin E - phospholipids complex|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill for 12 months.
3090296|NCT01957319|Placebo Comparator|placebo|sugar pill
3090297|NCT01957306|Experimental|Dr. Tagliaferri's Menoapause Formula|Administered as 2 grams PO BID.
3090298|NCT01957293|Experimental|Salbutamol|
3090299|NCT01957293|Placebo Comparator|Sugar Syrup|
3090300|NCT01957280|Experimental|Process 2 patritumab|Process 2 patritumab 18 mg/kg (loading dose) on Day 1 of Cycle 1 followed by Process 2 patritumab 9 mg/kg (maintenance dose) once every 21 days starting on Day 1 of Cycle 2 through Cycle 5.
3090301|NCT01957267||Glaucoma Group|Patients with clinically confirmed glaucomatous ONH or NFL defects, with or without VF abnormalities
3090302|NCT01957267||Normal Group|Volunteers with healthy eyes
3090303|NCT01957254||Severe Sepsis|Patient with severe sepsis
3090304|NCT01957241||Hepatocellular Carcinoma and Esophageal Cancer|
3090305|NCT01957228|Experimental|bone biopsies|
3090306|NCT01957215|Experimental|Indomethacin patch|Indomethacin patch to be applied on the sprained ankle twice a day (BID).
3090307|NCT01957215|Placebo Comparator|Placebo patch|Placebo patch to be applied on the sprained ankle BID.
3090308|NCT01957202|Experimental|Arm 1|Each Subject will be assigned to a sequence of three treatments (e.g ABC, BCD, ACD): A=Two, 50 microliter (mcqL) sprays per nostril of FF, total dose 100 microgram (mcg); B=Two, 50 mcqL sprays per nostril of levocabastine, total dose 200 mcg; C=Two, 50 mcql sprays per nostril of FF/levocabastine FDC, total daily dose 100 mcg FF and 200 mcg levocabastine; D=Two, 50 mcql sprays per nostril of placebo. There will be a wash out period of 14-28 days between two treatment periods
3090309|NCT01957189|Experimental|Dutasteride with/ without Tamsulosin|All subjects will be assigned to the same treatment group
3090310|NCT01957176|Experimental|Cohort A|Cohort A consists of subjects who had completed their treatment with eltrombopag (ELT) during their participation in a parent study for Myelodysplastic syndrome (MDS)/ Acute myeloid leukemia (AML). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 50 to 300 mg once daily (OD) for subjects of non- East Asian heritage. The dose ranges for subjects of East Asian heritage (i.e. Japanese, Chinese, Taiwanese, Thai and Korean) will be 25 to 150 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts.
3090311|NCT01957176|Experimental|Cohort B|Cohort B consists of adult subjects who have completed study treatment with ELT during their participation in a parent study for Idiopathic thrombocytopenic purpura (ITP). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 12.5 to 75 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts.
3090312|NCT01957176|Experimental|Cohort C|Cohort C consists of pediatric subjects who have completed study treatment with ELT during their participation in a parent study for Idiopathic thrombocytopenic purpura (ITP). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 12.5 to 75 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts.
3090313|NCT01957163|Experimental|FF/VI 100/25 mcg + UMEC (62.5mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via a DPI followed by one inhalation UMEC (62.5mcg) via DPI once-daily in the morning for 12 weeks.
3090314|NCT01957163|Experimental|FF/VI 100/25 mcg + UMEC (125mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of UMEC (125mcg) via a DPI once-daily in the morning for 12 weeks.
3090315|NCT01957163|Experimental|FF/VI 100/25 mcg + Placebo|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of matching placebo via a DPI once-daily in the morning for 12 weeks.
3090316|NCT01957150|Experimental|Fluticasone Furoate/Vilanterol 100/25 micrograms (mcg) QD|Subjects will self administer FF/VI 100/25 mcg inhalation powder once daily for 156 weeks via the NDPI.
3090317|NCT01957150|Experimental|Vilanterol 25 mcg QD|Subjects will self administer VI 25 mcg inhalation powder once daily for 156 weeks via the NDPI.
3090318|NCT01957137|Other|Continuous|The device parameter will be continuous.
3090319|NCT01957137|Other|Cycling Parameter #1|The device parameter will be cyclic program #1.
3090320|NCT01957137|Other|Cycling Parameter #2|The device parameter will be cyclic program #2.
3090321|NCT01957137|Other|Cycling Parameter #3|The device parameter will be cyclic program #3.
3090322|NCT01957137|Other|No Stimulation|Following the randomized portion of the study, an assessment was conducted to estimate the effect of a month of no stimulation on incontinence.
3090323|NCT01957124|Experimental|PRF application|
3090324|NCT01957111||Individuals with insomnia|
3090325|NCT01957111||Good sleepers|
3090326|NCT01957098|Placebo Comparator|0% pentose|Pure sucrose without pentoses added.
3090327|NCT01957098|Active Comparator|4% D-xylose|Sucrose drink supplemented with 4% D-xylose
3090328|NCT01957098|Active Comparator|8% D-xylose|Sucrose drink supplemented with 8% D-xylose
3090329|NCT01957098|Active Comparator|8% L-arabinose|Sucrose drink supplemented with 8% L-arabinose
3090330|NCT01957085||Hospitalized Patients|All patients admitted to Temple University Hospital on the study day
3090331|NCT01957072|Experimental|Behaviour change intervention|Intensive behaviour change intervention for 3 months, followed by a maintenance phase for 3 months
3090332|NCT01957072|Other|Wait-list Control|Usual care for 3 months, followed by intensive behaviour change intervention for 3 months
3090333|NCT01957059|Experimental|Dose escalation phase|In the dose-escalation phase, following screening assessment, two cohorts of three subjects each receive two single doses of BMN 053 in two study periods (i.e., four single doses in total per subject). In each study period they will receive BMN 053 by IV infusion and by SC injection (separated by one week). The proposed doses are 1 mg/kg (Cohort 1, study period 1), 3 mg/kg (Cohort 2, study period 1), 6 mg/kg (Cohort 1, study period 2) and 9 mg/kg (Cohort 2, study period 2). The actual doses may be amended or repeated based on emerging data from previous doses.
3090334|NCT01957059|Experimental|Regimen selection|After completion of the dose-escalation period of Cohort 1, the safety data of the subjects will be reviewed by a DSMB and if no safety concerns these subjects will continue to receive 6 mg/kg BMN053 weekly by SC injection for 48 weeks. 3 more treatment-naïve subjects will be entered into this Group. These 6 subjects will form Group 1 of the Regimen Selection phase who received 6 mg/kg SC. At the time of this amendment (4) this part of the study has been completed. Following completion of the dose-escalation study period of Cohort 2 (9 mg/kg), the planned review of the preliminary plasma PK data from the dose-escalation phase showed a relative bioavailability of 50% for BMN053 with SC dosing (50% lower plasma AUC after SC dosing compared to IV dosing). Taking into consideration the risk of injection site reactions noted with similar compounds when administered SC over longer term, the planned 9 mg/kg BMN053 weekly by SC injection will be discontinued to be replaced by an IV regimen.
3090335|NCT01957059|Experimental|48-week Treatment Phase|"Thirty additional treatment-naïve subjects will be recruited for the primary evaluation and will receive treatment at the recommended regimen for a total of 48 weeks. Subjects dosed initially in the dose escalation phase and/or the regimen selection phase of the study will not be included in the primary analysis.~Following completion of the 2nd study period for Cohort 2, the safety data will be reviewed by the DSMB and in the absence of safety concerns the subjects may enter the 48 week treatment phase and receive 9 mg/kg PRO053 once weekly by SC injection. Three new subjects will enter cohort 2 (i.e. 6 subjects in total at this dose level).~After the initial 12 subjects have completed 12 weeks of dosing the dose for the Treatment group (30 new subjects) will be selected based on the totality of the 12-week data from those initial 12 subjects. The initial 12 subjects will also be dosed on the selected dose (i.e. continue on their dose or [down-]titrate)."
3090336|NCT01957059|Experimental|Dosing extension|All subjects who have completed the dose escalation and regimen selection phase of the study (N=15), and subjects who have complete the treatment phase of the study who have tolerated the treatment will be offered to continue dosing in the dosing extension with ongoing assessment of efficacy, safety, and tolerability of BMN 053. Safety, efficacy, PK/PD and biomarker assessments will be performed at scheduled visits; adverse events (AEs) and concomitant medications and therapies will be continuously monitored. The dose extension phase will provide BMN 053 treatment for 48 weeks.
3090337|NCT01957046|Other|Oral Laxative|
3090338|NCT01957033|Experimental|Duration 6 weeks, frequency 3/week|Exercise and education 3 times/week for 6 weeks Manual therapy 3 times/week for 6 weeks
3090339|NCT01957033|Experimental|Duration 6 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks Manual therapy twice/week for 6 weeks
3090340|NCT01957033|Experimental|Duration 6 weeks, Frequency once/week|Exercise and education once/week for 6 weeks Manual therapy once/week for first 6 weeks
3090341|NCT01957033|Experimental|Duration 3 weeks, Frequency 3 times/week|Exercise and education 3 times/week for 6 weeks Manual therapy 3 times/week for first 3 weeks
3090342|NCT01957033|Experimental|Duration 3 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks Manual therapy twice/week for first 3 weeks
3090343|NCT01957033|Experimental|Duration 3 weeks, frequency once/week|Exercise and education once/week for 6 weeks Manual therapy once/week for first 3 weeks
3090344|NCT01957033|Experimental|Duration 0 weeks, Frequency 3 times/week|Exercise and education 3 times/week for 6 weeks No manual therapy
3090345|NCT01957033|Experimental|Duration 0 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks. No manual therapy
3090346|NCT01957033|Experimental|Duration 0 weeks, Frequency once/week|Exercise and education once/week for 6 weeks No manual therapy
3090347|NCT01957007|Experimental|Docetaxel|Drug: Docetaxel - administered intravenously
3110401|NCT01820689|Experimental|Tympanometry measurement|
3090350|NCT01956994|Active Comparator|Carbohydrate supplement|Subjects will be instructed to consume a carbohydrate supplement (iso-caloric to the whey supplement) each day for 12 weeks.
3090351|NCT01956981|Placebo Comparator|Magnesium|40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.
3090352|NCT01956981|Active Comparator|Dexmedetomidine|1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
3090353|NCT01956955|Active Comparator|enoxaparin and alteplase|After alteplase therapy , 4-6 hour later, activated partial thromboplastin time (APTT) was checked. According to initial SC LMWH use time, fixed dose SC LMWH, enoxaparin, was administered subcutaneous every 12 hours.
3090354|NCT01956955|Active Comparator|Unfractionated heparin and alteplase|After thrombolytic treatment, a bolus of 10 mg of alteplase followed by 90 mg over 2-h infusion, patients either administered a constant heparin infusion (18 U/Kg per hour) adjusted to maintain an activated partial thromboplastin time of 46-70 s.
3090355|NCT01956942|Experimental|Micropulse Laser Trabeculoplasty|Patient's randomized to MLT would be treated with the following settings: 300 micron spot size, 0.3 second duration, 15% duty cycle, and 1000 milliWatt power. They would be treated with confluent laser spots across the entire 360 degrees of the trabecular meshwork. Each patient would receive pre-treatment with a drop on iopidine or brimonidine to prevent post-operative intraocular pressure (IOP) spikes as per standard pre-laser trabeculoplasty protocol.
3090356|NCT01956942|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Patient's randomized to SLT would be treated with the following settings: 400 micron spot size, 0.3 second duration, and 1.00 milliWatt (mW) power. They would be treated with confluent laser spots across the entire 360 degrees of the trabecular meshwork. Each patient would receive pre-treatment with a drop on iopidine or brimonidine to prevent post-operative IOP spikes as per standard pre-laser trabeculoplasty protocol.
3090357|NCT01956929|Experimental|Metformin|2 weeks of Metformin use. First week 1000mg/day, Second week Max dose of 2000 mg/day.
3090358|NCT01956929|Placebo Comparator|Placebo|2 weeks of Placebo (lactulose pills)
3090359|NCT01956916|Experimental|Probiotics|Capsules containing lyophilized 6x10^9 Colony Forming Units (CFU)/die of Lactobacillus rhamnosus GG (LGG)
3090360|NCT01956916|Placebo Comparator|Placebo|Capsules containing maltodextrin
3090361|NCT01956903|Experimental|Allogenic Mesenchymal Stem Cell|Sequential Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell (MSC). Dosage 0,7 x 10e6 MSC/Kg/dose (cumulative minimum dose: 2,8 x 10e6 CSM/Kg.
3090362|NCT01956890|Other|diagnostic accuracy|diagnostic accuracy of PET and MRI for breast cancer diagnosis.
3090363|NCT01956877||Healthy volunteers|
3090364|NCT01956864|Experimental|Dose VD 1|Vitamin D
3090365|NCT01956864|Experimental|Dose VD 2|Vitamin D
3090366|NCT01956864|Experimental|Dose VD 3|Vitamin D
3090367|NCT01956864|Experimental|Dose VD 4|Vitamin D
3090368|NCT01956864|Experimental|Dose VD 5|Vitamin D
3090369|NCT01956864|Experimental|VD 6 Month Treatment|Vitamin D
3090370|NCT01956851||Normal Healthy|Normal Healthy: includes healthy patients eligible for enrolment,
3090371|NCT01956851||Diabetics on Oral Hypoglycemic Agents|Diabetics on Oral Hypoglycemic Agents: includes diabetic patients on oral diabetic drug therapy with all eligibility criterion fulfilled,
3090372|NCT01956851||Diabetics on Insulin Therapy|Diabetics on Insulin Therapy: includes diabetic patients on insulin therapy with all eligibility criterion fulfilled
3090373|NCT01956838|Experimental|Umami|intraduodenal infusion of umami
3090374|NCT01956838|Experimental|sweet|intraduodenal infusion of sweet tastant
3090375|NCT01956838|Experimental|bitter|intraduodenal infusion of bitter tastant
3090376|NCT01956838|Experimental|combination|intraduodenal infusion of a combination of tastants (umami, bitter and sweet)
3090377|NCT01956838|Placebo Comparator|placebo|intraduodenal infusion of placebo (tap water)
3090378|NCT01956825|Placebo Comparator|water|just water
3090379|NCT01956825|Experimental|"L-CARNITINE AND MAGNESIUM (slim water product)"|"The experimental arm will receive a product slim water, which contains 150 mg magnesium lactate and 2000 mg L-carnitine. The purpose is to follow the patients and examine several metabolic parameters over time (liver function test, lipid profile, liver fat content, etc.) and by that to show and prove the positive effect of the experimental treatment over placebo."
3090380|NCT01956812|Experimental|Arm A IMMU-107 and gemcitabine|IMMU-107 and low dose gemcitabine
3090381|NCT01956812|Active Comparator|Arm B Placebo and low dose gemcitabine|Placebo and low dose gemcitabine
3090382|NCT01956786|Active Comparator|Amlodipine|5mg amlodipine,once daily for 8 weeks
3090383|NCT01956786|Experimental|Amlodipine-FA tablet,low dose group|5mg amlodipine combined with 0.4mg of folic acid (FA),once daily for 8 weeks.
3090384|NCT01956786|Experimental|Amlodipine-FA tablet,high dose group|5mg amlodipine combined with 0.8mg of folic acid (FA),once daily for 8 weeks.
3090385|NCT01956773|Active Comparator|MeTree|MeTree collects family health history data and generates risk scores and specific risk-based recommendation for preventive care to patients and providers as clinical decision support.
3090386|NCT01956773|No Intervention|Control|to compare rates of risk management strategies in standard care during the time of MeTree use in the intervention arm.
3090387|NCT01956760|Experimental|Acupuncture|Acupuncture and intradermal acupuncture The acupuncture was applied at 5 acupoints(HT7 Shenmen, PC6 Neiguan, SP6 Sanyinjiao, KI6 Zhaohai, BL62 Shenmai) 3 times in a week. It was performed by a certified practitioner with sterile needles (0.25*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same acupoints, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20*8.0mm).attached to skin tape (10.0*10.0mm). The needles were inserted 3.0~5.0mm deep and maintained for 48~72 hours
3090445|NCT01956305|Experimental|Cohort C DS-7309 40 mg|DS-7309 40 mg twice daily
3090446|NCT01956305|Experimental|Cohort D DS-7309 75 mg|DS-7309 75 mg twice daily
3090447|NCT01956305|Experimental|Cohort E DS-7309 150 mg|DS-7309 150 mg twice daily
3090388|NCT01956760|Placebo Comparator|Placebo Acupuncture|Placebo acupuncture and placebo intradermal acupuncture The acupuncture was applied 3 times in a week at 2 sham points on the wrist and 3 sham points on the ankle, approximately 1cm lateral to the acupoints. It was performed by a certified practitioner with sterile needles (0.25*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same sham points, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20*8.0mm).attached to skin tape (10.0*10.0mm). The needles were inserted 3.0~5.0mm deep and maintained for 48~72 hours
3090389|NCT01956747||standard anticancer treatment|Patients older than 70 years of age with advanced malignancies of colorectum, breast or prostate, who will start with full standard anticancer treatment as decided by their oncologist.
3090390|NCT01956734|Experimental|DNX2401 and Temozolomide|"DNX2401: Virus injection in the brain parenchyma. Total dose will be 3x1010 vp suspended in 1 ml for all cases.~Temozolomide: 14 (window 14-28 days) days after the virus injection, patients will begin therapy with temozolomide in a dose of 150mg/m2 in days 1-7 and 15 -21 of a 28 days cycle, (dose dense scheme 7 days on, 7 days off), until a maximum of 2 x 28 days cycles in absence of toxicity."
3090391|NCT01956721|Experimental|Patients with heart failure (FEVG ≥ 50%)|Patients with heart failure (FEVG ≥ 50%)
3090392|NCT01956721|Experimental|Patients with heart failure (FEVG ≤ 35%),|Patients with heart failure (FEVG ≤ 35%),
3090393|NCT01956721|Other|Healthy Volunteers|Healthy Volunteers with no heart failure
3090394|NCT01956708|Active Comparator|RIPC|"Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):~after induction of anesthesia and before surgery: 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200mmHg and 5 minutes of reperfusion Anesthesia is with isoflurane (0.7-0.8% end-tidal) +sufentanil"
3090395|NCT01956708|Placebo Comparator|Placebo|"No Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):~after induction of anesthesia and before surgery: the cuff is left uninflated"
3090396|NCT01956695|Experimental|Lenalidomide & Rituximab|"Induction treatment : Lenalidomide 20 mg capsule on days 1 to 21 days of a 28 days cycle for the first cycle followed by 25 mg on daily on days 1 to 21 of a 28 days cycle for cycles 2 to 8 (in the absence of hematologic toxicity. Rituximab at day 1 of each induction course 375 mg/m² intravenous.~Maintenance : Lenalidomide 10 mg capsule on days 1 to 21 days of a 28 days cycle for 1 year or until progression or intolerance."
3090397|NCT01956682|Active Comparator|Infant formula|HA formula + starch + L. reuteri
3090398|NCT01956682|Placebo Comparator|Standard Formula|Standard Infant Formula
3090399|NCT01956669|Experimental|Pazopanib|Subjects will be treated with pazopanib GW786034 tablets at a dose of 450 mg/m^2/dose or as a powder in suspension at a dose of 225 mg/m^2/dose. The first subjects receiving powder for oral suspension will have extended pharmacokinetic sampling and will be closely monitored for safety and for occurence of DLTs . The maximum dose to be administered daily for tablets is 800 mg and for suspension is 400 mg. If 225 mg/m^2/dose is not tolerated (>=2 DLTs in 6 evaluable subjects), the dose for subjects who require suspension may be reduced to 160 mg/m^2/dose. A cycle will be defined as 28 days with no rest periods between cycles.
3090400|NCT01956656|Placebo Comparator|lotus leaf mouthwash|10 ml mouthwash to be used for 4days twice daily
3090401|NCT01956656|Placebo Comparator|placebo mouthwash|10 ml mouthwash to be used for 4 days twice daily
3090402|NCT01956643|Experimental|gum chewing|"Gum type was standardized with all subjects receiving sugar-free xylitol gum.~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (two tablets) 3 times daily in the morning, afternoon, and evening for 15 min. The administration of the therapy was implemented by ICU nurses and recorded in the clinical report form file. All gum-chewing patients completed their course of gum chewing until gas out."
3090403|NCT01956643|Placebo Comparator|Control|Routine care during NPO
3090404|NCT01956630|Experimental|Genetically modified DCs plus CIK cells|Patients received four subcutaneous injections of 2-5×10e7 cells of DCs at the groin, axilla, and neck respectively on days 7, 9, 11, and 13 and i.v. infusions of 2-15×10e9 CIK on days 11 and 13 per cycle. The cycle was repeated until Wilms' tumor 1(WT1) turned negative by polymerase chain reaction(PCR) or graft-versus-host disease(GVHD) appeared.
3090405|NCT01956630|Active Comparator|Donor leukocyte infusions (DLI)|Patients received DLI at a dose of 2×10e7/kg, 5×10e7/kg and 1×10e8/kg cluster of differentiation 3(CD3)+ cells at months 1, 2 and 3 respectively unless GVHD appeared.
3090406|NCT01956617|Other|injection volume|block success or failure determines a 5 ml decrease or increase for the subsequent patient, respectively
3090407|NCT01956604|Experimental|Clonidine|"Clonidine administered orally:~Day 1/loading doses: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days."
3090408|NCT01956604|Placebo Comparator|Placebo (sugar pill)|"Placebo administered orally (identical capsula as for expirimental drug):~Day 1/loading doases: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days."
3090409|NCT01956591||Axillary hyperhidrosis|Patients whose major complaint is excessive sweating in the axillary region (i.e, sweating in the armpit). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., palmar hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
3090410|NCT01956591||Palmar hyperhidrosis|Patients whose major complaint is excessive sweating in the palmar region (i.e, sweating in the hands). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
3090411|NCT01956591||Plantar hyperhidrosis|Patients whose major complaint is excessive sweating in the plantar region (i.e, sweating in the feet). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
3090412|NCT01956591||Cranio-facial hyperhidrosis|Patients whose major complaint is excessive sweating in the cranio-facial region (i.e, sweating in the face). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
3090448|NCT01956305|Experimental|Cohort F DS-7309 150 mg with escalating metformin doses|DS-7309 150 mg twice daily with escalating metformin doses
3090413|NCT01956591||Other sites hyperhidrosis|Patients whose major complaint is excessive sweating in other sites of the body (e.g., on the chest, on the abdomen). Patients that also have hyperhidrosis - but that are less bothersome on other sites previously grouped (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
3090414|NCT01956578|Experimental|Breathing Exercise Cohort|All patients enrolled will be asked to wear an external respiration band while performing a series of breathing exercises.
3090415|NCT01956565|Experimental|Inspiratory muscle training|Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
3090416|NCT01956565|No Intervention|Declining Inspiratory muscle training|No intervention. Interview and baseline assessment only.
3090417|NCT01956539||Heart Failure|All patients over 18 years with chronic heart failure, and all patients hospitalized for acute heart failure de novo or not. The diagnosis of heart failure is the responsibility of the cardiologist including patient.
3090418|NCT01956526|Experimental|CORolla™ TAA Stand Alone|Single arm study design including with patients with isolated HFpEF, in NYHA f. Cl. III-IV. These patients will receive the CORolla™ TAA device. For assessments of results, intra-patient comparisons of pre-procedure and follow-up data will be performed;
3090419|NCT01956526|Experimental|AVR and CORolla™ TAA Add On group|patients who require aortic valve replacement (AVR) due to aortic stenosis and have diastolic dysfunction will receive the CORolla™ TAA device.
3090420|NCT01956526|No Intervention|AVR and CORolla ADD On - Control|patients who require only the aortic valve replacement (AVR) due to aortic stenosis and have diastolic dysfunction.
3090421|NCT01956500|Experimental|Instaflex|Instaflex Joint Support supplement (3 capsules per day for 8 weeks)
3090422|NCT01956500|Placebo Comparator|Placebo|Placebo (3 capsules per day for 8 weeks)
3090423|NCT01956487|Other|Propafenone|Open label comparison of 2 formulations
3090424|NCT01956474|Other|Theralight crosslinking and Riboflavin|ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using UVA light and the photo- mediator riboflavin
3090425|NCT01956448|Experimental|Drug eluting stent (BioMatrix Flex)|Device: Percutaneous coronary intervention with implantation of drug eluting stent (BioMatrix Flex)
3090426|NCT01956448|Experimental|Drug eluting stent (Resolute Integrity)|Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
3090427|NCT01956435|Other|Excimer Light Treatment Right Leg, Control Left Leg|Excimer light treatment will be performed on the right leg of every subject, no treatment on the left or control leg of the subject.
3090428|NCT01956435|Other|Excimer Light Treatment Left Leg, Control Right Leg|Excimer light treatment will be performed on the left leg of every subject, no treatment on the right or control leg of the subject.
3090429|NCT01956422|Experimental|Continuous Positive Airway Pressure(CPAP)|In the first 24 hours after laparoscopic prostatectomy patients undergo 3 CPAP cycles (PEEP 7.5, FIO2 40% delivered with Helmet)lasting 2 hours.
3090430|NCT01956422|Active Comparator|Venturi Mask FiO2 40%|In the first 24 hours after laparoscopic prostatectomy patients breathe Oxygen 40% delivered with Venturi Mask
3090431|NCT01956409|Experimental|diagnostic accuracy of PET and MR spectroscopy|To investigate the diagnostic accuracy of 18F-Fluorocholine PET and proton MR spectroscopy of breast lesions, using pathology as gold standard.
3090432|NCT01956396|Experimental|Experimental: PrePex™ device|Adult male circumcision by the PrePex™ device
3090433|NCT01956383|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
3090434|NCT01956370|Experimental|PrePex™ device|Intervention 'PrePex™ device for adult male circumcision
3090435|NCT01956370|Active Comparator|Surgical|Adult male surgical circumcision
3090436|NCT01956357|Experimental|Aquatic exercise|"The aquatic aerobic training had a duration of 12 weeks and adopted the interval-training method, with intensities ranging between 85 and 100% of second ventilatory threshold (VT2) and total duration of 45 minute per session.~The sessions consisted of warm up, main part and calm down. The warm-up consisted of a walk in deep water at low intensity for three minutes. The main part was intended to aerobic training in deep water, in which subjects walked and / or ran, depending on your fitness level found in pre-training test. The calm down consisted of walking in deep water at low intensity for two minutes and stretching standardized, emphasizing the muscles worked in the main part of the session, with a total duration of approximately five minutes."
3090437|NCT01956357|Experimental|Land exercise|"The land aerobic training had a duration of 12 weeks and adopted the interval-training method, with intensities ranging between 85 and 100% of second ventilatory threshold (VT2) and total duration of 45 minute per session.~The sessions consisted of warm up, main part and calm down. The warm-up consisted of a walk in athletic track at low intensity for three minutes. The main part was intended to aerobic training in athletic track, in which subjects walked and / or ran, depending on your fitness level found in pre-training test. The calm down consisted of walking in athletic track at low intensity for two minutes and stretching standardized, emphasizing the muscles worked in the main part of the session, with a total duration of approximately five minutes."
3090438|NCT01956344|Experimental|Immediate Treatment|Cognitive-behavioral therapy
3090439|NCT01956344|No Intervention|Delayed Treatment|This group will receive the cognitive-behavioral therapy after a 16 week delay
3090440|NCT01956344|No Intervention|Healthy Control|This group is matched to the immediate treatment group on age and gender. They do not receive an active treatment and will be used a a healthy comparator group.
3090441|NCT01956318|Experimental|Crenobalneotherapy|18 days of balneotherapy session in 3 weeks. Patients are also delivered a booklet with advice on lifestyle.
3090442|NCT01956318|No Intervention|control group|patients are allowed to continue their usual drugs, compression therapy and are delivered a booklet with advice on lifestyle.
3090443|NCT01956305|Experimental|Cohort A 10mg DS-7309|DS-7309 10 mg twice daily
3090444|NCT01956305|Experimental|Cohort B 20mg DS-7309|DS-7309 20 mg twice daily
3090453|NCT01956266|Experimental|Emotional prosodic treatment|The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson & Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate.
3090454|NCT01956266|Active Comparator|Standard prosodic treatment|The standard treatment includes tasks in common clinical use for treating the three main aspects of prosodic insufficiency in PD, pitch/stress, loudness, and rate. To address pitch/stress, the investigators will use contrastive stress tasks. To address rate control the investigators will use hand tapping tasks which have been shown to be effective, and to address loudness, patients will be asked to produce sentences of increasing length while maintaining an appropriate loudness level. Participants will receive clinician feedback regarding accuracy of attempts as well as auditory and visual feedback on accuracy of stress/pitch and loudness control via the VisiPitch display.
3090455|NCT01956240|Experimental|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
3090456|NCT01956240|Experimental|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
3090457|NCT01956227|Experimental|Home-based Exercise|Participants will be taught a series of exercises targeting balance and lower limb strength in four instructional sessions. They will be asked to complete exercises 3 times a week for 12 weeks. Exercise compliance will be recorded with a diary.
3090458|NCT01956227|Experimental|Education|Participants will attend 4 education sessions focusing on interaction of beliefs, behaviors and symptoms on falls. They will be taught self-management principles to modify their fall risk.
3090459|NCT01956227|Experimental|Exercise plus education|Participants will attend 2 instructional exercise sessions as well as 2 education sessions. Participants will be asked to complete exercises at home 3 times per week and engage in behavior to minimize fall risk.
3090460|NCT01956227|No Intervention|Control|Participants will not receive any treatment.
3090461|NCT01956214|Experimental|FES exercise|Participants will receive FES
3090462|NCT01956214|Sham Comparator|Mock FES exercise|participant will receive Mock FES
3090463|NCT01956201|Experimental|Atorvastatin 20mg, Fenofibrate 160mg|Atorvastatin 20mg, Fenofibrate 160mg: po, q.d.
3090464|NCT01956201|Active Comparator|Atorvastatin 20mg, Placebo|Atorvastatin 20mg, Placebo for Fenofibrate 160mg po, q.d.
3090465|NCT01956188|Experimental|EPA and DHA supplementation|EPA (1800mg/d) and DHA (1200mg/d) supplementation
3090466|NCT01956188|Placebo Comparator|Placebo|Soy oil (3000 mg/d)
3090467|NCT01956175|Experimental|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation once daily for 10 minutes on three consecutive days.
3090468|NCT01956175|Sham Comparator|Sham stimulation|Sham stimulation once daily for 10 minutes on three consecutive days. If the subject cannot be decannulated after three days of sham stimulation, another three days of real electrical pharyngeal stimulation will be delivered.
3090469|NCT01956162|Experimental|"Group Orthèse Diabète"|"Using Orthèse Diabète, a new customized removable device with rocker sole for plantar off-loading"
3090470|NCT01956162|Active Comparator|Control Group|"Using Conventional devices, removable off-loading systems among the devices available in France"
3090471|NCT01956149|Experimental|Cabazitaxel|Cabazitaxel 20 mg/m2 over 1 hour i.v., repeated on day 22
3090472|NCT01956136|Experimental|Arm 1|The patients receive 10 weeks of Music-based Neurological Rehabilitation (MBNR) and Standard Care (SC) followed by 10 weeks of SC only.
3090473|NCT01956136|Experimental|Arm 2|The patients receive 10 weeks of Standard Care (SC) only followed by 10 weeks of Music-based Neurological Rehabilitation (MBNR) and SC.
3090474|NCT01956123|Experimental|A|FE 999049
3090475|NCT01956123|Active Comparator|B|Follitropin alfa (Gonal-F)
3090476|NCT01956110|Experimental|A|FE 999049
3090477|NCT01956110|Active Comparator|B|Follitropin Alfa (Gonal-F)
3090478|NCT01956097|Experimental|HX106 590mg|HX106 590mg/day
3090479|NCT01956097|Experimental|HX106 1180mg|HX106 1180mg/day
3090480|NCT01956097|Placebo Comparator|Placebo|Placebo
3090481|NCT01956084|Experimental|LMP1/2 CTLs (Group A)|Patients receiving CTLs as adjunctive therapy following allogeneic stem transplant
3090482|NCT01956084|Experimental|LMP1/2 CTLs (Group B)|Patients receiving CTLs in relapse following allogeneic stem cell transplant
3090483|NCT01956058|Experimental|brachytherapy remedial|
3090484|NCT01956045||Decision making|
3090485|NCT01956032||Participants with Parkinson's disease|"Participants diagnosed with Parkinson's disease and have continued disabling motor complications despite optimized per-oral or other treatment regimens suitable for Duodopa treatment in accordance with the Swedish Summary of Products Characteristics.~Other name for Duodopa is Levodopa Carbidopa Intestinal Gel (LCIG)."
3090486|NCT01956019|Experimental|MRI scanning|patients undergo special MRI techniques (DWI-MRI and DCE-MRI) after their routine MRI examinations while undergoing routine radiotherapy. 3 lots of scans in total. They will also have a blood test.
3090487|NCT01956006|Experimental|MIlrinone|ER milrinone
3090488|NCT01955993||Fentanyl use for surgical pain|Adolescent patient having surgery
3090489|NCT01955980|Experimental|Buparid; Treatment A|Buparid 1mg budesonide/2 ml nebulizer solution
3090490|NCT01955980|Active Comparator|Budes; Treatment B|Budes Nasal Spray 50 µg budesonide/pump
3090491|NCT01955967|Other|Lidocaine|
3090492|NCT01955954|Experimental|Canary Breathing System|Treatment with Canary Breathing System
3110402|NCT01820676||iUni G2+|iUni G2+ in all patients
3090493|NCT01955941||Cohort A|Patients with uveal melanoma for which brachytherapy is recommended will be considered and evaluated for enrollment into this study in order to describe the association between radiation treatment and changes in vision and blood flow within these treated eyes. Changes in vision and blood flow will be monitored at yearly intervals over a 5-year period. Up to 60 subjects will be recruited for this group.
3090494|NCT01955941||Cohort B|Patients with uveal melanoma who have previously undergone I-125 plaque brachytherapy will be considered for enrollment into this study to evaluate blood flow in eyes with more advanced radiation-induced changes. This group will only undergo a one-time study session. Up to 40 subjects will be recruited for this group.
3090495|NCT01955928|Experimental|Online Cognitive behavioral treatment for insomnia|Online Cognitive behavioral treatment for insomnia
3090496|NCT01955928|No Intervention|Waiting-list|Waiting-list
3090497|NCT01955915||Choroidal Tumor Group|15 patients diagnosed with small posterior choroidal tumors will be considered and evaluated for enrollment into this study
3090498|NCT01955902||Opioid addicts|Opioid addicts undergoing bup/nal maintenance therapy
3090499|NCT01955889|Experimental|Mobile Health Technology|Stretching and strengthening exercises provided via video using mobile health technology; walk daily using a pedometer; interact with a physical therapist remotely through an exercise application on a tablet device over 12 month period
3090500|NCT01955889|Active Comparator|Control|Stretching and strengthening exercises provided using printed photographs; walk daily using a pedometer; interact with a physical therapist at the beginning of the 12 month study; no use of mobile technology
3090501|NCT01955876||Group 1|
3090502|NCT01955863|Active Comparator|patient discharge on postoperative day 2|The patient was discharge on postoperative day 2 (as was done routinely)
3090503|NCT01955863|Experimental|patient discharge on postoperative day 1|The patient was discharge on postoperative day 1
3090504|NCT01955863|Experimental|patient discharge in the day of surgery|The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
3090505|NCT01955850|Experimental|Internet-delivered CBT for insomnia|Online Cognitive behavioral treatment for insomnia
3090506|NCT01955850|Experimental|Face-to-face CBT for insomnia|Face-to-face Cognitive behavioral treatment for insomnia
3090507|NCT01955850|No Intervention|Waiting-list|Waiting-list
3090508|NCT01955837|Experimental|TAS-102|
3090509|NCT01955837|Placebo Comparator|Placebo|
3090510|NCT01955824|Experimental|1% lignocaine|"Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (1%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients."
3090511|NCT01955824|Active Comparator|2% lignocaine|"Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (2%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients."
3090512|NCT01955811|Other|Platelet concentrate transfusion and Human Fibrinogen|Blood samples will be collected directly before the start of transfusion and 1 hour after the end of transfusion. These samples will be spiked with Human Fibrinogen and clotting tests will be performed. After 24 h after end of transfusion a clotting test will be performed again.
3090513|NCT01955798|Experimental|Trocar|Pyramidal tip reusable 11mm trocar
3090514|NCT01955798|Active Comparator|Veress needle|Veress needle
3090515|NCT01955785|Active Comparator|PC ventilation|Intervention with pressure controlled ventilator
3090516|NCT01955785|Active Comparator|PRVC ventilation|Intervention with Pressure Regulated Volume Controlled Ventilator
3090517|NCT01955772|Experimental|EN (Enteral Nutrition)|"NE group: According to the HAS and SFNEP recommendations and the good practice rules, a polyurethane or silicone NGT, 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months.~PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments."
3090518|NCT01955772|Other|PN (Parenteral Nutrition)|"NE group: According to the HAS and SFNEP recommendations and the good practice rules, a polyurethane or silicone NGT, 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months.~PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments."
3090519|NCT01955759|Experimental|beta blocker and amiodarone|The inteventin will be that patients will receive beta blocker Bisoprolol in adjusted dose + Amiodarone per os starting 7 days before coronary by-pass surgery, 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge
3090520|NCT01955759|Experimental|beta blocker and statin|The intervention will be that patients will receive beta blocker (Bisoprolol tab in adjusted dose)+ Rosuvastatin 20 mg. x 1 starting 7 days before coronary by-pass surgry untill discharge.
3090521|NCT01955759|Placebo Comparator|beta blocker|Patients will receive beta blocker (Bisoprolol tab in adjusted dose).
3090522|NCT01955746||Type 1 DM|
3090523|NCT01955733|Experimental|BI 695500|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
3090524|NCT01955720|Experimental|healthy subjects aged 45-64|Sequential Crossover to Placebo or BI 655075
3090525|NCT01955720|Experimental|healthy elderly subjects aged 65-80 year|Sequential Crossover to Placebo or BI 655075
3090526|NCT01955720|Experimental|mild renal impairment aged 45-80 years|Sequential Crossover to Placebo or BI 655075
3090527|NCT01955720|Experimental|mod renal impairment aged 45-80 years|Sequential Crossover to Placebo or BI 655075
3090530|NCT01955694|Experimental|BAY94-8862 (2.5 mg)|2.5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 5 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium
3090531|NCT01955694|Experimental|BAY94-8862 (5 mg)|5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 10 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium
3090532|NCT01955694|Active Comparator|Eplerenone|25 mg eplerenone every other day, i.e. one 25 mg eplerenone capsule on Day 1, Day 3, Day 5, etc. in the morning, 1 placebo capsule on Day 2, Day 4, Day 6, etc. in the morning, and 1 placebo tablet once daily in the morning, with possible up-titration to 25 mg eplerenone once daily at Visit 6 (Day 30), i.e. one 25 mg eplerenone capsule once daily in the morning and 1 placebo tablet once daily in the morning, and a possible up-titration to 25 mg once daily [if not performed at Visit 6 (Day 30)] or to 50 mg once daily [if up-titrated to 25 mg once daily at Visit 6 (Day 30)] at Visit 8 (Day 60), based on the value of blood potassium
3090533|NCT01955694|Experimental|BAY94-8862 (7.5 mg)|7.5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 15 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: This treatment group may be introduced into the study or not after safety and tolerability of these doses has been assessed by an independent Data Monitoring Committee (DMC) (1st dose recommendation DMC meeting).
3090534|NCT01955694|Experimental|BAY94-8862 (10 mg)|10 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 20 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: Only in case the above mentioned additional treatment arm (BAY94-8862, 7.5 mg) has been added, a second dose decision meeting of the DMC will take place, Again safety and tolerability of all doses will be assessed by an independent DMC (2nd dose recommendation DMC meeting). Based on this data, none or up to two treatment groups (BAY94-8862, 10 mg and BAY94-8862,15 mg) may be introduced into the study.
3090535|NCT01955694|Experimental|BAY94-8862 (15 mg)|15 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 20 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: Only in case the above mentioned additional treatment arm (BAY94-8862, 7.5 mg) has been added, a second dose decision meeting of the DMC will take place, Again safety and tolerability of all doses will be assessed by an independent DMC (2nd dose recommendation DMC meeting). Based on this data, none or up to two treatment groups (BAY94-8862, 10 mg and BAY94-8862,15 mg) may be introduced into the study.
3090536|NCT01955668|Experimental|AZD6738|Patients will receive a single dose on day 1 followed by ongoing multiple dosing until MTD or MFD is reached.
3090537|NCT01955655|Active Comparator|Baclofen|The starting dose was 0.75 mg/kg in four divided doses daily and was cautiously increased at three-day intervals until crying subsided or symptoms of over dosage or side effects appeared. The usual maximum dose was two mg/kg in four divided doses daily.
3090538|NCT01955655|Placebo Comparator|placebo|Placebo contained fructose powder in equal quantity in packets mimicking those of Baclofen.
3090539|NCT01955642||AVC|Patients with non-cardioembolic AIC requiring initiation of treatment with clopidogrel as usual indications
3090540|NCT01955629|Experimental|Aflibercept + XELOX (Oxaliplatin and Capecitabine)|Aflibercept 6 mg/kg every 3 weeks (q3w) in combination with Oxaliplatin 100 mg/m^2 q3w and Capecitabine 850 mg/m^2 twice daily orally (from Day 1 to Day 14 of each cycle), up to 6 cycles as induction therapy, followed by aflibercept 6 mg/kg q3w as maintenance therapy up to disease progression or unacceptable toxicity or participant's refusal of further treatment.
3090541|NCT01955616|Active Comparator|RM-131|RM-131 100 µg by subcutaneous injection daily in the morning
3090542|NCT01955616|Placebo Comparator|Placebo|by subcutaneous injection daily in the morning
3090543|NCT01955603|Experimental|Dose level 1|
3090544|NCT01955603|Experimental|Dose level 2|
3090545|NCT01955603|Experimental|Dose level 3|
3090546|NCT01955590|Experimental|Metacognitive therapy|The focus of metacognitive therapy (MCT) is on metacognitive beliefs thought to underlie the development and maintenance of posttraumatic symptomatology.
3090547|NCT01955590|Active Comparator|EMDR|Eye movement desensitization reprocessing (EMDR): participant is asked to focus on trauma-related imagery, negative cognitions and body sensations while simultaneously focusing attention to a bilateral physical stimulation.
3090548|NCT01955590|Active Comparator|Treatment as usual|A group of 30 patients matched for age, gender and personality disorders receiving treatment as usual (TaU) in an outpatient setting will be included as a non-randomized comparative control condition.
3090549|NCT01955577|Experimental|Vitamin D3 cholecalciferol|1000IU x3 daily in a period of 14 days. After 14 days 1000IU x 1 daily.
3090550|NCT01955577|Placebo Comparator|Placebo orally everyday|One placebo pill x3 daily in a period of 14 days. After 14 days x1 placebo pill daily.
3090551|NCT01955564|Experimental|Cohort 1|NW-3509a - 1mg or placebo
3090552|NCT01955564|Experimental|Cohort 2|NW-3509a 2mg or placebo
3090553|NCT01955564|Experimental|Cohort 3|NW-3509a 5mg or placebo
3090554|NCT01955564|Experimental|Cohort 4|NW-3509a 10 mg or placebo
3090555|NCT01955564|Experimental|Cohort 5|NW-3509a 20 mg or placebo
3090556|NCT01955564|Experimental|Cohort 6|NW-3509a 30 mg or placebo
3090557|NCT01955551|Experimental|Motiv. Interviewing|In the MI (motivational interviewing) study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
3090558|NCT01955551|Active Comparator|Anticipatory Guidance|In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
3090559|NCT01955538|Active Comparator|Control|Psychiatric treatment as usual for 6 months according to best clinical practice: 10 consultations with a medical doctor (medication and psycho-education) as well as 16 consultations with a psychologist.
3090560|NCT01955538|Experimental|Basic Body Awareness Therapy|Standard psychiatric treatment + Basic Body Awareness Therapy for 20 weeks, 1 hour/week.
3090562|NCT01955525||Acute coronary patients|Patients aged 18 and above who have been hospitalised with an ACS during the period of 2011 to 2013.
3090563|NCT01955512|Placebo Comparator|Placebo|Arm given placebo
3090564|NCT01955512|Experimental|Clopidogrel|Group given clopidogrel
3090565|NCT01955499|Experimental|Treatment (lenalidomide, ibrutinib)|Patients receive lenalidomide PO on days 1-21 and ibrutinib PO on days 1-28 (days 2-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3090566|NCT01955486|Experimental|flight simulation|flight simulation in pressure chamber
3090567|NCT01955473|Experimental|Sym004|
3090568|NCT01955460|Experimental|T-Cells + Chemotherapy|Patients receive T-cells transduced with DNRII as well as T- cells transduced with NGFR (as a control gene). Cytoxan administered at 60 mg/kg/day by vein over approximately 2 hours on Days -7 and -6. Mesna 60 mg/kg by vein over 24 hours on Days -7 and -6. Fludarabine 25 mg/m2 by vein daily over approximately 15-30 minutes on Days -5 to -1. On day 0, all patients receive the assigned dose level of transduced DNRII TIL, with an equal number of transduced NGFR TIL, up to a total of 1.5 x 10^11 TIL in NS. Twelve (12) to sixteen (16) hours after completing the T cell infusion, all patients receive high dose interleukin-2 (IL-2) on an inpatient basis at the standard dose of 720,000 IU/kg as an intravenous bolus over an approximate 15 minute period every 8-16 hours for up to 15 doses on Days 1 to 5 and 22-26.
3090569|NCT01955447|Placebo Comparator|Reference|no added plant-based ingredients
3090570|NCT01955447|Active Comparator|Low level plant-based ingredients|Low level addition of plant-based ingredients
3090571|NCT01955447|Active Comparator|Medium level plant-based ingredients|Medium level addition of plant-based ingredients
3090572|NCT01955447|Active Comparator|High level plant-based ingredients|High level addition of plant-based ingredients
3090573|NCT01955434|Experimental|Treatment (SMAC mimetic LCL161 and cyclophosphamide)|Patients receive SMAC mimetic LCL161 PO QD on days 1, 8, 15, and 22. Patients lacking a minor response by end of course 2 or partial response by end of course 4 may also receive cyclophosphamide PO QD on days 1, 8, 15, and 22 at the discretion of the treating physician. Patients taking cyclophosphamide with less than a 25% interval reduction in paraprotein receive SMAC mimetic LCL161 on days 2, 9, 16, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3090574|NCT01955421|Experimental|Erlotinib100|Patients will be randomized to buy and receive erlotinib 100mg qd.
3090575|NCT01955421|Experimental|Gefitinib250|Patients will be randomized to buy and receive gefitinib 250mg qd.
3090576|NCT01955408||Overactive bladder after Synergo|
3090577|NCT01955395|Active Comparator|Immediate Group|If the participant is assigned to the Immediate Group, the participant will immediately receive the Relaxation Response Resiliency Program (3RP) intervention (3 months), followed by 3 months of continuing to practice what the participant learned during the intervention.
3090578|NCT01955395|Active Comparator|Waitlist Group|If the participant is assigned to the Waitlist Group, the participant will wait for 3 months and then receive the full Relaxation Response Resiliency Program (3RP) intervention (3 months).
3090579|NCT01955382|Experimental|AS + oAC|All children will receive Artesunate (AS) 2.4 mg/kg IV at 0 and 12 h, 24 h, and 48 h. Children in the AS+oAC group will be given weight-based doses of oAC (Actidose Aqua) (Table 1) at 0, 6, 12, and 18 h. All children will then receive amodiaquine.
3090580|NCT01955382|Placebo Comparator|AS only (water)|Children in the AS only group will receive a weight-based volume of clean water (Bottled Water) to drink rather than the oAC.
3090581|NCT01955369||Amyotrophic lateral sclerosis patients|Patients were included into the registry if they had a new diagnosis of ALS, a minimum age of 18 years and lived in Rhineland-Palatinate for at least 6 months before date of diagnosis. Diagnosis was based upon the revised El Escorial criteria.
3090582|NCT01955356|Experimental|Scratching|induced endometrial injury
3090583|NCT01955356|No Intervention|No scratching|None intervention
3090584|NCT01955343||Lung cancer|Newly diagnosed and untreated non small cell lung cancer patients who underwent surgical resection for NSCLC (pathological stage I-III)
3090585|NCT01955343||Control|Subjects who will have surgery due to recurrent spontaneous pneumothorax Patients without lung cancer or other malignancies
3090586|NCT01955330||Hybrid robotic cabg patients|Postoperative (5-7 years)Hybrid CABG robotically assisted surgical revascularization patients
3090587|NCT01955317|Experimental|chlorhexidine intervention|The intervention arm will also receive hand hygiene counselling with chlorhexidine and a pump bottle with chlorhexidine lotion along with mothers and neonatal health counseling.
3090588|NCT01955317|Active Comparator|Control|This arm will receive maternal and neonatal health counselling which includes discussion and education about antenatal care, safe and clean delivery, recognition of danger signs for the mother and neonate, immediate new born care, and essential new born care. Each mother will receive a clean delivery kit and pictoral cue cards for danger sign recognition.
3090589|NCT01955304|Experimental|A-fasted dosing followed by fed dosing|Experimental: Fasted dosing of fruquintinib followed by fed dosing; Dosing in the fasted state followed by fed dosing
3090590|NCT01955304|Experimental|B-fed dosing followed by fasted dosing|Experimental: Fed dosing of fruquintinib followed by fasted dosing; Dosing in the fed state followed by fasted dosing
3090591|NCT01955291|Experimental|Reinforced Feedback in Virtual Environment|During the experiment, patients in the RFVE training group (Reinforced Feedback in Virtual Environment) will receive 1 hour of virtual reality-based therapy by means of RFVE and 1 hour of TNR treatment (Traditional Neuromotor Rehabilitation). Both treatments will last 1 hour a day, five days weekly for four weeks. The treatment is focused on motor function impairment of the upper extremity.
3090592|NCT01955291|Other|Traditional Neromotor Rehabilitation|The TNR training group (Traditional Neuromotor Rehabilitation) patients will be treated totally for two hours daily by means of a TNR programme. The treatment will last 4 weeks.
3090593|NCT01955278|Experimental|Creation of defitinive end colostomy|Patients undergoing elective laparoscopy assisted colorectal surgery, with the creation of a permanent end colostomy
3090594|NCT01955265|Experimental|Sports mentorship programme|1.5-hour sports mentorship session once a week, 18 weeks total.
3090595|NCT01955265|Active Comparator|Health promotion|The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
3090596|NCT01955252|Experimental|Azithromycin|"All participants older than 2 months (population 18,000) will be offered a single oral dose of oral azithromycin (tablets) 30 mg per Kg up to a maximum dose of 2g.~Women who tell the investigators they are pregnant and people with known allergy to macrolides will be offered benzathine benzylpenicillin.~This will be a single arm study. Study participants who met the inclusion criteria and agree to sign the consent form will be managed with proposed drug and systematically observed to measure outcomes of interest."
3090597|NCT01955239|Active Comparator|Standard IMRT|Standard IMRT in which the mean dose to both whole parotid glands is minimized.
3090598|NCT01955239|Experimental|Stem-cell Sparing IMRT|Stem-cell Sparing IMRT in which the mean dose to the stem cell containing region of the parotid gland is minimized
3090599|NCT01955226|Experimental|Tegaderm CHG clear dressing|Patients randomized to receive Tegaderm CHG clear dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
3090600|NCT01955226|Active Comparator|Standard clear Tegaderm dressing|Patients randomized to receive standard clear Tegaderm dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
3090601|NCT01955213||Morphine Sulphate|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
3090602|NCT01955213||Fentanyl|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
3090603|NCT01955213||Oxycodone|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
3090604|NCT01955200|Experimental|Intensified Anti-platelet Treatment-1|ASA + ticagrelor
3090605|NCT01955200|Experimental|Intensified Anti-platelet Treatment-2|ASA + double dose clopidogrel
3090606|NCT01955200|Experimental|Intensified Anti-platelet Treatment-3|ASA + clopidogrel + cilostazol
3090607|NCT01955200|Active Comparator|Regular DAPT (IPA≦60%)|ASA + clopidogrel
3090608|NCT01955200|Active Comparator|Regular DAPT (IPA>60%)|ASA + clopidogrel
3090609|NCT01955187|Experimental|Sequential therapy: Tacrolimus-Rituximab|Tacrolimus: Initial dose of 0.05 mg/Kg/day PO, adjusted to blood levels (5- 7 ng/ml) for six months. Starting at the end of month 6, tacrolimus will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
3090610|NCT01955187|Active Comparator|Cyclical therapy: Corticosteroids and Cyclophosphamide|Month 1, 3 and 5: 1g IV methylprednisolone daily for three doses, oral methylprednisolone (0.5mg/kg/day) Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day)
3090611|NCT01955174|Experimental|Botulinum toxin injection|Esophageal endoscopic injection of botulinum toxin
3090612|NCT01955174|Sham Comparator|No injection|No injection of botulinum toxin
3090613|NCT01955161|Placebo Comparator|Placebo|Placebo adjunct to 10 mg Donepezil
3090614|NCT01955161|Experimental|Idalopirdine 30 mg|Idalopirdine adjunct to 10 mg Donepezil
3090615|NCT01955161|Experimental|Idalopirdine 60 mg|Idalopirdine adjunct to 10 mg Donepezil
3090616|NCT01955148||Prior sPTB or PROM|Women who have had a previous delivery of a live born singleton between 20 weeks, 0 days and 36 weeks, 6 days due to spontaneous preterm premature labor or preterm rupture of fetal membranes
3090617|NCT01955148||Short cervical length|Short cervical length (≤25 mm) determined by transvaginal ultrasound
3090618|NCT01955148||Twin Pregnancy|Current twin pregnancy
3090619|NCT01955148||Prior cervicdal surgeries|Cervical cerclage in a prior pregnancy or prior cone biopsy or prior LEEP
3090620|NCT01955135|Active Comparator|sedation|The sedation group (Group S, n=30), received 1 mg/kg ketamine and 1 mg/kg propofol as a bolus for induction. The patients then received an infusion of 100-150 mcg/kg/min propofol and 0.25mg/kg/h of ketamine for maintenance.
3090621|NCT01955135|Active Comparator|general anesthesia|In the general anesthesia group (Group G, n=30), anesthesia was induced using 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen; endotracheal intubation was facilitated without use of a neuromuscular blocker agent. Anesthesia was maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen.
3090622|NCT01955122|Other|Group A|"Tandem Colonoscopy- Each patient will undergo 2 colonoscopy procedures:~a Standard view colonoscopy followed immediately by an EndoRings™ colonoscopy."
3090623|NCT01955122|Other|Group B|"Tandem Colonoscopy- Each patient will undergo 2 colonoscopy procedures:~an EndoRings™ colonoscopy followed immediately by a Standard view colonoscopy."
3090624|NCT01955109|Experimental|Viaskin Peanut 250 mcg|
3090625|NCT01955096|Experimental|fast-track surgery|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
3090626|NCT01955096|Other|conventional postoperative care|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
3090627|NCT01955083|Experimental|Pillar implant|"Arm 1- Pillar implant (Study group):~15 subjects undergo pillar implant surgery of the soft palate for the treatment of snoring."
3090628|NCT01955083|Active Comparator|Radiofrequency|"Arm 2- Radiofrequency (control group):~15 subjects undergo radiofrequency of the soft palate for the treatment of snoring."
3090629|NCT01955070|Experimental|Implementation|Multimedia Presentation for Ketamine sedation
3090631|NCT01955070|No Intervention|Control|Patients that received the standard consent with signed consent form
3090632|NCT01955057||Smokers with lung cancer|
3090633|NCT01955044|Experimental|"high dose LCPUFA"|"the high dose LCPUFA supplement is a drop that will be administered to ELBW infants."
3090634|NCT01955044|Experimental|"low dose LCPUFA"|"the low dose LCPUFA supplement is a drop that will be administered to ELBW infants."
3090635|NCT01955044|Placebo Comparator|placebo|"the placebo is a drop that will be administered to ELBW infants."
3090636|NCT01955031|Experimental|Telemonitoring|Patient with type 2 diabètes randomized in telemonitoring group have a telemonitoring device with educational Tools at their home
3090637|NCT01955031|Sham Comparator|Usual care|patient randomized in this group have a usual care
3090638|NCT01955018|Experimental|VeoTM|A new algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA) decreases the image noise up to 70% compared with the gold standard FBP model. Moreover, Veo improves spatial resolution with excellent detection of low and high contrast objects from a CT Dose Index (CTDIvol) equal to 0.3 mGy
3090639|NCT01955018|Other|gold standard FBP model|The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality
3090640|NCT01955005|Experimental|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
3090641|NCT01955005|Active Comparator|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
3090642|NCT01954992|Experimental|glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours on Day 1 of each 21-day cycle
3090643|NCT01954992|Active Comparator|5-FU|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
3090644|NCT01954979|Experimental|Abatacept|Abatacept will be administered for a total of 6 doses. Doses 1-3 will be administered at two week intervals (+/-2 days). One month following Dose 3, abatacept will be administered, and given at four-week intervals (+/-2 days) for three doses (Doses 4-6.) Patients will be followed for toxicity for 28 days following last dose of Abatacept. Patients will then be seen monthly for six months.
3090645|NCT01954966|Active Comparator|Progesterone 200 mg capsules|Subjects will be prescribed progesterone 200 mg capsules by the study Principal Investigator. Subjects will take 200 mg of progesterone daily for four days.
3090646|NCT01954966|Placebo Comparator|Progesterone 200 mg look-alike capsules|Subjects will be prescribed progesterone 200 mg look-alike placebo capsules by the study Principal Investigator. Subjects will take look-alike placebo capsules daily for four days.
3090647|NCT01954953||no intervention|
3090648|NCT01954940|Experimental|Whole Body Vibration Therapy|Group will receive daily whole body vibration therapy for up to 9 minutes maximum at a maximum of 18 Hz.
3090649|NCT01954940|No Intervention|Control group|Group will not receive whole body vibration therapy. This group will conduct all other tests and outcomes except whole body vibration therapy.
3090650|NCT01954927|Active Comparator|Gabapentin|Patients will be randomized to receive one dose of gabapentin.
3090651|NCT01954927|Placebo Comparator|Placebo|Patients will be randomized to receive one dose of placebo.
3090652|NCT01954914|Experimental|Plerixafor, Mozobil|Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
3090653|NCT01954901|Experimental|Standard treatment plus HBOT|The study treatment group will be compressed on air in the hyperbaric chamber to 2.0 atmospheres absolute (ATA), then placed on 100% oxygen by a head tent for 90 minutes.
3090654|NCT01954901|Placebo Comparator|Standard treatment with placebo room air|The study control group will be compressed to 2.0 ATA on air, then breath 21% oxygen and 79% nitrogen through the hood for 90 minutes.
3090655|NCT01954888|Active Comparator|Blind technique|Stellate ganglion block using the anterior paratracheal approach using surface landmarks.
3090656|NCT01954888|Active Comparator|Ultrasound-guided technique|Stellate ganglion block using the ultrasound-guided lateral approach at the sixth cervical vertebral level.
3090657|NCT01954875||Subjects with ALS|subjects diagnosed with amyotrophic lateral sclerosis
3090658|NCT01954875||subjects with non-ALS neurodegenerative disease|subjects diagnosed with non-ALS neurodegenerative disease
3090659|NCT01954875||healthy controls|
3090660|NCT01954862|Active Comparator|Air insufflation method.|Colonoscopy performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
3090661|NCT01954862|Experimental|CO2 insufflation|Colonoscopy performed with CO2 insufflation using the insufflation unit, allowing for washing as needed.
3090662|NCT01954862|Experimental|Water Immersion/CO2|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using CO2 insufflation.
3090663|NCT01954862|Experimental|Water Exchange/CO2|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using CO2 insufflation.
3090683|NCT01954745|Experimental|Cabozantinib|Patients will be treated with cabozantinib 60 mg daily administered orally continuously for 28-day cycles. Tumor assessments will be performed every 8 weeks until documented disease progression by RECIST criteria or drug intolerance.
3090684|NCT01954732|No Intervention|Group I (observation)|Patients undergo observation.
3090686|NCT01954732|Experimental|Group III (metformin hydrochloride)|Patients receive metformin hydrochloride as in Group II.
3090664|NCT01954862|Experimental|Water Immersion/AI|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using room air insufflation.
3090665|NCT01954862|Experimental|Water Exchange/AI|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using room air insufflation.
3090666|NCT01954849|Experimental|Probiotic formulation|Probiotic dissolving lozenge, at least 1 billion total CFU, taken at a certain prescribed regimen for 28 days.
3090667|NCT01954849|Placebo Comparator|Placebo|Placebo dissolving lozenge, with the exact same appearance as the treatment lozenge (including flavour, colour, shape and texture), and formulated with all the same ingredients except for the live bacteria, taken for 28 days at the same prescribed regimen as the probiotic lozenge.
3090668|NCT01954836|Experimental|Initial fasting|Fasting during chemotherapy of the first half of chemotherapy cycles (1 and 2 of four or 1 to 3 of six cycles)
3090669|NCT01954836|Active Comparator|Secondary fasting|Fasting during the second half of chemotherapy cycles (3 and 4 of four cycles or 4 to 6 of six cycles)
3090670|NCT01954823|Experimental|e-diary|The study group will have assess to an e-diary developed for people with MS, through the Internet and/or smart-phones. In addition, participants will continue to receive regular care at the MS clinic
3090671|NCT01954823|No Intervention|no use of e-diary|Participants of the control group will receive regular care at the MS clinic and will and no use of the e-diary
3090672|NCT01954810|No Intervention|Japanese encephaltis chimerix vaccine|This is a single-arm study. Japanese encephalitis chimeric vaccine (JECV) will be administered to all subjects and check for antibody response 4 weeks after vaccination.
3090673|NCT01954797||Physical Fitness|Patients from this group underwent 4 weeks of aerobic fitness training additional to normal supportive care, 5 times a week, for 50 minutes
3090674|NCT01954797||Relaxation|Patients of this group received 4-weeks of relaxation sessions additional to normal supportive care, 5 times a week, for 50 minutes.
3090675|NCT01954784|Experimental|Treatment (nonmyeloablative alloHSCT, lenalidomide)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate on days -5 to -3 and undergo TBI on day -1.~TRANSPLANT: Patients undergo allogeneic hematopoietic SCT on day 0.~GVHD PROPHYLAXIS: Patients receive standard GVHD prophylaxis comprising cyclosporine PO BID beginning on day -1 with taper beginning on day 100, mycophenolate mofetil PO BID on days 1-56, and bortezomib SC weekly from day 1 to day 91.~MAINTENANCE THERAPY: Beginning on day 100, patients receive lenalidomide PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3090676|NCT01954771|Active Comparator|Control Group|Patients will receive conventional care and keep on their usual SMBG(Self-monitoring of blood glucose) methods. Additionally, each patient will also wear a CGMS(continous glucose monitoring system) device for 72h in the first week and the last week, respectively.
3090677|NCT01954771|Active Comparator|SMBG-4 Group|Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
3090678|NCT01954771|Active Comparator|SMBG-7 Group|Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
3090679|NCT01954758|Experimental|Arm C-R: pET (ERA)|Patients will undergo a cycle of endometrial preparation following hormone replacement therapy (HRT) and will undergo an endometrial biopsy in this substituted cycle after five days (around 120 hours) of progesterone administration. The ERA test will analyze the endometrial receptivity to determine the most suitable time (the most receptive stage) for the embryo transfer. In a different cycle, patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI and vitrified. In a subsequent cycle, if a receptive profile was previously demonstrated by the ERA test, a personalized embryo transfer (pET) will be performed following the same conditions in which the ERA test was obtained using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).
3090680|NCT01954758|Experimental|Arm CNR: pET (ERA+ERA)|Patients will undergo a cycle of endometrial preparation following hormone replacement therapy (HRT) and will undergo an endometrial biopsy in this substituted cycle after five days (around 120 hours) of progesterone administration.The ERA test will analyze the endometrial receptivity to determine the most suitable time (the most receptive stage) for the embryo transfer. If the window of implantation (WOI) is displaced (profile non receptive), a new biopsy will be taken on a different day based on the result of the first ERA test to identify the personalized WOI. In a different cycle, patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI and vitrified.In a subsequent cycle, a personalized embryo transfer (pET) will take place according to the second ERA test result. A pET using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage) will be performed following the same conditions as in the second ERA test.
3090681|NCT01954758|Active Comparator|Arm A: Fresh embryo transfer (ET)|Patients will undergo a controlled ovarian stimulation cycle (COS) to obtain oocytes which will be fertilized by IVF/ICSI. In the same cycle, a fresh embryo transfer will be performed using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).
3090682|NCT01954758|Active Comparator|Arm B: Deferred embryo transfer (DET)|Patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI. In a subsequent cycle, following hormone replacement therapy (HRT), an elective deferred embryo transfer (DET) will be performed using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).
3090685|NCT01954732|Experimental|Group II (metformin hydrochloride)|Patients receive metformin hydrochloride PO BID for at least 7 days in the absence of disease progression or unacceptable toxicity.
3090687|NCT01954719|Experimental|cervix dilated after surgery|Digital cervical dilatation performed by surgeon
3090688|NCT01954719|No Intervention|control group|cervix not dilated after surgery
3090689|NCT01954706|Experimental|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
3090690|NCT01954706|Active Comparator|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
3090691|NCT01954693|Experimental|Everolimus (RAD001)|2x2.5mg daily
3090692|NCT01954693|Placebo Comparator|Placebo|2x2.5mg daily
3090693|NCT01954680|Experimental|COGFLEX-skill building levels|In the R33, children will be randomized to receive either COGFLEX with skill-building levels or just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
3090694|NCT01954680|Experimental|COGFLEX-control condition|In the R33, children will be randomized to receive either COGFLEX with skill-building levels or the control condition--which is just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
3090695|NCT01954667||obese and overweight|Group1 (n=30): overweight and obese (BMI ≥25 and/ or WHtR≥0.5)
3090696|NCT01954667||average body weight|Group2 (n=30): normal weight (BMI ≥ 18 to < 25 and/or WHtR ≥0.4 to <0.5)
3090697|NCT01954667||Control group|Control Group (n= 20): healthy subjects, matched for age and gender, were included in this study. All included controls had average weight (BMI ≥ 18 to < 25 and/ or WHtR ≥0.4 to <0.5)
3090698|NCT01954654|Experimental|Accelerated treatment|
3090699|NCT01954654|Active Comparator|Standard treatment|
3090700|NCT01954641|Experimental|ACCURE Navigator|For those patients assigned to the ACCURE Navigator, the ACCURE Real-Time Registry is programmed to automatically alert the Navigator when a patient misses a scheduled treatment appointment and to require the Navigator to include details as to how she addressed and resolved that missed appointment, ensuring the ACCURE Navigator's proactive approach to addressing such issues. In addition, a warning message will be produced if no follow-up appointments or procedures are scheduled within 21 days of the index visit.
3090701|NCT01954641|Active Comparator|Usual Care by Cancer Center Care Team|A list of registry warnings about all patients enrolled in the study will be delivered securely to a designated representative at the clinic.
3090702|NCT01954628|Experimental|AQX-1125|1 x AQX-1125 capsule daily
3090703|NCT01954628|Placebo Comparator|Placebo|1 x Placebo capsule daily
3090704|NCT01954615|Experimental|Group A 5 mg ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of 5 mg ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state.
3090705|NCT01954615|Experimental|Group B 20 mg ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of 20 mg ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state.
3090706|NCT01954615|Experimental|Group C ACT-281959 prodrug formulation I/placebo|Group C: 6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-B.
3090707|NCT01954615|Experimental|Group D ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-C.
3090708|NCT01954615|Experimental|Group E ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-D.
3090709|NCT01954615|Experimental|Group F ACT-281959 prodrug formulation I/placebo|Food effect dose group: 6 subjects to receive a single, oral dose ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Following a 7-10 day washout period, subjects will receive the identical treatments administered in the first period. Medication to be administered in the fed state. Dose selection will be based on pharmacokinetic data derived from Groups A-E.
3090710|NCT01954615|Experimental|Group G ACT-281959 prodrug formulation I & II/ACT-246475|9 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I (Treatment A), a single, oral dose of ACT-281959 prodrug formulation II (Treatment B), and a single, oral dose of ACT-246475 (Treatment C). Subjects will be equally randomized to one of 3 treatment sequences: ABC, BCA, and CAB. Treatments will be separated by 7-10 day washout periods. Medication to be administered in the fasted state. Data from Groups A-E will be used for pharmacometric modeling to guide the selection of doses to be used in Group G.
3090711|NCT01954602|Active Comparator|Touch group|Sphincterotome assisted guide-wire cannulation
3090712|NCT01954602|Experimental|No touch group|Guide-wire cannulation
3090713|NCT01954589|Experimental|ACT-462206 5 mg/Placebo|6 subjects received a single, 5 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
3090714|NCT01954589|Experimental|ACT-462206 25 mg/Placebo|6 subjects received a single, 25 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
3090715|NCT01954589|Experimental|ACT-462206 100mg/Placebo|6 subjects received a single, 100 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
3090716|NCT01954589|Experimental|ACT-462206 200mg/Almorexant 400mg/Placebo|"Subjects were assigned to one of two possible treatment sequences: A/B or B/A with a washout period of 14 days between treatment periods.~Treatment A: Single oral dose of ACT-462206 200 mg or placebo. Treatment B: Single oral dose of almorexant 400 mg or placebo. In each sequence 6 subjects received ACT-462206 or almorexant & 2 subjects received placebo"
3090717|NCT01954589|Experimental|Experimental: ACT-462206 400mg/Placebo|6 subjects received a single, 400 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
3090718|NCT01954589|Experimental|ACT-462206 1000 mg|6 subjects received a single, 1000 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
3090719|NCT01954589|Experimental|ACT-462206 1500mg/Placebo|6 subjects received a single, 1500 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
3090720|NCT01954576|Experimental|NovoTTF therapy|Patients undergo NovoTFF therapy at least 18 hours daily for 6 months (bevacizumab-naive) or 4 months (bevacizumab-refractory). Treatment may continue for up to 2 years in patients experiencing CR, PR, or SD.
3090721|NCT01954563|Experimental|Group 1|Receive 5x10^7 MVA85A by aerosol at day 0, followed by boost intradermal vaccination of 5x10^7 MVA85A at day 28.
3090722|NCT01954563|Experimental|Group 2|Receive 5x10^7 MVA85A by intradermal injection at day 0, followed by boost aerosol vaccination of 5x10^7 MVA85A at day 28.
3090723|NCT01954563|Experimental|Group 3|Receive 5x10^7 MVA85A by intradermal injection at day 0, followed by boost intradermal vaccination of 5x10^7 MVA85A at day 28.
3090724|NCT01954550|Experimental|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
3090725|NCT01954550|Sham Comparator|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
3090726|NCT01954537||Professional football players|Offensive and defensive professional football players ranging in age from 22 to 30 years old.
3090727|NCT01954537||Collegiate Football Players|Division III collegiate football players ranging in age from 20 to 23 years old.
3090728|NCT01954537||High School Football Players|High school football players ranging in age from 16 to 18 years old.
3090729|NCT01954524|Experimental|IV bolus injection of Sildenafil|CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil.
3090730|NCT01954511|No Intervention|Manual therapy|Upper cervical flexion mobilization, C5 central posterior-anterior mobilization, Pressure biofeedback device
3090731|NCT01954498|Experimental|Walnuts|2 ounces whole-shelled walnuts per day for 12 weeks
3090732|NCT01954498|Active Comparator|OTC (over-the-counter) multivitamin|OTC multivitamin tablet 2 per day for 12 weeks
3090733|NCT01954485|Experimental|LaserLok abutment|Laser microtexturing dental implant abutment
3090734|NCT01954485|Active Comparator|3inOne abutment|Standard dental implant abutment
3090735|NCT01954472|Experimental|Enhanced Portfolio plus structured exercise|Diet: The dietary portfolio advice: to limit saturated fat to <7% of total calories and cholesterol to <200 mg/d) plus inclusion of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and will emphasize current recommendations for fruit and vegetable intakes (5-10 servings/d).
3090736|NCT01954472|Active Comparator|High fiber diet plus routine exercise|A diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); reduced meat consumption; lower fat dairy foods and a control margarine
3090737|NCT01954459|Active Comparator|Sensor alone|Glucose sensor site will not have Insupatch
3090738|NCT01954459|Experimental|Sensor with Insupatch|Glucose sensor site with Insupatch
3090739|NCT01954446|Experimental|ContiPress vs. 3M|ContiPress vs. 3M passive and during exercise
3090740|NCT01954446|Experimental|ContiPress vs. Mobil-O-Graph|ContiPress vs. Mobil-O-Graph passive, then oscillometric passive, then oscillometric for 24 hrs every 15 mins.
3090741|NCT01954433||Operated TSA Patients|Patients with glenohumeral arthritis and/or rotator cuff tear arthropathy who were operated and received a total shoulder prosthesis
3090742|NCT01954433||Non-operated TSA Patients|TSA-patients, indicated for treatment with a total shoulder prosthesis, who decided not to operate
3090743|NCT01954433||Operated RCR Patients|Patients with rotator cuff tear who were operated and received a rotator cuff reconstruction by arthroscopy
3090744|NCT01954433||Non-operated RCR Patients|RCR-patients, indicated for rotator cuff reconstruction by arthroscopy, who decided not to operate
3090745|NCT01954433||Operated TMC OA Patients|Patients with trapeziometacarpal (TMC) osteoarthritis who were operated and received a resection interposition suspension arthroplasty of the TMC joint
3090746|NCT01954433||Non-operated TMC OA Patients|TMC OA-patients, indicated for surgical treatment (resection interposition suspension arthroplasty), who decided not to operate
3090747|NCT01954420|Other|Attention Control|"Standard care + cancer education~Participants receive a single session with a research nurse to discuss the importance of understanding cancer and cancer treatment strategies, and to introduce educational recordings available on an MP3 player. The educational recordings provide a selection of publicly available American Cancer Society patient information materials addressing topics related to cancer and cancer treatment strategies. Participants are asked to listen to at least one recording per day, or more frequently as desired."
3090748|NCT01954420|Experimental|Cognitive-Behavioral Intervention|"Standard care + Patient-Controlled Cognitive Behavioral Intervention~Participants will receive a single training session with a research nurse including: 1) Information about the causes of cancer-related pain, fatigue, and sleep disturbance. 2) An explanation of how cognitive-behavioral interventions may affect symptoms. 3) Review of the specific cognitive-behavioral strategies provided on the MP3 player. 4) Individualized recommendations for using the cognitive-behavioral strategies. The nurse interventionist and patient will develop a written plan for practicing the strategies with recommendations to use a strategy at least once a day, or more frequently as needed."
3090749|NCT01954407|No Intervention|Control: No Smoking-Related Messages|Respondents will answer questions about smoking-related beliefs and intentions to smoke before receiving the treatment smoking-related messages (they will still receive them at the end to make the groups comparable and still expose them to anti-smoking messages).
3090750|NCT01954407|Experimental|Promising Smoking-Related Messages|Respondents will receive one of the possible sets of promising smoking-related messages and these should affect smoking-related intentions to a greater extent (make respondents less likely to smoke) than less-promising smoking-related messages.
3090751|NCT01954407|Experimental|Less-Promising Smoking-Related Messages|Respondents will receive one of the possible sets of less-promising smoking-related messages and these should affect their intentions to a lesser extent than the promising smoking-related messages.
3090789|NCT01954121|Active Comparator|Carbamazepine|Carbamazepine 400 mg/day
3110520|NCT01819870|Active Comparator|Dilatrend IR tablet 25mg|
3090752|NCT01954394|Experimental|Alirocumab 75 or 150 mg Q2W|Alirocumab 75 mg or 150 mg every 2 weeks (Q2W) added to stable lipid-modifying therapy (LMT) for up to 168 additional weeks (or until the product was commercially available) in participants who completed the parent studies EFC12492, R727-CL-1112, EFC12732 and LTS11717.
3090753|NCT01954381|Other|control|
3090754|NCT01954381|Experimental|patient|
3090755|NCT01954368|Placebo Comparator|Intranasal placebo|Patients receiving intranasal placebo at ED admission
3090756|NCT01954368|Experimental|Intranasal sufentanil|Patients receiving intranasal sufentanil at ED admission
3090757|NCT01954355|Experimental|LDE225 & Paclitaxel|"Phase I, Part A: LDE225: dose escalation in cohorts of 3-6 patients (days 1-28) and Paclitaxel 80 mg/m2 (days 1, 8, 15)~Phase I, Part B and C: LDE225: RP2D established in Part A (days 1-28) and Paclitaxel 80 mg/m2 (days 1, 8, 15)"
3090758|NCT01954342||Pregnant|Obese pregnant women
3090759|NCT01954329||Patients suspected of TIA by the GP|
3090760|NCT01954316|Experimental|CFI-400945 fumarate|CFI-400945 fumarate tablets, dose levels 3, 6, 11, 16, 24, and 32 mg/day
3090761|NCT01954303||Troponin status|"Patients are divided into troponin positive (if hsTnT on first presentation is <14 ng/L) and troponin negative (if hsTnT on first presentation is >=14 ng/l)."
3090762|NCT01954303||Progress of CHD|
3090763|NCT01954290|Active Comparator|Hypertonic Saline (3%) and/or Mannitol arm|"The subjects in this arm will be given hypertonic saline and/or Mannitol.~For hypertonic saline,various concentrations are used clinically,up to 30-mL boluses of 23.4% saline.Rapid increases in sodium in this context do not appear to cause other neurologic complications observed with rapid correction of hyponatremia.Sodium levels up to 160 mmol/L may be acceptable,beyond which it may lead to worsening delirium,seizures,and overall poor outcome.~For Mannitol,every 4 hours serum osmolarity,serum glucose,urea,sodium and potassium will be measured till the therapy is given.Major complications include hypovolemia and hypotension.Strict fluid goals and volume replacement are essential.Impaired mannitol clearance may manifest as nephrotoxicity.Common practice includes repeating measurements of serum osmolarity and withholding repeat doses of mannitol when osmolarity exceeds 320 milliosmol(mOsm).Monitoring the osmole gap may be a more sensitive method for discerning mannitol clearance."
3090764|NCT01954290|Experimental|Conivaptan arm|The subjects in this arm will be given infusion of Conivaptan.
3090765|NCT01954277|Experimental|Electroacupuncture|All patients will receive 10 electroacupuncture sessions.
3090766|NCT01954277|Sham Comparator|Placebo Sham|All patients will receive 10 placebo sham sessions.
3090767|NCT01954264|Other|Survey 1 Group|One cross-sectional survey at the malaria peak transmission.
3090768|NCT01954251|Experimental|Co-Ad Group|The subjects assigned to the Co-Ad group will receive one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.
3090769|NCT01954251|Active Comparator|Control Group|The subjects assigned to the Control group will receive all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.
3090770|NCT01954238|Active Comparator|Rivaroxaban|Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease
3090771|NCT01954238|Placebo Comparator|Placebo|GCC-4401C matching placebo capsule
3090772|NCT01954238|Experimental|GCC-4401C|Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease. It is a novel molecule with a structural similarity to Rivaroxaban.
3090773|NCT01954225|Other|Udumbara sutra|The Udumbara Sutra is a standard medicated thread smeared with latex of Udumbara (Ficus Glomerata) which has cutting and healing property.
3090774|NCT01954212|Experimental|Enhanced complex oral health care intervention|The complex oral health care (OHC) intervention (SOCLE intervention) includes patient, staff and service level interventions.
3090775|NCT01954212|No Intervention|Usual oral health care|"Oral health care (OHC) will be provided in the standard manner, with no change to usual care.~Provision of this standard OHC will be sampled monthly. Surveys suggest that standard oral health care (OHC) in stroke care settings comprise poorly supported OHC interventions delivered by staff that lacked access to specialist training, products, equipment, assessments, protocols and dental services."
3090776|NCT01954199|Experimental|Neurodynamic group|Patients allocated to this group will receive three different neurodynamic techniques: a lumbar foramen dynamic opener; a side-lying slider and a slider in the slump position. Patients will be asked to perform home exercises (a slider and a tensioner technique). Treatment will receive four treatments during two weeks (two sessions/week).
3090777|NCT01954199|No Intervention|Control Group|"Patients allocated to Control Group (CG) will receive no intervention and will be advised according to the best evidence available; i.e, advice to remain active and to resume activities of daily living~Upon trial completion, treatment will be offered."
3090778|NCT01954186|Experimental|intravenous & intramuscular oxytocin|intravenous or intramuscular 10 iu oxytocin
3090779|NCT01954186|Active Comparator|after delivery & when anterior shoulder seen|oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered
3090780|NCT01954173|Experimental|3D conformal radiation therapy|Within 24 weeks of surgical resection, patients undergo conformal radiation therapy once daily 5 days per week for 28 fractions. Treatment continues in the absence of disease progression or unacceptable toxicity.
3090781|NCT01954160|Other|Early Symplicity Renal Denervation|Subjects undergo Symplicity Renal Denervation within 2 weeks of baseline visit will follow usual care after week 13 visit
3090782|NCT01954160|Other|Late Symplicity Renal Denervation|Subjects following usual care until week 13 visit will then undergo Symplicity Renal Denervation within 2 weeks of Week 13 visit
3090783|NCT01954147|Experimental|SC-GLP-1|Umbilical Cord Mesenchymal Stem Cell Infusion Combined With Liraglutide
3090784|NCT01954147|Experimental|SC|Umbilical Cord Mesenchymal Stem Cell Infusion
3090785|NCT01954147|Experimental|GLP-1|Liraglutide
3090786|NCT01954147|Active Comparator|Control|Standard Medical Treatment
3090787|NCT01954134||thyroid cancer, healty|Thyroid cancer group: patients with differentiated or dedifferentiated thyroid cancer Healty: control group
3090788|NCT01954121|Experimental|Levetiracetam|Levetiracetam 1000 mg/day
3090791|NCT01954108|Active Comparator|hyaluronic acid sodium salt|Two injections of 2% (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
3090792|NCT01954095||Group 1: No prior preterm birth & normal cervix length|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had one or more term births (no prior preterm births) and have a normal cervical length (> 25 mm). These women will serve as gestational age controls for all groups.
3090793|NCT01954095||Group 2: No prior preterm birth & short cervix length|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have no prior preterm births and have a short cervical length (20mm or less). These women may receive treatment (e.g. vaginal progesterone, cerclage, pessary, NSAIDs, or a combination thereof) or no treatment.
3090794|NCT01954095||Group 3: Prior preterm birth, normal cervix length, 17-OHPC|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had prior preterm birth, have a normal cervical length and will receive 17-OHPC treatment.
3090795|NCT01954095||Group 4: Prior preterm birth, normal cervix length, no treat|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had prior preterm birth, have a normal cervical length, and will not receive any treatment. These women will serve as controls for Group 3.
3090796|NCT01954082|Experimental|myo-Inositol 5% Injection|Within 12-72 hours of birth, infants will receive 80 mg myo-inositol 5% Injection per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.
3090797|NCT01954082|Placebo Comparator|5% glucose(dextrose)|Within 12-72 hours of birth, infants will receive 80 mg 5% glucose(dextrose) USP for intravenous infusion per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.
3090798|NCT01954069|Other|Semi-quantitative pregnancy test|Semi-quantitative urine pregnancy test (SQPT) (dBest One Step hCG Panel Test Kit)
3090799|NCT01954056|Active Comparator|Hydrocortisone|hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line
3090800|NCT01954056|Placebo Comparator|Placebo|Saline placebo
3090801|NCT01954043|Experimental|Arm A|Subjects will administer Dabrafenib from Day 1 to Day 15, Dabrafenib and Rabeprazole from Day 16 to Day 19, Dabrafenib and Rifampin from Day 20 to Day 29. The serial PK samples will be collected for 12 hours following dosing on Day 15 (Dabrafenib alone), Day 19 (Dabrafenib and Rabeprazole), and Day 29 (Dabrafenib and Rifampin).
3090802|NCT01954030|Experimental|CTO and Bevacizumab (Phase 1)|The combination of CTO with the standard dosing of bevacizumab of 10 mg/kg every 2 weeks among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have previously failed bevacizumab
3090803|NCT01954030|Experimental|Phase 2: CTO alone (Phase 2)|The first 25 patients will be treated with CTO alone at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study.
3090804|NCT01954030|Experimental|CTO and Bevacizumab (Phase 2)|The second group of 25 patients will be treated with the combination of CTO at the MTD established in the Phase 1 portion of this study and standard dosing of bevacizumab.
3090805|NCT01954017|Experimental|STP 206|Biological
3090806|NCT01954017|Placebo Comparator|Sterile Water|Sterile water
3090807|NCT01953991|Active Comparator|Cobalt chrome dentures|Cobalt chrome dentures are used as part of standard care for patients
3090808|NCT01953991|Active Comparator|PEEK dentures|PEEK dentures will be used as a comparator denture for patients
3090809|NCT01953978|Active Comparator|Dexamethasone|"Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed~Tablet Paracetamol 1 g orally and tablet Ibuprofen 400 mg orally. Both 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours."
3090810|NCT01953978|Placebo Comparator|Placebo|"Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed~Tablet Paracetamol 1 g orally and tablet Ibuprofen 400 mg orally. Both 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours."
3090811|NCT01953952|Experimental|Arm I (surgery, risk-based adjuvant therapy)|Patients undergo eHNS. Depending on post-operative pathology findings, patients may undergo IMRT QD five days a week for 6 weeks, beginning within 6 weeks after surgery. High-risk patients also receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 during radiation therapy.
3090812|NCT01953952|Active Comparator|Arm II (chemoradiotherapy)|Patients undergo IMRT QD five days a week for 7 weeks. Patients also receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 during radiation therapy.
3090813|NCT01953939|Experimental|Prosthetic Limb Users|Single lower limb amputees who are wearing their artificial limb all day and are using them outdoors for the majority of the time will be enrolled into this reliability study.
3090814|NCT01953926|Experimental|Neratinib monotherapy|Neratinib monotherapy in HER2 mutated cancers excluding colon cancer, lung cancer, breast cancer and bladder cancer, HER4 mutated cancer and in lung cancer containing EGFR exon 18 mutations, and fibrolamellar carcinoma.
3090815|NCT01953926|Experimental|Neratinib and Paclitaxel|Neratinib and Paclitaxel in HER2 mutated bladder cancers.
3090816|NCT01953926|Experimental|Neratinib, Fulvestrant and Trastuzumab|Neratinib, Fulvestrant and Trastuzumab in HER2 mutated hormone positive breast cancers.
3090817|NCT01953926|Experimental|Neratinib and Trastuzumab|Neratinib and Trastuzumab in ERBB2 mutated Hormone negative breast, lung, and colorectal cancers.
3090818|NCT01953913|Experimental|Afatinib|Patient will receive afatinib once daily
3090819|NCT01953900|Experimental|GD2 T cells plus VZV vaccine|
3090820|NCT01953887|Experimental|1 combination tablet EC905|
3090823|NCT01953874|Experimental|MV ASV+OMT|Minute Ventilation-targeted adaptive servo-ventilation therapy plus optimized medical treatment
3090824|NCT01953874|Active Comparator|OMT only|Optimized Medical Treatment for heart failure in accordance with applicable guidelines (ACCF/AHA Guideline for the Management of Heart Failure and HFSA Heart Failure Guidelines.
3090825|NCT01953861|Experimental|1: fasted|EC905 + fasted
3090826|NCT01953861|Experimental|2: low-fat breakfast|EC905 + low-fat breakfast
3090827|NCT01953861|Experimental|3: high-fat breakfast|EC905 + high-fat breakfast
3090828|NCT01953848|Experimental|1: Low dose EC905|
3090829|NCT01953848|Experimental|2: High dose EC905|
3090830|NCT01953835|Experimental|Cohort A|Cohort A is a single-sequence, open-label study in which each subject will receive Simvastatin 10 mg single dose oral tablet on Days 1 and 10, Rosuvastatin 10 mg single dose oral tablet on Days 3 and 12 and GSK2586184 standard formulation 400 mg twice daily oral tablet from Day 6 to Day 14 immediately after food. At Day 10 GSK2586184 and Simvastatin and at Day 12, GSK2586184 and Rosuvastatin will be co-administered.
3090831|NCT01953835|Experimental|Cohort B|Cohort B is a three-way crossover study in which each subject will receive a single dose of GSK2586184 standard formulation 400 mg oral tablet with food and two doses of a new formulation of GSK2586184 400 mg oral tablet, once with food and once in a fasted state, on Day 1, 4 and 7 according to their treatment sequence, with a 3-day wash out between doses.
3090832|NCT01953822||Cervarix vaccinated (exposed) female cohort|Female subjects vaccinated with at least one dose of Cervarix® between the ages of 9 to 25 years.
3090833|NCT01953822||Unexposed historical female cohort|Unexposed female subjects identified from historical data, will be frequency matched for age and practice region identifier to the subjects included in the vaccinated (exposed) cohort.
3090834|NCT01953822||Unexposed concurrent male cohort|Male population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®.
3090835|NCT01953822||Unexposed historical male cohort|Male population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®. Comparison of the unexposed concurrent male cohort with the unexposed historical male cohort will be used as an internal control for changes over time in Clinical Practice Research Datalink (CPRD) GOLD in reporting New Onset of Autoimmune Diseases (NOAD). The male subjects will be frequency matched for age and practice region identifier to the subjects included in the vaccinated (exposed) cohort.
3090836|NCT01953809|Experimental|Run-in Period|All subjects will receive EE/NE for first 21 days and EE/NE matching placebo for next 7 days before start of treatment phase
3090837|NCT01953809|Experimental|Group 1|Subjects upon completion of 28 days of run-in period will receive GSK1322322/Placebo + EE/NE in period 1 and only EE/NE in period 2 and 3 of treatment phase. Each period will be of 7 days
3090838|NCT01953809|Experimental|Group 2|Subjects upon completion of 28 days of run-in period will receive only EE/NE in period 1, GSK1322322/Placebo + EE/NE in period 2 and again EE/NE only in period 3 of treatment phase. Each period will be of 7 days
3090839|NCT01953809|Experimental|Group 3|Subjects upon completion of 28 days of run-in period will receive only OC in period 1 and 2, and GSK1322322/Placebo + EE/NE in period 3 of treatment phase. Each period will be of 7 days
3090840|NCT01953796|Experimental|Study of Stair-step Clomiphene Protocol|50 mg clomiphene given for 5 days beginning on day 2 of the cycle. Tv USS done at days 11-14. When there is no response (no follicle >10 mm), 100 mg clomiphene is initiated immediately for 5 days, and U/S is repeated 1 week after the first tvUSS at day 21. If there is no response, another 150 mg clomiphene is initiated immediately for 5 days and U/S is performed 1week after the second U/S (day28). Ovulation for the stair-step cycles was confirmed by folliculometry (follicle tracing) by tvUSS.
3090841|NCT01953796|Active Comparator|Traditional Protocol.|Clomiphene medication was initiated at day two of the cycle. The starting dose was 50 mg/day for 5 consecutive days. In case of absent response, the patient was treated with 10 mg medroxyprogesterone acetate (MPA) for10 days. Daily doses of clomiphene citrate were increased by 50 mg in the next cycle up to 3 treatment cycle. In each cycle monitoring of follicular growth was done by tvUSS at day 11-14 of each cycle. First ovulation was used as the endpoint and the duration of follow-up was three treatment cycles (up to 150mg). Ovulation was assessed by tvUSS monitoring of follicle growth.
3090842|NCT01953783|Experimental|IXAZOMIB|"Part A: Patients will receive a single dose of 4-mg [14C]- IXAZOMIB oral solution containing approximately 500 nCi of total radioactivity on Day 1 and remain at the clinic for 8 days. On Days 14 and 21, patients may be administered a single 4.0-mg capsule of IXAZOMIB. Patients will return to the clinic in the evening before Days 14, 21, 28, and 35 for a 24-hour overnight clinic visit.~Part B: Eligible patients from Part A may continue into Part B once they have completed their Day 35 assessments in Part A. Patients may receive IXAZOMIB capsules administered orally at a dose of 4.0-mg once weekly on Days 1, 8, and 15 of 28-day cycles. Patients will continue in this study until disease progression of unacceptable toxicity."
3090843|NCT01953770|Active Comparator|Cranial irradiation|Consolidation therapy with cranial irradiation in intermediate risk group patients
3090844|NCT01953770|Experimental|Additional TIT|Consolidation therapy with additional triple intrathecal therapy (N6) and without cranial irradiation in intermediate risk group patients
3090845|NCT01953770|Experimental|MTX 2,000 mg/m2|Consolidation therapy with High-dose Methotrexate 2,000 mg/m2/24 h i.v. biweekly in intermediate risk group patients
3090846|NCT01953770|Active Comparator|MTX 30 mg/m2|Consolidation therapy with Low-dose Methotrexate 30 mg/m2 i.m. weekly in intermediate risk group patients
3090847|NCT01953770|Experimental|PEG-asp 1,000 U/m2|Consolidation therapy with PEG-L-asparaginase cons 1,000 U/m2 biweekly in standard risk group patients
3090848|NCT01953770|Active Comparator|L-asp 5,000 U/m2|Consolidation therapy with E.coli L-asparaginase 5,000 U/m2 weekly in standard risk group patients
3090849|NCT01953770|Active Comparator|PEG-DNR+|Induction therapy without PEG-L-asparaginase and with Daunorubicin 45 mg/m2 in standard and intermediate risk group patients
3090850|NCT01953770|Experimental|PEG+DNR+|Induction therapy with PEG-L-asparaginase ind (1,000 U/m2 on day 3 of therapy)and daunorubicin 45 mg/m2 in standard and intermediate risk group patients
3090851|NCT01953770|Experimental|PEG+DNR-|Induction therapy with PEG-L-asparaginase ind (1,000 U/m2 on day 3 of therapy) without daunorubicin on day 8 in standard risk group patients
3090852|NCT01953757|Experimental|Vegan diet and vitamin B12 supplement|The diet/supplement group will be asked to follow a low-fat, vegan diet for 20 weeks, and take a vitamin B12 supplement daily.
3090853|NCT01953757|Active Comparator|Vitamin B12 supplement|The supplement group will be asked to take a daily vitamin B12 supplement, and to make no changes to their current diet.
3090854|NCT01953744|Experimental|Fluconazole|Fluconazole will be administered by oral route at 6-8mg/kg/day during 28 days.
3090855|NCT01953744|Active Comparator|Meglumine Antimoniate|Meglumine Antimoniate will be administered by intravenous route at 20mg/kg/day during 20 days.
3090856|NCT01953731|Experimental|Single-Arm Fixed-Sequence|Subjects will receive two different interventions in fixed-sequence two-period study. In the first period the subjects will receive a single-dose of palbociclib. In the second period, subjects will receive 12 days of rifampin and a single dose of palbociclib on day 8. In both periods, subjects will undergo pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
3090857|NCT01953705|Experimental|omega 3 polyunsaturated fatty acids|1.65 grams of EPA+DHA taken daily over 3 years
3090858|NCT01953705|Placebo Comparator|Soybean oil|1.65 grams of soybean oil taken daily over 3 years
3090859|NCT01953692|Experimental|Cohort 1: Myelodysplastic syndrome (MDS)|(Completed) 10 mg/kg by intravenous (IV) infusion every 2 weeks (Q2W). Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable adverse event(s) (AEs), intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the participant, participant withdraws consent, pregnancy of the participant, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after Complete Response (CR) if treatment has been administered for 24 weeks and 2 doses have been administered after CR.
3090860|NCT01953692|Experimental|Cohort 2: Relapse refractory/refractory multiple myeloma (MM)|(Completed) Participants receive pembrolizumab 200 mg by IV infusion every 3 weeks (Q3W). Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable AEs, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the participant, participant withdraws consent, pregnancy of the participant, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after stringent complete response (sCR) if treatment has been administered for 24 weeks and 2 doses have been administered after sCR.
3090861|NCT01953692|Experimental|Cohort 3: Relapsed/refractory (R/R) Hodgkin lymphoma (HL)|(Completed) 10 mg/kg by IV infusion Q2W. Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable AEs, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the participant, participant withdraws consent, pregnancy of the participant, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after CR if treatment has been administered for 24 weeks and 2 doses have been administered after CR.
3090862|NCT01953692|Experimental|Cohort 4A: R/R mediastinal large B cell lymphoma (MLBCL)|Participants receive pembrolizumab 200 mg by IV infusion every 3 weeks (Q3W). Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable AEs, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the participant, participant withdraws consent, pregnancy of the participant, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after CR if treatment has been administered for 24 weeks and 2 doses have been administered after CR.
3090863|NCT01953692|Experimental|Cohort 4B: R/R PD-L1-positive NHL|(Completed) Participants receive pembrolizumab 10 mg/kg by IV infusion Q2W. Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable AEs, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the participant, participant withdraws consent, pregnancy of the participant, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after CR if treatment has been administered for 24 weeks and 2 doses have been administered after CR.
3090864|NCT01953692|Experimental|Cohort 4C: Relapsed/refractory Follicular Lymphoma (FL)|Participants receive pembrolizumab 200 mg by IV infusion Q3W. Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable AEs, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the participant, participant withdraws consent, pregnancy of the participant, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after CR if treatment has been administered for 24 weeks and 2 doses have been administered after CR.
3090865|NCT01953692|Experimental|Cohort 4D: R/R Diffuse Large B-Cell Lymphoma (DLBCL)|Participants receive pembrolizumab 200 mg by IV infusion Q3W. Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable AEs, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the participant, participant withdraws consent, pregnancy of the participant, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after CR if treatment has been administered for 24 weeks and 2 doses have been administered after CR.
3090866|NCT01953692|Experimental|Cohort 5: R/R DLBCL combination treatment|(Discontinued) Participants receive pembrolizumab 200 mg by IV infusion Q3W + lenalidomide 25 mg capsule by mouth (PO) or recommended Phase II dose for 21 consecutive days with 7 days off. Treatment with pembrolizumab + lenalidomide will continue for up to 2 years or until documented disease progression, unacceptable AEs, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the participant, participant withdraws consent, pregnancy of the participant, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after CR if treatment has been administered for 24 weeks and they receive an additional 21 consecutive daily doses of lenalidomide + 2 doses of pembrolizumab after CR.
3090867|NCT01953679|Active Comparator|5mg UPA|Continuous regimen of oral daily 5 mg of ulipristal acetate (UPA) versus a cyclic regimen of 5 mg UPA for 24 days followed by a 4 day hormone free interval.
3090868|NCT01953679|Active Comparator|10mg UPA|Continuous regimen of oral daily 10 mg of ulipristal acetate (UPA) versus a cyclic regimen of 5 mg UPA for 24 days followed by a 4 day hormone free interval.
3090869|NCT01953666||Rehabilitation Group|People with spinal cord injury who have a rehabilitation program on a word prediction software with an occupational therapist.
3090870|NCT01953666||Self Training at Home Group|People with spinal cord injury who don't have a rehabilitation program with an occupational therapist but who have instructions for learning at home on a word prediction software
3091234|NCT01951300|Other|Gallium-68 citrate|Intravenous bolus injection of 200 MBq of Gallium-68 citrate
3090871|NCT01953666||No treatment Group|People with spinal cord injury who don't have instructions, rehabilitation programm on word prediction software. They have no treatment.
3090872|NCT01953653|Other|A: Begin with Interactive Voice Response (IVR) System|Group A participants are randomized the IVR system as Modality #1. After 33 days of diary completion using IVR, they switch to the interactive web response system (IWR)as Modality #2.
3090873|NCT01953653|Other|B: Begin with Interactive Web Response (IWR) System|Group B participants are randomized to the IWR system as Modality #1. After 33 days of diary completion using IWR, they switch to the interactive voice response (IVR)system as Modality #2.
3090874|NCT01953640||Ancillary-correlative (gene expression with CYP-17 inhibition)|Laboratory Biomarker Analysis: Tissue, blood, and urine samples are collected at baseline and after 12-14 weeks of treatment and assessed for circulating tumor cells, genome-wide SNP, and exome sequencing. Subjects will also receive a Quality-of-Life Assessment.
3090875|NCT01953627|Experimental|Surgical procedure with the system Kymerax|
3090876|NCT01953614|Sham Comparator|Placebo group|Ten people. Participants will receive what appears to be a chiropractic adjustment but which actually is not. This is the sham adjustment. Participants will also fill out Achenbach questionnaire. There will be a follow up in 7 days.
3090877|NCT01953614|Active Comparator|Chiropractic adjustment|Ten people. Group will be getting chiropractic adjustments. Participants will be filling out Achenbach questionnaire. There will be a follow up in 7 days.
3090878|NCT01953614|No Intervention|Control group|Ten people. This group will simply have their EEG recorded at baseline and after 7 days. There will be an Achenbach questionnaire like the two other groups.
3090879|NCT01953601|Experimental|Verubecestat 12 mg|Single 12 mg verubecestat tablet once daily, taken orally, for 104 weeks (Part I). Participants who complete Part I will continue to receive verubecestat 12 mg once daily for up to an additional 260 weeks (Part II).
3090880|NCT01953601|Experimental|Verubecestat 40 mg|Single 40 mg verubecestat tablet once daily, taken orally, for 104 weeks (Part I). Participants who complete Part I will continue to receive verubecestat 40 mg once daily for up to an additional 260 weeks (Part II).
3090881|NCT01953601|Placebo Comparator|Placebo/Verubecestat 40 mg|Matching placebo to verubecestat tablet once daily, taken orally, for 104 weeks (Part I). Participants who complete Part I will receive verubecestat 40 mg once daily for up to 260 weeks (Part II).
3090882|NCT01953588|Active Comparator|Arm I (anastrozole)|Patients receive anastrozole daily for 6 cycles followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
3090883|NCT01953588|Active Comparator|Arm II (fulvestrant)|Patients receive fulvestrant on days 1 and 15 of cycle 1 and day 1 of cycles 2-6 followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
3090884|NCT01953588|Active Comparator|Arm III (anastrozole and fulvestrant)|Patients receive anastrozole daily in combination with fulvestrant on days 1 and 15 of cycle 1, and on day 1 of cycles 2-6 followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
3090885|NCT01953575|Experimental|Mucosal Impedance|"Patients with Eosinophilic Esophagitis and patient without trouble swallowing,during your clinical endoscopy (a standard procedure that allows your doctor to look at the inside of your swallowing tube), the 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope. This device has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it.~The catheter (tiny tube) will be placed through the endoscope in your esophagus (swallowing tube) 5 cm above where your stomach and esophagus meet for 5 seconds.~At 10 cm above where your stomach and esophagus meet the catheter will be placed for 5 seconds~And at 20 cm above where your stomach and esophagus meet the catheter will be placed for 5 seconds."
3090886|NCT01953562||Intubated infants|
3090887|NCT01953549|Experimental|physical fitness training|aerobic physical fitness training
3090888|NCT01953549|Active Comparator|relaxation|non-aerobic training
3090889|NCT01953536|Experimental|Vintafolide|Participants receive intravenous (IV) vintafolide 2.5 mg on Days 1, 3, 5, 15, 17, and 19 of a 28-day cycle.
3090890|NCT01953536|Experimental|Vintafolide + Paclitaxel|Participants receive IV vintafolide 2.5 mg on Days 1, 3, 5, 15, 17, and 19 of one 28-day cycle and receive IV paclitaxel on Days 1, 8, 15, and 22 of a 28-day cycle.
3090891|NCT01953536|Active Comparator|Paclitaxel|Participants receive IV paclitaxel on Days 1, 8, 15, and 22 of a 28-day cycle.
3090892|NCT01953523|Experimental|Deployment of stromal vascular fraction|Administration of autologous adipose derived SVF
3090893|NCT01953510|Active Comparator|A: 3+1 PCV10|PCV10 administered at 2, 3, 4 and 9 months of age
3090894|NCT01953510|Experimental|B: 3+0 PCV10|PCV10 administered at 2, 3 and 4 months of age
3090895|NCT01953510|Experimental|C: 2+1 PCV10|PCV10 administered at 2, 4 and 9 months of age
3090896|NCT01953510|Experimental|D: 1+1 PCV10|PCV10 administered at 2 and 6 months of age
3090897|NCT01953510|Experimental|E: 2+1 PCV13|PCV13 administered at 2, 4 and 9 months of age
3090898|NCT01953510|No Intervention|F: control|No infant PCV vaccination. PCV10 administered at 18 and 24 months of age
3090899|NCT01953510|No Intervention|G: control|Recruited at 18 months of age (non-randomised). PCV10 administered at 24 months of age
3090900|NCT01953497|Placebo Comparator|Placebo|Placebo
3090901|NCT01953497|Active Comparator|URC102|URC102
3090902|NCT01953484|Experimental|Acute Respiratory Distress Syndrome|Acute hypoxemia, bilateral pulmonary infiltrates and no evidence of primary left atrial hypertension
3090903|NCT01953484|Experimental|Chronic Obstructive Pulmonary Disease|Acute-on-Chronic Respiratory Insufficiency (patients with Chronic Obstructive Pulmonary Disease)
3090904|NCT01953484|Experimental|Bridge to Lung Transplant|Acute-on-Chronic Respiratory Insufficiency (patients awaiting lung transplant)
3090905|NCT01953471||Allergic rhinitis|
3090906|NCT01953458||hepatitis C and/or B|
3090907|NCT01953445|Experimental|Treatment (PI3K inhibitor BKM120, paclitaxel)|Patients receive PI3K inhibitor BKM120 PO QD on days 1-28 and paclitaxel IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
3090908|NCT01953432|Experimental|Doxazosin|Doxazosin is a long-acting and selective alpha 1-NE blocker, which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system.
3090909|NCT01953432|Placebo Comparator|Placebo|Matched placebo daily dosing.
3090910|NCT01953419|Experimental|Treatment group|received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity
3090911|NCT01953406|Experimental|The 5-fluorouracil/mitomycin group|Systemic chemotherapy with 5-fluorouracil/mitomycin 5-fluorouracin 15mg/kg/day D1-6 civ + Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
3090912|NCT01953380|Active Comparator|extended information|Extended information on specific allergy
3090913|NCT01953380|No Intervention|Information according to clin. routine|Information according to clinical routine
3090914|NCT01953367|Experimental|Vantobra; Treatment A|Vantobra, 170 mg tobramycin/1.7 mL nebulizer solution
3090915|NCT01953367|Active Comparator|TOBI; Treatment B|TOBI, 300 mg tobramycin/5 mL nebulizer solution
3090916|NCT01953354|Experimental|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period
3090917|NCT01953354|Placebo Comparator|Placebo|Six doses of TSO placebo orally over a ten-week period
3090918|NCT01953341|Experimental|AMG 333|Subjects will receive a single oral dose of AMG 333 .
3090919|NCT01953341|Placebo Comparator|Placebo|Subjects will receive a single oral dose of placebo.
3090920|NCT01953328|Placebo Comparator|A5 Placebo Q2W|Participants received atorvastatin 5 mg (A5) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
3090921|NCT01953328|Placebo Comparator|A5 Placebo QM|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.
3090922|NCT01953328|Experimental|A5 Evolocumab Q2W|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3090923|NCT01953328|Experimental|A5 Evolocumab QM|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.
3090924|NCT01953328|Placebo Comparator|A20 Placebo Q2W|Participants received atorvastatin 20 mg (A20) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.
3090925|NCT01953328|Other|A20 Placebo QM|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.
3090926|NCT01953328|Experimental|A20 Evolocumab Q2W|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3090927|NCT01953328|Experimental|A20 Evolocumab QM|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.
3090928|NCT01953315|Experimental|Autologous Muscle Progenitor Cells|Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
3090929|NCT01953302|Experimental|"modified open mesh technique"|"We performed an open intraperitoneal mesh technique in all patients: we placed surgical mesh of appropriate size intraperitoneally with transfascial fixation and drainage."
3090930|NCT01953289||Appendicitis|Free fluid in perforated or non-perforated appendicitis
3090931|NCT01953276||Serial Electrocardiogram Arm|All study participants will receive serial electrocardiograms.
3090932|NCT01953263|Experimental|Autologous Muscle Fiber Fragments|Autologous Muscle Fiber Fragments administered via a single,direct injection into the bladder neck sphincter region
3090933|NCT01953250||Infiltrating endometriosis|272 patients that underwent laparoscopic sigmoid and/or rectum resection with the indication of deep infiltrating endometriosis, in the department of Abdominal Surgery, University Hospital Leuven, between the year 1997 and September 2011.
3090934|NCT01953237|Active Comparator|Control|Individuals randomized to the control condition will be provided with a smartphone free of charge with unlimited use of the phone's voice and internet capabilities. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period. All participants will be contacted by research staff to trouble-shoot problems with the smartphone at the end of the first week, but will receive no additional contact from research staff until the end of the trial.
3090935|NCT01953237|Experimental|MedActive|Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
3090936|NCT01953224|Experimental|Game-based intervention|This arm will receive the game intervention, which will include provision of a mobile smartphone device, cellular data service, the game application loaded onto the device, credit to load approximately 40-50 songs onto the device, headphones, and an armband for wearing the device. Participants will also receive weekly counseling calls.
3090937|NCT01953224|No Intervention|Wait list control|This group will receive no intervention until after completion of the final assessment of the randomized trial. Then, they will receive the full intervention.
3090938|NCT01953211||Healthy reproductive age women|These volunteers were previously taking the oral contraceptives of interest for a minimum of 3 months
3090939|NCT01953198||All study participants|A total of 44 healthy and trained volunteers, age between 18 and 70 years. Subjects must have basic mountaineering experience.
3090940|NCT01953185|Experimental|Manual diaphragm release technique|
3090941|NCT01953185|Sham Comparator|Control group|
3090942|NCT01953172|Placebo Comparator|Placebo capsules|Placebo capsules
3090943|NCT01953172|Experimental|AMP-886 (alpha-tocotrienol) in capsules|AMP-886 (alpha-tocotrienol) in capsules
3090944|NCT01953159||Patients with severe neuropathy|Patients with severe neuropathy after treatment with paclitaxel. Blood samples and patient questionnaires will be collected.
3090945|NCT01953159||Patients without neuropathy|Patients will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age (within 10 years), tumor type, chemotherapy regimen or total paclitaxel dosage, race, and ethnicity
3090946|NCT01953146||PCOS criteria|nfertile patients undergoing assisted reproduction were consecutively recruited at the Fertility Clinic, Arhus University Hospital from February 2011 to May 2013. Women aged < 38 years without endometriosis where more than > 8 oocytes were retrieved were eligible. Patients were categorized in PCOS and non-PCOS according to the Rotterdam criteria for PCOS, defined by the presence of anovulation and polycystic ovaries.
3090947|NCT01953133|No Intervention|Control|"Couples do not receive intervention (counseling sessions) during study period. They do undergo one group-based session.~Upon completion of 9 month follow-up, participants in this arm can undergo a condensed, 2 session version of the intervention."
3090948|NCT01953133|Experimental|Couples' Counseling Sessions|4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
3090949|NCT01953120|Experimental|Belatacept|Survival and rejection in patients switched to belatacept.
3090950|NCT01953107|Experimental|Ferrous Fumarate 300 mg + Vitamin C|300 mg once a day of Oral Ferrous Fumarate
3090951|NCT01953107|Placebo Comparator|Placebo + Vitamin C|300 mg of Placebo
3090952|NCT01953094|Other|Anal Screening Pap Smear - Negative|Anal Pap Smear with no High Resolution Anoscopy
3090953|NCT01953094|Other|Anal Pap Smear - Positive Result - High Resolution Anoscopy|Patient who have a positive anal pap smear will go on to have a high resolution anoscopy.
3090954|NCT01953081|Experimental|TD-8954|TD-8954 single infusion for 1 hour and 4 injections of saline every 6 hours
3090955|NCT01953081|Active Comparator|Metoclopramide|Metoclopramide 4 doses every 6 hours for 24 hours and 1 hour infusion of saline
3090956|NCT01953055|Experimental|Stereotactic ablative radiotherapy|40 Gy in 5 fractions over 4 weeks to prostate; 25 Gy in 5 fractions over 4 weeks to pelvic lymph nodes given simulataneously.
3090957|NCT01953042|No Intervention|Waitlist as Per Usual|Wait list as per usual with no additional information sessions
3090958|NCT01953042|Active Comparator|Waitlist and Psychoeducation|Patients remain on waitlist but also receive 4 additional educational sessions (8 hours each)
3090959|NCT01953029||non obstructive coronary disease|non obstructive coronary disease
3090960|NCT01953003|Active Comparator|Arm B : capecitabine|1250 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest
3090961|NCT01953003|Experimental|Arm A : iv vinflunine plus capecitabine|Vinflunine dose 280 mg/m² on day 1 of each cycle every 3 weeks, Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest.
3090962|NCT01952990|Experimental|Kovacaine Mist|"Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - Total dose is based on weight. Subjects weighing 10 to <20 kg will receive 1 intranasal spray of 100 μL. Subjects weighing 20 to <40 kg will receive 2 intranasal sprays of 100 μL (total dose 200 μL.~Subjects weighing 40 kg or more will receive 2 intranasal sprays of 200 μL (total dose 400 μL)."
3090963|NCT01952977|Active Comparator|MCT|MCT oil (20 g) was included in the test breakfast
3090964|NCT01952977|Placebo Comparator|LCT|Corn oil (20 g) was included in the test breakfast
3090965|NCT01952964|Experimental|JUC spray dressing|
3090966|NCT01952951|Experimental|chemoradiation followed by CapOx|preoperative chemoradiation 50.4Gy with capecitabine or 5-fluorouracil/leucovorin (pelvic radiation capecitabine 5-fluorouracil) followed by 2 cycles of chemotherapy (Capecitabine Oxaliplatin - CapOx) and surgery (total mesorectal excision)
3090967|NCT01952951|Active Comparator|chemoradiation|preoperative chemoradiation 50.4Gy with capecitabine or 5-fluorouracil/leucovorin (pelvic radiation capecitabine 5-fluorouracil) followed by rest for 8 weeks and surgery (total mesorectal excision)
3090968|NCT01952938||LINK SL|Patients
3090969|NCT01952938||EnduRo|Patients
3090970|NCT01952925|Experimental|Combined afib ablation and RA denervation|Patients with atrial fibrillation and resistant hypertension will be enrolled and undergo a single procedure consisting of pulmonary vein isolation and renal artery denervation.
3090971|NCT01952912|Active Comparator|PkEP|
3090972|NCT01952912|Active Comparator|OP|
3090973|NCT01952899||Albert Schweitzer Hospital|
3090974|NCT01952899||Erasmus MC Academic Hospital|
3090975|NCT01952899||Ikazia Hospital|
3090976|NCT01952899||IJsselland Hospital|
3090977|NCT01952899||Maasstad Hospital|
3090978|NCT01952899||Sint Franciscus Gasthuis Hospital|
3090979|NCT01952886|Experimental|Granisetron patch|Granisetron transdermal delivery system (supplied as a 52 cm^2 patch containing 34.3 mg of granisetron - 3.1 mg/day) is applied once per week.
3090980|NCT01952886|Active Comparator|Ondansetron tablet|Ondansetron 8 mg oral tablet is prescribed for once a day.
3090981|NCT01952873|Active Comparator|Rapid|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but <30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
3090982|NCT01952873|Experimental|Prolonged|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with <0.3 atm drop during that period.
3090983|NCT01952860|Experimental|Hatha Yoga|Participants receive 18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home. Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
3090984|NCT01952847|Placebo Comparator|mTOR Inhibitor Patient Group - Placebo|Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
3091024|NCT01952574|Experimental|Erenumab 7 mg QM|Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.
3090985|NCT01952847|Experimental|mTOR Inhibitor Patient Group - Glutamine|Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
3090986|NCT01952847|Placebo Comparator|Radiation Therapy to Esophagus Patient Group - Placebo|Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times.
3090987|NCT01952847|Experimental|Radiation Therapy to Esophagus Patient Group - Glutamine|Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times.
3090988|NCT01952834|Experimental|GoodBelly Probiotic and Vancomycin|Good Belly Probiotic 2.7 oz Daily x 6 weeks Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
3090989|NCT01952821||Test Group|This group will receive all listed outcome measures on 2 testing visits.
3090990|NCT01952808|Experimental|Intervention Group|Participants randomly assigned to this group will receive the intervention immediately.
3090991|NCT01952808|No Intervention|Control Group|Participants randomly assigned to this group will not receive the intervention until one year after enrollment.
3090992|NCT01952795|Active Comparator|Diet and exercise|Total caloric intake aimed at maintaining a diet with> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day. 3 sessions per week on a bicycle ergometer or on a treadmill (according to body fat distribution and other parameters) modifications carried out weekly, with a gradual increase as to exercise until maximal oxygen consumption 60 - 70% would always preceded by heating 5 minutes.
3090993|NCT01952795|No Intervention|No intervention|Usual diet and exercise
3090994|NCT01952782|Experimental|Naloxone, Kisspeptin, GnRH|"The study will involve 3 visits:~Outpatient screening visit~Inpatient admission where subjects receive an intravenous infusion of naloxone, intravenous doses of kisspeptin 112-121, and intravenous doses of Gonadotropin Releasing Hormone (GnRH)~Outpatient follow-up visit"
3090995|NCT01952769|Experimental|treatment of DIPG with MDV9300|treatment of diffuse pontine glioma with MDV9300 with the combination of radiation and low dose cyclophosphamide
3090996|NCT01952756|Active Comparator|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
3090997|NCT01952756|Placebo Comparator|Dummy Placebo|One tablet twice per day for 12 weeks
3090998|NCT01952743|Active Comparator|AF Ablation alone|Clinical AF ablation performed as deemed appropriate by operator
3090999|NCT01952743|Experimental|AF ablation with Renal Denervation|Renal denervation performed using the same ablation catheter after clinical AF ablation
3091000|NCT01952730|Experimental|Experimental Treatment Arm|GVAX, up to 6 vaccinations, administered via injection
3091001|NCT01952704|Experimental|Aerobic exercise|30 minutes x 3 times/week x 12 weeks of stationery cycling
3091002|NCT01952704|Placebo Comparator|Non-aerobic exercise|30 minutes x 3 times/week x 12 weeks of gentle non-aerobic stretching
3091003|NCT01952691|Experimental|kinesiotaping|all patients were implemented a kinesiotaping to align the hallux to correct position
3091004|NCT01952678||DaTscan™ - Non-Caucasian Participants|Non-Caucasian participants previously administered DaTscan™, with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the participant's final clinical diagnosis of PD or ET.
3091005|NCT01952678||DaTscan™- Caucasian Participants|Caucasian participants previously administered DaTscan™, with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the participant's final clinical diagnosis of PD or ET.
3091006|NCT01952665|Active Comparator|comfilcon A|Daily wear soft contact lens comfilcon A
3091007|NCT01952665|Active Comparator|lotrafilcon B|Daily wear soft contact lens lotrafilcon B
3091008|NCT01952652|Active Comparator|Group Naproxen sodium (Group N)|Group N received naproxen sodium 550 mg 60 minutes before surgery.
3091009|NCT01952652|Active Comparator|Group Naproxen sodium codeine phosphate (Group NC)|Group NC received naproxen sodium 550 mg+30 mg codeine 60 minutes before surgery.
3091010|NCT01952639|Experimental|30 g of wheat protein|Subjects will consume 30 g of wheat protein protein type and amount
3091011|NCT01952639|Experimental|30 g of wheat protein hydrolysate|Subjects will consume 30 g of wheat protein hydrolysate protein type and amount
3091012|NCT01952639|Active Comparator|30 g of whey protein|Subjects will consume 30 g of whey protein protein type and amount
3091013|NCT01952639|Active Comparator|30 g of casein|Subjects will consume 30 g of casein protein type and amount
3091014|NCT01952639|Experimental|60 g of wheat protein hydrolysate|Subjects will consume 60 g of wheat protein hydrolysate protein type and amount
3091015|NCT01952626|Active Comparator|ondansetron|Intravenous administration of ondansetron 4mg 15 minutes before spinal anesthesia
3091016|NCT01952626|Experimental|palonosetron|Intravenous administration of palonosetron 0.075mg 15 minutes before spinal anesthesia
3091017|NCT01952613|Experimental|Stroke - FES|Stroke population currently prescribed a FES orthotic device (< week)
3091018|NCT01952600||Chronic Kidney Disease (CKD)|Patients who have advanced chronic kidney disease, but are not currently on either hemodialysis (HD) or peritoneal dialysis (PD).
3091019|NCT01952600||Hemodialysis (HD)|Patients who have chronic kidney disease (CKD) and are currently on hemodialysis.
3091020|NCT01952600||Peritoneal Dialysis (PD)|Patients who have chronic kidney disease (CKD) and are currently on peritoneal dialysis.
3091021|NCT01952587|Other|HIV-infected women|A peripheral blood sample will be collected from HIV-infected women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed.
3091022|NCT01952587|Other|Healthy control women|A peripheral blood sample will be collected from healthy women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
3091023|NCT01952574|Placebo Comparator|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.
3091025|NCT01952574|Experimental|Erenumab 21 mg QM|Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.
3091026|NCT01952574|Experimental|Erenumab 70 mg QM|Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.
3091027|NCT01952561|Experimental|2 weeks|
3091028|NCT01952561|Experimental|1 week|
3091029|NCT01952561|Experimental|4 weeks|
3091030|NCT01952561|Experimental|8 weeks|
3091031|NCT01952561|Experimental|12 weeks|
3091032|NCT01952548|Experimental|Dose 1 Active|
3091033|NCT01952548|Experimental|Dose 2 Active|
3091034|NCT01952548|Experimental|Dose 3 Active|
3091035|NCT01952548|Experimental|Dose 4 Active|
3091036|NCT01952548|Experimental|Dose 5 Active|
3091037|NCT01952548|Experimental|Dose 6 Active|
3091038|NCT01952548|Experimental|Dose 7 Active|
3091039|NCT01952548|Placebo Comparator|Dose 1 Placebo|
3091040|NCT01952548|Placebo Comparator|Dose 2 Placebo|
3091041|NCT01952548|Placebo Comparator|Dose 3 Placebo|
3091042|NCT01952548|Placebo Comparator|Dose 4 Placebo|
3091043|NCT01952548|Placebo Comparator|Dose 5 Placebo|
3091044|NCT01952548|Placebo Comparator|Dose 6 Placebo|
3091045|NCT01952548|Placebo Comparator|Dose 7 Placebo|
3091046|NCT01952535|Experimental|HMS5552 dose 1|A single dose of HMS5552 tablets (5~50mg) taken orally.
3091047|NCT01952535|Experimental|HMS5552 dose 2|A single dose of HMS5552 tablets (5~50mg) taken orally.
3091048|NCT01952535|Experimental|HMS5552 dose 3|A single dose of HMS5552 tablets (5~50mg) taken orally.
3091049|NCT01952535|Experimental|HMS5552 dose 4|A single dose of HMS5552 tablets (5~50mg) taken orally.
3091050|NCT01952535|Experimental|HMS5552 dose 5|A single dose of HMS5552 tablets (5~50mg) taken orally.
3091051|NCT01952535|Experimental|HMS5552 dose 6|A single dose of HMS5552 tablets (5~50mg) taken orally.
3091052|NCT01952522|Experimental|Weighted brace|
3091053|NCT01952522|Placebo Comparator|non weighted brace|
3091054|NCT01952509||Cohort|
3091055|NCT01952496|Other|Force-measuring platform|"A force-measure platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.~Intervention: Assisted Standing Treatment Program. Assisted standing treatment program will include at least 2 hours a day, 5 days a week (a total of at least 10 hours a week) for a period of ~9 months."
3091056|NCT01952483||vitamin D deficient,|Vitamin D deficiency (serum level <20ng/ml)
3091057|NCT01952483||Vitamin D normal|Serum level >35 ng/ml
3091058|NCT01952470|Experimental|Dornase Alpha|Once daily, 2.5ml inhaled dornase alpha.
3091059|NCT01952470|Active Comparator|Isotonic Saline|Once daily, 5ml inhaled 0.9% normal saline.
3091060|NCT01952457|Experimental|Zilver PTX|Patients in the Zilver PTX arm have to be treated by placement of the Zilver PTX drug-eluting stent (Cook), according to standard procedures based on the Instructions for Use. The only pre-treatment allowed prior to placement of the Zilver PTX drug-eluting stent (Cook) is standard PTA. Diameter measurements must be performed of the healthy vessel proximal and distal to the previously stented area. Diameter selection of the Zilver PTX drug-eluting stent (Cook) should result in minimal oversizing. The target lesion needs to be completely covered by using as few stents possible. Post-dilatation can be performed according to the Instructions of Use.
3091061|NCT01952457|Active Comparator|prosthetic bypass|Patients in the bypass arm have to be treated with a prosthetic bypass graft according to the institution's standard of care and the Instructions for Use of the prosthetic bypass graft.
3091062|NCT01952444|Experimental|ETI-204|Intravenous (IV) single dose
3091063|NCT01952444|Experimental|ETI-204 and IV Ciprofloxacin and Oral Ciprofloxacin|Intravenous (IV) ETI-204 and IV Ciprofloxacin and Oral Ciprofloxacin
3091064|NCT01952431|Experimental|PulmOne MiniBox PFT|Total Lung Capacity (TLC) testing with PulmOne MiniBoxPFT
3091065|NCT01952431|Active Comparator|ZAN500|Total Lung Capacity (TLC) testing with ZAN500.
3091066|NCT01952418|No Intervention|"Standard monitor (24)"|"Endoscopists in this arm will perform colonoscopy using the standard size video monitor (24)."
3091067|NCT01952418|Active Comparator|"Large monitor (32)"|"Subjects randomized to this group will perform colonoscopy while viewing a large video monitor (32)."
3091068|NCT01952405|Experimental|Dialectical behavior therapy|Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
3091069|NCT01952405|Placebo Comparator|alternative psychotherapy|The therapists of the alternative psychotherapy in the comparison group are asked to provide the type and dose of therapy that they believed is most suited to the patient, with a minimum of 1 scheduled individual session per week. Ancillary treatment could be prescribed as needed. Case management strategies are also available in the comparison group (alternative psychotherapy group). No restrictions are placed on ancillary pharmacotherapy in either condition.
3091070|NCT01952392||Control group|Patients aged 18 years or more with an acute coronary syndrome, agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
3091071|NCT01952392||Case group|Patients aged 18 years or more with a history of acute coronary syndrome (i.e. a recurrent MI after myocardial history or unstable angina), agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
3091072|NCT01952379||Melasma|Women affected by symmetric facial malar melasma.
3091073|NCT01952366||Depressed patients|Patients admitted to specialist health care service of old age psychiatry
3091074|NCT01952353|Experimental|Preoperation TACE arm|In the preoperative TACE arm, patients underwent up to 2 sessions of TACE as initial treatments, and only patients who reevaluated as resectabe disease were subjected to surgical resection. Otherwise patients who showed unresectable disease was performed repeated TACE unless the end points of the TACE were reached
3091075|NCT01952353|Active Comparator|Resection arm|Liver resection Plus Thrombectomy
3091076|NCT01952340|Experimental|Flaxseed|30 grams of milled flaxseed on its own or baked into food products (ie: bagels, muffins, and snack bars)
3091077|NCT01952340|Placebo Comparator|Wheat/Mixed Dietary Oils|A combination of wheat, pecans, and/or mixed dietary oils on its own or baked into food products (ie: bagels, muffins, and snack bars)
3091078|NCT01952327|Other|plueurapump|Implantation of pleurapump system
3091079|NCT01952314|Placebo Comparator|Control groups with only analgesics|Control groups will receive only analgesics.
3091080|NCT01952314|Active Comparator|Naftopidil|This interventional group will receive analgesics and naftopidil 75mg po qd.
3091081|NCT01952301|Active Comparator|xenogeneic collagen matrix|Xenogeneic collagen matrix device placed on treatment wound bed site
3091082|NCT01952301|Active Comparator|Free Gingival Graft|Traditional free gingival graft (autogenous graft device harvested from patient's palate) placed on treatment site wound bed
3091083|NCT01952288|Experimental|simvastatin|simvastatin 40 mg/day
3091084|NCT01952288|Placebo Comparator|placebo|
3091085|NCT01952262||critically ill ICU patients|critically ill intensive care unit patients
3091086|NCT01952249|Experimental|Demcizumab|Demcizumab will be administered prior to paclitaxel by intravenous (IV) infusion.
3091087|NCT01952249|Experimental|Taxol|demcizumab combined with weekly paclitaxel
3091088|NCT01952236|Experimental|Web+Mobile|A best-practices Web-based smoking cessation program integrated with a tailored treatment program delivered using a smartphone application.
3091089|NCT01952236|Active Comparator|Web Only|A best-practices Web-based smoking cessation program.
3091090|NCT01952223|Experimental|ADT + pelvic RT|"ADT for a total duration of 3 years i.e.LHRH agonist or LHRH antagonist +/-Peripheral anti-androgen~Pelvic RT (by IMRT or IGRT protocol):~Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
3091091|NCT01952223|Experimental|ADT + Cabazitaxel + prostate RT|"ADT Cabazitaxel: 4 CT cycles~Prostate-only RT (IMRT or IGRT):~Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
3091092|NCT01952223|Experimental|ADT + cabazitaxel + pelvic RT|"ADT Cabazitaxel: 4 CT cycles~Pelvic RT (IMRT or IGRT):~Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
3091093|NCT01952223|Active Comparator|ADT + prostate radiotherapy|"ADT for a total duration of 3 years: LHRH agonist or LHRH antagonist +/- anti-androgen~Prostate-only RT (IMRt or IGRT):~Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
3091094|NCT01952210|Experimental|nutrition consultation and exercise program|individual nutritional consultation and exercise
3091095|NCT01952210|Active Comparator|usual care|pre-CCRT education included self-care during CCRT and body weight maintenance
3091096|NCT01952197|Experimental|Passive Leg Raise|The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
3091097|NCT01952184|Active Comparator|closed vitrification with closed storage|Half of the oocytes of every donor will be vitrified with the Cryo Bio Systems High Security vitrification (CBSvit HS) device; the standard device in our lab.
3091098|NCT01952184|Experimental|open vitrification with closed storage|Half of the oocytes of every donor will be vitrified with the Cryotop closed system (Cryotop SC).
3091099|NCT01952171||Congenital Heart Disease|Patients with Congenital Heart Disease
3091100|NCT01952145|Experimental|Insulin degludec/liraglutide OD plus metformin|
3091101|NCT01952145|Active Comparator|Insulin glargine OD plus metformin|
3091102|NCT01952132|Experimental|OMS643762 Low Dose|Orally administering OMS643762 low dose daily for 14 days
3091103|NCT01952132|Experimental|OMS643762 High Dose|Orally administering OMS643762 high dose daily for 14 days
3091104|NCT01952132|Placebo Comparator|Placebo|Orally administering placebo daily for 14 days
3091105|NCT01952132|Experimental|OMS643762 Medium Dose|Orally administering OMS643762 medium dose daily for 14 days
3091106|NCT01952119|No Intervention|Routine Care|Routine care, no intervention
3091107|NCT01952119|Active Comparator|Secure message reminder|Will receive a secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
3091108|NCT01952106|Experimental|distraction|use the computer game to distract children's pain and anxiety during venepuncture
3091109|NCT01952093||Usual care program|VLBW preterm infants who received usual medical care during hospitalization after birth.(in the previous study)
3091110|NCT01952093||Clinic-based intervention program|VLBW preterm infants who received specific early intervention program delivered at clinic before 1 year of corrected age (in the previous study)
3091111|NCT01952093||Home-based intervention program|VLBW preterm infants who received specific early intervention program delivered at home before 1 year of corrected age (in the previous study)
3091112|NCT01952093||Term control group|Healthy term infants
3091113|NCT01952080|Experimental|teduglutide|Open label teduglutide, subcutaneously injected.
3091114|NCT01952080|No Intervention|Standard of Care|
3091115|NCT01952067|Experimental|line-to-line reaming|Corail cemented femoral stem using line-to-line reaming and cementing technique, 28mm Alumine Biolox forte femoral head, Marathon cup
3091116|NCT01952067|Active Comparator|standard over-reaming|Corail cemented femoral stem using standard over-reaming with 2 broach sizes, 28mm Alumine Biolox forte femoral head, Marathon cup
3091117|NCT01952054|Experimental|Denosumab|Participants receive a single subcutaneous (SC) administration of Denosumab 120 mg every 4 weeks (+/- 5days). Starting week 5, in addition to receiving Denosumab every 4 weeks, participants receive a hormonal agent chosen by each physician, excluding the agent that participants received at adjuvant therapy setting.
3091118|NCT01952041|Experimental|Device: Smartphone|Participants in the smartphone intervention arm will receive treatment as usual in addition to receiving a smart phone with intervention application. The smartphone intervention application uses sensor streams to identify relapse signatures that prompts the individual and clinical team to provide enhanced services.
3091119|NCT01952041|Active Comparator|Treatment as Usual|Treatment as usual includes outpatient case management, linkage to services and medication monitoring.
3091120|NCT01952015|Experimental|Secukinumab|"All subjects will be assigned to receive secukinumab 150 mg. Secukinumab 150 mg s.c. injection will be administered at BSL, Weeks 1, 2, 3, 4. Prior to receiving the Week 8 dose, all subjects will be assigned to the following treatment group based on clinical components of their CGI evaluation at Week 8.~No up-titration group will receive 1 injection of secukinumab 150 mg at Weeks 8, 12, and each visit from Week 16 until Week 48.~Up-titration group will receive 2 injections of secukinumab 150 mg at Weeks 8, 9, 12 and each visit from Week 16 until Week 48.~Subjects receiving secukinumab 150 mg can be up-titrated to secukinumab 300 mg at any visit starting at Week 16 based on clinical components of their CGI evaluation and investigator's discretion."
3091121|NCT01952002||IMT - Inspiratory Muscle Training|21 (16 males/5 femalesen) with a mean age of 73 ± 7.4 years were studied. Among the 21 study participants, the most prevalent clinical condition was coronary artery disease (11 cases); four individuals showing a diagnosis of chronic obstructive pulmonary disease and/or asthma, two presented congestive heart failure and the last four had other diseases
3091122|NCT01951989|Experimental|Imiglucerase|"Primary purpose: to evaluate the pharmacokinetics of Imiglucerase activity into target cellular compartment depending on dose and frequency of infusions.~Secondary purposes : 1) to establish a possible relationship between the intra-monocytic activity of glucocerebrosidase and the clinical and biological activity of Gaucher disease and to define a possible threshold value of enzyme activity; 2) to establish a better correlation with known biomarkers of disease (routine markers and markers recently identified), which would better predict and / or monitor response to treatment ; 3) to compare the residual and natural rate of activity enzyme intra-monocytic for untreated patients (low severity disease)."
3091123|NCT01951976|Experimental|Intervention Condition|"Questionnaires and yoga classes.~Group will attend a series of 90-minute yoga classes twice a week for 12 weeks."
3091124|NCT01951963|Experimental|Ketamine|Ketamine, single dose, 0.3 mg/kg, IV
3091125|NCT01951963|Active Comparator|Morphine|Morphine, single dose, 0.05 mg/kg, IV
3091126|NCT01951950|Active Comparator|Nicardipine|"Subjects will receive a 15 mcg/kg bolus of nicardipine as needed followed by an infusion initiated at 5 mg/hr. Nicardipine may be titrated every 5 minutes, increasing 5 mg/hr and administering 15 mcg/kg bolus every minute to a maximum dose of 15 mg/hr. If systolic blood pressure (SBP) is not maintained < 140 mmHg 5 minutes after achieving the maximum dose of nicardipine, medication failure will be declared and rescue drug (medication to be determined per anesthesiologist discretion) will be administered. Infusions may be titrated down if SBP decreases below 90 mmHg."
3091127|NCT01951950|Active Comparator|Esmolol|"Subjects will receive a 0.5 mg/kg bolus of esmolol as needed followed by an infusion initiated at 50 mcg/kg/min. Esmolol may be titrated every 5 minutes, increasing 50 mcg/kg/min and administering 0.5 mg/kg bolus every minute to a maximum dose of 200 mcg/kg/min. If SBP is not maintained < 140 mmHg 5 minutes after achieving the maximum dose of esmolol, medication failure will be declared and rescue drug (medication to be determined per anesthesiologist discretion) will be administered. Infusions may be titrated down if SBP decreases below 90 mmHg."
3091128|NCT01951937|Active Comparator|Fish Meals|3 Fish meals per week for 4 months
3091129|NCT01951937|Placebo Comparator|Placebo|Habitual diet
3091130|NCT01951924|Experimental|Group A: I10E then Kiovig®|1 g/kg for 1-3 days up to 2 g/kg for 2-5 days every 4 to 8 weeks (±7 days)
3091131|NCT01951924|Experimental|Group B : Kiovig® then I10E|1 g/kg for 1-3 days up to 2 g/kg for 2-5 days every 4 to 8 weeks (±7 days)
3091132|NCT01951911|Active Comparator|Ketamine|Ketamine 1 mg per kg per 24 hours as subcutaneous infusion via syringe driver for 48 hours.
3091133|NCT01951911|Placebo Comparator|Placebo|Sodium chloride 0.9% administered as a subcutaneous infusion via syringe driver for 48 hours.
3091134|NCT01951898|Active Comparator|Montelukast|
3091135|NCT01951898|Sham Comparator|Vitamin B6|
3091136|NCT01951885|Active Comparator|Group A (tacrolimus, methotrexate)|Patients receive tacrolimus IV over 24 hours beginning on day -1 and then PO BID after engraftment with a taper from day 100 to day 180 (in the absence of GVHD). Patients also receive methotrexate IV on days 1, 3, 6, and 11.
3091137|NCT01951885|Experimental|Group B (tacrolimus, methotrexate, mycophenolate mofetil)|Patients receive tacrolimus as in group A and methotrexate (low dose) IV on days 1, 3, and 6. Patients also receive oral mycophenolate mofetil BID beginning on day 1, with a taper from day 45 to day 100 (in the absence of GVHD).
3091138|NCT01951872|Experimental|Immediate treatment|Immediate manual-based treatment for caffeine dependence: administered within approximately one week following intake.
3091139|NCT01951872|Experimental|Delayed treatment|Delayed manual-based treatment for caffeine dependence: administered within approximately six weeks following intake.
3091140|NCT01951859|Experimental|Topical Neuropathy/Ulcer Cream|an anti-inflammatory topical cream that contains homeopathic ingredients
3091141|NCT01951859|Placebo Comparator|Placebo Cream|
3091142|NCT01951846|Experimental|BIBF 1120|
3091143|NCT01951833||Cystic fibrosis (Ecomedics vs NDD)|No treatment, observational
3091144|NCT01951833||Healthy (Ecomedics vs NDD)|"Free of respiratory symptoms for at least two weeks and will not have any chronic or recurrent chest problem.~No treatment, observational"
3091145|NCT01951820|Active Comparator|Benzocaine|Benzocaine topical numbing gel will be applied to the gums before injection with other intervention, injection of local anesthetic articaine.
3091146|NCT01951820|Experimental|Pliaglis|Pliaglis topical numbing gel will be applied to the gums before injection with other intervention, injection of local anesthetic articaine.
3091147|NCT01951807|Experimental|Coping & Communication Skills|The CCI intervention focuses on bolstering stress management and problem solving abilities, identifying and expressing support needs constructively, facilitating the ability to cope with unchangeable issues, cognitive restructuring, and dealing effectively with body image and sexuality issues over seven weekly 60 minute sessions.
3091148|NCT01951807|Experimental|Supportive Counseling (SC)|The SC intervention incorporates a supportive, non-directive counseling approach in seven weekly 60 minute sessions
3091149|NCT01951807|No Intervention|Usual Care (UC)|Patients receive standard psychological and emotional care (usual care [UC]) (i.e., social work consultations and referral to a psychiatrist or psychologist, if requested or deemed necessary by the attending physician).
3091150|NCT01951781|Other|NEOCD64|NEOCD64 : dosage of CD64 blood marker in preterm newborn who are suspected of nosocomial infection (blood sample)
3091151|NCT01951768|Experimental|Garamycin Sponge (Gentamicin-Collagen Sponge)|Garamycin Sponge (Gentamicin-Collagen sponge) applied daily plus systemic antibiotic and standard ulcer care
3091152|NCT01951768|Active Comparator|Systemic Antibiotic|Systemic antibiotic therapy and standard ulcer care
3091153|NCT01951742|Placebo Comparator|Vehicle|vehicle without ANT-1401
3091154|NCT01951742|Experimental|Dose 1|lowest dose
3091155|NCT01951742|Experimental|Dose 2|second lowest dose
3091156|NCT01951742|Experimental|Dose 3|mid-level dose
3091157|NCT01951742|Experimental|Dose 4|second highest dose
3091158|NCT01951742|Experimental|Dose 5|highest dose
3091159|NCT01951729|Experimental|Pre-diabetes|Otherwise healthy individuals exhibiting hemoglobin A1c levels between 6.0% - 7.0%
3091160|NCT01951716|Experimental|Truncal Vagotomy|Healthy participants without diabetes who have undergone a complete truncal vagotomy
3091161|NCT01951716|Experimental|No Vagotomy|Healthy participants without diabetes who have not had a complete truncal vagotomy
3091162|NCT01951703|Active Comparator|Control, senofilcon A|Subjects received Control lens, senofilcon A during the first two weeks of the study then Test lens, senofilcon A in the last two weeks of the study.
3091163|NCT01951703|Experimental|Test, senofilcon A|Subjects received Test lens, senofilcon A during the first two weeks of the study then Control lens, senofilcon A in the last two weeks of the study.
3091164|NCT01951690|Experimental|VS-6063 (defactinib)|Administered orally BID in a 21 day cycle
3091165|NCT01951677|Active Comparator|HBsAg + alum adjuvant|HBsAg + standard alum adjuvant
3091166|NCT01951677|Experimental|HBsAg + Advax-1(TM)|HBsAg + Advax-1
3091167|NCT01951677|Experimental|HBsAg + Advax-2(TM)|HBsAg + Advax-2
3091168|NCT01951677|Experimental|HBsAg + Advax-3(TM)|HBsAg + Advax-3
3091169|NCT01951677|Active Comparator|preS HBsAg + alum adjuvant|preS HBsAg + alum adjuvant
3091170|NCT01951677|Experimental|preS HBsAg + Advax-1(TM)|preS HBsAg + Advax-1
3091171|NCT01951677|Experimental|preS HBsAg + Advax-2(TM)|preS HBsAg + Advax-2
3091172|NCT01951677|Experimental|preS HBsAg + Advax-3(TM)|preS HBsAg + Advax-3
3091173|NCT01951677|Active Comparator|high dose preS HBsAg + alum adjuvant|high dose preS HBsAg + alum adjuvant
3091174|NCT01951677|Experimental|high dose preS HBsAg + Advax-1(TM)|high dose preS HBsAg + Advax-1
3091175|NCT01951677|Experimental|high dose preS HBsAg + Advax-2(TM)|high dose preS HBsAg + Advax-2(TM)
3091176|NCT01951677|Experimental|high dose preS HBsAg + Advax-3(TM)|high dose preS HBsAg + Advax-3
3091177|NCT01951664|Experimental|Modified Yoga Program for HNC Survivors|Following the completion of baseline study measures, participants will be randomized to either do go directly into a Yoga program or to an 8 week wait-list control group. Those in the yoga program will undergo an initial Yoga Evaluation. Patients will receive customized yoga guided practice program, a home practice plan with ongoing modifications. Instructors will assess compliance. A satisfaction assessment is conducted at study-end.
3091178|NCT01951664|Active Comparator|Wait list control|Those in the wait list group will have the same assessments as those in the yoga program over the same period of time.
3091179|NCT01951651|Experimental|Exenatide|Exenatide 10 micrograms injected subcutaneously twice daily for 6 months
3091180|NCT01951651|Experimental|Glipizide|Glipizide 5 mg (tablet), one tablet twice daily orally for 6 months
3091181|NCT01951638|Experimental|Vericiguat (BAY1021189)(10 mg)|2.5 mg orally once daily for 2 weeks, up-titration to 5 mg orally once daily for 2 weeks, up-titration to 10 mg orally once daily for 8 weeks
3091182|NCT01951638|Experimental|Vericiguat (BAY1021189) (5 mg)|2.5 mg orally once daily for 2 weeks, then 5 mg orally once daily for 10 weeks (with sham titration)
3091183|NCT01951638|Experimental|Vericiguat (BAY1021189) (2.5 mg)|2.5 mg orally once daily for 12 weeks (with sham titrations)
3091184|NCT01951638|Experimental|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg orally once daily for 12 weeks (with sham titrations)
3091185|NCT01951638|Placebo Comparator|Placebo|Orally once daily for 12 weeks (with sham titrations)
3091186|NCT01951625|Experimental|Vericiguat (BAY1021189) (10 mg)|2.5 mg orally once daily for 2 weeks, up-titration to 5 mg orally once daily for 2 weeks, up-titration to 10 mg orally once daily for 8 weeks
3091187|NCT01951625|Experimental|Vericiguat (BAY1021189) (5 mg)|2.5 mg orally once daily for 2 weeks, then 5 mg orally once daily for 10 weeks (with sham titration)
3091188|NCT01951625|Experimental|Vericiguat (BAY1021189) (2.5 mg)|2.5 mg orally once daily for 12 weeks (with sham titrations)
3091189|NCT01951625|Experimental|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg orally once daily for 12 weeks (with sham titrations)
3091190|NCT01951625|Placebo Comparator|Placebo|Orally once daily for 12 weeks (with sham titrations)
3091191|NCT01951612|Experimental|Executive Function Training Program|Participants in this group will receive the novel intervention training.
3091192|NCT01951612|Active Comparator|Psychoeducational Training Program|Participants in this group will receive the control intervention training.
3091193|NCT01951599|Experimental|AZD9291 20mg (oral capsule fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule, in the fasted state.
3091194|NCT01951599|Experimental|AZD9291 20mg (oral solution fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a solution, in the fasted state.
3091195|NCT01951599|Experimental|AZD9291 20mg (oral tablet fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a tablet, in the fasted state.
3091196|NCT01951599|Experimental|AZD9291 20mg (oral fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fasted state.
3091197|NCT01951599|Experimental|AZD9291 20mg (oral fed)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fed state.
3091198|NCT01951586|Placebo Comparator|Placebo|Participants received placebo matching to denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received 4 mg zoledronic acid administered as an IV infusion Q4W or Q3W.
3091233|NCT01951313|Experimental|Egg consumption|No egg 75g of scrambled eggs 150g of scrambled eggs
3091199|NCT01951586|Experimental|Denosumab|Participants received 120 mg denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received placebo to zoledronic acid administered as an IV infusion Q4W or Q3W.
3091200|NCT01951573|Other|Delefilcon A MF, then AOAMF|Delefilcon A multifocal contact lenses first, followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.
3091201|NCT01951573|Other|AOAMF, then Delefilcon A MF|Lotrafilcon B multifocal contact lenses first, followed by delefilcon A multifocal contact lenses. Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.
3091202|NCT01951560|Experimental|valproic acid (Depacon)|Valproic acid by IV infusion over one hour
3091203|NCT01951560|Placebo Comparator|Isotonic saline solution|The placebo administered by IV infusion over 1 hour
3091204|NCT01951547|Experimental|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy given at baseline
3091205|NCT01951547|Active Comparator|Oral hygiene instructions|Oral hygiene instructions given at baseline
3091206|NCT01951534|Experimental|Breast Reconstruction Decisional Aid (BRDA)|In the BRDA arm, participants will be provided with a website address for using the Breast Reconstruction Decisional Aid, a secure password, and instructions for using the website for the decisional aid.
3091207|NCT01951534|Other|Usual Care (UC)|In the UC Condition, the participant will not be given the web-based decisional aid but will be given the Cancer Support Community pamphlet. This 56-page pamphlet contains information about the types of Breast Reconstruction, lists reasons why women choose reconstruction, key factors to considering when deciding, how to plan for surgery, possible risks, and a glossary of terms. The pamphlet is primarily informational. It is not customized, not interactive.
3091208|NCT01951521|Experimental|Boost|Boost radiation consists of 5 fractions of 3 Gy (total 15 Gy) delivered to the tumor (Gross Tumor Volume) additional to standard chemoradiation of 50 Gy with Capecitabine.
3091209|NCT01951521|No Intervention|Standard chemoradiation|Standard chemoradiation consisting of 25 x 2 Gy (total 50 Gy) with Capecitabine.
3091210|NCT01951508|Other|Methylphenidate, Modafinil, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but four treatment conditions in the same subject.
3091211|NCT01951482|Experimental|Bevacizumab and Pemetrexed/cisplatin|Bevacizumab 7.5mg/kg d1+Pemetrexed/cisplatin q21d
3091212|NCT01951482|Active Comparator|Pemetrexed/cisplatin|Pemetrexed/cisplatin q21d
3091213|NCT01951469|Experimental|Gefitinib and Pemetrexed/cisplatin|Gefitinib 250mg is Taken Orally on day 4-28,combined Pemetrexed/cisplatin chemotherapy on day 1-3, every 28 days
3091214|NCT01951469|Active Comparator|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
3091215|NCT01951456|Experimental|Resistance training|Participants will attend two, 45-60-minute progressive, moderate intensity resistance training sessions per week for 12 weeks. The program will maintain a format of a 5-minute warm-up, 35-50 minutes of resistance training and a 5-minute cool-down with flexibility and abdominal exercises.
3091216|NCT01951456|Active Comparator|Health and Wellness|Participants in this group will be required to attend the exact same number of sessions as those in the Resistance Training group. Each session will last approximately 45-60 minutes. Sessions will include a practical component/demonstration, an informational video, and a handout on a pertinent healthy lifestyle topic for adults.
3091217|NCT01951443|Experimental|Ginseng|Encapsulated 400mg Rg3-KRG extract
3091218|NCT01951443|Placebo Comparator|Wheat Bran|400mg Wheat Bran capsule
3091219|NCT01951430||Myelodysplastic syndrome patients|Patients affected by myelodysplastic syndrome enrolled in the observational study
3091220|NCT01951417|Experimental|Adapalene/BPO Gel/Foam Wash/Moisturizer|Adapalene BPO Gel Pump (once daily) in conjunction with a Foam Wash (twice daily) and Moisturizer SPF 30 (once daily)
3091221|NCT01951404|Active Comparator|Allopurinol|Participants in this arm will be given allopurinol with the dose gradually increasing weekly as tolerated up to the dose determined in the first phase of the study. The drug dose will be given orally 3 times weekly after dialysis for 1 year.
3091222|NCT01951404|Placebo Comparator|Placebo|Participants in this arm will be given placebo with the dose appearing to gradually increase weekly as tolerated up to the dose determined in the first phase of the study. The drug dose will be given orally 3 times weekly after dialysis for 1 year.
3091223|NCT01951391|Experimental|Soap recipient|Each subject's forearms will be washed with different soaps and then swabbed at different time points to determine the presence of bacteria then.
3091224|NCT01951378|Active Comparator|Hudson RCI® nebulizer|"Patients randomized to the standard arm will receive treatments as dictated by our standard ED asthma pathway (Fig. 1). All treatments will be administered with our standard ED nebulizer, the Hudson RCI® Up-Draft® Neb-U-Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ), and a simple mask (Hudson RCI®, Teleflex Medical®, Research Triangle Park, NJ)."
3091225|NCT01951378|Active Comparator|NebuTech® HDN® nebulizer|"Patients randomized to the NebuTech® arm will receive treatments as dictated by our trial pathway, referred to as the rapid Albuterol/Proventil delivery pathway (Fig. 2). All nebulizations in this arm will be administered via the Breath-Enhanced High Density Jet Nebulizer, NebuTech® HighDensityNebulizer®,(Salter Labs®, Arvin, CA). Respiratory Therapists (RT) will attempt to deliver all treatments with a mouthpiece, as that has been shown to be the most efficient and reliable mode of aerosol delivery for most children 31, 32. If the Respiratory Therapist feels that the child will not or cannot effectively use a mouthpiece, a mask will be used."
3091226|NCT01951365||Growing schwannoma|Overall volumetric growth rate more over than 10%
3091227|NCT01951365||Stable schwannoma|Overall volumetric growth rate less than 10%
3091228|NCT01951352|Experimental|Soap recipient|The forearms of all subjects will eventually be washed with the same soaps. There is only one arm for this study.
3091229|NCT01951339|Experimental|Sitagliptin plus placebo|100 mg sitagliptin plus 2 mg placebo once daily for three months
3091230|NCT01951339|Active Comparator|Glimepiride plus placebo|2 mg glimepiride plus 100 mg placebo once daily for three months
3091231|NCT01951326|Active Comparator|RHB-104|5 RHB-104 capsules administered orally BID
3091232|NCT01951326|Placebo Comparator|Placebo|5 placebo capsules administered orally BID
3091235|NCT01951287|Experimental|Acute beverage (Water) consumption|Acute beverage (Water)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points.
3091236|NCT01951287|Experimental|Acute beverage (Black Coffee) consumption|Acute beverage (Black Coffee)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
3091237|NCT01951287|Experimental|Acute beverage (Orange Juice) consumption|Acute beverage (Orange Juice)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
3091238|NCT01951287|Experimental|Acute beverage (Whole Milk) consumption|Acute beverage (Whole Milk) consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
3091239|NCT01951287|Experimental|Acute beverage (2% Milk) consumption|Acute beverage (2% Milk) consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
3091240|NCT01951287|Experimental|Acute beverage (Skim Milk) consumption|Acute beverage (Skim Milk)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
3091241|NCT01951274|Experimental|0.25 mg VPD-737|0.25 mg of VPD-737 daily by mouth for 42 days
3091242|NCT01951274|Experimental|1 mg VPD-737|1 mg VPD-737 taken daily by mouth for 42 days
3091243|NCT01951274|Experimental|5 mg VPD-737|5 mg tablets of VPD-737 to be taken daily by mouth for 42 days
3091244|NCT01951274|Placebo Comparator|Placebo|placebo tablets to be taken daily by mouth for 42 days
3091245|NCT01951261|Active Comparator|telemonitoring and telephone control|Early discharge from hospital with telemonitoring, telephone control and three nurse scheduled visits.
3091246|NCT01951261|No Intervention|home care|Early discharge from hospital with home care provided by hospital respiratory nurses and pulmonologists (dairy visits).
3091247|NCT01951248|Experimental|CPAP treatment|Patients with chronic kidney disease and moderate to severe obstructive sleep apnea is treated 3 months with CPAP treatment
3091248|NCT01951235|Experimental|Imeglimin (Dose 1)|
3091249|NCT01951235|Experimental|Imeglimin (Dose 2)|
3091250|NCT01951235|Experimental|Imeglimin (Dose 3)|
3091251|NCT01951235|Experimental|Imeglimin (Dose 4)|
3091252|NCT01951235|Placebo Comparator|Placebo|
3091253|NCT01951222|Experimental|V0162 dose1|
3091254|NCT01951222|Experimental|V0162 dose2|
3091255|NCT01951222|Placebo Comparator|placebo|Placebo
3091256|NCT01951209|Experimental|Rifaximin/Placebo|Rifaximin 550mg po bid for 12 weeks followed by crossover to matched placebo po bid x 12 weeks
3091257|NCT01951209|Experimental|Placebo/Rifaximin SSD|Matched placebo po bid for 12 weeks followed by crossover to Rifaximin 550mg po bid x 12 weeks
3091258|NCT01951196||Chronic kidney disease, CKD III+IV|150 patients with Chronic kidney disease, CKD stage III+IV.
3091259|NCT01951196||Healthy subjects|75 healthy subjects.
3091260|NCT01951183|Placebo Comparator|Placebo|
3091261|NCT01951183|Experimental|RO6811135|
3091262|NCT01951170|Experimental|Tocilizumab|Participants were administered subcutaneous tocilizumab for the treatment of rheumatoid arthritis for 24 weeks.
3091263|NCT01951157|Active Comparator|A - docetaxel|75 mg/m2 docetaxel day 1, 1-hour intravenous, every three weeks
3091264|NCT01951157|Experimental|B - lurbinectedin (PM01183)|3.2 mg/m2 PM01183, day 1, 1-hour intravenous, every three weeks
3091265|NCT01951157|Experimental|C - gemcitabine + lurbinectedin (PM01183)|800 mg/m2 gemcitabine / 1.6 mg/m2 PM01183 both on day 1 and day 8, 30-minutes gemcitabine/1-hour PM01183 intravenous, every three weeks
3091266|NCT01951144|Experimental|Cohort 1:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
3091267|NCT01951144|Experimental|Cohort 2:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
3091268|NCT01951144|Experimental|Cohort 3:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
3091269|NCT01951144|Experimental|Cohort 4 (optional cohort):|Two single doses of PF-06372865 or placebo or lorazepam to further investigate the pharmacodynamics of PF-06372865.
3091270|NCT01951118|Experimental|Donepezil Treatment & Atropine Challenge|Atropine nasal spray is administered at baseline for the atropine challenge which involves administration of the 40-item UPSIT immediately before and 45 minutes after atropine administration. Immediately after the atropine challenge, donepezil treatment is started and continues for 52 weeks.
3091271|NCT01951105|No Intervention|Observation|Individuals identified as having a recovering phenotype (SBPp) will be assigned to the observational arm and will be asked to continue his/her normal regime and return for the week 12 and week 24 visits for follow-up.
3091272|NCT01951105|Active Comparator|Carbidopa/Levodopa & Naproxen|"Individuals identified as having a persisting phenotype (SBPr) will be treated with Carbidopa/Levodopa on a flexible dose-titration designed intervention based on dose-response TID throughout the 12 week treatment period.~Naproxen (250mg) capsules will be administered orally, one capsule TID, throughout the 12 week treatment period."
3091273|NCT01951105|Placebo Comparator|Placebo & Naproxen|Individuals identified as having a persisting phenotype (SBPr) will be treated with placebo capsule plus 250mg naproxen tablet three times a day for 12 weeks.
3091274|NCT01951092|Experimental|Single Arm intervention study|All subjects receive text messages for: 1) medication reminders; 2) appointment reminders; 3) a text message addressing barriers (e.g., reminders to attend AA meetings). Each subject will undergo baseline assessments, choose personalized messages at that time. Subsequently monthly phone calls with study coordinator regarding frequency/changing messages, and then month 3 assessment, and month 6 (final assessment) with option for qualitative interview.
3091275|NCT01951079|Experimental|second trimester abortion , feticide|all patients admitting to second trimester abortion above 22 weeks will be injected intra-amniotic DIGOXIN for feticide .
3091368|NCT01950403|Placebo Comparator|Arm II (placebo)|Participants receive placebo PO QD on days 1-7.
3091276|NCT01951066|Experimental|Group 1 (dexamethasone implant/anti-VEGF)|Patients in group 1 received an injection of an dexamethasone implant at baseline followed by PRN anti-VEGF injections after crossover at week 16.
3091277|NCT01951066|Experimental|Group 2 (anti-VEGF/dexamethasone implant)|Patients in group 2 received prn anti-VEGF injections followed by injection of a dexamethasone implant after crossover at week 16.
3091278|NCT01951053|Experimental|Sequence 1|Participants will receive the study medications in the sequence of placebo, citalopram, and JNJ-40411813, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
3091279|NCT01951053|Experimental|Sequence 2|Participants will receive the study medications in the sequence of placebo, JNJ-40411813, and citalopram, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
3091280|NCT01951053|Experimental|Sequence 3|Participants will receive the study medications in the sequence of citalopram, placebo, and JNJ-40411813, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
3091281|NCT01951053|Experimental|Sequence 4|Participants will receive the study medications in the sequence of citalopram, JNJ-40411813, and placebo, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
3091282|NCT01951053|Experimental|Sequence 5|Participants will receive the study medications in the sequence of JNJ-40411813, placebo, and citalopram, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
3091283|NCT01951053|Experimental|Sequence 6|Participants will receive the study medications in the sequence of JNJ-40411813, citalopram, and placebo, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
3091284|NCT01951040||Oxytocin|Oxytocin was administered during labor
3091285|NCT01951040||No Oxytocin|Oxytocine was not administered during labor
3091286|NCT01951027|Experimental|Cohort 1|GX-G3 12.5 μg/kg or Placebo
3091287|NCT01951027|Experimental|Cohort 2|GX-G3 25 μg/kg or Placebo
3091288|NCT01951027|Experimental|Cohort 3|GX-G3 50 μg/kg or Placebo
3091289|NCT01951027|Experimental|Cohort 4|GX-G3 100 μg/kg or Placebo
3091290|NCT01951014|Experimental|Teen Social Media Education|See description under intervention description
3091291|NCT01951014|No Intervention|Healthcare Provider Insights|Healthcare providers providing care to pregnant adolescents will serve as key informants to provide an additional perspective for adolescent health beliefs and behaviors.
3091292|NCT01951001|Active Comparator|group 1|Fixed-dose Prasugrel of 10 mg/d
3091293|NCT01951001|Active Comparator|group 2|Fixed-dose Prasugrel of 5 mg/d
3091294|NCT01951001|Active Comparator|group 3|"Phenotype-based prasugrel dose~If patients show PRU ≤ 94, prasugrel dose will be reduced by 5 mg/d.~If patients show PRU > 94, prasugrel dose will continue 10 mg/d."
3091295|NCT01950988|Other|Children|
3091296|NCT01950988|Other|Adults|
3091297|NCT01950988|Other|Elderly people|
3091298|NCT01950975|Other|Parents|2 parents of child
3091299|NCT01950975|Other|infant|
3091300|NCT01950962|Other|slight periodontal disease|
3091301|NCT01950962|Other|moderate periodontal disease|
3091302|NCT01950962|Other|severe periodontal disease|
3091303|NCT01950949|Experimental|change respiratory parameters, volume expanding|
3091304|NCT01950936|Experimental|Procalcitonin-guidance|Discontinuation of Antibiotics. Procalcitonin is measured on day 1/2, day 3, day 5 and day 7 (all days where the patient is still admitted to hospital and antibiotics are discontinued, whenever Procalcitonin is <0.15 ng/ml and dis-encouraged whenever Procalcitonin is <0.25 ng/ml
3091305|NCT01950936|No Intervention|Control - Standard of Care|Antibiotics are administered according to current guidelines
3091306|NCT01950923|Experimental|Arm I (sildenafil citrate)|Patients receive sildenafil citrate PO before the initiation of standard robotic partial nephrectomy.
3091307|NCT01950923|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO before the initiation of standard robotic partial nephrectomy.
3091308|NCT01950910||subjects w/ non-motor neurodegen disease|subjects with ALS or with non-motor neurodegenerative disease
3091309|NCT01950910||subjects w/out motorneuron degenerative dis|subjects without motorneuron degenerative disease
3091310|NCT01950897||subjects dx'd clinically w/ muscular dystrophy|subjects with muscular dystrophy from whom muscle samples are obtained for clinical diagnosis or for any other medical purpose
3091311|NCT01950897||normal controls|subjects who do not have muscular dystrophy and from whom muscle samples are obtained for any medical purpose
3091312|NCT01950884|Experimental|Ezetimibe|Ezetimibe tablets plus lifestyle
3091313|NCT01950884|Active Comparator|lifestyle|lifestyle
3091314|NCT01950871|Other|single arm study|Prostate HistoScanning (HS) analysis with HS-guided biopsy will be used to sample two cores per suspicious area (displayed as red on an imaging monitor), up to a maximum of 3 suspicious areas per subject. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero (if no suspicious area is identified) up to a maximum of 6 cores.
3091315|NCT01950858|Experimental|Biological|6 weeks of HBO treatment as well as non weight bearing
3091316|NCT01950858|Active Comparator|Control|non weight bearing
3091317|NCT01950845|Experimental|Automated fluid management system (Closed-loop system)|cardiac output Vigileo® (Edwards Lifesciences) monitoring is connected to the closed loop system that will automatically provide per operative fluid bolus to optimize cardiac output by automated detection of fluid responsiveness state.
3091318|NCT01950845|Sham Comparator|Current practice manual fluid management|cardiac output Vigileo® (Edwards Lifesciences) monitoring will be used to help the anesthesiologist team to detect fluid responsiveness state for the manual fluid management optimization
3091319|NCT01950832||polycystic ovary syndrome (PCOS) group|Patients who were diagnosed as PCOS according to 2003 Rotterdam Criteria.
3091320|NCT01950832||Control|60 healthy volunteers
3091321|NCT01950819|Experimental|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
3091439|NCT01949948|Active Comparator|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
3091322|NCT01950819|Active Comparator|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
3091323|NCT01950806|Active Comparator|Pecan-containing diet|Test diet containing 1.5 oz pecans/2000 kcal/day for 28 days
3091324|NCT01950806|Placebo Comparator|Nut-free diet|Placebo diet containing no nuts or nut products, and identical in total fat and fiber as the test diet, for 28 days
3091325|NCT01950793|Active Comparator|steroid|"used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
3091326|NCT01950793|Experimental|Hyaluronic acid|"used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
3091327|NCT01950780|Experimental|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
3091328|NCT01950754|Other|depressive patients|
3091329|NCT01950754|Other|nondepressed controls|
3091330|NCT01950741|Experimental|aflibercept|Aflibercept 2 mg is injected into the vitreous cavity. Injections are given monthly three times, then are given bi-monthly to 12 months (month 0, 1, 2, 4, 6, 8, and 10; total 7 injections for 1 year).
3091331|NCT01950728|No Intervention|Control group|This group will not receive electrical stimulation. Volunteers will rest during 30 minutes.
3091332|NCT01950728|Active Comparator|Interferential current group|Interferential current will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
3091333|NCT01950728|Active Comparator|TENS Group|TENS will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
3091334|NCT01950728|Active Comparator|Aussie current group|Aussie current will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
3091335|NCT01950715|Other|sacral nerve stimulation|A single armed study to evaluate the on the gastro-colic response in IBS patients treated with sacral nerve stimulation
3091336|NCT01950702|Active Comparator|Lightwand intubation|"After standard total intravenous anesthesia using propofol and remifentanil continuous infusion, traditional lightwand intubation was done by pre-specified anesthesiologist who experienced more than 100 times of lightwand intubation.~Patient's head were fixed at neutral position during all intubation period."
3091337|NCT01950702|Experimental|Laryngoscope assisted lightwand intubation|After standard total intravenous anesthesia using propofol and remifentanil continuous infusion, lightwand intubation using specific device(Macintosh laryngosope, female:3/Male:4) was done by pre-specified anesthesiologist who experienced more than 100 times of laryngoscope assisted lightwand intubation.
3091338|NCT01950689|Placebo Comparator|Placebo|Placebo given in parallel with radiotherapy for 6 weeks.
3091339|NCT01950689|Experimental|Nimorazole|Nimorazole given in parallel with radiotherapy for 6 weeks
3091340|NCT01950676|No Intervention|Control|Individuals in the control group will not use the smart phone application
3091341|NCT01950676|Experimental|Intervention|Individuals in the intervention group will use the smart phone application in insulin titration
3091342|NCT01950663|Experimental|RETeval|RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy by measuring the response of the retina to a flash of light.
3091343|NCT01950650||Patients with diabetes|
3091344|NCT01950650||Physicians|
3091345|NCT01950637||Patients with type 2 diabetes mellitus (T2DM)|
3091346|NCT01950637||Healthcare professionals (HCPs)|
3091347|NCT01950611|Experimental|Bortezomib in treatment|
3091348|NCT01950598|Active Comparator|Fresh carrier graft for KPro|KPro implanted using fresh cornea, preserved in optisol GS
3091349|NCT01950598|Experimental|Frozen carrier graft for KPro|KPro implanted using frozen cornea, which was supplied as a whole globe cryopreserved at -80°C in gramicidin 0.025 mg/mL and polymyxin B sulfate 10 000 U/mL ophthalmic solution.
3091350|NCT01950572||1/Eligible cancer diagnosis|Subjects with mesothelioma, thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers
3091351|NCT01950559||Subjects who are allergic to Soy|Subject allergy to soy is determined by an oral food challenge or history of positive soy food challenge.
3091352|NCT01950546|Experimental|Nanosilver fluoride|This product is a solution composed of: 390 mg / ml 9nm silver nanoparticles ;21 mg / ml chitosan ; 22 mg / ml NaF.The cariostatic agent, nanosilver fluoride, was formulated in a similar way to silver diamine fluoride, so that this new formulation contained 5% nanosilver fluoride, while commercial diamine silver fluoride contains 30% silver fluoride. It will be applied once with a microbrush on tooth surfaces to check if it prevents the growth of S. mutans biofilms on dental surfaces.
3091353|NCT01950533||Peanut allergic|Subjects allergic to peanuts by oral food challenge
3091354|NCT01950533||Milk allergic|Subjects allergic to milk by oral food challenge
3091355|NCT01950533||Egg allergic|Subjects allergic to egg by oral food challenge
3091356|NCT01950494|Experimental|fiteBac Hand Sanitizer|Blinded fitBac Hand sanitizer
3091357|NCT01950494|Placebo Comparator|Blinded emollient therapy|Blinded emollient therapy
3091358|NCT01950481|Experimental|Normal Hepatic Function|Subjects with normal hepatic function
3091359|NCT01950481|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment
3091360|NCT01950481|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment
3091361|NCT01950481|Experimental|Severe Hepatic Impairment|Subjects with severe hepatic impairment
3091362|NCT01950468|Experimental|NAV5001|
3091363|NCT01950468|Active Comparator|DaTscan|
3091364|NCT01950455|Experimental|NAV5001|
3091365|NCT01950416|Experimental|Ticagrelor|Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD) starting 12±6 hours post LD, until discharge.
3091366|NCT01950416|Active Comparator|Clopidogrel|Clopidogrel 600mg loading dose (LD), followed by a 150mg once daily maintenance dose (MD) starting 12±6 hours post LD, until discharge.
3091367|NCT01950403|Experimental|Arm I (linaclotide acetate)|Participants receive linaclotide acetate PO QD on days 1-7.
3091369|NCT01950390|Active Comparator|Arm A (ipilimumab)|"INDUCTION THERAPY: Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning course 8, patients receive ipilimumab IV over 90 minutes on day 1. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity."
3091370|NCT01950390|Experimental|Arm B (ipilimumab and bevacizumab)|"INDUCTION THERAPY: Patients receive ipilimumab IV over 90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive bevacizumab as in Induction Therapy. Beginning course 8, patients also receive ipilimumab IV over 90 minutes on day 1. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity."
3091371|NCT01950364|Experimental|Arm A: Brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
3091372|NCT01950364|Experimental|Arm B: Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
3091373|NCT01950351|Experimental|Proton Beam Therapy|The total dose will be 55.5 Gy (RBE) delivered in 15 fractions of 3.7 Gy (RBE) to the prostate. Each fraction will be scheduled once daily allowing at least one day between treated fractions. Symptom questionnaire completed at baseline, during the last weeks of proton therapy, 6 months, 36 months, 48 months, and 60 months after therapy.
3091374|NCT01950338|Experimental|Dry needling group|The experimental group will receive a single session of DDN with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the gastrocnemius and tibialis anterior muscles.
3091375|NCT01950338|No Intervention|Control group|The control group will not receive any intervention.
3091376|NCT01950325|Experimental|Group 1|1mg/kg IV
3091377|NCT01950325|Experimental|Group 2 or Group 3|5 mg/kg IV (Group 2) or 5 mg/kg SC (Group 3)[only portion of the study that is randomized]
3091378|NCT01950325|Experimental|Group 4|20 mg/kg IV
3091379|NCT01950325|Experimental|Group 5|40 mg/kg IV
3091380|NCT01950312|Experimental|gevokizumab|Solution for subcutaneous injection
3091381|NCT01950299|Experimental|Anakinra (standard dose)|Anakinra 100 mg daily for 14 days
3091382|NCT01950299|Experimental|Anakinra (high dose)|Anakinra 100 mg twice daily for 14 days
3091383|NCT01950299|Placebo Comparator|Placebo|Placebo for 14 days
3091384|NCT01950273|Experimental|BI695500|BI695500, once a week for 4 weeks (4 administrations in total)
3091385|NCT01950273|Active Comparator|MabThera|MabThera, once a week for 4 weeks (4 administration in total)
3091386|NCT01950260|Experimental|Levothyroxine|In the intervention arm patients will start levothyroxine therapy at 4 weeks after RAI therapy. The initial dose of levothyroxine will be 25 mcg/day. It will be increased to 50 mcg/day 2 weeks later and then adjusted at 8 weeks post RAI based on a full face-to-face clinical and biochemical evaluation.
3091387|NCT01950260|Placebo Comparator|Placebo|In the control arm patients will receive placebo capsules and be evaluated for levothyroxine therapy during a full face-to-face evaluation at 8 weeks.
3091388|NCT01950247|Experimental|Injectafer|2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
3091389|NCT01950247|Active Comparator|IV Iron Standard of Care (SOC)|At a dose and administration regimen as determined by the study site investigator
3091390|NCT01950234|Experimental|ACTH|ACTH administered subcutaneously as a pulsed regimen of 3 consecutive days per month
3091391|NCT01950234|Placebo Comparator|Placebo|Placebo subcutaneous injections administered on 3 consecutive days per month
3091392|NCT01950221|Experimental|POMx|POMx is a 1,000 milligram capsule of natural pomegranate polyphenol extract.
3091393|NCT01950221|Placebo Comparator|Placebo|Composition of the Drug Placebo Component/Function/Weight/Percentage of Fill Weight = Cellulose/Bulk agent/658 mg/64.5% Caramel/Colorant/79mg/7.8% Beet root/Flavor Ingredient/263mg/25.8% Magnesium stearate/USP Lubricant/10mg/1.0% Silica Dioxide/FCC Glidant/10mg/1.0% Total = 1020 mg/100% The method of manufacture of the placebo is identical to that of the drug product, except cellulose, caramel, and beet root are added in place of the active ingredient.
3091394|NCT01950208||knee pain|patients suffering from knee injury
3091395|NCT01950195|Experimental|Brain|"A cohort of six (6) patients will be treated at Dosing Schedule 1. If the observed dose limiting toxicity (DLT) rate is less ≤33%, the dose cohort will be expended to a total of 15 patients. Brain and spine metastases will be evaluated as two separate cohorts.~If the first schedule produces DLTs in >33% of patients, the Second Dosing schedule will be implemented. If the second dosing schedule produces DLTs in >33% of patients, the Third Dosing schedule will be implemented.~After 6 patients were enrolled in a cohort, their safety and toxicity will be continuously monitored till 12 weeks (3 months) after the initial dose of Ipilimumab is given for evaluating dose-limiting toxicities."
3091396|NCT01950195|Experimental|Spine|"A cohort of six (6) patients will be treated at Dosing Schedule 1. If the observed dose limiting toxicity (DLT) rate is less ≤33%, the dose cohort will be expended to a total of 15 patients. Brain and spine metastases will be evaluated as two separate cohorts.~If the first schedule produces DLTs in >33% of patients, the Second Dosing schedule will be implemented. If the second dosing schedule produces DLTs in >33% of patients, the Third Dosing schedule will be implemented.~After 6 patients were enrolled in a cohort, their safety and toxicity will be continuously monitored till 12 weeks (3 months) after the initial dose of Ipilimumab is given for evaluating dose-limiting toxicities."
3091397|NCT01950182|Active Comparator|Palliative chemotherapy|Chemotherapy combined with trastuzumab. Chemotherapy could use the following drugs such as capecitabine , Vinorelbine, or Gemcitabine.
3091398|NCT01950182|Experimental|Palliative endocrine therapy|Endocrine therapy combined with trastuzumab. Endocrine therapy could use tamoxifen or aromatase inhibitors including anastrozole, letrozole, or exemestane.
3091399|NCT01950169|Active Comparator|Risedronate|35 mg risedronate orally administered once weekly for 12 months and orally administered Calcium 1000 mg and 800 IU vitamin D3 daily for 12 months. Group B (bisphosphonate group)
3091440|NCT01949935|Placebo Comparator|Control|Placebo made from Glaxal base Applied once 1 day preoperatively and bid for 3 days postoperatively.
3091400|NCT01950169|Active Comparator|Nutritional supplement|Oral liquid nutritional supplement (600kcal and 40 gram protein/day) for 6 months after the hip fracture besides Risedronate and calcium and vitamin D3. Group BN (bisphosphonate and nutritional supplemented group)
3091401|NCT01950169|Active Comparator|Calcium and vitamin D3|An oral dose of 1000 mg Calcium and 800 IU vitamin D3 daily for 12 months after hip fracture. Group C (control)
3091402|NCT01950156|Experimental|Vaccine|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant
3091403|NCT01950143|Active Comparator|Standard broccoli soup|26 volunteers
3091404|NCT01950143|Experimental|Beneforte broccoli soup|26 volunteers
3091405|NCT01950143|Experimental|Beneforte extra broccoli soup|26 volunteers
3091406|NCT01950130|Experimental|IABP group|Preoperative IABP insertion
3091407|NCT01950130|No Intervention|Control group|Preoperative conservative treatment
3091408|NCT01950117|Active Comparator|Conventional polypectomy|Colorectal polyps from 10 mm to 25 mm was found. Submucosal injection of saline solution before removal was not performed for polypectomy. The snare used for polypectomy was a dual loop wire snare with a loop size of 33/16 mm (SN-3316LX, Medico's Hirata Inc., Osaka, Japan). An ERBE ICC200 (Amco, Tokyo, Japan) was used in the Endocut mode with the effect 3 current set at output limit 120W and forced coagulation current set at output limit 35W for conventional polypectomy. Prophylactic clipping after polyp removal was routinely performed.
3091409|NCT01950117|Experimental|Endoscopic mucosal resection|Colorectal polyp from 10 mm to 25 mm was found. Submucosal injection of saline solution before removal was performed for EMR. The snare used for EMR was a dual loop wire snare with a loop size of 33/16 mm (SN-3316LX, Medico's Hirata Inc., Osaka, Japan). An ERBE ICC200 (Amco, Tokyo, Japan) was used in the Endocut mode with the effect 3 current set at output limit 120W and forced coagulation current set at output limit 35W for EMR. Prophylactic clipping after polyp removal was routinely performed.
3091410|NCT01950104|Active Comparator|Day 3 embryo biopsy|Embryo biopsy is applied at day 3 of the embryo development
3091411|NCT01950104|Experimental|Blastocyst biopsy|Embryo biopsy is applied at the blastocyst stage of the embryo development (day 5 or 6)
3091412|NCT01950091|Experimental|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
3091413|NCT01950091|Active Comparator|Alternative website control|Intervention is a Menu of links to 4 popular Websites offering back pain education
3091414|NCT01950091|No Intervention|Usual care control group|No contact; Control group
3091415|NCT01950078||surgical patients|grouped by receiving surgery
3091416|NCT01950078||Healthy volunteers group|grouped by healthy college students
3091417|NCT01950065|Experimental|Immediate Treatment with iovera|Immediate treatment with iovera
3091418|NCT01950065|Active Comparator|Delayed Treatment with iovera|Delayed Treatment with iovera
3091419|NCT01950052|No Intervention|Control group|No special diet, patients will continue with a normal diet
3091420|NCT01950052|Experimental|Diet group|Pre-operative liver shrinking diet of 800 Kcal diet is administered for 4 weeks
3091421|NCT01950039|Active Comparator|Betaine|
3091422|NCT01950039|Placebo Comparator|Placebo|
3091423|NCT01950026|Experimental|white|cryotherapy application
3091424|NCT01950026|Experimental|black|cryotherapy application
3091425|NCT01950026|Experimental|Brown|cryotherapy application
3091426|NCT01950026|Experimental|asian|cryotherapy application
3091427|NCT01950013|No Intervention|Passive Control|Hearing aid alone
3091428|NCT01950013|Experimental|Training|Auditory Training Program. Hearing aid plus auditory training
3091429|NCT01950013|Sham Comparator|Active control|Sham comparator: Active control. Hearing aid plus audio-book use
3091430|NCT01950000|Placebo Comparator|Placebo|Placebo Treatment: A sterile sodium chloride injection 0.9% 10 ml
3091431|NCT01950000|Experimental|Fentanest|"For this study Fentanest doses were adjusted based on published guidelines from the values recommended media to a whole number and differentiating two groups of patients (multiple trauma / surgical or medical) The maximum dose is 100 mcg Fentanest. The multiple trauma patients / surgical 1.5 mcg / kg and in medical patients 1.0 mcg / kg were given a single bolus Fentanest / Placebo by type of patient (surgical / multiple trauma or physician) 5 'before turning mobilization with personal hygiene.~The bolus is given slowly (30'') intravenously, to be preferred by a peripheral without vasoactive drugs (only with fluid therapy).~Pharmaceutical form:~Sterile solution for injection. Each mL of injectable solution contains the equivalent of 0.05 mg of Fentanest; Excipients: sodium chloride and water for injection."
3091432|NCT01949987|Active Comparator|2 hours after surgery|the investigators permit the patients to resume oral intake two hours after surgery and observe child's behavior and score; cry, facial expression, verbal expression, torso, legs, activity, and consolability
3091433|NCT01949987|Experimental|1 hour after surgery|the investigators permit the patients to resume oral intake one hour after surgery and observe child's behavior and score; cry, facial expression, verbal expression, torso, legs, activity, and consolability
3091434|NCT01949974|Experimental|Integral Attention Program (PAI)|"The key points of the PAI are:~To assess and manage pain and other symptoms resulting from disease progression.~To evaluate the information needs that may arise and to address them.~To encourage patient and family adaptation to the situation of advanced disease and in the terminal phase of it.~To provide guidance in decision-making while respecting patient autonomy.~To establish a plan of care and treatment, adapted to the evolution and needs of the patient.~To promote continuity of care."
3091435|NCT01949974|Active Comparator|Standard Palliative Chemotherapy and PAI|Standard palliative chemotherapy will be administered, depending on type of cancer, as well as PAI as been defined above.
3091436|NCT01949961|Active Comparator|Ultrasound|Patients eligible (NOR-SASS A/B) and ineligible (NOR-SASS C) for intravenous thrombolysis all receive intravenous ultrasound contrast (microbubbles). The groups are separately randomised to 2 megahertz (MHz) transcranial ultrasound treatment for one hour.
3091437|NCT01949961|Placebo Comparator|Sham ultrasound|Patients eligible (NOR-SASS A/B) and ineligible (NOR-SASS C) for intravenous thrombolysis all receive intravenous ultrasound contrast (microbubbles). The two groups are separately randomised to sham ultrasound treatment for one hour.
3091438|NCT01949948|Active Comparator|Tenecteplase|0.4 mg/kg single bolus intravenously
3091500|NCT01949519|Experimental|Docetaxel and Lycopene|
3091441|NCT01949935|Experimental|Mupirocin|Mupirocin ointment applied to nares once 1 day preoperatively and bid for 3 days postoperatively.
3091442|NCT01949922|Experimental|Injection of autologous muscle fibers in the anal sphincter|All patients, that still have relevant symptoms after completion of three months with individualized pelvic floor muscle training and dietary intervention to control defecatory function, will be offered injection of autologous muscle fiber fragments in the anal sphincter. A myscle biopsy will be taken from the leg, cut into small pieces in a saline solution and injected in the anal sphincter.
3091443|NCT01949909|Experimental|Alhydrogel CH-Alum50|intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)
3091444|NCT01949909|Experimental|CH-GLA2.5/50|intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
3091445|NCT01949909|Placebo Comparator|Control rabies vaccine Verorub TM TZ Ver|intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections
3091446|NCT01949909|Experimental|Alhydrogel TZ Alum 50|intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)
3091447|NCT01949909|Experimental|GLA-SE TZ GLA 2.5/10|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)
3091448|NCT01949909|Experimental|GLA-SE TZ GLA5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)
3091449|NCT01949909|Experimental|GLA-SE TZ GLA2.5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
3091450|NCT01949896|Other|Intervention: NPO|"Infants in this group will be made NPO approximately 4 hours prior to receiving a blood transfusion and will remain NPO until approximately 24 hours after the blood transfusion.~Pro-inflammatory cytokine response will be monitored at 3 times points."
3091451|NCT01949896|Other|Control: Continue feedings|"Infants in this group will be allowed to continue feedings during the transfusion at the discretion of the medical team.~Pro-inflammatory cytokine response will be monitored at 3 times points."
3091452|NCT01949883|Experimental|CPI-0610|
3091453|NCT01949870|Other|Selumetinib|25mg/day, 50mg/day and 75mg/day
3091454|NCT01949857|Experimental|Attenuated HAV Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\6.50 lgCCID50/ml in children aged 3-15 years \6.50 lgCCID50/ml in adults aged 16 up to 65 years old
3091455|NCT01949857|Experimental|Attenuated HAV Vaccine, L-A-1 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\6.50 lgCCID50/Vial in children aged 3-15 years \6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
3091456|NCT01949857|Experimental|Inactivated HAV Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months\320EU/Vial in children aged 3-15 years \640EU/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose
3091457|NCT01949857|Experimental|Inactivated HAV Vaccine, TZ84 Strain|250U/Vial in babies aged 18-35 months\250U/Vial in children aged 3-15 years \500U/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose
3091458|NCT01949844|Other|Suspected coronary artery disease (CAD)|"This pilot study has a single arm/group of subjects with suspected CAD based on the following inclusion criteria:~Prior nuclear myocardial perfusion scan (PET/SPECT) with a visual interpretation of definitely abnormal, or prior myocardial infarction; or,~Clinically stable individuals with suspected coronary artery disease on the basis of coronary angiography.~The study protocol involved only a myocardial perfusion MRI procedure for detection of ischemia (perfusion deficits) using an improved protocol with the administration of a vasodilator drug (Regadenoson/Lexiscan®) and gadolinium-based MRI contrast agent (Optimark®; dose: 0.2 mmol/kg). Lexiscan® was used off-label as a vasodilator drug during the MRI scan (0.4 mg/5mL) supplied by the manufacturer, Astellas Pharma U.S."
3091459|NCT01949831|No Intervention|Control|Usual care
3091460|NCT01949831|Experimental|Functional assessment|Assessment of functional ability in combination with follow-up at home
3091461|NCT01949818|Experimental|Yangzhengxiaoji Capsule combined with CHOP regimen|Yangzhengxiaoji Capsule combined with CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
3091462|NCT01949818|Experimental|CHOP regimen|CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
3091463|NCT01949805|Active Comparator|Hydroxyurea|Hydroxyurea capsules (500 mg each). Daily intake of doses from 500 mg Q2D to 3000 mg QD
3091464|NCT01949805|Experimental|Peg-P-IFN-alpha-2b (AOP2014)|Peg-P-IFN-alpha-2b at 50mcg to max 500 mcg, given every other week as one subcutanous injection
3091465|NCT01949792|Active Comparator|270 microg/kg rFVIIa|Each subject will receive one single injection of 270 microg/kg and three injections of 90 microg/kg rFVIIa (one injection every 3 hours) in a randomised order. The two administration days will be separated by a wash-out period of at least 48 hours
3091466|NCT01949792|Active Comparator|3x90 microg/kg rFVIIa|Each subject will receive one single injection of 270 microg/kg and three injections of 90 microg/kg rFVIIa (one injection every 3 hours) in a randomised order. The two administration days will be separated by a wash-out period of at least 48 hours
3091467|NCT01949779||TransForm OBC|
3091468|NCT01949753|Experimental|Nutritional supplement Pregnenolone|Exposure therapy, exposure with response prevention and pharmacological facilitation (nutritional supplement pregnenolone), orally two hours before exposure therapy.
3091469|NCT01949753|Placebo Comparator|Placebo|Exposure therapy, exposure with response prevention without pharmacological facilitation (Placebo), orally two hours before exposure therapy.
3091470|NCT01949740||Observational (patient preferences)|Patients participate in a 45-minute interview comprising assessment of priorities and quality of life at baseline, 1, 6, and 12 months.
3091471|NCT01949727||AIM 1/AIM 2: AECOPD Admitted Patients|"AIM 1:All patients admitted to the hospital (either to Pulmonary or General Medicine) will be recruited to enroll in this observational study. No specific intervention is planned for this group.~AIM 2: All patients admitted to the pulmonary ward for an AECOPD, including those who have completed Aim 1, will be offered participation into this arm of the study. Pulmonary rehabilitation will be conducted through the Breathe Easy Program at the Centre for Lung Health."
3091472|NCT01949714||Pheochromocytoma patients|Pheochromocytoma patients
3091473|NCT01949714||Incidentaloma patients|Incidentaloma patients
3091474|NCT01949701|Experimental|Vaccine|HLA-A*0201restricted URLC10 peptides
3091475|NCT01949688|Experimental|HLA-A*2402 restricted peptides|HLA-A*2402 restricted peptides with adjuvant
3091476|NCT01949688|Experimental|HLA-A*0201 restricted peptides|HLA-A*0201 restricted peptides with adjuvant
3091477|NCT01949675|Experimental|Study Group 1|Participants aged 1 through 4 years at enrollment
3091478|NCT01949675|Experimental|Study Group 2|Participants aged 5 through 14 years at enrollment
3091479|NCT01949675|Experimental|Study Group 3|Participants aged 15 years and above at enrollment
3091480|NCT01949662|Experimental|Lorazepam + Haloperidol|Participants given a single dose of lorazepam 3 mg by vein, in addition to a standardized dose of haloperidol 8 mg/day by vein, while in palliative care unit. Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete
3091481|NCT01949662|Active Comparator|Placebo + Haloperidol|Participants receive placebo, preservative free 0.9% normal saline, by vein plus a standardized dose of haloperidol 8 mg/day by vein, while in palliative care unit. Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete
3091482|NCT01949649|Active Comparator|Peer-Led Group Intervention|In the Peer-Led Group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique the thin-ideal ideal during 4 1-hr sessions and in homework activities which are led by peer leaders.
3091483|NCT01949649|Active Comparator|Clinician-Led Group Intervention|In the Clinician-Led Group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique the thin-ideal ideal during 4 1-hr sessions and in homework activities which are led by University clinicians.
3091484|NCT01949649|Active Comparator|Internet-Based Intervention|The Internet-Based Intervention consists of 6 40-min modules involving user-driven self-education activities and games (e.g., role-plays), writing/video contests, and off-line exercises designed to induce dissonance regarding pursuit of the thin-ideal, mirroring activities from the group Body Project.
3091485|NCT01949649|Active Comparator|Education Video|The Education Video describes eating disorders, their adverse effects, and the need for treatment, which is key information to provide to young women at elevated risk for eating disorders due to body dissatisfaction.
3091486|NCT01949636||lean adolescents|
3091487|NCT01949623||RP patients|Retinitis Pigmentosa patients
3091488|NCT01949623||Controls|Patients who will be undergoing surgery for macular hole, epiretinal membrane, or vitreomacular traction, patients who have a retinal detachment , patients with neovascular age related macular degeneration and patients with diabetic retinopathy.
3091489|NCT01949610|Experimental|14C-JNJ26489112|
3091490|NCT01949597||Patients with symptomatic endometriosis|
3091491|NCT01949571|Experimental|Mirtazapine|During the first and second phase of the study, subjects assigned to the control group received one tablet of placebo under daily basis, whereas the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, placebo group received same tablet under daily basis, whereas the mirtazapine group received 15 mg of mirtazapine.
3091492|NCT01949558|No Intervention|Control group|The control group receives a brochure on healthy dietary habits according to regular care.
3091493|NCT01949558|Experimental|Dietary intervention|12 week individual intervention based on a cognitive behavioral approach. It includes dietary restriction under guidance by a dietitian. Thereafter monthly follow-up takes place via email during the following 9 mo.
3091494|NCT01949545|Experimental|Normal Hepatic Function|Participants with normal hepatic function (bilirubin and aspartate aminotransferase (AST) ≤ the upper limit of normal (ULN)) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
3091495|NCT01949545|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (bilirubin > 1-1.5 x ULN or AST > ULN, but bilirubin ≤ ULN) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
3091496|NCT01949545|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (bilirubin > 1.5-3 x ULN, any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
3091497|NCT01949545|Experimental|Severe Hepatic Impairment|(Bilirubin > 3 × ULN; any AST) Participants with severe hepatic impairment (bilirubin > 3 x ULN; any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
3091498|NCT01949532|Experimental|Normal Renal Function|Participants with normal renal function (creatinine clearance [CrCl] ≥ 75 mL/min) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.
3091499|NCT01949532|Experimental|End Stage Renal Disease|Participants with end-stage renal disease (on hemodialysis) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.
3091501|NCT01949506|Other|Stereotactic Body Radiation Therapy|Arms: Stereotactic Body Radiation Therapy (SBRT) with Adaptive Radiation Therapy (ART) for all patients. A non-randomized study. Patients must have 1-5 pulmonary metastases all less than 5 cm in size. Pathologic confirmation of primary soft tissue sarcoma. All lesions to receive 3-5 fractions to each tumor. Treatments delivered with > 10 Gy per fraction will have a minimum of 48 hour interfraction interval. For treatments with ≤ 10 Gy per fraction will have a minimum 24 hour interfraction interval. Treatments will be ideally completed over 14 days for 3 fraction treatments and over 21 days for >5 fraction treatment schedules.
3091502|NCT01949493|Other|Care as usual|The patient will receive the usual care provided by the neurologists at VieCuri Medical Center. This may include an expectant strategy, a wrist splint, corticosteroid injection or carpal tunnel release surgery.
3091503|NCT01949493|Experimental|Mechanical traction|Twelve treatments with mechanical traction using the Phystrac traction apparatus.
3091504|NCT01949480|Active Comparator|Traditional approach paravertebral nerve block|After final needle placement, a hanging drop technique will be used to rule out intrapleural placement while the patient inhales and exhales deeply. After correct needle placement, 10 mL of 0.5% Ropivacaine will be injected incrementally through each needle after negative aspiration, followed by insertion of the nerve block catheter to a depth 5 cm beyond the tip of the needle. An additional 10 mL of 0.5% Ropivacaine will then be injected in 5 mL increments with negative aspiration in between, through the catheter yielding a total activation dose of 20 ml of 0.5% Ropivacaine. The catheter will be secured with Steri-strips and a transparent occlusive dressing.
3091505|NCT01949480|Experimental|Ultrasound assisted paravertebral nerve block|The 22 gauge catheter will be threaded through the needle and placed at previously found distance to paravertebral space on obtained ultrasound image. An additional 10 ml of 0.5% Ropivacaine will be administered through the catheter yielding a total activation dose of 20 ml of 0.5% Ropivacaine. The catheter will be secured with Steri-strips and a transparent occlusive dressing.
3091506|NCT01949467|Other|TDHS|20 Patients with Treated Dysmetabolic Hepatosiderosis (TDHS)
3091507|NCT01949467|Other|UDHS|20 patients with untreated Dysmetabolic Hepatosiderosis (UDHS)
3091508|NCT01949467|Other|TFPD|20 patients with treated Ferroportin Disease (TFPD)
3091509|NCT01949467|Other|UFPD|20 patients with untreated Ferroportin Disease (UFPD)
3091510|NCT01949467|Other|HV|20 Healthy volunteers (HV) patients
3091511|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt bid x4weeks|Fluorometholone 0.1% 1 drop two times daily for four weeks
3091512|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt bid x4 weeks|
3091513|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt qid x 4 weeks|Fluorometholone 0.1% 1 drop four times daily for four weeks
3091514|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt qid x4 weeks|
3091515|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt qid x 8 weeks|Fluorometholone 0.1% 1 drop four times daily for eight weeks
3091516|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt qid x8 weeks|
3091517|NCT01949441|Experimental|ToleroMune HDM|
3091518|NCT01949441|Placebo Comparator|Placebo|
3091519|NCT01949428||HDM-Induced Rhinoconjunctivitis Subjects|
3091520|NCT01949402||Haemodialysis|Patients with end-stage renal failure (ESRF) requiring long-term regular haemodialysis.
3091521|NCT01949402||Chronic Obstructive Pulmonary Disease|Patients with a confirmed diagnosis of COPD based on clinical history, obstructive spirometry (FEV1/VC ratio <70%) and radiology (e.g. hyperexpansion on plain chest radiograph; evidence of small airways disease or emphysema on cross-sectional imaging).
3091522|NCT01949402||Interstitial Lung Disease|Patients with a confirmed diagnosis of ILD based on clinical history and radiology (evidence of ILD on cross-sectional imaging).
3091523|NCT01949402||Control|Age-matched healthy volunteers with no history of cardiac, respiratory or renal disease.
3091524|NCT01949389|Experimental|Internet-based Cognitive Behavioral Therapy for Insomnia|This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
3091525|NCT01949376||HT Patients|any stage of breast cancer without brain metastasis, will undergo hormonal therapy without chemotherapy
3091526|NCT01949376||CT and HT Patients|any stage of breast cancer without brain metastasis, will undergo chemotherapy and hormonal therapy
3091527|NCT01949376||CT Patients|any stage of breast cancer without brain metastasis, has undergone surgery prior to screening, will undergo chemotherapy without hormonal therapy
3091528|NCT01949376||RT or NT Patients|any stage of breast cancer without brain metastasis, will not undergo chemotherapy or hormonal therapy; may undergo radiation therapy or have no therapy
3091529|NCT01949376||Controls|healthy, cognitively normal subjects
3091530|NCT01949363|Experimental|Stage 2 (Cohorts C and D)|Cohort C will first be given 1200mg cefixime orally once; Cohort D will be given 800mg cefixime orally three times (every 8 hours); 6 subjects in each cohort
3091531|NCT01949363|Experimental|Stage 1 (Cohorts A and B)|Cohort A will be given 400mg of cefixime orally once; Cohort B will be given 800mg of cefixime given orally once; 6 subjects in each cohort
3091532|NCT01949350|Active Comparator|Carbohydrate|CHO loaded test:
3091533|NCT01949350|Active Comparator|Carbohydrate protein|CHO-P loaded test:
3091534|NCT01949350|Active Comparator|Water|Starved as for surgery
3091535|NCT01949337|Experimental|Arm A: (enzalutamide)|Patients receive enzalutamide 160 mg PO QD. Treatment will continue until confirmed disease progression or unacceptable toxicity.
3091536|NCT01949337|Experimental|Arm B: (enzalutamide, abiraterone, prednisone)|Patients receive enzalutamide 160 mg PO QD, abiraterone 1000 mg PO QD, and prednisone 5 mg PO BID. Treatment will continue until confirmed disease progression or unacceptable toxicity.
3091537|NCT01949324|Experimental|NT-501 Implant|The investigational product is the NT-501 encapsulated cell system which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that were derived from the NTC-200 cell line by genetic modification so as to secrete recombinant human ciliary neurotrophic factor (CNTF).
3091538|NCT01949324|Sham Comparator|Sham procedure|Non-penetrating sham procedure to mimic implant procedure
3091539|NCT01949311|Experimental|Open-label Extension|
3091720|NCT01948115|Experimental|equimolar mixture of oxygen and nitrous oxide|
3091540|NCT01949298|Experimental|Immediate implant loading|The test group had implant immediately loaded by means of a implant supported mandibular denture connected with locator abutment.
3091541|NCT01949298|Active Comparator|Delayed implant loading group|The control group had implant loaded after 3 months of submerged healing by means of a implant supported mandibular denture connected with locator abutment.
3091542|NCT01949285|Sham Comparator|Grp#1: sham stimulation|"Group #1: Baseline clinical assessment; followed by two weeks training with no stimulation; then four weeks training + sham Transcutaneous Electrical Spinal Cord Stimulation; followed by repeat clinical assessment; then four weeks training + effective non-sham Transcutaneous Spinal Cord Stimulation; repeat clinical assessment.~Secondary outcome measurements: assess ability to stand with and without stimulation using a stance frame support; assess trunk function (core stability) with and without stimulation"
3091543|NCT01949285|Active Comparator|Grp#2: Control|"Group #2: Baseline clinical assessment; followed by two weeks training with no Transcutaneous Electrical Spinal Cord Stimulation; then four weeks training + effective Transcutaneous Electrical Spinal Cord Stimulation; followed by repeat clinical assessment.~Secondary outcome measurements: assess ability to stand with and without stimulation using a stance frame support; assess trunk function (core stability) with and without stimulation"
3091544|NCT01949272||ARDS|ARDS patients achieving stades II and III of Berlin 2011 Classification
3091545|NCT01949259||Retrospective collection|Retrospective collection of data from included lung cancer patients.
3091546|NCT01949246||CRT patients|Patients undergoing CRT device implantation
3091547|NCT01949246||Healthy patients|Healthy controls
3091548|NCT01949233|Experimental|Irbesartan 150-300mg (and doxycycline placebo)|Irbesartan 150-300mg capsules daily for 6 months Doxycycline placebo capsules daily for 6 months
3091549|NCT01949233|Experimental|Doxycycline 100-200mg (and irbesartan placebo)|Doxycycline 100-200mg capsules daily for 6 months Irbesartan placebo capsules daily for 6 months
3091550|NCT01949233|Experimental|Irbesartan 150-300mg and doxycycline 100-200mg|Irbesartan 150-300mg capsules daily for 6 months Doxycycline 100-200mg capsules daily for 6 months
3091551|NCT01949233|Placebo Comparator|irbesartan and doxycycline placebo|Irbesartan placebo capsules daily for 6 months Doxycycline placebo capsules daily for 6 months
3091552|NCT01949220||Von Willebrand factor deficient patient|Inherited von Willebrand disease
3091553|NCT01949207|Experimental|EVLA, phlebectomies & Trlop closure of incompetent perforators|endovenous laser ablation (EVLA) of great saphenous vein (GSV) plus phlebectomies plus TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
3091554|NCT01949207|Experimental|EVLA & phlebectomies|endovenous laser ablation (EVLA) of great saphenous vein (GSV) + phlebectomies.
3091555|NCT01949194|Experimental|Regorafenib|Single-agent regorafenib
3091556|NCT01949181|Experimental|Pulmonary cancer|
3091557|NCT01949168|Active Comparator|Boceprevir triple therapy with 5-day lead in|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets) for 5 days, followed by boceprevir plus • Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection plus • Rebetol® (ribavirin), 1000/1200mg, by mouth daily for 24 weeks. In patients who achieve an undetectable plasma HCV RNA level at week 4 of triple therapy (week 5 from baseline), and maintain an undetectable plasma HCV RNA at week 20 of triple therapy (week 21 from baseline), treatment will stop at week 25. Patients who have a detectable plasma HCV RNA at week 4 of triple therapy, but an undetectable plasma HCV RNA at week 20, will continue a with follow-on peginterferon-α-2b plus ribavirin for a further 23 weeks (stopping at week 48).
3091558|NCT01949168|Active Comparator|Boceprevir triple therapy|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets) plus Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection and Rebetol® (ribavirin), 1000/1200mg, by mouth daily for 24 weeks. In patients who achieve an undetectable plasma HCV RNA level at week 4 of triple therapy, and maintain an undetectable plasma HCV RNA at week 20 of triple therapy, treatment will stop at week 24. Patients who have a detectable plasma HCV RNA at week 4 of triple therapy, but an undetectable plasma HCV RNA at week 20, will continue a with follow-on peginterferon-α-2b plus ribavirin for a further 24 weeks (stopping at week 48).
3091559|NCT01949168|Active Comparator|Standard of Care|48 weeks of Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection and Rebetol® (ribavirin), 1000/1200mg by mouth daily (200mg tablets)
3091560|NCT01949155|Experimental|OTO-201|"OTO-201: Single, intratympanic injection:~One injection of 6 mg OTO-201 (ciprofloxacin in poloxamer 407) into each ear during surgery."
3091561|NCT01949155|Sham Comparator|Sham|"Sham: Simulated single, intratympanic injection:~One sham injection into each ear during surgery."
3091562|NCT01949142|Experimental|OTO-201|"OTO-201: Single, intratympanic injection:~One injection of 6 mg OTO-201 (ciprofloxacin in poloxamer 407) into each ear during surgery."
3091563|NCT01949142|Sham Comparator|Sham|"Sham: Simulated single, intratympanic injection:~One sham injection into each ear during surgery."
3091564|NCT01949129|Experimental|conditioning Flu/Thio/Treo or Flu/Thio/ivBu|patients > 4 years with a MSD or MD
3091565|NCT01949129|Active Comparator|conditioning TBI/VP16|VP16: 60 mg/kg, 1 day TBI: 12 Gray in 6 fractions over 3 days patients > 4 years with MSD and MD
3091566|NCT01949129|Other|for mismatched donor (MMD) transplantation|patients with mmd cordblood: Flu/Thio/Treo/ATG fres. or Alemtuzumab with haploidentical tx: Flu/Thio/Treo/ATG fres. or Alemtuzumab with mmd bm or pbsc:Flu/Thio/Treo or ivBU according country's decision
3091567|NCT01949116|Experimental|Low-dose methotrexate (LDMTX)|From study entry through Week 1, participants received 5 mg of LDMTX once a week. For participants who were clinically stable at the Week 1 study visit, the dose of LDMTX was increased to 10 mg once a week through Week 12. For participants who were clinically stable at the Week 12 study visit, the dose of LDMTX was increased to 15 mg once a week through Week 24. Participants who did not meet the criteria for dose escalation were re-evaluated at the following study visit. In addition to LDMTX, all participants also received 1 mg of folic acid once a day from study entry throughout Week 24. After taking the final dose of LDMTX, all participants continued taking folic acid for an additional 4 weeks.
3091606|NCT01948934|Experimental|amniotic membrane in big wounds|The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
3091607|NCT01948921|Placebo Comparator|placebo|1 ml normal saline will be given 5 minutes before EGD
3091568|NCT01949116|Placebo Comparator|Placebo|From study entry through Week 1, participants received 5 mg of placebo once a week. For participants who were clinically stable at the Week 1 study visit, the dose of placebo was increased to 10 mg once a week through Week 12. For participants who were clinically stable at the Week 12 study visit, the dose of placebo was increased to 15 mg once a week through Week 24. Participants who did not meet the criteria for dose escalation were re-evaluated at the following study visit. In addition to placebo, all participants also received 1 mg of folic acid once a day from study entry throughout Week 24. After taking the final dose of placebo, all participants continued taking folic acid for an additional 4 weeks.
3091569|NCT01949103|Experimental|TD-1607 or placebo (Dose1)|TD-1607 or placebo administered intravenously
3091570|NCT01949103|Experimental|TD-1607 or placebo (Dose 2)|TD-1607 or placebo administered intravenously
3091571|NCT01949103|Experimental|TD-1607 or placebo (Dose 3)|TD-1607 or placebo administered intravenously
3091572|NCT01949103|Experimental|TD-1607 or placebo (Dose 4)|TD-1607 or placebo administered intravenously
3091573|NCT01949103|Experimental|TD-1607 or placebo (Dose 5) [Optional]|TD-1607 or placebo administered intravenously
3091574|NCT01949103|Experimental|TD-1607 or placebo (Dose 6) [Optional]|TD-1607 or placebo administered intravenously
3091575|NCT01949090|Experimental|GSK2789869A F1 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3091576|NCT01949090|Experimental|GSK2789869A F2 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3091577|NCT01949090|Experimental|GSK2789869A F3 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3091578|NCT01949090|Experimental|GSK2789869A F4 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3091579|NCT01949090|Placebo Comparator|Placebo Group|Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3091580|NCT01949077||Sustained virological response|Patients who achieve sustained virological response (SVR) are defined as undetectable HCV RNA in serum obtained 12 weeks or beyond the end of antiviral therapy.
3091581|NCT01949077||Non-responders|Non-responders are defined as patients who have not achieved virological milestones during therapy or who have relapsed with detectable HCV RNA in serum after cessation of treatment.
3091582|NCT01949064|Active Comparator|Michigan-type occlusal splint|Occlusal splint, Michigan-type
3091583|NCT01949064|Active Comparator|Grindcare|Biofeedback device
3091584|NCT01949051|Experimental|Levocabastine Arm|Subjects will be assigned to one of six treatment sequences (ABC, BCA, CAB, ACB, BAC, CBA) in accordance with the randomisation schedule. A = Two, 50 microgram (mcg) sprays per nostril of levocabastine QD in the morning. Total dose of 200 mcg. Two, 0 mcg sprays from placebo to match vehicle in the evening; B = Two, 50 mcg sprays per nostril of levocabastine BID in the morning and evening. Total dose of 400 mcg; C = Two, 0 mcg sprays per nostril from placebo vehicle in morning and evenings.
3091585|NCT01949038|Placebo Comparator|Oral placebo|Patients receive one oral dose of placebo least 30 minutes before the procedure.
3091586|NCT01949038|Placebo Comparator|Sublingual placebo|Patients receive one oral dose of placebo at least 30 minutes before the procedure.
3091587|NCT01949038|Active Comparator|Sublingual alprazolam|Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.
3091588|NCT01949038|Active Comparator|Oral alprazolam|Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.
3091589|NCT01949025|Experimental|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
3091590|NCT01949025|No Intervention|Control group|
3091591|NCT01949012|No Intervention|Control|Standard monitoring
3091592|NCT01949012|Experimental|Capnography|Standard monitoring and capnography
3091593|NCT01948999|Active Comparator|ECT|Electroconvulsive Therapy Anesthesia and concomitant muscular paralysis
3091594|NCT01948999|Sham Comparator|SHAM ECT|Anesthesia and concomitant muscular paralysis
3091595|NCT01948986|Experimental|T2DM with No Renal Impairment|Participants with T2DM and with no renal impairment
3091596|NCT01948986|Experimental|T2DM with Mild Renal Impairment|Participants with T2DM and with mild renal impairment
3091597|NCT01948986|Experimental|T2DM with Moderate Renal Impairment|Participants with T2DM and with moderate renal impairment
3091598|NCT01948986|Experimental|T2DM with Severe Renal Impairment|Participants with T2DM and with severe (not on dialysis) renal impairment
3091599|NCT01948986|Experimental|Healthy Participants with No Renal Impairment|Healthy participants with no renal impairment
3091600|NCT01948973|Active Comparator|OFF, subsensory, suprasensory|Here the stimulator is turned OFF for the first 2 weeks, then set subsensory (90% of sensory threshold) for the next 2 weeks and finally set suprasensory for the last 2 weeks.
3091601|NCT01948973|Active Comparator|Subsensory, OFF, suprasensory|Here the stimulator is set subsensory (90% of sensory threshold), then turned OFF for the next 2 weeks and finally set suprasensory in the last 2 weeks.
3091602|NCT01948960|No Intervention|standard care|everolimus dose is continued independently of everolimus AUC
3091603|NCT01948960|Active Comparator|everolimus dose escalation|patients with an AUC below mean will have dose escalation of everolimus based on their AUC
3091604|NCT01948947|Experimental|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
3091605|NCT01948947|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
3091608|NCT01948921|Active Comparator|meperidine|25 mg intramuscular meperidine will be given 5 minutes before EGD
3091609|NCT01948908|Experimental|200 mcL VOA|Intranasal midazolam administered in 200 mcL VOA
3091610|NCT01948908|Experimental|500 mcL VOA|Intranasal midazolam administered in 500 mcL VOA.
3091611|NCT01948908|Experimental|1000 mcL VOA|Intranasal midazolam administered in 1000 mcL VOA.
3091612|NCT01948895|Experimental|Single-arm study|Desvenlafaxine 50mg/day Desvenlafaxine 100mg/day
3091613|NCT01948882|Experimental|ESS505|All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.
3091614|NCT01948869|Experimental|Phoenix II|Application over 29 days twice daily
3091615|NCT01948869|Active Comparator|Phoenix I|Application over 29 days twice daily
3091616|NCT01948869|No Intervention|Untreated skin|Untreated skin areas of subjects will be observed over 29 days
3091617|NCT01948856|Experimental|J022X ST|
3091618|NCT01948856|Placebo Comparator|Placebo|
3091619|NCT01948843|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethylene glycol
3091620|NCT01948830|Active Comparator|Group I ranibizumab 0.5 mg monthly|Ranibizumab 0.5 mg/0.05 mL (Monthly regimen) up to month 11
3091621|NCT01948830|Active Comparator|Group II ranibizumab 0.5 mg TER|Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen up to month 11
3091622|NCT01948817|Experimental|Deferasirox|Deferasirox 20mg/kg taken BID
3091623|NCT01948804|Experimental|IVF patients|patients that has applied to Yeditepe University Hospital assisted reproduction center
3091624|NCT01948791|Experimental|ENA713|Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks.
3091625|NCT01948778|Experimental|oXiris™ filter|oXiris™ filter
3091626|NCT01948778|Experimental|Toraymyxin Filter|Toraymyxin Filter
3091627|NCT01948778|Other|Standard of Care|Standard of Care CRRT if necessary
3091628|NCT01948765|Active Comparator|Xenon and propofol|
3091629|NCT01948765|Placebo Comparator|propofol|
3091630|NCT01948752|No Intervention|Menu - no nutrition information (control)|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included a normal menu with no nutrition information."
3091631|NCT01948752|Experimental|Calorie labels|Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with the calorie amounts displayed.
3091632|NCT01948752|Experimental|Calorie Traffic Light|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with calorie amounts in green/amber/red traffic lights to signify low/medium/high amounts."
3091633|NCT01948752|Experimental|Multi-Traffic Light|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with calorie amounts as well as sodium, fat, and sugar amounts in green/amber/red traffic lights to signify low/medium/high amounts."
3091634|NCT01948739|Experimental|BMI control of MAHI Exo-II|MAHI EXO-II exoskeleton augmented with BMI system will be used to actively include the patient in the control loop, thereby making the therapy 'active' and engaging patients with various impairment severity in rehabilitation tasks. Patients will receive longitudinal training with the BMI-robotic interface for 3-4 sessions per week, over a period of 3 months.
3091635|NCT01948726|Experimental|Hypofractionation with SIB|
3091636|NCT01948713|Experimental|Group 1|Strengthening of pelvic floor muscles.
3091637|NCT01948713|Experimental|Group 2|Strengthening of pelvic floor muscles associated with strengthening of hip muscles.
3091638|NCT01948700|Other|Brief Intervention|Motivational Interviewing (MI)
3091639|NCT01948700|Other|Standard Intervention|Education
3091640|NCT01948687||1. the control group|healthy adult volunteers
3091641|NCT01948687||2. patients with chronic hepatitis|patients with chronic hepatitis B or C (defined by the presence of serum anti hepatitis C antibody or serum hepatitis B surface antigen)
3091642|NCT01948687||3. liver cirrhosis type B or C|patients with liver cirrhosis type B or C
3091643|NCT01948674|Experimental|computerized tasks- adaptive|
3091644|NCT01948674|Active Comparator|computerized tasks - nonadaptive|
3091645|NCT01948661|Experimental|Anthocyanins+Phospholipidic Curcumin|Mirtoselect ® 500 mg tablet, 1000 mg (two oral tablets) per day and Meriva ®, 500 mg tablet, 1000 mg (two oral tablets) per day for 28 days
3091646|NCT01948661|Placebo Comparator|placeboA + placeboB|placeboA + placeboB per day for four weeks
3091647|NCT01948648|Active Comparator|Colesevelam|3.75g/day for 6 weeks
3091648|NCT01948648|Active Comparator|Fish Oil|1g/day for 6 weeks
3091649|NCT01948648|Active Comparator|Combination of Fish Oil and Colesevelam|3.75g/day of colesevelam and 1g/day of fish oil for 6 weeks
3091650|NCT01948635|Experimental|tapered PVC-cuffed tracheal tubes|Patients in this arm will be intubated with tapered PVC-tracheal tubes
3091651|NCT01948635|Active Comparator|Standard PVC-cuffed tracheal tube|Patients in this arm will be intubated with standard (barrel-shape cuffed) PVC tracheal tubes
3091652|NCT01948622|Active Comparator|Mulungu|500 mg Mulungu Matusa® (Erytrina mulungu, 2 capsules of 250 mg) administered v.o., one hour before the surgical procedure.
3091653|NCT01948622|Placebo Comparator|placebo|500 mg of starch (2 capsules of 250 mg) administered v.o., one hour before the surgical procedure.
3091654|NCT01948609||Treated with RRSO|Women with the BRCA gene 1/2 mutation who choose to undergo risk reducing salpingo-oophorectomy (RRSO) treatment.
3091655|NCT01948609||No RRSO treatment|Women with the BRCA gene 1/2 mutation who choose non-surgical treatment.
3091656|NCT01948596|Experimental|Omega-3 polyunsaturated fatty acids|1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily
3091657|NCT01948583|Active Comparator|Arm I: vaginal gel new formulation|"Application once a day at evening during the first study week of the vaginal gel new formulation (hyaluronic acid).~One week of wash-out (second week). Application once a day at evening during the third study week of the vaginal gel on the market (hyaluronic acid)."
3091717|NCT01948128|Experimental|Vitamin D3|Vitamin D3 40,000 iu per day by mouth
3091718|NCT01948128|Placebo Comparator|Placebo|Placebo taken daily by mouth
3091658|NCT01948583|Active Comparator|Arm II: vaginal gel on the market|"Application once a day at evening during the first study week of the vaginal gel on the market (hyaluronic acid).~One week of wash-out (second week). Application once a day at evening during the third study week of the vaginal new formulation (hyluronic acid)."
3091659|NCT01948570||not in therapy (GROUP 1)|A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0).
3091660|NCT01948570||in therapy (GROUP 2)|A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0). Group 2 will continue also the standardised treatment with topical or systemic retinoids, benzoyl peroxide, clindamycin or AHA until the end of the study
3091661|NCT01948557|Other|Infant feeding counselling and support|All mothers provided with counselling. Subsequent support interventions depended on mothers' selection of feeding practice
3091662|NCT01948544||chronic obstructive pulmonary disease|"More than 12 million adults are diagnosed with COPD~COPD is the 4th leading cause of death in the U.S.~Breathing difficulty is the major reason patients seek medical attention~COPD patients requiring hospitalization were associated with higher costs~Oximetry is an important tool for assessing need for Long-term oxygen therapy~LTOT has been proven to improve survival and quality of life~Patients will be provided a lightweight portable oxygen concentrator to:~support increased activity~improve quality of life~increase functional capacity"
3091663|NCT01948531|Experimental|Gynomunal® gel|The study will be conducted on 33 healthy volunteers of female sex aged between 35 and 65 years old; each subject will apply a fixed quantity of the Gynomunal gel on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage.
3091664|NCT01948518|Experimental|Oral sildenafil 20 mg|oral sildenafil, single dose at baseline
3091665|NCT01948505|Active Comparator|Intervention group|IV acetaminophen: 1000mg IV q 8 hrs (scheduled) until: a) tolerating PO and IV saline-locked or b) 48 hours reached on medication
3091666|NCT01948505|Placebo Comparator|Placebo Group|IV Normal Saline: 100ml IV q 8 hrs (scheduled) until: a) tolerating PO and IV saline-locked or b) 48 hours reached on medication
3091667|NCT01948492|Experimental|protein|varying protein intake in random order from deficient to excess
3091668|NCT01948479|Experimental|Insole optimised with inshoe analysis|
3091669|NCT01948479|Active Comparator|Routine insole provision|
3091670|NCT01948466|Experimental|Commercials|Schools Administered Commercials
3091671|NCT01948466|No Intervention|Control|Schools not Administered Commercials
3091672|NCT01948453|Active Comparator|Garlic|daily consumption of two odor controlled garlic tablets
3091673|NCT01948453|Placebo Comparator|Placebo|daily consumption of placebo
3091674|NCT01948440|Experimental|ASI-MV Solutions|The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions. The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
3091675|NCT01948440|No Intervention|Treatment as Usual|The Control group participants will complete the ASI-MV and receive their normal course of treatment. The Control group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
3091676|NCT01948414|Other|obese women with eating disorders|Obese women with eating disorders : women with BMI higher or equal 35 and disinhibition score to TFEQ strictly higher to 8
3091677|NCT01948414|Other|Obese women without eating desorders|Obese women without eating disorders : women with BMI higher or equal to 35 and disinhibition score to TFEQ lower or equal to 8
3091678|NCT01948414|Other|Lean women|Lean women : women with BMI from 18.5 to 24.5 and disinhibition score to Three-Factor Eating Questionnaire (TFEQ)lower or equal to 8
3091679|NCT01948401|Experimental|Controlled asthma|
3091680|NCT01948401|Experimental|Uncontrolled asthma with additional OCS|
3091681|NCT01948401|Experimental|Uncontrolled asthma without additional OCS|
3091682|NCT01948388|Active Comparator|corticotrophin 80 units|Ten (10) patients will receive 80 units of corticotrophin Subcutaneous (SC) weekly
3091683|NCT01948388|Active Comparator|corticotrophin 80 units twice a week|Ten (10) patients will receive 80 units of corticotrophin Subcutaneous (SC) twice a week
3091684|NCT01948375|Experimental|real needle- placebo needle|Participants received acupuncture with real needle in the first period, and with pragmatic placebo acupuncture needle in the second period.
3091685|NCT01948375|Experimental|placebo needle - real needle|Participants received acupuncture with pragmatic placebo needle in the first period, and with real acupuncture needle in the second period.
3091686|NCT01948362|Active Comparator|Sulforadex|Active compound
3091687|NCT01948362|Experimental|alpha Cyclodextrin|Placebo control arm
3091688|NCT01948349|No Intervention|Non-tongue scraping and twin brackets|Patients in this subgroup will be instructed to follow standard at-home oral hygiene protocols. They will be instructed by the study coordinators to utilize the traditional Bass brushing technique [31], brushing twice daily (morning and night) for 2 minutes each time. Patients will all be given the same toothbrush and toothpaste to use during the study. They will also be instructed on the method of flossing and be shown how to use interdental brushes to clean around the orthodontic appliances.
3091689|NCT01948349|Experimental|Tongue scraping with standard twin brackets|Patients allocated to this group will receive the same oral hygiene protocol as the non-tongue scraping subjects. However, they will also be in instructed and asked to use the tongue-scraping method of cleaning the tongue as part of their oral hygiene regimen. Patients will be instructed to scrape the tongue once during their nighttime oral hygiene session of brushing and flossing. All patients in this subgroup will be given the same tongue scraper.
3091690|NCT01948349|Experimental|No tongue scraping with self-ligating brackets|Patients in this group are treated with passive self-ligating Carrier brackets (Ortho Organizer). They will be instructed to use the traditional Bass brushing technique, brushing twice daily (morning and night) for 2 minutes each time. Patients will all be given the same toothbrush and toothpaste to use during the study. They will also be instructed on the method of flossing and be shown how to use interdental brushes to clean around the orthodontic appliances.
3091691|NCT01948349|Experimental|Tongue scraping with SLB|Patients in this group are treated with passive self-ligating Carrier brackets (Ortho Organizer). Patients allocated to this group will receive the same oral hygiene protocol as non-tongue scraping subjects. However, they will also be in instructed and asked to use the tongue-scraping method of cleaning the tongue as part of their oral hygiene regimen. Patients will be instructed to scrape the tongue once during their nighttime oral hygiene session of brushing and flossing. All patients in this subgroup will be given the same tongue scraper.
3091692|NCT01948336|Placebo Comparator|Control|The patients in group C (control) (n=30) were bolused with 1 mg kg-1 ketamine (Ketalar®, Eczacibasi, Luleburgaz, Turkey) (IV) and 1 mg kg-1 propofol (Propofol 1% Fresenius, Fresenius Kabi Deutschland, Bad Homburg, Germany) (IV) followed by 1 mg kg-1 hour-1 ketamine (IV) and 50 µg kg-1 min-1 propofol (IV) infusion. Additionally a loading dose of 1 ml kg-1 D5 0.3% NaCl IV given over 10 minutes, followed by 0.5 ml kg-1 hour-1 IV D5 0.3% NaCl infusion were administered.
3091693|NCT01948336|Active Comparator|Dexmedetomidine|The patients in group D (dexmedetomidine) (n=30) were bolused with 1mg kg-1 ketamine (IV), 1mg kg-1 propofol (IV) followed by 1 mg kg-1 hour-1 ketamine (IV) and 50 µg kg-1 min-1 propofol (IV) infusion. Additionally a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.
3091694|NCT01948323|Other|.HEDUAfrica IT package+ std care info|"The HEDUAfrica IT package website aims to target disadvantaged gravid women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, SA). A healthcare worker will assist women with the touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes. Patients participating in the IT package also receive std car info~Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group."
3091695|NCT01948323|No Intervention|Health awareness brochure + std care|Participants in the non-intervention group at another clinic in Soweto, will receive an enhanced form of standard care. This will include, in conjunction with the normal form of care at each clinic,a health awareness brochure that will focus specifically on health information relating to obesity, diabetes, diet, exercise and breastfeeding at each follow-up sessions. These participants will also be asked to fill out the 24 hour dietary recall assessment and short messaging service technology questionnaire (exactly the same as the intervention group) with help from a healthcare worker.
3091696|NCT01948310|Active Comparator|Ranolazine plus Exercise|Ranolazine 1000mg pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.
3091697|NCT01948310|Placebo Comparator|Placebo plus Exercise|Placebo pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.
3091698|NCT01948297|Experimental|Part A|Adaptive doses of Debio1347 (CH5183284) - (10 mg to 210 mg/day) until the recommended dose (RD) is determined.
3091699|NCT01948297|Experimental|Part B|Participants with various tumours receive Debio1347 (CH5183284) orally at the recommended dose established during Part A.
3091700|NCT01948284|Active Comparator|maximal suction pressure|The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
3091701|NCT01948284|Active Comparator|half-maximal pressure|The pressure level of the suction unit will be set at the half-maximal (-35 cm Hg).
3091702|NCT01948271|Experimental|TSO 7500|Subjects in this arm will receive doses of 7500 trichuris suis ova every two weeks, starting at the baseline visit, for a total of 8 doses.
3091703|NCT01948258||Fertility Monitor|Use of Clearblue Fertility Monitor
3091704|NCT01948245|Active Comparator|TaurolockTMHep100|"2-4 ml of TaurolockTMHep100 will be instilled into the central venous access device (CVAD)after each infusion of parenteral nutrition/intravenous fluids. The instillation varying between twice per week to once daily depending on the patients individual HPN programme. The catheter lock solution is kept in situ in the lumen to the next infusion.~The duration of TaurolockTMHep100 administration will be maximum 24 month or until occurence of primary outcome(CRBSI)."
3091705|NCT01948245|Placebo Comparator|Heparin 100 IE/ml|"2-4 ml of Heparin 100 IE/mk will be instilled into the central venous access device (CVAD)after each infusion of parenteral nutrition/intravenous fluids. The instillation varying between twice per week to once daily depending on the patients individual HPN programme. The catheter lock solution is kept in situ in the lumen to the next infusion.~The duration of Heparin 100 IE/ml administration will be maximum 24 month or until occurence of primary outcome(CRBSI)."
3091706|NCT01948232|Experimental|Perindopril|
3091707|NCT01948219|Experimental|ENTegral Artificial Larynx implant|ENTegral Artificial Larynx implantation
3091708|NCT01948206||Prolonged paced QRS group|Patients with implantable cardioverter-defibrillators with Prolonged Paced(>=150ms) QRS duration
3091709|NCT01948206||Narrow paced QRS group|Patients with Implantable Cardioverter-Defibrillators with Narrow Paced(<150ms) QRS duration
3091710|NCT01948193|Experimental|Study Group|Participants will receive Sanofi Pasteur's DTaP-IPV-Hep B-PRP~T combined vaccine (investigational vaccine) at 6, 10 and 14 weeks of age.
3091711|NCT01948180|Experimental|CMD-003|"Treatment consists of 2 infusions of 2x10E7 cells/m2 given on Days 1 and 15 intravenously via a peripheral or central line over a 1 to 10 minute period.~Subjects who tolerate the study treatment well and who do not require treatment with an alternative chemotherapeutic agent will be eligible for up to 3 additional infusions of 2x10E7 cells/m2 administered at week 8, month 3 and month 6."
3091712|NCT01948167|Experimental|Interpersonal Psychotherapy- Adolescent Skills Training|Interpersonal Psychotherapy- Adolescent Skills Training
3091713|NCT01948167|Experimental|Coping with Stress|Coping with Stress
3091714|NCT01948154||children with CP|Cerebral palsy (CP) encompass a group of non-progressive, non-contagious motor conditions that cause physical disability in human development. 2-12 years old (n=60-80)
3091715|NCT01948154||normal child|normal child 2-12 years old (50 subjects)
3091716|NCT01948141|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3091721|NCT01948102||subjects with ALS|subjects with ALS who are undergoing a percutaneous endoscopic gastrostomy
3091722|NCT01948102||subjects without ALS|subjects without ALS who are undergoing a percutaneous endoscopic gastrostomy
3091723|NCT01948089|Experimental|Variable Structured Cognitive Exercise|This training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. Each participant will receive 30 minutes of cognitive exercise per day, 3 days a week for 10 weeks.
3091724|NCT01948089|Experimental|Constant Structured Cognitive Exercise|This training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. Each participant will receive 30 minutes of cognitive exercise per day, 3 days a week for 10 weeks.
3091725|NCT01948076|Placebo Comparator|resident without GE vscan|baseline physical exam use
3091726|NCT01948076|Active Comparator|resident with GE vscan|residents with augmentation of physical exam by ultrasound
3091727|NCT01948063|Placebo Comparator|Control|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
3091728|NCT01948063|Experimental|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg of Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
3091729|NCT01948050|Experimental|real tDCS stimulation|non-invasive transcranial direct current stimulation (tDCS) at 2 milliamiampers (2mA)for 20 minutes at each session, on five consecutive days.
3091730|NCT01948050|Sham Comparator|Sham tDCS|sham non-invasive transcranial direct current stimulation (tDCS) consisting of 30 seconds of tDCS stimulation at 2mp and 19 minutes and 30 seconds of tdcs at 0mp stimulation,on five consecutive days.
3091731|NCT01948037|Active Comparator|hydrotherapy|
3091732|NCT01948037|Other|hot spring|30-minutes/per day;4weeks
3091733|NCT01948024|Active Comparator|Reference Arm - SAPHRIS|10 mg BID sublingual tablet
3091734|NCT01948024|Experimental|Test Arm - Asenapine|10 mg BID sublingual tablet
3091735|NCT01948011|Experimental|Racecadotril 10mg suspension|single oral dose
3091736|NCT01948011|Experimental|Racecadotril 30mg suspension|single oral dose
3091737|NCT01948011|Experimental|Racecadotril 60mg suspension|single oral dose
3091738|NCT01948011|Active Comparator|Racecadotril 60mg granules|single oral dose
3091739|NCT01947998||Rivaroxaban / Cohort 1|Patients who have been prescribed Rivaroxaban for the first time
3091740|NCT01947998||Standard of care / Cohort 2|Patients who have been prescribed Standard of care for the first time
3091741|NCT01947985||Rivaroxoban|Patients who have been prescribed Rivaroxaban for the first time
3091742|NCT01947985||Standard of care|Patients who have been prescribed standard of care for the first time
3091743|NCT01947972|Other|protein intake of 4g/kg/d|Tailored protein fortification and nutritional status of preterm neonate. 4.5g protein per kg for preterms with body weight less than 1000g and 4g protein per kg for preterms with body weight more than 1000g, after human milk analysis. Intervention regards protein supplementation to fulfil the exact protein needs of preterms
3091744|NCT01947959||Rivaroxaban|Patients who have been prescribed Rivaroxaban for the first time
3091745|NCT01947959||Standard of care|Patients who have been prescribed Standard of care for the first time
3091746|NCT01947946|Experimental|Benra 30 mg q.4 Weeks|Fixed 30 mg dose of benralizumab (every 4 weeks)
3091747|NCT01947946|Experimental|Benra 30 mg - Placebo q.8 Weeks|Fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administered at the 4 week interim treatment visits to maintain blind).
3091748|NCT01947946|Placebo Comparator|Placebo|A (Dummy) injection
3091749|NCT01947933|Placebo Comparator|Placebo IV|Participants with psoriasis will receive a single dose of placebo matching mirikizumab intravenously (IV)
3091750|NCT01947933|Experimental|Mirikizumab IV|Participants with psoriasis will receive a single escalating dose of 5 milligram (mg), 20 mg, 60 mg, 120 mg, 200 mg, 350 mg, or 600 mg mirikizumab, IV
3091751|NCT01947933|Experimental|Mirikizumab SC|Healthy participants will receive a single dose of 120 mg mirikizumab subcutaneously (SC).
3091752|NCT01947920|Experimental|1: Tramadol HCl 200 mg daily or placebo|Participants will receive one capsule of Tramadol hydrochloride (HCl) every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
3091753|NCT01947920|Experimental|2: Tramadol HCl 400 mg daily or placebo|Participants will recieve two capsules of Tramadol HCl every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
3091754|NCT01947920|Experimental|3: Tramadol HCl 600 mg daily or placebo|Participants will receive three capsules of Tramadol HCl every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
3091755|NCT01947907|Experimental|ACP-001, dose-level 1|Once weekly subcutaneous injection of ACP-001
3091756|NCT01947907|Experimental|ACP-001, dose-level 2|Once weekly subcutaneous injection of ACP-001
3091757|NCT01947907|Experimental|ACP-001, dose-level 3|Once weekly subcutaneous injection of ACP-001
3091758|NCT01947907|Active Comparator|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone (rhGH)
3091759|NCT01947894||Adult Growth Hormone deficient Patients|Patients with GHD on Genotropin® replacement therapy.
3091760|NCT01947881||Patients with DME|Patients with DME who need treatment with anti-VEGF injections of Lucentis.
3091761|NCT01947855|Experimental|Empagliflozin low dose|Empagliflozin low dose tablet once daily
3091762|NCT01947855|Experimental|Empagliflozin high dose|Empagliflozin high dose tablet once daily
3091763|NCT01947855|Placebo Comparator|Placebo|Placebo tablet once daily
3091764|NCT01947842|Experimental|Smartphone App|The pharmacist will download and configure the Dosecast smartphone application to remind the patient to take their medication in addition to pharmacist counseling on the importance of adherence.
3092061|NCT01945762||1. patient cohorts (40 patients/cohort)|RET positive patient cohorts
3091765|NCT01947842|No Intervention|Counseling Alone|This arm will receive only counseling from the pharmacist with no other intervention.
3091766|NCT01947829||Chronic Hemodialysis|
3091767|NCT01947816||Humira|Humira 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 160 mg and 2nd dosage of 80 mg in two weeks after the initial administration
3091768|NCT01947803|Experimental|Paliperidone Palmitate|
3091769|NCT01947790|Experimental|Pioglitazone group|Pioglitazone 15 mg/day will be given in this group for 9 months
3091770|NCT01947790|Active Comparator|Metformin group|Metformin 0.85 twice daily will be given in this group for 9 months as control.
3091771|NCT01947764|No Intervention|Usual Care|"The Usual Care components for the control clinics will include the following:~All clinicians (pediatricians, medical officers, clinical officers, and nurses) caring for children undergo the existing 3-day disclosure training~Chart materials to guide and document disclosure counseling and visits~The presence of the AMPATH SOP mandating disclosure to children ages 10 and older.~In Usual Care clinics, no specific personnel will be dedicated to disclosure."
3091772|NCT01947764|Experimental|HADITHI Intervention|"In addition to the Usual Care components, the HADITHI Intervention clinics will include:~Modified materials to guide disclosure sessions~Videotaped narratives for parental counseling~Dedicated disclosure counselors to initiate and conduct the disclosure process~Post-disclosure support groups for children~The disclosure counselors will avail themselves for conducting disclosure with any families referred to them by the AMPATH clinicians. They will post fliers that describe their services for parents and caregivers so that families can self-refer for disclosure counseling. Similarly, the post-disclosure support groups for children will be available for anyone enrolled in the clinic and families will be able to self-refer or to be referred by the clinicians."
3091773|NCT01947751|Active Comparator|CVC exchange|The CVC will be removed immediately.
3091774|NCT01947751|Experimental|CVC maintenance|The CVC will be maintained, and exchanged only if confirmed catheter-related infection or worsening of sepsis
3091775|NCT01947738|Experimental|VBY-891|VBY-891
3091776|NCT01947738|Placebo Comparator|Placebo|Capsules containing excipient but no active drug
3091777|NCT01947712|Placebo Comparator|milk chocolate|dosage form: orally given dosage:40 g milk chocolate (≤35% cocoa) frequency and duration: 40 g/day for one month
3091778|NCT01947712|Active Comparator|dark chocolate|dosage form: orally given dosage:40 g dark chocolate (≥85% cocoa) frequency and duration: 40 g/day for one month
3091779|NCT01947699|Experimental|Glyburide once daily|Timing of glyburide dosing will be changed, glucose will be monitored using continuous a glucose monitor.
3091780|NCT01947699|Experimental|Glyburide twice daily|Dose interval and timing of glyburide dose will be changed, glucose will be monitored using continuous a glucose monitor.
3091781|NCT01947699|Experimental|Mixed meal tolerance test.|Subjects will be admitted to the Clinical Translational Research Center, receive a Mixed meal tolerance test and have timed blood draws to assess the effect of glyburide on glucose and insulin metabolism.
3091782|NCT01947686||Patellofemoral Knee Arthroplasty|Patient who have received a robotically guided isolated patellofemoral implant.
3091783|NCT01947673|Experimental|Mindfulness Meditation|After individual instruction, participants in this arm will perform meditation by following a series of MM recordings during hemodialysis for the next 4 to 8 weeks.The MM instructor will also meet with the participants weekly to provide continued instruction. Participants will also be encouraged to perform MM using the MP3 player at home on non-dialysis days, and asked to keep a log of these sessions.
3091784|NCT01947673|Placebo Comparator|Health Education|Participants randomized to the control condition will undergo a 4 to 8 week health education series, with a parallel protocol as the MBSR intervention. Monitoring of adherence will be same as above.
3091785|NCT01947660|Experimental|Continuous regional anesthesia|
3091786|NCT01947660|Active Comparator|Systemic analgesia|
3091787|NCT01947647|Experimental|Transdiagnostic Behavior Therapy|A new transdiagnostic CBT protocol for the depressive/anxiety disorders was developed and revised through two demonstration studies and one focus group. The resulting protocol involves several primary components, including psychoeducation on the symptoms of depression and anxiety (session 1), assessment of motivation and setup of treatment plans (session 2), exposure therapy (sessions 3-15), and relapse prevention (final session). In addition to these primary components, optional modules are included to supplement exposure therapy later in treatment to address secondary symptoms (e.g., anger, sleep, hypervigilance, drinking to cope). The goal of these modules is to allow providers to tailor treatment to specific symptoms that may be present in any single or set of diagnoses that may be reducing the effects from the primary exposure approach. Session will be weekly for 45-60 minutes with homework assignments to be completed between sessions.
3091788|NCT01947647|Active Comparator|Behavioral Activation Therapy|To provide an evidence-based comparison for the transdiagnostic CBT condition, a second group of participants will receive manualized BAT. In general, BAT involves teaching patients to monitor their mood and daily activities with the goal of increasing pleasant, reinforcing activities and reducing unpleasant events. In the present study, the BAT condition will be manualized, following an existing protocol in the literature. BAT will be structurally equivalent to the transdiagnostic CBT with the same session length (45-60 minutes), frequency of sessions (weekly), duration of treatment (12-16 sessions), and amount of homework.
3091789|NCT01947634|Experimental|ResMed Apnea Link plus|Overnight respiratory polygraphy is performed in Fabry patients
3091790|NCT01947595|Active Comparator|high risk non-responder, intensified lifestyle intervention|"high risk non-responder:~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)~B) insulin resistance (ISI-Matsuda < 9,2)~C) elevated liver fat ( MRT > 5,56%)~A+B or A+C or B+C or A+B+C"
3091791|NCT01947595|Active Comparator|hight risk non responder, normal lifestyle intervention|"high risk non-responder:~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)~B) insulin resistance (ISI-Matsuda < 9,2)~C) elevated liver fat ( MRT > 5,56%)~A+B or A+C or B+C or A+B+C"
3091792|NCT01947595|Active Comparator|Responder, normal lifestyle intervention|"Responder:~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)~B) insulin resistance (ISI-Matsuda < 9,2)~C) elevated liver fat ( MRT > 5,56%)~No A, only B or C"
3091793|NCT01947595|Active Comparator|Responder, single lifestyle advice (control group)|"Responder:~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)~B) insulin resistance (ISI-Matsuda < 9,2)~C) elevated liver fat ( MRT > 5,56%)~No A, only B or C"
3091794|NCT01947582|Other|Application of ankle foot orthosis|All participants will receive ankle foot orthosis or orthoses. Outcomes will be compared to pre-bracing findings.
3091795|NCT01947569|Experimental|iDC recipients|iDC cells modified by in vitro engineering.
3091796|NCT01947569|Active Comparator|Control DC recipients|DC cells which have not been modified.
3091797|NCT01947569|Placebo Comparator|Placebo recipients|Saline injections.
3091798|NCT01947556|Other|insujet is tested first|first procedure: experiment with the investigational product (Insujet pen)containing insulin aspart; second procedure: control device (conventional Novopen III insulin pen) contains insulin aspart.
3091799|NCT01947556|Other|insujet is tested second|first procedure: experiment with the conventional Novopen III insulin pen containing insulin aspart; second procedure: investigational device (Insujet) contains insulin aspart.
3091800|NCT01947543||Ventricular tachycardia|Patients with ventricular tachycardia of unknown origin treated with an ICD.
3091801|NCT01947543||Family members|Family members (parents, siblings and children) for patients with results showing mutations in the calmodulin genes.
3091802|NCT01947530|Active Comparator|Navigational Bronch/Standard Bronch|Patient will have first the Navigational Bronchoscopy then the standard bronchoscopy completed.
3091803|NCT01947530|Active Comparator|Standard Bronch/Navigational Bronch|Patient will first have a standard bronchoscopy then a navigational bronchoscopy completed.
3091804|NCT01947517||Parasol Punctal Occluder Group|Randomized to receive Brand A punctal plugs
3091805|NCT01947517||Superflex Punctal Occluder Group|Randomized to receive Group B punctal plugs
3091806|NCT01947504|Experimental|education and support intervention|education and support intervention
3091807|NCT01947504|No Intervention|waiting list|waiting list and regular medical follow-up
3091808|NCT01947491|Experimental|DFD01 Spray|DFD01 Spray twice daily for 28 days
3091809|NCT01947491|Placebo Comparator|Vehicle Spray|Vehicle Spray twice daily for 28 days
3091810|NCT01947491|Active Comparator|Comp01 Lotion|Comp01 Lotion twice daily for 14 days
3091811|NCT01947491|Placebo Comparator|Vehicle Lotion|Vehicle Lotion twice daily for 28 days
3091812|NCT01947478|Experimental|MDT-2113 Drug-Eluting Balloon|Paclitaxel drug-eluting angioplasty balloon
3091813|NCT01947478|Active Comparator|Standard angioplasty balloon|Standard PTA balloon without Paclitaxel drug-elution
3091814|NCT01947465||Healthy controls|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 319 healthy controls will be enrolled and will receive hepatitis A and/or tetanus vaccination
3091815|NCT01947465||Patients with rheumatoid arthritis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with rheumatoid arthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
3091816|NCT01947465||Patients with axial spondylarthritis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with axial spondylarthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
3091817|NCT01947465||Patients with vasculitis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with vasculitis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
3091818|NCT01947452|Experimental|Jobs Only|Youth will be offered a 5-hour per day, 5-day per week employment opportunity over 7 weeks. They will be paid the Illinois minimum wage of $8.25 per hour.
3091819|NCT01947452|Experimental|Jobs plus Social-Emotional Learning|Youth will be offered a 3-hour per day, 5-day per week employment opportunity over 7 weeks. They will also be offered 2-hour per day, 5-day per week social-emotional learning programming, for which they will be paid the same hourly wage as their job ($8.25/hour).
3091820|NCT01947439|Experimental|Biolimus A9 eluting stent|biolimus A9 stent( Biomatrix or Biomatrix Flex) will be placed in under Percutaneous Coronary Intervention.
3091821|NCT01947439|Active Comparator|Zotarolimus-eluting stent|zotarolimus eluting stent (Resolute Integrity) will be placed in under Percutaneous Coronary Intervention.
3091822|NCT01947426|Experimental|DHA supplementation|mother consuming 400 mg/day of DHA and tehir neonates
3091823|NCT01947426|Placebo Comparator|Control (milk without DHA)|Mothers comsuming placebo and their neonates
3091824|NCT01947413|Experimental|iTBS group|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
3091825|NCT01947413|Experimental|cTBS group|In continuous theta burst stimulation (cTBS group), they received cTBS (80% of active motor threshold) on unaffected hemisphere.
3091826|NCT01947413|Sham Comparator|sham TBS group|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
3091827|NCT01947400||Hospitalists|AIDET Training
3091828|NCT01947387||Integra|
3091829|NCT01947387||Integra + NPWT (short-inpatient use only)|
3091830|NCT01947387||Integra + NPWT (long-all other durations)|
3091831|NCT01947387||Integra + STSG|
3091832|NCT01947387||Integra + Dermoinductive Agent|
3091833|NCT01947387||Free Flap|
3091834|NCT01947387||Local Tissue Flap|
3091835|NCT01947387||NPWT|
3091836|NCT01947387||NPWT then Integra (on same admission)|
3091837|NCT01947374|Experimental|Chondrocyte implantation|From a previous biopsy, articular cartilage matrix is digested and chondrocytes are cultured in 2 passages until implants with at least 6,000,000 cells are constructed. These constructus of 8 mm in diameter are implanted arthroscopically by means of biodegradable anchor (MINILOK QUICKANCHOR TM from DePuy-Mitek ) located at the defect and tied securely.
3091838|NCT01947374|Experimental|Microfractures|Subchondral bone perforations that allow a clot to be formed, and subsequent scar at the cartilage defect area.
3091839|NCT01947348|Experimental|treatment with A3 SVF|These patients that have been treated. The control patients that have not been treated.
3091840|NCT01947335|No Intervention|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention
3091841|NCT01947335|Active Comparator|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
3091842|NCT01947322|Experimental|Allogenic NK cells infusion|
3091843|NCT01947309||Multiple Myeloma Patients Treated with Revlimid (lenalidomide)|Single Cohort of Multiple Myeloma Patients Treated with Revlimid
3091844|NCT01947296||"Group  coordinated care"|"Patient living in place covered by cancer network participating to the study is in the group coordinated care"
3091845|NCT01947296||"Group  usual care "|"Patient living in place covered by cancer network non participating to the study or without cancer network is in the group usual care"
3091846|NCT01947283|Experimental|Intervention Providers & Patients|"Providers in this arm will receive the DECIDE-PC intervention. Patients in this arm will receive the DECIDE-PA intervention.~For intervention providers, the DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making.~For intervention patients, the DECIDE PA is designed to help patients identify concerns about their condition or treatment and generate questions for providers regarding these concerns. The DECIDE PA intervention consists of 3-4 brief training sessions for patients delivered by Care Managers."
3091847|NCT01947283|Experimental|Control Providers, Intervention Patients|"Control Providers will not receive the DECIDE-PC intervention. Intervention Patients will receive the DECIDE-PA intervention.~For intervention patients, the DECIDE PA is designed to help patients identify concerns about their condition or treatment and generate questions for providers regarding these concerns. The DECIDE PA intervention consists of 3-4 brief training sessions for patients delivered by Care Managers."
3091848|NCT01947283|Experimental|Intervention Providers, Control Patients|"Intervention providers will receive the DECIDE-PC intervention. Control patients will not receive the DECIDE-PA intervention.~For intervention providers, the DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making.~Control patients will receive a pamphlet called Managing Your Mental Health Care."
3091849|NCT01947283|No Intervention|Control Providers & Patients|"Control providers and patients will not receive the DECIDE-PA or DECIDE-PC intervention. Control patients will receive a pamphlet called Managing Your Mental Health Care."
3091850|NCT01947270||Control group|Patients of this group are hospitalized in a time frame where the multidisciplinary intervention program is not implemented in the medical department. Drug prescriptions are conducted under usual care in the department.
3091851|NCT01947270||Intervention group|Patients of this group are hospitalized in a time frame where the multidisciplinary intervention program is implemented in the medical department.
3091852|NCT01947257|Other|ventilated patients|
3091853|NCT01947244|Experimental|Doula Home Visiting|Participants assigned to the intervention group receive prenatal and short-term postpartum home visitation from doulas, and support from doulas at the hospital during labor, delivery, and with early breastfeeding. Additionally, these participants receive longer-term home visiting services from family support workers during pregnancy and after the birth.
3091854|NCT01947244|Active Comparator|Case Management|Mothers in the comparison group receive low intensity case management services during pregnancy and following the birth.
3091855|NCT01947231|Experimental|Global Postural Re-education|Global Postural Re-education is delivered in a single treatment session each week for nine weeks.
3091856|NCT01947231|Active Comparator|Standard manual physical therapy|Standard manual physical therapy is delivered in a single treatment session each week for 9 weeks.
3091857|NCT01947218|Experimental|smoking COPD|
3091858|NCT01947218|Experimental|smoking without COPD|
3091859|NCT01947218|Other|No Smoking Control|
3091860|NCT01947218|Experimental|severe asthma|
3091861|NCT01947205|Active Comparator|paracetamol|Duration
3091862|NCT01947205|Active Comparator|without drug|Control group
3091863|NCT01947205|Active Comparator|dexketoprofen trometamol|Study group
3091864|NCT01947205|Active Comparator|two puff xylocain administration on cervical surface|Study group
3091865|NCT01947205|Active Comparator|paracervical block with ultracaine|study group
3091866|NCT01947192|Experimental|Chlorhexidine|Dentin pre-treatment with a experimental solution (chlorhexidine), after the dentin acid etching
3091867|NCT01947192|Placebo Comparator|Water|Application of water (placebo) after dentin acid etching.
3091868|NCT01947179|No Intervention|Physical Health Training|The Physical Health Training condition will include information on the importance and benefits of a healthy lifestyle. Additionally, the program will discuss guidelines for a healthy lifestyle including information on diet, water consumption, exercise, and sleep.
3091869|NCT01947179|Experimental|Anxiety Risk Reduction|The anxiety risk reduction intervention will include psychoeducation focused on the nature of stress and its effect on the body. Interoceptive exposure exercises that were designed to correct the conditioned fear of bodily sensations will be explained and practiced.
3091870|NCT01947153|Experimental|Fixed dose combination|Linagliptin/Metformin
3091871|NCT01947153|Experimental|Free combination|Linagliptin and Metformin
3091872|NCT01947140|Experimental|Phase I: Schedule A|Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 8 of each 21 day cycle
3091873|NCT01947140|Experimental|Phase I: Schedule B|Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 15 of each 28 day cycle
3091874|NCT01947140|Experimental|Phase II|Subjects will receive Pralatrexate 25 mg/m2 and Romidepsin 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle
3091875|NCT01947127||High lactate|Initial venous lactate level equal to or more than 2.0 mmol/L
3091876|NCT01947127||Low lactate|Initial venous lactate level less than 2.0 mmol/L
3091877|NCT01947114|Active Comparator|Group Propofol|
3091878|NCT01947114|Active Comparator|Group Ketamine|
3091879|NCT01947101|Experimental|Ulcerative Colitis|Fecal Microbiota Transplant
3091880|NCT01947088|Experimental|Music Therapy Arm|Music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.) Pre-study and post-study scores from the neuropsychological assessments will be compared to determine if music therapy has a significant effect on the child's cognitive recovery. Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for music therapy (treatment group) for about 45 minutes, twice per week, for Weeks 1-8. CThe Music Therapy group will partake in interventions such as singing and playing musical instruments.
3091881|NCT01947088|Active Comparator|Unstructured Play Arm|Child life programs provide children with opportunities to engage in normal play and recreational activities that promote growth, development and feelings of success and fulfillment.All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). This is the standard of care for all brain surgery patients. The results of this assessment and will be used in this research study. In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
3091882|NCT01947075||Adults with fever|Every adult with fever will be screened for different infectious diseases and for nasopharyngeal respiratory viruses and bacteria
3091883|NCT01947075||Healthy volonteers|For every adult with fever included with a diagnosis of pneumonia, a healthy volunteer will be included. These healthy volunteers will be screened for nasopharyngeal respiratory viruses and bacteria.
3091884|NCT01947062|Active Comparator|Standard intravenous chemotherapy|Patients will receive standard intravenous chemotherapy based on cisplatin and etoposide.
3091885|NCT01947062|Experimental|Intravenous with metronomic chemotherapy|Patients will receive both intravenous (cisplatin and etoposide based) and metronomic chemotherapy (with oral cyclophosphamide).
3091886|NCT01947049|No Intervention|Control Arm|Participants in this arm will receive usual care (influenza testing and treatment)
3091887|NCT01947049|Experimental|Rapid Testing|Participants in this arm will receive rapid influenza testing with Xpert Flu.
3091888|NCT01947036||Healthy Subjects|Healthy adult controls (no auto-immune disease)
3091889|NCT01947036||Subjects with Crohn's Disease|Diagnosed with or suspected of having Crohn's disease (CD)
3091890|NCT01947036||Subjects with Rheumatoid Arthritis|Diagnosed with or suspected of having rheumatoid arthritis (RA)
3091891|NCT01947036||Subjects with Type 1 diabetes|Diagnosed with or suspected of having type 1 diabetes mellitus (T1D, T1DM)
3091892|NCT01947036||Subjects with Multiple Sclerosis (MS)|Diagnosed with or suspected of having MS
3091893|NCT01947036||Subjects with Psoriasis|Diagnosed with or suspected of having psoriasis (Ps)
3091894|NCT01947023|Experimental|Treatment (lapatinib ditosylate, dabrafenib)|"Patients receive dabrafenib* PO BID on days 1-28 and lapatinib ditosylate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients also receive dabrafenib PO for 2 weeks prior to beginning treatment with lapatinib ditosylate."
3091895|NCT01947010|Active Comparator|Crohn's patients treated with Azathioprine|Vaccination with PPV23 or Vaccination with PCV 13
3091896|NCT01947010|Active Comparator|Crohn's patients treated with Azathioprine and TNFa inhibitors|Vaccination with PPV23 or Vaccination with PCV 13
3091897|NCT01947010|Active Comparator|Crohn's disease patients without treatment|Vaccination with PPV23 or Vaccination with PCV 13
3091898|NCT01946997||Group 1: Non Diabetic|Normal retina
3091899|NCT01946997||Group 2: Diabetes with no retinopathy|Diabetic patients without diabetic retinopathy
3091900|NCT01946984|Active Comparator|Diclofenac,75 mg, 3 ml,|patients were given Diclofenac IM before ERCP.
3091901|NCT01946984|Placebo Comparator|Normal Saline, 3ml, IM|patients were given normal saline 3 ml before ERCP
3091902|NCT01946971|Experimental|PL|Placebo once a day orally for 7 days, then lansoprazole 1mg/kg once a day orally for 7 days
3091903|NCT01946971|Experimental|LP|Lansoprazole 1mg/kg orally once a day for 7 days, then placebo orally once a day for 7 days
3091904|NCT01946958|Experimental|Trained in Primary Care (PC) Triple P|This group received standardized training in Primary Care (PC) Triple P.
3091905|NCT01946958|Experimental|Care as Usal|This group provided care as usual. This group was not trained in PC Triple P interventions.
3091906|NCT01946945|No Intervention|Control - Standard ART treatment|
3091907|NCT01946945|Experimental|Test - PGS|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5,/6. Embryos will be vitrified. Patients will have a single hatching euploid blastocyst (*) replaced on a thawed cycle.
3091908|NCT01946932|Active Comparator|Cardiac Arrest 33°|survivors with temperature treatment 33°
3091909|NCT01946932|Active Comparator|Cardiac Arrest survivors 36°|survivors with temperature treatment 36°
3091910|NCT01946919||cinepazide|Inpatient using the cinepazide in department of neurology
3091911|NCT01946906|No Intervention|No treatment|patient receive no active treatment
3091912|NCT01946906|Experimental|Rifaximin|Patient takes Rifaximin 550mg twice daily for 14 days
3091913|NCT01946893|Experimental|Mindfulness Meditation|One session per week for 6 weeks online through study iPAD. The intervention is a standardized and structured program. The objectives are to: 1) help participants understand their personal reactions to stress, 2) teach them skills to modify their stress reactions, and 3) promote their desire for self-care and feelings of competence and mastery.
3091914|NCT01946893|Active Comparator|Education|Education sessions- 1 session per week for 6 weeks on study iPAD.
3091915|NCT01946880|Experimental|Mycophenolate Mofetil Withdrawal|These subjects will taper off MMF per the protocol-specified schedule over 12 weeks and remain off MMF for the rest of their study participation (up to Week 60 or until the primary endpoint of disease reactivation is met, whichever comes first).
3091916|NCT01946880|Active Comparator|Mycophenolate Mofetil Maintenance|These subjects will continue MMF treatment (1000-3000 mg/day) for the rest of their study participation (up to Week 60).
3091917|NCT01946867|Experimental|NBTXR3 IntraTumoral injection (IT)|Single intratumor injection
3091918|NCT01946867|Experimental|NBTXR3 Intra-Arterial Injection (IA)|Single intra-arterial injection
3091919|NCT01946854|Other|Observation Arm|Patients observed for 6 months, then will receive chemotherapy for 6 months.
3091920|NCT01946854|Active Comparator|Chemotherapy Group|Patients receive chemotherapy for 6 months, then observed for 6 months. The exact type of fluoropyrimidine-based chemotherapy is not mandated and final treatment decisions will be left to the medical oncologist who is administering the chemotherapy. All chemotherapy adjustments will be done by the treating medical oncologist according to standard of care.
3091921|NCT01946841|Experimental|RealDiet®Renal enteral nutrition|
3092062|NCT01945762||2. patient cohorts (40 patients/cohort)|RET negative patient cohorts
3091922|NCT01946828|Experimental|FIM|safety and efficacy of the FIM when exposed to a large and varied population of patients and users and operated according to its instructions for use
3091923|NCT01946815|Experimental|Atorvastatin|Atorvastatin (Lipitor) will be prescribed with 20mg,40mg,or 80mg by the unit of 28 tablets upon the result of lipid profile. Besides Clinical and lab test, follow-up CAG, IVUS(optional) and FFR will be performed in 12 months.
3091924|NCT01946802|Experimental|Frontal 4 channel EEG|Consecutive comatose patients admitted to the emergency ICU for postresuscitation care following successful cardiopulmonary resuscitation after nontraumatic out-of-hospital and in-hospital cardiac arrest.
3091925|NCT01946789|Experimental|ALT-803|
3091926|NCT01946776|Other|Reveal XT|People with drug-resistant epilepsy whose heart rhythm will be monitored continuously for 2 years using Reveal XT, an implantable heart rate monitor.
3091927|NCT01946763|No Intervention|safety of Anesthesia|No pre operative education
3091928|NCT01946763|Experimental|Behavioral : pre operative education|Behavioral pre operative education
3091929|NCT01946750|Experimental|Case|Hospitalized patient with clinical signs of Clostridium Difficile Infection and specific detection in stools of Clostridium Difficile toxins
3091930|NCT01946750|Other|Non-diarrheal control|Hospitalized patient and asymptomatic carrier of Clostridium Difficile
3091931|NCT01946737|Active Comparator|Invasive coronary angiography (ICA)|Routine diagnostic ICA
3091932|NCT01946737|Experimental|HD-CTCA with ASIR|HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)within 4 weeks of routine diagnostic ICA
3091933|NCT01946711|Experimental|Buparid; Treatment A|Buparid 1 mg budesonide/2 ml nebuliser solution
3091934|NCT01946711|Active Comparator|Budes; Treatment B|Budes® Nasal Spray 50 µg budesonide/pump
3091935|NCT01946698||Fertility patients|Women with endometriosis compared to women without endometriosis. Different samples will be collected (blood, follicular fluid, cells from the uterus)
3091936|NCT01946685|Experimental|600 mg/day Mifepristone|600 mg/day Mifepristone for 7 days
3091937|NCT01946685|Placebo Comparator|Placebo|No active treatment by intervention, supportive treatment avaialble.
3091938|NCT01946672|Experimental|isotopic intraoperative detection|Lower-limb drainage isotopic intraoperative detection
3091939|NCT01946659|Experimental|Adherence to Sleep Apnea Treatment|The intervention arm of the study receives tailored education regarding Sleep Apnea by the study health educator via telephone.
3091940|NCT01946659|Other|Standard Care Group|The standard care group gets the standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine.
3091941|NCT01946646|Experimental|S-1-CCRT|There are five dose levels and one arm only. Level 1: S-1, 25 mg/m2, bid, Day 1-14; RT 25 Gy/10 fx, Day 1-5, 8-12 Level 2: S-1, 25 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 3: S-1, 30 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 4: S-1, 30 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 Level 5: S-1, 35 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 All dose levels are followed by Gemcitabine/S-1 (G 1000 mg/m2, iv, D1 and 15 plus S-1 60/80/100 mg/day based on BSA, po, D1-7, D15-21, q4w) after the CCRT
3091942|NCT01946633|Experimental|Esophagogastroduodenoscopy（ECG）|n=15
3091943|NCT01946620|Experimental|Flutiform 250/10 micrograms|Flutiform 250/10 µg (2 puffs twice daily)
3091944|NCT01946620|Experimental|Flutiform 125/5 micrograms|Flutiform 125/5 µg (2 puffs twice daily)
3091945|NCT01946620|Active Comparator|Formoterol 12 micrograms|Formoterol 12 µg 1 puff twice daily
3091946|NCT01946607|Active Comparator|Citalopram|20 mg citalopram capsule, 1/ day, after breakfast (approximately 8am), for 7 days
3091947|NCT01946607|Placebo Comparator|Placebo|Placebo capsule 1/ day, after breakfast (approximately 8am), for 7 days
3091948|NCT01946594|Active Comparator|Acetaminophen Arm|"Acetaminophen Suspension 160 mg / 5 mL:~Oral dose immediately following IIV and every 4-6 hours up to 24 hours (Maximum 5 oral doses)"
3091949|NCT01946594|Placebo Comparator|Placebo Arm|"Placebo Suspension:~Oral dose immediately following IIV and every 4-6 hours up to 24 hours (Maximum 5 oral doses)"
3091950|NCT01946581||Cataract Surgery|
3091951|NCT01946568|Experimental|Single dose Dalbavancin|
3091952|NCT01946555||Worst pain, Average pain|"It is necessary that patients are treated for their baseline pain with opioid medications 3rd step (WHO guidelines), having seven different provisions molecules (morphine, methadone, fentanyl, buprenorphine, oxycodone, hydromorphone and tapentadol), and that they receive opioid rescue medication, based on free choice among the options available on the market (in the form of transmucosal fentanyl: OTFC - lollipop, buccal buccal tablets, sublingual tablets, nasal spray in aqueous solution, with pectin nasal spray, morphine or other opioid oral immediate release or intravenously)."
3091953|NCT01946542|Placebo Comparator|placebo|placebo drink, single dose, taste and color-matched to experimental drink
3091954|NCT01946542|Experimental|beet juice concentrate|single dose of beet juice concentrate, roughly 70 mL
3091955|NCT01946529|Active Comparator|Group A (Standard Risk)|Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide. Doxorubicin will be omitted following a total cumulative dose of 375 mg/m^2. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone, or surgery followed by radiation. Local control measures (surgery and/or radiation therapy) will be instituted after 6 courses of chemotherapy. Total duration of treatment is approximately 29 weeks.
3091956|NCT01946529|Active Comparator|Group B (High Risk)|Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, irinotecan, temozolomide, temsirolimus, bevacizumab, and sorafenib. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone or surgery followed by radiation.
3091957|NCT01946490||Radiotherapy in 2001|
3091958|NCT01946490||Radiotherapy in 2004|
3091959|NCT01946490||Radiotherapy in 2006|
3091960|NCT01946490||Radiotherapy in 2010|
3091961|NCT01946477|Experimental|Pomalidomide + dexamethasone|Each subject enrolled in the study will take oral pomalidomide (4 mg) once daily on Days 1-21 and dexamethasone 40 mg/day (< 75 years old) or 20 mg/day (>75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
3091994|NCT01946217||Observational (questionnaire administration)|Participants complete the IMPACTS survey comprising questions about socio-demographic information and clinical trial participation.
3091962|NCT01946477|Experimental|Pomalidomide + Dexamethasone + Daratumumab|"Each subject enrolled in the study will take oral pomalidomide (4 mg) once daily on Days 1-21 and dexamethasone 40 mg/day (< 75 years old) or 20 mg/ day (>75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle and daratumumab administered intravenously (IV) at a starting dose of 16 mg/kg at following schedule:~Days 1, 8, 15, and 22 of a 28-day cycle for Cycle 1 and Cycle 2~Days 1 and 15 for Cycle 3 through Cycle 6~Day 1 for Cycle 7 and each cycle thereafter until disease progression"
3091963|NCT01946464||undergoing surgery with general anesthesia|pts: edentulous, bearded, obstructive sleep apnea, Mallampati Class III or IV
3091964|NCT01946464||Mallampati I and II|Control group Mallampati I visualization of tonsils, uvula and soft palate Mallampati II visualization of hard and soft palate, and upper portion of tonsils and uvula.
3091965|NCT01946451||Idiophatic ERMs|
3091966|NCT01946451||Secondary ERMs|
3091967|NCT01946438|Experimental|Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)|Participants age 18 to < 65 years randomized to receive a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)
3091968|NCT01946438|Experimental|Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)|Participants age 18 to < 65 years randomized to receive a dose of Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation)
3091969|NCT01946438|Experimental|Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)|Participants age ≥ 65 years randomized to receive a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)
3091970|NCT01946438|Experimental|Elderly Fluzone® High-Dose, Influenza Vaccine (Group 4)|Participants age ≥ 65 years randomized to receive a dose of Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
3091971|NCT01946425|Experimental|Age 6 Months to <36 Months (Study Group 1)|Participants at 6 months to < 36 months of age at enrollment
3091972|NCT01946425|Experimental|Age 3 Years to <9 Years Group (Study Group 2)|Participants at 3 years to < 9 years of age at enrollment
3091973|NCT01946412|No Intervention|Observational Arm|
3091974|NCT01946412|Experimental|Ivacaftor|"Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the Week 84 Visit. The ivacaftor dose will be:~50 mg q12h for subjects 2 to <6 years of age and <14 kg,~75 mg q12h for subjects 2 to <6 years of age and ≥ 14 kg, or~150 mg q12h for subjects ≥ 6 years of age."
3091975|NCT01946399|Other|Ozurdex implant|Intravitreal injection of Ozurdex implant
3091976|NCT01946386|Experimental|LEO 90100|
3091977|NCT01946373|Experimental|Chemotherapy + T cells + IL-2|Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over15 minute period every 8-hours for up to 14 doses.
3091978|NCT01946373|Experimental|Chemotherapy + T cells + IL-2 + DCV|Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over15 minute period every 8-hours for up to 14 doses. After completion of the IL-2 treatment 3-5 doses of weekly intradermal vaccinations with up to 1.5 x 10^7 Dendritic cells pulsed with autologous tumor lysate and NY-ESO-1 peptide.
3091979|NCT01946360|No Intervention|ACLF and Acute Liver Failure (ALF)..|Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
3091980|NCT01946347|Experimental|Patients with type 2 diabetes|30 individuals with type 2 diabetes Intervention: mixed meal, acute in vivo induced hyperinsulinemia
3091981|NCT01946347|Active Comparator|Healthy subjects|30 healthy men and women with no metabolic syndrome Intervention: mixed meal, acute in vivo induced hyperinsulinemia
3091982|NCT01946334|Experimental|patients|
3091983|NCT01946321|Other|Post-amputation functional rehab|Patients will continue with their rehabilitation programme, as specified by their clinical team, following amputation. A series of functional outcome measures will be carried out at 3 or 4 time points during the first 3 months following delivery of their artificial limb.
3091984|NCT01946308|Experimental|conformational positioner & mattress|conformational positioner & mattress, five hours on each
3091985|NCT01946295|Experimental|Famotidine|Famotidine 100mg x 2 orally
3091986|NCT01946295|Placebo Comparator|Placebo|Placebo control
3091987|NCT01946282|Active Comparator|FIT Invitation Only|"Fecal Immunochemical Test (FIT) mailed to patient homes free of charge.~Intervention: Fecal Immunochemical Test (FIT) kits and an invitation letter to complete colorectal cancer screening are mailed to the homes of study eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3 consistent with guideline recommended annual FIT for colorectal cancer screening. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
3091988|NCT01946282|Active Comparator|FIT plus Incentive|"Fecal Immunochemical Test (FIT) mailed to patient homes, plus an incentive to complete the test.~Intervention: FIT kits and invitation letter with a gift card incentive in one of two small dollar amounts to complete screening are mailed to the homes of 2000 (1000 per group) randomly assigned eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
3091989|NCT01946269|Active Comparator|Standard group|
3091990|NCT01946269|Active Comparator|Goal-directed therapy (GDT) protocol|
3091991|NCT01946256|Active Comparator|Amoxicillin|Amoxicillin 500mg three times in a day for 1 week
3091992|NCT01946256|Placebo Comparator|Erythromycin|Erythromycin 500mg four times in a day for 1 week
3091993|NCT01946243|Experimental|Physician Readers|Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir F 18 as part of this study.
3091995|NCT01946204|Experimental|Treatment Arm A: Apalutamide|
3091997|NCT01946191|Experimental|Continued Coaching (CC)|Online self-monitoring along with health coach electronic communication and support and real-time updates to primary care physicians
3091998|NCT01946191|Active Comparator|Tracking Only (TO)|Online self-monitoring
3091999|NCT01946178|Experimental|Focused ultrasound treatment|Patients in this arm will receive fibroid treatment using the Mirabilis High-Intensity Focused Ultrasound Treatment System.
3092000|NCT01946165|Experimental|Abiraterone Acetate + Prednisone + Enzalutamide + LHRHa|Patients receive abiraterone acetate (1,000 mg daily) plus prednisone (5mg once daily) in combination with enzalutamide (160 mg daily) and LHRHa. Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
3092001|NCT01946165|Experimental|Abiraterone Acetate + Prednisone + LHRHa|Patients receive abiraterone acetate (1,000 mg daily) plus prednisone (5mg once daily) and LHRHa. Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
3092002|NCT01946152|Experimental|Pomalidomide + Dexamethasone + G-CSF|"Pomalidomide administered orally at escalating doses ranging from 4 mg to 10 mg (during Phase I), while Dexamethasone given at a fixed dose of 40 mg orally once weekly. Pomalidomide daily on Days 1-21 of each 28-day cycle for up to 6 cycles during a 6-month induction phase, after which dose 2 mg in maintenance phase. Granulocyte colony stimulating factor (G-CSF) administered by subcutaneous injection at 5 microgram/kilogram for five days during days 22-28 of each cycle of induction therapy. G-CSF not administered during maintenance phase dosing of Pomalidomide & Dexamethasone."
3092003|NCT01946139|Experimental|Screening (HSIL detection)|Patients undergo screening for the detection of HSIL using anal cytology, HPV hybrid capture 2, HPV mRNA assays, and OncoHealth HPVE6/E7 oncoprotein at baseline, at 6, 12, 18, and 24 months.
3092004|NCT01946126||Chronic Migraine Diagnosis|This is a retrospective chart review for patients diagnosed with Chronic Migraine. There is no intervention in this study.
3092005|NCT01946126||Other Headache Diagnoses|This is a retrospective chart review of patients with headache diagnoses other than Chronic Migraine. There is no intervention in this study.
3092006|NCT01946113||Retrospektive Cohort|Patients requiring renal replacement therapy from 2011 to 2012 on intensive care unit
3092007|NCT01946113||Prospektive Cohort|Patients requiring renal replacement on intensive care unit in 2013 and 2014
3092008|NCT01946100|Other|Multifocal Lung Adenocarcinoma|
3092009|NCT01946087|Experimental|RIPC group|
3092010|NCT01946087|Placebo Comparator|Control group|
3092011|NCT01946074|Experimental|Monotherapy|ABT-165 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-165
3092012|NCT01946074|Experimental|Cohort A|ABT-165 plus paclitaxel
3092013|NCT01946074|Experimental|Cohort B|ABT-165 plus FOLFIRI
3092014|NCT01946074|Experimental|Cohort C|ABT-165 plus ABBV-181
3092015|NCT01946074|Experimental|Cohort D|ABT-165 plus ABBV-181 plus paclitaxel
3092016|NCT01946061|Experimental|Treatment group|
3092017|NCT01946048|Experimental|mesenchymal stem cells|Stem cells implantation Patients with severe coronary artery disease with ischemic cardiomyopathy managed with intramyocardial administration of allogeneic mesenchymal stem cells.
3092018|NCT01946035|Placebo Comparator|Placebo|Participants will take 1 capsule placebo each evening
3092019|NCT01946035|Experimental|Doxazosin XL|Participants will take 1 capsule Doxazosin 4mg XL each evening
3092020|NCT01946022|Active Comparator|GnRH Agonist|GnRH long agonist protocol of invitro fertilization
3092021|NCT01946022|Active Comparator|GnRH Antagonist|GnRH fixed antagonist protocol of in vitro fertilization
3092022|NCT01946009|Experimental|Cidofovir 1%|Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.
3092023|NCT01945996|Active Comparator|TExT-MED only|Patients will receive TExT-MED intervention, but supporters will not receive additional messages
3092024|NCT01945996|Experimental|TExT-MED FANS|Patients get TExT-MED intervention, supporter gets FANS curriculum
3092025|NCT01945983|Active Comparator|Early norepinephrine|Norepinephrine 4 mg in 5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour, adjusted according to patient's body weight to achieve norepinephrine 0.05microgram/kg/min Continuous drip for 48 hours.
3092026|NCT01945983|Placebo Comparator|Placebo|5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour. Adjust rate of infusion according to patient's body weight to achieve dosage of norepinephrine comparable to 0.05 microgram/kg/min Continuous drip for 48 hours.
3092027|NCT01945970|Experimental|Black tea extract|Spray dried aqueous extract of a representative batch of black tea
3092028|NCT01945970|Active Comparator|Positive control|Spray dried aqueous extract of a batch of tea extract that has shown to improve FMD previously
3092029|NCT01945970|Placebo Comparator|Placebo|Food grade colouring, artificial tea flavour and an amount of caffeine matched to the caffeine in the Black tea extract
3092030|NCT01945957|Experimental|OT (24 IU)|Phase I Aim 1a. (fMRI) Will determine the effect of oxytocin dose (24 IU) on neural activation and connectivity compared to placebo. Aim 1 b (eye-tracking) will occur on a separate visit from fMRI scanning and will also assess response to oxytocin in an eye-tracking task (social vs. non-social image).
3092031|NCT01945957|Experimental|OT (8 IU and 40IU)|Each phase will require a separate subject consent. Phase II Aim 2a. (fMRI) Will determine the effect of oxytocin dose (8 or 40 IU) on neural activation and connectivity. Aim 1 b (eye-tracking) will occur on a separate visit from fMRI scanning and will also assess response to oxytocin (8 or 40 IU) in an eye-tracking task (social vs. non-social image).
3092032|NCT01945944|Placebo Comparator|Placebo|Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
3092033|NCT01945944|Experimental|Hypertonic Saline|Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
3092034|NCT01945931|Experimental|Safe Delivery Smartphone Application|The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The safe delivery smartphone application will be introduced to health workers in the intervention clusters.
3092035|NCT01945931|No Intervention|Control|Health workers in the control clusters will not have access to the Safe Delivery App
3092036|NCT01945918|Active Comparator|Self-management support education|Project staff will meet onsite with practice clinicians for a two-hour session to discuss what self-management support (SMS) is, why it is important, how primary care plays a role in this process, how others have approached it, and how it can be time and cost efficient for them to engage in SMS as part of standard diabetes care. Practices will have access to a website displaying general and local SMS resources. Discussion of the implementation of these resources into the practice will be facilitated. Two additional academic detailing visits will be made to check on progress on SMS adoption, provide additional information as needed, and answer questions. No input will be provided regarding how unique practice characteristics might be utilized for more effective implementation of SMS, and CTH will not be introduced.
3092037|NCT01945918|Active Comparator|Connection to Health Interactive Behavior Change Technology|Connection to Health (CTH) Arm: The number and length of staff visits to these practices will be the same as for the SMS Education Arm, but the content of the visits will center on the implementation and use of the CTH program as a way to implement SMS. Clinicians and selected staff members will be given hands-on experience using the system and will be provided with scenarios that will highlight the effective use of CTH as a tool for diabetes SMS. The practices will then implement CTH, using protocols selected from several suggested by the research team. Additional technical assistance with implementing CTH will also be provided as needed.
3092038|NCT01945918|Experimental|Connection to Health plus Coaching|"Connection to Health plus Coaching (CTH+C) Arm: This arm adds practice coaching as described above to CTH. The active coaching phase focuses on meetings of the practice improvement team, scheduled every other week for approximately 40 minutes each. The improvement team will consist of 6 - 10 diverse representatives of the practice (e.g., front office, medical assistants, physicians). The coach will assist the team in developing a CTH adoption plan and then help them break it down into small bites for rapid cycle change using the Plan-Do-Study-Act quality improvement (QI) model. Active coaching will last for 3 months, followed by monthly calls by the coach to review data regarding the practice's use of CTH and brief booster coaching to deal with problems."
3092039|NCT01945905|Experimental|Extramural|Extramural medication delivery and supervision
3092040|NCT01945905|Active Comparator|Intramural|Intramural medication delivery and supervision
3092041|NCT01945892||Irvine Gass Syndrome|"Patients older than 18 years who develop macula edema secondary to cataract surgery.~Group may receive intravitreal Ozurdex medication in case of persistent macular edema."
3092042|NCT01945879|Experimental|GFFC + LMWH|gemcitabine/ 5-flourouracil/folinic acid/ cisplatin as chemotherapeutic treatment plus enoxaparine as experimental addition
3092043|NCT01945866|Active Comparator|Sham + intravitreal ranibizumab 0.3 mg|Intravitreal ranibizumab will be given on the day of randomization. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first. Follow-up intravitreal injections of ranibizumab will be given up to every 4 weeks using defined treatment criteria.
3092044|NCT01945866|Experimental|Intravitreal dexamethasone+intravitreal ranibizumab 0.3mg|The initial intravitreal ranibizumab injection will be given on the day of randomization. The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
3092045|NCT01945853|Experimental|7 Tesla MRI|7T MRI will be done on ALS patients at baseline and at 6 month intervals.
3092046|NCT01945840|Active Comparator|Roux en Y Gastric Bypass|Participants will be those already scheduled to undergo Roux en Y Gastric Bypass Surgery
3092047|NCT01945840|Experimental|Gut hormone infusion (high dose)|Infusion of three gut hormones - GLP-1, PYY and oxyntomodulin subcutaneously.
3092048|NCT01945840|Experimental|Gut hormone infusion (low dose)|Infusion of three gut hormones - GLP-1, PYY and oxyntomodulin subcutaneously.
3092049|NCT01945840|Placebo Comparator|Placebo infusion|Saline infusion given subcutaneously
3092050|NCT01945840|Active Comparator|Very low calorie diet|Participants will be asked to follow a very low calorie diet for 4 weeks
3092051|NCT01945827||DeltaMaxx treated Patients|
3092052|NCT01945814|Experimental|CTL for CMV seropositive donors|CTL for CMV seropositive donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors- three different dose levels are selected, starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
3092053|NCT01945814|Experimental|CTL for CMV naïve donors|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton)for CMV naïve donors-each group will undergo an identical dose escalation. Three different dose levels are selected, starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
3092054|NCT01945801|Active Comparator|Lasilactone|Dosage form: One capsule taking in the morning Dosage: furosemide, 20mg, and spironolactone, 100 mg. Frequency and duration: One capsule daily for 7 days.
3092055|NCT01945801|Placebo Comparator|placebo pill|One capsule taking in the morning. Frequency and duration: One capsule daily for 7 days.
3092056|NCT01945801|Active Comparator|Sodium-Restricted Diet|The diet group will receive a regimen with a prescribed intake of three grams of sodium per day
3092057|NCT01945788|Active Comparator|Teriparatide Forteo|20 micrograms/day plus calcium and vitamin D
3092058|NCT01945788|Experimental|Teriparatide Osteofortil|20 micrograms/day plus calcium and vitamin D
3092059|NCT01945775|Experimental|talazoparib|Patient will be randomized 2:1 to receive talazoparib oral capsules (1.0 mg) once daily for 21 continuous days
3092060|NCT01945775|Active Comparator|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
3092063|NCT01945749|Experimental|Intraarticular steroid + Exercise|Intra-articular corticosteroid treatment with subsequent exercise therapy. Exercise therapy is commenced 2 weeks after injection
3092064|NCT01945749|Active Comparator|Intraarticular saline+Exercise|Combined intra-articular saline injection and subsequent exercise therapy. Exercise therapy is commenced 2 weeks after injection
3092065|NCT01945736||Cohort 1|> or = 90 days to < 2 years on enteral methadone. Dose schedule is per routine medical care.
3092066|NCT01945736||Cohort 2|2 years to < 6 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age > or = to 95 percentile.
3092067|NCT01945736||Cohort 3|6 years to < 18 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age > or = to 95 percentile.
3092068|NCT01945723||Healthy volunteers|Healthy volunteers
3092069|NCT01945710|Experimental|E7389-LF Schedule 1|"Schedule 1: E7389-LF administered as IV infusion on Day 1 of a 21-day cycle starting at 1 mg/m2 escalating up to 3.5 mg/m2.~Schedule 1a: E7389-LF administered as IV infusion on Day 1 of a 28-day cycle starting at 1 mg/m2 escalating up to 3.5 mg/m2 (only to be investigated in the event that a 21-day cycle is considered inappropriate)."
3092070|NCT01945710|Experimental|E7389-LF Schedule 2|Schedule 2: E7389-LF administered as IV infusion on Day 1 and Day 15 of a 28-day cycle starting at 1 mg/m2 escalating up to 3.5 mg/m2 (only to be investigated in the event that a 21-day cycle is considered appropriate).
3092071|NCT01945697||normal oral mucosa|
3092072|NCT01945697||oral precancerous lesion or oral cancer|
3092073|NCT01945684|Experimental|Botulinum toxin type A (DWP450)|DWP450: Botulinum toxin type A
3092074|NCT01945684|Active Comparator|Botulinum toxin type A (Botox®)|Botox®: Botulinum toxin type A
3092075|NCT01945645|Experimental|Intervention|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
3092076|NCT01945632|No Intervention|no treatment|Control group with no treatment.
3092077|NCT01945632|Experimental|root planing (gracey curettes)|treatment with root planing using conventional gracey curettes
3092078|NCT01945632|Experimental|Vertically oscillating ultrasonic device|Treatment done with vertically oscillating ultrasonic device
3092079|NCT01945632|Experimental|Device: piezoelectric ultrasonic scraper|Treatment using a piezoelectric ultrasonic scraper
3092080|NCT01945606|Experimental|Placebo and BAY1067197|Patients will get both treatment 1 and 2
3092081|NCT01945593|Experimental|BAX855|30-80 ±5 IU/kg twice weekly to once per week. After each consecutive 6 months of being treated in this study, the dose and/or frequency may be adjusted, depending on the participant's spontaneous annualized bleed rate (ABR) estimated at those intervals.
3092082|NCT01945580||Xenform|Prolapse Repair with Xenform Soft Tissue Repair Matrix
3092083|NCT01945580||Control|Prolapse Repair with Native Tissue Only
3092084|NCT01945567|Experimental|Dorsal zona incerta|Up to 3 mA, 60 us, 130 Hz deep brain stimulation
3092085|NCT01945567|Experimental|Caudal zona incerta|Up to 3 mA, 60 us, 130 Hz deep brain stimulation
3092086|NCT01945567|Experimental|Empirical deep brain stimulation|Empirical unblinded deep brain stimulation programming using any posterior subthalamic area electrode contact(s) and stimulation parameters to optimise clinical outcome.
3092087|NCT01945554|Experimental|Cervical disc herniation|Patients with cervical disc herniation and compression of nerve roots C3-C8.
3092088|NCT01945554|Experimental|Lumbar disc herniation|Patients with lumbar disc herniation and compression of nerve roots L1-S1.
3092089|NCT01945541|No Intervention|standard fluid management|postoperative BMC measurements
3092090|NCT01945541|Active Comparator|body composition monitoring preoperative|pre and postoperative BCM measurements
3092091|NCT01945528|Experimental|US-guided tenotomy with PRP|ultrasound guided percutaneous tenotomy with PRP injection each alternate week for a total of two interventions
3092092|NCT01945528|Active Comparator|US-guided tenotomy with lidocaine|ultrasound-guided percutaneous needle tenotomy with lidocaine injection each alternate week for a total of two interventions
3092093|NCT01945515|Experimental|Robot + anodal tDCS|Robotic-assisted gait training for 45 min after anodal tDCS on impaired motor cortex for 20 min
3092094|NCT01945515|Sham Comparator|Robot + sham tDCS|Robotic-assisted gait training for 45 min after sham tDCS on impaired motor cortex for 20 min
3092095|NCT01945502||nasal packing with dry packs|
3092096|NCT01945502||nasal packing with wet packs|
3092097|NCT01945502||nasal packing with Benzidamin-Clorhexsidin damped packs|
3092098|NCT01945502||no nasal packing|
3092099|NCT01945489|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) 100U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).
3092100|NCT01945489|Other|Placebo/OnabotulinumtoxinA|Placebo (Normal saline) injected into the detrusor on Day 1, followed by an injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).
3092101|NCT01945476|Experimental|midazolam|midazolam group
3092102|NCT01945476|Active Comparator|normal saline|control group
3092103|NCT01945450|Active Comparator|Antibiotic prophylaxis|antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3
3092104|NCT01945450|No Intervention|No treatment|No antibiotics
3092105|NCT01945437|Placebo Comparator|Control|Control group receive same volume of normal saline as in the magnesium group
3092106|NCT01945437|Experimental|magnesium|This group receive magnesium sulfate perioperatively.
3092107|NCT01945424||Pregnancy Cases|Pregnant women exposed to Sanofi Pasteur's Quadrivalent Influenza Vaccine (QIV)
3092108|NCT01945411|Experimental|Experimental|the length between incisor and mandible angle
3092109|NCT01945411|Active Comparator|Active comparator|the length between mouth corner-mandible angle
3092226|NCT01944501|Placebo Comparator|Sham TMS|Patients receiving sham transcranial magnetic stimulation
3092110|NCT01945398|Experimental|Inspiratory Muscle Training (IMT)|Patients from the inspiratory muscle training group will utilize a linear pressoric resistance equipment with an inspiratory charge of 30% of maximum inspiratory pressure (adjusted weekly), during 7 days of the week, session duration of 30 minutes, during 8 weeks.
3092111|NCT01945398|Placebo Comparator|Sham IMT|Patients in the placebo group will be submitted to inspiratory muscle training with the same equipment as the intervention group, however without a resistance generating spring.
3092112|NCT01945385|Experimental|Video intervention|Participants will view a seven - minute theory-based video of patient testimonials about their own postabortal LARC uptake.
3092113|NCT01945385|No Intervention|Control|Patients will view a 7 minute video about stress management delivered by local psychologist.
3092114|NCT01945372|Experimental|EEG NeuroFeedback - real feedback|Thw women in the experimental group will receive accurate realtime feedback corresponding to their performance on the task.
3092115|NCT01945372|Sham Comparator|EEG NeuroFeedback - sham feedback|The women in the sham group will receive neural feedback from another person in the study, thus unrelated to their mental practice
3092116|NCT01945359||Relapsing Remitting MS (RRMS)|
3092117|NCT01945346|Experimental|PRX167700|
3092118|NCT01945346|Placebo Comparator|Placebo|
3092119|NCT01945333|Active Comparator|Brain Basics for Impaired Tone Matchers|Cognitive remediation includes sensory processing training
3092120|NCT01945333|Active Comparator|Brain Basics for Intact Tone Matchers|Cognitive remediation includes sensory processing training
3092121|NCT01945333|Active Comparator|Brain Training for Impaired Tone Matcher|Cognitive remediation does not include sensory processing training
3092122|NCT01945333|Active Comparator|Brain Training for Intact Tone Matchers|Cognitive remediation does not include sensory processing training
3092123|NCT01945320||HD-BCM|"Patients at National Taiwan University Hospital~Patients who have received HD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years"
3092124|NCT01945307||Healthy adults|Healthy adults aged 18 to 70 years
3092125|NCT01945294|Experimental|Arm 1: 16-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 4 weeks of BOC + PR, for a total of 16 weeks of treatment. At Week 16, participants underwent 12 weeks of follow-up (participation complete at Week 28).
3092126|NCT01945294|Experimental|Arm 2: 28-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 16 weeks of BOC + PR, for a total of 28 weeks of treatment. At Week 28, participants underwent 12 weeks of follow-up (participation complete at Week 40).
3092127|NCT01945294|Experimental|Arm 3: 48-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with detectable HCV RNA were allocated to receive an additional 24 weeks of BOC + PR and an additional 12 weeks of PR, for a total of 48 weeks of treatment. At Week 48, participants underwent 12 weeks of follow-up (participation complete at Week 60).
3092128|NCT01945281|Experimental|Caspofungin|Caspofungin 2 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment
3092129|NCT01945281|Active Comparator|Amphotericin B Deoxycholate|Amphotericin B deoxycholate 1 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment
3092130|NCT01945268|Experimental|influenza vaccine|Participants at high risk for adverse vascular events will be immunized with 0.5 ml dose of inactivated trivalent influenza vaccine
3092131|NCT01945268|Placebo Comparator|placebo vaccination|Participants at high risk for adverse vascular events will be immunized with a 0.5 ml dose of sterile saline inactivated during the influenza season.
3092132|NCT01945255||HD-ABI|"Patients at National Taiwan University Hospital (NTUH)~Patients who have received PD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years"
3092133|NCT01945242||Alogilptin 25mg, tablets, orally, once daily, up to 12 months|
3092134|NCT01945229||Hyperthyroid patients|Patients with hyperthyroidism admitted for treatment with radioiodine or antithyroid drugs
3092135|NCT01945216||Aloglipin 25mg, tablets, orally, once daily, up to 36 months|
3092136|NCT01945203||PD-ABI|"Patients at National Taiwan University Hospital (NTUH)~Patients who have received PD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years."
3092137|NCT01945190|Experimental|True before sham electroacupuncture|Crossover design, individuals randomized to receive either true or sham acupuncture in first study day, and on the second study day whichever intervention was not administered on the first study day.
3092138|NCT01945190|Experimental|Sham before true electroacupuncture|Crossover design, individuals randomized to receive either true or sham acupuncture in first study day, and on the second study day whichever intervention was not administered on the first study day.
3092139|NCT01945177|No Intervention|white light endoscopy|white light endoscopy
3092140|NCT01945177|Active Comparator|narrow band imaging|narrow band imaging
3092141|NCT01945151|Experimental|Group 1 (G1) NMES is applied in the spastic antagonist muscle|The parameters considered for the application of NMES are: frequency of 50Hz, the wavelength of 350m / s, 10 seconds of contraction of 20 seconds of rest to total 15 minutes. During the application of NMES patients will be positioned supine on the bed with knees flexed semi supported on roller positioning. The G1 apply NMES on the motor point of the tibialis anterior and triceps surae lengthening held along with the contraction (reciprocal inhibition).
3092142|NCT01945138|No Intervention|Control|Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.
3092143|NCT01945138|Experimental|Closed Loop Insulin|Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
3092144|NCT01945125|No Intervention|THW Group|Patients under THW stimulation for RIT
3092145|NCT01945125|Other|rhTSH Group|Patients under rhTSH stimulation for RIT
3092146|NCT01945112|Experimental|Paper Tape|Paper tape will be applied to study participants' blister prone areas or a randomly selected spot (if no blister history on that foot) - with untaped areas of the same foot as control.
3092147|NCT01945099|Active Comparator|ePID closed loop system without hyaluronidase|Hyaluronidase will not be given while subject uses ePID closed loop system
3092148|NCT01945099|Experimental|ePID closed loop system with hyaluronidase at infusion site|Hyaluronidase will be injected at insulin pump infusion site prior to the time that subject uses ePID closed loop system
3092149|NCT01945099|Experimental|ePID closed loop system with hyaluronidase co-formulation|Hyaluronidase-insulin co-formulation will be used in study pump while subject uses ePID closed loop system
3092150|NCT01945086|Experimental|Ustekinumab 45 mg|
3092151|NCT01945086|Experimental|Ustekinumab 90 mg|
3092152|NCT01945086|Placebo Comparator|Placebo|
3092153|NCT01945073|No Intervention|Control (RC)|Routine clinical care with no intervention
3092154|NCT01945073|Experimental|Educational Booklet (BK)|Routine clinical care and educational booklet (BK) given
3092155|NCT01945073|Experimental|Educational Booklet and Counselling (CB)|Routine clinical care, aided by formal counselling and active discussions from the educational booklet (CB)
3092156|NCT01945060|Experimental|heart rate Control to Range System (hrCTR) using DiAs Platform|The Diabetes Assistant (DiAs) Control-to-Range system is notified of heart rate during exercise. The study team member will activate and deactivate a heart rate button when the subject's heart rate exceeds and then returns below 140 beats per minute.
3092157|NCT01945060|Placebo Comparator|DiAs Control-to-Range System not informed for heart rate|Using the DiAs Platform, the Control-to-Range system is not notified of the heart rate during exercise. Heart rate not of interest in this arm.
3092158|NCT01945047|Experimental|Ketamine|During Phase 1 patients will be randomly assigned to receive ketamine or active placebo.
3092159|NCT01945047|Active Comparator|Midazolam|In phase 1 patients will be randomized to receive active placebo
3092160|NCT01945034|Experimental|Topical IBU twice daily|
3092161|NCT01945034|Placebo Comparator|Placebo twice daily|
3092162|NCT01945034|Experimental|Topical IBU three times daily|
3092163|NCT01945034|Placebo Comparator|Placebo three times daily|
3092164|NCT01945021|Experimental|Crizotinib|Single-arm trial whereby all consented, enrolled, eligible patients receive crizotinib
3092165|NCT01945008||Hepatitis-C infected patients|Patients with Hepatitis-C infection untreated at the enrolment
3092166|NCT01944995|Experimental|group B|
3092167|NCT01944995|Experimental|group A|
3092168|NCT01944982|Experimental|Activated natural killer cells|Activated natural killer cells
3092169|NCT01944969|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
3092170|NCT01944943|Experimental|Vismodegib|Vismodegib 150 mg will be administrated orally at a dosage of 150 mg (1 capsule) once a day during 12 months.
3092171|NCT01944930|Experimental|Narrow Band Imaging Laparoscopy First|Study has single cohort assessed in crossover design. In this arm NBI laparoscopy will be performed first, followed by standard white-light laparoscopy.
3092172|NCT01944930|Experimental|Standard White-Light Laparoscopy First|Study has single cohort assessed in crossover design. In this arm standard white-light laparoscopy will be performed first, followed by NBI laparoscopy.
3092173|NCT01944917||Chronic musculoskeletal pain|Chronic musculoskeletal pain - treated with electromagnetic field Chronic musculoskeletal pain - placebo
3092174|NCT01944904|Placebo Comparator|Sugar Pill|Subjects will be asked to take the dietary supplement daily for 8 weeks. Blood samples will be taken at screen, baseline and week 8. An oral glucose tolerance test will be taken at baseline and week 8. Additionally subjects will be asked to collect their stool samples at Baseline, week 4, and 8. Subjects will also undergo a test to determine their body composition at baseline and week 8. Subjects will be asked to keep a diary of their bowel habits and any symptoms that might be related to the supplement. Subjects will be asked to recall the foods that they have eaten in the past 24 hours and to avoid any foods that contain XOS and probiotic bacteria during the study.
3092175|NCT01944904|Active Comparator|XOS 2.8|Subjects will be asked to take the dietary supplement daily for 8 weeks. Blood samples will be taken at screen, baseline and week 8. An oral glucose tolerance test will be taken at baseline and week 8. Additionally subjects will be asked to collect their stool samples at Baseline, week 4, and 8. Subjects will also undergo a test to determine their body composition at baseline and week 8. Subjects will be asked to keep a diary of their bowel habits and any symptoms that might be related to the supplement. Subjects will be asked to recall the foods that they have eaten in the past 24 hours and to avoid any foods that contain XOS and probiotic bacteria during the study.
3092176|NCT01944878||Patients with chronic hepatitis|Patients with chronic hepatitis, who experienced HVPG measurement via transjugular approach and EGD within 3 months of HVPG measurement
3092177|NCT01944878||Patients with liver cirrhosis|Patients with liver cirrhosis, who experienced HVPG measurement via transjugular approach and EGD within 3 months of HVPG measurement
3092178|NCT01944865|Experimental|Interval Training|The INTV consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, and in the last 30 s of each repetition was performed a maximal sprint, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.
3092179|NCT01944865|Experimental|Intermittent Training|The riders completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery (10-15 on the CR100 scale).
3092180|NCT01944852|Experimental|2 icodextrin bags/day|2 icodextrin bags + 1 glucose per day
3092181|NCT01944852|Active Comparator|1 icodextrin bag/day|1 icodextrin bag + 2 glucose bags per day
3092182|NCT01944839|Experimental|E10030 + ranibizumab|E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection
3092183|NCT01944839|Active Comparator|Sham + ranibizumab|E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection
3092184|NCT01944826||Tako-Tsubo And Cancer Registry|
3092185|NCT01944813|Experimental|Intervention: ACP conversation|Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
3092186|NCT01944813|No Intervention|No intervention: usual care|No intervention just usual care
3092187|NCT01944800|Experimental|Ticagrelor|
3092188|NCT01944800|Active Comparator|Prasugrel|
3092189|NCT01944787|Active Comparator|Routine|IV Hydration at 125 cc hour
3092190|NCT01944787|Experimental|Intervention|IV Hydration at 250 cc hour
3092191|NCT01944774|Experimental|Nemonoxacin 500 mg|Nemonoxacin 500mg/250mL.
3092192|NCT01944774|Experimental|Nemonoxacin 650 mg|Nemonoxacin 650 mg/325mL
3092193|NCT01944774|Active Comparator|Moxifloxacin 400 mg|Moxifloxacin 400mg/250mL
3092194|NCT01944761|Experimental|Immediate Group|The 15 patients in this group will be randomized to start the 12 week exercise intervention without delay (immediate condition).
3092195|NCT01944761|Experimental|Delayed Intervention|The 15 patients in this group will be randomized to start the intervention after the first group has completed the exercise intervention (delayed condition)
3092196|NCT01944748|Experimental|Family Mediation|Families receive FARS family mediation program after completing baseline survey.
3092197|NCT01944748|No Intervention|Wait-list control|Families receive FARS family mediation program after completing baseline, 6-week and 12-week surveys.
3092198|NCT01944735|Experimental|Active|Once daily oral capsule containing 50 or 100 mg of CTX-4430
3092199|NCT01944735|Placebo Comparator|Placebo|Once daily oral capsule containing mannitol, visibly identical to CTX-4430 capsules
3092200|NCT01944722|Experimental|BD Onclarity™ HPV assay on BD Viper™ LT|The LBC specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. Colposcopy will be performed on subjects who have abnormal cytology or HPV positive test results or from a random sampling of subjects with normal cytology and HPV negative test results.
3092201|NCT01944696|Active Comparator|continuous (uninterrupted) phototherapy|standard phototherapy
3092202|NCT01944696|Experimental|15 minute per hour cycled phototherapy|15 minute per hour cycled phototherapy
3092203|NCT01944683|Experimental|GGF2|"Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.~Each patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively."
3092204|NCT01944683|Placebo Comparator|Placebo|"Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.~Each patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively."
3092205|NCT01944670|Experimental|Internal Joint Stabilizer Group|Patients implanted with the Internal Joint Stabilizer - Elbow (IJS-E)
3092206|NCT01944657|Active Comparator|Standard Medication Monotherapy Group|A group of 15 patients will receive only standard antidepressant medication treatment.
3092207|NCT01944657|Active Comparator|Supplemental TMS plus Medication Group|A group of 15 patients will receive supplemental transcranial magnetic stimulation (TMS) plus standard antidepressant medication.
3092208|NCT01944644|Active Comparator|Active Low Field Magnetic Stimulation|LFMS will follow a previously published protocol for the treatment of a Major Depressive Episode (Rohan et al. 2004). Active Low Field Magnetic Stimulation treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain.
3092209|NCT01944644|Sham Comparator|Sham Low Field Magnetic Stimulation|Sham Low Field Magnetic Stimulation will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
3092210|NCT01944631|Placebo Comparator|Placebo|Nasal spray 4 times a day over 4 to 10 days
3092211|NCT01944631|Experimental|Iota-Carrageenan nasal spray|Nasal spray 4 times a day over 4 to 10 days
3092212|NCT01944618||T2DM patients newly prescribed Forxiga|A post-marketing evaluation of the safety of Forxiga (10 mg tablets, orally once daily for 6 months) through an observational prescription adverse event monitoring program (registry-based monitoring program) is warranted to assess real-world incidence of adverse events in routine clinical practice.
3092213|NCT01944605||Cardiac Arrest patients undergoing Therapeutic Hypothermia|Cardiac Arrest subjects with Return Of Spontaneous Circulation (ROSC) and undergoing treatment with Therapeutic Hypothermia will undergo sampling of blood, stool, and expired gas data at physiologically predetermined time points.
3092214|NCT01944592|Experimental|Gynaecology Training Associates (GTA's)|Final year (Year 5) medical undergraduates embarking upon their O&G clinical placement trained in pelvic examination with GTA's
3092215|NCT01944592|Active Comparator|Manikin training|Final year (Year 5) medical undergraduates embarking upon their O&G clinical placement trained in pelvic examination on manikins.
3092216|NCT01944579|Experimental|Control-Blackberry|Participants will receive a controlled diet with the control food (jello) first and then cross over to the controlled diet with blackberries.
3092217|NCT01944579|Experimental|Blackberry-Control|Participants will receive a controlled diet with blackberries first and then cross over to the controlled diet with the control food (jello).
3092218|NCT01944566|Experimental|heavy armpit odour|subjects with heavy armpit odour
3092219|NCT01944553|Experimental|prospective|Single Arm
3092220|NCT01944540|Active Comparator|conventional ESD|Conventional ESD arm indicates the group in which conventional ESD method is applied for the dissection of colorectal neoplasm.
3092221|NCT01944540|Experimental|Optimized ESD with snaring|Optimized ESD with snaring arm indicates the group in which optimized ESD with snaring method is applied for the dissection of colorectal neoplasm.
3092222|NCT01944514||Ischaemic cardiomyopathy group|Patients with ischaemic cardiomyopathy attending for ICD implantation / Ventricular tachycardia stimulation testing as part of ICD risk stratification
3092223|NCT01944514||Non-ischaemic cohort|Patients attending for ICD implantation / ventricular tachycardia stimulation test who do not have ischaemic cardiomyopathy.
3092224|NCT01944514||Control group|Patients attending for electrophysiological study with no conditions that place them at risk of sudden cardiac death.
3092225|NCT01944501|Active Comparator|Transcranial Magnetic Stimulation|Patients receiving real transcranial magnetic stimulation
3092227|NCT01944501|Active Comparator|Transcranial Direct Current Stimulation|Patients receiving real transcranial direct current stimulation
3092228|NCT01944501|Placebo Comparator|Sham TDCS|Patients receiving sham transcranial direct current stimulation
3092229|NCT01944488|Experimental|GnRH intervention|All participating subjects are assigned to receive an intravenous GnRH agonist injection.
3092230|NCT01944462|Experimental|Pharmacist Pneumococcal Vaccine Program (PPVP)|Individuals receiving the PPVP intervention which consists of the educational program delivered on site at the collaborating senior center.
3092231|NCT01944449|Experimental|Whey Protein (WPC) at breakfast|The subjects in Whey Protein (WPC) group will consume WPC (35gr) powder in bottles mixed with 250 ml milk, making a total of 42 g protein, at breakfast, for 12 weeks.
3092232|NCT01944449|Experimental|Other Protein Sources at breakfast|The subjects will consume also 42 g protein at breakfast but from different source, for 12 weeks.
3092233|NCT01944449|Active Comparator|Low Protein at breakfast|The subjects will consume 17 g protein breakfast namely from soy for 12 weeks.
3092234|NCT01944436||Parkinson's Disease Dementia|"Participants in the Parkinson's Disease Dementia group:~Must be taking a stable parkinsonian medication~Must have a diagnosis of clinically definite Parkinson's disease >1 year prior to cognitive deficit with at least two of the following symptoms: asymmetric resting tremor, rigidity or bradykinesia, and definite motor response to dopaminergic agents.~Response to cholinesterase inhibitor over a period of six months will be monitored."
3092235|NCT01944436||Dementia with Lewy Bodies|"Participants in the Dementia with Lewy Bodies group:~Diagnosis of clinically probable or possible Dementia with Lewy bodies with at least 1 of the following: Marked fluctuations in cognition, visual hallucinations or spontaneous parkinsonism.~Response to cholinesterase inhibitor over a period of six months will be monitored."
3092236|NCT01944423|Experimental|PSRT_DCS|Individuals in this condition will receive 7 weeks of panic and smoking reduction treatment (PSRT) and one pill of d-cycloserine (DCS) one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).
3092237|NCT01944423|Placebo Comparator|PSRT_PBO|Individuals in this condition will receive 7 weeks of panic and smoking reduction treatment (PSRT) and one pill placebo dose one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).
3092238|NCT01944410|Experimental|traumatic bone cyst|Patients with traumatic bone cyst defect are injected with PRP
3092239|NCT01944397||Atrial fibrillation|Patients with a diagnosis of atrial fibrillation recorded in primary or secondary care during the study period.
3092240|NCT01944384|Experimental|aldactone|aldactone 25 mg for 6 months
3092241|NCT01944384|No Intervention|without aldactone|
3092242|NCT01944371|Experimental|disulfiram 500mg|500mg disulfiram by mouth per day for 3 days
3092243|NCT01944371|Experimental|disulfiram 1000mg|1000mg disulfiram by mouth per day for 3 days
3092244|NCT01944371|Experimental|disulfiram 2000mg|2000mg disulfiram per mouth per day for 3 days
3092245|NCT01944358||Taiwan AIDS study group|
3092246|NCT01944332|Experimental|gamete treatment|The spermatozoa will be prepared in the standard fashion and utilized for injection after exposure to a membrane permeabilizing agent. The injected oocytes will be then exposed to the previously mentioned activating agents for the purpose of inducing embryo development. The successfully fertilized oocytes will be further kept in culture for up to 5 days as per standard IVF/ICSI.
3092247|NCT01944319|Active Comparator|Control group|The participants in control group will accept routine meropenem therapy
3092248|NCT01944319|Experimental|Study group|The participants in study group will accept meropenem therapy based on a PPK and PD model.
3092249|NCT01944306||Low birth-weight, obese|
3092250|NCT01944306||Low birth-weight, normal body weight|
3092251|NCT01944306||Normal birth-weight, obese|
3092252|NCT01944306||Normal birth-weight, normal body weight|
3092253|NCT01944293|Experimental|Ketamine|0.5 mg/kg, I.V. (in the vein)
3092254|NCT01944293|Active Comparator|Midazolam|0.02 mg/kg, I.V. (in the vein)
3092255|NCT01944280|Experimental|intervention|The intervention group will receive a 20 minute massage during each hemodialysis treatment for 2 weeks. Most patients receive dialysis 3 times per week resulting in 6 massage sessions. The massage will include both feet and legs up to and including the knee. Massage will include general light centripetal friction and point compression to bellies and myotendinous junction of muscles of the foot and calf not to exceed a perceived pain of 6 on a scale of 1 to 10, 10 being most severe and 1 being no pain.
3092256|NCT01944280|No Intervention|control|usual care
3092257|NCT01944267|Active Comparator|Apically positioned flap|"Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared surgical area will be measured apico-coronally and mesio-distally."
3092258|NCT01944267|Active Comparator|Free Gingival Graft|"Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.~Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision made. Gingiva coronal to horizontal incision remains intact.~Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures"
3092279|NCT01944150|Active Comparator|TENS|Patients with only transcutaneous electrical nerve stimulation (TENS),
3092280|NCT01944150|Experimental|TENS and hypnosis.|Patients with transcutaneous electrical nerve stimulation (TENS) and hypnosis simultaneously
3092259|NCT01944267|Active Comparator|Apically positioned flap with Mucograft|"Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.~Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures."
3092260|NCT01944254|Active Comparator|random to respiration|Cardiac output measurement at random to respiration
3092261|NCT01944254|Experimental|timed with expiration start|Cardiac output measurement synchronised at start of expiration.
3092262|NCT01944254|Experimental|timed to instructed exhalation|Cardiac output measurement timed to instructed exhalation. The patient will receive instructions to exhale slowly using a peak expiratory flow (PEF)-flute and the cardiac output measurement will be started (i.e bolus given) at the start of expiration.
3092263|NCT01944241||Women with cervical surgery|The cases will include women who have had cervical surgery, either LLETZ or cone biopsy
3092264|NCT01944241||women with no surgery|controls will be women who have attended colposcopy but who have not had surgery.
3092265|NCT01944228|Experimental|Vagal Nerve Stimulation|30 minutes of vagal nerve stimulation using a catheter in the IJV
3092266|NCT01944228|Sham Comparator|Sham stimulation|Catheter placed in the IJV without stimulation
3092267|NCT01944215|Active Comparator|Arm 4 - Fast vs Fast + External Heating|MBI will be performed in 52 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. The subject will receive the usual Mayo gown for breast imaging. A skin temperature sensor will be taped to the anterior of one breast and skin temperature will be recorded. The subject will be asked to sit for 15 minutes in the waiting room prior to injection of the Tc-99m sestamibi. Just prior to injection, skin temperature will be recorded again. After completion of the first study the subject will then be given a warm towel robe and a small heating pad to be placed over the chest area. After 30 minutes, skin temperature will be recorded again immediately prior to injection of the second dose of Tc-99m sestamibi. The second MBI study will then be performed.
3092268|NCT01944215|Active Comparator|Arm 3 - Fasting vs. Fasting + Caffeine|MBI will be performed in 52 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. The subject will then be instructed to consume 200 mg caffeine in tablet form. This is equivalent to the caffeine content of an 8 oz brewed coffee from Starbucks. After 45 minutes after consumption of the caffeine tablet, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
3092269|NCT01944215|Active Comparator|Arm 2-Resting vs. Exercising|MBI will be performed in 25 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. Patients will then be asked to perform moderate exercise on a treadmill for 6-10 minutes at a level of 70%-80% of maximum predicted heart rate. At ~10 minutes, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
3092270|NCT01944215|Active Comparator|Arm 1-Fasting vs. Fed|MBI will be performed in 25 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. Patients will then be instructed to consume 8-16 fluid oz of Ensure (350-700 calories). At 30 minutes after consumption of the meal, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
3092271|NCT01944202|Experimental|Educational Intervention|"Physicians in the intervention arm receive the following multi-faceted educational intervention on transthoracic echocardiogram appropriateness: 1) a lecture at the beginning of the study period, which describes the Appropriate Use Criteria (AUC) for echocardiography and highlights common clinical scenarios for which outpatient TTEs are ordered, 2) an electronic pocket card via email that provides tips on appropriate ordering of TTEs, and 3) an individualized monthly feedback report that categorized TTEs ordered over the preceding month. The feedback reports contains the number of TTEs ordered during the month and how many are classified as appropriate, inappropriate, or uncertain based on the 2011 AUC."
3092272|NCT01944202|No Intervention|Control group|Physicians in the control arm have their TTE orders tracked and classified, but do not receive any feedback on their ordering behavior.
3092273|NCT01944189|Experimental|Food Supplement|"Population PK Study will enroll 70 children receiving standard AL dose at 0, 8, 24, 36, 48, 60 hour with recommended milk or maize porridge plus oil. Both foods contain sufficient fat therefore will contribute to pool evaluations as a single cohort.~A subset, 48 children will have participated in nested comparative bio-availability study as follows Standard arm children receiving single dose with milk (12) Standard arm children receiving double dose with milk (12) Experimental arm children receiving single dose with maize porridge plus oil (12) Experimental arm children receiving double dose with maize porridge plus oil (12) The rest, 22 children will have participated exclusively in PPK, receiving appropriate single or double dose with milk similar to those in standard arm"
3092274|NCT01944189|Experimental|Food Supplement Arm|"Population PK Study will enroll 70 children receiving standard AL dose at 0, 8, 24, 36, 48, 60 hour with recommended milk or maize porridge plus oil. Both foods contain sufficient fat therefore will contribute to pool evaluations as a single cohort.~A subset, 48 children will have participated in nested comparative bio-availability study as follows Standard arm children receiving single dose with milk (12) Standard arm children receiving double dose with milk (12) Experimental arm children receiving single dose with maize porridge plus oil (12) Experimental arm children receiving double dose with maize porridge plus oil (12) The rest, 22 children will have participated exclusively in PPK, receiving appropriate single or double dose with milk similar to those in standard arm"
3092275|NCT01944176|Experimental|Simvastatin|simvastatin 20 mg/d is randomized to treat COPD patients for 4 weeks
3092276|NCT01944176|Placebo Comparator|B1-6-12|B1-6-12 one tablet a day is randomized to give to COPD patients for 4 weeks
3092277|NCT01944163|No Intervention|Usual care|GP provide care as usual to their CLBP patients.
3092278|NCT01944163|Other|Referral arm|GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
3092281|NCT01944137|No Intervention|Standard Care|Participant will receive standard cancer care
3092282|NCT01944137|Experimental|Nursing Intervention|Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy
3092283|NCT01944124|Experimental|Exercise Prescription + Mobile Health|Received a tailored exercise prescription and mobile health technology kit to track blood pressure, blood glucose, physical activity and body weight.
3092284|NCT01944124|Active Comparator|Exercise Prescription|Received a tailored exercise prescription only.
3092285|NCT01944111|Experimental|Plication|Prospective clinical trial comparing Standard Adustable Gastric Banding versus experimental Adjustable Gastric Banding
3092286|NCT01944098|Experimental|Lidocaine|Intraoperative continuous IV infusion of Lidocaine at 2mg/kg/hr
3092287|NCT01944098|Active Comparator|Placebo|Intraoperative continuous placebo infusion of dextrose at 2mg/kg/hr
3092288|NCT01944085|Active Comparator|Acetaminophen|Acetaminophen was administered 1 hour prior to pin removal (weight dependent dose)
3092289|NCT01944085|Active Comparator|Ibuprofen|Ibuprofen was administered 1 hour prior to pin removal (weight dependent dose)
3092290|NCT01944085|Placebo Comparator|Vitamin C (Placebo)|Vitamin C was administered 1 hour prior to pin removal (weight dependent dose)
3092291|NCT01944072|Other|60%|aerobic exercise training intensity of 60%Wmax
3092292|NCT01944072|Other|80%|aerobic exercise training intensity of 80%Wmax
3092293|NCT01944059|Active Comparator|Theramine|"2 capsules before breakfast and dinner (BID) for 16 weeks.~Migraine preventative medications will be permitted, but no changes in dosage will be allowed during the four month study. Migraine abortive meds will be permitted and will be administered per their standard routine."
3092294|NCT01944059|Placebo Comparator|placebo (l-alanine)|"2 capsules before breakfast and dinner (BID) for 16 weeks.~Migraine preventative medications will be permitted, but no changes in dosage will be allowed during the four month study. Migraine abortive meds will be permitted and will be administered per their standard routine."
3092295|NCT01944046|Placebo Comparator|Placebo Nasal Spray|Placebo
3092296|NCT01944046|Active Comparator|Oxytocin Nasal Spray|Oxytocin
3092297|NCT01944033|Active Comparator|Group Terbutaline|Group Terbutaline received 5 mg Terbutaline sulfate (2ml) and 3ml serum saline in nebulization repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
3092298|NCT01944033|Experimental|Group Terbutaline/IB|Group Terbutaline/Ipratropium Bromide received combination of 5 mg Terbutaline (2ml) and 0.5 mg Ipratropium bromide (2ml) and 1ml serum saline in nebulization repeated threeand every 4 hours during the first 24 hour protocol
3092299|NCT01944020|Experimental|Active CPAP|Active CPAP will be a therapeutic dose of positive airway pressure each night for 2 months
3092300|NCT01944007|Experimental|CLP 15 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
3092301|NCT01944007|Experimental|CLP 25 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
3092302|NCT01944007|Experimental|CLP 7.5 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
3092303|NCT01944007|Experimental|CLP 15 g fasted|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d 1 hour prior to 4 standardized meals/snack
3092304|NCT01943994|Experimental|Psilocybin-assisted treatment|Participants will receive a 13-week cognitive behavioral intervention for smoking cessation, with a high dose of psilocybin (30mg / 70kg) to be administered on the Target Quit Date in week 5.
3092305|NCT01943994|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will receive a 13-week cognitive behavioral intervention for smoking cessation, with a standard 8 to 10-week regimen of NRT to be administered beginning on the Target Quit Date in week 5. NRT for this study will be a transdermal nicotine patch administered according to recommended label usage (For individuals who smoke more than 10 cigarettes per day: 21mg daily weeks 1-6, 14mg daily weeks 7-8, 7mg daily weeks 9-10. For individuals who smoke 10 or less cigarettes per day: 14mg daily for weeks 1-6, 7mg daily for weeks 7-8).
3092306|NCT01943981||Optimal/inappropriate exercise response|
3092307|NCT01943968|Other|Systemic sclerosis patients|Systemic sclerosis patients will have blood tested for fibrotic enzyme levels
3092308|NCT01943955|Experimental|home-based computer gaming|computer gaming, balance exercises carried out at home for 20 minutes 5 days/week and monitored by a physical therapist.
3092309|NCT01943942|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
3092310|NCT01943942|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
3092311|NCT01943916|Experimental|Imagio OA/US (US and OA/US)|Imagio OA/US (gray scale and opto-acoustic)
3092312|NCT01943916|Experimental|Imagio gray scale ultrasound|Imagio gray scale ultrasound alone
3092313|NCT01943903||Cohort 1 - Standard of Care|Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of each subject considered for percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG), the investigator and the institution's heart team will review clinical data and results of the diagnostic tests to recommend a treatment strategy, according to the institution's standard practice. Cohort 1 of the study is an observational evaluation of resource utilization and outcomes based on standard practice for diagnosis and treatment of subjects with symptomatic suspected CAD and intermediate likelihood of obstructive CAD. Subjects will be followed for one year after enrollment.
3092314|NCT01943903||Cohort 2 - FFRCT-guided|Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of subjects considered for PCI and/or CABG, the investigator and the institution's heart team will review the results of all available diagnostic tests, including cCTA and FFRCT, and will recommend a treatment strategy accordingly. FFRCT is a non-invasive method to evaluate the hemodynamic significance of coronary artery lesions. FFRCT calculates FFR from subject-specific cCTA data using computational fluid dynamics under rest and simulated maximal coronary hyperemic conditions. FFRCT values range between 0 and 1, and values ≤0.80 are considered hemodynamically (HD)-significant.
3092315|NCT01943890|Experimental|Physiotherapy and hypertonic saline|Chest physiotherapy integrated with inhalation of hypertonic saline
3092316|NCT01943877|Experimental|Propolis|
3092317|NCT01943877|Sham Comparator|scaling and root planing|
3092411|NCT01943175||Genetic High Risk|
3092318|NCT01943864|Experimental|Trametinib (single tablet)|Subjects will receive, trametinib once daily as a single tablet of 2 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
3092319|NCT01943864|Experimental|Trametinib PK study (multiple tablet)|Subjects will receive on Day 1, trametinib as four tablets of 0.5 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
3092320|NCT01943864|Experimental|Trametinib PK study (single tablet)|Subjects will receive Day 2 onwards, trametinib once daily as a single tablet of 2 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
3092321|NCT01943851|Experimental|Part 1: GSK525762 QD Cohort|Subject will be administered a 5 milligram (mg) starting dose of GSK525762, oral tablets, QD. Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM for QD dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.
3092322|NCT01943851|Experimental|Part 1: GSK525762 BID Cohort|Subject will be administered a starting dose of GSK525762, oral tablets, 20 mg BID (12 hours apart, total daily dose of 40 mg). Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM, for BID dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.
3092323|NCT01943851|Experimental|Part 2: GSK525762 dose expansion cohort|After the MTD has been determined in Part1, Part 2 dose expansion cohorts will be opened for AML, NHL and MM.
3092324|NCT01943838|Experimental|SAR245408 polymorph E tablets|Escalating doses of SAR245408 polymorph E tablets, once daily dosing with morning meal every day for two 28-days cycles
3092325|NCT01943825|Experimental|Group 1: CYD dengue vaccine|Participants will receive a dose on CYD dengue vaccine at Day 0, and month 2 and 6, respectively
3092326|NCT01943825|Experimental|Group 2: CYD dengue vaccine|Participants will receive a dose on CYD dengue vaccine at Day 0, and month 6 and 12, respectively
3092327|NCT01943825|Experimental|Group 3: CYD dengue and IXIARO vaccines|Participants will receive a dose on CYD dengue and IXIARO (JE) vaccines at Day 0, JE at month 1, and CYD dengue at month 2 and 6 and 12, respectively
3092328|NCT01943825|Experimental|Group 4: IXIARO (JE) vaccine|Participants will receive a dose of IXIARO (JE) vaccines at Day 0 and at month 1; and CYD dengue at months 7, 9 and 13, respectively
3092329|NCT01943812|Experimental|Substituted FET cycle and GnRHa|Substituted FET GnRH-a 2 bolus two days before Estradiol 6 mg Progesterone (Crinone) 180 mg
3092330|NCT01943812|Active Comparator|Substituted FET cycle|substituted FET cycle Estradiol Progesterone
3092331|NCT01943799|Experimental|OAV Alone|Participants will continue their prebaseline OAV regimen alone from baseline to Week 48.
3092332|NCT01943799|Experimental|OAV + GS-4774 2 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 2 yeast units (YU) from baseline to Week 20.
3092333|NCT01943799|Experimental|OAV + GS-4774 10 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 10 YU from baseline to Week 20.
3092334|NCT01943799|Experimental|OAV + GS-4774 40 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 40 YU from baseline to Week 20.
3092335|NCT01943786||FOLFIRI + Cetuximab|Patients with advanced colorectal cancer and wild-type KRAS will receive FOLFIRI + Cetuximab according to regular clinical practice
3092336|NCT01943773|Experimental|Prehabilitation|The intervention will consist of nine 45 minute long physical therapy sessions. Sessions will occur three times weekly at the patient's home.
3092337|NCT01943773|Experimental|No Prehabilitation|The control group will undergo routine pre-operative management.
3092338|NCT01943760|Active Comparator|tramadol wound infiltration|2 mg / kg of tramadol diluted in 5 ml of 0.9% saline solution wound infiltration 20ml of 0.9% saline solution intravenously
3092339|NCT01943760|Experimental|tramadol intravenous administration|2 mg / kg of tramadol diluted 20ml of 0.9% saline solution intravenously 5 ml of 0.9% saline solution wound infiltration
3092340|NCT01943734|Experimental|Lifestyle counseling|Information passed on anthropometric assessment
3092341|NCT01943721|Experimental|VISION5 Product|VISION5 Product in both eyes
3092342|NCT01943708|Active Comparator|Continuous positive airway pressure (CPAP) device.|Standard CPAP therapy
3092343|NCT01943708|Experimental|Auto-CPAP device (SPAP).|Novel Auto-CPAP algorithm
3092344|NCT01943695|Experimental|Aerobic Training During Chemotherapy|The ultimate goal is for participants to complete approximately 130-180 minutes/week of non-linear aerobic training at 55% to 100% of the individually determined exercise capacity VO2peak), concurrent with chemotherapy. VO2peak will be determined by the CPET performed at baseline. The 130-180 minutes/week will be achieved via 3 individual aerobic training sessions at approximately 10 to 50 minutes/session (± 10 minutes). All sessions are required to be supervised.
3092345|NCT01943695|Experimental|Aerobic Training After Chemotherapy|The ultimate goal is for participants to complete approximately 130-180 minutes/week of non-linear aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), after the completion of chemotherapy. VO2peak will be determined by the CPET performed at midpoint, or pre-surgery for neoadjuvant patients. For patients receiving adjuvant therapy, (except those who have additional surgery after chemotherapy), the aerobic training intervention must begin within 2 weeks of the patient's midpoint CPET. For patients receiving neoadjuvant or adjuvant therapy and have additional surgery after chemotherapy, the aerobic training intervention will begin within approximately 6 weeks of surgery, per the discretion of the treating physician. The 130-180 minutes/week will be achieved via 3 individual aerobic training sessions at approximately 10 to 50 minutes/session (± 10 minutes). All sessions are required to be supervised.
3092412|NCT01943175||Healthy Control|
3092413|NCT01943162|Experimental|SMART-CPT|CPT with additional elements of cognitive rehabilitation
3092414|NCT01943162|Active Comparator|CPT|Standard Cognitive Processing Therapy
3092415|NCT01943136|Experimental|papaya 1% extract ointment|papaya 1% extract ointment twice a day for 1 week
3092346|NCT01943695|Experimental|Continuous Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of non-linear aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), during and after chemotherapy. For patients receiving adjuvant therapy (except those who have additional surgery after chemotherapy), VO2peak will be determined by the CPETs performed at baseline and midpoint. For patients receiving neoadjuvant or adjuvant therapy and have additional surgery after chemotherapy, VO2peak will be determined by the CPETs or at baseline, pre- surgery, and post-surgery. The 130-180 minutes/week will be achieved via 3 individual aerobic training sessions at approximately 10 to 50 minutes/session (± 10 minutes). All sessions are required to be supervised.
3092347|NCT01943695|Experimental|General Physical Activity Group|Patients will receive a home-based, general physical activity program. Specifically, all patients assigned to general physical activity will receive an initial, in-person consultation with staff exercise physiologist outlining a structured home-based aerobic walking program with a goal up to 150 minutes per week outside of their normal daily activity. Patients will be provided with a fitness tracker (e.g. FitBit) to evaluate exercise duration and intensity. Patients will be asked to record type, duration, and average heart rate during sessions in an exercise log to assess compliance. Staff exercise physiologists will contact patients to check progress, answer questions and record compliance.
3092348|NCT01943682|Experimental|CPX-351|CPX-351 is made up of two chemotherapy drugs that patients may have already received called cytarabine and daunorubicin that are now packaged together. Subjects will receive a single course of CPX-351 administered on Days 1, 3, and 5.
3092349|NCT01943669|Experimental|ReWalk™ device|Self-controlled group; single cohort.
3092350|NCT01943656|Experimental|Tobii™ Eyegaze System|Single arm, open label study.
3092351|NCT01943643|Experimental|CT angiography, coronary bifurcations|
3092352|NCT01943630|Active Comparator|AS101|Topical 15% AS101 gel, once a day (overnight)
3092353|NCT01943630|Placebo Comparator|Vehicle|Vehicle, Once a day topical application (Overnight)
3092354|NCT01943617|Active Comparator|Entecavir Therapy|Entecavir, 0.5mg, qd, oral, for 2 years
3092355|NCT01943617|Experimental|Entecavir plus thymosin therapy|Entecavir plus thymosin-α 1.6μg, Twice a week, ih, in the middle one year
3092356|NCT01943604|Experimental|Experimental|"Nutella Breakfast~Waffle Breakfast"
3092357|NCT01943591|Experimental|15-caliber platinum coils|Endovascular embolization coiling using 15-caliber platinum coils
3092358|NCT01943591|Active Comparator|10-caliber coils|Endovascular embolization coiling using standard 10-caliber platinum coils
3092359|NCT01943578||lung cancer patients|Non Small Cell Lung Cancer, Small Cell Lung Cancer
3092360|NCT01943565|Active Comparator|Hydromorphone 25mcg|The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
3092361|NCT01943565|Active Comparator|Hydromorphone 50mcg|The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
3092362|NCT01943565|Active Comparator|Hydromorphone 100mcg|The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
3092363|NCT01943552|Experimental|ipratropium|500 mcg four times a day
3092364|NCT01943552|Placebo Comparator|placebo|
3092365|NCT01943539|Experimental|EVO Game Play|Neuro-typical controls and ADHD will receive EVO game play.
3092366|NCT01943513|Experimental|BIIB023|Participants receive intravenous (IV) infusions of BIIB023
3092367|NCT01943513|Placebo Comparator|Placebo|Participants receive intravenous (IV) infusions of placebo
3092368|NCT01943500||Cancer or no prior history of cancer|Confirmed patients with breast, prostate, or colorectal cancer (OR) subjects with no prior history of cancer
3092369|NCT01943487|Experimental|1: verapamil + EC905|
3092370|NCT01943474|Experimental|AccuCath IV Catheter Device|AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal
3092371|NCT01943474|Active Comparator|Conventional IV Catheter Device|Conventional IV catheter (current catheter) will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal
3092372|NCT01943461|Experimental|Avelumab|
3092373|NCT01943435|Active Comparator|Medical Care|"Non-steroidal anti-inflammatory drugs (NSAIDs); adjunctive analgesics; adjunctive anti-depressants. Participants assigned to this group will see a board certified physical medicine and rehabilitation physician for a history and examination, after which a determination will be made about a course of treatment that involve medications that are individualized to the needs of each patient.~NSAIDs: ibuprofen, celecoxib, or diclofenac/misoprostol~Adjunctive analgesics: acetaminophen, tramadol, or gabapentin~Adjunctive antidepressant agents: nortriptyline, duloxetine, sertraline, trazodone, or mirtazapine~Lumbar epidural injection: these will be prescribed by the physician if warranted due to severity of symptoms or lack of adequate response to oral medications."
3092374|NCT01943435|Active Comparator|Group Exercise|Group Exercise: community setting. This arm will involve attendance at community based group exercise classes that are taught by senior physical fitness instructors. These classes are designed specifically for older adults. Exercise frequency will be 2 times per week, for a total of 12 visits over the 6-week research period. These exercise classes will be attended at local community senior centers which cater to the needs of older adults. The subjects can self-select which particular exercise class they prefer to attend, based upon their level of fitness and physical function.
3092375|NCT01943435|Active Comparator|Manual therapy and exercise|"This group of subjects will be treated with a combination of manual therapy and rehabilitative exercise procedures that are commonly used in the physical therapy and chiropractic professions. Subjects will be treated at a frequency of 2 times per week, for a total of 12 visits over the 6-week research period. Treatments will be provided by licensed physical therapists and chiropractors using a combination of Joint Mobilizations (spine, sacroiliac, hip), muscle stretching and strengthening exercises.~Individualized exercises: clinical setting. These exercises will be tailored to the individual needs of each research participant by the treating physical therapist or chiropractor."
3092376|NCT01943422|Experimental|Vemurafenib + IFNα-2b (10 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (10 MU/m2/d)~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
3092377|NCT01943422|Experimental|Vemurafenib + IFNα-2b(15 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (15 MU/m2/d)~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
3092378|NCT01943422|Experimental|Vemurafenib + IFNα-2b (20 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (20 MU/m2/d)~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
3092379|NCT01943409|Active Comparator|Intralipid|Patients will receive Intralipid, which is the standard lipid emulsion used in the hospital
3092380|NCT01943409|Experimental|ClinOleic|Patients that are randomized to receive ClinOleic as a lipid emulsion in their PN, instead of Intralipid. ClinOleic is approved by Health Canada. The amount of calories from the lipid emulsion will be equivalent in the standard of care group and in the ClinOleic group.
3092381|NCT01943396|Experimental|Rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. Best-corrected visual acuity, electroretinography and drusenoid retinal pigment epithelium detachment area will be examined. Changes of selected special immunologic parameters will be measured.
3092382|NCT01943396|No Intervention|without rheohemapheresis|Into the group the patients will be randomized with the same disease but without rheohemapheresis
3092383|NCT01943383||Diuretic|Patients who received a diuretic drug during the parent trial are eligible for participation.
3092384|NCT01943370|Experimental|Early saline irrigation|Initiation of early saline irrigation
3092385|NCT01943370|Active Comparator|Late or Routine Saline Irrigation|Routine initiation of saline irrigation
3092386|NCT01943357|Experimental|Diabetes Self-Management Program|Behavioral: Diabetes Self Management Program. Consists of either a six-week small-group face-to-face program with two peer leaders or an six-week peer-facilitated Internet-based program.
3092387|NCT01943344|Experimental|Treatment|Subjects that receive VIVASURE CLOSURE DEVICE™
3092388|NCT01943331||patients admitted to ICU|
3092389|NCT01943318||Alcohol|"Alcoholic Liver Cirrhosis~Participants will undergo liver biopsy. Participants will undergo hepatic venous pressure gradient measurement."
3092390|NCT01943318||Hepatitis B virus|Hepatitis B virus (HBV) Liver Cirrhosis
3092391|NCT01943318||Hepatitis C virus|Hepatitis C virus (HCV) Liver Cirrhosis
3092392|NCT01943318||Autoimmune|Autoimmune Cirrhosis
3092393|NCT01943318||Biliary|Primary or secondary biliary cirrhosis
3092394|NCT01943318||Toxic|Medication related cirrhosis
3092395|NCT01943318||Others|Hepatic venous pressure gradient (HVPG) measurement
3092396|NCT01943305|Experimental|Test arm|A total of 100 healthy adults, pre-screened to be negative for anti-dengue antibodies will be enrolled upon written informed consent. 75 subjects in the test arm will received 2 doses of inactivated Japanese Encephalitis vaccine and 1 dose of Yellow Fever vaccine.
3092397|NCT01943305|Experimental|Control arm|A total of 100 healthy adults, pre-screened to be negative for anti-dengue antibodies will be enrolled upon written informed consent. 25 subjects in the control arm will not receive Japanese Encephalitis vaccine but will receive 1 dose of Yellow Fever vaccine.
3092398|NCT01943292|Experimental|Defactinib|Oral defactinib (VS-6063) administered twice a day (BID) during a 21 day cycle.
3092399|NCT01943279|Active Comparator|Standard Follow-up (SFU)|Women selecting SFU at either site (BCBC or CIHC) will schedule their in-person follow-up appointment before leaving the BCBC clinic on Study Day 1, when they receive their medication. In-person follow-up appointment will be scheduled for Study Day 15 (± 3 days)where, as per usual care, includes a history and a Post-abortion Checklist, transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
3092400|NCT01943279|Experimental|Remote Follow-up (RFU)|On Study Day 1 in both sites, women selecting RFU will receive 3 laboratory requisition forms for serum β-hCG testing and will be instructed to have testing done at a laboratory site of her choice on Study Day 10-12. The follow-up telephone appointment will be scheduled to take place on Study Day 15 (±3 days). For the follow-up telephone appointment, the research nurse/nurse practitioner will calculate the percentage fall in the β-hCG value. She will contact the subject by phone at the specified time, take a history of the timing of misoprostol use, resulting symptoms and complete the symptom Post-abortion Check-list. The research nurse/nurse practitioner, in consultation with the clinic physician if necessary, will confirm the information, determine whether other follow-up is required.
3092401|NCT01943266|Experimental|protein intake|protein intake randomly fed from deficient to excess
3092402|NCT01943253|Active Comparator|Conventional ESD|Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
3092403|NCT01943253|Active Comparator|Hybridknife ESD|"Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)~Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)"
3092404|NCT01943240|Experimental|Group A|Paravertebral peripheral nerve blockade with with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of 0.375% ropivacaine for pectoral nerve block
3092405|NCT01943240|Active Comparator|Group S|Paravertebral peripheral nerve blockade with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of normal saline for pectoral nerve block.
3092406|NCT01943227|Experimental|Enthalpy|
3092407|NCT01943214||Type II DM body constitution|Type II diabetes mellitus, body constitution
3092408|NCT01943201|Experimental|new bedsheet|new bedsheet
3092409|NCT01943201|Placebo Comparator|conventional bedsheet|conventional bedsheet
3092410|NCT01943188|Experimental|Treatment (SBRT, autologous PBMC infusion)|"SBRT: Patients undergo standard of care SBRT over 1-2 weeks according to tumor volume and location.~LYMPHODEPLETION: Beginning 3 weeks later, patients receive cyclophosphamide PO BID for 3 days.~REINFUSION OF PBMC: Within 3-14 days of completing lymphodepletion with cyclophosphamide , patients undergo autologous PBMC infusion."
3092416|NCT01943136|Active Comparator|mupirocin 2% ointment|mupirocin 2% ointment twice a day for 1 week
3092417|NCT01943123|Experimental|probiotic drink|experimental group (30 subjects) were given 50 ml of probiotic drink for 6 months on daily basis
3092418|NCT01943123|Placebo Comparator|plain, unsweetend, unflavored pasturised milk|control group/ placebo group (30 subjects) were given pasteurized milk (50 ml) for 6 months on regular basis
3092419|NCT01943110|Experimental|Saline injection with ID adapters|"Each participant will receive six injections of 0.1 ml of sterile saline solution into the skin:~Upper deltoid with the side-load ID adapter~Upper deltoid with the AD ID adapter~Suprascapular (behind the shoulder) with the side-load ID adapter~Suprascapular with the AD ID adapter~Forearm with the side-load ID adapter~Forearm with the AD ID adapter"
3092420|NCT01943084|Experimental|Norditropin®|
3092421|NCT01943084|Active Comparator|Genotropin®|
3092422|NCT01943071|Experimental|Day care for patients with dementia|Day care for patients with dementia
3092423|NCT01943071|No Intervention|Care as usual|Care as usual
3092424|NCT01943058|Experimental|Arm A (megestrol acetate)|Patients receive megestrol acetate PO BID for up to 18 months in the absence of disease progression or unacceptable toxicity.
3092425|NCT01943058|Experimental|Arm B (levonorgestrel-releasing IUS)|Patients receive levonorgestrel-releasing IUS with continuous release for up to 18 months in the absence of disease progression or unacceptable toxicity.
3092426|NCT01943045|Experimental|NGM282 Dose 1|NGM Dose 1
3092427|NCT01943045|Experimental|NGM282 Dose 2|NGM Dose 2
3092428|NCT01943045|Experimental|NGM282 Dose 3|NGM Dose 3
3092429|NCT01943045|Placebo Comparator|Placebo|Placebo
3092430|NCT01943032||Primary Breast Tumor|Immunohistochemical staining of paraffin embedded tissue blocks of primary breast tumor for estrogen and progesterone receptors was performed.
3092431|NCT01943032||Axillary Lymph Nodes.|Immunohistochemical staining of paraffin embedded tissue blocks of axillary lymph nodes for estrogen and progesterone receptors was performed.
3092432|NCT01943019|Experimental|Linagliptin|Linagliptin daily
3092433|NCT01943006|Experimental|Hirudoid cream|"Patient treated with Hirudoid cream 0.3% Mucopolysaccharide polysulfate~Twice daily"
3092434|NCT01943006|Placebo Comparator|Placebo|"Patients treated with placebo cream without active substance~Twice daily"
3092435|NCT01942993|Experimental|Vemurafenib|960 mg (four tablets of 240 mg each) of vemurafenib PO BID
3092436|NCT01942980|Other|conventional postoperative whole-brain radiation therapy|conventional postoperative whole-brain radiation therapy (40 Gy in 20 fractions of 2 Gy)
3092437|NCT01942980|Other|whole-brain radiation therapy with hippocampal avoidance|Radiation therapy with hippocampal avoidance
3092438|NCT01942967||Preterm ≤ 32 weeks GA, on CPAP|Preterm infants less than 32 weeks gestational age requiring CPAP as a mode of respiratory support and admitted in the NICU.While the baby is on CPAP,tissue oxygen saturation monitoring will be started by applying NIRS(Near Infrared Spectroscopy Monitoring) sensors to the forehead and the abdomen. After 3 hours,echocardiography(including Superior Mesenteric Artery Doppler) will be done while the baby is on CPAP. Then, using the same machine, the mode of respiratory support will be changed to TrPA. After another three hours,another echocardiography will be done,then NIRS monitoring will be stopped and the mode of respiratory support will be changed back to CPAP.
3092439|NCT01942954|Experimental|Mobile health cognitive stimulation|Experimental group
3092440|NCT01942954|No Intervention|Treatment-as-usual|This group consists of treatment-as-usual for alcohol abstinence according to the Minnesota Model.
3092441|NCT01942941|Experimental|geko™ electrical stimulation|Applied to stimulate peroneal nerve unilaterally
3092442|NCT01942928|Active Comparator|Usual NHS care|
3092443|NCT01942928|Active Comparator|Usual NHS Care plus Osteopathic Manipulative Therapy|
3092444|NCT01942915|Experimental|umbilical cord blood mononuclear cells|Umbilical Cord blood come from healthy puerpera. Erythrocyte in umbilical cord blood was separated and deleted through sedimentation. Mononuclear cells in umbilical cord blood were then isolated with a conventional method and reagent,Ficoll,by density gradient centrifugation.
3092445|NCT01942902|Experimental|Continuous Glucose Monitoring System|
3092446|NCT01942889|Active Comparator|Antioxidant Supplementation|Vitamin antioxidant and trace elements combination that won't exceed the maximal nutritional dose recommended in France (Vit E, vit C, Selenomethionine, Zinc gluconate).
3092447|NCT01942889|Placebo Comparator|Placebo|Placebo
3092448|NCT01942876|Experimental|Intervention|The Quit Using Drugs Intervention Trial (QUIT) experimental arm includes: screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
3092449|NCT01942876|Sham Comparator|Control|This arm will receive a sham telephone intervention of equivalent duration on health behavior maintenance.
3092450|NCT01942863|Experimental|water exchange single balloon enteroscopy|
3092451|NCT01942863|Active Comparator|CO2 insufflation single balloon enteroscopy|
3092452|NCT01942850||No Treatment|Collect pilot data on the performance of the ICARS in patients younger than 10 years of age, as well as to introduce definitions for the various clinically defined stages of AT, and attempt to develop descriptors of change that could help in the assessment of patients longitudinally.
3092453|NCT01942837|Experimental|Enzalutamide|Participants will be treated with four 40 mg capsules (160 mg) once daily of enzalutamide taken orally. All participants without orchiectomy will be maintained on LHRH agonist/antagonist therapy. Participants will be evaluated clinically and with laboratory studies on day 1 of every 28 day cycle. Participants will maintain a drug diary from time of initiation of study treatment to time of discontinuation from the study (Appendix C).
3092454|NCT01942824|Experimental|Intervention|Text Message
3092455|NCT01942824|No Intervention|Usual Care|
3092456|NCT01942811|Experimental|Intervention|The Quit Using Drugs Intervention Trial (QUIT) experimental arm includes: screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
3092457|NCT01942811|No Intervention|Control|Usual care and a health education booklet and video on cancer prevention
3092526|NCT01942369||Deep Infiltrating Endometriosis (DIE)|
3093700|NCT01934504||Non-Tolerant AAV|Non-Tolerant participants with ANCA-associated vasculitis (AAV)
3092458|NCT01942798|Active Comparator|Cognitive Games|"The Cognitive Games group will receive 40 minute supervised group training three times per week for a period of four weeks. The group for the first week will be held at the clinic, while the remaining three weeks be conducted at the subject's home and supervised by the Trainer remotely using a tablet with video conferencing capability. At the end of the four-week Supervised Phase, subjects will retain the Wii units and they will be encouraged to use the program on their own for an additional period of four weeks (Unsupervised Phase).~Subjects in the control group will play cognitive oriented video games using Wii Big Brain Academy Degree program. BigBrain™ is a video gaming system which has games and exercises to improve cognitive function(identify, memorize, analyze, compute, and visualize). Subjects use the Wii handheld remote to participate in the games by pointing and clicking the remote to select on-screen answers in response to on-screen questions."
3092459|NCT01942798|Experimental|WiiNWALK Intervention|"The intervention group will also receive 40 minute supervised group training three times per week for a period of four weeks. Interventions conducted over the first week will be held at the clinic, while the remaining three weeks be conducted at the subject's home and supervised by the Trainer remotely. At the end of the four-week Supervised Phase, subjects will retain the Wii units and they will be encouraged to use the program on their own for an additional period of four weeks (Unsupervised Phase).~The WiiNWALK protocol consists of performing Nintendo WiiFit activities. Subjects stand on the WiiFit balance board and interact with the WiiFit games through weight shifting or by using the Wii handheld remote control. The intervention protocol will include selected exercises consisting of: 1) Yoga 2) Balance Tasks 3) Strength training and 4) Aerobics.~At the in-clinic sessions in Vancouver, a motion-sensing device will also record video and skeleton data of the participant."
3092460|NCT01942785|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label commercially available Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) antidepressant treatment (ADT)
3092461|NCT01942772|Experimental|experimental test of healthy subjects|wearing experiment，motion experiment
3092462|NCT01942759||Histologic grade|According to the modified criteria of Bloom and Richardson grading system: grade 1, 2 and 3
3092463|NCT01942759||Axillary metastasis|Group A: axillary lymph node metastasis Group B: no axillary lymphatic metastasis
3092464|NCT01942759||Modified Nottingham prognostic index|"NPI = pathological tumour size (cm) × 0.2 + lymph node stage (1, 2 or 3) + histological grade (1, 2 or 3)~The cut-off points of the index were 3.4 and 5.4 to divide patients into the good (≤3.4), moderate (3.41-5.4) and poor (>5.4) prognostic groups"
3092465|NCT01942759||Oestrogen receptor status|Negative Positive
3092466|NCT01942759||Progesterone receptor status|Negative Positive
3092467|NCT01942759||HER-2 neu status|Negative Positive
3092468|NCT01942746|Active Comparator|Blueberry Juice|Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue'). Volunteers consumed 300 mls of juice/day (247-271 mg anthocyanins (as C3G) daily) while on this intervention, for either 3 weeks (Blueberry Juice S2) or 12 weeks (Blueberry Juice L1).
3092469|NCT01942746|Active Comparator|Blueberry Capsules|Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue')was freeze dried to a powder and encapsulated in gelatin capsules (Blueberry Capsules S2). Volunteers consumed 3 capsules/daily (7.11mg anthocyanin (as C3G eq) for 3 weeks.
3092470|NCT01942746|Placebo Comparator|Placebo|Volunteers consumed in S2 three placebo capsules daily for 3 weeks. In L1 volunteers consumed 300ml placebo juice for twelve weeks. Placebo products contained no anthocyanins.
3092471|NCT01942746|No Intervention|Washout (S2 and L1)|Washout periods involved no study products. Washout was 3 weeks in S2 and or 8 weeks (L1) in duration.
3092472|NCT01942733|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant treatment (ADT)
3092473|NCT01942720|Other|Capsule endoscopy|
3092474|NCT01942707|Active Comparator|Abdominoplasty without Scarpa´s Facia|Anchor-line abdominoplasty where the Scarpa`s Fascia will be removed.
3092475|NCT01942707|Experimental|abdominoplasty with Scarpa`s Fascia|Anchor-line abdominoplasty where the Scarpa`s Fascia will be preserved.
3092476|NCT01942694|Placebo Comparator|Placebo|One pill daily
3092477|NCT01942694|Active Comparator|Vitamin D (Cholecalciferol)|One vitamin D pill daily
3092478|NCT01942681|Other|Propiverine Hydrochloride Administration|Administration of Propiverine Hydrochloride for 12 weeks
3092479|NCT01942668|Experimental|Treatment 1|Combined Estradiol / Progesterone formulation and placebo taken orally once a day
3092480|NCT01942668|Experimental|Treatment 2|Combined Estradiol / Progesterone formulation and placebo taken orally once a day
3092481|NCT01942668|Experimental|Treatment 3:|Combined Estradiol / Progesterone formulation and placebo, taken orally once a day
3092482|NCT01942668|Experimental|Treatment 4|Combined Estradiol / Progesterone formulation and placebo, taken orally once a day
3092483|NCT01942668|Placebo Comparator|Treatment 5|2 Placebo capsules taken orally once a day
3092484|NCT01942655|Experimental|Patients with recto-colic biopsies prescribed|45 patients
3092485|NCT01942629||Lung adenocarcinoma|"This group will include 100 patients with lung adenocarcinoma, the clinical outcomes will be retrospectively assessed.~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
3092486|NCT01942629||Breast adenocarcinoma|"This group will include 100 patients with breast adenocarcinoma, the clinical outcomes will be retrospectively assessed.~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
3092487|NCT01942629||Pancreatic ductal adenocarcinoma|"This group will include 100 patients with pancreatic ductal adenocarcinoma, the clinical outcomes will be retrospectively assessed.~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
3092488|NCT01942616|Experimental|Condition 1|"Each study arm contains different scenarios presented to the participant.~Condition 1 is a Perpetrator Positive scenario.~The content of the Condition 1 group is as follows:~Framing: Episodic Labeling: DV label Extraneous Information: Perpetrator positive non relevant Victim/Perp Characteristic: Negative victim"
3092639|NCT01941641|Experimental|neoadjuvant FOLFOXIRI|
3093737|NCT01934218|Active Comparator|Gel-One|3 mL, a single intra-articular injection of Gel-One
3092489|NCT01942616|Experimental|Condition 2|"Each study arm contains different scenarios presented to the participant.~Condition 2 is a Perpetrator Negative scenario.~The content of the Condition 2 group is as follows:~Framing: Thematic Labeling: Assault label Extraneous Information: Perpetrator neutral non relevant Victim/Perp Characteristic: Negative Perpetrator"
3092490|NCT01942616|Placebo Comparator|Condition 3|"Each study arm contains different scenarios presented to the participant.~The content of the Condition 3 group is as follows:~Framing: Neither Labeling: No label Extraneous Information: None Victim/Perp Characteristic: None"
3092491|NCT01942603||Observation|
3092492|NCT01942603||Complete Lymfnode Dissection|
3092493|NCT01942590|Experimental|Clenbuterol|Initially, 40 mcg each morning for one week. Then, increase to 40 mcg BID for the next 5 weeks. If tolerated, will increase to 80 mcg in the morning and 40 mcg in the evening for one week. Then, last dose increase will be 80 mcg BID until week 52.
3092494|NCT01942590|Placebo Comparator|Placebo Comparator|Initially, one capsule each morning for one week. Then, increase to one capsule BID for the next 5 weeks. If tolerated, will increase to two capsules in the morning and one capsule in the evening for one week. Then, last dose increase will be two capsules BID until week 52.
3092495|NCT01942577|No Intervention|No treatment|
3092496|NCT01942577|Active Comparator|NoSting|
3092497|NCT01942564||Case Subjects|"Age 18 years or older~Had a head injury that occurred at least 6 months prior to entering study~Have found lights more bothersome since injury"
3092498|NCT01942564||Control Subjects|"Age 18 years or older~Have not had a previous head injury~Have had a full eye examination at Ohio State University College of Optometry during last 6 months."
3092499|NCT01942551|Experimental|tadalafil, dutasteride|
3092500|NCT01942551|Experimental|dutasteride, tadalafil|
3092501|NCT01942538|Experimental|rTMS-rTMS|subjects receiving real rTMS treatment and real rTMS maintenance sessions
3092502|NCT01942538|Sham Comparator|sham - sham|subjects receiving sham treatment and presenting a clinical improvement : they will be submitted to sham maintenance sessions
3092503|NCT01942538|Sham Comparator|rTMS-sham|subjects receiving sham rTMS maintenance sessions after successful real rTMS treatment
3092504|NCT01942538|Experimental|rTMS|real rTMS for 3 weeks but without clinical improvement
3092505|NCT01942538|Sham Comparator|sham|sham treatment for 3 weeks without clinical improvement
3092506|NCT01942525||Intrauterine growth restriction|birth weight <10th percentile first intervention: aEEG second intervention: assessment of neurodevelopmental follow-up
3092507|NCT01942525||Appropriate for gestation age|control group with birth weight >10th percentile first intervention: aEEG second intervention: assessment of neurodevelopmental follow-up
3092508|NCT01942512||ARETA|All patients with intracranial aneurysms, ruptured or unruptured, treated by endovascular treatment
3092509|NCT01942499|Other|Community Exercise Group|Community-based exercise program for one year
3092510|NCT01942499|No Intervention|Usual Care|
3092511|NCT01942486|Experimental|Investigational Coating|
3092512|NCT01942473|Experimental|Automated FiO2 control|Infants will be changed to a specific ventilator device approved for clinical use in neonates in Germany (Avea, Carefusion 234 GmbH Hoechberg, Germany), which is capable to automatically adjust the FiO2 based on readings of an incorporated SpO2 monitoring device. Infants will be allowed to adjust for at least 2h using the ventilator settings as chosen by the clinical team responsible. Thereafter, data will be recorded for 24h experimental time.
3092513|NCT01942473|Placebo Comparator|Manual Adjustment|Infants will be exposed to the first study phase (clinical routine or automated FiO2 adjustment) for 24 h and then will be switched to the alternate mode (automated FiO2 adjustment or clinical routine) for another 24 h.
3092514|NCT01942460|Experimental|Ferumoxytol|
3092515|NCT01942447|Experimental|FMT|FMT
3092516|NCT01942447|Active Comparator|Standard|Vancomycin
3092517|NCT01942421|Experimental|Cultivated mucosal epithelial transplant|Cultivated mucosal epithelial transplantaion to limbal deficiency patients
3092518|NCT01942408|No Intervention|Standard care group|Patients will undergo an initial PVI procedure. Further management will be determined by AF recurrences at the responsible Consultant's discretion as per standard care.
3092519|NCT01942408|Active Comparator|Repeat study group|Following an initial PVI procedure, all patients (regardless of early AF recurrence) will undergo a repeat electrophysiology (EP) study at 8-10 weeks post-initial PVI, with repeat PVI of any PV reconnection identified
3092520|NCT01942395|Active Comparator|DASH/Sodium-Restricted Diet Intervention|Each patient will eat 3 weeks of the provided DASH/SRD diet for 21 days. The diet is patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants. At enrollment patients will be randomized to the DASH/SRD or Control Diet for 21 days and then cross over to the other for 21 days. Immediately following the provided DASH/SRD and Control Diet, patients will be instructed to adhere to the DASH/SRD for an additional eight weeks with dietary support.
3092521|NCT01942395|Active Comparator|Control Diet Intervention|Patients will consume 3 weeks of a specially prepared diet that will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants. At enrollment patients will be randomized to the DASH/SRD or Control Diet for 21 days and then cross over to the other for 21 days. Immediately following the provided DASH/SRD and Control Diet, patients will be instructed to adhere to the DASH/SRD for an additional eight weeks with dietary support.
3092522|NCT01942395|No Intervention|Healthy Control|Fifteen healthy age-matched and 10 young healthy control patients will be recruited. Age-matched healthy control subjects will undergo testing before and after 3 weeks of eating their habitual diet. Young healthy control subjects will only require 1 study visit with no dietary intervention.
3092523|NCT01942382|Experimental|Treatment A|Participants will receive 4 injections of paliperidone palmitate 150 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
3092524|NCT01942382|Experimental|Treatment B|Participants will receive 4 injections of paliperidone palmitate 75 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
3092525|NCT01942382|Experimental|Treatment C|Participants will receive 4 injections of paliperidone palmitate 75 milligram in the gluteal muscle on Days 1, 8, 36, and 64.
3092527|NCT01942356|Experimental|RL-TIVA Group|Propofol, ketamine and sufentanil administration for a TIVA (total intravenous anesthetic) will be administered using a Harvard 33 syringe pump connected via a RS 232 interface to the study computer running the RL (Reinforcement Learning) control software. This software platform will collect real time vitals and BIS valises and steer the target controlled infusion pumps and the closed loop controllers. The anesthesiologist will provide interventions based on protocol for TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia and TIVA - Tachycardia .
3092528|NCT01942356|Active Comparator|Manual TIVA Group|Manually titrated TIVA (total intravenous anesethetic) with proposal, ketamine and sufentanil will be administered using an Alaris infusion pump titrated by the anesthesiologist based on blood pressure and heart-rate as is traditionally done and is standard of care with intravenous anesthetics. The anesthesiologist will provide interventions based on protocol for TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia and TIVA - Tachycardia .
3092529|NCT01942356|Active Comparator|Inhaled Sevofluorane Group|An inhaled anesthetic with Sevofluorane will be titrated between 0.8-1.5 MAC (minimum alveolar concentration) by the anesthesiologist based on heart rate and blood pressure which is standard of care for inhaled anesthetics. The anesthesiologist will provide interventions based on protocol for INH - Hypotension, INH - Hypertension, INH - Bradycardia and INH - Tachycardia .
3092530|NCT01942343|Active Comparator|Arm 1 : Droperidol 1,25 mg|
3092531|NCT01942343|Active Comparator|Arm 2 : Droperidol 0,625 mg|
3092532|NCT01942343|Active Comparator|Arm 3 : Odansetron 4 mg|
3092533|NCT01942330|No Intervention|Traditional Laparoscopic-Assisted Colectomy|
3092534|NCT01942330|Experimental|Transvaginal Laparoscopic-Assisted Colectomy|Laparoscopic-Assisted Natural Orifice Surgery
3092535|NCT01942317|Experimental|Balneotherapy|16 balneotherapy treatments, each of 45 minutes, twice a week, for 8 consecutive weeks
3092536|NCT01942317|No Intervention|Physiotherapy|16 physiotherapy treatments (no balneotherapy), each of 45 minutes, twice a week, for 8 consecutive weeks
3092537|NCT01942304|Active Comparator|Anorganic bovine bone mineral in direct sinus augmentation|Anorganic bovine bone mineral
3092538|NCT01942304|Experimental|Alloplastic bone putty in direct sinus augmentation|Alloplastic bone putty
3092539|NCT01942291|Experimental|Niacin/Laropiprant|Extended-release niacin 1g/day associated with Laropiprant 1g/20mg (ERN/LRPT, Cordaptive, Merck, Sao Paulo, Brazil)
3092540|NCT01942291|Experimental|Niacin|Extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmaceutica, Sao Paulo, Brazil)
3092541|NCT01942278|No Intervention|Usual Care|Care is delivered according to baseline standard practice
3092542|NCT01942278|Experimental|BHOMA|Care is delivered according to the BHOMA intervention
3092543|NCT01942265|Experimental|Group 4|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21
3092544|NCT01942265|Experimental|Group 3|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
3092545|NCT01942265|Experimental|Group 1|100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
3092546|NCT01942265|Experimental|Group 2|100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
3092547|NCT01942265|Experimental|Group 5|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 21
3092548|NCT01942265|Experimental|Group 9|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21
3092549|NCT01942265|Experimental|Group 8|100 subjects receive 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 0 and 21
3092550|NCT01942265|Experimental|Group 7|100 subjects receive 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 21
3092551|NCT01942265|Experimental|Group 6|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 21
3092552|NCT01942265|Experimental|Group 10|100 subjects receive 45 mcg sanofi A/H7N9 antigen on Day 0 and 21
3092553|NCT01942239|Active Comparator|CGM-group|CGM-group: the intervention(s) to be administered is Continuous glucose monitoring with real time glycemia each 5 minutes
3092554|NCT01942239|No Intervention|IGM-group|IGM-group: the intervention(s) to be administered is intermittent capillary glucose testing (IGM-group) associated with a blind-CGMS to detect retrospectively missed hypoglycemia
3092555|NCT01942213||Subjects receiving Ranibizumab|150 Subjects diagnosed with Neovascular Age-Related Macular Degeneration receiving Ranibizumab 0.5 mg administered by intravitreal injection.
3092556|NCT01942213||Subjects receiving Aflibercept|150 Subjects diagnosed with Age-related Macular Degeneration receiving Aflibercept 2 mg administered by intravitreal injection
3092557|NCT01942200||Carcinoma, Oxaliplatin onkovis (Oxaliplatin)|Treatment in combination therapy for adjuvant treatment of colon carcinoma of stage III (Dukes C) after complete removal of the primary tumor, as well as for treatment of metastasizing colorectal carcinoma.
3092558|NCT01942187|Active Comparator|Medication Augmentation|Medication augmentation with aripiprazole (Abilify) starting at 5mg/day, and increasing weekly in 5mg increments to a maximum of 15mg (10mg/day is the target dose). Under conditions of nonresponse after 6 weeks, aripiprazole will be switched for bupropion (Wellbutrin), starting at 150mg, and possibly increasing to 300mg after 2 weeks.
3092559|NCT01942187|Active Comparator|Problem Solving Therapy|Treatment for 12 weeks with weekly sessions of Problem Solving Therapy, with a trained therapist.
3092560|NCT01942174|Other|Immediate group|"For these patients, the methotrexate treatment is initiated in the same time that the antipneumococcal vaccination by Prevenar13. A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination.~Interventions : biological/vaccine and drug"
3092561|NCT01942174|Experimental|period group|"Methotrexate treatment is initiated 1 month later the first antipneumococcal vaccination by Prevenar13.~A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination~Interventions : biological/vaccine and drug"
3092562|NCT01942161|Experimental|Low (2 mg/day)|Subjects in the 2 mg/day group will be administered 2 mg once daily for 6 weeks (42 days).
3092563|NCT01942161|Experimental|Mid (6 - 12 mg/day)|Subjects in the 6-12 mg/day group will be administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg in accordance with the criteria below.
3092564|NCT01942161|Experimental|High (24 - 30 mg/day)|Subjects in the 24-30 mg/day group will be administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg in accordance with the criteria below.
3092565|NCT01942148|Experimental|Aripiprazole|Aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over 52 weeks to subjects who complete the 031-09-003 study
3092566|NCT01942135|Experimental|Arm A|Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
3092567|NCT01942135|Active Comparator|Arm B|Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
3092568|NCT01942122|Experimental|DLBS1442 100|DLBS1442 capsules 3x100 mg daily, taken every day along the study period
3092569|NCT01942122|Experimental|DLBS1442 200|DLBS1442 capsules 3x200 mg daily, taken every day along the study period
3092570|NCT01942122|Active Comparator|Mefenamic acid|Mefenamic acid tablets 3 x 500 mg daily, only taken for five (5) days during the menstrual period, i.e. day 1st to day 5th of menstrual period.
3092571|NCT01942109|Active Comparator|Furosemide|This group will receive furosemide as a diuretic treatment
3092572|NCT01942109|Experimental|Torasemide|This group will receive torasemide as a diuretic treatment
3092573|NCT01942096||Competitive swimmers|Swimmers performing at national or international level
3092574|NCT01942096||Competitive indoor athletes|Indoor athletes performing at national or international level
3092575|NCT01942096||Healthy control individuals|Individuals performing sports at a recreational level
3092576|NCT01942083|Experimental|OPB-111077|orally, once daily
3092577|NCT01942070|Experimental|Bioresorbable vascular scaffold|Bioresorbable vascular scaffold (BVS)
3092578|NCT01942070|Active Comparator|Everolimus-eluting stent|Durable polymer everolimus-eluting metallic stent (EES)
3092579|NCT01942057||School Grades 1+2|Children currently enrolled in grades 1 and 2
3092580|NCT01942057||School Grades 6+7|Children currently enrolled in grades 6 and 7
3092581|NCT01942057||School Grades 11+12|Children currently enrolled in grades 11 and 12
3092582|NCT01942044|Experimental|Promus element|Promus element is a thin struts, 2-link design, evelolimus-eluting stents.
3092583|NCT01942044|Active Comparator|Xience Prime|Xience Prime is a thin struts, 3-link design, evelolimus-eluting stents.
3092584|NCT01942044|Active Comparator|Nobori|Nobori is a thick struts, 2-link design, biolimus-eluting stents.
3092585|NCT01942031|Experimental|structured collegial feed back|Structured feed back and information about stroke to the primary care center, to physicians and head of the center
3092586|NCT01942031|No Intervention|Control group|No structured feed back on stroke prevention. Ordinary educational activities only.
3092587|NCT01942018|Experimental|EGOO|Patients presenting with symptomatic gastroesophageal junction outflow obstruction (EGOO)who will be treated with Per oral endoscopic myotomy (POEM)
3092588|NCT01941992|Experimental|SAMITAL® sachets, oral suspension|SAMITAL® sachets for oral suspension, 20 mL, four times a day.
3092589|NCT01941992|Placebo Comparator|Placebo sachets|Placebo sachets for oral suspension, 20 mL, four times a day.
3092590|NCT01941979|Experimental|Adjuvant therapy|"5-FU, Leucovorin and Oxaliplatine (FLOX) OR Capecitabine and Oxaliplatin (CAPOX)~NOTE: If the patient was randomized for the arm experimental, the investigator can choose between intravenous (IV) treatment or oral treatment (PO). Both are considered equal by the principal investigator."
3092591|NCT01941979|No Intervention|Observation|
3092592|NCT01941966|Experimental|Chemo-radiotherapy|Capecitabine, PO, 825mg/m2 Mitomycin C, IV, 15 mg/m2 Radiotherapy - 50,4 - 54 Gy
3092593|NCT01941953|Experimental|Metformin and Flourouracil|
3092594|NCT01941940|Experimental|Tocilizumab|Tocilizumab at a fixed dose of 162 milligrams (mg) will be administered as subcutaneous (SC) injection alone or along with methotrexate and/or other non-biological DMARDs irrespective of body weight, once every week for a total of 52 weeks. After 52-weeks of treatment, at the discretion of the treating physician, participants can continue the study treatment with SC tocilizumab until it becomes commercially available in Italy.
3092595|NCT01941927|Experimental|Trametinib, GSK2141795|"Trametinib (GSK1120212)~Oral~2 mg~Daily~Number of Cycles: until progression or unacceptable toxicity develops~GSK2141795~Oral~25 mg~Daily~Number of Cycles: until progression or unacceptable toxicity develops"
3092596|NCT01941914|Experimental|Calcium electroporation|"The keloid will be treated with intratumoral injection of calcium chloride followed by electrotransfer. It is a once only treatment.~Calcium chlorid concentration is 9 mg/ml Total dose is 0,5ml/cm3 tumor volume."
3092597|NCT01941901|Experimental|Calcium electroporation|"The metastases will be treated with intratumoral injection of calcium chlorid followed by electrotransfer.~It is a once-only treatment. Calcium chlorid concentration: 9mg/ml. Total dose: 0,5ml/cm3 tumor volume."
3092598|NCT01941901|Active Comparator|Electrochemotherapy with bleomycin|"The metastases will be treated with intratumoral injection of bleomycin followed by electrotransfer.~It is a once only treatment. bleomycin concentration: 1000 IU/ml. Total dose: o,5 ml/cm3 tumor volume."
3092599|NCT01941888|Experimental|propofol|Patients in Group Propofol(n=70) were seated with propofol target concentration 1.2-1.6 µg/ml. Patients in both groups undergoing CS received also iv fentanyl (1μg/Kg) for pain control.
3092600|NCT01941888|Active Comparator|midazolam|Control Group: patients in Group midazolam (n=70) were sedated with midazolam 0.04 mg/kg if aged< 70 - 0.03 mg/kg if aged> 70. Patients in both groups undergoing CS received also iv fentanyl (1μg/Kg) for pain control.
3092601|NCT01941875|No Intervention|No Luteal Support|Control group: No luteal phase support or medication will be used
3092602|NCT01941875|Experimental|Luteal Vaginal Progesterone|Experiment group: Vaginal progesterone for luteal support beginning the first day after IUI
3092603|NCT01941862|Experimental|Anxiety Risk Reduction|The anxiety risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
3092745|NCT01940952|Active Comparator|Zydena 50mg|Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg
3092604|NCT01941862|Experimental|Mood Risk Reduction|The mood risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for perceived burdensomeness and thwarted belongingness. The psychoeducational component will focus on dispelling myths related to burdensomeness and belongingness and describe their role in the development of mood symptoms.
3092605|NCT01941862|Experimental|Combined Risk Reduction|The combined intervention will involve all of the interventions in the anxiety and mood risk reduction conditions and thus will not be matched for length.
3092606|NCT01941862|No Intervention|Repeated Contact Control|"Participants assigned to the repeated contact group will be assigned a personal study coordinator. The coordinator will contact them at specific intervals during the study. The rationale for these contacts will be provided (e.g., checking in on their status and helping to administer some brief measures). During the three weeks (corresponding to treatment session intervals for those in one of the active treatment conditions), the study coordinator will contact the participant once per week for a brief phone check in where suicide risk will be evaluated. Participants in the control group will also meet with their study coordinator during each of the scheduled follow-up visits."
3092607|NCT01941849|Experimental|Vandetanib + 131I-mIBG|"Vandetanib (100, 200 or 300 mg once daily) in combination with 131I-mIBG radiation therapy (activity to be prescribed to deliver whole body absorbed dose of 0.5 Gy) on day 1 of each 12-weekly cycle.~Patients will receive up to 4 cycles of vandetanib in combination with 131I-mIBG."
3092608|NCT01941836|Experimental|ETC-1002 120 mg/day|Orally, once daily in morning as capsules
3092609|NCT01941836|Experimental|ETC-1002 180 mg/day|Orally, once daily in morning as capsules
3092610|NCT01941836|Active Comparator|ezetimibe 10mg/day|Orally, once daily in morning as capsules
3092611|NCT01941836|Experimental|ETC-1002 120 mg/day + ezetimibe 10mg/day|Orally, once daily in morning
3092612|NCT01941836|Experimental|ETC-1002 180 mg/day + ezetimibe 10mg/day|Orally, once daily in morning
3092613|NCT01941823||Carnitine CRRT, prospective|CRRT patients given carnitine in TPN as part of clinical protocol. Will evaluate total and free, carnitine and acylcarnitine profile as well as cardiac function by standard and speckle tracking echo weekly during CRRT.
3092614|NCT01941823||CRRT Control, retrospective|Retrospective control group, CRRT patients who did not receive carnitine supplementation during CRRT and had carnitine levels measured and echo performed during CRRT.
3092615|NCT01941823||ICU Control (non-CRRT), prospective|Critically ill ICU patients not receiving any exogenous carnitine, and not receiving CRRT, will have total and free carnitine and acylcarnitine profile measured weekly during CRRT.
3092616|NCT01941810|Experimental|Supportive care (bovine lactoferrin supplement)|Patients receive bovine lactoferrin supplement PO TID for 1 month.
3092617|NCT01941797|Experimental|Peri-implant mucosa|
3092618|NCT01941797|Active Comparator|periodontal mucosa|
3092619|NCT01941784|Experimental|Supportive care (health education program)|See Detailed Description.
3092620|NCT01941771|Active Comparator|Arm A|Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
3092621|NCT01941771|Experimental|Arm B|Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.
3092622|NCT01941758|Experimental|Basic science (trivalent influenza vaccine)|Patients receive trivalent influenza vaccine on day 1.
3092623|NCT01941745|Placebo Comparator|half normal saline|Single dose of half normal saline at 2 ml/kg given intratracheally times one dose
3092624|NCT01941745|Experimental|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)in 2 ml/kg given intratracheally times one dose
3092625|NCT01941745|Experimental|High dose rhCC10|5 mg/kg of rhCC10 given in 2 ml/kg and administered intratracheally times one dose
3092626|NCT01941732|Experimental|Sildenafil|motor function to be tested before and after challenge with 100 mg sildenafil after taking normal anti-PD medication, and Again after discontinuation of anti-PD medication for 12 h
3092627|NCT01941719|Experimental|enhanced foot care education|Importance of daily foot self-care was reinforced at based by viewing personal barefoot plantar pressure in gait
3092628|NCT01941719|Active Comparator|Standard Foot Care Education|
3092629|NCT01941706|Experimental|Project UPLIFT (Treatment)|Participants randomly assigned to the Treatment group receive the UPLIFT Intervention immediately after completing the Baseline Assessment. Participants can chose to participate in the Web- or phone-delivery of UPLIFT.
3092630|NCT01941706|Experimental|Project UPLIFT (TAU Waitlist Control)|Participants randomly assigned to the Treatment-as Usual (TAU) Waitlist Control group will also receive the UPLIFT intervention. However, TAU Waitlist Control participants will begin the Intervention 8 weeks after completing the Baseline Assessment. During the initial 8 weeks, participants in this group will continue whatever treatment they are currently undergoing to prevent or treat mild depressive symptoms. Participants can chose to participate in the Web- or phone-delivery of UPLIFT.
3092631|NCT01941693|Experimental|Integrated care|"Integrated care:~Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders."
3092632|NCT01941693|Active Comparator|Usual care|Usual care
3092633|NCT01941680||ZPI|Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week
3092634|NCT01941680||ZPI+CHOP-21|"Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week~CHOP-21 Day1 = day 21 (3 cycles)~Day 1 Cyclophosphamide : 750 mg/m2, Doxorubicine : 50 mg/m2, Vincristine : 1,4mg/m2, Prednisone : 100mg/day PO.~day 2-Day 5 Prednisone~1mg/kg/day PO."
3092635|NCT01941680||ZPI +DHAP-21|"Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week~DHAP Day 1= day 21 (3 cycles) Day 1 : Cisplatina 100 mg/m2 Day 2 and day 3 : Aracytine 2000mg/m2/day Day 1-day 4 : Dexamethasone 40mg"
3092636|NCT01941667|Experimental|Daily Messages, virtual home visits|"Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level~Daily messages requesting weight, intake, pulse ox and pulse are automated~Virtual home visits occur twice weekly where the investigators see the infant and families."
3092637|NCT01941667|Placebo Comparator|Usual Care|Infants will have usual care as defined by cardiology.
3092638|NCT01941654|Experimental|preemptive local ablative therapy|
3092640|NCT01941628|Experimental|Rocuronium|In this group rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
3092641|NCT01941628|Active Comparator|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
3092642|NCT01941615|Experimental|BI 207127 + faldaprevir + Microgynon|Period A: Microgynon®; Period B: Microgynon® + FDV + BI 207127
3092643|NCT01941602||prophylactic|Prophylactic treatment with drugs to prevent venous thromboembolism in patients operated with open surgery for intracranial meningioma at the Department of neurosurgery at Karolinska Hospital, Stockholm, Sweden
3092644|NCT01941602||non-prophylactic|No use of prophylactic treatment with drugs to prevent venous thromboembolism in patients operated with open surgery for intracranial meningioma at the Departments of neurosurgery at University Hospital North Norway (UNN) and St.Olavs University Hospital (Tromsø and Trondheim respectively, both Norway)
3092645|NCT01941589|Active Comparator|present 5-ASA arm 1|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
3092646|NCT01941589|Active Comparator|5-ASA naive arm 1|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
3092647|NCT01941589|Active Comparator|present 5-ASA arm 2|IV corticosteroids only / PO Methylprednisolone
3092648|NCT01941589|Active Comparator|5-ASA naive arm 2|IV corticosteroids only / PO Methylprednisolone
3092649|NCT01941576|Experimental|rhBNP Group|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a rhBNP infusion 24 hours after operation. The dose of recombinant human brain natriuretic peptide (rhBNP) will be 1.5 mcg/kg for loading, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.
3092650|NCT01941576|Placebo Comparator|Placebo Group|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
3092651|NCT01941563|Experimental|SI-6603|SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
3092652|NCT01941563|Sham Comparator|Control|Sham injection
3092653|NCT01941550|Other|Cabazitaxel chemotherapy|"Patients undergo 6 cycles Cabazitaxel chemotherapy. Cabazitaxel suspension is given once per cycle as infusion intravenously, 1 mg/square meter.~For max. 6 times at all."
3092654|NCT01941537|Experimental|ILV-094|Forty patients will be enrolled in the ILV-094 treatment arm. A loading IV dose of 600 mg of ILV-094 will be given at baseline (Day 0), followed by five additional IV doses of 300 mg of ILV-094 every two weeks (Weeks 2, 4, 6, 8, and 10).
3092655|NCT01941537|Placebo Comparator|Placebo comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
3092656|NCT01941524|Active Comparator|Poractant goup|Newborns, who will be monitored by amplitude integrated electroencephalography (aEEG) and near infrared spectroscopy (NIRS) during poractant instillation.
3092657|NCT01941524|Active Comparator|Beractant group|Newborns who will be monitored by aEEG and NIRS during beractant instillation
3092658|NCT01941511|Experimental|Rivipansel/Placebo/Moxifloxacin|Rivipansel 4.8 gA IV infusion over 20 minutes Phosphate Buffered Saline (PBS) IV infusion over 20 minutes Moxifloxacin (Avelox) 400 mg single oral dose
3092659|NCT01941498|Experimental|WaveLight Refractive Suite|LASIK surgery (laser in situ keratomileusis) per standard of care
3092660|NCT01941485|Experimental|WaveLight Refractive Suite|LASIK surgery (laser in situ keratomileusis) per standard of care
3092661|NCT01941472|Experimental|Septic shock|Adult patients (at least 18 years of age) with refractory hypotension secondary to sepsis who, at the discretion of treating physicians, required fluid challenge in the presence of invasive hemodynamic monitoring. Refractory hypotension was defined as need of vasopressors to maintain systolic blood pressure (SBP) no less than 90 mmHg despite adequate fluid resuscitation.
3092662|NCT01941459||1 Custodiol|Custodiol
3092663|NCT01941459||2 Blood cardioplegia|Blood cardioplegia
3092664|NCT01941446|Experimental|pre-generated treatment scheme|Treatment A: Eravacycline (TP-434) 1.5 mg/kg administered intravenously over 60 minutes and one placebo oral tablet
3092665|NCT01941446|Placebo Comparator|Pre-generated tratment scheme|Treatment B: Placebo (0.9% sodium chloride) administered intravenously over 60 minutes and one moxifloxacin 400 mg oral tablet
3092666|NCT01941446|Placebo Comparator|Moxifloxacin|Treatment C: Placebo (0.9% sodium chloride) administered intravenously over 60 minutes and one placebo oral tablet
3092667|NCT01941433|Experimental|Arthritis Health Journal|Participants in this group will use the Arthritis Health Journal in the first 6 months of study.
3092668|NCT01941433|Other|Control|Participants in this group will receive a delayed intervention. They will receive usual care for the first 6 months of study, during which time they will contribute control data, and they will use the Arthritis Health Journal in the second 6 months of study, during which time they will contribute intervention data.
3092669|NCT01941420||1 Blood cardioplegia|Blood cardioplegia
3092670|NCT01941420||2 Crytalloid Cardioplegia|Crytalloid Cardioplegia
3092671|NCT01941407|Experimental|Association eribulin and bevacizumab|Drug: eribulin 1,23mg/m²; d1 and d8 in IV, all 3 weeks until 6 cycles or progression Drug: bevacizumab 15m/kg ; d1 in IV, all 3 weeks until 6 cycles or progression or toxicity
3092672|NCT01941394|Experimental|With MSC|infusion of Mesenchymal stem cells at dose 1 mln cells per kg
3092673|NCT01941394|No Intervention|Without MSC|Without MSC infusion
3092674|NCT01941381||Type B tympanogram|Patients with a clinical diagnosis of acute otitis media and a B type curve with tympanometry.
3092675|NCT01941381||Type A/C tympanogram|Patients with a clinical diagnosis of acute otitis media and a type A or C curve with tympanometry
3092676|NCT01941368|No Intervention|Control|Individuals assigned to Control Group will undergo baseline testing and then be asked to continue their normal exercise routine for 4 weeks and will undergo post-testing (visits 16 and 17) after this time period.
3092746|NCT01940952|Placebo Comparator|Placebo|Placebo + Donepezil 5mg or 10mg
3092677|NCT01941368|Placebo Comparator|Placebo + High-Intesnity Interval Training (HIIT)|On training days, individuals will consume 1 gram of placebo 30 min prior to training, 1gram placebo 1 hour post training, and 1gram placebo 3 hours post training. On non-training days, individuals will consume placebo 3 times per day (8am, 12pm and 4pm).
3092678|NCT01941368|Active Comparator|HMB-FA + HIIT|On training days, individuals will consume 1 gram HMB-FA 30 min prior to training, 1gram HMB-FA 1 hour post training, and 1gram HMB-FA 3 hours post training. On non-training days, individuals will consume HMB-FA 3 times per day (8am, 12pm and 4pm).
3092679|NCT01941355|Experimental|Exercise training, psycho-educative|
3092680|NCT01941355|Experimental|Psycho-educative component|
3092681|NCT01941355|Experimental|Exercise training component|
3092682|NCT01941355|No Intervention|Usual care|
3092683|NCT01941342|Active Comparator|Pancreatoduodenectomy|Instant pancreatoduodenectomy within one week after diagnosis including: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract.
3092684|NCT01941342|Experimental|ENBD and Pancreatoduodenectomy|"Consistent ENBD (Endoscopic Nasobiliary Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
3092685|NCT01941342|Experimental|EBD and Pancreatoduodenectomy|"Consistent EBD (Endoscopic Biliary Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
3092686|NCT01941342|Experimental|PTCD and Pancreatoduodenectomy|"Consistent PTCD (Percutaneous Transhepatic Cholangial Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
3092687|NCT01941329|Experimental|Ranimizumab + Panretinal photocoagulation (PRP)|3 Intravitreous injections of ranibizumab combined with standard PRP (2 ± 1 weeks after injection), at month-0, month-1 and month-2 that can be repeated after month-3, with always at least 1 month of interval between injections.
3092688|NCT01941329|Active Comparator|Panretinal photocoagulation (PRP)|"Panretinal photocoagulation treatment (PRP) between month-0 and month-2, with 1 mandatory laser session in month-0 and more laser sessions as needed until Month-2 to complete the PRP treatment.~After completing the PRP treatment, PRP sessions can be repeated from Month-3 to Month-11."
3092689|NCT01941316|Experimental|Phase II|"Phase II: Stratified, single arm trial using a starting dose of 20/36 mg/m2 of carfilzomib and 125 mg/m2 of irinotecan, in small cell lung cancer patients who have relapsed on a prior platinum regimen.~Stratification for phase II component:~Platinum sensitive disease: initial response to platinum-based chemotherapy with progression > 90 days after last treatment.~Platinum refractory disease: No response to platinum-based chemotherapy or progression within 90 days of completing platinum-based therapy. Subjects that progressed during or within one month of completion of platinum-based chemotherapy will be excluded."
3092690|NCT01941303||Advanced stage non-small cell lung cancer patients|
3092691|NCT01941290||Orsiro|
3092692|NCT01941277|Experimental|Intensive Exercise Group|Behavioral
3092693|NCT01941277|Experimental|Current Recommendations Exercise Group|Behavioral
3092694|NCT01941264|Active Comparator|community based screening and treatment|CHWs will identify pregnant women in the village and encourage to go to the antenatal care clinic, furthermore, once a month the community health worker will screen the pregnant women for malaria with a rapid diagnostic test and treat with artemether-lumefantrine in case of a positive test result.
3092695|NCT01941264|No Intervention|Control|All pregnant women will be identified in the study area and asked for participation to the study. No intervention will take place.
3092696|NCT01941251|Active Comparator|Navigated individualized αTMS|navigated Transcranial Magnetic Stimulation
3092697|NCT01941251|Sham Comparator|Sham TMS|navigated Transcranial Magnetic Stimulation using sham coil
3092698|NCT01941238||Insulin pump|
3092699|NCT01941238||MDI|
3092700|NCT01941225|Placebo Comparator|Placebo|Nebulized normal saline. Single administration
3092701|NCT01941225|Experimental|Inhaled iloprost 5.0 mcg|Single administration
3092702|NCT01941212|Active Comparator|Music therapy and Behavioral therapy|Music and behavioral therapy
3092703|NCT01941212|Active Comparator|Music only|Music therapy without behavioral therapy
3092704|NCT01941212|No Intervention|Control|Patients will not listen to music neither will get music therapy
3092705|NCT01941199|Experimental|D → M → D+M|D : DA-1229 5mg qd, M : metformin 1000mg bid
3092706|NCT01941199|Experimental|D → D+M → M|D : DA-1229 5mg qd, M : metformin 1000mg bid
3092707|NCT01941199|Experimental|M → D → D+M|D : DA-1229 5mg qd, M : metformin 1000mg bid
3092708|NCT01941199|Experimental|M → D+M → D|D : DA-1229 5mg qd, M : metformin 1000mg bid
3092709|NCT01941199|Experimental|D+M → M → D|D : DA-1229 5mg qd, M : metformin 1000mg bid
3092710|NCT01941199|Experimental|D+M → D → M|D : DA-1229 5mg qd, M : metformin 1000mg bid
3092711|NCT01941186|Experimental|Patient Decision Aid|After positive screen for a developmental concern the intervention group will receive the Patient Decision Aid (PDA), as well as, a text message reminder to follow up with Early Intervention.
3092712|NCT01941186|No Intervention|Routine Care|After screening positive for a potential development delay those in the control arm will receive routine care, in this case, a handout explaining Early Intervention services.
3092713|NCT01941173|Experimental|Treatment (ziv-aflibercept, FOLFIRI)|Patients receive ziv-aflibercept IV over 15-30 minutes followed by FOLFIFRI chemotherapy comprising leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
3092714|NCT01941160|Experimental|Amoxicillin/Clavulanic Acid and Lacidofil® STRONG|Participants are provided in double blinded fashion Lacidofil® STRONG to take with antibiotics
3092747|NCT01940952|Active Comparator|Zydena 100mg|Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg
3092715|NCT01941160|Placebo Comparator|Placebo|Participants are provided in double blinded fashion placebo to take with antibiotics
3092716|NCT01941147|Experimental|Pulsed ELF-MF|Nine patients will be treated daily for 5 consecutive days, starting within 48 h from the onset of stroke. Three dose cohorts of three patients each, will be stimulated with pulsed ELF-MF at increasing daily exposure (45, 120, 240 min).
3092717|NCT01941134|Experimental|Gastric bypass COC|"This is a before-and-after comparison. Women will enroll prior to planned gastric bypass surgery and complete one cycle of oral contraceptive use and evaluation. There will then be no more study procedures/interventions until 3-4 months after surgery. At that time, women will complete the second cycle of OC use and evaluation. Study participation is then complete.~Intervention: Ethinyl estradiol-levonorgestrel(EE 20mcg/LNG 150mcg)"
3092718|NCT01941121|Experimental|Linkage to PrEP or Care|Subjects screened for HIV at any CCTG consortium site will be offered Linkage to PrEP or Care, depending on HIV status. After results are received, HIV testers will obtain verbal consent from the subject to connect with the ALERT Specialist, or otherwise offer the subject the ALERT Specialist contact information. When contacted, the ALERT Specialist will coordinate with the subject the scheduling of the PrEP or Care visit, and remain in contact to ensure linkage.
3092719|NCT01941108|No Intervention|Standard HIV Care Arm|Patients in the standard HIV care arm will be escorted to their first HIV care appointment at the Moore Clinic at Johns Hopkins University Hospital. They will not receive any additional intervention regarding their care after that. Participants in this arm will be followed up by the study coordinator every 3 months for 9 months.
3092720|NCT01941108|Experimental|Peer Navigation Arm|Patients in the peer navigation arm will be escorted to their first HIV care appointment at the Moore Clinic at Johns Hopkins University Hospital. They will be assigned to a peer navigator who can assist them in overcoming obstacles to their HIV care. They will be given a smartphone with specialized software to help with their navigation. Participants in this arm will be followed up by the study coordinator every 3 months for 9 months and interact with their navigator when necessary.
3092721|NCT01941095|Experimental|Tocilizumab|Participants will receive tocilizumab 162 milligrams (mg) SC injection once a week (QW) either as monotherapy or in combination with methotrexate or other non-biologic DMARDs during the treatment period of 52 weeks. The choice of monotherapy or combination treatment is according to the physician's judgment up to Week 24. Depending upon the participant's response to study regimen, they may either continue/discontinue/switch to tocilizumab monotherapy or may lead to intensification of methotrexate/non-biologic DMARDs with tocilizumab at a fixed dose of 162 mg SC QW till Week 52. Participants who will complete the treatment phase before tocilizumab is commercially available will enter an extension phase until tocilizumab is commercially available in Greece. Permitted DMARDs include methotrexate, azathioprine, chloroquine, hydroxychloroquine, leflunomide, and sulfasalazine.
3092722|NCT01941082|Experimental|Part A: RO6867461|Single doses
3092723|NCT01941082|Experimental|Part B: RO6867461|Multiple doses
3092724|NCT01941069|Active Comparator|Internalizing Disorders|Students identified as being at-risk for or meeting criteria for Internalizing Disorders will assigned to this intervention arm. They will receive the FRIENDS for Life intervention. FRIENDS is a group Cognitive Behavioral Therapy (CBT) intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
3092725|NCT01941069|Active Comparator|Externalizing Disorders|Students identified as being at-risk for or meeting criteria for Externalizing Disorders will be assigned to this intervention arm. They will receive the Coping Power Program (CPP) intervention. CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
3092726|NCT01941056|Experimental|Treatment (CMV-MVA Triplex vaccine)|Participants receive multi-CMV epitope modified vaccinia Ankara vaccine IM followed by a booster injection 28 days later in the absence of unacceptable toxicity.
3092727|NCT01941043|Experimental|CERC-301, Treatment Sequence 1|Treatment Sequence 1 - 7 days on placebo and 28 days on study drug (either 12mg or 8mg)
3092728|NCT01941043|Experimental|CERC-301, Treatment Sequence 2|Treatment Sequence 2 - Placebo for 7 days and study drug for 28 days (8 mgs)
3092729|NCT01941043|Placebo Comparator|Placebo, Treatment Sequence 3|Treatment Sequence 3 - Placebo for 35 Day treatment period
3092730|NCT01941030|Experimental|Orbital Atherectomy System|Orbital Atherectomy (OA) is performed prior to adjunctive Balloon Angioplasty (BA)
3092731|NCT01941030|Active Comparator|Balloon Angioplasty|Balloon Angioplasty (BA) alone
3092732|NCT01941017||Minimal or mild endometriosis|Patients with minimal or mild endometriosis diagnosed via laparoscopy.
3092733|NCT01941017||Tubal obstruction without endometriosis|Patients with tubal obstruction due to infection or adhesion with absent evidence for endometriosis on laparoscopy
3092734|NCT01941004|Experimental|double blinded Fingolimod 6 mos + open label fingolimod 6 mos|Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
3092735|NCT01941004|Placebo Comparator|Placebo 6 mos + open label fingolimod 6 mos|Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
3092736|NCT01940991|Placebo Comparator|Dose B|Dose B: Placebo
3092737|NCT01940991|Experimental|Dose A|Dose A: Botulinum Toxin Type A
3092738|NCT01940978|Placebo Comparator|Control|Methylphenidate ER QD placebo BID
3092739|NCT01940978|Active Comparator|Methylphenidate ER, cyproheptadine 2.5mg|Methylphenidate ER QD cyproheptadine hydrochloride 2.5mg BID
3092740|NCT01940978|Active Comparator|Methylphenidate ER, cyproheptadine 5mg|Methylphenidate ER QD cyproheptadine hydrochloride 5.0mg BID
3092741|NCT01940965|Experimental|Lixisenatide + Biguanide|52-week treatment with Lixisenatide in combination with biguanide (usual maintenance dose in the label)
3092742|NCT01940965|Experimental|Lixisenatide + TZD|52-week treatment with lixisenatide in combination with TZD (usual maintenance dose in the label)
3092743|NCT01940965|Experimental|Lixisenatide + alpha-GI|52-week treatment with Lixisenatide in combination with alpha-GI (usual maintenance dose in the label)
3092744|NCT01940965|Experimental|Lixisenatide + Glinide|52-week treatment with Lixisenatide in combination with glinide (usual maintenance dose in the label)
3092748|NCT01940939|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 80% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 100 stimulation trains of 20 stimuli each (i.e., 2000 stimuli) and an intertrain interval of 9 sec. Treatment will be applied in sequential order to the left dorsolateral prefrontal cortex (DLPFC). Intervention: Device: Repetitive Transcranial Magnetic Stimulation
3092749|NCT01940939|Sham Comparator|Sham rTMS|Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but the coil will be reversed. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
3092750|NCT01940926|Experimental|68Ga-BNOTA-PRGD2|In patients with RA, single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 will be given at 30 minutes before PET/CT scanning to determine 68Ga-BNOTA-PRGD2 uptake in joints.
3092751|NCT01940913|Active Comparator|Probiotics|
3092752|NCT01940913|Placebo Comparator|Placebo|
3092753|NCT01940900|Experimental|E10030 + ranibizumab|E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection
3092754|NCT01940900|Active Comparator|Sham + ranibizumab|E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection
3092755|NCT01940887|Experimental|E10030 + bevacizumab or aflibercept|E10030 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection
3092756|NCT01940887|Active Comparator|Sham + bevacizumab or aflibercept|E10030 sham intravitreal injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection
3092757|NCT01940874||Cerebral oximetry|
3092758|NCT01940861||Traumatic brain injury|
3092759|NCT01940848|Experimental|STW5|2/3 patients with irritable bowel syndrome will be randomized in this arm
3092760|NCT01940848|Placebo Comparator|Placebo|1/3 patients with irritable bowel syndrome will be randomized in this arm
3092761|NCT01940835||Type 1 Diabetes|Subjects will have an upper endoscopy with small bowel biopsies and brushings. Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC). Stool samples will be collected at baseline for future microbiome and virome studies.
3092762|NCT01940835||Healthy Control Group|Subjects will have an upper endoscopy with small bowel biopsies and brushings. Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC). Stool samples will be collected at baseline for future microbiome and virome studies.
3092763|NCT01940822|Experimental|Energy drink first, then placebo drink|Participants will receive an energy drink at the first study visit, and a placebo drink at the second study visit.
3092764|NCT01940822|Experimental|Placebo drink first, then energy drink|Participants will receive a placebo drink at the first study visit and an Energy Drink at the second study visit.
3092765|NCT01940809|Experimental|Arm A1 (ipilimumab, dabrafenib, trametinib)|Patients receive dabrafenib PO BID and trametinib PO QD for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
3092766|NCT01940809|Experimental|Arm A2 (dabrafenib, trametinib, nivolumab, ipilimumab)|Patients receive dabrafenib PO BID and trametinib PO QD for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
3092767|NCT01940809|Experimental|Arm B1 (ipilimumab, trametinib)|Patients receive trametinib PO QD for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
3092768|NCT01940809|Experimental|Arm B2 (trametinib, nivolumab, ipilimumab)|Patients receive trametinib PO QD for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
3092769|NCT01940809|Experimental|Arm C1 (ipilimumab, dabrafenib)|Patients receive dabrafenib PO BID for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
3092770|NCT01940809|Experimental|Arm C2 (dabrafenib, nivolumab, ipilimumab)|Patients receive dabrafenib PO BID for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
3092771|NCT01940809|Experimental|Arm D1 (ipilimumab)|Patients receive ipilimumab IV over 90 minutes Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
3092772|NCT01940809|Experimental|Arm D2 (nivolumab, ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses
3092773|NCT01940796|Experimental|Brentuximab Vedotin|The dose of brentuximab Vedotin will be based on the cohort the participant is enrolled on. Dosing will be based on the participant's weight prior to each dose. Actual weight will be used except for participants weighing > 100 kg. The dose for participants weighing > 100 Kg will be calculated based on a weight of 100 kg. The dose should be rounded to the nearest whole number of milligrams. Brentuximab vedotin will be administered over approximately 30 minutes IV.Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
3092774|NCT01940783|Other|Intervention|All participants in the study will receive one pre-operative MRI, prior to cochlear implantation, and two cone-beam computed tomography scans, after cochlear implantation
3092775|NCT01940757|Experimental|25 Necator americanus Hookworm Larvae|
3092776|NCT01940757|Experimental|50 Necator americanus Hookworm Larvae|
3092777|NCT01940757|Experimental|75 Necator americanus Hookworm Larvae|
3092778|NCT01940744|Experimental|Prescriptive Mobilization|"The prescriptively applied non-thrust manipulation will be involve a central lumbar posterior-anterior directed at L4 and L5. The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Patients will be seen for 4 visits."
3092779|NCT01940744|Active Comparator|Pragmatic Mobilization|The pragmatically applied non-thrust manipulation will be based on the original concepts outlined by Maitland and will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
3092780|NCT01940731|Experimental|Colistimethate sodium|
3092781|NCT01940718|Experimental|Transdermal Testosterone|Transdermal Androgel 1.62% (20.25 mg testosterone = 1 pump actuations) to be applied once daily for 3.5 months. Initial dose will be at lowest level, 20.25 mg testosterone with dosing adjustments given in 20.25 mg testosterone increments.
3092782|NCT01940705|Active Comparator|Standard of care|standard of care hearing-aid orientation as provided by clinical audiologist
3092783|NCT01940705|Experimental|SoC plus hearing-aid informational guide|standard of care hearing-aid orientation as provided by clinical audiologist plus a take-home informational guide regarding their hearing aids
3092784|NCT01940705|Experimental|SoC plus a take-home DVD|standard of care hearing-aid orientation as provided by clinical audiologist plus a take-home DVD regarding hearing aids
3092785|NCT01940705|Experimental|SoC plus counseling with the teach-back technique|standard of care hearing-aid orientation as provided by clinical audiologist plus a teach-back technique counseling session reviewing information on the hearing aids
3092786|NCT01940692|Active Comparator|Intravenous tranexamic acid|Will receive 1.5g intravenous tranexamic acid preoperatively
3092787|NCT01940692|Experimental|Intra-articular tranexamic acid|Will receive 3g intra-articular tranexamic acid after wound closing
3092788|NCT01940679|Experimental|Fresh meat stick|Fresh meat stick w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.
3092789|NCT01940679|Experimental|Stored meat stick|Stored meat stick with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production
3092790|NCT01940679|Experimental|Fresh pound cake|Fresh pound cake w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.
3092791|NCT01940679|Experimental|Stored pound cake|Stored pound cake with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production.
3092792|NCT01940666||Controls|patients who have all androgens (TT, A4, FAI, and DHEA-S) lower than their cut-off values
3092793|NCT01940666||Total Testosterone >= 2.39|Patients who have only total testosterone higher than its cut-off value; (TT) >=2.39
3092794|NCT01940666||Androstenedione >= 2.99|Patients who have only androstenedione higher than its cut-off value; (A4) >=2.99
3092795|NCT01940666||Free Androgen Index >= 6.53|Patients who have only free androgen index higher than its cut-off value; (FAI) >=6.53
3092796|NCT01940666||DHEAs >= 181.55|Patients who have only dehyroepiandrosterone sulfate higher than its cut-off value; (DHEA-S)>=181.55
3092797|NCT01940653|Other|Progesterone|Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International). On the 5th (group A) of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
3092798|NCT01940653|Active Comparator|progesterone 3 days|Group B receives 3 days of micronized progesterone vaginally. On the 3rd day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
3092799|NCT01940640|Experimental|DHA supplementation|mothers consuming 900 mg DHA/day and their neonates.
3092800|NCT01940640|Active Comparator|Control|follow on capsules without probiotics
3092801|NCT01940627|Experimental|Ubiquinol|Firemen consuming 200 mg ubiquinol/day during two weeks
3092802|NCT01940627|Placebo Comparator|Control|Firemen consuming placebo capsules during two weeks
3092803|NCT01940601|Experimental|Balugrastim 300 ug/kg|Balugrastim 300 μg/kg subcutaneously (SC) administration once per chemotherapy cycle, approximately 24 h after chemotherapy, up to 4 cycles
3092804|NCT01940601|Experimental|Balugrastim 670 μg/kg|Balugrastim 670 μg/kg (maximum 40 mg) SC administration once per chemotherapy cycle, approximately 24 h after chemotherapy, up to 4 cycles
3092805|NCT01940601|Active Comparator|Filgrastim 5 μg/kg|Filgrastim will be administered at a dose of 5 μg/kg SC once a day for at least 5 consecutive days or until absolute neutrophil count (ANC) has returned to ≥2*10^9/L for each chemotherapy cycle up to 4 cycles. The maximum period of filgrastim administration is 14 days in each cycle.
3092806|NCT01940588||Neuropsychoanalytic treatment|Outpatient detoxification, intensive neuropsychoanalytic therapy, low dose naltrexone, monthly evaluations for six months - case series approach.
3092807|NCT01940575|Active Comparator|Restylane®|Inject Restylane® on right or left nasolabial fold
3092808|NCT01940575|Experimental|SkinPlus-Hyal®|Inject SkinPlus-Hyal® on right or left nasolabial fold
3092809|NCT01940562|Experimental|Eltrombopag|"Pediatric patients undergoing allogeneic UCB transplantation will receive eltrombopag from day +1 until platelet count has exceeded 50,000/microliter for 14 consecutive days without platelet transfusion.~Starting doses are 100 mg/d for children >40 kg body weight (BW), 50 mg/d for children 20-40 kg BW, and 2 mg/kg/d for children <20 kg BW.~If unsupported platelet count has not reached the threshold of 20,000/microliter, doses will be escalated every 2 weeks up to maximal doses of 200 mg/d for children ≥ 40 kg BW, 150 mg/d for children 20-40 kg BW and 3.5 mg/kg for children <20 kg BW."
3092810|NCT01940549|Sham Comparator|Trauma Focused Therapy + Sham tDCS|Trauma Focused Therapy will be conducted during the delivery of sham Transcranial Direct Current Stimulation
3092811|NCT01940549|Active Comparator|Trauma Focused Therapy + active tDCS|Trauma focused therapy will be conducted while active Transcranial Direct Current Stimulation is applied
3092812|NCT01940536|Active Comparator|Tranexamic Acid|1g tranexamic acid, intravenous, at time of sudy enrollment and again a surgical incision
3092813|NCT01940536|Placebo Comparator|Placebo Injection|Placebo injection (normal saline) a time of study enrollment and again at time of surgical incision
3092846|NCT01940315|Placebo Comparator|Placebo|0.5 mL dose of placebo will be administered intramuscularly (IM) given at Days 0, 28 ± 5 days, and 182 ± 9 days
3092847|NCT01940302|Experimental|LEHEL multi-nutrients supplement|75 g/d of LEHEL supplementation along with oral hypoglycemic agents such as glibenclamide and/or metformin.
3092814|NCT01940523|Active Comparator|Topical Tranexamic Acid|3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
3092815|NCT01940523|Active Comparator|Intravenous Tranexamic Acid|1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
3092816|NCT01940510|Experimental|Healthy subjects|
3092817|NCT01940497|Experimental|Trastuzumab (Vial)|Participants will receive trastuzumab 600 mg SC using a vial q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).
3092818|NCT01940497|Experimental|Trastuzumab (SID)|Participants will receive trastuzumab 600 mg SC using SID q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).
3092819|NCT01940484||Chronic Renal Anemia Participants|Participants with chronic kidney disease and who are on hemodialysis and on methoxy polyethylene glycol epoetin beta as per physician's discretion for treatment of chronic renal anemia will be observed for a period of 6-12 months.
3092820|NCT01940471|Experimental|TAF 25 mg|TAF + TDF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
3092821|NCT01940471|Active Comparator|TDF 300 mg|TDF + TAF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
3092822|NCT01940471|Experimental|Open-label TAF|All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study.
3092823|NCT01940445|Experimental|ResurFX treatment|Fractional Non Ablative (NA) treatment on one side of the face with the M22 ResurFX module
3092824|NCT01940445|Experimental|M22 ResurFX and QS treatment|Fractional NA treatment with the M22 ResurFX followed by Q-Switched (QS) laser treatment (SST) on one side of the face
3092825|NCT01940432|Experimental|electroacupuncture group|Bilateral BL33 are given acupuncture of 50-60mm with 30-45°angle to inward and downward. Bilateral BL35 are given acupuncture of 50-60mm to outward and upward. The electric stimulator is applied to bilateral BL33 and BL35.Every session lasts for 30 min per day.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all.
3092826|NCT01940432|Experimental|pelvic floor muscle training group|Standing/sitting/lying on back, knees bent to chest. A set consists of three contractions, each lasting 10s, with a 10s break between contractions. Counting or measuring the duration of contractions and breaks is accomplished without effort by taking advantage of the duration of normal breaths. As most men take about 10 breaths per minute, each breath can be used as 6s timing device.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all.
3092827|NCT01940419|Active Comparator|Tranexamic Acid|1g Tranexamic acid iv just before surgery
3092828|NCT01940419|Placebo Comparator|Placebo|sterile sodium chloride 9mg/ml iv
3092829|NCT01940406|Experimental|Stimulation procedure|Stimulation procedure
3092830|NCT01940393|Active Comparator|Cetirizine|Cetirizine
3092831|NCT01940393|Active Comparator|Desloratadine|desloratadine
3092832|NCT01940393|Active Comparator|Fexofenadine|Fexofenadine
3092833|NCT01940393|Active Comparator|Ebastine|ebastine
3092834|NCT01940393|Active Comparator|Bilastine|bilastine
3092835|NCT01940367|Active Comparator|PTNS Arm|Subjects randomized to the PTNS arm will undergo PTNS treatment once weekly for 30 minutes for 12 weeks total. If at 12 weeks they are considered to have a positive response to therapy, they will continue maintenance therapy in a tapered fashion: subjects will come in every 2 weeks for the next 8 weeks for 30 minute treatments (4 visits total), then every 3-4 weeks for 30 minute treatments for the remaining 32 weeks of the year (8-10 visits).
3092836|NCT01940367|Active Comparator|TENS Arm|Subjects randomized to the TENS arm of the study will begin therapy after their baseline evaluation is complete. They will be issued a home TENS device (EMPI TENS Select) and will administer self-treatment daily for 2 hours per day (1 hour in the morning and 1 hour in the evening) for a total of 12 weeks. If they are considered to have a positive response with TENS treatment, subjects will continue by weaning use over a three-month time period. They will begin with 3 x per week for 1 month, then 2 x per week for 1 month, then 1 x per week for 1 month, all at 2 hours per day.
3092837|NCT01940354|Experimental|Vascular access via study device|AccuCath IV Catheter System will be used for IV therapy during interventional radiology procedure. Intervention includes vascular access, fluid infusion, and blood sample removal.
3092838|NCT01940354|Active Comparator|Vascular access via control device|Conventional IV Catheter System (current catheter) will be used for IV therapy during interventional radiology procedure. Interventions include vascular access, administration of fluids, and blood sample removal.
3092839|NCT01940341|Experimental|TAF 25 mg|TAF + TDF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
3092840|NCT01940341|Active Comparator|TDF 300 mg|TDF + TAF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
3092841|NCT01940341|Experimental|Open-label TAF|All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study.
3092842|NCT01940328||Decompensated CHF|patients with acute pulmonary congestion or pulmonary edema
3092843|NCT01940328||Compensated CHF|patients with significant stable left HF (NYHA II-III) who are on optimal medical treatment for CHF, and are without clinical or laboratory evidence of pulmonary congestion
3092844|NCT01940328||Non CHF patients|patients without CHF and without uncontrolled hypertension.
3092845|NCT01940315|Active Comparator|rBV A/B|0.5 mL dose of rBV A/B (40 µg) will be administered intramuscularly (IM) in a three-dose dosing schedule given at Days 0, 28 ± 5 days, and 182 ± 9 days
3092848|NCT01940302|No Intervention|Control|Received only oral hypoglycemic agents.
3092849|NCT01940289|Active Comparator|asymptomatic subjects attending podiatry clinic for nail care|Algometric meter readings for perception of pain These subjects will have an algometric pressure threshold meter reading taken during their routine treatment visit to establish Algometric meter readings for perception of pain
3092850|NCT01940289|Active Comparator|forefoot pain|Algometric meter readings for perception of pain forefoot pain severity measured by both VAS and algometric pressure meter
3092851|NCT01940276|Experimental|Abiraterone Acetate and Prednisone|abiraterone acetate will be administered by the patient at a dose of 1000mg orally once daily with prednisone 5 mg BID in 4-week cycles
3092852|NCT01940263|Placebo Comparator|Placebo|placebo 320 mg daily for twelve weeks
3092853|NCT01940263|Experimental|Anthocyanin|Drug: MEDOX (natural purified anthocyanin) anthocyanin 320 mg daily for twelve weeks.
3092854|NCT01940250|Placebo Comparator|Sterile water|"Sterile water will be packaged identically to the active comparator.~Each patient randomized to the placebo arm of the trial will receive a loading dose of 0.5ml/kg intravenous over 20 minutes , followed by a maintenance dose of 0.3 ml/kg/hr to 0.5 ml/kg/hr randomly adjusted by an independent doctor to mimic adjustments made in the active comparator arm for 72 hrs."
3092855|NCT01940250|Active Comparator|Magnesium sulphate|"Each patient randomized to the treatment arm of the trial will receive a loading dose of 50mg/kg intravenous over 20 minutes (0.5ml/kg), followed by a maintenance dose of 30-50 mg/kg/hr (0.3 ml/kg/hr to 0.5 ml/kg/hr) for 72 hrs.~The maintenance dose will be determined by increasing the loading infusion dose 0.1 ml/kg/hr (10mg/kg/hr) every 15 minutes to a maximum dose of 0.5 ml/kg/hr (50 mg/kg/hr), with the following caveats:~If the systolic BP decreases to < 90th percentile for age, gender and length the dose will be reduced by 1 stage every 15 mins~If the systolic BP increases to the levels detailed in the study protocol for treatment failure, action will be taken as indicated~If the systolic BP decrease rapidly more than 25% over 15 minutes~If the plasma Mg level > 2.5 mmol/l or < 1.8 mmol/l a 25% increase or decrease in the infusion rate will be implemented as appropriate."
3092856|NCT01940237|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal psychotherapy (IPT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) in several controlled trials. This study will test the efficacy of IPT in a group of prostate, colorectal, lung and pancreatic cancer patients with a diagnosis of major depressive disorder.
3092857|NCT01940224|Active Comparator|Pregabalin & Morphine|Administration of pregabalin 300 mg to patients undergo laparoscopic colorectal surgery.Patients receive oral Pregabalin 150 mg the night before surgery, and another one dose of 150 mg 1 hour prior to surgery. Postoperative administration of morphine via PCA pump for 48 hours
3092858|NCT01940224|Placebo Comparator|Placebo & Morphine|Administration of placebo to patients undergo laparoscopic colorectal surgery.Patients receive oral Placebo the night before surgery, and another one dose 1 hour prior to surgery.Postoperative administration of morphine via PCA pump for 48 hours
3092859|NCT01940185||LINX device|Patients implanted with the LINX® Reflux Management System.
3092860|NCT01940172|Experimental|Birinapant with Conatumumab|
3092861|NCT01940159|Active Comparator|Active Comparator: SEP-363856|Dosing will be initiated at 25 mg SEP-363856 as a single oral dose. Subsequent cohorts will be dosed at 50, 100, and 150 mg of SEP-363856
3092862|NCT01940159|Placebo Comparator|Placebo|Matched placebo.
3092863|NCT01940146|Placebo Comparator|SPARC Placebo|
3092864|NCT01940146|Experimental|SPARC1310 I|
3092865|NCT01940146|Experimental|SPARC1310 II|
3092866|NCT01940146|Experimental|SPARC1310 III|
3092867|NCT01940133|Experimental|PQR309|Different dose evaluation
3092868|NCT01940120|Experimental|High Risk Registry Arm|Includes patients with a predicted procedural mortality of 12% or higher. The high risk registry arm of the study is powered to show superiority of safety of treatment with the MitraClip compared to mitral valve surgery. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip implant.
3092869|NCT01940107|Other|Control Group (CG)|Control Group, which were subjected only to evaluations and to no exercise
3092870|NCT01940107|Experimental|Study Group (SG)|Study group (SG), was oriented to perform domiciliary exercises for the upper limbs.
3092871|NCT01940094|Experimental|5 mg Prednisone|Subjects will be randomized to a prednisone dose of 5 mg per day for a 6 month period.
3092872|NCT01940094|Experimental|0 mg Prednisone|Subjects will be randomized to taper their prednisone dose from 5 mg per day to 0 mg per day for a 6 month period.
3092873|NCT01940081||Group A: Nonischemic cardiomyopathy - not admitted for surgery|"Patients with nonischemic cardiomyopathy with:~documented ventricular arrhythmia or~suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or~high risk for ventricular arrhythmia (LVEF ≤ 35%) or~intermediate risk for ventricular arrhythmia (LVEF ≤ 50% and late enhancement on contrast-enhanced MRI)~who are not admitted for cardiac surgery"
3092874|NCT01940081||Group B: Nonischemic cardiomyopathy -admitted for surgery|"Patients with nonischemic cardiomyopathy with:~documented ventricular arrhythmia or~suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or~high risk for ventricular arrhythmia (LVEF ≤ 35%)~who are admitted for cardiac surgery (e.g., mitral valve annuloplasty or CorCap)"
3092875|NCT01940081||Group C: Controls|"Patients without nonischemic cardiomyopathy (controls) who are admitted for:~Coronary artery bypass graft surgery and who do not have prior myocardial infarction~Aortic valve replacement"
3092876|NCT01940068|Experimental|New Thickened Amino acid based formula|
3092877|NCT01940068|Active Comparator|Amino acid based formula|
3092878|NCT01940055|Experimental|Experimental group|Dual Task Treadmill Walking Exercise Program
3092879|NCT01940055|Active Comparator|Control group|Dual task recumbent cycling exercise program
3092880|NCT01940042|Experimental|maneuver group|In the intervention group, CO2 was removed by means of Trendelenburg position (30 degrees) and a pulmonary recruitment maneuver consisting of five manual inflations of the lung.
3092881|NCT01940042|No Intervention|clasical group|no additional action will be taken after the operation
3092882|NCT01940016|Experimental|Arm I (health coach)|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and from a health coach. Participants in this arm of the study, interacted with the IVR system and had the option of interacting with the health coach.
3092883|NCT01940016|Active Comparator|Arm II (no coach condition)|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system. Participants in this arm of the study only interacted with the IVR system.
3092884|NCT01940003|No Intervention|Control|Usual care of service Institute of Medicine Professor Fernando Figueira(IMIP) prenatal
3092885|NCT01940003|Experimental|Aquatic exercise|Pool-based exercise classes will be completed in groups of 4 to 6 participants under the instruction of a physiotherapist. The exercise program will be conducted three times per week and each session lasting 45 minute. This will be conducted since GDM diagnosis (26-28th gestational week) to the end of the third trimester (38-39th gestational week). Thus, an average of 30 training sessions will be planned for each pregnant woman.
3092886|NCT01939990|Active Comparator|Nebivolol|Group A will be given Nebivolol 5 to 10mg per day
3092887|NCT01939990|Placebo Comparator|Placebo|Group B will be given Placebo.
3092888|NCT01939977|Experimental|Paricalcitol|Paricalcitol oral capsules.
3092889|NCT01939977|Active Comparator|Calcifediol|Calcifediol oral drops.
3092890|NCT01939964|Active Comparator|Activation Mist|Liquid mist preparation to be sprayed topically on wrinkle areas
3092891|NCT01939964|Placebo Comparator|Placebo|sugar pill
3092892|NCT01939951|Active Comparator|Activation Energy Serum|Activation Energy Serum 7 or 21 drops twice daily for 4 weeks
3092893|NCT01939951|Placebo Comparator|Placebo|sugar pill
3092894|NCT01939938|Experimental|All Subjects-Nasal and Oronasal PAP Mask|Each subject will be imaged in a dynamic MRI with both a oronasal and nasal mask at pressures of 5, 10, and 15 cm of H2O.
3092895|NCT01939925|Experimental|New plain language summary format|New plain language summary format of a Cochrane systematic review
3092896|NCT01939925|Active Comparator|Current plain language summary format|Plain Language Summary format for the public currently in use in Cochrane systematic reviews
3092897|NCT01939912|Experimental|Stimulation of carotid body chemoreceptors|Adenosine boluses will be administered through an intravascular catheter used to administer the contrast agent during the carotid artery arteriography.
3092898|NCT01939899|Experimental|IXAZOMIB|
3092899|NCT01939886|Experimental|Artemether- Lumefantrine|Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h [+/-90 min] after the initiation of treatment). AL is currently the first line treatment in Tanzania Other Name: Coartem;
3092900|NCT01939886|Active Comparator|Drug: Mefloquine-Artesunate, an alternative ACT|Treatment with the paediatric fixed dose combination Mefloquine-Artesunate (MQ-AS; Artequin; Mepha, Aesch, Basel, Switzerland, artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, given in three daily doses. The weight range of enrolled children is chosen to be recommended for this fixed dose combination. MQ-AS is available in Kenya as Artequin and has been extensively tested in uncomplicated malaria in children.
3092901|NCT01939873|Experimental|KRISTELLER|Uterine fundal pressure
3092902|NCT01939873|No Intervention|Control group|
3092903|NCT01939860|No Intervention|Usual pharmacy care|Participants will not receive any structured written education on hypertension and its treatment
3092904|NCT01939860|Experimental|usual pharmacy care plus structured information|Participants will be provided with validated verbal and written information on hypertension and its treatment, including information about class (es) of anti-hypertensive medication(s) used by each patient, and their common side-effects. The written material will be based on validated patient information leaflets from the British Heart Foundation and the Blood Pressure Association.
3092905|NCT01939847|Experimental|Molecular prolfiling in tissue|Participant's tumor will be analyzed by Foundation Medicine on their FoundationOne platform - a targeted whole exome sequencing of 182 cancer related genes (3,230 exons) as well as 37 introns from 14 genes commonly rearranged or altered in cancer via next-generation sequencing technology to provide a molecular profile for a possible treatment suggestion
3092906|NCT01939847|No Intervention|Molecular prolfiling in blood|Participant's blood sample will be analyzed by Foundation Medicine on their FoundationOne platform - a targeted whole exome sequencing of 182 cancer related genes (3,230 exons) as well as 37 introns from 14 genes commonly rearranged or altered in cancer via next-generation sequencing technology; however, this is just being done to see if it is possible to generate similar results in blood samples. We do not yet know if blood sample results may be used for treatment decision (this will be tested in a future study) and results will not be given to participants; therefore, no treatment suggestion will be given.
3092907|NCT01939834|Experimental|AAA Control|"Subjects will use their home insulin pump along with a continuous glucose monitor (CGM) receiver. A CGM will be worn for 7 days prior to the study admission. Four fingersticks completed each day and carbohydrates will be recorded in bolus calculator of their insulin pump prior to each meal.~Subjects will be asked to provide the study team their insulin pump data on Day 2 or 3 to ensure accuracy of data collection. Subjects will be asked to submit insulin pump, glucometer, and CGM data 1-2 days prior to their admission and again the evening prior to the study admission at a Research House.~During the Experimental Admission, the AAA system will be tested using the DiAs platform. Subjects will participate in 45 minutes of exercise during the 40 hour admission (n=36). A subset (n=5-7) will continue with 5 nights of consecutive closed loop control (23:00-07:00)."
3092908|NCT01939834|Active Comparator|CGM + insulin pump at home|"The experimental and control admissions (40hr admissions) are exactly the same except for the study admission. During the Control Admission, subjects will use their home insulin pump along with a continuous glucose monitor receiver without running any specialized mathematical equations.~The active comparator for subjects participating in 5 consecutive nights of closed loop control will be the sensor-augmented pump therapy at home."
3092909|NCT01939821|Experimental|Educational and counselling program|In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach
3092910|NCT01939821|Active Comparator|Educational program|The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level.
3092911|NCT01939821|No Intervention|Control group|The control group will not receive any educational program. It represents the present real life in nursing homes.
3110521|NCT01819857|Active Comparator|Droperidol 0.625 mg intravenously|
3092912|NCT01939808|Other|Wrist splinted in extended position|We propose to carry out a study to compare the outcomes (grip strength and range of movement) of flexor tendon repair in two groups of patients: one with wrists splinted in a neutral position and the other splinted in an extended position during their postoperative rehabilitation
3092913|NCT01939808|Other|Wrist Splinted in the Neutral postion|We propose to carry out a study to compare the outcomes (grip strength and range of movement) of flexor tendon repair in two groups of patients: one with wrists splinted in a neutral position and the other splinted in an extended position during their postoperative rehabilitation
3092914|NCT01939795|No Intervention|Healthy People|Control group
3092915|NCT01939795|Experimental|Untrained CRT|Untrained CRT patients
3092916|NCT01939795|Experimental|Exercise trained + CRT|Exercise-trained CRT patients
3092917|NCT01939782|Experimental|Type 2 diabetic patients (T2D)|"In type 2 diabetic patients (T2D), the investigators will evaluate the metabolic clock gene expression in PBC and serum glucose, insulin, triglycerides, free fatty acids (FFA), cortisol intact GLP-1, triglycerides ,cortisol, plasma free fatty acids (FFA l and DPP4 plasma activity in two different occasions:~No Breakfast (NoB): fasting until lunch at 12:00~Yes Breakfast (YesB): eating breakfast at 8:30 and lunch at 12:00 In both occasions the blood samples for glucose and insulin, cortisol and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch)."
3092918|NCT01939782|Active Comparator|Healthy No Diabetics|"In healthy No Diabetics,: the investigators will evaluate the metabolic clock gene expression in PBC and serum glucose, insulin, triglycerides, free fatty acids (FFA), cortisol intact GLP-1, triglycerides ,cortisol, plasma free fatty acids (FFA l and DPP4 plasma activity in two different occasions:~No Breakfast (NoB): fasting until lunch at 12:00~Yes Breakfast (YesB): eating breakfast at 8:30 and lunch at 12:00 In both occasions the blood samples for glucose and insulin, cortisol and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch)."
3092919|NCT01939756|Experimental|Intravesical baobab oil|Intravesical instillation of 50 ml sterile Baobab natural oil. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 60 min, followed by emptying of the bladder and removal of the catheter.
3092920|NCT01939743|Experimental|diclofenac suppository plus lidocaine gel|Intervention Drug with local anaesthetic
3092921|NCT01939743|Other|Lidocaine gel only|Used as local aneaethetic as a part of institutional prostate biopsy protocol
3092922|NCT01939730|Experimental|Rituximab + GM-CSF|All patients receive one (1) course of therapy consisting of four (4) doses of rituximab, a single dose 375 mg/m^2 administered once weekly for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly (tiw) for 8 weeks, starting 1 hour before the first dose of rituximab. In selected cases, the GM-CSF starts 1 week before, or 1 day after, the first rituximab dose.
3092923|NCT01939717|Other|Dance group|Participants allocated to this group will continue with their usual care and participate in a set dancing class.
3092924|NCT01939717|No Intervention|Control group|Participants allocated to this group will act as a control group and continue to receive their usual care only.
3092925|NCT01939704|No Intervention|Pediatric Primary Care Control|Baseline survey with a social needs assessment, health care status, health care satisfaction and health care utilization assessment and two telephone-based follow up surveys at 3 and 6 months.
3092926|NCT01939704|No Intervention|Pediatric Urgent Care Control|Baseline survey with a social needs assessment, health care status, health care satisfaction and health care utilization assessment and two telephone-based follow up surveys at 3 and 6 months.
3092927|NCT01939704|Experimental|Pediatric Primary Care Intervention|Baseline survey that includes social needs assessment, health care status, health care satisfaction and health care utilization assessment; 30 minute on-site intervention, twice monthly follow-up phone calls for up to 3 months to help address social needs
3092928|NCT01939704|Experimental|Pediatric Urgent Care Intervention|Baseline survey that includes social needs assessment, health care status, health care satisfaction and health care utilization assessment; 30 minute on-site intervention, twice monthly follow-up phone calls for up to 3 months to help address social needs
3092929|NCT01939691|Experimental|Difluprednate|Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
3092930|NCT01939691|Experimental|Nepafenac plus Prednisolone acetate|Nepafenac 0.1% 3 times a day until resolution; prednisolone acetate 1% 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at Week 4, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until Week 6, then decrease to 1 drop per day until Week 8, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
3092931|NCT01939691|Experimental|Difluprednate plus Nepafenac|Nepafenac 0.1% 3 times a day until resolution; Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
3092932|NCT01939665|Experimental|Irreversible electroporation|Single arm study: Percutaneous irreversible electroporation of locally advanced pancreatic carcinoma
3092933|NCT01939652|Active Comparator|Drag: Crystalloids and Colloids|Drag: Crystalloids and Colloids Intraoperative 10 ml/kg/per hour, postoperative 70-100 ml/per hour
3092934|NCT01939652|Experimental|Standard fluid regime|Drag: Crystalloids and Colloids Intraoperative 15 ml/kg/per hour, postoperative 150-200 ml/per hour
3092935|NCT01939639|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 30 min prior to the experiment
3092936|NCT01939639|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
3092937|NCT01939626|Experimental|Single-step medium|embryos will be cultured in a single-step medium for 5 days with no change
3092938|NCT01939613||Parkland group|Extensive burn patients are resuscitated with Parkland formula.In the first 24h of resuscitation,crystalloids were infused as the main fluid.
3092939|NCT01939613||TMMU group|Extensive burn patients are resuscitated with Third Military Medical University (TMMU) formula as a modified EVANS formula routinely used in China. In the first 24h of resuscitation, crystalloids and colloids were infused together.
3092940|NCT01939600|Experimental|All subjects|All subjects will undergo all 4 treatments, starch-free breakfast, Hi-Maize 260, Hylon VII and Amioca in randomized order
3092941|NCT01939587|Experimental|PBF-680 5 mg|5 mg of PBF-680
3092942|NCT01939587|Experimental|PBF-680 20 mg|20 mg of PBF-680
3092943|NCT01939587|Placebo Comparator|Placebo|Placebo
3092944|NCT01939574|Experimental|Chemoradiation & Adjuvant Therapy:|"Concurrent chemoradiation Therapy:~Radiation therapy:2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.~Temozolomide from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg.~Adjuvant Therapy:~Temozolomide once per day for 5 consecutive days of a cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose 200 mg/m2/day in subsequent cycles if no treatment-related adverse events> grade 2 are noted.~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg."
3092945|NCT01939561|Active Comparator|Lamotrigine|Participants are taken oral tablets Lamotrigine once daily. The dosis is escalating every other weeks, from 25 mg - 50 mg - 150 mg- 300mg during the period of 8 weeks.
3092946|NCT01939561|Placebo Comparator|Placebo|Participants are taken oral tablets placebo once daily. The dosis is escalating every other weeks, from 25 mg - 50 mg - 150 mg- 300 mg during the period of 8 weeks.
3092947|NCT01939548|Experimental|PF-02545920 (5mg)|
3092948|NCT01939548|Placebo Comparator|Placebo|
3092949|NCT01939548|Experimental|PF-02545920 (15mg)|
3092950|NCT01939535||Women with endometriosis|Women with endometriosis with the intention of surgery - no intervention
3092951|NCT01939522|Experimental|Prevenar13® (13-valent pneumococcal conjugate vaccine)|Prevenar13 administered as a single dose, 0.5ml Intramuscular liquid form intervention at baseline.
3092952|NCT01939509|Experimental|Atenolol-Bisoprolol|
3092953|NCT01939496|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 6 weeks.
3092954|NCT01939496|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 6 weeks.
3092955|NCT01939496|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 6 weeks.
3092956|NCT01939483|Experimental|Treatment (irinotecan hydrochloride)|"Patients receive irinotecan hydrochloride IV over 90 minutes on days 1, 8, 15, 22, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.~This arm also includes laboratory biomarker analysis as an intervention."
3092957|NCT01939470||Native American Women|Native American Women over the age of 50 yrs
3092958|NCT01939457|Experimental|misoprostol|400 mcg misoprostol sublingually
3092959|NCT01939444|Experimental|naloxone intranasal|2.0 mg by the nasal route
3092960|NCT01939444|Active Comparator|naloxone intravenous|1.0 mg intravenous
3092961|NCT01939418|Experimental|RAD001|gemcitabine 800mg/m2, D1 and D8 iv. every 3 weeks. cisplatin 30mg/m2, D1 and D8 iv. every 3 weeks. RAD001 5mg QD. po.
3092962|NCT01939405|No Intervention|standard physical activity counseling|
3092963|NCT01939405|Experimental|built environment use counseling|personalized counseling on active use of the built environment
3092964|NCT01939392|Experimental|Renal Denervation|Subjects randomized to the Renal Denervation arm will receive bilateral renal ablation with the OneShot system and be maintained on antihypertensive medication.
3092965|NCT01939392|No Intervention|Optimal Medical Therapy|Subjects randomized to the control arm will be maintained on antihypertensive medications.
3092966|NCT01939379|Active Comparator|15ml ropivacaine|Depending on what dose of ropivacaine the subject is randomized to he/she could receive the 15ml dose injected into the catheter every 6 hours
3092967|NCT01939379|Active Comparator|30ml ropivacaine|If the subject is randomized to 30ml ropivacaine he/she will be injected through the catheter every 6 hours.
3092968|NCT01939366|Experimental|Cebranopadol 300 µg|
3092969|NCT01939366|Experimental|Cebranopadol 600 µg|
3092970|NCT01939366|Active Comparator|Pregabalin|
3092971|NCT01939366|Placebo Comparator|Matching Placebo|
3092972|NCT01939366|Experimental|Cebranopadol 100 µg|
3092973|NCT01939353|Experimental|EB-1020 SR|100-500 mg flexible titration
3092974|NCT01939353|Placebo Comparator|Placebo|Matching Placebo
3092975|NCT01939327|Experimental|Lenalidomide/Rituximab|Association of Lenalidomide and Rituximab
3092976|NCT01939314|Active Comparator|Bupivacaine|Bupivicaine .03ml to each nare
3092977|NCT01939314|Placebo Comparator|Normal Saline|normal saline .03 ml to each nare
3092978|NCT01939301|Active Comparator|Inhaled Nitric Oxide|Inhaled nitric oxide
3092979|NCT01939301|Placebo Comparator|Placebo|Oxygen
3092980|NCT01939288|Experimental|Group 1|Half of recruited subjects (n=5)
3092981|NCT01939288|Experimental|Group 2|Other half of recruited subjects (n=5)
3092982|NCT01939275|Experimental|Diagnostic (copper Cu 64-DOTA-trastuzumab PET scan)|Patients receive copper Cu 64-DOTA-trastuzumab IV on day 1 and then undergo PET/CT scan on days 2 or 3.
3092983|NCT01939262|Experimental|Vegan Diet|Limitation of Animal Fat and Protein in the Diet. Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
3092984|NCT01939262|Placebo Comparator|Control|Subjects maintained their existing diet without modification.
3092985|NCT01939249|Active Comparator|Abbott Laboratories Xience|Subjects assigned to Abbott Laboratories Xience can be treated with either the Xience Prime or Xience Xpedition drug eluting stent (DES).
3092986|NCT01939249|Experimental|Biotronik Orsiro|Subjects assigned to Biotronik Orsiro will be treated with Biotronik Orsiro
3110522|NCT01819857|Active Comparator|Droperidol 1.25 mg intravenously|
3092987|NCT01939236|Experimental|traditional Chinese medicine|Subjects were treated with TCM 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient with chronic heart failure is qi deficiency and blood stasis. He will take drug of qi deficiency and blood stasis 2 times per day for 28 days.
3092988|NCT01939236|Placebo Comparator|placebo (gummeline)|Subjects were treated with placebo 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient with chronic heart failure is qi deficiency and blood stasis. He will take drug of qi deficiency and blood stasis 2 times per day for 28 days.
3092989|NCT01939223|Experimental|Regorafenib|4 regorafenib tablets taken orally in the morning daily, followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.
3092990|NCT01939223|Placebo Comparator|Placebo|4 placebo tablets taken orally in the morning daily,followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.
3092991|NCT01939210|Experimental|Arm I (breathing training sessions)|Patients participate in 3 50-minute breathing training sessions, including a psycho-educational component and meditation-based breathing training, over 10 days. Patients then undergo 4D-CT on day 14 and undergo image-guided SBRT or standard radiation therapy 5 times a week for up to 5 fractions or 25 fractions, respectively.
3092992|NCT01939210|Active Comparator|Arm II (control)|Patients receive standard care over 10 days. Patients then undergo 4D-CT on day 14 and undergo image-guided SBRT or standard radiation therapy 5 times a week for up to 5 fractions or 25 fractions, respectively.
3092993|NCT01939197|Experimental|ARM A|ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 weeks for participants receiving atazanavir once-daily or raltegravir twice-daily
3092994|NCT01939197|Experimental|ARM B|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 24 weeks for participants receiving atazanavir once-daily or raltegravir twice-daily
3092995|NCT01939197|Experimental|ARM C|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for participants receiving darunavir once-daily
3092996|NCT01939197|Experimental|ARM D|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for participants receiving darunavir twice-daily
3092997|NCT01939197|Experimental|ARM E|ABT-450/r/ABT-267 and ABT-333 for 12 weeks for noncirrhotic (at screening) GT1b-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
3092998|NCT01939197|Experimental|ARM F|ABT-450/r/ABT-267 and ABT-333 for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-naive participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
3092999|NCT01939197|Experimental|ARM G|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-naive participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
3093000|NCT01939197|Experimental|ARM H|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-experienced participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
3093001|NCT01939197|Experimental|ARM I|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for noncirrhotic (at screening) GT1a-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
3093002|NCT01939197|Experimental|ARM J|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 24 weeks for cirrhotic (at screening) GT1a-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
3093003|NCT01939197|Experimental|ARM K|ABT-450/r/ABT-267 coadministered with RBV for 12 weeks for participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily, dolutegravir once-daily or twice-daily, darunavir once-daily
3093004|NCT01939197|Experimental|ARM L|ABT-450/r/ABT-267 coadministered with RBV for 24 weeks for participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily, dolutegravir once-daily or twice-daily, darunavir once-daily
3093005|NCT01939184|Experimental|WC3055-01F|WC3055 12.5 mg tablet once daily for 12 weeks
3093006|NCT01939184|Experimental|WC3055-02F|WC3055 25 mg tablet once daily for 12 weeks
3093007|NCT01939184|Experimental|WC3055-03F|WC3055 50 mg tablet once daily for 12 weeks
3093008|NCT01939184|Experimental|WC3055-04F|WC3055 75 mg tablet once daily for 12 weeks
3093009|NCT01939184|Placebo Comparator|WC3055-07P|Placebo tablet once daily for 12 weeks
3093010|NCT01939171|Placebo Comparator|Non treated|Cadaver donor is cared and treated as usual protocol
3093011|NCT01939171|Experimental|TREATED|Cadaver donor receives one dose of thymoglobulin of 3 mg/kg iv in 2 hours after ganglia extraction and 3- 6 hours prior to organ procurement.
3093012|NCT01939158|Experimental|ACWY1d group|Subjects will receive 1 dose of the MenACWY-TT vaccine
3093013|NCT01939158|Experimental|ACWY2d group|Subjects will receive 2 doses of the MenACWY-TT vaccine 2 months apart
3093014|NCT01939158|Experimental|Co-ad group|Subjects will receive 1 dose of the MenACWY-TT vaccine co-administered with Prevenar 13™
3093015|NCT01939158|Active Comparator|PCV-13 group|Subjects will receive 1 dose of Prevenar 13™ and 1 dose of the MenACWY-TT vaccine 2 months later
3093016|NCT01939145|Active Comparator|Normal Saline|The use of Normal Saline as the solution for Negative Pressure Wound Therapy with instillation.
3093017|NCT01939145|Active Comparator|Prontosan|The use of Prontosan as the solution in Negative Pressure Wound Therapy with Instillation.
3093018|NCT01939132|Experimental|H.P. Acthar Gel SQ injection|Open-label H.P. Acthar Gel 80 units subcutaneously twice weekly for 12 weeks with a 12 week extension.
3093019|NCT01939119||retinal vascular occlusion|Patients with retinal vascular occlusion undergo a hematocrit dependent 5 day hemodilution
3093020|NCT01939106|Other|One Piece Drainable Pouch|This is a one piece drainable pouch designed for the purpose of collecting stool from subjects with an ileostomy stoma
3093021|NCT01939093|Experimental|Quetiapine|Quetiapine 100 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.
3093022|NCT01939093|Active Comparator|Haloperidol|Haloperidol 2 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.
3093023|NCT01939080|Active Comparator|Medical supervision|Exercise training with supervised sessions Classics training
3110523|NCT01819857|Active Comparator|Ondansetron 8 mg intravenously|
3093024|NCT01939080|Active Comparator|No medical supervision|Exercise training without supervised sessions Classics training
3093025|NCT01939067|Other|HHHFNC|"Treatment of respiratory distress by Heated Humidified High Flow Nasal Cannula (HHHFNC).~Escalation of the ventilatory support per protocol and the attending physician."
3093026|NCT01939067|Other|NCPAP|"Treatment of respiratory distress by nasal continuous positive airway pressure (NCPAP).~Escalation of the ventilatory support per protocol and the attending physician."
3093027|NCT01939054|Experimental|Nimotuzumab,docetaxel,capecitabine|Nimotuzumab 400mg/w,IV,once a week and Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
3093028|NCT01939054|Active Comparator|docetaxel,capecitabine|Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
3093029|NCT01939041|Experimental|Robot-assisted therapy with InMotion3 (IMT)|We will use the InMotion3 Wrist Robot (Figure 1) for the IMT group. During the InMotion3 therapy (IMT) session, participants will receive 5-minute of muscle tone normalization preparation and passive range of motion, then a 70-minute robot-assisted training followed by a 15-minute functional training. During the robot-assisted training, only the paretic hand will be trained and the participant will rest the forearm and hand on a cradle and the wrist and hand in a fixed positions. During the practice, a visual display will provide online visual feedback of accuracy and coordination success. And summary scores regarding movement accuracy and movement smoothness will be shown on the display periodically. After each IMT session, a 15 min functional task practice will be provided as described in the previous paragraph.
3093030|NCT01939041|Experimental|Robot-assisted therapy with Bi-Manu-Track (BMT)|During the Bi-Manu-Track training (BMT), participant will use both nonparetic and paretic hands. Participants will receive 5-munite of muscle tone normalization preparation and passive range of motion, then will practice about 5-minute in Mode 1, 25-minute in Mode 2, and 5-minute in Mode 3 in wrist and forearm respectively. The training repetitions of each mode fall within the range of the protocols used in previous studies which would not cause adverse events (Hesse et al., 2005). The total minutes of each robot-assisted will be 70 minutes. After each BMT session, a 15 min functional task practice will be provided based on the same principles as the one in the IMT group.
3093031|NCT01939041|Active Comparator|Control intervention group (CI)|The control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
3093032|NCT01939028|Experimental|Diagnostic (SLN mapping, biopsy, surgery)|Patients undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.
3093033|NCT01939015|Active Comparator|Standard titanium miniplate- single non compression miniplate|fixation will be perform by A single non compression miniplate with 4-hole 2-mm using 2-mm monocortical screws at superior border of the mandible according to ideal lines of osteosynthesis.
3093034|NCT01939015|Experimental|three dimensional titanium miniplate|3D curved strut miniplate* (Universal Mandible System, Stryker-Lei binger, Freiburg, Germany) , installed and stabilized with monocortical screws. The 3D plate will be place in such a way that a horizontal bar is perpendicular and a vertical bar is parallel to the fracture line.
3093035|NCT01939002|Experimental|BIIB017 plus current FLS therapy|Following a 4-week run-in period (starting 1 day after the Screening Visit) in which participants administer non-pegylated IFN therapy, participants receive BIIB017 at an initial dose of 63 μg followed by 94 μg dose at Week 2 and 125 μg every 2 weeks from Week 4 to Week 46, plus current FLS management regimen as determined by the clinician.
3093036|NCT01939002|Experimental|BIIB017 plus naproxen|Following a 4-week run-in period (starting 1 day after the Screening Visit) in which participants administer non-pegylated IFN therapy, participants receive BIIB017 at an initial dose of 63 μg followed by 94 μg dose at Week 2 and 125 μg every 2 weeks from Week 4 to Week 46, plus 500 mg naproxen administered twice daily up to 24 hours prior to BIIB017 treatment and continuing for 48 hours following the BIIB017 injection for the first 8 weeks of treatment, and as recommended by the treating physician subsequently.
3093037|NCT01938989|Other|Clear, then Blue Light Filter|Clear clip-on glasses first, followed by blue light filter clip-on glasses, as worn over habitual correction
3093038|NCT01938989|Other|Blue Light Filter, then Clear|Blue light filter clip-on glasses first, followed by clear clip-on glasses, as worn over habitual correction
3093039|NCT01938976|Experimental|Adolescent Asthma Action|Adolescent Asthma Action in Jordan (TAJ) Plus the added class smoke free pledge will be implemented in high schools in Jordan and will be compared to the TAJ alone for its efficacy in decreasing smoking rates, lowering CO1 levela and nicotine dependence.
3093040|NCT01938976|Experimental|TAJ|TAJ Plus the class smoke free pledge will be implemented in high schools in Jordan and compared to TAJ alone
3093041|NCT01938963|No Intervention|Care as usual|
3093042|NCT01938963|Experimental|Collaborations in Health (COACH)|COACH integrates the care provided by the older person's primary care provider (PCP) with that delivered by an Aging Worker (AW; a lay member of the village's Aging Association), supervised by a psychiatrist consultant. Based on chronic disease management principles, the PCP is trained to use evidence based practice guidelines for treatment of both HTN and depression, and provided with access to mental health consultation regarding optimal management of the patient's depression. The AW is trained to conduct a systematic assessment of the older person's social context to identify and reduce social and environmental barriers to treatment adherence and response. AWs participate with the PCP in developing multi-disciplinary care plans for their shared patients, reinforce treatment adherence and adoption of healthy behaviors, and emphasize activation and engagement of the older person in activities designed to improve their connectedness to others and to the community.
3093043|NCT01938950|Active Comparator|Aerobic Exercise|Participants will perform aerobic exercise using treadmills and/or ellipticals at 40-65% of VO2peak, three times per week, for 60 minutes/session.
3093044|NCT01938950|Active Comparator|Resistance Exercise|Participants will perform 2 sets (8-12 repetitions per set) of 8 exercises to the point of failure using weight stack equipment, three times per week, for 60 minutes/session. 2 sets of push-ups and sit-ups will also be performed.
3093045|NCT01938950|Active Comparator|Aerobic and Resistance Exercise|Participants will perform aerobic exercise using treadmills and/or ellipticals for 30 min at 40-65% of VO2peak and thereafter, perform 1 set of each of the above 10 resistance exercise for 30 min.
3093046|NCT01938937|Experimental|Transcranial bright light exposure|Transcranially administered bright light exposure for 12 minutes
3093047|NCT01938937|Sham Comparator|Transcranial sham exposure|Transcranially administered sham exposure for 12 minutes
3093048|NCT01938924|No Intervention|No intervention|No intervention
3093049|NCT01938924|Active Comparator|GekoTM|geko applied to bypass limb
3093050|NCT01938911|Experimental|Hypertensives with oxytocin and social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
3093051|NCT01938911|Experimental|Hypertensives with oxytocin without social support|80 normotensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
3093052|NCT01938911|Experimental|Hypertensives without oxytocin with social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
3093053|NCT01938911|Placebo Comparator|Hypertensives without oxytocin or social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
3093054|NCT01938911|Experimental|Normotensives with oxytocin and social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
3093055|NCT01938911|Experimental|Normotensives with oxytocin without social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
3093056|NCT01938911|Experimental|Normotensives without oxytocin with social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
3093057|NCT01938911|Placebo Comparator|Normotensives without oxytocin or social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
3093058|NCT01938898|Other|Potential NICOLA Participants|All potential participants identified through the sampling strategy and contacted to take part in the NICOLA study
3093059|NCT01938872||PEB angioplasty|paclitaxel eluting balloon angioplasty in below-the-knee lesions
3093060|NCT01938859|Experimental|Lithium combined with SGAs|SGAs (Second Generation Antipsychotics), quetiapine adjunctive to lithium therapy
3093061|NCT01938859|Experimental|lithium combined with TCM|TCM (Traditional Chinese Medicine), Shuganjieyu capsule adjunctive to lithium therapy.
3093062|NCT01938859|Active Comparator|Lithium monotherpy|Lithium monotherapy
3093063|NCT01938846|Experimental|BI 860585|Multiple ascending doses of BI 860585 administered continuously in a 28-day cycle, including food interaction cohorts
3093064|NCT01938846|Experimental|BI 860585 + paclitaxel|Multiple ascending doses of BI 860585 in combination with fixed dose paclitaxel
3093065|NCT01938846|Experimental|BI 860585 + exemestane|Multiple ascending doses of BI 860585 in combination with fixed dose exemestane
3093066|NCT01938833|Experimental|Treatment (Romidepsin and Abraxane)|Patients receive abraxane IV over 30 minutes and romidepsin IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3093067|NCT01938820|Active Comparator|Entecavir Therapy|"Entecavir monotherapy:~entecavir, 0.5mg, qd, oral, for 2 years."
3093068|NCT01938820|Experimental|Entecavir plus Thymosin-α|entecavir plus Thymosin-α 1.6μg, Twice a week, ih, in the middle of 1 year.
3093069|NCT01938807|Experimental|Intervention|The intervention group receives the CareCoach mobile application
3093070|NCT01938807|Active Comparator|Control|The control group receives standard care.
3093071|NCT01938781|Active Comparator|Entecavir monotherapy|entecavir, 0.5mg, qd, oral, for 2 years.
3093072|NCT01938781|Experimental|Entecavir plus peg-IFN Therapy|entecavir combined peg-IFN in the middle 1 year.
3093073|NCT01938768||Tranexamic acid|patients with multiple trauma who received tranexamic acid on the scene
3093074|NCT01938768||Non tranexamic acid|patients with multiple trauma who did not receive tranexamic acid on the scene
3093075|NCT01938755|Experimental|levobupivacaine I|group that was administered levobupivacaine plus 60mg dextrose
3093076|NCT01938755|Experimental|levobupivacaine II|group that was administered levobupivacaine plus 80 mg dextrose
3093077|NCT01938755|Experimental|levobupivacaine III|group that was administered levobupivacaine plus 100 mg dextrose
3093078|NCT01938742|Experimental|Group 1|100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
3093079|NCT01938742|Experimental|Group 2|100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
3093080|NCT01938742|Experimental|Group 3|100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
3093081|NCT01938742|Experimental|Group 4|100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21
3093082|NCT01938742|Experimental|Group 5|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 21
3093083|NCT01938742|Experimental|Group 6|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21
3093084|NCT01938742|Experimental|Group 7|100 subjects receive 45mcg sanofi A/H7N9 antigen on Day 0 and 21
3093085|NCT01938729|Experimental|HAI with FLOXURIDINE & DEXAMETHASONE & GEMCITABINE|"This is an open-label single arm study. multi-institution phase I dose escalating trial of adjuvant HAIP FUDR and Gemcitabine chemotherapy after curative resection of ICC. Hepatectomy with or without bile duct reconstruction and pump placement are performed. The patients will start therapy 4 weeks postoperatively. They will receive HAI FUDR/Dex and systemic gemcitabine in the following dose escalation levels of gemcitabine. The dose of HAI FUDR will be fixed. A classic 3+3 cohort dose escalation scheme will be used to identify the MTD of the combination.~Level 1: Systemic gemcitabine 650mg/m^2 Day 1 and 15 and HAI FUDR/Dex 0.12mg/kg/day Day 1-14 Level 2.Systemic gemcitabine 800mg/m^2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14 Level 3. Systemic gemcitabine 1000mg/m^2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14"
3093086|NCT01938716|Experimental|Gemcitabine Infusion|Gemcitabine administered intravenously as a dose of 500 mg/m2 at a fixed dose rate of 10 mg/m2/min for the first 5 patients (to validate hematologic safety). Next 15 subsequent patients receive 750 mg/m2 at a fixed dose rate of 10 mg/m2/min. The drug infusion started 50-75 minutes prior to complete gross tumor removal (timing dependent on dose) in order to have drug administration complete at tumor removal.
3093087|NCT01938690|Sham Comparator|Sham stimulation|Sham stimulation on the scalp of unaffected brain
3093088|NCT01938690|Experimental|transcranial magnetic stimulation|transcranial magnetic stimulation on unaffected brain
3093089|NCT01938677|Experimental|Initial Gamma knife|Patients with VS and preserved hearing, randomized to initial gamma knife radiosurgery will receive this treatment within a few months after enrollment
3093090|NCT01938677|No Intervention|Initial conservative|Patients with VS and preserved hearing, randomized to initial conservative treatment will initially be followed with repeated MRI and audiometry. If MRI show progression of VS requiring intervention, patients will receive treatment but still belong to the initial treatment arm, according to intention to treat.
3093091|NCT01938664|Active Comparator|Candesartan with brief Cognitive Behavior Therapy (CBT)|Dosage will be at 1 mg (capsule)for 1 week - with titration up to 8mg (capsule)through week 4. Participants will then be maintained at 8mg (capsule) through week 8. Once weekly cognitive-behavior therapy will be offered of up to 30 minutes duration.
3093092|NCT01938664|Placebo Comparator|Placebo|Dosage will be at 1 mg (placebo capsule)for 1 week - with titration up to 8mg (placebo capsule)through week 4. Participants will then be maintained at 8mg (placebo capsule) through week 8. Once weekly cognitive-behavior therapy will be offered of up to 30 minutes duration.
3093093|NCT01938651|Experimental|Diagnostic (7T ultra high-field MRI/MRS)|Patients undergo measurement of tumor perfusion and permeability using DCE-MRI, tumor cellularity using DW-MRI, phospholipid metabolism using 31P MRS, macromolecular content using MT-MRI, and cellular protein content using CEST-MRI. All of these procedures are integrated into a single MRI exam lasting under 60 min.
3093094|NCT01938638|Experimental|BAY1143572 [continuous]|BAY1143572 will be administered from cycle 1, day 1 (C1D1) onwards once daily continuously
3093095|NCT01938638|Experimental|BAY1143572 [on/off]|BAY1143572 will be administered from C1D1 in a 3 days on/4 days off schedule
3093096|NCT01938625|Experimental|Part 1|Participants with Metavir fibrosis score F1-F2 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with cyclosporine or tacrolimus as stable immunosuppressant therapy.
3093097|NCT01938625|Experimental|Part 2|Participants with Metavir fibrosis score F1-F4 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with tacrolimus as stable immunosuppressant therapy.
3093098|NCT01938612|Experimental|MEDI4736 Q2W|Evaluate MEDI4736 given every 2 weeks
3093099|NCT01938612|Experimental|MEDI4736 Q3W|Evaluate MEDI4736 given every 3 weeks
3093100|NCT01938612|Experimental|MEDI4736 Dose Expansion|evaluate MEDI4736 given every 2 weeks
3093101|NCT01938612|Experimental|MEDI4736 Q4W|Evaluate MEDI4736 given every 4 weeks
3093102|NCT01938612|Experimental|MEDI4736 combined with another drug|evaluate MEDI4736 in combination with another drug given every 4 weeks
3093103|NCT01938599|Experimental|AM001|AM001 Cream, 7.5%. 2x daily for 12 weeks.
3093104|NCT01938599|Placebo Comparator|Vehicle|Placebo of AM001 Cream. 2x daily for 12 weeks.
3093105|NCT01938586||Surgical excision|
3093106|NCT01938573|Experimental|Sirolimus, cisplatin, gemcitabine|Sirolimus day -2, cisplatin 70 mg/m2 IV Day 1 and gemcitabine hydrochloride 1000 mg/m2 IV days 1 and 8 every 21 days for 4 cycles followed by cystectomy (surgery)
3093107|NCT01938560||Physicians|Retigabine Physicians (e.g. neurologists/epileptologists/neurosurgeons) who have prescribed retigabine at least once in the last 12 months.
3093108|NCT01938560||Pharmacists|Pharmacists who have dispensed an anti-epileptic drug (AED) at least once in the last 3 months.
3093109|NCT01938547|Experimental|clevidipine|"An initial clevidipine IV infusion dose for the adolescent cohort has been specified per protocol. The initial dose for each of the subsequent age cohorts will be modified if necessary, based on the recommendation of the Data and Safety Monitoring Board (DSMB).~Following the initial dose, clevidipine will be up-titrated every 1.5 minutes, according to participant need, to achieve a systolic blood pressure (SBP) within the pre-specified SBP target range. Doses may be increased by less than doubling, and the time between dose adjustments may be lengthened, as the target blood pressure is approached. The infusion rate may be maintained for up to 96 hours, once the participant's SBP is within the target range, and titrated as necessary to maintain blood pressure within the range."
3093110|NCT01938534|Experimental|Experimental|"Omeprazole 30mg twice Clarithromycin 500mg twice Amoxicillin 1000mg twice~for 10 days"
3093111|NCT01938534|Active Comparator|Control|Tetracycline 500mg four times Omeprazole 30mg twice Bismuth 600mg twice Metronidazole 500mg three times for 10 days
3093112|NCT01938521|Experimental|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
3093113|NCT01938521|Placebo Comparator|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) similar powder to mimic 1000 mg of Red Grape Cells (RGC), once daily by mouth for three month
3093114|NCT01938508|Experimental|Test|Minocycline 100 mg capsules Darier SA Dermatological Laboratories de CV (Micromycin ®).
3093115|NCT01938508|Experimental|Reference|Minocycline 100 mg capsules (Micocin ®) Marketed and distributed by Triax Pharmaceuticals
3093150|NCT01938326|Active Comparator|SIDG|SIDG : pure single incision laparoscopic distal gastrectomy Reconstruction by the uncut Roux-en Y gastrojejunostomy
3111874|NCT01810653|Active Comparator|Macrogol (Forlax)|
3093116|NCT01938495|Experimental|NeuRx® Diaphragm Pacing System™ (DPS)|Patients randomized to the experimental arm will receive The NeuRx® Diaphragm Pacing System™ (DPS) device. Under general anesthesia, the intramuscular electrodes are surgically implanted in the diaphragm.
3093117|NCT01938495|No Intervention|Standard of Care|patients randomized to the standard of care arm will not have the Diaphragm Pacing System surgically implanted but will receive standard medical care.
3093118|NCT01938482|Experimental|Part 1|Subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as a single App 24h (22.5h) application to 400 cm^2 (0.3%), 400 cm^2 (1%) or 1200 cm^2 (1%), respectively, in each of three sequential cohorts
3093119|NCT01938482|Experimental|Part 2|Subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as 14 daily App24h (22.5h) application to 400 cm^2 (0.3%), 400 cm^2 (1%) or 1200 cm^2 (1%), respectively, in each of three sequential cohorts
3093120|NCT01938469|Other|Solid Meal|Participants in this group will be administered only solid meals on both study visits completed before surgery (T0) and 12-15 months after (T1).
3093121|NCT01938469|Other|Liquid Meal|Participants in this group will be administered only liquid meals on both study visits completed before surgery (T0) and 12-15 months after (T1).
3093122|NCT01938456|Experimental|Trametinib + Docetaxel + Filgrastim|Participants will receive Trametinib once daily for 21 days of each cycle + Intravenous Docetaxel once every three weeks over at least a one-hour infusion + Filgrastim (growth factor) subcutaneous injection once daily for prophylactic use.
3093123|NCT01938443|Experimental|Part 1|Part 1 will determine the MTD and RP2D based on the safety and tolerability of GSK2256098 administered with trametinib. Subject will be administered starting dose of 1.0 mg OD trametinib combined with 500 mg BID GSK2256098. Dose escalation will continue until the MTD is established.
3093124|NCT01938443|Experimental|Part 2|Based on determination of combination dose regimen in Part 1, dose expansion cohorts for Part 2 will be opened.
3093125|NCT01938430|Experimental|Cohort A, Group 1 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
3093126|NCT01938430|Experimental|Cohort A, Group 1 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
3093127|NCT01938430|Experimental|Cohort A, Group 2 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
3093128|NCT01938430|Experimental|Cohort A, Group 2 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
3093129|NCT01938430|Experimental|Cohort B, Group 3 (12 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3.
3093130|NCT01938430|Experimental|Cohort B, Group 3 (24 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3
3093131|NCT01938430|Experimental|Cohort B, Group 4 (12 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)
3093132|NCT01938430|Experimental|Cohort B, Group 4 (24 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)
3093133|NCT01938430|Experimental|Cohort B, Group 5 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
3093134|NCT01938430|Experimental|Cohort B, Group 5 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
3093135|NCT01938430|Experimental|Cohort B, Group 6 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
3093136|NCT01938430|Experimental|Cohort B, Group 6 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
3093137|NCT01938430|Experimental|Cohort B, Group 7 (12 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with FCH
3093138|NCT01938430|Experimental|Cohort B, Group 7 (24 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH
3093139|NCT01938417||adult patients treated with Osteoset® T (tobramycin sulfate)|10 g or 20 g of Osteoset® T
3093140|NCT01938404||Octaplas|Patients receiving Octaplas for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
3093141|NCT01938404||standard plasma products|Patients receiving standard plasma products (e.g., FFP, etc) for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
3093142|NCT01938391|Other|OAS + BA|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS), is used prior to adjunctive balloon angioplasty (BA)
3093143|NCT01938378|Other|Pediatric patients undergoing TPE|octaplas™
3093144|NCT01938365||Diabetes|
3093145|NCT01938365||Normal glucose regulation|
3093146|NCT01938352|Experimental|CR8020|CR8020 administered as a single 2-hour intravenous infusion
3093147|NCT01938352|Placebo Comparator|Placebo|Placebo administered as a single 2-hour intravenous infusion
3093148|NCT01938339|Experimental|PET/MR|Multi-radiotracer PET/MR will be performed to compare the accuracy of tumor detection in patient with primary prostate cancer
3093149|NCT01938326|Active Comparator|TLDG|No mini-laparotomy in the epigastrium Reconstruction by the uncut Roux-en Y gastrojejunostomy
3093151|NCT01938313|Active Comparator|ERAS perioperative cares|Patients planned to undergoing laparoscopic gastrectomy, following the ERAS protocols.
3093152|NCT01938313|Active Comparator|Conventional perioperative cares|Patents will be managed by our hospital's critical pathways.
3093153|NCT01938300|Experimental|Magnesium|"Magnesium sulfate infusion during a operation period.~Infusion regimen:~Bolus 50 mg/kg of magnesium sulfate in 100 ml normal saline over 15 minutes~Infusion 15 mg/kg/h of magnesium sulfate throughout the operation"
3093154|NCT01938300|Placebo Comparator|Control|administration of normal saline as a same volume of magnesium sulphate as a same method.
3093155|NCT01938287|Experimental|SENSIMED Triggerfish|
3093156|NCT01938274|Experimental|Educational intervention|Patients in this group will receive a brief educational intervention to assist them in setting the appropriate expectations for leisure activity after surgery with respect to the type, amount, intensity, and duration of activity.
3093157|NCT01938274|No Intervention|Control group|No intervention will be received. Patients will receive a written version of the education intervention at the end of the study.
3093158|NCT01938261|Placebo Comparator|Paracetamol effect on ductus|The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.
3093159|NCT01938261|Placebo Comparator|Paracetamol effect on pain|The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.
3093160|NCT01938248|Active Comparator|Control|Aspirin 81 mg once daily
3093161|NCT01938248|Experimental|Intervention|Apixaban, 5 mg twice daily (or 2.5 mg twice daily if 2 or more of: age > 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
3093162|NCT01938235|Experimental|Exenatide|"o Exenatide at a dose of 1.5 µg IV over 30 min followed by 1.2 µg/hr IV for 1.5 h (Rate1), followed by 1.9 µg/hr IV* for 22 h (Rate 2)~*Once the creatinine clearance is available, if the value is <60 mL/min, the rate at 2 hours will be maintained at Rate 1 for the duration of the infusion. If the value becomes available after the 2-hour point, and the rate has already been changed to Rate 2, the infusion will be titrated back down to Rate 1 if the creatinine clearance is <60 mL/min.~If the creatinine clearance is <30 mL/min, the infusion will be discontinued and the patient will otherwise continue with all study procedures.~A bolus administration of study medication is initiated preferably prior to reperfusion, or, if not possible, up to 30 minutes after the start of reperfusion to avoid delays in door-to-door balloon times."
3093163|NCT01938235|Placebo Comparator|Placebo|o Placebo bolus over 30 min followed by placebo infusion at 'Rate 1' for 1.5 h, followed by 'Rate 2' for 22 hours*.
3093164|NCT01938222||Short Stitch|Short stitch suture technique (6:1) for abdominal all closure stitch interval < 0,5 cm and lateral 0,5-0,8 cm
3093165|NCT01938209|Experimental|seated general thoracic spine manipulation|seated general thoracic spine manipulation
3093166|NCT01938209|Experimental|supine specific thoracic spine manipulation|Specific supine manipulation
3093167|NCT01938196|Experimental|KWA-0711 Dose1|
3093168|NCT01938196|Experimental|KWA-0711 Dose2|
3093169|NCT01938196|Experimental|KWA-0711 Dose3|
3093170|NCT01938196|Experimental|KWA-0711 Dose4|
3093171|NCT01938196|Placebo Comparator|Placebo|
3093172|NCT01938183|Placebo Comparator|Full-mouth PD+placebo gel|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of placebo gel (semi-solid suspension containing carbopol), overnight, during seven days.
3093173|NCT01938183|Active Comparator|Full-mouth PD+Metronidazole tablet|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + single oral dose of 750 mg tablets/day at night, during seven days.
3093174|NCT01938183|Active Comparator|Full-mouth PD+Metronidazole benzoate gel|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of 15% Mtz benzoate gel (semi-solid suspension containing carbopol), overnight, during seven days.
3093175|NCT01938170|Experimental|FluMist|Subjects receiving vaccine at home
3093176|NCT01938157|Experimental|High Risk Breast Cancer Patients|High Risk Breast Cancer Patients (all subjects)
3093177|NCT01938144|Experimental|Treatment A|IBU 200 mg/ PE 10 mg
3093178|NCT01938144|Experimental|Treatment B|IBU 200 mg/ PE 10 mg/CHLOR 4 mg
3093179|NCT01938144|Active Comparator|Treatment C|Acetaminophen 500 mg
3093180|NCT01938131|Placebo Comparator|placebo|Patients in this group will be subjected to a treatment with muscle released in which the probe of CroSystem instrument will be approached to the quadriceps, without making contact. The instrument in these conditions emits a buzz but not provokes muscle vibration
3093181|NCT01938131|Experimental|repeated Muscle Vibration|The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
3093182|NCT01938118|Experimental|Obesity Prevention Group|Mothers and families receive a developmentally appropriate educational intervention designed to promote healthy lifestyle behaviors for prevention of excessive weight gain between birth to 15 months of life. Educational content is delivered through eight home visits, five newsletters and twice weekly text messages. At several time points the mother identifies another family member/caregiver to actively participate in the program with her.
3093183|NCT01938118|Active Comparator|Injury Prevention Group|Mothers and families receive a developmentally appropriate educational intervention designed to promote automobile and home safety behaviors for prevention of childhood injury. Educational content is delivered through eight home visits, five newsletters and twice weekly text messages. At several time points the mother identifies another family member/caregiver, who is only asked to complete surveys/assessments.
3093184|NCT01938105|Experimental|Nimotuzumab+chemoradiotherapy|
3093185|NCT01938092|Active Comparator|Diazepam|Participated will be instructed to insert one 10mg tablet vaginally 1-2 times per day as needed for pain.
3093186|NCT01938092|Placebo Comparator|Placebo|Participated will be instructed to insert one 10mg tablet vaginally 1-2 times per day as needed for pain.
3093187|NCT01938079|Active Comparator|Sedative without Ketamine|Subjects will receive sedative drug regimen without Ketamine.
3093188|NCT01938079|Experimental|Sedative with Ketamine|Subjects will receive sedative drug regimen with Ketamine.
3093189|NCT01938066|Active Comparator|Negative Pressure with Procellera|Arm 2 is Negative Pressure Therapy and Procellera Dressing under the sponge dressing of the Negative Pressure Therapy. The dressing will be changed at the end of 5 days. This is the intervention arm of the study.
3093190|NCT01938066|Sham Comparator|Negative Pressure Therapy only|Arm 1 is Negative Pressure Therapy only with no Procellera Dressing and the dressing is changed every other day per standard of care when you use Negative Pressure Therapy with no dressing underneath the sponge.
3093191|NCT01938053|Other|Reminder card with no number|Patients receive a card to remind them of the time frame for results but no number is listed.
3093192|NCT01938053|Other|Card with number|Patients receive a card to remind them of the time frame for results but and a number to call for results is listed
3093193|NCT01938040|Active Comparator|Ibuprofen|800mg administered IV in 100cc of normal saline over 5 minutes
3093194|NCT01938040|Placebo Comparator|Sugar water|100mL of normal saline to be administered over 5 minutes
3093195|NCT01938027|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
3093196|NCT01938001|Experimental|Rituximab and Lenalidomide|
3093197|NCT01938001|Active Comparator|Rituximab and Placebo|
3093198|NCT01937988|Experimental|Doula Arm|Women in the doula arm will have standard procedure protocol with addition of doula support at the time of the procedure.
3093199|NCT01937988|No Intervention|Control Group|Women in the control arm will have standard procedure protocol at the time of the procedure.
3093200|NCT01937975|Experimental|Participants with End Stage Renal Disease on Hemodialysis|Participants with End Stage Renal Disease on hemodialysis received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days..
3093201|NCT01937975|Experimental|Participants with Severe Renal Impairment|Participants with Severe Renal Impairment (estimated glomerular filtration rate <30 mL/min/1.73 m^2) received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days.
3093202|NCT01937975|Experimental|Healthy Participants|Healthy participants (estimated glomerular filtration rate >=80 mL/min/1.73 m^2) received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days.
3093203|NCT01937949|Other|Endovascular|"Device: Custom-made Zenith® Fenestrated AAA Endovascular Graft. Instead of making a large incision in the abdomen,the physician makes two small incisions in the groin. Through these incision the devices are placed into the aorta.~Other names:~Endovascular stent Stent-graft"
3093204|NCT01937936|Experimental|CBT|Cognitive Behavioral Therapy (CBT)
3093205|NCT01937936|Active Comparator|Education|Health Education
3093206|NCT01937910|Experimental|Stroke Group|Participants in the stroke group will complete 10 training sessions of the TRAIT task.
3093207|NCT01937910|Active Comparator|Matched Healthy Control Group|Participants in the Matched Healthy Control group will complete 10 sessions of the TRAIT task
3093208|NCT01937897|Experimental|Left-Sided Massage|Unilateral massage on the left side of the body.
3093209|NCT01937897|Active Comparator|Right-Sided Massage|Unilateral massage on the right side of the body.
3093210|NCT01937897|Sham Comparator|Bi-Lateral Massage|Traditional massage on the back of the body.
3093211|NCT01937884|Experimental|Early Parenteral Nutrition|Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
3093212|NCT01937884|Active Comparator|Late Parenteral Nutrition|Patients receive supplemental parenteral nutrition 96 hours after enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
3093213|NCT01937871|Placebo Comparator|Placebo|Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.
3093214|NCT01937871|Experimental|5 mg Tadalafil|"Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.~Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period"
3093215|NCT01937871|Other|0.2 mg Tamsulosin|"Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.~Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period"
3093216|NCT01937858||Normal renal function|
3093217|NCT01937858||Stage 2 and 4 and 5 chronic kidney disease|
3093218|NCT01937858||End stage renal disease on hemodialysis|
3093219|NCT01937832|Active Comparator|Ertapenem|
3093220|NCT01937832|Experimental|Faropenem|
3093221|NCT01937819|Experimental|SMART arm|Using SMARTPHONE application for self judging bowel preparation
3093222|NCT01937819|No Intervention|Conventional arm|Non-using SMARTPHONE application for bowel preparation
3093223|NCT01937806|Experimental|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
3093224|NCT01937806|Active Comparator|Tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
3093225|NCT01937793|Active Comparator|effortful swallowing exercise|Subjects in the arm are asked to do the effortful swallowing exercise at home for 8 weeks. The training frequency is to exercise 3-4 days/week, 3 times/day, 10 repetitions per time. Besides the at home exercise, each subject is scheduled to meet the investigator at the hospital at weekly basis to discuss and review his/her exercise practice.
3093226|NCT01937793|Active Comparator|Mendelsohn swallowing exercise|Subjects in the arm are asked to do the Mendelsohn swallowing exercise at home for 8 weeks. The training frequency is to exercise 3-4 days/week, 3 times/day, 10 repetitions per time. Besides the at home exercise, each subject is scheduled to meet the investigator at the hospital at weekly basis to discuss and review his/her exercise practice.
3093227|NCT01937767|Active Comparator|Propofol|Induction: Propofol, fentanyl, rocuronium. Maintenance: Sevoflurane, remifentanil.
3093228|NCT01937767|Experimental|Remimazolam 6 mg/kg/hr|Induction: Remimazolam 6 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.
3093229|NCT01937767|Experimental|Remimazolam 12 mg/kg/hr|Induction: Remimazolam 12 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.
3093232|NCT01937728|Active Comparator|A: Peg-interferon alpha-2a & Ribavirin|Arm A: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
3093233|NCT01937728|Experimental|B: Peg-interferon alpha-2a & Ribavirin|"Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks.~(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)"
3093234|NCT01937728|Experimental|C: Peg-interferon alpha-2a & Ribavirin|"Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.~(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)"
3093235|NCT01937728|Active Comparator|D: Peg-interferon alpha-2a & Ribavirin|"Arm D: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.~(Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment)"
3093236|NCT01937728|Experimental|E: Peg-interferon alpha-2a & Ribavirin|"Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.~(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)"
3093237|NCT01937728|Experimental|F: Peg-interferon alpha-2a & Ribavirin|"Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks.~(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)"
3093238|NCT01937715|Experimental|Arm A|PF-05212384 plus FOLFIRI
3093239|NCT01937715|Active Comparator|Arm B|Bevacizumab plus FOLFIRI
3093240|NCT01937702|Experimental|Anti-diabetes medication|Insulin
3093241|NCT01937689|Experimental|Pyrotinib|Each subject will receive a single dose of pyrotinib on day 1, followed by 4-day observation period, and then subject will receive pyrotinib once daily for 28 days during cycle 1.Each cycle will consists of 28 days.
3093242|NCT01937676||Adults admitted to ER|All adult patients admitted to emergency department during the study period.
3093243|NCT01937663|Experimental|KWA-0711 Dose1|
3093244|NCT01937663|Experimental|KWA-0711 Dose2|
3093245|NCT01937663|Experimental|KWA-0711 Dose3|
3093246|NCT01937663|Experimental|KWA-0711 Dose4|
3093247|NCT01937650|Active Comparator|Radiotherapy plus metronidazole|Participants in the intervention arm received 1gm (2 suppositories) of metronidazole per rectum 30 minutes before radiotherapy for every other radiotherapy session with two rest days of Saturday and Sunday. The standard radiotherapy regimen for advanced cancer of the cervix composed of two phases of radiotherapy was used; phase 1 was tele-therapy via parallel-opposed portals from Co-60 radiation source, with a total dose of 50 Gy given in 25 fractions of 2 Gy/day for five weeks. The patients were then given a break of 1-4 weeks before getting the second phase of treatment. Phase 2 was brachy-therapy from a Cs-137 source, whereby a single dose of 30Gy was delivered at point A at a rate of 2.55 Gy/ hour for 7 hours and 50 minutes, via a uterine Tandem and two vaginal Ovoids.
3093248|NCT01937650|Placebo Comparator|Radiotherapy alone|Participants in the control arm received 500mg (two suppositories) of paracetamol as a placebo on similar days. This was in addition to the standard radiotherapy administration in two phases as described above.
3093249|NCT01937637|Other|Behavioral Intervention for Dyspnea|"In the first intervention session, enrolled participants will learn breathing and relaxation exercises designed to relieve breathlessness. The nurse practitioner will also provide handouts with directions for these exercises, an audio-recording with the relaxation exercises, and worksheets for daily home practice. During the second session, participants will again meet with the nurse practitioner to review the study exercises and to address any difficulties participants may have experienced in practicing the skills.~All participants will complete questionnaires before and after the study intervention as well as a brief follow-up interview with the research assistant to obtain feedback about ways to improve the intervention to relieve breathlessness in patients with lung cancer."
3093250|NCT01937624|Experimental|Diagnostic ultrasound|The diagnostic musculoskeletal ultrasound will be used to image bones in perpendicular and orthogonal planes over the distal radius visualizing the physis.
3093251|NCT01937624|Active Comparator|Radiographic imaging|X-ray imaging of the wrist
3093252|NCT01937611|Experimental|Dexmedetomidine|dexmedetomidine 1μg•kg-1
3093253|NCT01937611|Active Comparator|midazolam|midazolam 0.03 mg•kg-1
3093254|NCT01937598|Experimental|Sitagliptin, then Placebo|
3093255|NCT01937598|Experimental|Placebo, then Sitagliptin|
3093256|NCT01937585|Active Comparator|CDC brochure only condition|Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
3093257|NCT01937585|Experimental|Partner and CDC brochure condition|Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
3093258|NCT01937572|Experimental|Computer-aided TKA|The Visionaire system is a computer-aided system utilizing MRI of the knee prior to TKA surgeries. This technology achieves accurate rotational and A-P position. All of the commonly-referred anatomical landmarks (AP axis, epicondylar axis) are analyzed pre-operatively, allowing for the proper positioning of the implant for each patient.
3093259|NCT01937572|Other|Conventional TKA|A conventional TKA utilizes a jig system based on either intra-medullary or extra-medullary guides. No knee MRI is utilized for a conventional TKA.
3093260|NCT01937559|Experimental|Antifibrinolytic agent|Tranexaminic acid (TXA)
3093261|NCT01937559|Placebo Comparator|Saline|Normal saline
3093262|NCT01937546|Active Comparator|Anterior shoulder|Primary delivery of the anterior shoulder of the fetus
3093263|NCT01937546|Experimental|Posterior shoulder|Primary delivery of the posterior shoulder of the fetus
3093264|NCT01937533||Cervical Cancer|Patients with presumed early cervical cancer being considered for curative surgery
3093265|NCT01937520|Experimental|acupuncture|acupuncture will be administered after induction for a period of 30 minutes, followed by a 30 minute rest period and then resumption of acupuncture for 30 minutes.
3093266|NCT01937520|Placebo Comparator|device|no acupuncture will be done on this group of subjects
3093267|NCT01937507|Experimental|HAI with FOLFOX|Hepatic Artery Infusion with Oxaliplatin, 5FU, and Folinic Acid
3093268|NCT01937494|Experimental|asthma patients|patients who show a positive response at the first dos of histamine challenge test will be enrolled
3093269|NCT01937481|Experimental|Nutrition and Physical Activity|The Food Friends programs
3093270|NCT01937481|No Intervention|Control|Control group
3093271|NCT01937468|Experimental|Treg-enriched infusion plus 8-week low-dose Interleukin-2|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema. Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
3093272|NCT01937455|Experimental|Group A|rAAV1-PG9DP or placebo (v:p = 3:1)
3093273|NCT01937455|Experimental|Group B|rAAV1-PG9DP or placebo (v:p = 3:1)
3093274|NCT01937455|Experimental|Group C/C1|rAAV1-PG9DP or placebo (v:p = 3:1 in Group C, and v:p = 9:3 in Group C1)
3093275|NCT01937455|Experimental|Group D/D1|rAAV1-PG9DP or placebo (v:p = 3:1 in Group D, v:p = 4:1 in Group D1)
3093276|NCT01937442|Experimental|Thalidomide Celgene™ 200mg once daily|5-day period of thalidomide treatment
3093277|NCT01937429|Experimental|Colonoscopy with blue indigo Carmin®|Patients undergoing from a colonoscopy with instillation of tepid water (30°C) tinged with indigo Carmin® (0,08/1000) during the endoscope insertion from the anus to the caecum, and with insufflation of air only during withdrawal from the caecum to the anus.
3093278|NCT01937429|Active Comparator|Standard colonoscopy|Standard colonoscopy with insufflation of air
3093279|NCT01937416|Experimental|autologous bone marrow mononuclear cells|Bone marrow come from the patients himself/herself. With a conventional method and reagent,Ficoll, mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation.
3093280|NCT01937390||LAMA/LABA Patients|
3093281|NCT01937364|Placebo Comparator|Placebo|Placebo every eight hours as inpatients for 72 hours or until discharge if less than 72 hours.
3093282|NCT01937364|Active Comparator|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
3093283|NCT01937351|Experimental|Pantheris Treatment Arm|Intervention: Atherectomy using the Pantheris system.
3093284|NCT01937338|Experimental|AZD7624|
3093285|NCT01937338|Placebo Comparator|Placebo|
3093286|NCT01937325|Active Comparator|Ivacaftor|150mg orally twice daily
3093287|NCT01937325|Placebo Comparator|Placebo|Matching placebo
3093288|NCT01937312|Experimental|SIMBRINZA|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with prostaglandin analogue, 1 drop in each eye at bedtime, for 6 weeks
3093289|NCT01937312|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with prostaglandin analogue, 1 drop in each eye at bedtime, for 6 weeks
3093290|NCT01937299|Experimental|SIMBRINZA|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with travoprost 0.004% ophthalmic solution, 1 drop in each eye at bedtime, for 6 weeks
3093291|NCT01937299|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with travoprost 0.004% ophthalmic solution, 1 drop in each eye at bedtime, for 6 weeks
3093292|NCT01937260|Experimental|Brodalumab 140mg SC|open label, all subjects receive brodulamab
3093293|NCT01937260|Experimental|Midazolam (MDZ) 2mg oral, Brodalumab 210mg SC|MDZ 2mg oral (Day 1 and Day 9), Brodalumab 210mg SC (Day 2)
3093294|NCT01937247|Placebo Comparator|Standard process|The control group is placebo group and this is our standard practice. Patients will be induced in the operating room and at the end of surgery will be reversed with neostigmine 50µg/kg and glycopyrrolate 10µg/kg. Once extubated and rolled out of the room, the house keeper team will start cleaning the operating room
3093295|NCT01937247|Active Comparator|Redesigned process|Patients will be inducted in the induction room. At the end of surgery and after placement of the surgical dressing, the registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room. The patient will be reversed with sugammadex 4mg/kg IV
3093296|NCT01937234|Active Comparator|Metoclopramide|Intravenous injection of 10mg metoclopramide
3093297|NCT01937234|Placebo Comparator|Placebo|Intravenous injection of 0.9% sodium chloride
3093298|NCT01937221||mild cognitive impairment|
3093299|NCT01937221||mild to moderate cognitive impairment|
3093300|NCT01937221||normal or control group|
3093301|NCT01937208|Experimental|high-dose|concurrent chemoradiation:CT:DDP 25mg/m2 D1+docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：60Gy/30F/6W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 75mg/m2 D1+docetaxel 75mg/m2 D1, Q3W
3093302|NCT01937208|Active Comparator|standard dose|concurrent chemoradiation:CT:DDP 25mg/m2 D1+Docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：50Gy/25F/5W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 5mg/m2 D1+Docetaxel75mg/m2 D1, Q3W
3093303|NCT01937195|Experimental|AccuCath Intravenous Catheter System|AccuCath Intravenous Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal.
3093304|NCT01937182|Active Comparator|Selective Serotonin Reuptake Inhibitors|Intervention Drug: Citalopram
3093305|NCT01937182|Placebo Comparator|Placebo|Intervention Drug: Placebo
3093306|NCT01937169|Experimental|Drug + motor task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep.This group will be administered with a quarter of a Dopicar pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a motor task (e.g., walking) for 30 minutes."
3112235|NCT01808157|Placebo Comparator|vehicle|Placebo
3093307|NCT01937169|Placebo Comparator|Placebo + motor task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep. This group will be administered with a quarter of a Placebo pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a motor task (e.g., walking) for 30 minutes."
3093308|NCT01937169|Sham Comparator|Dopicar + Sham task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep. This group will be administered with a quarter of a Dopicar pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a non-motor task (e.g., crossword puzzle) for 30 minutes."
3093309|NCT01937156|Experimental|SP-01|
3093310|NCT01937156|Active Comparator|Granisetron Hydrochloride Tablet|
3093311|NCT01937143|Placebo Comparator|Control|General information about infant immunizations at birth of a newborn infant
3093312|NCT01937143|Active Comparator|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant
3093313|NCT01937143|Active Comparator|High intensity intervention|Pamphlet and video with information about pain management during infant immunizations at birth of a newborn infant
3093314|NCT01937130|Experimental|IDN-6556 5 mg|Dosed twice daily
3093315|NCT01937130|Experimental|IDN-6556 25 mg|Dosed twice daily
3093316|NCT01937130|Experimental|IDN-6556 50 mg|Dosed twice daily
3093317|NCT01937130|Placebo Comparator|Placebo|Dosed twice daily
3093318|NCT01937117|Experimental|Trastuzumab and Pertuzumab|Response to preoperative treatment with trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV) and pertuzumab (840 mg as a loading dose, then 420 mg every 3 weeks, IV) every 3 weeks for 4 doses (total 12 weeks or 3 months of treatment) as assessed by Positron Emission Tomography (PET)
3093319|NCT01937104|Experimental|Group 1|"Drug: Desflurane Anesthesia with desflurane in both Group 1 and Group 2 - adjust minimum alveolar concentration (MAC) to maintain bispectral index (BIS) between 40-60~Drug: Remifentanil Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%~Device: Ultrasonographic measurement of ONSD~Procedure/Surgery: Mechanical ventilation Maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.~Trendelenburg position - 30 degree"
3093320|NCT01937104|Experimental|Group 2|"Drug: Desflurane Anesthesia with desflurane in both Group 1 and Group 2 - adjust MAC to maintain BIS between 40-60~Drug: Remifentanil Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%~Device: Ultrasonographic measurement of ONSD~Procedure/Surgery: Mechanical ventilation Maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.~Reverse Trendelenburg position - 30 degree"
3093321|NCT01937091||Participants in trials|Participated in a trial of HAART for duration of > 48 weeks.
3093322|NCT01937091||Non-participants in trials|Never participated in clinical trials of HAART Must have been offered participation in a clinical trial and declined
3093323|NCT01937078|Active Comparator|active|Famotidine will be administered at total daily doses of 80, 120mg, or 160mg per day. Each patient will be randomized to receive each active dose of famotidine (80, 120, or 160mg/d and placebo). Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo.
3093324|NCT01937065||No treatment|
3093325|NCT01937052||Breast cancer patients|All patients planned to initiate hormonal therapy with either Tamoxifen, Raloxifene (Evista®), Anastrozole (Arimidex®), Letrozole (Femara®) or Exemestane (Aromasin®) are eligible to participate in sample collection and data for patient-reported outcomes/questionnaires.
3093326|NCT01937039||Breast cancer patients|Participants have a known diagnosis of breast cancer and are receiving a breast cancer evaluation and/or treatment, who agree to sample collection, access, and follow-up as part of the repository.
3093327|NCT01937039||Benign breast disease|Participants have benign breast disease and are receiving a diagnostic procedure and/or evaluation, who agree to sample collection, access, and follow-up as part of the repository.
3093328|NCT01937039||Healthy volunteer|Participants have no known diagnosis of breast disease or abnormality and are undergoing routine screening or diagnostic breast imaging procedures and/or other clinical evaluation, who agree to sample collection, access, and follow-up as part of the repository.
3093329|NCT01937026|Experimental|Baricitinib|Single oral dose of 4 milligrams (mg) baricitinib on Day 1
3093330|NCT01937026|Experimental|Baricitinib + Probenecid|Oral doses of 1000 mg probenecid once daily on Days 3 through 7, with a single oral dose of 4 mg baricitinib co-administered on Day 5
3093331|NCT01937013|Experimental|Intranasal Oxytocin|Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3
3093332|NCT01937013|Placebo Comparator|Saline Nasal Mist|Participants will be randomized to receive intranasal saline mist (placebo) on opposite visits from the interventional drug visit 2 or 3
3093333|NCT01936974|Experimental|Platinum, Gemcitabine and Bevacizumab|"Platinum:~Carboplatin* on day 1~*If a patient is allergic to carboplatin, then give~Cisplatin** on day 1~**If a patient is allergic to cisplatin and carboplatin, then give~Oxaliplatin on day 1~Gemcitabine on day 1 only~Bevacizumab on day 1"
3093334|NCT01936974|Active Comparator|Gemcitabine and Bevacizumab|"Gemcitabine on days 1 and 8~Bevacizumab on day 1"
3093335|NCT01936961|Experimental|CTLA-4 Antibody + hypofractionated radiotherapy|Hypofractionated radiotherapy completed at least 3 days prior to receipt of CTLA-4 Antibody
3093336|NCT01936948|Active Comparator|Clip closure + EndoCut|Clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp using clips. Resection is done using the EndoCut electrocautery mode.
3114169|NCT01794663|Placebo Comparator|Matching placebo|
3093337|NCT01936948|Active Comparator|Clip closure + Coagulation|Clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp using clips. Resection is done using the Coagulation electrocautery mode.
3093338|NCT01936948|No Intervention|No clip closure + EndoCut|No clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp. Resection is done using the EndoCut electrocautery mode.
3093339|NCT01936948|No Intervention|No clip closure + Coagulation|No clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp. Resection is done using the Coagulation electrocautery mode.
3093340|NCT01936935|Experimental|Low-fat dairy|3 servings/d of low-fat dairy
3093341|NCT01936935|Placebo Comparator|Sugar-sweetened beverages|3 servings/d of sugar-sweetened foods
3093342|NCT01936922|Experimental|Virtual reality device (GaitAid®)|This will be a within-subjects design. Each subject will first walk in a controlled laboratory setting as she or he would in daily life. After this, each participant will walk while using the virtual reality device (GaitAid®) for a brief period of time. The session will end with walking as usual.
3093343|NCT01936909|Experimental|Anakinra (short)|Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks
3093344|NCT01936909|Experimental|Anakinra (long)|Anakinra 100 mg daily for 12 weeks
3093345|NCT01936909|Placebo Comparator|Placebo|Placebo injections daily for 12 weeks
3093346|NCT01936896|Experimental|Alpha-1 anti-trypsin (AAT)|We will use plasma derived AAT 60 mg/Kg, single infusion, within 12 hours of hospital admission for ST-segment elevation myocardial infarction (STEMI)
3093347|NCT01936883|Active Comparator|LDR boost|After completion of 46 Gy of external beam radiotherapy subjects will undergo a permanent seed radioactive implant to the prostate using iodine-125 seeds to deliver a dose of 110 Gy
3093348|NCT01936883|Active Comparator|HDR boost|Subjects in this arm will undergo an HDR implant to deliver 15 Gy to the prostate prior to commencing the external beam component of their treatment.
3093349|NCT01936870||Fesoterodine (Toviaz)|
3093350|NCT01936857|Experimental|Buprenorphine/naloxone|Office based treatment of opioid dependence with buprenorphine/naloxone
3093351|NCT01936857|Active Comparator|Methadone Maintenance Therapy|Referral to methadone maintenance therapy for treatment of opioid dependence.
3093352|NCT01936844|Experimental|Anakinra (short)|Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14
3093353|NCT01936844|Placebo Comparator|Placebo|Placebo injections twice daily for the first 3 days then once daily for days 4-14.
3093354|NCT01936831|Experimental|Group 1: Patients with a TB strain that has an inhA mutation|"Participants who meet Step 2 entry criteria will be randomized 1:1:1 to receive the following treatments for 7 days:~5 mg cohort: Isoniazid 5 mg/kg daily plus vitamin B6 ≥25 mg daily~10 mg cohort: Isoniazid 10 mg/kg daily plus vitamin B6 ≥25 mg daily~15 mg cohort: Isoniazid 15 mg/kg daily plus vitamin B6 ≥25 mg daily"
3093355|NCT01936831|Experimental|Group 2: Patients with TB without inhA nor katG mutations|Participants who meet Step 2 entry criteria will receive Isoniazid 5 mg/kg daily plus vitamin B6 ≥25 mg daily for 7 days
3093356|NCT01936831|No Intervention|Group 3: Patients with an MTB isolate with a katG mutation|Participants with an M. tuberculosis isolate with a katG mutation will not receive study drug.
3093357|NCT01936805|Active Comparator|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
3093358|NCT01936805|Placebo Comparator|Control|A loading dose of placebo was administrated 24 h before the PCI.
3093359|NCT01936792||mild traumatic brain injury|Subjects with mild traumatic brain injury
3093360|NCT01936792||Controls|Controls with no premorbid health conditions
3093361|NCT01936779|Active Comparator|Dietary supplement: fatty acid active|4g/day n-3 fatty acids for 8 weeks
3093362|NCT01936779|Placebo Comparator|Dietary supplement: fatty acid placebo|4g/day olive oil for 8 weeks
3093363|NCT01936753|Experimental|Mentor Mother Peer Support|This is an enhanced behavioral intervention. Mentor Mothers trained with a standard study curriculum are assigned to pregnant HIV-positive women accessing care at Primary Healthcare Centers in study communities. Under close daily supervision, Mentor Mothers provide support and counseling for the mother-infant pairs until the exposed infant is 12 months old. Study participants in this arm also receive standard of care PMTCT services.
3093364|NCT01936753|No Intervention|Routine Peer Support|Pregnant HIV-positive women receive standard-of-care PMTCT services (drugs, appointments, tests). These women are, per routine, assigned peer counselors who are also HIV-positive women with PMTCT experience but who do receive little or no standardized formal training, and are not closely supervised.
3093365|NCT01936740|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 45ml/min, vacuum 600 mmHg, bottle height 100cm.
3093366|NCT01936740|Other|HF easyTip 2.8mm|The phacoemulsifications tip used was the easyTip 2.8mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
3093367|NCT01936727|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
3093368|NCT01936727|Other|infusion asissted easyTip|The phacoemulsifications tip used was an infusion assisted easyTip 2.2mm (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
3093369|NCT01936714|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 45ml/min, vacuum 600 mmHg, bottle height 100cm.
3093370|NCT01936714|Other|LF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 20ml/min, vacuum 400 mmHg, bottle height 100cm.
3093371|NCT01936701|Other|acrylic 3-piece IOL|same-day bilateral cataract surgery with implantation of intraocular lens Domilens KS-XS in one eye
3093372|NCT01936701|Other|silicone 3-piece IOL|same-day bilateral cataract surgery with implantation of intraocular lens Domilens KS-3Ai in one eye
3093373|NCT01936688|Experimental|MK-3222 200 mg + Placebo to Etanercept|MK-3222 200 mg subcutaneously (SC) on Weeks 0, 4, 16, and 28 and, optionally, every 12 weeks thereafter until Week 220, plus etanercept placebo twice weekly up to Week 12, and then once weekly through Week 28.
3093374|NCT01936688|Experimental|MK-3222 100 mg + Placebo to Etanercept|MK-3222 100 mg SC on Weeks 0, 4, 16, and 28 and, optionally, every 12 weeks thereafter until Week 220, plus etanercept placebo twice weekly up to Week 12, and then once weekly through Week 28.
3093375|NCT01936688|Placebo Comparator|Placebo to MK-3222 + Placebo to Etanercept|Placebo to MK-3222 administered SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12, then once weekly up to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive MK-3222 high dose or MK-3222 low dose on Weeks 12, 16, and 28 and, optionally, every 12 weeks thereafter through Week 220.
3093376|NCT01936688|Active Comparator|Placebo to MK-3222 + Etanercept 50 mg|Matching placebo to MK-3222 SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and then once weekly through Week 28.
3093377|NCT01936675|No Intervention|Framingham Risk Score|Patients in this arm will receive their Framingham Risk Score of having a heart attack.
3093378|NCT01936675|Active Comparator|Framingham and Genetic Risk Score|Patients in this arm will receive their Framingham Risk Score as well as their Genetic Risk Score of having a heart attack.
3093379|NCT01936662|Experimental|Largyngeal Mask Airway for EGD procedure|Patients randomized to LMA to maintain airway through EGD procedure
3093380|NCT01936662|Active Comparator|Endotracheal Tube for EGD procedure|Patients were randomized to ETT to maintain airway for EGD procedure. This is the standard of care at this hospital
3093381|NCT01936649|Experimental|AdreView (Iobenguane I 123 Injection)|Two administrations of single intravenous (i.v) injection of Iobenguane I 123 10 millicuries (mCi) (370 MBq) over 1 to 2 minutes within an interval of 5 to 14 days.
3093382|NCT01936636||Cancer patients treated for BTcP|"All patients 18 years of age and older with breakthrough cancer pain (BTcP) who are registered in the Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program and receiving Abstral® under the direction of a TIRF REMS Access program-registered physician are eligible for the study.~Patients or their proxy with a witness must be able to sign written informed consent to participate in the study; and the patient may also use a proxy caregiver to assist in the completion of the study questionnaires."
3093383|NCT01936623|Experimental|Computerized Brief Intervention|Computerized Brief Intervention is delivered using a talking, animated cartoon-like parrot that provides patient feedback, empathic reflection, and personalization regarding their drug use.
3093384|NCT01936623|Other|Delayed Computerized Brief Intervention|Participants receive only a substance abuse assessment at baseline. At three-month follow-up, they then receive the computerized brief intervention.
3093385|NCT01936610|Experimental|role play|In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section .
3093386|NCT01936610|Experimental|lecture|describe the advantages and disadvantages of normal delivery and cesarian section
3093387|NCT01936597|Active Comparator|Single set (control Arm)|method of external cardiac massage incentive based on a single set. Intervention : Therapeutic and preventive strategies
3093388|NCT01936597|Experimental|Controller|Audio continuous guidance method by the controller. Intervention : Therapeutic and preventive strategies
3093389|NCT01936597|Experimental|Audio|Audio continuous guidance method by the controller relayed by an audio. Intervention : Therapeutic and preventive strategies
3093390|NCT01936584||TAPP repair|TAPP repair for inguinal hernia
3093391|NCT01936584||TEP repair|TEP repair for inguinal hernia
3093392|NCT01936571||NSCLC|The cohort consists of approximately 250 patients. As a rule of thumb 5-10 events per variable are needed to avoid overfitting a model. To model 6 clinical variables + 9 biomarker variables 75-150 events are needed. Assuming a two-year survival of 40%, the calculated (constant) hazard rate is 0.46 per year. With an inclusion rate of 50 patients per year, and a follow-up time varying between 0.5 and 4 year, at the time of analysis (November/December 2013) it is expected that there will be 138 events available for analysis.
3093393|NCT01936558||Amputees|Amputee with one arm or one leg amputated/ Far infrared ray to the phantom limb site
3093394|NCT01936558||Healthy subjects|Healthy subjects under 30 years old/ Far infrared ray to the sole
3093395|NCT01936545|Experimental|propofol|The anesthesia was maintained with propofol during liver transplantation.
3093396|NCT01936545|Active Comparator|Desflurane|The anesthesia was maintained with desflurane during liver transplantation.
3093397|NCT01936532|Experimental|assessment of treatment lenalidomide, dexamethasone,MLN9708|
3093398|NCT01936519|Active Comparator|Arm B|Calcineurin inhibitor immunosuppression with mycophenolic acid
3093399|NCT01936519|Experimental|Arm A: Everolimus|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
3093400|NCT01936506|Experimental|Cognitive Training A|emotional memory training exercise
3093401|NCT01936506|Active Comparator|Cognitive Training B|memory training exercise
3093402|NCT01936493||Females with uterine fibroids|Participants will be females age of 18 or older who have be diagnosed with uterine leiomyoma. Study Subjects will be asked if mothers or siblings also have diagnosis of uterine leoimyoma (either past or present diagnosis) and these family members will be invited to participate in this trial. All participants will provide blood samples for serum aliquots for hormonal analysis and genomic DNA analysis, and will answer a baseline genetic epidemiology questionnaire.
3114823|NCT01790061|Experimental|Traditional treatments|Oral Tubing
3093403|NCT01936480|Experimental|Moxifloxacin group|Healthy volunteers with QT genotype score in the highest or lowest quintile
3093404|NCT01936480|Placebo Comparator|Placebo Group|Healthy volunteers with QT genotype score in the highest or lowest quintile
3093405|NCT01936467|Experimental|Standard suction|These are patients who will have endoscopic ultrasound-guided fine needle aspiration using the standard suction FNA technique: 15 to-and-fro movements within the lesion will be performed with use of 10cc suction syringe.
3093406|NCT01936467|Experimental|Capillary suction|These are patients who will have endoscopic ultrasound-guided fine needle aspiration using the capillary suction FNA technique: 15 to-and-fro movements within the lesion will be performed with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
3093407|NCT01936454||Cohort 1|n=20 women with insertion dates 3-5months prior to enrollment and followed for 2-6 months
3093408|NCT01936454||Cohort 2|n=20 women with insertion dates 9-11 months prior to enrollment and followed for 2-6 months
3093409|NCT01936454||Cohort 3|n=250 women with insertion dates 21-24 months prior to enrollment and followed through month 36
3093410|NCT01936454||Cohort 4|n=300 women with insertion dates 33-36 months prior to enrollment and followed through month 6
3093411|NCT01936441|Experimental|Cognitive Behavioral Therapy-Insomnia (CBT-I)|"Participants will have contact with a menopause counselor 6 times over 8 weeks. The first session will be in-person at a private research office. All other contacts will be by telephone. Women unable to attend the in-person session will receive a phone call. All in-person and telephone consultations will be 20-30 minutes.~Participants will receive reading materials before each phone call relating to menopausal changes, menopausal changes in sleep and strategies for lessening menopause related sleep disturbances. A daily sleep diary will be completed each week during the 8-week intervention period. The day before each telephone session, the participant will email that week's completed diary to a secure email address accessible only by the counselor; women who are unable to use email will provide their data by telephone directly to the counselor. During the weekly telephone calls, the reading and materials will be discussed and the sleep diary will be reviewed."
3093412|NCT01936441|Placebo Comparator|Menopause Education Control (MEC)|Participants will have contact with a menopause counselor 6 times over 8 weeks. The first session will be in-person at a private research office. All other contacts will be by telephone. Women who are unable to attend the in-person session will receive a phone call. All in-person and telephone consultations are designed to last 20-30 minutes. Participants will receive information about menopausal changes and ways to develop symptom management strategies. Women in the MEC will keep a daily sleep diary. The day before each telephone session, the participant will email that week's completed diary to a secure email address accessible only by the counselor; women who are unable to use email will provide their data by telephone directly to the counselor. During the weekly telephone calls, the reading material will be discussed and the sleep diary will be reviewed.
3093413|NCT01936428|Other|interview|
3093414|NCT01936415|Experimental|Regenerex|One of the two prosthesis investegated
3093415|NCT01936415|Active Comparator|Vanguard|
3093416|NCT01936402|Experimental|5-6cm Chest compression depth|"Control group is trained for 5-6cm Chest compression depth during education.~Depth 5-6cm, Rate 100-120/min, Full chest recoil"
3093417|NCT01936402|Experimental|6-7cm chest compression depth|"Experimental group is trained for 6-7cm Chest compression depth during education.~Depth 6-7cm, Rate 100-120/min, Full chest recoil"
3093418|NCT01936389|Experimental|0.5%|0.5% Rho-Kinase Inhibitor
3093419|NCT01936389|Experimental|0.7%|0.7% Rho-Kinase Inhibitor
3093420|NCT01936376||head & neck cancer patients, cisplatin treatment|
3093421|NCT01936376||cancer patients, no cisplatin, no nephrotoxic agent|
3093422|NCT01936363|Experimental|Pimasertib (once daily) plus SAR245409 and Pimasertib placebo|
3093423|NCT01936363|Experimental|Pimasertib (twice daily) plus SAR245409 placebo|
3093424|NCT01936350|Experimental|Sildenafil|12 patients will be in this group. They will take a sildenafil 50mg.
3093425|NCT01936350|Placebo Comparator|Placebo|12 patients will be in this group, they will take placebo
3093426|NCT01936337|Active Comparator|DLX105 Hydrogel|
3093427|NCT01936337|Placebo Comparator|Placebo Hydrogel|
3093428|NCT01936324|Experimental|DRM01B|Active treatment: DRM01B topical gel, 7.5%
3093429|NCT01936324|Placebo Comparator|Vehicle gel|Placebo: DRM01B Vehicle Gel
3093430|NCT01936311|No Intervention|Control Group|This group will receive usual care.
3093431|NCT01936311|Experimental|Self-Management Goal Elicitation|This group will receive usual care alongside a form that helps elicit self-management goals as well as preferred treatment modalities.
3093432|NCT01936298|Experimental|A-ROM Continuous Passive Rehabilitation|The group of patients with Active Range Of Motion (A-ROM) is subjected to two session per day in the morning and in the afternoon over a period of two weeks (5 days per week). Each session is composed by 30 min of continuous passive motion rehabilitation and 60 min of physical and occupational therapy.
3093433|NCT01936298|Experimental|P-ROM Continuous Passive Rehabilitation|The group of patients with Passive Range Of Motion (P-ROM), i.e. without active movements of the hand at the baseline, is subjected to two session per day in the morning and in the afternoon over a period of two weeks (5 days per week). Each session is composed by 30 min of continuous passive motion rehabilitation and 60 min of physical and occupational therapy.
3093434|NCT01936285|Placebo Comparator|Control group|Patients taking placebo
3093435|NCT01936285|Experimental|Colchicine|Active treatment group
3093436|NCT01936272|Active Comparator|Chhabra Shunt Placement|The shunting arm will comprise a standard frontal approach ventriculoperitoneal shunt using a silastic Chhabra system.
3093437|NCT01936272|Active Comparator|ETV/CPC|The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) arm will comprise a standard frontal approach with flexible endoscopy.
3093438|NCT01936246|Experimental|Increased protein|Full term infants will be on 4 g/kg/day of protein. Preterm infants will be on 4.5 g/kg/day of protein until term corrected age. Beneprotein powder will be used; if this is not tolerated, Complete Amino Acids will be used. Max protein will be 30 g/day. Increased protein will be given until 12 months corrected age.
3093439|NCT01936246|No Intervention|Standard diet|Infants will be given a usual diet. If infants in this arm have poor growth, protein or caloric supplementation may be given per the discretion of the clinical team.
3093442|NCT01936220|Experimental|Continuity of specialized care|Continuity of specialized inpatient and outpatient care (relapse prevention)
3093443|NCT01936220|Experimental|Continuity of specialized care and parent groups|Continuity of specialized care combined with Parent groups
3093444|NCT01936220|Active Comparator|Treatment as usual|Discontinuity of care, relapse prevention as usual
3093445|NCT01936207||One Group|
3093446|NCT01936194|Experimental|Docosahexaenoic Acid (DHA)|infants receiving capsule containing DHA.
3093447|NCT01936194|Other|High Olive Oil|infants receiving capsule without DHA and EPA.
3093448|NCT01936194|Experimental|DHA+EPA|infants receiving capsule containing DHA and EPA.
3093449|NCT01936181|Experimental|SB2 (proposed biosimilar to inflixmab)|SB2 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion up to Week 70
3093450|NCT01936181|Active Comparator|Remicade (infliximab)|Remicade 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion up to Week 46
3093451|NCT01936181|Experimental|Remicade (infliximab), switch to SB2|SB2 3mg/kg at week 54, 62, 70
3093452|NCT01936181|Active Comparator|Remicade (infliximab), continue as Remicade|Remicade 3mg/kg at week 54, 62, 70
3093453|NCT01936168|Active Comparator|RFA|Radiofrequency Ablation (RFA)
3093454|NCT01936168|Experimental|MOCA|Mechanochemical Endovenous Ablation (MOCA)
3093455|NCT01936155|Experimental|Oedema, Joint Mobility, Skin Oxygenation|Neuromuscular electrical stimulation (NMES) is to be applied using a custom-built, two-channel stimulator, Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 90 minutes. Its affect on oedema reduction, joint mobility and skin oxygenation will be assessed both before and after its application.
3093456|NCT01936142|No Intervention|No RenalGuard|Control group will undergo CRT implantation without using RenalGuard
3093457|NCT01936142|Experimental|RenalGuard|Use of the RenalGuard system during CRT implantation
3093458|NCT01936129|Active Comparator|Copaxone|COPAXONE (glatiramer acetate) will be administered as a subcutaneous dose (20mg) once, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.
3093459|NCT01936129|Placebo Comparator|Placebo|Placebo (buffered normal saline w/v)will be administered as a subcutaneous dose, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.
3093460|NCT01936116|Experimental|patients with intrauterine balloon catheter placement|In this group, during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
3093461|NCT01936116|Active Comparator|patients with intracervical balloon catheter placement|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
3093462|NCT01936103|Active Comparator|standard group|patients in this group received standard statin treatment： Atorvastatin statins 20mg / night .
3093463|NCT01936103|Experimental|intensive group|patients in this group received intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation , and thereafter 20mg / night .
3093464|NCT01936090|Experimental|Treatment (bortezomib, TBI, melphalan, stem cell transplant)|"Conditioning regimen: Patients receive bortezomib IV on days -5 and -2, TBI BID on days -5 and -2, and melphalan IV over 1 hour on days -4 and -3.~Transplant: Patients undergo autologous bone marrow or peripheral blood stem cell transplant on day 0."
3093465|NCT01936077|Experimental|GnRH antagomnist hyper-responders|Those defined as hyper-responders will be given recombinant LH.
3093466|NCT01936064|Active Comparator|Jobelyn + Cyclophosphamide-Epirubicin6|Cyclophosphamide- Epirubicin 6 course regimen to be used with Jobelyn
3093467|NCT01936064|Active Comparator|Placebo + Cyclophosphamide- Epirubicin 6|Routine drugs for treatment of Breast Cancer used with Placebo
3093468|NCT01936051||OCD patients|OCD patients being treated with any dose of escitalopram
3093469|NCT01936038|Placebo Comparator|Control Group|CPAP
3093470|NCT01936038|Experimental|EXPERIMENTAL GROUP|Upper Airway Toning for Improve the Compliance of CPAP
3093471|NCT01936025|Active Comparator|Sitagliptin|Placebo dextromethorphan + sitagliptin 100 mg
3093472|NCT01936025|Experimental|Dextromethorphan 30 mg + sitagliptin|Dextromethorphan 30 mg + sitagliptin 100 mg
3093473|NCT01936025|Experimental|Dextromethorphan 60 mg + sitagliptin|Dextromethorphan 60 mg + sitagliptin 100 mg
3093474|NCT01936025|Experimental|Dextromethorphan 90 mg + sitagliptin|Dextromethorphan 90 mg + sitagliptin 100 mg
3093475|NCT01936025|Experimental|Dextromethorphan 30 mg + placebo|Dextromethorphan 30 mg + placebo (sitagliptin)
3093476|NCT01936025|Experimental|Dextromethorphan 60 mg + placebo|Dextromethorphan 60 mg + placebo (sitagliptin)
3093477|NCT01936025|Experimental|Dextromethorphan 90 mg + placebo|Dextromethorphan 90 mg + placebo (sitagliptin)
3093478|NCT01936025|Placebo Comparator|Placebo|Placebo (dextromethorphan)+ placebo (sitagliptin)
3093479|NCT01936012|Experimental|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Dexa Medica was given to each of study subjects.
3093480|NCT01936012|Active Comparator|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Boehringer Ingelheim Indonesia was given to each of study subjects.
3093481|NCT01935999|Other|One piece closed pouch|One piece closed pouch
3093482|NCT01935986|Experimental|probiotic|dietary supplement
3093483|NCT01935986|Placebo Comparator|placebo|dietary supplement without probiotic
3093484|NCT01935973|Active Comparator|Arm I (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.
3093485|NCT01935973|Experimental|Arm II (trametinib and Akt inhibitor GSK2141795)|Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3093738|NCT01934218|Placebo Comparator|Phosphate Buffered Saline (PBS)|3 mL, a single intra-articular injection of PBS
3093486|NCT01935960|Experimental|Arm I (retinoid 9cUAB30)|Participants receive retinoid 9cUAB30 PO QD on days 1 and 8-36. Treatment continues in the absence of unacceptable toxicity.
3093487|NCT01935960|Placebo Comparator|Arm II (placebo)|Participants receive a placebo PO QD on days 1 and 8-36.
3093488|NCT01935947|Experimental|Arm I (azacitidine, entinostat, chemotherapy)|Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice comprising irinotecan hydrochloride IV on day 1, docetaxel IV on day 1, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3093489|NCT01935947|Experimental|Arm II (azacitidine, entinostat, chemotherapy)|Patients receive azacitidine PO on days 1-21 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice as in Arm A.
3093490|NCT01935947|Active Comparator|Arm III (chemotherapy)|Patients receive chemotherapy of the treating oncologist's choice as in Arm A.
3093491|NCT01935934|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3093492|NCT01935921|Experimental|Treatment (cetuximab, IMRT, and ipilimumab)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Treatment with cetuximab repeats every 4 weeks for 2 courses. Beginning in week 2 of course 1, patients undergo concurrent IMRT 5 days per week for 7 weeks. Beginning in week 4 (day 1 of course 2) patients also receive ipilimumab IV over 90 minutes once every 21 days for 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may undergo surgery after completion of therapy.
3093493|NCT01935908|No Intervention|Control Group|The control group will not receive levetiracetam as seizure prophylaxis.
3093494|NCT01935908|Active Comparator|Treatment Group|levetiracetam 500mg in adults, twice daily, administered by mouth, per tube, or IV. The route of administration will be dependent upon the patient's clinical status and ability to tolerate each form. In descending order of preference, route of administration will be: oral, per tube, IV.
3093495|NCT01935895||Exercise on Blood Pressure Reactivity|To test the hypothesis of the present study, volunteers were invited to participate in two randomly assigned visits in distint days, as follows: 1) combined resistance and aerobic exercises performed in a circuit mode; and 2) a control session without exercise. In both visits, blood pressure was measured at rest and at each 15 minutes post-session during 1 hour of recovery following the exercise and non exercise control sessions. In addition, blood pressure reactivity was evaluated using a cardiovascular stressor protocol (Cold Test Pressor) before and after the experimental sessions. The relationship between post-exercise blood pressure and blood pressure reactivity to stressor test was also examined.
3093496|NCT01935882|Active Comparator|Artemether-Lumefantrine|Artemether-Lumefantrine combination
3093497|NCT01935882|Experimental|Artemether-Lumefantrine-Primaquine 0.25|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine
3093498|NCT01935882|Experimental|Artemether-Lumefantrine-Primaquine 0.4|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine
3093499|NCT01935869|Experimental|LEO 90100|
3093500|NCT01935869|Placebo Comparator|Vehicle|
3093501|NCT01935869|Other|Petrolatum ointment|
3093502|NCT01935856|Experimental|KHK7580|
3093503|NCT01935843|Experimental|Anti-tumor responses of CART-HER-2|
3093504|NCT01935830|Experimental|LAAM arm|"[11C]LAAM 15-20 mCi (maximum administered mass of 10 ug)~Efavirenz, oral capsules, 600 mg~Ritonavir, oral capsules, 100 mg"
3093505|NCT01935817|Active Comparator|Silybin + vitamin E + phospholipids complex|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill per day for 12 months
3093506|NCT01935817|Placebo Comparator|sugar pill|one placebo pill per day for 12 months
3093507|NCT01935804|Experimental|Experimental: 1|Pioglitazone given 30mg/once daily for 12 months.
3093508|NCT01935804|Active Comparator|Active comparator: 2|Metformin given 850 mg/twice daily for 12 months.
3093509|NCT01935791|Placebo Comparator|Control|Saline
3093510|NCT01935791|Experimental|Hormone|Intravenous glucagon infusion up to 100nmol/kg/hr for up to 90 minutes.
3093511|NCT01935778|Active Comparator|capecitabine and oxaliplatin|Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1
3093512|NCT01935778|Experimental|Docetaxel and capecitabine and oxaliplatin|"Docetaxel 60 mg/m² will be intravenously infused over at least 1 hour on Day 1 every 3 weeks.~Oxaliplatin 100 mg/m² will be intravenously infused over at least 2 hours on Day 1 every 3 weeks.~Capecitabine 800 mg/m² will be orally administered twice daily from Day 1 evening to Day 15 morning every 3 weeks. (Total 1,600 mg/m² daily)"
3093513|NCT01935765|Experimental|Diabetes people|99 Type 1 diabetic patients aged 18 to 60 years, diagnosed since at least a year
3093514|NCT01935765|Experimental|healthy volunteers (controll group)|46 healthy volunteers matched by age, gender and body mass index
3093515|NCT01935752|Other|Fibromuscular dysplasia|Fibromuscular dysplasia:blood samples & vascular echotracking
3093516|NCT01935752|Other|healthy volunteer|healthy volunteer:blood samples & vascular echotracking
3093517|NCT01935752|Other|hypertensive patients|hypertensive patients:blood samples & vascular echotracking
3093518|NCT01935739||Primary Breast Tumor|Primary breast tumor were test for HER2/neu status.
3093519|NCT01935739||Axillary Lymph Nodes.|Axillary Lymph Nodes were tested for HER2/neu status.
3093520|NCT01935726||Pulmonary fibrosis patients or their caretaker/supporter|Patients with pulmonary fibrosis of any cause (idiopathic, related to connective tissue disease [e.g., rheumatoid arthritis, systemic sclerosis/scleroderma, dermato-/polymyositis, sjogren's syndrome], familial or genetic) or the primary supporter/caregiver of a patient with pulmonary fibrosis
3093521|NCT01935713|Experimental|Electronic Cigarette|Participants received the electronic cigarette for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
3093522|NCT01935713|Experimental|Dissolvable Tobacco Lozenge|Participants received the dissolvable tobacco lozenge for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
3115252|NCT01786876|Experimental|Radiolabeled SPD557|
3093523|NCT01935713|Experimental|Dissolvable Nicotine Lozenge (Nicorette)|Participants received the dissolvable nicotine lozenge (Nicorette) for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
3093524|NCT01935700|Experimental|chlchicine treated patients|2 tablets (0.5 mg/tablet) of colchicine three times per day (after breakfast, lunch and dinner); continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial
3093525|NCT01935687|Experimental|Using of instrumented wheel and ergometer roller|The same patient will receive two types of tests: instrumented wheel and ergometer roller.
3093526|NCT01935674|Experimental|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
3093527|NCT01935674|Experimental|Continue ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
3093528|NCT01935648||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the knee joint following hip arthroplasty. Total dose 200mls of 0.2% ropivacaine or 400mg at the time of surgery. This will be followed by a continuous infusion of 10mls/hour 0.2% ropivacaine for the subsequent 24 hours.
3093529|NCT01935635|Experimental|HPDCs-T immune therapy combined with IFN|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks
3093530|NCT01935635|Experimental|HPDCs-T immune therapy combined with ETV|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; Entecavir(ETV)therapy:0.5mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
3093531|NCT01935635|Experimental|HPDCs-T immune therapy combined with LdT|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; Telbivudine(LdT)therapy:600mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
3093532|NCT01935635|No Intervention|IFN treatment|IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks
3093533|NCT01935635|No Intervention|ETV treatment|Entecavir(ETV)therapy:0.5mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
3093534|NCT01935635|No Intervention|LdT treatment|Telbivudine(LdT)therapy:600mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
3093535|NCT01935622|Experimental|Doxycycline 100 mg|Doxycycline 100 mg twice daily for 14 days
3093536|NCT01935622|Experimental|Doxycycline 20 mg|Doxycycline 20 mg twice daily for 14 days
3093537|NCT01935622|Placebo Comparator|Placebo|Placebo
3093538|NCT01935609|Experimental|Couples counseling|Intervention to promote couples' adjustment (TCI) - The TCI was developed based upon considerable clinical experience and research review. The TCI is a structured approach to helping couples after brain injury address issues related to relationship quality and emotional well-being. The TCI is implemented in five or six (optional parenting session) session. Each session is in-person and lasts for 120 minutes.
3093539|NCT01935609|No Intervention|Waitlist Control|Couples are randomly assigned to the treatment group or waitlist control (WLC) group. Couples will complete the study measures on 2 occasions, 5 weeks apart. In fairness, WLC couples will then be offered the opportunity to participate in the intervention.
3093540|NCT01935596|Active Comparator|ropivacaïne 0,5%,|intrathecal administration of 15mg of ropivacaine 0.5%.
3093541|NCT01935596|Active Comparator|lévobupivacaïne 0,5%|intrathecal administration of 15mg of levobupivacaine 0.5%
3093542|NCT01935583|Experimental|Resilience/Adjustment Counseling|Intervention to promote resilience and adjustment (RAI) - The RAI was developed based upon considerable clinical experience and research review. The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment to injury. The RAI is implemented in seven, 60-minute, in-person sessions.
3093543|NCT01935583|No Intervention|Waitlist Control|Individuals are randomly assigned to the treatment group or waitlist control (WLC) group. Individuals will complete the study measures on 2 occasions, 5 weeks apart. In fairness, WLC participants will then be offered the opportunity to participate in the intervention.
3093544|NCT01935570|Experimental|Magnesium|
3093545|NCT01935557|Active Comparator|Continuous heparin infusion group|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
3093546|NCT01935557|Active Comparator|Intermittent heparin infusion group|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
3093547|NCT01935544|Experimental|botulinum toxin injections|The main objective is to compare the efficiency of botulinum toxin injections depending on the localization technique: ultrasound vs. electrical stimulation.
3093548|NCT01935544|Other|ultrasound guidance|The secondary objective is to demonstrate less painful localization associated to ultrasound-guidance
3093549|NCT01935531|Experimental|Diclofenac|3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is applied twice daily in the treatment area. 3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is to be applied 1cm beyond the single AK.
3093550|NCT01935518|Experimental|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
3093551|NCT01935505||Consulting group|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
3093552|NCT01935505||Drug intervention group|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
3093596|NCT01935245|Experimental|Mini extracorporeal circulation|Patients undergoing coronary artery bypass surgery on minimal extracorporeal circulation
3115253|NCT01786863||Neuromuscular blockade|
3093553|NCT01935505||Telephone intervention group|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
3093554|NCT01935505||Consulting+Telephone+Drug intervention|All the interventions above are include in this group
3093555|NCT01935492|Active Comparator|8 cycles of Paclitaxel & bevacizumab|8 cycles of Paclitaxel: 90 mg/m2 IV on days 1, 8 and 15 every 28 days & Bevacizumab: 10 mg/kg IV on days 1 and 15 every 28 days
3093556|NCT01935492|Active Comparator|2 x 4 cycles of Paclitaxel & bevacizumab|intermittent 2x4 cycles of Paclitaxel: 90 mg/m2 IV on days 1, 8 and 15 every 28 days & Bevacizumab: 10 mg/kg IV on days 1 and 15 every 28 days
3093557|NCT01935479|Experimental|AK159 SD 1|Single administration of AK159 dose level 1
3093558|NCT01935479|Experimental|AK159 SD 2|Single administration of AK159 dose level 2
3093559|NCT01935479|Experimental|AK159 SD 3|Single administration of AK159 dose level 3
3093560|NCT01935479|Experimental|AK159 SD 4|Single administration of AK159 dose level 4
3093561|NCT01935479|Active Comparator|MN-10-T SD|Single administration of teriparatide acetate
3093562|NCT01935479|Experimental|AK159 MD 1|Multiple administration of AK159 dose level 1
3093563|NCT01935479|Experimental|AK159 MD 2|Multiple administration of AK159 dose level 2
3093564|NCT01935479|Experimental|AK159 MD 3|Multiple administration of AK159 dose level 3
3093565|NCT01935479|Experimental|AK159 MD 4|Multiple administration of AK159 dose level 4
3093566|NCT01935479|Active Comparator|MN-10-T MD|Multiple administration of MN-10-T
3093567|NCT01935479|Placebo Comparator|Placebo MD|Multiple administration of placebo AK159
3093568|NCT01935466||Pioglitazone|Ever users of Pioglitazone
3093569|NCT01935466||Other drugs|Never users of pioglitazone
3093570|NCT01935453|Experimental|Recombinant HSV-1 Injection|Intratumoral injection Single dose: 4 groups -- 106 pfu, 107 pfu, 108 pfu and 4×108 pfu Multiple dose (three injections, every 2 weeks): 2 groups -- 108, 108, 108pfu and 4×108, 4×108, 4×108pfu Continuous treatment: Upon 4 weeks follow-up after administration, if the investigator deems that continuous treatment will benefit subjects, continuous intratumoral injection may be given, and the interval between each injection will be 2 weeks.
3093571|NCT01935440|Active Comparator|Prevention & Testing Control|The comparison condition is focused on basic HIV risk reduction , safety and preventing drug overdose.
3093572|NCT01935440|Experimental|Prevention & Testing Intervention|The intervention condition is training on peer outreach skills which includes talking to HIV positive social network members about HIV care, medication adherence and HIV risk reduction.
3093573|NCT01935427||Volunteer test subjects|Healthy volunteer with no cardiovascular disease
3093574|NCT01935414|Experimental|geko™|geko™ use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge
3093575|NCT01935414|Active Comparator|TEDS stockings|TEDS use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge
3093576|NCT01935401||Women with Bulimia Nervosa|"fNIR~- Functional near-infrared spectroscopy measured-brain activity"
3093577|NCT01935401||Healthy Controls|"fNIR~- Functional near-infrared spectroscopy measured-brain activity"
3093578|NCT01935388|Experimental|Common canister|Use of a single MDI (instead of assigning each patient an individual MDI) for multiple mechanically ventilated patients. Inhalers will undergo a stringent cleaning protocol between administrations and storage.
3093579|NCT01935388|No Intervention|Control|Each patient will be assigned an individual inhaler as per standard of care practice.
3093580|NCT01935375|Experimental|CNM Interpersonal Psychotherapy|CNM Interpersonal psychotherapy
3093581|NCT01935375|Active Comparator|Treatment as Usual|Treatment as Usual is psychotherapy with a mental health provider
3093582|NCT01935362|Placebo Comparator|placebo|Placebo administered to participant
3093583|NCT01935362|Active Comparator|Citrus supplement|Citrus supplement administered to participant
3093584|NCT01935349||Diabetes mellitus (DM) and hypertension (HT)|Diabetes mellitus (DM) and/or hypertension (HT) patients in Hong Kong
3093585|NCT01935336|Experimental|Ponatinib|Patients receive ponatinib hydrochloride taken by mouth once or twice a day. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3093586|NCT01935323|Experimental|High Intensity Interval Training|Participants will perform the HIIT protocol on an electronically-braked cycle ergometer (Quinton Excalibur, Quinton Instrument Company, Bothell, WA). Participants will perform a 20-minute protocol, consisting of four minutes of cycling at 15% of maximum anaerobic power (Max-AP) followed by 30 seconds at 85% of Max-AP. These workloads will be based upon pre-trial Wingate tests. This cycle was repeated four times within each protocol, ending with two minutes at 15% of Max-AP. This will be performed 3d/wk for 6wks, with at least 24 hrs between each session.
3093587|NCT01935323|Active Comparator|Moderate Intensity Training|Participants will perform 45-60 min (graduated over time to 60) of continuous cycling at 65% of VO¬2peak on a Monark cycle ergometer. Workload will be based upon pre-trial VO¬2peak testing. MIT exercise will be performed 5d/wk for 6wks.
3093588|NCT01935310|Experimental|imiquimod use in photoaging|Evaluate the efficacy and safety of imiquimod as a treatment option for photoaging photoaging equal to or greater than 3.
3093589|NCT01935297|Active Comparator|Exercise|8 weeks of supervised, structured, combined endurance and resistance training
3093590|NCT01935297|No Intervention|Control|Patients receive usual care, regular exercise is not recommended but also not prohibited
3093591|NCT01935284||Healthy Volunteers|
3093592|NCT01935271|Experimental|Muscle Armor Supplement|Treatment with a commercially available over the counter nutritional supplement
3093593|NCT01935271|Placebo Comparator|Placebo|Sugar-based placebo drink mix
3093594|NCT01935258|Experimental|Psychosomatic therapy|Psychosomatic therapy consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS. Psychosomatic therapy delivered by a psychosomatic therapist.
3093595|NCT01935258|Other|care as usual|Usual care of the general practitioner
3093597|NCT01935245|Active Comparator|Conventional extracorporeal circulation|Patients undergoing coronary artery bypass surgery on conventional extracorporeal circulation
3093598|NCT01935232||Men|140 Men
3093599|NCT01935232||Female|500 Female
3093600|NCT01935219|Experimental|Goal Management Training + Processing Speed Training|Group receives both Goal Management Training and as well as Processing Speed Training using DriveSharp software.
3093601|NCT01935219|Active Comparator|Processing Speed Training + Brain Health Workshop|Group receives both Processing Speed Training (using DriveSharp) and participates in a Brain Health Workshop that is matched to Goal Management Training for session length and contact with trainer.
3093602|NCT01935219|Placebo Comparator|Brain Health Workshop + computer assignments|Group participates in Brain Health Workshop and is provided with computer assignments to match for time spent on the computer in the other arms.
3093603|NCT01935206|Placebo Comparator|Placebo|The effect of naloxone (2 mg/kg) on secondary hyperalgesia 168 hours after a first-degree burn-injury is compared to the placebo effect.
3093604|NCT01935206|Experimental|Naloxone (2 mg/kg)|The effect of naloxone (2 mg/kg) on secondary hyperalgesia 168 hours after a first-degree burn-injury is compared to the placebo effect.
3093605|NCT01935193|Experimental|asa resistant|asa resistant patients receive endovenous infusion of lysine acetylsalicylate 288 mg and if asa resistance has been reversed they have been prescribed oral soluble salt of lysine acetylsalicylate.
3093606|NCT01935180|No Intervention|Standard colonoscopy|
3093607|NCT01935180|Active Comparator|Cap assisted colonoscopy|A transparent cap will be affixed to tip of the high-definition wide angle colonoscope.
3093608|NCT01935167|Experimental|A Group|DW1029M 600mg for 24 weeks
3093609|NCT01935167|Experimental|B Group|DW1029M 1200mg for 24 weeks
3093610|NCT01935167|Placebo Comparator|C Group|Placebo for 24 weeks
3093611|NCT01935154|Placebo Comparator|Placebo|Placebo will be administered evey 3 weeks from w0 to W15 than every 12 weeks until disease progression.
3093612|NCT01935154|Experimental|Vx-001|Vx-001 will be administered evey 3 weeks from w0 to W15 than every 12 weeks until disease progression.
3093613|NCT01935141|Experimental|Low-Dose IV Contrast|A single intravenous dose of 30 ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.
3093614|NCT01935141|Active Comparator|Full-Dose IV Contrast|A single intravenous dose of 100ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.
3093615|NCT01935128|Experimental|Arm 1 Everolimus/Reduced dose tacrolimus|In this arm, the myfortic® will be weaned off quickly and everolimus (Zortress®) initiated to achieve a target level of 3-8 ng/ml with a mean of 6 ng/ml. Once achieving a therapeutic dose of everolimus (Zortress®) the tacrolimus (Prograf® or Hecoria®) dose will be reduced a target level of 3-5 ng/ml.
3093616|NCT01935115|Active Comparator|Propofol|The control group will receive propofol 1 mg/kg and remifentanil 1 mcg/kg intravenously
3093617|NCT01935115|Experimental|Ketamine|Study group will receive ketamine 0.75 mg/kg and remifentanil 1 mcg/kg intravenously
3093618|NCT01935102||Chemotherapy|MBC patients treated with a first-line chemotherapy including paclitaxel without bevacizumab
3093619|NCT01935102||bevacizumab+chemotherapy|histologically confirmed HER2-negative MBC, treated with a first-line therapy including bevacizumab 10 mg/m2 i.v. on days 1 and 15 combined with first-line paclitaxel 90 mg/m2 i.v. on days 1, 8 and 15, every 4 weeks
3093620|NCT01935089|Experimental|Interferon alpha|pegylated Interferon alpha 2b (Pegintron) 1 µg/kg per week, 20 weeks
3093621|NCT01935076||Obese mother/ Macrosomic baby|Obese mother that delivers a macrosomic neonate to understand the effects neonatal exposure to maternal obesity.
3093622|NCT01935076||Obese mother/ normal weight baby|Obese mother that delivers a normal weight neonate to understand effects neonatal exposure to maternal obesity.
3093623|NCT01935076||Normal weight mother/ Macrosomic baby|Normal weight mother that delivers a macrosomic neonate
3093624|NCT01935076||Normal weight mother/ Normal weight baby|Normal weight mother who delivered a normal weight neonate
3093625|NCT01935063|Experimental|Cognitive Behavioral Couple Therapy|CBCT is a 12-session therapy that includes the following: re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviours and couple interactions; psychoeducation about PVD and its impact upon sexuality, defining/working the sexual script, mindfulness techniques, communication skills training, and sexual approach/avoidance goals work, defusion and acceptance approaches to coping with pain, among others.
3093626|NCT01935063|Active Comparator|Topical lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (Zolnoun, Hartmann, & Steege, 2003).
3093627|NCT01935050|Experimental|Guided Cognitive-Behavioral Self-Help|All participants will receive the experimental intervention: Guided Cognitive-Behavioral Self-Help. The 10 patient treatment modules will incorporate exercise, behavioral activation, thought monitoring and restructuring, relaxation training, worry control, and sleep hygiene. The four caregiver educational modules will provide caregivers with the skills needed to facilitate patients' practice of treatment techniques learned in session. For example, caregivers will be taught to help patients identify negative thoughts and replace them with more balanced alternatives and will be given tools to assist patients complete therapy goals (i.e., exercise, socializing).
3093628|NCT01935024|No Intervention|Normal Activity level|
3093629|NCT01935024|Active Comparator|Personalized Exercise Regimen|
3093630|NCT01935011||PD DBS 60 Hz, 130 Hz or DBS off|PD DBS on 60 Hz stimulation, 130 Hz stimulation or DBS off
3093631|NCT01934998||SCA6 and control|SCA6 and control
3093632|NCT01934998||SCA6 or controls|Twelve SCA6 patients and 8 controls to be studied
3093633|NCT01934985||Group 1|Patients scheduled to have clinically indicated stress MPI with low pre-test likelihood (0-15%) of coronary disease based on criteria of Diamond and Forrester. And those who have already had a clinical indicated stress MPI in the last three years with a low likelihood of having active coronary disease with no significantly narrowed coronary arteries.
3093673|NCT01934725||Patients w/ cryptogenic ischemic stroke|Patients aged 15 to 49 years with unexplained first-ever ischemic stroke
3116597|NCT01777750|No Intervention|Standard treatment|Standard treatment
3093634|NCT01934985||Group II|Patients in Group II who will have the dynamic imaging protocol studies after SCA, patients will be selected for protocol enlistment only if the decision is made by the patient's physician, based totally on clinical and social factors, that any considered revascularization intervention would not be performed on the day of diagnostic selective coronary angiography (SCA) and will be performed electively, at least 4 to 7 days later. Viability will be assessed in these patients only in the presence of WM abnormalities, and with serial analysis of WM, as described above. Patients will be followed for death or infarction or other events more than 3 months after study, for up to 3 years following participation in the protocol.
3093635|NCT01934985||Group III|"Patients found at SCA to have lesions of borderline clinical significance, preferably in the absence of other associated lesions."
3093636|NCT01934985||Group IV|Patients who were diagnosed with advanced heart failure including patients who had or will have cardiac resynchonization therapy (CRT) or a heart transplant.
3093637|NCT01934972|Experimental|CR + DCS|Subjects will receive Cognitive Remediation and active study drug.
3093638|NCT01934972|Active Comparator|CR + placebo|Cognitive Remediation and placebo
3093639|NCT01934959|Experimental|Probiotics|
3093640|NCT01934946|Experimental|comprehensive rehabilitation 10 days|comprehensive rehabilitation PT OT once per day for 10 times within 14 days hospitalization
3093641|NCT01934946|Placebo Comparator|home rehabilitation|home rehabilitation 6 times of PT home visit within 3 months after discharge
3093642|NCT01934933|Active Comparator|celebrex|celebrex capsule, 0.2 gram bid, 52 weeks
3093643|NCT01934933|Active Comparator|Enbrel|etanercept injection, 25mg per injection, 50mg/week, 52 weeks
3093644|NCT01934933|Active Comparator|Enbrel plus Celebrex|50mg/week Enbrel by hypodermic injection plus Celebrex 0.2 gram bid, 52 weeks
3093645|NCT01934907|Experimental|washed RBC|Packed RBCs are Washed and then, transfused.
3093646|NCT01934907|No Intervention|pack RBC|Packed RBCs are transfused.
3093647|NCT01934894|Experimental|cabazitaxel and lapatinib combination|"Cabazitaxel 1-hour IV infusion on Day 1 of each 3 week cycle (dose to be determined)~Lapatinib PO once daily (dose to be determined)~Treatment cycles will be repeated every 3 weeks."
3093648|NCT01934881|Experimental|group I|Voltage adjustment only
3093649|NCT01934881|Experimental|group II|Combined parameters adjustment
3093650|NCT01934868|Experimental|Prolotherapy Injections|"Each patient will be evaluated clinically and the spinal levels to be injected will be decided upon during each visit. The levels to be injected will largely depend on the pain referral patterns. All prolotherapy injections will be performed under ultrasound guidance.~A prolotherapy solution of 20% dextrose combined with 1% lidocaine will be injected to facet capsular ligaments and interspinous ligaments of the lumbar spine and the posterior sacroiliac ligaments. Six points will be injected in each treatment session. These sessions will be 4 weeks apart."
3093651|NCT01934868|Active Comparator|Epidural Steroid Injections (ESI)|Those patients assigned to the ESI group will receive epidural steroid injections with 80mg methylprednisolone and 10mg buvicaine to the interlaminar space. These will be performed 4 weeks apart and under fluoroscopy. The level that will be injected will depend both on the clinical presentation as well as the size of the interlaminar space seen under fluoroscopy.
3093652|NCT01934842|Experimental|TAP20-C|TAP20-C
3093653|NCT01934842|Active Comparator|SAFE-T-FILL|SAFE-T-FILL
3093654|NCT01934829|Experimental|urea-based cream|Advanced HCC throughout China were treated with 10% urea-based cream 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for up to 12 weeks
3093655|NCT01934829|Placebo Comparator|best supportive care|BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator
3093656|NCT01934816|Experimental|Glimepiride|4mg of Glimepiride once only before vascular testing and intradermal injections of GLP-1 and its analogues
3093657|NCT01934816|Placebo Comparator|Placebo tablet|Placebo tablet is given in the morning of the intradermal injections of GLP-1 and its analogues
3093658|NCT01934816|Active Comparator|Glyburide|10mg of Glyburide before study visit and intradermal injections of GLP-1 and its analogues
3093659|NCT01934803|Active Comparator|Zinc gluconate|Study participants will receive zinc gluconate supplements (15 mg for men and 12 mg for women) and will be instructed to take one pill daily for 18 months.
3093660|NCT01934803|Placebo Comparator|Placebo|Study participants will receive identically packaged placebo (sucrose) pills and will be instructed to take one pill daily for 18 months.
3093661|NCT01934790|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
3093662|NCT01934777|Experimental|TREATED GROUP|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg by mouth every day in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 6 months
3093663|NCT01934777|Placebo Comparator|PLACEBO GROUP|placebo: this group will treated with identical placebo pearls given orally in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 6 months
3093664|NCT01934764||autoimmune disease|
3093665|NCT01934751|Other|Opioid dependent|Subjects with a possible opioid use disorder, as determined by positive responses on the eligibility form: has used opioids within the past 30 days, opioid use has been a problem, and at least one harmful consequence of opioid use has been present (eg. withdrawal symptoms, or problems with family, friends, work, money etc.).
3093666|NCT01934751|Other|Alcohol dependent|Patients who indicate they have a problem with alcohol will be asked to complete the AUDIT, a validated, 10-item instrument that measures the severity of an alcohol problem. The AUDIT enquires about core features of alcohol dependence, such as failure to fulfill obligations. A score of 8 or more indicates possible alcohol dependence.
3093667|NCT01934738|Experimental|Group 1: Cohort 1|
3093668|NCT01934738|Experimental|Group 1: Cohort 2|
3093669|NCT01934738|Experimental|Group 1: Cohort 3|
3093670|NCT01934738|Experimental|Group 2: Cohort 4|
3093671|NCT01934738|Experimental|Group 1: Cohort 5|
3093672|NCT01934738|Experimental|Group 2: Cohort 6|
3093674|NCT01934725||Stroke-free control subjects|Stroke-free subjects age- and gender-matched to patients
3093675|NCT01934712|Experimental|FIAsp|Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits
3093676|NCT01934712|Active Comparator|NovoRapid®|Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits
3093677|NCT01934699|Active Comparator|MRI-Arm|Myocardial vitality determination based on MRI diagnostics.
3093678|NCT01934699|Experimental|Echo-Arm|Myocardial vitality determination using echocardiography in combination with 2D-Strain Analysis.
3093679|NCT01934686||Subjects with diabetes mellitus (type 2)|
3093680|NCT01934673||Subjects with diabetes (type 2)|
3093681|NCT01934647|Experimental|Dose Escalation|MK-8892 doses starting at 1 mg, are sequentially escalated, stopping at the HAT dose or a maximum of 14 mg.
3093682|NCT01934647|Experimental|HAT Dose|Dose of MK-8892 that is highest acutely tolerated or a maximum of 14 mg.
3093683|NCT01934634|Experimental|LCL161 +Gemcitabine +nab-Paclitaxel|LCL161 (tablets): 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days nab-paclitaxel IV: 100 or 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
3093684|NCT01934621|Experimental|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice. Participants use printed workbooks to learn and apply this method.
3093685|NCT01934621|Placebo Comparator|Attention Control|The attention control intervention will control for the non-specific effects of strategy training. The therapists will administer the standardized and dose-matched protocol, using scripted open-ended questions to facilitate participants' reflections on their rehabilitation activities and experiences. In lieu of the strategy training workbook materials, participants will complete a daily journal, and discuss their entries during attention control sessions.
3093686|NCT01934608|Experimental|Refill synch|Participants in this group will have their medication refill schedule synchronized.
3093687|NCT01934608|No Intervention|Control|Participants in this arm will receive usual care
3093688|NCT01934595|Experimental|Varying amounts of Beneprotein|1.5grams/kg/day, 2.0 grams/kg/day, and 2.5 grams/kg, day
3093689|NCT01934595|Active Comparator|1 Gram - Standard Therapy given in ICU|1 gram/kg/day of protein
3093690|NCT01934582|Experimental|Open label extension|
3093691|NCT01934569|Experimental|Active tratment|Pravastatin, midazolam, losartan, omeprazole, caffeine single dose alone or in combination with PF-05089771
3093692|NCT01934556|Active Comparator|Monthly|Monthly Cohort (30 eyes) - Study eyes will receive intravitreal injections of 0.3 mg ranibizumab every 4 weeks for 24 months.
3093693|NCT01934556|Active Comparator|TREX|(60 eyes) - Monthly intravitreal injections of 0.3 mg ranibizumab for four visits. At the fourth visit (Week 12), if the central foveal thickness is ≤ 325 μm then the eye will receive 0.3 mg ranibizumab and begin the extension phase of the study. For all subsequent visits in the extension phase, appropriate changes to the treatment interval with 0.3 mg ranibizumab (i.e. extend, maintain, reduce) will be made based on pre-specified SD (Spectral Domain)-OCT criteria. Treatment is rendered at every visit. The time between visits is individualized based on each subject's response to treatment. If the central foveal thickness is > 325 μm at week 12, then the patient will continue to receive monthly intravitreal injections of 0.3 mg ranibizumab until the central foveal thickness is ≤ 325 μm. Once the central foveal thickness is ≤ 325 μm, then the study eye will begin the extension phase of the study.
3093694|NCT01934556|Active Comparator|GILA|(60 eyes) - Monthly intravitreal injections of 0.3 mg ranibizumab for four visits combined with guided laser photocoagulation to all microaneurysms in the area of DME at visit 2 (Week 4) and then again every 3 months, if leakage is present on fluorescein angiography. If the central foveal thickness is ≤ 325 μm at visit 4 (Week 12), eyes will receive 0.3 mg ranibizumab and the extension phase will begin. For all subsequent visits in the extension phase, appropriate changes to the treatment interval with 0.3 mg ranibizumab (i.e. extend, maintain, reduce) will be made based on pre-specified SD-Optical coherence tomography criteria. If the central foveal thickness is > 325 μm at week 12, then the patient will continue to receive monthly intravitreal injections of 0.3 mg ranibizumab and possible guided laser every 3 months until the central foveal thickness is ≤ 325 μm. Once the central foveal thickness is ≤ 325 μm, then the study eye will begin the extension phase of the study.
3093695|NCT01934543|Experimental|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
3093696|NCT01934543|Experimental|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
3093697|NCT01934530|Active Comparator|Connective Tissue Graft - Control|The donor tissue was harvested from tissue palatal to maxillary premolars and anterior to the mesial of the first molars. A horizontal incision corresponding to the width of the recipient bed plus 4mm was made 3 mm apical to the gingival margin. A small secondary vertical incision was tolerated on the mesial aspect of the surgical site to allow for a split thickness technique. The flap was then positioned over the graft and sutured with attempts to cover the grafted tissue to 2mm coronal to the implant/abutment interface pending flap tension. Follow up was monitored over 6 months at various time-points.
3093698|NCT01934530|Experimental|Alloderm - Test|ADM graft was prepared according to the manufacturer's instructions. The preparation requires rehydration in 50ml sterile saline or Ringers Solution for five minutes and repeated twice. The graft was then transferred to the recipient bed with the basement membrane side facing up and connective tissue on the periosteum. The allograft was trimmed to cover the defect dimensions up to the implant-abutment interface. There was a 4mm margin added to the width on each side to account for lateral contraction as with the connective tissue. With sterile moist gauze, pressure was applied to the graft for proper adaptation to the wound bed. The graft was sutured with a single sling and the flap with a double sling. Simple interrupted sutures were used to close vertical releases.
3093699|NCT01934504||Tolerant AAV|Tolerant participants with AAV
3116710|NCT01776970|Placebo Comparator|Placebo|Placebo oromucosal spray
3093701|NCT01934504||Healthy Controls|Healthy participants that fulfill eligibility criteria -similar in age to Tolerant and Non-Tolerant AAV participants.
3093702|NCT01934504||AAV Discontinuing Immunosuppression|Participants have been in clinical remission and on minimal maintenance therapy for at least 2 years prior to screening. Their primary physicians have planned to discontinue immunosuppression medication in the next year after screening.
3093703|NCT01934491|Experimental|Cognitive Training A|emotional memory training exercise
3093704|NCT01934491|Active Comparator|Cognitive Training B|memory training exercise
3093705|NCT01934465||Avastin regimens|Patients who have either received or who are going to receive chemotherapy plus Avastin (bevacizumab)
3093706|NCT01934452||Complete Remission|Complete remission arm in mRCC patients treated with sunitinib.
3093707|NCT01934452||Non Complete Remission|Non complete remission arm in mRCC patients treated with sunitinib.
3093708|NCT01934439|Experimental|PAAD (Proximal Arm AMES Device)Treatments|"The PAAD flexes and extends the elbow, and it abducts and adducts the shoulder, where abduction is away from the side of the body, and adduction is towards it. Elbow extension occurs simultaneously with shoulder abduction, and elbow flexion occurs simultaneously with shoulder adduction. At the same time as the movements, vibrators are utilized to activate muscle spindle Ia receptors in the muscles of the arm to exaggerate the perception of movement."
3093709|NCT01934426||Admission High Risk|Admission High Risk
3093710|NCT01934413|Active Comparator|Technology-Enhanced TPC|In addition to receiving usual palliative care service in the hospital setting, Technology-Enhanced Transitional Palliative Care patients will receive Transitional Care from the Palliative Care consulting team beginning in the hospital within 24 hours of study enrollment and continuing post discharge for eight weeks in their homes in rural locations by means of video visits with the Palliative Care consulting team.
3093711|NCT01934413|Other|Usual standard of care|The control group will receive only the current standard palliative care service in the hospital setting, which includes standard in-hospital palliative care consultation and standard discharge planning.
3093712|NCT01934374|Experimental|Stroke|On the 30th day post stroke (D30), the exjperimental group will start to receive the task-oriented lower extremity strengthening training (TOLEST) program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.
3093713|NCT01934374|No Intervention|Control|The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity.
3093714|NCT01934361|Experimental|Lomustine+ buparlisib (Phase Ib)|
3093715|NCT01934361|Experimental|carboplatin+ buparlisib (Phase Ib)|
3093716|NCT01934361|Experimental|lomustine+ buparlisib (Phase II)|
3093717|NCT01934361|Placebo Comparator|lumustine + placebo (Phase II)|
3093718|NCT01934361|Experimental|carboplatin+ buparlisib (Phase II)|
3093719|NCT01934348|Experimental|Psychological First Aid|Behavioral intervention delivered to crime victims during 2-3 in-person interactions within 1 month of the assault.
3093720|NCT01934348|Active Comparator|Usual victim advocacy services|Standard victim advocacy services delivered to crime victims within 1 month of the assault.
3093721|NCT01934335|Experimental|Vandetanib|Vandetanib, 300 mg, PO, q day for 7-14 days prior to surgery
3093722|NCT01934335|Placebo Comparator|Placebo|Placebo, PO, q day for 7-14 days prior to surgery.
3093723|NCT01934322|Experimental|Case Management|"Furnish specific assistance and to provide referrals for the patients:~If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.~If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.~If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.~In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent."
3093724|NCT01934322|No Intervention|Control|Patients randomized to control group (usual care) will receive standard emergency care by physicians (resident or attending physician) and nurses, without the case manager been involved. Nevertheless, the mobile team will take contact with each patient of the control group, giving them short information through a flyer (flyer) which will underline the existence of the mobile team, its addresses and telephone numbers.
3093725|NCT01934309|Experimental|TB reminders|Receive existing reminders plus new patient-specific reminders about TB screening, prevention, and treatment
3093726|NCT01934309|No Intervention|No TB reminders|Only receive existing reminders; no TB reminders
3093727|NCT01934296|Experimental|chronic brain recording|This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.
3093728|NCT01934283|No Intervention|operated patients|small bowel obstrucion patients who needed surgery for treatment of obstruction.
3093729|NCT01934270|Experimental|Anaerobic Test|
3093730|NCT01934257|Other|Marketed milk-based lactose-containing infant formula|
3093731|NCT01934257|Other|Marketed milk-based lactose-free infant formula|
3093732|NCT01934257|Other|Marketed soy-based lactose-free infant formula|
3093733|NCT01934244||Per Protocol|All enrolled patients in which all inclusion/exclusion criteria were met and the NovaSure endometrial ablation was completed.
3093734|NCT01934244||Primary|All enrolled patients in whom the Novasure device was inserted.
3093735|NCT01934244||Intent to treat|All enrolled patients in which NovaSure device was attempted.
3093736|NCT01934231|Experimental|Single arm|Each participant will take Potassium Clavulanate (CVA)/ Amoxicillin (AMPC) corresponding 6.4/90 mg/kg/day in two divided doses (every 12 hours) just before lactation or meal for 7 days depending on his/her body weight at the start of treatment (Day 1). The actual daily dose depends on the body weight of the participant.
3093739|NCT01934205|Experimental|Part A(Cohort1)|Study BTZ116666 has two parts. Each part will consist of a maximum of 6 cohorts. Part A will be initiated with 4 initial cohorts/timepoints in order to minimize the number of healthy volunteers that undergo bronchoscopy in this study. After review of data from Cohorts 1 through 4 of Part A, the study team will determine if additional cohorts are needed to be studied in Part A and/ or if Part B is needed. If the study team determines that additional cohorts are needed, then only the necessary cohorts in Parts A and/or B will be executed. In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 2 hours x 1 dose
3093740|NCT01934205|Experimental|Part A (Cohort2)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 4 hours x 1 dose
3093741|NCT01934205|Experimental|Part A (Cohort3)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 8 hours x 1 dose
3093742|NCT01934205|Experimental|Part A (Cohort4)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 12 hours x 1 dose
3093743|NCT01934205|Experimental|Part A (Cohort5)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
3093744|NCT01934205|Experimental|Part A (Cohort6)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
3093745|NCT01934205|Experimental|Part B (Cohort1)|In Part B, participants will receive GSK2140944 1000 mg IV infusion, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
3093746|NCT01934205|Experimental|Part B (Cohort2)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
3093747|NCT01934205|Experimental|Part B (Cohort3)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
3093748|NCT01934205|Experimental|Part B (Cohort4)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
3093749|NCT01934205|Experimental|Part B (Cohort5)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
3093750|NCT01934205|Experimental|Part B (Cohort6)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
3093751|NCT01934192|Experimental|Initial randomization: GSK962040 Arm|Subjects in the GSK962040 Arm will receive 50 mg once daily enteral dose administered through NG tube up to 7 days.
3093752|NCT01934192|Placebo Comparator|Initial randomization: Placebo Arm|Subjects in the placebo arm will receive once daily dose enteral dose administered through NG tube up to 7 days.
3093753|NCT01934192|Experimental|Treatment change due to intolerance: GSK962040 Arm|Subjects that develop intolerance and that originally received Placebo will receive 50 mg once daily enteral dose administered through NG tube + placebo IV
3093754|NCT01934192|Active Comparator|Treatment change due to intolerance: Metoclopramide Arm|Subjects that develop intolerance and that originally received GSK962040 will receive metoclopramide 10 mg IV every 6 h + placebo NG
3093755|NCT01934179||Ancillary-correlative (real-time PCR)|Patients undergo blood collection for analysis via real-time PCR at baseline, 3 months, and 6 months.
3093756|NCT01934166|Experimental|Nalmefene 18 mg|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
3093757|NCT01934153|Experimental|Cohort A|Single dose of topical [14C]Umeclidinium was applied to the unoccluded axilla, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
3093758|NCT01934153|Experimental|Cohort B|Single dose of topical [14C]Umeclidinium was applied to the occluded axilla, and the drug which will be applied to the test site has remain on the application site for 8 hrs
3093759|NCT01934153|Experimental|Cohort C|Single dose of topical [14C]Umeclidinium was applied to the unoccluded palm, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
3093760|NCT01934153|Experimental|Cohort D|Single dose of topical [14C]Umeclidinium was applied to the occluded palm, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
3093761|NCT01934140|Experimental|ACWY-TT group|All subjects vaccinated with MenACWY-TT in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a booster dose of MenACWY-TT in this study.
3093762|NCT01934140|Active Comparator|MenPS group|All subjects vaccinated with Mencevax ACWY in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a dose of MenACWY-TT in this study.
3093763|NCT01934127|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 1 at a 21 day interval
3093764|NCT01934127|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 2 at a 21 day interval
3093765|NCT01934127|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 3 at a 21 day interval
3093766|NCT01934127|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 4 at a 21 day interval
3093767|NCT01934127|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK2789868A H7N1 vaccine formulation 5 at a 21 day interval
3093768|NCT01934127|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
3093769|NCT01934114||Under Treatment|Patients with locally advanced breast cancer, defined as being clinically appropriate for neoadjuvant therapy
3093770|NCT01934114||Normal Cohort|Healthy female volunteers with breast size and epithelial integrity adequate to allow NIR imaging exams
3093771|NCT01934101|Experimental|CHR-5154|CHR-5154
3093772|NCT01934101|Placebo Comparator|Placebo|Placebo
3093773|NCT01934088|Experimental|Propofol|Propofol in refract doses. Induction: 10-60 mg supplemented with 10-30 mg following an age correlated algorithm. Maintenance with refract bolus of 10-20 mg every 1-2 minutes after assessed need and condition
3093774|NCT01934088|Active Comparator|Fentanyl and Midazolam|0.025-0.05 mg of Fentanyl i.v. minimum 5 minutes before procedure as a single shot. Midazolam 1-2 mg i.v. for induction and 0.5-1 mg i.v. for maintenance after assessing needs and condition
3093775|NCT01934075|Experimental|Mental health treatment|Participants will receive twice-weekly exposure to 6 sessions of individual mental health treatment in a private room. Sessions will follow the intervention manual and be delivered by a full-time nurse facilitator who has a counseling background and receives supervision by a trained therapist.
3093776|NCT01934075|No Intervention|Standard of Care|Participants in the control condition will receive counseling that is the current standard of care for fistula patients at KCMC.
3093777|NCT01934062||Surgical patients|Pediatric patients having surgery at Nationwide Children's Hosp. between 1/1/2013 & 7/31/2013.
3093778|NCT01934049|Active Comparator|Dexmedetomidine|Dexmedetomidine in dex group is administered as 1ug/kg by intravenous infusion 10 min and then 0.6 ug/kg until 30 minutes before the operation finishes.
3093779|NCT01934049|Placebo Comparator|Saline|Participants in con group receive placebo(saline) as the same dose at the same time as dex group.
3093780|NCT01934036|Experimental|Obex, a nutritional supplement|Obex will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
3093781|NCT01934036|Placebo Comparator|Placebo|Placebo will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
3093782|NCT01934023|Active Comparator|Varenicline|FDA approved smoking cessation medication
3093783|NCT01934023|Placebo Comparator|Placebo Sugar Pill|sugar pill
3093784|NCT01934010|Experimental|AM-101 injection|AM-101 gel for intratympanic injection
3093785|NCT01933997|Experimental|MG01CI 1400 mg|
3093786|NCT01933984|Experimental|Individualized dosing|"Ventilator support~Determining personal target airway resistance~Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent~Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days~Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days~Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met (until ventilator discontinuation or the 28th day if ventilator-dependent)"
3093787|NCT01933984|Active Comparator|Fixed dosing|"Ventilator support~Determining personal target airway resistance~Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent~Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days~Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days~No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met"
3093788|NCT01933971|Other|Group 1: filgrastim 2.5 µg/kg/day for 7 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.~The sites, where the injections are to be performed, are planned as follows:~st injection: upper part of the upper arm, posterior surface~nd injection: upper part of the thigh~rd injection: abdomen with the exception of the umbilical area~th injection: upper part of the contra-lateral upper arm, posterior surface~th injection: upper part of the contra-lateral thigh~th injection: abdomen with the exception of the umbilical area~th injection: upper part of the same upper arm, posterior surface as for the 1st injection."
3093789|NCT01933971|Other|Group 2: filgrastim 5 µg/kg/day for 7 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.~The sites, where the injections are to be performed, are planned as follows:~st injection: upper part of the upper arm, posterior surface~nd injection: upper part of the thigh~rd injection: abdomen with the exception of the umbilical area~th injection: upper part of the contra-lateral upper arm, posterior surface~th injection: upper part of the contra-lateral thigh~th injection: abdomen with the exception of the umbilical area~th injection: upper part of the same upper arm, posterior surface as for the 1st injection."
3093790|NCT01933971|Other|Group 3: filgrastim 10 µg/kg/day for 5 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.~The sites, where the injections are to be performed, are planned as follows:~st injection: upper part of the upper arm, posterior surface~nd injection: upper part of the thigh~rd injection: abdomen with the exception of the umbilical area~th injection: upper part of the contra-lateral upper arm, posterior surface~th injection: upper part of the contra-lateral thigh."
3093791|NCT01933958||Group 1|Patients treated with Regorafenib under practical manner for gastrointestinal stromal tumors progressed after cancer chemotherapy.
3093792|NCT01933945||TACE + early Nexavar|Patients with early start of Sorafenib treatment. This cohort comprises all patients where the physician decides at the time of TACE non-eligibility to choose Sorafenib as the next treatment option (regardless of whether TACE treatment is continued or not).
3093849|NCT01933594|Placebo Comparator|Cohort 4-Arm 4B (Placebo for RMD)|Participants in Cohort 4, Arm 4B will receive 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0, 14, 28, and 42 study visits. Dose of sodium chloride for injection placebo will be 5 mg/m^2, with total dose based on the participant's BSA, which is determined by participant's height and weight.
3093793|NCT01933945||TACE without early Nexavar|Patients without early start of Sorafenib treatment. This cohort comprises all patients where the physician decides at the time of TACE non-eligibility not to choose Sorafenib as the next treatment option. This cohort also includes patients with TACE non-eligibility for whom the decision to treat with Sorafenib is made at a later point in time, patients who are never treated with Sorafenib as well as patients for whom another systemic cancer treatment has been chosen be the physician either at time of TACE non-eligibility or at a later point in time.
3093794|NCT01933932|Experimental|Selumetinib + Docetaxel|Three 25mg Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle
3093795|NCT01933932|Experimental|Placebo + Docetaxel|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
3093796|NCT01933919|Placebo Comparator|placebo|"In the double-blind placebo-controlled phase participants received one placebo tablet a day in week 1, then one placebo tablet twice a day (BID) in week 2 followed by a dose adjustment period from weeks 3 to 6 where the dose could be escalated by one tablet/day/week up to a maximum of three tablets twice a day. From weeks 7 to 10 participants received the same dose that was given during week 6. At the end of the 10-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to two tablets/day each week.~In the open-label long-term phase participants received 25 mg fluvoxamine once a day for the first week, 25 mg BID in week 2 followed by a flexible dose period from weeks 3 to 52 where the dose could be escalated by one tablet/day/week up to a maximum of 150 mg/day (three tablets BID). At the end of the 52-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to 50 mg/day each week."
3093797|NCT01933919|Experimental|Fluvoxamine|"In the double-blind placebo-controlled phase participants received 25 mg fluvoxamine once a day in week 1, 25 mg twice a day (BID) in week 2 followed by a dose adjustment period from weeks 3 to 6 where the dose could be escalated by 25 mg/day/week up to a maximum of 150 mg (three tablets BID). From weeks 7 to 10 participants received the same dose that was given during week 6. At the end of the 10-week treatment period there was a dose-tapering period of up to 4 weeks where the dose of decreased by up to 50 mg/day each week.~In the open-label long-term phase participants received 25 mg fluvoxamine once a day for the first week, 25 mg BID in week 2 followed by a flexible dose period from weeks 3 to 52 where the dose could be escalated by 25 mg/day/week up to a maximum of 150 mg/day (three tablets BID). At the end of the 52-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to 50 mg/day each week."
3093798|NCT01933906|Experimental|P1101|"P1101 50µg s.c. will be administered every 2 weeks in addition to preexisting imatinib treatment. In the absence of dose limiting toxicities after 12 weeks, the dose will be escalated to 100µg every 2 weeks.~Maximum treatment duration will not expand 18 months."
3093799|NCT01933880|Experimental|OROS-MPH Group|Participants with ADHD will receive OROS -MPH starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
3093800|NCT01933880|Active Comparator|Normal Group|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
3093801|NCT01933867|Experimental|Water immersion colonoscopy|Water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
3093802|NCT01933867|Active Comparator|Air insufflation colonoscopy|Standard room air insufflation during both colonoscope insertion and withdrawal.
3093803|NCT01933854||Riverside group|Women aged 20 years or over who are not pregnant living riverside area of the Amapa State Brazil.
3093804|NCT01933854||urban group|women aged 20years or over not pregnant and living urban area
3093805|NCT01933841||Days 1-30|Adult surgery patients whose operations occurred during Days 1-30 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
3093806|NCT01933841||Days 31-60|Adult surgery patients whose operations occurred during Days 31-60 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
3093807|NCT01933841||Days 61-90|Adult surgery patients whose operations occurred during Days 61-90 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
3093808|NCT01933841||Days 91-120|Adult surgery patients whose operations occurred during Days 91-120 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
3093809|NCT01933828|Active Comparator|OPEN lobectomy|Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
3093810|NCT01933828|Active Comparator|VATS lobectomy|Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
3093811|NCT01933828|Other|ROBOT-assisted lobectomy|Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
3093812|NCT01933815|Experimental|TPI 287 + bevacizumab|"All subjects in phase 1 & subjects randomized to the TPI 287 + bevacizumab arm in phase 2 will be administered a 1-hour IV infusion of TPI 287 once every 3 weeks (Days 1 & 22 of 42-day cycle) & a 30-90 minute IV infusion of bevacizumab once every 2 weeks (Days 1, 15, & 29).~In phase 1, the dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6, while the dose of bevacizumab remains constant (10 mg/kg). The first 5 dose levels will be 140, 150, 160, 170, & 180 mg/m2. Dose levels beyond 180 mg/m2 will be increased in increments of 20 mg/m2. Three subjects will be treated at a dose level halfway between the dose level that exceeds the MTD and the dose level immediately prior to further refine the MTD.~In phase 2, the dose of TPI 287 will be the MTD determined in phase 1, & the dose of bevacizumab will be the same as phase 1 (10 mg/kg).~Subjects may continue on treatment unless they meet one or more of the protocol discontinuation criteria."
3093850|NCT01933581||ACS undergoing CA and PCI|Patients with Acute Coronary Syndrome undergoing coronary angiography and PCI
3093813|NCT01933815|Active Comparator|Bevacizumab|"All subjects randomized to the bevacizumab alone arm in phase 2 will be administered bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29 of a 42-day cycle). The dose of bevacizumab will be 10 mg/kg.~Subjects will be withdrawn from the study if they meet one or more of the discontinuation criteria outlined in the protocol; however, treatment with bevacizumab may continue under the FDA approved labeling for bevacizumab at the discretion of the subject's doctor.~All subjects in phase 1 will be administered TPI 287 in combination with bevacizumab (i.e., there will be no bevacizumab alone arm during phase 1)."
3093814|NCT01933802|Experimental|autologous MSC-NP|intrathecal administration of autologous MSC-NP in three doses at three month intervals
3093815|NCT01933789|Experimental|Feedback Group|Subjects will complete surveys and assessments and will be given the Communication Feedback Form for Patients with Serious Illness to use prior to and during a target outpatient visit.
3093816|NCT01933789|No Intervention|Comparison/Usual Care Group|Subjects will only complete surveys and assessments.
3093817|NCT01933776|Experimental|Group 1: Adults|Participants 18 through 64 years of age will receive a single booster dose of Tdap vaccine (ADACEL).
3093818|NCT01933776|Experimental|Group 2: Children|Participants 4 through 8 years of age will receive a single booster dose of Tdap vaccine (ADACEL)
3093819|NCT01933763|Experimental|Group A|Participants in Group A will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo.
3093820|NCT01933763|Experimental|Group B|Participants in Group B will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo.
3093821|NCT01933750|No Intervention|Randomized/Control|7 patients randomized to deferred treatment/control cohort at the 3 sub-study control sites = 21
3093822|NCT01933750|Experimental|Non-Randomized/Treatment|Patients are non-randomized and if meet inclusion criteria receive the implantation of the PresVIEW device
3093823|NCT01933737|Experimental|Kinesio Taping Group|The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
3093824|NCT01933737|Experimental|Placebo tape group|The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
3093825|NCT01933724|Experimental|5 mg prednisone|Subjects will be randomized to 5 mg per day of prednisone for a 6 month period.
3093826|NCT01933724|Experimental|0 mg prednisone|Subjects will be randomized to 0 mg per day of prednisone dose for a 6 month period.
3093827|NCT01933711|Experimental|Rituximab maintenance|maintenance therapy with rituximab (375 mg/m2) administered every 3 months for 2 years.
3093828|NCT01933711|No Intervention|Observation|observational arm, no intervention
3093829|NCT01933698|Active Comparator|Amoxi-Ped|Single dose of 500 mg amoxicillin - AMOXI-PED - was administered after a 12-hour overnight fast.
3093830|NCT01933698|Active Comparator|Amoxil|Single dose of 500 mg amoxicillin - AMOXIL - was administered after a 12-hour overnight fast.
3093831|NCT01933685|Experimental|AIDSVAX B/E|AIDSVAX B/E at Weeks 0, 4, 24 and 48
3093832|NCT01933685|Placebo Comparator|AIDSVAX B/E Placebo|AIDSVAX B/E Placebo at Weeks 0, 4, 24 and 48
3093833|NCT01933672|Experimental|PF-04937319 once-daily|
3093834|NCT01933672|Experimental|PF-04937319 split-dose|
3093835|NCT01933672|Active Comparator|Sitagliptin once-daily|
3093836|NCT01933659|Experimental|group A: DSW group|ingesting DSW 200 cc four times a day (one hour before meal and bed time);
3093837|NCT01933659|Placebo Comparator|group B: non-DSW group|ingesting non-DSW drinking water 200 cc four times a day (one hour before meal and bed time).
3093838|NCT01933646||Cohort 1|
3093839|NCT01933633|Experimental|Exercise|Regular exercise training for 10 weeks prior to assisted fertilisation
3093840|NCT01933633|No Intervention|Control|Standard care
3093841|NCT01933607|Other|TOPS System|Post Marketing Study
3093842|NCT01933594|Experimental|Cohort 1-Arm 1A (RMD)|Participants in Cohort 1, Arm 1A will receive RMD intravenously (IV) over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of RMD will be 0.5 mg/m^2, with total dose based on the participant's body surface area (BSA), which is determined by participant's height and weight.
3093843|NCT01933594|Placebo Comparator|Cohort 1-Arm 1B (Placebo for RMD)|Participants in Cohort 1, Arm 1B will receive 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo will be 0.5 mg/m^2, with total dose based on the participant's BSA, which will be determined by weight and height.
3093844|NCT01933594|Experimental|Cohort 2-Arm 2A (RMD)|Participants in Cohort 2, Arm 2A will receive RMD IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of RMD will be 2 mg/m^2, with total dose based on the participant's BSA, which is determined by participant's height and weight.
3093845|NCT01933594|Placebo Comparator|Cohort 2-Arm 2B (Placebo for RMD)|Participants in Cohort 2, Arm 2B will receive 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo will be 2 mg/m^2, with total dose based on the participant's BSA, which will be determined by weight and height.
3093846|NCT01933594|Experimental|Cohort 3-Arm 3A (RMD)|Participants in Cohort 3, Arm 3A will receive RMD IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of RMD will be 5 mg/m^2, with total dose based on the participant's BSA, which is determined by participant's height and weight.
3093847|NCT01933594|Placebo Comparator|Cohort 3-Arm 3B (Placebo for RMD)|Participants in Cohort 3, Arm 3B will receive 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo will be 5 mg/m^2, with total dose based on the participant's BSA, which will be determined by weight and height.
3093848|NCT01933594|Experimental|Cohort 4-Arm 4A (RMD)|Participants in Cohort 4, Arm 4A will receive RMD IV over 4 hours (beginning at Hour 0) at the Day 0, 14, 28, and 42 study visits. Dose of RMD will be 5 mg/m^2, with total dose based on the participant's BSA, which is determined by participant's height and weight.
3093851|NCT01933568|Experimental|Radiation|combined CFRT and SABR with concurrent cisplatin
3093852|NCT01933555|Experimental|Empowerment program|The hour intervention, delivered over a 11-week period, consisted of an empowerment and additional components adapted from Freedom program run to support domestic abused women.
3093853|NCT01933555|No Intervention|Control group|Standard care, which was routine check ups and care provided by health care professionals.
3093854|NCT01933542|Active Comparator|Chlorzoxazone|"Oral administration of chlorzoxazone 500 mg (two 250 mg tablets)~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed"
3093855|NCT01933542|Placebo Comparator|Placebo|"Oral administration of two placebo tablets~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed"
3093856|NCT01933529|Experimental|ARA 290|ARA 290, 4.0 mg, injected subcutaneously once every morning during 28 days.
3093857|NCT01933529|Placebo Comparator|Placebo|Placebo, injected subcutaneously once every morning during 28 days,
3093858|NCT01933516|Experimental|GP2013|
3093859|NCT01933503|Experimental|OCA 5 mg|OCA 5 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 5 mg by mouth for 14 days.
3093860|NCT01933503|Experimental|OCA 10 mg|OCA 10 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 10 mg by mouth for 14 days.
3093861|NCT01933503|Experimental|OCA 25 mg|OCA 25 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 25 mg by mouth for 14 days.
3093862|NCT01933490|Other|a high carbohydrate test meal (control condition)|a high carbohydrate test meal (control condition)
3093863|NCT01933490|Active Comparator|high carbohydrate test meal after pre-treatment|a high carbohydrate test meal after pre-treatment with rapid acting aspart insulin (insulin condition)
3093864|NCT01933490|Active Comparator|high fructose low glucose test meal|high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal (fructose condition)
3093865|NCT01933477|No Intervention|Local Standard of Care|Arm A: Referral of post-partum women from the antenatal clinic to general adult ART services at approximately 4-8 weeks postpartum (the local current standard of care in this setting)
3093866|NCT01933477|Active Comparator|MCH-focused ART services|Arm B: Continued receipt of MCH-focused ART services based at the antenatal clinic throughout the period of breastfeeding. Post-partum women will only be referred to general adult ART services after the end of breastfeeding and once infants' final HIV status is determined.
3093867|NCT01933464|Experimental|Cromolyn|Subjects in this arm will be asked to apply their assigned medication twice daily to their entire face. The medication they will be receiving is cromolyn sodium ophthalmic solution, 4%.
3093868|NCT01933464|Placebo Comparator|Vehicle|Participants in this group will be assigned a solution consisting of only the inactive ingredients in cromolyn sodium ophthalmic solution to apply to their entire face twice daily.
3093869|NCT01933451|Experimental|Restrictive intraoperative fluid therapy|To Keep intraoperative pulse pressure variation above 18%.
3093870|NCT01933451|Other|Liberal intraoperative fluid therapy|To keep intraoperative pulse pressure variation below 13%.
3093871|NCT01933438|Experimental|Sup-ER protocol|Early shoulder repositioning (Sup-ER Splint)
3093872|NCT01933438|Active Comparator|Control|Standard treatment
3093873|NCT01933425|Active Comparator|Deep neuromuscular block followed by no neuromuscular block|"Deep neuromuscular blockade (PTC 0-1) with rocuronium 1 mg/kg followed by no neuromuscular blockade with sugammadex 8 mg/kg and placebo reversal.~Measurements of intraabdominal distance during deep neuromuscular blockade and without neuromuscular blockade"
3093874|NCT01933425|Placebo Comparator|No neuromuscular block followed by deep neuromuscular block|"No neuromuscular blockade with placebo followed by deep neuromuscular blockade (PTC 0-1) with rocuronium 1 mg/kg and reversal with sugammadex 8 mg/kg.~Measurements of intraabdominal distance during no neuromuscular blockade and during deep neuromuscular blockade."
3093875|NCT01933412|Experimental|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
3093876|NCT01933412|Active Comparator|Engerix B Hepatitis B Vaccine|Engerix B Hepatitis B Vaccine
3093877|NCT01933399|Other|Standard of Care|Medication based on physician prescriptions or overcounter use not germane to the study. Subjects also receive physical therapy for 2 weeks.
3093878|NCT01933399|Experimental|Extensible lumbosacral orthoses plus standard of care|This group receives a flexible/extensible lumbosacral orthosis, one that is commonly available over the counter
3093879|NCT01933399|Experimental|Inextensible lumbosacral orthoses and standard of care|This group receives an inextensible lumbosacral orthoses which leads to 14% increase in trunk stiffness compared to the other conditions.
3093880|NCT01933386|Other|SoundBite|SoundBite will be used for the first 30 days
3093881|NCT01933386|Other|Surgically Implanted BCD|The subject's own surgically implanted bone conduction device will be used for the first 30 days.
3093882|NCT01933373|Active Comparator|Toupet|Laparoscopic Myotomy + Toupet 180 degree partial posterior fundoplication.
3093883|NCT01933373|Experimental|Dor|Laparoscopic Myotomy + Dor anterior partial fundoplication. 90 degree partial fundoplication being the standard of care.
3093884|NCT01933360|Active Comparator|Misoprostol sublingual,1h|Administration of misoprostol sublingually 1h prior to surgery
3093885|NCT01933360|Active Comparator|Misoprostol sublingual. 3h|Administration of misoprostol sublingually 3h prior to surgery
3093886|NCT01933360|Active Comparator|Misoprostol vaginal,1h|Administration of misoprostol vaginally 1h prior to surgery
3093887|NCT01933360|Active Comparator|Misoprostol vaginal,3h|Administration of misoprostol vaginally 3h prior to surgery
3093888|NCT01933347|Experimental|Gefitinib 250mg/d|Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression, perform scheduled visits in investigational sites at interview day and complete related examinations during follow-up period.
3093916|NCT01933139|No Intervention|Control|standard physician interaction (control arm)
3093917|NCT01933126|Experimental|HCG administration|Intrauterine HCG injection
3093918|NCT01933126|Placebo Comparator|Placebo|G2 Medium
3093919|NCT01933113|Experimental|Single arm|DBS of the LHA
3093889|NCT01933334|Experimental|Pirfenidone: 4-Week Titration Group|Participants will receive one 267 milligrams (mg) oral pirfenidone capsule three times daily (TID) (801 mg per day [mg/day]) for 2 weeks followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 2 weeks (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 12 weeks maintenance period).
3093890|NCT01933334|Experimental|Pirfenidone: 2-Week Titration Group|Participants will receive one 267 mg oral pirfenidone capsule TID (801 mg/day) for 1 week followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 1 week (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 14 weeks (maintenance period).
3093891|NCT01933321|Experimental|Intrathecal autologous stem cells|Intrathecal stem cells will be administered to patients that fulfill the inclusion criteria.
3093892|NCT01933308|Experimental|Continuous high intensity training-CT80|All arms will receive standardized comprehensive self-management teaching from health care practitioners. At program completion, all subjects will receive the same standardized exercise recommendations. The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The duration of the training phase will be adjusted such that the total amount of work performed per session will be comparable between the three interventions. The training phase for the CT80 will consist of exercising at 80% of peak work rate (target training intensity) for 25 minutes, for a total session duration of 40 minutes.
3093893|NCT01933308|Experimental|Training at ventilatory threshold-CTVT|The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The duration of the training phase will be adjusted such that the total amount of work performed per session will be comparable between the three interventions. The training phase for the CTVT will consist of exercising at the ventilatory threshold for a duration that will result in a total amount of work equivalent to the work that each patient would have done if he/she had been assigned to the CT80 arm. This approach has been used successfully in the past to isolate the effect of training intensity from that of total training dose.
3093894|NCT01933308|Experimental|Interval training-IT|The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The training phase for the IT will consist of intervals of 30 seconds of exercise at 100% of work peak interspersed with intervals of 30 seconds of rest. This approach to IT was selected because it was successfully used by Vogiatzis et al. [33] and was shown to be as effective as continuous exercise training at a moderate intensity. As with the CTVT and CT80 arms, the duration of the training phase will be adjusted for the IT arm such that the total amount of work will be equivalent.
3093895|NCT01933295|Active Comparator|Sleep Education|Weekly educational emails sent to participants with information about sleep science and tips for better sleep.
3093896|NCT01933295|Experimental|Cognitive Behavioral Therapy for Insomnia|Behavioral treatment (5 component)
3093897|NCT01933295|Experimental|Sleep Restriction Therapy|Brief sleep restriction therapy.
3093898|NCT01933282|Experimental|MESA chemotherapy|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4 dexamethasone 20mg/ m2，VD d2，d3，d4，d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
3093899|NCT01933269|Experimental|FACBC|
3093900|NCT01933256|Experimental|600mg HIP2B|600mg HIP2B
3093901|NCT01933256|Placebo Comparator|Placebo|Placebo
3093902|NCT01933256|Experimental|400mg HIP2B|400mg HIP2B
3093903|NCT01933243|Experimental|Fish oil|Fish oil for 12 weeks
3093904|NCT01933243|Placebo Comparator|Placebo pill|Placebo pills for 12 weeks
3093905|NCT01933230|Other|Excel Cryo Cooling System Collar|An Excel Cryo Cooling System collar will be placed around the neck for a 2 hour neck cooling period. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level and pressure both in the head and in the blood.
3093906|NCT01933217|Experimental|Methylphenidate|The study medication will consist of identical capsules filled Concerta® over-encapsulated to preserve double-blinding. The weekly dosages will be low, medium, and high based on weight cut-offs. Participants weighing less than 25kg will receive 18mg (low), 27mg (medium), and 36mg (high) dosages and participants weighing above 25kg will receive 18mg (low), 36mg (medium), and 54mg (high) dosages during the 3-week upward titration trial. Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.
3093907|NCT01933217|Placebo Comparator|Placebo|The study medication will consist of identical capsules filled with an inert white power (placebo). Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.
3093908|NCT01933204|Experimental|Acupuncture|Using basic points combined with additional points. Basic points are fixed, while additional points will be selected from a list of points categorized by syndrome differentiation.
3093909|NCT01933204|Active Comparator|Climen 21 Tablets|COMPOSITION 11 white tablets each containing estradiol-17-valerate 2 mg, plus 10 pink tablets each containing estradiol-17-valerate 2 mg and cyproterone acetate 1 mg.
3093910|NCT01933191|Experimental|physical acticity|Experimental: Aerobic treadmill exercise (30 minutes, 70% VO2max)
3093911|NCT01933191|Placebo Comparator|placebo exercise|Aerobic treadmill exercise (30 minutes, 20% VO2max)
3093912|NCT01933178|Other|Cirrus AS-OCT|
3093913|NCT01933165|Other|LipiView|
3093914|NCT01933152||Group 1|
3093915|NCT01933139|Experimental|Audio-visual presentation|The intervention group will watch a 10-minute scripted video explaining the procedure, risks, benefits, expectations, and long term complications that relate to hysterectomies before face-to-face interaction with the surgeon. Patients in both arms will then sign the same standard pre-surgical informed consent form before undergoing the procedure.
3094102|NCT01931748|Active Comparator|MELSMON|6 times/ 12 days
3093920|NCT01933100|Experimental|Brown Rice Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
3093921|NCT01933100|Experimental|Polished Rice Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
3093922|NCT01933100|Experimental|Wheat Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
3093923|NCT01933087|No Intervention|Control with no hand hygiene promotion|no implementation of hand hygiene promotion
3093924|NCT01933087|Experimental|Hand hygiene promotion|Intervention to promote hand hygiene which is based on the WHO multimodal hand hygiene improvement strategy.
3093925|NCT01933061|Experimental|Abraxane 150 mg/m² Intravenous (IV)|
3093926|NCT01933061|Experimental|CC-486 orally plus Abraxane IV|
3093927|NCT01933048|Other|Healthcare Worker Administration|FluMist administered by a Healthcare Worker
3093928|NCT01933048|Experimental|Self-Administration|FluMist self-administered by subject
3093929|NCT01933035||Immune Thrombocytopenics|The study shall be a single institution prospective cohort study. Comparison will be made among individuals with known ITP . Those with known hypo-proliferative forms of thrombocytopenia [aplastic anaemia, chemotherapy induced thrombocytopenia, and myelodysplastic thrombocytopenia, and a control population.
3093930|NCT01933035||Hypo-proliferative thrombocytopenics|The study shall be a single institution prospective cohort study. Comparison will be made between individuals with known ITP versus those with known hypo-proliferative forms of thrombocytopenia [aplastic anaemia, chemotherapy--induced thrombocytopenia, and myelodysplastic thrombocytopenia], and a control population.
3093931|NCT01933035||Control Pupulation|comprised of healthy individuals with normal platelet counts, to confirm normal values for MPC and MPM
3093932|NCT01933022|Other|Single Arm: Eligard|Single Arm
3093933|NCT01932996|Active Comparator|Integrated Intensive Smoking + Alcohol|IS+A: 12-week treatment with nicotine patch plus nicotine gum/lozenge. An integrated intensive smoking along with an intensive alcohol intervention covering smoking cessation + alcohol abstinence using cognitive behavioral therapy, CBT, and will include weekly individual sessions for 3 months followed by study data collection visits for 3 months.
3093934|NCT01932996|Placebo Comparator|Usual Care|UC: 12-week treatment with nicotine patch plus nicotine gum/lozenge along with a one time brief smoking cessation and brief alcohol counseling both based on the USPHS's Guidelines
3093935|NCT01932983||TOF test|TOF - train of four test performed on patiens undergoing lumbar spine surgery where introperative neurophysiologic monitoring is applied. Stimulation of peripheral nerve - ulnar nerve resulting with muscle contractions and evaluation of responses by anesthesiologist and neurophysiologists. Stimulation with group of 0.2 millisecond pulses, spaced 500 millisecond apart, at a 2 Hz rate, current 20-60 mA to deliver four muscle contractions. Eligibility criteria included patients for study where subjective visual interpretation and quantitative interpretation of Adductor pollicis muscle responses is followed.
3093936|NCT01932970|Experimental|Etelcalcetide|Participants were treated with 5 mg etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session three times per week (TIW) for 4 weeks.
3093937|NCT01932957|Other|Laparotomy arm|Standard treatment
3093938|NCT01932957|Experimental|Laparoscopy arm|Treatment by laparoscopy
3093939|NCT01932944||No treatment|
3093940|NCT01932931|Active Comparator|Cholecalciferol supplement (50ug)|Cholecalciferol supplement is given for 1 year through randomisation of both MDD patients and healthy controls.
3093941|NCT01932931|Placebo Comparator|Placebo|Placebo treatment (tablet) is given for 1 year through randomisation of both MDD patients and healthy controls.
3093942|NCT01932918||PCA with morphine in liver transplant|Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.
3093943|NCT01932918||PCA with ketorolac in liver transplant|Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.
3093944|NCT01932918||Intravenous PCA in thoracic surgery|Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.
3093945|NCT01932918||PCEA in thoracic surgery|Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients.
3093946|NCT01932905|Active Comparator|deep rTMS-active doble coil|patients undergoing of deep rTMS real with doble coil
3093947|NCT01932905|Sham Comparator|deep rTMS-sham|patients undergoing to placebo deep rTMS
3093948|NCT01932905|Active Comparator|deep rTMS-active: H-coil|patients undergoing of deep rTMS real with H-coil
3093949|NCT01932892||Transhumeral prosthesis user|Transhumeral body-powered prosthesis user
3093950|NCT01932879|Experimental|Blackberry|Participants will consume blackberries twice/day as part of a 1-week controlled diet.
3093951|NCT01932879|Other|Control|Participants will consume jello twice/day as part of a 1-week controlled diet.
3093952|NCT01932866|Active Comparator|Control - diabetes risk score|the participants in the control group did not receive their diabetes risk score at the beginning of the trial, but did receive their scores to include baseline at the 12 and 24 week points.
3093953|NCT01932866|Experimental|Intervention - diabetes risk score|the subjects in the intervention arm received their diabetes risk scores at the beginning of the trial, 12 weeks and 24 weeks.
3093954|NCT01932853||Hemodialysis patients|Patients > 18y hemodialysis for at least 6 months at any center of Spain Fresenius Medical Care (FMC) meeting the inclusion criteria.
3093955|NCT01932840||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is an online panel which answer surveys every 8-10 weeks about diet and health
3093956|NCT01932827||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is a online consumer monitor panel which answers surveys every 8-10 weeks about diet and health.
3093957|NCT01932814||Aminoglycosides|have received aminoglycosides
3093958|NCT01932814||No Aminoglycosides|did not receive aminoglycosides
3093959|NCT01932801|No Intervention|Assessment-only|Assessment-only control condition
3117311|NCT01772745|Active Comparator|Group 1|SILS cholecystectomy
3093960|NCT01932801|Active Comparator|HRC|Harm reduction counseling, which entails provision of feedback and support of harm reduction goals and safer drinking provided at one-month intervals over a 3-month period.
3093961|NCT01932801|Experimental|XR-NTX+HRC|3 doses of active medication (380 mg injection/month) + Harm reduction counseling at one-month intervals over three months.
3093962|NCT01932801|Placebo Comparator|Placebo+HRC|3 doses of placebo + harm reduction counseling at one-month intervals over a three-month period
3093963|NCT01932788|Active Comparator|Vitamin D 4000 IU|Subjects randomized into this arm will receive supplementation with 4000 IU/day vitamin D3 in gummy vitamin form, plus the standard prenatal vitamin (containing 400 IU vitamin D3.
3093964|NCT01932788|Placebo Comparator|placebo gummy vitamin|Supplementation with placebo gummy vitamin form, plus the standard prenatal vitamin (containing 400 IU vitamin D3)
3093965|NCT01932775|Experimental|GlucoTab System|
3093966|NCT01932762|Experimental|GT2: Grazoprevir + Elbasvir + RBV (Arm A1)|During Part A of the study, GT2 participants will receive 100 mg grazoprevir + 50 mg elbasvir + standard weight-based dosing of RBV for 12 weeks.
3093967|NCT01932762|Experimental|GT2: Grazoprevir + RBV (Arm B1)|During Part B of the study, GT2 participants will receive 100 mg grazoprevir + standard weight-based dosing of RBV for 12 weeks.
3093968|NCT01932762|Experimental|GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)|During Part B of the study, GT4/GT5/GT6 participants will receive 100 mg grazoprevir + 50 mg elbasvir + standard weight-based dosing of RBV for 12 weeks.
3093969|NCT01932762|Experimental|GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)|During Part B of the study, GT4/GT5/GT6 participants will receive 100 mg grazoprevir + 50 mg elbasvir for 12 weeks.
3093970|NCT01932749|Active Comparator|bilateral repetitive transcranial magnetic stimulation|"Bilateral protocol:~Motor threshold 100% /LDLPFC/10Hz/5 second duration/10 second intertrain/ Motor threshold 120% /RDLPFC/1Hz/10 second duration/2second intertrain/"
3093971|NCT01932749|Active Comparator|unilateral repetitive transcranial magnetic stimulation|"Unilateral protocol:~Motor threshold 120% /RDLPFC/1Hz/10 second duration/2second intertrain"
3093972|NCT01932736|Experimental|healthy volunteers|healthy volunteers undergo pressure changes in ear canal
3093973|NCT01932723|Experimental|Lumbar Stabilization Exercises & Control|Lumbar stabilization exercises daily, 10 repetitions each (three times a day) for three months consecutively. All exercises were performed to a count of 7 seconds.
3093974|NCT01932710|Experimental|White Blood Cell Transfusion|Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment is tolerated. Patient receives a transfusion every 3-4 days (at least 2 a week) for up to 6 weeks.
3093975|NCT01932697|Experimental|Treatment (docetaxel, hyperfractionated IMRT)|Patients receive docetaxel IV over 1 hour on days 1 and 8 and undergo hyperfractionated IMRT BID 5 days a week on days 1-12 for a total of 20 fractions.
3093976|NCT01932684|Experimental|Incentive spirometry|Was utilized an incentive spirometer volume in this group.
3093977|NCT01932684|No Intervention|Control Group|
3093978|NCT01932684|Experimental|Breath Stacking|We used a face mask silicone connected to a check valve allowing only inspiration and is connected to a spirometer showed that the volume inspired by the individual.
3093979|NCT01932671||SMART|The SMART (Second Manifestation of ARTerial disease) cohort comprises patients at high-risk for or who have clinically manifest cardiovascular disease, including transient ischemic attack, cerebrovascular disease, peripheral artery disease, aneurysma aorta abdominalis, myocardial infarction, coronary ischemia for which coronary intervention is required, renal artery stenosis, diabetes mellitus, hyperlipidemia, hypertension, patients diagnosed with human immunodeficiency virus, pre-eclampsia, HELLP syndrome, abruption placentae and Intrauterine growth restriction in medical history. Participants are re-invited after 4 years for a second screening. This screening is performed to study the progression of atherosclerosis and evaluate the effects of the advice of the multidisciplinary team.
3093980|NCT01932658|Experimental|Hematopoietic stem cell transplantation|Lymphoablation followed by autologous hematopoietic stem cell transplantation rescue.
3093981|NCT01932645||Prostatitis patients|We will enroll patients from the outpatient clinic who are suffering from pelvic pain (perineal, suprapubic, testicular, penile etc), have urinary symptoms and sexual dysfunction (primarily pain associated with ejaculation). Patients with these symptoms and identified as having prostatitis will be approached to enroll.
3093982|NCT01932645||Controls|Male patients seen in the outpatient clinic who do not have prostatitis (not suffering from pelvic pain (perineal, suprapubic, testicular, penile etc), and do not have urinary symptoms and sexual dysfunction (primarily pain associated with ejaculation)) will be approached to enrol as controls.
3093983|NCT01932632|No Intervention|Usual Care|This group will receive care as similar as possible to care that they received prior to the study beginning. Their attending MDs will be instructed and reminded to avoid making parallel changes in the prescribing for the control patients unless there is a specific medical indication to which they would normally respond with a medication reduction. No other reminders or prompts about the study will be provided for these patients.
3093984|NCT01932632|Experimental|Medication Minimization|"Initial Medication Review (IMR) Completed by Attending MD and identifies potential medications to be considered for minimization as well as those UNSUITABLE (as per usual MD opinion)~Orders-Medication Update (OMU) (ref form) The attending MD will have identified one or more medications to be considered for minimization and in the IMR suggested a time when a reduced dose will be reviewed (recommended every 4 weeks). Each review will generate an OMU. This process will be repeated for every participant in the Medication Minimization arm until all medications are marked as having no further changes, ie no need for further OMU. At that time a participant's record will be marked as having completed medication minimization."
3093985|NCT01932606|Experimental|Nitrite|Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
3093986|NCT01932606|Placebo Comparator|Saline|Saline Placebo for Nitrite will be infused for 5 minutes during the cardiac catheterization procedure.
3093987|NCT01932593|Experimental|Infusion of autologous bone marrow|Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
3093988|NCT01932593|Placebo Comparator|Placebo|
3094103|NCT01931735|Experimental|Meniscectomy|This group will have a partial meniscectomy
3094104|NCT01931735|Active Comparator|Lavage|This group will have arthroscopy and lavage
3093989|NCT01932580|Other|FLOT chemotherapy|"Chemotherapy to be administered every 2 weeks for 4 cycles, before surgery. Then 4 more cycles will be given after surgery, at 2-week intervals.~5-FU 2600 mg IV/m2 in continuous infusion Leucovorin 200 mg IV/m2 Oxaliplatin 85 mg IV/m2 Docetaxel 50 mg IV/m2"
3093990|NCT01932567|Experimental|Positive expiratory pressure|Use of positive expiratory pressure during 3 minutes
3093991|NCT01932567|Experimental|Incentive spirometry|Use of incentive spirometry during 3 minutes
3093992|NCT01932567|Experimental|manual airway clearance technique|Use of manual airway clearance technique during 3 minutes
3093993|NCT01932554|Experimental|Abciximab|"Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission.~Patients will receive standard supportive care, including intravenous hydration, supplemental oxygen, incentive spirometry, ibuprofen, and parenteral narcotic pain medications (morphine, hydromorphone or fentanyl)"
3093994|NCT01932554|Placebo Comparator|Placebo|"Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission.~Patients will receive standard supportive care, including intravenous hydration, supplemental oxygen, incentive spirometry, ibuprofen, and parenteral narcotic pain medications (morphine, hydromorphone or fentanyl)"
3093995|NCT01932541|Experimental|Latuda (Lurasidone)|
3093996|NCT01932528|Experimental|500 mg LX606|All subjects will receive a single oral 500 mg dose of [14C]-LX1606.
3093997|NCT01932515|No Intervention|Screening|
3093998|NCT01932502|Experimental|clonazepam conversion to clobazam (Onfi)|Subject's clonazepam will be converted to clobazam (Onfi). This is an open label study without placebo control.
3093999|NCT01932489|Other|Sequencing of a metastatic lesion.|Biopsy of a metastatic lesion followed by a targeted cancer gene screen.
3094000|NCT01932476|Experimental|Celiac Disease Alone Gluten Challenge|
3094001|NCT01932476|Sham Comparator|Celiac Disease Alone Sham Challenge|
3094002|NCT01932476|Experimental|Celiac Disease and T1D Gluten Challenge|
3094003|NCT01932476|Sham Comparator|Celiac Disease and T1D Sham Challenge|
3094004|NCT01932463|Experimental|ExAb;ate MRgFUS|
3094005|NCT01932450|Experimental|renal sympathetic denervation|One-time standard bilateral renal sympathetic denervation by catheter-based radiofrequency ablation and using antihypertensive drugs which at least include an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB).
3094006|NCT01932450|Active Comparator|antihypertensive drugs|Blood pressure control in ADPKD patients with hypertension only using antihypertensive drugs which at least include an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB)
3094007|NCT01932437|Placebo Comparator|Placebo|Intramuscular (IM), single dose
3094008|NCT01932437|Experimental|ETI-204|Intramuscular (IM), single dose
3094009|NCT01932424|Experimental|Single arm|The intervention in this study involves taking blood sample from an existing arterial line for measurement of blood propofol levels. The drug in evaluation is Propofol 2% (Diprivan 2%, Astra Zeneca UK) administered as a target controlled infusion using the commercially available paediatric TCI models (Paedfusor and Marsh models). The dose range is usually between a target concentration of 3-8 mcg/ml. However the anaesthetic management is not changed for the study. The blood concentrations of propofol will be measured using Pelorus 1500 (Sphere Medical, UK), a CE marked device. The anaesthetist will be blinded from the measurements, unless the measured value was outside the safe limit ( < 3 mcg/ml or > 10mcg/ml).
3094010|NCT01932398||ADHD|A diagnosis of ADHD, classified by the DSM-IV.
3094011|NCT01932398||no ADHD|No diagnosis of ADHD, classified by the DSM-IV.
3094012|NCT01932385|Experimental|sorafenib|sorafenib 400mg, oral, twice a day until disease progression defined by RECIST.
3094013|NCT01932385|Active Comparator|Best Supportive Care|treatment mainly on nutrition and symptoms control
3094014|NCT01932372||Tofacitinib (Xeljanz)|Tablets 5 mg BID
3094015|NCT01932372||Standard of Care|Standard of Care for Rheumatoid Arthritis
3094016|NCT01932359|Active Comparator|rapidly absorbable suture (Vicryl Rapide)|
3094017|NCT01932359|Active Comparator|non-absorbable suture (Ethilon)|
3094018|NCT01932333|Experimental|Cohort 1|
3094019|NCT01932333|Experimental|Cohort 2|
3094020|NCT01932320|Experimental|Part 1|Participants will receive single dose of all the 3 formulations of JNJ-40411813 (Formulation A: hard gelatin capsule filled with beads; Formulation B: immediate release tablet, and Formulation C: Nanosuspension formulation) without food in 3 periods (Period 1, Period 2, and Period 3). The sequences will be based on a computer-generated randomization schedule prepared by the sponsor before the study. Each period will be separated by a wash out period (no treatment) of at least 1 week.
3094021|NCT01932320|Experimental|Part 2|Participants will receive single dose of the selected solid dose formulation of JNJ-40411813 (Formulation A or Formulation B) from Part 1 without food and with food in 2 periods (Period 1 and Period 2). The sequences will be based on a computer generated randomization schedule prepared by the sponsor before the study. Each period will be separated by a wash out period of at least 1 week.
3094022|NCT01932320|Experimental|Part 3|Participants will receive single dose of the selected solid dose formulation of JNJ-40411813 (Formulation A or Formulation B) from Part 1 on two occasions (Day 1 and Day 10) without food along with ketoconazole from Day 6 to Day 14 with food.
3094023|NCT01932307|Experimental|PGY1 General Surgery Residents|All first year general surgery residents at the University of British Columbia
3094024|NCT01932294||MedaMACS participants|All participants who have met the inclusion criteria.
3094025|NCT01932281|Experimental|SierraSil|SierraSil will be given in a dosage of 3 to 5, 667 mg capsules, according to body weight, daily for 3 weeks.
3094026|NCT01932281|Placebo Comparator|Placebo|This is a sugar pill and will be given in a dosage of 3 to 5 capsules daily for 3 weeks.
3094027|NCT01932268|Experimental|Rifampicin|experimentally check a change of the colchicine concentration from baseline at 1,2,4,8,24 hours after taking Rifampicin
3094028|NCT01932255||prophylactic spinal tap|Microvascular decompression surgery approach at the Karolinska University Hospital, i.e. a small craniectomy (removal of bone without putting it back), and postoperatively serial prophylactic lumbar tap
3094029|NCT01932255||no prophylactic spinal tap|Microvascular decompression surgery approach at St Olavs Hospital Trondheim University Hospital and the University Hospital of North Norway, i.e. not comprising a policy of preventing CSF leak by performing prophylactic lumbar taps or its equivalents
3094030|NCT01932242|Experimental|ETI-204|Intravenously (IV), repeat dose
3094031|NCT01932242|Placebo Comparator|Placebo|Intravenously (IV), repeat dose
3094032|NCT01932229|Experimental|Afatinib treatment|
3094033|NCT01932216|Active Comparator|Single-site robotic cholecystectomy|Single-site cholecystectomy using da Vinci robotic assisted surgery
3094034|NCT01932216|Active Comparator|Multi-port laparoscopic cholecystectomy|Multi-port cholecystectomy using laparoscopic surgery
3094035|NCT01932203|Active Comparator|aspirin|aspirin 100mg by mouth once a day for 104 weeks
3094036|NCT01932203|Experimental|Cilostazol|Pletaal SR 200mg by mouth once a day for 104 weeks
3094037|NCT01932190|Experimental|Early RRT strategy|"the early strategy : RRT is started immediately when a RIFLE F status is documented"
3094038|NCT01932190|Experimental|Delayed RRT strategy|"The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria"
3094039|NCT01932177|Active Comparator|Schedule A|Everolimus run-in period followed by continuous administration of everolimus and sorafenib
3094040|NCT01932177|Active Comparator|Schedule B|Sorafenib run-in period followed by continuous administration of everolimus and sorafenib
3094041|NCT01932177|Experimental|Schedule C|Everolimus and sorafenib in alternance
3094042|NCT01932177|Experimental|Schedule D|Continuous administration of everolimus and intermittent administration of sorafenib
3094043|NCT01932164|Experimental|cleft lip and palate|5 Patients with cleft unilateral lip and palate that have already performed the alignment of dental arches through the recommended orthodontic treatment will be selected to be submited to alveolar bone tissue engineering surgery
3094044|NCT01932151|Other|Terlipressin and albumin|Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.
3094045|NCT01932138|Experimental|Enhanced CHW intervention|CHWs will 1) identify pregnant women through home visits and refer them to ANC; 2) inform pregnant women on antenatal care ANC and PMTCT; 3) visit women at home to ascertain ANC attendance; and 4) follow up women who have missed ANC or PMTCT appointments.
3094046|NCT01932138|Other|Standard of care|Clinic-based health workers follow-up patients who have missed scheduled PMTCT appointments (through telephone calls and/or in-person visits). The standard of care does not include any specific interventions to improve ANC attendance.
3094047|NCT01932125||Cohort|
3094048|NCT01932112|Other|adenosine arm|single arm study
3094049|NCT01932099|Experimental|Single arm feasibility study|Prospective, multi-center, single arm feasibility study. Subjects will include patients with severe aortic valve stenosis who require replacement of their native aortic valve. The intervention is transcatheter aortic valve replacement.
3094050|NCT01932086|Experimental|White rice|
3094051|NCT01932086|Experimental|Brown rice|
3094052|NCT01932086|Experimental|Black rice|
3094053|NCT01932086|Active Comparator|Bread|
3094054|NCT01932086|Active Comparator|Glucose solution|
3094055|NCT01932073|No Intervention|Control Group|Receives institutional skin care protocol
3094056|NCT01932073|Experimental|Treatment Group|Receives institutional skin care protocol and, when applicable (if skin reactions develop), Low-Level Laser Therapy
3094057|NCT01932060|Experimental|Oxytocin Infusion 1|Oxytocin Infusion 15 U/hr to begin after the delivery of the fetus and to terminate at the time of patient discharge from the post-anesthesia care unit.
3094058|NCT01932060|Active Comparator|Oxytocin Infusion 2|Oxytocin infusion 2.5 U/hr to begin after the delivery of the fetus and to terminate at the time of discharge from the post-anesthesia care unit.
3094059|NCT01932034||Standard dosing|Vancomycin dosed and monitored according to standard practice
3094060|NCT01932034||BestDose Computer Software|Vancomycin dosed using BestDose computer software, targeting AUC rather than trough concentrations
3094061|NCT01932034||BestDose Computer Software 2|Vancomycin dosed using BestDose computer software, targeting AUC rather than trough concentrations and with computer-generated suggested optimal blood sampling times
3094062|NCT01932021|Experimental|adipose tissue grafting|
3094063|NCT01931995|Active Comparator|TMS to positively correlated DLPFC|High frequency TMS to a target region of dorsolateral prefrontal cortex which is positively correlated with the subgenual cingulate cortex
3094064|NCT01931995|Active Comparator|TMS to negatively correlated DLPFC|High frequency TMS to a target region of dorsolateral prefrontal cortex which is positively correlated with the subgenual cingulate cortex
3094065|NCT01931982|Active Comparator|victoza|The study is a cross over study. Patients randomised to start with victoza are treated with victoza for 10 weeks. After a wash out period of 2 weeks they cross over to 10 weeks of no treatment
3094066|NCT01931982|No Intervention|No treatment|
3094067|NCT01931969||IJVC intervention|
3094068|NCT01931956|Experimental|Non-High Risk|Includes patients who are candidate for mitral valve repair or replacement surgery, including cardiopulmonary bypass (i.e. non-high risk). The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant. This arm was evaluated as a separate study NCT00209274.
3094069|NCT01931956|Experimental|High Risk|Includes patients with a predicted procedural mortality risk calculated using the Society For Thoracic Surgeon (STS) surgical risk calculator of ≥12% or, in the judgment of a cardiac surgeon, the patient is considered a high risk surgical candidate due to the presence of pre-defined risk factors. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant. This arm was evaluated as a separate study NCT01940120.
3094105|NCT01931722|Active Comparator|Branched chain amino acid|Branched chain amino acid as food supplement
3094183|NCT01931176|Placebo Comparator|Placebo|Participants will receive a single injection of placebo at study entry.
3094070|NCT01931956|Experimental|Compassionate Use|Patients that did not meet REALISM High Risk or Non-High Risk eligibility criteria were evaluated for consideration for either Emergency Use (EU) or Compassionate Use (CU). The objective of the Compassionate and Emergency Use Group of the EVEREST II REALISM study is to provide access to the MitraClip Device, in a non-commercial setting, for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant.
3094071|NCT01931956|Experimental|Emergency Use|Patients that did not meet REALISM High Risk or Non-High Risk eligibility criteria were evaluated for consideration for either Emergency Use (EU) or Compassionate Use (CU). The objective of the Compassionate and Emergency Use Group of the EVEREST II REALISM study is to provide access to the MitraClip Device, in a non-commercial setting, for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant.
3094072|NCT01931943|Experimental|Selatinib Ditosilate Tablets|Selatinib Ditosilate either at 450,750,1000,1250mg, p.o. once daily
3094073|NCT01931930|Experimental|Perilla extract|Experimental arm: Perilla extract
3094074|NCT01931930|Placebo Comparator|Maltodextrin|Placebo arm: Maltodextrin
3094075|NCT01931917|Experimental|IY Parents and Babies Program|In the Incredible Years Parents and Babies Program, parents learn how to help their babies feel loved, safe, and secure. They learn how to encourage their babies' physical and language development. The parenting group format fosters peer support networks and shared learning. Trained Incredible Years facilitators use video clips of real-life situational vignettes to support the training and stimulate parenting group discussions and practice exercises with their babies. The program is group based with 6-8 mothers and partners attending 8 2 hour sessions with their babies.
3094076|NCT01931917|Active Comparator|Usual Care|Usual care consists of the elements that are being offered to all mothers in the participating municipalities which is 5 home visits by health visitors, a mothers group, a health nurse station and extra visits if needed.
3094077|NCT01931904||Trabeculectomy or Tube Shunt Patients|46 glaucoma patients undergoing trabeculectomy or tube shunt surgery to lower IOP
3094078|NCT01931891||prreclampsia|
3094079|NCT01931878|Placebo Comparator|Placebo , saline|The subject may be randomly assigned to receive Placebo, saline
3094080|NCT01931878|Active Comparator|IncobotulinumtoxinA Treatment|The subjects will be randomized to received injections of active study drug, incobotulinumtoxinA (Xeomin)
3094081|NCT01931865|Experimental|IncobotulinumtoxinA|The total dose will depend on the extent of the area involved by pain. The injections will be carried out through a 1cc syringe using a ½ to 1 inch needle intramuscularly or subcutaneously (or both). The ttoal dose will not exceed 100 units.
3094082|NCT01931852|Experimental|CMR-guided care|Participants in this group will receive a cardiac MRI
3094083|NCT01931852|Active Comparator|Invasive-based guideline-adherent care|Participants will receive care adherent with current ACC/AHA guideline recommendations. ( ACC/AHA Guideline adherent care )
3094084|NCT01931839|Experimental|Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h|Participants who received lumacaftor (LUM, VX-809) 600 milligram (mg) plus ivacaftor (IVA, VX-770) 250 mg fixed-dose combination (FDC) tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening, in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
3094085|NCT01931839|Experimental|Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening in this study VX12-809-105 up to Week 96.
3094086|NCT01931839|Experimental|Arm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
3094087|NCT01931839|Experimental|Arm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
3094088|NCT01931839|No Intervention|Arm 5 Part A: Observational Cohort|Participants who received either LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening OR LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening OR placebo matched to LUM and IVA in the morning and evening, in the previous study VX12-809-103 or VX12-809-104, and will be observed (will not receive study drug) in this study VX12-809-105 for up to 2 years.
3094089|NCT01931839|Experimental|Arm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in Cohort 4 of the previous study VX09-809-102, and will receive the same treatment in this study VX12-809-105 up to Week 96.
3094090|NCT01931839|Experimental|Arm 7 Part B: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in Cohort 4 of the previous study VX09-809-102, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
3094091|NCT01931826|Active Comparator|Endoscopic treatment alone|3 to 5 sessions of sclerotherapy till eradication of esophageal varices.
3094092|NCT01931826|Active Comparator|Total EGDS + endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
3094093|NCT01931813||Infants likely to present febrile convulsions|
3094094|NCT01931800||Presenting patients a pneumonia pneumococcique|
3094095|NCT01931800||Patients presenting a bacteremia pneumococcique|
3094096|NCT01931800||Patients affected by pneumococcique meningitis|
3094097|NCT01931787|Experimental|Treatment (CPI-613)|Patients receive CPI-613 IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3094098|NCT01931774||Acne Patients|
3094099|NCT01931774||Control Subjects|From General Population
3094100|NCT01931761|Experimental|[C14] selumetinib 75mg single dose|[C14] selumetinib 75mg single dose
3094101|NCT01931748|Experimental|UNCNT|6 times/ 12 days
3094106|NCT01931722|Active Comparator|Weight training|"Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1RM (repetition maximum). Instruction will be provided for all exercises and professional trainers will oversee all training sessions."
3094107|NCT01931709|Experimental|Diagnostic (FDG PET and DCE-MRI)|Patients undergo FDG PET and DCE-MRI 1-2 weeks prior to chemotherapy initiation, between 1-12 weeks after initiation of the first course of chemotherapy, and after the completion of chemotherapy (within 4 weeks prior to surgery).
3094108|NCT01931696|Experimental|Verum acupuncture|Verum acupuncture treatment once every two days + Albuterol sulfate HFA (Ventolin®™ 100 mcg Inhalation Aerosol) as needed + Prednisone Acetate Tablets(H31020675, 5 mg oral tablet) for exacerbation
3094109|NCT01931696|Sham Comparator|Sham acupuncture|Sham acupuncture treatment once every two days + Albuterol sulfate HFA (Ventolin®™ 100 mcg Inhalation Aerosol) as needed + Prednisone Acetate Tablets(H31020675, 5 mg oral tablet) for exacerbation
3094110|NCT01931683|Experimental|remifentanil|LMA removal was accomplished when remifentanil was maintained a predetermined concentration throughout the emergence periods.
3094111|NCT01931670|Experimental|Elagolix Dose 1|6 Month Treatment Period
3094112|NCT01931670|Experimental|Elagolix Dose 2|6 Month Treatment Period
3094113|NCT01931670|Placebo Comparator|Placebo|6 Month Treatment with matching Placebo
3094114|NCT01931657|Experimental|Mifepristone prior to Mirena|Pretreatment with mifepristone prior to Mirena insertion
3094115|NCT01931657|Placebo Comparator|Placebo prior to Mirena|Pretreatment with placebo prior to Mirena insertion
3094116|NCT01931644||Health Condition|Collect blood and other optional biospecimens from participants with a diagnosed health condition
3094117|NCT01931644||Healthy Control|Collect blood and other optional biospecimens from participants that have not been diagnosed with a health condition
3094118|NCT01931631|Experimental|Low-fat, low-Glycemic Index, vegan diet|Low-fat, low-Glycemic Index, vegan diet
3094119|NCT01931631|Active Comparator|ADA diet|American Diabetes Association diet
3094120|NCT01931618|Active Comparator|Usual care|"Receives two interventions:~Online screening and feedback.~Online booklet."
3094121|NCT01931618|Experimental|Extended follow-up|"Receives two interventions:~Online screening and feedback.~Online multi session follow-up."
3094122|NCT01931605|Experimental|Embolization procedure|selective prostatic arterial embolization using BeadBlock (Terumo) particules
3094123|NCT01931592|Active Comparator|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
3094124|NCT01931592|Placebo Comparator|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
3094125|NCT01931579|Experimental|confocal endo-microscopy|confocal endo-microscopy : CELLVIZIO endo-microscopy procedure is performed in every patient using the same extended working channel as for navigational bronchoscopy.
3094126|NCT01931566|Experimental|Pioglitazone|Pioglitazone tablets, orally, once daily for up to 5 years.
3094127|NCT01931566|Placebo Comparator|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 5 years.
3094128|NCT01931553|Experimental|Standardized attending morning rounds|"Pre-rounds discretion~Pre-rounds huddle~Bedside RN integration~Patient-centered rounding~Real-time order writing"
3094129|NCT01931553|No Intervention|Usual rounding practice|Usual rounding practice (as defined by each clinical team)
3094130|NCT01931540|Experimental|Exercise Training - 17 offspring of OM|4 months exercise training, OM: Obese mothers
3094131|NCT01931540|No Intervention|11 non-frail controls (9 LM)|Studied only at baseline
3094132|NCT01931540|Experimental|Exercise Training - 20 offspring of LM|4 months exercise training, LM:Lean/Normal Mothers
3094133|NCT01931527|No Intervention|Obese subjects with normal uric acid|Subjects with a body mass index = or > 30 kg/m² with normal uric acid (= or < 5 mg/dL)
3094134|NCT01931527|Experimental|Obese subjects with high uric acid|"Subjects with a body mass index = or > 30 kg/m² with high uric acid (>6 mg/dL)~Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min"
3094135|NCT01931488|Other|MIBG label with I123 or I124|evaluate the added value of PET-CT with 124I-MIBG tracer, compared to planar and SPECT imaging with the routine 123I-MIBG tracers/
3094136|NCT01931475|Experimental|Duloxetine|"Double Blind Treatment Phase:~60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.~Extension Treatment Phase:~60 mg duloxetine administered by mouth QD for 13 weeks.~Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs)."
3094137|NCT01931475|Placebo Comparator|Placebo|"Double Blind Treatment Phase:~Placebo administered by mouth once a day (QD) for 13 weeks.~Extension Treatment Phase:~60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.~Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs)."
3094138|NCT01931462|Experimental|Certus 140™|During the operation: use of Certus 140™ microwave device for pre-coagulation of the kidney tissue adjacent to the tumor.
3094182|NCT01931176|Experimental|rDEN2Δ30-7169 vaccine|Participants will receive a single injection of the rDEN2Δ30-7169 vaccine at study entry.
3094139|NCT01931449|Experimental|Modified digestive reconstruction|Modified method of digestive tract reconstruction: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract with an independent intestinal loop and pancreas end.
3094140|NCT01931449|Active Comparator|Routine pancreatoduodenectomy|Routine digestive tract reconstruction: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes;Reconstruct the common bile duct-jejunum and pancreatic duct-jejunum respectively.
3094141|NCT01931436|Experimental|Qing'E pill|Administered twice a day, and each 9 g
3094142|NCT01931423|Placebo Comparator|Drainage Group|early placental drainage plus cord traction
3094143|NCT01931423|No Intervention|Controlled Group|spontaneous removal placenta
3094144|NCT01931410|Placebo Comparator|sublingual|400 microgram mısoprostol will be administered sublıngually before elective caesarean
3094145|NCT01931410|Placebo Comparator|rectal|rectal 600 mgr misoprostol will be administered
3094146|NCT01931410|No Intervention|synpitan|
3094147|NCT01931384|Experimental|Intervention group|luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
3094148|NCT01931384|Placebo Comparator|control group|normal saline (placebo) intramuscular injection will be given on the day of FET and 6 days later
3094149|NCT01931371|Active Comparator|Recurrent anal fistula|Patients with a complex anal fistula that recurred after surgery with an Anal Fistula Plug or and Endorectal Advancement Flap
3094150|NCT01931371|Active Comparator|No recurrence of anal fistula|Patients with a complex anal fistula that did not develop recurrence after surgery with an Anal Fistula Plug or and Endorectal Advancement Flap
3094151|NCT01931358|Experimental|Group Ia|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24
3094152|NCT01931358|Placebo Comparator|Group Ib|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24
3094153|NCT01931358|Experimental|Group IIa|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12, 24 and 48
3094154|NCT01931358|Placebo Comparator|Group IIb|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12, 24 and 48
3094155|NCT01931358|Experimental|Group IIIa|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24; AIDSVAX B/E at Week 48
3094156|NCT01931358|Placebo Comparator|Group IIIb|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24; AIDSVAX B/E Placebo at Week 48
3094157|NCT01931358|Experimental|Group IVa|ALVAC-HIV at Weeks 0, 4 and 48; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24
3094158|NCT01931358|Placebo Comparator|Group IVb|ALVAC-HIV Placebo at Weeks 0, 4 and 48; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24
3094159|NCT01931345|Experimental|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
3094160|NCT01931345|Active Comparator|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
3094161|NCT01931332|Active Comparator|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) was performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hertz (Hz) with pulse width 0.1ms. Once a quadriceps muscle twitch was identified at a stimulated current between 0.2 and 0.5milliamperes (mA), 20mls of 0.375% levobupivacaine (75mg) was injected in fractionated amounts after negative aspiration
3094162|NCT01931332|Active Comparator|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
3094163|NCT01931319|Experimental|Intravenous Baclofen|Three subjects will receive 10 mg doses of IV baclofen, two or more days later the next three subjects will receive 15 mg baclofen intravenously, and two or more days later the last three subjects will receive 20 mg IV baclofen.
3094164|NCT01931293|Experimental|HLA-DR and DQ antigens|Isolation of patient's lymphocytes from 10 cc of blood to determine the HLA-DR and DQ antigens at the first visit.
3094165|NCT01931280|Experimental|Lifestyle Counseling|Participants will obtain access to an internet-based educational intervention.
3094166|NCT01931280|No Intervention|Usual Care (Self-Directed)|Participants receive information via email on health related topics that surround pregnancy, physical activity, nutrition, and gestational diabetes.
3094167|NCT01931267|Experimental|Tablet Computer Motivated Instruction|Using Tablet Computer Motivated Instruction to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects.
3094168|NCT01931267|Active Comparator|systematic instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
3094169|NCT01931241|Experimental|Cohort 1, 500 mg|Cohort 1 receives SDD 500 mg AHRO-001; one week later receives MDD of 500 mg bid 7 days, then 500 mg tid 7 days
3094170|NCT01931241|Experimental|Cohort 2, 750 mg|Cohort 2 receives SD of 750 AHRO-001, then 7 days of 750 mg BID AHRO-001, then 7 days of 750 mg TID AHRO-001.
3094171|NCT01931241|Experimental|Cohort 3, 1000 mg|Cohort 3 identical design as Cohorts 1 and 2, but SD is 1000 mg AHRO-001.
3094172|NCT01931241|Experimental|Cohort 4, 21 day dosing|Cohort 4 receives 21 days tid administration of AHRO-001 using the best tolerated dose as determined by cohorts 1, 2 & 3
3094173|NCT01931241|Experimental|Cohort 5, 12 weeks dosing|Cohort 5 receives 12 weeks tid administration of AHRO-001 using the best tolerated dose as determined by the first 4 cohorts.
3094174|NCT01931228|Experimental|MI-E plus manually assisted coughing|
3094175|NCT01931228|Experimental|Manually assisted coughing only|
3094176|NCT01931215|Active Comparator|morphine group|spinal anesthesia with intrathecal morphine
3094177|NCT01931215|Experimental|TAP group|TAP-block with ropivacaine and clonidine
3094178|NCT01931202|Placebo Comparator|Placebo Controlled Group|Blinded treatment with either escitalopram 10mg or placebo, increased to escitalopram 20mg or placebo at week 4 if depression has not remitted.
3094179|NCT01931202|Active Comparator|Open Group|Open treatment with 10mg of escitalopram, increased to 20mg if depression has not remitted at week 4.
3094180|NCT01931189|Experimental|NI-071|
3094181|NCT01931189|Active Comparator|Infliximab|
3094251|NCT01930617||Tromsø|Burr hole surgery with continuous irrigation
3094184|NCT01931163|Experimental|Everolimus|Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles Everolimus 10mg by mouth daily
3094185|NCT01931150|Experimental|Dapsone LEFT, Moisturizer RIGHT|Dapsone 5% gel to LEFT side of face and chest BID (morning and evening) Moisturizer to RIGHT side of face and chest BID (morning and evening) AND oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)
3094186|NCT01931150|Experimental|Dapsone RIGHT, Moisturizer LEFT|Moisturizer to LEFT side of face and chest BID (morning and evening) Dapsone 5% gel to RIGHT side of face and chest BID (morning and evening) AND oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)
3094187|NCT01931137|Experimental|Coating A|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
3094188|NCT01931137|Experimental|Coating B|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
3094189|NCT01931137|Experimental|Coating C|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
3094190|NCT01931124|Experimental|High Intensity Training|training at high intensities ranging from 85-95% of maximal heart rate
3094191|NCT01931124|Experimental|Moderate Intensity Training|training at intensities of 65-75% of maximal heart rate
3094192|NCT01931111||Norwegian Elderly Population|
3094193|NCT01931098|Experimental|A|Patients with recurrent Glioblastoma or gliosarcoma with no prior bevacizumab exposure
3094194|NCT01931098|Experimental|B|Patients with recurrent Glioblastoma or gliosarcoma with prior bevacizumab exposure
3094195|NCT01931072|Experimental|High-intensity interval training|The High-intensity interval training group was instructed to complete exercise sessions of 4x4-minutes intervals at 85-95% of maximal heart rate, 3 times a week for 8 weeks. This type of exercise include 10 minutes warm-up, followed by four intervals of four minutes high-intensity (85-95% of HRmax), with three minutes active breaks (70% of HRmax) between each interval, and ending with seven minutes cool-down. An exercise session last for 42 minutes, where the participants should breathe heavily and feel exhausted four times.
3094196|NCT01931072|Active Comparator|Moderate training|The moderate training group was instructed to complete exercise sessions of 50 minutes at 70% of maximal heart rate, 3 times a week for 8 weeks.
3094197|NCT01931072|No Intervention|Control|The control group followed the baseline and follow-up tests, and was asked to live normally and not change their dietary pattern or exercise habits during their participation in this project. Based on the well-known beneficial effects of exercise on general health, it was regarded unethical to demand the control group to desist from any types of physical activity during the project period. They got no further follow-up on exercise.
3094198|NCT01931059|Experimental|Risperidone then Placebo|This group will receive 2 mg (>200lbs), 1.5mg (150-200lbs.) or 1 mg (< 150lbs. of risperidone oral solution on the first day and a placebo on the second day.
3094199|NCT01931059|Experimental|Placebo then Risperidone|This group will receive a placebo on the first day and 2mg (> 200lbs.), 1.5mg (150-200lbs), or 1 mg (<150lbs.) of risperidone oral solution on the second day
3094200|NCT01931046|Experimental|Part 1|Treatment at one of three dose levels of Ad5-SGE-REIC/Dkk-3 in a sequential dose-escalating design with 4 cycles of therapy at each dose level permitted.
3094201|NCT01931046|Experimental|Part 2|Treatment with Ad5-SGE-REIC/Dkk-3 every 6-weeks for up to 4 cycles of therapy and may continue therapy if they have stable disease or are responding.
3094202|NCT01931033|Experimental|Oxytocin|Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
3094203|NCT01931020|Active Comparator|Sucrose|1ml of 24%sucrose will be administered prior to heel lance
3094204|NCT01931020|Experimental|Glucose|1ml of 25% glucose will be administered prior to heel lance
3094205|NCT01931007|Experimental|Autologous bone marrow concentrate|Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the autologous bone marrow aspirate concentrate. The contralateral knee will be injected with only sterile saline for placebo.
3094206|NCT01931007|Placebo Comparator|Placebo|Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the bone marrow concentrate. The contralateral knee will be injected with only sterile saline for placebo.
3094207|NCT01930994||Cohort 1|Twenty Sino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 6-month insertion anniversary.
3094208|NCT01930994||Cohort 2|TwentySino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 12-month insertion anniversary;
3094209|NCT01930994||Cohort 3|Twenty Sino-implant (II) and twenty Jadelle) users enrolled 1-3 months before their 24-month insertion anniversary
3094210|NCT01930994||Cohort 4|Twenty Sino-implant(II) and twenty Jadelle users enrolled 1-3 months before their 36-month insertion anniversary;
3094211|NCT01930994||Cohort 5|Forty Sino-implant (II) and forty Jadelle users enrolled 1-3 months before their 48-month insertion anniversary;
3094212|NCT01930994||Cohort 6|Forty Jadelle users enrolled 2-6 months before their 60-month insertion anniversary.
3094252|NCT01930617||Stockholm|Burr hole surgery with active subgaleal drainage
3094253|NCT01930604|Active Comparator|Palmar hyperhidrosis, Botox (onabotulinumtoxinA)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
3094254|NCT01930604|Placebo Comparator|Palmar hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
3094292|NCT01930383||Arm A|HCC patients who receive curative surgery or radiofrequency ablation therapy
3094213|NCT01930968||Ultrasound measurement|There is only 1 arm in this study. The ocular tumors will be imaged using ultrasound and the contrast agent. The patient's history will be noted, lung and heart auscultation will be performed, and blood pressure readings will be obtained to ensure the patient has no contraindications to using Definity®. If there are no contraindications, routine ocular ultrasonography, both A and B scans, will be performed using an Ellex Eye Cubed ultrasound machine. Definity® (the microbubble contrast agent) will be prepared per package instruction and the dose calculated according to the following formula: Patient weight (kg) X 10 microliters = Definity® dose. If necessary, a second 10 microliter/kg dose may be given 30 minutes after the first IV injection.
3094214|NCT01930955|Active Comparator|Amoxicillin|Amoxicillin were given to the children with acute upper respiratory tract infection characterized by fever and vomiting.
3094215|NCT01930955|No Intervention|control|Non-antibiotics were given to the children with acute upper respiratory tract infection characterized by fever and vomiting.
3094216|NCT01930942|Experimental|preoperative concurrent chemoradiation|Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
3094217|NCT01930929||Bariatric surgery operated patients|All patients who have operated in the Central and North Denmark Region 2006-2011
3094218|NCT01930916|Other|Not interventionnal|INR capillary measurement with INRatio 2 device antiphospholipid antibodies and lupus anticoagulant
3094219|NCT01930890|Experimental|BIIB023 3 mg/kg|Participants will receive BIIB023 3 mg/kg IV every 4 weeks through Week 100 plus background therapy including oral steroids (prednisone or equivalent) and mycophenolate mofetil (MMF).
3094220|NCT01930890|Experimental|BIIB023 20 mg/kg|Participants will receive BIIB023 20 mg/kg IV every 4 weeks through Week 100 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
3094221|NCT01930877|Active Comparator|Lidocaine|Intravenous Lidocaine bolus of 1.5 mg/kg followed by infusion of 1.5 mg/kg/hr
3094222|NCT01930877|Placebo Comparator|Placebo|Normal saline placebo infusion
3094223|NCT01930864|Experimental|metfomin + irinotecan|Irinotecan 350mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal
3094224|NCT01930851||Gastric bypass|All gastric bypass operated patients in the Central Denmark Region 2006-2011
3094225|NCT01930838||Controls|Matched on age, sex and body mass index
3094226|NCT01930838||Gastric bypass operation|Patients with gastric bypass operation between 2006 and 2011 in The Central Denmark Region
3094227|NCT01930812|Experimental|18F-NaF PET Imaging for Bone Scintigraphy|All participants will receive PET/CT Imaging using the investigational drug 18F-NaF and a 99mTc-medronate whole body bone scan with SPECT to compare the diagnostic ability of the two methods for the presence of bone metastases.
3094228|NCT01930799|Other|All Enrolled Patients|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
3094229|NCT01930786||onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
3094230|NCT01930773|Experimental|Genotyping Arm|Rapid genotyping to select optimal P2Y12-inhibitor for PCI.
3094231|NCT01930773|Experimental|Phenotying Arm|The use of platelet function testing to select the optimal P2Y12-inhibitor for PCI.
3094232|NCT01930773|No Intervention|Conventional Arm|Regular approach for performing elective PCI.
3094233|NCT01930760|Experimental|Educational Intervention Group|
3094234|NCT01930760|Experimental|Behavioural Intervention Group|
3094235|NCT01930747|Experimental|deep neuromuscular block|deep neuromuscular block is given after first measurement of lap workspace one bolus dose of 1 mg/kg rocuronium is given
3094236|NCT01930747|Experimental|inhalation with 1 MAC Sevoflurane|1 MAC Sevoflurane inhalation is given after first measurement of lap workspace
3094237|NCT01930747|Experimental|remifentanyl|remifentanyl infusion is given after first measurement of lap workspace
3094238|NCT01930734|Placebo Comparator|Normal Saline|"Normal Saline Placebo infusion containing Normal Saline NaCl 0.9% twice a week for a total duration of 6 months.~Placebo will be given at the same rate as the Dobutamine infusion, under the same measures."
3094239|NCT01930734|Experimental|Dobutamine|Twice weekly, IV Dobutamine infusion up to 5mcg/Kg/min infusion, for the duration of 6 months. Medication will be administered under medical supervision and continues ECG and vital sign monitoring. Routine electrolyte and renal function testing will be performed and electrolytes corrected as indicated.
3094240|NCT01930721|Experimental|incision angle of 60 degrees|episiotomy incision angle will be defined as 60 degree as measured before cutting.
3094241|NCT01930721|Experimental|incision angle 40 degree episiotomy|incision angle of episiotomy will be defined as 40 degree as measured before cutting.
3094242|NCT01930708|Experimental|DMF|120 mg capsule oral twice daily (BID) during the first week and 240 mg BID thereafter.
3094243|NCT01930682|Experimental|Early post-fibrinolytic catheterisation|For STEMI Patients, alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.Early routine catheterization after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
3094244|NCT01930682|Other|Primary PCI|For STEMI Patients,primary PCI is performed without fibrinolytic therapy.
3094245|NCT01930669|Other|All patients|To measure the autonomic nervous system activity elicited by a gravitational sympathetic stimulus in critically ill
3094246|NCT01930656||Group A, B, C|Group A- American cut-point Group B- Translational approach cut-point Group C- Cost-effectiveness cut-point
3094247|NCT01930643|Experimental|Electric muscle stimulation(EMS)|EMS:use programmed middle frequency electric stimulation device(HELEX 573)for both quadriceps stimulation, 32 minutes per day, 5 time per week.
3094248|NCT01930643|No Intervention|Control|Patients with routine passive rehabilitation program.
3094249|NCT01930630|Experimental|Extraesophageal saline injection (ESI)|Extraesophageal saline injection (ESI) guided by EUS in patients with advanced ESCC preoperatively
3094250|NCT01930617||Trondheim|Burr hole surgery with passive subdural drainage
3094255|NCT01930604|Active Comparator|Plantar hyperhidrosis, Botox (onabotulinumtoxinA)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
3094256|NCT01930604|Placebo Comparator|Plantar hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
3094257|NCT01930604|Active Comparator|Inguinal (groins/buttocks) hyperhidrosis, Botox (ona...)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
3094258|NCT01930604|Placebo Comparator|Inguinal (groins/buttocks) hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
3094259|NCT01930604|Active Comparator|Craniofacial hyperhidrosis, NeuroBloc/Myobloc (rima...)|Solution for injection, individual dosing, maximum dose 2500 units, single treatment session.
3094260|NCT01930604|Placebo Comparator|Craniofacial hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
3094261|NCT01930604|Active Comparator|Truncal hyperhidrosis, NeuroBloc/Myobloc (rimabotulinumtoxinB)|Solution for injection, individual dosing, maximum dose 5000 units, single treatment session.
3094262|NCT01930604|Placebo Comparator|Truncal hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
3094263|NCT01930591|Active Comparator|Clopidogrel arm|Clopidogrel 300 mg before PCI followed by 75 mg po OD
3094264|NCT01930591|Experimental|Ticagrelor arm|Ticagrelor 180 mg before PCI followed by 90 mg po BID
3094265|NCT01930578|Experimental|Treatment with 0.9% normal saline|1 litre of normal saline infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
3094266|NCT01930578|Experimental|Treatment with D5, 0.45 saline|1 litre of D5, 0.45 saline infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
3094267|NCT01930578|Experimental|Treatment with D5|1 litre of D5 infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
3094268|NCT01930565|Experimental|LFCO application|We made LFCO application(Lactobacillus Fermented Chamaecypris obtusa) containing cream to one side of patients' face to monitor effectiveness and safety in acne treatment.
3094269|NCT01930565|Active Comparator|TTO application|To compare effectiveness and safety of new LFCO, we applied existing TTO containing cream to the other side of face in the same patients
3094270|NCT01930552|Experimental|Cohort 1|aflibercept IV infusion for 1 hour followed by FOLFIRI IV infusion every 2 weeks
3094271|NCT01930539|Experimental|Ultraviolet B lamp|Intervention arm: Patients in the Ultraviolet B lamp group will continue vitamin D2/D3 daily and will receive 3 treatment sessions of Ultraviolet B light once a week for 12 weeks. Patients will receive Ultraviolet B light from Ultraviolet B lamp at a distance of 14 inches for duration of 5 minutes each area while wearing an Ultraviolet eye shield. Areas of skin exposure will include 3 different areas amounting to 27% of body surface area. 9% body surface area will include front of abdomen, lower back, each arm, each leg is 18%, each thigh. Ultraviolet B light sessions will be supervised and conducted by study personnel or Center for Clinical and Translational Research staff. A food questionnaire will be reviewed at each visit to assess dietary intake of calcium. Skin exam will be conducted at the beginning and end of the session.
3094272|NCT01930539|No Intervention|Control|Patients in control group will continue with their current dose of Vitamin D2/D3 for 12 weeks.Patients will remain on the same steady dose for the duration of the study.These patients will not receive Ultraviolet B light sessions.
3094273|NCT01930526|Experimental|Pulmonary Rehabilitation|Patients will undergo the usual pulmonary rehabilitation programme but instead of two-legged cycling they will undergo single leg cycling where they cycle with one leg for 10-15mins and then the other in the same session.
3094274|NCT01930500|Experimental|Individual neuropsychological rehabilitation|12 times 90 minutes, once per week or once per two weeks, during 5 months
3094275|NCT01930500|Experimental|Group based neuropsychological rehabilitation|12 times 120 minutes + a brake, once per week or once per two weeks, during 5 months
3094276|NCT01930500|No Intervention|Control group|Control group does not receive neuropsychological rehabilitation or any other intervention during the first 5 months. After the control period they will be randomized to receive either individual or group based rehabilitation.
3094277|NCT01930487|Experimental|supplement w/ antioxidants then placebo|dietary supplement with antioxidants, followed by placebo supplement
3094278|NCT01930487|Experimental|placebo then supplement w/ antioxidants|placebo supplement, followed by dietary supplement with antioxidants
3094279|NCT01930461|Experimental|SLIT (A)|SLIT tablets of HDM allergen extracts, 3 different doses (A)
3094280|NCT01930461|Experimental|SLIT (B)|SLIT tablets of HDM allergen extracts, 3 different doses (B)
3094281|NCT01930461|Experimental|SLIT (C)|SLIT tablets of HDM allergen extracts, 3 different doses (C)
3094282|NCT01930461|Placebo Comparator|Placebo|Placebo matching the SLIT tablets of HDM allergen extracts
3094283|NCT01930448||gastric bypass|Surgical group of obese patients with type 2 diabetes undergoing gastric bypass surgery
3094284|NCT01930448||gastric banding|surgical group of obese patients with type 2 diabetes undergoing gastric banding
3094285|NCT01930435|Experimental|Sterile Humidification Device, MyPurMist|Sterile Humidification Device Twice a day, 15 minutes each 12 weeks
3094286|NCT01930422|Experimental|Real tDCS|Direct transcranial electrical stimulation (tDCS procedure)
3094287|NCT01930422|Sham Comparator|Placebo tDCS|Sham procedure
3094288|NCT01930409|Active Comparator|Education Only|"A 1 hour education session in the acute setting~A toolkit with education, exercise and self management instructions for after hip fracture"
3094289|NCT01930409|Experimental|Education + Telephone Follow-up|"A 1 hour education session in the acute setting~A telephone delivered self management program , including a toolkit (education, exercise and self management instructions for after hip fracture), support to take an active role in recovery, including setting and monitoring goals, problem solving mobility barriers, and guidance on the recovery process following a hip fracture."
3094290|NCT01930396|Experimental|Tinzaparin|
3094291|NCT01930396|Active Comparator|Unfractionated Heparin|
3094293|NCT01930383||Arm B|patients who receive trans-arterial chemoembolization
3094294|NCT01930383||Arm C|patients who receive systemic therapy
3094295|NCT01930370|Experimental|Hemodialysis patients|Each patient will be evaluated during a total of 3.5 weeks correlating to routine dialysis treatment appointments. Each participant will start with low bicarbonate, followed by the washout phase (standard bicarbonate), then high bicarbonate, finishing with the follow up period. Dialysis prescription is standardized for each patient throughout the entire 3.5 week study period.
3094296|NCT01930357|Experimental|VRVg Group|Participants will receive receive 3 vaccinations of Purified Vero Rabies Vaccine Serum Free (VRVg)
3094297|NCT01930357|Active Comparator|Imovax® Rabies Group|Participants will receive receive 3 vaccinations of Human Diploid Cell Vaccine (HDCV), Imovax® Rabies
3094298|NCT01930344|Active Comparator|3D laparoscopic visual system|Laparoscopic cholecystectomy to be performed with 3D laparoscopic imaging system
3094299|NCT01930344|Placebo Comparator|2D Laparoscopic Visual System|Laparoscopic cholecystectomy to be performed using normal, 2D, laparoscopic visual system
3094300|NCT01930331|Experimental|ARCO treatment|Patients in this treatment arm will receive on Day 0 a single dose of standard treatment of artemisinin/naphthoquine (in a fixed oral dose of ARCO tablets). Treatment will be given under supervision.
3094301|NCT01930331|Active Comparator|Eurartesim treatment|Patients in this treatment arm will receive a dose of dihydroartemisinin/piperaquine phosphate (in a fixed oral dose of Eurartesim tablets) over three days (0,1,2). Treatment will be given under supervision.
3094302|NCT01930318|Placebo Comparator|PCA,Placebo,Placebo|PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery
3094303|NCT01930318|Placebo Comparator|PCA,placebo,tramadol|PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol in the day 3 to day 5 after surgery
3094304|NCT01930318|Experimental|PCA,parecoxib,placebo|PCA for 2 days after operation, i.v parecoxib in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery
3094305|NCT01930318|Experimental|PCA,parecoxib,celecoxib|PCA for 2 days after operation,i.v parecoxib in 2 days after surgery and oral celecoxib in the day 3 to day 5 after surgery
3094306|NCT01930292|Experimental|Part A: Debio 1143|Eligible participants receive Part A: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle according to dose escalation rules (in combination with Paclitaxel and Carboplatin standard of care)
3094307|NCT01930292|Experimental|Part B: Lung Cancer|Participants with Lung Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
3094308|NCT01930292|Experimental|Part B: Ovarian Cancer|Participants with Ovarian Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
3094309|NCT01930292|Experimental|Part B: Breast Cancer|Participants with Breast Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
3094310|NCT01930279||surface markers on T cells as assessed by FACS|
3094311|NCT01930266|No Intervention|Observational|Patients will receive general dietary instructions with an annual follow-up. At this follow up, a repeat BMD, dietary and laboratory evaluation will be performed.
3094312|NCT01930266|Active Comparator|Interventional.|Patients will receive detailed dietary instructions with periodic (3 month) follow up. At the follow-up patients will be assessed whether they reached their calcium intake goals both quantitatively and whether appropriate calcium sources were utilized.
3094313|NCT01930266|Experimental|Active interventional|Patients will receive detailed dietary instructions and active follow up with diary and email reports. Inclusion in group C will be predicated upon intake of 100% DRI of calcium primarily by food sources, with the addition of Calcium Carbonate 600 mg, if necessary
3094314|NCT01930253|Experimental|Bortezomib|Intravenous or subcutaneous dose of Bortezomib on days 1, 4, 8 and 11. Dosage for both administrations is 1.3mg/m2.
3094315|NCT01930240|Placebo Comparator|TRIA-662 Placebo|Single dose of nine placebo capsules matching TRIA-662 drug capsules
3094316|NCT01930240|Experimental|TRIA-662 Low Dose|Single-dose of TRIA-662 administered as three 30 mg TRIA-662 capsules and six matching placebo capsules
3094317|NCT01930240|Experimental|TRIA-662 High Dose|Single dose of TRIA-662 administered as nine 30mg TRIA-662 capsules
3094318|NCT01930227|Experimental|TEAS Treatment|Patients were given 30min of TEAS at PC6 after spinal anesthesia
3094319|NCT01930227|Sham Comparator|Non-acupoint stimulation|Patients were given 30min of electrical stimulation at shoulder after spinal anesthesia
3094320|NCT01930227|No Intervention|Control|No stimulation was given
3094321|NCT01930214||None/mild calcification|• Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis
3094322|NCT01930214||Moderate Calcification|• Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion
3094323|NCT01930214||Severe calcification|• Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion
3094324|NCT01930201||Standard general anesthesia|Patients receiving standard of care.
3094325|NCT01930201||Caudal Epidural Block|Patients receiving a caudal epidural block in addition to standard of care.
3094326|NCT01930188|Experimental|Semaglutide 0.5 mg + sitagliptin placebo|
3094327|NCT01930188|Experimental|Semaglutide 1.0 mg + sitagliptin placebo|
3094328|NCT01930188|Active Comparator|Sitagliptin 100 mg + semaglutide placebo 1.0 mg|
3094329|NCT01930188|Active Comparator|Sitagliptin 100 mg + semaglutide placebo 0.5 mg|
3094330|NCT01930175|Placebo Comparator|Placebo|matching placebo (infusion bag) to VAY736, a single dose administered intravenously over 2 hours.
3094331|NCT01930175|Experimental|VAY736 Dose 1|Intravenous infusion of VAY736 at Dose Level 1, a single dose administered intravenously for 2 hours
3094332|NCT01930175|Experimental|VAY736 Dose 2|Intravenous infusion of VAY736 at Dose Level 2, a single dose administered intravenously over 2 hours. Dose level 2 will be initiated following a safety review of patients receiving Dose Level 1 or placebo.
3094333|NCT01930162|Experimental|HSC835|Patients with hematologic malignancies requiring UCB transplant with a NMA conditioning regimen.
3094334|NCT01930149|Experimental|Mailed patient outreach intervention|Participants randomized to this arm will receive mailed letter from health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
3094335|NCT01930149|No Intervention|Usual Care Control Group|Participants randomized to this arm will receive usual care.
3094336|NCT01930136|Experimental|Calorie restriction (25%)|CR will correspond to a reduction of 25% from the total daily calorie expenditure calculated as Total Daily Energy Expenditure (TDEE) (kcal/d) using the formula from the validated Seven-Day Physical Activity Recall (PAR) Questionnaire (RMR x activity levels).
3094337|NCT01930136|Active Comparator|Ad libitum health diet|
3094338|NCT01930123|Experimental|Patients with NAFLD|70 subjects with biopsy-proven NAFLD; subjects will be challenged with a fructose infusion after a period for 12 hours fasting.
3094339|NCT01930123|Placebo Comparator|Health controls|15 healthy controls for comparison with NALFD patients.The 15 subjects will be challenged with a fructose infusion after a period for 12 hours fasting.
3094340|NCT01930110|Active Comparator|Single-hormone closed-loop system|In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels
3094341|NCT01930110|Active Comparator|Dual-hormone closed-loop system|In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels
3094342|NCT01930097|Active Comparator|CHO-dependant bolus|"An insulin bolus dependant of carbohydrate content will be given after each meal.~Each subject insulin-to-carbohydrate ratio (U per 10g CHO) will be used to calculate the insulin bolus to be given. The dual-hormone closed-loop strategy will give the remaining insulin needed based on the sensor readings."
3094343|NCT01930097|Active Comparator|CHO-independent bolus|An insulin bolus independent of carbohydrate content will be given after each meal. The dual-hormone closed-loop strategy will give the remaining insulin needed based on the sensor readings.
3094344|NCT01930097|Active Comparator|Conventional treatment|Patients will use conventional pump therapy to regulate glucose levels
3094345|NCT01930084|Experimental|Combination intervention + incentives|"Point of care CD4+ after HIV diagnosis~Accelerated ART initiation~SMS appointment reminders~Non-cash financial incentives (FI)"
3094346|NCT01930084|Experimental|Combination intervention strategy(CIS)|"Point of care (POC) CD4+ after HIV diagnosis~Accelerated ART initiation~SMS appointment reminders"
3094347|NCT01930084|No Intervention|Standard of care (SOC)|Standard of care, no intervention
3094348|NCT01930071|Experimental|PQ Bypass Guide Wire Delivery System|PQ Bypass Guide Wire Delivery System to complete percutaneous Fem-pop bypass
3094349|NCT01930058|Experimental|Panel A: HCV GT3 MK-8876 150 mg|Participants infected with HCV GT3 received 150 mg MK-8876 once daily (q.d.) by mouth for 7 days.
3094350|NCT01930058|Experimental|Panel B: HCV GT3 MK-8876 800 mg|Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days.
3094351|NCT01930058|Experimental|Panel E: HCV GT1a MK-8876 800 mg|Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.
3094352|NCT01930045|Experimental|Ralt→MAL4Ralt→Ralt4MAL→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Raltegravir (Ralt) alone in Period 1, MAALOX (MAL) followed 4 hrs later by Ralt in Period 2, Ralt followed 4 hrs later by MAL in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
3094353|NCT01930045|Experimental|MAL4Ralt→Ralt4MAL→Ralt→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: MAL followed 4 hrs later by Ralt in Period 1, Ralt followed 4 hrs later by MAL in Period 2, Ralt alone in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
3094354|NCT01930045|Experimental|Ralt4MAL→Ralt→MAL4Ralt→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt followed 4 hrs later by MAL in Period 1, Ralt alone in Period 2, MAL followed 4 hrs later by Ralt in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
3094355|NCT01930045|Experimental|Ralt→Ralt4MAL→MAL4Ralt→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt alone in Period 1, Ralt followed 4 hrs later by MAL in Period 2, MAL followed 4 hrs later by Ralt in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
3094356|NCT01930045|Experimental|MAL4Ralt→Ralt→Ralt4MAL→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: MAL followed 4 hrs later by Ralt in Period 1, Ralt alone in Period 2, Ralt followed 4 hrs later by MAL in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
3094357|NCT01930045|Experimental|Ralt4MAL→MAL4Ralt→Ralt→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt followed 4 hrs later by MAL in Period 1, MAL followed 4 hrs later by Ralt in Period 2, Ralt alone in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
3094358|NCT01930032||All subjects|
3094359|NCT01930019|Experimental|OE|OE - obese patients (BMI>40) in which etomidate was used,
3094360|NCT01930019|Other|NE|NE - patients with normal body mass (BMI<25), in which etomidate was used,
3094361|NCT01930019|Experimental|OT|OT - obese patients in which thiopental was used,
3094362|NCT01930019|Other|NT|NT - patients with normal body mass, in which thiopental was used
3094363|NCT01930006|Experimental|MGCD265|
3094364|NCT01929993|Experimental|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode.
3094365|NCT01929993|Active Comparator|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth.
3094366|NCT01929980|Experimental|Bortezomib|"Four doses of bortezomib, 1.3mg/m2, will be given intravenously (through a needle in a vein) or subcutaneously (under the skin) on Days 1, 4, 8, 11.~The format of receiving medications is- Therapy Dose and Route Frequency Rituximab 375 mg/m2 intravenously Once on day 1. Plasmapheresis 2 hours prior to Bortezomib Day 1,4, 8 and 11 Bortezomib 1.3 mg/m2 intravenously Day 1,4,8 and 11"
3094367|NCT01929967||Heterotaxy syndrome|Patients with a diagnosis of heterotaxy syndrome, as objectively defined by visceral heterotaxy (malrotation, interrupted inferior vena cava) with either documented polysplenia or asplenia by radiological imaging
3094368|NCT01929954|Experimental|Gintuit|Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The test treatment GINTUIT will be inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. An additional single layer of GINTUIT will cover the entire surface of the extraction socket at approx. 2-3 mm beyond the margins of the wound and fixed with non-resorbable sutures. The lower layer of this additional layer should be in contact with the previously applied GINTUIT.
3094369|NCT01929954|Active Comparator|Bio-Gide|Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The control treatment will be a collagen membrane (ie, Bio-Gide, applied per the Package Insert) inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. Crossed suspensory type sutures should also be placed over Bio-Gide, depending on the degree of stabilization needed. In all subjects, care should be taken in suturing to avoid advancement of the buccal gingival flap.
3094370|NCT01929941|Experimental|Group 1 INCB047986|
3094371|NCT01929941|Experimental|Group 2 Experimental: INCB047986, gemcitabine, nab-paclitaxel|
3094372|NCT01929928||Surgical Patients|
3094373|NCT01929915|Active Comparator|Epidural patient controlled analgesia|Epidural patient controlled analgesia
3094374|NCT01929915|Sham Comparator|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia for post operative pain control
3094375|NCT01929902||Surgical Patients|
3094376|NCT01929889|Experimental|Iloperidone|Patients currently taking an antipsychotic medication other than Fanapt® will switch from their current medicine to Fanapt® in a cross-titration at a rate that is determined by the study physician. Treatment with iloperidone will be initiated and dosage will increase until the subject has achieved clinical stability, or has achieved the maximum dose, or 8 weeks have elapsed. Subjects who do not achieve clinical stability (as defined in the inclusion criteria) for the final 2 weeks in this 8-week period at the maximum dose of iloperidone will be discontinued from the study. If patients achieve stabilization, the lowest effective dose will be maintained. Subjects who have achieved clinical stability will then enter the 12-week treatment phase of the study.
3094377|NCT01929876|Experimental|Cobimetinib + Itraconazole|
3094378|NCT01929863|Experimental|Arm A|Subjects will receive metformin 850 mg BID for 7 days, GSK2330672 45 mg BID on Days 1 and 2 and GSK2330672 90 mg BID on Days 3 to 7 in treatment period 1. Subjects will receive metformin 850 mg BID for 7 days, placebo (matching 45 mg GSK2330672) BID on Days 1 and 2 and placebo (matching 90 mg GSK2330672) BID on Days 3 to 7 in treatment period 2. Treatment periods will be separated by a washout period of 13 to 15 days in which subjects will continue metformin 850 mg BID only
3094379|NCT01929863|Experimental|Arm B|Subjects will receive metformin 850 mg BID for 7 days, placebo (matching 45 mg GSK2330672) BID on Days 1 and 2 and placebo (matching 90 mg GSK2330672) BID on Days 3 to 7 in treatment period 1. Subjects will receive metformin 850 mg BID for 7 days, GSK2330672 45 mg BID on Days 1 and 2 and GSK2330672 90 mg BID on Days 3 to 7 in treatment period 2. Treatment periods will be separated by a washout period of 13 to 15 days in which subjects will continue metformin 850 mg BID only
3094380|NCT01929850|Active Comparator|Surgery|Sleeve gastrectomy laparoscopic surgery plus Weight Watchers for morbidly obese patients
3094381|NCT01929850|Other|Control|Weight Watchers Program for morbidly obese patients.
3094382|NCT01929837|Experimental|E-fied navigated rTMS|Electrical field navigated transcranial magnetic stimulation
3094383|NCT01929837|Sham Comparator|sham E-field navigated rTMS|Sham electrical field navigated rTMS
3094384|NCT01929837|Experimental|non-navigated rTMS|non-navigated rTMS
3094385|NCT01929837|Experimental|Experimental, Navigated rTMS|Navigated rTMS,
3094386|NCT01929811|Experimental|Metformin arm|Docetaxel: 75mg/m2, d1, q3w*6 Epirubicin: 75mg/m2, d1, q3w*6 Cyclophosphamide: 500mg/m2, d1, q3w*6 Metformin: 500mg tid, orally (500mg daily in first cycle)
3094387|NCT01929811|Other|TEC|Docetaxel: 75mg/m2, d1, q3w*6 Epirubicin: 75mg/m2, d1, q3w*6 Cyclophosphamide: 500mg/m2, d1, q3w*6
3094388|NCT01929798|Experimental|Optimized basal/bolus with artificial pancreas|Portable artificial pancreas with optimization
3094389|NCT01929798|No Intervention|Nominal basal/bolus treatment|Portable artificial pancreas without optimization.
3094390|NCT01929785||Pre and Post Transplant|Research blood samples will be drawn pre-transplant, and at monthly post transplant visits at times corresponding to post-transplant, standard of care ImmKnowo and AlloMap clinical testing. A minimum of 12 visits per patient is expected
3094391|NCT01929785||One year post transplant|The second group will include heart transplant recipients at one year post transplant who consent to participate in the study. Research blood samples will be drawn at quarterly post transplant visits (standard of care in Year 2 post transplant) corresponding to ImmunKnow and AlloMap testing. A minimum of 4 visits per patient is expected.
3094392|NCT01929772||severe sepsis or septic shock|patients with severe sepsis or septic shock
3094393|NCT01929759|Other|Drug switching|Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
3094394|NCT01929746|Experimental|BIIB019, 75 mg|BIIB019 delivered via Subcutaneous Injection
3094395|NCT01929746|Experimental|BIIB019, 150 mg|BIIB019 delivered via Subcutaneous Injection
3094396|NCT01929720|Experimental|Arm I (CBT for worry, uncertainty & insomnia)|Patients wear a wrist actigraph and complete a sleep diary and worry record daily in weeks 1 and 5. Patients participate in a Behavioral Intervention (cognitive-behavioral therapy) in which they receive education on the components of anxiety (physical cognitive, and behavioral) and practice relaxation techniques and behavioral sleep strategies in weeks 2-5.
3094397|NCT01929720|Active Comparator|Arm II (wait-list control)|Patients wear a wrist actigraph and complete a sleep diary and worry record daily in weeks 1 and 5. This is a wait-list comparison, so after six weeks, patients in the control group complete the behavioral (cognitive-behavioral therapy)intervention for worry, uncertainty, and insomnia.
3094398|NCT01929707|Experimental|LY3050258|Single escalating dose of LY3050258 (2 milligram [mg] up to 200 mg) administered in up to two of two periods.
3094399|NCT01929707|Placebo Comparator|Placebo|Single dose of placebo matching LY3050258 administered in up to one of two periods.
3094400|NCT01929694|Active Comparator|Berocca Boost|Guarana and vitamin and mineral complex, one tablet dissolved in 250ml water taken once.
3094401|NCT01929694|Placebo Comparator|Placebo|Matched placebo tablet, one tablet dissolved in 250ml water taken once.
3094402|NCT01929681|Experimental|LFMS - active treatment|"Low Field Magnetic Stimulation (LFMS) active treatment~Active low field magnetic stimulation treatment applied with the LFMS Device; the device is on and magnetic field stimulation is present."
3094403|NCT01929681|Sham Comparator|LFMS - sham treatment|"Low Field Magnetic Stimulation - sham treatment~Inactive low field magnetic stimulation (no stimulation) treatment applied with the LFMS Device; the device is on, however no magnetic field stimulation is present."
3094404|NCT01929668|Active Comparator|polyethylene glycol|4L polyethylene glycol
3094405|NCT01929668|Experimental|polyethylene glycol with ascorbic acid|2L polyethylene glycol and ascorbic acid
3094406|NCT01929655|Experimental|Radium-223 dichloride|
3094407|NCT01929642|Experimental|Sirolimus or Everolimus|Oral solution or tablet,titrated to therapeutic serum trough range (sirolimus); Oral tablet, titrated to therapeutic serum trough range (everolimus)
3094408|NCT01929629|Placebo Comparator|Placebo fasting|Single or multiple dosing placebo
3094409|NCT01929629|Experimental|Active fed condition|AZD0914 given as single dose
3094410|NCT01929616|Experimental|Regorafenib|A treatment cycle is defined as a 4 weeks period. Regorafenib will be administered once a day orally at a dose of 160 mg (4 tablets of 40 mg), for 3 weeks.
3094411|NCT01929603|Experimental|Olaparib alone, olaparib+rifampicin|Sequential treatments of olaparib alone followed by olaparib+rifampicin, with a washout period inbetween.
3094412|NCT01929590|Active Comparator|PEG-3350 group 3|group 3: low-volume 2 L PEG-3350 solution (same day of the procedure 06:00-08:00 am).
3094413|NCT01929590|Active Comparator|PEG-3350 group 1|group 1 single dose (PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h)
3094414|NCT01929590|Experimental|PEG-3350 group 2|group 2: split-dose (PEG-3350 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
3094415|NCT01929577|Experimental|ASP015K Test Tablet - Fasting Conditions|ASP015K administered as a single tablet under fasting conditions.
3094416|NCT01929577|Experimental|ASP015K Reference Tablet - Fasting Conditions|ASP015K administered via multiple tablets under fasting conditions
3094417|NCT01929577|Experimental|ASP015K Test Tablet -Fed Conditions|ASP015K administered as a single tablet under fed conditions
3094418|NCT01929564|Active Comparator|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet.
3094419|NCT01929564|Placebo Comparator|Parthenon broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet.
3094420|NCT01929551|Other|Mango puree and pear juice beverage|Participants will drink 450 milliliters of the juice at time 0.
3094421|NCT01929551|Other|Commercial mango juice|Participants will drink 450 milliliters of the juice at time 0.
3094422|NCT01929551|Other|Fresh natural mango|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
3094423|NCT01929551|Other|Frozen natural mango|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
3094424|NCT01929551|Other|Processed natural mango pulp|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
3094425|NCT01929551|Other|Mix of natural mango and pear|Participants will eat 400 to 500 grams of a mixture of fresh natural fruit containing mango (73%) and pear (27%), along with 250 milliliters of water at time 0.
3094426|NCT01929551|Other|50 grams glucose load|Participants will drink 250 milliliters of the standard glucose load at time 0.
3094427|NCT01929538|Active Comparator|Covered biliary metal stent, 12 mm|ERCP and placement of a covered self-expanding biliary metal stent, 12mm in diameter
3094428|NCT01929538|Active Comparator|covered Biliary metal stent, 10 mm|ERCP and placement of a covered self-expanding biliary metal stent, 10 mm in diameter
3094429|NCT01929525||Silver Nitrate|Irrigation of fistula tract with 1% silver nitrate solution for all patients who accepts the study and signed the written informed consent form.
3094430|NCT01929512|Experimental|HCP1201, Part 1|Participants received a single oral dose of the HCP1201 750/20mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3094431|NCT01929512|Active Comparator|Metformin and Rosuvastatin, Part1|Participants received a single oral dose of coadministration of Metformin SR 750mg and Rosuvastatin 20mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3094432|NCT01929512|Experimental|HCP1201, Part 2|Participants received a single oral dose of the HCP1201 750/20mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3094433|NCT01929512|Active Comparator|Metformin and Rosuvastatin, Part 2|Participants received a single oral dose of coadministration of Metformin SR 750mg and Rosuvastatin 20mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3094434|NCT01929499|Experimental|synchronous CIK group|"After colectomy, patients will accept chemotherapy combined with cytokine-induced killer cells (CIK) therapy synchronously for 6 months.~For CapeOx regimen:~3×109 CIK cells on days 1-3; Oxaliplatin 130mg/m2 on day 7; Capecitabine 1000mg/m2 twice daily on days 7-20; Repeat every 3 weeks for 6-8 cycles.~For mFolfox6 regimen:~Oxaliplatin 85mg/m2 IV over 2 hours on day 1; Leucovorin 400mg/m2 IV over 2 hours on day 1; 5-FU 400mg/m2 IV bolus on day 1, then 2400mg/m2 IV continuous infusion over 46-48 hous; 3×109 CIK cells on days 9-11; Oxaliplatin 85mg/m2 IV over 2 hours on day 15; Leucovorin 400mg/m2 IV over 2 hours on day 15; 5-fluorouracil (5-FU) 400mg/m2 IV bolus on day 15, then 2400mg/m2 IV continuous infusion over 46-48 hours; Repeat every 4 weeks for 5-6 cycles."
3094435|NCT01929499|Experimental|sequence CIK group|After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens(the same as those in arm A), followed by 6-8 cycles of cytokine-induced killer cells (CIK) therapy at least 2 weeks later.
3094436|NCT01929499|No Intervention|control group|After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens （the same as those in arm A）.
3094437|NCT01929486|Experimental|<Phase Ia> Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg|<Phase Ia> Dose-escalation method with Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg. Mogamulizumab will be administered 8 times every week.
3094438|NCT01929486|Experimental|<Phase Ib> Mogamulizumab of the tolerated dose|<Phase Ib> Mogamulizumab of the tolerated dose in Phase Ia will be administered 8 times every week.
3094439|NCT01929486|Experimental|<Phase Ib> Mogamulizumab 0.1mg/kg|<Phase Ib> Mogamulizumab 0.1mg/kg will be administered 8 times every week.
3094440|NCT01929460|Other|Drug (Standard group)|"Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.~Ciprofloxacin 500mg by mouth twice a day for three days."
3094441|NCT01929460|Placebo Comparator|Intervention group|"Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration~Oral Placebo, one cap twice a day for three days."
3094442|NCT01929434|Active Comparator|rehabilitation|Patients in the group accept rehabilitation for three weeks in hospital and other eleven months in their home under the guidance of physical therapist.
3094443|NCT01929434|No Intervention|control|Patients receive no professional treatment in hospital or rehabilitation centre.
3094444|NCT01929434|Experimental|stem cell injection|Patients in the group accept cell therapy including four times stem cells transplant via intrathecal injection.
3094445|NCT01929421|Experimental|Gemcitabine/ s-1|
3094446|NCT01929395|Active Comparator|Arm 1 addition of supine MRI to conventional imaging|Arm 1 objective will be to determine whether the addition of supine MRI to conventional imaging with mammography and or sonography and prone MRI will result in a lower positive margin rate in patients undergoing breast conserving surgery.
3094447|NCT01929395|Active Comparator|Arm 2 randomize to SOC vs supine MRI + SOC|Arm 2 of the study patients with non-palpable invasive breast cancer or DCIS who desire breast conservation will be randomized to either a usual care group, or a group receiving a supine MRI in addition to conventional imaging (mammogram and prone MRI) and undergoing breast cancer resection without the wire localization technique.
3094448|NCT01929382|Active Comparator|Actimmune (interferon gamma 1b)|Subjects > 0.5m2 BSA will receive 50 mcg/m2 BSA and subjects ≤ 0.5m2 BSA will receive 1.5mcg/kg/dose, as SC injections three times weekly, from week 1 to week 3.
3094449|NCT01929382|Experimental|Actimmune(interferon gamma 1b) titration|30% of the recommended dose as SC injections three times weekly in week 1, 60% the recommended dose as SC injections three times weekly in week 2, and at the recommended dose as SC injections three times weekly in week 3
3094450|NCT01929369||CONTROL GROUP|Control group: index intervention guided by DSA; IVUS post-intervention only (50 patients)
3094451|NCT01929369||TEST GROUP|Test group: index intervention guided by IVUS + DSA (50 patients
3094452|NCT01929356|Experimental|chest physiotherapy|session of 20 minutes chest physiotherapy with physiotherapist, use of airway clearance techniques, PEP (positive expiratory pressure) device
3094453|NCT01929343|Experimental|lidocaine following cue-induced craving|Lidocaine will be administered immediately following craving induction. Lidocaine will administered at a loading dose of 2mg/kg initial bolus over 5 minutes lidocaine followed by continuous infusion at 2mg/kg /hour for 4 hours.
3094454|NCT01929343|Active Comparator|lidocaine following neutral stimulus|Lidocaine will be administered immediately following neutral stimulus. Lidocaine will administered at a loading dose of 2mg/kg initial bolus over 5 minutes lidocaine followed by continuous infusion at 2mg/kg /hour for 4 hours.
3094455|NCT01929343|Placebo Comparator|saline|Saline will be administered at same volume of lidocaine in active arms.
3094456|NCT01929330|Experimental|Sequence AB|Subjects will be hospitalized to the clinical unit on the evening of Day -1. All subjects will receive 1 x 0.5mg oral dose of dutasteride (Sequence A), in the morning; Subjects will remain in the clinical unit until completion of all assessments at 24 hours post-dose on Day 2 including collection of the 24 hour post-dose PK sample. Subjects will return to the unit for the remaining PK samples at 36, 48 and 72 hours. The subject will receive or 5 x 0.1mg oral dose of dutasteride (Sequence B) in similar fashion as that of Sequence A. The two treatment sequences will be separated by a minimum washout period of 28 days to ensure that dutasteride is effectively eliminated from the subject between dosing occasions.
3094457|NCT01929330|Experimental|Sequence BA|Subjects will be hospitalized to the clinical unit on the evening of Day -1. All subjects will receive 5 x 0.1mg oral dose of dutasteride (Sequence B) in the morning; Subjects will remain in the clinical unit until completion of all assessments at 24 hours post-dose on Day 2 including collection of the 24 hour post-dose PK sample. Subjects will return to the unit for the remaining PK samples at 36, 48 and 72 hours. The subjects will receive 1 x 0.5mg oral dose of dutasteride (Sequence A) in similar fashion as that of Sequence B, The two treatment sequences will be separated by a minimum washout period of 28 days to ensure that dutasteride is effectively eliminated from the subject between dosing occasions.
3094494|NCT01929109|Experimental|LY2409021 Severe Renal Impairment|Participants will receive a single 80 mg dose of LY2409021 orally on Day 1 of the study
3094495|NCT01929109|Experimental|LY2409021 End Stage Renal Disease|Participants will receive a single 80 mg dose of LY2409021 orally on Day 1 of Period 1 of the study and a single 80 mg dose of LY2409021 orally on Day 1 of Period 2 of the study
3094458|NCT01929317|Experimental|Ropinirole CR high-dose group|The subjects will receive Ropinirole CR 16mg/day for 4 weeks in screening phase. After randomization the subject will enter dose increase effect verification phase, where Ropinirole CR dose will titrated (2 mg /day/week) from 18 mg/day up to a maximum 24mg/day at intervals of 1 week or longer for 8 weeks, till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose for 4 weeks. This will be followed by a down titration phase of one week and long term phase of 39 weeks in which the subjects will receive incremental doses (2 mg /day/week) of Ropinirole CR from 18 mg/day till to a maximum of 24 mg/day till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose. Subjects completing the long term phase will undergo a down titration phase of 1 to 2 weeks.
3094459|NCT01929317|Experimental|Ropinirole CR maintenance group|The subjects will receive Ropinirole CR 16mg/day for 4 weeks in screening phase. After randomization the subject will enter dose increase effect verification phase and Ropinirole CR dose will maintained at 16mg/day and placebo will be increased at intervals of 1 week for 8 weeks till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose for 4 weeks. This will be followed by a down titration phase of one week and long term phase of 39 weeks in which the subjects will receive incremental doses (2 mg/day/week) of Ropinirole CR from 18 mg/day till to a maximum of 24 mg/day till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose. Subjects completing the long term phase will undergo a down titration phase of 1 to 2 weeks.
3094460|NCT01929304||Video|Patients in this group will be shown an informational video, narrated in English.
3094461|NCT01929304||Text|Patients in this group will read a single-page printed information sheet in English.
3094462|NCT01929291||Group A|Pre-adolescents (aged (≥10 years to ˂12 years), adolescents (aged ≥12 to ˂19 years), adults (aged 19 to 64 years) and elderly (≥ 65) who received Boostrix as a part of routine practice at a private clinic or hospital in Korea.
3094463|NCT01929278|Experimental|CT Gel patch|CT Gel is a reformulation of VELAC Gel that contains the same active ingredients (clindamycin 1% and tretinoin 0.025%) in a modified vehicle. The test article was placed on a separate occlusive patch at volumes of 200 µL per patch.
3094464|NCT01929278|Placebo Comparator|Vehicle gel patch|The test article was placed on a separate occlusive patch at volumes of 200 µL per patch.
3094465|NCT01929278|Experimental|Blank patch|Blank patches did not contain CT Gel or vehicle gel.
3094466|NCT01929265|Experimental|Rituximab - Bendamustine (RB)|"1 arm: Rituximab - Bendamustine (RB)~1 arm for all patients"
3094467|NCT01929252|Active Comparator|Dexmedetomidine|%0.25 40 ml levobupivacaine and 2 mcg/kg dexmedetomidine administered via wound infiltration just before the incision.
3094468|NCT01929252|Active Comparator|Levobupivacaine|%0.25 40 ml levobupivacaine administered via wound infiltration prior to incision.
3094469|NCT01929239|Experimental|Anti PSMA Designer T Cells|Open Label, subjects receive anti PSMA designer T cells, plus IL2, low or moderate dose.
3094470|NCT01929226|Experimental|ETI-204|Intravenously (IV), single dose
3094471|NCT01929226|Placebo Comparator|Placebo|Intravenously (IV), single dose
3094472|NCT01929213|Experimental|Udenafil|
3094473|NCT01929213|Experimental|Bosentan|
3094474|NCT01929213|Experimental|Udenafil/Bosentan|
3094475|NCT01929200|Experimental|1-year treatment with icotinib|Patients will receive 1-year treatment with icotinib after operation.
3094476|NCT01929200|Experimental|2-year treatment with icotinib|Patients will receive 2-year treatment with icotinib after operation.
3094477|NCT01929187|Active Comparator|Phytonail|Phytonail is a mixture of herbal active ingredients including tea tree oil, lavender oil and Australian blue cypress (ABC) oil with BioEqual carrier system.
3094478|NCT01929187|Active Comparator|amorolfine 5% nail lacquer|5% amorolfine
3094479|NCT01929174||Controls|Patients undergoing catheterization for other reasons who have a normal biventricular heart.
3094480|NCT01929174||Single ventricle Fontan|"Patients with a single functional ventricle (excluding hypoplastic left heart syndrome) palliated with a Fontan type operation involving passive blood flow to the lungs."
3094481|NCT01929161|Experimental|Oxytocin|Oxytocin intranasal spray, 6 intranasal sufflations which deliver a total of 24 international units of oxytocin
3094482|NCT01929161|Placebo Comparator|Placebo (for oxytocin)|Intranasal spray with all equivalent ingredients except oxytocin
3094483|NCT01929161|Experimental|Lovingkindness Meditation|Lovingkindness guided meditation experienced in the laboratory and 6 additional LKM meditations taken home on the iPod.
3094484|NCT01929161|Placebo Comparator|Mindfulness Meditation|Mindfulness guided meditation experienced in the laboratory and 6 additional Mindfulness meditations taken home on the iPod.
3094485|NCT01929148|Experimental|Laparoscopic myomectomy plus PBS|A Laparoscopic myomectomy plus Prophylactic bilateral salpingectomy will be performed in women which have accomplished their reproductive desire
3094486|NCT01929148|Active Comparator|Laparoscopic myomectomy without PBS|A standard laparoscopic myomectomy without any prophylactic salpingectomy will be performed
3094487|NCT01929135|Experimental|Medicated 2% atorvastatin dentifrice|A group of 19 patients received non surgical periodontal therapy accompanied by instruction for oral hygiene, using a medicated 2% atorvastatin dentifrice 2 times a day for two minutes each time, for 30 days.
3094488|NCT01929135|Placebo Comparator|Non-medicated dentifrice|A group of 19 patients received non surgical periodontal therapy accompanied by instruction for oral hygiene, using a non-medicated dentifrice as placebo 2 times a day for two minutes each time, for 30 days.
3094489|NCT01929122|Placebo Comparator|Placebo-Control|Randomized participants consume 1 meal and 1 snack per day that does not include either rice bran or navy bean powder for 28 days.
3094490|NCT01929122|Experimental|Cooked Navy Bean Powder|Randomized participants consume 1 meal and 1 snack per day containing cooked navy bean powder (35 g/day) for 28 days.
3094491|NCT01929122|Experimental|Rice Bran|Randomized participants consume 1 meal and 1 snack per day containing rice bran (30 g/day) for 28 days.
3094492|NCT01929109|Experimental|LY2409021 Mild Renal Impairment|Participants will receive a single 80 mg dose of LY2409021 orally on Day 1 of the study
3094493|NCT01929109|Experimental|LY2409021 Moderate Renal Impairment|Participants will receive a single 80 mg dose of LY2409021 orally on Day 1 of the study
3094496|NCT01929109|Experimental|LY2409021 Control|Healthy participants will receive a single 80 mg dose of LY2409021 orally on Day 1 of the study
3094497|NCT01929096|Experimental|Low-dose group|Compound Edaravone Injection, 12.5mg/dose (Edaravone 10mg, (+)-Borneol 2.5mg), one dose every 12 hours, continue for 14 days
3094498|NCT01929096|Experimental|Medium-dose group|Compound Edaravone Injection, 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days
3094499|NCT01929096|Experimental|High-dose group|Compound Edaravone Injection, 62.5mg/dose (Edaravone 50mg, (+)-Borneol 12.5mg), one dose every 12 hours, continue for 14 days
3094500|NCT01929096|Active Comparator|Control group|Edaravone Injection，30 mg/dose, one dose every 12 hours, continues for 14 days
3094501|NCT01929083|Experimental|Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
3094502|NCT01929083|Placebo Comparator|Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
3094503|NCT01929070|Experimental|Group 1|"R1: Coadministration of Crestor 5mg 4tab and Omacor capsupe 1g 4cap in the fasting state~R2: Coadministration of Crestor 5mg 4tab and Omacor capsupe 1g 4cap on the high-fat diet~T1: Single-dose of HCP1007 1g/5mg 4 cap in the fasting state~T2: Single-dose of HCP1007 1g/5mg 4 cap on the high-fat diet~R1 -> T2 -> R2 -> T1"
3094504|NCT01929070|Experimental|Group 2|R2 -> R1 -> T1 -> T2
3094505|NCT01929070|Experimental|Group 3|T1 -> R2 -> T2 -> R1
3094506|NCT01929070|Experimental|Group 4|T2 -> T1 -> R1 -> R2
3094507|NCT01929057||Acne patients|This group consists of patients who have at least moderate to severe acne on their back
3094508|NCT01929057||Healthy Controls|This group contains participants who do not have any active acne lesions on their back
3094509|NCT01929044|Experimental|Buscopan® (hyoscine butylbromide)|1st injection of Buscopan® solution 20mg, if necessary 2nd injection after 20min of the 1st injection
3094510|NCT01929044|Active Comparator|654-II(anisodamine)|1st injection of 654-II solution 10mg, if necessary 2nd injection after 20min of the 1st injection
3094511|NCT01929031|Other|Caffeine-Ibuprofen|Study Stage 1: One Caffeine 100 mg tablet after dental surgery; Arm Type: Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one ibuprofen 400 mg tablet, while awake, over 5 days; Arm Type: Active Comparator
3094512|NCT01929031|Other|Placebo-Ibuprofen/Caffeine|Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine tablet, while awake, over 5 days; Arm Type: Experimental
3094513|NCT01929031|Other|Ibuprofen/Caffeine-Ibuprofen/Caffeine|Study Stage 1: One Ibuprofen 400 mg/Caffeine 100 mg tablet after dental surgery: Arm Type Experimental - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type Experimental
3094514|NCT01929031|Other|Ibuprofen-Ibuprofen|Study Stage 1: One Ibuprofen 400 mg tablet after dental surgery; Arm Type Active Comparator - Study Stage 2: Subsequent to stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake, over 5 days; Arm type; Active Comparator
3094515|NCT01929031|Other|Caffeine-Ibuprofen/Caffeine|Study Stage 1: One Caffeine 100 mg tablet after dental surgery. Arm Type; Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type: Experimental
3094516|NCT01929031|Other|Placebo-Ibuprofen|Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake over 5 days; Arm Type: Active Comparator
3094517|NCT01929018|Experimental|Exercise, activity, and self-management|Exercise, Walking Program, and Health Self-Management Support. Participants will be visited at home once monthly and contacted by phone once weekly over 12 weeks to deliver the interventions.
3094518|NCT01929018|No Intervention|Home and phone visit|No intervention will be applied. Participants will be visited at home once monthly and contacted by phone once weekly over 12 weeks to monitor health status.
3094519|NCT01929005|No Intervention|Standard of Care|If patients are randomized to standard of care, they are not assigned to a Comprehensive Care Physician. They are asked to continue receiving their care as they normally would.
3094520|NCT01929005|Experimental|Comprehensive Care|Patients randomized to the Comprehensive Care group are assigned to a Comprehensive Care physician and are asked to see their assigned CCP for their primary care. The patients will receive their care by the CCP in the outpatient clinic and also if they were to be hospitalized.
3094521|NCT01928992||3D|Subjects that undergo 3D mammography
3094522|NCT01928992||2D|Subjects that undergo 2D mammography
3094523|NCT01928979||Group 1|
3094524|NCT01928966|Active Comparator|Group I - Pumpkin Seeds|First four weeks of study: consume perceived normal diet; Second four weeks of study: receive 1.5 ounces of pumpkin seeds per day for consumption; Third four weeks of the study: consume their perceived normal diet.
3094525|NCT01928966|Active Comparator|Group II - Pumpkin Seeds|First four weeks of study: consume perceived normal diet; Second four week period: consume perceived normal diet; Third four week period: receive 1.5 ounces of pumpkin seeds per day for consumption.
3094526|NCT01928940|Experimental|dabrafenib + trametinib|Combination therapy of dabrafenib and trametinib
3094527|NCT01928927|Experimental|Arm A: Telmisartan|Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48.
3094528|NCT01928927|No Intervention|Arm B: No Study Drug|Participants received no study drug and followed the week 0-48 evaluation schedule.
3094529|NCT01928914|Placebo Comparator|Group 1|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on three consecutive days of dosing
3094530|NCT01928914|Experimental|Group 2|Subjects in group 2 receive 400mg of tafenoquine and placebo for moxifloxacin on three consecutive days of dosing
3094531|NCT01928914|Active Comparator|Group 3|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for tafenoquine and 400mg moxifloxacin.
3094532|NCT01928914|Experimental|Group 4|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for moxifloxacin and 300mg of tafenoquine
3094609|NCT01928485|Experimental|Arm B (Sunphenon)|Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
3094533|NCT01928914|Experimental|Group 5|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for moxifloxacin and 600mg of tafenoquine
3094534|NCT01928901|Experimental|administration of Bronchipret|7 days of administration of Bronchipret, 2 FCT t.i.d
3094535|NCT01928901|Experimental|administration of Sinupret|7 days of administration of Sinupret, 2 CT t.i.d
3094536|NCT01928901|Placebo Comparator|administration of Bronchipret Placebo|7 days of administration of Bronchipret Placebo, 2 FCT t.i.d
3094537|NCT01928901|Placebo Comparator|administration of Sinupret Placebo|7 days of administration of Sinupret Placebo, 2 CT t.i.d
3094538|NCT01928888|Experimental|Arm HFP|1st heartburn episode Intervention Hydrotalcid, 2nd heartburn episode Famotidine, 3rd heartburn episode Placebo
3094539|NCT01928888|Experimental|Arm HPF|1st heartburn episode Intervention Hydrotalcid, 2nd heartburn episode Placebo, 3rd heartburn episode Famotidine
3094540|NCT01928888|Experimental|Arm FHP|1st heartburn episode Intervention Famotidine, 2nd heartburn episode Hydrotalcid, 3rd heartburn episode Placebo
3094541|NCT01928888|Experimental|Arm FPH|1st heartburn episode Intervention Famotidine, 2nd heartburn episode Placebo, 3rd heartburn episode Hydrotalcid
3094542|NCT01928888|Experimental|Arm PHF|1st heartburn episode Intervention Placebo, 2nd heartburn episode Hydrotalcid, 3rd heartburn episode Famotidine
3094543|NCT01928888|Experimental|Arm PFH|1st heartburn episode Intervention Placebo, 2nd heartburn episode Famotidine, 3rd heartburn episode Hydrotalcid
3094544|NCT01928875|Experimental|Adequacy of Anesthesia (AoA) Monitoring|Adequacy of Anesthesia monitoring with SPI and Entropy
3094545|NCT01928875|Active Comparator|Routine (Standard) Anesthesia Monitoring|
3094546|NCT01928862|Experimental|Prepopik® ½ Sachet x 2 (9-12 years)|Prepopik® ½ Sachet x 2 (9-12 years)
3094547|NCT01928862|Experimental|Prepopik® 1 Sachet x 2 (9-12 years)|Prepopik® 1 Sachet x 2 (9-12 years)
3094548|NCT01928862|Active Comparator|Oral polyethylene glycol (PEG) based preparation (9-12 years)|Local standard of care
3094549|NCT01928862|Experimental|Prepopik® 1 Sachet x 2 (13-16 years)|Prepopik® 1 Sachet x 2 (13-16 years)
3094550|NCT01928862|Active Comparator|Oral polyethylene glycol (PEG) based preparation (13-16 years)|Local standard of care
3094551|NCT01928849|Placebo Comparator|Cherry syrup|"Cherry Syrup: Patients randomized to the Control arm of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo."
3094552|NCT01928849|Experimental|Valproic Acid|"Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid."
3094553|NCT01928836||Non-suspected lung cancer group|"Aged 40 to 75 years;~Male smoker (≥400 cig/year), female smoker or non-smoker;~Visible lung nodule lesion in the chest (based on local CT result);~Without the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery."
3094554|NCT01928836||Suspected lung cancer group|"Aged 40 to 75 years;~Male smoker (≥400 cig/year), female smoker or non-smoker;~Visible lung cancer lesion in the chest (based on local CT result);~With the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery."
3094555|NCT01928823|Experimental|D-Cycloserine + CBT|Patients receiving CBT (cognitive behavioral therapy) and D-Cycloserine (3 times, 50 mg, oral) directly after an exposure
3094556|NCT01928823|Placebo Comparator|Placebo + CBT|Patients receiving CBT (cognitive behavioral therapy) and a placebo pill (3 times, looking identical to the DCS pill) directly after an exposure
3094557|NCT01928810|Experimental|70% VO2max|"Cognitive Behavioural Therapy (CBT)~+ aerobic exercise (30 minutes, 70% VO2max) prior to 5 in-vivo exposure sessions"
3094558|NCT01928810|Active Comparator|30% VO2max|"Cognitive Behavioural Therapy (CBT)~+ placebo exercise (30 minutes, 30% VO2max) prior to 5 in-vivo exposure sessions"
3094559|NCT01928797|No Intervention|Control group|The care provider will use blood pressure and heart rate data to administer vasopressor use. In the control group, vasopressors (phenylephrine and ephedrine) will be used as considered appropriate to maintain BP within 20% of baseline. The CO data is measured and blinded to the anesthesiologists in the control group, therefore the anesthesiologist choice of ephedrine or phenylephrine is based on the individual anesthesiologist standard of care preference
3094560|NCT01928797|Experimental|Study group|The care provider will use the cardiac output monitor data (intervention) to guide vasopressors (Phenylephrine and ephedrine) in addition to blood pressure and heart rate data based on a standardized protocol in addition to the blood pressure and heart rate data available in the control group.
3094561|NCT01928784|Experimental|Specific pain spot|Radial Extracorporeal Shock Wave Therapy 2000 impulses, Patients with specific pain spot for low back pain
3094562|NCT01928784|Experimental|No specific pain spot|Radial Extracorporeal Shock Wave Therapy 4000 impulses, Patients without specific pain spot for low back pain
3094563|NCT01928771|Experimental|Benralizumab 30 mg q.4 weeks|Benralizumab administered subcutaneously every 4 weeks
3094564|NCT01928771|Experimental|Benralizumab 30 mg q.8 weeks|Benralizumab administered subcutaneously every 8 weeks
3094565|NCT01928771|Placebo Comparator|Placebo|Placebo administered subcutaneously
3094566|NCT01928758|Experimental|Reduced Nicotine Content Cigarettes|The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.5, 8.6, 4.0, 1.8, 0.9 and 0.3 mg per cigarette) cigarettes, with each nicotine level smoked for 4 weeks, except the lowest level which continues for 8 weeks
3094567|NCT01928758|Placebo Comparator|Usual Nicotine Content Cigarettes|Research cigarettes matching the nicotine content of the participant's preferred brand of cigarettes (around 11.5mg)
3094568|NCT01928745||CABG patients|15 patient who underwent a CABG will be submitted in this study
3094569|NCT01928745||Sepsis patients|15 patients with a severe sepsis will be admitted in this study
3094570|NCT01928732|Active Comparator|CPT|Cognitive Processing Therapy (CPT) - a type of cognitive therapy for treating PTSD.
3094571|NCT01928732|Active Comparator|PE|Prolonged Exposure (PE) - a type of exposure therapy for treating PTSD.
3094572|NCT01928719|Experimental|Reduced Nicotine Content Cigarettes|the experimental group will smoke cigarettes with Gradually Reduced Nicotine Content (RNC) (8 [9 for menthol], 4, 1.7, 0.9 and 0.3 mg) cigarettes, each smoked for 3 weeks, except for the last period which will last 6 weeks to evaluate a longer-term adherence to the lowest nicotine content cigarette.
3094573|NCT01928719|Placebo Comparator|Same Nicotine Content Cigarettes|The Same Nicotine Control Group (SNC) will continue to smoke research cigarettes approximately matching the nicotine content of their preferred brand of cigarettes (about 11.4 mg)
3094574|NCT01928706|Experimental|Denture liner Mucopren Soft; Group 1|The existing mandibular dentures were relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22).
3094575|NCT01928706|Active Comparator|Denture liner Kooliner; Group 2|The existing mandibular dentures were relined with a a hard acrylic resin based denture liner (Kooliner; Group 2 n=22).
3094576|NCT01928693|Active Comparator|Besivance 0.6% Ophthalmic Suspension|A topical fluoroquinolone antimicrobial indicated for the treatment of bacterial conjunctivitis.
3094577|NCT01928693|Active Comparator|Zymaxid 0.5% Ophthalmic Solution|A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis.
3094578|NCT01928693|Active Comparator|Vigamox 0.5% Ophthalmic Solution|A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis.
3094579|NCT01928680|Experimental|Cisplatin/Capecitabine|"Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity.~This is a single arm phase II clinical trial."
3094580|NCT01928667||Microscopic Colitis|Group consists of subjects diagnosed with either collagenous of lymphocytic colitis between January 1, 2000 and December 31, 2012
3094581|NCT01928667||Healthy Controls|Control group consists of subjects with no history of microscopic colitis. Group is age and sex matched with the case-group
3094582|NCT01928654|Experimental|Micropulse laser treatment|Sub-threshold laser treatment covering the area of retinal thickening with a dense pattern
3094583|NCT01928654|Active Comparator|Laser modified ETDRS|Macular treatment using the modified ETDRS protocol, with barely visible laser burns to close microaneurysms, or with a grid pattern in the area of retinal thickening.
3094584|NCT01928641||Discrepancy in stroke onset|Patients with discrepancy in stroke symptom onset based on the diagnosis of the first neurologist who evaluated the patient at emergency room and the next day after admission
3094585|NCT01928628|Active Comparator|Lercanidipine 10mg|1 Tablet of Zanidip ® 10mg + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/V160 Placebo (8wks)
3094586|NCT01928628|Experimental|Lercanidipine10mg /Valsartan 80mg|1 Tablet of Zanidip ® 10mg Placebo +1 Tablet of L10/V80 + 1 Tablet of L10/V160 Placebo (8wks)
3094587|NCT01928628|Experimental|Lercanidipine 10mg /Valsartan 160mg|1 Tablet of Zanidip ® 10mg Placebo + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/ V160 (8wks)
3094588|NCT01928615|Experimental|Trastuzumab - Thigh first, then upper arm|In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the thigh for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the upper arm for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).
3094589|NCT01928615|Experimental|Trastuzumab - Upper arm first, then thigh|In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the upper arm for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the thigh for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).
3094590|NCT01928602|Experimental|Expressive Aphasia Group A|"Behavioral: TherAppy Language App~Behavioral: Mind-Games"
3094591|NCT01928602|Experimental|Expressive Aphasia Group B|"Behavioral: Mind-Games~Behavioral: TherAppy Language App"
3094592|NCT01928589|Active Comparator|PBI|270 cGy (centigray) x 15
3094593|NCT01928589|Experimental|PBI with chemotherapy|270 cGy (centigray) x 15 concurrent with chemotherapy of the treating medical oncologist's choice
3094594|NCT01928576|Experimental|Arm C|Nivolumab 3mg/kg every 2 weeks until progression
3094595|NCT01928576|Experimental|Arm D|"Every 28 days for 6 cycles Azacitidine 40mg/m2 days 1-5 and 8-10 Entinostat 5mg Days 3 and 10 Nivolumab 3mg/kg Days 1 and 15~Followed by:~Nivolumab 3mg/kg every 2 weeks until prgoression"
3094596|NCT01928563|Experimental|Dapoxetine|Dapoxetine is administered
3094597|NCT01928563|Experimental|Udenafil|Udenafil is administered
3094598|NCT01928563|Experimental|Udenafil and Dapoxetine|Udenafil and Dapoxetine are co-administered
3094599|NCT01928550||PDR patients|Patients suspected to have Proliferative Diabetic Retinopathy or PDR
3094600|NCT01928537|Experimental|rigosertib sodium|Rigosertib sodium will be administered as a 72-hr continuous intravenous infusion consisting of 3 consecutive doses of 1800 mg over 24 hours on Days 1, 2, and 3 of a 14-day cycle for the first 8 cycles and then on Days 1, 2, and 3 of a 28-day cycle for the following cycles.
3094601|NCT01928524|Experimental|DOS2W|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2nd week.
3094602|NCT01928524|Experimental|DOS3W|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3rd week.
3094603|NCT01928511|Active Comparator|Continued oral nucleos(t)ide therapy|Patients assigned to this arm will continue their nucleos(t) analogue
3094604|NCT01928511|Experimental|Add on peg-interferon|Patients assigned to this arm will continue their existing nucleos(t)ide therapy and also be assigned peg-interferon alpha 2b 1.5mcg/kg sc weekly
3094605|NCT01928511|Experimental|switch to peg-interferon|Patients assigned to this arm will stop their existing nucleos(t)ide therapy after one month overlap after starting peg-interferon alpha 2b 1.5mcg/kg sc weekly
3094606|NCT01928498|Experimental|Paclitaxel Eluting Balloon|Paclitaxel Eluting Balloon Angioplasty
3094607|NCT01928498|Active Comparator|Conventional uncoated balloon|Percutaneous Transluminal Angioplasty (PTA)
3094608|NCT01928485|Active Comparator|Arm A (active surveillance)|Patients undergo active surveillance for 52 weeks.
3094614|NCT01928459|Experimental|Metastatic breast cancer|Evaluation of safety and efficacy in patients with metastatic breast cancer whose tumors contain mutations to PIK3CA and alterations FGFR 1-3.
3094615|NCT01928459|Experimental|Solid tumor arm 1|Patients with solid tumors (except for colorectal cancer) whose tumors express mutations to PIK3CA.
3094616|NCT01928459|Experimental|Solid tumor arm 2|Patients with solid tumors (except for colorectal cancer) whose tumomrs express mutations to PIK3CA and alterations to FGFR 1-3
3094617|NCT01928459|Experimental|Dose escalation|To determine the MTD or RDE of the combination of BGJ398 with BYL719 in patients with advanced or metastastic solid tumors that express mutations to PIK3CA.
3094618|NCT01928446|Experimental|Lithium|Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
3094619|NCT01928446|Placebo Comparator|Placebo|Placebo tablets will be given to the subjects for the duration of follow-up (1 year). Dose adjustments will mimic the intervention arm of the study
3094620|NCT01928433|Experimental|Finafloxacin 5 days|"Intervention:~Finafloxacin 800 mg i.v. once daily and Ciprofloxacin placebo i.v. twice daily. Finafloxacin 800 mg tablets once daily and Ciprofloxacin placebo oral twice daily Finafloxacin verum (i.v. and oral) for a total of 5 days."
3094621|NCT01928433|Experimental|Finafloxacin 10 days|"Intervention:~Finafloxacin 800 mg i.v. once daily and Ciprofloxacin placebo i.v. twice daily. Finafloxacin 800 mg tablets once daily and Ciprofloxacin placebo oral twice daily Finafloxacin verum (i.v. and oral) for a total of 10 days."
3094622|NCT01928433|Active Comparator|Ciprofloxacin 10 days|"Intervention:~Ciprofloxacin 400 mg i.v. twice daily and Finafloxacin placebo i.v. once daily Ciprofloxacin 500 mg oral twice daily and Finafloxacin placebo tablets once daily Ciprofloxacin (i.v. and oral) for a total of 10 days."
3094623|NCT01928420|Experimental|NIC5-15|Subjects with Alzheimer's Disease Intervention: Drug: NIC5-15
3094624|NCT01928420|Placebo Comparator|Placebo|Subjects with Alzheimer's Disease Intervention: Drug: Placebo
3094625|NCT01928407|Experimental|ATAZANAVIR|The patient included in this Group 1 will receive their first antiretroviral regimen included : ATV + TDF/FTC (or Abacavir/Lamivudine, [ABC/3TC], if contre indicated of TDF/FTC) The dose : atazanavir/ritonavir 300/100mg/day and TDF/FTC 245 /200 mg day, 3 pills once a day, during 48 weeks during a meal
3094626|NCT01928407|Experimental|DARUNAVIR|The patients included in this Group 2 will receive their first antiretroviral regimen included Group 2 : DRV+ TDF/FTC (or ABC/3TC if contre-indicated of TDF/FTC) The dose : darunavir/ritonavir 800/100mg/day and TDF/FTC 245 /200 mg day, 4 pills once a day, during 48 weeks during a meal
3094627|NCT01928394|Experimental|Arm N - Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3094628|NCT01928394|Experimental|Arm N-I, Level 1: Nivolumab+Ipilimumab|Nivolumab 1 mg/kg solution intravenously plus Ipilimumab 1 mg/kg solution every 3 weeks for 4 doses followed by Nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3094629|NCT01928394|Experimental|Arm N-I, Level 2: Nivolumab+Ipilimumab|Nivolumab 1 mg/kg solution intravenously plus Ipilimumab 3 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3094630|NCT01928394|Experimental|Arm N-I, Level 2b: Nivolumab+Ipilimumab|Nivolumab 3 mg/kg solution intravenously plus Ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3094631|NCT01928394|Experimental|Arm N-I, Level 2c: Nivolumab+Ipilimumab|Nivolumab 3 mg/kg solution intravenously every 3 weeks combined with ipilimumab 1 mg/kg every 6 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3094632|NCT01928394|Experimental|Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib|Nivolumab 3 mg/kg solution intravenously every 3 weeks combined with ipilimumab 1 mg/kg every 6 weeks and cobimetinib 60mg once daily 21days on/7 days off until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3094633|NCT01928381|Placebo Comparator|placebo capsules|Capsules to match pregabalin and AZD5213
3094634|NCT01928381|Experimental|AZD5213 + pregabalin|AZD5213 in combination with pregabalin
3094635|NCT01928381|Active Comparator|pregabalin|pregabalin capsules
3094636|NCT01928368|Active Comparator|Experimental Arm|
3094637|NCT01928368|Placebo Comparator|Placebo Arm|
3094638|NCT01928355||metabolically healthy|
3094639|NCT01928355||Unhealthy|
3094640|NCT01928342|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
3094641|NCT01928342|Placebo Comparator|Placebo|Capsule without coenzyme A.
3094642|NCT01928329|Placebo Comparator|Placebo|2 mg, 1 per week via subcutaneous placebo self injection
3094643|NCT01928329|Experimental|Exenatide (Bydureon)|2 mg, of drug administration 1 per week via subcutaneous self injection
3094644|NCT01928316|Experimental|Sequence A|Healthy male volunteers will receive single oral dose of 10 mg imported mizolastine tablet on Day 1 and single oral dose of 10 mg domestic (made in China) mizolastine tablet on Day 8.
3094645|NCT01928316|Experimental|Sequence B|Healthy male volunteers will receive single oral dose of 10 mg domestic (made in China) mizolastine tablet on Day 1 and single oral dose of 10 mg imported mizolastine tablet on Day 8.
3094646|NCT01928303||Chronic Pain Patients taking opioid medications|Oral fluid, blood and urine samples will be obtained from chronic pain patients who are taking pain medications from the opioid class of drugs.
3094647|NCT01928303||Negative controls|At least 10% of the total subject population. Chronic pain patients who are not taking pain medication from the opioid class of drugs.
3094648|NCT01928290|Experimental|FOLFIRINOX|"Irinotecan 180 mg/m2 IV on Days 1 & 15.~Oxaliplatin 85 mg/m2 IV on Days 1 & 15.~Leucovorin 400 mg/m2 IV on Days 1 & 15.~Flurorouracil 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1 and Day 15."
3094721|NCT01927757|Experimental|Etanercept|Participants received etanercept 50 mg administered subcutaneously once a week with methotrexate for 24 weeks
3095181|NCT01924611|Experimental|Experimental Group|Atraumatic Restorative Technique using rubber dam.
3094649|NCT01928290|Experimental|FOLFIRINOX and Trastuzumab|"Trastuzumab 8 mg/kg on Cycle 1 Day 1 then 4 mg/kg on Day 15 and Day 1 of all future cycles.~Irinotecan 180 mg/m2 IV on Days 1 & 15.~Oxaliplatin 85 mg/m2 IV on Days 1 & 15.~Leucovorin 400 mg/m2 IV on Days 1 & 15.~Flurorouracil 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1 and Day 15."
3094650|NCT01928277||ICU-patients|ICU-patients weaning form mechanical ventilation
3094651|NCT01928264|Experimental|Physical activity|Physical activity group program over 12 weeks; 1 hour sessions, 2 times a week
3094652|NCT01928264|No Intervention|Leisure time activities|Predominantly sedentary leisure time group activities, like playing board games, doing handicrafts, etc.; 12 weeks, 1 hour sessions, 2 times a week
3094653|NCT01928251|Experimental|Informed early monetary incentive|Incentives of abstinence will be given to those who self-report abstinence for the past 7 days at 3-month follow-up and pass the 3-month biochemical validation (Exhaled carbon monoxide level < 4 ppm, saliva cotinine level < 10 ng/ml) (Group A-Q). Participants will be informed about the incentives through telephone follow-up at 1 week and 1 month. Those who have not quitted at 3 months (Group A-N) or those self-reported quitters who refuse to participate in biochemical validation will be informed again that they will be given the same incentive if they have quitted at 6 months and the quitting is validated.
3094654|NCT01928251|Experimental|Uninformed early monetary incentive|Incentives of abstinence will be given to those who self-report abstinence for the past 7 days and pass the 3-month biochemical validation (Group B-Q), but they will not be informed about the incentive at the 1-week and 1-month follow-up. Those who have not quitted at 3 months (Group B-N) or those self-reported quitters who refuse to participate in the biochemical validation will be informed that they will be given the same incentive if they have quitted at 6 months and the quitting is validated.
3094655|NCT01928251|No Intervention|Uninformed late monetary incentive|Incentives for the self-reported and biochemically-validated abstinence at 6-month follow-up will be given after the 6-month biomedical validation. They would not be informed about the incentive at the 1-week, 1-month and 3-month follow-up. Group C also has two subgroups, those who have quitted at 3 months (Group C-Q) and those who have not (Group C-N).
3094656|NCT01928238|Experimental|Arm 1|"Patients will have two 20-minute noninvasive periods :~Noninvasive neurally adjusted ventilatory assist (NIV-NAVA) and then Noninvasive pressure support ventilation (NPSV)"
3094657|NCT01928238|Experimental|Arm 2|"Patients will have two 20-minute noninvasive periods :~Noninvasive pressure support ventilation (NPSV) and then Noninvasive neurally adjusted ventilatory assist (NIV-NAVA)"
3094658|NCT01928225|Experimental|Human Papillomavirus vaccine|Participants receive the experimental quadrivalent Human Papillomavirus vaccine at entry, week 4 and week 26.
3094659|NCT01928225|Placebo Comparator|Saline placebo|The participants receive saline placebo at entry, week 4 and week 26.
3094660|NCT01928212||healthy control|Sex- and agematched healthy subjects
3094661|NCT01928212||Parkinson group|Patients with Parkinson's disease
3094662|NCT01928199|Active Comparator|Sitagliptin|"Sitaglipitin tablets will be administered orally for 3 months from randomization~Initial dose will be 100mg/daily, adjusted per renal function:~Creatinine clearance > or = 50mL/min: 100mg/day Creatinine clearance > or = 30 and <50mL/min: 50mg/day Creatinine clearance <30 mL/min or on dialysis: 25mg/day"
3094663|NCT01928199|Placebo Comparator|Placebo|Placebo tablets (identical to active comparator in appearance) will be administered orally for 3 months. Starting dose and adjustment based on renal function will be identical to active comparator
3094664|NCT01928186|Experimental|Diagnostic (FLT PET)|Patients undergo FLT PET at baseline and 1-6 weeks after the start of treatment.
3094665|NCT01928173|Active Comparator|Abbreviated cognitive behavioral therapy|Arm 1 is a multi-component package including sleep hygiene, stimulus control, cognitive therapy, and passive relaxation.
3094666|NCT01928173|Active Comparator|Sleep education/sleep hygiene|Arm 2 consists of education about sleep and fatigue as well as sleep hygiene recommendations (e.g., avoiding nicotine and caffeine late in the day).
3094667|NCT01928160|Experimental|Arm I (chemotherapy, erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21, pemetrexed disodium IV and carboplatin IV or cisplatin IV on day 1. Treatment repeats every 21 days for 4 courses. Patients then receive maintenance erlotinib hydrochloride PO QD on days 1-21 and pemetrexed disodium IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3094668|NCT01928160|Experimental|Arm II (chemotherapy)|Patients receive pemetrexed disodium and carboplatin or cisplatin as in Arm I. Treatment repeats every 21 days for 4 courses. Patients then receive maintenance pemetrexed disodium as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3094669|NCT01928147|Experimental|PPI-383 single dose escalation in healthy volunteers|There will be up to 10 sequential single dose cohorts to assess the bioavailability of different doses and formulations; a food effect cohort will be included.
3094670|NCT01928147|Experimental|PPI-383 multiple doses in healthy volunteers|Upon completion of the single dose cohorts, an additional cohort will receive the highest well-tolerated dose from the single dose cohorts or placebo once daily for five days; up to additional cohorts may receive multiple doses of different formulations or different regimens
3094671|NCT01928147|Experimental|PPI-383 multiple dose escalation in HCV Subjects|Upon completion of the single and multiple dose healthy volunteer cohorts, there will be 3, and potentially 4, sequential cohorts of HCV patients
3094672|NCT01928134|Experimental|A|Vit K2+ Vit D3+ calcium carbonate (CaCO3)
3094673|NCT01928134|Active Comparator|B|Vit K2+CaCO3
3094674|NCT01928121|Experimental|AF expert program|Care provided by the interdisciplinary, nurse-coordinated AF expert program
3094675|NCT01928121|No Intervention|Usual care|
3094676|NCT01928108||iPhone Application|"Participants using an iPhone will download the waterlogged application and use this to track daily water intake for 1 week."
3094677|NCT01928108||Android Application|"Participants using an Android cell phone will download the water your body application and use this to track daily water intake for 1 week."
3094678|NCT01928095||Carotid Endocardectomy Patients|Subsequent analyses will be performed on the basis of the pathological grading provided by UK Pathology (e.g do readouts of the Dicer pathway correlate with pathological plaque characteristics).
3094679|NCT01928082|Experimental|Transdermal estradiol|Transdermal estradiol 0.05 mg/day for 4 weeks, followed by 0.10 mg/day for 4 weeks
3095182|NCT01924598|Experimental|DBS surgery|
3094680|NCT01928043|Experimental|adjunctive curcumin|Curcumin will be added to their current medications for 8 weeks. Starting dose will be 500mg daily, increased to 500mg twice daily in week 2, then increased to 1000mg twice daily during weeks 3-8. A slower titration will be used for subjects who demonstrate tolerability problems.
3094681|NCT01928030|Experimental|recombinant human hyaluronidase|Phase 1. 450 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1, 3, 5, and 7 Phase 2: 900 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1 to 21
3094682|NCT01928017||Hematooncology patients|No intervention
3094683|NCT01928004|Experimental|implant placement|insertion of 2 interforaminal mandibular implants and conversion of the lower complete denture to an implant-overdenture
3094684|NCT01928004|Active Comparator|denture reline|conventional reline of mandibular complete denture
3094685|NCT01927991|Experimental|iCBT with therapeutic support|Participants work with the online self-help and receive additional therapeutic support on demand
3094686|NCT01927991|Active Comparator|iCBT without therapeutic support|Participants work with the online self-help on their own and do not receive additional therapeutic support
3094687|NCT01927978||esophageal cancer, 18F-FDG PET|
3094688|NCT01927965|Experimental|Minnelide™ 001|A Phase 1, Multi-Center, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™ given daily for 21 days followed by 7 days off schedule in patients with Advanced GI Tumors
3094689|NCT01927952|Active Comparator|Kirschner wire|surgical fixation using a Kirschner wire
3094690|NCT01927952|Active Comparator|Integra IPP-On PIP Fusion System|surgical fixation utilizing the Integra IPP-On PIP Fusion System
3094691|NCT01927952|Active Comparator|Stryker Smart-Toe implant|surgical fixation utilizing the Stryker Smart-Toe implant
3094692|NCT01927939||Histological proven breast cancer with bone lesion|
3094693|NCT01927926|Experimental|Whey-protein & polydextrose snack|Whey-protein & polydextrose snack bar.
3094694|NCT01927926|Placebo Comparator|Control snack|Control snack bar containing minimal protein and not polydextrose.
3094695|NCT01927913|Experimental|SPD602|
3094696|NCT01927913|Active Comparator|Deferasirox|
3094697|NCT01927900|Active Comparator|HMO1|HMO diluted in water
3094698|NCT01927900|Placebo Comparator|Glucose|Glucose diluted in water
3094699|NCT01927900|Active Comparator|HMO2|HMO diluted in water
3094700|NCT01927900|Active Comparator|HMO3|HMO diluted in water
3094701|NCT01927900|Active Comparator|HMO4|HMO diluted in water
3094702|NCT01927900|Active Comparator|HMO5|HMO diluted in water
3094703|NCT01927900|Active Comparator|HMO6|HMO diluted in water
3094704|NCT01927900|Active Comparator|HMO7|HMO diluted in water
3094705|NCT01927900|Active Comparator|HMO8|HMO diluted in water
3094706|NCT01927900|Active Comparator|HMO9|HMO diluted in water
3094707|NCT01927887|Experimental|Nanoparticle MRI|Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
3094708|NCT01927874|Active Comparator|Infiltration, analgesic effect|10ml 0.5% bupivacaine each side Block Injection of local anesthetic at pudendal nerve
3094709|NCT01927874|Active Comparator|Spinal block|10 mg of hyperbaric 0.5% bupivacaine Injection of anesthetic at subarachnoidal space
3094710|NCT01927861|Experimental|0.033 mg/kg/day|
3094711|NCT01927861|Experimental|0.066 mg/kg/day|
3094712|NCT01927848|Experimental|Rosehip|Dosage: 3 capsules once daily with meals (daily dose: 2.25 g powder).
3094713|NCT01927848|Placebo Comparator|Placebo|Dosage: 3 capsules once daily with meals
3094714|NCT01927835|Experimental|Group 1A: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
3094715|NCT01927835|Experimental|Group 1B: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
3094716|NCT01927835|Experimental|Group 2A: Treatment|Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
3094717|NCT01927835|Experimental|Group 2B: Treatment|Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
3094718|NCT01927835|Placebo Comparator|Group 3A: Placebo|Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.
3094719|NCT01927835|Placebo Comparator|Group 3B: Placebo|Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.
3094720|NCT01927822||Pregnancy|Women who underwent termination of pregnancy at second trimester due to a variety of causes
3094722|NCT01927744|Experimental|Chemotherapy + Erlotinib|Docetaxel 75 mg/m2 by vein followed by Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles, plus Erlotinib 150 mg by mouth daily continuously until the day before surgery. Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery. Phone call made to patient 1 time each year after the end of treatment visit.
3094723|NCT01927744|Experimental|Chemotherapy + Placebo|Docetaxel 75 mg/m2 by vein followed by Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles, plus placebo 150 mg by mouth daily continuously until the day before surgery. Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery. Phone call made to patient 1 time each year after the end of treatment visit.
3094724|NCT01927731|Active Comparator|Cord Blood Transplant (CBT) Group|Eltrombopag given as a single daily dose of 300 mg orally on an empty stomach (1 hour before or 2 hours after a meal) for 60 total days. Eltrombopag started on Day -1 (the day prior to stem cell infusion in cord blood patients).
3094725|NCT01927731|Active Comparator|Haploidentical Transplant Group|Eltrombopag given as a single daily dose of 300 mg orally on an empty stomach (1 hour before or 2 hours after a meal) for 60 total days. Eltrombopag started on Day +5 in patients receiving haploidentical transplant.
3094726|NCT01927718|Experimental|Thalidomide + Lenalidomide|"Thalidomide 100 mg by mouth daily for 28 days in a 28 day cycle started after the clinical documentation of biochemical progression.~Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle."
3094727|NCT01927705|Experimental|Treatment|"FURESTEM-AD Inj. 1. 2.5 x 10^7 stem cells after registration.~FURESTEM-AD Inj. 2. 5.0 x 10^7 stem cells after registration."
3094728|NCT01927692||MG subjects|MG subjects will have serum acetylcholine receptor (AChR) antibodies
3094729|NCT01927679|Other|Antioxidant (LB) + control (UB)|Antioxidant will be weighed and applied to an area on the lower back (LB) to be exposed with visible light at a concentration of 2 mg/cm^2. Control will also be weighed and applied to an area of the upper back (UB) to be exposed with visible light at a concentration of 2 mg/cm^2. These will be applied according to the randomization scheme.
3094730|NCT01927679|Other|Antioxidant (UB) and Control (LB)|Antioxidant will be weighed and applied to an area on the upper back (UB) to be exposed with visible light at a concentration of 2 mg/cm^2. Control will also be weighed and applied to an area of the lower back (LB) to be exposed with visible light at a concentration of 2 mg/cm^2. These will be applied according to the randomization scheme.
3094731|NCT01927666|Experimental|dietary intervention|To measure the variation in extent of ITC excretion in urine from a capsule delivered dose of 100mg glucoraphanin
3094732|NCT01927653||The patients with amnestic MCI|"The patients with single domain amnestic MCI have a Clinical Dementia Rating score of 0.5 with isolated memory impairment without deficits in other cognitive domains. A cutoff scores below 1.5 Standard Deviation (SD) (or 7 percentile) of one of the tests in domains of cognitions employed psychometric tests; They should meet the following criteria:~memory complaint~normal general cognition~normal activities of daily living~not demented"
3094733|NCT01927653||The patients with dysexecutive MCI|"The patients of dMCI have relatively focal dysfunction in executive domain with the tests of memory, language and visuospatial skills within normal limits. The patients with single domain dysexecutive MCI should meet the following criteria:~relatively focal executive dysfunction~Within reference range on tests of memory, language and visuospatial skills~normal general cognition~normal activities of daily living~not demented"
3094734|NCT01927653||The healthy volunteers|"The healthy volunteers should be normal neuropsychological assessments as well as CDR=0 without significant neuropsychiatric disorder, right-handed, gender balanced and meet the following criteria:~Age and gender matched healthy subjects without significant neuropsychiatric disorder~Able to understand and provide signed informed consent"
3094735|NCT01927640|Experimental|Dexmedetomidine and intranasal cocaine|Dexmedetomidine (0.3-0.6 mcg/kg) infusion after intranasal cocaine administartion
3094736|NCT01927640|Placebo Comparator|Normal saline and intranasal cocaine|During Visit 2 (Cocaine Study Day), intranasal cocaine will be administered. If randomized to this placebo arm, saline (over 10 minutes I.V. infusion) will then be administered followed by repeat myocardial contrast echocardiography.
3094737|NCT01927627|Experimental|Enzalutamide|Oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
3094738|NCT01927614||Cohort 1|20 patients 1-year post heart transplant will undergo standard of care invasive cardiac catheterization but will also have intravascular ultrasound performed to measure the maximal intimal thickness of the proximal left anterior descending artery. Patients will be dichotomized into those with MIT <0.5mm (10 patients) and those with MIT >0.5mm (10 patients). All 20 patients will undergo both cardiac CT and cardiac MRI with perfusion imaging.
3094739|NCT01927614||Cohort 2|10 patients 1 year post heart transplant classified as CAV grade 0 by standard cardiac catheterization will undergo both cardiac CT and cardiac MRI with perfusion imaging.
3094740|NCT01927614||Cohort 3|10 patients with a diagnosis of CAV grade 1 as assessed by routine coronary angiogram at any time point post heart transplantation, will undergo cardiac CT and cardiac MRI with perfusion imaging
3094741|NCT01927588|Experimental|Everolimus+Tacrolimus+Prednisone|Certican 3mg/daily for 12 months TACreduced 0,15mg/Kg/daily for 12 months Steroids 1mg/Kg/daily for 12 months
3094742|NCT01927588|Active Comparator|Mycophenolate+Tacrolimus+Prednisone|Myfortic 720mg twice daily for 12 months TACreduced full dose/Kg/daily for 12 months Steroids 1mg/Kg/daily for 12 months
3094743|NCT01927575|Active Comparator|Standard X-Ray + CT|Standard X-Ray + CT arm to be used as comparative arm for investigational imaging device. Investigators will determine standard of care to be used on a per subject basis.
3094744|NCT01927575|Active Comparator|Standard X-Ray + MRI|Standard X-Ray + MRI arm to be used as comparative arm for investigational imaging device. Investigators will determine standard of care to be used on a per subject basis.
3094745|NCT01927575|Experimental|Tomo|Fujifilm Digital Radiographic AcSelerate CsI System with Tomosynthesis
3094746|NCT01927562|Experimental|Duodenal Treatment|
3094780|NCT01927341|Experimental|Phase II: Patients with acquired mutant RAS mCRC|Patients with acquired mutant RAS mCRC who have been pretreated with anti-EGFR monoclonal antibody therapy, but have not been pre-treated with EGFR tyrosine kinase inhibitor therapy.
3094747|NCT01927549|Active Comparator|Immediate multivessel PCI|After diagnostic angiography the culprit lesion is identified and PCI should be performed using standard techniques. The use of drug-eluting stents is recommended but not mandatory. All additional lesions in other major coronary arteries defined by a diameter >2 mm with high grade stenoses (>70% by visual assessment) should be intervened using standard techniques. Other major coronary arteries are defined by stenoses of other vessels and are not confined to a diagonal branch if the left anterior descending coronary artery was identified as the culprit lesion.
3094748|NCT01927549|Active Comparator|Culprit lesion only PCI|After diagnostic angiography the culprit lesion is identified and PCI of the culprit lesion should be performed using standard techniques. The use of drug-eluting stents is recommended but not mandatory. All other lesions should be left untreated in the acute setting. Complete revascularization of the non-culprit lesions may be performed at a later time point as staged procedure depending on remaining ischemia (as per guideline recommendations either by PCI or CABG).
3094749|NCT01927536||Night Vision|White LED Flashlight, Red/Green Green Dominant LED Flashlight
3094750|NCT01927523|No Intervention|Control group|These youth will not receive the non-academic cognitive behavioral programming nor the intensive academic mathematics tutoring.
3094751|NCT01927523|Experimental|BAM Group Therapy & Match Math Tutoring|These youth will receive both the non-academic cognitive behavioral programming and the intensive academic mathematics tutoring.
3094752|NCT01927523|Experimental|BAM Group Therapy|These youth will receive the non-academic cognitive behavioral programming.
3094753|NCT01927523|Experimental|Match Math Tutoring|These youth will receive the intensive academic mathematics tutoring.
3094754|NCT01927510|Experimental|early mobilisation|intervention of early mobilisation
3094755|NCT01927510|No Intervention|Control|Standard care
3094756|NCT01927497|Experimental|Biological mesh closure|Biological mesh reconstruction of the pelvic floor after extralevator abdomino perineal resection
3094757|NCT01927497|Active Comparator|Primary perineal closure|Primary perineal closure after extralevator abdomino perineal resection
3094758|NCT01927484|Experimental|methotrexate|25mg oral methotrexate tablets
3094759|NCT01927484|Placebo Comparator|placebo|25 mg/week placebo tablets
3094760|NCT01927471||Regular menstrual cycles|Adult women will be assigned to this category if they report a history of regular menstrual cycles. We will aim to recruit 120 women in this category.
3094761|NCT01927471||Irregular menstrual cycles, no PCOS|Adult women will be assigned to this category if they report a history of irregular menstrual cycles, without a pre-existing diagnosis of PCOS. We will aim to recruit 120 women in this category.
3094762|NCT01927471||Irregular menstrual cycles, with PCOS|Adult women will be assigned to this category if they report a history of irregular menstrual cycles with a pre-existing diagnosis of PCOS by a physician. We will aim to recruit 120 women in this category.
3094763|NCT01927458|Experimental|anodal tDCS with treadmill training|Each subject will receive 4 weeks gait treadmill training at least 3 days per week in combination with anodal transcranial Direct Current Stimulation over the primary motor cortex up to 20 min
3094764|NCT01927445|No Intervention|Usual care|No standardized intervention for management of patients with atrial fibrillation. Instead participants receive interventions for management of chronic kidney disease.
3094765|NCT01927445|Experimental|quality improvement toolkit|The toolkit includes provider-focused strategies (education, audit and feedback, electronic decision support and reminders) plus patient-directed strategies (educational letters and reminders).
3094766|NCT01927432||Regular menstrual cycles|Adult women will be assigned to this category if they report a history of regular menstrual cycles.
3094767|NCT01927432||Irregular menstrual cycles|Adult women will be assigned to this category if they report a history of irregular menstrual cycles, including women with a pre-existing diagnosis of PCOS.
3094768|NCT01927419|Experimental|Nivolumab + Ipilimumab|Participants received (Part 1) 1 mg/kg of nivolumab + 3 mg/kg of ipilimumab solution intravenously every 3 weeks for 4 doses (4 cycles), then (Part 2) 3 mg/kg of nivolumab intravenously every 2 weeks until documented disease progression, toxicity, withdrawal of consent, or study completion.
3094769|NCT01927419|Experimental|Placebo + Ipilimumab|Participants received (Part 1) placebo-matching nivolumab + 3 mg/kg of ipilimumab solution intravenously every 3 weeks for 4 doses (4 cycles), then (Part 2) placebo-matching nivolumab solution intravenously every 2 weeks until documented disease progression, toxicity, withdrawal of consent, or study completion.
3094770|NCT01927406|Experimental|Prostaglandin Analog vs Timolol|In this group, with thyroid eye disease and increased intraocular pressure in both eyes, prostaglandin analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one - randomised eye. Timolol 0.5% eye drop will be administered topically in second, control eye, two times a day.
3094771|NCT01927406|Experimental|Prostaglandin Analog|In this group, with thyroid eye disease and increased intraocular pressure in only one eye Prostaglandin Analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one, affected eye.
3094772|NCT01927393|Experimental|Arm I (PCPI)|Patients undergo a comprehensive physical, psychological, social, and spiritual palliative care assessment. Patients also receive a workbook that covers physical and psychological well-being and social and spiritual well-being, delivered over 2 educational sessions.
3094773|NCT01927393|Active Comparator|Arm II (standard care plus attention control)|Patients receive standard care plus attention comprising two telephone contacts.
3094774|NCT01927380||brachytherapy|males undergoing elective laparoscopic radical prostatectomy steep trendelenburg position with pneumoperitoneum
3094775|NCT01927367|Other|Clinical Decision Support System for AF|Providers randomized to use the Clinical Decision Support System (CDSS, a web-based tool).
3094776|NCT01927367|No Intervention|Usual Care|Usual Care - providers are not eligible to access / use the CDSS.
3094777|NCT01927354||Head and neck cancer|Subjects who suffer from oral cancer. Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery.
3094778|NCT01927341|Experimental|Phase Ib: Dose escalation|Phase Ib: Dose escalation.
3094779|NCT01927341|Experimental|Phase II: Patients with mutant RAS mCRC|Patients with mutant RAS mCRC who have not been pretreated with an EGFR inhibitor (EGFRi), including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
3094781|NCT01927341|Experimental|Phase II: Patients with WT RAS mCRC (pretreated)|Patients with WT RAS mCRC who have not been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
3094782|NCT01927341|Experimental|Phase II: Patients with WT RAS mCRC (not pretreated)|Patients with WT RAS mCRC who have not been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
3094783|NCT01927328|No Intervention|Control|Standard Care as determined by the clinical team
3094784|NCT01927328|Active Comparator|Iron isomaltoside 1000|Intravenous Iron Isomaltoside 1000 (Monofer®)will be administered in line with the summary of product characteristics.
3094785|NCT01927315|Experimental|Fenofibrate|Fenofibrate 145 mg (Fulcrosupra) oral tablets daily for 12 weeks
3094786|NCT01927315|Placebo Comparator|Placebo|Placebo oral tablets daily for 12 weeks
3094787|NCT01927302|Experimental|Naming Deficits|Language treatment will focus on improving naming deficits in people who have aphasia. An experimental group will receive treatment focusing on naming objects and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
3094788|NCT01927302|Experimental|Spelling and/or Writing Deficits|Language treatment will focus on improving writing and/or spelling deficits in people who have aphasia. An experimental group will receive treatment focusing on improving spelling abilities and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
3094789|NCT01927302|Experimental|Sentence Processing|Language treatment will focus on improving sentence comprehension and production deficits in people who have aphasia. An experimental group will receive treatment focusing on improving sentence processing and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
3094790|NCT01927289|Active Comparator|Proximal Brachial Plexus block|15 mls of 1.5% Mepivacaine injected in the supraclavicular approach and 15 mls of saline injected in the distal forarm nerve blocks
3094791|NCT01927289|Active Comparator|Distal Forearm block|15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach
3094792|NCT01927276|Placebo Comparator|Gluten Free Flour (Control)|Gluten Free Flour 10 grams daily
3094793|NCT01927276|Active Comparator|Wheat Flour|Wheat Flour 10 grams daily
3094794|NCT01927263|Experimental|NI-071|
3094795|NCT01927263|Active Comparator|Infliximab|
3094796|NCT01927250|Experimental|Okada Health and Wellness program|12,166 Japanese volunteers with/without illness, who were interested in practicing Okada Health and Wellness program for 3 consecutive months.
3094797|NCT01927237|Experimental|HLR-first|"Patients in this arm will have the hypercapnia with low respiratory rate (HLR) strategy first. Once hypercapnia is achieved via inspired carbon dioxide, no additional changes will be made to the ventilator. Once steady-state is achieved, physiological measurements will be taken. The patient will be returned to baseline settings for a 15-minute rest period before starting the EHR strategy per the cross-over design."
3094798|NCT01927237|Experimental|EHR-first|"Patients in this arm will have the eucapnia with high respiratory rate (EHR) strategy first. Once hypercapnia is achieved via inspired carbon dioxide, respiratory rate will be increased until PetCO2 returns to baseline or up to 35 breaths per minute, as limited by the National Heart Lung and Blood Institute (NHLBI) ARDS Network protocol. fraction of inspired oxygen inspired oxygen fraction and set tidal volume will be maintained. Once steady-state is achieved, physiological measurements will be taken. The patient will be returned to baseline settings for a 15-minute rest period before starting the HLR strategy per the cross-over design."
3094799|NCT01927224|Experimental|Nifurtimox (Group 1)|Descriptive pharmacokinetic group
3094800|NCT01927224|Experimental|Nifurtimox (Group 2)|The assessment of bioequivalence of the two formulation (30mg vs.120mg)
3094801|NCT01927198|Experimental|RDEA3170 5 mg qd|No titration.
3094802|NCT01927198|Experimental|RDEA3170 10 mg qd|Increase from RDEA3170 5 mg to RDEA3170 10 mg qd at Week 2.
3094803|NCT01927198|Experimental|RDEA3170 12.5 mg qd|Increase from RDEA3170 10 mg to RDEA3170 12.5 mg qd at Week 4.
3094804|NCT01927198|Placebo Comparator|Placebo|Placebo group
3094805|NCT01927185|Active Comparator|Long Axis strategy|The central venous catheterization will be performed by the long axis approach
3094806|NCT01927185|Active Comparator|Short Axis Strategy|The central venous catheterization will be performed by the short axis approach
3094807|NCT01927172|Other|AirSonea|Use of AirSonea to detect wheeze sounds.
3094808|NCT01927159|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine (QFT-)|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant. This group limited to adults with negative Quantiferon Gold TB (QFT) test.
3094809|NCT01927159|Experimental|2 mcg ID93 + 2 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. Low dose of antigen and low dose of adjuvant.
3094810|NCT01927159|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant.
3094811|NCT01927159|Experimental|10 mcg ID93 + 5 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and high dose of adjuvant.
3094812|NCT01927159|Placebo Comparator|Saline|Three intramuscular injections of saline at Days 0, 28, and 112.
3094813|NCT01927146||Resectable gastric cancer|No intervention
3094814|NCT01927133||FIBROFRANCE Project|
3094815|NCT01927120|Experimental|GVHD Regimen|Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).
3094816|NCT01927107|Active Comparator|Probiotic mixture|Probiotic mixture including Lactobacillus acidophilus (4.3x108CFU/per sachet), Lactobacillus rhamnosus (4.3x108CFU/ per sachet), Bifidobacterium bifidum (4.3x108CFU/ per sachet), Bifidobacterium longum (4.3x108CFU/ per sachet), Enterococcus faecium (8.2x108CFU/ per sachet, per oral daily for 30 days in addition to standard approach
3094817|NCT01927107|Active Comparator|Control|Standard diet therapy
3094818|NCT01927094|Active Comparator|Probiotic|"Saccharomyces boulardii 1 x 250 mg per day for 5 days, PO or Lactobacillus GG 1 x 10(9) CFU per day for 5 days or~Lactobacillus reuteri 1 x 10(8) CFU per day for 5 days"
3094820|NCT01927081|Active Comparator|discussion group|Eight weekly group sessions in which participants will engage in discussions regarding issues related to coping with advanced cancer and pain
3094821|NCT01927081|Active Comparator|discussion group + exercise|Eight weekly group sessions in which participants will engage in discussions regarding issues related to coping with advanced cancer and pain and learn gentle exercise and breathing techniques
3094822|NCT01927068|Experimental|CVI Paclitaxel-Coated PTA Balloon Catheter|
3094823|NCT01927055|Active Comparator|Droxidopa|Droxidopa 100 mg, 200 mg, 300 mg
3094824|NCT01927055|Placebo Comparator|Placebo|Placebo
3094825|NCT01927042|Experimental|Expert Cares Helping Others plus Treatment as Usual|The experimental treatment (ECHOs plus TAU) will consist of the standard treatment consisting of group psychotherapy and skills training, nutritional counselling, and meal support, PLUS self-help unguided DVD series for carers, providing education about eating disorders and coping strategies for supporting those living with eating disorders.
3094826|NCT01927042|Active Comparator|Treatment as Usual|Treatment as usual (TAU) consists of group psychotherapy and skills training, nutritional counselling, and meal support.
3094827|NCT01927029|Experimental|Progesterone|Daily administration of vaginal progesterone, 180mg, in gel, from 18 weeks to 34 weeks.
3094828|NCT01927029|Placebo Comparator|Placebo|Placebo Gel, for daily use from 18 weeks to 34 weeks.
3094829|NCT01927016||Esophagectomy for cancer|Patients operated on for a cancer of the esophagus, a Siewert I or II cancer of the oesophago-gastric junction
3094830|NCT01927003|Experimental|Surgical flap|Dorsal digito-metacarpal flap is based on the dorsal digital artery and dorsal metacarpal artery.
3094831|NCT01926977|Active Comparator|Ranibizumab 0.5mg Intravitreal injection|Intravitreal injection of Ranibizumab 0.5mg once
3094832|NCT01926977|Active Comparator|Aflibercept 2.0mg Intravitreal injection|Intravitreal Aflibercept 2.0mg once
3094833|NCT01926964||Early breast cancer patients|Patients with ER-positive, HER2 negative, pN0 or pN1a and resected primary breast cancer R0 resection.
3094834|NCT01926951|Experimental|Renal Denervation|Renal Denervation using the Kona Surround Sound Externally Focused Therapeutic Ultrasound therapy.
3094835|NCT01926938||adults at risk|Latino adults with family history of type 2 diabetes
3094836|NCT01926938||controls|Latino adults without family history of type 2 diabetes and normal glucose tolerance
3094837|NCT01926925||1|Overweight Hispanic children/adolescents
3094838|NCT01926925||2|Lean Hispanic children/adolescents
3094839|NCT01926912||Participants with schizophrenia|
3094840|NCT01926899|Experimental|Bortezomib administration|0.7 milligrams per meter squared given on Day 0 and Day +3
3094841|NCT01926886|Experimental|Herceptin|
3094842|NCT01926873||Healthy volunteers|
3094843|NCT01926860|Experimental|Study group - Prevenar®13 and Hepatitis A vaccines|Study group (group 1) - Prevenar®13 and Hepatitis A: one dose of each vaccine administered on Day 0
3094844|NCT01926860|Active Comparator|Pneumococcal conjugate vaccine -Control group - Prevenar®13|PCV -Control group (group 2) - Prevenar®13: one vaccine injection administered on Day 0
3094845|NCT01926860|Active Comparator|HepA -Control group - Hepatitis A vaccine|HepA -Control group (group 3) - Hepatitis A vaccine: one vaccine injection administered on Day 0
3094846|NCT01926847|Experimental|Riociguat+Placebo|Randomization order 1: first single oral dose of 2 mg BAY63-2521, then matching placebo
3094847|NCT01926847|Experimental|Placebo+Riociguat|Randomization order 2: first matching placebo, then single oral dose of 2 mg BAY63-2521
3094848|NCT01926834|Experimental|Erigeron Injection|Erigeron Injection, 30ml,qd,i.v., for 7 days
3094849|NCT01926834|Placebo Comparator|placebo|normal saline, 500ml,i.v.,qd, for 7 days
3094850|NCT01926834|No Intervention|health volunteers|health volunteers, no drug to be given.
3094851|NCT01926821|Experimental|sonifilan|Group who get sonifilan
3094852|NCT01926821|No Intervention|control|No Sonifilan administered
3094853|NCT01926808||Vitamin D supplementation|
3094854|NCT01926795|Active Comparator|Short Leg Cast|Patient will be placed in a short leg cast for approximately 3 weeks or until radiographic union
3094855|NCT01926795|Experimental|No immobilization|No cast or splint will be applied to the injured extremity
3094856|NCT01926795|Other|Observational|Patient will be treated based on the parents comfort. This arm will consist of individuals in which the parent/guardian did not agree to randomization, but did consent for observational follow-up regardless of treatment.
3094857|NCT01926782|Placebo Comparator|Placebo Q2W|Two subcutaneous (SC) injections of placebo (for alirocumab) Q2W with or without stable statin therapy for 48 weeks.
3094858|NCT01926782|Experimental|Alirocumab 75 mg/ Up 150 mg Q2W|One SC injection of each Alirocumab 75 mg and placebo Q2W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
3094859|NCT01926782|Experimental|Alirocumab 300 mg/ Up 150 mg Q4W|Two SC injections of Alirocumab 150 mg Q4W alternating with two SC injections of placebo Q4W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
3094860|NCT01926769|Experimental|FOLFOX6+Metformin/FOFIRI+Metformin|
3094861|NCT01926756|Other|Straight catheterization (control)|The control arm is the current practice at our hospital (to perform straight catheterization for short procedures).
3094862|NCT01926756|Active Comparator|No straight catheterization|The experimental arm will void preoperatively and will not be straight catheterized intraoperatively. This is a change from the current practice at our hospital.
3094863|NCT01926743|Experimental|NIR with ICG group|
3094864|NCT01926730|No Intervention|Usual diet|Patients will follow a usual diet and consume at least 16 oz of water per day
3094865|NCT01926730|Experimental|Restriction diet|Participants will follow a diet that limits intake of selected food items. Patients will consume at least 16 oz of water per day.
3094866|NCT01926717||Single Roux-y of Pancreaticojejunostomy-choledochojejunostomy|
3094867|NCT01926717||Pancreaticoduodenectomy|
3094868|NCT01926704||healthy, young subjects|
3094869|NCT01926691||Acute First-ever Stroke|Patients over 50 years and without pre-stroke dementia, displaying an ischemic first-ever stroke or transient ischemic attack (TIA), onset within the last 72 hours, Israeli residents.
3094870|NCT01926678|Experimental|Swedish massage therapy|Swedish massage therapy once per week for 6 weeks
3094871|NCT01926678|Active Comparator|Light touch therapy|Light touch therapy once per week for 6 weeks
3094872|NCT01926678|Other|Wait list|A 6 week wait list, followed by randomization to massage therapy or light touch therapy once per week for 6 weeks
3094873|NCT01926665|Experimental|Carfilzomib|Carfilzomib given in four doses, days 1, 2, 15 and 16, every 28 days for 6 months starting within 6 months post ASCT. Doses given in an escalated phase 1 design, starting at 20/20 mg/m2, later increased to 20/27 mg/m2, 20/36 mg/m2 and 20/45 mg/m2. CFZ dose based on actual body surface area at baseline (cycle 1). Patients with a body surface area (BSA) greater than 2.2 m2 receive dose based upon a 2.2 m2 BSA. Adjustments are not made if weight gains or losses are less than or equal to 20% from baseline. Dexamethasone 4 mg by vein or mouth prior to each CFZ dose in cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, then it should be restarted and administered prior to subsequent doses for reactions.
3094874|NCT01926652|Experimental|candesartan|Single administration : candesartan cilexetil 32mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd
3094875|NCT01926652|Experimental|amlodipine|Single administration : amlodipine 10mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd
3094876|NCT01926639|Experimental|Radiotherapy , rituximab and DC|Treatment repeated 3 times and targeting different lymph nodes
3094877|NCT01926626|Experimental|Nicotine Patch+Moclobemide|After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
3094878|NCT01926613|Active Comparator|Supported Employment Only|Supported employment is an evidence based practice designed to help people with serious mental illness obtain competitive work. This vocational model adheres to the principles of zero inclusion, rapid job search, no prevocational training, attention to client preferences and integration with clinical services.
3094879|NCT01926613|Experimental|Thinking Skills for Work|The Thinking Skills for Work Program includes 5 components delivered by a Cognitive Specialist who works collaboratively with the consumer's Employment Specialist: a) assessing the consumer's strengths and weaknesses in cognitive functioning, and analysis of the contribution of cognitive impairments and other factors to job losses and difficulties obtaining a job; b) teaching coping strategies for dealing with cognitive challenges associated with job search or maintaining a job; c) computer cognitive training involving cognitive exercises with a commercially available software program, which is designed to improve the broad range of cognitive skills through a combination of practice and strategy coaching by the Cognitive Specialist; d) job search planning; and e) job support consultation.
3094880|NCT01926600||PO|administrated by per oral
3094881|NCT01926600||IV|Administrated by intravenous
3094882|NCT01926600||SL|administrated by sublingual
3094883|NCT01926587|Experimental|Oral rigosertib plus azacitidine|Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle. Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
3094884|NCT01926574|Experimental|long rehabilitation|a 3.5-week, in-patient rehabilitation program, organized as a 7-hour workday with weekends off, simulating a close to normal summer work-week in Norway, and mainly group-based with maximum 8 participants per group. Focus on mental training (aimed at increasing motivation and self-efficacy), physical training and work-related problem solving.
3094885|NCT01926574|Experimental|short rehabilitation|4+4 full days of rehabilitation at Hysnes Rehabilitation Center, separated by 2 weeks living at home. Group-based with 8 participants per group, focus on mental training (aimed at increasing motivation and self-efficacy), physical training and work-related problem solving. A workplace visit will be included in addition to the 4 + 4 rehabilitation days, if considered relevant.
3094886|NCT01926574|Active Comparator|Acceptance and commitment therapy|6 dynamic processes (committed action, self-as-context, presence in the moment, values, defusion and acceptance) are targeted both in group-sessions and individual meetings. Only the psychological part of the experimental interventions is applied, in an outpatient setting.
3094887|NCT01926574|No Intervention|Untouched|this group will be followed in registers at group level and not be aware of their participation in the study
3094888|NCT01926561||Hypotensive bradycardic event|The participants are assigned to hypotensive bradycardic event (HBE) group when they experience signs or symptoms associated with syncope, hypotension, or bradycardia, which are treated with vasopressors or inotropics following sitting position after interscalene brachial plexus block is done. Otherwise, they are assigned to non-HBE group.
3094889|NCT01926548|Experimental|CJ Imatinib 200mg|1 tablet(200mg) a day,PO,QD
3094890|NCT01926548|Active Comparator|Gleevec 100mg|2 tablet(100mg) a day,PO,QD
3094891|NCT01926535|Experimental|Implant of amniotic membrane grafts|Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
3094892|NCT01926535|Active Comparator|Therapeutic contact lenses|Therapeutic contact lenses were applied in all patients and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
3094893|NCT01926522|Experimental|Technological Rehabilitation|Experimental group receives a treatment of: 20 minutes of analyzing treadmill with feedback focused on symmetry and length of stride; 20 minutes of isokinetic dynamometric muscle strengthening of flexor and extensor muscles of tibiotarsal joint; 20 minutes of balance retraining on dynamic balance platform. Each patient receives 20 sessions over a period of 4 weeks (5 sessions per week).
3094926|NCT01926340||Early maintenance treatment group|Drug (quetiapine, 400mg/d) during the 12-month randomized phase of the study
3094927|NCT01926340||Early discontinuation group|Drug (placebo) during the 12-month randomized phase of the study
3095355|NCT01923506|Experimental|Treatment (SBRT)|Patients receive 5 fractions of SBRT over 1.5 weeks.
3094894|NCT01926522|Active Comparator|Control Rehabilitation|Control group receives the same number of treatment sessions of same duration as those in the experimental group: activities targeted to improve the endurance (instead of analyzing treadmill ), manual exercises of lower limb muscle strengthening, stretching exercises (instead of dynamometer), gait retraining on the floor for 20 minutes and static and dynamic balance exercises in upright position (instead of dynamic balance platform).
3094895|NCT01926509|Experimental|MK-8892 Panel A|Participants will be administered MK-8892 once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 3 mg (Days 15-21), 4 mg (Days 22-28).
3094896|NCT01926509|Experimental|MK-8892 Panel B|Participants will be administered MK-8892 orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 4 mg (Days 15-21), 4 mg (Days 22-28)
3094897|NCT01926509|Experimental|MK-8892 Panel C|Participants will be administered MK-8892 orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 4 mg (Days 15-21), up to 8 mg (Days 22-28).
3094898|NCT01926509|Placebo Comparator|Placebo (Panels A and B)|Participants will be administered placebo to MK-8892 once daily for 28 days.
3094899|NCT01926496|Experimental|Ingenol Mebutate|Arm A: Ingenol mebutate gel 0.015% applied daily for 3 consecutive days to the selected treatment area followed by 8 weeks' rest. Retreatment for another 3 consecutive days if the treatment field is not completely cleared of AKs at Week 8
3094900|NCT01926496|Active Comparator|Imiquimod|Arm B: Imiquimod 5% cream applied 3 days per week for 4 weeks to the selected treatment area followed by 4 weeks' rest. Retreatment for another 4 weeks if the treatment field is not completely cleared of AKs at Week 8
3094901|NCT01926483|Experimental|Neoadjuvant Treatment|Neoadjuvant Chemoradiotherapy
3094902|NCT01926470|Experimental|anteroposterior approach group|anteroposterior approach group
3094903|NCT01926470|Active Comparator|oblique approach group|oblique approach group
3094904|NCT01926457|Experimental|First Trimester Treatment of Prediabetes|"Patients randomized to first trimester treatment will receive the following intervention immediately initiated upon diagnosis of prediabetes at <15 weeks 0 days gestation~diabetes education~blood glucose monitoring~medications as needed per California Diabetes and Pregnancy established protocol~growth ultrasounds~antenatal testing"
3094905|NCT01926457|Active Comparator|Third Trimester Treatment of Prediabetes|"Patients randomized to third trimester treatment will receive the following intervention to be initiated at 28 weeks of gestation~diabetes education~blood glucose monitoring~medications as needed per California Diabetes and Pregnancy established protocol~growth ultrasounds~antenatal testing"
3094906|NCT01926444|Experimental|GIC-1001 low dose|GIC-1001 , 250 mg TID during 3 consecutive days + a last, 10th dose in the morning of Day 4 (colonoscopy day)
3094907|NCT01926444|Experimental|GIC-1001 mid-dose|GIC-1001 , 375 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
3094908|NCT01926444|Experimental|GIC-1001 , high dose|GIC-1001 , 500 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
3094909|NCT01926444|Placebo Comparator|GIC-1001 matching placebo|Placebo, TID during 3 consecutive days, + a 10 th dose in the morning of day 4 (colonoscopy day)
3094910|NCT01926431|Experimental|Exercise|60 minutes of high intensity treadmill running
3094911|NCT01926431|Experimental|Rest|60 minutes of seated rest (control trial)
3094912|NCT01926418|No Intervention|Control|The control group receives the TPB questionnaires but receives no intervention
3094913|NCT01926418|Experimental|Implementation intentions|Participants are asked to specify when, where and how they will use condoms in the future. They will be sent weekly email reminders of their implementation intentions.
3094914|NCT01926418|Experimental|Planning task|Participants will be asked to practice the Tower of Hanoi task four times per week for ten to fifteen minutes.
3094915|NCT01926405|Other|Subjects with narcolepsy or with idiopathic hypersomnia|
3094916|NCT01926405|Other|Control patients with no sleeping disorder|
3094917|NCT01926392|Experimental|water-soluble therapy|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
3094918|NCT01926392|Active Comparator|silver sulfadiazine|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
3094919|NCT01926379|Experimental|Combination Intervention Package (CIP)|Patients who enrolled in HIV care at a CIP site on or after January 1, 2013 and initiate Isoniazid Prevention Therapy (IPT) on or after study initiation on July 1, 2013 will receive the combination intervention components that is a part of the Combination Intervention Package (CIP).
3094920|NCT01926379|Other|Standard Of Care (IPT alone)|Patients are screened for tuberculosis (TB) at enrollment in HIV care at a HIV clinic and during each routine clinic visit using a simple symptom questionnaire. Eligible patients will receive the standard of care intervention, Isoniazid Prevention Therapy (IPT), per national guidelines. After IPT initiation, patients return to the HIV clinic monthly for monitoring of side effects, TB symptoms, self-reported 30-day adherence, and to receive a 30-day supply of isoniazid. If adherence problems are noted at any time, the nurse counsels the patient, and if the patient still wants to take IPT, it is continued.
3094921|NCT01926366|Experimental|Experimental: AZD6423|Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo.
3094922|NCT01926366|Placebo Comparator|Placebo to match AZD6423|Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo.
3094923|NCT01926353||Vantris|Patient who categorized as who underwent endoscopic correction procedure, were patients who under general anesthesia performed by a single experienced surgeon using a 10Fr Storz® cystoscope with PPC (Vantris®) subureteral or intraureteral injection, or a combination of both techniques, depending on the anatomy of the ureteral meatus and VUR grade.
3094924|NCT01926353||Cohen reimplantation|Patient underwent surgical management were all had ureteral re-implatation with Cohen technique done by single experienced pediatric urologist.
3094925|NCT01926353||Continuous Antibiotic Prophylaxis|Group of patient treated with conservative management were children treated with culture guided antibiotics and maintained on 1st or 2nd generation cephalosporin as continuous antibiotic prophylaxis until time of 1 year follow-up.
3094928|NCT01926327|Active Comparator|platelet reach plasma|The patients with osteoarthritis who underwent PRP injection.
3094929|NCT01926327|Placebo Comparator|placebo|The patients with osteoarthritis who underwent Normal Saline injection.
3094930|NCT01926314|Experimental|device|Patients in this group will be offered pelvic floor muscle rehabilitation program using PHENIX Neuromuscular Stimulation Therapy System device. The participants will start therapy once a week 42 days after delivery, and last 8 weeks.
3094931|NCT01926314|Active Comparator|usual home care without device|Patients in this group will receive usual home care without device.
3094932|NCT01926301||Hemodialysis|Patients with severe sepsis or septic shock with acute renal failure and requirement of continuous veno-venous hemodialysis
3094933|NCT01926301||No hemodialysis|Patients with severe sepsis or septic shock without acute renal failure and no requirement of continuous veno-venous hemodialysis
3094934|NCT01926288|Other|HBeAg positive group|"Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks ."
3094935|NCT01926288|Other|HBeAg-negative group|"Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks ."
3094936|NCT01926275|Experimental|NPPV+IMT|noninvasive positive pressure ventilation and inspiratory muscle training
3094937|NCT01926275|Active Comparator|NPPV|noninvasive positive pressure ventilation
3094938|NCT01926275|Active Comparator|IMT|inspiratory muscle training
3094939|NCT01926275|Placebo Comparator|LTOT|Long time oxygen therapy
3094940|NCT01926262|Experimental|Physical Exercise Group|Specific Strength Training for the Neck and Shoulder muscles
3094941|NCT01926262|No Intervention|Reference group|No Specific Strength Training
3094942|NCT01926249||Individuals at high risk of developing Alzheimer's dementia|"2000 participants with a newly identified cognitive deficit defined as performing worse than one standard deviation to the mean in one or more cognitive domain (memory, language, praxis, visuospatial abilities, attention and executive functions), not demented.~300 participants with an isolated cognitive complaint and an age of 60 years or more."
3094943|NCT01926236|Active Comparator|Arm A: Active symptom control (ASC)|Active Symptom Control
3094944|NCT01926236|Experimental|Arm B: ASC with OxMdG chemotherapy|Active Symptom Control with OxMdG chemo (Oxaliplatin, L-folinic acid & 5FU)
3094945|NCT01926223|Experimental|Home visiting Group|
3094946|NCT01926223|No Intervention|Control Group|
3094947|NCT01926210|Experimental|mild ovarian stimulation|Patients are stimulated with mild ovarian stimulation protocol,i.ed, from cycle day 3 to 7, letrozole 5mg per day are administrated and recombinant FSH 150 IU are given on day 4 and 6 . On cycle day 8, serum FSH LH, and estradiol levels are measured, and after then, the dose of recombinant FSH is adjusted according to the ovarian response and the maxim recombinant FSH dose is 150 IU/d. The GnRH-antagonist (Cetrotide) 0.25mg per day is administrated when the estradiol level reaches 200 pg/ml and the serum LH level rises above 2 times of basal LH level.
3094948|NCT01926210|Active Comparator|controlled ovarian stimulation|Patients are stimulated using controlled ovarian stimulation protocol,i.e., from cycle day 18-22 (day 7 after ovulation) of previous cycle, all participants are given short-acting GnRH agonist (Triptorelin 0.05mg/d) for 14 days, then after checking serum FSH, LH and estradiol to make sure that complete downregulation is achieved, exogenous gonadotropin (recombinant FSH) 300 IU/d is given for 5 days, then the dose of recombinant FSH is adjusted according to ovarian response.
3094949|NCT01926197|Active Comparator|mFFX|mFOLFIRINOX
3094950|NCT01926197|Experimental|mFFX+SBRT|mFOLFIRINOX + SBRT
3094951|NCT01926184|Experimental|ARTEMIS+CM|This is a 5-session, individually delivered intervention that is designed to enhance positive affect. It is designed to boost and extend the effectiveness of contingency management (CM).
3094952|NCT01926184|Placebo Comparator|Attention-Control+CM|Attention-matched, 5-session control condition consisting of brief-self report psychological measures and neutral writing exercises. Contingency management (CM) is also administered to this arm.
3094953|NCT01926171|Experimental|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus concurrent icotinib, which was administered orally three times per day.
3094954|NCT01926158|Experimental|Denosumab|Subcutaneous injection of denosumab 60 mg 4 weeks before surgery and 22 weeks after surgery
3094955|NCT01926158|Placebo Comparator|Placebo|Subcutaneous injection of placebo 4 weeks before surgery and 22 weeks after surgery
3094956|NCT01926132|Experimental|ascorbic acid 10g/20ml|Normal Saline 130ml+ ascorbic acid 10g/20ml , covered bottle for the blind allocation
3094957|NCT01926132|Active Comparator|Normal Saline 150ml|Normal Saline 150ml, covered bottle
3094958|NCT01926119|Experimental|TMS Intervention - 5 days|Application of Transcranial Magnetic Stimulation (TMS) once per day over 5 days.
3094959|NCT01926106|Experimental|nIPPV|the infants in the arm were supported by Nasal Intermittent Positive-Pressure Ventilation(nIPPV)
3094960|NCT01926106|Active Comparator|nCPAP|the infants in the arm were supported by Nasal Continuous Positive Airway Pressure(nCPAP)
3094961|NCT01926080|Other|DVD Intervention Arm|Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU— Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
3094962|NCT01926080|No Intervention|Standard Bereavement Care|Those randomized to control group (no DVD) Standard Bereavement Care Arm receive the bereavement materials given to families as standard-practice of care in the NICU at SLCH following the death of an infant
3094963|NCT01926054|Active Comparator|Acthar Gel 80 IU SC BIW|80 IU administered subcutaneously BIW for 6 months
3094964|NCT01926054|Active Comparator|Acthar Gel 80 IU SC TIW|80 IU administered subcutaneously TIW for 6 months
3094965|NCT01926041|Experimental|Intervention|The invention includes smoking cessation clinics for up to 16 weeks (from January to December of 2017) and coach-assisted lifestyle change (from January of 2017 to July of 2020 and later) for every participant joining intervention. Each participant in intervention group receives counseling for individualized smoking cessation techniques at each visit. In addition, each participant is assigned two lifestyle coaches giving weekly and standardized instruction in diet and physical activity to help reach the goals of at least a 7 percent weight loss within the first 6 months. Each coach of physical activity offers supervised physical activity sessions at least two times per week (perhaps through cell phone apps). We do not prescribe the nicotine replacement therapy because it may induce insulin resistance and confound our study outcome. Bupropion is not available for smoking cessation in our institutions.
3094966|NCT01926041|No Intervention|Self-management|Participants who decide NOT to attend the intervention program are classified as self-management group. All smokers with prediabetes in intervention and self-management group are provided with educational materials for lifestyle change. They are still provided with educational materials of standardized diet and exercise. They are prospectively followed up every 6 months till July of 2020 and later for FTND scores, breath CO levels, anthropometric indices and blood tests (Table 1, Figure 1). The skills of body weight self-management (with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week)19 are delivered through educational materials.
3094967|NCT01926028|Experimental|NDV-3A|Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
3094968|NCT01926028|Experimental|NDV-3|Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
3094969|NCT01926028|Placebo Comparator|Placebo|Placebo: aluminum hydroxide adjuvant
3094970|NCT01926015|Experimental|Concomitant RotaTeq™ and DTP-IPV|RotaTeq™ (2 mL oral dose) and DTP-IPV (0.5 mL subcutaneous injection) administered concomitantly at Visit 2 (>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).
3094971|NCT01926015|Active Comparator|Staggered RotaTeq™ and DTP-IPV|RotaTeq™ (2 mL oral dose) administered at Visit 1 (Day 1), Visit 3 (6-8 weeks after Visit 1), and Visit 5 (6-8 weeks after Visit 3) and DTP-IPV (0.5 mL subcutaneous injection) administered at Visit 2 (>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).
3094972|NCT01926002|Experimental|Low-Dose MK-8351|Low-dose MK-8351 administered as single inhaled dose.
3094973|NCT01926002|Experimental|High-Dose MK-8351|High-dose MK-8351 administered as a single inhaled dose.
3094974|NCT01926002|Placebo Comparator|Placebo to MK-8351|Matching placebo to low-dose or high-dose MK-8351 administered as a single inhaled dose.
3094975|NCT01925989|Experimental|LY2605541|LY2605541 administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Participants will continue to use mealtime insulin.
3094976|NCT01925989|Active Comparator|Insulin Glargine|Insulin glargine administered to participants with T1DM SQ QD for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Participants continue to use mealtime insulin.
3094977|NCT01925989|No Intervention|Control|Control Arm. Untreated healthy participants.
3094978|NCT01925976|Other|Individualized dietetic intervention|Behavioral: Individualized dietetic intervention-eating habits.
3094979|NCT01925963||Normal cohort|Normal, healthy adults without history of brain injury
3094980|NCT01925950|Placebo Comparator|Placebo|Control
3094981|NCT01925950|Experimental|orBec|Investigational drug
3094982|NCT01925937|Experimental|Coenzyme Q10 & Atorvastatin|10 mg Atorvastatin daily plus 100 mg Coenzyme Q10 pearl supplement twice daily for four months.
3094983|NCT01925937|Active Comparator|Atorvastatin & placebo|10 mg Atorvastatin daily and the placebo of Coenzyme Q10 pearl for four months.
3094984|NCT01925924|Experimental|Resin-modified glass ionomer cement|Resin-modified glass ionomer cement is used to attach the fixed orthodontic brackets (brace) to the teeth.
3094985|NCT01925924|Active Comparator|Composite resin|Composite resin is used to attach fixed orthodontic brackets (brace)to the teeth.
3094986|NCT01925898|Experimental|Ketamine|Oral ketamine
3094987|NCT01925898|Active Comparator|Midazolam|Oral Midazolam
3094988|NCT01925885|Active Comparator|PVI Ablation|Standard of care arm-pulmonary vein isolation (PVI)-involving moving the ablation catheter from point to point in a continuous line to surround the the orifices of the pulmonary veins in order to eliminate electrical conduction between the veins and left atrium.
3094989|NCT01925885|Experimental|FIRM Ablation|FIRM ablation for paroxysmal atrial fibrillation at sites of rotors or focal impulse formation as designated by using the mapping algorithm of RhythmView
3094990|NCT01925859|Experimental|EryDex System|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)
3094991|NCT01925833|Experimental|Both insertion and withdrawal|
3094992|NCT01925833|Active Comparator|Only withdrawal|
3094993|NCT01925820|Experimental|Arm 1|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks
3094994|NCT01925820|Active Comparator|Arm 2|Entecavir daily for 144 weeks.
3094995|NCT01925820|Active Comparator|Arm 3|180 mcg Peg-IFN alfa-2a once a week for 48 weeks
3094996|NCT01925807|Experimental|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
3094997|NCT01925794|Experimental|COBRA PzF Stent|
3094998|NCT01925781|Experimental|e-Cigarette|STAM 1100mAh CE4 eGo Clearomizer e-Cigarette
3094999|NCT01925781|Active Comparator|Nicotine polacrilex|Nicotine Replacement gum
3095071|NCT01925287|Experimental|Micronized curcumin powder|500 mg curcumin as micronized powder
3095072|NCT01925287|Experimental|Curcumin micelles|500 mg curcumin incorporated into liquid micelles
3095073|NCT01925274|Experimental|Arm A|PF-05212384 plus Irinotecan
3095074|NCT01925274|Active Comparator|Arm B|Cetuximab plus Irinotecan
3095000|NCT01925768|Experimental|Apremilast 30 mg|30 mg Apremilast tablets administered twice daily (BID) for 24 weeks during the double-blind placebo-controlled phase; followed by 30 mg Apremilast BID for 28 weeks of active treatment phase (up to the 52 week visit); original treatment assignments remain blinded until all participants have completed their 52 week visit or have discontinued. After the Wk 52 visit, all participants in the extension phase will continue to receive treatment with apremilast 30 mg BID until the end of the study (ie, up to Week 104 visit) or until early discontinuation from the trial.
3095001|NCT01925768|Placebo Comparator|Placebo|Oral placebo BID during the placebo controlled phase weeks 0 to 24; placebo treated participants whose improvement is <10% in both swollen and tender joint counts at Week 16 are eligible for early escape (based on the measure of clinical benefit from their current treatment as evidenced by improvement (or lack of improvement) in 1) the physician (evaluator's) global assessment (EGA), 2) patients pain (pain NRS), 3) the patient global assessments (PGA), and 4) the health assessment questionnaire disability index (HAQ-DI); Placebo-treated patients who early escape are transitioned to apremilast 30 mg PO BID during the active treatment phase up to their Week 52 visit; all those who complete the 52-week treatment phase will enter an open-label extension phase for an additional 52 weeks or until early discontinuation from the trial.
3095002|NCT01925755||Group 1|
3095003|NCT01925742|Experimental|Low Risk of aneuploidy|Integrated prenatal screening for Down's syndrome (with follow-up fetal karyotype if positive); Serum QUAD Assay for aneuploidy screening; Semiconductor MPSS NIPT assay using ccfDNA in maternal blood; Optical-based MPSS NIPT assay using ccfDNA in maternal blood; Harmony™ Test (Ariosa Diagnostics)
3095004|NCT01925742|Experimental|High risk of aneuploidy|Integrated prenatal screening for Down's syndrome (with follow-up fetal karyotype if positive); Serum QUAD Assay for aneuploidy screening; Semiconductor MPSS NIPT assay using ccfDNA in maternal blood; Optical-based MPSS NIPT assay using ccfDNA in maternal blood; Harmony™ Test (Ariosa Diagnostics) (subset)
3095005|NCT01925729|Experimental|ragweed|ragweed -- 1000PNU intranasal spray
3095006|NCT01925729|Experimental|histamine|5 mg intranasal spray
3095007|NCT01925729|Experimental|pseudoephedrine|pseudoephedrine -- 60 mg orally
3095008|NCT01925729|Experimental|oxymetazoline|oxymetazoline 0.05% solution intranasal spray
3095009|NCT01925716|Experimental|Corn oil/olive oil|Corn oil 56 g per day for 21 days followed by olive oil 56 g for 21 days
3095010|NCT01925716|Experimental|Olive Oil/Corn Oil|olive oil, 56g per day for 21 days followed by corn oil, 56 g for 21 days
3095011|NCT01925703|Experimental|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
3095012|NCT01925690|Active Comparator|Brief Education|Patients receive a brief educational packet along with treatment as usual
3095013|NCT01925690|Experimental|MI-CBT Treatment|Patients receive five 20 minute phone sessions of motivational interviewing/cognitive behavioral therapy weekly along with a brief educational packet.
3095014|NCT01925677|Experimental|da Vinci® Single-Site™|Robotic-assisted single-incision laparoscopic nephrectomy.
3095015|NCT01925664|Experimental|Doula|Mothers received doula home visiting services in addition to normal prenatal and obstetric clinical care and had access to social work case management.
3095016|NCT01925664|No Intervention|Usual Care|Mothers received normal prenatal and obstetric clinical care and had access to social work case management.
3095017|NCT01925651|Other|Low Risk - No bolus|No Bolus
3095018|NCT01925651|Other|Low- Risk Alternate Bolus|Alternate Bolus
3095019|NCT01925651|Other|High Risk - Alternate Bolus|Alternate Bolus
3095020|NCT01925651|Other|High Risk - Continuous bolus|Continuous bolus
3095021|NCT01925638|Experimental|BAY86-9766|The study will be conducted in two parts and study treatments will be administered as follows: •Part A: Three subjects will be enrolled and will receive 10 mg of refametinib on Day 1. Once daily dosing of ketoconazole 400 mg will be initiated on Day 5 and will continue until Day 12 with 10 mg of refametinib administered concomitantly on Day 8 •Part B: Fifteen subjects will be enrolled and will receive refametinib doses of 10 mg, 20 mg or 30 mg on Days 1 and 8 with the same dose administered on both days. Refametinib dose for Part B will be based on safety and refametinib pharmacokinetics in Part A. Ketoconazole 400 mg will be administered once daily on Days 5 to 12. Subjects will stay in the investigational site for a total period of 15 consecutive days
3095022|NCT01925625|No Intervention|Control|participants monitored for 10 years for lung cancer incidence.
3095023|NCT01925625|Active Comparator|Early CDT Lung Test|Early CDT lung blood test
3095024|NCT01925612|Experimental|Part 1: BV(1.2 mg/kg) + RCHOP|"Brentuximab vedotin 1.2 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.2 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP."
3095025|NCT01925612|Experimental|Part 1: BV(1.8 mg/kg) + RCHOP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.8 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP."
3095026|NCT01925612|Experimental|Part 2: BV(1.8 mg/kg) + RCHP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone~Part 2 of the study is a phase 2, non-randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy (rituximab, cyclophosphamide, doxorubicin, and prednisone). Patients in this treatment arm were enrolled into a dosing cohort with 1.8 mg/kg brentuximab vedotin administered in combination with RCHP."
3095027|NCT01925612|Active Comparator|Part 3: RCHOP|"Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone."
3095028|NCT01925612|Experimental|Part 3: BV(1.8 mg/kg) + RCHP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone. Randomization in this part of the study is for the purpose of evaluating the safety of 1.8 mg/kg brentuximab vedotin in combination with RCHP versus standard RCHOP chemotherapy.~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive 1.8 mg/kg brentuximab vedotin administered in combination with RCHP."
3095029|NCT01925573|Other|Optune+RT+Bevacuzimab|"Part 1:~Bevacizumab every 2 weeks plus Optune daily for 4 week cycles.~Part 2:~RT will begin post 3 round of Bevacizumab (hypofractionated radiotherapy: 30 Gy in 5 fractions or 35 Gy in 10 fractions) per physician choice.~Part 3:~Adjuvant Bevacizumab and Optune"
3095030|NCT01925560|Experimental|Group A- agave inulin or placebo|Participant in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo.
3095031|NCT01925560|Experimental|Group B- agave inulin or placebo|Participants in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo
3095032|NCT01925560|Experimental|Group C-agave inulin or placebo|Participants in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo
3095033|NCT01925547|Experimental|Micellar curcumin|Subjects receive three times per day four capsules of curcumin micelles. One capsule contains 20 mg of curcumin. At the beginning, after three and six weeks of intake, blood samples are collected.
3095034|NCT01925547|Placebo Comparator|Placebo|Subjects receive three times per day four capsules of placebo preparation. At the beginning, after three and six weeks of intake, blood samples are collected.
3095035|NCT01925534|Experimental|Optiflow|High-flow humidified nasal oxygen delivery system
3095036|NCT01925534|Active Comparator|Oxygen therapy|Standard oxygen therapy
3095037|NCT01925521|Experimental|Part1 : OPS-2071|Single dose, OPS-2071 30,60,120,240,300,600,900,1200mg/day
3095038|NCT01925521|Placebo Comparator|Part1 : Placebo of OPS-2071|Single dose, Placebo
3095039|NCT01925521|Experimental|Part2 : OPS-2071|Multiple dose
3095040|NCT01925521|Placebo Comparator|Part2 : Placebo of OPS-2071|Multiple doses, Placebo
3095041|NCT01925495|Experimental|healthy adults|Experiment 1 -- variation of ear-canal pressure; Experiment 2 -- varied middle-ear gas compositions; Experiment 3 -- variation of middle-ear pressure
3095042|NCT01925482|Other|Group 1 -- no history of otitis media|no history of otitis media
3095043|NCT01925482|Other|Group 2 --patent tympanostomy tube|at least 1 patent tympanostomy tube
3095044|NCT01925469|Experimental|Benzocaine|Benzocaine spray (14%), an FDA approved drug, will be used to assess whether this provides additional pain relief at time of hysterosalpingogram.
3095045|NCT01925469|Placebo Comparator|Saline spray|A saline placebo spray will be used in the placebo group.
3095046|NCT01925456|Other|Toviaz|Patients willingness to take Toviaz 4mg and 8mg
3095047|NCT01925443|Experimental|low level laser therapy|individuals will be subject to the application of low level laser therapy, but this group will have three subdivisions related to dose in joules that will be administered to the individual, and J 4, J 6, 8 J. To be administered in the quadriceps muscle.
3095048|NCT01925443|No Intervention|Control Group|will consist of individuals diagnosed with diabetes mellitus non-insulin-dependent, however, will not perform low level laser therapy, participate only in the evaluations
3095049|NCT01925443|Experimental|Placebo group|individuals will be subject to the application of low level laser therapy but with a dose of 0 Joules.
3095050|NCT01925430||Comparative product|A device which monitors sleep/wake states
3095051|NCT01925430||Screening device|This device will screen for sleep-breathing disorders
3095052|NCT01925417|Experimental|RBX2660 (microbiota suspension)|
3095053|NCT01925404|Experimental|Frequent User Arm|Park users will be able to earn rewards or prizes by coming more frequently to the park
3095054|NCT01925404|Experimental|Free Physical Activity Classes/programs|We will offer at least 100 free physical activity classes at the park
3095055|NCT01925404|Experimental|Combined arm|We will offer free classes and the frequent user program at the park
3095056|NCT01925404|No Intervention|Control|Business as usual, no special physical activity programs offered
3095057|NCT01925391|Active Comparator|Sevoflurane, oxygen, intraocular pressure|Intraocular measurements under induction with Sevoflurane in oxygen
3095058|NCT01925391|Active Comparator|Nitrous oxide/O2/tetracaine|intraocular pressures in children undergoing inhalation induction with nitrous oxide in oxygen
3095059|NCT01925378|Experimental|Nelfinavir|This is a single arm intervention trial of nelfinavir in women with grade 2/3 or grade 3 cervical intraepithelial neoplasia
3095060|NCT01925365|Experimental|Wholegrain cereal oats|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period.
3095061|NCT01925365|Placebo Comparator|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
3095062|NCT01925352|Experimental|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection in patients with ischemic heart disease into five left ventricular sites once.
3095063|NCT01925339|Experimental|Test (immediate restoration)|Test (immediate restoration): immediate restoration will be placed on immediately placed implants.
3095064|NCT01925339|Experimental|Control: delayed restoration|Control: delayed restoration: immediate placed implants will be restored at 4 months.
3095065|NCT01925313|Experimental|CJ-30044|
3095066|NCT01925313|Active Comparator|TALION TAB. 10mg|
3095067|NCT01925300|Experimental|Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab, qd|Single administration : 6 days, per oral
3095068|NCT01925300|Experimental|Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab, qd|Single administration : 6 days, per oral
3095069|NCT01925300|Experimental|Concor 5mg 2T and Crestor 20 mg 1Tab, qd|Combination administration : 6 days, per oral
3095070|NCT01925287|Active Comparator|Native curcumin powder|500 mg curcumin as native powder
3095075|NCT01925261|Placebo Comparator|TPX-100 Cohort 1|Cohort 1 will be 20mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
3095076|NCT01925261|Placebo Comparator|TPX-100 Cohort 2|Cohort 2 will be 50mg dose of TPX-100 in one randomized knee compared to placebo treated knee
3095077|NCT01925261|Placebo Comparator|TPX-100 Cohort 3|Cohort 3 will be 100mg dose of TPX-100 in one randomized knee compared to placebo treated knee
3095078|NCT01925261|Placebo Comparator|TPX-100 Cohort 4|Cohort 4 will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
3095079|NCT01925261|Placebo Comparator|Part B|Part B will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
3095080|NCT01925248|Active Comparator|Whey protein group|Patients will be randomized to receive whey protein
3095081|NCT01925248|Placebo Comparator|Placebo group|Patients will be randomized to receive placebo
3095082|NCT01925235||Control|patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure
3095083|NCT01925235||RIPC|patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure plus ischemic preconditioning (intermittent arm ischemia through 4 cycles of 5-minute inflation and 5-minute deflation of a blood pressure cuff)
3095084|NCT01925222||PCV-vaccinated infant, 3+1 schedule|
3095085|NCT01925222||PCV-vaccinated infant, 2+1 schedule|
3095086|NCT01925222||Control-vaccinated infant|
3095087|NCT01925222||PCV-vaccinated child, catch-up schedule|
3095088|NCT01925222||Control-vaccinated child, catch-up schedule|
3095089|NCT01925209|Experimental|BYM338/bimagrumab 10 mg/kg|Participants received study medication with BYM338 at 10 mg/kg from Day 1 to Week 52 and up to Week 104, administered by intravenous (i.v.) infusion every 4 weeks.
3095090|NCT01925209|Experimental|BYM338/bimagrumab 3 mg/kg|Participants received study medication with BYM338 at 3 mg/kg from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
3095091|NCT01925209|Experimental|BYM338/bimagrumab 1 mg/kg|Participants received study medication with BYM338 at 1 mg/kg from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
3095092|NCT01925209|Placebo Comparator|Placebo|Participants received matching placebo to BYM338 from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
3095093|NCT01925183|Experimental|28 weeks of treatment duration|All patients will receive 4 weeks of PEGIFN/RBV lead-in. Patients with undetectable HCV-RNA at treatment week 8 will be treated with 24 weeks of BOC/PEGIFN/RBV triple-therapy resulting in a total treatment duration of 28 weeks.
3095094|NCT01925183|Experimental|48 weeks of treatment duration|All patients will receive 4 weeks of PEGIFN/RBV lead-in. Patients with detectable HCV-RNA at treatment week 8 will receive 44 weeks of BOC/PEGIFN/RBV triple-therapy and a total treatment duration of 48 weeks
3095095|NCT01925170|Experimental|Mammography and Molecular Breast Imaging|Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (8-mCi) Technetium (99mTc) sestamibi injection.
3095096|NCT01925157|Experimental|LY3090106 (Healthy)|Healthy participants will receive a single dose of LY3090106 in dose escalation cohorts subcutaneously (SQ).
3095097|NCT01925157|Placebo Comparator|Placebo (Healthy)|Healthy participants will receive a single dose of placebo matching LY3090106 SQ.
3095098|NCT01925157|Experimental|LY3090106 (RA)|Participants with RA will receive a single dose of LY3090106 in dose escalation cohorts SQ or intravenously (IV).
3095099|NCT01925157|Placebo Comparator|Placebo (RA)|Participants with RA will receive a single dose of placebo matching LY3090106 SQ.
3095100|NCT01925144|Experimental|Baricitinib|Baricitinib - 10 milligram (mg) tablet administered orally, once, on Day 1.
3095101|NCT01925144|Experimental|Baricitinib + Omeprazole|Baricitinib - 10 mg tablet administered orally, once, on Day 10. Omeprazole - 40 mg capsule administered orally once daily (QD) for 8 days (Days 3 through 10).
3095102|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin)|Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3095103|NCT01925118|Experimental|High-dose IL-2|
3095104|NCT01925105|Experimental|Optimization of treatment|Optimization of treatment of diseases and symptoms
3095105|NCT01925105|Placebo Comparator|Control|Treatment as usual
3095106|NCT01925092|Experimental|mifepristone|Daily doses of mifepristone over 84 days.
3095107|NCT01925079|Experimental|Intensive Educational Group|The Intensive Educational Group will receive 5 visits, including 2 visits via phone contacts. The expected dates for each visit will be stamped on the follow-up brochure for convenience. Patient education in this group includes routine education at discharge; 4 educational brochures, a calendar with health tips, and follow-up brochure with medical expert letter sent to patients at the day for discharge (baseline); and educational short messages through message platform once a week. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded.
3095108|NCT01925079|Sham Comparator|Control Group|The Control Group will receive 3 visits and receive care as per usual practice by the treating doctor and a follow-up brochure without medical expert letter. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded. Blood lipid panel (4 items), hepato-renal functions, and creatine kinase will be examined; while, Morisky 8-item questionnaire will be used to evaluate medication compliance at outpatient visits. In addition, the occurrence of major cardiovascular events and AE/SAE will be collected during the study.
3095109|NCT01925066|Experimental|Aerosolized Vancomycin|
3095110|NCT01925053|Placebo Comparator|Ref meal|"The reference meal (REF) is based on WHO dietary guidelines for protein, fat and carbohydrate. It comprises everyday modern ingredients such as white rice."
3095111|NCT01925053|Active Comparator|PAL meal|Palaeolithic meal (PAL) is based on WHO dietary guidelines for protein, fat and carbohydrate but only uses ingredients that would have been available in Palaeolithic times (e.g. no cereals or dairy).
3095112|NCT01925040|Experimental|Venus Pearl|Placement of restoration using Venus Pearl in carious teeth or as a replacement of a defective previous restoration.
3095113|NCT01925040|Active Comparator|control resin-based filling material|Placement of restoration using a control resin-based filling material in carious teeth or as a replacement of a defective previous restoration.
3095114|NCT01925027|Experimental|NANO+ DES|The Nano+ Polymer-free Sirolimus-Eluting Coronary Stent System is device/drug combination products consisting of a drug-coated stent and a balloon expandable delivery system. The stent is coated with a formulation containing rapamycin, the active ingredient, adhered to 316L stainless bare stent scaffold with submicron micropores, and is approved by State Food and Drug Administration of China in 2011(No. 3460037).
3095115|NCT01925014|Experimental|Low-dose CT|Diagnostic CT with low-dose radiation
3095116|NCT01925014|Active Comparator|Standard-dose CT|Diagnostic CT with standard-dose radiation
3095117|NCT01925001|Experimental|MP4CO|Escalating doses of MP4CO, administered intravenously
3095118|NCT01925001|Active Comparator|Sodium chloride solution|Normal saline (0.9% Sodium Chloride Injection USP)administered intravenously
3095119|NCT01924988|Experimental|Prostatic Embolization|
3095120|NCT01924975|Active Comparator|Landmark group|An operator is not allowed to use an ultrasound. A 22 or 24 G catheter will be advanced blindly toward the expected location of the saphenous vein at the level of the medial malleolus. Once blood appears in the hub, then the catheter will be advanced into the saphenous vein.
3095121|NCT01924975|Active Comparator|Ultrasound group|An operator will identify the saphenous vein by using ultrasound with a linear transducer (L15-7io) in short axis view. A 22 or 24 G catheter will be advanced until the tip of the needle is seen on the ultrasound image. The needle is then advanced until blood appears in the hub. The catheter is then advanced into the saphenous vein.
3095122|NCT01924962|No Intervention|medical therapy|patients are treated with medical therapy only, intervention (stent) of other than (chronic occluded) target-vessel is allowed.
3095123|NCT01924962|Active Comparator|revascularisation|revascularisation and stent-implantation of chronic occluded coronary artery
3095124|NCT01924949|Experimental|LDV/SOF|Participants will receive LDV/SOF FDC for 12 weeks.
3095125|NCT01924936|Placebo Comparator|Email|Caring email (based on the caring letters literature) sent via secure email messaging. Of the interventions, it is by far the most minimal in clinical intensity and human resources needs for delivery.
3095126|NCT01924936|Experimental|DBT program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
3095127|NCT01924936|Experimental|Email + DBT program & Coach|"Caring Email + DBT online program & Coach: in addition to the DBT online program, will include personalized outreach and support for use of the program. An intervention coach will deliver this support exclusively via secure email messaging. The intervention coach will not provide psychotherapy, but instead provide reinforcement and contingency management surrounding completion of the three lessons. This intervention will utilize significantly greater ongoing clinical resources for its maintenance and offer greater clinical intensity for patients."
3095128|NCT01924923||Uveal Melanoma|Scheduled for enucleation surgery
3095129|NCT01924910|Placebo Comparator|Placebo Pill|Received identical pills that do not contain vitamin D. Blood levels of 25(OH)D determined at 10 days, 3 months, and 1 year following placebo dose.
3095130|NCT01924910|Active Comparator|Vitamin D|250,000 IU cholecalciferol as single, oral dose. Blood levels 25(OH)D measured at 10 days, 3 months, and 1 year following dose.
3095131|NCT01924897|Experimental|Exercise Training Arm|"Patients randomised to exercise training will be offered three sessions of aerobic interval exercise per week over the subsequent 4 weeks prior to their procedure. Each session will comprise 6 x 5 min repetitions at 60-80% peak VO2, with 2.5 min rest intervals. The aim will be to quickly progress patients to exercise intensities that correspond to and exceed the individual AT. Heart rate, clinical signs, blood pressure and perceived exertion will be recorded regularly throughout exercise.~Repeat CPET testing will then take place 4 weeks from the baseline test in the exercise laboratory (on the day prior to surgery) to determine changes (if any) in AT, VO2, VE/VCO2."
3095132|NCT01924897|No Intervention|No Exercise Training Arm|The patients in the non-exercise arm of the study will not undergo any exercise intervention but will be CPET tested in the exercise laboratory at the same time points as the exercise arm patients.
3095133|NCT01924884||Prospective|Patients newly referred to the Principal Investigator for intra-abdominal surgery and for whom the Principal Investigator anticipates using Negative-Pressure Wound Therapy.
3095134|NCT01924884||Retrospective|Patients who underwent intra-abdominal surgery by the Principal Investigator between January 1, 2011 and May 9, 2013 will be identified through patient medical records. Living patients will be contacted via letter from the Principal Investigator introducing the study along with the study's consent form for the patients' review. Interested patients will be consented either in person at the patient's next clinic visit or via telephone by a member of the study staff.
3095135|NCT01924884||Historical Controls|Patients who underwent intra-abdominal surgery without Negative-Pressure Wound Therapy by the Principal Investigator prior to January 1, 2011 will be enrolled as Historical Controls.
3095136|NCT01924884||De-Identified Retrospective|Patients who underwent intra-abdominal surgery by the Principal Investigator between January 1, 2011 and May 9, 2013 and are deceased or do not consent to be in the study will be enrolled in the De-Identified Retrospective Case Cohort.
3095137|NCT01924871|Active Comparator|Desflurane group|1.5 MAC desflurane until extubation
3095138|NCT01924871|Active Comparator|Desflurane with remifentanil group|1.0 MAC desflurane with 1.0ng/ml targeted concentration infusion of remifentanil
3095139|NCT01924858|Experimental|GSK2647544 oral and [18F]GSK2647544 IV bolus|All subjects will receive a single oral dose of GSK2647544 100 milligram (mg) approximately 2 hours before administration of [18F] GSK2647544 and a dynamic PET scan. [18F]-GSK2647544 will be administered to the subject as an IV bolus during the PET scan, which will be conducted for up to 120 minute post the injection of [18F]GSK2647544
3095140|NCT01924845|Experimental|BMN 701 20 mg/kg|BMN 701 IV Infusion 20mg/kg every 2 weeks for 24 weeks followed by an optional extension of 240 weeks (total duration of therapy 264 weeks)
3095141|NCT01924832|Experimental|BG00012 Part 1|BG00012 120 mg delivered to varying locations of the GI tract
3117312|NCT01772745|Active Comparator|Group 2|TPCL cholecystectomy
3095142|NCT01924832|Experimental|BG00012 Part 2|BG00012 240 mg delivered to varying locations of the GI tract
3095143|NCT01924819|Experimental|Preoperative chemoradiotherapy|"2 cycles preoperative chemotherapy with epirubicin + cisplatin + 5-fluorouracil. 5-fluorouracil may be replaced with capecitabine.~5 weeks preoperative chemoradiotherapy.~Gastric resection.~3 cycles adjuvant chemotherapy with epirubicin + cisplatin + 5-fluorouracil. 5-fluorouracil may be replaced with capecitabine."
3095144|NCT01924819|Active Comparator|Preoperative chemotherapy|"3 cycles preoperative chemotherapy with epirubicin + cisplatin + 5-fluorouracil. 5-fluorouracil may be replaced with capecitabine.~Gastric resection.~3 cycles adjuvant chemotherapy with epirubicin + cisplatin + 5-fluorouracil. 5-fluorouracil may be replaced with capecitabine."
3095145|NCT01924806|Active Comparator|WoundWand™ Debridement Device|Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound
3095146|NCT01924806|Active Comparator|Standard of Care sharp debridement|Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound
3095147|NCT01924793|Experimental|Formulation of DAS181-F02 Dry Powder in Bulk|"The DAS181-F02 nebulized formulation includes 10mL of normal saline to prepare a liquid solution referred to as DAS181-F02 nebulized.~Dry Powder Inhaled Dose:~Non-ventilated subjects, capable of using a cyclohaler, will be treated by Dry Powder Inhalation. Each subject will receive a targeted daily dose of 10mg for 7 days for a total of 70mg of DAS181-F02. If a subject requires ventilation, the subject will be allowed to continue dosing following the Nebulized formulation instruction."
3095148|NCT01924793|Experimental|Nebulized Formulation Inhaled Dose|"Subjects unable to use the Dry Powder Inhaler (as determined by site Investigator) on continuous positive airway pressure (CPAP), Bi-level positive airway pressure (BIPAP) or requiring mechanical ventilation will be treated by Nebulized formulation. The subject will remain on the nebulized formulation for the duration of the study regardless of ventilation status. DAS-F02 10 mg will be utilized to prepare the nebulized solution per the Study Reference Manual.~Multiple methods (T piece, face mask, direct to ET tube) will be allowed for the nebulized dose administration. Detailed specification for nebulized dose administration will be defined in the Study Reference Manual."
3095149|NCT01924780|Active Comparator|NEMOS device stimulation 10 minutes|Subject will be stimulated in the cymba concha with a vibro-tactile mechanical device for 10 minutes
3095150|NCT01924780|Active Comparator|NEMOS device 60 minutes stimulation|Subjects will be stimulated in the cymba concha with a vibro-tactile mechanical device for 60 minutes
3095151|NCT01924780|Sham Comparator|Sham 10 minutes|10 minutes of t-VNS stimulation by rotating the NEMOS ear electrode 180 degrees within the pinna, which will position the electrode on the earlobe
3095152|NCT01924767|Experimental|BI 10773 (dose group 3)|multiple doses as tablet
3095153|NCT01924767|Experimental|BI 10773 (dose group 4)|multiple doses as tablet
3095154|NCT01924767|Experimental|BI 10773 (dose group 1)|multiple doses as tablet
3095155|NCT01924767|Experimental|BI 10773 (dose group 2)|multiple doses as tablet
3095156|NCT01924754||Group 1|HPV vaccination regime-standard 3-dose needle injection IM regimen
3095157|NCT01924754||Group II|HPV vaccination regime-3-dose needle-free (NFI) IM injection regimen
3095158|NCT01924754||Group III|HPV vaccination regime - 3-dose needle-free intradermal injection regimen
3095159|NCT01924741||ALPPS|ALPPS is the most recent modification of the techniques developed for Two-stage hepatectomies. ALPPS allows to remove an extensive part of the liver in two steps. In the first step the liver parenchyma is transected along the intended line of resection and the future liver remnant cleaned by partial resections from all tumor tissue in the case of bilobar tumors. To this a portal ligation of the larger liver lobe that will have to be removed is added. After a waiting period of 1-2 weeks the second step is performed in which the deportalized liver is removed to render the patient completely tumor-free. (Ann Surg 2012; 255(3):405-14.)
3095160|NCT01924728|Active Comparator|Magnetic stimulation|Active magnetic stimulation delivered to the pelvic floor muscles
3095161|NCT01924728|Sham Comparator|Sham magnetic stimulation|Sham magnetic stimulation delivered to the pelvic floor muscles
3095162|NCT01924715||ISTDP|Patients provided Intensive Short term Dynamic Psychotherapy
3095163|NCT01924715||Control Group|Patients referred for ISTDP but never seen for any reason
3095164|NCT01924702|Active Comparator|anodal tDCS|Intensive language therapy with anodal transcranial direct current stimulation
3095165|NCT01924702|Sham Comparator|sham tDCS|Intensive language therapy with Sham-tDCS
3095166|NCT01924689|Experimental|Clostridium novyi-NT spores|
3095167|NCT01924676|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3095168|NCT01924676|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3095169|NCT01924676|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3095170|NCT01924650|Experimental|PH-797804 PARTICLE SIZE 9-11UM|
3095171|NCT01924650|Experimental|PH-797804 PARTICLE SIZE 9-11UM WITH SLS|
3095172|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 20UM|
3095173|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 20UM WITH SLS|
3095174|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 5UM|
3095175|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 5UM WITH SLS|
3095176|NCT01924637|Experimental|FIASP|Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal.
3095177|NCT01924637|Active Comparator|NovoRapid®|Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal.
3095178|NCT01924624|Experimental|Thalidomide|Thalidomide 100mg per day after the radical resection HCC
3095179|NCT01924624|Active Comparator|Control|No adjuvant Thalidomide treatment after curative hepatic resection
3095180|NCT01924611|Active Comparator|Control Group|Atraumatic Restorative Technique using cotton rolls.
3095183|NCT01924585||Frail patient|Patients will be stratified into groups frail and non-frail based on pre-operative frailty and disability.
3095184|NCT01924572|No Intervention|Immediate cord clamping|provider clamps and cuts the cord within 10 seconds after birth
3095185|NCT01924572|Experimental|cord clamping at 2 minutes|Provider places infant on maternal abdomen and cuts cord at 2 minutes after birth
3095186|NCT01924572|Experimental|cord clamping at 5 minutes|Provider places the infant on maternal abdomen and clamps and cuts cord at 5 minutes
3095187|NCT01924572|Experimental|cord milking|provider milks the cord 5 times from placenta to infant
3095188|NCT01924559|Active Comparator|Direct Laryngoscopy & standard clothing|Residents will intubate manikin using DL while wearing standard clothing.
3095189|NCT01924559|Active Comparator|Direct Laryngoscopy & Biohazard Gear|Residents will intubate manikins using DL while in Biohazard gear.
3095190|NCT01924559|Experimental|Glidescope & standard clothing|Residents will intubate manikins using Glidescope while wearing standard clothing.
3095191|NCT01924559|Active Comparator|Glidescope & Biohazard Gear|Residents will intubate manikins using Glidescope while wearing Biohazard gear.
3095192|NCT01924559|Active Comparator|Supraglottic Airway & standard clothing|Residents will intubate manikins using Supraglottic Airway while wearing standard clothing.
3095193|NCT01924559|Active Comparator|Supraglottic Airway and Biohazard gear|Residents will intubate manikins using Supraglottic airway while wearing biohazard gear.
3095194|NCT01924546|Experimental|Supplementary water|This arm receives up to 3 L of supplemental water during the course of the testing day plus encouragement to drink water.
3095195|NCT01924546|No Intervention|Control|No additional water provided during the day. Additional water provided at the end of the school day.
3095196|NCT01924533|Experimental|Olaparib+ paclitaxel|olaparib + paclitaxel
3095197|NCT01924533|Placebo Comparator|Placebo+paclitaxel|placebo+ paclitaxel
3095198|NCT01924520|Experimental|Group 1 (FK949E lower dose)|Oral
3095199|NCT01924520|Experimental|Group 2 (FK949E middle dose)|Oral
3095200|NCT01924520|Experimental|Group 3 (FK949E higher dose)|Oral
3095201|NCT01924507|Experimental|CPAP|Patients with apnea will be treated with CPAP during the night.
3095202|NCT01924507|No Intervention|Control|One arm group will be control and will not receive CPAP treatment during the ICU admission.
3095203|NCT01924494||Endoscopy procedures|Patients undergoing elective flexible gastrointestinal endoscopy procedures
3095204|NCT01924481|Experimental|low theobromine & low caffeine|Drink 1
3095205|NCT01924481|Experimental|low theobromine & high caffeine|Drink 2
3095206|NCT01924481|Experimental|high theobromine & low caffeine|Drink 3
3095207|NCT01924481|Active Comparator|no theobromine & high caffeine|Drink 4
3095208|NCT01924455||HBV-HIV coinfected subjects|HBV-HIV coinfected subjects seen at one of 7 participating centers.
3095209|NCT01924442||On-Pump|Cardiac bypass using Heart Lung Machine
3095210|NCT01924442||Off-Pump|Cardiac bypass surgery on beating heart
3095211|NCT01924429|Experimental|On Drug then off Drug|Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
3095212|NCT01924429|Experimental|Off drug then on drug|Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
3095213|NCT01924416|Experimental|Enhanced Care|Enhanced Care: Decision aid; QL-PRO immediate summary results; chemotherapy cycles and imaging studies as needed
3095214|NCT01924416|Active Comparator|Usual Care|Usual Care: Routine chemotherapy cycles and imaging studies
3095215|NCT01924403|Experimental|Staple Closure|Staple closure will be one technique employed to close the wound in primary total knee arthroplasty.
3095216|NCT01924403|Experimental|Running Subcuticular Closure|Running subcuticular closure will be one technique employed to close the wound in primary total knee arthroplasty.
3095217|NCT01924403|Experimental|Vertical Mattress Closure|Vertical mattress closure will be one technique employed to close the wound in primary total knee arthroplasty.
3095218|NCT01924390|Active Comparator|mineralized FDBA alone|Socket grafting with mineralized freeze-dried bone allograft alone
3095219|NCT01924390|Experimental|Combination of mineralized and deminieralized FDBA|Socket grafting with a combination of mineralized and demineralized freeze-dried bone allograft alone
3095220|NCT01924377|Other|standard circumferential pulmonary vein isolation (CPVI)|standard circumferential pulmonary vein isolation by radiofrequenvy ablation
3095221|NCT01924377|Experimental|CPVI + Rotor|standard circumferential pulmonary vein isolation + rotors' identification and ablation'
3095222|NCT01924364|Experimental|Fat grafting with TGI|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (TGI-CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
3095223|NCT01924364|Sham Comparator|Fat grafting without TGI - Standard of care|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be NOT processed by the Tissue Genesis Cell Isolation System™ (TGI-CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
3095224|NCT01924351|Other|HER2-positive Breast Cancer with Brain Metastasis|Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis
3095225|NCT01924338|Experimental|Skin types I and II|"Volunteers classified as skin types I and II according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
3095226|NCT01924338|Experimental|Skin type III|"Volunteers classified as skin type III according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
3095227|NCT01924338|Experimental|Skin type IV|"Volunteers classified as skin type IV according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
3095300|NCT01923857|Experimental|Healthy Volunteers|Healthy males age 18-80 with a body mass index(BMI) 25-42 mg/m^2.
3095228|NCT01924338|Experimental|Skin types V and VI|"Volunteers classified as skin types V and VI according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
3095229|NCT01924325|Active Comparator|Dual-antiplatelet Therapy|Receiving a 75 mg dose of clopidogrel and 75mg dose of aspirin from day 1 to day 21, with placebo apixaban twice daily
3095230|NCT01924325|Experimental|Apixaban 2.5mg|Receiving a 2.5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from day 1 to day 21
3095231|NCT01924325|Experimental|Apixaban 5mg|Receiving a 5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from day 1 to day 21
3095232|NCT01924312|Placebo Comparator|No Intervention|A placebo cohort of 40 subjects with MCI related to vascular risk factors (MCI-CVD) will be followed longitudinally with cognitive, imaging, blood and optional spinal fluid biomarkers providing insight into the natural disease course of MCI-CVD. This natural history group will serve as the control group for the treatment arm described below.
3095233|NCT01924312|Experimental|Treatment Group|A cohort of 40 subjects with MCI-CVD will be treated with a nursing-based educational program (Heart Health Intervention) including aggressive symptom monitoring and treatment of vascular risks in a 6 visit intervention block over 12 weeks after baseline and thereafter for every 6 months for the study duration of 3 years. These subjects will be followed identically to the subjects in the natural history arm described in the control group above with cognitive testing, imaging, blood, and optional spinal fluid testing.
3095234|NCT01924299|Experimental|Baricitinib + Ketoconazole|"Baricitinib - 10 milligrams (mg) administered orally once on Day 1 of Period 1 and on Day 6 of Period 2.~Ketoconazole - 400 mg administered orally once daily (QD) for 6 days (Day 3 through Day 8) in Period 2."
3095235|NCT01924299|Experimental|Baricitinib + Fluconazole|"Baricitinib - 10 mg administered orally once on Day 1 of Period 1 and on Day 7 of Period 2.~Fluconazole - 400 mg administered orally once on Day 3 of Period 2, followed by 200 mg administered orally QD for 6 days (Day 4 through Day 9) in Period 2."
3095236|NCT01924286|Experimental|Prednisone|Prednisone oral tablets 40mg daily for 2 weeks followed by 20mg daily for 2 weeks
3095237|NCT01924286|Placebo Comparator|Placebo|Placebo oral tablets 40mg daily for 2 weeks followed by 20mg daily for 2 weeks
3095238|NCT01924273|Other|Port Wine Stain Birthmarks|Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
3095239|NCT01924260|Experimental|Treatment (alisertib, gemcitabine)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3095240|NCT01924247|Other|Interventional Arm|Interventional Arm
3095241|NCT01924247|Other|Control Arm|Control Arm: Standard treatment by family physician
3095242|NCT01924234|Active Comparator|morphine|Volunteers are given morphine injection
3095243|NCT01924234|Active Comparator|remifentanil|Volunteers are given remifentanil infusion
3095244|NCT01924221||CRT|Patients with implanted cardiac resynchronization therapy defibrillator
3095245|NCT01924208|Active Comparator|Timothy|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
3095246|NCT01924208|Active Comparator|Live attenuated influenza virus|Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).
3095247|NCT01924208|Active Comparator|Timothy + attenuated influenza virus|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
3095248|NCT01924208|No Intervention|No intervention|No intervention (n=60, 50:50 atopic:non-atopic).
3095249|NCT01924195|Active Comparator|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3095250|NCT01924195|Placebo Comparator|Placebo Capsule|Placebo capsule QD po and it should be continued until disease progression or patients withdrawal of consent
3095251|NCT01924182|Other|IT group (Intrathecal Morphine Sulfate)|SynchroMed Infusion System and Intrathecal Morphine Sulfate
3095252|NCT01924182|Other|Conventional Medical Management|Conventional Medicine, and then SynchroMed Infusion System and Intrathecal Morphine Sulfate
3095253|NCT01924169|Experimental|Lenalidomide|Lenalidomide administered at the dose of 5 mg/day on Monday, Wednesday and Friday for 3 months. If Immunoglobulin G (IgG) levels improve by at least 25% of baseline, lenalidomide administration continued for 3 months on, and 3 months off for 2 years. If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years. Seasonal influenza vaccination (Trivalent Influenza Vaccine, Fluzone High Dose) administered yearly, during the fall/winter season and pneumococcal immunization (Pneumococcal Polysaccharide Vaccine, Pneumovax) administered once between month 6 and month 21.
3095254|NCT01924156|Experimental|adenovirus-transfected DC + CIK|adenovirus-transfected autologous DC vaccine plus CIK cells
3095255|NCT01924143|Experimental|TD-9855|
3095256|NCT01924130|Experimental|One Healthy Breakfast Program|Classroom feeding, nutrition education lessons, social marketing, and parent outreach.
3095257|NCT01924130|No Intervention|Control|Only receive assessments.
3095258|NCT01924117|No Intervention|Linear Array HPV Genotyping assay|Women submitted to colposcopy with a suspicion of squamous intraepithelial lesion were programmed a clinical follow up to cervical swab in order to extract DNA and perform a Linear Array HPV Genotyping assay (Roche®, Mannheim, Germany).
3095259|NCT01924104|Active Comparator|Low Molecular Weight Heparin|Low molecular weight heparin, 2500 milli-International unit/day, subcutaneously
3095260|NCT01924104|Active Comparator|Low dose aspirin|Low dose aspirin, 75mg/day, orally
3095261|NCT01924104|Active Comparator|Heparin & Aspirin|Heparin (40 mg/day, subcutaneously) and aspirin (70 mg/day, orally)
3095262|NCT01924104|Placebo Comparator|Sodium chloride (NaCl)|Equivalent volume of NaCl 0.9%, subcutaneously
3095301|NCT01923857|Experimental|Mild Renal Impairment|Males with mild renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m^2 (creatinine clearance 50-80 mL/min).
3095356|NCT01923493|Active Comparator|no intervention waiting list|Patients in the no intervention waiting list group will not receive a study intervention.
3095263|NCT01924091|Experimental|Dapivirine Gel|"As outlined above, multiple gel formulations of dapivirine have been developed for vaginal use.~Three formulations, Dapivirine Gel-001 (Gel-001), Dapivirine Gel-002 (Gel-002), and Dapivirine Gel 4750 (Gel 4750) are no longer in development. Dapivirine Gel 4789, which has been tested in one clinical trial (IPM012), and Dapivirine Gel 4759 were recently evaluated in clinical trials, IPM 014A and IPM 020. This trial will use Dapivirine Gel 4759."
3095264|NCT01924091|Experimental|Dapivirine Film|Dapivirine film is formulated in a polyvinyl alcohol (PVA) based vaginal film containing hydroxypropyl methyl cellulose (HPMC) E5 (5 cp), polyethylene glycol 8000 (PEG), propylene glycol, and glycerin. PVA constituted 55.1% (w/w) of the film. The target loading dose for the film is 1.25 mg dapivirine per film based on phase I studies using dapivirine gels at concentrations of 0.01%, 0.02% and 0.05%30-33. The quantity of gel administered in these studies was 2.5 mL. Consequently the administered dose corresponds to 0.25, 0.5 and 1.25 mg dapivirine, respectively.
3095265|NCT01924078|Experimental|Metronomic Capecitabine and AI|Postmenopausal Hormone receptor positive breast cancer patients who wanted to conserve breast were enrolled to receive capecitabine 500mg/tid p.o plus one of the aromatase inhibitors (AIs):Anastrozole 1mg/day p.o, and who had first line or second line Letrozole therapy failure were switched to capecitabine 500mg/tid p.o plus Exemestane 25mg/day p.o；or Exemestane therapy failure were switched to capecitabine 500mg/tid p.o plus Letrozole 2.5mg/day p.o.
3095266|NCT01924065|Active Comparator|Transesophageal Echocardiography group|This arm includes the patients with atrial fibrillation who undergo transesophageal echocardiography-guided cardioversion
3095267|NCT01924065|Active Comparator|Oral anticoagulant Group|This arm includes the patients with atrial fibrillation who take warfarin or new oral anticoagulant agents three weeks before electrical cardioversion.
3095268|NCT01924052|Active Comparator|Migraine patients with high genetic load|CGRP intravenous infusion 1.5 microgram/min for 20 min
3095269|NCT01924052|Active Comparator|Migraine patients with low genetic load|CGRP intravenous infusion 1.5 microgram/min for 20 min
3095270|NCT01924039|Experimental|Brief Motivational Enhancement Therapy|
3095271|NCT01924039|Other|treatment as usual|
3095272|NCT01924026||Affected MHP|With Phe between 360 and 600 micromoles/L
3095273|NCT01924026||Unaffected Siblings|With normal Phe levels
3095274|NCT01924013|Placebo Comparator|Group A|"Prenatal Period 0 IU; Postpartum Period 0 IU (placebo)~Overall:The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery. The Postpartum Period will last from delivery until 6 months postpartum."
3095275|NCT01924013|Experimental|Group B|Prenatal Period 4,200 IU/week of vitamin D3 (=600 IU/d); Postpartum Period 0 IU/week (placebo)
3095276|NCT01924013|Experimental|Group C|Prenatal Period 16,800 IU/week of vitamin D3 (=2,400 IU/d); Postpartum Period 0 IU/week (placebo)
3095277|NCT01924013|Experimental|Group D|Prenatal Period 28,000 IU/week of vitamin D3 (=4,000 IU/d); Postpartum Period 0 IU/week (placebo)
3095278|NCT01924013|Experimental|Group E|Prenatal Period 28,000 IU/week of vitamin D3 (=4,000 IU/d); Postpartum Period 28,000 IU/week(=4,000 IU/d)
3095279|NCT01924000|Experimental|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
3095280|NCT01924000|Placebo Comparator|Placebo|Placebo is applied twice daily to the other eyebrow.
3095281|NCT01923987|Experimental|SCRT/ChemoTx with Delayed Surgery|Short course radiotherapy (25 Gy in 5 fractions) followed by intensive chemotherapy, compromising of FOLFOX of FOLFIRI (+-Bevacizumab or Cetuximab), with delayed surgery for rectal cancer with synchronous distant metastasis
3095282|NCT01923974|Placebo Comparator|Placebo|IV formulation
3095283|NCT01923974|Active Comparator|Melatonin 10 mg|IV formulation, Melatonin 10 mg
3095284|NCT01923974|Active Comparator|Melatonin 100 mg|IV formulation, Melatonin 100 mg
3095285|NCT01923961|Experimental|Hemodiafiltration, NaCl infusion|5 M NaCl solution will be infused to increase the NaCl concentration in the infusion fluid during predilution hemodiafiltration.
3095286|NCT01923961|No Intervention|Hemodialysis|
3095287|NCT01923961|No Intervention|Hemodiafiltration|
3095288|NCT01923948|Active Comparator|Pregabalin|Single, 150 mg pre-operative oral dose of Pregabalin
3095289|NCT01923948|Placebo Comparator|Sugar Pill|Single, placebo pre-operative dose
3095290|NCT01923935|Experimental|BUSULFEX®, Alkeran®|"BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6~day-4)~Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3~day-2)"
3095291|NCT01923922|Other|CT Perfusion|Participants with suspected Glioblastoma Multiforme undergo CT perfusion prior to surgery or biopsy.
3095292|NCT01923909|Active Comparator|Intra-articular corticosteroid|Intra-articular corticosteroid injections Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the suprapatellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
3095293|NCT01923909|Experimental|Intra-articular platelet-rich plasma|IA PRP procedure This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the suprapatellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
3095294|NCT01923896|Experimental|Behavioral Intervention & DCS|Behavioral Feeding Intervention (15 total treatment sessions over 5 days) and D-cycloserine (0.7mg/kg DCS) to be taken acutely one hour prior to the onset of the first treatment session each day
3095295|NCT01923896|Active Comparator|Behavioral Intervention & Placebo|Behavioral Feeding Intervention (15 total treatment sessions over 5 days) and placebo (lactose powder) by method of intake (bottle; formula; tube)
3095296|NCT01923883|Active Comparator|Negative-pressure syringe|EUS-FNA with negative-pressure suction with syringe
3095297|NCT01923883|Experimental|Capillary sampling with slow-pull|EUS-FNA with capillary sampling with stylet slow-pull technique
3095298|NCT01923870|Experimental|Moderate Hepatic Impairment|Males age 18-70 with a BMI between 25-42 kg/m^2 with moderate hepatic impairment (Child-Pugh Class B)
3095299|NCT01923870|Experimental|Healthy Volunteers|Males age 18-70 with a BMI between 25-42 kg/m^2
3095302|NCT01923857|Experimental|Moderate Renal Impairment|Males with moderate renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m^2 (creatinine clearance 30-50 mL/min).
3095303|NCT01923857|Experimental|Severe renal impairment|
3095304|NCT01923844|Experimental|poractantalfa|preterm infants who received poractantalfa for respiratory distress syndrome
3095305|NCT01923844|Experimental|beractant|preterm infants who received beractant for respiratory distress syndrome
3095306|NCT01923844|No Intervention|Control|Preterm infants without respiratory distress syndrome
3095307|NCT01923831|Experimental|Magnesium group|
3095308|NCT01923831|Active Comparator|Dexamethasone group|
3095309|NCT01923818|Active Comparator|aspirin|Receiving a 100-mg dose of aspirin and placebo rivaroxaban from day 1 to day 30
3095310|NCT01923818|Experimental|Rivaroxaban 5mg|Receiving a 5-mg dose of rivaroxaban and placebo aspirin from day 1 to day 30
3095311|NCT01923818|Experimental|rivaroxaban 10mg|Receiving a 10-mg dose of rivaroxaban and placebo aspirin from day 1 to day 30
3095312|NCT01923805|Experimental|Treatment Group|Vitagel
3095313|NCT01923805|No Intervention|Control|Standard of care for surgical hemostasis.
3095314|NCT01923792||Placebo|Subjects previously randomised to receive placebo in study TH002
3095315|NCT01923792||ToleroMune HMD Group 1|Subjects previously randomised to receive ToleroMune HDM in study TH002
3095316|NCT01923792||ToleroMune HDM Group 2|Subjects previously randomised to receive ToleroMune HDM in study TH002
3095317|NCT01923779||TG002 Subjects|Subjects previously randomised in study TG002
3095318|NCT01923766|Experimental|Cytotoxic T lymphocytes (CTLs)|Cytotoxic T lymphocytes (CTLs). CMV/AdV /EBV specific T cells will be given by slow intravenous injection over 1-2 minutes. Four dose levels will be explored. The lowest dose level will be 5x106cells/m2 and the highest will be 2.5x107/m2. During the dose escalation phase two to six patients will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval.
3095319|NCT01923753|Experimental|Aerosure 15 Hz|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure. Order of presentation is randomised."
3095320|NCT01923753|Active Comparator|Aerosure 25 Hz|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure."
3095321|NCT01923753|Sham Comparator|Aerosure sham|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure."
3095322|NCT01923740|Experimental|Absorb BVS System|Absorb BVS System: Subjects receiving Absorb BVS System
3095323|NCT01923740|Active Comparator|XIENCE V EECSS|XIENCE V EECSS: Subjects receiving XIENCE V
3095324|NCT01923727|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 5 mCi of [89Zr]Df-IAB2M in mass doses of either 10 mg, 20 mg or 50 mg (optional).
3095325|NCT01923714||Glaucoma|Patients with open-angle glaucoma (OAG) that require topical intraocular pressure lowering therapy and that were scheduled to switch current therapy to preservative-free DTFC.
3095326|NCT01923701|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy group receives group, individual, and family Cognitive Behavioral Therapy in addition to standard care.
3095327|NCT01923701|No Intervention|Monitoring|This group receives standard care only.
3095328|NCT01923688|Experimental|Informatics Real-Time Alert|Alert/Nurse and Physician Intervention
3095329|NCT01923688|No Intervention|control-no intervention|
3095330|NCT01923675|Experimental|Group 1 block red light|Spectacles with red-blocking tint.
3095331|NCT01923675|Experimental|Group 2 blur image|Spectacles with holographic diffuser and color neutral tint
3095332|NCT01923675|Experimental|Group 3 blur image and block red light|Spectacles with holographic diffuser and red-blocking tint.
3095333|NCT01923675|Other|Group 4 neutral tint|Spectacles with color neutral tint
3095334|NCT01923662|Experimental|Neuroprosthesis|Eligible subjects will receive an implanted device (IRS-8 or IST-16) and surgically implanted electrodes to excite muscles that move paralyzed muscles. These electrodes are connected to the implanted stimulator that delivers electrical pulses to the nerves. These pulses cause the muscles to contract to perform functional movements or to exercise.
3095335|NCT01923649|Experimental|Lanreotide slow release 90 mg|Patients receive lanreatide slow release (Somatuline autogel) 90 mg every four weeks via a deep subcutaneous injection, three times. After a wash out period of 4 weeks they receive a similar placebo every for weeks, three times.
3095336|NCT01923649|Placebo Comparator|Placebo|Patients receive a deep subcutanous injection of placebo every four weeks, three times. After a wash out of three weeks, they will receive somatuline 90 mh via a deep subcutanous injection every four weeks, three times.
3095337|NCT01923636|Other|detection of CMV|Cohort of neonates less than 1 month with congenital CMV infection at birth objectified by the detection of CMV in a urine sample, in saliva or blood (fresh or Guthrie card) obtained in the first 10 days life
3095338|NCT01923623|Experimental|Block|Popliteal and saphenous Block with Ropivacaine
3095339|NCT01923623|Placebo Comparator|NaCl|
3095340|NCT01923610|Experimental|Main|MVA HIV-B
3095341|NCT01923597|Active Comparator|Green tea extract|Patients will receive four capsules ( one capsula = 200mg of epigallocatechin gallate) of green tea extract per day for 3 months.
3095342|NCT01923597|Placebo Comparator|Placebo (celulose)|Patients will receive four capsules of placebo (celulose) daily for 3 months.
3095343|NCT01923584|Active Comparator|EPI-743 400mg|EPI-743 at a dose of 400 mg three times daily
3095344|NCT01923584|Active Comparator|EPI-743 200mg|EPI-743 at a dose of 200 mg three times daily
3095345|NCT01923571||Normoglycemia|patients with intraoperative BGC in the 80-180 mg/dl range
3095346|NCT01923571||Hyperglycemia|patients with intraoperative BGC exceeding 180 mg/dl
3095347|NCT01923558|Experimental|Donepezil Hydrochloride Tablets, 23 mg|Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd
3095348|NCT01923558|Active Comparator|Aricept|Aricept® 23 mg tablet of Eisai Inc
3095349|NCT01923545|Experimental|DA-3031 3.6mg|PEG-G-CSF
3095358|NCT01923480|Experimental|15% CLINISOL 0.04 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.04 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
3095359|NCT01923480|Experimental|15% CLINISOL 0.08 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.08 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
3095360|NCT01923480|Experimental|15% CLINISOL 0.13 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.13 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
3095361|NCT01923467|Experimental|Project Quit plus NRT patches|All participants in the program will be offered the opportunity to complete the Project Quit stop smoking program. Project Quit is an individually-tailored, web-based program which has been scientifically proven to help people succeed at their quit attempts. All eligible participants will also receive a 2-week supply of Nicotine patches 21 mg.
3095362|NCT01923454|Experimental|Paracentesis|"Immediate anterior chamber paracentesis (ACP) with a 30-gauge needle as an initial treatment for acute primary angle closure.~Acetamide, given in this study, is a standard treatment for acute angle-closure glaucoma. The participant will receive 1 tablet(250mg) at 1 hours after paracentesis. The following dose will be adjusted according to the level of IOP. The maximal dose is 4 tablets per day. It will be discontinued if the IOP is less than 21 mmHg.~All affected eyes will receive laser peripheral iridotomy with 24 hours after presentation. This a standard treatment for Acute angle-closure glaucoma"
3095363|NCT01923441||Highschool athletes|
3095364|NCT01923441||midschool athletes|
3095365|NCT01923428|Experimental|5 mg BID|AZD1722
3095366|NCT01923428|Experimental|20 mg BID|AZD1722
3095367|NCT01923428|Experimental|50 mg BID|AZD1722
3095368|NCT01923428|Placebo Comparator|Placebo|
3095369|NCT01923415||Group 1: SLE|>=10 participants with systemic lupus erythematosus (SLE)
3095370|NCT01923415||Group 2: DLE|>=10 participants with discoid lupus erythematosus (DLE)
3095371|NCT01923415||Group 3: SCLE|>=10 participants with subacute cutaneous lupus erythematosus (SCLE)
3095372|NCT01923402||Exclusive cigarette smokers|
3095373|NCT01923402||Exclusive moist snuff consumers|
3095374|NCT01923402||Non-tobacco consumers|
3095375|NCT01923389|Placebo Comparator|Placebo|
3095376|NCT01923389|Experimental|100 mg PF-05231023|
3095377|NCT01923376|Other|Lactulose|per standard of care
3095378|NCT01923376|Active Comparator|polyethylene glycol 3350 (Golytely)|
3095379|NCT01923363|Experimental|Piperacillin/Tazobactam Standard Dose|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Then, they will be switched to higher dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
3095380|NCT01923363|Experimental|Piperacillin/Tazobactam High Dose|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Then, they will be switched to higher dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
3095381|NCT01923350|Experimental|Weight Reduction Intervention|
3095382|NCT01923350|Active Comparator|Weight Reduction Control Arm|
3095383|NCT01923350|Active Comparator|Tested for diabetes|
3095384|NCT01923350|Active Comparator|Not tested for diabetes|
3095385|NCT01923337|Experimental|Treatment (irinotecan, alisertib)|Patients receive irinotecan hydrochloride IV over 30 minutes on days 1 and 8 and alisertib PO BID on days 1-3 and 8-10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3095386|NCT01923324|Experimental|Physician telephone consultation|Received direct telephone consultation with pain physician about index patient
3095387|NCT01923324|Active Comparator|Usual family physician care|Usual family physician care (without direct telephone consultation with pain physician)
3095388|NCT01923311|Experimental|Cohort 1 (12 to < 18 years of age)|"Part A: No participants will be enrolled in Part A, as PK data is currently available for this age group.~Part B: Participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
3095389|NCT01923311|Experimental|Cohort 2 (6 to < 12 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days. Participants with HIV-1 RNA > 1,000 copies/mL will receive EVG along with a newly constructed background regimen that includes a Pl/r for 48 weeks. Participants with HIV-1 RNA > 1,000 copies/mL can continue after Week 48.~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. Participants who complete the 48-week follow-up in both Part A and Part B will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
3095390|NCT01923311|Experimental|Cohort 3 (2 to < 6 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days.~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
3095391|NCT01923311|Experimental|Cohort 4 (4 weeks to < 2 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days.~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
3095392|NCT01923298|Experimental|Estradiol|ESTRING® (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days.
3095393|NCT01923285|Experimental|AXIUM Neurostimulator System|The AXIUM Neurostimulator System is an investigational spinal cord stimulation device that is designed to stimulate the dorsal root ganglion (DRG) of the spine located on the back surface of the spinal cord where nerves exit the backbone. The device has 2 parts that are placed surgically (implanted) : 1) a pulse generator which is placed under the skin in the buttocks or abdomen, and 2) up to four wires (leads) that have one end attached to the pulse generator, and the other end secured to the tissue near the target treatment area.
3095394|NCT01923285|Active Comparator|Control Spinal Cord Stimulation Device|The Control Spinal Cord Stimulation Device is a commercially available spinal cord stimulator indicated for the treatment of chronic lower limb pain.
3095395|NCT01923272|Sham Comparator|Sham Device|inactive AlphaCore device
3095396|NCT01923272|Active Comparator|AlphaCore|Active AlphaCore device
3095397|NCT01923259|Experimental|Donepezil Hydrochloride Tablets, 23 mg|Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd
3095398|NCT01923259|Active Comparator|Aricept|Aricept® 23 mg tablet of Eisai Inc
3095399|NCT01923246|Experimental|Single WEB intervention|Web intervention recieved once.
3095400|NCT01923246|Experimental|Repeated WEB intervention|Web intervention recieved twice.
3095401|NCT01923246|Experimental|Single IVR intervention|IVR intervention recieved once
3095402|NCT01923246|Experimental|Repeated IVR intervention|IVR intervention recieved twice
3095403|NCT01923246|No Intervention|Control group|Untreated Control Group.
3095404|NCT01923233|Experimental|Treatment|Intradermal AlloStim(TM) (1ml) on day 0 and 3 in same location Intradermal AlloStim(TM) (1ml) on day 7 and day 10 in same location Radiofrequency ablation on day 14 followed by intralesional AlloStim (3ml) Intralesional AlloStim(TM)(3ml) on day 17 in same ablated lesion Intravenous AlloStim(TM)(5ml) on days 21, 49 and 78
3095405|NCT01923220|Experimental|HO/02/02|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
3095406|NCT01923220|Sham Comparator|Aloe Vera Jel|To be applied topically
3095407|NCT01923207|Experimental|DX-2930|DX-2930 administered by subcutaneous route
3095408|NCT01923207|Placebo Comparator|placebo|inactive formulation of DX-2930
3095409|NCT01923194|Experimental|Test Group|
3095410|NCT01923194|Active Comparator|Comparator Group|
3095411|NCT01923181|Experimental|1:Semaglutide tablets : 2.5 mg|2.5 mg for 26 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
3095412|NCT01923181|Experimental|2:Semaglutide tablets: 2.5 mg/5 mg|2.5 mg for 4 weeks, then 5.0 mg for 22 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
3095413|NCT01923181|Experimental|3:Semaglutide tablets: 5.0 mg/10 mg|5.0 mg for 4 weeks, then 10 mg for 22 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
3095414|NCT01923181|Experimental|4:Semaglutide tablets:5.0 mg/10 mg/20 mg|5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 18 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
3095415|NCT01923181|Experimental|5:Semaglutide tablets:5.0 mg/10 mg/20 mg/40 mg|"5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 4 weeks, then 40 mg for 14 weeks.~All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone."
3095416|NCT01923181|Experimental|6:Semaglutide tablets:5.0 mg/10 mg/20 mg/40 mg|5.0 mg for 8 weeks, then 10 mg for 8 weeks, then 20 mg for 8 weeks, then 40 mg for 2 weeks All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
3095417|NCT01923181|Experimental|7:Semaglutide tablets: 5.0 mg/10 mg/20 mg/40 mg|"5.0 mg for 2 weeks, then 10 mg for 2 weeks, then 20 mg for 2 weeks, then 40 mg for 20 weeks.~All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone."
3095418|NCT01923181|Placebo Comparator|8:Placebo tablets|All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
3095419|NCT01923181|Active Comparator|9:Semaglutide injections :0.25 mg/0.50 mg/1.0 mg|0.25 mg for 4 weeks, then 0.50 mg for 4 weeks, then 1.0 mg for 18 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
3095420|NCT01923168|Experimental|BYL719 + Letrozole|BYL719 + Letrozole in 120 patients
3095421|NCT01923168|Experimental|Buparlisib + Letrozole|Buparlisib + Letrozole in 120 patients
3095422|NCT01923168|Placebo Comparator|Placebo + Letrozole|Placebo (of Buparlisib or BYL719 ) with Letrozole in 120 patients
3117387|NCT01772264|Experimental|Arm A - active treatment|
3095423|NCT01923155|Active Comparator|Nurse endoscopists|Colonoscopy performed by nurse endoscopists supervised by senior medical endoscopists
3095424|NCT01923155|Active Comparator|Medical endoscopists|Colonoscopy performed by senior medical endoscopists
3095425|NCT01923142|Experimental|Outer-Root-Sheath Melanocytes Suspension|This arm includes all patients sides (left or right) treated with autologous outer-root-sheath melanocytes suspension followed by targeted UVB phototherapy
3095426|NCT01923142|Placebo Comparator|Placebo|This arm includes all patients sides (left or right) treated with placebo followed by targeted UVB phototherapy
3095427|NCT01923129|Experimental|24 hour postop catheter removal|group will receive the study medication prazosin ( 1 mg PO) 6 hours prior to catheter discontinuation (24 hours postoperatively)
3095428|NCT01923129|No Intervention|72 hour postoperative catheter removal|catheter removed on postoperative day 3 (72 hours postoperatively)
3095429|NCT01923116|Experimental|HPV-16 vaccine|
3095430|NCT01923090|Experimental|Finasteride|Finasteride treatment 5mg for 3 weeks
3095431|NCT01923090|Experimental|Dutasteride|Dutasteride treatment 0.5mg for 3 weeks
3095432|NCT01923077|Placebo Comparator|Conventional|Conventional treatment with simvastatin
3095433|NCT01923077|Active Comparator|Rosuvastatin|loading dose of rosuvastatin 80 mg at randomization followed by 40 mg daily in 12 month.
3095434|NCT01923064|Active Comparator|NBCA-lipiodol|Patients will receive injection of a mixture of cyanoacrylate and lipiodol to treat gastric varices
3095435|NCT01923064|Experimental|NBCA-lauromacrogol|Patients will receive injection of the mixture of cyanoacrylate and lauromacrogol to treat gastric varices
3095436|NCT01923038|Active Comparator|Patients ventilated with zero end expiratory pressure (ZEEP)|patients undergoing gynecologic laparoscopic surgery ventilated at zero end expiratory pressure
3095437|NCT01923038|Active Comparator|Patients ventilated with positive end expiratory pressure|patients undergoing gynecologic laparoscopic surgery ventilated at PEEP
3095438|NCT01923038|Active Comparator|recruitment plus PEEP|patients undergoing gynecologic laparoscopic surgery undergoing recruitment plus PEEP
3095439|NCT01923025|Experimental|RO5545965|
3095440|NCT01923012|Experimental|Vitamin K2|
3095441|NCT01922999|Active Comparator|Placebo controlled|comparison of placebo controlled to 1mg melatonin or 3mg melatonin
3095442|NCT01922999|Active Comparator|Melatonin|comparison of melatonin 1mg or melatonin 3mg
3095443|NCT01922986|Experimental|Active rTMS with conventional therapy|20 minutes of active rTMS followed by conventional stroke therapy
3095444|NCT01922986|Sham Comparator|sham rTMS with conventional therapy|20 minutes of sham rTMS stimulation followed by conventional stroke therapy
3095445|NCT01922973||normal men and women|normal volunteers: young and older men and women studied under fed and fasting (62.5h) conditions with frequent blood sampling for ghrelin and related hormones
3095446|NCT01922960|Other|micro-imaging|"Sublingual or subconjunctival micro-imaging of the microcirculation taken for 3 minute intervals at certain timepoints.~Timepoints for burn/trauma subjects: Day0, Day1,Day2,Day6 & Day7 Timepoints for general surgery population: post-induction, prior to resection, after resection,& closing of surgical wound."
3095447|NCT01922947|Active Comparator|Motivational Interviewing w/Social Network Counseling|Motivational Interviewing integrated with Social Network Counseling, 20-minute session.
3095448|NCT01922947|Sham Comparator|Health Counseling|
3095449|NCT01922934|Experimental|Intervention|"350 randomly-selected patients at 4 clinics get a toolbox of weight loss options, including self-monitoring tools; education materials; recreation center passes; commercial weight loss program (Weight Watchers); intensive group counseling (Colorado Weigh); meal replacements; and obesity pharmacotherapy. The initial assessment, a computer program, takes diet and exercise history and helps patients choose personal treatment goals. Interested patients get a starter kit with self-monitoring tools and meal replacements. Subjects must show self-monitoring of diet and exercise to get more intensive therapies. Patients pay a $5-$10 co-pay for the therapies. They select a primary intensive therapy, but are able to add/change depending on results, adherence and budget availability."
3095450|NCT01922934|No Intervention|Control|Registry patients not selected to be offered the toolbox will receive usual care for weight management. Usual care for obesity at DH includes brief weight loss advice provided by PCPs or prescribing of weight loss medication, for which patients pay out of pocket.
3095451|NCT01922921|Active Comparator|Arm I (placebo)|Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.
3095452|NCT01922921|Experimental|Arm II (polysaccharide-K)|Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.
3095453|NCT01922908|Active Comparator|MSC infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
3095454|NCT01922908|Placebo Comparator|SHAM infusion|Infusion of normal saline placebo
3095455|NCT01922895|Placebo Comparator|Placebo for Probiotic|Placebo capsule that matches the probiotic capsule in appearance will be given once daily for 180 days.
3095456|NCT01922895|Active Comparator|Lactobacillus Rhamnosus GG|Dietary supplement capsule (Lactobacillus Rhamnosus GG) will be given once daily for 180 days.
3095457|NCT01922882|Experimental|Amagugu Counseling Intervention|"The 'Amagugu' intensive 6 session home-based intervention. All 6 visits will be undertaken by a lay counsellor over a period of 8-10 weeks. The intervention includes 3 stages linked to the outcomes of the intervention:~family engagement, personal preparation, disclosure practice using intervention materials~health promotion training and a mother-child visit~play-for-communication and custody care planning"
3095458|NCT01922882|No Intervention|Standard of Care|"There is currently no Standard of Care in the South African DoH addressing the issue of parental disclosure of HIV status to HIV-uninfected children, beyond a recommendation to 'counsel to disclose'.~Therefore, for women who are randomized to the control group, we will ensure a Standard of Care for all mothers including a one-hour counselling session, focused specifically on disclosure, delivered at the primary health care facility as part of the HIV Programme.~We will orientate all health professionals in the enrolment clinic, including nurses, counsellors and community health care workers, on parental HIV disclosure, and provide a one-day training workshop (including training manual, role-plays and competency testing."
3117388|NCT01772264|Placebo Comparator|Arm B - placebo|
3095459|NCT01922869|Experimental|COB mixture|One time ingestion of flavonoid mixture from chocolate (80 g), orange juice (500 ml)and blackberries (160 g), also known as the 'COB mixture' providing approximately 640 mg of flavan-3-ols, 390 mg of anthocyanins and 342 mg of flavanones respectively.
3095460|NCT01922856|Experimental|Challenge (Vaccinated)|"The vaccine will be administered via the ID route to alternating upper arms on days 0, 21, and 42.~On the morning of challenge, subjects will drink 120 mL of bicarbonate buffer. Approximately 1 minute later, subjects will drink a solution of virulent H10407 bacteria suspended in the remaining 30 mL of bicarbonate buffer (2 x 10P7P cfu)."
3095461|NCT01922856|Experimental|Challenge (Unvaccinated)|On the morning of challenge, subjects will drink 120 mL of bicarbonate buffer. Approximately 1 minute later, subjects will drink a solution of virulent H10407 bacteria suspended in the remaining 30 mL of bicarbonate buffer (2 x 10P7P cfu).
3095462|NCT01922843|Experimental|DP001|DP001 softgel capsules, 440 ng taken orally three times weekly after dialysis for 12 weeks
3095463|NCT01922843|Placebo Comparator|Placebo|Placebo softgel capsules, taken orally three times weekly after dialysis for 12 weeks
3095464|NCT01922830|Experimental|Bio-25 (Supherb)|"Bio-25 (Supherb) once daily (2 capsules -50 billion bacteria) for 6 months (or 4 weeks for healthy participants).~The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines."
3095465|NCT01922830|Placebo Comparator|Placebo|"Identical placebo once daily (2 capsules) for 6 months (or 4 weeks for healthy participants).~The placebo supplementation is identical-looking to the Bio-25 supplement."
3095466|NCT01922817|Experimental|Saxagliptin|5mg once daily in addition to insulin therapy
3095467|NCT01922817|Sham Comparator|Placebo|Placebo and insulin therapy
3095468|NCT01922804|Experimental|K2 vitamin|K2 vitamin 375 microgram a day for 3 years
3095469|NCT01922804|Placebo Comparator|placebo|1 tablet a day for 3 years
3095470|NCT01922791|Active Comparator|Probiotic|Comparison of probiotics, fish oil and their combination to placebo
3095471|NCT01922791|Active Comparator|Fish oil|Comparison of probiotics, fish oil and their combination to placebo
3095472|NCT01922791|Active Comparator|Probiotics and Fish oil|Comparison of probiotics, fish oil and their combination to placebo
3095473|NCT01922791|Placebo Comparator|Placebo|Comparison of probiotics, fish oil and their combination to placebo
3095474|NCT01922778|Experimental|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. If the patient consents to the procedure, then this will usually be a D&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD device can be inserted at the time of her bariatric surgery.~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting. If the biopsy cannot be performed due to technical difficulty (cervical stenosis) or inadequate sampling, we will try again on a different day after a trial of vaginal misoprostol (Cytotec) 400 or 600 mcg per vagina the night before."
3095475|NCT01922765|Experimental|AOC group|AOC group: treated with amoxicillin, rabeprazole, clarithromycin for 7 days
3095476|NCT01922765|Experimental|AOM group|AOM group: treated with amoxicillin, rabeprazole, metronidazole for 7 days
3095477|NCT01922765|Experimental|Sequential group|Sequential group: treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days
3095478|NCT01922765|Experimental|concomitant group|concomitant group: treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days
3095479|NCT01922752|Experimental|CEP-37440|
3095480|NCT01922739|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain. If enrolled under the original protocol, there was a double-blind titration period of four weeks to adjust the dose taken in study 3103 (NCT01789970). If enrolled under the amended protocol, there was an open-label adjustment period of three weeks to adjust the dose taken in study 3103 (NCT01789970). Both versions of protocol 3104 followed the titration/adjustment period with a open-label treatment period of 22 weeks.
3095481|NCT01922713|Placebo Comparator|white maize|white maize and a corn oil capsule
3095482|NCT01922713|Experimental|orange maize|orange maize and a corn oil capsule
3095483|NCT01922713|Active Comparator|vitamin A|white maize and a vitamin A capsule
3095484|NCT01922687|Experimental|Amlodipine Plus Atorvastatin (Caduet)|amlodipine plus atorvastatin in a single tablet (Caduet, Pfizer, USA) was given once daily
3095485|NCT01922687|Active Comparator|Amlodipine (Norvasc)|amlodipine(Norvasc, Pfizer, USA) given once daily
3095486|NCT01922674|No Intervention|Watchful Waiting|Assess pain, physical function, and other outcomes in men with asymptomatic or minimally symptomatic inguinal hernia that do not have surgery
3095487|NCT01922674|Active Comparator|Standard open tension-free inguinal hernia repair with mesh|Assess pain, physical function, and other outcomes in men with asymptomatic or minimally symptomatic inguinal hernia that undergo a standard open tension-free repair with mesh.
3095488|NCT01922661|Experimental|Cohort 1|Dose 1 of REGN1908-1909 or placebo
3095489|NCT01922661|Experimental|Cohort 2|Dose 2 of REGN1908-1909 or placebo
3095490|NCT01922661|Experimental|Cohort 3|Dose 3 of REGN1908-1909 or placebo
3095491|NCT01922648||2-4 months|Infants aged between 2 and 4 months (Group 1), who have not yet been exposed to RSV
3095492|NCT01922648||6 - 12 months|Infants aged between 6 and 12 months (Group 2), who will have had exposure to one single RSV season in the winter of 2011/12
3095493|NCT01922648||3 - 6 years|Children aged between 3 and 6 years (Group 3), who have been exposed to RSV over several winter seasons
3095494|NCT01922635|Other|1|
3095495|NCT01922622||Bipolar hemiarthroplasty.|Group of patients who will stay in lateral position during whole surgery.
3095496|NCT01922622||Dynamic hip screw.|Group of patients who will be supine during surgery.
3095497|NCT01922609||Normal cerebrovascular reserve|Patients without preprocedural TCD signs of impaired cerebrovascular reserve
3095498|NCT01922609||Impaired cerebrovascular reserve|Patients with preprocedural TCD signs of impaired cerebrovascular reserve
3095499|NCT01922596|Experimental|Active FNB, placebo ACB|FNB with 30 ml of ropivacaine 0,2% and ACB with 30 ml of placebo (saline). The ACB will be performed just prior to the FNB. The blockades will be performed just after obtaining the baseline values (outcome measures) at time 0.
3095500|NCT01922596|Experimental|Active ACB, placebo FNB|ACB with 30 ml of ropivacaine 0,2% and FNB with 30 ml of placebo (saline.The ACB will be performed just prior to the FNB. The blockades will be performed just after obtaining the baseline values (outcome measures) at time 0.
3095501|NCT01922583|Experimental|Vial|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
3095502|NCT01922570|Experimental|Dietary supplements:parenteral nutrition|supplemental parenteral nutrition and enteral nutrition in case of failure (intake below 60% of energy needs) of enteral nutrition by day 3 after admission in the ICU or enteral nutrition only.
3095503|NCT01922557||NICOM|
3095504|NCT01922544||Conventional group|In this group CS lead was implanted in a conventional manner.
3095505|NCT01922544||EP-catheter group|In this group coronary sinus was canulated using a steerable electrophysiology catheter.
3095506|NCT01922531||Mild Traumatic Brain Injury|These were patients who presented to the ER within 6 hours of a witnessed head injury. Patients were also eligible if the patient had a self-reported head injury with evidence of head trauma.
3095507|NCT01922531||Orthopedic Injury|Patients were eligible as an orthopedic injured control who presented to the ER within 6 hours of an isolated extremity trauma that radiography and an Abbreviated Injury Scale (AIS) of less than or equal to 3.
3095508|NCT01922518|Active Comparator|Septal pacing group|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
3095509|NCT01922518|Active Comparator|Apex pacing group|Put RV lead around the apex
3095510|NCT01922505||PPI triple therapy|7-day PPI triple therapy regimen: PPI (esomeprazole 40 mg or omeprazole 20 mg or lansoprazole 30 mg or pantoprazole 40 mg or rabeprazole 20 mg) plus amoxicillin (1000mg) and clarithromycin (500mg) twice daily for 7 days.
3095511|NCT01922492|Experimental|Autologous islet transplantation|Autologous islet transplantation arm: autologous islet transplantation
3095512|NCT01922492|Active Comparator|Oral anti-diabetic drugs|Metformin (starting from 500mg qd with dose adjustment thereafter) with or without vildagliptin (starting from 50mg qd with dose adjustment thereafter)
3095513|NCT01922479|Experimental|Ferric Carboxymaltose|1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
3095514|NCT01922479|Active Comparator|Placebo|20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
3095515|NCT01922466|Experimental|Bee Venom Acupuncture|
3095516|NCT01922466|Experimental|Loxoprofen|
3095517|NCT01922466|Experimental|EWCT : Bee Venom Acupucture and Loxoprofen|
3095518|NCT01922453|Experimental|Music and Sound|Music and Sound applied to maternal abdomen through a special device for pregnant women.
3095519|NCT01922453|No Intervention|no music and sound|
3095520|NCT01922440||Chronic Hypoparathyroidism|A rare disease with a duration of longer than 6 months characterized by insufficient parathyroid hormone (PTH) secretion, which can result in hypocalcemia, hyperphosphatemia, and associated clinical findings.
3095521|NCT01922414|Active Comparator|Laser|Patients will undergo Laser lithotripsy
3095522|NCT01922414|Active Comparator|Ultrasonic|Patients will undergo ultrasonic lithotripsy
3095523|NCT01922401|Experimental|inverse ratio ventilation|in one group change the I:E ratio during pneumoperitoneum 1:2-1:2-2:1
3095524|NCT01922388|Active Comparator|Early Motor Complication|All subjects receive bilateral deep brain stimulation of the subthalamic nucleus and best medical treatment, and a half of them undergo PET imaging with 18F-AV-133 as the tracer.
3095525|NCT01922388|Active Comparator|Late Motor Complication|All subjects receive bilateral deep brain stimulation of the subthalamic nucleus and best medical treatment, and a half of them undergo PET imaging with 18F-AV-133 as the tracer.
3095526|NCT01922375|Experimental|Naftopidil dose 2|PO administration
3095527|NCT01922375|Placebo Comparator|Placebo|PO administration
3095528|NCT01922375|Experimental|Naftopidil dose 1|PO administration
3095529|NCT01922362|Experimental|Negative pressure drainage system|Negative pressure drainage system
3095530|NCT01922362|Active Comparator|Indirect wet dressing group|Indirect wet dressing
3095531|NCT01922349|Placebo Comparator|Placebo (Multiple dose)|Placebo
3095532|NCT01922349|Experimental|Dose 1, Single dose|Low dose
3095533|NCT01922349|Experimental|Dose 2, Single dose|Medium dose
3095534|NCT01922349|Experimental|Dose 3, Single dose|High dose
3095535|NCT01922349|Experimental|Dose 4, Multiple dose|Low dose
3095536|NCT01922349|Experimental|Dose 5, Multiple dose|Medium dose
3095537|NCT01922349|Experimental|Dose 6, Multiple dose|High dose
3095538|NCT01922349|Placebo Comparator|Placebo (Single dose)|Placebo
3095539|NCT01922336|Experimental|SB2|SB2 (Study drug)
3095540|NCT01922336|Active Comparator|EU Remicade|EU sourced Remicade (Reference drug)
3095541|NCT01922336|Active Comparator|US Remicade|US sourced Remicade (Reference drug)
3095542|NCT01922310|Other|Communication intervention|This study uses a single arm design with current 'controls' to explore an intervention, the procedure for providing information and requesting consent for donation, that uses new agreed best practice procedures led by specially trained intensive care health professionals. The study intervention is a staff education and training module intended to provide a framework and preparation for select critical care staff to conduct organ donation discussions in line with best practice.
3095543|NCT01922297|Experimental|Day Treatment MDFT-HIV|Multidimensional Family Therapy (MDFT)is an integrative treatment approach that has blended family therapy, individual therapy, drug counseling, and multiple systems oriented intervention approaches (Liddle 1999). DT-MDFT-HIV includes a state-of-the-art family-based HIV prevention component into the core MDFT intervention specifically targeting high-risk sexual behavior in clinical sample teens.
3095544|NCT01922297|Other|Day Treatment SAU|The DT-Services as Usual (SAU) condition is primarily a peer group-based and individual approach that uses cognitive-behavioral principles and interventions. It is an adolescent substance abuse treatment and services consistent with those recommended for juvenile justice-involved drug abusing youth (Cooper & Bartlett 1998; National Institute of Justice, 2001).
3095545|NCT01922284|Experimental|Group 1 - Combination arm|"All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 1 will receive 5 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8 16 and 20.~At weeks 16 and 20, individuals in group 1 will be given MVAC in a volume of 0.5mls into the upper left arm and also 100ug CN54rgp140 mixed with 5ug GLA-AF in a total volume of 0.4mls into the muscle of the upper right arm."
3095546|NCT01922284|Active Comparator|Group 2 - Non-combination arm|"All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 2 will receive 7 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8, 16, 20, 24 and 28.~At weeks 16 & 20 group 2 will receive only 0.5mls of MVAC into the muscle of the upper left arm. At weeks 24 and 28 they will receive injections of 100ug CN54rgp140 mixed with 5ugGLAAF in a total volume of 0.4mls into the muscle of the upper right arm."
3095547|NCT01922271|Experimental|NVA237 followed by tiotropium|Period 1: NVA237 plus placebo to tiotropium on day 1, followed by a 7 day washout. Period 2: tiotropium plus placebo to NVA237 on day 8. Salbutamol was used as rescue medication.
3095548|NCT01922271|Experimental|Tiotropium followed by NVA237|Period 1: tiotropium plus placebo to NVA237 on day 1, followed by a 7 day washout. Period 2: NVA237 plus placebo to tiotropium on day 8. Salbutamol was used as rescue medication.
3095549|NCT01922258|Placebo Comparator|Placebo|Matching Placebo Once-Daily
3095550|NCT01922258|Experimental|Brexpiprazole (flexible dose range 0.5 to 2 mg)|Titrate up from 0.25 mg/day brexpiprazole to 1 mg/day brexpiprazole. After achieving 1 mg/day target dose may be increased or decreased based on efficacy and tolerability. Allowable flexible doses will be 0.5 mg/day, 1 mg/day, or 2 mg/day.
3095551|NCT01922245|Experimental|anodal tDCS|Soterix 1x1 device: anodal tDCS administered to the left hemisphere
3095552|NCT01922219|Other|Cognitive Behavioral Therapy|Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).
3095553|NCT01922206|No Intervention|Wait-list Control|Participants in the wait-list control condition will receive a group-based version of the TRACK intervention after their 15-month follow up appointment.
3095554|NCT01922206|Experimental|TRACK Intervention|3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child
3095555|NCT01922193|Experimental|Test Group|
3095556|NCT01922193|Active Comparator|Control Group|
3095557|NCT01922180||COPD Exacerbation|COPD patients aged 18 years or more, were included at the time of an exacerbation episode leading to admission in our hospital, which corresponds to a severe episode. There were no exclusion criteria. Patients underwent chest CT scans and PFT. After a minimum of two weeks free of any acute symptom after discharge, CT scans and PFT were redone.
3095558|NCT01922167|Experimental|Leucine|2.5 g doses of leucine isolate three times per day (7.5 g total) of leucine, taken by mouth in powder form mixed with liquid for 12 consecutive weeks.
3095559|NCT01922167|Placebo Comparator|Alanine|2.5 g doses of alanine isolate three times per day (7.5 g total) of alanine, taken by mouth in powder form mixed with liquid for 12 consecutive weeks.
3095560|NCT01922154|Experimental|intravitreal ranibizumab|Ranibizumab was injected into vitreous cavity in the study eye once (0.5 mg/0.05 ml) at least 1 week before performing trabeculectomy with mitomycin C.
3095561|NCT01922141|Experimental|Aliskiren monotherapy|Aliskiren 150 mg, once a day, force titrated to Aliskiren 300 mg after 8 weeks in 50% of patients. Optional addition/titration of amlodipine 5 mg/10 mg and hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
3095562|NCT01922141|Experimental|Aliskiren dual therapy|Aliskiren 150 mg plus amlodipine 5 mg, once a day, force titrated to Aliskiren 300 mg plus amlodipine 5 mg after 8 weeks in 50% of patients. Optional titration of amlodipine 5 mg to 10 mg and optional addition/titration of hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
3095563|NCT01922141|Active Comparator|Ramipril monotherapy|Ramipril 5 mg, once a day, force titrated to Ramipril 10 mg after 8 weeks in 50% of patients. Optional addition/titration of amlodipine 5 mg/10 mg and hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
3095564|NCT01922128|Active Comparator|Drug, MC-1101|One eye drop of Active comparator, 0.5% MC-1101, 2 times per day, 28 days; followed by one drop of 1% MC-1101, 2 times per day, 28 days.
3095565|NCT01922128|Placebo Comparator|Placebo|One eye drop of Placebo comparator to MC-1101. Placebo contains all components of MC-1101 except for the active ingredient.
3095566|NCT01922115|Active Comparator|TROSPIUM CHLORIDE|Those with overactive bladder will be administered either a placebo or Sanctura XR extended release (Trospium chloride) for treatment (60 mg).
3095567|NCT01922115|Placebo Comparator|PLACEBO|Subjects may be administered a placebo rather than the Sanctura XR (Trospium Chloride).
3095568|NCT01922102|Experimental|Group I|0.5 mg ranibizumab driven by visual acuity stability criteria
3095569|NCT01922102|Experimental|Group II|0.5 mg ranibizumab driven by disease activity criteria
3095570|NCT01922102|Active Comparator|Group III|verteporfin PDT
3095571|NCT01922089|Experimental|LCZ696 Condensed|Up-titration to LCZ696 200 mg twice daily (bid) over 3 weeks
3095572|NCT01922089|Experimental|LCZ696 Conservative|Up-titration to LCZ696 200 mg bid over 6 weeks
3095573|NCT01922076|Experimental|Treatment (WEE1 inhibitor AZD1775, radiation therapy)|Patients undergo radiation therapy 5 days a week for 6 weeks (up to 30 fractions). Patients also receive WEE1 inhibitor AZD1775 PO on days 1-5 of weeks 1, 3, and 5; days 1-5 of weeks 1, 3, and 5 AND days 1, 3, and 5 of weeks 2, 4, and 6; OR days 1-5 of weeks 1-6 depending on dose level assignment. Treatment continues in the absence of disease progression or unacceptable toxicity.
3095612|NCT01921855|Experimental|BAY Factor VII (20 µg/kg) / Placebo|n = 4, randomized 3:1; 20 µg/kg BAY 86-6150 (B0189):Placebo
3095574|NCT01922063|Experimental|Physiotherapy Intervention|20 treatment sessions of a comprehensive physiotherapy program, 12 weeks' duration, with custom tailored instructions by the supervising physician; physicians discussed the course of therapy with the physiotherapist 1x/week. Patients had been treated by physiotherapist according to written prescriptions. Duration of treatment 30 min/ session. Patients were encouraged to practice regular home exercise.
3095575|NCT01922063|Sham Comparator|Sham neck massage|"received twenty sessions sham neck massage of 30 minutes' duration each with the patients lying in supine position on a massage bed and the head of the patient resting on the therapist's knees"
3095576|NCT01922063|No Intervention|No therapy|"no further therapy, patients were asked to wait and see for the first three months after operation, and no particular treatment was planned"
3095577|NCT01922050|Experimental|Part 1: LEO 43204 Formulation 1|Open-Label, Dose-Escalation, Once-Daily, 2-Day Treatment
3095578|NCT01922050|Experimental|Part 1: LEO 43204 Formulation 2|Open-Label, Dose-Escalation, Once-Daily, 2-Day Treatment
3095579|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 1 Dose X|Double-Blind, Once-Daily, 2-Day Treatment
3095580|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 1 Dose Y|Double-Blind, Once-Daily, 2-Day Treatment
3095581|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 2 Dose XX|Double-Blind, Once-Daily, 2-Day Treatment
3095582|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 2 Dose YY|Double-Blind, Once-Daily, 2-Day Treatment
3095583|NCT01922050|Placebo Comparator|Part 2: Placebo Formulation 1|Double-Blind, Once-Daily, 2-Day Treatment
3095584|NCT01922050|Placebo Comparator|Part 2: Placebo Formulation 2|Double-Blind, Once-Daily, 2-Day Treatment
3095585|NCT01922037|Experimental|Participants With Allergic Asthma|Participants with allergic asthma, who have decided to initiate treatment with omalizumab will be observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurs first.
3095586|NCT01922024||Prospective Fresh Clinical Specimens|Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against composite (comparator) which is based on routine clinical microbiology and a second PCR test
3095587|NCT01922024||Retrospective Frozen Clinical Specimens|Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against routine clinical microbiology
3095588|NCT01922011|Experimental|Daptomycin|Intravenous (IV) daptomycin was dosed as follows: age 12 years to <18 years (7 mg/kg); age 7 years to < 12 years (9 mg/kg); age 24 months to <7 years (12 mg/kg); age 12 months to <24 months (12 mg/kg). Drug was infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
3095589|NCT01922011|Active Comparator|Vancomycin or Nafcillin|IV vancomycin (or equivalent), 10 to 15 mg/kg, was infused over 60 (± 10) minutes q6h (± 1 hour) or IV nafcillin (or β-lactam equivalent) at 100-200 mg/kg/day, in divided doses was infused over 60 (± 10) min q6h (± 1 hour)
3095590|NCT01921998||Biomarker and health economics|Biomarkers will be taken throughout cycle 1. Health economics will be recorded using a patient side effect diary, a details of admission form, and a patient survey of healthcare use.
3095591|NCT01921985|Active Comparator|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
3095592|NCT01921985|Placebo Comparator|NaCl|Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
3095593|NCT01921972|Active Comparator|Galantamine and Placebo|Subjects in this group will receive 4 weeks of 8 mg/day galantamine CR, followed by 4 weeks of 16 mg/day and from week 9 up to the end of the trial of 24 mg/day.
3095594|NCT01921972|Experimental|Galantamine and Memantine|Galantamine titration will be performed as described above. Memantine titration will be performed over 4 weeks in steps of 5 mg/day up to 20mg/day (10 mg b.i.d.). 50 % of this group will receive galantamine first, 50 % of the group will receive memantine first to allow for differential qualitative evaluation of tolerability of a combination therapy.
3095595|NCT01921959||Partners of intervention women|Partners of women randomized to intervention
3095596|NCT01921959||Partners of no intervention women|Partners of women randomized to control
3095597|NCT01921946|Other|Part A|Fimasartan (7 days) → Fimasartan + Rosuvastatin (7 days)
3095598|NCT01921946|Other|Part B|Rosuvastatin (7 days) → Fimasartan + Rosuvastatin (7 days)
3095599|NCT01921933|Experimental|Optiflow|The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
3095600|NCT01921920|Active Comparator|Omeprazole 20mg aqueous|Treatment A: a single oral dose of omeprazole 20-mg aqueous-solvent based capsules (AstraZeneca - test)
3095601|NCT01921920|Active Comparator|Omeprazole 20mg organic|Treatment B: a single oral dose of omeprazole 20-mg organic-solvent based capsules (Merck - reference for Treatment A)
3095602|NCT01921920|Active Comparator|Omeprazole 40mg aqueous|Treatment C: a single dose of omeprazole 40-mg aqueous-solvent based capsules (AstraZeneca - test)
3095603|NCT01921920|Active Comparator|Omeprazole 40mg organic|Treatment D: a single dose of omeprazole 40-mg organic-solvent based capsules (Merck - reference for Treatment C)
3095604|NCT01921907|Experimental|Active|topical treatment
3095605|NCT01921907|Placebo Comparator|Placebo|topical treatment
3095606|NCT01921894|Experimental|Cholecalciferol 4000 IU|Cholecalciferol 4000 IU oral chewable tablet once daily for 8 weeks
3095607|NCT01921894|Experimental|Cholecalciferol 2000 IU|Cholecalciferol 2000 IU oral chewable tablet once daily for 8 weeks
3095608|NCT01921894|Active Comparator|Cholecalciferol 200 IU|Cholecalciferol 200 IU oral chewable tablet once daily for 8 weeks
3095609|NCT01921881|Experimental|St John's wort|"Subjects will undergo 3 oral glucose tolerance tests:~Without taking any St John's wort~After 3 weeks pretreatment with St John's wort~Minimum 6 weeks after last St John's wort ingestion"
3095610|NCT01921868|Experimental|Acetyl-L-Carnitine|Open-label administration of Acetyl-L-Carnitine, up to 2 g/day for 24 months.
3095611|NCT01921855|Experimental|BAY Factor VII (6.5 µg/kg) / Placebo|n = 4, randomized 3:1; 6.5 µg/kg BAY 86-6150 (B0189):Placebo
3095716|NCT01921192|Placebo Comparator|Sugar pill|
3095613|NCT01921855|Experimental|BAY Factor VII (50 µg/kg) / Placebo|n = 4, randomized 3:1; 50 µg/kg BAY 86-6150 (B0189):Placebo
3095614|NCT01921855|Experimental|BAY Factor VII (90 µg/kg) / Placebo|n = 4, randomized 3:1; 90 µg/kg BAY 86-6150 (B0189):Placebo
3095615|NCT01921842|Experimental|Nutrition and Physical Activity Training|NAP-SACC Child Care Wellness program administered in year 1 of study
3095616|NCT01921842|Other|Delayed Intervention Group|NAP-SACC Child Care Wellness Program is administered in year 2 of study.
3095617|NCT01921829|No Intervention|Usual Care|Participants randomized to the Usual Care group (control arm) will receive escalating diuretics and medical therapy per HF guidelines published by the American College of Cardiology (ACC)/American Heart Association (AHA) and Heart Failure Society of America (HFSA), dosed in variable fashion at the discretion of the treating cardiologist.
3095618|NCT01921829|Experimental|Protocolized Diuretic Strategy|Participants randomized to the Protocolized Diuretic Strategy group will receive escalating diuretics according to an algorithm targeting a goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide). If UO is < 3 L/day, diuretic regimen will be increased. If UO is 3-5 L/day, diuretic regimen will be continued at current doses. If UO is > 5 L/day, diuretic regimen will be reduced.
3095619|NCT01921816|Other|Prismocitrate 18/0|citrate-containing replacement solution (Prismocitrate 18/0, Gambro) will be administered at pre-filter port during continuous hemodiafiltration, for the purpose as replacement solution and anticoagulation
3095620|NCT01921803|Experimental|Arm 1|16 fractions à rato of 4 fractions a week over 4 weeks
3095621|NCT01921803|Experimental|Arm 2|25 fractions à rato of 5 fractions a week over 5 weeks
3095622|NCT01921790|Experimental|Avastin+ GemAOD|Avastin+ GemAOD means Avastin Combined With Gemcitabine, Oxaliplatin, Pegaspargase and Dexamethasone
3095623|NCT01921777|Experimental|Traumeel|Traumeel tablets by mouth the total amount for 72 hours will be 26 tablets
3095624|NCT01921777|Placebo Comparator|Placebo|The Placebo tablets (300 mg lactose monohydrate and 1,5 mg magnesium stearate) by mouth the total amount for 72 hours will be 26 tablets
3095625|NCT01921764|Experimental|Workplace physical exercise|Physical exercise (kettlebells, elastic bands, exercise balls) performed at the workplace with coaching
3095626|NCT01921764|Active Comparator|Home physical exercise|Physical exercise performed at home with elastic bands and bodyweight exercises with instruction to follow the exercises at http://www.jobogkrop.dk/Oevelser-til-nakke-og-ryg/Oevelser
3095627|NCT01921751|Experimental|Chemotherapy + high intensity radiation|Induction chemotherapy with four cycles of gemcitabine and nab-paclitaxel [randomized to this arm after 3rd cycle and no progression]; followed by concurrent high intensity radiation therapy and capecitabine; followed by consolidation chemotherapy with gemcitabine and nab-paclitaxel until progression or unacceptable toxicity
3095628|NCT01921751|Experimental|Chemotherapy + low intensity radiation|Induction chemotherapy with four cycles of gemcitabine and nab-paclitaxel [randomized to this arm after 3rd cycle and no progression]; followed by concurrent low intensity radiation therapy and capecitabine; followed by consolidation chemotherapy with gemcitabine and nab-paclitaxel until progression or unacceptable toxicity
3095629|NCT01921751|Active Comparator|Chemotherapy|Gemcitabine and nab-paclitaxel until progression or unacceptable toxicity [randomized to this arm after 3rd cycle and no progression]
3095630|NCT01921738|Experimental|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
3095631|NCT01921738|Experimental|Azithromycin capsule|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
3095632|NCT01921738|Placebo Comparator|Placebo Gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
3095633|NCT01921738|Placebo Comparator|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
3095634|NCT01921725|Experimental|Hydrophilic-based dressing (KoCarbonTM)|The wound is first cleansed with normal saline, and then applied with hydrophilic-based dressing (KoCarbonTM) and covered by sterile gauze. The frequency of dressing chang is depend on the amount of exudate.
3095635|NCT01921712|Experimental|PUR0200 low dose|PUR0200 low dose, single dose inhalation
3095636|NCT01921712|Experimental|PUR0200 mid dose|PUR0200 mid dose, single dose inhalation
3095637|NCT01921712|Experimental|PUR0200 high dose|PUR0200 high dose, single dose inhalation
3095638|NCT01921712|Placebo Comparator|Placebo|PUR0200 matched placebo, single dose, inhalation
3095639|NCT01921712|Active Comparator|Active Comparator|Active Comparator, single dose, inhalation
3095640|NCT01921699|Other|irrelevant|
3095641|NCT01921686||Gastroesophageal Reflux Disease (GERD)|"History of troublesome symptoms (e.g. heartburn, chest pain, acid regurgitation) secondary to reflux of gastric contents at least three times per week~AND, At least one of the following:~Mucosal breaks on endoscopy (at least Grade-A esophagitis based on Los Angeles classification)~Abnormal pH index (pH less than 4 for greater than 6% of study)~Abnormal MII-pH (greater than 73 episodes of total reflux per 24 hours)"
3095642|NCT01921686||Eosinophilic Esophagitis (EoE)|"History of troublesome esophageal symptoms (e.g. dysphagia, food impaction, vomiting, upper abdominal or chest pain)~Greater than or equal to 15 eosinophils in at least one high powered field (HPF) from distal OR proximal esophageal biopsy~Lack of histological response to 6-8 weeks of high dose Proton Pump Inhibitor (PPI) OR negative pH probe (pH less than 4 for less than 6% of study). Subjects with greater than 15 eosinophils/HPF and abnormal pH results may have an overlap syndrome and will be excluded from the primary analysis."
3095643|NCT01921686||Control|Patients with no history of troublesome esophageal symptoms or esophageal disease AND normal esophagoscopy (for example, patients undergoing evaluation for chronic abdominal pain, inflammatory bowel disease, celiac disease).
3095751|NCT01920893|Placebo Comparator|Placebo|Placebo (for dupilumab), 2 subcutaneous injections on Day 1 as a loading dose followed by a single injection every week (QW) from Week 1 to 15 added to Mometasone furoate nasal spray (MFNS).
3095644|NCT01921673|Experimental|Dovitinib plus docetaxel|"In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off~In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used."
3095645|NCT01921660|Experimental|Dipole density mapping|
3095646|NCT01921647|Experimental|YH4808, amoxicillin, clarithromycin|single administration of YH4808 or amoxicillin or clarithromycin or YH4808 + amoxicillin + clarithromycin
3095647|NCT01921647|Experimental|YH4808, amoxicillin and clarithromycin|7 days repeat administration of YH4808, amoxicillin and clarithromycin for H.pylori eradication
3095648|NCT01921647|Experimental|YH4808 and amoxicillin|7 days repeat administration of YH4808 and amoxicillin for H.pylori eradication
3095649|NCT01921647|Active Comparator|nexium, amoxicillin and clarithromycin|BID, 7 days repeat administration of nexium, amoxicillin and clarithromycin for H.pylori eradication
3095650|NCT01921634|Other|Standard analysis|Standard pathological analysis currently used.
3095651|NCT01921634|Other|Modified Pathologic Analysis|After undergoing standard pathologic analysis, each specimen will then undergo the modified pathologic analysis.
3095652|NCT01921621|No Intervention|Group A|Control: Group of Orthopedic Residents who receive arthroscopic surgery training at the Orthopedic Learning Center during a standard week-end Resident Arthroscopic Training Course
3095653|NCT01921621|Active Comparator|Group B - Simulation Training|Group B resident training includes the use of a dry model shoulder simulator for practicing the steps and avoiding the errors of an arthroscopic Bankart repair
3095654|NCT01921621|Experimental|Group C - Proficiency Based Progression|Group C - Proficiency Based Progression Group C residents must test to proficiency on the cognitive material contained in the orientation video, demonstrate arthroscopic knot tying proficiency to a pre-determined benchmark, and perform an arthroscopic Bankart repair on a dry shoulder simulator model to a pre-determined benchmark in order to progress in the training exercise
3095655|NCT01921608|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
3095656|NCT01921595|Experimental|Valanced salt colloid group|
3095657|NCT01921595|Active Comparator|Valanced salt crystalloid group|
3095658|NCT01921582|Experimental|Methylphenidate|"Methylphenidate (TEVA-METHYLPHENIDATE ER-C)~Dosage: 18 mg/day at Week 1; 36 mg/day at Week 2; 54 mg/day at Week 3; 72 mg/day at Week 4. Dosage levels may be maintained or decreased to manage medication side effects.~Dosage form: tablet~Dosage frequency: daily~Duration: 12 weeks total"
3095659|NCT01921582|Active Comparator|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy~12 individual 50-minute appointments over the course of up to 14 weeks~According to Fairburn, Marcus, and Wilson (1993)"
3095660|NCT01921569|Experimental|dHACM|Standard of Care Therapy plus dHACM injection at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
3095661|NCT01921569|Placebo Comparator|Saline Injection|Standard of Care Therapy plus normal saline injection instead of active agent at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
3095662|NCT01921556|Active Comparator|QualiCCare education|"QualiCCareeducation is a training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support."
3095663|NCT01921556|No Intervention|usual care|The practices randomized to the control group apply care as usual
3095664|NCT01921543|Experimental|CI/BNST stimulation on|
3095665|NCT01921543|Experimental|CI/BNST vs stimulation off|randomized, double blind, 1 week crossover
3095666|NCT01921543|Experimental|ITP stimulation on|
3095667|NCT01921543|Experimental|CI/BNST vs ITP vs stimulation off|randomized, double blind, two month crossover
3095668|NCT01921530|Active Comparator|Interbody Fusion|
3095669|NCT01921530|Active Comparator|Posterolateral Fusion|
3095670|NCT01921517|Experimental|Low Magnitude Mechanical Stimulation|10 minutes daily of 30 Hz/0.3g stimulation using a vibrating platform.
3095671|NCT01921517|Placebo Comparator|Sham Low Magnitude Mechanical Stimulation|10 minutes daily of placebo treatment using a sham vibrating platform.
3095672|NCT01921504|Experimental|Acupuncture|Participants in this group are given twice-a-week acupuncture treatment for 4 weeks.
3095673|NCT01921504|No Intervention|No treatment|The participants in this group are supposed to wait without any intervention for first 4 weeks. Then they receive the identical acupuncture treatments as in the treatment group for the following 4 weeks.
3095674|NCT01921491|Other|Standard of Care|Surgical debridement of DFU, followed by collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice Offloading. Reassessment weekly at office visit.
3095675|NCT01921491|Active Comparator|Other Commercially Available Product|Application of commercially available product with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional application of commercially available product will be applied weekly at weeks 2-11.
3095676|NCT01921491|Experimental|dHACM|Application of dHACM with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional piece of dHACM will be applied weekly at weeks 2-11.
3095677|NCT01921478||Cohort|
3095678|NCT01921465||multiparas having a planned cesarean section|elective cesarean section
3095679|NCT01921452|Experimental|POC TSH Kits + Third Generation TSH Kit|
3095680|NCT01921439|Active Comparator|Feedback|Participants in this group will receive individualized feedback based on their stage of change. Feedback will include health effects of smoking, money spent per month and per year on cigarettes, time spent smoking compared with time spent doing other daily tasks, and how the participant compares to past study participants in average number of cigarettes per day used and level of addiction.
3095681|NCT01921439|No Intervention|No Feedback- Treatment as Usual (TAU)|Participants will take the computer based survey, but will only receive a number to the Oklahoma Tobacco Helpline (Treatment-as-usual condition) instead of feedback.
3096099|NCT01918579|No Intervention|Control|Patients will not be tested by rapid POC CRP test
3095682|NCT01921426|Experimental|GC4419|Open label, dose escalation study of GC4419 administered in 14 doses, corresponding to the first 14 doses of radiation therapy. Each dose will be given intravenously over 60 minutes. The possible doses which may be tested are: 15mg, 30mg, 50mg, 75mg, 112mg, and 170mg.
3095683|NCT01921400||HCV-infected mothers|in situ hybridization
3095684|NCT01921400||Uninfected mothers|in situ hybridization
3095685|NCT01921387|Experimental|Treatment (90Y-BC8-DOTA, chemotherapy, PBSC)|Patients receive yttrium Y 90 anti-CD45 monoclonal antibody BC8 IV on day -14. Patients also receive carmustine IV over 3 hours on day -7, etoposide IV over 2 hours BID on days -6 to -3, cytarabine IV over 4 hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2. Patients then undergo autologous PBSC transplant on day 0.
3095686|NCT01921374|Experimental|sleep parameters|To assess the sleep parameters.
3095687|NCT01921374|Other|cardiovascular parameters|To assess the cardiovascular profile of control mothers and caregivers-mothers.
3095688|NCT01921374|Experimental|imflammatory and immunological profile|To assess the inflammatory profile of caregivers-mothers and control mothers
3095689|NCT01921374|Experimental|hormonal profile|To assess the hormonal profile of caregivers-mothers and control mothers.
3095690|NCT01921374|Experimental|metabolic profile|To assess the health profile of caregivers-mothers and control mothers.
3095691|NCT01921361|Active Comparator|Intravenous|Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous dexmedetomidine (dexmedetomidine diluted 1mcg/ml and than 1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)
3095692|NCT01921361|Active Comparator|Intrathecal|Intrathecal (3 ml) 15 mg levobupivacaine + (0.3 ml) 3 mcg dexmedetomidine (dexmedetomidine diluted 10 mcg/ml) and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)
3095693|NCT01921361|Placebo Comparator|Control|Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion).
3095694|NCT01921348|Experimental|Treatment|34 participants will be randomized to wear acupressure pellets in the designated acupressure points and apply pressure as instructed by the study personnel.
3095695|NCT01921348|Sham Comparator|Sham|33 participants will be randomized to wear acupressure pellets in non-specific areas of the ear and apply pressure as instructed by the study personnel.
3095696|NCT01921335|Active Comparator|ARRY-380 Twice Daily Dosage|ARRY-380 will be 450mg orally twice-daily. Trastuzumab will be given at the standard full dose with a loading dose of 8 mg/kg on Day 1, cycle 1, followed by 6 mg/kg in subsequent cycles. Participants who are within 5 weeks of a 6 mg/kg dose or within 2 weeks of a 2 mg/kg dose of trastuzumab at the time of initial study dosing will not be required to have a re-loading dose but will begin treatment at 6 mg/kg.ARRY-380 will be escalated until MTD is defined or the maximum planned dose has been evaluated. The dose for subsequent dose levels will be determined according to the treatment-related AE observed during the cycle 1 (21 days) in the previous dose level
3095697|NCT01921335|Active Comparator|ARRY-380 Once Daily|ARRY-380 will be 750mg orally once-daily. Trastuzumab will be given at the standard full dose with a loading dose of 8 mg/kg on Day 1, cycle 1, followed by 6 mg/kg in subsequent cycles. Participants who are within 5 weeks of a 6 mg/kg dose or within 2 weeks of a 2 mg/kg dose of trastuzumab at the time of initial study dosing will not be required to have a re-loading dose but will begin treatment at 6 mg/kg. ARRY-380 will be escalated until MTD is defined or the maximum planned dose has been evaluated. The dose for subsequent dose levels will be determined according to the treatment-related AE observed during the cycle 1 (21 days) in the previous dose level
3095698|NCT01921322|Experimental|Pump|Paradigm 722 insulin pump used for insulin infusion and continuous glucose monitoring
3095699|NCT01921322|Active Comparator|MDI|Multiple daily insulin injections used for treatment
3095700|NCT01921309|Experimental|Trinity CoC Total Hip System|total hip replacement with a ceramic femoral head and ceramic acetabular cup liner
3095701|NCT01921309|Active Comparator|Trinity Ceramic-on-Poly THR|total hip replacement with a ceramic femoral head and polyethylene acetabular cup liner
3095702|NCT01921296|Experimental|Cyclobenzaprine|Cyclobenzaprine (Flexeril) 5 milligrams orally 2 hours before bed, for a total of 24 weeks.
3095703|NCT01921283|Experimental|BIS group|The BIS group (n=90) was monitored for sedation depth using BIS during ESD.
3095704|NCT01921283|Active Comparator|No-BIS group|The no-BIS group (n=90) was monitored by observer's assessment alertness/sedation scale (OAA/S).
3095705|NCT01921270|Experimental|Dysport Injections|Participants with OMD who have been previously treated with any botulinum toxin Type A will be injected with Dysport®.
3095706|NCT01921257|Experimental|Treatment|Cat-PAD and Placebo
3095707|NCT01921244|No Intervention|Usual Care|"Approximately 120 families will be asked to participate as usual care subjects and will complete surveys before and immediately after their visit, and approximately 3 months after the visit. These families will not receive the decision aid nor will their provider have been trained how to use the decision aid. All participating providers will have up to 10 usual care patients enrolled at baseline prior to allocation. During the trial, the control group [usual care providers] will have up to 10 additional patients enrolled for ongoing usual care data collection. After the trial is complete, the control group providers will cross over to the intervention arm."
3095708|NCT01921244|Experimental|Intervention|Approximately 80 families/patients with regularly scheduled clinic follow-up visits in the Division of Developmental and Behavioral Pediatrics (DDBP) at Cincinnati Childrens with providers trained on shared decision making will receive the decision aid prior to their index visit and complete surveys before and immediately after their visit, and approximately 3 months later.
3095709|NCT01921231|Experimental|Hyperbaric prilocaine 1%|Solution for injection. Intradural use. In order to obtain Prilocaine 1% we charge a syringe with 2 mL Prilocaine 2%, and we add 1 mL Saline solution (0.9%) and 1 mL Glucose solution (33%). Administer 3 mL of syringe contains in two minutes.
3095710|NCT01921231|Active Comparator|Hyperbaric Bupivacaine 0.5%|Solution for injection. Intradural use. Charge a syringe with 1 mL of Bupivacaine (0.5%) and administer it in a minute.
3095711|NCT01921218|Experimental|Treatment|Belatacept (Nulojix) IV
3095712|NCT01921218|Active Comparator|Control|Calcineurin inhibitor based therapy (cyclosporine or tacrolimus)
3095713|NCT01921205|Experimental|Lacosamide|
3095714|NCT01921205|Placebo Comparator|Placebo|
3095715|NCT01921192|Active Comparator|Folic Acid, vit B6 and B12|
3095717|NCT01921179|Experimental|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
3095718|NCT01921179|Active Comparator|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
3095719|NCT01921166|Active Comparator|clomiphene plus gonadotropins|clomiphene plus gonadotropins
3095720|NCT01921166|Active Comparator|Leuprolide flare|Leuprolide flare
3095721|NCT01921153|Experimental|Short Intervention|All participants will be measured for (1) baseline, (2) two-week environmental intervention: Healthy meal plates and trays, and (3) withdraw of intervention.
3095722|NCT01921153|Experimental|Long Intervention|All participants will be measured for (1) baseline, (2) four-week environmental intervention: Healthy meal plates and trays, and (3) withdraw of intervention.
3095723|NCT01921140|Other|Fasted|Olaparib tablets following no breakfast
3095724|NCT01921140|Other|High-fat meal|Olaparib tablets after high-fat breakfast
3095725|NCT01921127||Symbicort|BFC patients new to ICS/LABA therapies
3095726|NCT01921127||Advair|FSC patients new to ICS/LABA therapies.
3095727|NCT01921114|Active Comparator|BioFlo™ PICC|BioFlo™ Peripherally Inserted Central Catheter (PICC)
3095728|NCT01921114|Active Comparator|Bard® PowerPICC SOLO2®|Bard® Dual-Lumen PowerPICC SOLO2®
3095729|NCT01921101|Other|intensive medical nutrition|participants will receive intensive medical nutrition from hospital admission to discharge
3095730|NCT01921101|Other|control|participants will not receive intensive nutritional support from hospital admission to discharge
3095731|NCT01921088|Experimental|Contingent|Contingent RT-fMRI-NF of brain activity in the target region of interest
3095732|NCT01921088|Sham Comparator|Non-contingent|Sham RT-fMRI-NF of brain activity of previously recorded subject
3095733|NCT01921075||Volunteers|young (age<30), healthy, lean (BMI<25) volunteers
3095734|NCT01921062|No Intervention|Control|Patients allocated to the control group only receive standard treatment.
3095735|NCT01921062|Experimental|Motor imagery|Patients allocated to this arm perform kinesthetic motor imagery during the immobilisation period.
3095736|NCT01921036|Experimental|combined exercise|90 minutes combined endurance and resistance exercise once a week plus 90 minutes traditional cardiac rehabilitation once a week over six months
3095737|NCT01921036|Active Comparator|traditional cardiac rehabilitation|The group-based program is offered for 90 minutes twice a week and is a combination of gymnastics, coordination and flexibility exercises, and includes educational components targeting diet and nutrition, stress and relaxation, methods for coping with CVD and behavioral and lifestyle change.
3095738|NCT01921010|Active Comparator|Niaspan|Patients will be randomized to Niaspan 1.5 g/d in addition to usual care statin lipid lowering agents. The dose of Niaspan will be titrated over a 4-week period and then patients will remain on study drug for additional 12 weeks. The dose of statin will be adjusted in a blinded fashion in both groups at week 10 to similarly achieve a LDL-C of less than 100mg/dl.
3095739|NCT01921010|Placebo Comparator|Control|patients will be randomized to placebo 1.5 g/d in addition to usual care statin lipid lowering agents. The dose of placebo will be titrated over a 4-week period and then patients will remain on study drug for additional 12 weeks. The dose of statin will be adjusted in a blinded fashion in both groups at week 10 to similarly achieve a LDL-C of less than 100mg/dl.
3095740|NCT01920997||No drug intervention|The objective of this study is to investigate the expression of NEI network and urine metabolomics of healthy women with normal menstrual cycles.
3095741|NCT01920984|Experimental|pretreatment of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy due to diabetic retinopathy.
3095742|NCT01920984|No Intervention|No pretreatment of bevacizumab|Patients will not receive bevacizumab pretreatment before vitreous surgery.
3095743|NCT01920971|Active Comparator|inferared therapy|hot pack therapy combined active infrared therapy over the low back (wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2) followed by 20-min supervised therapeutic exercise, for 3 times per week for a 4-week duration. Patients will be assessed at before treatment and follow-up assessments, including after 2 week of treatment; after 4 weeks of treatment; and 1 and 3 months, respectively, after treatment is terminated.
3095744|NCT01920971|Placebo Comparator|placebo infrared therapy|hot pack therapy combined placebo infrared therapy over the low back (wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2) followed by 20-min supervised therapeutic exercise, for 3 times per week for a 4-week duration. Patients will be assessed at before treatment and follow-up assessments, including after 2 week of treatment; after 4 weeks of treatment; and 1 and 3 months, respectively, after treatment is terminated.
3095745|NCT01920958||TachoSil®|TachoSil®, sterile absorbable patch, topical application, used during surgery in participants who had lymphadenectomy according to the Summary of Product Characteristics.
3095746|NCT01920945|Experimental|OnabotulinumtoxinA|
3095747|NCT01920932|Experimental|Treatment|Participants receive AEPA regimen (brentuximab vedotin, etoposide, prednisone, doxorubicin), and CAPDac regimen (cyclophosphamide, brentuximab vedotin, prednisone, dacarbazine(R)). Filgrastim may be given as clinically indicated. For those with lymph nodes that do not go into remission after 2 courses of AEPA chemotherapy, radiation therapy will be given. Some participants may volunteer to complete the quality of life assessment.
3095748|NCT01920919|Experimental|Dexamethasone 1 mg|Dexamethasone 1 mg per day, for 180 days
3095749|NCT01920919|Placebo Comparator|Placebo|Placebo tablet, for 180 days
3095750|NCT01920906|Experimental|Biopsy and blood tests|All subjects will undergo a skin biopsy and blood tests
3096096|NCT01918605|Active Comparator|Non-diluted spacer|Single dose of DuraSeal product injected between rectum and prostate
3096097|NCT01918592|Experimental|MRI/PET|
3095752|NCT01920893|Experimental|Dupilumab 300 mg QW|Dupilumab, 2 Subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection QW from Week 1 to 15 added to MFNS.
3095753|NCT01920880||ACNES patients|Patients being treated in past for anterior cutaneous nerve entrapment syndrome
3095754|NCT01920880||Healthy controls|Healthy controls
3095755|NCT01920867|Active Comparator|RB, ST, IV|Injections of BMSC retrobulbar (RB), subtenon (ST) and intravenous (IV)
3095756|NCT01920867|Active Comparator|RB, ST, IV, IVIT|Injections of BMSC retrobulbar, subtenon, intravenous and intravitreal ( IVIT )
3095757|NCT01920867|Active Comparator|RB, ST, IV, IO|Injection of BMSC retrobulbar, subtenon, intravenous and intraocular (IO) with vitrectomy
3095758|NCT01920854|Experimental|Soluble Ferric Pyrophosphate|Group/Cohort Designation: Ascending doses of SFP. Each subject will receive a defined dose of SFP IV administered under double-blind conditions. Pharmacokinetics of iron will be measured using a validated assay for iron and transferrin bound iron.
3095759|NCT01920854|Placebo Comparator|Control|Group/Cohort Designation: Each subject will receive placebo IV administered under double-blind conditions.
3095760|NCT01920841|Experimental|Left (A), Right (B)|Cream A applied to left thigh and Cream B to right thigh
3095761|NCT01920841|Experimental|Left (B) Right (A)|Cream B applied to left thigh and Cream A to right thigh
3095762|NCT01920815||Beta blocker therapy|Cohort will consist of those actively taking any beta blocker medication. Observation only.
3095763|NCT01920815||ARB therapy|Cohort will consist of those actively taking any angiotensin receptor blocker medication. Observation only.
3095764|NCT01920815||No therapy|Cohort will consist of those not taking either beta blocker nor angiotensin receptor blocker. Observation only.
3095765|NCT01920802|Experimental|olanzapine|5mg BID olanzapine for up to 4 weeks
3095766|NCT01920802|Experimental|iloperidone|6mg BID iloperidone up to 4 weeks
3095767|NCT01920802|Placebo Comparator|placebo|BID placebo up to 4 weeks
3095768|NCT01920789|Experimental|Stereotactic radiotherapy|Arm A: Stereotactic radiotherapy to a dose of 66 Gy at the isocenter with 22 Gy per fraction in 3 fractions during one week with body frame fixation and a planning target volume with a 5 mm margin around the macroscopic tumour. A heterogeneous dose distribution is used so 45 Gy will cover the PTV.
3095769|NCT01920789|Active Comparator|Conventionally fractionated radiotherapy|Arm B: Conventionally fractionated radiotherapy to a dose of 70 Gy with 2 Gy per fraction in 35 fractions during 7 weeks with fixation in a vacuum pillow and a planning target volume with a 2 cm margin around the macroscopic tumour.
3095770|NCT01920776|Experimental|Rutine treatment group, Ultrasound group|
3095771|NCT01920763||Surgical Patients|Patients with intracerebral hemorrhage who have been offered a parafascicular, minimally-invasive procedure for hematoma drainage, by the treating neurosurgeon.
3095772|NCT01920750|Experimental|Group 2|5 subjects will receive d single 0.1 ml intracutaneous injections of 3 titrated doses (1, 10, and 25 grams/ml) of MLCwA and one of mock antigen equally in two arms
3095773|NCT01920750|Experimental|Group 1|5 subjects received single 0.1 ml intracutaneous injections of 3 titrated doses (1, 10, and 25 grams/ml) of MLSA-LAM and one of mock antigen equally in two arms
3095774|NCT01920737|Experimental|Leukemia Patients|"The treatment plan has 6 treatment cycles. The cycle names are listed in the following order:~Induction Phase I - Induction Phase II - Intensification I - Re-induction I - Intensification II - Re-induction II Each cycle is given over a period of 4-6 weeks and the interval between them can range between 1-3 weeks. Based the patients medical condition, the doctor may decide to change the timing of the drugs, the interval between the drugs in a cycle, or the interval between the cycles. After receiving all cycles you will continue with a 36 months treatment part that is called Maintenance."
3095775|NCT01920724||wasting, obesity, stunting, normal|wasting (BMI for age Z-scores < -2 SD), normal (-1 SD ≤ BMI for age Z-scores ≤ +1 SD), obesity (BMI for age Z-scores > +2 SD), and stunting (HAZ < -2 SD).
3095776|NCT01920711|Experimental|LCZ696|Single Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of LCZ696 during the double blind period is 200 mg b.i.d.
3095777|NCT01920711|Active Comparator|Valsartan|Single Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of Valsartan during the double blind period is 160 mg b.i.d.
3095778|NCT01920698|Experimental|MitraClip Device|Subjects randomized to the MitraClip Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.
3095779|NCT01920698|Other|Control|Patients randomized to the Control group will receive optimal therapy alone
3095780|NCT01920685|Experimental|Immediate therapy|6 sessions of talking therapy, targeting anxiety processes associated with paranoia, will be delivered for a period of 8 weeks immediately after randomisation.
3095781|NCT01920685|Other|Delayed intervention|Therapy will be delayed until 12 weeks following randomisation, and then 6 sessions of talking therapy, targeting anxiety processes associated with paranoia, will be delivered over a period of 8 weeks.
3095782|NCT01920672|Experimental|Timed Planned Activity (TPA)|The TPA provides meaningful activities delivered at specific times in the daily diurnal cycle; it is theory-based, its components have been tested in pilot work; and it is portable and replicable (e..g, protocols are standardized). It involves involved 8 contacts (6 home visits and 2 phone calls) over 4 days. At baseline the CG completes the Pleasant Event Activity Survey. From the survey a careplan of meaningful activities are developed for the CG to administer. The suggested activities match the capabilities of an individual with moderate stage AD ie., based on repetitive motion (e.g., folding towels) and integrating multi-sensory stimulation (e.g., soft music, objects pleasant to touch). CG are instructed to introduce these activities during the late morning and early evening.
3095813|NCT01920477|Placebo Comparator|Placebo|Subject will receive subcutaneous administration of matching placebo of ofatumumab once every 4 weeks through Week 56, with an additional dose at both Week 0 and Week 4.
3096098|NCT01918579|Experimental|CRP intervention|Patients will be tested by rapid POC CRP test
3095783|NCT01920672|Active Comparator|Home Safety and Education Program|The active comparator intervention will be delivered by interventionists who will provide social attention, empathy and engagement similar to that afforded to the experimental group. The length of time spent will be comparable to the length of time spent in the treatment arm. The attention-control group will involve 6 in-home visits in the afternoon and 2 brief telephone education sessions in the morning. Control group subjects will be provided a copy of Mace and Rabins, The 36-Hour Day, a well-known practical guidebook for families caring for AD patients. Each contact will provide helpful education based on a specific book chapter including information about home safety, health promotion, and advanced care planning
3095784|NCT01920659|Experimental|High Intensity Training (HIT)|6 weeks of HIT, 3 times a week (3-5 1min on/off)
3095785|NCT01920659|Experimental|REHIT|6 weeks of HIT, 3 times a week (20sec)
3095786|NCT01920659|No Intervention|control|control
3095787|NCT01920646|Experimental|ALV|"300 gram cooked African leafy vegetables and school meal starch as daily school meal (5 days/weeks) for 3 months.~Selected African leafy vegetables:Amaranthus cruentus (amaranth), Vigna unguiculata (cowpea), Cleome gynandra (spiderplant), and Cucurbita maxima (pumpkin)."
3095788|NCT01920646|No Intervention|Control|normal school meal as daily meal (5 days/weeks) for 3 months
3095789|NCT01920633||People with Down syndrome|
3095790|NCT01920620|Experimental|Intervention Arm|Inpatient weight loss counseling Motivational interviewing and troubleshooting via phone
3095791|NCT01920620|No Intervention|Usual Care Arm|Participants in the usual care group were not provided with any specific instructions regarding weight loss, diet or exercise prior to discharge. Follow-up phone calls for usual care subject were used only to obtain weight and assess for changes in medications or health condition.
3095792|NCT01920607|Active Comparator|NMS|Implantation under general of local anesthesia of sacral nerve stimulation system (Interstim Therapy)
3095793|NCT01920607|Experimental|SAM|Implantation under general anesthesia of magnetic anal sphincter (Fenix)
3095794|NCT01920594|Experimental|GSK1278863|Subject will receive GSK1278863 300mg on Day-1 (12 +/- 4 hours prior to planned surgery) as a loading dose followed by GSK1278863 100mg once daily for 4 days starting from Day 0.
3095795|NCT01920594|Placebo Comparator|Placebo|Subject will receive GSK1278863 matching placebo on Day-1 (12 +/- 4 hours prior to planned surgery) as a loading dose followed by GSK1278863 matching placebo once daily for 4 days starting from Day 0.
3095796|NCT01920581||volunteers|
3095797|NCT01920568|Experimental|Denosumab 120 mg|Subjects will be administered with Denosumab 120 mg subcutaneous (SC) injection for a maximum of 13 doses and placebo IV infusion over &gt;=15 minutes once every 4 weeks.
3095798|NCT01920568|Experimental|Zoledronic acid 4 mg|Subjects will be administered with Zoledronic acid 4 mg IV infusion over a minimum of 15 minutes for a maximum of 13 doses and placebo SC once every 4 weeks.
3095799|NCT01920555|Active Comparator|Ketamine 0.1mg|Patients in this arm will receive 0.1 mg/kg of Ketamine - one single infusion
3095800|NCT01920555|Active Comparator|Ketamine 0.2mg|Patients in this arm will receive 0.2 mg/kg of Ketamine - one single infusion
3095801|NCT01920555|Active Comparator|Ketamine 0.5mg|Patients in this arm will receive 0.5 mg/kg of Ketamine - one single infusion
3095802|NCT01920555|Active Comparator|Ketamine 1.0mg|Patients in this arm will receive 1.0 mg/kg of Ketamine - one single infusion
3095803|NCT01920555|Placebo Comparator|Midazolam (Active Placebo)|Patients in this arm will receive 0.045 mg/kg of midazolam - one single infusion
3095804|NCT01920542|Experimental|no dexmedetomidine|no administration of dexmedetomidine
3095805|NCT01920542|Active Comparator|dexmedetomidine|administration of 0.5ug/kg dexmedetomidine for 10 min and infusion of 0.5ug/kg/h of dexmedetomidine until weaning of cardiopulmonary bypass
3095806|NCT01920529|Experimental|aerobic exercise|The study will consist of two groups: Group Comparison (GC) will be submitted to two evaluations at the beginning of a week and end of 6 weeks, without receiving any kind of physical training intervention. Group Training (GT) will undergo two assessments at the beginning of the end of the 1st and 6th week, however will be submitted to aerobic training for six weeks. Supervised aerobic training will be held three times a week for six weeks,treadmill in four consecutive steps each (05 minutes stretching, 05 minutes heating, 20 training minutes (1 st and 2 nd week) and 30 minutes (3 rd to 6 weeks) and cool down 05 minutes). The exercise intensity will be maintained through a desired percentage of heart rate for training (x%) from 70% to 80%, obtaining then the optimal heart rate training.
3095807|NCT01920529|Placebo Comparator|control|Investigators evaluated the distance walked during the 6-minute walk test and recorded variables such as heart rate, respiratory frequency, pulse oxygen saturation and a scale of perceived exertion (Borg) in the moments before and after the test. There was only evaluation without intervention.
3095808|NCT01920516||Melphalan|"Day +1:~Intra femoral infusion of Melphalan at the dosage 1mg/ Kg~Intra femoral infusion of Melphalan Second ILI treatment can be repeated at side effects recovery ( following oncologist ' s planning of cure).~Day +30: The above procedure is repeated.~Day +90: In case of response, a third administration following the above procedures will be repeated."
3095809|NCT01920503||doxorubicin|"Day +1:~Lobar Infusion ( lobe with dominant disease) of Doxorubicin preloaded into 2 ml of 70-150 µm M1 microspheres.~Second lobar infusion of Doxorubicin preloaded into 2 ml of 70-150 µm M1 microspheres can be administered at the same time contralaterally or in a further TACE Day +30: The above procedure is repeated. Day +90: In case of response, a third administration following the above procedures will be repeated"
3095810|NCT01920490|Experimental|GUILT-INCREASE-CORRELATION|Patients in this group will receive visual feedback that reinforces increasing the correlation in fMRI signal between the right superior anterior temporal and septal-subgenual regions during the retrieval of predefined guilt-related autobiographical episodes. During the indignation condition, visual feedback will reinforce stabilization of the preceding degree of correlation.
3095811|NCT01920490|Active Comparator|GUILT-STABILIZE-CORRELATION|Patients in this group will receive visual feedback that reinforces stabilization of the preceding degree of correlation in fMRI signal between the right superior anterior temporal and septal-subgenual regions during the retrieval of predefined guilt-related autobiographical episodes. During the indignation condition, visual feedback will also reinforce stabilization of the preceding degree of correlation.
3095812|NCT01920477|Experimental|Ofatumumab|Subject will receive subcutaneous administration of ofatumumab 20 mg once every 4 weeks through Week 56, with an additional 20 mg dose (that is 40mg total) at both Week 0 and Week 4.
3095814|NCT01920451|Experimental|Cognitive-Behavioral Therapy for Insomnia|Cognitive-Behavioral Therapy for Insomnia (CBTI) consists of an an individually-tailored sleep prescription intended to consolidate fragmented sleep; guidance on changing learned associations that are harmful to sleep using stimulus control theory; education on standard sleep hygiene and to correct unrealistic sleep expectations; and the identification and restructuring of maladaptive thoughts and beliefs about sleep.
3095815|NCT01920451|No Intervention|Wait List|Study participants who are randomized to the wait-list condition will not receive the intervention as part of this study protocol. They will, however, be offered the opportunity to receive CBTI at the end of their participation in this study. Wait-list participants will not be restricted in terms of additional therapies/treatments which they may seek for their sleep complaint.
3095816|NCT01920438|Experimental|PEG|Percutaneous Endoscopic Gastrostomy
3095817|NCT01920438|Experimental|RIG|Radiologically-guided Insertion of Gastrostomy
3095818|NCT01920425|Other|Hand-written diary first|Participants in this group will use the hand-written diary for the first two week and switch to Kinesia HomeView and the electronic diary for the second two weeks.
3095819|NCT01920425|Other|Kinesia HomeView first|Participants in this group will use Kinesia HomeView and the electronic diary for the first two week and switch to the hand-written diary for the second two weeks.
3095820|NCT01920412|Experimental|Left Atrial Appendage Occluder|Adopted non-comparative arm on Left Atrial Appendage Occluder.
3095821|NCT01920399|Placebo Comparator|Placebo|IV infusions of 0.9% normal saline
3095822|NCT01920399|Experimental|CAZ-AVI|IV infusion of AVI 500 mg + CAZ 2000 mg.
3095823|NCT01920386|Active Comparator|Tramadol hydrochloride/Acetaminophen Tab.|1tab PO within 5hours from teeth extraction
3095824|NCT01920386|Experimental|Tramadol hydrochloride/Acetaminophen SR Tab.|1tab PO within 5hours from teeth extraction and then 1tab more after 6hours
3095825|NCT01920373|Active Comparator|Group A (corticosteroid injection group)|Group A will receive one intra-articular injection of 2 ml of solution containing 1ml of 10mg/ml Triamcinolone suspended in 1 ml of 0.5% Bupivacaine solution per affected joint
3095826|NCT01920373|Experimental|Group B (platelet rich plasma injection)|Group B will receive a 2 ml intra-articular injection of a platelet rich plasma preparation per affected joint
3095827|NCT01920360|Experimental|SULPHUROUS WATERS IMMERSION BATHS|The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
3095828|NCT01920360|Experimental|NOT SULPHUROUS WATERS IMMERSION BATHS|The baths will be held in individual tubs, properly disinfected, supplied with not sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
3095829|NCT01920360|Experimental|CONTROL GROUP|This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
3095830|NCT01920347||Neurological Pupil index|The NPi will be measured during treatment
3095831|NCT01920334|Experimental|Zolpidem CR 12.5mg|Patients receive zolpidem CR 12.5mg at bedtime from the first night on the Cardiac Intensive Care Unit until their discharge from the hospital
3095832|NCT01920334|Placebo Comparator|Placebo|Patients receive placebo at bedtime from the first night on the Cardiac Intensive Care Unit until their discharge from the hospital
3095833|NCT01920321|Experimental|Endoscopic lung volume reduction|After usual sedation, bronchoscope is introduce to the lung and palced in segmental wedge position then hot salineis instilled. Same procedure to others affected segments.
3095834|NCT01920308||5 mm Bard LifeStent Vascular Stent|"The study population will be comprised of subjects who present with moderate lifestyle-limiting claudication to mild tissue loss (Rutherford Category 2-5) that are candidates for PTA and stenting.~Subjects with lesion(s) in the infra-inguinal segment (SFA and/or popliteal artery) will be considered for enrollment. The reference vessel diameter will be appropriate for treatment with available stent diameter of 5.0 mm (by visual estimate)."
3095835|NCT01920295|Experimental|Cryoballoon ablation|Cryoballoon ablation
3095836|NCT01920295|Active Comparator|Cryoballoon after medical therapy|Cryoballoon ablation
3095837|NCT01920295|Experimental|Cryoballoon as first-line therapy|Cryoballoon ablation
3095838|NCT01920295|Active Comparator|Cryoballoon after failed drug therapy|Cryoballoon ablation
3095839|NCT01920282|Active Comparator|Nebivolol|Subjects will be provided with daily 5 mg of nebivolol for the first 2 weeks. Subjects receive additional daily doses of 10 mg nebivolol for the remainder of the study period. The dose remains at 5 mg per day, however, if BP falls below 110/70 during the first 2 weeks. Subjects will continue taking the drug during the 2-week follow-up period.
3095840|NCT01920282|Active Comparator|Lifestyle Modification|Subjects will receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals were instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 minutes per week of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conformed to the Dietary Approach to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contained 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein. Sodium consumption was set at 2,400 mg/day for all subjects.
3095841|NCT01920282|Experimental|Nebivolol plus Lifestyle Modification|Subjects begin with 5 mg/day of nebivolol and increase to 10 mg/day if brachial blood pressure is greater than 120/80 mmHg during the first 2 weeks of therapy. Subjects also receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals will be instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 min/wk of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conforms to the Dietary Approaches to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contains 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein with sodium consumption set at 2,400 mg/day for all subjects.
3117389|NCT01772251|Experimental|Oshadi Icp & placebo|
3095842|NCT01920269|Active Comparator|Transurethral resection alone|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra—ie, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Response to treatment will be assessed with cystoscopy, biopsy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
3095843|NCT01920269|Active Comparator|Intravesical passive diffusion mitomycin|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Patients are scheduled to receive an initial 6 intravesical mitomycin treatments at weekly intervals commencing 2 weeks after endoscopic procedures. Patients are placed on fluid restriction and oral sodium bicarbonate before intravesical mitomycin treatments. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations. Response to treatment will be assessed with cystoscopy, biopsy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
3095844|NCT01920269|Active Comparator|Intravesical electromotive mitomycin|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Patients are scheduled to receive an initial 6 intravesical mitomycin treatments at weekly intervals commencing 2 weeks after endoscopic procedures. Patients are placed on fluid restriction and oral sodium bicarbonate before intravesical mitomycin. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations. Response to treatment will be assessed with cystoscopy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
3095845|NCT01920256|Experimental|Personalized type 2 diabetes care.|Remote, personalized type 2 diabetes clinic provided by an endocrinologist using frequent remote contacts for medication adjustments.
3095846|NCT01920256|Active Comparator|Usual Endocrine Care|Usual Endocrine care will be provided by an endocrinologist.
3095847|NCT01920243|Experimental|Health Mechanics- New Injuries|The Health Mechanics Program group receives the intervention. For this study, the Health Mechanics protocol is being applied to two areas of SCI management, bladder and bowel management, and administered over the telephone. The intervention will be administered as a series of modules delivered by a Health Coach (a health professional who works within the study team and is knowledgeable about SCI management). Individuals with new-onset traumatic spinal cord injuries are eligible for this group.
3095848|NCT01920243|No Intervention|Usual Care- New Injuries|This group will not receive the intervention. They will receive usual care. This group will be comprised of individuals with new-onset traumatic spinal cord injuries.
3095849|NCT01920243|Experimental|Health Mechanics- Chronic Injuries|The Health Mechanics Program group receives the intervention. For this study, the Health Mechanics protocol is being applied to two areas of SCI management, bladder and bowel management, and administered over the telephone. The intervention will be administered as a series of modules delivered by a Health Coach (a health professional who works within the study team and is knowledgeable about SCI management). Individuals who have had traumatic spinal cord injuries for at least one year are eligible for this group.
3095850|NCT01920243|No Intervention|Usual Care- Chronics|This group will not receive the intervention. They will receive usual care. This group will be comprised of individuals with who have had traumatic spinal cord injuries for at least one year.
3095851|NCT01920230|Experimental|Mindfulness-ACT-intervention|Group meetings face-to-face and web-based program using principles of mindfulness and ACT.
3095852|NCT01920230|Experimental|Control|Control group, no intervention.
3095853|NCT01920217||normal control|
3095854|NCT01920217||Sepsis group|
3095855|NCT01920204|Experimental|Midostaurin|Treatment with Midostaurin, twice daily 100 mg orally for 6 months continuously.
3095856|NCT01920191|Experimental|IMA 950 and Poly ICLC|
3095857|NCT01920178|Active Comparator|PinPointe Foot Laser|Active laser
3095858|NCT01920178|Sham Comparator|Sham laser group|Treatment with only localizing (aiming) beam of Pinpointe Foot Laser
3095859|NCT01920165||Full cohort|The population at risk for each time point is the number of children living in England aged 0-14 year
3095860|NCT01920152|Experimental|Autologous PRP Hip Injection|Patients (n=40) randomized to this group of treatment will receive 3 blinded hip intra-articular injections of autologous Platelet-Rich Plasma one week apart from each other.
3095861|NCT01920152|Active Comparator|Hyaluronic Acid Hip Injection|Patients (n=40) randomized to this group of treatment will receive 3 blinded hip intra-articular injections of hyaluronic acid (SUPARTZ hyaluronate/2.5ml) one week apart each other.
3095862|NCT01920139|Other|Breast cancer and Axillary Adenopathy|Women with breast cancer with abnormal appearing ipsilateral axillary nodes undergoing fine needle aspiration and core biopsy of a lymph node.
3095863|NCT01920126|Experimental|Sodium bicarbonate group|Sodium bicarbonate group
3095864|NCT01920126|Placebo Comparator|Saline group|Saline group
3095865|NCT01920113|Experimental|DR group|In Group DR, a bolus dose of 0.5mcg/kg dexmedetomidine was injected intravenously 5 minutes before the start of the procedure (Precedex®, Abbott, Istanbul, Turkey). And a continuous infusion dose of 0.3-0.7mcg/hr/kg was started.
3095866|NCT01920113|Active Comparator|PR group|In Group PR, a bolus injection of 1 mg/kg of propofol was followed by a continuous infusion at a rate of 3-5mg/hr/kg(Pofol®, Dongkook Pharm. Co. Ltd., Seoul, Korea) using an infusion pump (Syringe Pump TE-331, Terumo Japan).
3095867|NCT01920100||Memory clinic|People visiting a memory clinic at Ullevål University Hospital, St Olav Hospital or Innlandet Hospital Trust (n=400). The patients will be assessed three times over a three-year follow-up. Baseline inclusion started in January 2010. The final assessments will take place in spring 2014.
3095868|NCT01920100||Nursing homes|People admitted to a nursing home recruited from municipalities in Hedmark, Oppland, Nord-Trøndelag and Bergen (n=1000). Baseline assessments take place when the person is admitted to the nursing home. The patients will be assessed every six months over a three-year follow-up period. The first participant was included in March 2012, and baseline inclusion will be completed in December 2013.
3096002|NCT01919190|Active Comparator|EXPAREL|EXPAREL (266mg/20 ml) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP
3095869|NCT01920100||In-home care|People 70 years of age or older receiving in-home care recruited from municipalities in Hedmark, Oppland, Oslo, Østfold and Buskerud (n=995). The patients will be assessed three times over a three-year follow-up period. Baseline inclusion started in April 2009 and the final assessments will take place in December 2013.
3095870|NCT01920100||People without dementia|"People without dementia recruited from Nord-Trøndelag, Drammen and Oslo (n=400).~The participants will be assessed three times over a three-year follow-up period. Baseline inclusion will take place in autumn 2012 and the last follow-up will take place in autumn 2015."
3095871|NCT01920087|Experimental|ATNC05|Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.
3095872|NCT01920087|Placebo Comparator|Placebo|Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.
3095873|NCT01920074|Experimental|Rectiv|
3095874|NCT01920061|Experimental|Arm A|
3095875|NCT01920061|Experimental|Arm B|
3095876|NCT01920061|Experimental|Arm C|
3095877|NCT01920061|Experimental|Expansion Arm 1|
3095878|NCT01920061|Experimental|Expansion Arm 2|
3095879|NCT01920048|Experimental|Percutaneous Coronary Intervention and Optimal Medical Therapy|
3095880|NCT01920048|Active Comparator|Optimal Medical Therapy alone|
3095881|NCT01920035|Experimental|Local cooling/hypothermia|These patients will have the UroCool device inserted prior to RARP to induce localized cooling/hypothermia of the pelvic region prior to and during RARP surgery.
3095882|NCT01920035|No Intervention|Control Group: RARP without hypothermia|These patients will receive standard of care only for RARP surgery. They will not receive the UroCool investigational device.
3095883|NCT01920022|Experimental|Etonorgestrel and mifepristone|Quickstart, insertion of Nexplanon on the day of mifepristone in medical abortion
3095884|NCT01920022|Active Comparator|mifepristone|Mifepristone on day 1. Nexplanon insertion at 3 weeks FU after the medical abortion
3095885|NCT01920009|Active Comparator|Pharmacy care group|patients in this group will receive two counseling sessions with a motivational interview.
3095886|NCT01920009|No Intervention|Controlgroup|patients in this group will receive usual care by pharmacists
3095887|NCT01919996|Experimental|Azithromycin|Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
3095888|NCT01919983||Primary Prevention of Sudden Cardiac Death|No intervention will be administered. This is an observational study testing the association of inflammation and cardiac sympathetic innervation using I-123-MIBG gamma scintigraphy
3095889|NCT01919970|Experimental|Cognitive Behavioral Therapy Condition|This arm is the experimental condition; it consists of 12 weekly CBT sessions. The therapy protocol will begin with an introductory education session which will include development of a fear hierarchy, followed by 11 sessions of in vivo exposures to feared triggers.
3095890|NCT01919970|Active Comparator|Treatment as Usual|This arm acts as the comparison condition. Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
3095891|NCT01919957|No Intervention|memory outcome|
3095892|NCT01919944|Experimental|VLY-686 20 mg|Single dose, 20 mg VLY-686, administered as two 10 mg VLY-686 oral capsules
3095893|NCT01919944|Experimental|VLY-686 50 mg|Single dose, 50 mg VLY-686, administered as one 50 mg VLY-686 oral capsule and one placebo capsule mimicking the VLY-686 50 mg capsule
3095894|NCT01919944|Experimental|VLY-686 100 mg|Single dose, 100 mg VLY-686, administered as two 50 mg VLY-686 oral capsules
3095895|NCT01919944|Placebo Comparator|Placebo|Single dose, placebo, administered as either two 10 mg oral capsules or two 50 mg oral capsules
3095896|NCT01919931||Candida Infection|Patients infected with Candida albicans
3095897|NCT01919931||No infection|Patients with no Candida albicans infection
3095898|NCT01919918|Other|Heart Failure Patients|Patients with heart failure will undergo intervention of muscle contraction with metabolite solution administration. Maximal voluntary muscle contraction exercise with varying metabolite solution administration of adenosine triphosphate, lactate, and protons with phosphate buffer.
3095899|NCT01919918|Other|Control Participants|Healthy control participants will undergo intervention of muscle contraction with metabolite solution administration. Maximal voluntary muscle contraction exercise with varying metabolite solution administration of adenosine triphosphate, lactate, and protons with phosphate buffer.
3095900|NCT01919905|Active Comparator|High dose|High dose vitamin D group receiving Mozzarella cheese/pizza with 28000 IU vitD/serving once a week
3095901|NCT01919905|Placebo Comparator|Low dose|Low dose vitamin D group receiving Mozzarella cheese/pizza with 200 IU vitD/serving once a week
3095902|NCT01919892|Experimental|Lithium 450-900mg/day|An Open-Label, 6-week Pilot Study of Flexible Dose of Lithium in Bipolar Depression: The Effectiveness of Lower Lithium Levels
3095903|NCT01919879|Experimental|Arm A: Cetuximab + Afatinib|Afatinib 40 mg daily Cetuximab 500 mg/m2 every 2 weeks until progression
3095904|NCT01919879|Active Comparator|Arm B : Cetuximab alone|Cetuximab 500mg/m2 every 2 weeks until progression After progression: Cetuximab 500mg/m2 + Afatinib 40 mg per day until progression
3095905|NCT01919866|Experimental|Transplantation of CD3/CD19 depleted stem cells|Patients receive a minimum dosage of 10x10E6/kg bodyweight CD3/CD19 depleted CD34+ stem cells. Maximum dosage of residual T cells will be 1x10E5/kg BW
3095906|NCT01919853|Experimental|Mindfulness-Based Stress Reduction|The MBSR intervention is an 8-week course meeting 2 hours weekly. The curriculum is based on MBSR manuals with a brief CRF education component incorporated into the first and second class sessions, drawing from information from the National Comprehensive Cancer Network clinical practice guidelines for CRF. In general, the MBSR class includes guided meditation practice; mindful, gentle movement (hatha yoga); didactic material on self-regulatory responses to stress; and group discussion that includes the participants' growing incorporation of mindfulness in adapting to life experiences. Along with class time, each participant is asked to commit 20 minutes per day, six days per week to formal meditation practice using compact disk recordings of the teacher's voice.
3095907|NCT01919853|Active Comparator|Attention Control|"The attention control is an 8-week class meeting 2 hours weekly. The group sessions are supportive in tone, focus on pre-designated topics relevant to fatigue management (e.g., sleep hygiene, nutrition, exercise, emotional regulation), and involve weekly readings and open group discussion about session topics. This condition contains non-specific factors similar to MBSR (e.g., facilitator offering participants compassionate attention, empathy, genuine caring, and an opportunity to discuss what is important to them in a supportive environment); however, mindfulness is not presented/practiced in the group."
3095908|NCT01919840|Active Comparator|Group C|• conventional protocol, volume replacement with massive bleeding.
3095909|NCT01919840|Experimental|Group ROTEM|• Protocol according to the different tests to be performed with thromboelastography
3095910|NCT01919827|Experimental|MSC endobronchial infusion|
3095911|NCT01919814|Active Comparator|Appethyl™|Appethyl™ liquid once four hours after breakfast.
3095912|NCT01919814|Placebo Comparator|Placebo|Non-active
3095913|NCT01919801|Experimental|Icatibant|Icatibant at a dose of 30 mg will be administered as a single subcutaneous injection
3095914|NCT01919801|Placebo Comparator|Placebo|Placebo will be administered as a single subcutaneous injection
3095915|NCT01919788|Placebo Comparator|Control|"No insulin administered. Instead of insulin infusion, a small amount of saline is administered to keep the subject blinded.~Three muscle biopsies and two fat biopsies will be obtained. A palmitic acid tracer will be given to estimate fatty acid metabolism. Forearm pletysmography will be performed twice."
3095916|NCT01919788|Experimental|Insulin|Insulin (Insuman Rapid) is administered once as a bolus of 0,1 IU/kg. Three muscle biopsies and two fat biopsies will be obtained. A palmitic acid tracer will be given to estimate fatty acid metabolism Forearm pletysmography will be performed twice
3095917|NCT01919788|Experimental|Insulin and glucose|"Insulin (Insuman rapid) is administered once as a bolus injection of 0,1 IU/kg and glucose is given at the same time to avoid hypoglycemia in this arm.~Three muscle biopsies and to fat biopsies is obtained. A palmitic acid tracer is given to estimate fatty acid metabolism Forearm pletysmography will be performed twice"
3095918|NCT01919762||Bacteremia Positive Patients|"Symptomatic adult patients, confirmed via diagnostic blood culture and species identification followed by subsequent second blood culture results and species identification that are positive for each of the following species of bacteria (Target 6 Species).~Acinetobacter baumannii~Staphylococcus aureus~Klebsiella pneumonia~Pseudomonas aeruginosa~Enterococcus faecalis~Enterococcus faecium"
3095919|NCT01919762||Bacteremia Negative Patients|Adult patients confirmed via diagnostic blood culture and species identification and subsequent second blood culture and species identification as being negative for the Target 6 species
3095920|NCT01919749|Other|treatment|recommended treatment
3095921|NCT01919736|Active Comparator|Moderate gait retraining|a moderate 7 degree toe-in modification
3095922|NCT01919736|Active Comparator|Mild gait retraining|A 2 degree toe-in gait retraining
3095923|NCT01919723|Active Comparator|Ticagrelor and Eptifibatide bolus|Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)
3095924|NCT01919723|Active Comparator|Ticagrelor & Eptifibatide bolus+infusion|Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)
3095925|NCT01919710|Experimental|rHSA/GCSF for injection|rHSA/GCSF Start from 300mcg
3095926|NCT01919697|Experimental|Plecanatide 3.0 mg|Plecanatide 3.0 mg, one tablet by mouth daily for 52 weeks
3095927|NCT01919697|Experimental|Plecanatide 6.0 mg|Plecanatide 6.0 mg, one tablet by mouth daily for 52 weeks
3095928|NCT01919684|Active Comparator|Active|LGD-6972
3095929|NCT01919684|Placebo Comparator|Placebo (Captisol®)|Vehicle Control (Captisol®)
3095930|NCT01919671|Experimental|Tongxinluo capsule|Tongxinluo capsule,4 granules,t.i.d. po,for 90 days
3095931|NCT01919671|Placebo Comparator|placebo capsule|placebo capsule,4 granules,t.i.d. po,for 90 days
3095932|NCT01919658|Active Comparator|proximal nerve block|The anesthesiologist will administer a proximal nerve block if specified in the randomization envelope.
3095933|NCT01919658|Active Comparator|distal nerve block|The anesthesiologist will administer a distal nerve block if specified in the randomization envelope.
3095934|NCT01919645|Experimental|Combined Training Group|"Combined Training - (strength + aerobics).~A combined training (CT)is performed, having aerobics exercises (AE)using a stationary bicycle and strength training in workout devices.~The strength training (ST) will be performed by isotonic exercises recruiting the main muscle groups. They exercises are: Chest Press, Leg Press, Vertical Traction, Leg Extension and Abdominal Crunch."
3095935|NCT01919645|Placebo Comparator|Control Group|The control group patients did not perform any intervention through physical exercises. They were oriented on Sleep Hygiene and were followed during the study. They were asked to come to the following visits (at weeks 8 and 16) and to 2 additional visits to get and then return the actigraph. During this period, they were followed through phone calls once a month and were asked for sleep hygiene and were reminded of their assessment dates.
3095936|NCT01919632|Experimental|Lifestyle|The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. (?) jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
3095937|NCT01919619|Experimental|Lenalidomide + Ipilimumab|Patients receive lenalidomide by mouth alternating with ipilimumab for 4 cycles (lenalidomide for 21 days, then one dose of ipilimumab, then repeat lenalidomide 4 weeks later, etc.) Ipilimumab is fixed at 3 mg/kg and given by vein. One dose of ipilimumab (Cycle 2) given within 1-3 days from the last day of lenalidomide, then followed by 4 weeks of rest. Lenalidomide repeated daily for 21 days (Cycle 3) followed by one dose of ipilimumab (Cycle 4) within 1-3 days from the last dose of lenalidomide. Treatment repeated for a total of 8 cycles.
3095938|NCT01919606|Experimental|EXPAREL Group 1|EXPAREL 266 mg diluted with saline to a volume of 40 mL
3095939|NCT01919606|Experimental|EXPAREL Group 2|EXPAREL 266 mg diluted with saline to a volume of 60 mL
3095940|NCT01919593|Experimental|2% Chlorhexidine Gluconate|apply 2% Chlorhexidine Gluconate in 70% Alcohol on skin before venipuncture
3095941|NCT01919593|Active Comparator|10% povidone iodine|apply 10% povidone iodine on the skin before venipuncture
3095942|NCT01919580||Normal team|"Subjects who have problem at third molar of impacted tooth need to receive a surgery with general anesthesia.~Subjects must:~Should have a blood exam (20ml) before the surgery.~Site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample around third molar during the surgery."
3095943|NCT01919580||Oral dysplasia|"Subjects who are diagnosed with dysplasia of oral cavity.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
3095944|NCT01919580||Oral cancer|"Subjects who suffer from oral cancer.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
3095945|NCT01919567||Normal team|"Subjects who have problem at third molar of impacted tooth need to receive a surgery with general anesthesia.~Subjects must:~Should have a blood exam (20ml) before the surgery.~Site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample around third molar during the surgery."
3095946|NCT01919567||Oral dysplasia|"Subjects who are diagnosed with dysplasia of oral cavity.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
3095947|NCT01919567||Oral cancer|"Subjects who suffer from oral cancer.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
3095948|NCT01919554|Placebo Comparator|Placebo Sub Lingual Immunotherapy Tablets (SLIT)|Placebo tablets Matching the HDM allergen extract Sub Lingual Immunotherapy Tablets
3095949|NCT01919554|Experimental|SLIT of HDM allergen extracts|Sublingual Immunotherapy Tablets of House Dust Mite allergen extracts
3095950|NCT01919541|Other|Prehabilitation|All patients will receive a prehabilitation program involving an individualized exercise and nutrition program 4 weeks before surgery. Whole body protein kinetics and insulin resistance will be determined at the beginning of the program and at the end of the program.
3095951|NCT01919528|Experimental|axillary vein catheterization|central venous catheter placement into the axillary vein under ultrasound guidance
3095952|NCT01919515|Other|ZR Crown & Stainless Steel Crown|Each subject will have a maximum of one ZR Crown and one Stainless Steel Crown cemented on primary molars that are treatment planned for a crown.
3095953|NCT01919502|Other|Semi-quantitative urine pregnancy test|Semi-quantitative urine pregnancy test (Quanti5 Multilevel hCG Pregnancy Test)
3095954|NCT01919489|Experimental|Liraglutide + OADs|Liraglutide once daily in combination to oral anti-diabetic agents (OADs)
3095955|NCT01919489|Active Comparator|Glargine + OADs|Glargine once daily in combination to oral anti-diabetic agents (OADs)
3095956|NCT01919476|Active Comparator|Control Meal: Bagel, cream cheese|Control meal consists of bagel with cream cheese and apple juice.
3095957|NCT01919476|Experimental|Almond Meal: Bagel, almond butter|Almond meal consists of bagel with almond butter and apple juice.
3095958|NCT01919463|No Intervention|Control Group|Colonoscopy is completed without abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown to investigators for study but not to the colonoscopist for facilitating the intubation process.
3095959|NCT01919463|Experimental|Experimental Group 2 (Monitoring)|Colonoscopy is completed with abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown to investigators for study but not to the colonoscopist for facilitating the intubation process. The colonoscopist directs GI assistants to conduct compression by his subjective judgement.
3095960|NCT01919463|Experimental|Experimental Group 1 (Guiding)|Colonoscopy is completed with abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown both to investigators for study and to the colonoscopist for facilitating the intubation process. The colonoscopist directs GI assistants to conduct compression according to the guidance of magnetic endoscopic imaging system.
3095961|NCT01919450|Active Comparator|10 Second Delay|A 10 second delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
3095962|NCT01919450|Active Comparator|2 Minute Delay|A 2 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
3095963|NCT01919450|Active Comparator|4 Minute Delay|A 4 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
3095964|NCT01919450|Active Comparator|1 Minute Delay|A 1 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
3095965|NCT01919437|Experimental|Web-Enabled Cognitive Neuropsychological Evaluation System|
3095966|NCT01919424|Active Comparator|'The English-Wright nebulizer'|The English-Wright nebulizer will be used to perform a methacholine challenge.
3095967|NCT01919424|Active Comparator|Trudell AeroEclipse*II BAN nebulizer|The Trudell AeroEclipse*II BAN nebulizer will be used to perform a methacholine challenge
3095968|NCT01919411|Experimental|Amoxicillin-Potassium Clavulanate|All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.
3095969|NCT01919411|Placebo Comparator|Placebo|All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.
3095970|NCT01919398|Experimental|LY2940680|Oral LY2940680 will be administered at escalating doses (100 mg up to 400 mg) once daily in 28-day cycles. Treatment with LY2940680 may continue until disease progression, unacceptable toxicity, or other discontinuation criteria are met.
3095971|NCT01919385|Experimental|type 1 diabetes|Predictive Low Glucose Minimizer (PLGM) System
3095972|NCT01919372|Active Comparator|Conventional assistance|Usual treatment of obesity in terms of monitoring lifestyle habits
3095973|NCT01919372|Experimental|Telemedic assistance|telemedical assistance with a technological system to provide a continuous monitoring of lifestyle habits and individualized treatment of obesity
3095974|NCT01919359|Experimental|Facial filler w/vitamin,Placebo/Resurfacing w/vitamin, placebo|Multizyme 150C 2 caps 2 times/day between meals Day of tx for 30 days Cyruta Plus 90T 1 cap 3 times/day 30 days before and after tx or Multizyme 150C 2caps 2 times/day between meals Day of Tx for 30 days; SHEP 2caps 2 times/day 30 days before and after Tx Cellular Vitality 90C 1cap 3 times/day 30 days before and after Tx
3095975|NCT01919359|Placebo Comparator|Soft Tissue filler sugar pill|"Placebo Analog 2tabs 2 times/day between meals; Day of tx for 30 days; Placebo Analog 1tab 3 times/day 30 days before and after tx or Placebo Analog (A) 2~1cap 2 times/day between meals; Day of Tx for 30 days Placebo Analog (B) 2caps 2 times/day 30 days before and after Tx Placebo Analog (C) 1cap 3 times/day 30 days before and after Tx"
3095976|NCT01919346|Experimental|Eculizumab|Eculizumab 1200 mg (diluted in Sodium Chloride (NaCl) to 5mg/mL, volume = 240 mL) will be given intraoperatively at the time of transplantation prior to reperfusion of the renal allograft and again at 900 mg (diluted in NaCl to 5mg/mL, volume = 180 mL) 12-24 hours post-transplantation
3095977|NCT01919346|Placebo Comparator|Normal Saline|Administered at same volume and time as Experimental arm
3095978|NCT01919333||laparoscopic ovarian cystectomy|the group who laparoscopic ovarian cystectomy are performed for endometrioma
3095979|NCT01919333||laparoscopic non- ovarian pelvic surgery|the group whom laparoscopic non- ovarian pelvic surgery are performed
3095980|NCT01919320||CSS Console TAH-t Patients|All TAH-t patients implanted while supported with the CSS Console who were enrolled in the INTERMACS Registry and implanted with the TAH-t on or after June 20, 2012.
3095981|NCT01919320||C2 Driver System TAH-t Patients|200 TAH-t patients implanted while supported by the Companion 2 (C2) Driver System who were enrolled in the INTERMACS Registry and implanted with the TAH-t on or after June 20, 2012.
3095982|NCT01919320||All TAH-t Patient Records|All records for TAH-t patients enrolled in the INTERMACS Registry will be reviewed to support Objective 2 of the protocol.
3095983|NCT01919307|Experimental|Auricular acupuncture|Subjects will then receive auricular acupuncture (NADA Protocol) twice weekly for eight consecutive weeks. Subjects will be evaluated for seizure frequency changes by self-reported diary; adverse events; study feasibility; and mental and physiological symptoms at baseline, 12 weeks (completion of acupuncture), and 16 weeks (1 month after treatment follow up, end of study). A single sham procedure will be tested following treatment completion for use in future studies.
3095984|NCT01919294|Experimental|testosterone undecanoate|Open label testosterone injection. Testosterone Undecanoate (1 g in 4 ml oily base) will be given as slow (2 minute) intramuscular injections (Nebido, manufactured by Bayer-Schering). These will be administered by the study investigator or designated research nurse at time zero (baseline visit 2) and after 6, 18, 30 and 42 weeks.
3095985|NCT01919281|Experimental|strength training|The subjects will attend for supervised training three sessions per week for 10 weeks (9-12). The strength training program involves dynamic contraction at intensities of 60 - 70 % of 1 repetition maximum (RM) to improve strength and muscle hypertrophy. Each session will contain 8 exercises on the major muscle groups. Each drill consists of 10-12 repetitions (reps) x 3 sets separated by one minute rest between sets.
3095986|NCT01919281|Experimental|interval training|"High intensity interval training (HIT) three times per week. The three weekly supervised HIT sessions will include two 4x4 min interval sessions and one 10x1 min session. The HIT consist of uphill treadmill running/walking."
3095987|NCT01919281|No Intervention|control|Based on the Norwegian recommendation we will encourage the control group to perform 60 minutes of physical activity at moderate to high intensity on a daily basis.
3095988|NCT01919268|Experimental|Electrotherapy|Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
3095989|NCT01919268|Active Comparator|Pilates|Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of six weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
3095990|NCT01919255|Active Comparator|Picolight + Coolprep (Day-Prior)|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)[Day-Prior]
3095991|NCT01919255|Active Comparator|Picolight + Clicolon (Day-Prior)|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) [Day-Prior]
3095992|NCT01919255|Active Comparator|Picolight + Coolprep (Split-Dose)|Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)[Split-Dose]
3095993|NCT01919255|Active Comparator|Picolight + Clicolon (Split-Dose)|Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)[Split-Dose]
3095994|NCT01919242||with morbidity|patients who suffered from any type of morbidity after surgery
3095995|NCT01919242||without morbidity|patients who did not suffer from any type of morbidity after surgery
3095996|NCT01919229|Active Comparator|Letrozole|Letrozole 2.5 mg alone once daily
3095997|NCT01919229|Experimental|LEE011 400 mg + letrozole|Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.
3095998|NCT01919229|Experimental|LEE011 600mg + letrozole|Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.
3095999|NCT01919216|Active Comparator|Open Track|Open treatment with 20mg of citalopram, increased to 40mg if depression has not remitted at week 4.
3096000|NCT01919216|Placebo Comparator|Placebo Track|Blinded treatment with either citalopram 20mg or placebo, increased to citalopram 40mg or placebo at week 4 if depression has not remitted.
3096001|NCT01919203|Experimental|group R|The starting dose of remifentanil is 0.5μg/kg and a step size was 0.05μg/kg.
3096003|NCT01919190|Sham Comparator|Placebo|The placebo control will be established using a grade-2 sham, no infiltration will occur
3096004|NCT01919177|Active Comparator|Nitrate rich beetroot juice|Subjects with heart failure with preserved ejection fraction will receive 140 mL of Nitrate-rich concentrated beetroot juice (containing 12 mmol of NO-3). This will be a cross-over study. Therefore all subjects will receive both interventions, but the order of the interventions will be randomized.
3096005|NCT01919177|Placebo Comparator|Nitrate depleted beetroot juice|Subjects with heart failure with preserved ejection fraction will receive 140 mL of nitrate-depleted beetroot juice (containing <0.01 mmol of NO-3).This will be a cross-over study. Therefore all subjects will receive both interventions, but the order of the interventions will be randomized.
3096006|NCT01919164|Experimental|Treatment Arm 1: AS902330 (100 mcg)|AS902330 will be administered at a dose of 100 microgram (mcg) in 4 cycles, wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
3096007|NCT01919164|Experimental|Treatment Arm 2 : AS902330 (100 mcg) alternating with placebo|AS902330, 100 mcg, will be administered in Cycles 1 and 3 and matching placebo will be administered in Cycles 2 and 4, wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
3096008|NCT01919164|Experimental|Treatment Arm 3: AS902330 (30 mcg)|AS902330 will be administered at a dose of 30 microgram (mcg) in 4 cycles, wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
3096009|NCT01919164|Experimental|Treatment Arm 4 : AS902330 (30 mcg) alternating with placebo|AS902330, 30 mcg, will be administered in Cycles 1 and 3 and matching placebo will be administered in Cycles 2 and 4, wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
3096010|NCT01919164|Placebo Comparator|Arm 5: Placebo|Matching Placebo will be administered in 4 cycles, wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
3096011|NCT01919151||Gastrointestinal cancer patients|Patients with radiological suspected cancer in the pancreas Patients with radiological suspected colorectal liver metastasis
3096012|NCT01919138||severe sepsis, septic shock|
3096013|NCT01919125|Experimental|Cohort 1: Child-Pugh Class A|Participants with mild hepatic impairment (Child-Pugh Class A score = 5-6) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
3096014|NCT01919125|Experimental|Cohort 2: Child-Pugh Class B|Participants with moderate hepatic impairment (Child-Pugh Class B score = 7-9) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
3096015|NCT01919125|Experimental|Cohort 3: Child-Pugh Class C|Participants with severe hepatic impairment (Child-Pugh Class C score = 10-15) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
3096016|NCT01919112|Experimental|High dose anodal tDCS|High dose tDCS (2 milliamps twice daily) for 5 days will be administered concomitantly with swallowing exercises
3096017|NCT01919112|Active Comparator|Low dose anodal tDCS|This arm will use a low dose of current administered via tDCS (2 milliamps once daily) for 5 days will be administered concomitantly with swallowing exercises
3096018|NCT01919112|Sham Comparator|Sham Stimulation|Twice daily swallowing exercises only
3096019|NCT01919086|Experimental|Patients with Multiple Myeloma|This is a phase II, single center clinical trial designed to evaluate the response rate and toxicity of a response-adapted, sequential therapy, using bortezomib and dexamethasone, followed by the addition of lenalidomide in non-responders, in patients with untreated MM.
3096020|NCT01919073|Experimental|Immediate Treatment Group|The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
3096021|NCT01919073|Active Comparator|Delayed Treatment Group|The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (in about 11-12 months from the initial appointment).
3096022|NCT01919060||lesions in colon|
3096023|NCT01919060||lesions in extra-colon|
3096024|NCT01919047||Betanis group|Patients receiving Betanis for Overactive Bladder
3096025|NCT01919034||Patients undergoing abdominal surgery|Patients undergoing abdominal surgery and using morphine pain control analgesia (PCA) device will be involved. Pre- and Post- operative (after anesthesia and at the end of surgery) blood sampling (total 30 ml) plus normal liver tissue (10mm3) e will be harvested. Above protein(TM, IL-20, HD) amount change will be measured (ELISA for TM, IL-20 (serum) or flowcytometry (white cells) for TM, HD, IL-20 expression, stain or blotting for skin tissue). Patients will be included in this branch to check the correlation between morphine consumption and protein expression. Pain questionnaire (BPI, McGill) will be applied for pain evaluation. 2-D gel analysis will also be applied to screen further possible molecules.
3096026|NCT01919008|Experimental|Group 1 (FK949E low dose tablet-first group)|"Days 1 and 2: One FK949E low dose tablet~Days 3 to 6: Three FK949E low dose tablets~Days 7 to 10: One FK949E high dose tablet"
3096027|NCT01919008|Experimental|Group 2 (FK949E high dose tablet-first group)|"Days 1 and 2: One FK949E low dose tablet~Days 3 to 6: One FK949E high dose tablet~Days 7 to 10: Three FK949E low dose tablets"
3096028|NCT01918995|Experimental|Regadenoson low dose|Administered over approximately 10 seconds followed by 2 repeat low doses at 10 minute intervals
3096029|NCT01918995|Experimental|Regadenoson medium dose|Administered over approximately 10 seconds followed by 2 repeat medium doses at 10 minute intervals
3096030|NCT01918995|Experimental|Regadenoson high dose|Administered over approximately 10 seconds followed by 1 repeat high dose at 10 minute intervals
3096031|NCT01918995|Placebo Comparator|Placebo|Administered over approximately 10 seconds followed by 1 or 2 repeat doses at 10 minute intervals
3096032|NCT01918982||Aortic aneurysm|Patients with aortic aneurysm >30mm and < 50mm
3096033|NCT01918969||Blood donors|Blood donors with no exclusion criteria i.e with a very low probability to have an aortic aneurysm
3096095|NCT01918605|Experimental|Diluted spacer|Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
3096034|NCT01918956|Active Comparator|conventional regimen of PURETHAL Birch|"Initial treatment:~6 incremental weekly subcutaneous doses of 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 ml PURETHAL Birch, 20.000 AUM/ml (week 1, 2, 3, 4, 5, 6).~Maintenance treatment:~0.5 ml PURETHAL Birch, 20.000 AUM/ml, in intervals according to registered scheme (week 8, 10, 12)."
3096035|NCT01918956|Experimental|rush regimen of PURETHAL Birch|"Initial treatment:~3 incremental weekly subcutaneous doses of 0.1, 0.3, and 0.5 ml PURETHAL Birch, 20.000 AUM/ml (week 1, 2, 3)~Maintenance treatment:~0.5 ml PURETHAL Birch, 20.000 AUM/ml, in 2-weekly intervals (week 5, 7, 9)."
3096036|NCT01918943||PLIF and Aspen device patients|All patients will receive PLIF and Aspen device
3096037|NCT01918930|Experimental|MGA271|MGA271 (administered in main study CP-MGA271-01)
3096038|NCT01918917|Active Comparator|Levobupivacaine|Intraarticular 19 ml 0.5% levobupivacaine and 1 ml 0.9% sodium chloride administered. postoperative morphine administered for analgesia
3096039|NCT01918917|Active Comparator|Dexmedetomidine|Intraarticular 19 ml 0.5% levobupivacaine and 1 ml (100 mcg/ml) dexmedetomidine administered, postoperative morphine used for analgesia
3096040|NCT01918904|Experimental|Sodium Thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
3096041|NCT01918904|Placebo Comparator|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
3096042|NCT01918891|No Intervention|Usual Home Care|Regardless of study arm, all patients will receive usual home health services: a physician-ordered plan of care; skilled nursing and/or therapy services as prescribed by the MD; patient education, monitoring and hands-on care; and home health aide services depending on functional deficits and availability of unpaid caregivers.
3096043|NCT01918891|Experimental|Nurse Practitioner + Health Coach|The NP + HC arm will include the same protocol as the NP only arm plus 30 additional days of support. The HC will pick up the case after the initial 30 days and follow up with the plan of care jointly established by the patient, NP and HC. The focus will be on ongoing self-management coaching, providing preparation support for physician visits, and linking patient to additional community resources, as needed.
3096044|NCT01918891|Experimental|Nurse Practitioner Only|The NP only program will provide a 30 day intervention via in-home and telephone encounters for patients randomized to this group. In the first 30 days post-enrollment the NP will focus on medical case management and coordination with primary care providers and specialists, provide self-management coaching, and intervene if gaps in care are identified - all with a focus on BP reduction and preparing the patient for ongoing BP maintenance.
3096045|NCT01918878|Experimental|Aflibercept (EYLEA)|Intravitreal injection of aflibercept (EYLEA) 2mg/0.05ml at enrolment (day 0), 4 weeks, 8 weeks, 16 weeks and 24 weeks. Aflibercept will be provided for total period of 24 weeks
3096046|NCT01918865|Experimental|ISIS-PTP1BRx|Weekly Dosing for 26 Weeks
3096047|NCT01918865|Placebo Comparator|Placebo|Weekly Dosing for 26 Weeks
3096048|NCT01918852|Active Comparator|Capecitabine|Capecitabine 1250 mg/m2 for patients < 70 years of age, and 1000 mg/m2 for patients ≥ 70 years of age, orally b.i.d. day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1.
3096049|NCT01918852|Experimental|S1|S-1 30 mg/m2 orally b.i.d. irrespective of age, day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1.
3096050|NCT01918839|Experimental|VINCI Plus|One side has been treated with VINCI Plus
3096051|NCT01918839|Active Comparator|Restylane-L|One side has been treated with Restylane-L
3096052|NCT01918826|Active Comparator|TENS active|NEUROSTIMULATION TRANSCUTANEE AIMED ANALGESIC ACTIVE
3096053|NCT01918826|Placebo Comparator|TENS placebo|NEUROSTIMULATION TRANSCUTANEE AIMED ANALGESIC PLACEBO
3096054|NCT01918813|Experimental|Preoperative MRSA nasal colonization|Interventions in arm of preoperative MRSA nasal colonization consisted of antibiotic prophylaxis with a single dose of vancomycin 1g in addition to cephalosporins, and topical decolonization of MRSA with application of 2% mupirocin ointment twice daily to nares for 5 days
3096055|NCT01918800|Experimental|Fatigue: Take Control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
3096056|NCT01918800|Active Comparator|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
3096057|NCT01918787|Experimental|repetitive TMS|repetitive TMS over dorsolateral prefrontal cortex, posterior superior temporal sulcus and inion as control
3096058|NCT01918774|Other|Cognitive behavior therapy for work success|Seventy participants will take part in the 12 week CBTw program. All participants will receive standard SE services during the study. The longitudinal design will consist of assessments of competitive employment outcomes, important psychosocial outcomes, and background and demographic variables at baseline and at two follow-up periods' immediately following the conclusion of the CBTw program and six months after the conclusion of the program.
3096059|NCT01918761|Experimental|Dacomitinib, Pemetrexed|pemetrexed 500mg/m2 (i.V) q21d Dacomitinib 45mg/ orally (continuous)
3096060|NCT01918748|Experimental|MS & chronic stroke patients|"Intervention: 8 weeks of I-TRAVLE based training of proximal arm function, using the haptic master.~Each week participants will attend training sessions on 5 days per 2 weeks, during which they will train 2 times 30 minutes I-TRAVLE assisted therapy, of which 1x 30 minutes supervised self-training. The two times half an hour training sessions per day will be interspaced by at least half an hour to avoid (general) fatigue and overuse of the affected arm in the subjects."
3096061|NCT01918735|Experimental|Group/dose level 1a|25 mg GWP42006 oral solution. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
3096062|NCT01918735|Placebo Comparator|Group/dose level 1b|Matching placebo for Group/dose level 1a. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
3096063|NCT01918735|Experimental|Group/dose level 2a|75 mg GWP42006 oral solution. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
3096064|NCT01918735|Placebo Comparator|Group/dose level 2b|Matching placebo for Group/dose level 2a. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
3096065|NCT01918735|Experimental|Group/dose level 3a|200 mg GWP42006 oral solution (single dose) followed by an intravenous administration of 5 mg GWP42006 after the oral dose
3096066|NCT01918735|Placebo Comparator|Group/dose level 3b|Matching placebo for Group/dose level 3a
3096067|NCT01918735|Experimental|Group/dose level 4a|400 mg GWP42006 oral solution
3096068|NCT01918735|Placebo Comparator|Group/dose level 4b|Matching placebo for Group/dose level 4a
3096069|NCT01918735|Experimental|GWP42006 1, 2, or 3 times daily|Subjects will receive the selected dose of GWP42006 once, twice or three times daily (the number of daily doses and actual dose will be decided upon based on results from Part 1 of the study) for a total of 5 days, with the final dose given on the morning of Day 5.
3096070|NCT01918735|Placebo Comparator|Placebo 1, 2, or 3 times daily|Subjects will receive placebo once, twice or three times daily (the number of daily doses and actual dose will be decided upon based on results from Part 1 of the study) for a total of 5 days, with the final dose given on the morning of Day 5.
3096071|NCT01918722|Experimental|ICH-1|herbal medicine with Hirudo, Tabanus,8 herbals, promote blood circulation function
3096072|NCT01918722|Active Comparator|ICH-2|herbal medicine without Hirudo, Tabanus,Only 6 herbals
3096073|NCT01918722|Placebo Comparator|placebo herbal medicine|Placebo ：granula，dose twice a day by Oral or nasogastric tube for 10 days
3096074|NCT01918709|Experimental|Valsartan 160mg, Rosuvastatin 20mg|Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 7 days.
3096075|NCT01918709|Experimental|Rosuvastatin 20mg|Rosuvastatin 20mg is administered daily by mouth once a day for 7 days.
3096076|NCT01918709|Experimental|Valsartan 160mg|Valsartan 160mg is administered daily by mouth once a day for 7 days.
3096077|NCT01918696|Experimental|Anger Reduction Treatment|"This treatment consists of eight 15-minute sessions. Participants will read scenarios and imagine themselves in these situations: A driver does not let you over even though you have your blinker on. Next, another will appear to provide a less ambiguous interpretation. One letter will be missing from the key word of this sentence. The sentence will read They can't s_e you. The participant will fill in the missing letter (to form see). Next, this interpretation will be reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is the driver being disrespectful?). In each session 64 training scenarios will be presented. Participants will never see the same scenario twice over the course of the study."
3096078|NCT01918696|Active Comparator|Progressive Muscle Relaxation|"Participants will receive eight 15-minute sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release 10 different muscle groups. At the end of this procedure, participants will create a plan for when they will use the exercise. They will then type out the sentence: When I feel [write the feeling you decided on], then I will use this relaxation technique. They will then be told, Now, go over what you have written and say it quietly to yourself until you can repeat it word for word without having to read what you have written."
3096079|NCT01918696|Placebo Comparator|Control Condition|To control for expectancy effects, participants assigned to the control condition will complete eight computerized sessions consisting of psychoeducation on healthy behaviors. These sessions will be matched for time with the active conditions, lasting 15 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep, and will be taken from protocols developed from our ongoing research. This psychoeducation is perceived as credible but has no detectable impact on behavior. After the post-treatment session, participants will be provided with the active ART treatment free of charge if they wish to receive it.
3096080|NCT01918683|Other|A -Tace alone|A - TACE alone (control group, current practice and treatment)
3096081|NCT01918683|Experimental|B - Tace combined with SBRT|B- TACE combined with SBRT (experimental group).
3096082|NCT01918670||Pasteur|
3096083|NCT01918670||Grenoble|
3096084|NCT01918670||Nantes|
3096085|NCT01918670||Parly|
3096086|NCT01918670||Rennes|
3096087|NCT01918670||Rouen|
3096088|NCT01918657|Active Comparator|walnut powder|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded.
3096089|NCT01918657|Placebo Comparator|placebo arm|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
3096090|NCT01918644|Experimental|Treatment (SBRT, capecitabine, and surgery)|Patients undergo SBRT every other day over 2 weeks for a total of 5 fractions and receive capecitabine PO every 12 hours 5 days a week for 2 weeks. Patients then undergo definitive surgery after a minimum of 2 weeks from the completion of SBRT.
3096091|NCT01918631|Active Comparator|Entecavir|Entecavir 0.5mg QD for 48 weeks
3096092|NCT01918631|Active Comparator|tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300mg QD for 48 weeks
3096093|NCT01918618||Levosimendan|study group
3096094|NCT01918618||No Levosimendan|Control group
3096100|NCT01918566|Placebo Comparator|300ml tap water|Single intragastric instillation of 300ml tap water via nasogastric tube
3096101|NCT01918566|Active Comparator|Glucose|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
3096102|NCT01918566|Active Comparator|Glucose plus Lactisole|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole
3096103|NCT01918566|Active Comparator|Fructose|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
3096104|NCT01918566|Active Comparator|Glucose and Exendin|Single intragastric instillation of 75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39
3096105|NCT01918566|Sham Comparator|tap water, lactisole|Single intragastric instillation of 300ml tap water with 450ppm lactisole
3096106|NCT01918553|Experimental|Subject in the study ALIENOR|
3096107|NCT01918540|Active Comparator|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer.
3096108|NCT01918540|Active Comparator|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer.
3096109|NCT01918527|Other|A, Conventional treatment|Operation + 8 cycles of adjuvant chemotherapy, if indicated.
3096110|NCT01918527|Other|B, Neoadjuvant chemotherapy|3 cycles of neoadjuvant chemotherapy + operation. Adjuvant chemotherapy only if indicated.
3096111|NCT01918501|Experimental|Blood testing|Comparison of nutrition factors in MS patients and healthy volunteers as possibly source for the pathogenesis and for the remyelination process.
3096112|NCT01918488|Experimental|Nephropathy|Diabetics with diabetic nephropathy receiving first a standardized salt diet (200 mmol NaCl/day) for 4 days and then amiloride tablet 20 mg two times daily (morning and afternoon) for 2 days.
3096113|NCT01918488|Experimental|Control|Diabetics without nephropathy receiving a standardized salt diet (200 mmol NaCl/day) for 4 days, then amiloride tablet 20 mg two times daily (morning and afternoon) for 2 days.
3096114|NCT01918475|Active Comparator|Carbetocin first|Subjects receive carbetocin 0.1 mg intravenously in the first session and placebo (NaCl 0.9%) in the second session
3096115|NCT01918475|Active Comparator|Placebo first|Subjects receive placebo (NaCl 0.9%) intravenously in the first session and carbetocin 0.1 mg in the second session
3096116|NCT01918462||Alcoholic hepatitis|Patients with alcoholic hepatic; cases.
3096117|NCT01918462||Healthy controls|Persons undergoing hepatic resection; controls.
3096118|NCT01918449|No Intervention|Sleep Unit group|This group will have standard follow up in sleep unit at 1, 3 and 6 month. These patients will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counseling.
3096119|NCT01918449|Experimental|Primary Care group|This group will have standard follow up in primary care at 1, 3 and 6 month. These patients will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counseling.
3096120|NCT01918436|Experimental|TEAMS intervention|"Pre-school children age 3-6, from Region Zealand in Denmark, diagnosed with ADHD as primary diagnosis are offered participation in the RCT study of the TEAMS program.~The intervention groups participate in eight weekly group sessions consisting of separate parent- and children's groups.~In the child group, the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development."
3096121|NCT01918436|Active Comparator|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
3096122|NCT01918423||Children of obese women from a RCT|Children born to obese women who were in the active intervention arm of the randomized controlled trial LiP. The lifestyle intervention during pregnancy consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
3096123|NCT01918423||Children of obese mothers from a RCT, controls|Children born to obese mothers who were in the control arm of the randomized controlled trial LiP.
3096124|NCT01918423||Children born to normal weight women|Children born to women with a pregestationally normal BMI and who were not part of a lifestyle intervention programme during pregnancy.
3096125|NCT01918410|Active Comparator|Contact Lens with alginic acid|
3096126|NCT01918410|Placebo Comparator|Contact lens without alginic acid|
3096127|NCT01918397|Active Comparator|Dose 1|Levofloxacin 11mg/kg daily + Optimized Background Regimen (OBR)
3096128|NCT01918397|Experimental|Dose 2|Levofloxacin 14mg/kg daily + Optimized Background Regimen (OBR)
3096129|NCT01918397|Experimental|Dose 3|Levofloxacin 17mg/kg daily + Optimized Background Regimen (OBR)
3096130|NCT01918397|Experimental|Dose 4|Levofloxacin 20mg/kg daily + Optimized Background Regimen (OBR)
3096131|NCT01918384|Experimental|NPC-14|Intravenous drip, QW, 36 weeks, Dose will be adjusted and maintained by therapeutic drug monitoring of peak serum levels of NPC-14
3096132|NCT01918384|Placebo Comparator|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
3096133|NCT01918371||Patients with RVO|Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.
3096134|NCT01918371||Patients with DME|Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.
3096135|NCT01918358|Experimental|Fixed-dose combination VR 160/20 mg-1|Fixed-dose combination VR 160/20 mg-1 is administered by mouth at Day 1, 8 and 15.
3096136|NCT01918358|Experimental|Fixed-dose combination VR 160/20 mg-2|Fixed-dose combination VR 160/20 mg-2 is administered by mouth at Day 1, 8 and 15.
3096137|NCT01918358|Experimental|Valsartan 160mg placebo + Rosuvastatin 20mg|Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered by mouth at Day 1, 8 and 15.
3096190|NCT01918059|Experimental|Absorbable suture skin closure|The superficial eyelid skin will be repaired with simple interrupted sutures with absorbable suture (surgical gut) after repair of any deep component of the laceration.
3096138|NCT01918345|No Intervention|Standard Care (Control)|This group will receive a one-on-one counseling session during one visit with a Certified Diabetes Educator (CDE), who will provide standard advice on diabetes prevention and healthy lifestyle. They will receive a booklet on exercise and healthy diet as per current Canadian guidelines for healthy eating. This group will also receive a check-in telephone call from the Study Coordinator, half-way through the study. This group will not receive motivational interviewing, health coaching on low GI diet and/or exercise, or additional telephone follow-up.
3096139|NCT01918345|Experimental|Diet & Physical Activity Program with Health Coach|Participants assigned to this arm will receive a combination of the home-based physical activity program with health coach and the home-based low-GI diet program with health coach, as described in the respective individual arms. The Health Coach for this group will be a CDE.
3096140|NCT01918345|Experimental|Physical Activity Program with Health Coach|Participants will be counseled to follow physical activity recommendations for Canadians, which is at least 150 minutes of moderate physical activity per week. Participants will be asked to participate in aerobic, strength training and stretching activities. Health Coaches will use motivational interviewing, goal-setting and problem solving to assist participants in meeting their physical activity goals. More participants will be randomized to this group and the participants will either have CDE or a Registered Kinesiologist (R. Kin) as their health coach.
3096141|NCT01918345|Experimental|Diet Program with Health Coach|Participants will be counseled to follow recommendations for Canadians on healthy eating (Canada's Food Guide and Space on Your Plate. Low GI education will be layered on top of Canada's Food Guide recommendations. The goal for participants in the diet group is to lower their dietary GI by 8-10 units. Health Coaches will use motivational interviewing, goal-setting and problem solving to assist participants in meeting their dietary and low GI goals. The health coach for this group will be a CDE.
3096142|NCT01918332|Experimental|Valsartan 160mg, Rosuvastatin 20mg|Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 8 weeks.
3096143|NCT01918332|Active Comparator|Valsartan 160mg, Rosuvastatin 20mg placebo|Intervention : Drug : Both Valsartan 160mg and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
3096144|NCT01918332|Active Comparator|Valsartan 160mg placebo, Rosuvastatin 20mg|Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered daily by p.o. once a day for 8 weeks.
3096145|NCT01918332|Placebo Comparator|Placebo|Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
3096146|NCT01918319|Experimental|Lifestyle intervention|The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
3096147|NCT01918319|No Intervention|Control|
3096148|NCT01918306|Experimental|1PHIbA Arm A - cisplatin + GDC - 0941|"Determine the safety and tolerability of GDC-0941 given in combination with cisplatin in patients with AR- TN MBC. Determination of the maximally tolerated dose (MTD) of GDC-0941.~Cohort 1, 3 of 3 patients received:~Cisplatin 25 mg/m2 IV D1, 8, 15 GDC-0941 260 mg PO, days 2-6, 9-13, 16-20, 23-27, 28 day cycle GDC-0941 dose to start at Max dose of 260mg.~If no patient in the first cohort of 3 experiences a DLT, an additional cohort of 3 patients will be treated at the same dose level.~If 1 patient experiences a DLT in the first cohort, an additional cohort of 3 patients will be treated at the same dose level.~If ≤1 patient has a DLT in 6 treated at this same dose, this will be considered a tolerable dose to move to phase II~If patients experience a DLT considered related to GDC-0941, the patient may remain on GDC-0941 and/or Cisplatin after resolution of the DLT. All such cases will be considered a DLT for the purposes of defining the MTD."
3096149|NCT01918306|Experimental|1PHIbB - Arm B - Cisplatin + GDC 0941 dose level -1|"If 2 or more patients in 3 or 6 patients treated at a given dose experience DLT, the dose will be de-escalated to the next lower dose level. Once the lowest dose level is reached, if a DLT occurs, the regimen will be considered too toxic and the corresponding cohort within the study will be discontinued.~Determination of the maximally tolerated dose (MTD) of GDC-0941."
3096150|NCT01918306|Active Comparator|2PHII1 Arm 1 - Cisplatin|"Evaluate the efficacy, as measured by the overall response rate (ORR), of Cisplatin +GDC-0941 versus Cisplatin alone in patients with AR- TN MBC.~Patients will be randomized in a 1:1 fashion to arm 1: cisplatin, or arm 2: cisplatin + GDC-0941.~Arm 1 Cisplatin Only Patient received:~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle)."
3096151|NCT01918306|Experimental|2PHII2 - Arm 2 - Cisplatin + GDC - 0941|"Evaluate the efficacy, as measured by the overall response rate (ORR), of Cisplatin +GDC-0941 versus Cisplatin alone in patients with AR- TN MBC. Patients are randomized in a 1:1 fashion to arm 1: cisplatin, or arm 2: cisplatin + GDC-0941.~Arm 2 Cisplatin + GDC-0941 Patients received:~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle).~GDC-0941 260 mg PO, administered orally on days 2-6, 9-13, 16-20, 23-27 of a 28 day cycle."
3096152|NCT01918306|Experimental|2PHIICO|"Arm 2: Crossover post-progression~Patients who are randomized to Cisplatin alone (Arm 1) can crossover to receive Cisplatin + GDC-0941 upon disease progression.~Patient received:~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle).~GDC-0941 260 mg PO, administered orally on days 2-6, 9-13, 16-20, 23-27 of a 28 day cycle."
3096153|NCT01918293|Experimental|SMART arm|Using smartphone application for control of asthma
3096154|NCT01918293|No Intervention|conventional arm|non-using smartphone application for control asthma
3096155|NCT01918280|Experimental|Young group|Patient aged 15-22 years for seminal analyses and testicular biopsy
3096156|NCT01918280|Other|Adult group|Patient aged 23-55 years for seminal analyses and testicular biopsy
3096157|NCT01918267||Cohort|
3096158|NCT01918254|Experimental|Lumretuzumab Dose Escalation|Participants will receive escalating doses of lumretuzumab starting at 1000 mg IV (on Day 1, except Cycle 1 where lumretuzumab will be administered on Day 2) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 840 mg IV (on Day 1) initial dose followed by 420 mg IV, in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death.
3096191|NCT01918059|Experimental|Tissue Adhesive skin closure|The superficial eyelid skin will be repaired with layers of tissue adhesive (octyl-2-cyanoacrylate) after repair of any deep component of the laceration.
3096159|NCT01918254|Experimental|EPC1: Lumretuzumab (Prior Chemotherapy)|Extension phase Cohort 1 (EPC1): Participants will receive lumretuzumab 1000 mg IV (on Day 1) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 840 mg IV (on Day 1) initial dose followed by 420 mg IV, in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death.
3096160|NCT01918254|Experimental|EPC2: Lumretuzumab (Without Prior Chemotherapy)|Extension phase Cohort 2 (EPC2): Participants will receive lumretuzumab 2000 mg IV (on Day 1) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 420 mg IV (on Day 1), in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death. Only participants with no prior chemotherapy for metastatic disease and/or a maximum of only one prior chemotherapy regimen in adjuvant or neoadjuvant setting will be enrolled in this cohort.
3096161|NCT01918241|Experimental|pegfilgrastim,30mcg/kg|On the 3rd day and 6th day in Cycle 2, mean after 48h and 120h of chemotherapy, subjects will be received PEG-rhG-CSF(sc) in a fixed time(9:00±30 min), and the dosage is 30 mcg/kg.
3096162|NCT01918241|Experimental|pegfilgrastim, 60mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to PEG-rhG-CSF(sc, single) in a fixed time(9:00±30 min), and the dosage is 60 mcg/kg.
3096163|NCT01918241|Experimental|pegfilgrastim,100mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to PEG-rhG-CSF(sc, single) in a fixed time(9:00±30 min), and the dosage is 100 mcg/kg.
3096164|NCT01918241|Experimental|filgrastim,5mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to controlled group with rhG-CSF(sc, once a day) in a fixed time(9:00±30 min), and the dosage is 5mcg/kg, rhG-CSF must be injected for a continous 14 days, or twice observed the results for ANC from the nadir to counts≥5.0×10^9/L, but at least 7 days.
3096165|NCT01918228|Experimental|Intervention group|Talks on scientific status on back pain with the purpose of reducing LBP-related insecurity/fear, reducing the focus on the pain and providing participants with alternative explanation to their LBP. They were also provided with a folder (general stretching exercises) and had telephone access to health professional if they had questions about LBP during the follow-up year.
3096166|NCT01918228|No Intervention|Control group|No intervention will be provided by the study team.
3096167|NCT01918215|Other|Device Implantation|A prospective, blocked, randomised, placebo-controlled trial of primary prophylaxis ICD therapy or implantable loop recorder (ILR) insertion in patients with LVEF 36-50% and Late Gadolinium Enhancement(LGE)on CMR
3096168|NCT01918215|No Intervention|Observational Registry|A prospective observational registry of patients with LVEF 36-50% and no LGE on CMR
3096169|NCT01918202|Experimental|Cohort 1 - 20 mg|Cohort will include 4 HVs/completers who will receive a single 20 mg dose of PF-02545920.
3096170|NCT01918202|Experimental|Cohort 2 ( adaptive dose, optional)|Cohort 2 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.
3096171|NCT01918202|Experimental|Cohort 3 ( adaptive dose, optional)|"Cohort 3 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.~Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg. This cohort is optional"
3096172|NCT01918189|Experimental|10 week Pain EASE access|behavioral pain self-management intervention (Pain EASE) delivered via the Internet
3096173|NCT01918176|Experimental|Fixed sequence crossover|All the subjects will undergo the treatment of Palbociclib alone first and then treatment of Palbociclib and Rabeprazole.
3096174|NCT01918163|No Intervention|No Pills|Patients in this group will not receive Pomegranate pills.
3096175|NCT01918163|Active Comparator|Pomegranate pills|The reccruited patient will receive pomegranate pills every day for 12 weeks. The control group will not be exposed for the pills.
3096176|NCT01918150|Experimental|TITAN 2 stent - Hexacath France|Patients receiving Titan 2 stents (percutaneous coronary intervention)
3096177|NCT01918150|Active Comparator|Cobalt-Chromium BMS - Any firm|Patients receiving Cobalt-Chromium Bare Metal Stents (free of any coating)(percutaneous coronary intervention)
3096178|NCT01918137|Experimental|chocolate bar|
3096179|NCT01918137|Experimental|porridge|
3096180|NCT01918124|Experimental|radiotherapy combined with chemotherapy|"Arm Label: radiotherapy combined with chemotherapy:~Radiotherapy:~Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.~Cisplatin:~Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.~Cisplatin and Doxorubicin and Cyclophosphamide： Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) given at 3 week intervals following completion of radiotherapy.~Paclitaxel and Carboplatin： Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy."
3096181|NCT01918111|Experimental|RD group|Renal denervation group
3096182|NCT01918111|Active Comparator|Control group|Control group
3096183|NCT01918098|Experimental|Oxycodone/naloxone prolonged release tablets|Dose strength:5/2.5 mg,10/5mg, 20/10mg,PO,q12h.daily dose from 10/5mg to 50/25mg.treatment duration:12 weeks
3096184|NCT01918098|Active Comparator|Oxycodone prolonged release tablets|Dose strength:5mg,10mg, 20mg,PO,q12h.daily dose from 10mg to 50mg.treatment duration:12 weeks
3096185|NCT01918085|Other|Peristomal skin|The peel force used to remove two types of adhesive strips (Hydrocolloid strip and strata strip) from the Peristomal skin
3096186|NCT01918085|Other|Pre-stripped abdominal skin|The peel force used to remove two types of adhesive strips (Hydrocolloid strip and strata strip) from healthy abdominal skin
3096187|NCT01918072||1/PCP before innovation initiated|primary care providers in healthcare systems before the innovation has been initiated in those healthcare system
3096188|NCT01918072||2/PCP after innovation initiated|primary care providers in the same healthcare systems after the innovation has been initiated in those healthcare systems
3096189|NCT01918059|Experimental|Non-absorbable suture skin closure|The superficial eyelid skin will be repaired with simple interrupted sutures with non-absorbable suture (6-0 polypropylene) after repair of any deep component of the laceration.
3118547|NCT01764230|No Intervention|control group|no intervention
3096192|NCT01918033|Experimental|Desloratadine 5 mg|Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks
3096193|NCT01918033|Experimental|Desloratadine 10 mg|Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks
3096194|NCT01918033|Placebo Comparator|Placebo|Participants receive two placebo tablets orally once daily for up to 2 weeks
3096195|NCT01918020|Experimental|Go Wild with Fruits and Veggies!|This group will receive nutrition education to learn about fruits and vegetables and physical activities right from the start of the experiment.
3096196|NCT01918020|Other|Go Wild with Fruits and Veggies! delayed|This group will only receive nutrition education about 4 months after the experiment starts.
3096197|NCT01918007|Active Comparator|AT (adenotonsillectomy) Group|AT (adenotonsillectomy) immediately after the baseline study evaluation
3096198|NCT01918007|No Intervention|Control Group|No AT (adenotonsillectomy) for 3 months after the baseline study evaluation
3096199|NCT01917994|Experimental|Text Messages + Appointment Reminders|Participants in the intervention arm will receive supportive, informational, or motivational text messages three times a week for one year in addition to text message reminders about HIV primary care appointments.
3096200|NCT01917994|Active Comparator|Appointment Reminders|Participants in the control arm will receive text messages reminding them of HIV primary care appointments 48 hours before the scheduled appointment.
3096201|NCT01917981|Experimental|Personal Heart Rhythm Monitor|Intermittent cardiac monitoring with a Personal Heart Rhythm Monitor for three months.
3096202|NCT01917968||Uphold Lightweight Vaginal Support System|Transvaginal repair with mesh (Uphold LITE)
3096203|NCT01917968||Traditional native tissue repair|Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
3096204|NCT01917942|Active Comparator|Standard of Care|Standard of Care
3096205|NCT01917942|Experimental|Humidification|Humidification
3096206|NCT01917929|Other|Secur-Fit Advanced|Secur-Fit Advanced Hip Stem
3096207|NCT01917916|Experimental|BI 655064 dose group 1|subject to receive BI 655064 dose group 1 single dose
3096208|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 1|subject to receive placebo
3096209|NCT01917916|Experimental|BI 655064 dose group 2|subject to receive BI 655064 dose group 2 single dose
3096210|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 2|subject to receive a placebo
3096211|NCT01917916|Experimental|BI 655064 dose group 4|Subject to receive BI 655064 dose group 4 single dose
3096212|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 4|Subject to receive placebo
3096213|NCT01917916|Experimental|BI 655064 dose group 3|Subject to receive BI 655064 dose group 3 single dose
3096214|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 3|Subject to receive placebo
3096215|NCT01917903|Experimental|Identification of at risk variables|Individuals will come in for a single visit to perform all tasks / conditions. Measurements will be taken of spatial and temporal features of walking with and without a secondary task. In addition, cognitive tests of memory and attention will be performed. Outcomes will narrow measures to those most likely to show clinically significant change.
3096216|NCT01917903|Experimental|Gait-Cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
3096217|NCT01917890|Experimental|Curcumin Group|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of curcumin (as 6 capsules 500 mg)"
3096218|NCT01917890|Placebo Comparator|Placebo|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of placebo (as 6 capsules 500 mg)"
3096219|NCT01917877|Experimental|study group|Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
3096220|NCT01917877|Active Comparator|control|Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
3096221|NCT01917864|Experimental|iPad Application|Student participants will use specialized iPad software under the supervision of a speech-language pathologist over the course of 12 months, approximately one session per week, one hour per session.
3096222|NCT01917838|Experimental|MFG plus MyMFG|"MFG plus MyMFG will be tested and the aim is:~Greater quality of the Design and Do process rated by therapists, parents, and independent coders.~Greater quantity and quality of HW assignments rated by therapists and parents.~Greater quality of the Review process as rated by therapists, parents, and independent coders.~Greater satisfaction with treatment as rated by the parent, target child, and therapists."
3096223|NCT01917825|Experimental|MDT-15|The treatments will be administered to separate, sequential cohorts of 18 treated subjects in the following escalating doses:1 pellet, 3 pellets, and 6 pellets.
3096224|NCT01917812|Placebo Comparator|Blinded Digital Activity Tracker|Blinded Digital Activity Tracker = Group wears the tracker but is blinded to the numeric physical activity feedback information provided by the tracker.
3096225|NCT01917812|Experimental|Unblinded Digital Activity Tracker / No Smart Text Messaging|"Unblinded Digital Activity Tracker = Group unblinded to the numeric physical activity feedback information provided by the digital activity tracker.~No Smart Text Messaging = Group does not receive personalized, health coaching via smart text messages.~Note that the study occurred over two study phases after the 1-week blinded run-in. In the first 2-week phase, participants were randomized to unblinded or blinded tracking. In the second 2-week phase, the unblinded participants were randomized to receive smart texts or no texts."
3096226|NCT01917812|Experimental|Unblinded Digital Activity Tracker / Smart Text Messaging|"Unblinded Digital Activity Tracker = Group unblinded to the numeric physical activity feedback information provided by the digital activity tracker.~Smart Text Messaging = Group receives personalized, health coaching via smart text messages.~Note that the study occurred over two study phases after the 1-week blinded run-in. In the first 2-week phase, participants were randomized to unblinded or blinded tracking. In the second 2-week phase, the unblinded participants were randomized to receive smart texts or no texts."
3096227|NCT01917799|Experimental|Aspirin|75mg tab of aspirin once daily
3096228|NCT01917799|Active Comparator|Aspirin + heparin|75mg tab of aspirin once daily + 0.4 mL/day of injection of low molecular weight heparin
3096229|NCT01917786||Dexmedetomidine patients|Surgical patients receiving dexmedetomidine.
3118548|NCT01764204||Qingkailing Injection|
3096230|NCT01917786||Control patients|Surgical patients not receiving dexmedetomidine.
3096231|NCT01917773|Experimental|Octreotide|All patient received octreotide. We compared pre (fasting) and post octreotide colonic motility index.
3096232|NCT01917747|Active Comparator|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before and after any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test and any other follow up, as is standard practice.
3096233|NCT01917747|Experimental|Patient Navigator Group|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed.
3096234|NCT01917734||IM-SAM|Children 6-59 months with bilateral pitting edema, and/or WHZ < - 3 and/or MUAC < 115 mm.
3096235|NCT01917721|Experimental|Doxycycline|These patients will receive doxycycline at the acute phase of their disease
3096236|NCT01917721|Active Comparator|Standard care|The comparative arm of the study will receive standard care for Kawasaki disease, but not doxycycline
3096237|NCT01917708|Experimental|Abatacept|4 doses of abatacept 10 mg/kg/dose will be given on days -1, +5, +14, and +28.
3096238|NCT01917695|Active Comparator|Concurrent Radical Chemoradiation|Paclitaxel(175 mg/sq.m) + Cisplatin (75 mg/sq.m) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT + Brachytherapy (7Gy HDR x 3 doses) All to be completed within 8-10 weeks
3096239|NCT01917695|Experimental|Neoadjuvant Chemoradiation + Radical Hysterectomy|Paclitaxel(175 mg/m2) + Cisplatin(75 mg/m2) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT - completed within 5 weeks Radical Hysterectomy - 3 weeks after completion of RT All to be completed within 8-10 weeks
3096240|NCT01917695|Experimental|Neoadjuvant Chemotherapy + Radical Hysterectomy|Paclitaxel(175 mg/m2) + Cisplatin (75 mg/m2) chemotherapy - 3 cycles of 3 weekly cycle Radical Hysterectomy - 3 weeks after completion of chemotherapy All to be completed within 8-10 weeks
3096241|NCT01917682||Study Cohort|Subjects treated with CorPath-assisted Percutaneous Coronary Intervention (PCI)
3096242|NCT01917669||Lean Non-Diabetic Group|Variables measured will also include serum analyses (HbA1c, adiponectin, cholesterol) and patient vital signs.
3096243|NCT01917669||Pre-diabetics|These patients are anticipated to have elevated BMI, yet not be diabetics.
3096244|NCT01917669||Diabetic Patients|These patients will have good glucose control.
3096245|NCT01917669||Diabetic patients with poor glucocontrol|These patients are anticipated to have poor glucose control. They are usually taking insulin.
3096246|NCT01917656|Experimental|Liraglutide+Metformin|Liraglutide 1.8 mg administered once daily subcutaneously, in combination with pre-trial tablet metformin of unchanged dose.
3096247|NCT01917656|Active Comparator|Sulphonylurea and Metformin|Subjects continued on pre-trial sulphonylurea tablet treatment, in combination with pre-trial tablet metformin of unchanged dose.
3096248|NCT01917643||Symbicort|BFC patients new to ICS/LABA and LAMA therapies
3096249|NCT01917643||Spiriva|Tiotropium bromide patients new to ICS/LABA and LAMA therapies
3096250|NCT01917630|Experimental|ALV003|
3096251|NCT01917630|Placebo Comparator|Placebo|
3096252|NCT01917617|Experimental|Oral rehydration group（Short Hydration）|"Gemcitabine； gemzer Cisplatin；Cispulan Oral Rehydration Solution(ORS)；OS-1~Short hydration via oral rehydration solution (OS-1)~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively."
3096253|NCT01917617|Active Comparator|Standard group（Long Hydration）|"Drug: Gemcitabine , Cisplatin~Other Names:~Gemcitabine； gemzer Cisplatin； Cispulan~Standard hydration via intravenous infusion~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more."
3096254|NCT01917604|Experimental|open exposure and control|● surgically uncover the canine tooth and bone removal exposing the largest diameter of the ectopic canine crown make a window in the palatal soft tissue and bond bracket after 10 days
3096255|NCT01917604|Experimental|closed exposure and control|raising a flap in the area of impacted canine,bonding an attachment and resuturing the flap
3096256|NCT01917591|Active Comparator|MariGen Wound|Fish derived extra cellular matrix
3096257|NCT01917591|Active Comparator|Oasis Sheet|Pig intestine derived extra cellular matrix
3096258|NCT01917578|Experimental|Half Cycles Group|Patients complete half of the whole cycles of neoadjuvant chemotherapy.
3096259|NCT01917578|Experimental|Whole Cycles Group|Patients complete whole cycles of neoadjuvant chemotherapy.
3096260|NCT01917565||Airtraq laryngoscope group|The patients who will be intubated by using Airtraq laryngoscope
3096261|NCT01917565||Macintosh laryngoscope group|The patients who will be intubated by using Macintosh laryngoscope
3096262|NCT01917565||Fiberoptic bronchoscope group|The patients who will be intubated by using Fiberoptic bronchoscope
3096263|NCT01917552|Experimental|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
3096264|NCT01917552|No Intervention|observation|
3096265|NCT01917539|Sham Comparator|Sham Treatment|Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment. All subjects will come for their initial visit where evaluation and treatment #1 will take place. They will also attend 3 follow-up visits spaced approximately 3-4 weeks apart during which they will have subsequent treatments and/or evaluations for their dry eyes. The visit duration will range from approximately 60-90 minutes per clinic visit.
3096339|NCT01917006|Experimental|OnabotulinumtoxinA Dose 4|OnabotulinumtoxinA Dose 4 injected into specified muscle per protocol on Day 1.
3096340|NCT01917006|Experimental|OnabotulinumtoxinA Dose 5|OnabotulinumtoxinA Dose 5 injected into specified muscle per protocol on Day 1.
3096266|NCT01917539|Experimental|Pulsed Light Therapy|All subjects will come for their initial visit where evaluation and treatment #1 will take place. They will also attend 3 follow-up visits spaced approximately 3-4 weeks apart during which they will have subsequent treatments and/or evaluations for their dry eyes. The visit duration will range from approximately 60-90 minutes per clinic visit.
3096267|NCT01917526|Active Comparator|oxygen mask|Oxygen mask with oxygen flow 5 L/min will be given to allocated post general anesthesia patients. The incidence and causes of hypoxemia will be recorded.
3096268|NCT01917526|Active Comparator|Oxygen cannula|Oxygen cannula with oxygen flow 4 L/min will be given to allocated post general anesthesia patients. The incidence and causes of hypoxemia will be recorded.
3096269|NCT01917513|Experimental|G-EYE™ colonoscopy|G-EYE™ colonoscopy
3096270|NCT01917513|Active Comparator|Standard Colonoscopy|Standard Colonoscopy
3096271|NCT01917500||Cardiac ward 10 patients|10 patients from the cardiac ward.
3096272|NCT01917474|Experimental|Group A: Low-lipid diet|"Lifestyle counseling At the end of this run-in period all patients will be randomly attributed to one of the following two dietary regimens. Those in the experimental groupwill be given a low lipid diet with a lipid content < 20% of the total daily energy intake with the following composition:~Proteins (g) 77 (15% total energy intake) Lipids (g) 48 (22% total energy intake) Saturated (g) 9 (4% total energy intake) Monounsaturated (g) 31 (14% total energy intake) Polyunsaturated (g) 8 (4% total energy intake) Carbohydrates (g) 330 (63% total energy intake) Cholesterol (mg) 117 Fibres (g) 32 Total Energy (kcal) 1977"
3096273|NCT01917474|Active Comparator|normal lipid diet|"Patients in the active comparator will be given a diet with normal lipid intake and the following composition:~Proteins (g) 75 (15% total energy intake) Lipids (g) 67 (29% total energy intake) Saturated (g) 14 (6% total energy intake) Monounsaturated (g) 43 (19% total energy intake) Polyunsaturated (g) 10 (4% total energy intake) Carbohydrates (g) 307 (56% total energy intake) Cholesterol (mg) 128 Fibres (g) 32 Total Energy (kcal) 2048 lipid intake between 25-30% of the total daily energy intake."
3096274|NCT01917448|Sham Comparator|Control|The skin will be injected with local anesthetic without spinal block
3096275|NCT01917448|Active Comparator|Spinal morphine|0.15 mg spinal morphine
3096276|NCT01917435|Experimental|fiberoptic bronchoscope|Experimental: fiberoptic bronchoscope fiberoptic bronchoscope is used to facilitate for nasotracheal intubation.
3096277|NCT01917435|Experimental|video-stylet|Experimental: video-stylet video-stylet is used to facilitate for nasotracheal intubation.
3096278|NCT01917409|Experimental|conventional laryngoscopy|experimental conventional laryngoscopy group: laryngoscope is used to assist for nasotracheal intubation.
3096279|NCT01917409|Experimental|video-stylet|experimental video-stylet group:video-stylet is used to guide nasotracheal tube into trachea
3096280|NCT01917383|Experimental|Trabodenoson Plus Latanoprost|Experimental ophthalmic eye drop plus a prostaglandin analogue eye drop
3096281|NCT01917383|Active Comparator|Timolol Plus Latanoprost|A Beta-blocker eye drop plus a prostaglandin analogue eye drop
3096282|NCT01917370||ICC patients|patients with intrahepatic cholangiocarcinoma treated by surgical treatment
3096283|NCT01917357|Experimental|Quinvaxem in Uniject|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using the Uniject pre-filled injection device"
3096284|NCT01917357|Active Comparator|Quinvaxem in single dose vials|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using a needle and syringe from single dose vials"
3096285|NCT01917344|Other|Adults with PKU|MRI, EEG, neuropsychological testing, neurological examination, blood draw, diet diary, physical examination. These activities were performed for the study, but no drug or other interventions took place.
3096286|NCT01917331|Experimental|Beclometasone/Formoterol/Glycopyrrolate|CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations bid
3096287|NCT01917331|Active Comparator|Beclometasone/Formoterol|Foster® 100/6 mcg 2 inhalations bid
3096288|NCT01917318|Experimental|Iloperidone / Placebo|During 1st treatment period subjects will receive iloperidone. During 2nd treatment period subjects will receive placebo.
3096289|NCT01917318|Experimental|Placebo / Iloperidone|During 1st treatment period subjects will receive placebo. During 2nd treatment period subjects will receive Iloperidone.
3096290|NCT01917305|Experimental|platform-switched implant|platform-switched implant
3096291|NCT01917305|Active Comparator|platform-matched implant|platform-matched implant
3096292|NCT01917292|Other|Periodontal care|
3096293|NCT01917292|Experimental|One-Stage Full-Mouth Disinfection|
3096294|NCT01917279|Active Comparator|Intermittent Capecitabine|Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3 week cycle.
3096295|NCT01917279|Experimental|Metronomic Capecitabine|Capecitabine 500 mg/m2 three times daily on days 1-21 of each 3-week cycle
3096296|NCT01917266||Concordant|
3096297|NCT01917266||Discordant|
3096298|NCT01917253|Experimental|standard length catheter|Standard Device for peripheral vein cannulation
3096299|NCT01917253|Experimental|Long catheter|Standard Device for peripheral vein cannulation
3096300|NCT01917240|Experimental|Monophasic Media|Half of each patient's embryos will be randomly assigned to grow in monophasic media & the other half in sequential media. All embryos will undergo CCS & the best euploid embryo from each group will be transferred (DET). If there are only euploid embryos from one group, pt will have SET only (fresh or frozen)
3096301|NCT01917240|Placebo Comparator|Sequential Media|Half of each patient's embryos will be randomly assigned to grow in monophasic media & the other half in sequential media. All embryos will undergo CCS & the best euploid embryo from each group will be transferred (DET). If there are only euploid embryos from one group, pt will have SET only (fresh or frozen)
3096302|NCT01917227|Experimental|Video|
3096303|NCT01917214||Non-Interventional Study|
3096341|NCT01917006|Experimental|OnabotulinumtoxinA Dose 6|OnabotulinumtoxinA Dose 6 injected into specified muscle per protocol on Day 1.
3096304|NCT01917201|Other|IVUS-guided group|The coronary stenting under IVUS-control (with VH or i-MAP) is carried out: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS (with VH or i-MAP) is being used, the optimality of stent implantation is also being assessed.If criteria of optimal implantation guided by IVUS were not achieved, additional impact is being made. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. An additional impact based on OCT data is not being used.
3096305|NCT01917201|Other|Non-IVUS group|The coronary stenting under angiography control is carried out. After postdilatation control OCT is carried out. An additional impact based on OCT data is not being used.
3096306|NCT01917188|Active Comparator|Full simulation and education|Patients who will receive full simulation and education session prior to discharge.
3096307|NCT01917188|Other|See simulation room, usual education|Patients will be shown the simulation room prior to discharge but will only receive usual education.
3096308|NCT01917188|No Intervention|Usual care|Patients will receive usual care by bedside nurse.
3096309|NCT01917175||HIV+ patients with an estimated date of seroconversion|It was estimated that 564 individuals, will be enrolled at the Blood Bank Medical Centre, including 364 individuals already followed-up (former PRIMOCI ANRS 1220 cohort started in 1997) and 200 newly enrolled individuals in this study.
3096310|NCT01917162|Other|Nelfilcon A/UltraFilcon B|Nelfilcon A contact lenses, followed by UltraFilcon B contact lenses. Each product worn bilaterally for one week in a daily wear, daily disposable modality.
3096311|NCT01917162|Other|UltraFilcon B/Nelfilcon A|UltraFilcon B contact lenses, followed by Nelfilcon A contact lenses. Each product worn bilaterally for one week in a daily wear, daily disposable modality.
3096312|NCT01917149|Experimental|Metoprolol|Patients in the metoprolol group were started on 11.875-23.75mg of metoprolol succinct extended-release tablet once daily (11.875mg was recommended for patients with NYHA functional classes III-IV), and then doses were doubled every 2 weeks to achieve asymptomatic bradycardia (50-60 bpm of heart rate) over 4-6 weeks. Investigators were encouraged to up-titrate metoprolol to a maximum dose of 190mg whenever possible.
3096313|NCT01917149|Experimental|Low-dose valsartan|Patients randomized to low dose valsartan receive valsartan 80 mg until study completion.
3096314|NCT01917149|Experimental|Low dose Benazepril|Patients randomized to low dose Benazepril receive Benazepril 10 mg until study completion.
3096315|NCT01917149|Experimental|High dose valsartan|Patients randomized to high-dose valsartan were started on valsartan 80mg twice daily, and uptitrated to target doses within 7 days under in-hospital observation. The target high doses of valsartan is determined by left-ventricular end-diastolic diameter (LVEDD) (the maximal value of anteroposterior and lateral diameters) obtained by ECG at the randomization visit. A target dose of valsartan 320mg, 480mg, 640mg daily were assigned to patients with LVEDD of 50-59, 60-69, ≥70 mm respectively.
3096316|NCT01917149|Experimental|High dose Benazepril|Patients randomized to high-dose benazepril were started on benazepril 10mg twice daily, and uptitrated to target doses within 7 days under in-hospital observation. The target high doses of benazepril is determined by left-ventricular end-diastolic diameter (LVEDD) (the maximal value of anteroposterior and lateral diameters) obtained by ECG at the randomization visit. A target dose of benazepril 40mg, 60mg, 80mg daily were assigned to patients with LVEDD of 50-59, 60-69, ≥70 mm respectively.
3096317|NCT01917136|Experimental|11c-acetate and 18F-FDG, and cardiac MRI|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate and a 10 millicurie injection of 18F-FDG At baseline/6 months follow up, a cardiac MRI will be performed.
3096318|NCT01917123|Active Comparator|Stimol, Brachial Index, Powder agent|L-Citrulline malate,1gr,twice a day,2weeks
3096319|NCT01917123|Placebo Comparator|Placebo, Brachial Index, Powder agent|Placebo,1gr,twice a day,2weeks
3096320|NCT01917110|Experimental|omafilcon A|Contact Lens Group
3096321|NCT01917110|Active Comparator|Spectacle Group|Prescription at Baseline
3096322|NCT01917097||Dexmedetomidine patients|Patients that received dexmedetomidine during their surgery.
3096323|NCT01917097||No Dexmedetomidine|Patients that didn't receive dexmedetomidine during surgery.
3096324|NCT01917084|Experimental|Passive range of motion (ROM) exercise|A 10 - 15 minute passive range of motion (ROM) exercise program will be administered daily during hospitalization for up to 21 days or until discharge (whichever comes first).
3096325|NCT01917071|Experimental|Matched Group|Receives thoracic spine manipulation in the direction of motion limitation.
3096326|NCT01917058|Active Comparator|abatacept|
3096327|NCT01917058|Placebo Comparator|abatacept Subcutaneous vehicle|
3096328|NCT01917045|Experimental|low body fat percentage|body fat percentage less than 30%
3096329|NCT01917045|Experimental|heigh body fat percentage|body fat percentage more than 30%
3096330|NCT01917032|Active Comparator|Sprinkles|Micronutrient Powder Sprinkles 1 gram orally on weekdays during 11 weeks
3096331|NCT01917032|Placebo Comparator|Placebo|Maltodextrin 1 gram orally on weekdays during 11 weeks
3096332|NCT01917019|Placebo Comparator|Part A Placebo|Part A: All participants will receive placebo orally twice daily for the first 2 weeks and then be randomized to receive prolonged-release fampridine 10 mg or matching placebo tablets orally twice daily for up to 14 weeks.
3096333|NCT01917019|Experimental|Part A prolonged-release fampridine|Part A: All participants will receive placebo orally twice daily for the first 2 weeks and then be randomized to receive prolonged-release fampridine 10 mg or matching placebo tablets orally twice daily for up to 14 weeks.
3096334|NCT01917019|Experimental|Part B prolonged-release fampridine|Part B: Eligible participants will receive open label treatment with prolonged-release fampridine 10mg orally twice daily for up to 52 weeks.
3096335|NCT01917019|Experimental|Part C prolonged-release fampridine|Part C: Eligible participants will receive open label treatment with prolonged-release fampridine 10mg orally twice daily until marketed product is available.
3096336|NCT01917006|Experimental|OnabotulinumtoxinA Dose 1|OnabotulinumtoxinA Dose 1 injected into specified muscle per protocol on Day 1.
3096337|NCT01917006|Experimental|OnabotulinumtoxinA Dose 2|OnabotulinumtoxinA Dose 2 injected into specified muscle per protocol on Day 1.
3096338|NCT01917006|Experimental|OnabotulinumtoxinA Dose 3|OnabotulinumtoxinA Dose 3 injected into specified muscle per protocol on Day 1.
3096342|NCT01917006|Placebo Comparator|Placebo|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
3096343|NCT01916993|Experimental|Healthy Volunteers|single dose of NBI-98854 50 mg capsule
3096344|NCT01916993|Experimental|Mild Hepatic Impairment|single dose of NBI-98854 50 mg capsule
3096345|NCT01916993|Experimental|Moderate Hepatic Impairment|single dose of NBI-98854 50 mg capsule
3096346|NCT01916993|Experimental|Severe Hepatic Impairment|single dose of NBI-98854 50 mg capsule
3096347|NCT01916980|Experimental|Desloratadine: Eczema/Dermatitis|Participants with eczema/dermatitis receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient antipruritic efficacy and there is no safety concern.
3096348|NCT01916980|Experimental|Desloratadine: Dermal Puritus|Participants with dermal pruritus receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient anti-pruritic efficacy and there is no safety concern.
3096349|NCT01916967|Experimental|Desloratadine 5 mg|Participants receive desloratadine 5 mg, as one 5-mg tablet and one placebo tablet, orally, once daily in the evening for 2 weeks
3096350|NCT01916967|Experimental|Desloratadine 10 mg|Participants receive desloratadine 10 mg, as two 5-mg tablets, orally, once daily in the evening for 2 weeks
3096351|NCT01916967|Placebo Comparator|Placebo|Participants receive placebo, as two tablets, orally, once daily in the evening for 2 weeks
3096352|NCT01916954|Active Comparator|3-day artemether-lumefantrine|Standard artemether-lumefantrine regimen (3-day treatment)
3096353|NCT01916954|Experimental|5-day artemether-lumefantrine|Artemether-lumefantrine extended regimen (5-day treatment)
3096354|NCT01916941|Active Comparator|Prazosin|Prazosin titrated to 16 mg daily x 6 weeks
3096355|NCT01916941|Placebo Comparator|Placebo|Placebo X 6 weeks
3096356|NCT01916928||Non-viable pregnancy|Women presenting with stillbirth, defined as fetal death occurring after 20 weeks gestation or with miscarriage, defined as fetal death prior to 20 weeks gestation.
3096357|NCT01916915|Experimental|Tramadol 1|1 mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion
3096358|NCT01916915|Experimental|Tramadol 2|2mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion
3096359|NCT01916915|Placebo Comparator|Levobupivacaine|0.25% levobupivacaine 4ml/h infusion
3096360|NCT01916902|Active Comparator|Ticagrelor- Delayed Administration|Subjects receive 180 mg of ticagrelor during cardiac catheterization after diagnostic angiography and prior to stenting. OCT is performed prior to and after coronary artery stenting.
3096361|NCT01916902|Active Comparator|Ticagrelor- Immediate Administration|Subjects receive 180 mg of ticagrelor immediately after study enrollment. OCT is performed prior to and after coronary artery stenting.
3096362|NCT01916889|Experimental|RACY test|"4-question RACY delirium screening tool"
3096363|NCT01916876|No Intervention|Standard Care|At discharge, patients will be given a discharge plan by their attending caregiver as deemed appropriate.
3096364|NCT01916876|Other|Integrative medical follow-up package|"At discharge, patients will receive a discharge plan by their attending caregiver.~Thereafter, if randomised to this study arm they will receive the intervention as outlined elsewhere.~Integrated Medical Follow-up package"
3096365|NCT01916863|Experimental|LX4211|400 mg of LX4211
3096366|NCT01916863|Active Comparator|Canagliflozin|300 mg canagliflozin
3096367|NCT01916863|Placebo Comparator|Placebo|LX4211 placebo
3096368|NCT01916850|Experimental|LX4211 Low Dose|400 mg of LX4211 administered once daily for 10 consecutive days
3096369|NCT01916850|Experimental|LX4211 High Dose|800 mg of LX4211 administered once daily for 10 consecutive days
3096370|NCT01916850|Placebo Comparator|Placebo|Identical placebo administered once daily for 10 consecutive days
3096371|NCT01916837||Single arm|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery.
3096372|NCT01916824|Experimental|Participants with Major Depressive Disorder|Persons with a primary diagnosis of Major Depressive Disorder who start taking any FDA-approved antidepressant prescribed within standard dose range for 6 weeks
3096373|NCT01916824|No Intervention|Healthy Controls|Persons without a history of Major Depressive Disorder and without a current diagnosis of any mental illness
3096374|NCT01916798|Active Comparator|Intralipid infusion|100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.
3096375|NCT01916798|No Intervention|Control group|100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.
3096376|NCT01916785|Experimental|A1|Arm A1: Dasatinib dose adjustment based on Cmin ≥3nM value analysed on blood after 7-10 days dasatinib 100mg intake
3096377|NCT01916785|Active Comparator|A2|Arm A2: Dasatinib standard dose (100mg/d) with Cmin ≥ 3nM analysed on blood after 7-10 days dasatinib 100mg intake
3096378|NCT01916785|Active Comparator|B|Arm B : Dasatinib standard dose with Cmin < 3nM analysed on blood after 7-10 days dasatinib 100mg intake
3096379|NCT01916772||cherubism patients|no interventions
3096380|NCT01916759|Other|HIV uninfected adults|25 HIV uninfected adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
3096381|NCT01916759|Other|HIV infected adults on HAART|25 HIV infected adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
3096382|NCT01916759|Other|HIV-infected long-term non-progressors|10 HIV-infected long-term non-progressor adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
3096383|NCT01916746|Experimental|transvaginal resection of pregnancy tissue|
3096384|NCT01916733||Lower Extremity Bypass & open AAA|Lower Extremity Bypass (LEB) and open AAA patients will be placed on standard Fletcher Allen Health Care insulin protocol post op
3119084|NCT01760538|Experimental|exercise group|exercise training
3096385|NCT01916733||control|patients from the Vascular Study Group of New England centers without a defined program for glucose control after lower extremity bypass and open AAA repair will be used
3096386|NCT01916720|Experimental|SB-480848 40 mg|SB-480848 40 milligrams (mg) once a day (od) for 14 +/- 4 days followed by carotid endarterectomy. SB-480848 40 mg was administered as 2 SB-480848 20 mg tablets plus 2 placebo tablets.
3096387|NCT01916720|Experimental|SB-480848 80 mg|SB-480848 80 mg od for 14 +/- 4 days followed by carotid endarterectomy.SB-480848 80 mg was administered as 4 20 mg SB-480848 tablets.
3096388|NCT01916720|Placebo Comparator|Matching Placebo|Placebo for 14 +/- 4 days followed by carotid endarterectomy. Placebo was administered as 4 placebo tablets. Placebo tablets were identical in appearance to the SB-480848 20 mg tablets.
3096389|NCT01916707|Active Comparator|Standard Dosing|Patients will receive standard VTE prophylaxis of enoxaparin SQ every 12 hours.
3096390|NCT01916707|Experimental|Weight Based Dosing|Patients will receive weight adjusted VTE prophylaxis of enoxaparin SQ every 12 hours.
3096391|NCT01916694|Experimental|Smart phone app glucose monitoring|Home blood glucose monitoring results directly transmitted via a bluetooth enabled smart phone app to a central database to be reviewed by clinicians
3096392|NCT01916694|Active Comparator|Standard glucose monitoring|Home blood glucose monitoring results recorded by hand in a paper diary by the patient and reviewed by the clinical team in the outpatient clinic.
3096393|NCT01916681|Experimental|Cervical foley & Misoprostol|Patients randomized to this arm will receive a cervical foley and misoprostol to induce their labor.
3096394|NCT01916681|Experimental|Misoprostol only|Patients randomized to this arm will receive misoprostol only to induce their labor.
3096395|NCT01916681|Experimental|Cervical foley alone|Patients randomized to this arm will receive a cervical foley to induce their labor.
3096396|NCT01916681|Experimental|Cervical foley & Pitocin|Patients randomized to this arm will receive a cervical foley and pitocin to induce their labor.
3096397|NCT01916655|Placebo Comparator|Usual Care|standard and typical PAP educational and support protocol
3096398|NCT01916655|Experimental|Self-Management Care|Individualized self-management educational and support protocol
3096399|NCT01916655|Experimental|Self-Management Mobile Care|Individualized self-management educational and support protocol delivered in part by mobile health tool
3096400|NCT01916642|Placebo Comparator|Control|0.9% Normal Saline is given instead of Lidocaine in the same volume and duration. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
3096401|NCT01916642|Active Comparator|Lidocaine 1mg/kg|Lidocaine 1mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
3096402|NCT01916642|Active Comparator|Lidocaine 1.5mg/kg|Lidocaine 1.5mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
3096403|NCT01916642|Active Comparator|Lidocaine 2mg/kg|Lidocaine 2mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
3096404|NCT01916642|Active Comparator|Lidocaine 2.5mg/kg|Lidocaine 2.5mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
3096405|NCT01916629|Active Comparator|Photocil for Psoriasis|Active Drug - Photocil for Psoriasis
3096406|NCT01916629|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
3096407|NCT01916603|Experimental|Normative intervention|Normative intervention on diet & physical & breastfeeding: diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
3096408|NCT01916603|No Intervention|Routine care|Routine antenatal care according to national guidelines
3096409|NCT01916590|Active Comparator|Bupivacaine|All patients who give consent will undergo ultrasound guided placement of a femoral catheter with injection of 30 cc of 0.5% bupivacaine (without epinephrine)through the catheter. After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
3096410|NCT01916590|Placebo Comparator|Placebo|All patients who give consent will undergo ultrasound guided placement of a femoral catheter with injection of 30 cc of 0.5% bupivacaine (without epinephrine) through the catheter. After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with saline solution, and the infusion will be started at 6 ml/hr. gh the catheter.
3096411|NCT01916577|Active Comparator|Plerixafor (Mozobil) Control Arm|Plerixafor mobilization of autologous CD117 stem cells: Plerixafor will be given at 240mcg/kg subcutaneously once to 5 normal control patients (volunteers) at time zero with blood collected for flow cytometric analysis for CD117+ peripheral blood cells prior to the dose and then again 8 hours after the dose
3096412|NCT01916577|Experimental|Plerixafor (Mozobil) Experimental Arm|Plerixafor mobilization of autologous CD117 stem cells: Plerixafor will be given at 240mcg/kg subcutaneously once to 5 COPD, 5 Cystic Fibrosis, and 5 Pulmonary Fibrosis patients (awaiting lung transplantation) at time zero with blood collected for flow cytometric analysis for CD117+ peripheral blood cells just prior to the dose and then again 8 hours after the dose
3096413|NCT01916564|Active Comparator|Same-morning whole-dose|2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy
3096414|NCT01916564|Active Comparator|Split-dose|1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy
3096415|NCT01916538||Cases|Individuals with a current or past diagnosis of anorexia nervosa
3096416|NCT01916538||Controls|Individuals who have never been diagnosed with an eating disorder
3096460|NCT01916226|Placebo Comparator|Cetirizine Placebo arm|Subject will receive Cetirizine Placebo capsule by mouth OD in the morning for 14 days
3096501|NCT01915888||Complete Rotarix vaccination cohort|Subjects had received 2 doses of Rotarix within the vaccination window and the observation time is from the end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario) to end of observation.
3096417|NCT01916525|Experimental|Exercise based cardiac rehabilitation|Patients will receive written instructions and a referral to the exercise-based rehabilitation unit. The patient will be taught to use fitness room. Each session of training will be controlled by heart rate. Instruction will also be given for at-home training and filling in a training diary, and training will be scheduled at Verve once a week. On the first visit the patient will receive a device that measures physical activity during the study. Training will also be monitored from the training diary. Structured questionnaires will be used to check compliance and implementation of care will be determined from medication and other health-related habits once a month (during the first 6 months) and finally after 12 months.
3096418|NCT01916525|No Intervention|Control|A conventional post-acute care group treated according to finnish guidelines.
3096419|NCT01916499||"Switch trap-door re-implantation of the coronaries"|"Re-implantation of the coronary arteries into the neo-aortic sinuses through a trap-door as far distally as possible on the neo-aorta"
3096420|NCT01916499||"Switch non-trap-door re-implantation of the coronaries"|Re-implantation of the coronary arteries into the neo-aortic sinuses through small incisions or excision in the sinuses
3096421|NCT01916486|Experimental|Exercise training|Twice-weekly for the 6-month duration.
3096422|NCT01916486|Experimental|Complex mental and social activities|Twice-weekly for the 6-month duration.
3096423|NCT01916486|Active Comparator|Control: stretching and relaxation program|Twice-weekly for the 6-month duration.
3096424|NCT01916473|Active Comparator|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
3096425|NCT01916473|Experimental|Continuous wound infusion|The continuous wound infusion consists of 0.376% ropivacaine infusion in the wound area at a rate 2 ml per hour.
3096426|NCT01916460|Experimental|Gastroparetic patient|EUS FNA of the gastric wall prior to surgical placement of gastric neurostimulator
3096427|NCT01916447|Experimental|TAS-102 and CPT-11 with or without Bevacizumab|
3096428|NCT01916434|Experimental|High Pufa Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
3096429|NCT01916434|Experimental|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption
3096430|NCT01916434|Placebo Comparator|No salmon|The placebo group will continue to consume their habitual diet
3096431|NCT01916421|Active Comparator|EZ Shot|
3096432|NCT01916421|Active Comparator|Expect™|
3096433|NCT01916421|Active Comparator|EchoTip® Ultra|
3096434|NCT01916408|Active Comparator|Wobenzym plus|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
3096435|NCT01916408|Placebo Comparator|Placebo PL1|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
3096436|NCT01916395||Imitrex and Treximet|Imitrex 100mg as needed Treximet 85/500mg
3096437|NCT01916382|Experimental|Nitisinone|Homogentisic acid lowering drug intervention
3096438|NCT01916382|No Intervention|No treatment|comparrator
3096439|NCT01916369|Experimental|CTX DP|Human neural stem cell product, single dose administered once only, increasing doses
3096440|NCT01916356|Experimental|educational video|Change in participant's infertility knowledge before and after watching the educational video covering the topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
3096441|NCT01916343|Experimental|Study Laparoscopic Curriculum|Residents will perform a salpingectomy in the operating room, which will be video-recorded through the laparoscopic camera. The residents in the intervention group will then complete the salpingectomy at the conclusion of the curriculum. Following the completion of the curriculum, residents in the intervention group will undergo a multiple-choice examination as well as a repeat skills examination.
3096442|NCT01916343|No Intervention|Standard Clinical Education|Residents will perform a salpingectomy in the operating room, which will be video-recorded through the laparoscopic camera. The standard clinical education residents will perform the procedure as per standard of care.
3096443|NCT01916317|No Intervention|Arm B: No peritumoral Local Anesthesia prior to excision|: No injection of lignocaine prior to excision (Control arm)
3096444|NCT01916317|Active Comparator|Arm A: Peritumoral Local Anesthesia (Inj. Lignocaine) prior to|Arm A: 60mM of 0.5% lignocaine will be injected peri tumoral prior to excision.
3096445|NCT01916304|Experimental|Levothyroxine sodium new formulation|Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.
3096446|NCT01916291|Active Comparator|Propess insertion|
3096447|NCT01916278|Experimental|Emervel Lips Lidocaine|
3096448|NCT01916278|Experimental|Juvéderm Volbella with Lidocaine|
3096449|NCT01916265|Experimental|Glucagon level: 0,11 and 1 mg|Glucagon level: 0,11 and 1 mg
3096450|NCT01916265|Experimental|Glucagon level: 0,22 and 0,66 mg|Glucagon level: 0,22 and 0,66 mg
3096451|NCT01916265|Experimental|Glucagon level: 0,44 and 0,33 mg|Glucagon level: 0,44 and 0,33 mg
3096452|NCT01916252|Active Comparator|MEL-200|bortezomib/lenalidomide/dexamethasone (VRD-GEM) induction treatment followed by high-dose melphalan-200 (MEL-200)
3096453|NCT01916252|Active Comparator|BUMEL|bortezomib/lenalidomide/dexamethasone (VRD-GEM) induction treatment followed by busulfan-melphalan (BUMEL) chemotherapy and consolidation with VRD-GEM
3096454|NCT01916239|Experimental|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
3096455|NCT01916239|Experimental|Pomegranate extract formulation-1|New pomegranate extract formulation-1
3096456|NCT01916239|Experimental|Pomegranate extract formulation-2|New pomegranate extract formulation-2
3096457|NCT01916226|Experimental|FPNS arm|Subject will receive two sprays (200 mcg per day)of FP into each nostril once daily (OD) every morning for 14 days
3096458|NCT01916226|Placebo Comparator|FPNS Placebo arm|Subject will receive two sprays of FP placebo into each nostril OD every morning for 14 days
3096459|NCT01916226|Experimental|Cetirizine arm|Subject will receive Cetirizine capsule by mouth OD in the morning for 14 days
3096461|NCT01916213|Active Comparator|PICSI|PICSI dish ( MidAtlantic Diagnostics Inc) has been developed to select the specific sperm to be used for the ICSI procedure using the same principles as the Sperm Hyaluronan Binding Assay. HA-mediated ICSI sperm selection( PICSI) uses Falcon Petri dishes that feature three microdots of hyaluronan hydrogel attached to the interior bottom: mature, biochemically competent spermatozoa bind to hyaluronan, where they can be isolated and used for ICSI
3096462|NCT01916213|Active Comparator|ICSI|
3096463|NCT01916200|Experimental|Paroxetine CR group|Paroxetine CR plus IBS regular treatment group
3096464|NCT01916200|No Intervention|Blank group|IBS regular treatment group
3096465|NCT01916187|Experimental|Imetelstat|285 mg/m2/dose, IV, for 2 hours. Days 1 and 8 every three weeks.
3096466|NCT01916174|Experimental|Insulin degludec/liraglutide, B5|Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.
3096467|NCT01916174|Experimental|Insulin degludec/liraglutide, V2|Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.
3096468|NCT01916161||IBD patients|Ambulatory patients attending IBD clinics at Leeds Teaching Hospitals
3096469|NCT01916135|Experimental|[18F]-SKI- 249380 and PET/CT scanning|Patients will receive an injection of up to 7.5 (0.5-7.5) mCi of [18F]-SKI- 249380, followed by serial PET/CT scanning and blood draws, over a period of 3.5 hours, on a single day. PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. Each patient will be offered the opportunity to repeat the 18F-SKI-249380 injection and subsequent set of post-injection PET-CT scans, once, on a separate date. Each patient may or may not be receiving treatment with dasatinib therapy at the time of 18F-SKI-249380 PET, for their first PET study, as well as repeat PET study, at the discretion of their oncologist according to best clinical judgment.
3096470|NCT01916122|Experimental|(FES) PET/CT for Imaging|"FES PET/CT studies will be performed as hybrid PET/CT examinations for attenuation correction and lesion localization. A bolus of 5 mCi (+/- 10%) of FES PET/CT will be injected intravenously. 60 (+/- 10) minutes following tracer injection, the patient will be positioned on a GE Discovery PET/CT scanner. A low milliampere CT of from the mid skull to mid thigh will be acquired first, 60-80mAs, 120-140kVp, with a 5mm slice thickness while the patient was free breathing. PET will be acquired at 3-5 minutes per bed position using the 3D mode, approximately 6-7 bed positions. FES PET/CT imaging will take less than 60 minutes. Scans will be reconstructed with iterative reconstruction.~If follow-up FES PT/CT scans are performed on a patient, then the same parameters will be used as the initial FES PET/CT scan."
3096471|NCT01916109|Experimental|Gemcitabine, Carboplatin, and Panitumumab (GCaP)|Patients will receive four cycles of GCaP administered every 21 days. Panitumumab will be administered intravenously at a dose of 9mg/kg on day 1. Gemcitabine 1,000 mg/m2 on day 1 and 8 and carboplatin AUC 4.5 on day 1 will be administered intravenously on a 21-day cycle. A total of four cycles of therapy will be administered at 21-day intervals followed by radical cystectomy.
3096472|NCT01916096||Delica 28g Depth 3 vs Delica 30g Depth 3|30 subjects with diabetes
3096473|NCT01916096||Delica 28g Depth 5 vs Delica 30g Depth 5|30 subjects with diabetes
3096474|NCT01916096||Delica 28g Depth 7 vs Delica 30g Depth 7|30 subjects with diabetes
3096475|NCT01916096||Delica 28g Depth 3 vs Delica 33g Depth 3|30 subjects with diabetes
3096476|NCT01916096||Delica 28g Depth 5 vs Delica 33g Depth 5|30 subjects with diabetes
3096477|NCT01916096||Delica 28g Depth 7 vs Delica 33g Depth 7|30 subjects with diabetes
3096478|NCT01916070||patients with syncope|
3096479|NCT01916070||patients with near syncope|
3096480|NCT01916057|Experimental|18F-FDG PET Scan|18F-FDG PET Scan at Day 0 and M3
3096481|NCT01916044|Experimental|Lower Uterine Segment Ultrasound|Measure of Uterine Segment by Ultrasound
3096482|NCT01916044|No Intervention|control|no measure of Uterine Segment Ultrasound
3096483|NCT01916031|Experimental|Education|Upper Respiratory Infection education in Fall
3096484|NCT01916031|No Intervention|Standard Curriculum|
3096485|NCT01916018|Other|hypothyroid group|Clinical exams radiologic exams Blood sample
3096486|NCT01916005|Experimental|endocarditis|
3096487|NCT01915992|Other|Volunteer healthy|
3096488|NCT01915992|Active Comparator|leukemia patient's|
3096489|NCT01915979|Experimental|Plasma rich in growth factors|This group will receive a total of three intraarticular injections of 6-8 ml. One injection every two weeks.
3096490|NCT01915979|Active Comparator|Celestone cronodose (bethametasone)|This group will receive a total of three intraarticular injections of 2ml. One injection every two weeks.
3096491|NCT01915966|Experimental|Cardamom, ginger and orange juice gelatin|Dietary Supplement
3096492|NCT01915966|Active Comparator|Camomile infusion with lemon juice|Dietary Supplement
3096493|NCT01915953||anemia|Measuring Hb valuse on anemia patients
3096494|NCT01915940|Experimental|13 mg Bimatoprost Ocular Insert|Washout and placebo ocular insert in each eye for at least 4 weeks, followed by 13 mg Bimatoprost Ocular Insert in each eye and placebo eye drops twice a day in each eye for 6 months.
3096495|NCT01915940|Active Comparator|Timolol 0.5% + Placebo Ocular Insert|Washout and placebo ocular insert in each eye for at least 4 weeks, followed by Timolol (timoptic ophthalmic solution 0.5%) twice a day in each eye plus placebo ocular insert for 6 months.
3096496|NCT01915927|Other|1|Only 1 arm: treatment with MSC-AFP
3096497|NCT01915914|Experimental|fluticasone propionate|To evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream (twice per week) in reducing the risk of relapse when added to regular daily moisturization using PHYSIOGEL Lotion in paediatric subjects with stabilized atopic dermatitis
3096498|NCT01915914|Active Comparator|physiogel|To compare the efficacy and safety of fluticasone propionate 0.05% cream (twice per week) added to regular daily moisturization using Physiogel Lotion with Physiogel Lotion alone in paediatric subjects with stabilized atopic dermatitis
3096499|NCT01915901|Experimental|bismuth subsalicylate (Pepto-Bismol®) + DMF|Subjects will receive dimethyl fumarate (DMF) and bismuth subsalicylate (Pepto-Bismol®).
3096500|NCT01915901|Experimental|Placebo + DMF|Subjects will receive dimethyl fumarate (DMF) and placebo.
3096502|NCT01915888||Incomplete Rotarix vaccination cohort|Subjects had received one vaccination of Rotarix within the vaccination window and the observation time is from end of vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario)(if still observed) to end of observation.
3096503|NCT01915888||Historical unvaccinated cohort|Subjects did not receive any Rotarix vaccine dose within the vaccination window and the observation time is from end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario, if vaccination window ends on/before 12/31/2006) to end of observation.
3096504|NCT01915888||Contemporary unvaccinated cohort|Subjects did not receive any Rotarix vaccine dose within the vaccination window and the observation time is from end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario, if vaccination window ends after 1/1/2007) to end of observation.
3096505|NCT01915875|Experimental|sophrology sessions|The sophrology is a dynamic method of physical and psychical relaxation
3096506|NCT01915849|Experimental|Sequence 1: LIK066 15 mg/Placebo/LIK066 50 mg/LIK066 150 mg|Period 1- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 2- Placebo treatment once daily for 4 days Period 3 - LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 4- LIK066 150 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
3096507|NCT01915849|Experimental|Sequence 2: LIK066 50 mg/LIK066 15 mg/LIK066 150 mg/Placebo|Period 1- LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 2- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 3- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 4- Placebo treatment once daily for 4 days. 14 days washout periods between treatment periods.
3096508|NCT01915849|Experimental|Sequence 3: LIK066 150 mg/LIK066 50 mg/Placebo/LIK066 15 mg|Period 1- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 2- LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 3- Placebo treatment once daily for 4 days. Period 4- LIK066 15 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
3096509|NCT01915849|Experimental|Sequence 3: Placebo/LIK066 150 mg/LIK066 15 mg/LIK066 50 mg|Period 1- Placebo treatment once daily (q.d.) for 4 days. Period 2- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 3- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 4- LIK066 50 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
3096510|NCT01915836|Experimental|Alpha game testers and questionaires|"This a video game designed to help smokers quit & remain non-smokers. Before the start the game,the participant will fill out a brief questionnaire.~It should take about 5 minutes to complete. Once this is done, the game play should last about 30 minutes & will present with different scenes. These scenes will show situations that may trigger smoking urges such as walking into a room where another person is smoking. In the game, the participant will be able to use different ways of coping with urges to smoke such as taking several deep breaths or listening to music. The participant will be asked to talk aloud about what they think of the game. The participant will be video &/or audio recorded while doing this. Once finished testing the game, we will then ask you a few questions about what you thought of the game. We will also ask you how relevant different situations are to you as a smoker or someone who is trying to avoid smoking. The entire visit is expected to last about 1.5 hours."
3096511|NCT01915823|Active Comparator|Dymista|"(azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137mcg/50mcg: Mode of Administration: Topical/intranasal spray~Dose: 548 mcg azelastine hydrochloride / 200 mcg fluticasone propionate, total daily dose Regimen: 1 spray per nostril twice daily"
3096512|NCT01915823|Placebo Comparator|Dymista vehicle|Dose: vehicle only Regimen: 1 spray per nostril twice daily
3096513|NCT01915810|Other|No Physical Activity|Group 1 will not include any physical activity. Visits made to Windsor Village United Methodist Church 9 times on Weeks 3, 2, and 1 before quitting smoking, on quit day, and weeks 1, 2, 3, 4, and 8 after quitting smoking. During each visit questionnaires completed, along with a breath test to check for tobacco consumption. At 4 of the visits, height, weight, and waist and hip circumference measured. At 3 of these visits, heart rate also tested. Patients receive counseling about quitting smoking over the phone about 1 - 2 weeks before scheduled quit day, and a 6-week supply of the nicotine patch. Accelerometer worn 3 weeks before quitting smoking through 4 weeks after the quit day. Participants take part in a final audio recorded focus group 8 weeks after quitting smoking.
3096514|NCT01915810|Active Comparator|Physical Activity 2 Weeks Pre-Quit|Group 2 starts a walking program 2 weeks before their quit day and finish it 2 weeks after their quit day. Visits made to Windsor Village United Methodist Church 9 times on Weeks 3, 2, and 1 before quitting smoking, on quit day, and weeks 1, 2, 3, 4, and 8 after quitting smoking. During each visit questionnaires completed, along with a breath test to check for tobacco consumption. At 4 of the visits, height, weight, and waist and hip circumference measured. At 3 of these visits, heart rate also tested. Patients receive counseling about quitting smoking over the phone about 1 - 2 weeks before scheduled quit day, and a 6-week supply of the nicotine patch. Accelerometer worn 3 weeks before quitting smoking, through 4 weeks after the quit day. Participants take part in a final audio recorded focus group 8 weeks after quitting smoking.
3096515|NCT01915810|Active Comparator|Physical Activity Beginning on Quit Day|Group 3 starts walking program on their quit day and finish it 4 weeks after their quit day. Visits made to Windsor Village United Methodist Church 9 times on Weeks 3, 2, and 1 before quitting smoking, on quit day, and weeks 1, 2, 3, 4, and 8 after quitting smoking. During each visit questionnaires completed, along with a breath test to check for tobacco consumption. At 4 of the visits, height, weight, and waist and hip circumference measured. At 3 of these visits, heart rate also tested. Patients receive counseling about quitting smoking over the phone about 1 - 2 weeks before scheduled quit day, and a 6-week supply of the nicotine patch. Accelerometer worn 3 weeks before quitting smoking, through 4 weeks after the quit day. Participants take part in a final audio recorded focus group 8 weeks after quitting smoking.
3096516|NCT01915797||Patient having a cancer and abnormal development|Patient having developed a cancerous pathology and presenting one or several anomalies of the development.
3096517|NCT01915784|Experimental|Group A|Genuair® (Pressair™) first; Breezhaler® (Neohaler™) second
3096518|NCT01915784|Experimental|Group B|Breezhaler® (Neohaler™) first; Genuair® (Pressair™) second
3096519|NCT01915771|Experimental|lomitapide|It will comprise of 2 single oral doses with at least a 14-day washout between doses.
3096520|NCT01915758|Experimental|occlusive patch 200 uL of clindamycin1%/tretinoin0.025% Gel|occlusive patch 200 uL of clindamycin1%/tretinoin0.025% Gel
3119085|NCT01760538|Active Comparator|Control|usual care
3096521|NCT01915758|Placebo Comparator|occlusive patch 200uL of vehicle gel|occlusive patch 200uL of vehicle gel
3096522|NCT01915745|No Intervention|Usually health care|85 patients receive the usually health care. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
3096523|NCT01915745|Experimental|Short Message Service - SMS|85 patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in the Emergency Department emergencies. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
3096524|NCT01915732|Experimental|Duac™Once Daily Gel|Subjects will use Duac™Once Daily Gel (once daily in the evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit
3096525|NCT01915732|Active Comparator|1% clindamycin phosphate gel|Subjects will use 1% clinidamycin phosphate gel (twice daily in the morning and evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit
3096526|NCT01915719|Experimental|Early non invasive ventilation|Early non invasive ventilation
3096527|NCT01915719|Active Comparator|Oxygen therapy only|Oxygen therapy only
3096528|NCT01915706|No Intervention|Observation|Patients randomized to observation will be observed during the post-operative period for spontaneous Baerveldt-350 tube opening. The ripcord will not be removed unless deemed medically necessary by the study physician.
3096529|NCT01915706|Experimental|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3.
3096530|NCT01915693|No Intervention|Arm A: Self-expanding metal stents (SEMS) (Control Arm)|SEMS insertion will be undertaken in accordance with standard local protocols. Covered or partially covered metal stents will be used and the length type and mode of stent placement will be selected by the clinician. Insertion will occur within two weeks of randomisation.
3096531|NCT01915693|Experimental|Arm B: SEMS plus external beam radiotherapy (Intervention Arm)|External beam radiotherapy (EBRT) is routinely available at regional cancer centres across the UK. For palliation of dysphagia in oesophageal cancer, a radiotherapy course delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions within 4 weeks of SEMS insertion.
3096532|NCT01915680||Glaucoma|
3096533|NCT01915680||Control|
3096534|NCT01915667|Experimental|GLPG0634 capsule fasted|Single dose of GLPG0634 as capsules in fasted condition
3096535|NCT01915667|Experimental|GLPG0634 tablet fasted|Single dose of GLPG0634 as tablets in fasted condition
3096536|NCT01915667|Active Comparator|GLPG0634 tablet fed|Single dose of GLPG0634 as tablets in fed condition
3096537|NCT01915654||Study population|The study involves patients operated in the cardiothoracic and cardio-vascular surgery department of Besançon University Hospital between December 2008 and May 2009 (study population) or between December 2007 and May 2008 and between December 2009 and May 2010 (reference population).
3096538|NCT01915654||Reference population|The study involves patients operated in the cardiothoracic and cardio-vascular surgery department of Besançon University Hospital between December 2008 and May 2009 (study population) or between December 2007 and May 2008 and between December 2009 and May 2010 (reference population).
3096539|NCT01915641|Active Comparator|group A|group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement
3096540|NCT01915641|Sham Comparator|group B|group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
3096541|NCT01915628||BioMatrix Flex|percutaneous coronary intervention
3096542|NCT01915615||Hypertrophic cardiomyopathy|"None - this is an observational study.~Patients with hypertrophic cardiomyopathy will be observed for up to 5 years after index cardiac magnetic resonance imaging and blood draw for genetics and biomarkers"
3096543|NCT01915602|Experimental|Refametinib and Sorafenib (Nexavar)|In Cycle 1 reduced sorafenib dose (600 mg daily; 200 mg in the morning + 400 mg in the evening) is administered, which is escalated to the standard dose in Cycle 2, if no Hand-foot skin reaction (HFSR), fatigue, or gastrointestinal (GI) toxicities of grade 2 or higher occur. For the purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Progressive Disease (PD) {PD as defined by mRECIST criteria or clinical progression [e.g. Eastern Cooperative Oncology Group performance status (ECOG PS) of ≥3], treatment may be continued past radiological progression, provided the patient derives clinical benefit as judged by the treating physician.}, Death, Unacceptable toxicity, Subject withdraws consent, Treating physician determines discontinuation of treatment is in the subject's best interest, Substantial non-compliance with the protocol
3096544|NCT01915589|Experimental|Refametinib (BAY86-9766)|For purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Death Unacceptable toxicity Subject withdraws consent Substantial non-compliance with the protocol Treating physician determines discontinuation of treatment is in the subject's best interest. Radiological progression as determined by RECIST (Version 1.1) or mRECIST criteria or clinical progression (e.g. Eastern Cooperative Oncology group performance status - ECOG PS ≥3) patients may continue to receive study treatment if identified as having continued clinical benefit as judged by the treating physician.
3096545|NCT01915576|Experimental|BAY1125976 [once daily, dose-esc.]|Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
3096546|NCT01915576|Experimental|BAY1125976 [twice daily, dose-esc.]|Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
3096547|NCT01915576|Experimental|BAY1125976 [MTD]|Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
3096548|NCT01915563|No Intervention|SBT and extubation|After a SBT patients will be extubated as usual
3096549|NCT01915563|Experimental|SBT and rest 60 min before extubation|After SBT patients will be reconnected to mechanical ventilation during 60 min before extubation
3096550|NCT01915550|Active Comparator|metformin|metformin was added without raising the insulin dose
3096551|NCT01915550|Active Comparator|Raising Insulin|insulin dose is raised
3096552|NCT01915537|Experimental|Infliximab group|Infliximab with MTX treatment
3096553|NCT01915537|Active Comparator|Classic DMARDs treatment group|Classic DMARDs treatment（MTX 、LEF 、HCQ 、 LEF ）
3096554|NCT01915524|Experimental|CV9202 and local radiation|"CV9202 consisting of 6 RNActive-derived molecules coding for 6 different NSCLC associated antigens.~local radiation (4x5 Gy)"
3096555|NCT01915511||Subjects with a new IPF diagnosis|Subjects with a new diagnosis of IPF established at the time of enrollment in the registry.
3096556|NCT01915498|Experimental|AG-221|AG-221 administered orally. Multiple doses.
3096557|NCT01915485|Experimental|Lu 177|progressive metastatic medullary thyroid cancer
3096558|NCT01915472|Experimental|IMMU 130|
3096559|NCT01915459|Experimental|Botulinum toxin type A(Botulax®)|Botulinum toxin type A
3096560|NCT01915459|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A
3096561|NCT01915433|Experimental|Wahls Paleo Plus|Wahls Paleo Plus diet (ketogenic diet)
3096562|NCT01915433|Experimental|Wahls Diet|Wahls Diet (modified paleolithic diet)
3096563|NCT01915433|No Intervention|Usual Care|Control - usual care only.
3096564|NCT01915394||Hospitalized Respiratory Syncytial Virus Infected Newborns|All admitted newborns to the neonatal intensive care unit (NICU) will be enrolled in the study
3096565|NCT01915381|Active Comparator|Control group|follow up detraining effect of multimodal intervention
3096566|NCT01915381|Experimental|application smartphone-based group|Smartphone-based application group (SG) sample will have a reminder to do Phisical activity everyday where patients will have to select if they have done or they haven´t done physical activity.
3096567|NCT01915368|Active Comparator|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
3096568|NCT01915368|Experimental|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
3096569|NCT01915368|Experimental|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
3096570|NCT01915355|Experimental|Pulsed Dye Laser for fungus treatment|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
3096571|NCT01915342|Experimental|Focal muscle vibration|"Focal muscular vibration will be applied at mGCM of each subject for 10 minutes in each session.~Frequency: 40, 80, 120 Hz Amplitude: 0.1, 0.3, 0.5 mm"
3096572|NCT01915329|Experimental|Verum-RSS|RSS Stimulation with high frequency electric pulses
3096573|NCT01915329|Sham Comparator|Sham-RSS|Sham RSS Stimulation (no pulses are transmitted)
3096574|NCT01915316||Prostate cancer|Men. Subjects have undergone primary and at least one secondary prostate biopsy with negative diagnostics. Elevated PSA (Prostate Specific Antigen), typically above 10 ng/mL.
3096575|NCT01915303|Experimental|pasireotide +/- cabergoline|pasireotide alone or with cabergoline
3096576|NCT01915290||1600 elderly participants|Norwegian elderly population
3096577|NCT01915277|Experimental|Neonate dosing cohort 1|Neonate dexmedetomidine dosing cohort 1
3096578|NCT01915277|Experimental|Neonate dosing cohort 2|Neonate dexmedetomidine dosing cohort 2
3096579|NCT01915277|Experimental|Neonate dosing cohort 3|Neonate dexmedetomidine dosing cohort 3
3096580|NCT01915277|Experimental|Neonate dosing cohort 4|Neonate dexmedetomidine dosing cohort 4
3096581|NCT01915277|Experimental|Neonate dosing cohort 5|Neonate dexmedetomidine dosing cohort 5
3096582|NCT01915277|Experimental|Infant dosing cohort 1|Infant dexmedetomidine dosing cohort 1
3096583|NCT01915277|Experimental|Infant dosing cohort 2|Infant dexmedetomidine dosing cohort 2
3096584|NCT01915277|Experimental|Infant dosing cohort 3|Infant dexmedetomidine dosing cohort 3
3096585|NCT01915277|Experimental|Infant dosing cohort 4|Infant dexmedetomidine dosing cohort 4
3096586|NCT01915277|Experimental|Infant dosing cohort 5|Infant dexmedetomidine dosing cohort 5
3096587|NCT01915264||Group 1|
3096588|NCT01915212|Experimental|HSV1+or-/HSV2+|Healthy volunteers who are or are not infected (as determined by serology testing) with HSV-1 but are infected wtih HSV-2
3096589|NCT01915212|Experimental|HSV1+/HSV2-|Healthy volunteers who are infected wtih HSV-1 but not with HSV-2, as determined by serology testing.
3096590|NCT01915212|Experimental|HSV1-/HSV2-|Healthy volunteers who have not been infected with HSV-1 or HSV-2, as determined by serology testing
3096591|NCT01915199|Experimental|Intervention|Patients in this arm received a comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance.
3096592|NCT01915199|No Intervention|Control|Patients randomized in this group did not receive any intervention and treatment continued according to conventional practice.
3096593|NCT01915186|Experimental|Dihydroepiandrosterone (DHEA)|DHEA 25mg 3 times a day for 12 weeks
3096594|NCT01915186|Placebo Comparator|Placebo|Matched placebo capsules are given 3 times a day for 12 weeks
3096595|NCT01915173|Experimental|Supplement + Expanded Interview|Supplement, 2 tablets sublingually 3 times a day for 2 weeks.
3096596|NCT01915173|Placebo Comparator|Placebo + Standard Interview|Placebo, 2 tablets sublingually 3 times a day for 2 weeks.
3096597|NCT01915173|Experimental|Supplement + Standard Interview|Supplement, 2 tablets sublingually 3 times a day for 2 weeks.
3096598|NCT01915173|Placebo Comparator|Placebo + Expanded Interview|Placebo, 2 tablets sublingually 3 times a day for 2 weeks.
3096599|NCT01915160|Active Comparator|treatment as usual|Trauma Focused- Cognitive Behavioral Therapy (TF-CBT)
3096600|NCT01915160|Experimental|tablet assisted therapy toolkit|electronically assisted Trauma Focused-Cognitive Behavioral Therapy (eTF-CBT)
3096601|NCT01915147|Experimental|OXN PR followed by OxyPR tablets|OXN PR followed by OxyPR tablets
3096602|NCT01915147|Experimental|OxyPR followed by OXN PR tablets|OxyPR followed by OXN PR tablets
3096603|NCT01915134|Experimental|EGP group|the group of participants who undergoing Recombinant Human Endostatin plus Gemcitabine and cisplatin chemotherapy
3096604|NCT01915134|Active Comparator|GP group|the group of participants who undergoing only Gemcitabine and cisplatin chemotherapy
3096605|NCT01915121|Active Comparator|Education Intervention|In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer.
3096606|NCT01915121|Placebo Comparator|Nutrition Intervention|In this session, participant will be provided with information about nutrition information directly related to bladder cancer recovery
3096607|NCT01915108|No Intervention|group R0|remifentanil Ce of 0 ng/ml
3096608|NCT01915108|Active Comparator|group R0.5|remifentanil Ce of 0.5 ng/ml
3096609|NCT01915108|Active Comparator|group R1.0|remifentanil Ce of 1.0 ng/ml
3096610|NCT01915108|Active Comparator|group R1.5|remifentanil Ce of 1.5 ng/ml
3096611|NCT01915095|Active Comparator|Motor task+ Magnetic stimulation|Participants will be asked to complete a precision grip with the index and thumb finger at the same time as flexing or extending the wrist. magnetic stimulation to the brain will be administered and measurements will be taken during movement.
3096612|NCT01915095|Active Comparator|rTMS/sham rTMS|Participant will be randomly assigned to one of 3 groups: repetitive transcranial magnetic stimulation (rTMS), sham (fake) rTMS, or sham (fake) rTMS over control brain area will be administered to the brain. the stimulation will be targeting finger and wrist muscles during movement.
3096613|NCT01915095|Active Comparator|Training + rTMS/ Sham rTMS|Participants will be asked to follow a target line on the computer as accurately as possible while performing precision grips or foot movement . Magnetic stimulation will be given during rest and movement.
3096614|NCT01915082|Experimental|Azithromycin|"A first dose of azithromycin (25 mL po syrup = 1000 mg) will be given during preparation for subsequent lung transplantation (Day 0).~After lung transplantation, 'add on' treatment of azithromycin (6.25 mL = 250 mg) syrup will be given via (naso)gastric tube or per os every other day (days 1,3,5,7,9,11,13,15,17,19,21,23,25,27,29 and 31)."
3096615|NCT01915082|Placebo Comparator|Ora-Plus|"A first dose of placebo (25 mL po syrup) will be given during preparation for subsequent lung transplantation (Day 0).~After lung transplantation, 'add on' treatment of placebo (6.25 mL) syrup will be given via (naso)gastric tube or per os every other day (days 1,3,5,7,9,11,13,15,17,19,21,23,25,27,29 and 31)."
3096616|NCT01915069|Experimental|Cilostazol|The primary aim of the study is to assess the affects of oral Cilostazol taken at the FDA approved dose of 100mg PO bid on human oocyte maturation.
3096617|NCT01915056|No Intervention|Control Arm|Control Arm = Standard of Care. Patients who are randomized to the control arm will only have abnormal results on Geriatric Depression Scale (GDS) and cognitive evaluation communicated to their primary oncologist, as is customary. These results will be communicated to the primary team via electronic medical record and/or email communication. No other summary will be provided to oncologist.
3096618|NCT01915056|Experimental|Treatment Arm|Treatment Arm = Standard care plus GA results and recommendations. For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic (GA-driven intervention). The intervention consists of providing results of geriatric assessment in a summary to oncologists.
3096619|NCT01915043|Active Comparator|health education for lymphedema prevention|health education for lymphedema prevention
3096620|NCT01915043|Experimental|application smartphone-based group|Health education plus Smartphone-based application sample will have a reminder to do education everyday where patients will have to select if they have done or they haven´t done compliance
3096621|NCT01915030|Experimental|High protein diet|High protein diet during caloric restriction
3096622|NCT01915030|Placebo Comparator|Standard protein diet|Standard protein diet during caloric restriction
3096623|NCT01915017|Experimental|Cognitive Behavior Therapy for Psychosis|Cognitive behavior therapy for psychosis is a manual-driven collaborative talk-therapy designed to help the individual identify appraisal biases and cognitive distortion, identify alternative explanations for events, and find ways to cope with the distress caused by persistent psychotic symptoms.
3096624|NCT01915017|Experimental|Cognitive Adaptation Training|CAT is a manual driven treatment using environmental supports such as signs, alarms, checklists, electronic devices, and the organization of belongings to bypass cognitive and motivational impairments and to cue and sequence adaptive behavior.
3096625|NCT01915017|Experimental|Multi-modal Cognitive Therapy|Combines Cognitive Behavior Therapy for Psychosis and Cognitive Adaptation Training into one home-delivered intervention
3096626|NCT01915017|Active Comparator|Treatment as Usual|Medication follow up and limited case management provided by the local community mental health center
3096627|NCT01915004|Other|Standard Invididual Urotherapy|Educational Intervention. Standard individual urotherapy (bladder re-training) occurs in the pediatric urology clinic.
3096628|NCT01915004|Experimental|Bladder Training Video|Experimental Educational Intervention. Participants will watch a 7 minute animated bladder training video.
3096629|NCT01914991|Active Comparator|Control group|Conventional treatment: The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
3096630|NCT01914991|Experimental|Experimental group|dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
3096631|NCT01914978|Experimental|Handbook|Food allergy handbook for parents
3096632|NCT01914978|Placebo Comparator|Treatment as usual|Food allergy treatment as usual
3096673|NCT01914705|Active Comparator|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
3096760|NCT01914081|Placebo Comparator|Placebo|500 mg (1 capsule BID) of placebo for 12 months.
3096633|NCT01914965|Active Comparator|Bupropion|First treatment group: 150 mg bupropion or placebo once daily for 2 weeks, followed by 300 mg bupropion or placebo once daily for subsequent 8 weeks (until week 10; visit 4) First tapering and washout: 150 mg bupropion or placebo once daily for 7 days followed by a washout phase of 1 week on placebo
3096634|NCT01914965|Placebo Comparator|Placebo|Second treatment group (crossover): placebo or 150 mg bupropion once daily for 2 weeks, followed by placebo or 300 mg bupropion once daily for subsequent 8 weeks (until week 22; visit 6) Second tapering placebo or 150 mg bupropion once daily for 7 days
3096635|NCT01914952|Active Comparator|CaHMB Capsule|
3096636|NCT01914952|Active Comparator|HMB free acid gelcap|
3096637|NCT01914952|Active Comparator|HMB free acid in water|
3096638|NCT01914952|Active Comparator|CaHMB powder in water|
3096639|NCT01914952|Active Comparator|HMB free acid (oral not in gelcap or water)|
3096640|NCT01914939|Experimental|Social Skills Focused CBT|Twelve weekly 60-minute sessions of social skills focused CBT
3096641|NCT01914939|Active Comparator|Stress Management/Relaxation Training|Twelve weekly 60-minute sessions of stress management training
3096642|NCT01914939|Experimental|Oxytocin|Intranasal administration of 24 IU of oxytocin
3096643|NCT01914939|Placebo Comparator|placebo drug|Intranasal placebo drug
3096644|NCT01914926|Active Comparator|Metoprolol Study Group|Patients Receiving metoprolol administered at a dose of 0.15 mg/kg (to a maximum dose of 10 mg)
3096645|NCT01914926|Active Comparator|Diltiazem Study Group|Patients receiving diltiazem administered parenterally at a dose of 0.25 mg/kg (to a maximum dose of 30 mg)
3096646|NCT01914913|Other|BMMNCs|BMMNCs
3096647|NCT01914900|Experimental|induction TPF chemotherapy|
3096648|NCT01914887|Experimental|allogeneic ASCs|Treatment consists in a cell suspension (5 million cells/mL) in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
3096649|NCT01914874|Experimental|Mindfulness Meditation|12 weekly sessions in group format
3096650|NCT01914874|No Intervention|Wait-list|Patients will receive the mindfulness intervention after a 12-week wait period
3096651|NCT01914861||Men/Women, 21-65, following exposure to a traumatice event|
3096652|NCT01914848|Active Comparator|Control Group|A routine care discharge planning with the social service
3096653|NCT01914848|Experimental|Advance Care Planning ACP|Patient get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.
3096654|NCT01914835|Experimental|Motivational Chess & Active Control|Ten meetings of 90 minutes each.
3096655|NCT01914822|Experimental|methylphenidate hydrochloride|The study will include two sessions which will be conducted at the same time of the day, one week apart from each other. Each session will last approximately 6 hours. In each session subjects will be exposed to baseline experimental pain models and auditory tests. Then they will receive either one MP SR 20 mg tablet or an identical looking placebo.
3096656|NCT01914822|Placebo Comparator|Sugar pill|The study will include two sessions which will be conducted at the same time of the day, one week apart from each other. Each session will last approximately 6 hours. In each session subjects will be exposed to baseline experimental pain models and auditory tests. Then they will receive either one MP SR 20 mg tablet or an identical looking placebo.
3096657|NCT01914809|Experimental|group with a preeclampsia before 34 SA|
3096658|NCT01914809|Other|group with a normal pregnancy|
3096659|NCT01914796|Placebo Comparator|Single ascending doses|
3096660|NCT01914796|Placebo Comparator|Measurement of eye blink rate|
3096661|NCT01914783|Experimental|ultrafine particles|Subjects will be exposed to ultrafine particles for three hours in an exposure chamber. During that time participants will perform intermittent bicycle ergometer training. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. Blood pressure will be measured every 15 minutes. Ultrafine elemental carbon black particles are generated using a commercially available electric spark generator. Particle number, mass, and size distribution will be monitored during exposure.
3096662|NCT01914783|Active Comparator|ultrafine particles and ozone|Subjects will be exposed to ultrafine particles for three hours in an exposure chamber. During that time participants will perform intermittent bicycle ergometer training. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. Blood pressure will be measured every 15 minutes. Ultrafine elemental carbon black particles are generated using a commercially available electric spark generator. Particle number, mass, and size distribution will be monitored during exposure.Ozone is generated from medical oxygen in order to maintain a concentration of 250 ppb.
3096663|NCT01914783|Placebo Comparator|clean air|Subjects will be exposed to clean air for three hours in an exposure chamber controlled for temperature, humidity, and gas/particle composition. During that time they will perform intermittent bicycle ergometer training for 15 minutes alternating with 15 minutes rest. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. The blood pressure will be measured in time intervals of 15 minutes.
3096664|NCT01914770||Adults with systemic lupus erythematosus (SLE)|Subjects with SLE receiving ongoing stable SLE treatment
3096665|NCT01914757|Experimental|Benralizumab 30 mg q.4 weeks|Benralizumab administered subcutaneously every 4 weeks
3096666|NCT01914757|Experimental|Benralizumab 30 mg q.8 weeks|Benralizumab administered subcutaneously every 8 weeks
3096667|NCT01914757|Placebo Comparator|Placebo|Placebo administered subcutaneously
3096668|NCT01914744|Experimental|entecavir|entecavir 0.5 mg/day PO
3096669|NCT01914744|Active Comparator|lamivudine|lamivudine 100 mg/day PO
3096670|NCT01914731|Experimental|Capsule|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via frozen capsule"
3096671|NCT01914718|Experimental|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
3096672|NCT01914705|Active Comparator|Landmark Procedure|Using Landmarks to guide SCVC placement
3096674|NCT01914692|Experimental|Somatostatin group|Patients with Advanced Gastric Cancer After D2 Lymph Node Dissection accept the Somatostatin medical therapy.
3096675|NCT01914692|Placebo Comparator|Blank group|Use the normal saline instead of somatostatin.
3096676|NCT01914679|Experimental|Sham followed by device|4 weeks of inactive (sham) RINCE therapy involving no RINCE therapy followed by 12 weeks of RINCE therapy involving 24 total treatments
3096677|NCT01914666|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. Tapering week doses of 40 mg for first week and 20 mg for second week.
3096678|NCT01914653|Experimental|Pre-radiated|
3096679|NCT01914653|Experimental|Not radiated|
3096680|NCT01914653|Experimental|Post-radiated|
3096681|NCT01914640||Healthy adults living in Turkey|The group was enrolled from the 24 provinces of the 7 regions of Turkey. At least 3 provinces were selected from each region by a random sampling method. The populations of these 7 regions were obtained from the records of the 2000 census. The study sample included males and non-pregnant females aged between 20 and 83 years. The populations of city centers, districts, and villages were classified by using the stratified sampling method and then were selected from the data collected from the household identification forms by random sampling. The geography of Turkey was classified into three groups according to altitude. Sea level was accepted as zero. 0-300 m was taken as coastal, 300-900 m as moderate
3096682|NCT01914627|Experimental|Loion|
3096683|NCT01914627|Active Comparator|SA-Gel|
3096684|NCT01914614||Working Poor Survivors|Low Wage workers
3096685|NCT01914614||Non-Working Poor Survivors|Higher-Wage Salary Workers
3096686|NCT01914601|Active Comparator|Macintosh-King Vision|laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope
3096687|NCT01914601|Active Comparator|King Vision-Macintosh|laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
3096688|NCT01914588|Experimental|Telemonitoring + Standard care|
3096689|NCT01914588|Active Comparator|Standard care|
3096690|NCT01914575|Experimental|Dipole Density Mapping|
3096691|NCT01914562|Experimental|OCA 10 mg while fasted|OCA 10 mg orally in the fasting state
3096692|NCT01914562|Experimental|OCA 10 mg while Fed|OCA 10 mg orally in the fed state
3096693|NCT01914562|Experimental|OCA 25 mg while fasted|OCA 25 mg orally in the fasting state
3096694|NCT01914562|Experimental|OCA 25 mg while Fed|OCA 25 mg orally in the fed state
3096695|NCT01914549|Experimental|Dipole Density Mapping|
3096696|NCT01914536||Pompe patients|Adult onset pompe patients being or not treated with enzyme therapy replacement
3096697|NCT01914523|Placebo Comparator|Macintosh|tracheal intubation will be performed using a Macintosh
3096698|NCT01914523|Active Comparator|King Vision|tracheal intubation will be performed using a King Vision
3096699|NCT01914523|Active Comparator|Glidescope|tracheal intubation will be performed using a Glidescope
3096700|NCT01914523|Active Comparator|AirTraq|tracheal intubation will be performed using a AirTraq
3096701|NCT01914510|Experimental|ENMD-2076|ENMD-2067 will be taken orally at a dose of 275 mg, once a day, everyday. Patients with a body surface area of less than 1.65 m2 will receive a starting dose of 250 mg, once a day, everyday.
3096702|NCT01914497|Experimental|Acutus Medical System|Proprietary software algorithms will be used generate electrical activation maps based dipole density data acquired by the Acutus Medical Catheter during the procedures. These activation maps will then be applied to a 3D model of the endocardial surface to create a 3D activation map.
3096703|NCT01914484|Experimental|Nilotinib with Ruxolitinib|"Nilotinib: Given that recommended dose of Nilotinib for imatinib failed CML patients is 400mg twice daily, Nilotinib dose will remain fixed at 400mg bid throughout the cycles.~Ruxolitinib: In the phase I part of the study, dose escalation will follow a 3+3 study design. Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose. Ruxolitinib will be given at one of 3 fixed dose levels for the duration of their treatment, either 10mg twice daily, 15mg twice daily or 20mg twice daily."
3096704|NCT01914471|No Intervention|Control|These schools did not receive the intervention.
3096705|NCT01914471|Experimental|Students for Nutrition and eXercise|These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
3096706|NCT01914458|Experimental|Low-dose computed tomography (LDCT)|Patients will have one baseline LDCT scan.
3096707|NCT01914445|Experimental|Indigo Carmine|Indigo Carmine (2 mg per kilo) and 2nd half of PEG dose will be orally administered to patients prior to colonoscopy.
3096708|NCT01914432|Experimental|YH16410|PO, Once Daily, 8 weeks
3096709|NCT01914432|Active Comparator|Rosuvastatin|PO, Once Daily, 8 weeks
3096710|NCT01914432|Active Comparator|Telmisartan|PO, Once Daily, 8 weeks
3096711|NCT01914432|Placebo Comparator|Placebo|PO, Once Daily, 8 weeks
3096712|NCT01914419|Active Comparator|IV infusion|Oxytocin 10 IU will be administered by IV infusion according to randomization assignment as soon as possible after delivery of the baby.
3096713|NCT01914419|Active Comparator|IV bolus|Oxytocin 10 IU will be administered by IV bolus according to randomization assignment as soon as possible after delivery of the baby.
3096714|NCT01914419|Active Comparator|IM injection|Oxytocin 10 IU will be administered by IM injection according to randomization assignment as soon as possible after delivery of the baby.
3096715|NCT01914406|Other|high intense interval training|Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
3096716|NCT01914406|Active Comparator|continuous moderate training|Continued exercise 45 min.
3096717|NCT01914393|Experimental|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg, flexibly dosed, once daily
3096718|NCT01914380||Group 1|
3096719|NCT01914367|Active Comparator|Cervarix group|One sib of each twin pair will be given Cervarix according to the 0, 1, 6 month vaccination scheme.
3096720|NCT01914367|Active Comparator|Gardasil Group|One sib of each twin pair will be given Gardasil according to the 0, 1, 6 month vaccination scheme.
3096723|NCT01914315|Experimental|Cardiac Rehabilitation|Patients randomized to the multidisciplinary cardiac management program at the cardiac rehabilitation center will undergo evaluation by a trained rehabilitation physician and physiologist. The evaluation will include medical history, physical examination, vitals, review of post discharge graded exercise stress test and nursing staff consultation. Exercise prescription will be based on a pre-specified protocol in accordance with ESC position paper on cardiac rehabilitation of patients with heart failure.
3096724|NCT01914315|Active Comparator|Internal Medicine|Following discharge, patients will return to the internal medicine (IM) outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated.
3096725|NCT01914302||Delica Lancing Device|Subjects in this group either use the Delica lancing device or a meter that requires 1.0 microliters of blood
3096726|NCT01914302||Freestyle Flash Lancing Device|Subjects in this group either use the Flash lancing device or a meter that requires 0.3/0.6 microliters of blood
3096727|NCT01914302||Easy Touch Lancing Device|Subjects in this group either use the Easy Touch lancing device or a meter that requires 0.3/0.6 microliters of blood
3096728|NCT01914302||Glucoject Lancing Device|Subjects in this group either use the Glucoject lancing device or a meter that requires 0.3/0.6 microliters of blood
3096729|NCT01914302||Microlet Lancing Device|Subjects in this group either use the Microlet lancing device or a meter that requires 0.3/0.6 microliters of blood
3096730|NCT01914302||Multiclix Lancing Device|Subjects in this group either use the Multiclix lancing device or a meter that requires 0.3/0.6 microliters of blood
3096731|NCT01914302||Fastclix Lancing Device|Subjects in this group either use the Fastclix lancing device or a meter that requires 0.3/0.6 microliters of blood
3096732|NCT01914302||Reli-On Lancing Device|Subjects in this group either use the Reli-On lancing device or a meter that requires 0.3/0.6 microliters of blood
3096733|NCT01914289|Experimental|Resection|To observe prognosis of resection of icc
3096734|NCT01914289|Active Comparator|Radiotherapy|To observe the prognosis of radiotherapy treatment of icc
3096735|NCT01914263|Experimental|cytokine induced killer cell|The eligible patients are infused a single dose of 8x10^9 CIK cells.
3096736|NCT01914263|No Intervention|Control|The eligible patients are followed up for 30 days without any treatment.
3096737|NCT01914250|Active Comparator|2|Topical Anesthetic, 2% Tetracaine oral gel - Group A Topical Anesthetic, 20% Benzocaine oral gel - Group B
3096738|NCT01914237|Experimental|Castor Stent Graft|To study the safety and efficacy of Castor single-branched stent graft system in endovascular repair of aortic dissection.
3096739|NCT01914224|Experimental|Group 1|dietary education of low sodium and high potassium consumption
3096740|NCT01914224|Active Comparator|Group 2|dietary education of low sodium consumption only
3096741|NCT01914211||Acute Normovolemic Hemodilution|Patients that receive acute normovolemic hemodilution prior to surgery.
3096742|NCT01914211||Tranexamic Acid|Patients that receive tranexamic acid during surgery.
3096743|NCT01914198||Sleep study|Patients who are having a sleep study done at NCH to diagnose sleep apnea.
3096744|NCT01914185|No Intervention|Comparison Schools|Regular health promotion activities
3096745|NCT01914185|Experimental|Comprehensive School Health (CSH)|Full time School Health Facilitator present in each school on a day-to-day basis for 3.5 years responsible for facilitating implementation of Comprehensive School Health
3096746|NCT01914172||Online web-based questionnaire|Up to 200 patients with KS/CHH will be recruited to complete an online web-based questionnaire (less than 30 minutes to complete)
3096747|NCT01914172||Patient focus group|Focus groups (90-120 minutes in duration) with 6-12 patients. Up to 36 patients total
3096748|NCT01914172||Online web-based evaluation of patient education materials|Up to 100 patients with KS/CHH will be recruited to complete an online web-based questionnaire to evaluate patient education materials (less than 15 minutes to complete)
3096749|NCT01914159|Experimental|Ranibizumab|
3096750|NCT01914146|Other|Before Initiation of Insulin Therapy|Study sessions will occur before the initiation of insulin therapy (no insulin). Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
3096751|NCT01914146|Other|After Initiation of Insulin Therapy|Study session will take place 2-4 weeks after the initiation of insulin therapy. Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
3096752|NCT01914133|No Intervention|No Postprandial Hypotension (PPH)|Screening Meal Test performed and subject does not meet criteria for Postprandial Hypotension (PPH).
3096753|NCT01914133|Placebo Comparator|Placebo|Screening Meal Test performed and subject meets criteria for Postprandial Hypotension (PPH). At second Meal Test subject will receive a placebo and will take a placebo with the first bite of the next 3 meals.
3096754|NCT01914133|Active Comparator|Acarbose|Screening Meal Test performed and subject meets criteria for Postprandial Hypotension. During the second Meal Test subject will receive Acarbose 50mg and will take Acarbose 25mg with first bite of each of the next 3 meals.
3096755|NCT01914107|Experimental|standard cancer pain care|the standard cancer pain care group: 1.will be follow-up by the cancer nurse once a week to acknowledge the cancer pain intensity, the current analgesic medication, and the side effects. and also give recommendations. 2.filled in the patient'diary and hand over to researchers.
3096756|NCT01914107|Experimental|real-time monitoring and instruction of cancer pain|"real-time monitoring and treatment instruction of cancer pain group~1.follow the same pattern of standard cancer pain care. 2. using the cloud computing concept system, install the software in the mobile phone of patients. the patients will fill in the content of brief pain inventory, medication and side effect, and upload to researchers every 2 days. 3. Researcher monitor the cancer pain treatment in realtime and give instructions."
3096757|NCT01914094|No Intervention|Standard care|Received current standard care.
3096758|NCT01914094|Experimental|Prehab|Received pre-operative exercise therapy plus education classes concerning management of their risk factors for coronary artery disease at a local medical fitness facility.
3096759|NCT01914081|Active Comparator|Resveratrol|500 mg (1 capsule BID) of resveratrol for 12 months
3096761|NCT01914068|No Intervention|Control|No in hospital exercise training and no exercise advice.
3096762|NCT01914068|Active Comparator|Exercise Intervention|In hospital exercise training
3096763|NCT01914055|Active Comparator|angio-guided thrombus aspiration|thrombus aspiration guided by angiography
3096764|NCT01914055|Experimental|OCT-guided thrombus aspiration|thrombus aspiration guided by optical coherence tomography
3096765|NCT01914042|Experimental|Morphine|Morphine in changing dosages (range between 10-60 mg twice a day). Opioid titration proceeds as follows: starting at an oral dose of 10 mg twice per day, followed every 5 days by a dose increase of 10 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 120 mg per day had been reached.
3096766|NCT01914042|Active Comparator|Milnacipran|Milnacipran (Ixel)- a serotonin-norepinephrine reuptake inhibitor (SNRI), will be administrated in changing dosages (range between 12.5-75 mg twice daily). SNRI titration proceeds as follows: starting at an oral dose of 12.5 mg twice per day, followed every 5 days by a dose increase of 12.5 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 150 mg per day had been reached.
3096767|NCT01914016|Other|prolonged walk|
3096768|NCT01914003||CSID Mutations|Individual has one or more known CSID mutations.
3096769|NCT01914003||Control|Individual does not have any known CSID mutations.
3096770|NCT01913990|Other|Arm A: Standard Anti-emetic regimen|"The standard anti-emetic arm:~In this arm the treating medical oncologist will determine the choice of anti-emetic regimen that they perceive the patient would require and prescribe it. The treating physician will be blinded to result of the personalized composite emesis score. The physician may or may not choose to prescribe an NK-1 inhibitor as the study will not predetermine the type of anti-emetics used. In the event that the patient experienced chemo induced nausea and vomiting (CINV), modifications to the initial anti emetic regimen would be left to the treating physician."
3096771|NCT01913990|Experimental|Arm B: Dexamethasone, Ondansetron, Aprepitant|"The emesis risk model arm:~Prior to the start of intravenous chemotherapy an emesis risk score will be calculated for both acute and delayed emesis. The anti-emetic prophylaxis treatment will follow the emesis risk score. Whereby either an acute emesis score of ≥7 and/or a delayed emesis score of >16 will be considered high-risk. The anti-emetics will be prescribed reflecting this risk for pre-chemotherapy, 8 hrs post chemotherapy and day 2-3 post chemotherapy. Dexamethasone, Ondansetron and Aprepitant will be given in different combination and doses depending on what score the participant receives based on their responses to the diary. For subsequent cycle the anti-emetic score will be re-calculated prior to each cycle and the choice of anti-emetics adjusted if necessary."
3096772|NCT01913977|Experimental|Treatment with mechanical ventilation|Abylcap system with the oxygenator Lilliput2 as CO2 remover (Bellco, Italy).
3096773|NCT01913964|Experimental|Acetyl-L-carnitine|2 g daily for 12 months
3096774|NCT01913964|Placebo Comparator|placebo|
3096775|NCT01913951|Experimental|Treatment (vosaroxin, azacitidine)|Patients receive vosaroxin IV over 10 minutes on days 1 and 4 and azacitidine SC or IV over 15 minutes on days 1-7. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3096776|NCT01913938||patients with cytopenias|Patients with sepsis and concomitant cytopenias (leukopenia with thrombocytopenia and anemia) who are routinely treated with rhG-CSF will be followed for reconstitution of peripheral blood cell counts. In cooperation with the Department of Hematology, patients are examined for bone marrow cellularity and hemophagocytosis if G-CSF treatment does not result in leukocyte increase.
3096777|NCT01913925|Active Comparator|Tyrosine-Containing Food Bar|150 mg/kg dose of tyrosine per administration, administered twice
3096778|NCT01913925|Placebo Comparator|Placebo bar|0 mg/kg dose of tyrosine per administration, administered twice
3096779|NCT01913912|Active Comparator|Lisdexamfetamine dimesylate (LDX)|Children will continue their therapeutic dose of LDX during the DBPC phase (which is determined during the titration phase). Before each testing session there will be a washout period of at least 48 hours; the optimal dose of LDX will be given the morning of the testing at the DRUG unit. For blinding purpose we will blindfold the children when taking LDX at the DRUG unit.
3096780|NCT01913912|Placebo Comparator|Sugar pill|Children will continue their therapeutic dose of LDX during the DBPC phase (which is determined during the titration phase). Before each testing session there will be a washout period of at least 48 hours; the placebo will be given the morning of the testing at the DRUG unit. For blinding purpose we will blindfold the children when taking placebo at the DRUG unit.
3096781|NCT01913899|Experimental|Mirror therapy|60 minutes of mirror therapy each day over a period of 14 days starting directly post surgically (24-48 hours after surgery)
3096782|NCT01913899|Active Comparator|Occupational/ physical therapy|60 minutes of occupational/ physical therapy each day over a period of 14 days starting 24-48 hours post surgically
3096783|NCT01913886|Experimental|MSCs injection|Injection of autologous bone marrow-derived mesenchymal cells
3096784|NCT01913873|Experimental|Cardiac biomarkers concentration changes|"In 2012 the Third Global MI Task Force has presented a third universal definition of MI implying that MI associated with CABG is arbitrarily defined by elevation of cardiac biomarkers values > 10x99th percentile URL in patients with normal baseline cTn values (≤ 99th percentile URL), in addition with either (i) new pathological Q waves or new LBBB (left bundle branch block), or (ii) angiographic documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.~In this study we will measure the concentration changes over time of cardiac biomarkers (hs-cTN and CK-MB) and establish a threshold value for myocardial injury, diagnosed by ECG and approved -if necessary- by echocardiography."
3096785|NCT01913860|No Intervention|Control|Control group will receive usual care
3096786|NCT01913860|Active Comparator|Improve GP prescribing behaviour|Improve GP prescribing behaviour will be promoted through personalised audit and feedback reports, delivered through face to face workshops within practice.
3096787|NCT01913860|Active Comparator|Improved delayed GP prescribing|Improved delayed GP prescribing will be promoted through the antibiotic prescribing guidelines and personalised audit and feedback reports. Additional scientific evidence will be provided related to delayed prescribing.
3096790|NCT01913834|Active Comparator|Forsteo|Synthetic PTH 1-34 Single dose Subcutaneous administration 20.0 micrograms
3096791|NCT01913834|Experimental|CP046 PTH CriticalSorb 22.5 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 22.5 micrograms
3096792|NCT01913834|Experimental|CP046 PTH CriticalSorb 45.0 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 45.0 micrograms
3096793|NCT01913834|Experimental|CP046 PTH CriticalSorb 90.0 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 90.0 micrograms
3096794|NCT01913834|Experimental|CP046 PTH CriticalSorb 90.0 O|Synthetic PTH 1-34 Single dose Nasal administration 90 micrograms
3096795|NCT01913808|Experimental|Ferric carboxymaltose|Ferric carboxymaltose (Ferinject®, Vifor-France) was given as a single i.v. dose to correct the total iron deficit calculated by the Ganzoni formula (total iron deficit [mg] = 2.4 x patient's weight [kg] x (target Hb [13 g/dL] - current Hb [g/dL]) + 500 [mg iron stores]
3096796|NCT01913808|Active Comparator|Ferrous glycine sulphate|Ferrous glycine sulphate (Ferbisol-Bial Industrial Farmacéutica, Spain) was given as a once daily oral dose of 100 mg iron from the day of discharge (Day 7) to the rehabilitation visit 30 days after surgery
3096797|NCT01913795|Active Comparator|Environmental Intervention|4 classroom air purifiers and school integrated pest management environmental intervention
3096798|NCT01913795|Placebo Comparator|Sham and Control|4 sham air purifiers and no school integrated pest management environmental intervention
3096799|NCT01913795|Placebo Comparator|Active Air Purifier and Control|4 air purifiers and no school integrated pest management environmental intervention
3096800|NCT01913795|Sham Comparator|Sham and Integrated Pest Management|4 classroom sham air purifiers and school integrated pest management
3096801|NCT01913782||patients with low back pain|"Patients with disc herniation or radiculitis who are over 18 years of age.~Patients with a history of chronic function-limiting low back pain and lower extremity pain for at least one months' duration.~Patients who are competent to understand the study and provide written informed consent and participate in outcome measurements."
3096802|NCT01913769||Radiation therapy|Thoracic cancer patient s/p scheduled RT will be arranged to undergo Thallium-201 Myocardial Perfusion Study. The scheduled RT will be arranged by clinical judgments of radiation-oncologists. All of the patients will receive myocardial SPECT before and after the scheduled RT.
3096803|NCT01913756|Experimental|Gouda-type cheese|80 g/day Gouda-type cheese
3096804|NCT01913756|No Intervention|Low cheese intake|
3096805|NCT01913756|Experimental|Gamalost (Norwegian traditional cheese)|50 g/day Gamalost
3096806|NCT01913743||MINDSETS|overweight/obese
3096807|NCT01913730|No Intervention|No prolonged therapy is scheduled|
3096808|NCT01913730|Experimental|Bortezomib Dexamethasone (Biochemical relapse)|Patients randomized in this group will be observed. At the occurrence of biochemical relapse, 4 VD cycles will be administered: Bortezomib (SC) and Dexamethasone (PO) weekly.
3096809|NCT01913717|Experimental|External beam radiotherapy|External beam radiotherapy
3096810|NCT01913704|Placebo Comparator|Placebo device|"The placebo comparator is a placebo version of the active device which is a system to deliver oxygen from an oxygen generator topically to the wound bed via a proprietary device.~The device will be applied to the wound and attached to the placebo oxygen generator and the generator switched on at the time of enrolment. Secondary dressings will then be applied. The device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
3096811|NCT01913704|Active Comparator|NatroxTM Device|"A system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM oxygen delivery device will be applied to the wound and attached to the NatroxTM oxygen generator which will be switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
3096812|NCT01913678|Active Comparator|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
3096813|NCT01913678|Active Comparator|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
3096814|NCT01913678|Placebo Comparator|Complete diet|The participants will be given all dietary items in their diet.
3096815|NCT01913665|Active Comparator|B.Lactis|children with functional constipation
3096816|NCT01913665|Active Comparator|Inulin|children with functional constipation
3096817|NCT01913665|Active Comparator|B.Lactis+ınulin|children with functional constipation
3096818|NCT01913665|Placebo Comparator|plasebo|children with functional constipation
3096819|NCT01913652|Experimental|Cabazitaxel|"INN: Cabazitaxel Cabazitaxel will be administered at a dose of 25 mg/m² by intravenous infusion, over 1 hour, on day 1 of each 21 day cycle.~Treatment should be administered until disease progression, unacceptable toxicity or patient's refusal."
3096820|NCT01913639|Experimental|FOLFOX Plus Regorafenib|Regorafenib 160 mg daily on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets + mFOLFOX on Day 1 and Day 15 of each cycle. Each cycle consists of 28 days. All patients will receive systemic chemotherapy with the mFOLFOX regimen and regorafenib. The specific version of the FOLFOX regimen used at MSKCC is mFOLFOX6. mFOLFOX6 will be given on Day 1 of each cycle. Patients will receive Oxaliplatin 85 mg/m2 IV (over 120 minutes), leucovorin 400 mg/m2 IV (over 120 minutes), 5-FU 400 mg/m2 IVP, and 5-FU 1200 mg/m2/day CIVI x 2 days, every two weeks. Treatment will be performed on the scheduled day ± 7 days. In case of discontinuation of FOLFOX due to cumulative toxicity and administration as a single agent during the study, regorafenib for patient convenience will be administered 160 mg daily for 3 weeks on/1 week off. The 3 weeks on/1 week off schedule is supported by the single agent regorafenib data in colon cancer and GIST.
3096821|NCT01913626|Experimental|cognitive group therapy|patient with subjective memory complains will participate in cognitive group therapy including eight meetings of practicing cognitive strategy to improve the memory .
3096822|NCT01913613|Experimental|Treatment|Treatment with the IASD device
3096823|NCT01913600|Other|Resolute Integrity|Resolute Integrity Stent
3096824|NCT01913587|Experimental|Acupuncture & Nerve block|Acupuncture will be performed 3 times per week, total 9 sessions, during 3 weeks. Epidural nerve block and medial branch block will be performed once per week, total 3 sessions, during 3 weeks.
3096825|NCT01913587|Active Comparator|Nerve block|Epidural nerve block and medial branch block will be performed once per week, total 3 sessions, during 3 weeks.
3096826|NCT01913574|Experimental|Acupuncture & NCPB|The NCPB will be administered once at the start of the trial and the acupuncture will be performed 3 times per week for 2 weeks (6 times in total).
3096827|NCT01913574|Active Comparator|NCPB|The NCPB alone will be applied to the patients in this group, once at the start of the trial.
3096828|NCT01913561|Experimental|Master Caution Garment|"each patient will be connected simultaneously with two devices:~ECG gel electrodes~Master Caution Garment textile electrodes The two devices will be connected to hospital ECG telemetry."
3096829|NCT01913548||Sickle Cell Disease (SCD)|Patients with sickle cell diseases, 16 years or older with 10-20 years of transfusion (defined as 0.2-0.6mg Fe/kg/day exposure with annual ferritin levels greater than 2500 in at least 60% of years of chronic transfusion); 0 to 9 years old at the initiation of chronic transfusions; no exchange transfusions in the previous 6 months; and iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC (liver iron content) of greater than 7 mg/g dry wt in the previous 6 months or ferritin level greater than 1500mg/dl.
3096830|NCT01913548||Thalassemia Major (TM)|Patients with β-thalassemia major and transfusion-dependent E-beta THAL. 16 years or older with 10-20 years of chronic transfusion (defined above), 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
3096831|NCT01913548||Diamond Blackfan Anemia (DBA)|Patients with DBA, 16 years or older with 10-20 years of transfusion, 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
3096832|NCT01913535|Active Comparator|Low Dose Drug-Drug Arm|Patients in this arm will receive CERC-501 10.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
3096833|NCT01913535|Active Comparator|High Dose Drug-Drug Arm|Patients in this arm will receive CERC-501 20.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
3096834|NCT01913535|Other|Placebo/Low-Dose Drug Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and CERC-501 10.0 mg/day for 3 days (in Phase 2)
3096835|NCT01913535|Other|Placebo/High-Dose Drug Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and CERC-501 20.0 mg/day for 3 days (in Phase 2)
3096836|NCT01913535|Placebo Comparator|Placebo/Placebo Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
3096837|NCT01913522|Experimental|Standard cryoablation|"Patients randomized to the standard group will undergo cryoablation with target duration of 240 seconds. Once PVI is achieved a single bonus application of 240 seconds will be delivered after the rewarming phase (to +20oC)."
3096838|NCT01913522|Active Comparator|Irrigated RF Ablation|Patients randomized to irrigated RF group will undergo standard wide circumferential PVI with an irrigated radiofrequency catheter
3096839|NCT01913522|Experimental|Short Cryoablation|"Patients randomized to the multiple-freeze group will undergo cryoablation with target duration of 120 seconds. Once PVI is achieved a single bonus application of 120 seconds will be delivered after the rewarming phase (to +20oC)."
3096840|NCT01913509|Experimental|Combined Therapy of FES and BAT|Patients with hemiplegic shoulder pain is applied functional electrical stimulation and bilateral arm training (FES-BAT) one hour daily, 3 days per week for 4 weeks and a total of 12 sessions to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected arm.
3096841|NCT01913509|Active Comparator|Conventional Rehabilitation|The stroke patients in CR group receive a structure protocol using electrical modality such as transcutaneous electrical nerve stimulation (TENS) and bilateral arm training (TENS-BAT) one hour daily, 3 days per week for 4 weeks and a total of 12 sessions.
3096842|NCT01913496|Placebo Comparator|Standard care|standard care ,without the web application ebalance
3096843|NCT01913496|Active Comparator|ebalance|using the ebalance application for 14 weeks
3096844|NCT01913483|Experimental|Bivalirudin|Bivalirudin was administered as an intravenous (IV) bolus and infusion for the duration of the procedure (mean duration of 48.6 minutes). The bolus (0.75 milligrams (mg)/kilogram [kg]) was administered via systemic IV administration. Immediately after the bolus, an IV infusion of bivalirudin was initiated at a dose of 1.75 mg/kg/hour (h) (or 1 mg/kg/h for participants with an estimated glomerular filtration rate [eGFR] <30 milliliters/minute [mL/min]).
3096845|NCT01913483|Active Comparator|Unfractionated Heparin|UFH was administered as an IV bolus for the duration of the procedure (mean duration of 48.6 minutes). UFH was administered via weight-based IV bolus at a dose of 50 units (U)/kg to 70 U/kg. Additional bolus doses were administered per standard-of-care use.
3096846|NCT01913470|Experimental|Losartan then Placebo|0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks then placebo pill for 8 weeks
3096847|NCT01913470|Experimental|Sugar pill|placebo pill taken for 8 weeks then 0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks
3096848|NCT01913457||Adults w/ PH|Subjects above 18y scheduled to undergo RHC for Doppler ultrasound external right chest wall tests
3096849|NCT01913457||Children w/ PH|Children 0-18y old scheduled to RHC
3096850|NCT01913457||Children control|Children 0-18y old w/o PH for Lung Doppler tests as controls
3096851|NCT01913444|Experimental|Recombinant Antithrombin Infusion|The initial loading dose and maintenance continuous infusion will be calculated according to the following equations which are based on the patient's baseline AT activity level prior to ECMO. Loading dose(IU)=(100-baseline AT activity)/2.3 x Wt(kg). Maintenance Dose(IU/hour)=(100-baseline AT activity)/10.2 x Wt(kg). The loading dose will be administered as a 15-minute IV infusion once the patient is on ECMO. This will be followed by the maintenance continuous infusion. AT levels will be checked 2hours after the initiation of treatment. For AT levels that are <80% or >100%, the infusion rate will be increased or decreased, respectively, by 30% and a follow-up level will be checked 2hours after the adjustment. If the AT level is within goal range (80-100%), follow-up AT levels will be checked every 6hours unless dose adjustments are made. Once the patient is off ECMO, the continuous infusion will be discontinued and AT levels will no longer be checked.
3096852|NCT01913431|Experimental|Baracle Tab.®|(It can be also placebo) dosage: 2 tablets daily for 48 weeks
3096853|NCT01913431|Experimental|Baraclude Tab.®|(It can be also placebo) dosage: 2 tablets daily for 48 weeks
3096854|NCT01913418|Active Comparator|Suan-Zao-Ren Tang|The SZRT formula used in this study is manufactured as a herbal extract powder from the good manufacturing procedures (GMP) of the certified company Kaiser Pharmaceutical Co., Ltd. (Taiwan). Granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
3096855|NCT01913418|Placebo Comparator|Suan-Zao-Ren Tang placebo|The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
3096856|NCT01913405|Experimental|BAX855|"Pre-operative loading dose: Single loading dose, pre-surgery administered based on each study participant's individual PK results as well as target trough level for type and character of surgery, dental or invasive procedure being performed. In general, major surgery will target an 80-150% FVIII trough level, and minor surgery will target an initial 30-100% FVIII trough level.~Intra-operative and post-operative dosing of BAX855 must be based on pre-dosage measurements of FVIII and the type and character of the surgery performed."
3096857|NCT01913392|Other|morbidly obese, chronic renal disease|adult patients (> 18 years) who have stage 4 or 5 chronic renal disease (CrCl < 30 ml/min) who are being considered for possible future kidney transplantation. The study inclusion criteria are an indication for laparoscopic sleeve gastrectomy (BMI > 40 kg/m2, or BMI > 35 with at least one co-morbidity such as hypertension, dyslipidemia or diabetes)
3096858|NCT01913379|Experimental|1: MDV3100|
3096859|NCT01913379|Experimental|2: MDV3100 and gemfibrozil|
3096860|NCT01913379|Experimental|3: MDV3100 and itraconazole|
3096861|NCT01913366|Experimental|CM-PST|If you are assigned to CM-PST, you will be working with the same care manager from your introductory session. The care manager will continue to work with you on your problem-solving plan. Additionally, you will receive case management services.
3096862|NCT01913366|Experimental|SG-PST|If you are assigned to SG-PST, you will continue to work on your problem-solving plan, using the self-guided materials provided to you during the introductory session. Additionally, you will be partnered with a senior peer counselor who will support you in your SG-PST efforts.
3096863|NCT01913353|Experimental|Group 1|Two vaccinations; MVA BN ®; administered 4 weeks apart (Day 0 and Day 28) followed by a single vaccination of ACAM2000® vaccine 4 weeks after the second MVA BN® vaccination (Day 56).
3096864|NCT01913353|Active Comparator|Group 2|A single vaccination of ACAM2000® will be administered at Day 0.
3096865|NCT01913340|Active Comparator|Erythropoietin|1000 U/kg/dose x 5 doses
3096866|NCT01913340|Placebo Comparator|Normal saline|
3096867|NCT01913327|Experimental|aripiprazole|ariprazole with flexible, blind dosing between 7.5 mg and 30 mg, once daily.
3096868|NCT01913327|Active Comparator|risperidone|risperidone with flexible, blind dosing between 1 mg and 8 mg, once daily.
3096869|NCT01913314|Experimental|[^14C]-LY2835219|Single 150 milligram (mg) oral dose solution of LY2835219 containing 5 micro-curies of (µCi) [^14C] labeled drug
3096870|NCT01913301|Experimental|Alagebrium|
3096871|NCT01913288|Experimental|Biological Maternal Sounds|Daily Exposure to recorded mother's voice and heartbeat sounds via audio systems installed at the bedside
3096872|NCT01913288|Sham Comparator|Hospital Sounds|Exposure to standard hospital sounds; routine care.
3096873|NCT01913275|Active Comparator|endoscopic stenting|endoscopic stenting to reduce preoperative jaundice
3096874|NCT01913275|Active Comparator|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
3096875|NCT01913262||IFH Patients on Depression Registry|Patients at the Institute for Family Health who have a diagnosis of depression active on their problem list or have had a diagnosis of depression used as an encounter diagnosis in the past year or patients with a PHQ-9 score greater than or equal to 10.
3096876|NCT01913249|Experimental|Intervention|Seton through fistula 6 months prior to LIFT
3096877|NCT01913249|Active Comparator|Control|Seton through fistula 3 weeks prior to LIFT surgery
3096878|NCT01913236|Experimental|Implementation intervention|Tailored implementation intervention to address determinants of practice in primary care
3096879|NCT01913236|No Intervention|Control|Treatment as usual provided by general practitioners to elderly patients with depression
3096880|NCT01913223|Experimental|submucosal dissection by dissector water jet|
3096881|NCT01913197|Experimental|Pre-implant MRI images and planning|
3096882|NCT01913184|Active Comparator|Continuous nebulization|Continuous nebulization with AKITA
3096883|NCT01913184|Experimental|Discontinuous nebulization|Discontinuous nebulization with AKITA
3096884|NCT01913171|Active Comparator|Walking|WALK. The participants were instructed to walk daily, at first week 12minutes/day, week II 16mins/day, week III 20mins/day, week IV 24 mins/day, week V 28mins/day, week VI 32mins/day at a pace that would moderately increase heart rate and result in sweating
3096885|NCT01913171|Active Comparator|Hula-hooping|HULA. The participants were instructed to hula hoop daily, at first week 6minutes/day, week II 8mins/day, week III 10mins/day, week IV 12 mins/day, week V 14mins/day, week VI 16mins/day
3096886|NCT01913158|Placebo Comparator|Placebo suppository|Hydrogenated palm kernel oil suppositories
3096887|NCT01913158|Active Comparator|Anucort-HC, 25 Mg Rectal Suppository|Hydrocortisone Acetate suppositories
3096888|NCT01913145|Experimental|A1c, Self-collection, Blood sample|"Can a lay-persons safely and effectively self-collect a capillary blood sample of sufficient adequacy for A1c (HbA1c) testing in a clinical laboratory"
3096889|NCT01913132|No Intervention|Standard wound dressing|Standard wound dressing
3096890|NCT01913132|Experimental|PICO|Negative pressure wound therapy with PICO (Smith & Nephew)
3096891|NCT01913119|Experimental|Romidepsin|"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.~Dose and administration: 4-hour infusion of 14 mg/m2"
3096892|NCT01913106|Experimental|HSV-tk + Valacyclovir and Brachytherapy|You will be given an antibiotic (Ciproflaxin) to take twice a day beginning the day before the procedure, and continuing for a total of 3 - 5 days. You will also be given 4 pills called (Valtrex) valacyclovir to take three times a day for 14 days, beginning the day before the procedure. You will be given a pill diary in which you will record each dose of valacyclovir that you take. You will receive brachytherapy (radioactive seed placement) the day after you begin taking your pills. After the radioactive seeds are placed, while you are still in the operating room, you will receive an injection into your prostate of 1 or 2 ml (one-fifth or two-fifths of a teaspoon) of a solution of the vector carrying the gene.
3096895|NCT01913080|Active Comparator|Health Log|Patients who have a billing diagnosis RA (714.0)or seronegative inflammatory arthritis who are enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS)will be given the Health Log health management tool.
3096896|NCT01913080|No Intervention|Control Pill Box|Controls will be BRASS patients who continue to receive regular care and are also given a pill box instead of the Health Log health management tool.
3096897|NCT01913067|Experimental|Cabazitaxel|Eligible patients will receive intravenous 25mg/m2 cabazitaxel every 3 weeks. Contrast-enhanced whole brain MRI will be performed every two cycles. Patients who show ≥50% volumetric reduction in the size of the brain lesion(s) will continue on cabazitaxel until disease progression or unacceptable toxicity. Patients who show evidence of disease progression and/or developed progressive neurological symptoms will be taken off study and offered whole brain irradiation. Patients who do not meet both criteria can have the choice either to continue on study drug or to be taken off study according to the investigator discretion.
3096898|NCT01913054|Active Comparator|Fentanyl & Propofol|0.02 ml/kg(1 μg/kg) fentanyl is diluted to 10 ml with normal saline and infused within 1 min, 4 min advance. 0.5 mg/kg(0.025 ml/kg) propofol is infused within 15 to 20 s. And then, depending on the randomized result, 0.5 mg/kg is given every time until the patient falls asleep. During the operation, 0.5 mg/kg is given when it is needed.
3096899|NCT01913054|Experimental|fentanyl, propofol & etomidate|0.02 ml/kg(1 μg/kg) fentanyl is diluted to 10 ml with normal saline and infused within 1 min, 4 min advance. 0.5 mg/kg(0.025 ml/kg) propofol is infused within 15 to 20 s. And then, depending on the randomized result, 0.5 mg/kg etomidate is given every time until the patient falls asleep. During the operation, 0.5 mg/kg etomidate is given when it is needed.
3096900|NCT01913041||Investigation|This is an epidemiology study in which all the data from the subjects enrolled will be collected and analysis to investigate the current patient warming condition and actual perioperative hyperthermia rate in the elective operation with general anesthesia. During the whole procedure none intervention is administered.
3096901|NCT01913028|Experimental|MEDI9929|Solution of MEDI9929, SC
3096902|NCT01913028|Placebo Comparator|Placebo|Placebo solution for MEDI9929, SC
3096903|NCT01913015|Experimental|Arm I (abiraterone acetate, low then high fat breakfast)|Patients receive standard dose abiraterone acetate PO QD (held on days 2, 3, 9, and 10), and low-dose abiraterone acetate PO QD on days 3 and 10. Patients eat a low fat breakfast on day 3 and a high fat breakfast on day 10.
3096904|NCT01913015|Experimental|Arm II (abiraterone acetate, high then low fat breakfast)|Patients receive abiraterone acetate as in Arm I. Patients eat a high fat breakfast on day 3, and a low fat breakfast on day 10.
3096905|NCT01913002|Experimental|Treatment A|LX4211 800 mg
3096906|NCT01913002|Experimental|Treatment B|LX4211 2000 mg
3096907|NCT01913002|Active Comparator|Treatment C|moxifloxacin 400 mg
3096908|NCT01913002|Placebo Comparator|Treatment D|Placebo
3096909|NCT01912989|Experimental|Lifestyle counseling|NOURISH+ plus motivational interviewing
3096910|NCT01912976|Experimental|Er:YAG AFL-PDT|Right leg on each patients was assigned a single session of Er:YAG AFL-PDT.
3096911|NCT01912976|Active Comparator|MAL-PDT|Left leg on each patient was selected to receive 2 sessions of MAL-PDT
3096912|NCT01912963|Experimental|Pertuzumab, Trastuzumab and Eribulin|To evaluate the activity of trastuzumab and pertuzumab in combination with eribulin mesylate in women with metastatic or locally recurrent HER2-positive breast cancer that are refractory to trastuzumab-containing regimens.There will be a safety run-in prior to the start of the Phase II study. Each study treatment cycle lasts 21 days (3 weeks). The patient will receive eribulin on the first day (day 1) and on the 8th day (day 8) of the cycle. The patient will also receive trastuzumab and pertuzumab on day 1. All drugs will be given to the patient intravenously in clinic. The dose of pertuzumab and trastuzumab will be the same for everyone on study, and will be the standard approved dose for each of these medications.
3096913|NCT01912950|Experimental|Prowave LX IPL|"Prowave LX IPL, short pulse setting and snowflake mode On"
3096914|NCT01912950|No Intervention|No Treatment|No treatment administered.
3096915|NCT01912937|Experimental|DCB Arm|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
3096916|NCT01912898||1|
3096917|NCT01912885|Placebo Comparator|Group 1|Electrodes will be fixated to one leg and sessions will be held once a week.
3096918|NCT01912885|Experimental|Group 2|Electrical stimulation of the posterior tibial nerve of one leg once a week.
3096919|NCT01912885|Experimental|Group 3|Electrical stimulation of the posterior tibial nerve of one leg twice a week.
3096920|NCT01912885|Experimental|Group 4|Electrical stimulation of the posterior tibial nerve of two legs once a week.
3096921|NCT01912885|Experimental|Group 5|Electrical stimulation of the posterior tibial nerve of two legs twice a week.
3096922|NCT01912872|Experimental|Omalizumab + budesonide and formoterol|Participants will receive Omalizumab every 2 or 4 weeks depending on IgE level and body weight and will also receive budesonide and formoterol according to maximum daily dose.
3096923|NCT01912872|Active Comparator|Budesonide and formoterol|Participants will receive budesonide and formoterol according to maximum daily dose.
3096924|NCT01912859|Experimental|Nutrition/physical activity intervention|The intervention, Next Steps, comprises a network of community-led health maintenance programs offered to graduates of an initial intensive obesity course. These health maintenance programs will aim to help participants maintain and improve healthful behaviors and body mass indices.
3096925|NCT01912859|No Intervention|Usual care|"Participants in the No Intervention arm will not have access to the Next Steps programs and will receive only usual care through their health care clinic."
3096926|NCT01912846|Sham Comparator|Attention usual care intervention|"Interventions includes prognosis disclosure and discussions of EOL care as needed as in current clinical practices.~Interventions of the attention usual care arm include a consistent master prepared nurse on the study team will provide the attention portion of the care and a workbook and a video with educational materials. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department."
3096927|NCT01912846|Experimental|Interactive advance care planning|The intervention aims at facilitating patients, families, and primary physicians to discuss the patient's wishes for EOL care by clarifying a terminally ill cancer patient's understanding of his/her prognosis and treatment options and her/his readiness for engagement in ACP, appropriately weighting the benefits and burdens of medical treatments at EOL, and clearly defining and documenting the patient's preferences so as to be readily available later for the patient's primary physician to guide EOL care decision-making which will honor the patient's preferences for EOL care.
3096928|NCT01912820|Experimental|Arm I (quercetin, green tea extract)|Patients receive GT extract PO BID and quercetin PO BID for 3-6 weeks before undergoing prostatectomy.
3096929|NCT01912820|Placebo Comparator|Arm II (GT extract, placebo)|Patients receive GT extract PO BID and placebo PO BID for 3-6 weeks before undergoing prostatectomy.
3096930|NCT01912807|Experimental|Dextrose (D5NS)|The participants received Dexamethasone (dose 0,15 mg/Kg) as standard antiemetic prophylaxis and Dextrose 5% in 0.9 % Normal Saline (D5NS) was used as a second antiemetic, at an intravenous rate calculated based on their weight and determined for the purpose of the study.
3096931|NCT01912807|Active Comparator|Ondansetron (Control)|The control group received Dexamethasone (dose 0,15 mg/Kg) as standard antiemetic prophylaxis. Ondansetron (dose 0,05 mg/Kg) was used as a second prophylactic antiemetic.
3096932|NCT01912794|Experimental|Sensory Conditions|
3096933|NCT01912781|Experimental|FID 120974A|FID 120947A contact lens disinfecting solution used with gas permeable contact lenses (study lenses) on a daily basis for 90 days
3096934|NCT01912781|Active Comparator|Boston Simplus|Boston Simplus multi-action solution used with gas permeable contact lenses (study lenses) on a daily basis for 90 days
3096935|NCT01912768|Experimental|FID 120947A|FID 120947A contact lens disinfecting solution used with soft contact lenses (study lenses) on a daily basis for 90 days
3096936|NCT01912768|Active Comparator|renu fresh|Renu fresh multi-purpose solution used with soft contact lenses (study lenses) on a daily basis for 90 days
3096937|NCT01912755|Experimental|Articaine|injection of 1.8 mL buccal infiltrations of 4% articaine with 1:100,000 epinephrine in one tooth with a clinical diagnosis of symptomatic irreversible pulpitis.
3096938|NCT01912755|Active Comparator|Lidocaine|1.8 mL 2% lidocaine with 1:100,000 epinephrine injected as inferior alveolar nerve block in the mandible side with one tooth with a clinical diagnosis of symptomatic irreversible pulpitis.
3096939|NCT01912742|Experimental|Rapid weight loss group|The rapid weight loss group will follow a commercial very-low calorie diet (VLCD) during 4 weeks. The participants allocated to this group will follow a 550 (women) - 660 (men) kcal/day diet. The VLCD products provide 110kcal/pack and include a variety of milkshakes, smoothies and soups. In addition to VLCD products, calorie-free drinks and some low-starch vegetables (maximum 2 cups/day) will be allowed. Drinking at least 2.5 liters of non-caloric liquids will be recommended.
3096940|NCT01912742|Experimental|Slow weight loss group|The slow weight loss group will be prescribed an individualized low calorie diet (LCD) (1200-1500kcal/day), during 8 weeks, using meal replacements (such as smoothies, soups and cereal bars) and conventional foods. The macronutrient composition will be matched with that of the VLCD.
3096941|NCT01912729|Experimental|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a mobile phone application. Additionally, participants will have access to a private social network that connects them with other participants in the study. The social network will be moderated by a trained peer coach.
3096942|NCT01912729|Experimental|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a mobile phone application. Additionally, participants will have access to a private social network that connects them with other participants in the study. The social network will be moderated by a clinician coach.
3096943|NCT01912729|No Intervention|Wait List Control|Participants may be asked to wait for up to 8 weeks until minimum group size is met. After 4 weeks from baseline, if a group has not yet started, we will conduct another assessment. These participants will serve as the Wait List Control group.
3096944|NCT01912716|Experimental|high-dose indomethacin|200mg rectal indomethacin
3096945|NCT01912716|Active Comparator|standard dose indomethacin|100mg rectal indomethacin
3096946|NCT01912703||Preterm infants with IVH Grades I-II|Preterm infants (post-menstrual age 24-35 weeks) who were diagnosed with IVH Grades 1-2 in the neonatal intensive care unit (NICU).
3096947|NCT01912703||Control Group|Preterm infants (post-menstrual age 24-35 weeks) who had no imaging evidence of IVH in the neonatal intensive care unit (NICU).
3096948|NCT01912690|Placebo Comparator|standard of care|
3096949|NCT01912690|Active Comparator|aerobic training only|
3096950|NCT01912690|Active Comparator|Aerobic and strength training|
3096951|NCT01912677|Active Comparator|Nifedipine|Women will receive an initial dose of oral nifedipine 10mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 10mg dose can be provided each hour for two additional doses (30 mg total).
3096952|NCT01912677|Experimental|Methyldopa|Women will receive an initial dose of oral methyldopa 1000mg. No additional escalation in dose in the first 6 hours will be given.
3096953|NCT01912677|Experimental|Labetalol|Women will receive an initial dose of oral labetalol 200mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 200mg dose can be provided each hour for two additional doses (600 mg total).
3096954|NCT01912651|No Intervention|No antibiotic treatment|Withholding post-operative antibiotics following reconstructive surgery necessitating skin grafting for defects of the face or nose.
3096955|NCT01912651|Experimental|Antibiotics|All patients will receive peri-operative antibiotics per standard practice. This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week).
3096956|NCT01912638|Experimental|Implantation of Ologen in trabeculectomy|Ologen Collagen Matrix is implanted in primary limbal-based trabeculectomy. It should be placed on the top of the loosely-sutured scleral flap before suturing of the conjunctiva thus preventing the collapse of the subconjunctival space.
3096957|NCT01912638|Active Comparator|Provisc in trabeculectomy|Provisc is used in primary limbal-based trabeculectomy. At the end of the surgery cohesive viscoelastic (Provisc) is injected under the scleral flap to prevent early hypotony.
3096958|NCT01912625|Experimental|Treatment (trametinib, chemotherapy, radiation therapy)|"CONCURRENT CHEMOTHERAPY: Patients undergo IMRT or 3D-CRT QD 5 days a week for 6 weeks. Patients receive trametinib PO QD and carboplatin IV over 30 minutes and paclitaxel IV over 1 hour once weekly. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients without disease progression after completion of chemoradiation proceed to consolidation chemotherapy.~CONSOLIDATION CHEMOTHERAPY: Beginning 3 weeks after completion of concurrent chemoradiation, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on days 1 and 22. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity."
3096959|NCT01912612|Experimental|Arm 1|Duloxetine 30 mg daily x 1 week, then 60 mg daily x 4 weeks, then 30 mg daily x 2 weeks.
3096960|NCT01912599|Active Comparator|Non-Glaucomatous|Patients with no history of glaucoma. Subjects will be fitted with Sensimed Triggerfish for 24 observation of IOP and with a blood pressure monitor for 24 hour observation of blood pressure trends.
3096961|NCT01912599|Active Comparator|Glaucoma|Patients that are currently being treated for moderate to severe normal-tension glaucoma. Subjects will be fitted with Sensimed Triggerfish for 24 observation of IOP and with a blood pressure monitor for 24 hour observation of blood pressure trends.
3096962|NCT01912586|No Intervention|Arm A|Patients receive no interventions for ED after laparoscopic surgery
3096963|NCT01912586|Experimental|Arm B|sildenafil 25mg/day nightly without vacuum erection device for 3 months after surgery within one or two weeks.
3096964|NCT01912586|Experimental|Arm C|sildenafil 25mg/day nightly and together with using vacuum erection device to make erections for 10-15 minutes/day for 3 months after surgery within one or two weeks.
3096965|NCT01912573|Experimental|Intranasal (IN) naloxone|Intranasal (IN) naloxone as initial response to suspected opioid overdose
3096966|NCT01912573|Active Comparator|Standard of Care (TAU)|Standard of care (intravenous [IV], intramuscular [IM] or intraosseus [IO]delivery of naloxone) as initial response to suspected opioid overdose.
3096967|NCT01912560|Experimental|CAT-2003 or Placebo Dose 1|Daily for 28 days in patients with moderate hypertriglyceridemia
3096968|NCT01912560|Experimental|CAT-2003 or Placebo Dose 2|Daily for 28 days in patients with moderate hypertriglyceridemia
3096969|NCT01912560|Experimental|CAT-2003 or Placebo Dose 3|Daily for 28 days in patients with moderate hypertriglyceridemia
3096970|NCT01912560|Experimental|CAT-2003 or Placebo Dose 4|Daily for 28 days in patients with hypercholesterolemia who are on a statin
3096971|NCT01912547||Blood draw for TEG analysis|TEG analysis of blood from patients at different points in time
3096972|NCT01912534|Active Comparator|Valsartan|Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.
3096973|NCT01912534|Placebo Comparator|Placebo|Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.
3096974|NCT01912521|Experimental|Intervention|This arm is eligible for participation in the Mfangano Health Net Microclinic Program, a social network-based educational program.
3096975|NCT01912521|No Intervention|Comparison|This arm is not eligible for participation in the intervention. Participants still have access to usual care at the Sena Health Center or their health facility of choice.
3096976|NCT01912508||preterm labor|pregnant women with signs of preterm labor: uterine contractions or cervical shortening
3096977|NCT01912508||control|pregnant women with no signs or symptoms of preterm labor
3096978|NCT01912495|Experimental|Boceprevir, peginterferon ribavirin|All patients were intended to be treated in the 12 week peginterferon, ribavirin and boceprevir arm.
3096979|NCT01912482|Experimental|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
3096980|NCT01912482|Active Comparator|Ventilatory Training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
3096981|NCT01912482|No Intervention|Crontrol Group|This condition will last six weeks, this period will be held six lectures sixty minutes long and periodization weekly.
3096982|NCT01912469|Experimental|Traumeel|Traumeel tablets by mouth the total amount for 72 hours will be 26 tablets
3096983|NCT01912469|Placebo Comparator|Placebo|The Placebo tablets (300 mg lactose monohydrate and 1,5 mg magnesium stearate) by mouth the total amount for 72 hours will be 26 tablets
3096984|NCT01912456|Experimental|Higher-volume placebo, then low-volume C1-esterase inhibitor|A higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.
3096985|NCT01912456|Experimental|Low-volume C1-esterase inhibitor, then higher-volume placebo|A low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.
3096986|NCT01912456|Experimental|Low-volume placebo, then higher-volume C1-esterase inhibitor|A low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks then a higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.
3096987|NCT01912456|Experimental|Higher-volume C1-esterase inhibitor, then low-volume placebo|A higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.
3096988|NCT01912443||Bevacizumab Plus Chemotherapy|
3096989|NCT01912430|Experimental|ICC (Integrated Care Coaching)|Received evidence-based, protocol-driven integrated care coaching intervention to improve chronic illness health outcomes (clinical, financial).
3096990|NCT01912430|Experimental|Control Group|Matched cohort by age and chronic illness diagnoses - no intervention
3096991|NCT01912417|Experimental|Hemodialysis session with exercise|Patients were included in a randomly crossover study design such that each patient received one HD session with exercise (intervention) and the next session without exercise (control), alternating for six consecutive HD sessions.
3096992|NCT01912417|No Intervention|hemodialysis session without exercise|Each patient received one hemodialysis session without exercise
3096993|NCT01912404|Experimental|IDN-6556|IDN-6556 capsules, 25 mg BID
3096994|NCT01912404|Placebo Comparator|Placebo|Placebo capsules BID
3096995|NCT01912391|Experimental|Selegiline|Transdermal Selegiline 12 mg patch Apply (1) patch daily
3096996|NCT01912391|Placebo Comparator|Placebo (for Selegiline)|Transdermal Placebo patch Apply (1) patch daily
3096997|NCT01912378|Experimental|Oxytocin Nasal Spray|40 IUs of Oxytocin nasal spray will be administered to both parents at one time during the lab visit.
3096998|NCT01912378|Placebo Comparator|Placebo nasal spray|40 IUs of Placebo nasal spray will be administered to both parents at one time during the lab visit.
3096999|NCT01912365||Above Elbow Cast + Collar/cuff|Participants randomized to this group will be treated with an Above Elbow Cast & collar/cuff for 3 weeks
3097000|NCT01912365||Long Arms Splint + Collar/Cuff|Participants randomized to this group will be treated with a long arm splint & collar/cuff for 3 weeks
3097001|NCT01912352|Experimental|Methylphenidate|Participants were treated with methylphenidate (ranging from to 63mg) for 8 weeks. Doses of methylphenidate were titrated depending on symptoms and adverse eff ects at the 2nd and 4th weeks of treatment.
3097002|NCT01912339|Experimental|Treatment|Treatment: Rezūm System
3097003|NCT01912339|Other|Control|Control: Rigid Cystoscopy
3097004|NCT01912326|Active Comparator|AF Suppression On|AF Suppression Algorithm On, optimized AF Pacemaker Programming
3097005|NCT01912326|Active Comparator|AF Suppression Off|AF Suppression programmed Off, Optimized Pacemaker Programming
3097006|NCT01912313|Experimental|Rectal biopsy|
3097007|NCT01912300|Experimental|Lean adolescents|
3097008|NCT01912300|Experimental|Obese adolescents|
3097009|NCT01912287|Experimental|Yoga|The yoga intervention will apply Kundalini Yoga practices as taught by Yogi Bhajan. This is a well-known, accessible style of practice in the U.S. that incorporates all of the traditional components of yoga including physical postures and exercises, breathing techniques, relaxation exercises and meditation practices. It is a safe style of yoga that is registered with the Yoga Alliance that is readily and routinely adapted for therapeutic purposes. The 12-week yoga intervention will consist of 12 group classes and assigned daily home practice led by qualified and certified yoga instructors. Each group yoga session will include physical postures/exercises, breathing techniques, meditation and deep relaxation practice that are all easy to learn and do not require extensive practice or athletic ability to perform.
3097010|NCT01912287|Active Comparator|Cognitive Behavioral Therapy (CBT)|"The 12 session CBT treatment will be based on the standardized protocol developed at one of our centers (CARD) and widely available [88]. This protocol is comprised of four primary treatment modules including cognitive restructuring, progressive muscle relaxation, worry exposures, and in vivo exposure exercises. The initial sessions describe the cognitive behavioral model of worry and GAD. Each session consists of a different lesson. These lessons initially cover basic information about the nature of the anxiety and worry, the possible function and negative consequences of worrying, the maladaptive and paradoxical effects of attempting to control and suppress one's thoughts, the basic cognitive errors of probability overestimation and catastrophic thinking, adaptive strategies to deal with worries, such as problem solving, worry exposure, which may involve exploring and exposing the patient to negative images and scenarios that might be behind some of the worrisome thoughts."
3097011|NCT01912287|Sham Comparator|Stress Education|SE will also include 12 weeks of group and home practice sessions. SE will control for attention from instructors, expectancy effects, and group support effects, Stress Education (SE) will be employed as an active control intervention. SE is currently used in NIH-funded protocols at the Benson-Henry Institute for Mind-Body Medicine at MGH. In this condition, participants will be provided with detailed and extensive information about stress and health, but will not receive any CBT, yoga, or other mind-body training techniques.
3097012|NCT01912274|Experimental|Pracinostat with azacitadine|60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days 75 mg/m2 azacitadine for the first 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous (IV) infusion if SC injections are intolerable
3097013|NCT01912261|Active Comparator|FeraMax|FeraMax Polysaccharide iron complex oral iron supplement 150mg one capsule orally daily
3097014|NCT01912261|Placebo Comparator|Placebo|one capsule orally daily
3097015|NCT01912248||Heart failure|strength training
3097016|NCT01912248||Heart Transplant recipients|strength training
3097017|NCT01912248||patients with ischemic heart disease|strength training
3097018|NCT01912235|Active Comparator|Test Study 1: 2-15N glutamine|To determine the contributions make by glutamine to the provision of nitrogen for ornithine, citrulline and arginine syntesis in adults.
3097019|NCT01912235|Active Comparator|Test Study 2: 15N2 arginine &15N proline|administration of 15N2 arginine &15N proline to measure arginine and proline flux
3097020|NCT01912235|Active Comparator|Study Test 3: 1-13C glutamine|to determine to contribution of glutamine to the carbon skeleton of ornithine, citrulline and arginine in adults.
3097021|NCT01912222|Experimental|IXAZOMIB Arm 1|"Experimental: Arm 1 (Normal hepatic function) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 4 mg dose of IXAZOMIB capsule on Day 1.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
3097022|NCT01912222|Experimental|IXAZOMIB Arm 2|"Experimental: Arm 2 (Moderate hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 2.3 mg dose of IXAZOMIB capsule on Day 1.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
3097046|NCT01912118|Experimental|PROPOFOL TARGET BIS 30 + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS of 30.
3097095|NCT01911741|Experimental|Treatment C|Single dose of 2 tablets of MDV3100 formulation tablet C
3097023|NCT01912222|Experimental|IXAZOMIB Arm 3|"Experimental: Arm 3 (Severe hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 1.5 mg dose of IXAZOMIB capsule on Day 1.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
3097024|NCT01912209|Experimental|My Everyday Health Group|Subjects in this group will be randomized to a web based diet and weight modification program (MyEveryday Health) and provided personal access codes. They will also continue to have access to the WebMD website provided as part of their employment with Baptist Health South Florida.
3097025|NCT01912209|No Intervention|WebMD Group|This group will continue to have access to a website that is available for use of all employees (WebMD) at Baptist Health South Florida. This is the care-as-usual arm.
3097026|NCT01912196|Experimental|MSI-195|"Patients randomized to the MSI-195 arm will receive treatment with 2 tablets (800 mg) of MSI-195 plus on-going antidepressant therapy (ADT).~MSI-195 800 mg (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug)"
3097027|NCT01912196|Placebo Comparator|Placebo|"Patients randomized to the placebo arm will receive 2 tablets placebo plus on-going antidepressant therapy (ADT).~Placebo (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug)."
3097028|NCT01912183|Active Comparator|Monitoring device in PHR|Both groups will receive routine clinical care in the pediatric weight management program at McMaster Children's Hospital. Children/youth in both groups will receive a physical activity and sleep monitor and access to their PHR. The Active Comparator group will not receive any feedback or communication outside of clinic visits from the clinical team regarding their goal progress.
3097029|NCT01912183|Experimental|Communication through PHR outside clinic|Both groups will receive routine clinical care in the pediatric weight management program at McMaster Children's Hospital. Children/youth in both groups will receive a physical activity and sleep monitor and access to their PHR. The experimental group will receive regular communication with /access to the clinical team through a secure portal within the PHR(i.e. 2 way communication, weekly feedback to the families on their goal progress).
3097030|NCT01912170|Experimental|fish oil|Patients will receive fish oil capsules, at a dose of 2g/day. Each 1g capsule will contain 220mg of EPA and 170mg of DHA
3097031|NCT01912170|Experimental|Flaxseed Oil|Patients will receive flaxseed oil capsule, at a dose of 2g/day. Each 1g capsule will contain 550mg of ALA
3097032|NCT01912170|Placebo Comparator|Placebo Supplementation|Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil
3097033|NCT01912157|Placebo Comparator|No Intervention|The control condition are 3 sessions writing about individual time-management (placebo).
3097034|NCT01912157|Active Comparator|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing).
3097035|NCT01912144|Other|coffee|Coffee beverage
3097036|NCT01912131|Experimental|First 24 patients Cognitive interviewing|Part 1 - This first study phase will involve interviewing 24 patients to ask for their feedback on the appropriateness of questions being developed for use in the narrative interviewing in part 2 of the study. The cognitive interview will be audio-recorded. Demographics and ECOG performance status will be recorded prior to the cognitive interview.
3097037|NCT01912131|Active Comparator|usual care|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. Subjects will neither be shown the goals-of-care (GOC) video nor undergo the narrative interview process - they will be contacted as per re-assessment.
3097038|NCT01912131|Experimental|video-only arm|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
3097039|NCT01912131|Experimental|combined narrative and video (P-COCC) arm|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry & Behavioral Sciences.
3097040|NCT01912118|Experimental|PROPOFOL ONLY GROUP|In this study group measurements will be obtained before intubation or opioid administration. To that end plasma propofol concentration will be increased slowly from 0 to 4 μg/ml in steps of 0.5 μg/mL. After the highest target is reached, the propofol target concentration will be lowered to get a BIS value of 50. After 5-min, the laryngoscope will be inserted into the mouth. Next the laryngoscope will be removed. After 5-min the laryngoscope will be placed again and the patient will be intubated. This will be done without additional administration of muscle relaxant.
3097041|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET A|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 1 ng/ml remifentanil.
3097042|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET B|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 2 ng/ml remifentanil
3097043|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 3 ng/ml remifentanil.
3097044|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET D|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 4 ng/ml remifentanil.
3097045|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET E|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 5 ng/ml remifentanil.
3097047|NCT01912118|Experimental|PROPOFOL TARGET BIS 70 + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS 70.
3097048|NCT01912105|Experimental|treatment|Airway Medix Closed Suction System
3097049|NCT01912105|Active Comparator|control|standard closed suctioning systems
3097050|NCT01912092|Experimental|Askina Calgitrol Paste|
3097051|NCT01912066|Experimental|Stillen|Patients taking a tab of Stillen and a tab of placebo drug and a tab of NSAID
3097052|NCT01912066|Active Comparator|Cytotec|The subjects taking a tab of Cytotec, a tab of placebo drug, and a tab of NSAID
3097053|NCT01912053|Experimental|Therasphere®|Therasphere® in association with Gemcitabine and Cisplatin
3097054|NCT01912040||Patients|Administration of 123Iodine MIBG to the patients referred .
3097055|NCT01912027|Experimental|Arthroscopic Latarjet technique|Arthroscopic Latarjet technique
3097056|NCT01912027|Active Comparator|Open Latarjet technique|Open Latarjet technique
3097057|NCT01912014|Experimental|Psychosocial support and counselling|There is only one arm as this is a pilot and feasibility study.
3097058|NCT01912001|Other|Telephone follow-up.|A member of the Home Dialysis team will telephone patients to follow-up on their symptoms, dialysis and care.
3097059|NCT01911988||Colon&Rectal Stage II /Stage III|
3097060|NCT01911975|Placebo Comparator|Placebo|Patients with gain-of-function Nav 1.7 related small fiber neuropathy in this arm will receive placebo.
3097061|NCT01911975|Experimental|Lacosamide|Patients with gain-of-function Nav 1.7 related small fiber neuropathy in this arm will receive lacosamide.
3097062|NCT01911962||transabdominal laparoscope surgery|transabdominal laparoscope surgery
3097063|NCT01911962||transvaginal laparoscopic surgery|transvaginal laparoscopic surgery
3097064|NCT01911949|Experimental|Single shot femoral nerve block|Ultrasound guided Femoral Nerve Block-40ml of bupivacaine 0.5% with epinephrine
3097065|NCT01911949|Placebo Comparator|Placebo femoral nerve block|Sterile normal saline solution
3097066|NCT01911936|Experimental|LJM716|
3097067|NCT01911923|Active Comparator|No CPAP/PEEP and 100 % oxygen|This is the control group
3097068|NCT01911923|Experimental|CPAP/PEEP and 30 % oxygen|This is the intervention group
3097069|NCT01911910|No Intervention|Standard care|Usual care that would be provided by the NHS Health Check or equivalent.
3097070|NCT01911910|Experimental|Electronic coaching plus standard care|Tailored coaching for participants randomised to use the HAPPY e-coaching tool. Access to lifestyle and heart health scores and personalised advice to improve suboptimal behaviour.
3097071|NCT01911897|Experimental|MobiusHD|MobiusHD
3097072|NCT01911884|Other|Patients with a Rokitansky Syndrome|Patients with a Rokitansky Syndrome
3097073|NCT01911871||thalassemia|patients affected with thalassemia
3097074|NCT01911871||sickle cell disease|patients affected with sickle cell disease
3097075|NCT01911871||myelodysplasia|patients affected with myelodysplasia
3097076|NCT01911858|Experimental|Askina Calgitrol Paste|
3097077|NCT01911845|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
3097078|NCT01911832|Experimental|Gastrectomy and subtotal gastrectomy|to compare the quality of life between esophagojejunostomy after total gastrectomy(TG group) and Roux-en-Y gastrojejunostomy after subtotal gastrectomy(SG group)
3097079|NCT01911832|Experimental|Wide and narrow reconstruction tube|to compare the quality of life between wide tube reconstruction after subtotal gastrectomy(WG group) and narrow tube reconstruction after subtotal gastrectomy(NG group) in Roux-en-Y gastrojejunostomy
3097080|NCT01911819|Experimental|Sinus augmentation using Bio-oss|Sinus augmentation using Bio-oss
3097081|NCT01911819|Experimental|Sinus augmentation using Equimatrix|Sinus augmentation using Equimatrix
3097082|NCT01911819|Experimental|Sinus augmentation using OSSIF-i sem|Sinus augmentation using OSSIF-i sem
3097083|NCT01911806|Experimental|Back care pillow & standard physical therapy treatment|standard physical therapy treatment for 6 sessions of treatment, each around 30 minutes, during a period of 2 weeks & back care pillow use during the day for 2 weeks
3097084|NCT01911806|Active Comparator|standard physical therapy treatment|standard physical therapy treatment for 6 sessions of treatment, each around 30 minutes, during a period of 2 weeks
3097085|NCT01911793|Experimental|Stoma tube|Stoma tube (18 French) red robinson catheter inserted into stoma at the time of surgery
3097086|NCT01911793|No Intervention|Standard Stoma|Patients will have standard stoma created without insertion of stoma tube. Stoma tube will only be inserted postoperative if the patient is felt to have postoperative ileus, nausea, vomiting, and decreased stoma output as per standard protocol.
3097087|NCT01911780|Experimental|telmisartan + HCTZ + amlodipine|telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
3097088|NCT01911780|Active Comparator|telmisartan + HCTZ + placebo|telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
3097089|NCT01911767||dimethyl fumarate|Exposure to dimethyl fumarate since the first day of her last menstrual period (LMP) prior to conception or at any time during pregnancy
3097090|NCT01911767||Peginterferon beta-1a|Exposure to Peginterferon beta-1a since 14 days prior to the first day of her LMP prior to conception or at any time during pregnancy.
3097091|NCT01911767||Dalclizumab High Yield Process|Exposure to Dalclizumab High Yield Process 90 days prior to the first day of her LMP prior to conception or at any time during pregnancy.
3097092|NCT01911754|Experimental|Influenza Vaccine|One dose of the vaccine will be administered at a volume of 0.5 mL by intramuscular injection on Day 1 and 22
3097093|NCT01911741|Experimental|Treatment A|Single dose of 4 liquid-filled capsules of MDV3100 reference formulation
3097094|NCT01911741|Experimental|Treatment B|Single dose of 2 tablets of MDV3100 formulation tablet B
3097096|NCT01911728|Experimental|Multiple doses of MDV3100|Multiple doses of MDV3100 and a single dose of pioglitazone and a single dose of cocktail containing -warfarin, omeprazole and midazolam
3097097|NCT01911715|Experimental|Single Oral MDV3100 dose|
3097098|NCT01911702|Active Comparator|Conventional Group|In this group patients receive volemic standard treatment (conventional)
3097099|NCT01911702|Active Comparator|Restrictive Group|In this group patients receive volemic small treatment (restrictive)
3097100|NCT01911689||acute pancreatitis|acute pancreatitis group：(a) acute onset of abdominal pain; (b) pancreatitis at first onset; (c) three-fold elevated amylase or lipase, excluding other causes of elevated enzymes; and (5) abdominal MR examination.
3097101|NCT01911689||controlgroup|normal control group：without pancreatic disorders.The exclusion criteria in this study were as follows: (a) inability to cooperate when MR imaging was performed; (b) a history of chronic pancreatitis; (c) AP due to pancreatic carcinoma; (d) hypoproteinemia; and (e) with hypoproteinemia and other peritoneal/ retroperitoneal infection diseases ;(f) with iron deposition disorder (e.g. diabetes or blood system diseases).
3097102|NCT01911676|Experimental|PF-03463275 Active Dose #1|Active dose between 40mg
3097103|NCT01911676|Experimental|PF-03463275 Active Dose #2|Active dose between 60mg
3097104|NCT01911676|Placebo Comparator|Placebo|Placebo- no active dose of PF-03463275.
3097105|NCT01911663|Experimental|KRG|500 mg Korea red ginseng (KRG)
3097106|NCT01911663|Placebo Comparator|Placebo|500 mg placebo (corn starch)
3097107|NCT01911650|Experimental|Autologous Platlet Rich Plasma|This subject arm will receive one injection of autologous platelet rich plasma for the treatment of Achilles tendinopathy. In addition, they will be asked to undergo a palpatory exam of the Achilles tendon; complete Quality of Life Questionnaires at three different time points; and complete a 30 minute ultrasound imaging exam of the Achilles tendon.
3097108|NCT01911650|Other|Waitlist|Subjects in this arm will have already received standard of care interventions for Achilles tendinopathy with unsatisfactory outcomes. For this research they will be asked to undergo a palpatory exam of the Achilles tendon; complete Quality of Life Questionnaires at three different time points; and complete a 30 minute ultrasound imaging exam of the Achilles tendon.
3097109|NCT01911637|Experimental|VBY-036|VBY-036 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg
3097110|NCT01911637|Placebo Comparator|Placebo|Placebo
3097111|NCT01911624|Experimental|direct thrombin inhibition|dabigatran 110 mg BID, po argatroban (0.5 - 1 µg/kg/min) if peroral therapy is not possible
3097112|NCT01911624|Active Comparator|enoxaparin|enoxaparin 40 mg od, sc
3097113|NCT01911611|Placebo Comparator|Placebo|
3097114|NCT01911611|Experimental|RO6870868|
3097115|NCT01911598|Experimental|A: MEHD7945A+ Cisplatin + 5-FU|Participants with previously untreated R/M SCCHN will receive MEHD7945A 1650 milligrams (mg) intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or protocol violation. Cisplatin will be administered as 100 milligrams per square meter (mg/m^2) IV infusion on Day 1 of Cycles 1 to 6. 5-FU will be administered as 1000 mg/m^2/day administered as continuous infusion over Days 1-4 of Cycles 1 to 6.
3097116|NCT01911598|Experimental|B: MEHD7945A + Paclitaxel + Carboplatin|Participants with previously untreated R/M SCCHN will receive MEHD7945A 1650 mg IV infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or protocol violation. Carboplatin will be administered at a dose to achieve an area under the curve (AUC) of 6 milligrams/milliliter/minute (mg/mL/min) as an IV infusion on Day 1 of Cycles 1 to 6. Paclitaxel will be administered as 200 mg/m^2 IV infusion on Day 1 of Cycles 1 to 6.
3097117|NCT01911585|Active Comparator|90 minute Prolonged Exposure Sessions|Prolonged Exposure Therapy for PTSD consists of 10 to 15 weekly or twice-weekly sessions, each lasting about 90 minutes, with 40 to 60 minutes imaginal exposure.
3097118|NCT01911585|Experimental|60 minute Prolonged Exposure Sessions|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of 10 to 15 weekly or twice-weekly sessions, each lasting about 60 minutes, with 20 minutes imaginal exposure.
3097119|NCT01911572||Survivors|Individuals who have previously experienced an episode of invasive streptococcal infection or necrotising fasciitis.
3097120|NCT01911572||Family members|Parents of those survivors aged less than forty years without risk factors for streptococcal disease (forming mother-father-child trios), or first and second degree relatives of survivors from a family in which two or more individuals have been affected.
3097121|NCT01911559||constipated quadriplegic CP children|In this study we included children with CP, in the manifestation of severe diplegia or quadriplegia, who do not currently use the standing-frame.
3097122|NCT01911546|Experimental|everolimus + low-dose tacrolimus|Patients receiving everolimus will be on low dose tacrolimus.
3097123|NCT01911533|Experimental|extracorporeal CO2|
3097124|NCT01911520|Experimental|BMI < 50, Total Body Weight (TBW), 2mg/kg|Patients with a BMI < 50, who will be dosed according to total body weight.
3097125|NCT01911520|Experimental|BMI < 50, TBW, 4 mg/kg|Patients with a BMI < 50, who will be dosed according to total body weight.
3097126|NCT01911520|Experimental|BMI < 50, Ideal Body Weight (IBW), 2 mg/kg|Patients with a BMI < 50, who will be dosed according to ideal body weight.
3097127|NCT01911520|Experimental|BMI < 50, IBW, 4 mg/kg|Patients with a BMI < 50, who will be dosed according to ideal body weight.
3097128|NCT01911520|Experimental|BMI > 50, TBW, 2mg/kg|Patients with a BMI > 50, who will be dosed according to total body weight.
3097129|NCT01911520|Experimental|BMI > 50, TBW, 4mg/kg|Patients with a BMI > 50, who will be dosed according to total body weight.
3097130|NCT01911520|Experimental|BMI >50, IBW, 2 mg/kg|Patients with a BMI > 50, who will be dosed according to ideal body weight.
3097131|NCT01911520|Experimental|BMI >50, IBW, 4 mg/kg|Patients with a BMI > 50, who will be dosed according to ideal body weight.
3097132|NCT01911507|Experimental|Treatment ( INCB028, erlotinib)|Patients receive INC280 PO BID and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3097174|NCT01911273|Placebo Comparator|Placebo plus best supportive care (BSC)|Placebo, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
3097245|NCT01910779|Active Comparator|120 joule arm|120 joule as first biphasic shock energy
3097350|NCT01910012|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethlene glycol
3097133|NCT01911494|Experimental|Intervention|"The CLIP intervention consists of (i) community engagement including community leaders, the women of the communities themselves, and their mothers, husbands, and mothers-in-law, regarding pre-eclampsia, its origins, symptoms, signs, and potential consequences, pre-permissions for maternal transport, and fundraising activities around transport and treatment costs; (ii) provision of HDP oriented antenatal care through CLIP visits and use of CLIP PIERS on the Move mHealth tool (for risk stratification), and (iii) use of the CLIP package for women with a CLIP 'trigger' (i.e., oral antihypertensive therapy (methyldopa) when indicated, intramuscular (i.m.) magnesium sulfate when indicated; and appropriate referral to an CEmOC facility when indicated)"
3097134|NCT01911494|No Intervention|Control|Current standard of antenatal care
3097135|NCT01911481|Experimental|hydration|after recruitment the women in hydration group will be invited to drink 2 litres of water,in 2 hours
3097136|NCT01911481|No Intervention|control|
3097137|NCT01911468|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
3097138|NCT01911468|Active Comparator|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
3097139|NCT01911468|Active Comparator|metformin and liraglutide|In the metformin and liraglutide group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
3097140|NCT01911455|Active Comparator|acamprosate|The maximum dose of acamprosate to be used in this study is 666 mg three times daily (total 1998 mg/day) for subjects weight ≥ 50 kg and 1332mg for subjects that weigh < 50 kg.
3097141|NCT01911455|Placebo Comparator|Placebo|Placebo will be prescribed with the same frequency and duration as the acamprosate group.
3097142|NCT01911442|Experimental|Lurasidone 20 mg|Lurasidone 20 mg once daily
3097143|NCT01911442|Experimental|Lurasidone 60 mg|Lurasidone 60 mg once daily
3097144|NCT01911442|Placebo Comparator|Placebo|Placebo once daily
3097145|NCT01911429|Experimental|Lurasidone 40 mg|Lurasidone 40 mg once daily
3097146|NCT01911429|Experimental|Lurasidone 80 mg|Lurasidone 80 mg once daily Arm received the Lurasidone 40mg dose first, from Days 1-3, and then received the Lurasidone 80 mg dose from day 4 to Week 6
3097147|NCT01911429|Placebo Comparator|Placebo|Placebo 40 or 80 mg once daily
3097148|NCT01911416|Experimental|All participants|All participants on study
3097149|NCT01911403|Active Comparator|Angio-Seal|Closure procedure by Angio-Seal
3097150|NCT01911403|Active Comparator|Manual compression|Closure procedure by manual compression
3097151|NCT01911390|Placebo Comparator|Control Arm|No bean or rice bran additive in smoothie or muffin.
3097152|NCT01911390|Active Comparator|Bean powder|1/4 cup beans (17.5 grams powder)/day in smoothie or muffin.
3097153|NCT01911390|Active Comparator|Rice bran|15 grams rice bran/day in smoothie or muffin.
3097154|NCT01911390|Active Comparator|Bean powder and rice bran|9 grams bean powder/day and 8 grams rice bran /day in smoothie or muffin.
3097155|NCT01911377|Active Comparator|Arm 1: Botulinum Toxin Type A|"200 units of Botulinum Toxin Type a will be administered intradermally to the allodynic area chosen for study.The allodynic area will be mapped, and the number of injections needed to cover the allodynic area without exceeding 40 injection sites will be determined.~All participants will receive a cream formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes before the injections to minimize any discomfort caused by the injections."
3097156|NCT01911377|Placebo Comparator|Arm 2: Normal Saline for Injection|Normal saline for intradermal injection will be prepared by the Investigational Pharmacy in a manner as to be indistinguishable from active drug. The allodynic area will be mapped so as to determine the number of injections needed to cover the whole allodynic area without exceeding 40 injection sites. All participants will receive a cream formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes before the injections to minimize any pain caused by the injections.
3097157|NCT01911364|Experimental|BDP/FF/GB|CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations b.i.d
3097158|NCT01911364|Active Comparator|Tiotropium|Tiotropium bromide 18 mcg
3097159|NCT01911364|Active Comparator|BDP/FF + Tiotropium|"BDP/FF pMDI 100/6/12.5 mcg 2 inhalations b.i.d and Tiotropium 18 mcg daily~BDP/FF/GB versus BDP/FF + Tiotropium"
3097160|NCT01911351|No Intervention|standard management|Patients randomized to this arm will receive standard management alone for their minor procedure.
3097161|NCT01911351|Experimental|Nitrous Oxide|Patients randomized to this arm will receive nitrous oxide plus standard management for their minor procedure.
3097162|NCT01911338|Experimental|Real Time Feedback|Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
3097163|NCT01911338|Active Comparator|Tradicional Learning Method|Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8
3097164|NCT01911325|Experimental|Phase Ib: Buparlisib + docetaxel|Buparlisib (BKM120) oral once daily: 80 mg and 100 mg dose levels to be tested in the dose escalation part of the trial in combination with docetaxel every three week intravenous (i.v.) infusion: 75 mg/m2 as per label.
3097165|NCT01911325|Experimental|Phase II: Buparlisib + docetaxel|Buparlisib oral once daily: MTD/RP2D mg to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label.
3097166|NCT01911325|Placebo Comparator|Phase II: Placebo + docetaxel|Buparlisib matching placebo oral once daily to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label.
3097167|NCT01911312|Experimental|Intervention|
3097168|NCT01911312|Active Comparator|Body Temperature Control|Stimulation performed with body temperature control
3097169|NCT01911299|Experimental|Choline|Liquid glycerophosphocholine (GPC) supplement
3097170|NCT01911299|Placebo Comparator|Placebo|Liquid placebo supplement
3097171|NCT01911286||Standard group|Apnea test according to the recommendation
3097172|NCT01911286||CPAP group|Apnea test with CPAP connection
3097173|NCT01911273|Experimental|PF 03446962 plus best supportive care (BSC)|
3097175|NCT01911260|Active Comparator|Growth Deficit+zinc amino acid chelate|"Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD).~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
3097176|NCT01911260|Placebo Comparator|Growth Deficit receiving placebo|"Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD).~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
3097177|NCT01911260|Placebo Comparator|Normal Height receiving placebo|"For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex.~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
3097178|NCT01911260|Active Comparator|Normal Height+zinc amino acid chelate|"For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex.~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
3097179|NCT01911247|Experimental|Arm 1|
3097180|NCT01911234|Experimental|TNF-Kinoid|TNF Kinoid + ISA51
3097181|NCT01911234|Placebo Comparator|Placebo|Placebo + ISA51
3097182|NCT01911221|Experimental|rMenB+OMV NZ|A single 0.5mL dose of the study vaccine will be administered intramuscularly in the deltoid muscle.
3097183|NCT01911208|Experimental|RECRUIT intervention|Clinical sites will work with the RECRUIT team to enhance and individualize their recruitment methods.
3097184|NCT01911208|Experimental|Control|Clinical sites can use which ever recruitment methods they prefer.
3097185|NCT01911195|Active Comparator|Control Group: Cognitive Testing|Control arm will receive cognitive testing only without undergoing general anesthesia
3097186|NCT01911195|Experimental|ISOFLURANE- Experimental Arm|Experimental arm will receive cognitive testing before and after general anesthesia
3097187|NCT01911182|Experimental|Inhalation of low concentration of CO2|
3097188|NCT01911182|Active Comparator|caffeine only|
3097189|NCT01911169|Experimental|Vitamin D 5000|5,000 IU vitamin D (cholecalciferol) given orally daily
3097190|NCT01911169|Active Comparator|Vitamin D 400|cholecalciferol 400 IU daily by mouth
3097191|NCT01911156|Other|Discontinue NA treatment|Subjects will not receive NA during the 72 week study period
3097192|NCT01911156|Other|NA treatment|Subjects will continue to receive their prescribed NA during the 72 week study period
3097193|NCT01911117||Cardiac Surgical Patients|"Patients who undergo cardiac surgery will be included in this study.~Patients undergo cardiac surgery and are over 18 years of age.~Patients need bypass machine for their cardiac surgery and traditional CO measurement.~Patients who are competent to understand the study and provide written informed consent and participate in outcome measurements."
3097194|NCT01911104|Experimental|Exercise|10 weeks of aerobic exercise
3097195|NCT01911104|No Intervention|Active Control|Young athletes as a trained control
3097196|NCT01911091|Experimental|Group 1 - Regular exercise|Alternate interval training and aerobic training and exercise
3097197|NCT01911091|No Intervention|Group 2 - Athlete exercise|Athletes are not given any intervention
3097198|NCT01911091|No Intervention|Group 3 - Obese No Exercise|The Obese group will not receive intervention
3097199|NCT01911078|Other|Renal Denervation Group|Subjects receiving renal denervation procedure.
3097200|NCT01911078|No Intervention|Control Group|"Subjects not receiving renal denervation procedure.~Subjects are randomized in a 3:1 ratio to either Renal Denervation Group or Control Group."
3097201|NCT01911065|Experimental|Zostavax™ vaccine group|Participants > 50 years will receive a single dose 0.65 ml Zostavax™ (live, attenuated zoster vaccine) administered by subcutaneous injection.
3097202|NCT01911065|No Intervention|Natural-acquired VZV immunity|Participants 40-49 years of age will not receive any intervention with the objective of examining the influence of age and inherited factors on the varicella zoster virus (VZV)-specific immune response in those with a naturally-acquired VZV immunity (a prior history of chicken pox).
3097203|NCT01911052|Experimental|Intervention|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
3097204|NCT01911052|No Intervention|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care at Keimyung University Dongsan Medical Center
3097205|NCT01911052|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
3097206|NCT01911039|Experimental|Regulatory T Cells|Cohort 1 at 1x105 Treg cells/kg, Cohort 2 at 5x105 Treg cells/kg and Cohort 3 at 1.5x106 Treg cells/kg with an extension phase at the MTD (or maximum administered dose if the MTD is not reached).
3097244|NCT01910779|Active Comparator|100 joule arm|100 joule as first biphasic shock energy
3097207|NCT01911026|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus interventional instructions from reinforcement educated nurse such as 'Reinforcement Nurse Education'
3097208|NCT01911026|No Intervention|Standard preparation instructions|The control arm will receive written instructions on preparing for a colonoscopy per standard of care at Keimyung University Dongsan Medical Center
3097209|NCT01911013|Active Comparator|Cage and Plate|anterior cervical discectomy and fusion surgery at one segment is performed using cervical cage and plate system
3097210|NCT01911013|Experimental|Cage alone|anterior cervical discectomy and fusion surgery at one segment is performed using only cervical cage without plate
3097211|NCT01911000|Experimental|RTHT|RT and hyperthermia after TACE in the unresectable HCC patients who combined with PVTT
3097212|NCT01910987|Experimental|optimized retreatment, prolonged therapy|Patients will start therapy with retreatment with 6 cycles of bortezomib and dexamethasone (two 21-day cycles followed by four 35-day cycles) followed by a second randomization in a 1:1 ratio to 1 of 2 prolonged therapy schedules with bortezomib alone (Group A1: once weekly for the first 4 weeks in 35-day cycles; or Group A2: once every other week)
3097213|NCT01910987|Other|standard retreatment|Current Standard of Care: Patients will start retreatment with eight 21-day bortezomib and dexamethasone cycles, followed by posttreatment follow-up every 6 weeks.
3097214|NCT01910974|Experimental|endoscopic sub-mucosal dissection|
3097215|NCT01910961|Experimental|limb RIPC|limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
3097216|NCT01910961|No Intervention|convention|Adult patients undergoing elective open abdominal aortic aneurysm repair received no treatment after induction of anaesthesia.The control group had an uninflated cuff placed on the left upper arm for 30 min.
3097217|NCT01910948|Experimental|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
3097218|NCT01910935|Experimental|Physical activity prescription|24 weeks physical activity program. 1 hour, 3 times a week, moderate to vigorous intensity.
3097219|NCT01910935|No Intervention|No physical activity prescription|Provide information to patients about the benefits of physical activity and how to increase it safely.
3097220|NCT01910922||Repeated exposure Group (RE)|Exposure to basic salsify puree during E1-E8
3097221|NCT01910922||Flavour-flavour learning-salt (FFL-S)|Exposure to salty salsify puree during E1-E8
3097222|NCT01910922||Flavour-flavour learning-nutmeg (FFL-N)|Exposure to nutmeg-flavored salsify puree during E1-E8
3097223|NCT01910909|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy 60 Gy/3 fraction standard dose The highest allowable dose with maintain normal tissue constraints
3097224|NCT01910896|Experimental|Overnight Intensive Patch|Overnight intensive patch (OIP), on polyolefin foam basis containing acrylate, extractum cepae and allantoin is a class I, CE (Conformité Européenne) marked medical device. Subjects will have their two scars randomized for Overnight Intensive Patch application versus no treatment.
3097225|NCT01910896|No Intervention|No treatment|Subjects serve as their own control. Eligible subjects have two comparable scars in same body regions, one scar will be treated with Overnight Intensive Patch, the second scar will not be treated.
3097226|NCT01910883|Experimental|Group 1|Single doses of 200, 400 and 600 mg finafloxacin i.v.
3097227|NCT01910883|Experimental|Group 2|Single doses of 800 and 1000 mg finafloxacin i.v.
3097228|NCT01910883|Experimental|Group 3|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 600 mg i.v.
3097229|NCT01910883|Experimental|Group 4|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 600 mg i.v. (additional to Group 3)
3097230|NCT01910883|Experimental|Group 5|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 800 mg i.v.
3097231|NCT01910883|Experimental|Group 6|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 1000 mg i.v.
3097232|NCT01910870|Experimental|Cisplatin - Metronomic Cyclophosphamide|Cisplatin 25 mg/m² (day 1 to day 3) every 3 weeks Metronomic cyclophosphamide 150 mg (day 1 to day 14) every 3 weeks
3097233|NCT01910857|Experimental|Lifestyle counseling|Lifestyle counseling. 6 group meetings,facilitated by community health worker, focusing on lifestyle change, eg, weight loss, physical activity, low salt, stress reduction
3097234|NCT01910857|No Intervention|Control|Standard care
3097235|NCT01910844|Experimental|Cisplatin - Metronomic Cyclophosphamide|Cisplatin 25 mg/m² from day 1 to day 3 every 3 weeks Metronomic Cyclophosphamide 150 mg from day 1 to day 14 every 3 weeks
3097236|NCT01910831|Experimental|DerMend Moisturizing Bruise Formula|Apply LEFT treatment to LEFT arm or (vica versa) RIGHT treatment to RIGHT arm. Will not be known to the subject which arm is on the active treatment and which is on the placebo control. Applied twice daily for 12 weeks. Each subject will have one arm/hand that is either a)the experimental treatment or b) the placebo control.
3097237|NCT01910831|Placebo Comparator|Non-active placebo control|Apply LEFT treatment to LEFT arm or (vica versa) RIGHT treatment to RIGHT arm. Will not be known to the subject which arm is on the active treatment and which is on the placebo control. Each subject will have one arm/hand that is either a)the experimental treatment or b) the placebo control.
3097238|NCT01910818|Experimental|Fractional CO2 laser Treatment|This is the area getting treated with CO2 laser.
3097239|NCT01910818|Experimental|No Treatment|This is the area receiving no treatment.
3097240|NCT01910805|Experimental|Lifestyle and Risk Awareness class|Women will attend a 3- and 9-month postpartum group nutrition and physical activity education class.
3097241|NCT01910805|No Intervention|Standard Care|Women will receive standard postpartum care for gestational diabetes mellitus.
3097242|NCT01910792|Active Comparator|Group 2|Patients who have had gastric bypass surgery will be exposed to a Sperti Lamp 3x/week
3097243|NCT01910792|Active Comparator|Group 1|Patients with fat malabsorption syndromes will be exposed to a Sperti Lamp 3x/week
3097246|NCT01910766|Experimental|Coenzyme Q10/CC group|"Intervention:~Coenzyme Q10 (CoQ10) and clomiphene citrate group (55 patients, 82 cycles) Patients in CoQ10/CC group took CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6, and CoQ10 Mepaco, Enshas Elraml, Sharkhia, Egypt), in a dose of 60 mg 3 times day capsules orally starting on cycle day 2 and continued till the day of human chorionic gonadotropin (hCG) administration"
3097247|NCT01910766|Active Comparator|CC alone group|"Intervention:~CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6"
3097248|NCT01910753|Experimental|APA|Patient with neck cancer and accepting the physical activity program .
3097249|NCT01910740|Experimental|Enhanced Physical Activity|Participants in the Enhanced Physical Activity group will receive a program of enhanced physical activity in addition to the usual care.
3097250|NCT01910740|Active Comparator|Usual Care|The Usual Care group will receive usual therapy provided by a multidisciplinary team and social interaction.
3097251|NCT01910727|Experimental|Together on Diabetes-Hopkins|
3097252|NCT01910714|Active Comparator|Health Education Control Condition|The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
3097253|NCT01910714|Experimental|Focus on Youth Intervention (FOY)|Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.
3097254|NCT01910701|Experimental|Family Spirit Intervention|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
3097255|NCT01910688|Experimental|RFA treatment (Radiofrequency ablation)|If eligible for enrollment, patients receive initial RFA treatment at 0 month. Patients return to the study site at 3.5 months to review weight data since initial RFA. If the patient has not reached ideal body weight, the patient is scheduled for endoscopy with RFA at 4 months. All patients are seen at 7.5months and if the patient has not reached ideal body weight, the patient is scheduled for endoscopy with RFA at 8 months. All patients are seen at the study site at 12 months for final clinic weight.
3097256|NCT01910675|Experimental|PCC group|Twenty patients in the PCC group receive 15 IU/kg of Octaplex concentrate and 2 g of Riastap concentrate. Additional fibrinogen is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm.
3097257|NCT01910675|Active Comparator|FFP group|Twenty patients in the FFP group receive 4 units of FFP (Octaplas). Additional fibrinogen (Riastab) is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm. The fibrinogen content of the FFP will be taken into consideration (2.1 g in 4 units of FFP).
3097258|NCT01910662|Experimental|Part A:|Subjects in the Part A will receive an ID injection of 0.1 mg KLH as 0.1 mL of KLH (1 mg/mL) in the upper right forearm and an ID injection of 0.1 mL of buffer in the lower right forearm and lower and upper left forearm on Day 1.
3097259|NCT01910662|Experimental|Part B:Cohort 1A|Subjects in the Part B Cohort 1A arm will receive a SC immunisation of 5 mg KLH in the right deltoid. On Day 15 subjects will return to the unit for an ID injection of 0.1 mg KLH as 0.1 mL of KLH (1 mg/mL) in the lower right and lower left forearm. On Day 43, 0.1mL of KLH (1 mg/mL) will be injected ID into the upper left forearm and the upper right forearm (The dose can be changed to either 5mg/1mg or 1mg/0.1mg depending on the results from the first 3 subjects in Cohort 1).
3097260|NCT01910662|Experimental|Part B:Cohort 1B|Subjects in the Part B Cohort 1B arm will receive a SC immunisation of 5 mg KLH in the right deltoid on Day 1. On Day 15 subjects will return to the unit for an ID injection of 0.1 mg KLH in the lower right and lower left forearm. On Day 43 subjects will then receive an ID injection of 0.1 mg KLH in the upper right and upper left forearms (The dose can be changed to either 5mg/1mg or 1mg/0.1mg depending on the results from the first 3 subjects in Cohort 1).
3097261|NCT01910662|Experimental|Part B:Cohort 2|Subjects in the Part B Cohort 2 will receive an ID injection of 2TU (0.04 microg/mL) PPD in the upper right and upper left forearms on Day 1. On Day 3 (48 hours post challenge) If the induration is less than 6 mm, the subject will be re-challenged with 10 TU (0.04 microg/mL) PPD at a site at least 4 cm away from another challenge site. On Day 29 the subjects will have 2 ID injections of 2 TU or 10 TU (the same dose that produced an induration of 6 mm or more).
3097262|NCT01910662|Experimental|Part C: Cohort 1|Subjects in the Part C Cohort 1 will receive an ID injection of 0.1 mL PBS in the upper right forearm on Day 1. On Day 2 subjects will receive an ID injection of 0.1 ml PBS in the upper left forearm.
3097263|NCT01910662|Experimental|Part C: Cohort 2|Subjects in the Part C Cohort 2 will receive an ID injection of 2TU (0.04 microg/mL) PPD in the upper left forearms on Day 1. On Day 3 (48 hours post challenge) If the induration is less than 6 mm, the subject will be re-challenged with 10 TU (0.04 microg/mL) PPD at a site at least 4 cm away from another challenge site. On Day 29 the subjects will have 1 ID injections of 2 TU or 10 TU (the same dose that produced an induration of 6 mm or more).
3097264|NCT01910649|Experimental|Drisapersen|Extension phase of treatment. Intravenous dosing of drisapersen will be investigated as an alternative route of administration
3097265|NCT01910636|Experimental|Sofosbuvir+RBV 12 weeks|Participants will receive sofosbuvir+RBV for 12 weeks.
3097266|NCT01910623||Patients being studied|APL patients previously enrolled in GIMEMA AIDA 0493 and AIDA 2000 studies.
3097267|NCT01910610|Experimental|STRATEGY A|FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab
3097268|NCT01910610|Experimental|STRATEGY B|OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan
3097269|NCT01910597|Experimental|SBG|
3097270|NCT01910584||Novasure treated group|patients diagnosed menorrhea were treated with novasure endometrial ablation
3097271|NCT01910571|Experimental|P7435|"In Part A, there will be up to 6 cohorts of 8 subjects each (for the 2 cohorts undergoing food effect study, there will be 12 subjects in each cohort). At each dose level, every subject will participate in two periods (one with active, P7435 and the second period with matching placebo or vice versa) separated by appropriate wash-out period between the two periods. The randomization scheme will ensure that no subject undergoes the placebo period twice.~In Part B, there will be up to 3 cohorts of 10 subjects each. Each of the 3 cohorts will participate in two study periods of 10 days of dosing in each (one period with active, P7435 and the other period with matching placebo or vice versa) separated by appropriate wash-out period."
3097272|NCT01910571|Placebo Comparator|Placebo|"In Part A, there will be up to 6 cohorts of 8 subjects each (for the 2 cohorts undergoing food effect study, there will be 12 subjects in each cohort). At each dose level, every subject will participate in two periods (one with active, P7435 and the second period with matching placebo or vice versa) separated by appropriate wash-out period between the two periods. The randomization scheme will ensure that no subject undergoes the placebo period twice.~In Part B, there will be up to 3 cohorts of 10 subjects each. Each of the 3 cohorts will participate in two study periods of 10 days of dosing in each (one period with active, P7435 and the other period with matching placebo or vice versa) separated by appropriate wash-out period."
3097273|NCT01910558|Active Comparator|Alpha-cyclodextrin and digestible starch|Supplementation with three grams alpha cyclodextrin with three grams of digestible starch
3097274|NCT01910558|Experimental|Alpha-cyclodextrin|Supplementation with six grams of alpha-cyclodextrin
3097275|NCT01910558|Placebo Comparator|Digestible Starch|Supplementation with six grams of digestible starch
3097276|NCT01910545|Experimental|OTS167IV|single arm
3097277|NCT01910532|Experimental|Clevidipine|Using Clevidipine for the treatment of acute hypertension defined SBP > 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
3097278|NCT01910519|Experimental|Influenza A Vaccine with AS03 adjuvant|Subjects will receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant given 21 days apart
3097279|NCT01910519|Experimental|Influenza A Vaccine without AS03 adjuvant|Subjects will receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant given 21 days apart
3097280|NCT01910506|Experimental|RDEA3170|
3097281|NCT01910493|Active Comparator|ART no SMS reminders|control group
3097282|NCT01910493|Active Comparator|PMTCT no SMS reminders|control group
3097283|NCT01910493|Experimental|SMS reminders to PMTCT cohort|experimental group
3097284|NCT01910493|Experimental|SMS reminders to ART cohort|experimental group
3097285|NCT01910480|Experimental|NBI-98854 followed by NBI-98854 with ketoconazole|50 mg NBI-98854 on Study Days 1 and 6 and 200 mg ketoconazole twice daily on Study Days 5 through 9.
3097286|NCT01910467|Experimental|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases >5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
3097287|NCT01910467|Other|NIRS not visible and treatment as usual|NIRS measurements are not visible and the patients will be treated according to routine ('treatment as usual')
3097288|NCT01910454|Experimental|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|
3097289|NCT01910454|Active Comparator|Task Specific Training (TST)|
3097290|NCT01910441|Experimental|Group A: Vildagliptin plus metformin|Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily).
3097291|NCT01910441|Active Comparator|Group B: Glimepiride plus metformin|Participants received Glimepiride 1-6 mg once daily as an add-on to metformin (1000-1500mg daily).
3097292|NCT01910428|Experimental|L-asparaginase encapsulated in RBC|L-asparaginase encapsulated in RBC dose titration: 50, 100, 150 or 200 IU/kg
3097293|NCT01910415|Experimental|Part A|"Will consist of up to 4 cohorts with subjects receiving lumacaftor or placebo for 7 days.~Cohort 1: 600 mg lumacaftor once a day Cohort 2: 1000 mg lumacaftor once a day Cohort 3: 1200 mg lumacaftor once a day"
3097294|NCT01910415|Experimental|Part B|"Will consist of 3 cohorts. All cohorts will be dosed in parallel. Cohort A will receive 600 mg Lumacaftor once a day plus 250 mg Ivacaftor twice a day for 7 days. From day 8-14 subjects will receive a supratherapeutic dose of Lumacaftor (TBD) plus 450 mg Ivacaftor twice a day.~Cohort B will receive lumacaftor and ivacaftor matching placebo for 14 days Cohort C will receive a single dose of 400 mg moxifloxacin on day 14"
3097295|NCT01910402|Experimental|DTG/ABC/3TC FDC|As per the randomization schedule subjects will be administered with DTG/ABC/3TC (50mg/600mg/300mg) FDC tablet OD up to Week 48 and if continued if applicable in the Continuation Phase. DTG/ABC/3TC FDC may be administered with or without food
3097296|NCT01910402|Active Comparator|ATV +RTV +TDF/FTC FDC|As per the randomization schedule subjects will be administered with ATV (300mg capsule) +RTV (100mg tablet) + TDF/FTC (300mg/200mg tablet) FDC OD up to Week 48. ATV+RTV+ TDF/FTC FDC must be taken with food
3097297|NCT01910389|Active Comparator|Tadalafil|Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.
3097298|NCT01910389|Placebo Comparator|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
3097299|NCT01910376||Control cohort|Nursing home residents without cancer
3097300|NCT01910376||Cancer patient cohort|Patients in nursing homes with suspected or diagnosed active invasive cancer where a diagnostic or treatment decision has to be taken
3097301|NCT01910376||Biomarker cohort|Subgroup of individuals in the control cohort willing to provide a blood sample
3097302|NCT01910363|Experimental|A2NTX|single intramuscular injection of 300 units of A2NTX, a purified low molecular weight (150 kDalton) botulinum toxin preparation of type A2
3097303|NCT01910363|Active Comparator|BOTOX|single intramuscular injection of 300 units of BOTOX®, a commercially available botulinum toxin preparation of type A1
3097349|NCT01910025|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethlene glycol
3097304|NCT01910350|Experimental|Cancer prevention intervention|Cancer prevention intervention: Experimental group receives intensive 2 hour education in each breast and cervical cancer risks and prevention intervention, and face to face reading of post intervention surveys by an community health worker.
3097305|NCT01910350|Active Comparator|Control group receives standard care|The control group receives reading materials and brochures on breast and cervical cancer such as one would receive in a doctors office and post condition surveys. All materials are read by the participant without the interaction or assistance of the community health worker.
3097306|NCT01910337||Screening|this first day, the patient will be evaluated with polar and blood pressure monitor. These data will be the basal one.
3097307|NCT01910337||Intervation|One week later the screening, the patient underwent to the surgery to remove his lower third molar. In this day, will be analyzed 4 points: basal, after the anesthesia, after the avulsion and 20 minutes after the surgery.
3097308|NCT01910337||Post operative|One week later the surgery, the patients will be evaluated again.
3097309|NCT01910324|Experimental|Multidimensional Family Therapy Cross-Systems|In Stage 1 (in detention) Multidimensional Family Therapy Cross-Systems (MDFT-CS) consists of two major components: standard initial/engagement work with parents in the home and with adolescents in detention, plus a state-of-the-art HIV education prevention module. In Stage 2, MDFT-CS includes the standard MDFT components: 1) interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
3097310|NCT01910324|Other|Enhanced Services as Usual|In Stage 1 (in detention) ESAU includes two major components: standard drug treatment services delivered by detention staff, and state-of-the-art HIV education prevention intervention. In Stage 2, community drug treatment providers deliver high quality drug treatment on an outpatient basis.
3097311|NCT01910311|Experimental|Baricitinib|Single oral dose of 10 milligrams (mg) baricitinib on Day 1.
3097312|NCT01910311|Experimental|Baricitinib + Rifampicin|Oral doses of 600 mg rifampicin once daily on Days 3 to 11, with a single oral dose of 10 mg baricitinib co-administered on Day 10.
3097313|NCT01910298|Active Comparator|Breast reconstruction, direct to implant with Strattice|Subjects undergoing immediate post-mastectomy breast reconstruction with a breast implant and Strattice™
3097314|NCT01910298|Active Comparator|Two stage breast reconstruction|Subjects undergoing immediate, two-stage post-mastectomy breast reconstruction without reinforcement.
3097315|NCT01910285|Experimental|Remifentanyl- sufentanil placebo|3 mg/kg of propofol combined with 3 µg/kg of remifentanil
3097316|NCT01910285|Active Comparator|Sufentanil - remifentanyl placebo|3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil
3097317|NCT01910259|Experimental|Amiloride|Amiloride 5 mg twice per day (5 mg once per day for first 4 weeks) for 96 weeks
3097318|NCT01910259|Experimental|Riluzole|Riluzole 50 mg twice per day (50 mg once per day for first 4 weeks) for 96 weeks
3097319|NCT01910259|Experimental|Fluoxetine|Fluoxetine 20 mg twice per day (20 mg once per day for first 4 weeks) for 96 weeks
3097320|NCT01910259|Placebo Comparator|Placebo|Matched placebo 1 capsule twice per day (1 capsule a day for first 4 weeks) for 96 weeks
3097321|NCT01910246|Experimental|Metformin, Insulin Resistance, Cardiac Function,|Metformin Hydrochloride Tablets will be administered with a start dose of 500mg twice daily with meals.
3097322|NCT01910233||adult patients with acute dyspnea in ED|
3097323|NCT01910220|Placebo Comparator|Group 1|placebo
3097324|NCT01910220|Experimental|Group 2|REGN1033 (SAR391786)
3097325|NCT01910220|Placebo Comparator|Group 3|placebo + exercise regimen
3097326|NCT01910220|Experimental|Group 4|REGN1033 (SAR391786) + exercise regimen
3097327|NCT01910194|Other|Lyxumia|4 weeks Luxumia plus another 4 weeks combination
3097328|NCT01910194|Other|Lantus|4 weeks Lantus plus another 4 weeks combination
3097329|NCT01910181|Experimental|Vemurafenib: Pharmacokinetic Cohort|Participants will receive vemurafenib orally as 960 mg twice daily on Days 1 to 21 (morning dose only on Day 21), with a drug holiday from Days 22 to 27, and from Day 28 until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation.
3097330|NCT01910181|Experimental|Vemurafenib: Expansion Cohort|Participants will receive vemurafenib orally as 960 mg twice daily from Day 1 until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation.
3097331|NCT01910168||Cohort|
3097332|NCT01910155|Experimental|Test|Ciprofloxacin/Dexamethasone
3097333|NCT01910155|Active Comparator|Reference|Ciprodex (R)
3097334|NCT01910155|Placebo Comparator|Placebo|Placebo
3097335|NCT01910142|Active Comparator|calcium supplement with vitamin K|Milk product supplying about 420 mg Ca and 7.5 μg vitamin D3 and 100 μg vitamin K. Additional 200 mg calcium in the form of carbonate
3097336|NCT01910142|Placebo Comparator|calcium supplement without vitamin K|Milk product supplying about 420 mg Ca and 7.5 μg vitamin D3. no vitamin K. Additional 200 mg calcium in the form of carbonate
3097337|NCT01910129|Active Comparator|gammaCore|Active stimulation treatment
3097338|NCT01910129|Placebo Comparator|active sham gammaCore|Inactive stimulation treatment
3097339|NCT01910116|Placebo Comparator|Placebo|Placebo 2 capsules, twice daily, for 12 weeks.
3097340|NCT01910116|Active Comparator|Shinbaro|Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
3097341|NCT01910090|Experimental|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|FLURBIPROFEN, FAMOTIDINE 100/20 mg MULTI-LAYER TABLET one tablet, once
3097342|NCT01910090|Active Comparator|ANTADYS® and PEPCID®|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
3097343|NCT01910077|Experimental|Tacrobell capsule 1mg|Tacrolimus 1mg / 1 capsule
3097344|NCT01910077|Active Comparator|Prograf capsule 1mg|Tacrolimus 1mg / 1 capsule
3097345|NCT01910064|Experimental|GK530G|GK530G is the fixed-dose combination gel of Adapalene and Benzoyl Peroxide, BPO
3097346|NCT01910051||Generally healthy|Generally healthy
3097347|NCT01910051||Type 2 diabetes mellitus|Type 2 diabetes mellitus
3097348|NCT01910038|Experimental|Prednisone+Tocilizumab|Prednisone (0.7 mg/Kg/d and then progressively tapered to reach 0.1 mg/Kg/d at W24) + tocilizumab 8mg/Kg/4 weeks for a total of 4 infusions (S0, S4, S8, S12).
3097351|NCT01909999|Experimental|Immediate loading implants|The clinical and immunological comparisons compared implants that received Immediate loading prosthesis, i.e., full arch Branemark protocol prosthesis installed within 3 days after surgery, with unloaded implants.
3097352|NCT01909999|Active Comparator|Unloaded Implants|The variables, immunological and clinical, obtained in immediate loading groups were compared to unloaded implants, i.e., no prosthetic rehabilitation during osseointegration.
3097353|NCT01909986|Experimental|E1|[14C]-ONO-4053
3097354|NCT01909973|Experimental|MedLink System|For 12 weeks, the patient who is newly prescribed antidepressant medication will receive a mobile phone and a GSM enable pill bottle in order to provide and receive feedback regarding medication adherence.
3097355|NCT01909973|No Intervention|Treatment As Usual|Patients will continue to receive treatment as usual from their primary care doctor. Patients in this arm will also receive a free mobile phone for the 12 weeks of the intervention.
3097356|NCT01909960|Experimental|Surgery|Patients who will undergo flow imaging and neurosurgery (shunting). (25% of the studied population)
3097357|NCT01909960|Experimental|Clinical follow-up|Patients who will undergo flow imaging but not surgery (75% of the studied population)
3097358|NCT01909947||Intubated extreme preterm infants|Infants with a birth weight ≤ 1250 grams and requiring endotracheal tube and mechanical ventilation
3097359|NCT01909934|Experimental|Brentuximab vedotin|1.8 mg/kg IV infusion
3097360|NCT01909908|Experimental|ECM in Saline|
3097361|NCT01909908|Active Comparator|Blood Products|
3097362|NCT01909908|Experimental|ECM in Blood Products|
3097363|NCT01909895|Experimental|Anger induction|The participant will be asked to undergo a validated anger induction task.
3097364|NCT01909895|Experimental|Depressed Mood Induction|The participant will be asked to undergo a validated depression/sadness induction task.
3097365|NCT01909895|Experimental|Anxiety Induction|The participant will be asked to undergo a validated anxiety induction task.
3097366|NCT01909895|Other|Neutral emotion task|The participant will be asked to undergo a validated neutral task (i.e. count aloud by ones, starting with one and ending with 100, over and over, until the task period has ended).
3097367|NCT01909882|Other|Family member's massage therapy|Family member's massage therapy
3097368|NCT01909869|Experimental|EXCEL-Ⅱ|A new Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions.
3097369|NCT01909856|Experimental|Arm1|1st cycle Palonosetron, 2nd cycle Granisetron
3097370|NCT01909856|Experimental|Arm2|1st cycle Granisetron, 2nd cycle Palonosetron
3097371|NCT01909843|Experimental|ALX-0171 Oral inhalation|
3097372|NCT01909830|Experimental|Arm A : Gemcitabine + Pemetrexed|"Arm A : Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days."
3097373|NCT01909817||Routine coronary angiogram patients|
3097374|NCT01909804|Experimental|SOF+VEL 25 mg (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 25 mg for 12 weeks.
3097375|NCT01909804|Experimental|SOF+VEL 25mg+RBV (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 25 mg plus RBV for 12 weeks.
3097376|NCT01909804|Experimental|SOF+VEL 100 mg (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 100 mg for 12 weeks.
3097377|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 100 mg plus RBV for 12 weeks.
3097378|NCT01909804|Experimental|SOF+VEL 25 mg (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 25 mg for 12 weeks.
3097379|NCT01909804|Experimental|SOF+VEL 25 mg+RBV (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 25 mg plus RBV for 12 weeks.
3097380|NCT01909804|Experimental|SOF+VEL 100 mg (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 100 mg for 12 weeks.
3097381|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 100 mg plus RBV for 12 weeks.
3097382|NCT01909804|Experimental|SOF+VEL 25 mg (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
3097383|NCT01909804|Experimental|SOF+VEL 25 mg+RBV (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 12 weeks.
3097384|NCT01909804|Experimental|SOF+VEL 100 mg (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
3097385|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 12 weeks.
3097386|NCT01909791|Experimental|Prompt Laser + Deferred Aflibercept|Focal/grid laser followed by intravitreal aflibercept if vision worsens
3097387|NCT01909791|Active Comparator|Observation + Deferred Aflibercept|No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
3097388|NCT01909791|Experimental|Prompt Aflibercept|Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
3097389|NCT01909778|Experimental|BI 201335|BI 201335 two single oral doses, separated by 14 days washout period
3097390|NCT01909765|Active Comparator|Dorsal slite|Skin and mucosa insicion made together
3097391|NCT01909765|Experimental|Double incision|Skin and mucosa incision made separately
3097392|NCT01909752|Experimental|DRibble Vaccine Alone|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
3097435|NCT01909453|Experimental|LGX818|LGX818 300 mg QD
3097516|NCT01908933|Experimental|AeriSeal Emphysematous Lung Sealant Syst|This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
3097393|NCT01909752|Experimental|DRibble vaccine with imiquimod|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4) and for four days following each vaccine cycle. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
3097394|NCT01909752|Experimental|DRibble vaccine with GM-CSF|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
3097395|NCT01909739|Experimental|Statin group|
3097396|NCT01909739|Placebo Comparator|Placebo group|
3097397|NCT01909726||Interactive media|ScreenPlay
3097398|NCT01909726||Passive media|Silent nature video
3097399|NCT01909726||No media|Standard care
3097400|NCT01909713|Experimental|Facial Cleanser and Moisturizer SPF 30|All subjects used Cetaphil® DermaControl™ Oil Control Foam Wash and Cetaphil® DermaControl™ Oil Control Moisturizer SPF 30 at least once daily for 22 days.
3097401|NCT01909700|Experimental|Single Incision Mesh|intervention: single incision mesh implantation
3097402|NCT01909674|Experimental|Oronasal Mask|Initial administration of oronasal CPAP mask
3097403|NCT01909674|Experimental|Nasal Mask|Initial administration of nasal CPAP mask
3097404|NCT01909661|Experimental|Damira/Celia peptide hydrolyzed casein|Extensively Hydrolyzed (EH)casein infant formula
3097405|NCT01909661|Experimental|Picot riz/Celia rice/Sanutri arroz|Picot riz/Celia rice/Sanutri arroz Extensively Hydrolyzed (EH) rice protein infant formula
3097406|NCT01909648|Other|HbA2 Leuven|Presence of HbA2 Leuven mutation, demonstrated by molecular diagnosis on blood sample.
3097407|NCT01909635|Experimental|Food Feelings|If you are randomized to this group, you will be asked to think about your feelings of hunger, fullness, and the sensory qualities of the food (such as texture, smell, flavor) as you eat your meal.
3097408|NCT01909635|Experimental|Other Feelings|If you are randomized to this group, you will be asked to think about how hot or cold you feel, and how tired you are feeling as you eat your meal.
3097409|NCT01909622|Experimental|Vitamin D-fortified milk|Skim milk fortified with 600 IU vitamin D3 / 250 mL
3097410|NCT01909622|Active Comparator|Vitamin D-unfortified milk|Unfortified skim milk
3097411|NCT01909609|Sham Comparator|Parent Survival Guide|This arm of the study will focus on the document that is normally given to all parents of newborn infants. It contains information on newborn care such as feeding, cleaning of the baby's penis, etc.
3097412|NCT01909609|Experimental|AAP Documents + Parent Survival Guide.|This arm of the study will focus on documents created based off of the American Academy of Pediatrics 2012 policy statement. They contain information on the potential risks and benefits of neonatal circumcision. The Parent Survival Guide contains information on newborn care such as feeding, cleaning of the baby's penis, etc.
3097413|NCT01909596|Experimental|Knee osteoarthritis patients|Without orthoses 6° lateral wedge insoles 10° lateral wedge insoles Neutral customized foot orthoses 6° lateral customized foot orthoses 7° lateral customized foot orthoses 8° lateral customized foot orthoses 9° lateral customized foot orthoses 10° lateral customized foot orthoses Orthotist integrated lateral customized foot orthoses Orthotist lateral customized foot orthoses
3097414|NCT01909583|Active Comparator|STAGES PRE-GROUP|"INTERVENTION: this group will receive our STAGES booklet PRE-operatively"
3097415|NCT01909583|Placebo Comparator|STAGES POST-GROUP|INTERVENTION: This arm will only receive the STAGES-booklet POST-operatively
3097416|NCT01909570|Experimental|Elective single embryo transfer|After the FIV/ICSI procedure, in this arm the embryo transfer would be of a single embryo followed by the cryotransfer or a single embryo in case of no fresh conception
3097417|NCT01909570|Active Comparator|Double embryo transfer|After the FIV/ICSI procedure, in this arm the embryo transfer woub be of two fresh embryos
3097418|NCT01909557|Active Comparator|Acetyl-L-carnitine|Acetyl-L-carnitine 2 gr tablets
3097419|NCT01909557|Placebo Comparator|placebo|
3097420|NCT01909544|Experimental|Oxygen|
3097421|NCT01909544|Sham Comparator|Room air|
3097422|NCT01909518||pCLE examination|pCLE is used to distinguish the suspected lesions detected by I-SCAN in esophagus
3097423|NCT01909505||Normal Males|Males with normal levels of serum testosterone
3097424|NCT01909505||Hypogonadal males|Males known to have low levels of serum testosterone
3097425|NCT01909492||Group 1|Group 1 will consist of 10 subjects with suspected MS, who have had a clinical attack within the last 12 weeks, have at least one gadolinium-enhancing lesion on brain or spinal cord MRI taken within the prior 4 weeks, and for which they have not received any immunomodulating or immunosuppressant medication. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
3097426|NCT01909492||Group 2|Group 2 will consist of 10 subjects with clinically stable definite MS, with no evidence of clinical relapse for at least the past 12 weeks, and have no gadolinium enhancing lesions on MRI in the prior 4 weeks. These subjects will fulfill the Revised (2010) McDonald's Criteria for the Diagnosis of MS. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
3097427|NCT01909492||Group 3|Group 3 will consist of 10 subjects without evidence of inflammatory systemic or inflammatory central nervous system disease, who require CSF removal for some other cause, such treatment of benign intracranial hypertension or as part of the procedure for insertion of an intrathecal medication delivery system. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
3097428|NCT01909479|Experimental|MOD-4023|
3097429|NCT01909479|Placebo Comparator|Placebo|
3097430|NCT01909466|Other|Gluteal Injection|
3097431|NCT01909466|Other|Deltoid Injection|
3097432|NCT01909453|Experimental|LGX818 450 mg + MEK162|LGX818 450 mg QD + MEK162 45 mg BID
3097433|NCT01909453|Active Comparator|Vemurafenib|Vemurafenib 960 mg BID
3097434|NCT01909453|Experimental|LGX818 300 mg + MEK162|LGX818 300 mg QD + MEK162 45 mg BID
3097436|NCT01909440|Experimental|Arm I (RT + PS)|Patients undergo total body high-intensity RT thrice weekly and perform static stretching exercises after each session. Exercises progress from low intensity and high volume to higher intensity and lower volume over the course of the 12-week program. Patients also receive whey protein supplementation orally twice a day for 12 weeks.
3097437|NCT01909440|Experimental|Arm II (total body RT)|Patients undergo total body RT and stretching as in Arm I.
3097438|NCT01909440|Experimental|Arm III (protein supplementation)|Patients receive whey protein supplementation as in Arm I. Patients also undergo a home flexibility program 3 times per week, consisting of the same static stretching exercises performed after RT. After 12 weeks, patients may undergo the RT program as in Arm I.
3097439|NCT01909440|Active Comparator|Arm IV (attention control)|Patients undergo the home flexibility program as in Arm III. After 12 weeks, patients may undergo total body RT as in Arm I.
3097440|NCT01909427|Placebo Comparator|Placebo/CNTO 6785 200 mg+Methotrexate (MTX)|
3097441|NCT01909427|Experimental|CNTO 6785 200 mg+MTX|
3097442|NCT01909427|Experimental|CNTO 6785 100 mg+MTX|
3097443|NCT01909427|Experimental|CNTO 6785 50 mg+MTX|
3097444|NCT01909427|Experimental|CNTO 6785 15 mg+MTX|
3097445|NCT01909414|Experimental|Arm A: GEO-D03 DNA and MVA/HIV62B vaccines|At study entry and Week 8, participants will receive the GEO-D03 DNA vaccine administered as 1 mL intramuscularly (IM) in either deltoid. At Weeks 16 and 24, they will receive the MVA/HIV62B vaccine administered as 1 mL IM in either deltoid.
3097446|NCT01909414|Placebo Comparator|Arm B: Placebo for GEO-D03 and MVA/HIV62B|At study entry and Week 8, participants will receive the placebo for GEO-D03 DNA vaccine administered as 1 mL IM in either deltoid. At Weeks 16 and 24, they will receive the placebo for MVA/HIV62B vaccine administered as 1 mL IM in either deltoid.
3097447|NCT01909388|Experimental|MRI-TRUS fusion guided real time HDR|Patients treated with dose escalation to Dominant Intraprostatic Lesions
3097448|NCT01909362||Early recurrence (≤ 12 months)|Biospecimens from 25 patients who have had early recurrence (≤ 12 months) of their metastatic colorectal cancer
3097449|NCT01909362||Late recurrence (> 12 months)|Biospecimens from 25 patients who have had late recurrence (> 12 months) of their metastatic colorectal cancer
3097450|NCT01909349|No Intervention|Control Group|Control Group will gain access to the intervention after the intervention group has finished the program (>8 weeks after signing up)
3097451|NCT01909349|Experimental|Intervention Group I|Self-regulation support Behavior sequence: Physical activity, then fruit & vegetable intake
3097452|NCT01909336|Active Comparator|Group 1: 0.3% Saline in 3.3% dextrose (intravenous)|Group 1: 0.3% Saline in 3.3% dextrose (intravenous)
3097453|NCT01909336|Active Comparator|Group 2: 0.45% Saline in 5% dextrose (intravenous)|Group 2: 0.45% Saline in 5% dextrose (intravenous)
3097454|NCT01909336|Active Comparator|Group 3: 0.9% Saline in 5% dextrose (intravenous)|Group 3: 0.9% Saline in 5% dextrose (intravenous)
3097455|NCT01909323|Placebo Comparator|sugary dessert cream|
3097456|NCT01909323|Experimental|maltitol alone|
3097457|NCT01909323|Experimental|maltitol 85% / FOS 15%|
3097458|NCT01909323|Experimental|maltitol 68% / FOS 32%|
3097459|NCT01909323|Experimental|maltitol 50% / FOS 50%|
3097460|NCT01909323|Experimental|FOS alone|
3097461|NCT01909310|Active Comparator|with head support|patients are ventilated with their heads positioned on a support
3097462|NCT01909310|Sham Comparator|without head support|patients are ventilated without head support
3097463|NCT01909297|Active Comparator|ProSeal LMA|Supraglottic airway device
3097464|NCT01909297|Active Comparator|suprema LMA|Supraglottic airway device
3097465|NCT01909297|Active Comparator|I-gel LMA|Supraglottic airway device
3097466|NCT01909284|Experimental|Acupuncture & Epidural nerve block|acupuncture plus epidural block
3097467|NCT01909284|Active Comparator|Epidural nerve block|epidural block alone
3097468|NCT01909271|Experimental|Stroke Education Film Viewing Intervention Group|A novel, culturally tailored intervention using storytelling (narrative persuasion) in the form of two professionally produced 12-min films (in English and Spanish), in minority populations in New York City.
3097469|NCT01909271|Other|Usual Care Group|"Usual Care: Stroke Education pamphlet and brochure distribution."
3097470|NCT01909258||The study population.|"Healthy volunteers 20 to 40 years of age.~Intervention: Goniometric measure of pelvic extension reserve. Intervention: Photographic measure of pelvic extension reserve. Intervention: EOS measure of pelvic extension reserve."
3097471|NCT01909245|Experimental|Single Arm Study|
3097472|NCT01909232|Experimental|Active rTMS treatment|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
3097473|NCT01909232|Sham Comparator|Sham rTMS treatment|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
3097474|NCT01909219|Active Comparator|Group A: standard regimen|Patients in the group A (standard regimen) will be instructed to take the two sachets of sodium picosulphate/magnesium citrate diluted in a glass of water 2-4 hours apart, starting at 5 pm the day before colonoscopy.
3097475|NCT01909219|Active Comparator|Group B|Patients in the group B (split regimen) will be instructed to take the first sachet of sodium picosulphate/magnesium citrate at 7 pm the day before colonoscopy and the second one at 6 am in the morning on the day of colonoscopy.
3097476|NCT01909193|Experimental|Attention Bias Modification (ABM)|Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
3097477|NCT01909193|Experimental|Cognitive Behavior Therapy|CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
3097478|NCT01909180|Experimental|Cardiac|Revolution CT Cardiac Imaging Scan
3097479|NCT01909180|Experimental|Body/Extremity|Revolution CT Body and/or Extremity Imaging Scan
3097480|NCT01909180|Experimental|Neuro|Revolution CT Brain and Spinal Cord Imaging Scan
3097481|NCT01909167|Active Comparator|Treatment as usual (TAU)|Patients randomized to the treatment as usual arm will follow advice by their GP(general practitioner), mental health midwife or perinatal psychiatric team concerning treatment.
3097517|NCT01908920|Other|OMT|Each osteopathic session is based on structural evaluation and treatment using indirect techniques.
3097758|NCT01907243|Active Comparator|spreader flap|Usage of spreader flap of upper lateral cartilage
3097482|NCT01909167|Active Comparator|Online Cognitive Behavioral Therapy|CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
3097483|NCT01909154|Experimental|Mesenchymal stromal cell therapy|Autologous bone marrow adult mesenchymal stem cells expanded in vitro. Administered by Intrathecal injection (subarachnoid and intramedullary). Depending on centromedullary post-traumatic injury: bone marrow stromal stem cells administration (MSCs) at the minimum dose of 100x106 followed by subarachnoid administration of 30x106 MSCs,3 months later
3097484|NCT01909141|Active Comparator|arm 1:letrozole-pioglitazone -metformin group|Arm 1 will receive letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.
3097485|NCT01909141|Active Comparator|arm 2: clomiphene citrate-pioglitazone-metformin|Arm 2 will receive clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.
3097486|NCT01909128|Experimental|fermented milk|
3097487|NCT01909128|Experimental|fermented rice|
3097488|NCT01909128|Placebo Comparator|placebo|
3097489|NCT01909115|Active Comparator|1000 units of Vitamin D Daily|Vitamin D capsule 1000 IU
3097490|NCT01909115|Experimental|4000 IU vitamin D daily|Vitamin D capsule 4000 IU
3097491|NCT01909102|Experimental|ACT-based intervention|The ACT-based intervention integrates educational topics on heart healthy behaviours with mindfulness and acceptance training regarding difficult thoughts and feelings, clarification of health-related values and commitment to behave in the valued direction while contacting difficult experiences.
3097492|NCT01909102|Active Comparator|Usual care|Usual care is based on current guidelines for the long-term multi-disciplinary rehabilitation and prevention of cardiac patients.
3097493|NCT01909089|Experimental|Chloroprocaine|Up-down sequential allocation.
3097494|NCT01909076|Active Comparator|Control PCPs and their patients|PCPs randomized to the control condition will receive electronic decision support tools. Patients of control PCPs will receive education materials that will be developed and made available to both control and intervention patients.
3097495|NCT01909076|Experimental|Intervention PCPs and patients|The Intervention Condition has three main components: access to nurse care management, access to the patient registry, and academic detailing for intervention PCPs. Intervention PCPs will also receive the control intervention of electronic decision support tools, and patients of intervention PCPs will receive the same patient education materials as patients of control PCPs.
3097496|NCT01909063|Experimental|Arm A|200 IU vitamin D and 700 mg of calcium per day in 2 glasses of juice per day for 2 weeks
3097497|NCT01909063|Experimental|Arm B|"200 IU vitamin D, 12 IU vitamin E, 2000 IU vitamin A as beta carotene, and 700 mg of calcium per day in 2 glasses of juice~Vitamin D, Vitamin E, and Vitamin A"
3097498|NCT01909063|Placebo Comparator|Arm C|"Control, 700 mg of calcium per day in 2 glasses of juice~Control, 700 mg Calcium"
3097499|NCT01909050||refractory celiac disease|
3097500|NCT01909050||well-controlled celiac disease|
3097501|NCT01909050||uncontrolled celiac disease|either newly diagnosed with celiac disease or not on a gluten-free diet
3097502|NCT01909050||gluten-sensitivity|
3097503|NCT01909050||disorders other than celiac disease.|
3097504|NCT01909037|Experimental|Flexofytol (bio-optimized curcumin)|
3097505|NCT01909024|Experimental|embolisation of pelvic veins & treatment of leg varicose veins|transjugular coil embolisation of pelvic veins followed by endovenous treatment of leg recurrent varicose veins
3097506|NCT01909024|Active Comparator|endovenous treatment of leg recurrent varicose veins alone|endovenous treatment of leg recurrent varicose veins alone
3097507|NCT01909011|Experimental|Active CES|The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.
3097508|NCT01909011|Sham Comparator|Sham CES|The CES sham group will receive sham CES (device off)for 20 minutes 5 times per week for two weeks.
3097509|NCT01908998|Active Comparator|Sandal|
3097510|NCT01908972|Active Comparator|Prednisolone|Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
3097511|NCT01908972|Experimental|Propranolol|Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
3097512|NCT01908959|Experimental|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received an Omron pedometer and learned to monitor walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks, in-group, to walk at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
3097513|NCT01908959|No Intervention|Attention-control|"Participants in the attention receive monthly brief telephone calls by research technicians and collection of study data on-site at the Maricopa Medical Center and other community based sites at baseline, 6, and 12 months (T1, T3, T5). The staff did not give advice or support specific to walking, which enabled a valid evaluation of the intervention effect. The content given to the attention-control group did not include the active ingredients of the Madres para la Salud intervention. The attention-control group received monthly mailings of health-related information regarding common postpartum or newborn concerns, such as breastfeeding, infant sleep, sibling rivalry, emotional support related to new parenthood, and early childhood development topics."
3097514|NCT01908946|Experimental|SMS Reminders|SMS reminders
3097515|NCT01908946|No Intervention|Standard verbal counseling|One time standard verbal counseling at the time of initial visit and timing for EPI vaccines at 6, 10 and 14 weeks
3097624|NCT01908140|Active Comparator|Salmeterol / Fluticasone propionate|Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks
3119086|NCT01760525|Experimental|CGM097 - Dose escalation|
3097518|NCT01908920|Other|SHAM|"Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. A pre-determined protocol has been used. The practitioner's attention was distracted by subtracting calculation in silence."
3097519|NCT01908920|Other|CONTROL|No intervention
3097520|NCT01908907|Active Comparator|DHA oil|DHA oil administered 50 mg/d (0.18ml)as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
3097521|NCT01908907|Placebo Comparator|(MCT) control oil|MCT oil administered 0.18ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
3097522|NCT01908894|Experimental|BIOD-123|SC administration of 0.20 U/kg
3097523|NCT01908894|Experimental|BIOD-125|SC administration of 0.20 U/kg
3097524|NCT01908894|Active Comparator|Humalog|SC administration of 0.20 U/kg
3097525|NCT01908881|Active Comparator|Control (usual care)|"This arm receives usual care (control group) consisting in: home visits, evaluation by social worker and planning interventions according to multidisciplinary team usually done en Family Primary Health Care Centers"
3097526|NCT01908881|Experimental|Intervention (group workshop+usual care)|Group intervention (group workshop) described elsewhere
3097527|NCT01908868|Experimental|EBUS-TBNA|EBUS-TBNA (with endobronchial and transbronchial lung biopsy)
3097528|NCT01908868|Active Comparator|Conventional TBNA|Conventional TBNA (with endobronchial and transbronchial lung biopsy)
3097529|NCT01908855|Experimental|ENCERT|ENCERT contains 1) psychoeducation (session1), 2) relaxation techniques for coping with stress (sessions 2-4), 3) non-judgmental awareness of body perceptions, (sessions 5-7), 4) modifying illness behavior and accepting unpleasant body perceptions (sessions 8-13), 5) attention defocusing on positive perceptions plus emotional self-support (sessions 14- 15), 6) analyzing interpretation processes to understand situational cues (sessions 16-17), and 7) change of behavior and interpretations (sessions 18-20). The innovative elements of ENCERT are: improving the awareness for the association of somatic symptoms with emotions, learning non-judgmental awareness and acceptance of unpleasant body perceptions, achieving high-frequent skill exercising with the emotion regulation audio training.
3097530|NCT01908855|Active Comparator|CBT|"This arm is based on traditional cognitive-behavioral therapy that can be considered the current treatment of choice, being the only intervention with an evidence grade 1a (Kroenke, 2007). As such, it presents the reference of efficacy and safety for new regimen. The strictly manualized program includes the following components focusing on the special needs of chronic somatoform patients: psychoeducation providing a framework for psychotherapy, attention defocusing, reduction of over-interpretation of symptoms, increase of physical activity, stress reduction."
3097531|NCT01908842|Active Comparator|Buprenorphine; then OL BNX film, then BNX tablets|Days 1-2: Generic buprenorphine sublingual tablets (blinded); Days 3 to 14: Buprenorphine/naloxone sublingual film (open-label); Days 15-21: BNX sublingual tablets (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets
3097532|NCT01908842|Experimental|BNX tablets, then OL BNX tablets, then BNX film|Days 1-2: BNX sublingual tablets (blinded); Days 3 to 14: BNX sublingual tablets (open-label); Days 15-21: Buprenorphine/naloxone sublingual film (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets
3097533|NCT01908829|Experimental|Combination (solifenacin + mirabegron)|Participants received solifenacin 5 mg, mirabegron 25 mg and solifenacin 10 mg matching placebo once daily for the first 4 weeks of double-blind period. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron tablet was replaced by a 50 mg mirabegron tablet. Placebo was given for the 2 week single-blind safety follow-up period.
3097534|NCT01908829|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg, mirabegron 25 mg matching placebo and solifenacin 10 mg matching placebo once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period
3097535|NCT01908829|Active Comparator|Solifenacin 10 mg|Participants received solifenacin 5 mg matching placebo, mirabegron 25 mg matching placebo and solifenacin 10 mg once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period.
3097536|NCT01908816|Experimental|ranibizumab|
3097537|NCT01908803|Experimental|AL-60371/AL-817|AL-60371/AL-817 otic suspension, 200 μL in affected ear(s) through tympanostomy tube on Day 1 (Visit 1)
3097538|NCT01908803|Active Comparator|CIPRODEX|Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension, 4 drops in affected ear(s) twice daily through tympanostomy tube for 7 days
3097539|NCT01908790||Heart Failure Patients|Acute and chronic heart failure patients already receiving right heart catheterization (RHC) as part of their usual care
3097540|NCT01908777|Experimental|high dose chemo w/asct + maintenance txt|High dose chemotherapy (Carmustine), VP-16 (etoposide, Vepesid®), Cytarabine (Ara-C), Melphalan (Alkeran)with autologous stem cell transplant followed by maintenance therapy with Romidepsin (Istodax)
3097541|NCT01908764|Experimental|AL-60371/Posology 1|AL-60371 otic suspension, single dose of 200 µL following surgical insertion of tympanostomy tubes
3097542|NCT01908764|Experimental|AL-60371/Posology 2|AL-60371 otic suspension, single dose of 4 drops following surgical insertion of tympanostomy tubes
3097543|NCT01908751|Experimental|Sliding Hip Screw and Vitamin D supplementation|Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
3097544|NCT01908751|Experimental|Sliding Hip Screw and Vitamin D placebo|Participants in the placebo group will receive an identical bottle of placebo drops with no active ingredient. Similarly, they will be instructed to take two drops daily for six months. The placebo supplement is also manufactured by the Ddrops Company.
3097545|NCT01908751|Experimental|Cancellous Screws and Vitamin D supplementation|Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
3097546|NCT01908751|Experimental|Cancellous Screws and Vitamin D placebo|Participants in the placebo group will receive an identical bottle of placebo drops with no active ingredient. Similarly, they will be instructed to take two drops daily for six months. The placebo supplement is also manufactured by the Ddrops Company.
3097547|NCT01908738|Experimental|paracervical block with 1%lidocaine and 0.9%NSS spray(placebo)|first groups receive paracervical block with 1%lidocaine and 0.9%NSS spray(placebo)
3097548|NCT01908738|Experimental|10%lidocaine spray and paracervical block with 0.9%NSS|the second groups receive 10%lidocaine spray and paracervical block with 0.9%NSS(placebo)
3097549|NCT01908738|Placebo Comparator|receive placebo both paracervical block and spray|the third groups receive placebo both paracervical block and spray
3097550|NCT01908725|Experimental|Lamazym|1 mg Lamazym/kg body weight
3097551|NCT01908712|Experimental|Lamazym|1 mg Lamazym/kg body weight
3097552|NCT01908699|Experimental|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration.
3097553|NCT01908699|Experimental|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR.
3097554|NCT01908686|Active Comparator|Pivotal Response Training|Pivotal Response Training with children ages 4-35 years of age with an Autism Spectrum Disorder diagnosis
3097555|NCT01908686|No Intervention|Waitlist Control|Children in WL will be offered treatment following WL condition.
3097556|NCT01908673|Active Comparator|HRV biofeedback|heart rate variability biofeedback
3097557|NCT01908673|Active Comparator|ASTM|Automatic Self Transcedental Meditation
3097558|NCT01908660||Antiretroviral drugs|Pre-treated or treatment-naive HIV-infected patients with chronic hepatitis B and/or chronic hepatitis C who change an existing antiretroviral regimen or who start a new regimen.
3097559|NCT01908647|Experimental|Exp RT fMRI/Exp Cognitive Training|Both experimental conditions.
3097560|NCT01908647|Experimental|Exp RT fMRI/Ctrl Cognitive training|Experimental real-time fMRI and control cognitive training.
3097561|NCT01908647|Experimental|Ctrl RT fMRI/Exp Cognitive Training|Control RT fMRI (real-time functional MRI) and experimental cognitive training.
3097562|NCT01908647|Sham Comparator|Ctr RT fMRI/Ctr Cognitive Training|Control real-time fMRI and control cognitive training.
3097563|NCT01908634|Active Comparator|Milk-based Strawberry Beverage|Strawberry beverage with milk
3097564|NCT01908634|Experimental|Water-based Strawberry Beverage|Strawberry beverage with water
3097565|NCT01908634|Active Comparator|Milk-based Fruit-mixed Beverage|Fruit-Mixed beverage with milk
3097566|NCT01908634|Experimental|Water-based Fruit-Mixed Beverage|Fruit-Mixed beverage with Water
3097567|NCT01908621|Active Comparator|G-CSF (filgrastim)|Patients will receive G-CSF(filgrastim) at 10 μg/kg per day (divided into two doses every 12 hours) subcutaneously for up to 7 days. On day 5, circulating CD34+ level will be determined. Leukapheresis will be started when the CD34+ blood level will reach at least 10/µl. If the level will be not achieved, G-CSF administration will be continued until CD34+ level will decrease compared to the preceding day. Leukaphereses will be performed using Spectra-Optia Apheresis System (TherumoBCT Inc, Lakewood, CO, USA) according to the manufacturers protocols for mononuclear cell harvesting, processing 2 total blood volumes. In case of failing to harvest targeted number of stem cells (5 × 10^6 CD34+ cells/kg), next leukapheresis can be performed on following two days (maximum 3 leukaphereses) if circulating CD34+ cell level will remain as described above.
3097568|NCT01908621|Active Comparator|Cytosine arabinoside + G-CSF (filgrastim)|Cytosine arabinoside will be administered as a 2-hour i.v. infusion at a dose of 0.4 g/m2 twice daily on days 1 and 2 (total dose 1.6 g/m2). G-CSF (filgrastim) 5-10 ug/kg will be started on day 5 and continued until last leukapheresis. The number of circulating CD34+ cells will be first evaluated after neutrophil recovery from nadir. Leukapheresis will be started when the CD34+ blood level will reach at least 10/µl. If the level will be not achieved, G-CSF administration will be continued until CD34+ level will decrease. Leukaphereses will be performed using Spectra-Optia Apheresis System (TherumoBCT Inc, Lakewood, CO, USA) according to the manufacturers protocols for mononuclear cell harvesting, processing 2 total blood volumes. In case of failing to harvest targeted number of stem cells (5 × 10^6 CD34+ cells/kg), next leukapheresis can be performed on following two days (maximum 3 leukaphereses) if circulating CD34+ cell level will remain as described above.
3097569|NCT01908595|Experimental|M518101|Proper quantity twice daily
3097570|NCT01908582|Experimental|Evacetrapib|130 milligram (mg) evacetrapib administered orally, once on Day 1
3097571|NCT01908582|Experimental|Evacetrapib + Rifampin|"Rifampin: 600 mg administered orally, once daily (QD) for 14 days (Days 9-22)~Evacetrapib: 130 mg administered orally once on Day 16"
3097572|NCT01908569|Active Comparator|NO MACS + Time-lapse technology|The sperm capacitation will be performed through a density gradient. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).
3097573|NCT01908569|Experimental|MACS + time-lapse technology|The sperm capacitation will be performed through a density gradient. After that, it will be subjected to the MACS technique in order to select the non-apoptotic spermatozoids. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).
3097574|NCT01908556|Experimental|Letrozol|All patients are treated with letrozole 2.5 mg for 5 years for the adjuvant treatment of postmenopausal patients with a hormone receptor positive primary breast cancer. Patients are treated according to the authorities' approval of the drug. Of all patients a germline DNA sample will be obtained before the treatment starts and serum samples will be taken at months 0, 6 and 12. Furthermore the paraffin embedded tissue block will be sent to a central pathology laboratory for central assessment of tumor biomarkers.
3097575|NCT01908543|Experimental|Iron treatment|"INTERVENTION: Ferrous sulphate 200mg oral tablet~This is a single arm study. Individuals in this arm will~have an additional 15 mls of supplementary research bloods taken with their usual clinic bloods~receive a single tablet of ferrous sulphate 200mg~fill in questionnaires that formally evaluate their nosebleed losses and dietary iron intake in the preceding 12 months~have a second blood sample later that day (20 mls of blood~Total number of participants in arm = 100"
3097576|NCT01908530|Experimental|Microprobe Glucose Sensor|The microprobe array continuous glucose sensor will be applied to healthy volunteers (in phases 1 and 2) and then to participants with type 1 diabetes (in phases 3 and 4).
3097577|NCT01908517|Experimental|HPV Vaccine Electronic Reminders|Parents in the intervention group will receive 1 electronic message per month in addition to the baseline and final assessments which equates to 8 contacts over a 7 month period. Specifically, intervention group participants will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey.
3097578|NCT01908504|Other|PET-CT|
3097579|NCT01908491|Active Comparator|IV PCA|hydromorphone with ketorolac
3097580|NCT01908491|Experimental|Continuous wound infusion|ON-Q Painbuster with ropivacaine
3097581|NCT01908478|Experimental|Combination: veliparib, gemcitabine, and IMRT|
3097582|NCT01908465|Active Comparator|Ebastine|Ebastine
3097583|NCT01908465|Placebo Comparator|placebo|Placebo
3097584|NCT01908452|Experimental|vitamin B6 (pyridoxine)|The 150 participating subjects will be randomized into 2 groups: 75 patients will receive vitamin B6 (1200 mg/day) and 75 patients will receive placebo, each for 12 weeks in a double-blind mode
3097585|NCT01908452|Placebo Comparator|placebo|The 150 participating subjects will be randomized into 2 groups: 75 patients will receive vitamin B6 (1200 mg/day) and 75 patients will receive placebo, each for 12 weeks in a double-blind mode
3097586|NCT01908439|Experimental|Whole-body vibration|A new method for muscle reflex latency measurement
3097587|NCT01908426|Experimental|Cabozantinib (XL184)|Cabozantinib (XL184) 60 mg tablet once daily
3097588|NCT01908426|Placebo Comparator|Placebo|Oral cabozantinib-matched placebo tablet once daily
3097589|NCT01908413|Experimental|CUDC-427|
3097590|NCT01908400|Other|BMMNCs|Intravenous transfer of (BMMNCs)
3097591|NCT01908387|Experimental|Oral azacitidine|
3097592|NCT01908374|Active Comparator|DHA-rich fish oil|DHA-rich fish oil versus Phospholipid-rich fish oil Fish oil in triglyceride form (12 capsules/d providing 575 mg/d EPA; 1843 mg/d DHA; 259 mg/d n-3 DPA)
3097593|NCT01908374|Experimental|Phospholipid-rich fish oil|DHA-rich fish oil versus Phospholipid-rich fish oil Fish roe high in EPA/DHA phospholipids [(12 capsules/d providing 628 mg/d EPA; 1810 mg/d DHA; 137 mg/d n-3 docosapentaenoic acid (DPA)]
3097594|NCT01908361|Experimental|Unilateral Hybrid (InMotion3 plus CIT) Intervention|Participants will receive 3 weeks of robot-assisted therapy (RT) using the InMotion3 Wrist Robot, followed by 3 weeks of CIT training.
3097595|NCT01908361|Experimental|Bilateral Hybrid (BMT plus BAT) Intervention|Participants in this bilateral treatment group will receive 3 weeks of RT using the Bi-Manu-Track (BMT) robot (Reha-Stim Co., Berlin, Germany), followed by 3 weeks of therapist-based BAT.
3097596|NCT01908361|Active Comparator|Conventional Rehabilitation (CR)|The CR intervention will be designed to match the duration and intensity of the hybrid interventions.
3097597|NCT01908348|Experimental|Erythritol|Orange-flavored beverage containing 6, 12, or 18 grams of erythritol
3097598|NCT01908335|Experimental|A (PEG-IFN-SA /RBV low dose)|PEG-IFN-SA 0.75μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW＜75kg，1000mg/d；BW≥75kg，1200mg/d）
3097599|NCT01908335|Experimental|B (PEG-IFN-SA /RBV middle dose)|PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW＜75kg，1000mg/d；BW≥75kg，1200mg/d）
3097600|NCT01908335|Experimental|C (PEG-IFN-SA /RBV high dose)|PEG-IFN-SA 2.0μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW＜75kg，1000mg/d；BW≥75kg，1200mg/d）
3097601|NCT01908335|Active Comparator|D (Pegasys /RBV)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW＜75kg，1000mg/d；BW≥75kg，1200mg/d）
3097602|NCT01908322||Group 1|
3097603|NCT01908309|Active Comparator|Iodixanol|Patients randomized to coronary angiography/angioplasty with Iodixanol 320
3097604|NCT01908309|Active Comparator|Iobitridol|Patients randomized to coronary angiography/angioplasty with Iobitridol 350
3097605|NCT01908296|Experimental|FK949E group|receiving FK949E with and without fluvoxamine
3097606|NCT01908283|Experimental|Patient non immunosuppressed|Group 1 : patient without immunosuppressive treatment
3097607|NCT01908283|Experimental|Patient immunosuppressed|Group 2 : patient with immunosuppressive treatment
3097608|NCT01908270|Experimental|Yoga|Yoga intervention 12 weeks, weekly 90-minute intervention Yoga postures, breathing, relaxation, and meditation
3097609|NCT01908270|Other|Usual care|Patients continue usual care by their practitioner
3097610|NCT01908257|Experimental|Sequence 1 fasted|"Day 1: Lesinurad 400 mg once daily (qd)~Day 5: Ranitidine 150 mg twice daily (bid)~Day 6: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad.~Day 7: Ranitidine 150 mg (bid)"
3097611|NCT01908257|Experimental|Sequence 2 fasted|"Day 1: Ranitidine 150 mg (bid)~Day 2: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad~Day 3: Ranitidine 150 mg (bid)~Day 7: Lesinurad 400 mg (qd)"
3097612|NCT01908244|No Intervention|Control|No pentatonic music
3097613|NCT01908244|Experimental|Music|
3097614|NCT01908231||Pulmonary Embolism|Consecutive adult patients (minimum age eighteen) who presented to the ED of the hospitals participating in the study with clinical suspicion of PE will be considered for the study. We excluded patients with life expectancies of less than 3 months, and patients with first symptoms 15 days or more before inclusion.
3097615|NCT01908218||ULBT group|344 adult patients undergoing general anesthesia with orotracheal intubation
3097616|NCT01908205|Experimental|Intranasal Oxytocin (Syntocinon)|The proposed dosing schedule is 0.4 IU/kg, taken twice daily, for a maximum of 24 IUs per dose
3097617|NCT01908205|Placebo Comparator|Placebo|The proposed dosing schedule is 0.4 IU/kg, taken twice daily, for a maximum of 24 IUs per dose
3097618|NCT01908192|Experimental|NaBen®|NaBen® is a white oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.
3097619|NCT01908192|Placebo Comparator|Placebo|The control treatment is placebo.
3097620|NCT01908166|Experimental|Diagnostic (ultrasound elastography)|Patients undergo ultrasound elastography.
3097621|NCT01908153||Overweight/Obese|Children with BMI percentile of 85 or above.
3097622|NCT01908153||Healthy Weight|Children with BMI percentile between 15 and 85.
3097623|NCT01908140|Experimental|Aclidinium Bromide / Formoterol Fumarate|Aclidinium Bromide 400 μg / Formoterol Fumarate 12 μg BID for 24 Weeks
3097759|NCT01907243|No Intervention|Control group|performing of rhinoplasty without spreader flap
3097625|NCT01908127|Active Comparator|tell- show- do procedure|"Group I (Tell- Show- Do Group): Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant in the operation room.~In the second session,injection of loal anesthesia solution including a mandibular alveolar nerve block technique and the occlusal cavity preparation was performed."
3097626|NCT01908127|Experimental|film modelling|"Group II (Filmed modelling Group): the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.~In the second session, injection of loal anesthesia solution including a mandibular alveolar nerve block technique and the occlusal cavity preparation was performed."
3097627|NCT01908114|No Intervention|Group A|Routine Polio Program activities will be carried out with out any active intervention
3097628|NCT01908114|Experimental|Group B|"Expanded intervention with following components~Community support groups for both male and female at village/community level~Enhanced communication package and involvement of local social networks for group counseling on promotion of nutrition, hygiene and Expanded Program of Immunization (EPI) vaccinations~Involvement of Private sector (General Physicians,health care providers etc.) through advocacy and inclusion in Supplementary Immunization activities (SIAs)~Delivery of interventions & commodities through low cost health camps during National Immunization days (NIDs) and SIAs (will also assist in mop-up campaigns)"
3097629|NCT01908114|Experimental|Group C|All Interventions of Group A and B Plus combined bOPV/IPV strategy in the SIAs during the project
3097630|NCT01908101|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3097631|NCT01908088|Experimental|fibroblast transplant|Transplantation of autologous cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hand deformity
3097632|NCT01908075||BDP/FOR|Patients receiving ICS/LABA therapy as FP/SAL (Seretide®) who, at an index prescription date (IPD): Change their therapy to BDP/FOR (Fostair®) at same or lower BDP-equivalent ICS dose
3097633|NCT01908075||FP/SAL|Patients receiving ICS/LABA therapy as FP/SAL (Seretide®) who, at an index prescription date (IPD) : Remain on FP/SAL at the same BDP-equivalent ICS dose
3097634|NCT01908062|Active Comparator|Treatment as Usual|The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy. HIV-infected patients with alcohol use disorders are typically referred for residential, outpatient, and self-help groups.
3097635|NCT01908062|Experimental|Extended Release Naltrexone|Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
3097636|NCT01908049|Experimental|Probiotic|A probiotic (Saccharomyces boulardii) 2 caps/ 8h for 12 weeks.
3097637|NCT01908049|Placebo Comparator|Placebo|No active substance is given.
3097638|NCT01908023|Experimental|exercise|
3097639|NCT01908010|Experimental|Group 1, low dose|ABT-354
3097640|NCT01908010|Experimental|Group 2, high dose|ABT-354
3097641|NCT01907997|Experimental|Group L|Intravenous lidocaine infusion group
3097642|NCT01907997|Placebo Comparator|Group C|Intravenous normal saline infusion - control group
3097643|NCT01907984|Experimental|Diclofenac and Midazolam|Diclofenac 100 mg tablet and Midazolam 7.5 mg tablet were administered by mouth as premedication 30 minutes before surgical interventions.
3097644|NCT01907984|Active Comparator|Midazolam|Midazolam 7.5 g tablet was administered as premedication by mouth 30 minutes before surgical interventions.
3097645|NCT01907971||Ebstein anomaly|Patients with Ebstein anomaly
3097646|NCT01907945|Experimental|Intervention|Participant households in this arm are eligible for participation in the social network-based water treatment education program (referred to as the Microclinic Water Program). Participant households who do not enroll in the Microclinic Water Program receive household-based education identical to that of the 'comparison' arm.
3097647|NCT01907945|Active Comparator|Comparison|Participant households in this arm receive household drinking water treatment education at the household level.
3097648|NCT01907932|Experimental|normal and various degrees splenomegaly|"VScan Ultrasound (GE Healthcare, USA) all subjects will be measured by 5 different medical residents~Each resident will complete questionaire:~Adequacy of image quality~What is best view obtained~Greatest Longitudinal Measure~Diagnosis~Diagnostic Certainty~Time to Complete exam"
3097649|NCT01907919||conventional group,RM-GIC|1. Group A: Five teeth were treated with traditional rotating instruments, the cavities were prepared with diamond drills by turbine, multiple-blade drills by headpiece for removing the decayed dentine and, after cleaning and control of bleeding with cotton pellets with saline solution,RM-GIC (3M ESPE, USA) light-hardening paste was placed gently on the exposed part of the pulp and cavity floor next final restoration with composite z350 flow able and p60 (3M ESPE, USA).
3097650|NCT01907919||Diode 808 nm laser-assisted group|"2. Group B : Five teeth cavities were prepared as the same with group one with traditional rotating instruments, hemostatic and cavities sterilization were achieved by a diode 808 nm (Picasso- AMD, USA) laser using following parameters:~Hemostatic: 1.5 W, CW, fiber diameter 400µm, in contact, 2s per 1mm, vertical and horizontal scanning movement on exposure site.~Cavity sterilization: 1W, CW, fiber diameter 400µm, in contact, 2mm per s, circular movement.~After hemostatic and cavity sterilization, RM-GIC (3M ESPE, USA) light-hardening paste was placed on the exposed part of the pulp and cavity floor next final restoration with composite z350 flow able and p60 (3M ESPE, USA)."
3097651|NCT01907906|Experimental|Arm 1: Mirasol-treated WB then untreated WB|Screening Period (14 days); Treatment Period 1 (49 days): Donation of WB treated with Mirasol System for Whole Blood on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49); WB Donation Deferral Period (35-49 days); Treatment Period 2 (49 days): Donation of WB, UNTREATED on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49) Study Exit on Treatment Period 2, Day 49
3097678|NCT01907737|Active Comparator|Active tDCS and active PNS|1 SESSION OF ACTIVE TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS)OF THE HEMISPHERE AFFECTED BY THE STROKE AND ACTIVE PERIPHERAL NERVE STIMULATION
3119087|NCT01760525|Experimental|CGM097 - Dose Expansion at MTD or RP2D|
3097652|NCT01907906|Experimental|Arm 2: Untreated WB then Mirasol-treated WB|Screening Period (14 days); Treatment Period 1 (49 days): Donation of WB, UNTREATED on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49); WB Donation Deferral Period (35-49 days); Treatment Period 2 (49 days): Donation of WB treated with Mirasol System for Whole Blood on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49) Study Exit on Treatment Period 2, Day 49
3097653|NCT01907893|Experimental|Trauma Collaborative Care Plus Treatment as Usual|Three components: (1) Services provided through the Trauma Survivors Network (TSN) Program; (2) Provider training to reinforce referral to and use of TSN programs; and (3) Enhancement of collaborative care through the use of a TSN Coordinator (TSN-C).
3097654|NCT01907893|No Intervention|Treatment as Usual|Study patients treated at Control Sites will have access to all services typically available to patients treated at these centers.
3097655|NCT01907880|Active Comparator|Pamidronate and placebo|Patients will receive two infusions simultaneously, at each study visit, one of Pamidronate and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.
3097656|NCT01907880|Active Comparator|Zoledronic acid and placebo|Patients will receive two infusions simultaneously, at each study visit, one of Zoledronic acid and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.
3097657|NCT01907867|Experimental|Cohort 1|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 3 hours after the oral dose.~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 6 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
3097658|NCT01907867|Experimental|Cohort 2|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 8 hours after the oral dose.~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose.~Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
3097659|NCT01907867|Experimental|Cohort 3|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose.~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose.~Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 24 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
3097660|NCT01907854|Experimental|Liraglutide + metformin + sitagliptin placebo|
3097661|NCT01907854|Experimental|Sitagliptin + metformin + liraglutide placebo|
3097662|NCT01907841|Experimental|Ischemic Preconditioning|IPC (4 x 5 minute cycles @ 220 mmHg) with 5 min reperfusion between trials.
3097663|NCT01907841|Placebo Comparator|Ischemic Preconditioning Placebo|Placebo (4 x 5 minute cycles @ 20mmHg) with 5 minutes between each cycle
3097664|NCT01907828|Experimental|Cardiac ablation + renal artery ablation|Renal artery ablation with the EnligHTN™ Renal Denervation System
3097665|NCT01907828|Active Comparator|Cardiac ablation|Cardiac ablation
3097666|NCT01907815|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|Trametinib orally once daily (PO QD) and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3097667|NCT01907802|Experimental|Treatment (dabrafenib)|Patients receive dabrafenib PO BID on days 1-28 (QD on day 1 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3097668|NCT01907789||Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
3097669|NCT01907789||Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO)|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
3097670|NCT01907789||Risk-Reducing Salpingo-Oophorectomy (RRSO)|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
3097671|NCT01907776|Experimental|ME1100|ME1100 inhalation solution (arbekacin for oral inhalation at 150 mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
3097672|NCT01907776|Placebo Comparator|Placebo|ME1100 placebo inhalation solution
3097673|NCT01907763|Experimental|SOTB07 200mg|One tablet of SOTB07 200mg and One tablet of SOTB 400mg Placebo are administered twice a day.
3097674|NCT01907763|Experimental|SOTB07 400mg|One tablet of SOTB07 400mg and One tablet of SOTB 200mg Placebo are administered twice a day.
3097675|NCT01907763|Placebo Comparator|Placebo|One tablet of SOTB 200mg Placebo and One tablet of SOTB 400mg Placebo are administered twice a day.
3097676|NCT01907750|Active Comparator|Transanastomotic tube|use of transanastomotic tube.
3097677|NCT01907750|Active Comparator|Transcystic tube|use of transcystic tube to drain bile duct
3097679|NCT01907737|Other|Active tDCS and sham PNS|1 SESSION OF ACTIVE TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS)OF THE HEMISPHERE AFFECTED BY THE STROKE AND SHAM PERIPHERAL NERVE STIMULATION
3097680|NCT01907737|Other|Sham tDCS and active PNS|1 SESSION OF SHAM TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS)OF THE HEMISPHERE AFFECTED BY THE STROKE AND ACTIVE PERIPHERAL NERVE STIMULATION
3097681|NCT01907737|Sham Comparator|Sham tDCS and sham PNS|1 SESSION OF SHAM TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS)OF THE HEMISPHERE AFFECTED BY THE STROKE AND SHAM PERIPHERAL NERVE STIMULATION
3097682|NCT01907724|Experimental|IDX719 + RTV|Participants take IDX719 150 mg once daily (QD) + ritonavir 30 mg QD on Days 1-7, and then take IDX719 150 mg QD + simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 8-14.
3097683|NCT01907724|Experimental|Simeprevir/TMC647055 + RTV|Participants take simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 1-7, and then take IDX719 150 mg QD + simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 8-14.
3097684|NCT01907711|Sham Comparator|Sham Acupuncture.|That through the center of the guide tube is inserted blunt rod, producing the sensation of a prick in each of the eight points that are not acupuncture points. No intervention is a completely inert as it involves some type of peripheral stimulus, but the technique is closer to a placebo and offers interesting option from a methodologic al point of view showing and ability to mimic real acupuncture The points are not used acupuncture points but are fictional points. The patient should remáis lying prone during the 20 minutes of the session, so the placebo technique remains hidden. Every five minutes the acupuncturist will repeat the action in the corresponding eigh points.
3097685|NCT01907711|Active Comparator|True acupuncture|The AV is an energy balance treatment with the aim of restoring health and well-being of the patient. Since each patient may have moré than three diagnoses of Traditional Chinese Medicine, will undertake a Major effort of synthesis of acupuncture points for treatment in a session, use the AV 8 - 12 needles, are held in place for 20 minutes with bidirectional rotation of the sleeve needle for one minute every five minutes (a total of four rotations for session). And in the AS 8 tube rod guides with blunt tip for 20 minutes. The same time be devoted to the patients in each treatment group similar, the time requested for the period of pre and post-treatment will be identical in all cases.
3097686|NCT01907698||Vaginal coitus group|Pregnant women assigned to have vaginal coitus at least twice a week
3097687|NCT01907698||Control group|Pregnant women assigned to have no vaginal intercourse
3097688|NCT01907685|Experimental|AVE8062 / Docetaxel|AVE8062 30-minute IV, 11.5 to 42 mg/m2, followed by Docetaxel, 1-hour IV, 75 and 100 mg/m2 in 3-week cycles until disease progression or unacceptable toxicity or study discontinuation criteria
3097689|NCT01907672|Experimental|Rapid Diagnostic Test|Rapid Diagnostic Test for malaria to direct antimalarial dispensing decisions in Chemical Shops
3097690|NCT01907672|No Intervention|No RDT|Chemical sellers dispense antimalarials as per their own decisions without the benefit of test results
3097691|NCT01907659|No Intervention|Standard of care|Standard of care for respiratory infections
3097692|NCT01907659|Experimental|Release of test results|Health care providers will receive viral PCR and PCT test results along with an algorithm recommending antibiotic treatment based on PCT level.
3097693|NCT01907646|Experimental|Bladder training group|The patients of this group were submitted to passive vesical gymnastic during the second and third postoperative days, throughout the closure of the catheter for 3 h and open it for 15 min all day long.
3097694|NCT01907646|Experimental|No bladder training group|The patients of this group were not submitted to passive vesical gymnastic during the second and third postoperative days
3097695|NCT01907633||Domperidone/ a proton pump inhibitor/metoclopramide users|Study patients had at least one prescription for domperidone, a proton pump inhibitor, or metoclopramide. Proton pump inhibitors observed in this study are: omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole.
3097696|NCT01907620|Other|Normal pregnancy|women pregnant
3097697|NCT01907620|Other|pregnancy complicated by pre-eclampsia|women with pregnancy complicated by pre-eclampsia
3097698|NCT01907607|Experimental|PD-0332991|"Adult patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib.~PD-0332991 is formulated as gelatin capsules of 100 mg and 25 mg respectively."
3097699|NCT01907594|Active Comparator|D-cycloserine|The investigators will randomize participants to either DCS 250 mg or placebo, administered daily for four days.
3097700|NCT01907594|Placebo Comparator|Gelatin Capsule|The investigators will randomize participants to either DCS 250 mg or placebo, administered daily for four days.
3097701|NCT01907581|Other|Patients admitted to an ICU|
3097702|NCT01907568||Patients with schizophrenia|With and without hallucinations
3097703|NCT01907568||Patients with borderline personality disorder|With and without hallucinations
3097704|NCT01907568||Patients with hearing impairment|With and without hallucinations
3097705|NCT01907568||Patients with visual loss|With and without hallucinations
3097706|NCT01907568||Patients with Parkinson's Disease|With and without hallucinations
3097707|NCT01907568||Patients with Alzheimer's Disease|With and without hallucinations
3097708|NCT01907568||Patients with dementia with Lewy Bodies|With and without hallucinations
3097709|NCT01907568||Patients with Posttraumatic Stress Disorder|With and without hallucinations
3097710|NCT01907568||Patients with delirium|With and without hallucinations
3097711|NCT01907568||Healthy participants|With and without hallucinations
3097712|NCT01907568||Patients with mood disorder|With and without hallucinations
3097713|NCT01907555||- Patients presenting Cohen syndrome and two VPS13B mutations|
3097714|NCT01907555||Patients presenting Cohen syndrome without a VPS13B mutation|
3097715|NCT01907555||Patients presenting neutropenia|
3097716|NCT01907542|Active Comparator|Monocryl suture skin closure|Monocryl skin suture
3097717|NCT01907542|Active Comparator|Stapled skin closure|stapled skin closure
3097718|NCT01907529|Experimental|Chemo plus Endostar|Docetaxel, epirubicin and cyclophosphamide plus endostar
3097719|NCT01907529|Active Comparator|Chemo only|docetaxel, epirubicin and cyclophosphamide
3097720|NCT01907516|Active Comparator|Cell phone-internet first|Cell phone-internet home glucose reporting system first
3097721|NCT01907516|Placebo Comparator|Voicemail first|Voicemail home blood glucose reporting first
3097722|NCT01907503|Other|Patients with Primary hip osteoarthritis|Patients with Primary hip osteoarthritis
3097723|NCT01907503|Other|Healthy volunteer|Healthy volunteer
3097724|NCT01907490|Experimental|1|Ha44 Gel 0.74%, topical solution, maximum feasible amount applied for 10 minutes
3097725|NCT01907477|Other|neutropenic patients|
3097726|NCT01907464|Experimental|Patients with anorexia nervosa|This arm is the experimental arm composed of patients
3097727|NCT01907464|Active Comparator|controls subjects|This arm is composed of healthy volunteers
3097728|NCT01907451||The control group|"will receive support traditional10 hours per week: techniques called neuro-facilitators"
3097729|NCT01907451||test group|enjoy the same support as control group at 7 hours week, coupled with a personalized retraining effort ergometer for 3 hours per week: after a 5 minute warm to 50% of Heart Rate Maximum (HRmax) of the initial test effort (TE), continuous work of 20 minutes at an intensity corresponding to 70% HRmax, followed by a recovery period of 5 min between active 40 and 50% of maximum heart rate (5 times per week).
3097730|NCT01907438||non-carriers|Tissues from premenopausal women undergoing esthetic breast surgery with no family history of breast or ovarian cancers will be obtained.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
3097731|NCT01907438||BRCA1 mutation carriers|Tissues from risk-reducing mastectomy in healthy premenopausal women with BRCA1 mutations undergoing.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
3097732|NCT01907438||BRCA2 mutation carriers|Tissues from risk-reducing mastectomy in healthy premenopausal women with BRCA2 mutations undergoing.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
3097733|NCT01907425|Other|Pre-natal Patient|
3097734|NCT01907412|No Intervention|Control Group|Couples in the Control group did not receive the Family Foundations Coparenting Program.
3097735|NCT01907412|Experimental|Intervention Group|Couples randomly assigned to the Intervention Group received the Family Foundations Coparenting Program.
3097736|NCT01907399|Other|obese patients|(BMI> 30 kg/m2) androids (waist circumference> 102 cm in men and> 88 cm in woman)
3097737|NCT01907399|Other|obese patients with type 2 diabetes|(BMI> 30 kg/m2) androids (waist circumference> 102 cm in men and> 88 cm in woman)with diabetes
3097738|NCT01907399|Other|healthy volunteers|free of disease inflammatory or infectious and will have a BMI <25 Kg/m2et fasting glucose <1g / L
3097739|NCT01907386|Other|QSE-LSME and SSWI ultrasound|"QSE-LSME and SSWI ultrasound examinations combined with a clinically required CT-scan. We will screen 3 groups of 15 patients each, with at least one-year follow-up after EVAR, matched for sex, age and aneurysm diameter at baseline (before EVAR).~Group 1. Patients without endoleak and a maximal diameter reduction at one year of at least 10% and a volume reduction of 20%.~Group 2. Patients with a stable sac volume and diameter (less than 10% volume and 5% diameter variation within a year).~Group 3. Patients with type I, type II or type V endoleak (endotension) with more than 10% diameter progression and 20% volume progression."
3097740|NCT01907373|Active Comparator|olmesartan medoxomil, PK of olmesartan|drug: olmesartan medoxomil; dosage form: oral tablet; dosage: 20mg/time; frequency: once a day; duration: 4 days
3097741|NCT01907373|Experimental|olmesartan medoxomil+probenecid, PK of olmesartan|drug1: olmesartan medoxomil; dosage form: oral tablet; dosage: 20mg/time; frequency: once a day; duration: 4 days; drug2: probenecid; dosage form: oral tablet; dosage: 500mg/time; frequency: 2 times/day; duration: 1 day
3097742|NCT01907360|Experimental|Adolescents (13-17yrs)|Drug: B-HLD200 54mg capsules (Methylphenidate Modified Release B Formulation) or Drug: C-HLD200 54mg capsules (Methylphenidate Modified Release C Formulation)
3097743|NCT01907360|Experimental|Children (6-11 yrs)|Drug: B-HLD200 54mg capsules (Methylphenidate Modified Release B Formulation) or Drug: C-HLD200 54mg capsules (Methylphenidate Modified Release C Formulation)
3097744|NCT01907347||ICU patients|
3097745|NCT01907334|Active Comparator|Advair Diskus100/50 µg and Advair Diskus 100/50 µg|The Advair Diskus 100/50 µg and Advair Diskus 100/50 µg will be administered in a blinded fashion. One hour after receiving the dose of Advair a methacholine challenge will be performed to determine the PC40R5. After the PC40R5 has been reached or a negative result after the highest methacholine concentration, 64 mg/mL, subjects will inhale albuterol through a valved holding chamber to reverse bronchoconstriction and their lung function will be monitored until it has returned to within 20% of that day's baseline R5.
3097746|NCT01907334|Active Comparator|Advair Diskus 100/50 µg and Flovent Diskus 100 µg|The Advair Diskus 100/50 µg and Flovent Diskus 100 µg will be administered in a blinded fashion. One hour after receiving the dose of Advair and Flovent a methacholine challenge will be performed to determine the PC40R5. After the PC40R5 has been reached or a negative result after the highest methacholine concentration, 64 mg/mL, subjects will inhale albuterol through a valved holding chamber to reverse bronchoconstriction and their lung function will be monitored until it has returned to within 20% of that day's baseline R5.
3097747|NCT01907321|Experimental|Expiratory muscle strength training (EMST)|Participants will complete 5 weeks of EMST training, 5 repetitions per set, 5 sets per day, 5 days per week.
3097748|NCT01907321|Placebo Comparator|Placebo expiratory training|Same look and feel of EMST with no resistance. Same protocol - 5 repetitions of 5 sets, 5 days per week
3097749|NCT01907308|Experimental|Combination of AMG 386 with Docetaxel|All treated patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
3097750|NCT01907295||Patients|Patients diagnosed with idiopathic, anorexigen-induced or heritable PAH
3097751|NCT01907295||Relatives and controls|Relative has a family member diagnosed with idiopathic, anorexigen-induced, or heritable PAH Self declared healthy individuals
3097752|NCT01907282|Experimental|Family Focused Treatment|Family-Focused Treatment (FFT) consists of 18 sessions of psychoeducation, communication enhancement training, and problem-solving skills training in six months
3097753|NCT01907282|Active Comparator|Enhanced Care|Enhanced care is a 3-session family psychoeducational therapy focused on prevention of psychotic symptoms
3097754|NCT01907269|Experimental|Video-based intervention|"Video-based intervention providing personalized feedback regarding patients' risk of subsequent fractures, customized information regarding osteoporosis care, and messaging to activate patients to become more engaged in improving osteoporosis treatment and doctor-patient communication. This novel content will use story-telling delivered via the Internet and DVDs. The content will be uniquely tailored to each person based on their reported barriers to care, age and race/ethnicity. The video-based intervention materials will be augmented by a personal phone call and interactive voice response messaging."
3097760|NCT01907230|Experimental|Entecavir, Prophylactic group|Participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
3097761|NCT01907230|No Intervention|Control group (pre-emptive treatment)|Patients will start entecavir therapy, 0.5 mg/day orally, when reactivation of HBV (defined as detectable HBV viral loads for 2 consecutive visits with at least one month apart), and continued entecavir treatment until undetectable HBV viral loads for 1 year (consistent with current APASL recommendation).
3097762|NCT01907217|Active Comparator|Bilateral ECT Mecta 5000M|Modified bilateral ECT (bitemporal electrode positions) twice weekly at 1.5 times the seizure threshold. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0mg/kg) for muscle relaxation.
3097763|NCT01907217|Experimental|High-dose unilateral ECT Mecta 5000M|High-dose right modified unilateral ECT twice weekly at 6 times the seizure threshold. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0mg/kg) for muscle relaxation.
3097764|NCT01907204|Active Comparator|Oral|Oral drug (methylprednisolone) administration
3097765|NCT01907204|Experimental|Metered dose inhaler|
3097766|NCT01907204|Experimental|Nebulized|
3097767|NCT01907191|Experimental|Liposomal bupivacaine|Ultrasound guided injection of liposomal bupivacaine
3097768|NCT01907191|Active Comparator|Bupivacaine|Bupivacaine (around the anterior, lateral and medial aspect of hip joint)
3097769|NCT01907178||Postoperative pain management|The postoperative pain level will be assessed during hospitalization and at home, in patients undergoing total knee replacement
3097770|NCT01907165|Experimental|Maintenance Temozolomide + Disulfram|"Beginning 4-6 weeks after completion of radiation therapy, patients receive maintenance temozolomide 150-200 mg/m2 PO QD on Days 1-5 every 28 days for 6 months. Disulfiram (dose level 0 = 500 mg PO QD or dose level 1 1000 mg PO QD) on days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
3097771|NCT01907165|Experimental|Maintenance Temozolomide + Disulfiarm + Copper Gluconate|"Beginning 4-6 weeks after completion of radiation therapy, patients receive maintenance temozolomide 150-200 mg/m2 PO QD on Days 1-5 every 28 days for 6 months, disulfiram 500 mg PO QD (dose of disulfiram determined to be the MTD) on Days 1-28, and copper gluconate 6 mg PO QD on Days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
3097772|NCT01907152|Experimental|Protein enriched yoghurt drink and bread|Yoghurt drink enriched with Whey Protein Concentrate Whole wheat bread enriched with cereal protein and soy
3097773|NCT01907152|No Intervention|Regular yoghurt drink and bread|Commercially available yoghurt drink and whole wheat bread
3097774|NCT01907139|Experimental|Distributed constraint-induced therapy (dCIT)|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks.
3097775|NCT01907139|Experimental|Robot-assisted therapy (RT)|The ArmeoSpring (Hocoma AG, Switzerland) will be adopted in this study. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. The ArmeoSpring g provides weight support for the arm across a large 3D workspace, enabling naturalistic movement across approximately 66% of the normal workspace in the vertical plane and 72% in the horizontal plane. Its main structure consists of an arm exoskeleton with elastic bands that relieve the weight of the limb and provide a sense of arm flotation at all positions in the available workspace. A custom grip sensor consisting of a water-filled cylindrical bladder detects grip pressure and finger movement and allows incorporation of grasp and release practice into arm training.
3097776|NCT01907139|Active Comparator|Dose-matched control therapy (DMCT)|The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening.
3097777|NCT01907139|Experimental|RT + dCIT|In this combination therapy group, the participants will received 2 weeks of RT using the ArmeoSpring and followed by 2 weeks of distributed CIT. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively. This combined intervention group may integrate proximal (shoulder and elbow) to distal (wrist and hand) training of the UL and help transfer from motor ability gained to functional performance improvement. That is, it appears to associate with the advantages/effects of each RT and dCIT intervention.
3097778|NCT01907126|Experimental|Women's Prison CoOp (WPC)|Will receive 5 group psychoeducation sessions plus individual pre-release and post-release goal planning sessions. Psychoeducation sessions will cover HIV risk and violence prevention, interpersonal violence-specific sexual safety skills, empowerment through knowledge and treatment, and skills for increasing affect regulation and social support.
3097779|NCT01907126|Placebo Comparator|Nutrition program (NP)|Participants in this condition will receive dose-matched nutrition education.
3097780|NCT01907113|Experimental|BI 10773 / Group 2|Single Dose Administration (type 2 diabetes and mild renal impairment)
3097781|NCT01907113|Experimental|BI 10773 / Group 3|Single Dose Administration (type 2 diabetes and moderate renal impairment)
3097782|NCT01907113|Experimental|BI 10773 / Group 4|Single Dose Administration (severe renal impairment 8)
3097783|NCT01907113|Experimental|BI 10773 / Group 5|Single Dose Administration (kidney failure)
3097784|NCT01907113|Experimental|BI 10773 / Group 1|Single Dose Administration (type 2 diabetes and normal renal function)
3097785|NCT01907100|Placebo Comparator|Placebo + pemetrexed/cisplatin|Placebo controlled arm
3097786|NCT01907100|Experimental|Nintedanib 200mg + pemetrexed/cisplastin|Experimental arm
3097787|NCT01907087|Experimental|BMN190|recombinant human tripeptidyl peptidase-1 (rhTPP1/cerliponase alfa)
3097788|NCT01907074|Experimental|Cholates Compound|
3097966|NCT01905787||Group 3 - Schneider group|50 patients will be included in the study
3097789|NCT01907061|Active Comparator|600 mg N-acetylcysteine or placebo IV|600 mg N-acetylcysteine or placebo IV perfused over 15 minutes during the transplant procedure, prior to reperfusion,
3097790|NCT01907061|Active Comparator|600 mg N-acetylcysteine or placebo NG|600 mg NAC or placebo administered via NG tube starting at 12 hrs + 30 min post O.R. infusion,
3097791|NCT01907061|Active Comparator|N-acetylcysteine or placebo q 12 hour|600 mg NAC or placebo administered via NG tube every 12 hrs + 30 min for 3 additional doses (at 24, 36 and 48 hrs post O.R. infusion). The total administration will be 3000 mg over a 48 hr period.
3097792|NCT01907048||Group 1|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
3097793|NCT01907048||Group 2|Survey to measure patient awareness and understanding of the key messages in the patient card.
3097794|NCT01907035|Experimental|Cognitive-behavioral intervention|Cognitive-behavioral intervention: Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with practitioner plus routine therapy in the field of primary care in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
3097795|NCT01907035|Active Comparator|Usual care|Family practice attention without the psychologist support
3097796|NCT01907022|Experimental|Left dorsolateral prefrontal cortex (DLPFC) Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.
3097797|NCT01907009|Experimental|Registration.|"MELCAP study has only one arm. All suitable patients will receive 3 cycles of melphalan and lenograstim alternately.~Patient will start with a 3 day lenograstim (at 10mcg/kg/day) to boost up the blood cell count.~Upon reaching sufficient blood cell count, patients will undergo a venesection and roughly a pint of blood is taken. After this patients will receive first cycle of Melphalan (60mg/m2). The following day patient will receive back the previously given whole blood. A treament break of 6 days between the cycles is given. After the break the patient will be given Lenograstim (10mcg/kg/day)for 6 days (until sufficient).~The above regimen is repeated for cycle 2 and cycle 3 with only exception of Melphalan is given at 40mg/m2. After the cycle 3, Lenograstrim is given at 263 mcg/day for 10 days.~Upon treatment completion, patients will be followed for 2 years. If the patients show disease progression, they will start hormone therapy."
3097798|NCT01906996||proximal row carpectomy|patients were treated with a proximal row carpectomy
3097799|NCT01906996||four corner fusion|patients were treated with a four corner fusion
3097800|NCT01906983||Doppler ultrasound.|Doppler ultrasound will be performed to All patients 18 and up, admitted to Rambam Medical Center with diagnosis of blunt splenic trauma and agree to participate the study.
3097801|NCT01906970|Experimental|ClampArt|ClampArt
3097802|NCT01906957|Experimental|Elderly healthy subjects|"Randomization into :~high intensity interval training (HIIT)(n=20)~or~moderate intensity intensity continuous exercise (n=20)"
3097803|NCT01906957|Experimental|Patients with metabolic syndrome|"Randomization into :~high intensity interval training (HIIT)(n=20)~or~moderate intensity intensity continuous exercise (n=20)"
3097804|NCT01906957|Experimental|coronary patients|"Randomization into :~high intensity interval training (HIIT)(n=20)~or~moderate intensity intensity continuous exercise (n=20)"
3097805|NCT01906957|Experimental|heart failure patients|"Randomization into :~high intensity interval training (HIIT)(n=20)~or~moderate intensity intensity continuous exercise (n=20)"
3097806|NCT01906944|Active Comparator|Trigger point injection|Trigger point injection under ultrasound guidance into the fascial layer above the external oblique or rectus muscle, whichever corresponds to patient's identifiable trigger point. The injectate will include 5 ml of bupivacaine 0.25% mixed with triamcinolone 20 mg.
3097807|NCT01906944|Active Comparator|Transversus abdominis plane block|Injection into transversus abdominis plane layer under ultrasound guidance on the affected side along the mid-axillary line. The injectate will include 10 ml of bupivacaine 0.25% mixed with triamcinolone 20 mg.
3097808|NCT01906931|Experimental|Portable Oxygen Concentrator first|
3097809|NCT01906931|Active Comparator|Portable oxygen cylinder first|
3097810|NCT01906918|Experimental|IRPC, Remote preconditioning|This group will be submitted to ischemic preconditioning
3097811|NCT01906918|Placebo Comparator|Control|This patients will be submitted to the standard surgery protocol in the institution. The patients will not be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion.
3097812|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation|Active TMS (1)
3097813|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation 2|Active TMS (2)
3097814|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation 3|Active TMS (3)
3097815|NCT01906892|Experimental|1a|6 weeks of group drumming workshops
3097816|NCT01906892|Experimental|1b|6 weeks of group drumming workshops
3097817|NCT01906892|Experimental|2a|2 weeks of active group drumming followed by 2 weeks of control activity involving a literary-based activity
3097818|NCT01906892|Active Comparator|2b|2 weeks of the literary-based comparative activity followed by 2 weeks of watching live group drumming
3097819|NCT01906892|Active Comparator|2c|2 weeks of listening to live group drumming followed by 2 weeks of listening to recordings of group drumming
3097820|NCT01906892|Active Comparator|2d|2 weeks of listening to recorded group drumming followed by 2 weeks of participation in group drumming
3097821|NCT01906892|Experimental|3a|10 weeks of participatory group drumming workshops
3097822|NCT01906892|Active Comparator|3b|10 weeks of engagement with other non-musical social activities
3097823|NCT01906879|Active Comparator|Triple therapy (A)|lansoprazole, 30mg, twice daily, for 14 days, po clarithromycin, 500mg, twice daily, for 14 days, po amoxicillin, 1gm, twice daily, for 14 days, po
3097824|NCT01906879|Experimental|non-bismuth quadruple therapy|Group (B): non-bismuth quadruple therapy for 10 days: lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg bid
3097866|NCT01906580|Experimental|Peg-IFNα-2a monotherapy|Participants will receive 180ug peg-IFNα-2a therapy for 72 weeks, and then followed to 96 weeks.
3097825|NCT01906879|Experimental|bismuth quadruple therapy for 10 days|Group (C): bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid
3097826|NCT01906866|Active Comparator|Circadin 2/5/10 mg|
3097827|NCT01906866|Placebo Comparator|Placebo|Placebo arm
3097828|NCT01906853|No Intervention|No BCG|No BCG
3097829|NCT01906853|Experimental|BCG|Mycobacterium bovis BCG (Bacille Calmette Guérin) vaccine, Danish Strain 1331
3097830|NCT01906840|Experimental|drug: turmeric capsule|Intervention is turmeric (one capsule with each meal containing 500 mg turmeric, of which 22.1 mg was the active ingredient curcumin; three capsules daily) for 8 weeks
3097831|NCT01906840|Placebo Comparator|Drug: placebo,capsule|Intervention is daily starch capsules 500 mg for 8 weeks
3097832|NCT01906827||pregnant with ICP|pregnant with ICP
3097833|NCT01906814|Experimental|3 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
3097834|NCT01906814|Active Comparator|6 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
3097835|NCT01906801|Experimental|Glucosamine sulfate & Diacerein|Glucosamine sulfate (sachet) 1500 mg and Diacerein 50 mg tablet by mouth once daily for 24 weeks
3097836|NCT01906801|Active Comparator|Glucosamine sulfate & Placebo|Glucosamine sulfate 1500 mg and Placebo (for Diacerein) 50 mg by mouth once daily for 24 weeks
3097837|NCT01906788|Active Comparator|Group 1|Active comparator: Artemether Lumefantrine 6 dose regime orally
3097838|NCT01906788|Experimental|Group 2|Experimental: Artemether Lumefantrine 6 dose regime Plus single dose Primaquine (0.75/kg) on day 0
3097839|NCT01906788|Experimental|Group 3|Experimental: Artemether Lumefantrine 6 dose regimen plus single dose of Primaquine (0.75/kg) on day 2
3097840|NCT01906775||Patients with PIT|Identification of patients with pacemaker-induced ventricular tachycardias
3097841|NCT01906762|Experimental|Acetaminophen|Specified dosage for Acetaminophen was 15 mg/kg. so based on the patient`s weight(averagely 70 kg), about 1gr Acetaminophen (one complete Apotel Ampule) was used.
3097842|NCT01906762|Experimental|Morphine|Specified dosage for Morphine was 0.1 mg/kg. so based on the patient`s weight(averagely 70 kg), about 7 mg Morphine was used.
3097843|NCT01906749|Placebo Comparator|Placebo|Placebo
3097844|NCT01906749|Active Comparator|Colchicine|Colchicine 0.5mg once daily for 24 months
3097845|NCT01906710|Placebo Comparator|usual care|During admission patients receive standard, non - ward based, pharmaceutical care from a pharmacy team in taking responsibility for the appropriate, safe and cost-effective use of medication from a central hospital pharmacy. The pharmaceutical care consist of daily screening of generated alerts by the Computerized physician order entry (CPOE) system and consultation by phone. Dependent on the local situation the current medication reconciliation process is being performed by nursing and/or medical staff either protocolised or not.
3097846|NCT01906710|Active Comparator|integrated medicines management|"integrated medicines management consists of~patient centred medication reconciliation~intermediate medication review~discharge counseling~transfer of information to primary care"
3097847|NCT01906697|Active Comparator|group B|middle turbinate resection
3097848|NCT01906697|Active Comparator|group C|middle turbinate medialization
3097849|NCT01906697|Active Comparator|group A|middle turbinate Radio Frequency (RF) turbinoplasty
3097850|NCT01906684|Experimental|Acthar Gel|Acthar Gel is supplied as 5 mL multi-dose vial (63004-8710-1) containing 80 USP Units per mL. H.P. Acthar Gel (repository corticotropin injection). Acthar Gel will be administered as a subcutaneous daily dose of 80 units for up to 2 weeks.
3097851|NCT01906671|Experimental|Puri-Nethol|Tablet formulation of 6-mercaptopurine
3097852|NCT01906671|Experimental|Xaluprine|Oral liquid formulation of 6-mercaptopurine
3097853|NCT01906658|Experimental|Acthar 80 U (1.0 mL) SC twice weekly|Acthar (Repository Corticotropin Injection) 80 U (1.0 mL) SC twice weekly
3097854|NCT01906658|Experimental|Acthar 24 U (0.3 mL) SC daily|Acthar (Repository Corticotropin Injection) 24 U (0.3 mL) SC daily
3097855|NCT01906658|Experimental|Acthar 56 U (0.7 mL) SC twice weekly|Acthar (Repository Corticotropin Injection) 56 U (0.7 mL) SC twice weekly
3097856|NCT01906658|Experimental|Acthar 16 U (0.2 mL) SC daily|Acthar (Repository Corticotropin Injection) 16 U (0.2 mL) SC daily
3097857|NCT01906645|No Intervention|Usual Care|Usual care consists of 1) a routine nurse intake 2) medication reconciliation performed by treating physicians. Given resource constraints (routine medication reconciliation did not include corroborating medication histories with outpatient pharmacies, routine use of pill cards or pill boxes, or review of Medicaid formularies) Uninsured patients were financially responsible for most medications at discharge. 3) Discharge patient education was performed by inpatient nurses and treating physicians at the time of discharge. 4) Patients without a usual source of primary care were often given a list of the fourteen area safety-net clinics, which have limited capacity for uncompensated care.
3097858|NCT01906645|Experimental|C-TraIn|Care Transitions Innovation (C-TraIn) was delivered in addition to usual care, and includes (1) transitional nurse coaching and education, including post-discharge phone calls and home visits for highest risk patients; (2) pharmacy care that includes patient education, medication reconciliation, guidance to inpatient providers to encourage low-cost medications, and provision of 30 days of medications after discharge for those without prescription drug coverage; (3) post-hospital primary care linkages; (4) and explicit efforts at system integration through monthly quality improvement meetings.
3097859|NCT01906632|Other|gene expression profile|
3097860|NCT01906619||Febrile illness WITH febrile seizure|The cohort comprises children aged between 3 months and 5 years who had a febrile seizure during the actual febrile disease.
3097861|NCT01906619||Febrile illness WITHOUT febrile seizure|The cohort comprises children aged between 3 months and 5 years with a febrile illness who had never a febrile seizure.
3097862|NCT01906606|Experimental|Parenting Program|12 session community-based parenting program
3097863|NCT01906606|No Intervention|Control Group|received visual aids on nutrition
3097864|NCT01906593||Tiantan biologial's vaccine|Tiantan Biological's vaccine group is the population injected with this vaccine.
3097865|NCT01906593||other group|Other vaccine group is the population injected with other manufacturers' vaccine except Tiantan Biological CO, Ltd.
3097867|NCT01906580|Experimental|Sequential therapy|Participants will receive entecavir monotherapy for 12 weeks, and 180ug peg-IFNα-2a therapy is added for the following 12 weeks. After that, entecavir will be stopped and 180ug peg-IFNα-2a monotherapy for the following 48 weeks. All participants will followed to 96 weeks.
3097868|NCT01906580|Experimental|Combination therapy|Participants will receive 180ug peg-IFNα-2a combined with entecavir therapy for 72 weeks, and then followed to 96 weeks.
3097869|NCT01906567||severe preeclamptic women|"Severe preeclampsia is defined as the presence of 1 of the following symptoms or signs in the presence of preeclampsia:~• SBP of 160 mm Hg or higher or DBP of 110 mm Hg or higher on 2 occasions at least 6 hours apart~• Proteinuria of more than 5 g in a 24-hour collection or more than 3+ on 2 random urine samples collected at least 4 hours apart~• Pulmonary edema or cyanosis~• Oliguria (< 400 mL in 24 h)~• Persistent headaches~• Epigastric pain and/or impaired liver function~• Thrombocytopenia~• Oligohydramnios, decreased fetal growth, or placental abruption"
3097870|NCT01906567||mild preeclamptic women|Mild preeclampsia is defined as the presence of hypertension (BP ≥140/90 mm Hg) on 2 occasions, at least 6 hours apart, but without evidence of end-organ damage in the patient.
3097871|NCT01906567||Healthy Pregnant Women|healthy pregnant women at term who not developed any complication of pregnancy
3097872|NCT01906554|Experimental|Egg Dose|
3097873|NCT01906541|Experimental|ex-vivo gene-therapy|transplantation of genetically modified autologous CD34+ cells
3097874|NCT01906528|Experimental|Males vs females|Constant-rate IV infusions of Mivacurium, range 1.0 - 3 micro/kg/min, duration 150 - 180 min
3097875|NCT01906515|No Intervention|Control Group|Control Group received standard anesthesia care including intraoperative blood sampling when estimated blood loss was ≥15% of total blood volume and transfusion when hemoglobin was ≤10 g/dL.
3097876|NCT01906515|Experimental|SpHb Group.|Continuous non-invasive hemoglobin monitoring (SpHb monitoring) was provided to the anesthesiologist to influence administration of care
3097877|NCT01906502|Experimental|Device|Portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization.
3097878|NCT01906489|Experimental|AKB-6548|
3097879|NCT01906489|Placebo Comparator|Placebo|
3097880|NCT01906476|Experimental|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
3097881|NCT01906476|Active Comparator|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
3097882|NCT01906450|Experimental|Scaling and root planing plus Azithromycin|Single session of scaling and root planning. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
3097883|NCT01906450|Placebo Comparator|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
3097884|NCT01906450|No Intervention|baselline screening only|Dental prophylaxis is offered
3097885|NCT01906437||Cardiac Magnetic Resonance|Cardiac Magnetic Resonance scan at visits 1 and 2
3097886|NCT01906424|Other|Control Grp#1: Training w/ and w/o Stim|Control- Group #1: 4 weeks training without any transcutaneous electrical stimulation followed by 2 weeks of training plus transcutaneous electrical spinal cord stimulation applied to one or two locations of the cervical (neck) region of the spinal cord.
3097887|NCT01906424|Active Comparator|Grp#2: Training+Single Site Stimulation|Group #2: Four weeks of training plus transcutaneous electrical spinal cord stimulation applied to one location along the cervical (neck) region of the spinal cord; followed by 2 weeks of training without stimulation
3097888|NCT01906424|Active Comparator|Grp #3: Training + Two Site Stimualtion|Group #3: Four weeks of training plus transcutaneous electrical spinal cord stimulation applied to two locations along the cervical (neck) region of the spinal cord; followed by 2 weeks of training without stimulation
3097889|NCT01906411||subjecst with different BMI|
3097890|NCT01906398|Other|Experimental: ketogenic diet|Treatment will consist of KD will consist of 3:1 [fat]: [protein + carbohydrate] weight ratio, with 1600 kcal restriction for patients with body mass index (BMI) of ≥ 21. The diet will be initiated with a 24 hour fast to induce ketosis. The diet will be supplemented with vitamins, calcium and phosphorus supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard. If seizure frequency does not improve after 3 months of KD treatment, [fat]: [protein + carbohydrate] weight ratio will be increased to 4:1
3097891|NCT01906385|Experimental|Rhenium Liposome Treatment|
3097892|NCT01906372|Experimental|Acthar Gel|Acthar Gel (Adrenocorticotropic Hormone Gel)in refractory PM and DM patients using an open label design for 6 months. We will enroll 10 active and refractory PM/DM patients over a 15 month period, followed by 6 months of additional follow-up for each subject. Study subjects will self-administer subcutaneously H.P. Acthar Gel 80 units (1 ml) twice a week for a period of six months. Outcome measures were not evaluated on subjects who did not reach the 8 week time point in the trial.
3097893|NCT01906359|Experimental|Dietary fat - PO|Native palm olein (IV56)
3097894|NCT01906359|Experimental|Dietary fat - IPO|Chemically interesterified palm olein (IV56)
3097895|NCT01906359|Experimental|Dietary fat - HOS|High oleic sunflower oil
3097896|NCT01906346|Experimental|Low Value Alternative Reinforcer|A low value reinforcer will be made available as an alternative to cocaine and placebo.
3097897|NCT01906346|Experimental|Medium Value Reinforcer|A medium value reinforcer will be made available as an alternative to cocaine and placebo.
3097898|NCT01906346|Experimental|High Value Reinforcer|A high value reinforcer will be made available as an alternative to cocaine and placebo.
3097899|NCT01906333|Experimental|Exercise & Glucose|2 hour exercise while getting glucose-supplementation
3097900|NCT01906333|Experimental|Exercise & Fasted|2 hour exercise while staying fasted
3097901|NCT01906320|Experimental|Training group|
3097902|NCT01906320|No Intervention|Control Group|
3097903|NCT01906307|Experimental|LJPC-501|LJPC-501, continuous infusion
3097904|NCT01906294||Type 2 Diabetes Mellitus|Patients with antidiabetic treatment for Type 2 Diabetes Mellitus
3098048|NCT01905215|Experimental|Group A|Subjects in this group will receive a single dose of formulation 1 of RSV vaccine
3097905|NCT01906281||Inflammatory knee osteoarthritis|One group of patients with inflammatory condition in physical evaluation. We will make a blood analyse and arthrocentesis when synovial fluid were found in ultrasound examination. Ultrasound of affected knee and carotid artery will be performed.
3097906|NCT01906281||Non-inflammatory knee osteoarthritis|Patients with no inflammatory condition in physical examination. We will make a blood analyse and arthrocentesis when synovial fluid were found in ultrasound examination. Ultrasound of affected knee and carotid artery will be performed.
3097907|NCT01906268|Experimental|TAU + ABMT active|"Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor~Attention Bias Modification Treatment (ABMT) - active"
3097908|NCT01906268|Sham Comparator|TAU + AMBT placebo|"Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor~Attention Bias Modification Treatment (ABMT) - placebo (sham)"
3097909|NCT01906255||FTC/TDF for PrEP|HIV-1 negative adults (any sex/gender, including transgender) who are participating in observational or clinical studies on FTC/TDF for PrEP
3097910|NCT01906242|Placebo Comparator|Water|Patients' dentures are treated with water (placebo) once a week for 10 min.
3097911|NCT01906242|Active Comparator|sodium hypochlorite|Patients' dentures are treated with a solution of sodium hypochlorite 0.5% once per week for 10 min
3097912|NCT01906242|Active Comparator|0.5% chlorhexidine|Patients' dentures are treated with 0.5% chlorhexidine once a week for 10 min.
3097913|NCT01906242|Active Comparator|0.12% sodium bicarbonate|Patients' dentures are treated with sodium bicarbonate 0.12% once a week for 10 min.
3097914|NCT01906229||Acute respiratory distress syndrome (ARDS)|
3097915|NCT01906229||Systemic inflammatory response syndrome (SIRS)|
3097916|NCT01906229||ARDS+SIRS|
3097917|NCT01906216|Active Comparator|Sorafenib|All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). Sorafenib may be taken either with a low/moderate fat meal or without food. Subjects are to continue sorafenib according to the study protocol if the adverse events could be safely controlled.
3097918|NCT01906216|Experimental|Sorafenib combined with TACE|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). In addition, the subjects in this arm will receive the treatment of conventional transarterial chemoembolization. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents(doxorubicin) and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads.
3097919|NCT01906203|Experimental|ultramarathon|
3097920|NCT01906190|Experimental|vaccinated group|Vaccinated group means that subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine.
3097921|NCT01906164|Experimental|ALS-008176|
3097922|NCT01906164|Placebo Comparator|Placebo|
3097923|NCT01906151|Other|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
3097924|NCT01906138|Other|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
3097925|NCT01906125|Experimental|Palbociclib given to Healthy Volunteers|
3097926|NCT01906112|No Intervention|Controlled|No surgery for primary breast tumor.
3097927|NCT01906112|Experimental|Study|Surgery for primary breast tumor.
3097928|NCT01906099|Experimental|legume enriched diet|legume consumption, 4 servings per week, for 6 weeks
3097929|NCT01906099|Active Comparator|healthy dietary recommendations|no nutritional intervention
3097930|NCT01906086|Experimental|legume consumption|legume consumption, 4 servings per week, for 6 weeks
3097931|NCT01906086|Active Comparator|healthy dietary recommendations|no nutritional intervention
3097932|NCT01906073|Experimental|intranasal fentanyl spray|Fentanyl for nasal administration (NF), is supplied as sprays containing a phosphate buffered solution of fentanyl citrate. NF is available in three strengths: 0.5 mg/ml, 1 mg/ml and 2 mg/ml in multiple-dose sprays. The corresponding doses are 50, 100 and 200 µg/puff. NF is applied as one puff in one nostril. One puff defines and equals one dose. Applying a puff to each nostril the upper dose can be increased to 400 µg. The doses used in this study are 50, 100, 200 ad 400µg. Fentanyl may be administered for up to 6 pain episodes/ 24 hours. For each pain episode, a dose of NF is self-administrated in one nostril. If pain relief is not achieved, another dose of NF could be administered in the opposite nostril after 15 minutes.
3097933|NCT01906073|Active Comparator|slow release morphine|The active substance is released gradually during its transit through the gastrointestinal tract. Slow release (SR) morphine is available in 5, 10, 30, 60, 100 and 200 mg. SR morphine is administered twice a day, usually every twelfth hour.
3097934|NCT01906060|Experimental|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Intubation Laryngeal Mask and subsequently intubated with a commercially available endotracheal tube via the Intubation Laryngeal Mask.
3097935|NCT01906034|Experimental|Exercise with supervision|The expert panel selected balance and strength / power exercises which can be performed with one's own bodyweight or with the help of small, low-cost exercise equipment (i.e., small weights, resistance bands, unstable surfaces). In this study, intensity during training will be regulated using the Borg Rating of Perceived Exertion scale (i.e., 6-20 points, maximal exertion at 20 points). According to the individual fitness level, exercises should be performed with a perceived exertion between 12 and 16 points (somewhat hard - hard) during balance and strength / power training. Exercise intensity will be progressed individually using the Borg Rating of Perceived Exertion scale and varying the balance and strength / power exercises in order to sufficiently stimulate the neuromuscular system. Strength / power exercises will be progressed from single to multiple joint, isometric to dynamic muscle contraction, short to long lever arm and slow to fast exercises.
3097964|NCT01905800|Experimental|Barbecue treatment with acceleartion|Treatment of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient starts in supine position and will be rotated about a horizontal axis from head to feet. The patient will be rotated 360 degrees with a succession of eight fast rounds in the axial plane towards the unaffected side.
3097965|NCT01905787||Group 2 - Dana group|50 patients will be included in the study.
3097936|NCT01906034|Experimental|Home-based without supervision|The expert panel selected balance and strength / power exercises which can be performed with one's own bodyweight or with the help of small, low-cost exercise equipment (i.e., small weights, resistance bands, unstable surfaces). In this study, intensity during training will be regulated using the Borg Rating of Perceived Exertion scale (i.e., 6-20 points, maximal exertion at 20 points). According to the individual fitness level, exercises should be performed with a perceived exertion between 12 and 16 points (somewhat hard - hard) during balance and strength / power training. Exercise intensity will be progressed individually using the Borg Rating of Perceived Exertion scale and varying the balance and strength / power exercises in order to sufficiently stimulate the neuromuscular system. Strength / power exercises will be progressed from single to multiple joint, isometric to dynamic muscle contraction, short to long lever arm and slow to fast exercises.
3097937|NCT01906034|No Intervention|control group|The control group is a traditional waiting group and will receive a supervised training program after the completion of this study
3097938|NCT01906021|Experimental|1|Intra-patient comparison of temperature map obtained during CT/CBCT with standard ablation temperature measurements
3097939|NCT01906008|Experimental|Minocycline|Group 2 receives minocycline 200 mg orally for the first dose, then 100 mg orally every 12 hours for 4 months beginning at chemotherapy initiation. Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit. Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
3097940|NCT01906008|Placebo Comparator|Placebo|Group 1 receives a placebo 200 mg orally for the first day of chemotherapy, then 100 mg doses every 12 hours for 4 months beginning at chemotherapy initiation. Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit. Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
3097941|NCT01905995||Patients with advanced Parkinson's disease|no intervention - observational study
3097942|NCT01905982|Experimental|Conventional breathing therapy|first: conventional breathing therapy, second: reflectory breathing therapy
3097943|NCT01905982|Experimental|Reflectory breathing therapy|first: Reflectory breathing therapy second:Conventional breathing therapy
3097944|NCT01905969||Biomarker positive|NF-kB(+)/JNK(-) in curatively removed specimens
3097945|NCT01905969||Biomarker negative|NF-kB(-)/JNK(+) in curatively removed specimens
3097946|NCT01905956|Active Comparator|IQP-AK-102|2 capsules per dose, three times daily
3097947|NCT01905956|Placebo Comparator|Placebo|2 capsules per dose, 3 times daily
3097948|NCT01905943|Experimental|Obinutuzumab|Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of Cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6 either alone as single agent, or in combination with chemotherapy (Fludarabine/Cyclophosphamide [FC], Bendamustine or Chlorambucil) at the investigator's discretion. Each cycle is of 28-days duration.
3097949|NCT01905930|Experimental|PCM Cervical Disc|Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
3097950|NCT01905930|Active Comparator|Ant. Cervical Discectomy & Fusion(ACDF)|Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
3097951|NCT01905917|No Intervention|Control|Usual care
3097952|NCT01905917|Experimental|Tele-Rehabilitation|A tele-rehabilitation intervention involving weekly video-conferencing with a therapist, training exercise videos and use of wearable sensors to capture patient participation in exercises.
3097953|NCT01905904|Active Comparator|sevorane|Sevorane 4% concentration during anesthesia induction
3097954|NCT01905904|Active Comparator|sevorane %7|Sevorane 7% concentration during anesthesia induction
3097955|NCT01905891|Other|Subjects at risk of skin cancer|Subjects at risk of skin cancer (sun-damaged skin) a superficial shave biopsy will be performed.
3097956|NCT01905891|Other|Subjects with healthy skin|Subjects without sun-damaged skin a superficial shave biopsy will be performed.
3097957|NCT01905878|Experimental|single dose DLBS1033|Before taking the drug, blood samples will be collected from subject to assess PAP complex level, serum creatinine, SGOT, SGPT, PT and aPTT. After that, subjects will instructed to take three tablets enteric coated of DLBS1033 in front of investigator. After take the medicine blood sample will be collected on 30 minute, 60 minute, 90 minute, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, and 24 hour to evaluate serial PAP complex. Subjects will undergo a clinical assessment including vital signs and the presence of adverse events at the time of blood sampling. On this trial, subjects are only permitted to eat food from investigator.
3097958|NCT01905878|Experimental|steady state of DLBS1033|On day 1 blood samples will be collected to assess PAP complex level, serum creatinine, SGOT, SGPT, PT and aPTT. After that, subjects will instructed to take one tablet of DLBS1033 in front of investigator. Study drug packages (that consist of 8 tablets) will dispense to the subjects at day-1 and instructed to take the drug 3 times daily 30 minutes before meals. Subjects also will instructed to record any adverse events and concomitant medication prescribed in diary card. Subjects have to take the drug on 3 days (day 1, 2, and 3). On day 4, blood sample will be collected on 0 minutes, 30 minute, 60 minute, 90 minute, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, and 24 hour to evaluate serial PAP complex. Subjects will undergo a clinical assessment including vital signs and the presence of adverse events at the time of blood sampling. On this trial, subjects are only permitted to eat food from investigator.
3097959|NCT01905813|Experimental|INCB040093|
3097960|NCT01905813|Experimental|INCB040093 in combination with itacitinib (INCB039110)|
3097961|NCT01905800|Active Comparator|Nystagmus in normal population|Investigate positional nystagmus in normal population using a biaxial rotational chair.
3097962|NCT01905800|Experimental|BPPV treatment in TRV chair|BPPV treatment in Biaxial rotational chair, describe and measure efficacy of treatment.
3097963|NCT01905800|Active Comparator|Barbecue treatment without acceleration|Treatment of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient is positioned in supine position and rotated 30 degrees stepwise towards the unaffected ear, thus applying an overall 360 degrees rotation. The patient remains in each position for 30 seconds
3097967|NCT01905787||Group 4 - Detroit group|100 patients will be included in the study, Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+) will be included).
3097968|NCT01905787||Group 1 - Emek group|100 patients will be included in the study, including Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+ patients will be included).
3097969|NCT01905774||Deferasirox|The patients will be treated by the primary physician according to clinical status. The Deferasirox dose range is between 20 to 40 mg/kg/day once daily dose. The treatment is a continuous treatment and not a single course.
3097970|NCT01905748|Experimental|Patients during Migraine attacks|Patients with Migraine before, during and after Migraine attacks. Acute phase reaction profile, and activation of the coagulation system will be investigated together with thrombophilia profile.
3097971|NCT01905748|Experimental|Control group|Patients with acute neurologic events like convulsions not related to fever or central nervous system (CNS) infections will be studied including acute phase reaction laboratory tests, thrombophilia and activation of the coagulation system
3097972|NCT01905735|Placebo Comparator|placebo|1/2 ml of dispensing alcohol administered orally at every 7 day for 5 month .
3097973|NCT01905735|Active Comparator|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
3097974|NCT01905722|Other|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
3097975|NCT01905722|Experimental|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
3097976|NCT01905709|Experimental|All patients|150-500 ml of human fecal matter
3097977|NCT01905696|Experimental|N-Acetylcysteine (NAC)|After initial measurements of SNO-Hb level, forearm blood flow in response to exercise and hypoxia, subjects will take oral NAC 600 mg twice daily. Measurements will then be repeated.
3097978|NCT01905683|Experimental|16-20 Units per kg body weight incobotulinumtoxinA|
3097979|NCT01905670|Experimental|Implant|Implant of the WiCS-LV system
3097980|NCT01905657|Experimental|Pembrolizumab 2 mg/kg|Participants received pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes Q3W for up to 2 years.
3097981|NCT01905657|Experimental|Pembrolizumab 10 mg/kg|Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.
3097982|NCT01905657|Active Comparator|Docetaxel 75 mg/m^2|Participants received docetaxel 75 mg/m^2 IV over 1 hour Q3W for up to 2 years. Participants who experienced disease progression, may have been eligible to crossover to receive pembrolizumab 200 mg IV Q3W.
3097983|NCT01905644|Experimental|With ultrasound|"Patients in this group will have perineal ultrasound for the detection of anal sphincter ruptures.~Intervention: Perineal ultrasound"
3097984|NCT01905644|No Intervention|Without ultrasound|Patients in this group will not have perineal ultrasound for the detection of anal sphincter ruptures.
3097985|NCT01905618|Experimental|Multi Modal Education (MME)|Medical students in the medical schools randomized to the MME will receive four interventions during the course of their medical education. The four interventions/components are: 1) web-based curriculum on tobacco dependence treatment; 2)tobacco counseling role play; 3) preceptor training and teaching medical students, preceptor modeling the 5As, student observation, and student feedback; and 4)booster session.
3097986|NCT01905618|No Intervention|Traditional Education (TE)|Medical schools randomized to the Traditional Education (TE) will represent usual care and includes the current content and mode for tobacco teaching in the medical school.
3097987|NCT01905605|Experimental|phosphatidylcholine supplementation|Phosphatidylcholine supplementation to be administered BID for 8 weeks
3097988|NCT01905605|Placebo Comparator|placebo supplementation|Placebo to be administered BID for 8 weeks
3097989|NCT01905592|Active Comparator|Physician's choice|Physician may select from 4 active comparators
3097990|NCT01905592|Experimental|niraparib|Patients will be randomized 2:1 to receive niraparib 3 oral capsules (100mg) once daily for 21 continuous days
3097991|NCT01905579|Experimental|patients with uveitis|Paracentesis of the anterior chamber in Paients with uveitis undergoing cataract surgery
3097992|NCT01905579|Experimental|patients without uveitis|Paracentesis of the anterior chamber in patients without uveitis undergoing routine cataract surgery
3097993|NCT01905566|Active Comparator|Clopidogrel|clopidogrel: 75mg once a day
3097994|NCT01905566|Experimental|Ticagrelor|ticagrelor: 90mg twice a day
3097995|NCT01905553|Experimental|SSP-004184SS (fed)|21.8 mg/kg (oral capsule form) given once on Day 1 under fed conditions
3097996|NCT01905553|Experimental|SSP-004184SS (fasted)|21.8 mg/kg (oral capsule form) given once on Day 1 under fasted conditions
3097997|NCT01905540|Experimental|SSP-004184AQ (single dose)|40 mg/kg (oral capsule form) given once on Day 1
3097998|NCT01905540|Experimental|SSP-004184SS (single dose)|21.8 mg/kg (oral capsule form) given once on Day 1
3097999|NCT01905540|Experimental|SSP-004184AQ (2 doses)|40 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1
3098000|NCT01905540|Experimental|SSP-004184SS (2 doses)|21.8 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1
3098001|NCT01905527||Standard Services of Group A (Group A1)|
3098002|NCT01905527||Customized Services of Group A (Group A2)|
3098003|NCT01905527||Group B|
3098004|NCT01905514|No Intervention|control|using Medication event monitoring system
3098005|NCT01905514|Active Comparator|internet mobile application|using both mobile internet application and medication event monitoring system
3098006|NCT01905501|Active Comparator|Total intravenous anesthesia|Total intravenous anaesthesia
3098007|NCT01905501|Experimental|Balanced anesthesia|
3098008|NCT01905488||Group N|patients who didn't show internal jugula vein valve incompetency (IJVVI)
3098009|NCT01905488||Group PT|patients who showed IJVVI after pneumoperitoneum or Trendelenburg position
3098010|NCT01905488||Group S|patients who showed IJVVI in supine position
3098011|NCT01905475|Experimental|POL6326|POL6326 intravenous infusion
3098012|NCT01905475|Placebo Comparator|Placebo|Placebo intravenous infusion
3098013|NCT01905462||Exposed cohort|Women with the first day of LMP between 30 days before and 45 days after any Cervarix dose and between 30 days before and 90 days after any Cervarix dose.
3098014|NCT01905462||Non-exposed cohort|Women with the first day of LMP between 120 days and 18 months after their last Cervarix dose (and no further Cervarix dose before the outcome).
3098015|NCT01905449|Experimental|Ultrasound plus prosodic cues|One sound in error is treated with ultrasound visual feedback while also cueing prosodic variation (7 one-hour sessions). Another sound in error is treated with the ultrasound visual feedback with no prosodic variation (7 one-hour sessions). Prosodic variations are cues to coordinate production of the target sound with intonation patterns such as questions (rising intonations), commands (loud/emphatic), or statements (neutral)
3098016|NCT01905449|Experimental|Ultrasound vs Traditional treatment|One sound in errors is treated with ultrasound visual feedback for approximately half of each session and traditional treatment for half of the session (7 one-hour sessions). Another sound in error is treated with no ultrasound visual feedback, using traditional treatment for the entire session (7 one-hour sessions). These traditional cues include verbal instructions on how to move the tongue to achieve a particular speech sound.
3098017|NCT01905436||Annual Mass Drug Administration|This group will receive annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Liberian Ministry of Health.
3098018|NCT01905436||Semiannual Mass Drug Administration|This group will receive semi-annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Liberian Ministry of Health.
3098019|NCT01905423||Annual MDA treated Group|This group will receive annual MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will be administered by the Indonesian Ministry of Health as part of their national filariasis elimination program.
3098020|NCT01905423||Semiannual MDA treated group|This group will receive semiannual MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will also be administered by the Indonesian Ministry of Health.
3098021|NCT01905410|Experimental|single treatment - VVZ-149 Injection|"single ascending dose escalation~0.25, 0.5, 1, 2, 4, 6, and 8 mg/kg Cohorts~4 hours IV infusion"
3098022|NCT01905410|Placebo Comparator|single treatment - placebo|"The matching volume of placebo (water for injection) to each experimental cohort~4 hours IV infusion"
3098023|NCT01905410|Experimental|multiple treatment - VVZ-149 Injection|"Based on the results of SAD trials, low and high dosage are determined for MAD trials.~high and low dosage~4 hours IV infusion x 2 times/day x 3 days"
3098024|NCT01905410|Placebo Comparator|multiple treatment - placebo|"The matching volume of placebo (water for injection) to each experimental cohort~4 hours IV infusion x 2 times/day x 3 days"
3098025|NCT01905397|Active Comparator|Negative Pressure Wound Therapy|The Prevena Incision Management System is a 510K cleared device that covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump (also 510K cleared) may be used in some cases with the Prevena dressings as to achieve the negative pressure
3098026|NCT01905397|Active Comparator|Conventional wound therapy|Traditional wound therapy (sterile bandages and dressing)
3098027|NCT01905384|Active Comparator|U-SEMS group|Patients undergoing routine care ERCP and randomized to 10 mm diameter Uncovered Self-expanding metal biliary stents (U-SEMS) (Wallflex, Boston Scientific).
3098028|NCT01905384|Active Comparator|C-SEMS Group|Patients undergoing routine care ERCP and randomized to a 10 mm diameter Covered Self-Expanding metal biliary stents (C-SEMS) (Wallflex, Boston Scientific)
3098029|NCT01905371|Experimental|Dextroamphetamine + Physical therapy (PT)|"Treatment with d-amphetamine + physical therapy administered under two regimens administered sequentially:~10 mg of d-amphetamine combined with 1 hr PT session beginning 1 hr after drug administration every 4 days, for a total of 6 or 10 sessions"
3098030|NCT01905371|Placebo Comparator|Placebo + Physical Therapy (PT)|"Treatment with placebo + physical therapy administered under two regimens administered sequentially:~Regimen 1: 10 mg of placebo combined with 1 hr PT session beginning 1 hr after placebo administration every 4 days, for a total of 6 or 10 sessions"
3098031|NCT01905345|Experimental|Endurance and Resistance Training|Endurance and resistance exercise
3098032|NCT01905345|Experimental|Resistance Training|resistance exercise (12wk)
3098033|NCT01905345|Experimental|Resistance and resistance Training|resistance exercise (24 wk)
3098034|NCT01905332|Experimental|Literacy promoting home based program|Those 4 year old children who fall below the cutoff score on the literacy screening will be randomized to either receive standard of care (literacy toolkit) or will be given a referral to a home -based literacy promoting program through the Columbus Metropolitan Library.
3098035|NCT01905332|Active Comparator|Literacy Toolkit|Children who fall below the cut off score on the GRTR-R will be randomized to either receive a literacy toolkit (current standard of care) or a referral to a home based literacy promoting program. The toolkit will contain age-appropriate books and games.
3098036|NCT01905319||Subsequent new juvenile arthritis cases|During years 1998-2000, all new subsequent cases of juvenile idiopathic arthritis diagnosed in Estonia were included in the study group.
3098037|NCT01905306|Experimental|computer guided implant planning|radiographic and clinical evaluation of full-arch dental implant rehabilitation
3098038|NCT01905306|Experimental|free hand implants placement|radiographic and clinical evaluation of full-arch dental implant rehabilitation
3098039|NCT01905293|Experimental|100% portion size|100% portion size condition
3098040|NCT01905293|Experimental|150% portion size|150% portion size condition
3098041|NCT01905293|Experimental|200% portion size|200% portion size condition
3098042|NCT01905280|Experimental|Acellular dermal matrix|A ridge preservation graft will be performed and then covered using acellular dermal matrix as a membrane.
3098043|NCT01905280|Active Comparator|Non-resorbable membrane|A ridge preservation graft will be performed and then covered using a non-resorbable PTFE membrane.
3098044|NCT01905267|Experimental|Treatment|Participants randomized to the experimental condition will receive 8 weeks of individual treatment with Rumination-Focused Cognitive Behavior Therapy
3098045|NCT01905267|No Intervention|Control|Participants randomized to the control arm will complete questionnaires and receive mood monitoring for the duration of the study
3098046|NCT01905254|Other|Transient elastography and liver biopsy|All patients with Autoimmune hepatitis (AIH) were investigated with Transient Elastography before liver biopsy
3098047|NCT01905228|Experimental|CBL0137|"Dose Level 9: 150 mg/m2, IV~Dose Level 10: 180 mg/m2, IV~Dose Level 11: 240 mg/m2, IV~Dose Level 12: 320 mg/m2, IV~Dose Level 13: 400 mg/m2, IV~Dose Level 14: 540 mg/m2, IV~Dose Level 15: 700 mg/m2, IV~Dose Level 16: 920 mg/m2, IV~Dose Level 17: 1200 mg/m2, IV~Dose Level 18: 1600 mg/m2, IV~Dose Level 19: 2100 mg/m2, IV~Dose Level 20: 2700 mg/m2, IV"
3098049|NCT01905215|Experimental|Group B|Subjects in this group will receive a single dose of formulation 2 of RSV vaccine
3098050|NCT01905215|Experimental|Group C|Subjects in this group will receive a single dose of formulation 3 of RSV vaccine
3098051|NCT01905215|Experimental|Group D|Subjects in this group will receive a single dose of formulation 4 of RSV vaccine
3098052|NCT01905215|Experimental|Group E|Subjects in this group will receive a single dose of formulation 5 of RSV vaccine
3098053|NCT01905215|Experimental|Group F|Subjects in this group will receive a single dose of formulation 6 of RSV vaccine
3098054|NCT01905215|Placebo Comparator|Group Placebo 1|Subjects in this group will receive a single dose of placebo
3098055|NCT01905215|Placebo Comparator|Group Placebo 2|Subjects in this group will receive a single dose of placebo
3098056|NCT01905202|Experimental|Secretrol|Secretrol Capsules 80/80 once daily for 6 months
3098057|NCT01905189|Experimental|Hemodynamic study, cardiac pacing|We propose to study the hemodynamic response to a temporary atrio-dual right ventricular stimulation in pulmonary arterial hypertension subjects.Patients will be is own comparator.
3098058|NCT01905176|Experimental|Predischarge educational intervention|In person education on heart failure topics before discharge
3098059|NCT01905176|Experimental|Telephone educational intervention|Telephone support and education post-discharge
3098060|NCT01905176|Experimental|Combination|Pre-discharge in person education and post-discharge telephone education and support
3098061|NCT01905176|No Intervention|Usual care (control group)|Patients receive the routine care provided by the hospital which does not involve protocol driven discharge-planning
3098062|NCT01905163|Experimental|laparoscopic management|Tumor Debulking Surgery by laparoscopy
3098063|NCT01905150|Experimental|G-FLIP+VitaminC, then G-FLIP-DM+VitaminC|G-FLIP in combination with Vitamin C, then G-FLIP-DM in combination with Vitamin C
3098064|NCT01905150|Active Comparator|G-FLIP, then G-FLIP-DM|G-FLIP alone, then G-GLIP-DM alone
3098065|NCT01905137|Active Comparator|Botulinum Toxin Type A|Patients in the treatment group will receive 200 Units of Botulinum toxin diluted in 20 mL of saline injected globally into their pelvic floor muscles followed by 8 treatments of pelvic floor physical therapy.
3098066|NCT01905137|Placebo Comparator|Saline|Patients in the placebo group will receive 20 mL of saline injected globally into their pelvic floor muscles followed by 8 treatments of pelvic floor physical therapy.
3098067|NCT01905124|Experimental|Drug: CF101|CF101 1 mg q12 hours
3098068|NCT01905124|Placebo Comparator|Placebo tablets of CF101|Placebo tablets q12 hours
3098069|NCT01905111|Experimental|BI 853520|BI 853520 once daily in a dose escalation schedule
3098070|NCT01905098|Experimental|Observation-First Arm|"A group that first attends 4 observation visits without sauna, and then attends sauna sessions 5 times a week for 3.5 hours per visit for 3 weeks.~Participants in this Arm will undergo both listed interventions: Observation and Sauna Protocols."
3098071|NCT01905098|Active Comparator|Sauna-First Arm|"A group that first attends sauna sessions 5 times a week for 3.5 hours per visit for 3 weeks and then attends 4 observation visits without sauna.~Participants in this Arm will undergo both listed interventions: Observation and Sauna Protocols."
3098072|NCT01905072|Experimental|Education Home Visits|The intervention group will receive the full intervention delivered by community health workers (CHWs) through home visits. CHWs will deliver the intervention in the subjects' homes. Home visits will be arranged at subjects' convenience and occur on a planned schedule. The intervention content will be based on the Institute of Medicine recommendations.
3098073|NCT01905072|No Intervention|Control Group|The control group will receive only measurement visits, with no intervention or interaction during the home visits. They will receive only support from their WIC clinic.
3098074|NCT01905059|Active Comparator|monoPI - boosted lopinavir or boosted darunavir|"boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)~This arm has been stopped on advise of DSMB (approved by Scientific Committee), patients are switched to standard second line triple therapy and followed until the end of the study at week 96."
3098075|NCT01905059|Active Comparator|bi therapy - (boosted lopinavir or darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD
3098076|NCT01905046|Experimental|Arm I: metformin hydrochloride|Patients receive metformin hydrochloride PO QD or BID for 24 months. Patients will continue metformin 850 mg PO BID for months 13-24. Patients will undergo RPFNA at 24 months. Follow up visits will be performed at 36 and 48 months after the start of treatment.
3098077|NCT01905046|Placebo Comparator|Arm II: placebo|Patients receive placebo PO QD or BID for 12 months. Patients may crossover to Arm I for months 13-24.
3098078|NCT01905020|Active Comparator|Conventional insulin pump therapry|Subjects will use conventional pump therapy to regulate their glucose levels.
3098079|NCT01905020|Active Comparator|Single-hormone closed-loop system|Variable subcutaneous insulin infusion rate will be used to regulate glucose levels. Insulin Aspart (Novorapid) will be infused using a subcutaneous infusion pump. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer-generated recommendations of infusion rates.
3098080|NCT01905020|Active Comparator|Dual-hormone closed-loop system|Insulin Aspart (Novorapid) and glucagon (Paladin) will be infused using two separate subcutaneous infusion pumps. The glucose levels as measured by the real time sensor will be entered manually into the computer every 10 minutes. The pumps' infusion rate will then be changed manually based on the computer generated-recommendation delivery levels.
3098081|NCT01905007|Active Comparator|Defibrillation testing|Defibrillation testing at initial ICD implantation
3098082|NCT01905007|No Intervention|No defibrillation testing|No defibrillation testing at initial ICD implantation
3098083|NCT01904994|No Intervention|Standard of Care|Participants will be managed per standard of care following prevailing Swaziland Ministry of Health guidelines.
3098084|NCT01904994|Experimental|Combined Intervention Strategy|Point-of-care (POC) CD4+ (cluster of differentiation 4) Count Accelerated ART initiation for ART eligible participants Basic care and prevention package Cellular Appointment Reminders and Follow-Up Financial Incentives
3098085|NCT01904981|Experimental|Atenolol|Atenolol group
3098086|NCT01904981|Experimental|Valsartan|Valsartan group
3098089|NCT01904916|Other|Histological biopsy procedure|This is a diagnostic multicenter study combining histological biopsy of tumor material with DNA sequencing using Ion Torrent®, Next Generation Sequencing (NGS) platform. The study aims improve stratification of cancer patients by obtaining fresh tumor biopsies for next-generation sequencing for participation in clinical trials.
3098090|NCT01904903|Experimental|HER2 targeted therapies, cardiac medications|"Cardiac intervention - cardiac assessment that includes baseline study echocardiogram, beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses~Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:~Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.~Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.~Ado-trastuzumab emtansine: 3.6mg/kg IV every three weeks."
3098091|NCT01904890|Experimental|CRC Prevention and Screening Education|Intervention Lay Health Workers (LHWs) will be taught to teach their participants about CRC screening through 2 outreach sessions and 2 telephone calls aimed at increasing their CRC screening receipt.
3098092|NCT01904890|Active Comparator|Nutrition Education|LHWs and participants in the comparison group will receive a bilingual CRC brochure as well as 2 lectures on healthy nutrition for cardiovascular health delivered by a health educator and an optional post- intervention LHW outreach session on CRC screening.
3098093|NCT01904877||HIV testing|Enhancing HIV testing: By partnering with the local CDC and the gay community, we will use SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing.
3098094|NCT01904877||Phase II: 367 HIV positive MSM|"Linking to care:~Providing enhanced HIV care."
3098095|NCT01904864|Active Comparator|NovaFerrum®|Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks.
3098096|NCT01904864|Active Comparator|Ferrous Sulfate|Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, ferrous sulfate, for 12 weeks.
3098097|NCT01904851||Stent|The patient received one or more stents to the superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries in AT LEAST one of the lesions treated during the course of the procedure.
3098098|NCT01904851||Non-Stent|The patient did not receive a stent to the superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries in ANY of the lesions treated during the course of the procedure.
3098099|NCT01904838||Patients in Pittsburgh, Pennsylvania|persons receiving treatment at integrative and conventional medicine clinics in Pittsburgh, Pennsylvania
3098100|NCT01904838||Internet sample|internet sample of persons reporting that they receive, or have received in the past year, integrative medicine or conventional medical treatments.
3098101|NCT01904812|Other|Lupus erythematosus|
3098102|NCT01904799|Other|Cognitive Assessment|
3098103|NCT01904786|Experimental|Melatonin|Melatonin 40 mg every 8 hours for a total of six doses given over 48 hours orally (per nasogastric tube).
3098104|NCT01904786|Placebo Comparator|Placebo|Placebo consists of the solvent solution without melatonin. Solvent solution consists of 5 mL of saline/alcohol mixture in a ratio of 90:1
3098105|NCT01904773|Placebo Comparator|Placebo|
3098106|NCT01904773|Experimental|low dose AZD5213|
3098107|NCT01904773|Experimental|high dose AZD5213|
3098108|NCT01904760|Experimental|dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
3098109|NCT01904760|Placebo Comparator|control|Drug: Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
3098110|NCT01904747|Experimental|Palbociclib given to healthy volunteers|
3098111|NCT01904734|Active Comparator|No previous male hormone treatment|Clomiphene
3098112|NCT01904734|Active Comparator|Previously treated with testosterone|Clomiphene
3098113|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 1 Twice Daily|Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 28 days.
3098114|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 1 Once Daily|Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp once daily for 28 days.
3098115|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 2 Twice Daily|Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 28 days.
3098116|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 2 Once Daily|Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp once daily for 28 days.
3098117|NCT01904721|Experimental|Stage 2: Bimatoprost Solution 1 Twice Daily|Stage 2: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 6 months.
3098118|NCT01904721|Experimental|Stage 2: Bimatoprost Solution 2 Twice Daily|Stage 2: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 6 months.
3098119|NCT01904721|Placebo Comparator|Stage 2: Bimatoprost Vehicle Twice Daily|Stage 2: Bimatoprost Vehicle applied evenly onto pre-specified area on the scalp twice daily for 6 months.
3098120|NCT01904708|No Intervention|Sedentary Visit|Subjects will do quiet, sedentary activities for 8 hours. Hourly blood draws and breath sampling will be collected. Bolus C13-Lysine will be given at hour 4.
3098121|NCT01904708|Active Comparator|Exercise Visit|Subjects will do quiet, sedentary activities until hour 5. Blood and breath samples will be collected. At hour 4, subject will consume a bolus of C13-Lysine and immediately walk on a treadmill at a moderate intensity (exercise at 75% of max heart rate) for 45 minutes.
3098122|NCT01904695|Experimental|Antihypertensive drugs & Herbs|Thiazide diuretics and ACE inhibitor and β-blocker & Herbs for 8 weeks
3098123|NCT01904695|Active Comparator|Antihypertensive drugs|Thiazide diuretics and ACE inhibitor and β-blocker for 8 weeks
3098124|NCT01904682|Experimental|Oral rigosertib|Patients will take 560 mg oral rigosertib (two 280 mg capsules) in the morning and 280 mg (one 280 mg capsule) in the afternoon, in fasting conditions, for 21 consecutive days of 21-day cycle (continuous regimen).
3098502|NCT01901913|Experimental|MD-bolus calculator for pre meal bolus|closed loop session with MD-bolus calculator for pre-meal bolus.
3098125|NCT01904669||Women who are trying to conceive|Women ages 18-44 without a history of fertility problems who are in a stable relationship with a male partner who have regular access to the Internet and have been trying to conceive <3 months.
3098126|NCT01904656|Experimental|Arm I|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
3098127|NCT01904656|Active Comparator|Arm II|"Participants are exposed to a Healthy Eating Peaches!- media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
3098128|NCT01904643|Experimental|Treatment (lenalidomide, combination chemotherapy)|"LENALIDOMIDE PRIMING: Patients receive lenalidomide PO for 5 or 7 days.~RE-INDUCTION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-5. Patients failing to achieve blast count < 5% at 21 days may receive a second course of induction therapy. Patients achieving complete remission proceed to lenalidomide priming.~LENALIDOMIDE PRIMING: Within 4-6 weeks, patients receive lenalidomide PO for 5 or 7 days and then proceed to consolidation therapy.~CONSOLIDATION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-4. Treatment repeats every 28-35 days for up to 2 courses in the absence of disease progression or unacceptable toxicity."
3098129|NCT01904630||CRC high risk|Participants belong to a family with increased risk for CRC, will be analyzed with gene sequencing
3098130|NCT01904617|Experimental|D5NS at 125 mL/hr|5% dextrose in normal saline at 125 mL/hr
3098131|NCT01904617|Experimental|D2.5NS at 250mL/hr|2.5% dextrose in normal saline at 250 mL/hr
3098132|NCT01904617|Experimental|NS at 250mL/hr|Normal saline at 250mL/hr
3098133|NCT01904604|Placebo Comparator|Placebo Patch|Subjects apply placebo Viaskin® patch daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an oral food challenge (OFC) and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC crossover to active treatment (using the same 21-day graduated dosing period used in the blinded phase) and dose with a high-dose DBV712 Viaskin® patch containing 250 μg peanut protein for a total active treatment period of 30 months (130 weeks).
3098134|NCT01904604|Experimental|100 µg Peanut Patch|Subjects apply low-dose DBV712 Viaskin® patch containing 100 micrograms (μg) peanut protein daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an OFC and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC crossover to active treatment (using same 21-day graduated dosing period used in blinded phase for subjects 4-<6 years old at enrollment or who had Grade 2 reaction or higher within previous 2 months) and dose with a high-dose DBV712 Viaskin® patch containing 250 μg peanut protein for a total active treatment period of 30 months (130 weeks).
3098135|NCT01904604|Experimental|250 µg Peanut Patch|Subjects apply high-dose DBV712 Viaskin® patch containing 250 micrograms (μg) peanut protein daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an OFC and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC continue active treatment with a high-dose DBV712 Viaskin® patch for a total active treatment period of 30 months (130 weeks).
3098136|NCT01904591|Experimental|Selenium and Vitamin E|single arm, all subjects receive both vitamins for 1 year from time zero.
3098137|NCT01904578|Experimental|true acupressure|Massage the effective pressure points as a self-care method at home [ Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the centre line between the ends of the eyebrows] for 10 minutes. It was done 1 to 2 hours before sleeping, each night (except Fridays) by circular massage with a 1 Cm circle diameter.
3098138|NCT01904578|Sham Comparator|sham acupressure|Massage the sham pressure points as a self-care method at home for 10 minutes. It was done 1 to 2 hours before sleeping, each night (except Fridays) by circular massage with a 1 Cm circle diameter.
3098139|NCT01904578|No Intervention|control|The control group only received the weekly control of blood pressure and speech communication .
3098140|NCT01904565|Experimental|Thermoradiotherapy|Patients subjected to the planned therapeutic intervention of local hyperthermia and proton beam therapy
3098141|NCT01904552|Experimental|apical periodontitis (AP)|clinical pulp necrosis periapical index scores of 3, 4 or 5
3098142|NCT01904552|Experimental|normal periapex (NP)|clinical pulp vitality periapical index score of 1
3098143|NCT01904539|Experimental|Healthy Volunteer|Healthy volunteers receiving a single dose of obeticholic acid 10 mg.
3098144|NCT01904539|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment defined as Child-Pugh class A receiving a single dose of obeticholic acid 10mg.
3098145|NCT01904539|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment defined as Child-Pugh class B receiving obeticholic acid 10mg.
3098146|NCT01904539|Experimental|Severe Hepatic Impairment|Subjects with severe hepatic impairment defined as Child-Pugh class C receiving obeticholic acid 10 mg.
3098147|NCT01904526|Experimental|Guanfacine|Guanfacine 3 mg/day immediate release followed by Guanfacine 4mg/day extended release followed by Guanfacine 6 mg/day extended release
3098148|NCT01904513|Experimental|Probiotic|Daily consumption of yogurt supplemented with L. rhamnosus GR-1 at ~10^10 CFU/day
3098149|NCT01904513|Other|Milk|Daily consumption of pasteurized whole milk
3098150|NCT01904500|Other|Cefazolin 2 grams|
3098151|NCT01904500|Active Comparator|Cefazolin 3 grams|
3098152|NCT01904487|Experimental|PET scans|Both alcoholics and healthy controls will undergo two [11C]flumazenil PET scans: one at baseline and one post administration of 0.2 mg/kg Tiagabine.
3098584|NCT01901302|Placebo Comparator|Placebo|Placebo BID for a 12-week treatment period
3098153|NCT01904474|Experimental|Next.Step|"Experimental group participants, in addition to the standard treatment program are invited to get restricted access to the e-therapeutic platform (Next.Step), which includes a diverse set of resources, such as: educational resources (videos, brochures, menus, weekly tips, access to other links), self-monitoring (food, weight and physical activity records), social support (chats, discussion forums and personalized messages), interactive training modules (self-assessment quizzes, making their own diets) and motivational tools (personal goals planning, treatment progression registry, positive reinforcement).~Intervention length will be 36 weeks (24 weeks of direct intervention with a follow-up of 12 weeks), being based on case management methodology."
3098154|NCT01904474|Active Comparator|Standard protocol|The control group will follow the POC/HSM standard treatment protocol, which includes a baseline evaluation session with a paediatrician for initial screening, followed by appointments with the nutritionist and exercise physiologist. The second set of appointments will take place one month after for adjustments. After this, the adolescent will have appointments at 3, 6, 9 and 12 months. These adolescents will join a waiting list and nine months (36 weeks) after having started the standard treatment, they will receive the personal codes for accessing Next.Step.
3098155|NCT01904461|Experimental|Vacuum device surgery|At first the surgeon proceed to the dissection of children tonsils and at last he uses the innovative vacuum device to obtain wounds hemostasis
3098156|NCT01904461|Active Comparator|Conventional surgery|At first the surgeon proceed to the dissection of children tonsils and at last he uses a bipolar forceps to obtain wounds hemostasis
3098157|NCT01904448|Experimental|Auditory Brainstem Implant|single-arm study of auditory brainstem implantation in children
3098158|NCT01904422|Experimental|conventional periodontal treatment|Treatment group by quadrant in five weeks. Patients in this group will receive periodontal treatment including plaque control instructions, supragingival and subgingival debridement and root planing. This treatment is done in 5 sessions with a periodicity of 1 session per week. In the first session patients will receive hygiene instruction and supragingival debridement performed with and ultrasonic device. In the following session, there will be done the scaling and root planing to one quadrant per session, using site specific hand curettes. In case of being partially edentulous patients will be implemented at least 3 teeth per quadrant in each session.
3098159|NCT01904422|Experimental|Intensive periodontal treatment|Intensive treatment group in 24 hours: Patients in this group will receive periodontal treatment including: plaque control instructions, supragingival and subgingival debridement and scaling and root planing. This treatment is carried out in 2 sessions within 24 hours. In the first session hygiene instruction and supragingival and scaling and root planing of the teeth in right side at the upper jaw and mandible will be performed. The implementation of each upper and lower hemiarcade will be made until the periodontist treating check manually the removal of all subgingival calculus deposit and feel the smoothness of the root surface. In the second session, there will be an identical procedure in the arch left.
3098160|NCT01904409|Placebo Comparator|Placebo|Placebo tablets once daily.
3098161|NCT01904409|Experimental|Rifaximin SSD 40 mg IR tablet|Rifaximin soluble solid dispersion (SSD) 40 mg immediate release (IR) tablet once daily.
3098162|NCT01904409|Experimental|Rifaximin SSD 80 mg IR tablet|Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet once daily.
3098163|NCT01904409|Experimental|Rifaximin SSD 40 mg SER tablet|Rifaximin soluble solid dispersion (SSD) 40 mg sustained extended release (SER) tablet once daily.
3098164|NCT01904409|Experimental|Rifaximin SSD 80 mg SER tablet|Rifaximin soluble solid dispersion (SSD) 80 mg sustained extended release(SER) tablet once daily.
3098165|NCT01904409|Experimental|Rifaximin SSD 80mgIR/80mgSER tablet|Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet + rifaximin SSD 80 mg sustained extended release (SER) tablet once daily.
3098166|NCT01904396|Experimental|CarnitineDeficient|Patients identified with primary and secondary carnitine deficiency in the cardiomyopathy population will be prescribed with carnitine supplements to assess cardiac muscle function and status.
3098167|NCT01904383||Trazenta|
3098168|NCT01904357|Active Comparator|Cefazolin 1 GM Injection|Subjects weighing ≥25 kg and < 50 kg will receive the 1g dose.
3098169|NCT01904357|Active Comparator|Cefazolin 2 GM Injection|Subjects weighing ≥50 kg to ≤85 kg will receive the 2g dose.
3098170|NCT01904344|Other|Sensor testing and validation|
3098171|NCT01904331||Breast cancer patients|Women who were curatively treated with chemo- and/or radiotherapy for breast cancer
3098172|NCT01904331||Controls|Women matched on age and general practitioner with the breast cancer patients
3098173|NCT01904318|Experimental|IDP-73152 mesylate 40 mg|
3098174|NCT01904318|Experimental|IDP-73152 mesylate 80 mg|
3098175|NCT01904318|Experimental|IDP-73152 mesylate 160 mg|
3098176|NCT01904318|Experimental|IDP-73152 mesylate 320 mg|
3098177|NCT01904318|Experimental|IDP-73152 mesylate 640 mg|
3098178|NCT01904318|Experimental|IDP-73152 mesylate 1280 mg|
3098179|NCT01904318|Placebo Comparator|Placebo|
3098180|NCT01904305||Patients receiving bronchoscopy|Patients suspected of having pneumonia received bronchoscopy to examine the lungs and to capture alveolar lavage culture
3098181|NCT01904292|Experimental|Tocilizumab|Participants will receive SC dose of tocilizumab based on body weight; participants with <30 kg will receive 162 milligrams (mg) of tocilizumab Q2W and those participants =>30 kg will receive 162 mg of tocilizumab QW, for 52 weeks.
3098182|NCT01904279|Experimental|TCZ SC 162 mg Q3W|Participants with body weight less than (<) 30 kilograms (kg) will be administered 162 milligrams (mg) of TCZ as a SC injection every 3 weeks (Q3W) for 52 weeks.
3098183|NCT01904279|Experimental|TCZ SC 162 mg Q2W|Participants with body weight greater than or equal to (>/=) 30 kg will be administered 162 mg of TCZ as a SC injection every 2 weeks (Q2W) for 52 weeks.
3098184|NCT01904266|Sham Comparator|GA + sham block|Patients will receive general anesthetic plus a sham paravertebral block
3098185|NCT01904266|Experimental|GA + paravertebral block|Patients will receive general anesthetic plus a paravertebral block
3098186|NCT01904253|Experimental|TAS-102|
3098187|NCT01904253|Active Comparator|Investigator Choice of Amrubicin or Topotecan|Investigator Choice of Amrubicin (Japan only) or Topotecan (Europe and Japan)
3098188|NCT01904240||Parkinson's disease patients|Patients with Parkinson's disease
3098189|NCT01904240||Subjects without Parkinson's disease|Control subjects without Parkinson's disease
3098190|NCT01904227|Experimental|Inpatient Adaptation of DBT|"Patients are in treatment 5 days a week, during 12 weeks. Staff is only present in daytime. During the weekends the patients stay at home.~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly.~Patients also receive daily mindfulness classes, 2 hours of drama therapy, psycho educational classes about sexuality, substance abuse and medication, and the possibility to get help in applying principles of validation and behavioral analysis skills."
3098191|NCT01904227|Active Comparator|Outpatient DBT|Control condition: Standard outpatient DBT
3098192|NCT01904214|Experimental|severe renal impairmnt|
3098193|NCT01904214|Experimental|moderate renal impairment|
3098194|NCT01904214|Experimental|mild renal impairment|
3098195|NCT01904214|Experimental|healthy subjects|
3098196|NCT01904188||SIRS positive|Adult (> or = 18 years) patients with 3 of 4 systemic inflammatory response syndrome (SIRS) characteristics (1. tachycardia, 2. fever or hypothermia, 3. tachypnea, 4. leukocytosis), who have blood cultures drawn and urine collected for the evaluation of suspected sepsis, along with any other bodily fluid suspected to be the source of infection.
3098197|NCT01904175||Reduced Intensity Allogeneic Transplant|Subjects undergoing a reduced intensity allogeneic stem cell transplant
3098198|NCT01904162|Experimental|healthy young adult males|healthy young adult males receiving 400 mg finafloxacin single dose
3098199|NCT01904162|Experimental|healthy young adult females|healthy young adult females receiving 400 mg finafloxacin single dose
3098200|NCT01904162|Experimental|healthy elderly adult males|healthy elderly adult males receiving 400 mg finafloxacin single dose
3098201|NCT01904162|Experimental|healthy elderly adult females|healthy elderly adult females receiving 400 mg finafloxacin single dose
3098202|NCT01904149|Experimental|DKP/TRAM followed by DKP/TRAM|Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
3098203|NCT01904149|Active Comparator|DKP followed by DKP|Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
3098204|NCT01904149|Active Comparator|TRAM followed by TRAM|Tramadol-single dose followed by Tramadol-multiple doses
3098205|NCT01904149|Other|Placebo followed by DKP/TRAM|Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
3098206|NCT01904149|Other|Placebo followed by DKP|Placebo single dose followed by Dexketoprofen-multiple doses
3098207|NCT01904149|Other|Placebo followed by TRAM|Placebo single dose followed by Tramadol-multiple doses
3098208|NCT01904136|Experimental|Expanded Natural Killer (NK) Cells|"Melphalan 140 mg/m^2 by vein on Day -7. Fludarabine 40 mg/m^2 by vein daily on Days -7 to -4.~Escalating doses of NK cells used, between 1x10^5/kg and 1x10^8/kg CD3- CD56+ cells/kg. First infusion of expanded NK cells on Day -2 and the other 2 infusions use cryopreserved expanded NK cells.~Bone marrow transplant on Day 0. Mesna 10 mg/kg by vein on Day +3 and +4, repeated every 4 hours for total of ten doses. Cyclophosphamide 50 mg/kg by vein on Day +3 and +4. Tacrolimus 0.015 mg /kg by vein daily starting on Day +5 and continued by mouth for at least 4 months post transplant. Mycophenolate mofetil (MMF) 15 mg/kg by mouth starting on Day +5. It is recommended start tapering at Day +180, unless otherwise indicated, weekly over at least 3 weeks.~Day +7 and Day +28 second and third NK infusions.~G-CSF 5 mcg/kg/day subcutaneously once a day daily starting on Day +7 until neutrophil recovery.~All patients receive total body irradiation (TBI) 200 cGy administrated on Day -3."
3098209|NCT01904123|Experimental|WP1066|"Participants include those with recurrent malignant glioma (glioblastoma, anaplastic glioma), and melanoma patients with progressive brain metastasis.~Each 28 day cycle consists of two weeks of treatment with WP1066 administered twice per day (BID) on Monday, Wednesday, and Friday followed by a two-week cycle of no administration.~Dose escalation proceeds according to an Accelerated Titration Design followed by a 3 + 3 design algorithm.~Part I starting dose of WP1066 6 mg/kg by mouth 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle.~Part II starting dose maximum tolerated dose from Part I."
3098210|NCT01904123|Experimental|WP1066 + Tumor Surgery|Cohort includes recurrent malignant glioma participants that are pre-dosed with WP1066 14 (+ 3) days prior to surgery. Part III participants receive maximum tolerated dose from Part II. Each 28 day cycle consists of two weeks of treatment with WP1066 administered twice per day (BID) on Monday, Wednesday, and Friday followed by a two-week cycle of no administration. Participants imaged prior to treatment with WP1066 and within 72 hours of surgical resection. Surgery takes place within 3 working days of last WP1066 dose. Drug administration can restart 2 weeks after surgery, provided participants have recovered from surgery. Participants continue to receive WP1066 after surgery is completed, in the absence of DLT, unacceptable toxicity, or disease progression.
3098211|NCT01904110|Experimental|Risenex M|Patients who were treated with Resenex M (Risendronate/Cholecalciferol combination in one tablet) once a month for 12months
3098212|NCT01904110|Active Comparator|Risenex Plus|Patients who were treated with Risenex plus (Risendronate/Cholecalciferol combination in one tablet) once a week for 12months
3098213|NCT01904097|Sham Comparator|Pregabalin, Sham tDCS|Patients will receive pregabalin 150 mg oral (PO) twice per day (BID), and sham transcranial direct current stimulation (sham tDCS) five times per week during 2 weeks, and then twice per week until week 8th. The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
3098214|NCT01904097|Experimental|Pregabalin, tDCS|Patients will receive pregabalin 150 mg oral(PO) twice per day (BID), and transcranial direct current stimulation (tDCS) five times per week during 2 weeks, and then twice per week until week 8th. The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
3098215|NCT01904084|Active Comparator|Volar locked plating|One group with distal radius fracture is operated with Locking plate
3098216|NCT01904084|Active Comparator|Hoffman external fixator|One group with distal radius fracture is operated with Hoffman external fixator
3098217|NCT01904071|Experimental|UFNB|Ultrasound guided 3 in 1 femoral nerve block: The UFNB was performed by first visualizing the femoral nerve in a transverse orientation just inferior to the inguinal ligament and lateral to the common femoral artery.
3098218|NCT01904071|Experimental|UFIB|Ultrasound Guided Fascia Iliaca Compartment Block: For the UFIB, the two fascial planes, the fascia lata and the fascia iliaca, were sonographically visualized with the probe transverse to the thigh just inferior to the inguinal ligament and one-third of the distance from the anterior superior iliac spine to the pubic tubercle.
3098219|NCT01904071|Active Comparator|IVMS|IV Morphine: IV Morphine patients were also monitored for a minimum of one hour after they were given a second dose of IV morphine, 0.1 mg/kg, once the radiographs demonstrated fracture. The control group was also eligible to receive rescue analgesia of an additional 0.1 mg/kg of IV morphine, followed by repeat doses of 0.05 mg/kg
3098220|NCT01904058|Experimental|LUM001 and Ursodeoxycholic Acid (UDCA)|Administered orally once daily
3098221|NCT01904058|Placebo Comparator|Placebo and Ursodeoxycholic Acid (UDCA)|Administered orally once daily
3098222|NCT01904032|Experimental|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
3098223|NCT01904032|Active Comparator|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
3098224|NCT01904006|Experimental|New Culture Condition|Intervention group embryos cultured grouped under low oxygen tension in benchtop incubators.
3098225|NCT01904006|Active Comparator|Standard Culture Condition|Control group embryos cultured individually under atmospheric oxygen tension in large-box incubators.
3098226|NCT01903993|Active Comparator|Docetaxel|Participants received docetaxel 75 milligram per meter square (mg/m^2) administered intravenously on Day 1 of each 21 day cycle until disease progression or unacceptable toxicity or death.
3098227|NCT01903993|Experimental|Atezolizumab|Participants were administered atezolizumab intravenously on Day 1 of each 21 day cycle at a fixed dose of 1200 mg. Atezolizumab treatment were to continued as long as participants were experiencing clinical benefit as assessed by the investigator.
3098228|NCT01903980||EFN Cases|Cases of patients with epipericardial fat necrosis CT findings
3098229|NCT01903967||"Control Group"|Patients cured with no evidence of disease up to 5 years will be the controls.
3098230|NCT01903967||"Case Group"|Patients, in recurrence or progression before 5 years will be the cases
3098231|NCT01903954|Active Comparator|Active Comparator|Pplacebo in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)
3098232|NCT01903954|Experimental|Setrobuvir|Setrobuvir (800 mg orally b.i.d loading dose followed by 200 mg orally .b.i.d.) in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)
3098233|NCT01903941|Experimental|Training|Aerobic
3098234|NCT01903941|Placebo Comparator|Control|Not exercise
3098235|NCT01903928|Experimental|ASP0113 group|
3098236|NCT01903915||Patients|Schizophrenia group
3098237|NCT01903915||Control|Healthy control group
3098238|NCT01903902|Experimental|Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting SeQuent Please drug-eluting balloon in native small coronary artery (vessel diameter > 2.25 mm and ≤ 2.75 mm)
3098239|NCT01903889|Active Comparator|Clinic based intervention|basic intervention is introduced, whereby HIV/AIDS providers are trained on contraception for HIV-positive women. They are charged with counseling C&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
3098240|NCT01903889|Experimental|clinic and community based intervention|The basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services. This includes training of C&T providers on gender-based influences on health behaviors; provision of couples' HIV testing and FP counseling services; and community-based education for men to promote gender equitable norms and male participation in health services.
3098241|NCT01903876|Placebo Comparator|General Health promotion|A 3-hour general mental health web-based program.
3098242|NCT01903876|Experimental|Bystander & Sexual Violence Prevention|A 3-hour web-based program designed to teach male college student bystanders to intervene.
3098243|NCT01903863|Experimental|Scheduled fresh frozen plasma|Patients enrolled in this arm will receive scheduled fresh frozen plasma treatment every 48 hours.
3098244|NCT01903863|Active Comparator|Control|Patients in this arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
3098245|NCT01903850|Experimental|spray cryotherapy|spray cryotherapy: 4 -5 second sprays at Baseline (possible additional tx. to be determined at follow up)
3098246|NCT01903837|Experimental|Low Dose|Olanzapine + low dose samidorphan tablets taken once daily
3098247|NCT01903837|Experimental|Medium Dose|Olanzapine + medium dose samidorphan tablets taken once daily
3098248|NCT01903837|Experimental|High Dose|Olanzapine + high dose samidorphan tablets taken once daily
3098249|NCT01903837|Placebo Comparator|Placebo|Olanzapine + placebo tablets taken once daily
3098250|NCT01903824|Experimental|CEP-26401 5 μg, 25 μg, 125 μg, placebo|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 in each of the dose options: 5, 25 and 125 μg, and one dose that only contains the placebos.)
3098251|NCT01903824|Experimental|CEP-26401 5 μg, 25 μg, placebo, donepezil|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 at 5 and 25 μg, and donepezil at 10mg and one dose that only contains the placebos.)
3098252|NCT01903824|Experimental|CEP-26401 5 μg, 125 μg, placebo, modafinil|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 at 5 and 125 μg, and modafinil at 200mg) and one dose that only contains the placebos.)
3098253|NCT01903811|Experimental|Arm I (dexamethasone, low-dose carfilzomib)|Patients receive dexamethasone IV and low-dose carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II.
3098254|NCT01903811|Experimental|Arm II (dexamethasone, high-dose carfilzomib)|Patients receive dexamethasone IV and high-dose carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3098255|NCT01903798|Active Comparator|Continue Prednisolone (Lille <0.45)|Continue prednisolone 40 mg/day (current standard of care) for 21 days.
3098256|NCT01903798|Experimental|Rilonacept + Prednisolone (Lille <0.45)|Prednisolone (40mg/day) and rilonacept (Arcalyst®) subcutaneously once a week for 21 days (320 mg on study Day 8 and 160 mg on study Day 15 and study Day 22).
3098257|NCT01903798|No Intervention|Standard of Care (Lille ≥ 0.45)|Standard of care therapy (continue prednisolone, stop all therapy and/or offer palliative care)
3098258|NCT01903798|Experimental|Mycophenolate + Prednisolone (Lille ≥ 0.45)|Prednisolone (40 mg/day) and mycophenolate mofetil for 21 days (500 mg BID for first 4 days followed by 1000 mg BID for the next 17 days).
3098259|NCT01903785|Experimental|Salbutamol|400ug of salbutamol (one single inhalation) will be inhaled 60min prior to the begin of a time trial. Mean power output during the following 10km time trial will be described to 1600ug salbutamol and placebo.
3098260|NCT01903785|Placebo Comparator|Placebo|400ug of placebo (one single inhalation) will be inhaled 60min prior to the begin of a time trial. Mean power output during the following 10km time trial will be described to 400ug and 1600ug salbutamol.
3098261|NCT01903772|Experimental|Inspiratory Muscle Training|Procedure: Inspiratory Muscle Training Three times daily inspiratory muscle training (2x30 breaths) at an intensity of >50% Pi,max
3098262|NCT01903772|Sham Comparator|Sham Inspiratory Muscle Training|Twice daily inspiratory muscle training (3x30 breaths) at an intensity of 5 centimeters of water (H2O)
3098263|NCT01903759|Other|Patients with spontaneous rupture of the fetal membranes|
3098264|NCT01903746||Patients in septic shock|
3098265|NCT01903720|Experimental|OZURDEX®|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
3098266|NCT01903707|Experimental|Cognitive Remediation Therapy|Participants will undertake approximately 30 minutes of computerized CRT training for 8 weeks, 5 days per week. They will meet a therapist once per week to discuss any difficulties, help motivation.
3098267|NCT01903707|Placebo Comparator|Placebo Comparator|Participants will meet therapist once per week but will not undertake the Computerized Cognitive remediation training.
3098268|NCT01903694|Active Comparator|sorafenib|800 mg of sorafenib twice daily orally.
3098269|NCT01903694|Experimental|sorafenib-pravastatin|800 mg of sorafenib twice daily oral doses associated with 40 mg of pravastatin in a taken per os. Pravastatin will be taken during dinner.
3098270|NCT01903681|Active Comparator|Circadin 10 mg|Second arm higher dose
3098271|NCT01903681|Active Comparator|Circadin 2 mg|First arm lower dose
3098272|NCT01903655|Other|patients with a first episode of major depressive disorder|a group of patients with a first episode of major depressive disorder according to DSM-IV-TR including depressive episodes with melancholic features
3098273|NCT01903655|Other|patients with recurrent depressive disorder|a group of patients with recurrent depressive disorder according to DSM-IV-TR including depressive episodes with melancholic features (at least three episodes of depression)
3098274|NCT01903655|Other|control group|patient with no depressive disorder during the study period and no psychiatric history
3098275|NCT01903642|Other|Patients with inflammatory syndrome|
3098276|NCT01903629|Experimental|magnetic-controlled capsule endoscocpy (MCE)|patients were assigned to swallow MCE first, followed by the gastroscopy
3098277|NCT01903603||Healthy Children|Inclusion criteria for healthy children were as follows: ages of 4-20 y/o ; good cognition and cooperation; and healthy children.
3098278|NCT01903603||CP subjects|Inclusion criteria for subjects with brain damage by CP were as follows: a diagnosis of CP and aged 4-20 years old.
3098279|NCT01903590|Active Comparator|Transvaginal Tape Surgery|Randomized 50 patients undergoing TVT
3098280|NCT01903590|Experimental|Transobturator tape surgery|Randomized 50 patients undergoing TOT
3098281|NCT01903577|Experimental|Novice Laparoscopic and Robotic Surgeons|"Students and surgical trainees with less than 100 laparoscopic and less than 50 robotic cases.~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
3098282|NCT01903577|Experimental|Expert Laparoscopists, Novice Roboticists|"Surgeons with more than 100 laparoscopic cases, less than 50 robotic cases.~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
3098283|NCT01903577|Experimental|Expert robotic and laparoscopic surgeons|"Surgeons with greater than 100 laparoscopic and greater than 50 robotic cases.~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
3098284|NCT01903564||normal|pregnant women with uncomplicated pregnancies
3098285|NCT01903564||high-risk|pregnant women with pregnancies complicated by fetal arrhythmia or the risk of fetal arrhythmia
3098286|NCT01903551|Experimental|Loco-regional catheter|A suprafascial catheter will be positioned at the end of cardiac intervention during the thoracotomy closure. The catheter will be connected to a elastomeric pump, which delivers the analgesic drug (ropivacaine).
3098287|NCT01903551|No Intervention|Intravenous analgesia|At the end of the cardiac intervention each patient will receive intravenous analgesia with morphine at 0.8 mg/h.
3098288|NCT01903538|Experimental|Cathodal transcranial direct current stimulation|
3098289|NCT01903538|Sham Comparator|Sham transcranial direct current stimulation|
3098290|NCT01903525|Placebo Comparator|Placebo|The placebo capsules are supplied as 950 mg capsules consisting of 475 mg corn oil and 475 mg soy oil. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the placebo for 12 weeks.
3098291|NCT01903525|Experimental|Docosahexaenoic Acid (DHA)|The DHASCO capsules are supplied as 950 mg capsules with an effective dose of 500 mg DHA per capsule. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the DHA for 12 weeks.
3098292|NCT01903512||arthrocentesis in TMJ internal derangement|30 patients with TMJ internal derangement and pain with history of failed conservative management.
3098293|NCT01903499|Active Comparator|Bean patty|Bean Patty
3098294|NCT01903499|Active Comparator|Beef patty|Beef patty
3098332|NCT01903252|Active Comparator|Asacol 400 mg (Tillotts Pharma)|week 1 - week 12 (blinded), switch to TP05 for weeks 13-38 (open label)
3098295|NCT01903486|Other|Prednisone|Prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
3098296|NCT01903473|Experimental|Donor Treg infusion arm|Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be first treated with Rapamycin while CNI (if any) will be discontinued and infused whith Treg cells 3-4 weeks after.
3098297|NCT01903473|Active Comparator|Control|Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be treated with Rapamycin which is an alternative immunosupression strategy allowing to fight againt GVHD and CNI (if any) will be discontinued.
3098298|NCT01903460|Experimental|LUM001|LUM001 administered orally once each day
3098299|NCT01903460|Placebo Comparator|Placebo|Placebo administered orally once each day
3098300|NCT01903447|Active Comparator|SSRI|sertraline: 100-200mg, citalopram 20-40mg, escitalopram 10-20mg, paroxetine 20-60mg; fluoxetine 20-80mg
3098301|NCT01903447|Active Comparator|CBT|12 weeks of individual cognitive behavioral therapy
3098302|NCT01903434|Experimental|Evacetrapib -- Solid Fraction Test|Single oral dose of 130 milligram (mg) evacetrapib tablet on Day 1 of up to two of three periods
3098303|NCT01903434|Experimental|Evacetrapib -- Solid Fraction Reference|Single oral dose of 130 mg evacetrapib tablet on Day 1 of up to two of three periods
3098304|NCT01903421|Active Comparator|Spinal anesthesia group|Spinal anesthesia group will receive bupivacaine 10-15mg anesthesia according to the standard practice. Supplemental sedation with intravenous anesthetics (midazolam/propofol) will be optional.
3098305|NCT01903421|Active Comparator|General anesthesia group|Induction of anesthesia will be achieved with propofol 1.5-2mg/kg and fentanyl 1-3g/kg. Anesthesia will be maintained with inhalational anesthesia (isoflurane or sevoflurane) at the discretion of anesthesiologist in charge of the case. A mixture of Air/O2 will be used to maintain adequate oxygenation. Nitrous oxide will not be used.
3098306|NCT01903408|Other|Arm 1: Boost to prostate|IMRT of the pelvic lymphatic drainage (51 Gy) and integrated boost to the prostate (76.5 Gy) in 34 fractions Arm finished recruitment and follow-up
3098307|NCT01903408|Other|Arm 2: Boost to prostate and lymph node metastases|IMRT of the pelvic lymphatic drainage (51 Gy), SIB to the prostate (76.5 Gy) & pelvic lymph node mets (61.2 Gy) in 34 Fx
3098308|NCT01903408|Other|Arm 3: Boost to prostate bed|IMRT of the pelvic lymphatic drainage (51 Gy) and integrated boost to the prostate bed (68 Gy) in 34 fractions Arm finished recruitment and follow-up and is published
3098309|NCT01903408|Other|Arm 4: Boost to prostate bed and lymph node metastases|IMRT of the pelvic lymphatic drainage (51 Gy), SIB to the prostate bed 68 Gy) & lymph node metastases (61.2 Gy) in 34 Fx
3098310|NCT01903408|Other|Arm 5: Boost to lymph node metastases|Patients with previous irradiation of the prostate bed: IMRT of the pelvic lymphatic drainage (46.8 Gy) above the previous treatment fields, SIB to lymph node metastases (63.2 Gy) in 26 Fx
3098311|NCT01903395|Experimental|Nurse-led counselling|First-degree relatives of patients undergoing active treatment for colorectal cancer are offered a nurse-led counselling by telephone regarding emotional and cognitive barriers to screening utilization.
3098312|NCT01903395|No Intervention|Usual Care|Usual print media, offered standardly by the recruiting centres.
3098313|NCT01903382||Adult patients|All patients undergoing general anesthesia between January 2006 and December 2013
3098314|NCT01903369||Elective orthopaedic surgery patients|All patients presenting for elective orthopaedic surgery >16 years of age.
3098315|NCT01903356||Patients with T2DM|
3098316|NCT01903343||Healthy Volunteers|Healthy male medical students at Ninewells Hospital & Medical School, Dundee.
3098317|NCT01903330|Experimental|(ERC1671/GM-CSF/Cyclophosphamide)+bevacizumab|"ERC1671 and GM-CSF will be intradermally administered, while cyclophosphamide is orally administered. GM-CSF dose is 250 µg/m² and cyclophosphamide dose is 50 mg/day. Bevacizumab is administered as standard of care at 10 mg/kg.~The treatment will be repeated every 28 days until progression of disease or intolerance."
3098318|NCT01903330|Placebo Comparator|(Placebo Injection/Placebo Pill) +Bevacizumab|"The control group will have the same study schedule except that the patients will be receiving the Oral Control on the Cyclophosphamide treatment days and the Injectable control on the GM-CSF + ERC1671 treatment days. The control group will receive bevacizumab just as the active treatment group above.~The treatment will be repeated every 28 days until progression of disease or intolerance."
3098319|NCT01903317||Topical Therapy|Subjects who use topical therapy as the standard treatment of care for their psoriasis.
3098320|NCT01903317||Phototherapy and Systemic Therapy|Subjects who use phototherapy and systemic therapy as the standard treatment of care for their psoriasis.
3098321|NCT01903317||Biologic Therapy|Subjects who use biologic therapy as the standard treatment of care for their psoriasis.
3098322|NCT01903304|Experimental|olive oil|intervention with olive oil for 3 months
3098323|NCT01903304|Placebo Comparator|Placebo|Intervention with placebo for 3 months
3098324|NCT01903291||dimethyl fumarate|To be taken according to the United States Prescribing Information (USPI)
3098325|NCT01903278|Experimental|PEG-IFN-SA /RBV T1(Genotype2,3)|PEG-IFN-SA/RBV, 1.5μg/kg/week im and RBV 1000mg-1200mg/d po bid（BW＜75kg,1000mg/d; BW≥75kg, 1200mg/d）,24 weeks
3098326|NCT01903278|Active Comparator|Pegasys /RBV C1(Genotype 2,3)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW＜75kg，1000mg/d；BW≥75kg，1200mg/d）for 24 weeks
3098327|NCT01903278|Experimental|PEG-IFN-SA /RBV T2(Non-genotype 2,3)|PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW＜75kg，1000mg/d；BW≥75kg，1200mg/d）for 48 weeks
3098328|NCT01903278|Active Comparator|Pegasys /RBV C2(Non-genotype 2,3)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW＜75kg，1000mg/d；BW≥75kg，1200mg/d）for 48 weeks
3098329|NCT01903265|Experimental|TNX-102 SL 2.8 mg|Patients will take 1 tablet of TNX-102 SL sublingually each day at bedtime for 12 weeks.
3098330|NCT01903265|Placebo Comparator|Placebo|Patients will take 1 tablet of placebo sublingually each day at bedtime for 12 weeks.
3098331|NCT01903252|Experimental|TP05 (Mesalazine) 1600mg|week 1 - week 12 (blinded), week 13 - week 38 (OpenLabel)
3098585|NCT01901289|Experimental|Drug-Eluting Stent|
3098333|NCT01903239|Other|Low-Risk BCC Excisional Margins|This is a study investigating the efficiency of 1-2 mm margins for the excision of low-risk basal cell carcinoma.
3098334|NCT01903226|Experimental|High intensity training|Patients in this group will perform high aerobic intensity training, in 30 minutes, twice a week, in a 12 week period.
3098335|NCT01903226|Experimental|Moderate intensity training|Patients in this group will perform moderate aerobic intensity training, in 45 minutes, three times a week, in a 12 week period.
3098336|NCT01903226|No Intervention|controll|Patients in this group will perform no (additional) training.
3098337|NCT01903213||Kiklin group|Oral
3098338|NCT01903200|Experimental|FK949E Fed Group|FK949E is administered after breakfast
3098339|NCT01903200|Experimental|FK949E Fasted Group|FK949E is administered in the morning under fasting conditions
3098340|NCT01903187|Experimental|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
3098341|NCT01903187|Active Comparator|Sham procedure|Sham procedure
3098342|NCT01903174|Experimental|AeroForm Tissue Expansion|AeroForm Breast Tissue Expander placed after mastectomy
3098343|NCT01903161|Experimental|delayed remote ischemic preconditioning|applying pneumatic cuff on upper extremity (5 minutes cycles of limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times)
3098344|NCT01903161|Placebo Comparator|control|All the procedures were the same in the control group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
3098345|NCT01903135|Other|[HCO3-] >= 27 mmol/L (Group 1)|All obese patients with plasmatic[HCO3-] >= 27 mmol/L will be addressed to a pneumologist. The pneumology investigations will establish(or not) the diagnosis of OHS
3098346|NCT01903135|Other|[HCO3-]< 27mmol/L+pneumologist (Group 2)|Among obese patients with serum [HCO3-]< 27 mmol/L, 300 randomized patients will be addressed to a pneumologist. The pneumology investigations will refute(or not)the diagnosis of OHS.
3098347|NCT01903135|Other|[HCO3-]< 27 mmol/L (Group 3)|Obese patients with a [HCO3-]<27 mmol/L randomized to group 3 will receive usual medical follow-up (end of study)
3098348|NCT01903122|Active Comparator|Cevimeline|Single Dose 30 mg Capsule
3098349|NCT01903122|Active Comparator|Evoxac|Single dose 30 mg capsule
3098350|NCT01903109|Active Comparator|Cevimeline first, the Evoxac|Single dose 30 mg cevimeline capsule, then single dose 30 mg Evoxac capsule (after washout period)
3098351|NCT01903109|Active Comparator|First Evoxac, then cevimeline|Single dose 30 mg Evoxac capsule, then single dose 30 mg cevimeline capsule (after washout period)
3098352|NCT01903096|Experimental|Cognitive Behavioral Treatment (CBT)|Cognitive Behavioral Treatment. Seven 90-minute sessions of group treatment along 24 weeks.
3098353|NCT01903096|Active Comparator|Treatment-As-Usual (TAU)|Primary Care Treatment As Usual
3098354|NCT01903083|Experimental|Immunochemoradiotherapy|Immunotherapy with oral tadalafil daily; three doses of chemotherapy with IV Gemcitabine in 21-day cycles for up to 4 cycles; three fractions of external beam radiation to the pancreas and and regional lymph nodes; pancreaticoduodenectomy (surgical resection) for eligible patients.
3098355|NCT01903070|Experimental|Linagliptin in TD2 subjects|Linagliptin in TD2 subjects with normal renal function
3098356|NCT01903070|Experimental|Linagliptin in TD2 subjects with impaired renal function|Linagliptin in TD2 subjects with impaired renal function
3098357|NCT01903057|Experimental|Combination treatment|"Combination treatment with azithromycin, ivermectin and albendazole on day 1, followed by placebo on day 8~Placebo has same appearance and dosing as azithromycin."
3098358|NCT01903057|Placebo Comparator|Control (Standard of Care)|"Standard treatment with placebo, ivermectin and albendazole on day 1, followed by azithromycin on day 8~Placebo has same appearance and dosing as azithromycin."
3098359|NCT01903044|Experimental|BM-MNC injection|Injection of autologous bone marrow-derived mononuclear cells
3098360|NCT01903031|Experimental|NuvaRing and no ART (Arm A)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days).
3098361|NCT01903031|Experimental|NuvaRing with EFV plus ≥2 NRTIs (Arm B)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). EFV is a non-nucleoside reverse transcriptase inhibitor taken at a dose of 600 mg once daily.
3098362|NCT01903031|Experimental|NuvaRing with ATV/r plus TDF + ≥1 NRTIs (Arm C)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). ATV/r is a combination protease inhibitor taken at a dose of 300/100 mg once daily. Tenofovir disoproxil fumarate (TDF) is a nucleoside reverse transcriptase inhibitor (NRTI) taken at a dose of 300 mg daily.
3098363|NCT01903018|Experimental|P276-00|
3098364|NCT01903005|Experimental|Open-label BNX sublingual tablets|Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.
3098365|NCT01902992|Experimental|Depiquick® Birch|At the screening visit (Visit 1), patients will be instructed how to complete the eDiary. Eligible patients will return for visit 2 as soon as they experience significant allergic symptoms. Significant allergic symptoms are defined by a symptom score ≥ 2. If the patients' eligibility has been confirmed according to inclusion/exclusion criteria checklist, randomization to one of the 2 treatment arms will be conducted. Patients will receive two consecutive subcutaneous injections of study medication (0,2 and 0,3 ml) with a time lag of ≥ 30 minutes. Patients return to the study site in weekly intervals for visit 3, visit 4, visit 5, visit 6, and visit 7 to receive study medication injections (0,5 ml each). If treatment is completed before the end of the tree pollen season, patients will be followed-up by telephone calls every 4 weeks until the end of the tree pollen season. The study completion visit will take place 4 weeks after the end of the tree pollen season.
3098390|NCT01902784|Experimental|Storytelling Interview|"Participants assigned to receive the intervention will participate in an interview with a trained interventionist who will facilitate the telling of their 'story' - the personal experience they went through as a surrogate decision-maker for a loved one in the intensive care unit (ICU), who subsequently died after decisions were made to limit life-sustaining treatments (LST).~These participants will be evaluated with questionnaires at baseline, 3 months, and 6 months after the death of their loved one (ICU patient)."
3119338|NCT01758783|Experimental|Glutamine group|
3098366|NCT01902992|Placebo Comparator|Placebo|At the screening visit (Visit 1), patients will be instructed how to complete the eDiary. Eligible patients will return for visit 2 as soon as they experience significant allergic symptoms. Significant allergic symptoms are defined by a symptom score ≥ 2. If the patients' eligibility has been confirmed according to inclusion/exclusion criteria checklist, randomization to one of the 2 treatment arms will be conducted. Patients will receive two consecutive subcutaneous injections of study medication (0,2 and 0,3 ml) with a time lag of ≥ 30 minutes. Patients return to the study site in weekly intervals for visit 3, visit 4, visit 5, visit 6, and visit 7 to receive study medication injections (0,5 ml each). If treatment is completed before the end of the tree pollen season, patients will be followed-up by telephone calls every 4 weeks until the end of the tree pollen season. The study completion visit will take place 4 weeks after the end of the tree pollen season.
3098367|NCT01902979|Experimental|Lifestyle intervention|In Weeks 1 and 6, people in the intervention group will meet with a Registered Dietitian and an Exercise Physiologist for personalized sessions. They will receive a pedometer and instructions on how to log in to the e-health site (https://sspanli.mtroyal.ca). They will wear the pedometer daily and log in to the website each week for a nutrition education session, a weekly step goal, and tips.
3098368|NCT01902979|No Intervention|Usual Care|
3098369|NCT01902966|Experimental|Propranolol + Relaxation/Guided Imagery|A starting dose of propranolol 20 mg is taken by mouth twice a day (40 mg/day). If patient tolerates the initial dose (no hypotension or bradycardia), dose increased to 40 mg by mouth twice a day at start of second month of therapy. Patients record study medication taken each day in a pill diary. Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes. Relaxation diary completed stating whether patient was able to complete the sessions and whether they had any difficulties with it. Questionnaires completed at baseline, 2 months, and 4 months.
3098370|NCT01902953|Experimental|Lymphoseek and VBD SLN dissection|Ex-Vivo Lymphoseek and VBD SLN dissection
3098371|NCT01902940||Natural History|Assessment of natural history in IBM and CCFDN
3098372|NCT01902927|Experimental|COPD patients|COPD patients will perform a constant workrate treadmill exercise test until exhaustion with positve/neutral/negative visual distraction images during the exercise test assigned in a randomized order
3098373|NCT01902914|Experimental|Hearing Aids, Model P02|A body-worn, local made, digital hearing aids Hearing Aids evaluation
3098374|NCT01902914|Active Comparator|Other hearing aids|Other Hearing Aids, Hearing Aids Evaluation
3098375|NCT01902901|Active Comparator|Usual care|Requested carrier status testing.
3098376|NCT01902901|Experimental|Whole Genome Sequencing|These participants will receive the carrier status testing they requested from their provider, plus whole genome sequencing.
3098377|NCT01902888||Popliteal aneurysm|GORE® VIABAHN® Endoprosthesis used to treat popliteal aneurysm
3098378|NCT01902875||TP regimen + CIK group|This group are treated with Preconditioning Chemotherapy （Paclitaxel + Cisplatin） Combined with Cytokine Induced Killer Cell Immunotherapy （CIK cell therapy）.
3098379|NCT01902875||TP regimen group|This group are treated with Chemotherapy （Paclitaxel + Cisplatin） only.
3098380|NCT01902862|Experimental|Bortezomib plus rituximab|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3. Rituximab will be administered as intravenous infusion as 375 mg per m^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
3098381|NCT01902849||Group 1 - TIVA-TCI|"include 35 patients with colorectal cancer undergoing surgery~anaesthesia is induced and maintained with total intravenous target-controlled infusion ( TIVA-TCI) of propofol and remifentanil.~for propofol initial target plasma concentration (Cp) is set to 4 micrograms/ml (modified Marsh model)( Base Primea™, Fresenius, France) and then adjusted in steps 0.2 micrograms/ml to maintain the BIS values between 40-55 during surgery.~for Remifentanil initial Cp is set at induction at 4 ng/ml and then the Cp is maintained between 3-8 ng/mL(increments of 0.5 ng/ml in case of inadequate anesthesia).~intervention:blood sampling for IL measurement"
3098382|NCT01902849||Group II- ISOFLURANE|"include 35 patients with colorectal cancer undergoing surgery~anesthesia is induced with propofol bolus 1,5-2 mg/kg and remifentanil TCI mode (Minto model) (Base Primea™, Fresenius, France) with an initial Cp 4 ng/ml~maintenance of anesthesia is achieved with isoflurane 1-1.5 MAC in order to maintain the BIS value between the values of 40-55 and remifentanil TCI with Cp between 3-8 ng/mL (increments of 0.5 ng/ml in case of inadequate anesthesia)~intervention:blood sampling for IL measurement"
3098383|NCT01902836|Experimental|Conventional Treatment plus DLE|"Conventional treatment plus DLE~Conventional treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend;~Dialyzed Leukocyte Extracts as Adjuvant Treatment: oral DLE (Transferon) (2mg/5mL), then every day for 5 days, and then every 72hrs to complete one month."
3098384|NCT01902836|Placebo Comparator|Conventional treatment plus placebo|"Conventional treatment plus placebo:~oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend; plus oral placebo, every day for 5 days, then every 72hrs to complete one month."
3098385|NCT01902823|No Intervention|No Nurse Navigator Services|
3098386|NCT01902823|Experimental|Services from a Nurse Navigator|
3098387|NCT01902810|Active Comparator|Propranolol|Propranolol by mouth given daily throughout hospitalization
3098388|NCT01902810|Placebo Comparator|Sugar Pill|Placebo by mouth given daily throughout hospitalization
3098389|NCT01902797|Experimental|Household|In each camp, the camp residences are divided into different sections (as clusters for sampling) by camp registration. In the first stage, sections are selected using Population-proportion-to size (PPS) method. In the second stage, households are randomly selected from the household list in each section provided by NGO and local committee. When a household is not responding, a nearest household on the north will be used as replacement. All family members and overnight guests aged above 5 years in the selected household will be invited for venous blood sample (2 ml); for children aged 1-5 years old, the blood sample (100 microL) will be obtained by finger prick; children younger than 1 year old are excluded. The head of household will be invited for a short questionnaire.
3098391|NCT01902784|No Intervention|Monitoring of well-being|Participants assigned to the Monitoring of well-being group will receive follow up phone calls from study staff and be evaluated with questionnaires at baseline, 3 months, and 6 months after the death of their loved one (ICU patient).
3098392|NCT01902771|Experimental|DC Vaccine + Lysate|"Leukapheresis: Baseline, post-surgery;~Dendritic Cell Vaccine (DC Vaccine): Post-Leukapheresis, administered intradermally once weekly via intradermal injection, for 4 weeks for a total of four vaccinations;~Tumor Lysate (Lysate): Post-DC Vaccine therapy. Administered intradermally during weeks 8, 12, 16, and 28;~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
3098393|NCT01902758|Experimental|ambrisentan and theophylline|ambrisentan (5mg) once daily for 2 consecutive days theophylline (400mg) once daily for 2 consecutive days
3098394|NCT01902758|Placebo Comparator|placebo|matched placebo tablets wil be given at the same time to the comparison group as the medications to the experimental group
3098395|NCT01902745|Active Comparator|Fatigue Reduction Diet|"The FRD maintains a participant on a diet with their typical caloric intake and replaces some of their calories with the following foods on a daily basis; whole grains, vegetables (one leafy green, one tomato, and on yellow/orange), fruit (one high in vitamin C), fatty fish and nuts and/or seeds.~A social cognitive theory intervention method will take place that motivates the participant to change their behavior and lifestyle for overall well being."
3098396|NCT01902745|Active Comparator|General Health Curriculum|"Counseling sessions on oral health, healthy eyesight, over-the-counter drug disposal, skin and hair health, cell phone and health, hearing loss, colorectal cancer screening, and preventing colds and flu.~A social cognitive theory intervention method will take place that motivates the participant to change their behavior and lifestyle for overall well being."
3098397|NCT01902732|Other|Implantation of valves (IBV)|Following catheter-based measurement of collaertal ventilation, each patient is treated by a complete occlusion of the targeted lobe by intrabronchial valves.
3098398|NCT01902719|Experimental|Community Health Worker (CHW) Intervention|Participants randomized to this arm will receive the Community Health Worker Intervention that will include training in the use of home blood pressure machine, education on diet and exercise, and one-on-one support to assist with overcoming barriers to hypertension control (e.g., accessing healthcare, social and community services).
3098399|NCT01902719|Experimental|CHW Intervention and Communication Skills Training|Participants randomized to this arm will receive the Community Health Worker Intervention and a communication skills training to partner with their physician providers in a way that encourages their greater involvement and shared decision-making with their physicians about hypertension care.
3098400|NCT01902719|Experimental|CHW and Problem Solving Skills Training|Participants randomized to this arm will receive the Community Health Worker Intervention and the Problem Solving Skills Training Intervention, a 9-week peer based self-management intervention to help patients improve their hypertension self-management by learning and employing skills to overcome their self-identified barriers to self-management.
3098401|NCT01902693||HIV & chemotherapy|"Participants will be aged ≥ 18 years, aware of their HIV status and the diagnosis of malignancy, have a plasma viral load of < 50 HIV-1 RNA copies/ml (on suppressive HAART) at enrolment and be designated to receive cytotoxic chemotherapy including one or more of the following agents: R-CHOP, ABVD, Liposomal doxorubicin (Caelyx) or liposomal daunorubicin (Daunoxome) or Paclitaxel.~There is no intervention for this study. Blood samples will be taken and if available from routine care surplus cerebrospinal fluid."
3098402|NCT01902680|Experimental|Focal brachytherapy|Focal brachytherapy with permanent I125 localized implant.
3098403|NCT01902667||Curative intent surgery alone|Patients with retroperitoneal sarcoma randomised into surgery alone arm.
3098404|NCT01902667||Pre-operative radiotherapy plus surgery|Patients with retroperitoneal sarcoma randomised to Arm 2: pre-operative radiotherapy plus surgery.
3098405|NCT01902654||Knee osteoarthritis|Patients over 50 years who presented to an outpatient rheumatology for 1 year and who had knee osteoarthritis.
3098406|NCT01902654||Hand osteoarthritis|Patients over 50 years who presented to an outpatient rheumatology for 1 year and who had hand osteoarthritis.
3098407|NCT01902654||Soft tissue disease|All patients over 50 years who presented during the same period of time of other cohorts, to an outpatient rheumatology and who had soft tissue disease with no other rheumatic condition.
3098408|NCT01902641|Active Comparator|Succinylcholine|Patient received succinylcholine as a muscle relaxant(0.5 mg /kg)for induction of anaesthesia for rigid bronchoscopy.
3098409|NCT01902641|Active Comparator|Rocuronium/Sugammadex|Patient received rocuronium (0.25 mg/ kg) as muscle relaxant for induction of anaesthesia for rigid bronchoscopy, at the end of procedure rocuronium was reversed with sugammadex (0.5mg/kg.)
3098410|NCT01902641|Active Comparator|Rocuronium|Patients received rocuronium (0.25 mg /kg)as muscle relaxant for induction of anaesthesia for rigid bronchoscopy.
3098411|NCT01902628||Participants with CKD|This single cohort included participants with CKD not receiving dialysis (Stages 3 and 4), with renal anemia, treated with MIRCERA according to usual clinical practice.
3098412|NCT01902615||Cohort|
3098413|NCT01902589||Patients with Helicobacter pilorii in biopsy|Patients with Helicobacter pylori in biopsy, cultures will be obtained and subsequently sensitivity to antibiotics studied.
3098414|NCT01902550|Experimental|Metoprolol plus placebo then Metoprolol plus JNJ-54452840|Metoprolol tartrate immediate-release (metoprolol IR) will be administered as single oral dose of 100 milligram (mg) tablet or capsule. After two hours, placebo (normal saline) will be administered intravenously over 1 minute on Day 1.
3098415|NCT01902550|Experimental|Metoprolol plus JNJ-54452840 then Metoprolol plus placebo|Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule. After two hours, JNJ-54452840 (12 milliliter [ml] solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
3098416|NCT01902537||Participants With Constipation|Participants with constipation receiving prucalopride will be observed for for the health related quality of life (QoL).
3098417|NCT01902524|Experimental|Fentanyl-TTS|Study drug administered in a form of one patch, either 21.0 cm2 or 10.5 cm2.
3098418|NCT01902511|Experimental|G-CSF + Erythropoietin|
3098419|NCT01902511|Active Comparator|G-CSF|
3098420|NCT01902498|Experimental|Aspirin 162mg twice daily|Patients will receive 162mg twice daily during the postoperative period, until day 7 postop or the end of hospitalization.
3119339|NCT01758757|Active Comparator|Proliferative diabetic retinopathy|
3098421|NCT01902498|Active Comparator|Aspirin 325mg daily|Patients will receive 325mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
3098422|NCT01902498|Active Comparator|Aspirin 81mg daily|Patients will receive 81mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
3098423|NCT01902485|Active Comparator|Quickstart|Immediate start
3098424|NCT01902485|Active Comparator|Afterstart|Delayed start
3098425|NCT01902472||FTC/TDF for PrEP|HIV-1 negative adults (any sex/gender, including transgender) who seroconvert while taking FTC/TDF for PrEP
3098426|NCT01902459|Active Comparator|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch consists of human fibrinogen and human thrombin embedded in a flexible composite patch component.
3098427|NCT01902459|Other|Standard of Care|Standard of Care (SoC) is manual compression with or without a topical absorbable hemostat.
3098428|NCT01902446||Chlorhexidine gluconate|Intubated subjects transported by one air service will be treated with 5 mL chlorhexidine gluconate 0.12% applied for at least 30 seconds during helicopter transport.
3098429|NCT01902446||Normal saline (placebo)|Intubated subjects assigned transported by another air service will not have any additional treatment (in addition to usual care) during helicopter transport.
3098430|NCT01902433|Experimental|Astym|A form of soft tissue mobilization using instruments
3098431|NCT01902433|Active Comparator|Eccentric Exercise|Eccentric exercise is a form of exercise where the benefit comes from applying a controlled lengthening stress to the muscle and tendon.
3098432|NCT01902420||patients with acromegaly|patients with acromegaly caused by a growth hormone secreting pituitary adenoma
3098433|NCT01902420||healthy control|healthy volunteers without a personal or family history of pituitary adenoma
3098434|NCT01902407||Diagnostic MRI and CT scan of the airway|"All patients seen at CCHMC (up to 90 years of age) who are scheduled to have a clinical sleep MRI or CT scan for their OSA airway or lung disease.~Scheduled for both Sleep diagnostic tests (Sleep MRI and CT scans)."
3098435|NCT01902394|Experimental|Whole grain rich diet|Participants in the whole grain (WG) group will receive a diet providing 100% of energy requirements in a diet rich in whole grains.
3098436|NCT01902394|Placebo Comparator|Refined grain rich diet|Participants in the refined grain (RG) group will receive a diet providing 100% of energy requirements in a diet rich in refined grains.
3098437|NCT01902394|No Intervention|Negative control|Subjects randomized to the negative control group will consume their own usual diet (i.e. not receive foods and beverages from the study).
3098438|NCT01902381|Experimental|Treatment (6, 8-bis(benzylthio) octanoic acid)|Patients receive treatment 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3098439|NCT01902368|Other|screen detected, early diagnosis cohort|Subjects will be informed they have celiac disease and will be started on the gluten free diet.
3098440|NCT01902368|No Intervention|screen detected, delayed diagnosis cohort|Subjects will not be told they have celiac disease and will not start the gluten free diet.
3098441|NCT01902355|Experimental|modified Seldinger technique|Use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
3098442|NCT01902355|Active Comparator|Seldinger technique|The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
3098443|NCT01902342|Experimental|CES1 gene variant group|Oseltamivir 75 mg 1 cap
3098444|NCT01902342|Experimental|CES1 gene wild type group|Oseltamivir 75 mg 1 cap
3098445|NCT01902329|Experimental|SGN-CD33A + HMA|SGN-CD33A with hypomethylating agent
3098446|NCT01902329|Experimental|SGN-CD33A Monotherapy|SGN-CD33A
3098447|NCT01902303|Placebo Comparator|Matching Placebo|Matching Placebo
3098448|NCT01902303|Experimental|BTL-TML-HSV|Experimental Product
3098449|NCT01902290|Placebo Comparator|Placebo|Administered by subcutaneous (SC) injections until week 24.
3098450|NCT01902290|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injections until week 24.
3098451|NCT01902277||Adult critically ill patients|All adult patients treated within study time frame on Intensive Care Units across Norfolk, Suffolk, and Cambridgshire, UK
3098452|NCT01902264|Experimental|EE20/DRSP/L-5-MTHF|
3098453|NCT01902251|Experimental|Enzalutamide tablet|Multiple once daily oral doses of enzalutamide formulated as a tablet for approximately 8 weeks
3098454|NCT01902251|Active Comparator|Enzalutamide capsule|Multiple once daily oral doses of enzalutamide formulated as liquid-filled soft gelatin capsule for approximately 8 weeks
3098455|NCT01902238|Experimental|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol/lipiodol (1:1 mixture), typically 1 to 1.5 ml.
3098456|NCT01902225|Experimental|Istodax, Doxil|"Istodax; Intravenous; 8-14 mg/m2; Days 1, 8, and 15; over 4 hours~Doxil; Intravenous; 20 mg/m2; Day 1; over 1 hour"
3098457|NCT01902212|Experimental|Oral Nutritional Supplement|2 servings a day
3098458|NCT01902199|Active Comparator|TRAA|participants will be given the active TRAA intervention where landscape images are linked with a push motion, and portrait images linked with a pull motion. Pictures will exclusively be related to smoking.
3098459|NCT01902199|Placebo Comparator|Control|participants will be given a mix of landscape and portrait pictures, equally divided into push or pull. the images will be a mix of smoking related pictures and non smoking pictures.
3098460|NCT01902186|Experimental|raltegravir|raltegravir and atazanavir and ritonavir
3098461|NCT01902186|Active Comparator|tenofovir/emtricitabine|tenofovir/emtricitabine and atazanavir and ritonavir
3098500|NCT01901926|Active Comparator|Periodontal Treatment|"Periodontal Treatment in the form of Full mouth scaling and root planning will be given at one time only i.e. at baseline after full mouth dental checkup.~Checkup will be repeated at 3, 6 & 9 month interval along with HbA1C levels"
3098462|NCT01902173|Experimental|Treatment (Akt inhibitor GSK2141795, dabrafenib, trametinib)|"Dabrafenib and Akt inhibitor GSK2141795: Patients receive dabrafenib PO BID and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Dabrafenib, trametinib, and Akt inhibitor GSK2141795: Patients receive dabrafenib PO BID, trametinib PO QD, and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity"
3098463|NCT01902160|Experimental|Treatment (temsirolimus, brentuximab vedotin)|Patients receive temsirolimus IV over 30-60 minutes on days 1 and 8 or days 1, 8, and 15 and brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
3098464|NCT01902147||Elective major abdominal, thoracic, and arthroplasty surgery|All consenting patients scheduled for elective major abdominal, thoracic, and arthroplasty surgery will be followed for 8 weeks after surgery to measure the quality of recovering using the PQRS.
3098465|NCT01902134|Experimental|DKP/TRAM followed by DKP/TRAM|Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
3098466|NCT01902134|Active Comparator|DKP followed by DKP|Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
3098467|NCT01902134|Active Comparator|TRAM followed by TRAM|Tramadol-single dose followed by Tramadol-multiple doses
3098468|NCT01902134|Other|Placebo followed by DKP/TRAM|Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
3098469|NCT01902134|Other|Placebo followed by DKP|Placebo single dose followed by Dexketoprofen-multiple doses
3098470|NCT01902134|Other|Placebo followed by TRAM|Placebo single dose followed by Tramadol-multiple doses
3098471|NCT01902121|Experimental|TI 30 units (10 unit + 20 unit|Technosphere® Insulin 30 units given as 2 cartridges: one 10 unit cartridge + one 20 unit cartridge
3098472|NCT01902121|Experimental|TI 30 units (30 unit cartridge|Technosphere® Insulin 30 units given as one 30 unit cartridge
3098473|NCT01902108|Experimental|Clonidine|Clonidine 150μg added to bupivacaine in a local infiltration before wound incision
3098474|NCT01902108|Active Comparator|Bupivacaine|Bupivacaine 0.25 % alone in the wound infiltration
3098475|NCT01902095|Experimental|Tooth powder (test) arm|Experimental arm: tooth powder
3098476|NCT01902095|Active Comparator|Tooth Paste (control)|Tooth Paste
3098477|NCT01902082|Experimental|Mesenchymal stem cell arm|Patients received one dose of 1x 10^6 allogeneic adipose-derived mesenchymal stem cells/kg body weight intravenously within 48 hours of enrollment.
3098478|NCT01902082|Placebo Comparator|Placebo|Patients received one dose of normal saline.
3098479|NCT01902069|Experimental|Phosholean dietary supplement|Subjects in the PhosphoLean group will receive two capsules of PhosphoLEAN orally daily (total of 55 mg of NOPE and 100 mg of EGCG), one capsule consumed 60 minutes prior to lunch and one capsule 60 minutes prior to dinner.
3098480|NCT01902069|Placebo Comparator|Placebo (rice flour) group|The control (placebo) group will receive a placebo (identical in appearance, but containing 100 mg of rice flour per capsule), one capsule consumed 60 minutes prior to lunch and one capsule 60 minutes prior to dinner.
3098481|NCT01902056|Active Comparator|one layer allograft|One layer allograft as a positive control
3098482|NCT01902056|Experimental|Two layer allograft|Two layer allograft as the test group.
3098483|NCT01902030||Proven/Probable IA Patients|Case Population
3098484|NCT01902030||possible/No IA Patients|Control population
3098485|NCT01902017|Experimental|Operative, Ketotifen|Ketotifen 5mg orally twice per day for 6 weeks.
3098486|NCT01902017|Experimental|Non-operative, Ketotifen|Ketotifen 5mg orally twice per day for 6 weeks.
3098487|NCT01902017|Placebo Comparator|Operative, Placebo|Placebo oral medication twice daily for 6 weeks.
3098488|NCT01902017|Placebo Comparator|Non-operative, Placebo|Placebo oral medication twice daily for 6 weeks.
3098489|NCT01902004|Active Comparator|Escitalopram and Memantine|Participants will take a combination of Escitalopram and Memantine for 12 months
3098490|NCT01902004|Active Comparator|Escitalopram and placebo|Participants will take a combination of Escitalopram and placebo for 12 months
3098491|NCT01901991|Experimental|Radioactive seed localization (RSL)|"Patients are randomised for preoperative lesion localization with either radioactive seed localization (RSL) or wire-guided localization (WGL).~In this arm 205 patients will have RSL performed. The radioactive seed is introduced through a gauge needle using standard ultrasound guidance. Once guided to the nonpalpable breast lesion, the seed is deployed into the breast tissue by advancing a stilette in the needle. The exact location is confirmed by mammography. The nonpalpable lesion is located during the operation with a handheld gamma probe, identical to the one used for the sentinel node procedure. The surgical specimen is orientated and examined at the Department of Radiology and Pathology in accordance with the existing guidelines of WGL."
3098492|NCT01901991|Active Comparator|Wire-guided localization (WGL)|"Patients are randomised for preoperative lesion localization with either radioactive seed localization (RSL) or wire-guided localization (WGL).~In this arm 205 patients will have WGL performed. Guided by ultrasound or mammography a flexible wire is introduced into the breast by the radiologist just before the operation. The tip of the wire must mark the nonpalpable lesion, and correct localization is verified by mammography. The surgeon uses the wire and mammography as a guide during the operation. The surgical specimen is orientated and examined at the Department of Radiology and Pathology in accordance with the existing guidelines of WGL."
3098493|NCT01901978|Experimental|Weight Loss|Caloric restrictive diet
3098494|NCT01901965|Experimental|NMES|neuromuscular electrical stimulation (NMES) of the quadriceps muscle with Kneehab
3098495|NCT01901965|Experimental|eccentric training|unilateral eccentric resistance exercises
3098496|NCT01901965|Sham Comparator|sham NMES|neuromuscular electrical stimulation of the quadriceps muscle with intensity which causes no visible contraction or displacement of the leg (activation below motor threshold)
3098497|NCT01901952|Active Comparator|Standard of care|
3098498|NCT01901952|Experimental|Intensive education and support|
3098499|NCT01901939|Experimental|exercise|daily bedside tailored low intensity pedaling exercise
3098501|NCT01901926|No Intervention|Non treatment group|this group will only receive detailed dental check ups at the specified time 0, 3, 6 and 9 months respectively and there will be no scaling done. HbA1C levels will be estimated at the above specified times
3098503|NCT01901913|Active Comparator|No MD-bolus calculator for pre-meal bolus|closed loop session without MD-bolus calculator for pre-meal bolus
3098504|NCT01901887|Experimental|Study Juice|"3,300 mg of Omega-3 HUFAs per day for 6 months~Other names: none"
3098505|NCT01901887|Placebo Comparator|Placebo Juice|"3,300 mg of macadamia nut oil per day for 6 months~Other names: none"
3098506|NCT01901861|Active Comparator|Sitagliptin|Sitagliptin 100mg is given before meal ingestion
3098507|NCT01901861|Placebo Comparator|Placebo|Placebo is given before meal ingestion
3098508|NCT01901848|Experimental|CPT+ICSC|This arm includes 12 sessions of Cognitive Processing Therapy, or CPT, 6 sessions of Integrated Care for Smoking Cessation (ICSC), involvement in smokefreeVET.gov's text messaging program for smoking cessation, Bupropion use, and nicotine replacement therapy.
3098509|NCT01901848|Active Comparator|ICSC only|This arm includes 6 sessions of Integrated Care for Smoking Cessation (ICSC), involvement in smokefreeVET.gov's text messaging program for smoking cessation, Bupropion use, and nicotine replacement therapy.
3098510|NCT01901835|Experimental|Arm I (humorous followed by non-humorous movies)|Participants are provided headphones and a tablet and choose among a selection of humorous movies. Upon the third course of chemotherapy, participants are provided a selection of non-humorous movies.
3098511|NCT01901835|Experimental|Arm II (non-humorous followed by humorous movies)|Participants are provided headphones and a tablet and choose among a selection of non-humorous movies. Upon the third course of chemotherapy, participants are provided a selection of humorous movies.
3098512|NCT01901822|Active Comparator|Sutured separately|The soft tissue and the allograft will each be sutured separately using a continuous sling suture.
3098513|NCT01901822|Experimental|Sutured together|The soft tissue and the allograft will be sutured together using a continuous sling suture.
3098514|NCT01901809|Active Comparator|Bolus furosemide and no dopamine|"If the patient is not on a prior diuretic dose, a standard dose of furosemide 40mg IV every 12 hrs, with total dose of 80 mg IV over 24 hrs will be initiated.~If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose every 12 hrs. (i.e if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose will be furosemide 80mg IV twice daily)."
3098515|NCT01901809|Active Comparator|Continuous infusion furosemide and no dopamine|"If the patient is not on a prior diuretic dose, a standard dose of furosemide 80mg IV over 24 hrs, will be initiated.~If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose continuously over 24 hrs. . (i.e. if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose would be furosemide 160mg IV to be administered continuously over 24 hrs)."
3098516|NCT01901809|Active Comparator|Bolus furosemide plus dopamine|Intermittent furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min
3098517|NCT01901809|Active Comparator|Continuous furosemide plus dopamine|Continuous furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min
3098518|NCT01901796|Experimental|Screening and CBT|Screening and Cognitive Behavioral Therapy. The intervention group will be screened and if they need criteria they will complete the 6, 30-minute online, interactive CBT modules over 6 weeks.
3098519|NCT01901796|No Intervention|Usual care|Usual prenatal care
3098520|NCT01901783|Active Comparator|With primary closure|The ridge augmentation graft will be covered with a barrier membrane and the soft tissue will be primarily closed.
3098521|NCT01901783|Experimental|Without primary closure|The ridge augmentation graft will be covered with a barrier membrane and the soft tissue will not be primarily closed.
3098522|NCT01901770|Experimental|Arm I-HPV vaccine education|"The educational intervention is that parents and providers receive materials about HPV by mail including HPV/ cervical cancer videos and brochures, fact sheets, HPV/cervical cancer resource lists. Clinics receive posters, brochures, tabletop/reminder cards, resource lists, newsletters, and invitation to be vaccinated letters for parents."
3098523|NCT01901770|Active Comparator|Arm II- Flu vaccine education|The educational intervention is that parents and providers receive materials about Flu by mail including Flu brochures, fact sheets, Flu resource lists. Clinics receive posters and brochures.
3098524|NCT01901757|Experimental|HCP1201, Fasted followed by fed|HCP1201 dosing in the fasted state followed by fed dosing
3098525|NCT01901757|Experimental|HCP1201, Fed followed by fasted|HCP1201 dosing in the fed state followed by fasted dosing
3098526|NCT01901744|Experimental|Patients undergoing cataract surgery|
3098527|NCT01901731|Experimental|Embolisation of pelvic veins & treatment of leg varicose veins|Transjugular coil embolisation of pelvic veins followed by endovenous treatment of leg varicose veins
3098528|NCT01901731|Active Comparator|Endovenous treatment of leg varicose veins alone|Endovenous treatment of legs varicose veins only
3098529|NCT01901718||Subsys|Cancer patients experiencing breakthrough pain.
3098530|NCT01901705|Active Comparator|Indigo|The Indigo naturalis ointment will be provided and patients are instructed to use it twice daily for 8 weeks or achieve completely skin clearing whichever comes first.
3098531|NCT01901705|Placebo Comparator|Placebo|The Placebo will be provided and patients are instructed to use it twice daily for 8 weeks or achieve completely skin clearing whichever comes first.
3098532|NCT01901692|Experimental|TACE+External beam RT|Transarterial chemoembolization plus external beam radiation therapy
3098533|NCT01901692|Active Comparator|Sorafenib|Sorafenib 800 mg/day orally
3098534|NCT01901679|Experimental|Celebrex|10 days treatment with Celebrex to evaluate reduction of PGE-M in urine
3098535|NCT01901666|Experimental|Growth hormone deficient group|0.3mg/kg/week GH in seven divided doses will be given subcutaneously for one year.
3098536|NCT01901653|Experimental|Rovalpituzumab tesirine|Rovalpituzumab tesirine will be administered as a single agent, at increasing dose levels as permitted based on real-time assessment of safety and tolerability, intravenously over 30 minutes. Doses will be repeated on Day 1 of each 21-day or 42-day cycle until either unacceptable toxicity or evidence of disease progression occurs.
3098537|NCT01901640|Experimental|DA-8159|Udenafil(The study had one arm.)
3098538|NCT01901627||Adalimumab|Chinese adult patients with a diagnosis of AS who meet the requirements per the local label for treatment with adalimumab.
3098586|NCT01901276|Experimental|Omeprazole 40 mg bid x 4-8 weeks|See study description for further details.
3098539|NCT01901614|Experimental|LALAK|laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.
3098540|NCT01901614|Active Comparator|IEK|Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.
3098541|NCT01901601|Experimental|LALAK|laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.
3098542|NCT01901601|Active Comparator|IEK|Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.
3098543|NCT01901588|Experimental|Dexmedetomidine|dexmedetomidine/precedex
3098544|NCT01901588|Placebo Comparator|Placebo|patients receive saline solution.
3098545|NCT01901575|Experimental|Remifentanil IV PCA|patients with PVC's prior to administration of remifentanil
3098546|NCT01901562|Experimental|Ductoscopic papillomectomy|Ductoscopic papillomectomy to treat pathological nipple discharge
3098547|NCT01901549|Active Comparator|PCI+Renal denervation|
3098548|NCT01901549|Active Comparator|PCI alone|
3098549|NCT01901536|Experimental|Intervention Group|Couples randomly assigned to the Intervention Group received the Family Foundations Coparenting Program.
3098550|NCT01901536|No Intervention|Control Group|Couples in the Control group did not receive the Family Foundations Coparenting Program.
3098551|NCT01901523|Experimental|Provision of information|Reporting of discrepancy to journal
3098552|NCT01901510|Active Comparator|chromoendoscopy|The intervention arm will have Indigo carmine added to the colonic preperation to perform chromoendoscopy
3098553|NCT01901510|Other|Control|The control arm will have minimal Indigo carmine added to the colonic prep in a concentration which will not be enough to perform chromoendoscopy
3098554|NCT01901497|Experimental|Solo nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb Solo nebulizer associated with a bilevel ventilator
3098555|NCT01901497|Experimental|Pro nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb Pro nebulizer associated with a bilevel ventilator
3098556|NCT01901497|Experimental|NIVO nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb NIVO nebulizer associated with a bilevel ventilator
3098557|NCT01901484|Active Comparator|Drug: Praziquantel|Praziquantel 40mg/Kg - single dose
3098558|NCT01901484|Active Comparator|Praziquantel|double dose
3098559|NCT01901471|Experimental|CsA Group|
3098560|NCT01901471|Placebo Comparator|Placebo group|
3098561|NCT01901458|Experimental|IDL-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® IDL-Set in combination with the Spectra Optia® cell separator and the WBC-D program
3098562|NCT01901458|Active Comparator|MNC-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® Collection Set in combination with the Spectra Optia® cell separator and the MNC program
3098563|NCT01901445|Experimental|Educational action group|
3098564|NCT01901445|No Intervention|Control group|
3098565|NCT01901432|Experimental|Givinostat|"In Part A patients will treated in dose levels at the following daily doses of Givinostat:~50 mg b.i.d.,~100 mg b.i.d.;~150 mg b.i.d.,~200 mg b.i.d.;~150 mg t.i.d.;~200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.~In Part B patients will be treated at the Maximum Tolerated Dose established in Part A.~The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each."
3098566|NCT01901419|Experimental|High-dose NTG|Nitroglycerin infusion 1-5 mcg/kg/min
3098567|NCT01901419|Active Comparator|Low-dose NTG|Nitroglycerin infusion 0-0.1 mcg/kg/min
3098568|NCT01901406||ERM|idiopathic epiretinal membrane patients
3098569|NCT01901393|Experimental|IV ibuprofen|800mg ibuprofen
3098570|NCT01901393|Active Comparator|ketorolac|30mg ketorolac
3098571|NCT01901380||extensively hydrolysed casein formula + LGG|children receiving extensively hydrolysed casein formula plus Lactobacillus GG
3098572|NCT01901380||other formulas|children receiving formulas without supplementation of Lactobacillus GG
3098573|NCT01901367|Experimental|Arm I (intervention)|Patients receive standard of care individualized diet and exercise plan and monthly booster follow-up sessions from the nutritionist and exercise physiologist and weekly phone counseling with a trained health coach to address barriers to improve plan adherence.
3098574|NCT01901367|No Intervention|Arm II (control)|Patients receive standard of care individualized diet and exercise plan
3098575|NCT01901354|Active Comparator|Low-tidal-volume ventilation|Subjects will be ventilated with a goal tidal volume of 6 cc/kg predicted body weight (PBW), a goal plateau pressure of <30 cm H2O, and a goal respiratory rate of 6‐35 bpm to achieve a goal arterial pH of 7.30 to 7.45. Positive end‐expiratory pressure is set as per the ARDSNet Positive end‐expiratory pressure table
3098576|NCT01901354|Active Comparator|Airway pressure release ventilation (APRV)|"Airway Pressure Release Ventilation (APRV) is a time cycled, inverse‐ratio, pressure controlled strategy that allows spontaneous breathing throughout the respiratory cycle.~Initial settings: Pressure high will be set initially to equal the plateau pressure on baseline ARDSNet settings. Time low will be set to 0.5‐0.8 seconds to achieve an end expiratory flow 25‐50% of peak expiratory flow, and Time high will be set to obtain a set respiratory rate 60%‐70% that of baseline settings. Time high will be adjusted to achieve similar continuous exhaled carbon dioxide levels as baseline ARDSNet settings. Low pressure will be set at <5 cm H20."
3098577|NCT01901341|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice daily (BID) for a 12-week treatment period
3098578|NCT01901341|Placebo Comparator|Placebo|Placebo administered orally BID for a 12-week treatment period
3098579|NCT01901328|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice dailly (BID) for a 12-week treatment period
3098580|NCT01901328|Placebo Comparator|Placebo|Placebo administered orally BID for a 12-week treatment period
3098581|NCT01901315|Experimental|Online consultation|Monthly video consultations with psychiatrist
3098582|NCT01901315|Experimental|Face-to-face consultation|Monthly face-to-face consultations with psychiatrist
3098583|NCT01901302|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice daily (BID) for a 12-week treatment period
3098587|NCT01901263||patient with alzheimer's disease|"Cohort of patients with psychological symptoms of dementia hospitalised in Cognitive and Behaviorial Units (CBUs)~Evaluation of these units through the observation of the behavioral and psychological symptoms of dementia evolution : NPI score, caregivers quality of life, caregivers burden, collection of psychotropic drugs, the rehospitalisation rate"
3098588|NCT01901250|Experimental|Xylitol GB|Xylitol gummy bears 7.8g/day throughout the 9 month kindergarten year, oral health education, fluoride varnish, and dental sealant
3098589|NCT01901250|Placebo Comparator|Fiber GB|Sugar free fiber gummy bears 20g/day throughout the 9 month kindergarten year, oral health education, fluoride varnish, and dental sealant
3098590|NCT01901237|Other|Hatha Yoga Program|Single-arm pilot study of a 7-week home/hospice-based Hatha yoga program for adolescent and young adults with non-curative cancer.
3098591|NCT01901224|Experimental|Metformin 1000 mg|Subjects will be randomized in a double-blind, placebo-controlled manner to 1) metformin 1000 mg twice daily or 2) matching placebo twice daily. In order to avoid gastrointestinal side effects, the starting dose of metformin will be 500 mg twice daily. After one week, the dose will be increased to 1000 mg twice daily (as two 500 mg tablets twice daily). In order to maintain blinding during the titration period, individuals randomized to placebo will receive one placebo tablet twice daily for one week, followed by an increase to 2 placebo tablets twice daily. Subjects will be instructed to take medications with breakfast and with dinner. All outcome measurements will be made at baseline and 12 weeks following randomization.
3098592|NCT01901224|Placebo Comparator|Control|Subjects will be randomized in a double-blind, placebo-controlled manner to 1) metformin 1000 mg twice daily or 2) matching placebo twice daily. In order to avoid gastrointestinal side effects, the starting dose of metformin will be 500 mg twice daily. After one week, the dose will be increased to 1000 mg twice daily (as two 500 mg tablets twice daily). In order to maintain blinding during the titration period, individuals randomized to placebo will receive one placebo tablet twice daily for one week, followed by an increase to 2 placebo tablets twice daily. Subjects will be instructed to take medications with breakfast and with dinner. All outcome measurements will be made at baseline and 12 weeks following randomization.
3098593|NCT01901211|Experimental|Exergaming|In this arm, the participants will participate in the exergaming intervention.
3098594|NCT01901211|No Intervention|Comparison Arm|In this arm of the study, participants will engage in their typical physical activity routines for the ten week duration. Participants will receive a call from the RA each week. The RA will ask the child to report on all the physical and social activities that they engaged in for that week.
3098595|NCT01901198|Experimental|Human Serum Albumin/interferon alpha2a|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.
3098596|NCT01901198|Active Comparator|Pegasys|Peginterferon 180 mcg single dose S.C.
3098597|NCT01901185|Experimental|Etanercept / Autoinjector A|Participants self-injected 50 mg etanercept subcutaneously using autoinjector A at the study center on Day 1 and then once a week from Weeks 1 to 5 (total of 6 injections).
3098598|NCT01901172|Experimental|Extension|
3098599|NCT01901172|Experimental|Part 1: Drug-drug interaction|
3098600|NCT01901172|Experimental|Part 2: Relative bioavailability|
3098601|NCT01901172|Experimental|Part 3: Food effect|
3098602|NCT01901159|Experimental|RO4995819 capsule|
3098603|NCT01901159|Experimental|RO4995819 tablet|
3098604|NCT01901146|Experimental|ABP 980|Epirubicin and cyclophosphamide followed by ABP 980 plus paclitaxel. Surgery (breast and sentinel node or axillary lymph node resection) will be completed within 3 to 7 weeks after the last dose of investigational product in the neoadjuvant phase.
3098605|NCT01901146|Active Comparator|trastuzumab|"Epirubicin and cyclophosphamide followed by trastuzumab plus paclitaxel.~Surgery (breast and sentinel node or axillary lymph node resection) will be completed within 3 to 7 weeks after the last dose of investigational product in the neoadjuvant phase."
3098606|NCT01901133|Experimental|A: Mild hepatic impairment subjects + control|
3098607|NCT01901133|Experimental|B: Moderate hepatic impairment subjects + control|
3098608|NCT01901120||Betanis|the usual adult dosage of mirabegron once daily after a meal
3098609|NCT01901107||Kiklin group|
3098610|NCT01901094|Other|Arm 1: ALND + nodal radiation therapy|"Surgery: For patients randomized to axillary lymph node dissection (ALND), it is recommended that a complete level I and II dissection with resection of minimum of a total of 8 lymph nodes (SLN and ALND together) be done. Level III dissection is not required, but may be performed at the discretion of the surgeon. If fewer than 8 lymph nodes (SLN and ALND together) are resected, then the patient will discontinue protocol treatment.~Radiation Therapy: Radiation is delivered to the breast/chest wall, undissected axilla, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks."
3098611|NCT01901094|Other|Arm 2: Axillary radiation and nodal radiation therapy|Radiation Therapy: Radiation is delivered to the breast/chest wall, full axilla including Levels I, II, III, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks.
3098612|NCT01901081|Experimental|Prosthetic Training with IMES prosthesis|
3098613|NCT01901068||MonoMax|Elective primary laparotomy
3098614|NCT01901055|Experimental|Active CPAP treatment|Treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP)
3098615|NCT01901055|Placebo Comparator|Sham-CPAP|Device that appears like the treatment of obstructive sleep apnea, a continuous positive airway pressure device, but that does not provide treatment.
3098616|NCT01901042|Experimental|Symbiotic|Patients in this group received sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
3098617|NCT01901042|Placebo Comparator|Maltodextrin|patients in this group received sachets five grams of maltodextrin per sachet with identical casing and identical aspect to the product of the other arm group, and were instructed to proceed in the same way as those of the symbiotic group
3098618|NCT01901029||men of floating population|males who live in Dongguan more than 6 months and without residence cards
3098619|NCT01901029||men of non-floating population|males who live in Dongguan more than 6 months and with residence cards
3098620|NCT01901016|Experimental|Jacobson progressive muscular relaxation|Jacobson progressive muscular relaxation
3098621|NCT01901016|Experimental|Schultz's autogenic training|Schultz's autogenic training
3098622|NCT01901016|No Intervention|control|
3098623|NCT01901003|Placebo Comparator|placebo group|placebo
3098624|NCT01901003|Active Comparator|no premedication group|no premedication
3098625|NCT01901003|Experimental|Lorazepam group|lorazepam
3098626|NCT01900990|Experimental|Noninvasive ventilation weaning|Patients in this group were weaned by noninvasive ventilation
3098627|NCT01900990|No Intervention|Conventional weaning|Patients in this group were weaned by conventional stratiges.
3098628|NCT01900977|Active Comparator|Arm A Universal Testing w/Immediate ART|
3098629|NCT01900977|Active Comparator|Arm B ART according to National Guidelines|
3098630|NCT01900977|Other|Standard of Care|"Includes:~Strengthening of HIV testing and ART services according to national guidelines at health facilities and other venues; Strengthening of male circumcision and PMTCT services available at health facilities and other venues in the community; and Treatment of STIs and provision of condoms at health facilities and other venues in the community."
3098631|NCT01900964|Active Comparator|PTFE membrane|A non-resorbable PTFE (polytetrafluoroethylene) membrane will be used as a positive control treatment.
3098632|NCT01900964|Experimental|Collagen membrane|A resorbable collagen membrane will be used in the test group.
3098633|NCT01900951|Experimental|Temozolomide|"Patients in the study will receive the following for the duration of the study:First-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cycles of therapy for the first-line chemotherapy. After first-line treatment, temozolomide will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.~Re-staging will be performed every 2 cycles (every 8 weeks) during the study"
3098634|NCT01900938|Active Comparator|Intermittent bolus injection of propofol|A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
3098635|NCT01900938|Active Comparator|Continuous infusion of propofol|Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
3098636|NCT01900925|Active Comparator|Low back treatment only (pragmatic)|"advise to stay active,~discourage bed rest,~appropriate medication use,~reassurance.~Short term use of manipulation/medication,~supervised exercise,~cognitive behavioral therapy,~multidisciplinary treatment,~termination of use of modalities."
3098637|NCT01900925|Experimental|LBP treatment and Hip treatment|Group two will receive the same pragmatically applied, guideline-oriented treatment that is recommended from group 1. In addition, group 2 will receive prescriptive hip exercises that include 1) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge, and the manual therapy treatment techniques of; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone.26 (See Appendix A for photos of the techniques and descriptions)
3098638|NCT01900912|Experimental|CLTS communities|Assigned to a community led total sanitation (CLTS) intervention, carried out by the government with support from Unicef (n=60 communities). The CLTS intervention includes a triggering session facilitated by the government to encourage community members to build their own latrines and stop open defecation. Regular monitoring is conducted by government program staff until the community is declared open defecation free.
3098639|NCT01900912|No Intervention|Rural communities|No intervention will be delivered (n=61 communities)
3098640|NCT01900899|Experimental|ACWY-TT group|Subjects primed and boosted with the MenACWY-TT vaccine.
3098641|NCT01900899|Active Comparator|MenCCRM group|Subjects primed and boosted with the Meningitec vaccine.
3098642|NCT01900886||Pegasys, injection subcutaneous|Hepatitis C Virus (HCV) patients monoinfected or coinfected, all genotypes, treatment naive to Peginterferon alfa-2a and Ribavirin (RBV)
3098643|NCT01900873|Experimental|Inspiratory Muscle Strength Training|High intensity inspiratory muscle training
3098644|NCT01900873|Sham Comparator|Inspiratory Muscle Endurance Training|Sham inspiratory muscle training at low intensity
3098645|NCT01900860|Active Comparator|vitamin D 10,000 IU|Subjects in this arm receive 10,000 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
3098646|NCT01900860|Active Comparator|Vitamin D 4000 IU|Subjects in this arm receive 4,000 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
3098647|NCT01900860|Active Comparator|Vitamin D 400 IU|Subjects in this arm receive 400 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
3098648|NCT01900847|Active Comparator|Morphine and placebo|Patient's will receive morphine during the usual course of their emergency department care and will receive a saline in a volume equivalent to the ketamine administered in the experimental arm of the stuy
3098649|NCT01900847|Experimental|Morphine and Ketamine|Patient's will receive a 0.3mg/kg dose of ketamine in addition to morphine given in the usual course of emergency department care
3098650|NCT01900834||All participants|
3098651|NCT01900821||Women|All women having mammograms
3098652|NCT01900808||Patients with chronic liver disease|
3098653|NCT01900795|Experimental|V117957|
3098654|NCT01900795|Active Comparator|Ibuprofen|
3098655|NCT01900795|Placebo Comparator|Placebo|
3098656|NCT01900782|Experimental|Dosing Regimen 1|Subcutaneous injection
3098657|NCT01900782|Active Comparator|Active Comparator|Subcutaneous injection
3098658|NCT01900782|Placebo Comparator|Placebo|Subcutaneous injection
3098659|NCT01900782|Experimental|Dosing Regimen 2|Subcutaneous injection
3098660|NCT01900769|Experimental|Blood Volume Dilution|
3098661|NCT01900756|Active Comparator|Behavioral|"Pre-appointment phone text~In-clinic educational video~Patient report card~Post-clinic phone text~Outpatient stroke registry"
3098662|NCT01900756|No Intervention|Standard care|Routine and customary management.
3098717|NCT01900379|No Intervention|control group|Patients without any apnea syndrome
3098663|NCT01900743|Experimental|Arm A|Regorafenib (160 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.
3098664|NCT01900743|Placebo Comparator|Arm B|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
3098665|NCT01900730|Placebo Comparator|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks. Patient contacted by phone to assess tolerance and instruction to increase dose. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
3098666|NCT01900730|Experimental|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
3098667|NCT01900717|Active Comparator|chimiotherapy alone|"LV5FU2 simplified,~5-fluorouracil/leucovorin with oxaliplatin 4 (FOLFOX) simplified,~fluorouracil, leucovorin, and irinotecan(FOLFIRI) modified."
3098668|NCT01900717|Experimental|chemiotherapy + bevacizumab 5 mg/kg/ 2 weeks|"LV5FU2 simplified,~FOLFOX 4 simplified,~FOLFIRI modified.~Bevacizumab 5 mg/kg/ 2 weeks"
3098669|NCT01900704|Experimental|SER120 750 ng|SER120 750 ng
3098670|NCT01900704|Experimental|SER120 1500 ng|SER120 1500 ng
3098671|NCT01900704|Placebo Comparator|Placebo|Placebo
3098672|NCT01900691|Experimental|Evolution® Esophageal Stent|
3098673|NCT01900678|Experimental|VytronUS Ablation System|Treatment with the VytronUS Ablation System.
3098674|NCT01900665|Experimental|Solanezumab|Solanezumab 400 milligrams (mg) every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.
3098675|NCT01900665|Placebo Comparator|Placebo|Placebo every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.
3098676|NCT01900652|Experimental|Arm A: Emibetuzumab plus Erlotinib|750 milligram (mg) Emibetuzumab flat dose given as a 1.5 hour intravenous (IV) infusion on Days 1 and 15 of a 28-day cycle and Erlotinib 150 mg given orally once daily on a 28-day cycle.
3098677|NCT01900652|Experimental|Arm B: Emibetuzumab|750 mg Emibetuzumab flat dose given as a 1.5-hour IV infusion on Days 1 and 15 of a 28-day cycle.
3098678|NCT01900639|Active Comparator|aspirin on awakening|intake of 80 acetylsalicylic acid on awakening for 2 weeks
3098679|NCT01900639|Experimental|aspirin at bedtime|intake of 80mg acetylsalicylic acis at bedtime
3098680|NCT01900626|Active Comparator|single epidural catheter|
3098681|NCT01900626|Active Comparator|double epidural catheter|
3098682|NCT01900613|Experimental|Intervention|Niños Sanos Familia Sana consists of CBPR developed nutrition education and economic vouchers for fruit and vegetable purchase in Firebaugh supermarket
3098683|NCT01900613|Active Comparator|Comparison|Comparison community of San Joaquin
3098684|NCT01900600|Placebo Comparator|Placebo|Placebo
3098685|NCT01900600|Active Comparator|Canakinumab 50 mg quarterly|Canakinumab 50 mg quarterly
3098686|NCT01900600|Active Comparator|Canakinumab 150 mg quarterly|Canakinumab 150 mg quarterly
3098687|NCT01900600|Active Comparator|Canakinumab 300 mg quarterly|Canakinumab 300 mg quarterly
3098688|NCT01900587|Experimental|Tapentadol Extended release (ER) TRF then tapentadol ER PR2|Single dose of tapentadol ER 50 milligram (mg), tamper-resistant formulation (TRF) tablet will be administered under fasted condition in first treatment period; after that in second treatment period, single-dose of tapentadol ER 50 mg, prolonged released (PR2) tablet will be administered under fasted condition. A washout period of 7 to 14 days will be maintained between each treatment period.
3098689|NCT01900587|Experimental|Tapentadol ER PR2 then tapentadol ER TRF|Single dose of tapentadol ER 50 milligram (mg), PR2 tablet will be administered under fasted condition in first treatment period; after that in second treatment period, single-dose of tapentadol ER 50 mg, TRF tablet will be administered under fasted condition. A washout period of 7 to 14 days will be maintained between each treatment period.
3098690|NCT01900574|Experimental|Golimumab|
3098691|NCT01900561|Experimental|IVR Intervention|The intervention will consist of two components, both with content design based on established theories for self-management support: 1) automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach, and 2) personally tailored newsletters that incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Intervention-group participants will receive four automated assessment and self-management support calls over a 3-month period (at baseline, 1-month, 2-month, 3-months). Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
3098692|NCT01900561|No Intervention|Enhanced Usual Care|Because of the strong evidence documenting symptom burden in PC survivors, the investigators believe that providing control subjects with some information about symptom self-management is warranted. The investigators further believe, based on the investigators' prior experience conducting RCTs, that offering some type of educational material for Veterans randomized to the control arm will increase their willingness to enroll in the study (as opposed to a pure usual care arm where they would not receive any such materials). Therefore, survivors randomized to the control condition will receive written material at the time of enrollment designed to educate them about PC symptoms and symptom management. Material will be approximately six pages in length, also written at or below an 8th grade reading level, and will include a summary of common symptoms experienced by prostate cancer survivors.
3098693|NCT01900548|Experimental|Whey protein (HPHL)|Whey protein supplementation and resistance training for four month.
3098694|NCT01900548|Experimental|Soy protein (HPLL)|Soy protein supplementation and resistance training for four month.
3098695|NCT01900548|Placebo Comparator|Placebo (P)|Maltodextrin supplementation and resistance training for four month.
3098696|NCT01900522|Experimental|Multiple Rising Dose (MRD) Phase: Ascending ITI-214 Doses|ITI-214 Doses (A, B, C, D, matching placebo), solution, orally, once daily for 14 days.
3098697|NCT01900522|Experimental|Neuroimaging Phase: ITI-214 Doses|ITI-214 (E,F, G, H, matching Placebo) Oral solution, once daily for 7 days in 3 periods with placebo and two of the ITI-214 Doses (E, F, G and H) in a cross-over fashion with minimum 7 days washout between periods
3098698|NCT01900509|Experimental|Treatment|"All participants who meet eligibility for this study will follow the same treatment regimen.~INTERVENTIONS: bendamustine, clofarabine, etoposide (or etoposide phosphate), dexamethasone."
3098699|NCT01900496|Experimental|Brentuximab vedotin & Rituximab|"Brentuximab vedotin:~Will be administered at 1.8 mg/kg IV over 30 minutes is given for up to 10 doses (cycles), with a cycle length of 21 days. Brentuximab vedotin is first given on day 1 of cycles 1, 2, 3, and 4 as a single agent (weeks 0, 3, 6, and 9, respectively). Four cycles are chosen because of the 12-week median time to CR in the pivotal phase 2 trial of brentuximab vedotin after autologous BMT for HL.~Brentuximab vedotin will be administered with Rituximab at 375 mg/m2 IV is given for up to 8 induction doses: day 1 of week 6, 7, 8, and 9; day 1 of week 12, 15, 18 and 21. This is followed by rituximab maintenance (375 mg/m2 IV once every 3 months x 2 doses) to complete a ~ 1 year total course of therapy."
3098700|NCT01900483||pre bariatric surgery|
3098701|NCT01900483||post bariatric surgery|
3098702|NCT01900470|Experimental|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT CHWs conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
3098703|NCT01900470|No Intervention|Usual Primary Care|Patients will be encouraged to make follow-up appointments as needed with their primary care clinic for support towards their health goals. During these appointments, clinicians will help patients determine progress made on existing proximal goals, adjust goals based on self-efficacy, and help patients to create new proximal goals as needed. They will also work with PCPs to adjust medications when appropriate, provide health behavior education and make referrals to community-based services based on patient need.
3098704|NCT01900457|Active Comparator|Volunteer healthy|healthy volunteers
3098705|NCT01900457|Experimental|patients|vestibular defective patients
3098706|NCT01900444|Experimental|IMOJEV Group|Participants who received a single dose of IMOJEV in study JEC12 (NCT01396512) will receive a booster dose in this study.
3098707|NCT01900431|Placebo Comparator|Placebo|Placebo (for Sarilumab) subcutaneous (SC) injection every 2 weeks (q2w) for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and <80 mg/day as single therapy or in combination with Methotrexate (MTX) 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
3098708|NCT01900431|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and <80 mg/day as single therapy or in combination with MTX 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
3098709|NCT01900418|Active Comparator|Walking|Walk with Ease
3098710|NCT01900418|No Intervention|Wait list control|Wait list control receiving the active intervention 6 weeks later.
3098711|NCT01900405||Dexmedetomidine|All children undergoing
3098712|NCT01900392|No Intervention|Control Arm|No other financial incentive other than for the 3-, 6-, 9-, & 12-month weigh-ins and surveys. Participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). Two weigh-ins will be required during Phase II, one at 9 months and the other at 12 months.
3098713|NCT01900392|Experimental|Direct payment|"In addition to the incentives for the 3-, 6-, 9-, & 12-month weigh-ins, participants who meet their daily goal will be eligible to receive an incentive for each day their goal is met during the first 6 months of the study. All daily incentive earnings will be paid out after verifying participants' weights during an in person weigh in at a Weight Watchers location at months 3 and 6. Winnings will be proportional to weight loss. For example, if a participant's goal was to lose 6 pounds by month 3, but he/she only lost 3 pounds, that participant would only receive 50% of their total eligible winnings.~Similar to the control arm, participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weigh-ins at 9- and 12-months will also be required."
3098714|NCT01900392|Experimental|Lottery|"In addition to the incentives for the 3-, 6-, 9-, & 12-month weigh-ins, participants who meet their daily goal will be eligible for the daily lottery during the first 6 months of the study. The expected daily winning for the lottery is the same as for the direct payment arm. All daily incentive earnings will be paid out after verifying participants' weights during an in person weigh in at a Weight Watchers location at months 3 and 6. Winnings will be proportional to weight loss. For example, if a participant's goal was to lose 6 pounds by month 3, but he/she only lost 3 pounds, that participant would only receive 50% of their total eligible winnings.~Similar to the control arm, participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weigh-ins at 9- and 12-months will also be required."
3098715|NCT01900379|Experimental|OSA/CPAP|OSA patients intervention : CPAP treatment
3098716|NCT01900379|Sham Comparator|OSA/sham CPAP|OSA patients intervention : Sham CPAP treatment
3098718|NCT01900366||Obese subjects for fat biopsy|10 patients recruited during fat biopsies for sample collection
3098719|NCT01900366||Lean controls for fat biopsy|5 Lean controls will be recruited
3098720|NCT01900353|Active Comparator|horizontal brushing method|brushing methods
3098721|NCT01900353|Active Comparator|Vertical brushing method|brushing methods
3098722|NCT01900340|Placebo Comparator|iv saline, intraduodenal saline|intravenous infusion of saline plus intraduodenal administration of saline
3098723|NCT01900340|Active Comparator|IV exendin(9-39) plus intraduodenal (ID) saline|intravenous infusion of exendin(9-39) plus intraduodenal administration of saline
3098724|NCT01900340|Placebo Comparator|IV saline, intraduodenal nutrient|intravenous infusion of saline plus intraduodenal administration of nutrient
3098725|NCT01900340|Active Comparator|Exendin(9-39) plus ID nutrient|Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
3098726|NCT01900327|Experimental|neoadj. Treatment|Neoadjuvant CRT with weekly Gemcitabine neoadjuvant 300mg/m2 for 6 weeks combined with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions will be followed by classical or pylorus-preserving partial pancreato-duodenectomy (PD) and adjuvant chemotherapy (CTx), preferentially using Gemcitabine adjuvant (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle).
3098727|NCT01900327|Active Comparator|Upfront Surgery|Upfront PD followed by adjuvant CTx, preferentially with Gemcitabine adjuvant (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle).
3098728|NCT01900314|Active Comparator|Active rTMS|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the FDA-approved device label (10 Hz) to a targeted area of the brain. After these sessions, a second fMRI will be completed then 5 additional tapering treatments of rTMS over a 2 week period.
3098729|NCT01900314|Sham Comparator|Sham rTMS|20 sham sessions, within a 4 week period, where subjects receive inactive treatments (0 Hz) of repetitive Transcranial Magnetic Stimulation (rTMS). After 20 sessions and completion of a second fMRI scan, patients in this group will then be unblinded and transitioned to the active arm and will receive a full course (25 sessions) of active rTMS over a 6 week period.
3098730|NCT01900301|Experimental|Scopolamine .4mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
3098731|NCT01900301|Placebo Comparator|Intranasal placebo|Participants will be randomized to a placebo, administered via nasal drops, prior to each session of exposure therapy
3098732|NCT01900301|Experimental|Scopolamine .5mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
3098733|NCT01900301|Experimental|Scopolamine .6mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
3098734|NCT01900288|Experimental|HPN Group Clinic Appointments (Group 1)|"A mobile device (iPad mini) is loaned to Group 1 subjects providing a connection to HPN Internet information for the 6 to 12 months of the study. Two scheduled times during the study period, visual connections to geographically distant professionals and peers over the iPad mini (HPN Group Clinic Appointment) will be held for approximately 1 ½ to 2 hours each time (called Healthy Living Connections).~On the iPad mini screen during the HPN Group Clinic Appointments, subjects will be able to see professionals and peers all at the same time and they will be able to see them in their home. This group will also receive electronic prompts about healthy activities."
3098735|NCT01900288|Placebo Comparator|Mobile Device Access (Group 2)|"A mobile device (iPad mini) is loaned to Group 2 subjects providing a connection to Internet information for the 6 to12 months of the study. At the end of the study period, Group 2 subjects will have 1 scheduled time during the study to connect to professionals and peers over the iPad mini for approximately 1 ½ to 2 hours (called Healthy Living Connections) before the study concludes.~On the iPad mini screen during the placebo control group clinics, subjects will be able to see professionals and peers all at the same time and they will be able to see them in their home. This group will also receive one electronic prompt about healthy activities as a comparison control to the intervention group."
3098736|NCT01900275||Septic shock or major trauma|Patients admitted within 24 hours to ICU for septic shock or major trauma (ISS > 15). Septic shock is defined by sepsis with hypotension requiring >4 hours of vasopressor support over previous 24 hours.
3098737|NCT01900262|Experimental|Strengthening|Novice recreational runners from the Calgary area.
3098738|NCT01900262|Experimental|Balance Training|Novice recreational runners from the Calgary area.
3098739|NCT01900262|Experimental|Stretching|Novice recreational runners from the Calgary area.
3098740|NCT01900249|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2%
3098741|NCT01900249|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%
3098742|NCT01900249|Placebo Comparator|Placebo|Placebo Ophthalmic Solution, 1 drop per eye twice a day for 12 weeks.
3098743|NCT01900236|No Intervention|Control|Control arm participants will receive standard clinical care (i.e. receive usual clinic treatment)
3098744|NCT01900236|Experimental|Motivation Behavioral Technique|Behavioral: 4 sessions of tailored, interactive agenda based on behavioral motivational interviewing (MI) techniques. Each iENGAGE intervention session includes: interventionist-delivered educational content for managing HIV medical care appointment-keeping and information sessions for learning to manage HIV medications. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order in order to achieve viral suppression and improve overall health.
3098745|NCT01900223||Shoulder prosthesis bearer|
3098746|NCT01900210|Experimental|WaySafe|WaySafe -- Participants in this arm received a curriculum titled WaySafe that focused on identifying, planning for, and avoiding HIV risk behaviors after release from prison. WaySafe included 6 hour-long, group-based, highly interactive sessions normally held weekly with homework assignments given between sessions.
3098747|NCT01900210|No Intervention|Treatment as usual|Participants in this arm completed pre- and post-surveys and attended normal substance abuse programming.
3098816|NCT01899729|Placebo Comparator|Placebo|Saline (placebo) q wk x 12 wks
3098748|NCT01900197||Iron deficiency anemia|Patients with iron deficiency anemia treated on the doctor's discretion with 10% Iron Isomaltoside 1000 (Monofer®) as standard treatment according to current practice
3098749|NCT01900184|Experimental|500 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
3098750|NCT01900184|Experimental|750 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
3098751|NCT01900184|Experimental|1,000 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
3098752|NCT01900184|Placebo Comparator|Placebo|The placebo will be administered in solution with 200 mL of purified water.
3098753|NCT01900171|Experimental|10 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3098754|NCT01900171|Experimental|50 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3098755|NCT01900171|Experimental|125 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3098756|NCT01900171|Experimental|250 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3098757|NCT01900171|Experimental|500 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3098758|NCT01900171|Experimental|750 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3098759|NCT01900171|Experimental|1,000 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3098760|NCT01900171|Experimental|1,250 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3098761|NCT01900171|Placebo Comparator|Placebo|The placebo was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3098762|NCT01900158|Experimental|Amphinex and Gemcitabine|Arm A Phase II: Stented patients. Amphinex administration on day 0, followed by gemcitabine administration (1000 mg/m2) intravenously over 30 minutes and laser light application (652 nm) on day 4 followed by systemic gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) given on Day 1 and Day 8 of each 21-day cycle, commencing between 7 and 21 days after the laser light application
3098763|NCT01900158|Active Comparator|Gemcitabine and Cisplatin|Arm B Phase II: Stented patients. Systemic gemcitabine (1000 mg/m2) intravenously over 30 minutes and cisplatin intravenously over a period of 1 hour (25 mg/m2) given on Day 1 and Day 8 of each 21-day cycle, commencing within 21 days after randomization.
3098764|NCT01900106|Experimental|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
3098765|NCT01900106|Active Comparator|ABC/3TC + DRV/r|abacavir/lamivudine + darunavir/ritonavir
3098766|NCT01900093|Experimental|Acthar Gel|80 units of subcutaneous Acthar Gel therapy daily
3098767|NCT01900080|Experimental|Same-Day ART Group|"Same-Day HIV testing and ART initiation:~All participants in the same-day ART group will receive rapid HIV antibody testing, CD4 cell testing, clinically relevant testing for OIs, WHO staging, counseling and social support, and ART initiation on the day of presentation for HIV testing."
3098768|NCT01900080|Active Comparator|Standard ART Group|"Standard ART Initiation:~The standard group will receive the same services as the same-day ART group (including same-day HIV and CD4 cell testing) except that instead of same-day ART, they will receive the standard GHESKIO protocol of 3 sequential visits for ART readiness counseling and testing for OIs prior to ART initiation."
3098769|NCT01900080|Experimental|Sub-Study - Same-Day ART, CD4>500|Sub-Study - Same-Day CD4 Count and ART Initiation for Patients with CD4 Count >500 cells/mm3: Participants will receive counseling and start ART on the day of study enrollment. They will have follow-up visits with the physician on Days 3, 10, 17, and 24, and with the social worker on Days 3, 10, and 17. They will have also have physician visits at weeks 8 and 12. Participants who are clinically stable, asymptomatic, and adherent at week 12 will then qualify for expedited care at future visits, which includes dispensing of ART directly by nurses in the clinic every four weeks, to reduce waiting time for patients. Participants who are symptomatic or non-adherent will be referred to a physician for evaluation.
3098770|NCT01900080|Active Comparator|Sub-Study - Pre-ART Care, CD4>500|Participants will receive standard GHESKIO pre-ART care, which includes a monthly visit with a physician for 3 months, and then every other month physician visits.
3098771|NCT01900067|Active Comparator|Active warming|BARRIER® EasyWarm Active Self-Warming Blanket
3098772|NCT01900067|No Intervention|Control|no active warming, standard of care
3098773|NCT01900054|Experimental|TAU-284|Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
3098774|NCT01900041|Experimental|Pantovigar + Minoxidil 2%|Minoxidil 2% is given as background therapy in both arms
3098775|NCT01900041|Other|Minoxidil 2% only|Minoxidil 2% is given as background therapy in both arms
3098776|NCT01900028|Experimental|Olaparib alone, olaparib+itraconozole|Sequential treatments of olaparib alone followed by olaparib+itraconazole, with a washout period in between.
3098777|NCT01900015|Active Comparator|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
3098778|NCT01900015|Active Comparator|Efavirenz|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
3098779|NCT01900002|Experimental|Sorafenib and Yttrium-90|Starting dose of Sorafenib 400 mg 2 times a day starting on Day 1 of Cycle 1, 4 weeks before starting TheraSphere treatment. After 4 weeks Sorafenib therapy, Y-90 procedure performed. TheraSphere administered via infusion under imaging guidance through an hepatic arterial catheter appropriately positioned in the arterial anatomy to permit selective infusion of TheraSphere into the target tissue selected for treatment. The procedure should take about 1½ to 3 hours to complete.
3098817|NCT01899716|Experimental|Exercise|Aerobic Exercise, 3 times peer week, A dose of 16.5 kcal/kg weight peer week.
3098818|NCT01899716|No Intervention|Control|
3098934|NCT01898819|Experimental|dexmedetomidine|dexmedetomidine infusion from beginning of the anesthesia to just before returning to horizontal position
3098780|NCT01899989|Experimental|A) >5cm,Chemo eligible (closed to accrual)|Patients will receive five fractions of either 8, 10, or 12 Gy to the gross tumor only. Following SBRT patients will be evaluated by their medical oncologist for consideration of adjuvant chemotherapy, starting 6-8 weeks post-RT. All patients will be followed for one year. Patients will be assessed for toxicity by their radiation oncologist at 4 to 6 weeks post-RT and during chemotherapy by their medical oncologist. Follow up after completion of all treatment will consist of CT chest scans at 6 and 12 months post-SBRT and toxicity assessments every 3 months from the end of SBRT for one year.
3098781|NCT01899989|Experimental|B) 3-5cm OR Chemo ineligible|Using intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT), the choice of which is determined by the radiation oncologist, patients will be treated in < 5 fractions every other day. The total treatment dose will be between 45 and 54 Gy in < 5 fractions per standard of care. All patients will be followed for one year. Patients will be assessed for toxicity by their radiation oncologist at 4 to 6 weeks post-RT and during chemotherapy at the discretion of their medical oncologist. Follow up after completion of all treatment will consist of CT chest scans at 6 and 12 months post-SBRT and toxicity assessments every 3 months from the end of SBRT for one year. FDG PET/CT scans and Pulmonary Function Tests (PFTs) will be obtained at 3 months and 9 months after SBRT.
3098782|NCT01899976|Other|X-Suit NIR Covered Biliary Stent|Stent implantation in the biliary tree
3098783|NCT01899963||Tele-ophthalmology Referral Group|This group includes patients referred to a retinal specialist via a teleophthalmology referral system.
3098784|NCT01899963||Conventional Referral Group|This group includes patients referred to a retinal specialist via a conventional fax system.
3098785|NCT01899924|Experimental|Event Related Potentials|
3098786|NCT01899911|Experimental|Vital Signs Patch (VSP)|Infrared and Red absorbance measurement on chest
3098787|NCT01899898|Experimental|Simplified Modified Atkins Diet|
3098788|NCT01899898|Active Comparator|Antiepileptic drugs alone|
3098789|NCT01899885|No Intervention|historic control group|Standard treatment in the historic control group
3098790|NCT01899885|Active Comparator|Intervention group|"AHA (Acute Highrisk Abdominalsurgery): Optimized Course:~Intervention before, during and after abdominal surgery.~Focus on fast track with multimodal standardized intervention:~standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)~GDT-LiDCO fluid management pre-, per- and postoperative~Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score~Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively"
3098791|NCT01899872|Experimental|Patients with type 1 diabetes|Patients with type 1 diabetes
3098792|NCT01899859|Active Comparator|Cohort 1|Patient receives dose of GR-MD-02 or placebo
3098793|NCT01899859|Active Comparator|Cohort 2|Patient receives dose of GR-MD-02 or Placebo
3098794|NCT01899859|Active Comparator|Cohort 3|Patient receives dose of GR-MD-02 or placebo
3098795|NCT01899846|Experimental|Cohort 1|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation following first dose
3098796|NCT01899846|Experimental|Cohort 2|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation 24 - 28 weeks gestation
3098797|NCT01899846|Experimental|Cohort 3|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation 32 - 36 weeks gestation
3098798|NCT01899833|Experimental|99mTc-EC-DG, Diagnostic|99mTc-EC-DG (25 ± 5 mCi, up to 250 µg EC-DG) will be administered by intravenous (IV) bolus injection. Other Name:Technetium-99m-labeled Ethylenedicysteine-Deoxyglucose
3098799|NCT01899820|Active Comparator|Artemether lumefantrine|Tablets, 1-4 tablets (weight calculated dose), BD, at hr 0, 8, 24, 36, 48 and 60.
3098800|NCT01899820|Experimental|Dihydroartemisinin piperaquine|Tablets, 2 paediatric tablets/1 adult tablet, OD, every 24 hours for 48 hours
3098801|NCT01899807|Other|Single Arm|
3098802|NCT01899794|Active Comparator|TVT-O|mid-urethral sling
3098803|NCT01899794|Active Comparator|Oxytrol|medication
3098804|NCT01899781|Active Comparator|with antibiotic and without antibiotic|
3098805|NCT01899768|Experimental|Part A|Subjects will receive treatment A (placebo) or treatment B (GSK2339345) in 3 visits of part A (one treatment per visit) in one of the following four sequences: ABA, ABB, BAA, and BAB.
3098806|NCT01899768|Experimental|Part B|Subjects will receive treatment A or treatment B in 2 visits of part B (one treatment per visit) in one of the following two sequences: AB and BA. Subjects will then orally inhale 10 microliter (mcL) of a capsaicin solution of strength ranging from 0.49 micromolar (mcM) to 1000 mcM, which will be administered using a breath activated dosimeter approximately 5 minutes post-dosing with treatment A or B at Visits 4 and 5.
3098807|NCT01899768|Experimental|Part C|Subjects will receive treatment A or treatment B in 2 visits of part C (one treatment per visit) in one of the following two sequences: AB and BA. Subjects will then orally inhale 10 mcL of a citric acid solution of strength ranging from 0.03 to 4.0 M, which will be administered using a breath activated dosimeter approximately 5 minutes post-dosing with treatment A or B at Visits 6 and 7.
3098808|NCT01899755|Experimental|GSK2800528 Arm|Subjects will be assigned to treatments in accordance with the randomization schedule in Cohorts 1 to 3. Treatments will be randomized with placebo in a 3:1 ratio. The final randomization code will also pre-define the sentinel subjects to ensure that of the first two subjects in each cohort, one will receive GSK2800528 and the other will receive placebo.
3098809|NCT01899755|Placebo Comparator|Placebo Arm|Subjects will be assigned to treatments in accordance with the randomization schedule in Cohorts 1 to 3. Treatments will be randomized with placebo in a 3:1 ratio. The final randomization code will also pre-define the sentinel subjects to ensure that of the first two subjects in each cohort, one will receive GSK2800528 and the other will receive placebo.
3098810|NCT01899755|Active Comparator|Adalimumab Arm|In Cohort 4, all subjects will receive adalimumab 40 mg (0.8 mL solution) as subcutaneous injection
3098811|NCT01899742|Experimental|Umeclidinium/Vilanterol|Long-acting muscarinic antagonist (LAMA)/Long-acting Beta agonist (LABA)
3098812|NCT01899742|Active Comparator|Tiotropium|Long-acting muscarinic antagonist (LAMA)
3098813|NCT01899729|Experimental|IMO-8400 regimen 1|IMO 8400 at 0.075 mg/kq q wk x 12 wks
3098814|NCT01899729|Experimental|IMO-8400 Regimen 2|IMO-8400 at 0.15 mg/kg q wk x 12 wks
3098815|NCT01899729|Experimental|IMO-8400 Regimen 3|IMO_8400 at 0.3 mg/kg q wk x 12 wks
3098819|NCT01899703|Experimental|GSK2330672|Subject will receive GSK2330672 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods. Patients were randomized to one of two sequences receiving either (i) GSK2330672 followed by placebo; OR (ii) placebo followed by GSK2330672.
3098820|NCT01899703|Experimental|Placebo|Subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. Patients were randomized to one of two sequences receiving either GSK2330672 followed by placebo; OR placebo followed by GSK2330672.
3098821|NCT01899690|Experimental|antibiotic|7 days of preventive antibiotics after surgery
3098822|NCT01899690|No Intervention|No antibiotic|No preventive postoperative antibiotics
3098823|NCT01899677|Experimental|symbiotic|symbiotic preparation 1/2 sachet twice daily during 30 days
3098824|NCT01899677|Placebo Comparator|distilled water|2 x 0.5 cc distilled water will be given during 30 days
3098825|NCT01899664|Other|Primary Study Population|Study participants (primary study population) will include patients with spinal cord injury at the mid cervical level who are undergoing evaluation for possible surgical treatment with nerve transfers and or tendon transfer/tenodesis to improve their upper extremity function. All enrolled participants will receive the same standard of care surgical procedures.
3098826|NCT01899651||Infants of 30-34 weeks gestation.|Inclusion criteria will be infants 30-34 weeks gestation. Exclusion criteria will be any infants with evidence of pre-existing skin condition, breakdown, rashes, or problems with skin integrity. Infants with a known neurological condition (hydrocephalus, Dandy Walker malformation, craniosynostosis, arteriovenous malformation) will be excluded as well. Also, secondary to the nature of the device and the surface area it takes up, infants on continuous positive airway pressure will be excluded as well.
3098827|NCT01899638|Experimental|UMEC/VI 125/25 mcg|Combination in high dose
3098828|NCT01899638|Experimental|UMEC/VI 62.5/25 mcg|Combination in low dose
3098829|NCT01899638|Experimental|UMEC 125 mcg|LAMA mono in high dose
3098830|NCT01899638|Experimental|UMEC 62.5 mcg|LAMA mono in low dose
3098831|NCT01899638|Experimental|VI 25 mcg|LABA mono
3098832|NCT01899625|Active Comparator|Motivation Enhanced BWL|12 week treatment program consisting of 2, 90-minute individual sessions with a focus on motivation, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Participants will pick from one of three dietary goals and one of three physical activity goals.
3098833|NCT01899625|Active Comparator|Brief Behavioral Weight Loss (BWL)|12 Week treatment program consisting of 2, 90-minute individual sessions, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Treatment consistent with behavioral weight loss, low calorie, low fat diet. Increased physical activity of up to 250 minutes/week.
3098834|NCT01899612||Symptomatic postmenopausal women|Postmenopausal women with vulvovaginal symptoms
3098835|NCT01899612||Asymptomatic postmenopausal women|Postmenopausal women without vulvovaginal symptoms
3098836|NCT01899599|Experimental|Gatipotuzumab|1700mg, i.v., q3w
3098837|NCT01899599|Placebo Comparator|Placebo|matching placebo
3098838|NCT01899586|Experimental|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
3098839|NCT01899586|Experimental|Aerobic Exercise (AE)|Whole-body aerobic exercise at >50% of heart rate reserve (HRR) for 45 minutes, three days per week.
3098840|NCT01899573|Experimental|Treatment|
3098841|NCT01899560|Other|Unique arm|Experimental and comparator
3098842|NCT01899547|Experimental|Arm I|Patients undergo laparoscopic-assisted rectal resection.
3098843|NCT01899547|Active Comparator|Arm II|Patients undergo conventional open rectal resection.
3098844|NCT01899534|No Intervention|Paper-based screening|Paper-based screening. Women will complete a mental health screening tool on paper (usual care).
3098845|NCT01899534|Experimental|E-screening|Women will complete mental health screening on a tablet
3098846|NCT01899521|Placebo Comparator|Placebo zinc and placebo SAMe|Placebo tablet of zinc sulfate once daily and placebo tablet of s-adenosylmethionine twice daily
3098847|NCT01899521|Active Comparator|Active zinc and placebo SAMe|Zinc sulfate 220 mg once daily and placebo tablet of s-adenosylmethionine twice daily
3098848|NCT01899521|Active Comparator|Placebo zinc and active SAMe|Placebo tablet of zinc sulfate once daily and s-adenosylmethionine 400 mg twice daily
3098849|NCT01899521|Active Comparator|Active zinc and active SAMe|Zinc sulfate 220 mg once daily and s-adenosylmethionine 400 mg twice daily
3098850|NCT01899508|Experimental|Pain Coping Training with 3D viewer|All participants will receive a 1 and a half hour pain coping training while using the virtual reality viewer. We are testing the feasability of using the 3D viewer in collaboration with Pain Coping training to see if people who suffer from Osteoarthritis of the knee experience some pain relief.
3098851|NCT01899495|Experimental|High sodium diet and low sodium diet|Each subject experiences both a high sodium and a low sodium diet.
3098852|NCT01899482|Experimental|Manual Lymphatic Drainage|One educational session in group, and 10 individual sessions of manual lymphatic drainage in lower extremity, during approximately one month.
3098853|NCT01899482|Active Comparator|Control|One educational session in group.
3098854|NCT01899469|Experimental|Electromagnetic therapy (EM)|The group had performed 20 sessions of EM therapy for 20 minutes and after had a 25 minutes from Back School intervention.
3098855|NCT01899469|Experimental|Transcutaneous Electrical Neurological Stimulation (TENS)|The group had performed 20 sessions of TENS therapy for 20 minutes and after had a 25 minutes from Back School intervention.
3098856|NCT01899469|Experimental|Back School (BS)|The group had performed 20 sessions of Back School therapy for 25 minutes.
3098857|NCT01899456|No Intervention|Medical therapy|Best medical therapy using guideline recommended drugs in each disease state.
3098858|NCT01899456|Experimental|Catheter-based renal denervation|Renal denervation will be performed in the native renal arteries of patients after renal transplantation. Access side is the contralateral femoral artery.
3098931|NCT01898858||HYPERCAPNIA|
3098932|NCT01898858||HYPOXIA + HYPERCAPNIA|
3098859|NCT01899443||Total hip and knee replacement patients|This study will select up to 20 high volume (>275 cases annually) public and private hospitals across Australia. A random sample of c.2200 patients with diagnosis of osteoarthritis undergoing primary total hip or knee replacement surgery will be recruited.
3098860|NCT01899430|Active Comparator|metformin|In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
3098861|NCT01899430|Experimental|liraglutide|In the LIRA group liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
3098862|NCT01899417||ConforMIS iTotal® Knee Replacement|knee joint replacement
3098863|NCT01899417||Standard Knee Replacements|knee joint replacement
3098864|NCT01899404|Experimental|18-FDG PET/CT, DWI, DCE-MRI|
3098865|NCT01899378|Experimental|daily probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis daily for one month
3098866|NCT01899378|Experimental|weekly probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis weekly for one month
3098867|NCT01899378|Experimental|bi-weekly probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis bi-weekly for one month
3098868|NCT01899378|No Intervention|control|
3098869|NCT01899365||Multifaceted|"brief structured interview with the physician about pneumococcal risk and vaccination,~information sheet delivered to patients with explanation about risk and benefit of APV,~letter given to patient for his/her general practitioner stating that the patient is at-risk for pneumococcal infection and could benefit of APV,~3 SMS every 2 weeks to remind patients talking of pneumococcal risk with general practitioner."
3098870|NCT01899365||Control|"information sheet delivered to patients with explanation about the aim of the study,~brief interview with the physician about study."
3098871|NCT01899352|Other|Tracheostomy|The investigators will enroll all the critical ill patients undergoing tracheostomy performed in intensive care units
3098872|NCT01899339||pulmonary embolism|patients with submassive pulmonary embolism
3098873|NCT01899326|Experimental|Treatment (desipramine, filgrastim)|Patients receive desipramine hydrochloride PO daily on days -3 to +4 and filgrastim PO BID on days 1-4. Stem cell collection begins on day 6.
3098874|NCT01899313|Experimental|CBT- based SMS text messaging intervention|cognitive behavioral therapy- (CBT-) based short message service (SMS) text messaging intervention
3098875|NCT01899313|Placebo Comparator|Placebo Texts|Placebo texts will be given instead of interventional texts
3098876|NCT01899300|Experimental|Metal Stent|The WallFlex™ Esophageal Fully Covered Metal Stent (FCMS)is being evaluated for the treatment of refractory benign esophageal strictures caused by caustic ingestion.
3098877|NCT01899287|Experimental|education in skin care|"The experimental intervention consists of:~A. Group education on general skin-protective behaviour. B. Group education and counselling on work-related skin-protective behaviour, which might extend to a work-place visit.~C. Social guidance related to OHE. D. Telephone hot-line for work and case-related problems, maintained by nurse."
3098878|NCT01899287|No Intervention|no intervention|The control group will not have access to the group education, the profession specific information and the social guidance or the telephone hotline.
3098879|NCT01899274|Experimental|bant Group|Subjects in the bant Group will receive care as usual, as well as an iPhone loaded with the bant iPhone application and a bluetooth enabled glucometer. Participants will have their A1C levels measured every 3 months (for 1 year), and also complete questionnaires/interviews relating to their diabetes management and lifestyle.
3098880|NCT01899274|No Intervention|Control Group|Subjects in the control group will continue care as usual with their diabetes team, without supplementation of the bant application. Participants will have their A1C levels measured every 3 months (for 1 year), as well as complete questionnaires/interviews relating to their diabetes management and lifestyle.
3098881|NCT01899261|Experimental|Treatment (SBRT)|Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.
3098882|NCT01899248||Sevoflurane|Performing liver transplantation under general anesthesia using sevoflurane
3098883|NCT01899248||Desflurane|Performing liver transplantation under general anesthesia using desflurane
3098884|NCT01899235|Active Comparator|Stent|drug eluting stent (Resolute)
3098885|NCT01899235|Experimental|drug eluting balloon|drug eluting balloon (Elutax)
3098886|NCT01899222|Experimental|Subjects imaged with handheld fundus camera|Subjects imaged with handheld fundus camera
3098887|NCT01899209|Experimental|Group A|STARR
3098888|NCT01899209|Experimental|Group B|Laparoscopic ventral Rectopexy
3098889|NCT01899196|Other|no Arm|
3098890|NCT01899170|Sham Comparator|Sham-DBS|Only patients. Inactive deep brain stimulation for the initial three months following implantation.
3098891|NCT01899170|Active Comparator|Active DBS|Only patients. Active deep brain stimulation for the initial three months following surgery.
3098892|NCT01899170|Experimental|TMS and PET imaging|This experiment includes all participants (cases and controls). Each subject will undergo both active and sham stimulation (cross-over) with Cervel Neurotech Multi-coil TMS and related test/re-test PET imaging with 11C-Carfentanil. Only patients will proceed into deep brain stimulation experiments.
3098893|NCT01899157||Survey|"Thai naive HIV-infected patients~Thai HIV-infected patient reciering highly active antiretroviral therapy"
3098894|NCT01899144|Experimental|Albuterol Spiromax 90 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, one of the DPIs contains Albuterol Spiromax 90 mcg; the other three devices contained placebo."
3098895|NCT01899144|Experimental|Albuterol Spiromax 180 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, both of the DPIs contain Albuterol Spiromax 90 mcg for a total dose of 180 mcg; the MDIs contained placebo."
3098896|NCT01899144|Active Comparator|ProAir HFA 90 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, one of the MDIs contains ProAir HFA 90 mcg; the other three devices contained placebo."
3098897|NCT01899144|Active Comparator|ProAir HFA 180 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, both of the MDIs contain ProAir HFA 90 mcg for a total dose of 180 mcg; the DPIs contained placebo."
3098898|NCT01899144|Placebo Comparator|Placebo|At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind. In this arm, all devices contain placebo.
3098899|NCT01899131|Other|platform-switch tapered internal implants|2 platform-switch tapered internal implants placed in 10 participants.clinical and radiographic assessment in 6,12,24, month post implant insertion
3098900|NCT01899118|Experimental|Nimotuzumab plus chemoradiotherapy|
3098901|NCT01899105|Experimental|Part A|A single dose of 2 fixed-dose combination tablets of 200mg lumacaftor/125mg ivacaftor (total of 400mg lumacaftor/250mg ivacaftor) in the fed state and fasted state with a 14 day washout period in between each dosing occasion
3098902|NCT01899105|Experimental|Part B|A single dose of 3 fixed-dose combination tablets of 200mg lumacaftor/83mg ivacaftor (total of 600mg lumacaftor and 250mg ivacaftor) in the fed with a 14 day washout period in between dosing occasions
3098903|NCT01899092|Experimental|Escalating Dose of TT-034|The study contains one dose escalation arm with active drug.
3098904|NCT01899066|Experimental|Lucentis; chemotherapy|"Lucentis: 0.5mg/0.05 ml;Other Name: Ranibizumab;monthly for the first six months.~Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months."
3098905|NCT01899066|Active Comparator|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
3098906|NCT01899053|Experimental|MLN0128 + MLN1117 Arm A|MLN0128 and MLN1117 will be administered in combination to subjects for 3 days each week.
3098907|NCT01899053|Experimental|MLN0128 + MLN1117 Arm B|MLN0128 and MLN1117 will be administered in combination to subjects for 3 days each week.
3098908|NCT01899053|Experimental|MLN0128 + MLN1117 Arm C|MLN0128 and MLN1117 will be administered in combination to subjects for 3 days each week.
3098909|NCT01899040|Active Comparator|active device|A standardized active neuromodulation waveform will be used for all active Device patients at all Study sites. The Device will be used twice daily.
3098910|NCT01899040|Placebo Comparator|placebo device|A standardized placebo neuromodulation waveform will be used for all placebo Device patients at all Study sites. The Device will be used twice daily.
3098911|NCT01899027|Active Comparator|Rosuvastatin Group|Patients will be randomized to receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
3098912|NCT01899027|Placebo Comparator|Placebo group|Patients will be randomized to receive two overnight high doses of Placebo before RNA and another placebo dose 2 h before the procedure
3098913|NCT01899001|Experimental|CBT and Nutrition Counseling|8 weeks of Cognitive Behavioral Therapy (CBT) and 16 weeks of Nutrition Counseling
3098914|NCT01899001|Other|Nutrition Counseling|16 weeks of Nutrition Counseling alone
3098915|NCT01898975||500ml fluid loading|All enrolled patients
3098916|NCT01898962|Experimental|Definitive locoregional treatment|All sites of active disease should be treated definitively (with one of the interventions listed below). Definitive treatment does not have to be the same for all sites of disease.
3098917|NCT01898949|Experimental|Cold Exposure|
3098918|NCT01898936|Experimental|Pretreatment CO2 laser|"The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.~The laser settings will be as follows:~The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluato"
3098919|NCT01898936|Sham Comparator|Only photodynamic therapy|This group will not get pretreatment with CO2 laser
3098920|NCT01898923|Experimental|WH-1 ointment|WH-1 ointment(1.25%),15g ointment per tube. Twice daily for up to 16 weeks.
3098921|NCT01898923|Other|Aquacel® Hydrofiber® dressing|Aquacel® Hydrofiber® dressings will be changed daily, on alternate days or three times a week according to need, but not longer than 7 days.
3098922|NCT01898910|Active Comparator|PVI+renal denervation+OMT|
3098923|NCT01898910|Active Comparator|PVI+GP ablation+OMT|
3098924|NCT01898897|Active Comparator|robot general anesthesia|"General anesthesia for robot assisted laparoscopic urogenital surgery includes premedication with alprazolam (0.5 mg per os), induction with sufentanil, propofol (1-2 mg/kg), neuromuscular blocking agents (rocuronium 0.5 mg/kg) to facilitate tracheal intubation. Anesthesia is maintained with volatile agents (sevoflurane, desflurane) and reinjection of rocuronium and sufentanil as needed.~Robotic assisted laparoscopic interventions are realised with Da Vinci surgical robot, known to assure a minimally invasive approach with good results in urologic surgery. The system consists of an ergonomic surgeon console, a patient cart with four interactive robotic arms, a 3D high resolution visualization interface and specific EndoWrist articulated tools."
3098925|NCT01898897|Experimental|robot combined anesthesia|Combined anesthesia is defined as association of epidural analgesia to general anesthesia. Epidural catheter is inserted at low thoracic level in the operation theatre before the induction of anesthesia. Correct position is verified with 15 mg bupivacaine plain 0.5%. Infusion is started after the incision at a rate of 6-8 ml/ hour.Epidural continuous infusion of local anesthetic is maintained 12 hours postoperative in the postoperative anesthesia care unit.
3098926|NCT01898884|Experimental|Single dose of VP 20629 or placebo|Four groups of 8 subjects each will receive a single dose of VP 20629 (150 mg, 450 mg, 900 mg, or 1200 mg) or placebo.
3098927|NCT01898884|Experimental|Multiple doses of VP 20629 or placebo|Three groups of 8 subjects each will receive multiple doses of VP 20629 (300 mg, 600 mg, or 900 mg total daily dose) or placebo. VP 20629 or placebo will be administered every 8 hours for 7 days with a single morning dose on Day 8.
3098928|NCT01898871|Experimental|Ready to Use Suplementary Food (RUSF)|A daily ration of 40 kcal/kg of body weight during 56 days
3098929|NCT01898871|Active Comparator|Corn Soya Blend (CSB+)|A daily ration of 40 kcal/kg of body weight during 56 days
3098930|NCT01898858||HYPOXIA|
3098935|NCT01898819|Placebo Comparator|saline|Saline infusion from same time period.
3098936|NCT01898806|Experimental|IL TAC 2.5 mg/ml|"Intralesional Triamcinolone 2.5 mg/ml (IL TAC 2.5 mg/ml):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20"
3098937|NCT01898806|Experimental|IL TAC 5 mg/ml|"Intralesional Triamcinolone 5mg/ml (IL TAC 5 mg/ml):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20."
3098938|NCT01898806|Experimental|IL TAC 10 mg/ml|"Intralesional Triamcinolone 10mg/ml (IL TAC 10 mg/ml):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20."
3098939|NCT01898806|Placebo Comparator|Placebo|"Intralesional Saline (Placebo):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20. Open label treatment with IL kenalog at the dose deemed most appropriate may be administered after the 1st 6 months in nonresponders or partial responders."
3098940|NCT01898793|Experimental|Level 1: 0.5 x 10^6/kg CIML NK cells (Phase I)|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.~CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.~Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)"
3098941|NCT01898793|Experimental|Level 2: 1.0 x 10^6/kg CIML NK cells (Phase I)|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.~CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.~Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)"
3098942|NCT01898793|Experimental|Level 3: Maximum NK cell number/kg (Phase I)|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.~CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.~Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)"
3098943|NCT01898793|Experimental|Lead-in Cohort & Phase II: Maximum NK cell/number kg|"Lymphodepleting Preparative Regimen: Patients receive fludarabine and cyclophosphamide on Day -6.~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.~CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.~Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5)."
3098944|NCT01898780|Experimental|horizontal mattress|pancreaticojejunostomy with horizontal mattress suture
3098945|NCT01898780|Experimental|interrupted suture|pancreaticojejunostomy with interrupted suture
3098946|NCT01898767||Mild asthma|Diagnosis of mild asthma as defined by pre-albuterol forced expiratory volume in the first second (FEV1) of >70% predicted.
3098947|NCT01898754|Experimental|Pre-ART Oligonucleotide Assay (OLA)|Pre-ART OLA will be tested for resistance at 5 pol codons conferring high-level resistance to NNRTI and 3TC (K103N, V106M, Y181C, G190A and M184V)
3098948|NCT01898754|No Intervention|No OLA (Standard of Care [SOC])|The participants will receive standard of care as per Kenya guidelines but will be offered OLA resistance testing after 12 months
3098949|NCT01898741|Experimental|irradiation|24 Gy in 3 fractions
3098950|NCT01898728|Active Comparator|Liquid preoperative medications|Liquid preoperative medications
3098951|NCT01898728|Active Comparator|Gel preoperative medications|Gel preoperative medications
3098952|NCT01898715|Experimental|ATR-101|ATR-101 will be administered as capsules or tablets by mouth once or twice per day to ascending dose cohorts
3098953|NCT01898702|Experimental|Diabetes expert patients programme|Diabetes expert patients programme: Participate in a scheduled and standardized expert patients programme course
3098954|NCT01898702|Placebo Comparator|No intervention|Don't participate in a scheduled and standardized expert patients programme course
3098955|NCT01898689|Experimental|Ropivacaine 0.1%|Ropivacaine 0.1% at 8 mL/h basal for 6 hours
3098956|NCT01898689|Active Comparator|Ropivacaine 0.4%|Ropivacaine 0.4% at 2 mL/h basal for 6 hours
3098957|NCT01898676|Active Comparator|Divalproex Sodium Extended Release 250mg|Treatment A: A single 2-tablet dose of divalproex sodium extended-release tablet, 250mg. Each subject will have 2 treatments with this medication and two treatments with a single 2-tablet dose of DEPAKOTE 250mg tablet.
3098958|NCT01898676|Active Comparator|DEPAKOTE 250mg|Treatment B: A single 2-tablet dose of DEPAKOTE ER tablet, 250mg. Each subject will have 2 treament period with this medication and 2 treatment periods with a single 2-tablet dose of Divalproex Sodium Extended-Release 250mg tablet.
3098959|NCT01898663|Experimental|Adenovirus-transfected DC + CIK|Adenovirus-transfected autologous DCs + CIK cells
3098960|NCT01898650|Experimental|craniofacial abnormalities|Subjects with craniosynostosis or other craniofacial abnormalities associated with ICP who will undergo an MR scan.
3098961|NCT01898650|Active Comparator|normal control|normal control subjects who will undergo an MR scan
3098962|NCT01898637|Active Comparator|Proven pulmonary embolism.|Augmented pulse oximetry using incentive spirometer. Emergency Department patients with pulmonary embolism.
3098963|NCT01898637|Other|Control patients|Augmented pulse oximetry using incentive spirometer. Emergency Department patients who do not have pulmonary embolism.
3098964|NCT01898624||Betanis group|mirabegron treated group
3098965|NCT01898611|Active Comparator|Ghrelin plus resistance training|Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
3098966|NCT01898611|Placebo Comparator|Placebo plus resistance training|Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
3098967|NCT01898598|Placebo Comparator|Placebo|Participants will receive matching placebo to vismodegib capsule orally once daily for 12 weeks.
3098968|NCT01898598|Experimental|Vismodegib|Participants will receive vismodegib 150 milligrams (mg) capsule orally once daily for 12 weeks.
3098969|NCT01898585|Experimental|Zelboraf Arm|
3098970|NCT01898572||Newly diagnosed T2DM|Newly diagnosed T2DM with no CVD. Standard care.
3098971|NCT01898572||Control individuals|Control individuals matched by age, gender, dyslipidemia, hypertension and smoking habit. Standard care.
3098972|NCT01898559|Experimental|Black & Mild little cigars|"Participants switch from smoking their own brand of cigarettes to only smoking Black & Mild little cigars.~Other: Switch to smoking only little cigars"
3098973|NCT01898559|Experimental|King Edward little cigars|"Participants switch from smoking their own brand of cigarettes to only smoking King Edward little cigars.~Other: Switch to smoking only little cigars"
3098974|NCT01898546|Experimental|Primary angioplasty and postconditioning|Primary angioplasty followed by postconditioning
3098975|NCT01898546|Active Comparator|Primary angioplasty|Primary angioplasty alone
3098976|NCT01898520|Active Comparator|Sativex|Oromucosal spray containing delta-9-tetrahydrocannabinol (THC) (27 mg/mL):cannabidiol (CBD) (25 mg/mL). Each 100 μL spray to the sub-lingual or oral mucosa delivered THC 2.7 mg and CBD 2.5 mg. The maximum number of daily sprays was 12.
3098977|NCT01898520|Placebo Comparator|Placebo|Oromucosal spray containing ethanol: propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum number of daily sprays was 12.
3098978|NCT01898507|Experimental|Low nicotine cigarettes|"Participants will smoke their own brand cigarettes during a baseline 5 day period, followed by a 15-day period of smoking low nicotine content cigarette level 1: 0.25 mg nicotine content, followed by a 15-day period of smoking low nicotine content cigarette level 2: 0.08 mg nicotine content.~Other: Low nicotine cigarettes"
3098979|NCT01898494|Experimental|Arm A (TOS)|Patients undergo transoral surgical resection of the oropharyngeal tumor.
3098980|NCT01898494|Experimental|Arm B (TOS, low-dose IMRT)|Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo low-dose IMRT QD five days a week for 5 weeks.
3098981|NCT01898494|Experimental|Arm C (TOS, standard-dose IMRT)|Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo standard-dose IMRT QD five days a week for 6 weeks.
3098982|NCT01898494|Experimental|Arm D (TOS, standard-dose IMRT, chemotherapy)|Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo standard-dose IMRT QD five days a week for 6-7 weeks. Patients also receive cisplatin IV over 60 minutes or carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiation therapy.
3098983|NCT01898481||Health Care Triads|This is an exploratory pilot study of 25 health care triads. Triads will include: (1) a patient diagnosed with advanced cancer, (2) a loved one, and (3) an oncology provider.
3098984|NCT01898468|Active Comparator|Intracostal Closure Technique|Closure involves drilling four evenly spaced holes using a 5-mm bit attached to the end of a Stryker drill into the bed of the sixth rib.
3098985|NCT01898468|Active Comparator|Pericostal Closure Technique|Closure involves placing sutures around the ribs in the standard pericostal fashion
3098986|NCT01898455|Experimental|Intranasal Cooling|RhinoChill Intranasal cooling, administered for 20 minutes. 10 treatment sessions per participant.
3098987|NCT01898442|Active Comparator|Ticagrelor 180|Standard ticagrelor 180mg loading dose
3098988|NCT01898442|Experimental|Ticagrelor 270mg|High ticagrelor 270mg loading dose
3098989|NCT01898442|Experimental|Ticagrelor 360mg|High ticagrelor 360mg loading dose
3098990|NCT01898429|Active Comparator|Left-sided SCC DBS|Active Stimulation of the left-sided electrode
3098991|NCT01898429|Active Comparator|Right-sided SCC DBS|Active stimulation of the right-sided electrode
3098992|NCT01898416|Experimental|5-AminoLevulinicc Acid|consists of 60mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia and surgical tumor resection. Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In the case of positive margins (for tumor presence), a second surgical intervention followed by second 60mg/kg 5-ALA administration will be performed.
3098993|NCT01898403|Experimental|Sentinel Lymph Node (SLN) Detection|All patients receive peri-tumoral, intradermal injections of isosulfan blue and indocyanine green solution for detection of melanoma in lymph nodes. In addition, lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC) will be conducted for all participants with the same objective.
3098994|NCT01898390|Experimental|Transplant|Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
3098995|NCT01898390|No Intervention|Control|comparison group of controls, will receive the same observational and scanning assessments but will not receive any surgical procedures
3098996|NCT01898377|Experimental|Imatinib mesylate, Mycophenolate mofetil|"MMF 15-20mg/kg (Max 1 g) bid + Imatinib mesylate qd~Dose of imatinib : starting dose 260 mg/m2/d (Max. 400 mg)~Imatinib dose adjustment : Dose is adjusted according to the guidelines if there is serious adverse event, toxicity, or intolerance."
3098997|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 5 mg|Intravenous infusion of 5mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks
3098998|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 10 mg|Intravenous infusion of 10mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks.
3098999|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 20 mg|Intravenous infusion of 20mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks.
3099000|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 5 mg|Intravenous infusion of 5mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
3099001|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 10 mg|Intravenous infusion of 10mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
3099081|NCT01897818|Experimental|ALS patients|
3099002|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 20 mg|Intravenous infusion of 20mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
3099003|NCT01898351|Other|Fava bean, Lupin, Beef meat, Green pea, Hemp, Buckwheat|"The intervention visit involves a test meal to be consumed by subjects attending the Human Nutrition Unit in the morning, following an overnight fast. The meal will be consumed within 15 minutes and blood (69 mL) and urine samples will be collected during 24 hours.~The test meals are designed to contain the same amount of proteins. Alternative protein meals: a number of bread buns for each meal containing individual alternative protein flours (green pea, lupin, hemp, buckwheat, fava beans). These will deliver 30 g of protein, the remainder being provided by white flour. The control (meat) meal: a lean beef steak containing 30 g of protein and a bun containing the same amount of white flour as used for the alternative protein bread buns.~The semi structured interview guide: will take place within the Human Nutrition Unit during one of the scheduled visits, once initial screening has taken place and participants have been selected. All interviews will be digitally recorded."
3099004|NCT01898338|Experimental|Fosfomycin and Daptomycin|fosfomycin 2gr/6h + 10mg/kg/24h iv during 14 or 28 days
3099005|NCT01898338|Active Comparator|Daptomycin|daptomycin 10mg/kg/cada 24h iv during 14 or 28 days
3099006|NCT01898325|Other|Naïve GD patients|"Naïve GD patients~Intervention: device - Fibroscan"
3099007|NCT01898325|Other|GD treated with ERT|GD treated with ERT Intervention: device - Fibroscan
3099008|NCT01898325|Other|Healthy control|Healthy control Intervention: device - Fibroscan
3099009|NCT01898325|Other|NonAlcoholic Steatohepatitis Patients|Patients with NonAlcoholic Steatohepatitis( NASH) Intervention: device - Fibroscan
3099010|NCT01898312|Experimental|Mifepristone|treatment with oral mifepristone 50 mg every second day for 12 weeks in 30 women with BRCA 1 or 2 mutation
3099011|NCT01898312|Placebo Comparator|TrioBe|treatment with a quarter of a tablet of TrioBe every second day for 12 weeks
3099012|NCT01898299|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) treatments will take place for 20 minutes per day for 5 consecutive days
3099013|NCT01898299|Sham Comparator|Sham tDCS|Sham tDCS(inactive)treatment (transcranial Direct Current Stimulation) will take place for 20 minutes per day for 5 consecutive days.
3099014|NCT01898286|Experimental|DiaPep277®|Administration of DiaPep277® to patients previously enrolled in the Phase 3 Study 1001 (NCT01103284)
3099015|NCT01898273|Experimental|Single|I-124-CLR1404, open-label
3099016|NCT01898260|Other|BYO Daily, then MyDay|Ultrafilcon B contact lenses, followed by stenfilcon A contact lenses. Each product worn bilaterally for 1 week in a daily wear, daily disposable modality.
3099017|NCT01898260|Other|MyDay, then BYO Daily|Stenfilcon A contact lenses, followed by ultrafilcon B contact lenses. Each product worn bilaterally for 1 week in a daily wear, daily disposable modality.
3099018|NCT01898247|No Intervention|Traditionally-trained Procedures|Patients who undergo thoracentesis procedures by traditionally-trained residents who have not undergone simulation-based mastery learning.
3099019|NCT01898247|Experimental|Simulator-trained Procedures|Patients who undergo thoracentesis procedures by residents who have undergone simulation-based mastery learning.
3099020|NCT01898234|Experimental|Revaclear|
3099021|NCT01898234|Experimental|Helixone high flux|
3099022|NCT01898234|Experimental|Xevonta|
3099023|NCT01898234|Experimental|Helixone low flux|
3099024|NCT01898221|Active Comparator|Standard Catheter Ablation Patient Group|Patients will have a standard procedure ablation
3099025|NCT01898221|Active Comparator|Vein of Marshall and Standar procedure|The doctor will inject Ethanol through a balloon catheter into the VOM
3099026|NCT01898208|Experimental|Control|Standard Mayo practices (bacterial culture and susceptibility testing) will be used. FilmArray testing will not be performed.
3099027|NCT01898208|Experimental|FilmArray test|Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.
3099028|NCT01898208|Experimental|FilmArray plus antimicrobial stewardship|Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.
3099029|NCT01898195|Active Comparator|Standard Care|Participants in this arm will receive varenicline for smoking cessation.
3099030|NCT01898195|Experimental|Standard Care + Text message|Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts.
3099031|NCT01898195|Experimental|Standard Care + Text Message + ABT|Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts and seven phone developed Adherence Behavioral Therapy sessions
3099032|NCT01898182|Experimental|Kinerase|Kinetin (N6-furfuryladenine) is an essential bio growth factor that regulates cell growth and is proven to delay and reverse the signs of aging. Kinerase has been found out to significantly improve the appearance of skin texture, mottled hyperpigmentation and fine wrinkles. It does not cause the cutaneous side effects that result from other commonly used anti-aging products. The Kinerase cream contains: Water, glyceryl stearate, propylene glycol, butylenes glycol, glycerin, cetyl alcohol, stearic acid, isopropyl palmitate, squalene, stearyl alcohol, glycene soja sterols, dimethicone, laureth-23, aloe barbadensis leaf juice, phenoxyethanol, carbomer, ethylhexyglycerin, sodium hydroxide, soluble collagen, kinetin, panthenol, tocopherol, citric acid, sodium citrate, hydrolysed elastin.
3099033|NCT01898169|Experimental|NJOY King 26 mg nicotine Electronic Nicotine Delivery System|
3099034|NCT01898156|Experimental|BIW-8962|"Phase 1 - Dose escalation based on the BIW-8962 tolerability and safety data obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur~Phase 2 - Recommended dose determined in Phase 1"
3099035|NCT01898143|Other|Whole body vibration in COPD|Patients with COPD GOLD III or IV
3099036|NCT01898143|Other|Whole body vibration in ILD|PAtients with interstitial lung disease
3099037|NCT01898130|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3099038|NCT01898117|Active Comparator|Carbo/cyclo|Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 Q 4 weeks
3099039|NCT01898117|Active Comparator|Carbo/cyclo + Atezolizumab|Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 atezolizumab 840 mg d1,15 Q 4 weeks
3099040|NCT01898117|Active Comparator|Paclitaxel|Paclitaxel 90 mg/m2 d1, 8, 15 Q 4 weeks
3099041|NCT01898117|Active Comparator|Paclitaxel + atezolizumab|Paclitaxel 90 mg/m2 d1, 8, 15 atezolizumab 840 mg d1,15 Q 4 weeks
3099042|NCT01898104|Active Comparator|SCRT|short course radiotherapy (SCRT) alone 25 Gy in 5 fractions over one week.
3099043|NCT01898104|Active Comparator|V-SCRT|Valproic acid (V) + short course radiotherapy
3099044|NCT01898104|Active Comparator|C-SCRT|capecitabine (C) + short course radiotherapy
3099045|NCT01898104|Active Comparator|VC-SCRT|valproic acid + capecitabine + short course radiotherapy
3099046|NCT01898091|Experimental|Neem Mouthrinse|Participants will rinse for 30 seconds with the measured 10ml dose of the assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
3099047|NCT01898091|Placebo Comparator|Placebo Mouthrinse|Participants will rinse for 30 seconds with the measured 10ml dose of the assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
3099048|NCT01898078|Experimental|MLN8237|
3099049|NCT01898065|Experimental|PET imaging, 18 F-miso|Single Arm study
3099050|NCT01898052|Experimental|multimodal drug injection|Multimodal drug injection Levobupivacaine 150 mg, epinephrine(1:1000) 0.6 mL(0.6 mg), morphine sulfate 5 mL(5 mg), ketorolac 1 mL (30 mg) and mixed with normal saline up to 100 mL
3099051|NCT01898052|Active Comparator|Single anaesthetic drug|Single anaesthetic drug levobupivacaine 150 mg and epinephrine (1:1000) 0.6 ml (0.6 mg)
3099052|NCT01898039|Experimental|A2/4-1BBL melanoma vaccine|"On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm.~On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered at the day care unit. On day 14 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed. Four additional doses of the vaccine will be administered at intervals of 21 days."
3099053|NCT01898026|Experimental|PGX|samples of white bread, mashed potatoes, muffin, hot breakfast cereal with the addition of soluble fibre blend
3099054|NCT01898026|Other|Control|samples of white bread, mashed potatoes, muffin, hot breakfast cereal without the addition of soluble fibre blend
3099055|NCT01898013|Active Comparator|Pregnenolone|"Pregnenolone fixed escalating up to 500mg/day will consist of the following schedule:~Visit 1 (week -1, screening visit) and pain symptom assessment (no study medication) Visit 2 (week 0) placebo lead-in (all participants) Visit 3 (week 1, baseline visit): 50mg PO, BID x 1 week, Visit 4 (week 2): 150mg PO, BID x 1 week, Visit 5 (week 3): 250mg PO, BID for two weeks. Visit 6 (week 5): No medication will be dispensed; study medication will be tapered by 100mg per day and then discontinued."
3099056|NCT01898013|Placebo Comparator|Placebo|"Placebo will be administered exactly the same as the active comparator (pregnenolone) and will consist of the following schedule:~Visit 1 (week -1, screening visit) and pain symptom assessment (no study medication) Visit 2 (week 0) placebo lead-in (all participants) Visit 3 (week 1, baseline visit): placebo PO, BID x 1 week, Visit 4 (week 2): placebo PO, BID x 1 week, Visit 5 (week 3): placebo PO, BID for two weeks. Visit 6 (week 5): No medication will be dispensed; study medication will be tapered in the exact manner as active study medication and then discontinued."
3099057|NCT01897987|Experimental|Pneumostem®|A single intratracheal administration of Pneumostem® (1.0 x 10^7 cells/kg)
3099058|NCT01897987|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
3099059|NCT01897974||Seizure disorder|Patients that are on medications for seizure disorder.
3099060|NCT01897961|Other|Patients whose renal disease of origin is a GEM|Patients whose renal disease of origin is a GEM
3099061|NCT01897961|Other|Transplanted Patients of origin is a GEM having done it again|Transplanted Patients of origin is a GEM having done it again
3099062|NCT01897961|Other|Transplanted patients, and having developed a GEM of novo|Transplanted patients, and having developed a GEM of novo
3099063|NCT01897948|Experimental|Milk-based beverage with DHA at mid-level|
3099064|NCT01897948|Experimental|Milk-based beverage with DHA at high level|
3099065|NCT01897948|Active Comparator|Milk-based beverage without DHA|
3099066|NCT01897922|Active Comparator|Marketed routine infant formula|
3099067|NCT01897922|Experimental|Infant formula containing a probiotic source|
3099068|NCT01897909||HIV positive with H. pylori infection|HIV positive patients with H. pylori infection
3099069|NCT01897909||HIV positive without H. pylori infection|HIV positive patients without H. pylori infection
3099070|NCT01897909||HIV negative|HIV negative blood donors
3099071|NCT01897896|Experimental|Switch Subject Cohort|Switch subjects are those who are currently receiving stable doses of tetrabenazine for treatment of chorea associated with HD and convert to SD-809 ER based on an algorithm designed to achieve comparable exposure to total (α+β)-HTBZ metabolites.
3099072|NCT01897896|Experimental|Rollover Subject Cohort|Rollover subjects are those who have successfully completed Study SD-809-C-15 and are continuing on long-term SD-809 ER after a 1-week wash out period.
3099073|NCT01897883||One Group|Full Analysis Set (FAS) will be the primary analysis set. All post ischemic stroke patients within 6-12 months from attack (i.e., with inclusion criterion No.2 fulfilled) except the screening failure patients, i.e., those who withdraw from the study once the informed consent is given, will be included in the FAS.
3099074|NCT01897870|Experimental|HomeCoMe-program group|the arm receiving the pharmacist home visit
3099075|NCT01897857|Experimental|DM kidney transplantation|patient with DM undergoing undergoing kidney transplantation
3099076|NCT01897857|Active Comparator|without DM undergoing kidney transplantation|patient without DM undergoing undergoing kidney transplantation
3099077|NCT01897844|Experimental|ITF2984/Placebo 2000 mcg sc bid|ITF2984/Placebo 2000mcg s.c. b.i.d. for 14 days
3099078|NCT01897844|Experimental|ITF2984/Placebo 3000 mcg sc bid|ITF2984/Placebo 3000mcg s.c. b.i.d. for 14 days
3099079|NCT01897844|Experimental|ITF2984/Placebo 100 mcg sc bid|ITF2984/Placebo 100mcg s.c. b.i.d. for 14 days
3099080|NCT01897831|Experimental|xin te mie|1.5-3.0g,iv,bid or tid for 7-14 days
3099082|NCT01897805|Experimental|Heart-protecting Musk Pill|Patients will get standard treatment for coronary artery disease plus 2 Heart-protecting Musk Pills each time, three times a day by mouth for 24 months
3099083|NCT01897805|Placebo Comparator|Placebo|Patients will get standard treatment for coronary artery disease plus 2 placebo pills each time, three times a day by mouth for 24 months
3099084|NCT01897792|Experimental|Vitamins C and E|Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
3099085|NCT01897792|Placebo Comparator|0.9% saline and sugar pill|100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
3099086|NCT01897779|Experimental|Single and multiple dose of RPX7009|Single and multiple dose of RPX7009
3099087|NCT01897779|Experimental|Single and multiple dose of RPX2014|Single and multiple dose of RPX2014
3099088|NCT01897779|Placebo Comparator|Normal Saline|Single and multiple dose of normal saline
3099089|NCT01897779|Experimental|Combination RPX7009 and RPX2014|Single and Multiple dose of Combination RPX7009 and RPX2014
3099090|NCT01897766||Somatropin|Patients administered Somatropin.
3099091|NCT01897753||Small For Gestational Age (SGA) Children|SGA children under growth hormone treatment for more than 36 months.
3099092|NCT01897727|Active Comparator|Spironolactone|Spironolactone 25 mg administered following baseline measurements and uptitrated to 50 mg if BP > 140/90 mm Hg throughout the 3 month study.
3099093|NCT01897727|Sham Comparator|Standard of care BP treatment|Antihypertensive medication added and/or uptitrated to keep BP < 140/90 mm Hg throughout the study.
3099094|NCT01897714|Experimental|Melflufen and dexamethasone in combination|Intravenous infusion of melflufen Day 1 of 21 day cycles, in combination with 40 mg dexamethasone (oral or i.v.) day 1, 8 and 15 of the 21 day cycles.
3099095|NCT01897701|Experimental|Group A|High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 & 21
3099096|NCT01897701|Experimental|Group B|Intermediate dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 & 21
3099097|NCT01897701|Experimental|Group C|Intermediate dose Monovalent Avian Influenza VLP (H7N9) and Low dose Adjuvant 1; IM; Day 0 & 21
3099098|NCT01897701|Experimental|Group D|Low dose Monovalent Avian Influenza VLP (H7N9) and Low dose Adjuvant 1; IM; Day 0 & Day 21
3099099|NCT01897701|Experimental|Group E|Intermediate dose Monovalent Avian Influenza VLP (H7N9) and High dose Adjuvant 1; IM; Day 0 & 21
3099100|NCT01897701|Experimental|Group F|Low dose Monovalent Avian Influenza VLP (H7N9) and High dose Adjuvant 1; IM; Day 0 & 21
3099101|NCT01897701|Experimental|Group G|Placebo; IM; Day 0 & 21
3099102|NCT01897688|Experimental|Islet Cell Transplant|All qualified subjects will be put on United Network for Organ Sharing (UNOS) Islet Transplant wait list for potential islet cell transplant.
3099103|NCT01897675|Active Comparator|Incision and Drainage with Packing|Abscess is cared for in the standard fashion, using an incision and drainage with packing (wick) placement. Packing to be changed every 2-3 days, at the discretion of the treating clinician, until abscess is considered resolved
3099104|NCT01897675|Experimental|Loop Drainage|Abscess is cared for using a minimally invasive abscess drainage with loop placement technique. Two (or more) stab incisions are made in the abscess, the cavity is probed and pus is drained, and a vessel loop is inserted and tied off. The patient manipulates the loop 3 times per day, and removes the loop when all redness is gone and no more pus is present
3099105|NCT01897662|Experimental|NUTRIOSE|Group of volunteers fed with NUTRIOSE
3099106|NCT01897662|Active Comparator|GLUCIDEX|Group of volunteers fed with GLUCIDEX
3099107|NCT01897649|Experimental|NUTRIOSE|group of volunteers fed with NUTRIOSE
3099108|NCT01897649|Active Comparator|GLUCIDEX|gruop of volunteers fed with GLUCIDEX
3099109|NCT01897636|Experimental|EUS-guided fine-needle injection of DCs vaccinations|
3099110|NCT01897623|Other|ultrasound of aorta|
3099111|NCT01897610|No Intervention|control group|The study subjects randomly assigned to the control group is given Nexavar chemotherapy according to the clinical test plans.
3099112|NCT01897610|Experimental|Immuncell-LC group|The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after baseline by administering Nexavar chemotherapy same as control group with Immuncell-LC (10 times).
3099113|NCT01897597|Experimental|BI 144807 PfoS Treatment A|intermediate dose of BI 144807
3099114|NCT01897597|Experimental|BI 144807 PfoS Treatment C|high dose of BI 144807
3099115|NCT01897597|Experimental|BI 144807 Tab Treatment B|intermediate dose of BI 144807
3099116|NCT01897597|Experimental|BI 144807 Tab Treatment D|high dose of BI 144807
3099117|NCT01897597|Experimental|BI 144807 Tab Treatment E|intermediate dose of BI 144807, fasted
3099118|NCT01897597|Experimental|BI 144807 Tab Treatment F|intermediate dose of BI 144807, fed
3099119|NCT01897597|Experimental|BI 144807 Tab Treatment G|intermediate dose of BI 144807, fasted
3099120|NCT01897584|Experimental|Inverse IE|in only one group, inspiration to expiration ratio 1:2 to 1:1 will be applied during pneumoperitoneum
3099121|NCT01897571|Experimental|Tazemetostat (formerly known as EPZ-6438 and E7438): Phase 1|This portion comprises dose escalation and dose expansion to establish the recommended Phase 2 dose (RP2D) when tazemetostat is given BID (twice daily) orally on a continuous basis. Additionally, in separate cohorts in Phase 1, the effect of food on the bioavailability of tazemetostat as well as the drug-drug interaction (DDI) potential of tazemetostat are evaluated. CLOSED TO ENROLLMENT
3099122|NCT01897571|Experimental|Tazemetostat (formerly known as EPZ-6438 and E7438): Phase 2|This portion is restricted to subjects with DLBCL or FL for the determination of efficacy and safety of tazemetostat monotherapy and tazemetostat in combination with prednisolone as defined by histology, cell of origin and EZH2 mutation status.
3099123|NCT01897558|Active Comparator|Ventricular pacemaker electrode|receives an active fixation ventricular pacemaker electrode
3099124|NCT01897558|Active Comparator|Passive fixation ventricular pacemaker electrode|receives a passive fixation ventricular pacemaker electrode
3099125|NCT01897545|Active Comparator|PV isolation|
3099133|NCT01897493|Active Comparator|Digoxin|0.5 milligram (mg) digoxin administered orally once daily (QD) on Day 1
3099134|NCT01897493|Experimental|Evacetrapib + Digoxin|130 mg evacetrapib administered orally, QD for 14 days (Days 6 to 19) with a single oral dose of 0.5 mg digoxin coadministered on Day 15
3099135|NCT01897480|Experimental|LY2875358 plus Erlotinib|"Lead In: Approximately 8 weeks of erlotinib 150 milligram (mg) given orally per day.~Randomization: Erlotinib 150 mg given orally per day plus 750 mg LY2875358 given as 1.5 hours intravenous (IV) infusions on Days 1 and 15 of 28-day cycles."
3099136|NCT01897480|Active Comparator|Erlotinib|"Lead In: Approximately 8 weeks of erlotinib 150 mg given orally per day.~Randomization: Continue Erlotinib 150 mg given orally per day, in 28-day cycles."
3099137|NCT01897467|Placebo Comparator|Control|"The control is a wait-list control, and will have the option to participate in the intervention at the end of the initial 12-week study period. The control group will be asked to not change any of their dietary or exercise habits over the course of the 12 weeks."
3099138|NCT01897467|Experimental|Wii Fit|"Participants in the intervention group will be assigned a Wii console and a Wii Fit balance board. The intervention group will be asked to play for 30 minutes a day, 3 times per week, using only the participant profile pre-programmed for them. They will complete yoga poses and strength training exercises for the first 10 minutes and balance coordination games for the remaining 20 minutes. They will be asked to complete each exercise at least twice, preferably by cycling through all exercises. Participants will be asked to do all of the exercises in one 30-minute session, rather than breaking them up throughout the day.~All participants will be asked to keep a record of which games they play and for how long. The Wii Fit software also keeps a digital record of which exercises were completed and how long they were performed. At the end of the intervention the investigator will use the information stored in the Wii, as well as activity logs, to assess compliance."
3099139|NCT01897454|Experimental|Treatment (FOLFIRINOX, IMRT, and gemcitabine hydrochloride)|"CHEMOTHERAPY REGIMEN: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on day 1, and fluorouracil IV over 46 hours on days 1-3. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving disease progression proceed to chemoradiotherapy.~CHEMORADIOTHERAPY REGIMEN: Beginning 4-6 weeks after completion of chemotherapy, patients undergo IMRT on 5 consecutive days per week for a total of 28 fractions and receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Treatment continues in the absence of disease progression or unacceptable toxicity."
3099140|NCT01897441|Experimental|Stratum A (HER2-positive disease)|Patients receive paclitaxel IV over 1 hour and trastuzumab IV over 30-90 minutes weekly for 12 weeks. Beginning 2-3 weeks after the last dose of paclitaxel, patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes every 2 weeks for 8 weeks
3099141|NCT01897441|Experimental|Stratum B (paclitaxel followed by AC)|Patients receive paclitaxel, doxorubicin hydrochloride, and cyclophosphamide as in Stratum A.
3099142|NCT01897441|Experimental|Stratum C (AC followed by paclitaxel)|Patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes every 2 weeks for 8 weeks. Patients then receive paclitaxel IV over 1 hour weekly for 12 weeks.
3099143|NCT01897428|Active Comparator|Reference arm|Treated with Reference (bepotastine besilate 10 mg)
3099144|NCT01897428|Experimental|Test arm|Treated with Test (bepotastine salicylate 9.64 mg)
3099145|NCT01897415|Experimental|Autologous T cells|Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
3099146|NCT01897402|Experimental|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
3099147|NCT01897402|Active Comparator|US Licensed Vaccine|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
3099148|NCT01897389|Experimental|Sequence 1: abiraterone acetate|Treatment sequence 1 is defined as: AEBD
3099149|NCT01897389|Experimental|Sequence 2: abiraterone acetate|Treatment sequence 2 is defined as: BACE
3099150|NCT01897389|Experimental|Sequence 3: abiraterone acetate|Treatment sequence 3 is defined as: CBDA
3099151|NCT01897389|Experimental|Sequence 4: abiraterone acetate|Treatment sequence 4 is defined as: EDAC
3099152|NCT01897389|Experimental|Sequence 5: abiraterone acetate|Treatment sequence 5 is defined as: DECA
3099153|NCT01897389|Experimental|Sequence 6: abiraterone acetate|Treatment sequence 6 is defined as: EADB
3099154|NCT01897389|Experimental|Sequence 7: abiraterone acetate|Treatment sequence 7 is defined as: ABEC
3099155|NCT01897389|Experimental|Sequence 8: abiraterone acetate|Treatment sequence 8 is defined as: BCAD
3099156|NCT01897376|Other|Pfannenstiel incision|
3099157|NCT01897376|Other|vertical skin incision|
3099158|NCT01897363||Infants with Prader-Willi Syndrome|Infants between ages 2 to 12 months of age with Prader-Willi Syndrome.
3099159|NCT01897350||CMR following ST segment myocardial infarction|
3099160|NCT01897337|Experimental|Aprepitant group|We administrate aprepitant with small amount of water to aprepitant group in pre treatment room (Before patient get in the operating room)
3099161|NCT01897337|Placebo Comparator|placebo group|Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
3099162|NCT01897324|Experimental|The Long protocol|Patients in the group A received a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) which started on day 21 of preceding cycle at a dose of 0.1 mg/day. On the second day of menstruation HMG was started and this was associated with reduction of triptorelin to 0.05 mg/day. This reduced daily dose was administered until the day hCG was given. Growth hormone co-treatment was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
3099163|NCT01897324|Experimental|The Short protocol|The short agonist protocol was started on cycle day 1 with triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. Human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) were also administered starting from days 2 to 3 of cycle. The dose was adjusted for each patient according to the diameter of the follicles detected in their follow up ultrasound. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
3099275|NCT01896544|Active Comparator|Cholecalciferol Dose II|Oral suspension cholecalciferol 400,000 IU
3099164|NCT01897324|Experimental|The Antagonist protocol|Gonadotrophins IM daily (HMG 75 IU, Merional, IBSA)was administrated from day 2 of the cycle. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration. The GnRH antagonist (Cetrotide) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
3099165|NCT01897324|Experimental|The Microflare protocol|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
3099166|NCT01897311|Experimental|grupo TENS com frequência de 100 Hz|TENS application of high frequency (100 Hz, 100 μs)
3099167|NCT01897311|Experimental|grupo TENS com frequência de 4 Hz|Application of low-frequency TENS (4 Hz, 100 μs)
3099168|NCT01897311|Placebo Comparator|Placebo with TENS off|TENS application when off
3099169|NCT01897298|Experimental|Urban training Intervention|Patients will be advised to walk in the defined urban trails.
3099170|NCT01897298|No Intervention|Usual care|Patients will continue their usual care
3099171|NCT01897285|Experimental|All study participants: AQUACEL® foam adhesive dressings|Original adhesive + test adhesive
3099172|NCT01897272||Splinting After Surgery|This group will be fitted for a splint and given instructions on wearing their splint after their short-incision Carpal Tunnel Release
3099173|NCT01897272||No Splinting After Surgery|This group will not be splinted after the short-incision carpal tunnel release
3099174|NCT01897259|Active Comparator|Corticosteroid Injections|Patients will receive 1 cc Kenalong 10 mg injection to the site every 6 weeks until clinical symptoms have resolved. They will also receive an anesthetic of 1cc 1% lidocaine in conjunction with the corticosteroid injection.
3099175|NCT01897259|Active Comparator|Prolotherapy|Participants receive 1cc 50% Dextrose and 1 cc Sodium Morrhuate to the site every 6 weeks until symptoms resolve. These participants will also receive an anesthetic of 1cc 1% lidocaine.
3099176|NCT01897259|Placebo Comparator|Placebo|Participants will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
3099177|NCT01897259|Active Comparator|Physical Therapy|Participants will be prescribed NSAIDS (Diclofenac 75 mg BID) for 2 weeks. Participants will attend therapy for muscle stretches, soft tissue mobilization, and gradual strengthening.
3099178|NCT01897246|Active Comparator|Computer-assisted pre-operative planning|Patients enrolled in this arm will undergo corrective surgery of the distal radius, with pre-operative computer-assisted planning and virtual osteotomy.
3099179|NCT01897246|Active Comparator|Conventional pre-operative planning|Patients in this group will undergo corrective osteotomy of the distal radius wit conventional pre-operative planning.
3099180|NCT01897233|Experimental|Lumacaftor/Ivacaftor (LUM/IVA)|"Part A Cohort 1: Participants aged 6 through 8 years will receive LUM 200 milligram (mg) in fixed-dose combination with IVA 250 mg orally every 12 hours (q12h) for 14 days.~Part A Cohort 2: Participants aged 9 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 14 days.~Part B: Participants aged 6 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 24 weeks."
3099181|NCT01897220||University Hospital Patients|Consecutive patients with cardiovascular disease(s) undergoing non-cardiac surgery
3099182|NCT01897207|Experimental|Dendritic cell application|
3099183|NCT01897194||Coma Patients|Observation of EEG patterns in coma patients.
3099184|NCT01897181|Active Comparator|Hearing aids|Patients who agree to use hearing aids
3099185|NCT01897181|No Intervention|No hearing aids|Patients who did not agree to use hearing aids
3099186|NCT01897168||No grouping|
3099187|NCT01897155|Other|SBP 20-30% under baseline|Induction of anesthesia was performed with remifentanil, pentothal 3 mg/kg and atracurium 0.5 mg/Kg. Anaesthesia was maintained with remifentanil (0.4 ug/Kg/min) and isoflurane adjusted to bispectral index (40-60). Patients received a phenylephrine infusion to maintain systolic blood pressure (SBP) 20% to 30% under baseline. The lower limit of SBP was 75 mmHg. In the recovery room, morphine was administered routinely at doses of 3 mg IV every 15 minutes until pain was less than 4 estimated by visual analog scale (VAS). VAS and pain threshold with von Frey filaments were assessed at 2, 6, 12 and 24 postoperative hours. All patients, received ketorolac 30 mg IV every 8 hours and intravenous morphine administered by patient controlled analgesia system (PCA) during the first 24 hours.
3099188|NCT01897155|Other|SBP 20-30% over baseline|Induction of anesthesia was performed with remifentanil, pentothal 3 mg/kg and atracurium 0.5 mg/Kg. Anaesthesia was maintained with remifentanil (0.4 ug/Kg/min) and isoflurane adjusted to bispectral index(40-60). Patients received a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over baseline. The upper limit of SBP was 165 mmHg. In the recovery room, morphine was administered routinely at doses of 3 mg IV every 15 minutes until pain was less than 4 estimated by visual analog scale (VAS). VAS and pain threshold with von Frey filaments were assessed at 2, 6, 12 and 24 postoperative hours. All patients, received ketorolac 30 mg IV every 8 hours and intravenous morphine administered by patient controlled analgesia system (PCA) during the first 24 hours.
3099189|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 1|
3099190|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 2|
3099191|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 3|
3099192|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 4|
3099193|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 5|
3099194|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 6|
3099195|NCT01897129||Early pregnancy|Women in early pregnancy at around the time of the nuchal translucency scan. The prevalence of HPV will be determined
3099196|NCT01897129||Chorionic villous sampling|Women undergoing chorionic villous sampling for the purpose of prenatal diagnostics.
3099197|NCT01897129||Spontaneous abortion|Women with miscarriage at a gestational age up to 22 weeks
3099198|NCT01897129||Preterm birth|Women with spontaneous preterm birth/premature primary rupture of membranes at a gestational age week 22-32
3099199|NCT01897129||Vaginal delivery at term|Women with spontaneous vaginal delivery at term (week 37+0-)
3099200|NCT01897129||Elective ceaserean section at term|Women undergoing elective cesarean section at term (week 37+0-)
3099201|NCT01897090|Experimental|Elimination Diet|"thirty (30) patients will be on the Crohn's Disease Diet (primarily an anti-inflammatory diet that is an elimination diet - gluten-free, casein-free based with limited carbohydrate)"
3099202|NCT01897090|Active Comparator|Dietary Guidelines for Americans|The DASH eating plan is based on 1,600, 2,000, 2,600 and 3,100 calories.
3099203|NCT01897077|Experimental|Peanut Allergic|Only one intervention will be given. Peanut allergic study subjects, will receive gradually increasing doses of the dissolving peanut film.
3099204|NCT01897077|Active Comparator|Healthy Volunteers|Healthy volunteers will receive active peanut dissolving films in an expedited manner in order to determine safety dissolving films.
3099205|NCT01897064|Experimental|Aerobic Exercise|Up to 36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric treatment.
3099206|NCT01897064|Active Comparator|Standard Psychiatric Treatment|12 weeks of standard psychiatric treatment.
3099207|NCT01897051|Experimental|Combination therapy|Rifaximin(normix®)+nonselective beta-blocker(Propranolol)
3099208|NCT01897051|Placebo Comparator|Monotherapy|nonselective beta-blocker(Propranolol) + Placebo(of Rifaximin)
3099209|NCT01897038|Experimental|Cohort 1 (Onartuzumab)|
3099210|NCT01897038|Experimental|Cohorts 2/3 (Onartuzumab + Sorafenib)|
3099211|NCT01897025|Active Comparator|real-tDCS with MI-BCI|"10 sessions of the following: 20 minutes of tDCS prior to each session of motor training with the MI-BCI system.~Direct current at an intensity of 1mA with anode placed over the M1 motor cortex of the affected hemisphere and the cathode placed over the unaffected M1.~After initial calibration, MI-BCI training will involve motor imagery of reaching tasks using the clock game interface of the MIT-Manus robotic system to perform multi-directional reaching movements. Upon detection of the intention to move towards the target on BCI, the robotic arm will complete the reaching movement towards the target. Each training session will last for 40 minutes excluding set-up time."
3099212|NCT01897025|Sham Comparator|sham-tDCS with MI-BCI|"10 sessions of sham tDCS with BCI motor training, each session of which will be conducted as follows:~The same electrode placement and stimulation parameters will be employed for sham tDCS as for real tDCS. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation. This method of sham stimulation has also been validated (Gandiga et al., 2006). Current intensity will be increased and decreased gradually to decrease perception.~MI-BCI training will be the same as the real-tDCS group and will similarly last for 40 minutes."
3099213|NCT01897012|Experimental|Treatment (alisertib, romidepsin)|Patients receive alisertib PO BID on days 1-7 (dose levels 1-4) or days 1-3, 8-10, and 15-17 (dose levels 5-8). Patients also receive romidepsin IV over 4 hours on days 1 and 8 (dose levels 1-4) or 2, 9, and 16 (dose levels 5-8). Treatment repeats every 21 days (dose levels 1-4) or 28 days (dose levels 5-8) for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3099214|NCT01896999|Experimental|Phase I Arm I (brentuximab vedotin, ipilimumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 and ipilimumab IV over 30 minutes on day 1 of courses 1-4, 8, 12, and 16. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
3099215|NCT01896999|Experimental|Phase I Arm II (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of courses 1-16 and nivolumab IV over 30 minutes on day 1 of courses 1-46. Treatment repeats every 21 days for up to 16 courses and every 14 days beginning course 17 for up to 46 courses in the absence of disease progression or unacceptable toxicity.
3099216|NCT01896999|Experimental|Phase I Arm III (brentuximab vedotin, nivolumab, ipilimumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of courses 1-16, nivolumab IV over 30 minutes on day 1 of courses 1-46, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 16 courses and every 14 days beginning course 17 for up to 46 courses in the absence of disease progression or unacceptable toxicity.
3099217|NCT01896999|Experimental|Phase II Arm I (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of courses 1-16 and nivolumab IV over 30 minutes on day 1 of courses 1-34. Treatment repeats every 21 days for up to 34 courses in the absence of disease progression or unacceptable toxicity.
3099218|NCT01896999|Experimental|Phase II Arm II (brentuximab vedotin, nivolumab, ipilimumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of courses 1-16, nivolumab IV over 30 minutes on day 1 of courses 1-34, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 34 courses in the absence of disease progression or unacceptable toxicity.
3099219|NCT01896986||PRD patrients|"Children/adolescent females 12-26 years with a PRD such as JIA (Juvenile Idiopathic Arthritis) or SLE (Systemic Lupus Erythematosus)~Subgroups:~receiving immunosuppressant therapy~not on immunosuppressant therapy"
3099220|NCT01896986||IBD patients|"Children/adolescent females 12-26 years diagnosed with IBD.~Subgroups:~3. receiving immunosuppressant therapy 4. not on immunosuppressant therapy"
3099221|NCT01896973|Experimental|Vortx Rx - Histotripsy BPH Device|The Vortx Rx is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.
3099222|NCT01896960|Active Comparator|2 ml Bupivacaine|2 ml Bupivacaine with 15 micrograms of fentanyl
3099223|NCT01896960|Active Comparator|1.5 ml Bupivacaine|1.5 ml Bupivacaine with 15 micrograms of fentanyl
3099224|NCT01896947||MRI and MRA group|All patients will receive 3T MRI and MR arthrogram
3099225|NCT01896934|Experimental|Sertraline|50-200mg daily
3099226|NCT01896921|Experimental|Maraviroc + Raltegravir or Dolutegravir|Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks
3099227|NCT01896908|Experimental|Intervention|Sodium restriction (1.6g sodium daily - 4g salt) combined with 800 ml of fluid intake
3099228|NCT01896908|No Intervention|Control|Normal sodium diet (4g sodium daily - 10g salt) and free fluid intake
3099229|NCT01896895|Experimental|IncobotulinumtoxinA (Xeomin) 25U per eye|Main Period: one injection session, 25 Units per eye. Open-Label Extension: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
3099230|NCT01896895|Experimental|IncobotulinumtoxinA (Xeomin) 12.5U per eye|Main Period: one injection session, 12.5 Units per eye. Open-Label Extension Period: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
3099231|NCT01896895|Placebo Comparator|Placebo|"Main Period: Placebo to IncobotulinumtoxinA (Xeomin)(12.5 or 25U/eye), one injection session.~Open-Label Extension: IncobotulinumtoxinA (Xeomin), one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection."
3099232|NCT01896882|Experimental|Intervention|Nutritional education on sodium restriction diet.
3099233|NCT01896882|No Intervention|Control|Standard treatment.
3099234|NCT01896869|Experimental|Ipilimumab + Vaccine|Ipilimumab and vaccine will be administered every 3 weeks for 4 doses, then every 8 weeks.
3099235|NCT01896869|Experimental|FOLFIRINOX|Administered every 14 days (one cycle)
3099236|NCT01896856|Active Comparator|Phase 2: Arm B regorafenib or TAS-102|In phase 2, we will compare SGI-110 + irinotecan to regorafenib or TAS-102.
3099237|NCT01896856|Active Comparator|Phase 2: Arm A SGI-110 + irinotecan|In phase 2, we will compare SGI-110 + irinotecan to regorafenib or TAS-102
3099238|NCT01896830|Experimental|Vaccine Group|Participants will receive the candidate C. difficile toxoid vaccine
3099239|NCT01896830|Placebo Comparator|Placebo Group|Participants will receive a placebo vaccine
3099240|NCT01896791|Active Comparator|Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation: the anode electrode is placed in the area of the motor cortex M1 C3 or C4 position of the dominant hemisphere (International 10-20 EEG System). The cathode electrode is placed over the contralateral supraorbital region to the anode electrode. Treatment time and intensity of the stimulus: tDCS: 2mili Ampere, 20min, 10 days.
3099241|NCT01896791|Placebo Comparator|Sham Stimulation|Sham Stimulation: appliance off during the entire period without active stimulation, with the position of the electrodes in the same sites of active stimulation
3099242|NCT01896778|Experimental|Arm I (B-WARM for 30 minutes)|Patients undergo B-WARM at 39 degrees C for 30 minutes.
3099243|NCT01896778|Experimental|Arm II (B-WARM for 2 hours)|Patients undergo B-WARM at 39 degrees C for 2 hours.
3099244|NCT01896765|Experimental|Intensive prevention program|"Standard care with respect to medical and interventional therapy plus intensive prevention program with study nurse-coordinated education sessions, regular telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available)."
3099245|NCT01896765|Other|Usual care|Standard care with respect to medical and interventional therapy.
3099246|NCT01896739|Experimental|Experimental group with 0-2-4-6 schedule|HB at 0, Eutravac at 2-4-6
3099247|NCT01896739|Active Comparator|Active comparator group with 0-2-4-6 schedule|Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)
3099248|NCT01896739|Experimental|Experimental group with 2-4-6 schedule|Eutravac at 2-4-6
3099249|NCT01896739|Active Comparator|Active comparator group with 2-4-6 schedule|Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)
3099250|NCT01896726|Experimental|Baricitinib + Microgynon|Microgynon [30 micrograms (µg) ethinyl estradiol and 150 µg levonorgestrel] administered orally, once daily (QD), on Days 1 and 29. Baricitinib, 10 milligrams (mg), administered orally QD on Days 23 through 30.
3099251|NCT01896713|Other|Diagnostic: Single Arm|Imaging (MS3TMRI)
3099252|NCT01896700|Experimental|Methylphenidate|"Intervention: An escalating dose of methylphenidate taken by mouth: 20mg for 2 weeks, 40mg for 2 weeks, 60mg for 2 weeks. All doses divided twice/day.~Other name: Ritalin"
3099253|NCT01896700|Placebo Comparator|Placebo|Placebo pill, bid for 6 weeks
3099254|NCT01896687|Experimental|Scrambler therapy|Scrambler therapy applied to region of low back pain for 30 minutes x 10 days
3099255|NCT01896687|Sham Comparator|Sham Scrambler treatment|Sham treatment applied to region above low back pain at nontherapeutic dose for 30 minutes x 10 days
3099256|NCT01896661|Experimental|Diuretics|Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
3099257|NCT01896661|Active Comparator|Calcium Channel Blockers|Amlodipine 10 mg daily, taking in the morning
3099258|NCT01896648||Type 2 diabetic women|
3099259|NCT01896635|Active Comparator|FMT infusions|FMT infusions constituted from stool provided by healthy, screened donors
3099260|NCT01896635|Placebo Comparator|Placebo arm|Placebo infusions
3099261|NCT01896622|Experimental|A|Ritonavir
3099262|NCT01896622|Experimental|B|Cobicistat
3099263|NCT01896609|Experimental|Arm 1 (Standard therpy)|"Arm 1 : subject randomized to this arm will be receiving the standard care therapy for 48 weeks:~Reiferon Retard® 160 µg /week subcutaneous injection.~Ribavirin in a dose of 13 mg/kg/day orally"
3099264|NCT01896609|Experimental|Arm 2 ( Xerovirinc)|"Arm 2 : Subjects randomized to this arm will be receiving the following medications for 48 weeks;~Reiferon Retard® 160 µg /week subcutaneous injection~Ribavirin in a dose of 13 mg/kg/day orally~Xerovirinc® 500mg twice daily orally."
3099265|NCT01896609|Experimental|Arm 3 ( Bon one )|"Arm 3: Subjects randomized to this arm will be receiving the following medications for 48 weeks:~Bon-One ® 0.5 µg daily orally~Reiferon Retard® 160 µg /week subcutaneous injection~Ribavirin in a dose of 13 mg/kg/day orally~Xerovirinc® 500mg twice daily orally."
3099266|NCT01896596|Active Comparator|Menjugate|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with Menjugate (at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
3099267|NCT01896596|Active Comparator|Menitorix|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with Menitorix (at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
3099268|NCT01896596|Active Comparator|NeisVac-C|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with NeisVac-C(at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
3099269|NCT01896583|Experimental|ASP7147|ASP7147, 300 mg, tablet, twice per day for 4 weeks oral
3099270|NCT01896583|Placebo Comparator|Placebo|oral
3099271|NCT01896570||Group A: cardioversion at AT|after achievement of AT, pts were cardioverted
3099272|NCT01896570||Group B: ablation to SR|After AT has been achieved, all subsequent AT were ablated with the endpoint of procedural SR termination
3099273|NCT01896557|Experimental|omeprazole|Omeprazole 20 mg (oral route) twice a day will be given to the subjects for one week. This intervention will be compared with ranitidin 150 mg (oral route) twice a day.
3099274|NCT01896557|Experimental|ranitidine|Ranitidine 150 mg (oral route) twice a day will be given to the subjects for one week.
3099276|NCT01896544|Placebo Comparator|Placebo|Oral suspension of placebo cholecalciferol
3099277|NCT01896544|Active Comparator|Cholecalciferol Dose I|Oral suspension cholecalciferol 200,000 IU
3099278|NCT01896531|Experimental|GDC-0068 + mFOLFOX6|Participants will receive oral GDC-0068 on Days 1 to 7 of each 14-day cycle in combination with mFOLFOX6, administered on Day 1 of each cycle.
3099279|NCT01896531|Placebo Comparator|Placebo + mFOLFOX6|Participants will receive the placebo equivalent to GDC-0068 on Days 1 to 7 of each 14-day cycle in combination with mFOLFOX6, administered on Day 1 of each cycle.
3099280|NCT01896518|No Intervention|Counseling|
3099281|NCT01896518|Experimental|Nicotine lozenge|Participants will receive nicotine lozenge to use as needed for 12 weeks.
3099282|NCT01896518|Experimental|Tobacco lozenge|Participants will receive tobacco lozenge to use as needed for 12 weeks.
3099283|NCT01896505|Experimental|Arm 1 - Treatment A, B, C, D|"There are 4 treatment formulations of KCP-330:~A: fasted, tablet formulation B: high-fat meal, tablet formulation C: low-fat meal, tablet formulation D: low-fat meal, capsule formulation~In Arm 1, the following order will be utilized:~Week 1, day 1: Treatment A Week 2, day 1: Treatment B Week 3, day 1: Treatment C Week 4, day 1: Treatment D~(Note that recruitment has been completed for this arm)"
3099284|NCT01896505|Experimental|Arm 2 - Treatment B, A, D, C|"There are 4 treatment formulations of KCP-330:~A: fasted, tablet formulation B: high-fat meal, tablet formulation C: low-fat meal, tablet formulation D: low-fat meal, capsule formulation~In Arm 2, the following order will be utilized:~Week 1, day 1: Treatment B Week 2, day 1: Treatment A Week 3, day 1: Treatment D Week 4, day 1: Treatment C~(Note that recruitment has been completed for this arm)"
3099285|NCT01896505|Experimental|Arm 3|"﻿To evaluate tumor response in sarcoma patients (RECIST v1.1 criteria) on KCP-330.~(Note that recruitment has been completed for this arm)"
3099286|NCT01896505|Experimental|Arm 4 - Treatment A, B, C|"There are 3 treatment formulations of KCP-330:~A: Current (1st generation) tablets, 60 mg B: New (2nd generation) tablets, 60 mg C: Suspension dose of current (1st generation) tablets, 60 mg~In Arm 4, the following order will be utilized:~Week 1, day 1: Treatment A Week 2, day 1: Treatment B Week 3, day 1: Treatment C"
3099287|NCT01896505|Experimental|Arm 5 - Treatment C, A, B|"There are 3 treatment formulations of KCP-330:~A: Current (1st generation) tablets, 60 mg B: New (2nd generation) tablets, 60 mg C: Suspension dose of current (1st generation) tablets, 60 mg~In Arm 5, the following order will be utilized:~Week 1, day 1: Treatment C Week 2, day 1: Treatment A Week 3, day 1: Treatment B"
3099288|NCT01896505|Experimental|Arm 6 - Treatment B, C, A|"There are 3 treatment formulations of KCP-330:~A: Current (1st generation) tablets, 60 mg B: New (2nd generation) tablets, 60 mg C: Suspension dose of current (1st generation) tablets, 60 mg~In Arm 6, the following order will be utilized:~Week 1, day 1: Treatment B Week 2, day 1: Treatment C Week 3, day 1: Treatment A"
3099289|NCT01896492|Active Comparator|N-acetyl cystien and clomiphen citrate|N-acetyl cystien and clomiphen citrate,in induction of ovulation in newly diagnosed PCOS,1-2gm schats of NAC PLUS 100 mg of cc in the therd day of the cycle till day 8,with monitoring of follicular growth usin ultrasonography.HCG is giving to trigger of ovulation fo follicular size 18mm or more.
3099290|NCT01896492|Placebo Comparator|Clomiphen citrate and placebo|CC plus placebo compared to cc and NAC in induction of ovulation in PCOS new cases.
3099291|NCT01896492|No Intervention|N-acetyl cystien|In addition to the CC, each patient was selected randomly to receive either NAC (Sedico, Cairo, ARE), in a dose of 1.2 g/d orally, or a placebo (sugar) of the same volume twice daily from day 3 until day 7
3099292|NCT01896479|Experimental|Cabozantinib (XL184) 140 mg|Cabozantinib (XL184) 140 mg as capsules and placebo tablets administered orally once a day.
3099293|NCT01896479|Experimental|Cabozantinib (XL184) 60 mg|Cabozantinib (XL184) 60 mg as tablets and placebo capsules administered orally once a day.
3099294|NCT01896466|Active Comparator|Young Adults - Intervention|Healthy subjects between the ages of 18-39 will participate in Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
3099295|NCT01896466|Active Comparator|Healthy Older Adults - Control|Healthy subjects between age 65+ will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
3099296|NCT01896466|Active Comparator|Healthy Older Adults - Intervention|Healthy subjects age 65+ will participate in Cranial Nerve Non-Invasive Neuromodulation enhanced gait and balance training.
3099297|NCT01896466|Sham Comparator|Older Fallers - Control|Subjects who are age 65+ with a history of 1-3 falls in the previous six months will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
3099298|NCT01896466|Experimental|Older Fallers - Intervention|Subjects who are age 65+ with a history of 1-3 falls in the previous six months will participate in Cranial Nerve Non-Invasive Neuromodulation enhanced gait and balance training.
3099299|NCT01896466|Active Comparator|Young Adult - Control|Healthy subjects between the ages of 18-39 will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
3099300|NCT01896453|Active Comparator|tDCS real + TENS real|"Real transcranial direct current stimulation associated with real transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes, 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
3099301|NCT01896453|Experimental|tDCS real + TENS sham|"Real transcranial direct current stimulation associated with sham transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes (30 seconds ON), 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
3099302|NCT01896453|Experimental|tDCS sham + TENS real|"Sham transcranial direct current stimulation associated with real transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes, 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
3099303|NCT01896453|Sham Comparator|Sham tDCS + Sham TENS|"Sham transcranial direct current stimulation associated with sham transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes (30 seconds ON), 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
3099583|NCT01894490||Nasojejunal catheter|Patients who received a nasojejunal catheter
3099304|NCT01896440|Active Comparator|Group A - standard ondansetron dose first|Group A will receive the standard dose of ondansetron (0.15 mg/kg) with the first cycle of chemotherapy and the high dose (0.3 mg/kg) with second cycle.
3099305|NCT01896440|Active Comparator|Group B - high dose ondansetron first|Group B patients will receive the higher dose of ondansetron (0.3 mg/kg) with the first cycle of chemotherapy and the standard dose (0.15 mg/kg) with the second.
3099306|NCT01896427|Active Comparator|Dexamethazone IO|For the case group, after the inferior alveolar block injection and before starting the surgery, single dose of dexamethasone (8mg) will injected into medial pterygoid and pterygomandibular space
3099307|NCT01896427|Active Comparator|Dexamethasone IM|For the case group, after the inferior alveolar block injection and before starting the surgery, single dose of dexamethasone (8mg) will injected into medial pterygoid and pterygomandibular space
3099308|NCT01896414|Experimental|EPA (marine fatty acids)|Subjects will receive EPA , four 1 gram capsules daily.
3099309|NCT01896414|Placebo Comparator|Placebo|Subjects will be randomized to receive placebo, four 1 gram capsules daily.
3099310|NCT01896401|Experimental|InSeal's Vascular Closure Device|Use of the experimental VCD to close the access site of the artery
3099311|NCT01896388|Active Comparator|Ifenprodil Tartrate|Oral Administration of Ifenprodil Tartrate 40mg/day (20mg After breakfast, 20mg After supper)
3099312|NCT01896388|Placebo Comparator|Placebo|Oral Administration of Placebo (After breakfast, After supper)
3099313|NCT01896349|Experimental|IPT+antidepressant drugs|"Interpersonal Psychotherapy protocol (IPT) consist of 16 sessions of manualized interpersonal psychotherapy for depression. Patients are allowed to reschedule 3 sessions if they miss their appointments.~Antidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetin, citalopram, escitalopram, fluvoxamine, venlafaxin, duloxetin, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride."
3099314|NCT01896349|Active Comparator|Antidepressant Drugs|"Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice.~Antidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine, venlafaxine, duloxetine, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride."
3099315|NCT01896336|Experimental|5mg sublingual Zolpidem hemitartrate|1 QD
3099316|NCT01896336|Active Comparator|10 mg oral Zolpidem hemitartrate|1 QD.
3099317|NCT01896323|Experimental|CC-223|CC-223 administration on study day 1 of Period 1 and study day 5 of Period 2
3099318|NCT01896323|Active Comparator|Ketokonazole|Ketoconazole administration on study days 1 through 8 of Period 2
3099319|NCT01896310||pCLE examination|patients will be prospectively recruited and examined first with high-definition endoscopy (EG-2990i, Pentax, Japan) followed by probe-based confocal laser endomicroscopy
3099320|NCT01896297|Other|dabigatran etexilate|75mg BID by oral
3099321|NCT01896284|Experimental|0.5mg AFLIBERCEPT injection|Patients will receive intravitreal injection of aflibercept 0.5mg at baseline, week 4,8,16,24 and 32. Optionally, if intra or subretinal fluid persists at week 12, patients will receive an additional injection.
3099322|NCT01896271|Experimental|treatment|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion; SABR dose varying from 8Gy-20Gy in 1-3 fractions.
3099323|NCT01896258||Regional emergency centers|
3099324|NCT01896258||Local emergency centers|
3099325|NCT01896245|Active Comparator|sevoflurane 1,0|sevoflurane 1,0: sevoflurane is administered with a concentration of 1,0 MAC
3099326|NCT01896245|Active Comparator|sevoflurane 1,2|sevoflurane 1,2: sevoflurane is administered with a concentration of 1,2 MAC
3099327|NCT01896245|Active Comparator|sevoflurane 1,4|sevoflurane 1,4: sevoflurane is administered with a concentration of 1,4 MAC
3099328|NCT01896232|Active Comparator|Cinacalcet|Participants were randomized to receive oral cinacalcet once daily and placebo intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 30 mg daily and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
3099329|NCT01896232|Experimental|Etelcalcetide|Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW, and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.
3099330|NCT01896219|Active Comparator|Gesture performed under control tomodensitometric (CT)|Conventional
3099331|NCT01896219|Experimental|Gesture performed under Navigation-assisted procedure (NAV)|Use of the IMACTIS-CT® Navigation System
3099332|NCT01896206|Experimental|CNAP monitor|Subjects undergoing bariatric surgery and monitored using the CNAP monitor.
3099333|NCT01896193|Experimental|SOF+RBV 16 Weeks|SOF+RBV for 16 weeks
3099334|NCT01896193|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
3099335|NCT01896180|Experimental|ALZ-1101|ALZ-1101 ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular adminstration
3099336|NCT01896180|Active Comparator|Latanoprost|Latanoprost 0.005% ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular administration
3099337|NCT01896167|Active Comparator|Hypoxia|Inhalation of air with 8-12% oxygen content
3099338|NCT01896167|Placebo Comparator|Atmospheric air|Inhalation of atmospheric air, with oxygen content at 21%
3099339|NCT01896154|Experimental|NPS from yeast|Powder containing the active ingredients (500mg NPS from yeast) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks. 2 weeks before vaccination and 3 weeks after vaccination.
3099585|NCT01894477|Experimental|Arm B|"Arm B: Treosulfan, Fludarabine Phosphate, TBI~Treosulfan and fludarabine phosphate as in Arm A and undergo low -dose total-body irradiation (TBI) on day 0"
3099340|NCT01896154|Experimental|NPS from shiitake|Powder containing the active ingredient (500mg NPS from shitake) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
3099341|NCT01896154|Experimental|NPS from oat|Powder containing the active ingredient (10g NPS from oat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
3099342|NCT01896154|Experimental|NPS from wheat|Powder containing the active ingredient (10g NPS from wheat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
3099343|NCT01896154|Experimental|NPS from Lactobacillus mucosae|Powder containing the active ingredient (2,3g NPS from L. mucosae) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
3099344|NCT01896154|Placebo Comparator|Maltodextrin|12.0 g Maltodextrin and flavour with identical/similar appearance and taste (when mixed in drink), consumed once daily as described for the active products (NPS.
3099345|NCT01896128|Experimental|Armodafinil|150 mg armodafinil administered 2 hours prior to start of therapeutic regimen for 10 consecutive days
3099346|NCT01896128|Placebo Comparator|Placebo|inactive agent administered 2 hours prior to start of therapeutic regimen for 10 consecutive days
3099347|NCT01896115|Experimental|Short PW|Patients with a Vercise DBS system programmed to 30 microseconds pulse width
3099348|NCT01896115|Experimental|Conventional PW|Patients with a Vercise DBS system programmed to 60 microseconds pulse width
3099349|NCT01896115|Experimental|Ventral current steering|Patients with a Vercise DBS system programmed to steer current ventrally
3099350|NCT01896115|Experimental|Dorsal current steering|Patients with a Vercise DBS system programmed to steer current dorsally.
3099351|NCT01896102|Experimental|Lenti-D Drug Product|
3099352|NCT01896076||Pediatric patients in urologic surgery|Pediatric patients undergoing caudal block for urologic surgery were included in this study.
3099353|NCT01896063|Experimental|Electroacupuncture preconditioning|
3099354|NCT01896050||AI therapy|Subjects who started treatment with any of the three aromatase inhibitor (AI) medications
3099355|NCT01896050||Tamoxifen|Subjects who started treatment with tamoxifen
3099356|NCT01896037|Experimental|Omega-3 supplements|Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
3099357|NCT01896024|Active Comparator|General Psychiatric Management (GPM; Gunderson & Links, 2008)|psychodynamic-psychiatric treatment for borderline personality disorder
3099358|NCT01896024|Experimental|GPM plus Motive-Oriented Therapeutic Relationship|use of Plan Analysis and Motive-oriented therapeutic relationship, as add-on variable to GPM
3099359|NCT01896011|Active Comparator|Teriparatide 20 mcg daily|Teriparatide (Forteo) 20 mcg daily by injection pen for 12-24 months
3099360|NCT01896011|Placebo Comparator|Placebo|Placebo injection pen identical to active drug injection pen
3099361|NCT01895985|Experimental|Latanoprostene Bunod|Participants will instill 1 drop of latanoprostene bunod 0.024% topically into each eye QD in the evening for 14 days.
3099362|NCT01895972|Experimental|Latanoprostene Bunod|Latanoprostene bunod 0.024% instilled into the eye once daily (QD) over a 1-year treatment period.
3099363|NCT01895959|Other|Euflexxa|EUFLEXXA® is a hyaluronate hydrogel produced from bacteria, in a phosphate-buffered saline solution. It is given as a three week treatment regimen. It involves injecting of 2cc or 20mg intra-articularly once per week.
3099364|NCT01895946|Experimental|Part A: Formulation Switch|AZD5363 tablet twice daily followed by AZD5363 capsule twice daily on an intermittent regimen (4 days on, 3 days off).
3099365|NCT01895946|Experimental|Part B: Food effect|AZD5363 tablet twice daily on an intermittent regimen (4 days on, 3 days off) with/without food on one occasion
3099366|NCT01895933|Active Comparator|Active / control|One side has been treated with SurgiShield
3099367|NCT01895933|No Intervention|No intervention|One side has no intervention
3099368|NCT01895920|Experimental|HIV infection|20 HIV infected subjects
3099369|NCT01895907||Special Olympic athletes|
3099370|NCT01895894|Experimental|Mycophenolate mofetil|
3099371|NCT01895894|No Intervention|Control|
3099372|NCT01895881|Experimental|Estradiol Daily|1 mg Estradiol daily for 180 days.
3099373|NCT01895881|Placebo Comparator|Placebo|Placebo for 180 days.
3099374|NCT01895868|Active Comparator|Simulation-based training|Participants in the intervention group receive simulation training using two types of ultrasound simulators: The Scantrainer (Medaphor) and the BluePhantom (CAE). All participants are training to pre-established proficiency-criteria.
3099375|NCT01895868|No Intervention|Control|Clinical training alone.
3099376|NCT01895855|Experimental|PXVX0200|Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension
3099377|NCT01895855|Placebo Comparator|Placebo|Biological: Placebo physiological saline
3099378|NCT01895842|Experimental|Ruxolitinib|"Part 1: Dose of ruxolitinib received will depend when patient joined study. The first group of patients receive the lowest dose of ruxolitinib. Starting dose level for Part 1, 5 mg by mouth twice a day for a 28 day cycle. The second group of patients receive the lowest dose of ruxolitinib for 1 cycle and if no intolerable side effects are seen, the dose will increase to the next higher dose for Cycles 2 and beyond. The third group of patients receive the higher dose taken by the second group for 1 cycle and if no intolerable side effects are seen, the dose will be increased for Cycles 2 and beyond. The fourth group of patients take the higher dose taken by the third group for 1 cycle and if no intolerable side effects are seen, the dose will increase to the next higher dose for Cycles 2 and beyond.~If patients enrolled in Part 2, they will receive ruxolitinib at the highest dose that was tolerated in Part 1."
3099623|NCT01894256|Other|Mild renal impairment|Patients with calculated serum creatinine clearance 51-80 mL/min (using Cockcroft-Gault equation).
3099379|NCT01895829|Experimental|Ferumoxytol + Magnetic Resonance Imaging (MRI)|"On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. The study MRI performed in the same way that a standard MRI is performed.~On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed."
3099380|NCT01895816|Experimental|fertility coated tablet|700 mg fertility coated tablet containing 8 herbal powders by mouth every 12 hours for 180 days
3099381|NCT01895803||smoking woman 18-60 years old|
3099382|NCT01895790|Experimental|Pancreatic Duct|Consecutive adult patients (18-80 years of age) with cytopathologic diagnosis of unresectable pancreatic cancer complaining of pain due to pancreatic duct obstruction will receive a pancreatic duct stent.
3099383|NCT01895777|Experimental|dabigatran etexilate|Dabigatran etexilate capsules, pellets or liquid formulation given BID in an open label fashion for 3 months
3099384|NCT01895777|Active Comparator|standard of care|Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
3099385|NCT01895764|Active Comparator|Adalimumab|adalimumab 40mg every 2 weeks
3099386|NCT01895764|Experimental|Adalimumab + Methotrexate|adalimumab 40mg every 2 weeks and methotrexate 10mg per week
3099387|NCT01895751|No Intervention|Conservative therapy|"Conservative therapy group involves optimal medical therapy according to local hospital protocols with selective invasive management as clinically appropriate. Patients assigned to the conservative group may be referred for invasive management if the patient meets one of the following pre-specified criteria:~Recurrent or refractory (class III or IV) angina with documented ischaemic ECG changes while on optimal medical therapy.~New ST segment elevation in two contiguous leads without Q waves or T wave inversion greater than 3 mm or development of hemodynamic instability Deterioration in heart failure status (defined as Killip class 3 or 4)."
3099388|NCT01895751|Active Comparator|Invasive management|Invasive management is timed as appropriate according to local NHS protocols. Usually, invasive management is expected to be performed in line with contemporary guidelines.
3099389|NCT01895738|Experimental|WrapAround Care|Participants randomized to the intervention arm will be met in the emergency department by a support worker who has lived experience. They will start to build a relationship with the participant at that time (i.e. during the teachable moment) and will work with the participant for approximately one year, delivering WrapAround Care. Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
3099390|NCT01895738|No Intervention|Standard of Care|Standard of Care is typically a sheet of community resources potentially handed out by the emergency physician, nurse or social worker.
3099391|NCT01895712||Orsiro|
3099392|NCT01895699|Experimental|contrast group (Ioversol)|Each individual will be given 80 ml Ioversol via intravenous injection within 5 minutes
3099393|NCT01895699|Placebo Comparator|Placebo group|
3099394|NCT01895699|Other|alpha-lipoic acid group|Alpha-lipoic acid 600 mg in 0.9% sodium chloride 250 ml was administrated 1 hour before contrast agents via venous. and only 0.9% sodium chloride 250 ml was administrated for other 2 groups.
3099395|NCT01895686||Open angle glaucoma|patients diagnosed with open angle glaucoma
3099396|NCT01895686||Narrow angle|patients diagnosed with narrow angles
3099397|NCT01895686||Angle Closure Glaucoma|patients diagnosed with angle closure glaucoma
3099398|NCT01895673||PET-MRI|Twenty patients with RFA/MWA for CRLM or RFA/MWA of recurrent liver lesions after prior local treatment of CRLM and are eligible to undergo MRI-scanning are included when they have adequate renal function. Patients that do not meet inclusion criteria for undergoing an MRI scan are excluded.
3099399|NCT01895660|Experimental|Group with continuous constraint and daily therapy|
3099400|NCT01895660|Experimental|Group with continuous constrainit and 3 days a week therapy|
3099401|NCT01895660|Experimental|Group with part-time constraint and daily therapy|
3099402|NCT01895660|Experimental|Group with part-time constraint and 3 days a week therapy|
3099403|NCT01895660|Active Comparator|Usual and customary treatment group|
3099404|NCT01895647|Experimental|Biceps stimulation|EMS
3099405|NCT01895647|Experimental|Quadriceps stimulation|EMS
3099406|NCT01895647|No Intervention|Control|Control group without electric muscle stimulation
3099407|NCT01895634|Experimental|Treatment|Intervention Device: Rev-01
3099408|NCT01895621|Experimental|Lipoic|Median nerve decompression at the wrist, followed by Alpha lipoic acid post median nerve decompression: lipoic acid, 800 mg daily for 40 days from the day of the operation, tablets.
3099409|NCT01895621|Placebo Comparator|placebo|Median nerve decompression at the wrist, followed by placebo in the same form frequency and duration as alpha lipoic acid
3099410|NCT01895608|Experimental|Balance rehabilitation + dual-tasking|Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant can safely perform the primary balance or gait task.
3099411|NCT01895608|Active Comparator|Standard balance rehabilitation|Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
3099412|NCT01895608|Experimental|Cognitive training (speed of processing)|Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
3099413|NCT01895608|Active Comparator|Cognitive training (general cognition)|General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
3099460|NCT01895257|Active Comparator|A: systemic chemotherapy LV5FU2 alone|Modified LV5FU2 as described in protocol (6.2.1) D1-2 +/- bevacizumab or cetuximab or panitumumab (according its previous use) every 2 weeks
3099414|NCT01895595|Experimental|Guided Imagery|The guided imagery program curriculum, added to the lifestyle education curriculum, consists of 12 weekly, 45-minute modules, delivered one-on-one immediately following the lifestyle education class each week. Guided imagery was based on 2 major underlying theoretical principles: 1) relaxation/stress reduction imagery; and 2) imagery designed to improve eating and physical activity behaviors.
3099415|NCT01895595|Active Comparator|"Digital storytelling (Control)"|The digital storytelling program curriculum, to control for contact time with research staff, consists of 12 weekly 45-minute modules delivered one-on-one immediately following the lifestyle education class each week.
3099416|NCT01895582||Active TB-infected patients|TB-infected patients with bacteriological and histological evidences
3099417|NCT01895582||Non active TB-infected patients (already met TB)|some of elders have already met M tuberculosis before active antibiotherapy exists
3099418|NCT01895582||Non active TB-infected patients (other diagnosis)|same symptoms than two others groups but an other diagnosis
3099419|NCT01895569|Experimental|Type 2 diabetic patients|Type 2 diabetic patients, naive to treatment, and not well controlled by diet (glycate hemoglobin > 6.5%, and < 9.0%) will be instructed to take metformin, followed by metformin plus pioglitazone, and then metformin plus pioglitazone plus sitagliptin.
3099420|NCT01895556|Experimental|Information|Information about male circumcision and HIV risk
3099421|NCT01895556|Placebo Comparator|Control|Control
3099422|NCT01895543|Experimental|EBX10|Elobixibat 10 mg
3099423|NCT01895530|No Intervention|Control group|Conventional treatment with no probiotic supplementation
3099424|NCT01895530|Experimental|Probiotic group|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
3099425|NCT01895517|Active Comparator|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
3099426|NCT01895517|Experimental|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
3099427|NCT01895504|Experimental|ColoAssist|Screening colonoscopy with a new colonoscope with gradual stiffness
3099428|NCT01895504|Active Comparator|MEI|Screening colonoscopy with colonoscopes compatible with and guided by MEI
3099429|NCT01895491|Experimental|CohortⅠ|VM206DNA 6mg and VM206Ad 3*10^9VP injected into the brachial muscle
3099430|NCT01895491|Experimental|CohortⅡ|VM206DNA 12mg and VM206Ad 3*10^9VP injected into the brachial muscle
3099431|NCT01895491|Experimental|CohortⅢ|VM206DNA 24mg and VM206Ad 3*10^9VP injected into the brachial muscle
3099432|NCT01895478|Experimental|PACCI-ED|PACCI-ED attendings were given the PACCI-ED use intervention.
3099433|NCT01895478|No Intervention|Control|Control attendings were not given the PACCI-ED use intervention.
3099434|NCT01895465|Experimental|A slitted diaper|An ordinary pediatric urine collection bag used in the ED that will be used together with the slitted diaper
3099435|NCT01895452|Experimental|ALKS 9072, Low Dose|
3099436|NCT01895452|Experimental|ALKS 9072, High Dose|
3099437|NCT01895439|Experimental|MSCs injection|Autologous bone marrow derived stem cells injected intrathecally to enrolled MS patients
3099438|NCT01895413|Experimental|Mesenchymal stem cells|Bone marrow aspiration, Autologous bone marrow-derived mesenchymal stem cells
3099439|NCT01895400|Active Comparator|Renexin|Renexin 1T bid for 12 weeks
3099440|NCT01895400|Placebo Comparator|Placebo|Placebo 1T bid for 12 weeks
3099441|NCT01895387|Experimental|Whole grains and legumes|
3099442|NCT01895387|Placebo Comparator|Refined rice|
3099443|NCT01895374|Experimental|amniotic membrane dressing|We compare the efficacy of amniotic membrane and hydrocolloid in same subjects to avoid confounders.
3099444|NCT01895374|Active Comparator|Hydrocolloid dressing|Same subjects received amniotic membrane and hydrocolloid dressing at the same time in different wound.
3099445|NCT01895361|Experimental|High-dose SelG1|IV Infusion, once every 4 weeks through Week 50
3099446|NCT01895361|Experimental|Low-dose SelG1|IV Infusion, once every 4 weeks through Week 50
3099447|NCT01895361|Placebo Comparator|Placebo|IV Infusion, once every 4 weeks through Week 50
3099448|NCT01895348|Active Comparator|propofol only|
3099449|NCT01895348|Active Comparator|propofol-remifentanil|
3099450|NCT01895348|Active Comparator|dexmedetomidine-remifentanil|
3099451|NCT01895335|Experimental|Teriflunomide|Teriflunomide 14 mg or 7 mg according to local labelling once daily (QD) orally for 48 weeks.
3099452|NCT01895322|Experimental|OPC-41061|
3099453|NCT01895309|Experimental|SB4 (proposed biosimilar to etanercept)|SB4 50 mg/week via subcutaneous injection
3099454|NCT01895309|Active Comparator|Enbrel (etanercept)|Enbrel 50 mg/week via subcutaneous injection
3099455|NCT01895296|Experimental|Pasireotide|pasireotide 300 microgram s.c. t.i.d.
3099456|NCT01895296|Placebo Comparator|Placebo|saline s.c. t.i.d.
3099457|NCT01895283|Experimental|Moderate-intensity training|Regular supervised moderate-intensity training on a bike ergometer, three times per week, for 30 minutes a total of 10 weeks.
3099458|NCT01895270|Experimental|Isradipine|Isradipine controlled-release formulation, 10 mg/day maintenance dose, will be administered according to the following dose procedures: Isradipine ingestion will occur under supervision 6 days per week, and a take-home dose will be given on Saturday for participants to take on Sunday. The initial dose of isradipine or placebo will be given on Day 3 of Week 1. The initial dose of isradipine will be 5 mg/day; the dose will increase to 10 mg/day on Day 3 of Week 3 and will continue through Day 2 of Week 7. On Day 3 of Week 7, isradipine will be decreased to 5 mg/day for 7 days. On Days 3-5 of Week 8, all participants will receive placebo. If ISR side effects are too severe at the 10-mg dose, isradipine will be decreased to 5 mg/day. If ISR side effects are too severe at 5 mg/day, isradipine will be discontinued and the participant will be discharged from the study and referred to local treatment agencies.
3099459|NCT01895270|Placebo Comparator|Placebo|Placebo will consist of microcrystalline cellulose. Two placebo capsules will be administered per day starting week 1 day 3 through the end of the isradipine taper.
3099541|NCT01894789|Experimental|stable CAD management|Experimental: Ticagrelor (BrilintaTM) 90 mg tablet by mouth twice a day
3099461|NCT01895257|Active Comparator|B:SIR-spheres+systemic chemotherapy LV5FU2|ARM B: (Hepatic Arterial Infusion) HAI-90Y radioembolization (SIR-spheres injection) + modified LV5FU2 +/- bevacizumab or cetuximab or panitumumab according its previous use (refer to protocol).
3099462|NCT01895244|Experimental|Conditioning with CYC/ antithymocyte globulin (ATG)|Each patient receives stem cell transplantation open label with cluster of differentiation (CD)34 selected stem cells mobilisation and conditioning depending on manifestation If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
3099463|NCT01895244|Experimental|Conditioning with CYC/Thiotepa/ATG|In patients with cardiac manifestations as defined in the protocol the conditioning for stem cell transplantation is changed to Cyclophosphamide (CYC), thiotepa and ATG
3099464|NCT01895231|Experimental|Iron isomaltoside 1000|Monofer® 1000 mg IV infusion over 15 minutes
3099465|NCT01895231|Placebo Comparator|Placebo|0.9 % saline Infusion over 15 min
3099466|NCT01895218|Experimental|Iron isomaltoside 1000 (Monofer®)|
3099467|NCT01895218|Active Comparator|Standard medical Care|
3099468|NCT01895205|Experimental|Iron isomaltoside 1000|A single dose of 1500 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9% sodium chloride and given over approximately 15 min.
3099469|NCT01895205|Active Comparator|Red blood cell transfusion|"Allogenic RBC transfusion is dosed to trigger Hb:~Women with Hb 5.5 - 6.4 g/dL (3.5-3.9 mmol/L) will receive 2 units of RBC~Women with Hb 6.5 - 8.0 g/dL (4.0-5.0 mmol/L) will receive 1 unit of RBC"
3099470|NCT01895192|Other|Fertile men|Assessment of sperm morphology by high magnification with interference contrast microscopy.
3099471|NCT01895179|Experimental|Time-Restricted Feeding (early in the day eating)|Participants will consume all meals early in the day and within a 6-hour window.
3099472|NCT01895179|Placebo Comparator|Grazing|Participants will eat meals spread out over the course of the day.
3099473|NCT01895166|Experimental|EBUS-GS group|The EBUS probe and GS are confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
3099474|NCT01895166|Active Comparator|EBUS-GS-X-ray group|The EBUS probe and GS are confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained under fluoroscopic guidance.
3099475|NCT01895153||pentosan polysulfate cohort|pentosan polysulfate monotherapy
3099476|NCT01895153||hydrodistension(HD) cohort|hydrodistension(HD) monotherapy
3099477|NCT01895153||combination cohort|combination therapy of pentosan polysulfate and hydrodistension.
3099478|NCT01895140|Experimental|Early renal denervation|Renal denervation takes place immediately after patient is randomized.
3099479|NCT01895140|Other|Delayed renal denervation|Renal denervation takes place 6 months after the patient is randomized.
3099480|NCT01895127|Active Comparator|Standard of Care|"Plasmapheresis (PP) x 3, at 40-60 cc/kg.~Immunoglobulin (IVIg), to be administered after each PP"
3099481|NCT01895127|Experimental|Soliris (eculizumab)|"1200 mg first dose (Time: Screening/Week 0, after Biopsy Proven AMR)~900 mg weekly for 4 doses (Weeks 1, 2, 3, 4)~1200 mg week 5~Week 6: If donor specific antibody < 50% of baseline DSA then no further treatment, otherwise 1200 mg weeks 7, 9"
3099482|NCT01895101|Placebo Comparator|pericardial lavage with 200 ml normothermic saline solution|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.~This arm also receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid."
3099483|NCT01895101|No Intervention|No pericardial lavage|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.~In this arm the subjects receives as in standard care no pericardial lavage."
3099484|NCT01895101|Experimental|2 gr tranexamic acid diluted in 200 ml normothermic saline|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.~This arm receives also pericardial lavage with 2 gr TA diluted in 200 ml normothermic saline solution (NaCl 0.9%)."
3099485|NCT01895088|Experimental|Patients prev. impl. with ACI 7000 PDT|AcuFocus Corneal Inlay ACI 7000 PDT
3099486|NCT01895075|Experimental|Inhaled budesonide|Inhaled budesonide 1mg/dose (2ml) three tid
3099487|NCT01895075|Placebo Comparator|Normal saline|Normal saline inhalation 2ml tid
3099488|NCT01895062|Experimental|active cNEP @ -45cmw|cNEP @ -45 cmw is applied to the anterior surface of the neck with a soft collar attached to a vacuum source.
3099489|NCT01895062|No Intervention|no intervention|Routine care is administered without the application of cNEP.
3099490|NCT01895049|Active Comparator|Mycophenolate sodium|Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium, and late introduction of tacrolimus
3099491|NCT01895049|Experimental|Everolimus|Induction therapy with Thymoglobulin, prednisone, everolimus, and late introduction of tacrolimus.
3099492|NCT01895036|Experimental|Naltrexone|PO naltrexone titration on a mixed inpatient/outpatient basis, followed by administration of Vivitrol four days following the 1st dose of naltrexone
3099493|NCT01895023|Experimental|Dexmedetomidine group|The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min and oral saline 30 min before induction of anaesthesia
3099494|NCT01895023|Active Comparator|Midazolam group|The midazolam group received intranasal saline 45 min and oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
3099495|NCT01895023|Placebo Comparator|Placebo Group|The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
3099496|NCT01895010|Experimental|Acupoint and tropisetron|acupoint electric stimulation combined with tropisetron 6mg before TACE
3099497|NCT01895010|Active Comparator|tropisetron|treated with tropisetron 6mg before TACE
3099542|NCT01894789|Active Comparator|CAD comparison group|Active comparator: clopidogrel 75 mg plus placebo tablet by mouth twice a day.
3099584|NCT01894477|Experimental|Arm A|"Arm A: Treosulfan, Fludarabine Phosphate~Treosulfan intravenously (IV) over 2 hours on days -6 to -4 and fludarabine phosphate IV over 30 minutes on days -6 to -2."
3099818|NCT01893008|No Intervention|Usual care (no IMT)|
3099498|NCT01894997|Experimental|DVT Prophylaxis|"Neuromuscular electrical stimulation is to be applied using a custom-built, two-channel stimulator (Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 5 minutes.~Intermittent pneumatic compression is to be applied using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 3 second duration over a period of 5 minutes."
3099499|NCT01894984||Risperidone|Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor [SSRI]) will be maintained and will cease at Week 3.
3099500|NCT01894984||Oral atypical anti-psychotic|Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
3099501|NCT01894971|Experimental|twice coagulated side of fallopian tube|twice coagulated side of fallopian tube once coagulated sied of fallopian tube
3099502|NCT01894958|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
3099503|NCT01894958|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water
3099504|NCT01894945||Patients with suspected lymphoma.|
3099505|NCT01894932|Experimental|MBCT Group for stress patient|Mindfulness-based cognitive Group therapy will be administered on stress patient.
3099506|NCT01894932|Experimental|MBCT Group for depression patient|Mindfulness-based cognitive Group therapy will be administered on depression patient.
3099507|NCT01894932|Experimental|SR group for stress patient|psycho-physiological stress regulation group will be administered on stress patient.
3099508|NCT01894932|Experimental|SR group for depression patient|psycho-physiological stress regulation group will be administered on depression patients.
3099509|NCT01894932|No Intervention|normal|normal, no intervention.
3099510|NCT01894932|No Intervention|Drug treatment remission patient|Drug treatment remission patient
3099511|NCT01894919|Experimental|A|5th dose of vaccine
3099512|NCT01894919|No Intervention|B|Blood draw only
3099513|NCT01894919|Experimental|C|4th dose of vaccine (3 ½, 5 + booster at 11 months of age)
3099514|NCT01894919|No Intervention|D|Blood draw only
3099515|NCT01894919|Experimental|E|4th dose of vaccine (6, 8 + booster at 11 months of age)
3099516|NCT01894919|No Intervention|F|Blood draw only
3099517|NCT01894919|Experimental|G|3rd dose of vaccine (0,2-month schedule, Subjects 2 to 5 years of age)
3099518|NCT01894919|No Intervention|H|Blood draw only
3099519|NCT01894919|Experimental|I|3rd dose of vaccine (0,2-month schedule, Subjects 6 to 10 years of age)
3099520|NCT01894919|No Intervention|J|Blood draw only
3099521|NCT01894919|Experimental|K|Naïve subjects (35-47 months of age)
3099522|NCT01894919|Experimental|L|Naïve subjects (4 to 7 years old)
3099523|NCT01894919|Experimental|M|Naïve subjects (8 to 12 years old)
3099524|NCT01894906|Placebo Comparator|Control|Each subject will receive one control treatment and 5 treatments with SFP added to dialysate. The 5 SFP treatments will encompass 5 different conditions which may impact the intradialytic transfer of iron to the subject: new dialyzer, reused dialyzer, low blood/dialysate flow rate, low machine delivered bicarbonate concentration, and a different synthetic dialysis membrane (PAES).
3099525|NCT01894906|Experimental|Soluble Ferric Pyrophosphate|Group/ cohort designation: Cellulose dialysis membrane (CT-190)/ Polyamide membrane. Each subject will receive one control treatment and 5 treatments with SFP added to dialysate. The 5 SFP treatments will encompass 5 different conditions which may impact the intradialytic transfer of iron to the subject: new dialyzer, reused dialyzer, low blood/dialysate flow rate, low machine delivered bicarbonate concentration, and a different synthetic dialysis membrane (PAES).
3099526|NCT01894893||Breastfeeding mothers|
3099527|NCT01894880|Active Comparator|early SSC|Early SSC: bonding straight after birth
3099528|NCT01894880|Other|late SSC|late SSC: bonding after termination of operation
3099529|NCT01894867|Experimental|magnesium|will get magnesium for 6 weeks
3099530|NCT01894867|Placebo Comparator|placebo|will get placebo for 6 weeks
3099531|NCT01894854|No Intervention|Stem collar|The stem has two versions, one with and one without a collar. This arm will have stems with a collar. The classical Furlong HAC had a collar.
3099532|NCT01894854|Active Comparator|No Stem collar|The stem has two versions, one with and one without a collar. This arm will have stems without a collar. The classical Furlong HAC had a collar.
3099533|NCT01894841|Experimental|CLASP Intervention|A 6 month adjunctive intervention consisting of 3 individual meetings, one family session, and 11 brief phone contacts with patient and identified significant other.
3099534|NCT01894841|Other|Safety Assessment and follow up Evaluation|Treatment as usual plus enhanced monitoring.
3099535|NCT01894828|Active Comparator|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily
3099536|NCT01894828|No Intervention|Control|Patients are asked to keep on to their normal diet. No supplementation is introduced
3099537|NCT01894815|Experimental|Active tDCS / placebo pill|transcranial direct current stimulation, using the parameters specified in Interventions.
3099538|NCT01894815|Active Comparator|Sham tDCS / escitalopram|Escitalopram oxalate (Reconter), 10mg/day (first 3 weeks) and 20mg/day (week 3 to week 10).
3099539|NCT01894815|Placebo Comparator|Sham tDCS / placebo pill|"For sham tDCS, the device is automatically turned off after 30 second of stimulation and remains turned off during the 30-min session.~For placebo pill, the pill has the same size, taste and color than escitalopram, and placebo and escitalopram will be provided in identical bottles, differing only according to a random-generated number placed in the label."
3099540|NCT01894802|Experimental|Brain-Machine Interface Users|All participants enrolled in the study who meet eligibility criteria will be individuals implanted with microelectrodes in their brain to record neural activity. There is no control group.
3099582|NCT01894490||Jejunostomy|Patients who received a jejunostomy
3099543|NCT01894776|Experimental|Maraviroc|"Two period pharmacokinetic drug-drug interaction Period one -Maraviroc alone; Period two -Maraviroc and Rifabutin~Substance: Maraviroc (Celsentri, MVC) tablets, 300 mg; dose: oral, 300 mg (1 tablet) twice daily~Substance: Rifabutin (mycobutin, RFB) capsules, 150 mg; dose: oral, 300 mg (2 capsules) once daily"
3099544|NCT01894763|Active Comparator|Small-diameter stent|Placement of a 23 mm self-expandable metal stent
3099545|NCT01894763|Active Comparator|Large-diameter stent|Placement of a 28-mm self-expandable metal stent
3099546|NCT01894750|Experimental|skill bulding Intevention|group-based skill building self-care program
3099547|NCT01894750|No Intervention|usual care|
3099548|NCT01894737|Placebo Comparator|immobilisation and placebo|Seven days of one-legged knee immobilisation with placebo supplementation
3099549|NCT01894737|Experimental|immobilisation and creatine|Seven days of one-legged knee immobilisation with creatine supplementation
3099550|NCT01894724|Experimental|NeuroSave Device|Targeted Hypothermia with NeuroSave Device
3099551|NCT01894711||Patients with HER2 positive tumors|Patients with HER2 positive tumors treated with trastuzumab or not treated with trastuzumab
3099552|NCT01894685|Experimental|Mesalazine|Mesalazine, 3 grams once daily for six months
3099553|NCT01894685|Placebo Comparator|Placebo|Placebo, 3 grams, once daily for six months
3099554|NCT01894672|Experimental|LGX818|LGX818 capsules will be administered orally on a once -daily schedule (QD) dosing at a dose of 300 mg/day, 2 weeks on followed by a 2 week break. This schedule of 2 weeks on, followed by 2 weeks off, will continue for the duration of time the patients remains on the clinical trial. After the follow up visit patients will be contacted approximately every 12 weeks until they have received a subsequent therapy or until they have been off treatment for a year to monitor their survival.
3099555|NCT01894659|No Intervention|Control|Neonates randomized to this arm will receive the standard of practice at Loma Linda University NICU.
3099556|NCT01894659|Experimental|24% oral sucrose with pacifier|Neonates randomized to this arm will receive 24% sucrose before every painful procedure on days of life 3-7 in the NICU.
3099557|NCT01894659|Experimental|30% oral glucose with pacifier|Neonates randomized to this arm will receive 30% oral glucose before every painful procedure on days of life 3-7.
3099558|NCT01894646|Experimental|Young healthy individuals (ages 18-50)|Positron Emission Tomography (PET) Imaging
3099559|NCT01894646|Experimental|Elderly healthy individuals (ages 60-85)|Positron Emission Tomography (PET) Imaging
3099560|NCT01894646|Other|Patients with Alzheimer's disease or mild cognitive impairment|Positron Emission Tomography (PET) Imaging
3099561|NCT01894633|Experimental|Chloroquine, radiosensitizer|The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the CLQ plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days.
3099562|NCT01894633|Placebo Comparator|Placebo|30 Gy of whole-brain radiotherapy in 10 daily fractions and an oral matching placebo for 28 days
3099563|NCT01894620|Placebo Comparator|rTMS with sham coil|rTMS real-sham and rTMS sham-real interventions. Each patient will receive both real and sham treatment in two different blocks of time. The assessments after the sham treatment will serve as placebo effect compared to those after real treatment.
3099564|NCT01894620|Active Comparator|rTMS with real coil|rTMS real-sham and rTMS sham-real interventions. Each patient will receive both real and sham treatment in two different blocks of time. The assessments after the sham treatment will serve as placebo effect compared to those after real treatment.
3099565|NCT01894607|Experimental|Contrast Enhanced Intraoperative Ultrasound|"During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier.~Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having."
3099566|NCT01894594|Experimental|Sodium Bicarbonate|Patients will be monitored at baseline bi-weekly intervals for 12 weeks, the first 4 weeks to establish a stable baseline, followed by 8 weeks of alkali therapy, as follows:
3099567|NCT01894581|Experimental|Obese Women|Women with a BMI of greater than or equal to 30 kg/m2 underwent all study interventions, including taking 5 g daily of LOVAZA. Women underwent 8 hours of frequent blood sampling every 10 minutes both at baseline and after LOVAZA supplementation. Each frequent blood sampling included IV administration of GnRH at 6 hours.
3099568|NCT01894581|Active Comparator|Normal Weight|Women with a BMI of between 18-25 kg/m2 underwent all study interventions, including taking 5 g daily of LOVAZA for one cycle. Women underwent 8 hours of frequent blood sampling every 10 minutes both at baseline and after LOVAZA supplementation. Each frequent blood sampling included IV administration of GnRH at 6 hours.
3099569|NCT01894568|Experimental|LY2605541|LY2605541 administered subcutaneously (SC) once daily for 26 weeks.
3099570|NCT01894568|Active Comparator|Insulin Glargine|Insulin Glargine administered SC once daily for 26 weeks.
3099571|NCT01894555|Experimental|Aspirin|Participants treated with aspirin - there is no control group. Participant's baseline will act as their control.
3099572|NCT01894542|Experimental|Cod protein from presscake|
3099573|NCT01894542|Experimental|Cod protein from presscake + stickwater|
3099574|NCT01894542|Placebo Comparator|Control|Control group will receive tablet containing only tablet fillers (the same as in the cod protein tablets).
3099575|NCT01894529||Ischemic stroke|Patients with an ischemic stroke admitted within 6 hours of symptom onset, with a minimum severity in the NIHSS of 3 and treated with systemic or intraarterial thrombolysis
3099576|NCT01894529||Healthy subjects|Age-matched individuals free of acute neurological injury
3099577|NCT01894516|Experimental|GLPG0634 50mg QD|2 capsules of 25mg GLPG0634 in the morning
3099578|NCT01894516|Experimental|GLPG0634 100mg QD|2 capsules of 50mg GLPG0634 in the morning
3099579|NCT01894516|Experimental|GLPG0634 200mg QD|2 capsules of 100mg GLPG0634 in the morning
3099580|NCT01894516|Placebo Comparator|Placebo|2 placebo capsules in the morning
3099581|NCT01894503|Experimental|S8 Sinus Implant|Bilateral in-office placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
3099586|NCT01894464|Experimental|Teacher led intervention|Teachers will conduct teacher-led interventions that are individualized for each student to prevent emerging truancy among elementary students.
3099587|NCT01894464|No Intervention|Control Group|
3099588|NCT01894451|Experimental|89Zr-bevacizumab-PET/CT Scan|"89Zr-bevacizumab-PET/CT will be performed at baseline, after 2 cycles of preoperative chemotherapy, and at the completion of preoperative chemotherapy.~The 89Zr-bevacizumab-PET/CT imaging procedure is detailed in Appendix A and is briefly described below.~Participants will be injected with 1 mCi of 89Zr-bevacizumab intravenously and PET/CT images will be obtained at 3-4 days after 89Zr-bevacizumab administration to allow time for antibody accumulation in the tumor. Imaging will be performed on a Centers for Quantitative Imaging Excellence (CQIE) qualified PET/CT scanner at the Dana-Farber Cancer Institute. After the baseline scan, subsequent scans will be obtained on the same PET/CT scanner for an individual participant."
3099589|NCT01894438|No Intervention|Control Group|This arm will receive written general advice for a healthy lifestyle.
3099590|NCT01894438|Experimental|Mediterranean Diet Group|Mediterranean Diet Group participants will attend a comprehensive program,focusing on Mediterranean diet, comprising of seven 60-min group counseling sessions, conducted every two weeks for the first 2 months and every month for the following 4 months, until the 6-month evaluation.
3099591|NCT01894438|Experimental|Mediterranean Lifestyle Group|Mediterranean Lifestyle Group participants will attend a comprehensive program,focusing on Mediterranean lifestyle, comprising of seven 60-min group counseling sessions, conducted every two weeks for the first 2 months and every month for the following 4 months, until the 6-month evaluation.
3099592|NCT01894425||Study population|"The study population consists of couples under care for infertility in the participating centers. Gamete donations are not included. Please see inclusion and exclusion criteria.~Intervention: HPV screening for women Intervention: HPV screening for men"
3099593|NCT01894412|Experimental|HD 203|prefilled syringe
3099594|NCT01894412|Active Comparator|Enbrel|prefilled syringe
3099595|NCT01894399|Experimental|Cohort 1|100 mg HM61713 single dose in Korean
3099596|NCT01894399|Experimental|Cohort 2|200 mg HM61713 single dose in Korean
3099597|NCT01894399|Experimental|Cohort 3|300 mg HM61713 single dose in Korean
3099598|NCT01894399|Experimental|Cohort 4|200 mg HM61713 single dose in Japanese
3099599|NCT01894399|Experimental|Cohort 5|300 mg HM61713 single dose in Japanese
3099600|NCT01894399|Experimental|Cohort 6|200 mg HM61713 single dose in Caucasian
3099601|NCT01894399|Experimental|Cohort 7|300 mg HM61713 single dose in Caucasian
3099602|NCT01894386|Experimental|Sequence 1|Subjects will receive treatment A, B, C, D in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
3099603|NCT01894386|Experimental|Sequence 2|Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
3099604|NCT01894386|Experimental|Sequence 3|Subjects will receive treatment C, A, D, B in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
3099605|NCT01894386|Experimental|Sequence 4|Subjects will receive treatment D, C, B, A in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment C, A, D, B in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
3099606|NCT01894373|Experimental|CIK, psoriasis|
3099607|NCT01894360|Experimental|Belimumab 200 mg/mL, prefilled syringe|Subjects will be randomly assigned in a 1 to 1 ratio to receive a single dose of 200 mg belimumab SC (1.0 mL injection) via prefilled syringe on Day 0.
3099608|NCT01894360|Experimental|Belimumab 200 mg/mL, Autoinjector|Subjects will be randomly assigned in a 1 to 1 ratio to receive a single dose of 200 mg belimumab SC (1.0 mL injection) via prefilled syringe contained within an autoinjector device on Day 0.
3099609|NCT01894347||Colistin inhalative|"Adult ICU patients with~invasive ventilation with assumed or assured bacteria with an elevated resistance pattern found in a tracheal or bronchial secretion with or without clinical signs of infection~indicated colistin co-therapy or eradication-attempt with inhalative colistin (β-Lactam) therapy according to the standard operation procedure (SOP) of the hospital~Patients included into the study group receive additional TDM, Monitoring of Neuro-and Nephropathology"
3099610|NCT01894334|No Intervention|Control group|no intervention
3099611|NCT01894334|Experimental|Tranexamic acid group|tranexamic acid ，intravenous 30mg/kg/d，Preoperative
3099612|NCT01894334|Experimental|Edaravone group|edaravone, iv, 1mg/kg/d,Preoperative
3099613|NCT01894334|Experimental|Ulinastatin group|Ulinastatin ,iv，20,000 U /kg/d，Preoperative
3099614|NCT01894308|Active Comparator|Forearm dose|Half of Ss will receive their dose of Testosterone on the inner aspects of their forearms.
3099615|NCT01894308|Active Comparator|Chest Dose|Half of Ss will receive their dose of Testosterone on the chest.
3099616|NCT01894295|Experimental|Vitamin D analogue|1-α hydroxyvitamin D3; dose 0.25, 0.5 and 1 microgram.
3099617|NCT01894295|Placebo Comparator|Placebo|Corn oil pearl Capsules 1 gram
3099618|NCT01894282|Active Comparator|Manual Therapy|Spinal Manipulative therapy (SMT) for the purpose of this study we will allow the use of other types of MT, including non-thrust spinal mobilization and flexion-distraction technique.
3099619|NCT01894282|Experimental|Mind Body Intervention (MBI)|"Mind Body Intervention will consist of a combination of the previously described manual therapy and Cognitive Behavioral Therapy for pain (CBT-p). Cognitive Behavioral Therapy for pain management has three basic components. The treatment rationale, coping skills training and application and maintenance of learned coping skills."
3099620|NCT01894269|Experimental|Anti-viral treatment|Oral antiviral drugs will be commenced after TACE. That is: Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
3099621|NCT01894269|No Intervention|Control|No anti-viral therapy after TACE.
3099622|NCT01894256|Other|Normal renal function|Patients with calculated serum creatinine clearance ≥81 mL/min (using Cockcroft-Gault equation).
3099624|NCT01894256|Other|Moderate renal impairment|Patients with calculated serum creatinine clearance 31-50 mL/min (using Cockcroft-Gault equation).
3099625|NCT01894243|Other|Normal hepatic function|"Patients with:~(i) negative result for serum hepatitis B surface antigen and hepatitis C antibody (ii) total bilirubin ≤1.5 x institutional upper limit of normal (ULN), albumin and prothrombin time within normal limits and must not have ascites (unless related to disease under study) or encephalopathy (iii) aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST), alanine aminotransferase or serum glutamic pyruvic transaminase (ALT) ≤2.5 x institutional ULN unless liver metastases are present in which case it must be ≤5 x ULN"
3099626|NCT01894243|Other|Mild hepatic impairment|As defined by the Child-Pugh Classification System.
3099627|NCT01894243|Other|Moderate hepatic impairment|As defined by the Child-Pugh Classification System.
3099628|NCT01894230|Experimental|Genotype results plus usual care|SLCO1B1*5 allele testing, results reported at randomization: genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at randomization.
3099629|NCT01894230|Active Comparator|Usual care only|SLCO1B1*5 allele testing, results reported at end of study: genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at end of study
3099630|NCT01894217|Experimental|Genetic testing|Genetic testing and reporting for SLCO1B1*5 allele
3099631|NCT01894204|Other|HTPPE|No drug and no placebo were used in this study. For all the patients who participated at the study PADIS-EP, somme exams must be performed.
3099632|NCT01894191|Active Comparator|air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
3099633|NCT01894191|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy.
3099634|NCT01894191|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
3099635|NCT01894178|Active Comparator|Parker Flex-Tip® Tracheal Tube|Intubation of obese patients with the Parker Flex-Tip® Tracheal Tube
3099636|NCT01894178|Active Comparator|Portex® Tracheal Tube|Intubation of obese patients with the Portex® Tracheal Tube
3099637|NCT01894165|Experimental|ALXN1101|Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.
3099638|NCT01894165|Placebo Comparator|Placebo|Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.
3099639|NCT01894152||XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
3099640|NCT01894139|Experimental|High-protein/Low-GI Diet|High-protein (25-28 E%), especially marine- and dairy-protein (8-10 E%) and low-GI (GI<55) ad libitum Diet in accordance with the principles of palatability and sustainability of the New Nordic Diet.
3099641|NCT01894139|Active Comparator|Low-protein/High-GI Diet|Ad libitum diet based on the Danish National Guidelines (NNR) (protein 10-20 E%; no information on restricting glycaemic load (GI ~ 60)) and in accordance with the principles of palatability and sustainability of the New Nordic Diet.
3099642|NCT01894126|Experimental|Two-way SMS dialogue|Women will receive SMS messages with prompts to reply. They will have the ability to text back to the system and both respond to and initiate SMS dialogue
3099643|NCT01894126|Experimental|One-way SMS Messaging|Women will receive scheduled one-way SMS messages
3099644|NCT01894126|No Intervention|Control|
3099645|NCT01894113|Active Comparator|transbronchial forceps lung biopsy|transbronchial lung biopsy forceps
3099646|NCT01894113|Active Comparator|transbronchail cryo lung biopsy|transbronchial lungbiopsy with cryoprobe
3099647|NCT01894100|Other|Delayed Intervention Group|This group will not receive shoe lifts during the first 3 months after baseline. At 3 months, they will begin the shoe lift correction for leg length inequality.
3099648|NCT01894100|Experimental|Immediate Intervention Group|At baseline, participants in this group will begin shoe lift correction for leg length inequality.
3099649|NCT01894087|Active Comparator|Therapist-led brief intervention (TBI) - Cohort 1|"Participants will receive a therapist-led, computer-assisted intervention session with a master's level therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
3099650|NCT01894087|No Intervention|Enhanced usual care - Cohort 1|
3099651|NCT01894087|Active Comparator|Therapist-led brief intervention (TBI) - Cohort 2|"Participants will receive a therapist-led, computer-assisted intervention session with a master's level therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
3099652|NCT01894087|No Intervention|Enhanced usual care - Cohort 2|
3099653|NCT01894074|Placebo Comparator|Placebo|Lifestyle counseling:standard dietary education and counseling with a goal of reducing calories to 1500-1800 kcal/day
3099654|NCT01894074|Active Comparator|Intensive Dietary Intervention|Intensive Dietary Intervention employing very low energy diet (800 kcal/day) x 12 weeks followed by transition to regular foodstuffs over 4-6 weeks.
3099655|NCT01894061|Experimental|Bevacizumab and NovoTTF-100A|Bevacizumab will be administered intravenously on days 1 and 15 of each 28 day cycle.The dose of bevacizumab will be 10 mg/kg of actual body weight.
3099656|NCT01894048|Experimental|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
3099657|NCT01894035||Group 1|
3099658|NCT01894022|Experimental|Ambrisentan Arm|All subjects will receive ambrisentan initially at a dose of 5 mg once daily (OD). Based on the investigator's best judgment, the subject may continue on 5 mg OD, or be up-titrated to 10 mg OD. The dose may also be adjusted back to 5 mg OD at investigator discretion.
3099659|NCT01894009|Active Comparator|Foot manipulation|"Asymmetry of the feet was treated by thrusting of the cuboid bone and the subtalar joint was treated with gapping thrust. Mobilisation of the distal tibia-fibula was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given with morning exercises. Four types of exercises were recommended: 1) Foot training with pro-and supination of the feet from dorsal to plantar flexion. 2)Caterpillar walk. 3) Training the take off of the great toes along a normal walking line and 4) Mobility of lateral malleoli and the talo-crural joint by dorsal flexion of feet while bending the knees."
3099660|NCT01894009|Sham Comparator|Sham foot manipulation|Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones with the patient in the supine position on a psoas pillow. Further, light pressure on the Achilles tendon, with the patient standing against a wall with the feet 40 cm off the wall with bent knees on order to simulate the tibio-fibular mobilisation. Home exercises in the mornings to be repeated 8 times.
3099661|NCT01893996|Experimental|Adalimumab|Active Study Drug is Adalimumab (Humira) which is FDA approved to treat rheumatoid arthritis since 2003.
3099662|NCT01893996|Placebo Comparator|Placebo|Placebo is inert and matches study drug, including the pre-filled syringe, and is supplied by Abbvie, the study drug manufacturer.
3099663|NCT01893983|Experimental|Motivational Coaching|Telephone based Motivational Coaching sessions
3099664|NCT01893983|No Intervention|Referral alone|This is the current standard of care
3099665|NCT01893970|Experimental|SWIFT: Acute Social Work Intervention in the ED and Follow Up|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
3099666|NCT01893970|Active Comparator|SWIFT-Acute Only: Acute social work intervention in the ED|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
3099667|NCT01893957|Experimental|Healthy|Healthy women undergoing high voltage electrical stimulation
3099668|NCT01893957|Experimental|Axillary lymphadenectomy|Axillary lymphadenectomy volunteers undergoing to high voltage electrical stimulation
3099669|NCT01893944|Experimental|Virtual Reality|- Participate in this group 20 women to be treated by means of games Xbox 360 ®, attributed to this, custom applications using virtual and augmented reality to be developed.
3099670|NCT01893944|Experimental|Vibration therapy|- participate in this group 20 women who will undergo 15 minutes of continuous vibration by vibration of the upper mantle, with a frequency of 40 Hz, 3 function and intensity tolerable, keeping the limb supported and raised to 120 °.
3099671|NCT01893944|Active Comparator|control group|- participate in this group 20 women who are treated with conventional cinesioterapia through muscle stretching exercises, dissociation girdle, active and active-assisted exercises for groups flexors, extensors, abductors and adductors of the upper limbs, which will be three series 10 repetitions for each exercise.
3099672|NCT01893931|Placebo Comparator|Satisfaction Survey|Within 1-3 days after ED discharge, patients will be called by a nurse to complete a brief satisfaction survey.
3099673|NCT01893931|Active Comparator|ED Discharge and Medication Call|Within 1-3 days after ED discharge, patients will receive a follow up phone call from a nurse to review discharge instructions, review medication instructions, and provide any necessary patient navigation.
3099674|NCT01893918||COPD patients|COPD patients, males and females, older than 65 years, with smoking history > 20 pack/years
3099675|NCT01893905|Experimental|CS+SG|Chondroitin sulfate 1200mg+ glucosamine sulfate 1500mg orally administered once a day for 24 weeks
3099676|NCT01893905|Placebo Comparator|Placebo|Placebo of chondroitin sulfate + glucosamine sulfate orally administered once a day for 24 weeks
3099677|NCT01893892|Experimental|Arm I (levocarnitine start)|Patients receive levocarnitine PO BID during weeks 1-4. Washout is weeks 5-8. Patients then cross-over to placebo for weeks 9-12.
3099678|NCT01893892|Placebo Comparator|Arm II (placebo start)|Patients receive placebo PO BID during weeks 1-4. Washout is weeks 5-8. Patients then cross-over to levocarnitine for weeks 9-12.
3099679|NCT01893879|Experimental|(RS)2-(3-benzoylphenyl)-propionic acid|"Patients receive study drug PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.~Laboratory biomarker analysis will be performed."
3099680|NCT01893879|Placebo Comparator|placebo for study drug|"Patients receive placebo PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.~Laboratory biomarker analysis will be performed."
3099681|NCT01893866|Experimental|A|
3099682|NCT01893866|Experimental|B|
3099683|NCT01893853|Other|Water|Electrolyte- and mineral-free water with exercise intervention
3099684|NCT01893853|Placebo Comparator|Placebo|Calorie- and electrolyte-free, sweetened flavored water with exercise intervention
3099685|NCT01893853|Experimental|Carbohydrate-electrolyte beverage|Commercially-available flavored beverage carbohydrate-electrolyte beverage with Exercise Intervention
3099686|NCT01893840|Experimental|FlowOx|5 minutes of pulsating negative pressure (10 sek og -40mmHg/7 sek of athmospheric pressure) will be Applied to the patient's leg
3099687|NCT01893827|Active Comparator|XR-NTX|Xr-NTX 380mg IM injection monthly x 6 months
3099688|NCT01893827|Active Comparator|Oral Naltrexone|Oral naltrexone 50mg/day x 6 months
3099689|NCT01893814|Active Comparator|Probiotics|
3099690|NCT01893814|Placebo Comparator|Control|
3099691|NCT01893801|Experimental|nab-paclitaxel+Cisplatin+gemcitabine|This is a phase Ib/II open-label, pilot study evaluating the preliminary efficacy and safety of nab-paclitaxel 125mb/m2, cisplatin 25mg/m2, and gemcitabine 1000mg/m2, all administered intravenously (IV) on Days 1 and 8 every 21 days until development of toxicity that is unacceptable in the opinion of the patient or the Investigator or upon disease progression.
3099692|NCT01893788|Active Comparator|Aliskiren|Aliskiren group treated with 150-300mg daily aliskiren without diuretics or ACE inhibitors or angiotensin receptor blockers.
3099693|NCT01893788|Active Comparator|Eplerenone|Eplerenone group treated with 50-100mg daily eplerenone without diuretics or ACE inhibitors or angiotensin receptor blockers
3099694|NCT01893775|Experimental|1|Hu-Mik-Beta-1 every 3 weeks
3099819|NCT01892995|Experimental|Ketamine|active arm
3099695|NCT01893762|Experimental|16 rowers|Adult rowers, aged between 18 and 25, training >6 times a week are subjected to both an aerobic and a an anaerobic exercise challenge. Between the two challenges there must a pause of at least a week.
3099696|NCT01893749|Experimental|CATCH-IT|"200 randomized teens 13-18 year old (inclusive) will be enrolled into the online program that contains 14 modules focused various therapeutic techniques, a booster session of 6 modules at the end of the online program and three 15 minute visits with their primary care doctor to discuss the benefits and disadvantages of the program.~Parents will also be invited to participant in a partnering online program involving 4 modules online and 1 optional module. They will be asked to then participate in three 15 minute interviews with a member of the study team to discuss the benefits and disadvantages of the program."
3099697|NCT01893749|No Intervention|Health Education|"200 randomized teens, ages 13-18 year old (inclusive) receiving an online program with 14 modules that focus on general health education, depression, diet, exercise, hygiene and safety.~Parents will also be invited to participate in an online program with 4 modules that also focus on general health education."
3099698|NCT01893736|No Intervention|Control|In-hospital usual care consists of routine intrapartum and postnatal obstetric care. No extra intervention will be provided by research team.
3099699|NCT01893736|Experimental|In-hospital professional support|"The participants in in-hospital professional support arm will receive three 30-minute one-to-one hands-on breastfeeding counseling sessions during postpartum hospitalization."
3099700|NCT01893736|Experimental|Postpartum telephone follow-up support|"Participants in postpartum telephone follow-up support arm will receive telephone support in the first 4 weeks postpartum."
3099701|NCT01893723|Experimental|ANI guided remifentanil arm|remifentanil targets are increased or decreased depending on ANI readings. In case of high blood pressure associated with elevated ANI, nicardipine is administered.
3099702|NCT01893723|Other|ANI blind arm|remifentanil target is adapted as is usual during general anesthesia, depending on hemodynamic reactions to nociceptive surgical stimulations. In case of elevated blood pressure despite a maximum target of 10 ng/ml (Minto Pk/pD model), then nicardipine is administered.
3099703|NCT01893710||Control, PD|'Biopsy sampling': Peritoneal biopsies from children without kidney disease, i.e. diseases not related to the kidney and not affecting the peritoneum, will be compared with biopsies from patients with chronic kidney disease, at time of catheter insertion, intercurrent abdominal surgery and at time of renal transplantation.
3099704|NCT01893697||Healthy Participants|HRCT scan in a specific postural position
3099705|NCT01893684|Experimental|Protein + Exercise|PRO diet recommendations will include high quality proteins with an emphasis on lean meats, with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams. The exercise program will require attendance of 3 nonconsecutive days per week. A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period.
3099706|NCT01893684|Experimental|Protein|PRO diet recommendations will include high quality proteins with an emphasis on lean meats, with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams.
3099707|NCT01893684|Experimental|Carbohydrate + Exercise|Diet will provide dietary protein at 0.8 g.kg-1.d-1 (~ 18% of energy intake) with a ratio of carbohydrates/protein > 3.5 and dietary lipids at ~30% energy intake. Again, energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The exercise program will require attendance of 3 nonconsecutive days per week. A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period.
3099708|NCT01893671||LASIK|Subjects undergoing routine LASIK for the correction of myopia or hyperopia.
3099709|NCT01893658|Active Comparator|Omalizumab and Prednisone|"Omalizumab in addition to prednisone. Omalizumab will be given once subcutaneously at a dose of 375 mg within 24 hours after receiving prednisone~Standard clinical therapy with prednisone.~Day 1-14: 60 mg/day 14 days (2 weeks)~Day 15-28: 40 mg/day (2 weeks)~Day 29-35: 30 mg/day (1 week)~Day 36-42: 20 mg/day (1 week)~Day 43-49: 10 mg/day (1 week)~Day 50-56: 5 mg/day (1 week)~Subjects will stop taking prednisone on day 57~If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose)."
3099710|NCT01893658|Active Comparator|Prednisone|"Standard clinical therapy with prednisone.~Day 1-14: 60 mg/day 14 days (2 weeks)~Day 15-28: 40 mg/day (2 weeks)~Day 29-35: 30 mg/day (1 week)~Day 36-42: 20 mg/day (1 week)~Day 43-49: 10 mg/day (1 week)~Day 50-56: 5 mg/day (1 week)~Subjects will stop taking prednisone on day 57~If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose)."
3099711|NCT01893645||Pregnant women|Pregnant women admitted to the British Columbia Women's Hospital for vaginal or cesarean delivery will get their Hb values spot-checked using the Pronto-7 device.
3099712|NCT01893632|Experimental|Gabapentin|All study medication will be over-capsulated with riboflavin to assess compliance using quantitative fluoroscopy. All participants will take three capsules three times per day throughout the study period. During week 1, GBP will be titrated over a five-day period to the dose target (GBP 1200 mg three times daily) or the maximum tolerated dose. Medication dosing will continue at GBP 1200 mg three times daily or placebo through the end of the study period (week 12). Dose reductions will be made for tolerability if necessary.
3099713|NCT01893632|Placebo Comparator|Placebo|Capsules filled with riboflavin.
3099714|NCT01893606|Placebo Comparator|Starch capsule|During the two weeks screening phase of the study, the daily dose of 3 tablets will be taken before breakfast, lunch and supper.
3099715|NCT01893606|Experimental|N-acetyl-D-glucosamine|During the 8-week treatment phase of the study,the dose of 100mg(3 tablets)per day will be taken.
3099716|NCT01893593|Other|Control|Usual care
3099717|NCT01893593|Active Comparator|Intervention|Multifaceted intervention to improve clinical systems
3099718|NCT01893580|Experimental|1. Experimental|Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery.
3099719|NCT01893580|Experimental|2. Experimental|Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery.
3099720|NCT01893580|Experimental|3. Experimental|Exercise in a team initiated two weeks after surgery.
3099721|NCT01893580|Other|4. Usual care|Exercise in a team initiated six weeks after surgery.
3099722|NCT01893567|Experimental|Clobex spray|
3099723|NCT01893554|Experimental|Group 1: RSV vaccine|Healthy RSV-seropositive children ages 12 to 59 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
3099724|NCT01893554|Placebo Comparator|Group 1: Placebo|Healthy RSV-seropositive children ages 12 to 59 months will receive one dose of the placebo administered as nose drops at study entry.
3099725|NCT01893554|Experimental|Group 2: RSV vaccine|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
3099726|NCT01893554|Placebo Comparator|Group 2: Placebo|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the placebo administered as nose drops at study entry.
3099727|NCT01893554|Experimental|Group 3: RSV vaccine|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
3099728|NCT01893554|Placebo Comparator|Group 3: Placebo|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the placebo administered as nose drops at study entry.
3099729|NCT01893554|Experimental|Group 4: RSV vaccine|Healthy infants between the ages 4 to 6 months who have not been screened for RSV serostatus will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
3099730|NCT01893554|Placebo Comparator|Group 4: Placebo|Healthy infants between the ages 4 to 6 months who have not been screened for RSV serostatus will receive one dose of the placebo administered as nose drops at study entry.
3099731|NCT01893541|Active Comparator|EBL PLUS PROPRANOLOL|The EBL procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices were obliterated. The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.
3099732|NCT01893541|Active Comparator|ENDOSCOPIC BAND LIGATION|The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.
3099733|NCT01893528|Experimental|REGN2009 dose level 1|Cohort A - REGN2009 or placebo; Cohort B - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
3099734|NCT01893528|Experimental|REGN2009 dose level 2|Cohort C - REGN2009 or placebo; Cohort D - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
3099735|NCT01893528|Experimental|REGN2009 dose level 3|Cohort E - REGN2009 or placebo; Cohort F - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
3099736|NCT01893515|Experimental|PRC-4016|PRC-4016, oral administration once daily, capsule
3099737|NCT01893515|Placebo Comparator|Placebo|Placebo, oral administration once daily, capsule
3099738|NCT01893502|Active Comparator|Group 1|Participants will receive weekly proactive and live telephone counselling from Quitline (run by the Health Promotion Board) for one month
3099739|NCT01893502|Active Comparator|Group 2|Participants will receive weekly proactive and live telephone counselling from Quitline (run by the Health Promotion Board) for six months
3099740|NCT01893489|Active Comparator|Atherosclerosis|coronary artery disease patients with carotid plaques confirmed by a ultrasound study
3099741|NCT01893489|Sham Comparator|control|no coronary artery disease patients without carotid plaques confirmed by a ultrasound study
3099742|NCT01893476|No Intervention|control|In this arm, practitioners will provide usual care for COPD patients.
3099743|NCT01893476|Other|adherence to guideline|Implementation educational programme: guideline adherences. The results of this trial will be directly applicable to primary care settings. Should the interventions delivered at the level of the GP practice be found to be effective in improving patients' quality of life then the findings would have a wider application.
3099744|NCT01893463||Patients which received the iTClamp as treatment|Use of the iTClamp50 will be determined by the EMS and ER physicians. Patients who have received treatment will be tracked from pre-hospital to patient discharge (chart review). EMS care providers and physicians will answer a survey about their experience with the iTClamp50.
3099745|NCT01893450|Active Comparator|methimazole|methimazole 30 mg daily during one year
3099746|NCT01893450|Active Comparator|methimazole, bromocriptine|methimazole 30 mg daily during one year, bromocriptine 5 mg twice a day during one year
3099747|NCT01893450|Active Comparator|pentoxifylline|methimazol 30 mg daily and pentoxifylline 400 mg twice a day during one year
3099748|NCT01893437|Experimental|Single oral dose group|
3099749|NCT01893424|Active Comparator|Sativex buccal spray|volunteers will receive a single dose of 8 actuations of Sativex® which will be administrated within 1-2 min by the study physician. The dose of THC and CBD to be administered is the following: THC 21.6 mg and CBD 20 mg. Sativex® actuations will be directed sublingually and at the buccal mucosa.
3099820|NCT01892995|Sham Comparator|Diphenhydramine|sham arm
3099750|NCT01893424|Experimental|CBD-THC-Piperine-PNL capsule|12 volunteers will receive a single oral dose of THC:CBD P-PNL capsule with 200 mL of water. The dose of THC and CBD to be administered is the same as in the Sativex arm: THC 21.6 mg and CBD 20 mg.
3099751|NCT01893411|Experimental|16 Units per kg body weight incobotulinumtoxinA (Xeomin)|
3099752|NCT01893411|Experimental|12 Units per kg body weight incobotulinumtoxinA (Xeomin)|
3099753|NCT01893411|Experimental|4 Units per kg body weight incobotulinumtoxinA (Xeomin)|
3099754|NCT01893398|Experimental|rehabilitation (MST) program|The Multidimensional Stimulation group therapy (MST) involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.
3099755|NCT01893398|No Intervention|Usual care program|Usual care PWA program
3099756|NCT01893385|Experimental|vitamin D|The entire project will collect new information on the merits of the use of vitamin D in aging. A better knowledge of mechanisms involved and the impact of aging on them is a necessary prerequisite the definition of a new strategy using this drug in the elderly particularly fragile in order to improve its autonomy. This definition seems a sociological interest obvious economic knowing the current aging population and its impact future of our health system
3099757|NCT01893385|Other|INTANZA 15|The entire project will collect new information on the merits of the use of vitamin D in aging. A better knowledge of mechanisms involved and the impact of aging on them is a necessary prerequisite the definition of a new strategy using this drug in the elderly particularly fragile in order to improve its autonomy. This definition seems a sociological interest obvious economic knowing the current aging population and its impact future of our health system
3099758|NCT01893372|Experimental|Eltrombopag|Eltrombopag 200 mg by mouth daily in a 28 day cycle.
3099759|NCT01893372|Experimental|Eltrombopag + Hypomethylating Agent (HMA)|"Eltrombopag in combination with continuation of hypomethylating agent in 28-day cycles. Eltrombopag 200 mg by mouth daily in a 28 day cycle.~The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study. Eltrombopag should be initiated at the start of the next HMA cycle whenever possible so the start date of both agents is consistent."
3099760|NCT01893359|Experimental|LASIK followed by Cross-linking (Continuous Wave)|Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 2 minutes continuous UVA.
3099761|NCT01893359|Experimental|LASIK followed by Cross-linking (Pulsed)|Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off.
3099762|NCT01893359|Placebo Comparator|LASIK Only|Eyes assigned to this arm will receive standard LASIK with no cross-linking.
3099763|NCT01893346|Experimental|CAZ-AVI|This arm will include 4 cohorts. Patients will be stratified by age.
3099764|NCT01893333|Experimental|Nerve sparing radical hysterectomy group|"sparing hypogastric nerve~sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament~sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve"
3099765|NCT01893333|Active Comparator|Radical hysterectomy group|Conventional radical hysterectomy
3099766|NCT01893320|Experimental|Vosaroxin + Decitabine|"The first 6 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5).~Following the phase I portion, patients in phase II receive the following induction:~Vosaroxin intravenously on days 1 and 4 at a dose of 70 mg/m2 for a total dose of 140 mg/m2/cycle (days 1 and 4), or the final induction dose (MTD) determined in phase I.~Decitabine intravenously at a dose of 20 mg/m2 for 5 consecutive days (days 1 to 5), or the final induction dose (MTD) determined in phase I."
3099767|NCT01893307|Experimental|Intensity-Modulated X-Ray Therapy (IMRT)|"Radiation therapy dosage 70 Gy (RBE) delivered 1 time each day, 5 days a week (Monday through Friday) for up to 33 treatments (about 6 ½ weeks).~Treating physician evaluate each patient for possible chemotherapy.~Modified barium swallow (MBS) performed at baseline, end of treatment visit, and at 6, 12, and 24 months after radiation therapy.~Questionnaires completed at baseline, each week while receiving radiation therapy, at end of treatment visit, at 10 - 12 weeks after radiation, and at 6, 12, and 24 months after radiation therapy."
3099768|NCT01893307|Experimental|Intensity-Modulated Proton Beam Therapy (IMPT)|"Radiation therapy dosage 70 Gy (RBE) delivered 1 time each day, 5 days a week (Monday through Friday) for up to 33 treatments (about 6 ½ weeks).~Treating physician evaluate each patient for possible chemotherapy.~Modified barium swallow (MBS) performed at baseline, end of treatment visit, and at 6, 12, and 24 months after radiation therapy.~Questionnaires completed at baseline, each week while receiving radiation therapy, at end of treatment visit, at 10 - 12 weeks after radiation, and at 6, 12, and 24 months after radiation therapy."
3099769|NCT01893294|Experimental|Treatment (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IT on day 1. Within 33 hours, patients receive standard chemotherapy comprising fluorouracil IV on days 1, 8, 15, 22, 29, and 36 and undergo standard radiation therapy 5 days a week for 6 weeks.
3099770|NCT01893281|Experimental|Topical Testosterone Solution|Topical Testosterone Solution 30 milligrams up to 120 milligrams per day (mg/day) administered topically to axillae titrated based on testosterone levels.
3099771|NCT01893268||Cohort|
3099772|NCT01893255||Cohort|
3099773|NCT01893242|Experimental|Aleglitazar Arm|
3099774|NCT01893242|Placebo Comparator|Placebo Arm|
3099775|NCT01893229|Experimental|Valproate|Name: Valproate; dosage form: tablet, 250mg; dosage and frequency: 800mg-- 1200mg/d; duration: 6 weeks.
3099776|NCT01893229|Experimental|Oxcarbazepine|Name: Oxcarbazepine, dosage form: 300mg, tablet; dosage and frequency: 600-1200mg/d; duration: 6 weeks
3099777|NCT01893229|Experimental|Quetiapine|name: Quetiapine, dosage form: 200mg,tablet; dosage and frequency: 600mg-- 800mg/d; duration: 6 weeks
3099778|NCT01893229|Experimental|Olanzapine|Name: Olanzapine, dosage form: 5mg tablet; dosage and frequency: 10mg--20mg/d; duration: 6 weeks
3099779|NCT01893229|Experimental|Ziprasidone|Name: Ziprasidone, dosage form: 10mg tablet; dosage and frequency: 80mg—160mmg/d; duration: 6 weeks
3099780|NCT01893229|Experimental|Lithium|name: lithium; dosage form: 250mg Tablet; dosage and frequency: 750mg—2000mg/d;serum Li level: 0.6mmol—1.2mmol/L; duration: 6 weeks
3099781|NCT01893216||with depression or anxiety|Hospital Anxiety and Depression Scale score over 9 points
3099782|NCT01893216||without depression or anxiety|Hospital Anxiety and Depression Scale score less than 8 points
3099783|NCT01893203|Other|BF-200 ALA vs MAL|BF-200 ALA cream and MAL (Metvix, Galderma) used in a randomized split-face design
3099784|NCT01893190|Active Comparator|Nimodipine|Nimodipine 60mg q4h for 21 days - oral
3099785|NCT01893190|Experimental|Nimodipine Microparticles|Single intraventricular injection
3099786|NCT01893177|Experimental|Elderly subjects aged over 60 years|
3099787|NCT01893177|Experimental|Adults from 18 to 60 years old inclusive|
3099788|NCT01893164|Experimental|moderate cubital tunnel syndrome|Sensory,Intermittent paresthesias; vibratory perception normal or decreasedMotor,Measurable weakness in pinch or grip strengthTests,Elbow flexion test or Tinel's sign is positive; finger crossing may be abnormal.Treated by simple decompression,anterior subcutaneous transposition and anterior intramuscular transposition of the ulnar nerve.
3099789|NCT01893164|Experimental|severe cubital tunnel syndrome|Sensory,Persistent paresthesias; vibratory perception decreased; abnormal two-point discrimination(static >6 mm, moving >4 mm)Motor,Measurable weakness in pinch and grip plus muscle atrophyTests,Positive elbow flexion test or positive Tinel's sign may be present; finger crossing usually abnormal.Treated by simple decompression,anterior subcutaneous transposition and anterior intramuscular transposition of the ulnar nerve.
3099790|NCT01893151|Experimental|Iguratimod|Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
3099791|NCT01893151|Placebo Comparator|Iguratimod placebo|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week;Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week
3099792|NCT01893138|Other|Roll-in|Roll-in patients are allowed in the study (up to 12 per site) and are randomized and treated exactly the same as standard study patients.
3099793|NCT01893138|Placebo Comparator|Placebo|
3099794|NCT01893138|Experimental|AMDC for USR|
3099795|NCT01893125|Experimental|CNV2197944|CNV2197944 75mg tid 21 days
3099796|NCT01893125|Placebo Comparator|Placebo|Placebo 1 cap tid 21 days
3099797|NCT01893112|Experimental|Unity Workshop|The intervention is a workshop facilitated by a peer advocate (an African American woman who is also HIV positive) and a social worker. It has exercises, videos and group discussions intended to equip participants with coping skills to overcome HIV related stigma and the negative outcomes related to stigma. The workshop will last about 8 hours total across 2 two days (4 hours per day). The researcher in the current study has done a lot of work in adapting this intervention for African American women. The workshop has been piloted in Seattle and had promising results. Based on results in the pilot study, a 2 hour booster session has been added 6 months after the initial workshop
3099798|NCT01893112|Other|Breast Cancer Screening|The time and attention control group workshop will be facilitated by a research coordinator. The control group program is based on another program that is designed explore issues related to breast cancer screening among African American women. The program has the same format as the Unity Workshop, with video and group discussion. Although breast cancer may be associated with stigma, we anticipated that breast cancer stigmas would not be related to HIV-associated stigma, which is our primary outcome of interest. The control groups will be held during the same week as the Unity Workshops, and control group participants will complete assessments on the same schedule as the Unity Workshop participants.
3099799|NCT01893099|Experimental|Sorafenib- Cohort 1|Sorafenib 400 mg BID will be started 14 days after the administration of SIRT with SIR-Sphere®.
3099800|NCT01893099|Experimental|Sorafenib- Cohort 2|Sorafenib 400 mg BID will be started 11 days after the administration of SIRT with SIR-Sphere®.
3099801|NCT01893099|Experimental|Sorafenib- Cohort 3|Sorafenib 400 mg BID will be started 3 days after the administration of radioembolization with SIR-Sphere®.
3099802|NCT01893099|Experimental|Sorafenib- Cohort 4|Sorafenib 400 mg BID will be started 7 days prior to the administration of radioembolization with SIR-Spheres® and be given continuously, without drug holidays.
3099803|NCT01893086|Active Comparator|LH alone|LH, laparoscopic hysterectomy
3099804|NCT01893086|Experimental|LH with opportunistic salpingectomy|LH, laparoscopic hysterectomy
3099805|NCT01893073|Active Comparator|Mindful walking|A weekly 60 minutes walking group exercise program consisting of a combination of walking and mindfulness over 8 weeks.
3099806|NCT01893073|No Intervention|Waiting group|
3099807|NCT01893060|Experimental|Povidone-Iodine|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
3099808|NCT01893060|Experimental|Chlorhexidine|Umbilical stump care. ChloraPrep® Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
3099809|NCT01893060|Experimental|Pluronic Cream|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin), applied twice a day to cord stump while umbilical line(s) are in place
3099810|NCT01893060|Sham Comparator|Control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
3099811|NCT01893047|No Intervention|no music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
3099812|NCT01893047|Experimental|live music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
3099813|NCT01893047|Experimental|recorded music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
3099814|NCT01893034|Active Comparator|Conservative treatment|Physiotherapy and activity modification
3099815|NCT01893034|Active Comparator|Surgical treatment|Arthroscopic treatment of femoroacetabular impingement
3099816|NCT01893021||Postpartum Malawian women|
3099817|NCT01893008|Experimental|Usual care + Inspiratory Muscle Training (IMT)|
3099822|NCT01892982|Experimental|Problem Solving Education tailored to NICU|NICU-PSE integrates motivational interviewing and problem solving, with ongoing monitoring and linkage to mental health services for mothers with worsening depressive symptoms over time. The intervention is provided over six sessions, including three tailored, post-discharge sessions, which address issues common to families of preterm infants: caregiver burden, complexity of medical follow-up, and social reintegration following hospitalization.
3099823|NCT01892982|No Intervention|Control|Both study groups receive standard NICU medical, social work, and nursing services. At each study site, attending neonatologists and pediatrics residents constitute the medical team, and all families are assigned a social worker.
3099824|NCT01892969||HEART AND LUNG FAILURE|Patients with Heart failure or Respiratory Failure with Hyperglycemia
3099825|NCT01892956||Healthy volunteers|
3099826|NCT01892943||Patients with LHON|
3099827|NCT01892930|Experimental|Treatment (SBRT, nephrectomy)|Patients undergo SBRT on day 1 and undergo partial or radical nephrectomy on day 29.
3099828|NCT01892904|Experimental|EE20/DRSP(BAY86-5300)-flexibel extended regimen|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day with flexible extended regimen (24-day to 120-day active tablet intake followed by 4-day tablet free interval)
3099829|NCT01892904|Active Comparator|EE20/DRSP(BAY86-5300)-28 days cyclic regimen|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day with 28-day cyclic regimen (24-day active tablet intake followed by 4-day placebo tablet intake)
3099830|NCT01892891|Experimental|VBY-036|VBY-036 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg
3099831|NCT01892891|Placebo Comparator|Placebo comparator|Placebo
3099832|NCT01892878|Other|Single Arm Study|All patients will receive treatment
3099833|NCT01892865|Active Comparator|Historical means method|Operative time will be predicted using historical service means. Schedule will be constructed using this time
3099834|NCT01892865|Experimental|Predictive Modeling System (PMS)|Operative time will be predicted using a regression model. Schedule will be constructed using this time
3099835|NCT01892852|Experimental|Acupuncture|Acupuncture treatment
3099836|NCT01892852|No Intervention|Control|No other active treatment or sham acupuncture for this symptoms
3099837|NCT01892839|Experimental|high dialysate flow, larger dialyzer|high dialysate flow, larger dialyzer
3099838|NCT01892839|Active Comparator|low dialysate flow, smaller dialyzer|low dialysate flow, smaller dialyzer
3099839|NCT01892826|Experimental|hCG group|
3099840|NCT01892826|No Intervention|LH pic|
3099841|NCT01892813|Experimental|Tailored intervention|Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.
3099842|NCT01892813|Active Comparator|Enhanced standard of care|Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.
3099843|NCT01892800||Study population - lung resection|Patients with suspected lung cancer undergoing lung resection by anatomic lobectomy
3099844|NCT01892787|Experimental|Formoterol (Atimos Modulite)|Atimos Modulite 1 puff (12 micrograms) twice a day
3099845|NCT01892787|Active Comparator|Salmeterol (Serevent Accuhaler)|Serevent Accuhaler 1 puff (50 micrograms) of twice a day
3099846|NCT01892761||TCL/MMF Group|
3099847|NCT01892761||CyA/MMF Group|
3099848|NCT01892748|Active Comparator|Cholecalciferol 50.000IU/week|patients will receive vitamin D3 (50.000 IU/week) for 24weeks
3099849|NCT01892748|Placebo Comparator|Placebo|patients receive placebo in similar capsules of cholecalciferol for 24weeks
3099850|NCT01892722|Experimental|Fingolimod (FTY720)|Fingolimod is administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight) with the aim to achieve systemic exposure in range of that in adults at the licensed 0.5 mg dose.
3099851|NCT01892722|Active Comparator|Interferon beta-1a|An intramuscular (IM) injection of Interferon beta-1a is administered once weekly.
3099852|NCT01892709|Experimental|Hydromorphone|"All eligible patients will receive 1 mg IV hydromorphone. Thereafter, they will be repeatedly asked the question, Do you want more pain medicine? This question will be asked 30 minutes after they answered no or 30 minutes after the completion of the next dose of 1 mg IV hydromorphone, which occurs when the patients answers yes. Patients will receive a maximum of 4 mg IV hydromorphone over a 4 hour period."
3099853|NCT01892696|Other|mechanically ventilated patients|"patients admitted to a 18-bed medical surgical intensive care unit of the military hospital of Tunisia and were mechanically ventilated fully adapted to their ventilator and in sinus rhythm.~intervention:varying inspiratory flow waveforms"
3099854|NCT01892683||Propofol|This study will investigate patients that undergo routine anesthesia for elective surgical procedure at the hospital of the University of Munich(Klinikum der Universität München. Patients will receive intravenous anesthesia with propofol.
3099855|NCT01892670|Experimental|Filtered whole blood|"Leukocyte-reduced whole blood, 2 hours holding-time after collection. Gravitational filtration.~Device: Terumo IMUFLEX WB(Whole blood)-SP(saving platelets) collection bag system"
3099856|NCT01892670|Experimental|Unfiltered whole blood|"Non-leukocyte-reduced whole blood, 2 hours holding-time after collection.~Device: Terumo IMUFLEX WB-SP collection bag system"
3099857|NCT01892670|Experimental|Warm-filtered whole blood|"Leukocyte-reduced whole blood, no holding-time after collection. Gravitational filtration.~Device: Terumo IMUFLEX WB-SP collection bag system"
3099858|NCT01892670|Experimental|Forced warm-filtration of whole bood|"Leukocyte-reduced whole blood, no holding-time after collection. Forced filtration.~Device: Terumo IMUFLEX WB-SP collection bag system"
3099859|NCT01892670|Experimental|RCC produced from cold-stored whole blood|"RCC production from 7 days old, cold-stored, leukocyte-reduced whole blood. Units stored for another 35 days. (42 days of storage in total).~Devices: Terumo IMUFLEX WB-SP/WB-RP collection bag systems."
3099860|NCT01892670|Experimental|RCC produced from cold-stored non-filtered whole blood|"RCC production from 7 days old, cold-stored, non-leukocyte-reduced whole blood. Units stored for another 35 days. (42 days of storage in total).~Devices: Terumo IMUFLEX WB-SP/WB-RP(removing platelets) collection bag systems."
3099861|NCT01892657|Experimental|Facial Moisturizer with SPF 50+|All subjects received Cetaphil Daily Facial Moisturizer with SPF 50+
3099862|NCT01892644|Active Comparator|Deferasirox HC|10 patients with hemochromatosis treated with Deferasirox
3099863|NCT01892644|Active Comparator|Venesection HC|10 patients with hemochromatosis treated with venesection
3099864|NCT01892644|Active Comparator|Deferasirox MDS|20 patients with myelodysplastic syndrome treated with Deferasirox
3099865|NCT01892644|No Intervention|Controls|10 healthy control persons to assess the normal level of investigational blood tests.
3099866|NCT01892631|Other|Standard care|Practices in the standard care arm will proceed with their seasonal influenza campaign as planned.
3099867|NCT01892631|Experimental|Text messaging intervention|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
3099868|NCT01892618|Active Comparator|Pneumovax|Pneumovax, 1x 0.5 ml injection
3099869|NCT01892618|Experimental|Prevenar 13|Prevenar 13, 1x 0.5 ml injection
3099870|NCT01892605|Experimental|music listening, no music|The clinical application and mechanism of music therapy The clinical application and mechanism of music therapy (Mozart's effect) on epilepsy (Mozart's effect) on epilepsy
3099871|NCT01892592|No Intervention|Usual Care|No Interventions
3099872|NCT01892592|No Intervention|Medication enhancement|Pharmacist will optimize current Kaiser medication protocol for treatment of hypertension.
3099873|NCT01892592|Experimental|Diet and Lifestyle Arm|Patients will receive up to 16 wellness coaching sessions focusing on DASH doest and lifestyle changes - Behavioral Intervention
3099874|NCT01892579|Experimental|Tailored Activity Program|"The Tailored Activity Program unfolds over 3 phases: Phase I (sessions 1-2) involves assessment of Person with Dementia (PwD)capacity and interests, caregiver (CG) interactions and the physical environment and CG education. Phase II (sessions 3-6) involves identifying and implementing 3 Activity Prescriptions tailored to PwD's cognitive and interest profile using an algorithmic guide. The prescription summarizes PwD capabilities in lay language, identifies the activity and a specific activity goal, and provides specific instructions for introducing the activity. CGs are trained to integrate activities in daily care. Also provided are simple deep breathing stress reduction techniques to address CG upset. Phase III (sessions 7-8) involves instructing CGs in simplifying activities for future cognitive declines and applying simplification principles to other care challenges."
3099875|NCT01892579|Active Comparator|Home Safety and Education Program|This arm receives 6 in-home and 2 brief telephone education sessions. Each contact is structured to provide helpful education. Sessions include information on home safety, fall risk assessment, talking to your doctor, advanced planning, identifying resources, and caring for the caregiver (CG). Each session is prescriptive and designed to maximize attention; yet, sessions will not involve any component of the intervention group. To engage the person with dementia (PwD), the interventionist will socially engage the person briefly in select sessions. Time spent with CG and PwD in the control group is comparable to that for intervention dyads.
3099876|NCT01892566|No Intervention|Usual care for COPD|Usual care for AECOPD in the JHHCC consists of patient-initiated contact with the clinic for change in respiratory symptoms. Participants will be asked to complete a weekly symptom diary assessment which will be returned to the study staff at every 3-month visits. Participants contacting research staff with a worsening in respiratory symptoms will be referred to their assigned clinical providers.
3099877|NCT01892566|Experimental|mHealth Intervention|For the mHealth intervention, investigators will use of the eResearch Technology, Inc system (ERT®; Philadelphia, PA) for home-based monitoring of spirometry and respiratory symptoms. In conjunction, wireless sensor-based inhalers will monitor the frequency of rescue inhaler use (Asthmapolis®; Madison, WI). As well, on a daily basis, participants in the early identification group will complete eight respiratory symptom questions from the COPD Assessment Test (CAT). Participants' short acting beta-agonist inhaler use will be monitored by an Asthmapolis Spiroscout Inhaler Tracker. Based on participant responses, flags or electronic notifications can be generated. Based on severity of symptoms and guidelines for recommended care, participants will be instructed to self-manage by optimizing inhaler use (if symptoms are mild) or present for an acute care visit at JHHCC if necessary.
3099878|NCT01892553|Experimental|motor/premotor cortex stimulation|Active and sham tDCS applied over the motor/premotor cortex
3099879|NCT01892553|Experimental|insular cortex stimulation|Active and sham tDCS applied over the insular cortex
3099880|NCT01892540|Experimental|Diagnosis (FDG PET/CT and PET/MRI)|Patients undergo clinical FDG-PET/CT followed by prone breast PET/CT and/or prone breast PET/MRI with or without DTPA.
3099881|NCT01892527|Experimental|Tivantinib plus Cetuximab|Single arm
3099882|NCT01892514|Experimental|Demineralized Bone Marrow (DBM)|core decompression of necrotic area and graft with a biological product based on Demineralized Bone Matrix (DBM), Platelet-Rich-Fibrin (PRF) and Concentrated Bone Marrow (CBM)
3099883|NCT01892514|Experimental|Lyophilized Bone Chips (LBC)|core decompression of the necrotic area and graft with a biological product based on homologous Lyophilized Bone Chips (LBC), Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
3099884|NCT01892501|Other|hypermetabolic mediastinal lymph nodes in PET,|hypermetabolic mediastinal lymph nodes in PET,in a context of New cancer or cancer recurrence.
3099885|NCT01892488|Placebo Comparator|lactose pill|Placebo for 5 days as supplement to standard of care for patients with AE-COPD
3099886|NCT01892488|Experimental|Sultamicillin|Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD
3099887|NCT01892475|Experimental|Cash Only (CO)|As part of the Incentive-based physical activity program, drivers assigned to the Cash Only (CO) arm will earn incentives in the form of cash for meeting specified monthly step goals from Months 1 to 4.
3099888|NCT01892475|Experimental|Mental-Accounting (MA) based|As part of the Incentive-based physical activity program, drivers assigned to the Mental-Accounting (MA) based arm will receive incentives in the form of taxi rental credits for meeting specified monthly step goals from Months 1 to 4.
3099889|NCT01892449|Experimental|prolonged I:E ratio (1:1) group|
3099890|NCT01892449|Active Comparator|conventional I:E ratio (1:2) group|
3099943|NCT01892098|Active Comparator|Zinc Sulfate|Subjects enrolled in this arm will receive 9mg elemental zinc (23mg zn sulfate)/day for 4 weeks.
3099944|NCT01892098|Placebo Comparator|Cellulose Pill|Subject enrolled in this arm will receive a placebo.
3099891|NCT01892436|Experimental|Secukinumab 75mg|Subjects will initially continue to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may be escalated to 150 mg or 300 mg as judged appropriate by investigator
3099892|NCT01892436|Experimental|Secukinumab 150mg|Subjects will initially continue to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may be escalated to 300 mg as judged appropriate by the investigator
3099893|NCT01892423|Experimental|Cetaphil Moisturizing Lotion Daily Advance|Each subject had Cetaphil Moisturizing Lotion Daily Advance applied
3099894|NCT01892410|Experimental|Cetaphil Restoraderm Skin Restoring Body Wash|All subjects receive Cetaphil Daily Advance Ultra Hydrating Lotion
3099895|NCT01892397|Experimental|Optune (NovoTTF-100A)|The treatment plan is to have patients use the Optune device in monotherapy for ≥ 18 hours per day as per the treatment standard established from prior studies. A medical professional will see each patient at least once per month while on the device for toxicity assessment, compliance evaluation via downloading of the log-file on the device by the Novocure technician (which involves the technician simply attaching the device to a computer via USB where software reads how many hours per day on each day the device was used), and physical examination. Extent of disease evaluations will occur at baseline, 8 weeks, and then every 8 weeks thereafter. These evaluations will include MRI of the brain with and without contrast and perfusion (or CT head if a patient cannot undergo MRI).
3099896|NCT01892384|Experimental|BI 409306 dose 1|low dose, once daily
3099897|NCT01892384|Experimental|BI 409306 dose 2|medium dose, once daily
3099898|NCT01892384|Experimental|BI 409306 dose 3|high dose, once daily
3099899|NCT01892384|Placebo Comparator|Placebo|placebo, once daily
3099900|NCT01892371|Experimental|Quizartinib + Cytarabine|Quizartinib administered orally daily for 28 days of every cycle. For the first cycle only, quizartinib administered starting on day 5 of the cycle. All subsequent cycles quizartinib will start concomitantly with AZA or cytarabine. Cytarabine administered subcutaneously twice daily for 10 days of every cycle (Days 1-10) as determined by the treating physician.
3099901|NCT01892371|Experimental|Quizartinib + AZA|Quizartinib administered orally daily for 28 days of every cycle. For the first cycle only, quizartinib administered starting on day 5 of the cycle. All subsequent cycles quizartinib will start concomitantly with AZA or cytarabine. AZA administered subcutaneously or intravenously for 7 days of every cycle (Days 1-7) as determined by the treating physician.
3099902|NCT01892358|Active Comparator|SKIN Intervention|Participants will receive the SKIN intervention at Baseline and 1-mo interviews.
3099903|NCT01892358|Placebo Comparator|Assessment-Only|Participants in this arm will receive treatment-as-usual
3099904|NCT01892345|Placebo Comparator|Placebo|Placebo contains the same buffer components without the active ingredient
3099905|NCT01892345|Experimental|Eculizumab|"Induction Phase: 900 mg IV weekly X 4~Maintenance Phase: 1200 mg IV every 2 weeks"
3099906|NCT01892332|Other|lidocaine with fentanyl 75ug|
3099907|NCT01892319||All patients|
3099908|NCT01892306|Experimental|Treatment as usual plus UP CBT|Existing psychiatrist-administered psychopharmacotherapy plus weekly transdiagnostic CBT
3099909|NCT01892306|Active Comparator|Treatment as usual|Existing psychiatrist-administered psychopharmacotherapy
3099910|NCT01892293|Experimental|Autologous genetically modified T cells|Patients with a confirmed diagnosis of myeloma, with measurable disease, and who have received prior therapy for their myeloma that includes an IMiDs and a proteasome inhibitor and who have relapsed or progressive disease, will receive treatment with NY-ESO-1c259-modified T cells. An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to < 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.
3099911|NCT01892280|Experimental|Teenwork Group|Teen/family will receive the Teenwork intervention at each quarterly study visit.
3099912|NCT01892280|Experimental|Teenwork/Text Message Group|Teen/family will receive the Teenwork intervention at each quarterly study visit. Teen will receive text message reminders to check blood glucose levels at self-selected times.
3099913|NCT01892280|Experimental|Text Message Group|Teen will receive text message reminders to check blood glucose levels at self-selected times.
3099914|NCT01892280|No Intervention|Usual Care Group|Teen/family will receive routine clinical care for the first year of the study (the time period for assessment of primary outcomes). After year 1, teen/family will receive the Teenwork intervention at each remaining study visit and teen will receive text message reminders to check blood glucose levels at self-selected times.
3099915|NCT01892267|Experimental|Self-propelled PEGJ feeding tube|Patients in this arm will receive self-propelled balloon PEGJ tube.
3099916|NCT01892267|Active Comparator|Standard PEGJ feeding tube|Patients in this arm will receive the standard commercially availabel PEGJ tube.
3099917|NCT01892254|Experimental|Metformin-Placebo|Metformin, 2x 2 tablets a day, 500 mg tablets for 12 weeks, 6 weeks wash-out, 12 weeks placebo
3099918|NCT01892254|Placebo Comparator|Placebo-metformin|Placebo tablets, 2x 2 tablets per day for 12 weeks, 6 weeks wash-out, 12 weeks metformin, 2x 2 tablets per day, 500 mg per tablet
3099919|NCT01892241|Experimental|180µg of peginterferon alfa-2a|Cases in group A receive 180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
3099920|NCT01892241|Active Comparator|Entecavir|cases in group B received an continual entecavir therapy(0.5 mg orally once daily)
3099921|NCT01892241|No Intervention|Control group|Those in group C didn't accept any antiviral regiment .
3099922|NCT01892228|Experimental|Two counties: Zhongshan and Pubei|"Immediate post-screening treatment education for HIV-positive participants residing in the Zhongshan and Pubei pilot sites in the Treat-All HIV Pilot Program"
3099923|NCT01892215|Experimental|Cephalad-caudad|Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
3099924|NCT01892215|Experimental|Transversal expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
3099945|NCT01892085|Experimental|Early initiation|Initiation of breast milk expression <1 hour following delivery.
3099946|NCT01892085|Experimental|Intermediate expression|Initiation of milk expression 1-<3 hours following delivery.
3099947|NCT01892085|Other|Late initiation|Initiation of milk expression >3-6 hours following delivery.
3099925|NCT01892189|Experimental|Sequence 1: Placebo + TAK-063 3 mg + TAK-063 30 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 3 milligram (mg), orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
3099926|NCT01892189|Experimental|Sequence 2: TAK-063 3 mg + TAK-063 30 mg + Placebo|"Period 1, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
3099927|NCT01892189|Experimental|Sequence 3: TAK-063 30 mg + Placebo + TAK-063 3 mg|"Period 1, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
3099928|NCT01892189|Experimental|Sequence 4: Placebo + TAK-063 3 mg + TAK-063 300 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
3099929|NCT01892189|Experimental|Sequence 5: TAK-063 3 mg + TAK-063 300 mg+ Placebo|"Period 1, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period"
3099930|NCT01892189|Experimental|Sequence 6: TAK-063 300 mg + Placebo + TAK-063 3 mg|"Period 1, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
3099931|NCT01892189|Experimental|Sequence 7: Placebo + TAK-063 30 mg + TAK-063 300 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight:~Period 2, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period"
3099932|NCT01892189|Experimental|Sequence 8: TAK-063 30 mg + TAK-063 300 mg + Placebo|"Period 1, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
3099933|NCT01892189|Experimental|Sequence 9: TAK-063 300 mg + Placebo + TAK-063 30 mg|Period 1, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight. Period 1 & 2 are followed by 7 day washout period
3099934|NCT01892176|Experimental|Coenzyme Q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
3099935|NCT01892163|Active Comparator|Ozurdex PRN dosing|Ozurdex PRN dosing versus Ozurdex fixed dosing
3099936|NCT01892163|Experimental|Ozurdex fixed dosing|
3099937|NCT01892150|Experimental|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
3099938|NCT01892137|Other|Open label active|
3099939|NCT01892124|Experimental|Motivational Interviewing/Cognitive Behavioral-based Therapy|Receives an immediate weekly 10 session intervention based on a culturally-adapted, motivational interviewing and Cognitive Behavioral Therapy grounded protocol.
3099940|NCT01892124|Experimental|Wait-List Control|Receives a weekly 10 session intervention based on a culturally-adapted, motivational interviewing and Cognitive Behavioral Therapy grounded protocol after a three month, no-intervention waiting period.
3099941|NCT01892111|Experimental|structured exercise program (SET)|SET one month before and during ARTs. IVF/ICSI procedure.
3099948|NCT01892072||HCC patients|Hepatocellular carcinoma patients treated by surgical treatment
3099949|NCT01892059|Experimental|Segmental artery clamping|Patients with Renal tumor are randomized into this group,they will received laparoscopic partial nephrectomy. During operation, the technique of segmental renal artery clamping will performed.
3099950|NCT01892059|Active Comparator|Main renal artery clamping|Patients with renal tumor are randomized into this group,they will received laparoscopic partial nephrectomy. During operation, the technique of traditional main renal artery clamping will be performed.
3099951|NCT01892046|Experimental|SNX-5422|Open label administration of SNX-5422 capsules every other day (QOD) for 21 days of a 28 day cycle. Dose escalation will be based on safety outcomes defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level. During the dose escalation phase, subjects will receive carboplatin and paclitaxel once every 21 days for a total of 4 courses. During the maintenance phase, SNX-5422 at the MTD will be dosed every other day (QOD) for 21 days of a 28 day cycle.
3099952|NCT01892033|Experimental|Aerobic Exercise|The aerobic exercise intervention is a 12-week program consisting of four 30- to 40-minute exercise sessions of brisk walking per week.
3099953|NCT01892020|Experimental|Treatment sequence 1 (Group A)|Group A will receive BIAsp 50 BID during the first 4 weeks (treatment period 1) then switch to BHI 50 BID for further 4 weeks (treatment period 2)
3099954|NCT01892020|Experimental|Treatment sequence 2 (Group B)|Group B will receive BHI 50 BID during the first 4 weeks (treatment period 1), then switch to BIAsp 50 BID for further 4 weeks (treatment period 2)
3099955|NCT01892007|Experimental|Cogmed RM (adaptive)|Online training intervention: An adaptive version of Cogmed RM working memory training. Task difficulty (number of to-be-remembered items) increases based on individual performance, in order to maintain average daily performance levels of approximately 60% of trials correct. Participants complete 35-45 minutes of active training per day, 5 days a week for 5 weeks.
3099956|NCT01892007|Placebo Comparator|Active control: Cogmed RM (non-adaptive, placebo)|Online training intervention: A non-adaptive placebo version of Cogmed RM working memory training. Tasks are fixed at a low-difficulty practice level (three to-be-remembered items) and do not increase in difficulty over the course of the intervention. Participants complete 35-45 minutes of active placebo training per day, 5 days a week for 5 weeks.
3099957|NCT01891994|Experimental|Eltrombopa|administration of eltrombopag for 6 months
3099958|NCT01891981|Experimental|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
3099959|NCT01891968|Experimental|Bortezomib|Bortezomib administered via subcutaneous route at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11 of a 21 day cycle. A course of treatment will be 21 days.
3099960|NCT01891955|Active Comparator|Diet A|Healthy diet with grains and dairy
3099961|NCT01891955|Active Comparator|Diet B|Healthy diet without grains and dairy
3099962|NCT01891942|Experimental|COPD patients|All of the COPD patients included in this study were stable with no episodes of exacerbation within the previous 2 months. Patients with COPD were not currently being treated with oral corticosteroids.
3099963|NCT01891942|Experimental|normal subjects|Fifteen healthy men with normal lung function
3099964|NCT01891929|Experimental|RECOS|The RECOS program (COgnitive REmediation for Schizophrenia) was designed by SBT Company and adapted by Vianin et al (2007) for specific use in schizophrenia. It includes computer based and paper and pencil exercises that target 6 main cognitive functions (selective attention; verbal memory; visuo-spatiale attention and memory, working memory, reasoning, and speed of execution) which have been recommended by the MATRICS consensus. Each exercise has 10 difficulty levels. Allocation of the training modules in RECOS is determined according to the standard scores obtained in the comprehensive neuropsychological assessment. Each patient participates in the module corresponding to his/her most altered cognitive area.
3099965|NCT01891929|Active Comparator|TAU (Treatment as Usual)|The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.
3099966|NCT01891916|No Intervention|extensively hydrolysed casein formula|extensively hydrolysed casein formula
3099967|NCT01891916|Active Comparator|Extensively hydrolyzed casein formula + LGG|Extensively hydrolized formula plus LGG
3099968|NCT01891890|Active Comparator|Lamotrigine|Lamotrigine 7.0 mg/kg tablets or chewable tablets administered daily in 2 equally divided doses
3099969|NCT01891890|Active Comparator|Oxcarbazepine|Oxcarbazepine 25 mg/kg tablets or liquid administered daily in 2 equally divided doses
3099970|NCT01891890|Active Comparator|Levetiracetam|Levetiracetam 30 mg/kg tablet or liquid administered daily in 2 equally divided doses
3099971|NCT01891877||Current or Former Football Players|Any former or current high school or college football players who carries sickle cell trait.
3099972|NCT01891864|Experimental|GP2015 Etanercept|Solution for subcutaneous injection in pre-filled syringe. The drug is administered in a dose of 50 mg twice weekly for the first 12 weeks and 50 mg once weekly thereafter
3099973|NCT01891864|Active Comparator|Enbrel ® Etanercept|Solution for subcutaneous injection in pre-filled syringe. The drug is administered in a dose of 50 mg twice weekly for the first 12 weeks and 50 mg once weekly thereafter
3099974|NCT01891851|Experimental|TMC435350 / Ritonavir|TMC435350 2 capsules of 100-mg twice daily / Ritonavir one 100-mg capsule twice daily
3099975|NCT01891838|Active Comparator|Volume controlled ventilation|Volume controlled ventilation: tidal volume of 7 mL/kg ideal body weight, frequency of 12 cycles/minute, I/E ratio of 1:2, no positive end expiratory pressure. Ventilatory frequency is changed if necessary to maintain end-expiratory pressure of CO2 between 35 and 40 mmHg.
3099976|NCT01891838|Experimental|Pressure-controlled ventilation|initial pressure of 15 cm H2O, frequency of 12 cycles/minute, I/E ratio of 1:2, no positive end expiratory pressure. Pressure is modified to maintain a tidal volume of 7 mL/kg of ideal body weight and frequency ventilation is modified to maintain end-expiratory pressure of CO2 between 35 and 40 mmHg
3099977|NCT01891825|Active Comparator|Pecutaneous AF ablation|Percutaneous catheter ablation of atrial fibrillation
3099978|NCT01891825|Active Comparator|Surgical AF ablation|Minimally invasive thoracoscopic surgical ablation of atrial fibrillation
3099979|NCT01891812|Experimental|Nitrous oxide 50%|Nitrous oxide 50% administered for 15 minutes.
3100008|NCT01891565|Experimental|Activity Feedback|Feedback
3099980|NCT01891799||PMTCT Options Evaluation|All HIV positive pregnant women not on ART engaging in PMTCT services at the study sites will be included. This will include HIV+ women not on ART enrolling in PMTCT services and pregnant women newly testing HIV+ in the ANC. All women will eventually receive the intervention of Option B+ as each clinic transitions from Option A to B+.
3099981|NCT01891786|No Intervention|Usual Care|The participant's General practitioner (GP) practice and/or practice nurse will provide care as normal for their patient.
3099982|NCT01891786|Active Comparator|Group Self-Management Intervention (SMI)|Participants will be asked to attend a total of 4 SMI sessions delivered on a weekly basis.
3099983|NCT01891786|Active Comparator|SMI + Risk Results|The participant will provide a saliva sample for analysis. They will attend an appointment with their nurse to receive personalised results on their combined genetic and lifestyle risk for developing CHD in the next 10 years. They will then be asked to attend the 4 week SMI programme.
3099984|NCT01891773|Experimental|School-based therapy|Daily dose of medication to be provided in the school setting.
3099985|NCT01891773|No Intervention|Usual Care|Daily medication to be taken at home.
3099986|NCT01891760|Experimental|Treatment|Dermagraft - Allogenic Neonatal Dermal Fibroblasts Seeded on poly(glycolide-co-L-lactide)(PGLLA)Scaffold
3099987|NCT01891760|Active Comparator|Reference Therapy|Profore - Four-layer compression bandaging therapy
3099988|NCT01891747|Experimental|L-methylfolate with Bevacizumab & Temozolomide|28-day cycle, dose levels L-methylfolate: Phase I 15 mg (once a day) 30 mg (15 mg twice a day) 60 mg (30 mg twice a day) 90 mg (45 mg twice a day) Phase II will use the MTD of L-methylfolate daily with bevacizumab & temozolomide.
3099989|NCT01891734|Experimental|Problem Solving Therapy plus Moving Forward (PST-MF)|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
3099990|NCT01891734|Active Comparator|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
3099991|NCT01891721|Experimental|Specific Perceptual Training - Brain Fitness Program (BFP)|In each session, participants will work on 4 of the 6 BFP exercises (15 min per exercise). Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
3099992|NCT01891721|Experimental|Broad Cognitive Training - Cognitive Package (Cogpack)|In each session, participants will work on a different subset of 4 to 6 Cogpack exercises. Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
3099993|NCT01891721|Active Comparator|Control Treatment - Commercial Computer Games (Sporcle)|In each session, participants will play between 8 and 16 games (1 to 15 min per game). Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
3099994|NCT01891695|Experimental|Reduced Intensity Radiation|39.6 Gy radiation to clinically uninvolved cervical lymphatics
3099995|NCT01891682||Critically Ill Pediatric Patients|Critically ill septic pediatric patients, Age 1 month-3 years, Age 4-12 years and Age 13-19 years, males and females
3099996|NCT01891669|Experimental|Part 1|
3099997|NCT01891656|Experimental|Motivational Interviewing|"Participants randomized to the MI group will receive a single 60-minute MI session focused on motivation to initiate and engage in treatment. The MI session will be organized around the Check-Up format, with additional planning components as desired by the client."
3099998|NCT01891656|No Intervention|Supervision As Usual|Participants randomized to the SAU group will receive the standard agency intake process as well as baseline and follow-up research interviews, but will not receive any additional intervention as part of the study. They will be referred to a treatment program as per the normal routine.
3099999|NCT01891656|Experimental|Motivational Computer|Participants randomized to the MC group will complete a 60 minute computer intervention focused on motivation to initiate and engage in treatment. The program will be self-guided, interactive, and to the extent possible, will mirror the features of MI session. The MC program will have two main components: a motivation component and a planning component.
3100000|NCT01891643|Experimental|Arm 1: Lenalidomide + Dexamethasone|"Lenalidomide 25 mg capsules by mouth once daily (on Days 1-21), repeat every 28 days until subject meets criteria for discontinuation of study drug~Dexamethasone 40 mg tablets by mouth weekly (on Days 1, 8, 15, 22), repeat every 28 days until subject meets criteria for discontinuation of study drug"
3100001|NCT01891643|Experimental|Arm 2: Lenalidomide + Dexamethasone + Elotuzumab|"Lenalidomide 25 mg capsules by mouth once daily (Days 1-21)~Dexamethasone 28 mg tablets by mouth once daily [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15(cycles 3-18); Day 1 (cycle 19 & beyond)]~Dexamethasone 40 mg tablets by mouth once daily [Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 & beyond)]~Dexamethasone 8 mg IV (intravenous) solution once daily [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15 (cycles 3-18); Day 1 (cycle 19 & beyond)]~Elotuzumab 10 mg/kg IV solution weekly [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15 (cycles 3-18)]~Elotuzumab 20 mg/kg IV solution on Day 1 (cycle 19 & beyond)~Repeat above-mentioned dose cycles every 28 days until subject meets criteria for discontinuation of study drug"
3100002|NCT01891630||AA children|African-American children with moderate-to-severe asthma living in a defined geographical area whose asthma is poorly controlled, and up to 30 moderate-to-severe African-American asthmatic children living in the same defined geographical area whose asthma is well controlled.
3100003|NCT01891617|Experimental|Exercise-high-fat diet|Two bouts of exercise followed by a high-fat meal
3100004|NCT01891617|Experimental|Exercise-high-carbohydrate diet|Two bouts of exercise followed by a high-carbohydrate meal
3100005|NCT01891617|Experimental|Sedentary-high-fat diet|Sedentary trial with two high-fat meals
3100006|NCT01891617|Experimental|Sedentary-high-carbohydrate diet|Sedentary trial with two high-carbohydrate meals
3100007|NCT01891591||obese female subjects|16 obese female subjects with BMI > 40 kg/m2 on a waiting list for bariatric surgery
3100012|NCT01891539||doxorubicin|"Day +1:~Lobar Infusion ( lobe with dominant disease) of Doxorubicin preloaded into 2 ml of drug-eluting microspheres.~Second lobar infusion of Doxorubicin preloaded into 2 ml of drug eluting microspheres can be administered at the same time contralaterally or in a further TACE Day +30: The above procedure is repeated. Day +90: In case of response, a third administration following the above procedures will be repeated"
3100013|NCT01891526||Hepatic patients|patients with hepatic insufficiency
3100014|NCT01891526||Healthy Controls|Healthy adults
3100015|NCT01891513||ACE inhibitor + exercise|In addition to exercise training, participants will receive an initial perindopril dose of 4 mg/day which will be titrated to 8 mg/day.
3100016|NCT01891513||Thiazide diuretic + exercise|In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
3100017|NCT01891513||Angiotensin receptor blocker + exercise|In addition to exercise training, participants will receive an initial losartan dose of 50 mg/day which will be titrated to 100 mg/day.
3100018|NCT01891500|Experimental|Early inhaled nitric oxide|Patients randomized to receive iNO at OI 10-15.
3100019|NCT01891500|Placebo Comparator|Bioinert inhaled gas (nitrogen gas)|Patients randomized to bioinert inhaled gas at OI 10-15.
3100020|NCT01891500|Active Comparator|Crossover iNO|Patients who deteriorate (OI >20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
3100021|NCT01891487|Active Comparator|Track A|Those on active study medication
3100022|NCT01891487|Placebo Comparator|Track B|Those on placebo.
3100023|NCT01891474|Experimental|U-health care|voice inception technique based U-healthcare service
3100024|NCT01891474|No Intervention|control|conventional treatment
3100025|NCT01891461|Experimental|Floseal|"Floseal will be administered during the procedure and prior to release of the tourniquet (if used PRN during the cementing procedure (±10 minutes)) and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissue by the use of a delivery syringe. Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.~Preparation of Floseal requires mixing 5,000 US units of package thrombin (bovine-derived) made up to 5 milliliters of saline solution, to the Gelatin Matrix solution. In this study, 2-4 vials (15-20 mls total) will be used."
3100026|NCT01891461|No Intervention|standard of care|For patients randomized to the control arm, the surgery will proceed in an otherwise identical fashion (with release of the tourniquet if used PRN during cementing procedure (±10 minutes)) and hemostasis followed by drain insertion and wound closure.
3100027|NCT01891448|Experimental|WebCONSORT tool|This WebCONSORT tool allows authors to combine different extensions relevant to their trial and generate a list of items and a flowchart specific to their trial design and the type of intervention tested.
3100028|NCT01891448|Other|Modified WebCONSORT tool|This tool will include the flowchart part of the WEBCONSORT tool but not the main checklist or elements relating to CONSORT extensions.
3100029|NCT01891435|Active Comparator|oral paracetamol|patients in this arm will receive 1000mg of oral paracetamol
3100030|NCT01891435|Active Comparator|Intravenous paracetamol|patients in this arm will receive 1000 mg of intravenous paracetamol
3100031|NCT01891435|Active Comparator|Intramuscular Diclofenac|patients in this arm will receive 75 mg of intramuscular diclofenac sodium
3100032|NCT01891409|Other|Single arm|Single arm study study for use of Shang Ring device for male circumcision in children
3100033|NCT01891396|Placebo Comparator|Saline|Single injection of 0.9% saline supplied as a 4 mL unit dose in a 5mL glass syringe
3100034|NCT01891396|Experimental|Hyaluronic Acid and TH|Single injection of sodium hyaluronate with triamcinolone hexacetonide (TH) supplied as a 4 mL unit dose in a 5 mL glass syringe
3100035|NCT01891396|Active Comparator|Hyaluronic Acid|Single injection of sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe
3100036|NCT01891383||History of TBI|The history of TBI will be assessed by the subject's answers to the Ohio State University Traumatic Brain Injury Identification Method Short Form (OSU TBI-ID SF).
3100037|NCT01891383||No history of TBI|The history of TBI will be assessed by the subject's answers to the Ohio State University Traumatic Brain Injury Identification Method Short Form (OSU TBI-ID SF).
3100038|NCT01891357|Experimental|Paclitaxel + Lapatinib + Trastuzumab|Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment
3100039|NCT01891344|Experimental|Ovarian cancer|rucaparib
3100040|NCT01891331|Experimental|VT-1161 300mg QD|
3100041|NCT01891331|Experimental|VT-1161 600mg QD|
3100042|NCT01891331|Experimental|VT-1161 600mg BID|
3100043|NCT01891331|Active Comparator|Fluconazole 150mg|
3100044|NCT01891318|Experimental|Treatment (radiosurgery, surgery)|Patients undergo radiosurgery on day 0. Within 2 weeks, patients undergo surgical resection.
3100045|NCT01891305|Experimental|VT-1161 200/50mg|
3100046|NCT01891305|Experimental|VT-1161 600/150mg|
3100047|NCT01891305|Experimental|VT-1161 1200/300mg|
3100048|NCT01891305|Placebo Comparator|Matching placebo|
3100049|NCT01891292|No Intervention|Control|
3100050|NCT01891292|Active Comparator|Enalapril|
3100051|NCT01891292|Active Comparator|N-Acetylcysteine|
3100052|NCT01891279|Experimental|elemental formula, Elecare®|Babies will receive elemental formula, Elecare®, if breast milk is not available.
3100053|NCT01891279|Experimental|part hydrolyzed formula, Pregestimil®|Babies will receive partially hydrolyzed formula, Pregestimil®, if breast milk is not available.
3100054|NCT01891266|Experimental|Non-tourniquet assisted TKA|
3100055|NCT01891266|Other|Tourniquet assisted TKA|
3100056|NCT01891253||ventilated patients|ventilated patients in an internal medicine ICU with existing PiCCO invasive hemodynamic monitoring
3100057|NCT01891240||First time, low risk mothers|The study population will consist of first time, low risk mothers attending for antenatal care in one of the participating clinical centres.
3100085|NCT01891032||the patients with open partial nephrectomy|the adult patients with open partial nephrectomy
3100086|NCT01891032||laparoscopic|the adult patients with laparoscopic partial nephrectomy
3100058|NCT01891227|Experimental|Capecitabine and Bendamustine|"Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).~Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).~Eligible patients will receive capecitabine in combination with bendamustine for a maximum of eight cycles and afterwards capecitabine mono will be continued until disease progression or unacceptable toxic effects. Safety assessments will be conducted in 3-weekly intervals; efficacy assessments will be conducted every 9 weeks."
3100059|NCT01891214||Ulcerative Colitis and Crohn's Disease|
3100060|NCT01891201||Not exposed to oxytocin|Mother-child dyads in which Oxt had not been administered during the birth process
3100061|NCT01891188||Cardiac Cath|All pediatric patients requiring cardiac catheterization who consent
3100062|NCT01891175|Experimental|Intermittent pneumatic compression|With intermittent pneumatic compression of the lower extremities (Covidien / Kendall SCD ™ sequential compression systems) plus phenylephrine perfusion (usual treatment)in elective caesarean section under spinal anaesthesia.
3100063|NCT01891175|Active Comparator|Only pheniyephrine perfussion|No intermittent pneumatic compression of the lower extremities in elective caesarean section under spinal anaesthesia.
3100064|NCT01891162||Control|Assessment will be carried out general quality of life beyond the functional evaluation of the pelvic floor through the PERFECT
3100065|NCT01891162||Study|Will be held evaluate the quality of life for general and specific pelvic floor dysfunction beyond the functional assessment of the pelvic floor through the PERFECT.
3100066|NCT01891149||Malawian women|Malawian women who present for care at the Fistula Care Centre
3100067|NCT01891136|Experimental|Peanut protein|Subjects to receive varying amounts of peanut protein as peanut oral immunotherapy.
3100068|NCT01891123|Placebo Comparator|body surface area|patients receive fixed dose of PTX or DOC based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2. Patients should finish up to 6 cycles chemotherapy
3100069|NCT01891123|Active Comparator|Detection Kit|PTX 175mg/m2, DOC 75mg/m2 at first cycle. the dose of PTX or DOC will adjust based on the pharmacokinetic results of previous cycle. A optimal target of PTX(TC>0.05) and DOC(AUC) have been set from published PK model with an established limited sampling strategy
3100070|NCT01891110|Experimental|ES of the abdominal muscles|ES with surface electrodes, fixed stimulation parameters and individual mA
3100071|NCT01891110|Experimental|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
3100072|NCT01891110|Experimental|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
3100073|NCT01891097|Active Comparator|Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, Neiguan PC6, Shenmen HT7, Sanyinjiao SP6, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (ITO ES160, Japan) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.4 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
3100074|NCT01891097|Experimental|Acupuncture plus auricular acupuncture|Subjects will be treated with electroacupuncture plus auricular acupuncture for 3 weeks. The acupuncture regimen, is the same as in electroacupuncture group. In additional to electroacupuncture, subjects will receive auricular acupuncture using borneol. The following 6 ear acupoints points will be selected: Ear Shenmen, Heart, Kidney, Liver, Spleen, Occiput, and Subcortex. In each treatment borneol crystals will be attached to the left or right side of the ear in alternation with adhesive plaster in each acupuncture treatment visit. Subjects will be asked to press the borneol crystals lightly for five minutes in the morning, afternoon and evening everyday and reminded them to remove the plaster and borneol crystals after 48 hours. We will check for skin irritation at each treatment visit.
3100075|NCT01891097|No Intervention|Waiting-list control|This group will receive no treatment. Subjects will be assessed at baseline and the 4th and 7th week; afterwards, they will be randomized to one of the other two groups in the ratio of 1:1.
3100076|NCT01891084|Active Comparator|Paracetamol|"Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose. Precautionary statement (Do not exceed 8 tablets daily) will be printed on the dispensary label to avoid overdose.~Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable."
3100077|NCT01891084|Placebo Comparator|Placebo|"(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose. Precautionary statement (Do not exceed 8 tablets daily) will be printed on the dispensary label to avoid overdose.~Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable"
3100078|NCT01891071|Experimental|Lung volume recruitment|Lung volume recruitment twice daily for 9 months
3100079|NCT01891071|No Intervention|Standard care|Standard care
3100080|NCT01891058|Active Comparator|drug-shock vs shock only|For ED patients with RAFF, Investigators will compare conversion to normal sinus rhythm between the two strategies of i) attempted pharmacological cardioversion with intravenous procainamide followed by DC cardioversion if necessary (Drug-Shock), and ii) DC cardioversion alone (Shock Only).
3100081|NCT01891058|No Intervention|pad positions|For ED RAFF patients undergoing DC cardioversion, Investigators will compare conversion to normal sinus rhythm between the i) antero-posterior and ii) antero-lateral pad positions.
3100082|NCT01891045|No Intervention|Control|Patients merely monitored on background variables to function as a baseline of comparison
3100083|NCT01891045|Active Comparator|Prediction|Patients randomized to this condition completes the OQ-45.2 weekly, but the reports are withheld from therapists and patients.
3100084|NCT01891045|Experimental|Intervention|Patients and therapists uses the feedback-system as intended, with real-time feedback to the therapist and full use of the suggested interventions
3100088|NCT01891032||robotic|the adult patients with robotic partial nephrectomy
3100089|NCT01891006|Experimental|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy (NPWT) is an alternative method of conservative wound management, which uses negative pressure to promote wound healing in both chronic and acute wounds. The rationale for using NPWT is that it mechanically stimulates the formation of new tissue and removes wound fluid and infectious material
3100090|NCT01891006|Other|A standard wound dressing|The standard wound dressing is a hydrofiber or alginate dressing, used for open wound
3100091|NCT01890993||Liraglutide|
3100092|NCT01890993||DPP-4|
3100093|NCT01890980|Experimental|WT-1-vaccine Montanide + GM-CSF|The study will be a randomized phase II trial to determine the 1-year progression free survival after treatment with WT-1 analog peptide vaccine in patients with MPM after completion of combined modality therapy.
3100094|NCT01890980|Active Comparator|Montanide adjuvant + GM-CSF|The study will be a randomized phase II trial to determine the 1-year progression free survival after treatment with WT-1 analog peptide vaccine in patients with MPM after completion of combined modality therapy.
3100095|NCT01890967|Experimental|20 mg LY3015014 Q4W|"20 milligrams (mg) LY3015014 given subcutaneously (SC) once every 4 weeks (Q4W) for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
3100096|NCT01890967|Experimental|120 mg LY3015014 Q4W|"120 mg LY3015014 given SC Q4W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
3100097|NCT01890967|Experimental|300 mg LY3015014 Q4W|"300 mg LY3015014 given SC Q4W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
3100098|NCT01890967|Experimental|100 mg LY3015014 Q8W|"100 mg LY3015014 given SC once every 8 weeks (Q8W) for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
3100099|NCT01890967|Experimental|300 mg LY3015014 Q8W|"300 mg LY3015014 given SC Q8W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
3100100|NCT01890967|Placebo Comparator|Placebo Q4W|"Placebo given SC Q4W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
3100101|NCT01890954|Active Comparator|DiAs-closed-loop system|eight hours using Closed Loop Control (DiAs) under both, miss insulin bolus for 30 grams of carbohydrates snack or under bolus for an 80 grams of carbohydrates lunch
3100102|NCT01890954|No Intervention|Sensor Augmented Pump|8 hours observational under both, missed insulin bolus for 30 gr carbohydrates snack and under bolus for an 80 gr carbohydrates lunch. Sensor augmented pump used the patients own insulin settings (basal rate, meal boluses and correction boluses) and a CGM provided by the study team to be used during admission. No DiAs use during this admisssion
3100103|NCT01890941|Experimental|KCT-0809 Lower Dose|
3100104|NCT01890941|Experimental|KCT-0809 Higher Dose|
3100105|NCT01890941|Placebo Comparator|Placebo|
3100106|NCT01890928||Critically Ill Septic Pediatric Patients|Age 5-12 years; weight ≥ 17kg and Age 13-19 years, males and females
3100107|NCT01890928||Healthy Adolescents|Age 13-19 years, males and females
3100108|NCT01890915||Tetraplegia|Persons with spinal cord injury, level of injury C4-T1, American Spinal Injury Association (ASIA) impairment levels A-B and duration of injury greater than 1 year. Ages 18-65 years old.
3100109|NCT01890915||Control|Age and gender-matched able-bodied controls. Ages 18-65 years old.
3100110|NCT01890902|Experimental|Impracor (Ketoprofen 10% Cream)|Topical Cream over a period of 14 days
3100111|NCT01890902|Placebo Comparator|Placebo Cream:|Topical Cream over a period of 14 days
3100112|NCT01890889|Active Comparator|Ad-Chol-Pre|A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
3100113|NCT01890889|Active Comparator|Half-dose Ad-Chol-Pre|A half-dose of the active comparator in arm one is administered. A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
3100114|NCT01890889|Placebo Comparator|Capsule containing inactive component of defatted egg yolk|Placebo capsule is filled with defat egg yolk only without specific IgY which is anti-NPC1L1 IgY, designed to look and taste the same as the active product capsule, but does not contain the active component.
3100115|NCT01890876|Active Comparator|Low altitude|Walking uphill Walking downhill
3100116|NCT01890876|Active Comparator|High altitude|Walking uphill Walking downhill
3100117|NCT01890863|Experimental|Sequence 1|Subjects will receive treatment A and B in following sequence in four treatment periods (one treatment per period): ABBA, where treatment A is 7 doses of FSC (100/50 mcg) delivered via the Ddpi and treatment B is 7 doses of FSC (100/50mcg) delivered via the Rdpi. Subjects will be dosed twice daily for 3 days and once on the fourth day in the morning (a single inhalation of 100/50mcg per dose).
3100118|NCT01890863|Experimental|Sequence 2|Subjects will receive treatment A and B in following sequence in four treatment periods (one treatment per period): BAAB, where treatment A is 7 doses of FSC (100/50 mcg) delivered via the Ddpi and treatment B is 7 doses of FSC (100/50mcg) delivered via the Rdpi. Subjects will be dosed twice daily for 3 days and once on the fourth day in the morning (a single inhalation of 100/50mcg per dose).
3100119|NCT01890850||Pertussis Group|Infants less than one year of age diagnosed with pertussis/whooping cough infection within 12 months from birth (first year of life, between July 1, 2005 and September 30, 2010).
3100120|NCT01890850||Control Group|Infants with no evidence of pertussis/whooping cough during within 12 months from birth (first year of life, between July 1, 2005 and September 30, 2010).
3100121|NCT01890837|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID/3 times per day (15g/day)
3100122|NCT01890837|Placebo Comparator|Placebo|Placebo TID
3100123|NCT01890824||Breast Cancer Patients|Breast cancer patients to be studied before and after chemotherapy
3100124|NCT01890824||Healthy Female Controls|Healthy female controls will be compared to breast cancer patients before and after chemotherapy and to healthy male controls
3100125|NCT01890824||Healthy Male Controls|Healthy male controls will be compared to healthy female controls to determine gender differences
3100126|NCT01890811|Experimental|Boost High Protein|Boost high protein with added spirulina
3100127|NCT01890798|Experimental|Drisapersen (DMD117402)|The protocol is open only to the subjects who completed GSK protocol DMD114876 and participated in protocol DMD115501, United States citizens who have completed protocol DMD114044, or United States citizens who are participating in protocol DMD114349 outside the United States and want to end their participation in the DMD114349 study. Eligible subjects will receive drisapersen 6 milligram (mg)/kilograms (kg) once a week via subcutaneous (SC) injection.
3100128|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Fasting|lisdexamfetamine dimesylate 70 mg capsule administered under fasted conditions
3100129|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Vanilla Yogurt|Lisdexamfetamine Dimesylate 70mg capsule mixed into vanilla yogurt
3100130|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Orange Juice|Lisdexamfetamine Dimesylate 70mg capsule mixed into orange juice
3100131|NCT01890772|Active Comparator|VitD+telaprevir+peginterferon+ribavirin|Participants randomized to the treatment group will receive 5,000IU/day of vitamin D3 during the lead-in phase. When the serum 25(OH)D level is ≥35ng/ml the participant will begin telaprevir + vitamin D3 (15,000IU/week) + peginterferon alfa-2a (180ug/week) + weight based ribavirin treatment.
3100132|NCT01890772|Active Comparator|Telaprevir + Peginterferon + Ribavirin|Participants randomized to the control group immediately begin treatment with telaprevir + 180ug of peginterferon alfa-2a (Pegasys) per week and either weight based ribavirin.
3100133|NCT01890759|Experimental|Meningococcal Diphtheria Toxoid Vaccine|Participants at age 9 to 17 months of enrollment will receive 2 doses on Menactra vaccine at 3 to 6 months apart
3100134|NCT01890746|Experimental|Eltrombopag arm|Subject will receive induction chemotherapy consisting of daunorubicin bolus intravenous (IV) infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by Eltrombopag once daily orally starting on Day 4 of initial induction chemotherapy. If platelet count is not greater than 100 Gi/L after 7 days the dose will be increased until a platelet count of at least 200 Gi/L is achieved/until remission is assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who are not aplastic after first cycle of induction chemotherapy will receive second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
3100135|NCT01890746|Placebo Comparator|Placebo arm|Subject will receive induction chemotherapy consisting of daunorubicin bolus IV infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by matching placebo once daily oral dose starting on Day 4 of initial induction chemotherapy. If platelet count is not greater than 100 Gi/L after 7 days the matching placebo will be given until a platelet count of at least 200 Gi/L is achieved/ until remission is assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who are not aplastic after first cycle of induction chemotherapy will receive a second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
3100136|NCT01890733|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridment, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
3100137|NCT01890733|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridment, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
3100138|NCT01890720|Experimental|iNPWT|Negative Pressure Wound Therapy (NPWT) is a mechanical wound care treatment using controlled sub-atmospheric pressure to assist and accelerate wound healing. Incisional Negative Pressure Wound Therapy (iNPWT) is a new NPWT devices, which can be used over clean closed surgical incisions. The device behaves in a similar fashion to existing conventional NPWT devices, i.e. transmission of negative pressure levels at the wound bed, tissue contraction and establishing a characteristic pattern of peri-wound blood flow and that it reduces and normalises tissue stresses at the incision
3100139|NCT01890720|Active Comparator|Standard wound dressing|The standard postoperative wound dressing is a normal wound dressing, used over clean closed incisions.
3100140|NCT01890707|Active Comparator|Deep Sedation|Deep sedation
3100141|NCT01890707|Other|General Anesthesia|Administration of general anesthesia. Propofol given IV, succinylcholine and rocuronium given IV and Sevoflurane via the endotracheal tube.
3100142|NCT01890694|Placebo Comparator|Placebo|"Subjects will receive placebo once daily.~They will undergo the following procedures in every visit: Vitals (blood pressure, heart rate, respiration, temperature, weight, height), Laboratory Tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin), ascites assessment, evaluation for edema. Quality of life assessments (SF-36, and LDQOL 1.0) will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge. Hepatic encephalopathy assessment (Number Connection Test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status) will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge."
3100143|NCT01890694|Experimental|Tolvaptan|"Subjects will receive Tolvaptan once daily.~They will undergo the following procedures in every visit: Vitals (blood pressure, heart rate, respiration, temperature, weight, height), Laboratory Tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin), ascites assessment, evaluation for edema. Quality of life assessments (SF-36, and LDQOL 1.0) will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge. Hepatic encephalopathy assessment (Number Connection Test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status) will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge."
3100144|NCT01890681|Active Comparator|Back to Sleep|"The Back to Sleep arm will encourage safe sleep practices to reduce the risk of Sudden Infant Death Syndrome (SIDS) in child care and at home. This include:~center and family self-assessment,~center intervention materials delivered several times over the 6-month period, and;~parent handouts~After the intervention period, comparator centers will receive an abbreviated version of the Baby NAP SACC intervention."
3100145|NCT01890681|Experimental|Baby NAP SACC|"The intervention will include four complementary and mutually reinforcing components:~center and family self-assessment;~targeted technical assistance by Baby NAP SACC consultant for providers and parents;~training workshops for child care providers; and~parent outreach and support."
3100146|NCT01890668|Experimental|Osteopathic Manipulative Treatment|Randomization and first OMT will take place at discharge (Day 3); second osteopathic therapy will be performed by the same osteopath practitioner at Day10.
3100147|NCT01890668|Placebo Comparator|Control group|Control group consists in classical medical and paramedical breastfeeding support. OMT on the newborn will be realized by osteopath dissimulated behind a screen. Placebo OMT consists to mimic, without the knowledge of parents, osteopathic techniques on a dolly.
3100148|NCT01890655|Experimental|MT-1303-Low|MT-1303-Low Dose
3100149|NCT01890655|Experimental|MT-1303-Middle|MT-1303-Middle Dose
3100150|NCT01890655|Experimental|MT-1303-High|MT-1303-High Dose
3100151|NCT01890642|Sham Comparator|J tip Noise|This group will have a J tip deployed without medication to create the noise that the device makes. They will also receive Pain Ease spray if > age 1 yr or sucrose if < 1 yr
3100152|NCT01890642|Other|Pain Ease|This group will receive Pain Ease Spray only if > 1 yr or sucrose only if child < 1 yr
3100153|NCT01890642|Experimental|J tip|This group will receive 1% buffered lidocaine via Jet Injection. They will receive placebo cooling spray (normal saline spray) to maintain blinding if > 1 yr and will receive sucrose is < 1 yr
3100154|NCT01890629|Experimental|Gemigliptin + Metformin|Gemigliptin 50 mg + Metformin 500 mg to 1000mg for 12 weeks
3100155|NCT01890629|Active Comparator|Sitagliptin + Metformin|Sitagliptin 100 mg + Metformin 500 mg to 1000mg for 12 weeks
3100156|NCT01890629|Active Comparator|Glimepiride + Metformin|Glimepiride 2 mg + Metformin 500 mg to 1000mg for 12 weeks
3100157|NCT01890616|Experimental|Motility|This arm will ingest the SmartPill.
3100158|NCT01890603|Experimental|Care Coordination Arm|
3100159|NCT01890603|Active Comparator|Quality Measure Improvement|
3100160|NCT01890590|Experimental|Cyberknife|You will receive a series of Cyberknife Radiosurgery treatments, with the amount of radiation dosing adjusted for the size of your tumor. The treatment will ideally take place over the course of 3-4 days, but not more than 14 days overall. (3 or 4 fractions of radiation therapy delivered by cyberknife)
3100161|NCT01890577||Study population|Single cohort of dialysis patients
3100162|NCT01890564||Bariatric surgery|Patients undergoing bariatric surgery.
3100163|NCT01890551|Other|affected knee|Interest was to evaluate the patellofemoral joint biomechanics with KINE-MRI in adolescents with affected and unaffected knees in a case-control study
3100164|NCT01890551|Other|unaffected knee|Interest was to evaluate the patellofemoral joint biomechanics with KINE-MRI in adolescents with affected and unaffected knees in a case-control study
3100165|NCT01890538|Active Comparator|Piracetam|2 g intravenous piracetam
3100166|NCT01890538|Active Comparator|Dimenhydrinate|Dimenhydrinate 100 mg intravenous
3100167|NCT01890525||PROMISE study patients|
3100168|NCT01890512||ImageReady Pacemaker|patients previously implanted with a Boston Scientific MR Conditional pacemaker(ImageReady)
3100169|NCT01890499|Experimental|Low residue diet arm|"Two arm randomized controlled trial. First arm is the Clear feeds on postoperative day one arm.~The second arm (interventional arm) is the Low Residue diet on postoperative day one arm."
3100170|NCT01890499|Active Comparator|Clear feeds arm|Standard of care is to start clear feeds on postoperative day one for elective colorectal surgery patients.
3100171|NCT01890473|Experimental|Arm 1: Abatacept (autoinjector)|Abatacept 125 mg/syringe subcutaneously through autoinjector, one dose in 71 days
3100172|NCT01890473|Experimental|Arm 2: Abatacept (prefilled syringe)|Abatacept 125 mg/syringe subcutaneously with prefilled syringe, one dose in 71 days
3100173|NCT01890447||Questionnaire design group|A focus group (group of experts) such as physicians, nurses, or other professionals invited by the investigator.
3100174|NCT01890447||Adaptive questionnaire group|Adults who are contacts of newborns or expecting mothers in their last trimester of pregnancy or their partners. The data of the subjects in this group will be analysed using the adaptive choice based conjoint (ACBC) technique.
3100175|NCT01890447||Standard questionnaire group|Adults who are contacts of newborns or expecting mothers in their last trimester of pregnancy or their partners. The data of the subjects in this group will be analysed using the standard discrete choice experiment (DCE) technique.
3100176|NCT01890434|Experimental|Gadobutrol 0.1 mmol/kg body weight|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
3100177|NCT01890421|Experimental|Gadobutrol 0.1 mmol/kg body weight|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
3100178|NCT01890408|Experimental|ropivacaine|patients scheduled to undergo open liver resection Age > 18 years Free from pain in preoperative period
3100179|NCT01890408|Placebo Comparator|placebo|patients scheduled to undergo open liver resection Age > 18 years Free from pain in preoperative period
3100180|NCT01890395|Other|blood collection|procedure: Blood draws as the intervention
3100181|NCT01890382|Placebo Comparator|Control|alanine
3100182|NCT01890382|Experimental|whey protein|
3100183|NCT01890382|Experimental|soy protein|
3100184|NCT01890382|Experimental|leucine supplementation|
3100185|NCT01890382|Experimental|whey plus creatine|
3100186|NCT01890369|Experimental|Early leucine refeed|15g Mixed Essential Amino Acids. 90 min delay. 3g Leucine
3100187|NCT01890369|Experimental|Early EAA refeed|15g Mixed Essential Amino Acids. 90 min delay. 15g Mixed Essential Amino Acid REFEED
3100188|NCT01890369|Experimental|Mid latency EAA refeed|15g Mixed Essential Amino Acids. 150 min delay. 15g Mixed Essential Amino Acid REFEED
3100189|NCT01890369|Experimental|Late latency EAA refeed|15g Mixed Essential Amino Acids. 210 min delay. 15g Mixed Essential Amino Acid REFEED
3100190|NCT01890356|Experimental|Transcranial electrical stimulation|
3100191|NCT01890343|Experimental|Frontotemporal Disorder|Subjects with frontotemporal disorder (FTD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F and a one-time IV bolus injection of 185 MBq of 18F-FDG.
3100231|NCT01890083|Active Comparator|Health Education|Participants will three attend heath education sessions per week for 26 weeks.
3100192|NCT01890343|Experimental|Cognitively Normal|Cognitively normal (CN) subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
3100193|NCT01890343|Experimental|Alzheimer's Disease|Subjects with Alzheimer's disease (AD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
3100194|NCT01890330|Experimental|Canola Oil 25 g/d|Participants randomized to this arm will be provided with food items including entrées, side dishes, salad dressing, baked goods, and desserts prepared with traditional canola oil to incorporate into their usual eating pattern. They will consume one or two food items per day containing a total of 25 g/d of Canola oil.
3100195|NCT01890330|Active Comparator|Non-Canola Oil Mixture 25 g/d|Participants randomized to this arm will be provided with food items including entrées, side dishes, salad dressing, baked goods, and desserts prepared with an oil mixture representing the typical Western diet to incorporate into their usual eating pattern. They will consume one or two food items per day containing a total of 25 g/d of the non-canola oil mixture.
3100196|NCT01890317|Experimental|Mild hypothermia|Induction of mild hypothermia for 24 hr with invasive cooling in addition to primary percutaneous coronary intervention and optimal medical therapy
3100197|NCT01890317|No Intervention|Control|Percutaneous coronary intervention and optimal medical therapy according to current guidelines
3100198|NCT01890304|Other|Magnetic Resonance Imaging (MRI)|Athletes at risk for mild traumatic brain injury during the course of competitive play or practice. An MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
3100199|NCT01890291||Non-treatment Group|Patients who were in non-treatment group in phase 3 clinical trial IIC-I01(NCT00699816).
3100200|NCT01890291||Immuncell-LC Group|Patients who were in Immuncell-LC group in phase 3 clinical trial IIC-I01(NCT00699816).
3100201|NCT01890278|Active Comparator|Whole Brain IMRT|Whole brain radiation therapy delivered via IMRT (37.5 Gy to brain tumor, 30 Gy to the uninvolved brain in 15 fractions), mean dose of less than 18 Gy to scalp.
3100202|NCT01890278|Active Comparator|Conventional whole brain RT|Conventional whole brain radiation therapy (37.5 Gy to the brain tumors and uninvolved brain in 15 fractions).
3100203|NCT01890265|Experimental|Study Drug (FG-3019)|"Study Drug, FG-3019, 30 mg/kg; 10 mg/ml, single dose vials, by intravenous infusion every 3 weeks for a total of 16 infusions over 45 weeks~For the substudy, the dose will be the same but for a total of 8 infusions over 21 weeks"
3100204|NCT01890265|Placebo Comparator|Placebo|"Sterile, clear aqueous solution, 10 mg/ml, single dose vials, by intravenous infusion every 3 weeks for a total of 16 infusions over 45 weeks~For the substudy, the dose will be the same but for a total of 8 infusions over 21 weeks"
3100205|NCT01890252|Experimental|Hyper CL|Hyper osmotic contact lens
3100206|NCT01890252|Experimental|Hyper CL + Saline solution|combined treatment of hyper osmotic contact lens+ hypertonic solution
3100207|NCT01890252|Active Comparator|saline solution|hypertonic solution
3100208|NCT01890239|Experimental|Care Programme for the Last Days of Life|The Care Programme for the Last Days of Life will be implemented in the acute geriatric hospital wards randomized to the experimental group. Subsequently, older patients hospitalized in one of these experimental wards and for who the multidisciplinary team has decided that he or she has entered the dying phase, will benefit from this Care Programme.
3100209|NCT01890239|No Intervention|Usual care|Care will be provided as usual, also for patients who have entered the dying phase.
3100210|NCT01890226|No Intervention|Control|
3100211|NCT01890226|Experimental|Experimental: Intervention|Participants randomized to the intervention arm will receive the mobile personal health record.
3100212|NCT01890213|Experimental|Vaccine|AVX701 Vaccine:4 x 10EE8 IU intramuscularly every 3 weeks for 4 total immunizations
3100213|NCT01890200|Experimental|TCM-700C (low dose)|an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
3100214|NCT01890200|Experimental|TCM-700C (high dose)|an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
3100215|NCT01890200|Placebo Comparator|Placebo|placebo add on(t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
3100216|NCT01890187||Advanced dry AMD with geographic atrophy|Patients diagnosed with advanced dry AMD with geographic atrophy
3100217|NCT01890174||AMD with macular drusen|Patients diagnosed with dry AMD with macular drusen
3100218|NCT01890161|Experimental|AXP1275|AXP1275 50 mg (2 × 25-mg capsules) once daily for 14 days
3100219|NCT01890161|Placebo Comparator|AXP1275 matching placebo|AXP1275 matching placebo (2 capsules) once daily for 14 days
3100220|NCT01890148|Experimental|1|oral BD administration of 45 mg AZD5069
3100221|NCT01890135|Active Comparator|endothelin receptor antogonist|10 mg of zibotentan
3100222|NCT01890135|Placebo Comparator|placebo|matched placebo
3100223|NCT01890122|Active Comparator|Metformin HCl 500 mg|Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.
3100224|NCT01890122|Active Comparator|Alogliptin 12.5 mg|Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.
3100225|NCT01890122|Experimental|Alogliptin 12.5 mg + Metformin HCl 500 mg FDC|Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
3100226|NCT01890122|Placebo Comparator|Placebo|Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
3100227|NCT01890109|Placebo Comparator|Placebo|Participants received a single dose of placebo administered by subcutaneous injection.
3100228|NCT01890109|Experimental|Erenumab|Participants received a single dose of 70 mg erenumab administered by subcutaneous injection.
3100229|NCT01890096|Experimental|HDR 2 fractions|HDR brachytherapy of 27 Gy delivered in 2 fractions one week apart
3100230|NCT01890096|Experimental|HDR 1 fraction|HDR brachytherapy of 19 Gy delivered in a single fraction
3100937|NCT01885767||NF2|Patients meeting clinical and/or genetic criteria for Neurofibromatosis 2
3100232|NCT01890083|Experimental|Exercise|Participants will engage in a public health dose of moderate-to-vigorous aerobic exercise for 26 weeks.
3100233|NCT01890070|Placebo Comparator|STANDARD DIET|"each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fiber)~Three weeks of washout to avoid additive effects on treatments to follow."
3100234|NCT01890070|Experimental|STANDARD DIET WITH HAZELNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification~Three weeks of washout to avoid additive effects on treatments to follow."
3100235|NCT01890070|Experimental|STANDARD DIET WITH RED WINE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day :~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 200 ml of Italian organic Red Wine.~Three weeks of washout to avoid additive effects on treatments to follow."
3100236|NCT01890070|Experimental|STANDARD DIET WITH CHESTNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100 g of Italian organic chestnuts.~Three weeks of washout to avoid additive effects on treatments to follow."
3100237|NCT01890070|Experimental|STANDARD DIET WITH CHOCOLATE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day :~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
3100238|NCT01890070|Experimental|STANDARD DIET WITH WILD MIXED GREEN|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
3100239|NCT01890070|Experimental|STANDARD DIET WITH OLIVE OIL|"Intervention type: each patient is administered a food plan for four weeks. Every patient patient is required to consume per day :~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100g of Italian organic Olive Oil~Three weeks of washout to avoid additive effects on treatments to follow."
3100240|NCT01890070|Placebo Comparator|HIGH FAT DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%)~Three weeks of washout to avoid additive effects on treatments to follow."
3100241|NCT01890070|Experimental|HIGH FAT WITH HAZELNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 40g of Italian hazelnuts from Piedmont with Protected Geographical Indication Certification.~Three weeks of washout to avoid additive effects on treatments to follow."
3100242|NCT01890070|Experimental|HIGH FAT WITH RED WINE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%)with 200 ml of Italian organic Red Wine~Three weeks of washout to avoid additive effects on treatments to follow."
3100243|NCT01890070|Experimental|HIGH FAT WITH CHESTNUT|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 g of Italian organic chestnuts.~Three weeks of washout to avoid additive effects on treatments to follow."
3100244|NCT01890070|Experimental|HIGH FAT WITH CHOCOLATE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
3100245|NCT01890070|Experimental|HIGH FAT WITH WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
3100246|NCT01890070|Experimental|HIGH FAT WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 of Italian organic Olive oil~Three weeks of washout to avoid additive effects on treatment following."
3100247|NCT01890070|Placebo Comparator|LOW CARBOHYDRATE DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%)~Three weeks of washout to avoid additive effects on treatments to follow."
3100248|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH HAZELNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification~Three weeks of washout to avoid additive effects on treatments to follow."
3100249|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH RED WINE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 200 ml of Italian organic Red Wine~Three weeks of washout to avoid additive effects on treatments to follow."
3100250|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH CHESTNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 g of Italian organic chestnuts~Three weeks of washout to avoid additive effects on treatments to follow."
3100251|NCT01890070|Experimental|LOW CARBOHYDRATE DIET CHOCOLATE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
3100252|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
3100253|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 of Italian organic Olive Oil~Three weeks of washout to avoid additive effects on treatments to follow."
3100254|NCT01890070|Placebo Comparator|HIGH PROTEIN DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%)~Three weeks of washout to avoid additive effects on treatments to follow."
3100255|NCT01890070|Experimental|HIGH PROTEIN DIET WITH HAZELNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification"
3100256|NCT01890070|Experimental|HIGH PROTEIN DIET WITH RED WINE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 200 ml of Italian organic Red Wine~Three weeks of washout to avoid additive effects on treatments to follow."
3100257|NCT01890070|Experimental|HIGH PROTEIN DIET WITH CHESTNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 g of Italian organic chestnuts~Three weeks of washout to avoid additive effects on treatments to follow."
3100258|NCT01890070|Experimental|HIGH PROTEIN DIET WITH CHOCOLATE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
3100259|NCT01890070|Experimental|HIGH PROTEIN DIET WITH ITALIAN ORGANIC WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
3100260|NCT01890070|Experimental|HIGH PROTEIN DIET WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 of Italian organic Olive Oil~This is followed by a 3 week wash out period, to neutralize any additive effects."
3100261|NCT01890057|Experimental|Young adults|To find out the the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block : Dixon's up-and-down method
3100262|NCT01890057|Experimental|Elderly adults|To find out the the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block : Dixon's up-and-down method
3100263|NCT01890044||Moderate to highest risk for VTE|Patients admitted to the hospital for care of traumatic injuries who have from a moderate to highest level of VTE risk. These risk levels are assessed within the first 24 hours following hospital admission as mandated by the Surgical Quality Improvement Project (SCIP) Guidelines. Individual risk level will be assessed and determined according to each individual reporting institution's risk assessment protocol. This will be a prospective registry of trauma patients without any study based interventions.
3100264|NCT01890031|No Intervention|Low Risk, No ICAT|Low risk, not randomized to use the Interactive Cholesterol Advisory Tool, no study physician visits
3100265|NCT01890031|Other|Low risk, ICAT|Low risk, randomized to use the Interactive Cholesterol Advisory Tool, no study physician visits
3100266|NCT01890031|Other|Low risk, ICAT, and study physician|Low risk, assigned to use the Interactive Cholesterol Advisory Tool, and study physician visits.
3100267|NCT01890031|Other|Moderate risk, no ICAT|Moderate risk, study physician visits, and not randomized to use the Interactive Cholesterol Advisory Tool
3100268|NCT01890031|Other|Moderate risk, ICAT|Moderate risk, study physician visits, and randomized to use the Interactive Cholesterol Advisory Tool
3100269|NCT01890018|Active Comparator|Control|"This arm will use GlowCaps to have their adherence tracked with no additional modifications:~Arm 1. Control group no modifications~Electronic Pill Bottle tracking"
3100270|NCT01890018|Experimental|Feedback group|"This arm will use GlowCaps to have their adherence tracked with the following modifications:~Arm 2. Feedback group participants will receive an adherence message after 48 hours of not using the GlowCaps~Electronic Pill Bottle tracking; Adherence Messaging"
3100271|NCT01890018|Experimental|Adherence partner group|"This arm will use GlowCaps to have their adherence tracked with the following modifications:~Arm 3. Adherence partner group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient~Electronic Pill Bottle tracking; Social Influence"
3100272|NCT01890018|Experimental|Adherence partner along with feedback|"This arm will use GlowCaps to have their adherence tracked with the following modifications:~Arm 4. Adherence partner along with feedback group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient, both the patient and partner will receive a message after 48 hours of not using the GlowCaps~Electronic Pill Bottle tracking; Adherence Messaging; Social Influence"
3100273|NCT01890005|Experimental|Aspirin|Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
3100274|NCT01890005|Placebo Comparator|Placebo|Placebo (identical to low dose aspirin (100 mg)) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
3100336|NCT01889628|Other|Chinese ethnicity|Three nutritional formulae (Isocal, Protinex and Diasip) and liquid glucose
3100275|NCT01889992|Active Comparator|Cardiac biopsy C4D stain|A procedure that removes a very small sample of your heart muscle so that it can be evaluated in the lab. This procedure may be done to determine the cause of cardiac myopathy (a weakened heart muscle) or to check for rejection after a heart transplant.
3100276|NCT01889992|Experimental|Genetic Mechanism of M-TOR|"To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.~Sirolimus dosage is based on blood levels."
3100277|NCT01889992|Active Comparator|Cardiac MRI|Cardiac Magnetic Resonance Imaging (MRI) produces no side effects from the magnetic fields and radio waves and doesn't carry a risk of cancer or birth defects. Serious reactions to the special contrast dyes used for MRI are very rare. The MRI examination poses almost no risk to the average patient when appropriate safety guidelines are followed, however side effects are possible and include headache, nausea, dizziness, change in taste and allergic reaction. Such reactions usually are mild and easily controlled by medication.
3100278|NCT01889992|Active Comparator|Coronary Angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
3100279|NCT01889992|Active Comparator|Cardiopulmonary Exercise Test (CPET)|Is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
3100280|NCT01889992|Experimental|MTor Immunosuppression|"Sirolimus~Sirolimus dosage is based on blood levels.~To assess the potential of mTOR immunosuppressant Sirolimus in attenuation of CAR in HTx recipients and therefore, improve pre-existing cardiac allograft function, vasculopathy, and exercise capacity."
3100281|NCT01889992|Experimental|Cardiac Allograft Remodeling|A surgical procedure in wich a diseased heart is replaced with a healthy heart from a deceased person.
3100282|NCT01889979|Experimental|Tramadol|100 mg of tramadol SC (single dose) = 2 mL
3100283|NCT01889979|Placebo Comparator|Placebo|2 mL of a sterile solution SC
3100284|NCT01889966|Experimental|Sildenafil|oral Sildenafil 20 mg three times a day for 90 days
3100285|NCT01889953|Other|EUS-guided biliary drainage|Patients in this arm will receive EUS-guided biliary drainage.
3100286|NCT01889940|No Intervention|Pre-intervention group.|"The initial assessment includes pre-intervention measures (baseline) for the patient, his/her relative (or main caregiver) and the rehabilitation staff.~Patients are assessed during the first week (or ≥ 10 days of SCI Unit admission) and at discharge (an expected average of 8 weeks). At the time of each patient's discharge, their family or main caregiver is also surveyed.~Lastly, rehabilitation team members are also assessed across the pre-intervention phase."
3100287|NCT01889940|Other|Post-intervention group.|Once intervention and coaching period for professionals has ended, post-intervention sample (patients, family and professionals) is assessed with the same time criteria than the pre-intervention sample.
3100288|NCT01889927|No Intervention|Group 1: Control|Control Group (Arm 1): Children randomised to the control group will receive 24-months of current model of specialist CF care.
3100289|NCT01889927|Active Comparator|Group 2: Exercise Intervention|Intervention group (Arm 2): Children randomised to the intervention group will receive 24-months of current model of specialist CF care PLUS a weekly structured, individually prescribed and personally supervised exercise intervention at a local fitness facility or at school.
3100290|NCT01889914|Experimental|continuous infusion of insulin by pump|"in this arm called continuous infusion of insulin with a pump the patient receive continuous rapid insulin (APIDRA ®)with an external pump.~An hepatic IRM and a botnia test will be practice before and six months after the beginning of this treatment(continuous insulin)"
3100291|NCT01889914|Experimental|discontinuous insulin multiple injections|"An arm called  intensification of the multiple daily injections : the patient will receive an additional injection of basal insulin LEVEMIR® : five injections per day (2 injections of Levemir® and 3 injections of Apidra®) instead of four previously (1 injection of Levemir® and 3 injections of Apidra®).~An hepatic IRM and a botnia test will be practice before and six months after the beginning of the treatment"
3100292|NCT01889901|No Intervention|Control Group|The control group will receive instruction to maintain their physical activity. The intention is to study the existing levels of physical activity through step count via the Fitbit pedometer. The control group will receive information about epilepsy (attention placebo)and will be able to upload step counts wirelessly to the Fitbit website. Participants will not receive a password to access the website to follow their accumulating data during the intervention period (first 6 months). At the start of the 6-month monitoring period (second 6 months), the control group will be provided with a password to access the pedometer web page that allows them to create and view a visual map of their progress giving them a clear picture of how they are doing and where they are headed.
3100293|NCT01889901|Experimental|Intervention Group|Enhanced walking program supported by behavioral modification counselling. (0-6 months)
3100294|NCT01889888|Experimental|ADRC injection|
3100295|NCT01889875|No Intervention|Control group|
3100296|NCT01889875|Active Comparator|Subcutaneous Immunotherapy (SCIT)|"Treatment using ALK AluTard 225 Phleum pratense"
3100297|NCT01889875|Active Comparator|Sublingual Allergen Immunotherapy Tablets (AIT)|"Treatment using ALK Grazax 75,000 SQ-T Phleum pratense"
3100298|NCT01889862|Active Comparator|BMN165 20mg/day|BMN165 20mg/day self-administered daily
3100299|NCT01889862|Placebo Comparator|Low Placebo|Low Placebo self-administered daily
3100300|NCT01889862|Active Comparator|BMN165 40mg/day|BMN165 40mg/day self-administered daily
3100301|NCT01889862|Placebo Comparator|High Placebo|High Placebo self-administered daily
3100337|NCT01889628|Other|Malay ethnicity|Three liquid nutritional formulae (Isocal, Diasip and Protinex) and liquid glucose
3100338|NCT01889628|Other|Indian Ethnicity|Three liquid nutritional formulae (Isocal, Diasip and Protinex) and liquid glucose
3100339|NCT01889615||Suspected ovarian cancer|dual time PET/CT
3100302|NCT01889849|Experimental|BIP48|Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks. Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number. The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
3100303|NCT01889849|Active Comparator|Pegasys|Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks. Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number. The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
3100304|NCT01889836|Experimental|MenCC-Bio|The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.
3100305|NCT01889836|Active Comparator|MENJUGATE®|The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE®.
3100306|NCT01889823|Experimental|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
3100307|NCT01889823|Experimental|Hyperoxia|Subjects will be breathing 100% of oxygen
3100308|NCT01889810|Active Comparator|Vitamin D3 supplementation|Patients will take 3000IU (75 µg) Vitamin D3 supplementation per day for a period of 26 weeks.
3100309|NCT01889810|Placebo Comparator|Placebo|Placebo group
3100310|NCT01889797|Active Comparator|Arm A: Rituximab|Rituximab 375 mg/m² IV weekly for 4 weeks.
3100311|NCT01889797|Experimental|Arm B: GA101|GA101 1,000 mg IV weekly for 4 weeks.
3100312|NCT01889784|Other|Individuals with diabetes mellitus (phototherapy 150J)|The intervention of this study is phototherapy through light emitting diode (LED) and dose of 150J each muscle. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscles bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
3100313|NCT01889784|Other|Health individuals - 150J (phototherapy 150J)|The intervention of this study is phototherapy through light emitting diode (LED) and dose of 150J each muscle. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscle bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
3100314|NCT01889784|Other|Individuals with diabetes mellitus (phototherapy 300J)|The intervention of this study is phototherapy through light emitting diode (LED) with 300J. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surale muscles bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
3100315|NCT01889784|Other|Health individuals (phototherapy 300J)|The intervention of this study is phototherapy through light emitting diode (LED). The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscle bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
3100316|NCT01889771|Experimental|Nicotine Patch (4 weeks)|participants receive one 4-weeks supply of nicotine patches
3100317|NCT01889771|Experimental|Nicotine Patch (8 weeks)|participants receive up to 8 weeks of nicotine patches in up to two 4-week supplies
3100318|NCT01889758|Active Comparator|Sequence 1|Tacrolimus Hi for 1 week with full PK on Day 7, then tacrolimus Lo for 1 week with full PK on Day 14, then Prograf for 1 week with full PK on Day 21, then tacrolimus Hi with full PK on Day 28, then Prograf for 1 week with full PK on Day 35, and then tacrolimus Lo for 1 week with full PK on Day 42
3100319|NCT01889758|Active Comparator|Sequence 2|Tacrolimus Lo for 1 week with full PK on Day 7, then Prograf for 1 week with full PK on Day 14, then tacrolimus Hi for 1 week with full PK on Day 21, then tacrolimus Lo with full PK on Day 28, then tacrolimus Hi for 1 week with full PK on Day 35, and then Prograf for 1 week with full PK on Day 42
3100320|NCT01889758|Active Comparator|Sequence 3|Prograf for 1 week with full PK on Day 7, then tacrolimus Hi for 1 week with full PK on Day 14, then tacrolimus Lo for 1 week with full PK on Day 21, then Prograf with full PK on Day 28, then tacrolimus Lo for 1 week with full PK on Day 35, and then tacrolimus Hi for 1 week with full PK on Day 42
3100321|NCT01889732||ROTEM|
3100322|NCT01889719|Experimental|Vaccination with MVA-CMDR Group 1|Six to 27 subjects who previously received vaccination with DEC-205, will receive vaccination with MVA-CMDR
3100323|NCT01889719|Active Comparator|Vaccination with MVA-CMDR Group 2|Six to 27 subjects who previously did not receive vaccination with DEC-205, will receive vaccination with MVA-CMDR
3100324|NCT01889693||acute coronary syndrome|patients with acute myocardial infarction and unstable angina
3100325|NCT01889693||chronic stable angina|patients with chronic stable angina
3100326|NCT01889693||control|control subjects without coronary artery disease
3100327|NCT01889680|Active Comparator|Arm 1: 5-FU + LV|Patients receive mFOLFOX6 plus ziv-aflibercept every 14 days for 6 cycles (induction regimen), followed by 5-FU/LV every 14 days until disease progression (continuation regimen)
3100328|NCT01889680|Experimental|Arm 2: 5-FU + LV + ziv-aflibercept|Patients receive mFOLFOX6 plus ziv-aflibercept every 14 days for 6 cycles (induction regimen), followed by 5-FU/LV plus ziv-aflibercept every 14 days until disease progression (continuation regimen)
3100329|NCT01889667|Experimental|ORMD-0801 Dose # 1|Oral Insulin Formulation
3100330|NCT01889667|Experimental|ORMD-0801 Dose # 2|Oral Insulin Formulation
3100331|NCT01889667|Placebo Comparator|Placebo|Oil Capsules
3100332|NCT01889654||patient|
3100333|NCT01889654||healthy volunteers|
3100334|NCT01889641||Patients with lupus|Patients with lupus (four levels of activity disease)
3100335|NCT01889641||healthy volunteers|Subjects controls
3100340|NCT01889602|Experimental|Topiramate|Topiramate; 100mg, 150 mg or 200 mg, po,1x
3100344|NCT01889576|Experimental|Supplementation of Magnesium oxide.|Supplementation of magnesium oxide (450 mg up to 3 times daily maximum), aiming at a serum magnesium concentration of >= 1,9 mg/dL).
3100345|NCT01889576|No Intervention|No supplementation or minimal dose.|No supplementation (or a minimal dose to keep serum magnesium concentration ≥ 1.2mg/dL depending on the treating physician).
3100346|NCT01889563|Experimental|Physical exercise training program|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
3100347|NCT01889563|No Intervention|No Physical Exercise Training Program|No Physical Exercise Training Program
3100348|NCT01889550|Active Comparator|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
3100349|NCT01889550|Placebo Comparator|Access to the website www.ouh.dk|Access to the usual information from the hospital website
3100350|NCT01889537|Experimental|VR during burn care with Ketamine|Comparing Virtual Reality during burn care with Ketamine
3100351|NCT01889537|Experimental|VR durin burn care without Ketamine|Comparing virtual reality during burn care without Ketamine.
3100352|NCT01889524|Active Comparator|NIV plus jet|Noninvasive ventilation-NIV plus jet nebulizer
3100353|NCT01889524|Experimental|NIV plus Mesh|Noninvasive ventilation- NIV plus Mesh nebulizer
3100354|NCT01889511|Experimental|Intervention group - texts|The intervention group will receive text messages for 21 days that are tailored to their oral agent regimen.
3100355|NCT01889511|No Intervention|Control group|The control group will receive usual care, which consists of standard care and materials provided by the oncology office or pharmacy. In general, this includes instructions and information on the oral agent regimen (i.e., amount and timing), common side effects, how to manage symptoms, general ways to remember to take your pill (e.g., calendar or pill box), medication safety (i.e., storage), and how to contact a clinician for problems that arise.
3100356|NCT01889498|No Intervention|control group with no acetazolamide|Treatment as usual without acetazolamide treatment
3100357|NCT01889498|Active Comparator|Acetazolamide|Treatment arm
3100358|NCT01889472|Active Comparator|oro-nasal mask|Oro-nasal mask during 1 month of auto CPAP
3100359|NCT01889472|Experimental|Nasal mask and oral appliance|Nasal mask and oral appliance during 1 month of auto CPAP
3100360|NCT01889459||PCI for CTO|
3100361|NCT01889446|Placebo Comparator|Calcium propionate|Addition of calcium propionate (PA arm) in a capsule (1000 mg) consumed together with a mixed meal of 500 kCal in the morning following an overnight fast. Blood is taken at baseline and every 30 minutes for 4 hours. This arm is compared to a placebo capsule (following identical protocol). Following a washout period of a week, the arms will be crossed over and the PA arm participants will repeat the same protocol in the 'placebo arm'.
3100362|NCT01889446|Placebo Comparator|Placebo|Addition of placebo (PA arm) in a capsule consumed together with a mixed meal of 500 kCal in the morning following an overnight fast. Blood is taken at baseline and every 30 minutes for 4 hours. This arm is compared to the PA arm (PA, 1000 mg in a capsule). Following a washout period of a week, the arms will be crossed over and the PA arm participants will repeat the same protocol in the 'placebo arm', and vice versa.
3100363|NCT01889433|Experimental|Algeron|Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg).
3100364|NCT01889433|Active Comparator|Pegasys|Pegasys in a dose of 180 µg subcutaneously, once a week, in combination with Rebetol, orally, at a daily dose of 800 mg for patients with genotype 2 or 3, and for genotypes 1 or 4 at a daily dose of 1000 mg (for body weight <75 kg) or 1200 mg (for body weight ≥75 kg)
3100365|NCT01889420|Experimental|Combination therapy|Pomalidomide: 1 tablet orally, daily for 21 days of a 28 day cycle (dose per cohort) Everolimus: 1 tablet orally for 21 days of a 28 day cycle (dose as per cohort) Dexamethasone 40 mg (20 mg >75yrs) orally, days 1, 8,15, 22 of a 28 day cycle
3100366|NCT01889407||IA regimen|IA regimen: Patients receive idarubicin (8mg/m2.d) iv drip on days 1-3 and cytarabine (100-200mg/ m2.d) iv drip on days 1-7.
3100367|NCT01889407||DA regimen|Patients receive daunomycin (45mg/ m2.d) iv drip on days 1-3 and cytarabine (100－200mg/ m2.d) iv drip on days 1-7.
3100368|NCT01889394|Active Comparator|limberg flap|primary wound closure using a limberg flap
3100369|NCT01889394|Active Comparator|secondary wound healing|secondary wound healing
3100370|NCT01889381|Experimental|Treatment (Transplantation)|Face transplantation in combination with a novel donor bone marrow cell-based therapy followed by single-drug immunosuppression with potential weaning.
3100371|NCT01889368|Active Comparator|Grape Seed Extract|This is a 30 day arm. At the baseline study visit, subjects will consume one 300 mg capsule of MegaNatural Gold followed by 3 high fat meals: breakfast, lunch, and dinner. Blood will be drawn at specified intervals throughout the day. Flow mediated dialysis will be performed before breakfast and again 1.5 hours later, after capsule consumption and breakfast. A minimum 14 day washout period will be between arms if this is the first arm in the randomized cross-over.
3100372|NCT01889368|Placebo Comparator|Placebo|This is a 30 day arm. At the baseline study visit, subjects will consume one placebo (maltodextrin) capsule followed by 3 high fat meals: breakfast, lunch, and dinner. Blood will be drawn at specified intervals throughout the day. Flow mediated dialysis will be performed before breakfast and again 1.5 hours later, after capsule consumption and breakfast. A minimum 14 day washout period will be between arms if this is the first arm in the randomized cross-over.
3100373|NCT01889355|Other|Enhanced meter feature usability|Home diabetes monitoring by patient using provided blood glucose monitoring system.
3100374|NCT01889342|Experimental|Metacognitive therapy|The treatment is based on the generic manual by Wells (2009).
3100375|NCT01889342|Active Comparator|Cognitive behavorial therapy|CBT includes the diagnose specific manuals for panic disorder (Clark, 1986), Social Phobia (Clark & Wells, 1995) and PTSD (Foa, 2007).
3100379|NCT01889316|Other|AN24 in addition to new device (Novii)|"FDA-cleared device (The AN24 device) used in conjunction with the new device (Novii).~Both devices will be placed on the patient's abdomen. Hence the patient acts as their own control."
3100380|NCT01889303|Active Comparator|Arm A|"chemotherapy regimen:Oxaliplatin 85mg/m2 IV d1,Leucovorin 400mg/m2 IV d1,5-FU 400mg/m2 IV bolus d1 ,then 2400mg/m2 over 46h continuous infusion Q2W for 3 cycles → 5-FU 400 mg/m2 IV and Leucovorin 20 mg/m2 IV on the first four and the last three days of radiotherapy + RT 45Gy (5weeks)→ Rest for 4 weeks →Oxaliplatin 85mg/m2 IV d1,Leucovorin 400mg/m2 IV d1,5-FU 400mg/m2 IV bolus d1 ,then 2400mg/m2 over 46h continuous infusion Q2W for 3 cycles.~Radiation: concurrent chemoradiotherapy with 5-FU/CF.Radiotherapy consisted of 45Gy of radiation at 1.8Gy per day, five days per week for five weeks."
3100381|NCT01889303|Experimental|Arm B|"chemotherapy regimen:Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W x 2 cycles → Docetaxel 35mg iv D1,Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy (5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W x 2 cycles~Radiation: concurrent chemoradiotherapy with DC.Radiotherapy consisted of 45Gy of radiation at 1.8Gy per day, five days per week for five weeks."
3100382|NCT01889290|Experimental|Methylnaltrexone|Pharmacokinetics of methylnaltrexone administered once daily
3100383|NCT01889277|Experimental|MT-3995-Low|MT-3995-Low Dose
3100384|NCT01889277|Experimental|MT-3995-High|MT-3995-High Dose
3100385|NCT01889277|Placebo Comparator|Placebo|Placebo
3100386|NCT01889264||Critically Ill Pediatric Patients|Critically ill septic pediatric patients, Age 1 month-3 years, Age 4-12 years and Age 13-19 years, males and females
3100387|NCT01889251|Experimental|Ocriplasmin|Ocriplasmin administered as a single intravitreal injection to the study eye at baseline
3100388|NCT01889251|Sham Comparator|Sham injection|Single sham injection to the study eye at baseline
3100389|NCT01889238|Experimental|Enzalutamide|160 mg administered as four 40 mg soft gelatin capsules orally once daily
3100390|NCT01889225||Multiple Risk Factor Intervention Trial - Usual Group|
3100391|NCT01889225||Multiple Risk Factor Intervention Trial - Referred Group|
3100392|NCT01889225||Framingham Heart study|
3100393|NCT01889225||Framingham Offspring cohort|
3100394|NCT01889225||Atherosclerosis Risk In Communities|
3100395|NCT01889225||Charleston Heart study|
3100396|NCT01889225||Cardiovascular Health study|
3100397|NCT01889225||Rancho Bernardo study|
3100398|NCT01889225||Nurses' Health I study|
3100399|NCT01889225||Panel Study Income Dynamics|
3100400|NCT01889225||MRFIT Referred Care|
3100401|NCT01889225||HDFP Referral Care|
3100402|NCT01889225||Alameda County Health and Ways of Living Study|
3100403|NCT01889225||Nurses' Health II study|
3100404|NCT01889225||Tecumseh County Health study|
3100405|NCT01889225||EPESE-East Boston|Established Populations for Epidemiologic Studies of the Elderly-East Boston
3100406|NCT01889225||EPESE-Duke|Established Populations for Epidemiologic Studies of the Elderly-Duke
3100407|NCT01889225||EPESE-Iowa|Established Populations for Epidemiologic Studies of the Elderly-Iowa
3100408|NCT01889225||EPESE-New Haven|Established Populations for Epidemiologic Studies of the Elderly-New Haven
3100409|NCT01889212|Experimental|NSCLC, erlotinib treatment, 11C-erlotinib PET/CT|
3100410|NCT01889199|Placebo Comparator|Sugar pill|Placebo intervention
3100411|NCT01889199|Experimental|Flutamide|Flutamide 125 mg orally daily for six 28-day cycles.
3100412|NCT01889186|Experimental|Single arm|Single arm
3100413|NCT01889173|Experimental|TNX-102 SL Tablets at 2.8 mg|1 x TNX-102 SL Tablets (with potassium phosphate) at 2.8 mg
3100414|NCT01889173|Experimental|TNX-102-B SL Tablets at 2.8 mg|1 x TNX-102-B SL Tablets (with sodium phosphate) at 2.8 mg
3100415|NCT01889173|Experimental|TNX-102-C SL Tablets at 2.8 mg|1 x TNX-102-C SL Tablets (with trisodium citrate) at 2.8 mg
3100416|NCT01889173|Active Comparator|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine oral tablet
3100417|NCT01889160|Experimental|Part A Active|AZD4721 Solution
3100418|NCT01889160|Placebo Comparator|Part A Placebo|Placebo for AZD4721
3100419|NCT01889160|Experimental|Part B solution|AZD4721 Solution
3100420|NCT01889160|Active Comparator|Part B Suspension|AZD4721 Suspension
3100421|NCT01889147|Active Comparator|14C-hRESCAP|Peak plasma concentration response of a dose hRESCAP will be examined and compared with the saline condition
3100422|NCT01889147|Placebo Comparator|saline|Peak plasma concentration response of different dosages of hRESCAP will be examined and controlled with the saline condition
3100423|NCT01889147|Active Comparator|Microdose|Peak plasma concentration of a very low dose of hRESCAP as a first test in humans (first starting dose, before the other arms).
3100424|NCT01889134|Experimental|Alendronate|Sedron (alendronate) 70 mg taken orally once a week for 12 months
3100425|NCT01889134|Active Comparator|Parathyroidectomy|Selective parathyroidectomy
3100426|NCT01889134|No Intervention|Control group|No intervention
3100427|NCT01889121||Methadone maintenance program|Mothers on methadone treatment at time of delivery who delivered at Good Samaritan Hospital but were not enrolled in psychosocial intervention offered through the HOPE (Helping Opiate-addicted Pregnant women Evolve) program.
3100428|NCT01889121||Psychosocial intervention|Pregnant women who were in methadone maintenance program PLUS structured psychosocial intervention at the time of delivery (HOPE Program).
3100429|NCT01889108|No Intervention|Control|Usual care
3100430|NCT01889108|Experimental|Intervention group|Intervention with SPEEDI
3100431|NCT01889095|Experimental|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
3100432|NCT01889095|Active Comparator|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
3100433|NCT01889082|Active Comparator|Face to Face Behavioral Weight Loss|12-week treatment program consisting of weekly, in-person group meetings and brief, bi-weekly individual check-ins
3100434|NCT01889082|Active Comparator|Web Based Behavioral Weight Loss|12-week treatment program consisting of an initial in-person group session (weight loss 101 and intro to website), followed by weekly web-based program and e-coaching
3100435|NCT01889082|Active Comparator|Web Based Behavioral Weight Loss Plus Optional Group Sessions|12-week treatment program consisting of an initial in-person group session (weight loss 101 and intro to website), followed by weekly web-based program and e-coaching. Participants in this arm will also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training). *New material / content is not provided in these optional sessions, rather they are meant to serve as a place to practice applying the core content from the lessons.
3100436|NCT01889069|Experimental|Rituximab|Participants will receive at least 4 doses of rituximab 1400 mg SC once a month during the Induction period, and at least 6 doses of rituximab 1400 mg SC once every two months during the Maintenance period, in addition to standard chemotherapy. Standard chemotherapy regimen included cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP); or cyclophosphamide, vincristine and prednisone (CVP); or bendamustine as per standard local practice.
3100437|NCT01889056|Experimental|Erythropoietin (Epoetin beta)|Short infusion of 60.000 IU Epoetin beta in 0.9% sodium chloride solution (250 ml)
3100438|NCT01889056|Placebo Comparator|0.9% sodium chloride solution|Short infusion of 0.9% sodium chloride solution (250 ml)
3100439|NCT01889030||Target population|This observational, cross-sectional, national multicenter designed study will describe the frequency of use of different evaluation methods (risk scores or subjective assessment) employed to determine the cardiovascular risk of patients in a primary care setting, at both General Practitioners (GPs) or Cardiologists offices.
3100440|NCT01889004|Experimental|Dexmedetomidine|Intravenous dexmedetomidine using target controlled infusion
3100441|NCT01889004|Experimental|Propofol|Intravenous propofol using target controlled infusion
3100442|NCT01888991|No Intervention|water with resting condition|
3100443|NCT01888991|Experimental|glucose with resting condition|
3100444|NCT01888991|Experimental|water with exercise condition|
3100445|NCT01888991|Experimental|glucose with exercise condition|
3100446|NCT01888978|Experimental|Modified FOLFOX-6|Oxaliplatin 85 mg/m2 day 1 and 5-fluorouracil 400 mg/m2 day 1 and Leucovorin 400 mg/m2 day 1 and 5-fluorouracil 2400 mg/m2 over 46 hours on day 1-3 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
3100447|NCT01888978|Experimental|Ox-Tax|Docetaxel 65 mg/m2 and Oxaliplatin 100 mg/m2 on day 1 every 3 weeks All drugs will be administered until disease progression or unacceptable toxicity are observed
3100448|NCT01888978|Experimental|FOLFIRI|Irinotecan 180 mg/m2 on day 1 and 5-FU 400 mg/m2 on day 1 and Leucovorin 400 mg/m2 day 1 and 5-FU 2400 mg/m2 over 46 hours, days 1-3 as a continuous infusion All drugs will be administered until disease progression or unacceptable toxicity are observed
3100449|NCT01888978|Experimental|Tax-Iri|2 weeks on, 1 week off of Docetaxel 35 mg/m2/week and Irinotecan 50 mg/m2/week Both administered on day 1 of each week of treatment All drugs will be administered until disease progression or unacceptable toxicity are observed
3100450|NCT01888978|Experimental|Gem-Ox|Gemcitabine: 1000 mg/m2 over 100 minutes on Day 1 Oxaliplatin: 100 mg/m2 over 120 minutes on Day 2 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
3100451|NCT01888978|Experimental|Gem-5FU|Gemcitabine: 1000 mg/m2 over 30 minutes 5-FU 2000/m6 as a 24 hour infusion on days 1, 8, and 15 of every 28 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
3100452|NCT01888978|Experimental|Gem-Tax|Gemcitabine 1000 mg/m2 over 30 minutes and Docetaxel 35 mg/m2 over 60 minutes on days 1, 8, and 15 of every 28 day cycle
3100453|NCT01888965|Experimental|Dovitinib|Dovitinib 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years
3100454|NCT01888952|Experimental|Roflumilast and Prednisone|"Roflumilast 500 mcg will be administered orally daily for 21 consecutive days (a 21-day cycle).~In Cycle 1, prednisone 60 mg/m2 up to a maximum of 100 mg oral (PO) daily will be taken on Days 8 through 14 at the same time as roflumilast.~In Cycle 2 and subsequent cycles, prednisone 60 mg/m2 PO up to a maximum of 100 mg daily will be taken on Days 1 through 7 at the same time as roflumilast."
3100455|NCT01888900|Experimental|Hepatitis C Virus Genotype 1A with QUAD|Subjects will be started on combination therapy with asunaprevir, daclatasvir, peginterferon alfa-2a and ribavirin for 24 weeks.
3100456|NCT01888900|Experimental|Hepatitis C Virus Genotype 1B with DUAL|Subjects will receive combination therapy with asunaprevir and daclatasvir alone for 24 weeks and undergo paired liver biopsies, pre-treatment and either at 2 or 4 weeks after starting therapy.
3100457|NCT01888887|Experimental|Cetaphil Daily Facial Cleanser|All subjects receive Cetaphil Daily Facial Cleanser
3100458|NCT01888874|Experimental|GLPG0634 25mg BID|1 capsule of 25 mg GLPG0634 and 1 placebo capsule both in the morning and in the evening
3100459|NCT01888874|Experimental|GLPG0634 50mg QD|1 capsule of 50 mg GLPG0634 and 1 placebo capsule in the morning and 2 placebo capsules in the evening
3100460|NCT01888874|Experimental|GLPG0634 50mg BID|1 capsule of 50 mg GLPG0634 and 1 placebo capsule both in the morning and in the evening
3100461|NCT01888874|Experimental|GLPG0634 100mg QD|1 capsule of 100 mg GLPG0634 and 1 placebo capsule in the morning and 2 placebo capsules in the evening
3100462|NCT01888874|Experimental|GLPG0634 100mg BID|1 capsule of 100 mg GLPG0634 and 1 placebo capsule both in the morning and in the evening
3100463|NCT01888874|Experimental|GLPG0634 200mg QD|2 capsules of 100 mg GLPG0634 in the morning and 2 placebo capsules in the evening
3100464|NCT01888874|Placebo Comparator|Placebo|2 placebo capsules both in the morning and in the evening
3100465|NCT01888861|Experimental|alpha-lipoic acid|the patients in this arm were received 900mg alpha-lipoic acid for 10 days through nasogastric(NG) tube.
3100466|NCT01888861|Placebo Comparator|placebo|the patients in this arm were received 900mg placebo through NG tube.
3100467|NCT01888848|Experimental|blueberry|Participants randomized into this arm of the study consume freeze-dried blueberry.
3100468|NCT01888848|Placebo Comparator|placebo|Participants randomized into this arm of the study consume a blueberry placebo.
3100469|NCT01888835|Active Comparator|Mirtazapine|mirtazapine 30 mg orally per day
3100470|NCT01888835|Placebo Comparator|Placebo|placebo (30 mg) orally per day
3100471|NCT01888822|Placebo Comparator|Placebo|Intravenous infusion of 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
3100472|NCT01888822|Active Comparator|Ampicillin-sulbactam|Intravenous infusion of 3gr ampicillin-sulbactam in 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
3100473|NCT01888822|Active Comparator|Ciprofloxacin|Intravenous infusion of 400 mg ciprofloxacin in 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
3100474|NCT01888809|Experimental|Comprehensive preventive services|Combined comprehensive services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
3100475|NCT01888809|Active Comparator|Screening and referral|Annual screening and referral for services as needed
3100476|NCT01888796|Active Comparator|Linagliptin|Linagliptin 5 mg (tablets) once daily for 6 month
3100477|NCT01888796|Placebo Comparator|Placebo|Placebo (tablets) once daily for 6 month
3100478|NCT01888783|Experimental|CRPS Type I|Patients diagnosed with complex regional pain syndrome type I of the upper limb
3100479|NCT01888783|Active Comparator|Median Nerve Neuropathy|Patients diagnosed with a neuropathy of the median nerve of the upper limb.
3100480|NCT01888783|Active Comparator|Healthy Controls|Healthy adult persons.
3100481|NCT01888770||Normotensive Term|Infants born at term (>37 weeks) to Normotensive pregnancies
3100482|NCT01888770||Term Preeclampsia|Infants born at term (>37 weeks gestation) and exposed to a preeclamptic pregnancy
3100483|NCT01888770||Preterm Normotensive|Infants born to Normotensive pregnancies at <37 weeks gestation
3100484|NCT01888770||Preterm Hypertensive|Infants born to hypertensive pregnancies at <37 weeks completed gestation
3100485|NCT01888770||Term Pregnancy-induced Hypertension|Infants born at term (>37 weeks gestation) and exposed to pregnancy-induced hypertension
3100486|NCT01888757|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
3100487|NCT01888757|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 50 mg of GlaxoSmithKline Research Triangle Park, NC
3100488|NCT01888744|Active Comparator|Group 1 (GnRH agonist group)|The long GnRH agonist protocol starts on day 21 of the preceding cycle with the administration of GnRH agonist, Decapeptyl® 0,1 mg subcutaneously daily or buserelin acetate, Suprefact® 600 μg daily intranasal. The administration of highly purified human menopausal gonadotropin (hp-HMG), Menopur® 225 IU subcutaneously is started after three weeks of desensitization. The desensitization is checked by ultrasound (absence of cysts) and hormonal measurement (Estradiol levels < 80 pg/ml, FSH ≤ 10 IU/l and progesterone < 1,5ng/ml)
3100489|NCT01888744|Active Comparator|Group 2 (GnRH antagonist group)|Ovarian stimulation is started at day 2 of the menstrual cycle with 225 IU of HMG (Menopur ®) subcutaneously. At day 6 of the stimulation GnRH antagonist (Orgalutran®) 0,25 mg subcutaneously is added. Basal hormonal status will be confirmed in the antagonist group before starting.
3100490|NCT01888731|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
3100491|NCT01888731|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 50 mg of GlaxoSmithKline Research Triangle Park, NC
3100492|NCT01888718|Experimental|Fexofenadine Hydrochloride Orally Disintegrating|Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg of Dr.Reddy's Laboratories Ltd
3100493|NCT01888718|Active Comparator|ALLEGRA|ALLEGRA orally disintegrating tablets 30 mg of Sanofi Aventis
3100494|NCT01888705||Control group|Group of nonsmokers individuals without respiratory disease.
3100495|NCT01888705||NE|Smokers wiht normal spirometry.
3100496|NCT01888705||LV|Patients with COPD level I, mild.
3100497|NCT01888705||MOD|Patients with COPD level II, moderate.
3100498|NCT01888705||GV|Patients with COPD level III, severe.
3100499|NCT01888705||MGV|Patients with COPD level IV, very severe.
3100500|NCT01888679|Experimental|head movement|head movement in extension, flexion, right and left rotation
3100501|NCT01888666||rapid palatal expansion (RPE) using the Haas appliance|
3100502|NCT01888666||slow palatal expansion (SPE)|
3100503|NCT01888653|Placebo Comparator|Comparison-Training-Program|Placebo-training program: The placebo condition is identical to the ABMT protocol except that during the presentation of the trials where a threat face is presented, the probe will appear with equal frequency in the position of the threat and neutral faces. Thus, neither threat nor neutral faces provide information regarding the position of the target probe, and there is no contingency between the position of either threat or neutral words, and the position of the probes.
3100504|NCT01888640|Placebo Comparator|Placebo TENS|This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
3100505|NCT01888640|No Intervention|Standard Care|Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.
3100506|NCT01888640|Active Comparator|Active TENS|Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
3100507|NCT01888627|Experimental|Integrated care|The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
3100508|NCT01888614||Sickle Cell Patients|Patients with Sickle Cell, over 18 years of age
3100509|NCT01888601||NSCLC eligible for primary surgery|NSCLC eligible for primary surgery
3100510|NCT01888588||Cases|Patients with symptomatic peptic ulcer (UPU)
3100511|NCT01888588||Control group|Control group without symptomatic peptic ulcer (UPU).
3100512|NCT01888575||Aspirin discontinuers; Aspirin non-discontinuers|Patients on low dose ASA for secondary prevention that discontinue aspirin and those not discontinuing aspirin
3100513|NCT01888575||Drug|PPI continuous use; No PPI use
3100514|NCT01888562|Experimental|Ponatinib|Ponatinib 45mg po daily for 4 weeks (4 weeks equal 1 cycle).
3100515|NCT01888549|Experimental|arm1-High dose PPI|
3100516|NCT01888549|Active Comparator|arm2-standard dose PPI|
3100517|NCT01888549|Placebo Comparator|arm3-placebo|Esomeprazole placebo
3100518|NCT01888536|Experimental|Limaprost & Placebo|Limaprost 5㎍ tablet and a capsule of Pegabalin-Placebo thrice a day for 8 weeks.
3100519|NCT01888536|Active Comparator|Pregabalin & Placebo|Pregabalin 75mg capsule and a tablet of Limaprost-Placebo thrice a day for 8 weeks.
3100520|NCT01888536|Active Comparator|Limaprost+Pregabalin|Limaprost 5㎍ tablet and Pregabalin 75mg capsule thrice a day for 8 weeks.
3100521|NCT01888523|Experimental|Everyday experiences writing|Involves logging in to an online survey and writing in the survey about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
3100522|NCT01888523|Experimental|Expressive writing|Involves logging in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
3100523|NCT01888510|Experimental|Diagnostic (imaging studies)|Patients undergo conventional free breathing CT, 4D CT, ABC CT, ABC CBCT, and free breathing CBCT before undergoing radiation therapy.
3100524|NCT01888497|Experimental|Arm A|
3100525|NCT01888497|Experimental|Arm B|
3100526|NCT01888497|Active Comparator|Arm C|
3100527|NCT01888497|Placebo Comparator|Arm D|
3100528|NCT01888484|Experimental|Octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
3100529|NCT01888471|Other|Cases Group|"Cases Group will be defined as:~Maternal subjects identified with invasive GBS disease from the enrolled maternal-newborn dyad Study cohort: Cases will be classified as follows:~EOD (Early onset disease): isolation of GBS from the blood or cerebrospinal fluid (CSF) within 0-6 days of birth.~LOD (Late onset disease): isolation of GBS from the blood or cerebrospinal fluid (CSF) within 7-90 days of birth."
3100530|NCT01888471|Other|Controls Group|Controls will be defined as newborns to mothers, enrolled into the study and identified as colonized by a serotype which is homologous to that of cases, but who do not develop invasive GBS disease.
3100531|NCT01888458|Experimental|Micafungine|
3100532|NCT01888445|Experimental|ASP1517 Low dose group|
3100533|NCT01888445|Experimental|ASP1517 Middle dose group|
3100534|NCT01888445|Experimental|ASP1517 High dose group|
3100535|NCT01888445|Active Comparator|Darbepoetin group|
3100536|NCT01888432|Experimental|Everolimus + reduced tacrolimus|Everolimus + reduced tacrolimus ± corticosteroids
3100537|NCT01888432|Active Comparator|Standard tacrolimus|Standard tacrolimus ± corticosteroids
3100538|NCT01888419|No Intervention|No active treatment|Clinical follow-up, no active intervention.
3100539|NCT01888419|Experimental|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site.
3100540|NCT01888406|Experimental|Guided Self-Help|Participants receive self-help materials, including a book (Overcoming Binge Eating by C. Fairburn, handouts, and online resources. In addition, participants receive 8 individual sessions with a peer coach who supports participants in working the self-help program.
3100541|NCT01888406|Other|Pure Self-Help|Participants receive self-help materials, including a book (Overcoming Binge Eating by C. Fairburn, handouts, and online resources.
3100542|NCT01888393|Experimental|Group A|Approximately 12 subjects (male and female) with moderate hepatic impairment
3100543|NCT01888393|Experimental|Group B|Approximately 12 healthy subjects (male and female)
3100544|NCT01888380|Experimental|Foetuses|"still birth and termination of pregnancies~intervention: minimally invasive, virtual autopsy"
3100545|NCT01888380|Experimental|Newborns|"who died of natural- and non-natural cause~intervention: minimally invasive, virtual autopsy"
3100546|NCT01888380|Experimental|Children and adolescents|"who died of natural- and non-natural cause~intervention: minimally invasive, virtual autopsy"
3100547|NCT01888367|Experimental|DFA-02 Antibiotic Gel|Up to 20 mL of DFA-02 antibiotic gel will be placed in the surgical incision after closure of the fascia and before skin closure.
3100548|NCT01888367|Placebo Comparator|DFA-02 Placebo Gel|Up to 20 mL of DFA-02 placebo gel will be placed in the surgical incision after closure of the fascia and before skin closure.
3100549|NCT01888367|No Intervention|Standard of Care|Prior to final closure of the surgical incision, the incision will be irrigated with normal saline and no gel will be applied.
3100550|NCT01888354|Experimental|Acthar Gel 80 IU x 14 days|Acthar Gel 80 IU SQ x 14 days
3100551|NCT01888354|Experimental|Acthar Gel 80 IU x 5 days|Acthar Gel 80 IU SQ x 5 days
3100552|NCT01888341|Experimental|Isotretinoin capsules, 20 mg|Isotretinoin Capsules, 20 mg of Dr.Reddy's Laboratories Ltd
3100553|NCT01888341|Active Comparator|ACCUTANE|ACCUTANE 20 mg of Roche Laboratories Inc
3100554|NCT01888328|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
3100555|NCT01888328|Active Comparator|ACCUTANE|ACCUTANE 40 mg of Roche Laboratories Inc
3100556|NCT01888315|Experimental|Catheter-based renal denervation|"One procedure will be performed using one of the CE-marked devices for renal denervation:~Device: Renal denervation with Symplicity Flex Medtronic/Ardian Device: Renal denervation with EnligHTN St. Jude Medical Device: Renal denervation with Paradise Recor Device: Renal denervation with V2 Vessix"
3100557|NCT01888315|No Intervention|Medical therapy|Best medical therapy using guideline recommended drugs in each disease state.
3100558|NCT01888302|Experimental|Treatment (cisplatin, gemcitabine hydrochloride, sirolimus)|Patients receive cisplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and sirolimus PO daily or three times weekly. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3100559|NCT01888289|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
3100560|NCT01888289|Active Comparator|ACCUTANE|ACCUTANE 40 mg of Roche Laboratories Inc
3100561|NCT01888276|Other|healthy volunteers|evaluation of word generation and of motivation
3100562|NCT01888276|Other|compulsive gamblers|evaluation of word generation and of motivation
3100563|NCT01888263|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
3100564|NCT01888263|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC
3100565|NCT01888250|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
3100566|NCT01888250|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC
3100567|NCT01888237|Active Comparator|Sequential therapy (ST)|10 day Sequential therapy: lansoprazole 30 mg b.d. plus amoxicillin 1000 mg b.d. for 5 days then lansoprazole 30 mg b.d., metronidazole 400 mg b.d. and clarithromycin 500 mg b.d. for the remaining 5 days
3100568|NCT01888237|Experimental|High dose PPI triple therapy(TT)|10 day high dose PPI triple therapy: lansoprazole 60 mg b.d. plus clarithromycin 500 mg b.d. and amoxycillin 1000 mg b.d. for 10 days
3100569|NCT01888224|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
3100570|NCT01888224|Active Comparator|AMNESTEEM|AMNESTEEM 40 mg of Mylan Pharmaceuticals Inc
3100571|NCT01888211|Experimental|Omega 3 fatty acid supplementation|Omacor 2 grams daily
3100572|NCT01888211|Placebo Comparator|Olive Oil|Olive Oil capsule 2 grams daily
3100573|NCT01888198||renal mass ablation candidates|Standard of care interventions for the treatment of renal masses using energy ablation will be studied. Data collection can be divided into five basic categories: 1) Patient demographics and relevant history, 2) Renal mass characteristics, 3) Ablation procedure details, 4) Imaging studies, and 5) Patient-reported quality of life.
3100574|NCT01888185||Parkinson's Disease (PD)|Patients with a clinical diagnosis of PD (in various stages)
3100575|NCT01888185||Progressive supranuclear palsy (PSP)|Patients with a clinical diagnosis of PSP (in various stages)
3100576|NCT01888185||Multiple system atrophy (MSA)|Patients with a clinical diagnosis of MSA (in various stages)
3100577|NCT01888185||Controls|Age and gender-matched adults free from neurological disease
3100578|NCT01888172|Experimental|Weight Watchers Online|
3100579|NCT01888172|Experimental|Weight Watchers Online + ActiveLink|
3100580|NCT01888172|Active Comparator|Internet Delivered Eating and Activity Program|
3100581|NCT01888159|Active Comparator|Tubal Sterilization with bipolar|Salpingectomy vs Tubal Sterilisation
3100582|NCT01888159|Active Comparator|Bilateral Salpingectomy|Salpingectomy vs Tubal Sterilisation
3100583|NCT01888146|Experimental|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
3100584|NCT01888146|No Intervention|Treatment as usual|Patients in this arm will receive care as usual and utilize services as they currently exist in the health plan system.
3100585|NCT01888133|Experimental|Group Walk First|Participants attend a weekly walking group session from weeks 1-6 and are not required to attend from weeks 7-12.
3100586|NCT01888133|Experimental|Individual Walk First|Participants are not required to attend a weekly group walking sessions from weeks 1-6 and attend a weekly walking group session from weeks 7-12.
3100587|NCT01888120||Severe Chronic Pain|
3100588|NCT01888107|Experimental|Risperidone Long-acting Injectable (LAI)|Risperidone LAI will be administered in dosages of 25, 37.5, and 50 mg.
3100589|NCT01888094|Experimental|ultrasound guided for cannulation and examination|Prospective, randomized controlled clinical unicentric study, in ICU, Cannulation of the subclavian venous and examination guided with ultrasound
3100590|NCT01888094|Other|landmark method and examination with chest radiography|Prospective, randomized controlled clinical unicentric study, in ICU, Cannulation of the subclavian venous and examination guided with ultrasound
3100591|NCT01888081|Experimental|A-dmDT390-bisFv(UCHT1) with Ionizing Radiation|A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation
3100592|NCT01888068||No treatment|
3100593|NCT01888055|Experimental|transcranial direct current stimulation|
3100594|NCT01888055|Placebo Comparator|sham stimulation|
3100595|NCT01888042|Experimental|Everolimus|Everolimus will be administered per os every day at the same hour immediately after a meal with a glass of water 10 mg (1 tablet of 10 mg)
3100596|NCT01888029|Experimental|transcranial direct current stimulation|
3100597|NCT01888029|Placebo Comparator|sham stimulation|
3100598|NCT01888016|Experimental|fascial manipulation|
3100599|NCT01888016|Active Comparator|standard treatment|
3100600|NCT01888003|Active Comparator|Anemia Treatment Group (AMG)|Group of patients who are diagnosed preoperatively as being anemic (defined as a Hgb < 13.0 g/dL and MCV < 100 fL, with a hematocrit between 30% and 39%, for males and females), who will receive an ESA (PROCRIT) and iron (Venofer) preoperatively.
3100601|NCT01888003|Other|Conventional Treatment Group (CTG)|Group of patients who are diagnosed preoperatively as being anemic (defined as a Hgb < 13.0 g/dL and MCV < 100 fL, with a hematocrit between 30% and 39%, for males and females), who will receive our current, conventional perioperative standard of care, which does not involve any preoperative anemia management (other than laboratory testing). CTG patients will undergo routine perioperative laboratory testing/screening.
3100602|NCT01888003|Other|Non Anemia Group (NAG)|Group of patients who are not anemic preoperatively, who will receive our current, conventional perioperative standard of care.
3100603|NCT01887990|Active Comparator|Suicidal, Depression with Ketamine|suicidal ideation and depression (no substance use disorder) 0.2 mg/kg IV ketamine administered as a one time dose
3100604|NCT01887990|Placebo Comparator|Suicidal, Depression with Saline|Suicidal ideation and depression (no substance use disorder) comparable amount of placebo (saline)
3100605|NCT01887990|Active Comparator|Suicidal, opioid use with ketamine|suicidal ideation,depression, opioid use disorder 0.2 mg/kg IV ketamine one time dose
3100606|NCT01887990|Placebo Comparator|Suicidal, opioid use with Saline|Patients with suicidal ideation and depression with opioid use disorder who are given comparable amount of placebo (saline) as would have been used with the Ketamine arm
3100607|NCT01887977|Experimental|Computational modeling|
3100608|NCT01887964|Other|Community-1|Received control flour first and then Resistant starch type 4 (RS4) flour
3100609|NCT01887964|Other|Community-2|Received RS4 flour first and then control flour
3100610|NCT01887951|Active Comparator|Tramadol|Tramadol HCL. Dosage form: Injection Strength: 50mg/ampoule Frequency: 1 time
3100905|NCT01886027|No Intervention|Wait-list control|Standard medical care until the 3-month follow-up is completed
3100611|NCT01887951|Experimental|Penthrox|Dosage form: Inhalation; Strength: 3ml/bottle; Frequency: Up to 6ml per day. Total weekly dose should not exceed 15ml.
3100612|NCT01887938|Experimental|Cohort 1 (10 mg)|HGT-1110 (Recombinant human arylsulfatase A ), 10 mg EOW by IT injection
3100613|NCT01887938|Experimental|Cohort 2 (30 mg)|HGT-1110 (Recombinant human arylsulfatase A ), 30 mg EOW by IT injection
3100614|NCT01887938|Experimental|Cohort 3 (100 mg)|HGT-1110 (Recombinant human arylsulfatase A ), 100 mg EOW by IT injection
3100615|NCT01887938|Experimental|Cohort 4 (100mg)|HGT-1110 (Recombinant human arylsulfatase A ), 100 mg EOW by IT injection
3100616|NCT01887925||breast cancer|breast cancer patients receiving chemotherapy
3100617|NCT01887912|Experimental|C. difficile Vaccine Group|Participants will receive 1 injection of the C. difficile toxoid vaccine at Days 0, 7, and 30, respectively.
3100618|NCT01887912|Placebo Comparator|Placebo Vaccine Group|Participants will receive 1 injection of placebo (0.9% normal saline) at Days 0, 7, and 30, respectively.
3100619|NCT01887899|Experimental|transcranial direct current stimulation|
3100620|NCT01887899|Placebo Comparator|sham stimulation|
3100621|NCT01887886|Experimental|Onartuzumab + Erlotinib|
3100622|NCT01887886|Active Comparator|Placebo + Erlotinib|
3100623|NCT01887873|Other|Hyaluronan Thiomer i.o. implantable device|active treatment
3100624|NCT01887860|Experimental|Cetaphil Daily Facial Moisturizer SPF50|All subjects receive Cetaphil Daily Facial Moisturizer SPF 50
3100625|NCT01887847|Experimental|sublingual nicotine tablet|investigational 2 mg sublingual nicotine tablet
3100626|NCT01887847|Active Comparator|COMMIT nicotine lozenge|COMMIT 2 mg nicotine lozenge
3100627|NCT01887834|Placebo Comparator|Kyodophilus matching placebo capsules|"Kyodophilus Matching Placebo Capsules~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
3100628|NCT01887834|Active Comparator|Kyodophilus multi strain probiotic capsules|"Kyodophilus multi-strain probiotic capsules~The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:~Lactobacillus gasseri KS-13 1.2~Bifidobacterium bifidum G9-1 0.15~Bifidobacterium longum MM-2 0.15~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
3100629|NCT01887821|Active Comparator|Chloroquine|25mg base/kg for 3 days
3100630|NCT01887821|Active Comparator|Dihydroartemisinin/Piperaquine|Dihydroartemisinin 40 mg + piperaquine phosphate 320 mg per tablet; once daily for three days, doses depend on weight
3100631|NCT01887808|Experimental|Cetaphil DermaControl Oil Control Moisturizer SPF 30|All subjects receive Cetaphil DermaControl Oil Control Moisturizer SPF 30
3100632|NCT01887795|Experimental|1. WBRT alone|Selected 224 patients with multiple brain metastases from NSCLC, they will be randomized to WBRT or Erotinib concurrent WBRT. It was enough to compare the efficacy of Erotinib concurrent WBRT vs. WBRT
3100633|NCT01887795|Experimental|2. Erlotinib concurrent WBRT|Selected 224 patients with multiple brain metastases from NSCLC, they will be randomized to WBRT or Erotinib concurrent WBRT. It was enough to compare the efficacy of Erotinib concurrent WBRT vs. WBRT
3100634|NCT01887782|Experimental|HFL rTMS|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4 weeks
3100635|NCT01887782|Active Comparator|iTBS|intermittent Theta Burst Stimulation (iTBS) five days per week for 4 weeks
3100636|NCT01887769||Lung cancer patient at diagnosis|
3100637|NCT01887756|Experimental|Single arm study|The clients will receive tele-rehabilitation treatment via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback is given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software generates a report which includes the duration and type of exercises performed by the subject.
3100638|NCT01887743|Experimental|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
3100639|NCT01887730|Active Comparator|arm 2|Hand washing with soap and water according to instructions. The effect of intervention is assessed by following occurrence of infections.
3100640|NCT01887730|Placebo Comparator|arm 0|No specific advice on hand hygiene. The effect of intervention is assessed by following occurrence of infections.
3100641|NCT01887730|Active Comparator|Arm 3|Hand cleaning with alcohol-containing hand rub
3100642|NCT01887717|Active Comparator|Standard of care treatment|All patients in the Control group will receive SOC treatment with sorafenib in accordance with the package insert.
3100643|NCT01887717|Experimental|TheraSphere|Patients will receive treatment with yttrium-90 microspheres in accordance with the package insert.
3100644|NCT01887704|Experimental|Rotablator|"Rotablator plus conventional angioplasty and/or stenting was performed in 120 patients in the R group.~Rotablator using 140, -160, 000 rpm, small rota burr (burr-to-artery ratio, 0.6:1), avoid drop of >5000 rpm for 5s.~Conventional intervention will be performed in the rotablator group. All subjects were given 100 mg/day aspirin and clopidogrel (300 mg loading dose and 75 mg/day maintenance dosage) at least 24 h before the procedure. A cutting balloon, buddy wire balloon, buddy wire, or DES (including sirolimus-eluting stent, paclitaxel-eluting stent, everolimus-eluting stent,zotarolimus-eluting stent) was implemented at the discretion of the operator in both groups."
3100676|NCT01887470|Experimental|Full dose preparation; PM colonoscopy|Four hourly doses of lactulose for oral solution are taken in the evening. The colonoscopy is initiated after noon on the following day.
3100906|NCT01886014|Experimental|oxytocin|application of intranasal oxytocin 40IE
3100645|NCT01887704|Active Comparator|Conventional|"Conventional angioplasty and/or stenting was performed in 120 patients in the C group.~Conventional intervention without rotablator was performed in the C group. All subjects were given 100 mg/day aspirin and clopidogrel (300 mg loading dose and 75 mg/day maintenance dosage) at least 24 h before the procedure. A cutting balloon, buddy wire balloon, buddy wire, or DES (including sirolimus-eluting stent, paclitaxel-eluting stent, everolimus-eluting stent,zotarolimus-eluting stent) was implemented at the discretion of the operator in both groups."
3100646|NCT01887691|Experimental|eszopiclone|We will evaluate the impact of pharmacologic enhancement of effective sleep with nightly eszopiclone (taken before bedtime for 1 week, home environment) on glycemic profiles (continuous glucose monitoring, 72 hrs) in prediabetics and diabetics compared to pretreatment baseline. The dose of eszopiclone will be the lowest tolerated dose (1-3 mg) via dose escalation and side effect profile assessment.
3100647|NCT01887678|Experimental|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one intra articular (IA) injection) on treatment days 1, 8 and 15.
3100648|NCT01887678|Placebo Comparator|Placebo injectable solution|Injection volume of placebo is 4.2 mL as well (taken from the 10.0 mL vial by unblinded staff member, rest to be kept for drug accountability)
3100649|NCT01887665|Experimental|Incentives|Prize-based financial incentives, informed by contingency management principles, are offered to patients who attend treatment visits.
3100650|NCT01887652|Active Comparator|conventional ovarian stimulation|women whose protocol of ovarian stimulation was based on age, ovarian size and previous treatment
3100651|NCT01887652|Active Comparator|individualized ovarian stimulation|women whose protocol of ovarian stimulation was based on anti-mullerian hormone
3100652|NCT01887639||Unipolar major depression|Outpatients Individuals between 18 and 75 years old with a current episode of non-psychotic unipolar major depression that are treated with an antidepressant drug according to physician´s current and usual practice.
3100653|NCT01887626|Experimental|A|Ticagrelor 90 mg as a whole tablet
3100654|NCT01887626|Experimental|B|Ticagrelor 90 mg tablet crushed and suspended in water
3100655|NCT01887626|Experimental|C|Dispersed ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the the stomach
3100656|NCT01887613||Regnite group|Patients who receive Regnite
3100657|NCT01887600|Experimental|Roxadustat|Study drug will be dosed three times weekly (TIW) during correction period and three times weekly (TIW) during the maintenance period. Dose adjustments will be made during the study
3100658|NCT01887600|Placebo Comparator|Placebo|Placebo will be dosed three times weekly (TIW) during correction period and three times weekly (TIW) during the maintenance period. Dose adjustments will be made during the study
3100659|NCT01887587|Experimental|(modified VXLD) plus MLN9708|"Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22~Dexamethasone- 10 mg/m2 orally or IV on days 1-14~Doxorubicin- 60 mg/m2 on day 1 by IV bolus.~For patients without CNS involvement:~Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)~Methotrexate 12 mg will be administered intrathecally on day 8 (+/-1 day)~For patients with CNS involvement:~-Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day))."
3100660|NCT01887574|Experimental|Open|
3100661|NCT01887561|No Intervention|treatment|
3100662|NCT01887548|Experimental|Active CD|Patients whose CDAI score >150 points would be enrolled in this group.
3100663|NCT01887548|Active Comparator|Quiescent CD|Patients whose CDAI score ≤150 points would be enrolled in this group.
3100664|NCT01887535|Experimental|Cohort 1: JNJ-54861911 3 mg|Participants will be administered single doses of JNJ-54861911 on Days 1 to 14. Initially the doses will be once per day, but the frequency of daily dosing (eg, once-daily, twice-daily, three times daily) may change prior to or during study conduct depending on the pharmacokinetic data from the ongoing single-ascending dose study (54861911ALZ1001) or ongoing cohorts in this current study. Actual dose levels as well as the magnitude of dose escalation will depend on the results of the ongoing single-ascending dose study, the observed safety and tolerability profile as well as the observed exposures.
3100665|NCT01887535|Experimental|Cohort 2: JNJ-54861911 10 mg|
3100666|NCT01887535|Experimental|Cohort 3: JNJ-54861911 30 mg|
3100667|NCT01887535|Experimental|Cohort 4: JNJ-54861911 80 mg|
3100668|NCT01887535|Experimental|Cohort 5: JNJ-54861911 25 mg|
3100669|NCT01887535|Placebo Comparator|Cohorts 1-4: Placebo|Participants in Cohorts 1-4 will receive matching placebo.
3100670|NCT01887522|Experimental|VINILO|"VINILO-arm: Vinblastine and nilotinib given in combination at the RD defined in the Phase I part:~Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28 Recommended doses of the drug combination will be reconsidered at an interim stage of the phase II trial after the analysis of the delayed toxicity encountered in the first 20 patients treated at the initial RD (adaptive design)."
3100671|NCT01887522|Active Comparator|Control Vinblastine only|"Control Vinblastine only arm:~· Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~Each 28-day cycle is repeated on Day 29/Day 1.~In both treatment groups, dose reductions and/or administration delays will be performed in case of severe hematological and/or non hematological toxicities while on treatment.~Vinblastine will be temporarily stopped in case of neutropenia <1 x109/L or thrombopenia <75 x 109/L. It could be re-started at a reduced dose after complete recovery.~Patients benefiting from study treatment may continue up to 12 cycles as long as the toxicity-benefit ratio is adequate."
3100672|NCT01887496||Chickenpox complications|Cases were identified by International Classification of Disease of the Tenth Revision (ICD-10) diagnostic codes for chickenpox infection or chickenpox-associated complications, if available.
3100673|NCT01887483|Active Comparator|Vetal Laban active|Vetal Laban with L. acidophilus
3100674|NCT01887483|Placebo Comparator|Placebo|Vetal Laban -like product without L. acidophilus
3100675|NCT01887470|Experimental|Full dose preparation; AM colonoscopy|Four hourly doses of lactulose for oral solution are taken in the evening. The colonoscopy is initiated prior to noon on the following day.
3100677|NCT01887470|Experimental|Split dose preparation; AM colonoscopy|Three hourly doses of lactulose for oral solution are taken in the evening prior to the day of the colonoscopy procedure; one dose is taken on the morning of the procedure. The colonoscopy is initiated prior to noon.
3100678|NCT01887470|Experimental|Split dose preparation; PM colonoscopy|Three hourly doses of lactulose for oral solution are taken in the evening prior to the day of the colonoscopy procedure; one dose is taken on the morning of the procedure. The colonoscopy is initiated after noon.
3100679|NCT01887457|Experimental|Voriconazole|Standard adult Voriconazole (VFEND) Loading (1 hr infusion): 6mg/kg at 1 hour and 12 hours on day 1. Followed by standard maintenance dose 4mg/kg at 1 hour and 12 hours on day 2 (1 hour infusion). Day 3 follows the same schedule, expect the dose is adjusted, this dose is used on Day 4 and a further dose adjustment is made that is administered as above on Day 5.
3100680|NCT01887444|Experimental|Lactobacillus reteuri|Dietary Supplement: Lactobacillus reuteri DSM17938 probiotic 2 x 10(8) CFU/day 21 days
3100681|NCT01887444|Placebo Comparator|Placebo|Other: Placebo
3100682|NCT01887431|Experimental|Telecare|Each patient will transmit glucometer and pump data electronically via a web site to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control.
3100683|NCT01887431|Active Comparator|Conventional therapy|3-month routine clinic visits
3100684|NCT01887418|Experimental|QuickShot™ - 100 mg Treatment A|QuickShot™Testosterone - Auto-injector device for SC use
3100685|NCT01887418|Experimental|QuickShot™ - 50 mg Treatment B|QuickShot™Testosterone- Auto-injector device for SC use
3100686|NCT01887418|Active Comparator|Delatestryl 200 mg IM Treatment C|Commercially available Testosterone enanthate 200 mg IM dosage - 'standard of care' arm for reference
3100687|NCT01887405|Active Comparator|Adrenaline: Session 1 Jext, 2 Epipen|Subjects will be randomised 1:1 to use Jext in session 1 and EpiPen in session 2.
3100688|NCT01887405|Active Comparator|Adrenaline: Session 1 Epipen, 2 Jext|Subjects will be randomised 1:1 to use EpiPen in session 1 and Jext in session 2.
3100689|NCT01887392|Experimental|Wave A|LTC Homes randomized into Wave A will receive the intervention first. The intervention includes Knowledge Translation Education Sessions.
3100690|NCT01887392|Experimental|Wave B|LTC Homes randomized into Wave B will receive the intervention after Wave A. The intervention includes Knowledge Translation Education Sessions.
3100691|NCT01887379|Experimental|GRDF furosemide fasting conditions|Subjects will be tested under fasting conditions after administration of GRDF Furosemide.
3100692|NCT01887379|Experimental|GRDF furosemide fed conditions|Subjects will be tested under fed conditions after administration of GRDF Furosemide.
3100693|NCT01887366|Experimental|TV-1380 150 mg|
3100694|NCT01887366|Experimental|TV-1380 300 mg|
3100695|NCT01887366|Placebo Comparator|Placebo|
3100696|NCT01887353|Active Comparator|Ranolazine|
3100697|NCT01887353|Placebo Comparator|Placebo|
3100698|NCT01887340|Experimental|Cohort 1|"PET-TDM~carboplatine: Dose (mg) = AUC x (GFR + 25)~GFR : glomérulaire filtration (ml/min)~AUC : area under curve (mg/ml x min)"
3100699|NCT01887340|Experimental|Cohort 2|"PET-TDM~ETOPOSIDE (100 mg/m2 D1 to D5) and CISPLATINE (20 mg/m2 de D1 to D5)~carboplatine: Dose (mg) = AUC x (GFR + 25)~GFR : glomérulaire filtration (ml/min)~AUC : area under curve (mg/ml x min)"
3100700|NCT01887327|Placebo Comparator|Placebo|Placebo
3100701|NCT01887327|Experimental|3.0 mg/kg stannsoporfin|3.0 mg/kg stannsoporfin
3100702|NCT01887327|Experimental|4.5mg/kg stannsoporfin|4.5mg/kg stannsoporfin
3100703|NCT01887314|Experimental|Standardized Ginger extract soft gel capsules|Patients receive 2 soft gel capsules of Ginger extract, twice a day
3100704|NCT01887314|Placebo Comparator|Placebo soft gel capsules|Patients receive 2 soft gel capsules of Placebo, twice a day
3100705|NCT01887301|Active Comparator|Group 1: mild hepatic impairment|Mild hepatic impairment: eight patients of Child-Pugh Grade A (Score 5-6). All patients received Sativex treatment.
3100706|NCT01887301|Active Comparator|Group 2: Moderate hepatic impairment|Moderate hepatic impairment: eight patients of Child-Pugh Grade B (Score 7-9). All patients received Sativex treatment.
3100707|NCT01887301|Experimental|Group 3: Pugh Grade B (Score 7-9).|Severe hepatic impairment: eight patients of Child-Pugh Grade C (Score 10-15). All patients received Sativex treatment.
3100708|NCT01887301|Active Comparator|Group 4: Control group|Control Group: eight healthy subjects matched with respect to age (±10 years), weight (±10% body mass index [BMI]) and sex to the severe or most severe evaluable patients. All patients received Sativex treatment.
3100709|NCT01887288|Experimental|Capecitabine with Digoxin|"Capecitabine PO daily b.i.d., no breaks, starts at day 1 of the first cycle; Digoxin: once daily, starts at day -7 of the first cycle~(1 cycle - 4 weeks)"
3100710|NCT01887275|Experimental|medical ozone therapy with humares|
3100711|NCT01887275|Active Comparator|conventional interferon-α|
3100712|NCT01887262|Experimental|Intervention|Incident peritoneal dialysis (PD) patients who are randomly allocated to BCM-guided fluid management will receive BCM measurement every two months over 1-year period. The BCM results will be notified to the physicians and the participating subjects. Based on the BCM results along with the clinical information such as blood pressure, edema and weight, the physicians will prescribe PD fluid and diuretics, targeting within 1L of overhydration status. They will prescribe dietary education to the patient, if necessary.
3100713|NCT01887262|Active Comparator|Control|BCM will be measured at the beginning and end of the study, respectively. However, the BCM results will be blinded to the physicians and the control group. The physician will prescribe drugs, PD fluids, and dietary education to the patients based on the clinical information alone - such as blood pressure, edema and body weight.
3100714|NCT01887249|Experimental|15 day sequential eradication therapy|the 15-day sequential therapy regimen, which consisted of esomeprazole (40 mg) plus amoxicillin (1000 mg) twice a day for 5 days, then esomeprazole (40 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for 10 days.
3100715|NCT01887249|Active Comparator|10-day sequential eradication therapy|the 10-day sequential therapy regimen, which consisted of esomeprazole (40 mg) plus amoxicillin (1000 mg) twice a day for 5 days, then esomeprazole (40 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for another five days
3100936|NCT01885767||NF1|Patients meeting clinical and/or genetic criteria for Neurofibromatosis 1
3100716|NCT01887249|No Intervention|7-day PPI triple eradication therapy|7-day PPI triple therapy regimen, which consisted of esomeprazole (40mg) plus amoxicillin (1000mg) and clarithromycin (500mg) twice daily for 7 days.
3100717|NCT01887236|Active Comparator|Step Physical Activity|A physical activity program that is based on the Step Apparatus Training Program
3100718|NCT01887236|Active Comparator|Stability Ball|A physical activity program that is based on the Stability Ball
3100719|NCT01887223|Experimental|Transconjunctival needling revision|Eyes with primary glaucoma surgery failure with encapsulated bleb submitted to surgical revision
3100720|NCT01887223|Active Comparator|Medical treatment|Eyes with primary glaucoma surgery failure with encapsulated blebs were treated with medical treatment (hypotensive eye drops)
3100721|NCT01887210|Experimental|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
3100722|NCT01887210|Active Comparator|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
3100723|NCT01887197|Experimental|Repeatability|Subjects perform two sequential absorptive clearance scans (within 30 days) to determine the repeatability of the technique. Subjects also perform a third scan two years later so that longitudinal change can be measured.
3100724|NCT01887197|Experimental|Response|Subjects perform three different absorptive clearance scans. One is a baseline measurement while the other two measure absorptive clearance after an intervention (inhaled hypertonic saline, mannitol inhalation powder).
3100725|NCT01887184|Placebo Comparator|Normal Saline|Normal saline was given intranasally
3100726|NCT01887184|Active Comparator|Dexmedetomidine|1.5mcg dexmedetomidine was given intranasally before procedure
3100727|NCT01887171|Experimental|Tacrolimus + HTK|During back-table operation 1000 ml of HTK solution cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
3100728|NCT01887171|No Intervention|HTK|During back-table operation 1000 ml of HTK solution cooled to 2-4˚C would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin under gravity pressure of 40 cm H2O.
3100729|NCT01887158|Active Comparator|bisacodyl plus 2-Liter Polyethylene glycol|Patients randomized to the low-volume arm, will be invited to consume 2 sachets of Lovol-esse (Polyethylene glycol) in one liter of water at 8:00 PM the evening before the colonoscopy and 2 sachets in one liter of water 4 hours before their scheduled colonoscopy appointment; furthermore, the patients will be instructed to take three 5-mg tablets of bisacodyl the day before the procedure, at 5:00 PM.
3100730|NCT01887158|Active Comparator|4-Liter Polyethylene glycol|Patients assigned to the high-volume arm will be invited to consume 2 envelopes of Selg-esse 1000 (polyethylene glycol) in 2 litres of water and drink the resulting solution in about 2-3 hours starting at 6:00 PM the evening before the colonoscopy; the day of the procedure, starting 5 hours before the procedure, the patients will be invited to complete the preparation with 2 others envelopes of Selg-esse 1000 (polyethylene glycol) dissolved in 2 litres of water.
3100731|NCT01887145|Active Comparator|Open surgery|Open surgery is Open carpal tunnel release
3100732|NCT01887145|Experimental|Endoscopic surgery|Endoscopic surgery is 2-portal endoscopic carpal tunnel release
3100733|NCT01887132|Experimental|Open-Label Donepezil|
3100734|NCT01887132|Experimental|Donepezil - Blinded|
3100735|NCT01887132|Placebo Comparator|Placebo|
3100736|NCT01887119|Active Comparator|Eplerenone|Eplerenone 50 mg 1dd during four weeks
3100737|NCT01887119|Placebo Comparator|Placebo|Eplerenone-matched placebo
3100738|NCT01887106|Experimental|GLPG1205 single dose|Single oral dose of GLPG1205 suspension - ascending doses
3100739|NCT01887106|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension
3100740|NCT01887106|Experimental|GLPG1205 multiple doses|Multiple oral doses of GLPG1205 suspension - ascending doses
3100741|NCT01887106|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
3100742|NCT01887093|Experimental|Morning walking|Participants were requested to walk in the morning at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks. We demanded everyone to record the situation of walking including duration, distance and time daily in a log book. Each participant was telephoned at least once a week to ensure the adherence to the exercise program. Patients were called back every month to hand in the log book and to understand the information about medication use. Furthermore, at the beginning and end of the 12-week program, both the walking groups were supervised by researchers to walk for continuous three days and the duration and distance of walking were recorded.
3100743|NCT01887093|Experimental|Evening walking|Participants were requested to walk in the evening at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks. We demanded everyone to record the situation of walking including duration, distance and time daily in a log book. Each participant was telephoned at least once a week to ensure the adherence to the exercise program. Patients were called back every month to hand in the log book and to understand the information about medication use. Furthermore, at the beginning and end of the 12-week program, both the walking groups were supervised by researchers to walk for continuous three days and the duration and distance of walking were recorded.
3100744|NCT01887093|No Intervention|No walking|The control group was requested to maintain their usual level of physical activity.
3100745|NCT01887080|Experimental|Exercise|Experimental group 1 performed cardiovascular rehabilitation home-based program
3100746|NCT01887080|Experimental|Exercise afther Microcurrent|Experimental group 2 performed cardiovascular rehabilitation home-based program just after microcurrent.
3100747|NCT01887080|Other|Cardiovascular Risk Factors|Education about risk factors
3100748|NCT01887067|Experimental|Renal denervation therapy|
3100749|NCT01887054|Active Comparator|Training Group|"There are 2 study visits. Subjects in this group will complete the following:~Visit 1~Gait evaluation~Neuropsychological testing~Questionnaires and assessments~Taught how to complete a visual problem-solving task (Tower of Hanoi)~Given a diary to record training at home.~In-home~•For 6 weeks at home, complete the in-home visual problem-solving tasks as instructed at Visit 1~Visit 2~Gait evaluation~Neuropsychological testing~Questionnaires and assessments"
3100750|NCT01887054|Placebo Comparator|Non Training Group|"There are 2 study visits. Subjects in this group will complete the following:~Visit 1~Gait evaluation~Neuropsychological testing~Questionnaires and assessments~Visit 2~Gait evaluation~Neuropsychological testing~Questionnaires and assessments"
3100751|NCT01887041|Active Comparator|Stent|Arm B, after randomisation the biliary tract stents shall remain. The patients in study arm B will also receive chemotherapy and gemcitabine, according to the recommended palliative therapy for a pancreas carcinoma.
3100752|NCT01887041|Active Comparator|Biliodigestive anastomosis|"Study arm A will, after randomisation, have a biliodigestive anastomosis inserted. After the healing of the wound (al least 14 days postoperative) the treatment using gemcitabine, according to the plan mentioned below.~Gemcitabine shall be administered on days 1, 8 and 15 of each 4 week cycle. The cycle is defined as a weekly, over a period of 3 consecutive weeks, applied infusions, followed by 1 week pause. On the day of therapy a dosage of 1000 mg/ml body surface shall be administered, intravenous, over a period of 30 minutes."
3100753|NCT01887028|Experimental|12mmHg intraperitoneal pressure (cool, dry CO2 gas )(n=20)|
3100754|NCT01887028|Other|12mmHg intraperitoneal pressure (warmed, humidified CO2 gas)|
3100755|NCT01887028|Other|8mmHg intraperitoneal pressure with cool, dry CO2 gas (n=20)|
3100756|NCT01887028|Other|8mmHg intraperitoneal pressure (warmed, humidified CO2 gas)|
3100757|NCT01887015|Experimental|Standard oxygen therapy|Our hypothesis is that, compared with standard oxygen therapy, early application of nasal high flow oxygen therapy can reduce the need for postoperative NPPV for postoperative hypoxemia (defined as PaO2/FiO2 ratio <300).
3100758|NCT01887015|Other|nasal high flow oxygen therapy|Our hypothesis is that, compared with standard oxygen therapy, early application of nasal high flow oxygen therapy can reduce the need for postoperative NPPV for postoperative hypoxemia (defined as PaO2/FiO2 ratio <300).
3100759|NCT01887002|Experimental|Experimental Arm 1|ONO-2952 Active tablets, every day for 2 weeks
3100760|NCT01887002|Placebo Comparator|Placebo Arm|ONO-2952 Matching Placebo every day for 2 weeks
3100761|NCT01886989|Experimental|Cocoa|Cocoa polyphenols (960mg)
3100762|NCT01886989|Placebo Comparator|Placebo|Placebo powder (109mg polyphenols) in water
3100763|NCT01886976|Experimental|anti-CD138 CAR T cells|Patients receive anti-CD138-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
3100764|NCT01886963|Active Comparator|Control - Blinded use of SPY Elite|Group A will consist of intraoperative abdominal wall imaging prior to incision, followed by ventral hernia repair with subcutaneous advancement flaps without viewing the imaging contained within the Spy Elite system. A digital photograph will be taken before and immediately after initial incision, as well as immediately prior to and after closure. The patient will have digital photographs of the surgical wound taken by the surgical team daily until discharge, and on follow-up visits at one week, two weeks, four weeks and twelve weeks. After twenty patients have completed phase I, the surgical team will be unblinded to Spy Elite imaging. The Spy Elite imaging and all digital photographs of all patients will be reviewed.
3100765|NCT01886963|Experimental|SPY - Unblinded Use of SPY Elite|Group B will have incision and advancement flap performed based on assessment of blood supply using the Spy Elite system, as well as potential flap revision if portions of the flap appear under-perfused in the pre-closure imaging. Patients will be blinded to whether or not their intraoperative Spy Elite imaging was used for operative planning. All patients will have digital photographs of the surgical wound taken by a blinded member of the surgical team daily until discharge, and on follow-up visits at one to two weeks, four weeks, and 12 weeks post-operatively. Digital photographs will be reviewed by a blinded surgeon, who will assess the wound for complications.
3100766|NCT01886937|Experimental|37.5 mg Phentermine daily for 7 days|"In this arm, participants receive 37.5mg phentermine for one week followed by 2 weeks of placebo.~Other names for phentermine:~adipex ionamin"
3100767|NCT01886937|Placebo Comparator|Placebo (for phentermine 37.5mg)|In this arm, participants receive Placebo (for 37.5mg phentermine) for two weeks followed by phentermine 37.5mg for 7 days.
3100768|NCT01886924|Experimental|Brief Computer MI for Smoking Cessation|Brief computer MI intervention to motivate tobacco quitline use
3100769|NCT01886924|Active Comparator|Nutrition Control|Computer delivered nutrition education
3100770|NCT01886911|Active Comparator|Control for Attention Intervention|Attentional Control Game is an active control group. We expect subjects in this group to play a control game for 2 weeks (plus or minus 7 days).
3100771|NCT01886911|Experimental|Prosocial Training Intervention Game|The prosocial intervention group, which we expect will be play the experimental prosocial training game for 2 weeks (plus or minus 7 days).
3100772|NCT01886911|Experimental|Attention Training Intervention Game|The attention intervention group, which we expect will be play the experimental attention training game for 2 weeks (plus or minus 7 days).
3100773|NCT01886911|Active Comparator|Control for Prosocial Intervention|This is an active control group. We expect subjects in this group to play a control game for 2 weeks (plus or minus 7 days).
3100774|NCT01886898|Placebo Comparator|Standard starter infant formula|starter infant formula from enrollment till 16 weeks of age
3100775|NCT01886898|Experimental|starter infant formula with prebiotics|starter infant formula from enrollment till 16 weeks of age
3100776|NCT01886898|Experimental|starter infant formula with pro and prebiotics|starter infant formula from enrollment till 16 weeks of age
3100777|NCT01886898|Other|breastfeeding group|exclusively breastfeeding during the first 16 weeks of age
3100778|NCT01886885||MBCPM|There is just one group of participants of no more than 20 people.
3100779|NCT01886872|Active Comparator|Arm I (rituximab, bendamustine hydrochloride)|Patients receive rituximab IV on day 1 (day 0 course 1) and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.
3100780|NCT01886872|Experimental|Arm II (ibrutinib)|Patients receive ibrutinib PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3100781|NCT01886872|Experimental|Arm III (ibrutinib, rituximab)|Patients receive ibrutinib as in Arm II. Patients receive rituximab IV on days 1, 8, 15, and 22 of course 2 and on day 1 of courses 3-6. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3100782|NCT01886859|Experimental|Treatment (ibrutinib and lenalidomide)|Patients receive a run-up course of ibrutinib PO daily on days 1-28. Patients then receive ibrutinib PO and lenalidomide PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 12 courses, patients who have achieved CR/CRi, nodular PR, partial remission or who have stable disease discontinue lenalidomide and continue ibrutinib.
3100783|NCT01886833||Mother-Infant Pair|"The study will involve consenting mother-infant pairs from Kamwala health facility in Lusaka where the Maternal Child Health (MCH). Those generally interested will be invited to the research clinic, where more detailed information about the study is offered. Motivated mothers will be recruited and taken through the written informed consent process by the study nurse.~Enrolled mother-infant pairs will undergo baseline procedures as earlier described. They will then be followed prospectively until about December 2016. They will be expected to come to the clinic for scheduled visits at baseline, 1, 3, 12, 15 and 42 months. They will be urged to come to the clinic for unscheduled visit should the infant be unwell at any time, and particularly each time the infant experiences diarrhoea."
3100784|NCT01886820|Experimental|[18F]NAV4694|Intravenous [18F]NAV4694 radioactive dose 8.1 mCi(300 MBq) given once
3100785|NCT01886807|Other|(DL group)|direct laryngoscopy for nasotracheal intubation without oxygen insufflation
3100786|NCT01886807|Other|(DL-O2 Group)|direct laryngoscopy for nasotracheal intubation with oxygen insufflation
3100787|NCT01886807|Experimental|(VL Group)|nasotracheal intubation using the Truview PCD video laryngoscope
3100788|NCT01886794|Experimental|Postmenopausal, topical vaginal cream|Postmenopausal participants randomized to topical vaginal cream containing estrogen or placebo for about one month's use prior to scheduled surgery.
3100789|NCT01886794|No Intervention|Pre-menopausal, no topical vaginal cream|
3100790|NCT01886781|Experimental|Lactobacillus plantarum 299v|Lactobacillus plantarum 299v capsules
3100791|NCT01886781|Placebo Comparator|Crytalline cellulose powder|Placebo capsule, filled with micro-crystalline cellulose powder
3100792|NCT01886781|No Intervention|Run in period|Run in period of one to two weeks, no treatment. At baseline randomization and treatment commenced.
3100793|NCT01886781|No Intervention|Wash out period|Wash out period of two weeks, no treatment.
3100794|NCT01886768|Experimental|Double pledget nasal anesthesia|All patients in the double pledget nasal anesthesia group receive endoscopic-guided gauze nasal pledgetting to both the inferior nasal meatus and middle nasal meatus. Each patient will receive an anterior rhinoscopy to select the most patent meatus by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up a right-angled gauze strip. A preloaded biopsy forceps is protruded slowly into the middle meatus first under endoscope monitoring. The second gauze pledgetting procedure is performed two minutes after the first gauze pledgetting which serves to induce turbinate size reduction to both the INT and MNT. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
3100795|NCT01886768|Active Comparator|Single pledget nasal anesthesia|All patients in the single pledget nasal anesthesia group receive endoscopic-guided gauze nasal pledgetting to either the inferior nasal meatus or middle nasal meatus determined by anterior rhinoscopy. Each patient will receive an anterior rhinoscopy to select the most patent meatus by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up a right-angled gauze strip. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
3100796|NCT01886755|Experimental|ORS with probiotic and zinc|ORS with probiotic and zinc Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate
3100797|NCT01886755|Placebo Comparator|Placebo Comparator|Standard oral rehydration solution
3100798|NCT01886742|Active Comparator|Control group|Standard dose group (2 g intravenous (IV) cefazolin dose for patients <120 kg, and 3 g IV cefazolin for patients >120 kg)
3100799|NCT01886742|Experimental|Treatment group|Weight-based dose group (30 mg/kg cefazolin IV)
3100800|NCT01886729|Active Comparator|tDCS simultaneously with hyperbaric oxygen therapy|
3100801|NCT01886729|Active Comparator|tDCS 3 weeks after start tinnitus|
3100802|NCT01886716|Experimental|Anxiety Attention Training only|Participants will receive Anxiety Attention Training and placebo Alcohol training.
3100803|NCT01886716|Experimental|Alcohol Attention Training only|Participants will receive Alcohol Attention Training and placebo Anxiety training.
3100804|NCT01886716|Experimental|Anxiety + Alcohol Attention Training|Participants will receive both Anxiety Attention Training and Alcohol Attention Training.
3100805|NCT01886716|Placebo Comparator|Control Training|Participants will receive placebo Anxiety Training and placebo Alcohol training.
3100806|NCT01886703|Experimental|Walking Intervention|Pedometer Walking Program
3100807|NCT01886690|Experimental|New Eye Drop Formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
3100808|NCT01886690|Active Comparator|REFRESH PLUS®|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
3100809|NCT01886677|Experimental|Immediate diet and exercise intervention|A healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week
3100810|NCT01886677|Other|Delayed diet and exercise intervention|This arm will receive the same diet and exercise intervention as the experimental arm once recovery from prostatectomy is achieved.
3100811|NCT01886664|Active Comparator|Sevoflurane|Performing liver transplantation under general anesthesia using sevoflurane
3100812|NCT01886664|Experimental|Desflurane|Performing liver transplantation under general anesthesia using desflurane
3100813|NCT01886638|Experimental|Abacavir|Abacavir 600mg (as two 300mg tablets) once daily for 15 days
3100814|NCT01886625|Experimental|Sympathicotomy|unilateral single-port VATS sympathicotomy
3100853|NCT01886352|Active Comparator|Infiltration of portal sites with 0,5% levobupivacaine.|The first group of patients will receive the standard treatment (paracetamol, diclofenac and an opioid if necessary) with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine).
3100903|NCT01886027|Experimental|Emotional Awareness and Expression|Emotional awareness and expression training (EAET) is an emotional processing intervention.
3100904|NCT01886027|Active Comparator|Relaxation|Relaxation training will teach patients different relaxation training skills.
3100815|NCT01886612|Experimental|DVT Prophylaxis|"Neuromuscular electrical stimulation is to be applied using a custom-built, two-channel stimulator (Duo-STIM (stimulator), Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 5 minutes.~Intermittent pneumatic compression is to be applied using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 1 second duration over a period of 5 minutes."
3100816|NCT01886599|Experimental|Arm A: Subjects with normal renal function|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
3100817|NCT01886599|Experimental|Arm B: Subjects with end stage renal disease|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
3100818|NCT01886599|Experimental|Arm C: Subjects with mild renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
3100819|NCT01886599|Experimental|Arm D: Subjects with moderate renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
3100820|NCT01886599|Experimental|Arm E: Subjects with severe renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
3100821|NCT01886586|Active Comparator|Problem Solving Therapy|8-12 sessions of Problem Solving Therapy (both members of dyad)
3100822|NCT01886586|Active Comparator|Problem Solving Therapy + Exercise|6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
3100823|NCT01886586|Active Comparator|Enhanced Usual Care|Staff will will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
3100824|NCT01886573|Experimental|Treatment (azacitidine, entinostat)|Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Patients undergo surgery between days 11-20 (this period can be extended 10 more days if adverse events from therapy impose a surgical risk).
3100825|NCT01886560|Placebo Comparator|Placebo|Adding eatable flour into the pills
3100826|NCT01886560|Experimental|Doxycycline treatment|Doxycycline treatment 50mg bid x 14 days then 50mg qd x 10 weeks
3100827|NCT01886547||New patient presented with prostate disease|prostate disease identified
3100828|NCT01886534|Experimental|Enhanced Caregiver Support with Caregiver|"Standardized Heart Failure Discharge Summary to Primary Care Physicians©~Standardized education sessions~Heart Failure Diuretic Decision Support Tool for Patient Self Management©~Digital talking scale"
3100829|NCT01886534|Other|Usual Care with Caregiver|Usual care
3100830|NCT01886534|Experimental|Enhanced Support without Caregiver|"Standardized Heart Failure Discharge Summary to Primary Care Physicians©~Standardized education sessions~Heart Failure Diuretic Decision Support Tool for Patient Self Management©~Digital talking scale"
3100831|NCT01886534|Other|Usual Care without Caregiver|Usual Care
3100832|NCT01886521|Experimental|Lumbar drain group|Lumbar drain
3100833|NCT01886521|Active Comparator|Ventricular drain|Ventricular drain
3100834|NCT01886508|Experimental|NSRH|patients in Arm NSRH undergo nerve-spring radical hysterectomy (NSRH)
3100835|NCT01886508|Active Comparator|RH|patients in Arm RH undergo radical hysterectomy (RH)
3100836|NCT01886495|Active Comparator|nutrition intervention|high protein diet
3100837|NCT01886495|No Intervention|control diet|
3100838|NCT01886482|Active Comparator|nutrition intervention|high protein diet
3100839|NCT01886482|No Intervention|no intervention|control diet
3100840|NCT01886469|Experimental|Adolescents (12-17yrs)|
3100841|NCT01886469|Experimental|Children (6-11 yrs)|
3100842|NCT01886456|Experimental|PLT|patients treated with patterned laser trabeculoplasty
3100843|NCT01886456|Active Comparator|SLT|patients treated with selective laser trabeculoplasty
3100844|NCT01886443|Experimental|Combined drug approach, safety study|
3100845|NCT01886430|Experimental|Functional Electrical Stimulation|Functional Electrical Stimulation for 10 days
3100846|NCT01886430|Placebo Comparator|Control Electrical Stimulation|Control Electrical Stimulation for 10 days
3100847|NCT01886404||Efavirenz Group|Participants will be taking efavirenz as part of their antiretroviral regimen.
3100848|NCT01886391|Experimental|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 [5-min DBR], 1 for week 2 [10-min DBR], 1 for weeks 3-8 [15-min DBR]), developed by the PI, to use to practice their deep breathing.
3100849|NCT01886378|Experimental|UX007|UX007 dosing titrated to a target dose of 25-35% of total caloric intake or maximum tolerated dose. Participants are followed to evaluate the effects of UX007 over 24 weeks (Treatment Period), then continued treatment in the Extension Period for an additional 54 weeks for a total of 78 weeks of treatment.
3100850|NCT01886365|Active Comparator|Group A|With start of the cardiopulmonary bypass, computerized algorithmic application of insulin was performed with a dedicated computerized syringe pump system (Space GlucoseControl System, B. Braun, Germany). The targeted corridor for blood glucose was determined with 80 - 150 mg/dl. During surgery, blood glucose was measured every 30 min, and on the ICU every 2 hours. TGC management was continued until ICU discharge.
3100851|NCT01886365|Active Comparator|Group B|Corresponding computerized algorithmic application of insulin management was used as for group A. However, only the interval of blood glucose measurement during surgery was adjusted to 15 minutes.
3100852|NCT01886365|Other|Group C|With start of the cardiopulmonary bypass conventional therapy with a fixed insulin dosing scheme was initiated. If blood glucose was > 150 mg/dl, manual insulin therapy was started following a fixed insulin dosing scheme. Measurements of blood glucose were performed during surgery every 30 minutes, and on the ICU every 2 hours until discharge (Routine Care).
3100896|NCT01886079|Experimental|Dexmedetomidine group|
3100897|NCT01886079|Placebo Comparator|Saline group|
3100898|NCT01886066|Experimental|Indocyanine Green|All patients on study will have ICG injection for SLN mapping
3100854|NCT01886352|Experimental|Additional injection of 0.5% levobupivacaine via a trocar|The second group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional injection of the local anesthetic ( 0.5% levobupivacaine, non -diluted) in the peritoneal cavity via a trocar both at the beginning and the end of the surgery.
3100855|NCT01886352|Experimental|Additional intraperitoneal atomization of levobupivacaine.|The third group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional intraperitoneal atomization of the local anesthetic.
3100856|NCT01886339||Healthy population|
3100857|NCT01886326|Experimental|Consumption of 42 g of salted peanuts|Consumption of 42 grams of peanuts daily
3100858|NCT01886326|Experimental|Consumption of 42 g of unsalted peanuts|Consumption of 42 grams of peanuts daily
3100859|NCT01886326|Experimental|Consumption of 42 g of spicy peanuts|Consumption of 42 grams of peanuts daily
3100860|NCT01886326|Experimental|Consumption of 42 g of honey peanuts|Consumption of 42 grams of peanuts daily
3100861|NCT01886326|Experimental|Consumption of 42 g of 3 diff. varieties|Consumption of 42 grams of peanuts daily
3100862|NCT01886326|Experimental|Consumption of 42 g of var. of types|Consumption of 42 grams of peanuts daily
3100863|NCT01886313|Active Comparator|Civamide Nasal Spray|Civamide Nasal Spray 0.01% 20ug/dose (20ul), 10ul in each nostril, twice daily, for 6 weeks
3100864|NCT01886313|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 10ul in each nostril, twice daily, for 6 weeks
3100865|NCT01886300||Cohort|
3100866|NCT01886287|Experimental|Octreotide Long-acting Release (LAR)|Octreotide LAR will be administered at a dose of 60 mg intramuscularly (IM) every 4 weeks.
3100867|NCT01886274|Experimental|tDCS|The experimental group received tDCS to the occipital cortex in 12 sessions, 3 days per week.
3100868|NCT01886274|Sham Comparator|control|The control group received sham stimulation to the occipital cortex in 12 sessions, 3 days per week.
3100869|NCT01886274|No Intervention|healthy subjects|This group was submitted to one evaluation session of cortical excitability.
3100870|NCT01886248|Experimental|Antithrombin-III Human 500IU|"Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU~Units required (IU)/kg = 50 + [(desired-baseline AT-III level) x weight (kg) / 1.4]"
3100871|NCT01886235|Experimental|Diagnosis (intravital microscopy)|Patients receive fluorescein sodium IV followed by intravital microscopic observation over 10-15 minutes during excision of the melanoma.
3100872|NCT01886222|Experimental|Long-term mild hypothermia|Focused intervention
3100873|NCT01886222|Other|Normothermia|Standard management
3100874|NCT01886209|Experimental|Cohort 1|Prednisone 10 mg tablet on Day 1 and 7; VX-509 200 mg tablets on Days 2 thru 7
3100875|NCT01886209|Experimental|Cohort 2|Methylprednisolone 8 mg tablet on Day 1 and 7; VX-509 200 mg tablets on Days 2 thru 7
3100876|NCT01886196|Experimental|Non-steroidal anti-inflammatory drug|ibuprofen after exercise training sessions (400 mg, 3 times per week for 9 months)
3100877|NCT01886196|Placebo Comparator|placebo|placebo after exercise training sessions(3 times per week for 9 months)
3100878|NCT01886196|Experimental|resistance exercise|3 sets of 8-12 repetitions of resistance exercises focused on distal radius to be performed 3 times/week for 9 months
3100879|NCT01886196|Sham Comparator|flexibility training|flexibility training to be performed 3 days/week for 1 hour for 9 months
3100880|NCT01886183|Experimental|Virtual Reality Training|The virtual reality training will be done by experimental group with ten games of Nintendo Wii Fit.
3100881|NCT01886183|Active Comparator|Control group: Physical Therapy|The Control Group will be trained by conventional Physical Therapy exercises.
3100882|NCT01886170|No Intervention|Hemoglobin A1C|The arms apply to the second phase of the study. This is the control arm. Participants will receive information regarding their diabetes control using the hemoglobin A1C value (standard medical information)
3100883|NCT01886170|Experimental|Experimental Format #1|In phase II of the study, participants in this arm will receive information about their current diabetes control conveyed using experimental format #1. The experimental formats will be determined based on the results from Phase I of the study.
3100884|NCT01886170|Experimental|Experimental Format #2|In phase II of the study, participants in this arm will receive information about their current diabetes control conveyed using experimental format #2. The experimental formats will be determined based on the results from Phase I of the study.
3100885|NCT01886157|Active Comparator|Corticosteroid injection|Standard corticosteroid injection.
3100886|NCT01886157|Experimental|Corticosteroid Injection and Trigger Splint|Corticosteroid Injection + Trigger Splint + Education + Home Exercises
3100887|NCT01886144||Knee OA|People with knee OA of one knee
3100888|NCT01886131|Experimental|Synchronised video-polysomnography|
3100889|NCT01886118|Experimental|Autologous Endometrial Co-Culture|The embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5.
3100890|NCT01886118|Active Comparator|Conventional media culture|Patients in this arm will have their embryos cultured in conventional media
3100891|NCT01886105|Experimental|SmEDTMP/Autologous Stem Cell Infusion/RT|Samarium tracer infusion of 1 mCi/kg administered. SPECT images wil be used to determine the distribution of dose delivered to the tumor. This information will be used to determine target doses of external beam radiotherapy. The treatment infusion of Samarium, 30 mCi/kg, will be administered and dosimetry will confirm total dose delivered, and information will be used to finalize doses of external beam radiotherapy. Approximately 14 days after treatment infusion, autologous stem cells infusion is administered. Radiotherapy will be delivered according to the judgement of the treating radiation oncologist.
3100892|NCT01886092|Active Comparator|Active rTMS1|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex
3100893|NCT01886092|Active Comparator|Active rTMS2|Temporal low frequency repetitive transcranial magnetic stimulation of left primary auditory cortex
3100894|NCT01886092|Active Comparator|Active rTMS3|Frontal low frequency repetitive transcranial magnetic stimulation of left dorsolateral prefrontal cortex
3100895|NCT01886092|Sham Comparator|Sham Condition|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex
3100907|NCT01886014|Placebo Comparator|placebo|"application of intranasal saline~Both sprays (saline/oxytocin) are delivered in identical containers manufactured by the University pharmacy to assure blinding."
3100908|NCT01886001|Experimental|Povidone-Iodine (Betadine)|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
3100909|NCT01886001|Experimental|Chlorhexidine|Umbilical stump care. ChloraPrep® Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
3100910|NCT01886001|Experimental|Pluronic|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied once a day to cord stump while umbilical line(s) are in place
3100911|NCT01886001|Sham Comparator|Control (no application)|Control arm, no product is applied, which is standard of care.
3100912|NCT01885988|Active Comparator|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
3100913|NCT01885988|Placebo Comparator|Sugar pill|Sugar pill 5, 10 or 20 mg tablet, orally, daily. Sugar pill dosage will be titrated per blood pressure results.
3100914|NCT01885962|No Intervention|Treatment as Usual (TAU)|Participants in this group engage in typical rehabilitation and perform usual skin care routine.
3100915|NCT01885962|Experimental|TAU + iSHIFTup|Participants in this group engage in typical rehabilitation and use iSHIFTup, Internet Skin Health Intervention for Targeted Ulcer Prevention. Participants are instructed to perform program recommendations to engage in preventive skin care behaviors.
3100916|NCT01885949|Experimental|Experimental Treatment Arm|Tivozanib, taken daily for 21 days followed by a 7 day break Enzalutamide taken daily for 28 days
3100917|NCT01885936|Experimental|Albuterol|Initially 4 mg daily for one week, then 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
3100918|NCT01885936|Placebo Comparator|Placebo Comparator|Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
3100919|NCT01885923|Active Comparator|20% antisychotic dose increase in prodromes|Antipsychotic dose increase upon prodromes occurence detected by Device- ITAREPS system. All antipsychotics currently registered in Czech Republic will be allowed in this study. All patients will remain on antipsychotic treatment adjusted prior enrollment, so that dose adjustment will be based on their ordinary medication. Participants will be instructed to complete the 10-item EWS Questionnaire upon SMS request sent automatically weekly to their mobile phones. EWSQ detects proportional worsening of the symptoms compared to the last week's score of the questionnaire. Individual EWSQ scores will be sent by participants back to the ITAREPS system as a SMS. If the total score exceeds the given score threshold, an immediate ALERT would be declared and announced to the investigator as an e-mail message and a therapeutic intervention is requested. After detecting the early warning signs by ITAREPS, an immediate 20% increase in the dose of antipsychotic will be required.
3100920|NCT01885923|No Intervention|Treatment as usual|In the control group (treatment-as-usual) participants will not be enrolled in the ITAREPS system.
3100921|NCT01885910|Experimental|doxy + aczone|Subjects will start treatment with doxycycline 100mg once daily and Aczone 5% gel applied to the face twice daily and those who improve significantly are continued on Aczone gel alone to see if it can maintain therapeutic response
3100922|NCT01885897|Experimental|Study treatment|Weekly dose of ALT-803 at assigned dose, ranging from 1mcg/kg to 30 mcg/kg (based on phase 1 dose escalation schedule,) IV once a week for 4 weeks.
3100923|NCT01885884|Experimental|Supportive Care Intervention|Monthly (minimum) patient & caregiver visits with a Supportive Care physician, embedded within their standard oncological care (through collaboration with oncology providers).
3100924|NCT01885884|No Intervention|Usual Care|Participants will receive standard oncology care from their oncology providers.
3100925|NCT01885871|Experimental|Picosecond QS Nd:YAG Laser|Laser Treatment with Investigational Device
3100926|NCT01885858|Other|Sequence 1|Clinics receive first the indigenous and then the mestizo profile.
3100927|NCT01885858|Other|Sequence 2|Clinics receive first the mestizo and then the indigenous profile.
3100928|NCT01885845|Experimental|BRASSS-V drape|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
3100929|NCT01885845|Experimental|Indirect weight method|"Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml."
3100930|NCT01885832|Experimental|Treatment|In the treatment arm, autologous stromal vascular fraction (SVF) will be injected into joints of 20 patients with grade 2, 3, or 4 radiographic OA severity.
3100931|NCT01885819|Experimental|Treatment|Autologous stromal vascular fraction cells
3100932|NCT01885806|Experimental|Repetitive TMS|"Patients will receive 10 consecutive sessions of repetitive transcranial magnetic stimulation with the following protocol:~Frequency: 10 Hz Intensity: 90% motor limiar Session duration: 16 minutes (20 sequencies of 6 seconds of stimulation followed by intervals of 30 seconds); Localization: Left pre-frontal dorsolateral cortex;"
3100933|NCT01885806|Sham Comparator|Sham TMS|Patients will receive 10 consecutive sessions of sham transcranial magnetic stimulation following the same protocol as the intervention arm, but with no magnetic stimulation of the brain.
3100934|NCT01885793||Cuffed endotracheal tube|Surgical patients who require endotracheal intubation with a cuffed endotracheal tube (ETT).
3100935|NCT01885780|Experimental|Astigmatic keratotomy|
3100938|NCT01885767||SchW|Patients meeting clinical and/or genetic criteria for Schwannomatosis
3100939|NCT01885754||Lung cancer patient with cachexia|Muscle lumbar area < 55cm2/m2 for men and < 39 cm2/m2 for women
3100940|NCT01885754||Lung cancer patients without cachexia|Muscle lumbar area over 55cm2/m2 for men and 39 cm2/m2 for women
3100941|NCT01885741|Experimental|IPBS|
3100942|NCT01885728|Active Comparator|Arginine rich nutritional supplement|237 ml of an arginine rich nutritional supplement 4 times a day for the five days preceding surgery.
3100943|NCT01885728|No Intervention|No nutritional supplement|No specific nutritional requirements have to be met in this group.
3100944|NCT01885715|Placebo Comparator|Rocuronium-placebo|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
3100945|NCT01885715|Active Comparator|Rocuronium-neostigmine 10 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0."
3100946|NCT01885715|Active Comparator|Rocuronium-neostigmine 20 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
3100947|NCT01885715|Active Comparator|Rocuronium-neostigmine 40 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
3100948|NCT01885715|Placebo Comparator|Cisatracurium-placebo|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
3100949|NCT01885715|Active Comparator|Cisatracurium-neostigmine 10 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
3100950|NCT01885715|Active Comparator|Cisatracurium-neostigmine 20 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
3100951|NCT01885715|Active Comparator|Cisatracurium-neostigmine 40 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
3100952|NCT01885702|Experimental|MSI-positive CRC patients|I) Adjuvant DC vaccinations for MSI-positive CRC patients (n=5)
3100953|NCT01885702|Experimental|Carriers of germline MMR-gene mutation|II) Preventive DC vaccinations for carriers of germline MMR-gene mutation (n=20) withhout manifestation of CRC
3100954|NCT01885689|Experimental|Treatment (clofarabine, melphalan, transplant)|"CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4.~TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure."
3100955|NCT01885676|Experimental|PRGF-Endoret|
3100956|NCT01885676|Placebo Comparator|Saline Solution|
3100957|NCT01885663|Experimental|Umbilical cord blood therapy|Umbilical cord blood therapy
3100958|NCT01885650|Experimental|Normal airway clearance|The patients usual airway clearance technique
3100959|NCT01885650|Experimental|Non-Invasive Ventilation|The addition of positive pressure via a non-invasive ventilator to the participants usual airway clearance technique
3100960|NCT01885637|No Intervention|Control group|In the control group, the patients continue to be attached to the health care system in line with current practice. This means that the patient typically remains in hospital or ambulatory and may have contact with one or more hospitals, GP and possibly homecare later in the process. Caregivers in the control group may receive psychological counseling through referral from a GP.
3100961|NCT01885637|Other|Intervention Group|Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
3100962|NCT01885624|Experimental|TAB08|Single TAB08 i.v. infusion
3100963|NCT01885611|Active Comparator|Multi-Drug Therapy (Novartis Ⓡ)|"Multi-Drug Therapy PB pack consists of 600 milligrams (mg) of rifampicin (NovartisⓇ) single dose once a month and 100mg of dapsone (NovartisⓇ) daily for six months (PB patients)~Multi-Drug Therapy MB pack consists of 600mg of rifampicin (NovartisⓇ), 300mg of clofazimine (NovartisⓇ) as a single dose monthly and 50mg of clofazimine (NovartisⓇ) and 100mg of dapsone (NovartisⓇ) daily for six months (MB patients)"
3100964|NCT01885611|Experimental|Virgin Coconut Oil (VCO) with MDT|"VCO 10 milliliters (mL) three times a day in addition to MDT of 600mg of rifampicin (NovartisⓇ) single dose once a month and 100mg of dapsone (NovartisⓇ) daily for a period of six months (PB patients)~VCO 10mL three times a day in addition to MDT of 600mg of rifampicin (NovartisⓇ), 300mg of clofazimine (NovartisⓇ) as a single dose monthly and 50mg of clofazimine (NovartisⓇ) and 100mg of dapsone (NovartisⓇ) daily or a period of six months (MB patients)"
3100965|NCT01885598||Nonvalvular Atrial Fibrillation patients with risk of Stroke|Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release
3100966|NCT01885585||Patients with risk of VTE|Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release
3100967|NCT01885572|Other|TiLOOP Bra|Treatment with TiLOOP Bra
3100968|NCT01885559|Placebo Comparator|ACE-I + placebo|Monotherapy of lisinopril and placebo. Standard blood pressure control of 110-130/80 mm Hg
3100969|NCT01885559|Active Comparator|ACE-I + ARB|Dual therapy of lisinopril and telmisartan treatments. Standard blood pressure control of 110-130/80 mm Hg.
3100970|NCT01885546|Other|Enhanced meter feature usability|Home diabetes monitoring by patient using provided blood glucose monitoring system.
3100971|NCT01885533||Post-radioiodine medication|Anti-thyroid drugs
3100972|NCT01885533||Post-radioiodine medications|anti-thyroid drugs and thyroxine
3100973|NCT01885533||Post-radiodione medication|watchful monitoring
3100974|NCT01885520|Experimental|fasting condition|eperisone SR administrated under fasting condition
3100975|NCT01885520|Active Comparator|Fed condition|eperisone SR administrated under fed condition
3100976|NCT01885507||Control phase (before)|Process of care and outcomes before the educational program
3100977|NCT01885507||Training phase (after)|"Process of care and outcomes after the educational program which recommends:~the use of tidal volume < 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)~extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough"
3100978|NCT01885494||15µg AFFITOPE® PD01A|Patients With Parkinson's Disease vaccinated with 4 injections of 15µg AFFITOPE® PD01A adsorbed to adjuvant during AFF008
3100979|NCT01885494||75µg AFFITOPE® PD01A|Patients With Parkinson's Disease vaccinated with 4 injections of 75µg AFFITOPE® PD01A adsorbed to adjuvant during AFF008
3100980|NCT01885494||Control group|Untreated control group
3100981|NCT01885481|Active Comparator|ESI-1|epidural steroid injection using dexamethasone
3100982|NCT01885481|Experimental|ESI-2|epidural steroid injection using betamethasone
3100983|NCT01885455|Active Comparator|Usual Care Arm|Participants who are assigned to the usual care arm may receive the following services: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
3100984|NCT01885455|Experimental|Intervention Arm|"The PN will provide each patient with a copy of the NCI's What You Need to Know About Lung Cancer booklet and encourage them to re-contact his/her primary care physician (or the physician who diagnosed their probable/proven NSCLC) to discuss treatment options.~The PNs will provide patients with their contact information and brief patients on their role. The PNs will navigate study participants for up to 4 months (16 weeks, 112 days) after NSCLC diagnosis, until the patient is deemed ineligible for LDTCI (i.e., lung resection or SBRT) by their physician(s), until receipt of LDTCI, or death (whichever comes first).~During the EPDPN intervention period, PNs will contact each intervention group participant by telephone (or in-person) on weekly basis (at minimum)."
3100985|NCT01885442|Experimental|In-bed leg cycle ergometry|
3100986|NCT01885429|Experimental|Positive Control|Group 1 (Positive(+) Control) will receive: 25g of whey protein. Positive Control
3100987|NCT01885429|Experimental|Negative Control|Group 2 (Negative(-) Control) will receive: 6.25g whey. Negative Control
3100988|NCT01885429|Experimental|Low Protein + Low Leucine Spike|Group 3 (Low Protein + Low Leucine Spike) will receive: 6.25g whey + low added leucine. Low Protein Low Leucine Spike
3100989|NCT01885429|Experimental|Low Protein + High Leucine Spike|Group 4 (Low Protein + High Leucine Spike) will receive: 6.25g whey + high added leucine. Low Protein High Leucine Spike
3100990|NCT01885429|Experimental|Low Protein + High Leucine + BCAA Spike|Group 5 (Low Protein + High Leucine + BCAA Spike) will receive: 6.25g whey + added branched-chain amino acids. Low Protein + High Leucine + BCAA Spike
3100991|NCT01885416|Active Comparator|high fat meal without dairy products|high fat meal without dairy products
3100992|NCT01885416|Experimental|high fat meal with additional milk|high fat meal with additional milk
3100993|NCT01885416|Experimental|dairy product meal|dairy product meal
3100994|NCT01885403|Experimental|Respiratory Parameters Measurements|
3100995|NCT01885390|Experimental|Experimental: Group A|ROX Coupler + continuing standard antihypertensive medications
3100996|NCT01885377|Experimental|Specific exercise group|A progressive program of strength-endurance exercises for the rotator cuff and scapula stabilizing muscles combined with mobilization of the joint capsule when needed
3100997|NCT01885377|Active Comparator|Control exercise group|General movements for the neck and shoulder and self-stretching. No progression some addition of exercises during the three month period.
3100998|NCT01885364|Placebo Comparator|Placebo & propofol|Pretreatment with normal saline before injection of propofol
3100999|NCT01885364|Experimental|esmolol 0.05 mg/kg & propofol|Pretreatment with esmolol 0.05 mg/kg before injection of propofol
3101000|NCT01885364|Experimental|esmolol 1 mg/kg & propofol|Pretreatment with esmolol 1 mg/kg before injection of propofol
3101001|NCT01885364|Active Comparator|remifentanil 0.35 ug/kg & propofol|Pretreatment with remifentanil 0.35 ug/kg before injection of propofol
3101002|NCT01885351|Experimental|Phase II: MyCRCS+Prefs|
3101003|NCT01885351|Experimental|Phase II: MyCRCS+Prefs+Barriers|
3101004|NCT01885351|No Intervention|Phase II: Usual Care|The IPHR will be programmed so that where the IPHR-CRCS would normally present patients, who based on their demographics and health conditions, with content advising them to seek CRCS and links to third-party sites, they would instead be randomized to receive the usual care (IPHR-CRCS).
3101005|NCT01885338|Experimental|N-acetylcysteine (NAC)|Capsules containing N-acetylcysteine 600mg, with inactive ingredients of cellulose, L-leucine, and silica used as filler. Dosage is 2 capsules by mouth twice daily for 8 weeks.
3101006|NCT01885338|Placebo Comparator|Inactive placebo capsule|A placebo capsule is used that is identical to the active treatment but lacks NAC. The inactive ingredients in the placebo capsule are cellulose, L-leucine, and silica. Dose is 2 capsules by mouth twice daily for 8 weeks.
3101007|NCT01885325|Experimental|Physical Activity Preschool Intervention|Preschools randomized to the multi-component physical activity preschool intervention received four major components: Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical Activity in classroom, academic lessons), and enhancing the social environment to promote Physical Activity.
3101008|NCT01885325|No Intervention|Control|The preschools in the control group did not receive the intervention
3101009|NCT01885312|Active Comparator|Tailored not adaptive based Intervention|Tailored Text Messaging - not adaptive in the moment and once a day intervention to reduce problem drinking
3101010|NCT01885312|Other|Ecological Momentary Assessment|Mobile Assessment only
3101011|NCT01885312|Experimental|Tailored Adaptive Text Messaging|Tailored Adaptive Text Messaging intervention to reduce problem drinking
3101012|NCT01885312|Active Comparator|Consequence based text messaging|Consequence based Text Messaging intervention to reduce problem drinking
3101013|NCT01885299||Patients being treated by SRS/SBRT|Patients with a condition being considered for treatment by SRS/SBRT
3101014|NCT01885273|Experimental|Pressurized irrigation method|Cleansing wound with pressurized irrigation technique using a pressurized irrigation device.
3101015|NCT01885273|Active Comparator|Swabbing wound cleansing method|All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack), and received the 'standardized usual care'. Frequency of dressing change depended on the amount of exudates.
3101016|NCT01885260|Experimental|ISIS-GCGRRx Dose Level 1|ISIS-GCGRRx Dose Level 1
3101017|NCT01885260|Experimental|ISIS-GCGRRx Dose Level 2|ISIS-GCGRRx Dose Level 2
3101018|NCT01885260|Placebo Comparator|Placebo|Placebo
3101019|NCT01885234|Experimental|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
3101020|NCT01885234|Placebo Comparator|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
3101021|NCT01885221|Experimental|Multimedia Support Intervention|(a) access to a website providing the content of our supporter guidebook, supplemented with interactive components, video elements, and a supporters' forum, and (b) a mailed copy of our supporter guidebook
3101022|NCT01885221|No Intervention|Delayed Treatment Control|Access to the Multimedia Intervention after participant completes the final follow-up assessment
3101023|NCT01885208|Experimental|Semaglutide 1.0 mg|
3101024|NCT01885208|Active Comparator|Exenatide ER 2.0 mg|
3101025|NCT01885195|Experimental|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
3101026|NCT01885182|Experimental|Oxycodone/Naloxone|5/2.5mg, 10/5mg, 20/10mg or 40/20mg
3101027|NCT01885182|Active Comparator|Oxycodone|5mg, 10mg, 20mg or 40mg
3101028|NCT01885169||Cohort A|Participants with CF; Flumist®-naïve
3101029|NCT01885169||Cohort B|Siblings of Cohort A without CF; Flumist®-naïve
3101030|NCT01885169||Cohort C|Participants with CF; Flumist®-experienced
3101031|NCT01885156|Placebo Comparator|Placebo Cream|Topically applied once daily
3101032|NCT01885156|Experimental|Naftin 1% Cream|Topically applied once daily
3101033|NCT01885143||Artifact Correction|A minimum of 6 subjects will be recruited for the purpose of evaluating artifact correction
3101034|NCT01885143||Lossy Compression|A minimum of 6 subjects will be recruited for the purpose of evaluating lossy compression
3101035|NCT01885130|Experimental|Cetaphil Daily Advance Ultra Hydrating Lotion|All subjects receive Cetaphil Daily Advance Ultra Hydrating Lotion
3101036|NCT01885117|Experimental|TIVf (18 to ≤ 60 years)|Adult subjects aged 18 to ≤ 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere
3101037|NCT01885117|Experimental|TIVf (≥ 61 years)|Adult subjects aged ≥ 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere
3101038|NCT01885104|Experimental|PEG 3350|Participants will receive a 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment.
3101039|NCT01885104|Placebo Comparator|Placebo|Participants will receive a 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment.
3101040|NCT01885091|Experimental|Kinerase|
3101041|NCT01885078|Experimental|Baricitinib 4 mg|"Baricitinib 4 milligrams (mg) administered orally once daily throughout the 84 month treatment period. Placebo administered orally to maintain blind.~Participants may continue to receive the background non-investigational, open-label conventional disease-modifying antirheumatic drugs (cDMARD), nonsteroidal anti-inflammatory drug (NSAID), corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
3101042|NCT01885078|Experimental|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily throughout the 84 month treatment period. Placebo administered orally to maintain blind.~Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
3101043|NCT01885065|Experimental|Gel-based artificial saliva|Continuous oral intake of edible gel-based artificial saliva (30-50 ml/day) for four weeks
3101044|NCT01885052|Active Comparator|3|Receives two week countdown messages to quit date, receives mulitiple messages per day post quit date with tips, encouragement and supportive messaging
3101045|NCT01885052|Active Comparator|2|Receives two week countdown messaging to quit date, and weekly assessment messages post quit date
3101046|NCT01885052|Placebo Comparator|1|Receives weekly assessment messages ONLY
3101047|NCT01885026|Experimental|eScreen|Web based self-monitoring of problematic alcohol and drug use.
3101048|NCT01885026|Experimental|Control|No intervention except for assessment of alcohol and drug use.
3101049|NCT01885013|Experimental|Metformin + Myocet + Cyclophosphamide|"arm A : Metformin 1000 mg, 2 times daily per os*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.~* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day."
3101050|NCT01885013|Active Comparator|Myocet + Cyclophosphamide|arm B : Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days
3101051|NCT01885000|Experimental|Brimonidine tartrate 0.5% gel|once-daily brimonidine tartrate 0.5% gel
3101052|NCT01885000|Placebo Comparator|Vehicle|once-daily brimonidine tartrate vehicle gel
3101053|NCT01884987||group one will receive non-GM1 conservative therapy|"Group one will receive conservative therapy such as hyperbaric therapy or corticosteroids therapy or wait and see policy"
3101054|NCT01884974||myeloproliferative disease|Patients with Myeloproliferative Diseases as specified under inclusion and exclusion criteria
3101055|NCT01884961|Experimental|arm A|"Boost of radiotherapy + high dose IL-2 treatment: Three daily doses boost radiotherapy at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of IL-2 (Interleukin 2). The first day of administration of IL-2 of each cycle is the day +1.~Treatment with IL-2 (dose 18 MIU/m2/day in 500cc by continuous IV (intravenous) infusion for 72 hours) will start on day +1 and will be administered every 3 weeks up to 4 cycles, than every 3-4 weeks for a further 2 cycles.~Patients will be evaluated every 8 weeks with computed tomography to determine the response, and every 3 months after completion of treatment until death."
3101056|NCT01884948|Active Comparator|Omegaven™|Omegaven™ (approval number:54750 Swissmedic)- 100ml intravenously. The first dose (Omegaven™ or placebo) is administered in the evening before surgery, the second dose at the beginning of anesthesia. The maximum infusion rate must be adjusted to bodyweight (0.5 ml Omegaven™/kg/hour).
3101057|NCT01884948|Placebo Comparator|NaCl 0.9%|100ml of saline is used as a placebo comparator and administered as described above.
3101058|NCT01884935|Experimental|Natalizumab|300 mg intravenously (IV) every 4 weeks
3101059|NCT01884922|Experimental|Dose escalation|"Nilotinib (Tasigna®): 115 to 350 mg/m2 twice daily (BID) orally given continuously (115 mg/m2 once daily if de-escalation requested~Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle."
3101060|NCT01884909|Active Comparator|'TOPROL-XL®' ER Tablets 200 mg|'TOPROL-XL®' ER Tablets 200 mg of Astrazeneca LP, USA
3101061|NCT01884909|Experimental|Metoprolol Succinate ER Tablet 200 mg|Metoprolol Succinate ER Tablet 200 mg of Ipca Laboratories Limited, India
3101062|NCT01884896|Active Comparator|'TOPROL-XL®' ER Tablets 200 mg|'TOPROL-XL®' ER Tablets 200 mg of Astrazeneca LP, USA
3101063|NCT01884896|Experimental|Metoprolol Succinate ER Tablet 200 mg|Metoprolol Succinate ER Tablet 200 mg of Ipca Laboratories Limited, India
3101064|NCT01884883|Other|Internal unicompartmental knee brace|
3101065|NCT01884870|Other|Surgical Treatment|Silent Ureteral Stone - Surgical Treatment
3101066|NCT01884857|Active Comparator|'TOPROL-XL®' ER Tablets 50 mg|'TOPROL-XL®' ER Tablets 50 mg of Astrazeneca LP, USA
3101067|NCT01884857|Experimental|Metoprolol Succinate ER Tablets 50 mg|Metoprolol Succinate ER Tablets 50 mg of Ipca Laboratories Limited, India
3101068|NCT01884844|Experimental|Vitamin D3|Vitamin D3, Cholecalciferol, 5000IU po qday for 12 weeks
3101069|NCT01884844|Placebo Comparator|Placebo|methylcellulose po qday for 12weeks
3101070|NCT01884831|Experimental|cell therapy|study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions
3101071|NCT01884818|Experimental|Manipulation|Subjects will receive 6 manipulation treatments within 3 weeks period. The manipulated segments are determined individually in baseline assessment.
3101072|NCT01884818|Sham Comparator|TNS for thoracic spine|6 TNS treatments at home for 20min in limited power of devices in three weeks period.
3101073|NCT01884805|Other|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|
3101074|NCT01884792|Placebo Comparator|Sitting Oral Glucose Tolerance Test|An OGTT is performed while the subject sits at their desk for the entire 2-hour period. 5 blood sugar measurements are taken and a 75g dextrose beverage is consumed following the first, baseline blood sugar reading. The blood sugar is then measured every 30 minutes up to 120 min.
3101075|NCT01884792|Experimental|Standing Oral Glucose Tolerance Test|The participant stands at their desk for the duration of the 2-hour blood sugar test. The same procedure is performed as in the sitting condition.
3101076|NCT01884792|Placebo Comparator|Sitting Continuous Glucose Monitor|A continuous blood glucose monitor is worn for 5 days while at work. In the sitting condition the participant only sits at their desk for the duration of the week. Blood sugar is monitored 4 times per day to calibrate the CGM and an accelerometer is worn to track physical activity.
3101077|NCT01884792|Experimental|Standing Continuous Glucose Monitor|Participants are instructed to stand intermittently for at least half of their work day during this 5 day period. Blood sugar is monitored and physical activity is tracked with an accelerometer.
3101078|NCT01884766||Epilepsy|All kind of epilepsy, including febrile seizures
3101079|NCT01884766||Control|children without seizures at presentation in the emergency but fever due to banal infections
3101080|NCT01884753||Adult women with lower urinary tract symptoms|Adult women (not less than 20 year-old) with lower urinary tract symptoms
3101081|NCT01884740|Experimental|SIACI of Erbitux and Bevacizumab|Superselective Intraarterial Cerebral Infusion (SIACI) of Erbitux (200 m/m2) and Bevacizumab (15 mg/kg)
3101082|NCT01884727|Active Comparator|ASEA water|Subjects to consume 4-ounces of ASEA water at 9:00 am before breakfast and 4-ounces of ASEA water at 10:15 pm prior to bedtime. 24-h resting energy expenditure and RQ to be measured.
3101083|NCT01884727|Placebo Comparator|Salt water|Subjects to consume 4-ounces of salt water at 9:00 am before breakfast and 4-ounces of salt water at 10:15 pm prior to bedtime. 24-h resting energy expenditure and RQ to be measured.
3101084|NCT01884714|Experimental|High fat/high calorie meal|All subjects are provided a high calorie (~1300kcal) and high fat (~60g fat) breakfast meal.
3101085|NCT01884701|Experimental|Intervention|Intervention
3101086|NCT01884688|Experimental|ENK Cell Infusion|Expanded Natural Killer Cell Infusion
3101087|NCT01884675|Experimental|Ambrisentan|Subjects in this arm will receive ambrisentan 5 mg tablet once daily during the treatment period.
3101088|NCT01884675|Placebo Comparator|Placebo|Subjects in this arm will receive ambrisentan-matching placebo tablet once daily during the treatment period.
3101453|NCT01882179|Placebo Comparator|Placebo|Intravenous saline bolus prior to PPCI followed by oral placebo for 3 months
3101089|NCT01884662|Experimental|Virtual walking|A 3D video of legs walking from a first person perspective have been developed in consultation with persons with SCI and virtual reality experts. Participants are provided with a 3D monitor and Blue Ray player for daily viewing of the tape for two weeks.
3101090|NCT01884662|Active Comparator|Wheeling tape|A 3D video was produced of legs in a wheelchair covering the identical conditions of the walking experimental video.
3101091|NCT01884649||Group of Hashimoto thyroiditis patients|
3101092|NCT01884649||Healty control group|
3101093|NCT01884636|Experimental|isavuconazole and methotrexate|Methotrexate single dose on days 1 and 8. Isavuconazole three times a day (TID) on days 4 and 5 followed by isavuconazole once daily (QD) on days 6 - 9
3101094|NCT01884623|Experimental|Cetuximab|Dosing schedule: 500 mg/m², every two weeks (q2w) Mode of administration: IV
3101095|NCT01884623|Active Comparator|Methotrexate|Dosing schedule: 40mg/m2 weekly (q1w) Mode of administration: IV
3101096|NCT01884597|Active Comparator|Cohort 1|12 monthly, intravitreal injections of 2.0mg ranibizumab followed by 12 monthly, intravitreal injections of 1.0mg ranibizumab
3101097|NCT01884597|Active Comparator|Cohort 2|6-months of monthly, intravitreal injections of ranibizumab 2.0mg followed by 18 months of monthly, intravitreal injections of ranibizumab 1.0mg
3101098|NCT01884597|Active Comparator|Cohort 3|24 months of monthly, intravitreal injections of ranibizumab 1.0mg
3101099|NCT01884584|Experimental|Indocyanine green (ICG)|ICG will be administered by intravenous infusion over a 20 second period in a 2-8 hour time window before the time of completion of the surgical procedure.
3101100|NCT01884571|Experimental|Immunosuppression Regimen|Basiliximab Methylprednisolone Prednisone Tacrolimus Mycophenolate mofetil
3101101|NCT01884558|Experimental|isavuconazole and metformin|Metformin single dose on days 1 and 8. Isavuconazole three times a day (TID) on Days 4 and 5 followed by isavuconazole once daily (QD) on Days 6-9.
3101102|NCT01884545|Active Comparator|Standard Risk Assessment (SRA)|Subjects will receive a standard risk assessment only for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
3101103|NCT01884545|Experimental|SRA plus Health Coaching (HC)|In addition to the standard risk assessment for CHD and T2D subjects will receive health coaching intervention for 6 months
3101104|NCT01884545|Experimental|SRA plus Genetic Risk Counseling (GRC)|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
3101105|NCT01884545|Experimental|SRA+HC+GRC|In addition to the standard risk assessment for CHD and T2D subjects will receive genetic risk counseling and health coaching intervention for 6 months.
3101106|NCT01884532||2 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 2 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3101107|NCT01884532||3 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 3 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3101108|NCT01884532||4 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 4 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3101109|NCT01884532||5 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 5 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3101110|NCT01884532||6 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 6 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3101111|NCT01884519|Experimental|Fluarix/Influsplit 18-60 Years Group|Subjects 18-60 years of age received 1 dose of Fluarix/Influsplit SSW 2013-2014 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
3101112|NCT01884519|Experimental|Fluarix/Influsplit > 60 Years Group|Subjects above 60 years of age received 1 dose of Fluarix/Influsplit SSW 2013-2014 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
3101113|NCT01884506|Experimental|labeled iron meal|Test meal (bread with honey) with a labeled iron solution
3101114|NCT01884506|Experimental|labeled iron and ascorbic acid meal|Test meal (bread with honey) with a labeled iron solution and ascorbic acid
3101115|NCT01884493|Experimental|real iTBS|The paradigm will use a theta burst stimulation pattern (TBS) in which 3 pulses of stimulation will be given at 50Hz, repeated every 200 ms. In the iTBS, a 2-second train of TBS is repeated every 10 seconds for a total of 190 seconds (600 pulses). Subjects will be 8 courses of iTBS stimulation in 10 business days.
3101116|NCT01884493|Sham Comparator|sham iTBS|Subjects will be 8 courses of sham iTBS stimulation in 10 business days.
3101117|NCT01884480||500 Stable renal transplant recipients|cohort of 500 stable RTRS. A subset of this group who required dose adjustment after conversion will be compared to a matched cohort not requiring dose adjustment. Genotyping for Cyp3A5 will be done for both cohorts
3101118|NCT01884480||500 renal transplant recipients|500 Stable renal transplant recipients converted from prograf to advagraf
3101119|NCT01884467|Experimental|Gentamicin|Intervention: Gentamicin; Dosage form: 120mg reconstituted in 250cc of normal saline; Dosage: 30mL; Frequency: nightly instillation into bladder (to remain overnight until draining it out in morning); Duration: 1 year
3101120|NCT01884467|Placebo Comparator|Placebo|Drug: Normal saline; Dosage form: N/A; Dosage: 30 mL; Frequency: nightly bladder instillation; Duration: 1 year
3101121|NCT01884454||Total sleep deprivation|Healthy volunteers will be submitted to total sleep deprivation (TSD) for 48 hours.
3101122|NCT01884454||moderate to severe OSA|Patients diagnosed with moderate to severe obstructive sleep apnea syndrome (OSA) with normal or overweight body mass index (BMI), will be recruited.
3101123|NCT01884454||REM sleep deprivation|Healthy volunteers will be submitted to selective REM sleep deprivation (REMSD) for 48 hours.
3101124|NCT01884454||Control|The control group will be subjects with an apnea hypopnea index <5/h.
3101125|NCT01884441|Experimental|BeGEV|Bendamustine, Gemcitabine and Vinorelbine (BeGEV)
3101126|NCT01884428|Experimental|Panobinostat + IGEV|Panobinostat + IGEV regimen (Ifosfamide, Gemcitabine, Vinorelbine, Prednisolone)
3101127|NCT01884415|Experimental|Second HBV vaccination cycle|Second cycle of HBV vaccination (0, 1 and 2 months)will be administered. Three intramuscular doses of 40 µg.
3101128|NCT01884415|Active Comparator|Single dose of HBV vaccine|Single dose (40µg) of HBV vaccine will be administered at 6 months after 1 cycle of HBV vaccination
3101129|NCT01884402||Pegasys, injection subcutaneous|HCV patients monoinfected or coinfected genotype 1/4 treated with Peginterferon alfa-2a and Ribavirin
3101130|NCT01884389|Experimental|Patient Navigation|"Patients are admitted to the navigation program, provided through a local community partner agency. Each of these subjects will be assigned an advanced practice nurse (APN) and licensed social worker (LSW) as co-case managers, with their relative contributions depending on the nature of the subject's needs. Level of need (1, 2 or 3) will be confirmed for each patient, and the level will inform the amount of in-person and phone call contacts made to provide on-going support and monitoring of patients. Additionally, this group will meet with the research team for data collection at enrollment and at four 9-month intervals for a total of 5 time points."
3101131|NCT01884389|No Intervention|Usual Care|"The control group will receive usual care - medical care and support provided by their primary care provider. They will not receive any of the navigation program services. To provide control for the effects of attention, we will contact these subjects at baseline and every other month thereafter by phone. During these contacts, we will ask a scripted social query (e.g. How are things going for you?). A subject who raises any health issues or need for specific information will be referred to the primary care provider. Additionally, this group will meet with the research team for data collection at enrollment and at four 9-month intervals for a total of 5 time points."
3101132|NCT01884376|Experimental|Neuromaix implantation|Implantation of Neuromaix during an diagnostic nerve biopsy
3101133|NCT01884363|Experimental|Walnuts|This group will receive one ounce of walnuts per day
3101134|NCT01884363|No Intervention|Usual diet (no walnuts)|Control group (does not receive walnuts in the diet)
3101135|NCT01884350|Experimental|Arm 1: Apixaban (Primary SOC information)|Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Primary SOC information
3101136|NCT01884350|Experimental|Arm 2: Apixaban (Additional Educational Program)|Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Additional Educational Program
3101137|NCT01884337|Experimental|Apixaban (2.5 mg)|Apixaban 2.5 mg tablets by mouth twice daily, 12 days for TKR subjects or 35 days for THR subjects
3101138|NCT01884324|No Intervention|Late delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
3101139|NCT01884324|Experimental|Early delivery|The early group will undergo induction of labor at 34 weeks with cesarean delivery reserved for obstetrical indications.
3101140|NCT01884311|Experimental|Subgam-VF|Subgam-VF is a 16% IgG and will be administered weekly, by subcutaneous infusion. The total duration of treatment will be for 26 weeks.
3101141|NCT01884298|Experimental|patients with isolated systolic hypertension|patients combined with isolated systolic hypertension undergoing abdominal surgery
3101142|NCT01884285|Experimental|Part A: AZD8186 monotherapy|Patients will receive a single dose on Day 1 followed by ongoing multiple dosing. The initial schedule will use intermittent dosing of AZD8186.
3101143|NCT01884285|Experimental|Part C2: AZD8186/abiraterone|Part C2: AZD8186 & Abiraterone (prednisone) dose expansion
3101144|NCT01884285|Experimental|Part D1: AZD8186 and AZD2014|Part D1: AZD2014 and AZD8186 dosing finding
3101145|NCT01884285|Experimental|Part B: AZD8186 monotherapy|Part B - multiple dosing of intermittent dose schedule
3101146|NCT01884285|Experimental|Part D2: AZD8186/ AZD2014|Part D2: AZD8186/ AZD2014 dose expansion
3101147|NCT01884285|Experimental|Part C1: AZD8186 & abiraterone|Part C1: AZ8186 & abiraterone (prednisone) dose finding
3101148|NCT01884272|Experimental|Lesinurad 400 mg and naproxen 250 mg|Lesinurad once daily (qd) Day 1, naproxen twice daily (bid) Day 2-6, lesinurad qd with naproxen bid Day 7-14.
3101149|NCT01884272|Active Comparator|Lesinurad 400 mg and indomethacin 25 mg|Lesinurad qd Day 1, indomethacin bid Day 2-6, lesinurad qd with indomethacin bid Day 7-14.
3101150|NCT01884259|Active Comparator|A|"Patients receive 3 cycles (cycle duration 21 days) of docetaxel (75mg/m²), cisplatin (75mg/m²) and 5-fluorouracil (750mg/m²) followed by Cetuximab (weekly, starting with 400mg/m² then continuing with 250 mg/m²) with radiotherapy (concomitant boost for 6 weeks).~Active comparator is 5-fluorouracil for first three cycles."
3101151|NCT01884259|Experimental|B|"All patients receive 3 cycles (cycle duration 21 days) of docetaxel (75mg/m²), cisplatin (75mg/m²) Cetuximab (weekly, starting with 400mg/m² and continuing with 250 mg/m²), followed by Cetuximab (weekly 250 mg/m²) with radiotherapy (concomitant boost for 6 weeks).~Experimental: cetuximab for the first three cycles."
3101152|NCT01884246|Experimental|Self-care CVD risk reduction|A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
3101153|NCT01884246|Active Comparator|Referral to primary care provider|The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
3101154|NCT01884233|Experimental|Text Messaging CBT|This condition will receive CBT based text messaging (TXT-CBT). Those assigned to TXT-CBT will also be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have an initial meeting with a CBT clinician to review the Life-Steps concepts. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
3101155|NCT01884233|Active Comparator|Standard Care|Those assigned to the Standard Care condition will receive the standard monthly medical management physician visit typically associated with HIV care. In addition, a pamphlet with information about HIV, the importance of ART adherence, and relapse prevention will be provided to participants in this condition.
3101156|NCT01884220||Patients with Disease|Patients with Wolman disease (WD), Cholesteryl Ester Storage Disease (CESD), or Lysosomal acid lipase (LAL) deficiency.
3101157|NCT01884207||orbital tumors|
3101158|NCT01884194||Retinoblastoma patients|patients with diagnosed retinoblastoma
3101159|NCT01884194||non-retinoblastoma patients|aged matched control cohort without the diagnosis of ocular or brain tumor
3101160|NCT01884181||Huntington Disease Group|Established diagnosis by a neurological examination and genetic assessment of CAG expansion in the Htt gene.
3101161|NCT01884181||Healthy Controls|"The healthy control subjects without a clinically significant neuropsychiatric disorders.~Able to understand and provide signed informed consent.~Age range and gender matched with Patients with Huntington Disease Group."
3101162|NCT01884168||gene expression profile|T-Cell Receptor/B-Cell Receptor gene expression in cavity effusion is detected by micro-array to explore the mechanism that DC-CIK immunotherapy controls the malignant cavity effusion.
3101163|NCT01884155|Experimental|Allogeneic umbilical cord blood therapy|Allogeneic umbilical cord blood therapy
3101164|NCT01884142|No Intervention|Heart Failure Untrained Group|Control Group
3101165|NCT01884142|Experimental|Heart Failure Exercise-trained Group|Aerobic Exercise Training
3101166|NCT01884116|Active Comparator|NSAID patch group|administer the NSAID patch
3101167|NCT01884116|Experimental|NSAID patch + transcutaneous electric nerve stimulation group|
3101168|NCT01884116|Experimental|NSAID patch + heating pad group|
3101169|NCT01884116|Experimental|NSAID patch + topical capsaicin group|
3101170|NCT01884103||EMS Providers|Field Triage Decision-making for older adult patients with potential TBI.
3101171|NCT01884090|Experimental|Youth Empowerment Solutions (YES)|Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
3101172|NCT01884090|Active Comparator|Standard After School Programming|Youth in the comparison arm of the study will participate in standard after-school programming administered by Flint Community Schools and Genesee Intermediate School District. The standard program is the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009)
3101173|NCT01884077|Active Comparator|Reverse Shoulder Arthroplasty|Shoulder Joint Replacement Reverse Arthroplasty Implant to surgically replace arthritic shoulder
3101174|NCT01884077|Active Comparator|Total Shoulder Arthroplasty|Shoulder Joint Replacement Total Arthroplasty Implant used to surgically replace osteoarthritic shoulder joint
3101175|NCT01884064|Experimental|inhibitory rTMS|Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, 1800 pulses, delivered to premotor cortex. Patients held a pencil and made movements that did not elicit dystonic symptoms during rTMS. Intervention was delivered every day for 5 days.
3101176|NCT01884064|Placebo Comparator|Sham rTMS|Sham Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, 1800 pulses, delivered to premotor cortex. Patients held a pencil and made movements that did not elicit dystonic symptoms during rTMS. Intervention was delivered every day for 5 days.
3101177|NCT01884051||PAH patients|Patients diagnosed with WHO Group 1 PAH
3101178|NCT01884051||Healthy subjects|Subjects who have been evaluated for heart and lung disease and found to be healthy
3101179|NCT01884038|Experimental|1|
3101180|NCT01884038|Placebo Comparator|2|
3101181|NCT01884025|Experimental|Get Moving and Get Well|Walking class developed for Veterans with serious mental illness and administered as part of the PRRC
3101182|NCT01884025|Sham Comparator|Health and Humor Class|Equally engaging attention control condition
3101183|NCT01884012|Experimental|Supplemental oxygen|Supplemental oxygen 3 liters/minute given via a nasal cannula for 16 hours a day
3101184|NCT01884012|Sham Comparator|Sham room air|Room air given at a flow rate of 3 liters per minute for 16 hours a day
3101185|NCT01883999|Experimental|GORE® EXCLUDER® Iliac Branch Endoprosthesis|GORE® EXCLUDER® Iliac Branch Endoprosthesis
3101186|NCT01883986|Experimental|Intervention|This is a 3 month nurse-led telephone based program integrating palliative care into usual oncologic care for patients diagnosed within 2 months of any type and stage of lung cancer.
3101187|NCT01883986|No Intervention|Usual Care|Subjects randomized to usual care will receive medical oncology, radiation oncology, pulmonary, CT surgery as indicated by the type of cancer. At the completion of 3 months of usual care, subjects are invited to join the intervention arm.
3101188|NCT01883973||MER guidance|Will undergo DBS implantation in the awake state using a frame based stereotactic technique and intraoperative microelectrode recording to guide final lead placement.
3101189|NCT01883973||MRI Guidance|Will undergo DBS implantation under general anesthesia using anatomical targeting in an operating room equipped with an intraoperative MRI to guide electrode placement
3101190|NCT01883960||healthy adults|Inclusion criteria for healthy adults were as follows: 40-70 y/o; good cognition and cooperation; and healthy adults.
3101191|NCT01883960||stroke subjects|Inclusion criteria for subjects with brain damage by stroke were as follows: a diagnosis of first-time-onset stroke and aged 40-70 years old.
3101192|NCT01883960||CP subjects|Inclusion criteria for subjects with brain damage by CP were as follows: a diagnosis of CP and aged 16-18 years old.
3101193|NCT01883960||healthy children|Inclusion criteria for healthy children were as follows: ages of 6-18 y/o ; good cognition and cooperation; and healthy children.
3101194|NCT01883947|Experimental|Touch massage|Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
3101195|NCT01883947|Sham Comparator|non-TENS|The sham treatment will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
3101196|NCT01883934|Experimental|Enhanced clinic-based support/counseling|Scheduling a consult with a licensed social worker to discuss embryo disposition options. Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
3101197|NCT01883934|Active Comparator|Patients receiving standard of care|Patients who receive standard of care regarding embryo disposition options
3101198|NCT01883921||Immunoglobulin Therapy|
3101199|NCT01883908|Experimental|Acupuncture with Seirin® needles|Participants will be randomized to receive acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
3101200|NCT01883908|Active Comparator|Usual medical care|Participants will be randomized to receive usual medical care for 8 weeks coinciding with their chemoradiation treatments. Patients will receive usual medical care such as viscous Lidocaine for relief of pain.
3101201|NCT01883895|Other|exercise treatment|"Concentric exercise: subject will utilize a dumbbell with elbow flexion exercise.~Isometric exercise: Subjects will perform 5 sets of sustained muscle contraction.~Control: Subjects will undergo a control arm where they will rest for approximately 10 minutes.~Pain testing conducted by Forgionei-Barber pressure pain-stimulator for both the control and exercise treatments."
3101202|NCT01883882|Experimental|taper support|Weekly visits with pharmacological and psychological support for opioid taper at 10% of original dose per week
3101203|NCT01883882|No Intervention|Usual care|Usual care for chronic pain. All care allowed except buprenorphine.
3101204|NCT01883869|Experimental|ticagrelor|180 mg orally once and then 90 mg orally daily for 7 days or until hospital discharge if sooner
3101205|NCT01883869|Placebo Comparator|placebo|One loading dose and then daily for 7 days or until hospital discharge if sooner
3101206|NCT01883856|Active Comparator|Silicone Plate Ahmed Glaucoma Valve|Silicone plate Ahmed Glaucoma Valve
3101207|NCT01883856|Experimental|Porous Plate Ahmed Glaucoma Valve|Porous Plate Ahmed Glaucoma Valve
3101208|NCT01883843|Experimental|real tDCS + TOCT|"Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode.~The current reaches 0.5mA and decreases with a ramp of 10 seconds."
3101209|NCT01883843|Active Comparator|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
3101210|NCT01883830|Experimental|gaming therapy (Xbox)|Subjects belonging to the first group will receive a gaming therapy protocol using the Xbox console. They will receive 24 sessions of treatment within 8 weeks (3 sessions per week). Patients will be required to concentrate in games whose major purposes are increasing balance, selective attention and attention shifting. During sessions the patient will be carefully controlled by a researcher who will prevent the risk of falling and impulsiveness reactions.
3101211|NCT01883830|Active Comparator|Dynamic balance platform training|Control group will receive the same amount of therapy (24 sessions) using a dynamic balance platform (Biodex).
3101212|NCT01883817|Placebo Comparator|Placebo|Corn/soy oil placebo capsules that are similar in shape and color to the DHA capsules given over 10 weeks
3101213|NCT01883817|Experimental|DHA Omega-3|Long-chain omega-3 fatty acid docosahexaenoic acid (DHA) at 1,200 mg/day, 600 mg twice daily for 10 weeks
3101214|NCT01883804|Experimental|Study group|All participants selected to continue with Methyldopa administration.
3101215|NCT01883791|Experimental|SBIRT|The SBIRT condition will include the WHO's Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) and its accompanying brief intervention that uses motivational interviewing techniques to provide feedback, emphasize personal responsibility, give advice, provide a menu of options, convey empathy, and promote self-efficacy.
3101216|NCT01883791|Other|Health Education|The control group will receive a Health Education (HE) session, informational brochures and a contact information for addiction treatment sites that we will develop with Ventura County. The session will be administered in an individual format for 30-minutes and will address general health, wellness and lifestyle topics.
3101217|NCT01883778||Emergency Department Patients|
3101218|NCT01883778||Emergency Medicine Physicians|
3101219|NCT01883765|Experimental|Neurofeedback active|Active neurofeedback training, theta/beta-protocol
3101220|NCT01883765|Sham Comparator|Neurofeedback sham|Neurofeedback training is simulated to subjects in this condition
3101221|NCT01883765|Active Comparator|Metacognitive Training|Metacognitive training, cognitive behavioral therapy
3101222|NCT01883752|No Intervention|Control|Baseline crystalloid infusion of 5 mL/kg/hr of body weight.
3101223|NCT01883752|Experimental|Goal-directed Therapy group|Goal-direct therapy
3101224|NCT01883739|Experimental|Parental Presence at Handover Rounds|"Subjects will receive an educational document prior to transfer rounds introducing the concept of Patient and Family Centered Care and the role of a parent in transfer rounds. These parents will have the option of meeting with a parental peer support person for a coaching or training session prior to their participation in transfer rounds. During the transfer rounds parents will be actively included in discussion of their child's medical management plan upon discharge to the wards."
3101225|NCT01883726|Experimental|Grayson NAM|Intervention: Grayson nasoalveolar molding This technique uses an acrylic plate to mold the alveolar segments and uses an extension to mold the alar cartilage of the nasal component. The construction is made by gradual modification of the acrylic plate with periodic acrylic add on and grinding. When the alveolar gap is reduced to 5 mm, nasal component are added to gradually mold the nasal cartilage and other nasal structures.
3101226|NCT01883726|Experimental|Figueroa NAM|Intervention: Figueroa's nasoalveolar molding Figueroa technique uses labial tapes and acrylic relief to the palatal plate to approximate alveolar gap [3]. The nasal component is added in the beginning of the treatment to mold the nasal cartilage.
3101227|NCT01883713||Heart surgery during CPB|All patients undergoing heart surgery using cardiopulmonary bypass who have a pre-operative Hb value greater than 90 g/L, no evidence of hypoxemia (SaO2 > 90%) and no history of congenital methemoglobinemia. Exclusion criteria will include severe hypoxemia, acute or chronic renal failure requiring dialysis, emergency surgery or the lack of a PA catheter. Non invasive brain oximetry will be used to assess the brain oxygen tension during surgical procedure.
3101228|NCT01883700|Experimental|Low-GI, High-GL Meal|Boiled Pasta
3101229|NCT01883700|Experimental|Low-GI, High GL Meal|Boiled Chickpeas with Oil
3101230|NCT01883700|Experimental|High-GI, High-GL Meal|Instant Mashed Potatoes
3101231|NCT01883700|Experimental|High-GI, Low-GL Meal|Instant Mashed Potatoes with Egg Whites
3101232|NCT01883687|Experimental|Septoplasty|patients will receive septoplasty together with Le Fort I osteotomy
3101233|NCT01883687|No Intervention|No septoplasty|patient will only receive Le Fort I osteotomy
3101234|NCT01883674|Experimental|Milk proteins|This group will do a resistance training + milk proteins (milk beverage)
3101235|NCT01883674|Experimental|Essential amino acids (add to soya bvg)|This group will do a resistance training + essential amino acids (added to soya beverage)
3101236|NCT01883674|Placebo Comparator|No protein (control)|This group will do a resistance training + ingestion of the control beverage (no protein, rice beverage)
3101237|NCT01883661|Other|BMMNC|Administration of of Bone Marrow derived Mono Nuclear Stem Cell (MNCs)
3101238|NCT01883648|Experimental|Coconut Oil Beverage|The treatment will consist of a 1.25 oz serving size taken orally, two times daily by subjects. This treatment arm will last 3 months.
3101239|NCT01883648|Placebo Comparator|Placebo Beverage|The treatment will consist of a 1.25 oz serving size taken orally, two times daily by subjects.This will similar in look and taste but not have the same ingredients of the actual coconut oil beverage. This treatment arm will last 3 months.
3101240|NCT01883635|Active Comparator|Individual Exercise Intervention|Survivor-only progressive walking and resistance exercise
3101241|NCT01883635|Experimental|Dyadic Exercise Intervention|Dyadic progressive walking and resistance exercise
3101242|NCT01883622||Type 1 diabetes|Pregnant women affected by type 1 diabetes mellitus
3101243|NCT01883622||GDM|Pregnant women affected by gestational diabetes mellitus
3101244|NCT01883622||Healthy|Healthy pregnant women
3101245|NCT01883609|Active Comparator|Group 1|Group 1 receive combination vaccination strategy: RTS,S/AS01B at weeks 0, ChAd63 ME-TRAP at week 2, RTS,S/AS01B at weeks 4 and 8, then MVA ME-TRAP at week 10 followed by sporozoite challenge (mosquito bite) at week 12.
3101246|NCT01883609|Active Comparator|Group 2|Group 2 receive three vaccinations (RTS,S/AS01B) at weeks 0, 4 and 8 followed by sporozoite challenge (mosquito bite) at week 12.
3101247|NCT01883609|No Intervention|Group 3|Groups 3 is an infectivity-control group for the sporozoite challenge procedures: these volunteers will not be vaccinated. Group 3 will undergo sporozoite challenge at the same time as Group 1 and 2 volunteers (week 12).
3101248|NCT01883609|No Intervention|Group 4|Group 4 is an infectivity-control group for the sporozoite challenge procedures: these volunteers will not be vaccinated. Group 4 volunteers will be used as infectivity controls if any volunteers from groups 1 and 2 are rechallenged 5 - 7 months after the initial CHMI. CHMI may be administered in two separate cohorts if necessary due to limitations on volunteer availability.
3101249|NCT01883596|Experimental|0.12% Chlorhexidine|Bexident® (0.12% chlorhexidine) solution, applied topically, every 8 hrs.
3101250|NCT01883596|Placebo Comparator|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
3101251|NCT01883583|Experimental|Pilot group|Contrast-enhanced Ultrasound And Sonoelastography of transplanted kidney will be performed for acquisition of a number of parameters and time-intensity curves, before ultrasound guided biopsy of transplanted kidney.
3101252|NCT01883570|Experimental|trained visual search strategy|An expert's visual search strategy for reading the chest x-ray was recorded using a gaze tracking device. This strategy was reproduced using a dynamic cursor and will be made available to participants in the experimental group using an interactive website.
3101253|NCT01883570|Active Comparator|not trained in visual search strategy|Participants will learn to read chest x-rays by having access to a library of chest x-rays identical to the one used by the experimental arm, but without the search strategy.
3101254|NCT01883544|Experimental|ALXN1007|Infusion of ALXN1007
3101255|NCT01883544|Placebo Comparator|placebo|Infusion placebo
3101256|NCT01883531|Placebo Comparator|Inhaled Placebo|Eight-week treatment period with inhaled placebo b.d.
3101257|NCT01883531|Active Comparator|Inhaled Mannitol|Eight-week treatment period Inhaled Mannitol 400 mg b.d.
3101258|NCT01883518|Experimental|Autologous dendritic cell vaccine|Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
3101259|NCT01883505|Experimental|ND0612|levodopa and carbidopa solution
3101260|NCT01883505|Placebo Comparator|Placebo|Saline
3101261|NCT01883492|Experimental|BIOLOX delta head|"Uncemented Femoral Stem is inserted into femoral medullary canal. Uncemented Acetabular Cup is inserted into acetabular cavity with or without fixation screw(s).~Acetabular Liner, which is made of E1 highly crosslinked polyethylene, is fitted into Acetabular cup.~Biolox delta head is inserted onto the taper of the Femoral stem, and is articulating against Acetabular Liner made of E1."
3101262|NCT01883492|Active Comparator|CoCr head|"Uncemented Femoral Stem is inserted into femoral medullary canal. Uncemented Acetabular Cup is inserted into acetabular cavity with or without fixation screw(s).~Acetabular Liner, which is made of E1 highly crosslinked polyethylene, is fitted into Acetabular cup.~CoCr head is inserted onto the taper of the Femoral stem, and is articulating against Acetabular Liner made of E1."
3101263|NCT01883479|Experimental|Exercise|Telephone-based intervention designed to increase exercise among postpartum women.
3101264|NCT01883479|Experimental|Wellness/Support|Telephone-based intervention designed to provide support to postpartum women.
3101265|NCT01883479|No Intervention|Usual care|Participants receive usual care and will receive their choice of the interventions at 9 months.
3101266|NCT01883466|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise
3101267|NCT01883466|Experimental|Biodiesel exhaust exposure|1 hour exposure to dilute biodiesel exhaust (generated at same running conditions as diesel exhaust) during intermittent exercise
3101268|NCT01883453|Placebo Comparator|Saline+glucose nasal spray|A nasal spray with isotone saline + 5% glucose, dosing one puff 5 times daily in each nostril at the first treatment day and thereafter trice daily for a total of one week
3101269|NCT01883453|Active Comparator|Nasal spray with glucose oxidase+glucose|A nasal spray with 200U/ml of glucose oxidase + 5% glucose. Treatment starts with 5 puffs in each nostril at the first day, and thereafter trhee times daily for a total treatment time of one week.
3101270|NCT01883440|Placebo Comparator|Saline+glucose|A nasal spray with isotone saline + 5% glucose in a bag-on-valve nasal spray device. The spray will be administered with one puff in each nostril 5 times day one and thereafter trice daily for a total treatment time of one week
3101271|NCT01883440|Active Comparator|Glucose oxidase + glucose|A nasal spray (bag-on-valve device) with 200U/ml glucose oxidase + 5% glucose in isotone saline. One puff in each nostril 5 times daily day one and 3 times daily thereafter. A total treatment time of one week.
3101272|NCT01883427|Placebo Comparator|Placebo: Saline+glucose nasal spray|Subjects received nasal spray containing both saline+glucose twice daily for 3 months
3101273|NCT01883427|Active Comparator|Nasal spray with glucose oxidase+glucose|Nasal spray in a bag-on-valve device with 50U/ml containing both glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.
3101274|NCT01883414|Active Comparator|Group A|Subjects randomized to Group A will receive Ultherapy™ treatment on the superior or lateral half of the scar.
3101275|NCT01883414|Active Comparator|Group B|Subjects randomized to Group B will receive Ultherapy™ treatment on the inferior or medial half of the scar.
3101276|NCT01883401|Experimental|High dose strawberry|50g freeze-dried strawberries/day
3101277|NCT01883401|Experimental|Low-dose strawberry|25g freeze-dried strawberries/day
3101278|NCT01883401|Other|Fiber/calorie control (high dose)|Dietary fiber (8g)
3101279|NCT01883401|Other|Fiber/calorie control (low dose)|Dietary fiber (4g)
3101280|NCT01883375|Experimental|Dignity Talk dyad completers|Those dyads where both patient and family member co-participant complete the protocol using the Dignity Talk Communication Topics
3101281|NCT01883375|Experimental|Dignity Talk non-completers|Those dyads where patient and family member co-participant either do not complete the protocol or do not use the Dignity Talk Communication Topics (November 2016 - the investigators have not as yet enrolled any participants who have not completed the study without using the Dignity Talk Topics. However some participants have withdrawn from the study without completing.
3101282|NCT01883362|Experimental|Standard of Care (SOC) with Midostaurin|Patients will receive standard of care in the post SCT setting in addition to Midostaurin 50mg twice a day for 12 months (cycles).
3101283|NCT01883362|Active Comparator|Standard of Care (SOC)|Patients will receive standard of care alone in the post SCT setting
3101284|NCT01883349||ESRD patients|ESRD patients awaiting renal transplantation who are expected to get a renal transplant in the next few months
3101285|NCT01883323|Experimental|Cyclophosphamide and Fludarabine followed by TILs and IL-2|Cyclophosphamide, i.v., 60mg/kg per day for 2 days and Fludarabine, i.v., 25mg/m2 per day for 5 days; then Tumor-Infiltrating Lymphocytes, i.v., 1x10^10 - 1.6x10^11 cells and Low-Dose Interleukin, i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
3101286|NCT01883310|Active Comparator|sham tDCS + TOCT|The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
3101287|NCT01883310|Experimental|real tDCS + TOCT|the real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
3101288|NCT01883297|Experimental|Re-Stimulated Tumor-Infiltrating Lymphocytes and interleukin-2|Cyclophosphamide will be given prior to Re-Stimulated Tumor-Infiltrating Lymphocytes, and interleukin-2.
3101289|NCT01883284|Experimental|Cystic Fibrosis patients (CF)|Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects
3101290|NCT01883284|Other|Control subjects (non CF)|Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects
3101291|NCT01883271|Experimental|High intensity aerobic interval training|Older adults will complete 8 weeks of high intensity aerobic interval exercise training.
3101292|NCT01883271|Experimental|Continuous moderate intensity exercise|Older adults will complete 8 weeks of continuous moderate intensity exercise training.
3101293|NCT01883271|No Intervention|Non-exercise control group|Older adults assigned to the non-exercise control group will maintain their normal lifestyle for 8 weeks.
3101294|NCT01883271|No Intervention|Young Healthy controls|Young healthy subjects will be assigned to the healthy control group and will undergo baseline measures only.
3101295|NCT01883258|Experimental|High intensity aerobic interval training|Type 2 diabetes subjects will complete 8 weeks of high intensity aerobic interval exercise training.
3101296|NCT01883258|Experimental|Continuous moderate intensity exercise|Type 2 diabetes subjects will complete 8 weeks of continuous moderate intensity exercise training.
3101297|NCT01883258|No Intervention|Non-exercise control group|Type 2 diabetes subjects assigned to the non-exercise control group will maintain their normal lifestyle for 8 weeks.
3101298|NCT01883258|No Intervention|Healthy control group|Healthy subjects will be assigned to the healthy control group and will undergo baseline measures only.
3101299|NCT01883245|Active Comparator|sham tDCS|This group will receive sham-tDCS for 5 days. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 30 seconds, with an intensity of 1 milliampere.
3101417|NCT01882413||Patients with Planned Cataract Removal|Patients with planned cataract removal surgery are evaluated for the presence of inflammatory dry eye disease. No treatment is administered.
3101300|NCT01883245|Experimental|real tDCS|"This group will receive continuous stimulation lasting 20 minutes daily, for 5 days.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 20 minutes, with an intensity of 1 milliampere."
3101301|NCT01883232|Active Comparator|2% lidocaine with 1:100,000 epinephrine|2% lidocaine with 1:100,000 epinephrine
3101302|NCT01883232|Experimental|Onset Mixing Pen by Onpharma|Sodium Bicarbonate 8.4% mixed with the onset mixing pen
3101303|NCT01883219|Experimental|TKI therapy|Treatment with TKI will be initiated if the level of BCR-ABL transcript in the bone marrow is detectable and transcript levels increased for two consecutive tests. TKIs will be given for patients without BCR/ABL mutations and sensitive TKIs will be given for those with mutations.
3101304|NCT01883193|Experimental|Arm 1: Preconception|Arm 1 will commence the comprehensive maternal nutrition intervention at 3-7 months postpartum. Delivery of the intervention will be monitored biweekly by collection of empty and unused sachets of the lipid-based supplement (LNS), maternal report, and casual observation of household behavior. Arm 1 participants will be weighed monthly and Body Mass Index (BMI) calculated. If BMI <20 an additional energy supplement will be provided. Menstrual history will be obtained at each visit and a urine pregnancy test will be performed if menses is delayed.
3101305|NCT01883193|Experimental|Arm 2: Pregnancy|Participants in Arm 2 will commence the same comprehensive maternal nutrition intervention at 12 weeks gestation.
3101306|NCT01883193|No Intervention|Arm 3: Control|Participants in Arm 3 will receive biweekly visits to monitor pregnancy status. No health advice will be given other than information about prenatal care, location of delivery, and breastfeeding education in the third trimester.
3101307|NCT01883180|Experimental|ATG 7.5mg/kg|ATG 7.5mg/kg group refers to treatment with ATG in the total dose of 7.5mg/kg.
3101308|NCT01883180|Experimental|ATG 10mg/kg|ATG 10mg/kg group refers to treatment with ATG in the total dose of 10mg/kg.
3101309|NCT01883167|Experimental|Febuxostat|"Days 1-7: febuxostat 40 mg qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.~Days 15-21: RDEA3170 10 mg or placebo qd."
3101310|NCT01883167|Experimental|RDEA3170|"Days 1-7: RDEA3170 10 mg or placebo qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.~Days 15-21: febuxostat 40 mg qd."
3101311|NCT01883154||IUGR pregnancies|Pregnancies complicated with IUGR. Fetal growth beneath the 10th percentile
3101312|NCT01883154||pregnancies with Gestational Diabetes|Normal glucose levels before 20 weeks, and positive Oral glucose tolerance test
3101313|NCT01883154||Pre Gestational Diabetes|A diagnosis of Diabetes before pregnancy or elevated glucose levels before 20 weeks.
3101314|NCT01883154||IVF pregnancies|
3101315|NCT01883141|Experimental|MultiSpot pacing|
3101316|NCT01883141|Experimental|MultiVein pacing|
3101317|NCT01883141|Active Comparator|Standard biventricular pacing|
3101318|NCT01883128|Experimental|Whole body MRI|Comparing the detection rate of metastases of whole body MRI compared to current standard of care tests - Choline PET and Bone scan.
3101319|NCT01883128|Experimental|MRI Targeted Biopsies|Transperineal MRI-targeted biopsies and whole-gland transperineal prostate mapping biopsies
3101320|NCT01883128|Experimental|Focal Salvage Therapy|Focal salvage HIFU and cryotherapy of recurrent prostate cancer tumors only
3101321|NCT01883115||Telescopic group|All eligible patients referred with inguinal/femoral hernias will be enrolled into the study from February 2013
3101322|NCT01883102|Experimental|Capsaicin 0.1%|Capsaicin cream 0.1% will be applied to site A or B on the subject's abdomen daily for 7 days.
3101323|NCT01883102|Placebo Comparator|Placebo/cream without 0.1% capsaicin|The placebo cream will be applied to site A or B on the subject's abdomen daily for 7 days.
3101324|NCT01883089|Other|Other|Participants will be recruited to complete a 90 day daily monitoring study during which time will be invited to participate in a 4 week brief alcohol intervention during days 31-60 (i.e., second month).
3101325|NCT01883076|Experimental|autologous cell-based delivery|autologous cell-based delivery a target dose of 3 million cells / kg of body weight will be delivered into the right heart muscle at the time of surgery. Cells are derived from autologous (self) umbilical cord blood.
3101326|NCT01883063|Experimental|WRx™ Intramedullary Nail|Patients in this arm of the study will be treated with a minimally invasive WRx™ Intramedullary Nail for their wrist fracture.
3101327|NCT01883063|Active Comparator|Non surgical treatment (Cast)|Patients in this arm of the study will be treated with a cast for their wrist fracture.
3101328|NCT01883050|Other|Self Monitoring of Software Application|log into self monitoring software application from a home computer. Log on 3-4 times weekly for 12 weeks for important reminders, care tips and educational materials.
3101329|NCT01883050|No Intervention|No Intervention|No Intervention
3101330|NCT01883037||Laboratory blood glucose|Blood glucose value from Lab
3101331|NCT01883037||HemoCue Glucose 201 RT|Blood glucose value from HemoCue Glucose 201 RT
3101332|NCT01883024|Other|Type 1 diabetes|
3101333|NCT01883011|Experimental|Piracetam|"IV infusion 12 g piracetam in 60 ml~IV Ampoules 3 g piracetam in 15 ml~Oral solution 33 % piracetam (bottle of 125 ml)~Oral tablets 1200 mg piracetam (blisters of 10 tablets)"
3101334|NCT01883011|Placebo Comparator|Placebo|"IV infusion 12 g placebo in 60 ml~IV Ampoules 3 g placebo in 15 ml~Oral solution 33% placebo (bottle of 125 ml)~Oral tablets 1200 mg placebo (blisters of 10 tablets)~All IV forms were identical in presentation, size and color to allow a double blind design.~All oral forms were identical in shape, size, color and taste to allow a double blind design."
3101335|NCT01882998|Experimental|Women-Extended Repeat Testing and Enhanced Counseling|Pregnant/breastfeeding women enrolled individually and randomized to the intervention arm will receive extended repeat HIV testing and enhanced counseling at the time of labor and delivery and throughout the lactation period at 3, 6, 12, 18 and 24 months postpartum or until cessation of breastfeeding, whichever occurs first.
3101415|NCT01882426|Active Comparator|Enhanced treatment algorithm|Treatment algorithm featuring the early use of combination therapy, treatment intensification guided by objective assessments of inflammation and the use of remission as a therapeutic goal
3101336|NCT01882998|Experimental|Couples-Extended Repeat Testing and Enhanced Counseling|Pregnant/breastfeeding women enrolled in couples with their male partners and randomized to the intervention arm will receive extended repeat HIV testing and enhanced counseling at the time of labor and delivery and throughout the lactation period at 3, 6, 12, 18 and 24 months postpartum or until cessation of breastfeeding, whichever occurs first.
3101337|NCT01882985|Experimental|Treatment (docetaxel and lycopene)|Patients receive docetaxel IV over 1 hour on day 2 and lycopene PO once daily on days 1-21. Treatment repeats every 21days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
3101338|NCT01882972|Experimental|Exercise|Exercise 12 week home-based resistance exercise training intervention. Participants will be coached to engage in resistance training 3 days per week and aerobic exercise for 30 minutes at least 5 days per week for 12 weeks.
3101339|NCT01882972|Placebo Comparator|control|Participants in the attention control arm will not be asked to cease activity they already participate in but will be instructed not to begin a new exercise program for 12 weeks. Participants will receive a meditation CD to use daily to account for the time intervention arm participants are engaged in exercise.
3101340|NCT01882959||Placebo|
3101341|NCT01882959||Intervention|Radiofrequncy Denervation
3101342|NCT01882946|Experimental|DCVax-Direct|DCVax-Direct: autologous, activated dendritic cells for intratumoral injection
3101343|NCT01882933|Experimental|Curative Gastrectomy + HIPEC|Curative gastrectomy with D1-D2 lymph node dissection + HIPEC with oxaliplatin
3101344|NCT01882933|Other|Curative Gastrectomy|Curative gastrectomy with D1-D2 lymph node dissection
3101345|NCT01882920|Experimental|Goal directed therapy intravenous restricitve fluid protocol|
3101346|NCT01882920|Active Comparator|Control arm|
3101347|NCT01882907|Experimental|vildagliptin|vildagliptin add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
3101348|NCT01882907|Active Comparator|pioglitazone|Pioglitazone add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
3101349|NCT01882894|Experimental|Custom PFO orthosis|This is a custom made orthosis
3101350|NCT01882894|Placebo Comparator|Faux foot orthosis|Foam insert without arch support
3101351|NCT01882881|Active Comparator|Healthy American Control Diet|
3101352|NCT01882881|Experimental|Dark Chocolate/Cocoa Diet|
3101353|NCT01882881|Experimental|Almond Diet|
3101354|NCT01882881|Experimental|Dark Chocolate/Cocoa + Almond Diet|
3101355|NCT01882868|Experimental|Aflibercept + FOLFIRI|Aflibercept 4 mg/kg intravenous (IV) infusion (1-2 hours) on Day 1 of Cycle 1 and every 2 weeks (q2w) thereafter, in combination with FOLFIRI regimen on Days 1-3 of Cycle 1 and q2w thereafter until disease progression (DP), unacceptable toxicity or participant's refusal. FOLFIRI regimen: IV infusions of levofolinate 200 mg/m^2 (2 hours) and irinotecan 180 mg/m^2 (90 minutes) simultaneously, followed by 5-FU 400 mg/m^2 IV bolus injection followed by continuous IV infusion of 5-FU (46 hours) at 2400 mg/m^2.
3101356|NCT01882842|Experimental|Endometrial biopsy arm|Participants randomised to this arm arm will undergo an endometrial biopsy procedure using Pipelle endometrial sampler (Pipelle de Cornier, Laboratoire CCD, Paris, France) or Wallace/ Wallach endometrial sampler as an alternative device on cycle day LH+7 to LH+9 of the cycle directly preceding commencement of down-regulation prior to IVF or ICSI treatment. A transvaginal ultrasound scan will be performed prior to the biopsy.
3101357|NCT01882842|No Intervention|Control group|Participants randomised to control group will undergo a transvaginal ultrasound scan on day LH+7 to LH+9 of the cycle directly preceding commencement of IVF/ICSI treatment.
3101358|NCT01882829|Experimental|Nuedexta (dextromethorphan/quinidine)|45/10 mg every 12 hours x 8 weeks
3101359|NCT01882816|Experimental|IMRT and doxorubicin|All patients will undergo radiation treatments using IMRT with concurrent low-dose radiosensitizing doxorubicin at 10 mg/m2 will be administered.
3101360|NCT01882803|Experimental|IPI-145|
3101361|NCT01882777|No Intervention|Existing water management and cooking practices|Households in the control arm continue following their existing drinking water management and cooking practices
3101362|NCT01882777|Active Comparator|Provision of water filters and improved cookstoves|Households in intervention arm are provided with drinking water filters and improved cook stoves
3101363|NCT01882764|Experimental|HMPL-004 1800 mg/day|HMPL-004 600 mg tablet given t.i.d.
3101364|NCT01882764|Placebo Comparator|Placebo|600 mg Placebo tablet given t.i.d.
3101365|NCT01882751||ConforMIS|Patients with ConforMIS implants
3101366|NCT01882751||Standard Total Knee Implant|Patients implanted with standard total knee implant
3101367|NCT01882725|Experimental|Erchonia HP Scanner (HPS)|The Erchonia HP Scanner (HPS) Laser contains 3 independent diodes mounted in scanner devices and positioned equidistant from each other and titled at a 30 degree angle. Each scanner emits 17 milliwatts (mW), 635 nm of red laser light.
3101368|NCT01882712|Experimental|CD07805/47 Gel 0.5%|active arm
3101369|NCT01882712|Placebo Comparator|CD07805/47 Gel Placebo|Comparator arm
3101370|NCT01882699|Experimental|Cereve sleep system|Cereve sleep system
3101371|NCT01882686|Experimental|Classification Based Cognitive Functional Therapy|
3101372|NCT01882673|Experimental|Brief Computer Motivational Interviewing for Smoking Cessation|Brief computer motivational interviewing intervention to motivate tobacco quitline use
3101373|NCT01882673|Active Comparator|Nutrition Control|Computer delivered nutrition education
3101374|NCT01882660|Experimental|Decitabine treatment|Treatment with decitabine
3101375|NCT01882647|Experimental|Active Arm|Topical lotion, applied twice daily
3101376|NCT01882647|Placebo Comparator|Vehicle Arm|Topical lotion, applied twice daily
3101377|NCT01882634|Experimental|Ultrasound arm|
3101378|NCT01882621|Active Comparator|Monosialoganglioside(GM1)|Monosialoganglioside(GM1)80mg + N.S 250ml,qd,D0-D3
3101379|NCT01882621|Placebo Comparator|normal saline|placebo 80mg + N.S 250ml,qd,D0-D3
3101380|NCT01882608|No Intervention|Treatment-as-usual|Treatment-as-usual, with no active intervention or follow-up. TAU patients will have readmission events monitored over the six-month interval by the study RA via periodic chart reviews and updates from their clinicians
3101416|NCT01882426|Placebo Comparator|Usual Care|These subjects will be managed according to local treatment guidelines for the treatment of UC.
3101381|NCT01882608|Experimental|Mental Health Telemetry (MHT)|Patients in the MHT group will be encouraged to provide daily symptom self-reports using MHT. MHT patients will also have readmission events monitored over the six-month interval by the study RA via periodic chart reviews and updates from their clinicians
3101382|NCT01882595|Experimental|Nebulization through the tracheostomy|Each subjects received two nebulization sessions. The first session was performed prior the tracheostomy removal (through the tracheostomy) and the second one when the when the tracheostome was totally scared (through the mouth)
3101383|NCT01882595|Active Comparator|Nebulization through the mouth|Each subjects received two nebulization sessions. The first session was performed prior the tracheostomy removal (through the tracheostomy) and the second one when the when the tracheostome was totally scared (through the mouth)
3101384|NCT01882569||Back surgery|
3101385|NCT01882556|Experimental|Botulinum Toxin - Type A (onabotulinumtoxinA)|Botulinum Toxin - Type A. One set of injections of up to 200 Units of Botox (Allergan). Injected to Biceps, Brachialis, Flexor Dig Superficialis, Flexor Dig Profundus, Flexor Carpi Radialis and Flexor Carpi Ulnaris.
3101386|NCT01882556|Placebo Comparator|0.9% NaCl Saline Injection|Saline - Injected to Biceps, Brachialis, Flexor Dig Superficialis, Flexor Dig Profundus, Flexor Carpi Radialis and Flexor Carpi Ulnaris.
3101387|NCT01882543|Experimental|AQX-1125|1 x AQX-1125 Capsule daily
3101388|NCT01882543|Placebo Comparator|Placebo|1 x placebo capsule daily
3101389|NCT01882530|Placebo Comparator|Control group C: Placebo|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
3101390|NCT01882530|Experimental|Group P: Paracetamol|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
3101391|NCT01882530|Experimental|Group N: Nefopam|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
3101392|NCT01882530|Experimental|Group K: Ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
3101393|NCT01882530|Experimental|Group PN: paracetamol and nefopam|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
3101394|NCT01882530|Experimental|Group PK: paracetamol and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
3101395|NCT01882530|Experimental|Group NK: nefopam and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
3101396|NCT01882530|Experimental|Group PNK: paracetamol, nefopam and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
3101397|NCT01882517|Active Comparator|Yogurt that contains plant stanol esters|Dietary Supplement: Yogurt that contains plant stanol esters
3101398|NCT01882517|Placebo Comparator|Placebo yogurt|Dietary Supplement: Placebo yogurt
3101399|NCT01882504|Experimental|gevokizumab|Solution for subcutaneous injection
3101400|NCT01882491|Placebo Comparator|Placebo|
3101401|NCT01882491|Experimental|gevokizumab|
3101402|NCT01882478||failure to respond to RF ablation|patients undergoing endoscopic RF ablation therapy with persistent BE with HGD or IMCA despite 2 or more serial RF ablation treatment sessions
3101403|NCT01882465|Other|etafilcon A/2-HEMA, EGDMA/hefilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
3101404|NCT01882465|Other|etafilcon A/hefilcon A/2-HEMA, EGDMA Non-ionic|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the hefilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
3101405|NCT01882465|Other|2-HEMA, EGDMA Non-ionic/etafilcon A/hefilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the etafilcon A lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
3101406|NCT01882465|Other|2-HEMA, EGDMA Non-ionic/hefilcon A/etafilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the hefilcon A lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
3101407|NCT01882465|Other|hefilcon A/2-HEMA, EGDMA Non-ionic/etafilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
3101408|NCT01882465|Other|hefilcon A/etafilcon A /2-HEMA, EGDMA Non-ionic|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the etafilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
3101409|NCT01882452|Experimental|Memory Specificity Training|Five weekly one-hour sessions of memory specificity training administered in groups of 5-8 participants.
3101410|NCT01882452|Active Comparator|Education and Support|Five weekly one-hour sessions of an education-and-discussion supportive intervention, administered in groups of 5-8 participants.
3101411|NCT01882439|Experimental|Treatment Sequence A|Tofacitinib 5 mg BID for 6 months
3101412|NCT01882439|Experimental|Treatment Sequence B|Tofacitinib 10 mg BID for 6 months
3101413|NCT01882439|Placebo Comparator|Treatment Sequence C|Placebo for 3 months then tofacitinib 5 mg BID for 3 months
3101414|NCT01882439|Placebo Comparator|Treatment Sequence D|Placebo for 3 months then tofacitinib 10 mg BID for 3 months
3101418|NCT01882400|Experimental|Bisphosphonate treatment|Add a weekly bisphosphonate to adequate doses of calcium and vitamin D supplements
3101419|NCT01882387|Experimental|TXA127, blood draws, physical exams|Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing allogeneic peripheral blood stem cell transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect. Treatment dose is 300 mcg/kg/day TXA127.
3101420|NCT01882374|Experimental|TXA127, blood draws, physical exams|Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of hematologic malignancies. Treatment dose is 300 mcg/kg/day TXA127.
3101421|NCT01882361|Active Comparator|injectable naltrexone|One dose of injectable extended release naltrexone (Vivitrol), 380mg dosage, given every four weeks in a 48-week trial.
3101422|NCT01882361|Placebo Comparator|placebo injection for naltrexone|placebo comparator injection starting at week 24 in a 48-week trial.
3101423|NCT01882348|No Intervention|Usual Care Control|"Control groups will receive equal number of contacts for training in preparation for enrollment and data collection for the study.~Clinicians will be given the option to receive a standard American Academy of Pediatrics tobacco control pamphlet to distribute.~Control groups have the option to receive access to the CEASE online module intervention at the conclusion of the research study which allows practitioners in this group to receive 26 continuing education credit hours."
3101424|NCT01882348|Experimental|Intervention|The Intervention Group will receive the CEASE Intervention
3101425|NCT01882335|Experimental|Behavioral|Peer support for mothers to encourage them to exclusively breastfeed their babies for 6 months
3101426|NCT01882335|No Intervention|Control|No peer support for exclusive breastfeeding
3101427|NCT01882322|Experimental|Advagraf conversion group|Oral
3101428|NCT01882322|Active Comparator|Prograf maintenance group|Oral
3101429|NCT01882296|Experimental|AGSPT_10|tablet, 10mg, QD, 7days
3101430|NCT01882296|Experimental|AGSPT_20|tablet, 20mg, QD, 7days
3101431|NCT01882296|Experimental|AGSPT_40|tablet, 20mg x 2, QD, 7days
3101432|NCT01882296|Active Comparator|Pantoprazole_20|tablet, 20mg, QD, 7days
3101433|NCT01882296|Active Comparator|Pantoprazole_40|tablet, 40mg, QD, 7days
3101434|NCT01882283|Experimental|Tea Treatment Group|5 cups brewed tea beverage per day for 28 days, brewed from 700 mg of black tea solids per cup
3101435|NCT01882283|Placebo Comparator|Placebo Group|5 cups tea-like placebo per day for 28 days. Placebo was exactly matched to tea except for flavonoid composition. Placebo was flavonoid-free.
3101436|NCT01882270||Mild Pericoronitis|Those with mild signs/symptoms of pericoronitis affecting at least one lower 3rd molar with adjacent 2nd molar will be monitored for 12 months following study entry or 3 months for those electing to have 3rd molar extraction.
3101437|NCT01882257|No Intervention|Normal sleep breathing|Home-based sleep studies indicate no obstructive sleep apnea or nocturnal hypoventilation. No intervention.
3101438|NCT01882257|Experimental|BiPAP -Auto for sleep apnea|Patients whose home-based sleep study detects obstructive sleep apnea, but no nocturnal hypoventilation. Noninvasive ventilatory support will be prescribed according to standard clinical criteria.
3101439|NCT01882257|Experimental|BiPAP (AVAPS) for nocturnal hypoventilation|Patients whose home-based sleep study detects nocturnal hypoventilation in the presence or absence of obstructive sleep apnea. Noninvasive ventilatory support will be prescribed according to standard clinical criteria. BiPAP/AVAPS (Phillips Respironics) is worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation.
3101440|NCT01882244|Experimental|Neural Pathfinder Training|Neural Pathfinder training (PATH) will involve 6-8 weeks of training sessions with a trainer (1-2 hour sessions, average of 1 session per week), up to 3 hours of telephone contact with the trainer (about 15 minutes per week), and approximately 20 hours of home practice). Some subjects will only receive the PATH intervention.
3101441|NCT01882244|Active Comparator|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of training sessions with a trainer (1-2 hour sessions, average of 1 session per week), up to 3 hours of telephone contact with the trainer (about 15 minutes per week), and approximately 20 hours of home practice). Some subjects will only receive the EDU intervention. Some subjects will receive both the PATH and EDU interventions.
3101442|NCT01882231|Other|DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI|Patients will have dynamic contrast-enhanced (DCE), diffusion-weighted (DW), magnetization transfer (MT), and chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) performed before and after 1 cycle of chemotherapy.
3101443|NCT01882218|Active Comparator|Standard treatment|Standard liver surgery and post-operative treatment
3101444|NCT01882218|Experimental|Galactose|Standard liver surgery with direct peritoneal resuscitation with galactose after surgery.
3101445|NCT01882205|Active Comparator|OLYMPUS CHROMO|Group A: HDTV Olympus colonoscopes and Chromo-endoscopy, methylene blue 0.1%
3101446|NCT01882205|Experimental|OLYMPUS NBI|Group B: Virtual chromoendoscopy: HDTV Olympus colonoscopes and Narrow band Imaging (NBI)
3101447|NCT01882205|Active Comparator|FUJINON CHROMO|Group C: CCD Fujinon colonoscopes and Chromo-endoscopy, methylene blue 0.1%
3101448|NCT01882205|Experimental|FUJINON FICE|Group D: Virtual chromoendoscopy: CCD Fujinon colonoscopes and Fujinon Intelligent Color Enhancement n° 4
3101449|NCT01882205|Active Comparator|PENTAX CHROMO|Group E: HD-Pentax colonoscopes and Chromo-endoscopy, methylene blue 0.1%
3101450|NCT01882205|Experimental|PENTX i-scan|Group F: Virtual chromoendoscopy: HD Pentax colonoscopes and I-scan 2 settings
3101451|NCT01882192|Experimental|Family physical activity planning|The intervention condition will receive the same guidelines as the comparison condition but will also be provided with family physical activity planning material.
3101452|NCT01882192|No Intervention|Control|The standard (comparison group) package will consist of Canada's family guide to physical activity guidelines recommending 60 minutes of activity a day in bouts as short as five to ten minutes for children and a breakdown of ways for the family to achieve this physical activity (structured, unstructured, endurance, strength, activities, less than 60 minutes of sustained sedentary activity, reduce screen viewing by 30 min per day) commensurate with this guide. This will include the new insert by CSEP. The guide also contains arguments and information about the benefits of physical activity.
3101454|NCT01882179|Active Comparator|Mineralocorticoid receptor antagonist|"1st dose (day 0) given i.v. (potassium-canrenoate), before primary PCI day 1 - 12 weeks: spironolactone 25mg daily, which is uptitrated to 50mg daily after 2 weeks, if possible~In case the LVEF <40% on baseline MRI and the patient shows signs of heart failure or is diabetic, the patient will receive open label eplerenone instead of the study drug, according to current guidelines."
3101455|NCT01882166|Experimental|fostimon|subcutaneous 150 IE Fostimon®. When leading follicles are > 17 mm ovulation will be induced by Ovitrelle® 500μg sc(hCG-injection). Ovum pick up (OPU) will be performed 32-36 hours later.
3101456|NCT01882166|Experimental|puregon|subcutaneous 150 IE Puregon®. When leading follicles are > 17 mm ovulation will be induced by Ovitrelle® 500μg sc(hCG-injection). Ovum pick up (OPU) will be performed 32-36 hours later.
3101457|NCT01882153|Experimental|Developmentally Based Intervention|
3101458|NCT01882153|Experimental|Behaviorally Based Intervention|
3101459|NCT01882140|Experimental|Study Group|Patients in the Study Group will receive daily treatment for 60 minutes. The treatment is initiated within 24 hours following surgery to achieve graft. Use of Electrical Stimulation by Capacitive Field was the only addition to the current standard of care of the Emergency Unit of HC-FMRP/USP. These Electrical Stimulation by Capacitive Field devices do not produce heat or cause any sensation in tissue. The equipment will produce an electrical stimulation of low intensity pulsed output (1.5 MHz, 1:4 duty cycles, 30mW). The electrodes consist of two metal plates (20x20cm) separated by an insulating material.
3101460|NCT01882140|Placebo Comparator|Control Group (Sham devices)|Patients in the control group (Sham group) will receive the same treatment but the device remains off. Use of Electrical Stimulation by Capacitive Field was the only addition to the current standard of care of the Emergency Unit of HC-FMRP/USP.
3101461|NCT01882127|Active Comparator|High dose-DEX|40 patients are enrolled to take dexamethasone orally at a dose of 40 mg daily for 4 days
3101462|NCT01882127|Experimental|ATRA & High dose-DEX|40 patients are enrolled to take Dexamethasone orally at 40mg a day for 4 days and all-trans retinoic acid at 10mg tablet every 8 hours a day for 12 consecutive weeks.
3101463|NCT01882101|Experimental|Posterior tibial nerve stimulation|
3101464|NCT01882101|Experimental|Biofeedback|
3101465|NCT01882088|Experimental|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
3101466|NCT01882075|Active Comparator|Open loop|fluid replacement (hydroxyethyl starch 130/0.4) is decided by the physicians according to continuous cardiac output measured by LidCO rapid device
3101467|NCT01882075|Experimental|Closed-loop|Fluid replacement is automated. An algorithm has been developed ; the input value is continuous cardiac output measured by LidCO rapid device; the computer steers iv infusion of hydroxyethyl starch 130/0.4.
3101468|NCT01882062|Experimental|Triheptanoin 1g/kg/day|All patients received Triheptanoin oil at 1g/kg/day during 1 month
3101469|NCT01882049|Experimental|Treatment|Use of Realize gastric band (Ethicon) in adolescents for weight reduction
3101470|NCT01882036|Active Comparator|Gastric Bypass w/ matched hypocaloric diet|
3101471|NCT01882036|Active Comparator|Hypocaloric Diet|
3101472|NCT01882023||Eating disorder|Patients currently in treatment for eating disorders
3101473|NCT01882023||Healthy Controls|Age- and gender matched healthy controls
3101474|NCT01882010|Sham Comparator|Controls|Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
3101475|NCT01882010|Placebo Comparator|PD Patients placebo|PD patients that receive placebo, have blood draw, physical exam and UPDRS part III assessment, MEG, Motion analysis.
3101476|NCT01882010|Experimental|PD Patients sargramostim|PD patients that receive Leukine, have blood draw, physical exam and UPDRS part III assessment, MEG, Motion analysis.
3101477|NCT01881997|Placebo Comparator|Normal Saline|IM normal saline
3101478|NCT01881997|Experimental|Fentanyl|IM Fentanyl
3101479|NCT01881984|Experimental|Ravicti|Open Label Study
3101480|NCT01881971|Placebo Comparator|Placebo|manufactured sugar pill to mimic rouvastatin once a day for 24 weeks
3101481|NCT01881971|Experimental|Rouvastatin calcium|Rouvastatin calcium once a day by mouth for 24 weeks.
3101482|NCT01881958|Experimental|DiaPep277®|
3101483|NCT01881945|Experimental|Physiological measurments|
3101484|NCT01881932|No Intervention|Standard Care|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). In standard care arm, patients will not receive additional therapy for CIPN. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels. All patients will follow the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed.
3101485|NCT01881932|Experimental|Acupuncture|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). The patients will be randomly assigned to receive acupuncture until the end of their chemotherapy. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels. All patients will follow the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed. In standard care arm, patients will not receive additional therapy for CIPN.
3101486|NCT01881932|Active Comparator|Sham Acupuncture|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). The patients will be randomly assigned to receive sham acupuncture until the end of their chemotherapy while following the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels.
3101487|NCT01881919|Experimental|Treatment|Daily intake of Quercetin supplement 500mg tablet for 28 days with meal (breakfast preferred.)
3101488|NCT01881919|Placebo Comparator|Placebo|Daily intake of Placebo (lactose) tablet for 28 days with meal (breakfast preferred)
3101599|NCT01881204|Experimental|Hesperidin|Subjects will consume 4 cookies containing Hesperidin, 552mg, daily
3101489|NCT01881906|Other|Control - usual care|"The patients randomized to the control group received no training but are offered the chance to participate in the supervised training after they have completed their antineoplastic treatment, at least after twelve weeks. Patients in early 2nd line treatment (switch maintenance) will be offered training after 12 weeks, although they have not completed chemotherapy."
3101490|NCT01881906|Other|Exercise + usual care|The supervised exercise training is carried out in groups of 12-16 patients and each session has a duration of 1.5 hours. The training comprised warm up exercises, strength and fitness training as well as stretching. Warm up exercises consisted of 10 minutes of light, stationery cycling, adjusted to 60-90% of the patient's maximum HR. The practical aim of strength training was to complete 3 series of 5-8 sets, with 70-90% of 1RM. Cardiovascular training was carried out as interval training on stationery bikes. Intensity was equivalent to 85-95% of each patient's maximum HR and lasted approximately 10-15 minutes. After the training session, 5-10 minutes were dedicated to stretching the large muscle groups in order to increase agility. Following each training session, progressive relaxation of 15-20 minutes was performed.
3101491|NCT01881893|No Intervention|Usual Care|Patients in this arm of the study will continue to receive their regular level of care.
3101492|NCT01881893|Experimental|ACHD-CARE Program|"Group based psychosocial intervention.~Educational: congenital heart disease information~Behavioral: cognitive behavioral therapy~Behavioral: social interactions and communication skills"
3101493|NCT01881880|Other|Tomosynthesis|Bilateral mammography with 4 views Tomosynthesis
3101494|NCT01881867|No Intervention|Cohort I (no therapy)|Patients receive no treatment (observation) after completion of standard sipuleucel-T therapy.
3101495|NCT01881867|Experimental|Cohort II (glycosylated recombinant human interleukin-7)|Patients receive glycosylated recombinant human interleukin-7 SC every week for 4 weeks (on days 0, 7, 14, and 21) beginning 3-7 days after completion of standard sipuleucel-T therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
3101496|NCT01881854||craniopharyngioma|Patients treated for craniopharyngioma, most of them on pituitary substitution therapy
3101497|NCT01881854||Healthy controls|matched for gender, age and BMI to the patients
3101498|NCT01881841|No Intervention|Treatment As Usual|Those randomized to Treatment as Usual (TAU) will not complete cMET but will receive standard treatment from the doctor.
3101499|NCT01881841|Experimental|cMET|Those randomized to cMET will complete a 2-session computerized Motivational Enhancement Therapy (cMET) intervention.
3101500|NCT01881828|Experimental|Metformin|Metformin 2000 mg per day
3101501|NCT01881828|Placebo Comparator|Oral Placebo|"A central pharmacy will compound a placebo to match the metformin tablets.~The placebo product will contain the following components:~Micosolle™, silica based excipient~Silicified Micro Crystalline Cellulose, National Formulary~Safflower Oil, United States Pharmacopeia~K-30 Povidone Powder~Magnesium Stearate, National Formulary (Vegetable source)~Fumed Silica, National Formulary"
3101502|NCT01881815||No treatment|No cohort as this study is not using a treatment or intervention only swabs are being collected.
3101503|NCT01881802||morphine or heroin dependence patients|
3101504|NCT01881802||normal control group|
3101505|NCT01881789|Experimental|Oprozomib, Lenalidomide and Dexamethasone (ORd)|Subjects will receive oprozomib administered orally, once daily on Days 1, 2, 8, 9, 15,16, 22 and 23 in combination with lenalidomide at a dose of 25 mg on Days 1-21, and dexamethasone at a dose of 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28-day cycles.
3101506|NCT01881789|Experimental|Oprozomib, Cyclophosphamide and Dexamethasone (OCyd)|Subjects will receive oprozomib administered orally, once daily on Days 1, 2, 8, 9, 15, 16, 22 and 23 in combination with oral cyclophosphamide at a dose of 300 mg/m2 on Days 1, 8, and 15, and dexamethasone at a dose of 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28-day cycles
3101507|NCT01881776|Active Comparator|Single ISB (SISB) group|Patients in this group received single injection (SISB) interscalene brachial plexus block
3101508|NCT01881776|Active Comparator|Continuous ISB (CISB) group|Patients in this group received continuous (CISB) interscalene brachial plexus block
3101509|NCT01881776|No Intervention|General anesthesia (GA) group|Patients in this group received general anesthesia (GA)
3101510|NCT01881763|Experimental|Ketamine|Participants will be randomized 1:1 to either Ketamine (experimental condition) or Methohexital anesthesia (active comparator)
3101511|NCT01881763|Active Comparator|Methohexital|Participants will be randomized 1:1 to either Ketamine (experimental condition) or Methohexital anesthesia (active comparator)
3101512|NCT01881750|Experimental|PRT|
3101513|NCT01881750|Placebo Comparator|PEG|
3101514|NCT01881737|Experimental|Pregnenolone|Pregnenolone up to 500 mg per day
3101515|NCT01881724|No Intervention|Usual Care|
3101516|NCT01881724|Experimental|sleep education program|
3101517|NCT01881711|Experimental|SCMP plus Imaging|SCMP plus Imaging will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery.
3101518|NCT01881711|Active Comparator|Imaging Alone|Imaging alone will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery.
3101519|NCT01881711|Experimental|SCMP Rule Out for Low Risk Cases|"SCMP results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Negative Predictive Value in ruling out shunt malfunction"
3101520|NCT01881711|Active Comparator|Imaging Rule for Low Risk Cases|"Imaging results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Negative Predictive Value in ruling out shunt malfunction"
3101553|NCT01881490|Active Comparator|Group 2|120 children with Crohn's disease undergoing colonoscopy will be recruited and will have an MRE/pelvic MRI performed. The two or three contending versions of each index (PICMI and pMEDIC) developed based on Group 1, will be then subjected to head-to-head evaluation of Group 2.
3101554|NCT01881477|Experimental|kinetics modalities|passive movements active movements assisted movements resisted movements
3101521|NCT01881711|Experimental|SCMP plus Imaging in Uncertain Cases|"SCMP plus imaging results in patients who are admitted for observation results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Positive and Negative Predictive Value"
3101522|NCT01881711|Active Comparator|Imaging alone in Uncertain Cases|"Imaging results in patients who are admitted for observation results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Positive and Negative Predictive Value"
3101523|NCT01881672||Coma patients in ICU under mechanical ventilation|
3101524|NCT01881659||Women attending cervical screening|Women aged 30-64 years who signed informed consent and comply with inclusion and exclusion criteria.
3101525|NCT01881646|Experimental|Positron emission tomography (PET)|Positron emission tomography (PET) using [11C]PBR28
3101526|NCT01881633|Experimental|ISU302|15 U/kg I.V. injection
3101527|NCT01881633|Experimental|ISU302 30 U/kg|Drug ISU302 I.V. injection
3101528|NCT01881633|Experimental|ISU302 60 U/kg|Drug ISU302 I.V. injection
3101529|NCT01881633|Placebo Comparator|Placebo|ISU302 Placebo I.V. injection
3101530|NCT01881620|Experimental|COMBI TEP : PET / enhanced CT scan|COMBI TEP : PET / enhanced CT scan
3101531|NCT01881607|No Intervention|Control|Schoolchildren aged 12-13 years in the first year of Compulsory Secondary Education (Enseñanza Secundaria Obligatoria in the Spanish educational system) in the city of Terrassa. The CONTROL arm is formed by schoolchildren in schools that willnot receive the intervention and will continue with ongoing (usual) health education sessions.
3101532|NCT01881607|Experimental|Intervention|"The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program."
3101533|NCT01881594|Active Comparator|No stimulation|unstimulated patients prior to surgery,ileostomy closure surgery without prior stimulation of efferent limb.
3101534|NCT01881594|Experimental|Stimulation|stimulation of the efferent limb of the ileostomy prior to ileostomy closure.
3101535|NCT01881581|Experimental|Lower dose DNA or Placebo|2.0 mL lower dose D-GPEi (0.5mg) or Saline solution at weeks 0
3101536|NCT01881581|Experimental|Medium dose DNA or Placebo|2.0 mL medium dose D-GPEi (2mg) or Saline solution at weeks 0
3101537|NCT01881581|Experimental|High dose DNA or Placebo|2.0 mL high dose D-GPEi (4mg) or Saline solution at weeks 0
3101538|NCT01881581|Experimental|Lower dose MVA or Placebo|100μL lower dose M-GPE (3×10^7pfu) or Saline solution at weeks 0
3101539|NCT01881581|Experimental|Medium dose MVA or Placebo|100μL medium dose M-GPE (1×10^8pfu) or Saline solution at weeks 0
3101540|NCT01881581|Experimental|High dose MVA or Placebo|300μL high dose M-GPE (3×10^8pfu) or Saline solution at weeks 0
3101541|NCT01881581|Experimental|Low dose DNA+MVA or Placebo control|The dose below the maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1; The dose below the maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
3101542|NCT01881581|Experimental|High dose DNA+MVA or Placebo control|The maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1;The maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
3101543|NCT01881568|Experimental|Experimental|"Topical administration of 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride) as follow:~50mL by irrigation before wound closure~50mL by intraarticular administration (Drenofast) after wound closure.~Intravenous administration of Normal saline (0.9% sodium chloride) as follow:~100mL before tourniquet realised~100mL 3 hours after surgery"
3101544|NCT01881568|Active Comparator|Comparator|"Topical administration of Normal saline (0.9% sodium chloride) as follow:~50mL by irrigation before wound closure~50mL by intraarticular administration (Drenofast) after wound closure~Intravenous administration of two dosis of Tranexamic Acid as follow:~15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), before tourniquet realised~15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), 3 hours after surgery"
3101545|NCT01881555|Other|FRACTIONAL FLOW RESERVE|"Patients will have FFR measured in each diseased vessel identified by the coronary angiographic evaluation. Intra-coronary adenosine (at least 100 micrograms performed 2 times) OR intravenous adenosine (at a dose of 140µg/kg/min during at least 4 minutes) will be administered prior to FFR assessment.~Revascularization strategy will be based upon FFR findings and revascularization either by coronary stenting or CABG will only be performed on target lesions with FFR≤0.8."
3101546|NCT01881555|Other|ANGIOGRAPHY|Patients undergo an angiography. Based on angiographic evaluation, the physicians define the revascularization strategy.
3101547|NCT01881529||Limited Scleroderma|
3101548|NCT01881529||Diffuse Scleroderma|
3101549|NCT01881516|Active Comparator|Acupuncture|Participants will receive 30-min sessions of true acupuncture per week after randomization for 6 weeks
3101550|NCT01881516|Sham Comparator|sham acupuncture|Participants will receive 30-min sessions of sham acupuncture per week after randomization for 6 weeks.
3101551|NCT01881503|Other|All subjects|all qualifying subjects will receive HBOC-201 (Hemopure) to treat their life-threatening anemia
3101552|NCT01881490|Active Comparator|Group 1|120 Children with Crohn's disease undergoing MRE & colonoscopy will be enrolled and followed for 18 months. MRE exam will be repeated at 18 months.
3101597|NCT01881217|Experimental|BAY1179470 (expansion)|Expansion cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
3101598|NCT01881204|Experimental|Hesperidin and Calcilock|Subjects will consume 4 cookies containing Hesperidin and Calcilock.
3101555|NCT01881464||endothelial dysfunction assessment|This study is a one arm study . In this arm we will assess endothelial function (with Endopath device) in patients with Crohn's disease, before and after treatment of anti TNF α and other medication, and evaluate the possible role of tumor necrosis factor (TNF)-α in the pathophysiology of this abnormality.
3101556|NCT01881438||Participants exposed to oral fluoroquinolones|Oral fluoroquinolones in this study are ciprofloxacin, levofloxacin, gatifloxacin, gemifloxacin, moxifloxacin, norfloxacin, and ofloxacin.
3101557|NCT01881425|Experimental|InnFocus MicroShunt|InnFocus MicroShunt
3101558|NCT01881425|Active Comparator|Trabeculectomy|glaucoma surgery to reduce IOP
3101559|NCT01881412|Experimental|Inhaled corticosteroid (fluticasone)|Child receives: 1) standardized asthma discharge instructions, and the intervention which is 2) inhaled corticosteroid prescription with accompanying instructions.
3101560|NCT01881412|Placebo Comparator|Routine Asthma Care|Child receives: 1) Standard Asthma Discharge Instructions. No intervention in this arm (placebo controlled)
3101561|NCT01881399|Experimental|Fluorescence/Virtual cholangiography/IOC|"Prior to cholecystectomy, patients will undergo:~Fluorescence cholangiography (visualization following up to a maximum of 0.5 mg/kg ICG - usually 10 ml of 0,5 mg/ml solution)~Virtual cholangiography (enhanced-reality) superimposed on fluorescence images~Conventional IOC (intraoperative cholangiography)"
3101562|NCT01881386||Lymphoma|Lymphoma patients before and after receiving standard CHOP therapy
3101563|NCT01881386||Metastatic Colorectal|Patients with metastatic colorectal cancer
3101564|NCT01881386||Phase 1|Patients enrolled in Phase 1 clinical trials of new agents, whose mechanism of action is expected to lead to changes in lactate concentration
3101565|NCT01881386||Brain|Patients with primary brain tumours and patients with cerebral lymphoma
3101566|NCT01881373|Experimental|CHL program|Multiple component environmentally focused intervention designed with a community engagement process.
3101567|NCT01881373|No Intervention|Comparison community|Comparison community that participated in community engagement process and will receive delayed optimized program.
3101568|NCT01881360|Experimental|Gluten-free diet|
3101569|NCT01881360|Active Comparator|Hypocaloric diet|
3101570|NCT01881347|Experimental|Active First|Active resveratrol first, placebo second
3101571|NCT01881347|Experimental|Placebo first|Placebo first, active resveratrol second
3101572|NCT01881321|Experimental|Group 1: Counseling Intervention|Contraceptive counseling session based on the principles of motivational interviewing
3101573|NCT01881321|No Intervention|Group 2: Usual Care|The standard clinic-based contraceptive counseling with no additional or theory-based contraceptive counseling session
3101574|NCT01881308|Active Comparator|Stable dose TNF inhibitor|Stable dose TNF inhibitor. Any co-medication with synthetic DMARDs kept stable.
3101575|NCT01881308|Experimental|Stepdown and withdrawal of TNF inhibitor|Half-dose of TNF inhibitor for the first four months, thereafter withdrawal of TNF inhibitor. Any co-medication with synthetic DMARDs kept stable.
3101576|NCT01881308|Active Comparator|Stable dose synthetic DMARD|Stable dose of synthetic DMARDs, either monotherapy or combination therapy.
3101577|NCT01881308|Experimental|Synthetic DMARD dose reduction|Half-dose synthetic DMARDs (monotherapy or combination therapy) for the first 12 months of the study. Patients classified as non-failures are re-randomized at 12 months to either continue half-dose synthetic DMARD(s) or withdraw all DMARD(s).
3101578|NCT01881308|Other|ARCTIC follow-up|Patients are treated according to the ARCTIC treatment schedule based on disease activity.
3101579|NCT01881295|Placebo Comparator|Placebo control|Subjects will consume tablets containing no potassium in addition to a basal diet containing 2336 mg potassium
3101580|NCT01881295|Experimental|Low dose potassium gluconate|Subjects will consume 720 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
3101581|NCT01881295|Experimental|Medium dose potassium gluconate|Subjects will consume 1440 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
3101582|NCT01881295|Experimental|High dose potassium gluconate|Subjects will consume 2160 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
3101583|NCT01881295|Experimental|Low dose potato|Subjects will consume 720 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
3101584|NCT01881295|Experimental|Medium dose potato|Subjects will consume 1440 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
3101585|NCT01881295|Experimental|High dose potato|Subjects will consume 2160 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
3101586|NCT01881295|Experimental|High dose French fries|Subjects will consume 2160 mg potassium in the form of french fries daily in addition to a basal diet containing 2336 mg potassium
3101587|NCT01881295|Experimental|Basal diet control|Subjects will consume a basal diet containing 2336 mg potassium daily
3101588|NCT01881282|Experimental|Carraghenates Cream|
3101589|NCT01881282|Active Comparator|Mayinglong Musk Hemorrhoid Ointment|
3101590|NCT01881269||No treatment|No treatment, prospective observational
3101591|NCT01881243||Adult patients resuscitated from cardiac arrest|
3101592|NCT01881230|Experimental|nab-Paclitaxel plus Gemcitabine|Treatment Arm A: nab-Paclitaxel 125 mg/m^2 by intravenous (IV) administration over 30 minutes, followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 of each 21-day cycle by IV administration over 30 minutes
3101593|NCT01881230|Experimental|nab-Paclitaxel plus Carboplatin|Treatment Arm B: nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin at an Area Under the Curve (AUC) of 2 on Days 1 and 8 of each 21-day cycle by IV administration
3101594|NCT01881230|Active Comparator|Gemcitabine plus Carboplatin|Treatment Arm C: Gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin AUC 2 on Days 1 and 8 of each 21-day cycle by IV administration
3101595|NCT01881217|Experimental|BAY1179470 (Dose escalation)|BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
3101596|NCT01881217|Experimental|BAY1179470 (additional)|Additional cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
3101751|NCT01880112|Active Comparator|2 gram dose|Pre-operative prophylactic dose of 2 grams of cefazolin
3101600|NCT01881204|Placebo Comparator|Control|Subjects will consume 4 cookies daily without Hesperidin or Calcilock.
3101601|NCT01881191||Aubagio MRI|Patients with relapsing-remitting multiple sclerosis who take Aubagio will have an MRI, eye test, blood drawn, and complete a questionnaire.
3101602|NCT01881191||Healthy controls|Subjects who are otherwise healthy, without neurological disorders will have an MRI, eye test, blood drawn, and complete a questionnaire.
3101603|NCT01881178|Active Comparator|Apricot|Supplement: Apricot Juice
3101604|NCT01881178|Experimental|Nopalea|Supplement: Nopalea
3101605|NCT01881165|Experimental|Cranberry|Each capsule contains 500 mg of cranberry powder at a concentration ratio of 36:1 (36 grams of cranberries equals 1 gram of concentrate).
3101606|NCT01881165|Placebo Comparator|Placebo|A capsule containing control formulation
3101607|NCT01881152|Experimental|Intervention|Educational campaign
3101608|NCT01881152|Other|Control|Usual care
3101609|NCT01881139|Experimental|experimental 1|men with exercise training for 3 months
3101610|NCT01881126|Active Comparator|bimatoprost 0.01% and hypromellose 0.3%|Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
3101611|NCT01881126|Active Comparator|travatan 0.004% and timolol 0.5%|Travatan 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
3101612|NCT01881113|Experimental|AC-170 0.24%|
3101613|NCT01881113|Placebo Comparator|AC-170 0%|
3101614|NCT01881100|Experimental|resin infiltration|The test group (41 children) had caries lesions treated with the infiltration technique using Icon (DMG, Hamburg, Germany) and fluoride varnish (Duraphat, Colgate Palmolive, Hamburg, Germany)at baseline evaluation. Fluoride varnish was applied every control visit every three months during 1 year.
3101615|NCT01881100|Active Comparator|fluoride varnish|The control group (40 children) had all tooth surfaces including WSL treated with fluoride varnish (Duraphat Colgate Palmolive, Hamburg, Germany)only at baseline evaluation and every control visit every three months during 1 year.
3101616|NCT01881087|Experimental|Levo-7.5 mg|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 7.5 mg. Single Dose.
3101617|NCT01881087|Experimental|Levo-9.37|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 9.37 mg. Single Dose.
3101618|NCT01881087|Active Comparator|Levo-11.25|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 11.25 mg. Single Dose.
3101619|NCT01881074||Triclosan containing toothpaste|Patients with type II diabetes will receive triclosan containing toothpaste and will be asked to brush their teeth using only this toothpaste for the duration of the study (12 months). Patients will be asked to return for an oral exam, dental cleaning and sample collection for up to 12 months following their baseline appointment.
3101620|NCT01881074||Non-triclosan containing toothpaste|Patients with type II diabetes will receive non-triclosan containing toothpaste and will be asked to brush their teeth using only this toothpaste for the duration of the study (12 months). Patients will be asked to return for an oral exam, dental cleaning and sample collection for up to 12 months following their baseline appointment.
3101621|NCT01881048|No Intervention|Arm I|Patients undergo observation.
3101622|NCT01881048|Experimental|Arm II (fish oil)|Patients receive omega-3 fatty acid by mouth everyday until the morning of surgery.
3101623|NCT01881048|Experimental|Arm III (celecoxib)|Patients receive celecoxib by mouth twice a day until the morning of surgery.
3101624|NCT01881035|Experimental|Renal nerve denervation|Renal nerve denervation
3101625|NCT01881022|Experimental|Psychosexual Intervention|The intervention will consist of 6 weekly sessions of couples psychosexual counseling delivered via videoconferencing.
3101626|NCT01881022|No Intervention|Wait-list Control|Participants in the wait-list control will not receive the intervention.
3101627|NCT01881009|Experimental|Overnight Closed Loop Control (OCL)|Overnight Closed Loop Control with Remote Monitoring using the ePID Algorithm on an Android Platform with Remote Monitoring
3101628|NCT01881009|No Intervention|Control Nights|Sensor augmented pump without OCL (overnight closed loop) or remote monitoring
3101629|NCT01880996|Experimental|Tai-chi/Qi-gong|30 gynecological cancer patients scheduled for the first or second line of chemotherapy treatment will be recruited for this study to receive Tai-chi/qigong treatment initiated at the beginning of chemotherapy therapy, once a week (45 min each), for 10 weeks.
3101630|NCT01880996|No Intervention|Usual Care|30 gynecological cancer patients scheduled for primary or secondary chemotherapy treatment, will be evaluated by the same measures as the intervention group.
3101631|NCT01880970|Active Comparator|Starter infant formula with pro and prebiotics|starter infant formula from enrollment till 6 months of age, followed by a commercially available Nestlé follow-up formula from 6 to 12 months of age
3101632|NCT01880970|Placebo Comparator|starter infant formula without pro and prebiotics|starter infant formula from enrollment till 6 months of age, followed by a commercially available Nestlé follow-up formula from 6 to 12 months of age
3101633|NCT01880970|No Intervention|Breastfeeding group|exclusively breastfeeding during the first 3 months of age, followed by a commercially available Nestlé starter infant formula from 4 to 6 months of age (if applicable) and the follow-up infant formula from 6 to 12 months of age
3101634|NCT01880957|Other|Lithium|Patients in this condition will receive lithium administered as follows: Day 1, 2 and 3, 300 mg bid; Days 4-7 lithium 300 qam and 600 qhs. Lithium level will be checked as close to Day 7 as possible and titrated to a therapeutic plasma level of 0.8-1.2 mEq/l. Subjects will not undergo lithium monotherapy if they have a documented history of at least two failed trials of lithium of at least 4 weeks duration with therapeutic blood levels for a major depressive episode
3101635|NCT01880957|Other|Lamotrigine|Patients who have not respond to adequate prior lithium treatment while depressed, or who refuse lithium, will be given lamotrigine. Lamotrigine will be started at 25 mg bid and increased to 50 mg bid after 2 weeks and again increased to 100 mg bid after an additional 2 weeks.
3101636|NCT01880944||ER-spine trauma|patients with spinal trauma, who initially visits in emergency room
3101637|NCT01880944||OUT-spine trauma|patients with spinal trauma, who initially visits in outpatient clinic
3101638|NCT01880931|Experimental|Normotensive patients|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
3101639|NCT01880931|Experimental|Hypertensive patients|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
3101640|NCT01880918||ColonRing|The ColonRing device is intended to be used for the creation of intestinal anastomoses in colorectal surgery in both open and laparoscopic surgeries. This indication is within the currently cleared indication of the ColonRing device, which has been cleared by the US FDA and carries the CE Mark for use throughout the alimentary trct for the creation of circular end-to-end, side-to-end or side-to-side anastomosis.
3101641|NCT01880905|Experimental|female undergoing gynecological surgery|
3101642|NCT01880892|Experimental|Post cricopharyngeal myotomy|There is only one arm to the study. This is patients who have undergone cricopharyngeal myotomy for Zenker's diverticulum. Their levels of laryngopharyngeal reflux will be measured using the Restech Dx-pH device.
3101643|NCT01880879|Experimental|helios stent|the group with helios stent implanted
3101644|NCT01880866|Experimental|(-)-Epicatechin|A single dose of 100mg or 200mg (-)-Epicatechin to be administered orally
3101645|NCT01880853|Experimental|group 1|screening with mammography alone
3101646|NCT01880853|Experimental|group 2|screening with ultrasonography alone
3101647|NCT01880853|Experimental|group 3|screening with both mammography and ultrasound
3101648|NCT01880840|Active Comparator|Astepro 0.15% Nasal Spray|Nasal Spray at a dosage of 1 spray per nostril twice daily
3101649|NCT01880840|Active Comparator|Astepro 0.1% Nasal Spray|Nasal Spray at a dosage of 1 spray per nostril twice daily
3101650|NCT01880827|Experimental|Royx-en-Y surgery|Blood flow after surgery
3101651|NCT01880827|Active Comparator|Control|Healthy volunteer group, GIP, GLP-1 and MMS studies
3101652|NCT01880827|Experimental|Sleeve gastrectomy|Blood flow after surgery
3101653|NCT01880814|Experimental|Cognitive Behavioral Therapy (CBT)|Type of talk therapy that focuses on individual behavioral and cognitive skills.
3101654|NCT01880814|Experimental|Caregiver-Child Treatment|Type of talk therapy that involves the child and the caregiver and focuses on behavioral and cognitive skills.
3101655|NCT01880788||CNV secondary to CSC|
3101656|NCT01880788||CSC without CNV|
3101657|NCT01880788||CNV secondary to advanced AMD|
3101658|NCT01880775|Experimental|prilocaine heavy 2%& fentanyl|prilocaine heavy 2% 30 mg and fentanyl 20 micgr ampoule intrathecal
3101659|NCT01880775|Active Comparator|bupivacaine heavy 0.5% & fentanyl|bupivacaine heavy 0.5% 7.5 mg and fentanyl 20 micg ampoule intrathecal
3101660|NCT01880749|Experimental|RAD001|RAD001 taken by mouth 10mg daily for 10 days before surgery
3101661|NCT01880736|Experimental|IDeg OD Flexible Dose|
3101662|NCT01880736|Experimental|IDeg OD Fixed Dose|
3101663|NCT01880736|Experimental|IDeg OD Simple|
3101664|NCT01880736|Experimental|IDeg OD Stepwise|
3101665|NCT01880723|Experimental|Albuterol|2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
3101666|NCT01880723|Placebo Comparator|Saline (healthy only)|nebulized 3 ml normal saline using a Power Neb2 nebulizer
3101667|NCT01880710|Active Comparator|Total hysterectomy|removal of the entire uterus including the cervix. open abdominal surgery. No specific procedures were asked of the surgeon. They were free to do the procedure the way they were used to doing it.
3101668|NCT01880710|Experimental|Subtotal Hysterectomy|removal of the uterine body only leaving the cervix in situ. The surgeon was free to do the procedure as he was used to. The only direction was that the cervical canal should be electrocoagulated.
3101669|NCT01880697|Experimental|TIVc (≥18 to ≤ 60 years) + TIVc (≥ 61 years)|Subjects in each age cohort received one dose of the cell-derived trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVc) formulation 2013/2014 Northern Hemisphere
3101670|NCT01880684||Passive Leg Rising|
3101671|NCT01880671|Experimental|Migraine Medical Device|
3101672|NCT01880671|Placebo Comparator|Inactive Migraine Medical Device|
3101673|NCT01880658|Experimental|Capecitabine|Patients undergo R0-R1 resection and receive adjuvant chemotherapy FOLFOX or Capox for no less than 4 months. Radiotherapy may be applied for patients with rectal cancer if clinicians suspect that is necessary. Then patients receive oral capecitabine for 12 months maintenance.
3101674|NCT01880645|Other|Ultrasound + Breast Surgery + Lymph Node Removal|Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s). If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected. Standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction) performed.
3101675|NCT01880632|Experimental|XELOX|Clinically diagnosed stage T2-3/N+M0,orT4aN+M0 according to CT/MRI scan, and resectable
3101676|NCT01880619|Placebo Comparator|Group A|Patients in this group will receive placebo
3101677|NCT01880619|Active Comparator|Group B|Patients in this group will receive Tamsulosin
3101678|NCT01880619|Active Comparator|Group C|Patients in this group will receive Solifenacin
3101679|NCT01880606||patients with PSC-IBD|Only patients, colonoscopy with endomicroscopy
3101680|NCT01880593|Experimental|Ketamine and Lithium|Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study
3101681|NCT01880593|Placebo Comparator|Ketamine and Placebo|Subjects in this arm take placebo pills at night for duration of the study.
3101682|NCT01880580||Normal Group|In Group I, up to 100 women, at least 40 years of age, who have had a routine standard mammogram read as BI-RADS® 0, 1, 2, or 3 will also undergo 3D breast imaging using a cone beam CT scanner specifically designed to image the breast. Of these 100, we hope to enroll at least 30 subjects with mammograms read as BI-RADS® 0 and at least 30 read as BI-RADS® 3. The BI-RADS® 0 category refers to patients for whom additional imaging is required after a screening mammogram provided incomplete diagnostic information.
3101715|NCT01880346|Active Comparator|100,000 IU D-50 powder|Vitamin D oil vs powder. 100,000 IU powder form of vitamin D, assessment of D3 absorption. One Dose of vitamin D powder format administered. Absorption rate monitored over 72 hour period
3101752|NCT01880099|Placebo Comparator|placebo|Placebo (sugar Pill) will be given daily for 7 weeks.
3101683|NCT01880580||Diagnostic Group|The goals of Group II will be to compare the CBCT study with standard imaging for the diagnosis of breast disease in palpable or non-palpable breast lesions (having a BI-RADS® score of 4 or 5). Forty (40) women, who have had abnormalities detected by physical exam or an imaging modality and are also scheduled for breast biopsy of the index lesion, will also undergo a CBCT of the breast(s), prior to biopsy.
3101684|NCT01880567|Experimental|Relapsed and/or Refractory MCL|"Ibrutinib administered orally at 560 mg daily for 28 days (one cycle) up to Cycle 9. Starting at Cycle 10, a 2-month supply of Ibrutinib dispensed every other cycle. Starting in Cycle 24, a 4-month supply of Ibrutinib dispensed every 4 cycles.~Rituximab given Cycle 1 Days 1, 8, 15 and 22 +/- 1 day by vein at a fixed dose of 375 mg/m2 (Cycle 1), followed by Rituximab on Day 1 of every cycle starting in Cycles 3 - 8. Following Cycle 8 Rituximab given on Day 1 of every other cycle for up to 2 years. After 2 years, patients treated with Ibrutinib in continuous cycles until progression of disease or unacceptable toxicity."
3101685|NCT01880567|Experimental|Newly-Diagnosed Untreated MCL Over 65|"Ibrutinib administered orally at 560 mg daily for 28 days (one cycle) up to Cycle 9. Starting at Cycle 10, a 2- month supply of Ibrutinib dispensed every other cycle up to 2 years or until progressive disease (PD) or intolerance. Starting in Cycle 24, a 4-month supply of Ibrutinib dispensed every 4 cycles.~Rituximab given Days 1, 8, 15 and 22 +/- 1 day by vein at a fixed dose of 375 mg/m2 (Cycle 1, followed by Rituximab on Day 1 of every cycle starting in Cycles 3 - 8. Following Cycle 8 Rituximab given on Day 1 of every other cycle for up to 2 years. After 2 years, patients treated with Ibrutinib in continuous cycles until progression of disease or unacceptable toxicity."
3101686|NCT01880554|Other|Contrast-enhanced intraoperative ultrasound|Contrast-enhanced intraoperative ultrasound
3101687|NCT01880541|Experimental|hypnosedation|hypnosedation
3101688|NCT01880541|Other|general anesthesia|general anesthesia
3101689|NCT01880528|Experimental|Arm I (lisinopril)|Beginning within 7 days of beginning radiation therapy, patients receive lisinopril PO QD on days 1-7.
3101690|NCT01880528|Placebo Comparator|Arm II (placebo)|Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD on days 1-7.
3101691|NCT01880515|Experimental|Tetracycline|Patients will receive tetracycline 250mg every 12 hours for 1 month plus general dermatological recommendations (sunscreen and emollient cream)
3101692|NCT01880515|No Intervention|No Tetracycline|This arm only with general dermatologic recommendations. Patients in this arm can receive tetracycline after week 4 of assessment only if rash grade 3-4 occur
3101693|NCT01880502|Experimental|Belviq 10mg|
3101694|NCT01880502|Experimental|Belviq 20mg|
3101695|NCT01880502|Placebo Comparator|Placebo|
3101696|NCT01880489|Experimental|MI + CBST Intervention|Seven sessions of Motivational Interviewing and Cognitive Behavioral Skills Training
3101697|NCT01880489|No Intervention|Wait List Control Condition|
3101698|NCT01880476|Experimental|Home visits and group program|
3101699|NCT01880463|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
3101700|NCT01880463|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
3101701|NCT01880463|Placebo Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~fish oil placebo"
3101702|NCT01880463|Active Comparator|Vitamin D + fish oil|"Vitamin D (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
3101703|NCT01880450|Experimental|Project Prepared|
3101704|NCT01880450|Active Comparator|TEEN-Teen Education & Employment Network|
3101705|NCT01880437|Experimental|Vismodegib|
3101706|NCT01880424|Placebo Comparator|controlled arm|
3101707|NCT01880424|Experimental|treatment arm|
3101708|NCT01880411|Experimental|PEK Fusion Protein Vaccine|PEK Fusion Protein Vaccine Injection 0.1mg, 0.3mg and 1.2mg One injection at one week intervals
3101709|NCT01880398||Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
3101710|NCT01880385|Experimental|bevacizumab, inflammatory breast cancer|Neoadjuvant therapy associating bevacizumab, cyclophosphamide, fluorouracil and epirubicin hydrochloride q3w, 4 cycles Adjuvant therapy by docetaxel q3w, 4 cycles +/- trastuzumab q3w, 18 cycles if tumors overexpress HER2
3101711|NCT01880372|Experimental|Alpha Lipoic Acid Assignment Group|Alpha lipoic acid assignment group will follow routine care and receive 600 mg oral administration of lipoic acid daily.
3101712|NCT01880372|No Intervention|Alpha Lipoic Acid Control Group|The control group will follow routine care alone.
3101713|NCT01880359|Placebo Comparator|Radiotherapy+ Cisplatin+ Placebo|Accelerated radiotherapy (Therapeutic Planning Target Volume (PTV): 70 Gray (Gy), 6 fractions/week, 35 fractions of 2 Gy, prophylactic PTV: 54.25 Gy, 6 fractions/week, 35 fractions of 1.55 Gy) + concomitant cisplatin (weekly schedule of 40mg/m2 (delivered on day 1, 8, 15, 22, 29) Patients will receive placebo (1.2 g/m2) 90 min (+/- 30 min) prior to each radiotherapy fraction but no more than 5 times a week (If the 6th radiotherapy fraction in a week is given on a separate day from the 5th fraction of radiotherapy, no nimorazole/placebo dose is received that day. If the 6th fraction of radiotherapy is given on the same day as the 5th fraction, nimorazole/placebo is given 90 minutes before the 5th radiotherapy fraction, only).
3101714|NCT01880359|Experimental|Radiotherapy+ Cisplatin+ Nimorazole|"Accelerated radiotherapy (Therapeutic PTV: 70 Gy, 6 fractions/week, 35 fractions of 2 Gy, prophylactic PTV: 54.25 Gy, 6 fractions/week, 35 fractions of 1.55 Gy) + concomitant cisplatin (weekly schedule of 40mg/m2 (delivered on day 1, 8, 15, 22, 29) .~Patients will receive nimorazole (1.2 g/m2) 90 min (+/- 30 min) prior to each radiotherapy fraction but no more than 5 times a week (If the 6th radiotherapy fraction in a week is given on a separate day from the 5th fraction of radiotherapy, no nimorazole/placebo dose is received that day. If the 6th fraction of radiotherapy is given on the same day as the 5th fraction, nimorazole/placebo is given 90 minutes before the 5th radiotherapy fraction, only)."
3101750|NCT01880112|Experimental|4 gram dose|Pre-operative prophylactic dose of 4 grams of cefazolin
3101716|NCT01880346|Active Comparator|100,000 IU Maximum D3 in oil|Vitamin D oil vs powder. One Dose of 100,000 IU vitamin D oil format administered. Absorption rate monitored over 72 hour period
3101717|NCT01880333|Experimental|Children on Modified Atkin Diet|
3101718|NCT01880320|Experimental|CD0271 0.3% /CD1579 2.5% Gel|active arm
3101719|NCT01880320|Active Comparator|CD0271 0.1% / CD1579 2.5%|Comparator arm
3101720|NCT01880320|Placebo Comparator|Topical Gel Vehicle|Placebo arm
3101721|NCT01880307|Experimental|Top-down|Infliximab and azathioprine; patients will receive 5 infliximab infusions of 5 mg/kg (IFX induction at week 0, 2 and 6, followed by 2 maintenance infusions every 8 weeks). IFX will be discontinued after 5 IFX infusions. Patients will also receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
3101722|NCT01880307|Active Comparator|Step-up|Prednisolon and azathioprine; Patients will receive induction treatment with oral prednisolone 1 mg/kg (maximum 40 mg) once daily for 4 weeks, then tapering of prednisolone in 6 weeks until stop, and receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
3101723|NCT01880294||Asian participants with chronic constipation|Asian participants diagnosed with chronic constipation using Asian Neurogastro-enterology and Motility Association (ANMA) diagnostic questionnaire.
3101724|NCT01880281|Active Comparator|Meat diet without any vegetables or fruits|"The volunteers will follow a diet of 3 days with at least 400g of meat per day. The 3rd day, the volunteers will do a collect of 24-hour urine.~The investigational's day, they will receive 50meq of ammonium chlorid over a period of one hour in order to avoid the effect of nausea."
3101725|NCT01880281|Active Comparator|Vegetarian diet without any sources of protein|"The volunteers will follow a diet of 3 days with at least 600g of fruits and vegetables per day without any proteins (animal or vegetal like soybean). The 3rd day, the volunteers will do a collect of 24-hour urine.~The investigational's day, they will receive 1g of bicarbonate."
3101726|NCT01880268|Experimental|BCI-then-Standard Rehab Group (Group A)|Participants will take 8 weeks of BCI rehabilitation first (3 rehabilitation sessions each week, a total of 24 sessions); participants receive 100 minutes of standard rehabilitation and 20 minutes BCI rehabilitation training using BCI-controlled neurorehabilitation device during each session. After finishing 8 weeks of BCI rehabilitation, participants will take 3 standard rehabilitation therapy sessions (for 2 hours) each week for 8 weeks (a total of 24 sessions)
3101727|NCT01880268|Experimental|Standard-then-BCI Rehab Group (Group B)|Participants will take 8 weeks of standard rehabilitation therapy first (3 sessions per week, 2 hours for each session, a total of 24 sessions). After that, participants will take 8 weeks of BCI rehabilitation (3 rehabilitation sessions each week, a total of 24 sessions); participants receive 100 minutes of standard rehabilitation and 20 minutes BCI rehabilitation training using BCI-controlled neurorehabilitation device during each session.
3101728|NCT01880255|Active Comparator|Active rTMS|"Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 25 stimulation trains of 30 stimuli each (i.e., 750 stimuli) and an intertrain interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right dorsolateral prefrontal cortex (DLPFC). The order of bilateral stimulation (i.e. right then left or left then right) will be held constant for all 20 treatments.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
3101729|NCT01880255|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
3101730|NCT01880242||Orsiro DES|"Subjects requiring coronary revascularization with Drug Eluting Stents (DES). subgroups: Subjects presenting with~Diabetes (all types)~Small vessels (≤2.75 mm)~Chronic total occlusion (CTO)~Acute Myocardial Infarction (incl. STEMI and NSTEMI)"
3101731|NCT01880229||non-frail|Categorized as non-frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
3101732|NCT01880229||pre-frail|Categorized as pre-frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
3101733|NCT01880229||frial|Categorized as frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
3101734|NCT01880216|Active Comparator|Enoxaparin sodium|subcutaneous for 7±2 days and starting on Day 2 additionally the oral anticoagulant warfarin
3101735|NCT01880216|Experimental|Bemiprin sodium|Bemiparin sodium (LMWH) s.c. for 7±2 days and starting on Day 2 additionally the oral anticoagulant warfarin
3101736|NCT01880203|Experimental|aspiration for Molecular Cytogenetic Analysis.|
3101737|NCT01880190|Active Comparator|Ringer's Lactate|Crystalloid solution
3101738|NCT01880190|Active Comparator|HES 130/0.4 and Ringer's Lactate|Colloid solution
3101739|NCT01880177||Current smokers|Current smokers (>10 pk yrs.)
3101740|NCT01880177||Ex-smokers|Ex-smokers with a history of >10 pk yrs
3101741|NCT01880177||Never-smokers|Never-smokers, defined as ≤100 cigarettes/pipes/cigars over life
3101742|NCT01880164||Nonoperative|Adult spinal deformity (degenerative or idiopathic) with an ODI of 30 or greater
3101743|NCT01880151|Experimental|Prodromal AD|Presence of memory impairment Absence of impairment in activities of daily life EEG
3101744|NCT01880151|Experimental|Mild AD dementia|Presence of memory impairment Presence of impairment in activities of daily life EEG
3101745|NCT01880151|Experimental|Healthy control group|Absence of memory impairment Absence of impairment in activities of daily life Absence of known neurological conditions EEG
3101746|NCT01880138|Experimental|watching animated cartoon|
3101747|NCT01880138|Placebo Comparator|not watching animated cartoon|
3101748|NCT01880125|Other|Group A|Period 1: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state
3101749|NCT01880125|Other|Group B|Period 1: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state
3101753|NCT01880099|Active Comparator|galantamine 8mg|Galantamine extended release (8mg) will be given daily for 7 weeks.
3101754|NCT01880099|Active Comparator|Galantamine 16mg|Galantamine extended release (16mg) will be given daily for 5 weeks starting at week 3 after a two week titration with 8mg galantamine.
3101755|NCT01880086|Experimental|Clomiphene citrate|The initial dose of clomiphene citrate will be 25 mg (po, pill by mouth) every other day. This will be started at visit 2, week 0 of the study following diagnosis of low baseline testosterone (serum total testosterone <350 ng/dl in men <55 years, <300 ng/dl in men 55-65 years). Clomiphene citrate dose will be titrated up to a maximum of 50 mg daily according to serum total testosterone levels measured at follow-up visits during the 3 month duration of the study.
3101756|NCT01880086|Placebo Comparator|Placebo|Placebo pill will be administered (po, pill by mouth) every other day starting at week 0 of the study in men diagnosed with low testosterone. Treatment will be delayed in these men until the 3 month completion of the study, at which time this group may also receive testosterone replacement therapy.
3101757|NCT01880073|Experimental|FemVue device|FemVue would be used in conjunction with the laparoscopic chromopertubation to determine if it is as effective.
3101758|NCT01880060|Experimental|INCENT weight loss program|INCENT: The INCENT intervention is an internet-delivered weight loss program with periodic financial incentives for weight loss. INCENT participants receive daily e-mail support with nutritional and physical activity suggestions to enhance weight loss. Monetary incentives are earned on a quarterly basis for weight loss and participants receive monthly checks that reflect the percent weight loss. A regularly calibrated scale with a built in digital camera captures an image of the participant during a weigh-in, and is used to objectively obtain weight data from participants at each quarterly weigh-in.
3101759|NCT01880060|Experimental|Livin My Weigh|Livin My Weigh: The Livin My Weigh (LMW) intervention is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
3101760|NCT01880047|Active Comparator|Eltrombopag|Subjects in the study will receive 75 mg eltrombopag and then be randomized to receive either an additional 25 mg of eltrombopag or matching placebo tablet dispensed by the research pharmacy. Subjects and investigators will be blinded to randomization. Randomization will be stratified according to splenectomy status. Randomization will be performed at the time of informed consent with a computer generated randomization table. Subjects and investigators will be blinded to assignment and treatment in this phase.
3101761|NCT01880047|Placebo Comparator|Placebo|Subjects will be randomly allocated in a two to one ratio to receive treatment or placebo. All subjects in the study will receive 75 mg eltrombopag and then be randomized to receive either an additional 25 mg of eltrombopag or matching placebo tablet dispensed by the research pharmacy. Subjects and investigators will be blinded to randomization. Randomization will be stratified according to splenectomy status.
3101762|NCT01880034||Regional Anesthesia Section Heads|This group will consist of Regional Anesthesia Section Heads at anesthesia residency training programs.
3101763|NCT01880008||Treatment|All patients included in this study were treated with temozolomide and radiotherapy after subtotal resection of a WHO grade III or IV glioma.
3101764|NCT01879982||Wellness Wearable System & Smartphone|
3101765|NCT01879969|Experimental|asymmetric patients, classic procedure|random selected
3101766|NCT01879969|Experimental|asymmetric patients, computer assisted|random selected
3101767|NCT01879956|Active Comparator|OGI Method|- experimental group: use the OGI method to improve the executive functioning of patients with refractory schizophrenia.
3101768|NCT01879956|Placebo Comparator|craft activities|- control group: use of craft activities, attend the same-number of sessions, but without the intervention of therapists.
3101769|NCT01879943|Experimental|PillCam COLON 2 and Standard Colonoscopy|"Patients will have videocapsule colonoscopy after bowel preparation, followed by standard colonoscopy the next day.~Interventions:~Device: PillCam COLON 2 on D0~Procedure: Standard colonoscopy on D1"
3101770|NCT01879930|Active Comparator|doxycycline|Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL
3101771|NCT01879930|Placebo Comparator|placebo|Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland
3101772|NCT01879917|Active Comparator|Liraglutide|1.8 mg
3101773|NCT01879917|Placebo Comparator|Saline|
3101774|NCT01879904|Experimental|Endoscopic submucosal dissection (ESD)|Endoscopic submucosal dissection (ESD)
3101775|NCT01879891|Other|Non-Biopsy|"The Non-Biopsy group will complete a VO2 maximum test, are provided food 2 days prior to assessments, exercise in the metabolic chamber, have a Resting Energy Expenditure test, complete a DEXA and have blood drawn. This group will stay overnight in the metabolic chamber and have the clamp procedure. Exercise training is exactly the same for both groups.~Those who select the Non-Biopsy group, in lieu of the biopsy test, will complete an Activities of Daily Living (ADL) test that involves sub-maximal VO2 assessment. The participants will also be asked to where an accelerometer home for 4 consecutive days after the ADL test."
3101776|NCT01879891|Other|Biopsy|The Biopsy group will also complete a VO2 maximum test, are provided food 2 days prior to assessments, exercise in the metabolic chamber, have a Resting Energy Expenditure test, complete a DEXA and have blood drawn. As with the Non-Biopsy group, this group will stay overnight in the metabolic chamber and have the clamp procedure. Exercise training is exactly the same for both groups. One week following the overnight metabolic chamber visit, participants in this group will undergo a muscle biopsy. This group will not complete the Activities of Daily Living (ADL) test nor will they be asked to wear an accelerometer.
3101777|NCT01879878|Experimental|Verum, broccoli sprout grain|Active sulforaphane distributed in capsules each containing broccoli sprout grain
3101778|NCT01879878|Placebo Comparator|Placebo|Inactive substances (methylcellulose) with identical capsule and portion distribution
3101779|NCT01879865|Other|Non-stimulation|No auditory stimulation during dexmedetomidine infusion and recovery.
3101780|NCT01879865|Other|Stimulation|Auditory stimulation during dexmedetomidine infusion and recovery.
3101781|NCT01879852|Active Comparator|Standard Rehabilitation|Standard meniscectomy rehabilitation including knee range of motion and strengthening exercises.
3101782|NCT01879852|Experimental|Standard Rehabilitation + Quadriceps intensive strengthening|The intervention includes high-intensity neuromuscular electrical stimulation and eccentric exercises for the quadriceps muscle in addition to the standard rehabilitation protocol.
3101783|NCT01879839|No Intervention|Control Group|Patients who don't follow a special diet.
3101784|NCT01879839|Other|Diet Group|Patients who subsist on a special diet.
3101785|NCT01879826|Sham Comparator|Aculaser applied to sham points|"The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure."
3101786|NCT01879826|Experimental|Aculaser applied to kidney points|The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
3101787|NCT01879813|Active Comparator|Phospholipid drink|Participants will consume a phospholipid drink daily for 6 weeks
3101788|NCT01879813|Placebo Comparator|Placebo milk drink|Participants will consume a placebo drink (no added phospholipids) daily for 6 weeks
3101789|NCT01879800|No Intervention|Treatment As Usual/Waitlist|Treatment As Usual/Waitlist
3101790|NCT01879800|Experimental|Acceptance and Commitment Therapy plus Illness Management|Acceptance and Commitment Training plus Illness Management (ACT-IM) Patients in the ACT-IM group will attend a 1-day group workshop. Three broad areas will be covered: 1) Illness Management will cover the importance of physical and psychological self-care for the management of co-morbid depression/anxiety and vascular problems 2) Behavioral Change Training will involve i) teaching patients how to recognize ineffective patterns of behavior and habits, ii) exploring and setting life goals and those related to mental and physical health, and iii) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 3) Mindfulness and Acceptance Training will emphasize new ways of managing troubling thoughts, feelings, and physical sensations .
3101791|NCT01879787|Experimental|physiotherapy + anodal tDCS + mCIMT|Before a anodal tDCS with duration of 13 minutes and intensity of 1mA applied at the injured motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
3101792|NCT01879787|Experimental|Physiotherapy + cathodal tDCS + mCIMT|Before a cathodal tDCS with duration of 9 minutes and intensity of 1mA applied at the healthy motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
3101793|NCT01879787|Experimental|Physiotherapy+bi-hemispheric tDCS+mCIMT|Before a bi-hemispheric tDCS with duration of 13 minutes and intensity of 1mA applied at the healthy (cathode) and injured (anode) motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
3101794|NCT01879787|Sham Comparator|Physiotherapy+sham tDCS+mCIMT|Before a sham tDCS with duration of 30 seconds and intensity of 1mA applied at the injured motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
3101795|NCT01879787|Experimental|Physiotherapy+tDCS+mental practice|Before a tDCS protocol applied during de mental practice training , the patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
3101796|NCT01879787|Sham Comparator|Physiotherapy+sham tDCS+mental practice|Before a sham tDCS protocol applied during the mental practice training, the patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
3101797|NCT01879787|No Intervention|Physiotherapy|The patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
3101798|NCT01879774|Other|Neuropsychological and motoric tests|Neuropsychological and motoric tests are conducted.
3101799|NCT01879761||Immunosuppressed|"Immunosuppressed includes patients with any one of the following:~a diagnosis of a hematological malignancy~a diagnosis of HIV~myelosuppressive chemotherapy in the previous 90 days~immune-modulating medications in the previous 90 days"
3101800|NCT01879761||Non-Immunosuppressed|Subject does not fit immunosuppressed criteria
3101801|NCT01879748|Experimental|Rasagiline|Rasagiline mesylate oral tablets (AZILECT®) are provided at dose strengths of 0.5 and 1 mg (based on rasagiline base). Rasagiline oral tablets will be dispensed for 10 consecutive days of treatment. The oral dose will be administered each day with 240 mL water at room temperature after an overnight fast of at least 10 hours.
3101802|NCT01879748|Placebo Comparator|Placebo|Placebo tablets match in size and appearance to rasagiline tablets for each dose strength. Placebo tablets will be dispensed for 10 consecutive days of treatment. The oral dose will be administered each day with 240 mL water at room temperature after an overnight fast of at least 10 hours.
3101803|NCT01879735|Experimental|ICG's effect on 11C-CSar transport|"Examine the effect of ICG on the kinetics of the hepatic transport of 11C-CSar. If no effect is seen on the kinetics, ICG will be used during the infusion method experiments."
3101804|NCT01879735|Experimental|Infusion method|Determine wether bolus or constant infusion of 11C-CSar is optimal for the PET/CT scanning. If ICG does not affect the kinetics of 11C-CSar it will be used during these experiments to calculate hepatic blood flow.
3101805|NCT01879722|Experimental|TAK-063 3 mg|TAK-063 3 mg, tablets, orally, once daily for 7 days.
3101806|NCT01879722|Experimental|TAK-063 10 mg|TAK-063 10 mg, tablets, orally, once daily for 7 days.
3101807|NCT01879722|Experimental|TAK-063 20 mg|TAK-063 20 mg, tablets, orally, once daily for 7 days.
3101808|NCT01879722|Experimental|TAK-063 30 mg|TAK-063 30 mg, tablets, orally, once daily for 7 days.
3101809|NCT01879722|Experimental|TAK-063 100 mg|TAK-063 100 mg, tablets, orally, once daily for 7 days.
3101810|NCT01879722|Placebo Comparator|Placebo|Placebo matching TAK-063, tablets, orally, once daily for 7 days.
3101811|NCT01879709|Experimental|Yoga Training Group|Yoga Training: Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols).
3101812|NCT01879709|Placebo Comparator|Treatment as Usual Group|Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided
3101813|NCT01879709|Active Comparator|Physical Exercise Group|Physical Exercise: This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises.
3101814|NCT01879696|Experimental|Treatment|Treatment are subjects will have catheter vacuum active for the removal of fluid from the muscle compartment.
3101815|NCT01879696|No Intervention|Control|Treatment are subjects will have catheter vacuum in-active for the removal of fluid from the muscle compartment.
3101816|NCT01879683|Experimental|LiRIS® 400 mg|LiRIS® 400 mg (Lidocaine Releasing Intravesical System 400 mg); a drug-device combination product, placed in the urinary bladder, and releases lidocaine into the bladder over a 14 day period.
3101817|NCT01879670||Synergy|Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team for implantation of a CircuLite Synergy left ventricular assist device.
3101818|NCT01879670||Control|Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team to continue current optimal medical and device therapy.
3101819|NCT01879657|Experimental|68Ga-DOTATATE PET scans|"Will perform 68Ga-DOTATATE PET scans on subjects. The same anatomic areas will be imaged with 68Ga-DOTATATE PET and 111In-penteoctreotide Scintigraphy to ensure relevant comparison of lesion detection.~The images from 68Ga-DOTATATE PET/CT will be reported by an experienced nuclear medicine physician who will be unaware of the results of the previous 111Inpenteoctreotide study. Areas of abnormal focal uptake will be documented. These areas of abnormal uptake will be compared with cross-sectional imaging (CT or MRI)to confirm the presence of lesions. The images from 111In- penteoctreotide Scintigraphy will be reported independently by another experienced nuclear medicine physician."
3101820|NCT01879644|Active Comparator|Neurofeedback with Psychoeducation (NF + PE)|Neurofeedback plus Parental Psychoeducation
3101821|NCT01879644|Active Comparator|Self-Management with Psychoeducation (SM + PE)|Self-management + parental psychoeducation
3101822|NCT01879644|Active Comparator|NF+PE and additional Social Support (SU)|Neurofeedback + parental psychoeducation enhanced with social support
3101823|NCT01879644|Active Comparator|SM+PE and additional Social Support (SU)|Self-management + parental psychoeducation enhanced with social support
3101824|NCT01879631||mild to moderate keratoconus cases|keratoconus with a central corneal thickness (CCT) over 400µm, poor corrected visual acuity (≤0.4 at Snellen visual acuity charts), contact lens intolerance, no apical scarring, no ocular or systemic problem other than keratoconus
3101825|NCT01879618|Experimental|Fragmin|Fragmin given according to the flexible dosing regimen outlined in the protocol
3101826|NCT01879605|Experimental|Enema|Docusate natrium and sorbitol, 240 ml enema, the evening before surgery
3101827|NCT01879605|Active Comparator|Suppository|Bisacodyl, suppository 10 mg, the evening before surgery.
3101828|NCT01879605|No Intervention|Control grup|No intervention
3101829|NCT01879592||Asthma + sickle cell disease|African American children affected with both sickle cell disease and asthma
3101830|NCT01879592||Sickle cell disease|African American children affected with sickle cell disease but who do not have asthma
3101831|NCT01879592||Asthma|African American children affected with asthma but without sickle cell disease
3101832|NCT01879592||Healthy control|African American children who are healthy with no chronic disease
3101833|NCT01879579|Experimental|Mobile Insulin Titration Intervention|Mobile Insulin Titration Intervention (MITI) arm patients will relay their fasting blood glucose levels to the study staff via text message. The patient will receive insulin titration instructions through a weekly phone call with a diabetes nurse.
3101834|NCT01879579|No Intervention|Current Best Practice|Current Best Practice (CBP) arm patients will be treated according to the current best practice of insulin titration. They will attend scheduled clinic visits during which the provider will review their blood glucose logs and provide insulin titration instructions.
3101835|NCT01879553|Experimental|TIV (18 to ≤ 60 years)|Adult subjects 18 to ≤60 years received one dose of a trivalent, surface antigen inactivated subunit influenza virus vaccine (TIV) formulation 2013/2014 Northern Hemisphere
3101836|NCT01879553|Experimental|TIV (≥ 61 years)|Adult subjects ≥61 years received one dose of a trivalent, surface antigen inactivated subunit influenza virus vaccine (TIV) formulation 2013/2014 Northern Hemisphere
3101837|NCT01879540|Experimental|aTIV|Adult subjects ≥65 years of age received one dose of a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere
3101838|NCT01879527|Active Comparator|Amiloride hydrochlorothiazide|5,68 mg Amiloridhydrochloride 2H20 (analogue 4,32 mg Amilorid) und 50 mg Hydrochlorothiazid. Trade name of the agent: Amilostad HCT 5/50mg tablets Manufacturer: Stada initial dose: 1 x 5/50mg once daily target dose: 2 x 5/50mg once daily Patients will be provided with capsules (size 00) containing one tablet of study medication and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication
3101839|NCT01879527|Placebo Comparator|Sugar pill|Patients will be provided with capsules (size 00) containing sugar and instructed to take these capsules once daily in the morning together with breakfast.
3101840|NCT01879514|Experimental|Combination Group|Chinese Herb Prescription Granule, 6g, Bid, po. 48weeks plus prednisone, 0.5mg-1mg/kg·d, po. 48weeks
3101841|NCT01879514|Placebo Comparator|Placebo|Placebo of Chinese Herb Prescription Granule, 6g, Bid, po. 48weeks plus prednisone, 0.5mg-1mg/kg•d, po. 48weeks
3102144|NCT01877434||Reversed TESS|Patient undergone reversed shoulder arthroplasty
3101842|NCT01879501|Experimental|Low Vision Self-Management Program|Intervention: The program will work with participants to choose a specific and achievable goal they wish to achieve, involve participants in the learning process, provide information, explore experiences with low vision, and solutions to develop problem solving skills to enhance self efficacy. Participants will learn new techniques to cope with their activities of daily living. In addition to this, local guest experts in the field will be sourced and invited to provide training in aspects of low vision care.
3101843|NCT01879501|No Intervention|Usual Care|Usual care delivered at the Singapore National Eye Centre
3101844|NCT01879488|Active Comparator|Nebulization during pressure support ventilation|Patients ventilated in pressure support mode during nebulization
3101845|NCT01879488|Active Comparator|Nebulization during volume assist control mode|Patients ventilated in volume assist control mode during nebulization
3101846|NCT01879475|Experimental|032-11|032-11 topical haemostat.
3101847|NCT01879475|Active Comparator|Floseal (R)|Floseal(R) topical haemostat
3101848|NCT01879462|Experimental|Cohort A|Subjects in this cohort will receive 3 treatments (either active drug or placebo for each dose level) in 3 treatment periods (one per period). Subjects will receive GSK2878175 5 mg, GSK2878175 50 mg, and GSK2878175 200 mg in treatment period 1, 2, and 3 respectively in fasted state (with 1:3 ratio of placebo to active treatment at each treatment period).
3101849|NCT01879462|Experimental|Cohort B|Subjects in this cohort will receive 3 treatments (either active drug or placebo for each dose level) in 3 treatment periods (one per period). Subjects will receive GSK2878175 15 mg in fasted state, GSK2878175 100 mg in fasted state, and GSK2878175 100 mg in fed state in treatment period 1, 2, and 3 respectively (with 1:3 ratio of placebo to active treatment at each treatment period).
3101850|NCT01879462|Experimental|Cohort C|Subjects in this cohort will receive GSK2878175 15 mg single dose or placebo for 7 days in fasted state (with 1:4 ratio of placebo to active treatment).
3101851|NCT01879462|Experimental|Cohort D|Subjects in this cohort will receive placebo and GSK2878175 50 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
3101852|NCT01879462|Experimental|Cohort E|Subjects in this cohort will receive placebo and GSK2878175 100 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
3101853|NCT01879462|Experimental|Cohort F|Subjects in this cohort will receive placebo and GSK2878175 200 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
3101854|NCT01879436||Pregnant women|"Women during first trimester of pregnancy (age: 18-45)~Group contain 50 healthy pregnant women, age 18-45. Sera will be taken from: 1. the same branula that will be introduced into the pregnant women as a routine during pregnancy termination procedure.2. from the vein of volunteered pregnant women which do not terminate pregnancy. First trimester placenta will be collected after pregnancy termination.~The measure of outcome is composite and includes several changes:~Changes in:~cell death (% from tested cells)~cell cycle (% cells in G1, G2 and S phases)~cell migration (% closure in Scratch test)~cell invasion (% cells passing through membrane in Transwell assay)~RNA repertoire (Fold change)~miRNA repertoire (Fold change) Investigators will not treat the women with any drug."
3101855|NCT01879436||Non pregnant women|Group contain 50 healthy women, age 18-45. Sera will be taken from the vein of the volunteered women. Investigators will not treat the women with any drug.
3101856|NCT01879423|Experimental|Lamotrigine (Lamictal) D/C 5mg*5, Crossover|Single dose of lamotrigine dispersible/chewable (D/C)5mg*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg*1 tablet at Day15
3101857|NCT01879423|Experimental|Lamotrigine (Lamictal) Compressed 25mg, Crossover|Single dose of lamotrigine compressed 25mg*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg*5 tablets at Day15
3101858|NCT01879410|Experimental|UMEC/ VI via NDPI + placebo ACCUHALER/DISKUS arm|Subjects will receive one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning via the NDPI and one inhalation of placebo in the morning and evening via ACCUHALER/DISKUS inhaler
3101859|NCT01879410|Active Comparator|FSC via ACCUHALER/DISKUS + placebo NDPI arm|Subjects will receive one inhalation of FSC 250/50 mcg in the morning and evening via ACCUHALER/DISKUS inhaler and one inhalation of placebo administered once-daily in the morning via NDPI
3101860|NCT01879397||CEA Group|Subjects with atherosclerotic stenosis of the carotid artery and are scheduled for a clinically indicated Carotid Endarterectomy (CEA) procedure to remove the atherosclerotic plaque. Prior to CEA procedure, a research ultrasound exam will be performed. The plaque tissue removed during the CEA will be collected and processed into histological slides.
3101861|NCT01879397||Normal Group|Subjects who are not scheduled for a Carotid Endarterectomy (CEA) procedure and have had no prior carotid artery interventions. Subjects will have a Research Ultrasound Exam performed.
3101862|NCT01879384|Experimental|Microdialysis with CMA 70 catheter|CMA 70 catheter directly positioned in bone tissue
3101863|NCT01879371|Active Comparator|Ibuprofen (Brufen®)|film-coated tablet
3101864|NCT01879371|Active Comparator|Ibuprofen (Nurofen Immedia®)|film-coated tablet
3101865|NCT01879371|Experimental|Ibuprofen+caffeine|fixed-dose-combination (FDC)
3101866|NCT01879358|Active Comparator|ORSIRO stent|ORSIRO stent group
3101867|NCT01879358|Active Comparator|NOBORI stent|NOBORI stent group
3101868|NCT01879345|Experimental|BIA 2-093 - 1800 mg (Group 1)|3 tablets of BIA 2-093 600 mg
3101869|NCT01879345|Experimental|BIA 2-093 - 2400 mg (Group 2)|4 tablets of BIA 2-093 600 mg
3101870|NCT01879345|Placebo Comparator|Placebo|placebo tablets
3101871|NCT01879332|Placebo Comparator|Placebo|Matching placebo tablets for oral administration
3101872|NCT01879332|Experimental|BIA 2-093 3000 mg once daily|Subjects in Cohort 2 received a dose of 3000 mg once daily (5 x 600 mg eslicarbazepine acetate tablets)
3101873|NCT01879332|Experimental|BIA 2-093 3600 mg once daily|Subjects in Cohort 1 received a dose of 3600 mg once daily (6 x 600 mg eslicarbazepine acetate tablets)
3101874|NCT01879319|Experimental|Evolocumab AMD|Participants received evolocumab 420 mg once a month subcutaneously using an automated mini-doser (AMD) (one 3.5 mL injection) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
3101909|NCT01879059|Experimental|Exercise|5 days of inactivity followed by a 1 day return to physical activity
3101875|NCT01879319|Experimental|Evolocumab AI/pen|Participants received evolocumab 420 mg once a month subcutaneously using an autoinjector/pen (AI/pen) (three 1.0 mL injections) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
3101876|NCT01879293|Experimental|Metformin group|In this group, metformin 0.5 three times daily for one year.
3101877|NCT01879293|Placebo Comparator|Placebo group|In this group, placebo will be given twice daily for one year.
3101878|NCT01879280|Experimental|osteoplastic craniotomy|Half of the study population will be randomized to traditional pterional craniotomy as the method of exposure. The other half will be randomized to osteoplastic craniotomy as the method of exposure. All other aspects of medical care will remain the same.
3101879|NCT01879280|Active Comparator|traditional pterional craniotomy|traditional pterional craniotomy
3101880|NCT01879267|Other|Exercise Training: HD subjects|Endurance exercise for 6 months (30 min per week) starting one week after a 6-months natural course observation
3101881|NCT01879267|Other|Exercise Training: healthy subjects|6 months of exercise training (2 times 30 min per week)
3101882|NCT01879254||DBS for OCD|
3101883|NCT01879241|Experimental|Rasagiline|"Rasagiline~1 mg/day; 18 months"
3101884|NCT01879241|Placebo Comparator|Placebo|once daily, 18 months
3101885|NCT01879228|Experimental|Sitagliptin|The dose of sitagliptin (Januvia®) will be 100 mg tablet orally each morning for 6 months.
3101886|NCT01879228|Placebo Comparator|Placebo|Placebo tablet will be orally each morning for 6 months.
3101887|NCT01879215|Active Comparator|Suprapatellar Approach|Suprapatellar Approach to Intramedullary Nailing. Surgeons will be allowed to use any size intramedullary tibial nail through an suprapatellar incision and splitting the quadriceps tendon.
3101888|NCT01879215|Active Comparator|Infrapatellar Approach|Infrapatellar Approach Intramedullary Nailing. Surgeons will be allowed to use any size intramedullary tibial nail through an infrapatellar incision using either a medial parapatellar approach or a transpatellar approach. The knee will then be scanned using T1Rho MRI at 2 weeks postoperatively and 6 months postoperatively.
3101889|NCT01879202|Active Comparator|Methylphenidate modified release|The active agents is racemic methylphenidate hydrochloride, modified release, a mild central nervous system stimulant (pharmacotherapeutic group: psychostimulants). Study medication will be taken once daily. Initially patients will be provided with 20mg and 30mg capsules of study medication. They are instructed to take 20mg within the first week and within the second week 30mg capsules. Visit 2 is scheduled two weeks after baseline and at Visit 2 patients will be provided with 40mg capsules and instructed to take them for the rest of the study.
3101890|NCT01879202|Placebo Comparator|Maltodextrin|Study medication has to be taken once daily. Initially patients will be provided with 20mg and 30mg capsules of study medication. They are instructed to take 20mg within the first week and within the second week 30mg capsules. Visit 2 is scheduled two weeks after baseline and at Visit 2 patients will be provided with 40mg capsules and instructed to take them for the rest of the study.
3101891|NCT01879189|Experimental|Decision Aid|Those in the decision aid arm of the study will be given access to the breast cancer screening decision aid.
3101892|NCT01879189|No Intervention|Standard of Care|Those in the standard of care arm will not be given access to the decision aid.
3101893|NCT01879176|Experimental|CytoSorb|For the intervention group, the CytoSorb filter will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 200ml.min-1 .
3101894|NCT01879176|No Intervention|Control|No filter will be installed on the CPB machine.
3101895|NCT01879163|Experimental|Group A|The first six volunteers will receive an intradermal injection of 1x10^7 pfu MVA85A-IMX313 (non-randomised).
3101896|NCT01879163|Active Comparator|Group B|12 subjects receiving intradermal injection of 5x10^7 pfu MVA85A-IMX313 (following completion of group A, subjects will be randomised to either group B or group C).
3101897|NCT01879163|Active Comparator|Group C|12 subjects receiving intradermal injection of 5x10^7 pfu MVA85A (following completion of group A, subjects will be randomised to either group B or group C).
3101898|NCT01879150|Experimental|CYCLAPLEX bone anchors|"Following a 28-day screening period, eligible subjects requiring surgical correction for HV deformity (1st IMA >12degree, =<20 degree) will be enrolled to undergo HV deformity correction procedure with CYCLAPLEX under local or spinal anesthesia.~The device is implanted via small holes drilled in 1st and 2nd metatarsals. Complementary normal medical procedures such as bunionectomy, soft tissue release and HV angle correction will be performed as required.~Subjects will be followed-up for 50 weeks post-procedure."
3101899|NCT01879137||healthy adults|
3101900|NCT01879137||Patients with a polyuria-polydipsia syndrome|
3101901|NCT01879124||Kidney transplant recipients|All de novo renal allograft recipients transplanted at the University Hospitals Leuven between March 2004 and October 2007
3101902|NCT01879111|Experimental|state-of-art depression screening + patient-targeted feedback|Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
3101903|NCT01879111|No Intervention|state-of-art depression screening|
3101904|NCT01879098|Placebo Comparator|Placebo|Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
3101905|NCT01879098|Experimental|Probiotic: Bacillus subtilis|Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
3101906|NCT01879098|Experimental|Probiotic: Lactobacillus plantarum|Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
3101907|NCT01879098|Experimental|Probiotic: Bifidobacterium animalis|Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
3101908|NCT01879085|Experimental|Combination therapy|Dose Level\Docetaxel IV\ Gemcitabine IV\Vorinostat PO\Pegfilgrastim 1\75 mg/m2\900 mg/m2\300 mg once daily\6 mg on day 9 2\75 mg/m2\900 mg/m2\200 mg twice daily\6 mg on day 9 3\75 mg/m2\900 mg/m2\300 mg twice daily\6 mg on day 9 4\75 mg/m2\900 mg/m2\400 mg twice daily\6 mg on day 9
3101910|NCT01879046|Experimental|Surgical intervention|Blood, bone marrow and Hoffa's fat pad samplings during surgical intervention
3101911|NCT01879033|Active Comparator|Obese adolescents|Those with BMI more than or equal to 95th percentile. This group was further divided into two subgroups on the basis of Oral Glucose Tolerance Test (OGTT) into normal and impaired glucose tolerance groups. Reactive hyperemia peripheral artery tonometry (Rh-PAT)score and blood levels for glucose, insulin, lipids and adipocytokines will be measured in the study.
3101912|NCT01879033|Placebo Comparator|Lean adolescents|BMI between 5th-85th percentile.Reactive hyperemia peripheral artery tonometry (Rh-PAT)score and blood levels of glucose, insulin, lipids and adipocytokines will be measured in the study.
3101913|NCT01879020|Experimental|TA-8995 1 mg|
3101914|NCT01879020|Experimental|TA-8995 2.5 mg|
3101915|NCT01879020|Experimental|TA-8995 5 mg|
3101916|NCT01879020|Experimental|TA-8995 10 mg|
3101917|NCT01879020|Experimental|TA-8995 25 mg|
3101918|NCT01879020|Placebo Comparator|Placebo (TA-8995 1mg)|
3101919|NCT01879020|Placebo Comparator|Placebo (TA-8995 2.5mg)|
3101920|NCT01879020|Placebo Comparator|Placebo (TA-8995 5mg)|
3101921|NCT01879020|Placebo Comparator|Placebo (TA-8995 10mg)|
3101922|NCT01879020|Placebo Comparator|Placebo (TA-8995 25mg)|
3101923|NCT01879007|Experimental|group 1|received one intravenous administration and one oral medication with interval of 1 week,
3101924|NCT01879007|Experimental|group 2|received one oral administration and one intravenous medication with interval of 1 week
3101925|NCT01878994|Placebo Comparator|Counselling Group|Each family will receive a single monthly meeting, a total of 8 with 10 minutes duration each one. The sessions will take place in the consultation of the paediatrician and it will be delivered by the child's nurse or/and paediatrician. The sessions' contents are about promotion of healthy eating and physical activity habits.
3101926|NCT01878994|Experimental|Nereu Group|The Nereu treatment program is an intensive family-based behavioural multi-component lifestyle intervention. Consist in an intensive treatment of 8 months duration (from October to May, that is, an academic year). The intervention is a multidisciplinary intervention consisting in 4 structured components: (a) physical activity training for children, (b) family theoretical and practical sessions for parents, (c) behaviour strategies, that involves both parental and child participation (d) weekend extra activities.
3101927|NCT01878968|Experimental|Script and Video|Patients in the Script and CPR/Mechanical ventilation video arm will receive information on CPR and mechanical ventilation via a script and a video.
3101928|NCT01878968|Experimental|Script only|Patients in the Script only arm will receive information on CPR and mechanical ventilation via a script only.
3101929|NCT01878955||->6 4-9 mm follicles in bilateral ovaries|Between the ages of 18-35 patients diagnosed with PCOS according to the Roterdam criteria
3101930|NCT01878942|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.
3101931|NCT01878929|Active Comparator|Allergen(Tree, Grass, Weeds) -Held|"Allergen(Tree, Grass, Weeds)-Held~Weekly administration of Greer manufactured allergen extract at same dose and concentration patient was on prior to allergen season for the duration of patients allergen season."
3101932|NCT01878929|Active Comparator|Allergen(Tree, Grass, Weeds) -Build-up|"Allergen(Tree, Grass, Weeds) -Build-up~Weekly administration of Greer manufactured allergen extract at escalating dose and concentration patient for the duration of patients allergen season."
3101933|NCT01878903||i-pad VAS|All patients will be in one arm and they will be asked for post-operative pain using verbal NRS and visual VAS with i-pad
3101934|NCT01878890|Experimental|Efavirenz|Efavirenz
3101935|NCT01878864|Experimental|Bupivacaine lozenge|Single dose administration of a 25 mg bupivacaine lozenge before the scaling and root planning was performed.
3101936|NCT01878864|Active Comparator|Lidocaine-adrenalin injection|Xyloplyin Dental Adrenalin (20 mg/ml lidocaine, 12.5 microgram/ml adrenaline). Frequency and duration of injections was decided by the dentist preforming the scaling and root planning.
3101937|NCT01878851||pulpotomy|
3101938|NCT01878838|Active Comparator|Catalys Treated Eyes|Patient's aged 22 and older with visually significant cataracts undergoing Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser
3101939|NCT01878838|Active Comparator|LenSx Treated Eyes|Patient's aged 22 and older with visually significant cataracts undergoing Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser.
3101940|NCT01878825|Experimental|Fluviral 18-60 Years Group|Subjects aged between 18 and 60 years, received 1 dose of Fluviral™ vaccine on Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3101941|NCT01878825|Experimental|Fluviral >60 Years Group|Subjects aged > 60 years, received 1 dose of Fluviral™ vaccine on Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm
3101942|NCT01878812|Experimental|Fluarix/Influsplit Tetra® Adult Group|Subjects 18-60 years of age receiving Fluarix/Influsplit Tetra® 2013-2014, administered intramuscularly in the deltoid region of the non-dominant arm.
3101943|NCT01878812|Experimental|Fluarix/Influsplit Tetra® Elderly Group|Subjects >60 years of age receiving Fluarix/Influsplit Tetra® 2013-2014, administered intramuscularly in the deltoid region of the non-dominant arm.
3101944|NCT01878799|Experimental|HIV|Subjects with HIV and HCV
3101945|NCT01878786|Experimental|ERL & TAC|Concentration controlled everolimus(ERL) & Low dose tacrolimus(TAC) + corticosteroid withdraw
3101946|NCT01878786|Experimental|ERL & TAC --> MMF/MPA|Concentration controlled everolimus & low dose tacrolimus --> mycophenolate mofetil (MMF) at Month 3 + corticosteroid
3101947|NCT01878786|Experimental|Standard dose TAC + MMF/MPA|Standard dose of tacrolimus + mycophenolate mofetil + corticosteroid withdraw
3101948|NCT01878773|Other|High Quality Volume CT Scan; MRI Scan|Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI Scan.
3101949|NCT01878747|Experimental|P-TIPS group|Provider Tailored Intervention for Perioperative Stress (P-TIPS) aims at reducing preoperative anxiety in children via modifying adults' behavior.P-TIPS program is developed from the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors.
3102145|NCT01877421|Experimental|2 mg KSL-W (Phase 1, 1a)|one 2 mg KSL-W tablet at day 0 at Phase 1
3101950|NCT01878747|No Intervention|Control Group|Subjects in this group will not be trained with the P-TIPS method. They will receive a 2-hour seminar on the management of preoperative anxiety and postoperative pain and otherwise will provide standard care to patients.
3101951|NCT01878734|No Intervention|Control|This arm will act as a control and will not receive Micronutrient Powders
3101952|NCT01878734|Experimental|Micronutrient Powders|This is the treatment arm, which will be receiving Micronutrient Powders (MNP)
3101953|NCT01878721||Staphylococcus aureus bacteremia|PET/CT in patients with Staphylococcus aureus bacteremia
3101954|NCT01878721||Salmonella spp. bacteremia|PET/CT in patients with Salmonella spp. bacteremia
3101955|NCT01878721||Endocarditis|PET/CT in patients with infective endocarditis
3101956|NCT01878721||Pacemaker infection|PET/CT in patients with pacemaker infection
3101957|NCT01878721||Vasculitis|PET/CT in patients with vasculitis
3101958|NCT01878708|Experimental|PEG-L-asparaginase/Dexamethasone|Patients will receive Oncaspar® (PEG-asparaginase) at a dose of 2,000 IU/m2 administered intramuscularly on day 3 of each 3 week cycle, with dexamethasone 40mg given orally on days 1-4.
3101959|NCT01878695|Experimental|IV and oral n-acetylcysteine|"50-150mg/kg of n-acetylcysteine intravenously once a week for at least two weeks.~600mg n-acetylcysteine orally twice daily except on day of infusion"
3101960|NCT01878669|Placebo Comparator|saline|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
3101961|NCT01878669|Experimental|n-acetyl cysteine|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
3101962|NCT01878656|Active Comparator|Sevoflurane|administration of sevoflurane with oxygen and nitrous oxide as same ratio of 3 L/min for maintenance of general anesthesia
3101963|NCT01878656|Active Comparator|Desflurane|administration of desflurane with oxygen and nitrous oxide as same ratio of 3 L/min for maintenance of general anesthesia
3101964|NCT01878643|Placebo Comparator|Drug: Placebo|normal saline 2 mL nebulized Q 8 hours placebo for gentamicin or vancomycin
3101965|NCT01878643|Experimental|Drug: vancomycin or gentamicin|vancomycin 120 mg every 8 hours or gentamicin 80 mg every 8 hours
3101966|NCT01878630|Experimental|Remote Patient Management|intervention group
3101967|NCT01878630|Active Comparator|Usual Care|control group
3101968|NCT01878617|Experimental|Stratum W1: Low Risk|Participants in stratum W1 will undergo reduced dose Craniospinal Irradiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
3101969|NCT01878617|Experimental|Stratum W2: Atypical|Participants in stratum W2 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
3101970|NCT01878617|Experimental|Stratum W3: High Risk|Participants in stratum W3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
3101971|NCT01878617|Experimental|Stratum S1: Standard Risk|Participants in stratum S1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
3101972|NCT01878617|Experimental|Stratum S2: High Risk|Participants in stratum S2 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
3101973|NCT01878617|Experimental|Stratum N1: Standard Risk|Participants in stratum N1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
3101974|NCT01878617|Experimental|Stratum N2: Intermediate Risk|Participants in stratum N2 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
3101975|NCT01878617|Experimental|Stratum N3: High Risk|Participants in stratum N3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
3101976|NCT01878604||Homozygous Familial Hypercholesterolemia|Gene Analysis for Homozygous Familial Hypercholesterolemia cases
3101977|NCT01878591||Women in active second stage of labour|Ultrasound examinations
3101978|NCT01878578|Experimental|Eslicarbazepine acetate|ESL 600 mg tablets
3101979|NCT01878578|Active Comparator|phenytoin|Hidantina® 100 mg tablets
3101980|NCT01878578|Placebo Comparator|Placebo|Placebo tablets
3101981|NCT01878565|Experimental|Drug treatment|Drug: Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20μg of HBV vaccine subcutaneously at day 6.
3101982|NCT01878565|Other|GM-CSF control|GM-CSF was given four times as control in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with GM-CSF intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
3101983|NCT01878552||ARDS|Mechanically ventilated patients with Acute Respiratory Distress Syndrome
3101984|NCT01878539|Experimental|Health Center training|The intervention will consist of a patient training programme involving the provision of information and practical training concerning their condition and its treatment, as well as how to use a portable blood coagulation monitoring device and adjust their anticoagulant dose.
3101985|NCT01878526|Experimental|Omeprazole plus alginic acid and placebo of domperidone|
3101986|NCT01878526|Experimental|Omeprazole plus domperidone and placebo of alginic acid|
3101987|NCT01878513|Experimental|Low-dose-titration condition|Poor and intermediate CYP2D6 metabolizers will be randomized to either low-dose-titration condition or treatment-as-usual condition. In the low-dose-titration condition, patients will be treated with risperidone 0.5mg bid for 5 days, then 1mg bid for 5 days, which may be increased to 1.5mg bid for another 5 days.
3101988|NCT01878513|Experimental|Treatment-as-usual condition|Poor and intermediate CYP2D6 metabolizers will be randomized to either low-dose-titration condition or treatment-as-usual condition. In the treatment-as-usual condition, patients will be treated with risperidone 1mg bid for 5 days, then 2mg bid for 5 days, which may be increased to 3mg bid for another 5 days.
3101989|NCT01878513|Experimental|Open-label treatment-as-usual condition|Extensive and ultrarapid CYP2D6 metabolizers will be treated open-label in the treatment-as-usual condition. Patients will be treated with risperidone 1mg bid for 5 days, then 2mg bid for 5 days, which may be increased to 3mg bid for another 5 days.
3101990|NCT01878500|Experimental|Intraoperative stereotactic imaging|Surgeon will use intraoperative stereotactic imaging with VectorVision® Cranial Guided Image System by Brainlab Inc. to assist in bladder exstrophy closure.
3101991|NCT01878487|Other|Only one arm|All patients will receive the same treatment, i.e. there is no randomization. There is therefore only one arm, all patients will by treated as per standard practice with thrombus aspiration and stenting as required, the lumen size of the vessel will be assessed with intravascular ultrasound at baseline, after thrombus aspiration and after stenting.
3101992|NCT01878474|Experimental|Single ascending dose in Caucasian men|
3101993|NCT01878474|Experimental|Age-effect in Caucasian men|
3101994|NCT01878474|Experimental|Gender-effect in Caucasian women|
3101995|NCT01878474|Experimental|Single ascending dose in Japanese men|
3101996|NCT01878474|Placebo Comparator|Placebo: Single ascending dose in Caucasian men|
3101997|NCT01878474|Placebo Comparator|Placebo: Age-effect in Caucasian men|
3101998|NCT01878474|Placebo Comparator|Placeo: Gender-effect in Caucasian women|
3101999|NCT01878474|Placebo Comparator|Placebo: Single ascending dose in Japanese men|
3102000|NCT01878461|Placebo Comparator|Vehicle|Proper quantity twice a day
3102001|NCT01878461|Experimental|M518101|Proper quantity twice a day
3102002|NCT01878448|Experimental|Anlotinib|
3102003|NCT01878435|Experimental|SMS reminder|
3102004|NCT01878435|Experimental|SMS reminder and Travel subsidy|
3102005|NCT01878435|No Intervention|Control|
3102006|NCT01878435|Experimental|SMS reminder and Travel subsidy 2|
3102007|NCT01878422|Experimental|Arm A: FOLFIRI or FOLFOX + Bevacizumab|"BEVACIZUMAB: Day 1,1st cycle 5 mg/kg IV infusion of 90 min Day 1, 2nd cycle if well tolerated, 5 mg/kg IV infusion of 60 min Day 1, 3rd cycle and subsequent cycles if well tolerated, 5 mg/kg IV infusion of 30 min after 5-FU bolus~FOLFIRI Day 1: Irinotecan 180 mg/m2 IV infusion 30-90 min~Day 1,2:~L-Folinic acid 100 mg/m2 IV infusion of 2 hours 5-Fluorouracil 400 mg/m2 as a bolus 5-Fluorouracil 600 mg/m2 continuous IV infusion of 22 hours~- FOLFOX Day 1: Oxaliplatin 85 mg/m2 IV infusion of 2hours~Day 1,2:~L-Folinic acid 100 mg/m2 IV infusion of 2 hours 5-Fluorouracil 400 mg/m2 as a bolus 5-Fluorouracil 600 mg/m2 continuous IV infusion of 22 hours"
3102008|NCT01878422|Experimental|Arm B: FOLFIRI or FOLFOX|If FOLFIRI: FOLFIRI as specified in arm A without Bevacizumab If FOLFOX: FOLFOX as specified in arm A without Bevacizumab
3102009|NCT01878422|Experimental|Arm C: FOLFIRI or FOLFOX|Arm C: FOLFIRI or FOLFOX: for patients from arm A: FOLFIRI or FOLFOX (the CT schedule not received in 1st line trial, as defined in arm B)
3102010|NCT01878422|Experimental|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB: for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in 1st line trial, as described in arm B) plus CETUXIMAB
3102011|NCT01878422|Experimental|Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB|for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in the 1st line trial, as defined in arm B) plus BEVACIZUMAB
3102012|NCT01878422|Experimental|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB;|for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in the first-line trial, as defined in arm B) plus BEVACIZUMAB and CETUXIMAB; cycle to be repeated every 2 weeks, whilst cetuximab will be administered weekly.
3102013|NCT01878409||Parkinson Disease|Patients with Parkinson Disease
3102014|NCT01878409||Healthy Subjects|Healthy Subjects
3102015|NCT01878396||Mutated Anti-B-RAF|Fourth stage Melanoma patients with both measurable and not measurable lesions undergoing treatment with selective B-RAF inhibitors.
3102016|NCT01878383||Non-pregnant women/active HSV lesions|Women presenting to local health department
3102017|NCT01878383||Pregnant women/no active HSV lesions|Women presenting in active labor
3102018|NCT01878370|Experimental|High risk|Feedback reports focusing on the identification and management of patients who appear to have poorly managed diseases and who may require recall into clinic.
3102019|NCT01878370|Experimental|Best Practice|Feedback reports focusing on the achievement of optimal care targets for patients with chronic disease.
3102020|NCT01878357|Experimental|DHP monthly|Three mass screening and selective treatment using dihydroartemisinin-piperaquine and primaquine i.e. on month 1 (MST1), month 2 (MST2), and month 3 (MST3) with an interval of 6 weeks between each MST
3102021|NCT01878357|Experimental|DHP bi-monthly|Two mass screenings and selective treatment using dihydroartemisinin-piperaquine and primaquine i.e. on month 1 (MST1) and month 3 (MST3) with an interval of 3 months.
3102022|NCT01878357|No Intervention|Arm 3|Without MST
3102023|NCT01878344|Experimental|n-acetyl cysteine|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
3102024|NCT01878344|Placebo Comparator|Saline|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
3102025|NCT01878331||Roxolid|Patient do not receive an intervention in the extension study. Rather they are followed on the implant treatment from the core study which included a split-mouth design where all patients received both a Roxolid and SLActive implant.
3102026|NCT01878331||SLActive|Patient do not receive an intervention in the extension study. Rather they are followed on the implant treatment from the core study which included a split-mouth design where all patients received both a Roxolid and SLActive implant.
3102027|NCT01878318|Experimental|RoActemra/Actemra|
3102028|NCT01878305||MARS|Study patients are treated with albumin dialysis (Molecular Adsorbents recirculating system), based on the clinical judgement by the treating physician. Of the 20 patients, two did not need MARS and the rest received MARS treatment with varying treatment cycles.
3102029|NCT01878292|Placebo Comparator|Placebo|Dose-matched placebo tablets, once per day, oral administration
3102030|NCT01878292|Experimental|Vilazodone 15 mg|15 mg vilazodone tablets, once per day, oral administration
3102031|NCT01878292|Experimental|vilazodone 30 mg|30 mg vilazodone tablets, once per day, oral administration
3102032|NCT01878279||HIV negative|
3102033|NCT01878279||HIV positive|HIV positive children in care
3102034|NCT01878266|Active Comparator|Hypofractionated Arm (1)|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed
3102035|NCT01878266|Active Comparator|Hypofractionated Arm (2)|The same planning and treatment procedures will be performed. The total dose will be 4500 cGy in 15 fractions in 3 weeks; giving 300 cGy per fraction.
3102036|NCT01878266|Other|Conventional Arm (3)|The same planning and treatment procedures will be performed with 54.0 Gy in 30 fractions giving 1.8 Gy per fraction.
3102037|NCT01878253|Experimental|Investigational|This arm will include all subjects who are implanted with the investigational Sidus Stem-Free Total Shoulder Arthroplasty System.
3102038|NCT01878240|Active Comparator|EVAR|Endovascular repair of an Abdominal Aortic Aneurysm
3102039|NCT01878240|Experimental|Coil embolization during EVAR|coil embolization during Endovascular repair
3102040|NCT01878227|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
3102041|NCT01878227|Active Comparator|Fenofibrate 200mg|Fenofibrate 200mg per day
3102042|NCT01878214|Experimental|Intervention group|Targeted messaging
3102043|NCT01878214|Active Comparator|Control group|Standard messaging
3102044|NCT01878201|Experimental|Fimasartan 30 mg|Take one capsule filled with a Fimasartan 30 mg in the every morning
3102045|NCT01878201|Active Comparator|Valsartan 80 mg|Take one capsule filled with a Valsartan 80 mg in the every morning
3102046|NCT01878188|Experimental|BC-819/PEI and BCG alternating|4 weekly treatments of BC-819/PEI alternating with BCG
3102047|NCT01878188|Experimental|BC-819/PEI and BCG Vaccine sequential|4 weekly treatments of BC-819/PEI followed by 4 weekly treatments of BCG
3102048|NCT01878188|Experimental|bi-weekly treatments of BC-819 and BCG|6 bi-weekly treatments of BC-819/PEI and BCG
3102049|NCT01878175|Experimental|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
3102050|NCT01878162|Experimental|Exercise|Exercise will occur 3 times weekly for 6 months in 20-minute exercise sessions. Sessions will take place independently. Follow-up and progression of the home program will be completed in person or by video teleconferencing at regular intervals throughout the intervention phase.
3102051|NCT01878149||VEO® Lateral Access and Interbody Fusion System|
3102052|NCT01878149||eXtreme Lumbar Interbody Fusion (XLIF®)|
3102053|NCT01878136|Active Comparator|Intraventricular tPA|"Tissue Plasminogen Activator (tPA)~Dose: 1 mg Q8 hr x 12 doses, or until blood is cleared from the ventricles and cisterns Adminstration: Intraventricular; via previously placed external ventricular drain"
3102054|NCT01878136|Placebo Comparator|Placebo|"Placebo~Dose 1 mL sterile saline"
3102055|NCT01878123|Experimental|AMP-110|Escalating doses of AMP-110
3102056|NCT01878123|Placebo Comparator|Placebo|
3102057|NCT01878110|Experimental|COMB|
3102058|NCT01878097|Experimental|Green Dot Bystander Training|Green Dot intervention
3102059|NCT01878097|Active Comparator|Control|Awareness Eduation
3102060|NCT01878084|Sham Comparator|empty extraction socket|Extraction sockets will be left empty
3102061|NCT01878084|Experimental|bioactive glass (sol-gel)|Bone regeneration utilizing tissue engineering principles and approach via using porous bioactive glass prepared by sol gel technique to properly fill the empty socket after tooth extraction. The target is to preserve the buccal and lingual alveolar plates of the socket regarding width and height, to avoid bone resorption and to stimulate bone regeneration. This novel technique will be evaluated via histological (biopsy), radiographic, and bone density measurements in addition to clinical assessment.
3102062|NCT01878071||Single group cross sectional|
3102063|NCT01878058|Other|MRI Scan|Patients will receive an extra MRI scan in addition to their routine scan.
3102102|NCT01877681|Experimental|Assisted Care|Assisted care (Tele=assistance) provided by an expert nurse through a informatic online application
3102064|NCT01877967|Experimental|Intervention|This group will intake the recommended daily amount of the food supplement VSL#3 (two sachets of the supplement in powder form) every day for twelve weeks. The two sachets will either be taken together or one in the morning and one in the evening.
3102065|NCT01877967|Placebo Comparator|Placebo|This group will intake two sachets (2x4.4g) of a placebo each day for 12 weeks. The placebo is in the same powdered form as the food supplement taken by the intervention group. The two sachets will either be taken together or one in the morning and one in the evening.
3102066|NCT01877954||IPDI Qvar|ICS initiation as Extra-fine hydrofluoroalkane beclometasone dipropionate
3102067|NCT01877954||IPDI FP|ICS initiation as fluticasone propionate
3102068|NCT01877941|Active Comparator|Cardiac output monitoring|Patients undergoing surgery who will have their cardiac output monitored by pulmonary artery catheter (PAC) and endotracheal cardiac output monitoring (ECOM) during surgery and during post-surgical recovery, will also have sensors placed on the arm, finger and leg to calculate pulse wave transit time (PWTT) using the estimated Continuous Cardiac Output system (ecCCO).
3102069|NCT01877928|Experimental|Boussignac CPAP device|Patients previously diagnosed with obstructive sleep apnea and who are undergoing abdominal or peripheral surgery will have the Boussignac CPAP mask applied for 1 hour starting immediately post-extubation
3102070|NCT01877928|Active Comparator|standard CPAP|Patients previously diagnosed with obstructive sleep apnea who are undergoing peripheral or abdominal surgical procedures will receive the standard-of-care for obstructive sleep apnea. This typically involves CPAP application only at night
3102071|NCT01877915|Experimental|Rivaroxaban 2.5 mg|Each participant will receive 2.5 mg of rivaroxaban twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
3102072|NCT01877915|Placebo Comparator|Placebo|Each participant will receive matching placebo twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
3102073|NCT01877902||Pemetrexed 500 mg/m 2|
3102074|NCT01877889|Experimental|Part 1: Cana|Each volunteer will receive 300 mg of canagliflozin once daily for 4 days.
3102075|NCT01877889|Experimental|Part 2: Sequence 1 (Dapa/Cana)|Each volunteer will receive 10 mg of dapagliflozin once daily for 4 days (treatment period 1) followed by 300 mg of canagliflozin once daily for 4 days (treatment period 2). Each treatment period will be separated by a 12- to 14-day washout period (with no medication).
3102076|NCT01877889|Experimental|Part 2: Sequence 2 (Cana/Dapa)|Each volunteer will receive 300 mg of canagliflozin once daily for 4 days (treatment period 1) followed by 10 mg of dapagliflozin once daily for 4 days (treatment period 2). Each treatment period will be separated by a 12- to 14-day washout period.
3102077|NCT01877876||Patient undergoing spine surgery|
3102078|NCT01877863|Experimental|intradialytic exercise|baseline data prior to starting exercise program will be obtained and then compared to the data after 12 weeks of an intradialtyic biking program
3102079|NCT01877850||case|patients with BPAW-M more than 15 or between 10 and 15, but with Tobin <100 will be weaned with the weaning protocol by nurses
3102080|NCT01877850||control|patients with any BWAP-M will be weaned by clinical judgment of physicians
3102081|NCT01877837|Experimental|Related donor|"Matched sibling donors (9-10/10 marrow/PBSC or 5-6/6 UCB (single) with a total TNC dose of greater than 5 x 107/kg recipient weight), age 2-30 years after conditioning regimen Alemtuzumab , Fludarabine, and Melphalan.~1) Patients will receive a conditioning regimen composed of Alemtuzumab, Fludarabine, and Melphalan as detailed in the table below.~Day Treatment~-22 Alemtuzumab 3mg IV (test dose)~-21 Alemtuzumab 10mg IV~-20 Alemtuzumab 15mg IV~-19 Alemtuzumab 20mg IV~-8 Fludarabine 30mg/m2 IV~-7 Fludarabine 30mg/m2 IV~-6 Fludarabine 30mg/m2 IV~-5 Fludarabine 30mg/m2 IV~-4 Fludarabine 30mg/m2 IV~-3 Melphalan 140mg/m2 IV~-2 Rest Day~-1 Rest Day~0 Stem Cell Infusion"
3102082|NCT01877824|Experimental|Fast-track training|A skills-lap course (1 day) followed by opportunity to perform 20 planned surgical procedures of each type (open groin hernia repair and laparoscopic cholecystectomy) under supervision and within 4-8 weeks. Videorecording at start, mid and end and at follow-up before ending first year of training.
3102083|NCT01877824|No Intervention|Control|Follows the existing training program without intervention. Video recording of the trainee performing a open groin hernia repair and a laparoscopic cholecystectomy procedure at start end end of first training year.
3102084|NCT01877811|Experimental|RXDX-105|
3102085|NCT01877798|Experimental|△PCO2/Ca-vO2|△PCO2/Ca-vO2 directed group
3102086|NCT01877798|Experimental|ScvO2|ScvO2 directed group
3102087|NCT01877785|Experimental|MHAA4549A Arm|
3102088|NCT01877785|Placebo Comparator|Placebo Arm|
3102089|NCT01877772|Active Comparator|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
3102090|NCT01877772|Active Comparator|Control|The control group will undergo standard rotator cuff repair
3102091|NCT01877759|Other|Mesenchymal stem cell|hUMAN MESENCHYMAL STEM CELLS
3102092|NCT01877746|Experimental|R1 - combined immunosuppressive therapy|application of the combined immunosuppressive therapy in the first dosing regimen
3102093|NCT01877746|Experimental|R2 - combined immunosuppressive therapy|application of the combined immunosuppressive therapy in the second dosing regimen
3102094|NCT01877746|Other|S - standard therapy|only standard medical therapy of chronic heart failure without application of the combined immunosuppressive therapy
3102095|NCT01877733|Experimental|Maximal strenght training|Training maximal strength training 3 times a week/1 physiotherapy session for 8 weeks
3102096|NCT01877733|No Intervention|Standard rehabilitation|2-3 physiotherapy sessions a week for 8 weeks/telephone contact by project leader once a week/writing training diary
3102097|NCT01877720|Experimental|NAVA-PS|noninvasive NAVA first for 15 minutes and then PSV for 15 minutes
3102098|NCT01877720|Experimental|PS-NAVA|noninvasive PSV first for 15 minutes and then NAVA for 15 minutes
3102099|NCT01877707|Other|Cystic Fibrosis patients|Patients with a diagnosis of cystic fibrosis, who are able to produce daily sputum samples. With a history of at least two pulmonary infective exacerbations within the past 12 months.
3102100|NCT01877694|Experimental|Auriclosene Solution 0.3%|Dosed QID for 4 Days
3102101|NCT01877694|Placebo Comparator|Auriclosene Vehicle|Dosed QID for 4 days
3102185|NCT01877187|Other|Lipiodol|Lipiodol, 10cc per TACE.
3102103|NCT01877681|Active Comparator|Active comparator|Usual care as stated by the Clinical Practice Guidelines for Pressure Ulcers treatment
3102104|NCT01877668|Experimental|Tofacitinib 5 mgBID x 12 months|
3102105|NCT01877668|Experimental|Tofacitinib 10 mg BID x 12 months|
3102106|NCT01877668|Active Comparator|Adalimumab 40 mg q2 weeks x 12 months|
3102107|NCT01877668|Placebo Comparator|Placebo x3 months, then tofacitinib 5 mg BIDx 9 months|
3102108|NCT01877668|Placebo Comparator|Placebo x 3 months, then tofacitinib 10 mg BID x 9 months|
3102109|NCT01877655|Experimental|ASP0113|ASP0113 arm
3102110|NCT01877655|Placebo Comparator|Placebo|Placebo arm
3102111|NCT01877642|Other|Open Label (lorazepam 1 mg + Inhaled loxapine 10 mg)|Inhaled Staccato loxapine 10 mg + IM lorazepam 1 mg to confirm tolerability of combined treatment
3102112|NCT01877642|Other|Treatment Sequence ABC|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
3102113|NCT01877642|Other|Treatment Sequence ACB|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
3102114|NCT01877642|Other|Treatment Sequence BCA|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
3102115|NCT01877642|Other|Treatment Sequence BAC|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
3102116|NCT01877642|Other|Treatment Sequence CAB|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
3102117|NCT01877642|Other|Treatment Sequence CBA|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
3102118|NCT01877629|Experimental|ACT-129968 tablet/capsules|Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period.
3102119|NCT01877629|Experimental|ACT-129968 capsules/tablet|Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period.
3102120|NCT01877616|Other|diagnostic test|all persons with a definitive diagnosis of a major sleep disorder (insomnia, hypersomnia, sleep-disordered breathing) will be followed annually for at least five years
3102121|NCT01877603||type 2 diabetes|We select 200 newly diagnosed type 2 diabetic patients. Plasma irisin levels will be measured, and endothelial function will be determined.
3102122|NCT01877590|Placebo Comparator|placebo group|An identical placebo daily
3102123|NCT01877590|Experimental|alpha-lipoic acid group|alpha-lipoic acid 600 mg daily for one year.
3102124|NCT01877577|Active Comparator|2000 I/U Vitamin D3|2000 I/U Vitamin D3 Daily
3102125|NCT01877577|Active Comparator|4000 I/U Vitamin D3|4000 I/U Vitamin D3 Daily
3102126|NCT01877564|Experimental|Group 1 - Metformin|oral metformin at 500 mg twice a day for 14-21 days followed by surgery
3102127|NCT01877564|No Intervention|Group 2 - No treatment|
3102128|NCT01877551|Active Comparator|tauroursodeoxycholic acid|This group will receive 1.75 grams per day of tauroursodeoxycholic acid given once daily for 30 days.
3102129|NCT01877551|Placebo Comparator|placebo|This group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
3102130|NCT01877538||[11C]donepezil PET|[11C]donepezil is a radiopharmaceutical. It is evaluated whether the binding of [11C]donepezil in various peripheral tissues is in accordance with known distribution of the parasympathetic nervous system.
3102131|NCT01877525||All patients in one cohort|Consecutive adult patients undergoing colonoscopy for colorectal cancer screening or routine surveillance indications were prospectively enrolled between October 2011 and October 2012.
3102132|NCT01877512|Active Comparator|Low dose Growth Hormone|Halve of the group of men and group of women will receive a decrease of their regular dose of Growth Hormone treatment, with the IGF-I target level of -2 - -1 SD score (low dose=LD).
3102133|NCT01877512|Active Comparator|High dose Growth Hormone|Halve of the group of men and group of women will receive an increase of their regular dose of Growth Hormone treatment, with the IGF-I target level of 1 - 2 SD score (high dose=HD).
3102134|NCT01877499||optimization of HDF key parameters|The cohort is composed of patients with end-stage renal disease receiving dialysis for at least 6 weeks, either as standard hemodialysis (low- or high-flux) or hemodiafiltration (HDF).
3102135|NCT01877486||Cryoballoon ablation|After pre-treatment with dofetilide and conversion of persistent AF to sinus rhythm, performance of PVI using cryoballoon
3102136|NCT01877473|Active Comparator|Reverse remodeling|Pretreatment with dofetilide or sotalol and restoration of sinus rhythm followed by PVI only ablation
3102137|NCT01877473|Active Comparator|Standard ablation|PVI ablation with additional CFAE and/or linear LA ablation
3102138|NCT01877460|Experimental|Sodium alginate-free chocolate milk|Sodium alginate-free chocolate milk (1% fat) (Beatrice Ltd., Toronto, Ontario)
3102139|NCT01877460|Experimental|1.25% sodium alginate chocolate milk|Chocolate milk (Beatrice Ltd., Toronto, Ontario) with 1.25% sodium alginate
3102140|NCT01877460|Experimental|2.5% sodium alginate chocolate milk|Chocolate milk (Beatrice Ltd., Toronto, Ontario) with 2.5% sodium alginate
3102141|NCT01877460|Experimental|2.5% sodium alginate milk-free water-based solution|Water solution with 2.5% sodium alginate
3102142|NCT01877447|Experimental|cathodal F4|"Transcranial Direct Current Stimulation~Cathodal tDCS over F4 (right dorsolateral prefrontal cortex) Anodal tDCS over the left deltoid (extra-cephalic) n=15"
3102143|NCT01877447|Experimental|Anodal F3|"Transcranial Direct Current Stimulation'~Anodal tDCS over F3 (right dorsolateral prefrontal cortex) Cathodal tDCS over the right deltoid (extra-cephalic) n=15"
3102146|NCT01877421|Experimental|4 mg KSL-W (Phase 1, 2a; Phase 2a, 1b)|one 4 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. one 4 mg KSL-W tablet on days 1-6; two 4 mg KSL-W tablets on days 7-13 and days 14-20; and three 4 mg tablets at days 21-27 at Phase 2a.
3102147|NCT01877421|Experimental|6 mg KSL-W (Phase 1, 3a; Phase 2a, 2b)|One 6 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 6 mg KSL-W tablet on days 1-6; two 6 mg KSL-W tablets on days 7-13 and days 14-20; and three 6 mg tablets at days 21-27 at Phase 2a.
3102148|NCT01877421|Experimental|10 mg KSL-W (Phase 1, 4a; Phase 2a, 3b)|One 10 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 10 mg KSL-W tablet on days 1-6; two 10 mg KSL-W tablets on days 7-13 and days 14-20; and three 10 mg tablets at days 21-27 at Phase 2a.
3102149|NCT01877421|Experimental|20 mg KSL-W (Phase 1, 5a; Phase 2a, 4b)|One 20 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 20 mg KSL-W tablet on days 1-6; two 20 mg KSL-W tablets on days 7-13 and days 14-20; and three 20 mg tablets at days 21-27 at Phase 2a.
3102150|NCT01877421|Experimental|30 mg KSL-W (Phase 1, 6a; Phase 2a, 5b)|One 30 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 30 mg KSL-W tablet on days 1-6; two 30 mg KSL-W tablets on days 7-13 and days 14-20; and three 30 mg tablets at days 21-27 at Phase 2a.
3102151|NCT01877421|Experimental|50 mg KSL-W (Phase 1, 7a; Phase 2a, 6b)|One 50 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 50 mg KSL-W tablet on days 1-6; two 50 mg KSL-W tablets on days 7-13 and days 14-20; and three 50 mg tablets at days 21-27 at Phase 2a.
3102152|NCT01877421|Experimental|75 mg KSL-W (Phase 1, 8a; Phase 2a, 7b)|One 75 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 75 mg KSL-W tablet on days 1-6; two 75 mg KSL-W tablets on days 7-13 and days 14-20; and three 75 mg tablets at days 21-27 at Phase 2a.
3102153|NCT01877421|Experimental|100 mg KSL-W (Phase 1, 9a)|one 100 mg KSL-W tablet at day 0 at Phase 1
3102154|NCT01877421|Placebo Comparator|Placebo|Placebo
3102155|NCT01877408|Active Comparator|Open surgical circumcision|The open surgical technique, which is commonly used for circumcision in South Africa, requires good surgical skills and minor complications are common.
3102156|NCT01877408|Experimental|Unicirc device with tissue adhesive|Coupling removal of the foreskin using the disposable Unicirc device with wound sealing using tissue adhesive results in a procedure that can be performed by generalist doctors with minimal training.
3102157|NCT01877395|Experimental|Purified Vero Rabies Vaccine Group|Participants will receive the Purified Vero Rabies Vaccine (VRVg)
3102158|NCT01877395|Experimental|Imovax® Rabies Vaccine Group|Participants will receive the Imovax® Rabies vaccine
3102159|NCT01877382|Experimental|DS-3032|DS-3032b will be administered as an oral capsule. It will be supplied in 5 mg, 20 mg, 80 mg, and 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.
3102160|NCT01877356|Experimental|bilateral spinal anesthesia|bilateral spinal anesthesia prilocaine plain 20% 50 mg ambulatory surgery
3102161|NCT01877356|Experimental|unilateral spinal anesthesia|unilateral spinal anesthesia prilocaine hyperbaar 2% 30 mg ambulatory surgery
3102162|NCT01877343|Experimental|CVInsight (TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical)and blood pressure will be measured at different table positions (different angles). A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
3102163|NCT01877330|Active Comparator|Injection in interscalene groove|Patients undergoing shoulder arthroscopy will have an interscalene nerve block by injection of ropivacaine in the interscalene groove anterior and posterior to the brachial plexus nerves.
3102164|NCT01877330|Active Comparator|Injection between nerve roots|Patients undergoing shoulder arthroscopy will have an interscalene nerve block by injection of ropivacaine in the interscalene groove inbetween the C5 and C6 nerve roots.
3102165|NCT01877317|Experimental|SelfFit adjusted hearing device|Hearing impaired people with mild to moderate sensorineural hearing loss (PTA124<50 dB) in the test ear compare the performance of their hearing aids adjusted through SelfFit mobile medical App (I-Pad) with the performance of their hearing aids adjusted through conventional audiogram-based fitting.
3102166|NCT01877304|Experimental|AKITA with program central deposition|Nebulization for central deposition
3102167|NCT01877304|Active Comparator|AKITA with program for peripheral deposition|Nebulization for peripheral deposition
3102168|NCT01877291||Nonsmokers|Young healthy nonsmokers
3102169|NCT01877291||Smokers<2.5 pack years|"Young healthy or asymptomatic smokers (aged < 35 y.o.) with smoking history <2.5 pack years"
3102170|NCT01877291||Smokers≥ 2.5 pack-years|"Young healthy or asymptomatic smokers (aged < 35 y.o.) with smoking history ≥ 2.5 pack-years"
3102171|NCT01877278|Active Comparator|active|Group wearing the active device emitting pulsed electromagnetic fileds
3102172|NCT01877278|Placebo Comparator|placebo|Group wearing the device non-emitting pulsed electromagnetic fileds
3102173|NCT01877265|Experimental|LY2605541 - Source 1|Each healthy participant will receive a single subcutaneous (SQ) injection of 0.5 units per kilogram (U/kg) of LY2605541 on Day 1 of three treatment periods
3102174|NCT01877265|Experimental|LY2605541 - Source 2|Each healthy participant will receive single SQ injection of 0.5 U/kg of LY2605541 on Day 1 of one of three treatment periods
3102175|NCT01877265|Experimental|LY2605541 - Source 3|Each healthy participant will receive single SQ injection of 0.5 U/kg of LY2605541 on Day 1 of one of three treatment periods
3102176|NCT01877252||Endovascular treatment|Angioplasty +/- stent
3102177|NCT01877252||Open treatment|Bypass (vein or prosthetic)
3102178|NCT01877252||Patchplasty/Hybrid treatment|Femoral artery patchplasty +/- profundoplasty +/- endovascular treatment
3102179|NCT01877252||Conservative treatment|no vascular intervention
3102180|NCT01877239||Full Analysis Set|Full Analysis Set (FAS): The FAS contains any patient that has given written informed consent.
3102181|NCT01877226|Experimental|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
3102182|NCT01877213|Experimental|Coaching with coordinate care|After discharge from hospital, patients randomized in the coaching group will be coached by a coordinator nurse.
3102183|NCT01877213|No Intervention|Usual care|After discharge from hospital, patients randomized in the no intervention group will be managed as usually.
3102184|NCT01877200||Subjects with diabetes (type 2)|
3102186|NCT01877174||MICHI(TM) NPS+f|Patients routinely treated with the CE marked MICHI(TM) NPS+f System
3102187|NCT01877161|Experimental|Middle temporal gyrus|Repetitive magnetic stimulation to middle temporal gyrus
3102188|NCT01877161|Sham Comparator|Control group|Repetitive magnetic stimulation (Sham)
3102189|NCT01877161|Experimental|Superior temporal gyrus|Repetitive magnetic stimulation to superior temporal gyrus
3102190|NCT01877148|Experimental|Physiotherapy + anodal tDCS|The patients will be submit to anodal tDCS applied in the motor cortex and after the patient will be submit to a 30 minutes of physiotherapy protocol.
3102191|NCT01877148|Sham Comparator|Physiotherapy + sham tDCS|The patients will be submit to sham tDCS and after the patient will be submit to a 30 minutes of physiotherapy protocol.
3102192|NCT01877135||Anal AIN3|patients > 18 years, with anal AIN3, without history of anal carcinoma
3102193|NCT01877122|Experimental|Proflex® Mesh|Device: Partially absorbable lightweight mesh Intervention: Mesh implantation
3102194|NCT01877122|Active Comparator|Marlex® Mesh|Device: Non-absorbable Heavyweight mesh Intervention: Mesh implantation
3102195|NCT01877109||Lymphoma|Lymphoma patients
3102196|NCT01877096|Experimental|Motivational Interviewing|Participants will undergo a brief (20-30 minutes) motivational interviewing session after their primary care appointment
3102197|NCT01877096|Active Comparator|Attention Control|Participants will undergo a brief (20-30 minutes) attention control session after their primary care appointment
3102198|NCT01877083|Experimental|Lenvatinib|
3102199|NCT01877070||early stage prostate patients & their partners/close allies|
3102200|NCT01877057|Experimental|Saturn|For the different prototypes of pea protein extract used in this study pea protein NUTRALYS F85M or F85G, Acacia Gum 381A or 396I and water will be used.
3102201|NCT01877044|Placebo Comparator|Placebo|Maltodextrin
3102202|NCT01877044|Experimental|NAXUS 7.5 grams|Arabinoxylan
3102203|NCT01877044|Experimental|NAXUS 15.0 grams|Arabinoxylan
3102204|NCT01877031|Active Comparator|Ultrasound|Ultrasound only guidance of central line insertion - current standard of care.
3102205|NCT01877031|Experimental|Virtual Reality|Use of ultrasound plus virtual reality guidance to insert central line
3102206|NCT01877018|Experimental|electronic reminder|Electronic reminder introduced into primary care medical health record.
3102207|NCT01877018|No Intervention|Usual care|Usual care control group
3102208|NCT01877005|Experimental|Ruxolitinib|"Induction period: Ruxolitinib will be given twice daily during 6 cycles of 28 days.~Maintenance period: patients who achieve at least a stable disease (according Cheson 2007) at the end of cycle 6 and for whose a clinical benefit is observed according to the Investigator's opinion will be eligible for maintenance treatment by ruxolitinib twice daily every day of 28-day cycles."
3102209|NCT01876992|Experimental|Metformin|"Doses will be increased incrementally. Decisions to escalate the metformin dose will be made based upon tolerability of side effects as described in the schedule of evaluations to follow. All subjects will be monitored for safety while receiving metformin. Any participant with blood glucose of <60mg/dl at any time while receiving metformin will have therapy stopped and will be withdrawn from the study.~For children <50kg:~Baseline:250mg po qd, Week 2:250mg po bid, Week 4:500mg po am/250mg po pm, Week 8:500mg po bid.~For children ≥50kg:~Baseline:500mg po qd, Week 2:500mg po bid, Week 4:1000mg po am/500mg po pm, Week 8:1000mg po bid.~For adults:~Baseline:500mg po qd,Week2:500mg po bid,Week 4:1000mg po am/500mg po pm,Week 8:1000mg po bid."
3102210|NCT01876992|No Intervention|Obese Controls|"Three obese but otherwise healthy adult participants will be recruited into the study as controls. These will be individuals who are not currently (or previously) on any diabetic medication including metformin.~There will be a single study visit and no medication will be administered. They will be administered a meal and pre and post-prandial blood samples will be drawn."
3102211|NCT01876979|Active Comparator|IMF Screws|Use of IMF screws as a means to wire the jaws.
3102212|NCT01876979|Active Comparator|Erich Arch Bars|Use of Erich Arch bars in the wiring of the jaws.
3102213|NCT01876966|Experimental|ETR, artemether/lumefantrine|treatment with artemether/lumefantrine 80/480 mg during 3 days (treatment A) and treatment during 22 days with etravirine for 22 days and artemether/lumefantrine 80/480 mg from day 8 to day 11 (treatment B) with a washout of at least 4 weeks between the 2 treatment periods
3102214|NCT01876966|Experimental|DRV/rtv, artemether/lumefantrine|treatment with artemether/lumefantrine 80/480 mg during 3 days (treatment A) and treatment during 22 days with darunavir/ritonavir and artemether/lumefantrine 80/480 mg from day 8 to day 11 (treatment B) with a washout of at least 4 weeks between the 2 treatment periods
3102215|NCT01876953|Experimental|Treatment (cytarabine, idarubicin, and dasatinib)|Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
3102216|NCT01876940|Active Comparator|Fiberoptic Intubation performed by an expert|Tracheal intubation will be performed by an expert anesthesia attending with and without use of the air-Q
3102217|NCT01876940|Experimental|Fiberoptic Intubation performed by a novice|Tracheal intubation will be performed by an anesthesia trainee with and without use of the air-Q
3102218|NCT01876927|Experimental|Arm A|"DOX 4 cycles - Surgery - Follow-up~DOX:~Docetaxel 35 mg/m2 day 1 and 8 by one hour infusion; Oxaliplatin 80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.~Treatment should be administered for 4 cycles before surgery. Each cycle will be repeated every 3 weeks."
3102219|NCT01876927|Experimental|Arm B|"DOX 2 cycles - Surgery - DOX 2 cycles - Follow-up~DOX:~Docetaxel 35 mg/m2 day 1 and 8 by one hour infusion; Oxaliplatin 80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.~Treatment should be administered for 2 cycles before surgery and for further 2 cycles after surgery, unless progression of disease or unacceptable toxicity occurs, or patient refusal. In these cases patients will go off treatment.~Each cycle will be repeated every 3 weeks."
3102220|NCT01876914||DME patients|Patients suspected to have a problem with at least one eye called diabetic macular edema or DME
3102221|NCT01876901|Experimental|ACAD|ACAD
3102222|NCT01876901|Experimental|ACAI|ACAI
3102260|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 4)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
3102223|NCT01876875|Experimental|Intervention group|The patients of this group were randomized to receive an energy-restricted diet (20 kcal/kg/ideal body weight/day) enriched of n-3 PUFAs (average 2.6 g/d).
3102224|NCT01876875|Active Comparator|Control group|The participants of this group are randomized to receive drug therapy alone, continuing their usual diet
3102225|NCT01876862|Experimental|STOP ART|"Antiretroviral treatment interruption in 3 successive groups of 5 patients.~Zero-risk strategy If after 8 weeks of treatment interruption, at least 1 patient from group 1 does not present any of the failure criteria, patients from group 2 will be included and their treatment interrupted. If after 8 weeks of treatment interruption, at least 2 patients from groups 1 and 2 do not present any failure criteria, patients from group 3 will be included and their treatment interrupted."
3102226|NCT01876849|Experimental|Group A|Exenatide injection 5mcg or 10 mcg, twice daily
3102227|NCT01876836|Experimental|i-gel|i-gel placed after induction
3102228|NCT01876836|Active Comparator|C-LMA|C-LMA placed after induction
3102229|NCT01876823|Experimental|es-citalopram and Memantine Treatment|concurrent es-citalopram plus memantine were administered for 48 weeks.
3102230|NCT01876810|Experimental|Gemfibrozil|600 mg of gemfibrozil (one capsule) twice daily for two weeks.
3102231|NCT01876810|Placebo Comparator|Placebo pill|One lactose pill twice a day for two weeks.
3102232|NCT01876797|Other|ticagrelor-prasugrel|in period 1, 180 mg of ticagrelor will be administrated at a single oral dose. in period 2, 60 mg of prasugrel will be administrated at a single oral dose.
3102233|NCT01876784|Experimental|Vandetanib|Vandetanib 300 mg tablet, orally once daily until disease progression or death.
3102234|NCT01876784|Placebo Comparator|Placebo|Placebo matched to vandetanib tablet, orally once daily until disease progression or death.
3102235|NCT01876771|Experimental|[177]Lu-DOTA-TATE Therapy|"Nominal, induction stage dose of 150 mCi (5.55 GBq) [177]Lu-DOTA-TATE every 10 - 14 weeks for 4 treatments.~Nominal maintenance stage dose of 75 mCi (2.78 GBq) [177]Lu-DOTA-TATE every 22 - 40 weeks, up to a maximum of 8 treatments."
3102236|NCT01876758|Experimental|Cognitive Intervention: Memory Training|Memory training before and after ECT
3102237|NCT01876758|Active Comparator|Comparable general mental stimulation|Puzzle games before and after ECT
3102238|NCT01876758|No Intervention|Treatment as Usual|No memory training or puzzle games, just the study evaluations
3102239|NCT01876745||NovoSeven® (activated recombinant factor VII)|
3102240|NCT01876732|Experimental|Vitamin B12|Those with an MMA over 800nmol/L are given 1000mcg of intramuscular (IM) vitamin B12 weekly for the first month and then monthly for 3 consecutive months.
3102241|NCT01876719|Experimental|0.5 mg AR08|0.5 mg AR08, QD for 7 weeks
3102242|NCT01876719|Experimental|1.0 mg AR08|1.0 mg AR08, QD for 7 weeks
3102243|NCT01876719|Experimental|2.0 mg AR08|2.0 mg AR08, QD for 7 weeks
3102244|NCT01876719|Placebo Comparator|Placebo|Placebo, QD for 7 weeks
3102245|NCT01876706|Experimental|UroLift® System|Single-arm of qualified subjects receiving UroLift® System intervention.
3102246|NCT01876693|No Intervention|control|nutrition counselling with nasogastric tube insertion in the cases of weight loss more than 10% or severe mucositis developed during chemoradiotherapy
3102247|NCT01876693|Experimental|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
3102248|NCT01876680|Experimental|Group 1: Stretching and aerobic exercise|Group 1 undertook a stretching programme for neck/shoulder muscles three times weekly and performed aerobic exercise för 30 minutes three times weekly.
3102249|NCT01876680|Experimental|Group 2: Strength training|Group 2 undertook a stretching programme for neck/shoulder muscles three times weekly, performed aerobic exercise three times weekly and performed weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.
3102250|NCT01876667|Active Comparator|Intervention (CPCRS) Group|CPCRS will ensure patients have regular laboratory monitoring and blood pressure measures, appropriate lipid-lowering and antihypertensive medications, and receive follow-up in a timely manner.
3102251|NCT01876667|Placebo Comparator|Usual Care|Usual Care: Patients randomized to Usual Care will continue to receive interventions/procedures they normally receive according to standard/usual care practices
3102252|NCT01876654|Experimental|TruMatch® patient specific cutting guide|In patients randomized to experimental arm, TKR components will be implanted using TruMatch® patient specific cutting guides.
3102253|NCT01876654|No Intervention|Conventional cutting guide|In patients randomized to control arm, TKR components will be implanted using Attune® instrumentation (femoral intra-medullary guide, tibial extra-medullary guide), without TruMatch® patient specific cutting guides.
3102254|NCT01876641|Experimental|Study Treatment|In Cohorts 1-4, a subcutaneous dose of decitabine will be administered three times/week over a 2 week period. Cohorts 5 and 6 will receive decitabine two times a week for 8 weeks and Cohorts 7 and 8 will receive decitabine three times a week for 8 weeks. Patients will start treatment with decitabine initially at the cohort in which they enter the study. Patients will remain in the cohort in which they were initially enrolled for the entire treatment course. Vemurafenib + Cobimetinib will be given continuously for subjects in Cohorts 5, 6, 7 and 8. Vemurafenib will be given on a 28-day cycle at the standard dose of 960 mg p.o. BID. Cobimetinib will be given on a 21-day cycle with a 7-day rest between cycles. Decitabine will be given for 2 cycles only. Each cycle will be 28 days long. Vemurafenib + Cobimetinib will be continued indefinitely until disease progression.
3102255|NCT01876628|Placebo Comparator|Flucloxacillin and placebo|Intravenous or oral Flucloxacillin with an oral placebo
3102256|NCT01876628|Active Comparator|Flucloxacillin and Clindamycin|Intravenous or oral Flucloxacillin with oral Clindamycin
3102257|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac(arm 1)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
3102258|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 2)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
3102259|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 3)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
3102310|NCT01876329||Autoimmune Thyroid Disease (AITD)|Participants with autoimmune thyroid disease without other known systemic or organ specific autoimmune illnesses.
3102261|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm5)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
3102262|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm6)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
3102263|NCT01876602|Experimental|Exercise prescription|"Participants are given an exercise prescription in the form of a target heart rate range for exercising. The range is determined based on their personal preferences so that it is an intensity that feels good."
3102264|NCT01876602|Active Comparator|traditional exercise|participants are given an exercise prescription based on percent of vo2 peak
3102265|NCT01876589|Active Comparator|Bioresorbable vascular scaffold|Paritcipants will receive a bioresorbable vascular scaffols (BVS)
3102266|NCT01876589|Active Comparator|Xience Prime|Participant will receive a Xience Prime stent
3102267|NCT01876576|Active Comparator|clear liquids|Clear liquids the day of bowel preparation up to 2.5 hrs before colonoscopy
3102268|NCT01876576|Active Comparator|low residue diet|Low residue breakfast and lunch up to 1pm; clear liquids thereafter up to 2.5 hrs before colonoscopy
3102269|NCT01876563|Active Comparator|diabetes, vitamin D|patients with type 2 diabetes who receive 4000 IU/day vitamin D
3102270|NCT01876563|Placebo Comparator|placebo, diabetes|patients with type 2 diabetes who receive one tab placebo
3102271|NCT01876550|Experimental|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.)
3102272|NCT01876550|Active Comparator|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline)
3102273|NCT01876550|Placebo Comparator|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.)
3102274|NCT01876537|Active Comparator|Usual surgery|
3102275|NCT01876537|Active Comparator|Hardware wound healing|
3102276|NCT01876524|Experimental|tRNS over Anterior Cingulate|Dual Pathology (Substance Use Disorder plus another psychiatric trait) 75 patients with diagnosed SUDs plus another psychiatric disorder will be receive tRNS in the disease-specific Anterior Cingulate Cortex (ACC), be studied blindly to evaluate the craving reduction after 35 tRNS sessions.
3102277|NCT01876524|Experimental|tRNS applied over DLPFC|Dual Pathology (Substance Use Disorder plus another psychiatric trait) 75 patients with diagnosed SUDs plus another psychiatric disorder will be receive tRNS in the dorso-lateral-prefrontal-cortex (DLPFC), be studied blindly to evaluate the craving reduction after 35 tRNS sessions.
3102278|NCT01876524|Sham Comparator|Sham Group|75 patients will be receive tRNS sham 35 sessions.
3102279|NCT01876511|Experimental|MSI Positive Colorectal Cancer|
3102280|NCT01876511|Experimental|MSI Negative Colorectal Cancer|
3102281|NCT01876511|Experimental|MSI Positive Non-Colorectal Cancer|
3102282|NCT01876511|Experimental|MSI Negative with Mutator Phenotype|
3102283|NCT01876498||Patient with M. Dupuytren|Xiaflex Surgery
3102284|NCT01876485|Experimental|Arm 1: Empowering Patients in Chronic Care (EPIC)|Patients in the intervention arm will receive the Empowering Patients in Chronic Care group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
3102285|NCT01876485|Active Comparator|Arm 2: Enhanced Usual Care (EUC)|The Enhanced Usual Care (EUC) arm will serve as a concurrent control group to compare to the intervention arm of the study. Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
3102286|NCT01876472||Children aged 3 - 10 years|Assessment of music perception skills with cochlear implant recipients aged 3 - 10 years
3102287|NCT01876472||Teenagers aged 11 - 15 years|Assessment of music perception skills with cochlear implant recipients aged 11 - 15 years
3102288|NCT01876472||Adults aged 16 - 70 years|Assessment of music perception skills with cochlear implant recipients aged 16 - 70 years
3102289|NCT01876459|Other|"Alzheimer's Disease arm"|Patient with Alzheimer's disease
3102290|NCT01876459|Other|"Lewy Body Disease arm"|Patient with Lewy Body Disease
3102291|NCT01876446|Experimental|Treatment (pegylated irinotecan NKTR 102)|Patients receive pegylated irinotecan NKTR 102 IV over 90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
3102292|NCT01876433|Active Comparator|Beta-3-agonist|Mirabegron 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.
3102293|NCT01876433|Placebo Comparator|Placebo|Placebo 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.
3102294|NCT01876420|Experimental|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 & 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
3102295|NCT01876407|Experimental|Low energy laser|Administration of a low energy laser for oral mucositis.
3102296|NCT01876407|Placebo Comparator|Placebo|
3102297|NCT01876394|Experimental|Coconut oil|
3102298|NCT01876394|Experimental|Canola oil|
3102299|NCT01876394|Experimental|Grapeseed oil|
3102300|NCT01876394|Experimental|Chia oil|
3102301|NCT01876394|Placebo Comparator|Butter|
3102302|NCT01876381|Experimental|OPC-41061|
3102303|NCT01876368|Experimental|LCZ696 200 mg|Patients will be treated with one LCZ696 200 mg tablet and one placebo of olmesartan 20 mg capsule once daily for 8 weeks.
3102304|NCT01876368|Active Comparator|Olmesartan 20 mg|Patients will be treated with one placebo of LCZ696 200 mg tablet and one olmesartan 20 mg capsule once daily for 8 weeks.
3102305|NCT01876355|Experimental|Clonidine|
3102306|NCT01876355|Placebo Comparator|Sodium chloride|
3102307|NCT01876342|Experimental|Open repair|Open minimal repair (OMR) of Sportsman's hernia using 2-0 continuous sutures
3102308|NCT01876342|Active Comparator|Endoscopic TEP repair|Totally Endoscopic extraperitoneal repair (TEP)using lightweight mesh
3102309|NCT01876329||Rheumatoid Arthritis|Patients with seropositive or seronegative Rheumatoid Arthritis
3102311|NCT01876329||Control|Participants without Rheumatoid Arthritis, AITD, or other systemic or organ specific autoimmune illnesses
3102312|NCT01876316|Active Comparator|Moxifloxacin|single oral administration of 400mg of moxifloxacin
3102313|NCT01876316|Placebo Comparator|Placebo|single oral administration of 400mg of placebo
3102314|NCT01876303||Ancillary-Correlative (genetic epidemiology of Ewing sarcoma)|Genomic DNA is extracted from participants' saliva samples and analyzed for expression of EWS-FLI1 and other ES-target genes.
3102315|NCT01876290|Experimental|Dexamethasone and Ondansetron|Each patient will receive Dexamethasone and Ondansetron
3102316|NCT01876290|Placebo Comparator|Placebo|Each patient will receive placebo instead of Dexamethasone and Ondansetron
3102317|NCT01876277||Adolescent males with cancer|Males aged 13-21 who have been treated at the Royal Marsden Hospital for cancer.
3102318|NCT01876264|Experimental|Extended resection|Patients undergoing an extended resection are subjected to a traditional ileocolic resection with a 2cm macroscopically normal proximal margin. A further 8cm of ileum is then resected from the proximal margin prior to formation of the ileocolic anastomosis
3102319|NCT01876264|Active Comparator|Conventional resection|Patients undergoing a traditional ileocolic resection for Crohn's disease with a 2cm proximal macroscopically disease-free margin
3102320|NCT01876251|Experimental|PF-03084014 plus docetaxel|PF 03084014 will be administered orally, continuously, twice daily at doses from 80 to 150 mg in combination with docetaxel given every 3 weeks at doses from 75 to 100 mg/m^2
3102321|NCT01876238|Experimental|T-PAT Intervention|Prognosis discussion intervention with study team.
3102322|NCT01876238|Active Comparator|Control: Standard Care|Usual care appointment
3102323|NCT01876225|No Intervention|No coughing|Cervical punch biopsy without forced coughing intervention
3102324|NCT01876225|Experimental|coughing|Forced coughing during cervical punch biopsy
3102325|NCT01876212|Experimental|Vaccine + dasatinib|"Patients will start vaccine on cycle 1, day 1 and dasatinib on cycle 2, day 1 (week 5).~All patients will receive dasatinib at a starting dose of 70 mg twice daily by mouth in the outpatient setting. Dasatinib will be supplied as 50 mg and 20 mg tablets. Patients will take 1 of the 50 mg tablets and 1 of the 20 mg tablets twice daily, approximately every 12 hours, at the same time each day.~The DC vaccine will be administered by a single intradermal injection of approximately 10e7 cells, with all the DCs being administered on days 1 and 15 of each cycle. The intradermal administration will be in the vicinity of the four nodal drainage groups of the four extremities."
3102326|NCT01876212|Experimental|Vaccine + dasatinib from cycle 1|"Patients will start vaccine on cycle 1, day 1 and dasatinib on cycle 1, day 1.~All patients will receive dasatinib at a starting dose of 70 mg twice daily by mouth in the outpatient setting. Dasatinib will be supplied as 50 mg and 20 mg tablets. Patients will take 1 of the 50 mg tablets and 1 of the 20 mg tablets twice daily, approximately every 12 hours, at the same time each day.~The DC vaccine will be administered by a single intradermal injection of approximately 10e7 cells, with all the DCs being administered on days 1 and 15 of each cycle. The intradermal administration will be in the vicinity of the four nodal drainage groups of the four extremities."
3102327|NCT01876199|Experimental|Intense follow up|2-week follow up appointment with addition of a reminder mobile phone call or short text message (SMS) if possible, plus a home visit by a community counselor if the participant fails to present on the appointed date.
3102328|NCT01876199|No Intervention|standard follow-up|2-week follow-up appointment with no reminders
3102329|NCT01876186|Experimental|Solifenacin for 12 weeks group|Solifenacin (5 mg qd) for 12 weeks
3102330|NCT01876186|Active Comparator|Solifenacin for 24 weeks group|Solifenacin (5 mg qd) for 24 weeks
3102331|NCT01876173|Experimental|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
3102332|NCT01876173|No Intervention|Usual care|The control group will not receive the patient decision aid prior to consultation with the physician.
3102333|NCT01876160|Experimental|threshold of sensory perception|Eighty healthy volunteers were evaluated; 40 women and 40 men divided into two equal groups of young and elderly subjects. Half of the individuals in each group were stimulated with 5 and 50Hz frequency, with pulse duration of 20, 100, 400, 1000 and 3000µs applied on the flexor muscle bellies of the wrist and fingers. The threshold of sensory perception was identified as the first sensation of increased current intensity and the threshold of motor response as the minimum muscle contraction detected.
3102334|NCT01876160|Experimental|threshold of motor response|Eighty healthy volunteers were evaluated; 40 women and 40 men divided into two equal groups of young and elderly subjects. Half of the individuals in each group were stimulated with 5 and 50Hz frequency, with pulse duration of 20, 100, 400, 1000 and 3000µs applied on the flexor muscle bellies of the wrist and fingers. The threshold of motor response as the minimum muscle contraction detected.
3102335|NCT01876147||Order of vision tests 1|Undergo testing with BRVT first, FrACT second.
3102336|NCT01876147||Order of vision tests 2|Undergo testing with FrACT first, BRVT second.
3102337|NCT01876134||Elective cardiac surgery|
3102338|NCT01876121||Celecox group|
3102339|NCT01876108|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity.
3102340|NCT01876108|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
3102341|NCT01876095|Experimental|Multidisciplinary medication review|"The multidisciplinary medication review consists of 5 steps:~Step #1: Assessing patients' experiences and preferences regarding medicine use en assessing their medical history, allergies and lab results Step #2: Drug reviewing to assess contra-indicated medication and duplicate medication using consensus criteria e.g. START STOPP Beers criteria Step #3: Reflecting on results of drug reviewing Step #4: Setting up a pharmacotherapeutical action plan Step #5: Execution of pharmacotherapeutical action plan"
3102342|NCT01876095|No Intervention|usual care|Includes medication safety monitoring and ad hoc medication reviews on clinical indication that differ in quality and frequency, but no standardized multidisciplinary multistep medication reviews in the way as described for the intervention arm
3102343|NCT01876082|Experimental|PAZOPANIB|"Pazopanib~800 mg per day~oral administration~at least 1 hour before or 2 hours after a meal,~until disease progression or for 12 months maximum"
3102344|NCT01876082|Active Comparator|Vinblastine and Methotrexate|vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
3102345|NCT01876069|Active Comparator|22 gauge ProCore needle aspiration|EUS-guided pancreatic mass aspiration with 22 gauge ProCore needle
3102346|NCT01876069|Active Comparator|22 gauge Fine needle aspiration|EUS-guided pancreatic mass aspiration with 22 gauge Fine needle
3102347|NCT01876056|Experimental|Brief CaCBTp|The experimental group will receive brief for of Culturally adapted CBT for psychossis
3102348|NCT01876056|No Intervention|Treatment As Usual|Treatment as usual means seeing a mental health professional and taking the prescribed anti psychotics and being cared by family members
3102349|NCT01876043|Experimental|plitidepsin|plitidepsin
3102350|NCT01876030|Experimental|FES|All subjects will receive a 15-30 minutes a day treatment for 5 days a week. When the subjects achieves the ability to walk with supervision, but with no physical assistance, safely and consistently during the physiotherapy sessions, then either the FES will be provided to the subject to allow ongoing gait practice with the nursing staff in the ward environment. After discharge, the assistive device will be provided for home usage till the end of the research.
3102351|NCT01876030|No Intervention|Conventional|Treated with regular gait re-education with or without AFO fitting. All subjects will receive a 15-30 minutes a day treatment for 5 days a week. When the subjects achieves the ability to walk with supervision, but with no physical assistance, safely and consistently during the physiotherapy sessions, then either the AFO will be provided to the subject to allow ongoing gait practice with the nursing staff in the ward environment. After discharge, the assistive device will be provided for home usage till the end of the research.
3102352|NCT01876017|Other|BMMNC|Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
3102353|NCT01876004|Experimental|Methotrexate|Administered a single intramuscular dose of 50 mg/m2 of Methotrexate.
3102354|NCT01876004|Placebo Comparator|Placebo|Prescribed Placebo intramuscularly.
3102355|NCT01875991|Experimental|Autoinjector A|Participants self-injected 50 mg etanercept once a week (RA) or twice a week (PsO) using Autoinjector A for 4 weeks.
3102356|NCT01875991|Experimental|Autoinjector B|Participants self-injected 50 mg etanercept once a week (RA) or twice a week (PsO) using Autoinjector B for 4 weeks.
3102357|NCT01875978|Active Comparator|Phytosterols & placebo|Group A:daily 1.8g phytosterols powder for 4 weeks first;group B:placebo for 4 weeks first
3102358|NCT01875952|Other|one arm|All patients with response to positive purified protein derivative (PPD) test are treated
3102359|NCT01875939|Other|Oral WCK 2349 fed/fasting|This is a single center, randomized, open label, 2X2 oral IV cross over, food-effect and absolute bioavailability study. The study will be conducted in three parts i.e., Period 1 and Period 2 (foodeffect study) and Period 3 (absolute bioavailability study).
3102360|NCT01875939|Other|IV WCK771|This is a single center, randomized, open label, 2X2 oral IV cross over, food-effect and absolute bioavailability study. The study will be conducted in three parts i.e., Period 1 and Period 2 (foodeffect study) and Period 3 (absolute bioavailability study).
3102361|NCT01875926|Experimental|ALX-0171 Oral Inhalation - Single Dose (SD)|
3102362|NCT01875926|Experimental|ALX-0171 Oral Inhalation - Multiple Dose (MD)|
3102363|NCT01875926|Experimental|ALX-0171 Intravenous (IV)|
3102364|NCT01875913|Experimental|Standard Message|Participants will receive email messages that encourage them to complete their VHR.
3102365|NCT01875913|Experimental|Curiosity Message|"Participants receive email messages containing curiosity-inducing questions. The messages tell the participants that they will receive the answer to the question after they complete their VHR."
3102366|NCT01875900|Active Comparator|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) digital video disc (DVD) will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
3102367|NCT01875900|Experimental|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
3102368|NCT01875887||treat bilateral maxillofacial deformties|treatment of bilateral maxillofacial post-traumatic deformities
3102369|NCT01875874|Experimental|ELAD plus standard of care|Continuous ELAD treatment for a minimum of 3 days to a maximum of 10 days in addition to a standard of care for subjects with acute liver failure.
3102370|NCT01875861|Experimental|Intervention|Evidence-Based Quality Improvement plus external facilitation to promote uptake of QI tools and improvement strategies available as part of a national initiative (the MIAMI Project) to disseminate recommendations, QI tools, and improvement strategies relevant to metabolic monitoring and management.
3102371|NCT01875861|No Intervention|Comparison|"Usual care, in the context of the MIAMI Project."
3102372|NCT01875848|Experimental|buprenorphine/naloxone|induction onto buprenorphine/naloxone from opioid treatment
3102373|NCT01875848|Active Comparator|opioid dose escalation|increase of up to 25% of current opioid dose
3102374|NCT01875835|Active Comparator|DES|Everolimus-Eluting Stent implanted in patients with ST-segment elevation myocardial infarction (STEMI)
3102375|NCT01875835|Active Comparator|BMS|Bare-Metal Stent implanted in patients with ST-segment elevation myocardial infarction (STEMI)
3102376|NCT01875822|Experimental|Supercurcumin|The study protocol stipulates that subjects diagnosed as DSM IV-TR (Diagnostic Statistical Manual IV-Transitional Revised) would be receiving either 1 gm Super-Curcumin@ capsule once daily or 4 gm Super-Curcumin@ once daily for a total of 16 weeks. Super-Curcumin@ in capsule form is a patented formulation of curcumin certified by Sabinsa Corp.NJ USA and produced by America's Finest Inc. 1 gm-capsule Super-Curcumin@ consist of 1 gm Curcumin C-3 complex and 5 mg of Bioperine.
3102377|NCT01875809||Renal denervation (RDN)|Change of catecholamine spill-over during RDN
3102378|NCT01875809||Electrophysiology (EP) Ablation|Change of catecholamine spill-over during EP ablation
3102418|NCT01875523|Experimental|Group 1 Treatment with serelaxin|Patients with severe renal impairment will receive a single 4 hour i.v. infusion of serelaxin
3102379|NCT01875796|Experimental|Cannabis & Anxiety Reduction Treatment|Cognitive-behavioral treatment program that integrates strategies to manage both cannabis use and anxiety with techniques to address motivation to change cannabis use.
3102380|NCT01875796|Active Comparator|Motivation/cognitive-behavioral therapy|Motivational Enhancement Therapy (MET) and cognitive-behavioral therapy (CBT) that includes techniques to address motivation to change cannabis use with strategies to manage use.
3102381|NCT01875783|Experimental|OCT imaging|All study participants will undergo optical coherence tomography imaging and will be referred to a retina specialist for further standard care evaluation and management if they are identified as having diabetic macular edema or the scan quality is not sufficient to evaluate macular status.
3102382|NCT01875770||Treated with Ranibizumab in previous trial|Treated with Ranibizumab in previous trial
3102383|NCT01875757|Experimental|Vitamin D3 1000 IU/day|Infants will be supplemented with vitamin D and/or placebo to receive a total amount of vitamin D3 of 1.000 IU/day during the first year of life, taking into account the vitamin D received with artificial milk
3102384|NCT01875757|Active Comparator|Vitamin D3 400 IU/day|Infants will be supplemented with vitamin D and/or placebo to receive a total amount of vitamin D3 of 400 IU/day during the first year of life, taking into account the vitamin D received with artificial milk
3102385|NCT01875744|Experimental|Polyethylene glycol small dose|Polyethylene glycol 4000: 0.3 g/kg/day for 6 weeks
3102386|NCT01875744|Active Comparator|Polyethylene glycol high dose|Polyethylene glycol 4000: 0.7g/kg for 6 weeks
3102387|NCT01875731|Experimental|BPS (Bacterial Pneumonia Score)|Strategy based on BPS guided antibiotic use
3102388|NCT01875731|Active Comparator|Guideline|Strategy based on enforced guideline guided antibiotic use
3102389|NCT01875718|Active Comparator|UC1010 low dose|
3102390|NCT01875718|Active Comparator|UC1010 high dose|
3102391|NCT01875718|Placebo Comparator|Vehicle|
3102392|NCT01875705|Experimental|Stage I-Dose Escalation|
3102393|NCT01875705|Experimental|Stage II-Cohort-Expansion|
3102394|NCT01875679|Active Comparator|Conventional residency training|This group will continue their regular surgical training without any specific intervention.
3102395|NCT01875679|Experimental|Comprehensive Surgical Coaching (SCS)|The participants will receive an analysis of the technical performance as observed on baseline recordings of the index procedure. Training needs will be identified and a personalized coaching concept will be designed. Coaching sessions will include video debriefing of the participant's performance (sample recordings will be submitted by the participant during the sessions) and video assisted behavioral modeling using examples of good and poor technical performance. Coaching will also target increasing awareness of weaknesses and potential pitfalls in surgical technical task execution (error recognition).
3102396|NCT01875666|Active Comparator|Trastuzumab|single dose intravenous infusion administration of trastuzumab (8 mg/kg)
3102397|NCT01875666|Active Comparator|pertuzumab|single dose infusion of pertuzumab (840 mg)
3102398|NCT01875666|Active Comparator|trastuzumab plus pertuzumab|single dose infusion of combination trastuzumab (8 mg/kg) plus pertuzumab (840 mg)
3102399|NCT01875666|Active Comparator|trastuzumab plus lapatinib|combination of single dose infusion of trastuzumab (8 mg/kg) plus oral lapatinib (1000 mg daily for 7 days)
3102400|NCT01875653|Active Comparator|Autologous PBMCs in GM-CSF (MC)|"DOSE/ROUTE/REGIMEN:~Treatment Duration: Doses of MC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.~Dosage: Each dose of MC contains approximately 10 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.~Mode of Administration: Subcutaneous (SC) injections."
3102401|NCT01875653|Experimental|Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|"DOSE/ROUTE/REGIMEN:~Treatment Duration: Doses of DC-TC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.~Dosage: Each dose of DC-TC contains approximately 10-20 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.~Mode of Administration: Subcutaneous (SC) injections."
3102402|NCT01875640||Usual Care|After obtaining consent, we will audio-record standard clinical consultations with specialists represented on the DSD team. These appointments will not utilize the Decision Support Tool. A qualitative analysis of these recordings will assess quality assurance and provide guidance for the development of the Decision Support Tool.
3102403|NCT01875640||Use of Decision Support Tool|After obtaining consent, we will audio-record standard clinical consultations with specialists represented on the DSD team. These appointments will utilize the Decision Support Tool (DST). A qualitative analysis of these recordings will assess the practicality of use and possible benefits of the DST's implementation.
3102404|NCT01875627|Placebo Comparator|Carbohydrate Noodles|0g Konjac Noodles
3102405|NCT01875627|Experimental|Carbohydrate and Konjac Noodles|Half Carbohydrate and Half Non-Caloric Konjac Noodles - 122.5g Konjac
3102406|NCT01875627|Experimental|Konjac Noodles|Non-Caloric Konjac Noodles (viscous gel meal) - 240g Konjac
3102407|NCT01875614|Experimental|Dipole Density Mapping|
3102408|NCT01875601|Experimental|A|NK cell infusion (dose escalation)
3102409|NCT01875601|Experimental|B|NK cell infusion + escalating doses of rhIL15
3102410|NCT01875575|Active Comparator|Glucose 10g|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)via nasogastric tube
3102411|NCT01875575|Active Comparator|Glucose 25g|25g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)via nasogastric tube
3102412|NCT01875575|Placebo Comparator|Placebo|intragastric tap water
3102413|NCT01875562|Experimental|Qishe Pill|
3102414|NCT01875549|Active Comparator|Unilateral stent insertion group|the use of unilateral stent insertion in malignant hilar obstruction for using endoscopic retrograde cholangiopancreatography(ERCP)
3102415|NCT01875549|Active Comparator|Bilateral stent insertion group|the use of bilateral stent insertion in malignant hilar obstruction for using endoscopic retrograde cholangiopancreatography(ERCP)
3102416|NCT01875536|Experimental|rTMS|The experimental group received rTMS to the primary motor cortex of the unaffected side in 10 sessions, 3 days per week, and conventional physical therapy
3102417|NCT01875536|Sham Comparator|control|The control group received sham stimulation (same area as the experimental group) in 10 sessions, 3 days per week, and conventional physical therapy
3102456|NCT01875250|Experimental|Arm B|Enzalutamide 3 months + PSA-TRICOM on weeks 1, 3, 5, 9,13,17 and 21
3102419|NCT01875523|Experimental|Group 2 Treatment with serelaxin|Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment
3102420|NCT01875523|Experimental|Group 3 Treatment with serelaxin|Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and treatment and PK will be done in dialysis-free interval
3102421|NCT01875523|Experimental|Group 4 Treatment with serelaxin|Healthy volunteers will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment
3102422|NCT01875510|Active Comparator|Fish-oil emulsions|Fish-oil emulsions:Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg.
3102423|NCT01875510|Placebo Comparator|soybean-oil emulsion|Preterm infants will receive a soybean-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and the third day and after 3gr/kg
3102424|NCT01875497|Experimental|Dietary Supplement|Before the exercise, the individuals intake only one capsule with 205 mg of the grape fruit extract in capsule with 205 mg.
3102425|NCT01875484||High miR-126 group|
3102426|NCT01875484||Moderate miR-126 group|
3102427|NCT01875484||Low miR-126 group|
3102428|NCT01875471|Active Comparator|delefilcon A|Spherical daily disposable soft contact lens
3102429|NCT01875471|Experimental|narafilcon A|Spherical daily disposable soft contact lens Class 1 UV blocking
3102430|NCT01875458||CASES|Adults with current or past history of bisphosphonate treatment (exposed) with Bisphosphonate related Osteonecrosis of the Jaws (BRONJ), or, Adults with current or past history of bisphosphonate treatment (exposed) with atypical fracture
3102431|NCT01875458||COUNTER MATCHED CONTROLS|Adults with current or past history of bisphosphonate treatment (exposed) without bisphosphonate related osteonecrosis of the jaws (BRONJ, or, Adults with current or past history of bisphosphonate treatment (exposed) with typical fracture or joint replacement or osteoporosis
3102432|NCT01875458||MATCHED CONTROLS|Adults without current bisphosphonate treatment (unexposed) with Typical fracture (healthy fracture patients) Adults without current bisphosphonate treatment (unexposed) without BRONJ (healthy oral surgery subjects or adults with radionecrosis of the jaws)
3102433|NCT01875458||Healthy Adult Volunteers|Healthy volunteers with or without current bisphosphonate treatment without jaw or extremity pathologies or injuries to contribute blood and saliva samples only.
3102434|NCT01875445|Placebo Comparator|Placebo|Matched dosage of inositol daily.
3102435|NCT01875445|Active Comparator|Inositol|Powder form, 2g TID up to 6g TID
3102436|NCT01875419|Experimental|Patients tDCS|A group of 30 patients will receive active tDCS stimulation once a week for 8 weeks, immediately prior to CBT.
3102437|NCT01875419|Sham Comparator|Patients - Sham|Another group of 30 patients will receive sham stimulation once a week during 8 weeks, immediately prior to CBT.
3102438|NCT01875406|Experimental|diagnostic exercises|The three diagnostic exercises will be administered in random order to minimize effects of order and period on the results. Enrollment logs and study randomization will be administered electronically via a respective REDCap data modules. The enrollment, randomization and diagnostic tests will be administered by research coordinator or PI. The patients will be independently evaluated and scheduled for SIJ injection by Cleveland Clinic pain clinic staff and fellow pain physicians.
3102439|NCT01875393|Experimental|TOOKAD® Soluble|TOOKAD® Soluble, lyophilized formulation,given at a dose of 4 mg/kg.
3102440|NCT01875380|Experimental|Regorafenib|Regorafenib will be administered orally at the initial dosage of 160 mg per day for 3 weeks,followed by one week of rest, according to the 3/1 regimen.
3102441|NCT01875367|Experimental|Trastuzumab subcutaneous inyection vial|Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles
3102442|NCT01875367|Experimental|Trastuzumab subcutaneous device administration|Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
3102443|NCT01875354|Placebo Comparator|Placebo and Low Fat Eating Plan|"Placebo Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Placebo Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Placebo Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)~The placebo group will be instructed to consume every day, a low fat standard of care eating plan delivering approximately 1200-1500 Kcals."
3102444|NCT01875354|Experimental|Dietary Supplements and TR90 Eating Plan|"Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)~Experimental group will be instructed to consume every day, dietary supplements and a moderate protein eating plan delivering approximately 1200-1500 Kcals."
3102445|NCT01875341|Active Comparator|Active treatment with NCPAP|This group will receive treatment with NCPAP, Nasal Continuous Positive Airway Pressure for 6 weeks. Nasal Continuous Positive Airway Pressures will be increased until apneas & hypopneas are prevented during all sleep stages.
3102446|NCT01875341|Sham Comparator|Sub- active treatment with NCPAP|This group will receive treatment with Nasal Continuous Positive Airway Pressure at sub-therapeutic levels for 6 weeks. Patients will be taught how to use NCPAP in the sleep lab. Pressures will be left unchanged at the lowest possible value for the NCPAP device. After completion of treatment patients will be provided usual NCPAP therapy.
3102447|NCT01875328|Experimental|Telemedicine|Telemedicine group
3102448|NCT01875328|Active Comparator|Clinic|Clinic group
3102449|NCT01875289|Experimental|Ropivacain|Local anaesthesia
3102450|NCT01875289|Placebo Comparator|NaCl 0.9%|Saline
3102451|NCT01875276||Persistent Patients|Defined as those with ≥1 treatment for allergic rhinitis in the six months preceding the IPD (defined as the first script of the hay fever season - May to August)
3102452|NCT01875276||Seasonal Rhinitis|No treatment for allergic rhinitis in the six months preceding the IPD
3102453|NCT01875263|Experimental|Experimental|Cloxacillin 2g / 4 hours iv, 5 days followed levofloxacin 500 mg po / 24, 9 days.
3102454|NCT01875263|Active Comparator|Control|Cloxacillin 2g / 4 hrs iv 14 days
3102455|NCT01875250|Experimental|Arm A|Enzalutamide for 3 months
3102457|NCT01875237|Experimental|Stem Cell Transplant + Modified T-Cells + Chemotherapy|The first component is stem cell transplant. Goal is to administer more than 3 x 106 CD34+ cells/kg of peripheral blood progenitor cells (PBPC). The second component is the planned DLI infusion. iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 10^6/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64. The transplant day is referred to as day zero (D0), treatment plan activities prior or after D0 are denoted as day minus (D-) or day plus (D+). Patients receive standard reduced intensity regimen using fludarabine, melphalan, and alemtuzumab to achieve engraftment with a low risk of GVHD. At approximately 60 days post transplant patients who are alive and without GVHD, receive DLI to enhance graft-vs.-malignancy and immune reconstitution.
3102458|NCT01875224|Experimental|Belatacept and CellCept|Belatacept administered based on patient's weight once a month after initial period, Cellcept taken twice daily.
3102459|NCT01875224|Active Comparator|Tacrolimus and CellCept|Tacrolimus and CellCept taken twice daily based on patient response.
3102460|NCT01875198|Experimental|RAMPS|Radical Antegrade Modular Pancreatectomy with Splenectomy
3102461|NCT01875198|Active Comparator|RAMP|Radical Antegrade Modular Pancreatectomy without splenectomy
3102462|NCT01875185|Experimental|Aspirin|The patients are given aspirin 81 mg orally for 7 days.
3102463|NCT01875172|Experimental|Bupropion SR|Study medication (150 mg bupropion SR) daily for 14 days. Women still smoking at 2-weeks & 4-weeks were encouraged to increase their medication to two times per day (150 mg bid). Women received smoking cessation counseling at baseline, 2, 4, 6, and 8 weeks.
3102464|NCT01875172|Placebo Comparator|Placebo|Study medication (placebo) daily for 14 days. Women still smoking at 2-weeks & 4-weeks were encouraged to increase their medication to two times per day. Women received smoking cessation counseling at baseline, 2, 4, 6, and 8 weeks.
3102465|NCT01875159|Experimental|Caffeine|Caffeine citrate 6 mg/kg/day
3102466|NCT01875159|No Intervention|Active Comparator: no caffeine|Compare extended use of caffeine citrate 6 mg/kg/day to no caffeine (usual care) in regard to extent of intermittent hypoxia from 35 weeks postmenstrual age (PMA) to 40 weeks PMA.
3102467|NCT01875146|Active Comparator|4x4 min HIT|Conventional 4x4 min high-intensity interval training
3102468|NCT01875146|Experimental|4x4 min HIT + WBV (18 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 18 Hz during the active rest
3102469|NCT01875146|Experimental|4x4 min HIT + WBV (30 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 30 Hz during the active rest
3102470|NCT01875146|Active Comparator|whole-body vibration at 30 Hz|4x3 min whole-body vibration at 30 Hz
3102471|NCT01875133|Other|A: low-intermediate-high altitude|Altitude exposure sequence A, 490-1630-2590m
3102472|NCT01875133|Other|B: low-high-intermediate altitude|Altitude exposure sequence B, 490-2590-1630 m
3102473|NCT01875133|Other|C: intermediate-high-low altitude|Altitude exposure sequence C, 1630-2590-490 m
3102474|NCT01875133|Other|D: high-intermediate-low altitude|Altitude exposure sequence D, 2590-1630-490 m
3102475|NCT01875120||Female patients with increased risk to experience PONV.|
3102476|NCT01875107|Experimental|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
3102477|NCT01875094|Experimental|Self-Management / MTM via Health IT|Stroke survivors are trained to measure and enter BP into an online health management tool
3102478|NCT01875094|No Intervention|Usual Care|
3102479|NCT01875081|No Intervention|Control group|Best Supportive care
3102480|NCT01875081|Experimental|1-time injection group: Livercellgram|Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery.
3102481|NCT01875081|Experimental|2-time injection group: Livercellgram|Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery. Within 1 month after cell injection, re-inject autologous bone marrow-derived mesenchymal stem cells.
3102482|NCT01875068|Experimental|NPs & PAs referral discussions with a supervising physician|required consultations between NPs and PAs and their supervising physicians
3102483|NCT01875068|Other|NPs and PAs - no consultations with supervising physisians|NPs and PAs who are not required to discuss patient referrals
3102484|NCT01875055|Experimental|NIRS derived cerebral oximetry|NIRS derived cerebral oximetry device used but data not visable to ICU caregivers
3102485|NCT01875055|Active Comparator|NIRS and Algorithm|NIRS derived cerebral oximetry device used and the caregiver in the ICU will see the data in order to guide the use of the interventional algorithm to treat the cerebral desaturation
3102486|NCT01875042|Experimental|TENS|Transcutaneous Electrical Nerve Stimulation
3102487|NCT01875042|Sham Comparator|Sham TENS|Sham Transcutaneous Electrical Nerve Stimulation
3102488|NCT01875029|Sham Comparator|sham-tDCS + Back School|"This group will receive sham-tDCS for 5 days before back school beginning. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 30 seconds, with an intensity of 1 milliampere.~The back school session, a behavioural intervention,will be given 10 times for 4 weeks."
3102489|NCT01875029|Experimental|real-tDCS + Back School|"This group will receive continuous stimulation lasting 20 minutes daily, for 5 days before back school beginning. The back school session, a behavioural intervention,will be given 10 times for 4 weeks.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 20 minutes, with an intensity of 1 milliampere."
3102515|NCT01874834|Experimental|Diesel Exhaust, No ozone|2 hr exposure to whole diesel exhaust (300 ug/m3; gases + particles) with intermittent exercise; no ozone
3102516|NCT01874834|Experimental|Ozone + Diesel Exhaust|2 hr exposure to a combination of 300 ppb ozone an 300 ug/m3 whole diesel exhaust with intermittent exercise
3102490|NCT01875003|Experimental|Lebrikizumab High|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500−2000 micrograms [mcg] of fluticasone propionate dry powder inhaler [DPI] or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (high dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.
3102491|NCT01875003|Experimental|Lebrikizumab Low|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500−2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (low dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.
3102492|NCT01875003|Placebo Comparator|Placebo|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500−2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab matching placebo Q4W for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at high or low dose will be administered from Weeks 52 to 76 or 104 to participants who are willing to take part in optional active-treatment extension period.
3102493|NCT01874990|Experimental|women with a history of severe preeclampsia|women with a history of severe preeclampsia(< 34 weeks gestation) between 5 and 10 years ago
3102494|NCT01874990|Experimental|control|women with no history of pregnancy-related hypertensive complications
3102495|NCT01874977|Experimental|Pedometer only|This group will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer. Participants will be shown how to wear the pedometer, and instructed to wear it from the time they get out of bed in the morning until they go to bed at night, except while showering or bathing. (If any subjects begin a swimming- or cycling-based activity program, we will ask them to remove the pedometer at that time but track the time they are in the water. Step counts will be adjusted to account for this time by adding 150 steps for every minute engaged in swimming and/or cycling.)
3102496|NCT01874977|Experimental|Pedometer + step count goals|Pedometer + step goals. This group will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
3102497|NCT01874977|Other|Education materials|"Educational materials. This group will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment. They will receive follow-up contact at the same time points as the intervention groups, although the Week 0 and Week 1 contacts will be by phone instead of in-person and the content of contacts will be different."
3102498|NCT01874964|Experimental|Methadone Maintenance|Participants assigned to Arm 1 will be maintained on ther pre-incarceration methadone dosage during short term incarceration (6 months or less) and will be actively transferred back to their community methadone clinic upon release from incarceration. Additionally, the study will pay for the cost of methadone maintenance treatment for 10 weeks after re-enrollment post release.
3102499|NCT01874964|Active Comparator|Methadone Detoxification|Individuals assigned to Arm 2 will undergo methadone detoxification as is standard procedure at the Rhode Island Department of Corrections. They will receive active assistance with returning to their home methadone clinic upon release from incarceration and 10 weeks financial assistance to pay for treatment.
3102500|NCT01874951|Placebo Comparator|Placebo|In this arm, patients will receive placebo for three weeks.
3102501|NCT01874951|Experimental|Naltrexone|In this arm, patients will receive low dose naltrexone for three weeks.
3102502|NCT01874938|Experimental|LY2875358|LY2875358 will be administered intravenously (IV) at 2000 milligram (mg) bi-weekly in 28 day Cycle.
3102503|NCT01874899|Active Comparator|Manual, then Automatic Stimulation|The RestoreSensor neurostimulator will be programed for manual stimulation adjustments and the patients will crossover to automatic stimulation group after 1.5 months
3102504|NCT01874899|Active Comparator|Automatic, then Manual Stimulation|The RestoreSensor neurostimulator will be programed for automatic stimulation adjustments and the patients will crossover to manual stimulation group after 1.5 months.
3102505|NCT01874886||Cannabis users|⋄Heavy Marijuana Users : 60-80 years old; Marijuana use initiated in adolescence with marijuana use of no more than 1-2 x/month after 30 years of age; Used marijuana more than 20 times/month for at least 1 year during this period. Cigarette smoking (tobacco) and alcohol will be allowed in both groups, which will be matched on number of smokers and nicotine dependence, measured according to the Fagerstrőm Test for Nicotine Dependence. Light alcohol use will also be allowed in and matched across both groups (< 14 drinks/week for men; < 7 drinks/week for women; may not meet DSM-IV criteria for alcohol dependence).
3102506|NCT01874886||Clean or Non-Users|⋄No marijuana use, may smoke cigarettes, fewer than 7 drinks/week (women) or 14 drinks/week (men). 60-80 years old.
3102507|NCT01874873|Experimental|Anlotinib|
3102508|NCT01874860|Experimental|Extensive treatment group|"Doxycycline capsule, 100 mg, taken twice daily; sunscreen SPF 30 or higher applied to exposed skin areas at least 30 minutes before going outdoors each morning; moisturizer applied to the face, hands, feet, neck, back, and chest each morning after sunscreen; Hydrocortisone 1% topical cream applied to the face, hands, feet, neck, back, and chest each evening.~For patients with grade 1 rash, hydrocortisone 1% cream and clindamycin 1% gel (tetracycline antibiotic) are recommended for daily use.~For patients with grade 2 rash, hydrocortisone cream and doxycycline 100mg twice daily or minocycline (tetracycline antibiotic) 100mg once daily is recommended.~For patients with grade 3 rash, systemic steroid therapy (a Medrol dose-pack) will be added to the grade 2 treatment."
3102509|NCT01874860|Experimental|Standard care group|Patient will not receive preventive treatment but will be allowed to use sunscreen and moisturizer if desired.
3102510|NCT01874847|Experimental|Melatonin 10mg|Melatonin 10mg capsule(high dose arm), oral, once at night, given for 28 days
3102511|NCT01874847|Placebo Comparator|Sugar Pill|Sugar Pill, one capsule, once at night, 28 days
3102512|NCT01874847|Experimental|Melatonin 3mg|Melatonin 3mg capsule (low dose arm), once, at night, 28 days
3102513|NCT01874834|Placebo Comparator|Filtered air exposure|2 hr exposure to clean, filtered air with intermittent exercise
3102514|NCT01874834|Experimental|Ozone|2 hr exposure to 300 ppb ozone with intermittent exercise
3102517|NCT01874821|Experimental|Dynasplint|Along with standard manual physical therapy, patients will have a stretching device (Dynasplint) used in rehabilitation to regain ROM in stiff joints. Patients will use this device 20-30 minutes 2 times per day at home.
3102518|NCT01874821|Other|Control|Patient's in the Physical Therapy Group will have the standard manual treatments during their usual physical therapy visits with no additional intervention
3102519|NCT01874808||Healthy|Healthy
3102520|NCT01874808||ALS with postural instability|ALS with postural instability
3102521|NCT01874808||ALS without postural instability|ALS without postural instability
3102522|NCT01874795|Experimental|Ganglionar Electrical Stimulation|TENS intervention consisted of continuous flow, symmetrical and rectangular TENS biphasic pulses. The frequency ofstimulation was 80 Hz and the pulse duration was 150 μs, with the intensity in adjusted to the point of muscle contraction.
3102523|NCT01874795|Sham Comparator|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
3102524|NCT01874782|Experimental|Transcranial electrical stimulation|Subject will be determined as autonomically complete or incomplete injury with measuring of the sympathetic skin responses (SSR+), an established protocol for measuring integrity of sympathetic spinal pathways, versus complete autonomic injury (SSR-).
3102525|NCT01874769||Blood collection and skin biopsies|
3102526|NCT01874756|Experimental|LY500307 150mg|LY500307 150mg
3102527|NCT01874756|Placebo Comparator|placebo|placebo 6 pills of inactive drug
3102528|NCT01874756|Experimental|LY500307 75mg|LY500307 75mg
3102529|NCT01874743|Experimental|Rosuvastatine 20 mg|Rosuvastatin 20 mg/day, once a day during 3 months
3102530|NCT01874730|Other|Standard of Care (SOC)|Intraoperative fluid management includes Volulyte® (6% hydroxyethyl starch {HES} 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg. Intraoperative anesthesia and postoperative analgesia will follow the established practice of the individual institution.
3102531|NCT01874730|Active Comparator|Enhanced Recovery Strategy (ERS) group|GDFT regimen using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg. Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
3102532|NCT01874717|Experimental|oral midazolam|oral administration of midazolam : the dose administered is twice the individual dose determined in session 1.
3102533|NCT01874717|Other|intravenous midazolam|intravenous administration of midazolam at the individual dose determined in session 1
3102534|NCT01874704|Other|biomarkers of stress|Comparison of biomarkers of stress in emergency physicians working a 24-hour shift or a 14-hour night shift
3102535|NCT01874691||acute myocardial infarction|acute myocardial infarction including ST-elevation and non ST-elevation myocardial infarction
3102536|NCT01874678|Experimental|TS-1/Cisplatin|single arm
3102537|NCT01874665|Experimental|Cohort A|Participants with KIT exon 11-mutant GIST.
3102538|NCT01874665|Experimental|Cohort B|Participants with GIST that lack KIT exon 11 mutations (Cohort B).
3102539|NCT01874652|Experimental|Light Weight Breast Implants|Assessment of Safety and Efficacy of Light Weight Breast Implant
3102540|NCT01874639|Experimental|hepatectomy ( conventional hemostasis )|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~- Control group: hepatectomy with conventional hemostasis using standard bipolar coagulation"
3102541|NCT01874639|Other|hepatectomy with Aquamantys|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~- Test group: hepatectomy with Aquamantys®"
3102542|NCT01874626|Active Comparator|Active|SST-0225 Topical Ibuprofen Cream (investigational product) Dose: 2.7 grams of cream containing 200 mg ibuprofen
3102543|NCT01874626|Placebo Comparator|Placebo|Placebo topical formulation (Reference product)
3102544|NCT01874613|Experimental|Skull bone reconstruction|Patients with skull bone defect
3102545|NCT01874613|Experimental|Orbital floor defect|Patients with orbital floor defect
3102546|NCT01874600||Epilepsy Patients|This study will compare accuracy of seizure detection by the study device to simultaneously collected data of seizure detection by video EEG.
3102547|NCT01874587|No Intervention|standard radiotherapy|single pre-treatment planning before radiotherapy
3102548|NCT01874587|Experimental|adaptative radiotherapy|adaptive Radiotherapy based on a weekly replanning
3102549|NCT01874574|Experimental|Single shot Hylan G-F 20 (Synvisc)|Intra-articular injection of the Single shot 6 mL of Hylan G-F 20 (Synvisc)
3102550|NCT01874574|Active Comparator|Corticosteroid (Triamcinolone acetonide)|Intra-articular injection of 1 mL of 40 mg Triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline injected at the knee by single shot
3102551|NCT01874561|Experimental|Group 1|"Group 1: investigational product (custirsen) will receive:~320 mg of custirsen + 5 mg of dexamethasone on day 1~480 mg of custirsen + 5 mg of dexamethasone on day 3~640 mg of custirsen + 3 mg of dexamethasone on day 5~640 mg of custirsen on day 7 under fasting conditions"
3102552|NCT01874561|Placebo Comparator|Group 2|"Group 2: placebo (normal saline) will receive:~placebo + 5 mg of dexamethasone on day 1~placebo + 5 mg of dexamethasone on day 3~placebo + 3 mg of dexamethasone on day 5~placebo on day 7 under fasting conditions"
3102553|NCT01874561|Active Comparator|Group 3|"Group 3: positive control (moxifloxacin) will receive:~placebo + 5 mg of dexamethasone on day 1~placebo + 5 mg of dexamethasone on day 3~placebo + 3 mg of dexamethasone on day 5~400 mg of moxifloxacin + placebo (immediately after moxifloxacin administration) on day 7 under fasting conditions"
3102554|NCT01874548||Normal cervix|Control group (n=30) comprising surgical candidates with normal cervical tissue will be collected for comparison.
3102555|NCT01874548||Cervical cancer|"1st year: 30 surgical candidates with cervical cancer tissue collected during operation.~2nd year: Enroll another 30 surgical candidates and complete the data regarding clinical MRS/DWI and tissue high resolution MRS. Together with the 30 cancer subjects in part one there will be in total 60 cancer subjects for analysis.~3rd year: enroll 60 patients primarily treated with CCRT and collect the data using clinical MR and tissue high resolution MRS."
3102725|NCT01873534|Experimental|FMX-8 (0.5 mg/kg)|0.5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
3102556|NCT01874535|Other|GERD Los Angeles A and B|Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily
3102557|NCT01874522|Experimental|TAS-102 tablets|
3102558|NCT01874522|Experimental|TAS-102 oral solution|
3102559|NCT01874509|Active Comparator|Check Your Drinking screener|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
3102560|NCT01874509|Experimental|Alcohol Help Centre|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
3102561|NCT01874496|Experimental|GDS, meal|GDS, meal
3102562|NCT01874496|Experimental|GDS, no meal|GDS, no meal
3102563|NCT01874496|Active Comparator|control, no meal|control, no meal
3102564|NCT01874496|Active Comparator|control, meal|control, meal
3102565|NCT01874483|Experimental|BI 187004 dose 1|multiple dose given over 14 days
3102566|NCT01874483|Experimental|BI 187004 dose 2|multiple dose given over 14 days
3102567|NCT01874483|Experimental|BI 187004 dose 3|multiple dose given over 14 days
3102568|NCT01874483|Experimental|BI 187004 dose 4|multiple dose given over 14 days
3102569|NCT01874483|Experimental|BI 187004 dose 5|multiple dose given over 14 days
3102570|NCT01874483|Experimental|BI 187004 dose 6|multiple dose given over 14 days
3102571|NCT01874483|Placebo Comparator|Placebo|placebo
3102572|NCT01874483|Experimental|BI 187004 dose 7|multiple dose given over 14 days
3102573|NCT01874470|Placebo Comparator|standard medication|Standard Medication: Continued usage of 3 or more antihypertensive medications of different classes, including a diuretic
3102574|NCT01874470|Experimental|renal denervation|Allegro Renal Denervation System (AngioCare)
3102575|NCT01874444|Experimental|Active rTMS1|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex .
3102576|NCT01874444|Experimental|Active rTMS2|Temporal low frequency rTMS of left primary auditory cortex.
3102577|NCT01874444|Experimental|Active rTMS3|Frontal low frequency rTMS of left dorsolateral prefrontal cortex .
3102578|NCT01874444|Sham Comparator|Sham rTMS4|sham treatment Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.
3102579|NCT01874431|Experimental|Finerenone (BAY 94-8862) (1.25 mg)|1.25 mg dose oral once daily for 90 days
3102580|NCT01874431|Experimental|Finerenone (BAY 94-8862)(2.5 mg)|2.5 mg dose oral once daily for 90 days
3102581|NCT01874431|Experimental|Finerenone (BAY 94-8862)(5 mg)|5 mg dose oral once daily for 90 days
3102582|NCT01874431|Experimental|Finerenone (BAY 94-8862)(7.5 mg)|7.5 mg dose oral once daily for 90 days
3102583|NCT01874431|Experimental|Finerenone (BAY 94-8862) (10 mg)|10 mg dose oral once daily for 90 days
3102584|NCT01874431|Experimental|Finerenone (BAY 94-8862) (15 mg)|15 mg dose oral once daily for 90 days
3102585|NCT01874431|Experimental|Finerenone (BAY 94-8862)(20 mg)|20 mg dose oral once daily for 90 days
3102586|NCT01874431|Placebo Comparator|Placebo|Placebo oral dose once daily for 90 days
3102587|NCT01874418|Other|Biomarker study|Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
3102588|NCT01874392|Experimental|T1DM|Adults aged 21-65 years with type 1 diabetes mellitus for at least one year who are using an insulin infusion pump with rapid-acting insulin for at least six months
3102589|NCT01874379|Experimental|Guided Imagery|The therapist will instruct the patient on the Guided Imagery protocol and will provide the patient with headphones and an MP-3 player to use for the guided imagery intervention. The patient will listen to the Guided Imagery for 18min 30 sec.
3102590|NCT01874379|Active Comparator|Standard of Care|This group will serve as the control arm
3102591|NCT01874379|Experimental|'M'-Technique®|The 'M'-Technique will be administered to the patient's hands and feet for a total of 18-20 minutes, to be equally divided between extremities used according to limitations as outlined. Any hand or foot that is accessed by an IV will be avoided.
3102592|NCT01874366|Experimental|P11187|"Part I: Step wise dose escalation in subsequent cohorts and will be based upon the review of safety and tolerability results of the preceding cohort~Part II: Step wise dose escalation in the multiple dosing for 14 consecutive days after review of the safety and tolerability of the preceding cohorts~Part III: Study drug will be administered under the fasted or fed conditions in two different periods separated by a wash-out interval of 7-10 days"
3102593|NCT01874366|Placebo Comparator|Placebo|Placebo capsules will be matching in appearance with the active drug capsules of P11187.
3102594|NCT01874353|Experimental|Olaparib 300mg tablets|Taken orally twice daily
3102595|NCT01874353|Placebo Comparator|Placebo tablets|Taken orally twice daily
3102596|NCT01874340|Experimental|AIN457 low dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 low dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis.
3102597|NCT01874340|Placebo Comparator|Placebo|Matching placebo will be administered intravenously. Approximately 105 patients will be randomized to placebo (65 in Stage 1 and 40 in Stage 2).
3102598|NCT01874340|Experimental|AIN457 middle dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 middle dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis
3102599|NCT01874340|Experimental|AIN457 high dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 high dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis.
3102600|NCT01874327|Active Comparator|Baby JASPER|This classroom will spend the majority of the time focusing on social-communication goals
3102601|NCT01874327|Active Comparator|Standard Baby Classroom|This classroom will focus more heavily on developing motor and cognitive skills
3102602|NCT01874314|Experimental|SQ109 450 mg|Single daily dose of oral 450mg SQ109 for 7 days.
3102603|NCT01874314|Active Comparator|Moxifloxacin|Single daily dose of oral 400mg moxifloxacin for 7 days followed by 7 days washout period.
3102604|NCT01874314|Placebo Comparator|SQ109 Placebo|Single daily dose of oral SQ109 placebo for 7 days followed by 7 days washout period.
3102605|NCT01874314|Experimental|SQ109 300 mg|Single daily dose of oral 300mg SQ109 for 7 days followed by 7 days washout period.
3102606|NCT01874301|Experimental|High quantity probiotic food product|
3102607|NCT01874301|Experimental|Low quantity probiotic food product|
3102608|NCT01874301|Placebo Comparator|Placebo|
3102609|NCT01874288|Experimental|0.5 mg/m2 DI-Leu16-IL2|0.5 mg/m2 DI-Leu16-IL2 subcutaneous dose administered to patients thrice weekly every three weeks for a total of 18 doses. Patients may receive approximately 6 cycles of DI-Leu16-IL2 and will remain on the same dose throughout the Phase 1 of the study.
3102610|NCT01874288|Experimental|1.0 mg/m2 DI-Leu16-IL2|1.0 mg/m2 DI-Leu16-IL2 subcutaneous dose administered to patients thrice weekly every three weeks for a total of 18 doses. Patients may receive approximately 6 cycles of DI-Leu16-IL2 and will remain on the same dose throughout Phase 1 of the study.
3102611|NCT01874288|Experimental|2.0 mg/m2 DI-Leu16-IL2|2.0 mg/m2 DI-Leu16-IL2 subcutaneous dose administered to patients thrice weekly every three weeks for a total of 18 doses. Patients may receive approximately 6 cycles of DI-Leu16-IL2 and will remain on the same dose throughout the study.
3102612|NCT01874288|Experimental|4.0 mg/m2 DI-Leu16-IL2|4.0 mg/m2 DI-Leu16-IL2 subcutaneous dose administered to patients thrice weekly every three weeks for a total of 18 doses. Patients may receive approximately 6 cycles of DI-Leu16-IL2 and will remain on the same dose throughout Phase 1 of the study.
3102613|NCT01874288|Experimental|6.0 mg/m2 DI-Leu16-IL2|6.0 mg/m2 DI-Leu16-IL2 subcutaneous dose administered to patients thrice weekly every three weeks for a total of 18 doses. Patients may receive approximately 6 cycles of DI-Leu16-IL2 and will remain on the same dose throughout Phase 1 of the study.
3102614|NCT01874288|Experimental|8.0 mg/m2 DI-Leu16-IL2|8.0 mg/m2 DI-Leu16-IL2 subcutaneous dose administered to patients thrice weekly every three weeks for a total of 18 doses. Patients may receive approximately 6 cycles of DI-Leu16-IL2 and will remain on the same dose throughout Phase 1 of the study.
3102615|NCT01874288|Experimental|10.0 mg/m2 DI-Leu16-IL2|10.0 mg/m2 DI-Leu16-IL2 subcutaneous dose administered to patients thrice weekly every three weeks for a total of 18 doses. Patients may receive approximately 6 cycles of DI-Leu16-IL2 and will remain on the same dose throughout Phase 1 of the study.
3102616|NCT01874288|Other|50mg/m2 Rituximab|Pre-treatment with Rituximab will occur on Day 1 if patient's Rituximab level is <10 μg/mL; intended to bring their level above10 μg/mL.
3102617|NCT01874275|Experimental|VECTTOR|nerve stimulator treatment twice daily for duration of study - 365 days
3102618|NCT01874275|Placebo Comparator|Device - sham|placebo treatment - no electrical stimulation treatment twice daily for duration of study, 180 days - if VECTTOR arm experiencing improvement, subjects in Device-Sham arm will be crossed over into the VECTTOR group and followed for an additional 180 days, for a total study involvement (duration) of 365 days>
3102619|NCT01874262|Experimental|Active group|The software application used on the patients' smart phones in the active group, will contain both the e-diary and the mobile-phone based patient support. Patients will receive feedback by the mobile-phone based support not only on the data they enter into the mobile-phone based patient support but also on their reported daily ticagrelor use.
3102620|NCT01874262|Placebo Comparator|The control group|In this group the patients will have access to the e-diary only, in which they will report their daily use of ticagrelor. The patients in the control group will not receive any feed-back.
3102621|NCT01874249|Experimental|Electronic detailed information|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease.
3102622|NCT01874249|Experimental|NAFLD Score|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score.
3102623|NCT01874249|Experimental|NAFLD Score plus Transient elastography|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score and transient elastography.
3102624|NCT01874249|Experimental|Transient elastography|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by transient elastography.
3102625|NCT01874249|No Intervention|Standard of care|Standard of care for patients with diagnosis of fatty liver by ultrasound.
3102626|NCT01874236|Active Comparator|1st sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
3102627|NCT01874236|Active Comparator|2nd sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
3102628|NCT01874236|Active Comparator|3rd sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
3102629|NCT01874223||IPF-diagnosed patients|A group of up to 40 patients with a diagnosis of mild to severe IPF per American Thoracic Society (ATS) guidelines, either with no cough at baseline to severe cough at baseline, will be followed for at least a one-time assessment and every six months for up to 18 months to establish validity, responsiveness, and reliability of cough, dyspnea, and QOL instruments in patients with IPF.
3102630|NCT01874210||Hemodialysis|Hemodialysis patients
3102631|NCT01874210||Control|"Household contacts on the same diet~Healthy unrelated controls"
3102632|NCT01874197|Other|B -TEVAR|Implantation of the B-TEVAR device
3102633|NCT01874184|Experimental|Arm I (DEEM intervention)|Participants take part in weekly 2-hour group counseling sessions for 6 months with taper beginning at 3 months. Group sessions include education, group process, and experiential learning on the benefits of physical activity, balanced nutrition, and mindfulness techniques. Participants set goals for changing their dietary habits with the help of a mental health counselor and are also encouraged to exercise 3-4 times per week, including experiential group activities such as brisk walking, yoga, Zumba, and group fitness.
3102634|NCT01874184|No Intervention|Arm II (usual care)|Participants receive their usual care and are provided with study materials on healthy diet and exercise at the end of the study.
3102635|NCT01874171|Active Comparator|Cisplatin|Three doses of cisplatin 100mg/m2 given at days 1, 22 and 43 from start of radiotherapy.
3102724|NCT01873547|No Intervention|control|Patients receive no professional treatment in hospital or rehabilitation centre.
3102636|NCT01874171|Experimental|Cetuximab|Initial dose of 400mg/m2 one week before start of radiotherapy followed by seven weekly doses of 250 mg/m2 during radiotherapy.
3102637|NCT01874158||TV postive women|All women who are TV positive by wet prep or in-pouch and meet the inclusion exclusion requirements.
3102638|NCT01874145|Active Comparator|GA 20 mg/mL every day|Glatiramer acetate (GA) 20 mg in 1 mL SC injection administered every day (QD) for the 4 months of the core study.
3102639|NCT01874145|Experimental|GA 40 mg/mL 3 times a week|"Glatiramer acetate (GA) 40 mg in 1 mL SC injection administered three times a week (TIW) for the 4 months of the core study.~During the Extension period, all participants to continue treatment with GA 40 mg/mL TIW until this dose regimen is commercially available for the treatment of RRMS patients."
3102640|NCT01874132|Experimental|Aerobic exercise training|Dose response
3102641|NCT01874132|Experimental|Aerobic and resistance exercise training|Dose response
3102642|NCT01874132|No Intervention|Control|Non-exercising control group
3102643|NCT01874119|Experimental|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
3102644|NCT01874119|Placebo Comparator|Placebo|During placebo admission, intravenous 0.9% saline every 48 hours during 6-day hospital admission
3102645|NCT01874106|Experimental|Diet therapy|The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
3102646|NCT01874106|Other|Control Group|The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
3102647|NCT01874093|Experimental|Active Stimulation|INS implantation, 5 Days of Ischemic Stroke System (ISS) Stimulation + Standard of Care
3102648|NCT01874093|Sham Comparator|Sham Stimulation|Sham implantation, 5 Days of Sham Stimulation + Standard of Care
3102649|NCT01874080|Experimental|Arm A: Saxagliptin/Metformin XR FDC (Mt. Vernon/Humacao)|Saxagliptin 5 mg /Metformin 1000 mg (Mt. Vernon/Humacao) tablet by mouth once daily on Day 1 of Periods 1 and 2
3102650|NCT01874080|Experimental|Arm B: Saxagliptin/Metformin XR FDC (Mt. Vernon)|Saxagliptin 5 mg/Metformin 1000 mg (Mt. Vernon) tablet by mouth once daily on Day 1 of Periods 1 and 2
3102651|NCT01874080|Experimental|Arm C: Saxagliptin/Metformin XR FDC (Mt. Vernon/Humacao)|Saxagliptin 5 mg/Metformin 500 mg (Mt. Vernon/Humacao) tablet by mouth once daily on Day1 of Periods 1 and 2
3102652|NCT01874080|Experimental|Arm D: Saxagliptin/Metformin XR FDC (Mt. Vernon)|Saxagliptin 5 mg/Metformin 500 mg (Mt. Vernon) tablet by mouth once daily Day 1 of Periods 1 and 2
3102653|NCT01874067||Arthritis glove|Early inflammatory, rheumatoid or hand osteoarthritis with hand/wrist swelling and pain
3102654|NCT01874054|Experimental|Brentuximab Vedotin + Bendamustine|Brentuximab vedotin 1.8 mg/kg every 3 weeks for up to 16 cycles by IV infusion and bendamustine 90 mg/m2 on Days 1 and 2 every 3 weeks by IV infusion for up to 6 cycles
3102655|NCT01874041|Experimental|Massage group|The massage group was submitted to three weekly 30-minute sessions of massage of the muscles of mastication over four consecutive weeks.
3102656|NCT01874041|Experimental|The occlusal splint group|The occlusal splint group was submitted to treatment with an occlusal splint for four weeks.
3102657|NCT01874041|No Intervention|Control group|The control group was not submitted to any form of intervention and was evaluated on two occasions, with a four-week interval between evaluations.
3102658|NCT01874028|Experimental|Trientine dihydrochloride|
3102659|NCT01874015|Active Comparator|mesenchymal cell and fibroblast transplantaion|The patients with crohn's disease who underwent mesenchymal cell and fibroblast injection.
3102660|NCT01874015|Active Comparator|mesenchymal cell transplantaion|The patients with Crohn's disease who underwent mesenchymal cell transplantation.
3102661|NCT01874002||Combo stent|Consecutive patients in whom a treatment with a Combo stent in the setting of routine clinical care is attempted are entered into the registry.
3102662|NCT01873989|Experimental|Testosterone replacement|Testosterone replacement for hypogonadism.
3102663|NCT01873989|Other|Waitlist control|This arm involves watchful waiting.
3102664|NCT01873976||Incident DCM|A case of dilated cardiomyopathy that presents to the study site for the first time.
3102665|NCT01873976||Incident/Recent HCM|A new or existing diagnosis of idiopathic or familial hypertrophic cardiomyopathy, diagnosed within the past 2 months and with a cMRI within 2 months of diagnosis.
3102666|NCT01873976||Prevalent HCM or DCM|Any child with a diagnosis of dilated cardiomyopathy or idiopathic or familial hypertrophic cardiomyopathy who has survived transplant-free at least 24 months from the date of cardiomyopathy diagnosis.
3102667|NCT01873963||Pediatric cardiomyopathy|Diagnosis of primary or idiopathic dilated, hypertrophic or restrictive cardiomyopathy. Diagnosis must have been made before the age of 18 and must be confirmed by established echocardiographic criteria or cardiac MRI (cMRI) at the time of diagnosis.
3102668|NCT01873950|Experimental|Ranolazine 1500mg|Ranolazine
3102669|NCT01873950|Experimental|Dofetilide 500mcg|Dofetilide
3102670|NCT01873950|Experimental|Verapamil HCl 120 mg|Verapamil
3102671|NCT01873950|Experimental|Quinidine sulfate 400mg|Quinidine sulfate
3102672|NCT01873950|Placebo Comparator|Placebo|Placebo
3102673|NCT01873937|Experimental|Red LED|Irradiation parameters: 630 nm, 60 sec and 18 J/cm² per point.
3102674|NCT01873937|Experimental|infrared LED|Irradiation parameters: 850 nm, 60 sec and 18J/cm² per point
3102675|NCT01873937|Active Comparator|LASER|Irradiation parameters: 780 nm, 60 sec and 105 J/cm²
3102676|NCT01873924||Batten disease|Individuals with any form of Batten disease (Neuronal Ceroid Lipofuscinosis)
3102677|NCT01873898|Experimental|Single Arm|This is a single arm, prospective study to collect data on the safety and effectiveness of the Rex Medical Closer™ Vascular Closure System. Only subjects who are scheduled to undergo an interventional diagnostic procedure that requires closure of the femoral access site are eligible for study participation.
3102678|NCT01873885|Experimental|Cohort 1: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 1 - Single 30 minute infusion Vasomera (PB1046) at 0.01 mg/kg diluted in 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
3102679|NCT01873885|Experimental|Cohort 2: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 2 - Single 30 minute infusion Vasomera (PB1046) at 0.005mg/kg in 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
3102680|NCT01873885|Experimental|Cohort 3: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 3 - Single 30 minute infusion Vasomera (PB1046) at 0.02mg/kg 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
3102681|NCT01873872|Active Comparator|Theralac probiotic|
3102682|NCT01873872|Active Comparator|Culturelle probiotic|
3102683|NCT01873872|Placebo Comparator|Placebo|
3102684|NCT01873859|Active Comparator|On-metformin|Diabetic patients receiving contrast media without discontinuing metformin.
3102685|NCT01873859|No Intervention|Off-metformin|Diabetic patients receiving contrast media with discontinuation of metformin.
3102686|NCT01873833|Experimental|Treatment (chemotherapy, lapatinib ditosylate, trastuzumab)|Patients receive capecitabine PO QD, cyclophosphamide PO QD, and lapatinib ditosylate PO QD on days 1-21 and trastuzumab IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3102687|NCT01873820|Experimental|Calcium ascorbate -> ascorbic acid|
3102688|NCT01873820|Experimental|Ascorbic acid -> calcium ascorbate|
3102689|NCT01873807|Experimental|IDA-Etoposide Intensified Conditioning|
3102690|NCT01873807|Active Comparator|Non-IDA Conditioning|
3102691|NCT01873794|Active Comparator|Bright white light|using systematic light exposure (SLE), consisting of a daily 30-minute exposure to as much as 10,000 lux of light from a commercially available light box
3102692|NCT01873794|Active Comparator|Dim red light|using systematic light exposure (SLE), consisting of a daily 30-minute exposure to as much as 10,000 lux of light from a commercially available light box
3102693|NCT01873781||30 healthy male and female subjects|30 healthy male and female subjects aged 18-35
3102694|NCT01873768|Active Comparator|Tranexamic acid (TXA)|1g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 50ml of saline will be infused over 30 minutes beginning at the time of wound closure.
3102695|NCT01873768|Active Comparator|ε-Aminocaproic Acid (EACA)|7g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 50ml saline will be infused over 30 minutes beginning at the time of wound closure.
3102696|NCT01873755|Experimental|asthma physical activity intervention|two schools will receive intervention
3102697|NCT01873742|Experimental|The use of STIC feedback system|This will constitute the experimental condition, using of STIC feedback system.
3102698|NCT01873742|Experimental|Treatment as usual|This conditions will not include the use of the STIC feedback system.
3102699|NCT01873729|Experimental|Naltrexone|Naltrexone
3102700|NCT01873716|Experimental|Injection of Indocyanine Green|Injection of Indocyanine Green prior to carotid endarterectomy surgery. Collection of specimen during surgery with subsequent carotid tissue analysis.
3102701|NCT01873716|No Intervention|No injection|No injection prior to carotid endarterectomy surgery. Collection of specimen during surgery with subsequent carotid tissue analysis.
3102702|NCT01873703|Experimental|pracinostat plus azacitadine|"60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.~75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
3102703|NCT01873703|Placebo Comparator|Placebo with Azacitadine|"Placebo by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.~75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
3102704|NCT01873690|Placebo Comparator|Placebo|Placebo
3102705|NCT01873690|Active Comparator|Ciprofloxacin|Ciprofloxacin
3102706|NCT01873677|Placebo Comparator|Vehicle|Proper quantity twice a day
3102707|NCT01873677|Experimental|M518101|Proper quantity twice a day
3102708|NCT01873664|Experimental|Jaw tapping|All subjects performed the jaw-tapping for 4 weeks at home.
3102709|NCT01873651|Experimental|Delta III|Implantation of a Delta III Prosthesis
3102710|NCT01873638|Other|Minilaparotomy|Minilaparotomy cholecystectomy as a day surgery
3102711|NCT01873638|Other|Laparoscopy|Laparoscopic cholecystectomy as a day surgery
3102712|NCT01873625|Placebo Comparator|placebo|Normal salin injection in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
3102713|NCT01873625|Active Comparator|mesencymal stem cell|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
3102714|NCT01873612|Experimental|Sedation with dexmedetomidine|Sedation with dexmedetomidine
3102715|NCT01873612|Experimental|Sedation with propofol|Sedation with propofol
3102716|NCT01873599|Experimental|Intervention|Participants in the intervention condition will be asked to write for 15 minutes on three days each week to one of the seven positive affect writing prompts on www.stressvax.com. Subjects who do not complete a journal entry within 7 days will receive an email reminder, in case they have lost their password or have some technical problem accessing the site.
3102717|NCT01873599|No Intervention|Control|As there is no clinical standard of care treatment for psychological distress, patients randomized into this condition will receive their usual care. At the end of three months, subjects in this condition will be given access to the positive affect journaling intervention.
3102718|NCT01873586|Experimental|OsteoStrux Collagen Ceramic Scaffold|OsteoStrux Collagen Ceramic Scaffold
3102719|NCT01873573|Active Comparator|EGD with Dilation|Standard of Care: Esophagogastroduodenoscopy (EGD) with dilation alone. If participants are assigned to Arm A and are not showing any clinical improvements as determined by their physician after the first three endoscopic dilation sessions, then they will be crossed over into Arm B.
3102720|NCT01873573|Active Comparator|EGD with Dilation, plus Triamcinolone|Standard of Care: EGD with dilation and Triamcinolone injection.
3102721|NCT01873560||FFRpost|"FFRpost <0.9 group the patient with FFR values less than 0.9 after DES procedure~FFRpost ≥0.9 group the patient with FFR values greater than 0.9 after DES procedure"
3102722|NCT01873547|Active Comparator|rehabilitation|Patients in the group accept rehabilitation for three weeks in hospital and other eleven months in their home under the guidance of physical therapist.
3102723|NCT01873547|Experimental|cell therapy|Patients in the group accept cell therapy including four times stem cells transplant via intrathecal injection.
3102726|NCT01873534|Experimental|FMX-8 (5 mg/kg)|5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
3102727|NCT01873534|Experimental|FMX-8 (15 mg/kg)|15 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
3102728|NCT01873521|Active Comparator|NIV PS|The patients in this arms will received non invasive ventilation in PS mode.
3102729|NCT01873521|Active Comparator|NIV NAVA|The patients in this arm will received non invasive ventilation in NAVA mode.
3102730|NCT01873508|Experimental|Fast release MR capsule|
3102731|NCT01873508|Experimental|Slow release MR capsule|
3102732|NCT01873508|Experimental|Target release MR capsule|
3102733|NCT01873495|Experimental|Omacetaxine: Consolidation/Maintenance|
3102734|NCT01873482|Experimental|Movement with rhythm|Subjects will move for 1 hour in time to the Congolese rhythm called Zebola.
3102735|NCT01873469||Radiochemotherapy|glioblastoma patients with indication to radiochemotherapy
3102736|NCT01873456|Experimental|Multifactorial nutritional intervention|dietician, resistance type exercise, dysphagia assessment and treatment
3102737|NCT01873456|No Intervention|usual care|usual care
3102738|NCT01873443|Experimental|Rituximab, MTX, folic acid|
3102739|NCT01873430|Active Comparator|Melatonin: Melatonin cream 2,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied
3102740|NCT01873430|Active Comparator|Melatonin: Melatonin cream 0,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.
3102741|NCT01873430|Active Comparator|Melatonin: Melatonin cream 12,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.
3102742|NCT01873430|Placebo Comparator|placebo cream|One square on the back of each volunteers will be randomized to have placebo cream (vehicle) applied.
3102743|NCT01873430|No Intervention|No treatment|One square on the back of each volunteers will be randomized to receive no treatment.
3102744|NCT01873417|Experimental|Dimethyl Fumarate|120 mg DMF twice daily (BID) for the first 7 days and 240 mg DMF BID thereafter for 12 weeks of treatment. Participants will be instructed to take the DMF dose with food (with a meal or within 1 hour after a meal).
3102745|NCT01873404|Experimental|BG00010|Administered as an IV injection at various dose levels 3 times per week for 1 week
3102746|NCT01873404|Placebo Comparator|Placebo|Matched placebo IV injection 3 times per week for 1 week
3102747|NCT01873391|Active Comparator|Normal saline|Normal saline is a distension media of uterine cavity in diagnostic hysteroscopy.
3102748|NCT01873391|Active Comparator|Carbon dioxide|Carbon dioxide is a distension media of uterine cavity in diagnostic hysteroscopy.
3102749|NCT01873378|Experimental|GnRH agonist pretreatment|triptorelin 3.75 mg, im, monthly, three times
3102750|NCT01873378|No Intervention|No pharmacological treatment|
3102751|NCT01873365||Prospective Group|Japanese adults, aged greater than or equal to sixty years, diagnosed with HZ.
3102752|NCT01873352|Active Comparator|CA+RD|Catheter ablation of atrial fibrillation plus renal sympathetic denervation
3102753|NCT01873352|Active Comparator|CA (control)|Catheter ablation of atrial fibrillation (control group)
3102754|NCT01873339|Experimental|Darapladib|The subjects will receive a single oral dose of midazolam 5 mg on Day 1. The subjects will receive darapladib 160 mg once daily on Days 3-14. The subjects will also receive a single dose of midazolam 5 mg on Day3 and 14.
3102755|NCT01873326|Experimental|Paclitaxel, Ifosfamide and Cisplatin (TIP)|"Paclitaxel 120 mg/m2 IV over 120-180 min Days 1 and 2 (+/- 4 days)* Mesna 120 mg/m2 IV (duration of infusion per institutional guidelines) approximately 30 minutes prior to initiation of ifosfamide Days 1-5 (+/- 4 days)* Ifosfamide 1200 mg/m2 IV over approximately 60 to 120 min Days 1-5 or per institutional guidelines (mixed 1:1 with mesna) (+/- 4 days)* Mesna** 1200 mg/m2 IV over approximately 60-120 min or per institutional guidelines (mixed 1:1 with ifosfamide)(+/- 4 days)* Cisplatin 20 mg/m2 IV over approximately 30 min Days 1-5 (+/- 4 days)*~**Additional mesna may be given at the discretion of the investigator~*Paclitaxel or Ifosfamide or Mesna or Cisplatin or any combination of these agents can be held as needed for patient safety on a given day between days 1-5 but must be made up within 4 days to avoid a protocol violation."
3102756|NCT01873326|Active Comparator|Bleomycin, Etoposide and Cisplatin (BEP)|"Cisplatin 20 mg/m2 IV over approximately 30 min Days 1-5 (+/- 4 days)* Etoposide 100 mg/m2 IV over approximately 1 hour Days 1-5 (+/- 4 days)* Bleomycin 30 U flat dose IV push Days 2, 8 and 15 (all +/- 4 days)~*Etoposide or Cisplatin or both can be held as needed for patient safety on a given day between days 1-5 but must be made up within 4 days to avoid a protocol violation."
3102757|NCT01873313||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the knee joint following knee arthroplasty. Total dose 200mls of 0.2% ropivacaine or 400mg at the time of surgery plus up to 5 top-up boluses (40mls of 0.2% ropivacaine or 80mg) postoperatively.
3102758|NCT01873300|Experimental|treatment group|Patients undergoing POEM procedure
3102759|NCT01873274|Active Comparator|basic yogurt enriched with MK-7|one study group will receive daily two basic dairy products enriched with MK-7 (50 μg)
3102760|NCT01873274|Active Comparator|MK-7 containing capsule|one study group will receive daily a softgel capsule consisting of 50 μg MK-7
3102761|NCT01873274|Active Comparator|nutrient enriched yogurt with MK-7|one study group will receive daily two nutrient-enriched dairy products containing extra nutrients and omega-3 FA (fish-oil)
3102762|NCT01873248|Experimental|Diagnostics with PET|68Ga-DOTATATE PET scans will be performed on subjects
3102763|NCT01873235||Main Cohort|This is an observational prospective cohort study of adults with autosomal dominant polycystic kidney disease (ADPKD) with estimated GFR at least 15cc/min/1.73m2. There are no therapeutic interventions in this observational cohort study.
3102764|NCT01873222|Experimental|OFDI-guided PCI & IVUS|"Assessment by IVUS at post-PCI~Assessment by OFDI at a 8-month follow-up"
3102765|NCT01873222|Active Comparator|IVUS-guided PCI & OFDI|"Assessment by OFDI at post-PCI~Assessment by OFDI at a 8-month follow-up"
3102766|NCT01873196|Experimental|Receive extra oil|This arm will receive enough oil to prepare the CSB they receive in the newly recommended proportion of 100g CSB: 30g oil. They will receive education and instructions on the new method of preparation.
3102767|NCT01873196|No Intervention|Control-No extra oil received|This group will continue to receive only 1L of oil with their CSB has they already have been. They also will not receive any new education.
3102768|NCT01873196|Experimental|Receives behavior changed messages on CSB package|Group receiving CSB repackaged into 2kg packages with messages on package on how to prepare. Only in Phase II.
3102769|NCT01873196|No Intervention|Control-No repackaged CSB|
3102770|NCT01873183|Experimental|The IGDT group|"30 morbidly obese subjects scheduled for bariatric surgery by laparoscopic Roux-en-Y gastric bypass (RYGB) will be consecutively enrolled for the study.~The individualized goal-directed therapy (IGDT) with focus on level of venous return will be implemented in two steps in the intervention group. First, preoperative optimizing of venous return will be performed 45 minutes before surgery in a preoperative room with TTE. Second, after induction of anaesthesia perioperative fluid therapy will be implemented by utilizing the FloTrac-device."
3102771|NCT01873183|No Intervention|The control group|20 morbidly obese subjects scheduled for bariatric surgery by laparoscopic Roux-en-Y gastric bypass (RYGB) will consecutively be enrolled for the study. Conventional monitoring will be conducted perioperatively.
3102772|NCT01873170||Combined Oral Contraceptive pills|Levonorgestrel/ethinyl estradiol 0.15mg/30mcg daily oral tabs x21 then 7 inert tabs
3102773|NCT01873170||depot medroxyprogesterone acetate|150mg DMPA intramuscular injection once every 3 months
3102774|NCT01873170||Levonorgestrel-intrauterine device|52mg levonorgestrel intrauterine device
3102775|NCT01873170||Copper intrauterine device|Copper T380A intrauterine device
3102776|NCT01873170||Etonogestrel contraceptive implant|68mg etonogestrel subdermal implant
3102777|NCT01873170||Control|Low risk of pregnancy due to sterilization, heterosexual abstinence, or consistent condom use
3102778|NCT01873157|Placebo Comparator|Placebo (NaCl solution)|"Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11."
3102779|NCT01873157|Active Comparator|Bortezomib (Velcade®)|"Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11."
3102780|NCT01873144|Active Comparator|HSS (3%) + epinephrine|Nebulized solution containing 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of HSS(3%) every 4h for three times and afterwards at physician in charge criteria.
3102781|NCT01873144|Experimental|HHHFNC+epinephrine+Normal Saline(0.9%)|Flow depending on weight (Tidal volume x respiratory rate x 9) and nebulized solution containing 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of Normal Saline (NS) (0.9%) every 4h and afterwards at physician in charge criteria.
3102782|NCT01873131|Experimental|Topical Timolol|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the timolol arm will receive twice daily topical application of a physician-specified amount of timolol maleate 0.5% ophthalmic solution (hereby referred to as topical timolol) for up to six months.
3102783|NCT01873131|No Intervention|Observation|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the observation arm will be followed at study visits according to protocol.
3102784|NCT01873131|Experimental|Pulsed Dye Laser|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the pulsed dye laser arm will receive a series of six weekly to semi-weekly laser treatments treatments for up to 6 treatments with potential for reduced number of treatments if the hemangioma completely resolves. A 595-nm pulsed-dye laser (PDL, V-beam Perfecta, Candela Corp, Wayland, MA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions.
3102785|NCT01873118|No Intervention|Usual Care Control hospital unit|This study involves implementation of interventions across entire hospital units. This arm is a usual care control unit paired to the intervention unit.
3102786|NCT01873118|Experimental|implementation unit|"3 implementation protocols implemented sequentially:~RN-RHDS: implementation of discharge readiness assessment by the discharging nurse~RN-RHDS+PT-RHDS: implementation of discharge readiness assessment by the discharging nurse which is informed by patient self-assessment of discharge readiness~RN-RHDS+PT-RHDS+NIAF: implementation of discharge readiness assessment by the discharging nurse which is informed by patient self-assessment of discharge readiness followed by documentation of nurse actions initiated in response to the assessment. Nurse are instructed that action must be taken if any assessment item scores less than 7 ( on a 10 point scale)."
3102787|NCT01873105|Other|Health team educational intervention|Agency for Healthcare Research and Quality (AHRQ) TeamSTEPPS approach will be used to redesign health team communication processes regarding preparation for discharge. This redesign will be followed by education for all health team members.
3102788|NCT01873092||Patients with COPD|Patients who meet criteria for chronic obstructive pulmonary disease
3102789|NCT01873079|Active Comparator|Esomeprazole|esomeprazole 40mg bd for 10 days
3102790|NCT01873079|Sham Comparator|Standard care|No other study drug or placebo will be given
3102791|NCT01873066|Experimental|Closed-loop insulin delivery|Glucose level is controlled by the automated closed-loop glucose control system. After initial training with the closed-loop system devices, subjects will use the closed-loop system day and night at home for a total duration of 7 days (phase 1) and 21 days (phase 2).
3102792|NCT01873066|Active Comparator|real-time CGM alone|Glucose level will be controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM) during the day and night over 7 days (phase 1) and 21 days (phase 2).
3102793|NCT01873053|Experimental|1st group : WIN-34B 900mg|Patients assigned to 1st group take WIN-34B 450mg BID for 12weeks
3102794|NCT01873053|Experimental|2nd group : WIN-34B 1800mg|Patients assigned to 2nd group take WIN-34B 900mg BID for 12weeks
3102795|NCT01873053|Placebo Comparator|3rd group : Placebo|Patients assigned to 3rd group take Placebo BID for 12weeks
3102796|NCT01873040|Experimental|Social media plus information pages|Participants will have access to the vaccine social media website with information pages and social media features including discussion forums, blogs, chat with an expert, and ask an expert.
3102797|NCT01873040|Experimental|Information Pages|Participants will have website access to vaccine information pages.
3102798|NCT01873040|No Intervention|Usual Care|Participants will not have access to the vaccine website. They will receive pediatric care as usual.
3102831|NCT01872832|Experimental|2.5 mg RDEA3170|RDEA3170 2.5 mg or placebo fasted and fed
3102799|NCT01873027|Experimental|OFDI-guided PCI|"OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI~Follow-up contact at the time of hospital discharge, 8 months and 12 months after PCI."
3102800|NCT01873027|Active Comparator|IVUS-guided PCI|"IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI~Follow-up contact at the time of hospital discharge, 8 months and 12 months after PCI."
3102801|NCT01873014|Experimental|high Iodine intake|
3102802|NCT01873014|Active Comparator|low Iodine intake|
3102803|NCT01873001|Experimental|Abiraterone acetate + pioglitazone HCl|Participants will receive 15 mg pioglitazone on Day 1 (Period 1). On Day 8 (Period 2), participants will receive 1000 mg abiraterone acetate followed by 15 mg of pioglitazone one hour later.
3102804|NCT01872988|Active Comparator|Tenofovir treatment|Start to administer Tenofovir treatment 300mg PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
3102805|NCT01872988|Placebo Comparator|Placebo|Start to administer placebo 1 Tab PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
3102806|NCT01872975|Active Comparator|Group 1A Lumpectomy: no regional nodal XRT with WBI|Lumpectomy patients undergo whole breast radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.
3102807|NCT01872975|No Intervention|Group 1B Mastectomy: No regional nodal or chestwall XRT|Mastectomy patients do not undergo radiation therapy.
3102808|NCT01872975|Experimental|Group 2A lumpectomy: Regional nodal XRT with WBI|Lumpectomy patients undergo regional nodal radiation therapy with whole breast radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.
3102809|NCT01872975|Experimental|Group 2B Mastectomy: Regional nodal XRT and chestwall XRT|Mastectomy patients undergo regional nodal radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks.
3102810|NCT01872962|Experimental|Induction chemotherapy+IMRT and concurrent cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
3102811|NCT01872962|Active Comparator|IMRT and concurrent cisplatin|Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
3102812|NCT01872936|Other|Miravirsen every other week dosing|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 6 every other week doses at 5 mg/kg in combination with telaprevir and ribavirin.
3102813|NCT01872936|Other|Miravirsen monthly dosing|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 3 monthly doses at 7 mg/kg in combination with telaprevir and ribavirin.
3102814|NCT01872923|Experimental|Amphinex based PCI of bleomycin|The photosensitiser Amphinex is activated by Laser to enhance the effect of Bleomycin
3102815|NCT01872910|Placebo Comparator|Placebo|"Part A: Single oral administration of placebo matching corresponding LY3023703 dose administered orally once as a capsule post dental surgery.~Part B: Single oral administration of placebo matching corresponding LY3023703 administered orally once as a capsule, post dental surgery and post dialysate probe placement.~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
3102816|NCT01872910|Experimental|30 milligrams (mg) LY3023703|"Part A: Single oral administration of 30 milligrams (mg) LY3023703 administered orally once as a 30-milligrams (mg) capsule post dental surgery.~Part B: Single oral administration of 30 milligrams (mg) LY3023703 administered orally once as a 30-mg capsule, post dental surgery and post dialysate probe placement.~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
3102817|NCT01872910|Active Comparator|400 mg Celecoxib|"Part A: Single oral administration of 400 mg celecoxib (Positive control) administered orally once as two 200-mg capsules post dental surgery (Positive control).~Participants received two 200-mg celecoxib capsules during Pre-Part B.The purpose of Pre-Part B was to develop proficiency in the dialysate placement, collection, and maintenance techniques before moving to Part B.~Celecoxib was not administered in Part B.~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
3102818|NCT01872897|Active Comparator|Sodium Alginate Double Action Tablets|Four Compound Sodium Alginate Double Action Chewable Tablets administered as a single dose
3102819|NCT01872897|Placebo Comparator|Placebo tablets|Single dose of 4 Placebo tablets
3102820|NCT01872884|Experimental|General anaesthesia|General anaesthesia with mechanical ventilation. Sevorane Remifentanil. Bloodpressure control, systolic pressure 140-180 mmHg.
3102821|NCT01872884|Placebo Comparator|Sedation|Sedation with spontaneous breathing. Remifentanil. Bloodpressure control, systolic pressure 140-180 mmHg
3102822|NCT01872871|Placebo Comparator|local anasthetic drops|topical anaesthetic drop with placebo
3102823|NCT01872871|Active Comparator|Paracetamol|Topical anaesthetic drop with Paracetamol
3102824|NCT01872858|Active Comparator|Aspirin|Aspirin, 100mg, Q.D, p.o, 2yr
3102825|NCT01872858|Experimental|Cilostazol|cilostazol, 100mg, B.I.D, p.o, 2yr
3102826|NCT01872845|Active Comparator|Rosuvastatin|All study subjects will be received percutaneous coronary intervention (PCI) with Biolimus-eluting stent as index procedure at the time of enrollment After index procedure, patients will be randomly assigned to receive pravastatin 40mg or rosuvastatin 20mg in a 1:1 ratio. a> Test group: Pravastatin 40mg PO daily for 1year from the day of BES implantation b> Control group: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
3102827|NCT01872845|Experimental|Pravastatin|All study subjects will be received percutaneous coronary intervention (PCI) with Biolimus-eluting stent as index procedure at the time of enrollment After index procedure, patients will be randomly assigned to receive pravastatin 40mg or rosuvastatin 20mg in a 1:1 ratio. a> Test group: Pravastatin 40mg PO daily for 1year from the day of BES implantation b> Control group: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
3102828|NCT01872832|Experimental|5 mg RDEA3170|RDEA3170 5 mg or placebo fasted and fed
3102829|NCT01872832|Experimental|10 mg RDEA3170|RDEA3170 10 mg or placebo fasted and fed
3102830|NCT01872832|Experimental|15 mg RDEA3170|RDEA3170 15 mg or placebo fasted and fed
3102832|NCT01872819|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive 1 of 160 possible interventions based on high throughput drug sensitivity assay.
3102833|NCT01872806|Experimental|Experimental: Mobile phone radiation|Dialing mobile phone placed against the ear/chest for a duration of 15 minutes, before and after 15 minutes sham phone will be placed against the ear/chest.
3102834|NCT01872780|Active Comparator|rosiglitazone|avandia
3102835|NCT01872780|Active Comparator|genetic polymorphism|avandia CYP2C8 genotype
3102836|NCT01872767||Cirrhotics/ Acute on chronic liver failure admitted to ICU|
3102837|NCT01872754|Active Comparator|2: Propofol|Control arm: the use of TCI of hypnotic (Propofol) during realization bronchial fibroscopy.
3102838|NCT01872754|Experimental|1: Remifentanil|Interventional arm: the use of TCI of morphinomimetic (Remifentanil) during realization bronchial fibroscopy.
3102839|NCT01872741|Active Comparator|Ruptured intracranial aneurysms|Pterional craniotomy Minipterional craniotomy
3102840|NCT01872741|Active Comparator|Unruptured intracranial aneurysms|Pterional craniotomy Minipterional craniotomy
3102841|NCT01872728|Placebo Comparator|Control|placebo for the realization of the facial block and morphine for intraoperative analgesia
3102842|NCT01872728|Active Comparator|Levobupivacaine|Levobupivacaine for the realization of the facial block and placebo for intraoperative analgesia
3102843|NCT01872715|Experimental|Oracea|"Oracea (doxycycline USP, 40mg[30mg immediate release/ 10mg delayed release beads] taken once daily in the morning on an empty stomach, one hour before meals or two hours after.~Oral dose for 12 weeks"
3102844|NCT01872702|Experimental|malaria elimination using DP and low-dose primaquine|Two villages randomly allocated to intervention (chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages the entire population will be invited to receive three, monthly rounds of treatment with dihydroartemisinin-piperaquine and primaqunine to kill malaria parasites. The micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.
3102845|NCT01872702|No Intervention|Control villages|"Two villages randomly allocated to control (no chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages only the micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.~From June 2013 to June 2014 Cambodia site conducted surveys with no medical intervention (treatment arm). In July 2015 Cambodia implemented the TCE protocol with two intervention and two control villages. Primaquine is not used in the TCE treatment regimen in Cambodia. Both studies were approved under OxTREC reference no. 1017-13 and 1015-13."
3102846|NCT01872689|Placebo Comparator|Monotherapy (Cohort A): Placebo|Participants will receive monotherapy with placebo matched to lebrikizumab administered via subcutaneous (SC) injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
3102847|NCT01872689|Experimental|Monotherapy (Cohort A): Lebrikizumab|Participants will receive monotherapy with lebrikizumab at a dose of 250 milligrams (mg) administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
3102848|NCT01872689|Placebo Comparator|Combination Therapy (Cohort B): Placebo + Pirfenidone|Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day [9 capsules daily] for a total of 2403 mg/day) or at maximum tolerated dose (MTD) administered orally along with placebo matched to lebrikizumab administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
3102849|NCT01872689|Experimental|Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone|Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day [9 capsules daily] for a total of 2403 mg/day) or at MTD administered orally along with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
3102850|NCT01872676|Experimental|Manipulation|The experimental group received upper thoracic manipulation of the T3 vertebra. The volunteer was instructed to lie in the supine position, interlace her fingers and position her hands in the posterior region of the base of the neck. The therapist than positioned a stabilizing hand in a pistol grip immediately caudal to the T3 vertebra, pushing the volunteer's arms downward to generate flexion of the upper thoracic spine.
3102851|NCT01872676|Sham Comparator|Sham|The placebo group was placed precisely as the experimental group, with the exception of the positioning of the therapist's hand, which remained with the palm open and not in a pistol grip. Once positioned, the volunteers were instructed to breathe deeply. The maneuver was terminated after one cycle of deep breathing.
3102852|NCT01872663|Experimental|Incentive spirometry (Voldyne®)|Individuals will be treated with incentive spirometry, Voldyne Model 5000® in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
3102853|NCT01872663|Experimental|Continuous positive airway pressure|Individuals will be treated with flow generator(Whisperflow, Caradyne, Ireland)and valve PEEP type spring-loaded which remain 10 cmH2O, in the immediate and the first postoperative day, twice a day, in sessions 30 minutes each, with an interval of four hours between them.
3102854|NCT01872663|Experimental|Expiratory Positive Airway Pressure|Subjects will be treated with oronasal mask affixed to the face, with the PEEP valve set at 10 cmH2O, in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
3102887|NCT01872468|Active Comparator|Structured intervention|Initial training session based on significant learning and follow up visits every four months at physicians and nurses´ offices over a two-year period
3102888|NCT01872455|Active Comparator|Group CON|patients who refused to assume the n-3 rich diet and continued their usual diet
3103035|NCT01871467|Experimental|Sargramostim administration|Subjects will receive sargramostim.
3102855|NCT01872663|Experimental|Intermittent positive pressure breathing|Subjects will be treated with application of Müller Resuscitator (Engesp®) through a nozzle, using a pressure endotracheal 20-30 cmH2O, refering to 2-3 kgf/cm², adjusted throttle valve oxygen, according to the patient's comfort and the micronebulizer coupled only saline as the diluent. The procedure will be performed in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
3102856|NCT01872663|Experimental|Bi-level positive airway pressure|Individuals will be treated with positive pressure in the BiPAP mode (Bi-level positive airway pressure) in the immediate and the first postoperative day, twice a day, in sessions 30 minutes each, with an interval of four hours between them.
3102857|NCT01872663|Experimental|Breath Stacking|Subjects will be treated with a siliconized mask connected to a unidirectional valve and adapted to the patient's face, allowing only the inspiration and the expiratory limb remains occluded, while the volunteer is instructed to perform successives inspiratory efforts, in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
3102858|NCT01872663|No Intervention|Control|Individuals will be treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
3102859|NCT01872650|No Intervention|Control|No placement of an adhesion barrier
3102860|NCT01872650|Experimental|C-Qur|C-Qur film placement beneath the incision. Possibly placement of C-Qur film at other sites considered to be adhesiogenic (but not around the anastomosis)
3102861|NCT01872637|Experimental|Progressive Multi-Component Intervention|Patients in this exercise group will receive 10-18, 45-60 minute, physical therapy visits in their home. This group will consist of progressive resistance exercises for the upper and lower extremity with a portable training device, a motor control-based program of gait/balance training, Activities of Daily Living (ADL) training, and mobility training.
3102862|NCT01872637|Active Comparator|Usual Care Group|"The patients in this group will receive approximately five visits of usual home care but the total number of visits will be determined by the therapist as part of usual care. These visits will likely occur at 1-2 times per week for 3-4 weeks. This group will receive intervention as determined by the physical therapist's initial examination. Interventions may include patient education, home exercises, low intensity strengthening exercise, training in gait, balance and transfers; home safety and assistive device assessment."
3102863|NCT01872624|Active Comparator|Valves plus cells|Bronchoscopy Five patients will be selected to receive bone-marrow derived mesenchymal stromal cells delivered bronchoscopically right before insertion of one-way endobronchial valves.
3102864|NCT01872624|Placebo Comparator|Valves plus saline|Bronchoscopy Five patients will be selected for treatment with one-way endobronchial valves only, with saline injected prior to valve insertion.
3102865|NCT01872611|Experimental|Nepafenac|With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
3102866|NCT01872611|Placebo Comparator|Vehicle|With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
3102867|NCT01872598|Experimental|Group 1|Masitinib 3mg/kg/day
3102868|NCT01872598|Experimental|Group 2|Masitinib 4.5mg/kg/day
3102869|NCT01872598|Placebo Comparator|Group 3|Placebo 3 mg or 4.5mg/kg/day
3102870|NCT01872585|Experimental|Mentalization based therapy|Women who are the primary caregivers of a child between the ages of 0-7 years and are involved with mental health services for themselves or a child.
3102871|NCT01872572|Other|Cohort 1|Cohort 1: 6 subjects received Subcutaneous RB006 0.5 mg/kg and 2 subjects received SC placebo
3102872|NCT01872572|Other|Cohort 1-A|Cohort 1-A: 4 subjects received open-label Subcutaneous RB006 0.5 mg/kg
3102873|NCT01872572|Other|Cohort 2|Cohort 2: 6 subjects received Subcutaneous RB006 1.0 mg/kg and 2 subjects received SC placebo
3102874|NCT01872572|Other|Cohort 3|Cohort 3: 6 subjects received Subcutaneous RB006 3.0 mg/kg and 2 subjects received SC placebo
3102875|NCT01872572|Other|Cohort 4|"8 subjects received subcutaneous RB006 2.0 mg/kg as well as the following:~4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration"
3102876|NCT01872559||3D sonographic analysis|The study is designed to evaluate a new imaging modality, 3D sonographic volumetric analysis, and compare it to the conventional 2-dimmensional analysis that is currently in place. Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do no require any additional sonograms, tests, or interventions.
3102877|NCT01872546|Experimental|Adalimumab|
3102878|NCT01872533|Experimental|Hypoxia Exposure|There was only one study arm: All participants slept in moderate hypoxia (see description below).
3102879|NCT01872520||the Injection of DanShenDuoFenSuanYan|Patient who use the Injection of DanShenDuoFenSuanYan
3102880|NCT01872507|Active Comparator|biofeedback training|usual treatment+12 treatment of biofeedback training
3102881|NCT01872507|No Intervention|control|usual treatment
3102882|NCT01872494|Experimental|Local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
3102883|NCT01872494|Active Comparator|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
3102884|NCT01872481|Placebo Comparator|Sham stimulation|"rTMS with sham coil. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks."
3102885|NCT01872481|Experimental|Active stimulation|rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.
3102886|NCT01872468|No Intervention|Control|There is not intervention in this group.
3103033|NCT01871480|Experimental|Group A|Gefitinib combination with CIK cell immunotherapy
3102889|NCT01872455|Experimental|Group DIET|the patients assumed n-3 rich diet: Patients of the DIET group were requested to follow a diet specifically designed to increase the intake of n-3 PUFAs and to decrease the ratio n-6/n-3 by using natural foods.
3102890|NCT01872442|Experimental|Dasatinib|Dasatinib,Bristol Myers Squibb
3102891|NCT01872442|Experimental|Peg-Interferon alpha2b|Peg-Interferon alpha2b (Peg-IFN α2b), Merck
3102892|NCT01872429||Short-term group|Patients with postoperative 6-month laboratory data were included in the short-term group
3102893|NCT01872429||Long-term group|Patients with postoperative more than 6-month laboratory data were included in the long-term group
3102894|NCT01872416|Experimental|Refractory and relapsed SCLC|Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
3102895|NCT01872403|Experimental|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung
3102896|NCT01872390|Experimental|CIP Participants|Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients, and in addition the Combination Intervention Package (CIP) with the programmatic, structural, and psychosocial components.
3102897|NCT01872390|Other|SOC Participants|Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients. TB and HIV services are fully integrated in a one-stop model, while at hospitals, ART is provided in the TB clinic for TB/HIV coinfected patients.
3102898|NCT01872377|Experimental|Radiotherapy Boost|All participants will receive the CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost treatment however, there are 5 dose levels that could be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Participants will be assigned to either receiving 6, 7, 8, 9 or 10 Gy X 3Fr.
3102899|NCT01872364||Dominican Republic patients at NPO Outpatient Surgery Center|
3102900|NCT01872351||pre and 12 months post ENT|"Compare the clinical status of CFS patients after at least 12 months of ENT to their status before ENT.~ENT consists of:~Daily conditioning exercise: 35-40 minutes~Nutraceutical supplements: acetyl-L-carnitine 500 mg bid, alpha-lipoic acid (Alpha Lipoic Sustain 300) 300 mg qd, CoQ10 (Ubiquinol QH-absorb) 100 mg qd, docosahexanoic acid (maxDHA) 300 mg qd, plus a multivitamin (Centrum Silver) ½ tab bid.~Diet: 25% protein, 35- 40% carbohydrate, 35-40% fat"
3102901|NCT01872338|Active Comparator|Mindfulness-Based Cognitive Therapy + Treatment As Usual|Psychotherapeutic intervention that integrates mindfulness meditation with Safety Planning, with a specific focus on reducing suicide risk.
3102902|NCT01872338|Other|Treatment As Usual|VA standard care for suicide prevention
3102903|NCT01872325||Training site|All emergency medical dispatchers at a central ambulance communication centre in Ontario will participate in an educational program designed to improve cardiac arrest diagnostic accuracy.
3102904|NCT01872325||Control site|All emergency medical dispatchers at a central ambulance communications centre geographically remote from the Training Site and has a similar rate to the Training Site for cardiac arrests, bystander CPR rate, and survival
3102905|NCT01872312|Other|treatment|Loading IBV® Valve System
3102906|NCT01872299||Control|Healthy control subjects
3102907|NCT01872299||Heart failure without co-morbidities|Patients with a clinical diagnosis of chronic heart failure without co-morbidities
3102908|NCT01872299||Heart failure with co-morbidities|Patients with a clinical diagnosis of chronic heart failure with co-morbidities
3102909|NCT01872299||Type 2 diabetes mellitus|Patients with type 2 diabetes mellitus and without heart failure
3102910|NCT01872286|Experimental|Pillcam SB2 first|patients were assigned to swallow PSB first, followed by the AKE
3102911|NCT01872286|Experimental|AKE-1 first|patients were assigned to swallow AKE first, followed by the PSB
3102912|NCT01872260|Experimental|LEE011 + letrozole Arm 1|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating), letrozole - 2.5 mg/day
3102913|NCT01872260|Experimental|BYL719 + letrozole Arm 2|BYL719 - daily (dose escalating) letrozole - 2.5 mg/day
3102914|NCT01872260|Experimental|LEE011 + BYL719 + letrozole Arm 3|LEE011 - 28 day cycles (21 days followed by a 7 day break -dose escalating), BYL719 - daily (dose escalating), letrozole 2.5 mg/day
3102915|NCT01872260|Experimental|LEE011+ BYL719+letrozole Arm 4|LEE011-daily (dose escalating), BYL719 -daily (dose escalating), letrozole 2.5 mg/day
3102916|NCT01872234|Experimental|Device Arm: Two Lead CRT-P|Intervention: Device: Two-lead CRT-P. Patients will be implanted with a two lead CRT-P system: right atrial lead, left ventricular lead and a dual chamber pacemaker. Patients in this group will also be under optimal pharmacologic therapy.
3102917|NCT01872234|No Intervention|Control: Optimal Pharmacologic Therapy|The control group will be managed on optimal pharmacologic therapy only. They will not be implanted with a device.
3102918|NCT01872221|Experimental|Surgery and radio-chemotherapy|Surgery (on the basis of all preoperative multimodal MRI) followed by standard radio-chemotherapy stupp protocol
3102919|NCT01872208|Experimental|HAVG graft|HAVG graft implantation to study participants.
3102920|NCT01872195|Experimental|* Before checklists|The comprehensive patient safety checklist system
3102921|NCT01872195|Experimental|* After checklists|Without the comprehensive patient safety checklist system
3102922|NCT01872182|Experimental|Test arm|ALS-L1023 300mg in two tablets
3102923|NCT01872182|Placebo Comparator|Comparator arm|placebo in two tablets
3102924|NCT01872169|Other|Disordered eating screening questionnaire|
3102925|NCT01872156|Experimental|Intervention GESTABAC|"Intervention based on the Clinician`s Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth."
3102926|NCT01872156|Other|Control Group|The group control will act according to usual management.
3102927|NCT01872143|Experimental|transcranial Direct Current Stimulation|daily or twice-a-day administration of transcranial Direct Current Stimulation
3102928|NCT01872117|Experimental|Applications of shortwave diathermy|
3102929|NCT01872117|Experimental|Applications of microwave diathermy|
3102930|NCT01872104|No Intervention|Chemotherapy alone|Group that be scheduled to undergo chemothrapy only using FOLFOX4 protocol.
3102931|NCT01872104|Experimental|PDT and Chemotherapy|Group that not only be scheduled to undergo chemothrapy using FOLFOX4 protocol,but also receive colonscopy-assisted PDT.
3102932|NCT01872091|Experimental|cryotherapy by immersion|Cryotherapy group immersion (GI) composed of 20 volunteers, which will be subjected to immersion cryotherapy upper limb dominant in cold water (6°C ± 2°C), at the level of the elbow joint.
3102933|NCT01872091|Experimental|Control group|(CG) consisted of 20 volunteers, which will be submitted to immersion of the dominant upper limb in water at room temperature indifferent to the level of the elbow joint;
3102934|NCT01872078|Experimental|AZD4901 20 mg once a day|AZD4901 20 mg once a day
3102935|NCT01872078|Experimental|AZD4901 20mg twice a day|AZD4901 20mg twice a day
3102936|NCT01872078|Experimental|AZD4901 40 mg twice a day|AZD4901 40 mg twice a day
3102937|NCT01872078|Experimental|Placebo to match AZD4901|
3102938|NCT01872065|Experimental|ARC-520|Single dose, intravenous administration of ARC-520.
3102939|NCT01872065|Placebo Comparator|Normal Saline|Single dose, intravenous administration of Normal Saline
3102940|NCT01872052|Experimental|Acutus Medical System|
3102941|NCT01872039|Active Comparator|Weight-based adjustment group|Dosage regimen according to the current Package Insert approved by SFDA
3102942|NCT01872039|Experimental|Non-weight-based adjustment group|Dosage regimen according to the Package Insert approved by FDA
3102943|NCT01872026|Experimental|Part 1- single administration|The lowest, middle and the highest dose ASP7991 as a single oral administration on non-dialysis day in step 1 to 3 and the highest dose on day of dialysis in step 4.
3102944|NCT01872026|Experimental|Part 2- repeated administration|The lowest, middle and the highest dose ASP7991 as repeated oral administration in step 1 to 3.
3102945|NCT01872013|Experimental|low dose ASP7991|
3102946|NCT01872013|Experimental|middle dose ASP7991|
3102947|NCT01872013|Experimental|high dose ASP7991|
3102948|NCT01872013|Placebo Comparator|Placebo|
3102949|NCT01872000|Experimental|Multifocal IOL|Phacoemulsification and IOL inserted following cataract surgery
3102950|NCT01872000|Active Comparator|Standard IOL|Phacoemulsification and IOL inserted following cataract surgery
3102951|NCT01871987|Experimental|fasted group|receiving FK949E in fasted condition
3102952|NCT01871987|Experimental|low fat group|receiving FK949E after low fat meal
3102953|NCT01871987|Experimental|high fat group|receiving FK949E after high fat meal
3102954|NCT01871974|Experimental|low-dose group FK949E|oral
3102955|NCT01871974|Experimental|high-dose group FK949E|oral
3102956|NCT01871961|Experimental|Methotrexate|
3102957|NCT01871948|No Intervention|Patient survey at 2 points in time|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later.
3102958|NCT01871948|Experimental|"WeWant to Know campaign, patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
3102959|NCT01871935|Active Comparator|Remifentanil|Anaesthesia with remifentanil/propofol
3102960|NCT01871935|Active Comparator|Sufentanil|Anaesthesia with sufentanil/propofol
3102961|NCT01871922|Placebo Comparator|General anesthesia + placebo|Propofol/remifentanil anesthesia + saline
3102962|NCT01871922|Active Comparator|General anesthesia + atropine|Propofol/remifentanil anesthesia + atropine
3102963|NCT01871909||Physical trauma|Patients with report of physical trauma within 24 hours of presentation to the hospital.
3102964|NCT01871896|Experimental|Weight Gain|Patients who previously underwent bariatric surgery who failed to lose the expected weight or regained weight.
3102965|NCT01871883|Experimental|Sensitive Skin|Subjects with sensitive skin, diagnosed by the lactic acid stinging test. Skin biopsy Oral mucosa specimen
3102966|NCT01871883|Active Comparator|Non-sensitive skin|Subjects without sensitive skin, determined by a negative lactic acid stinging test Skin biopsy Oral mucosa specimen
3102967|NCT01871870|Experimental|Artificial Pancreas Control Software|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 28 hours. For the entire study, the adaptive component of Artificial Pancreas Control Software will be used to control the subject's blood glucose.
3102968|NCT01871857|Active Comparator|Normal saline and epinephrine|0.9 % saline with 0.5 ml of 1:1000 epinephrine inhalation
3102969|NCT01871857|Experimental|Hypertonic saline and epinephrine|3 ml 7% saline with 0.5 ml of 1:1000 epinephrine inhalation
3102970|NCT01871844|Experimental|ITF2984 500 mcg/Placebo sc bid for 7 days|TF2984 500 mcg/Placebo sc bid for 7 days
3102971|NCT01871844|Experimental|ITF2984 1000 mcg/Placebo sc bid for 7 days|ITF2984 1000 mcg/Placebo sc bid for 7 days
3102972|NCT01871844|Experimental|ITF2984 2000 mcg/Placebo sc bid for 7 days|ITF2984 2000 mcg/Placebo sc bid for 7 days
3102973|NCT01871844|Active Comparator|octreotide 50 mcg tid|octreotide 50 mcg tid
3102974|NCT01871818|Experimental|Combined program|"Combined program with physiotherapy, endurance training and resistance training.~120 patients will receive this combined program"
3102975|NCT01871818|Active Comparator|Physiotherapy|Active comparator: physiotherapy in private practice 120 patients will receive this usual rehabilitation
3102976|NCT01871805|Experimental|Alectinib: Phase I (Dose Escalation)|Participants will receive escalating doses of alectinib capsules orally until disease progression, death or withdrawal for any other reasons.
3102977|NCT01871805|Experimental|Alectinib (Phase II: RP2 dose)|Participants will receive recommended Phase II dose as determined from Phase I until disease progression, death or withdrawal for any other reasons.
3102978|NCT01871792|Experimental|Pitavastatin|Pitavastatin 4 mg/day for 7 days before coronary angiography/intervention
3102979|NCT01871792|Placebo Comparator|Placebo|Placebo tablet for 7 days before coronary angiography/intervention
3102980|NCT01871779|Experimental|Standard Treadmill Exercise|The first group would undergo standard treadmill exercise to the point of pain and repeat these cycles for a total period of 35-45 minutes twice weekly for 12 weeks
3103034|NCT01871480|Active Comparator|Group B|Gefitinib alone
3102981|NCT01871779|Experimental|Intermittent Treadmill & Resistance Training|The second group would have a combination of intermittent treadmill and some resistance training with weights. They will undergo repeated cycles to a maximum of 35-45 minutes twice weekly for 12 weeks
3102982|NCT01871766|Experimental|Low-Risk, Subset 1|"Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin and cyclophosphamide). They are then evaluated to determine how the tumor responded to treatment. Twelve additional weeks of chemotherapy (vincristine and dactinomycin) is given, followed by evaluation for tumor response. No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.~Participants also receive ^1^1C-methionine as described in the intervention section."
3102983|NCT01871766|Experimental|Low-Risk, Subset 2|"Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated to determine how it responded to treatment. Radiation therapy and/or surgical resection is performed to destroy or remove the remaining tumor. Twelve additional weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is given, followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants then receive 16 weeks of additional chemotherapy (vincristine, dactinomycin and cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor will be given if needed.~Participants also receive ^1^1C-methionine as described in the intervention section."
3102984|NCT01871766|Experimental|Intermediate-Risk|"Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated for treatment response. Radiation therapy and/or surgical resection is done. Twelve weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants receive 16 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) followed by 12 weeks of maintenance treatment (bevacizumab, sorafenib, oral cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.~Participants also receive ^1^1C-methionine as described in the intervention section."
3102985|NCT01871766|Experimental|High-Risk|"Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 6 weeks (2 cycles) chemotherapy (vincristine and irinotecan). The tumor is evaluated for treatment response. 3 cycles of chemotherapy [vincristine, doxorubicin, cyclophosphamide/ifosfamide, etoposide (or etoposide phosphate) (VDC/IE)] are given. Dexrazoxane is given prior to each dose of doxorubicin. Radiation therapy begins at week 4 or 20 (depending on tumor location) while receiving vincristine and irinotecan. 2 cycles of VDC/IE, 4 cycles of modified vincristine, dactinomycin, cyclophosphamide (VAC), then 2 cycles of modified vincristine/irinotecan (total of 54 weeks). High risk participants also receive additional maintenance therapy beginning week 55 with anti-angiogenic chemotherapy (bevacizumab, sorafenib, cyclophosphamide). Myeloid growth factor is given as needed.~Participants also receive ^1^1C-methionine as described in the intervention section."
3102986|NCT01871753|Experimental|Antibiotics|10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up).
3102987|NCT01871753|No Intervention|No treatment|no antibiotics delivered in case of asymptomatic bacteriuria, independently of the number of asymptomatic episodes.
3102988|NCT01871740|Experimental|Enalapril maleate and folic acid tablets|A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
3102989|NCT01871740|Active Comparator|Enalapril maleate|Enalapril maleate 10 mg per day is given
3102990|NCT01871727|Experimental|E7777|
3102991|NCT01871714||XLHED affected Males|All males ages 4 and up affected by XLHED
3102992|NCT01871714||Females affected by XLHED|Adult females (ages 18-45) affected by XLHED
3102993|NCT01871714||Unaffected females|Unaffected adult female controls (ages 18-45)
3102994|NCT01871701|Experimental|Quetiapine|Quetiapine 100 mg (Seroquel, Tablet)
3102995|NCT01871701|Experimental|Moxifloxacin|Moxifloxacin 400 mg (Avelox, Tablet)
3102996|NCT01871701|Experimental|Escitalopram|Escitalopram 20 mg (Lexapro, Tablet)
3102997|NCT01871701|Placebo Comparator|Placebo|Water intake
3102998|NCT01871688|Other|pelvic floor exercise|pelvic floor rehabilitation program with neuromodulation
3102999|NCT01871675|Experimental|Arm 1: IPI-145 plus Rituximab|"IPI-145 will be administered orally, twice daily, in 28-day (4-week) cycles, on a continuous basis at the maximum tolerated dose of 25 mg twice-daily (BID), as determined in the dose escalation phase. Twelve (12) cycles of IPI-145 will be administered. Patients who benefit from treatment may continue on study for additional cycles until toxicity or progressive disease.~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Day 1 once weekly during a 28 day cycle; 2 cycles of rituximab will be administered."
3103000|NCT01871675|Experimental|Arm 2: IPI-145 plus Rituximab/Bendamustine|"IPI-145 will be administered orally, twice daily, in 28 day cycles, on a continuous basis, until disease progression, unacceptable toxicity or patient refusal. The maximum tolerated dose of IPI-145 will be 25 mg twice-daily (BID) as determined in the dose escalation phase. Twelve (12) cycles of IPI-145 will be administered. Patients who benefit from treatment may continue on study for additional cycles until toxicity or progressive disease.~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Day 1 once weekly of each 28 day cycle. A maximum of 6 cycles of rituximab will be given. Bendamustine 90 mg/m2 IV will be administered on Days 1 and 2, of each 28 day cycle. Rituximab should be administered prior to bendamustine."
3103001|NCT01871662|Active Comparator|Group C: RIB + Peg-IFN|Ribavirin(800-1400 mg/day,divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC)for 25 weeks if RVR has been achieved or 49 weeks if EVR has been achieved
3103002|NCT01871662|Experimental|Group B:Legalon® SIL + RIB + Peg-IFN|Silibinin (20 mg/Kg/day) for 6 days, followed by Silibinin + ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) for 15 days, followed by ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) + 2 days of Silibinin per week for 9 weeks, followed by ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) for 13 weeks if RVR has been achieved (for a total of 25 weeks of treatment) or 37 weeks if EVR has been achieved (for a total of 49 weeks of treatment)
3103003|NCT01871662|Experimental|Group A: Legalon® SIL + RIB|Silibinin (20 mg/Kg/day) for 6 days, followed by Silibinin + ribavirin (800-1400 mg/day, divided BID PO) for 15 days, followed by ribavirin (800-1400 mg/day, divided BID PO) + 2 days of Silibinin per week for 9 weeks, followed by ribavirin (800-1400 mg/day, divided BID PO) for 13 weeks if RVR has been achieved (for a total of 25 weeks of treatment) or 37 weeks if EVR has been achieved (for a total of 49 weeks of treatment)
3103004|NCT01871649|Active Comparator|methotrexate|methotrexate is the active comparator, it will be compared to golimumab + methotrexate
3103005|NCT01871649|Experimental|golimumab and methotrexate|The combination of golimumab en methotrexate will be compared to methotrexate alone.
3103006|NCT01871636|Active Comparator|endoscopic mucosal resection|Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
3103007|NCT01871636|Active Comparator|Waterjet-assisted ESD|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
3103008|NCT01871623|Experimental|Segmental Le Fort I Osteotomy|For some cases that bone filling over cleft site is not good enough for tooth movement, it is possible that we put them into this group which means by using Segmental Le Fort I Osteotomy to approximate two dental alveolar segments.
3103009|NCT01871623|Active Comparator|One-piece Le Fort I Osteotomy|For patients having ideal bone graft result over cleft site, traditional One-piece Le Fort I Osteotomy will be performed.
3103010|NCT01871610|Experimental|Alzheimer disease after mild traumatic brain injury|Based on the TBI registry databank, to recruit patients 1, 5, 10, 15 years after mTBI for cognitive evaluatio
3103011|NCT01871610|Experimental|mild traumatic brain injury without Alzheimer disease|To recruit patients 1, 5, 10, 15 years after mTBI with or without cognitive impairment and age-gender-matched controls (a total of 3 groups) for amyloid- positron emission tomography (A-PET)
3103012|NCT01871610|Experimental|Normal control|People aged 30 or older without mTBI or AD
3103013|NCT01871597|Experimental|Intervention Group|Intervention - Pulmonary Artery Energy Seal
3103014|NCT01871584|Experimental|Hydrocolonic cleansing|Subjects undergo colon cleansing by hydrotherapy with the study device
3103015|NCT01871584|Active Comparator|Standard preparation solution|Subjects undergo colon cleansing by standard preparation solution
3103016|NCT01871571|Experimental|Treatment (bevacizumab, mFOLFOX7)|Patients receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil IV continuously over 46-48 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity. Within 6-8 weeks after treatment, patients undergo surgery.
3103017|NCT01871558|Active Comparator|SU+metformin + Basal Insulin|Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG
3103018|NCT01871558|Experimental|Metformin/vildagliptin + Basal Insulin|Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG
3103019|NCT01871545|Experimental|Magnetic Resonance Imaging|dynamic contrast-enhanced MRI measuring arterial and portal flow
3103020|NCT01871532|Experimental|Low Dose Gonal-f® Protocol|Gonal-f was administered subcutaneously daily at a starting dose of 50 International unit (IU) for Week 1, then dose was gradually increased by 12.5 IU for two weeks, with a final increase of 25 IU, up to maximum dose of 100 IU, until Week 4 for subjects with minimal response. After adequate follicular development was achieved, the subject was administration human chorionic gonadotropin (hCG) within 24-48 hours of last Gonal-f injection as per investigator discretion.
3103021|NCT01871532|Active Comparator|Standard Low Dose Gonal-f® Protocol|Gonal-f was administered subcutaneously daily at a starting dose of 50 International Units (IU) for Week 1, then dose was gradually increased by 12.5 IU for two weeks, up to maximum dose of 125 IU, until Week 4 for subjects with minimal response. After adequate follicular development was achieved, the subject was administration human chorionic gonadotropin (hCG) within 24-48 hours of last Gonal-f injection as per investigator discretion.
3103022|NCT01871519|Other|Balloon Kyphoplasty|This group of patients will be treated with balloon kyphoplasty in the treatment of painful, acute VCFs associated with either osteoporosis or cancer.
3103023|NCT01871506|Experimental|Standard Care (SC)|"Participants randomized to standard care (SC) will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice."
3103024|NCT01871506|Experimental|Intensive Counseling (IC)|"Participants randomized to intensive counseling (IC) will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:~Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).~Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication [varenicline, bupropion, or combination NRT (patch + lozenge)] at no cost to the participant."
3103025|NCT01871493|Experimental|LY2605541-Part A|1.42 units per kilogram (U/kg) of LY2605541 given once daily (QD) for 1 day, subcutaneously (SQ) in 1 of 4 treatment periods.
3103026|NCT01871493|Active Comparator|Insulin Lispro-Part A|Single dose 0.36 U/kg of insulin lispro given QD for 1 day, SQ in 1 of 4 treatment periods.
3103027|NCT01871493|Experimental|LY2605541/Lispro Mix 1-Part A|Single dose 0.54 U/kg of LY2605541 and 0.36 U/kg insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.
3103028|NCT01871493|Experimental|LY2605541/Lispro Mix 2-Part A|Single dose 1.42 U/kg of LY2605541 and 0.36 insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.
3103029|NCT01871493|Active Comparator|Insulin Lispro-Part B|0.18 U/kg insulin lispro given twice daily (BID) for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
3103030|NCT01871493|Experimental|LY2605541/Lispro Mix-Part B|0.71 U/kg LY2605541 and 0.18 U/kg insulin lispro mixture given BID for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
3103031|NCT01871493|Experimental|LY2605541 QD-Part B|0.54 U/kg of LY2605541 given QD for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
3103032|NCT01871493|Experimental|LY2605541 BID-Part B|0.71 U/kg of LY2605541 given BID for 1 day SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
3103036|NCT01871454|Experimental|radiotherapy (SABR) plus pentoxifylline|standard of care radiotherapy (SABR) plus pentoxifylline and Vitamin E
3103037|NCT01871441|Experimental|Treatment (haploidentical allogeneic HSCT)|"Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANT: Patients undergo haploidentical allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV beginning on day -1 with taper beginning on day 42, and mycophenolate mofetil IV BID from day -1 to day 28."
3103038|NCT01871428|Experimental|Aleglitazar|
3103039|NCT01871428|Placebo Comparator|Placebo|
3103040|NCT01871415|Experimental|Aleglitazar + metformin|
3103041|NCT01871415|Active Comparator|Placebo + metformin|
3103042|NCT01871402|Experimental|Active Arm|Topical lotion, applied twice daily
3103043|NCT01871402|Placebo Comparator|Vehicle Arm|Topical lotion, applied twice daily
3103044|NCT01871389||cholecalciferol|
3103045|NCT01871389||usual treatment|
3103046|NCT01871376|Active Comparator|Previously Treated|"Patients that have previously received treatment for polypoidal choroidal vasculopathy.~Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for previously treated arm."
3103047|NCT01871376|Active Comparator|Treatment-Naive|"Patients that have not received treatment for polypoidal choroidal vasculopathy.~Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for treatment-naive arm."
3103048|NCT01871363|Experimental|preoperative chemoradiation|"radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.~capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),~bevacizumab: at dose 5 mg/kg on days -1, 15,31.~Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
3103049|NCT01871350|Experimental|Protein and Fish Oil|"Low Dose (FFM <49kg): 30.00g milk protein + 12.75g maltodextrin and 6g fish oil~High dose (FFM >49kg): 40.00g milk protein + 17.00g maltodextrin and 8g fish oil"
3103050|NCT01871350|Experimental|Protein|"Low Dose (FFM <49kg): 30.00g milk protein + 12.75g maltodextrin and 6g olive oil~High dose (FFM >49kg): 40.00g milk protein + 17.00g maltodextrin and 8g olive oil"
3103051|NCT01871350|Placebo Comparator|Placebo|"Low Dose (FFM <49kg): 12.75g maltodextrin and 6g olive oil~High dose (FFM >49kg): 17.00g maltodextrin and 8g olive oil"
3103052|NCT01871337|Experimental|Paula method|"the Paula method, a circular muscle exercise, invented in Israel by Paula Garbourg.The method is based on the principle that all sphincters in the body are synchronized, with the movement of one affecting the other.One can rehabilitate damaged muscles by contracting and relaxing specific circular muscles in other parts of the body."
3103053|NCT01871324|Experimental|Lifestyle counseling|
3103054|NCT01871311|Experimental|Nilotinib + Cetuximab|All patients with receive Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly
3103055|NCT01871298|Other|Website access|While this pilot intervention is not a randomized trial, study participants who report internet use at least once a month will told of a Pilot Website Evaluation Component that they will be able to access for a 4-week study period. This website will contain a educational information tailored to the health needs of drug users. Web content will be similar to materials and public health messages released by the NYC Department of Health and therefore, harm is not likely to arise from viewing such content.
3103056|NCT01871298|No Intervention|No website access|Participants who report internet use less than once a month will not receive access to the Pilot Website Evaluation Component.
3103057|NCT01871285|Experimental|MSE Dose Group 1|Morning and evening dose of buprenorphine HCl buccal film (300 μg) + placebo capsule in one period, and then placebo film + over-encapsulated ATC opioid (morphine sulfate or oxycodone) at 50% MSE daily dose in the alternate period
3103058|NCT01871285|Experimental|MSE Dose Group 2|Morning and evening dose of buprenorphine HCl buccal film (450 μg) + placebo capsule in one period, and then placebo film + over-encapsulated ATC opioid (morphine sulfate or oxycodone) at 50% MSE daily dose in the alternate period
3103059|NCT01871272||Meniscus Injury Patients|Patients having surgery for a meniscal tear.
3103060|NCT01871246||People with COPD & recent exacerbation|The group consists of people with COPD who have had an exacerbation in the last year.
3103061|NCT01871220|Active Comparator|Divergent Abutment|Divergent Transition Profile
3103062|NCT01871220|Experimental|Concave Abutment|Concave Transition Profile
3103063|NCT01871207||Diabetic patients|Diabetic patients who underwent vitrectomy for Proliferative Diabetic Retinopathy
3103064|NCT01871207||Non-diabetic patients|Non-diabetic patients who underwent vitrectomy for macular hole or pucker
3103065|NCT01871194||Rivaroxaban|This is a non-interventional study
3103066|NCT01871194||Alternative anticoagulant therapy|This is a non-interventional study
3103067|NCT01871181|Experimental|Ilioinguinal block|Patients in this group will receive an ultrasound-guided ilioinguinal nerve block.
3103068|NCT01871181|Active Comparator|Local infiltration|Patients in this group will receive the standard method of local infiltration of local anesthetic around the surgical site.
3103069|NCT01871168|Sham Comparator|Sham TAP block|Patients receive TAP catheters but saline infusion instead of local anesthetic
3103070|NCT01871168|Experimental|TAP block|Patients receive a continuous TAP block
3103071|NCT01871155|Experimental|Nutri-jelly along with radiotherapy|Continuous intake: orally take 1-3 boxes / day for at least 3 days/ week during radiotherapy
3103072|NCT01871155|No Intervention|Radiotherapy only|Receive either definitive (total of 30-35 fractions) or palliative ( total of 10 fractions) radiotherapy with no continuous intake of Nutri-Jelly
3103073|NCT01871142|Experimental|Randomized crossover assignment|Participants will receive, in a random order, a placebo prior to exercise in normoxia, a placebo prior to exercise in hypoxia, 1000 mg of Aes-103 prior to exercise in hypoxia, and 3000 mg of Aes-103 prior to exercise in hypoxia. Each intervention is separated by a 7 day washout period.
3103193|NCT01870375||MPS II|Hunter syndrome patients
3103074|NCT01871129|Placebo Comparator|Saline group|Difference from the normal protocol actualizes at the point when propofol infusion is cut off. From there on the patient in this group receives saline infusion up to the point where 15 minutes have passed after the extubation procedure.
3103075|NCT01871129|Active Comparator|Dexmedetomidine group|Difference from the normal protocol happens when normally the propofol infusion is cut off. From there on the patient in this group receives dexmedetomidine infusion up to the point where 15 minutes have passed after the extubation procedure.
3103076|NCT01871116|Experimental|POWER-remote|Participants will start a weight loss program called POWER-remote for Breast Cancer Survivors. This program involves two main components: an online portion accessed on a computer through the internet and a telephone portion to help monitor progress.
3103077|NCT01871116|Active Comparator|Self-directed|"Participants will receive a pamphlet entitled Aim for a Healthy Weight, to help guide weight loss goals without access to the web-based POWER-remote system and coach support."
3103078|NCT01871103|Other|Surgical flap|The dorsal homodigital island flap is a perforator type flap based on the DB, which uses the dorsal skin of the injured finger to provide soft tissue coverage for a volar defect.
3103079|NCT01871090|Active Comparator|Interrogation with unpaired remote transmitter|Interrogation with an unpaired remote monitoring transmitter for devices that are compatible.
3103080|NCT01871090|No Intervention|Interrogation with programmer|Interrogation with programmer according to usual standard of care
3103081|NCT01871077|Experimental|PRO-156|Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
3103082|NCT01871038||Rotavirus Positive Cases|Children <6 years of age born on or after 8/10/2008 enrolled in active surveillance for AGE who tested positive for rotavirus.
3103083|NCT01871038||Rotavirus Negative Controls|Children <6 years of age born on or after 8/10/2008 enrolled in active surveillance for AGE who tested negative for rotavirus
3103084|NCT01871025|Experimental|Hospital and home exercise training|Usual care plus hospital exercise training (aerobic and strength) followed by exercise training at home until 90 days to discharge.
3103085|NCT01871025|Other|Usual care|Usual care in COPD
3103086|NCT01871012||non-diabetes mellitus group|Subjects undergoing Total Knee Replacement are not diagnosed with diabetes mellitus.
3103087|NCT01871012||diabetes mellitus group|subjects have been diagnosed diabetes mellitus mora than three years without serious nerve system complications.
3103088|NCT01870999|Experimental|400 mg Aripiprazole IM Depot|400 mg aripiprazole IM (intramuscular) depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
3103089|NCT01870999|Experimental|300 mg Aripiprazole IM Depot|300 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
3103090|NCT01870999|Experimental|200 mg Aripiprazole IM depot|200 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
3103091|NCT01870986|Experimental|A|PF-06410293
3103092|NCT01870986|Active Comparator|B|Adalimumab-EU
3103093|NCT01870986|Active Comparator|C|Adalimumab-US
3103094|NCT01870973|Experimental|root canal treatment|root canal treatment, anesthesia with 2% lidocaine with 1:100,000 epinephrine, pain medication (1000 mg acetaminophen and 600 mg ibuprofen every 6 hours)five day supply, antibiotic (500 mg penicillin, if allergic 300 mg clindamycin)
3103095|NCT01870973|Active Comparator|no root canal treatment|no root canal treatment, anesthesia with 2% lidocaine with 1:100,000 epinephrine, pain medication (1000 mg acetaminophen and 600 mg ibuprofen every 6 hours)five day supply, antibiotic (500 mg penicillin if allergic 300 mg clindamycin)
3103096|NCT01870960|Other|right control|the patient is his own control The right side will be treated as normal while the left side will also receive the emdogaim
3103097|NCT01870960|Other|left control|the patient is his own control The left side will be treated as normal while the right side will also receive the emdogaim
3103098|NCT01870947|Experimental|'Assisted-Rate' Exercise Intervention|Subjects in the assisted exercise group will cycle on the same stationary exercise bike; however, a motor will provide assistance to the patient in order to maintain a pedaling rate 35% greater than their voluntary rate. Subjects in the exercise groups will complete 45 minute to 1-hour sessions, three times per week for eight weeks.
3103099|NCT01870947|Experimental|'Voluntary-Rate' Exercise Intervention|Subjects in the voluntary group will exercise on a stationary recumbent exercise cycle and pedal at their preferred rate. Subjects in the exercise groups will complete 45 minute to 1-hour sessions, three times per week for eight weeks.
3103100|NCT01870934||Telemedicine, Diabetes, foot ulcer|
3103101|NCT01870921|Experimental|Ticargrelor|90 mg/tablet, 1 tablet bid
3103102|NCT01870908||tacrolimus + biological agents|
3103103|NCT01870895|Experimental|YM060 group|
3103104|NCT01870895|Placebo Comparator|Placebo group|
3103105|NCT01870882|Active Comparator|Retraining|Using the PED, participants repeatedly complete a version of attentional bias task that orients their attention away from drug-related cues.
3103106|NCT01870882|Sham Comparator|Control|Using the PED, participants repeatedly complete versions of the attentional bias task in which their attention is oriented toward and away from drug-related cues on an equal number of trials.
3103107|NCT01870856|Experimental|Spectacles, Stage 1|Spectacles per participant's habitual perscription worn for 2 weeks
3103108|NCT01870856|Active Comparator|1-DAY ACUVUE, Stage 1|Etafilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
3103109|NCT01870856|Experimental|DAILIES TOTAL1, Stage 2|Delefilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
3103110|NCT01870856|Active Comparator|1-DAY ACUVUE, Stage 2|Etafilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
3103111|NCT01870843|Experimental|Escitalopram|Participants will receive escitalopram 10 mg per day for 1 week and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
3103112|NCT01870830|Other|A: low-intermediate-high altitude|Altitude exposure sequence A, 490-1650-2590m
3103113|NCT01870830|Other|B: low-high-intermediate altitude|Altitude exposure sequence B, 490-2590-1650m
3103114|NCT01870830|Other|C: intermediate-high-low altitude|Altitude exposure sequence C, 1650-2590-490m
3103115|NCT01870830|Other|D: high-intermediate-low altitude|Altitude exposure sequence D, 2590-1650-490m
3103116|NCT01870817|Active Comparator|Home jejunostomy feeding|Six weeks of post hospital discharge home enteral feeding
3103117|NCT01870817|No Intervention|Control|Standard care
3103118|NCT01870804|Active Comparator|Rosuvastatin|Rosuvastatin (40 mg on-admission followed by 20 mg/day) until discharge; then 20 mg/day (10 mg/day if creatinine clearance < 30 ml/min)
3103119|NCT01870804|Active Comparator|Atorvastatin|atorvastatin (80 mg on-admission followed by 40 mg/day before and after discharge)
3103120|NCT01870791|Experimental|Omegaven|Omegaven in combination with EOX chemotherapy
3103121|NCT01870778|Experimental|Serelaxin (RLX030)|Participants received continuous intravenous infusion of serelaxin 30 ug/kg/day for 48 hours.
3103122|NCT01870778|Placebo Comparator|Placebo|Participants received continuous intravenous infusion of matching placebo to serelaxin for 48 hours.
3103123|NCT01870765|Active Comparator|non-invasive ventilation|Performance of bronchoscopy during non-invasive ventilation.
3103124|NCT01870765|Experimental|high-flow oxygen|Performance of bronchoscopy during high-flow oxygen therapy.
3103125|NCT01870739|Experimental|sacubitril/valsartan (LCZ696)|"Single drug treatment period: Patients received LCZ696 200mg once daily (q.d.) + placebo to 20 mg olmesartan q.d for 2 weeks. After 2 weeks, patients were dosed at the maintenance dose level (400 mg qd LCZ696 + placebo to 40 mg qd olmesartan) for 10 weeks.~Add-on Period: After 12 weeks on single-drug treatment, patients continued in the study on the blinded maintenance dose and if required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to the treatment regimen and titrated according to the investigator's discretion to achieve target blood pressure."
3103126|NCT01870739|Active Comparator|olmesartan|"Single drug treatment period: Patients received 20 mg olmesartan q.d + placebo to LCZ696 200mg once daily (q.d.) for 2 weeks. After 2 weeks, patients were dosed at the maintenance dose level (40 mg olmesartan q.d + placebo to 400 mg qd LCZ696) for 10 weeks.~Add-on Period: After 12 weeks on single-drug treatment, patients continued in the study on the blinded maintenance dose and if required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to the treatment regimen and titrated according to the investigator's discretion to achieve target blood pressure."
3103127|NCT01870726|Experimental|Phase Ib|To estimate the safe dose of the combination INC280 and buparlisib
3103128|NCT01870726|Experimental|Phase II|To estimate anti-tumor efficacy of INC280 single agent and in combination with buparlisib
3103129|NCT01870713||type 2 diabetes patients with gastric bypass surgery.|Participants who have type 2 diabetes and with decreased glucose after gastric bypass surgery.
3103130|NCT01870713||Weight matched non-operated controls|Participants who are overweight to moderately obese, and have no personal of family history of Type 1, Type 2, or Gestational Diabetes.
3103131|NCT01870700|Experimental|lactobacillus reuteri|Intervention: supplementation with the probiotic Lactobacillus reuteri (DSM 17938),Reuflor, was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks.
3103132|NCT01870700|Placebo Comparator|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
3103133|NCT01870687|Experimental|VAC BNO 1095 2x10 mg FCT|VAC BNO 1095 2x10 mg FCT 2 tablets of verum in the morning, oral, 3 months treatment
3103134|NCT01870687|Placebo Comparator|Placebo|2 tablets in the morning, oral, 3 months treatment
3103135|NCT01870674|Experimental|YH12852|"<SAD cohort>~Experimental: YH12852 1mg/single dose, qd~Experimental: YH12852 3mg/single dose, qd~Experimental: YH12852 10mg/single dose, qd~<FSD cohort>~Experimental: YH12852 0.5mg/single dose, qd~Experimental: YH12852 1mg/single dose, qd~Experimental: YH12852 2mg/single dose, qd~Experimental: YH12852 3mg/single dose, qd~<MAD cohort>~Experimental: YH12852 0.5mg/repeat dose, qd~Experimental: YH12852 1mg/repeat dose, qd~Experimental: YH12852 2mg/repeat dose, qd~Experimental: YH12852 3mg/repeat dose, qd~Each dosing group(except MAD cohort 0.5mg which has single treatment arm taking YH12852 only) contains 12 subjects. 12 subjects are administered YH12852 or placebo/active comparators.(YH12852:placebo:active=8:2:2)"
3103136|NCT01870674|Active Comparator|Prucalopride|<each cohort> Prucalopride succinate 1.321mg
3103137|NCT01870674|Placebo Comparator|Placebo|<each cohort> Matching Placebo
3103138|NCT01870661|Experimental|Long axis ultrasound placement of IV|Long axis ultrasound placement of IV catheter
3103139|NCT01870661|Active Comparator|Short axis ultrasound placement of IV|Long axis ultrasound placement of IV catheter
3103140|NCT01870648|Experimental|Ondansetron|"4 mg oral disintegrating tablet of ondansetron~Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)"
3103141|NCT01870648|Placebo Comparator|Placebo (sugar pill)|
3103142|NCT01870635|Experimental|Ondansetron|"4 mg oral disintegrating tablet of ondansetron~Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)"
3103143|NCT01870635|Placebo Comparator|Placebo (sugar pill)|
3103144|NCT01870622|Active Comparator|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
3103145|NCT01870622|Experimental|Flow waves|Flow waves will be used to confirm correct tube placement
3103146|NCT01870609|Active Comparator|defactinib (VS-6063)|2 x 200 mg defactinib (VS-6063) tablets, administered orally, twice daily
3103147|NCT01870609|Placebo Comparator|Placebo|2 placebo tablets, administered orally, twice daily
3103148|NCT01870596|Experimental|Arm A (cytarabine, Chk1 inhibitor SCH 900776)|Patients receive cytarabine IV continuously over 72 hours on days 1-3 and 10-12 and Chk1 inhibitor SCH 900776 IV over 30 minutes on days 2, 3, 11, and 12.
3103149|NCT01870596|Active Comparator|Arm B (cytarabine)|Patients receive cytarabine as in Arm A.
3103284|NCT01869881|Active Comparator|Sarpogrelate|
3103150|NCT01870583|Active Comparator|Combination iodine and chlorhexidine|The combincation skin preparation will utilize the iodine based preparation first followed by the chlorhexidine based skin preparation prior to cesarean delivery.
3103151|NCT01870583|Active Comparator|Chlorhexidine|Chlorhexidine based skin preparation solution applied to skin prior to cesarean delivery
3103152|NCT01870583|Active Comparator|Iodine povidone|Iodine povidone based skin preparation solution applied to skin prior to cesarean delivery
3103153|NCT01870570|Other|Reference Glucose|Glucose Standard (50g of Glucose)
3103154|NCT01870570|Experimental|Food Product A: Corn Flakes|Corn Flakes
3103155|NCT01870570|Experimental|Food Product B: Ginger Bread|Ginger Bread
3103156|NCT01870570|Experimental|Food Product C:Sandwiched Breakfast Biscuit|Sandwiched Breakfast Biscuit
3103157|NCT01870570|Experimental|Food Product D: Crackers Nature|Crackers Nature
3103158|NCT01870570|Experimental|Food Product E: Breakfast Biscuit|Breakfast Biscuit
3103159|NCT01870570|Experimental|Food Product F: White Bread|White Bread
3103160|NCT01870557||Diabetes Mellitus type 1|n=100
3103161|NCT01870557||Diabetes Mellitus type 2|n=100
3103162|NCT01870544|Experimental|LGG Administration|Lactobacillus Rhamnosus GG (LGG) will be taken orally for 44 days. The daily dose is 2*10^10 organisms. The LGG is contained in capsules (1*10^10 organisms per capsule), and two capsules will be taken per day.
3103163|NCT01870544|Placebo Comparator|Placebo|Placebo to be taken orally for 44 days.
3103164|NCT01870518|Active Comparator|Parkinson's patients with MCI|Procedure: deep brain stimulation surgery
3103165|NCT01870518|Active Comparator|Parkinson's patients without MCI|Procedure: deep brain stimulation surgery
3103166|NCT01870505|Experimental|Arm A: BYL719 plus Letrozole|For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on letrozole, and BYL719 will be added. A treatment cycle will consist of 28 days. Treatment doses for each AI will be fixed at the established dose. Patients will continue on treatment until progression of disease or unacceptable toxicity. The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
3103167|NCT01870505|Experimental|Arm B: BYL719 plus Exemestane|For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on Exemestane, and BYL719 will be added. A treatment cycle will consist of 28 days. Treatment doses for each AI will be fixed at the established dose. Patients will continue on treatment until progression of disease or unacceptable toxicity. The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
3103168|NCT01870505|Experimental|Arm C: BYL719 plus Letrozole|For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added.Letrozole 2.5mg orally once daily with BYL719 given on days 1-7 and 15-21 of a 28 day cycle. The starting dose of BYL719 in Arms C will be 250mg daily. Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
3103169|NCT01870505|Experimental|Arm D: BYL719 plus Exemestane|For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added. Exemestane 25mg orally once daily BYL719 Days 1-5, 8-12, 15-19, 22-26 of 28 day cycle. For Arm D, the established dose is 350mg for BYL719 we are currently enrolling 10 patients to the corresponding arm in the expansion phase of the study. Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
3103170|NCT01870492||Acute ischemic stroke or TIA|Patients presenting with acute ischemic stroke or transient ischemic attack and underwent treatment using Activase and/or endovascular therapy.
3103171|NCT01870479|Experimental|Live music|Patient preferred live music during chemotherapy session.
3103172|NCT01870479|Active Comparator|Taped music|Patient preferred taped music during chemotherapy
3103173|NCT01870479|No Intervention|Control|Usual care during chemotherapy
3103174|NCT01870466|Experimental|C -> C + S|cilostazol (C) in period 1, cilostazol + simvastatin (C+S) in period 2
3103175|NCT01870466|Experimental|C + S -> C|cilostazol + simvastatin (C+S) in period 1, cilostazol (C) in period 2
3103176|NCT01870466|Experimental|S -> S + C|simvastatin (S) in period 1, simvastatin + cilostazol (S+C) in period 2
3103177|NCT01870466|Experimental|C + S -> S|cilostazol + simvastatin (C+S) in period 1, simvastatin (S) in period 2
3103178|NCT01870466|Experimental|R -> C + R|rosuvastatin (R) in period 1, cilostazol + rosuvastatin (C+R) in period 2
3103179|NCT01870466|Experimental|C + R -> R|cilostazol + rosuvastatin (C+R) in period 1, rosuvastatin (R) in period 2
3103180|NCT01870453||Isoflurane Anesthesia|Recruited subjects that were anesthetized with isoflurane for their surgery.
3103181|NCT01870453||Sevoflurane Anesthesia|Recruited subjects that were anesthetized with sevoflurane for their surgery.
3103182|NCT01870453||Desflurane Anesthesia|Recruited subjects that were anesthetized with desflurane for their surgery.
3103183|NCT01870453||Propofol Anesthesia|Recruited subjects that were anesthetized with propofol for their surgery.
3103184|NCT01870440|Experimental|Ozurdex Injection|Ozurdex Intravitreal Injection (0.7 mg)
3103185|NCT01870427|Experimental|Aflibercept (2.0 mg)|Intravitreal Aflibercept (2.0 mg)
3103186|NCT01870414|Other|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes [2, 17], temperature of 4º C [22, 24], water level at 20 cm.
3103187|NCT01870401|Experimental|Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
3103188|NCT01870401|Active Comparator|PTA Catheter|Standard Uncoated PTA Catheter
3103189|NCT01870388|Experimental|Baricitinib (Healthy)|Group 1: 4 milligrams (mg) baricitinib administered once, orally, to participants with normal hepatic function.
3103190|NCT01870388|Experimental|Baricitinib (Moderate)|Group 2: 4 mg baricitinib administered once, orally, to participants with moderate hepatic impairment.
3103191|NCT01870388|Experimental|Baricitinib (Mild)|Group 3: 4 mg baricitinib administered once, orally, to participants with mild hepatic impairment. Enrollment is contingent on data from Groups 1 and 2.
3103192|NCT01870375||MPS IH, MPS IHS, MPS IS|MPS IH (Hurler syndrome) patients; MPS IHS (Hurler-Scheie syndrome) patients; and MPS IS (Scheie syndrome) patients
3103194|NCT01870375||MPS IV|Morquio syndrome patients who will be considered for enrollment in the study on an individual basis
3103195|NCT01870375||MPS VI|Maroteaux-Lamy syndrome patients
3103196|NCT01870375||MPS VII|Sly syndrome patients who will be considered for enrollment in the study on an individual basis
3103197|NCT01870362|Experimental|Probiotic (Inersan) Arm|Inersan Lozenges (2 Lozenges bid). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
3103198|NCT01870362|Placebo Comparator|Placebo Arm|Placebo Lozenges (2 lozenges bid). Placebo lozenge contains only excipients (without probiotic).
3103199|NCT01870349||Titanium Implant Abutments|Gingival Crevicular Fluid Sampling
3103200|NCT01870349||Zirconium Implant Abutments|Gingival Crevicular Fluid Sampling
3103201|NCT01870336|Experimental|Lateral customized foot orthoses|Foot orthoses with arch support and lateral inclination set at 7° (alone)
3103202|NCT01870336|Experimental|Knee brace|OdrA Knee brace (alone)
3103203|NCT01870336|Experimental|Combination of the two treatments|Combination of Lateral customized foot orthoses and knee brace
3103204|NCT01870323|Experimental|SMART Behavioral Group|Intervention condition which has access to SMART Group Wall on Facebook and receives privately-delivered weekly behavioral modules. (SMART Facebook Group + video-based behavioral modules)
3103205|NCT01870323|Active Comparator|SMART Informational Group|Comparison condition (i.e., attentional control) has access to SMART Group Wall on Facebook, and receives privately-delivered weekly text-based messages with generic content. (SMART Facebook Group + NO video-based behavioral modules)
3103206|NCT01870310|No Intervention|Standard medical therapy|
3103207|NCT01870310|Experimental|Renal denervation + standard medical therapy|Patients in this arm will undergo catheterised renal denervation in addition to having optimization of medical therapy for heart failure.
3103208|NCT01870297|Experimental|LY3025876|Part A: Escalating doses (0.5 milligram [mg] up to 20 mg) of LY3025876 administered as once daily (QD) subcutaneous (SQ) injections for up to 28 days
3103209|NCT01870297|Placebo Comparator|Placebo|Part B: Placebo matching LY3025876 administered as QD SQ injections for up to 28 days
3103210|NCT01870297|Experimental|LY3025876 + Liraglutide|Part B: LY3025876 (dose will be determined by Part A) and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.
3103211|NCT01870297|Placebo Comparator|Placebo + Liraglutide|Part B: Placebo doses matching LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.
3103212|NCT01870284|Experimental|Ixekizumab Dosing Regimen 1|Administered by 80 milligram (mg) subcutaneous (SC) injection
3103213|NCT01870284|Experimental|Ixekizumab Dosing Regimen 2|Administered by 80 mg SC Injection
3103214|NCT01870284|Placebo Comparator|Placebo|Placebo for ixekizumab and placebo for adalimumab administered by SC injection
3103215|NCT01870284|Active Comparator|Adalimumab|Administered by 40 mg SC injection
3103216|NCT01870271|Experimental|DCPT|Treatment with developmentally adapted D-CPT. 30 to 36 individual treatment sessions. Treatment sections comprise a commitment phase (5 sessions), emotion regulation phase (6 sessions), CPT (15 sessions) and a final phase targeting developmentally-related challenges (4 sessions).
3103217|NCT01870258|Placebo Comparator|those without MI in 2 weeks|patient without MI in 2 weeks
3103218|NCT01870258|Active Comparator|patient with MI|group with MI in 2 weeks
3103219|NCT01870245|Experimental|ACHN-975|
3103220|NCT01870245|Placebo Comparator|Placebo|
3103221|NCT01870232|Experimental|US guided block|Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
3103222|NCT01870219|Active Comparator|Group S|In group S, sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered, at which time it was turned off.
3103223|NCT01870219|Active Comparator|Group K|In group K, ketamine was given to 1mg/kg ıv bolus.
3103224|NCT01870206|Experimental|Trivalent OPV Birmex|Newborns receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine. A second dose four weeks after the first application.
3103225|NCT01870206|Active Comparator|Trivalent OPV Sanofi Pasteur|Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine. A second dose four weeks after the first application.
3103226|NCT01870193||Young controls|Young controls will be studied before and after receiving cysteine and glycine for 2 weeks
3103227|NCT01870193||Elderly group|Elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine or alanine for 4 months, and be studied at baseline, 2 weeks and 4 months
3103228|NCT01870180|Experimental|EyeBag|Eye self-treated with heated eyebag in the morning and evening each day as per manufacturer's instructions (see http://www.eyebagcompany.com/how)
3103229|NCT01870180|Placebo Comparator|Placebo|Non-heated EyeBAG: As with eyebag arm but second eyebag applied on other eye at same time BUT not heated
3103230|NCT01870167|Placebo Comparator|placebo|Placebo
3103231|NCT01870167|Experimental|co-amoxiclav|co-amoxiclav is a combination antibiotic consisting of amoxicillin trihydrate, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor
3103232|NCT01870154|Experimental|Intervention group|The intervention consists of 16 hours of training, to be held at the subject's health center. The workshop involves mixed learning, comprising 4 sessions, each 2 hours long, in addition to personal work previous to and after each session of reading relevant bibliography and performing exercises, self-evaluation, and case studies (8 hours of individual work).
3103233|NCT01870154|Active Comparator|Control group|Usual care
3103234|NCT01870141|Experimental|Psychological Intervention|Cognitive Behavioural Intervention
3103235|NCT01870141|No Intervention|Current standard of care|
3103236|NCT01870128|Active Comparator|Methotrexate|Single agent Methotrexate 15 to 25 mg PO per week
3103237|NCT01870128|Active Comparator|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
3103238|NCT01870128|Experimental|Combination Steroid|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day Methylprednisolone 1000 mg intravenous per day for 3 days
3103239|NCT01870115|Placebo Comparator|Fiber pill|2 plant fiber pills taken p.o. (by mouth) nightly for one year
3103240|NCT01870115|Active Comparator|strontium/melatonin/Vitamins K2 and D3|2 pills taken p.o. (by mouth) nightly for one year. Each pill contains strontium citrate (225 mg), melatonin (2.5 mg), Vitamin K2 (MK7) (30 mcg) and Vitamin D3 (1000 IU)
3103241|NCT01870102|Active Comparator|Pelubiprofen IR (Pelubiprofen 30 mg)|
3103242|NCT01870102|Experimental|Pelubiprofen SR (Pelubiprofen 45 mg)|
3103243|NCT01870102|Other|Pelubiprofen SR (Pelubiprofen 45 mg) fasting condition|
3103244|NCT01870102|Other|Pelubiprofen SR (Pelubiprofen 45 mg) fed condition|
3103245|NCT01870089|Experimental|Study group|
3103246|NCT01870076|Experimental|Healing Touch Intervention|Healing Touch performed one hour prior to bed.
3103247|NCT01870076|Sham Comparator|Healing Touch Sham|Healing Touch Sham provided one hour prior to bed.
3103248|NCT01870076|Active Comparator|Control, Presence|Control, Presence Intervention in the room one hour prior to bed.
3103249|NCT01870076|No Intervention|Control, No Presence|No Presence in the room one hour prior to bed.
3103250|NCT01870063||open heart surgery|
3103251|NCT01870050|Active Comparator|dapsone gel - verum|dapsone gel - verum
3103252|NCT01870050|Placebo Comparator|dapsone gel - vehicle only|
3103253|NCT01870037|Placebo Comparator|Placebo (PBS-20% sucrose)|PBS-20% sucrose administered during two single treatment dose levels (16000 µg and 24000 µg) by direct bladder wall IM injections - 20 to 30 injections depending on active dose comparator.
3103254|NCT01870037|Active Comparator|hMaxi-K|Single Treatment/ two escalating dose levels (16000 µg and 24000 µg by IM injection- 20-30 injections, respectively). In each dose level, 6 participants will receive hMaxi-K and 3 will receive placebo
3103255|NCT01870024|Active Comparator|1: Lorazepam + Placebo|[ L + P ] = lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes) + placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
3103256|NCT01870024|Active Comparator|2: Clonazepam + Placebo|[ C + P ] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + placebo 20 mg/kg by intravenous infusion over a period of 2 15 minutes
3103257|NCT01870024|Active Comparator|3: Clonazepam + Fosphenytoin|[ C + F ] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
3103258|NCT01870011|Experimental|Desflurane balanced anesthesia group|
3103259|NCT01870011|Active Comparator|Propofol total intravenous anesthesia group|
3103260|NCT01869998||Low risk group (A)|(A)Vortex depth≥0.45
3103261|NCT01869998||High risk group 1 (B)|(B)Vortex depth<0.45 with anticoagulation
3103262|NCT01869998||High risk group 2 (C)|(C)Vortex depth <0.45 without anticoagulation
3103263|NCT01869985|Experimental|HCP1104|HCP1104
3103264|NCT01869985|Active Comparator|Mulex Tab. and Airtal Tab.|Eperisone Hydrochloride and Aceclofenac
3103265|NCT01869972||Wide PHE group|Subjects prescribed diet alone to treat their PKU who have >1/3 of monitoring phenylalanine levels (with at least 3 levels measured) outside the target treatment range in the 6 months preceding enrolment. Target therapeutic range is 120 - 360 umol/L for age <12 years and 120 - 600 umol/L for age ≥ 12 years.
3103266|NCT01869972||Target PHE group|Subjects prescribed diet alone to treat their PKU who have ≤ 1/3 of monitoring phenylalanine levels (with at least 3 levels measured) outside the target treatment range in the 6 months preceding enrolment. Target therapeutic range is 120 - 360 umol/L for age <12 years and 120 - 600 umol/L for age ≥ 12 years.
3103267|NCT01869972||Kuvan(TM) group|Subjects on Kuvan(TM) (any dose for at least 3 months with no dosage change for most recent 1 month) ± diet therapy
3103268|NCT01869972||Control group|Subjects with non-PKU hyperphenylalaninemia (maximum phenylalanine level 120 - 599 umol/L on no therapy).
3103269|NCT01869959|Placebo Comparator|Placebo|Participants received placebo-matching LY2405319 injected subcutaneously (SC) once daily for 28 days.
3103270|NCT01869959|Experimental|3 mg LY2405319|Participants received 3 milligrams (mg) LY2405319 injected SC once daily for 28 days.
3103271|NCT01869959|Experimental|10 mg LY2405319|Participants received 10 mg LY2405319 injected SC once daily for 28 days.
3103272|NCT01869959|Experimental|20 mg LY2405319|Participants received 20 mg LY2405319 injected SC once daily for 28 days.
3103273|NCT01869946||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the hip joint following hip arthroplasty. Total dose 180mls of 0.2% ropivacaine or 360mg at the time of surgery.
3103274|NCT01869933|Experimental|1% OC-10X|Subjects selected to Cohort I will receive active 1% OC-10X in OD (Oculus Dexter - right eye) and placebo (vehicle) in OS (Oculus Sinister - left eye) in the Period 1 dosing. On Study Day 1 the subjects will have a drop instilled in each eye by personnel at study hours 0, 3, 6 and 9, and be evaluated frequently throughout the day. Subjects will be examined on Study Day 2 (24 hours after first dose). On Study Day 3 (48 hours after the first dose), these subjects will commence Period 2 dosing, with the active (OD) or placebo (OS). Dosing will continue q.i.d. for an additional 13 days.
3103275|NCT01869933|Experimental|2% OC-10X|Subjects selected to Cohort II will receive active 2% OC-10X in OD (Oculus Dexter - right eye) and placebo (vehicle) in OS (Oculus Sinister - left eye) in the Period 1 dosing. On Study Day 1 the subjects will have a drop instilled in each eye by personnel at study hours 0, 3, 6 and 9, and be evaluated frequently throughout the day. Subjects will be examined on Study Day 2 (24 hours after first dose). On Study Day 3 (48 hours after the first dose), these subjects will commence Period 2 dosing, with the active (OD) or placebo (OS). Dosing will continue q.i.d. for an additional 13 days.
3103276|NCT01869920|Experimental|intervention group|Intervention group receive a training education on breastfeeding. Education training is provided by an expert group from General Direction of Primary Care
3103277|NCT01869920|Other|Controll group|Usual care
3103278|NCT01869907|Placebo Comparator|Placebo|Placebo, once daily
3103279|NCT01869907|Active Comparator|Amitriptyline|Amitriptyline 25mg, once daily
3103280|NCT01869907|Active Comparator|Minocycline|Minocycline 100mg, once daily
3103281|NCT01869894|Active Comparator|uncovered double bare metallic stent (S&G Biotech.)|uncovered double bare metallic stent
3103282|NCT01869894|Active Comparator|uncovered single bare metallic stent (S&G Biotech.)|uncovered single bare metallic stent
3103283|NCT01869894|Active Comparator|uncovered single bare metallic stent (Taewoong Medical.)|uncovered single bare metallic stent
3103287|NCT01869855|Active Comparator|110 patients with cSDH assigned to subdural drainage|Randomization of 110 patients with cSDH to one treatment group (subdural or subperiosteal drainage) out of the 220 patients included in the study.
3103288|NCT01869855|Active Comparator|110 patients with cSDH assigned to subperiosteal drainage|Randomization of 110 patients with cSDH to one treatment group (subdural or subperiosteal drainage) out of the 220 patients included in the study.
3103289|NCT01869842|Active Comparator|DM, angio group|
3103290|NCT01869842|Experimental|DM, OCT group|
3103291|NCT01869842|Active Comparator|non DM, angio group|
3103292|NCT01869842|Experimental|non DM, OCT group|
3103293|NCT01869829||Pediatric Invasive Candidiasis|Pediatric patients (age > 120 days and < 18 years) with documented proven or probable invasive candidiasis
3103294|NCT01869790|Experimental|Meal challenge|Different fat types
3103295|NCT01869777|Experimental|Diagnostic (bioelectric impedance analysis)|Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment. Patients with AML undergo a second measurement just prior to the nadir marrow. Patients also undergo bioelectrical impedance measurements prior to any invasive procedures (bone marrow biopsy, leukapheresis, PICC line placement, etc.).
3103296|NCT01869764|Experimental|Arm I (omega-3 fatty acid)|Patients receive omega-3 fatty acid PO daily for 7-14 days.
3103297|NCT01869764|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 7-14 days.
3103298|NCT01869751||Prucalopride|Slow-transit constipation with treatment with prucalopride
3103299|NCT01869738|Experimental|MGuard Prime|MGuard Prime stent
3103300|NCT01869738|Active Comparator|Control|(BMS/DES) Includes FDA approved bare metal or drug eluting stents, including ENDEAVOR, TAXUS Liberte, XIENCE Prime, PROMUS Element, ION, RESOLUTE, Driver, Vision, VeriFlex and Integrity.
3103301|NCT01869725|Experimental|Diagnostic (gallium Ga 68-edotreotide PET/CT)|Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed.
3103302|NCT01869712|Experimental|Cupping therapy (randomized)|Use retained cupping as the main cupping method, supplemented with flash cupping and/or moving cupping. First use empty cupping, which means the cups are removed after suction without delay, then practitioners should control the suction by gently moving the cup toward direction of DU and/or BL, repeat this moving for several times, finally cupping practitioners utilize the flaming heating power to achieve suction (minus pressure) inside the cups to make them apply on the desired part of the body. Cups should retain for 10 minutes daily, patients accept the treatment three times weekly for totally 15 times.
3103303|NCT01869712|Experimental|Cupping therapy (non-randomized)|Use retained cupping as the main cupping method, supplemented with flash cupping and/or moving cupping. First use empty cupping, which means the cups are removed after suction without delay, then practitioners should control the suction by gently moving the cup toward direction of DU and/or BL, repeat this moving for several times, finally cupping practitioners utilize the flaming heating power to achieve suction (minus pressure) inside the cups to make them apply on the desired part of the body. Cups should retain for 10 minutes daily, patients accept the treatment three times weekly for totally 15 times.
3103304|NCT01869712|Active Comparator|Acupuncture (non-randomized)|Sterilize the selected points with alcohol, and then select the specific size of needles to do the acupuncture. Do the manual stimulation for seconds after needles' insertion, including twist, pull up and deeper insert. Needles should be withdrawn after 30 minutes. Patients accept the treatment three times weekly for totally 15 times.
3103305|NCT01869712|Active Comparator|Acupuncture (randomized)|Sterilize the selected points with alcohol, and then select the specific size of needles to do the acupuncture. Do the manual stimulation for seconds after needles' insertion, including twist, pull up and deeper insert. Needles should be withdrawn after 30 minutes.
3103306|NCT01869699|Placebo Comparator|Normal saline placebo|Normal saline 100 mLs intravenous, administered over 15 minutes
3103307|NCT01869699|Experimental|Acetaminophen|Acetaminophen 1 gram/100 mLs intravenous, single dose administered over 15 minutes
3103308|NCT01869686|Experimental|Denosumab|single subcutaneous injection
3103309|NCT01869673|Active Comparator|Face Mask|Patients will be ventilated with a face mask first and with a oral mask thereafter
3103310|NCT01869673|Experimental|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
3103311|NCT01869660|Experimental|Shared Decision Making|The present SDM intervention is based on principles derived from previous randomized controlled trials of SDMs. SDM meetings comprise at least 4 weekly 20 minutes sessions. Meetings have at least three professionals: a case manager (psychiatrists or nurses), a primary doctor, and a nurse/social worker. The focus of the meeting is to empower patients to discuss their attitudes and preferences toward treatments.
3103312|NCT01869660|No Intervention|Usual Care|Patients with no special program about decision making.
3103313|NCT01869647|Active Comparator|"high likelihood of stone group"|"Subjects in the high likelihood of stone group will be eligible to get either ULDCT or expectant management. The choice will be determined by the primary clinician in conjunction with the patient. If ULDCT is elected, the scan will be read diagnostically by the radiologist and the clinician will treat the patient based on these results. If the expectant management option is chosen, no CT will be done during the ED visit and they will be treated as if they have a kidney stone. Participants in this group will receive Ultra low dose CT scan."
3103314|NCT01869647|Active Comparator|"moderate likelihood of stone group"|"Subjects in the moderate likelihood of stone group will be given the option to receive either a standard dose CT or ULDCT. Again, the decision of which imaging option to choose will be made by the primary clinician in conjunction with the patient. Participants in this group will receive regular or low dose CT scan."
3103315|NCT01869647|Active Comparator|"low likelihood of stone group"|"In the low likelihood of stone group the RA will present the data from the stone score to the physician and explain that patient is unlikely to have a kidney stone and they will be advised that probability of a stone is very low and that alternate imaging choices may be warranted. If they still choose to order a CT Flank Pain Protocol they will be asked to provide reasoning and the patient will receive a regular dose CT Flank Pain Protocol. Participants in this group will not receive imaging."
3103605|NCT01867775|Active Comparator|Mirtazapine|Mirtazapine, 15 mg once a day, at night for 14 days
3103316|NCT01869634|Active Comparator|HIV positive naive to ART|HIV subjects will receive open-label darunavir 800 mg in combination with ritonavir 100 mg tablets and fixed-dose combination viread + emtricitabine (Truvada®) to be taken once daily without regard to food. Subjects will undergo upper endoscopy, CT cardiac angiogram, intimal-medial thickening, and peripheral blood collection before and after 12 months of ART.
3103317|NCT01869634|No Intervention|normal control volunteers|HIV negative age-matched controls will undergo the same interventions and procedures without receiving ART at study entry and after 12 months.
3103318|NCT01869621|Experimental|Metformin|6 days treatment with metformin
3103319|NCT01869608|Experimental|postpartum screening|Oral glucose tolerance test 2 days post-partum
3103320|NCT01869582|Experimental|Doppler, Fetal heart rate|Eligible women in labour randomized to intermittent fetal heart rate assessments using a wind-up, hand-held Doppler
3103321|NCT01869582|Experimental|Fetoscope, Fetal heart rate|Eligible women in labour randomized to intermittent fetal heart rate assessments using a Pinard fetoscope, which is the current standard management
3103322|NCT01869582|Experimental|Upright Resuscitator, Resuscitation|Non-breathing newborn infants in need of positive pressure ventilation randomized to an Upright Resuscitator
3103323|NCT01869582|Experimental|Standard Resuscitator, Resuscitation|Non-breathing newborn infants in need of positive pressure ventilation randomized to a standard horizontal Resuscitator, which is the current standard management
3103324|NCT01869569|Active Comparator|Pregabalin|Arm I:At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
3103325|NCT01869569|Placebo Comparator|Placebo|Arm II:At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
3103326|NCT01869556|Active Comparator|Oxytocin only|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
3103327|NCT01869556|Active Comparator|Oxytocin + Ergot|Oxytocin 5IU IV bolus + Ergot 0.25mg IV, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
3103328|NCT01869556|Active Comparator|Oxytocin + Carboprost|Oxytocin 5IU IV bolus + Carboprost 0.25mg IM, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
3103329|NCT01869543|Experimental|Stand Alone Air Cleaner-True/Sham|The participant will have stand alone air cleaners placed in their home. They will have true filtration followed by sham filtration.
3103330|NCT01869543|Experimental|Stand Alone Air Cleaner-Sham/True|Participants will have stand alone air cleaners placed in their homes. They will begin with sham filtration.
3103331|NCT01869543|Experimental|HVAC modification-True/Sham|Participants will have their HVAC system modified to include high efficiency filtration. They will begin true filtration followed by sham filtration.
3103332|NCT01869543|Experimental|HVAC Modification-Sham/True|Participants will have their HVAC system modified to include high efficiency filtration. They will begin sham filtration.
3103333|NCT01869530||Healthy children|
3103334|NCT01869517|Active Comparator|Intrastromal corneal continuous ring (Myoring)|
3103335|NCT01869517|Active Comparator|Intrastromal corneal ring segments (Keraring)|
3103336|NCT01869504|Experimental|Balloon-tipped intercostal drain|Subjects who have given written informed consent and who fulfill the inclusion and exclusion criteria will proceed to have the study drain inserted at the earliest opportunity as per standard hospital protocols using local anaesthetic, and conscious sedation where appropriate. All other aspects of their treatment will be identical to usual clinical care, including chest drain checks and fluid drainage strategies.
3103337|NCT01869491|Active Comparator|Sodium Alginate Double Action Tablets|Compound Sodium Alginate Double Action Chewable Tablets, 2 tablets four times daily
3103338|NCT01869491|Placebo Comparator|Matching placebo tablets|Matching placebo tablets, 2 tablets four times daily
3103339|NCT01869478|Active Comparator|Intravenous Thrombolysis|0.9mg/kg intravenous rt-PA (max dose 90mg) - 10% administered as a bolus over 1 minute and the remainder infused over 60 minutes.
3103340|NCT01869478|Active Comparator|Endovascular Arterial Reperfusion|Therapeutic options will include mechanical thrombectomy/clot disruption (Penumbra aspiration system, Solitaire device, and/or Reflex catheter) and/or intracranial stent deployment.
3103341|NCT01869465|Active Comparator|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration. A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above ,basic principles of health education and in communication skills through a 2 days training workshop. The trained head teachers and heath teachers will in turn, deliver the messages to the children through face to face interactions during school assemblies, twice a week.
3103342|NCT01869465|Experimental|Snack arm|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers. The snack is estimated to cost about 1 US $ per child.
3103343|NCT01869452|Other|therapeutic education class 1|patients in class 1 will have a follow up call with therapeutic education every 3 months. this is the light follow up.
3103344|NCT01869452|Other|therapeutic education class 2|patients in class 2 will have a follow up call with therapeutic education every month. this is the moderate follow up
3103345|NCT01869452|Other|therapeutic education class 3|patients in class 3 will have a follow up call with therapeutic education twice a month. this is the heavy follow up.
3103346|NCT01869439|Experimental|External wounds measured for length by width using a ruler|This is a single arm study of subjects who have an external wound that is currently measured for length and width using a ruler. A study subject may have up to 3 qualifying external wounds.
3103347|NCT01869426|Active Comparator|VSL#3 drops|31 infants will receive 10 drops active product that should be taken daily (preferably in the morning before feeding) for 21 days.
3103348|NCT01869426|Placebo Comparator|VSL#3 drops placebo|31 infants will receive 10 drops of placebo product that should be taken daily (preferably in the morning before feeding) for 21 days.
3103349|NCT01869413|Experimental|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours). For example, an 80 kg patient would receive 800 mg prior to incision and a 400 mg/hr infusion for the duration of surgery. For a 6 hour procedure, the total dose administered would be 3200 mg.
3103350|NCT01869413|Placebo Comparator|Placebo control|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
3103351|NCT01869400||Yondelis-Pegylated liposomal Doxorubicin|30 mg/m² PLD i.v. followed by 1.1 mg/m² Yondelis® i.v. 3 h, q3weeks
3103352|NCT01869387|No Intervention|Standard treatment|Standard treatment consists in bronchodilator and parenteral corticosteroids and oxygen therapy.
3103353|NCT01869387|Experimental|Standard treatment plus non-invasive ventilation|This arm consists in bronchodilator and parenteral corticosteroids and oxygen therapy plus non-invasive ventilation.
3103354|NCT01869374|Experimental|Magnetic Seizure Therapy (MST)|MagVenture MagPro MST device
3103355|NCT01869374|Active Comparator|RUL ECT|Right Unilateral ECT with the Somatics Thymatron device using Ultrabrief stimulus
3103356|NCT01869361|Placebo Comparator|Placebo|The patient will be given a loading dose of 50mg placebo by mouth followed by 25mg by mouth every six hours for a total of eight doses over 48 hours.
3103357|NCT01869361|Active Comparator|Indomethacin|The patient will be given a loading dose of 50mg indomethacin by mouth followed by 25mg by mouth every six hours for a total of eight doses over 48 hours.
3103358|NCT01869348|No Intervention|Wait list control|This group will receive no intervention until after data collection for the randomized trial is completed. Then, they will receive the monitor intervention.
3103359|NCT01869348|Experimental|Monitor intervention|This arm will receive the monitor intervention, including provision of a wristband activity monitor and mini-tablet as well as weekly counseling phone calls
3103360|NCT01869335|Active Comparator|radiography|Arm1: patients undergo mammographic localizations and radiography of the specimen after surgical resection.
3103361|NCT01869335|Active Comparator|MRI (magnetic resonance imaging)|Arm2: patients undergo MRI localization and ex vivo MRI after surgical resection.
3103362|NCT01869322|Experimental|Sling and Swathe|In this arm, study subjects will receive sling and swathe immobilization for humeral shaft fracture.
3103363|NCT01869322|Active Comparator|Coaptation Splint|In this arm participants receive a coaptation splint for humeral shaft fracture.
3103364|NCT01869309|No Intervention|Non-HPR group|The non-HPR group will have PD and genetic testing, with no change in medication.
3103365|NCT01869309|Active Comparator|HPR Group|This arm will be split into Group A and Group B which will receive Ticagrelor/Prasugrel in a crossover manner.
3103366|NCT01869296|Active Comparator|higher flow rates endoscope pump|higher flow rates endoscope water pump : 10.4 ml/sec
3103367|NCT01869296|Experimental|lower flow rates endoscope water pump|lower flow rates endoscope water pump : 1.7 ml/sec
3103368|NCT01869283|Experimental|Kinesiotherapy group|The volunteer will be subjected to the following protocol: cervical traction, 3 sets of 1 minute, 30-second rest between sets; mobilization grade III postero-anterior on the spines processes of vertebrae C2 to C7, 10 oscillations for each vertebrae; myofascial release of the upper trapezius muscle, 3 sets of 1 minute for each side; static stretching of the upper trapezius muscle, 3 sets of 30 seconds, with an interval of 10 seconds between sets.
3103369|NCT01869283|Experimental|kinesiotherapy + static ultrasound group|Same protocol group kinesiotherapy + ultrasound on the trigger points of the upper trapezius muscle in a static way, with 1 MHz, continuous dose of 1.5 W/cm2, for 1.5 minutes.
3103370|NCT01869283|Experimental|kinesiotherapy + diadynamic currents group|Same protocol group kinesiotherapy + diadynamic currents, with negative electrode (7.0 x 7.0 cm) placed on the myofascial trigger point, while the positive electrode (7.0 x 7.0 cm) is placed between the shoulder blades. Will apply 4 minutes from the biphasic mode (DF) and 6-minute short period (CP), the first of which intesidade the sensory threshold and the second threshold motor, both bearable for the patient.
3103371|NCT01869283|No Intervention|Control group|The volunteers of this group will not be subjected to any form of treatment, was evaluated in three stages, as the other groups. It is noteworthy that, after the volunteer's participation, will be offered at the same physical therapy for myofascial pain.
3103372|NCT01869257|Active Comparator|control|regular suture not coated with triclosan
3103373|NCT01869257|Experimental|triclosan|Experimental group will receive abdominal wound closure with suture matherial that is coated with triclosan
3103374|NCT01869244||hand resting splint|Patients with hand resting splint treatment
3103375|NCT01869231|Experimental|major surgery|colic surgery
3103376|NCT01869231|Experimental|minor surgery|appendectomy; cholecystectomy
3103377|NCT01869231|Experimental|ileostomy and colostomy|ileostomy colostomy
3103378|NCT01869231|Experimental|other surgery|all of others abdominal surgical intervention
3103379|NCT01869218||Pre-treatment tumor biopsies|Patients who meet eligibility criteria will undergo a fresh tumor biopsy and collection of research blood samples. Archived tumor specimens will also be obtained and analyzed. At the time of disease progression, fresh tumor biopsies and blood samples will be collected in patients who have evaluable pre-biopsy specimens and who are eligible to be screened for another study.
3103380|NCT01869205|Experimental|Endobronchial valve:|Endobronchial valve (size 4.0 - 7.0 mm or 5.5 - 8.5 mm) insertion for target bronchi
3103381|NCT01869192|Active Comparator|Arm A|Arm A: Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then surgery, then Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment
3103382|NCT01869192|Active Comparator|Arm B|Arm B: Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then surgery, then Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment
3103383|NCT01869179|Experimental|Choir program|Participants will receive the 12 month choir program as soon as possible after study enrollment.
3103384|NCT01869179|No Intervention|Wait-list Control|Waits six months, and at the end of the six months is offered the option of participating in the 12 month choir program.
3103385|NCT01869166|Experimental|anti-tumor response of CART-EGFR|
3103386|NCT01869153||Preterm infants|Preterm infants born at either <32 weeks gestation or < 1750g birth weight
3103387|NCT01869140|Sham Comparator|sham spinal manual therapy|activator set to zero
3103388|NCT01869140|Experimental|percussive spinal manual therapy|activator set to the maximum force
3103389|NCT01869140|Experimental|Firm thoracic spinal manual therapy|Firm thoracic manipulation
3103390|NCT01869127|No Intervention|Control|Standard care
3103391|NCT01869127|Experimental|Shoes|Shoes
3103392|NCT01869114|Experimental|High risk Myleodysplastic Syndrome (MDS)|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3103393|NCT01869114|Experimental|Acute Myeloid Leukemia (AML)|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3103394|NCT01869088|Active Comparator|TACE Only|TACE with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
3103395|NCT01869088|Experimental|TACE Plus Adenovirus|After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0*1011vp：0.5ml*3） will be first infused through the target artery of HCC patient and followed with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg) and lipiodol emulsion or/and polyvinyl alcohol particles(dependent on the tumor size) Procedure: TACE (Transcatheter arterial chemoembolization)
3103396|NCT01869075|Experimental|AMI - Knowledge Translation toolkit|AMI - Knowledge Translation (KT) toolkit includes use of pre-printed orders, audit and feedback, pharmacist as a reminder and education of staff
3103397|NCT01869075|No Intervention|AMI - Usual Care|Usual care
3103398|NCT01869075|Experimental|MGS - Knowledge Translation Toolkit|Knowledge Translation toolkit involves use of pre-printed orders, audit and feedback, pharmacist as reminder and education of staff
3103399|NCT01869075|No Intervention|MGS - Usual Care|Usual Care
3103400|NCT01869075|Experimental|HFS - Knowledge Translation Toolkit|Knowledge Translation Toolkit consists of pre-printed orders, audit and feedback, pharmacist as a reminder and education of staff
3103401|NCT01869075|No Intervention|HFS - Usual Care|Usual Care
3103402|NCT01869062|Other|SonR CRT Optimization 'On'|CRT-D device with the SonR optimization algorithm programmed being 'on'.
3103403|NCT01869062|Other|SonR CRT Optimization 'Off'|CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
3103404|NCT01869049||ITP patients accepted splenectomy|
3103405|NCT01869049||Trauma with spleen rupture underwent splenectomy|
3103406|NCT01869036|Active Comparator|caudal anesthesia|
3103407|NCT01869036|Active Comparator|caudal anesthesia supplemented with morphine|
3103408|NCT01869023|Other|6 h infusion Gemcitabine and Cisplatin|Gemcitabine 250 mg/m2 Cisplatin 30 mg/m2
3103409|NCT01869010||HIV Tenofovir|
3103410|NCT01869010||HIV No tenofovir|
3103411|NCT01869010||Seronegative controls|
3103412|NCT01868997|Placebo Comparator|Placebo|A placebo infusion (normal saline) administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions.
3103413|NCT01868997|Experimental|Teprotumumab|Teprotumumab administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions. All participants start treatment at a dose of 10 mg/kg. At Week 3, the dose is escalated to 20 mg/kg and kept constant for the remainder of the study.
3103414|NCT01868984|Sham Comparator|Standard Therapy Alone|"Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).~For this control group, no paclitaxel is administered. The sham treatment is a period of 10 minutes that is allowed to elapse followed by the performance of a final completion angiogram to be labeled as PaciFIST Study Completion Angiogram. Any additional lesions identified with this study are then treated appropriately following standard technique."
3103415|NCT01868984|Active Comparator|Standard Therapy Plus Paclitaxel|"Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).~For this treatment group, Paclitaxel solution treatment of each lesion encountered from proximal to distal will be attempted until the 20 mg Paclitaxel dose limit is met."
3103416|NCT01868971|Other|Colonoscopy procedure with the EndoRings|Colonoscopy procedure using an add-on device (EndoRings) that is attached to the distal tip of the endoscope
3103417|NCT01868958||CSM subjects|Subjects with clinical indications of cervical spondylotic myelopathy (CSM).
3103418|NCT01868958||Control group|Aged matched to the CSM group but with no signs of CSM
3103419|NCT01868945|Experimental|5 µg/day Hy.D Calcifediol|
3103420|NCT01868945|Experimental|10 µg/day Hy.D Calcifediol|
3103421|NCT01868945|Experimental|15 µg/day Hy.D Calcifediol|
3103422|NCT01868945|Active Comparator|20 µg/day vitamin D3|
3103423|NCT01868932|Experimental|hypertonic saline|inhalation of 4 ml nebulized study solution containing 3% hypertonic saline (HS, study group). Each dose of study solution will also contain a standard dose of bronchodilator (salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) 1,2 added by the ED staff. Initial therapy will consist of 3 consecutive nebulizations given in rapid succession (back-to-back, approximately every 20 minutes).
3103424|NCT01868932|Active Comparator|saline|inhalation of 4 ml nebulized study solution containing saline 0.9% saline (NS, control group). Each dose of study solution will also contain a standard dose of bronchodilator (salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) 1,2 added by the ED staff. Initial therapy will consist of 3 consecutive nebulizations given in rapid succession (back-to-back, approximately every 20 minutes).
3103425|NCT01868919|Experimental|Positive Parenting Program|Level 3 or 4 of Triple P
3103426|NCT01868906|Other|Arm-A: 18F-FMISO-PET without SCS|One 18F-FMISO-PET study for assessment of tumor hypoxia before radiotherapy and Temozolomide, without spinal cord stimulation.
3103427|NCT01868906|Other|Arm-B: 18F-FMISO-PET without/with SCS|"Two 18F-FMISO-PET studies for assessment of tumor hypoxia before radiotherapy and Temozolomide: one without and one with spinal cord stimulation"
3103428|NCT01868893|Experimental|Obinutuzumab + Chlorambucil|Obinutuzumab was administered intravenously for 6 cycles (28-day cycles) as: 100 mg on Day 1, 900 mg on Day 2, and 1000 mg on Days 8 and 15 for Cycle 1; and 1000 mg on Day 1 of Cycles 2 to 6. Chlorambucil was administered orally at a dose of 0.5 mg/kg body weight on Days 1 and 15 for Cycles 1 through 6 (28-day cycles).
3103429|NCT01868880|Experimental|ivabradine plus beta-blocker(bisoprolol)|Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
3103430|NCT01868880|Active Comparator|beta-blocker (bisoprolol) titration|Beta blocker Bisoprolol will be titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
3103431|NCT01868867|Experimental|Intervention|Receives on line training and text messaging for treatment
3103432|NCT01868867|No Intervention|Treatment as Usual|Treatment as usual (TAU) for similar duration as intervention group. Intervention provided following TAU period.
3103433|NCT01868854||Radiographic Plane 1|the tip of peritoneal dialysis catheter is located at the bottom of the pelvis, below a line connecting the head of the femur
3103434|NCT01868854||Radiographic Plane 2|the tip of the peritoneal dialysis catheter is located above the plane 1 and below a line connecting the two iliac spines
3103435|NCT01868854||Radiographic plane 3|The location of the catheter tip is on the line connecting iliac spines and below a line connecting the iliac crests
3103436|NCT01868854||Radiographic plane 4|The location of the catheter tip is on the line connecting the iliac crests
3103437|NCT01868841|Active Comparator|Adreview LFOV SPECT Imaging followed by SFOV-HE Imaging|SPECT imaging of 10 millicurie of Adreview
3103438|NCT01868841|Active Comparator|AdreView SFOV-HE SPECT Imaging followed by LFOV Imaging|SPECT imaging of 10 millicurie of Adreview
3103439|NCT01868828|Experimental|PAD Followed by ASCT|"Drug: Bortezomib(1.3mg/m2, iv, on day 1, 4, 8, 11)~Drug: Epidoxorubicin(15 mg/m2, iv, on days 1-4)~Drug: Dexamethasone(40mg, orally, on days 1-4)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.~Not suitable for transplant patients will continue accept treatment for 8 cycles."
3103440|NCT01868828|Experimental|VCD Followed by ASCT|"Drug: Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11)~Drug: Cyclophosphamide (200mg/m2, orally, on days 1-5)~Drug: Dexamethasone(40mg, orally, on days 1-4)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.~Not suitable for transplant patients will continue accept treatment for 8 cycles."
3103441|NCT01868802|Experimental|Ketamine treated|
3103442|NCT01868802|Placebo Comparator|Control, placebo treated|
3103443|NCT01868789|Experimental|Weightbearing CT (AAFD group)|Weightbearing CT scan of affected foot
3103444|NCT01868789|Active Comparator|Weightbearing CT (control group)|Weightbearing CT scan of normal foot
3103445|NCT01868776|Experimental|buffered lidocaine|4% lidocaine with 1:100,000 epinephrine/0.18 mEq/mL sodium bicarbonate.
3103446|NCT01868776|Active Comparator|nonbuffered lidocaine|4% lidocaine with 1:100,000 epinephrine
3103447|NCT01868763|No Intervention|control (C) group|The control group will remain in routine care for 12 weeks.
3103448|NCT01868763|Experimental|telemedical (TM) group|Participants in the telemedical (TM) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre.
3103449|NCT01868763|Experimental|telemedical coaching (TMC) group|Participants in the telemedical coaching (TMC) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. Additionally, they will be called once per week for 12 weeks from the study centre aiming to discuss measured data and to fix target agreements.
3103450|NCT01868750|Active Comparator|Vitamin D (Calcitriol)|Calcitriol, 1.0ug twice daily for 7 days prior to surgery
3103451|NCT01868750|Placebo Comparator|Control|Placebo pill taken twice daily for 7 days prior to surgery
3103452|NCT01868737|Experimental|HIV exposed infants|Probiotic: L. rhamnosus GG (0.35 x 109 colony-forming units [CFU]) and B. infantis (0.35 x 109 CFU) daily
3103453|NCT01868737|Placebo Comparator|HIV- exposed infants|MCT oil
3103454|NCT01868737|Placebo Comparator|HIV-unexposed infants|MCT oil
3103455|NCT01868737|Experimental|HIV-unexposed|Probiotic: L. rhamnosus GG (0.35 x 109 colony-forming units [CFU]) and B. infantis (0.35 x 109 CFU) daily
3103606|NCT01867775|Placebo Comparator|Placebo|Placebo 15 mg, once a day at night for 14 days
3103456|NCT01868711|Experimental|*Cognitive behavior therapy *Therapy|Depressed patient will receive 14 sessions of cognitive behavior therapy (CBT) for depression. Includes behavior activation, correcting distorted thoughts, and other tools to reduce symptoms
3103457|NCT01868698|Experimental|Kinesiotherapy|Will be made active and resisted exercises of the lower limbs.
3103458|NCT01868698|Experimental|shortwave diathermy|Will be applied for 20 minutes on the lower limbs.
3103459|NCT01868698|Experimental|high-voltage electrical stimulation|The therapeutic current will be applied for 20 minutes on lower limbs.
3103460|NCT01868685|Placebo Comparator|Placebo|
3103461|NCT01868685|Experimental|BYM338|
3103462|NCT01868672|No Intervention|Control|Participant receives usual care.
3103463|NCT01868672|Experimental|Intervention|Educational print materials and coaching call: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
3103464|NCT01868659|Experimental|Diagnostic checklist|Diagnostic checklist used before patient discharged
3103465|NCT01868659|Placebo Comparator|Usual care|No diagnostic checklist used during patient encounter
3103466|NCT01868646|Experimental|Subetta|"Standard therapy of type II diabetes mellitus + Subetta (1 tablet 4 times a day).~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
3103467|NCT01868646|Placebo Comparator|Placebo|"Standard therapy of type II diabetes mellitus + Placebo (1 tablet 4 times a day).~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
3103468|NCT01868633|Active Comparator|Dexamethasone & spinal morphine|intrathecal morphine administered at time of spinal anesthesia. After cesarean delivery 8mg (2ml) of Dexamethasone given intraoperatively
3103469|NCT01868633|Placebo Comparator|Placebo injection and spinal morphine|intrathecal morphine administered at time of spinal anesthesia. After cesarean delivery 2ml of placebo (Normal saline) drawn to mimic active drug given intraoperatively
3103470|NCT01868620|Experimental|Iontophoretic CXL|The iontophoretic CXL involves a constant current source and two electrodes. The main electrode is a circular cup, with a surrounding annular suction ring to affix the device on the cornea during the procedure. The electrode itself is a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with riboflavin solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated by a UVA light for 3mW/cm2 during 30 minutes.
3103471|NCT01868620|Active Comparator|Standard CXL|In the standard CXL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes.
3103472|NCT01868607||Adult lung function|
3103473|NCT01868594|Experimental|Subetta (1 tablet 4 times a day)|Oral administration. Per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
3103474|NCT01868594|Placebo Comparator|Placebo (1 tablet 4 times a day)|Placebo under Subetta regimen.
3103475|NCT01868581|Experimental|insulin degludec|
3103476|NCT01868581|Experimental|IDegAsp|
3103477|NCT01868568|Experimental|IDegAsp 30 + placebo|
3103478|NCT01868568|Experimental|Insulin aspart + insulin degludec - low concentration 1|
3103479|NCT01868568|Experimental|IDegAsp 40 + placebo|
3103480|NCT01868568|Experimental|Insulin aspart + insulin degludec - high concentration 1|
3103481|NCT01868568|Experimental|IDegAsp 45 + placebo|
3103482|NCT01868568|Experimental|Insulin aspart + insulin degludec|
3103483|NCT01868568|Experimental|IDegAsp 55 + placebo|
3103484|NCT01868568|Experimental|Insulin aspart + insulin degludec - high concentration|
3103485|NCT01868568|Active Comparator|BIAsp 30 + placebo|
3103486|NCT01868555|Experimental|IDegAsp 30|
3103487|NCT01868555|Experimental|IDegAsp 45|
3103488|NCT01868555|Experimental|insulin degludec (B)|
3103489|NCT01868555|Experimental|insulin degludec (E)|
3103490|NCT01868542|Experimental|3-0-3 Algorithm|A once daily dosage of Insulin detemir (Levemir®) 100 U/mL 3 mL FlexPen® for subcutaneous administration was selected for this trial.During the treatment period insulin detemir was adjusted by the subject themselves (self-titration). Self-titration was performed every 3 days based on the lowest of three previous consecutive pre-breakfast SMPG values.Based on this glucose value, self-adjustment of insulin detemir dose was done. Metformin and Sulfonlylurea were allowed as OADs. For SMPG values, the following insulin detemir dose adjustments were done : >6.1 mmol/L (>110 mg/dL) +3U insulin detemir, 4.4-6.1 mmol/L (80-100 mg/dL) No adjustment in insulin detemir, < 4.4 mmol/L (<80 mg/dL) -3U insulin detemir.
3103491|NCT01868542|Experimental|2-4-6-8 Algorithm|A once daily dosage of Insulin detemir (Levemir®) 100 U/mL 3 mL FlexPen® for subcutaneous administration was selected for this trial. During the treatment period insulin detemir was adjusted by the subject themselves (self-titration). Self-titration was performed every 3 days based on the lowest of three previous consecutive pre-breakfast SMPG values.Based on this glucose value, self-adjustment of insulin detemir dose was done. Metformin and Sulfonlylurea were allowed as OADs. For SMPG values , the following insulin detemir dose adjustments were done : >10.0 mmol/L (180 mg/dL) +8U insulin detemir, 9.1-10.0 mmol/L (163-180 mg/dL) +6U insulin detemir, 8.1-9.0 mmol/L (145-162 mg/dL) +4 U insulin detemir, 7.1-8.0 mmol/L (127-144 mg/dL) +2U insulin detemir, 6.1-7.0 mmol/L (109-126 mg/dL) +2U insulin detemir, 4.1-6.0 mmol/L (73-108 mg/dL) No adjustment in insulin detemir, 3.1-4.0 mmol/L (56-72 mg/dL) -2U insulin detemir, <3.1 mmol/L (<56 mg/dL) -4U insulin detemir.
3103492|NCT01868529|Experimental|Low dose|
3103493|NCT01868529|Experimental|Medium dose|
3103494|NCT01868529|Experimental|High dose|
3103495|NCT01868516|Placebo Comparator|Placebo|One tablet of placebo to be administered orally twice a day.
3103496|NCT01868516|Experimental|0.5 mg dexmecamylamine (TC-5214)|One tablet of 0.5 mg dexmecamylamine to be administered orally twice a day.
3103497|NCT01868516|Experimental|1 mg dexmecamylamine (TC-5214)|One tablet of 1 mg dexmecamylamine to be administered orally twice a day.
3103498|NCT01868516|Experimental|2 mg dexmecamylamine (TC-5214)|One tablet of 2 mg dexmecamylamine to be administered orally twice a day.
3103607|NCT01867762|Experimental|JNJ 49095397|
3103608|NCT01867762|Placebo Comparator|Placebo|
3103499|NCT01868503|Experimental|Lapatinib Plus Radiation Therapy|Patients receive lapatinib ditosylate PO QD on day 1 until completion of radiation therapy. Beginning on day 7, patients undergo radiation therapy for 5-7 weeks and will have their blood banked for laboratory biomarker analysis.
3103500|NCT01868490|Experimental|drug|single-group studies
3103501|NCT01868477|Experimental|Erythropoietin alpha|Patients will receive erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be switched to the combination arm. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study.
3103502|NCT01868477|Experimental|Deferasirox + Erythropoietin alpha|Patients will receive deferasirox dispersible tablet (DT) 10 mg/kg/day or deferasirox film-coated tablet (FCT) 7 mg/kg/day in combination with erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, erythropoietin dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be discontinued from the study. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study. Patients will continue deferasirox treatment.
3103503|NCT01868464|Experimental|BCG 16x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 16x10^6 cfu
3103504|NCT01868464|Experimental|BCG 2x10^6 CFU|30 subjects, one dose of Tice Bacillus Calmette-Guerin vaccine (BCG) intradermally, 2x10^6 colony forming units (cfu)
3103505|NCT01868464|Experimental|BCG 4x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 4x10^6 cfu
3103506|NCT01868464|Experimental|BCG 8x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 8x10^6 cfu
3103507|NCT01868451|Experimental|Cohort 1 (completed accrual)|Patients received 4 cycles of brentuximab vedotin & AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, & Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. This may be followed by 30 Gy involved site radiotherapy. Involved site radiotherapy should be initiated from 12 days to 42 days after completion of chemotherapy. It is mandatory to administer prophylactic growth factor support starting with cycle 1. Choice of growth factor and dosing can be determined at the discretion of the treating physican.
3103508|NCT01868451|Experimental|Cohort 2|Patients with early stage, unfavorable risk Hodgkin lymphoma. The definition of disease bulk, one of the unfavorable risk features, has been updated, and is defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm OR coronal maximal diameter > 7.0 cm. Patients will receive 4 cycles of brentuximab vedotin & AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 & 15 of each 28 day cycle. This may be followed by 20 Gy involved site radiotherapy.
3103509|NCT01868451|Experimental|Cohort 3|Eligible patients will have early stage, unfavorable risk classical Hodgkin lymphoma with disease bulk defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm or coronal maximal diameter > 7.0 cm. Patients will receive 4 cycles of brentuximab vedotin and AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. This may be followed by 30.6 Gy CVRT.
3103510|NCT01868451|Experimental|Cohort 4|Eligible patients will have early stage, unfavorable risk classical Hodgkin lymphoma with disease bulk defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm or coronal maximal diameter > 7.0 cm. In this cohort. Patients will receive 4 cycles of brentuximab vedotin and AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. Patients whose PET scan is negative after 4 cycles of brentuximab vedotin and AVD chemotherapy will not receive RT. Patients whose PET scan is positive after 4 cycles of brentuximab vedotin and AVD chemotherapy, but subsequent biopsy is negative, will also receive no RT.
3103511|NCT01868438|Active Comparator|Pyronaridine-artesunate granules (Period 1)|"In first dosing period, single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate.~In second dosing period, cross-over to single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate."
3103512|NCT01868438|Active Comparator|Pyronaridine-artesunate tablets (Period1)|"In first dosing period, single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate.~In second dosing period, cross-over to single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate."
3103513|NCT01868425|Experimental|multimodal:acetaminophen, gabapentin, ketamine, bupivacaine|aggresssive multimodal plus standard care, which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflourane
3103514|NCT01868425|Placebo Comparator|placebo pills and injectables|standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflourane
3103515|NCT01868412|Experimental|Resin & honey|Abilar 10% resin salve
3103516|NCT01868412|Active Comparator|Resin vs. honey|Activon Tube 25 g
3103517|NCT01868399||Suspected dengue fever subjects|No any intervention
3103518|NCT01868399||Community Healty Residents|No intervention
3103519|NCT01868386|Experimental|Dose Level 1|Hypofractionated therapy, 26 treatments at 2.5 Gy
3103520|NCT01868386|Experimental|Dose Level 2|Hypofractionated therapy, 20 treatments at 2.83Gy
3103521|NCT01868386|Experimental|Dose Level 3|Hypofractionated therapy,15 treatments at 3.36 Gy
3103522|NCT01868386|Experimental|Dose Level 4|Hypofractionated therapy, 10 treatments at 4.26 Gy
3103523|NCT01868373|Other|microbiota transplantation|Two hundred mL of the bacterial suspension (microbiota transplantation) will be instilled into the small intestine via a catheter introduced through the biopsy channel of the endoscope and the flushed with 25 mL of sterile pre-reduced 0.9% saline. After removal of the endoscope, after recovery, patients will be allowed to resume a normal diet and physical activities.
3103567|NCT01868022|Experimental|Arm A: GSK3052230 + paclitaxel/carboplatin|Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + paclitaxel (constant infusion for 3 hrs) and carboplatin (constant infusion for 30 to 60 minutes) iv on Day 1 of each 21-day cycle. The number of cycles of paclitaxel/carboplatin will be limited to 4 to 6 cycles.
3103524|NCT01868360|Experimental|Group A subconjunctival aflibercept|"Patients will receive 2mg (0.05mL) subconjunctival aflibercept injection in addition to standard of care treatment (steroids and cyclosporine). Patients will receive one injection four weeks (+/- 1 week) prior to transplantation. They will receive a second injection at the conclusion of corneal transplantation.~Patients may receive as-needed repeat injections (minimum of 30 days in between treatments) for recurrence of corneal neovascularization (defined as >1.0 mm crossing onto the cornea, past the limbus, or extension of vessels beyond previously documented extent) during the follow-up period."
3103525|NCT01868360|Placebo Comparator|Group B: Standard of care only|Patients will receive standard of care (steroids and cyclosporine) treatment only.
3103526|NCT01868347|Active Comparator|control|PEEP after pneumoperitoneum and trendelenburg
3103527|NCT01868347|Experimental|Treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
3103528|NCT01868334|Experimental|Intervention with the Toolkit|"Pillar 1: Convenient Vaccination Services Pillar 2: Patient notification Pillar 3: Enhanced Office Systems Pillar 4: Motivation~13 clinical practices (intervention sites) will receive the Toolkit in Year 1 to increase their adult influenza, PPSV, Tdap/Td vaccination rates. In Year 2, those who choose to continue will maintain use of the Toolkit and online resources available but will receive no active intervention from study staff."
3103529|NCT01868334|No Intervention|12 clinical practices (control sites)|12 diverse clinical practices will receive no additional assistance in Year 1 to increase their adult influenza, PPSV, Tdap/Td vaccination rates, they will follow guidelines for usual care. In Year 2 however they will become intervention sites and receive the 4 Pillars Toolkit for use in increasing vaccination rates
3103530|NCT01868321||Mechanical Ventilation|Patients under mechanical ventilation in the ICU
3103531|NCT01868308||Preterm Labor|"Symptomatic women with singleton pregnancy at high risk for preterm birth between 22 - 33 6/7 weeks gestational age. We define high risk for preterm birth as women who present to our triage unit with complaints of preterm labor, including but not limited to preterm contractions, abdominal cramping, back pain, vaginal pressure, and vaginal bleeding."
3103532|NCT01868295|Experimental|Sleeping with denture|Sleeping with denture at night
3103533|NCT01868295|No Intervention|Sleeping without denture|Sleeping without denture at night
3103534|NCT01868282|Experimental|Group 1|Hamstrings block
3103535|NCT01868282|Active Comparator|Group 2|Obturator block
3103536|NCT01868282|Sham Comparator|Group 3|Control group
3103537|NCT01868269|Other|Dexamethasone Cyclophosphamide Rituximab|
3103538|NCT01868256|Experimental|Early discharge (< 72 h)|Patients randomized the early discharge group will be discharged from the hospital in < 72 hours
3103539|NCT01868256|Active Comparator|Conventional discharge|Patients randomized to the conventional discharge group will be discharged according to the local hospital protocol and/or treating physician criterion
3103540|NCT01868243|Experimental|Dabigatran|Dabigatran 110 mg BID
3103541|NCT01868243|Active Comparator|Warfarin|Warfarin adjusted-dose
3103542|NCT01868230|Experimental|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
3103543|NCT01868230|No Intervention|Health and Wellness|Standard of care.
3103544|NCT01868191|Placebo Comparator|Placebo for benfotiamine|Placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
3103545|NCT01868191|Experimental|Benfotiamine|Treatment with benfotiamine 600 mg/day for 3 months followed by 300 mg/day for 9 months
3103546|NCT01868178||BIS Spectral Entropy Group|intraoperative monitoring with BIS and Spectral Entropy
3103547|NCT01868139|Experimental|Cryotherapy|Liquid nitrogen spray cryotherapy with the truFreeze device
3103548|NCT01868126|Experimental|Group 1: DE-117 ophthalmic solution|One drop DE-117 Low Dose in each eye daily for 28 days
3103549|NCT01868126|Experimental|Group 2: DE-117 ophthalmic solution|One drop DE-117 Low Middle Dose in each eye daily for 28 days
3103550|NCT01868126|Experimental|Group 3: DE-117 ophthalmic solution|One drop DE-117 High Middle Dose in each eye daily for 28 days
3103551|NCT01868126|Experimental|Group 4: DE-117 ophthalmic solution|One drop DE-117 High Dose in each eye daily for 28 days
3103552|NCT01868126|Active Comparator|latanoprost ophthalmic solution|One drop latanoprost 0.005% in each eye daily for 28 days
3103553|NCT01868126|Placebo Comparator|placebo (vehicle of DE-117) ophthalmic solution|One drop DE-117 vehicle in each eye once daily for 28 days
3103554|NCT01868113|Active Comparator|Inhaled fluticasone propionate|Inhaled corticosteroid
3103555|NCT01868113|Placebo Comparator|Inhaler propellant|Placebo
3103556|NCT01868100|No Intervention|self-completion questionnaire|
3103557|NCT01868087|Experimental|Impact Advanced Recovery®|3 briks daily (240 mL per brik) of Impact Advanced Recovery® to be take for 5 days before and after RC surgery
3103558|NCT01868087|Placebo Comparator|Boost Plus®|3 briks daily (240 mL per brik) of Boost Plus® to be take for 5 days before and after RC surgery
3103559|NCT01868074|No Intervention|Usual|Participants who are not randomized to the fitted insole intervention
3103560|NCT01868074|Experimental|Insole|Participants randomized to use of a custom-molded insole during pregnancy
3103561|NCT01868061|Experimental|Lebrikizumab (125 mg)|Participants will receive SC injection of lebrikizumab (125 mg) every 4 weeks for 104 weeks.
3103562|NCT01868061|Experimental|Lebrikizumab (37.5 mg)|Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.
3103563|NCT01868061|Placebo Comparator|Placebo|Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.
3103564|NCT01868048|Experimental|Sativex|"Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.~Subjects received study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg."
3103565|NCT01868048|Placebo Comparator|Placebo|Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
3103566|NCT01868035|Experimental|Single Arm|tositumomab and iodine I-131 tositumomab
3103568|NCT01868022|Experimental|Arm B: GSK3052230 + docetaxel|Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + docetaxel as 1 hour iv infusion on Day 1 of each 21-day cycle. Subjects may continue to receive docetaxel until disease progression or as long as they are considered to derive benefit from treatment.
3103569|NCT01868022|Experimental|Arm C: GSK3052230 + pemetrexed and cisplatin|Subject will receive GSK3052230 as 30 minute iv infusion once a week (Day 1, Day 8, Day 15) of each 21 day cycle + pemetrexed iv infusion over 10 minutes on Day 1 of each 21 day cycle followed 30 minutes later by iv Cisplatin infused over 2 hours
3103570|NCT01868009|Experimental|ELLIPTA Period 1 and DISKUS Period 2 Arm|Subjects will use the ELLIPTA inhaler once daily for 5 to 9 days during the first period followed by the DISKUS inhaler twice daily for 5 to 9 days during the second period.
3103571|NCT01868009|Experimental|DISKUS Period 1 and ELLIPTA Period 2 Arm|Subjects will use the DISKUS inhaler twice daily for 5 to 9 days during the first period followed by the ELLIPTA inhaler once daily for 5 to 9 days during the second period.
3103572|NCT01867996|Experimental|Retosiban and EFZ|All subjects will receive on Day 1, a 6 mg bolus of retosiban for 5 min, followed by a 6 mg/hr infusion for 12 hrs. On Day 2 a washout day will occur. On Days 3-17, subjects will receive EFZ 600 mg OD dose of in the evening. On Day 18, subjects will receive a 6 mg bolus of retosiban for 5 mins, followed by a 6 mg/hr infusion for 12 hrs plus a 600 mg dose of EFZ.
3103573|NCT01867983|Active Comparator|Control|Behavioral: Smoking cessation
3103574|NCT01867983|Experimental|Simultaneous|Behavioral: Weight gain prevention and smoking cessation
3103575|NCT01867983|Experimental|Sequential|Behavioral: Weight gain prevention and smoking cessation
3103576|NCT01867970|Experimental|Tool + Self-management Support Program|"The system consists of three elements: a 3D accelerometer worn on the hip together with; an application (app) on a smartphone; a server and a website. The patient receives three types of feedback on the mobile phone concerning the amount of activity, the amount of activity in relation to an activity goal, and the response of a nurse based on the measured activity. Practice nurses will use a consultation approach to coach patients in their self-management regarding physical activity based on a five A's cycle counselling technique (assess-advise-agree-assist-arrange). Motivational interviewing, risk assessment, and goal setting are specific aspects of this approach.The patient comes to the practice four times: in the first week, after 2 weeks, after 8-12 weeks and after 16-24 weeks."
3103577|NCT01867970|Experimental|Self- management Support Program|"Practice nurses will use a consultation approach to coach patients in their self-management regarding physical activity based on a five A's cycle counselling technique (assess-advise-agree-assist-arrange). Motivational interviewing, risk assessment, and goal setting are specific aspects of this approach.The patient comes to the practice four times: in the first week, after 2 weeks, after 8-12 weeks and after 16-24 weeks."
3103578|NCT01867970|No Intervention|Care as usual|Patients attend the practice regularly: at least once a year for a consultation with the GP. In addition, COPD patients have consultations (15-30 minutes) with the practice nurse once or twice a year. Most patients with diabetes type 2 see the GP ones per year and the practice nurse three times per year for a health check.Normally, physical activity is not high on the agenda during consultations with the practice nurse. Barriers for paying attention are the competition with other topics that should also be covered during consultations, co-morbidity and limitations of patients, and the assumption of most practice nurses that nowadays the patient decides on the topics of the consultation. All interviewees agreed that many patients do not perceive physical activity as an important issue.
3103579|NCT01867957|Experimental|Low-dose GC1109|
3103580|NCT01867957|Placebo Comparator|Low-dose Placebo|
3103581|NCT01867957|Experimental|High-dose GC1109|
3103582|NCT01867957|Placebo Comparator|High-dose Placebo|
3103583|NCT01867944|Experimental|Perineal Self-Acupressure|Participants in this group (intervention group) will receive education in perineal self-acupressure in addition to education in conventional treatment options for constipation.
3103584|NCT01867944|Active Comparator|Educational Control|Participants in this group (the control group) will receive education in conventional treatment options for chronic constipation.
3103585|NCT01867931||Erosive Esophagitis|
3103586|NCT01867931||Non-erosive Reflux Disease|
3103587|NCT01867931||Heatlhy volunteers|
3103588|NCT01867918|Experimental|Cheomotherapy and local treatment|Standard chemotherapy + local treatment
3103589|NCT01867918|Placebo Comparator|Cheomotherapy|Standard chemotherapy
3103590|NCT01867905||Severe sepsis and septic shock|Patients who present in severe sepsis or septic shock will have blood cultures taken before and after antibiotic administration. The antibiotic choice will be determined by the emergency physician and the patients will be treated as per routine hospital protocol. No therapeutic interventions will be administered.
3103591|NCT01867892|Experimental|ICT of oxaliplatin,irinotecan,5-FU and leucovorinon and CCRT|Arm1:oxaliplatin,irinotecan,5-FU and leucovorinon D1,15 every 28days for 3 cycles,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
3103592|NCT01867892|Active Comparator|ICT of gemcitabine,oxaliplatin,5-FU,leucovorin and CCRT|Arm 2:gemcitabine,oxaliplatin,5-FU,leucovorin on D1,15 every 28 days for 3 cycles,Evaluation of Tumor Response,CR/PR/SD or localized disease RT 5,040cGy in 28 fractions/ 5.5 wks Arm 2: Gem 400mg/m2 iv 40min weekly
3103593|NCT01867879|Experimental|TAS-102|
3103594|NCT01867879|Placebo Comparator|Placebo|
3103595|NCT01867866|Experimental|TAS-102|
3103596|NCT01867866|Experimental|FTD (Trifluridine)|
3103597|NCT01867853||successful weaning|the SUCCESS of SBT or not need for reintubation or noninvasive ventilation within 48 h following extubation
3103598|NCT01867853||failed weaning|the failure of SBT or the need for reintubation or noninvasive ventilation within 48 h following extubation
3103599|NCT01867840||arthritis|
3103600|NCT01867827|Experimental|Neurofeedback and Physical Exercise|This group will undergo neurofeedback intervention in the fMRI scanner in weeks 1,5 and 12. They will also undergo physical exercise training on WiiFit device once a week after the first month till the end of the study at 12 weeks.
3103601|NCT01867827|Active Comparator|Physical Exercise|This group will undergo Physical Exercise intervention on the WiiFit device 3 times a week in the first month and once a week after the first month till the end of the study at 12 weeks.
3103602|NCT01867814|Experimental|Pneumoperitoneum|Patients undergoing laparoscopic surgery
3103609|NCT01867749|Experimental|Group Interpersonal Psychotherapy (IPT-G)|Participants in the IPT-G condition will receive 12 group therapy sessions over 2 weeks as well as 2 individual (pre-group and 1-month booster sessions). In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. This study adapted IPT for treatment of depression after perinatal loss.
3103610|NCT01867749|Active Comparator|Coping with Depression (CWD)|The Coping with Depression (CWD) course is a highly structured, manualized psycho-educational group treatment for MDD. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. CWD will consist of an individual pre-group interview, 12 group therapy sessions over 12 weeks and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
3103611|NCT01867736|Experimental|Passeo-18 Lux DRB|Passeo-18 Lux Drug Releasing Balloon catheter
3103612|NCT01867736|Active Comparator|Standard PTA (POBA)|Uncoated Passeo-18 PTA balloon catheter
3103613|NCT01867723|Experimental|Internet communication application|Experiment 1 Effect of internet support program on cancer patients and their caregivers
3103614|NCT01867723|No Intervention|Control group|Control group get usual care
3103615|NCT01867710|Experimental|AA + prednisone 5 mg twice daily|Abiraterone acetate in combination with prednisone 5 mg twice daily
3103616|NCT01867710|Experimental|AA + prednisone 5 mg once daily|Abiraterone acetate in combination with prednisone 5 mg once daily dose
3103617|NCT01867710|Experimental|AA + prednisone 2.5 mg twice daily|Abiraterone acetate in combination with prednisone 2.5 mg twice daily
3103618|NCT01867710|Experimental|AA + dexamethasone 0.5 mg once daily|Abiraterone acetate in combination with dexamethasone 0.5 mg once daily
3103619|NCT01867697|Active Comparator|Biweekly cetuximab with continuously FOLFIRI|Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI (irinotecan 180 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)
3103620|NCT01867697|Experimental|Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6|Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI alternating with FOLFOX6 (Oxaliplatin: 85 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)
3103621|NCT01867684|No Intervention|Treatment as usual|Standard NHS care for the patient group (NHS care will vary as participants will be recruited from a variety of NHS clinics).
3103622|NCT01867684|Experimental|Psychotherapy|Brief psychotherapy intervention delivered over 8 weeks in addition to standard care.
3103623|NCT01867671|Experimental|Peanut Oral Immune Therapy (OIT)|Peanut OIT for 134 weeks followed by peanut avoidance for 26 weeks.
3103624|NCT01867671|Placebo Comparator|Peanut Placebo|Peanut placebo for 134 weeks followed by peanut avoidance for 26 weeks. The placebo extract will be derived from oat flour source material.
3103625|NCT01867658|Experimental|Progel® Pleural Air Leak Sealant|
3103626|NCT01867645|Active Comparator|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
3103627|NCT01867645|Placebo Comparator|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
3103628|NCT01867632||Prospective group|Prospective cohort where all patients routinely received ADM during cleft palate surgery. A tailored piece of Acellular Dermal Matrix will be placed between the oral and nasal layers at the time of a Furlow Palatoplasty for repair of a Cleft Palate.
3103629|NCT01867632||Retrospective group|Retrospective cohort of cleft palate patients treated at the same institution and by the same surgeon. These patients received ADM selectively for certain cases (tenuous nasal layer closure, tight oral closure, wide cleft).
3103630|NCT01867619|Experimental|Lomustine + Temozolomide + Thalidomide|Maximum Tolerated Dose Lomustine derived from starting dose 30 mg/m^2 by mouth daily on Day 1 and 29. Temozolomide 75 mg/m^2 by mouth daily on Days 1 to 42. Thalidomide 200 mg/m^2 by mouth daily.
3103631|NCT01867606|Experimental|Arm I (serum-derived bovine immunoglobulin protein isolate)|"Patients receive SBI PO BID on days 1-28.~Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
3103632|NCT01867606|Placebo Comparator|Arm II (placebo)|"Patients receive placebo PO BID on days 1-28.~Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
3103633|NCT01867593|Experimental|C-11 methionine PET|C-11 methionine PET pre and post radiation
3103634|NCT01867580|Experimental|V.A.C.Ulta with Prontosan instillation|Treatment Arm
3103635|NCT01867580|Active Comparator|V.A.C.Ulta without instillation|Control Arm
3103636|NCT01867567|Experimental|6 Hours|Removal of bandage after 6 hours
3103637|NCT01867567|Active Comparator|24 hours|removal of bandage after 24 hours
3103638|NCT01867554||Intellectual disability|patients with intellectual disability or psycho-motor retardation and their parents and sibs (affected or not)
3103639|NCT01867528|Experimental|Laparoscopic adhesiolysis|
3103640|NCT01867528|Active Comparator|Open adhesiolysis|
3103641|NCT01867515|Active Comparator|Younger normally-hearing listeners|"Participants with auditory thresholds within the normal limits.~age between 18 and 35~individuals with hearing thresholds of 20 dB HL or better at all octave frequencies between 250 Hz and 4000 Hz Acoustic distortion of speech"
3103642|NCT01867515|Active Comparator|Hearing-impaired listeners|"individuals with bilateral sensorineural hearing losses with thresholds between 25 and 70 dB HL and no losses greater than 70 dB HL at frequencies of 4000 Hz or below~age 18 to 65 Acoustic distortion of speech"
3103643|NCT01867515|Active Comparator|Older normally-hearing listeners|"Participants with auditory thresholds within the normal limits.~age between 36 and 65~individuals with hearing thresholds of 20 dB HL or better at all octave frequencies between 250 Hz and 4000 Hz Acoustic distortion of speech"
3103690|NCT01867125|Experimental|Lebrikizumab (37.5 mg)|Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.
3104001|NCT01864941|Active Comparator|Catheter Venography & Balloon Venoplasty|Patients will undergo catheter venography with balloon venoplasty procedure.
3103644|NCT01867502|Other|MET + Glibenclamide Group|"Usual Metformin stipulated: 500 or 850mg 3 times a day, if tolerated by patients.~The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). When the adjustments will be done, the dose may reaching the maximum dose allowed, which is 20 mg / day."
3103645|NCT01867502|Other|MET + Vildagliptin Group|"Usual Metformin stipulated: 500 or 850mg 3 times a day, if tolerated by patients.~Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks."
3103646|NCT01867489||Chemotherapy, Cancer|Adult cancer patients (with any type of cancer) being treated with chemotherapy
3103647|NCT01867476||Healthy Normals|
3103648|NCT01867463|Experimental|Group 1|Group 1: n=20, randomized to receive 16 g Pfs25-EPA/Alhydrogel (n=10) or the comparator (EuvaxB, n=10) on D0, D56
3103649|NCT01867463|Experimental|Group 2|Group 2: n=30, randomized to receive 47 g Pfs25-EPA/Alhydrogel (n=15) or the comparator (EuvaxB and Menactra , n=15) on D0, D56, D112, D480
3103650|NCT01867463|Experimental|Group 3|Group 3: n=70 randomized to receive 47 g Pfs25-EPA/Alhydrogel (n=35) or the comparator (EuvaxB and Menactra , n=35) on D0, D56, D112, D480
3103651|NCT01867437|Active Comparator|RM-493|Double blind RM-493 will be administered at a dose of 1 mg/24 hrs via subcutaneous infusion for 3 days
3103652|NCT01867437|Placebo Comparator|Placebo|Double blind placebo will be administered via subcutaneous infusion for 3 days
3103653|NCT01867424|Active Comparator|Participants with Advanced Disease|Advanced disease: who have failed hormone therapy and who have sufficient tissue from a soft tissue or metastatic bone lesion (measuring 1.5cm in diameter at computed tomography (CT) or magnetic resonance imaging (MRI) scan) available for organic anion-transporting polypeptide 1B3 (OATP1B3) immunohistochemistry (IHC) or must have a soft tissue or metastatic bone lesion that can be biopsied and be willing to undergo percutaneous biopsy to obtain tissue for OATP1B3 expression.
3103654|NCT01867424|Active Comparator|Participants with Localized Disease|Localized disease: must have image guided biopsy confirmed prostate cancer and sufficient tissue available for OATP1B3 IHC.
3103655|NCT01867333|Experimental|A|Enzaluatmide alone
3103656|NCT01867333|Experimental|B|Enzaluatmide with PSA-TRICOM
3103657|NCT01867307|Experimental|Healthy Controls|healthy controls
3103658|NCT01867307|Experimental|Patients|patients with type 2 diabetes mellitus
3103659|NCT01867294|Experimental|Arm I (Study I)|Patients apply spironolactone topically to face BID for 4 weeks.
3103660|NCT01867294|Experimental|Arm I (Study II)|Patients apply spironolactone topically to face and body BID for 4 weeks.
3103661|NCT01867294|Placebo Comparator|Arm II (Study I)|Patients apply placebo topically to face BID for 4 weeks.
3103662|NCT01867294|Active Comparator|Arm II (Study II)|Patients receive modified preemptive therapy regimen consisting of skin moisturizer topically BID, sunscreen topically as needed, hydrocortisone topically QD, and doxycycline PO BID for 4 weeks.
3103663|NCT01867281|Active Comparator|Intervention: Aspirin|Participants will undergo aspirin desensitization over a 2-day period with increasing doses of aspirin (60, 125, 325 and 625 mg). Thereafter,they will be followed with 625 mg aspirin bid.
3103664|NCT01867281|Placebo Comparator|Control: placebo|Participants will receive placebo
3103665|NCT01867268|Experimental|Acetazolamide|administration of Acetazolamide for 10 days following the surgery
3103666|NCT01867268|No Intervention|Control|control group without any intervention
3103667|NCT01867268|Experimental|Prone positioning|Positioning the patient following surgery for 10 days
3103668|NCT01867268|Experimental|Acetazolamide and Prone positioning|applying both Acetazolamide and prone positioning
3103669|NCT01867255|Other|venlafaxine ER|venlafaxine ER (extended-release) 75 mg once
3103670|NCT01867242|Experimental|Usual Brand Cigarette|Smoking usual brand cigarette controls, who after 8-weeks will be offered Camel Snus and instructed for partial or complete substitution of cigarettes (subject's choice);
3103671|NCT01867242|Experimental|Complete Substitution Ad libitum|Complete substitution (i.e., no smoking) and snus use ad libitum
3103672|NCT01867242|Experimental|Partial Substitution (Snus and Cigarettes) Ad libitium|Partial substitution of snus for cigarettes and snus use is ad libitum
3103673|NCT01867242|Experimental|Partial Substitution (Snus and Cigarettes) with Instructions|Partial substitution with instructions for the use of snus and ad libitum smoking.
3103674|NCT01867242|Experimental|Complete Substitutuion with Insruction|Complete substitution (no conventional cigarettes) with instruction given for snus use.
3103675|NCT01867229||FEC- TC|Fluorouracil- Epiadriamycine- Cyclophosphamide Taxotère-Cyclophosphamide
3103676|NCT01867216|Placebo Comparator|Placebo|Multiple oral dose of placebo administered to participants with diabetes once or twice daily for 28 days
3103677|NCT01867216|Experimental|LY2922470|Multiple ascending dose of LY292470 (starting at 60 mg) administered orally to participants with diabetes once or twice daily for 28 days
3103678|NCT01867203||Statin users|
3103679|NCT01867190|Experimental|ASCT01|CD34+ and CD45+ cells in ASCT01 preparation
3103680|NCT01867177|Other|HIV testing|Identification of HIV infection among recently infected adults
3103681|NCT01867177|Experimental|HIV care utilization|Improved access to HIV care and HIV care utilization, particularly among newly diagnosed adults
3103682|NCT01867177|Active Comparator|standard of care|Standard of HIV care; standard of linkage to HIV care
3103683|NCT01867164|Experimental|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
3103684|NCT01867164|Experimental|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
3103685|NCT01867151|Experimental|Gluten free diet|BMS patients following a GFD
3103686|NCT01867151|Sham Comparator|Normal Diet|Patients with BMS maintaing a normal diet
3103687|NCT01867138|Experimental|Cefazolin group|Initial empirical treatment with cefazolin and amikacin
3103688|NCT01867138|Active Comparator|Vancomycin|Initial empirical treatment with vancomycin and amikacin
3103689|NCT01867125|Experimental|Lebrikizumab (125 mg)|Participants will receive SC injection of lebrikizumab (125 milligrams [mg]) every 4 weeks for 104 weeks.
3103691|NCT01867125|Placebo Comparator|Placebo|Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.
3103692|NCT01867112|Active Comparator|Individualized Program|Based on personal fitness an individualized physical activity program will be built and followed by each individual in the arm
3103693|NCT01867112|Active Comparator|General Physical Activity Guidelines|The entire group of individuals in this arm will follow a physical activity program according to the General Physical Activity Guidelines
3103694|NCT01867099||Post-successful ablation|Patients who had undergone PVI ablation for AF and were free of AF for at least one year
3103695|NCT01867086|Experimental|Vigil™ Vaccine|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
3103696|NCT01867073||Advanced solid tumours|
3103697|NCT01867060|Other|Personal Heart Rhythm Monitor|Automated Cardiac Event Recorder in parallel with Personal Heart Rhythm Monitor.
3103698|NCT01867047|Experimental|Continuation Group|Subjects randomized to this group will continue their ACE-I through the day of surgery
3103699|NCT01867047|Experimental|Cessation Group|Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose >48 hours prior to surgery)
3103700|NCT01867034|Active Comparator|Bare Metal stent|Stent that has not been impregnated with an anti-restenotic drug
3103701|NCT01867034|Active Comparator|Drug Eluting Stent|Stent that has been impregnated with an anti-restenotic drug
3103702|NCT01867021|Experimental|Agriflu|A single 0.5 mL dose of Investigational vaccine TIV (Agriflu) at visit 1, administered intramuscularly
3103703|NCT01867021|Active Comparator|Fluvirin|A single 0.5 mL dose of control vaccine TIVf (Fluvirin) at visit 1, administered intramuscularly
3103704|NCT01866995|Experimental|Raylis|"This arm (10 men with symptoms of prostatostasis) will get Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months"
3103705|NCT01866995|Active Comparator|standard prostatostasis therapy|This arm (20 men with symptoms of prostatostasis) will get the standard (pathogenetic) therapy of prostatostasis
3103706|NCT01866995|Experimental|Raylis plus standard prostatostasis therapy|"This arm (20 men with symptoms of prostatostasis) will get Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months together with standard prostatostasis therapy"
3103707|NCT01866982|Active Comparator|Umbilical Cord Milking|Milking the umbilical cord 4 times towards the infants at a speed of 20cm/2 seconds
3103708|NCT01866982|Active Comparator|Delayed Cord Clamping|Delayed clamping of the umbilical cord for 45-60 seconds
3103709|NCT01866969|Experimental|Supportive care (quality of life questionnaire)|Caregivers complete a self-administered questionnaire about factors associated with increased caregiver burden and decreased quality of life.
3103710|NCT01866943|Placebo Comparator|Group 1|Patients undergo primary total hip arthroplasty and have a wash of 100cc of normal saline applied to the tissues under the skin prior to skin closure. The wash sits in the wound for 5 minutes then is suctioned out and the skin is closed.
3103711|NCT01866943|Experimental|Group 2|Patients undergo primary total hip arthroplasty and have a wash of 100cc of normal saline plus 1.5 g (100 mg/mL)Tranexamic Acid is applied to the tissues under the skin prior to skin closure. The wash sits in the wound for 5 minutes then is suctioned out and the skin is closed.
3103712|NCT01866930|Experimental|Cohort A: GT-2 or -3 HCV Treatment Naïve Subjects|"Pegylated Interferon Lambda 180 µg solution, injection subcutaneously once weekly for 24 weeks~Ribasphere 200 mg tablets (800 mg per day: two 200 mg tablets in the morning and two 200 mg tablets in the evening) by mouth twice daily for 24 weeks~Daclatasvir 30 mg, 60 mg, or 90 mg tablets (depending on concomitant HIV regimen) once daily for 12 weeks"
3103713|NCT01866930|Experimental|Cohort B: GT-1 or -4 HCV Treatment Naïve Subjects|"Pegylated Interferon Lambda 180 µg solution, injection subcutaneously once weekly for 24 or 48 weeks~Ribasphere 200 mg tablets, (1000 mg per day: two 200 mg tablets in the morning and three 200 mg tablets in the evening for subjects weighing <75 kg and 1200 mg per day: three 200 mg tablets in morning and three 200 mg tablets in evening for subjects weighing ≥75 kg) by mouth twice daily for 24 or 48 weeks~Daclatasvir 30 mg, 60 mg, or 90 mg tablets (depending on concomitant HIV regimen) once daily for 12 weeks"
3103714|NCT01866917|Experimental|TAP|Ropivicaine 0.5% 20cc injectate bilaterally
3103715|NCT01866917|Placebo Comparator|Saline|Normal saline 20cc injectate bilaterally
3103716|NCT01866904||Stable CAD patients aged 50 years or older|Stable CAD patients aged 50 years or older with documented history of presumed spontaneous MI with their most recent MI occurring 1 to 3 years prior to enrollment and have at least 1 additional risk factor
3103717|NCT01866891|Experimental|single arm|
3103718|NCT01866878|Experimental|A group enjoying a corrective touch|"At first, the patient is asked to gradually define the different types of touch that is applied to the hyposensitive area (fixed or mobile touches) with different textures and then compare them with the healthy side. In a second step, the patient is asked to associate multiple items sensation shape and texture, shape and weight. In a third step is used everyday objects.~Desensitisation techniques find their interest mainly when symptoms or dysesthetic hyperesthésique. The objective is to increase the threshold of sensitivity to textures and particles eventually reduce dysaesthetic sensations.~The patient class in order of increasing tolerance 10 textures. Dysesthetic area is stimulated 5 to 10 minutes by the first texture to numb the area by saturation of the action potential. This helps promote functional work and recognition of objects. As soon as the texture causes more trouble we go to the next texture by applying the same job."
3104374|NCT01862146||Former Smokers underwent TCA|subjects who do not smoke since 7 years
3103719|NCT01866878|Experimental|A group receiving TENS (TENS)|Well known in the management of neuropathic pain based on the gate control theory, the application of TENS in the rehabilitation of touch remains to be demonstrated. A recent study applied to the September highlighted the long-term interest of the transcutaneous electrical nerve stimulation (TENS) to improve sensitivity tact arguing possible action on brain plasticity.
3103720|NCT01866878|No Intervention|A control group|
3103721|NCT01866826|Experimental|HIV Infected Subjects|HIV infected subjects with viral suppression on ART.Double-blinded/placebo controlled trial with cross-overdesign.
3103722|NCT01866813|No Intervention|Waiting list control group|Waiting list control group who is offered cognitive training at the end of the data collection period.
3103723|NCT01866813|Experimental|Cognitive training intervention group|"Cognitive training intervention group: 6 weeks of intervention with the online cognitive training scientific brain training pro for 40-60 minutes a day/ 5 days a week. Reminders and motivational phone-calls throughout the intervention period. Phone and Internet-based technical support is available."
3103724|NCT01866800|Active Comparator|Renal Guard|Renal Guard in addition to Saline and N-Acetylcysteine
3103725|NCT01866800|Placebo Comparator|Conventional Treatment|Saline and N-Acetylcysteine
3103726|NCT01866787||Study cohort|
3103727|NCT01866774|Experimental|Fecal calprotectin level|Fecal calprotectin level
3103728|NCT01866774|No Intervention|Symptom questionnaire|
3103729|NCT01866761||Periodontitis, Lifestyle-related disease|
3103730|NCT01866748|Experimental|Part A (single dose)|
3103731|NCT01866748|Experimental|Part B (multiple dose)|
3103732|NCT01866735|No Intervention|Usual Care|
3103733|NCT01866735|Experimental|Standardized Rehabilitation Therapy|"Standardized Rehabilitation Therapy (SRT):~Participants randomized to the Standardized Rehabilitation Therapy arm will receive three types of interventions - Passive Range of Motion (PROM), Physical Therapy (PT) and Progressive Resistance Exercise (PRE). The SRT protocol will be administered by the BICU Mobility Team within 80 hours of ventilation and contains four levels of activity therapy. This Protocol will be delivered 7 days a week. Patients will be assessed daily and if appropriate will receive 3 separate sessions of activity each day."
3103734|NCT01866722|Active Comparator|Usual Care|Participants will get a brief (<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
3103735|NCT01866722|Active Comparator|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
3103736|NCT01866722|Active Comparator|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
3103737|NCT01866709|Active Comparator|Sodium Polystyrene Sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
3103738|NCT01866709|Placebo Comparator|Silicified microcrystalline cellulose|Oral suspension of placebo blended with pigment to have the same appearance, taste, odor and mode of administration as SPS.
3103739|NCT01866696|Experimental|guided implant insertion and immediate loading|This work was designed as a prospective case series clinical study. Twenty patients have been consecutively rehabilitated with an immediately loaded oral implant supported fixed full prosthesis. A total of 120 oral implants (Nobel Replace Tapered Groovy; Nobel Biocare AB, Goteborg, Sweden) supporting 23 bridges (8 mandible, 15 maxilla) were placed , 22 of which in fresh post extraction sockets. 117 out of 120 oral implants were immediately loaded.
3103740|NCT01866683|Experimental|Group 1|1 month respiratory training
3103741|NCT01866683|Experimental|Group 2|1 month waiting period
3103742|NCT01866670|Experimental|spiritual support|"-Spiritual Support: deep breathing + guided image + meditation~Each patient will participate individually in three sequential meetings (A1, A2 and A3).~In the experimental group, it will be developed the support spiritual intervention in all three meetings.~In all meetings, namely A1, A2 and A3 the physiological parameters will be recorded (PA, SpO2, HR) through the monitor BM5."
3103743|NCT01866670|Active Comparator|relaxation therapy|"Relaxation Therapy Each patient will participate individually in three sequential meetings (A1, A2 and A3).~In the control group, it will be performed just relaxing in all three meetings. In all meetings, namely A1, A2 and A3 the physiological parameters will be recorded (PA, SpO2, HR) through the monitor BM5."
3103744|NCT01866657|Experimental|Intervention cohort|Open cerebral oximetry monitoring; observed desaturations will be treated with an intervention algorithm including increase FiO2, head/neck repositioning,vasoconstrictor agents, IV fluid bolus, increase ETCO2, additional anesthesia, RBC transfusion.
3103745|NCT01866657|No Intervention|Blinded cerebral oximetry monitoring|These subjects will have continous cerebral oximetry monitoring like the experimental cohort but the values will be blinded to all clinicians and research staff. There will be no cerebral desaturation interventions in this group because the clinicians will not be aware of a desaturation as the monitor's output is blinded in this group.
3103746|NCT01866644|Experimental|N-acetylcysteine|At portal level, a cannula is inserted with the usual technique of infusion of 3000 ml of preservation fluid to free fall as containing or not scrambling inserted by the NAC scrub nurse then (400 mg of N-acetylcysteine at 10%, 4 ml ).
3103747|NCT01866644|Placebo Comparator|Saline|With usual technique
3103748|NCT01866631||No treatment|
3103749|NCT01866618||Natural IVF Cycle|All patients will undergo a natural IVF cycle using trigger shots of Leuprolide Acetate(Lupron) and human chorionic gonadotropin (hCG) to ensure the patient surges.
3103750|NCT01866605|Placebo Comparator|1|Single un-warmed cotton blanket over body and limbs, and reassurance, during preoperative period in anaesthetic room
3103751|NCT01866605|Active Comparator|2|Single un-warmed cotton blanket over body and limbs, reassurance and intravenous midazolam 30 µg/kg i.v, during preoperative period in anaesthetic room
3103752|NCT01866605|Active Comparator|3|Single un-warmed cotton blanket, reassurance and forced-air warming with a Bair Hugger, during preoperative period in anaesthetic room
3103790|NCT01866319|Active Comparator|Ipilimumab|Participants receive ipilimumab, 3 mg/kg IV Q3W for a total of 4 doses.
3103753|NCT01866592|Other|Single-Arm, open-label extension trial|Single-arm, open label extension trial to continue treatment with Humira (Adalimumab) subcutaneous injection 80mg initial dose followed by 40mg maintenance dose every other week for up to 52 weeks.
3103754|NCT01866579||ethambutol optic neuropathy|
3103755|NCT01866566|Placebo Comparator|HBV-3|one dose HBV
3103756|NCT01866566|Placebo Comparator|HBV-6|one dose HBV
3103757|NCT01866566|Experimental|varicella-3|2 doses varicella vaccine either BCHT or Kengen and 3 month of the interval time
3103758|NCT01866566|Experimental|varicella-6|2 doses varicella vaccine either BCHT or Kengen and 6 month of the interval time
3103759|NCT01866553|Experimental|Nilotinib, Pegylated interferon α2b|"Patients will be treated with nilotinib 300 mg BID during the first 3 months. Then the combination phase ensues with continued daily nilotinib 300 mg BID combined with PegIFN 25 ug/week for 3 months up to the Month 6 time point. If the patient has no more than grade 1 non-hematological toxicity or grade 2 hematological toxicity, the dose will be increased to 40 μg/w until Month 12. The follow-up phase with daily nilotinib 300 mg BID covers the next 12 months period (Month 12 to 24). until Month 12, which is followed by monotherapy phase of nilotinib 300 mg BID. Overall study duration for the individual patient is 24 months."
3103760|NCT01866540|Experimental|Fluenz vaccine|LAIV vaccine
3103761|NCT01866527||all newborns born 1991-2006|all newborns born 1991-2006
3103762|NCT01866514|Experimental|Anesthesia Arm|proximal humerus intraosseous vascular access will be established bilaterally in the proximal humerus using the anesthesia approach in which the arm is abducted from the body.
3103763|NCT01866501|Experimental|Blended Technique|Using the blended technique device operators will establish proximal humerus intraosseous vascular access.
3103764|NCT01866488|Experimental|Cook Catheter, Oral Misoprostol|Cook Catheter is placed and a 50mcg misoprostol tablet is given orally. A repeat dose is administered in 3 hours.
3103765|NCT01866488|Placebo Comparator|Cook Catheter, Oral Placebo|Cook Catheter is placed and a placebo tablet is given orally. A repeat dose is administered in 3 hours.
3103766|NCT01866475|Active Comparator|Renal Disease|Those with mild to moderate renal disease and had an EZ-IO for 48 hours
3103767|NCT01866475|Active Comparator|Diabetes|Those with controlled diabetes and had an EZ-IO for 48 hours
3103768|NCT01866475|Active Comparator|Renal disease and diabetes|Those with both mild to moderate renal disease and controlled diabetes and had an EZ-IO for 48 hours
3103769|NCT01866475|Active Comparator|Healthy adults|Those who are healthy, defined as lacking co-morbidities that are a study exclusion, and had an EZ-IO for 48 hours
3103770|NCT01866462|Experimental|Metformin, NM504|metformin 500mg b.i.d. with NM504 b.i.d. for 1 week followed by metformin 500mg t.i.d. with NM504 b.i.d. for 1 week.
3103771|NCT01866462|Placebo Comparator|Metformin, Placebo|metformin 500mg b.i.d. with Placebo b.i.d. for 1 week followed by metformin 500mg t.i.d. with Placebo b.i.d. for 1 week.
3103772|NCT01866449|Experimental|Cabazitaxel|Cabazitaxel will be given at a dose of 25mg/m² as 1h infusion every 3 weeks
3103773|NCT01866436|Experimental|Multimedia group|The multimedia group is the interventional arm of the study
3103774|NCT01866436|Experimental|Study Day Group|The study day group are the control arm of the study
3103775|NCT01866423|Experimental|Treatment (orteronel)|Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3103776|NCT01866410|Experimental|Treatment (cabozantinib-s-malate, erlotinib hydrochloride)|Patients receive cabozantinib-s-malate PO daily and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3103777|NCT01866397|Experimental|Cidofovir pharmacokinetics|Patient received cidofovir due to clinical necessity (therapy resistant HCMV retinitis) while being on continuous hemofiltration. Pre- and postfilter plasma samples were taken at multiple timepoints during 24 hours.
3103778|NCT01866384|Other|Normal Temperature|72 hours of Normal Temperature (36-37 degrees Celcius). Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
3103779|NCT01866384|Experimental|Mild Induced Hypothermia|72 hours of mild induced hypothermia (32-34 degrees Celcius). Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
3103780|NCT01866371||Retinal degeneration|This group will include patients with retinal degeneration and vision abnormalities. The group will participate in retinal imaging procedures including adaptive optics imaging, optical coherence tomography and fundus photography. Vision may be assessed using microperimetry, visual fields, and visual acuity.
3103781|NCT01866371||Normal control|This group will include individuals without retinal degeneration. The group will participate in retinal imaging procedures including adaptive optics imaging, optical coherence tomography and fundus photography. Vision may be assessed using microperimetry, visual fields, and visual acuity.
3103782|NCT01866358|Placebo Comparator|Umbilical vein infusion|using umbilical vein infusion for resucitation
3103783|NCT01866358|Experimental|Intraosseous infusion|using intraosseous infusion for resucitation
3103784|NCT01866345|Active Comparator|Conventional orthodontic treatment|conventional orthodontic treatment in the mandibular anterior region
3103785|NCT01866345|Experimental|Surgically facilitated Orthodontics|Surgically facilitated Orthodontic treatment in the mandibular anterior region
3103786|NCT01866332|Active Comparator|Conventional Physical Therapy|Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
3103787|NCT01866332|Experimental|Conventional Physical Therapy plus Kinesiotaping|"Patients will receive conventional physical therapy plus an application of Kinesiotaping in their lumbar spine.~Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)."
3103788|NCT01866319|Experimental|Pembrolizumab Q2W|Participants receive pembrolizumab, 10 mg/kg intravenously (IV), Q2W for up to 2 years. With Amendment 05, all Second Course participants will be treated with a fixed dose of pembrolizumab 200 mg Q3W.
3103789|NCT01866319|Experimental|Pembrolizumab Q3W|Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to 2 years. With Amendment 05, all Second Course participants will be treated with a fixed dose of pembrolizumab 200 mg Q3W.
3103791|NCT01866306|Experimental|Healthy 10 TCID50 (Part 1)|Healthy participants were treated with 10 Tissue Culture Infective Dose 50 (TCID50) administered by spraying an atomized viral suspension of RV16UB into a single nostril.
3103792|NCT01866306|Experimental|Healthy 100 TCID50 (Part 1)|Healthy participants were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
3103793|NCT01866306|Experimental|Healthy 1000 TCID50 (Part 1)|Healthy participants were treated with 1000 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
3103794|NCT01866306|Experimental|Asthmatic non-LABA 10 TCID50 (Part 1)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 10 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
3103795|NCT01866306|Experimental|Asthmatic non-LABA 100 TCID50 (Part 1)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
3103796|NCT01866306|Experimental|Asthmatic LABA 100 TCID50 (Part 1)|Participants with mild to moderate asthma, concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
3103797|NCT01866306|Experimental|Asthmatic non-LABA 100 TCID50 (Part 2)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
3103798|NCT01866293|Experimental|Cabozantinib (XL184)|Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.
3103799|NCT01866280|Experimental|Normal sleep Normal meals|Normal sleep/Normal meal times
3103800|NCT01866280|Experimental|Normal sleep Late meals|Normal sleep/Late meal times
3103801|NCT01866280|Experimental|Late sleep Late meals|Late sleep/Late meal times
3103802|NCT01866280|Experimental|Late sleep Normal meals|Late sleep/Normal meal times
3103803|NCT01866267|Other|Maraviroc|Patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen [Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
3103804|NCT01866254|Experimental|Hydromorphone|100 mg, intrathecal administration
3103805|NCT01866254|Active Comparator|Morphine|200 mg, intrathecal administration
3103806|NCT01866241|Experimental|Arm A: sublingual misoprostol 600µg|Misoprostol is a uteretonic drug
3103807|NCT01866241|Placebo Comparator|Arm B: 10 IU Oxytocin|Oytocin is a standard of care treatment for PPH
3103808|NCT01866228|No Intervention|No Consultation Recording|Participant does not receive consultation recording
3103809|NCT01866228|Experimental|Consultation Recording|Participant receives consultation recording
3103810|NCT01866215|Experimental|Study1a|exercice performed 90 min before 13C fructose meal ingestion
3103811|NCT01866215|Experimental|study 1b|exercise performed 90 min after 13C fructose meal ingestion
3103812|NCT01866215|No Intervention|study 1c|no exercise
3103813|NCT01866215|Experimental|study 2a|meals containing fructose, cream and whey proteins over 24 hours after a glycogen/intramyocellular lipid depleting exercise
3103814|NCT01866215|Active Comparator|study 2b|meals containing glucose, cream and whey proteins over 24 hours after a glycogen/intramyocellular lipid depleting exercise
3103815|NCT01866189|Experimental|PET and MRI|Included patients will have F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF) as soon as possible after stroke onset (less than 36 hours). A second brain MRI (MRI-2) will be performed on day 7.
3103816|NCT01866176|Experimental|Knee osteoarthritis patients|Knee osteoarthritis patients with Kellgren & Lawrence grade I, II or III Stabilizing Knee Brace Valgus Knee Brace New Knee Brace
3103817|NCT01866163|Experimental|LEO 90100|LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
3103818|NCT01866163|Placebo Comparator|Vehicle|Aerosol foam vehicle
3103819|NCT01866150||Cohort|
3103820|NCT01866137||no treatment|no treatment
3103821|NCT01866124|Experimental|Cash transfer|"Mothers are the primary recipient of the CT. The proposed approach will be based on monthly seasonal CTs during 5 months, from May to September, for two years (2013 and 2014). A monthly 10 000 FCFA will be transferred to the selected households.~These CTs will be done via mobile phones, in collaboration with the mobile phone company Airtel."
3103822|NCT01866124|No Intervention|Comparison group|
3103823|NCT01866111|Placebo Comparator|Placebo|Placebo
3103824|NCT01866111|Experimental|YKP3089 Low Dose|YKP3089 Low Dose
3103825|NCT01866111|Experimental|YKP3089 Medium Dose|YKP3089 Medium Dose
3103826|NCT01866111|Experimental|YKP3089 High Dose|YKP3089 High Dose
3103827|NCT01866098|Experimental|Naltrexone 50mg|Oral Naltrexone 50mg capsule taken once daily for 52 weeks
3103828|NCT01866098|Placebo Comparator|Placebo|Oral placebo capsule taken once daily for 52 weeks
3103829|NCT01866098|Experimental|Naltrexone 25mg|Oral Naltrexone 25mg capsule taken once daily for 52 weeks
3103830|NCT01866085|Active Comparator|AdVance|sling procedure
3103831|NCT01866085|Active Comparator|ARGUS|sling procedure
3103832|NCT01866072||AVH|AVH: Patients with Acute Viral Hepatitis
3103833|NCT01866072||ACLF|ACLF: Patients with Acute on Chronic Liver Failure
3103834|NCT01866059|Experimental|Calcium silicate cement|Biodentine
3103835|NCT01866059|Active Comparator|Glass Ionomer Cement|Fuji IX
3103836|NCT01866059|Active Comparator|Resin Modified Glass Ionomer Cement|Fuji II LC
3103837|NCT01866046|Experimental|RESPECT-IPV|Rapid HIV testing and risk prevention intervention for victims of intimate partner violence
3103907|NCT01865539|Active Comparator|Custom Foot Orthotic|Custom foot orthotic
3103908|NCT01865539|Sham Comparator|Sham Orthotic|Will be a sham orthotic that will be the same as the actual orthotic without the custom support pads.
3104451|NCT01861639|Sham Comparator|ineffective rTMS - Sham TBS - fMRI|
3103838|NCT01866033|Experimental|PCI-32765|During Period 1, all patients will receive PCI-32765 560 mg administered by mouth (Treatment A). In Periods 2 and 3, patients will receive PCI-32765 560 mg administered by mouth without grapefruit juice (Treatment B) and PCI-32765 140 mg administered by mouth with grapefruit juice (Treatment C) according to a randomization schedule. An intravenous dose of 13C6 PCI-32765 will be administered 2 hours after each oral dose for reference purposes.
3103839|NCT01866007|Experimental|Group 1|40 participants will receive a single subcutaneous (SC) injection of 100 mg guselkumab prepared from lyophilized formulation.
3103840|NCT01866007|Experimental|Group 2|40 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with UltraSafe Passive Delivery System (PFS-U).
3103841|NCT01866007|Experimental|Group 3|40 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with a prefilled syringe facilitated injection device (PFS FID).
3103842|NCT01866007|Experimental|Group 4|20 participants will receive a single intravenous (IV) infusion of 100 mg guselkumab prepared from liquid formulation.
3103843|NCT01865994||Pediatric cardiac surgery|Children scheduled for elective cardiac surgery
3103844|NCT01865981||Hereditary VF|Patients with hereditary ventricular fibrillation, negative for known mutations
3103845|NCT01865981||Brugada|Patients suffering from Brugada syndrome
3103846|NCT01865968|Experimental|Inactivated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with one-dose regimen.
3103847|NCT01865968|Active Comparator|Live attenuated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received live attenuated HAV vaccine containing 6.50 lgCCID50/vial with one-dose regimen.
3103848|NCT01865968|Experimental|Two-dose inactivated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with two-dose regimen.
3103849|NCT01865955|No Intervention|Palpation|Palpation will be used to determine placement of the spinal needle.
3103850|NCT01865955|Experimental|Ultrasound|Ultrasound will be used prior to placement of the spinal needle.
3103851|NCT01865942|Active Comparator|open surgery|One arm receives open surgery. In our department open surgery is considered as the standard procedure since all spine surgeons are preforming this operation.
3103852|NCT01865942|Active Comparator|Minimal access surgery|We compare to well-known types of surgery for metastatic spinal cord compression. The other arm receive open surgery. In our department minimal access surgery is considered as a standard procedure but it is not preformed by all spine surgeons.
3103853|NCT01865929|Active Comparator|Robotic hysterectomy|Minimally invasive hysterectomy by robotic surgery
3103854|NCT01865929|Active Comparator|Vaginal or laparoscopic hysterectomy|Minimal invasive hysterectomy by vaginal or traditional laparoscopic surgery.
3103855|NCT01865916|Active Comparator|2 Liters Bi-Peglyte|Subjects will be asked to take split dose of 2 Liters PEG + 15mg bisacodyl for bowel preparation the day before colonoscopy.
3103856|NCT01865916|Experimental|2 Liters Moviprep|Subject will be asked to take split dose of 2 Liters PEG + ascorbic acid for bowel preparation the day before colonoscopy
3103857|NCT01865903||Cohort 1|All with diagnose of NSCLC in Oslo during 6 months
3103858|NCT01865903||Cohort 2|All NSCLC in Ulleval university hospital whom are in need of palliative chemotherapy
3103859|NCT01865890||patient on hemodialysis taking plavix|patient on hemodialysis taking plavix
3103860|NCT01865877||PD Cohort|Subjects diagnosed with Parkinson's disease
3103861|NCT01865864||1|Compliant with CPAP
3103862|NCT01865864||2|noncompliant with CPAP
3103863|NCT01865851|Active Comparator|Start with Classic Face Mask Group|The volunteers will be asked to breathe normally (Tidal Volume Breathing) through face mask for 5 minutes. After 5 minutes, the volunteers will be asked to breathe room air for 5 minutes and then breathe through a NuMask for 5 minutes. This will be followed by room air breathing for 5 minutes. At the end of the 5 minutes of room air breathing, the same volunteers will be asked to breathe through the face mask for 5 minutes.
3103864|NCT01865851|Active Comparator|Start with NuMask Group|The volunteers will be asked to breathe through the NuMask for 5 minutes, followed by room air breathing for 5 minutes, then 5 minutes of breathing through the face mask. This will be followed by room air breathing for 5 minutes and then 5 minutes of NuMask breathing.
3103865|NCT01865838|Active Comparator|Seprafilm (Sanofi, USA)|Patients in this arm received Seprafilm during surgery.
3103866|NCT01865838|No Intervention|Control|Patients in this arm does NOT receive Seprafilm during surgery.
3103867|NCT01865825||Esophageal barium xray|"We will recruit 20 patients with GERD without dysphagia for an esophageal barium xray for esophageal diameter measurements.~The 20 Gastroesophageal Reflux Disease (GERD) patients will complete the Mayo Dysphagia Questionnaire 30-day and the Eosinophilic Esophagitis Actitivy Index (EEsAI) questionnaires"
3103868|NCT01865812|Experimental|OCA: 10 mg|obeticholic acid, oral administration, 10 mg, 8 weeks
3103869|NCT01865799||FTC/TDF for PrEP|This prospective case series is composed of every subject in a database containing de-identified patient-level data from all healthcare channels in the US, of individuals that are exposed to FTC/TDF or its components for any indication.
3103870|NCT01865786||FTC/TDF for PrEP|The study has one target prospective cohort defined as HIV-1 negative women who had been prescribed FTC/TDF for pre-exposure prophylaxis (PrEP); with two strata: a) those who continue to take FTC/TDF for PrEP during their pregnancy, and b) those who decide to stop FTC/TDF for PrEP during pregnancy.
3103871|NCT01865786||ARV population|The study has one comparison cohort defined as HIV-positive women who were on any antiretroviral (ARV) medication at the time the pregnancy was detected. This is a propensity score matched retrospective cohort selected from the prospective arm of the APR. This cohort is assembled retrospectively in order to appropriately match the subjects by calendar time and the correlates of exposure, with exposure being defined as being on FTC/TDF for PrEP vs being exposed to other ARVs.
3103872|NCT01865773|Experimental|HFR|We selected 8 inflamed chronic HD patients, which underwent a single 240 minutes HFR session
3103997|NCT01864967||carbon dioxide infusion|Group I: receive carbon dioxide infusion
3103998|NCT01864967||control|did not receive carbon dioxide
3103999|NCT01864954|Experimental|Enhanced Web+phone|Engaging and interactive website access plus phone calls from personal coach.
3103873|NCT01865760|Experimental|Gastric bypass surgery, hypoglycemia|Subjects with previous gastric bypass surgery (more then 1 year ago) and symptomatic hypoglycemia according to Whipples triade. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal. They will furthermore undergo two additional liquid mixed meal; one with concomitant treatment with synthetic Exendin 9-39 and another with treatment with Octreotide. All tests will be separated by at least one week.
3103874|NCT01865760|Active Comparator|Gastric bypass surgery, asymptomatic|Subjects with previous gastric bypass surgery (more then 1 year ago) without any signs of hypoglycemia. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.
3103875|NCT01865760|Sham Comparator|Sleeve-gastrectomi|Subjects with previous sleeve-gastrectomi (more then 1 year ago) regardless of signs of hypoglycemia or not. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.
3103876|NCT01865760|Other|Controls|Healthy non-operated control subjects, matched on BMI, age and sex. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.
3103877|NCT01865747|Experimental|Cabozantinib (XL184)|Cabozantinib (XL184) 60 mg tablet once daily.
3103878|NCT01865747|Active Comparator|Everolimus (Afinitor)|Everolimus (Afinitor) 10 mg tablet once daily.
3103879|NCT01865734|Experimental|Early Physical Therapy|Physical therapy after initial podiatry visit
3103880|NCT01865734|Active Comparator|Usual Podiatric Care|Usual care provided by podiatry
3103881|NCT01865721|Active Comparator|Continuous administration of Entonox|Patients randomized to this arm will be asked to inhale Entonox throughout the insertion phase of colonoscopy
3103882|NCT01865721|Active Comparator|As required administration of Entonox|Patients randomised to this arm will be asked to use Entonox if and when they have pain
3103883|NCT01865708|Other|Ethanol lock|Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
3103884|NCT01865695|Placebo Comparator|Placebo|Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.
3103885|NCT01865695|Active Comparator|Creon|Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.
3103886|NCT01865669|No Intervention|Control|A control sample from each patient (no oxytocin applied) will be measured concurrently with samples treated with varying concentrations of oxytocin.
3103887|NCT01865669|Experimental|Oxytocin|Samples from each patient will be bathed in a solution containing varying concentrations of oxytocin.
3103888|NCT01865656|Other|4 intervention first referral units|"A Quasi-experimental intervention/control trial will be implemented to assess the impact of the following interventions on the outcome measures in a cluster of 4 intervention sites relative to a matched cluster of 4 control sites:~Refresher/simulation training to improve provider skills/knowledge Implementation of Emergency Obstetric Drills Revised Case sheets(for data collection and therefore part of both control and intervention sites), Mentoring and Supportive supervision, and Referral Strengthening"
3103889|NCT01865656|No Intervention|Control Arm|
3103890|NCT01865643|Other|Standard GlideScope intubation|This standard GlideScope (GS) technique involves a midline larygoscopy followed by insertion of a styleted endotracheal tube, once an adequate view of the vocal cords is achieved.
3103891|NCT01865643|Experimental|Alternative GlideScope intubation|"Alternative GlideScope (GS) intubation involves the insertion of the endotracheal tube under direct vision as a fish hook at the side of the mouth before the GS blade is introduced into the oropharynx."
3103892|NCT01865630|Experimental|Etanercept|Patients with aneurysmal subarachnoid hemorrhage will be treated with etanercept, 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
3103893|NCT01865617|Experimental|Treatment (anti-CD19-CAR autologous T cells)|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~DOSE DENSE EXPANSION COHORT: An additional cohort will receive a second anti-CD19-CAR lentiviral vector-transduced autologous T cell infusion without additional lymphodepleting chemotherapy 10-21 days after the first infusion if adequate CD19 CAR-T cells can be produced and appropriate criteria are met."
3103894|NCT01865604|Experimental|Anodal tDCS|anaodal transcranial direct current stimulation
3103895|NCT01865604|Active Comparator|Cathodal tDCS|cathodal transcranial direct current stimulation
3103896|NCT01865604|Sham Comparator|Sham tDCS|no stimulation
3103897|NCT01865591|Experimental|Renal denervation|Subjects are treated with unfocussed ultrasound-based renal denervation and are maintained on baseline anti-hypertensive medications.
3103898|NCT01865578|Experimental|tDCS|Transcranial direct current stimulation
3103899|NCT01865578|Sham Comparator|sham stimulation|sham stimulation
3103900|NCT01865565||Imatinib treat|"• Locally advanced unresectable GIST without metastasis at~EC junction requiring total gastrectomy,~Duodenum requiring Whipple operation;~Large GIST requiring multiviceral resection;~Rectum: requiring APR."
3103901|NCT01865552|Experimental|SB4 and EU sourced Enbrel in Part A|SB4 followed by EU sourced Enbrel
3103902|NCT01865552|Experimental|EU sourced Enbrel and SB4 in Part A|EU sourced Enbrel followed by SB4
3103903|NCT01865552|Experimental|SB4 and US sourced Enbrel in Part B|SB4 followed by US sourced Enbrel
3103904|NCT01865552|Experimental|US sourced Enbrel and SB4 in Part B|US sourced Enbrel followed by SB4
3103905|NCT01865552|Other|EU and US sourced Enbrel in Part C|EU sourced Enbrel followed by US sourced Enbrel
3103906|NCT01865552|Other|US and EU sourced Enbrel in Part C|US sourced Enbrel followed by EU sourced Enbrel
3103909|NCT01865526|Active Comparator|Low protein diet|The patients of this group received a classical low protein diet (LPD),according to their desired body weight (DBW), obtained by multiplying the squared value of the height times a reference body mass index (BMI) value of 23. LPD were individually prepared and explained to the patients by a dedicated dietician and contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
3103910|NCT01865526|Experimental|Six point diet|These patients were assigned to receive the 6-points-diet, and were given by the Nephrologist the list of six items indicating how to modify their dietary habits; all the items were thoroughly explained and discussed with the patients
3103911|NCT01865500|Active Comparator|Metil prednisolone & Budesonide 4mg|
3103912|NCT01865500|Active Comparator|Metil prednisolone & Budesonide 8 mg|
3103913|NCT01865500|Active Comparator|Budesonide 4 mg & Budesonide 8 mg|
3103914|NCT01865487|Experimental|Dose Finding AERAS-456 / IC31or Placebo|QFT Negative 2 Doses
3103915|NCT01865487|Experimental|3 Dose TBD AERAS-456/IC31 or Placebo|QFT Negative Dose level to be determined based on results of Arm 1
3103916|NCT01865487|Experimental|2 Dose TBD AERAS-456 / IC31 or Placebo|QFT Positive 2 Doses Dose level to be determined based on results of Arm 1
3103917|NCT01865487|Experimental|3 Doses TBD AERAS-456 / IC31 or Placebo|QFT Positive 3 Doses Dose level to be determined based on results of Arm 1
3103918|NCT01865474|Experimental|Treatment I|DLBS1033 bioactive fraction tablet 490 mg thrice daily
3103919|NCT01865474|Experimental|Treatment II|Placebo tablet of DLBS1033, thrice daily
3103920|NCT01865448|Active Comparator|omega-3 DHA|Patients in this group will receive 500 mg/day supplement of DHA omega-3 fatty acid in capsule form, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme.
3103921|NCT01865448|Placebo Comparator|Control|Patients in this group will receive an placebo capsule, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme
3103922|NCT01865435|Experimental|new borns|
3103923|NCT01865422|Experimental|chronic cough|
3103924|NCT01865409|Active Comparator|Kangoroo care|"While performing Kangaroo care the infant should be held skin-to-skin contact with her mother for 30-60 minutes. The baby, who is naked except for a diaper and a piece of cloth covering his or her back (either a receiving blanket or the parent's clothing), is placed in an upright position against a parent's bare chest. The values of heart rate variability will be measured during and also without Kangaroo Care in the same infants but different times."
3103925|NCT01865396|Experimental|early palliative care|Interventional palliative care, after diagnosis and once a month.
3103926|NCT01865396|Active Comparator|Standard care|Patients will receive the standard oncologic care.
3103927|NCT01865383|Experimental|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
3103928|NCT01865383|No Intervention|Control|Control: Participants will receive delayed HIV prevention training at the conclusion of the intervention involving participants in the other condition.
3103929|NCT01865370|Experimental|Kochujang Pills|
3103930|NCT01865370|Placebo Comparator|Placebo|
3103931|NCT01865357|Experimental|Patient|Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially beginning multiple sclerosis (MS) whatever the mode of presentation
3103932|NCT01865357|Experimental|Control|healthy subject
3103933|NCT01865344||Heart surgery|Pain monitoring at different time periods
3103934|NCT01865331|Experimental|Low dose, insulin degludec|
3103935|NCT01865331|Experimental|Medium dose, insulin degludec|
3103936|NCT01865331|Experimental|High dose, insulin degludec|
3103937|NCT01865331|Experimental|IDegAsp 50|
3103938|NCT01865318|Experimental|Part 1 (Once-daily dosing regimen, high concentration)|
3103939|NCT01865318|Experimental|Part 2 (Twice-daily dosing regimen, high concentration)|
3103940|NCT01865318|Experimental|Part 3 (Once-daily dosing regimen, low concentration)|
3103941|NCT01865305|Experimental|Trial part 1|
3103942|NCT01865305|Experimental|Trial part 2|
3103943|NCT01865292|Experimental|Insulin degludec|
3103944|NCT01865292|Active Comparator|Insulin glargine|
3103945|NCT01865279|Experimental|Trial part 1|
3103946|NCT01865279|Active Comparator|Trial part 2|
3103947|NCT01865266|Experimental|NUTIG|"The normal dose of ulinastatin for injection group(NUTIG):~Ulinastatin(Techpool inc,Guangdong,China) was administered to the group as a bolus of 100,000 U diluted in 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
3103948|NCT01865266|Experimental|HUTIG|"The high dose of ulinastatin for injection group(HUTIG):~Ulinastatin(Techpool inc,Guangdong,China) was administered to the group as a bolus of 200,000 U diluted in 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
3103949|NCT01865266|Placebo Comparator|CG|"The compare group(CG):~The group was given 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
3103950|NCT01865253|Experimental|Renal Denervation|Renal Denervation treatment
3103951|NCT01865240|Experimental|Renal Denervation Group|participants randomised to undergo the renal denervation procedure
3103952|NCT01865240|No Intervention|Usual care|participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
3103953|NCT01865227|Active Comparator|Group Counseling|The major aim of the post-operative counseling groups is to engage patients in discussing and exchanging their thoughts on issues of concern related to their surgery and overall well-being. The selected patients will be informed about the purpose of these support groups and will be made aware that their attendance is entirely voluntary.
3103954|NCT01865227|No Intervention|Standard treatment|
3104000|NCT01864954|Active Comparator|Basic Static Web|Static website access only, only introductory call.
3104452|NCT01861639|Sham Comparator|Effective rTMS - Sham TBS - fMRI|
3103955|NCT01865201|Experimental|Edaravone group|Edaravone was used at a dose of 30mg,intravenously, twice per day, for 14 days. All patients also received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
3103956|NCT01865201|Experimental|Control group|All patients in this group received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
3103957|NCT01865188|Experimental|LCZ696 200 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg once daily for 8 weeks.
3103958|NCT01865188|Experimental|LCZ696 400 mg|Patients randomized to this treatment arm will receive LCZ696 400 mg once daily for 8 weeks.
3103959|NCT01865188|Active Comparator|Amlodipine 5 mg|Patients randomized to this treatment arm will receive amlodipine 5 mg once daily for 8 weeks.
3103960|NCT01865188|Active Comparator|Amlodipine 10 mg|Patients randomized to this treatment arm will receive amlodipine 10 mg once daily for 8 weeks.
3103961|NCT01865188|Experimental|LCZ696 200 mg and amlodipine 5 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 8 weeks.
3103962|NCT01865188|Experimental|LCZ696 200 mg and amlodipine 10 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 200 mg and amlodipine 10 mg once daily for 7 weeks.
3103963|NCT01865188|Experimental|LCZ696 400 mg and amlodipine 5 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 400 mg and amlodipine 5 mg once daily for 7 weeks.
3103964|NCT01865188|Experimental|LCZ696 400 mg and amlodipine 10 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 400 mg and amlodipine 10 mg once daily for 7 weeks.
3103965|NCT01865188|Placebo Comparator|Placebo|Patients randomized to this treatment arm will receive placebo once daily for 8 weeks.
3103966|NCT01865175|Active Comparator|ionic iron|Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine folloowed by 7 days of heme iron.
3103967|NCT01865175|Experimental|heme iron polypeptide|Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
3103968|NCT01865162|Experimental|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
3103969|NCT01865149||both optic nerve sheath diameter|
3103970|NCT01865136|Other|Medical Post Abortion Care by Midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
3103971|NCT01865136|No Intervention|Medical Post Abortion Care by physician|Women with incomplete abortion is diagnosed and treated with misoprostol by physician
3103972|NCT01865123|Experimental|Transcendental Meditation|TM is a simple, natural, effortless mental technique practiced with eyes closed sitting for 20 minutes twice a day. This allows the practitioner to experience lesser excited levels of the mind and correspondingly greater degrees of physical relaxation. TM is a traditional meditation technique that has its origin in the ancient Vedic tradition of India.
3103973|NCT01865123|Active Comparator|Prolonged Exposure|Prolonged Exposure (PE) is a specialized type of Cognitive Behavorial Therapy employing a manualized, trauma-focused behavioral treatment for PTSD and is based on exposure principles and emotional processing theory.
3103974|NCT01865123|Placebo Comparator|Educational Control|Didactic based instructional classes will provide health education which will include the benefits of proper diet, exercise, and reducing smoking and alcohol. No stress management techniques will be taught.
3103975|NCT01865110|Experimental|Induction experimental arm|R-CHOP / R-HAD : Alternating 3 cycles of R-CHOP administered in 3 week cycles + 3 cycles of R-HAD administered in 4 week cycles.
3103976|NCT01865110|Active Comparator|Standart induction arm|8 cycles of R-CHOP administered in 3 week cycles
3103977|NCT01865110|Experimental|Maintenance experimental arm|lenalidomide + rituximab : 13 cycles of rituximab SC 1400 mg administered in 8 week cycles + 26 cycles Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
3103978|NCT01865110|Active Comparator|Maintenance standart arm|13 cycles of rituximab SC 1400 mg administered in 8 week cycles for 24 months
3103979|NCT01865097|Experimental|Relaxation guided imagery|
3103980|NCT01865097|Active Comparator|Relaxing music|
3103981|NCT01865084|Experimental|Placebo|Placebo taken orally once daily.
3103982|NCT01865084|Experimental|0.3 mg/kg Tadalafil|0.3 milligram per kilogram (mg/kg) tadalafil taken orally once daily.
3103983|NCT01865084|Experimental|0.6 mg/kg Tadalafil|0.6 mg/kg tadalafil taken orally once daily.
3103984|NCT01865071|Experimental|loop ileostomi|Compare early vs. late closer of the protecting ileostoma in patients requiring rectal resection for rectal cancer
3103985|NCT01865058||DLBCL|Patients with newly diagnosis of diffuse large B-cell lymphoma is offered enrollment in this protocol.
3103986|NCT01865045||no treatment|no treatment
3103987|NCT01865032||Skin Ulcers|Skin ulcers. No intervention. Subjects will be followed up by their respective primary providers.
3103988|NCT01865019||volume controlled|volume ontrolled ventilation
3103989|NCT01865019||pressure controlled|pressure controlled ventilation
3103990|NCT01865006||Ligasure LF1212|
3103991|NCT01865006||Ultracision|
3103992|NCT01865006||Conventional|
3103993|NCT01864993|Experimental|suspected NC gluten sensitive subjects|Patients referring gastrointestinal functional disorders will be selected and they will follow a gluten free diet
3103994|NCT01864993|Experimental|suspected NC gluten sensitive|Patients referring gastrointestinal functional disorders will be selected and they will follow a gluten free diet
3103995|NCT01864980||Hb group:15 patients|scheduled for elective surgery associated with undetected, i.e., difficult to reliably monitor intraoperative blood loss.
3103996|NCT01864980||SpHb group: 15 patients|scheduled for elective surgery associated with undetected, i.e., difficult to reliably monitor intraoperative blood loss.
3104453|NCT01861639|Experimental|ineffective rTMS - Active TBS - EEG|
3104002|NCT01864941|Sham Comparator|Catheter Venography Only|Patients will undergo catheter venography only.
3104003|NCT01864928||Stroke population|Adults with ischemic stroke.
3104004|NCT01864915|Experimental|No Booster-low dose prucalopride booster|low dose prucalopride booster arm
3104005|NCT01864915|Experimental|Prucalopride Booster-high dose prucalopride booster|additional 2mg prucalopride at time of capsule ingestion
3104006|NCT01864915|Experimental|Picosalax Booster Arm|One sachet of Picosalax 2hrs after capsule ingestion and 1/2 sachet at 4 hrs after swallowing colon capsule.
3104007|NCT01864902|Experimental|anti-CD33 CAR T cells|Patients receive anti-CD33-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
3104008|NCT01864889|Experimental|anti-CD19 CAR T cells|Patients receive anti-CD19-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
3104009|NCT01864876|Experimental|GLA-AF|5 mcg GLA-AF given as one subcutaneous injection.
3104010|NCT01864876|Experimental|GLA-SE|5 mcg GLA-SE given as one intramuscular injection.
3104011|NCT01864876|Experimental|EM060G (SE)|EM060G (SE) given as one intramuscular injection.
3104012|NCT01864863|Experimental|Test→Reference|HGP1206 125 mg 1 tablet → Traclear 62.5 mg 2 tablets
3104013|NCT01864863|Experimental|Reference→Test|Traclear 62.5 mg 2 tablets → HGP1206 125 mg 1 tablet
3104014|NCT01864850|Active Comparator|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
3104015|NCT01864850|Experimental|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
3104016|NCT01864837||Functional dyspepsia|They should meet the Rome III criteria for functional dyspepsia.
3104017|NCT01864824|Experimental|methyl donor|"Methyl donor is made up of:~2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure."
3104018|NCT01864824|Placebo Comparator|placebo|placebo: The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
3104019|NCT01864811|Experimental|Baby-CIMT|The infants will be prevented from using the preferred hand while the other hand will be trained using amusing and easily handled toys.
3104020|NCT01864811|Experimental|baby-massage|The infants will receive baby massage
3104021|NCT01864798|Experimental|Denosumab|
3104022|NCT01864785|Other|Fixation Alone|Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
3104023|NCT01864785|Other|Fixation Combined With Fusion|Posterior Fixation Combined With Articular Process Fusion in thoracolumbar Fracture.
3104024|NCT01864772|Experimental|Carbo, 5FU, Cetuximab|"6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity"
3104025|NCT01864759|Experimental|ICOVIR5|ICOVIR-5 oncolytic adenovirus, single administration, endovenous, dose escalation from 1E11 vp to 1E13 vp.
3104026|NCT01864746|Experimental|Palbociclib|Palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
3104027|NCT01864746|Placebo Comparator|Placebo|Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a28-day cycle for thirteen cycles
3104028|NCT01864733|Experimental|intervention group|"1) The 'intervention' group: 3-month multimodal approach associating exercise rehabilitation, ONS, n-3 PUFAs and androgen substitution:~Physical rehabilitation including endurance and resistance exercises two to three times a week.~Oral nutritional supplements: Fortimel max® (Nutricia®) (300 ml, 720 kcal, 29 g de proteins), once per day.~n-3 polyunsaturated fatty acids : DHA phospholipids (GPL-DHA®), 240 mg/day.~Testosterone: Testopatch® 2.4 mg in men and 1.2 mg in women; 2 patches renewed every two days."
3104029|NCT01864733|Other|control group|2) The 'control' group: no multimodal approach but the treatment currently recommended: heart rehabilitation and dietary counseling during 3 months.
3104030|NCT01864720|Active Comparator|Professionally Administered CBT-I (Standard Care)|Patients assigned to this group will receive 6 weekly sessions of cognitive-behavioral therapy for insomnia (CBT-I) of approximately 50 minutes, offered individually by a licensed psychologist with significant experience (at least 2 years) in the administration of CBT-I with cancer patients.
3104031|NCT01864720|Experimental|Stepped Care CBT-I|Patients having an ISI score > 7 but < 15 (approximately 100 patients), will all receive first a web-based CBT-I for six weeks. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). Patients with an ISI score > 14 (approximately 100 patients) will receive six weekly sessions of CBT-I administered individually by a professional.
3104032|NCT01864707|Experimental|usual care + acupuncture|standardized acupuncture treatment in addition to usual care
3104033|NCT01864707|Experimental|usual care+mbsr|mindfulness based stress reduction in addition to usual care not recruiting anymore
3104034|NCT01864707|Active Comparator|usual care|usual care without additional treatment
3104035|NCT01864694|Experimental|TLC-Diet|Participants receive diet intervention through automated telephone system: TLC-Diet
3104036|NCT01864694|Experimental|WEB-Diet|Participants receive diet intervention through web-based system: WEB-Diet
3104037|NCT01864694|Experimental|Control|Assessment-only control group
3104038|NCT01864681|Experimental|Arm A|Gefitinib and metformin. Metformin starting at a dose of 500 mg twice a day, orally with meals. After one week, increase the dose of metformin to 1000 mg as the first dose of the day and 500 mg as the second dose. After another week, increase to 1000 mg of metformin two times a day. Metformin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for metformin loading.
3104039|NCT01864681|Placebo Comparator|Arm B|Gefitinib and placebo. Placebo was given to patients in the same way as that of metformin in Arm A.
3104040|NCT01864655|Experimental|Saracatinib group 1|This group will receive AZD0530 (saracatinib) experimental oral drug , once daily, for a duration of 4 weeks. Dosage is 50mg per day.
3104041|NCT01864655|Experimental|Saracatinib group 2|Group 2 will receive saracatinib at a daily oral dose determined by the response to 50mg P.O. daily. Duration is 4 weeks.
3104042|NCT01864655|Experimental|Saracatinib group 3|Group 3 will receive saracatinib at a dose determined by the response to 50mg P.O. daily, as well as dose given to group 2. Duration is 4 weeks.
3104043|NCT01864655|Placebo Comparator|Placebo group 1-3|Subjects receiving saracatinib in groups 1-3 will be compared to subjects receiving daily, oral, placebo drug.
3104044|NCT01864642|Experimental|osteopathic manipulative treatment|osteopathic manipulative treatment (OMT)
3104045|NCT01864629|Other|Contraception after preterm birth|Intervention name: Focused contraception counseling This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
3104046|NCT01864629|No Intervention|Control Group|Participants will receive the standard postpartum contraception counseling that is received by all patients who deliver at our institution.
3104047|NCT01864616|Experimental|Group 3|Vitamin D3, 10,000 IU daily
3104048|NCT01864616|Experimental|Group 2|Vitamin D3 2,000 IU daily
3104049|NCT01864616|Experimental|Group 1|Vitamin D3 600 IU daily (Control group, RDA level)
3104050|NCT01864603|Experimental|1st: universal test and treat; 2nd: targeted PrEP and cascade|"Intervention arm first phase: annual universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery~Intervention arm second phase: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery + targeted PrEP, targeted HIV testing, and targeted care interventions"
3104051|NCT01864603|Active Comparator|1st: baseline community testing; 2nd: universal test & treat|"Intervention arm first phase: baseline community-based HIV and multi-disease testing~Intervention arm second: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery"
3104052|NCT01864590|Experimental|Open Abdomen - Vacuum Pack|Patients that Require open abdomen
3104053|NCT01864590|Active Comparator|Double Sylo Bag - Mesh Protocol|Open Abdomen
3104054|NCT01864577|Experimental|With negative pleural suction|Patients are put on negative pleural suction at - 20 cm H2O
3104055|NCT01864577|Active Comparator|With water seal|Patients al left on water seal only
3104056|NCT01864564|No Intervention|Routine Screening|"Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.~All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation."
3104057|NCT01864564|Experimental|Early Screening|"Obese women will be randomized to be screened at 14-18 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-18 weeks will be re-screened at 24-28 weeks per the standard of care.~All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation."
3104058|NCT01864551|Active Comparator|lamotrigine|maintenance treatment of the patients with bipolar disorder with olanzapine or lamotrigine
3104059|NCT01864551|Active Comparator|olanzapine|maintenance treatment of the patients with bipolar disorder with olanzapine or lamotrigine
3104060|NCT01864538|Experimental|TH-302|480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
3104061|NCT01864525|Placebo Comparator|Inactive capsule|Participants will receive a pill/capsule with an inactive ingredient during the placebo arm of this study.
3104062|NCT01864525|Experimental|Octanoic acid|Participants will receive a pill/capsule with octanoic acid (amount determined by the participant's weight) during the experimental arm of this study.
3104063|NCT01864512||ITP patients receiving eltrombopag therapy|
3104064|NCT01864499|Experimental|Tumor Resection|
3104065|NCT01864499|Active Comparator|Biopsy Brain Tumor|
3104066|NCT01864486|Experimental|Intelligent Retinal Implant System|
3104067|NCT01864473|Other|Kshar Sutra|
3104068|NCT01864460|Experimental|Diet, Physical Activity and Balance Enhancement Program (DPAE|Subjects in the DPAEP group will undergo a structured weight loss for approximately 6 months, followed by approximately 6 months of weight maintenance, as well as 12 months of aerobic exercise. This intervention stresses a personalized program emphasizing activities that are meaningful to and are tailored to individual participants; provides consistent contact between the participants and research staff; and allows monitoring of activity levels using questionnaires, actigraphy, monitoring of heart rate, direct and telephone contact. Participants dietary and physical activity goals as assessed by the dietician and trainer will be discussed at face-to face meetings to re-establish these goals. These programs will be tailored to meet the realistic goals of the individual participant. The program stresses aerobic exercise, rather than other types of exercise interventions, as aerobic exercise appears to correlate best with improved autonomic function.
3104069|NCT01864460|Active Comparator|Standard Care (SC)|The SC group will be assigned an interventionist assessor. This assessor will meet with the subjects during their orientation meeting and will be provided guidelines and a weight loss and physical activity target to achieve by the end of the program at their orientation meeting. Participants will contacted approximately weekly during the approximate 12 month period.
3104115|NCT01864174|Active Comparator|Arm 2: Metformin IR and Placebo matching with Metformin IR|"Metformin Immediate Release (IR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks~Placebo matching with Metformin IR 0 mg tablets by mouth twice daily (BID) for 24 weeks"
3104116|NCT01864161|Experimental|oral liposomal iron|patients receive a dose of liposomal 30 mg/die iron (equivalent to 1 cp Sideral forte).
3104294|NCT01862861||Peri or post-menopausal women.|Women with peri or post-menopausal vasomotor symptoms between 30 and 60 years of age.
3104070|NCT01864447|Experimental|VTE REHABILITATION|"The exercise prescription emphasizes gradual progression to longer duration (45-60 minutes per session), lower intensity (60-70% peak heart rate (PHR) exercise. Subjects have an exercise expenditure goal of >3000 kcal/wk, attained after 2 to 4 weeks of gradually lengthening exercise bouts. All exercise sessions will be performed onsite for the first two weeks, after which subjects will perform 2 additional sessions a week in the home environment. Exercise logs will be reviewed weekly.~The Dietary Behavioral Weight Loss Intervention(BWL) intervention consists primarily of 12 small group sessions led by a dietician emphasizing dietary records, itemization of food, and caloric content. Subjects will be given individualized daily caloric goals 500 kcal less than predicted maintenance calories based on their baseline body weight."
3104071|NCT01864447|No Intervention|CONTROL|The 12-week program will consist of monthly phone contacts to check-in to capture physical activity done outside of the intervention setting.
3104072|NCT01864434||Patients with a Stryker Triathlon CR TKA|Patients implanted with a Stryker Triathlon Posterior Cruciate Retaining Total Knee Arthroplasty.
3104073|NCT01864434||Patients with a Zimmer PCR TKA|Patients implanted with a Zimmer NexGen Posterior Cruciate Retaining Total Knee Arthroplasty.
3104074|NCT01864421||Deferred Clamping|Infants undergoing a deferring of umbilical cord clamping for 30 seconds or more
3104075|NCT01864421||Immeadiate Cord Clamping|Infants undergoing immediate umbilical cord clamping in the first 20 seconds of life.
3104076|NCT01864408|Other|Group 1|"Group 1: subjects will receive usual practice counseling regarding pelvic organ prolapse after new patient history and physical exam."
3104077|NCT01864408|Experimental|Group 2|"Group 2: subjects will receive usual practice counseling in addition to interactive patient/provider counseling using the pelvic organ prolapse web-based tool (iPad) after new patient history and physical exam."
3104078|NCT01864395|Experimental|Control (CF)|Centrifugation Method (CF): currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
3104079|NCT01864395|Experimental|Online MUF|Online MUF: hemofilter is used online while the heart-lung machine is connected to the patient.
3104080|NCT01864395|Experimental|Offline MUF|Offline MUF: hemofilter is used offline when the heart-lung machine is not connected to the patient.
3104081|NCT01864382|Other|Standard Physiotherapy Exercises|Standard Physiotherapy Exercises 5 days a week during 5 weeks
3104082|NCT01864382|Experimental|Core stability|Core stability.5 days a week during 5 weeks
3104083|NCT01864369|Active Comparator|Control: eInfo + Usual Care|Usual Care + eInfo on general guidelines for heart healthy living
3104084|NCT01864369|Experimental|Behavioral: eCounseling + Usual Care|Behavioral:eCounseling + Usual Care: interactive web pages utilized to provide e-counseling messages and e-tools.
3104085|NCT01864356|Experimental|NT100 Dose 1|NT100 Dose 1
3104086|NCT01864356|Experimental|NT100 Dose 2|NT100 Dose 2
3104087|NCT01864356|Placebo Comparator|Placebo|Placebo
3104088|NCT01864343|Experimental|Pre- and perinterventional hypothermia|Cooling will be initiated by the application of cooling pads in the out-of-hospital setting followed by an infusion of 1000-2000ml of cold saline. In the cath lab a endovascular cooling catheter will be placed into the inferior vena cava via a femoral vein to achieve a core temperature of <35°C prior to revascularization.
3104089|NCT01864330|Experimental|Dry Eye Syndrome I|20 patients with moderate dry eye syndrome
3104090|NCT01864330|Active Comparator|Dry Eye Syndrome II|20 patients with moderate dry eye syndrome
3104091|NCT01864330|Active Comparator|Dry Eye Syndrome III|20 patients with moderate dry eye syndrome
3104092|NCT01864317|Experimental|Primary Open Angle Glaucoma|30 patients with primary open angle glaucoma
3104093|NCT01864317|Experimental|Normal Tension Glaucoma|30 patients with normal tension glaucoma
3104094|NCT01864317|Experimental|Ocular Hypertension|30 patients with ocular hypertension
3104095|NCT01864317|Other|Healthy subjects|30 healthy control subjects
3104096|NCT01864304||Williams Syndrome|Children and adults with Williams Syndrome
3104097|NCT01864304||Control Group|Controls will be recruited in 2 ways: 1) a gender matched and age- and BMI-similar control for each WS patient, and, 2) sibling controls when available
3104098|NCT01864291|Experimental|Non-NF2 ABI surgery|All subjects will be part of a single arm involving placement of the ABI541 Auditory Brainstem Implant (ABI) device. The Nucleus 24 was discontinued and is no longer available.
3104099|NCT01864278||Lutonix Drug Coated Balloon|Paclitaxel coated ballooncatheter
3104100|NCT01864265|Active Comparator|Certolizumab Pegol|
3104101|NCT01864265|Placebo Comparator|Placebo|
3104102|NCT01864252|Sham Comparator|Group 1 Control (65 patients)|Sham Remote ischaemic preconditioning with IV normal saline 2-5ml/hour.
3104103|NCT01864252|Active Comparator|Group 2 (65 patients)|Patients administered a Remote Ischaemic preconditioning protocol (three-5 min cycles of simultaneous inflation to cuffs placed on upper arm and thigh) prior to surgery and IV normal saline 2-5 mL/h during surgery.
3104104|NCT01864252|Experimental|Group 3 GTN (65 patients):|Patients administered sham simulated Remote Ischaemic Preconditioning protocol prior to surgery and IV Glyceryl Trinitrate 2-5ml/h during surgery.
3104105|NCT01864252|Experimental|• Group 4 RIPC+GTN (65 patients):|Patients administered Remote Ischaemic Preconditioning protocol and IV Glyceryl Trinitrate during surgery
3104106|NCT01864239|Experimental|Patient-centred tailored intervention|Medicines Advice Service
3104107|NCT01864239|No Intervention|Control|Usual care
3104108|NCT01864226|Placebo Comparator|Placebo|
3104109|NCT01864226|Experimental|RO5545965|
3104110|NCT01864213|Experimental|Ametop cream|
3104111|NCT01864200|Experimental|CroFab|crotalidae polyvalent immune fab (ovine) per approved labeling
3104112|NCT01864200|Placebo Comparator|Saline placebo|Saline placebo
3104113|NCT01864187|Experimental|Dexmedetomidine|Each team will be administered for 1μg/kg of dexmedetomidine eace one.
3104114|NCT01864174|Active Comparator|Arm 1: Metformin XR and Placebo matching with Metformin XR|"Metformin Extended Release (XR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks~Placebo matching with Metformin XR 0 mg tablets by mouth twice daily (BID) for 24 weeks"
3104289|NCT01862887|Experimental|PH-797804|Subjects will receive a single 24 mg dose in the fed state
3104117|NCT01864161|Active Comparator|endovenous iron|patients receive a total dose 1000 mg of intravenous iron gluconate divided into administrations of 125 mg diluted in 250 mL normal saline infused weekly for 3 months
3104118|NCT01864148|Experimental|BIIB033, 3 mg/kg|"BIIB033 3 mg/kg once every 4 weeks intravenous (IV) infusion up to Week 72.~Avonex once-weekly intramuscular (IM) injection up to Week 84."
3104119|NCT01864148|Experimental|BIIB033, 10 mg/kg|"BIIB033 10 mg/kg once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
3104120|NCT01864148|Experimental|BIIB033, 30 mg/kg|"BIIB033 30 mg/kg once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
3104121|NCT01864148|Experimental|BIIB033, 100 mg/kg|"BIIB033 100 mg/kg once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
3104122|NCT01864148|Placebo Comparator|Placebo|"Placebo once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
3104123|NCT01864135|Experimental|MRI|Comparison of targeted transrectal ultrasound guided prostate biopsies based on 3T multiparametric MRI findings to systematic non-targeted transrectal ultrasound guided prostate biopsies
3104124|NCT01864109|Experimental|Patients with localized disease|"Patients with localized disease will receive six cycles of the combination as maintenance therapy following standard chemotherapy.~Cycles 4-6 will include:~Ifosfamide 2,800 mg/m2/day on days 1-5~Etoposide 100 mg/m2/day on days 1-5~Cycle 7 will include :~Cyclophosphamide will be given on days 1 and 2 at a dose of 2,100 mg/m2/day, or for patients < 10 years of age at a dose of 70 mg/kg/day~Doxorubicin will be given on days 1 and 2 at a dose of 37.5 mg/m2/day~Vincristine will be given on day 1 at a dose of 2 mg/m2 or 0.067 mg/kg (whichever is lower, to a max dose of 2 mg)~Cycles 8-13 will include:~Irinotecan will be given on 10 days over weeks 1 and 2 of a cycle at a dose of 20 mg/m2/day intravenously~Temozolomide will be given daily on the first 5 days of irinotecan administration at a dose of 100 mg/m2/day orally or intravenously"
3104125|NCT01864109|Experimental|Patients with metastatic disease|"Patients will get 10 cycles of the combination intercalated between the final 4 cycles of standard chemotherapy.~Cycles 4, 5, 7, 8, 10, 11, 13, 14, 16, and 17 will include:~Irinotecan will be given on 10 days over weeks 1 and 2 of a cycle at a dose of 20 mg/m2/day intravenously~Temozolomide will be given daily on the first 5 days of irinotecan administration at a dose of 100 mg/m2/day orally or intravenously~Cycles 6, 9, and 12 will include:~Ifosfamide 2,800 mg/m2/day on days 1-5~Etoposide 100 mg/m2/day on days 1-5~Cycle 15 will include:~Cyclophosphamide will be given on days 1 and 2 at a dose of 2,100 mg/m2/day, or for patients < 10 years of age at a dose of 70 mg/kg/day~Doxorubicin will be given on days 1 and 2 at a dose of 37.5 mg/m2/day~Vincristine will be given on day 1 at a dose of 2 mg/m2 or 0.067 mg/kg (whichever is lower, to a max dose of 2 mg)"
3104126|NCT01864096|Experimental|Metformin|
3104127|NCT01864096|Placebo Comparator|Placebo|
3104128|NCT01864083|Experimental|Local staging patients|Breast MR and FACBC PET/PEM will be scheduled within one week of each other. Breast MR is a standard clinical examination and will be performed as standard.
3104129|NCT01864083|Experimental|Neoadjuvant chemotherapy patients|Baseline FACBC PET/PEM will be scheduled within 1 week of beginning neoadjuvant therapy. A repeat FACBC PET/PEM will be scheduled after the conclusion of neoadjuvant therapy, and before definitive surgical management.
3104130|NCT01864070|Experimental|TheraSphere + Everolimus|"Each cycle is 28 days. Target dose of TheraSphere is fixed at 120 Gy to entire tumor bearing portion of liver given at a single session on Cycle 1 Day 15. The dose of everolimus will be escalated in 2 sequential cohorts of 6 TheraSphere-treated patients each. Starting dose of everolimus is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg PO daily starting cycle 3 day 1.~Once DLT is defined or dose level 2 has been completed, a dose expansion cohort of 10 patients with advanced low to intermediate grade neuroendocrine tumor will be enrolled.~At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had."
3104131|NCT01864057|Active Comparator|Cambodian mothers|thiamine hydrochloride 100 mg orally daily for 5 days
3104132|NCT01864057|No Intervention|American mothers|Baseline blood and breast milk sample collection
3104133|NCT01864018|Experimental|Treatment (ixazomib citrate, cyclophosphamide, dexamethasone)|"INDUCTION THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15 and cyclophosphamide PO and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3104134|NCT01864005|Experimental|Ticagrelor|
3104135|NCT01864005|Active Comparator|clopidogrel|
3104136|NCT01863979||Acute Atrial Fibrillation|
3104137|NCT01863966|Experimental|Hot water drinking therapy|Hot water drinking before,after meal and before sleep
3104138|NCT01863966|Active Comparator|Pneumatic dilation|Patients who are unsatisfied with hot water drinking therapy are to receive standard pneumatic dilation
3104139|NCT01863953|Experimental|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
3104140|NCT01863953|Active Comparator|Bimatoprost Ophthalmic Solution 0.01% and Vehicle|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
3104141|NCT01863953|Active Comparator|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
3104142|NCT01863940|Experimental|Wound catheter|Wound catheters will be placed subcutaneously in the skin graft donor site in the lateral thigh while the patient remain intra-operative. The patients will receive a continuous infusion of procaine 0.5% at 4-5mL/hr using an elastomeric infusion device for 48 hours. Patients will be asked to asses pain on a 0-10 scale immediately prior to dressing changes, during dressing changes and 1 hour post dressing changes.
3104143|NCT01863940|No Intervention|Control|Patients will receive the standard of care pain medication regimen of Analgin/Metamizole 1 g IM and Ketorolac 3%- 30 mg IM for post-operative pain treatment. The patients will be asked to rate pain on a scale of 0-10 immediately prior to dressing changes, during dressing changes and 1 hour after dressing changes.
3104144|NCT01863927|Experimental|Research arm|Each of the participants will be randomly exposed to 4 conditions during four separate consecutive days.
3104335|NCT01862432|Experimental|immediate skin-to-skin|
3104145|NCT01863914|Placebo Comparator|Placebo|Placebo tablet contains only inactive ingredient. The placebo tablets will be taken once daily for 4 weeks (1 week before operation and 3 weeks after creation of AV fistula)
3104146|NCT01863914|Active Comparator|Rosuvastatin|Rosuvastatin (CrestorÒ, Astrazeneca) 5mg once daily for 4 weeks (1 week before operation and 3 weeks after creation of AV fistula)
3104147|NCT01863901|Experimental|Treatment with the Cryo-Touch III Device|
3104148|NCT01863888|Experimental|teriflunomide (HMR1726)|Participants administered 14mg Teriflunomide once daily, oral. For participants who permanently discontinue Teriflunomide, an accelerated elimination procedure with either cholestyramine or charcoal will be administered.
3104149|NCT01863888|No Intervention|Reference population|Untreated healthy subjects
3104150|NCT01863875||Childhood cochlear implant recipients|The sample includes all childhood cochlear implant (CI) recipients at Oslo University Hospital in Norway from 1988-2012. The participant must have at least one year of CI-user time. Possible sample size is 530 children. The age span is from 1 to 50 years.
3104151|NCT01863875||Normal hearing people|Reference group: A group of normal hearing people matching the target group on gender and age.
3104152|NCT01863862|Experimental|Clinical complete responders.|Patients with complete clinical response obtained 8 weeks after chemoradiation or 10 weeks after short-course radiation.
3104153|NCT01863849|Other|suspension for injection|
3104154|NCT01863836|Experimental|Fluoroscopy|Patients will undergo bronchoscopy and radial endobronchial ultrasound-guided biopsy of a peripheral lung lesion like patients in the other group. However, single-plane fluoroscopy will be used to help locate the lesion (with the help of a steerable curette) in case of failure to locate the lesion, and it will also be used to guide tissue sampling and ensure appropriate sampling tool function. Transbronchial biopsies, transbronchial needle aspiration, brushings, and bronchoalveolar lavage will be performed for each lesion.
3104155|NCT01863836|Active Comparator|No fluoroscopy|Patients will undergo biopsy of peripheral lung lesions using radial endobronchial ultrasound guidance only, without the use of fluoroscopy. Transbronchial biopsies, transbronchial needle aspiration, brushings, and bronchoalveolar lavage will be performed for each lesion.
3104156|NCT01863823|Other|Amoxicillin and Tetracyclines|drug treatment
3104157|NCT01863823|Other|Mouth washing|Mouth washing
3104158|NCT01863810|Experimental|KW21052|This arm will be pre-treated with Lyrica 150mg (75mg bid) for titration period of 1 week and then be treated with KW21052 300mg and Placebo of Lyrica for intervention period of 8 weeks.
3104159|NCT01863810|Active Comparator|LYRICA|This arm will be pre-treated with Lyrica 150mg (75mg bid) for titration period of 1 week and then be treated with Lyrica 300mg (150mg bid) and Placebo of KW21052 300mg for intervention period of 8 weeks.
3104160|NCT01863797|Active Comparator|Early induction|"Induction was performed if membranes were still intact and cervical dilation was less than four centimetres five hours after medication for therapeutic rest. For participants with an unripe cervix intravaginal prostaglandin E2 (PgE2, dinoproston) was used. A transcervical catheter (BARD) was inserted if this procedure was possible 19 and if cervical dilatation permitted, amniotomy was performed. The physician in charge performed all assessments and procedures except amniotomy.~When the participants reached the active phase they were monitored according to the clinical guidelines."
3104161|NCT01863797|Experimental|expectant management|The participants in the control group awaited spontaneous onset of labour as long as possible (expectant management). If contractions had ceased or subsided after the therapeutic rest women could be discharged from hospital, but were still included in the study. When reaching the active phase of labour women were monitored according to the clinical guidelines.
3104162|NCT01863784|Experimental|JNJ-38518168|
3104163|NCT01863771|Experimental|Golimumab|
3104164|NCT01863771|Placebo Comparator|Placebo|
3104165|NCT01863758|Experimental|Human-cl rhFVIII|Up to 60-80 IU/kg of intravenous Human-cl rhFVIII was administered at an individually determined dose and dose interval.
3104166|NCT01863745|Experimental|nilotinib|16 patients who are currently enrolled in a Novartis- sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study receiving nilotinib and has fulfilled all their requirements in the parent study will be enrolled.
3104167|NCT01863732|Experimental|Secukinumab 75 mg|Secukinumab in PFS for s.c. self-administration Q4W
3104168|NCT01863732|Experimental|Secukinumab 150 mg|Secukinumab in PFS for s.c. self-administration Q4W
3104169|NCT01863719|Experimental|Cohort 1|9 Subjects
3104170|NCT01863719|Experimental|Cohort 2|9 Subjects
3104171|NCT01863719|Experimental|Cohort 3|9 Subjects
3104172|NCT01863719|Experimental|Cohort 4|12 Subjects
3104173|NCT01863706|Experimental|Misoprostol|400µg oral misoprostol
3104174|NCT01863706|Active Comparator|Oxytocin|20 IU oxytocin
3104175|NCT01863693||Cohort|
3104176|NCT01863680|Experimental|COL-1620|
3104177|NCT01863667|Experimental|Omarigliptin|Participants receive an omarigliptin (MK-3102) 25 mg capsule once weekly and glimepiride placebo tablet(s) once daily, for 54 weeks.
3104178|NCT01863667|Active Comparator|Glimepiride|Participants receive glimepiride 1 mg and/or 2 mg tablet(s) (maximum dose 6 mg/day) once daily and an omarigliptin placebo capsule once weekly, for 54 weeks.
3104179|NCT01863654|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3104180|NCT01863654|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3104181|NCT01863641|Experimental|treatment group|Patients will receive calcitriol at a fixed dose daily.
3104182|NCT01863641|Active Comparator|control group|Patients will receive placebo daily.
3104183|NCT01863628|Placebo Comparator|psychoeducation|including delivering knowledge on symptoms, discussion of suffering mental difficulties, and general coping techniques
3104184|NCT01863628|Experimental|aerobic exercise|The aerobic exercise would include cycling, jogging, table tennis,and playing badminton for 40 mins at least 3 times per week for 3 months. In each exercise, participants are supposed to exercise to the extent of getting sweaty
3104185|NCT01863615|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3104186|NCT01863615|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3104290|NCT01862887|Experimental|Moxifloxacin|Subjects will receive a single 400 mg dose in the fed state
3104187|NCT01863602||Subjects prescribed lamotrigine tablets|Subjects with epilepsy with partial seizures, tonic-clonic seizuresm or generalized seizures of Lennox-Gastaut syndrome to whom lamotrigine tablets are administered.
3104188|NCT01863589||Subjects prescribed adefovir tablets|Subjects with chronic hepatitis B or hepatic cirrhosis B to whom adefovir tablets are administered
3104189|NCT01863576|Active Comparator|Omega-3|This group is receiving omega-3 supplement.
3104190|NCT01863576|Placebo Comparator|Oil Corn|This group is receiving the placebo comparator.
3104191|NCT01863563|Experimental|QuickClot|QuickClot sponge will be applied for one minute each site of tonsillectomy and Adenoidectomy.
3104192|NCT01863550|Experimental|Arm A (bortezomib, lenalidomide, dexamethasone)|Patients receive bortezomib SC or IV on days 1, 4, 8, and 11 of courses 1-8 and days 1 and 8 of courses 9-12; lenalidomide PO daily on days 1-14; and dexamethasone PO daily on days 1, 2, 4, 5, 8, 9, 11, and 12 of courses 1-8 and days 1, 2, 8, and 9 of courses 9-12. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
3104193|NCT01863550|Experimental|Arm B (carfilzomib, lenalidomide, dexamethasone)|Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16; lenalidomide PO daily on days 1-21; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
3104194|NCT01863550|Experimental|Arm C (lenalidomide)|Patients receive lenalidomide PO daily on days 1-21. Treatment repeats every 4 weeks for 24 courses in the absences of disease progression or unacceptable toxicity.
3104195|NCT01863550|Experimental|Arm D (lenalidomide)|Patients receive lenalidomide PO daily on days 1-21. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3104196|NCT01863537|Experimental|Intervention|Multimedia Connect and the Multimedia facilitator training curriculum with a 4-day, face-to-face structured orientation and training for implementation, and planned, investigative team initiated telephone consultations with CBO staff to provide technical assistance at 2 and 4 months following the training workshop;
3104197|NCT01863537|Active Comparator|Traditional Connect|The original, manualized version of Connect (CDC DEBI)and manualized facilitator training curriculum with a 4-day, face-to-face structured orientation and training for implementation, and planned, investigative team initiated telephone consultation with CBO staff to provide technical assistance at 2 and 4 months following the training workshop.
3104198|NCT01863511|Active Comparator|usual care|IV loop diuretics
3104199|NCT01863511|Active Comparator|Usual care plus tolvaptan|IV loop diuretic plus Tolvaptan 30 mg orally once daily
3104200|NCT01863511|Active Comparator|ultrafiltration|Volume removal through a brachial line extended length catheter or a quad lumen catheter via the internal jugular vein
3104201|NCT01863498|Active Comparator|PCA pain control|Patients will have PCA for pain control
3104202|NCT01863498|Active Comparator|Epidural pain control|Patients will have an epidural for pain control
3104203|NCT01863485|Experimental|CM082|CM082 tablet
3104204|NCT01863472|Active Comparator|HeartLight(TM) Laser Balloon|Safety and efficacy of pulmonary vein isolation using the HeartLight(TM) Laser Balloon (endoscopically guided ablation)
3104205|NCT01863472|Active Comparator|irrigated radiofrequency current ablation|Safety and efficacy of pulmonary vein isolation using the irrigated radiofrequency current ablation
3104206|NCT01863459|Experimental|Lidexamfetamine Dimesylate|"Lisdexamfetamine dimesylate (Vyvanse) is a central nervous system (CNS) stimulant, approved for the treatment of ADHD Lisdexamfetamine dimesylate is to be started at a dose of 30 mg/day for one week, increased to 50 mg/day for week 2 and to 70 mg/day for week 3. Doses are increased to the maximally tolerated/efficacious dose. Thirty milligrams of Lisdexamfetamine dimesylate per day, is the minimum dose that must be achieved.~Duration of treatment in this arm is 8 weeks; tablet is taken once per day"
3104207|NCT01863459|Placebo Comparator|Placebo|"Placebo will be dosed in the same fashion as the active intervention - 3 potential dose levels.~Placebo is taken once per day for 8 weeks"
3104208|NCT01863446|Experimental|Lighting1|Ocular light exposure of a red wavelength light for one or two nights
3104209|NCT01863446|Experimental|Lighting2|Ocular light exposure of a blue-green wavelength light for one night
3104210|NCT01863446|Experimental|Lighting3|Ocular light exposure to a red wavelength light on night 1 and to a blue-green wavelength light on night 2
3104211|NCT01863433|Experimental|Trivalent Influenza Vaccine|The study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
3104212|NCT01863420||Rectal cancer patients|For rectal cancer patients before surgery, IMRT is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.The dose constraints for active bone marrow are V5<95%, V10<88%,V20<80%,V30<65%, V40<45%.
3104213|NCT01863420||Gastric cancer patients|For gastric cancer patients after surgery and chemotherapy,the 4500 cGy of radiation was delivered in 25 fractions, five days per week. Concurrent chemotherapy regimen is monotherapy with capecitabine 1600mg∙m2 twice a day (b.i.d.).The dose constraints for active bone marrow are V5<90%, V10<80%,V20<70%,V30<55%, V40<35%.
3104214|NCT01863407|Experimental|DAM Solution|Preheated to a temperature level, mixed the DAM Solution 2ml and Normal Saline 250ml, poured into abdominal cavity and infiltrate the operative field before the abdominal closure
3104215|NCT01863407|Placebo Comparator|Normal Saline|Preheated the Normal Saline 250ml to a temperature level, poured into abdominal cavity and infiltrate the operative field before the abdominal closure
3104216|NCT01863394|Active Comparator|Screening by community health workers|"One Community Health Worker (CHW) will be trained per village in the comparator arm. The training the CHWs receive will be identical to that delivered in the Community Management of Acute Malnutrition program run by ALIMA/BEFEN (Bien Être de la Femme et l'Enfant Niger) over the last 3 years. This involves 6 hours theoretical training and a practical session in the health centre.~CHWs will screen children 06-59 months in their village once a month"
3104291|NCT01862887|Experimental|Placebo|Subjects will receive a single placebo dose
3104292|NCT01862874|Experimental|V501|Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
3104217|NCT01863394|Experimental|Screening by mothers|"Mothers in the intervention health district will be trained in small womens' groups in their village. Training will have a theoretical component and a practical demonstration component on children in the village~During the first baseline door to door mass screening campaign, mothers will also receive individual training on conducting a Mid Upper Arm Circumference (MUAC) classification and looking for pedal oedema. they will receive a brief recap during the three monthly door-to-door mass screening campaigns~Mothers will be asked to check their child's MUAC and look for pedal oedema~whenever the child does not seem to be in 'good health' to the mother~whenever the mother feels that the child is 'unwell' or 'sick'~whenever it seems to the mother that her child has lost weight~whenever the mother thinks that it is necessary to do so"
3104218|NCT01863381|Experimental|Hydrocephalus/Pseudotumor|Patients between the ages of 18-65 years with suspected hydrocephalus or idiopathic intracranial hypertension (IIH), also known as pseudotumor cerebri, who are recommended by their doctor based on standard clinical criteria to undergo intracranial pressure monitoring. The interventions include tympanic membrane displacement (TMD) and DPOAE.
3104219|NCT01863368|Experimental|Systane Ultra|Systane® ULTRA lubricant eyedrops, 1 drop in each eye 4 times a day for 35 days (Phase I), followed by 55 days additional use as needed (Phase II).
3104220|NCT01863368|Active Comparator|Optive|OPTIVE® lubricating eyedrops, 1 drop in each eye 4 times a day for 35 days (Phase I), followed by 55 days additional use as needed (Phase II).
3104221|NCT01863355|Experimental|B0|(basal rate 0cc/hr, bolus 3cc, lockout time 10min)
3104222|NCT01863355|Active Comparator|BL|(basal rate 1cc/hr, bolus 2cc, lockout time 10min)
3104223|NCT01863355|Active Comparator|BH|(basal rate 2cc/hr, bolus 1cc, lockout time 10min)
3104224|NCT01863342||CSI score < 40|CSI cutoff value<40
3104225|NCT01863342||Group 2: CSI score ≥ 40|CSI cutoff value≥40
3104226|NCT01863329||both optic nerve sheath diameter|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
3104227|NCT01863316|Experimental|1) I gel group|using supraglottic airway I gel
3104228|NCT01863316|Active Comparator|2) LMA Supreme group|using supraglottic airway LMA Supreme
3104229|NCT01863290||Former inmates|Former inmates with a chronic disease condition or aged 50 years and above engaged into primary care through an innovative primary care redesign model of the Transitions Clinic Network.
3104230|NCT01863277|Active Comparator|Melatonin|Melatonin 14mg/daily given over 14 days
3104231|NCT01863277|Placebo Comparator|sugar pill|sugar pill given over 14 days
3104232|NCT01863264|Experimental|Cold Thin Liquid Barium|"Poland Spring Natural Spring Water will be placed in a refrigerator set to 36 °F, this will allow the water to cool to approximately 4-9 °C. As described by several authors, these waters will be used to mix the barium powder (Varibar® Thin Liquid Barium Sulfate for Suspension) to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula.~the infant will be required to swallow 5 boluses of this cold liquid barium while bottle feeding."
3104233|NCT01863251|Experimental|Atomoxetine|Patients assigned to atomoxetine will receive atomoxetine 40 mg daily, beginning on Day 5. Atomoxetine dose will be increased to 80 mg daily for all patients beginning on Day 12. Atomoxetine will be increased to 120 mg daily for patients with persistent ATS use after 4 weeks of treatment.
3104234|NCT01863251|Placebo Comparator|Placebo|Placebo inactive medication
3104235|NCT01863238||Ivacaftor Treated|
3104236|NCT01863225|Experimental|Group A|RVX000222 200 mg (100 mg b.i.d.) + Atorvastatin 40 mg
3104237|NCT01863225|Experimental|Group B|RVX000222 200 mg (100 mg b.i.d.) + Rosuvastatin 20 mg
3104238|NCT01863225|Experimental|Group C|RVX000222 200 mg (100 mg b.i.d.) + Atorvastatin 80 mg
3104239|NCT01863225|Experimental|Group D|RVX000222 200 mg (100 mg b.i.d.) + Rosuvastatin 40 mg
3104240|NCT01863212|Experimental|Risk allele carriers|Individuals homozygous for the risk allele (A/A) The interventions administrated to this group: 'Blood sampling for genetic analyse', 'Stroop test', 'fMRI'
3104241|NCT01863212|Experimental|Non risk allele carriers|Individuals homozygous for the non-risk allele (T/T) The interventions administrated to this group: 'Blood sampling for genetic analyse', 'Stroop test', 'fMRI'
3104242|NCT01863199|Active Comparator|Lucentis every 4 weeks|Lucentis 0.5mg administered intravitreally every four weeks for 12 months
3104243|NCT01863199|Active Comparator|Lucentis every 12 weeks|Lucentis 0.5mg administered intravitreally every 12 weeks
3104244|NCT01863199|Experimental|Treat and extend|Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.
3104245|NCT01863186|Active Comparator|Lofexidine HCl (2.4mg dose)|225 subjects will be randomized to receive 2.4 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 2.4 mg (one tablet in each dose will be a placebo tablet to maintain the blind) for up to 7 days.
3104246|NCT01863186|Active Comparator|Lofexidine HCl (3.2mg dose)|225 subjects will be randomized to receive 3.2 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 3.2 mg for up to 7 days.
3104247|NCT01863186|Placebo Comparator|Placebo|150 subjects will be randomized to receive placebo during the double-blind period of the study. Subjects will take 4 tablets QID for up to 7 days.
3104248|NCT01863186|Other|Open Label Lofexidine HCl|During the open-label portion of the study, subjects will be given the option to receive lofexidine HCl tablets for up to 7 days. Dosing regimens are at the discretion of the Investigator.
3104249|NCT01863173|Active Comparator|metoprolol|patient or intervention group
3104250|NCT01863173|Active Comparator|placebo group|control group
3104251|NCT01863160|Other|0.1% ZEP-3 cream|250 mg of ZEP-3 Cream 0.1% is applied on the right ventral forearm and 250 mg placebo is applied on the left ventral forearm 4 times daily
3104252|NCT01863160|Other|placebo|250 mg of ZEP-3 Cream 1.0% is applied on the right ventral forearm and 250 mg placebo is applied on the left ventral forearm 4 times daily
3104253|NCT01863147|Experimental|Sitagliptin|Sitagliptin 0.1 daily for 1 year
3104254|NCT01863147|Active Comparator|acarbose|acarbose 150mg daily for 1 year
3104293|NCT01862874|Placebo Comparator|Placebo|Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
3104255|NCT01863134|Experimental|Eptifibatide|Patients were given a bolus of eptifibatide (Integrillin; 180µg/kg of body weight) and an intravenous infusion of 2 µg/kg/min followed by acetylsalicylic acid (150mg orally daily until the day of the procedure) and enoxaparin (1mg/kg subcutaneous - with the last dose 12 hours before surgery).
3104256|NCT01863134|Placebo Comparator|Placebo|Patients were given placebo infusion (0,9% Natrium Chloride) and an intravenous infusion of 2 µg/kg/min followed by acetylsalicylic acid (150mg orally daily until the day of the procedure) and enoxaparin (1mg/kg subcutaneous - with the last dose 12 hours before surgery).
3104257|NCT01863121||Cirrhotic Patients|Patients of cirrhosis
3104258|NCT01863108|Experimental|GeniusVac-Mel4|Sub-cutaneous injections of GeniusVac-Mel4 in patients with melanoma.
3104259|NCT01863095|Experimental|Lifestyle counseling|MJ users assigned to this condition will participate in 4 individualized intervention sessions that are based on Motivational Interviewing principles. They will receive personalized feedback on their MJ use and will be provided a smart phone app on which they report their MJ use episodes, which also is designed to promote the use of exercise/physical activity as an alternative to MJ use. Level of Physical activity will be measured using accelerometers.
3104260|NCT01863095|Active Comparator|Personalized Feedback only|MJ users assigned to this condition will participate in 4 individualized intervention sessions that are based on Motivational Interviewing principles. They will only receive personalized feedback on their MJ use.
3104261|NCT01863082|Experimental|exercise|the patients will be submitted to an exercise protocol
3104262|NCT01863056|Experimental|Intervention during Period 1|Cross-over trial: so this group got the intervention in period 1 and didn't get the intervention in period 2 (serving as control for self).
3104263|NCT01863056|Experimental|Intervention during period 2|Cross-over trial: so this group got the intervention in period 2 and didn't get the intervention in period 1 (serving as control for self).
3104264|NCT01863043|Active Comparator|Routine aspiration of gastric contents|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
3104265|NCT01863043|Experimental|No aspiration of gastric contents|Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
3104266|NCT01863030||Phasix mesh|Mesh being used for approved use. Mesh for ventral and incisional hernias.
3104267|NCT01863017|Sham Comparator|Sham tDCS|Five consecutive sessions of no tDCS. Each session will last approximately 30 minutes. Current will be applied for 20 minutes. Less than 3 minutes of tDCS has been shown to induce no lasting effects. Normal weight control participants will receive one sham session and one active session.
3104268|NCT01863017|Experimental|Active tDCS|Five consecutive sessions of tDCS administered. Each session will take about 30 minutes. Normal weight control participants will receive one sham session and one active session.
3104269|NCT01863004|Experimental|Bortezomib (Velcade®)|"This study tests whether salvage of mis-sense mutated dysferlin through proteasomal inhibition seen in cultured muscle cells can be translated into patients harboring dysferlin mis-sense mutations. The proteasomal inhibitor Bortezomib (Velcade®) is already approved as a medication for the treatment of multiple myeloma in Switzerland and in other countries.~Following an administration of a single dose of Bortezomib repeated needle muscle biopsies and blood draws will be performed to assess dysferlin levels in skeletal muscle and blood monocytes over a five day period."
3104270|NCT01862991|Placebo Comparator|Dilapan-Placebo|The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S)(4mm x 65mm). The patient will be administered a placebo pill orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
3104271|NCT01862991|Active Comparator|Dilapan-Mifepristone|The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator.Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
3104272|NCT01862991|Experimental|Mifepristone|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
3104273|NCT01862978|Experimental|Heparin|Patient receiving Heparin
3104274|NCT01862978|Experimental|Nadroparin|Patient receiving nadroparin
3104275|NCT01862978|Placebo Comparator|Placebo|Patients receiving placebo
3104276|NCT01862965|Experimental|PredEver|Prednisone and Everolimus
3104277|NCT01862952|Active Comparator|antiepileptic treatment as used in daily clinical practice|Antiepileptic treatment as used in daily clinical practice.
3104278|NCT01862952|No Intervention|No medication|
3104279|NCT01862939|Experimental|part 1 DS-7309 ascending dose|1, 2.5, 5, 10, 20 mg blinded DS-7309 powder in bottle.
3104280|NCT01862939|Experimental|part 2 DS-7309|1, 2.5, 5, and 15mg DS-7309 powder in bottle for oral solution.
3104281|NCT01862939|Placebo Comparator|part 2 placebo|placebo to match part 2 DS-7309
3104282|NCT01862926|Experimental|Rituximab|1g given at baseline and two weeks.
3104283|NCT01862926|Active Comparator|Cyclophosphamide|Intravenous dose of 600 mg/m2 body surface area. 6 doses given 4 weekly.
3104284|NCT01862913|Experimental|Computer-assisted CBT|"Usual medical treatment in accordance with a decision algorithm based on the Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile.~Eight sessions of a computer-assisted cognitive-behavioral therapy. Trained psychologists administer this program in face to face meetings."
3104285|NCT01862913|Active Comparator|Usual care treatment|"- Usual psychological and medical treatment in accordance with a decision algorithm based on the Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile."
3104286|NCT01862900|Experimental|15 Gy|Patients receive a radiation dose of 15 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
3104287|NCT01862900|Experimental|20 Gy|Patients receive a radiation dose of 20 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
3104288|NCT01862900|Experimental|25 Gy|Patients receive a radiation dose of 25 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
3104295|NCT01862835|Experimental|Degarelix/Te/placebo/ placebo|Degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral placebo once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
3104296|NCT01862835|Experimental|degarelix/Te/anastrozole/ placebo|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral anastrozole 2.0 mg once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
3104297|NCT01862835|Experimental|degarelix/Te/ anastrozole/E2 patch|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral anastrozole 2.0 mg once daily x 22 days; and an E2 patch calibrated to deliver 0.05 mg/day E2 beginning on day 1 and changed every 3 days through day 22.
3104298|NCT01862835|Experimental|degarelix/ placebo/placebo/no patch|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; placebo i.m. given on day 1, 8 and 15; Oral placebo once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
3104299|NCT01862822|Experimental|upright position|Upright position during urine bag collection
3104300|NCT01862822|No Intervention|usual position|
3104301|NCT01862796|Experimental|Obese|Obese randomized to received a 35% calorie reduced diet
3104302|NCT01862796|Experimental|Obese: WMEN|Randomized to receive a weight-maintaing diet
3104303|NCT01862796|Experimental|Lean|Normal weight individuals receiving a weight-maintaining energy needs diet
3104304|NCT01862718|Experimental|1|Ablation plus radiation
3104305|NCT01862705|Experimental|Thoracic spine manipulation thrust|Thoracic spine manipulation thrust
3104306|NCT01862705|Sham Comparator|Thoracic spine manipulation non-thrust|Thoracic spine manipulation non-thrust
3104307|NCT01862692|Active Comparator|Developmental Awareness Skils|
3104308|NCT01862692|Experimental|Baby-Net condition|
3104309|NCT01862679|Experimental|8 weeks HF haemodialysis / 8 weeks HD-filtration|8 weeks high-flux haemodialysis followed by 8 weeks haemodiafiltration
3104310|NCT01862679|Experimental|8 weeks HD-filtration /8 weeks HF haemodialysis|8 weeks haemodiafiltration followed by 8 weeks high-flux haemodialysis
3104311|NCT01862653|Experimental|Auricular Acupuncture|An insomnia auricular acupuncture protocol will be administered for 30 minutes, three times per week, for three weeks in the intervention group.
3104312|NCT01862653|No Intervention|Control|The control group is a wait-list control group and will be offered the auricular acupuncture intervention after the study is complete. No intervention will be performed on control group.
3104313|NCT01862640|Placebo Comparator|Placebo|Matching Placebo Once-Daily
3104314|NCT01862640|Experimental|brexpiprazole 1mg|titrate up from 0.25 mg/day brexpiprazole to 1 mg/day brexpiprazole
3104315|NCT01862640|Experimental|brexpiprazole 2mg|titrate up from 0.25 mg/day brexpiprazole to 2 mg/day brexpiprazole
3104316|NCT01862627||Macular retinoschisis and detachment|
3104317|NCT01862601|Experimental|JetTouch injections|
3104318|NCT01862562|Active Comparator|Open surgery|Conventional procedure
3104319|NCT01862562|Experimental|Laparoscopic surgery|Minimum invasive procedure
3104320|NCT01862549|Experimental|DBT for children|Dialectical Behavior Therapy for children is a 26 session intervention (it consists of 2 pre-treatment sessions and 24 treatment sessions; treatment sessions are to be delivered in 30 weeks total) with once per week meetings, including 30 min. individual child therapy, 20 min. meeting with a caregiver and 40 min. of skills training with both.
3104321|NCT01862549|Active Comparator|TAU|Children in active comparison conditions will receive Treatment as Usual (TAU) that primarily consists of supportive individual psychotherapy and adjunctive family interventions. Individual therapy included cognitive behavioral skills training (e.g., psychoeducation, cognitive modifications, thought blocking) and non-directive supportive therapy. Family therapy includes parenting skills training (e.g., limit setting, reinforcement techniques), structuring household environment, and safety planning.
3104322|NCT01862536|Placebo Comparator|Placebo|Placebo tablet
3104323|NCT01862536|Experimental|Tadalafil|Daily use of tadalafil (study drug) at 40 mg orally.
3104324|NCT01862523|Placebo Comparator|diluent|diluent
3104325|NCT01862523|Experimental|capsaicin|capsaicin
3104326|NCT01862523|No Intervention|control healthy volunteers|control healthy volunteers
3104327|NCT01862497||Carvedilol (for Aim 3 only)|"Eligible case subjects from aims 1-2 will participate in a randomized crossover study where each subject will receive carvedilol and prazosin for 8 weeks each(under randomized treatment sequence) with a 1 week washout period included in between treatments.~The first arm will include subjects that are assigned to the randomization sequence: Carvedilol x 8 weeks (titrated up to 50 mg po bid), washout x 1 week, Prazosin x 8 weeks (titrated up to 16 mg daily)"
3104328|NCT01862497||Prazosin (for Aim 3 only)|"Eligible case subjects from aims 1-2 will participate in a randomized crossover study where each subject will receive carvedilol and prazosin for 8 weeks each(under randomized treatment sequence) with a 1 week washout period included in between treatments.~The first arm will include subjects that are assigned to the randomization sequence: Prazosin x 8 weeks, washout x 1 week, Carvedilol x 8 weeks"
3104329|NCT01862484|Experimental|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
3104330|NCT01862484|Sham Comparator|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet.
3104331|NCT01862471|Experimental|DVT prophylaxis|"Neuromuscular electrical stimulation using a custom-built, two-channel stimulator (Duo-STIM (stimulator), Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation was applied every 20 seconds over a period of 5 minutes.~Intermittent pneumatic compression using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 1 second duration over a period of 5 minutes."
3104332|NCT01862458|Active Comparator|tPA alone|tPA alone used to treat empyema
3104333|NCT01862458|Experimental|tPA plus dornase|tPA plus dornase used to treat empyema
3104334|NCT01862445||Study group|Patients receiving Chlorambucil plus Rituximab
3104336|NCT01862432|No Intervention|control|
3104337|NCT01862419|Experimental|Alert|Text page sent to patient's covering provider and unit pharmacist informing them of the presence of AKI as detected by changes in serum creatinine.
3104338|NCT01862419|No Intervention|Usual Care|Usual care arm. No alert will be provided to the patient's covering provider or unit pharmacist.
3104339|NCT01862406|Experimental|Generic Label|Purportedly generic version of the analgesic presented
3104340|NCT01862406|Active Comparator|Brand-name Label|actual brand-name analgesic presented
3104341|NCT01862393|Experimental|400 microseconds|Electrically-induced torque generated with stimulus phase duration set at 400 microseconds.
3104342|NCT01862393|Experimental|700 microseconds|Electrically-induced torque generated with stimulus phase duration set at 700 microseconds.
3104343|NCT01862393|Experimental|1000 microseconds|Electrically-induced torque generated with stimulus phase duration set at 1000 microseconds.
3104344|NCT01862380|Experimental|Cases|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively in female patients with non classical 21-hydroxylase deficiency.
3104345|NCT01862380|Experimental|Control|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively in healthy female controls.
3104346|NCT01862367||rFXIII|
3104347|NCT01862354|Active Comparator|Group TAP block|Patients in this group received a transverse abdominal plan block with local anesthetics and clonidine as postoperative analgesia.
3104348|NCT01862354|Active Comparator|Group : Continuous wound infusion|Patients in this group received continuous wound infusion with local anesthetics and clonidine as postoperative analgesia.
3104349|NCT01862341|Experimental|Milk powder|ANMUM In-Shape Nutritional Milk Powder for Active Mothers. The dose of the milk powder is 40g added to 200ml of drinkable water and will be taken twice a day.
3104350|NCT01862328|Experimental|MLN4924 and Docetaxel (Arm 1)|
3104351|NCT01862328|Experimental|MLN4924 + Paclitaxel + Carboplatin (Arm 2)|
3104352|NCT01862328|Experimental|MLN4924 + Gemcitabine (Arm 3)|
3104353|NCT01862315|Experimental|No prior chemo or responded/stable with prior chemo|All patients receive HAI FUDR ([0.12 mg/kg/day kg 30] / pump flow rate)& dexamethasone ({1 mg/m2/day30} pump flow rate) on Day 1 of each cycle. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. All patients receive Gemcitabine (800 mg/m2 IV over 30 minutes) & Oxaliplatin (85 mg/m2 IV over 120 minutes) on Days 1 & 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, & then every 2 weeks thereafter. Clinical MRI examinations of the abdomen & pelvis are obtained at baseline following surgery, prior to treatment initiation & 4 weeks after initiation of HAI FUDR. Subsequently, the patient will undergo MRI approximately at months 3, 6 & 9 thereafter A non-contrast CT of chest, abdomen & pelvis will also be obtained as part of routine clinical care.
3104354|NCT01862315|Experimental|patients who have failed systemic therapy|All patients receive HAI FUDR ([0.12 mg/kg/day kg 30] / pump flow rate)& dexamethasone ({1 mg/m2/day 30}/ pump flow rate) on day 1 of each cycle. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. All patients receive Gemcitabine (800 mg/m2 IV over 30 minutes) & Oxaliplatin (85 mg/m2 IV over 120 minutes) on Days 1 & 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, & then every 2 weeks thereafter. Clinical MRI examinations of the abdomen & pelvis are obtained at baseline following surgery, prior to treatment initiation & 4 weeks after initiation of HAI FUDR. Subsequently, the patient will undergo MRI approximately at months 3, 6 & 9 thereafter A non-contrast CT of chest, abdomen & pelvis will also be obtained as part of routine clinical care.
3104355|NCT01862315|Experimental|pts who have had prior oxaliplatin & have existing neuropathy|All patients receive will receive gemcitabine alone with HAI FUDR/Dex Gemcitabine (800 mg/m2 IV over 30 minutes) alone on Days 1 and 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, and then every 2 weeks thereafter.
3104356|NCT01862302|Active Comparator|Haloperidol|Haloperidol 1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
3104357|NCT01862302|Placebo Comparator|Placebo|1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
3104358|NCT01862289|Experimental|Severe uncontrolled asthma|Asthmatics patients with uncontrolled symptoms despite a daily treatment by high doses of inhaled steroids and LABA. Diagnostic of chronic hyperventilation syndrome.
3104359|NCT01862263|Experimental|Vildagliptin|Vildagliptin 50 mg twice daily (bid) + Insulin 20 to 40 IU/day
3104360|NCT01862263|Placebo Comparator|Placebo|Insulin 20 to 40 IU/day + Vildagliptin Placebo twice daily (bid)
3104361|NCT01862250|Experimental|Clonidine infants with HIE|Infants in this group will receive Intravenous clonidine at 1µg/kg/dose either every 6 or 8 hrs from the start of cooling to the end of re-warming
3104362|NCT01862237|Experimental|Patients with type II diabetes|Type II diabetes patients with aortic valve stenosis referred for aortic valve replacement.
3104363|NCT01862237|Experimental|Patients without type II diabetes|No type II diabetes patients with aortic valve stenosis referred for aortic valve replacement.
3104364|NCT01862224|Experimental|JNJ-38518168|JNJ-38518168 30 mg once daily for 52 weeks.
3104365|NCT01862224|Placebo Comparator|Placebo/JNJ-38518168|Matching placebo once daily for 12 weeks followed by JNJ-38518168 30 mg once daily for 40 weeks.
3104366|NCT01862211|Experimental|members of family of children with a DA1AT|
3104367|NCT01862211|Experimental|children with a DA1AT|
3104368|NCT01862198|Experimental|hybrid metallic stent|Patients group who were inserted a hybrid metallic stent
3104369|NCT01862185|Experimental|semi-quantitative procalcitonin|patients whom checked semi-quantitative procalcitonin examination
3104370|NCT01862185|No Intervention|control|patients whom do not checked semi-quantitative procalcitonin examination
3104371|NCT01862172|Other|additional MRI|
3104372|NCT01862159||Operated patients|Patients undergoing laparoscopic gastric bypass surgery between 1st of May 2007 until 30th of september 2012
3104373|NCT01862146||Current Smoker underwent TCA|subjects who smokes daily
3104375|NCT01862133||Patient Preferences|Patients were eligible if they had visited their primary care physician at least twice in the previous 1 year and were fluent in English. Each patient subject used an online program to record their preferences what each of their providers can see. The electronic medical record (EMR) will then apply them to data displays.
3104376|NCT01862133||Primary Care Providers|All healthcare providers (physicians, nurses, and other clinic staff) were eligible to participate in this study. For those enrolled, display of patient data in the EMR was dictated by the patient subject's preferences for who should see what data.
3104377|NCT01862120|Experimental|interleukin-2|Dose D1 of interleukin-2
3104378|NCT01862120|Experimental|Dose D2 of interleukin-2|Dose D2 of interleukin-2
3104379|NCT01862120|Experimental|Dose D3 of interleukin-2|Dose D3 of interleukin-2
3104380|NCT01862120|Placebo Comparator|placebo|placebo
3104381|NCT01862081|Experimental|Arm A: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily for 21 consecutive days (beginning from Day 1) in each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
3104382|NCT01862081|Experimental|Arm B: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily for 28 consecutive days (beginning from Day 1) in each 28-day cycle along with Paclitaxel on Days 1, 8, 15 and 22 of each 28-day cycle.
3104383|NCT01862081|Experimental|Arm C: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Day 1 and Days 8-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
3104384|NCT01862081|Experimental|Arm D: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Days 2-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
3104385|NCT01862081|Experimental|Arm E: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Days 1-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
3104386|NCT01862081|Experimental|Arm F: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily on a 5-days on, 2-days off schedule in each 28-day cycle along with Paclitaxel on Days 1, 8, 5 and 22 of each 28-day cycle.
3104387|NCT01862081|Experimental|Arm G: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily on a 3-days on, 4-days off schedule in each 28-day cycle along with Paclitaxel on Days 1, 8, 5 and 22 of each 28-day cycle.
3104388|NCT01862068||GPA patients|GPA patients with an active disease at inclusion
3104389|NCT01862068||MPA patients|
3104390|NCT01862068||Healthy Blood Donors|
3104391|NCT01862068||Atherosclerotic patients|
3104392|NCT01862068||EGPA (Eosinophilic Granulomatosis With Polyangiitis)|
3104393|NCT01862055||SAS cohort|Consecutive patients undergoing planned cesarean section under spinal anesthesia
3104394|NCT01862042|Other|Supportive and Palliative care|A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
3104395|NCT01862029|Experimental|Roflumilast|
3104396|NCT01862016|Active Comparator|VAC mode, Controlled ventilation|From randomization, patients are put under controlled ventilation with specific settings
3104397|NCT01862016|Experimental|APRV mode, Spontaneous breathing|During 1 to 3 hours after randomization, patients are put under controlled ventilation with specific settings for baseline data. After that, they are placed under APRV mode with specific settings
3104398|NCT01862003|Experimental|Arm 1|AZD8931 160 mg bd, on days 1-4, + FOLFIRI in a 2 weekly schedule
3104399|NCT01861990|Experimental|Treatment arm|All participants will be enrolled on to one, open-label arm. Participants will be treated with valproic acid in addition to standard of care therapy.
3104400|NCT01861977|Experimental|Cognitive Behavioral Therapy|Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.
3104401|NCT01861977|Active Comparator|Informational Workshop|Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
3104402|NCT01861964|Placebo Comparator|Sugar Pill|
3104403|NCT01861964|Active Comparator|Xylooligosarcharide 2.8g|Xylooligosarcharide 2.8grams
3104404|NCT01861964|Active Comparator|Xylooligosarcharide 1.4g|
3104405|NCT01861951|Experimental|Pazopanib|"Pazopanib 800 mg, p.o., daily~Duration of treatment:~Until disease progression, treatment failure, or death due to any cause, whichever occurs first"
3104406|NCT01861951|Active Comparator|Doxorubicin|"Doxorubicin 75 mg/m² BSA, d1, q3wk, i.v.~Duration of treatment:~Six cycles (approximately 18 weeks) or until disease progression, treatment failure, or death due to any cause, whichever occurs first"
3104407|NCT01861938|Experimental|Melanoma vaccine|
3104408|NCT01861925||Normal eye|Astigmatism smaller than 1.5 diopters
3104409|NCT01861925||Large regular astigmatism|Astigmatism of > 1.5 diopters, regular astigmatism.
3104410|NCT01861925||Large irregular astigmatism|Astigmatism of > 1.5 diopters, irregular astigmatism.
3104411|NCT01861912|Active Comparator|Arsenic trioxide TACE|Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.
3104454|NCT01861639|Experimental|Effective rTMS - Active TBS - EEG|
3104455|NCT01861639|Sham Comparator|ineffective rTMS - Sham TBS - EEG|
3104456|NCT01861639|Sham Comparator|Effective rTMS - Sham TBS - EEG|
3104457|NCT01861626|Other|sequence 1 : Test drug - Reference|
3104458|NCT01861626|Other|Sequence 2 : Reference - Test drug|
3104459|NCT01861613|Experimental|HBV vaccine|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)
3104412|NCT01861912|Experimental|Arsenic trioxide TACE+IV|"Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.~Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9% sodium chloride solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE."
3104413|NCT01861899||SI-Joint Dysfunction|Device- SI-LOK
3104414|NCT01861886|Experimental|ESS505|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
3104415|NCT01861873|Other|liver metastases|measuring liver function by PET/CT at patients where SBRT is planned for liver metastases
3104416|NCT01861860|Experimental|New OPERA Criteria|TAXUS™ Element long stent
3104417|NCT01861847|Placebo Comparator|Placebo Group|Placebo Comparator
3104418|NCT01861847|Active Comparator|Drug group|7 Keto-DHEA
3104419|NCT01861821|Active Comparator|Multiport flexible catheter|Multiport flexible catheter has three ports for the delivery of epidural medication for labor analgesia
3104420|NCT01861821|Active Comparator|Uniport flexible catheter|Uniport flexible catheter has one port for the delivery of epidural medication for labor analgesia
3104421|NCT01861808|Other|lumbar puncture|That's not really an arm label because the only intervention on the patients is the lumbar puncture
3104422|NCT01861795||Preterm Neonates|Preterm neonates born at or above 27+0 weeks of gestational age sufficiently stable on nasal continuous positive airway pressure (CPAP) will be treated by standard of care.
3104423|NCT01861782|Experimental|Dead Sea Solar and Water Treatment|Dead Sea Solar and Water Treatment
3104424|NCT01861782|Experimental|Sulfur Pool & Medicinal Mud|Sulfur Pool & Medicinal Mud
3104425|NCT01861769|Experimental|Technology-enhanced Teleconsultation|Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.
3104426|NCT01861769|Experimental|Standard Teleconsultation|Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
3104427|NCT01861769|No Intervention|No consultation|No Consultation/Fidelity Monitoring Only. Participants assigned to this condition will receive no post-workshop expert consultation, but will be subject to the same audiorecorded session-uploading and client-outcome reporting as the other conditions. This condition allows us to assess the effect of clinicians knowing that their sessions are subject to fidelity assessment.
3104428|NCT01861756|Experimental|Diabetes Medication Choice Decision Aid|
3104429|NCT01861756|No Intervention|Standard care|
3104430|NCT01861743|Experimental|Multimodal analgesia|multiple analgesic medications utilized in a synergistic manner to control pain while minimizing side-effects of individual drugs due to decreased doses. This includes pre-operative patient education, intra-operative pain management and post-operative pain protocols.
3104431|NCT01861743|Active Comparator|Patient Controlled analgesia|Pain management using patient controlled narcotic analgesia.
3104432|NCT01861730|Experimental|Cohort 1 Aeras404 (5ug H4/100nmol IC31) or Placebo|1 Dose; Subject ≥ 168 to ≤ 196 days of age
3104433|NCT01861730|Experimental|Cohort 2 AERAS-404 (5ug H4/500nmol IC31) or Placebo|1 Dose; Subject ≥ 168 to ≤ 196 days of age
3104434|NCT01861730|Experimental|Cohort 3A AERAS-404 (5ug H4/500nmol IC31) or Placebo|2 Doses; Subject ≥ 168 to ≤ 189 days of age
3104435|NCT01861730|Experimental|Cohort 3B AERAS-404 (15ug H4/500nmol IC31) or Placebo|2 Doses; Subject ≥ 168 to ≤ 189 days of age
3104436|NCT01861730|Experimental|Cohort 4 AERAS-404 (15ug H4/500nmol IC31) or Placebo|3 Doses; Subject ≥ 84 to ≤ 98 days of age
3104437|NCT01861730|Experimental|Cohort 5 AERAS-404 (50ug H4/500nmol IC31) or Placebo|3 Doses; Subject ≥ 84 to ≤ 98 days of age
3104438|NCT01861730|Experimental|Cohort 6 AERAS-404 (dose level pending) or Placebo|3 Doses; Subject ≥ 64 to ≤ 83 days of age
3104439|NCT01861717|Experimental|Somatuline Depot SC|Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.
3104440|NCT01861704|Active Comparator|Lyric|Silver Lyric device
3104441|NCT01861704|Active Comparator|Lyric2|Lyric2 (Barracuda) device
3104442|NCT01861691|Active Comparator|Open surgery|Open colectomy
3104443|NCT01861691|Experimental|Laparoscopic surgery|Laparoscopic colectomy
3104444|NCT01861678|Active Comparator|High tie of IMA|In High tie group, IMA was transected at its origin from the abdominal aorta.
3104445|NCT01861678|Experimental|Low tie of IMA|In the low tie of the IMA, IMA was separated after branching to the left colic artery. The lymph node dissection around the IMA at its origin was performed.
3104446|NCT01861665|Active Comparator|Marcaine administered pre-incision.|Pre-operative administration, using both the specific drug - Marcaine 0.25%- and total amount - 5cc per incision.
3104447|NCT01861665|Active Comparator|Marcaine administered post-incision|Marcaine 0.25% administered post-incision, total amount 5cc per incision.
3104448|NCT01861652|Experimental|Venous health systems Vasculaire leg compression device|Vasculaire leg compression device
3104449|NCT01861639|Experimental|ineffective rTMS - Active TBS - fMRI|
3104450|NCT01861639|Experimental|Effective rTMS - Active TBS - fMRI|
3104460|NCT01861600|Experimental|Experimental (EF) 1|For 8 weeks, infants will consume ad libitum per day S-26 Gold EF1
3104461|NCT01861600|Active Comparator|Standard Formula|For 8 weeks, infants will consume ad libitum per day. S-26 Gold
3104462|NCT01861600|Experimental|Experimental 2 (EF2) S-26 Gold|For 8 weeks, infants will consume ad libitum per day. S-26 Gold EF2
3104463|NCT01861600|Other|Human milk (HM)|For 8 weeks, infants will consume ad libitum per day. Human Milk
3104464|NCT01861600|Experimental|Experimental formula (EF) 3|For 8 weeks, infants will consume ad libitum per day. S-26 Gold EF3
3104465|NCT01861587|Experimental|Real tDCS:Active Comparator|For Real tDCS, stimulation will be delivered in 20-minute-sessions using 2mA current. The anode will be placed over left BA9 or the motor cortex corresponding with the painful area (if applicable). The cathode will be placed over right BA43 (for GI pain) or right BA9 (located via the international 10-20 EEG system).
3104466|NCT01861587|Experimental|Sham tDCS: Sham Comparator|For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
3104467|NCT01861574|Experimental|Both Real TMS|Participants in the Both Real TMS group receive 20 minutes of Real TMS 45 minutes after gastric-bypass surgery and then another 20 minutes of Real TMS 4 hours after surgery.
3104468|NCT01861574|Sham Comparator|Sham then Real TMS|Participants in the Sham then Real TMS group, receive Sham TMS 45 minutes after gastric-bypass surgery and 20 minutes of Real TMS 4 hours after surgery.
3104469|NCT01861574|Sham Comparator|Real then Sham TMS|Participants in the Real then Sham TMS group receive 20 minutes of Real TMS 45 minutes after gastric-bypass surgery and then 20 minutes of Sham TMS 4 hours after surgery.
3104470|NCT01861574|Sham Comparator|Both Sham TMS|Participants in the Both Sham TMS group, receive Sham TMS 45 minutes after gastric-bypass surgery and then another 20 minutes of Sham TMS 4 hours after surgery
3104471|NCT01861561|Experimental|Low-dose intravenous cyclophosphamide|Low-dose intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months for 7 doses. Total duration is 6 months for the induction treatment.
3104472|NCT01861561|Active Comparator|High-dose intravenous cyclophosphamide|High-dose intravenous cyclophosphamide 1,000 mg/m2/dose, the first dose will be started with 500 mg/m2/dose and steped up to 750 mg/m2/dose for the second dose. Then the dosage will be increased to 1,000 mg/m2/dose for the third dose and continued the dosage through the seventh dose. Total duration is 6 months for the induction treatment.
3104473|NCT01861548||Children (up to 24 months after birth)|Investigators include into the study children delivered from women observed starting from between 8-12 weeks of single pregnancy, not assisted with reproductive technology, and not expected to be finished as spontaneous abor-tion. All women with the serious chronic diseases specified in study protocol such as diabetes, hypertension, nephrop-athy, epilepsy and cancer are excluded from the study. The same refers to suspicion of serious child malformations known to exist at the inclusion into the study.
3104474|NCT01861535|Experimental|Primary Imiquimod|Treatment with imiquimod will be patient self-administered for a period of 4 months with possible extension to 6 months. A thin layer of imiquimod cream should be applied to the lesion and remain overnight without a cover. Application will be once a week for 2 weeks, then twice a week the following 2 weeks and, if tolerated, 3 times a week for the last weeks. In case of severe side-effects the number of applications can be reduced; a treatment-free period of no more than 1 week is permitted
3104475|NCT01861535|Active Comparator|Primary surgery|The type of surgery (excision or ablation) will be based on clinical findings and surgeon`s judgement. After excision the specimen will be histologically analyzed to assess resection margins and rule out invasion.
3104476|NCT01861522|Experimental|TAU-284|Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
3104477|NCT01861522|Placebo Comparator|Placebo|Two placebo tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
3104478|NCT01861509|Experimental|BP-C1 IM Injections|BP-C1 given in daily intramuscular doses of 0.035 mg/kg bodyweight in one syringe per day during a total treatment of 32 days.
3104479|NCT01861496|Experimental|LiPlaCis|Dose escalation of LiPlaCis - a liposomal formulation of cisplatin will be administered intravenously in cycles every 3 weeks on day 1, day 8. Upon the investigator's judgement the patient may continue treatment for more than 3 cycles when benefiting from the study drug.
3104480|NCT01861470||Preterm infants|all <32 weeks
3104481|NCT01861457|Experimental|Nozin® Nasal Sanitizer®|Non-antibiotic, alcohol-based antiseptic
3104482|NCT01861457|Placebo Comparator|Phosphate-buffered saline|Placebo
3104483|NCT01861444||Cohort|
3104484|NCT01861431|Active Comparator|HIVSRR|4 sessions of HIV sexual risk reduction
3104485|NCT01861431|Experimental|HIVSRR + Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
3104486|NCT01861418|Placebo Comparator|Sham manipulation|Each participant will lie in a supine position. The treating investigator (TI) will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The TI will side bend the participant's spine towards the non-painful side, reach through the participant's hands and perform a spinal rotation away from the painful side. The TIs other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side. Lastly, the TI will take up the slack and maintain the pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If the participant can tolerate the pressure for at least 5 seconds. Then, the subjects will be re-positioned to the starting position.
3104487|NCT01861418|Experimental|Lumbopelvic Manipulation, Chicago|Each participant will lie in supine position. The treating investigator (TI) will stand opposite of the low back pain. Participant will clasp his/her hand behind the neck. TI will side bend the participant's spine toward non-painful side, reach through participant's hands and perform a spinal rotation away from the painful side. TI's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side. The TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from the participant and the TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
3104592|NCT01860716|Placebo Comparator|Solution for infusion|Solution for infusion administrated via nasogastric tube
3104488|NCT01861405||Cerebral metastases subjects|Prior to each subject's radiation treatment (either whole brain radiation therapy or stereotactic radiosurgery), he/she will have fMRI scanning and neuropsychological testing and conduct a quality of life assessment. Each subject will then have standard of care WBRT or SRS treatment. Following WBRT or SRS treatment, subjects will have 4 month follow up fMRI scanning, and have neuropsychological testing and a quality of life assessment 4 months and 12 months post treatment.
3104489|NCT01861405||Healthy participants|Healthy control subjects will be matched by age, gender, education, ect. to cerebral metastases subjects. Each will have fMRI scannings (3 total), neuropsychological testings (3 total), and quality of life assessments (3 total) at the same time points as their matched cerebral metastases subject.
3104490|NCT01861392|Active Comparator|sensory-motor training|Guidelines + sensory-motor training.Evaluation Biomechanical data will be collected (balance, baropodometry, electromyography strength and joint position sense), as well as questionnaires ADDQoL and BESTest. The intervention will be twice a week for 45 minutes for 12 weeks, divided into three phases: heating, sensory-motor training and cool-down, with monitoring of blood pressure and blood glucose.
3104491|NCT01861392|Active Comparator|guidelines|receive the same guidelines and reviews that group orientation and training sensorineural engine and will be guided home exercises for postural twice a week 45 minutes for 12 weeks.
3104492|NCT01861379|Experimental|Ghost Ileostomy|The patients were subjected to laparoscopic anterior rectal resection with performance of ghost ileostomy
3104493|NCT01861379|Placebo Comparator|No protective stoma|The patients were subjected to laparoscopic anterior rectal resection without simultaneous construction of any protective stoma.
3104494|NCT01861366|Experimental|External facilitator|The external facilitation is a one year multifaceted intervention, including support, guidance, practice audit and feedback, training targeted to a team of practitioners involving the unit manager, the nurses and diet aides at the nursing home. The facilitator is a researcher and dietician.
3104495|NCT01861366|Active Comparator|Educational outreach visit|The outreach visit is a three hour lecture about the nutritional guidelines targeted to a team of practitioners including the unit manager, the nurses and diet aides at the nursing home. The trained person giving the lecture is a researcher and dietician.
3104496|NCT01861353|Experimental|Cranberry-lingonberry juice|"Cranberry-lingonberry juice. Cranberry 12.8%, Lingonberry 12.4%, together 38g/l, contains added sugars 10g/dL.~Dose is 5 mL/kg/day, max. 300 ml/day per day. Juice was manufactured and donated by Eckes-Granini, Finland"
3104497|NCT01861353|Placebo Comparator|Placebo juice|"Contains no cranberry or lingonberry extracts. Added sugars 10g/dL (same as in the active juice group). Contains natural cranberry flavour and red anthocyanin colour. Contains 5.5 g/L citric acid. Has been tested by chemists and does not contains PAC-compounds which are thought to be the main active compound in cranberry juice.~Placebo juice was manufactured by Eckes-Granini. Dose is 5 mL/kg/day, max. 300 mL/day."
3104498|NCT01861340|Experimental|Lenalidomide, Dexamethasone, and MEDI-551|Eligible patients will receive Lenalidomide and dexamethasone as per standard of care guidelines for 2 cycles. Patients with a clinical response to lenalidomide and dexamethasone after 2 cycles will proceed to get MEDI-551 for 2 cycles. MEDI-551 will be dosed at 4mg/kg IV on days 1 and 8 of cycle 3 and 4mg/kg IV on day 1 of cycle 4.
3104499|NCT01861327|Experimental|lower limb angioplasty with CO2|lower limb angioplasty made with carbon dioxide as contrast media
3104500|NCT01861327|Active Comparator|lower limb angioplasty with Iodine|lower limb angioplasty made with Iodine as contrast media
3104501|NCT01861327|Experimental|aorto-iliac angioplasty with CO2|aorto-iliac angioplasty made with carbon dioxide as contrast media
3104502|NCT01861327|Active Comparator|aorto-iliac angioplasty with Iodine|aorto-iliac angioplasty made with Iodine as contrast media
3104503|NCT01861327|Experimental|endovascular AAA correction with CO2|endovascular abdominal aortic aneurysm (AAA) correction made with carbon dioxide as contrast media
3104504|NCT01861327|Active Comparator|endovascular AAA correction with Iodine|endovascular abdominal aortic aneurysm (AAA) correction made with Iodine as contrast media
3104505|NCT01861314|Experimental|Treatment (bortezomib, sorafenib tosylate, decitabine)|"STEP A: Patients receive bortezomib SC on days 1 and 4, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 5-14.~STEP B: Patients receive bortezomib SC on days 1, 4, and 8 or 1, 4, 8 and 11, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 9-18 or 12-21.~STEP C: Patients receive bortezomib SC on days 1, 4, and 8 or 1, 4, 8 and 11, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 5-14.~Treatment repeats every 28 days for up to 4 courses in the absence of unacceptable toxicity. Patients achieving CR or CRi receive maintenance therapy comprising decitabine IV on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3104506|NCT01861301|Experimental|Treatment (tivantinib)|Patients receive tivantinib 360 PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
3104507|NCT01861288||Adults and children with and without IBD|"The study includes adult and pediatric patients with and without IBD who, as part of an ongoing investigation or treatment, have to undergo a sigmoidoscopy (for children: colonoscopy).~Inclusion of adult patients, age 15-67 years: 50 patients with UC in remission, 50 patients with active UC, 50 patients without IBD~Inclusion of pediatric patients, <15 years: We expect to include: 10 UC / CD patients in remission,10 UC / CD patients in relapse,10 non-IBD patients."
3104508|NCT01861275||Nasal CPAP|We want to study the nasal-cpap treatment and it`s compliance in sleep apnea patients with ischaemic stroke.
3104509|NCT01861275||no Nasal CPAP|No nasal-cpap in sleep apnea patients with ischaemic stroke.
3104510|NCT01861262|Experimental|Measurement of StO2|The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
3104511|NCT01861249|Experimental|SAR339658|SAR339658, every 2 weeks (Q2W) or every 4 weeks (Q4W) according to clinical response at Week 8 in the ACT12688 trial
3104512|NCT01861236||Advanced Prostate Cancer|Advanced Prostate Cancer that receive Firmagon therapy in the context of usual clinical practice
3104513|NCT01861223|Experimental|afatinib + nimotuzumab|
3104514|NCT01861210|Experimental|Couples Counseling and Testing|Couples Voluntary HIV Counseling and Testing, adapted for use with male couples from the standard African couples testing service.
3104515|NCT01861210|Active Comparator|Individudal Counseling and Testing|"Individual Voluntary Counseling and Testing involves HIV testing and individual, client-centered HIV prevention counseling. This service is provided by counselors trained in Centers for Disease Control and Prevention's Fundamentals of HIV Prevention Counseling training."
3104516|NCT01861197|Experimental|Dovitinib monotherapy|
3104517|NCT01861184||LRTI group|Non-pneumonic LRTI (no radiological consolidation but the presence of clinical signs) or community acquired pneumonia (radiological consolidation) Able to give fully informed consent (mental capacity assessed using trust guidelines) Age>18yrs old Fluent English speaker
3104518|NCT01861184||Control group|Able to give fully informed consent (mental capacity assessed using trust guidelines) Age>18yrs old Fluent English speaker
3104519|NCT01861171|Placebo Comparator|Placebo|Crossover randomized controlled double-blinded trial. Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
3104520|NCT01861171|Active Comparator|Green Tea|Crossover randomized controlled double-blinded trial. Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
3104521|NCT01861158|Experimental|Parenting Wisely|Immediate access to the online Parenting Wisely program
3104522|NCT01861158|Active Comparator|Parenting Wisely + Community Forum|Immediate access to the online Parenting Wisely program, as well as access to a community form where parents can receive social support from other online users of the program and a moderator
3104523|NCT01861158|No Intervention|Delayed Parenting Wisely|Delayed (6-month) access to the Parenting Wisely program. Parents will receive access to PW after the final, 6-month, follow-up assessment.
3104524|NCT01861145|Active Comparator|Bed Alarm|Patients in the control arm will use only the bed alarm for treatment of their enuresis
3104525|NCT01861145|Experimental|Bed alarm + intranasal steroids|"Intervention: Nasonex (Mometasone furoate aqueous nasal spray) Children 5-11: 50 mcg/metered spray, 1 sprays in each nostril daily for 3 months in conjunction with nightly use of the bed alarm.~Children ≥ 12: 50 mcg/metered spray, 2 sprays in each nostril daily for 3 months in conjunction with nightly use of the bed alarm."
3104526|NCT01861132||Healthy pregnant women|Healthy pregnant women for C-section under spinal anesthesia
3104527|NCT01861119|Experimental|Silicone gel|Silicone gel (Kelo-cort™; Advanced Bio-Technologies, Silverdale, WA, USA) From the day of suture removal, the treatment was applied three times daily for 3 months.
3104528|NCT01861119|Active Comparator|Onion extract gel|Onion extract gel (Contractubex™; Merz Pharma, Frankfurt, Germany) From the day of suture removal, the treatment was applied three times daily for 3 months.
3104529|NCT01861119|No Intervention|No treatment|Subjects who assigned In the no treatment group did not receive any topical scar emollients.
3104530|NCT01861106|Active Comparator|Group A|10/10 HLA Matched Related Donor or Unrelated DonorTransplant.
3104531|NCT01861106|Active Comparator|Group B|9/10 HLA Matched Related Donor or Unrelated Donor Transplant
3104532|NCT01861106|Active Comparator|Group C|Haploidentical Related Donor Transplant
3104533|NCT01861106|No Intervention|Group E|Donor
3104534|NCT01861080||incident hypertensives|"Inclusion Criteria:~age≧30years~primary incident hypertension~signed informed consent"
3104535|NCT01861067|Experimental|LESS-TLH|laparoendoscopic single-site (LESS) total laparoscopic hysterectomy (TLH)
3104536|NCT01861067|Active Comparator|LESS-LAVH|laparoendoscopic single-site (LESS) laparoscopically-assisted vaginal hysterectomy (LAVH)
3104537|NCT01861054|Experimental|Treated patients|Patients eligible will be treated with Reparixin as add-in monotherapy
3104538|NCT01861041|Experimental|Heavy Bupivacain, Local anesthetic, Amp|Heavy bupivacaine 7.5 mg (1.5 ml), 20 microgram fentanyl(0.4 ml), 1.1 ml saline , Total 3 ml
3104539|NCT01861041|Active Comparator|Isobaric spinal, Local anesthetic, Amp|7,5 mg isobaric bupivacaine, 20 microgram (0.4 ml)fentanyl, 1.1 ml saline, Total 3 ml
3104540|NCT01861028||Phase I|A series of 50 consecutive primary iTotal patients will be compared to assess the fit of the tibial tray intra-operatively. These patients will have a series of tibial templates from Standard TKR implant sets trialed on the operative knee. Each template will be optimally sized and positioned based on the surgeon's judgment. Implant fit data (overhang and underhang) on the tibia for all templates will be taken from intra-operative measurements
3104541|NCT01861028||Phase II|The Phase I (50 consecutive primary iTotal patients) will also have implant fit data assessed for the femur. After final implantation is complete measurement will be assessed and recorded. A series of 25 primary knees that are scheduled for Standard TKR implants will then undergo the same measurements of the femur.
3104542|NCT01861015|Experimental|Epinephrine|In the epinephrine group, we used a dilute epinephrine, 0.5 mg of epinephrine ([1/2] vial of 1mg/mL) in 50 mL of saline solution, taking care to use no more than 20 mL of solution per a subject.
3104543|NCT01861015|Active Comparator|Vasopressin|In the vasopressin group, a dilute vasopressin, 5 units in 50 mL of saline solution, taking care to use no more than 20 mL of solution per a subject was injected.
3104544|NCT01861002|Experimental|Dose Level 1|"Azacytidine 75 mg/m2/day~Fludarabine 30 mg/m2/dose~Cytarabine 2000 mg/m2/dose"
3104545|NCT01861002|Experimental|Dose Level 0|"Azacytidine 50 mg/m2/day~Fludarabine 30 mg/m2/dose~Cytarabine 2000 mg/m2/dose"
3104546|NCT01860989|Experimental|Cohort 1|6-12 subjects with Plasmodium falciparum malaria will receive 75 mg KAE609 as a single dose
3104547|NCT01860989|Experimental|Cohort 2|6-12 subjects with Plasmodium falciparum malaria will receive 150 mg KAE609 as a single dose
3104548|NCT01860989|Experimental|Cohort 3|6 to 12 subjects with Plasmodium falciparum malaria will receive 225 mg KAE609 as a single dose
3104549|NCT01860989|Experimental|Cohort4|6- 12 subjects with Plasmodium falciparum malaria will receive 300 mg KAE609 as a single dose
3104550|NCT01860976|Experimental|Abatacept|Abatacept 125 mg/syringe (125 mg/mL) solution subcutaneously once a week for 168 days double blind/197 days open label/365 days long term extension
3104551|NCT01860976|Placebo Comparator|Placebo|Placebo matching with Abatacept 0 mg solution subcutaneously once a week 168 days double blind
3104552|NCT01860963|Active Comparator|IBD patients on immunosuppression|Patients on azathioprine/6-mercaptopurine (6MP), prednisone, methotrexate, infliximab, adalimumab, certolizumab, natalizumab, and etanercept are included.
3104553|NCT01860963|Active Comparator|IBD patients off immunosuppressants|Patients off immunosuppressants, on 5-aminosalicylic acid (5-ASA) agents, antibiotics, or no treatment for IBD are included.
3104554|NCT01860963|Active Comparator|Healthy controls|Age-matched healthy controls enrolled from the hospital, outpatient clinics, and from the general public via flyers and online advertisements.
3104555|NCT01860950|Experimental|Real TDCS: Active Comparator|20 minutes real transcranial Direct Current Stimulation (tDCS)
3104556|NCT01860950|Experimental|Sham TDCS: Sham Comparator|20 minutes sham transcranial Direct Current Stimulation (tDCS)
3104557|NCT01860937|Experimental|Cohort 1 (MRD)|Patients with no morphologic evidence of disease at the time of T cell infusion, (<5% blasts in the bone marrow) as assessed by morphology or flow cytometry. Participating site PI to determine cohort stratification in the event of morphology/flow cytometry blast count discrepancy. Cohort 1 patients will receive conditioning chemotherapy followed by 1x10^6 19-28z+ T cells/kg over 1 to 2 days. During formulation of End of Production (EOP) T cells, under or over estimation of CAR modified T-cells may occur. Patients may receive an altered fractionation of the total doses (e.g. ½ on Day 0 and ½ on Day +1) or up to 35% over total cell dose with approval by the participating site PI. In both cohorts, patients will be allowed to receive a 2nd treatment of 19-28z+ T cells if they benefited from the first infusion and did not experience any non-hematologic grade 4 toxicities.
3104558|NCT01860937|Experimental|Cohort 2 (Morphologic Disease)|Pts with morphologic evidence of disease at the time of T cell infusion, (≥5% blasts in the bone marrow) as assessed by morphology or flow cytometry. Participating site PI to determine cohort stratification in the event of morphology/flow cytometry blast count discrepancy. Pts with increased blasts (5-10% blasts) that are immunophenotypically consistent with recovering marrow from prior re-induction chemo may be treated under Cohort 1 with approval of the participating site PI. Cohort 2 pts will get conditioning chemo followed by 1x10^6 19-28z+ T cells/kg over 1 to 2 days. During formulation of EOP T cells, under or over estimation of CAR modified T-cells may occur. Pts may get up to 35% over total cell dose with approval by the participating site PI. Both cohorts, pts will be allowed to receive a 2nd treatment of 19-28z+ T cells if they benefited from the first infusion & did not experience any non-hematologic grade 4 toxicities.
3104559|NCT01860924|Active Comparator|health education|health education control
3104560|NCT01860924|Experimental|exercise|vigorous supervised exercise
3104561|NCT01860911|Experimental|Insulin-Sensitive|One group consists of insulin sensitive volunteers.
3104562|NCT01860911|Experimental|Insulin-Resistant|One group consists of insulin resistant volunteers.
3104563|NCT01860898|Other|Skin Biopsy|
3104564|NCT01860885||Patients requiring naloxone for respiratory depression|
3104565|NCT01860872||CF Group|Cystic Fibrosis group with MRI and CT of chest
3104566|NCT01860872||Control group|Non-CF controls will have MRI and no CT of chest
3104567|NCT01860872||Combined Group|MRI Quality & Image Relatedness
3104568|NCT01860859|Other|Unlocked double layer|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium avoiding the inclusion of the decidua and a second unlocked continuous suture that approximate the upper portion of the myometrium.
3104569|NCT01860859|Other|Locked single layer closure|As reported in Williams Obstetrics textbook
3104570|NCT01860859|Other|Locked double layer|Double layer closure with a first continuous locked suture and a second imbricating continuous suture.
3104571|NCT01860846||Participants with moderate to severe Crohn's Disease|Participants for whom the treating physician had recently initiated an anti-Tumor Necrosis Factor (TNF) treatment
3104572|NCT01860833|Active Comparator|diclofenac 75 mg/day|diclofenac 75 mg once day slow release
3104573|NCT01860833|Active Comparator|diclofenac 150 mg/day|diclofenac 75 mg bid
3104574|NCT01860833|Active Comparator|ibuprofen 1200 mg/day|ibuprofen 600 mg bid
3104575|NCT01860833|Active Comparator|ibuprofen 1800 mg/day|ibuprofen 600 mg tid
3104576|NCT01860833|Active Comparator|celecoxib 200 mg/day|celecoxib 200 mg once day
3104577|NCT01860833|Active Comparator|celecoxib 400 mg/day|celecoxib 200 mg bid
3104578|NCT01860820|No Intervention|Best Medical Therapy|Participants will follow standard post-transplant protocols with IPC
3104579|NCT01860820|Active Comparator|Geko device|Participants will be fitted with the device to ensure that it functions according to the manufacturer's instructions by a trained technician. This device will be changed every 24 hours. The device is worn on both legs and is worn for 24 hours a day. The device will first be put on the first day following the day of surgery and will then be changed the following day at the same time for a total of 7 days after surgery.
3104580|NCT01860807|Experimental|Ibudilast|Ibudilast 50 mg twice daily
3104581|NCT01860807|Placebo Comparator|Placebo|matching placebo twice daily
3104582|NCT01860794|Other|Mesencephalic Neuronal Precursor Cells|
3104583|NCT01860781|Experimental|paliperidone palmitate|paliperidone palmitate
3104584|NCT01860768||acute aortic dissectin patients|definite diagnosis by computed tomography arteriography (CTA).
3104585|NCT01860768||acute chest pain patients|aortic dissection is exclude by aorta CTA
3104586|NCT01860755|Experimental|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport. This group also received the control intervention.
3104587|NCT01860755|Active Comparator|Control|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
3104588|NCT01860742|Active Comparator|Interferon alpha-2b|Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day until progression or unacceptable adverse event from a clinical or a patient point of view.
3104589|NCT01860742|Active Comparator|177Lu-DOTATATE|intravenous injection of 177Lu-octreotate with simultaneous infusion of an aminoacid solution
3104590|NCT01860729|Experimental|Anacetrapib|100 mg tablet, oral, once daily for 24 weeks
3104591|NCT01860729|Placebo Comparator|Placebo|Matching tablet to Anacetrapib 100 mg, oral, once daily for 24 weeks
3104593|NCT01860716|Experimental|Melatonin|30 mg melatonin administrated via nasogastric tube in the Intensive Care Unit when included in the study and 30 mg melatonin 60 minutes before transfer to the operating room.
3104594|NCT01860703|Experimental|Arm A - Maximum Therapeutic Dose|Single dose of 33 mg/kg rounded to the nearest 250 mg of deferiprone tablets
3104595|NCT01860703|Experimental|Treatment Arm B - Supratherapeutic Dose|Single dose of 50 mg/kg rounded to the nearest 250 mg of deferiprone tablets
3104596|NCT01860703|Experimental|Arm C - Placebo Control|Single dose of matching deferiprone and moxifloxacin placebo tablets.
3104597|NCT01860703|Experimental|Arm D - Positive Control|Single dose of one 400 mg moxifloxacin tablet.
3104598|NCT01860690|Experimental|MTX , treatment outcome|patient receiving MTX. in a dosage of 50 mg/m^2 , IM , in single dose
3104599|NCT01860677|Active Comparator|Active stimulation|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies. The device has been designated by the FDA to be minimally invasive and has FDA approval to be used to reduce symptoms associated with anxiety, depression, pain and insomnia. The unit is locked at the factory to deliver a maximal output of 4 mA of current and has a timer that prevents it from staying on longer than 20 minutes. Current will be limited to a maximum of 2 mA.
3104600|NCT01860677|Placebo Comparator|Sham stimulation|Participants are outfitted with a device that is identical to the Fisher Wallace Cranial Stimulator in appearance but does not deliver any current.
3104601|NCT01860664|Experimental|hydrocortisone ophthalmic ointment 0.5%|Topical ophthalmic corticosteroid ointment, is produced in a concentration of 0.5% of hydrocortisone Acetate in a vehicle composed of mineral oil and white petrolatum
3104602|NCT01860664|Placebo Comparator|Placebo|mineral oil and white petrolatum
3104603|NCT01860651|Active Comparator|Web-monitoring|"There is two arms for intervention:~1) Patients in treatment with medicine administrated at home and 2) patients in treatment with biologicals."
3104604|NCT01860651|No Intervention|Control|"Patients in treatment with medicine administrated at home: routine outpatient controls, four times a year.~Patients in treatment with biologicals: retrospective routine treatment algorithm"
3104605|NCT01860638|Experimental|First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC|Participants will receive first-line treatment with radiotherapy, temozolomide, and bevacizumab. All three treatments will be given concurrently for the first 6 weeks, followed by 6 cycles (28 days each) of temozolomide plus bevacizumab, followed by bevacizumab monotherapy until PD1 or unacceptable toxicity. At PD1, participants randomized to bevacizumab will receive bevacizumab plus lomustine until PD2. Following PD2, participants will continue with blinded bevacizumab with the addition of appropriate SOC. Following PD3, for subsequent treatment lines blinded bevacizumab may continue or open-label bevacizumab may be given at the discretion of the investigator and the participant.
3104606|NCT01860638|Placebo Comparator|First-Line Bevacizumab followed by Placebo + Lomustine/SOC|Participants will receive first-line treatment with radiotherapy, temozolomide, and bevacizumab. All three treatments will be given concurrently for the first 6 weeks, followed by 6 cycles (28 days each) of temozolomide plus bevacizumab, followed by bevacizumab monotherapy until PD1 or unacceptable toxicity. At PD1, participants randomized to placebo will receive placebo plus lomustine until PD2. Following PD2, participants will continue with blinded placebo with the addition of appropriate SOC. Following PD3, for subsequent treatment lines blinded bevacizumab may continue or open-label bevacizumab may be given at the discretion of the investigator and the participant.
3104607|NCT01860625|Experimental|1(12.5㎠)|"drug : 9 people, 43.75mg/12.5㎠~placebo : 3 people, 12.5㎠"
3104608|NCT01860625|Experimental|2(25㎠)|"drug : 9 people, 87.5mg/25㎠~placebo : 3 people, 25㎠"
3104609|NCT01860625|Experimental|3(50㎠)|"drug : 9 people, 175mg/50㎠~placebo : 3 people, 50㎠"
3104610|NCT01860612|Experimental|PMA Cohort|Study participants that meet the inclusion/exclusion criteria for the study may be enrolled in the compassionate use treatment arm. The artificial iris will be implanted in the eye with an iris defect. The fellow eye can be treated 1 month after the primary eye.
3104611|NCT01860612|Experimental|Compassionate Use Cohort|Study participants that do not meet the inclusion/exclusion criteria for the study may be enrolled in the compassionate use treatment arm. The artificial iris will be implanted in the eye with an iris defect. The fellow eye can be treated 1 month after the primary eye.
3104612|NCT01860612|Experimental|Continued Access Cohort|Study participants that meet the inclusion/exclusion criteria for the study may be enrolled in the Continued Access cohort, after enrollment in the PMA cohort is complete.The fellow eye can be treated 1 month after the primary eye.
3104613|NCT01860599|Other|Prediabetes with exercise|150 minutes of moderate exercise per week
3104614|NCT01860599|Other|Prediabetes without exercise|Pre-study activity level (i.e. no exercise)
3104615|NCT01860586|Experimental|Bevacizumab|Bevacizumab will be injected into the study eye at end of retinal detachment (rd) surgery and monthly for the following 3 months (total of 4 intravitreal bevacizumab injections)
3104616|NCT01860573|Active Comparator|Standard amino acids|Receive 1-2 gm/kg/day amino acids at birth and advanced by 0.5 gm/kg/day for goal of 4 gm/kg/day
3104617|NCT01860573|Experimental|High amino acids|Receive 3-4 gm/kg/day amino acids at birth and advanced to goal of 4 gm/kg/day as soon as possible after birth
3104618|NCT01860560|Experimental|CPAP First / HFT Second|Subjects to receive both therapies, order-randomized to receive Continuous Positive Airway Pressure (CPAP) therapy study first, followed by a washout period, and a follow-on High-Flow Therapy (HFT) therapy study
3104619|NCT01860560|Experimental|HFT First / CPAP Second|Subjects to receive both therapies, order-randomized to receive High-Flow Therapy (HFT) therapy study first, followed by a washout period, and a follow-on Continuous Positive Airway Pressure (CPAP) therapy study.
3104620|NCT01860547|Experimental|bilberry|
3104621|NCT01860547|Experimental|sea buckthorn berry|
3104622|NCT01860547|Experimental|sea buckthorn phenolic extract|
3104623|NCT01860547|Experimental|sea buckthorn oil|
3104658|NCT01860313|Experimental|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
3104659|NCT01860313|No Intervention|Waiting List group|This group was used as control group and did not receive any intervention.
3104660|NCT01860300|Experimental|Antibiotic|Amoxicillin-Potassium Clavulanate Combination
3104624|NCT01860534|Experimental|Eye patches covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and patched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
3104625|NCT01860534|No Intervention|no eye patches covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and patched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
3104626|NCT01860521|Active Comparator|Programmed Intermittent Epidural Bolus|
3104627|NCT01860521|Active Comparator|Continuous Epidural Infusion|
3104628|NCT01860508|Experimental|pemetrexed|
3104629|NCT01860495||perforated membrane group|perforated membrane group (G1- 15 sites)
3104630|NCT01860495||occlusive membrane group|occlusive collagen membrane that are tradetionally used in guided tissue regeneration , control occlusive group (G2-15 sites)
3104631|NCT01860482|Experimental|Newrabell single arm|Newrabell® Tablet 10mg b.i.d PO during 8 weeks
3104632|NCT01860469|Active Comparator|plain mesh|standard practice of using plain mesh (non vancomycin-soaked) for open hernia repair
3104633|NCT01860469|Experimental|vancomycin-soaked mesh|use of vancomycin-soaked mesh for open hernia repair
3104634|NCT01860456||CML Imatinib/Nilotinib|Patients affected by chronic myeloid leukemia and treated with imatinib or nilotinib
3104635|NCT01860443|Experimental|Telepsychiatry collaborative program|"Online training on the diagnosis and management of adolescent depression for health professionals from primary care clinics participating in active branch.~Clinical management of depression by primary care professionals, according to algorithms based on the Clinical Guidelines of the Chilean Ministry of Health (MINSAL).~Supervision of primary care professionals through an internet site run by a team of specialists.~Telephone monitoring of patients by personnel trained on clinical progress, treatment adherence, and side effects (applicable for patients taking drugs)."
3104636|NCT01860443|Active Comparator|Usual care|"Online training on the diagnosis and management of adolescent depression for health professionals from primary care centers participating in active branch.~Clinical management of depression by primary care professionals, according to algorithms based on the Clinical Guidelines of the Chilean Ministry of Health (MINSAL)."
3104637|NCT01860430|Experimental|Treatment Arm|Cetuximab/IMRT Plus Ipilimumab (14 Week Regimen) IMRT, Weeks 2-8: 70-74.0 Gy with 2.0 Gy daily fractions delivered in 7-7.5 weeks Cetuximab, Weeks 1-8 Week 1: 400 mg/m2 Weeks 2-8 (concurrent with IMRT): 250 mg/m2/week Ipilimumab, Weeks 5, 8, 11, 14 Ipilimumab dose will be determined by cohort (1, 3, 6, or 10 mg/kg)
3104638|NCT01860417|Experimental|Allogenic Mesenchymal Stromal Cells|Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intradiscal injection of 25 millions MSC in 2 ml of saline
3104639|NCT01860417|Active Comparator|Mepivacaine|Infiltration of paravertebral musculature close to the affected disc(s) with 2 ml of 1% Mepivacaine
3104640|NCT01860404|Placebo Comparator|Placebo|Placebo will be administered orally twice daily for 21 days
3104641|NCT01860404|Experimental|Branched Chain Amino Acids (27g BID)|27 grams of BCAA's will be administered twice-daily for 21 days
3104642|NCT01860404|Experimental|Branched Chain Amino Acids (22.5g BID)|22.5 grams of BCAA's will be administered twice-daily for 21 days
3104643|NCT01860404|Experimental|Branched Chain Amino Acids (15g BID)|15 grams of BCAA's will be administered twice-daily for 21 days
3104644|NCT01860404|Experimental|Branched Chain Amino Acids (7.5g BID)|7.5 grams of BCAA's will be administered twice-daily for 21 days
3104645|NCT01860391|Experimental|Application of Diammine SIlver Fluoride|"GROUP A (6 TEETH): 18 mcL will be expressed from a Hamilton syringe into a dappen dish, and then a single preweighed microbrush will be used to apply the material to the tooth surface after drying with cotton gauze. The 6 teeth will be treated consecutively until all the material in the dappen dish will be used. Then the brush will be reweighed to establish the non-applied amount.~GROUP B (28 TEETH) Measure out 3 mcL X number of teeth present into dappen dish. Procedure is the same."
3104646|NCT01860378|Active Comparator|No Video: Full price & $5 off|Participants will not view the pertussis video
3104647|NCT01860378|Experimental|Video: Full price & $5 off|Participants will watch a brief (~ 1 minute) video about Tdap vaccination
3104648|NCT01860365|Experimental|Complementary medicine counseling|Patients receiving chemotherapy who are referred by their oncology provider to complementary medicine consultation and treatment provided in addition to conventional supportive care
3104649|NCT01860365|Active Comparator|Conventional supportive care|Patients receiving conventional supportive care
3104650|NCT01860352|Other|Fish Oil|
3104651|NCT01860339||Gene-expanded (GE)|Children at risk for HD who have a CAG repeat length of 40 and above.
3104652|NCT01860339||Gene Non-Expanded (GNE)|Children at risk for HD who have a CAG repeat length of 39 or less
3104653|NCT01860339||Healthy Controls (HC)|Healthy children with no medical or psychiatric disorder and no history of HD in their family
3104654|NCT01860339||Case Parent|Parent of participant at risk for Huntington Disease
3104655|NCT01860339||Control Parent|Parent of healthy control participant
3104656|NCT01860326|Experimental|Alisporivir|Single 200 mg oral dose
3104657|NCT01860313|Experimental|Web-based interactive educational group|This group was submited to the web-based interactive education created for train teachers in child mental health, how to identify mental health problems in children and to know how to deal with problematic children in class.
3104661|NCT01860300|Placebo Comparator|Placebo|Placebo
3104662|NCT01860287|Placebo Comparator|Placebo group|Healthy volunteers receive placebo during session (within-subjects design).
3104663|NCT01860287|Experimental|Drug group|Healthy volunteers receive buprenorphine during session (within-subjects design).
3104664|NCT01860274|Experimental|Mesh|Bypass to the diagonal is performed with a composite conduit made including the patient safen vein into a mesh
3104665|NCT01860274|Active Comparator|Control|Bypass to the diagonal branch is performed with a traditional safen vein.
3104666|NCT01860261|Experimental|Aerobic and Strength Training|Participants in the Aerobic and Strength Training intervention group will receive a standardized aerobic and strength training exercise program for 12 weeks, including paid gym membership, personal training, and 3 workshops in ChiWalkRun technique.
3104667|NCT01860261|No Intervention|Control (delayed onset of intervention)|After 12 weeks of active observation, this group will receive a modified version of the exercise intervention consisting of a free gym membership for 12 weeks, with limited personal training.
3104668|NCT01860248|Experimental|Vapocoolant spray|Vapocoolant is administered in 20 centimeters distance for 20 seconds to the patients as anesthetic before ABG.
3104669|NCT01860248|Placebo Comparator|Water spray|The Patients in this arm will receive water spray as anesthetic before ABG.
3104670|NCT01860235|Experimental|sextant 1|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (EMLA)
3104671|NCT01860235|Active Comparator|sextant 2|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (Injectable anesthesia)
3104672|NCT01860235|Active Comparator|sextant 3|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (2% Benzocaine)
3104673|NCT01860235|Placebo Comparator|sextant 4|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (Placebo)
3104674|NCT01860222|Active Comparator|SR|
3104675|NCT01860222|Experimental|PLAT|
3104676|NCT01860209|Experimental|Group A|the first polysomnography (PSG) is performed before hemodialysis (HD), followed by a post-HD PSG on the subsequent night
3104677|NCT01860209|Experimental|Group B|the first PSG is performed after hemodialysis (HD), followed by a pre-HD PSG, on the subsequent night
3104678|NCT01860196|Active Comparator|Treatment-Placebo Group|Treatment on 0 day Placebo at 5th week
3104679|NCT01860196|Active Comparator|Placebo-Treatment Group|Placebo on 0 day Treatment at 5th week
3104680|NCT01860183|Experimental|MMF 3g daily|
3104681|NCT01860183|Active Comparator|MMF 2 g daily|
3104682|NCT01860170|Active Comparator|Cohort 1-Bortezomib (Velcade®)|Bortezomib (Velcade®) 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
3104683|NCT01860170|Active Comparator|Cohort 2-Bortezomib (Velcade®)|Bortezomib (Velcade®) 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
3104684|NCT01860170|Active Comparator|Cohort 3-Bortezomib (Velcade®)|Bortezomib (Velcade®) 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
3104685|NCT01860157|Sham Comparator|Sham H1 Coil|deep rTMS sham treatment
3104686|NCT01860157|Active Comparator|Active H1|deep rTMS active treatment
3104687|NCT01860144||bevacizumab|Patients with metastatic colorectal cancer who accept treatment with chemotherapy and bevacizumab
3104688|NCT01860131|Active Comparator|Weight Wise Community Modules: Workshops|Groups workshops (10 in total) designed to improve weight management skills and enhance self-efficacy, delivered over 3 months, prior to entering a multidisciplinary bariatric care.
3104689|NCT01860131|Active Comparator|Weight Wise Community Modules: Online|Online modules (13 in total) designed to improve weight management skills and enhance self-efficacy, delivered over 3 months, prior to entering a multidisciplinary bariatric care.
3104690|NCT01860131|No Intervention|Educational Written Materials|"Educational pamphlets about healthy living and tips on self-management strategies.~Delivered by mail 3 months prior to entering a multidisciplinary bariatric care.~This is minimal intervention and considered the control arm."
3104691|NCT01860118||Parkinson's Disease|1) the presence of bradykinesia and either rest tremor or rigidity; 2) asymmetric onset; 3) progressive motor symptoms 4) age at onset 21-99 years.
3104692|NCT01860118||Healthy Control|Healthy controls between ages of 21-99 years and a lack of PD in first-degree blood relatives
3104693|NCT01860105|Active Comparator|75mg MDCO-157|iv
3104694|NCT01860105|Active Comparator|150mg MDCO-157|iv
3104695|NCT01860105|Active Comparator|300mg MDCO-157|iv
3104696|NCT01860105|Active Comparator|300mg PLAVIX|oral
3104697|NCT01860092||Argus II Retinal Prosthesis|Patients implanted with the Argus II Retinal Prosthesis
3104698|NCT01860079|Active Comparator|Early discharge group|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
3104699|NCT01860079|No Intervention|Standard discharge group|Patients who stay longer (96-120 hours) as of a standard procedure
3104700|NCT01860066|Experimental|QVA149|QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.
3104701|NCT01860066|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.
3104702|NCT01860053|Experimental|behavioral intervention|
3104703|NCT01860053|No Intervention|no treatment control|
3104704|NCT01860040|Experimental|Cisplatin and pemetrexed|Cisplatin on day 1 and pemetrexed on day 1, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
3104705|NCT01860040|Experimental|Cisplatin and gemcitabine|Cisplatin on day 1 and gemcitabine on days 1 and 8, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
3104706|NCT01860027||Children with reading disabilities|Children diagnosed with reading disabilities (age 7 to 13).
3104707|NCT01860027||Children with eye movement disorders|Children diagnosed with eye movement disorders (age 7 to 13).
3104708|NCT01860027||Control Group|Children with normal reading ability and normal eye movements (age 7 to 13.
3104709|NCT01860014|Active Comparator|Beractant|Beractant (Survanta): 100 mg/kg-intratracheal, just after pulmonary hemorrhage
3105268|NCT01856244|Active Comparator|conventional treadmill training|conventional treadmill control
3104710|NCT01860014|Active Comparator|Poractant alfa|Poractant alfa (Curosurf): 100 mg/kg-intratracheal, just after pulmonary hemorrhage
3104711|NCT01859988|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection every week (qw) from Week 1 to Week 15.
3104712|NCT01859988|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
3104713|NCT01859988|Experimental|Dupilumab 300 mg q2w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 15.
3104714|NCT01859988|Experimental|Dupilumab 200 mg q2w|Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.
3104715|NCT01859988|Experimental|Dupilumab 300 mg q4w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab every 4 weeks (q4w) and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
3104716|NCT01859988|Experimental|Dupilumab 100 mg q4w|Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
3104717|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin|PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin dosed in combination
3104718|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin|PPI-668, BI 207127 Dose 2, BI 207127 Placebo, Faldaprevir, and Ribavirin dosed in combination
3104719|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 1, and Faldaprevir|PPI-668, BI 207127 Dose 1, and Faldaprevir dosed in combination
3104720|NCT01859949|Experimental|Genotropin (somatropin)|
3104721|NCT01859936|Experimental|preoperative breast MRI|The intervention is that preoperative MRI breast will be performed in women under 56 years with newly diagnosed breast cancer
3104722|NCT01859936|No Intervention|no MRI breast|The arm type description implies that no MRI breast will be performed to women under 56 years with newly diagnosed breast cancer
3104723|NCT01859923|Experimental|Group 1: 12 to 17 years of age|100 mg Delamanid BID for 6 months + OBR
3104724|NCT01859923|Experimental|Group 2: 6 to 11 years of age|50 mg Delamanid BID for 6 months + OBR
3104725|NCT01859923|Experimental|Group 3: 3 to 5 years of age|25 mg Pediatric Formulation Delamanid BID for 6 months + OBR
3104726|NCT01859923|Experimental|Group 4: Birth to 2 years of age|"Delamanid Pediatric Formulation (DPF) for 6 months + OBR. DPF dose based on patient's body weight during baseline visit:~Patients > 10 kg will receive DPF 10 mg BID + OBR~Patients > 8 kg and ≤ 10 kg will receive DPF 5 mg BID + OBR~Patients ≤ 8 kg will receive DPF 5 mg QD + OBR~Delamanid dose will be adjusted as needed for Group 4 patients based on the weight measurement at specified study visits (Visits 5, 7, 9, 11, and 12)."
3104727|NCT01859910|Experimental|compression|compression and scrub of lid margin for 5 circles before cataract surgery
3104728|NCT01859910|Active Comparator|control|no compression or scrub of lid margin
3104729|NCT01859897||Optimal therapy|All subjects will be treated by optimal medical therapy and lifestyle modification.
3104730|NCT01859884|Experimental|Inform Me: web-based education tool|Intervention will receive the standard of care, the Inform Me intervention, a post-test evaluation, and 1 week recall test.
3104731|NCT01859884|No Intervention|Control Standard of Care|This group receives standard of care with a post test.
3104732|NCT01859871|No Intervention|Control Arm|Study participants will take the self-administered pre-test and receive the standard of care. After taking the pre-test, control arm participants will be done with study participation for that day and will attend the transplant center's education sessions. All participants will receive a letter and follow-up call at about two weeks later to schedule the final survey. They will take a final survey via telephone about 3 weeks later. The final survey includes the same topics as the pre-test. They will receive a thank you letter and gift card by mail after completing the final survey.
3104733|NCT01859871|Experimental|Website Intervention|Navigate website plus standard of care
3104734|NCT01859858|Experimental|curcumin + irinotecan (part 1)|Oral Curcumin (1, 2, 3,or 4 grams per day) for 4 days prior to irinotecan + 200 mg/m2 irinotecan IV, days 1 and 15
3104735|NCT01859858|Experimental|curcumin + irinotecan (part 2)|MTD oral Curcumin as determined in part 1 + 200 mg/m2 irinotecan IV, days 1 and 15
3104736|NCT01859845|No Intervention|Control Study Arm|The control participants will first interact with the simulated melanoma back model to learn clinical unaided visual inspection skills and then view a passive image projected onto a screen for dermoscopy learning. Remediation of inappropriate clinical decisions will be carried out by the research coordinator and is based on predefined feedback consistent across both arms of the study. Along with the projected images, the coordinator will provide each control participant with worksheets for the clinical Asymmetry, Border, Color, Diameter (ABCD) and Dermoscopy 3-point check list. A copy of the completed worksheet will be made at the end of the workshop.
3104737|NCT01859845|Experimental|smartphone|Each participant in the educational intervention arm will have access to a smartphone with a preloaded android software package. The smartphone software allows the participant to visualize a dermoscopic image of the pigmented lesion at the surface of the simulated melanoma model. Participants are given the freedom to navigate through the program via the smartphone to learn at their own pace with reinforcement of correct clinical management decisions and correction of weaknesses. The software content is limited to the dermoscopy information available to the positive control arm through the coordinator and the dermoscopic images projected onto the screen, thus a comparison of retention rates across both arms is possible.
3104738|NCT01859832||Enrolled participants|"All participants enrolled in this study will have been previously consented to the study entitled, A Comparison of Effects of Standard Dose vs Low Dose Advagraf with Il-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB-based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response. This is an observational study with only one group/cohort in which all participants have bloodwork collected pre-transplant and at various time points post-transplant and these samples are analyzed using the Cylex ImmuKnow Assay."
3104739|NCT01859819|Experimental|Group B|"De-novo Mature CD 20 + B-NHL excluding PMBL histology. Good Risk FAB Group B includes patients with St. Jude Stages I /II (unresected) and stage III/IV with diagnostic LDH <2 X ULN.~REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate INDUCTION:Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin CONSOLIDATION: Rituximab, Methotrexate, Leukovorin, Cytarabine"
3104740|NCT01859819|Experimental|Group C, CNS negative|"De-novo Mature CD 20 + B-ALL (> 25% Bone marrow blasts) without CNS involvement.~REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Prednisone, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, Etoposide, Cytarabine"
3104741|NCT01859819|Experimental|Group C, CNS Positive|"De-novo Mature CD 20 + B-NHL with CNS involvement:~Any L3 blasts in CSF~Cranial nerve palsy (if not explained by extracranial tumor)~Clinical spinal cord compression~Isolated intracerebral mass~Parameningeal extension: cranial and/or spinal REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine, IT Liposomal ARA-C, Vincristine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Cyclophosphamide, Methotrexate, Leukovorin, Doxorubicin, IT Liposomal ARA-C,"
3104742|NCT01859806|Active Comparator|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
3104743|NCT01859806|Active Comparator|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
3104744|NCT01859793|Placebo Comparator|Matching Placebo|Matching Placebo for Sitagliptin
3104745|NCT01859793|Active Comparator|Sitagliptin|100mg pill, PO administered once daily.
3104746|NCT01859780|Experimental|Prescription packages (vials and blisters)|"Stage I Prescription vials and wallets (packaging) with three levels of distractor placement (hidden, absent and obvious) will be tested for an effect of placement on selection behavior and time to package selection.~Stage II Prescription vials and wallets (packaging) with and without distractors will be tested for an effect on time to open and number of successful openings."
3104747|NCT01859767|Experimental|[123I]MNI-672 SPECT|[123I]MNI-672 single photon emission tomography (SPECT)imaging
3104748|NCT01859754||Octagam 5%|Primary Immune Deficiency Syndrome patients receiving Octagam 5% by infusion who have been treated with a marketed IVIG product for at least 6 months.
3104749|NCT01859754||Other marketed IVIG product|Primary Immune Deficiency Syndrome patients receiving marketed IVIG product other than Octagam 5% by infusion as treatment for at least 6 months.
3104750|NCT01859741|Experimental|OMP-59R5 Combination with Etoposide and Cisplatin|
3104751|NCT01859741|Experimental|Etoposide and Cisplatin plus Placebo|
3104752|NCT01859728|Experimental|IP (irinotecan and cisplatin)|Irinotecan 65mg/m² D1 and D8 q21 days plus Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.
3104753|NCT01859728|Active Comparator|GC (gemcitabine and cisplatin)|Gemcitabine 1000mg/m² D1 and D8 every 21 days plus cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.
3104754|NCT01859715|Active Comparator|Oxycodone group|Subjects given either oxycodone 5mg by ED provider decision or by triage nurse randomization.
3104755|NCT01859715|Active Comparator|Nausea-observational group|Patients given ondansetron 4mg by ED provider decision or by triage nurse. This is an observational cohort only.
3104756|NCT01859715|Active Comparator|Hydrocodone/Acetaminophen group|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
3104757|NCT01859702|Experimental|VIGADEXA|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution, 1 drop instilled in the study eye 2 days before surgery, followed by 1 drop instilled 4 times a day the day before surgery. On the day of surgery, 1 drop was instilled 60 minutes prior to the procedure.
3104758|NCT01859689|Experimental|Treatment (image-guided HDR brachytherapy)|Patients undergo 3 fractions of image-guided HDR brachytherapy over 2 days.
3104759|NCT01859663||Women with a past diagnosis of PCOS|We aim to recruit 120 women with a past diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
3104760|NCT01859663||Women with a history of regular menstrual cycles|We aim to recruit 120 women with a history of regular menstrual cycles. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
3104761|NCT01859650||NSCLC patients undergoing RT|
3104762|NCT01859637|Experimental|Zarzio®/Filgrastim HEXAL®|Zarzio®/Filgrastim HEXAL® was administered according to Summary of Product Characteristics (SmPC). It was provided as solution for injection in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU).
3104763|NCT01859624|Experimental|Albuterol|This study includes the off-label administration of oral albuterol (4 mg pill) and tracking the effect of motor function at two additional visits, 6 and 12 weeks following the initiation of the study drug. The initial dose of albuterol will be a 4 mg daily for the first 6 weeks. If the 4 mg is well tolerated, the dose will be increased to 8 mg at the 6 week visit.
3104764|NCT01859611|Experimental|Radiofrequency|Radiofrequency (RF) treatment with the TriActive+ RF device on the peri-oral and/or peri-orbital areas of the face once a week for eight weeks.
3104765|NCT01859585|Experimental|Parecoxib|Parecoxib
3104766|NCT01859585|Experimental|Ketorolac|Ketorolac
3104767|NCT01859585|No Intervention|No medication|No medication
3104768|NCT01859559|Experimental|Easy Access|This arm will included emergency department patients that are judged to have easy intravenous access in at least one of the upper extremities by the ED technician.
3104881|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
3104769|NCT01859559|Experimental|Difficult Access By Clinician Judgment|This arm will include patients that at least one vein is visible or palpable in one of the upper extremities but either the ED technician and/or ED nurse judges the patient to have difficult intravenous access.
3104770|NCT01859559|Experimental|Non visible and Non palpable|This arm will include patients for whom neither the ED technician nor an ED nurse can identify a visible or palpable vein that is suitable for an intravenous access line in either upper extremity.
3104771|NCT01859546|No Intervention|One time standard verbal counseling|The control group will receive one time standard verbal counseling at the time of initial visit related to EPI vaccination
3104772|NCT01859546|Experimental|SMS Reminders|Short message service (SMS) - SMS reminders for EPI vaccination at 6, 10 and 14 weeks of life sent in the week that these vaccines are due
3104773|NCT01859533|Experimental|Neopuff group|includes 34 newborns showing signs of TTN who received CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).
3104774|NCT01859533|No Intervention|Control group|includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010).
3104775|NCT01859520|Experimental|Swim up, density gradient|swim-up and density gradient sperm preparation techniques in male factor infertility and unexplained infertility groups
3104776|NCT01859507|Experimental|BOTOX group|Injection of BOTOX in the perineal muscles in resistant cases of vaginismus. Proper informed consent forms will be signed. The injection procedure is done under local anesthesia for most of our patients. We followed up the patient by phone calls for possible adverse effects following the procedure for 4 days.The patient is then instructed to attend dilatation sessions twice weekly in the clinic, in the presence of the husband, for 3-4 weeks. We use silicone dilators, of ascending sizes, covered by lubricated condoms. In the initial phase of the dilatation procedure we start each session with the appropriate size of the dilator according to the capacity of the introitus and the degree of vaginismus, and thereafter increase the size gradually.
3104777|NCT01859494|Experimental|Users of the Monitoring System|Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.
3104778|NCT01859481|Placebo Comparator|Placebo|
3104779|NCT01859481|Experimental|Eletriptan HBr 40 mg|
3104780|NCT01859481|Experimental|Eletriptan HBr 80 mg|
3104781|NCT01859468|Experimental|Amorphous calcium carbonate|200 mg elemental calcium tablets, 2 in the morning and 2 in the evening, after a meal
3104782|NCT01859468|Placebo Comparator|StarLac|Tablets containing 300 mg StarLac (starch cellulose and lactose blend) to be used as placebo, 2 tablets in the morning and 2 tablets in the evening, after a meal.
3104783|NCT01859455|Experimental|Patient: LGT209 50 mg|50 mg LGT209 subcutaneous (SC) (1 mL injection x 1 site) in statin patients
3104784|NCT01859455|Experimental|Patient: LGT209 300 mg|300 mg LGT209 subcutaneous (SC) (1 mL injection x 2 sites) in statin patients
3104785|NCT01859455|Experimental|Healthy Volunteers: LGT209 300 mg|300 mg LGT209 or placebo subcutaneous (SC) (1 mL injection x 2 sites) in healthy volunteers
3104786|NCT01859455|Placebo Comparator|Patient: Placebo|matching placebo subcutaneous (SC) of LGT209 50 mg or 300 mg in statin patients
3104787|NCT01859455|Placebo Comparator|Healthy volunteers: Placebo|matching placebo subcutaneous (SC) of LGT209 300 mg in healthy volunteers
3104788|NCT01859442|Active Comparator|Exercise group|6 week structured responsive interval exercise training programme
3104789|NCT01859442|Sham Comparator|Control group|Negative, unsupervised, out of hospital control group
3104790|NCT01859429|Experimental|Stepped Care|Structured stepped requirement of psychosocial support
3104791|NCT01859429|No Intervention|Care as usual|Unstructured requirement of psychosocial support
3104792|NCT01859416|Experimental|Oral nutritional supplement|2 * 125 mL low volume, energy and nutrient dense ONS per day (2 * 300 kcal) in addition to usual nutritional care
3104793|NCT01859416|No Intervention|Control|Usual nutritional care
3104794|NCT01859403|Placebo Comparator|Usual Care|Usual care for veterans as part of the MOVE! program
3104795|NCT01859403|Active Comparator|Personalized Genomics|Personalized genomics information from the FIT Test, Pathway Genomics
3104796|NCT01859390|Experimental|AquADEKs-2|Two control multivitamin softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 4 weeks for the screening run in period. For those subjects randomized to the AquADEKs-2 arm, two AquADEKs-2 softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 16 weeks.
3104797|NCT01859390|Active Comparator|Control multivitamin|Two control multivitamin softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 4 weeks for the screening run in period for all participants and for 16 weeks for those randomized to this comparative therapy.
3104798|NCT01859377|Other|Sequence 1|Test Drug (V0498 - A mg) - Reference (Ibuprofen)
3104799|NCT01859377|Other|Sequence 2|Reference (Ibuprofen) - Test drug(V0498 - A mg)
3104800|NCT01859351|Experimental|WX-037|PI3K inhibitor
3104801|NCT01859351|Experimental|WX-037 in combination with WX-554|PI3K inhibitor in combination with MEK inhibitor
3104802|NCT01859338||MRI, CBCT, FBCT|Patients undergo MRI and fan beam CT (FBCT) at baseline, within the first 3 weeks of radiotherapy and between week 4 and 6 of radiotherapy. Patients with lung cancer may undergo 4D cone beam x-ray CT (CBCT) on the same day as the second and third MRI and FBCT.
3104803|NCT01859325|Experimental|Vaccine|HIV-MAG pDNA vaccine prime will be administered at a dose of 3000 g (1500 g of the HIV-1 gag/pol plasmid and 1500 g of the HIV-1 net/tat/vif, env plasmid) at week 0, 4, 12, and 36. Each construct of HIV-MAG pDNA vaccine (1500 g each) will be mixed and combined with 1000 g of the IL-12 pDNA adjuvant. The resulting mixture will be divided into 2 IM injections and administered as 0.75 mL IM injection in the left deltoid and 0.75 mL IM injection in the right deltoid with EP using the TDS device. IL-12 pDNA adjuvant will be mixed with the HIV-MAG pDNA vaccine prime, as noted above, and administered at a dose of 1000 g (500 g in each IM injection) at week 0, 4, 12, and 36. rVSV HIV gag booster vaccine--The total dose, 1x107 pfu, will be administered as 1 mL (5x106 pfu) IM injection in the left deltoid and 1 mL (5x106 pfu) IM injection in the right deltoid at week 24 and 48.
3104882|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
3104804|NCT01859325|Placebo Comparator|Placebo|Placebo for the IL-12 pDNA adjuvant and HIV-MAG pDNA vaccine (sodium chloride for injection, USP 0.9%) will be administered as 0.75 mL IM injection in the left deltoid and 0.75 mL IM injection in the right deltoid at weeks 0, 4, 12, and 36 with EP using the TDS device. Placebo for the rVSV HIV gag (sodium chloride for injection, USP 0.9%) will be administered as 1 mL IM injection in the left deltoid and 1 mL IM injection in the right deltoid at week 24 and 48.
3104805|NCT01859312|Experimental|Continuous Subcutaneous Hydrocortisone Infusion|Enrolled participants with congenital adrenal hyperplasia (CAH) received continuous subcutaneous hydrocortisone (Solucortef) infusion (CSHI) via insulin pump (Medtronic) (MMT-722Na) to achieve near-physiologic cortisol replacement therapy. Participants were their own controls; participant's baseline outcomes/lab values while on conventional glucocorticoid therapy were compared to outcomes/lab values after 6 months of treatment using CSHI via insulin pump.
3104806|NCT01859286||regular sign out process|
3104807|NCT01859273|No Intervention|Standard Care|Standard Care after kidney transplantation
3104808|NCT01859273|Experimental|mHealth|subjects provided with electronic medication tray, electronic blood pressure cuff, and a smart phone.
3104809|NCT01859260|No Intervention|Control|
3104810|NCT01859260|Experimental|Intervention|CPAP/autopap
3104811|NCT01859247|Active Comparator|Dorsal Premotor rTMS|0.2 Hz rTMS for 15 minutes
3104812|NCT01859247|Active Comparator|Primary motor cortex rTMS|0.2 Hz rTMS for 15 minutes
3104813|NCT01859247|Active Comparator|Supplemental Motor Area rTMS|0.2 Hz rTMS for 15 minutes
3104814|NCT01859247|Active Comparator|Anterior Cingulate rTMS|0.2 Hz rTMS for 15 minutes
3104815|NCT01859247|Sham Comparator|Sham rTMS|0.2 Hz rTMS for 15 minutes
3104816|NCT01859234|Experimental|89Zr-bevacizumab PET scan|all patients included in the study will have a 89Zr-bevacizumab PET scan
3104817|NCT01859221|Experimental|Castration Resistant|There are two different prognostic categories, hormones receptive and castration resistant, that have differing historical disease progression rates. We have therefore stratified the trial so that we can independently monitor the hypothesized improvement provided by radiation therapy in these two groups. Both groups will receive the same radiation modality which is interventional stereotactic radiation with two possible schedules of SBRT and SHRT.
3104818|NCT01859221|Experimental|Hormone Receptive|There are two different prognostic categories, hormones receptive and castration resistant, that have differing historical disease progression rates. We have therefore stratified the trial so that we can independently monitor the hypothesized improvement provided by radiation therapy in these two groups. Both groups will receive the same radiation modality which is interventional stereotactic radiation with two possible schedules of SBRT and SHRT.
3104819|NCT01859195||Focus Group Stage|~20-24 participants, to comprise 3-6 focus groups
3104820|NCT01859195||Cognitive Interview Stage|~12-16 participants in individual cognitive interviews
3104821|NCT01859182|Experimental|Treatment (selumetinib, Akt inhibitor MK2206)|Patients receive Akt inhibitor MK-2206 PO on days 1, 8, 15, and 22 (days 8, 15, and 22 of course 1) and selumetinib PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3104822|NCT01859169||Control Group|Group that be administrated biliary drainage only
3104823|NCT01859169||PDT Group|Group that be administrated photodynamic therapy and biliary drainage
3104824|NCT01859156||Carbon Monoxide Exposure|
3104825|NCT01859143|Experimental|Trivalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
3104826|NCT01859143|Placebo Comparator|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
3104827|NCT01859130|Other|Persona TKA|Primary total knee arthroplasty subjects that receive the Zimmer Persona Total Knee System
3104828|NCT01859117|Experimental|3 x 10^6 cells|3 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
3104829|NCT01859117|Experimental|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
3104830|NCT01859117|Experimental|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
3104831|NCT01859117|Experimental|100 x 10^6 cells|100 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
3104832|NCT01859104|Other|Smartphone Arm|This is a feasibility trial and thus all participants in the study will be provided a smartphone app to assist them in making lifestyle modifications
3104833|NCT01859091|Experimental|Fat Reduction|
3104834|NCT01859078|Experimental|Baricitinib + Digoxin|"Digoxin - 0.5 milligrams (mg) administered orally, twice daily (BID), 12 hours apart on Day 1. Then, 0.25 mg administered orally, once daily (QD) on Days 2 through 16.~Baricitinib - 10 mg administered orally, QD, on Days 8 through 16."
3104835|NCT01859065|Placebo Comparator|Control|Mothers receive routine anticipatory guidance
3104836|NCT01859065|Experimental|Intervention|Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
3104837|NCT01859052|Other|Obese migraineurs|Low carbohydrate diet
3104838|NCT01859052|Other|low-fat diet|Obese Migraineurs
3104839|NCT01859052|Other|Controls|Controls receiving AHA diet recommendations
3104840|NCT01859039||Egg allergic children|Administration of Live attenuated influenza vaccine
3104841|NCT01859026|Experimental|Phase I - Dose Escalation|"For the Phase I portion, patients will start MEK162 by mouth (p.o.) on cycle 1, day 1 and erlotinib on cycle 1, day 2. The MEK162 will be dosed once daily (QD) or twice (b.i.d.), and erlotinib will be dosed daily (QD) on a 28-day cycle.~Phase I will be followed by an expansion Phase Ib."
3104842|NCT01859026|Experimental|Arm A: Dose Expansion|"Phase Ib Arm A: EGFR Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.~The treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
3104843|NCT01859026|Experimental|Arm B: Dose Expansion|"Phase Ib Arm B: KRAS Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.~The treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
3104844|NCT01859013|Experimental|Topiramate|Four (4) weeks of meal replacement therapy, followed by 28-weeks of topiramate therapy. Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks.
3104845|NCT01859013|Placebo Comparator|Sugar Pill|Four (4) weeks of meal replacement therapy, followed by 28-weeks of placebo (sugar pill) therapy.
3104846|NCT01859000|Experimental|Multidimensional Family Therapy|MDFT is a multi-systems family-based approach (Liddle, 2002a) designed to address the multiple developmental disruptions and symptoms that result from interacting individual, family, peer, and community risk factors (Liddle, 2002a). MDFT assesses and intervenes at multiple levels and in multiple domains of the adolescent's life -- individual, familial and extrafamilial.
3104847|NCT01859000|Other|Group CBT|The group treatment employed in the proposed study is a state-of-the-art peer group-based CBT model. The treatment will be based on established guidelines for CBT therapy for teen substance abuse (CSAT, 1999; Waldron & Kaminer, 2004) as well as trauma (La Greca & Silverman, in press). The treatment adopts a risk and protective factor framework, seeking to reduce substance use both by targeting cognitions about use directly and by focusing on accompanying problem behaviors such as poor academic performance and limited social skills (Hawkins et al, 1992).
3104848|NCT01858987|Active Comparator|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
3104849|NCT01858987|Experimental|LigaSure Hepatectomy|Liver resection using LigaSure for transection of the parenchyma
3104850|NCT01858961|Experimental|Group 1|BI 201335 in combination with BI 207127 and ribavirin for 24 weeks
3104851|NCT01858961|Experimental|Group 2|Telaprevir in combination with PegIFN and ribavirin for 24 weeks or 48 weeks
3104852|NCT01858948|Experimental|Quitiapine plus Omega|Patients will be randomized to EPA+DHA supplements (OmegaRx) for 24 weeks
3104853|NCT01858948|Placebo Comparator|Quetiapine plus Placebo|Patients will be randomized to similar in shape an color placebo supplements (corn oil)
3104854|NCT01858935|Experimental|ND-L02-s0201 Injection 0.03 mg/kg|
3104855|NCT01858935|Experimental|ND-L02-s0201 Injection 0.1 mg/kg|
3104856|NCT01858935|Experimental|ND-L02-s0201 Injection 0.2 mg/kg|
3104857|NCT01858935|Experimental|ND-L02-s0201 Injection 0.4 mg/kg|
3104858|NCT01858935|Experimental|ND-L02-s0201 Injection 0.5 mg/kg|
3104859|NCT01858935|Experimental|ND-L02-s0201 Injection 0.6 mg/kg|
3104860|NCT01858935|Experimental|ND-L02-s0201 Injection 0.8 mg/kg|
3104861|NCT01858935|Placebo Comparator|Placebo|
3104862|NCT01858922|Experimental|Rapid Early Responders|All patients will have initial treatment utilizing ABVE-PC x2 cycles. Those patients with rapid early response (RER) determined by FDG-PET/CT scan after two cycles of ABVE-PC will receive two more cycles of ABVE-PC. If subsequent PET/CT scan indicates a complete response (CR), therapy will stop and regular follow-up will begin. If the subsequent PET/CT for RER patients indicates a partial response, those patients will undergo IFRT.
3104863|NCT01858922|Experimental|Slow Early Responders|"All patients will have initial treatment utilizing ABVE-PC x2 cycles. Those patients determined to have a slow early response (SER) determined by PET/CT scan after two cycles of ABVE-PC will receive 2 courses of DECA. If after PET/CT, the patient has a partial or complete response, then 2 additional courses of ABVE-PC will be given. If subsequent PET/CT scan indicates PR or CR, those patients will then undergo IFRT.~If stable or progressive disease is found at either PET/CT scan, the patient will be taken off-study and follow up will begin."
3104864|NCT01858909|Placebo Comparator|Control|saline every 12 hours for 28 days
3104865|NCT01858909|Experimental|Melatonin|Oral 30mg/12hours melatonin 28 days
3104866|NCT01858896|Active Comparator|Glucagon-Like Peptide -1 (GLP-1) infusion|Infusion of GLP-1 during experimental period
3104867|NCT01858896|Placebo Comparator|Saline Infusion|Saline infusion during experimental period
3104868|NCT01858883|Experimental|itacitinib, gemcitabine, nab-paclitaxel, filgrastim|
3104869|NCT01858870||Lacosamide|patients with Partial Crisis of epilepsy treated with Lacosamide for at least 12 months
3104870|NCT01858857||Geriatric psychiatric in patients|
3104871|NCT01858844|Active Comparator|CHEST COMPRESSION TECHNIQUE 2|The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR(respiratory rate)(timer for 1 minute); HR (heart rate) and SpO2(oxygen saturation) through pulse oximetry in infants without atelectasis.
3104872|NCT01858844|Experimental|CHEST COMPRESSION TECHNIQUE|The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR (timer for 1 minute); HR and SpO2 through pulse oximetry in infants with atelectasis.
3104873|NCT01858831|Experimental|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
3104874|NCT01858831|Active Comparator|Atovaquone 750 mg|Atovaquone 750 mg
3104875|NCT01858831|Active Comparator|Atovaquone 1500 mg|Atovaquone 1500 mg
3104876|NCT01858818||healthy 18 year old males|
3104877|NCT01858805||detection of circulating tumors cells|This prospective, single-institution study conducted at the University Hospital Hamburg-Eppendorf (Hamburg, Germany) enrolled 123 patients with ECs that were initially considered resectable. Only patients with histologically proven EC were included. Peripheral blood samples for CTC analysis were collected immediately before surgery.
3104878|NCT01858792||Baseline Health-Related Quality of Life (HRQOL)|Quality of life assessment tools were similar across the treatment groups and indicated that there was impairment in quality of life of subjects in the Low C+anti-dsDNA Population
3104879|NCT01858792||SLE Medication Usage at Baseline|All subjects in the Low C+anti-dsDNA Population
3104880|NCT01858779||Study-cohort|"Patients after ischemic stroke without a history of atrial fibrillation will perform measurements of peripheral pulse three times daily and in case of symptomatic arrhythmic episodes. Results will be entered into a diary which will be send to the center every month. In parallel to the measurements, patients will transmit ECGs via a mobile ECG recorder to the study center.~At 3 and 6 months after inclusion patients will be evaluated using 72h holter ECG. During the whole study period AEs as well as SAEs and changes in medications are recorded."
3105269|NCT01856231|Experimental|8 week group|Lifestyle physical activity self-efficacy
3104883|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT2/4/5/6)|Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
3104884|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT2/4/5/6)|Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
3104885|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT3)|Participants with genotype 3 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
3104886|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT3)|Participants with genotype 3 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
3104887|NCT01858766|Experimental|SOF+VEL 25 mg 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 8 weeks.
3104888|NCT01858766|Experimental|SOF+VEL 25 mg + RBV 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.
3104889|NCT01858766|Experimental|SOF+VEL 100 mg 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 8 weeks.
3104890|NCT01858766|Experimental|SOF+VEL 100 mg + RBV 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.
3104891|NCT01858766|Experimental|SOF+VEL 25 mg 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg for 8 weeks.
3104892|NCT01858766|Experimental|SOF+VEL 25 mg + RBV 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.
3104893|NCT01858766|Experimental|SOF+VEL 100 mg 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg for 8 weeks.
3104894|NCT01858766|Experimental|SOF+VEL 100 mg + RBV 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.
3104895|NCT01858753|Experimental|Autologous fibroblasts|Autologous fibroblasts grown in culture from skin biopsy taken from patient. The cells will be injected into the scars to be treated.
3104896|NCT01858753|Placebo Comparator|Sterile saline|Sterile saline will be injected into the scar to be evaluated.
3104897|NCT01858740|Experimental|Treatment (CD45RA+ T cell depleted PBSCT)|"CONDITIONING REGIMEN: Patients undergo TBI BID on days -10 to -7, receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.~TRANSPLANT: Patients undergo CD34+ enriched, CD45RA+ T cell-depleted allogeneic PBSCT on day 0.~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and continuing through day 50 with taper. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
3104898|NCT01858727|Active Comparator|forced air warming group|30 minutes before the preoperative will use forced air warming.
3104899|NCT01858727|No Intervention|control group|do not heating group
3104900|NCT01858714|Active Comparator|Behavior Therapy (BT)|"Active Comparator: Behavior Therapy~Behavioral treatment strategies will be utilized to facilitate adherence to the treatment goals in all three treatments. Participants in the BT condition will receive only the BT intervention. Strategies that will be emphasized are listed below:~Self monitoring Stimulus control Changing eating behaviors Goal setting Problem solving Social support Cognitive restructuring Relapse prevention"
3104901|NCT01858714|Experimental|Behavior Therapy + Environment|Participants will receive standard behavioral therapy with an emphasis on environmental strategies.
3104902|NCT01858714|Experimental|Acceptance-based BT + Environment|Participants will receive acceptance-based behavioral therapy with an emphasis on environmental strategies.
3104903|NCT01858701|Other|AO for Astig / Biofinity Toric|Lotrafilcon B toric contact lenses worn in Period 1, followed by comfilcon A toric contact lenses in Period 2, as randomized. Each product will be worn bilaterally on a daily wear basis for 30 days, removed nightly. A minimum 1-day washout of no contact lens wear will precede each wear period.
3104904|NCT01858701|Other|Biofinity Toric / AO for Astig|Comfilcon A toric contact lenses worn in Period 1, followed by lotrafilcon B toric contact lenses in Period 2, as randomized. Each product will be worn bilaterally on a daily wear basis for 30 days, removed nightly. A minimum 1-day washout of no contact lens wear will precede each wear period.
3104905|NCT01858688|Experimental|Accuracy of multi-parametric MRI relative to prostate biopsy|Determine the sensitivity and specificity of MP-erMRI relative to repeat 12 core TRUS biopsy for classifying upgrading of disease extent or Gleason grade in men considering AS.
3104906|NCT01858675|Experimental|Biomarkers, total blood volume|
3104907|NCT01858662|Active Comparator|oxaliplatin +leucovorin L+5FU+ cetuximab|oxaliplatin +leucovorinL+5-Fluorouracile +cetuximab+'Metastases Resection ( multiple steep surgery possible)
3104908|NCT01858662|Active Comparator|Irinotecan+ + leucovorinL +5-Fluorouracil +cetuximab|Irinotecan+ + leucovorinL +5-Fluorouracile + cetuximab +'Metastases Resection ( multiple steep surgery possible)
3104909|NCT01858649|Active Comparator|Folfox: oxaliplatin +leucovorin+ 5FU|FOLFOX (oxaliplatin +leucovorin+ 5FU) +bevacizumab+ metastases resection
3104910|NCT01858649|Active Comparator|FOLFIRI: irinotecan+leucovorin+5FU|FOLFIRI (irinotecan+leucovorin+5FU) +bevacizumab +metastases resection
3104911|NCT01858636||Angio-Seal VIP Vascular Closure|
3104912|NCT01858623|Other|Losartan / Hydrochlorothiazide100 mg/25mg|Losartan / Hydrochlorothiazide100 mg/25mg fixed dose combination
3104913|NCT01858623|Other|Losartan 100 mg|Losartan 100 mg alone
3104914|NCT01858623|Other|hydrochlorothiazide 25 mg|hydrochlorothiazide 25 mg alone
3104915|NCT01858610|Other|Irbesartan alone|Irbesartan 300 mg alone
3104916|NCT01858610|Other|Hydrochlorothiazide 25 mg alone|Hydrochlorothiazide 25 mg alone
3104917|NCT01858610|Other|Irbesartan 300 mg + Hydrochlorothiazide 25 mg|Irbesartan 300 mg + Hydrochlorothiazide 25 fixed dose combination
3104918|NCT01858597||gestational diabetes mellitus|Those women (subjects) with gestational diabetes mellitus
3104919|NCT01858597||control|Those healthy pregnant women
3104920|NCT01858584|Experimental|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~Infants weighing <5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~Infants weighing> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
3104999|NCT01858077|Active Comparator|ABSORB BVS™|Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
3104921|NCT01858584|Active Comparator|Thickened Formula|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
3104922|NCT01858584|No Intervention|control group|
3104923|NCT01858571|Experimental|Low dose chemotherapy|"Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~Daily oral Thalidomide (at 3mg/kg)~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~Daily oral Etoposide (50 mg/m2/d)~Cycle B~Daily oral Thalidomide (at 3mg/kg)~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
3104924|NCT01858571|Placebo Comparator|Best supportive care|"Placebo: Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration)~Capsules of same size and color as used in metronomic therapy Best supportive care~Management of pain as per WHO standard for pain management"
3104925|NCT01858558|Experimental|aMIL Arm|Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)
3104926|NCT01858558|Active Comparator|No aMIL|Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)
3104927|NCT01858545|Experimental|Experimental|MatriStem MicroMatrix and MatriStem Wound Matrix
3104928|NCT01858545|Active Comparator|Comparator|Cellular Dermal Replacement Tissue
3104929|NCT01858532|Active Comparator|Atrasentan|Subjects randomized to the atrasentan arm will receive active drug, atrasentan.
3104930|NCT01858532|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will receive placebo.
3104931|NCT01858519||CF patients receiving PERT|Cystic fibrosis (CF) patients receiving pancreatic enzyme replacement therapy (PERT)
3104932|NCT01858519||Matched control patients unexposed to PERT|Patients unexposed to pancreatic enzyme replacement therapy (PERT); matched on age and location of residence to PERT-exposed CF patients with chronic disease.
3104933|NCT01858506|Experimental|I-ACE intervention arm|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
3104934|NCT01858506|Active Comparator|Standard lifestyle advice arm|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
3104935|NCT01858493|Experimental|Continence promotion group education|A single 1-hour continence promotion group education workshop, facilitated by the research coordinator, aimed at changing knowledge and beliefs about urinary incontinence and different treatment options. An evidence-based self-management tool will be distributed at the end of the workshop.
3104936|NCT01858493|Sham Comparator|Sham health lecture|A single 1-hour group education workshop on other health topics of concern to older women such as memory, hearing, insomnia
3104937|NCT01858480|Active Comparator|D-ribose|D-ribose administered via peripheral intravenous for 24 hours followed by oral D ribose dosing for 3 months versus placebo in subjects with CHF who have been stabilized following hospitalization for acute decompensation.
3104938|NCT01858480|Placebo Comparator|Placebo|Placebo dosage form designed to mock active.
3104939|NCT01858467|Experimental|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway (Airway Device) with gastric tube. Preoxygenation, rapid sequence induction and cricoid pressure. Propofol 2 to 3mg/kg with 100mg succinylcholine. General anaesthesia with sevoflurane.
3104940|NCT01858467|Active Comparator|Endotracheal Intubation|Endotracheal intubation (Airway Device) using Macintosh Laryngoscope with tracheal tube with gastric tube insertion after placement. Preoxygenation, rapid sequence induction and cricoid pressure. Propofol 2 to 3mg/kg with 100mg succinylcholine. General anaesthesia with sevoflurane.
3104941|NCT01858454|Experimental|HALS for myomectomy|Hand-assisted laparoscopic surgery for myomectomy
3104942|NCT01858454|Active Comparator|Open myomectomy|Open surgery for myomectomy
3104943|NCT01858441|Other|Abiraterone Acetate|
3104944|NCT01858428|Active Comparator|Bare PTA|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
3104945|NCT01858428|Experimental|Drug-Coated PTA|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
3104946|NCT01858415|Experimental|Single arm|
3104947|NCT01858402|Active Comparator|Paracetamol|15 mg/kg paracetamol, IV (in the vein)(premixed with 0.9% sodium chloride to a total of 50 ml)single dose
3104948|NCT01858402|Active Comparator|Dipyrone|15 mg/kg IV (in the vein)dipyrone received (premixed with 0.9% sodium chloride to a total of 50 ml), single dose
3104949|NCT01858389|Experimental|Cohort A|Patients with NSCLC whose tumor has a documented T790M mutation in exon 20 of the Epidermal Growth Factor Receptor.
3104950|NCT01858389|Experimental|Cohort B|Patients with NSCLC. No requirement of a specific molecular signature, but excluding known T790M mutations.
3104951|NCT01858376|Other|Capros dietary supplement|Subjects will take Capros supplement (1 capsule) twice a day for 12 weeks.The subjects then will have blood drawn seven times throughout the course of the study.
3104952|NCT01858363|Experimental|Paclitaxel-coated balloon|Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.
3104953|NCT01858363|Placebo Comparator|Bare balloon|Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.
3104954|NCT01858350|Other|Active Music Therapy|Active Music Therapy: A music therapist plays music to patients for 15 minutes
3104955|NCT01858350|Other|Passive Music Therapy|Passive Music Therapy: A music therapist plays a compact disc (CD) to patients for 15 minutes
3104956|NCT01858350|No Intervention|No intervention|
3104957|NCT01858350|Other|Distraction Therapy|Distraction Therapy: A child life specialist plays with patients for 15 minutes
3104958|NCT01858337|Experimental|green beans group,|1 of the 2 vegetable groups. The infants were weaned only with vegetables. With green beans every other day and another vegetable on the days in between.
3105000|NCT01858077|Active Comparator|XIENCE™|XIENCE PRIME everolimus eluting coronary stent system and the XIENCE Xpedition everolimus eluting coronary stent system
3104959|NCT01858337|Experimental|Artichoke group|1 of the 2 vegetable groups. The infants were weaned only with vegetables. With Artichoke every other day and another vegetable on the days in between
3104960|NCT01858337|Active Comparator|Apple group|1 of the 2 fruit groups. The infants were weaned only with fruits. With Apple every other day and other fruits on the days in between
3104961|NCT01858337|Active Comparator|Plums group|1 of the 2 fruit groups. The infants were weaned only with vegetables. With Plums every other day and other fruits on the days in between
3104962|NCT01858324|Experimental|educational tools|Subjects will receive at time 0 the educational tools (pamphlet-including a graphic-based summary, a magnet and a 12 minutes video). They will then have to answer a questionnaire 1 month later about knowledge, anxiety and satisfaction.
3104963|NCT01858324|No Intervention|Usual antenatal care|Subjects in this group will not receive any more educational tools that what is generally offered in routine antenatal care.
3104964|NCT01858311||Placebo vehicle|(2) placebo capsules following AM meal and (2) placebo capsules following PM meal.
3104965|NCT01858311||Tocotrienol capsules (400 mg)|(2) 100mg TCT capsules following AM meal and (2) 100mg TCT capsules following PM meal.
3104966|NCT01858311||Tocotrienol Capsules (800 mg)|(2) 200mg TCT capsules following AM meal and (2) 200mg TCT capsules following PM meal.
3104967|NCT01858298|Experimental|pulpectomy|The technique of pulpectomy will be performed in one appointment according to clinical guidelines and followed by a composite resin crown.
3104968|NCT01858298|Experimental|tooth extraction|The technique of tooth extraction of primary teeth will be performed according to clinical guidelines
3104969|NCT01858285||Epilepsy, genetics|
3104970|NCT01858272|Experimental|H5.020CMV.PDGF-b and limb compression bandage|This study will use a standard, three-six Phase I dose escalation scheme. Three subjects will be treated at the lowest dose. If zero of three experience dose limiting toxicity (DLT), three new subjects will be treated at the next higher dose. If one of three of the subjects at the lowest dose had experienced DLT, then three more for a total of six will receive the lowest dose. Of the six subjects who received the lowest dose, if only one of six experience DLT, then the dose will be escalated to the next higher dose. However, if more than one of six experiences DLT (i.e., any of the additional subjects), then the MTD will be declared and the next lower dose will be the recommended dose for future trials.
3104971|NCT01858259||cyclophosphamide|Patients receiving cyclophosphamide
3104972|NCT01858259||azathioprine|Patients receiving azathioprine
3104973|NCT01858259||mycophenolate mofetil|Patients receiving mycophenolate mofetil
3104974|NCT01858259||methotrexate|Patients receiving methotrexate
3104975|NCT01858259||no therapy|Patients receiving no immunosuppressive therapy
3104976|NCT01858246|Active Comparator|Bonebridge|Implantation with a Bonebridge
3104977|NCT01858246|Active Comparator|Bone Anchored Hearing Aid|Implantation with a Bone Anchored Hearing Aid
3104978|NCT01858233|Experimental|Intensive Behavioral Modification|intensive dietary counseling, increased activity, lactation consult
3104979|NCT01858233|No Intervention|Routine care|standard dietary counseling
3104980|NCT01858220||Video capsule examinee|Every subject having capsule endoscopy for any indication
3104981|NCT01858207|Active Comparator|TACE+ RFA|"This arm will be conventional TACE(Transcatheter Arterial Chemoembolization) plus RFA(radiofrequency ablation.~use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor."
3104982|NCT01858207|Active Comparator|RFA|Recent advances in local ablation are aimed to expand the ablation size (> 3cm in diameter) in a minimal session by utilizing the switching RF controller and simultaneous 2 or 3 RF electrodes placement. The procedure of RFA was according to manufacture algorithm. RFA was performed within 7 days after TACE because the embolization effect in reducing blood flow will be not evident afterwards.
3104983|NCT01858194|Experimental|Renal sympathetic denervation|Catheter-based Renal Sympathetic Denervation Ablation Arm
3104984|NCT01858194|Placebo Comparator|VT ablation alone|No further therapy in addition to VT ablation
3104985|NCT01858181|Experimental|Cohort 1|SC ocaratuzumab 40 mg weekly x 4 doses
3104986|NCT01858181|Experimental|Cohort 2|SC ocaratuzumab 80 mg weekly x 4 doses
3104987|NCT01858181|Experimental|Cohort 3|SC ocaratuzumab 80 mg weekly x 8 doses
3104988|NCT01858168|Experimental|One|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle
3104989|NCT01858168|Experimental|Two|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle Irinotecan, given by IV once per day on days 1-7 of each cycle
3104990|NCT01858155|Experimental|Melatonin|
3104991|NCT01858142|Experimental|Preparation intervention|The parental presence decision tool will be delivered as an App shown to families using an iPAD and a set of headphones. This App will include information on what to expect in the operating room as well as the role of the parents. The App incorporates the basic principles of other effective perioperative preparation interventions (e.g., providing both sensory and procedural information) and is tailored to the local context. In addition to preparatory information, the App will also inform parents of the role of parent anxiety on children's outcomes in the operating room.
3104992|NCT01858142|Placebo Comparator|Standard preparation|In standard preparation condition, treating nurses and anesthesiologists will provide information to parents as they standardly do when parents are present at induction; this includes information on logistical issues and safety in the operating room (e.g., where to stand, how to put on gown) and risks of anesthesia induction. Additionally, parents in the standard preparation condition will view a summary of this standard information as text on an iPAD.
3104993|NCT01858129|Experimental|Inhaled steroids (Budicort)|Inhaled Budicort
3104994|NCT01858129|Placebo Comparator|Control|Inhaled NS 0.9%
3104995|NCT01858116|Experimental|[68Ga]ABY-025|
3104996|NCT01858090|Placebo Comparator|Control Group|Control Group, Group C: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ Serum saline
3104997|NCT01858090|Active Comparator|Group Fentanyl|Group Fentanyl, Group F: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml+fentanyl (10 µg)
3104998|NCT01858090|Active Comparator|Group sufentanil|Group sufentanil, Group S: spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ sufentanil (2.5 µg)
3105001|NCT01858064|Experimental|OROS-MPH|OROS-MPH is administered in capsule form daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90mg/day.
3105002|NCT01858051|Active Comparator|Cholecalciferol Bolus Dose|70 patients will receive a bolus pre-operative oral dose of 150,000 IU cholecalciferol 3-7 days before surgery
3105003|NCT01858051|Active Comparator|Cholecalciferol Divided Dose|70 patients will receive an oral 100,000 IU cholecalciferol dose 3-7 days before surgery and an additional oral 50,000 IU cholecalciferol dose on post-operative day 1
3105004|NCT01858051|Placebo Comparator|Sugar Pill|35 patients will receive a placebo pill orally 3-7 days before surgery
3105005|NCT01858038|No Intervention|Control|The scar will be randomized and demarcated as the following: (1) treatment site and (2) control site (no treatment, no intervention) The treatment condition assigned for each site will be kept the same for all following treatment sessions
3105006|NCT01858038|Experimental|Intervention Fractional Laser treatment|Intervention: An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
3105007|NCT01858025|Experimental|Pencil Beam Scanning Radiation|Pencil Beam Radiation daily, Monday-Friday, for 5-6 weeks Mitomycin-C via IV on Days 1 and 29 5-Fluorouracil via infusion pump over 4 days, starting Day 1 and 29 of chemotherapy
3105008|NCT01858012||HCV infection|patients with hepatitis C infection
3105009|NCT01858012||non-HCV infection|healthy controls
3105010|NCT01857999|Experimental|Losartan|Losartan 50 mg bid orally
3105011|NCT01857999|Placebo Comparator|Placebo|Placebo 1 pill bid orally
3105012|NCT01857986|Experimental|Study group|Subjects in the study group will be connected to the AnapnoGuard 100 control unit operating in the normal clinical mode (automatic CO2 leak measurement above the cuff, cuff pressure control, evacuation of secretions and tracheal rinsing)
3105013|NCT01857986|Active Comparator|Control group|Subjects in the control group will be connected to the AnapnoGuard 100 control unit. In the control group, the cuff pressure control of the AnapnoGuard 100 control unit will be disabled (OFF). CO2 level above the cuff will be recorded. Suction and rinsing function will operate after the system detects no CO2.
3105014|NCT01857973|Experimental|Hybrid Closed Loop|In-clinic evaluation of the HCL System under various conditions.
3105015|NCT01857960||Adolescents|Acne survey among Mexican adolescents
3105016|NCT01857947|No Intervention|AECOPD Mr proADM|Patients involved in this study will have a simple blood sample collected for Mr proADM assessment at the end of study
3105017|NCT01857934|Experimental|Treatment|"Participants receive IV hu14.18K322A with each course of chemotherapy (cyclophosphamide, topotecan, cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide). Mesna will be given prior to and after cyclophosphamide infusion. Peripheral blood stem cell harvest (PBSC) and surgical resection of primary tumor will be performed, if feasible. Intensification therapy includes busulfan, melphalan, and levetiracetam with peripheral blood stem cell transplantation. A course of hu14.18K322A with natural killer cell infusion will be given to consenting participants. Radiation therapy will follow PBSC transplant with the exception of any patient requiring emergent radiotherapy. MRD treatment includes hu14.18K322A, G-CSF, GM-CSF, interleukin-2 and isotretinoin.~Cells for infusion are prepared using the CliniMACS System."
3105018|NCT01857921|Active Comparator|Pravastatin group|
3105019|NCT01857921|Experimental|Combination of Atorvastatin and trimetazidine group|
3105020|NCT01857908||Abiraterone acetate|All patients will be receiving abiraterone acetate as per standard of care
3105021|NCT01857895|Experimental|Exenatide infusion in Part A|Subjects in Part A will receive exenatide as a subcutaneous infusion at a constant rate for 24 hours.
3105022|NCT01857895|Experimental|Exenatide infusion in Part B|Subjects in Part B will receive exenatide with daily increases in the infusion rate.
3105023|NCT01857882|Experimental|Decision Support Workshop|The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.
3105024|NCT01857882|No Intervention|Standard Care|Routine pre-consultation education
3105025|NCT01857869|Experimental|0,1,7M Group (delayed fractional dose group)|0.5 mL dose of RTS,S/AS01B given at 0 and 1 months and followed six months later (month 7) by 0.1 mL dose of RTS,S/AS01B
3105026|NCT01857869|Experimental|0,1,2M Group|Three doses of 0.5 mL RTS,S/AS01B given one month apart (0,1 and 2 months)
3105027|NCT01857869|Experimental|Infectivity Control|Volunteers who will not receive any immunization but will undergo sporozoite challenge
3105028|NCT01857869|Experimental|0,1,7M P-No-Bo subgroup|Subjects from 0,1,7M delayed fractional group protected during first challenge, randomized to receive no boost at Booster Phase Study Day 0
3105029|NCT01857869|Experimental|0,1,7M P-Bo subgroup|Subjects from 0,1,7M delayed fractional group protected during first challenge, randomized to receive 0.1 mL RTS,S/AS01B boost at Booster Phase Study Day 0
3105030|NCT01857869|Experimental|0,1,7M NP-Bo subgroup|Subjects from 0,1,7M delayed fractional Group not protected during first challenge, to receive 0.1 mL RTS,S/AS01B boost at Booster Phase Study Day 0
3105031|NCT01857869|Experimental|0,1,2M P-No-Bo subgroup|Subjects from 0,1,2M Group protected during first challenge, randomized to receive no boost at Booster Phase Study Day 0
3105032|NCT01857869|Experimental|0,1,2M P-Bo subgroup|Subjects from 0,1,2M Group protected during first challenge, randomized to receive 0.1 mL RTS,S/AS01B boost at Booster Phase Study Day 0
3105033|NCT01857869|Experimental|0,1,2M NP-Bo subgroup|Subjects from 0,1,2M not protected during first challenge, to receive 0.1 mL RTS,S/AS01B boost at Booster Phase Study Day 0
3105034|NCT01857869|Experimental|Infectivity control rechallenge|Volunteers who will not receive any immunization but will undergo sporozoite challenge
3105035|NCT01857856|No Intervention|No treatment|no medical treatment
3105036|NCT01857856|Active Comparator|Eplerenone|Eplerenone (Inspra, 50 mg for 3 years once daily) oral, film-coated tablet 50 mg for 3 years once daily
3105037|NCT01857843|Experimental|ZES group|
3105038|NCT01857843|Active Comparator|EES group|
3105039|NCT01857843|Experimental|Vytorin group|
3105040|NCT01857843|Active Comparator|Mevalotin group|
3105083|NCT01857505||Posterior Approach Hip Replacement|105 consecutive patients previously operated on by a less invasive posterior approach at the same institution. These surgeries occurred prior to March, 2010.
3105041|NCT01857830|Experimental|Meditation Retreat Group|Participants in this group will participate in a 6 day meditation retreat at the La Costa Resort and Spa in Carlsbad, CA. They will be self-selected to participate in the retreat or are novice meditators randomized into this retreat.
3105042|NCT01857830|Active Comparator|Relaxation/Control Group|Participants in this group will stay at La Costa Resort and spa for a 6 day period and will participate in the Active Comparator Relaxation Group activities (i.e. series of lectures on longevity and health, shared meals, and other leisure activities).
3105043|NCT01857817|Experimental|VT-122 with physician's choice therapy|Participants will receive oral doses of 66 mg propranolol and 680 mg etodolac daily. Propranolol will be administered 44 mg with breakfast and 22 mg in the mid-afternoon (3PM). Etodolac will be administered 340 mg with breakfast and 340 mg with dinner.
3105044|NCT01857817|Placebo Comparator|Placebo with physician's choice therapy|Participants will receive physician's choice therapy as the standard of care as well as the placebo capsules that are of the same weight as propranolol and etodolac.
3105045|NCT01857804|Experimental|antibiotics and local antiseptics|systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with chlorhexidine gluconate 0,2%
3105046|NCT01857804|Experimental|antibiotics without local antiseptics|systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with saline
3105047|NCT01857804|Experimental|local antiseptics no antibiotics|no systemic antibiotics + implant surface decontamination with chlorhexidine gluconate 0,2%
3105048|NCT01857804|Placebo Comparator|no antibiotics and no local antiseptics|no systemic antibiotics + implant surface decontamination with saline
3105049|NCT01857791|Experimental|multidisciplinary, behavior modification|
3105050|NCT01857778||Lactating Women|
3105051|NCT01857765|Active Comparator|Standard of Care|
3105052|NCT01857765|Experimental|Rehabilitation|
3105053|NCT01857752|Experimental|temozolomide|
3105054|NCT01857726|Experimental|The TACE/TACI combination group|Transarterial chemoembolization with doxorubicin/transarterial chemoinfusion with cisplatin combination
3105055|NCT01857726|Active Comparator|The TACE-only group|Transarterial chemoembolization with doxorubicin
3105056|NCT01857713|Active Comparator|Reza Band UES Assist Device|Patient is own control. Compare baseline to last follow-up after using device
3105057|NCT01857700|Experimental|Conditional economic compensation|A scratch off card will be used to randomly determine which of the compensations will be offered: compensation for transport cost, compensation for lost wages, or compensation for transport cost and lost wages
3105058|NCT01857700|Placebo Comparator|Standard of Care|
3105059|NCT01857687||patients with coronary artery stenosis|
3105060|NCT01857661|Other|control|hearing aid without an integrated sound generator
3105061|NCT01857661|Experimental|sound generator|hearing aid with an integrated sound generator
3105062|NCT01857648|Experimental|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
3105063|NCT01857648|No Intervention|Control|Control group.
3105064|NCT01857622|Experimental|SRI 15mg|DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks.
3105065|NCT01857622|Experimental|Normal/MiRI low-dose group|DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors (body weight of ≤ 60 kg or the presence of concurrent treatment with quinidine or verapamil). DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors.
3105066|NCT01857622|Experimental|Normal/MiRI high-dose group|DU-176b was orally administered at a dose of 60 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors. DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors.
3105067|NCT01857609|Experimental|Metformin only|metformin 750mg(D-1), metformin 500mg (D1)
3105068|NCT01857609|Experimental|Metformin and Pantoprazole|pantoprazole 40mg(D-2)/ metformin 750mg + pantoprazole 40mg(D-1)/metformin 500mg + pantoprazole 40mg(D1)
3105069|NCT01857609|Experimental|Metformin and Rabeprazole|rabeprazole 20mg(D-2)/metformin 750mg+rabeprazole 20mg(D-1)/metformin 500mg+rabeprazole 20mg(D1)
3105070|NCT01857596|Experimental|Bupropion -> Lorexys LO -> Lorexys HI|Crossover with all on positive comparator,lower-dose Lorexys,higher-dose Lorexys
3105071|NCT01857583|Experimental|SRI 15mg (15 mL/min ≤ CLCR < 20mL/min)|Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.
3105072|NCT01857583|Experimental|MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min)|Mild Renal Impairment group orally administered 30mg DU-176b once daily for 14 days.
3105073|NCT01857583|Active Comparator|Fondaparinux (20 mL/min ≤ CLCR < 30mL/min)|Fondaparinux subcutaneously administered at a dose of 1.5mg once daily for 14 days.
3105074|NCT01857583|Experimental|SRI 15mg (20 mL/min ≤ CLCR < 30mL/min)|Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.
3105075|NCT01857570||Adult, clinical suspicion fractures wrist or carpus|- Patients (18 years and older) who are referred to our hospital for conventional radiography of the wrist and carpus
3105076|NCT01857557|Experimental|Aerobic Exercise|Fitness program for migraine patients in addition to usual headache care.
3105077|NCT01857557|No Intervention|Control Group|Patients receiving usual headache care but no exercise program
3105078|NCT01857544|Experimental|Aflibercept 2.0mg|Single arm - Intravitreal Aflibercept 2.0mg, 0.05 milliliters, monthly for 6 months.
3105079|NCT01857531|Experimental|Ganaxolone -- Nicotine Patch|"Pre-Quit Period:~Ganaxolone -- 400mg daily for the first 3 days, 800mg daily for the next 3 days and 1200mg daily for the remainder of the first 2 wks.~Nicotine Patches -- 21mg/24h nicotine patches applied daily during wks. 3 and 4.~Post-Quit Period:~Ganaxolone -- 1200mg daily for wk. 5, 800mg daily for 3 days, and 400mg daily for 3 days.~Nicotine Patches -- 21mg/24h for 4 wks., 14mg/24h for 1 wk., and 7mg/24h for 1 wk."
3105080|NCT01857518|Other|Depressed adolescents Group|Adolescents with a major depressive episode diagnosis
3105081|NCT01857518|Other|Healthy adolescent control Group|Healthy adolescents recruited from general population
3105082|NCT01857505||Direct Anterior Approach hip replacement|Single surgeon series of 105 consecutive patients who underwent hip replacement via the direct anterior approach on a fracture table
3105084|NCT01857492|Sham Comparator|SHAM|We will apply sham tDCS on the primary motor cortex. We will use the same montage and parameters of active tDCS. However the current will be applied for 30 seconds in the beginning of the procedure and after that the current is turned off. This parameter for sham stimulation was chosen based on previous studies that have shown that perceived sensations on the scalp such as tingling usually fade out in the first 30 seconds of tDCS. It should be noted that less than 3 minutes of tDCS induces no effects on cortical excitability [29] and also using 30 seconds of sham is a reliable method of blinding as shown by a randomized controlled study [30]. Subjects will also meditate while receiving stimulation
3105085|NCT01857492|Active Comparator|ACTIVE|"A 1x1 Low-intensity DC Stimulator such as the Soterix Medical Inc. (Model 1224-B New York, NY, USA) or an equivalent device will be used to deliver direct current through 35cm² saline-soaked electrodes. The anodal electrode will be placed over the left primary motor cortex (M1) while the cathodal electrode will be placed over the contralateral supra-orbital area. Primary motor cortex will be localized using the 10/20 EEG system (C3 or C4) and this is a reliable method for the technique of tDCS [5]. During active tDCS, a 2mA constant current will be delivered for 20 minutes while the subject meditates. The primary motor cortex is a reliable entry port to modulate dysfunctional activity in pain-related neural networks."
3105086|NCT01857479|Active Comparator|Inhaled budesonide|Nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day]
3105087|NCT01857479|Experimental|Inhaled budesonide plus amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day].~The first dose will be administered under direct supervision."
3105088|NCT01857466|Experimental|Floseal|In the Floseal group, the sites of bleeding were covered with Floseal under direct vision with a laparoscopic applicator and ovarian cortex was closed on itself and waited for 2 minutes for Floseal to act. Then, subsequently bleeding sites were reexamined with irrigation.
3105089|NCT01857466|Active Comparator|Bipolar coagulation|In the bipolar group, hemostasis of the ovarian parenchyma was achieved with selective minimal (20-30 watt current) bipolar coagulation without excessive coagulation of surgical defect to avoid damaging the ovary.
3105090|NCT01857453|Experimental|teatment arm|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
3105091|NCT01857440||Subjects with glaucoma (Cases)|This group will consist of patients with glaucoma who are under care at the Ohio State University Havener Eye Institute.
3105092|NCT01857440||Subjects without glaucoma (Controls)|This group will consist of matched controls who are free of glaucoma and other complications, and who received a comprehensive eye examination at the Ohio State University College of Optometry.
3105093|NCT01857401||Observational study|Blood draw only, observational study
3105094|NCT01857388|Experimental|ParentCorps|Teachers from Intervention schools will receive ParentCorps training and support.
3105095|NCT01857388|No Intervention|Wait List Control|Teachers from control schools will not receive training and support in Year 1, but will receive training and support in Year 2.
3105096|NCT01857375||Group receiving insulin via vial/syringe|This group will receive their insulin via vial/syringe
3105097|NCT01857375||Insulin Pen|Patients receiving insulin via insulin pen
3105098|NCT01857362|Active Comparator|Nitisinone 2 x 10 mg|Two nitisinone 10 mg capsules by mouth as a single dose
3105099|NCT01857362|Experimental|Nitisinone 1 x 20 mg capsule|One nitisinone 20 mg capsule by mouth as a single dose
3105100|NCT01857349|Active Comparator|Chlora Prep|Food and Drug Administration (FDA)-approved, surgical skin preparation solution: ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol; Enturia, El Paso, Texas)
3105101|NCT01857349|Active Comparator|Dura Prep|Food and Drug Administration (FDA)-approved, surgical skin preparation solution:DuraPrep (0.7% available iodine and 74% isopropyl alcohol; 3MHealthcare, St. Paul, Minnesota).
3105102|NCT01857336|Experimental|infusion group|Patients with PGF were planed to infusion peripheral harvest. The peripheral cell harvest was aphaeresis on the fourth or fifth day after mobilization with recombinant human granulocyte colony stimulating factor.
3105103|NCT01857323|Experimental|Albuterol Spiromax®|The approximate 50-day treatment period consisted of 180 mcg (90 mcg/dose cycle, 2 dose cycles) twice daily study medication administration with Albuterol Spiromax with dose-counter.
3105104|NCT01857310|Experimental|Folic acid and zinc supplementation|5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.
3105105|NCT01857310|Placebo Comparator|Placebo|Matching placebo, taken orally daily for 6 months.
3105106|NCT01857297|Experimental|Adults (aged 18 to 59 years)|The study vaccine (Enzira® vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
3105107|NCT01857297|Experimental|Older Adults (aged 60 years or older)|The study vaccine (Enzira® vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
3105108|NCT01857284|Experimental|Group 1|Tauroursodeoxycholic Acid Capsules,250mg,tid.
3105109|NCT01857284|Active Comparator|Group 2|Ursodeoxycholate acid capsules, 250mg,tid,
3105110|NCT01857271|Experimental|Treatment (erlotinib hydrochloride and thoracotomy)|Patients receive erlotinib hydrochloride PO QD for 2 months and then undergo thoracotomy.
3105111|NCT01857258|Experimental|Green Tea|Participants will be provided a confection containing green tea concentrate
3105112|NCT01857258|Active Comparator|Control|Participants will be provided a confection devoid of green tea concentrate
3105113|NCT01857245|Experimental|Modified Directly Observed Therapy (mDOT)|In our mDOT model, pegylated interferon is administered once weekly, and one daily dose of oral medication is administered at the methadone window.
3105114|NCT01857245|Experimental|Concurrent Group Treatment (CGT)|In our CGT model, patients initiate HCV treatment within a once weekly treatment group which provides social support to mitigate fears of side effects, promote efficient education, and deliver weekly injections.
3105115|NCT01857245|Active Comparator|Treatment as Usual|In the TAU arm, subjects will receive all medications monthly (or more often as needed) at the clinic.
3105116|NCT01857232|Active Comparator|Control|OND + DEX + FOS followed by oral DEX
3105117|NCT01857232|Placebo Comparator|Placebo|OND + PLACEBO followed by oral PLACEBO
3105118|NCT01857232|Experimental|Low dose|OND + APD403 followed by oral APD403 low dose
3105119|NCT01857232|Experimental|Mid dose|OND + APD403 followed by oral APD403 mid dose
3105120|NCT01857232|Experimental|High dose|OND + APD403 followed by oral APD403 high dose
3105121|NCT01857219|Experimental|Role of Tai Chi in Fibromyalgia|"Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM.~In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. For the remaining sessions, the subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm-up and self-massage and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture.30"
3105122|NCT01857206|Experimental|TIVc|Subjects ≥4 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.
3105123|NCT01857206|Active Comparator|TIVf|Subjects ≥4 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.
3105124|NCT01857193|Experimental|L-R-E arm|LEE011 + everolimus + exemestane triple combination
3105125|NCT01857193|Experimental|L-E arm|LEE011 + exemestane double combination
3105126|NCT01857180|Experimental|Curriculum|Participants in the curriculum group took part in a structured, comprehensive curriculum consisting of a 1 hour didactic cognitive component, a 1 hour didactic non-technical (team-based skills) component, and 6 hours of structured technical skills practice in peg transfer, intracorporeal suture, and VR simulator tasks. Participants had the opportunity to ask questions and engage in discussion with experts after the didactic sessions, and received subjective feedback from circulating residents in addition to objective feedback in the technical skills tasks.
3105127|NCT01857180|No Intervention|Self-directed|Participants in the control (self-directed) group took part in 8 hours of self-directed learning with written materials for cognitive and non-technical skills components and unstructured surgical simulation practice of technical skills with only objective feedback from the simulator for the VR tasks or time for the peg transfer and intracorporeal suture tasks.
3105128|NCT01857167|Experimental|Fish Oil Supplementation|Patients will receive fish oil capsules, at a dose of 4g/day. Each 1g capsule will contain 300mg of EPA and 200mg of DHA.
3105129|NCT01857167|Experimental|Flaxseed Oil Supplementation|Patients will receive flaxseed oil capsule, at a dose of 4g/day. Each 1g capsule will contain 630mg of ALA
3105130|NCT01857167|Placebo Comparator|Placebo Supplementation|Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil.
3105131|NCT01857154|Active Comparator|Bisphosphonates/Micronized Calcium Carbonate/Vitamin D3|Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3
3105132|NCT01857154|Active Comparator|Bisphosphonates/Non-Micronized Calcium Carbonate/Vitamin D3|Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.
3105133|NCT01857154|Active Comparator|Non-Micronized Calcium Carbonate/Vitamin D3|Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.
3105134|NCT01857154|Active Comparator|Micronized Calcium Carbonate/Vitamin D3|Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3
3105135|NCT01857141|Experimental|dexmedetomidine|
3105136|NCT01857141|Placebo Comparator|normal saline|
3105137|NCT01857128|Experimental|Drawtex Hydroconductive Dressing|Gauze-like dressing placed onto wound
3105138|NCT01857128|Active Comparator|Negative Pressure Wound Therapy|Usual care including vacuum and canister
3105139|NCT01857115|Experimental|CCyd|"Treatment schedule for 9 cycles of induction:~Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.~Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.~Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8, 15 of Cycle 1, then for all subsequent doses 70 mg/m2 IV once daily on days 1, 8, 15, followed by 14-day rest period (day 16 through 28).~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib at the MTD defined by phase I study IV once daily on days 1, 8, 15."
3105140|NCT01857102|Active Comparator|etafilcon A/etafilcon A for Astigmatism|Subjects were randomized to one of two sequences of lens wear.
3105141|NCT01857102|Experimental|etafilcon A for Astigmatism/etafilcon A|Subjects were randomized to one of two sequences of lens wear.
3105142|NCT01857089|Experimental|Pressure Measurement|
3105143|NCT01857076|Active Comparator|Clinical|Subject submitted to clinical obesity treatment
3105144|NCT01857076|Active Comparator|Gastric bypass surgery|Subjects submitted to Gastric Bypass Surgery
3105145|NCT01857076|Active Comparator|Surgical ileal transposition with sleeve|Subjects submitted to surgical ileal transposition with sleeve
3105146|NCT01857063|Experimental|Montelukast/Placebo|Participants receive montelukast 5 mg chewable tablets for 7 days during Period 1 and receive placebo chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.
3105147|NCT01857063|Experimental|Placebo/Montelukast|Participants receive placebo chewable tablets for 7 days during Period 1 and receive montelukast 5 mg chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.
3105148|NCT01857037|Other|Single arm|Single arm
3105149|NCT01857011|Experimental|IV Iron|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
3105150|NCT01857011|Active Comparator|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
3105151|NCT01856998|Active Comparator|Diprivan® 20 mg/mL (AstraZeneca)|"Dosage form: lipid emulsion~Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER~Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS <40 with regard to individual condition and the respective surgery)~Duration: Until end of surgery"
3105152|NCT01856998|Experimental|Propofol 2% (20 mg/mL) MCT Fresenius|"Dosage form: lipid emulsion~Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER~Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS <40 with regard to individual condition and the respective surgery)~Duration: Until end of surgery"
3105153|NCT01856985|Experimental|Misoprostol at clinic|"Eligible women will receive 200 mg mifepristone to be administered at home or at the clinic and will receive either 800 µg misoprostol buccally (study 1) or 800 µg misoprostol sublingually (study 2) to self administer at home.~Participants will be asked to return to the hospital 14 days later for a follow-up visit."
3105154|NCT01856972|Experimental|Instrument Assisted Soft Tissue Mobilization|Subjects randomized into this treatment arm will receive Instrument Assisted Soft Tissue Mobilization to the Gastrocnemius/Soleus complex, as well as a standard stretching/ROM protocol
3105155|NCT01856972|Experimental|Rearfoot joint mobilization|Subjects randomized into this treatment arm will receive a rear-foot joint mobilization as well as a standard stretching/ROM protocol
3105156|NCT01856972|Active Comparator|Static stretching/ROM exercises|This is the control group consisting of Static stretching/ROM exercises. No manual intervention is performed with the group. The subjects will perform the standard stretching and ROM protocol
3105157|NCT01856959|Experimental|nebulized magnesium sulfate|nebulized magnesium sulfate 150mg and consisted about 5 min,which used only once
3105158|NCT01856959|Experimental|nebulized magnesium sulfate & albuterol|nebulized magnesium sulfate 150mg & albuterol 2.5mg and consisted about 5 min,which used only once
3105159|NCT01856959|Active Comparator|nebulized albuterol|nebulized albuterol 2.5mg and consisted about 5 min,which used only once
3105160|NCT01856946|Experimental|4,000 IU Vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
3105161|NCT01856933|Experimental|PSMA ADC|2.5 mg/kg, IV, over 60 minutes every 3 weeks
3105162|NCT01856920|Experimental|A|GI-6207 for 1 year
3105163|NCT01856920|Experimental|B|6 months of surveillance followed by GI-6207 for 1 year
3105164|NCT01856907|Experimental|Sitagliptin-Metformin|50 mg/1000 mg twice a day (BID)
3105165|NCT01856907|Placebo Comparator|Placebo pill|1 pill/BID for 16 weeks
3105166|NCT01856907|Active Comparator|Metformin|1000 mg BID
3105167|NCT01856881|Active Comparator|AMG 876|
3105168|NCT01856881|Placebo Comparator|Placebo|
3105169|NCT01856868|Experimental|Treatment with Epicatechin|Purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
3105170|NCT01856855|Experimental|Stereotactic Body Radiation Therapy with Integrated Boost|
3105171|NCT01856842|Active Comparator|Interlock fibered IDC Occlusion System|Pulmonary angiography and embolotherapy technique using Interlock (TM) fibered IDC Occlusion System(TM)
3105172|NCT01856842|Active Comparator|Nestor Coil|Pulmonary angiography and embolotherapy technique using Nestor coils
3105173|NCT01856829|Placebo Comparator|Control|Control participants will take placebo capsules daily for 4 weeks before and for the duration of the test. At week 4, participants will undergo a training protocol consists of a series of five sessions consecutively performed at intervals of 3 to 7 days. Taking products will be made more specifically 30 minutes before the start of the sessions.
3105174|NCT01856829|Experimental|Omega-3|Omega-3 participants will take capsules daily for 4 weeks before and for the duration of the test. At week 4, participants will undergo a training protocol consists of a series of five sessions consecutively performed at intervals of 3 to 7 days. Taking products will be made more specifically 30 minutes before the start of the sessions.
3105175|NCT01856816|Experimental|Meal Pattern Treatment A|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group A.
3105176|NCT01856816|Experimental|Meal Pattern Treatment B|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group B.
3105177|NCT01856816|Other|Treatment Group C|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group C.
3105178|NCT01856803|Active Comparator|routine prophylaxis|In this group, CSA plus MMF and MTX adopted as prevention of GVHD.
3105179|NCT01856803|Experimental|ATG prophylaxis|In this group,ATG+MMF+CsA+MTX was adopted as prevention of GVHD
3105180|NCT01856790|Active Comparator|ePID closed loop system without liraglutide|liraglutide will not be given while subject uses ePID closed loop system
3105181|NCT01856790|Experimental|ePID closed loop system with liraglutide|liraglutide will be given while subject uses ePID closed loop system
3105182|NCT01856777|Other|High sensitivity urine pregnancy test|Standard medical care and high sensitivity urine pregnancy test
3105183|NCT01856777|Other|Semi-quantitative panel test|Standard medical care and semi-quantitative panel test
3105184|NCT01856764|Experimental|0.5% Roflumilast Cream|Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.
3105185|NCT01856764|Placebo Comparator|Vehicle Cream|Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.
3105186|NCT01856751||haemophilia|Patients with acquired haemophilia. Patients with haemophilia A with inhibitor.
3105187|NCT01856738|Placebo Comparator|Placebo|placebo capsule for oral use 6,0 mg BID during 24 months of follow-up
3105188|NCT01856738|Experimental|Rivastigmine|rivastigmine capsule for oral use 6,0 mg BID during 24 months of follow-up
3105189|NCT01856725|Active Comparator|MultiPoint Pacing programming based on hemodynamics|"CRT device implant with MultiPoint Pacing~Hemodynamic measurements for CRT device programming"
3105190|NCT01856725|Experimental|MultiPoint Pacing programming without hemodynamics|"CRT device implant with MultiPoint Pacing~CRT device programming without hemodynamics"
3105191|NCT01856712|Active Comparator|oral naltrexone|an initial 50 mg oral dose of naltrexone prior to hospital discharge plus a 30-day prescription for oral naltrexone
3105192|NCT01856712|Experimental|injectable naltrexone|a single 380 mg intramuscular injection of naltrexone (duration of action = 30 days)prior to hospital discharge followed by a second injection one month later.
3105193|NCT01856699||Study Group|Patients with cortical superficial siderosis and possible or probable cerebral amyloid angiopathy meeting the modified Boston criteria.
3105194|NCT01856699||Control Group|Patients with possible or probable cerebral amyloid angiopathy meeting the classic Boston criteria but without any cortical superficial siderosis.
3105195|NCT01856686|Experimental|BP22042013|This group of patients receive 2.000 kilocalories diet(60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
3105196|NCT01856686|Experimental|Low carbohydrate Diet|the second group of patients receive diet of 2.000 Kilo calories without rapidly absorbed carbohydrates and without proteins supplements
3105197|NCT01856673|Experimental|ARM 1: Component-Based Intervention|Common Elements Treatment Approach (CETA) only
3105198|NCT01856673|Experimental|ARM 2: Community Group Therapy|Narrative Community Group Therapy (NCGT) only
3105199|NCT01856673|Other|ARM 3: Standby group|Standby group without intervention, but under monthly monitoring.
3105200|NCT01856660|Experimental|Low-Fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
3105201|NCT01856660|Experimental|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow a low-carbohydrate diet where the daily carbohydrate target is 50g/d. There is no energy restriction. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
3105202|NCT01856647||lean (BMI≤ 24.9 Kg/m2)|Adipose tissue biopsy (fat biopsy) in 9 lean (BMI≤ 24.9 Kg/m2)
3105203|NCT01856647||obese (BMI= 30-40 Kg/m2)|9 obese (BMI= 30-40 Kg/m2)
3105204|NCT01856647||psoriatic lean|9 psoriatic lean
3105205|NCT01856647||psoriatic obese|9 psoriatic obese
3105206|NCT01856634|Experimental|Group 1: 12 to 17 years of age|Group 1: 100 mg Delamanid BID for 10 days + OBR
3105207|NCT01856634|Experimental|Group 2: 6 to 11 years of age|50 mg Delamanid BID for 10 days + OBR
3105208|NCT01856634|Experimental|Group 3: 3 to 5 years of age|25 mg Pediatric Formulation Delamanid BID for 10 days + OBR
3105209|NCT01856634|Experimental|Group 4: Birth to 2 years of age|"Delamanid Pediatric Formulation (DPF) for 10 days + OBR. DPF dose based on patient's body weight during baseline visit:~Patient's > 10 kg will receive DPF 10 mg BID + OBR~Patient's > 8 kg and ≤ 10 kg will receive DPF 5 mg BID + OBR~Patients ≤ 8 kg will receive DPF 5 mg QD + OBR"
3105210|NCT01856621|Active Comparator|Seretide Diskus and charcoal|Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal
3105211|NCT01856621|Active Comparator|Seretide Diskus|Single-dose of Seretide Diskus (50/500 mcg/inhalation)
3105212|NCT01856621|Experimental|SF Easyhaler and charcoal|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal
3105213|NCT01856621|Experimental|SF Easyhaler|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)
3105214|NCT01856595|Experimental|PF-06291874|
3105215|NCT01856595|Placebo Comparator|Placebo|
3105216|NCT01856582|Experimental|CD34+ selected stem cell infusion|An infusion of selected CD34+ stem cells will be given without any preparative regimen.
3105217|NCT01856569||observational|
3105218|NCT01856556|Experimental|NRX-1074, 1 mg|1 mg IV
3105219|NCT01856556|Placebo Comparator|Placebo|Saline
3105220|NCT01856556|Experimental|NRX-1074, 5 mg|5 mg IV
3105221|NCT01856556|Experimental|NRX-1074, 10 mg IV|10 mg
3105222|NCT01856556|Experimental|NRX-1074, 50 mg IV|50 mg
3105223|NCT01856556|Experimental|NRX-1074, 25 mg PO|25 mg
3105224|NCT01856556|Experimental|NRX-1074, 125 mg PO|125 mg
3105225|NCT01856543|Placebo Comparator|Eucerin|Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve application of the cream. Patients will be instructed to apply cream to the upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner quadrant, as well as irradiated nodal fields. They will be instructed to apply cream in a thin, uniform layer twice a day, in the morning and evening, and not within the immediate 4 hours prior to radiation treatment. Patients will be informed that application immediately following radiation treatment is acceptable for those scheduled to receive morning treatments. Patients will be provided diaries to record the date and time they applied the study cream. Pts should return the completed diaries on their weekly status checks and at the 2 weeks +/- 2 business days following the completion of RT.
3105266|NCT01856257|Experimental|Basiliximab+20 weeks of tacrolimus+MMF + belatacept|"Induction basiliximab and methylprednisolone, administration of NULOJIX® (belatacept) 24 hours post reperfusion (+/-12 hrs); maintenance immunosuppression with 1. )20 week course of Prograf® (tacrolimus) or equivalent 2.) CellCept® (mycophenolate mofetil- MMF), or Myfortic® (mycophenolate sodium), or equivalent.~Subjects participating in this arm may have tacrolimus reinstated, at a dose to be determined by the site investigator, if any of the following events occur: 1 - An acute rejection episode 2- Request of the subject or site Investigator."
3105267|NCT01856244|Experimental|sensorimotor treadmill training|specific treadmill control using oscillating platform
3105226|NCT01856543|Experimental|Mometasone Furoate 0.1%|Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve application of the cream. Patients will be instructed to apply cream to the upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner quadrant, as well as irradiated nodal fields. They will be instructed to apply cream in a thin, uniform layer twice a day, in the morning and evening, and not within the immediate 4 hours prior to radiation treatment. Patients will be informed that application immediately following radiation treatment is acceptable for those scheduled to receive morning treatments. Patients will be provided diaries to record the date and time they applied the study cream. Patients should return the completed diaries on their weekly status checks and at the 2 weeks +/- 2 business days following the completion of RT.
3105227|NCT01856530|Experimental|Oxytocin|Liquid intranasal oxytocin, 24 IU, administered once
3105228|NCT01856530|Placebo Comparator|Placebo|Matched placebo nasal spray
3105229|NCT01856517|Placebo Comparator|placebo|saline administration over 24 h following full optimization of patient according to current guidelines
3105230|NCT01856517|Active Comparator|clonidine|clonidine 1 mcg.kg-1.h-1 over 24 h following full optimization of the patient according to current guidelines
3105231|NCT01856504||CCTA Patient|"Consenting adult patients ≥18 years of age;~Suspected but without known prior history of CAD~Not actively taking heart rate lowering agents at least 48 hours prior to study (e.g., AV nodal blockers such as beta blockers, calcium channel blockers or digoxin)~Glomerular filtration rate >60 ml/min~CCTA and ICA within 1 week of each other with no interscan event (e.g., myocardial infarction or coronary revascularization)"
3105232|NCT01856491|Other|RELIANCE 4-FRONT™ Passive Fixation|Single arm, all patients will be implanted with the RELIANCE 4-FRONT™ Passive Fixation lead
3105233|NCT01856478|Experimental|afatinib|oral intake, once daily
3105234|NCT01856478|Active Comparator|methotrexate|intravenous bolus injection, once weekly
3105235|NCT01856465||Bariatric surgery of morbid obese|Morbid obese patient who undergo Bariatric surgery with NAFLD (NASH or SS) status
3105236|NCT01856452|Active Comparator|radioisotope|sentinel lymph node operation using radioisotope in the breast cancer patients
3105237|NCT01856452|Experimental|the mixture including indocyanine green|sentinel lymph node operation using the mixture of indocyanine green, blue dye and radioisotope in the breast cancer patients
3105238|NCT01856439|Other|Long term follow up|Long term follow up of patient's who received ProSavin in previous study
3105239|NCT01856426|Experimental|1- EDP239|EDP239 given once a day.
3105240|NCT01856426|Placebo Comparator|Placebo|1 treatment arm will be placebo, dose given once a day.
3105241|NCT01856426|Experimental|2- EDP239|EDP239 given once a day.
3105242|NCT01856426|Experimental|3-EDP239|EDP239 given once a day.
3105243|NCT01856426|Experimental|4-EDP239|EDP239 given once a day.
3105244|NCT01856413|Experimental|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
3105245|NCT01856387||normal pregnancy outcomes|do not expect poor pregnancy outcomes on normal patients
3105246|NCT01856387||adverse pregnancy outcome|high ratio of Neutrophil / lymphocyte ratio may predict preeclampsia eclampsia
3105247|NCT01856374|Active Comparator|Cypher group|
3105248|NCT01856374|Experimental|Xience group|
3105249|NCT01856374|Active Comparator|Pravastatin group|
3105250|NCT01856374|Experimental|Atorvastatin group|
3105251|NCT01856361|Experimental|Ramipril|The initial dose of ramipril will be 2.5 mg that will be started at visit 2, week zero of the study. The dose will be increased to 5 mg during visit 3, 4 weeks into the study, for a total of 32 weeks.
3105252|NCT01856361|Sham Comparator|Placebo|The placebo group will get a similar pill that will be started at visit 2, week zero of the study. Subjects will be asked to double the dose by taking two pills during visit 3, four weeks into the study, for a total of 32 weeks.
3105253|NCT01856348|Experimental|1, 25 dihydroxyvitamin D3 intake|This is a single arm study.
3105254|NCT01856322|Active Comparator|Sulindac|one tablet twice daily
3105255|NCT01856322|Placebo Comparator|Placebo|one tablet twice daily
3105256|NCT01856322|Other|Normal Volunteers (or control group)|Normal volunteers (or control group) enrolled with the only purpose to validate assays and the shipping method.
3105257|NCT01856309|Experimental|Sirukumab 100 mg|
3105258|NCT01856309|Experimental|Sirukumab 50 mg / placebo|
3105259|NCT01856296|Experimental|Arm A|ARM A patients with an identified oncogenic driver mutations/amplifications/translocations), who will potentially benefit from targeted therapies, either on the market or in clinical trials according to existing knowledge of matching oncogenic events with actionable drugs. This will be detected through Next Generation Sequencing (NGS) performed by Foundation Medicine, CLIA certified.
3105260|NCT01856296|Experimental|Arm B|patients negative for oncogene events (which remains the majority), for whom genome based relevant information will be obtained through functional genomics (micro arrays and gene expression profiling) performed by Institut Gustave Roussy, and innovative computational methods enabling a rational choice of therapies. For such patients we will apply a new prediction model of efficacy of existing and under clinical trial drugs, based on differences in gene expression profiling between tumor and normal biopsies to be matched with relevant genes that are related to drug activities.
3105261|NCT01856283|Experimental|Nilotinib|study of nilotinib 300 mg BID
3105262|NCT01856270|Experimental|Amitriptyline Immediate|The Amitriptyline Immediate group will begin study drug immediately after enrollment. Immediate Drug participants will be started on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
3105263|NCT01856270|Experimental|Amitriptyline Delayed|The Amitriptyline Delayed group will start the study drug at the Day 30 visit on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
3105264|NCT01856257|Active Comparator|Thymoglobulin®+tacrolimus+MMF|Induction with Thymoglobulin®, methylprednisolone, and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF)
3105265|NCT01856257|Experimental|Thymoglobulin®+belatacept+MMF|Induction with Thymoglobulin®, methylprednisolone, and maintenance with belatacept and mycophenolate mofetil (MMF)
3105270|NCT01856218|Experimental|UX003|"During the initial 14-week treatment period of the study, participants receive 2 mg/kg UX003 every other week (QOW) for 12 weeks. At Week 14, participants continue on UX003 therapy and begin a forced dose titration period for an additional 24 weeks at the dose sequence of 1, 4, and 2 mg/kg UX003 QOW as follows: 1 mg/kg UX003 for 8 weeks beginning on Week 14; then 4 mg/kg UX003 for 8 weeks beginning on Week 22; then 2 mg/kg UX003 for 8 weeks beginning on Week 30. Following the 24 week forced dose titration period, participants who continue on treatment (continuation period) received 2 mg/kg UX003 QOW beginning at Week 38 for up to an additional 36 weeks.~After the first phase of the study, participants who elect to continue drug treatment are transitioned to the long-term extension phase, where they are treated with UX003 at 4 mg/kg beginning at Week 74, for up to an additional 168 weeks."
3105271|NCT01856205|Placebo Comparator|IVIG in JE (JE-positive)|We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.
3105272|NCT01856205|Placebo Comparator|IVIG in Non-JE(JE-negative)|We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.
3105273|NCT01856192|Experimental|Arm A (rituximab, combination chemotherapy, lenalidomide)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1; prednisone PO on days 1-5; and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3105274|NCT01856192|Active Comparator|Arm B (rituximab, combination chemotherapy)|Patients receive rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone as in Arm A. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3105275|NCT01856179|Experimental|Echium oil young|"BMI<25,~age 20-30"
3105276|NCT01856179|Experimental|Echium oil older|age 40-70 BMI <25
3105277|NCT01856179|Experimental|Echium oil older, overweight|age 40-70 BMI >25
3105278|NCT01856166|Active Comparator|CEI-PCEA|Continuous Epidural Infusion coupled with Patient Controlled Epidural Analgesia
3105279|NCT01856166|Experimental|PIEB-PCEA|Programmed Intermittent Epidural Bolus coupled with Patient Controlled Epidural Analgesia
3105280|NCT01856153|Other|Before meal|Strawberry-Placebo-Placebo
3105281|NCT01856153|Other|With Meal|Placebo-Strawberry-Placebo
3105282|NCT01856153|Other|After Meal|Placebo-Placebo-Strawberry
3105283|NCT01856140|Experimental|1 million cells/ml of ALLO-ASC|1 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.
3105284|NCT01856140|Active Comparator|10 million cells/ml of ALLO-ASC|10 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.
3105285|NCT01856127|Experimental|Vilazodone|Vilazodone
3105286|NCT01856127|Active Comparator|Sertraline|Sertraline
3105287|NCT01856114|Experimental|Fentanyl Buccal Tablet|After a six minute walk test, participant will sit down and rest for up to 1 hour. They will then be given a Fentanyl tablet to put in between upper gum and cheek. Study physician will determine the morphine equivalent daily dose (MEDD) in real time using standardized equianalgesic ratios. Based on clinical practice and similarly to the dose used for breakthrough pain, an FBT dose equivalent to 20-50% of the MEDD used. After 30 minutes, participant asked about any side effects they may be having, and repeat the walking test. During each walk test, participant asked 6 times how hard it is to catch their breath. The total distance walked will also be recorded. Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
3105288|NCT01856114|Placebo Comparator|Placebo Buccal Tablet|After a six minute walk test, participant will sit down and rest for up to 1 hour. They will then be given a Placebo tablet to put in between upper gum and cheek. After 30 minutes, participant asked about any side effects they may be having, and repeat the walking test. During each walk test, participant asked 6 times how hard it is to catch their breath. The total distance walked will also be recorded. Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
3105289|NCT01856101|Experimental|BEZ235, powder|"Group 1: patients without PI3K pathway activation; no loss of PTEN and no activating PIK3CA mutation.~Group 2: patients with PI3K pathway activation as defined by PIK3CA mutation and/or PTEN loss"
3105290|NCT01856088|Experimental|Inspiron Stent|Stent Inspiron with Sirolimus
3105291|NCT01856088|Active Comparator|Biomatrix Flex Stent|Stent Biomatrix Flex with biolimus
3105292|NCT01856075||Patients treated with dronedarone|Patients treated with dronedarone at inclusion
3105293|NCT01856075||Patients treated with other antiarrhythmic drugs of interest|"The antiarrhythmic drugs of interest to which dronedarone will be compared are:~Class 1a/1c antiarrhythmics~Sotalol~Amiodarone"
3105294|NCT01856062|Experimental|Clomiphene plus dexamethasone|Oral dexamethasone will be added to clomiphene citrate
3105295|NCT01856062|Placebo Comparator|Clomiphene plus placebo|A placebo of dexamethasone will be given with clomiphene citrate
3105296|NCT01856049|Other|Umbilical Cord Blood Collection|Umbilical Cord Blood is drawn from the umbilical cord of newborn babies diagnosed with Hypoplastic Left Heart Syndrome, before placental detachment. Cord blood is packaged in a Credo Cube, and sent at a temperate state to the manufacturer immediately after draw. At least 65 mL of cord blood is needed to produce a stem cell product during manufacturing. Once processed, the patient's autologous cord blood stem cells will be frozen for their potential future use in a clinical trial.
3105388|NCT01855373|Active Comparator|PEAK ATP®|Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)
3105297|NCT01856036|Experimental|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
3105298|NCT01856023|Active Comparator|Treatment Arm 1|Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab.
3105299|NCT01856023|Active Comparator|Treatment Arm 2|Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.
3105300|NCT01856010||ECT Treatment|Those who were referred for ECT treatment for behavior refractory to standard care and who opted to undergo ECT treatment
3105301|NCT01856010||Standard Care (Non-ECT Group)|Those who were referred for ECT treatment for behavior refractory to standard care, but who opted to not undergo ECT treatment and continue with standard care.
3105302|NCT01855997||Adult CHB Participants Treated With Peg-IFN Alfa-2a|Adult participants with CHB infection, and who have completed at least 24 weeks of Peg-IFN alfa-2a with/without nucleoside analogue therapy and at least 24 weeks of follow-up, will be included. Participants will be recruited from Roche clinical trials or general practice; no treatment will be administered in this non-interventional study.
3105303|NCT01855984|Experimental|Oral mixed tocotrienols|2 capsules containing 100mg mixed tocotrienols per capsule taken orally once a day for 6 months
3105304|NCT01855984|Placebo Comparator|Placebo|2 capsules containing soya bean oil taken orally once a day for 6 months
3105305|NCT01855971|Active Comparator|Fragile X syndrome active group|"Administration of 400 mg/day of epigallocatechin-3-gallate (EGCG). Life Extension, Mega Green Tea Extract Decaffeinated, a dietary supplement containing EGCG extract (45% EGCGC).~Dosage form: capsules Route of administration: orally Dosage: 2 capsules per day (400 mg EGCG/day) Frequency: one capsule in the morning (fasting state) and a second capsule in the afternoon (before dinner).~Treatment period: 3 months~Cognitive training: non-pharmacological cognitive training 3 sessions per week (1 hour per session) by using the Feskits program."
3105306|NCT01855971|Placebo Comparator|Fragile X syndrome placebo|"Placebo administration. Placebo consists in same capsules containing rice flour.~Dosage form: capsules Route of administration: orally Dosage: 2 capsules per day Frequency: one capsule in the morning (fasting state) and a second capsule in the afternoon (before dinner).~Cognitive training: non-pharmacological cognitive training 3 sessions per week (1 hour per session) by using the Feskits program."
3105307|NCT01855958|Experimental|DIMST|The investigators used acupuncture needles with guide tubes (Suzhou Huanqiu Acupuncture Medical Appliance Co. Ltd., 218, China) that were 40 mm in length and 0.25 mm in diameter. The needling in DIMST was applied using an electro acupuncture device (Cosmotron, São Paulo, Brazil) in the dermatomes corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). DIMST using was administered maintaining a distance from the spinous process line of 2 cm. The anatomic sites of peripheral DIMST were the muscles vastus medialis, rectus femoris, vastus lateralis, tibialis anterior; and the pes anserinus bursae. All subjects received one 30min session using a frequency of 2 Hz.
3105308|NCT01855958|Sham Comparator|Placebo-sham|The investigators used the same electro acupuncture device (Cosmotron, Sao Paulo, Brazil), which was previously set to prevent the current to pass through the electrodes. Subjects were informed that it would be a stimulus of low intensity and high frequency that they probably would not have any sense of it. The electrodes were placed on the same points where the active stimulation was applied while the nerve stimulation unit was left in front of the subject, for 30 minutes. This positioning ensured that the intermittent diode simulating the electrical stimulus was visible and audible.
3105309|NCT01855945|Experimental|Group A|3.75 µg H3N2c HA + 0.125 mL MF59
3105310|NCT01855945|Experimental|Group B|7.5 µg H3N2c HÁ + 0.250 mL MF59
3105311|NCT01855945|Experimental|Group C|15 µg H3N2c unadjuvanted
3105312|NCT01855932|Experimental|Technology Supported|
3105313|NCT01855919|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for first 3 days and 20 mg for last 4 days of week.
3105314|NCT01855919|Placebo Comparator|Placebo|Placebo administered orally once every day for 15 weeks.
3105315|NCT01855906|Active Comparator|Gap balanced surgical technique|Study patients in this arm of the study will have their knee replacement done using the gap balanced technique. Gap balancing adjusts the bony cuts for femoral rotation to balance the soft tissues of the knee in flexion.
3105316|NCT01855906|Active Comparator|Measured resection surgical technique|Study patients in this arm of the study will have their knee replacement done using the measured resection surgical technique. Pre-determined bony cuts are made and appropriate balance is obtained by judicious soft tissue releases as required.
3105317|NCT01855893|Experimental|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
3105318|NCT01855893|Other|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
3105319|NCT01855880|Experimental|AbGn-168H Low Dose|Subject to receive low dose of AbGn-168H intravenously
3105320|NCT01855880|Experimental|AbGn-168H: High Dose|Subject to receive high dose of AbGn-168H intravenously
3105321|NCT01855880|Placebo Comparator|Placebo AbGn-168H|Subject to receive placebo
3105322|NCT01855867|Other|Stribild|Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg) taken for 28 days, within 72 hours of a possible sexual exposure to HIV
3105323|NCT01855854|Experimental|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or unacceptable toxicity.
3105324|NCT01855841|Active Comparator|Hemin|A peripheral perfusion of 4mg/kg of hemin (Normosang) diluted in 100mL NaCL (sodium chloride) 0.9% will be administered in 30-60minutes as soon as possible after the end of the ERCP, followed by 100mL of NacL 0.9% to flush the vein
3105325|NCT01855841|Placebo Comparator|Placebo|The same amount of NaCl 0.9% (100 ML followed by a flushing perfusion of 100mL) will be perfused to the patient as soon as possible after the end of the ERCP
3105326|NCT01855828|Experimental|Chemo plus Pertuzumab,Trastuzumab|During weeks 1-12, patients will receive pertuzumab, trastuzumab, and paclitaxel at the same time; during weeks 13-24 patients will receive pertuzumab and trastuzumab at the same time with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC).
3105327|NCT01855789|Experimental|Non-Randomized Participants (TCZ + MTX)|All participants will receive initial treatment with open-label TCZ + MTX. Participants who complete 24-week treatment with open-label TCZ + MTX and did not achieve a DAS28 score </=3.2 at Week 24, will continue receiving TCZ + MTX in open label manner up to Week 52.
3105328|NCT01855789|Experimental|Randomized Participants (TCZ + MTX)|Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score </=3.2 at Week 24, will be randomized to receive TCZ along with MTX up to Week 52.
3105329|NCT01855789|Active Comparator|Randomized Participants (TCZ + PBO)|Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score </=3.2 at Week 24, will be randomized to receive TCZ along with MTX matched placebo (PBO) up to Week 52.
3105330|NCT01855776|Other|Control Group|"The control group will receive a usual care educational programme at baseline created by the Singapore Health Promotion Board. This guide describes the importance of physical activity and illustrates one possible physical activity programme. It also discusses strategies for adopting a healthy lifestyle. They will not receive the Fitbit Zip wireless pedometer from the study team. However, they will receive $4 per week, regardless of physical activity levels."
3105331|NCT01855776|Experimental|Programme Only Group|This group receives the Fitbit Zip, and access to the Fitbit website. Fitbit Zip counts the number of steps walked, calories burned, and distance travelled. Participants can set goals for their physical activity levels, and will have access to personalised feedback from Fitbit. This group will also receive $4 per week, regardless of physical activity levels.
3105332|NCT01855776|Experimental|Cash Incentive Group|"This group receives the Fitbit Zip and the opportunity to earn money each week based on the number of steps logged on the pedometer during that week. We will offer the following incentive schedule:~$0 SGD for less than 50,000 steps during the week~$15 SGD for 50,000 - 69,999 steps during the week (max of 20,000 steps per day)~$30 SGD for 70,000 or more steps during the week (max of 20,000 steps per day) Participants will receive monthly payments in cash after their physical activity is confirmed. The incentive will be calculated separately for each week of the 6-month incentive programme."
3105333|NCT01855776|Experimental|Charitable Incentive Group|This group is identical to the cash incentive group except that incentive payments will be donated directly to a tax-exempt nonprofit charity of the participant's choice. The charity will be selected at the start of the programme but will be limited to the most common tax-exempt nonprofit charities operating in Singapore. As a motivational feedback component of the programme, participants will receive a thank-you email or letter from the charity.
3105334|NCT01855763|Experimental|metformin|group A1:Consists of patients with GDM who were given drug metformin as treatment group B1:Consists of patients with type 2 diabetes in pregnancy were given the drug metformin as treatment intervention with drug metformin is given for control of diabetes in esclation dose of 500mg /day upto 2.5 grams per day in two to three divided doses till delivery
3105335|NCT01855763|Active Comparator|insulin|GroupA2:gestational diabetes on insulin treatment Group B2:type 2 diabetes on insulin treatment intervention:insulin treatment till delivery
3105336|NCT01855750|Placebo Comparator|Treatment Arm A: placebo + R-CHOP|Treatment Arm A = placebo + R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone)
3105337|NCT01855750|Experimental|Treatment Arm B: ibrutinib + R-CHOP|Treatment Arm B = ibrutinib + R-CHOP
3105338|NCT01855737||Warfarin Using Group|
3105339|NCT01855724|Experimental|Gemcitabine-Pazopanib|"Gemcitabine 1000 mg/m2 administered intravenously on days 1 and 8 and Pazopanib 800 mg administered per os on days 1 to 21 every 21 days.~Treatment with gemcitabine/pazopanib combination will continue until disease progression, appearance of significant toxicity, completion of 8 cycles or informed consent withdrawal.~Upon completion of 8 treatment cycles with the combination, and in the absence of disease progression, administration of pazopanib monotherapy as maintenance treatment will be continued until disease progression, appearance of significant toxicity or informed consent withdrawal."
3105340|NCT01855711|Experimental|GR68755 (Alosetron hydrochrolide) group|GR68755 1 mg tablets QD in the morning every day for 28 days
3105341|NCT01855698||All patients registered|
3105342|NCT01855685|Experimental|Open label|X vivo gene therapy
3105343|NCT01855672|Active Comparator|Perceivable Stimulation|Stimulation of the occipital nerves.
3105344|NCT01855672|Active Comparator|Non-Perceivable|Stimulation of the occipital nerves.
3105345|NCT01855659||COPD patients|Patients who are stratified in the subgroups of COPD based on the severity: stages II, III, IV
3105346|NCT01855633|Experimental|Tradtional Theta burst stimulation (TBS) rTMS|Participants will receive continuous theta burst stimulation (cTBS) rTMS to contralesional hemisphere based on a previous study (Huang et al., 2005)
3105347|NCT01855633|Active Comparator|Modified TBS rTMS|Participants will receive modified cTBS rTMS to contralesional hemisphere based on a previous study (Nyffeler et al., 2006)
3105348|NCT01855633|Sham Comparator|Sham rTMS|Participants will receive sham cTBS rTMS to contralesional hemisphere.
3105349|NCT01855620||Normal weight women|Women with implant for more than twelve months who have BMI <25.
3105350|NCT01855620||Overweight women|Women with implant for more than twelve months who have BMI > or = 25 and <30.
3105351|NCT01855620||Obese women|Women with implant for more than twelve months who have BMI > or = 30.
3105352|NCT01855607|Experimental|topical menthol|topical menthol cream to hands and feet
3105353|NCT01855607|Placebo Comparator|placebo cream|topical cream without menthol
3105354|NCT01855594|Experimental|Lithium treatment group|Lithium carbonate, 250mg/tablet. The dose starts with three times a day and one tablet each time for a week. The daily dose will then be adjusted according to serum lithium level and clinical finding. Target serum lithium level is 0.6 - 1.2mmol/L.
3105355|NCT01855594|Placebo Comparator|Control group|The dose of the placebo will be adjusted according to the dummy serum level report.
3105356|NCT01855581||sedation group|Children requiring sedation for MRI/CT
3105385|NCT01855386||Controls without Gestational Diabetes|Matched control subjects without Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
3105386|NCT01855373|Other|Placebo|No active ingredient
3105387|NCT01855373|Active Comparator|PEAK ATP® with GlycoCarn®|Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)and Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)
3105357|NCT01855568|Experimental|Single-dose methotrexate protocol|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell <15% between day 11 and 14."
3105358|NCT01855568|Experimental|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell <15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
3105359|NCT01855555||sedation group|Children requiring sedation for MRI/CT
3105360|NCT01855542|Experimental|0.9% saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
3105361|NCT01855542|Active Comparator|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
3105362|NCT01855529|Experimental|Ropivacaine arm|Ropivacaïne 2 mg/ml 10ml/h
3105363|NCT01855529|Placebo Comparator|NaCl arm|NaCl 0,9% 250ml 10 ml/h
3105364|NCT01855516|Active Comparator|UFH 5000 U three times a day|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
3105365|NCT01855516|Active Comparator|UFH 5000 U two times a day|Study subjects will be randomized to receive heparin 5000 U subcutaneous two times a day.
3105366|NCT01855503||Metastatic Breast Cancer|
3105367|NCT01855490|Experimental|Single-arm treatment with Exenatide|Exenatide 5 mcg sc. injection 15 minutes prior to a MMTT and IVGTT
3105368|NCT01855477|Other|Histological biopsy procedure|This is a multicenter study combining histological biopsy of tumor material with DNA sequencing using Next Generation Sequencing (NGS) platform. The study aims to obtain a more accurate pre-treatment stratification of cancer patients by obtaining fresh tumor biopsies for next-generation sequencing to obtain a mutational profile.
3105369|NCT01855464|Experimental|wedge resection+parietal pleurectomy|Surgical treatment includes parietal pleurectomy and wedge resection of the tip of the lung.
3105370|NCT01855464|Active Comparator|parietal pleurectomy|Surgical therapy is limited to parietal pleurectomy.
3105371|NCT01855451|Active Comparator|Radiation Therapy + Cetuximab|RT (70 Gy in 35 fractions, 5 days a week over 7 weeks) with weekly Cetuximab (400 mg/m2 loading dose IV prior to radiation, followed by weekly cetuximab 250 mg/m2 for the duration of the radiotherapy)
3105372|NCT01855451|Active Comparator|Radiation Therapy + Cisplatin|RT(70 Gy in 35 fractions, 5 days a week over 7 weeks) with weekly Cisplatin (40 mg/m2 IV for the duration of the radiotherapy)
3105373|NCT01855438|No Intervention|Usual Care|Kidney transplant candidates randomized to this arm will receive only the education provided by the transplant center. After data collection activities have concluded, transplant candidates in this arm will be offered the opportunity to attend a program session.
3105374|NCT01855438|Experimental|Living Donor Transplant Education 1|Participants randomized to Living Donor Transplant Education 1 will receive education on living donor kidney transplantation and its discussion.
3105375|NCT01855438|Experimental|Living Donor Transplant Education 2|Participants randomized to Living Donor Transplant Education 2 will receive education on living donor kidney transplantation and its discussion; they will also have the opportunity to practice discussing living kidney transplantation with simulated patients portraying participants' conversational partners.
3105376|NCT01855425|Other|Investigational CBCT|Radiation
3105377|NCT01855412||Claudication (Rutherford 2-3)|Patients who have been diagnosed with PAD and are classified as on the Rutherford Scale as Rutherford 2-3. Patients may be treated with any FDA-cleared endovascular PAD treatment.
3105378|NCT01855412||CLI Rutherford 4-5|Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 4-5. Patients may be treated with any FDA-cleared endovascular PAD treatment.
3105379|NCT01855412||CLI Rutherford 6|Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 6. Patients may be treated with any FDA-cleared endovascular PAD treatment.
3105380|NCT01855399|Experimental|Coaching with Decision Aid|All participants will be assigned to one of up to 87 peer coaches, who also are Detroit VA diabetes patients who previously had poor glycemic control but are currently in good control. After their baseline assessment, participants in both arms will receive information on their lab and blood pressure values and will be randomized to one of the two study arms. Participants in the TEC arm will be scheduled for an initial visit with their coach to review the decision aid, which has incorporated their personal baseline data.
3105381|NCT01855399|Active Comparator|Coaching without the Decision Aid|Participants randomized to the 'print materials' group will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns and develop an action plan to address barriers to self-management they have identified. During the next six months coaches in both arms will call their assigned peers once a week to provide support for their action steps.
3105382|NCT01855399|No Intervention|Observational Control Group|"For the investigators' 174 usual care observed group, the investigators will use CDW data to measure A1c levels. More than 85% of diabetes patients who meet the investigators' eligibility criteria receive A1c testing at recommended intervals, which should ensure adequate numbers of patients with follow-up A1c levels in the investigators' control sample. The study team will have no contact with this group."
3105383|NCT01855399|Experimental|Coach participants|Up to 87 peer coaches will participate in the intervention, as described above. All study measures will be captured for this group in order to investigate whether the activity of being a coach may have a positive effect on key measures.
3105384|NCT01855386||Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
3105389|NCT01855373|Active Comparator|GlycoCarn®|Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)
3105390|NCT01855360|Experimental|TUDCA and Doxycycline|TUDCA taken orally, 250 mg three times daily. Doxycycline taken orally, 100 mg twice daily
3105391|NCT01855347||Preterm infants|Preterm infants (32 to 36 weeks of postmenstrual age) will be evaluated with a Near infrared Spectroscopy monitor device.
3105392|NCT01855334|Experimental|Spironolactone + Placebo|Spironolactone 25 mg by mouth daily + Placebo L-arginine-liquid formulation by mouth 3 times daily
3105393|NCT01855334|Placebo Comparator|Double Placebo|Placebo spironolactone-1 tablet by mouth daily + Placebo L-arginine liquid formulation by mouth 3 times daily
3105394|NCT01855334|Experimental|Spironolactone + L-arginine|Spironolactone 25 mg daily + L-arginine 3 grams orally 3 times daily
3105395|NCT01855334|Experimental|L-arginine + Placebo|L-arginine 3 grams by mouth 3 times daily + Placebo spironolactone 1 tablet by mouth daily
3105396|NCT01855321|Active Comparator|Vitamin D|the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
3105397|NCT01855321|Placebo Comparator|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
3105398|NCT01855308||Single site robotic chole|Cholecystectomy performed through a single incision with the robot.
3105399|NCT01855295|Experimental|Protein Supplementation|Hemodialysis patients with inflammation and low body mas index to receive protein dietary advice and protein supplements while on dialysis
3105400|NCT01855282|Experimental|Behavioral intervention|Behavioral intervention consisting of 10 educational sessions promoting healthy diet and increased physical activity.
3105401|NCT01855282|Active Comparator|Control|Control arm received no behavioral intervention
3105402|NCT01855269|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
3105403|NCT01855269|Active Comparator|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil, foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
3105404|NCT01855269|Placebo Comparator|Sterile water|Sterile water: 5 drops, 30 minutes after feeding, once per day for 3 weeks
3105405|NCT01855256|Experimental|oxybutynin|Oxybutynin was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks.
3105406|NCT01855256|Placebo Comparator|Placebo|Placebo was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks.
3105407|NCT01855243|Active Comparator|glargine plus supplemental glulisine|Patients who will be recruited to be treated with glargine/glulisine, will received 50% of TDD as detailed demonstrated in Umpierrez et al., studies . as This includes administration of glargine (Lantus®) once every night plus glulisine (Apidra®) before each meal for BG ≥ 150 mg/dL. Glargine dose will be calculated as 0.2 U/kg/day for admission BG less than 200 mg/dL or 0.3 U/kg/day for BG exceeding 200 mg/dL. Glargine was given using Solostar Flex-Pen® once daily in the evening around 8:00 pm. Glulisine was given using the Solostar Flex-Pen® three times just before the meals for BG > 150 mg/dL according to hospital sliding scale. To avoid hypoglycemia, if for any reason, a subject missed a meal, the dose of glulisine will be held.
3105408|NCT01855243|Active Comparator|70/30 insulin plus supplemental lunch insulin|Modified split-mixed insulin protocol adopted by Umpierrez et al., will be applied to patients treated with 70/30 insulin. Insulin dose will be started at 0.4 U/kg/day for admission BG less than 200 mg/dL or 0.5 U/kg/day for BG above 200 mg/dL. Two thirds of total daily dose (TDD)will be given before breakfast and 1/3 of TDD before dinner. Supplemental lunchtime regular insulin dose will given for BG > 150 mg/dL . Patients previously treated with 70/30 insulin before admission initially will receivethe same regimen as at in home.
3105409|NCT01855243|Active Comparator|Sliding Scale insulin (SSI)|For SSI group, regular insulin will be administered three times daily subcutaneously approximately 30 min before meal for BG > 150 mg/dL (or every 8 hours if a patient was not eating) according to hospital sliding scale table
3105410|NCT01855230|Experimental|ASM-024|Dry Powder for Inhalation, b.i.d., 14 days
3105411|NCT01855230|Placebo Comparator|Placebo|Dry Powder for Inhalation, b.i.d., 14 days
3105412|NCT01855217|Active Comparator|Sugammadex total body weight|1 mg/kg total body weight
3105413|NCT01855217|Active Comparator|Sugammadex ideal body weight|1 mg /kg ideal body weight
3105414|NCT01855217|Placebo Comparator|placebo|placebo 0,9% NaCl
3105415|NCT01855204|Active Comparator|Conventional|Computed tomographic urography was done with conventional protocols.
3105416|NCT01855204|Experimental|Reduced|Computed tomographic urography was done with the protocols of low voltage and low iodine concentration.
3105417|NCT01855191||Standard|
3105418|NCT01855191||Standard + saliva collection|
3105419|NCT01855165|Experimental|Advice on DDIs|Attending physician will be randomly assigned to intervention arm care as usual; in the intervention arm, he/she will receive advice about DDIs between medications prescribed to patients on top of general heart failure advice.
3105420|NCT01855165|No Intervention|General advice|
3105421|NCT01855152|Experimental|Optimised WHELD intervention|The optimised WHELD intervention combining person centred care, promoting person centred activities and interactions and provide care home staff and general practitioners with updated knowledge regarding the optimal use of psychotropic medications for persons with dementia in care homes, is more effective in improving the quality of life and mental health, than usual care for people with dementia living in nursing homes.
3105422|NCT01855152|Experimental|Treatment as usual|Treatments delivered as usual
3105423|NCT01855139||Rivaroxaban|
3105460|NCT01854814|Active Comparator|losartan|maximus tolerated labeled dose of losartan
3105461|NCT01854801|Experimental|Experimental|Patients who declare themselves to be intolerant to electromagnetic fields benefit from medical care in occupational and environmental diseases centers and from a measurement of individual electromagnetic exposures and symptoms episodes. Each patient is his own control.
3105424|NCT01855126|Experimental|Blue light|"Participants will wear an actigraph for 2 weeks prior to coming to the lab for phase assessment. Participants will provide saliva samples for dim light melatonin onset (DLMO). The DLMO data from this baseline week, in conjunction with the Dimesimeter data will determine the time of light administration during weeks 6 and 9. There will be 2 weeks off between experimental sessions. During weeks 6 and 9 participants will be wearing the light measuring and delivery system, which is composed of the Dimesimeter, a computer, and the light mask. The light mask (red or blue) will be automatically programmed to be turned on for 120 min at the appropriate time for that evening, based on the feedback from the Dimesimeter data."
3105425|NCT01855126|Placebo Comparator|Red light|"Participants will wear an actigraph for 2 weeks prior to coming to the lab for phase assessment. Participants will provide saliva samples for dim light melatonin onset (DLMO). The DLMO data from this baseline week, in conjunction with the Dimesimeter data will determine the time of light administration during weeks 6 and 9. There will be 2 weeks off between experimental sessions. During weeks 6 and 9 participants will be wearing the light measuring and delivery system, which is composed of the Dimesimeter, a computer, and the light mask. The light mask (red or blue) will be automatically programmed to be turned on for 120 min at the appropriate time for that evening, based on the feedback from the Dimesimeter data."
3105426|NCT01855113||INVISALIGN®|those with an Invisalign® Treatment for orthodontic correction
3105427|NCT01855113||braces|those with braces for orthodontic correction.
3105428|NCT01855100||Rivaroxaban|
3105429|NCT01855074|Experimental|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
3105430|NCT01855061||Irinotecan|"Patients will be subjected to a their metastatic solid tumor. Radiological response will be evaluated after each 2 cycles: 1. percentage change in radiological volume of the index lesion (radiological measurable lesion that underwent biopsy) after the first two cycles of irinotecan; 2. radiological response according to RECIST 1.1 after each 2 cycles. Patients are intended to receive irinotecan until progressive disease or unacceptable toxicity. Patients will be subjected to another biopsy of the index lesion at definitive discontinuation of irinotecan. Patients will also be subjected to blood draws for determining patient's genetic background variation.~Side studies include:~pharmacogenetics~pharmacokinetics of SN-38~carboxylesterase activity in the index lesion~midazolam clearance test (only in Rotterdam patients)"
3105431|NCT01855048|Experimental|N-Rephasin® SAL200|N-Rephasin® SAL200, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg
3105432|NCT01855048|Placebo Comparator|INT200-Placebo|Placebo
3105433|NCT01855035|Experimental|prolonged ECG monitoring|Prolonged ECG monitoring: 10-day Holter ECG at months 0, 3 and 6
3105434|NCT01855035|Other|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
3105435|NCT01855022|Experimental|MI + IVR|90 days of motivational interviewing and 30 days of interactive voice response monitoring
3105436|NCT01855022|No Intervention|Usual Care|Usual care that a patient would receive absent the intervention
3105437|NCT01855009|Active Comparator|MannaBears|Subjects will take 4 MannaBears daily
3105438|NCT01855009|Active Comparator|MannaBears, AlgaeCal Calcium, Vitamin D3|Subjects will take 4 MannaBears daily and 3 Calcium/Vit D capsules (2 with breakfast and 1 with dinner or vice-versa) daily
3105439|NCT01855009|Active Comparator|MannaBears, Calcium Carbonate, Vitamin D3|Subjects will take 4 MannaBears daily and 3 Calcium/Vit D capsules (2 with breakfast and 1 with dinner or vice-versa) daily
3105440|NCT01854996|Experimental|Oral disperion fasted|A single dose of 450 mg PF-05089771 TS oral dispersion in fasted conditions.
3105441|NCT01854996|Experimental|Capsule fasted|single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fasted conditions
3105442|NCT01854996|Experimental|Capsule fed|single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fed conditions
3105443|NCT01854970|Experimental|Patient|
3105444|NCT01854957|Experimental|Autologous Mesenchymal Stem Cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
3105445|NCT01854957|Placebo Comparator|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
3105446|NCT01854944|Experimental|Brexpiprazole 1mg to 4mg|"Three cohorts of subjects will be evaluated:~- Cohorts 1 and 3 will receive high doses of brexpiprazole, and Cohort 2 will receive low doses of brexpiprazole."
3105447|NCT01854931|Other|Tai Ji Quan|Single aim intervention - 2 twice per week for 48 weeks
3105448|NCT01854918|Experimental|evolocumab (AMG 145) and standard of care|evolocumab (AMG 145) and standard of care
3105449|NCT01854918|Active Comparator|Standard of care|Standard of care therapy as per local practice
3105450|NCT01854905||Patients Attending Consultation for LASIK|Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
3105451|NCT01854892|Experimental|Manipulation|Spinal manipulation
3105452|NCT01854892|Experimental|Mobilization|Spinal mobilization
3105453|NCT01854892|Experimental|Laser Therapy|Cold laser therapy
3105454|NCT01854866|Experimental|Drug-packaging Microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
3105455|NCT01854853|Experimental|STYLE Brazil|STYLE-BRazil Multifamily Group HIV/STI Prevention intervention
3105456|NCT01854853|Active Comparator|Health Promotion|Health Promotion Intervention - Adolescents only
3105457|NCT01854840||Celesten in prevention of hyaline membrane disease.|Pregnant women that received at least a first injection of Celesten in the prevention of hyaline membrane disease.
3105458|NCT01854827|Experimental|IVIG active treatment|Intravenous immunoglobulin (IVIG) 10% 1 gm/kg body weight/dose Day 3-5,30, 60 post HPE
3105459|NCT01854814|Experimental|mycophenolate mofetil|mycophenolate mofetil 1.5g/day and maximum tolerated labeled dose of losartan
3105462|NCT01854788|Active Comparator|Autogenic drainage|All patients performed all interventions in a randomized order. Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
3105463|NCT01854788|Active Comparator|Slow expiration with glottis opened in lateral posture|All patients performed all interventions in a randomized order.Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
3105464|NCT01854788|Active Comparator|Temporary-Positive Expiratory Pressure|All patients performed all interventions in a randomized order. Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
3105465|NCT01854775|Experimental|Cohort 1 (12 to < 18 years of age)|Participants within the ages of 12 and <18 years old will receive E/C/F/TAF STR once daily with food.
3105466|NCT01854775|Experimental|Cohort 2 (6 to < 12 years of age)|Participants within the ages of 6 and <12 years old and weighing ≥ 25 kg will receive E/C/F/TAF STR once daily with food.
3105467|NCT01854762|Experimental|Raltegravir|Use of Raltegravir plus backbone treatment for pregnant women
3105468|NCT01854762|Active Comparator|Lopinavir/Ritonavir|Use of standard PI treatment (Lopinavir/r) plus backbone treatment for pregnant women
3105469|NCT01854749|Experimental|S1 combined with cisplatin|
3105470|NCT01854736|Active Comparator|GRAZAX|Tablet 75.000SQ-T once daily
3105471|NCT01854736|Placebo Comparator|Placebo|Tablet with no active grass component
3105472|NCT01854723|Experimental|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
3105473|NCT01854723|Active Comparator|Continuation of insulin glargine|Patients in this arm will continue on insulin glargine and serve as a control group.
3105474|NCT01854710|Other|Treatment sequence ABC|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
3105475|NCT01854710|Other|Treatment sequence ACB|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
3105476|NCT01854710|Other|Treatment sequence BCA|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
3105477|NCT01854710|Other|Treatment sequence BAC|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
3105478|NCT01854710|Other|Treatment sequence CAB|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
3105479|NCT01854710|Other|Treatment sequence CBA|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
3105480|NCT01854697|Experimental|Arm A: 3-DAA + RBV in GT1a|ABT-450/r/ABT-267 150 mg/100 mg/25 mg once daily (QD) and ABT-333 250 mg twice daily (BID) and weight-based RBV for 12 weeks (3 direct-acting antivirals [DAAs] with RBV in GT1a)
3105481|NCT01854697|Active Comparator|Arm B: TPV/PR in GT1a|Telaprevir (TPV) 750 mg every 8 hours (q8h) and pegIFN 180 µg/week and weight-based RBV (PR) for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1a)
3105482|NCT01854697|Experimental|Arm C: 3-DAA + RBV in GT1b|ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID and weight-based RBV for 12 weeks (3 DAAs with RBV in GT1b)
3105483|NCT01854697|Experimental|Arm D: 3-DAA in GT1b|ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID for 12 weeks (3 DAAs without RBV in GT1b)
3105484|NCT01854697|Active Comparator|Arm E: TPV/PR in GT1b|Telaprevir 750 mg q8h and pegIFN 180 µg/week and weight-based RBV for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1b)
3105485|NCT01854684|Experimental|Treatment (surgery and intraoperative PDT)|Patients receive temoporfin IV over no less than 6 minutes and then undergo standard surgical resection with intraoperative PDT.
3105486|NCT01854671|No Intervention|standard care|
3105487|NCT01854671|Experimental|family planning counseling led by community health worker|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
3105488|NCT01854658|Experimental|FF MDI (PT005)|FF MDI administered as two puffs BID
3105489|NCT01854658|Experimental|GP MDI (PT001)|GP MDI administered as two puffs BID
3105490|NCT01854658|Experimental|GFF MDI (PT003)|GFF MDI administered as two puffs BID
3105491|NCT01854658|Placebo Comparator|Placebo MDI|Inhaled placebo administered as two puffs BID
3105492|NCT01854645|Experimental|GFF MDI|Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) (PT003)
3105493|NCT01854645|Experimental|GP MDI|Glycopyrronium (GP) MDI (PT001)
3105494|NCT01854645|Experimental|FF MDI|Formoterol Fumarate (FF) MDI (PT005)
3105495|NCT01854645|Active Comparator|Open-label tiotropium bromide inhalation powder|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
3105496|NCT01854645|Placebo Comparator|Placebo|Placebo MDI
3105497|NCT01854632|Experimental|SIIL Live Attenuated Influenza Vaccine|Single 0.5 mL dose of trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
3105498|NCT01854632|Placebo Comparator|Matched placebo|Single 0.5mL inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
3105654|NCT01853618|Experimental|4/Arm C (never opened)|MTD of Tremelimumab + RFA or TACE
3105499|NCT01854619|Active Comparator|Saline irrigation|Saline irrigation via syringe will be administered using a sinus irrigation catheter under endoscopic control.
3105500|NCT01854619|Active Comparator|Double photodisinfection treatment|Patients in the double treatment arm will receive a second photodisinfection treatment 4 weeks following the first treatment with regular follow-up visits
3105501|NCT01854619|Active Comparator|Single photodisinfection treatment|The single-treatment group will receive a single photodisinfection treatment of all involved paranasal sinuses with multiple follow-up visits.
3105502|NCT01854606|Experimental|AEB071 and EVEROLIMUS|AEB071 and EVEROLIMUS will be taken together in this open-label non-randomized study
3105503|NCT01854593|Active Comparator|Bevacizumab injection and vitrectomy|0.16 mg/0.05 ml bevacizumab intravitreal injection one day before vitrectomy.
3105504|NCT01854593|Sham Comparator|Sham injection and vitrectomy|Sham injection one day before vitrectomy.
3105505|NCT01854580||Integrated care|Insured people in the Techniker Krankenkasse that are registered in the integrated care project.
3105506|NCT01854580||Control group|Insured people in the Techniker Krankenkasse that are not registered in the integrated care project.
3105507|NCT01854567|Experimental|Active|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
3105508|NCT01854567|Active Comparator|Control|Infusion of two unexpanded cord blood units.
3105509|NCT01854554|Experimental|Intensity Modulated Proton Radiotherapy (IMPT)|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
3105510|NCT01854554|Experimental|Intensity Modulated Radiotherapy (IMRT)|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
3105511|NCT01854541||Radiotherapy|All patients receiving radiotherapy
3105512|NCT01854528|Experimental|3-DAA/RBV|3-DAA (ABT-450/r/ABT-267 [150 mg/ 100 mg/ 25 mg once daily] and ABT-333 [250 mg twice daily]) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
3105513|NCT01854528|Active Comparator|TPV/RBV|TPV (750 mg every 8 hours) coadministered with pegIFN (180 micrograms subcutaneously [SC] weekly) and weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks, followed by pegIFN (180 micrograms SC weekly) and weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for either 12 or 36 weeks, per local prescribing information.
3105514|NCT01854515|Active Comparator|Budesonide|1 mg diluted in 4 cc of sterile water for 20 minutes, one hour preceding extubation. After extubation patients received nebulizing Budesonide via oxygen mask at the same dose every 12 h. for 48 h.
3105515|NCT01854515|Experimental|Dexamethasone|0.15 mg/kg before extubation. After extubation, the administration of intravenous Dexamethasone continued at the same dose every 12 h. for 48 h.
3105516|NCT01854502|Experimental|Oral hygiene and fluoride use|Parents of young children were given counseling of their own oral hygiene and the use of fluoride on their child's visit to public dental service. The child was given multi-faceted counseling for good oral health habits.
3105517|NCT01854502|No Intervention|Control|"Control, The parents were not given any intervention on their child's visit to public dental service.~The child was given multi-faceted counseling for good oral health habits."
3105518|NCT01854502|Experimental|Diet and use of xylitol|Parents of young children were given counseling of their own diet and the use of xylitol on their child's visit to public dental service. The child was given multi-faceted counseling for good oral health habits.
3105519|NCT01854489|Active Comparator|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
3105520|NCT01854489|Placebo Comparator|Placebo|The volunteers will be given oral placebo at 20.00 for 7 days
3105521|NCT01854489|Active Comparator|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
3105522|NCT01854476|Experimental|Tranexamic acid|pad-gauze with tranexamic acid (Hemostopan™)
3105523|NCT01854476|Placebo Comparator|Pad gauze|Pad gauze with no tranexamic acid
3105524|NCT01854463|Experimental|Vitamin D3|25-hydroxy vitamin d 2000 IU and elemeental calcium 200mg daily for 24 weeks
3105525|NCT01854463|Placebo Comparator|placebo|administered elemental calcium 200mg daily for 24 weeks
3105526|NCT01854450|Experimental|Asymmetrical Lateral Decubitus|Women in labor are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion
3105527|NCT01854450|Other|control|usual obstetrical care
3105528|NCT01854437||Mg Oxide|Mg Oxide (Mg®, 21st Century®) 250 mg orally for 4 weeks
3105529|NCT01854437||placebo|placebo 1 tab TDS
3105530|NCT01854424||ARDS|Ventilated patients with ARDS criteria (Berlin criteria) will be recruited in 3 ICU (2 from Bichat Hospital and 1 from Tenon Hospital, Paris) during the first 48 hours of their evolution. The patients will considered in 2 groups during analysis by taking into account their vital status at day-28 of inclusion.
3105531|NCT01854411||analgesic dose measure|breastfeeding mother who will take analgesics
3105532|NCT01854398|Experimental|CPAP group|
3105533|NCT01854398|Sham Comparator|sham-CPAP group|
3105534|NCT01854385|Experimental|Sumatriptan|Open label study of sumatriptan to treat post-traumatic headache. Subjects will use sumatriptan 100 mg at the onset of headache pain and may repeat the dose if not pain-free in 2 hours. Subjects will receive a maximum of 18 pills for use over two months. Subjects will maintain a daily headache diary.
3105535|NCT01854372|Experimental|R-HCVAD and R-MC Chemotherapy|"R-HCVAD - Rituximab (375 mg/m2), Cyclophosphamide (300 mg/m2), Mesna (600 mg/m2), Doxorubicin (50 mg/m2), Vincristine (2 mg total), Dexamethasone (40 mg total), Methotrexate (12 mg), Cytarabine (100mg).~R-MC -Rituximab (375 mg/m2),Methotrexate (200 mg/m2 - 800mg/m2), Cytarabine (3000mg/m2), Leucovorin (15mg - 50mg)."
3105536|NCT01854346|Experimental|Social skills group training KONTAKT|N= 144 participants are offered group training KONTAKT. The intervention includes 12 (brief intervention) and 24 (long intervention) sessions.
3105537|NCT01854346|No Intervention|Control group (TAU), the usual intervention / treatment|N = 144 participants are received treatment as usual (pharmacological therapy, family therapy, Cognitive behavioral therapy etc).
3105538|NCT01854333|Other|ADOS module 1-4, ADI-R|Individuals recruited within clinical services in child psychiatry and child medicine in Stockholm county and Lund for whom assessments with ADOS module 1-4 or ADI-R are appropriate.
3105539|NCT01854320|Experimental|Acceptance-based treatment|Behavioral therapy for weight loss focusing on acceptance-based cognitive strategies and techniques.
3105540|NCT01854320|Active Comparator|Standard behavioral treatment|"Standard behavioral therapy for weight loss, the gold standard treatment."
3105541|NCT01854307|Experimental|Pneumoperitoneum and SVV/PPV|
3105542|NCT01854294|Experimental|GM604 treated|8 subjects will receive GM604. Each GM604 treated subject will receive a slow IV bolus injection (~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
3105543|NCT01854294|Placebo Comparator|Placebo comparator|4 subjects will receive placebo. 6.4 mL Bacteriostatic saline will be used for the Placebo group. Injections will be given to the subject in the same manner as in GM604 treated group. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
3105544|NCT01854281||Patent foramen ovale dive A group|Divers with a previously diagnosed patent foramen ovale observed after Dive A.
3105545|NCT01854281||Closure dive A group|Divers with a patent foramen ovale previously closed by a catheter-based procedure observed after Dive A.
3105546|NCT01854281||patent foramen ovale dive B group|Divers with a previously diagnosed patent foramen ovale observed after Dive B.
3105547|NCT01854281||closure dive B group|Divers with a patent foramen ovale previously closed by a catheter-based procedure observed after Dive B.
3105548|NCT01854268|Experimental|Healthy adults who receive capsaicin|Single treatment consisting of healthy adults.
3105549|NCT01854255|Experimental|Intraperitoneal Chemotherapy|Patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4-6 weeks, applied intraperitoneally as pressurized aerosol chemotherapy. Duration of treatment will be 3 single doses in 6 weeks intervals, thus the duration of treatment is 18 weeks.
3105550|NCT01854242||Glycogen Storage Disease type Ia patients|The participants will have one blood draw for this study. The test will be performed on the blood.
3105551|NCT01854229|Active Comparator|Prospective pump candidates|New candidates who will receive the Prometra Programmable Intrathecal Infusion Pump
3105552|NCT01854229|Active Comparator|Previous IDE study subjects continuing with the therapy|Patients who were part of the previous IDE study, still have an active Prometra Programmable Intrathecal Infusion Pump, and are willing to continue in a study protocol.
3105553|NCT01854216|Experimental|Rotigotine in Japanese subjects|Repeated-Dose application of 1,2, and 4 mg / 24 hours Rotigotine in healthy Japanese subjects; Transdermal patch over 24 hours
3105554|NCT01854216|Experimental|Rotigotine in Caucasian subjects|Multiple-Dose application of 1, 2, and 4 mg / 24 hours Rotigotine in healthy Caucasian subjects; Transdermal patch over 24 hours
3105555|NCT01854203|Experimental|IInductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30 mg/m2，on day 1) repeated every weeks for 6 cycles during radiotherapy.
3105556|NCT01854203|Experimental|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
3105557|NCT01854190||Resistant hypertension|"Patients with uncontrolled blood pressure despite 3 medications, including diuretic.~Endothelial function assessed by peripheral arterial tonometry (PAT) by EndoPAT and the OSA diagnosis also through PAT, using the portable device WatchPAT."
3105558|NCT01854190||Controlled hypertension|Patients with controlled blood pressure by medications. These drugs are the same used in both groups.
3105559|NCT01854177|Active Comparator|aprepitant|aprepitant 125 mg
3105560|NCT01854177|Placebo Comparator|placebo|inert capsule
3105561|NCT01854164|Experimental|HGE(hydrolyzed ginseng extract)|HGE capsules(2cap/d, 960mg/d) for 8 weeks.
3105562|NCT01854164|Placebo Comparator|Placebo|Placebo for 8 weeks
3105563|NCT01854151|No Intervention|Standard Practice|Parents whose children are prescribed medication and meet inclusion/exclusion criteria will fill their medication at their regular pharmacy and receive medication with labeling and dosing instruments as per routine
3105564|NCT01854151|Experimental|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication and meet inclusion/exclusion criteria will receive medications with health literacy informed labels and dosing instruments
3105565|NCT01854138|No Intervention|Control|Retrospectively reviewed patients who underwent Total Knee or Hip Arthroplasty and received traditional gauze dressing to cover their clean surgical wound.
3105566|NCT01854138|Experimental|Prevena Knee/Hip|Prospectively enrolled patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty and receiving Prevena Incision Management System on the clean surgical wound.
3105567|NCT01854125|Active Comparator|autologous bone marrow mesenchymal stem cells transplantation|Every patient is given 1x106 MSCs per kg infused via liver artery
3105568|NCT01854125|Active Comparator|mesenchymal stem cells transplantation|autologous bone marrow mesenchymal stem cells transplantation
3105569|NCT01854125|Experimental|stem cells transplantation|autologous bone marrow mesenchymal stem cells transplantation
3105570|NCT01854112||T-cell lymphoma|
3105571|NCT01854099|Active Comparator|5 Day TMZ with PEP-CMV on Day 6-8|Standard TMZ (200 mg/m2/day x 5 days) with PEP-CMV vaccination on Day 6-8 of each monthly TMZ cycle
3105572|NCT01854099|Active Comparator|5 day TMZ with vaccine on day 22-24|Standard TMZ (200 mg/m2/day x 5 days) with vaccination on Day 22-24 of each monthly TMZ cycle
3105573|NCT01854099|Active Comparator|21 day TMZ wtih vaccine on day 22-24|Dose-intensified TMZ (100 mg/m2/day x 21 days) with vaccination on day 22-24 of each monthly TMZ cycle
3105574|NCT01854086||Postmenopausal women|Postmenopausal women treated with bisphosphonates
3105575|NCT01854073|Active Comparator|Group A|Group A, will receive injection Hyoscine butyl bromide 20 mg first dose at the time of amniotomy, and second dose 2 hours after.
3105576|NCT01854073|Placebo Comparator|Group B|Group B, will receive normal saline same volume first dose at the time of amniotomy, and second dose 2 hours after.
3105577|NCT01854060||irritable bowel syndrome|All new cases of clinical diagnosis of irritable bowel syndrome
3105655|NCT01853618|Experimental|5/Arm D|MTD of Tremelimumab + Cryoablation
3105578|NCT01854047|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1), followed by a single 300 mg injection q2w from Week 2 to Week 22 added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
3105579|NCT01854047|Experimental|Dupilumab 200 mg q2w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1), followed by a single 200 mg injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
3105580|NCT01854047|Experimental|Dupilumab 300 mg q4w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 300 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
3105581|NCT01854047|Experimental|Dupilumab 200 mg q4w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 200 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
3105582|NCT01854047|Placebo Comparator|Placebo q2w|2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 (Week 1) followed by a single injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
3105583|NCT01854034|Experimental|AUY922 Treatment Arm|AUY922 administered once weekly via intravenous, 70 mg/m2
3105584|NCT01854021|Experimental|inhalational anesthesia|inhalational anesthesia
3105585|NCT01854021|Experimental|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
3105586|NCT01854021|Experimental|intravenous anesthesia|intravenous anesthesia
3105587|NCT01854008|Experimental|rehabilitation program more the urban circuit|One group, the urban circuit group (UCG), received a triptych that included urban walking circuits,the remaining patients formed the non circuit group (NCG).These circuits can be obtained on the website http://www.mataro.cat/web/portal/ca/salut/salut_publica/itineraris/index
3105588|NCT01854008|Experimental|rehabilitation program non circuit group .|One group, the urban circuit group (UCG), received a triptych that included urban walking circuits,the remaining patients formed the non circuit group (NCG)
3105589|NCT01853995|Experimental|FLMGM Treatment Group|Cl II/1 patients treated with Fixed Lingual Mandibular Growth Modificator (FLMGM)
3105590|NCT01853995|No Intervention|Untreated Class II Control Group|control group
3105591|NCT01853982|Experimental|Ceftolozane/Tazobactam|3000 milligrams (mg) ceftolozane/tazobactam (comprised of 2000 mg ceftolozane and 1000 mg tazobactam), administered intravenously (IV), every 8 hours for 8 days
3105592|NCT01853982|Active Comparator|Piperacillin/Tazobactam|4500 mg piperacillin/tazobactam (comprised of 4000 mg piperacillin and 500 mg tazobactam), administered IV, every 6 hours for 8 days
3105593|NCT01853969||Patients who have carpal tunnel release surgery|
3105594|NCT01853956|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
3105595|NCT01853956|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
3105596|NCT01853943||Patent radial artery|Patient with patent radial artery after the percutaneous coronary procedure
3105597|NCT01853943||Occluded radial artery|Patients with occluded radial artery after the procedure
3105598|NCT01853930|Other|Laboratory training|Patients will be trained in the laboratory by a rehabilitation therapist
3105599|NCT01853930|Other|Home-based training|Patients will self instruct using the computer-based training with remote intervention by a therapist
3105600|NCT01853917||questionaires and structured interview|HIV infected women who are pregnant and receiving care in Harris County Hospital District single arm study Single arm study
3105601|NCT01853904|Other|Channel Suction first|This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
3105602|NCT01853904|Other|Syringe Suction first|This arm is for patients who will receive syringe suction first to obtain the specimen then channel suction to obtain the specimen.
3105603|NCT01853891|No Intervention|usual condition|sleep in usual room light condition for 5 nights
3105604|NCT01853891|Experimental|dLAN|sleep with dim light at night for 5 nights
3105605|NCT01853878|Experimental|PRAME ASCI group|Subjects will receive 13 doses of GSK2302032A Antigen-Specific Cancer Immunotherapeutic.
3105606|NCT01853878|Placebo Comparator|Placebo group|Subjects will receive 13 doses of placebo. As of 18 July 2014, all patients randomised to the placebo group were withdrawn from the study
3105607|NCT01853865|No Intervention|Follow-up|Patients in this arm attend regular follow-up examinations, as is the current standard, at the department of gynecology following surgery.
3105608|NCT01853865|Experimental|Self-referral|Instead of regular follow-up examinations, this group is carefully instructed in alarm symptoms that require contact with a physician.
3105609|NCT01853852|Experimental|50 mg|GR181413A/AT1001
3105610|NCT01853852|Experimental|150 mg|GR181413A/AT1001
3105611|NCT01853852|Experimental|450 mg|GR181413A/AT1001
3105612|NCT01853852|Placebo Comparator|Placebo|placebo
3105613|NCT01853826|Experimental|afatinib|Patients will receive afatinib once daily
3105614|NCT01853813|Other|Bevacizumab and FOLFIRI|Bevacizumab 5 mg/kg d1 q14 in combination with FOLFIRI (Irinotecan, leucovorin, 5FU I.V.bolus and 5FU I.V. c.i.)
3105615|NCT01853800|Experimental|Rivaroxaban (Treatment A) suspension (BN03501), fasted|Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment A, Batch number BN03501) under fasting conditions in any intervention period.
3105616|NCT01853800|Experimental|Rivaroxaban (Treatment B) suspension (BN03501), fed|Subjects received single oral dose of Rivaroxaban suspension 20 mg (Treatment B, Batch number BN03501) under fed conditions in any intervention period.
3105617|NCT01853800|Experimental|Rivaroxaban (Treatment C) suspension (BR05701), fasted|Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment C, Batch number BR05701) under fasting conditions in any intervention period.
3105656|NCT01853618|Experimental|6/Arm E|MTD of Tremelimumab + RFA
3105618|NCT01853800|Experimental|Rivaroxaban (Treatment D) IR tablet, fasted|Subjects received single oral dose of Rivaroxaban IR tablet 10 mg (Treatment D) under fasting conditions in any intervention period.
3105619|NCT01853787|Experimental|Formoterol Fumarate|At study day n°1 the patients will be randomized to take either Salmeterol or Formoterol in a double blind way.
3105620|NCT01853787|Active Comparator|Salmeterol|The second study arm represents the crossing over arm. Every patient, at study day number 2 will take a different medication (Salmeterol 50 mcg or Formoterol 12 mcg) from that taken at the study day n° 1.
3105621|NCT01853774|Experimental|Tailored Navigation|Participants will receive tailored navigation phone calls to assist them with barriers in making a clinic appointment or attending the clinic. The tailored navigation intervention protocol will be used to guide individuals from an especially hard-to-reach, multicultural, and underinsured population into primary care clinics and, subsequently, track the effects of this intervention through a clinic navigation program to complete Colorectal cancer screening.
3105622|NCT01853774|No Intervention|Control|Participants in the control arm will receive phone calls to support data collection and tracking, but not receive tailored messages
3105623|NCT01853761|Experimental|Exercise after, Transcutaneos, 25-10Hz|Experimental group 1 performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
3105624|NCT01853761|Experimental|25-50Hz microcurrent|Experimental group 2 performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50Hz.
3105625|NCT01853761|Experimental|percutaneous microcurrent|Experimental group 3 performed aerobic exercise just after microcurrent in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
3105626|NCT01853761|Experimental|Exercise at same time|Experimental group 4 performed aerobic exercise at the same time microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
3105627|NCT01853761|Placebo Comparator|Control Group|Control group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, but microcurrent device was switched off.
3105628|NCT01853748|Active Comparator|Study Drug|T-DM1 every three weeks by IV for 17 treatments (total of 51 weeks)
3105629|NCT01853748|Active Comparator|Standard of Care|Paclitaxel and Trastuzumab once per week by IV for 12 weeks. Beginning week 13, Trastuzumab only by IV injection every three weeks for 13 treatments
3105630|NCT01853735||bowel injury, NPO|
3105631|NCT01853735||bowel injury, EN|
3105632|NCT01853735||no bowel injury, NPO|
3105633|NCT01853735||no bowel injury, EN|
3105634|NCT01853722|Experimental|DCN01|
3105635|NCT01853722|Placebo Comparator|Unisol|
3105636|NCT01853709|Experimental|Multidisciplinary approach|"The multidisciplinary approach will include:~Education Fiber free diet Bisacodyl: 10 mg 2 days before the procedure, 20 mg the day before the procedure and 10 mg 3 hours before the procedure Adjuvants: Olive Oil:60 mL/Apple Juice: 200 mL PEG: 1 L the night before the procedure and 1 L 3 hours before the procedure"
3105637|NCT01853709|Active Comparator|Conventional approach|"The conventional approach will include:~Education Fiber free diet Polyethylene glycol (PEG): 2 L the night before the procedure, 2 L 3 hours before the procedure"
3105638|NCT01853696|Active Comparator|Loteprednol|Loteprednol etabonate 0.5% gel applied topically 4 times daily for 2 months, 3 times daily for 1 month, twice daily for one month and once daily for 7 months
3105639|NCT01853696|Active Comparator|Prednisolone acetate|Prednisolone acetate 1% ophthalmic solution applied 4 times daily for two months, 3 times daily for one month, twice daily for one month, and once daily for 7 months
3105640|NCT01853683|Experimental|Conservative Management|Children randomized to conservative management will be seen in the clinic 6-10 weeks after discharge and phoned to follow up every 3 month for a total follow-up of a year. Family will be instructed to come back to the hospital or call the treating physician if the child develops any abdominal pain or fever.
3105641|NCT01853683|Active Comparator|Operative Management|Children randomized to IA will be scheduled for an interval appendectomy 6-10 weeks after discharge, and will be seen in the clinic 6-8 weeks following the interval appendectomy and phoned for follow-up every 3 month for a total of one year.
3105642|NCT01853670|Experimental|definitive radiation + concomitant chemo|"Concurrent chemo + IGRT:~These patients will have chemotherapy during the time of radiation treatment"
3105643|NCT01853670|Experimental|neoadjuvant chemo|"Neoadjuvant chemo + IGRT:~These patients will have chemotherapy prior to other radiation treatment."
3105644|NCT01853657|Active Comparator|Virological monitoring|In addition to routine clinical and immunological monitoring with CD4 counts
3105645|NCT01853657|No Intervention|Routine monitoring|Immunological and clinical monitoring
3105646|NCT01853644|Experimental|Treatment (Tivozanib)|Tivozanib 1.5mg orally given daily for 3 weeks with one week off to complete a 4 week cycle until disease progression or adverse effects prohibit further therapy
3105647|NCT01853631|Experimental|CD19 CAR T Cells and Lymphodepletion for Bcell ALL|"3 daily doses of cyclophosphamide together with fludarabine with be administered finishing at least 24 hours before T cell infusion.~CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0."
3105648|NCT01853631|Experimental|CD19 CAR T Cells for Bcell ALL|CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0.
3105649|NCT01853631|Experimental|CD19 CAR T Cells and Lymphodepletion for Bcell NHL/CLL|"3 daily doses of cyclophosphamide together with fludarabine will be administered finishing at least 24 hours before T cell infusion.~CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0."
3105650|NCT01853631|Experimental|CD19 CAR T Cells for Bcell NHL/CLL|CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0.
3105651|NCT01853618|Experimental|1/Arm A1|Escalating doses of Tremelimumab + RFA or TACE
3105652|NCT01853618|Experimental|2/Arm A2|MTD of Tremelimumab + RFA or TACE
3105653|NCT01853618|Experimental|3/Arm B|MTD of Tremelimumab + TACE
3105657|NCT01853605|Experimental|Augmentation|Women undergoing breast augmentation.
3105658|NCT01853605|Experimental|Reconstruction|Women undergoing breast reconstruction.
3105659|NCT01853605|Experimental|Revision-Augmentation|Women undergoing revision of previous breast augmentation.
3105660|NCT01853605|Experimental|Revision-Reconstruction|Women undergoing revision of previous breast reconstruction.
3105661|NCT01853579|Experimental|1|Experimental: Drug: Levothyroxine The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
3105662|NCT01853579|Placebo Comparator|2|"Placebo Comparator: Drug: Placebo Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
3105663|NCT01853566|Experimental|growth hormone|GH group received an initial dose of 0.5 units (UI)/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study (6 months).
3105664|NCT01853553|Experimental|Spironolactone|Active arm
3105665|NCT01853553|Placebo Comparator|Sugar Pill|Placebo
3105666|NCT01853527||Angina pectoris, non-obstructive CAD|Contrast stress echocardiography will be performed in patients with angina pectoris and non-obstructive CAD on CT-angiography to detect presence of myocardial ischemia
3105667|NCT01853514||Low income|Income level equal or less than 250% above the poverty level
3105668|NCT01853501|Experimental|POF,treatment,ADSC|Fat from POF patients undergo Autologous fat grafting operation were separated, from which Adipose Derived Stem Cell were then purified and injected into the both ovaries of patients.
3105669|NCT01853488||Spinal Cord Injury|Persons with spinal cord injury Osteodensitometry DXA pQCT
3105670|NCT01853488||Reference|Reference population (able-bodied) Osteodensitometry DXA pQCT
3105671|NCT01853475|Experimental|Treatment A|PQP tablets 1440mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.
3105672|NCT01853475|Experimental|Treatment B|PQP tablets 960mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.
3105673|NCT01853475|Active Comparator|Treatment C - Reference|PQP Tablets 1440 mg and OZ439 PIB 800mg + full fat cow's milk
3105674|NCT01853462|Experimental|proprioceptive neuromuscular facilitation|proprioceptive neuromuscular facilitation exercise program
3105675|NCT01853462|Experimental|balance|balance exercise program
3105676|NCT01853449|Experimental|CWS+Fentanyl Citrate (250 mcg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
3105677|NCT01853449|Placebo Comparator|CWS+0.9% saline placebo|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
3105678|NCT01853449|Active Comparator|No CWS+Fentanyl Citrate (250 mcg)|No chest wall strapping (unloaded control) + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
3105679|NCT01853449|Placebo Comparator|No CWS+0.9% saline placebo|No chest wall strapping (unloaded control) + single-dose inhalation of 0.9% saline placebo
3105680|NCT01853436|Experimental|Single stage reconstructions|as defined for use in the Experimental arm
3105681|NCT01853436|Other|Two stage breast reconstructions|CONTROL: standard two stage breast reconstructions without Acellular dermal matrices (ADM), in patients who are clinically suitable candidates for reconstruction with Acellular dermal matrices(ADM)based single stage reconstruction technique. Reconstructions with Strattice™ Reconstructive Tissue Matrix
3105682|NCT01853423|Experimental|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
3105683|NCT01853410|Experimental|gekoTM device application|Single arm study. Application of gekoTM device as described above with assessment of effect on coronary flow and endothelial function.
3105684|NCT01853397|Experimental|Treatment at level 1|Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)
3105685|NCT01853397|Experimental|Treatment at level 2|Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)
3105686|NCT01853397|Experimental|Treatment at level 3|Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)
3105687|NCT01853397|Active Comparator|Treatment with 3 passes at 60 J/cm2|Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)
3105688|NCT01853384|Experimental|HP802-247 plus compression therapy|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days. Subjects randomized to HP802-247 will receive Vehicle on alternate weeks.
3105689|NCT01853384|Placebo Comparator|HP802-247 Vehicle plus compression therapy|fibrinogen solution & thrombin solution without cells. Subjects randomized to HP802-247 Vehicle will receive Vehicle weekly.
3105690|NCT01853371|Experimental|Wet cupping and conventional treatment|"Wet cupping: Will be administered through 3 sessions, with 4 weeks interval between each session and the other.~Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department."
3105691|NCT01853371|Active Comparator|Conventional treatment|Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department.
3105729|NCT01853059||IMRT|Prospective longitudinal assessment of patients receiving intensity-modulated radiation therapy for anal cancer
3105730|NCT01853059||Conventional|Cross-sectional analysis of patients receiving conventional radiotherapy
3105958|NCT01851590|Active Comparator|Terbinafine|250 mg of Terbinafine taken orally once daily for 3 months (Generics).
3105692|NCT01853358|Experimental|NK Cell infusion|"Cell collection~o Lymphocytes will be harvest from the original and consenting donor as soon as possible around day 60 post transplantation~NK Cell selection~o Cells will be obtained after double selection: CD3+ depletion followed by CD56+ selection using an european approved device (Miltenyi corporation)~NK Cell ex-vivo activation~o ex-vivo activation: interleukin-2 according to a classical procedure (7 days at 37°C with RPMI clinical grade medium supplemented with 10% of foetal calf serum, 0.5 x 106 cellules / ml, 1000 U/ml d'IL-2 (interleukin, proleukin)~NK Cell infusion (60 to 90 days after transplantation)"
3105693|NCT01853345||Refractory/Recurrent/High Risk Solid Tumors|
3105694|NCT01853332||Cross-Sectional|New participant: The purpose of the study is to learn about physical health in midlife and how it has been influenced by experiences and relationships. The study specifically targets health differences and the development of heart disease and diabetes.
3105695|NCT01853332||Longitudinal|Former participants (or the partner of a former participant) of the Adolescent and Family Development Project, Young Adult Development Project, Across Generations Project, and/or Paths Over Time Project may already know that this research shows how people grow, individually and as part of a familial and social network, throughout the course of life. This study focuses on learning about former participants' physical health in midlife and how it has been influenced by their experiences and relationships.
3105696|NCT01853319|Experimental|Regorafenib|Regorafenib, 40 mg tablets
3105697|NCT01853306|Experimental|Veliparib formulation A|veliparib formulation A
3105698|NCT01853306|Experimental|Veliparib formulation B|Veliparib formulation B
3105699|NCT01853306|Experimental|Veliparib formulation C|veliparib formulation C
3105700|NCT01853293|Active Comparator|Kudzu extract|Participants will take two 500-mg capsules of Kudzu extract, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
3105701|NCT01853293|Placebo Comparator|Placebo|Placebo capsule contains sugar beet filler. Participants will take two 500-mg capsules, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
3105702|NCT01853280|Experimental|L-Methylfolate|15 mg of L-Methylfolate (Deplin®) daily for 12 weeks as a supplement to OROS-Methylphenidate.
3105703|NCT01853280|Placebo Comparator|Placebo|15 mg matched placebo comparator, with open-label OROS-Methylphenidate
3105704|NCT01853267|Active Comparator|Control group (Packing)|The perianal abscess cavity will continue to be packed after discharge until healing is complete
3105705|NCT01853267|Experimental|Intervention Group (Non-Packing)|The cavity will be allowed to heal by secondary intention without packing.
3105706|NCT01853254|Experimental|Peginterferon alfa-2a monotherapy or combined with ribavirin|The treating investigator decided the most appropriate treatment. It was recommended that participants receive combination therapy.
3105707|NCT01853241||Single balloon|Single Balloon Enteroscopy
3105708|NCT01853241||Spirus|Spirus Enteroscopy
3105709|NCT01853228|Experimental|Decitabine and cytarabine|
3105710|NCT01853215|Experimental|Sternal intraosseous vascular access|Sternal intraosseous vascular access using T.A.L.O.N. Intraosseous System.
3105711|NCT01853202|Experimental|Group 1 - Supervised aerobic exercise training|This group will participate in 3 supervised exercise sessions/week at an intensity of 50%-70% of the individually determined VO2max between 30-45 min/session for 12 weeks. The aerobic training intervention will closely mimic the standard exercise-based guidelines adopted in cardiac rehabilitation. All intervention sessions will be performed in a supervised setting with one-on-one supervision by an American College of Sports Medicine-certified exercise physiologist. Aerobic exercise training will be prescribed based on the guiding ACSM principles with the aim of improving VO2max. Walking was chosen because it is the preferred mode of exercise training in cancer patients.
3105712|NCT01853202|No Intervention|Group 2|The 12-week program will consist of monthly phone contacts to check in with patient and review their exercise log entries for that month in order to capture physical activity done outside of the intervention setting.
3105713|NCT01853189|Other|OMT + Usual Care|
3105714|NCT01853189|Other|Usual Care|
3105715|NCT01853176|Experimental|Liposomal injection bupivicaine (Exparel)|Patients will have the maximum approved dose of Exparel, 266 mg, diluted in 20 mL normal saline, infiltrated into the rectus fascia and subcutaneous tissues at the time of abdominoplasty.
3105716|NCT01853176|Active Comparator|Standard bupivicaine|Patients will receive the maximum safe allowance of 0.25% bupivacaine, or 1.5 mg/kg (eg. 150 mg or 60 mL for a 100 kg patient) infiltrated into the rectus fascia and subcutaneous tissues at the time of abdominoplasty.
3105717|NCT01853163|Other|Gadolinium contrast agent|Patients who have received Gadolinium contrast agents in the past
3105718|NCT01853150|Experimental|rTMS Motor cortex|rTMS will be applied over the motor cortex
3105719|NCT01853150|Active Comparator|rTMS Supplementary motor area|rTMS will be applied over the supplementary motor area
3105720|NCT01853137|Experimental|FLMGM Treatment Group|
3105721|NCT01853137|No Intervention|Untreated Class II Control Group|
3105722|NCT01853124|Experimental|Lacidofil|Lacidofil sachet containing active ingredients
3105723|NCT01853124|Placebo Comparator|Placebo|Placebo sachet containing inactive ingredients
3105724|NCT01853111|Experimental|Interleukin 2|Subjects who receive a tolerogenic drug protocol
3105725|NCT01853098|Experimental|Positive Affect Training (PAT)|The intervention will be conducted in groups with 6-8 participants and 2 facilitators/therapists per group. The groups will meet once a week for 12 successive weeks and each session will be approximately 60 minutes long.
3105726|NCT01853085||Patients with POAG or OHT|Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
3105727|NCT01853072|Experimental|Nepafenac|With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
3105728|NCT01853072|Placebo Comparator|Vehicle|With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
3105731|NCT01853046|Experimental|Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment|Participants with normal/mild renal impairment received Regorafenib 160 mg o.d.as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.
3105732|NCT01853046|Experimental|Regorafenib (Stivarga, BAY73-4506)-Severe Renal Impairment|Participants with severe renal impairment received Regorafenib 160 mg o.d. as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.
3105733|NCT01853033|Experimental|Group 1|Randomized 6 drug/2 placebo by group
3105734|NCT01853033|Experimental|Group 2|Randomized 6 drug/2 placebo by group
3105735|NCT01853033|Experimental|Group 3|Randomized 6 drug/2 placebo by group
3105736|NCT01853020|Active Comparator|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
3105737|NCT01853020|Placebo Comparator|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
3105738|NCT01853007|No Intervention|Usual care|Patients in this arm will receive only the education offered by the transplant center, as required by Medicaid. Upon completion of all data collection activities, patients in this arm will be offered the program.
3105739|NCT01853007|Experimental|COACH Program|Participants randomized to the intervention condition will attend a COACH session held in a small group format. The session provides information on living and deceased donor transplantation (i.e., the processes, risks and benefits) and on the key communication skills needed to effectively initiate and maintain conversations about transplantation.
3105740|NCT01852994|Other|Exercise training|Aerobic and strength exercise training
3105741|NCT01852994|Other|Testosterone replacement|Testosterone replacement will be done quarterly
3105742|NCT01852994|Other|Testosterone replacement+Exercise|Both Testosterone replacement and Exercise will done
3105743|NCT01852981|Experimental|Lifestyle counseling|Physical activity promotion using methods based on health education.
3105744|NCT01852981|Experimental|Supervised exercise|Supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations.
3105745|NCT01852981|No Intervention|Control|Control group.
3105746|NCT01852968||Patients with type 1 diabetes|"Hippocampal neurochemistry and metabolism will examined in Patients with type 1 diabetes using magnetic resonance spectroscopy.~Patients with type 1 diabetes will also undergo neurocognitive testing to assess hippocampal function"
3105747|NCT01852968||healthy controls|"Hippocampal neurochemistry and metabolism will be examined in healthy controls using magnetic resonance spectroscopy.~Healthy controls will also undergo neurocognitive testing to assess hippocampal function"
3105748|NCT01852955|Active Comparator|IV acetaminophen|Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure.
3105749|NCT01852955|Placebo Comparator|Placebo|Administration of placebo (sterile normal saline)group-same volume of saline solution administered in the same fashion as the acetaminophen
3105750|NCT01852942|Experimental|Losartan|
3105751|NCT01852942|Placebo Comparator|Sugar Pill|
3105752|NCT01852929|Other|Apnea patients on and off PAP in order A|Subject using usual positive airway pressure therapy while sleeping for one night, then crossing over to not using usual apnea therapy while sleeping for another night.
3105753|NCT01852929|Other|Apnea patients on and off PAP in order B|Subject not using apnea therapy while sleeping for one night, then crossing over and subject using usual positive airway pressure therapy while sleeping for one night.
3105754|NCT01852916|Active Comparator|Nasal CPAP|Nasal CPAP using Infant flow
3105755|NCT01852916|Experimental|NHFOV|Nasal High Frequency Oscillatory Ventilation using Dräger Babylog® VN500 ventilator machine
3105756|NCT01852903|Experimental|calcium ascorbate|
3105757|NCT01852903|Active Comparator|ascorbic acid|
3105758|NCT01852903|Placebo Comparator|placebo|
3105759|NCT01852890|Experimental|50g Ascorbate|"This arm is the initial starting dose. The first study participant will be assigned the 50g ascorbate arm.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 50 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
3105760|NCT01852890|Experimental|75g Ascorbate|"If the 50g arm is tolerated, the study opens the 75g arm.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 75 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
3105761|NCT01852890|Experimental|100g Ascorbate|"If the 75g arm is tolerated, the study opens the 100g arm.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 100 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
3105762|NCT01852890|Experimental|25g Ascorbate|"This study arm will only be used if participants cannot tolerate the 50g arm. If participants cannot tolerate 50 grams of Ascorbate, the 25g arm is opened.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 25 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
3105795|NCT01852656|Active Comparator|IVR Only Reminder Group|In the IVR reminder intervention, targeted members will be contacted by the interactive voice response system
3105763|NCT01852877||Jail: HIV testing, corrections case mgt|For all jail detainees regardless of HIV status, we observed the uptake of opt-out and opt-in HIV testing. For HIV-positive jail detainees leaving jail, we observed 1) health outcomes for corrections case management versus other than corrections case management, 2) the impact of an incentive to visit an HIV service organization after release from jail
3105764|NCT01852877||Prison: telemed, corrections case mgt|We compared outcomes for for HIV-positive prisoners before and after the implementation of telemedicine to deliver HIV medical care. For HIV-positive prisoners released from prison and returning to Chicago, we observed health outcomes for those enrolled in corrections case management those not enrolled in corrections case management.
3105765|NCT01852864|Experimental|Degarelix treated group|240mg degarelix s.c. injection to be administered 7 days prior to radical prostatectomy for high/intermediate risk prostate cancer.
3105766|NCT01852851|Active Comparator|Intervention Group|The intervention group will participate in the on-line eLearning program, an ergonomic assessment by an Occupational Therapist and job retention vocational counselling by a Vocational Rehabilitation Counsellor
3105767|NCT01852851|No Intervention|Control Group|"The control group will receive usual care and receive printed educational materials about work and arthritis."
3105768|NCT01852838||Lung cancer patients, pre treatment|Patients who have diagnosed with lung cancer before treatment
3105769|NCT01852838||High risk patients for lung cancer|high risk patients who are age and co-morbidity matched controls without proof of lung cancer.
3105770|NCT01852825|Experimental|NAC + MK-8237 (Part 2)|Nasal Allergen Challenge (NAC) treatment consisting of 1800 Biological Units (BU) of HDM extract on Days -14, 56 and 84; starting on Day 1 a single tablet of MK-8237 with 12 Development Units (DUs), administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
3105771|NCT01852825|Placebo Comparator|NAC + Placebo (Part 2)|NAC treatment consisting of 1800 BU of HDM extract on Days -14, 56 and 84; starting on Day 1 a single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
3105772|NCT01852825|Experimental|NAC (Part 1)|Nasal Allergen Challenge (NAC) consisting of 100 µl fixed volume of 10,000 biological units (BU) of HDM extract delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1
3105773|NCT01852812|Experimental|Montelukast 4 mg OG/1-5 year olds|Participants receive montelukast 4 mg OG in one sachet orally (PO) once daily (QD) at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)
3105774|NCT01852812|Experimental|Montelukast 5 mg CT/6-9 year olds|Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks
3105775|NCT01852812|Experimental|Montelukast 5 mg CT/10-15 year olds|Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks
3105776|NCT01852799|Experimental|PAD Followed by ASCT|"Drug: Bortezomib, Adriamycin (Doxorubicin) /Epidoxorubicin(EPI), Dexamethasone.~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators."
3105777|NCT01852786||Contraceptives, Oral, Combined|The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy.
3105778|NCT01852786||Controls|The women, presenting for non- hormonal contraception- barrier contraception methods -BCM- or natural family planning methods- NFPM.
3105779|NCT01852773||Blunt Aortic Injury Patients|Trauma patients with blunt aortic injury. This Cohort of trauma patients will require management with one of two interventions. They will require either; Open repair of thoracic aorta injury (Intervention #1) or TEVAR (Intervention #2). As of yet the short term and long term outcomes of these two treatments have not been directly compared.
3105780|NCT01852760||UC in Remission|Patients with UC in remission
3105781|NCT01852760||UC Mild Disease|Patients with mild UC disease activity based on partial Mayo Score
3105782|NCT01852760||UC Moderate to severe|Patients with ulcerative colitis with moderate to severe disease activity based on partial Mayo score
3105783|NCT01852747|Experimental|Multilevel Spinal Fusion w/ Actifuse ABX®|An osteostimulatory,phase pure,porous,silicate substituted calcium phosphate bone graft substitute used during multilevel spinal fusion.
3105784|NCT01852747|No Intervention|Multilevel Spinal Fusion|Multilevel spinal fusion without Actifuse ABX.
3105785|NCT01852734|Other|embolizations, uterine fibroid|embolization interventions with microspheres
3105786|NCT01852721|Experimental|Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
3105787|NCT01852721|Experimental|Women and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
3105788|NCT01852708||Pregnant Women|Women and their partners (presumed biological father of the fetus) who are currently pregnant and carrying a fetus that has been diagnosed with a microdeletion/duplication syndrome, aneuploidy or another genetic disorder (positive karyotype result or positive result on microarray test).
3105789|NCT01852695|Experimental|Family Integrated Care Arm|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
3105790|NCT01852695|No Intervention|Control Arm|Regular care by nurse will be provided to patients admitted to control sites.
3105791|NCT01852682|Experimental|PA21|
3105792|NCT01852669|Experimental|Inversion, Hydration, ESWL|ESWL with hydration and inversion
3105793|NCT01852669|Active Comparator|ESWL, Hydration|ESWL with hydration
3105794|NCT01852656|Active Comparator|Postcard Only Reminder Group|In the postcard reminder intervention, the member will receive a single postcard, addressed to the member with asthma or COPD.
3105796|NCT01852656|Active Comparator|Postcard and IVR Reminder Group|In this group, individuals will receive both a postcard reminder and an IVR reminder.
3105797|NCT01852643|Active Comparator|Spreader graft|
3105798|NCT01852643|Active Comparator|Lateral crural overlay|
3105799|NCT01852630|Experimental|cefepime + Albumin|cefepime 1g iv 8 hourly + Albumin will be given for 2 days.
3105800|NCT01852630|Active Comparator|Imipenem + Albumin|Imipenem 1g iv 8 hourly + Albumin will be given for 2 days.
3105801|NCT01852617|Experimental|Implementation of intervention|"Midwife facilitators in the intervention clinics will be identified and trained to deliver the 5 A's to pregnant women and will then disseminate and implement the program. The 5 A's (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide"
3105802|NCT01852617|No Intervention|No implementation of the intervention|Standard in-service activities
3105803|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 50/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 50 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
3105804|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 100/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 100 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
3105805|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 150/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 150 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
3105806|NCT01852604|Experimental|Part B: GT 1b, 4 - samatasvir 25/simeprevir/RBV|Part B: Participants with genotype 1b or 4 received samatasvir 25 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
3105807|NCT01852604|Experimental|Part B: GT 1b, 4 - samatasvir 100/simeprevir/RBV|Part B: Participants with genotype 1b or 4 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
3105808|NCT01852604|Experimental|Part B: GT 6 - samatasvir 100/simeprevir/RBV|Part B: Participants with Genotype 6 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
3105809|NCT01852604|Experimental|Part C: GT 1a, 1b - samatasvir 50/simeprevir/TCM647055/RTV|Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily plus RTV 30 mg once daily for 12 weeks
3105810|NCT01852604|Experimental|Part C: GT 1a, 1b - samatasvir 50/simeprivir/TCM647055/RTV/RBV|Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily, plus RTV 30 mg once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
3105811|NCT01852591|Experimental|PCV 13|Pneumococcal conjugate vaccine (PCV 13), 0.5ml, 3 to 30 days prior to transplant and then again at 7-10 and 21-24 days after transplant
3105812|NCT01852578|Experimental|1|
3105813|NCT01852565|Experimental|Darapladib+Diltizem Arm|Each subject will receive darapladib EC tablet 160 mg once daily for 10 days followed by darapladib EC tablet 160 mg once daily + diltiazem 240mg once daily for 14 days and then diltiazem 240mg once daily alone for three days
3105814|NCT01852552||Transcatheter aortic valve implantation|All consecutive patients undergoing TAVI at participating centres during study period
3105815|NCT01852552||Aortic Valve Replacement|All consecutive patients aged ≥ 80 years or with Logistic Euroscore≥ 15% undergoing AVR for AS at participating centers during the period of enrollment
3105816|NCT01852539|Experimental|dexmedetomidine|After intravenous infusion of dexmedetomidine for 2 min, propofol 2.0 mg/kg was administrated. And laryngeal mask airway device was inserted(LMA # 3,4).
3105817|NCT01852526|Experimental|hybrid system|hybrid system (PLIF + flexible pedicle screw system above the fusion) (Dynamic Rod®: AESCULAP AG, Tuttlingen: Germany
3105818|NCT01852526|Active Comparator|Plif posterior lumbar intervertebral fusion|Conventional monosegmental posterior lumbar intervertebral fusion (PLIF) (Fixateur: S4®: AESCULAP AG, Cage: Wave® Cage, Fa. AMT®)
3105819|NCT01852513|Active Comparator|QNASL nasal spray|QNASL 320 mcg once-daily administered as two sprays in each nostril; 2 weeks of treatment
3105820|NCT01852513|Placebo Comparator|Placebo nasal spray|Placebo nasal spray once-daily administered as two sprays in each nostril; 2 weeks of treatment
3105821|NCT01852500|Experimental|Sham OMT|patients under standard medical care plus sham OMT
3105822|NCT01852500|Other|Control|patients under standard medical care plus only osteopathic evaluation
3105823|NCT01852487|Active Comparator|Pumpkin Seed Oil|400mg/ day during 6 months
3105824|NCT01852487|Placebo Comparator|sweet potato starch|400mg/day during 6months
3105825|NCT01852474|Experimental|Active tDCS|Subjects will receive active tDCS stimulation for 5 sessions (20m/each) over one week.
3105826|NCT01852461|Active Comparator|Beractant|Beractant;bovine lung extract; both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
3105827|NCT01852461|Active Comparator|Poractant alfa|Poractant alfa; porcine lung extract; initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
3105828|NCT01852448||Patients with Cystic Fibrosis|Blood or Saliva Sample Collection and Glucose -potentiated arginine (GPA) stimulation tests will be completed for all enrolled patients.
3105829|NCT01852435|Active Comparator|R-CHOP-50|R-CHOP-50 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 50mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
3105830|NCT01852435|Experimental|R-CEOP-70|R-CEOP-70 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 70mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
3106205|NCT01849770|Placebo Comparator|Placebo|Placebo, by mouth per day for 12 weeks.
3105831|NCT01852435|Experimental|R-CEOP-90|R-CEOP-90 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 90mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
3105832|NCT01852422||Pelvic prolapse|
3105833|NCT01852409|Experimental|bevacizumab|The study evaluate 4 dose level of bevacizumab:2.5mg /kg;5 mg /kg;7.5mg /kg; 1.25mg /kg;
3105834|NCT01852396|Experimental|Regional anesthesia|Recruit 50 patient having elbow, forearm, wrist or hand surgery and block brachial plexus using the novel retroclavicular approach
3105835|NCT01852383|Experimental|Duloxetine|"A minimum 1-week psychotropic medication washout, and a washout of 3 weeks for fluoxetine and monoamine oxidase inhibitors(MAOIs), was required. Duloxetine was prescribed at 20 mg daily for the first week, 30 mg daily for the second week, then 60 mg daily for another 4 weeks. Patients could subsequently be raised to 90 mg daily for another 2-4 weeks and then to a maximum dose of 120 mg daily.~At all visits, the study psychiatrist had the option of adjusting the dose based on clinical response and side effects.~Administration was as a single a.m. dose."
3105836|NCT01852370|Experimental|BOLT+BMT|All patients will receive a double lung transplant followed by a hematopoietic stem cell transplant. The lungs and stem cells are from the same partially HLA-matched cadaveric donor. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
3105837|NCT01852357|Sham Comparator|Sham control|This group will receive 12 sham neurofeedback sessions in which the feedback is based on pre-recorded data.
3105838|NCT01852357|Experimental|Neurofeedback|The intervention will be 24 sessions of beta/SMR neurofeedback.
3105839|NCT01852344|Other|Placebo Easy|Healthy participant to be given 20 mgs of a placebo one hour before task performance and will perform an easy task.
3105840|NCT01852344|Other|Placebo Hard|Healthy participants are given 20 mgs of placebo one hour before task performance and will perform a hard task.
3105841|NCT01852344|Other|Methylphenidate Easy|Healthy participants are given 20 mgs of methylphenidate one hour before task performance and will perform an easy task.
3105842|NCT01852344|Other|Methylphenidate Hard|Healthy participants are given 20 mgs of methylphenidate one hour before task performance and will perform a hard task.
3105843|NCT01852331|Active Comparator|PGD granules|While continuing current antipsychotic medications, subjects will receive adjunctive Peony-Glycyrrhiza Decoction (PGD) granules (equivalent to 45 g raw materials in total per day). They need to take the granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
3105844|NCT01852331|Placebo Comparator|Placebo|While continuing current antipsychotic medications, subjects will receive adjunctive treatment with placebo granules. They need to take the placebo granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
3105845|NCT01852318|Experimental|Pregabalin|pregabalin 75mg daily for 12 weeks
3105846|NCT01852318|Active Comparator|fexofenadine|fexofenadine 60 mg daily for 12 weeks
3105847|NCT01852318|Placebo Comparator|Placebo|placebo 75 mg for 12 weeks
3105848|NCT01852305|Experimental|Lab Sleep Study (group 1)|The patients in the Sleep Study group will be referred to a sleep medicine specialist who is part of the Bariatric Surgery Psychosocial Program. In the Sleep Study group, patients will undergo sleep studies overnight in a sleep laboratory. At the same time, they will also wear the oximeter wristwatch to measure overnight oximetry.
3105849|NCT01852305|Active Comparator|Oximetry group (group 2)|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI>10 events/hour will be referred to the sleep medicine specialist.A split- night polysomnography(PSG) will be employed to confirm obstructive sleep apnea OSA) diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night.
3105850|NCT01852292|Experimental|Buparlisib + weekly Paclitaxel|Patients who were randomized to this arm on a 1:1 randomization, took buparlisib 100 mg daily and paclitaxel 80 mg/m^2 weekly.
3105851|NCT01852292|Placebo Comparator|Buparlisib matching placebo + Paclitaxel|Patients who were randomized to this arm on a 1:1 randomization, took buparlisib matching placebo 100 mg daily and paclitaxel 80 mg/m^2 weekly.
3105852|NCT01852279|Experimental|Active muscle stimulation|Muscle stimulation delivered by Brain Computer Interface
3105853|NCT01852279|Active Comparator|Passive muscle stimulation|FES will be delivered by therapist
3105854|NCT01852266|Experimental|RSV cps2 Vaccine|Participants will receive one dose of the RSV cps2 vaccine administered as nose drops at study entry.
3105855|NCT01852266|Placebo Comparator|Placebo|Participants will receive one dose of placebo administered as nose drops at study entry.
3105856|NCT01852253|Active Comparator|2% chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline and 1 minute of local application of a 2 % chlorhexidine solution. After 1 minute of saline rinsing the gingival flap will be returned slightly apical (in order to reduce pockets) and will be firmly sutured. The surgery is followed by 2 weeks of rinsing with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds.
3105857|NCT01852253|Sham Comparator|0.12% chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline and 1 minute of local application of a 0.12 % chlorhexidine solution. After 1 minute of saline rinsing the gingival flap will be returned slightly apical (in order to reduce pockets) and will be firmly sutured. The surgery is followed by 2 weeks of rinsing with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds.
3105858|NCT01852240||erectile dysfunction|"Inclusion criteria:~male patients with ED defined by an IIEF-5 score of ≤ 21~age between 18-45a~Exclusion criteria:~systemic diseases (e.g. diabetes mellitus, heart disease, hypertension, neurological disorders etc.)~pure psychogenic (non-organic) ED with good spontaneous / nightly erections~periodontal treatment within the last 3 months~antibiotic intake within the last 3 months"
3105893|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) at 1.5h|Cangrelor IV + oral prasugrel (60mg) administered at 1.5h after the cangrelor infusion start time.
3107589|NCT01840345|Experimental|N-acetyl-L-cysteine|n-acetyl-l-cysteine 1200 mg BID x 4 weeks
3105859|NCT01852214|Active Comparator|Prasugrel first, then ticagrelor|Patients randomized to prasugrel will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (ticagrelor), which will be administered for 1-week.
3105860|NCT01852214|Active Comparator|Ticagrelor first, then prasugrel|Patients randomized to ticagrelor will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (prasugrel), which will be administered for 1-week.
3105861|NCT01852201|No Intervention|Best medical therapy|"Patients randomized to the control group will receive best conventional MT for acute ischemic stroke as determined by the attending stroke physician. Standardization of medical management in both arms will occur according to the following:~General medical management according to AHA/ASA guidelines~Admission to monitored or intensive care unit for at least 24 hours~Aggressive hypertensive-hypervolemic therapy should be used only in the case of symptomatic blood pressure fluctuations or if blood pressure drops below the normal range for the patient~Antithrombotics: ASA 325 mg PO qd for 7 days (clopidogrel may be used as adjunctive therapy if indicated for cardiac disease) then per discretion of treating physician~Close monitoring of BP and glucose with treatment according to AHA/ASA guidelines~Follow-up imaging study required in any patient with neurologic deterioration"
3105862|NCT01852201|Experimental|Endovascular treatment|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
3105863|NCT01852188|Other|Nonsterile|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
3105864|NCT01852188|Other|Sterile|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
3105865|NCT01852175|Active Comparator|Prasugrel|Prasugrel 60mg loading dose and 10 mg maintenance dose
3105866|NCT01852175|Active Comparator|Ticagrelor|Ticagrelor 180mg loading dose and 90mg bid maintenance dose
3105867|NCT01852162|Experimental|Dabigatran|Dabigatran 150mg
3105868|NCT01852162|Placebo Comparator|Placebo|Placebo
3105869|NCT01852149|Experimental|MPAS Implant|MPAS Implant
3105870|NCT01852136||NEXT 31G x 5mm|Subjects will use their current pen needle or the BD NEXT 31G x 5mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
3105871|NCT01852136||NEXT 31G x 8mm|Subjects will use their current pen needle or the BD NEXT 31G x 8mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
3105872|NCT01852136||NEXT 32G x 4mm|Subjects will use their current pen needle or the BD NEXT 32G x 4mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
3105873|NCT01852123|Other|Early implementation|The high-sensitivity troponin I assay will be implemented after a 6 month validation phase
3105874|NCT01852123|Other|Late implementation|The high-sensitivity troponin I assay will be implemented after a 12 month validation phase
3105875|NCT01852110|Experimental|MK-7622 High Dose - 45 mg (Stage 1)|Single 45 mg MK-7622 capsule once daily, taken orally. Dose escalated as follows: 15 mg MK-7622 once daily for 1 week; 30 mg MK-7622 once daily for 1 week; and 45 mg MK-7622 once daily for the remainder of treatment.
3105876|NCT01852110|Placebo Comparator|Placebo (Stage 1)|Matching placebo to MK-7622 capsule once daily, taken orally.
3105877|NCT01852110|Experimental|MK-7622 Low Dose - 5 mg (Stage 2)|Single 5 mg MK-7622 capsule once daily, taken orally.
3105878|NCT01852110|Experimental|MK-7622 Mid Dose - 15 mg (Stage 2)|Single 15 mg MK-7622 capsule once daily, taken orally.
3105879|NCT01852110|Experimental|MK-7622 High Dose - 45 mg (Stage 2)|Single 45 mg MK-7622 capsule once daily, taken orally. Dose escalated as follows: 15 mg MK-7622 once daily for 1 week; 30 mg MK-7622 once daily for 1 week; and 45 mg MK-7622 once daily for the remainder of treatment.
3105880|NCT01852110|Placebo Comparator|Placebo (Stage 2)|Matching placebo to MK-7622 capsule once daily, taken orally.
3105881|NCT01852097|Experimental|CBT based online intervention|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.
3105882|NCT01852097|No Intervention|Control group|Care as Usual. Participants in the control group will be able to access the online intervention after they complete their last follow-up questionnaire.
3105883|NCT01852071|Experimental|Autologous transplant of ADA gene corrected bone marrow|Autologous transplantation of EFS-ADA transduced bone marrow CD34+ cells
3105884|NCT01852058|Experimental|OnabotulinumtoxinA Dose A|OnabotulinumtoxinA Dose A injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
3105885|NCT01852058|Experimental|OnabotulinumtoxinA Dose B|OnabotulinumtoxinA Dose B injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
3105886|NCT01852058|Experimental|OnabotulinumtoxinA Dose C|OnabotulinumtoxinA Dose C injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
3105887|NCT01852045|Experimental|OnabotulinumtoxinA Dose A|OnabotulinumtoxinA Dose A injected into the detrusor wall on Day 1.
3105888|NCT01852045|Experimental|OnabotulinumtoxinA Dose B|OnabotulinumtoxinA Dose B injected into the detrusor wall on Day 1.
3105889|NCT01852045|Experimental|OnabotulinumtoxinA Dose C|OnabotulinumtoxinA Dose C injected into the detrusor wall on Day 1.
3105890|NCT01852032|Experimental|Breast cancer Patients|Tomosynthesis Breast Scanning is done and breast CT Scanning is done.
3105891|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) post infusion|Cangrelor IV + Oral prasugrel (60mg) administered within 5 minutes after cangrelor IV discontinuation
3105892|NCT01852019|Experimental|Day 8 - Prasugrel (10mg) Dosing (5 doses)|Prasugrel discontinued 48h (n=6) prior to initiation of cangrelor infusion (2h)
3105894|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) a 1.0h|Cangrelor IV + oral prasugrel (60mg) administered at 1.0h after the cangrelor infusion start time.
3105895|NCT01852019|Experimental|Day 8 - Prasugrel (10mg) Dosing (6 doses)|Prasugrel discontinued 24h prior to initiation of cangrelor infusion (2h)
3105896|NCT01852006|Experimental|COPD AB ON|"Abdominal Binder ON"
3105897|NCT01852006|No Intervention|COPD AB OFF|"Abdominal Binder OFF (control)"
3105898|NCT01851993|Experimental|Inhaled Ondansetron (8 mg)|Single-dose inhalation of nebulized ondansetron (8 mg)
3105899|NCT01851993|Placebo Comparator|Inhaled 0.9% saline placebo|Single-dose inhalation of 0.9% saline placebo
3105900|NCT01851980|Experimental|CWS+Furosemide (40 mg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (40 mg)
3105901|NCT01851980|Placebo Comparator|CWS+0.9% saline placebo|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
3105902|NCT01851980|Experimental|CWS+Furosemide (120 mg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (120 mg)
3105903|NCT01851967|Experimental|MoodGYM|This study is a single-arm intervnetion. All subjects will be assigned to receive six weeks of online CBT through MoodGYM.
3105904|NCT01851954|Experimental|clarithromycin|Population PK
3105905|NCT01851941|Experimental|mFOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
3105906|NCT01851915|Active Comparator|Cognitive Behavioral therapy (CBT)|Short term therapy for treatment of depression
3105907|NCT01851915|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal short term therapy for treatment of depression
3105908|NCT01851902||CHA2DS2-VASc Score 2 - 4|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a low risk cohort.
3105909|NCT01851902||CHA2DS2-VASc Score 5 - 6|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a medium risk cohort.
3105910|NCT01851902||CHA2DS2-VASc Score 7 - 9|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a high risk cohort.
3105911|NCT01851889||CF-LVAD pump speed.|
3105912|NCT01851876|Experimental|Endometrial injury|The patients in this group will be subjected to endometrial injury procedure in preceding IVF cycle.
3105913|NCT01851876|No Intervention|No endometrial injury|The patients in this group will not be subjected to endometrial injury procedure in presiding IVF cycle. The patients will be stimulated with standard IVF protocol.
3105914|NCT01851863|Active Comparator|Flupentixol-Melitracen(psychological and GI) + Omeprazole|The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
3105915|NCT01851863|Active Comparator|Flupentixol-Melitracen(psychological) + Omeprazole|The patients in Group 2 were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
3105916|NCT01851863|Active Comparator|Flupentixol-Melitracen(without explanation) + Omeprazole|In Group 3, the patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
3105917|NCT01851863|Active Comparator|proton pump inhibitor|Prescribe Omeprazole.
3105918|NCT01851850|Experimental|Drug|
3105919|NCT01851837|Active Comparator|Group I|Study group I (57 participants) received the continuous training of exercise time.
3105920|NCT01851837|Active Comparator|Group II|Study group II (58 participants) received the interval training of exercise time.
3105921|NCT01851824|Experimental|Acenocoumarol + Vemurafenib|
3105922|NCT01851798||ambulatory orthopedic surgery patients with OSA|ambulatory orthopedic surgery patients with home sleep test preoperative AHI => 5
3105923|NCT01851798||ambulatory orthopedic surgery patients without OSA|ambulatory orthopedic surgery patients with home sleep test preoperative AHI < 5
3105924|NCT01851785|No Intervention|Attention control|Subjects randomized to the attention control arm will receive an educational program (an NIH-developed booklet) that summarizes how to live with knee OA but does not specifically mention joint replacement. This booklet provides information about OA, examples of exercises one could do to improve pain and reduce stiffness, types of non-drug pain relief such as massage, and information about various medications. The interventionist will give the participant the booklet and describe what can be found inside. They are also encouraged to ask their doctor any questions they may have about the information in the booklet or questions they may have about their OA. The purpose of this educational program is to provide a tangible clinical incentive to the control group for participating in this additional component of the study.
3105925|NCT01851785|Experimental|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
3105953|NCT01851616|Active Comparator|Glucose 10g|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)
3105954|NCT01851603|Experimental|AVL-3288|Oral administration of AVL-3288
3105955|NCT01851603|Placebo Comparator|Sugar pill|Placebo
3105956|NCT01851590|Experimental|Resin Lacquer|Topical 30% Resin Lacquer applied once daily for 9 months (Abicin® 30% Nail Lacquer).
3105957|NCT01851590|Active Comparator|Amorolfine|Topical 5% Amorolfine Lacquer applied once weekly for 9 months (Loceryl® 5% Nail Lacquer).
3105926|NCT01851772|Experimental|Treatment|"Subjects enrolled will undergo brachytherapy treatment in combination with EBRT. The maximum length of treatment will be 56 days. The treating physician will determine the appropriate course of treatment based on the physician's current practice or experience using Iridium-192 or Cesium HDR after-loaders to administer cervical brachytherapy treatments.~Subjects enrolled will be treated with approximately 80-90 Gy total treatment dose over 4-6 fractions. Examples of commonly used dose regimens in the US are listed in section 7.6.7. This study will include data collection from the initiation of EBRT through administration of the final Xoft Axxent treatment fraction, and at one (1) month and three (3) months."
3105927|NCT01851759|Experimental|Cinepazide, Stroke, Injection|Test drug：Methanesulfonic acid cinepazide injection（5ml/125mg）
3105928|NCT01851759|Placebo Comparator|palcebo,Stroke,Injection|Placebo：simulation agent of Methanesulfonic acid cinepazide injection（5ml sterile water for injection）
3105929|NCT01851733|Experimental|Arm B: (MLA, doxorubicin hydrochloride at 6-8 weeks)|"Patients undergo MLA (MRI-guided laser heat ablation). A subset of patients will have a biopsy at time of MLA.~Beginning 6-8 weeks later, patients receive doxorubicin hydrochloride 20 mg/m2 intravenously (IV) over 5 minutes once weekly for 6 weeks.~Biomarker blood draws will be drawn at different time points.~DSC-MRI: no more than 2 weeks prior to MLA, within approximately 3 days after MLA, 2/4/6 weeks after MLA, 10 weeks after MLA only if 6-week scan shows prolonged disruption of the blood brain barrier, 14 weeks after MLA only if week 10 MRI shows contined blood brain barrier disruption, and every 8 weeks until disease progression (these scans do not have to be DSC-MRI)"
3105930|NCT01851733|Experimental|Arm C: (MLA, doxorubicin hydrochloride at 72 hours)|"Patients undergo MLA (MRI-guided laser heat ablation).~Beginning within 72 hours later, patients receive doxorubicin hydrochloride 20 mg/m2 IV over 5 minutes once weekly for 6 weeks.~DSC-MRI: no more than 2 weeks prior to MLA, within approximately 3 days after MLA, 2/4/6 weeks after MLA, 10 weeks after MLA only if 6-week scan shows prolonged disruption of the blood brain barrier, 14 weeks after MLA only if week 10 MRI shows contined blood brain barrier disruption, and every 8 weeks until disease progression (these scans do not have to be DSC-MRI)"
3105931|NCT01851720|Active Comparator|Control group / Standard of Care|"IV fentanyl bolus 25-50 mcg every 1-2 hrs as needed for pain~(Bolus dose can be titrated up in 25 mcg increments if necessary)~Maximum dose of 100 mcg/hr"
3105932|NCT01851720|Active Comparator|Low dose IV fentanyl PCA|"Initially: 10 mcg demand dose every 12 minutes~No initial bolus and no continuous infusion~Demand dose increased 10 mcg every 12 minutes if necessary~Maximum dose of 100 mcg/hr"
3105933|NCT01851707|Experimental|IPI-145, low dose BID|
3105934|NCT01851707|Experimental|IPI-145, medium dose BID|
3105935|NCT01851707|Experimental|IPI-145, high dose BID|
3105936|NCT01851707|Placebo Comparator|Placebo BID|
3105937|NCT01851694|Experimental|GLP-1|The incretin, Glucagon-Like-peptide-1 (GLP-1) will be infused into the veins starting 30 minutes prior to initiating the GPA test. This infusion will continue for a total of 90 mins. (during the GPA for 230 mg/dL glucose levels) and then this will be stopped. The GPA test will be performed for the 340 mg/dL glucose levels but no incretin will be infused during this part of the test. These data will be compared when the subject repeats the GPA test with a placebo (saline or salt containing solution) infusion.
3105938|NCT01851694|Experimental|GIP|The incretin, Glucose-dependent Insulinotropic Polypeptide (GIP) will be infused into the veins starting 30 minutes prior to initiating the GPA test. This infusion will continue for a total of 90 mins (during the GPA for 230 mg/dL glucose levels) and then this will be stopped. The GPA test will be performed for the 340 mg/dL glucose levels but no incretin will be infused during this part of the test. These data will be compared when the subject repeats the GPA test with a placebo (saline or salt containing solution) infusion.
3105939|NCT01851681|Active Comparator|Amoxicillin taken 2 g preoperatively|2 g amoxicillin 1h preop then placebo tid x 7 days
3105940|NCT01851681|Active Comparator|Amoxicillin 2g taken preoperatively and 500mg tid x 7 days|2g amoxicillin 1h preop then tid x 7 days
3105941|NCT01851668||Preterm inter-hospital transfers|preterm infants <31 weeks gestation and <=day 3 of life
3105942|NCT01851668||Preterm infants inborn|Preterm infants <31 weeks gestation and <=3 days old born and remaining at same hospital.
3105943|NCT01851668||Ex-preterm infants back transfered|Mature ex-preterm infants transferred back to referring hospital
3105944|NCT01851655|Experimental|Plyometric Exercise - High intensity|The exercises should produce a higher peak vertical ground reaction force than those in the low group based on literature findings (e.g. single leg jumps, jumps from higher heights, higher percent effort).
3105945|NCT01851655|Active Comparator|Plyometric Exercise - Low intensity|A lower peak vertical ground reaction force will be generated in the low intensity group compared to the high intensity group based on findings in the literature (e.g. lower box heights, only two-legged jumps, lower percent effort)
3105946|NCT01851642||AAT Deficiency|Those diagnosed with Alpha-1 Antitrypsin (AAT) Deficiency. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
3105947|NCT01851642||Cystic Fibrosis|Those diagnosed with Cystic Fibrosis (CF) with mutation Delta F508. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
3105948|NCT01851642||Without Lung Disease Diagnosis|Those without the diagnosis of AAT Deficiency or CF. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
3105949|NCT01851629|Experimental|ADAPT Locomotor Training|Individuals receive 15 sessions of ADAPT-locomotor training for 3 weeks. During ADAPT-locomotor training, stepping in response to obstacles and walking challenges are practiced on a treadmill and overground.
3105950|NCT01851629|Active Comparator|Basic Locomotor Training|Individuals will receive 15sessions of the traditional form of basic locomotor training for 3 weeks. Repetitive stepping patterns are practiced on the treadmill and overground.
3105951|NCT01851629|Other|Cross-Sectional Testing|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
3105952|NCT01851616|Active Comparator|Glucose 25g|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)
3107590|NCT01840332|Experimental|L-thyroxin|this is one arm study
3105959|NCT01851577|Experimental|Family Foundations coparenting program|Family Foundations is a coparenting prevention program that will be administered concurrently with ongoing home visiting.
3105960|NCT01851577|Active Comparator|Home visiting|"Home visiting as usual will be provided without the added Family Foundations coparenting prevention program."
3105961|NCT01851564|Experimental|SEMS for primary variceal haemorrhage|Use of the Self-expanding mesh-metal oesophageal stent (SEMS) as primary therapy for Acute Variceal Haemorrhage.
3105962|NCT01851564|Active Comparator|Standard Therapy - Primary Haemorrhage|Use of standard medical and endoscopic therapy for the treatment of primary variceal haemorrhage.
3105963|NCT01851564|Experimental|SEMS for Failure to Control Bleeding|Use of the self expanding mesh-metal stent for failure of standard therapy in oesophageal variceal haemorrhage.
3105964|NCT01851564|Active Comparator|Standard Therapy - Failure of Control|Use of standard medical and endoscopic therapy for failure of standard therapy in oesophageal variceal haemorrhage.
3105965|NCT01851551|Experimental|VSLI plus rituximab|VSLI (vincristine sulfate liposome injection) plus rituximab
3105966|NCT01851538||Chronic heart failure patients visiting the outpatient clinic|
3105967|NCT01851525|Active Comparator|Contact Force Sensing (CFS) Blinded|Contact Force Sensing (CFS) Blinded: Operator will be blinded to data provided by the integrated force sensor in the ablation catheter (ThermoCoolSmartTouch ablation catheter)
3105968|NCT01851525|Active Comparator|Contact Force Sensing (CFS) Guided|Contact Force Sensing (CFS) Guided: Operator will be guided by integrated force sensor in the ablation catheter (ThermoCoolSmartTouch ablation catheter)
3105969|NCT01851512|Experimental|T-R (Test-Reference drug)|DA-3803 Injection is injected first and Ovidrel liquid injection is injected after 3-week period
3105970|NCT01851512|Experimental|R-T (Reference-Test drug)|Ovidrel liquid injection is injected first and DA-3803 Injection is injected after 3-week period
3105971|NCT01851499|Experimental|Ultramicronized PEA (Normast)|"Normast is ultramicronized Palmitoylethanolamide (PEA) classified as Dietary foods for special medical purposes."
3105972|NCT01851499|Placebo Comparator|Microgranules|Same as Normast, without active component.
3105973|NCT01851486|Active Comparator|Clonidine+ Saline|Clonidine 0.15 mg and saline 0.15 mg/kg
3105974|NCT01851486|Active Comparator|Clonidine + Naloxone|Clonidine 0.15 mg and Naloxone 0.15 mg/kg
3105975|NCT01851486|Active Comparator|Placebo +Naloxone|Placebo 0.15 mg+ naloxone 0.15 mg/kg
3105976|NCT01851486|Placebo Comparator|Placebo +saline|Placebo 0.15 mg+ saline 0.15 mg/kg
3105977|NCT01851460|Experimental|RFA|All subjects enrolled onto this study will receive treatment of their liver abscess (es) by RFA ablation
3105978|NCT01851408|Experimental|Temsirolimus + Sorafenib|Temsirolimus intravenous (IV) over 30 minutes on days 1, 8,15, and 22 and oral sorafenib once or twice daily on days 1-28.
3105979|NCT01851382||Cohort 1|Healthy volunteers.
3105980|NCT01851369|Experimental|1|combination treatment with oral TRC102 and oral TMZ for days 1-5 of 28-day cycles
3105981|NCT01851343|Experimental|1|All patients will receive the same treatment
3105982|NCT01851330|Experimental|LDV/SOF 8 Week|Participants will receive LDV/SOF FDC for 8 weeks.
3105983|NCT01851330|Experimental|LDV/SOF+RBV 8 Week|Participants will receive LDV/SOF FDC plus RBV for 8 weeks.
3105984|NCT01851330|Experimental|LDV/SOF 12 Week|Participants will receive LDV/SOF FDC for 12 weeks.
3105985|NCT01851317||Intracuff pressure|Procedure/Surgery: Cuffed endotracheal tube
3105986|NCT01851304|Placebo Comparator|Control Bread|A 100 g portion of Control Bread with no extra fiber added. The control bread will be consumed in the intervention Satiety of breads
3105987|NCT01851304|Experimental|Bread Crust Bread|A 100 g portion of Bread Crust Bread with 3 g bread crust per 100 g portion of control bread. The bread crust bread will be consumed in the intervention Satiety of breads.
3105988|NCT01851304|Experimental|Coffee Melanoidins Bread|A 100 g portion of Coffee Melanoidins Bread with 3 g of isolated coffee melanoidins per 100 g portion of control bread. The coffee melanoidins bread will be consumed in the intervention Satiety of breads.
3105989|NCT01851304|Experimental|beta-Glucans Bread|A 100 g portion of beta-Glucans Bread with 3 g of barley beta-glucans per 100 g portion of control bread. The beta-glucans bread will be consumed in the intervention Satiety of breads.
3105990|NCT01851304|Placebo Comparator|Control Pudding|A 150 g portion of Control Pudding without the addition of any extracts. The control pudding will be consumed in the intervention Satiety of puddings.
3105991|NCT01851304|Experimental|Gentian extract pudding|A 150 g portion of Gentian Pudding with the addition of 1 g Gentian extract per 100 g pudding. The Gentian extract pudding will be consumed in the intervention Satiety of puddings.
3105992|NCT01851304|Experimental|Encapsulated Gentian Extract Pudding|A 150 g portion of Microencapsulated Gentian extract pudding with the addition of 1 g of a microencapsulated Gentian extract per 100 g pudding. The Microencapsulated Gentian extract pudding will be consumed in the intervention Satiety of puddings.
3105993|NCT01851278|Active Comparator|high dose|intraarticular wrist injection of 40mg, 2ml
3105994|NCT01851278|Active Comparator|low dose|intraarticular wrist injection of 20mg, 1ml.
3105995|NCT01851265|Other|Fasted|Olaparib capsules following no breakfast
3105996|NCT01851265|Other|Standard meal|Olaparib capsules after standard breakfast
3105997|NCT01851265|Other|High Fat|Olaparib capsules after high fat breakfast
3105998|NCT01851252|Experimental|Methacetin (for BT) before / after Propanolol treatment.|The methacetin breath test (MBT) will be performed before and after (within 2 hours) injection of Propanolol (BB) dose and once again after 60 days of oral administration of Propanolol.
3105999|NCT01851239||medical ICU inpatients|
3106000|NCT01851239||surgical ICU inpatients|
3106001|NCT01851226|Experimental|5 minutes group|The time limit of attempt selective cannulation by trainees is limited to 5 minutes. If the trainees failed to enter the targeted duct within 5 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
3106002|NCT01851226|Experimental|10 minutes group|The time limit of attempt selective cannulation by trainees is limited to 10 minutes. If the trainees failed to enter the targeted duct within 10 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
3107714|NCT01839383|Active Comparator|DCa1.5|using dialysate calcium concentration 1.5mmol/L
3106003|NCT01851226|Experimental|15 minutes group|The time limit of attempt selective cannulation by trainees is limited to 15 minutes. If the trainees failed to enter the targeted duct within 15 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
3106004|NCT01851213||FoundationOne™ Test Ordered|Patients for whom a FoundationOne™ test was ordered and a report is delivered.
3106005|NCT01851200|Experimental|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
3106006|NCT01851187|Experimental|emotional management (EM) group|emotional management (EM) group received antenatal psychological intervention
3106007|NCT01851187|Active Comparator|the usual care (UC) group|the usual care (UC) group was given routine prenatal care only
3106008|NCT01851174|Experimental|Gemcitabine and nab-Paclitaxel|"Gemcitabine (1,000 mg/m^2) administered intravenously on days 1 and 15, every 28 days~nab-Paclitaxel (125 mg/m^2) administered intravenously on days 1 and 15, every 28 days"
3106009|NCT01851161||Diagnostic (CT and 4D CT in supine and prone positioning)|Patients undergo conventional CT scan and 4D CT scan in both supine and prone positioning before undergoing radiation therapy.
3106010|NCT01851148|Sham Comparator|sham therapy|subtracting serial sevel (McPartland 2003)
3106011|NCT01851148|Other|usual care|triptans treatment only
3106012|NCT01851148|Experimental|OMT|8 sessions of osteopathic manipulative treatment
3106013|NCT01851135|Experimental|Patients with NF1|
3106014|NCT01851135|Other|Healthy controls|
3106015|NCT01851122|Placebo Comparator|Placebo|
3106016|NCT01851122|Experimental|l-theanine|
3106017|NCT01851109|No Intervention|Control|
3106018|NCT01851109|Experimental|Genetic counseling|After randomization the participant is offered a referral to a genetic counselor.
3106019|NCT01851096|Experimental|SNX-5422|Open label administration of SNX-5422 tablets every other day for 21 days on a 28 day cycle. Dose escalation of SNX-5422 based on safety outcomes
3106020|NCT01851083|Experimental|autologous bone marrow mononuclear cells|a bone marrow harvest will be performed, followed by a single intravenous infusion of autologous bone marrow mononuclear cells within 48 hours of injury.
3106021|NCT01851083|Placebo Comparator|placebo infusion|a sham harvest will be performed, followed by a single intravenous placebo infusion within 48 hours of injury.
3106022|NCT01851070|Placebo Comparator|Normal Saline Placebo|Placebo will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
3106023|NCT01851070|Active Comparator|Allogeneic Mesenchymal Precursor Cells|Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
3106024|NCT01851057|Active Comparator|Education Only|Education only arm (8 total sessions)
3106025|NCT01851057|Experimental|STAR: Education and Problem Solving|Problem-solving and education intervention (8 total sessions)
3106026|NCT01851044|Placebo Comparator|Vehicle (Saline)|2 ml of saline is injected to the proximal insertion of extensor carpi radialis brevis (ECRB) muscle.
3106027|NCT01851044|Active Comparator|Whole Blood|2 ml of patient own venous blood is injected to the proximal insertion of ECRB.
3106028|NCT01851044|Experimental|Platelet Rich Plasma|9 ml of patient own venous blood is centrifuged using The Arthrex ACP® Double Syringe System and 2 ml of platelet rich plasma is injected to the proximal insertion of ECRB.
3106029|NCT01851031|Experimental|the minor approach group|Thirty-six patients (the minor parotid anterior approach group) were treated with minor parotid anterior approach
3106030|NCT01851031|Other|control group|24 patients (control group) were treated with the retromandibular approach
3106031|NCT01851018|Experimental|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
3106032|NCT01851018|Active Comparator|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists.
3106033|NCT01851005|Placebo Comparator|Group 1|General anesthesia with sevoflurane. Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
3106034|NCT01851005|Placebo Comparator|Group 2|General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
3106035|NCT01851005|Experimental|Group 3|General anesthesia with sevoflurane. Infusion of dexmedetomidine (0.4 ug/kg/hr) during anesthesia. Administer rocuronium 0.8 mg/kg for induction.
3106036|NCT01851005|Experimental|Group 4|General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of dexmedetomidine (0.4 ug/kg/hr) during surgery. Administer rocuronium 0.8 mg/kg for induction.
3106037|NCT01850992|Active Comparator|ACtive CPAP|Continuous positive airway pressure (CPAP) to treat obstructive Sleep Apnea
3106038|NCT01850992|Placebo Comparator|Sham CPAP|This is placebo CPAP
3106039|NCT01850979|Active Comparator|tacrolimus|tacrolimus 0,03% eye drops (olive oil as vehicle) every 12/12 hours for 3 months placebo as olive oil eye drops every 12/12h hours for 3 months
3106040|NCT01850979|Placebo Comparator|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
3106041|NCT01850966||Iguratimod|
3106042|NCT01850953|Placebo Comparator|Sugar Pill|This is a sugar pill that will be used as a placebo comparator.
3106043|NCT01850953|Active Comparator|Varenicline|Varenicline will be titrated to steady-state levels of 2mg/day over 4 days (0.5mg BID for day 1 and 1.0mg BID for days 2-4) before testing at 2mg/day on days 5 and 6.
3106044|NCT01850940||Tolvaptan Group|Tolvaptan,qd, po
3106045|NCT01850940||Conventional therapy|control group:Conventional therapy without tolvaptan
3107059|NCT01844206|Placebo Comparator|Epidural Saline|Group receiving epidural saline 6ml, 24 hours after receiving epidural morphine 3mg.
3106046|NCT01850927|Active Comparator|Intervention|Patients will receive remote ischaemic preconditioning prior to surgery. After the induction of anaesthesia, a blood pressure cuff will be placed on an upper arm and inflated to 200mmHg for 5 minutes, then deflated for 5 minutes, repeated for a total of 3 inflation-deflation cycles.
3106047|NCT01850927|Sham Comparator|Control|Patients will have the same procedure as for the intervention group, however the blood pressure cuff valve will be left open throughout the 30 minute treatment. Patients will be kept under anaesthesia for this additional time.
3106048|NCT01850914||Shunted patients with INPH|Cases: Patients with normal pressure hydrocephalus who have underwent surgery. Controls: Sex- and age-matched community based controls.
3106049|NCT01850914||Populationbased elderly.|A group of populationbased elderly, matched according to age and sex to the patients with INPH. Vascular risk factors studied.
3106050|NCT01850901|Experimental|Renal sympathetic denervation|Catheter-based renal nerve ablation
3106051|NCT01850901|No Intervention|Usual care|Antihypertensive treatment according to guidelines
3106052|NCT01850888|Experimental|131 I-MIBG Treatment Arm|Therapeutic 131 I-Metaiodobenzylguanidine (131I-MIBG) will be infused intravenously, intravenous fluids will be administered to help maintain urine flow and isotope excretion. Potassium iodide solution will be administered to protect thyroid function. G-CSF will be used if necessary for neutrophil recovery. Hematopoietic stem cell infusion if meets the criteria.
3106053|NCT01850875|Experimental|Eye-Movement-Desensitization-Reprocessing|Eye-Movement-Desensitization-Reprocessing
3106054|NCT01850875|No Intervention|Treatment as usual (control group)|treatment as usual
3106055|NCT01850862|Experimental|Collective group exercise program in patients with KOA|Collective exercises program for patients with osteoarthritis and orientation about this disease
3106056|NCT01850862|Active Comparator|Control group (without exercise)|Orientation about osteoarthritis disease but without any exercise program
3106057|NCT01850849|Experimental|LEO 39652 cream|Active drug
3106058|NCT01850849|Placebo Comparator|LEO 39652 cream vehicle|Placebo drug
3106059|NCT01850836|Active Comparator|Real rTMS|19 subacute stroke pts with aphasia received 10 rTMS (5sessions/week) for 2 successive weeks
3106060|NCT01850836|Sham Comparator|Sham rTMS|10 patients received sham rTMS stimulation (5 sessions/week) for 2 successive weeks
3106061|NCT01850823|Placebo Comparator|placebo|Placebo
3106062|NCT01850823|Active Comparator|NASONEX® Nasal Spray (Schering Corporation)|Mometasone Nasal spray
3106063|NCT01850823|Experimental|Mometasone Nasal Spray (Watson Laboratories, Inc)|Mometasone Nasal spray
3106064|NCT01850810|Experimental|Experimental Study Product|1 serving of a nutritional product for people with diabetes.
3106065|NCT01850810|Placebo Comparator|Control Study Product|1 serving of control beverage.
3106066|NCT01850797||NOAC|Patients receiving NOAC and suffering from ischemic stroke or intracranial bleeding.
3106067|NCT01850784|Active Comparator|High energy formula|High energy formula (Similac)
3106068|NCT01850784|Active Comparator|Standard formula|Standard formula
3106069|NCT01850771|Active Comparator|Regenexx PL-Disc|Injection of Regenexx PL-Disc into the epidural space once a week for two weeks.
3106070|NCT01850771|Active Comparator|Steroid Epidural|Injection of steroid into the epidural space once a week for two weeks
3106071|NCT01850758|Active Comparator|Regenexx SD|Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged ligament.
3106072|NCT01850758|Active Comparator|Exercise Therapy|Subjects will be instructed in a set of appropriate rotator cuff strengthening exercises and given an instructional hand-out to take home.
3106073|NCT01850745||Control|Retrospective control group. Usual treatment with peginterferon-2a and ribavirin. No multidisciplinary support program
3106074|NCT01850745||Validation cohort|Prospective group. Usual treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
3106075|NCT01850745||Pilot cohort|Prospective intervention group. Usual pharmacological treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
3106076|NCT01850732|Other|ultrasound of aorta|
3106077|NCT01850719|Experimental|Arthroscopic Partial Meniscectomy|
3106078|NCT01850719|Active Comparator|Physical Therapy|
3106079|NCT01850693||Coronary artery disease, Stroke|Coronary artery disease, stroke, coronary CT angiography
3106080|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 1|First dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
3106081|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 2|Second dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
3106082|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 3|Third dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
3106083|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 4|Fourth dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
3106084|NCT01850680|Placebo Comparator|Placebo Dose 5|Placebo to match Sarilumab (SAR153191, REGN88) in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
3106085|NCT01850667|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy for unresectable hepatocellular carcinoma after incomplete trans-arterial chemo-embolization
3106086|NCT01850654|Other|Probands|Participants with colorectal or endometrial cancer.
3106087|NCT01850654|Other|First-degree relatives of the participants with CRC|The first-degree relatives of the CRC probands (participants with colorectal cancer).
3106088|NCT01850654|Other|At-risk relatives|The relatives of the participants found to have Lynch syndrome.
3106089|NCT01850641|Experimental|PA21|
3106090|NCT01850628||Paclitaxel plus trastuzumab or trastuzumab/pertuzumab|Patient received paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination administered per investigators discretion
3106091|NCT01850615|Experimental|FIAsp and basal insulin + metformin|Subjects will receive FIAsp combined with their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.
3106206|NCT01849757|Active Comparator|Human Albumin|Human albumin solution used as part of the priming volume for the cardiopulmonary bypass circuit.
3106092|NCT01850615|Active Comparator|Basal insulin + metformin|Subjects will continue their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.
3106093|NCT01850602|Experimental|PA21|
3106094|NCT01850602|Active Comparator|Sevelamer hydrochloride|
3106095|NCT01850589|Other|Conservative Therapy|"Conservative therapy:~Subjects counseled by vascular attending/fellow during office appointment to stop smoking.~Counseling consists of:~Self-help materials including Smart Move: A Stop Smoking Guide from the American Cancer Society A brief educational discussion on the benefits of smoking cessation.~Patients randomized to Group 1 will be offered adjunctive treatment with nicotine replacement therapy at no cost."
3106096|NCT01850589|Other|Aggressive Therapy|"8 week comprehensive smoking cessation and pharmacotherapy program consisting of:~One hour group counseling sessions, focusing on patient education and behavior modification.~Behavior modifications including recognition; coping skills; stress management; and relapse prevention skills.~Counseling including information on nutrition, exercise, and chemical dependency.~Counseling sessions will be held 256C Mason Avenue. Pharmacotherapy adjuncts offered at no cost are as follows: Chantix (varenicline) GlaxoSmithKline, Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline."
3106097|NCT01850576|Experimental|Intervention|Those randomized to the intervention group will be invited to attend the risk reduction intervention.
3106098|NCT01850576|No Intervention|Control|The control group will receive usual care. Both treatment and control groups will have received the video-based risk reduction intervention.
3106099|NCT01850563|Other|HBO feasibility|
3106100|NCT01850550|No Intervention|Control|"Participants in the control condition will be given written information at the baseline visit from the NIH website Aim for a Healthy Weight to provide a basic understanding of weight loss and access to basic online resources, but will not participate in group weight loss sessions with peer leaders."
3106101|NCT01850550|Experimental|Weight Loss Groups|Participants in this arm will receive peer-led facilitation within groups using an adaptation of the Diabetes Prevention Program.
3106102|NCT01850537|Experimental|single arm study|treatment of degenerative disc disease using the PROW LIF
3106103|NCT01850524|Active Comparator|IXAZOMIB|IXAZOMIB + Lenalidomide + Dexamethasone
3106104|NCT01850524|Placebo Comparator|Placebo|Placebo + Lenalidomide + Dexamethasone
3106105|NCT01850511|Experimental|Vibrissae trimming|Patients will serve as their own control, with assessment of primary outcomes pre- and post-trimming of vibrissae.
3106106|NCT01850498||Partial seizures|Partial seizures with secondary generalization which results in visible clonic or tonic-clonic motor behavior
3106107|NCT01850498||Generalized seizures|Primarily generalized seizures (in patients with either primary [idiopathic] or secondary [symptomatic] generalized epilepsy), which may involve the following depending on the motor manifestation observed: myoclonic seizures, clonic seizures, tonic-clonic seizures, or atonic seizures.
3106108|NCT01850485||normothermia, 36 degrees|microcirculation after cardiac arrest by SDF and NIRS, in patients treated with 36 degrees, difference is temperature, in this group 36
3106109|NCT01850485||33 degrees, therapeutic hypothermia|microcirculation after cardiac arrest by SDF and NIRS, in patients treated with 33 degrees, difference is temperature, in this group 33
3106110|NCT01850472||Healthy controls|Individuals with no psychiatric diagnosis as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment. There is no intervention administered in this study.
3106111|NCT01850459||Autism Spectrum Disorder group|Diagnosis of autistic disorder as confirmed by a clinical interview, utilizing the DSM-V
3106112|NCT01850459||IQ-Matched Control Subjects|
3106113|NCT01850459||Age-Matched Neurotypical Controls|
3106114|NCT01850459||Shipped Biomarker Control Group Subjects|These subjects provide a blood sample only that serves as a shipping control that is shipped along with all blood samples from Autistic Disorder Subjects, IQ-Matched Control Subjects or Age-Matched Neurotypical Control Subjects. For these shipping control samples, blood samples will also be drawn from the subjects.
3106115|NCT01850446|Experimental|Ergoferon (1 tablet 3 times a day)|
3106116|NCT01850446|Active Comparator|Oseltamivir (Tamiflu) - 1 capsule (75mg) two times a day|
3106117|NCT01850433|Experimental|Internet CBT|
3106118|NCT01850420|Experimental|IMC-1|Experimental intervention
3106119|NCT01850420|Placebo Comparator|Matching placebo|
3106120|NCT01850407|No Intervention|Education Counseling|Education of caregivers to counter lack of Preparedness for Children Undergoing Sexual Abuse Medical Examination
3106121|NCT01850394|Placebo Comparator|Control group|physiologic saline 25 ml
3106122|NCT01850394|Active Comparator|TXA-250 group|A total of 25-ml solution with 250-mg tranexamic acid
3106123|NCT01850394|Active Comparator|TXA-500 group|A total of 25-ml solution with 500-mg tranexamic acid
3106124|NCT01850381|Experimental|GM608|4 subjects will receive 320 mg of GM608. 6.4 mL of GM608 (50 mg/mL) will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
3106125|NCT01850381|Placebo Comparator|Placebo comparator|2 subjects will receive matching placebo (bacteriostatic saline). 6.4 mL Bacteriostatic saline will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
3106126|NCT01850368|Experimental|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy for HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein)
3106127|NCT01850355|Experimental|Buspirone|Buspirone administered in tablets twice daily titrated to a maximum daily dose of 60mg for 8 weeks.
3106128|NCT01850342|Experimental|Fat micrograft enhanced with ADRC|
3106129|NCT01850329|No Intervention|control|No computed-assisted information program will be administered.
3106130|NCT01850329|Experimental|intervention|computed-assisted information program will be administered.
3106131|NCT01850316|Experimental|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
3106132|NCT01850303|Other|Surveillance|
3106133|NCT01850303|Experimental|Maintenance|Pemetrexed for non squamous NSCLC Gemcitabine for squamous NSCLC
3106134|NCT01850290||Dopamine Imaging|
3106135|NCT01850277|Experimental|Rhythm control|"In this group a strategy to restore and maintain SR, including amiodarone and an external electrical cardioversion (EEC), is implemented. A procedure of AF ablation is possible but not obligatory.~At baseline, patients assigned to the group undergo a standard 12-lead ECG, a 6-minute walk test (6MWT), a cardiopulmonary exercise test(CPX), an echocardiography(ECHO), a standard device control; a serum thyroid -stimulating hormone (TSH) level is assessed and patients fill the Minnesota Living With Heart Failure Questionnaire (MLHFQ). Control visits are performed every 3 months including a 12-lead ECG measurement and a device control. On the visits in the 3rd and 12th month an ECHO, a CPX, a 6MWT are performed and a MLHFQ is filled; control TSH levels are assessed every 6 months."
3106136|NCT01850277|Active Comparator|Rate control|"In the latter group a pharmacotherapy to slow and control ventricular rate by means of pharmacotherapy and an atrio-ventricular junction ablation (AVJA) is implemented.~At baseline, each patient assigned to the rate control group undergoes a standard 12-lead ECG, a 6MWT, a CPX, an ECHO, a standard device control and a serum TSH level assessed. Moreover, the patient fills the Minnesota Living With Heart Failure Questionaire (MLHFQ). The control visits are performed for one year, every 3 months including a standard 12-lead ECG measurement and standard control of the device. On the visits in the 3rd and 12th month additionally an ECHO, a CPX, a 6MWT are performed and a MLHFQ is filled. The control TSH levels are assessed every 6 months."
3106137|NCT01850264|Active Comparator|Quadripolar LV electrode|Application of a quadripolar LV electrode
3106138|NCT01850264|Active Comparator|Bipolar LV electrode|Application of a bipolar LV electrode
3106139|NCT01850251|Experimental|Supplement with HMB and vitamin D|Oral administration of 440 mL (2 bottles) of nutritional supplement with HMB and vitamin D each day during 8 weeks.
3106140|NCT01850251|Active Comparator|Standard nutritional supplement|Oral administration of 440 mL (2 bottles) of standard nutritional supplement each day during 8 weeks.
3106141|NCT01850238|Placebo Comparator|Placebo (adjuvant in saline solution)|"Placebo patients will receive 1 dose of placebo per month over 3 months, for a total of 3 administrations.~Placebo consists of vaccine adjuvant in saline solution. Placebo is administered subcutaneously."
3106142|NCT01850238|Experimental|AADvac1|"AADvac1 patients will receive 1 dose of AADvac1 per month over 3 months, for a total of 3 administrations.~AADvac1 is a vaccine (single-use vials with solution ready for injection) AADvac1 is administered subcutaneously."
3106143|NCT01850225|Experimental|Device implantation|Implantation of device
3106144|NCT01850212||Male (≥ 50 years), TDF|Male (≥ 50 years of age) on regimens containing tenofovir disoproxil fumarate (TDF)
3106145|NCT01850212||Male (≥ 50 years of age), Non-TDF|Male (≥ 50 years of age) on non-TDF (tenofovir disoproxil fumarate) based nucleoside reverse transcriptase inhibitors (NRTIs)
3106146|NCT01850212||Female (Postmenopausal), TDF|Female (postmenopausal) on regimens containing tenofovir disoproxil fumarate (TDF)
3106147|NCT01850212||Female (Postmenopausal), Non-TDF|Female (postmenopausal) on non-TDF (tenofovir disoproxil fumarate) based NRTIs
3106148|NCT01850199|Active Comparator|Usual management (presential visits)|Patient will follow the usual care program, which includes in-person appointment (weekly/biweekly)
3106149|NCT01850199|Experimental|Smart telemedicine remote monitoring for gestational diabetes|After receiving an structured education on the matter, patients will be followed remotely by analysing glucose and diet/physical activity/other events data with a periodicity no longer than 48 hours
3106150|NCT01850186|Experimental|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
3106151|NCT01850186|Placebo Comparator|Stabilized kilnman trio|Patients will receive treatment by stabilized kilnman trio for four weeks on all the face (one application per day). At the beginning of week 5, Patient will receive stabilized kilnman trio on the hemi-face during three months (side not treated by dual yellow laser, split body study). The stabilized kilnman trio will be prescribed for one month at inclusion (applied all over the face), and on the half of the face not treated by laser at weeks 4, 8 and 12.
3106152|NCT01850173|Experimental|static work with a vertical vibration platform|The training was designed to perform static work of the lower limbs. Patients worked in a squatting position, with 30º of hip flexion and 55º of knee flexion, holding onto the bars of the WBV platform.
3106153|NCT01850173|No Intervention|Control group|general recommendations about physical activity and lifestyle
3106154|NCT01850160|Experimental|GROUP A: Valsartan plus Chlorthalidone|GROUP A: Combination therapy of Valsartan plus Chlorthalidone. Valsartan 80 mg/Chlorthalidone 12,5 mg. Once daily during 12 weeks.
3106155|NCT01850160|Experimental|GROUP B: Valsartan|GROUP B: Treatment with Monotherapy. Valsartan 80 mg. Once daily during 12 weeks.
3106156|NCT01850160|Experimental|GROUP C: Chlorthalidone|GROUP C: Treatment with Monotherapy. Chlorthalidone 12,5 mg. Once daily during 12 weeks.
3106157|NCT01850147|Experimental|Sunitinib|
3106158|NCT01850134|Placebo Comparator|Control Study Product|1 serving of control beverage.
3106159|NCT01850134|Experimental|Experimental Study Product|1 serving of a nutritional supplement for people with diabetes.
3106160|NCT01850121||Infliximab|Patients with active AS defined as BASDAI score above 4 and no exclusion criteria were consecutively included in this single-armed unblinded trial.
3106161|NCT01850108|Experimental|Non-Myeloablative Conditioning and Bone Marrow Transplantation|
3106162|NCT01850095|Active Comparator|treatment 1|topical acid azelaic, used 2 times a day for 6 months
3106163|NCT01850095|Active Comparator|treatment 2|contraceptive with drospirenone/ethinyl estradiol used for 6 months
3106164|NCT01850095|No Intervention|control|control group ( only take biopsies and blood samples )
3106165|NCT01850082|Other|Endoscopic Vein Harvest (EVH)|An endoscopic vein harvest allows a portion of vein from the inside of the leg to be removed through small incisions. This reduces the length of the incision by several inches. An endoscope, or video camera, is used to view the vein and remove the needed length.
3106166|NCT01850082|Other|Open Vein Harvest (OVH)|"Open vein harvesting is the traditional method for vein harvesting. It is performed under direct vision using a single long incision or, more commonly, multiple-smaller incisions (referred to as bridging technique) along the course of the vein."
3106167|NCT01850069||Intracranial hypertension|Patients with raised intracranial pressure
3106168|NCT01850056|Experimental|drug eluting balloon catheter|use drug eluting balloon catheter to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
3106169|NCT01850056|Active Comparator|common balloon catheter(uncoated drug)|use common balloon catheter to inflate stenosis or occlusion in SFA and/or popliteal artery
3106170|NCT01850043||Military Conscripts|A term of whole military conscripts per year in one Reserve Force Battalion. Military conscripts gather from all around area in Korea randomly
3106171|NCT01850030|Experimental|Dydrogesterone 30 mg|
3106172|NCT01850030|Experimental|Micronized Progesterone 600 mg|
3106173|NCT01850017|Experimental|Methadone and dexmedetomidine|"Standard American Society of Anesthesiology monitors. Midazolam 1-2 mg for pre-operative sedation. Lidocaine 0.5-1 mg/kg with induction. Propofol 1-2 mg/kg with induction. Fentanyl 0.5-1 mcg/kg with induction. Rocuronium 0.5 -1 mg/kg with induction. Total intravenous anesthesia with propofol for maintainence of anesthesia. Titrated to maintain BIS (bispectral index) between 30-60.~Methadone 0.2 mg/kg ideal body weight and dexmedetomidine 1 mcg/kg load over 20 minutes followed by a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure."
3106174|NCT01850017|No Intervention|Methadone and placebo|"Standard American Society of Anesthesiology monitors. Midazolam 1-2 mg for pre-operative sedation. Lidocaine 0.5-1 mg/kg with induction. Propofol 1-2 mg/kg with induction. Fentanyl 0.5-1 mcg/kg with induction. Rocuronium 0.5 -1 mg/kg with induction. Total intravenous anesthesia with propofol for maintainence of anesthesia. Titrated to maintain BIS (bispectral index) between 30-60.~Methadone 0.2 mg/kg ideal body weight and placebo (normal saline) 1 mcg/kg load over 20 minutes followed by a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure"
3106175|NCT01850004|Experimental|Dasatinib|Dasatinib 50, 80, 100, 140, 180 mg tablets by mouth, once daily, up to 60 months
3106176|NCT01849991|Active Comparator|Lactobacillus reuteri|The first arm of the cohort will include 30 patients on LR (5x10^8 cfu's orally once daily.)
3106177|NCT01849991|Placebo Comparator|Sunflower Oil|The second arm includes 15 subjects on placebo (sunflower oil.)
3106178|NCT01849978|Active Comparator|Control arm|"Participants in this arm will receive the newsletter about their reported minutes of physical activity and the benefits of physical activity specific to breast cancer survivors, and the brochure Changing your habits, developed by the NIH."
3106179|NCT01849978|Active Comparator|Habit Formation Arm|Participants in this arm will receive all of the intervention materials.
3106180|NCT01849965|Active Comparator|DSC127|DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
3106181|NCT01849965|Placebo Comparator|Vehicle gel|Vehicle gel comprising HEC with parabens
3106182|NCT01849965|Placebo Comparator|Standard of Care gel|Aquasite gel, as standard of care gel
3106183|NCT01849939|Experimental|Fludarabin|
3106184|NCT01849926|Active Comparator|Ibuprofen|Tablet, over capsulated, 600mg three times a day for three days.
3106185|NCT01849926|Active Comparator|Mecillinam|Tablet, over capsulated, 200mg three times a day for three days.
3106186|NCT01849913|Experimental|Group B & Group C|Group B equal to low-level laser therapy dosis 5,9 j per point Group C equal to Placebo group
3106187|NCT01849913|No Intervention|Group A & Group C|Group A equal to Control (no intervention) Group C equal to Placebo group
3106188|NCT01849900|Other|Healthy Lifestyle|60 women randomly assigned to the control group
3106189|NCT01849900|Other|Knowing your body|60 women randomly assigned to intervention group
3106190|NCT01849887|Active Comparator|mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
3106191|NCT01849887|Placebo Comparator|Placebo|Placebo
3106192|NCT01849874|Experimental|MEK162|
3106193|NCT01849874|Active Comparator|Physician's choice chemotherapy|
3106194|NCT01849861|Experimental|Methimazole,|"Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.~Variables considered in this study:~TSH and FT4~Questionnaire of Quality of life for older adults (WHOQOL-OLD)~Mini-Mental State Examination~Geriatric Depression Scale~Cardiopulmonary exercise testing - cardiopulmonary capacity"
3106195|NCT01849848|Experimental|SyB L-0501|
3106196|NCT01849835|Experimental|trans-rectal|trans-rectal to perform the prostate biopsy
3106197|NCT01849835|Experimental|trans-perineal|trans-perineal to perform the prostate biopsy
3106198|NCT01849822|Experimental|Neural Prosthetic System|The Neural Prosthetic System consists of two Neuroport Arrays, which are described in detail in the intervention description. Both Neuroport Arrays are inserted into the posterior parietal cortex, an area of the brain used in reach and grasp planning. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subjects will participate in study sessions 3-5 times per week in which they will learn to control an end effector by thought. They will then use the end effector to perform various reach and grasp tasks.
3106199|NCT01849809|Experimental|Gamma Ventral Capsulotomy|
3106200|NCT01849796|Active Comparator|Group A: Anodal tDCS|Group A will receive one block of real excitatory anodal tDCS over the motor cortex and one block of sham.
3106201|NCT01849796|Sham Comparator|Arm B: Cathodal tDCS|Group B will receive one block of inhibitory cathodal tDCS over the somatosensory cortex and one block of sham.
3106202|NCT01849783|Experimental|autologous stem cell transplant|"Induction : DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide)~Maintenance: Year 1 - VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
3106203|NCT01849770|Active Comparator|Mexiletine, 300 milligrams|Mexiletine, 300 milligrams by mouth per day for 12 weeks.
3106204|NCT01849770|Active Comparator|Mexiletine, 900 milligrams|Mexiletine, 900 milligrams by mouth per day for 12 weeks.
3106207|NCT01849757|Active Comparator|Voluven or hydroethylstarch HES 130/0.4|Hydroethylstarch HES 130/0.4 used as part of the priming volume for the cardiopulmonary bypass circuit.
3106208|NCT01849757|Placebo Comparator|Crystalloid|Crystalloid will be used to prime the cardiopulmonary bypass circuit
3106209|NCT01849744|Experimental|VS-4718|Oral VS-4718 administered BID (QD during first cohort) during a 28 day cycle.
3106210|NCT01849731|Experimental|Intervention A|Face-to face intervention
3106211|NCT01849731|Experimental|Intervention B|Face-to-face intervention plus telephone reinforcement
3106212|NCT01849731|No Intervention|Control Group|
3106213|NCT01849718||CBT - Cognitive Behavioural Therapy|"40 participants will receive cognitive behavioural therapy in a clinical setting.~The duration of the individual sessions are one hour, and there are 1-2 sessions per. week, totaling 20 hours, incl. 4 hours of transition conversations.~The conversations will be exclusively CBT-based. Number of hours for conversational therapy: 20 hours of individual psychotherapy"
3106214|NCT01849718||Nacadia Therapy|"40 participants will receive garden therapy in a designed, natural environment.~The individual sessions last three hours with two sessions per week the first and last week and three sessions per week in week 2-9. This gives a total of 96 hours, including 4 x 3 hours transition conversation and 10 x ½ hour individual interviews.~Experiences and activities related to the garden environment are integrated with mindfulness exercises. The individual conversations in the Nacadia-therapy will be mindfulness-based CBT.~10 x ½ an hour of individual psychotherapy."
3106215|NCT01849705||All subjects|No intervention
3106216|NCT01849692|Experimental|ESBA1008 1.2 mg/10 μL|Cohort 1: One intravitreal injection on Day 0, followed by one intravitreal (IVT) injection of ESBA1008 6 mg/50 μL on Day 28
3106217|NCT01849692|Experimental|ESBA1008 1 mg/8.3 μL|Cohort 2: One intravitreal infusion on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
3106218|NCT01849692|Experimental|ESBA1008 0.6 mg/10 μL|Cohort 3: One intravitreal injection on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
3106219|NCT01849692|Experimental|ESBA1008 0.5 mg/8.3 μL|Cohort 4: One intravitreal infusion on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
3106220|NCT01849692|Active Comparator|Ranibizumab 0.5 mg in 50 μL|Cohorts 1-4: One intravitreal injection on Day 0, followed by another intravitreal injection on Day 28
3106221|NCT01849679||Post-Extubation Subjects|
3106222|NCT01849666|Active Comparator|A: phenprocoumon single dose|
3106223|NCT01849666|Experimental|B: vemurafenib + phenprocoumon single dose|
3106224|NCT01849653||Women - Upcoming routine clinic visit|This group of women will self-obtain vaginal swabs at home on the day of their medical appointment and bring the specimens to the clinic. Subjects will then self-obtain another set of vaginal swabs at the clinic. Clinician/nurse will obtain another set of vaginal swabs from the subject at the clinic.
3106225|NCT01849653||Women - Recruited while at the clinic|This group of women will self-obtain vaginal swabs at the clinic. Clinician/nurse will obtain another set of vaginal swabs from the subject at the clinic. Within 24 hours of their clinic visit, subjects will self-obtain another set of vaginal swabs at their home and mail them to the laboratory.
3106226|NCT01849640|Active Comparator|DHA-piperaquine with Primaquine|3-day treatment course of DHA-piperaquine with 45mg single dose primaquine
3106227|NCT01849640|Active Comparator|DHA-piperaquine without Primaquine|3-day treatment course of DHA-piperaquine
3106228|NCT01849627|Experimental|Low-ED|This condition will focus lowering on the energy density of the diet of the diet. This prescription does not include goals for any other nutrients, thus there are no energy goals.
3106229|NCT01849627|Experimental|Energy Balance|This condition will focus have an energy balance prescription. Participants will be asked to consume a daily energy intake at estimated energy needs for weight loss maintenance.
3106230|NCT01849614||Patient group|Women with left-sided breast cancer
3106231|NCT01849601|Experimental|PTA catheter|
3106232|NCT01849588|Experimental|Treatment Arm|Sorafenib taken orally twice per day
3106233|NCT01849575|Active Comparator|Intervention|The intervention: Giving communication about risk of cardiovascular disease in the form of written and graphical information about silent atheroscslerosis measured by carotid ultrasound examination as carotid intima-media thickness, highlighted as vascular age, and plaque formation, visualized as a traffic light (green - no plaque, red - plaque).The ultrasound results are given to the study person and his/her physician, in addition to information about conventional risk factors for cardiovascular disease
3106234|NCT01849575|No Intervention|Control|The comaparator is that the study person and his/her physician do not get any information about carotid ultrasound results on silent atherosclerosis. They are only informed about results of measured conventional CVD risk factors
3106235|NCT01849562|Active Comparator|Sovaprevir 200 mg, ACH-3102 150/50 mg, RBV 1000-1200mg|Sovaprevir 200 mg QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg QD + RBV weight-based 1000-1200mg QD for 12 weeks
3106236|NCT01849562|Active Comparator|Sovaprevir 400 mg, ACH-3102 150/50mg,RBV1000-1200mg|Sovaprevir 400 mg QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg QD + RBV weight-based 1000-1200mg QD for 12 weeks
3106237|NCT01849562|Placebo Comparator|Placebo|Placebo for Sovaprevir capsule QD + placebo for ACH-3102 150 mg loading dose on Day 1 followed by 50 mg capsule QD + placebo for weight-based RBV QD for 12 weeks
3106238|NCT01849549|Experimental|brain damaged subjects|patients with circumscribed brain injury, selective disorders of cognitive development or degenerative disorders responsible for focal troubles
3106239|NCT01849549|Sham Comparator|healthy volunteers|healthy controls
3106240|NCT01849536|Experimental|SENSIMED Triggerfish®|SENSIMED Triggerfish®
3106241|NCT01849523|Experimental|Web-based information and support|Web-based tailored information and support
3106242|NCT01849523|No Intervention|Standard care|Standard care
3106243|NCT01849510|Experimental|dose intensified|hypofractionated 12x3 Gy + integrated boost 12x4 Gy
3106244|NCT01849510|Active Comparator|standard|hypofractionated 10x3 Gy
3106245|NCT01849497|Experimental|Evolocumab PFS|Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled syringe (PFS). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
3106246|NCT01849497|Experimental|Evolocumab AI/pen|Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled autoinjector/pen (AI/pen). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
3106247|NCT01849484|Experimental|hippocampal sparing radiotherapy|Radiation according to indication with hippocampal sparing
3106248|NCT01849484|Active Comparator|Control|Radiation according to indication without hippocampal sparing
3106249|NCT01849471||patients with prostate cancer|questionnaires
3106250|NCT01849458||BioFiber|Subjects implanted with BioFiber Scaffold or BioFiber-CM Scaffold
3106251|NCT01849445|Active Comparator|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
3106252|NCT01849445|Active Comparator|Home physiotherapy excercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
3106253|NCT01849432||Control|Healthy Controls
3106254|NCT01849432||Posttraumatic Stress Disorder|Participants with Posttraumatic Stress Disorder
3106255|NCT01849432||Panic Disorder|Participants with Panic Disorder
3106256|NCT01849432||Specific Phobia|Participants who have specific phobias
3106257|NCT01849419|Experimental|Single group|Healthy volunteers received all drug conditions (MDMA, oxytocin, and placebo) using a within-subjects design.
3106258|NCT01849406|Active Comparator|Nasal spray Budesonide|one week therapy of nasal budesonide (twice per day)
3106259|NCT01849406|Placebo Comparator|Nasal spray Normal Saline|one week therapy of nasal normal saline (twice per day)
3106260|NCT01849393||Study Population|Participants must meet the eligibility requirements will complete a questionnaire on the computer.
3106261|NCT01849380|Experimental|Epirubicin-cyclophosphamide-S-1( ECS)|S-1(SuLi,QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration followed by a 14-day rest, combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly.
3106262|NCT01849380|Active Comparator|Epirubicin-cyclophosphamide-5-FU (ECF)|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively), combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly.
3106263|NCT01849367|Experimental|Active tDCS (1)|
3106264|NCT01849367|Active Comparator|Active tDCS (2)|
3106265|NCT01849354||Endometriosis patients|Endometriosis patients to be operated in Turku university hospital 2013-2015
3106266|NCT01849354||Control patients|Patients who will be operated because of an adnexal finding other than endometriosis, for example ovarian cyst. Also patients with laparoscopic sterilization will be recruited to the control group.
3106267|NCT01849341|Experimental|Roflumilast alternated days|Intervention: 500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
3106268|NCT01849341|Active Comparator|Roflumilast 500 mcg per day|Roflumilast 500μg standard dosage
3106269|NCT01849328||Breast Cancer|
3106270|NCT01849328||Healthy|
3106271|NCT01849315|Placebo Comparator|Control|Sedentary intervention
3106272|NCT01849315|Active Comparator|AKIDS II|Physically active group
3106273|NCT01849302|Experimental|High protein/ High fat beverage|"Beverage based on milk protein: 1.8 MJ, 40 E% Protein, 42 E% fat~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
3106274|NCT01849302|Experimental|High protein/ Normal CHO beverage|"Beverage based on milk protein: 1.8 MJ, 40 E% Protein, 47 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
3106275|NCT01849302|Experimental|Low protein/ High fat beverage|"Beverage based on milk protein: 1.8 MJ, 9 E% Protein, 63 E% fat~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
3106276|NCT01849302|Experimental|Low protein/ High CHO beverage|"Beverage based on milk protein: 1.8 MJ, 9 E% Protein, 71 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
3106277|NCT01849302|Experimental|Normal protein/ Normal CHO beverage 1|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
3106278|NCT01849302|Experimental|Normal protein/Normal CHO beverage 2|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
3106279|NCT01849302|Experimental|Normal protein/Normal CHO beverage 3|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
3106280|NCT01849289|Experimental|Insulin Degludec|
3106281|NCT01849289|Experimental|Insulin Glargine|
3106282|NCT01849276|Experimental|Treatment (enzyme inhibitor and chemotherapy)|Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10.
3106283|NCT01849263|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease at the end of course 2 may continue on therapy until the end of course 5 at the discretion of the treating physician.
3106284|NCT01849250|Experimental|Arm I (docosahexaenoic acid)|Patients receive docosahexaenoic acid PO BID for 12 weeks.
3106285|NCT01849250|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 12 weeks.
3106286|NCT01849237|Active Comparator|Standard therapy of septic shock|according to Surviving Sepsis Campaign 2012 Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
3106287|NCT01849237|Experimental|Mesenchymal stromal cells+ standard therapy of septic shock|"MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l).~according to Surviving Sepsis Campaign 2012: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids"
3106288|NCT01849224|Experimental|Pelvic and lower extremity exercise|Experimental arm will be educated the guidelines for prevention and early detection of lower extremity edema. Additionally, pelvic and lower extremity exercise will be educated and participants will continue exercise for 1 year at home.
3106289|NCT01849224|No Intervention|Control|Control group will be educated the guidelines for prevention and early detection of lower extremity edema
3106290|NCT01849211|Other|neuromuscular block|
3106291|NCT01849198|Other|Group trapezius|Assessment of intubation conditions after onset of the neuromuscular block at the m. trapezius
3106292|NCT01849198|Other|group adductor pollicis|assessment of intubation conditions after onset of the neuromuscular block at the m. adductor pollicis
3106293|NCT01849185|Active Comparator|BIO 25 (food supplements)twice a day for 8 weeks|BIO 25 - Innovative Formula contains 11 different strains of probiotic bacteria patents and more than 25 billion active bacteria in each capsule.
3106294|NCT01849185|Placebo Comparator|Placebo twice a day for 8 weeks|Placebo twice a day for 8 weeks
3106295|NCT01849172|Experimental|acupuncture|Electroacupuncture at RN4, EX-CA1，ST25, SP6 (double sides). One session will be given every two days, 3 sessions per week (24 sessions in all) and each session lasts for 30 minutes.
3106296|NCT01849172|Sham Comparator|sham acupuncture|"Electroacupuncture at non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides).~One session will be given every two days, 3 sessions per week (24 sessions in all) and each session lasts for 30 minutes."
3106297|NCT01849159|Active Comparator|MSC group|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution. Infusions will be performed every 2 months for 1 year
3106298|NCT01849159|Placebo Comparator|Control Group|400 mL of 0.9% NaCl solution. Infusions will be performed every 2 months for 1 year
3106299|NCT01849146|Experimental|Arm I (adavosertib, temozolomide, radiation)|"INITIATION COURSE: Patients receive adavosertib PO on days 1, 3, and 5 or 1-5 weekly and temozolomide PO QD for 6 weeks. Patients also undergo concurrent radiation therapy 5 days per week for 6 weeks.~MAINTENANCE COURSES: Beginning in week 10, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3106300|NCT01849146|Experimental|Arm II (adavosertib, temozolomide)|Patients receive adavosertib PO QD on days 1, 3, and 5 or 1-5 weekly, and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3106301|NCT01849133|Experimental|ELIOT|intraoperative radiotherapy
3106302|NCT01849133|Active Comparator|EXTERNAL RT|external fractionated radiotherapy
3106303|NCT01849120||Near-infrared spectroscopy (NIRS)|After cardiac surgery, all subjects will have EQUANOX Advance 8004CB sensors applied to peripheral sites (left and right calf and side of abdomen).
3106304|NCT01849107|Experimental|Plasma citrulline|
3106305|NCT01849094|Experimental|Milrinone 6mg|"single oral dose of 6mg ER milrinone tablet (Part A).~1. single intravenous infusion of milrinone (per Alfred Hospital protocol. 50ug/kg loading dose over 15 mins followed by infusion at 0.375 ug/kg/min for 6 hrs) - Part B."
3106306|NCT01849094|Active Comparator|Milrinone 10mg ER|single oral dose of 10 mg ER milrinone tablet (Part A) single oral dose of 10 mg ER milrinone tablet (Part B)
3106307|NCT01849094|Active Comparator|Milrinone 14mg|single oral dose of 14 mg ER milrinone tablet (Part A) single dose of 14 mg ER milrinone tablet 4. single oral dose of 18 mg ER milrinone tablet (if the group average plasma milrinone levels is less than 150 ug/L with 15 mg dose) - (Part B)
3106308|NCT01849081|Experimental|CPAP|Subjects in this arm with receive treatment with CPAP for fatty liver disease.
3106309|NCT01849081|Active Comparator|Lifestyle Intervention|Subjects in the lifestyle arm will undergo 12 weeks of dietary counseling.
3106310|NCT01849068|Experimental|Ezetimibe|
3106311|NCT01849068|Placebo Comparator|Placebo|
3106312|NCT01849055|Placebo Comparator|Placebo|Placebo matching LY3023703 administered orally, once daily (QD), for 28 days
3106313|NCT01849055|Experimental|LY3023703|Escalating doses (2.5 milligram [mg] up to 30 mg) of LY3023703 administered orally, QD, for 28 days
3106314|NCT01849055|Active Comparator|Celecoxib|400 mg celecoxib administered orally, QD, for 28 days. (Positive control.)
3106315|NCT01849042|Other|donepezil maintain group|continue already taking same dose (5mg or 10mg per day) of donepezil who assigned donepezil group
3106316|NCT01849042|Active Comparator|add-on Ebixa oral pump group|Ebixa dosage titration (5mg per day for 1week, then 10mg per day for 1week, then 15mg per day for 1week, then up to 20mg per day) add-on already taking donepezil (5mg or 10mg per day)
3106317|NCT01849029|Experimental|Cognitive Processing Theapy-Cognitive|Immediate group receives Cognitive Processing Therapy-Cognitive CPT-C intervention within one week of being consented into the study
3106318|NCT01849029|Other|Cognitive Processing Threapy-Cognitive|Wait list group: waits 6 weeks before receiving the Cognitive Processing Therapy-Cognitive (CPT-C) intervention. During this period no intervention is received
3106319|NCT01849016|Experimental|N-Acetylcysteine|N-Acetylcysteine 600mg 1 oral tablet twice daily during 6 months
3106320|NCT01849016|Placebo Comparator|Placebo|Placebo 1 oral tablet twice daily during 6 months
3106321|NCT01849003|Experimental|Cohort 1|Participants will receive a single 10 mg dose of GS-6615.
3106322|NCT01849003|Experimental|Cohort 2|Participants will receive a single 20 mg dose of GS-6615.
3106323|NCT01849003|Experimental|Cohort 3|Participants will receive a single 30 mg dose of GS-6615.
3106324|NCT01849003|Experimental|Cohort 4|Participants will receive a single 60 mg dose of GS-6615.
3106325|NCT01849003|Experimental|Cohort 5|"Participants will receive single doses of GS-6615 as follows:~Day 1: 20 mg (loading dose)~Day 2: 40 mg (loading dose)~Days 3-7: 6 mg (maintenance dose) once daily~If a participant has a QTcF value of ≤ 420 msec on 2 consecutive time points after the 20 mg dose on Day 1, the participant will receive the maintenance dose of 6 mg on Day 2."
3106326|NCT01849003|Experimental|Cohort 6|"Participants will receive single doses of GS-6615 as follows:~Day 1: 50 mg (loading dose)~Day 2-3: 10 mg once daily~Days 4-7: 20 mg once daily"
3106327|NCT01848990|Experimental|Commercial Hylenex Recombinant (Formulation 1)|Hylenex Formulation 1: For 6 months, participants received their regular treatment of rapid-acting continuous subcutaneous insulin infusion (CSII) (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the commercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).
3106328|NCT01848990|Experimental|Precommercial Hylenex Recombinant (Formulation 2)|Hylenex Formulation 2: For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the precommercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).
3106329|NCT01848990|Active Comparator|Standard Rapid-Acting Insulin CSII|Participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.
3106330|NCT01848977|Experimental|vascular occlusion test|"The pediatric SomaSensor™ probe of INVOS® and the 15-mm sensor of InSpectra™ are placed on each thenar muscle in the same subject. The side on which the probe will be placed is randomly determined. INVOS® updates data every 5 s and data (SrO2) will be manually recorded. The data of InSpectra™ (StO2) are automatically collected and sampled every 2 s.~Vascular occlusion test (VOT) is done as follows:Adult-size blood pressure cuffs are placed around each upper arm. The both cuffs are simultaneously inflated to 30 mmHg above the initial systolic blood pressure and kept inflated until the SrO2 or StO2 decreased to 40%. When the value reaches 40% or just below it, the cuff on the same side is deflated rapidly. The data will be collected until the SrO2 and StO2 values returned to the baseline."
3106331|NCT01848964|Experimental|Evaluation|"First, the assessment will be performed to evaluate the relationship between pressure repartition pattern, clinical evaluation and motor capabilities. All the patients and volunteers will be concerned by this first part.~A second part will be conducted in 15 amputees within the 40 patients. Assessments of pressure pattern during gait and standing will be repeated two times: by the same investigator and by a different investigator, in order to test intra- and inter-evaluator reproducibility.~After the first assessment, the prosthesis may be modified in order to solve clinical problems. In that case, a new assessment will be proposed 2 to 8 weeks after in order to test the effect of the prosthesis modification on pressure pattern, gait, posture and clinical parameters."
3106332|NCT01848951||Epidural|The skin will be disinfected with 2% chlorhexidine. Under sterile technique, the epidural will be placed.Epidural catheter will be placed at thoracic vertebral levels T5 to T10. Level chosen as clinically indicated. The epidural solution should contain UNMCs standard solution of Bupivicaine 0.05% and hydromorphone 10 mcg/cc. However, solution type should be clinically indicated.
3106333|NCT01848951||TAP Block|The skin will be disinfected with 2% chlorhexidine. The bilateral dual TAP infiltrative blocks will be placed using high-frequency ultrasound.2.The TAP blocks will be performed using lipospheric bupivacaine (Exparel) with the following dosing regimen.A 266mg (20cc) vial of lipospheric bupivacaine will be equally into 2 30 ml syringes using strict sterile technique. The solution will be diluted in each syringe with 20cc preservative free sterile 0.9% normal saline to a total volume of 30 ml in each syringe. Once the transversus abdominal plane is identified then a 5-10 ml of plain 0.9% normal saline will be injected to open the fascial plane. Once the plane is opened then the 15cc of diluted lipospheric bupivacaine will be administered under direct ultrasound visualization in all 4 TAP quadrants ( subcostal position x2 and lateral position x2)
3106334|NCT01848938|Active Comparator|Smartphone treatment|Smartphone treatment with PFMT.
3106335|NCT01848938|No Intervention|Waiting list|Waiting list for three months. They receive the smartphone application after follow-up.
3106336|NCT01848925|Experimental|SANGUINATE™|PEG-bHb-CO
3106337|NCT01848925|Active Comparator|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
3106338|NCT01848912||Bone Marrow Transplant Patients|
3106339|NCT01848899|Experimental|Ioxaglate Arm|
3106340|NCT01848899|Experimental|Iodixanol arm|
3106341|NCT01848886|Other|Grp 1: ERAH, Mammarioradial (Y-graft)|Endoscopic radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an composite graft (Y-graft).
3106342|NCT01848886|Other|Grp 2: ERAH, Aortoradial (Free RA)|Endoscopic radial artery harvest Aortooradial (free RA) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an free RA graft.
3106343|NCT01848886|Other|Grp 3: ORAH, Mammarioradial (Y-graft)|Open radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an open procedure and positioned on the heart as an composite graft (Y-graft).
3106344|NCT01848886|Other|Grp 4: ORAH, Aortoradial graft (Free RA)|Aortooradial graft (free RA) Open radial artery harvest In this group the radial artery is harvested as an open procedure and positioned on the heart as an free RA graft.
3106345|NCT01848873|Experimental|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid (FA),once daily for 8 weeks.
3106346|NCT01848873|Experimental|amlodipine-FA tablet ,high dose group|5mg amlodipine combined with 0.8 mg of folic acid (FA), once daily for 8 weeks.
3106347|NCT01848873|Active Comparator|amolodipine|5 mg amlodipine, once daily for 8 weeks.
3106348|NCT01848860|Sham Comparator|Control group|In this group, only thoracoscopic bullectomy and pleural abrasion will be done.
3106349|NCT01848860|Experimental|Mesh group|In this group, absorbable mesh coverage of the staple line will be performed after thoracoscopic bullectomy and pleural abrasion.
3106350|NCT01848847|Experimental|Full Bladder|Hysteroscopy conducted under full bladder.
3106351|NCT01848847|Experimental|Empty Bladder|Hysteroscopy conducted under empty bladder.
3106352|NCT01848834|Experimental|Cohort A: Triple negative breast cancer|Participants receive pembrolizumab, 10 mg/kg, intravenously (IV) once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
3106353|NCT01848834|Experimental|Cohort B: Head & neck cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
3106354|NCT01848834|Experimental|Cohort C: Urothelial cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
3106355|NCT01848834|Experimental|Cohort D: Gastric cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
3106356|NCT01848834|Experimental|Cohort B2: Head & neck cancer expansion|Participants receive pembrolizumab, 200 mg, IV once every 3 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
3106357|NCT01848821|Other|OASIS half of wound|OASIS will be applied to one half of the wound and standard of care consisting of wound vac only will be applied to the other half.
3106358|NCT01848821|Other|Standard therapy half of wound|Standard therapy to half of wound will consistent of non-stick mesh and wound VAC application.
3106359|NCT01848808|Experimental|Wobenzym PS|During the 4-week of the Wobenzym supplementation, participants will take 6 tablets of Wobenzym: 2 tablets 3 times daily at least 45 minutes before meal.
3106360|NCT01848808|Placebo Comparator|Placebo|During the 4-week of placebo phase, participants will take 6 tablets of placebo: 2 tablets 3 times daily at least 45 minutes before meal.
3106361|NCT01848795|Experimental|EndoBarrier Gastrointestinal Liner|The treatment in this arm is the endoscopic positioning of the EndoBarrier Gastrointestinal Liner and follow up.
3106362|NCT01848795|Active Comparator|Intragastric Balloon|The treatment in this arm is the endoscopic positioning of the intragastric balloon (Easy life balloon) as a comparator and follow up.
3106363|NCT01848782|Experimental|abstract with limitation section added|we add a limitation section in each selected abstract, the limitation section will focus on the quality of included studies.
3106364|NCT01848782|Active Comparator|abstract without limitation section|We selected 30 abstracts with a conclusion in favour the experimental treatment from a sample of systematic reviews that evaluate the effect of health care intervention.
3106365|NCT01848769|Experimental|CHF1535 pMDI + AC Plus|Fixed combination of Beclomethasone Dipropionate and Formoterol 50/6 mcg with Aerochamber Plus spacer device
3106366|NCT01848769|Active Comparator|BDP and Formoterol + AC Plus|Beclomethasone Dipropionate 50 mcg and Formoterol 6 mcg with Aerochamber Plus spacer device
3106367|NCT01848756|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle. Subjects will continue treatment on a 28-day cycle at the discretion of the principal investigator based on safety.
3106368|NCT01848743|Active Comparator|Tenofovir|All enrolled patients are randomized to tenofovir arm who receives tenofovir 300 mg qd for 36 months
3106369|NCT01848743|Placebo Comparator|lamivudine|All enrolled patients are randomized to lamivudine arm who received lamivudine 100 mg qd for 6 months, followed by tenofovir for another 30 months.
3106370|NCT01848730|Experimental|CNV2197944|CNV2197944 75mg tid 21 days
3106371|NCT01848730|Placebo Comparator|Placebo|Placebo tid 21 days
3106372|NCT01848717|Experimental|Lift thread|
3106373|NCT01848704|Active Comparator|abstract with spin|30 abstracts of 2 parallel arms negative RCTs (ie, non-statistically significant primary outcome) evaluating treatment in the field of cancer and having spin in the abstract conclusion according to a classification developed previously
3106374|NCT01848704|Experimental|abstract without spin|The abstracts with spin were systematically rewritten without spin
3106375|NCT01848691|Experimental|Sickle Cell|This arm will include 20 children with sickle cell anemia
3106376|NCT01848691|Active Comparator|Control|This arm will include 20 children without sickle cell anemia
3106377|NCT01848665|Experimental|Drug|Indomethacin, 1.2 mg kg 1 dose
3106378|NCT01848665|Placebo Comparator|Placebo|generic flour placebo capsule
3106379|NCT01848652|Experimental|MYOCET|
3106380|NCT01848639|Active Comparator|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
3106381|NCT01848639|Placebo Comparator|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
3106382|NCT01848613|Experimental|Arm A|•Arm A: first cycle of IV vinorelbine (30 mg/m2) and second cycle of PO vinorelbine (60mg/m2)
3106383|NCT01848613|Experimental|Arm B|• Arm B: first cycle with PO vinorelbine (60mg/m2) followed by a second cycle of IV vinorelbine (30mg/m2)
3106384|NCT01848600|Experimental|abstract without limitation section|the experimental arm is abstract without the limitation section
3106385|NCT01848600|Other|abstract with limitation section|the control arm is abstract with the original limitation section
3106386|NCT01848587|Experimental|acupuncture|5 acupuncture sessions over a 4 week period plus standard treatment
3106387|NCT01848587|Active Comparator|usual care|standard treatment (pregnancy belt, behavioral recommendations, exercises, pain killers as prescribed by usual health care professional)
3106388|NCT01848574|No Intervention|Usual procedure|Investigators will give medical information to their patients as usual.
3106389|NCT01848574|Experimental|Experimental procedure|"You must use the standardized patient information. The final Information of the patient before the final output should be clear and concise in the presence of trustworthy people if the patient wishes.~Deliver the following information in the orde of the items below:~Decline your identity and function Provide a final diagnosis, indicating the affected organ and Inform prognosis (any severity), and the potential duration of affection~Briefly additional tests:~Radio show~Explain the main abnormalities Explain treatment modalities and setpoint monitoring Finish with an open question: Do you have questions? If you think the state anxiety or depression alters the patient's understanding, still deliver all the information listed above."
3106390|NCT01848561||Adalimumab (Humira) Treatment|Patients who are prescribed and treated with Adalimumab
3106391|NCT01848561||Immunomodulatory Therapy|Patients who are being prescribed and treated with Immunomodulatory Therapy
3106392|NCT01848548||Assessment of Superior Laryngeal Nerve Block Technique|
3106393|NCT01848535|Placebo Comparator|GOS addition|All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 1 receives a drink with GOS (2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.
3106394|NCT01848535|Placebo Comparator|placebo (maltodextrine)|All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 2 receives a drink with placebo, maltodextrin(2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.
3106395|NCT01848509|No Intervention|Without telemonitoring|Without teletransmission of alerts
3106396|NCT01848509|Experimental|With telemonitoring|With teletransmission of alerts
3106397|NCT01848496|Experimental|Cordless technique|This technique does not employ a gingival cord to obtain gingival displacement.
3106398|NCT01848496|Active Comparator|Conventional technique|This technique employ a gingival cord to obtain gingival displacement.
3106399|NCT01848483|Experimental|AIDS EPC Package plus MI|AIDS EPC Package plus MI: AIDS Early Palliative Care (EPC) Package and Motivational Interviewing (MI) At least one early Palliative Care visit plus four weekly MI sessions within a 3 month period of time.
3106400|NCT01848483|Other|Standard of Care (SOC)|Standard of Care (SOC): Routine Infectious Disease Program HIV-care clinic appointment
3106401|NCT01848470|Experimental|E1. CG400549 640mg|CG400549 640mg BID on Day 1-5 and QD on Day 6 in the fed-state
3106402|NCT01848470|Experimental|E2: CG400549 320mg|CG400549 320mg QD on Day 1-5 in the fed-state.
3106403|NCT01848470|Experimental|E3: CG400549 640mg|CG400549 640mg QD on Day 1-5 in the fed-state.
3106404|NCT01848470|Experimental|E4: CG400549 960mg|CG400549 960mg QD on Day 1-5 in the fed-state.
3106405|NCT01848470|Placebo Comparator|P1 Placebo|Placebo 640mg BID on Day 1-5 and QD on Day 6 in the fed-state
3106406|NCT01848470|Placebo Comparator|P2: Placebo 320mg|Placebo 320mg QD on Day 1-5 in the fed-state
3106407|NCT01848470|Placebo Comparator|P3 Placebo 640mg|Placebo 640mg QD on Day 1-5 in the fed-state.
3106408|NCT01848470|Placebo Comparator|P4: Placebo 960mg|Placebo 960mg QD on Day 1-5 in the fed-state.
3106409|NCT01848457|Experimental|Arm 1|Cycles 1 and 2: HDMTX administered as a 4-hour infusion and pantoprazole is administered with cisplatin Cycles 3 and 4: HDMTX administered as a 12-hour infusion and cisplatin is administered alone
3106410|NCT01848457|Experimental|Arm 2|Cycles 1 and 2: HDMTX administered as a 4-hour infusion and cisplatin is administered alone Cycles 3 and 4: HDMTX administered as a 12-hour infusion and pantoprazole is administered with cisplatin
3106411|NCT01848457|Experimental|Arm 3|Cycles 1 and 2: HDMTX administered as a 12-hour infusion and pantoprazole is administered with cisplatin Cycles 3 and 4: HDMTX administered as a 4-hour infusion and cisplatin is administered alone
3106412|NCT01848457|Experimental|Arm 4|Cycles 1 and 2: HDMTX administered as a 12-hour infusion and cisplatin is administered alone Cycles 3 and 4: HDMTX administered as a 4-hour infusion and pantoprazole is administered with cisplatin
3106413|NCT01848444||Lactating women who give her breastmilk to a milkbank|180 women will be included in 6 milk banks in France during 18 months
3106414|NCT01848431||anaemia group|no blood transfusions will be given until hct falls under 25%
3106415|NCT01848431||normal hct group|patients in group 2 will receive transfusions as is currently standard protocol outside the study
3106416|NCT01848392||physical activity CF cohort|adult patients with CF at time of their yearly assessment at Cochin adult CF centre
3106417|NCT01848379|Experimental|Antidiabetic Therapy(ADT)+Full Mouth Decontamination(FD)|"ADT:~(Par-)enteral, anti-diabetic medication, diet and dietetic supervision, physiotherapy and physical exercises~FD:~The oral use of topical antiseptics prior and after mechanical tooth debridement, tooth as well as root surface planing and soft tissue decontamination in combination with systemic antibiotics (a combination of amoxicillin and metronidazole - if no microbial resistances were detected)"
3106418|NCT01848379|Active Comparator|Full Mouth Deconatamination(FD)|"FD:~The oral use of topical antiseptics prior and after mechanical tooth debridement, tooth as well as root surface planing and soft tissue decontamination in combination with systemic antibiotics (a combination of amoxicillin and metronidazole - if no microbial resistances were detected)"
3106419|NCT01848379|No Intervention|No Treatment|Healthy individuals to be monitored cross-sectional
3106420|NCT01848366|Experimental|Biowave Treatment|Twelve weekly treatments
3106421|NCT01848353|Active Comparator|Standard payment, phase 1|All participants will perform exercise training. Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes during weeks 1-16 (phase 1). All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
3106422|NCT01848353|Active Comparator|Standard payment, phase 2|All participants will perform exercise training. Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes during weeks 17-32 (phase 2). All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
3106423|NCT01848353|Active Comparator|Ramp-down payment, phase 3|All participants will perform exercise training. This phase will last from weeks 33-48 (phase 3). Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes, but the value of the payments will decrease weekly (ramp-down) until reaching zero in week 41. All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
3106424|NCT01848353|Experimental|Incentivized payment, phase 1|All participants will perform exercise training. Participants in this arm will receive an increasing amount of money when they increase exercise frequency (number of days) during weeks 1-16 (phase 1). All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior
3106425|NCT01848353|Experimental|Incentivized payment, phase 2|All participants will perform exercise training. Participants in this arm will receive an increasing amount of money when they exercise for longer than 20 minutes per session during weeks 17-32 (phase 2). All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior
3106510|NCT01847885|Experimental|Smartpatch Treatment Group|Subjects in the Treatment Group will have a Smartpatch Lead placed in the shoulder, will use the Smartpatch Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
3106426|NCT01848353|Experimental|Raffle payment, phase 3|All participants will perform exercise training. In weeks 33-48 (phase 3)participants in this arm will receive fewer financial incentives than in the prior 32 weeks but they will be delivered through a raffle system to utilize a variable reinforcement approach. All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior.
3106427|NCT01848353|No Intervention|Normal weight, low activity group|This group of participants will complete only the baseline tests and assessments and will serve as a reference group. They will be selected to have low physical activity and fitness like the intervention group. Therefore differences in their results with the intervention group will reflect the effects of overweight/obesity on the variables of interest.
3106428|NCT01848353|No Intervention|Normal weight, high activity group|This group of participants will complete only the baseline tests and assessments and will serve as a reference group. They will be selected to have higher physical activity and fitness than the intervention group. They will therefore serve as a healthy reference group and differences in their results with the intervention group will reflect the effects of both overweight/obesity and physical activity on the variables of interest.
3106429|NCT01848340|Experimental|Part A: 14C-GSK1265744 Arm|Each subject will receive a single 30 mg oral solution dose of GSK1265744 containing 14C-GSK1265744 of approximately 70 mcgCi (0.96 MSv) of radioactivity.
3106430|NCT01848340|Experimental|Part B: GSK1265744 Arm|In Part B - 8 subjects will be randomised to receive a single dose of GSK1265744 150 mg
3106431|NCT01848340|Placebo Comparator|Part B: Placebo Arm|In Part B - 2 subjects will be randomised to receive a single dose of placebo
3106432|NCT01848327|Experimental|Caprylic Triglyceride|Caprylic Triglyceride (40 gram packet orally once a day for 90 days)
3106433|NCT01848327|Placebo Comparator|Placebo|Placebo (40 gram packet orally once a day for 90 days)
3106434|NCT01848314|Experimental|Patients undergoing renal denervation|patients diagnosed with resistant hypertension, eligible to undergo renal denervation
3106435|NCT01848301|Experimental|Single arm|All subjects will undergo a Brachial Artery Flow Medicated Dilation prior to heart catheterization. After routine heart catheterization, images of their coronary artery will be recorded by Optical Coherence Tomography (OCT) during infusion of Acetylcholine.
3106436|NCT01848288|Experimental|CENTURION|First surgical eye randomized to CENTURION® Vision System, with second surgical eye (fellow eye) assigned to INFINITI® Vision System. Second eye surgery conducted within 14 days of the first eye surgery. Duration of surgery less than 30 minutes each eye.
3106437|NCT01848288|Active Comparator|INFINITI|First surgical eye randomized to INFINITI® Vision System, with second surgical eye (fellow eye) assigned to CENTURION® Vision System. Second eye surgery conducted within 14 days of the first eye surgery. Duration of surgery less than 30 minutes each eye.
3106438|NCT01848275|Active Comparator|Group 1|Group 1 received ablation from distal to ostial of bilateral renal arteries
3106439|NCT01848275|Experimental|Group 2|group 2 received ablation at proximal of bilateral renal arteries
3106440|NCT01848262|Active Comparator|ECALMIST|ECALMIST will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant
3106441|NCT01848262|Experimental|InSurE|InSurE will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant
3106442|NCT01848249||Deceased-Donor Cohort|We will collect urine samples from approximately 1600 deceased donors and approximately 600 perfusate samples from machine-pumped kidneys from participating organ procurement organizations (OPOs).
3106443|NCT01848249||Recipient Cohort (Overall and Detailed)|No samples will be collected from the recipients. Only clinical data and outcomes will be collected from the recipients.
3106444|NCT01848236|Experimental|Vitamin D2|Total of 500,000 IU vitamin D2 (50,000 IU twice weekly for 5 weeks)
3106445|NCT01848236|Experimental|Vitamin D3|Total of 500,000 IU vitamin D3 (50,000 IU twice weekly for 5 weeks)
3106446|NCT01848223||late menopause|
3106447|NCT01848210|Experimental|Coumarin 30 mg + Troxerutin 180 mg|Coumarin 30 mg, troxerutin 180 mg fixed-dose combination tablets, orally, three times daily for up to 16 weeks.
3106448|NCT01848210|Placebo Comparator|Placebo|Coumarin + troxerutin placebo-matching tablets, orally, three times daily for up to 16 weeks.
3106449|NCT01848197|Experimental|EC-P2|all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then intravenous paclitaxel 2-week intervals for 4 cycles.
3106450|NCT01848197|Active Comparator|EC-P1|all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then intravenous paclitaxel 1-week intervals for 12 cycles.
3106451|NCT01848184||PARIETEX™ Composite Ventral Patch|PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra‐peritoneal positioning
3106452|NCT01848171|Active Comparator|L-thyroxine|Oral administration, tablets, starting dose 25 or 50 micrograms once daily, during the follow-up period
3106453|NCT01848171|No Intervention|blank|No intervention
3106454|NCT01848158|Experimental|Acupuncture|Acupuncture treatment three times per week for up to two weeks.
3106455|NCT01848158|Sham Comparator|Sham Acupuncture|Sham acupuncture three times per week for up to two weeks
3106456|NCT01848145|Experimental|Ofatumumab|Rapid Infusion of Ofatumumab
3106457|NCT01848132|Active Comparator|R-CHOP|"6 cycles every 21 days.~Rituximab: intravenous, 375 mg/m2, day 1~Cyclophosphamide: intravenous, 750 mg/m2, day 1~Doxorubicin: intravenous, 50 mg/m2, day 1~Vincristine: intravenous, 1,4 mg/m2, day 1~Prednisone: oral, 100 mg, days 1-5"
3106458|NCT01848132|Experimental|B-R-CAP|"6 cycles every 21 days~Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15~Rituximab: intravenous, 375 mg/m2, day 1~Cyclophosphamide: intravenous, 750 mg/m2, day 1~Doxorubicin: intravenous, 50 mg/m2, day 1~Prednisone: oral, 100 mg, days 1-5"
3106459|NCT01848119|Active Comparator|Gabapentin|Gabapentin 600mg, 1 dose preoperatively, followed by Gabapentin 200mg tid for 5 doses.
3106460|NCT01848119|Placebo Comparator|Placebo|lactose capsules
3106461|NCT01848106|Active Comparator|Bivalirudin|Bivalirudin bolus and infusion
3106462|NCT01848106|Experimental|Reg 1 (pegnivacogin/anivamersen)|Bolus pegnivacogin plus anivamersen active control agent
3106463|NCT01848093||COPD exacerbation|"COPD Stadium 2 and 3 during pulmonary exacerbation~sputum collection"
3106464|NCT01848080|Experimental|Tai chi program via Telerehabilitation|An individualized exercise program, based on Tai Chi, was developed by our team for previous studies aiming to improve balance in elderly, diabetic individuals and in frail, elderly individuals with balance problems. The exercise program consists of movements based on a combination of alignments and body-specific orientations, weight transfers and changes in direction inspired by Tai Chi. This group will receive this program via telerehabilitation.
3106465|NCT01848080|Active Comparator|Tai chi program via home visits|An individualized exercise program, based on Tai Chi, was developed by our team for previous studies aiming to improve balance in elderly, diabetic individuals and in frail, elderly individuals with balance problems. The exercise program consists of movements based on a combination of alignments and body-specific orientations, weight transfers and changes in direction inspired by Tai Chi. This group will receive this program via home visits.
3106466|NCT01848067|Experimental|Treatment (alisertib, abiraterone acetate, prednisone)|Patients receive alisertib PO BID on days 1-7, abiraterone acetate PO daily, and prednisone PO BID. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3106467|NCT01848054|Experimental|BNX Sublingual Tablets Induction|"Day 1-2 (Blinded Induction): BNX sublingual tablets~Day 3-28 (Open-label Maintenance): BNX sublingual tablets"
3106468|NCT01848054|Active Comparator|Buprenorphine Induction|"Day 1-2 (Blinded Induction): Generic buprenorphine sublingual tablets~Day 3-28 (Open-label Maintenance): BNX sublingual tablets"
3106469|NCT01848041|Experimental|RVL-1201 once daily|RVL-1201 0.1% ophthalmic solution dosed one full drop per eye in the morning; one full drop of vehicle (placebo) per eye approximately 8 hours after the morning dose
3106470|NCT01848041|Experimental|RVL-1201 twice daily|RVL-1201 0.1% ophthalmic solution dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose
3106471|NCT01848041|Placebo Comparator|RVL-1201 vehicle (placebo)|RVL 1201 ophthalmic solution vehicle (placebo) dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose
3106472|NCT01848028||Fumaric acid ester|Intervention: Drug: conventional systemic: Fumaric acid ester, all dosages, frequencies and durations prescribed
3106473|NCT01848028||Methotrexate|Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
3106474|NCT01848028||Cyclosporine A|Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
3106475|NCT01848028||Efalizumab (withdrawn)|Intervention: Biological: Efalizumab, all dosages, frequencies and durations prescribed
3106476|NCT01848028||Etanercept|Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed
3106477|NCT01848028||Infliximab|Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed
3106478|NCT01848028||Adalimumab|Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed
3106479|NCT01848028||Ustekinumab|Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
3106480|NCT01848028||Golimumab|Intervention: Biological: Golimumab, all dosages, frequencies and durations prescribed
3106481|NCT01848028||Secukinumab|Intervention: Biological: Secukinumab, all dosages, frequencies and durations prescribed
3106482|NCT01848028||Apremilast|Intervention: Small molecule: Apremilast, all dosages, frequencies and durations prescribed
3106483|NCT01848028||Certolizumab|Intervention: Biological: Certolizumab, all dosages, frequencies and durations prescribed
3106484|NCT01848028||Retinoids|Intervention: Drug: conventional systemic: Retinoids, all dosages, frequencies and durations prescribed
3106485|NCT01848028||Leflunomids|Intervention: Drug: conventional systemic: Leflunomids, all dosages, frequencies and durations prescribed
3106486|NCT01848028||systemic PUVA|Intervention: Drug: conventional systemic: systemic PUVA, all dosages, frequencies and durations prescribed
3106487|NCT01848015||CTCs positive|
3106488|NCT01848002|Experimental|rFXIII|
3106489|NCT01848002|Placebo Comparator|Placebo|
3106490|NCT01847989|Experimental|rFXIII|
3106491|NCT01847989|Placebo Comparator|Placebo|
3106492|NCT01847976|Experimental|Doxycycline|100 mg of Doxycycline orally twice a day for 12 weeks.
3106493|NCT01847963|Experimental|Sindhuvallathy mezhugu|Sindhuvallathy mezhugu (SVM) 500 mg Twice daily per Oral 45 days duration
3106494|NCT01847963|Experimental|Kalladaippu Kudineer|Kalladaippu Kudineer (KK) 130 ml decoction Twice daily Per oral 45 days Duration
3106495|NCT01847963|Experimental|Sindhuvallathy + Kalladaippu Kudineer|Sindhuvallathy mezhu -500 mg capsules twice daily + Kalladaippu kudineer -130 ml decoction twice daily-per oral for 45 days.
3106496|NCT01847950|Experimental|short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
3106497|NCT01847950|Placebo Comparator|Maltodextrin|maltodextrins are consummed at 5g/day for 6 weeks
3106498|NCT01847937||Diabetics Type I non-neuropathic|Diabetics with type 1 diabetes and without neuropathy
3106499|NCT01847937||Diabetics Type II non-neuropathic|Diabetics with type 2 diabetes without neuropathy
3106500|NCT01847937||Diabetics Type I neuropathic|Diabetics with type 1 diabetes and neuropathy
3106501|NCT01847937||Diabetics Type II neuropathic|Diabetics with type 2 diabetes and neuropathy
3106502|NCT01847937||Hereditary axonal neuropathic|
3106503|NCT01847937||Hereditary demyelinated neuropathic|This will mainly be patients with Chronic inflammatory demyelinating polyneuropathy (CIDP).
3106504|NCT01847924|Active Comparator|MLC901|Brand: Neuroaid II. Dosage: 2 capsules 3 times a a day
3106505|NCT01847924|Placebo Comparator|placebo|MLC901 matching placebo made by the same manufacturer for this study dosage: 2 capsules 3 times a day.
3106506|NCT01847911|Experimental|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
3106507|NCT01847911|Active Comparator|instructor training|A standard hands-on training with a face-to-face instructor following a pre-validated OSCE program guidelines.
3106508|NCT01847898|Experimental|Vertebral Body Stenting (VBS)|
3106509|NCT01847898|Experimental|Balloon Kyphoplasty|
3106511|NCT01847885|Sham Comparator|Smartpatch Control Group|Subjects in the Control Group will have a Smartpatch Lead placed in the shoulder, will use the Smartpatch Peripheral Nerve Stimulation (PNS) System, but will not receive any electrical stimulation.
3106512|NCT01847872|Experimental|IPV IM (Visit 1)|IM IPV vaccine using syringe and needle pair is given at visit 1 followed by MR vaccine at visit 2 and YF vaccine at visit 3
3106513|NCT01847872|Experimental|IPV IM (Visit 2)|MR vaccine at visit 1 followed by IM IPV vaccine using syringe and needle pair at visit 2, then YF vaccine at visit 3
3106514|NCT01847872|Experimental|IPV IM (Device - Visit 2)|YF vaccine at visit 1 followed by IPV given IM using a Jet injector device at visit 2 and MR vaccine at visit 3
3106515|NCT01847872|Experimental|IPV IM and MR (Visit1)|IM IPV using syringe and needle pair is given alongside MR at visit 1 followed by YF vaccine at visit 2
3106516|NCT01847872|Experimental|IPV IM and YF (Visit 1)|IM IPV using syringe and needle pair is given alongside YF vaccine at visit 1 followed by MR at visit 2
3106517|NCT01847872|Experimental|IPV ID (Visit 2)|MR and YF vaccines are co-administered at visit 1 followed by ID IPV using syringe and needle pair is given at visit 2
3106518|NCT01847872|Experimental|IPV IM and MR and YF (Visit 1)|IM IPV using syringe and needle pair is given alongside YF vaccine and MR vaccine at visit 1
3106519|NCT01847872|Experimental|IPV (ID Device Visit 2)|MR vaccine is given at visit 1 followed by IPV vaccine by ID Jet injector device at visit 2 and YF vaccine at visit 3
3106520|NCT01847859|Experimental|Ultrasound performed by nurses|Focused examination of the pleural and pericardial cavity. Cardiologists perform reference ultrasound examinations.
3106521|NCT01847833||Patients with brain tumors|
3106522|NCT01847820||Symptomatic|Individuals with signs, symptoms or suspicion of membrane rupture at 11 to 42 weeks gestation that will receive the AmniSure ROM test.
3106523|NCT01847807|Active Comparator|High-dose Astragalus group|treatment with 10 gram astragalus
3106524|NCT01847807|Active Comparator|Low-dose Astragalus group|treatment with 5 gram astragalus
3106525|NCT01847807|No Intervention|MS control|
3106526|NCT01847794|Experimental|chemotheropy|
3106527|NCT01847781|Active Comparator|IgG-deficient patients|Prevenar13
3106528|NCT01847781|Active Comparator|Healthy controls|Prevenar13
3106529|NCT01847768|Experimental|Asthmatic Group|"Subjects with well-controlled, mild-moderate allergic asthma.Subjects will be inoculated with a total dose of 1000 TCID50 of HRV- 39.~The inoculum is diluted, as appropriate, in lactated Ringer's solution and delivered via the following procedure: 0.5 ml per nostril is administered by pipette while the subject tilts their head back."
3106530|NCT01847768|Active Comparator|Healthy Non-Asthmatic Control Group|"Healthy volunteers. Subjects will be inoculated with a total dose of 1000 TCID50 of HRV- 39.~The inoculum is diluted, as appropriate, in lactated Ringer's solution and delivered via the following procedure: 0.5 ml per nostril is administered by pipette while the subject tilts their head back."
3106531|NCT01847755|Experimental|120 Hyperbaric treatments at 1.5 ATA|Patient receives 120 treatments of Hyperbaric at 1.5 ATA. Non randomized trial. Pt will have cognitive assessments and Spect scans at various treatment points. Oxygen is at 1.5 atmospheric pressure.
3106532|NCT01847742|Experimental|EMDR intervention|40 participants with trauma symptoms will be randomly assigned to treatment group and receive EMDR intervention for trauma symptoms.EMDR is a trauma focused therapy starts with resource development and continue with bilateral stimulation while working on the most troubling traumatic memory.
3106533|NCT01847742|No Intervention|Waiting List|40 participants with trauma symptoms will be randomly assigned to waiting list as the control group.
3106534|NCT01847729||Patients on OST prescribed to treat opiate dependence|Collecting socio-demographic data, data concerning opiate dependence, data about other substance use disorder, data regarding gambling practice, psychopathological data.
3106535|NCT01847716||PH with wasting|This group of patients with idiopathic pulmonary arterial hypertension exhibit quadriceps wasting
3106536|NCT01847716||PH no wasting|This groups of patients with idiopathic pulmonary arterial hypertension exhibit no evidence of muscle wasting
3106537|NCT01847716||Controls|This group of volunteers does not have pulmonary arterial hypertension and would not be expected to have muscle wasting
3106538|NCT01847703|Experimental|Robotic surgery|Experimental method, to be compared with standard care
3106539|NCT01847703|Active Comparator|Abdominal surgery|Conventional open surgery (laparotomy)
3106540|NCT01847690|Placebo Comparator|Placebo|Treatment B is placebo (2 placebo tablets).
3106541|NCT01847690|Active Comparator|Hydrocortisone|Treatment A is 10 mg hydrocortisone (2 tablets Cortef, 5 mg each),Stress-dose will be taken per os one time 2 tablets 10 mg of Cortef 60 min before start of exercise. Cortef tablets 5 mg produced by Pharmacia and Upjohn . One day.
3106542|NCT01847677|Active Comparator|Paclitaxel & Carboplatin|"Preoperative treatment Cycle 1 to 4 (4 cycles every 3 weeks of chemotherapy pre-surgery)~Carboplatin AUC 6 i.v. first day~Paclitaxel 175 mg/m2 i.v. first day~Surgery~Post-Operative treatment~Cycle 5 to 7 (3 cycles every 3 weeks of chemotherapy post-surgery):~Carboplatin AUC 6 i.v. first day~Paclitaxel 175 mg/m2 i.v. first day~Bevacizumab 15 mg/Kg i.v. first day1~When the chemotherapy treatment is completed, the patient will continue with maintenance bevacizumab until 15 months length treatment."
3106543|NCT01847677|Experimental|Paclitaxel & Carboplatin & Bevacizumab|"4 cycles every 3 weeks (at least 3 Bevacizumab neoadjuvant cycles): Carboplatin AUC 6 i.v. first day Paclitaxel 175 mg/m2 i.v. first day Bevacizumab 15 mg/Kg i.v. first day.~b) Surgery Ovarian cancer surgery should be performed according to FIGO guidelines.~c) Postoperative treatment~Both arms:~Cycle 5 to 7 (3 cycles every 3 weeks of chemotherapy post-surgery):~Carboplatin AUC 6 i.v. first day Paclitaxel 175 mg/m2 i.v. first day Bevacizumab 15 mg/Kg i.v. first day.~When the chemotherapy treatment is completed, the patient will continue with maintenance bevacizumab until 15 months length treatment."
3106544|NCT01847664|Experimental|Rifamycin SV-MMX® 400 mg b.i.d.|Rifamycin SV-MMX® 800 mg
3106545|NCT01847664|Experimental|Rifamycin SV-MMX® 600 mg t.i.d.|Rifamycin SV-MMX® 1800 mg
3106546|NCT01847664|Placebo Comparator|Rifamycin SV-MMX® Placebo|Rifamycin SV-MMX® placebo
3106547|NCT01847651|Active Comparator|LOLA|"Other Names:~Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA~Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)"
3106548|NCT01847651|Placebo Comparator|Placebo|
3106549|NCT01847638|Active Comparator|Prolensa (bromfenac 0.07%)|Subjects will instill one drop Prolensa (bromfenac 0.07%) into the study (operative) eye once daily for a maximum of 25 days. Dosing will begin three days prior to surgery (Day 3), continue on the day of surgery and for 21 days after surgery.
3106550|NCT01847638|Active Comparator|Ilevro (nepafenac 0.3%)|Subjects will instill one drop into the study (operative) eye once daily for a maximum of 25 days. Dosing will begin three days prior to surgery (Day 3), continue on the day of surgery and for 21 days after surgery.
3106551|NCT01847625||Physicians experienced in lead extraction|Physicians experienced in lead extraction
3106552|NCT01847612|Experimental|indocyanine green fluorescent cholangiography|use of indocyanine green fluorescent cholangiography in the patients of this arm, an indocyanine green fluorescent cholangiography is performed
3106553|NCT01847612|Active Comparator|methylene blue|injection of methylene blue during the surgery
3106554|NCT01847599|Other|capecitabine|patients treated by capecitabine alone (n=100)
3106555|NCT01847599|Other|capecitabine + lapatinib|patients treated by capecitabine and lapatinib (n=100)
3106556|NCT01847586|Experimental|Alzheimer's disease-rPAS|The intervention procedure will done in this group is r-Paired Associative Stimulation. This involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC
3106557|NCT01847586|Placebo Comparator|Alzheimer's disease-rPAS-C|The intervention procedure being done with this group is PAS-C. This is a control Paired Associative Stimulation paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
3106558|NCT01847586|Other|Control|Controls will have a one time Paired Associative Stimulation-Control (PAS-C) paradigm intervention in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
3106559|NCT01847573|Experimental|Cohort 1: HT-100 tablet, Dose 1|"Single dose administration: Dose 1~Multiple dose administration: Dose 1"
3106560|NCT01847573|Experimental|Cohort 2: HT-100 tablet, Dose 2|"Single dose administration: Dose 2~Multiple dose administration: Dose 2"
3106561|NCT01847573|Experimental|Cohort 3: HT-100 tablet, Dose 3|"Single dose administration: Dose 3~Multiple dose administration: Dose 3"
3106562|NCT01847573|Experimental|Cohort 4a: HT-100 tablet, Dose 4|"Single dose administration: Dose 4~Multiple dose administration: Dose 4"
3106563|NCT01847573|Experimental|Cohort 4b: HT-100 tablet, Dose 5|* Multiple dose administration: Dose 5
3106564|NCT01847573|Experimental|Cohort 5: HT-100 tablet, Dose 6|* Multiple dose administration: Dose 5
3106565|NCT01847560||Dabigatran|
3106566|NCT01847560||Warfarin or other NOACs|
3106567|NCT01847547||Dabigatran|
3106568|NCT01847547||Warfarin|
3106569|NCT01847534|Other|Standard Care|Standard care: Nutrition will be managed as per best practice and local policy including the use of small bowel feeding tubes, prokinetics and PN if required to meet nutrition needs.
3106570|NCT01847534|Experimental|Supplemental PN|"Supplemental PN to complete inadequate EN provision~Patients allocated to the supplemental PN (intervention) group will have PN commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation.~EN will be managed as per local protocol however EN must not be reduced based on the supplemental PN being administered.~The adequacy of nutrition provision from both PN and EN will be assessed at midday each day for 7 days or until ICU discharge. The dose of PN will be adjusted according to a prespecified schedule."
3106571|NCT01847521|Experimental|Capsule containing Luteolin, Quercetin, and Rutin|One capsule containing Luteolin (100 mg/capsule), Quercetin (70 mg/capsule), and Rutin (30 mg/capsule). 1 capsule per 10 kg weight per day with food
3106572|NCT01847508|Active Comparator|PHILOS +|Proximal Humeral Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
3106573|NCT01847508|Active Comparator|PHILOS|Proximal Humeral Internal Locking System (PHILOS)
3106574|NCT01847495|Experimental|Low-Dose Irinotecan & CyberKnife SBRT|Irinotecan 40mg/m2 x 3-5 days + CyberKnife SBRT 45-60Gy x 3-5 fractions
3106575|NCT01847482|Experimental|Therapeutic Hypothermia|
3106576|NCT01847469|Experimental|Zonisamide|Participants in this arm will receive zonisamide for 12 weeks.
3106577|NCT01847469|Placebo Comparator|Placebo|Participants in this arm will receive placebo medication for 12 weeks.
3106578|NCT01847456|Experimental|insulin nasal spray|160 Units of human insulin as nasal spray
3106579|NCT01847456|Placebo Comparator|Placebo nasal spray|Nasalspray containing placebo solution
3106580|NCT01847443|Experimental|Test nicotine gum (2 mg)|A single dose of Nicotine Mint Gum (2 mg) to be chewed.
3106581|NCT01847443|Experimental|Test nicotine gum (4 mg)|A single dose of Nicotine Mint Gum (4 mg) to be chewed.
3106582|NCT01847443|Active Comparator|Reference nicotine gum (2 mg)|A single dose of reference nicotine gum (2 mg) to be chewed.
3106583|NCT01847443|Active Comparator|Reference nicotine gum (4 mg)|A single dose of reference nicotine gum (4 mg) to be chewed.
3106584|NCT01847430|Experimental|HBV Group|Subjects received a single dose of Engerix™-B Kinder vaccine (HBV). The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3106585|NCT01847417|Experimental|Overall Study Arm|"All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order in fed condition.~Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet"
3106586|NCT01847404|Experimental|Overall Study Arm|All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order after an overnight fasting of at least 10 hours fast in each period. Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet
3106587|NCT01847391|Experimental|Cohort 1|Randomized to 6 mg once daily (Days 1-7) followed by 3 mg once daily (Days 8-21) of GS-6615 or matching placebo
3106588|NCT01847391|Experimental|Cohort 2|Randomized to 12 mg once daily (Days 1-7) followed by 6 mg once daily (Days 8-21) of GS-6615 or matching placebo
3106589|NCT01847391|Experimental|Cohort 3|Randomized to 20 mg once daily (Days 1-7) followed by 9 mg once daily (Days 8-21) of GS-6615 or matching placebo
3106590|NCT01847378||Catheter ablation|Patients with chronic chagasic disease and documented monomorphic ventricular tachycardia
3106591|NCT01847365|Experimental|Retinitis Pigmentosa|Transcorneal electrical stimulation (TES) administered to one eye for 6 months, followed by monitoring period without treatment for 6 months.
3106592|NCT01847352|Other|Iron-deficient|Healthy volunteers meeting iron-deficient entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
3106593|NCT01847352|Other|Iron-replete|Healthy volunteers meeting iron-replete entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
3106594|NCT01847339|Experimental|bupivacaine soaked sponges|Patients will be randomized using a reproducible set of computer-generated random numbers. In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure
3106595|NCT01847339|Placebo Comparator|saline soaked sponges|Patients will be randomized using a reproducible set of computer-generated random numbers. In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in saline solution and then will be placed by the surgeon in the epidural space before final closure.
3106596|NCT01847326|Experimental|Treatment (induction therapy and AFHX or AXX)|See Detailed Description
3106597|NCT01847313|Active Comparator|Liraglutide|Liraglutide 0.6mg daily
3106598|NCT01847313|No Intervention|Control|Standard diabetes care including renin angiotensin aldosterone system inhibitor or antagonist
3106599|NCT01847300|Experimental|cSBI-M|Participants in this group will complete the cSBI-M screening and brief intervention program
3106600|NCT01847300|No Intervention|Treatment as Usual|Participants in this group will receive treatment as usual.
3106601|NCT01847287||Tysabri|All subjects took Tysabri and also had an MRI which we use for the baseline evaluation. Over 5 years, some patients remained on Tysabri, some started another drug and others were off Tysabri for a time but then restarted.
3106602|NCT01847274|Active Comparator|Niraparib|2:1 Ratio administered once daily continuously during a 28 day cycle.
3106603|NCT01847274|Placebo Comparator|Placebo|Administered once daily continuously over a 28 day cycle.
3106604|NCT01847261|Experimental|Soy Dairy Protein Blend|30 grams of Soy Dairy Protein Blend given as a single beverage following leg resistance exercise
3106605|NCT01847261|Active Comparator|Positive Control (Dairy Whey Protein)|30 grams of Dairy Whey Protein will be given as a single beverage following leg resistance exercise
3106606|NCT01847248||sepsis|Patients with sepsis but not severe sepsis
3106607|NCT01847248||Severe sepsis|Patients with severe sepsis
3106608|NCT01847248||SIRS|Patients with SIRS after major orthopedics surgery
3106609|NCT01847248||Control|Healthy volunteers
3106610|NCT01847235|Experimental|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days
3106611|NCT01847222|Experimental|SANGUINATE™|PEG-bHb-CO
3106612|NCT01847222|Placebo Comparator|Normal Saline Solution|Saline Solution
3106613|NCT01847209|Experimental|CT Marking and VATS lung wedge resection|Each patient with a lung nodule meeting criteria will undergo marking with fiducials followed at the same time by Video-Assisted Thoracic Surgery (VATS) lung wedge resection under CT fluoroscopy.
3106614|NCT01847196|Experimental|Angel® Catheter|All eligible subjects will receive an Angel® Catheter.
3106615|NCT01847183|Experimental|Click City®: Alcohol|Receive the Click City®: Alcohol program as part of their school curriculum.
3106616|NCT01847183|No Intervention|Usual Curriculum|Students receive their usual alcohol curriculum
3106617|NCT01847170|Experimental|Fecal Microbial Transplantation|
3106618|NCT01847157|Experimental|tDCS & epidermis anesthesia & repeated passive movement|"The patients in the experiment group will receive multi-strategy combination treatment mode- combined tDCS and sensory input regulation treatment mode, including bilateral tDCS , epidermis anesthesia in the proximal hand of affected side and in the distal hand of unaffected side , and repeated passive movement training for the hand of affected side.~Treatment modes are 3 times a week, 30 minutes each time, lasting for 8 weeks, and totally 24 trainings. The treatment content of each strategy is separately described in the following."
3106619|NCT01847157|Sham Comparator|Shame tDCS & sham anesthesia & repeated passive movement|"the control group is repeated passive movement stimulation, including sham bilateral tDCS, sham epidermis anesthesia in the proximal hand of affected side and in the distal hand of unaffected side, and repeated passive movement training for the hand of affected side.~Treatment modes are 3 times a week, 30 minutes each time, lasting for 8 weeks, and totally 24 trainings. The treatment content of each strategy is separately described in the following."
3106620|NCT01847144|Active Comparator|Gliclazide - Sitagliptin|Gliclazide 80mg OD and Sitagliptin 100mg OD
3106621|NCT01847144|Active Comparator|Sitagliptin - Gliclazide|Gliclazide 80mg OD and Sitagliptin 100mg OD
3106622|NCT01847131|Active Comparator|oxymetazoline|0.05% oxymetazoline nasal sprays 2 sprays in each nostril twice daily
3106623|NCT01847131|Placebo Comparator|placebo|placebo nasal spray 2 sprays in each nostril twice daily
3106624|NCT01847118|Experimental|Sevacizumab|2mg/kg、5mg/kg、7.5mg/kg、10mg/kg、12.5mg/kg、or 15mg/kg. d1, d29, d43, d57
3106625|NCT01847105|Experimental|RevitaLens|AMO's RevitaLens contact lens solution
3106626|NCT01847092|Active Comparator|AZD1722|AZD1722 in 5, 15, 30, or 60 mg capsules. Starting dose is 15 mg BID PO for 12 Weeks
3106627|NCT01847092|Placebo Comparator|Placebo|Placebo capsule BID PO for 12 Weeks
3106628|NCT01847079|Other|Intervention group, procalcitonin|procalcitonin to guid obtaining bloodcultures in the ICU
3106629|NCT01847079|No Intervention|Control group, ICIS, procalcitonin|Measurement of PCT and ICIS.
3106630|NCT01847066|Active Comparator|Erbium plus cosmetics plus Impact|Erbium 2940 plus cosmetics plus Impact Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
3106631|NCT01847066|Active Comparator|Erbium 2940 plus cosmetics|Erbium 2940 plus cosmetics Patient shall be treated with erbium 2940nm laser, cosmetics
3106632|NCT01847066|Active Comparator|Erbium 2940 plus cosmetics plus Impact|Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
3106633|NCT01847066|Active Comparator|Erbium 2940nm plus cosmetics|Patients shall be treated with Erbium 2940nm laser plus cosmetics only.
3106634|NCT01847053|Placebo Comparator|Oatmeal control|Oatmeal control, around 70g; without cinnamon
3106635|NCT01847053|Active Comparator|Ground cinnamon, 3g|3 g ground cinnamon in Oatmeal (~70 g)
3106636|NCT01847053|Active Comparator|Cinnamon extract, 3 g|3 g cinnamon extract in Oatmeal (~70 g)
3106637|NCT01847053|Active Comparator|Cinnamon extract, 6 g|6 g cinnamon extract in Oatmeal (~70 g)
3106638|NCT01847040||TBI while Deployed|Active duty service members returning from Afghanistan or Iraq who were screened positive for Mild TBI
3106639|NCT01847040||No TBI while Deployed|Active duty service members returning from Afghanistan or Iraq who screened negative for mild TBI.
3106640|NCT01847027|Active Comparator|Active supplement|NutraStem, 2 tablets daily, Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg).
3106641|NCT01847027|Placebo Comparator|Sugar pill|"The placebo is identical in appearance to the NutraStem® supplement and contains the following ingredients in a Vegi Capsule:~MCC200 DICALCIUM PHOSPHATE BROWN LAKE BLEND (SENSIENT # 09127 ) RED DYE DB-088 (COLORCON) MAGNESIUM STEARATE BLUE #1 ALUM LAKE (POWDER)"
3106642|NCT01847014|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
3106643|NCT01847001|Experimental|Propranolol + Neoadjuvant Chemotherapy|"Subjects will receive 2 types of chemotherapy regimens plus propranolol treatment.~Regimen I, involves paclitaxel (may be substituted with nab-paclitaxel; maybe given with premedication), and~Regimen II involves doxorubicin (maybe given with anti-nausea therapy) and cyclophosphamide (maybe given with Pegfilgrastim).~If your tumor is HER2 positive, you will also receive trastuzumab and pertuzumab.~After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor.~DOT imaging will be done at 4 additional time points, including beo."
3106644|NCT01846988|Active Comparator|Group 1 crossover treatment|crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks APAP settings then 4 weeks CPAP settings.
3106645|NCT01846988|Active Comparator|Group 2 crossover treatment|crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks CPAP settings then 4 weeks APAP settings.
3106646|NCT01846975|Experimental|Switch from SC to IV Abatacept and back|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
3106647|NCT01846962|Experimental|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
3106648|NCT01846962|Experimental|fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
3106649|NCT01846962|Experimental|Budesonide|The administered dose of topical steroid was 400mcg/day or 800 mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
3106650|NCT01846962|Experimental|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1 or mg/day (<150 cm or >150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
3106651|NCT01846936|Experimental|DLT with conventional technique|"The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.~One lung ventilation is initiated after the lumen of operative lung is clamped and opened."
3106652|NCT01846936|Active Comparator|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under fiberoptic bronchoscopy (FOB) vision by turning the device's steering wheel.~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation. And then, dependent lung is ventilated."
3106653|NCT01846936|Active Comparator|Disconnection technique|Disconnection technique; 1) before initiating OLV, we turned-off the ventilator and fully opened the adjustable pressure limiting valve allowing both lungs to collapse, and 2) after loss of the carbon dioxide trace on the capnograph, 3) inflated the BB cuff with air, and 4) turned-on the ventilator allowing only dependent-lung reventilation.
3106654|NCT01846923|Experimental|PCV13|
3106655|NCT01846910|Active Comparator|Motivational Counseling|The extended counseling group will receive one to three, 45-minute individual motivational counseling sessions using a motivational interviewing approach to Express empathy, Develop discrepancy, Roll with resistance, and Support self-efficacy.
3106656|NCT01846910|Experimental|Tooth Whitening Incentive|The tooth whitening group will receive all of the interventions previously described for the Motivational Counseling Group, and as an extra incentive against relapse, will also be offered complimentary tooth whitening procedures if biochemically verified as tobacco-free by Carbon Monoxide monitor (bleaching at 3-weeks, whitening strips at 3-months, and whitening touch-up at 1 year).
3106657|NCT01846871|Experimental|Tivozanib|1.5 mg daily for 3 weeks, with 1 week off.
3106658|NCT01846858||CO2 Laser|
3106659|NCT01846858||Monopolar energy|
3106660|NCT01846845|Active Comparator|Conventional TF Socket System|Conventional Prosthetic Transfemoral Socket System
3106661|NCT01846845|Experimental|Novel TF Socket System|Novel Prosthetic Transfemoral Socket System
3107195|NCT01843218|Other|Register R|Evaluation of erectile dysfunction in the management of localized rectal cancer
3106662|NCT01846832|Experimental|TMC435 + PegIFNα-2a + RBV|TMC435 will be administered as triple therapy with pegylated interferon alfa-2a (PegIFNα-2a) and ribavirin (RBV).
3106663|NCT01846819||Ambulatory cirrhotic patients|"Severity of liver disease will be assessed through a detailed clinical examination of ascites grade, history of complications from cirrhosis (hepatic coma, spontaneous bacterial peritonitis, gastrointestinal bleeding), laboratory tests (TBili, Albumin, INR, hemoglobin).~Depression will be assessed with the following questionnaires: Beck Depression Inventory (BDI), EQ-5D, Psychological General Well-Being Index (PGWBI), LDQOL.~Fatigue will be assessed with the FIS and 6 Minute Walk Test.~Hepatic Encephalopathy will be assessed with the number connection, digit-symbol coding and inhibitory control test."
3106664|NCT01846806|Experimental|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
3106665|NCT01846793|Experimental|Open Label Injection of NX-1207|Intraprostatic injection of 2.5 mg NX-1207
3106666|NCT01846780||Venous outflow obstruction lower limb|Patients with unilateral post-thrombotic iliac vein/common femoral vein obstruction undergoing PTA & stenting (possibly with additional endophlebectomy and AV-fistula)
3106667|NCT01846767|Experimental|Type 2 diabetes|Diabetic patients Oral glucose breath test
3106668|NCT01846767|Experimental|Healthy controls|non-diabetic Oral glucose breath test
3106669|NCT01846754||Hemodialysis patients|
3106670|NCT01846741|Other|Model 106 VNS Therapy System|
3106671|NCT01846728|Experimental|Estrogen suppression|Estrogen production will be suppressed using Lupron, a drug that blocks normal production of ovarian hormones
3106672|NCT01846715|Experimental|NKA Treatment|Patients will receive an implantation of autologous selected renal cells (SRC).
3106673|NCT01846702|Placebo Comparator|Placebo|Single dose of placebo matching LY3084077 administered subcutaneously (SC).
3106674|NCT01846702|Experimental|LY3084077|Single escalating doses (1 mg up to 300 mg) of LY3084077 administered SC.
3106675|NCT01846689|Experimental|ESS|Prescription medical food erythropoietin stimulating system
3106676|NCT01846676|Active Comparator|Program counseling|Active branch, subject to the rehabilitation program
3106677|NCT01846676|Placebo Comparator|No counseling|Passive branch, which was control, with usual management (no intervention).
3106678|NCT01846663|Experimental|Rifaximin|Rifaximin, oral, 550 mg BID, 6 months of treatment
3106679|NCT01846663|Placebo Comparator|Placebo|Placebo, oral, 0 mg BID, 6 months of treatment
3106680|NCT01846650|Experimental|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
3106681|NCT01846650|Active Comparator|XELODA|Single oral XELODA 2000mg qd
3106682|NCT01846637|Experimental|2 cm from pylorus|at laparoscopic sleeve gastrectomy the distal point of gastric division is 2 cm from the pylorus.
3106683|NCT01846637|Active Comparator|6 cm from pylorus|at laparoscopic sleeve gastrectomy the distal point of gastric division is 6 cm from the pylorus
3106684|NCT01846624|Experimental|Decitabine, then midostaurin|"INDUCTION THERAPY Subjects receive decitabine intravenously (IV) over 1 hour on days 1 to 10 and midostaurin orally (PO) twice daily (BID) on days 11 to 28. Treatment repeats every 28 days until documented bone marrow response is achieved or for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving documented bone marrow response by course 6 continue treatment with induction therapy; patients achieving response after course 6 proceed to post-remission therapy.~POST-REMISSION THERAPY Subjects receive decitabine IV over 1 hour on days 1 to 5 and midostaurin PO BID on days 6 to 28. Treatment repeats every 28 days for up to 12 courses (including induction therapy) in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed up for up to 1 year."
3106685|NCT01846611|Experimental|Arm A: trabectedin + DOXIL|Participants will receive DOXIL 30 millgram per meter square (mg/m^2) administered as an intravenous (IV) infusion over approximately 90 minutes followed by trabectedin 1.1 mg/m^2 administered as an IV infusion over approximately 3hours, every 3 weeks. Participants will be pretreated with 20 mg dexamethasone IV (or the IV equivalent) approximately 30 minutes before DOXIL study drug. As of Amendment 6, treatment with trabectedin will be discontinued for participants on treatment with trabectedin and no new participants will receive trabectedin. Participants who, in the opinion of the investigator, are deriving clinical benefit may continue treatment with single-agent DOXIL as per the local standard of care.
3106686|NCT01846611|Active Comparator|Arm B: DOXIL|Participants will receive DOXIL, 50 mg/m^2 administered as an IV infusion over approximately 90 minutes every 4 weeks.
3106687|NCT01846585|Other|ABTI|Arousal Based Therapy for Insomnia
3106688|NCT01846585|Other|CBTI|Cognitive Behavioral Therapy for Insomnia
3106689|NCT01846559|Experimental|Clopidogrel & Endotoxin|"Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily~E.coli Endotoxin Day 7 - 2 ng/kg"
3106690|NCT01846559|Placebo Comparator|No antiplatelet medication & Endotoxin|"No antiplatelet medication~E.coli Endotoxin Day 7 - 2 ng/kg"
3106691|NCT01846559|Experimental|Ticagrelor & Endotoxin|"Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily~E.coli Endotoxin Day 7 - 2 ng/kg"
3106692|NCT01846546||Severe Traumatic Brain Injury|Patients with severe TBI (Glasgow Coma Scale GCS score of 8 or less) requiring continuous lumbar drainage of CSF
3106693|NCT01846520|Experimental|Arm I (FCPCI)|Participants receive FCPCI with an APN, comprising 4 home education sessions once weekly followed by 4 telephone support sessions for 30 minutes once monthly and 24 hour telephone support available for 6 months.
3106694|NCT01846520|No Intervention|Arm II (usual care)|Participants receive usual care.
3106695|NCT01846507|Experimental|Tranexamic acid|Subjects will complete a baseline menses (no treatment) followed by 3 menses using tranexamic acid.
3106696|NCT01846494||Hepatitis C Virus (HCV) patients exposed to BMS-986094|Hepatitis C infected patients with previous exposure to BMS-986094
3106697|NCT01846494||HCV patients not exposed to BMS-986094|Hepatitis C patients without exposure to BMS-986094
3106698|NCT01846481|Experimental|RBP-8000 100mg/Placebo|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by a 100mg intravenous infusion of RBP-8000~Day 6: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo"
3106763|NCT01846117|Active Comparator|secoisolariciresinol diglucoside|Secoisolariciresinol diglucoside (SDG) supplementation as 1.6g/day of BeneFlax containing 600 mg SDG. 1000 IU vitamin D as standard of care.
3106699|NCT01846481|Experimental|Placebo/RBP-8000 100mg|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo~Day 6: 50mg intravenous infusion of cocaine followed by a 100mg intravenous infusion of RBP-8000"
3106700|NCT01846481|Experimental|RBP-8000 200mg/Placebo|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by a 200mg intravenous infusion of RBP-8000~Day 6: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo"
3106701|NCT01846481|Experimental|Placebo/RBP-8000 200mg|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo~Day 6: 50mg intravenous infusion of cocaine followed by a 200mg intravenous infusion of RBP-8000"
3106702|NCT01846468|Experimental|Stage 1 : LHW090, Healthy Volunteers|Healthy Volunteers will receive single dose of LHW090 on Day 1.
3106703|NCT01846468|Experimental|Stage 2: LHW090, Healthy Volunteer|Healthy Volunteers across 7 single ascending dose cohorts will be administered LHW090 or matching placebo day 1
3106704|NCT01846468|Experimental|Stage 3: LHW090, Healthy Volunteer|Healthy Volunteers across 6 multiple ascending dose cohorts will be administered LHW090 or matching placebo for 14 days.
3106705|NCT01846468|Experimental|Stage 4: LHW090, Patients|Subjects with Chronic Renal Insufficiency across 3 cohorts will be administered a single dose of LHW090 in Day 1.
3106706|NCT01846455|Experimental|Hepatic Impairment: Child-Pugh A|Participants with chronic liver disease and classified as Child-Pugh Grade A had a score of 5-6 (out of 15) which correlates with a good prognosis. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
3106707|NCT01846455|Experimental|Hepatic Impairment: Child-Pugh B|Participants with chronic liver disease and classified as Child-Pugh Grade B had a score of 7-9 (out of 15) which correlates with significant functional liver compromise. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
3106708|NCT01846455|Experimental|Hepatic Impairment: Child-Pugh C|Participants with chronic liver disease and classified as Child-Pugh Grade C had a score of 10-15 (out of 15) which correlates with decompensated liver disease. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
3106709|NCT01846455|Experimental|HCV Without Hepatic Impairment|Participants with hepatitis C virus (HCV) without hepatic impairment received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
3106710|NCT01846455|Active Comparator|No Hepatic Disease or Impairment|Participants with no hepatic disease or impairment received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
3106711|NCT01846442|Placebo Comparator|Placebo|
3106712|NCT01846442|Experimental|0.25% DHEA|
3106713|NCT01846442|Experimental|0.5% DHEA|
3106714|NCT01846442|Experimental|1.0% DHEA|
3106715|NCT01846429|Experimental|Sodium Bicarbonate Treatment|A 3+3 design for Phase I component and a two staged design for Phase II were to be used. Treatment: Sodium Bicarbonate Capsules (900 mg).
3106716|NCT01846416|Experimental|Atezolizumab (MPDL3280): 1L Participants|Participants with no prior chemotherapy for advanced NSCLC disease will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.
3106717|NCT01846416|Experimental|Atezolizumab (MPDL3280): 2L+ Participants|Participants who progress during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
3106718|NCT01846416|Experimental|Atezolizumab (MPDL3280): 2L+ Brain Metastases Participants|Participants with previously treated brain metastases and who progress during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
3106719|NCT01846403|Other|Semi-quantitative pregnancy test|Semi-quantitative urine pregnancy test (dBest One Step hCG Panel Test Kit)
3106720|NCT01846390|Experimental|romidepsin, gemcitabine, dexamethasone and cisplatin|A traditional phase I dose escalation design is proposed to assess the feasibility and tolerability of romidepsin in combination with GDP, where treatment will be escalated. Treatment will be given for 6 cycles unless there is evidence of progression prior to completion of the 6 cycles or tolerability to the regimen is not sustained.
3106721|NCT01846377|Experimental|G4H-Diab-Nano|Intervention - play two videogames Diab and Nanoswarm (9 sessions each, 18 total sessions) over a 12-week time period.
3106722|NCT01846377|No Intervention|Wait List Control|5-months after baseline assessment they will receive the two video games: 1) Diab and 2) Nanoswarm.
3106723|NCT01846364|Experimental|A|Subjects with proliferative thyroid disease
3106724|NCT01846338|Experimental|green tea extract EGCG|experimental: green tea extract EGCG, 500mg , tid, 4 weeks
3106725|NCT01846338|Placebo Comparator|cellulose|Placebo Comparator: cellulose, 500 mg tid, 4 weeks
3106726|NCT01846325|Experimental|DHA plus vitamin E|Cap DHA 460mg plus vitamin E 600mg per day
3106727|NCT01846325|Active Comparator|VitaminE plus placebo|vitamin E 600 mg plus placebo
3106728|NCT01846325|Placebo Comparator|placebo plus placebo|DHA shaped placebo plus vitamin E shaped placebo
3106729|NCT01846325|Active Comparator|DHA plus placebo|460 mg DHA plus placebo
3106730|NCT01846312||All participants|
3106731|NCT01846299|Experimental|Ranibizumab|A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
3106732|NCT01846299|Sham Comparator|Sham control|Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At month 1, if treatment was needed, sham was administered. At month 2, participants switched to open-label ranibizumab on an as needed basis.
3106733|NCT01846286||Newly Diagnosed HNC|For AIM 2 and AIM3, Newly diagnosed and previously untreated patients with locoregional squamous cell carcinoma of the head and neck recruited at MD Anderson: Pain assessed at baseline, weekly during treatment, and during clinic visits (every 6-8 weeks) for a period of 3 months after treatment. Quantitative sensory testing performed at baseline and at 3 months from completion of treatment to determine nociceptive versus neuropathic component.
3106734|NCT01846273|Experimental|Ranibizumab plus verteporfin PDT|After treatment initiation with combination therapy of ranibizumab and verteporfin PDT, re-treatment need with either ranibizumab alone or combined with verteporfin PDT will be determined at monthly visits based on defined retreatment criteria
3106735|NCT01846273|Active Comparator|Ranibizumab monotherapy|After treatment initiation with combination therapy of ranibizumab and sham PDT, re-treatment need with either ranibizumab alone or combined with sham PDT will be determined at monthly visits based on defined retreatment criteria.
3106736|NCT01846247|Placebo Comparator|Standard Care|Standard stroke unit rehabilitation care
3106737|NCT01846247|Experimental|Standard Care + VEM|Standard stroke unit rehabilitation care in addition to a very early rehabilitation protocol
3106738|NCT01846234||MS patients|MS patients
3106739|NCT01846221|Experimental|Clonidine|Participants randomized to this arm of the study receive 100 micrograms clonidine with the bupivacaine in their epidural when requesting pain relief in advanced labor
3106740|NCT01846221|Experimental|Fentanyl|Participants randomized to this arm of study will receive 100 mcg fentanyl with the bupivacaine in their epidural when requesting pain relief in advanced labor
3106741|NCT01846208|Experimental|Egg OIT Randomized|Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
3106742|NCT01846208|Experimental|Baked Egg Randomized|"Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and safe commercial products with up to four oral food challenges as directed by the protocol."
3106743|NCT01846208|Experimental|Egg OIT Assigned|Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
3106744|NCT01846195|Sham Comparator|no blood draw|CM 1500 with no blood draw
3106745|NCT01846195|Active Comparator|blood draw|CM 1500 with blood draw
3106746|NCT01846182|Active Comparator|Group 1|60 mg of duloxetine in the AM for 20 weeks
3106747|NCT01846182|Active Comparator|Group 2|300 mg of pregabalin in the PM for 20 weeks
3106748|NCT01846182|Placebo Comparator|Group 3|placebo in the AM & PM for 20 weeks
3106749|NCT01846169|Experimental|food deliveries|After baseline screening, participants receive weekly or bi-weekly food deliveries and brief nutrition education.
3106750|NCT01846156|Experimental|Abrreviated MgSO4 protocol|- Category B : 80 patients given abbreviated doses of MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip only for 12 hours) in the postpartum period.
3106751|NCT01846156|Experimental|No maintenance protocol|- Category C : 80 patients who will take only loading dose of MgSO4 (6 grams of MgSO4 on 250 ml ringer solutions over 20 minutes) with no postpartum maintenance sulfate
3106752|NCT01846156|Active Comparator|standard MgSO4 protocol|- Category A : 80 patients given full dose of maintenance MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip for 24 hours) in the postpartum period.
3106753|NCT01846143|Experimental|Arm A: pBCAR3-phosphopeptide + tet vaccine plus polyICLC|"pBCAR3-phosphopeptide + tet vaccine plus polyICLC~The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
3106754|NCT01846143|Experimental|Arm B: pIRS2-phosphopeptide + tet vaccine plus polyICLC|"The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
3106755|NCT01846143|Experimental|Arm C: 2-MpP+ tet vaccine plus polyICLC|"The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
3106756|NCT01846130|No Intervention|Control|Control bed rest group
3106757|NCT01846130|Experimental|Leucine|Leucine will be administered in mixed meal 3 times a day at 0.06g/kg lean body mass/meal
3106758|NCT01846130|Experimental|Exercise|Daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate.
3106759|NCT01846130|Experimental|Leucine + Exercise|Leucine (0.06 g/kg lean body mass/meal, 3 meal/day) and exercise daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate.
3106760|NCT01846130|Experimental|Whey protein|22 g of whey isolate 3x a day (with meals)
3106761|NCT01846130|Experimental|Whey protein + exercise|22 g whey isolate 3x day (with meals) and daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate
3106762|NCT01846130|No Intervention|Skewed|Protein intake is distributed similar to typical American diet with low protein intake at breakfast, intermediate at lunch and high at dinner.
3106764|NCT01846117|Placebo Comparator|Whey powder|Natural Factors Whey Factors whey protein (unflavored). An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
3106765|NCT01846104|Experimental|50-μg booster dose RVEc|Subjects will be receive one 50-μg dose of RVEc
3106766|NCT01846091|Experimental|Treatment (MV-NIS)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IT on day 1.
3106767|NCT01846078|Experimental|Mean absolute errors, median absolute errors|
3106768|NCT01846039|Experimental|JUVÉDERM VOLUMA®|Participants treated with JUVÉDERM VOLUMA® up to 3 mLs administered by intradermal injection.
3106769|NCT01846026|Experimental|Vitamin D|"Decristol (cholecalciferol) 20000 IU per capsule~1 capsule per week"
3106770|NCT01846026|Placebo Comparator|Placebo|capsule with peanut oil
3106771|NCT01846013|Experimental|Stand|
3106772|NCT01846013|Experimental|Move|
3106773|NCT01846013|Experimental|Stand and Move|
3106774|NCT01846013|No Intervention|General Wellness|
3106775|NCT01846000|Experimental|Muscles of mastication|This group with TMD will receive low-level laser treatment at masseter and temporal muscles - three points on the masseter (upper, middle and lower) and one point on the anterior temporal
3106776|NCT01846000|Experimental|TMJ and muscles|This group with TMD will receive a mixed application of low-level laser treatment- TMJ and muscles of mastication.
3106777|NCT01846000|Placebo Comparator|Placebo|This group with TMD will receive a low-level laser placebo treatment at TMJ and muscles of mastication. The same equipment will be used with a pen that emits a red guide light and a warning sound, but without the emission of laser
3106778|NCT01846000|Experimental|Tempormandibular Joint|This group with TMD will receive low-level laser treatment in TMJ region - five points around the TMJ.
3106779|NCT01846000|No Intervention|Withou TMD|This will be a follow up group, with volunteers without TMD.
3106780|NCT01845987|Placebo Comparator|Placebo|
3106781|NCT01845987|Experimental|CNTO 1959|
3106782|NCT01845974|Experimental|Low Flow Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
3106783|NCT01845974|Active Comparator|High Flow Catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
3106784|NCT01845948|Placebo Comparator|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
3106785|NCT01845948|Experimental|parental training programme|The parental training programme was run in small groups of 8 to 12 parents over four consecutive weeks. They consisted of four group sessions, each lasting about two hours. The major focus of the parental intervention included teaching parents: (1) to use more active listening skills, (2) to engage less in harsh parenting practices, (3) to use more praise and encouragement and (4) to set reasonable expectations in the rearing of their children. Each session was started with revision of skills or concepts discussed in previous sessions, therefore, each session built on the previous session.
3106786|NCT01845935|Experimental|only one treatment group|Patients presenting inoperable venous vascular malformations in soft tissues with indication of cryoablation.
3106787|NCT01845922|Experimental|Low sodium diet|Low sodium diet
3106788|NCT01845922|No Intervention|Control|Standard diet regime
3106789|NCT01845909||young adults - Central region of Portugal|
3106790|NCT01845896|Experimental|Combined exercise|12 weeks combined exercise programme (supervised)
3106791|NCT01845896|Experimental|High intensity interval training|12 weeks high intensity interval exercise programme (supervised)
3106792|NCT01845896|No Intervention|Control|sedentary/habitual lifestyle
3106793|NCT01845883|Other|Deep Brain Stimulator|Some of our subjects that participate to the study have Deep Brain Stimulation implanted. They will perform the behavioral task twice, with the stimulation ON or OFF.
3106794|NCT01845870||urinary albumin ＞300mg/24h|none extra intervention was given by the investigator
3106795|NCT01845870||urinary albumin ＜30mg/24h|none extra intervention was given by the investigator
3106796|NCT01845870||urinary albumin 30 to 300mg/24h|none extra intervention was given by the investigator
3106797|NCT01845857|Experimental|Chronic Disease Self-Management Workshop|Longitudinal study of participants who take the CDSMP workshop
3106798|NCT01845844|Experimental|Ranibizumab 0.3mg (12 months)|Intravitreal injection of ranibizumab 0.3mg/0.05cc
3106799|NCT01845844|Active Comparator|Ranibizumab 0.3mg (6 months)|Intravitreal injection of ranibizumab 0.3mg/0.05cc
3106800|NCT01845831|Experimental|Sitagliptin + glargine (Hospital)|Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
3106801|NCT01845831|Active Comparator|Basal bolus (Hospital)|Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
3106802|NCT01845831|Experimental|Metformin and Sitagliptin|Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months
3106803|NCT01845831|Experimental|Metformin and sitagliptin + glargine 50%|Patients with HbA1c between 7% and 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (50% of the inpatient glargine dose) for 6 months
3106804|NCT01845831|Experimental|Metformin and sitagliptin + glargine 80%|Patients with HbA1c > 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (80% of the inpatient glargine dose) for 6 months
3106805|NCT01845818||Patients with Ankylosing Spondylitis and Psoriatic Arthritis|Patients with Ankylosing Spondylitis and Psoriatic Arthritis and in whom adalimumab treatment is initiated. All medication will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.
3106806|NCT01845805|Experimental|Arm A: CC-486|"CC-486 (oral azacitidine), 300 mg total (three 100mg tablets), taken daily on days 1-21 (of a 28 day cycle); indefinite cycles until visible tumor recurrence, then first line chemotherapy"
3107196|NCT01843205|Placebo Comparator|Placebo|Subjects will be maintained on placebo.
3106807|NCT01845805|Active Comparator|Arm B: observation|"Observation, indefinite until visible tumor recurrence, then first line chemotherapy"
3106808|NCT01845792|Experimental|Cabazitaxel with Abiraterone Acetate|Cabazitaxel administered as a single intravenous dose every 3 weeks, in combination with abiraterone acetate and prednisone taken daily.
3106809|NCT01845792|Active Comparator|Cabazitaxel Alone|Cabazitaxel administered as a single intravenous dose every 3 weeks
3106810|NCT01845779|Experimental|patients in complete response|
3106811|NCT01845766|Experimental|rehabilitation arm|daily standardized exercise rehabilitation during the admission period, and daily standardized self exercise after discharge
3106812|NCT01845766|No Intervention|control arm|
3106813|NCT01845753||All colorectal cancer patients|
3106814|NCT01845740|Experimental|Milatuzumab SC 250 mg|Milatuzumab 250 mg will be administered subcutaneously once weekly for 4 weeks.
3106815|NCT01845740|Experimental|Milatuzumab 150 mg SC|Milatuzumab 150 mg will be administered subcutaneously once weekly for 4 weeks.
3106816|NCT01845740|Placebo Comparator|Placebo SC|Placebo will be administered subcutaneously once weekly for 4 weeks.
3106817|NCT01845727|Experimental|Topical Amphotericin B three times per day|Anfoleish applied 3 times per day for 4 weeks (TID group)
3106818|NCT01845727|Experimental|Topical Amphotericin B two times per day|Anfoleish applied 2 times per day for 4 weeks (BID group)
3106819|NCT01845714|Active Comparator|Cross Linking Group (CxL group)|Patients that received CXL
3106820|NCT01845714|Active Comparator|Cross Linking with topo-guided PRK (tCxL)|Patients that received tCxL
3106821|NCT01845701|Experimental|Artesunate-Amodiaquine|As a fixed-dose combination of artesunate-amodiaquine developed by Sanofi-Aventis (France). It has the advantage of being a 3-day regimen usable by all age groups and potentially low cost. tablets are administered per every day at dose of 25mg/67.5mg for those between 4,5kg and 9kg for 48H
3106822|NCT01845701|Experimental|Dihydroartemisinine_Piperaquine|As a fixed-dose combination of dihydroartemisinin-piperaquine which is produced by Fouley (China). It is a potentially low cost 2-day regimen that has been used in children between 5-10kg as half a tablet of 40mg/320mg every day for 48H
3106823|NCT01845701|Active Comparator|Artemeter-Lumefantrine|This is the active comparator as a fixed-dose combination of artemether and lumefantrine which is produced by Novartis (Switzerland). The drug will be used as the comparator because it is the only fixed-dose combination with artemether currently available. Administered in children as tablets containing Artemether-Lumefantrine at (20mg/120mg) for body weights of 5-10kg every 12H within 48H.
3106824|NCT01845688|Experimental|Losartan Tablets & QingReMoShen Granule|Losartan Tablets: 50mg, qd, po. QingReMoShen Granule: 12g, tid, po.
3106825|NCT01845688|Placebo Comparator|Losartan Tablets & Placebo Granule|Losartan Tablets: 50mg, qd, po. Placebo Granule: 12g, tid, po.
3106826|NCT01845675|Experimental|temozolomide or dacarbazine-based chemotherapy, endostatin|Endostatin 15mg/d，IV infusion, d1-d14 Temozolomide 150-200mg/m2/d，p.o., d1-d7 or dacarbazine 250mg/m2/d, IV infusion, d1-5, 5-FU 500mg/m2/d, IV infusion d1-5 Repeat every 3 weeks.
3106827|NCT01845662||surgical or non-surgical management|Patients with non traumatic cause of splenic rupture such as infectious disease (e.g. malaria)and myeloproliferative that have been treated conservatively in one group and operatively in another group.
3106828|NCT01845649|Active Comparator|Active|Estradiol Vaginal Gel (0.03 mg estradiol / g )
3106829|NCT01845649|Sham Comparator|Vehicle|Vehicle Vaginal Gel
3106830|NCT01845636|Experimental|Donepezil Treatment & Atropine Challenge|Atropine nasal spray is administered at baseline for the atropine challenge which involves administration of the 40-item University of Pennsylvania Smell Identification Test (UPSIT) immediately before and 45 minutes after atropine administration. Immediately after the atropine challenge, donepezil treatment is started and continues for 52 weeks.
3106831|NCT01845623|Experimental|Treatment A|
3106832|NCT01845623|Experimental|Treatment B|
3106833|NCT01845623|Placebo Comparator|Treatment C|
3106834|NCT01845610|Experimental|Fortified fat-based paste with EFAs, DHA, ARA and phytase|Complementary food supplement providing micronutrients and both essential fatty acids, DHA, ARA, phytase and L-lysine, potassium, phosphorous, magnesium and manganese
3106835|NCT01845610|Experimental|Fortified fat-based paste with essential fatty acids|Complementary food supplement providing micronutrients and essential fatty acids (EFAs)
3106836|NCT01845610|No Intervention|Control group|The control group will receive a delayed intervention
3106837|NCT01845597||MAKOplasty® medial UKA|Patients who have received a MAKOplasty® robotically guided unilateral knee arthroplasty (UKA) and received a medial MCK onlay implant.
3106838|NCT01845584|Experimental|NPB-01|Intravenous immunoglobulin
3106839|NCT01845571||Retinal detachment group|400 patients patients, who received surgery due to retinal detachment exclusion: if patients had prior vitrectomy or scleral buckel if patients have no adequate follow-up
3106840|NCT01845558|Experimental|Wobenzym® plus|Treatment with the licenced drug Wobenzym® plus (3x4 Capsules/ day)
3106841|NCT01845558|Placebo Comparator|Placebo equates Wobenzym® plus but without active ingredients|3x4 capsules/ day
3106842|NCT01845545|No Intervention|Late intervention|CPSL will support the establishment of self-help groups after 18 months of start of the study.
3106843|NCT01845545|Experimental|Early intervention|CPSL will support the establishment of Women's self-help group. Microfinance will be provided to this group from the first 18 months of the study. The women in these groups will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help groups.
3106844|NCT01845532|Experimental|TPI group|
3106845|NCT01845532|Active Comparator|ELMA group|
3106846|NCT01845532|No Intervention|None group|
3106847|NCT01845519|Experimental|Tailored Group|
3106848|NCT01845519|Active Comparator|Targeted Group|
3106849|NCT01845506|Experimental|Wireless pressure transducer|Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
3106850|NCT01845506|Active Comparator|Cardiorespiratory Monitor|Following informed consent, each subject will be also be fitted with ECG leads (five), and an oxygen saturation monitor. This information as well as blood pressure and temperature will be recorded at 5-minute intervals by a nurse.
3106851|NCT01845493|Active Comparator|Sulforaphane-rich supplement|Intervention: broccosprout homogenate (rich in Sulforaphane) taken orally daily x 3 days
3106852|NCT01845493|Placebo Comparator|Alfalfa Sprout Homogenate|Placebo: Alfalfa sprout homogenate taken daily x 3 days (poor in sulforaphane)
3106853|NCT01845480|Experimental|Healthful eating phys activity coaching|The healthful eating and physical activity skills coaching intervention is designed to help children set goals and self-monitor healthful eating and physical activity; teach kitchen skills for fruit and vegetable snack preparation; teach children enjoyable physical activities to do at home (e.g., dancing); and provide modeling and social support for physical activity and healthful eating.
3106854|NCT01845480|Active Comparator|Health education coaching|Health education coaching is designed to help children set goals and self-monitor behavior; educate children on a range of relevant health promotion behaviors (e.g., tooth brushing, not smoking, physical activity, etc.); and provide modeling and social support for practicing healthful behavior.
3106855|NCT01845467||Auto-immune pancreatitis, suspected|Patients suspected with auto-immune pancreatitis (AIP) and undergoing secretin assisted MRCP as per the standard of care at our institute.
3106856|NCT01845454|Active Comparator|Dose 1|The first 15 patients enrolled will receive a dose of 1 application of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
3106857|NCT01845454|Active Comparator|Dose 2|If a second cohort of 15 participants is necessary, the next dose will include 1 application of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
3106858|NCT01845454|Active Comparator|Dose 3|If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
3106859|NCT01845454|Active Comparator|Dose 4|If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
3106860|NCT01845441|Experimental|Dexmedetomidine arm|Precedex will be started after randomization/prior to catheterization and will be stopped at the end of the procedure. It will be used for an average of 90 minutes and will be used as a continuous intravenous infusion started at 0.3 mcg/kg/hour. If HR > 80 and BP > 120/70, a full loading dose (1.0 mcg/kg/hour) will be administered over 10 minutes. If HR is 60 - 80 or systolic BP is 90 - 120, or age > 65 years, a reduced loading dose of 0.5 mcg/kg will be given over 10 minutes. If no volume overload history, 500mL of colloid (hespan or albumin) will be bolused with 0.2mg of glycopyrrolate. Every 10 minutes, Precedex will be titrated by 0.1 mcg/kg/hour to achieve and maintain RASS of 0 to -1.
3106861|NCT01845441|Active Comparator|Control arm|Our usual standard of care is to attempt the intervention without sedation. As per attending physician discretion, Fentanyl (50mcg) and/or Midazolam (0.5 mg) intravenous boluses will be used to control aggressive patient movement that adversely affects the technical capacity of the procedure. The boluses will be repeated at interval of 10 minutes, as necessary. Control arm patients will receive a normal saline placebo drip for the purposes of ensuring patient assessor blindness.
3106862|NCT01845428|Other|pravastatin|All participants will receive pravastatin 20mg daily
3106863|NCT01845415|Active Comparator|Social Marketting Only|Two communities receive a social marketing campaign to reduce child falls in the home.
3106864|NCT01845415|No Intervention|No treatment Control|two communities receive no intervention
3106865|NCT01845415|Active Comparator|Social Marketing plus Intervention|Two communities receive the social marketing campaign and additional intervention components
3106866|NCT01845402||congenital cardiac diseases|blood sample and urine sample.
3106867|NCT01845389|Experimental|Epidural|epidural anesthesia was administered via a 20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air. Bupivacaine 0.5% 5 ml every 5 minutes for T10 sensory level
3106868|NCT01845389|Active Comparator|Spinal|An18-gauge Tuohy peel-away epidural sheath was introduced into the epidural space by using loss of resistance technique to air. Epidural introducer was removed leaving epidural sheath to be a pathway for Wiley spinal catheter. A flexible, convenience curve 27-gauge atraumatic pencil point tip spinal needle was introduced through the epidural sheath. After CSF flow was confirmed, a 23-gauge flexible cannula was threaded over the spinal needle. Peel-away epidural sheath was removed and flexible cannula was continually advanced over the spinal needle into the intrathecal space cephaled. Bupivacaine 0.5% 0.5 ml every 5 minutes for T10 sensory level.
3106869|NCT01845376|Experimental|local anesthesia group|In the local anesthesia group, patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine. Surgeons will be taught to do the local anesthetic technique in a standardized manner.
3106870|NCT01845376|Experimental|spinal anesthesia group|In the spinal anesthesia group, patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected. Sensory block (T4 and below dermatomes) to cold and pinprick will be tested before starting operation. An incremental dose containing 1 mg of midazolam and 25 mcg of fentanyl will be intravenously given if patients in the LA and SA group require.
3106871|NCT01845376|Experimental|general anesthesia group|In the general anesthesia group, patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
3106872|NCT01845363|Other|Cefazolin|"Cefazolin used in antimicrobial prophylaxis~Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.~The samples were processed by High Pressure Liquid Chromatography (HPLC)."
3106873|NCT01845350|Other|M2 macrophages|M2 macrophage introduction
3106874|NCT01845337|Active Comparator|Capecitabine single agent|Capecitabine 1250 mg/m2 twice daily, days 1-14 every 21 days
3107057|NCT01844219||Patients who underwent aortic surgery|Patients who underwent aortic surgery in Samsung Medical Center during the period between 2004 and 2010
3106875|NCT01845337|Active Comparator|Capecitabine /Oxaliplatin|Capecitabine 1000 mg/m2 twice daily, days 1-14 every 21 days (in frail or elderly patients, a CAP dose of 750 mg/m2 BD should be considered). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
3106876|NCT01845337|Active Comparator|Teysuno single agent|Teysuno will be administered at a dose of 30 mg/m2 twice daily, for 14 days, with a subsequent 7-day rest period. Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 40mg (BSA < 1.5 m2), 45 mg (BSA 1. 5 to < 1.7 m2), 55mg (BSA 1.7 - 1.9 m2),
3106877|NCT01845337|Active Comparator|Teysuno/ Oxaliplatin|Teysuno will be administered orally at a dose of 25mg/m2 twice daily, days 1-14 every 21 days Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 35mg (BSA < 1.5 m2), 40mg (BSA 1.5 to < 1.7 m2), 45mg (BSA 1.7 - 1.9 m2), 50mg (BSA >1.9 m2). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
3106878|NCT01845324||Diabetes Mellitus in pregnancy|Our cohort will include all consequtive women with Diabetes Mellitus atending our clinic
3106879|NCT01845311|Experimental|ReZolve2 Treatment Group|
3106880|NCT01845298|Experimental|HIV-infected subjects|HIV-infected subjects who have not yet initiated highly active antiretroviral therapy (HAART). All enrolled subjects will receive a single dose of rifampicin 600 mg.
3106881|NCT01845285||aortic valve disease|aortic valve replacement
3106882|NCT01845272|Experimental|Part 1|"single administration : candesartan cilexetil 32mg, qd, 10days(oral).~combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
3106883|NCT01845272|Experimental|Part 2|"single administration : amlodipine 10mg, qd, 10days(oral).~combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
3106884|NCT01845259|Experimental|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
3106885|NCT01845259|Placebo Comparator|Liraglutide placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
3106886|NCT01845246|No Intervention|Standard doses of colistin will be used.|Patients will receive the standard doses of colistin without TDM (Therapeutic drug monitoring).
3106887|NCT01845246|Experimental|Prospective TDM (Therapeutic drug monitoring)of colistin arm|CMS dose will be adjusted based on protocol obtained TDM levels.
3106888|NCT01845233||Non invasive ventilation|
3106889|NCT01845220|Active Comparator|Broccoli Sprout Extract|Each subject will act as his/her own control and receive both treatment and placebo on adjacent skin regions.
3106890|NCT01845220|Placebo Comparator|Placebo|Each subject will act as his/her own control and receive both treatment and placebo on adjacent skin regions.
3106891|NCT01845207||Aortic valve replacement|Patients aged ≥70 years referred for surgical or transcatheter aortic valve replacement.
3106892|NCT01845194|Experimental|Drug application|"Two treatment periods:~Treatment period 1:~three sequential oral and i.v. doses of 5 mg Metoprolol, 50 mg Talinolol, 2.5 mg Torsemide, 0.2 mg Midazolam and 50 mg Caffeine. At least 1 week of wash out between drug application~Treatment period 2:~combined application of a single oral dose of 2.5 mg Talinolol, 0.25 mg Torsemide, 5 mg Pravastatin, 1 mg Midazolam and 5 mg Codeine.~Treatment period 2 may take place after or before treatment period 1 with a time interval of at least 1 week"
3106893|NCT01845181|Placebo Comparator|Dose Level I - Group A - Placebo|2 capsules of placebo
3106894|NCT01845181|Experimental|Dose Level II - Group B - Active|20 mg: 1 capsule of 20 mg PBF-680
3106895|NCT01845181|Placebo Comparator|Dose Level II - Group B - Placebo|1 capsule of placebo
3106896|NCT01845181|Experimental|Dose Level I - Group A - Active|10 mg: 2 capsules of 5 mg PBF-680
3106897|NCT01845181|Experimental|Dose Level III - Group C - Active|40 mg: 2 capsules of 20 mg PBF-680
3106898|NCT01845181|Placebo Comparator|Dose Level III - Group C - Placebo|2 capsules of placebo
3106899|NCT01845181|Experimental|Dose Level IV - Group D - Active|60 mg: 3 capsules of 20 mg PBF-680
3106900|NCT01845181|Placebo Comparator|Dose Level IV - Group D - Palcebo|3 capsules of placebo
3106901|NCT01845168|Active Comparator|Computer-alert|2 arm study active group: 'A computer alert which pops up when the GP prescribes NSAID/ASA to a patient with risk-factors
3106902|NCT01845168|No Intervention|controlgroup, normal procedures|The control-group: GP working in normal procedures
3106903|NCT01845155|Experimental|Music Therapy|Neuro-Music-Therapy according to the Heidelberg Model
3106904|NCT01845155|Active Comparator|Counselling|Counselling
3106905|NCT01845142|Active Comparator|intramuscular 100.000 I.U. vitamin D3|intramuscular 100.000 I.U. vitamin D3
3106906|NCT01845142|Placebo Comparator|intramuscular placebo|intramuscular 0.9% sodium chloride
3106907|NCT01845142|Active Comparator|subcutaneous 100.000 I.U. vitamin D3|subcutaneous 100.000 I.U. vitamin D3
3106908|NCT01845142|Placebo Comparator|subcutaneous placebo|subcutaneous 0.9% sodium chloride
3106909|NCT01845129|Experimental|anodal tDCS|atDCS will be administered for 20 minutes with 1 milliampere (1 mA) to the left primary hand motor cortex
3106910|NCT01845129|Sham Comparator|sham tDCS|sham tDCS will be administered to the left primary hand motor cortex
3106911|NCT01845116|Other|Single Arm|Single Omegaven® Intervention Arm
3106912|NCT01845090|Active Comparator|Lanthanum carbonate|Lanthanum carbonate 375mg~750 mg tid for 6 months
3106913|NCT01845090|Active Comparator|Calcium carbonate|Calcium carbonate 500mg~1000 mg tid for 6 months
3106914|NCT01845077|Active Comparator|5 mg Linagliptin/1000 mg Metformin, fed|3 single tablets under fed conditions
3106915|NCT01845077|Experimental|5 mg Linagliptin/1500 mg Metformin FDC|2 FDC tablets under fasted conditions
3106916|NCT01845077|Active Comparator|5 mg Linagliptin/1500 mg Metformin|4 single tablets under fasted conditions
3106917|NCT01845077|Experimental|5 mg Linagliptin/1000 mg Metformin FDC|1 fixed dose combination(FDC) tablet under fasted conditions
3106918|NCT01845077|Active Comparator|5 mg Linagliptin/1000 mg Metformin|3 single tablets under fasted conditions
3106919|NCT01845077|Experimental|5mg Linagliptin/1000mg Metformin, FDCfed|1 FDC tablet under fed conditions
3106920|NCT01845064|Experimental|Part A - SAD in healthy subjects|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and/or female subjects. Subjects will receive DM199 subcutaneously (sc).
3106921|NCT01845064|Experimental|Part B - SAD in type 2 diabetic patients|A randomized, partially double-blinded, placebo-controlled, sequential SAD study in male and/or female type 2 diabetes mellitus patients. Subjects will receive DM199 subcutaneously (sc).
3106922|NCT01845064|Experimental|Part C - MAD in healthy subjects|A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive sequential doses of DM199 sc for 14 days.
3106923|NCT01845064|Experimental|Part D - POC in type 2 diabetes patients|A randomized, double-blinded, placebo-controlled, 28-day multiple-dose proof of concept (POC) study in male and/or female type 2 diabetes mellitus patients. Subjects will receive doses of DM199 sc for 28 days.
3106924|NCT01845064|Placebo Comparator|Part A - Healthy subjects SAD placebo|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and/or female subjects. Subjects will receive placebo subcutaneously (sc).
3106925|NCT01845064|Placebo Comparator|Part B - Type 2 diabetic patients SAD placebo|A randomized, partially double-blinded, placebo-controlled, sequential SAD study in male and/or female type 2 diabetes mellitus patients. Subjects will receive placebo subcutaneously (sc).
3106926|NCT01845064|Placebo Comparator|Part C - Healthy subjects MAD placebo|A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive placebo sc for 14 days.
3106927|NCT01845064|Placebo Comparator|Part D - Type 2 diabetic patients POC placebo|A randomized, double-blinded, placebo-controlled, 28-day multiple-dose proof of concept (POC) study in male and/or female type 2 diabetes mellitus patients. Subjects will receive placebo sc for 28 days.
3106928|NCT01845051||Migraine group|Patients diagnosed with migraine
3106929|NCT01845051||Healthy group|Healthy subjects with no migraine as control
3106930|NCT01845038|Experimental|OTX-TPa|OTX-TPa is a hydrogel punctum plug eluting travoprost in sustained release of ~4µg/day over approximately 2 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
3106931|NCT01845038|Experimental|OTX-TPb|OTX-TPb is a hydrogel punctum plug eluting travoprost in sustained release of ~3µg/day over approximately 3 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
3106932|NCT01845038|Active Comparator|Timolol|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily (BID). For study masking purposes, subjects in this arm will also have a hydrogel punctum plug with no drug placed for approximately 3 months.
3106933|NCT01845025|Experimental|FOM 12 mcg + FP|Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation
3106934|NCT01845025|Active Comparator|fluticasone propionate (FP)|fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation
3106935|NCT01845012|Experimental|Daily hemodialysis at low dialysate flow|
3106936|NCT01844999|Other|Usual patient education + standard educational websites|
3106937|NCT01844999|Experimental|Usual patient education + P3P decision support website|
3106938|NCT01844986|Experimental|Olaparib tablets p.o. 300mg twice daily|Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity
3106939|NCT01844986|Placebo Comparator|Placebo tablets p.o. twice daily|Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity
3106940|NCT01844973|Placebo Comparator|Vehicle|
3106941|NCT01844973|Active Comparator|M518101|
3106942|NCT01844960|Active Comparator|Multiple Incision Gastric Band Insertion|Current standard surgical approach for laparoscopic gastric band insertion
3106943|NCT01844960|Experimental|Single Incision Gastric Band Insertion|New surgical approach for gastric band insertion
3106944|NCT01844947|Experimental|vinflunine + sorafenib|Single arm study.
3106945|NCT01844934|No Intervention|Standard treatment|The no intervention group will receive standard treatment that includes a four hour class pre-surgery consisting of a description of the surgery, what to expect in the hospital and during recovery and some exercises to be done in preparation for surgery.
3106946|NCT01844934|Experimental|Prehabilitation|Prehabilitation:The experimental group will receive a three week prehabilitation program prior to surgery in addition to standard treatment.
3106947|NCT01844908|Experimental|Electroacupuncture|
3106948|NCT01844895|Experimental|Abatacept (Autoinjector and Prefilled Syringe)|"Abatacept (prefilled syringe) 125 mg/device solution subcutaneously weekly for 3 months~Abatacept (autoinjector) 125 mg/device solution subcutaneously weekly for 1 month"
3106949|NCT01844882||Chronic Kidney Disease|
3106950|NCT01844869|Experimental|omacetaxine mepesuccinate|"Period A: 7-day pharmacokinetic assessment period in which all patients will be administered a single subcutaneous radiolabeled dose of 1.25-mg/m2 omacetaxine.~Period B: omacetaxine will be administered as an sc injection at a dosage of 1.25 mg/m2 twice daily for 7 days (patients with solid tumors) or 14 days (patients with hematologic malignancies) of every 28-day cycle for up to 6 cycles."
3106951|NCT01844856|Experimental|Eravacycline, 1.0 mg/kg q12h|Eravacycline was administered intravenously (IV) at a dose of 1.0 milligram per kilogram of body weight (mg/kg) every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days. Eravacycline treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
3106952|NCT01844856|Active Comparator|Ertapenem, 1.0 g q24h|Ertapenem was administered IV at a dose of 1.0 gram (g) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days. Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
3106953|NCT01844843|Experimental|TCD-10023 drug eluting stent|All patients will be treated with the new Drug eluting stent TCD-10023
3107058|NCT01844206|Active Comparator|Epidural Morphine|Group receiving 3mg epidural morphine, 24 hours after the initial dose
3106954|NCT01844830|Experimental|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - Subjects weighing more than 10kg and less than 20kg, will receive 1 spray of 100µL; Subjects weighing more than 20kg and less than 40kg, will receive 2 sprays of 100µL (200µL total); subjects weighting more than 40kg will receive 2 sprays of 200µL (400µL total);
3106955|NCT01844830|Placebo Comparator|Placebo|Placebo - Subjects weighing more than 10kg and less than 20kg, will receive 1 spray of 100µL; Subjects weighing more than 20kg and less than 40kg, will receive 2 sprays of 100µL (200µL total); subjects weighting more than 40kg will receive 2 sprays of 200µL (400µL total);
3106956|NCT01844817|Experimental|OGX-427|Three loading doses of OGX-427 at 600mg IV will be administered Days -9 to -1. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8, 15, and 22 of each 28 day cycle during the Treatment Phase.
3106957|NCT01844817|Placebo Comparator|Placebo|Three loading doses of placebo will be administered Days -9 to -1. Following the loading dose period, placebo will be administered weekly Days 1, 8, 15, and 22 of each 28 day cycle.
3106958|NCT01844804|Experimental|A = PF-06438179|
3106959|NCT01844804|Active Comparator|B = Infliximab-EU|
3106960|NCT01844804|Active Comparator|C = Infliximab-US|
3106961|NCT01844791|Experimental|OCZ103-OS, Platinum, Gemcitabine|OCZ103-OS in combination with Platinum-Gemcitabine as standard of care
3106962|NCT01844778|Active Comparator|TIS/TIP|During the first cycle of treatment, participants received nebulized TIS, 300 mg twice per day for 28 days followed by 28 days off-treatment. During the second cycle, participants received 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
3106963|NCT01844778|Active Comparator|COLI/TIP|During the first cycle, participants received nebulized COLI, 1 million or 2 million units twice or thrice per day (or the participant's usual dose and regimen) for 56 days (no off-treatment period) or 28 days on-treatment followed by 28 days off-treatment (cycling regimen), depending on local treatment guidelines. During the second cycle, participants received TIP, 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
3106964|NCT01844778|Active Comparator|TIP/TIP|During the first and second cycles, participants received TIP, 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
3106965|NCT01844765|Experimental|Newly diagnosed and untreated Ph+ CML in first CP|Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.
3106966|NCT01844765|Experimental|Resistant/intolerant Ph+ CML in CP|Resistant or Intolerant to either imatnib or dasatnib
3106967|NCT01844765|Experimental|Resistant/intolerant Ph+ CML in AP|Resistant or intolerant to either imatnib or dasatnib - at the point of reporting interim results, no patients were enrolled in this arm.
3106968|NCT01844752|Experimental|NVN1000 1% Gel|NVN1000 1% Gel twice daily
3106969|NCT01844752|Experimental|NVN1000 4% Gel|NVN1000 4% Gel twice daily
3106970|NCT01844752|Placebo Comparator|Vehicle Gel|Vehicle Gel twice daily
3106971|NCT01844739|Experimental|NVN1000 4% Gel|NVN1000 4% Gel twice daily to the face for 2 weeks
3106972|NCT01844739|Placebo Comparator|Vehicle Gel|Vehicle Gel twice daily to the face for 2 weeks
3106973|NCT01844726|Experimental|GLYX-13|Single IV infusion of GLYX-13, 5mg/kg,
3106974|NCT01844726|Placebo Comparator|Placebo|Single IV administration of placebo
3106975|NCT01844713|Experimental|Experimental: Workbook|Distribution of the sun protection educational workbook
3106976|NCT01844713|No Intervention|Control|Distribution of general skin care information
3106977|NCT01844700|Active Comparator|Ziprasidone|(20-160mg/d, bid) for 12 weeks
3106978|NCT01844700|Active Comparator|Aripiprazole, quetiapine, risperidone|Aripiprazole (2-30mg/d), Quetiapine (25-800mg/d) or Risperidone (0.1-8mg/d) for 12 weeks
3106979|NCT01844687|Other|Active marijuana (MJ) with 0 mg CBD|Active MJ cigarettes contain 5.30% THC
3106980|NCT01844687|Other|Active MJ with 200 mg CBD|Active MJ cigarettes contain 5.30% THC
3106981|NCT01844687|Other|Active MJ with 400 mg CBD|Active MJ cigarettes contain 5.30% THC
3106982|NCT01844687|Other|Active MJ with 800 mg CBD|Active MJ cigarettes contain 5.30% THC
3106983|NCT01844687|Other|Inactive MJ with 0 mg CBD|Inactive MJ cigarettes contain 0.01% THC
3106984|NCT01844687|Other|Inactive MJ with 200 mg CBD|Inactive MJ cigarettes contain 0.01% THC
3106985|NCT01844687|Other|Inactive MJ with 400 mg CBD|Inactive MJ cigarettes contain 0.01% THC
3106986|NCT01844687|Other|Inactive MJ with 800 mg CBD|Inactive MJ cigarettes contain 0.01% THC
3106987|NCT01844674|Experimental|Pharmacokinetic Population|All participants will receive a 3-period treatment including single-dose tizanidine on Day 1, twice-daily vemurafenib on Days 2 to 21, and both agents together on Day 22.
3106988|NCT01844661|Experimental|CELYVIR|Patients will received weekly (n=6) IV infusion of Celyvir.
3106989|NCT01844648|Experimental|NH004 tropicamide|tropicamide 1 mg thin film, twice daily for 7 days
3106990|NCT01844648|Placebo Comparator|NH004 placebo|placebo thin film, twice daily for 7 days
3106991|NCT01844635|Experimental|2.5 mg/kg/day of Thymoglobulin for 5 days|2.5 mg/kg/day of Thymoglobulin for 5 days
3106992|NCT01844635|Active Comparator|3.5 mg/kg/day of Thymoglobulin for 5 days|3.5 mg/kg/day of Thymoglobulin for 5 days
3106993|NCT01844622|Other|Domperidone|Domperidone will be given at 10 mg before each meal and at bedtime. At completion of the study, patients will receive standard medical therapy
3106994|NCT01844609|Experimental|Self Study Journal Club|25 Chinese Medical Professionals that will be participating in Self Study Journal Club Meetings three times a week for one hour for 8 weeks with interactive questions and answers and discussion of the journal articles.
3106995|NCT01844609|Experimental|Intensive Journal Club|25 Chinese Medical Professionals that will be participating Face to Face Journal Club Meetings three times a week for one hour for 8 weeks along with a native English speaking mentor.
3106996|NCT01844596|No Intervention|Usual Care|Usual Care: Community Health Workers (CHW) with standard training on recruitment of individuals.
3106997|NCT01844596|Experimental|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
3107024|NCT01844427|Placebo Comparator|Placebo|Masked placebo administered in capsule form twice daily for 12 weeks. Placebo titration will be titrated according to the same procedure as active memantine.
3106998|NCT01844596|Experimental|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
3106999|NCT01844583|Experimental|alisertib|Timeframe: 21 days
3107000|NCT01844570||Levamlodipine Maleate (Xuanning)|Primary hypertensive patients who take Levamlodipine Maleate (Xuanning) as the only anti-hypertensive medication or one of their medications
3107001|NCT01844570||Amlodipine Besylate (Norvasc)|Primary hypertensive patients who take Amlodipine Besylate (Norvasc) as the only anti-hypertensive medication or one of their medications
3107002|NCT01844557||Group 1(High Accountability-Human Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. Participant to tell whether they did as many repetitions as possible and if not, why they were not able to do as many as possible. This portion of the experiment will be videotaped. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
3107003|NCT01844557||Group 2(Low Accountability-Human Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
3107004|NCT01844557||Group 3(Low Accountability-Technological Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. The videocamera will tape participant's session so evaluation can be made as to exercise accuracy. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
3107005|NCT01844544||patients after femur neck fracture|
3107006|NCT01844531|Experimental|FDC empagliflozin dose 1 and metformin|fix dose combination tablet after intake of a high fat, high caloric meal
3107007|NCT01844531|Active Comparator|empagliflozin dose 1 + metformin tablets|single tablets after intake of a high fat, high caloric meal
3107008|NCT01844531|Experimental|FDC empagliflozin dose 2 and metformin|fix dose combination tablet after intake of a high fat, high caloric meal
3107009|NCT01844531|Active Comparator|empagliflozin dose 2 + metformin tablets|single tablets after intake of a high fat, high caloric meal
3107010|NCT01844518|Experimental|Short and Long Terms: Orencia|"Short Term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 4 months~Long term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 20 months"
3107011|NCT01844505|Experimental|Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Ipilimumab 0 mg/kg solution intravenously on weeks 1, 4 and Placebo matching with Nivolumab on weeks 4 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3107012|NCT01844505|Experimental|Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab|Nivolumab 1 mg/kg solution intravenously combined with Ipilimumab 3 mg/kg solution intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Nivolumab on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3107013|NCT01844505|Experimental|Arm C: Ipilimumab+Placebo for Nivolumab|Ipilimumab 3 mg/kg solution intravenously every 3 weeks for a total of 4 doses plus Placebo matching with Nivolumab 0 mg/kg solution intravenously on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends (Placebo matching with Nivolumab is no longer required)
3107014|NCT01844492|Active Comparator|ICU Usual Care Control|described below
3107015|NCT01844492|Experimental|The PARTNER Intervention|described below
3107016|NCT01844479|Active Comparator|Standard innersole|"Per sequence cross over design. Order of testing innersoles was randomized and each testing condition lasted 15 minutes.~The industry standard diabetic innersole will be used as the active comparator"
3107017|NCT01844479|Experimental|Diabetic Foot Orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
3107018|NCT01844466|Experimental|stroke patients|
3107019|NCT01844453|Experimental|Luteal Phase Arm|Local Endometrial Injury in mid-luteal phase (cycle day 21-26) prior to the treatment cycle.
3107020|NCT01844453|Experimental|Proliferative Phase Arm|Local Endometrial Injury in early proliferative phase of current treatment cycle (cycle day 2-3).
3107021|NCT01844453|No Intervention|Control Arm|No Local Endometrial Injury will be performed. Patients will undergo a routine fresh IVF treatment cycle.
3107022|NCT01844440|Experimental|HRM|
3107023|NCT01844427|Active Comparator|Memantine HCl|Memantine administered in capsule form twice daily for 12 weeks and titrated up to a maximum daily dose of 20mg.
3107197|NCT01843205|Experimental|Buspirone|Subjects will be maintained on buspirone.
3107025|NCT01844414|Experimental|Parolee Comprehensive Care + Phone Coach|PCPC Intervention: Eight specialized nurse case managed hepatitis education sessions, the Hepatitis A/B vaccine series and coach-facilitated mentoring.
3107026|NCT01844414|Experimental|Parolee Brief HBV program + Phone Coach|PBPC Intervention: Eight twenty minute hepatitis education sessions, coach facilitated mentoring and the Hepatitis A/B vaccine series.
3107027|NCT01844414|Active Comparator|Usual Care Group|UC Control Group: One brief general health information program, one-on-one coaching and the Hepatitis A/B vaccine.
3107028|NCT01844401|Experimental|Spiromax/ProAir|Single dose of Albuterol Spiromax® 180 mcg followed by a 4 to 14 day washout period then a single dose of ProAir® HFA 180 mcg
3107029|NCT01844401|Experimental|ProAir/Spiromax|Single dose of ProAir® HFA 180 mcg followed by a 4 to 14 day washout period then a single dose of Albuterol Spiromax® 180 mcg
3107030|NCT01844388|Experimental|Carboxymethylcellulose Based Eye Drop Formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
3107031|NCT01844388|Active Comparator|REFRESH CONTACTS®|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
3107032|NCT01844375|Experimental|Carbohydrate group|The carbohydrate (CHO) group will be given the carbohydrate drink (12.5% carbohydrates, 50 kcal/100 ml, 240 mOsmol/l, pH 5.0) 800 mL of one of the drinks the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning of the operation day. The last drink will be no later than 3 hours before the scheduled induction of anesthesia. Of note, the last meal on the day before the operation will be no later than 1800 h. Following this meal, no food or drink will be allowed except the carbohydrate drink. The pharmacy department is responsible for preparing the carbohydrate drink.
3107033|NCT01844375|Active Comparator|Control group|The control group will be given pure water 800 mL of one of the drinks the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning of the operation day. The last drink will be no later than 3 hours before the scheduled induction of anesthesia. Of note, the last meal on the day before the operation will be no later than 1800 h. Following this meal, no food or drink will be allowed except pure water.
3107034|NCT01844362|Experimental|Uterine transplantation|Patients undergo transplantation of the uterus from live donor.
3107035|NCT01844336|Experimental|PBASE system 1.1 + CT100 (active treatment)|
3107036|NCT01844336|Placebo Comparator|PBASE system 1.1 + CT100 (placebo treatment)|
3107037|NCT01844323|Active Comparator|Treatment A|treatment A, reference, 20 micron palbociclib and lubrication level 1
3107038|NCT01844323|Active Comparator|Treatment B|treatment B, test, 50 micron palbociclib and lubrication level 1
3107039|NCT01844323|Active Comparator|Treatment C|treatment C, test, 20 micron palbociclib and lubrication level 2
3107040|NCT01844323|Active Comparator|Treatment D|treatment D, test, 20 micron palbociclib and lubrication level 3
3107041|NCT01844310|Active Comparator|RAL +TDF+ LPV/r|Arm A: RAL +TDF+ KELETRA(LPV/r) Group A will be assigned with RAL+TDF+LPV/r.
3107042|NCT01844310|Active Comparator|3TC+ TDF+LPV/r|Arm B: 3TC+ TDF+KELETRA(LPV/r) Group B will be assigned with 3TC+TDF+LPV/r
3107043|NCT01844297|Other|TDF+3TC+EFV|
3107044|NCT01844284|Experimental|Absorb™ BVS|Subjects receiving Absorb™ BVS
3107045|NCT01844284|Active Comparator|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
3107046|NCT01844271|Placebo Comparator|Placebo Low Level Laser|Application of low level laser without any dose (0 Joule) before strenuous exercise. A laser device with a cluster of 5 diodes (810 nm, 200 mW) each diode was used for this study.
3107047|NCT01844271|Experimental|2 Joules Low Level Laser|Application of 2 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
3107048|NCT01844271|Experimental|6 Joules Low Level Laser Therapy|Application of 6 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
3107049|NCT01844271|Experimental|10 Joules Low Level Therapy|Application of 10 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
3107050|NCT01844271|Experimental|Power of 100mW|After assigning ideal dose of application it was delimited two experimental groups which was irradiated with the dose established by the first part of the study and power of 100mW.
3107051|NCT01844271|Experimental|Power of 400mW|After assigning ideal dose of application it was delimited two experimental groups which were irradiated with the dose established by the first part of the study and power of 400mW.
3107052|NCT01844258|Experimental|Modified technique for I/A group|"In the modified cataract surgery procedure, the size of the capsulorhexis opening will be decreased to 1.0-1.5 mm in diameter.~The capsulorhexis will be located in the peripheral area of the lens instead of the central area.~A 0.9 mm phacoemulsification probe will be used to remove the cataractous lens.~One drop of 0.5% or 1% atropine and an antibiotic/steroid ointment will be placed in the eye, which will then be patched."
3107053|NCT01844258|Active Comparator|Traditional technique for I/A group|• In traditional technique group, the cataractous lens will be removed through an anterior continuous curvilinear capsulorhexis (ACCC) that is about 5-6 mm in diameter.
3107054|NCT01844245|Experimental|Endobiliary RFA group|"Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive endobiliary radiofrequency ablation (Endobiliary RFA) followed by plastic stent(s) placement.~Three months later, subjects will receive the second RFA therapy followed by biliary stents (plastic or SEMS) placement.~During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA"
3107055|NCT01844245|No Intervention|Control group|"Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive plastic biliary stent(s) placement only.~Three months later, subjects will receive the second endoscopic intervention for stents (plastic or SEMS) exchange.~During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA"
3107056|NCT01844232|Experimental|Arbaclofen Extended Release (ER) Tablets|Arbaclofen Extended Release Tablets, 20 mg/day, 30 mg/day or 40 mg/day
3107060|NCT01844193|No Intervention|Standard Therapy|This arm of the study will follow the standard therapy course after total knee arthroplasty.
3107061|NCT01844193|Experimental|Standard Therapy + NMES|This arm will follow the standard course of therapy but also incorporate daily neuromuscular electrical stimulation into the daily therapy regimen after total knee arthroplasty through use of the Compex Rehab device.
3107062|NCT01844180|Experimental|Experimental Arm 1|ONO-2952 low dose every day for 4 weeks
3107063|NCT01844180|Experimental|Experimental Arm 2|ONO-2952 high dose every day for 4 weeks
3107064|NCT01844180|Placebo Comparator|Placebo Arm|ONO-2952 Matching Placebo every day for 4 weeks
3107065|NCT01844167|Active Comparator|Physical therapy arm (PT)|"The TENS device used: FDA K071951~Patients will be treated with standard physical therapy, including the electrical stimulation. Manual therapy, cold/heat therapy or exercise will be applied at the discretion of the physical therapist for about 60 minutes in each session. Patient education and self-care instructions will be provided. TENS will also be performed in each session for about 30 minutes based on the typical PT guidelines, which will serve both as a part of the standard of care and as a placebo equivalent. It will typically be set at Normal/Modulate mode and 120 Hertz rate."
3107066|NCT01844167|Experimental|Noxipoint Therapy arm (NT)|"Patients will be treated with TENS following Noxipoint Therapy guidelines as highlighted below:~The TENS device used: FDA K071951~TENS is calibrated to allow for maximum range in the specifications.~A pair of electrode pads is placed at the corresponding pair of Noxipoints of the injured muscle/soft tissue, for about 2- 5 minutes during each application.~The electrical stimulation is set to induce the C-fiber response based on the feedback of the patient.~If the corresponding pain is not eliminated or reduced after a couple of applications on correct Noxipoints, apply an ice pack for about 10-15 minutes on site before and during the next Noxipoint stimulation."
3107067|NCT01844141|Experimental|alcohol - clorhexidine|Ingrown toenail irrigated using 70% alcohol - 0.5% clorhexidine
3107068|NCT01844141|Active Comparator|70% alcohol|Ingrown toenail irrigated using 70% alcohol
3107069|NCT01844128||overweight women with infertility|
3107070|NCT01844115|Placebo Comparator|Placebo|Dose-matched placebo tablets, oral administration
3107071|NCT01844115|Experimental|Vilazodone|Vilazodone tablets, oral administration
3107072|NCT01844102|Experimental|PrePex|PrePex circumcision procedures will be offered as part of the minimum package of HIV prevention services recommended by the Zambian Ministry of Health (MOH)
3107073|NCT01844076|Experimental|Phase I - Determine tolerability|Each group will have 1 to 6 patients enrolled in it. If the patients in a lower group do not have any significant side effects the next patient will start at the next group dose. Group 1: quinacrine at a dose of 100 mg every 2 days (days 1,3,5,7,9,11,13); Group 2: quinacrine at a dose of 100 mg once a day (days 1-14); Group 3: quinacrine at a dose of 100 mg twice a day (days 1-14)
3107074|NCT01844076|Experimental|Phase II - Quinacrine, Capecitabine|Quinacrine 100 mg tablets po bid q12 daily day 1-14; Capecitabine 1000 mg/m2 po bid q12 daily day 1-14 21 days for 3 weeks.
3107075|NCT01844063|Experimental|Conventional treatment|Participants will receive conventional treatment and then be followed until the week 72 study visit.
3107076|NCT01844063|Experimental|Conventional plus BM-MSC treatment|Participants will receive conventional treatment plus a dose of BM-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.
3107077|NCT01844063|Experimental|Conventional plus UC-MSC treatment|Participants will receive conventional treatment plus a dose of UC-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.
3107078|NCT01844050|Experimental|Chinese herbal medicine|Individualized Treatment with Chinese herbal
3107079|NCT01844050|Placebo Comparator|Placebo|Individualized Treatment with placebo Chinese herbal which Containing 2% of Chinese herbal medicine.
3107080|NCT01844037|Other|Renal denervation|Patients will be treated with the OneShot ablation system
3107081|NCT01844024|Other|misoprostol by midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
3107082|NCT01844024|No Intervention|Misoprostol by physician|Women with incomplete abortion is diagnosed and treated with misoprostol by physician
3107083|NCT01844011|Experimental|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart.
3107084|NCT01844011|No Intervention|Education only|All women enrolled in the trial will receive a paper-based kick count chart, will be educated in the use of the kick count chart, and will be instructed to keep track of their fetal movements on a daily basis.
3107085|NCT01843998|Experimental|Sirolimus 0.1% ointment|Sirolimus 0.1% ointment
3107086|NCT01843985||1. Eligible RCT/Elect RCT|Eligible for regular chemotherapy, elects and receives regular chemotherapy
3107087|NCT01843985||2. Eligible RCT/Elect LDC|Eligible for regular chemotherapy, elects and receives low-dose chemotherapy
3107088|NCT01843985||3. Eligible RCT/Elect PCO|Eligible for regular chemotherapy, elects and receives palliative care only
3107089|NCT01843985||4. Ineligible RCT/Elect LDC|Ineligible for regular chemotherapy, elects and receives low-dose chemotherapy
3107090|NCT01843985||5. Ineligible RCT/Elect PCO|Ineligible for regular chemotherapy, elects and receives palliative care only
3107091|NCT01843972|Experimental|BI 691751 dose 2 (part I)|single dose given as oral solution
3107092|NCT01843972|Experimental|BI 691751 dose 3 (part I)|single dose given as oral solution
3107093|NCT01843972|Experimental|BI 691751 dose 4 (part I)|single dose given as oral solution
3107094|NCT01843972|Experimental|BI 691751 dose 5 (part I)|single dose given as oral solution
3107095|NCT01843972|Experimental|BI 691751 dose 6 (part I)|single dose given as oral solution
3107096|NCT01843972|Experimental|BI 691751 dose 7 (part I)|single dose given as oral solution
3107097|NCT01843972|Experimental|BI 691751dose 1 (part I)|single dose given as oral solution
3107098|NCT01843972|Placebo Comparator|Placebo (part I)|placebo solution
3107099|NCT01843972|Experimental|BI 691751 tablet (part II)|single dose given as 1 tablet
3107100|NCT01843972|Active Comparator|BI 691751 solution (part II)|single dose given as oral solution
3107193|NCT01843231|Experimental|g-Cath EZ Treatment Group|Evaluate the safety and effectiveness of the g-CathTM EZ Suture Anchor Delivery Catheter as an early weight loss intervention
3107101|NCT01843959||Emirati Population|"The individuals enrolled in this study will be divided into children (5-16 years of age) and adults (above 18). The groups will be further divided into BMI categories and glucose tolerance groups.~* Group 1: Underweight (adjusted BMI <10th percentile) and no diabetes~Group 2:~Normal weight (adjusted BMI 10th to 84.9th percentile) and no diabetes~Group 3:~Overweight or obese children (adjusted BMI >= 85th percentile) and no diabetes~Group 4:~Normal weight (adjusted BMI 10th to 84.9th percentile) and T1DM~Group 5:~Overweight or obese children (adjusted BMI ≥ 85th percentile) and T1DM~Group 6:~Normal weight (adjusted BMI 10th to 84.9th percentile) and T2DM~Group 7:~Overweight or obese children (adjusted BMI ≥ 85th percentile) and T2DM"
3107102|NCT01843933|No Intervention|Standard monitoring and blinded to capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion will be used to collect and record data but staff will be blinded to the monitor output.
3107103|NCT01843933|Active Comparator|Capnography|Capnography will be added to standard monitoring practices. A portable capnography monitor (Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion) will be used to collect and record data.
3107104|NCT01843920|Active Comparator|Post surgery without glaucoma drops|This will be for the group that had gas duration surgery using SF6 (Sulfur Hexafluoride) or C3F8 (perfluoropropane gas tamponade) and only uses the standard post-operative topical drops.
3107105|NCT01843920|Experimental|Post surgery with glaucoma drops|This will be for the group that had gas duration surgery (using SF6 or C3F8). In addition to the standard post-operative topical drops, glaucoma drops, Timolol-dorzolamide (timolol 0.5%-dorzolamide 2%) will be given.
3107106|NCT01843907|Other|Empowerment|Patients in the intervention group 1 receive a communication report which will also be sent to the physician and home care. In communication report includes the results and interpretation and explanation of the measurements in layman's terms. The report also includes relevant and targeted information on pain management, depression among the elderly, dementia and disability in old age and ways to maintain and improve functional capacity. Links and addresses of relevant, local organizations, and networks are also included. The information material is also included in the report sent to the General Practitioner (GP) and home care.
3107107|NCT01843907|Other|Conversation with Nurse|"Patients in the intervention group 2 gets clarification and follow-up conversation with a nurse anchored in both medical department and municipalities. The nurse is blinded in relation to the patient's screening results. Problems identified in connection therewith are communicated to the GP and home care."
3107108|NCT01843907|No Intervention|Controle Group|Patients in the control group are undergoing the same measurements and records at discharge, as the intervention group, but are otherwise receiving treatment and care as usual without further intervention.
3107109|NCT01843894|Placebo Comparator|placebo|In Stage I, each patient will instill 1 drop of placebo into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
3107110|NCT01843894|Experimental|RU-101|In Stage I, each patient will instill 1 drop of RU-101 ophthalmic solution (5%, 10%, or 15%) into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop of RU-101 ophthalmic solution (selected dose from Stage I) into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
3107111|NCT01843881|Experimental|Exendin 9, 39|Exendin 9, 39 will be infused at 300pmol/kg/min in either first intervention period or second intervention period.
3107112|NCT01843881|Placebo Comparator|Placebo|A saline infusion will be administered in either first intervention period or second intervention period.
3107113|NCT01843868|Other|R-CHOP and standard anti-emetics|"This is a single arm study.~All patients receive R-CHOP every 14 or 21 days for a minimum of 3 cycles. Standard anti-emetics will be used as follows:~5HT3 (5-Hydroxytryptamine 3) antagonists (ondansetron, granisetron or tropisetron) used as the local institutional standard of care will be permitted, although the preferential use of ondansetron or granisetron will be encouraged.~Dexamethasone will not to be used as patients receive hydrocortisone and oral prednisolone in R-CHOP. In this study, the use of oral prednisolone on day 1 will be regarded as equivalent to dexamethasone. Prednisolone will be given PRIOR to the chemotherapy with the 5HT3 antagonist.~Anti-emetics (metoclopramide, prochlorperazine and lorazepam) may be prescribed to be used 'as needed' for breakthrough emesis.~Patients 'failing' the standard Chemotherapy Induced Nausea and Vomiting prophylactic regimen will be eligible to receive aprepitant (Days 1 to 3) for subsequent cycles."
3107114|NCT01843855|Experimental|Exendin 9,39|Subjects randomized to this arm will receive an infusion of exendin 9,39 of 300mmol/kg/min for 360 minutes.
3107115|NCT01843855|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a saline infusion for 360 minutes.
3107116|NCT01843842|Experimental|Ergoferon (5 ml 3 times a day)|
3107117|NCT01843842|Placebo Comparator|Placebo (5 ml 3 times a day)|
3107118|NCT01843829|Experimental|Carboplatin and Paclitaxel Arm|"2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)~then CRT: Paclitaxel 50mg/m2 Days 1,8,15,22,29 (IV infusion); Carboplatin AUC 2 Days 1,8,15,22,29 (IV infusion) XRT: 45 Gy in 25 fractions~then surgery.~All drugs will be sourced from local stock"
3107119|NCT01843829|Experimental|Oxaliplatin and Capecitabine Arm|"2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)~then CRT: Oxaliplatin 85mg/m2 Days 1, 15, 29 (IV infusion); Capecitabine 625mg/m2 bd (oral) only on days when receiving RT XRT: 45 Gy in 25 fractions*~then surgery.~All drugs will be sourced from local stock"
3107120|NCT01843816||healthy subjects|18-65 aged healthy subjects who have no disorder that may disturb posture or erect position (inflammatory diseases, kyphosis, scoliosis, joint deformities)
3107121|NCT01843803|Experimental|patient inventory|prior to the encounter with his/her provider, the patient completes an inventory that includes information about patient contextual factors (e.g., life circumstances), resources and preferences for care delivery
3107122|NCT01843803|Active Comparator|attention control|prior to the encounter, the patient will view a brief video containing general health information.
3107123|NCT01843790|Placebo Comparator|Placebo, saline|Saline, dosed weekly for 8 weeks
3107124|NCT01843790|Experimental|GCS-100 low dose|Low dose of GCS-100 given IV once per week for 8 weeks
3107125|NCT01843790|Experimental|GCS-100 high dose|High dose of GCS-100 given IV once per week for 8 weeks
3107126|NCT01843777|Active Comparator|Standard-of-Care|"The standard-of-care control group will review and practice with the audiologist content such as: 1) information on hearing-aid batteries and how to change them, 2) cleaning/daily care of the hearing aids, and 3) inserting and removing the hearing aids."
3107127|NCT01843777|Experimental|Treatment|The treatment group, on the other hand, will use a motivational tool (exploring importance) in a manner that is consistent with the spirit of motivational interviewing.
3107128|NCT01843764||children with malaria|Tanzanian children between 6-59 months with an uncomplicated P.falciparum monoinfection, followed after arthemeter-lumefantrine treatment according to national treatment guidelines
3107129|NCT01843751|Active Comparator|Physician Office|Buprenorphine/naloxone via physician office (B-PO) x 10 months
3107130|NCT01843751|Experimental|Specialist Center|Buprenorphine/naloxone via specialist center (B-SC) x 3 months followed by B-PO x 7 months. The specialist center in this trial will be a methadone clinic.
3107131|NCT01843738|Experimental|All participants|
3107132|NCT01843725|Experimental|Metronomic arm|capecitabine 1100 to 1600 mg/m2/day orally in association with aflibercept 6mg/kg intravenous every 3 weeks
3107133|NCT01843725|Experimental|Intermittent arm|capecitabine 1700 to 2500 mg/m2/day orally 2 weeks out of 3 and aflibercept 6mg/kg intravenous every 3 weeks
3107134|NCT01843699|Experimental|Topiramate|A 12-week topiramate flexible dose administration plus 4 sessions of a manualized cognitive restructuring intervention.
3107135|NCT01843699|Placebo Comparator|Placebo|A 12-week placebo matching tablets plus 4 sessions of a manualized cognitive restructuring intervention.
3107136|NCT01843686|Experimental|Autologous Platelet Rich Plasma (PRP)|Magellan Autologous Platelet Separator used to extract Platelet Rich Plasma from autologous whole blood. PRP is mixed with calcified thrombin to create a gel, which is place on the excised wound bed prior to application of split thickness autograft.
3107137|NCT01843686|Placebo Comparator|Saline Gel, Standard of Care|Normlgel Saline is placed on the excised wound bed prior to application of split thickness autograft.
3107138|NCT01843673|Experimental|in-room imaging systems|Patients undergo FBCT once before treatment and once weekly for a total of 6-7 scans, dual CBCT up to 5 times weekly for a total of 33-35 scans, 2-D x-ray with Varian kV OBI 5 times weekly for a total of 33-35 scans, 2-D x-ray with Brain Lab ExacTrac 5 times weekly for a total of 33-35 scans, 2-D x-ray with Varian MV OBI once weekly for a total of 6-7 scans, and EPID imaging up to 5 times weekly for a total of 33-35 scans while undergoing IGART.
3107139|NCT01843660|Experimental|Tramadol Hydrochloride (HCl)-Paracetamol|
3107140|NCT01843647|Experimental|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.
3107141|NCT01843647|Active Comparator|Chemotherapy|Patients receive 8-week icotinib induction treatment before surgery and 4-cycle adjuvant chemotherapy with vinorelbine/cisplatin regimen after surgery.
3107142|NCT01843634|Experimental|ODSH|
3107143|NCT01843621|Experimental|Total vaccinated|The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003
3107144|NCT01843608|No Intervention|Control Group|"Patients in this group will be asked to maintain the same activity level until the baseline assessments.~They cannot change physical activity and nutritional habits."
3107145|NCT01843608|Experimental|Physical Intervention Group|"They have to perform two days per week of guide and planned exercise during three months. All classes are composed by different parts: aerobic exercise, to improve cardiovascular capacity, strength, to work muscle mass and flexibility to increase joint movements.~They have to present an attendance above or equal to 80%."
3107146|NCT01843595|Experimental|REFIT Intervention|This arm will receive the REFIT intervention immediately after randomization.
3107147|NCT01843595|No Intervention|Wait-list control|This arm will receive a modified version of the REFIT program after the 6-month assessment.
3107148|NCT01843569|Experimental|IVM|All patients registered in this study will undergo natural cycle IVF with In Vitro maturation (IVM) performed on all immature retrieved oocytes.
3107149|NCT01843556|Experimental|E2022 Tape Formulation|
3107150|NCT01843543|Experimental|MBSR participants|Subjects in this arm will participate in an 8 week Mindfulness Based Stress Reduction Course
3107151|NCT01843543|No Intervention|No MBSR Participants|Subjects in this arm will not participate in the Mindfulness Based Stress Reduction Course.
3107152|NCT01843530|Experimental|Group 1|Cortisone, Clemastin + BERINERT
3107153|NCT01843530|Placebo Comparator|Group 2|Cortinsone, Clemastin + NaCl
3107154|NCT01843517||endogenous pain facilitation|Pain facilitation is studied by a simple test of applying over the counter capsaicin cream to the skin for only 30 min, then removing it and heating the skin to a non-noxious temperature.
3107155|NCT01843517||endogenous pain inhibition|Pain inhibition is studied by a simple test of mild pain on one area of the body reducing response to a pain stimulus in another area.
3107156|NCT01843504|Active Comparator|Platelet Rich Plasma|Subjects in Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous platelet-rich plasma at week 0 (baseline).
3107157|NCT01843504|Placebo Comparator|Group 2|Subjects in Group 2 (saline control) will receive a single injection of 5 mL 0.9% normal saline at week 0.
3107158|NCT01843491|Experimental|Ad-PfCA|Single injection of Ad-PfCA containing 2 x 10^10 pu total dose in 1 ml of Final Formulation Buffer by intramuscular injection
3107159|NCT01843478|Experimental|HPV Self-Collection|The intervention is a self-collected HPV test, followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
3107160|NCT01843478|Placebo Comparator|Usual Care|In the usual care arm, women do not receive the HPV test. They are encouraged to have Pap testing. In addition, there is a phone call as an attention control, where women are reminded to make a Pap test appointment about 2-3 weeks after the baseline visit.
3107161|NCT01843465||Cryoablation of atrial fibrillation|
3107192|NCT01843257||No bariatric surgery control|"Control group of women with age and BMI similar to those in the cross-sectional arm of the study who have not undergone bariatric surgery.~Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery."
3107198|NCT01843192||VATS for suspected or confirmed NSCLC|Single arm study
3107162|NCT01843452|Experimental|Capecitabine, mitomycin, panitumumab and radiotherapy|"RADIOTHERAPY: daily fraction dose of 1.8Gy , 5 days a week between day 1 and 45 Intensity modulated radiotherapy (IMRT), using a linac based facility or helical tomotherapy, is obligatory.~The first treatment sequence consists of a total dose of 36 Gy in 20 daily fractions of 1.8 Gy on five days a week.~The second treatment sequence consists of a total dose of 23.4 Gy in 13 daily fractions of 1.8 Gy on five days a week.~PANITUMUMAB: 6 mg/kg IV over 60 min infusion on days 1, 15 and 29~MITOMYCIN: 10 mg/m2 IV over 15 min infusion on days 1 and 29~CAPECITABINE: 825 mg/m2 oral twice daily on days 1 to 45"
3107163|NCT01843439|Experimental|Intervention|"We designed a intervention study to correct additional risk factors in elderly asthma patients.~We offer following specific interventions simultaneously to intervention arm and will measure the effects of interventions after 1 years.~popularize and educate the asthma action plan~run a emergency call system for acute exacerbation~educate the proper techniques using inhalers~correct the deficiency of magnesium (magnesium 500mg per day)"
3107164|NCT01843426|Experimental|Low-volume, Low-concentration contrast (Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
3107165|NCT01843413|Experimental|Treatment (SRS)|Patients undergo SRS guided by CT and MRI.
3107166|NCT01843400||Group 1|
3107167|NCT01843387|Experimental|Cohort 1|Mesenchymal Precursor Cells (MPCs) - Dose 1 or Placebo
3107168|NCT01843387|Experimental|Cohort 2|Mesenchymal Precursor Cells (MPCs) - Dose 2 or Placebo
3107169|NCT01843374|Experimental|Tremelimumab|Tremelimumab
3107170|NCT01843374|Placebo Comparator|Placebo|Placebo
3107171|NCT01843361||acute ischemic stroke|Determing cardiovascular risk factors or medication on clopidogrel response rates after an acute ischemic stroke
3107172|NCT01843348|Active Comparator|TAC+MPA|
3107173|NCT01843348|Experimental|TAC+Certican|
3107174|NCT01843348|Experimental|CycA+Certican|
3107175|NCT01843322|Experimental|navigation technology|custom made navigation technology integrated in a Siemens angiography suite for feasibility evaluation in endoleak repair procedure
3107176|NCT01843309|Experimental|Spironolactone 200mg|Spironolactone 100 mg twice a day orally
3107177|NCT01843309|Placebo Comparator|Placebo|Placebo twice a day orally
3107178|NCT01843309|Experimental|Spironolactone 100mg|Spironolactone 100mg once a day
3107179|NCT01843296|Active Comparator|Magnesium|Patients in group C received a premixed solution of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc) and 50 mg of magnesium sulfate 50% (0.1 ml) (Pasteur Institute Co, Tehran, Iran) for spinal anesthesia
3107180|NCT01843296|Active Comparator|Fentanyl|Patients in Fentanyl group received a premixed solution of of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc),plus 0.1 cc preservative free 0.9% normal saline for spinal anesthesia
3107181|NCT01843296|Active Comparator|Bupivacaine|Patients in Bupivacaine group(control) received a premixed solution of 15 mg of hyperbaric bupivacaine 0.5% (3 ml), plus 0.6 cc preservative free 0.9% normal saline for spinal anesthesia
3107182|NCT01843283|Experimental|Daily Enhancement Meaningful Activity (DEMA)|The group member will receive Self-management Toolkit and 6 bi-weekly individualized sessions, 2 face-to-face and 4 via telephone delivered by a trained intervener. DEMA will provide autonomy support by helping patients to identify and prioritize activities, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed.
3107183|NCT01843283|Active Comparator|Information Support (IS)|The IS group will receive 2 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer Association, educational brochure. Then they will receive 4 biweekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials.
3107184|NCT01843270|Experimental|ideal body weight|LMA size based on ideal body weight
3107185|NCT01843270|Experimental|actual body weight|LMA size according to actual body weight
3107186|NCT01843257||Gastric Bypass longitudinal|Morbidly obese subjects undergoing gastric bypass surgery. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
3107187|NCT01843257||Gastric Banding longitudinal|Morbidly obese subjects undergoing laparoscopic gastric banding surgery. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
3107188|NCT01843257||Gastric Bypass (cross-sectional)|Subjects who underwent gastric bypass surgery 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
3107189|NCT01843257||Gastric Banding (cross-sectional)|Subjects who underwent gastric banding surgery 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
3107190|NCT01843257||Sleeve gastrectomy (longitudinal)|Morbidly obese subjects who will undergo sleeve gastrectomy. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
3107191|NCT01843257||Sleeve gastrectomy (cross-sectional)|Subjects who underwent sleeve gastrectomy 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
3107194|NCT01843231|Active Comparator|Diet and exercise Control Group|Diet and Exercise only control group
3107199|NCT01843179|Experimental|Sulindac Treatment Arm|Induction Chemotherapy followed by treatment with sulindac
3107200|NCT01843166|Active Comparator|Treatment group|These patients will utilize a pessary and be given instructions for use and prescription for Premarin vaginal cream 2g at bedtime twice weekly.
3107201|NCT01843166|Placebo Comparator|Control group|These patients will utilize a pessary with an inactive placebo cream.
3107202|NCT01843153|Other|intermittent|injection of ropivacaine on demand
3107203|NCT01843153|Other|continuous|continuous ropivacaine infusion
3107204|NCT01843140||Young female cancer survivors|
3107205|NCT01843127|Active Comparator|Placebo, Ranolazine, Exenatide|
3107206|NCT01843127|Active Comparator|Ranolazine, Placebo, Exenatide|
3107207|NCT01843114|Other|Patients with Type I Diabetes|24 patients with type I diabetes with no or mild non-proliferative retinopathy
3107208|NCT01843114|Other|Healthy subjects|24 healthy age-and sex- matched control subjects
3107209|NCT01843101|Other|Healthy volunteers|10 healthy volunteers
3107210|NCT01843101|Other|Corneal Neovascularisation|5 patients with corneal neovascularisation
3107211|NCT01843101|Other|Keratoconus|5 patients with keratoconus
3107212|NCT01843088|Experimental|Mannitol cream|cream containing 25% mannitol, applied as often and as much as needed to one leg ( chosen at random), on the day of a 10 km run, following the run and for five days afterwards
3107213|NCT01843088|Placebo Comparator|Placebo cream|Same carrier cream as that containing the active ingredient, mannitol, but without the active ingredient. Placebo cream to be applied to the painful areas of the other leg, chosen at random, on the day of a 10 km or more race, following the race, and as needed for the five days after the race. It is to be noted that, as almost no mannitol is absorbed through the skin, it is highly unlikely that this would involve the pain levels in the placebo leg.
3107214|NCT01843075|Experimental|Liraglutide|Daily administration of 1.8 mg liraglutide by subcutaneous injection
3107215|NCT01843075|Placebo Comparator|Placebo|Daily administration of matched placebo by subcutaneous injection
3107216|NCT01843062|Experimental|Selumetinib|Selumetinib plus Radioactive Iodine Therapy
3107217|NCT01843062|Placebo Comparator|Placebo|Placebo plus Radioactive Iodine Therapy
3107218|NCT01843049|Experimental|radiotherapy+chemotherapy|"Radiotherapy:~LEVEL 1: dose given at PTV-G and PTV-C will be 64Gy/32 fractions and 50Gy/25 fractions.~LEVEL 2: dose given at PTV-G and PTV-C will be 63Gy/28 fractions and 50.4Gy/28 fractions.~LEVEL 3: dose given at PTV-GR (with an integrated boost to the 50% SUVmax area of the primary tumor of the pre-treatment 18FDG-PET/CT scan), PTV-G and PTV-C will be 70Gy/28 fractions, 63Gy/28 fractions and 50.4Gy/28 fractions.~LEVEL 4: dose given at PTV-GR (with an integrated boost to the 50% SUVmax area of the primary tumor of the pre-treatment 18FDG-PET/CT scan), PTV-G and PTV-C will be 70Gy/25 fractions, 62.5Gy/25 fractions and 50Gy/25 fractions.~Chemotherapy:~Concurrent chemotherapy: Cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24 hours daily on Days 1-4 and 29-32.~Consolidation chemotherapy: Cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks for 2 cycles."
3107219|NCT01843036|Experimental|Durham Connects Eligible|From January 1, 2014 - June 30, 2014, all odd-birth-date residential births in Durham County, North Carolina will be randomly assigned to receive the Durham Connects nurse home visiting program.
3107220|NCT01843036|No Intervention|Control|From January 1, 2014 - June 30, 2014, all even-birth-date residential births in Durham County, North Carolina will be randomly assigned to a control group condition. These families will be assigned to receive services as usual and serve as the randomized comparison group for evaluating Durham Connects program impact.
3107221|NCT01843023|Experimental|Extended Release Naltrexone|Participants randomly assigned to XR-NTX who do not have opioid withdrawal signs or symptoms within 4 hours of administration of the 25 mg oral dose naltrexone will be given an intramuscular injection of XR-NTX [Vivitrol®] at a dose of 4cc (380mg of naltrexone)] and will subsequently have the same dose administered to alternating sides of the buttocks every four weeks for up to 6 months. All participants will also receive psychosocial treatment.
3107222|NCT01843023|Active Comparator|Treatment as Usual|Participants randomly assigned to TAU will participate in the standard youth opioid program at the treatment center which includes either buprenorphine taper or ongoing buprenorphine treatment during the 6 months of the study for as long as they and their physicians think is appropriate. The general target dose will be 12-20 mg buprenorphine per day. All participants in TAU will receive psychosocial treatment.
3107223|NCT01843010|Active Comparator|Parecoxib|Intravenously Parecoxib 40mg at 30min before intubation, 8h and 20h after surgery.
3107224|NCT01843010|Placebo Comparator|Placebo|Normal saline 5ml will be intravenously infused at the same time points., respectively.
3107225|NCT01842997|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg made by Shanghai Institute of Biological Products lot number: 200909008
3107226|NCT01842984|Experimental|I-SOCIAL intervention|Participants in this group will have up to 10 personal meetings with activities counselors and several group meetings.
3107227|NCT01842984|No Intervention|Control group|Participants in this group will not have meetings with the activities counselors, and will not take part in the group meetings.
3107228|NCT01842971|Experimental|two stage hepatectomy|the two stage hepatectomy is defined as a two step procedure: first step: hepatotomy with ligature of the right branch of the portal vein second step (one week after the first step): right hepatectomy
3107229|NCT01842958|Active Comparator|4.1 mm implant diameter|Placement of a Straumann Bone Level Implants, 4.1 mm implant diameter, for single tooth replacement in the anterior and pre-molar region
3107230|NCT01842958|Experimental|3.3 mm implant diameter|Placement of a Straumann Bone Level Implants, 3.3 mm implant diameter, for single tooth replacement in the anterior and pre-molar region
3107231|NCT01842945|No Intervention|Wait-list control|
3107232|NCT01842945|Experimental|Treatment with therapist contact|
3107233|NCT01842945|Experimental|Treatment without therapist contact|
3107234|NCT01842932|Experimental|Phloroglucin & Placebo|Phloroglucin 20ml before examination & Placebo 1ml before examination
3107235|NCT01842932|Experimental|Cimetropium bromide & Placebo|Cimetropium bromide 1ml before examination & Placebo 20ml before examination
3107357|NCT01841892|No Intervention|Usual Care Control|
3107236|NCT01842919|Other|Huntington patient|This group will perform Magnetic Resonance Imaging (MRI), kinesthetic test and psychological questionnaires before and after 8 months of dance lessons
3107237|NCT01842919|Other|Assisting Person|This group will perform MRI, kinesthetic test and psychological questionnaires before and after 8 months of dance lessons
3107238|NCT01842919|Other|Pilot subject|Healthy volunteers to set up the kinesthetic test
3107239|NCT01842906|Experimental|Theravent|A singe use, disposable, positive end expiratory pressure device worn over the nostrils while sleeping.
3107240|NCT01842906|Sham Comparator|Control|A visibly identical sham device that does not provide positive end expiratory pressure.
3107241|NCT01842893|Experimental|Fentanyl / Placebo|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
3107242|NCT01842880||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
3107243|NCT01842867||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
3107244|NCT01842854||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
3107245|NCT01842841|Experimental|velaglucerase alfa|15 to 60 U/kg, EOW via intravenous infusion
3107246|NCT01842828|Active Comparator|Standard care plus electronic cigarettes|Standard care for smoking cessation plus electronic cigarettes
3107247|NCT01842828|Other|Standard care|Standard care for smoking cessation
3107248|NCT01842815|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser for Treatment of unwanted, non cosmetic tattoos
3107249|NCT01842802|Experimental|Diode Laser Treatment Before Abdominoplasty|Patient will be treated with Diode Laser prior to abdominoplasty.
3107250|NCT01842802|Experimental|YAG Laser Treatment Before Abdominoplasty|Patients will be treated with YAG prior to abdominoplasty
3107251|NCT01842789|Other|Acessa Procedure w/o TAG|Acessa Procedure without the use of Targeting Animation Guidance
3107252|NCT01842789|Other|Acessa Procedure with TAG|Acessa Procedure with Targeting Animation Guidance
3107253|NCT01842750|Experimental|Endorectal Balloon insertion|A cone Beam scan will be performed prior to balloon insertion and then again with balloon in situ. The scans will be compared to see if the organs are stabilised. Questionnaires will be completed by the radiographer and the patient.
3107254|NCT01842737|Experimental|Spinal Treatment|Participant receives High Velocity Low Amplitude Spinal Manipulation (HVLA) to the low back only from a doctor of chiropractic. Also receives focused palpation procedures to the low back paired with visual input of these procedures using a tablet computer. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. The doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
3107255|NCT01842737|Active Comparator|Foot Massage|The doctor of chiropractic will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
3107256|NCT01842724|Active Comparator|Motec total wrist arthroplasty|
3107257|NCT01842724|Active Comparator|Remotion total wrist arthroplasty|
3107258|NCT01842698|Experimental|ultrasoundguided paravertebral catheter|ultrasoundguided paravertebral catheter
3107259|NCT01842685|Experimental|Bladder Thermal Distention|Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using a specific 3 ways catheter. The procedure will last 1 hour. Saline will be irrigated by the PelvixTT system.
3107260|NCT01842672|Experimental|Mitoxantrone/Clofarabine|Clofarabine Dose escalation starting 20 mg/m2/d days 1-5 Mitoxantrone 12 mg/m2/d days 3-6. Rituximab in patient with CD20+ disease only 375 mg/m2 day 1, 8, 15. IT Depocyt 35 or 50 mg/dose day 1 per cycle. IT ARA-C in children < 3 years age based dosing.
3107261|NCT01842659|Experimental|Pregnant women requiring amniocentesis|Pregnant women requiring amniocentesis
3107262|NCT01842646|Experimental|PF-04449913 Treatment|Treatment will be administered on an outpatient basis. All patients will be treated with an oral dose PF-04449913 at 100 mg daily in 4-week cycles for a total of 4 cycles. Patients who demonstrate no evidence of progressive disease (i.e. stable disease or better) may continue on treatment until disease progression or loss of response, limiting toxicity, or death.
3107263|NCT01842633|Experimental|Paracetamol/ Caffeine Caplets|Two caplets of paracetamol/caffeine combination plus 2 placebo caplets to be administered
3107264|NCT01842633|Active Comparator|Ibuprofen Caplets|Two ibuprofen caplets plus two placebo caplets to be administered
3107265|NCT01842633|Placebo Comparator|Placebo Caplets|Four placebo caplets to be administered
3107266|NCT01842620|Experimental|OXEMET 1000 mg coated tablets|Generic undergoing bioequivalence study against reference
3107267|NCT01842620|Active Comparator|GLAFORNIL 500 mg tablets|Reference drug for bioequivalence study
3107268|NCT01842607|Experimental|Mepolizumab Arm|Subjects will receive 100 mg of Mepolizumab (in polypropylene syringe) injected subcutaneously (SC) once every 4 weeks for 12 months
3107269|NCT01842594|Experimental|Sirolimus and hydroxychloroquine|Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally once daily(QD) for 2 cycles . Each treatment cycle is 28 days.
3107270|NCT01842581|Experimental|Rifaximin|550 mg tablet BID
3107271|NCT01842581|Experimental|Rifaximin and Lactulose|Rifaximin 550 mg tablet BID plus lactulose
3107272|NCT01842555||PDT registry patients|Any newly diagnosed lung or esophageal cancer that is being being treated with PDT at a participating institution.
3107273|NCT01842542|Experimental|Transcranial Magnetic Stimulation (TMS)|"Patients will receive NeuroStar Transcranial Magnetic Stimulation (TMS) therapy treatments 5 times a week for up to 8 weeks during the acute phase, 3 times during the first week, 2 times during the second week and 1 time during the third week of the taper phase.~Efficacy Assessments will be conducted throughout the acute and taper phase at protocol specific timepoints."
3107715|NCT01839383|Active Comparator|DCa1.75|using dialysate calcium concentration 1.75mmol/L
3107274|NCT01842529|Active Comparator|CABG+ Botulinum toxin|All patients underwent conventional CABG. After the main stage of the surgery botulinum toxin (Xeomin, incobotulinumtoxin A, Merz Pharma GmbH & Co KGaA, Germany; 50 U/1 mL at each fat pad; botulinum toxin group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
3107275|NCT01842529|Active Comparator|Control|All patients underwent conventional CABG. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad; placebo group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
3107276|NCT01842516|Experimental|LCB01-0371 800mg|LCB01-0371 800mg
3107277|NCT01842516|Experimental|LCB01-0371 1200mg|LCB01-0371 1200mg
3107278|NCT01842516|Placebo Comparator|Placebo|Placebo
3107279|NCT01842503|Active Comparator|GET 73|300 mg (3 capsules) tid for 3 days
3107280|NCT01842503|Placebo Comparator|inactive ingredients capsule|3 capsules tid for 3 days
3107281|NCT01842477|Experimental|Implantation surgery|All the patients will have the implantation surgery. This trial is a one-arm study.
3107282|NCT01842464||Anterior Sacro-Spinous Support|Anterior sacro-spinous mesh implants supported patients
3107283|NCT01842451|Experimental|VX-135 High Dose with Daclatasvir|12 weeks of a high dose of VX-135 in combination with Daclatasvir
3107284|NCT01842451|Experimental|VX-135 Low Dose with Daclatasvir|12 weeks of a low dose of VX-135 in combination with Daclatasvir
3107285|NCT01842438|Experimental|Behavioral: psychosexual intervention|6-sessions of couple support focused on relationships and psychosexual functioning
3107286|NCT01842438|No Intervention|Control|This group will not receive the intervention during the life-span of the project
3107287|NCT01842412||claudication|
3107288|NCT01842412||healthy|
3107289|NCT01842399|Placebo Comparator|Experimental 1|2x/day orally
3107290|NCT01842399|Experimental|Experimental 2|75 mg, 2x/day, orally
3107291|NCT01842399|Experimental|Experimental 3|150 mg, 2x/day, orally
3107292|NCT01842386|Experimental|Single|This is a Phase 1, single-arm, open label study.
3107293|NCT01842373|Experimental|LMX4|3 g of LMX4 will be applied to one half of the face for 60 minutes
3107294|NCT01842373|Active Comparator|BLT|3 g of BLT will be applied to half of face for 60 minutes
3107295|NCT01842360|Experimental|MV130|The subjects will receive daily dose of MV130 during 12 months
3107296|NCT01842360|Placebo Comparator|Placebo|The subjects will receive daily dose of placebo during 12 months
3107297|NCT01842347|Experimental|Pediatrics, C. Diff.|Fecal Microbiota Transplantation in children with c. difficile infection
3107298|NCT01842334|Experimental|D-cycloserine|250 mg D-cycloserine once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy.
3107299|NCT01842334|Placebo Comparator|Placebo|one placebo capsule once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy
3107300|NCT01842321|Experimental|Abiraterone Acetate|
3107301|NCT01842308|Experimental|Treatment|"CONDITIONING: Patients receive carfilzomib IV over 30 minutes on days -6, -5, -2, and -1. Patients also receive melphalan IV over 1 hour on days -4 and -3.~TRANSPLANT: Patients undergo autologous stem cell transplant on day 0."
3107302|NCT01842295|No Intervention|Bariatric surgery|Obese men with associated co-morbidities selected for bariatric surgery by multidisciplinary team
3107303|NCT01842282|Experimental|Amlexanox|
3107304|NCT01842269|Experimental|My-Rept® Tablet|My-Rept® Tablet, Mycophenolate Mofetil 500mg, orally
3107305|NCT01842269|Active Comparator|My-Rept® Capsule|My-Rept® Capsule, Mycophenolate Mofetil 250mg, orally
3107306|NCT01842256|Experimental|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|
3107307|NCT01842256|Active Comparator|Atorvastatin 40mg|
3107308|NCT01842243|Active Comparator|Apical Pacing|Pacemaker programmed to pacing the heart at apex for 9 months.
3107309|NCT01842243|Active Comparator|Septal Pacing|Pacemaker programmed to pacing the heart at the septum for 9 months.
3107310|NCT01842230|Experimental|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|
3107311|NCT01842230|Active Comparator|Telmisartan 80mg and S-amlodipine 5mg|
3107312|NCT01842217|Other|Premenopausal women|healthy female subjects: premenopausal
3107313|NCT01842217|Other|Postmenopausal women|healthy female subjects: postmenopausal
3107314|NCT01842204|Experimental|active kit|Patient receives an active kit with pulsed electromagnetic field over wound surface area.
3107315|NCT01842204|Placebo Comparator|non-active kit|Patient receives a non-active kit.
3107316|NCT01842191|Experimental|Fish oil|
3107317|NCT01842191|Placebo Comparator|Placebo|
3107318|NCT01842178|Experimental|scratching|"Patients will have an endometrial injury done on purpose, between 18-24 days prior to IVF cycle with a transfer catheter on the surgery outpatient department.~Endometrial Injury~Done between 18-24 days prior to embryo transfer cycle.~Using transfer catheter.~Introduction of the same to the uterine fundus.~Systematic scrapping of the four uterine walls, lengthwise.~Performed by a skilled doctor.~Subsequent ultrasound control"
3107319|NCT01842178|Placebo Comparator|scratching simulation|Patients will come to control visit between day 18-24. A scratching simulation will be done.
3107358|NCT01841892|Experimental|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
3107320|NCT01842165|Other|177Lu-octreotate therapy|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
3107321|NCT01842139|Experimental|Arm A (vaccine with Montanide)|Patients receive WT1 126-134 peptide vaccine emulsified in Montanide ISA 51 VG SC on day 0 and then once every 2 weeks.
3107322|NCT01842139|Experimental|Arm B (vaccine with poly-ICLC)|Patients receive WT1 126-134 peptide vaccine in poly-ICLC SC on day 0 and then once every 2 weeks.
3107323|NCT01842139|Experimental|Arm C (vaccine therapy, monoclonal antibody)|Patients assigned to Arm C receive basiliximab IV over 30 minutes on day -7 and WT1 126-134 peptide vaccine as in Arm A or Arm B, whichever had a superior cellular immune response.
3107324|NCT01842126|Experimental|Single Ascending Dose (SAD): BG00010|Up to five cohorts of healthy volunteers will receive a single dose of intravenous (IV) BG00010 followed by a single SC dose of BG00010 2 weeks apart.
3107325|NCT01842126|Experimental|SAD: Placebo|Up to five cohorts of healthy volunteers will receive a single IV dose of placebo followed by a single SC dose of placebo 2 weeks apart.
3107326|NCT01842126|Experimental|Multiple Ascending Dose (MAD): BG00010|Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of BG00010.
3107327|NCT01842126|Experimental|Multiple Ascending Dose (MAD): Placebo|Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of placebo.
3107328|NCT01842113|Active Comparator|Lactulose and Rifaximin Placebo|Standard portal hypertension care, standard nutritional advice, Lactulose 30ml three times a day and Rifaximin (Xifaxan) Placebo twice a day.
3107329|NCT01842113|Active Comparator|Rifaximin and Lactulose Placebo|Rifaximin (Xifaxan) twice a day and Lactulose Placebo three times a day.
3107330|NCT01842100|Active Comparator|Universal antibiotic prophylaxis|In the universal prophylaxis group, all women received doxycycline 100 mg twice daily for 7 days starting on the day of induced abortion. Screening for sexually transmitted diseases was done as baseline but the results were not revealed to the patients.
3107331|NCT01842100|Active Comparator|Screen-and-treat|In the screen-and-treat group, the results of screening for sexually transmitted infections (STI) were revealed to the patients. They would only receive appropriate specific antibiotics treatment only if they were screened positive for any of the STIs. If they were found to have STI, their sexual partners would also be referred to the local social hygiene clinics for contact tracing and treatment. Contraception by barrier methods would also be advised.
3107332|NCT01842087|Placebo Comparator|Control Foods|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
3107333|NCT01842087|Experimental|Fiber Fortified Foods|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
3107334|NCT01842074|Experimental|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
3107335|NCT01842061|Experimental|Active Living Program|Participants in the intervention group will receive a self-management program designed to reduce sedentary behaviour and increase physical activity. Specifically, they will be given an EASY Program Manual with strategies to break up sitting time during the day and increase utilitarian activity; this will include a section on how to set, monitor and maintain achievable goals. They will also be offered a pedometer program, group education sessions and encouraged to use public transport by providing free bus tickets.
3107336|NCT01842061|Active Comparator|Education|Control group participants will be offered monthly drop-in sessions that target information on general health and well-being unrelated to physical activity.
3107337|NCT01842048|Experimental|External-beam radiotherapy combine hyperthermia|Hyperthermia 42℃ ± 0.5℃ for 40min, 2 times/week within 2hr after irradiation. Radiation protocol are 3Gy 5 times a week for a total of 30Gy/10fx/2 weeks
3107338|NCT01842048|Active Comparator|External-beam radiotherapy alone|External-beam radiotherapy alone comprising 30Gy/10 fractions, 5 times a week, administered with 2 weeks.
3107339|NCT01842035|Experimental|Regadenoson|Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.
3107340|NCT01842022|Other|Better glucose tolerance|Take meals with isomaltulose, sucrose or glucose
3107341|NCT01842022|Other|Better glucose tolerance / Levels fall|Take meals with isomaltulose, sucrose or glucose
3107342|NCT01842022|Other|Poorer tolerance levels remain high|Take meals with isomaltulose, sucrose or glucose
3107343|NCT01842022|Other|Poorer glucose tolerance / Levels fall|Take meals with isomaltulose, sucrose or glucose
3107344|NCT01842009|Experimental|Active anodal HD-tDCS|Subjects will undergo 20 minutes active HD-tDCS.
3107345|NCT01841996|Experimental|ME1111 solution|
3107346|NCT01841996|Placebo Comparator|Vehicle Solution|
3107347|NCT01841983|Experimental|Intervention|Be Well Work Well
3107348|NCT01841983|No Intervention|Control|No intervention
3107349|NCT01841970|Other|HET Arm|Active arm. A single procedure with HET was used to treat Grade I and Grade II hemorrhoids
3107350|NCT01841957|Experimental|ISBCS|Immediate Simultaneous Bilateral Cataract Surgery
3107351|NCT01841957|Active Comparator|DSBCS|Delayed Sequential Bilateral Cataract Surgery
3107352|NCT01841944|Active Comparator|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
3107353|NCT01841944|Placebo Comparator|Corn oil|3x capsules of corn oil pr day
3107354|NCT01841918|Experimental|A/17/turkey/Turkey/05/133 (H5N2)|100 participants will be admitted in the isolation ward for 5 days after each immunization mainly for safety assessment. Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
3107355|NCT01841918|Placebo Comparator|Placebo|50 participants will be admitted in the isolation ward for 5 days after each administered placebo mainly for safety assessment. Two doses placebo will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
3107356|NCT01841905||Observational Study|Pre-Symptomatic Alzheimers' Disease
3107359|NCT01841879|Experimental|Intervention Program|Receives the full Healthy, Safe, and Tobacco-Free Worksites intervention
3107360|NCT01841879|Other|Delayed Intervention Control|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
3107361|NCT01841866|Active Comparator|deep anesthetic state|LMA removal
3107362|NCT01841866|Placebo Comparator|awake|LMA removal
3107363|NCT01841853|Experimental|Senior meetings|The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting.The main purpose of the senior meetings is to give information and facilitate discussion of the ageing process and provide tools and suggest strategies to enable the clients to solve the various problems that may arise at home in order to remain living at home in a safe and secure way. The information will also include what the municipality provides in the form of local meeting places, activities run by local associations, physical training for seniors, walking groups, possibilities of offering or accepting help on a voluntary basis. Furthermore, they will be informed about help and support available in their city district. Identification of risks for, and advice on, how to prevent falls will also be included.
3107364|NCT01841853|No Intervention|Control group|The control group will receive conventional care on their own initiative.
3107365|NCT01841840|No Intervention|Control|This arm involves not implementing any form of intervention (passive vibration)on the subject during this visit.
3107366|NCT01841840|Experimental|Low-Frequency Pasive Vibration|This arm involves exposing the subject to a 10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude.
3107367|NCT01841840|Experimental|High-Frequency Passive Vibration|This arm involves exposing the subject to a 10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude.
3107368|NCT01841827|Active Comparator|Cilostazol|Capsule of Cilostazol 200 mg are taken orally on each study day
3107369|NCT01841827|Placebo Comparator|Placebo|A capsule of placebo containing starch are taken orally on each study day.
3107370|NCT01841814|Experimental|lymphoma|
3107371|NCT01841801|Active Comparator|Marketed Thermal Adhesive Patch|Group of subjects wearing comparative predicate device for 8 hours daily for 7 days.
3107372|NCT01841801|Experimental|Thermal Adhesive Patch|Group of subjects wearing the experimental patch for 8 hours daily for 7 days.
3107373|NCT01841801|Placebo Comparator|Placebo Patch|Group of subjects wearing the placebo patch for 8 hours daily for 7 days.
3107374|NCT01841788|Experimental|Thermal Adhesion Patch|Group of subjects wearing the experimental patch for 8 hour study duration
3107375|NCT01841788|Active Comparator|Marketed Thermal Adhesion Patch|Group of subjects wearing comparative predicate device for 8 hour study duration.
3107376|NCT01841788|Placebo Comparator|Placebo Patch|Group of subjects wearing the placebo patch for 8 hour study duration
3107377|NCT01841762|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily
3107378|NCT01841749|Other|Surgery|sentinel node biopsy and mastectomy
3107379|NCT01841736|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3107380|NCT01841736|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of progressive disease, patients may cross-over to Arm I.
3107381|NCT01841723|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3107382|NCT01841710||Women|
3107383|NCT01841697|Experimental|Omarigliptin 25 mg once weekly|Participants receive omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continue pre-study stable dose of metformin (total daily dose ≥1500 mg) throughout the study. Participants may receive glimepiride (total daily dose of 1-6 mg) as rescue therapy.
3107384|NCT01841697|Active Comparator|Sitagliptin 100 mg once daily|Participants receive sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continue pre-study stable dose of metformin (total daily dose ≥1500 mg) throughout the study. Participants may receive glimepiride (total daily dose of 1-6 mg) as rescue therapy.
3107385|NCT01841684|Experimental|Anacetrapib|Participants receive anacetrapib 100 mg orally once daily for 12 weeks.
3107386|NCT01841684|Placebo Comparator|Placebo|Participants receive placebo orally once daily for 12 weeks.
3107387|NCT01841671|Experimental|IPV/IPV/IPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, IPV, IPV at 8, 16 and 24 weeks of age respectively, Rotarix at 8 and 16 weeks if parents accept (optional), and mOPV type 2 at 28 weeks of age
3107388|NCT01841671|Active Comparator|IPV/IPV/bOPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, IPV, bOPV at 8, 16 and 24 weeks of age respectively and Rotarix at 8 and 16 weeks f age (optional) and mOPV type 2 at 28 weeks of age
3107389|NCT01841671|Active Comparator|IPV/bOPV/bOPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, bOPV, bOPV at 8, 16 and 24 weeks of age respectively and Rotarix at 8 and 16 weeks of age (optional)and mOPV type 2 at 28 weeks of age
3107390|NCT01841658|Experimental|Folic Acid Normal Weight|Folic acid, tablet, 800 mcg, daily, eight weeks. Normal Weight individuals, each will serve as her own control.
3107391|NCT01841658|Experimental|Folic acid Obese|Folic acid, tablet, 800 mcg, daily, eight weeks. Obese individuals, each will serve as her own control.
3107392|NCT01841645|Other|CLA depletion-repletion|
3107393|NCT01841632|Experimental|MultiStem|"Dose escalation~Cohort 1~Drug: MultiStem, Dose 1 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)~Cohort 2~Drug: MultiStem, Dose 2 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)~Cohort 3~Drug: MultiStem, Dose 3 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)~Cohort 4~Drug: MultiStem, Dose 4 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)"
3107394|NCT01841619|Active Comparator|IVIg as a monotherapy|IVIg will be used as a first line treatment. Topical treatment will be stopped at the beginning of IVIg therapy.
3107395|NCT01841606|Experimental|Ondansetron|4mg of IV ondansetron 5 minutes prior to initiation of spinal anesthesia
3107396|NCT01841606|Placebo Comparator|Placebo|10mL of IV normal saline 5 minutes prior to initiation of spinal anesthesia
3107397|NCT01841593|Experimental|Group A|DAYS 1 to 7: raltegravir 400 mg BID DAYS 8 to 14: raltegravir 400 mg BID PLUS amlodipine 5 mg OD DAYS 15 to 21: amlodipine 5 mg OD
3107398|NCT01841593|Experimental|Group B|DAYS 1 to 7: amlodipine 5 mg OD DAYS 8 to 14: raltegravir 400 mg BID PLUS amlodipine 5 mg OD DAYS 15 to 21: raltegravir 400 mg BID
3107399|NCT01841567|Other|dressing|
3107400|NCT01841554|Experimental|Single|
3107401|NCT01841541|Experimental|Ombda Locality: informal providers|"Ombda locality is located in Western Khartoum and populated with population size of 988,163.~Intervention: 380 unpaid Informal providers trained to recognise TB symptoms and to refer presumptive TB cases to formal health care facilities within the area."
3107402|NCT01841541|No Intervention|Jabal Awlia Locality|The control arm: A locality in south eastern site of Khartoum state populated with 942,429. No intervention took place
3107403|NCT01841528|Experimental|fresh embryo transfer group|rFSH/GnRH antagonist will be administered for ovarian stimulation. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
3107404|NCT01841528|Experimental|frozen-thawed embryo transfer group|rFSH/GnRH antagonist will be administered for ovarian stimulation. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with hormone replacement therapy (HRT) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
3107405|NCT01841515|Experimental|Desmopressin|Twenty five patients with chronic kidney disease and who were taking antiplatelet agents and needed an emergent catheter insertion for hemodialysis
3107406|NCT01841502|Active Comparator|paroxetine alone|paroxetine 20 mg tablet once daily oral
3107407|NCT01841502|Experimental|paroxetine + telaprevir|paroxetine 20 mg tablet once daily + telaprevir 1125 mg (3 tablets 375mg) twice daily oral
3107408|NCT01841489|Experimental|Sequence 1|
3107409|NCT01841489|Experimental|Sequence 2|
3107410|NCT01841489|Experimental|Sequence 3|
3107411|NCT01841489|Experimental|Sequence 4|
3107412|NCT01841476|Experimental|POL6326|2-hour single intravenous infusion doses of POL6326
3107413|NCT01841463|Experimental|P1446A-05|"The study will be conducted in two phases- Phase I ('Dose escalation' phase), and Extension phase:-~In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of three to six patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~In the 'Extension' phase, sixty patients with BRAF V600E/K mutations (forty patients naïve to selective BRAF inhibitor therapy, and twenty progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity"
3107414|NCT01841450|Experimental|iStent|Implantation of one iStent in conjunction with cataract surgery
3107415|NCT01841450|Active Comparator|Cataract surgery|Cataract surgery alone
3107416|NCT01841437||iStent|
3107417|NCT01841424|No Intervention|Control|Subjects receive usual care for pregnancy and postpartum.
3107418|NCT01841424|Experimental|Dietary Counseling and Food Diary|Dietary counseling before 16 weeks of pregnancy Maintain food diary during pregnancy
3107419|NCT01841411|Experimental|Metronidazole + N-Acetyl cysteine|the second patient group will use NAC sachets containing 200 mg as a vaginal douche once daily plus oral metronidazole 500 mg twice daily for 7 days
3107420|NCT01841411|Experimental|N- Acetyl cysteine|the third patient group will use NAC sachets containing 200 mg as a vaginal douche only without taking metronidazole
3107421|NCT01841411|Active Comparator|Metronidazole|the first group of patients will take oral metronidazole 500 mg twice daily for a week
3107422|NCT01841398|Active Comparator|Multimedia Lifestyle Improvement|Includes goal setting, self monitoring and participants will receive regular health messaging using electronic media regarding smoking, dietary habits & physical activity
3107423|NCT01841398|Placebo Comparator|Usual Care|Includes usual advice and no regular health messaging.
3107424|NCT01841385|Experimental|Pilates Group|"Sedentary volunteers, but that would begin activities with the Pilates method and evaluated in three months.~Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions.~For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load."
3107425|NCT01841385|No Intervention|Control Group|Sedentary volunteers and remain sedentary and evaluated in three months. The volunteers comprised the control group did not perform any physical activity during the study period.
3107426|NCT01841372|Active Comparator|Group Phone Conference Call|Group phone clinic will be conducted weekly during the first 9 months and twice/month during the final 9 months (3 to 12 months).
3107427|NCT01841372|Experimental|Second Life (2L)|2L group meeting will be conducted weekly during the first 9 months and twice/month during the final 9 months
3107467|NCT01841112|Experimental|Dose 1, EM, single dose|Extensive Metaboliser (EM), single dose part, low dose
3107468|NCT01841099|Experimental|Mesalamine|Mesalamine. Mesalamine granules. 30 mg/kg/day oral for 7 days followed by 50 mg/kg/day oral for 21 days if tolerated.
3107469|NCT01841099|Placebo Comparator|Placebo granules|Placebo granules
3107470|NCT01841086|Active Comparator|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
3107471|NCT01841086|Experimental|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
3107828|NCT01838590|Experimental|SOF+RBV 12 Weeks|Participants will receive SOF+RBV for 12 weeks.
3107428|NCT01841359|Other|Pramlintide (Symlin)|"Participants in this study will be asked to complete 4 study visits. Study visit 1 will be for screening. Eligible individuals who provide informed consent will be asked to keep a 3-day log of food intake, blood glucose (8 per day), as well as any hypoglycemic symptoms. At study visit 2, a baseline mixed meal tolerance test will be performed. Glucose, hormonal responses, and satiety will be assessed. Glucose and symptom log will be reviewed. Pramlintide will be prescribed, with instructions for titration from minimal to maximal dose (15 to 120 µg). During treatment, the participants will keep a record of all hypoglycemic symptoms and blood glucose measurements at those times.~Study visit 3 will occur at week 4 of treatment and focus on evaluation of symptoms and side effects. Participants will again complete a food and glucose diary for 3 days. During study visit 4 (week 8 of treatment), participants will undergo a repeat mixed meal tolerance test."
3107429|NCT01841346||PCI patients|Patients undergoing PCI for elective or ACS will be enrolled.
3107430|NCT01841333|Experimental|PF-04449913|Beginning 80 days after allogeneic stem cell transplant, patients receive PF-04449913 (100mg) orally once daily on days 1-28. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
3107431|NCT01841320|Experimental|Intervention|Participants who are assigned to intervention arm will receive ART and methadone maintenance at an integrated methadone and antiretroviral therapy (iMART) clinic and ART adherence support through the use of mobile phone technologies.
3107432|NCT01841320|No Intervention|Standard of Care|Participants will be referred to standard HIV outpatient clinics and methadone maintenance clinics.
3107433|NCT01841307|Experimental|Gastrocrom|4 ingestions (at 2h intervals) of a 200 mL of a 1mg/mL solution of cromolyn sodium (inpatient) OR 2 ingestions (at 4h intervals) of a 200 mL of a 1mg/mL solution of cromolyn sodium (outpatient)
3107434|NCT01841294|Experimental|Intravenous Lidocaine|Patients undergoing laparoscopic surgery for resection of colorectal cancer will benefit of an infusion of intravenous lidocaine from the induction of anesthesia untill one hour after PACU admission
3107435|NCT01841294|Placebo Comparator|Placebo|Infusion of normal saline form the induction of anaesthesia untill one hour after PACU admission
3107436|NCT01841281|Active Comparator|Low Exhaled Nitric Oxide (NO)|"Subjects with a baseline exhaled NO level less than or equal to 20 ppb will be enrolled in the Low Exhaled Nitric Oxide arm.~All subjects will receive L-arginine and placebo in this cross-over design study."
3107437|NCT01841281|Active Comparator|High Exhaled Nitric Oxide (NO)|"Subjects with a baseline exhaled NO level greater than or equal to 25 ppb will be enrolled in the High Exhaled Nitric Oxide arm.~All subjects will receive L-arginine and placebo in this cross-over design study."
3107438|NCT01841268||Preterm Infants|Infants born prematurely will have their skin, sebum, microbiota, blood, and mother's breast milk analyzed for changes between 0, 2, and 4 weeks of life.
3107439|NCT01841268||Term Infants, Control|Term infants enrolled in the UC Davis Lactation Study (protocol # 216198) will serve as the control group for this study; they will have their skin, sebum, microbiota, and mother's breast milk analyzed for changes between 0, 2, and 4 weeks of life.
3107440|NCT01841255|Sham Comparator|Tidal breathing using the facemask|Control
3107441|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM, device, no instruction|First experimental measure
3107442|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM device, instructions|Second experimental measure
3107443|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM, device, nose clip|Third experimental measure
3107444|NCT01841242|Active Comparator|alcoholic povidone iodine|Betadine Alcoolique 5% One cutaneous application before implant procedure
3107445|NCT01841242|Experimental|alcoholic chlorhexidine|ChloraPrep 2% One cutaneous application before implant procedure
3107446|NCT01841216|Experimental|Low Back Pain|Lower Body Exercises with and without resistance
3107447|NCT01841216|Experimental|Healthy|Lower Body Exercises with and without resistance
3107448|NCT01841203||DPP/RPR-TPHA comparison|The evaluation of T1 (treponemal line) will be conducted by using the T1 positivity identified by naked eye or automated reader to compare with that of TPHA; while the evaluation of T2 (non-treponemal line) will be conducted by using the T2 positivity identified by naked eye, or automatic reader at cut-off value of 20, to compare with the result of RPR.
3107449|NCT01841190||PROCALCITONIN|
3107450|NCT01841190||DELTA SOFA|
3107451|NCT01841177|Experimental|Therapeutic Drug Monitoring|The intervention is [1] regular measurement of milrinone levels; [2]physician feedback of plasma levels in experimental arm by the ICU pharmacist ( this process currently occurs for other drugs such as vancomycin).
3107452|NCT01841177|Active Comparator|Standard Care|Standard care involves titration of milrinone infusion based on clinical examination by the treating team. The control group will receive standard care: with milrinone dose modification on clinical assessment. Control patients will have milrinone plasma levels drawn but not analysed until the end of the study.
3107453|NCT01841164|Experimental|Montelukast|5 to 7 days of treatment with montelukast 10 mg 2 tablets bid. Efficacy of treatment is evaluated on airway responsiveness to inhaled leukotriene E4.
3107454|NCT01841164|Placebo Comparator|Sugar pill|Placebo for montelukast 5-7 days 2 tablets bid. Efficacy of treatment is evaluated on airway responsiveness to inhaled leukotriene E4.
3107455|NCT01841151|Active Comparator|SCP training|Neurofeedback 1 (NF1) Slow Cortical Potential (SCP) training
3107456|NCT01841151|Active Comparator|Live Z-score training|Neurofeedback 2 (NF2) Live Z-score training
3107457|NCT01841151|Active Comparator|WM training|Working Memory training (WMt)
3107458|NCT01841151|No Intervention|Waiting-list|
3107459|NCT01841125|Experimental|escitalopram|escitalopram 15mg
3107460|NCT01841125|Placebo Comparator|Placebo|placebo 15mg
3107461|NCT01841112|Placebo Comparator|Placebo (Multiple dose part)|Placebo tablet
3107462|NCT01841112|Experimental|Dose 2, EM, single dose|Extensive Metaboliser (EM), single dose part, medium dose
3107463|NCT01841112|Experimental|Dose 3, EM, single dose|Extensive Metaboliser (EM), single dose part, high dose
3107464|NCT01841112|Experimental|Dose 3, PM, single dose|Poor Metaboliser (PM), single dose part, high dose
3107465|NCT01841112|Experimental|Dose 3, PM, multiple dose|Poor Metaboliser (PM), multiple dose part, high dose
3107466|NCT01841112|Placebo Comparator|Placebo (Single dose part)|Placebo tablet
3107472|NCT01841073|Experimental|Inulin|Subject will take 10g inulin for 2 weeks, 20g of inulin for the next 2 weeks and then 30g for the remainder of the investigations.
3107473|NCT01841073|Placebo Comparator|Cellulose|Subjects will take 10g cellulose a day for 2 weeks, followed by 20g a day for 2 weeks, then 30g a day for the rest of the study.
3107474|NCT01841060|Experimental|Radiofrequency ablathermy|Radiofrequency ablathermy
3107475|NCT01841047|Other|Radiotherapy|Evaluation of the combination of radiotherapy with tomotherapy coil (54 Gy) followed by surgery in liposarcomas retroperitoneal.
3107476|NCT01841034||Conceptio|Any patient receipt within the framework of the coverage(care) of an infertility in the pole ORG, whatever is the étiologie and the type of treatment proposing and presenting during at least two spermogrammes an oligospermie and\or an asthénospermie. The necessity of realizing 2 spermogrammes different to determine the pathological character of the values of a spermogramme takes into account the personal variability of the results.
3107477|NCT01841021|Experimental|Brentuximab Vedotin Treatment|Brentuximab vedotin will be given intravenously with a dose of 1.8 mg/kg every 21 days, over 30 minutes for 16 cycles in the clinic.
3107478|NCT01841008|Experimental|Tacrolimus ointment 0.1%|
3107479|NCT01841008|Placebo Comparator|Group Placebo|
3107480|NCT01840995||stellate ganglion block|Patients receiving stellate ganglion block at our pain management clinic
3107481|NCT01840982|Experimental|Mixed grain 1(Giant embryonic brown rice )|
3107482|NCT01840982|Experimental|Mexed grain 2 (Giant embryonic rice )|
3107483|NCT01840982|Active Comparator|White rice|
3107484|NCT01840982|Active Comparator|Glucose solution|
3107485|NCT01840969||CAOD group|Single arm study group
3107486|NCT01840956|Experimental|HAVG|Surgical placement of HAVG
3107487|NCT01840943|Experimental|CAELYX|Participants will receive CAELYX 50 mg per square meter intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing PK evaluation.
3107488|NCT01840943|Active Comparator|Topotecan hydrochloride (HCl)|Participants will receive topotecan HCl 1.25 mg per square meter per day, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
3107489|NCT01840917||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
3107490|NCT01840904||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
3107491|NCT01840891|Experimental|Noro virus shedder|Lactose H2 breath test (LH2BT)
3107492|NCT01840891|Active Comparator|No norovirus shedding|Lactose H2 breath test (LH2BT)
3107493|NCT01840878||Acute Diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
3107494|NCT01840865|Experimental|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
3107495|NCT01840865|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
3107496|NCT01840852||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
3107497|NCT01840839|Experimental|0,75 Hz stimulation|transcranial slow oscilliating stimulation (tSOS)during periods of SWS
3107498|NCT01840839|Sham Comparator|no stimulation|Sham stimulation during periods of SWS
3107499|NCT01840826|Experimental|RED-D Care Management|Patients randomized to receive the Intervention work with a RED-D Care Manager post-discharge. The Care Manager meets with the patient in the hospital, prior to discharge, and post-discharge via weekly phone calls. Patients have access to a range of treatment options, overseen by the Care Manager, including: (1) medication; (2) cognitive behavioral therapy (CBT); (3) complementary and alternative medicine (CAM) information and referral; (4) Self-help, such as reading a book, making a change in diet and/or exercise in order to improve mood; (5) active surveillance; and (6) any combination of 1, 2, 3, 4 & 5.
3107500|NCT01840826|No Intervention|RED and Behavioral Health Referral|"Patients randomized to the control group will receive the regular RED intervention, including a follow-up phone call two days post-discharge from the hospital to review and confirm medications, and a referral to behavioral health."
3107501|NCT01840813|Active Comparator|Misoprostol|4 misoprostol tablets (Misotac® 200 micrograms tablet) dissolved in 20 ml of normal saline injected to umbilical vein
3107502|NCT01840813|Placebo Comparator|Normal saline|Normal saline 0.9%, 20 ml was injected in the umbilical vein in cases of retained placenta
3107503|NCT01840800|Active Comparator|Active FEM+ONP|Nerveblock of n. femoralis (FEM) with 10 ml Ropivacaine 7.5 mg/ml and nerveblock of obturator nerveposterior branch (ONP) with 10 ml Ropivacaine 7.5 mg/ml.
3107504|NCT01840800|Active Comparator|Active SAPH+ONP|Nerveblock of n.saphenous (SAPH) with 5 ml Ropivacaine 7.5 mg/ml and nerveblock of obturator nerve, posterior branch (ONP) with 10 ml Ropivacaine 7.5 mg/ml
3107505|NCT01840800|Placebo Comparator|Placebo|Saline 9 mg/ml
3107506|NCT01840787|Experimental|Contralateral lens comfort comparisons|Subjects will be randomized into receiving balafilcon A (8.3), or balafilcon A (8.6), or senofilcon A in one eye, and balafilcon A (8.3), or balafilcon A (8.6), or senofilcon A in the other eye.
3107507|NCT01840774|Active Comparator|Low-dose pain medication|80min IV infusion of a low-dose pain medication
3107508|NCT01840774|Placebo Comparator|saline placebo|80min IV infusion of a saline placebo
3107509|NCT01840761|Experimental|herbal drug|Traditional Chinese herbal drug
3107510|NCT01840761|Placebo Comparator|Placebo|
3107511|NCT01840748||no vasodilator|patients receiving no vasodilator
3107512|NCT01840748||CCB|patients receiving a calcium channel blocker (CCB) for digital vasculopathy
3107513|NCT01840748||i.v. prostanoids or PDE5i or ETRAs|patients treated with i.v. prostanoids or phosphodiesterase-5 inhibitors (PDE5i) or endothelin receptor antagonists (ETRA), regardless of whether a calcium channel blocker is given in addition
3107514|NCT01840735|Active Comparator|GS-5737|The GS-5737 85 μg dose is contained in 4 mL of 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline.
3107515|NCT01840735|Placebo Comparator|Placebo|The vehicle (placebo) control contains 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline in 4 mL.
3107545|NCT01840553|Experimental|oral sodium phosphate tablets|oral Sodium Phosphate tablets administered as 32 tablets (20+12) with 2 Liters of liquid
3107829|NCT01838590|Experimental|SOF+RBV 24 Weeks|Participants will receive SOF+RBV for 24 weeks.
3107516|NCT01840722|No Intervention|NIDA Standard HIV Education|NIDA Standard HIV Education Participants in this condition will be given HIV education using NIDA standard pre and post-test counseling, HIV and HCV rapid testing, and an information packet on existing community drug abuse and HIV/HCV resources
3107517|NCT01840722|Experimental|MI-based HIV Risk Reduction|MI-based HIV Risk Reduction -- In addition to what is received in the HIV-Ed group, participants in this condition will also receive a CDC evidence-based brief intervention for high-risk women focused on an individualized plan for enhancing motivation to reduce risk behaviors and to use health and behavioral health services in the community.
3107518|NCT01840709|Experimental|Psychotherapy treatment|The experimental group will be treated with Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks.
3107519|NCT01840709|No Intervention|control group|the patients in this group will be just assessed with the same questionnaires at baseline and after 20 weeks, without psychotherapy.
3107520|NCT01840696|Experimental|Regadenoson|
3107521|NCT01840683|Experimental|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|A total of 8 apheresis therapies with the H.E.L.P. Plasmat Futura System will be performed over a period of 12 weeks.
3107522|NCT01840644||all participants|Walking on treadmill, different velocities and incline
3107523|NCT01840631|Active Comparator|Group nutritional counseling|In this arm, the Nutritionist will conduct the nutritional counseling with numerous patient families as a group
3107524|NCT01840631|Active Comparator|Individual nutritional counseling|In this arm the nutritionist conducts the nutritional counseling with one patient family at a time
3107525|NCT01840618||Obese PCOS and sleep apnea|"BMI >95%ile AND Polysomnography with AHI >2.5~Will initiate Nasal Continuous positive airway pressure (CPAP)"
3107526|NCT01840618||Obese PCOS without sleep apnea|BMI >95%ile AND Polysomnography with AHI <2.5
3107527|NCT01840618||Normal weight Controls|BMI <85%ile AND regular menses
3107528|NCT01840618||Lean PCOS and sleep apnea|"BMI <85%ile AND Polysomnography with AHI >2.5~Will initiate Nasal Continuous positive airway pressure (CPAP)"
3107529|NCT01840618||Lean PCOS without sleep apnea|BMI <85%ile AND Polysomnography with AHI <2.5
3107530|NCT01840605|Experimental|TAU-284|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day, once after breakfast and once before bed.
3107531|NCT01840605|Active Comparator|ketotifen fumarate|Two TAU-284 5mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day, once after breakfast and once before bed.
3107532|NCT01840592|Experimental|Sorafenib plus Doxorubicin|Doxorubicin 60 mg/m2 IV on Day 1 of each 3 weeks cycle until unacceptable toxicity Sorafenib 400 mg PO BID or last dose patient from previous sorafenib based therapy, until unacceptable toxicity or disease progression, after which sorafenib can be continued as a single agent.
3107533|NCT01840579|Experimental|Pembrolizumab 2 mg/kg|In Part A, participants receive intravenous (IV) Pembrolizumab 2 mg/kg on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days).
3107534|NCT01840579|Experimental|Pembrolizumab 10 mg/kg|In Part A, participants receive IV Pembrolizumab 10 mg/kg on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days).
3107535|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Pemetrexed|In Part B, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 + IV Pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pemetrexed in combination with IV pembrolizumab is permitted per standard of care, followed by IV pembrolizumab 200 mg every 3 weeks for up to 2 years.
3107536|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Pemetrexed|In Part B, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 5 mg/mL/minute + IV Pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pemetrexed in combination with IV pembrolizumab is permitted per standard of care, followed by IV pembrolizumab 200 mg every 3 weeks for up to 2 years.
3107537|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Paclitaxel|In Part C, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 6 mg/mL/minute + IV Paclitaxel 200 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks for up to 2 years.
3107538|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Nab-paclitaxel|In Part C, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 6 mg/mL/minute on Day 1 of each 21-day cycle + IV Nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks for up to 2 years.
3107539|NCT01840579|Experimental|Pembrolizumab+Ipilimumab|In Part D, participants receive IV Pembrolizumab 200 mg on Day 1 of each 21-day cycle + IV Ipilimumab 1 mg/kg on Day 1 of every other 21-day cycle (every 42 days) for a maximum of 18 cycles of Ipilimumab (35 doses of Pembrolizumab).
3107540|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Etoposide|In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks for up to 2 years.
3107541|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Etoposide|In Part E, participants receive IV Pembrolizumab 200 mg + IV IV Carboplatin AUC 5 mg/mL/minute on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks for up to 2 years.
3107542|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Etoposide+G-CSF|In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles + lasting G-CSF (pegfilgrastim) 3.6 mg on Day 4 of Cycle 1. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks for up to 2 years.
3107543|NCT01840566|Experimental|HIGH DOSE CHEMOTHERAPY AND ASCT|This is a phase 1 dose escalation study designed to determine the maximum tolerated dose (MTD) of CAR modified T cells in patients with relapsed and refractory aggressive B-NHL. Three dose levels (5 x 106 19-28z T cells/kg, 1 x 107 19-28z T cells/kg, and 2 x 107 19-28z T cells/kg) are considered for the MTD.
3107544|NCT01840553|Active Comparator|polyethylene glycol|4 Liters of PEG administered split in 2 doses
3107586|NCT01840371|Experimental|Propofol based group|
3107546|NCT01840540|Experimental|infusion of autologous mesenchymal stem cells|Patients will undergo a subcutaneous fat biopsy for expansion of mesenchymal stromal (stem) cells (MSC) in the Human Cell Therapy Laboratory. Patients will be admitted to the inpatient Clinical Research Unit of the Mayo Clinic Center for 3 days prior to treatment, for pre-infusion tests. Renal angiography will be performed to deliver a single intra-arterial dose of MSC's into one affected kidney. Patients will be observed for 24 hours for acute adverse events. Patients will have remote visits at 1 week, 4 weeks,8 weeks, and 6 months. At 3 months, patients will return for repeat evaluation of kidney function, blood flow and structural alterations within the clinical research unit at St. Mary's Hospital, Rochester, Minnesota. Thereafter, health assessment and blood draws will be repeated at 12 and 24 months with urinary cytology and MRI.
3107547|NCT01840527||Group 1|Advanced Melanoma
3107548|NCT01840527||Group 2|Stage II/III Melanoma
3107549|NCT01840501|Experimental|Part 1: Panel 1 (0.1 mg JNJ-42721458)|6 participants will receive a single dose of 0.1 mg of JNJ-42721458.
3107550|NCT01840501|Experimental|Part 1: Panel 2 (0.3 mg JNJ-42721458)|6 participants will receive a single dose of 0.3 mg of JNJ-42721458.
3107551|NCT01840501|Experimental|Part 1: Panel 3 (1.0 mg JNJ-42721458)|6 participants will receive a single dose of 1.0 mg of JNJ-42721458.
3107552|NCT01840501|Experimental|Part 1: Panel 4 (2.5 mg JNJ-42721458)|6 participants will receive a single dose of 2.5 mg of JNJ-42721458.
3107553|NCT01840501|Experimental|Part 1: Panel 5 (5.0 mg JNJ-42721458)|6 participants will receive a single dose of 5.0 mg of JNJ-42721458.
3107554|NCT01840501|Experimental|Part 1: Panel 6 (10.0 mg JNJ-42721458)|6 participants will receive a single dose of 10.0 mg of JNJ-42721458.
3107555|NCT01840501|Experimental|Part 1: Panel 7 (20.0 mg JNJ-42721458)|6 participants will receive a single dose of 20.0 mg of JNJ-42721458.
3107556|NCT01840501|Experimental|Part 1: Panel 8|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-7 in Part 1.
3107557|NCT01840501|Experimental|Part 1: Panel 9|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-8 in Part 1.
3107558|NCT01840501|Experimental|Part 1: Panel 10|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-9 in Part 1.
3107559|NCT01840501|Placebo Comparator|Part 1: Placebo|2 participants from each panel will receive a single dose of placebo.
3107560|NCT01840501|Experimental|Part 2: Panel 1 (5.0 mg JNJ-42721458)|6 participants will receive multiple doses of 5.0 mg of JNJ-42721458.
3107561|NCT01840501|Experimental|Part 2: Panel 2 (10.0 mg JNJ-42721458)|6 participants will receive multiple doses of 10.0 mg of JNJ-42721458.
3107562|NCT01840501|Experimental|Part 2: Panel 3|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-2 in Part 2.
3107563|NCT01840501|Experimental|Part 2: Panel 4|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-3 in Part 2.
3107564|NCT01840501|Experimental|Part 2: Panel 5|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-4 in Part 2.
3107565|NCT01840501|Experimental|Part 2: Panel 6|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-5 in Part 2.
3107566|NCT01840501|Placebo Comparator|Part 2: Placebo|2 participants from each panel will receive multiple doses of placebo.
3107567|NCT01840488|Experimental|Irosustat (BN83495)|Single oral administration of irosustat
3107568|NCT01840475||Botulinum toxin type A (BoNT-A) injection (Dysport®) Naïve|Subjects naïve to BoNT-A treatment.
3107569|NCT01840475||Botulinum toxin type A (BoNT-A) Pre-treated|"Subjects pre-treated with BoNT-A.~Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics [SmPC])."
3107570|NCT01840462||Subjects naïve to botulinum toxin A (BoNT-A) treatment|Patients naïve to botulinum toxin A treatment
3107571|NCT01840462||Subjects pre-treated with botulinum toxin A (BoNT-A) injection|"Patients pre-treated with botulinum toxin A for at least 2 years.~4 injection cycles, each at 3 to 4 months intervals. Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics)."
3107572|NCT01840449||Neuroendocrine Tumours|The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
3107573|NCT01840449||Acromegaly|The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
3107574|NCT01840436|Placebo Comparator|Placebo|This arm receives a placebo (saline solution) mouthwash treatment twice a day.
3107575|NCT01840436|Experimental|MUCIPLIQ 0.05 mg/mL|This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.05 mg/mL twice a day.
3107576|NCT01840436|Experimental|MUCIPLIQ 0.015 mg/mL|This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.015 mg/mL twice a day.
3107577|NCT01840423|Experimental|ODM-104|Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days
3107578|NCT01840423|Placebo Comparator|Placebo|Oral capsules given once daily for one day or three times daily for 7 days
3107579|NCT01840423|Active Comparator|entacapone + levodopa/carbidopa|entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day
3107580|NCT01840410|Experimental|Ranibizumab|A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
3107581|NCT01840410|Sham Comparator|Sham control|Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.
3107582|NCT01840397||Spine surgery|Patients undergoing spine surgery
3107583|NCT01840397||Bone surgery|Patients undergoing bone surgery for fracture treatment other than spine fractures
3107584|NCT01840384|Experimental|Multi-micronutrients|Multi-micronutrients
3107585|NCT01840384|Placebo Comparator|Maltodextrin and Lactose|Placebo contained maltodextrin and lactose
3107591|NCT01840319||1|Patients previously included in the initial protocol WYETH 3074A1-4448 / B1811030. (To collect only status survival data 30 days after the last dose of treatment)
3107592|NCT01840306||Cohort 1: HER2 positive breast cancer|Female patients with newly diagnosed (including metastatic) HER2 positive breast cancer.
3107593|NCT01840306||Cohort 2: HER2 negative breast cancer|Female patients with newly diagnosed HER2 negative breast cancer
3107594|NCT01840293||Primary Breast Cancer|
3107595|NCT01840293||Recurrent/Metastatic Breast Cancer|
3107596|NCT01840280||Carcinoma, Irinotecan onkovis (Irinotecan)|Treatment in mono- or combination therapy with Irinotecan of advanced colorectal carcinoma.
3107597|NCT01840267||laparoscopic surgery under general anesthesia|pediatric patients undergoing laparoscopic surgery under general anesthesia
3107598|NCT01840254|Experimental|dexmedetomidine|addition of dexmedetomidine to fentanyl-based intravenous patient controlled analgesia (PCA)
3107599|NCT01840254|Placebo Comparator|normal saline|normal saline as a placebo
3107600|NCT01840241|Experimental|BIVON group|
3107601|NCT01840241|Placebo Comparator|Placebo group|normal saline infusion
3107602|NCT01840228|Active Comparator|Micronized progesterone suppository|Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
3107603|NCT01840228|Placebo Comparator|Placebo suppository|One placebo suppository vaginally daily until 36 6/7 weeks' gestation.
3107604|NCT01840215||Controls|Patients scheduled for elective ophthalmic surgery with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
3107605|NCT01840215||Primary open-angle Glaucoma|Patients scheduled for an elective glaucoma surgery that present with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
3107606|NCT01840215||Normal Tension Glaucoma|Patients scheduled for an elective glaucoma surgery that present with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg.
3107607|NCT01840202||Control|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
3107608|NCT01840202||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
3107609|NCT01840202||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
3107610|NCT01840189|Active Comparator|Cortef|Treatment A is oral hydrocortisone replacement( Cortef 5 mg)with weight-adjusted doses as suggested by Mah et al , will take 2 months
3107611|NCT01840189|Active Comparator|Solu-cortef|This is the treatment B by continuous subcutaneous hydrocortisone infusion. Solu-cortef infusion will be given as Solu-Cortef Act-o-Vial 50mg/ml, , produced by Pfizer. Pump designed for subcutaneous insulin infusion can be used for subcutaneous administration.
3107612|NCT01840176|No Intervention|Routine|These women are randomized to receive no McCall culdoplasty at the time of their total laparoscopic hysterectomy.
3107613|NCT01840176|Other|McCall culdoplasty|The women in this arm are those randomized to undergo a McCall culdoplasty at the time of their total laparoscopic hysterectomy.
3107614|NCT01840163|Other|CanSORT Online Tool|Comprehensive decision tool
3107615|NCT01840163|Other|Static version of CanSORT tool|Static version (non-interactive) version of CanSORT decision tool
3107616|NCT01840150|Experimental|Treatment (NA-NOSE breath test)|Patients undergo breath sample collection for the NA-NOSE breath test at baseline (2 pre-treatment samples), and post-treatment samples at regularly scheduled follow up visits, for 2 years in the absence of disease progression.
3107617|NCT01840137|Experimental|Prehabilitation|The progressive, pre-operative exercise training program includes 3 supervised exercise sessions per week for 4 weeks. The first week of training will include an acclimation period accomplished via a ramping protocol. Subjects will warm-up on a treadmill for 5-minutes. Subjects will then complete 1 set of 15 repetitions exercising 8 major muscle groups during week one; during week #2 they will complete 2 sets with a goal of at least 12 repetitions; if subjects reach 15 repetitions on the second set, the resistance will be increased by 10% at the next training session to ensure progression. After completion of the resistance training portion of each session, subjects will walk on a treadmill for 30 minutes at a low/moderate intensity followed by a 5 minutes cool-down period.
3107618|NCT01840124|Experimental|Acessa|All women in the trial will be in this group who receive treatment using the Acessa device.
3107619|NCT01840098|Active Comparator|control|Isocaloric carbohydrate drink
3107620|NCT01840098|Active Comparator|low leucine content drink|A soy protein drink
3107621|NCT01840098|Active Comparator|high content of leucine drink|A whey protein drink
3107622|NCT01840098|Active Comparator|low leucine content + HMB drink|Soy protein drink added HMB
3107623|NCT01840085|Experimental|0.03% DSC127 topical gel|
3107624|NCT01840072|Experimental|Active antihypertensive treatment|Active antihypertensive treatment
3107625|NCT01840072|No Intervention|Usual care|Discontinue all home BP medications.
3107626|NCT01840059|Experimental|Renal sympathetic denervation|Renal denervation using the Medtronic Symplicity catheter.
3107627|NCT01840059|No Intervention|Control|HF-PEF patients who will serve as control.
3107628|NCT01840046|Experimental|Interleukin 2|"The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:~5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.~The dosage is as follows:~S1: 1.5 mille-International unit (MIU) / day D1 to D5, S3, S6 and S9: 3 mille-International unit /Jour D1 to D5."
3107665|NCT01839734|Experimental|Arm A|4 weeks of treatment with lubiprostone 24 mcg by mouth (PO) once-daily (Interventional Group)
3107666|NCT01839734|No Intervention|Arm B|No intervention
3107629|NCT01840033|Active Comparator|Group B|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
3107630|NCT01840033|Experimental|Group A|PICC Line (group A) : patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
3107631|NCT01840020||Gastric bypass|patients recruited from Central Norway
3107632|NCT01840020||Gastric sleeve|patients recruited from Central Norway
3107633|NCT01840007|Experimental|Metformin|"The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.~Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken."
3107634|NCT01839994|Experimental|CF-CRT combined with BT or SBRT boost|"Conventionally fractionated CRT (IMRT or Rapid Arc) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND two 10 Gy fractions of real- time HDR brachytherapy OR CRT combined with two stereotactic body radiotherapy boosts of 10 Gy per fraction delivered with dynamic SBRT technique (IMRT or Rapid Arc).~The choice between two ways of delivering radiation dose to the boost volume will be based solely on clinical criteria, decision made by interdisciplinary team, according to the institutional protocol (in non-randomized fashion).~Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients."
3107635|NCT01839994|Active Comparator|CF-CRT alone|"Conventionally fractionated external beam conformal radiotherapy (IMRT or Rapid Arc) to the prostate and seminal vesicles (intermediate risk group) or to the prostate, SV and pelvic lymph nodes (high risk group) to the total dose of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).~Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients."
3107636|NCT01839981|Experimental|Treatment (6,8-bis(benzylthio)octanoic acid)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5 of week 1 (pre-course 1 only), days 1 and 4 of weeks 2 and 3 (course 1 only), and days 1 and 4 of weeks 1-3 (courses 2-6). Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3107637|NCT01839968||Study patients|Acute coronary syndrome patients with a recent loading dose of prasugrel (6-24h)
3107638|NCT01839955|Experimental|Arm I (Dose Escalation Group)|Erlotinib hydrochloride and quinacrine dihydrochloride. The first three or six patients will be entered in this part of the study. Then this part will end.
3107639|NCT01839955|Experimental|Arm II (Extension Group)|Erlotinib hydrochloride and quinacrine dihydrochloride. The next 12 patients will enter into the second part of this study.
3107640|NCT01839942||no gap closure|no hernia gap closure
3107641|NCT01839942||extracorporal gap closure|"extracorporal hernia gap closure~extracorporal suturing of gap"
3107642|NCT01839942||intracorporal gap closure|intracorporal hernia gap closure
3107643|NCT01839929|Experimental|Prograf/Advagraf|conversion from Prograf to Advagraf
3107644|NCT01839916|Experimental|Treatment (DLI)|Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity.
3107645|NCT01839903|Active Comparator|RIH EDIS|Data will be collected in two steps at the RIH site: step one will be care as usual. Step 2 will involve changes to the EDIS system
3107646|NCT01839903|Active Comparator|Care as usual|Care as usual in the ED will be tracked
3107647|NCT01839890|Experimental|Bare metal Stent plus Paclitaxel Balloon|Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux)®
3107648|NCT01839890|Active Comparator|Bare metal Stent|Conventional Bare Stent
3107649|NCT01839877|Experimental|HIA DEBIRI + systemic FOLFOX|Intra-arterial hepatic beads loaded with irinotecan with systemic FOLFOX
3107650|NCT01839864|Experimental|Promotora plus standard care model|Promotora plus standard physical screening exam, hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count
3107651|NCT01839851||Asthma|Treatment with any inhaled corticosteroid
3107652|NCT01839851||Allergic rhinitis|Treatment with any intranasal glucocorticoid
3107653|NCT01839851||Asthma and allergic rhinitis|Inhaled corticosteroid + intranasal glucocorticoid
3107654|NCT01839825|Experimental|QuietCare|QuieCare system installed
3107655|NCT01839825|No Intervention|control|no system installed
3107656|NCT01839812|Other|cosyntropin stimulation test|All patients enrolled in the study are administered cosyntropin stimulation tests to assess their adrenal response.
3107657|NCT01839799|Experimental|Arm 1|
3107658|NCT01839799|Experimental|Arm 2|
3107659|NCT01839786||PHTN patients|2. Patients who underwent RHC in the past and were diagnosed with PHTN (retrospective arm)
3107660|NCT01839773|Experimental|DHP107 (oral paclitaxel)|DHP107 (oral paclitaxel) will be administered weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.
3107661|NCT01839773|Active Comparator|Taxol® (IV paclitaxel)|Taxol® (IV paclitaxel) will be administered 3-weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.
3107662|NCT01839760||Inpatient cohort|Patients admitted to general wards
3107663|NCT01839760||ICU cohort|Patients admitted to ICU
3107664|NCT01839747|Experimental|Imaging|PET-MRI PET-CT
3107667|NCT01839721|Active Comparator|Bifilact® probiotics standard dose|concentration of 1.3 billion of Lactobacillus acidophilus LAC-361 and Bifidobacterium longum BB-536. one pill twice a day. Each capsule contained maltodextrin and magnesium stearate as excipient
3107668|NCT01839721|Active Comparator|Bifilact® probiotics high dose|containing 10 billion Lactobacillus acidophilus LAC-361 and Bifidobacterium longum BB-536. One pill three times a day. Each capsule contained maltodextrin and magnesium stearate as excipient
3107669|NCT01839721|Placebo Comparator|placebo|Each capsule contained maltodextrin and magnesium stearate as excipient. One pill twice a day
3107670|NCT01839708|Experimental|Lifestyle Counseling|Intervention group: in addition to usual WIC care, watch the DVDs at home, complete action plan worksheets, call in to moderated (MI) group discussions.
3107671|NCT01839708|No Intervention|No Lifestyle Counseling|Comparison group: usual WIC care; read printed materials at home
3107672|NCT01839695|Experimental|Valiant Mona LSA Stent Graft System|TEVAR procedure using Medtronic Stent Graft
3107673|NCT01839669|Active Comparator|Foot Orthoses Only|including Patient Education; Abbreviation: FOO
3107674|NCT01839669|Experimental|Foot Orthoses and Eccentric Exercise|including Patient Education; Abbreviation: FOE
3107675|NCT01839669|Sham Comparator|Sham Foot Orthoses|including Patient Education; Abbreviation: FOS
3107676|NCT01839656|Experimental|Cohort 1 (n=4)|
3107677|NCT01839656|Experimental|Cohort 2 (n=4-16)|
3107678|NCT01839643|Active Comparator|2.4 g meloxicam vaginal ring|Vaginal ring, 2.4 g, continuosly during one menstrual cycle
3107679|NCT01839643|Active Comparator|3.0 g meloxicam vaginal ring|Vaginal ring, 3.0 g, continuosly during one menstrual cycle
3107680|NCT01839630||Group 1|
3107681|NCT01839617|Active Comparator|Early parenteral nutrition|Parenteral nutrition starts at 2nd postoperative day.
3107682|NCT01839617|Active Comparator|Late parenteral nutrition|Parenteral nutrition starts at 7th postoperative day.
3107683|NCT01839604|Experimental|AZD9150|There are two parts, dose escalation phase (Part A) and dose expansion phase (Part B).
3107684|NCT01839591|Experimental|Bronchial Thermoplasty|bronchoscopy bronchial thermoplasty catheter ALAIR Boston SCientific asthma
3107685|NCT01839578|Experimental|RCA Group|SHF-CVVHD with regional citrate anticoagulation
3107686|NCT01839578|Experimental|Heparin group|SHF-CVVHD with systemic heparin anticoagulation
3107687|NCT01839565||Patients|Patients undergoing osteosynthesis of acetabular fractures by using the Quadrilateral Surface Plate
3107688|NCT01839552|Experimental|Fentanyl Citrate Nasal Spray (FCNS)|Treatment for breakthrough pain with Fentanyl Citrate Nasal Spray (FCNS)
3107689|NCT01839539|No Intervention|B|After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will only regularly follow up.
3107690|NCT01839539|Experimental|A|After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will receive 2-3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK) treatment (every 4 weeks).
3107691|NCT01839526|Other|Glomerular Filtration Rate by Plasma Iohexol Clearance (iGFR)|Evaluations of renal and cardiac function
3107692|NCT01839500||Cohort I: HER2-Positive mGC Treated With Trastuzumab|HER2-positive metastatic gastric cancer (mGC) participants who are treated with trastuzumab will be included in this cohort. As this is an observational study, treatment schedule will be at the clinician's discretion in accordance with routine care practice and not dictated by the protocol.
3107693|NCT01839500||Cohort II: HER2-Positive mGC not Treated With Trastuzumab|HER2-positive mGC participants who are not treated with trastuzumab will be included in this cohort.
3107694|NCT01839500||Cohort III: HER2-Positive non-mGC|HER2-positive non-mGC participants will be included in this cohort.
3107695|NCT01839500||Cohort IV: HER2-Negative mGC|HER2-negative mGC participants will be included in this cohort.
3107696|NCT01839500||Cohort V: HER2-Negative non-mGC|HER2-negative non-mGC participants will be included in this cohort.
3107697|NCT01839487|Experimental|PEGPH20|PEGPH20+nab-paclitaxel+Gemcitabine
3107698|NCT01839487|Active Comparator|nab-paclitaxel + gemcitabine|nab-paclitaxel + gemcitabine x1/week
3107699|NCT01839474|Experimental|CPAP|Children will be placed on nasal CPAP until they have an age appropriate respiratory rate and receive standard medical therapy.
3107700|NCT01839474|No Intervention|Control|Children will receive standard medical therapy.
3107701|NCT01839448||GD diagnosis before 24 weeks|"Patients in this group are diagnosed with gestational diabetes (GD) before 24 weeks of amenorrhea by means of a fasting blood glucose test >= 0.92 g/l.~Intervention: Post-partum oral glucose tolerance test"
3107702|NCT01839448||GD diagnosed at 24 to 28 weeks|"Patients in this group are diagnosed with gestational diabetes between 24 and 28 weeks of amenorrhea based on a normal fasting blood glucose level before 24 weeks of amenorrhea AND an abnormal oral glucose tolerance test between 24 and 28 weeks of amenorrhea.~Intervention: Post-partum oral glucose tolerance test"
3107703|NCT01839435|Experimental|outpatient patients|Outpatient surgery will be proposed to all patients
3107704|NCT01839422|Experimental|Controls|Memory assessment. Brain imaging examination MRI.
3107705|NCT01839422|Experimental|Beginner Alzheimer's Disease patients|Memory assessment. Brain imaging examination MRI.
3107706|NCT01839422|Experimental|Severe Alzheimer's Disease patients|Memory assessment. Brain imaging examination MRI.
3107707|NCT01839409|No Intervention|control|Control without vestibular stimulation
3107708|NCT01839409|No Intervention|Bilateral areflexia|Patient with vestibular bilateral areflexia
3107709|NCT01839409|No Intervention|Areflexia controls|Controls for patients with vestibular bilateral areflexia, matched in sex and age
3107710|NCT01839409|Experimental|vestibular stimulation|Subjects submitted to vestibular stimulation in order to improve circadian rhythms
3107711|NCT01839396|Active Comparator|Medium continuous dose of stimulation|Subjects in this arm will receive stimulation settings at a medium continuous dose of Deep Brain stimulation that may have been effective in previous DBS patients.
3107712|NCT01839396|Sham Comparator|Low intermittent dose of stimulation|Subjects in this arm will receive stimulation settings at a lower intermittent dose of Deep Brain stimulation which is less likely to be effective.
3107713|NCT01839383|Active Comparator|DCa1.25|using dialysate calcium concentration 1.25 mmol/L(DCa1.25)
3107716|NCT01839370|Experimental|Closed Loop with Pramlintide|The experimental condition consists of closed loop admission with the Adaptive Insulin Meal Supervisor system (AIMS) system with pramlintide 30 mcg at meal time. During this admission, the Diabetes Assistant (DiAs), a Cell Phone Medical Platform and the central component of the system, will provide basal insulin to maintain glucose levels within a prescribed range.
3107717|NCT01839370|Placebo Comparator|Open Loop with Pramlintide|Insulin delivery will be controlled by the DiAs system running in Open Loop mode. Subjects will be permitted to administer correction boluses and set temporary temporary basal levels at any time during the admission, whether or not they are eating a scheduled meal. Subjects will inject Pramlintide 30 mcg prior to meal time.
3107718|NCT01839357|Experimental|Rivaroxaban|
3107719|NCT01839344|Experimental|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
3107720|NCT01839344|Active Comparator|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
3107721|NCT01839344|Placebo Comparator|Placebo|An oral single dose of a solid, colored empty capsule.
3107722|NCT01839331|Experimental|Low Dose Ampion|4 mL Ampion
3107723|NCT01839331|Placebo Comparator|Placebo|4 mL placebo
3107724|NCT01839331|Experimental|High Dose Ampion|10 mL Ampion
3107725|NCT01839331|Placebo Comparator|10 mL Placebo|10 ml Placebo
3107726|NCT01839318|Experimental|DAILIES AquaComfort Plus|Nelfilcon A contact lenses worn first, followed by etafilcon A and omafilcon A in randomized order. Each product worn for 1 day, 12 hours.
3107727|NCT01839318|Active Comparator|1-DAY ACUVUE MOIST|Etafilcon A contact lenses worn first, followed by nelfilcon A and omafilcon A in randomized order. Each product worn for 1 day, 12 hours.
3107728|NCT01839318|Active Comparator|Proclear 1 day|Omafilcon A contact lenses worn first, followed by etafilcon A and nelfilcon A in randomized order. Each product worn for 1 day, 12 hours.
3107729|NCT01839305|Experimental|Hidrotherapy|Patients performed hydrotherapy 2 twice a week, for 16 weeks, to check if there was any effect on the outcome measures for women with fibromyalgia
3107730|NCT01839292|Active Comparator|uncovered D-type stent|uncovered D-type stent, which effectively reduces stent migration, especially in malignant colorectal obstruction
3107731|NCT01839292|Active Comparator|double-layered ComVi stent|double-layered ComVi stent, which is a modified covered stent with an additional outer bare wire mesh to overcome both tumor ingrowth and stent migration
3107732|NCT01839279|Experimental|Tizanidine|Oral dose of 2 and 4 milligram (mg) tablets
3107733|NCT01839279|Placebo Comparator|Placebo|Placebo followed by a single dose 400 mg moxifloxacin tablets.
3107734|NCT01839279|Active Comparator|Moxifloxacin|Single dose of 400 mg moxifloxacin followed by placebo.
3107735|NCT01839266||acute PE survivor, acute PE nonsurvivor|acute PE survivor, acute PE nonsurvivor (in-hospital death)
3107736|NCT01839253|Experimental|Atenolol|In each group, premedication with either b-blocker (Atenolol) or ACE inhibitor (enalapril) or nothing (control group) in the preparation room.
3107737|NCT01839253|Active Comparator|Enalapril|In each group, premedication with either b-blocker (Atenolol) or ACE inhibitor (enalapril) or nothing (control group) in the preparation room.
3107738|NCT01839253|Placebo Comparator|control|none of antihypertensive agents
3107739|NCT01839240|Experimental|Treatment (azacitidine, cytarabine, and mitoxantrone)|"INDUCTION: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5, cytarabine IV over 4 hours on days 6 and 10, and mitoxantrone hydrochloride IV over 60 minutes on days 6 and 10.~CONSOLIDATION: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients ineligible for allogeneic stem cell transplantation continue on to maintenance.~MAINTENANCE: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
3107740|NCT01839227|Experimental|regional cerebral oxygen saturation|
3107741|NCT01839214|Experimental|VB-201 160mg|Subjects will received 80mg twice daily for 24 weeks.
3107742|NCT01839214|Placebo Comparator|Placebo with crossover to VB-201 160mg|Subjects on placebo will crossover to VB-201 160 at week 12.
3107743|NCT01839201|Active Comparator|etomidate/sevoflurane|Anesthesia induction: etomidate, maintenance: sevoflurane
3107744|NCT01839201|Active Comparator|propofol/sevoflurane|2.induction: etomidate, maintenance: sevoflurane
3107745|NCT01839201|Active Comparator|propofol/propofol|Anesthesia induction:propofol, maintenance:propofol
3107746|NCT01839188|Experimental|PR5I/Pediacel/PR5I|PR5I/Pediacel/PR5I mixed schedule with concomitant Prevenar 13 / NeisVac-C / RotaTeq
3107747|NCT01839175|Experimental|Group 1|
3107748|NCT01839175|Active Comparator|Group 2|
3107749|NCT01839162|Experimental|Pelvic drape|Pelvic shield drape over the patient
3107750|NCT01839162|Experimental|Arm drape|Right radial arm drape over the patient
3107751|NCT01839162|Experimental|Pelvic and arm drape|Pelvic and arm drpaes placed over the patient
3107752|NCT01839162|Sham Comparator|No drapes|Standard radioprotection devices
3107753|NCT01839149|Experimental|TI-001 (intranasal oxytocin)|TI-001 is intranasal oxytocin
3107754|NCT01839149|Placebo Comparator|Placebo|Placebo for TI-001 is the same intranasal formulation without oxytocin
3107755|NCT01839136|Experimental|Intrauterine transfer of gametes|After the oocyte retrieval, the oocytes will be selected depending on the morphology of the granular cells. The transfer will be conducted in up to 2 hours after the oocytes collection, when the semen and up to 3 oocytes will be transferred. Surplus oocytes will be cryopreserved for future use. We will use a Sydney catheter (Cook Medical Inc., Bloomington, IN, USA) coupled to a 1 mL syringe to perform the transfer. The catheter will be loaded with oocytes and semen prepared in the following sequence: 10 µL of the prepared semen, a small space of air, 20 µL of the medium containing the oocytes, another small space of air and more 10 µL of prepared semen. The catheter will be placed through the endocervical canal up to the endometrial cavity guided by transabdominal ultrasound, where the liquid will be released. We will try to place the point of the catheter 1.0-1.5cm before touching the fundus of the endometrial cavity and release the liquid slowly, in approximately 30 seconds.
3107893|NCT01838109|Experimental|ONS group|oral administration of Encover 2 package for day starting at the time of discharge (200ml/package x 2, total 400Kcal/day) total 87 patients
3107756|NCT01839136|Active Comparator|intrauterine transfer of embryos|The oocytes will be denuded and those considered to be mature will be selected for fertilization up to the number of seven. In vitro fertilization will be performed and up to two embryos will be transferred 2-3 days after the oocyte retrieval. The other embryos will be cryopreserved for future use. We will use Sidney catheter (Cook Medical Inc.) coupled to a 1 mL syringe to perform the transfer. The catheter will be loaded with embryos in the following sequence: 10 µL of culture medium, a small space of air, 20 µL of the medium containing embryos, another small space of air, and more 10 µL of culture medium. The catheter will be placed through the endocervical canal up to the endometrial cavity, guided by transabdominal ultrasound, where the liquid will be released. We will try to place the point of the catheter 1.0-1.5cm before touching the fundus of the endometrial cavity and release the liquid slowly, in approximately 30 seconds.
3107757|NCT01839123|Active Comparator|Non-Vacuum Socket|Prosthetic suction or pin socket
3107758|NCT01839123|Experimental|Vacuum Socket|Prosthetic LimbLogic vacuum socket
3107759|NCT01839110|Active Comparator|Ranolazine|Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day
3107760|NCT01839110|Placebo Comparator|Placebo|Placebo by mouth twice per day
3107761|NCT01839110|No Intervention|Observational|Patients with pulmonary hypertension who have normal RV function (RVEF >=45%) will undergo same procedures in the observational arm but will not receive an intervention.
3107762|NCT01839097|Experimental|Dose Finding Phase|"This is a Phase 1 dose finding study using the traditional escalation rule of 3+3 design to evaluate the Maximum Tolerated Dose of Belinostat when administered in combination with CHOP. In Part A of the study, up to three sequential dose cohorts will enroll a maximum of 6 patients each.~Enrollment will begin with the enrollment of patients into Cohort 3.~On Day 1 of each 21-day treatment cycle, the study treatment will start with belinostat followed by CHOP regimen."
3107763|NCT01839084|Experimental|Xenon|Gaseous anesthetic, dosage: 60% (v/v) in 40% oxygen, continuous application during surgery
3107764|NCT01839084|Active Comparator|Isoflurane|Inhalative anesthetic, dosage: 1.2% (v/v) in 40% oxygen/medical air , continuous application during surgery
3107765|NCT01839071|Other|biopsy of fat tissue|
3107766|NCT01839058||Non Cardiac Chest Pain Patients|Patients with Chest Pain where Coronary Artery Disease has been formally ruled out are to undergo esophageal manometry testing.
3107767|NCT01839058||Healthy Controls|Healthy volunteers without esophageal symptoms are to undergo esophageal manometry testing.
3107768|NCT01839045||Breast Cancer|ACR BI-RAD Category 3 or 4 result
3107769|NCT01839032|Experimental|Vinorelbine cisplatin radiotherapy|Induction period + radio chemotherapy
3107770|NCT01839019|Placebo Comparator|Placebo|Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.
3107771|NCT01839019|Experimental|ODM-102|Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.
3107772|NCT01839006||patients with supranormal renal function|Patients with preoperative HN and supranormal renal function in DTPA renography
3107773|NCT01838993|Active Comparator|Lidocaine|Inhalation of lidocaine before intubation
3107774|NCT01838993|Placebo Comparator|Control|Normal saline inhalation before intubation
3107775|NCT01838980|Experimental|Colonoscopy|
3107776|NCT01838967|Experimental|C - V - C+V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
3107777|NCT01838967|Experimental|V - C - C+V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
3107778|NCT01838967|Experimental|V - C+V - C|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
3107779|NCT01838967|Experimental|C+V - V - C|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
3107780|NCT01838967|Experimental|C+V - C - V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
3107781|NCT01838967|Experimental|C - C+V - V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
3107782|NCT01838954|Active Comparator|Short-wave diathermy|Short-wave diathermy device turned on
3107783|NCT01838954|Placebo Comparator|control|Short-wave diathermy device turned off
3107784|NCT01838941|Experimental|Betaine|Betaine will be given orally to all participants and dose will be adjusted to body weight.
3107785|NCT01838928|Experimental|Bupivacaine|
3107786|NCT01838915|Experimental|Dietary Supplement: Prebiotics+Glutamine|
3107787|NCT01838915|Placebo Comparator|Placebo|
3107788|NCT01838902|Other|Eurartesim (control)|All participants will receive a complete course of DHA-PPQ (Eurartesim)
3107789|NCT01838902|Experimental|Primaquine 0.75mg base/kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.75mg/kg body weight
3107790|NCT01838902|Experimental|Primaquine 0.4mg base /kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.4mg base/kg Body weight
3107791|NCT01838902|Experimental|Primaquine 0.2mg base/kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.2mg base/kg body weight
3107792|NCT01838889|Experimental|Culturally adapted psychological intervention (PHP)|Depressed Mothers randomized to experimental arm will undergo a 12 week group psychological intervention on the 'positive health programme'.
3107793|NCT01838889|No Intervention|Treatment as usual (TAU)|Depressed mothers randomized to TAU arm will receive treatment as usual.
3107794|NCT01838876|Experimental|Cariprazine|Cariprazine, flexible dose, oral administration, once daily for 26 weeks
3107894|NCT01838109|No Intervention|Control group|no intervention total 87 patients
3107795|NCT01838863|Experimental|Plasma|If the patient is randomized to experimental arm, 2 units of frozen type AB plasma (FP24) will be thawed in the Plasmatherm Dry Thawing and Warming Device according to the operator manual as approved by the FDA in the ambulance and infusion will commence as soon as the type AB plasma is ready, and will continue during transport to the emergency department (ED). After infusion of 2 units of type AB plasma is completed, subsequent care will proceed per institutional, Advanced Trauma Life Support (ATLS) guided resuscitation with acute packed red blood cells (pRBC) administration determined by the hemodynamic response and additional blood component administration guided by rapid thrombelastography (rTEG) and coagulation panel assessment in conjunction with clinical scenario.
3107796|NCT01838863|Active Comparator|Standard|If the patient is randomized to the standard arm, the patient will be given intravenous crystalloid fluid (normal saline) as the initial resuscitation fluid with 2 large bore IVs based on the current ATLS guidelines, the standard of care. Subsequent care will proceed per institutional, ATLS guided resuscitation with acute packed red blood cells pRBC administration determined by the hemodynamic response and additional blood component administration guided by rTEG and coagulation panel assessment in conjunction with clinical scenario.
3107797|NCT01838850|Experimental|CS8635 20/5/12.5mg and placebo|Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this triple fixed dose combination therapy (CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5mg) + placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 40/5/12.5mg (OM/AML/HCTZ 40/5/12.5 mg).
3107798|NCT01838850|Active Comparator|Olmetec® Plus 20/12.5mg and placebo|Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this dual fixed dose combination therapy (Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5mg) + Placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5 mg).
3107799|NCT01838824|Experimental|Speed of Processing Training - Group 1|Group 1 will receive speed of processing training immediately following baseline testing. They will have an evaluation immediately following treatment and a long-term follow-up 6 weeks after finishing treatment.
3107800|NCT01838824|Experimental|Speed of Processing Training - Group 2|Group 2 will receive speed of processing training 6 weeks following baseline testing. They will have an evaluation immediately following treatment and a long-term follow-up 6 weeks after finishing treatment.
3107801|NCT01838798||Study population|"See in inclusion/exclusion criteria.~Interventions: Baseline activities; Clinical interview with a psychologist; Telephone interview 2 months after ICU discharge; Clinical interview with a psychologist ."
3107802|NCT01838785|Experimental|18F-DTBZ AV-133|18F-DTBZ AV-133 imaging
3107803|NCT01838772|Other|Pegylated-Interferon and Ribavirin|"Pegylated-interferon 1.5 microgr/kg, subcutaneously, once weekly for 48 weeks*. Ribavirin, weight-based dosage, divided in two daily doses for 48 weeks*.~*patients with genotype 2 and 3, moderate liver fibrosis, and rapid virologic response will receive therapy for 24 weeks."
3107804|NCT01838759||Hypovolemic hyponatremia|"Negative values of Overhydration measured by Bioimpedance spectroscopy"
3107805|NCT01838759||Hypervolemic hyponatremia|"Positive values of Overhydration measured by Bioimpedance spectroscopy"
3107806|NCT01838746||PCI|Patients undergoing PCI
3107807|NCT01838746||CABG|Patients undergoing CABG
3107808|NCT01838733||Cerebral Desaturation|Patients who suffer an intra-operative cerebral desaturation
3107809|NCT01838720|Experimental|zero ischemia laparoscopic RFA assisted TE|RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.
3107810|NCT01838720|Active Comparator|conventional laparoscopic partial nephrectomy|Renal hilum will be accurately isolated and then the artery only will be clamped during surgery.
3107811|NCT01838707|Active Comparator|Bupivacaine|0.125% Bupivacaine HCL @ 4-5 ml/h
3107812|NCT01838707|Active Comparator|Bupivacaine, Morphine|0.125% Bupivacaine HCL , Morphine sulphate 3 mg @ 3-5 ml/h
3107813|NCT01838707|Active Comparator|Bupivacaine, Fentanyl|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h
3107814|NCT01838694|Placebo Comparator|Placebo|Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes.
3107815|NCT01838694|Experimental|Ala-Cpn10|Recombinant minimally modified Chaperonin10 (Cpn10) Multiple doses in the range 10mg twice weekly to 100mg twice weekly administered intravenously by infusion over 60 minutes.
3107816|NCT01838681|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
3107817|NCT01838681|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available ADT
3107818|NCT01838668|Placebo Comparator|Part I Placebo|"Placebo orally twice a day. In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID~Participants will begin the study by taking 1 capsule orally BID for first 7 days and escalate their dosing from day 8 to 2 matching capsules orally BID."
3107819|NCT01838668|Experimental|Part I BG00012|BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg BG00012 twice daily (BID) for the first 7 days and 240 mg BG00012 BID thereafter.) In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID
3107820|NCT01838668|Experimental|Part II BG00012|Part II: All participants will receive BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg (1 capsule) BG00012 twice daily (BID) for the first 7 days and 240 mg (2 capsules) BG00012 BID thereafter.
3107821|NCT01838655|Experimental|Nitisinone|Oral administration of nitisinone
3107822|NCT01838642|Active Comparator|RET mutation positive participants|Rearranged during transfection (RET) mutation positive
3107823|NCT01838642|Active Comparator|RET mutation negative participants|Rearranged during transfection (RET) mutation negative
3107824|NCT01838629||thyroid nodule|
3107825|NCT01838616|Experimental|Tapentadol Prolonged Release (PR)|
3107826|NCT01838616|Active Comparator|Oxycodone/Naloxone Prolonged Release|
3107827|NCT01838603||Interventional pain management patients|Patients passed through interventional pain management program
3107895|NCT01838096|Experimental|THA|
3107830|NCT01838577||Case cohort|"Patients with proven EGFR mutation in exons 18-21 from tumor material. Patients with unknown or failed tumor EGFR genotyping will be ineligible. Patients subsequently undergoing re-genotyping which demonstrates an EGFR mutation will become eligible for the case cohort.~No known somatic KRAS, HER2, LKB1, BRAF, or PI3K, mutation or ALK gene rearrangement (or ALK3+ immunohistochemistry). If these mutations are known to be present the patient will be ineligible. However, patients will not be tested specifically for these mutations for this study and patients with unknown status are acceptable. If patients are subsequently tested after enrollment and found to harbor any of these mutations they will be considered ineligible and will be replaced.~No known Li Fraumeni, Li Fraumeni-like, or Peutz Jeghers syndrome family, or known germline carriers of mutant LKB1 or TP53. Patients will not have to be tested specifically for these syndromes to be eligible for this study."
3107831|NCT01838577||Control cohort|"Patients known to be somatic EGFR wild-type, i.e. no mutation detected in exons 18-21 from tumor material.~Patients with unknown or failed EGFR genotyping will be ineligible. Patients subsequently undergoing re-genotyping which demonstrates an EGFR wild-type will become eligible for the control cohort.~Never smoker (<100 cigarettes in lifetime) or ex-light smoker (stopped ≥1 year ago and smoked ≤10 pack-years)."
3107832|NCT01838564|Active Comparator|Routine data collection|Routine collection of patient-reported symptom and Quality of life data using PediQUEST surveys
3107833|NCT01838564|Experimental|Feedback of patient-reported outcomes|Routine collection of QOL and symptom data + feedback
3107834|NCT01838551|Experimental|COR-003|Male or female, ≥18 year of age, or of a minimal age as required by the local regulations with confirmed diagnosis of CS as defined according to the criteria in the guidelines for diagnosis of CS (Nieman 2008).
3107835|NCT01838538|Experimental|Bevacizumab+TC|The treatment group were accepted intraperitoneal injection with bevacizumab (avastin) 300mg after each intraperitoneal hyperthermic perfusion chemotherapy for 6 weeks.
3107836|NCT01838538|Active Comparator|TC|patients were treated with TC chemotherapy (paclitaxel 135mg/m2 ,iv d1+ carboplatin AUC=5, iv d1), 1 time/3 weeks for 6 weeks, and with intraperitoneal hyperthermic perfusion chemotherapy combined with intraperitoneal cisplatin 40mg/m2，1 time/2 weeks for 6 weeks
3107837|NCT01838525||SIRS, SEPSIS|
3107838|NCT01838525||sepsis, severe sepsis, septic shock|
3107839|NCT01838525||health, SIRS, Sepsis|
3107840|NCT01838512||IMiDs|"Diagnosed relapsed/refractory multiple myeloma patients who receive IMiD treatment~Note: Additional use of corticosteroids and/or cytotoxic agents (eg, alkylating agents) is permitted for all 3 cohorts."
3107841|NCT01838512||Proteasome inhibitors|"Diagnosed relapsed/refractory multiple myeloma patients who receive Proteasome inhibitor treatment~Note: Additional use of corticosteroids and/or cytotoxic agents (eg, alkylating agents) is permitted for all 3 cohorts."
3107842|NCT01838512||Combination novel therapies|"Diagnosed relapsed/refractory multiple myeloma patients who received combinations novel therapies (an IMiD plus a proteasome inhibitor) treatment~Note: Additional use of corticosteroids and/or cytotoxic agents (eg, alkylating agents) is permitted for all 3 cohorts."
3107843|NCT01838499|Experimental|MEDI8968|
3107844|NCT01838499|Placebo Comparator|Saline|
3107845|NCT01838486|Experimental|Bladder Thermal Distention (BTD)|Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using the PelvixTT system
3107846|NCT01838473|Active Comparator|General 1 g pouch|Oral pouch 0.3-1g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
3107847|NCT01838473|Active Comparator|Catch Licoice 1 g pouch|Oral pouch 1g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
3107848|NCT01838473|Active Comparator|Catch Licorice Mini 0.5 g pouch|Oral pouch 0.5g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
3107849|NCT01838473|Active Comparator|Catch Licorice dry mini 0.3 g pouch|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
3107850|NCT01838460|Experimental|6 mg dose of sublingual nicotine tablets|6 mg dose of sublingual nicotine tablets, single dose.
3107851|NCT01838460|Active Comparator|PSWM 0.5 g (16 mg nicotine/g)|Swedish portion snus, smokeless tobacco, PSWM 0.5 g (16 mg nicotine/g), single dose
3107852|NCT01838460|Active Comparator|PSWL 1.0 g (8 mg nicotine /g)|Swedish portion snus, smokeless tobacco, PSWL 1.0 g (8 mg nicotine /g), single dose
3107853|NCT01838460|Active Comparator|PSWL 1.0 g (16 mg nicotine /g)|Swedish portion snus, smokeless tobacco, PSWL 1.0 g (16 mg nicotine /g), single dose
3107854|NCT01838460|Active Comparator|PSWL (8 mg nicotine /g) 2x1.0 g|Swedish portion snus, smokeless tobacco, PSWL (8 mg nicotine /g) 2x1.0 g, single dose
3107855|NCT01838447|No Intervention|Usual care group|This group will receive daily cholecalciferol (vitamin D3) based on the Adequate Intake (AI) for infants and the Recommended Dietary Allowance (RDA) for children over 1 year. Specific dose amounts are 400 IU per day for infants (0-1 year), and 600 IU per day for children between 1-17 years. Infants under 12 months of age who are formula fed will be given a placebo solution.
3107856|NCT01838447|Experimental|High Dose Group|This group will receive cholecalciferol (vitamin D3) based on the age-specific tolerable daily upper intake level (UL). Specific dose amounts are 1600 IU per day for infants (0-1 year), and 2400 IU per day for children between 1-17 years. Infants under 12 months of age who are formula fed will be given a dose of 1200 IU per day to account for vitamin D in formula.
3107857|NCT01838434|Active Comparator|lenalidomide (Phase II)|Lenalidomide will be administered orally at 20 mg daily on days 1-21, repeated every 28 days for a maximum of 12 cycles (48 weeks). (Phase II)
3107858|NCT01838434|Experimental|lenalidomide and idelalisib (Phase II)|Lenalidomide will be administered orally and daily on days 1-21, repeated every 28 days for a maximum of 12 cycles (48 weeks). Idelalisib will be orally administered for continuous 28-day cycles until progression, intolerance, or patient/physician discretion. Dosing will be determined by the Phase I portion of the study. (Phase II)
3107859|NCT01838421||Children under 12 years of age|Children under 12 years of age who underwent surgery in the Charité - University Medicine Berlin, Campus Virchow - Klinikum in the years 2011/12
3107860|NCT01838408|Experimental|EZ2go Complete|EZ2go complete: Peg 3350, Magnesium Citrate and Simethicone
3107861|NCT01838408|Active Comparator|LoSo Prep ™|LoSo Prep ™: Magnesium citrate and Bisacodyl
3107896|NCT01838083|Experimental|Insulin glargine new formulation (test T formulation)|Once daily for 6 days
3107862|NCT01838395|Experimental|BL-8040 + Ara-C|"Eligible subjects will receive subcutaneous (SC) injections of BL-8040 (monotherapy period) over two days (one injection per day) followed by concurrent administration of BL-8040 with standard salvage chemotherapy (combined period) over 5 days. During the combined period, BL-8040 will be administered 4 hours prior to chemotherapy. The chemotherapy will consist of cytarabine (Ara-C) 1.5 or 3 g/m2/d per dose (based on age), administered intravenously (IV) over 3 hours, for 5 days and will not be escalated."
3107863|NCT01838382|Experimental|laparoscopic hysterectomy group|female patients undergoing total laparoscopic hysterectomy.
3107864|NCT01838369|Experimental|BI-505|
3107865|NCT01838356||No treatment.|
3107866|NCT01838343|No Intervention|No Ultrasound|Patients randomized to no ultrasound will get standard diagnostic and therapeutic interventions that are clinically indicated during the rapid response event.
3107867|NCT01838343|Experimental|Ultrasound|Patients randomized to ultrasound will get a goal-directed ultrasound performed by a critical care fellow along with standard diagnostic and therapeutic interventions that are clinically indicated during the rapid response event.
3107868|NCT01838330|Experimental|Chronic Kidney Disease Stage 3-4|Study participants with stage 3 or 4 CKD will receive 15 grams/day of soluble fiber psyllium for the first week, followed by 30 grams/day of a soluble fiber psyllium for 4 months.
3107869|NCT01838330|No Intervention|Chronic Kidney Disease Stage 1-2|Study participants with stage 1 or 2 CKD will not receive study treatment
3107870|NCT01838317|Experimental|Pioglitazone|
3107871|NCT01838304|Active Comparator|Monitoring|Standard of care sedation by CRNA using proposal with manual recording of drug dosing
3107872|NCT01838304|Experimental|Probability ramp control|Propofol titrated to deep sedation using PRC software.
3107873|NCT01838291||Patients on Ferriprox therapy <1 month|
3107874|NCT01838278|Experimental|Vojta physiotherapy Method|Children in the experimental group or Vojta group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
3107875|NCT01838265||AS: Active Surveillance Alone|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
3107876|NCT01838265||MRI-AS: MRI+ Active Surveillance|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
3107877|NCT01838252|Experimental|Hyaluronic acid|Patients in this arm will receive hyaluronic acid fillers to the lower lid.
3107878|NCT01838252|Sham Comparator|Saline|
3107879|NCT01838239|Experimental|Fish oil|
3107880|NCT01838226|Experimental|Group Prevention Clinics|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to cardiovascular disease (CVD)-related behaviors (e.g., smoking and weight reduction).
3107881|NCT01838226|No Intervention|Treatment as usual control|Usual VA care
3107882|NCT01838200|Experimental|Cohort 1|"Cohort 1 will include patients with an induration <10 mm in diameter after the pre-study PPD reactivity test. These patients will be enrolled into 3 groups sequentially, each given a single dose IL dose of BCG vaccine into a single selected melanoma lesion on Study Day 1. Each group will include 3 patients to be given a BCG at 16 - 0.64 x 106 cfu BCG (200 µl volume), 0.8 - 3.2 x 106 cfu BCG (200 µl volume), and 4.0 - 16.0 x 106 cfu BCG (200 µl volume)for groups 1, 2, and 3 respectively~All patients in these 3 groups will receive 300 mg daily doses of Isoniazid, commencing 28 days following the BCG injection and continuing for 4 weeks, and Ipilimumab administered intravenously starting 5 weeks after BCG, on Day 36. Four doses of 3 mg/kg ipilimumab are to be given every 3 weeks."
3107883|NCT01838200|Experimental|Cohort 2|Cohort 2 will include maximum 9 patients with a pre-study PPD reactivity to tuberculin that is ≥10 mm. Patients will receive 0.16 - 0.64 x 106 cfu BCG (200 µl volume) followed by administration of 300 mg daily doses of Isoniazid, commencing 28 days after the BCG and continuing for 4 weeks. Ipilimumab is administered intravenously starting 5 weeks after BCG, on Day 36. Four doses of (3 mg/kg) ipilimumab are to be given every 3 weeks.
3107884|NCT01838174|Experimental|Acthar Gel (ACTH)|15 days of intramuscular (IM) or sub-cutaneous corticotropin (SQ) Acthar (ACTH).
3107885|NCT01838174|Active Comparator|IV methylprednisolone (steroids) with oral taper|3 days of IV methylprednisolone followed by 11 days of oral prednisone
3107886|NCT01838161|No Intervention|Part I - Parent Interviews|Interview questions will focus on reticence to vaccinate children.
3107887|NCT01838161|Experimental|Part II|"We will pilot the vaccination vignettes in a health department (clinical) setting with eligible parents of adolescents.~a pretest survey~the video vignette~and a post-test survey measuring intention to receive appropriate adolescent vaccines"
3107888|NCT01838161|Experimental|Part III|"enhanced video educational intervention (video vignettes + standard of care vaccine event)~standard of care vaccination event"
3107889|NCT01838135|No Intervention|Group-based information sessions|Control group subjects will take part in 6 x 1.5 hour sessions of group-based information sessions facilitated by a trained instructor, consisting of topics on general wheelchair use, transportation, pain and fatigue management, nutrition, and internet resources. The instructor will be trained to not provide any training on wheelchair skills, and will be instructed to divert any wheelchair skills related questions.
3107890|NCT01838135|Experimental|WheelSeeU Training Program|Experimental group subjects will attend 6 x 1.5 hour training sessions (1-2 sessions/week) with a peer-Trainer. The peer-Trainer will facilitate WheelSeeU sessions and will lead participants through practice of wheelchair use goals.
3107891|NCT01838122||Study Arm|This group/cohort will have subjects having infertility due to PCOS (as per Rotterdam criteria)
3107892|NCT01838122||Control arm|This group/cohort will have subjects without PCOS but with any other diagnosis of infertility or any other complain.
3107897|NCT01838083|Experimental|Insulin glargine new formulation (reference R formulation)|Once daily for 6 days
3107898|NCT01838070||Study Group|Participants that has received AVAXIM 160U vaccine administered under the routine practice according to Summary of Product Characteristics
3107899|NCT01838057||painPREMIER cohort|
3107900|NCT01838057||Control cohort|
3107901|NCT01838044|Experimental|Arm A|The group of patients who are randomized to receive concomitant treatment of pregabalin and celecoxib during the first study period.
3107902|NCT01838044|Other|Arm B|The group of patients who are randomized to receive celecoxib monotherapy during the first study period.
3107903|NCT01838031|No Intervention|the control group|The serum will be stored and the measurements will be obtained after the delivery
3107904|NCT01838031|Active Comparator|the thyroid screening group|The thyroid function and antibody will be measured during pregnancy. The subclinical hypothyroidism will be treated individually.
3107905|NCT01838018||PKAN|This group consists of individuals diagnosed with PKAN using a combination of MRI and PANK2 gene sequencing.
3107906|NCT01838018||Healthy volunteers|This is a control group of healthy volunteers, matched with the PKAN group for age and sex.
3107907|NCT01838005|No Intervention|Standard of Care|"Routine implementation of the national PMTCT guidelines which are an adaptation of the WHO's Option A"
3107908|NCT01838005|Experimental|Conditional Cash Transfer|Financial incentive to attend regular clinic visits and receive PMTCT care
3107909|NCT01837992|Active Comparator|Standard dose|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, and will be administered the standard recommended primaquine dose of 0.25mg/kg for 14 consecutive days.
3107910|NCT01837992|Active Comparator|High dose|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, and will be administered a primaquine dose of 0.5mg/kg/day for 14 consecutive days.
3107911|NCT01837992|Other|Control|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, but will not receive primaquine until the time of confirmed recurrent parasitaemia or completion of 3 months follow up.
3107912|NCT01837979||DBS screening test|cell-free fetal DNA for Dried blood spots samples in high risk pregnant women.
3107913|NCT01837979||maternal serum screening test|cell-free fetal DNA for maternal serum screening test samples in high risk pregnant women.
3107914|NCT01837966|Active Comparator|Lavender oil|Lavender oil aromatherapy
3107915|NCT01837966|Placebo Comparator|Placebo|Placebo -- unscented oil aromatherapy
3107916|NCT01837953|Other|Unguided Self-Help, No Further Treatment for 16 Weeks|All participants will first receive 10 weeks of unguided self-help (USH), followed by no further treatment for 16 weeks. Participants will be offered a follow up referral to the eating disorders program at The Ottawa Hospital after the 16 week no-treatment period.
3107917|NCT01837953|Experimental|Unguided Self-Help, GPIP|All participants will first receive 10 weeks of unguided self-help (USH). For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy condition, this second step will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy.
3107918|NCT01837940|Placebo Comparator|Placebo|
3107919|NCT01837940|Active Comparator|dietary supplement|Lactobacillus reuteri DSM 17938
3107920|NCT01837927|Experimental|NVA237|NVA237 inhaled via the Breezhaler® device once daily
3107921|NCT01837927|Active Comparator|Tiotropium|Tiotropium 5μg inhaled via the Respimat® device once daily
3107922|NCT01837914|Experimental|Maxillary expansion as First treatment|Orthodontic expansion of upper jaw, then cross-over to adenotonsillectomy
3107923|NCT01837914|Active Comparator|Adenotonsillectomy as First treatment|surgical removal of tonsils and adenoids, then cross-over to maxillary expansion
3107924|NCT01837901|Sham Comparator|Sham|No stimulation transcorneal electrostimulation
3107925|NCT01837901|Experimental|150%|transcorneal electrostimulation with 150% of phosphene threshold
3107926|NCT01837901|Experimental|200%|transcorneal electrostimulation with 200% of phosphene threshold
3107927|NCT01837888|No Intervention|Standard training provided by clinician|Participants in the control group will receive the current standard of care. (i.e., any training provided by the clinician or vendor who prescribes/provides the wheelchair). Participants will receive one follow up phone call to remind them of followup testing.
3107928|NCT01837888|Experimental|WheelSee Training Program|Participants allocated to the intervention group will take part in WheelSee in groups of 2-4. The WheelSee intervention consists of 6 (twice weekly, minimum 3 days apart) x 1.5 hour sessions. Participants will be encouraged to bring a family member to each session, who may act as a spotter during the practice of wheelchair skills. If no family member is available, a student volunteer spotter will be available to ensure a 1:1 spotter: wheelchair user ratio. All spotters will be trained in appropriate spotting techniques.
3107929|NCT01837875|No Intervention|Control|Mailed informational literature
3107930|NCT01837875|Active Comparator|Set Menu|Intervention: Enrollment in a local Chronic Disease Self-Management program (CDSMP) and monthly follow up calls to gauge progress and comfort
3107931|NCT01837875|Experimental|Intervention|Intervention: Each individualized intervention plan (IIP) will include 1-4 options, including a mail-delivered arthritis kit, addition and access to a listserv, participation in a support group, and enrollment in local self-management program(s).
3107932|NCT01837862|Experimental|Low-grade Glioma|Patients on the low-grade arm will receive treatment with seven 10-week cycles of carboplatin, vincristine, temozolomide, and mebendazole.
3107933|NCT01837862|Experimental|High-grade Glioma/Pontine Glioma|Patients on the high-grade glioma/pontine glioma arm will receive treatment with twelve 28-day cycles of bevacizumab, irinotecan, and mebendazole.
3107934|NCT01837836|Experimental|Health education|The arm includes all the villages under study. Health education will be provided targeting following groups: 1. Home makers 2. School children 3. Water tank operators.
3107935|NCT01837823|Experimental|rosuvastatin|All subjects will receive rosuvastatin 40mg/day
3107936|NCT01837810|Experimental|Ibuprofen|800mg ibuprofen every 8 hours prn pain.
3107937|NCT01837810|Placebo Comparator|Methylcellulose Powder|Subjects receive inert methylcellulose powder as placebo
3108395|NCT01834612|Sham Comparator|No blood draw|CM 1500 with no blood draw
3107938|NCT01837797|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
3107939|NCT01837797|Experimental|Brexpiprazole 1 mg|Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week followed by 1 mg/day.
3107940|NCT01837797|Experimental|Brexpiprazole 3 mg|Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week, 1 mg/day in the second week, followed by 3 mg/day.
3107941|NCT01837784||Elderly patients|
3107942|NCT01837784||Patients with diabetes mellitus|
3107943|NCT01837784||Patients with heart failure|
3107944|NCT01837784||Patients with resistant hypertension|
3107945|NCT01837771|Active Comparator|Diaphragmatic stimulation|Diaphragmatic stimulation via electrode for 4 weeks
3107946|NCT01837771|No Intervention|No intervention|
3107947|NCT01837758||Dialysis|Platelet function will be documented during the first 48 hours of veno-venous hemofiltration using the Multiplate system.
3107948|NCT01837745|Active Comparator|Ablation group|"Administration of 1.1 GBq of I131 is given after the second intramuscular injections of rhTSH (0.9 mg). A whole body scan (WBS) is performed 2 to 5 days after the administration or I131 with determination of the neck uptake.~Follow-up consists in:~10 (+/- 2 months) after randomization: neck ultrasound + a serum Tg measurement after rhTSH stimulation~2 years (+/- 2 months) after randomization: serum Tg measurement under LT4 treatment (Tg/LT4)~3 years (+/- 2 months) after randomization: neck ultrasound and a serum Tg/LT4~4 years (+/- 2 months) after randomization: a serum Tg/LT4~5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4"
3107949|NCT01837745|Experimental|Follow up group|Patients randomized in the follow up group neither received 131I nor rhTSH. Patients will undergo the same followup procedures as patients randomized to the ablation group, except that at 10 months after randomization, Tg will be measured under LT4 treatment and not after rhTSH stimulation.
3107950|NCT01837732|Experimental|A: relational touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
3107951|NCT01837732|Active Comparator|B: relational|Relational: 10 mn verbal patient's centered exchanges
3107952|NCT01837719|Experimental|Treatment A: Atazanavir + Cobicistat coadministered|Participants received a single dose of atazanavir, 300 mg as capsule, coadministered with cobicistat,150 mg as tablet, following a light meal on Day 1 or 8
3107953|NCT01837719|Experimental|Treatment B: Atazanavir/Cobicistat FDC|Participants received a single fixed-dose combination (FDC) of atazanavir, 300 mg/cobicistat, 150 mg, following a light meal on Day 1 or 8
3107954|NCT01837719|Experimental|Treatment C: Atazanavir + Cobicistat coadministered|Participants received a single dose of atazanavir, 300 mg as capsule, coadministered with cobicistat,150 mg as tablet, in the fasted state on Day 15 or 22
3107955|NCT01837719|Experimental|Treatment D: Atazanavir/Cobicistat FDC|Participants received a single FDC dose of atazanavir, 300 mg/cobicistat, 150 mg, in the fasted state on Day 15 or 22
3107956|NCT01837719|Experimental|Treatment E: Atazanavir/Cobicistat FDC|Participants received a single FDC dose of atazanavir, 300 mg/cobicistat, 150 mg, following a high-fat meal on Day 29
3107957|NCT01837706||Emergency Room Patients|
3107958|NCT01837693|No Intervention|one year follow up|A random sample of HPV positive women with negative cytology will be invited to repeat HPV DNA test and biomarkers after a year, as recommended by the current screening protocols based on HPV DNA
3107959|NCT01837693|Experimental|direct sending in colposcopy|Experimental: immediate colposcopy. A random sample of HPV positive women with negative cytology will be sent to immediate colposcopy
3107960|NCT01837680|Active Comparator|Levemir|Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will take half of the short-acting dose with breakfast and the other half with lunch. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
3107961|NCT01837680|Active Comparator|NPH|Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will get the entire dose of short-acting insulin with breakfast. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
3107962|NCT01837667|Experimental|LB-100 for Injection and Docetaxel|Part 1: LB-100 infusion. Part 2: LB-100 infusion and docetaxel infusion.
3107963|NCT01837654|Experimental|Plantarflexion|Plantarflexion
3107964|NCT01837641|Experimental|LY3002813-Single 0.1 mg/kg then multiple 0.3 mg/kg|0.1 milligram per kilogram (mg/kg) single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks intravenously (IV)
3107965|NCT01837641|Experimental|LY3002813-Single then multiple 0.3 mg/kg|0.3 mg/kg single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
3107966|NCT01837641|Experimental|LY3002813-Single then multiple 1 mg/kg|1 mg/kg single dose then 1 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
3107967|NCT01837641|Experimental|LY3002813-Single then multiple 3 mg/kg|3 mg/kg single dose then 3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
3107968|NCT01837641|Experimental|LY3002813-Single then multiple 10 mg/kg|10 mg/kg single dose then 10 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
3107969|NCT01837641|Placebo Comparator|Placebo-Single then multiple|Placebo given once, then every 4 weeks for up to 16 weeks IV
3107970|NCT01837641|Experimental|LY3002813-SC|Up to 3 mg/kg LY3002813 given once subcutaneously (SC)
3107971|NCT01837641|Experimental|LY3002813-IV|Up to 3mg/kg LY3002813 given once intravenously (IV)
3107972|NCT01837628|Active Comparator|Lidocaine gel|Intraurethral Lidocaine gel 2%
3107973|NCT01837628|Experimental|Paraffin Oil|Intraurethral injection
3107974|NCT01837615|Experimental|Photopill treatment|
3107975|NCT01837602|Experimental|cMet positive breast cancer patients|Metastatic breast cancer patients with an accessible tumor (cutaneous, subcutaneous, or superficial) and/or a palpable adenopathy/mass, with ≥ 30% tumor cells expressing cMet as demonstrated on immunohistochemical analysis . The intensity for cMet IHC should be greater than or equal to 1+. The targeted tumor must be accessible (i.e. is not near a great vessel or the spinal cord) and can be surgically excised or biopsied.
3107976|NCT01837589|Other|QCT and DXA|All the patients will have both QCT and DXA
3107977|NCT01837576|Experimental|Calcipotriol plus BDP gel in different doses|A-E: calcipotriol, BDP gel in different concentrations
3107978|NCT01837550|Active Comparator|Control group|no professional support
3107979|NCT01837550|Experimental|Intervention group|Professional support via Internet
3107980|NCT01837537||no treatment|no treatment, prospective observational
3107981|NCT01837524|Experimental|Grocery-Store-Based Visit Arm|25 participants will be randomized to this arm. They will receive a baseline 30-minute phone call with the study dietitian to determine their current health problems, dietary patterns, shopping and cooking habits and health goals. They will then have 3 in-person visits with the dietitian conducted during grocery shopping trips at a local supermarket. These in-person visits will be conducted monthly over a 3 month period. The information delivered in the visits will be similar in content to that delivered in an in-office visit, including how to pick the best types of foods or ingredients for a given health condition, how to read and understand food labels, healthy recipes, how to track food and drink intake, and basic nutritional knowledge.
3107982|NCT01837524|Active Comparator|Office-Based Visit Arm|25 participants will be randomized to this arm. They will receive a baseline 30-minute phone call with the study dietitian to determine their current health problems, dietary patterns, shopping and cooking habits and health goals. They will then have 3 in-person visits with the dietitian conducted in an office at one of our medical office buildings. These in-person visits will be conducted monthly over a 3 month period. The information delivered in the visits will include how to pick the best types of foods or ingredients for a given health condition, how to read and understand food labels, healthy recipes, how to track food and drink intake, and basic nutritional knowledge.
3107983|NCT01837511||Cancer Group|Patients with pathologically proven stage I, II and III NSCLC.
3107984|NCT01837498||Neostigmine group|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
3107985|NCT01837498||Sugammadex group|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
3107986|NCT01837485|Experimental|Lactol|
3107987|NCT01837485|Placebo Comparator|Placebo|
3107988|NCT01837472|Experimental|Probiotic|
3107989|NCT01837472|Placebo Comparator|Placebo|
3107990|NCT01837459||Obese-Normal|Obese with Apnea Hypopnea index (AHI) <1
3107991|NCT01837459||Obese-SDB|Obese and with AHI>1
3107992|NCT01837459||Lean-Normal|Non-obese with AHI<1
3107993|NCT01837459||Lean-SDB|Non-obese with AHI>1
3107994|NCT01837446|Experimental|Morphine mouthwash|The morphine group uses the mouthwash of 2% morphine solution (20 mg morphine sulfate diluted in 100 mL of water), 10 mL every three hours; six times a day. The morphine solution is prepared by the faculty of pharmacy under supervision of the Food and Drug Organization of the local Medical University.
3107995|NCT01837446|Active Comparator|Magic mouthwash|The magic group uses a mouthwash contained a mixture of 240 mL magnesium aluminum hydroxide (Alborz Co., Iran), 25 mL 2% viscous lidocaine (SinaDaru Co., Iran), and 60 mL diphenhydramine (Emad Co., Iran), 10 mL every three hours; six times a day.
3107996|NCT01837433|Experimental|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
3107997|NCT01837433|Active Comparator|Prednisone 6 weeks|Oral 30 mg/day of prednisone will be administered as the initial dose for the treatment of SAT in first week,then tapered by 5mg every 1 week,the duration of prednisone will be 6 weeks.
3107998|NCT01837420|Other|Placebo with crossover to VB-201 160mg|Subjects on placebo will crossover to VB-201 160 at week 16.
3107999|NCT01837420|Experimental|VB-201 80mg|Subjects will receive VB-201 80mg/day for 24 weeks
3108000|NCT01837420|Experimental|VB-201 160mg|Subjects will received 80mg twice daily for 24 weeks
3108001|NCT01837407|Other|Surgical flap|The flap includes the nerve for repair of the soft tissue and nerve defects
3108002|NCT01837394|Active Comparator|Block arm|Ultrasound guided block of the SN and ONP with 7.5 ml of Ropivacaine 7.5 mg/ml injected at each site, respectively, immediately prior to induction of general anesthesia. Standard postoperative analgesia with paracetamol 1 g every 6 hours and Morphine 5 mg as needed. Ondansetron or Metoclopramide as needed for nausea.
3108003|NCT01837394|Placebo Comparator|Placebo arm|Ultrasound guided placebo block of the SN and ONP with 7.5 ml of isotonic saline solution injected at each site, respectively, immediately prior to induction of general anesthesia. Standard postoperative analgesia with paracetamol 1 g every 6 hours and Morphine 5 mg as needed. Ondansetron or Metoclopramide as needed for nausea.
3108004|NCT01837381|Other|Transarterial Ethanol Ablation (TEA)|Two treatment sessions at 2 months apart were given and started within 4 weeks after randomization.
3108005|NCT01837355|Placebo Comparator|Placebo|placebo once daily for 12 weeks
3108006|NCT01837355|Experimental|Lactobacillus rhamnosus|lactobacillus rhamnosus once daily for 12 weeks
3108007|NCT01837342|Other|Sigmoidectomy arm|Standard of care arm : sigmoid reserction after randomisation
3108008|NCT01837342|Experimental|Control arm|laproscopic drainage and washing
3108009|NCT01837329|Experimental|Tetrathiomolybdate|"Dose Escalation - It is aimed at determining the maximum tolerated dose of TM in combination with carboplatin and pemetrexed.~Dose Expansion - The dose expansion portion of the study will begin after completion of the dose escalation phase."
3108010|NCT01837316|Experimental|FF/VI|A single dose inhalation of FF/VI 100/25 mcg in the morning
3108011|NCT01837316|Placebo Comparator|Placebo|A single dose inhalation of matching placebo in the morning
3108012|NCT01837303||Liquid based cytology|All participants will undergo both manual and conventional automated liquid based cytology (pap smear, cervical cytology).
3108013|NCT01837290|Active Comparator|Group Dexmedetomidine (Group D)|Midazolam 0.02 mg/kg intravenously + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication + Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
3108014|NCT01837290|Placebo Comparator|Group Control (Group C)|Midazolam 0.02 mg/kg + saline infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5mg) (n=30)
3108015|NCT01837277|Experimental|Raltegravir|Intervention: Patients will receive ART regimen based on investigational drug Raltegravir 400 mg BID + TDF 300 mg QD+ 3TC 150 mg BID
3108016|NCT01837277|Active Comparator|Efavirenz|Intervention: Patients will receive ART regimen based efavirenz (EFV 600 mg QD +TDF 300 mg QD+ 3TC 300 mg QD) for one year
3108017|NCT01837264|Experimental|Bone Marrow Cell Concentrate|
3108018|NCT01837251|No Intervention|Control Arm|Patients receive bevacizumab 15 mg/kg iv on day 1 followed by gemcitabine 1000mg/m² iv on day 1 & 8 and carboplatin AUC4 iv on day 1 every 3 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
3108019|NCT01837251|Experimental|Research Arm|Patients receive bevacizumab 10 mg/kg iv on day 1 & 15 followed by PLD 30mg/m² iv on day 1 carboplatin AUC4 iv on day 1 every 4 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
3108020|NCT01837238|Experimental|beta-hydroxy beta-methylbutyrate|Calcium-HMB (3g) will be consumed daily for 6 months by all participants assigned to the HMB group.
3108021|NCT01837238|Placebo Comparator|Placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
3108022|NCT01837225||Control|Patients in the control arm will not receive the fluorescent contrast agent (5-ALA); however, intraoperative fluorescence imaging will still be performed. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
3108023|NCT01837225||Low Dose Contrast Agent|Patients in the low dose arm will receive 15 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
3108024|NCT01837225||High Dose Contrast Agent|Patients in the high dose arm will receive 30 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
3108025|NCT01837199|Experimental|Smoking|Metronidazole plus Amoxicillin
3108026|NCT01837199|Experimental|Non-Smoking|Metronidazole plus Amoxicillin
3108027|NCT01837186||EFP|Empyema following pneumonectomy
3108028|NCT01837186||nEFP|No empyema following pneumonectomy
3108029|NCT01837173||Extracapsular LNI|Patients with positive lymph nodes that show extracapsular lymph node involvement
3108030|NCT01837173||Intracapsular LNI|Patients with positive lymph nodes that show NO extracapsular lymph node involvement
3108031|NCT01837160||Healthy Volunteers|"10 patients with normal echocardiogram studies and no history of ischaemic heart disease.~Patients to recieve CT-PET with fluciclatide, cardiac MRI scan, CT-coronary angiogram and echocardiogram."
3108032|NCT01837160||Moderate Aortic Stenosis (n=10)|"Patients with moderate aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
3108033|NCT01837160||Mild Aortic Stenosis (n=10)|"Patients with mild aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
3108034|NCT01837160||Severe aortic Stenosis (n=10)|"Patients with severe aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
3108035|NCT01837160||Severe Aortic Stenosis for AVR (n=10)|"Patients with severe aortic stenosis proceeding to aortic valve replacement. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo a repeat CT-PET scan 3 months after the operation.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 months after the operation."
3108036|NCT01837147|Experimental|Web-based Tracking Group|Technology-Based Physical Activity Promotion
3108037|NCT01837147|Active Comparator|Pedometer Group|Participants assigned to this group will receive a pedometer.
3108038|NCT01837134|No Intervention|control (C) group|The control group will remain in routine care for 12 weeks. After 12 weeks they will also be given a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. During the next 12 weeks they will get care calls from the study centre aiming to discuss measured data and to fix target agreements.
3108039|NCT01837134|Experimental|telemedical (TM) group|Participants in the telemedical (TM) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre.
3108040|NCT01837134|Experimental|telemedical coaching (TMC) group|Participants in the telemedical coaching (TMC) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. Additionally, they will be called once per week for 12 weeks from the study centre aiming to discuss measured data and to fix target agreements. After 12 weeks the care calls be be given once per month for further 9 months.
3108041|NCT01837121|Other|the SMS group|the diabetic retinopathy patient in the SMS group will receive a SMS reminder message about the revisit time,address 1 week and 3 day before the appointment.
3108042|NCT01837121|No Intervention|the control group|the diabetic retinopathy patient in the control group won't get any reminder message before the appointment.
3108043|NCT01837108|Placebo Comparator|Placebo|fully mimicking placebo 50 mg bid during 8 days
3108044|NCT01837108|Experimental|eplerenone|eplerenone 50 mg bid during 8 days
3108045|NCT01837095|Experimental|POL6326|POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
3108046|NCT01837082|Active Comparator|Iron|ferric carboxymaltose
3108047|NCT01837082|Placebo Comparator|Placebo|Sodium chloride 0.9%
3108459|NCT01834144|Active Comparator|Moderate intensity exercise|150-200 minutes of weekly moderate intensity exercise (45-55% of peak fitness)
3108048|NCT01837069|Active Comparator|Treatment|Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
3108049|NCT01837069|No Intervention|Control|Standard of care
3108050|NCT01837043|Experimental|Belatacept|Subjects will be converted from standard of care CNI therapy to Belatacept 10 mg/kg IV on post renal transplant Day 7 (+/- 3 days). As suggested in the package insert for de novo dosing, further dosing of belatacept will be given as 10 mg/kg IV at weeks 2, 4, 8 and 12 then 5 mg/kg at week 16 and then every 4 weeks (+/- 5 days) through week 52. CNI will be stopped during the first belatacept infusion.
3108051|NCT01837043|Active Comparator|Calcineurin Inhibitor|Patients randomized to this arm will remain on the current CNI as prescribed by post-transplant standard of care therapy.
3108052|NCT01837030|Other|Oral Iron|
3108053|NCT01837030|Other|Oral Iron and Capsule Endoscopy|
3108054|NCT01837017|Experimental|Home-based Exercise|The home-based exercise group attends 4 exercise instructional sessions lead by a train exercise specialist. The exercise protocol focuses on improving balance, walking, lower limb and core muscle strength, and spasticity. The instructional session teaches participants a standardized series of exercises that focus on balance, muscle strength, and stretching. The exercises target lower limb & core muscle function. Once taught, participants will perform the exercises 3 times a week in their home as outlined in a manual. Subjects return in the first month and second month to ensure that exercises are being executed with correct form and appropriate intensity level. Compliance of at-home exercise will be assessed with diaries that participants complete every other week.
3108055|NCT01837017|No Intervention|Control|Wait-list control.
3108056|NCT01837004|Experimental|CORTEX|The CORTEX group will attend 10, 2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task & cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
3108057|NCT01836991|Other|D2 surgery|D2 surgery(No.1、No.3、No.4sb、No.4d、No.5、No.6、No.7 and No.8a、No.9、No.11p、No.12a lymph node)
3108058|NCT01836991|Experimental|D2+ surgery|D2+ surgery(D2+8p、12b、13、14v lymph node)
3108059|NCT01836978|No Intervention|Control|Patients in this group will follow standard MUHC clinical guidelines. This group will receive general instructions, by the preoperative clinic nurse, on exercises (breathing, ankle rotation) to be done before and after surgery. They will also be seen by a nutritionist who will provide general counseling for healthy eating.
3108060|NCT01836978|Experimental|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program, and stress reduction strategies.
3108061|NCT01836965|Experimental|Social Skills Intervention|The intervention is a 12-week social skills training program that will consist of a 90 minute group therapy session followed by a 90 minute peer generalization session (in the form of a photography class with typically developing peers) meeting once per week. Each cohort will consist of 6 adolescents with Aspergers or high-functioning autism, who will be joined by 6 typically-developing peers for the photography class. During the group therapy session adolescents will discuss and watch video clips addressing social skills topics relevant to their age group. They will have a chance to practice these skills when paired with a typically developing peer for the photography class.
3108062|NCT01836952||Infants|Infant born via vaginal delivery
3108063|NCT01836939|Active Comparator|TSO 2500|TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
3108064|NCT01836939|Active Comparator|TSO 7500|TSO 7500: 7500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
3108065|NCT01836926|Active Comparator|Open intersphincteric resection|surgical Instruments for open approach intervention: Open laparotomy through abdominal incision and mobilization of the colon and rectum up to the splenic flexure with high ligation of the inferior mesenteric vessels and mesorectal excision till the levator ani then the peranal approach to resect the distal margin of the rectum through high or low intersphincteric resection in the plane between internal and external anal sphincters.
3108066|NCT01836926|Active Comparator|laparoscopic intersphincteric resection .|"instruments used: 4 or 5 laparoscopic trocars (two or three (10-mm) trocar, Two 5-mm trocars and a 12-mm trocar with reducers),Three 5-mm fenestrated grasping forceps, Five-millimetre coagulating shears, a 5-mm straight grasping forceps, Harmonic scalpel, 5 or 10 mm, a 10-mm fenestrated forceps, a 10-mm dissector,5 mm Bipolar grasper, a 5-mm needle holder, Twelve-millimetre linear staplers~intervention:~Trocar Placement and Exposure~Rectosigmoid Mobilization and Control of Inferior Mesenteric Vessels~Taking Down the Splenic Flexure~rectal dissection till the levator ani muscle and resection of thye lateral ligaments~then the peranal phase as in the laparotomy approach."
3108067|NCT01836913||Radiotherapy for esophageal cancer|Patients with histology proven esophageal cancer who are planned for high dose radiotherapy with or without chemotherapy with or without surgery.
3108068|NCT01836900|Active Comparator|Standard Therapy|Endoscopic therapy with Standard Clip + injection of epinephrine solution or thermal therapy + injection of epinephrin-solution
3108069|NCT01836900|Experimental|OTSC (Over The Scope Clip)|Endoscopic therapy with Application of OTSC Clip and Injection of epinephrin-solution
3108070|NCT01836887|Placebo Comparator|Intervention 1|Very low polyphenol fruit based drink (control)
3108071|NCT01836887|Active Comparator|Intervention 2|Polyphenol-enriched fruit-based drink - low
3108072|NCT01836887|Active Comparator|Invervention 3|Polyphenol-enriched fruit-based drink - high
3108073|NCT01836874||Topiramate|
3108074|NCT01836861|Experimental|IPI-145 and [14C] IPI-145|
3108075|NCT01836848|Experimental|indocyanine green|in this arm we do the Intervention 'measuring cerebral perfusion by NIRS with ICG', the pat. gets before a CT-Scan with perfusion measurement a indocyanine green bolus i.v. and a measurement of cerebral perfusion with near-infrared-spectroscopy
3108076|NCT01836835||Hyperemesis gravidarum|Women diagnosed with hyperemesis gravidarum admitted to hospital Pregnancy Unique Questionnaire of Emesis (PUQE) and 24 hours self-reported nutritional intake form administered
3108077|NCT01836835||Healthy pregnant women|Women with presumed normal pregnancy Pregnancy Unique Questionnaire of Emesis (PUQE) and 24 hours self-reported nutritional intake form administered
3108493|NCT01833832|Experimental|1|Cytoreductive surgery followed by HIPEC with cisplatin
3108078|NCT01836822|Experimental|Bronchoscopic lymph node sampling|Several different sampling techniques will be used in each patient. They include: EBUS guided transbronchial needle aspiration (EBUS-TBNA), EBUS guided transbronchial forceps biopsy (EBUS-TBFB), large bore (19G) histologic needle biopsy of the mediastinal lymph nodes, forceps biopsy of bronchial mucosa in central and peripheral bronchi
3108079|NCT01836809|Experimental|Total Artificial Heart|Nesiritide
3108080|NCT01836809|Placebo Comparator|Total Artificial Heart: Placebo|Control arm for subjects receiving the Total Artificial Heart and randomized to receive placebo
3108081|NCT01836809|Active Comparator|LVAD: Nesiritide|Active arm of the LVAD group
3108082|NCT01836809|Placebo Comparator|LVAD: Placebo|Control arm for subjects receiving LVAD and randomized to placebo
3108083|NCT01836796|Active Comparator|Lactobacillus Reuteri low|100 million Lactobacillus Reuteri once daily
3108084|NCT01836796|Active Comparator|Lactobacillus Reuteri High|10 billion Lactobacillus Reuteri once daily
3108085|NCT01836796|Placebo Comparator|Placebo|
3108086|NCT01836783|Experimental|Amnion Allograft|Atraumatic tooth extractions and amnion allograft procedures
3108087|NCT01836783|Active Comparator|Allograft|Atraumatic tooth extractions and allograft procedures
3108088|NCT01836770||Transforaminal Epidural Steroid Injection|Patients with a history of lumbosacral radiculopathy or lumbar herniated nucleus pulposus, scheduled for Transforaminal Epidural Steroid Injection.
3108089|NCT01836757|Experimental|MSM group|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
3108090|NCT01836757|Placebo Comparator|Placebo Group|Placebo 3 gr twice a day for 26 weeks (6 gr/day total)
3108091|NCT01836744|Active Comparator|survival rate autologous bone|dental implant placement in the previous sinus lift side with autologous bone; dental implant placement in the previous sinus lift side with xenograft material side;
3108092|NCT01836744|Active Comparator|survival rate axenograft material|dental implant placement in the previous sinus lift side with xenograft material side;
3108093|NCT01836731|Experimental|Classic Intervention|"The standard classic approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones."
3108094|NCT01836731|Experimental|Minimum Intervention|"The lite trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers."
3108095|NCT01836731|No Intervention|Control|"The control group is not enrolled in the CBEHPP.~Because of the government's commitment for the national roll out to the CBEHPP, the control population will receive the intervention as soon as possible following the conclusion of the trial phase. Nevertheless, we will continue to evaluate the sustained impact of the intervention for two additional years by monitoring various behavioural outcomes and indicators and their impact on exposure outcomes (drinking water, hand hygiene, consumption, schooling and labour market participation etc.). We will use data from the RCT phase and clinical records to estimate the effect of any sustained impact on health. Long term impacts can be inferred by using data from the trial as well as data on long term behavioural outcomes."
3108096|NCT01836718||HCV RNA (-) on anti-viral therapy|Patients undergoing liver transplantation who are documented HCV viral load undetectable while on antiviral therapy
3108097|NCT01836718||HCV RNA (+) on anti-viral therapy|Patients undergoing liver transplantation who are receiving anti-viral therapy and who have a documented detectable HCV viral load
3108098|NCT01836718||HCV RNA (+) not on anti-viral therapy|Patients undergoing liver transplantation who are not currently receiving anti-viral therapy and are documented viral load positive will be included and serve as a comparison group
3108099|NCT01836705|Experimental|Single-sequence|SAR302503 Placebo (1 day)-SAR302503 (500 mg, oral, qd, 14 days)
3108100|NCT01836692|Experimental|Thoracic radiotherapy|Intensity Modulated Radiotherapy treatment (delivered twice daily on consecutive weekdays over 4.5 weeks)
3108101|NCT01836679|Experimental|Arm 1|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive Chidamide 20mg orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred.
3108102|NCT01836679|Placebo Comparator|Arm 2|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive placebo orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred.
3108103|NCT01836653|Experimental|mFOLFOX + Bmab|mFOLFOX plus bevacizumab
3108104|NCT01836653|Active Comparator|mFOLFOX + Cmab|mFOLFOX plus cetuximab
3108105|NCT01836627|Experimental|Treatment Hyperinsufflation Therapy|Treatment group will have 15 minute hyperinsufflation treatments twice a day for one year.
3108106|NCT01836627|No Intervention|Control|The control group will continue with their current daily care
3108107|NCT01836614|Active Comparator|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes. The bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion
3108108|NCT01836614|Placebo Comparator|Saline|The saline will be administered over an infusion pump over 10 minutes and followed by a bolus. The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion.
3108109|NCT01836601|No Intervention|Pre-nighttime communication intervention arm|This arm is the pre-intervention arm of parents, nurses, and residents before the nighttime communication bundle has been enacted.
3108110|NCT01836601|Experimental|Post-nighttime communication intervention arm|This arm is the post-intervention arm of parents, nurses, and residents after the nighttime communication bundle has been enacted.
3108111|NCT01836588|Active Comparator|gentle tissue extraction (curettage)|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
3108112|NCT01836588|Active Comparator|conventional cervix biopsy|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
3108113|NCT01836575|Experimental|Arm B|Pemetrexed, 500mg/m2 + appropriate vitamin supplementation + Carboplatin [Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle] + Antiemetic therapy at investigator's discretion.
3108114|NCT01836575|Active Comparator|Arm A:|Pemetrexed, 500mg/m2 + appropriate vitamin supplementation + Antiemetic therapy at investigator's discretion.
3108115|NCT01836562|Other|STEM CELL|intra thecal injection of MNC stem cell therapy
3108116|NCT01836549|Experimental|Treatment (imetelstat sodium)|"Molecular Biology Phase: Patients will receive one infusion of imetelstat prior to surgery. Surgery will take place 12-24 hours after the infusion of imetelstat. Patients will continue to receive therapy on the same schedule as the Phase II patients starting 14-21 days after surgery.~Phase II: Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
3108117|NCT01836536|Other|BEVACIZUMAB|BEVACIZUMAB standard of care
3108118|NCT01836523|Experimental|Liraglutide 0.6 mg + insulin|
3108119|NCT01836523|Experimental|Liraglutide 1.2 mg + insulin|
3108120|NCT01836523|Experimental|Liraglutide 1.8 mg + insulin|
3108121|NCT01836523|Placebo Comparator|Liraglutide placebo 0.6 mg + insulin|
3108122|NCT01836523|Placebo Comparator|Liraglutide placebo 1.2 mg + insulin|
3108123|NCT01836523|Placebo Comparator|Liraglutide placebo 1.8 mg + insulin|
3108124|NCT01836484||Surgically staged endometrial and cervical carcinoma|
3108125|NCT01836471|Experimental|QAW039 450 mg qd Non-atopic|QAW039 450 mg (3 capsules of QAW039 150 mg) qd combined with background ICS (100 μg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1.
3108126|NCT01836471|Placebo Comparator|Placebo Non-atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with background ICS (100 μg fluticasone, bid). Non-atopic randomized in ratio of approximately 1:1.
3108127|NCT01836471|Experimental|QAW039 450 mg qd Atopic|QAW039 450 mg (3 capsules of QAW039 150 mg) qd combined with background ICS (100 μg fluticasone, bid). Atopic patients randomized in a ratio of approximate 1:1:1
3108128|NCT01836471|Active Comparator|Fluticasone 150 mcg bid Atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with 150 μg ICS and with background ICS (100 μg fluticasone, bid). As a consequence total ICS was 250 μg fluticasone bid. Atopic patients randomized in ratio of approximately 1:1:1
3108129|NCT01836471|Placebo Comparator|Placebo Atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with background ICS (100 μg fluticasone, bid). Atopic patients andomized in ratio of approximately 1:1:1
3108130|NCT01836458|Experimental|Dose 1: 30 mg|Single dose of KAE609 30 mg
3108131|NCT01836458|Experimental|Dose 2: 20 mg|Single dose of KAE609 20 mg
3108132|NCT01836458|Experimental|Dose 3: 10 mg|Single dose of KAE609 10 mg
3108133|NCT01836458|Experimental|Dose 4: 15 mg|Single dose of KAE609 15 mg
3108134|NCT01836445|Experimental|Keep It Up! Intervention|The KIU! intervention is a multi-media online HIV prevention program developed specifically for young (18-29 years old) men who have sex with men (MSM) who recently tested HIV negative. Intervention content includes discussions of community involvement, scenarios on hooking-up online, communication skills in relationships (including negotiating safer sex), condom use, HIV knowledge, and HIV/STI risks. Information is presented in various formats like games, animation, and videos to address gaps in HIV knowledge, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors. The intervention is completed across three sessions, done at least 24 hours apart (i.e. at least 3 days), and takes about 2 hours total to complete.
3108135|NCT01836445|Active Comparator|HIV Knowledge Control|The control condition reflects HIV information that is currently available on many websites so as to understand how the KIU! intervention improves upon what is currently available online. It is not tailored to YMSM, non-interactive, and focused on HIV/STI knowledge. The control is completed across three sessions done at least 24 hours apart (i.e. at least 3 days).
3108136|NCT01836432|Experimental|FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy|"Arm 1A: SOC FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy~Day 71-80 Disease evaluated: New distant disease = salvage regimen Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total.~Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation+ HAPa on days 1 and 15 of Chemoradiotherapy.~Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for up to 18 doses total.~Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue FOLFIRINOX bi-weekly + HAPa bi-weekly 7 days offset from FOLFIRINOX up to18 doses of algenpantucel-L Immunotherapy.~Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total."
3108192|NCT01836068|Experimental|Enfuvirtide monotherapy|Enfuvirtide 90 mg subcutaneously every 12 hours will be also be administered during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions with conditioning regimens in patients who require ritonavir-boosted PI containing ART regimens.
3108193|NCT01836055||Clinically Isolated Syndrome|Patients diagnosed with Clinically Isolated Multiple Sclerosis
3108194|NCT01836055||Relapsing Remitting MS|Patients diagnosed with Relapsing Remitting Multiple Sclerosis
3108137|NCT01836432|Active Comparator|FOLFIRINOX (SOC) ALONE|"Arm 2A: FOLFIRINOX (Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours) given days 1, 15, 29, 43 & 57~Day 71-80 Disease eval: New disease = salvage Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m^2 IV over 30-60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest~Day 71-80 Disease eval: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy~Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine~Ineligible for surgical resection & stable disease = continue FOLFIRINOX~Ineligible for surgical resection & progressive disease = salvage Gem/Nab-Paclitaxel"
3108138|NCT01836432|Experimental|Gemcitabine/Nab-Paclitaxel+Algenpantucel-L HAPa Immunotherapy|"Arm 1B: Gemcitabine/Nab-Paclitaxel + Algenpantucel-L (HAPa) Immunotherapy~Day 71-80 Disease evaluated: New distant disease = salvage regimen FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total.~Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation + HAPa on days 1 and 15 of Chemoradiotherapy.~Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given days 1 and 15 for up to 18 doses total.~Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue Gem/Nab-Paclitaxel + HAPa given on days 8 and 22 for up to18 doses of algenpantucel-L Immunotherapy.~Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total."
3108139|NCT01836432|Active Comparator|Gemcitabine/Nab-Paclitaxel (SOC) Alone|"Arm 2B: Gemcitabine/Nab-Paclitaxel (SOC) Alone~SOC Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m^2 IV over 30-60 minutes for 3 weeks with 1 week rest. Given on days 1, 8, 15, 29, 36, 43, 57, 64 and 71~Day 71-80 Disease evaluated: New distant disease = salvage FOLFIRINOX given every 14 days~Day 71-80 Disease evaluation: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy~Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine~Ineligible for surgical resection & stable disease = continue gem/nab-paclitaxel given for 3 weeks (days 1, 8 and 15) with 1 week rest~Ineligible for surgical resection & progressive disease = salvage FOLFIRINOX given every 14 days"
3108140|NCT01836419|Experimental|young adult group|young adult patients undergoing minor urologic surgery or lower extremity surgery
3108141|NCT01836419|Active Comparator|elderly group|elderly patients undergoing minor urologic surgery or lower extremity surgery
3108142|NCT01836406|Experimental|Keromin Group|
3108143|NCT01836406|Placebo Comparator|Placebo Group|
3108144|NCT01836393|Experimental|placebo and plai|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of …%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
3108145|NCT01836380|Experimental|Swimming Training|The swimming training will be performed at two swimming pools on the campus of The University of Texas at Austin (University Aquatic Center or Gregory Gym pool). In the first 2-3 weeks a swimming instructor will provide personalized skill feedback to the subjects in the swim training group. Subjects will swim 15-20 minutes/day at a relatively low intensity of exercise while they receive swimming skill instructions. As their overall level of fitness and exercise skill improve, the intensity and duration of exercise will increase to 40-45 minutes/day at a moderate intensity of 70-75% of maximal heart rate. Exercise training will be performed three days per week.
3108146|NCT01836380|Experimental|Cycling Training|The cycling training will be conducted in the newly-constructed Exercise Training Intervention Core-Laboratory in the Department of Kinesiology and Health Education on the University of Texas campus. In the first 2-3 weeks a cycling instructor will provide personalized skill feedback to the subjects in the cycle training group. Subjects will cycle 15-20 minutes/day at a relatively low intensity of exercise while they receive cycling skill instructions. As their overall level of fitness and exercise skill improve, the intensity and duration of exercise will increase to 40-45 minutes/day at a moderate intensity of 70-75% of maximal heart rate. Exercise training will be performed three days per week.
3108147|NCT01836367|Experimental|Ingenol Mebutate 0.015%|two cycles of ingenol mebutate 0.015%
3108148|NCT01836354|Active Comparator|DESERVE education|Intervention group will receive education on stroke preparedness plus risk factor reduction education, and help accessing follow up care with health workers.
3108149|NCT01836354|No Intervention|Usual Care|The usual care group will only receive written preparedness education, which is the standard care for the hospital.
3108150|NCT01836341|Experimental|Afatinib w Cisplatin Pemetrexed Chemoradiation|"induction afatinib 40mg daily x 28days Cisplatin or Carboplatin (can be used if patient is not eligible for cisplatin) + Pemetrexed + 50Gy to pretreatment field boost to 60Gy to residual tumor + afatinib dose escalation*~*afatinib dose levels: 20mg daily, 30mg daily & 40mg daily (3+3 design) Then adjuvant afatinib x 2 years"
3108151|NCT01836328|Active Comparator|Parenteral /oral methadone ratio 1:2|"Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase.~Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient.~Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization.~INTERVENTION: Patients randomized to this arm will receive the double of OPTIMISED DOSE of parenteral METHADONE, orally every 24h in 3 administrations during the following 3 days."
3108195|NCT01836055||Control Subjects|Aged Matched Healthy volunteers
3108196|NCT01836042||Randomized iStent|Implantation of one iStent in conjunction with cataract surgery, patients randomized to group
3108197|NCT01836042||Randomized cataract surgery|Cataract surgery alone, patients randomized to group
3108198|NCT01836042||Non-randomized iStent|Implantation of one iStent in conjunction with cataract surgery, patients not randomized to group
3108152|NCT01836328|Experimental|Parenteral /oral methadone ratio 1:1.2|"Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase.~Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient.~Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization.~INTERVENTION: Patients randomized to this arm will receive the following Oral Methadone dose: 20% increase of optimised parenteral methadone dose every 24h in 3 administrations during the following 3 days."
3108153|NCT01836315||Obese|Defined by a BMI >35 kg/M2
3108154|NCT01836315||Non-Obese|Defined by a BMI <35 kg/M2
3108155|NCT01836302||Patients with Cerebral Desaturation|We will compare the primary and secondary outcomes between the patients who experience cerebral desaturations and those that do not.
3108156|NCT01836302||Patients without cerebral desaturation|We will compare the primary and secondary outcomes between the patients who experience cerebral desaturations and those that do not.
3108157|NCT01836289|Experimental|High-dose Cyclophosphamide|High-dose Cyclophosphamide
3108158|NCT01836276|Experimental|African American (AA) Smokers|
3108159|NCT01836276|Active Comparator|White Smokers|
3108160|NCT01836263||Prevention arm: CCB & i.v. iloprost|prevention arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)
3108161|NCT01836263||Prevention arm: bosentan & sildenafil|prevention arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil
3108162|NCT01836263||Healing arm: CCB & i.v. iloprost|healing arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)
3108163|NCT01836263||Healing arm: bosentan & sildenafil|healing arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil
3108164|NCT01836237|Experimental|Alexis group|In experimental group patients, the surgeon will use Alexis - a wound protector during surgery.
3108165|NCT01836237|No Intervention|Control group|In no intervention group patients, the surgeon will not use any wound protector during surgery.
3108166|NCT01836224|Active Comparator|Noradrenaline|Noradrenaline: Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65.
3108167|NCT01836224|Experimental|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
3108168|NCT01836211|Experimental|Fast strategy|High sensitivity cardiac troponin T followed by computed coronary tomography angiography
3108169|NCT01836211|Active Comparator|Standard of care strategy|Standard of care strategy based on serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
3108170|NCT01836198|Experimental|LY2409021 Only (Cohort 1)|Part A, Period 1. Participants will receive a single oral 20 mg dose of LY2409021 on Day 1.
3108171|NCT01836198|Experimental|LY2409021+Gemfibrozil (Cohort 1)|Part A, Period 2. Participants will receive a morning (AM) and evening (PM) oral dose of 600 milligram (mg) gemfibrozil on Days 1-20 and an AM oral dose only of 600 mg gemfibrozil on Day 21. Participants will also receive a single 20 mg oral dose of LY2409021 on Day 4.
3108172|NCT01836198|Experimental|LY2409021 Only (Cohort 2)|Part A, Period 1. Participants will receive a single oral 20 mg dose LY2409021 on Day 1.
3108173|NCT01836198|Experimental|LY2409021+Ketoconazole (Cohort 2)|Part A, Period 2. Participants will receive a 400 mg oral dose of ketoconazole on Days 1-21 and a single oral dose of 20 mg LY2409021 on Day 4.
3108174|NCT01836198|Experimental|LY2409021+Clarithromycin|Part B. Participants will receive a 500 mg oral dose of clarithromycin on Days 1-21 and a single oral dose of 20 mg LY2409021 on Day 4.
3108175|NCT01836185|Experimental|Evacetrapib (Healthy)|Group 1: 130 mg evacetrapib administered once, orally, to participants with normal hepatic function
3108176|NCT01836185|Experimental|Evacetrapib (Hepatic, Mild)|Group 2: 130 mg evacetrapib administered once, orally, to participants with mild hepatic impairment
3108177|NCT01836185|Experimental|Evacetrapib (Hepatic, Moderate)|Group 3: 130 mg evacetrapib administered once, orally, to participants with moderate hepatic impairment
3108178|NCT01836185|Experimental|Evacetrapib (Hepatic, Severe)|Group 4: 130 mg evacetrapib administered once, orally, to participants with severe hepatic impairment
3108179|NCT01836172|Placebo Comparator|Placebo t.i.d.|Placebo t.i.d.
3108180|NCT01836172|Placebo Comparator|YJP-14 25 mg t.i.d.|YJP-14 25 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
3108181|NCT01836172|Placebo Comparator|YJP-14 50 mg t.i.d.|YJP-14 50 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
3108182|NCT01836172|Placebo Comparator|YJP-14 100 mg t.i.d.|YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems. YJP-14 100 mg t.i.d.
3108183|NCT01836159|Other|Standard/ Usual Care|Patients may receive outpatient rehabilitation as required as part of usual/standard care. No experimental intervention will be given to this group.
3108184|NCT01836159|Experimental|iPad Intervention|Patients randomized to the iPad arm will be instructed to self-administer 20 minutes of game sessions per day for 10 days over a 2 week (14 day) period.
3108185|NCT01836146|Experimental|Renal Artery Ablation|
3108186|NCT01836133||Erlotinib 150 mg|Participants received 150 mg erlotinib once daily, orally, as tablets, until disease progression or unacceptable toxicity, up to 3 years.
3108187|NCT01836120|Experimental|Raltitrexed plus Docetaxel|
3108188|NCT01836120|Active Comparator|Docetaxel|
3108189|NCT01836094|Experimental|Methylene Blue|Methylene Blue, 280mg, oral, one time
3108190|NCT01836094|Placebo Comparator|Placebo|FD&C Blue No. 2 (food dye), oral, one time
3108191|NCT01836081|Experimental|fluid responsiveness|
3108266|NCT01835535|Experimental|Severe Resistant HTN|Patients presenting with resistant hypertension and office systolic blood pressure of 160 mmHg (150 mmHg for DM) or greater
3108199|NCT01836029|Experimental|chemotherapy and cetuximab plus VTX-2337|"VTX-2337 (3.0 mg/m2) will be administered on Day 8 and Day 15 of a 21-day cycle for 6 cycles, followed by dosing on Days 8 and 22 of 28-day cycles until disease progression.~Cisplatin (100 mg/m2) OR carboplatin (AUC 5 mg/mL/min) will be administered on Day 1 of a 21-day cycle for a maximum of 6 cycles.~5-FU (1000 mg/m2) will be administered on Days 1-4 of a 21-day cycle for a maximum of 6 cycles.~Cetuximab (initial dose: 400 mg/m2; remaining doses: 250 mg/m2) will be administered weekly until disease progression."
3108200|NCT01836029|Active Comparator|chemotherapy and cetuximab plus placebo|"Placebo (3.0 mg/m2) will be administered on Day 8 and Day 15 of a 21-day cycle for 6 cycles, followed by dosing on Days 8 and 22 of 28-day cycles until disease progression.~Cisplatin (100 mg/m2) OR carboplatin (AUC 5 mg/mL/min) will be administered on Day 1 of a 21-day cycle for a maximum of 6 cycles.~5-FU (1000 mg/m2) will be administered on Days 1-4 of a 21-day cycle for a maximum of 6 cycles.~Cetuximab (initial dose: 400 mg/m2; remaining doses: 250 mg/m2) will be administered weekly until disease progression."
3108201|NCT01836016|Experimental|conventional medicine|According to the individualized assessment of symptoms and exacerbation risk recommended by revised 2011 GOLD, patients in this group will be given conventional medicine treatment including three drugs, which are Salbutamol (Ventolin®), Formoterol (Oxis Turbuhaler®), Salmeterol / fluticasone (Seretide®).
3108202|NCT01836016|Experimental|traditional Chinese medicine|Patients in this group will receive four types of TCM treatment according to traditional Chinese syndrome differentiation and treatment, which are Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule.
3108203|NCT01836016|Experimental|conventional medicine + TCM|Patients in this group will receive conventional medicine and traditional Chinese medicine.
3108204|NCT01836003|Experimental|Tokafatso programmatic intervention|Antenatal clinic receives the Tokafatso programmatic intervention, including educational session, SMS-based facilitation of CD4 result delivery, and patient tracing support.
3108205|NCT01836003|No Intervention|Usual Care|Has not yet received Tokafatso combination programmatic intervention
3108206|NCT01835990|Experimental|geko|For subjects randomized to the experimental treatment arm, one gekoTM device will be applied to each leg according to the manufacturer's instructions by the subject's primary care nurse. All nurses applying the devices must be trained on proper application technique. The old devices will be removed and new devices applied daily. The subject will continue to use the devices until he or she exits the study.
3108207|NCT01835990|Active Comparator|IPCs|The control treatment will consist of the hospital's standard IPC devices. The IPCs will be applied to each leg by the subject's primary care nurse according to the manufacturer's instructions. They will continue to be applied until exit from the study. At the time of withdrawal from the study, the decision regarding continued use of IPCs will be made by the treating physician.
3108208|NCT01835977|Active Comparator|Focal ablation|Focal ablation of unilateral histopathologically confirmed, organ confined prostate cancer using IRE
3108209|NCT01835977|Active Comparator|Extended ablation|Extended ablation unilateral histopathologically confirmed, organ confined prostate cancer using IRE
3108210|NCT01835964|Experimental|Glucose Variability Observation|The study procedures will start after CGM device training & practice using the blinded CGM for 2 days and will continue over the course of ~33 days. The study team will collect data about diabetes management including blood glucose data from fingerstick and CGM values along with insulin pump records throughout the 4 week observation period. Insulin sensitivity will be evaluated at home with predetermined meals' carbohydrate count. At the mid-study point glucose variability will be simulated in clinic with a metabolic challenge (liquid mixed meal) followed 4 hours later by the induction of hypoglycemia with an intravenous insulin injection. Insulin sensitivity, as well as glucagon and epinephrine counterregulatory responses will be evaluated to be related to overall Glucose Variability.
3108211|NCT01835951|Other|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
3108212|NCT01835951|Other|Grouped Debriefing|Grouped debriefing consists in the analysis of the management of the anaesthesia crisis simulated in the presence of all the subject included in the Grouped Debriefing group.
3108213|NCT01835938|Experimental|1- Erlotinib|"Erlotinib is a first class HCV entry inhibitor. In this study, Erlotinib will be administered in escalating doses in sequential patient cohorts for 14 days as follows:~Dose level (DL) 1 = 50 mg / day,~Dose level (DL) 2 = 100 mg / day, and~Dose level (DL) 3 = 150 mg / day .~Each Dose Level (DL) includes 4 patients (3 patients treated with Erlotinib and one patient treated with the Placebo). Dose escalation will proceed to the subsequent DL in the absence of DLT (dose-limiting toxicity) in 2 patients receiving Erlotinib."
3108214|NCT01835938|Placebo Comparator|placebo|
3108215|NCT01835925||Tissue specmien|
3108216|NCT01835912|Placebo Comparator|Flavoured water placebo for acute dosing|500 milliliters flavoured water (placebo for the acute dosing intervention of sodium citrate)
3108217|NCT01835912|Experimental|Sodium Citrate Dihydrate Acute|dose: 0.5 g/kg of body mass dissolved in 500 milliliters of flavoured water
3108218|NCT01835912|Placebo Comparator|Flavoured water placebo chronic dosing|500 milliliters flavoured water (placebo for the chronic dosing intervention of sodium citrate)
3108219|NCT01835912|Experimental|Sodium Citrate Dihydrate Chronic|3 days of 0.1g/kg of body mass of sodium citrate and 4th day at 0.3 g/kg of body mass of sodium citrate in 500 milliliters of flavoured water
3108220|NCT01835899|Experimental|Placebo to BI 1015550|placebo
3108221|NCT01835899|Experimental|BI 1015550 low dose 1|powder for oral solution
3108222|NCT01835899|Experimental|BI 1015550 low dose 2|powder for oral solution
3108223|NCT01835899|Experimental|BI 1015550 medium dose 1|powder for oral solution
3108224|NCT01835899|Experimental|BI 1015550 medium dose 2|powder for oral solution
3108225|NCT01835886|Experimental|Performs stair-climbing|Performs stair climbing
3108226|NCT01835873|Active Comparator|Lactated Ringer's|Crystalloid solution - 1000 ml preload
3108227|NCT01835873|Active Comparator|HES 130/0.42|Hydroxyethyl starch (HES 130/0.42) - 500 ml preload
3108228|NCT01835860|Other|Embolization|Prostate artery embolization
3108229|NCT01835847|Experimental|A single-arm study|
3108267|NCT01835509|Experimental|Intervention, Camp + Reunions|5 day , day camp plus 5 monthly reunions
3108268|NCT01835509|No Intervention|Control, Newsletters|
3108230|NCT01835834|Experimental|zirconia bridge restoration|"The device is a ceramic core made of shaded zirconium with an anatomic contour core with a minimum of 0.6 mm** thickness and minimal connector size of 4.0 x 3.0 / 9.4 (height x width [mm] / area [mm2])** of high strength zirconia framework providing homogenous veneering material thickness as an external coating with 1.0 - 2.0 mm* wall thickness. The core is veneered with dental porcelain at the dental laboratory.~Intended use and indications:~NobelProceraTM Bridge Shaded Zirconia consists of an individualized, supporting substructure in a ceramic bridge construction for tooth/teeth replacement.~NobelProceraTM Bridge Zirconia is intended for patients in need of prosthetic oral reconstruction in order to restore chewing function. Zirconia bridges for natural tooth restorations are customized, designed, and milled from pre-sintered blanks of zirconia. The multi-unit restorations can be placed in all positions in the mouth."
3108231|NCT01835821|Experimental|prosthesis|"NobelProcera™ Crown shaded zirconia:~The device is an individual, ceramic core (figure a) made of shaded zirconium with an anatomic contour providing homogenous veneering material thickness and a minimum core thickness of 0.4 or 0.7mm. The core is veneered with dental porcelain (IPS e.max Ceram) at the dental laboratory"
3108232|NCT01835808||Fractional Flow Reserve|Coronary artery disease patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation).
3108233|NCT01835795|Active Comparator|Radial Extracorporeal Shock Wave|Swiss DolorClast® CLASSIC applicator
3108234|NCT01835795|Placebo Comparator|Placebo|Swiss DolorClast® CLASSIC placebo applicator
3108235|NCT01835782|Active Comparator|2.5 grams BID|5 Patients will be evenly randomized into this group
3108236|NCT01835782|Active Comparator|.5 grams BID|5 Patients will be evenly randomized into this group
3108237|NCT01835782|Active Comparator|7.5 grams BID|5 Patients will be evenly randomized into this group
3108238|NCT01835782|Active Comparator|15 grams BID|5 Patients will be evenly randomized into this group
3108239|NCT01835756|Active Comparator|Erchonia MLS|The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light.
3108240|NCT01835756|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia MLS but does not emit any therapeutic light.
3108241|NCT01835743|Active Comparator|Erchonia HPS Laser|The Erchonia HPS Laser contains 3 independent diodes mounted in scanner devices and positioned equidistant from each other and titled at a 30 degree angle. Each scanner emits 17 milliwatts (mW), 635 nm of red laser light.
3108242|NCT01835743|Placebo Comparator|Placebo Laser|The Placebo Laser is identical in appearance and operation to the Erchonia HPS Laser but does not emit any therapeutic light.
3108243|NCT01835730|Experimental|PE0139 Injection|Single subcutaneous injection of PE0139, 40 mg/mL
3108244|NCT01835730|Placebo Comparator|Placebo|Single subcutaneous injection of 0.9% Sodium Chloride (NaCl) (Placebo)
3108245|NCT01835717||Cognitively normal individuals|
3108246|NCT01835704||Chronic pain associated to facet-joints|Patients where the pain can be localized to the facet joints.
3108247|NCT01835704||Chronic pain of other origin|Patients with pain that can not be localized to facet joints.
3108248|NCT01835691|Experimental|Vitamin D2 (ergocalciferol)|50,000 units once a week for 12 weeks
3108249|NCT01835691|Experimental|Vitamin D3 (cholecalciferol)|50,000 units once a week for 12 weeks
3108250|NCT01835678|Active Comparator|Linagliptin|Linagliptin
3108251|NCT01835678|Placebo Comparator|Placebo|Placebo
3108252|NCT01835665|Experimental|Nimodipine|
3108253|NCT01835652|Active Comparator|Active Exercise|Aerobic Exercise Intervention (stationary cycling)
3108254|NCT01835652|Other|Passive Exercise|Passive Exercise (stretching and balance based exercise)
3108255|NCT01835639|Experimental|Vitamin D Supplementation|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
3108256|NCT01835626|Experimental|Vismodegib and Radiation Therapy|150mg Vismodegib will be taken once a day, daily. Radiation therapy will be started after the patient has completed taking vismodegib for 12 weeks. The patient will take daily vismodegib through the completion of radiation therapy. The patient will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
3108257|NCT01835613|Other|Tocilizumab|"Biomarkers Measures~At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers."
3108258|NCT01835600|Active Comparator|with PEEP|10 cmH2O PEEP added to the respiratory curcuit during suspension of mechanical ventilation
3108259|NCT01835600|Placebo Comparator|without PEEP|0 cmH2O PEEP added to the respiratory curcuit during suspension of mechanical ventilation
3108260|NCT01835587|Experimental|Oral Azacitidine|Dose of 150mg, 200mg, or 300mg once daily (QD) for the first 7, 10, or 14 days of each 28-day cycle, starting 42-84 days after transplantation.
3108261|NCT01835574|Other|Conditional Cash Transfer and Cognitive-behavioral aftercare|Pre- and post- CCT+AC intervention comparison
3108262|NCT01835561|Experimental|Part 1: Severe liver disease and healthy volunteer match|Subjects with severe liver disease (Group 2) and healthy volunteer subjects (Group 1) matched to the subjects with liver disease
3108263|NCT01835561|Experimental|Part 2: Mild and moderate Liver disease|Subjects with moderate (Group 3) and/or mild (Group 4) liver disease
3108264|NCT01835548|Experimental|NT0102|After the screening/washout period, all participants will receive study drug NT0102 once daily for 4 weeks during the dose optimization period. After completion of the dose optimization period, the optimized dose of the study drug will be selected, and participants will stay on that dose for 1 week (dose stabilization period). At the end of this period, participants will be randomized to a treatment. Participants in this arm will be given 20-60 mg of NT0102 as oral disintegrating tablet (ODT) once daily for one week during the double-blind treatment period.
3108265|NCT01835548|Placebo Comparator|Placebo|After the screening/washout period, all participants will receive study drug NT0102 once daily for 4 weeks during the dose optimization period. After completion of the dose optimization period, the optimized dose of the study drug will be selected, and participants will stay on that dose for 1 week (dose stabilization period). At the end of this period, participants will be randomized to a treatment. Participants in this arm will be given placebo as matching ODT once daily for one week during the double-blind treatment period.
3108269|NCT01835496|No Intervention|Ferriprox|single 1500 mg dose of Ferriprox
3108270|NCT01835470|Experimental|Abatacept|Abatacept 10 mg/kg (for body weight less than 75 kg), 750 mg (for body weight between 75 and 100 kg), and 1g (for body weight above 100kg) intravenous infusion on Week 0 (Day 1), Week 2 (Day 15), Week 4 (Day 29) and every 4 weeks (28 days) thereafter up to the end of the study
3108271|NCT01835457|Experimental|Concentration/meditation group|Subjects in this arm will be performing the concentration/meditation technique of Wim Hof (The Iceman) prior to, during and after intravenously injected 2 ng/kg Lipopolysaccharide
3108272|NCT01835457|Active Comparator|Control group|Subjects in this group will be intravenously injected with 2 ng/kg Lipopolysaccharide
3108273|NCT01835444||MD model|Hospital wards at which ward care is provided only by Medical Doctors (MDs)
3108274|NCT01835444||PA/MD model|Hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
3108275|NCT01835431|Experimental|Insulin degludec/insulin aspart|
3108276|NCT01835431|Active Comparator|Insulin detemir|
3108277|NCT01835418|Experimental|Lisinopril|bedtime administration of lisinopril 20mg
3108278|NCT01835418|Experimental|Amlodipine|Bedtime administration of amlodipine 5mg
3108279|NCT01835405|Active Comparator|LiquiBand Flex|LiquiBand® Flex skin adhesive is indicated for topical application only, to hold closed easily approximated skin edges from surgical incisions, including punctures from minimally invasive surgery, and simple, thoroughly cleansed trauma-induced lacerations. It may be used in conjunction with, but not in place of deep dermal sutures.
3108280|NCT01835405|Active Comparator|Dermabond Advanced|Dermabond Advanced™ adhesive is intended for topical application only, to hold closed easily approximated skin edges of wounds from surgical incisions, including incisions from minimally invasive surgery, and simple, thoroughly cleansed, trauma-induced lacerations. Dermabond Advanced ™ adhesive may be used in conjunction with, but not in place of, deep dermal stitches.
3108281|NCT01835405|Active Comparator|Sutures (Prolene)|Prolene™ Suture is indicated for use in general soft tissue approximation and/or ligation, including use in cardiovascular, ophthalmic and neurological procedures.
3108282|NCT01835392|Experimental|Remote Ischemic Preconditioning|Four 5-minute cycles of leg ischemia interspersed with 5-minute cycles of reperfusion using a blood pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure.
3108283|NCT01835392|Sham Comparator|Control|Placement of blood pressure cuff around leg without inflation for 40 minutes
3108284|NCT01835379|Experimental|Oasis|Oasis
3108285|NCT01835379|Other|Standard|Standard Care
3108286|NCT01835353|Experimental|Prasugrel 100mg loading dose|Prasugrel 100mg loading dose
3108287|NCT01835353|Active Comparator|Prasugrel 60mg loading dose|
3108288|NCT01835340|Experimental|propofol|Propofol Patients will receive propofol anesthesia on the study day
3108289|NCT01835327||Exposed|Cerebral oximetry desaturation below 65% for a minimum of 3 minutes
3108290|NCT01835327||Not Exposed|Those patients who do not experience a cerebral oxygen desaturation below 65% for a minimum of 3 minutes
3108291|NCT01835301||DES|Patients who received a DES stent > 3 years ago.
3108292|NCT01835301||BMS|Patients who received BMS stents > 3 years ago.
3108293|NCT01835288|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1-2 hours daily for up to 45 days. Patients achieving complete remission, receive arsenic trioxide IV over 1-2 hours daily 5 days a week for 4 weeks. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3108294|NCT01835275|Experimental|Music conditioning|Subjects are tested with music, sound, and silence, after conditioning to enhance music induced analgesia
3108295|NCT01835275|Active Comparator|Sound|Subjects are tested with music, sound, and silence, after conditioning to enhance sound induced analgesia
3108296|NCT01835275|No Intervention|Calibration|Subjects are tested with music, sound, and silence, with no enhanced audio received
3108297|NCT01835262|Active Comparator|Morphine|Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP
3108298|NCT01835262|Experimental|Ketamine Group|Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP
3108299|NCT01835249|Experimental|Intensive BP Arm|"Participants randomized into the Intensive BP arm will have a goal of SBP <120mmHg. Drugs will be added and/or titrated at each visit (monthly) to achieve SBP <120 mmHg. At periodic milepost visits, addition of another drug will be required if not at goal."
3108300|NCT01835249|Active Comparator|Standard BP Arm|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg. Intensify therapy if SBP ≥160 mmHg @ 1 visit; ≥140 mmHg @ 2 consecutive visits; Down-titration if SBP <130 mmHg @ 1 visit; <135 mmHg @ 2 consecutive visits.
3108301|NCT01835236|Active Comparator|Trastuzumab, Pertuzumab, T-DM1|First line therapy: Trastuzumab, Pertuzumab Second line therapy: T-DM1
3108302|NCT01835236|Active Comparator|Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine plus T-DM1|First line therapy: Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine Second line therapy: T-DM1
3108303|NCT01835223|Experimental|Treatment (tivozanib)|Patients receive tivozanib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3108304|NCT01835210||Quality of life|Teenager with acne vulgaris This is an observational study, in which the disease of interest is acne vulgaris.
3108305|NCT01835197|Experimental|SAD Cohorts 1-8 Experimental Arm|
3108306|NCT01835197|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
3108307|NCT01835197|Experimental|MAD Cohorts 3 through 5 Experimental Arm|
3108308|NCT01835197|Placebo Comparator|MAD Cohorts 3 through 5 Placebo Arm|
3108309|NCT01835197|Experimental|MAD Cohorts 6 and 7 Experimental Arm|
3108310|NCT01835197|Placebo Comparator|MAD Cohorts 6 and 7 Placebo Arm|
3108311|NCT01835197|Experimental|MAD Cohort 8 Experimental Arm|
3108312|NCT01835197|Placebo Comparator|MAD Cohort 8 Placebo Arm|
3108313|NCT01835197|Experimental|MAD Cohort 9 Experimental Arm|
3108314|NCT01835197|Placebo Comparator|MAD Cohort 9 Placebo Arm|
3108315|NCT01835184|Experimental|Treatment (cabozantinib-s-malate, vemurafenib)|Patients receive cabozantinib-s-malate PO QD and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3108697|NCT01832220||PiMZ not on therapy|Individuals with the PiMZ genotype not on augmentation therapy.
3108316|NCT01835158|Active Comparator|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3108317|NCT01835158|Active Comparator|Arm II (sunitinib malate)|Patients receive sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3108318|NCT01835145|Experimental|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3108319|NCT01835145|Experimental|Arm II (temozolomide or dacarbazine)|Patients receive temozolomide PO daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. If temozolomide is not available, patients receive dacarbazine IV over 15-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3108320|NCT01835132|Experimental|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
3108321|NCT01835119|Experimental|chewing gum|"Gum type was standardized with all subjects receiving sugar-free peppermint-flavored gum.~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (one stick) 3 times daily in the morning, afternoon, and evening at least 5 min. The administration of the therapy was implemented by ward nursing staff and recorded in the patients file. All gum-chewing patients completed their course of gum chewing until bowel function."
3108322|NCT01835119|No Intervention|control group|no gum
3108323|NCT01835106|Active Comparator|Epidural|Epidural catheter is used postoperatively
3108324|NCT01835106|Experimental|Fascia Iliaca Compartment|Fascia iliaca compartment catheter is used postoperatively
3108325|NCT01835093|Experimental|A single-arm study|
3108326|NCT01835067|Sham Comparator|Control Group (A)|Ranibizumab only (active control). Participants will receive a 'sham injection' to simulate C3F8 and/or tPA administration.
3108327|NCT01835067|Experimental|C3F8 Only Group (B)|C3F8 given. Ranibizumab given as standard.
3108328|NCT01835067|Experimental|tPA and C3F8 Group (C)|Both C3F8 gas and tPA given. Ranibizumab given as standard.
3108329|NCT01835067|Experimental|tPA Only Group (D)|tPA given. Ranibizumab given as standard.
3108330|NCT01835054||Patients with mitral regurgitation|"At study entry, patients have 1) a clinical assessment including metabolic risk profile; 2) a blood sample for analysis of metabolic, cardiac neurohormonal blood biomarkers and DNA collection; 3) a complete rest doppler echocardiography; 4) an exercise stress doppler echocardiography; 5) a cardiopulmonary exercise testing; 6) a magnetic resonance Imaging (MRI); 7) a 24-hour Holter ECG.~At follow-up, patients have 1) a clinical events assessment; 2) a blood sample analysis; 3) a resting echocardiography every year; 4) MRI (at preop. evaluation in the subset of patients undergoing surgery); 5) a 24-hour Holter ECG (at 2-year and postop.)."
3108331|NCT01835041|Experimental|Treatment (6,8-bis[benzylthio]octanoic acid, mFOLFIRINOX)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 3. Patients also receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously over 46 hours on day 1. Treatment repeats every 2 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
3108332|NCT01835028||Classical Low-Flow, Low-Gradient AS|"Observational study in patients with Classical Low-Flow, Low-Gradient Aortic Stenosis and Low LV Ejection Fraction undergoing surgical aortic valve replacement, transcatheter aortic valve replacement, or conservative management:~I- Baseline visit: Medical history, physical / functional evaluation, blood biomarkers, resting echocardiography, stress echocardiography, aortic valve calcium scoring by computed tomography, myocardial fibrosis by magnetic resonance imaging II- Follow-up: clinical outcomes, physical / functional evaluation, echocardiography, blood biomarkers"
3108333|NCT01835028||Paradoxical Low-Flow, Low-Gradient AS|"Observational study in patients with Paradoxical Low-Flow, Low-Gradient Aortic Stenosis and Preserved LV Ejection Fraction undergoing surgical aortic valve replacement, transcatheter aortic valve replacement, or conservative management:~I- Baseline visit: Medical history, physical / functional evaluation, blood biomarkers, resting echocardiography, stress echocardiography, aortic valve calcium scoring by computed tomography, myocardial fibrosis by magnetic resonance imaging II- Follow-up: clinical outcomes, physical / functional evaluation, echocardiography, blood biomarkers"
3108334|NCT01835015|Experimental|CLG561, Concentration Level A|Single 50 μL intravitreal injection of CLG561, Dose Level A
3108335|NCT01835015|Experimental|CLG561, Concentration Level B|Single 50 μL intravitreal injection of CLG561, Dose Level B
3108336|NCT01835015|Experimental|CLG561, Concentration Level C|Single 50 μL intravitreal injection of CLG561, Dose Level C
3108337|NCT01835015|Experimental|CLG561, Concentration Level D|Single 50 μL intravitreal injection of CLG561, Dose Level D
3108338|NCT01835015|Experimental|CLG561, Concentration Level E|Single 100 μL intravitreal injection of CLG561, Dose Level E
3108339|NCT01835002|Experimental|OkuStim|Electrostimulation Standard Treatment with OkuStim
3108340|NCT01834989|Active Comparator|Insulin-like growth factor I|3 injection (1 mg), once a week the first 3 weeks of the 12 weeks of intervention
3108341|NCT01834989|Placebo Comparator|Placebo injections|3 Injections of saline into the patellar tendon 3 times during the first 3 weeks of the 12 weeks interventions period
3108342|NCT01834963|Experimental|Interferon Alfa、Fluorouracil|"Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks"
3108343|NCT01834963|Experimental|Cisplatin、Fluorouracil|"Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks"
3108344|NCT01834950|Experimental|Trastuzumab|The study is a single arm prospective study, aiming at identifying biomarkers of early response to trastuzumab
3108345|NCT01834924|Active Comparator|HELPix|Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
3108346|NCT01834924|No Intervention|Control|Standard provider medication counseling
3108347|NCT01834911|Experimental|Tetrabenazine withdrawal|Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently taking the medication.
3108393|NCT01834625||Florbetapir -ve patients|Florbetapir -ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months
3108348|NCT01834898||Controlled-release oxycodone|Controlled-released oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
3108349|NCT01834885|Experimental|QVA149|QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.
3108350|NCT01834885|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.
3108351|NCT01834872|Experimental|Amigo|Ablation completed with Amigo
3108352|NCT01834872|Active Comparator|Manual|Ablation completed with manual catheter
3108353|NCT01834859|Experimental|Outpatient|Multidisciplinary outpatient program including both individual and group-based therapy. During the first visit, there will be offered an individual consultation with the dietician, physiotherapist and psychiatric nurse. Follow-up will be in groups meeting every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
3108354|NCT01834859|Experimental|Inpatient|"Inpatient lifestyle program consisting of a continuous care weight loss program offered at a rehabilitation center, with three intermittent stays (each with 3-week duration) over a one year period."
3108355|NCT01834846|Experimental|no-touch|no-touch technique of harvesting the saphenous vein graft for coronary artery bypass grafting
3108356|NCT01834846|Active Comparator|conventional|conventional technique of harvesting the saphenous vein graft for coronary artery bypass grafting
3108357|NCT01834833|No Intervention|Control|usual care without systematic cardiology evaluation between 1 and 2 weeks
3108358|NCT01834833|Experimental|Follow-up|Evaluation by a cardiologist using echocardiography, completed by education of the patient if necessary
3108359|NCT01834820|Experimental|Epinephrine and Dexamethasone|First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes. And one treatment of nebulized dexamethasone every 24h for three days.
3108360|NCT01834820|Experimental|Hypertonic Saline 3%|3 treatments of nebulized HS 3% 4ml in first day of treatment with interval 20 minutes And one treatment of nebulized HS 3% 4ml every 24 hours for 3 days
3108361|NCT01834820|Active Comparator|Normal Saline 0.9%|3 treatments of nebulized Normal Saline 0.9% 4ml in first day of treatment with interval 20 minutes. And one treatment of nebulized Normal Saline 0.9% 4ml every 24 hours for 3 days
3108362|NCT01834807||Cohort|
3108363|NCT01834794|Experimental|MET/CBT/CM plus NRT|"Motivational Enhancement Therapy, Cognitive Behavior Therapy, Contingency Management plus Nicotine Replacement Therapy (MET/CBT/CM) + NRT~Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT."
3108364|NCT01834781|Active Comparator|Pulsed electromagnetic fields|Pulsed electromagnetic fields is applied transcranially 30 minutes twice a day for 7 days a week over 6 consecutive weeks
3108365|NCT01834781|Placebo Comparator|Wearing the inactive device|The inactive device is worn on the head for 30 minutes twice a day for 7 days a week over 6 consecutive weeks
3108366|NCT01834768|Experimental|A|Eplerenone
3108367|NCT01834755|Other|single arm|Evaluation of psychological phenotype with several questionnaire (Big Five, EPADV-16), physical activity with a self-administered questionnaire (Baecke) and several test ( SPPB, Handgrip Strengh test, MicroFET 2 Digital Dynamometer)
3108368|NCT01834742|Experimental|Part A, arm 1|Evening dose 1 plus fixed morning dose
3108369|NCT01834742|Experimental|Part A, arm 2|Evening dose 2 plus fixed morninf does
3108370|NCT01834742|Experimental|Part A, arm 3|Evening dose 3 plus fixed morning dose
3108371|NCT01834742|Active Comparator|Part A, arm 4|Moviprep
3108372|NCT01834742|Experimental|Part B, arm 1|Fixed evening dose plus morning dose 1
3108373|NCT01834742|Experimental|Part B, arm 2|Fixed evening dose plus morning dose 2
3108374|NCT01834742|Experimental|Part B, arm 3|Fixed evening dose plus morning dose 3
3108375|NCT01834742|Experimental|Part B, arm 4|Fixed evening dose plus alternative morning dose
3108376|NCT01834729|Experimental|Alfuzosin|"In Part A, subjects randomized to this arm will receive a single dose of oral alfuzosin immediate release (IR) 2.5 mg.~In Part B, only constipated patients will receive oral alfuzosin (10 mg extended release (ER)) capsules."
3108377|NCT01834729|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a single placebo capsule identical to the study drug.
3108378|NCT01834716|Experimental|Aerobics exercise|Participants in this group will be randomized to aerobics exercise.
3108379|NCT01834716|Experimental|Non-Aerobics Exercise|Participants in this group will be randomized to a non-aerobics exercise group.
3108380|NCT01834703|Active Comparator|UAE treatment|After randomization, patient recruited will be arranged to receive UAE treatment. 100 patients will be recruited for UAE treatment
3108381|NCT01834703|Active Comparator|HIFU|After randomization, patient recruited will be arranged to receive HIFU treatment. 100 patients will be recruited for HIFU treatment
3108382|NCT01834690||liver transplantation recipients|adult liver transplantation recipients (>=20 years at the date of surgery)
3108383|NCT01834677||Healthy Human|
3108384|NCT01834677||Depressed Human|
3108385|NCT01834677||Depressed Human, Undergoing Electroconvulsive Therapy|Electroconvulsive Therapy is being received as standard of care, not as a study intervention.
3108386|NCT01834677||Human Diagnosed with Parkinson's Disease|
3108387|NCT01834664|Other|STEM CELL|Transfer of autologous stem cell [MNCs ]intrathecally
3108388|NCT01834651|Experimental|Treatment (cabozantinib)|Cabozantinib 60mg orally daily until disease progression
3108389|NCT01834638|Experimental|ABT-126 low dose|ABT-126 low dose
3108390|NCT01834638|Experimental|ABT-126 middle dose|ABT-126 middle dose
3108391|NCT01834638|Experimental|ABT-126 high dose|ABT-126 high dose
3108392|NCT01834625||Florbetapir +ve NPH patients|Florbetapir +ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months
3108394|NCT01834612|Active Comparator|Blood draw|CM1500 with blood draw
3108396|NCT01834599||anterior placenta|"Cerebral oximetry device used to obtain:~Saturation value of the placenta probe with no oxygen, saturation value of the placenta probe with oxygen, saturation value of the myometrium probe with no oxygen saturation value of the myometrium probe with oxygen saturation value of the forearm probe with no oxygen, saturation value of the forearm probe with oxygen saturation value of the leg probe with no oxygen saturation value of the leg probe with oxygen Timing between the contractions measure by cardiotocography"
3108397|NCT01834586|Other|Anesthetic Topical Adhesive Synera|"Anesthetic Topical Adhesive Synera. For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week."
3108398|NCT01834573|Active Comparator|Intervention|Patients of the intervention arm receive a 10 week exercise program
3108399|NCT01834573|No Intervention|Control|Patients of the control arm do not participate in exercise
3108400|NCT01834547|Experimental|Methylphenidate|Methylphenidate
3108401|NCT01834547|Experimental|modafinil|modafinil
3108402|NCT01834547|Experimental|caffeine|caffeine
3108403|NCT01834547|Placebo Comparator|placebo|placebo
3108404|NCT01834534|Experimental|CarePartners for depression|For one year, patients receive weekly automated telemonitoring of mood and self-management, while their CarePartners receive weekly reports of the patient's assessment results with tailored instructions on supporting the patient's depression self-management.
3108405|NCT01834534|No Intervention|Usual care|Usual medical care.
3108406|NCT01834521|Experimental|Web-based screening and tailored support|A personalized website (username/password) will become available to patients assigned to the intervention arm for 12 subsequent weeks. Key features of the website are self-screening, tailored patient education and self-referral. Self-screening will be performed by an online version of the Dutch Distress thermometer (DT) and Problem List (PL). Patients will receive digital feedback on their DT score immediately after test completion together with information regarding problems reported on the PL, (self)help options and possibilities for referral to professional care. Contact information of one of the investigators will also be available to discuss questions, problems and/or referral needs. Patients may also request a telephone call.
3108407|NCT01834521|No Intervention|Standard care|Patients assigned to standard convalescent care will receive the usual follow-up care delivered by their treating oncologists. Patients will be referred to psychosocial or allied care by their oncologist and/or oncology nurse if certain physical and/or psychosocial problems require more in-depth professional care
3108408|NCT01834508|Other|Treatment group|
3108409|NCT01834495|Experimental|Balloon expandable stent|study design is 1:1 randomization design. Patients will be randomized in a 1:1 manner according to different two (balloon expandable versus Self expandable)stents. Randomization procedure will be performed using a web-based program
3108410|NCT01834495|Active Comparator|Self expandable stent|same to Balloon expandable stent
3108411|NCT01834482|Active Comparator|Modified Atkins diet plus KetoCal|Patients will receive the modified Atkins diet in combination with a KetoCal tetrapak daily for the first month. The second month, no tetrapaks will be given.
3108412|NCT01834482|Active Comparator|Modified Atkins diet|Patients will receive the modified Atkins diet for the first month. The second month, they will be given the choice to also use KetoCal in addition to the modified Atkins diet if they choose to do so.
3108413|NCT01834469|Other|ICG NIR imaging|see Summary and description iv injection of ICG
3108414|NCT01834456|Experimental|Med Complex Children Intervention|"Children with Medical Complexity, previously defined in research as, children with complex chronic conditions, children with life-limiting conditions, fragile children, complex chronic illness, or a subset of children with special healthcare needs. Meeting criteria for complexity is a combination of high utilization, multiple chronic diagnoses, use of medical technology (g-tube, tracheostomy, shunt, etc.), functional impairment, and contextual needs.~Medically Complex Children in the Intervention group will be treated at an innovative primary care facility designed for their care. This includes actively addressing QOL, care coordination, and behavioral needs of the child, and addressing contextual and support needs for the child's family."
3108415|NCT01834456|No Intervention|Med Complex Children Control|"Children with Medical Complexity, previously defined in research as, children with complex chronic conditions, children with life-limiting conditions, fragile children, complex chronic illness, or a subset of children with special healthcare needs. Meeting criteria for complexity is a combination of high utilization, multiple chronic diagnoses, use of medical technology (g-tube, tracheostomy, shunt, etc.), functional impairment, and contextual needs.~The control group will continue to receive usual care as they did before they enrolled in this study"
3108416|NCT01834443|Experimental|GVS CL|Transmastoid galvanic vestibular stimulation is applied, with the cathode placed on the left mastoid
3108417|NCT01834443|Experimental|GVS CR|Transmastoid galvanic vestibular stimulation is applied, with the cathode placed on the right mastoid
3108418|NCT01834443|Sham Comparator|GVS Sham|Transmastoid galvanic stimulation set-up is applied, with only 30s of stimulation
3108419|NCT01834430|Experimental|EN group|The EN group gradually restored enteral nutrition, while the PN group continued to receive parenteral nutrition treatment. Both groups received between 20 to 25 kcal/kg/day and 1.5 g/kg/day of protein. Because of the low volume, concentration, and calorie amount, on the first day, tube feeding utilized 500 ml with the speed of 30 ~ 50 ml/h. On the second day, tube feeding utilized 1000 ml with the speed of 60 ~ 80 ml/h. On the third day, tube feeding utilized 1500 ~ 2000 ml with the speed of 100 ~ 120 ml/h. If enteral nutrition could not meet a patient's caloric requirements, PN supplement was started on the fourth day. The required calories and protein for each individual in the two groups was assumed to be achieved after three days of therapy. The PN group continued to receive parenteral nutrition.
3108420|NCT01834430|No Intervention|parenteral nutrient group|
3108421|NCT01834404|Experimental|Phentermine-Topiramate ER|Qualifying participants were assigned to the Phentermine-Topiramate ER for a minimum of 5 days. The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
3108698|NCT01832220||PiMM with COPD|Individuals with the PiMM genotype and COPD.
3108422|NCT01834404|Placebo Comparator|Placebo|Qualifying participants were assigned to placebo for a minimum of 5 days. Placebo pills matched the study drug in appearance for the 2 dose levels.
3108423|NCT01834391||Geriatric Traumatic Injury|Geriatric trauma pateints being admitted to Saint Marys Hosptial.
3108424|NCT01834378|No Intervention|No intervention|
3108425|NCT01834378|Experimental|Low intensity intervention|
3108426|NCT01834378|Experimental|High intensity intervention|
3108427|NCT01834365|Experimental|Structured education & checklist|Formatted education and checklist every month for 3 months
3108428|NCT01834365|Active Comparator|Structured education|Formatted education every month for 3 months
3108429|NCT01834365|Active Comparator|Without Structured Education with checklist|No structured education with checklist
3108430|NCT01834352|Active Comparator|Walnut protein flour|Walnut protein flour that is ingested in gradually increasing amounts up to a maintenance dose.
3108431|NCT01834352|Placebo Comparator|Oat flour|Oat flour administered in identical increasing amounts as the active walnut protein flour.
3108432|NCT01834339|Active Comparator|AlloDerm|The subject will be treated with the standard of care, AlloDerm, to cover the defect in the mouth.
3108433|NCT01834339|Experimental|EVPOME|An ex-vivo produced oral mucose equivalent (EVPOME) will be used to cover the defect in the top of the mouth.
3108434|NCT01834326|Active Comparator|Palatal Oral Mucosa (POM) Graft|Standard of care palatal oral mucosa (POM) graft will be taken from the palate and then surgically placed onto the defect area
3108435|NCT01834326|Experimental|Ex vivo Produced Oral Mucosa Equivalent|Palatal biopsy will be harvested for fabrication of autogenous ex vivo produced oral mucosa equivalent (EVPOME) and then surgically placed onto the defect area
3108436|NCT01834300|Experimental|Control|Unsupervised exercise training This group will be given 1 hour lifestyle counseling by the exercise trainer after which they will have no contact with the exercise trainer to the end of the intervention period. The exercise intervention will be offered to the subjects once the post studies are completed.
3108437|NCT01834300|Experimental|lifestyle counseling and exercise|Supervised exercise training Four months exercise training intervention will be either gym-based or patients will choose the mode of exercise that suits their lifestyle. Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
3108438|NCT01834287|Experimental|Physical Activity Intervention|Motivationally-tailored, Spanish Language, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
3108439|NCT01834287|Active Comparator|Wellness Control|Internet-based, Spanish language, Wellness Contact control intervention addressing relevant health topics other than Physical Activity.
3108440|NCT01834274|Experimental|Fasiglifam 50 mg|Fasiglifam (TAK-875) 50 mg tablets, orally, once daily, Sitagliptin placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum-tolerated dose), tablets, orally, daily for up to 24 weeks.
3108441|NCT01834274|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, tablets, once daily, TAK-875 placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum-tolerated dose), tablets, orally, daily for up to 24 weeks.
3108442|NCT01834261|Active Comparator|Oxytocin|Healthy adult subjects will receive several puffs of Syntocinon Nasal Spray, 40IU, once, prior to MRI and/or MEG scanning.
3108443|NCT01834261|Placebo Comparator|Placebo|Healthy adult subjects will receive several puffs of Syntocinon Placebo Formulation, 40IU, once, prior to MRI and/or MEG scanning.
3108444|NCT01834248|Experimental|Treatment (CDX-1401, Poly ICLC, decitabine)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 SC and ID and poly-ICLC SC on days -14 and 15 of course 1 and on day 15 for courses 2-4. Patients also receive decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3108445|NCT01834235|Active Comparator|Abraxane, gemcitabine|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30 minute infusion for 3 consecutive weeks followed by a week of rest.
3108446|NCT01834235|Experimental|Abraxane, gemcitabine, NPC-1C|"Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30 minute infusion for 3 consecutive weeks followed by a week of rest.~Patients on arm B will receive NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 4-week cycle. This will be administered 30minutes after completion of the gemcitabine infusion."
3108447|NCT01834222||1|Korean adults aged 50 years and older who receive Prevenar13™ in a routine clinical setting
3108448|NCT01834209|Experimental|Abiraterone acetate + prednisone/prednisolone|
3108449|NCT01834196|Other|retinal vascular occlusion arm|Patients with existing retinal microvascular disease will undergo imaging.
3108450|NCT01834183|Experimental|Tivozanib/Gemcitabine|Segment 1: Tivozanib, taken orally days 1-21 of each 28 day cycle. Segment 2: Tivozanib, taken orally days 1-21 of each 28 day cycle. Gemcitabine, taken intravenously, Days 1 and 8 of each 28 day cycle.
3108451|NCT01834170|Experimental|Intratumoral gemcitabine injection|Intratumoral injection of gemcitabine by means of endoscopic ultrasound.
3108452|NCT01834157||methotrexate|methotrexate with or without low-dose corticosteroids
3108453|NCT01834157||other DMARDs|other DMARDs (leflunomide, azathioprine, mycophenolate mofetil) with or without low-dose corticosteroids
3108454|NCT01834157||low-dose corticosteroids|low-dose corticosteroids without DMARDs
3108455|NCT01834157||No DMARD or corticosteroids|No DMARD or corticosteroid treatment
3108456|NCT01834157||CPH/CSA - Exploratory cohort|cyclophosphamide or cyclosporine-A with or without other DMARDs or low-dose corticosteroids
3108457|NCT01834157||Biologics - Exploratory cohort|Biologic therapy with or without other DMARDs or low-dose corticosteroids
3108458|NCT01834157||Combinations - Exploratory cohort|Combination of two or more DMARDs with or without low-dose corticosteroids
3108460|NCT01834144|Active Comparator|Moderate + Vigorous Intensity Exercise|150-200 minutes of weekly moderate intensity exercise, with short bouts of vigorous intensity exercise (80-90% of peak fitness)
3108461|NCT01834131|No Intervention|Usual Care|Clinics assigned to usual care will not receive any of the intervention components. Physicians in these clinics will continue to treat patients using their usual methods. Participants from these clinics will not receive community health worker visits or the mobile health intervention
3108462|NCT01834131|Experimental|Comprehensive Intervention|"Physicians will receive training in the use of treatment algorithms based on hypertension guidelines.~Community health workers (CHW) will be trained in facilitating behavioral change through BP monitoring, medication management, and lifestyle modifications. CHW will serve as a source of education, motivation, and social support, and as facilitators of healthcare utilization for participants. CHW will conduct home visits, schedule appointments with primary care physicians, deliver antihypertensive medications to patients' homes, and provide tailored counseling to address barriers to behavior change.~Individualized text messages to promote lifestyle changes and reminders to reinforce medication adherence will be sent to participants weekly."
3108463|NCT01834105|Experimental|Liuwei Dihuang Pills|
3108464|NCT01834092|Active Comparator|Fresh frozen plasma|2 portions of FFP will be transfused prior to reperfusion
3108465|NCT01834092|Experimental|Fresh non-frozen plasma|2 portions of non-frozen plasma will be transfused prior to reperfusion
3108466|NCT01834079|Other|STEM CELL|intra thecal injection of MNC stem cell therapy
3108467|NCT01834066|Other|STEM CELL|Intra thecal transplantation of autologous Stem Cell MNCs
3108468|NCT01834053|Other|STEM CELL|Transfer of autologous Stem cell( MNCs) intrathecally
3108469|NCT01834040|Other|intralesional and Intravenous|Intralesional/ Intravenous of Autologous Stem cells.
3108470|NCT01834027|Experimental|Jazz music|Jazz music will be played through headphones to post-surgical hysterectomy patients while they are in the post anesthesia care unit.
3108471|NCT01834027|Active Comparator|No music|The patients in this group with have headphones but no music will be played.
3108472|NCT01834014|Experimental|mFOLFOX + Bmab|mFOLFOX plus bevacizumab
3108473|NCT01834014|Active Comparator|mFOLFOX + Cmab|mFOLFOX plus cetuximab
3108474|NCT01833988|Experimental|Bi-hormonal Bionic Pancreas|Bi-hormonal Bionic Pancreas
3108475|NCT01833988|Active Comparator|Usual Care|Usual Care
3108476|NCT01833975|Other|stem cell [ MNCs ]|transplantation of autologous stem cell [MNCs ]
3108477|NCT01833962||Actifuse|Patients who recieved Actifuse synthetic bone brafting material
3108478|NCT01833949|Active Comparator|ULOD arm (N=49)|"Unilateral laparoscopic drilling~In the ULOD group, we treated the right ovary.The thermal dose of 60 J applied per one cubic centimeter of ovarian volume was calculated from the mean total energy applied on a 10 cm3 ovary (627 J) from three earlier ULOD reports. Ovarian volume had been measured by ultrasound at baseline to determine the total thermal dose to apply on the right ovary. The number of punctures (Np) was also calculated for each patient according to the following formula:~Np = 627 J / 30 W / 4 s Therefore, patients in the ULOD group differed in the number of punctures and energy received by the right ovary, depending on its volume."
3108479|NCT01833949|Active Comparator|BLOD arm (N=47)|"Bilateral laparoscopic drilling~In the comparator, BLOD group, all patients received 600 J per ovary (totaling 1200 J) through five punctures at 30 W for 4 s each (5 punctures x 4 s x 30 W = 600 J).~The ovaries in both groups were cooled after the drilling by irrigating the abdominal cavity with 200-300 mL of physiological saline."
3108480|NCT01833936|Active Comparator|Group 1- Compex® muscle stimulator|Group 1 will receive an active muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will use the stimulator for three 20 minute sessions per day.
3108481|NCT01833936|Sham Comparator|Group 2 -(inactive) muscle stimulator|Group 2 will receive a placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
3108482|NCT01833923|Experimental|anlotinib|dosage form:capsule dosage:5mg,10mg,16mg,12mg frequency:once one day duration:Continuous two weeks then stop a week
3108483|NCT01833910|Experimental|Video-only - DVD|CPR Training with AHA CPR Anytime DVD presented on a TV with DVD player and no psychomotor skill practice.
3108484|NCT01833910|Experimental|Video-only - iPad|CPR Training with AHA CPR Anytime DVD presented on a portable video player and no psychomotor skill practice.
3108485|NCT01833910|Experimental|Video-only with Household Object|CPR Training with AHA CPR Anytime DVD and practice on a household item
3108486|NCT01833910|Experimental|Video Self Instruction Kit|CPR Training with AHA CPR Anytime Video Self-Instruction kit including manikin
3108487|NCT01833897|Experimental|Ketamine and DCS treatment|Standard of Care: Subjects will receive treatment with either quetiapine, olanzapine-fluoxetine, or lurasidone. If after about 2 week, subjects are symptomatic, subjects will receive infusion of ketamine hydrochloride (0.5 mg/kg). After the ketamine phase, subject who show improvement will begin an 8-week treatment of oral D-cycloserine.
3108488|NCT01833884|Other|Single arm|Collection of blood specimen for Cytokines dosing scheduled before, during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
3108489|NCT01833871|Experimental|myometrial fibroid/adenomyoma|Patients scheduled for myomectomy or hysterectomy with preoperative diagnosis of uterine myoma, adenomyosis or both by ultrasound .Trans-vaginal 3D power Doppler and uterine artery doppler will be done for all participants prior to surgery.
3108490|NCT01833858|Placebo Comparator|Placebo +rFSH|Patients received rFSH injections with a placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
3108491|NCT01833858|Active Comparator|Low dose HCG with rFSH|Low dose hCG (200 IU per day) will be given daily with rFSH when at least six follicles of 12 mm will be observed and E2 levels are higher than 600 ng/l, until the day of the hCG trigger administration
3108492|NCT01833845|Experimental|Ribavirin+HCQ|Administration of RBV monotherapy for a period of 8 weeks following administration of up to 16 weeks combination therapy with ribavirin(RBV) plus Hydroxychloroquine(HCQ).
3108494|NCT01833819|Other|Opiod-free group|Opioid-free anesthesia (Group DL) with dexmedetomidine (0.6 mg/kg loading, 0.3 mg/kg/h infusion), lidocaine (1.5 mg/kg loading, 2 mg/kg/h infusion), and propofol infusions (3-12 mg/kg/h).
3108495|NCT01833819|Other|Opioid-based group|Opioid-based anesthesia (Group RF) with single dose fentanyl (2μg/kg), remifentanil (0.25μg/kg/min), and propofol infusions (3-12 mg/kg/h).
3108496|NCT01833806|Experimental|ExAblate Test Arm|Focused Ultrasound Surgery delivered by ExAblate MRgFUS
3108497|NCT01833793||Group 1|
3108498|NCT01833780||GBS carriage status|
3108499|NCT01833780||GBS status during labor|
3108500|NCT01833767|Experimental|Cyclophosphamide and Interleukin-2|Cytoxan IV on day 1, IL2 IV on days 1-5
3108501|NCT01833754|Experimental|Group 1: Stage 4 Renal Impairment|Participants with stage 4 renal impairment (defined as an estimated glomerular filtration rate [eGFR] 15 to 29 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.
3108502|NCT01833754|Experimental|Group 2: ESRD Requiring Hemodialysis|Participants with end stage renal disease (ESRD) requiring hemodialysis received a single subcutaneous injection of 210 mg romosozumab on day 1.
3108503|NCT01833754|Experimental|Group 3: Healthy Participants|Healthy participants (eGFR ≥ 80 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.
3108504|NCT01833741|Experimental|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.
3108505|NCT01833728|Experimental|nefopam-propacetamol combination group|
3108506|NCT01833728|Active Comparator|propacetamol alone group|
3108507|NCT01833715|Active Comparator|Morphine|morphine group 0.08 mg / kg, to start surgery
3108508|NCT01833715|Experimental|Methadone|methadone group 0.08 mg / kg, to start surgery
3108509|NCT01833702||Automated response|Canned responses are provided at the end of daily entries
3108510|NCT01833702||No automated feedback|Canned responses are not provided at the end of daily entries
3108511|NCT01833689|Placebo Comparator|food consumption: control|The control product will be 50g glucose powder dissolved in 250ml of water
3108512|NCT01833689|Active Comparator|food consumption: product|The test food will provide 50g of available carbohydrate
3108513|NCT01833676|Active Comparator|Desflurane|Patient receiving Desflurane for maintenance of general anaesthesia
3108514|NCT01833676|Active Comparator|Sevoflurane|Patient receiving Sevoflurane for maintenance of general anaesthesia
3108515|NCT01833663|Experimental|Solifenacin Succinate Tablets and Estrogen capsules|Solifenacin Succinate Tablets (5mg/d) + local estrogen for 12 weeks
3108516|NCT01833663|Active Comparator|Solifenacin Succinate Tablets|Solifenacin Succinate Tablets (5mg/d) for 12 weeks
3108517|NCT01833650|No Intervention|Standard care|This arm represents the current standard care in patients with thyroid cancer undergoing radioiodine.
3108518|NCT01833650|Experimental|Candy plus thymus honey mouthwash 12|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 12 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
3108519|NCT01833650|Experimental|Candy plus thymus honey mouthwash 24|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 24 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
3108520|NCT01833650|Experimental|Candy plus thymus honey mouthwash 1|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting immediate after the ingestion of 131I therapy (about 1 hour) and for a duration of no more than 4 days
3108521|NCT01833637|No Intervention|Arm A: Control Group|Patients randomized to the control group will be asked to fill out a patient symptom questionnaire using an iPad at the time of registration and then every 24 hours until released from the hospital. It should take about 10 minutes to complete the questions each time. The survey will not interfere with the care the healthcare team will be providing. Patients will be asked to fill our a Patient Satisfaction Questionnaire at the time of discharge.
3108522|NCT01833637|Active Comparator|Arm B: APN Intervention Group|Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
3108523|NCT01833624|Active Comparator|Sondalis® HP|The Control Group that will receive Sondalis ® HP (a whole-peptide formula).
3108524|NCT01833624|Experimental|Peptamen® AF|In this arm, patients have enteral nutrition with Peptamen® AF
3108525|NCT01833611|Experimental|ETV group|Entecavir 0.5mg at first year; then open with entecavir 0.5mg qd for 2nd, 3rd year
3108526|NCT01833611|Placebo Comparator|Placebo group|Placebo at first year, then opne with entecavir 0.5mg qd for 2nd, 3rd year
3108527|NCT01833598|Active Comparator|PNT + PRP|percutaneous needle tenotomy with peritendinous platelet-rich plasma injection
3108528|NCT01833598|Active Comparator|PNT alone|percutaneous needle tenotomy alone
3108529|NCT01833585|Experimental|peripheral blood mononuclear cells|peripheral blood mononuclear cells will be injected to calf muscle of critical limb ischemia
3108530|NCT01833572|Experimental|Gefitinib|A total of 42 cases of resectable stage II-IIIA NSCLCs patients with EGFR activating mutations will be enrolled in this arm.Gefitinib 250 mg/day oral daily is given to patients after enrolment for 42 days or until disease progression or unacceptable toxicity.
3108531|NCT01833559|Other|Incidence of GDM|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
3108532|NCT01833559|Other|Gestational outcomes|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
3108533|NCT01833559|Other|Metabolic disorder|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
3108534|NCT01833546|Experimental|TH-302|
3108535|NCT01833546|Experimental|TH-302 plus Gemcitabine|
3108536|NCT01833533|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3108537|NCT01833533|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks plus placebo RBV (twice daily) for 12 weeks
3108538|NCT01833520|Experimental|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I.~Up to 3 groups of 3 participants will be enrolled in the Phase I portion of the study, and up to 6 participants will be enrolled in Phase II."
3108539|NCT01833507|Active Comparator|self-exercise|Intervention will include a video(DVD) on exercise, and 2 self-help manuals on exercise and nutrition, in addition to a journal and pedometer.
3108540|NCT01833507|Placebo Comparator|usual care|Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics.
3108541|NCT01833494|Experimental|PA21|
3108542|NCT01833481||THA using direct-anterior surgical approach|Patients will have undergone THA using a direct-anterior surgical approach and will undergo fluoroscopy surveillance while walking.
3108543|NCT01833481||THA using anterior-lateral approach|Patients will have undergone THA using an anterior-lateral surgical approach and will undergo fluoroscopy surveillance while walking.
3108544|NCT01833481||THA using posterior-lateral approach|Patients will have undergone THA using a posterior-lateral surgical approach and will undergo fluoroscopy surveillance while walking.
3108545|NCT01833455|Placebo Comparator|PVC Suppression then Placebo|This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
3108546|NCT01833455|Placebo Comparator|Placebo then PVC Suppression|This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
3108547|NCT01833442|Active Comparator|Kundalini Yoga Meditation|Kundalini Yoga Meditation is going to be use as therapy for OCD, and it will be compare with Relaxation Response Meditation.
3108548|NCT01833442|Active Comparator|Relaxation Response Meditation|Relaxation Response Meditation is going to be use as therapy for OCD, and it will be compare with Kundalini Yoga Meditation.
3108549|NCT01833429||Resistant Hypertension|The current definition of resistant hypertension (RH) includes both patients whose blood pressure (BP) is uncontrolled on three or more medications and those whose BP is controlled when using four or more antihypertensive medications
3108550|NCT01833403|Other|Measurement of insulin sensitivity|All participants will undergo a hyperinsulinemic-euglycemic clamp to measure insulin sensitivity
3108551|NCT01833390|Experimental|HXe MRI lung ventilation|Each subject will inhale a dose of HXe gas (up to one liter HXe) while lying inside an MRI scanner. A high-resolution 3D map of the lung spaces filled with HXe gas will be acquired during a short breath-hold. Additionally, proton MRI of the chest cavity will be recorded during the same breath-hold for registering the lung boundaries. All subjects will undergo Pulmonary Function Tests. Subjects suffering from obstructive lung disease will have Tc-99m DTPA lung scintigraphy performed for comparing with HXe images.
3108552|NCT01833377|Experimental|caraway sample|caraway sample
3108553|NCT01833377|Active Comparator|Placebo|
3108554|NCT01833364|Experimental|Implantation of Perpherial Nerve Graft|Subjects own peripheral nerve tissue that will be used to create the graft for implantation. The autologous peripheral nerve graft will then be implanted unilaterally into the substantia nigra of the subject after the placement of DBS electrodes.
3108555|NCT01833351|Experimental|Phase I, IV Vitamin C Healthy Normals|Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.
3108556|NCT01833351|Experimental|Phase 1 IV Vitamin C- Cancer Patients|Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.
3108557|NCT01833338|Other|Single arm|There is only one arm in this study. All patients undergo MSCT, IVUS and OCT.
3108558|NCT01833325|Experimental|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
3108559|NCT01833312|Experimental|Hypothermia|Best medical treatment + hypothermia 34-35°C for 24h
3108560|NCT01833312|No Intervention|Control|Best medical treatment
3108561|NCT01833299|Sham Comparator|TACE group|Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.
3108562|NCT01833299|Experimental|TACE+sorafinib|TACE+sorafinib
3108563|NCT01833286|Experimental|TACE+RFA|TACE was performed according to the following protocol: All patients underwent a distal super-selective catheterization of the hepatic arteries using a coaxial technique and micro-catheters (2.9 Fr, Terumo Corporation, Tokyo, Japan). Then, the same three chemotherapeutic agents at the same dosages were used throughout this study, regardless of tumor number and size. Hepatic artery infusion chemotherapy was performed using carboplatin 300 mg. After that, chemolipiodolization was performed using epirubicin 50 mg, and mitomycin C 8 mg mixed with 5 mL of lipiodol. If the territory of the chemolipiodolized artery did not show stagnant flow, pure lipiodol was then injected. RFA was performed after TACE in 2 months by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).
3108690|NCT01832272|Experimental|Reinflation after early deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled (Reinflation after early tourniquet deflation).
3108699|NCT01832207|Active Comparator|MTS|Motor threshold of stimulation
3108564|NCT01833286|Active Comparator|re-resection|Re-resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. We performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
3108565|NCT01833273|Experimental|PolyMVA|This arm will be taking 8 tsp/day of the study compound (PolyMVA) in addition to receiving normal care as determined by his/her neuro-oncologist.
3108566|NCT01833260|Experimental|With music|Pulmonary rehabilitation with music in the room
3108567|NCT01833260|No Intervention|Without music|
3108568|NCT01833247||Epilepsy inpatients|Patients with epilepsy recorded in an inpatient video-EEG monitoring unit after a seizure.
3108569|NCT01833234||People with epilepsy|People with epilepsy who have have had at least one seizure in the prior year.
3108570|NCT01833221|Experimental|Neurotized facial muscle patients|injection of 1% lidocaine, 2mL for facial nerve block
3108571|NCT01833208|Experimental|Treatment (radiation therapy)|Patients undergo single-fraction radiation therapy to at least 1 bone lesion 2 days after the first sipuleucel-T dose.
3108572|NCT01833195||Heart transplant recipients|Heart transplant rejection surveillance including AlloMap testing
3108573|NCT01833182|Placebo Comparator|Sham intervention|"Those randomized to the sham or placebo treatment group will receive an ADL kit treatment designed only to address fine motor upper extremity function.A series of six 90-minute sessions will be provided to each participant in the sham condition using a standardized protocol."
3108574|NCT01833182|Experimental|Tailored home intervention|Those randomized to the study treatment group will receive a tailored home modification intervention delivered in a series of six 90-minute sessions via a standardized protocol. The tailored treatment may include medical equipment and modifications to the home.
3108575|NCT01833169|Experimental|BKM120|BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28- day cycle
3108576|NCT01833156|Experimental|patient with local edema by histamin|Measuring at 3 locations (on the histmin spot, at 5 cm and 10 cm border (is the control) at 7 times: T0 - T10 minutes - T20 - T30 - T45 - T60 - T75
3108577|NCT01833143|Experimental|Bortezomib|Bortezomib will be administered by subcutaneous injection twice weekly for 2 weeks (Days 1, 4, 8, and 11) at 1.3 mg/m2/dose followed by a 10-day rest period for a 21 day cycle. Dose modifications are permitted as per a prescribed algorithm. Acyclovir at 400mg daily is recommended as prophylaxis for herpes zoster. Restaging scans, with evaluation of response, will be done every 2 cycles (6 weeks of treatment ± 7 days). Treatment will continue until clinical disease progression, unacceptable toxicity, treatment delay > 2 weeks, or at the discretion of the treating physician or patient.
3108578|NCT01833130|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 155 units (U) total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
3108579|NCT01833130|Placebo Comparator|Placebo (Normal saline)|Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
3108580|NCT01833117|Experimental|FID 119515A|FID 119515A, 1 drop instilled in the study eye, single dose
3108581|NCT01833117|Active Comparator|Blink|Blink® Tears, 1 drop instilled in the study eye, single dose
3108582|NCT01833104|Experimental|Training Cohort 1 (TC1)|"(N = 80) in the order Presence - Affect - Perspective"
3108583|NCT01833104|Experimental|Training Cohort 2 (TC2)|"(N = 81) in the order Presence - Perspective - Affect"
3108584|NCT01833104|No Intervention|Retest Control Cohort 1 (RCC1)|(up to N = 30) this is a non-intervention control group to access measurement effects and will be tested at each timepoint.
3108585|NCT01833104|Active Comparator|Training Cohort 3 (TC3)|"(N = 81) here, the Affect Module only intervention is administered."
3108586|NCT01833104|No Intervention|Retest Control Cohort 2 (RCC2)|(up to N = 60) this is a non-intervention control group to access measurement effects and will be tested at each timepoint.
3108587|NCT01833091|Experimental|intervention|creat light period 12 hours with cover on incubator
3108588|NCT01833091|No Intervention|control|
3108589|NCT01833078|Other|7 day ghrelin dosing - all participants|All participants will receive an injection of ghrelin (7.5mcg/kg) dose subcutaneously once daily on Days 1, 2 and 7 in the research center and will self-administer the subcutaneous injection before breakfast on Days 2-6 at home.
3108590|NCT01833065|Experimental|EBX 10|Elobixibat 10 mg/day
3108591|NCT01833065|Experimental|EBX 5|Elobixibat 5 mg/day
3108592|NCT01833065|Placebo Comparator|PLCBO|Placebo
3108593|NCT01833052|Other|Cerebral Protection Filter|Patient is treated with Cerebral protection Filter.
3108594|NCT01833052|Other|No Cerebral Protection Filter|Patient is not treated with Cerebral protection Filter.
3108595|NCT01833039|Experimental|Ibrutinib|Ibrutinib
3108596|NCT01833026|Experimental|COPD assessment and management recommendations|"Patients with a physician-diagnosed COPD or asthma suspicious for COPD being managed by the physician randomized to the intervention group will perform a spirometry test and provide information regarding their medical history on their initial visit, which is 90 minutes before their doctor's appointment. A letter containing the interpretation of spirometry test results, and recommendations for guideline based therapy based on GOLD guidelines will be available to the primary care doctor at the time of the patient's clinic visit. The doctor may review the results and use his or her own judgment in moving forward with the subject's diagnosis and management. A copy of the spirometry results and assessment based on the GOLD criteria at the time of the test of your subject will be uploaded to his or her electronic health record for future reference.~Outcomes will be assessed every 3 months for up to one year through patient telephone calls and medical chart reviews."
3108691|NCT01832272|No Intervention|No reinflation after early deflation|The tourniquet is released after cement implant fixation, and remained deflated without reinflation, even after hemostasis.
3108692|NCT01832259|Placebo Comparator|Placebo arm|Participants receiving placebo
3108693|NCT01832259|Experimental|Pazopanib arm|Participants receiving Pazopanib
3108700|NCT01832207|Active Comparator|STS|Sensorial threshold of stimulation
3108597|NCT01833026|Placebo Comparator|Usual Care|"Patients with a physician-diagnosed COPD or physician-diagnosed asthma suspicious for COPD being managed by the physician randomized to the usual care group will provide medical history, not initially have a spirometry, and will be observed as usual care.~Outcomes will be assessed every 3 months for up to one year through patient telephone calls and medical chart reviews. At the conclusion of the research study which will be 12 months from the patients' initial visit, patients being managed by the physician randomized to the usual care group will have a spirometry test and these results will not be shared with the doctor or the patients during the study but will be uploaded to the electronic health record after the end of the study for future reference."
3108598|NCT01833013|Other|endometriosis cohort|females suffer from endometriosis
3108599|NCT01833000|Other|newborn suspected to suffer from necrotizing enterolitis|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler
3108600|NCT01832987|Experimental|co-trimoxazole|On 4, 5 or 6 consecutive days, 960 mg co-trimoxazole (oral) will be added to the normal treatment of tuberculosis.
3108601|NCT01832974|Other|Part 1- 1 μg/kg|Up to 6 participants receiving IL-13-PE 1 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
3108602|NCT01832974|Other|Part 1 - 2 μg/kg|If lower dose was tolerated, 3-6 participants receiving IL-13-PE 2 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
3108603|NCT01832974|Other|Part 1 - 3 μg/kg|If lower dose was tolerated, 3-6 participants receiving IL-13-PE 3 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
3108604|NCT01832974|Experimental|Part 2 - All Participants|All participants in Part 2, receiving maximum tolerated dose of IL-13-PE 1-3 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), 3 times per monthly cycle for up to 4 cycles (or longer for participants receiving clinical benefit)
3108605|NCT01832961|Experimental|flutter valve exercises|30 minutes of breathing exercises with flutter device
3108606|NCT01832961|Sham Comparator|flutter-sham exercises|30 minutes of breathing exercise with flutter-sham device
3108607|NCT01832948|Experimental|Treatment|Endostar d1-d7 15mg/d Oxaliplatin 85 mg/m2 d6 Folinic acid 400 mg/m2 d6 5-FU 400 mg/m2 d6, and then 5-FU 2,400 mg/m2 INTRAVENOUS over 46 h
3108608|NCT01832935|Active Comparator|insulin glargine|patients receiving variable doses of Insulin glargine.start with 0.2 to 0.6unit per kg
3108609|NCT01832935|Active Comparator|Insulin NPH|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
3108610|NCT01832922|Experimental|Significant Comorbidiities|Significant comorbidities as defined by Cumulative Illness Rating Score (CIRS) of ≥7.
3108611|NCT01832922|Active Comparator|Significant renal dysfunction|Significant renal dysfunction defined as CrCL 15-40 mL/min, but not receiving dialysis.
3108612|NCT01832909|Experimental|Walnut Diet first, then Control Diet|Controlled diet with 1.5 oz/d of walnuts, followed by controlled diet without walnuts.
3108613|NCT01832909|Experimental|Control Diet first, then Walnut Diet|Controlled diet without almonds first (control), then controlled diet with 1.5 oz/d of almonds.
3108614|NCT01832896|Experimental|Ecallantide|"Study Medication, Dose, and Mode of Administration:~Single dose of ecallantide subcutaneous dosing:~Age less than 10: Weight <25 Kg: 10mg subcutaneously at one site; 25-50kg: 20mg subcutaneously, 10mg per site for 2 separate sites; >50 kg 30mg subcutaneously, 10mg per site for 3 separate sites. Dosing will not exceed 30mg.~Age greater than 10: 10mg per site for 3 separate sites. Dosing will not exceed 30mg."
3108615|NCT01832883||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
3108616|NCT01832883||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~VA <20/40 and 2 logMAR lines difference in normal eye~Mild amblyopia (>20/40)~Moderate amblyopia (20/40 and <20/100)~Severe amblyopia (≥20/100 or worse)~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~Constant: >2 PD at near and or distance.~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~'hypermetropia' (≥3.5 D),~'myopia' (≥-4.0 D),~'astigmatism' (≥1.5 D).~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
3108617|NCT01832883||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
3108618|NCT01832870|Experimental|Treatment|Patients enrolled will receive the standard 3-dose treatment of sipuleucel-T, followed by treatment(s) of ipilimumab.
3108619|NCT01832857|Experimental|CPI-613 Alone|This arm is for patients that have failed, or are not eligible for, all available therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
3108620|NCT01832844|Active Comparator|"Group  with scan prior to infiltration "|
3108621|NCT01832844|Placebo Comparator|"Group  without scan "|"Patients will have a dummy lumber spine evaluation in order to put patients in blind conditions"
3108622|NCT01832831||Continent Men|
3108623|NCT01832831||Incontinent Men|
3108624|NCT01832818|Experimental|NuNec Cervical Disc|Each patient will be implanted with the NuNec Cervical Disc in a single level from C3 to C7. Postoperatively, patient evaluated at discharge, 6 weeks, 3, 6, 12 and 24 months.
3108625|NCT01832805|Experimental|Theta burst stimulation|Specific developed sham coil.
3108626|NCT01832792|Experimental|Self-help|In this condition, participants complete a self-help intervention with the support of a therapist. This lasts 12 weeks.
3108627|NCT01832792|Other|Waiting List|One third of participants will be allocated to a treatment waiting list, after which they will be randomised to one of the other two arms.
3108628|NCT01832779||Achalasia subjects|Information about teh subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after the subject's medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
3108629|NCT01832766|Active Comparator|dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
3108630|NCT01832766|Placebo Comparator|sugar pill|one capsule given by mouth at 8:00 a.m.
3108631|NCT01832753|Placebo Comparator|Treatment Phase: Months 6-18|"Subject who are found to have SCH at the 6-month visit will be randomized to receive either levothyroxine or placebo during months 6-12. Levothyroxine dose will be between 0.5 - 1 mcg/kg/day. There will be 1 blood draw visit at month 7.5 (6 weeks after randomization) and 1 study visit at month 12 that will provide the opportunity for dose adjustments if needed.~From months 12-18, all subjects will receive levothyroxine. Levothyroxine dose will be between 0.5 - 1 mcg/kg/day. There will be one blood draw visit at month 13.5 that will provide the opportunity for dose adjustments if needed."
3108632|NCT01832753|No Intervention|Observation Phase: Months 0-6|"Subjects will be observed for the first 6 months of the study to ensure that the subclinical hypothyroidism is persistent. Subjects who do not have SCH at 6 months will not proceed to the treatment phase.~Subjects that have TSH >10 mIU/L during the 6 month Observational Phase will not be considered subclinical and will not qualify to continue the study. They will be referred to an endocrinologist for treatment."
3108633|NCT01832740|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
3108634|NCT01832740|Experimental|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
3108635|NCT01832727|Experimental|5 consecutive days bimonthly (Phase 1b)|Subjects will receive oprozomib administered orally, once daily, on Days 1-5 of a 14-day cycle in combination with 20 mg of dexamethasone on Days 1, 2, 8, and 9. Treatment will be administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
3108636|NCT01832727|Experimental|2 consecutive days weekly (Phase 1b/2)|Subjects will receive oprozomib administered orally, once daily, on Days 1, 2, 8, and 9 of a 14-day cycle in combination with 20 mg of dexamethasone on Days 1, 2, 8, and 9. Treatment will be administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
3108637|NCT01832701|Experimental|coffee|4 cups of soluble coffee per day (2.5g per cup)
3108638|NCT01832701|Placebo Comparator|Maltodextrine with caffeine|4 cups per day containing 2.5 g of product each
3108639|NCT01832688||Baseline cohort|The baseline survey will be implemented among pregnant women in randomly selected villages using a continuous enrollment schedule over the period of 18 months
3108640|NCT01832688||Optimization cohort|The programmatic impact of optimized prenatal care services on women's health and behavior will be assessed among pregnant women in randomly selected villages (Programmatic prenatal care optimization)
3108641|NCT01832675|Active Comparator|Bupivacaine lozenge|The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
3108642|NCT01832675|Active Comparator|Xylocain, cutaneous spray, solution|The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
3108643|NCT01832662|Experimental|Coffee|4 cups/day of 2.5g of coffee each
3108644|NCT01832662|Active Comparator|coffee polyphenols mixed with placebo|4 cups/day of 2.5g of product each
3108645|NCT01832662|Placebo Comparator|maltodextrin enriched with caffeine|4 cups/day of 2.5g of product each
3108646|NCT01832649|Experimental|Exercise|Moderate-vigorous intensity strength exercise. 50 minutes per session, 2 times per week, 8 weeks.
3108647|NCT01832649|Active Comparator|Health education|Health education sessions. 50 minutes per session, 2 times per week, 8 weeks.
3108648|NCT01832636|Active Comparator|Alanyl-Glutamine 3g/d|Alanyl-Glutamine orally 3g/day for 10 days
3108649|NCT01832636|Active Comparator|Alanyl-Glutamine 6g/d|Alanyl-Glutamine orally 6g/day for 10 days
3108650|NCT01832636|Active Comparator|Alanyl-Glutamine 12g/d|Alanyl-Glutamine orally 12g/d for 10 days
3108651|NCT01832636|Placebo Comparator|Glycine 12.5g/d|Glycine orally 12.5 g/d for 10 days. This dose is calculated to be isonitrogenous to 12g of Alanyl-Glutamine.
3108652|NCT01832623|Experimental|Exploration of Vitamin D roles|Various exams will be performed during two visits (the same day or within three months) in order to answer the objectives of the study.
3108653|NCT01832610||HVAD® Pump|
3108654|NCT01832584|Experimental|RGC1|200 mg of Red Grape Cell (RGC) powder; daily oral dose
3108655|NCT01832584|Experimental|RGC2|1000 mg of Red Grape Cell (RGC) powder; daily oral dose
3108656|NCT01832584|Placebo Comparator|Placebo|1000 mg placebo to Red Grape Cell (RGC) powder; daily oral dose
3108657|NCT01832571|Experimental|Once daily Truvada®|One tablet of Truvada (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) daily
3108658|NCT01832558|Experimental|Eplerenone|Eplerenone 25-50mg daily additionally to standard ACE-inhibition with enalapril 20mg daily
3108659|NCT01832558|Placebo Comparator|Placebo|Placebo additionally to standard ACE-inhibition with enalapril 20mg daily
3108660|NCT01832545|Active Comparator|Educational Program|The communitarian PESO program is based on appropriate clinical guidelines and on validated behavior change principles. Implemented by an intervention team with expertise gained from current scientific research in weight control determinants, this program as well PICO, is free of charge for all interested adults who wish to manage their weight and health. It operates since 2005 with the aims to prevent obesity or reduce excess weight, as well as, some of the risks associated with obesity in adults through a change to steady healthy habits, attitudes and behaviors. PESO has 3 months duration and it is structured in 12 sessions of one and a half hour, once a week.
3108694|NCT01832233|Experimental|Renal Denervation|Patients with resistant hypertension and chronic kidney disease (GFR between 15 and 60) will receive Renal Denervation as a treatment
3108695|NCT01832220||PiZZ not on therapy|Individuals with the PiZZ genotype not on augmentation therapy.
3108696|NCT01832220||PiZZ on therapy|Individuals with the PiZZ genotype on augmentation therapy.
3108661|NCT01832545|Experimental|Aquatic Exetcise|Aquatic Exercise program is organized in 24 sessions distributed over 12 consecutive weeks, with a frequency of twice a week. The duration of each session will be 60 minutes, being that 10 minutes are for patient reception, blood pressure control, pain register or others and the effective time inside the water is 45 minutes. The indoor pool works with an air temperature around 27±1ºC and water temperature is controlled for 30.5±5ºC. Workout is organized in order to have a progressive overload every week or every two sessions, when occurs an introduction of a new stimulus. Water is the main instrument to create resistance and only in the last weeks, according with participants progression and if the self-reported pain controlled, drag equipment will be added.
3108662|NCT01832532|Experimental|Treatment group- liraglutide|Treatment group- liraglutide daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose.
3108663|NCT01832532|No Intervention|Control group|Control group
3108664|NCT01832519||CF group|Infants with Cystic Fibrosis will receive 2 chest MRIs with contrast, 2 HRCTs and blood for proteomics and metabolomics at 12 month interval.
3108665|NCT01832519||Non-CF Control|1 chest MRI with contrast and blood for proteomics and metabolomics
3108666|NCT01832506|Experimental|MSC2156119J|
3108667|NCT01832493|Experimental|Cardiac Resynchronization Therapy|Patients implanted with a cardiac resynchronization therapy device
3108668|NCT01832480|Active Comparator|MTZ 2 g|Single dose MTZ
3108669|NCT01832480|Experimental|MTZ 500 mg BID x 7 days|Multi dose MTZ
3108670|NCT01832467|Experimental|cetuximab-containing chemotherapy|"Cetuximab may be given at either one of the following schedules at the investigator's discretion:~2-weekly: Cetuximab is started on day 1 of each cycle of chemotherapy, at 500mg/m2 every 2 weeks over 120/90/60minutes.~Weekly: Cetuximab may be given at a loading dose of 400mg/m2 on day 1over 120 minutes, followed by weekly dosing at 250mg/m2 on day 1, over 60 minutes of each cycle of chemotherapy.~Chemotherapy: Only one of the following regimens may be combined with cetuximab at the investigator's discretion according to institutional standard. Some recommended regimens used in Hong Kong.~Regimens to be combined with biweekly cetuximab:~Irinotecan at 2-weekly schedule.~FOLFIRI (as inpatient or via ambulatory pump).~FOLFOX (as inpatient or via ambulatory pump)."
3108671|NCT01832454|Other|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
3108672|NCT01832441|Other|Transfer of autologous MNC intrathecally|single arm Intra thecal transplantation of autologous MNC
3108673|NCT01832428|Other|Transfer of autologous MNC intrathecally|Intra thecal transplantation of autologous stem cells 100 Millions per dose in 3 divided doses at interval of 7days.
3108674|NCT01832415||Use of bevacizumab (Avastin ®) - First-line ovarian cancer|Patient receiving bevacizumab in ovarian cancer first line treatment
3108675|NCT01832402|Experimental|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD). FPNS administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test. Walk test administered before first dose of FPNS. Participant will rest for 30 minutes after walk test. FPNS administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. FPNS administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes. Questionnaires completed at baseline, before each walk test, and at end of final walk test. Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
3108676|NCT01832402|Placebo Comparator|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test. Walk test administered before first dose of placebo nasal spray. Participant will rest for 30 minutes after walk test. Placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes. Questionnaires completed at baseline, before each walk test, and at end of final walk test. Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
3108677|NCT01832389|Active Comparator|Group P|PiCCO-controlled group
3108678|NCT01832389|No Intervention|Group C|control group
3108679|NCT01832376|Experimental|Ultrasound guided needle lavage|Ultrasound guided needle lavage
3108680|NCT01832363|Experimental|HXe MRI guided treatment sequence for BT|Patients in this arm will undergo bronchial thermoplasty treatment where the first session of the procedure will target the six most problematic airways as determined with HXe imaging. Patients will have the remaining of the airways treated in the two subsequent sessions.
3108681|NCT01832363|Active Comparator|Standard treatment sequence for BT (control)|Patients in this arm will undergo standard treatment sequence of bronchial thermoplasty. To preserve the blind of the procedure to the subjects, the same timeline and clinical measures will be followed as for HXe guided patients.
3108682|NCT01832350|Experimental|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day (every 12 hours), during a 26-week period.
3108683|NCT01832337|Experimental|precondition|
3108684|NCT01832311|Experimental|senile cataract with NSAID|"15 non-diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac."
3108685|NCT01832311|Experimental|diabetic cataract with NSAID|"17 diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac."
3108686|NCT01832311|No Intervention|senile cataract without NSAID|"17 non-diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup not receiving topical ketorolac."
3108687|NCT01832311|No Intervention|diabetic cataract without NSAID|"12 diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup not receiving topical ketorolac."
3108688|NCT01832298|Experimental|Simmitecan Hydrochloride for Injection|Dissolving in 2ml water for injection, then transfering to 500 mL of 5% dextrose for i.v.90 minutes
3108689|NCT01832285|Experimental|Fluvoxamine|Tablets of Fluvoxamine in dosage 100mg/day will be added to the treatment regimen and continued for 6 weeks
3108702|NCT01832194|Experimental|Botox|"Botox:~A concentrated dose of Onabotulinum Toxin A of 100 units dissolved in 2 cc of 2% xylocaine for a one-time injection."
3108703|NCT01832181||Metformin|
3108704|NCT01832181||Control|
3108705|NCT01832168|Other|Control|Robotic Assisted Laparoscopic Prostatectomy with application of absorbable hemostat.
3108706|NCT01832168|Experimental|AmnioFix|Robotic Assisted Laparoscopic Prostatectomy with application of dehydrated human amniotic membrane.
3108707|NCT01832155|Experimental|yoga intervention|The yoga intervention received eight 60 minute weekly Hatha yoga intervention classes and asked to practice additional 30 minute yoga per day at home.
3108708|NCT01832155|Other|wait list control|The wait list control group received the same 8-week Hatha yoga intervention involving group and home-based exercise sessions after the yoga intervention group completed the intervention at the end of 8 weeks.
3108709|NCT01832129|Active Comparator|i.m. injection of Vitamin B12|Weekly i.m. injections of 1 mg Cyanocobolamin after 1, 2, and 3 weeks.
3108710|NCT01832129|Experimental|Oral administration of vitamin B12|High dose (1 mg/day) oral Cyanocobolamin will be adminstrated with electronic adherence monitoring.
3108711|NCT01832116|Experimental|Tracerinjection|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
3108712|NCT01832103|Experimental|MK-7145|MK-7145 2 mg IR administered as a single oral dose.
3108713|NCT01832090|Experimental|Radiesse® Injectable Dermal Filler|Device: Radiesse Dermal Filler mixed with 2% lidocaine-HCl (final concentration: 0.3% lidocaine-HCl)
3108714|NCT01832090|Active Comparator|Delayed Treatment|Untreated controls crossed over to treatment with Radiesse Dermal Filler mixed with 2% lidocaine-HCl (final concentration: 0.3% lidocaine) at 3 months
3108715|NCT01832077||rural doctor|examine patient's fundus by 90D fundus pre-set lens
3108716|NCT01832077||grader|grade fundus pictures in ZOC
3108717|NCT01832064|Experimental|Mailed Chronic Disease Self-Management|Mailed Chronic Disease Self-Management Program: self management information and self assessment
3108718|NCT01832051|Experimental|HER2-PET|Injection of 89Zr-trastuzumab followed by PET scan
3108719|NCT01832038|Experimental|Lacosamide|Lacosamide treatment of 100 - 400 mg/day for long-term
3108720|NCT01832025|Active Comparator|Internal|internal maxillary sinus floor elevation technique with simultaneous implant placement
3108721|NCT01832025|Active Comparator|External|external maxillary sinus floor elevation technique with simultaneous implant placement
3108722|NCT01832012|Active Comparator|Video refresher|Group 3, received 7 minute video refresher prior to examination.
3108723|NCT01832012|Experimental|Video refresher and hands-on practice|Group 4, received same 7 minute video refresher, along with hands-on practice along with the video on a Laerdal BLS manikin.
3108724|NCT01832012|No Intervention|No intervention|Group 2
3108725|NCT01831999|Experimental|RecoveryTrack - Extended Care (RT-E)|Counselors will conduct monitoring and feedback sessions using the RecoveryTrack-Extended Care (RT-E) web-based monitoring system for clients newly admitted to Intensive Outpatient (IOP) treatment. Counselors will be instructed to document their reminders, contact attempts, and scheduling of RT-E appointments within a Contact Log incorporated into RT-E. All RT-E sessions will be audio recorded.
3108726|NCT01831999|No Intervention|Treatment as Usual (TAU)|Counselors will conduct standard treatment during IOP/OP in this condition. Exceptions to this condition are that counselors will: audio record their first 3 biweekly and subsequent 7 monthly individual in-person sessions; document on a Contact Log outreach attempts; and complete a Counselor Activity Log for client participants. There are several steps that counselors typically take when a client misses a session. Clients are called to reschedule for the same week, if the client doesn't return for their next scheduled session, the counselor sends a letter asking the client to return, etc.
3108727|NCT01831986|Experimental|Pregnenolone + L-Theanine|The 60 participating subjects will be randomized into 2 groups: 30 patients will receive PREG (50 mg/day) with L-theanine (400 mg/day) and 30 patients will receive a placebo, each for 8 weeks in a double-blind manner.
3108728|NCT01831986|Placebo Comparator|Sugar caps.|Placebo (4 caps/day)
3108729|NCT01831973|Experimental|Lipotecan, injection for chemotherapy|Patients receive TLC388 (50 mg/m2) given as a 30-minute IV infusion, on Days 1, 8, and 15 of a 28-day cycle.
3108730|NCT01831960|Experimental|Cortexolone 17α-Propionate|Topical cream, 1.0% concentration, applied every twelve hours
3108731|NCT01831947|Experimental|Ranibizumab fixed dose|Injection of 0.5 mg Ranibizumab every 2 months for one year, following a monthly injection during the first 3 months.
3108732|NCT01831947|Experimental|Ranibizumab on demand|Injection of 0.5 mg Ranibizumab on demand for one year, following a monthly injection during the first 3 months.
3108733|NCT01831934|Experimental|MELAS group:13-60 years of age.|Fluzone® 2010-2011 Formula or 2011-2012 depending on year
3108734|NCT01831934|Experimental|Control Group: 18-65 years of age|Fluzone® 2010-2011 Formula or 2011-2012 depending on year
3108735|NCT01831921|Experimental|Lifestyle Weight-Loss|Participants in the Behavioral: Lifestyle Weight Loss arm will take part in a group program aimed at achieving modest weight loss (5-7%) through promoting healthy eating and increasing physical activity. The intervention sessions will take place at churches and other community locations and will be coordinated and facilitated by Latino Health Advisors (LHAs). The lifestyle intervention will be delivered in 2 phases: Phase 1 will last for 6 months and consist of weekly group meetings; Phase 2 will last for 18 months and consist of one LHA-led group session or one telephone contact from the LHA per month. Participants in this treatment arm will also receive individual visits with a registered dietitian during months 1, 3, and 6 of phase 1. All participants will be seen for assessment visits as baseline, 6, and 12 months. Some participants will also complete 18 and 24 month visits, depending on the date of randomization.
3108736|NCT01831921|Active Comparator|Enhanced Usual Care|Participants in the Behavioral: Counseling arm will receive two individual sessions with a registered dietitian and monthly newsletters that focus on existing community resources.All participants will be seen for assessment visits as baseline, 6, and 12 months. Some participants will also complete 18 and 24 month visits, depending on the date of randomization.
3108737|NCT01831908|Sham Comparator|Lifestyle counseling|These persons will be advised on their cardiovascular status and will receive information on how to improve it.
3108811|NCT01831453|Placebo Comparator|isopropylmyristate oil|placebo Soft gelatinous capsules filled with isopropylmyristate oil
3108738|NCT01831908|No Intervention|People not seeking attention|Evaluation of cardiovascular health status will be performed in these persons as part of yearly door-to-door survey that will perform in Atahualpa up to the end of the study
3108739|NCT01831895|Experimental|MobiusHD™|MobiusHD™
3108740|NCT01831882||Major Depressive Disorder|
3108741|NCT01831882||Healthy Control|
3108742|NCT01831869|Active Comparator|L-thyroxine|Oral administration, starting dose 25 or 50 micrograms once daily.
3108743|NCT01831869|No Intervention|blank|no intervention
3108744|NCT01831856|Experimental|F373280|
3108745|NCT01831856|Placebo Comparator|Placebo|
3108746|NCT01831843|Placebo Comparator|Group C|non-heated, non-humidified conventional breathing circuit was used in group C patient
3108747|NCT01831843|Experimental|Group E|breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer & Paykel)was used in group E patient
3108748|NCT01831843|Experimental|Group M|Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
3108749|NCT01831830|No Intervention|control condition|The control group receives two attention-control calls.
3108750|NCT01831830|Experimental|The Veterans' in-home program|The VIP intervention consists of 8 sessions (up to 6 in the home and 2 phone calls) from an occupational therapist. This is delivered to Veterans and their family members.
3108751|NCT01831817|Experimental|5% calcium sodium phosphosilicate/ sodium monofluorophosphate|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
3108752|NCT01831817|Active Comparator|0% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
3108753|NCT01831817|Active Comparator|Sodium monofluorophosphate|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
3108754|NCT01831817|Active Comparator|Sodium fluoride|Dentifrice containing 1100 ppmF as sodium fluoride
3108755|NCT01831804|Experimental|Cohort 1 Part A|Healthy subjects in this arm will receive single applications of GSK1278863 or placebo (with 6:2 ratio) on intact skin in two escalating dosing periods each separated by 10 days. The first application will be with a single dose of 0.3 mg and second application will be single dose of 3 mg.
3108756|NCT01831804|Experimental|Cohort 2 Part A|Subjects with diabetic foot ulcer (DFU) will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on intact skin and second application directly on DFU. Dose will be based on wound area and review from previous cohort data.
3108757|NCT01831804|Experimental|Cohort 3 Part A|Subjects with DFU will receive single application of GSK1278863 or placebo directly on DFU. Dose will be based on wound area and review from previous cohort data.
3108758|NCT01831804|Experimental|Cohort 4 Part A|Subjects with DFU will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on DFU and second application on intact skin. Dose will be based on wound area and review from previous cohort data.
3108759|NCT01831804|Experimental|Cohort 5 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
3108760|NCT01831804|Experimental|Cohort 6 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
3108761|NCT01831804|Experimental|Cohort 7 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
3108762|NCT01831791|Experimental|Dutasteride Arm|Subjects will receive 1 capsule of Dutasteride 0.5 mg orally once daily for 52 weeks (12 months).
3108763|NCT01831778||all women|women receiving mammography at one of 6 mammography registries across the country.
3108764|NCT01831765|Experimental|Meal time FIAsp and insulin detemir|
3108765|NCT01831765|Active Comparator|Meal time insulin aspart and insulin detemir|
3108766|NCT01831765|Experimental|Post meal FIAsp and insulin detemir|
3108767|NCT01831752||Type 1 Diabetes Melitus|Subjects aged 12 through 75, previously diagnosed with type 1 diabetes mellitus, currently using insulin to treat their diabetes.
3108768|NCT01831739||Multi-organ|Non-acute presentation, any Scadding stage, evidence of 5 or more organ systems involved, chronic or uncertain clinical course.
3108769|NCT01831739||Non-acute, Stage I, untreated|Non-acute presentation, Scadding stage I, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
3108770|NCT01831739||Stage II-III, treated|Non-acute presentation, Scadding stages II or III, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, treated for at least 3 months.
3108771|NCT01831739||Stage II-III, untreated|Non-acute presentation, Scadding stage II or III, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
3108772|NCT01831739||Stage IV treated|Non-acute presentation, Scadding stage IV, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, treatment current and for at least 3 months.
3108773|NCT01831739||Stage IV untreated|Non-acute presentation, Scadding stage IV, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
3108812|NCT01831453|Active Comparator|experimental|omega-3 1 gram three times daily for 6 months
3108774|NCT01831739||Acute Sarcoidosis, untreated|Acute presentation, Scadding stages I, II, or III, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
3108775|NCT01831739||Remitting, untreated|Remitting clinical course, no treatment for at least 3 months.
3108776|NCT01831739||Cardiac defining therapy|Chronic or uncertain clinical course, no multi-organ involvement, cardiac manifestations defining need for systemic corticosteroid and/or immunomodulatory therapy.
3108777|NCT01831726|Experimental|TKI258|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
3108778|NCT01831713||CHF patients and Controls|CHF patients refer to Decompensated patients and Compensated patients
3108779|NCT01831700|Experimental|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India
3108780|NCT01831700|Active Comparator|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA
3108781|NCT01831687|Active Comparator|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA
3108782|NCT01831687|Experimental|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India
3108783|NCT01831674|Experimental|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
3108784|NCT01831674|Active Comparator|GLUCOPHAGE®XR|GLUCOPHAGE®XR tablet 750 mg of Bristol-Myers Squibb Company, USA
3108785|NCT01831661|Active Comparator|GLUCOPHAGE®XR|GLUCOPHAGE®XR (Metformin HCl extended-release tablets) 750 mg of Bristol-Myers Squibb Company, USA
3108786|NCT01831661|Experimental|Metformin Hydrochloride Extended-Release Tablets USP 750 mg|Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
3108787|NCT01831648|Experimental|Volonteers|Blood sample
3108788|NCT01831635||Myeloproliferative neoplasm case|"Patients with Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) will be recruited based on the WHO diagnostic criteria.~Exclusion Criteria~younger than 18 years old.~where the clinician/General Practitioner (GP) does not provide consent.~incapable of giving informed consent.~physically or cognitively incapable of completing the questionnaire.~too ill to participate."
3108789|NCT01831635||General Practice Control|"For each MPN case one GP control will be randomly selected and frequency matched to the distribution of cases by 5-year age band, geographic location (Belfast and Southampton) and gender.~The following patient groups will be excluded. Those:~younger than 18 years old.~where the clinician/GP does not provide consent.~incapable of giving informed consent.~physically or cognitively incapable of completing the questionnaire.~too ill to participate. The WHO performance evaluation scale will be used at the stage of participant identification. Only those scoring 0-3 will be considered eligible for inclusion in the study. Those scoring 3 are described as Symptomatic >50% in bed but not bedbound."
3108790|NCT01831635||Non-blood relative or family control|Recruitment of 100 non-blood relative/friend controls will be undertaken by asking cases to pass on a flyer to up to 2 or 3 non-blood relatives/friends aged 18 years or older.
3108791|NCT01831622|Experimental|Behavioral|"Cognitive testing of participants. Asterisk applies for patient group.~Day 1:~Patient arrives having abstained medication for minimum 20 hours.*~Administer either Ritalin or placebo intervention, and wait 60 minutes before computer-testing.*~Case Report Form (CRF), ASRS and Wechsler Adult Intelligence Scale (WAIS) subtests.~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment.*~Day 2:~Patient arrives having abstained medication for a minimum of 20 hours.*~Administer either Ritalin or placebo intervention (opposite of Day 1), and wait 60 minutes before computer-testing.*~CRF 3, ASRS and Edinburgh Handedness Inventory (EHI).~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment.*"
3108792|NCT01831622|Experimental|fMRI-arm|"Asterisk applies only for patient group.~Day 1:~Patient arrives having abstained medication for minimum 20 hours.*~Administer either Ritalin or placebo intervention, and wait 60 minutes before MRI testing.*~CRF 2, Adult ASRS and WAIS subtests.~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment to ensure the patients have not been withheld from medication for too long while keeping blind.*~Day 2 (after 14 - 40 days):~Patient arrives having abstained medication for a minimum of 20 hours.*~Administer either Ritalin or placebo intervention, and wait 60 minutes before testing (opposite of Day 1).*~CRF 3, ASRS and EHI.~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment.*"
3108793|NCT01831596|Experimental|ciSNaP|
3108794|NCT01831583|Experimental|Measurement of PPG waveforms|Collection of photoplethysmograph(PPG)waveform data from patients with obstructive sleep apnea for 4-8 hours
3108795|NCT01831583|Experimental|Measurement of Pulse Arrival Time (PAT)|Collection of PAT waveform data from patients with obstructive sleep apnea for 4-8 hours
3108796|NCT01831570|Other|symptomatic and radiographic hand osteoarthritis|Patients above 35-years old with symptomatic and radiographic hand osteoarthritis
3108797|NCT01831557||Childrens' Milk Intake|The milk intake of children will be reconciled with body measurement index and blood samples will be taken for gene sequencing
3108798|NCT01831544|Experimental|MVAD® Pump|Implant of HeartWare MVAD® System
3108799|NCT01831531|Experimental|S-1|"Patients will receive chemoradiation with S-1.~Interventions:~Drug: S-1 Radiation: Radiation therapy"
3108800|NCT01831518|Experimental|CRT Eligible|ACC/AHA/HRS/ESC guidelines for device-based therapy
3108801|NCT01831505|Experimental|Multiple drug microinjection|Multiple drug microinjection with locally injected rituximab, vincristine, doxorubicin, bendamustine, prednisolone, or a combination of them
3108802|NCT01831492|Active Comparator|zeolite + dolomite|28 trained subjects receive encapsulated zeolite + dolomite
3108803|NCT01831492|Placebo Comparator|cellulose|28 trained subjects receive encapsulated micro-crystalline cellulose
3108804|NCT01831479|Experimental|Rosuvastatin and Olmesartan|A multiple-dose administration of rosuvastatin, a multiple-dose administration of olmesartan, and a multiple-dose administration of rosuvastatin and olmesartan, given orally with a washout period of 8 days between each administrations
3108805|NCT01831466|Experimental|Treatment Group A|
3108806|NCT01831466|Experimental|Treatment Group B|
3108807|NCT01831466|Placebo Comparator|Treatment Group C|
3108808|NCT01831466|Experimental|Treatment Group D|
3108813|NCT01831440|Other|medicine combined CBT|Besides clinical routine antidepressant treatment,participants receive CBT weekly for 8 weeks and monthly until the end of the study.
3108814|NCT01831440|Other|medicine (SSRI antidepressants)|clinical routine antidepressant treatment——Selective serotonin reuptake inhibitors（SSRIs）.
3108815|NCT01831427|Experimental|GS-5745|"(IV dose at 0.3 mg/kg, 1.0 mg/kg, 2.5 mg/kg, or 5.0 mg/kg and subcutaneous dose at 150 mg)~Participants will receive GS-5745 as follows:~SAD cohort - single IV dose;~MAD cohort - multiple (three) IV doses every two weeks;~Adaptive MAD cohort - a single subcutaneous dose for 5 consecutive weeks"
3108816|NCT01831427|Experimental|Placebo to match GS-5745 + GS-5745 (Adaptive MAD)|"Participants will receive placebo to match GS-5745 as follows:~SAD cohort - single IV dose;~MAD cohort - multiple (three) IV doses every two weeks;~Participants will receive GS-5745 150 mg as follows:~Adaptive MAD cohort - a single subcutaneous dose for 5 consecutive weeks"
3108817|NCT01831414|Experimental|Water immersion at cervical level|Lung function of spinal cord injury patients will be studied with a water immersion at cervical level
3108818|NCT01831414|Experimental|Water immersion at xyphoid level|Lung volumes of spinal cord injury patients will be studied with a Water immersion at xyphoid level
3108819|NCT01831401|Experimental|0° Head Down (horizontal) & Standard Introducer.|Operating table position 0° head down (horizontal) & standard straight acetabular component introducer without alignment guide.
3108820|NCT01831401|Experimental|0° Head Down (horizontal) & Modified 35° Introducer.|Operating table position 0°head down (horizontal) & modified 35° acetabular component introducer.
3108821|NCT01831401|Experimental|0°Head Down (horizontal) & Inclinometer-assisted Introducer.|Operating table position 0°head down (horizontal) & standard straight acetabular component introducer without alignment guide.
3108822|NCT01831401|Experimental|7° Head Down & Standard Introducer.|Operating table position 7° head down & standard straight acetabular component introducer without alignment guide.
3108823|NCT01831401|Experimental|7° Head Down & Modified 35° Introducer.|Operating table position 7° head down & modified 35° acetabular component introducer.
3108824|NCT01831401|Experimental|7° Head Down & Inclinometer-assisted Introducer.|Operating table position 7° head down & inclinometer-assisted acetabular component introducer.
3108825|NCT01831401|Experimental|Y° Head Down & Standard Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & standard straight acetabular component introducer without alignment guide.
3108826|NCT01831401|Experimental|Y° Head Down & Modified 35° Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & modified 35°acetabular component introducer.
3108827|NCT01831401|Experimental|Y° Head Down & Inclinometer-assisted Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & inclinometer-assisted acetabular component introducer.
3108828|NCT01831388|Experimental|The breath training program|Approximately 30-minutes of group instruction session on breathing techniques delivered at a Main Campus outpatient clinic, followed by approximately 15 minutes twice daily home practice for six weeks with weekly telephone coaching. The intervention will conclude at about week 6. Patients will be encouraged to continue the practice, but there will be no further phone calls to remind patients or to confirm their continuing practice.
3108829|NCT01831375|Experimental|Speak Up|Participants will learn how to speak up to their medical doctors for improving their medical care.
3108830|NCT01831375|Other|Get Connected|Attention control group
3108831|NCT01831362|Experimental|Focused Awareness (FA)|This 8 week program consists solely of focused awareness practices, i.e. selected attention to an object (breath etc) and deselection of other stimuli
3108832|NCT01831362|Experimental|Open-Monitoring (OM)|This 8-week program consists solely of open monitoring practices, or noticing and/or labeling the contents of ongoing experience ( thoughts, body sensations, emotions, seeing, hearing etc) without focusing on or deselecting any stimuli
3108833|NCT01831362|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|The 8 week MBCT program follows the 2nd Edition (2012) manual (Segal, Williams, Teasdale) and includes both focused awareness and open- monitoring practices
3108834|NCT01831336||Orsiro DES|
3108835|NCT01831323||mesalazine|10 female patients with first diagnosis of SUDD will take mesalazine 1,6g per day for 14 days (1 tablet 800mg twice daily)
3108836|NCT01831323||VSL#3|10 female patients with first diagnosis of SUDD will take VSL#3 2 sachets a day for 14 days (1 sachet twice a day, for a total of 900 billion bacteria per day)
3108837|NCT01831323||Rifaximin|10 female patients with first diagnosis of SUDD will take 800mg/day of rifaximin (2 tablets of 200mg twice a day)
3108838|NCT01831323||fiber|10 female patients with first diagnosis of SUDD will take fibers for 14 days (psyllium 10grams per day)
3108839|NCT01831310|Active Comparator|Control (standard) (Kabiven)|an isocaloric and iso-nitrogenous standard parenteral nutrition (Kabiven)
3108840|NCT01831310|Experimental|Standard parenteral-glutamine (S-D)|alanine-glutamine (aln-gln) (Dipeptiven) supplemented parenteral nutrition (S-D group, n=8),
3108841|NCT01831310|Experimental|Standard-Omega-3 fatty acid (S-O)|Omega-3 fatty acid (Omegaven) supplemented parenteral nutrition (S-O group, n=8)
3108842|NCT01831310|Experimental|Standard-glutamine-omega 3 (S-D-O)|ala-gln and omega 3 fatty ascid supplemented parenteral nutrition (S-D-O group, n=10).
3108843|NCT01831297||syncope|
3108844|NCT01831284||heroin injecting drug users|Sigmoidoscopy with biopsy, in medically stable active injecting drug users
3108845|NCT01831284||healthy controls|Sigmoidoscopy with biopsy, in non-injecting controls-
3108846|NCT01831284||Former heroin injection drug users|Sigmoidoscopy with biopsy, in former injectors of heroin with or without other agents
3108847|NCT01831271|Other|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
3108915|NCT01830855|Experimental|rLP2086 lot 1|
3108916|NCT01830855|Experimental|rLP2086 lot 2|
3108917|NCT01830855|Experimental|rLP2086 lot 3|
3108848|NCT01831271|Other|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
3108849|NCT01831258|Experimental|SensAwake On|The comfort feature 'SensAwake' will be turned on
3108850|NCT01831258|Active Comparator|SensAwake Off|The comfort feature 'SensAwake' will be turned off
3108851|NCT01831232|Experimental|Treatment (pravastatin sodium, idarubicin, and cytarabine)|Patients receive pravastatin sodium PO QD on days 1-8, idarubicin IV over 10-15 minutes on days 4-6, and cytarabine IV continuously on days 4-7. Treatment repeats every 28-56 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3108852|NCT01831219||ROBODOC|The ROBODOC group received total hip arthroplasty using the ROBODOC Surgical system for preparation of the femoral canal for a femoral stem implant.
3108853|NCT01831219||Conventional|The conventional group received total hip arthroplasty using the conventional manual tools including a broach to prepare the femoral cavity for femoral stem replacement.
3108854|NCT01831206|Experimental|Collagen cross-linking|Collagen cross-linking with standard treatment
3108855|NCT01831206|No Intervention|standard treatment|Standard treatment alone
3108856|NCT01831193|Active Comparator|Diabetic|
3108857|NCT01831193|Active Comparator|Non-diabetic|
3108858|NCT01831180||Premenopausal women 19-25 yrs|
3108859|NCT01831180||Postmenopausal 60 yrs +|
3108860|NCT01831167|Experimental|dynamic light|dynamic light
3108861|NCT01831167|No Intervention|reference|normal light
3108862|NCT01831154|Experimental|Tight Glycemic Group|The tight glycemic group received a continuous intravenous infusion of regular insulin in the intraoperative period titrated per a modified Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial bolus of insulin and insulin infusion was initiated prior to induction of anesthesia if the morning blood glucose was greater than 149 mg/dl or any time intraoperatively the blood glucose elevated above 149 mg/dl.The titration of insulin for the tight glycemic group maintained blood glucose levels between 110-149 mg/dl throughout the intraoperative period. The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes.Upon transfer to the intensive care unit the protocol ended and all subjects received the same glycemic control.
3108863|NCT01831154|Experimental|Conventional Glycemic Group|The conventional glycemic group received a continuous intravenous infusion of regular insulin in the intraoperative period titrated per a modified Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial insulin bolus and infusion was initiated prior to induction of anesthesia if the morning blood glucose was greater than 180 mg/dl or any time intraoperatively that the blood glucose elevated above 180 mg/dl. The insulin infusion was titrated throughout the intraoperative period to maintain blood glucose levels between 150-180 mg/dl.The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes. Upon transfer to the ICU the intraoperative protocol ended and all subjects received the standardized glycemic control for the ICU.
3108864|NCT01831154|Experimental|Standard Glycemic Group|The standard glycemic group received intravenous injections of regular insulin in the intraoperative period titrated per the usual care protocol utilized at the study site. The initial bolus of insulin was initiated prior to induction of anesthesia if the morning blood glucose is greater than 180 mg/dl or any time intraoperatively that the blood glucose rises above 180 mg/dl. The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes.Upon transfer to the ICU the intraoperative protocol ended and all subjects received the standardized glycemic control for the ICU.
3108865|NCT01831128||ASV Treatment|AutoSet CS, PaceWave
3108866|NCT01831128||Control|No ASV treatment
3108867|NCT01831102||non-Latino white|no Latino ancestry, Caucasian
3108868|NCT01831102||Mexican American|Mexican American ancestry
3108869|NCT01831089|Experimental|Treatmen|PM01183 + paclitaxel +/- bevacizumab
3108870|NCT01831076|Experimental|Treatment (exemestane, surgery)|Patients receive exemestane orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
3108871|NCT01831063|No Intervention|1|This group received the traditional seizure teaching. This consisted of verbal instruction from health care professionals on acute seizure management and administration of the rescue medication.
3108872|NCT01831063|Experimental|2|This group received the traditional seizure teaching as well as the supplemental simulation based seizure management teaching. The simulation based seizure teaching consisted of numerous opportunities to manage a simulated seizure with instructor guidance and feedback. This session was deemed complete when caregivers verbalized confidence with seizure management.
3108873|NCT01831050|Experimental|G1: Sanofi bOPV Control|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
3108874|NCT01831050|Experimental|G2: Sanofi bOPV Control|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
3108875|NCT01831050|Experimental|G3: Trivalent OPV Control|100 infants receiving Trivalent Oral Polio Vaccine (tOPV)' at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
3108876|NCT01831050|Experimental|G4: Sanofi bOPV, Sanofi IPV|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
3108877|NCT01831050|Experimental|G5: Sanofi bOPV, Sanofi 2 IPV|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
3108878|NCT01831050|Experimental|G6: Sanofi bOPV, GSK IPV|50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Glaxo SmithKline IPV (GSK IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
3108918|NCT01830855|Active Comparator|Control|Havrix (HAV) and Saline
3108879|NCT01831050|Experimental|G7: Sanofi bOPV, GSK 2 IPV|190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Glaxo SmithKline IPV (GSK IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
3108880|NCT01831050|Experimental|G8: Sanofi bOPV, SII IPV|50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Serum Institute of India IPV (SII IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
3108881|NCT01831050|Experimental|G9: Sanofi bOPV, SII 2 IPV|190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Serum Institute of India IPV (SII IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
3108882|NCT01831037||Regression of fibrosis|Group conformed by patients experiencing improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
3108883|NCT01831037||No regression of fibrosis|Group conformed by patients not showing the predefined improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
3108884|NCT01831024|Experimental|Treatment Group|Dignicap System
3108885|NCT01831024|No Intervention|Control Group|Concurrent age and chemotherapy matched control
3108886|NCT01831011|Experimental|mildronate|infusion of mildronate
3108887|NCT01831011|Active Comparator|cinepazide maleate|infusion of cinepazide maleate
3108888|NCT01830998||control,MCI, Olfactory dsfunction|There are different groups:control,MCI, Olfactory dsfunction.
3108889|NCT01830998||control, MCI|control and MCI group.Glycaemic control
3108890|NCT01830998||control and MCI|treatment and without treatment
3108891|NCT01830998||MCI and Olfactory function|observation between MCI and Olfactory function groups.
3108892|NCT01830985|Experimental|Single Arm VX-509|
3108893|NCT01830972|Experimental|Crossover Participants|"Participants completing the 48-week study (UX001-CL201; NCT01517880) were enrolled into Part I of the study:~Part I: participants continued on 6 g/day SA-ER for 12 weeks~Part II: 12 g/day SA (1.5 g of SA-ER and 1.5 g of SA-IR treatment 4 times per day [QID]) for 36 months~Part III: 6 g/day or 12 g/day SA (both SA-ER and SA-IR)~Part IV: 6 g/day or 12 g/day SA (SA-ER only)"
3108894|NCT01830972|Experimental|Naïve Participants|"Treatment naïve participants with GNE myopathy were enrolled into Part II of the study:~Part II: 12 g/day SA (1.5 g of SA-ER and 1.5 g of SA-IR treatment QID) for 36 months~Part III: 6 g/day or 12 g/day SA (both SA-ER and SA-IR)~Part IV: 6 g/day or 12 g/day SA (SA-ER only)"
3108895|NCT01830959|Experimental|Roflumilast|Roflumilast
3108896|NCT01830959|Placebo Comparator|Placebo|Placebo
3108897|NCT01830946|Experimental|Whey Protein and Exercise Training|This arm involves 4 weeks of consuming a whey protein supplement late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
3108898|NCT01830946|Placebo Comparator|Carbohydrate and Exercise Training|This arm involves 4 weeks of consuming a carbohydrate placebo late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
3108899|NCT01830946|Experimental|Casein Protein and Exercise Training|This arm involves 4 weeks of consuming a casein protein supplement late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
3108900|NCT01830933|Experimental|BreastCARE Intervention|"Intervention Clinic Patients: The RA will welcome the patient upon arrival at the clinic and again explain study procedures and field any questions. The RA will have the patient sign the HIPAA authorization form and then demonstrate how to enter information and answer questions on the tablet-PC and the patient will indicate their consent electronically before beginning the assessment.~Intervention Patient Report. Once the patient completes the BreastCare Computer survey, the program will immediately generate a personal feedback report containing information about her risk factors and recommendations to reduce her risk. This report will be printed and given to the patietns before she meets with her doctor."
3108901|NCT01830933|No Intervention|BreastCARE Comparison|"Patients will be randomized into the intervention or comparison groups at the time of recruitment. Block-randomization will be used to assign patients to intervention or comparison groups.~Comparison Clinic Patients. Contact and baseline interview procedures will be the same for patients from the comparison clinics, however there will be no computer assessment at the time of their clinic visit. An RA will meet the patient 10 minutes prior to her appointment time to obtain written HIPAA authorization."
3108902|NCT01830920|Placebo Comparator|Placebo|An identical appearing placebo will be administered.
3108903|NCT01830920|Experimental|THR-184 Dose 1|THR-184 initial pre-surgery low dose followed by (3) post surgery doses at the low dose.
3108904|NCT01830920|Experimental|THR-184 Dose 2|THR-184 initial pre-surgery mid-dose followed by (3) post surgery doses at the low dose.
3108905|NCT01830920|Experimental|THR-184 Dose 3|THR-184 initial pre-surgery high dose followed by (3) post surgery doses at the low dose.
3108906|NCT01830920|Experimental|THR-184 Dose 4|THR-184 initial pre-surgery high dose followed by (3) post surgery doses ~80% of the pre-surgery dose.
3108907|NCT01830907|Active Comparator|Enteral|Enteral nutrition composed of carbohydrates and vitamins
3108908|NCT01830907|Active Comparator|Parenteral|
3108909|NCT01830894|Experimental|spontaneous ICH bleeding|An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - on the 3rd -5th day after bleeding
3108910|NCT01830894|Experimental|chronic sub dural bleeding|An initial Baseline MRI is to be done at the time of diagnosis. second MRI which serves as review -within two weeks.
3108911|NCT01830894|Experimental|acute sub-dural bleeding|An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - within two weeks.
3108912|NCT01830881|Placebo Comparator|placebo-cherry syrup and ibuprofen|5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
3108913|NCT01830881|Active Comparator|Midazolam and ibuprofen|5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
3108914|NCT01830868||Zonisamide tablets|
3108919|NCT01830842|Placebo Comparator|Nicotine, placebo|Nonsmokers will be measured following a nicotine polacrilex lozenge (2mg) on one occasion and placebo on another occasion.
3108920|NCT01830842|Other|Nicotine withdrawal or satiety|Smokers will be measured in a normal satiated condition and following 24-hours of smoking abstinence
3108921|NCT01830829|Experimental|Jaylyn|Jalyn: dutasteride 0.5 mg/day and tamsulosin 0.4 mg/day combination tablet
3108922|NCT01830829|Placebo Comparator|Placebo|Placebo
3108923|NCT01830816|Experimental|Arm 1 (Normal renal function)|"In the 15 day period that constitutes Part A of the trial, patients will receive a single oral dose of ixazomib (MLN9708) capsule on Day 1.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive ixazomib (MLN9708) on Days 1, 8, and 15 of a 28-day cycle. In Part B at the discretion of the investigator, dexamethasone 40 mg may be administered to patients with RRMM on Days 1, 8, 15 and 22 (20 mg if >75 years old) of each 28-day cycle."
3108924|NCT01830816|Experimental|Arm 2 (Severe renal impairment)|"In the 15 day period that constitutes Part A of the trial, patients will receive a single oral dose of ixazomib (MLN9708) capsule on Day 1 of a 15-day cycle.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive ixazomib (MLN9708) on Days 1, 8, and 15 of a 28-day cycle. In Part B at the discretion of the investigator, dexamethasone 40 mg may be administered to patients with RRMM on Days 1, 8, 15 and 22 (20 mg if >75 years old) of each 28-day cycle."
3108925|NCT01830803||HowRU/HowRwe|All participants will fill out the HowRwe and HowRU questionnaires. Although this questionnaire may be considered an intervention, it is not the goal of this study to investigate the questionnaires as an intervention but to investigate whether they are reliable questionnaires.
3108926|NCT01830790|Active Comparator|Healthy Controls|Healthy individuals >65 years old without ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
3108927|NCT01830790|Experimental|AMD patients|Age-related macular degeneration (AMD) patients >65 years old without other ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
3108928|NCT01830777|Experimental|Experimental Arm|Brentuximab Vedotin + MEC
3108929|NCT01830764|Other|Red light dose (PDT) 75 J/cm2|Subjects in Cohort 1 will receive active and vehicle solution followed by a red light dose of 75 J/cm2 at 25 mW/cm2
3108930|NCT01830764|Other|Red Light (PDT) 150 J/cm2|Subjects in Cohort 2 will receive active and vehicle solution followed by a red light dose of 150 J/cm2 at 40 mW/cm2
3108931|NCT01830751|Experimental|Limit trunk flexion upon rising|Immediately upon rising particpants perform the Restrained Sitting Treatment intervention for one hour.
3108932|NCT01830751|Sham Comparator|Limit trunk flexion before going to bed|Immediately prior to going to bed, particpants perform the Restrained Sitting Treatment intervention for one hour.
3108933|NCT01830738|Experimental|Peri-umbilical single-port|"Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.~Intervention: Single-port, peri-umbilical hysterectomy"
3108934|NCT01830738|Active Comparator|Multi-port|"Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.~Intervention: Multi-port hysterectomy"
3108935|NCT01830725||Gout/Hyperuricemia|Subjects with a diagnosis of hyperuricemia (defined as a uric acid of > 7.2 mg/dl) and/or gout.
3108936|NCT01830725||Control|Approximate age and gender matched controls without hyperuricemia or gout
3108937|NCT01830712||Chart review|
3108938|NCT01830699|Active Comparator|Rilonacept|160 mg of rilonacept will be injected in the subacromial bursa of participants in this arm.
3108939|NCT01830699|Placebo Comparator|Corticosteroid|80 mg (2 cc of 40 mg/mL) Kenalog intra-bursal once
3108940|NCT01830686|Experimental|Sugarcane bagasse|10 subjects will consume food (brownies and cookies) made with 13 g of sugarcane bagasse everyday for 4 weeks
3108941|NCT01830686|Active Comparator|Non-caloric, non-fermentable fiber|10 subjects will consume food (brownies and cookies) made with 13 g of non caloric, non-fermentable fiber everyday for 4 weeks
3108942|NCT01830686|Placebo Comparator|Minimal fiber|10 subjects will consume food (brownies and cookies) made with 4 g of dietary fiber everyday for 4 weeks
3108943|NCT01830673||under SIT|patients completed second or third year of SIT. We include the patients directly after last SIT vaccination.
3108944|NCT01830673||after SIT|Patients completed three years of SIT for at least three years. We included them as a follow up.
3108945|NCT01830673||no SIT|These patients were determined randomly. They have a clinically relevant grass pollen allergy. They never had a SIT.
3108946|NCT01830660|Experimental|hetrombopag|hetrombopag either at 2.5,5,10,20,30 or 40mg, p.o. once daily
3108947|NCT01830660|Placebo Comparator|placebo|Subjects will be randomized (5:1 eltrombopag : placebo) to receive either eltrombopag or placebo.
3108948|NCT01830647||Cohort|
3108949|NCT01830634|Experimental|Theraband with strengthening and stretching exercise|
3108950|NCT01830621|Active Comparator|BBI608|BBI608 480 mg two times daily (960 mg total daily dose)+ Best Supportive Care
3108951|NCT01830621|Placebo Comparator|Placebo|Placebo two times daily + Best Supportive Care
3108952|NCT01830608||300 patients with AMD|
3108953|NCT01830595|Active Comparator|Recombinant Lactoferrin|Recombinant lactoferrin will be administered by mouth twice daily
3108954|NCT01830595|Placebo Comparator|Placebo|Matched placebo will be administered by mouth twice daily
3108955|NCT01830582|Experimental|1 A|The patients will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 24 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the second week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
3108956|NCT01830582|Experimental|1 B|The patient will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 48 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the third week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
3108990|NCT01830335|Placebo Comparator|Placebo|flour capsule
3109268|NCT01828411||Cardiopulmonary bypass group|Patients requiring normothermic (or mild hypothermic) cardiopulmonary bypass.
3108957|NCT01830582|Experimental|1 C|The patient will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 72 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the fourth week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
3108958|NCT01830582|Experimental|2|The last patient patients that will undergo a standard pre-chemoradiation MRI scan, followed by a repeat research scan either 24, 48 or 72 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the second, third or fourth week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
3108959|NCT01830569|Experimental|EBMeDS group|The regular Evidence Linker and the EBMeDS system will be available in this group.
3108960|NCT01830569|Other|Control group|The regular Evidence Linker will be available in this group.
3108961|NCT01830556|Active Comparator|Arm A: cetuximab with 5FU and carboplatin or cisplatin|Arm A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h maintenance treatment thereafter with cetuximab 500 mg/m2 every second week until PD or toxicity
3108962|NCT01830556|Experimental|Arm B: cetuximab paclitaxel and carboplatin|Arm B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter maintenance treatment day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
3108963|NCT01830543|Experimental|rivaroxaban 2.5 mg twice daily|rivaroxaban 2.5 mg tablet twice daily plus low-dose aspirin (ASA) 75 to 100 mg once daily and clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by rivaroxaban 15 mg tablet (or 10 mg for subjects with moderate renal impairment) once daily plus low-dose ASA for 12 months
3108964|NCT01830543|Experimental|vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) once daily (target International Normalized Ratio (INR) 2.0 to 3.0) plus low-dose ASA, 75 to 100 mg per day, and clopidogrel 75 mg once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by dose-adjusted VKA once daily (target INR 2.0 to 3.0 or 2.0 to 2.5 at the investigator discretion) plus low-dose ASA for 12 months
3108965|NCT01830543|Experimental|rivaroxaban 15 mg once daily|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) for 12 months
3108966|NCT01830530|Experimental|Telmisartan/nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
3108967|NCT01830530|Placebo Comparator|Placebo|Two tablets containing placebo daily in the morning
3108968|NCT01830517|Experimental|amlodipine camsylate|amlodipine camsylate 5mg
3108969|NCT01830517|Active Comparator|losartan potassium|losartan potassium 50mg
3108970|NCT01830504|Experimental|NVP-BKM120 (BKM120) PI3K inhibitor|
3108971|NCT01830491|Experimental|Clopidogrel napadisilate|aspirin 100mg
3108972|NCT01830491|Active Comparator|clopidogrel bisulfate|aspirin 100mg
3108973|NCT01830478|Experimental|Lenalidomide and Rituximab|Lenalidomide 20 mg once daily on days 1-21 of 28 days cycle for up to 6 courses and Rituximab 375 mg/m2 at day 14 of every course.
3108974|NCT01830465|Experimental|Bortezomib + Rituximab|Single arm. Patients will be treated with Bortezomib, 1,3 mg/m2 intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of 21 day cycle for 6 cycles and Rituximab 375 mg/m2 intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
3108975|NCT01830452|Experimental|Parietex Progrip mesh|Ventral hernioplasty using a (self gripping / self adhering / self fixating) Progrip mesh not needing fixation devices
3108976|NCT01830452|Active Comparator|Parietex Mesh|Ventral hernioplasty using a polyester mesh fixed with non absorbable sutures as described by Lichtenstein/Amid
3108977|NCT01830439|Experimental|Fed PA-824 200mg|200 mg PA-824 (4 x 50 mg tablets) in Phase A was administered 30 minutes after the start of a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
3108978|NCT01830439|Experimental|Fasted PA-824 200 mg|200 mg PA-824 (4 x 50 mg tablets) in Phase A was administered 30 minutes after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
3108979|NCT01830439|Experimental|Fed PA-824 50mg|50 mg PA-824 (1 x 50 mg tablets) in Phase B was administered 30 minutes after the start of a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
3108980|NCT01830439|Experimental|Fasted PA-824 50mg|50 mg PA-824 (1 x 50 mg tablets) in Phase B was administered after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
3108981|NCT01830413||Stenting|cerebral artery stenting for systematic Intracranial artery stenosis
3108982|NCT01830400||Eslicarbazepine Acetate tablets|
3108983|NCT01830387||Polymetric clips|The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump. All subjects enrolled in the study will have their medical chart reviewed from consent to 30 days post operatively.
3108984|NCT01830387||Endoscopic Staplers|The study team will retrospectively identify patients who have undergone laparoscopic appendectomy during a one year time span by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
3108985|NCT01830374||Women with bulimia nervosa|This is not a treatment study. All participants will go through the same steps.
3108986|NCT01830361|Experimental|midostaurin (PKC412), capsules|midostaurin 50 mg (two 25 mg capsules) is given in combination with the second of two induction cycles and in combination with three cycles of high-dose cytarabine (HiDAC) consolidation chemotherapies and maintenance treatment in patients with c-kit or FLT3-ITD positive t(8;21) AML in an open-label one-arm design. The first cycle of induction is not part of the study.
3108987|NCT01830348|Active Comparator|DSC127|DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
3108988|NCT01830348|Placebo Comparator|Vehicle gel|Vehicle gel comprising HEC with parabens
3108989|NCT01830335|Experimental|Drug|Indomethacin 1.2 mg kg 1 dose
3108991|NCT01830322|Experimental|CPI-613 Alone|This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
3108992|NCT01830322|Active Comparator|Any non-gemcitabine chemotherapies or best supportive care|This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. This arm includes any best-practice standard-of-care chemotherapies deemed appropriate by the clinical investigators, including the option for supportive care, following good clinical practice.
3108993|NCT01830322|Experimental|Gemcitabine + CPI-613 in combination|This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. When gemcitabine and CPI-613 are administered in combination, gemcitabine will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. CPI-613 will be infused twice a week, administered on Days 1 and 4 for 3 consecutive weeks, followed by a week-of-rest, the same as gemcitabine. The dose of CPI-613 will be 710 mg/m2 infused IV over 2-hours (this is approximate maximum tolerated dosing [MTD] found from Phase I studies in combination with gemcitabine). To note, the dose of CPI-613 may be increased from 710 mg/m2 if ongoing Phase I trial data shows that the MTD of CPI-613 is higher than 710 mg/m2 CPI-613, diluted with D5W.
3108994|NCT01830322|Experimental|Gemcitabine alone or in combination with therapeutic agent(s)|This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. Gemcitabine, or Gemcitabine-based, chemotherapy will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. This arm includes any best-practice standard-of-care Gemcitabine-based chemotherapies deemed appropriate by the clinical investigators following good clinical practice.
3108995|NCT01830309|Experimental|Sequence 1|Drug: CJ-12420 200mg Period1: CJ-12420 under fed condition Period2: CJ-12420 under fasting condition
3108996|NCT01830309|Experimental|Sequence 2|Drug: CJ-12420 200mg Period1: CJ-12420 under fasting condition Period2: CJ-12420 under fed condition
3108997|NCT01830296|Active Comparator|Remifentanil+Morphine|Morphine(M) Remifentanil+Morphine(MR)
3108998|NCT01830296|Active Comparator|IV morphine PCA|IV remifentanil+morphine PCA
3108999|NCT01830283|Active Comparator|1 dose varicella vaccine|The providers would get the 2nd dose since they had one dose varicella vaccine
3109000|NCT01830283|Experimental|2 dose varicella vaccine|The provider never get the varicella vaccine
3109001|NCT01830270|Experimental|PET regimen|
3109002|NCT01830257|Experimental|sending message|The investigators would send the tip to the children's guardian
3109003|NCT01830244|Experimental|Nab-Paclitaxel 125mg/m2|"Epirubicin 90 mg/m2 and cyclophosphamide 600mg/m2 IV every 3 weeks for 4 cycles.~Nab paclitaxel 125mg/m2 IV days 1, 8 and 15 for 12 weeks In case of HER2 positive tumour patients will receive trastuzumab in combination with nab-Paclitaxel"
3109004|NCT01830231|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m2 q3w. Cabazitaxel will be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion
3109005|NCT01830231|Active Comparator|Vinflunine|"• Vinflunine will be given intravenously once every 21 days, starting at a dose of:~320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation~280 mg/m2 in patients aged >75 - ≤80 years, and/or with PS 1 and/or prior pelvic radiation,~250 mg/m2 in patients aged >80 years."
3109006|NCT01830218||Obstetric anesthesia and analgesia|Women in labor undergoing anesthesia care
3109007|NCT01830205|Experimental|Group A (Normal renal function): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
3109008|NCT01830205|Experimental|Group B (End Stage Renal Disease): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
3109009|NCT01830205|Experimental|Group C (Moderate renal impairment): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
3109010|NCT01830205|Experimental|Group D (Severe renal impairment): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
3109011|NCT01830192|Other|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
3109012|NCT01830192|Other|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
3109013|NCT01830166|Experimental|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
3109014|NCT01830153|Experimental|RAD001|RAD001 was given as 10 mg orally once daily, and one cycle was defined as 28 days.
3109015|NCT01830140|Experimental|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
3109016|NCT01830140|Active Comparator|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
3109017|NCT01830127|Experimental|cohort A CPA|Cohort A CPA BI 207127/QD Faldaprevir Ribavirin
3109018|NCT01830127|Experimental|cohort A CPB|Cohort B CPB BI 207127/QD Faldaprevir Ribavirin
3109019|NCT01830114|Experimental|Web app evaluation group|
3109020|NCT01830101|Experimental|TMZ plus concurrent re-irradiation|TMZ plus concurrent re-irradiation
3109021|NCT01830101|Experimental|TMZ alone|TMZ alone
3109022|NCT01830088|Experimental|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
3109023|NCT01830088|Active Comparator|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
3109024|NCT01830075|No Intervention|Control group|The control group receives care as usual.
3109025|NCT01830075|Experimental|Consultations|An intervention of two consultations with a spiritual counselor supported by an e-application.
3109026|NCT01830062|Experimental|CACS and NIRS|All patients will undergo NIRS to at least 2 major epicardial vessels as a research related intervention. Patients will be considered to be enrolled in the trial upon completion NIRS evaluation. Patients who had a clinically indicated CT with CACS evaluation within 3 months prior to the cardiac catheterization with NIRS evaluation will not have any other research related interventions. Patients who have not had a clinically indicated CT with CACS within 3 months prior to the cardiac catheterization with NIRS evaluation will have the CACS after NIRS imaging prior to discharge from the hospital.
3109027|NCT01830049||Group I|Older males with ED
3109028|NCT01830049||Group II|Older males with normal erectile function
3109029|NCT01830049||Gourp III|Young males with normal rectile function
3109030|NCT01830036||Quality of Life (SF12), 2-channel Polygraphy|cardiological treatment
3109031|NCT01830023||cardiac ultrasound examination|
3109032|NCT01830010|Experimental|Study Part 1: KRP203|All patients to receive KRP203 for 111days
3109033|NCT01830010|Experimental|Study Part 2: lower KRP203 dose|in this treatment arm patients will receive the lower KRP203 dose for 111 days on top of the standard treatment with cyclosporine A and methotrexte for GVHD prophylaxis
3109034|NCT01830010|Experimental|Study Part 2: higher KRP203 dose|in this treatment arm patients will recieve the higher KRP203 dose for 111 days on top of standard treatment with tacrolimus and methotrexate for GVHD prophylaxis
3109035|NCT01829997|Experimental|nanOss Bioactive 3D BVF|Bilateral, instrumented posterolateral fusion surgery where nanOss Bioactive 3D will be hydrated with autologous BMA and placed bilaterally on a bed of local autograft bone spanning the transverse processes of the treated segment. If an interbody fusion is performed, only a PLIF or TLIF with PEEK IBF devices may be performed.
3109036|NCT01829984||control injection teaching|The first 25 subjects recruited into the study will be that control group. Subjects accrued during the control phase will receive the control injection teaching, which at MSKCC is verbal instruction. To minimize practice variation, the teaching will be provided by the office-practice nurse guided by a verbal script. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
3109037|NCT01829984||intervention group|The subsequent 25 subjects enrolled into the study will be in the intervention group. Subjects accrued during the intervention phase will receive the verbal and written injection teaching, plus demonstration and return demonstration using an injection model. It is anticipated that the intervention teaching will take no longer then 5 additional minutes, however time will be evaluated as a secondary objective as well in both groups. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
3109038|NCT01829971|Experimental|MRX34|Single agent MRX34
3109039|NCT01829958|Experimental|Pre-Phase Arm|They will be treated with a single dose of rituximab 375mg/m2, once, by intravenous infusion 3-10 days prior to initiation of planned R-CHOP-like chemoimmunotherapy, and prednisone 50mg to 100 mg (preferred dose is 100mg) PO daily for 5-7 days (preferred duration is 7 days) of the 14 days prior to initiation of planned R-CHOP, R-EPOCH or R-CEPP chemoimmunotherapy. Pre-phase therapy may be given in either the inpatient or outpatient setting. After completion of a single course of pre-phase rituximab and prednisone as described above, further treatment will be according to the choice of the attending physician, in accordance with appropriate medical practice. It is expected, based on the inclusion criteria, that patients enrolled on the pre-phase arm will most often receive initial therapy consisting of R-CHOP, R-EPOCH or RCEPP chemoimmunotherapy for ≥ 2 cycles, but alternative therapies as deemed appropriate by the treating physician will not be considered violations of this protocol.
3109040|NCT01829958|Experimental|Geriatric Assessment (GA) only arm|Patients enrolled on the GA only arm of the study will be treated according to the choice of the attending physician. This arm of the study is non-therapeutic.
3109041|NCT01829932|Active Comparator|High Factor Diet|Patients will be on a factor altered diet to see effects on their lactulose breath test and symptoms.
3109042|NCT01829932|Active Comparator|Low Factor Diet|Patients will be on a factor altered diet to assess its effects on symptoms and lactulose breath test.
3109043|NCT01829919|Experimental|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate) Capsules taken orally with 240 mL of water for 20 days.
3109044|NCT01829906|Experimental|Outpatient group|Multidisciplinary outpatient programme including both individual and group-based therapy. During the first visit, every patient will have an individual consultation with the dietician, physiotherapist and psychiatric nurse. After this, the patients will be followed up in groups every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
3109045|NCT01829906|Experimental|Inpatient group|"Inpatient lifestyle programme offered at a rehabilitation center consisting of a continuous care weight loss program, with three intermittent stays (each with three-week duration) over a one year period."
3109046|NCT01829893|Active Comparator|Reference arm|Treated with Reference (in combination of 0.2mg tamsulosin and 5mg finasteride) Intervetion: In combination of 0.2mg finasteride and 5mg tamsulosin simultaneously
3109047|NCT01829893|Experimental|Test arm|Treated with Test formulation (single pill combination of 0.2mg finasteride and 5mg tamsulosin) Intervention : GL2701 capsule
3109048|NCT01829880||Chronic heart failure patients|Patients with chronic heart failure who attend to internal medicine outpatient clinic.
3109049|NCT01829867|Experimental|sNN0031|
3109050|NCT01829841|Experimental|Famitinib|Famitinib 25 mg qd p.o., 6 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
3109051|NCT01829841|Active Comparator|Sunitinib|Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
3109052|NCT01829828||Inpatients with cancer pain|Inpatients admitted for cancer pain management
3109053|NCT01829815|Experimental|"Parents Make the Difference"|Caregivers are enrolled in the 10-session Parents Make the Difference intervention.
3109303|NCT01828177|Placebo Comparator|Vehicle|Foam, twice daily for up to 12 weeks
3109054|NCT01829815|Other|Waitlist Control|Caregivers assigned to the control group received the 10-session Parents Make the Difference intervention after the study was completed.
3109055|NCT01829802|Experimental|RAL+ATA/r|Raltegravir 400 mg BID plus Ritonavir Boosted Atazanavir 300/100 mg QD
3109056|NCT01829802|Active Comparator|TDF/FTC (or 3TC) +ATA/r|TDF/FTC (or 3TC)- Fixed dose combination of Tenofovir 300 mg plus Emtricitabine 200 mg (or Lamivudine 300 mg) QD plus Ritonavir Boosted Atazanavir 300/100 mg QD
3109057|NCT01829789|Experimental|G-CRT|Group Community Reinforcement Training for parents
3109058|NCT01829789|Active Comparator|I-CRT|Individual Community Reinforcement Training for parents
3109059|NCT01829776|Experimental|education|Educational intervention
3109060|NCT01829763|Experimental|botox|
3109061|NCT01829750|Sham Comparator|Control|"(Stage 1) No active intervention after standard surgical treatment~(Stage 2) Rescuing transplantation by cardiac progenitor cell infusion is applicable in patients, along with their written consent, 4 months after palliations who were assigned as control group in stage 1."
3109062|NCT01829750|Active Comparator|Cardiac progenitor cell infusion|(Stage 1) single dose, intracoronary infusion of 0.3 million cells/kg cardiac progenitor cells
3109063|NCT01829711|Experimental|Moxetumomab pasudotox 40 µg/kg|Patients will receive Moxetumomab Pasudotox IV over 30 minutes on days 1, 3, 5 of each 28 day cycle for a maximum of 6 cycles or until disease progression, unacceptable toxivity, initiation of alternate therapy or documented CR.
3109064|NCT01829698|Experimental|tauroursodeoxycholic|tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
3109065|NCT01829698|Active Comparator|ursodeoxycholic|control arm: ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
3109066|NCT01829685|Active Comparator|Group I|oral entecavir 1mg daily and adefovir 10mg daily for 144 weeks
3109067|NCT01829685|Active Comparator|Group II|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
3109068|NCT01829672|Experimental|Other: pulmonary vascular disease|Dual-energy computed tomography investigation
3109069|NCT01829659||AA Ticagrelor|African Americans who present with acute coronary syndrome (ACS) to the cath lab, and receive ticagrelor during their hospital stay.
3109070|NCT01829633||Rotator cuff tears|Patients who were diagnosed with a symptomatic full-thickness tear of the rotator cuff. Tear examination by sonography and MRI showed a repairable tear. All patients were initially treated conservatively by physiotherapy.
3109071|NCT01829620|Active Comparator|Treatment as Usual (TAU)|The Treatment as Usual (TAU) control group will reflect current clinical practices for treating suicidal Soldiers and Marines.
3109072|NCT01829620|Experimental|Continuing Contacts via Text (CCVT)+TAU|The intervention group will receive Continuing Contacts via Text (CCVT) in addition to Treatment as Usual (TAU).
3109073|NCT01829607|Active Comparator|Functional electrical stimulation|Functional electrical stimulation of lower limbs
3109074|NCT01829607|Placebo Comparator|Placebo|
3109075|NCT01829594|Experimental|Case Management|
3109076|NCT01829581||oral anticoagulation associated intracerebral hemorrhage|
3109077|NCT01829568|Experimental|Treatment (lenalidomide, ibrutinib, and rituximab)|Patients receive lenalidomide PO QD on days 1-21 and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and once weekly at weeks 13, 21, 29, and 37.
3109078|NCT01829555|Experimental|contingency management|The intervention will provide escalating financial reinforcement for self-monitored blood glucose testing.
3109079|NCT01829542|Active Comparator|319 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
3109080|NCT01829542|Active Comparator|639 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
3109081|NCT01829542|Active Comparator|766 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
3109082|NCT01829542|Active Comparator|1466 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
3109083|NCT01829542|Active Comparator|1791 mg total blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
3109084|NCT01829542|Placebo Comparator|O mg blueberry polyphenols|Macro- and micronutrient matched control drink
3109085|NCT01829529|Experimental|Amoxicillin|All subjects receive one dose of 2 g Amoxicillin
3109086|NCT01829516|Experimental|Oxytocin|50 moderate to heavy social alcohol users will receive a single dose 40 IU of intranasal oxytocin.
3109087|NCT01829516|Placebo Comparator|Placebo|"50 moderate to heavy social alcohol users will receive a single dose 40 IU of intranasal placebo.~NOTE: This is a cross-over design and subjects will participate in both arms."
3109088|NCT01829503|Experimental|decitabine and cytarabine|
3109089|NCT01829490|Experimental|Starter Group|The first six volunteers will receive one dose of 5x10^9vp of ChAdOx1 85A intramuscular injection.
3109090|NCT01829490|Experimental|Group A|12 subjects will receive one dose of 2.5x10^10vp of ChAdOx1 85A intramuscular injection.
3109091|NCT01829490|Experimental|Group B|12 subjects will receive one dose of 2.5x10^10vp of ChAdOx1 85A by intramuscular injection, followed by a boost dose of 1x10^8pfu of MVA85A by intramuscular injection 56 days later.
3109092|NCT01829490|Experimental|Group C|12 subjects will receive two doses of 2.5x10^10vp of ChAdOx1 85A by intramuscular injection at day 0 and day 28, followed by a boost dose of 1x10^8pfu of MVA85A by intramuscular injection at day 119.
3109093|NCT01829477|Experimental|TAK-875 50 mg|TAK-875 50 mg tablet, orally, once daily and glimepiride 6 mg (or Maximum Tolerated Dose), tablets, orally, once daily for up to 24 weeks.
3109094|NCT01829477|Placebo Comparator|Placebo|TAK-875 placebo-matching tablet, orally, once daily and glimepiride 6 mg (or Maximum Tolerated Dose), tablets, orally, once daily for up to 24 weeks.
3109095|NCT01829464|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up 24 weeks.
3109096|NCT01829464|Experimental|TAK-875 25 mg|TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up to 24 weeks
3109097|NCT01829464|Experimental|TAK-875 50 mg|TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up to 24 weeks
3109098|NCT01829451|Experimental|Hyaluronic acid gel|Hyaluronic acid gel is placed into the uterus after endometrial ablation
3109099|NCT01829451|Placebo Comparator|No hyaluronic acid gel|An empty Pipelle device is taken into the uterus after endometrial ablation as an placebo procedure
3109100|NCT01829438|No Intervention|Without music|6MWT without music
3109101|NCT01829438|Experimental|With fast music|6MWT with a fast music
3109102|NCT01829438|Experimental|With slow music|6MWT with a slow music
3109103|NCT01829438|Experimental|With preferred music|6MWT with the preferred music of the child
3109104|NCT01829425|Active Comparator|Anticholinergic medications|Either of two standard, long acting anti-cholinergic medications (Long acting Tolterodine or Extended Release Oxybutynin)will be given. Subjects receive 8 weeks of medication counseling in conjunction with the medications. Medications will be continued for 1 year.
3109105|NCT01829425|Active Comparator|Hypnotherapy|Subjects will receive approximately weekly hypnotherapy sessions over 8 weeks and will receive/download digital recordings for home practice. Subjects will be encouraged to practice self-hypnosis +/or listen to their recordings for 1 year.
3109106|NCT01829412|Experimental|DW- MRI|"The patients will perform the DW-MRI, WB-MRI and MRI of the spine in the same session with the following timing:~Patients at first-line treatment for MM:~Within 15 days before the start of the treatment~Within one month after the end of the first-line treatment~Six (6) months after the end of the first-line treatment~Patients at relapse after disease response (CR or PR) lasting at least 6 months~At relapse~Within 15 days after the end of the treatment of relapse~Six (6) months after the end of the treatment of relapse Each DW-MRI, WB-MRI, MRI of the spine and skeletal X-Ray will be independently read and interpreted by two radiologists with proven experience in MM. ."
3109107|NCT01829399|Experimental|Injected with Bupivacaine|A subcutaneous axillary ring of 10 to 15 mL of 0.25% Bupivacaine with epinephrine 1:200,000 will be injected in the arm 15 minutes prior to tourniquet inflation.
3109108|NCT01829399|Sham Comparator|Injected with saline|A subcutaneous axillary ring of 10 to 15 mL of normal saline will be injected in the arm 15 minutes prior to tourniquet inflation.
3109109|NCT01829386||Non heme iron levels on MRI|"Intervention: MRI scans To develop a reliable MR based measurement of Non-heme iron in brain tissue of patients with hemorrhagic stroke : on day 3, 14 and 30 after stroke to assess the non heme iron levels on MRI.~To evaluate the role of iron chelators following a hemorrhagic stroke/parenchymal hemorrhage."
3109110|NCT01829373|Experimental|Vaccine plus oral beta glucan|Vaccine plus oral beta glucan
3109111|NCT01829360|Experimental|Treatment|In Study 1, words will be randomized to the treatment or comparison arm but all children will receive treatment on half the words and no treatment on half the words. Children will hear new words during storybook reading. Children will hear the word in the text of the book but also will be told additional information about the word including a synonym, a definition, and a supportive context.
3109112|NCT01829360|Experimental|Comparison1|In Study 2, children will be randomized to two treatment versions. In Study 2, children will receive a treatment that is balanced between the number of times a word is read in the book and the number of times that the book is read. Children will also be randomized a second version that is more heavily weighted towards word repetitions .
3109113|NCT01829360|Experimental|Comparison2|In Study 2, children will be randomized to two treatment versions. In Study 2, children will receive a treatment that is balanced between the number of times a word is read in the book and the number of times that the book is read. Children will also be randomized a second version that is more heavily weighted to number of times the book is read.
3109114|NCT01829347|Experimental|ELAD (plus Standard of Care)|ELAD is a human cell-based bio-artificial liver support system developed to improve survival of patients with acute liver failure and to provide liver support continuously to a subject with compromised liver function. Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
3109115|NCT01829347|Other|Standard of Care (Control)|Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD.EASL Guidelines.
3109116|NCT01829334|Active Comparator|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
3109117|NCT01829334|Experimental|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
3109118|NCT01829334|Experimental|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
3109119|NCT01829334|Experimental|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
3109120|NCT01829321|Experimental|GLPG0974|1 capsule of 200 mg GLPG0974 twice daily
3109121|NCT01829321|Placebo Comparator|Placebo|1 capsule placebo twice daily
3109122|NCT01829308|Experimental|Specialist|The brief interventions are delivered by behavioral health counselors.
3109123|NCT01829308|Active Comparator|Generalist|The brief interventions are delivered by the primary care provider.
3109124|NCT01829295|Experimental|Methotrexate|oral methotrexate
3109125|NCT01829295|Experimental|Mycophenolate Mofetil|oral mycophenolate mofetil
3109126|NCT01829282|Experimental|Risk Reduction|"The Risk Reduction group will receive the Eban II Intervention upon enrollment. This group will do the following:~Provide HIV and STI test results~First Interview~Attend 8 sessions - 1 session per week~Second interview occurs immediately following the 8th session with HIV and STI tests~Third interview occurs 3 months after the 8th session with HIV and STI tests"
3109127|NCT01829282|Active Comparator|Waitlist|"The Waitlist group will receive the same intervention after waiting for the Risk Reduction group to complete the entire intervention.~Provide HIV and STI test results~First Interview~No sessions for 8 weeks~Second interview and proof of HIV and STI status occurs after the 8 weeks from when you were enrolled~Third interview occurs 3 months after the 8th session with HIV and STI tests The Waitlist Group will then be invited to participate in the Risk Reduction group activities.~Attend 8 sessions - 1 session per week~Fourth interview occurs immediately after the 8th session with HIV and STI tests~Fifth interview occurs 3 months after the 8th session with HIV and STI tests"
3109128|NCT01829269||Patients with a defibrillator|The study population is that of patients with a defibrillator to have a change of probe.
3109269|NCT01828411||Hypothermic Cardiopulmonary Bypass Group|Patients requiring (deep) hypothermic cardiopulmonary bypass.
3109129|NCT01829256|Experimental|Pharmacist Telehealth Intervention|Will receive a tailored multi-factorial clinical pharmacist-administered telehealth intervention, which includes medication management and behavioral-educational components. The intervention will occur monthly over 3 years.
3109130|NCT01829256|No Intervention|Education Control|Will receive educational material about management of kidney disease
3109131|NCT01829243|Experimental|Milnacipran|Eligible subjects will receive milnacipran (12.5 mg-200 mg/day) in the forces titration schedule in flexible doses to the maximum tolerated dose starting with 12.5 mg qd for 1 day, 12.5 mg bid for 2 days, 25 mg bid for 4 days, 50 mg bid for 7 days and 100 mg bid thereafter. Patients who cannot tolerate higher doses will have a step-wise reduction in doses (e.g. 200 mg/day dose will be reduced to 100 mg/day; 100 mg/day will be reduced to 50 mg/day). Drug will be discontinued at the end of the study.
3109132|NCT01829243|Placebo Comparator|Placebo|Eligible subjects will receive placebo (12.5 mg-200 mg/day) in the forces titration schedule in flexible doses to the maximum tolerated dose starting with 12.5 mg qd for 1 day, 12.5 mg bid for 2 days, 25 mg bid for 4 days, 50 mg bid for 7 days and 100 mg bid thereafter. Patients who cannot tolerate higher doses will have a step-wise reduction in doses (e.g. 200 mg/day dose will be reduced to 100 mg/day; 100 mg/day will be reduced to 50 mg/day). Drug will be discontinued at the end of the study.
3109133|NCT01829230|Experimental|Test lens C|Test lens C from previous study
3109134|NCT01829230|Active Comparator|Test lens A|Test lens A from previous study
3109135|NCT01829217|Experimental|Sunitinib|42 day cycle, taken orally every day for the first 28 days followed by 14 days off
3109136|NCT01829204||Non pregnant asymptomatic|Asymptomatic, non-pregnant, healthy women ages 21 to 75 years with no previous history of any chronic or recurrent vulvovaginal condition who attend our clinical offices for their annual well-woman physical examination
3109137|NCT01829204||Non pregnant symptomatic|Non-pregnant women ages 12 to 75 years being evaluated for any gynecological vulvovaginal condition.
3109138|NCT01829204||Pregnant asymptomatic|Pregnant women ages 12 to 75 years who are both asymptomatic and healthy
3109139|NCT01829204||Pregnant symptomatic|Pregnant women ages 12 to 75 who have any gynecological vulvovaginal condition
3109140|NCT01829191|Experimental|Test Lens A|Test lenses will be worn in a daily wear modality
3109141|NCT01829191|Experimental|Test Lens C|Test lenses will be worn in a daily wear modality
3109142|NCT01829178|Placebo Comparator|Control arm|Placebo 420 mg daily in three divided doses for 65 days as control along with [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2]
3109143|NCT01829178|Active Comparator|Exprimental: Silymarin and chemotherapy|silymarin 420 mg daily in three divided doses for 65 days along with standard chemotherapy [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2 control
3109144|NCT01829165|Experimental|rTMS Treatment|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered using neuro-navigation based on participants' own fMRI images. Daily treatment regiments will last 36.5 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
3109145|NCT01829165|Sham Comparator|Sham Treatment|"rTMS will be delivered for 20 sessions over 4 weeks. Placebo 10Hz rTMS will be delivered through sham stimulation electrodes. The rTMS coil will be positioned using neuro-navigation based on participants' own fMRI images, mimicking active rTMS treatment. Daily treatment regiments will last 36.5minutes and sham rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sham sessions for adverse events and/or side effects.~Upon completing the sham 20 sessions participants are unblinded and offered 20 further treatments of guaranteed open-label treatment. The open-label treatment would follow the active rTMS treatment protocol."
3109146|NCT01829152|No Intervention|Control|Subjects in the Control Group will receive Heart Failure care as routinely delivered by the SMH HF clinicians according to their standards of care.
3109147|NCT01829152|Experimental|CHM Intervention Group|The Intervention Group subjects will receive Converged Health Management (CHM) in addition to continuing to receive care as routinely delivered by the SMH HF clinicians.
3109148|NCT01829139||Wait-and-see group|After endoscopic clearance of their bile duct stones, this group of patients will be follow up without additional managements
3109149|NCT01829139||Choleretics group|After endoscopic clearance of their bile duct stones, this group of patients receives choleretic agents during 3 months
3109150|NCT01829126||CCB|Patients receiving calcium channel blockers (CCB)
3109151|NCT01829126||ACEi|Patients receiving angiotensin converting enzyme inhibitors (ACEi)
3109152|NCT01829126||CCB and ACEi|Patients receiving calcium channel blockers (CCB) and angiotensin converting enzyme inhibitors (ACEi)
3109153|NCT01829126||No treatment|Patients not receiving calcium channel blockers (CCB) and/or angiotensin converting enzyme inhibitors (ACEi)
3109154|NCT01829113|Experimental|OGX-427|Three loading doses of OGX-427 at 600mg intravenously (IV) will be administered over 9 days. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of OGX-427 administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle.
3109155|NCT01829113|Placebo Comparator|Placebo|Three loading doses of placebo will be administered intravenously (IV) over 9 days. Following the loading dose period, placebo will be administered IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of placebo administered IV weekly Days 1, 8 and 15 of each 21 day cycle.
3109156|NCT01829100|Experimental|Group Behavioral Activation Therapy|Group Behavioral Activation Therapy (GBAT)
3109157|NCT01829100|No Intervention|waitlist|15-week waitlist
3109158|NCT01829087|Experimental|Botox injection|
3109159|NCT01829087|Placebo Comparator|Control|
3109160|NCT01829061||No Treatment|
3109161|NCT01829048|Experimental|PF-02545920|
3109162|NCT01829048|Placebo Comparator|Placebo|
3109163|NCT01829035|No Intervention|Arm S|sorafenib 400mg bid daily po until progression
3109164|NCT01829035|Experimental|Arm C|after the first Conventional Transarterial Chemoembolization is completed, sorafenib po and cTACE on demand until progression
3109165|NCT01829022||E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
3109166|NCT01829009|No Intervention|General Recommendations Group|General information about sarcopenia will be provided to the participants, as well as general recommendations of healthy habits. We will contact the participants weekly by phone to answer questions about sarcopenia, and remind them of their next appointment and about adverse events occured during this period of time. The frequent contact with the participants has also the purpose to prevent losses or rejections for future evaluations
3109167|NCT01829009|Experimental|Resistance Exercise Group|"An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.~Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24"
3109168|NCT01828996|Active Comparator|Shock wave therapy|This group of patient will be treated with the shock wave head in the first 4 sessions then crossover to have the stand-off placebo for another 4 sessions.
3109169|NCT01828996|Placebo Comparator|Placebo|This group of patient will be treated with the stand-off placebo for the first 4 sessions then crossover to have the shock wave head in the other 4 sessions .
3109170|NCT01828983|Experimental|Telephone support groups|Telephone support groups, each with participants and a trained group leader. Each hour-long telephone group will meet bi-monthly for six months for a total of 12 meetings. Groups are structured with education, skills building, and support. Participants will receive and use a Spouse Workbook with information and activities.
3109171|NCT01828983|Active Comparator|Education webinars|Education Webinar session topics are the same that are covered in the intervention arm without telephone interaction/support and skills building components. Each session is 30-minutes. Each participant receives a Spouse Workbook with information and activities.
3109172|NCT01828970|Experimental|Basal-bolus specific insulin regimen|Basal-bolus detemir-aspart insulin regimen in hemodialyzed diabetic patients
3109173|NCT01828957|Experimental|Pneumostem®|A single intratracheal administration of Pneumostem® (1.0 x 10^7 cells/kg)
3109174|NCT01828957|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
3109175|NCT01828944|Active Comparator|Extra virgin olive oil|Extra virgin olive oil
3109176|NCT01828944|Experimental|Enriched extra virgin olive oil|Enriched extra virgin olive oil
3109177|NCT01828944|Placebo Comparator|refined olive oil|refined olive oil
3109178|NCT01828931|Active Comparator|Usual Care|Standard care provided via participants' family physicians, diabetes nurses, and psychiatrists.
3109179|NCT01828931|Experimental|Lifestyle Intervention|A lifestyle intervention based on the Look AHEAD study intervention, involving counselling related to dietary and physical activity habits.
3109180|NCT01828918|Other|early recurrence|find the postoperative early relapse out
3109181|NCT01828905|Experimental|Cerament|"CERAMENT™|BONE VOID FILLER as bone graft substitute"
3109182|NCT01828905|Active Comparator|Bone graft|Autologous cancellous bone graft (iliac crest)
3109183|NCT01828892|Experimental|PRFG treatment|As described in our previous study, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage. Prior to application, frozen cryoprecipitate and thrombin stored were thawed in a 37°C water bath. Aminomethylbenzoic Acid (1ml: 1mg, Sigma-Aldrich, St Louis, MO) was added into the cryoprecipitate in the volume ratio of 1:10.
3109184|NCT01828892|Sham Comparator|Control|Patients in this group only received standard of care when their fistula output < 200ml/24h.
3109185|NCT01828892|Experimental|Commercial FG|Commercial FG (Zhejiang Puji Porcine fibrin sealant) was applied to close fistulas.
3109186|NCT01828879|Experimental|Tacrolimus ointment|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
3109187|NCT01828866|Active Comparator|Community Reinforcement Approach|Treatment as usual, provided in out-patient setting
3109188|NCT01828866|Experimental|Community Reinforcement Approach + EMDR|Treatment as usual + additional sessions of EMDR
3109189|NCT01828840|Active Comparator|morphine, epidural|Epidurally administrated morphine
3109190|NCT01828840|Active Comparator|fentanyl, epidural|epidurally administrated fentanyl
3109191|NCT01828840|Active Comparator|methadone, epidural|epidurally administrated methadone
3109192|NCT01828840|Active Comparator|morphine, intervenous|intravenously administrated morphine
3109193|NCT01828827|Experimental|Fed 1000 mg PA-824|Each dose will be 1000 mg PA-824 (5 x 200 mg tablets), and will be administered with 240 mL tap water approximately 30 minutes after a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast.
3109194|NCT01828827|Experimental|Fasting 1000 mg PA-824|Each dose will be 1000 mg PA-824 (5 x 200 mg tablets), and will be administered with 240 mL tap water after a minimum 10-hour overnight fast.
3109195|NCT01828814||RUSF (500kcal/day) and cash transfer|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 500kcal per day associated with cash transfer during hunger gap (5 months) then RUSF 500kcal/day for 10 months
3109196|NCT01828814||Super Cereal Plus (SC+)|Monthly distributions of SC+ 800kcal per day during hunger gaps (5 months twice) and SC+ 400kcal per day in-between (5 months)
3109197|NCT01828814||RUSF|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 500kcal per day during hunger gaps (5 months twice) and RUSF 250kcal per day in-between (5 months)
3109198|NCT01828814||RUSF (250kcal/day) and cash transfer|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 250kcal per day associated with cash transfer during hunger gap (5 months) then RUSF 250kcal/day for 10 months
3109199|NCT01828814||SC+ and cash transfer|Monthly distributions of Super Cereal Plus (SC+) 800 kcal per day associated with cash transfer during hunger gap (5 months)
3109200|NCT01828814||SC+ and household ration|Monthly distributions of Super Cereal Plus (SC+) 800 kcal per day associated with food ration for household support during hunger gap (5 months)
3109201|NCT01828814||Cash transfer|Monthly distributions of cash transfer only during hunger gap (5 months)
3109202|NCT01828801||Pre-Op|Pre-operative patients who will undergo a total hip replacement.
3109258|NCT01828489|Experimental|Experimental DxEC and experimental FLADx|Experimental treatment with DaunoXome in course one (DxEC) and experimental treatment with FLADx in course two
3109203|NCT01828801||1 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 1 year post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3109204|NCT01828801||2 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 2 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3109205|NCT01828801||3 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 3 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3109206|NCT01828801||4 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 4 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3109207|NCT01828801||5 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 5 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3109208|NCT01828801||6 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 6 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3109209|NCT01828801||7 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 7 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3109210|NCT01828801||8 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 8 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3109211|NCT01828788|Experimental|Ropivacaïne|Prospective, controlled, randomised, parallel, single-centre, single-blinded trial, comparing to a control (conventional care with no locoregional anaesthesia) an infusion of ropivacaine through two multihole catheters placed lateral to the sternum. In both groups, postoperative analgesia will be achieved by paracetamol plus titrated then self-administered intravenous morphine.
3109212|NCT01828788|Placebo Comparator|Placebo|Prospective, controlled, randomised, parallel, single-centre, single-blinded trial, comparing to a control (conventional care with no locoregional anaesthesia) an infusion of ropivacaine through two multihole catheters placed lateral to the sternum. In both groups, postoperative analgesia will be achieved by paracetamol plus titrated then self-administered intravenous morphine.
3109213|NCT01828775|Experimental|Arm I (early PCI)|Patients receive part I of the PCI comprising quantitative surveys, comprehensive palliative care assessment by the Research Nurses, and goals of care discussions beginning prior to administration of the first dose of phase I treatment. Patients then receive part II of the PCI comprising recommendations from the interdisciplinary team, patient educational sessions, and supportive care referrals following the first dose of phase I treatment and is completed within one month of the first treatment.
3109214|NCT01828775|Experimental|Arm II (delayed PCI)|Patients receive usual care until 12 weeks post-treatment initiation. Patients then receive both part I and II of the PCI.
3109215|NCT01828762|Experimental|DC-TC+GM-CSF|
3109216|NCT01828749||CT abdomen and pelvis|blunt trauma patients without suspected fractures of the pelvis, hip or lumbar spine in two age groups: ages 3-17 years and 18-60 years
3109217|NCT01828736|Active Comparator|Arm A: Platinum + Gemcitabine|"Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV~+ If Creatinin Clearance > 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance < 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
3109218|NCT01828736|Experimental|Arm B: Platinum+Gemcitabine+Trastuzumab|"Trastuzumab: Charging dose = 8mg/kg on day 1; then 6mg/kg every 21 days given IV + Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV~+ If Creatinin Clearance > 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance < 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
3109219|NCT01828723|Experimental|SVF-Enriched Lipoinjection|
3109220|NCT01828710|Sham Comparator|Myo-inositol normospermic|29 normospermic treated with 4000mg/die of myo-inositol and 400 µg of folic acid
3109221|NCT01828710|Active Comparator|Myo-inositol OAT|13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid
3109222|NCT01828710|Placebo Comparator|Folic acid normospermic|20 normospermic patients treated with 400 µg of folic acid
3109223|NCT01828697|Active Comparator|Low dose LMWH|"Fixed low dose low-molecular-weight heparin:~Fixed low dose nadroparin, or;~Fixed low dose enoxaparin, or;~Fixed low dose dalteparin, or;~Fixed low dose tinzaparin."
3109224|NCT01828697|Active Comparator|Intermediate dose LMWH|"Intermediate dose low-molecular-weight heparin. Dosing is weight-adjusted according to the protocol.~Intermediate dose nadroparin, or;~Intermediate dose enoxaparin, or;~Intermediate dose dalteparin, or;~Intermediate dose tinzaparin."
3109225|NCT01828684|Experimental|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks
3109226|NCT01828684|Sham Comparator|Sham Lens Coating|Subjects will wear a sham lens coating for 2 weeks
3109227|NCT01828671|Active Comparator|Oral Glucose Solution 296 ml|Study Participants will consume oral glucose solution 296 mls. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer. Per standard glycemic index testing protocols, this will be repeated at another visit.
3109259|NCT01828476|Experimental|ARM A|Abiraterone with ABT-263
3109260|NCT01828476|Experimental|ARM B|Abiraterone with both ABT-263 and Hydroxychloroquine
3109261|NCT01828463|No Intervention|no treatment|comparrator
3109228|NCT01828671|Active Comparator|Corn Tortilla|Study Participants will consume 2 to 3.5 corn tortillas (12-15 cm in diameter each) with a total serving of 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
3109229|NCT01828671|Active Comparator|Low Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with a low amount of soy flour that is 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
3109230|NCT01828671|Active Comparator|Moderate Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with moderate amount of soy flour that has 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
3109231|NCT01828671|Active Comparator|High Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with a high amount soy flour that has 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
3109232|NCT01828658|No Intervention|Clinical (control)|In the clinical arm, dry weight and ultrafiltration prescription were done exclusively using traditional clinical methods of volume assessment.
3109233|NCT01828658|Active Comparator|Bioimpedance arm|Strict bioimpedance guided dry weight prescription arm. All patients dry weights were permanently maintained in the dry weight interval recommended by the BCM device (+/- 1,1 kg); BCM measurements were performed every 3 months.
3109234|NCT01828645|No Intervention|Control|Patients will be submitted to upper digestive endoscopy in the morning bearing traditional NPO (nil per oral)fast after 11:00PM
3109235|NCT01828645|Experimental|Intervention|The patients belonging to the intervention group will fast from 11:00 PM the night before but will drink 200 mL of a Carbohydrate plus whey protein enriched drink 2h before the exam.
3109236|NCT01828632|Experimental|Respiratory Physical Therapy|Patients assigned to interventional group (Respiratory Physical Therapy) were undergone a program of inspiratory muscular training (IMT) and incentive spirometer for a period of 30 days before the actual date of surgery. PiMAX, PeMAX and spirometry parameters were measured at the randomization day (baseline values)
3109237|NCT01828632|No Intervention|Control|Usual care for the four weeks before surgery. PiMAX, PeMAX and spirometry parameters were measured at the randomization day (baseline values).
3109238|NCT01828619||modified BuFlu, HSCT, elder/intolerable|The study group is the hematlogic malignant patients that older than 55years and/or with severe concurrent medical conditions, who will undergo HLA-matced allogenic HSCT to cure the disease. The patients will received a modified BuFlu conditioning.
3109239|NCT01828606|Experimental|Coban 2 system|The two layer system is more stiff and the material is different designed
3109240|NCT01828606|Experimental|coban lite systems|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
3109241|NCT01828593|Placebo Comparator|Placebo|Matching Placebo
3109242|NCT01828593|Active Comparator|SBI 2.5 g|Serum-derived bovine immunoglobulin protein isolate (SBI) 2.5 g
3109243|NCT01828593|Active Comparator|SBI 5.0g|Serum-derived bovine immunoglobulin protein isolate (SBI)5.0g
3109244|NCT01828580|Experimental|AutoLap|
3109245|NCT01828567|Experimental|Intervention|Primary care phone-based prevention coaching using shared decision making following a Healthy Living Assessment
3109246|NCT01828567|No Intervention|Control|Usual care
3109247|NCT01828554|Experimental|Xeloda (Capecitabine)|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
3109248|NCT01828541|Other|Standard Care|Subjects in this condition will receive our standard care for itch, which includes a stepped based algorithm of medications.
3109249|NCT01828541|Experimental|Hypnosis Condition|Subjects in this condition will receive standard care plus the addition of 4 sessions of hypnosis delivered over a two month period.
3109250|NCT01828528||NAFLD after SG|26 patients with NAFLD undergoing sleeve gastrectomy (SG).
3109251|NCT01828515|Experimental|Vilazodone and Hydrocortisone, then Placebo and Hydrocortisone|Vilazodone titrated to 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days (19 days) and hydrocortisone 160 mg x 4 days (days 16-19) following vilazodone pre-treatment. After a 23 day medication washout the procedure will be repeated using placebo daily for 19 days and hydrocortisone 160 mg x 4 days (days 16-19) following placebo pre-treatment.
3109252|NCT01828515|Experimental|Placebo and Hydrocortisone, then Vilazodone and Hydrocortisone|Placebo daily for 19 days and hydrocortisone 160 mg x 4 days (days 16-19) following placebo pre-treatment. After a 23 day medication washout the procedure will be repeated using Vilazodone titrated to 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days (19 days) and hydrocortisone 160 mg x 4 days (days 16-19) following vilazodone pre-treatment.
3109253|NCT01828502|Experimental|Active Intervention|Those randomized to the active intervention will receive education about secondhand smoke exposure and feedback using the cotinine test strip.
3109254|NCT01828502|Other|Education only|Those randomized to the education only group will receive only the education about secondhand smoke exposure.
3109255|NCT01828489|Active Comparator|Standard arm MEC and ADxE|Standard protocol arm with mitoxantrone in first course (MEC) and standard ADxE treatment in course two
3109256|NCT01828489|Experimental|Experimental DxEC and standard ADxE|Experimental arm with DaunoXome in course one (DxEC) and standard ADxE treatment in course two
3109257|NCT01828489|Experimental|Standard arm MEC and experimental FLADx|Experimental arm with standard MEC in the first course (MEC) and experimental treatment with FLADx in course two
3109262|NCT01828463|Experimental|Nitisinone 1mg|interventional
3109270|NCT01828398|Sham Comparator|sham-tDCS + UE robot-assisted therapy|This group will receive the same robot-assisted therapy of the intervention group, in association of sham-tDCS. This consists in a 30 seconds stimulation, with the same instrumentation and electrodes placement. This method of sham stimulation was previously validated.
3109271|NCT01828398|Experimental|real-tDCS + UE robot-assisted therapy|"This group will receive continuous stimulation lasting 30 minutes during the session of robot-assisted therapy. The training session, which includes multiplanar, repetitive and target reaching movements, will be given 5 times a week for 2 weeks(REO Therapy System; Motorika, Medical LTD, Israel). Each session will last about 30 minutes.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the affected hemisphere and the cathode on the contralateral M1 area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries (Brainstim, EMS, Italy). This continuous stimulation lasted 30 minutes, with an intensity of 1mA."
3109272|NCT01828385|Experimental|Group Mg|Magnesium sulfate 40 mg.kg-1 + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1
3109273|NCT01828385|Active Comparator|Group C|Saline 100 ml + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1
3109274|NCT01828372|Other|additional blood withdrawals|"Theoretical anyone with taking a drug of interest (see list of substances and metabolites of interest) can join this trial. But we turn mainly our attention to patient groups who are excluded in modern drug approval studies."
3109275|NCT01828359|Experimental|Amosartan® tab|Amlodipine 5mg /Losartan 100mg
3109276|NCT01828359|Active Comparator|Cozaar® plus pro tab|Losartan 100mg/ HCTZ 12.5mg
3109277|NCT01828346|Experimental|Treatment|5-Azacitidine plus birinapant
3109278|NCT01828333||Intravenous artesunate - new routine in DRC|"350 patients to be enrolled~A first study group with the currently used standard for treatment of severe malaria in the DRC, i.v. quinine, was enrolled from 21 October 2012 to 15 January 2013. This study was initially planned as limited scope implementation study with pure observational character (routine diagnosis and treatment, time and motion study, feasibility assessment and costing) and thus not registered. Due to additional publications on i.v. artesunate, non-routine testing for hemoglobin levels before and after treatment plus non-routine follow up was added: Registration of study at this point."
3109279|NCT01828320|Experimental|Treatment 1|Integrates evidence-based treatments derived from basic research on the circadian system
3109280|NCT01828320|Active Comparator|Treatment 2|Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
3109281|NCT01828307|Active Comparator|Standard Aftercare Treatment|Standard aftercare treatment consists of once per week group counseling for six months. Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
3109282|NCT01828307|Experimental|Standard Aftercare Treatment + Exercise Intervention|In addition to attending standard aftercare treatment, participants will receive three 50-minute motivational enhancement therapy sessions focused on exercise, plus 24 weekly contingency management sessions for exercise.
3109283|NCT01828294|Other|Study Population|Study population will include patients (18-80 years old) with non-thymomatous myasthenia gravis MGFA Class II-IV receiving a minimum of 30mg of Prednisone daily and no other immunosuppression and no more 240 mgs per day of Cholinesterase inhibitor. Patients will receive Subcutaneous immunoglobulins weekly for 6 months.
3109284|NCT01828281|Active Comparator|Therapeutic CPAP|Therapeutic CPAP
3109285|NCT01828281|Sham Comparator|control|subtherapeutic CPAP using 4 cm water
3109286|NCT01828268||HIV infectors|100 confirmed HIV-1 infected patients who meet inclusion criteria.
3109287|NCT01828255|Experimental|SENSIMED Triggerfish®|Device: portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization.
3109288|NCT01828242|Experimental|Empowerment model to Diabetes|Empowerment model to improve dietary intake
3109289|NCT01828242|Active Comparator|Control group following conventional approach|Control group following conventional approach
3109290|NCT01828229|Experimental|female inactivity and hypercaloric diet|inactivity and hypercaloric diet in women for two weeks
3109291|NCT01828229|Experimental|inactivity|Inactivity for two weeks
3109292|NCT01828229|Experimental|inactivity and hypercaloric diet|inactivity and hypercaloric diet for two weeks
3109293|NCT01828229|Experimental|normal activity and hypercaloric diet|Normal activity and hypercaloric diet for two weeks
3109294|NCT01828229|Active Comparator|inactivity and iso-caloric diet|inactivity and iso-caloric diet for two weeks
3109295|NCT01828216|Active Comparator|Conventional polysomnography|Conventional PSG will be performed as in-patient at Prince of Wales Hospital for every subject in this group, recording electroencephalogram, electro-oculogram, submental electromyogram, bilateral anterior tibial electromyogram, electrocardiogram, chest & abdominal wall movement by inductance plethysmography, airflow measured by a nasal pressure transducer & supplemented by oronasal airflow thermistor, & finger pulse oximetry.
3109296|NCT01828216|Active Comparator|Home sleep study|The home sleep study is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events.
3109297|NCT01828203|Experimental|Minocycline|Minocycline twice daily infused over 30 minutes through central venous access as follows 800 mg + 700 mg on Day 1, 600 mg + 500 mg on Day 2, and 400 mg thereafter from Day 3 thru Day 7
3109298|NCT01828203|Placebo Comparator|Placebo|250 ml normal saline and infused over 30 minutes through central venous access twice daily for 7 days
3109299|NCT01828190|Experimental|Hyperbaric oxygen|hyperbaric oxygen therapy will be given for 2 months. TNF alpha blocker therapy will remain the treatment received before recruitment.
3109300|NCT01828177|Experimental|PDI-320|Foam, twice daily for up to 12 weeks
3109301|NCT01828177|Experimental|PDI-320 Monad #1|Foam, twice daily for up to 12 weeks
3109302|NCT01828177|Experimental|PDI-320 Monad #2|Foam, twice daily for up to 12 weeks
3109304|NCT01828164|Experimental|Treatment Arm|20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated.
3109305|NCT01828164|Sham Comparator|Control Arm|The transducers are not activated on the control side of the device.The subjects wear the device for 20 minutes per day for the duration of the study. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the control arm consist of the side of the mouth with the transducers deactivated.
3109306|NCT01828151||Developed skin lesions|Patients treated with noninvasive ventilation for an episode of acute respiratory failure
3109307|NCT01828138|Other|Preeclampsia|"patients with preeclampsia are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement."
3109308|NCT01828138|Other|Controls|"Controls are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement"
3109309|NCT01828138|Other|not-pregnant women|"This arm is also a control- group. Controls are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement"
3109310|NCT01828125|Active Comparator|Hyperinsulinemic hypoglycaemic clamp 1mg glucagon|A 1.0mg glucagon dose will be given during the hyperinsulinemic hypoglycaemic clamp
3109311|NCT01828125|Active Comparator|Hyperinsulinemic hypoglycaemic clamp 0.1 or 0.2mg glucagon|A dose of 0.1mg or 0.2mg will be given during the hyperinsulinemic hypoglycaemic clamp.
3109312|NCT01828112|Experimental|Ceritinib|Patients in this arm received 750 mg of ceritinib.
3109313|NCT01828112|Active Comparator|Chemotherapy|Patients in this arm received chemotherapy of either pemetrexed or docetaxel as determined by BIRC.
3109314|NCT01828099|Experimental|Ceritinib|Ceritinib patients were on continuous oral dosing of ceritinib 750 mg once daily in fasted state.
3109315|NCT01828099|Active Comparator|Chemotherapy|Chemotherapy patients (Induction per Investigator's choice) were on four 21-day cycles of Pemetrexed 500mg/m2 iv + Cisplatin 75 mg/m2 or Pemetrexed 500 mg/m2 iv + Carboplatin AUC 5-6 iv followed by Pemetrexed 500 mg/m2 every 21 days followed by Pemetrexed maintenance in non-progressors, etc (other usual rule to stop treatment).
3109316|NCT01828086|Experimental|CJM112|CJM112 in different doses; single ascending and multiple ascending
3109317|NCT01828086|Placebo Comparator|Placebo|Placebo to match
3109318|NCT01828086|Active Comparator|Secukinumab|Active investigational drug.
3109319|NCT01828073||Cohort 1: HIV-infected women & their full-term infants|The group will consist of HIV-infected pregnant women receiving 400 mg raltegravir (RAL) twice daily for at least 2 weeks prior to delivery and continuing to receive ARVs during labor. The group will also include the infants born to these women.
3109320|NCT01828073||Cohort 2: HIV-infected women & their low birth weight infants|The group will consist of HIV-infected pregnant women receiving at least one dose of 400 mg RAL within 2 to 24 hours prior to delivery. The group will also include the women's infants who weigh less than or equal to 2,500 grams at birth.
3109321|NCT01828060|Experimental|Jobelyn™|Dietary supplement Jobelyn™, 500mg daily for 8 weeks Jobelyn is a sorghum bicolor extract marketed as dietary supplement Other Name: Sorghum bicolor extract
3109322|NCT01828060|Placebo Comparator|Placebo|Placebo capsules
3109323|NCT01828047||Elective colorectal surgeries|Patients undergoing elective colorectal procedures with an Enhanced Recovery Program. Orthogonal polarization spectral (OPS) imaging will be used to measure sublingual microcirculation
3109324|NCT01828034|Experimental|Gemcitabine, Cisplatin and MEK162|Phase I component of the study, a classic 3+3 cohort dose escalation scheme will be used to identify the MTD of MEK162 when administered with gemcitabine at dose 800 mg/m2 and cisplatin given at dose 20 mg/m2 week 2 & 3 of a 3 week cycle. The final cohort will receive gemcitabine 1000mg/m2 and cisplatin 20mg/m2 week 2 and 3 of a 3 week cycle in combination with MEK162 at the MTD as determined above. In the phase II part of the study, patients will receive MEK162 at the MTD dose plus gemcitabine and cisplatin at the dose level determined acceptable in the phase I portion. In the phase II part of the study, patients will receive MEK162 at 45mg BID plus gemcitabine (800 mg/m2) and cisplatin (20 mg/m2) as determined by the phase I portion.
3109325|NCT01828021|Experimental|margetuximab|Monotherapy of Anti-HER2 monoclonal antibody
3109326|NCT01827995|Other|Duo test|Self assessment
3109327|NCT01827995|Other|Routine follow up|Follow up in the clinic
3109328|NCT01827982|Experimental|Part 1 - Cohort 1: JNJ-54861911 1 mg|Following each dose level the observed safety and tolerability profile will be evaluated. The dose will be escalated only if the observed safety and tolerability profile is acceptable.
3109329|NCT01827982|Experimental|Part 1 - Cohort 2: JNJ-54861911 3 mg|
3109330|NCT01827982|Experimental|Part 1 - Cohort 3: JNJ-54861911 9 mg|
3109331|NCT01827982|Experimental|Part 2 - Cohort 4: JNJ-54861911 9 mg|
3109332|NCT01827982|Experimental|Part 2 - Cohort 5: JNJ-54861911 27 mg|
3109333|NCT01827982|Experimental|Part 2 - Cohort 6: JNJ-54861911 81 mg|
3109334|NCT01827982|Experimental|Part 2 - Cohort 7: JNJ-54861911 160 mg|
3109335|NCT01827982|Experimental|Part 3 - Cohort 8: JNJ-54861911 (dose to be determined [tbd])|
3109336|NCT01827982|Placebo Comparator|Parts 1 through 3 - Placebo|Participants in each cohort will receive matching placebo.
3109337|NCT01827969|Experimental|ablathermy focused ultrasound|ablathermy focused ultrasound
3109338|NCT01827956||Blood sample|Blood sample for identifying the polymorphism
3109339|NCT01827943|Experimental|TORISEL|Torisel
3109340|NCT01827930|Experimental|Imatinib|an adaptation strategy of dosage of Imatinib Mesylate versus a standard strategy
3109341|NCT01827917|Experimental|rabies vaccine|When injured by the animal who carries the rabies virus, the patient after standard treatment would survive or die
3109342|NCT01827904|Experimental|Transcranial ExAblate|Transcranial ExAblate
3109343|NCT01827904|Sham Comparator|Sham Transcranial ExAblate|Sham Treatment with Transcranial ExAblate
3109565|NCT01826461|Experimental|PDI-192 Foam, 0.15%|topical foam, 0.15% concentration, twice daily
3109344|NCT01827891|Placebo Comparator|control group|Control participants did not experience the procedure of transient upper-limb ischemia.
3109345|NCT01827891|Active Comparator|remote ischemic preconditioning (RIPC) group|Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at < 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.
3109346|NCT01827878|Active Comparator|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA
3109347|NCT01827878|Experimental|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India
3109348|NCT01827865|Active Comparator|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA
3109349|NCT01827865|Experimental|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India
3109350|NCT01827852||Cohort|
3109351|NCT01827839|Experimental|HZ Group|Subjects will receive 2 doses of the HZ/su vaccine at Month 0 and Month 2.
3109352|NCT01827826|Active Comparator|Intervention|Participants assigned to the intervention group worked with the study interventionist over the phone to reduce their risk for developing Diabetes Mellitus, Type 2. The intervention lasted for 24 weeks, with weekly phone calls for the first 12 weeks and 4 maintenance calls over the second 12 weeks. Study measurements were taken at baseline, 12 weeks, 24 weeks, and 52 weeks. After 24 weeks, the investigators randomly divided the intervention group in half. The first group did not receive any more phone calls from the interventionist. The second group continued to receive monthly 20-minute phone calls from the interventionist. At 52 weeks post-baseline participants from both groups had their labs drawn, wore a pedometer for 3 days, and called in with a self-reported weight.
3109353|NCT01827826|No Intervention|Control|Participants randomized into this group did not receive any intervention, although they were encouraged to follow-up with their doctor and follow through with usual clinical care.
3109354|NCT01827813|Active Comparator|Saturation biopsy|Saturation biopsy was performed in left lateral decubitus position after application of sedo-analgesia by the anesthesiologists on an outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. After injecting 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region, prostatic size was measured and changes in the zonal anatomy and ultrasonographic view of the tissue were defined. Next, biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen. As a total,24,26 or 28 biopsies were taken depending on prostate volume.
3109355|NCT01827813|Active Comparator|10-12 core biopsy|10-12 core biopsy was performed in left lateral decubitus position without sedo-analgesia on an outpatient basis. After preparation of the probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. After injecting 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region, prostatic size was measured and changes in the zonal anatomy and ultrasonographic view of the tissue were defined. Next, biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. As a total 10 or 12 core biopsies were taken depending on prostate volume. The biopsies were taken form right base, right mid, right apex, right far-lateral base, right far-lateral mid and left base, left apex, left far-lateral base, and left far-lateral mid in 10 core biopsy, also two additional transitional zone biopsies were taken in 12 core biopsies.
3109356|NCT01827800|Experimental|eHealth weight loss intervention|The 12-month eHealth behavioral intervention includes interactive self-monitoring and feedback, tailored skills training materials, telephone counseling calls from a study coach, and primary care provider counseling.
3109357|NCT01827800|No Intervention|Usual care|Participants in the usual care arm will receive the usual primary care services offered by their community health center primary care providers.
3109358|NCT01827787|Experimental|Hormone Receptor Positive|Eribulin Monotherapy
3109359|NCT01827787|Experimental|Triple Negative Breast Cancer|Eribulin Monotherapy
3109360|NCT01827774|Experimental|Surgisis® Soft Tissue Graft|
3109361|NCT01827761||Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
3109362|NCT01827748|Experimental|Intraoperative Autorefractor IAR-1|This is a auto refractor mounted on an operating microscope.
3109363|NCT01827748|Active Comparator|Hartmann-Shack Auto Refractor|The Hartmann-Shack type auto refractor used with the subject sitting upright in front of the instrument.
3109364|NCT01827722|Experimental|Ozurdex Arm|Ozurdex intravitreal injection (combination with monthly sham injection) administered at a 16 week interval beginning on Day 1 and ending at Week 16.
3109365|NCT01827722|Experimental|Ranibizumab Arm|Ranibizumab injection (combination with sham injections beginning on Day 1 and Week 16) administered at monthly intervals beginning Day 1 and ending at Week 20.
3109366|NCT01827722|Experimental|Combination Ozurdex with Ranibizumab PRN|"Ozurdex intravitreal injection administered at 16 week intervals beginning on Day 1 and ending at Week 16 with an initial IV Ranibizumab injection administered at Day 1, then treated with Ranibizumab according to reinjection parameters assessed monthly (in combination with sham if reinjection parameters are not met).~Reinjection Parameters:~10 letter drop from best corrected visual acuity or a 100 µm increase in central retinal thickness according to optical coherence tomography (Spectralis HRA + OCT)."
3109367|NCT01827696|Experimental|Treatment|American Ginseng ingestion
3109368|NCT01827696|Placebo Comparator|Placeobo|non-active ingredient
3109369|NCT01827683|Active Comparator|Hyperbaric oxygen therapy group|hyperbaric oxygen therapy during the first 2 months
3109370|NCT01827683|Other|Crossed group|no active intervention during the first 2 months.After 2 months will be crossed to HBOT
3109371|NCT01827670|Experimental|0.454% stannous fluoride dentifrice|Participants to brush whole mouth with 1-inch strip of the test dentifrice (0.454% SnF) for one timed minute, followed by rinsing with 5 milliliter (mL) of water.
3109372|NCT01827670|Active Comparator|0.76% sodium monofluorophosphate dentifrice|Participants to brush whole mouth with 1-inch strip of the control dentifrice (0.76% NaMFP) for one timed minute, followed by rinsing with 5 mL of water.
3109373|NCT01827657|Experimental|Part 1 Cohort 1 - Mild hepatic impairment|Subjects with mild hepatic impairment will be enrolled in Cohort 1 and will receive a single dose of 60 mg GSK2336805
3109374|NCT01827657|Experimental|Part 1 Cohort 2 - Moderate hepatic impairment|Subjects with moderate hepatic impairment will be enrolled in Cohort 2 and will receive a single dose of 60 mg GSK2336805
3109375|NCT01827657|Experimental|Part 1 Cohort 3 - Matched healthy volunteers to Cohort 2|Control subjects will be matched for gender, age (+/- 10 years), body mass index (BMI) (+/- 20%), and smoking status to the subjects in the moderate hepatic impairment arm. These healthy volunteers will receive a single dose of 60 mg GSK2336805
3109376|NCT01827657|Experimental|Part 2 Cohort 4 - Severe hepatic impairment|Subjects with severe hepatic impairment will be enrolled in Cohort 2 and will receive a single dose of 60 mg GSK2336805. The decision to move forward into Part 2 (severe hepatic impairment) will be based on a review of the preliminary safety and pharmacokinetic data from subjects with moderate hepatic impairment
3109377|NCT01827657|Experimental|Part 2 Cohort 5 - Matched healthy volunteers to Cohort 4|Based on emerging data from Part 1, the sponsor may decide to enroll matched controls to the severe hepatic group (i.e. in case of a change in dose or the demographics of the severe hepatic group are not well matched with the moderate control data). The subjects in this optional control cohort will be matched for gender, age (+/- 10 years), BMI (+/- 20%), and smoking status to the subjects in the severe hepatic impairment category
3109378|NCT01827644|Experimental|Sequence 1|Subjects will receive single doses of AFU HPMC capsule administered in a fasted state, AFU ECT administered in a fasted state, AFU HPMC capsule administered in a fed state and AFU GC administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
3109379|NCT01827644|Experimental|Sequence 2|Subjects will receive single doses of AFU ECT administered in a fasted state, AFU ECT administered in a fed state, AFU GC administered in a fasted state and AFU GC administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period.
3109380|NCT01827644|Experimental|Sequence 3|Subjects will receive single doses of AFU GC administered in a fasted state, AFU GC administered in a fed state, AFU ECT administered in a fed state and AFU HPMC capsule administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period.
3109381|NCT01827644|Experimental|Sequence 4|Subjects will receive single doses of AFU GC administered in a fed state, AFU HPMC capsule administered in a fed state, AFU HPMC capsule administered in a fasted state and AFU ECT administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
3109382|NCT01827644|Experimental|Sequence 5|Subjects will receive single doses of AFU ECT administered in a fed state, AFU HPMC capsule administered in a fasted state, AFU GC administered in a fed state and AFU HPMC capsule administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
3109383|NCT01827644|Experimental|Sequence 6|Subjects will receive single doses of AFU HPMC capsule administered in a fed state, AFU GC administered in a fasted state, AFU ECT administered in a fasted state and AFU ECT administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
3109384|NCT01827631|Experimental|GSK1605786 500 mg once daily|GSK1605786 500 mg is given once daily in the morning
3109385|NCT01827631|Experimental|GSK1605786 500 mg twice daily|GSK1605786 500 mg is given twice daily in the morning and in the evening
3109386|NCT01827618|Experimental|Rapamycin|Rapamycin 3mg orally daily x 4weeks prior to radical cystectomy
3109387|NCT01827618|No Intervention|Control|
3109388|NCT01827605|Experimental|Arm A RIT|Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc). Zevalin® will be delivered as per indications and should thus be provided at expenses following regular supplies procedures.
3109389|NCT01827605|Experimental|ARM B ASCT|BEAM conditioning regimen (or in alternative FEAM regimen with fotemustine to replace BCNU) and reinfusion of CD34+ cells of ≥ 2x106/Kg CD34+ day 0 (optimal dose to reinfuse 4x106/Kg CD34+). G-CSF 5 mcg/Kg from day 2 until ANC>1500/mmc. Patients who failed mobilization will directly proceed to rituximab maintenance
3109390|NCT01827592|Experimental|EBX 10|Elobixibat 10 mg/day
3109391|NCT01827592|Experimental|EBX 5|Elobixibat 5 mg/day
3109392|NCT01827592|Placebo Comparator|PLCBO|Placebo
3109393|NCT01827579|Experimental|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10^5 /kg at day 30 post-SCT, 3 x 10^5 /kg at day 60 and 10^6 /kg at day 90 post transplant
3109394|NCT01827579|No Intervention|Control (normal HSCT)|Patients randomised to the control arm with undergo stem cell transplantation according to site local practice.
3109395|NCT01827566|Active Comparator|gluten|10 grams of gluten in each sachet to be dispersed daily on food for ten days, while maintaining a gluten free diet
3109396|NCT01827566|Placebo Comparator|gluten free flour|10 grams of gluten free flour in each sachet to be dispersed daily on food for ten days, while maintaining a gluten free diet
3109397|NCT01827553|Experimental|Induction CT, chemoradiotherapy|Induction chemotherapy with gemcitabine or FOLFIRINOX; Radiotherapy, 28 x 1.8 Gy; Chemotherapy, gemcitabine;
3109398|NCT01827553|Active Comparator|Induction CT, chemotherapy|Induction chemotherapy with gemcitabine or FOLFIRINOX; Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy
3109399|NCT01827540|Experimental|Cenicriviroc + Midazolam, and CVC + DTG|Grp 1: CVC 150mg qd alone from Days 1-10; CVC 150mg qd + DTG 50mg qd from Days 11-20. A single dose of midazolam 5mg administered alone on Day -1 & w/ CVC 150mg on Day 9.
3109400|NCT01827540|Experimental|Dolutegravir , and DTG + CVC|Grp 2: DTG 50 mg qd alone from Days 1-10, DTG 50 mg qd + CVC 150 mg qd from Days 11-20.
3109401|NCT01827527||Healthy Adult|This is a protocol development study, with no interventions or treatments.
3109402|NCT01827514||People with diagnosed cancer|People wich were diagnosed with one of specific type of cancer: breast, lung, colon, head, neck and lymphoma
3109403|NCT01827501|Experimental|Group GDT|Goal-directed Management according to pulse contour analysis (PulsioflexTM Monitoring)
3109404|NCT01827501|No Intervention|Group Co|Conventional fluid management
3109405|NCT01827475|Active Comparator|Ibuprofen|Ibuprofen 800 mg
3109406|NCT01827475|Active Comparator|Acetaminophen|Acetaminophen 1 gm
3109407|NCT01827475|Experimental|Ibuprofen-acetaminophen combination|Ibuprofen 800 mg plus acetaminophen 1 gm
3109408|NCT01827462|Experimental|18-30 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.~Beginning with 2014-2015 season, Quadrivalent, inactivated influenza vaccine (IIV4) was given."
3109409|NCT01827462|Experimental|60-80 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.~Beginning with 2014-2015 season, High-Dose trivalent, inactivated influenza vaccine (TIV High-Dose) was given."
3109410|NCT01827462|Experimental|80-100 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.~Beginning with 2014-2015 season, High-Dose trivalent, inactivated influenza vaccine (TIV High-Dose) was given."
3109411|NCT01827436|Active Comparator|Conventional physical therapy|Includes traditional physical treatment, such as gait and balance training and muscle strengthening.
3109412|NCT01827436|Active Comparator|Asymmetrical gait training|Includes walking on a split-belt treadmill with the belts moving at different speeds under each leg, alternated with overground walking training.
3109413|NCT01827423|Experimental|Surgical removal of sinonasal papiloma|The study group consisted of patients following a surgical removal of sinonasal papiloma, in which the SCCA blood levels were assessed in pre-defined intervals.
3109414|NCT01827410||patients with a ventral hernia repair|All patients with a ventral hernia repair performed in Region Zealand and registered in The Danish Ventral Hernia Database during October 1st 2010 to October 1st 2011
3109415|NCT01827397|Experimental|EN41-UGR7C HIV vaccine|Group 1: IM injection of 210 µg UGR7-C in 560 µg of Alum at month 0, 1 and 4
3109416|NCT01827397|Placebo Comparator|NaCl|Group 2: IM injection of 700 µL of 0.9% sodium chloride (NaCl) at month 0, 1 and 4
3109417|NCT01827384|Experimental|Arm A (mutation/amplification determined treatment regimen)|"Patients are assigned to 1 of 4 treatment regimens corresponding to one of their mutation/amplification categories. Patients may cross over to a second mutation/amplification determined regimen within Arm A, if there is one, upon disease progression.~REGIMEN I: Patients receive veliparib PO BID on days 1-7 and temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~REGIMEN II: Patients receive WEE1 inhibitor MK-1775 PO BID for 5 doses starting on day 1 and carboplatin IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~REGIMEN III: Patients receive everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~REGIMEN IV: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3109418|NCT01827384|Active Comparator|Arm B (physician assigned treatment regimen)|Patients are assigned to 1 of the 4 treatment regimens as in Arm A from the complementary set (not corresponding to one of their mutation categories). Patients may cross over to Arm A upon disease progression.
3109419|NCT01827371|Experimental|Arm C|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 22.
3109420|NCT01827371|Experimental|Arm B|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 15.
3109421|NCT01827371|Experimental|Arm A|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 29.
3109422|NCT01827371|Experimental|Arm D|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via Stratis™ on Days 1 and 29.
3109423|NCT01827358|Experimental|Group 1|Subjects receive a 5-day course of mupirocin calcium ointment 2 % 20 mg intranasally applied every 8 hours and a topical skin application (umbilical and perianal area) of mupirocin calcium cream 2% 20 mg applied every 8 hours for a total of 15 doses
3109424|NCT01827358|No Intervention|Group 2|No treatment
3109425|NCT01827345|Experimental|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
3109426|NCT01827332|Active Comparator|Oxytocin|intranasal administration
3109427|NCT01827332|Placebo Comparator|Saline|intranasal administration
3109428|NCT01827306|Active Comparator|Biofreeze|Apply 5 minutes before therapy by applying a small coin sized amount to the painful area. Subjects will then complete a standard shoulder therapy program.
3109429|NCT01827306|No Intervention|Control|Subjects in this arm will complete a standard shoulder therapy program as normal, with no intervention.
3109430|NCT01827293|Active Comparator|Promethazine|IV promethazine (25 mg)
3109431|NCT01827293|Active Comparator|lorazepam|IV lorazepam (2 mg)
3109432|NCT01827280|Experimental|Metformin|Metformin 850mg/pill will be administered at lunch time and dinner time for 30 days
3109433|NCT01827280|Experimental|Vildagliptina|Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
3109434|NCT01827267|Experimental|neratinib monotherapy|240 mg once daily with food, continuously in 21 day cycles
3109435|NCT01827267|Experimental|neratinib plus temsirolimus|240 mg neratinib plus 8 mg temsirolimus IV with optional dose escalation to 15 mg temsirolimus
3109436|NCT01827254||Non-Interventional Study|
3109455|NCT01827098|Experimental|Immediate Induction|Blood clot is induced after disinfection of the canal during the same visit. Endodontic regeneration is performed.
3109437|NCT01827241||Colonoscopy Outcomes|Data collected from endoscopy reports to complete a descriptive analysis of demographics, colonoscopy procedure performance, and assess type of benign colon polyps detected during screening and surveillance from 02/01/2009 - 12/31/2020.
3109438|NCT01827228|Experimental|Primary Recent infection network tracing|"Subjects: LAg+ recent HIV infection testees & referrals with recent/acute infection; those in social/risk networks of index subjects; people who go to their venues. We'll network trace direct contacts of Index Cases & network/venue members of contacts; and maybe 3rd ring as exploratory part of project. We'll test network/venue members for recent & acute HIV. If they have recent/acute HIV infection, their network/venue contacts will be traced. We'll refer HIV+ Primary arm participants for medical/social evaluation and treatment; those with recent/acute infection on expedited scheduling and case management. We will distribute community alerts to warn people in the social environments of recent/acute infectees to be super-careful in their behaviors for the next 6 months; to tell them how to be safer; and to repeat the importance of assisting rather than stigmatizing anyone they suspect has recently become infected."
3109439|NCT01827228|Active Comparator|Contact tracing of long-term HIV+ people|We will start with 50 subjects in each city who test HIV+ but LAg negative—and who report they have just learned they are HIV+. We will recruit their sexual and injection partners, and other risk environment contacts, for two steps, as in Primary Arm. HIV+ will be referred for treatment; recent/acutes on expedited and assisted basis.
3109440|NCT01827228|Active Comparator|HIV negative comparison arm|This comparison arm will consist of 150 uninfected people in each city whom we screen in the course of testing. The key comparisons here are on two of the central variables: adverse/supportive events and behavior change. This comparison arm will help mitigate social desirability effects that can lead to inaccurate reporting and/or Hawthorne effects and related processes that can lead to behavior changes simply based on the interview. Participants in this arm will be matched on age (within five years), risk group, and gender with an Arm 1 member.
3109441|NCT01827215|Experimental|Intervention (Virtual Patient Advocate)|The Intervention Virtual Patient Advocate (VPA) Group participants will be given a username and secure password to log on to the Gabby site for the 12 months of the intervention. They will be encouraged to log on at least monthly, but using the system is voluntary. They will be given the contact information of the Program Manager in the event that they have any issues or questions about the system. The research team will call each intervention participant after 12 months to conduct a follow-up phone call to collect outcome data. At that point, intervention participants will be invited to participate a focus group session.
3109442|NCT01827215|No Intervention|Control (Letter)|The control group will receive a letter listing the preconception risks identified in the risk assessment and they will be encouraged to see their clinician to discuss them.
3109443|NCT01827202|Active Comparator|Aliskiren|After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking aliskiren 150 mg once daily for 4 weeks. Thereafter, the dose will be increased to 300 mg once daily for another 4 weeks.
3109444|NCT01827202|Active Comparator|Candesartan|After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking candesartan 8 mg once daily for 4 weeks. Thereafter, the dose will be increased to 16 mg once daily for another 4 weeks.
3109445|NCT01827189||Comprehensive primary care practices|Comprehensive primary care practices are the intervention group.
3109446|NCT01827189||Comparison practices|Comparison practices are the case-control group--the matched set of practices in a comparison area--whose patients' outcomes will be compared to those of intervention practices.
3109447|NCT01827176||Recurrent Acute Rhinosinusitis|Recurrent Acute Rhinosinusitis is defined as acute rhinosinusitis more than 3 times/6 months or more than 4 times/year
3109448|NCT01827163|Experimental|Paclitaxel With Trastuzumab and Lapatinib|Paclitaxel (T) at 175 mg/m2 q 2 weeks x 4 with filgrastim/pegfilgrastim + trastuzumab (H) + daily oral lapatinib (L), followed by trastuzumab q 3 weeks x 15 doses + daily oral lapatinib (HL). Pegfilgrastim 6mg will be given subcutaneously (SQ) on day # 2 of each paclitaxel administration. Filgrastim may be used in lieu of pegfilgrastim at physician's discretion. Trastuzumab will be administered weekly (4 mg/kg bolus followed by 2 mg/kg weekly) starting with paclitaxel treatment cycle # 1. After 4 cycles of paclitaxel, pts will receive trastuzumab on a q 3 weeks x 15 doses (to complete about one year). The q 3 week trastuzumab may be started from 1-3 weeks after the last dose of paclitaxel. A total of 15 infusions of trastuzumab will be given q 3 weeks after the completion of paclitaxel during the HL phase. Lapatinib will be given orally at 1000 mg daily, starting with paclitaxel during the THL phase & continued for the remaining year during the HL phase for about a year.
3109449|NCT01827150|Experimental|Redbull, optic nerve|"15 subjects will each be drinking a can of Redbull (250 ml) and an equal amount of water (250 ml) in two different sessions. The order in which they will do so, is determined by randomization.~Intervention: Drug: Redbull, energy drink"
3109450|NCT01827137|Experimental|vaccine|Vaccinations will be initiated 12-22 days following autologous stem cell transplantation. Six vaccinations of the WT1 peptide preparation (1.0 ml of emulsion) will be administered on weeks 0, 2, 4, 6, 8, & 10. All vaccinations will be administered subcutaneously with vaccination sites rotated among extremities. Injection sites will be pre-stimulated with Sargramostim (GM-CSF 70 μg) injected subcutaneously on days -2 (± 1 day) & 0 of each vaccination. Note: during each vaccination, the Sargramostim (GM-CSF)& the vaccine emulsion will be administered to the same anatomical site. Patients will be observed for at least 30 minutes after vaccination. Patients, who are clinically stable (no active infection with fevers & no cardiovascular or respiratory compromise) & have not had disease progression, may receive up to 6 more vaccinations administered appropriately every month. The use of post-stem cell transplant maintenance therapy is allowed starting 3 months or more after transplant.
3109451|NCT01827124|Experimental|carbetocin and placebo|100microgram carbetocin IV and 1cc normal saline(placebo)infusion
3109452|NCT01827124|Experimental|oxytocin and placebo|20Interntional unit oxytocin infusion and 1cc normal saline IV
3109453|NCT01827111|Experimental|ABI-007 + Ipilimumab|Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. Ipilimumab 3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses. Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
3109454|NCT01827098|Experimental|Delayed induction|The root canal is disinfected and calcium hydroxide is placed in the canal. Blood clot is induced in the canal 4 weeks later. Endodontic Regeneration is performed.
3109456|NCT01827085||Macintosh laryngoscope|Patients will be intubated with a conventional Machintosh laryngoscope
3109457|NCT01827085||Videolaryngoscope|Intubation with Stortz video laryngoscope
3109458|NCT01827072|Experimental|NPB-01|Intravenous immunoglobulin
3109459|NCT01827059|Active Comparator|Bosentan|Tracleer, 125-mg orange-white, round, biconvex, film-coated tablets
3109460|NCT01827059|Placebo Comparator|Placebo|Placebo tablet
3109461|NCT01827046|Experimental|MIS plus rt-PA management|Subjects randomized to the MIS plus rt-PA management arm will undergo minimally invasive surgery followed by up to 9 doses of 1.0 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
3109462|NCT01827046|No Intervention|Medical management|Subjects randomized to medical management will receive the standard medical therapies for the treatment of intracerebral hemorrhage, which includes ICU care only and no planned surgical intervention.
3109463|NCT01827033|Other|meditation training|
3109464|NCT01827020|Active Comparator|Group L (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of 12 mL lidocaine 2%, 1mg/kg into nasal cavity.
3109465|NCT01827020|Active Comparator|Group K (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of 12 mL ketamine 0.5 mg/kg plus lidocaine 2% 1 mg/kg of the intranasal cavity.
3109466|NCT01827020|Placebo Comparator|Group S (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of saline 12 mL into intranasal cavity.
3109467|NCT01827007|Experimental|Study arm, elevation of PEEP|
3109468|NCT01826994|Other|patients|heart type fatty acid binding protein testing
3109469|NCT01826981|Experimental|Cohort 1,Group 1: LDV/SOF + RBV 12 wk (GT1 SOF retreatment)|LDV/SOF + RBV for 12 weeks in participants with genotype 1 HCV infection and who failed to achieve sustained virologic response (SVR) in a previous Gilead sofosbuvir study
3109470|NCT01826981|Experimental|Cohort 1,Group 2:SOF+Peg-IFN+RBV 12 wk (GT2,3 SOF retreatment)|SOF + PEG + RBV for 12 weeks in participants with genotype 2 or 3 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study
3109471|NCT01826981|Experimental|Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, liver disease)|LDV/SOF+RBV for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis
3109472|NCT01826981|Experimental|Cohort 2,Group 2: LDV/SOF+GS-9669 12wk (GT1 TE, liver disease)|LDV/SOF + GS-9669 for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis
3109473|NCT01826981|Experimental|Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)|LDV/SOF for 12 weeks in treatment-naive participants with genotype 3 HCV infection
3109474|NCT01826981|Experimental|Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)|LDV/SOF + RBV for 12 weeks in treatment-naive participants with genotype 3 HCV infection
3109475|NCT01826981|Experimental|Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)|LDV/SOF for 12 weeks in treatment-naive or treatment-experienced participants with genotype 6 HCV infection
3109476|NCT01826981|Experimental|Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)|LDV/SOF + RBV for 12 weeks in treatment-experienced participants with genotype 3 HCV infection
3109477|NCT01826981|Experimental|Cohort 3,Group 1: LDV/SOF 12 wk (GT1 cirrhotic CPT B)|LDV/SOF for 12 weeks in participants with genotype 1 HCV infection and Child-Pugh Turcotte (CPT) B cirrhosis
3109478|NCT01826981|Experimental|Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN noncirrhotic)|SOF+VEL (25 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
3109479|NCT01826981|Experimental|Cohort 4,Group 2:SOF+VEL 25mg+RBV 8 wk (GT3 TN noncirrhotic)|SOF+VEL(25 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
3109480|NCT01826981|Experimental|Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN noncirrhotic)|SOF+VEL (100 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
3109481|NCT01826981|Experimental|Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN noncirrhotic)|SOF+VEL (100 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
3109482|NCT01826981|Experimental|Cohort 5,Group 1: LDV/SOF + RBV 24 wk (SOF retreatment)|LDV/SOF+RBV for 24 weeks in participants with genotype 1, 2, 3, or 6 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study
3109483|NCT01826981|Experimental|Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HBV coinfection)|LDV/SOF for 12 weeks in participants with genotype 1 HCV and hepatitis B virus (HBV) coinfection
3109484|NCT01826968|Experimental|Recruitment Group|The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. In this group PEEP was set to 8 cmH2O, after the recruitment maneuver, and was left until the end of the operation.
3109485|NCT01826968|No Intervention|Control Group|We did not used alveolar recruitment maneuver
3109486|NCT01826955||Open gastrectomy|patient who undergoing open gastrectomy
3109487|NCT01826955||laparoscopic gastrectomy|patient who undergoing laparoscopic gastrectomy
3109488|NCT01826942|Experimental|Thin skin|Single fractional CO2 treatment at surgical area closure procedure on thin skin
3109489|NCT01826942|Experimental|Thick skin|Single fractional CO2 treatment at surgical area closure procedure on thick skin
3109490|NCT01826929|Experimental|Therapeutic education|Organized intervention strategy:Informed active patient, shared decision making, appointment planning, primary care doctor-nurse teamwork, actions based on scientific evidence.
3109491|NCT01826929|No Intervention|Usual care model|
3109492|NCT01826916|Experimental|5mg/m2 DX-88 IV|5mg/m2 DX-88 (ecallantide)administered intravenously
3109493|NCT01826916|Experimental|10mg/m2 DX-88 IV|10mg/m2 DX-88(ecallantide)administered intravenously
3109494|NCT01826916|Experimental|20mg/m2 DX-88 IV|20mg/m2 DX-88 (ecallantide) administered intravenously
3109495|NCT01826916|Experimental|30 mg DX-88 SC|30mg DX-88(ecallantide)administered subcutaneously
3109496|NCT01826903||depressed mother/child dyad - intervention|
3109497|NCT01826903||depressed mother/child dyad - no intervention|
3109498|NCT01826903||non-depressed mother/child dyad|
3109563|NCT01826474|Experimental|PRO045, cohort 6|48 week treatment phase
3109499|NCT01826890|Experimental|NAVA technology|Following randomisation, a NAVA catheter will be introduced. The Electrical Activity of the Diaphragm (EAdi) will be viewed primarily to ensure a minimum level of diaphragm activation during the weaning phase. NAVA mode suitability/safety assessments will be conducted in all patients prior to the first initiation of the NAVA mode. The NAVA preview function on the Maquet Servo-i ventilators will be used to transfer from the previous mode to the NAVA mode, and the assessment will last for a maximum of 30 minutes. We are recommending the use of the NAVA ventilation mode during the weaning period. Following the commencement of weaning, sedation holds and spontaneous breathing trials will be conducted according to local protocols.
3109500|NCT01826890|No Intervention|Standard Care|A NAVA catheter will be inserted following randomisation. The NAVA capabilities of the ventilator will be disabled. Patients will be ventilated according to local weaning protocol as per current standard care with either Pressure Support, Synchronised Intermittent Mandatory Ventilation, Volume Controlled Ventilation, Pressure Controlled Ventilation or Pressure Regulated Volume Controlled Ventilation. Following the commencement of weaning, sedation holds and spontaneous breathing trials will be conducted according to local protocols.
3109501|NCT01826877|Experimental|Treatment (autologous dendritic cells)|Patients receive AdGMCAIX-transduced autologous dendritic cells ID on days 1, 15, and 29.
3109502|NCT01826864|Experimental|Arm I (sargramostim and sentinel lymph node biopsy)|Patients receive sargramostim SC 3-5 days prior to undergoing sentinel lymph node biopsy.
3109503|NCT01826864|Active Comparator|Arm II (hypertonic saline and sentinel lymph node biopsy)|Patients receive hypertonic saline SC 3-5 days prior to undergoing sentinel lymph node biopsy.
3109504|NCT01826851|Experimental|Exparel|266 mg Exparel, single-dose injection.
3109505|NCT01826851|Placebo Comparator|Placebo|0.9% Normal saline, single-dose injection.
3109506|NCT01826838|Experimental|Dasatinib|Three dasatinib dose levels will be evaluated, 50 mg/day, 70 mg/day and 100 mg/day. Dasatinib will begin with day #1 of radiation and will be discontinued once radiation is completed.
3109507|NCT01826825||Clock in the box|Results of the Clock in the box cognitive screening test.
3109508|NCT01826825||Mini-Cog|Results of the mini-cog cognitive screen
3109509|NCT01826812||Dry Eye|"The patients with Sjogren Syndrome related or non-Sjogren Syndrome related dry eye. The participants will be asked some questions. Before and after reading a text silently in 30 minutes 30 minutes sustained reading, a detailed dry eye exam will be performed."
3109510|NCT01826812||Controls|"The patients without dry eye. The participants will be asked some questions. Before and after reading a text silently in 30 minutes 30 minutes sustained reading, a detailed dry eye exam will be performed."
3109511|NCT01826799||adult ICU patients|All adult patients without hearing disabilities and admitted to the ICU more than 48 hours ago, with a Richmond Agitation-Sedation Scale (RASS) of -2 or higher and the capability to understand Dutch are eligible.
3109512|NCT01826786|Experimental|JNJ-42165279 (100 mg)|
3109513|NCT01826786|Placebo Comparator|Placebo|
3109514|NCT01826773|Experimental|Stress only CardioPET™|"Group I will consist of 15-20 patients and will have CardioPET™ imaging performed with a repeat identical stress component at ≥ 48 hours and ≤ 10 days after the initial stress MPI study. There should be no intervention or change in symptoms between the tests, and the patient must have an angiography scheduled to be performed within 30 days.~The analysis of the acquired imaging data will determine if CardioPET™ is suitable for identifying myocardial flow defects that were observed in exercise or pharmacologic stress Tc-99m MPI imaging. The goal for this CardioPET™ imaging group is to measure blood flow at near maximal stress."
3109515|NCT01826773|Experimental|Rest only CardioPET™|"Group II will consist of 15-20 subjects will have undergone either, stress, Tc-99m MPI study or stress-echocardiography indicating ≥2 segments of ischemia. These patients must have been referred and scheduled for coronary angiography. If initial evaluation was performed with stress echocardiography, subjects will have either exercise or pharmacologic stress MPI.~CardioPET™ imaging in these subjects must be performed ≥ 48 hours and ≤ 10 days from the initial stress (stress MPI or echocardiography) at rest only. An angiography must be scheduled to be performed within 30 days."
3109516|NCT01826760||acute-on-chronic hepatitis B liver failure, training group|ACHBLF was defined as an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic HBV infection according to consensus recommendations of the Asian Pacific Association for the Study of the Liver in 2009. ACHBLF patients were assigned to a training cohort and a validation cohort randomly. One of the major limitations of ANN is over-training, which can lead to good performance on training sets but poor performance on relatively independent validation sets. To avoid over-training during building ANN, a part of ACHBLF patients were again randomly selected from the training group to train the network and the remaining were used for cross-validation.
3109517|NCT01826760||acute-on-chronic hepatitis B liver failure, testing group|ACHBLF was defined as an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic HBV infection according to consensus recommendations of the Asian Pacific Association for the Study of the Liver in 2009. To avoid over-training during building ANN, a part of ACHBLF patients were again randomly selected from the training group to train the network and the remaining were used for cross-validation.
3109518|NCT01826747|Experimental|experimental|
3109519|NCT01826734||Patients with dacryolits|The study population consisted of patients following a dacryolit extraction procedure. The extraction procedure was not a part of this study.
3109520|NCT01826721|No Intervention|Standard of Care|Patients in the Standard of Care arm receive the usual in-hospital post-transplant medication teaching class led by a transplant pharmacist.
3109521|NCT01826721|Active Comparator|TMITT|Patients in this arm receive the standard of care plus the TMITT educational intervention.
3109522|NCT01826708|No Intervention|Psychomotor retardation syndromic|Psychomotor retardation syndromic by Identification of breakpoints
3109523|NCT01826695|Placebo Comparator|Placebo group|35 women are recruited in order to the inclusion criteria for the study. Placebo controlled. They received only standard treatment without neurodynamic intervention. They are diagnosed with Fibromyalgia attending to the Fibromyalgia Association of Granada. The study include subjects who can complete the assessment battery of tests at the beginning and end.
3109564|NCT01826461|Experimental|PDI-192 Foam, 0.1%|topical foam, 0.1% concentration, twice daily
3109524|NCT01826695|Active Comparator|Neurodynamic technique group|35 women are recruited, diagnosed with Fibromyalgia attending to the Fibromyalgia Association of Granada. The study include subjects who can complete the assessment battery of tests at the beginning and at the end.
3109525|NCT01826682|Placebo Comparator|Medical treatment|29 people are being recruited in order to the inclusion criteria for the study. Placebo controlled.
3109526|NCT01826682|Active Comparator|Physiotherapy program+medical treatment|29 people are recruited in order to the inclusion criteria for the study. Experimental group
3109527|NCT01826669|Active Comparator|Stretching|"The respiratory muscle stretching were developed bilaterally as follows:~Upper trapezius: head lateral flexion with a hand therapist supports the the occipital region and his shoulder, promotes the stretching;~Sternocleidomastoid: was stretched with flexion lateral and rotation of the head to the side which hands on the occipital region and in the sternal region;~Scalene: with one hand on the occipital region and the other in the sternum, the two points was stretched;~Pectoralis major: the arm was abducted, flexed the forearm and hand was in the occipital region the therapist hands in the arm and in the side of the upper chest, which was stretched craniocaudal direction;~Intercostal: therapist performs with both hands to mobilize and stretch the ribs in cranial-caudal directions."
3109528|NCT01826669|No Intervention|Rest|COPD patients were not submitted to any intervention, remaining at rest in the same place, position and time period to the treatment group.
3109529|NCT01826656|Other|post-menopausal osteoporotic women|Subjects of test group will follow a tooth extraction and they will perform a CBCT scan within 10 days from the extraction and after 3 months (+/-15 days)
3109530|NCT01826656|Active Comparator|non-osteoporotic post-menopausal women|Subjects of the control group will follow a tooth extraction and will perform a CBCT scan within 2 days from the extraction and after 3 months (+/- 2 days)
3109531|NCT01826630|Active Comparator|CLn BodyWash|CLn BodyWash will be used to wash hands of patients with Hand Atopic Dermatitis
3109532|NCT01826630|Active Comparator|Cetaphil Daily Facial Cleanser|Cetaphil Daily Facial Cleanser will be used to wash hands of patients with Hand Atopic Dermatitis
3109533|NCT01826617||Prostate Cancer- Indolent type|Patients diagnosed with Indolent type will be classified according to Epstein Criteria on histopathology results and National Comprehensive Cancer Network (NCCN) guideline recommended classification
3109534|NCT01826617||Prostate cancer- aggressive type|Patients diagnosed with aggressive type will be classified according to Epstein criteria on final histopathology findings and NCCN guideline recommended classification
3109535|NCT01826617||Acute Prostatitis|Patient diagnosed with Acute prostatitis- according to histopathology description of Biopsy result
3109536|NCT01826617||Chronic Prostatitis|Patient diagnosed with Chronic prostatitis- according to histopathology description of Biopsy result
3109537|NCT01826617||Benign Prostatic Nodular Hyperplasia|Patient diagnosed with Benign Prostatic Nodular Hyperplasia- according to histopathology description of Biopsy result
3109538|NCT01826604|Experimental|Alexis O C-section retractor|Alexis O C-section retractor will be used.
3109539|NCT01826604|Other|Control- Conventional retractors|Conventional retractors for C-sections will be used.
3109540|NCT01826591|Experimental|Experimental: Low-Carbohydrate Diet|Healthy, Low-Carbohydrate Diet
3109541|NCT01826591|Experimental|Experimental: Low-Fat Diet|Healthy, Low-Fat Diet
3109542|NCT01826578|Experimental|single port arm|
3109543|NCT01826578|No Intervention|Conventional arm|Using 3-4 port for laparosocpic surgery
3109544|NCT01826565|No Intervention|Control|i-gel will be inserted without rotation
3109545|NCT01826565|Experimental|Rotation|Rotational technique applied
3109546|NCT01826552|Experimental|Orsiro|The Patient group who are treated with Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
3109547|NCT01826552|Active Comparator|Resolute Integrity|The Patient group who are treated with ② Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
3109548|NCT01826539|Other|Innervated finger flap|donor nerve attached with the flap for finger pulp reconstruction
3109549|NCT01826526|Active Comparator|TauroSept®|"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months."
3109550|NCT01826526|Placebo Comparator|Saline solution 0.9%|"5 ml of saline will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of saline administration in this trial will be 12 months."
3109551|NCT01826513|Experimental|Unblinded Investigational Arm|Participants participated in an unblinded investigational phase of the trial prior to, and separate from, the single-blind cross-over phase of the trial. Data was collected from the his phase to aid the final development of the algorithm before proceeding to algorithm validation (ie. cross-over phase).
3109552|NCT01826513|Active Comparator|Standard AutoSet algorithm|Participants first received therapy with the Standard AutoSet algorithm for one night, and then received therapy with the Modified AutoSet algorithm (an AutoSet device with an algorithm developed for sleep breathing parameters specific to females) the following night.
3109553|NCT01826513|Experimental|Modified AutoSet algorithm|Participants first received therapy with the Modified AutoSet algorithm (an AutoSet device with an algorithm developed for sleep breathing parameters specific to females) for one night, and then received therapy with the standard AutoSet algorithm the following night.
3109554|NCT01826500||Patients|"Patients having any of the following criteria:~Patients with embryo transfer fresh or frozen~Patients from an IVF cycle,~Patients supported surgically for endometriosis"
3109555|NCT01826500||Controls|Controls
3109556|NCT01826487|Active Comparator|Ataluren|10, 10, 20 mg/kg
3109557|NCT01826487|Placebo Comparator|Placebo|Matching placebo
3109558|NCT01826474|Experimental|PRO045, cohort 1|0.15 mg/kg until dose-titration
3109559|NCT01826474|Experimental|PRO045, cohort 2|1.0 mg/kg until dose-titration
3109560|NCT01826474|Experimental|PRO045, cohort 3|3.0 mg/kg until dose-titration
3109561|NCT01826474|Experimental|PRO045, cohort 4|6.0 mg/kg until dose-titration
3109562|NCT01826474|Experimental|PRO045, cohort 5|9.0 mg/kg until move to 48 week treatment phase
3109566|NCT01826461|Placebo Comparator|Vehicle Foam|topical foam, 0% concentration, twice daily
3109567|NCT01826448|Experimental|Dose extension cohort|Patients will take PLX3397 and vemurafenib at the recommended phase 2 dose. This will be determined by the tolerability and safety of these drugs in the previous 3 cohorts.
3109568|NCT01826448|Experimental|Cohort 3|Patients will take 1000mg/day of PLX3397 and 960mg BID of vemurafenib
3109569|NCT01826448|Experimental|Cohort 2|Patients will take 800mg/day of PLX3397 and 960mg BID of vemurafenib
3109570|NCT01826448|Experimental|Cohort 1|Patients will take 800mg/day of PLX3397 and 720mg BID of vemurafenib
3109571|NCT01826435|Experimental|Electronic Intervention|Over the three months, participants will receive a technology intervention. This will include text or email encounter notifications associated with appropriate mobile or online self-management information for medication adherence and behavior change.
3109572|NCT01826422|Experimental|EPA and DHA|Supplementation of 2.7 g/d of EPA and DHA were provided in 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes were specially for children to improved the feeding process and its presentation is in gelatin capsules. The supplement is purified fish oil with pharmaceutical grade.
3109573|NCT01826422|Placebo Comparator|Placebo Comparator|Supplementation of placebo with sunflower fatty at doses of 2.7 g/d were provided in 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes are specially for children to improved the feeding process. This placebo is sunflower oil, so, it did not present anti-inflammatory or insulin sensitivity effects.
3109574|NCT01826409|Experimental|Fermented red ginseng|
3109575|NCT01826409|Placebo Comparator|Placebo|
3109576|NCT01826396|Experimental|high dose irinotecan|high dose irinotecan based on UGT1A1 genotype, 5-fluorouracil, and leucovorin (FOLFIRI) for first-line treatment of locally advanced colon cancer
3109577|NCT01826383|Experimental|Active Video|This is a five-minute video that coaches parents about how to soothe their infant post-immunization.
3109578|NCT01826383|Placebo Comparator|Placebo Video|This is a video identical to that of the active video, except no specific instructions regarding how to soothe an infant post-immunization are given.
3109579|NCT01826370||Linagliptin|
3109580|NCT01826331|No Intervention|Control Group|Participants will be incentivized for assessments only
3109581|NCT01826331|Experimental|Incentives for Participation|Participants will be incentivized for each assessment and for each smoking cessation session they complete
3109582|NCT01826331|Experimental|Incentives for Cessation|Participants will be incentivized for each assessment and biochemically confirmed abstinence at 12 and 24 months
3109583|NCT01826318|Experimental|intervention|"Participants received a 10 minute instruction to cope with stress by loudly posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention group)"
3109584|NCT01826318|No Intervention|Control|Students in the control group did not receive any further instructions.
3109585|NCT01826305|Active Comparator|Formal Rehabilitation Therapy|Patients randomized to the formal rehabilitation therapy cohort will receive a prescription for therapy for twelve weeks following their primary knee replacement.
3109586|NCT01826305|Experimental|Independent Exercise Cohort|Patients randomized to the independent exercise cohort will receive online access to a twelve-week protocol of exercises to perform at home to strengthen and improve function of the replaced knee.
3109587|NCT01826279|Experimental|Resveratrol|Resveratrol 500mg 3 times daily for 1 month
3109588|NCT01826279|Placebo Comparator|Placebo|Placebo 1 tablet 3 times daily for 1 month
3109589|NCT01826266|Placebo Comparator|PER977-Dose 1|Dose titration
3109590|NCT01826266|Placebo Comparator|PER977-Dose 2|Dose Titration
3109591|NCT01826266|Placebo Comparator|PER977-Dose 3|Dose Titration
3109592|NCT01826266|Placebo Comparator|PER977-Dose 4|Dose Titration
3109593|NCT01826266|Placebo Comparator|PER977-Dose 5|Dose Titration
3109594|NCT01826266|Placebo Comparator|PER977-Dose 6|Dose Titration
3109595|NCT01826266|Placebo Comparator|PER977-Dose 7|Dose Titration
3109596|NCT01826253||Hypovolemia|Fluid expansion
3109597|NCT01826240|Experimental|MBCT+SPI|Note: There is only one condition in this study. Mindfulness-Based Cognitive Therapy (MBCT) is combined with Safety Planning Intervention (SPI). All individuals who choose to participate will receive MBCT+SPI.
3109598|NCT01826227|Experimental|Positron Emission Tomography|This is a pilot study to determine the ability of intraoperative PET probe to detect and localize recurrent disease. Patients with evidence for a first recurrence of ovarian, fallopian tube or primary peritoneal carcinoma, with evidence of 18F-FDG avid disease on 18F-FDG PET/CT and who are able to undergo secondary CRS are eligible. 20 patients will be studied. All patients will undergo secondary cytoreduction guided by intraoperative PET probe survey. Intraoperative count levels as well as exvivo counts of the resected specimens will be done. Specimens detected with probe only will be labeled so and will be submitted to pathology for histopathologic confirmation.
3109599|NCT01826214|Experimental|LDE225-400|Patients who were randomized to Schedule A, and received 400 mg LDE225 twice daily for the first two weeks only and then after two weeks, received 800 mg LDE225 once daily until disease progression, toxicity, withdrawal of consent, death, discretion of the investigator or early termination of the study.
3109600|NCT01826214|Experimental|LDE225-800|Patients who were randomized to Schedule B, received 800 mg LDE225 once daily until disease progression, toxicity, withdrawal of consent, death, discretion of the investigator or early termination of the study.
3109601|NCT01826201|Experimental|10% MOL4239 ointment & placebo ointment|10% MOL4239 ointment to one target lesion and placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
3109602|NCT01826188|Active Comparator|THC 5 mg/ml and CBD 50 mg/ml.|olive oil containing THC 5 mg/ml and CBD 50 mg/ml. which will be taken twice daily.
3109603|NCT01826188|Placebo Comparator|Placebo|olive oil but without any active ingredients.
3109604|NCT01826175|Experimental|Ticagrelor|Subjects receive 180 mg of ticagrelor immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
3109605|NCT01826175|Active Comparator|Clopidogrel|Subjects receive 600 mg of clopidogrel immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
3109606|NCT01826162|Experimental|sigmoidoscopy|2 actetate concentrations and 1 placebo are administered in randomized order after clipping a catheter in the proximal colon (sigmoidoscopy)
3109607|NCT01826162|Experimental|colonoscopy|2 actetate concentrations and 1 placebo are administered in randomized order after clipping a catheter in the distal colon (colonoscopy)
3109608|NCT01826149|Experimental|Propofol 1.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 1.0mcg/ml using target controlled infusion.
3109609|NCT01826149|Experimental|Propofol 2.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 2.0mcg/ml using target controlled infusion.
3109610|NCT01826149|Experimental|Propofol 3.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 3.0mcg/ml using target controlled infusion.
3109611|NCT01826136|Experimental|Acapella|use of the Acapella device postoperatively
3109612|NCT01826136|No Intervention|Control|
3109613|NCT01826123|Active Comparator|Conventional laboratory testing|"After being randomized to the group conventional coagulating testing, hemostatic therapy will be based exclusively on conventional standard coagulation analyses like International normalized ratio (INR), activated prothrombin time (aPTT), fibrinogen and platelet concentration or Activated clotting time (ACT. Analyses will be performed at i) fixed time points (preoperative and at admission to ICU) and ii) variable timepoints depending on the decision of the attending physician. Hemostatic therapy will be based on a specific hemostatic therapy algorithm. Intraoperatively, analyses of ACT (activated clotting time) and INR will be performed following institutional standards using specific POC tests."
3109614|NCT01826123|Active Comparator|POC testing (ROTEM and Multiplate)|"After being randomized to the group POC testing, hemostatic therapy will be based exclusively on POC measures obtained by i) viscoelastic tests (ROTEM(R), TEM international, Munich, Germany) and aggregometric tests (multiplate, ROCHE AG, Grenzach, Germany). Analyses will be performed at variable timepoints depending on the decision of the attending physician. Hemostatic therapy will be based on a specific hemostatic therapy algorithm. Intraoperatively, analyses of ACT (activated clotting time) and INR will be performed following institutional standards using specific POC tests."
3109615|NCT01826110|Experimental|[11C]PIB|[11C]PIB
3109616|NCT01826097|Experimental|Vibration|Whole body vibration applied to a group of 20 bladder cancer patients.
3109617|NCT01826071|No Intervention|Symptomatic Treatment|
3109618|NCT01826071|Experimental|Static Stretch|Home exercise program with static stretching
3109619|NCT01826071|Experimental|Active Elongation|Home exercise program with active elongation exercises
3109620|NCT01826058|Experimental|Stereotactic body radiation therapy|"SBRT in one to four fractions~Irradiated total RT dose to gross tumor volume (GTV) according to fraction size~1 fx: 16 to 24 Gy~2 fx's: 20 to 26 Gy~3 fx's: 21 to 30 Gy~4 fx's: 24 to 36 Gy"
3109621|NCT01826045|Experimental|Poly-gamma Glutamic Acid|Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered Poly-gamma Glutamic Acid for 4 weeks.
3109622|NCT01826045|Placebo Comparator|Placebo|Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered placebo for 4 weeks.
3109623|NCT01826032|Experimental|CPAP|"Patients with CPAP treatment. Titration will be performed by polysomnography or automatic CPAP to determine the optimal treatment pressure.~This group will also be instructed in hygienic-dietary measures and sleep hygiene counselling."
3109624|NCT01826032|Active Comparator|Standard care for OSA|Sleep hygiene ( regular sleep schedule, avoid sedative drugs, alcohol and tobacco, physical exercise) and dietary counselling
3109625|NCT01826019|Experimental|Intervention|Intensive CV risk detection, counselling and follow-up program by NPHW; recommended CV medications will include combinations of anti-hypertensive medications (both low and high doses) and a lipid lowering agent (e.g. statin) in accordance with treatment algorithm [precise formulations used may differ in each country]; use of treatment supporters to reinforce adherence.
3109626|NCT01826019|Other|Control - Usual Care|Participants in control communities will be referred to usual care.
3109627|NCT01826006|Active Comparator|Excimer laser|After wire crossing, Excimer Laser will be performed. Consequently, intracoronary adenosine will be selectively administered through the guiding catheter.
3109628|NCT01826006|Active Comparator|Manual Thrombus Aspiration|After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary adenosine will be selectively administered.
3109629|NCT01825993|Experimental|PCA endovenous|1mg/10 min Morphine
3109630|NCT01825993|Active Comparator|PERIDURAL CATHETER|Peridural L-bupivacaine 0.25%
3109631|NCT01825993|Active Comparator|TANSABDOMINAL BLOCK (TAP)|L-BUPIVACAINE im
3109632|NCT01825980|Experimental|BZF961|
3109633|NCT01825980|Placebo Comparator|Placebo|
3109634|NCT01825967||Acute Diverticulitis|We measured C-reactive protein in all the patients diagnosed with acute diverticulitis
3109635|NCT01825954|Active Comparator|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device
3109636|NCT01825954|Active Comparator|8-week RINCE|RINCE - active RINCE therapy involving 16 total treatment applications from NeuroPoint device, followed by 8 sham applications from the NeuroPoint device
3109637|NCT01825954|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
3109638|NCT01825941|Active Comparator|Metoclopramide + Diphenhydramine|Metoclopramide 10 milligrams + Diphenhydramine 50 milligrams, administered as an intravenous drip over 15 minutes
3109639|NCT01825941|Placebo Comparator|Metoclopramide + placebo|Metoclopramide 10mg + placebo, administered intravenously over 15 minutes
3109640|NCT01825928|Experimental|paliperidone|paliperidone arm,3mg/pill,3mg/day.last84 days.
3109641|NCT01825928|Placebo Comparator|placebo|placebo group,3mg/pill,3mg/day non-forced titration method,last84 days.
3109642|NCT01825915|Active Comparator|Laparoscopic Hysterectomy|Laparoscopic hysterectomy involving removal of both uterine corpus and cervix
3109643|NCT01825915|Active Comparator|Laparoscopic Supracervical Hysterectomy|Laparoscopic hysterectomy involving removal of the uterine corpus alone with conservation of the cervix.
3109644|NCT01825902|Experimental|Diagnostic (18F-FLT PET, 18F-FDG PET, DW-MRI)|Patients undergo 18F-FLT PET, 18F-FDGPET, and DW-MRI the week prior to induction therapy, within one week after the completion of induction therapy, the week prior to RT (for patients that received surgery), and within 1 week of completion of RT.
3109645|NCT01825889|Experimental|Evacetrapib (Renal)|Part A: 130 mg evacetrapib administered once, orally to participants with severe renal impairment
3109646|NCT01825889|Experimental|Evacetrapib (Healthy)|Part B: 130 mg evacetrapib administered once, orally, to participants with normal renal function
3109647|NCT01825876|Active Comparator|Warfarin|15 milligram (mg) warfarin administered as a single oral dose
3109648|NCT01825876|Experimental|Evacetrapib + Warfarin|130 milligram (mg) evacetrapib administered once daily (QD), orally, for 16 days with 15 milligram (mg) warfarin co-administered once orally on Day 10
3109649|NCT01825863|Active Comparator|Active abdominal wall block|60ml ropivacaine 0.375% single shot
3109650|NCT01825863|Placebo Comparator|Placebo abdominal wall block|60ml saline 9% single shot
3109651|NCT01825850|Experimental|Gemigliptin|Gemigliptin 50mg q.d. during 7 days
3109652|NCT01825850|Experimental|Irbesartan|Irbesartan 300mg q.d. during 7 days
3109653|NCT01825850|Experimental|Gemiglitin + Irbesartan|Gemigliptin 50mg + Irbesartan 300mg q.d. during 7 days
3109654|NCT01825837|Experimental|BIA 2-093 1800 mg (Group 1)|BIA 2-093 1800 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
3109655|NCT01825837|Experimental|BIA 2-093 900 mg (Group 2)|BIA 2-093 900 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
3109656|NCT01825837|Experimental|BIA 2-093 300 mg (Group 3)|BIA 2-093 300 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
3109657|NCT01825837|Experimental|ESL (Part I)|In Part I, all participants received open-label treatment with BIA 2-093 900 mg once daily for 2 weeks.
3109658|NCT01825824|Experimental|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma with size ≤ 5 cm and 3cm apart from gastrointestinal tract after incomplete trans-arterial chemo-embolization
3109659|NCT01825811|Experimental|TissueGene-C (Low dose)|TissueGene-C (1.0 x 10^6 cells per cm^2 of the cartilage defect) combined with fibrin-glue
3109660|NCT01825811|Experimental|Experimental: TissueGene-C (High dose)|TissueGene-C (3.0 x 10^6 cells per cm^2 of the cartilage defect) combined with fibrin-glue
3109661|NCT01825798|Placebo Comparator|Placebo Hydrochloride Oral Solution|
3109662|NCT01825798|Experimental|Metformin|
3109663|NCT01825785|Placebo Comparator|Treatment A|16 subjects will be randomized to receive AMG 785 or placebo in a 3:1 ratio and will receive 6 doses of 1 mg/kg
3109664|NCT01825785|Placebo Comparator|Treatment B|16 subjects will be randomized to receive AMG 785 or placebo in a 3:1 ratio and will receive 3 doses of 3 mg/kg
3109665|NCT01825785|Placebo Comparator|Treatment C|8 subjects will be randomized to receive AMG 785 or placebo in a 3:1 ratio and will receive 6 doses of 2 mg/kg
3109666|NCT01825785|Placebo Comparator|Treatment D|8 subjects will be randomized to receive AMG 785 or placebo in a 3:1 ratio and will receive 3 doses of 2 mg/kg
3109667|NCT01825759|Experimental|danshen dripping pill|danshen dripping pill 27mg ten pills by mouth every 8 hours for one year
3109668|NCT01825746|Active Comparator|Early implementation practices|"9 practices that will initially field the MOHR assessment for up to 6 months. These practices will serve as intervention sites for the effectiveness outcomes measured by the patient experience survey."
3109669|NCT01825746|Other|Delayed implementation practices|"9 practices that will field the MOHR assessment for up to 6 months but starting 4 months after the early implementation practices. These practices will serve as control sites for the effectiveness outcomes measured by the patient experience survey. However, they will provide intervention data with respect to Reach and cost during the delayed phase."
3109670|NCT01825733|Experimental|ramosetron|
3109671|NCT01825733|Active Comparator|palonosetron|
3109672|NCT01825720|Experimental|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
3109673|NCT01825720|Active Comparator|normal saline group|same rate of normal saline
3109674|NCT01825707|Experimental|[14C]-YH4808 200 mg|[14C]-YH4808 200 mg
3109675|NCT01825694|No Intervention|Standard of Care|The Standard of Care condition includes: 1) an individual session with the counselor, once per week; 2) a treatment group with the counselor, twice per week; and 3) parents of youth are invited to attend parent-only educational sessions weekly.
3109676|NCT01825694|Experimental|Trauma-focused Substance Abuse Intervention|See Intervention Arm description.
3109677|NCT01825681|Experimental|positive affect intervention|positive affect intervention
3109678|NCT01825681|No Intervention|wait list control|wait list control
3109679|NCT01825668|Experimental|High cholesterol|600 mg cholesterol/day in 240 ml milk shake
3109680|NCT01825668|Experimental|Plant sterols|2.0 g of plant sterols/day in 240 ml milk shake containing 50 mg cholesterol
3109681|NCT01825668|Placebo Comparator|Placebo|50 mg cholesterol/day in 240 ml of milk shake
3109682|NCT01825655|Active Comparator|Cetirizine|zyrtec 10mg, oral, one time
3109683|NCT01825655|Placebo Comparator|Sugar pill|Placebo, one pill, one time
3109684|NCT01825642|Active Comparator|Control Group|nerve-sparing radical prostatectomy
3109685|NCT01825642|Active Comparator|Treatment Group|seminal vesicle-sparing radical prostatectomy
3109686|NCT01825629|Experimental|Multidisplinary Therapy|The multidisciplinary therapy involves the application of physical therapy, manual therapy and deontology therapy. This multidisciplinary therapy will be administered twice a week for 15 weeks.
3109687|NCT01825629|Placebo Comparator|One technique of myofascial release|"A physiotherapist administered 15 sessions of induction occipital once a week."
3109688|NCT01825616|Experimental|Vitamin D2 mushroom powder|4000 IU/day vitamin D2 mushroom powder
3109689|NCT01825616|Placebo Comparator|Placebo|Mushroom powder without vitamin D2 (not exposed to UV radiation)
3109690|NCT01825603|Experimental|Treatment (ADH-1, cisplatin, gemcitabine hydrochloride)|Patients receive ADH-1 IV over 20-80 minutes on days 1, 4, 8, 11, 15, and 18, cisplatin IV and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease may receive maintenance therapy with cisplatin and gemcitabine hydrochloride.
3109691|NCT01825590||Subjects undergoing sodium alignment|Dialysate and serum sodium concentration aligned
3109692|NCT01825590||Subjects not undergoing sodium alignment|Dialysate and serum sodium concentration not aligned
3109693|NCT01825577|Experimental|Transdermal Methylphenidate|2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
3109694|NCT01825551|Active Comparator|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor 10 microgram/ kg/ day for 5 days subcutaneously
3109695|NCT01825551|Placebo Comparator|Placebo|normal saline 0.01 ml/kg/day for 5 days subcutaneously
3109696|NCT01825538||COPD, pulmonary fibrosis|observational study, no interventions to be administered
3109697|NCT01825525|Experimental|Cardiac device patients.|Exposure to ScopeGuide - patients with cardiac devices exposed to ScopeGuide as per study protocol
3109698|NCT01825512|Experimental|Deferiprone|75-100 mg/kg/day seven days per week
3109699|NCT01825512|Active Comparator|Deferasirox|20 to 40 mg/kg/day seven days per week
3109700|NCT01825499||Very low birth weight infants|Infants 401 to 1500 g or 22 to 29 weeks gestational age admitted to Vermont Oxford Network member centers within 28 days of birth
3109701|NCT01825486||accidental falls|
3109702|NCT01825473|Experimental|Erythromycin|50 mg/kg/day divided every 6 hours oral for 7 days
3109703|NCT01825473|Placebo Comparator|Placebo|Dextrose 5 Water (D5W) equal amount as experimental every 6 hours oral for 7 days
3109704|NCT01825460|Experimental|Manual Therapy Protocol|A protocol with five techniques on thoracic area applied twice a week.
3109705|NCT01825460|Active Comparator|Two manual techniques|Two manual therapies on thoracic area applied twice a week.
3109706|NCT01825447|Placebo Comparator|Treatment A|
3109707|NCT01825447|Experimental|Treatment B|
3109708|NCT01825447|Active Comparator|Treatment C|
3109709|NCT01825434|Active Comparator|Treatment Group|yogurt containing polydextrose, L. acidophilus NCFM® (ATCC 700396) and B. lactis HN019 (AGAL NM97/09513) 1 time per day, for 30 days.
3109710|NCT01825434|Placebo Comparator|Placebol group|regular yogurt, 1 time per day for 30 days.
3109711|NCT01825421|No Intervention|Control (continue antibiotics) group|The antibiotics will be continued for at least another 24h i.e. for 48h, pending blood culture results at 48h, as per standard practice in the NICU.
3109712|NCT01825421|Active Comparator|Study (discontinue antibiotics) group|The intervention is to discontinue antibiotics at 24h, and he/she will be kept under observation in the NICU for at least an additional 24h, pending blood culture results at 48h.
3109713|NCT01825408|Active Comparator|Doxycycline, 3 weeks|Subjects with chronic rhinosinusitis with nasal polyps (CRSwNP) will receive Doxycycline 100mg BID or if allergic to doxycycline, then Augmentin 875mg BID for 3 weeks duration. These patients will also receive a course of Prednisone (30mg x 3d, 20mg x 3d, 10mg x3d, 10mg every other day for 6 days (3 doses)) which is standard of care treatment for patients with chronic sinusitis with nasal polyps.
3109714|NCT01825408|Active Comparator|Doxycycline, 6 weeks|Subjects with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)will receive Doxycycline 100mg BID or if allergic to doxycycline, then Augmentin 875mg BID for 6 weeks duration. These patients will also receive a course of Prednisone (30mg x 3d, 20mg x 3d, 10mg x3d, 10mg every other day for 6 days (3 doses)) which is standard of care treatment for patients with chronic sinusitis with nasal polyps.
3109715|NCT01825408|Active Comparator|Azithromycin, 3 weeks|Subjects with Chronic Rhinosinusitis without Nasal Polyps will receive Azithromycin 250mg daily, or if allergic to azithromycin, then Augmentin 875mg BID for 3 weeks duration.
3109716|NCT01825408|Active Comparator|Azithromycin, 6 weeks|Subjects with chronic Rhinosinusitis without Nasal Polyps will receive Azithromycin 250mg daily, or if allergic to azithromycin, then Augmentin 875mg BID for 6 weeks duration.
3109717|NCT01825382|No Intervention|Accu-chek Meter|Patients receiving the Accu-chek nano meter for use during the study.
3109718|NCT01825382|Experimental|iBGStar meter interventional Arm|Subjects are given iBGstar meter along with iPhone to use as interventional meter.
3109719|NCT01825369|Experimental|IV L-carnitine|L-carnitine (25, 50, or 100mg/kg IV) will be given, 30-60 minutes prior to the initiation of CPB, and a second dose ~2 hr. following separation from CPB (with a minimum of 4 hrs from initial dose). The first 5 subjects will receive 25 mg/kg, with an escalation of dose after each 5 subjects enrolled. The study drug will be brought to the operating room and administered over 5 minutes by the anesthesiologist after an IV has been placed. Prior to the administration of the study drug, and again 24 and 48 hrs after CPB, 3.0 ml of blood will be collected for determinations of carnitine levels (free, total, and acylcarnitine), mitochondrial function, ROS and bioavailable NO as described in Aim 3A. Additional blood (0.5-1.0 ml) will be obtained to determine carnitine levels before CPB, and then before and 0.5, 1.5, 3, 5, 9, 12, and 24h after the second dose.
3109720|NCT01825356|Active Comparator|Dorsal Cheilectomy no Amniotic Membrane Tissue Implantation|Dorsal cheilectomy is a surgery for hallux rigidus(degenerative arthritis and stiffness due to bone spurs that affect the joint at the base of the big toe). No amniotic membrane will be used for this group.
3109721|NCT01825356|Experimental|Dorsal Cheilectomy-Amniotic Membrane Tissue Implantation|Dorsal cheilectomy procedure with the addition of the amniotic membrane. Amniotic membrane represents a biologic therapy that has the ability to actively regulate myrofibroblast formation and activity within the joint space and surgical site
3109722|NCT01825330|Active Comparator|NeuroAD|NeuroAD treatment, synchronized TMS and cognitive training stimulation
3109723|NCT01825330|Sham Comparator|Sham TMS+Cog|Sham device, has the same appearance and sound as the real device, combined with sham cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
3109724|NCT01825317|Active Comparator|NeuroAD|Treatment by the NeuroAD device, real treatment by synchronized TMS+cognitive training
3109725|NCT01825317|Sham Comparator|Sham NeuroAD|Sham TMS+cog, has the same sound and appearance, patients come for the same number of treatments and are exposed to the same procedure.
3109726|NCT01825304|Active Comparator|esophageal pressure ,titrated setting|
3109727|NCT01825304|Other|ARDSNet recommendations,peep|
3109728|NCT01825291||sleep apnea|
3109729|NCT01825278||Single group, obese surgical patients with monitoring strip|All eligible patients will have a monitoring strip prospectively applied to their right chest
3109730|NCT01825265|Experimental|RAD001 + Docetaxel|RAD001 30 mg orally on Days 1 and 8. Docetaxel 40 mg/m^2 intravenous (IV) over 1 hour on Day 1. Dexamethasone 8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
3109731|NCT01825252|Experimental|Social Network Intervention|Approximately 20% of people in this condition will be trained to have discussions endorsing less risky behaviors with their social network members.
3109732|NCT01825252|Active Comparator|Counsel, Test, and Treat|People in this arm will only receive standard-of-care counseling, testing, and treatment for HIV and STDs.
3109733|NCT01825239|Other|Electrophysiology Study|This is a single arm study, all study participants will be referred for an Electrophysiology Study
3109734|NCT01825226|Experimental|Program participation|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
3109735|NCT01825226|No Intervention|Control|
3109736|NCT01825213||Multispectral CT of the liver|Images of lesions and liver will be compared to histology.
3109737|NCT01825200|Active Comparator|Flublok|Flublok containing 3x45µg (135µg total) of recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL
3109738|NCT01825200|Placebo Comparator|Afluria|Afluria, containing 3x15µg (45µg total), of trivalent, inactivated influenza vaccine (licensed IIV) containing influenza antigen derived from A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL
3109739|NCT01825187|Active Comparator|Treatment Group 1|Patients in this group will be randomized to receive the ULTRAPRO mesh
3109740|NCT01825187|Active Comparator|Treatment Group 2|Patients in this group will be randomized to receive the 3DMAX Mesh
3109741|NCT01825187|Other|Evaluation of Surgical Residents|Surgical residents will be evaluated on the ease of use and the amount of time it takes for them to perform the surgery using these two different meshes.
3109742|NCT01825174|Active Comparator|Non-overweight children in ball games program|twice a week different ball games 90min
3109743|NCT01825174|Experimental|Overweight children in nutrition counseling program|9 units of 90min each of nutrition counseling
3109744|NCT01825174|Placebo Comparator|Control group overweight children|No intervention during six months
3109745|NCT01825174|Experimental|Overweight children in ball games program|twice a week different ball games 90min
3109746|NCT01825174|Experimental|Overweight children in ball games and nutrition counseling|twice a week different ball games 90min and 9 units of 90min each of nutrition counseling
3109747|NCT01825174|Placebo Comparator|Non-overweight control (no intervention)|
3109748|NCT01825148||Type 1 Diabetes|patients with long standing T1D
3109749|NCT01825148||Healthy volunteer|healthy volunteers with normal glucose tolerance
3109750|NCT01825135|Experimental|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) will be applied to the quadriceps muscles for 30 minutes
3109751|NCT01825135|Sham Comparator|Sham stimulation|Sham stimulation will be applied to the quadriceps for 30 minutes
3109752|NCT01825122|Placebo Comparator|Placebo|placebo
3109753|NCT01825122|Experimental|Active, nadolol|Active
3109754|NCT01825109|Experimental|6 weeks RV & normal breast feeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
3109755|NCT01825109|Experimental|6 weeks RV & delayed breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
3109756|NCT01825109|Experimental|14 weeks RV & Normal breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
3109757|NCT01825109|Experimental|14 weeks RV & delayed breastfeedin|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
3109758|NCT01825096||baseline|No intervention. Participants are scanned at baseline.
3109759|NCT01825083|Active Comparator|Ketamine|Ketamine administered 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.
3109760|NCT01825083|Placebo Comparator|Placebo|Saline group will received the same volume in saline as the ketamine dose
3109761|NCT01825070|Experimental|low dose|Montmorency cherry concentrate, 30 mls
3109762|NCT01825070|Experimental|higher dose|Montmorency cherry concentrate, 60 mls
3109763|NCT01825057|Active Comparator|Workshop (See One)|MI workshop training (referred to as SEE ONE).
3109764|NCT01825057|Experimental|Workshop plus live supervision (Do One)|MI workshop training plus live supervision of bedside practice (DO ONE).
3109765|NCT01825057|Experimental|Workshop plus consultation-liason service (Order One)|MI workshop training plus capacity to order MI from CL (ORDER ONE).
3109766|NCT01825044|Active Comparator|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
3109767|NCT01825044|Active Comparator|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
3109768|NCT01825031|Experimental|Antiretroviral Therapy|Raltegravir twice daily for 12 weeks from antiretroviral therapy (ART) initiation in addition to 3 standard ARVs (2NRTIs/1NNRTI) compared with 3 standard ARVs
3109810|NCT01824823|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD on days 1-28.
3109890|NCT01824264|Experimental|LIK066 10 mg|Patients receive 10 mg of LIK066 once daily for 12 weeks
3109769|NCT01825031|Experimental|Opportunistic Infection (OI) Prophylaxis|Immediate isoniazid/pyridoxine and cotrimoxazole, plus 12 weeks fluconazole, 5 days azithromycin and a single dose of albendazole compared with immediate cotrimoxazole (if not already taking this) in all patients plus (not malawi)isoniazid/pyridoxine after 12 weeks.
3109770|NCT01825031|Experimental|Nutritional Support|Supplementation with Ready to Use Supplementary Food (RUSF) for 12 weeks compared with supplementation for those with severe malnutrition as local practice.
3109771|NCT01825018|Experimental|Social Network Leader Endorsement|Leaders of social networks randomized to this arm will be taught to endorse compliance with medical guidelines, safer behaviors, and effective ways to communicate these concepts to social network members.
3109772|NCT01825018|Active Comparator|Comparison Group|Members of social networks assigned to this group will receive only HIV counseling at the baseline session.
3109773|NCT01825005||group 1:surgery|treatment = surgery only
3109774|NCT01825005||group 2: radiotherapy|treatment = radiotherapy only
3109775|NCT01825005||group 3: RT and CT, and/or hyperthermia|treatment= radiotherapy combined with chemotherapy and/or hyperthermia
3109776|NCT01825005||group 4: stage IVb , any treatment|cervical cancer stage IV b, treatment = any systemic or radiation therapy and supportive care
3109777|NCT01824992|No Intervention|Observation|subject only got observation
3109778|NCT01824992|Experimental|Drug|subject were treated with Yallaferon®， the recombinant human interferon α-2b gel
3109779|NCT01824979|Experimental|Pilairo mask|Pilairo nasal pillows mask during CPAP titration
3109780|NCT01824979|Active Comparator|Other CPAP mask|Other CPAP mask during CPAP titration
3109781|NCT01824966||SRC<50%|Adenocarcinoma containing < 50% of signet ring cells
3109782|NCT01824966||SRC>50%|Adenocarcinoma containing > 50% of signet ring cells
3109783|NCT01824953||atrophy-/Hp- group|Subjects without Helicobacter pylori infection and without atrophy
3109784|NCT01824953||atrophy-/Hp+|Subjects with Helicobacter pylori infection and without atrophy
3109785|NCT01824953||atrophy+/Hp+|Subjects with Helicobacter pylori infection and with atrophy
3109786|NCT01824953||atrophy+/Hp-|Subjects without Helicobacter pylori infection and with atrophy
3109787|NCT01824940|Placebo Comparator|Standard of Care|The Standard of Care interventions are the blanket interventions.
3109788|NCT01824940|Active Comparator|WASH|"One of two active interventions to be studied in this 2X2 (two by two) Factorial trial:~Intervention 1: a package of interventions to improve household sanitation and hygiene (WASH)"
3109789|NCT01824940|Active Comparator|Nutrition|"One of two active interventions to be studied in this 2X2 Factorial trial:~Intervention 2: a package of interventions to improve infant and young child feeding (IYCF)"
3109790|NCT01824940|Active Comparator|WASH and Nutrition|This arm receives a combination of all standard care interventions, all WASH and all IYCF interventions.
3109791|NCT01824927|Active Comparator|First eye (FE)|Phacoemulsification cataract extraction surgery of first eye
3109792|NCT01824927|Active Comparator|Second eye (SE)|Phacoemulsification cataract extraction surgery of second eye
3109793|NCT01824927|Experimental|Steroids eye drops|Dexamethasone eye drop, 1 drop, qid, for 3 days before surgery
3109794|NCT01824914|Experimental|McGrath Videolaryngoscope|to compare the Cormack-Lehane grade in sedation and anesthesia by McGrath videolaryngoscope
3109795|NCT01824901|Experimental|Phase I|Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 2-15 of course 1 and days 1-14 of all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3109796|NCT01824901|Experimental|Arm I (docetaxel; phase II step I)|Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who experience progressive disease may then register to step II treatment and receive FGFR inhibitor AZD4547 PO BID on days 1-14.
3109797|NCT01824901|Experimental|Arm II (docetaxel and AZD4547; phase II step I)|Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 1-14. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3109798|NCT01824901|Experimental|Phase II step II|Patients receive FGFR inhibitor AZD4547 PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3109799|NCT01824888|Active Comparator|Control|Following standard one-minute handwashing, both hands were immersed up to the mid-metacarpals for 5 seconds into a contamination fluid containing E. coli. Handrubs were performed by using 60% propan-2-ol into the cupped hands and rub vigorously for 30 seconds, the procedure was completed by a 5 seconds rinse of the fingers under running tap water and excess water was shaken off.
3109800|NCT01824888|Experimental|JUC solution|Following standard one-minute handwashing, both hands were immersed up to the mid-metacarpals for 5 seconds into a contamination fluid containing E. coli. Handrubs were performed by pouring 1.5 ml of JUC into the cupped hands and rub vigorously for 30 seconds, the procedure was completed by a 5 seconds rinse of the fingers under running tap water and excess water was shaken off.
3109801|NCT01824875|Experimental|Arm A (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
3109802|NCT01824875|Experimental|Arm B (temozolomide and capecitabine)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
3109803|NCT01824862||eyes without diabetic retinopathy|eyes of patients with diabetes mellitus type 2 that does not have retinopathy
3109804|NCT01824862||CSME without centre involvement|eyes with CSME without thickening in the 500 µm adjacent to the centre of the macula
3109805|NCT01824862||CSME with centre involvement|eyes with CSME with thickening in the 500 µm adjacent to the centre of the macula
3109806|NCT01824849|Experimental|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients.
3109807|NCT01824849|Experimental|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients.
3109808|NCT01824836|Experimental|Supportive care (anastrozole)|Patients receive anastrozole PO QD for 12 months.
3109809|NCT01824823|Experimental|Arm A (afatinib)|Patients receive afatinib PO QD on days 1-28.
3109811|NCT01824810|Experimental|Intramuscular Stimulation|Participants in this group will receive up to 12 sessions of Intramuscular Stimulation (IMS). Each session may last from 30 to 60 minutes. Primary and secondary outcome measures will be assessed prior to the first treatment, after completion of the last treatment, and 6 months after treatment is complete.
3109812|NCT01824810|Experimental|myoActivation|Participants in this group will receive up to 12 sessions of myoActivation treatment. Each treatment is approximately 15 minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
3109813|NCT01824810|Experimental|Neural Prolotherapy|Participants in this group will receive up to 12 sessions of neural prolotherapy. treatment. Each treatment is approximately 30 to 60 minutes minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
3109814|NCT01824810|Sham Comparator|Sham Needling Control|Participants in this group will receive up to 12 sessions of sham needle treatment. Each treatment is approximately 15 to 60 minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
3109815|NCT01824797||Roux-en-Y Gastric Bypass|Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Serum will be collected from subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in bone metabolism.
3109816|NCT01824797||Sleeve Gastrectomy|Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Serum will be collected from subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in bone metabolism.
3109817|NCT01824758|Experimental|brevibloc (esmolol)|Group E will receive esmolol (1 mg/kg), Group L lidocaine (1.5 mg/kg)and Group C placebo(NaCl 0.9%, 5 mL)
3109818|NCT01824758|Active Comparator|Aritmal (Lidocaine)|Group E: esmolol (1 mg/kg) Group L: lidocaine (1.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)
3109819|NCT01824758|Placebo Comparator|Placebo (NaCl 0.9%, 5 ml)|Group E: esmolol (1 mg/kg) Group L: lidocaine (1.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)
3109820|NCT01824745|Experimental|Arm I (SCP-BCS template booklet and counseling)|Participants receive SCP-BCS template booklet and receive counseling sessions with a patient navigator for 40 minutes twice weekly for 4 sessions.
3109821|NCT01824745|Active Comparator|Arm II (SCP-BCS template booklet)|Participants receive SCP-BCS template booklet and receive standard follow-up care.
3109822|NCT01824732||Allergic group|All patients who used Tanreqing Injection have anaphylaxis.
3109823|NCT01824732||Control group|All patients who used Tanreqing Injection don't have anaphylaxis.One allergic group patient should matched four control group patients.
3109824|NCT01824719||Allergic group|All patients who used Reduning Injection have anaphylaxis.
3109825|NCT01824719||Control group|All patients who used Reduning Injection don't have anaphylaxis.One allergic group patient should matched four control group patients.
3109826|NCT01824706||craniectomy|craniectomy
3109827|NCT01824693|Experimental|Arm I (busulfan, cyclophosphamide, melphalan)|"CONDITIONING REGIMEN: Patients receive busulfan IV QD, every 12 hours, or every 6 hours over 2-3 hours on days -8 to -5, cyclophosphamide IV QD over 60 minutes on days -4 and -3, and melphalan IV over 15-30 minutes on day -1.~TRANSPLANT: Patients undergo allogeneic HCT no sooner than 24 hours after the last dose of chemotherapy.~Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor)."
3109828|NCT01824693|Experimental|Arm II (busulfan, fludarabine phosphate)|"CONDITIONING REGIMEN: Patients receive busulfan as in Arm I and fludarabine phosphate IV over 1 hour on days -5 to -2.~TRANSPLANT: Patients undergo allogeneic HCT as in Arm I.~Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor)."
3109829|NCT01824680|Experimental|obesity|
3109830|NCT01824667|Experimental|B-GOS|2.75g daily for 4 weeks
3109831|NCT01824667|Placebo Comparator|Maltodextrin|2.75g daily for 4 weeks
3109832|NCT01824654|Experimental|Rigid and Elastic registration softwares|
3109833|NCT01824641|Experimental|Eliminate|Eliminate aspiration catheter
3109834|NCT01824641|Active Comparator|Conventional primary angioplasty|Patients treated with conventional primary angioplasty
3109835|NCT01824628||• HIV positive subjects receiving antiretroviral regimen|
3109836|NCT01824628||• HIV negative subjects from the pre-admission surgical clinic|
3109837|NCT01824615|Experimental|Sunitinib|Use Sutent for treatment of recurrent / persisted OCCA
3109838|NCT01824602|Experimental|Group 1|Eslicarbazepine acetate 1800 mg
3109839|NCT01824602|Experimental|Group 2|Eslicarbazepine acetate 1200 mg
3109840|NCT01824602|Experimental|Group 3|Eslicarbazepine acetate 600 mg
3109841|NCT01824602|Placebo Comparator|Group 4|Placebo pills
3109842|NCT01824589|Active Comparator|Group A|tidal volume setting of 6ml/kg with the -7cm H2O ITPR as first device
3109843|NCT01824589|Active Comparator|Group B|tidal volume setting of 8ml/kg with the -7cm H2O ITPR as first device
3109844|NCT01824589|Active Comparator|Group C|tidal volume setting of 6ml/kg with the -12cm H2O ITPR as first device
3109845|NCT01824589|Active Comparator|Group D|tidal volume setting of 8ml/kg with the -12cm H2O ITPR as first device
3109846|NCT01824576|Experimental|ITPR|Use of the ITPR for 120 minutes.
3109847|NCT01824563||study population|Subjects will need to be standard CI patients acording to national implant criteria and the study criteria.
3109848|NCT01824550|Experimental|home-based exercise training condition|Home based endurance exercise training
3109849|NCT01824550|No Intervention|attention control condition|Attention control condition - home based flexibility training
3109850|NCT01824537|Active Comparator|HPV vaccine, Gardasil 9|HPV vaccine intervention: The intervention vaccine will be Gardasil 9, a 9-valent vaccine by Merck. This vaccine was chosen because it allows for the observation of 9 HPV outcomes (HPV 6, 11, 16 and18) (the other available vaccine, Cervarix, protects against HPVs 16 and 18, only).
3109851|NCT01824537|Placebo Comparator|Hepatitis A vaccine|"The placebo comparator will be Havrix, by GSK. This control vaccine was chosen because hepatitis A immunization provides a similar health prevention incentive as HPV vaccination to study participants while preserving the scientific cogency of a placebo comparator. Gardasil 9 requires administration of 3 doses, while Havrix only requires 2 doses. For this reason, a placebo injection (saline solution) will be added in between the Havrix vaccination regimen. Consequently, both treatment and control vaccines will have similar regimens, i.e., study entry, 2 months, and 6 months."
3109852|NCT01824524|Experimental|OROS Hydromorphone|
3109853|NCT01824511|Experimental|Smokers Cease Smoking|Participants are paid to quit smoking without using any medications.
3109854|NCT01824498|Experimental|Low Fat, High Fat, Low Fat High Omega 3|See Intervention Description
3109855|NCT01824498|Experimental|Low Fat, Low Fat High Omega 3, High Fat|See Intervention Description
3109856|NCT01824498|Experimental|High Fat, Low Fat, Low Fat High Omega 3|See Intervention Description
3109857|NCT01824498|Experimental|High Fat, Low fat High Omega 3, Low Fat|See Intervention Description
3109858|NCT01824498|Experimental|Low Fat High Omega 3, High Fat, Low Fat|See Intervention Description
3109859|NCT01824498|Experimental|Low Fat High Omega 3, Low Fat, High Fat|See Intervention Description
3109860|NCT01824485|Experimental|Group 2|Patients from Group 2 will receive an intra-articular injection of 1 ampoule (2ml) of OSTEONIL®, on a weekly basis, for 3 weeks (total of 3 injections)
3109861|NCT01824485|Experimental|Group 1|Patients from Group 1 will receive a single intra-articular injection of 3 ampoule (6ml) of OSTEONIL®
3109862|NCT01824472|Active Comparator|CPAP+CC|CPAP therapy for sleep apnea and contact control (placebo/sham for cognitive-behavioral therapy for insomnia)
3109863|NCT01824472|Sham Comparator|sham CPAP+CC|sham CPAP (ineffective CPAP--placebo/sham for sleep apnea) and contact control (placebo/sham for cognitive-behavioral therapy for insomnia)
3109864|NCT01824472|Active Comparator|CPAP+CBT|CPAP therapy for sleep apnea and cognitive-behavioral therapy for insomnia
3109865|NCT01824459|Active Comparator|S-1 + cisplatin(SP)|S-1：40~60mg bid，d1~14 q3W cisplatin：60mg/m2，iv drip ，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
3109866|NCT01824459|Experimental|S-1+Oxaliplatin（SOX）|S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
3109867|NCT01824446|Experimental|Radiolabeled SPD602|
3109868|NCT01824433|Active Comparator|venlafaxine|venlafaxine 75-225mg qd
3109869|NCT01824433|Active Comparator|fluoxetine|fluoxetine 20-60mg qd
3109870|NCT01824420|Experimental|Study group|Tolterodine (Detrusitol) 4mg QD and Oxybutynin (Ditropan) ER 5mg QD
3109871|NCT01824420|Experimental|Control group|Tolterodine (Detrusitol) 4mg QD
3109872|NCT01824407|Active Comparator|Active device plus standard of care|Active device plus standard of care
3109873|NCT01824407|Sham Comparator|Sham device plus standard of care|dermaPACE device that uses a dummy applicator that does not emit shock waves
3109874|NCT01824394|Experimental|nMARQ Catheter|nMARQ Catheter System
3109875|NCT01824394|Active Comparator|NaviStar ThermoCool Catheters|THERMOCOOL® Navigational family of catheters
3109876|NCT01824381|Experimental|Amniotic membrane in large wounds|
3109877|NCT01824368|Experimental|People with liver transplantation|People with liver transplantation over 2 years following treatment with immunosuppression including cyclosporine or tacrolimus.
3109878|NCT01824355|Experimental|Intended Users of the Monitoring System|"Untrained subjects with diabetes used the Ninja 3 PLUS Investigational BG Monitoring System. General enrollment criteria for the 'Intended Users' population:~At least 60% of subjects were younger than 65 years of age.~At least 20% had type 1 diabetes.~At least 50% with type 2 diabetes were insulin users."
3109879|NCT01824342|Experimental|Denosumab|Participants received denosumab 120 mg subcutaneously every 4 weeks for up to 3 years in this open-label extension study.
3109880|NCT01824329|Active Comparator|Prostate capsule sparing cystectomy Group|Prostate capsule sparing cystectomy involves removing the entire bladder.
3109881|NCT01824329|Active Comparator|Nerve sparing cystectomy Group|Nerve sparing cystectomy involves removal of the whole bladder and the entire prostate.
3109882|NCT01824303|Experimental|LiRIS 400 mg|LiRIS 400 mg: investigational drug-delivery system which contains Lidocaine; the system remains in the bladder for 14 days. If eligible, participants could participate in the Open Label Extension where all participants were treated with LiRIS 400 mg.
3109883|NCT01824303|Placebo Comparator|LiRIS Placebo|LiRIS Placebo: investigational drug-delivery system which contains Lactose and no Lidocaine; the system remains in the bladder for 14 days. If eligible, participants could participate in the Open Label Extension where all participants were treated with LiRIS 400 mg.
3109884|NCT01824290|Experimental|Tadalafil|"Period 1 (6-month double-blind): Final tadalafil doses will be assigned after the weight cohort completion from H6D-MC-LVIG (NCT01484431). Tadalafil doses may range from 5 milligram (mg) to 40 mg depending on body weight cohorts. Heavy weight cohort ≥40 kilogram (kg), Middle weight cohort ≥25 kg to <40 kg: administered orally by tablets once a day. Light weight cohort <25 kg: administered orally by suspension once a day.~Period 2 (2-year open-label extension): Participants receiving tadalafil in Period 1 will continue at same dose in Period 2."
3109885|NCT01824290|Placebo Comparator|Placebo|"Period 1 (6-month double-blind): Final placebo dose will be assigned after the weight cohort completion from H6D-MC-LVIG (NCT01484431) to maintain blinding depending on body weight cohort.~Period 2 (2-year open-label extension): Participants receiving placebo in Period 1 will receive tadalafil in Period 2 at the corresponding tadalafil dose in that participant's weight group."
3109886|NCT01824277|No Intervention|Group 1|Group 1 - Standard Pre-operative Diabetes Care
3109887|NCT01824277|Experimental|Group 2|Group 2 - Structured Pre-operative Diabetes Optimization
3109888|NCT01824264|Experimental|LIK066 2.5 mg|Patients receive 2.5 mg of LIK066 once daily for 12 weeks
3109889|NCT01824264|Experimental|LIK066 5 mg|Patients receive 5 mg of LIK066 once daily for 12 weeks
3109891|NCT01824264|Experimental|LIK066 25 mg|Patients receive 25 mg of LIK066 once daily for 12 weeks
3109892|NCT01824264|Experimental|LIK066 50 mg|Patients receive 50 mg of LIK066 once daily for 12 weeks
3109893|NCT01824264|Experimental|LIK066 100 mg|Patients receive 100 mg of LIK066 once daily for 12 weeks
3109894|NCT01824264|Experimental|LIK066 150 mg|Patients receive 150 mg of LIK066 once daily for 12 weeks
3109895|NCT01824264|Active Comparator|Sitagliptin 100 mg|Patients receive 100 mg sitagliptin once daily for 12 weeks
3109896|NCT01824264|Placebo Comparator|Placebo|Patients receive placebo for 12 weeks
3109897|NCT01824251|Experimental|NPB-01|Intravenous immunoglobulin
3109898|NCT01824238|Experimental|Anacetrapib|Participants will receive 100-mg anacetrapib tablet, orally, once-daily for 12 weeks.
3109899|NCT01824238|Placebo Comparator|Placebo|Participants will receive placebo tablet, orally, once daily for 12 weeks.
3109900|NCT01824225|Active Comparator|PRN injection of aflibercept|Intravitreal aflibercept
3109901|NCT01824225|Active Comparator|Two months injection of aflibercept|Intravitreal afilibercept
3109902|NCT01824212||ICD-patients|Patients to whom cardiac fibrillation will be induced during the implantation of an implantable cardioverter defibrillator (ICD) or patients with an already implanted ICD, which function needs to be revised and during the revision cardiac defibrillation will be induced.
3109903|NCT01824199|Experimental|Omeprazole|Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire 30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
3109904|NCT01824186|Experimental|SILC|Subjects in this arm were randomized to undergo single-incision laparoscopic cholecystectomy, through a transumbilical incision
3109905|NCT01824186|Active Comparator|LC|Subjects in this arm were randomized to undergo conventional 4-port laparoscopic cholecystectomy. Wound sites at umbilicus, right hypocondrium, epigastrium and right flank
3109906|NCT01824173|Experimental|Amino Acid Infusion in Lean|Amino Acid Infusion in Lean
3109907|NCT01824173|Experimental|Amino acid Infusion in Obese|Amino acid Infusion in Obese
3109908|NCT01824173|Experimental|Exercise in lean|Exercise in lean
3109909|NCT01824173|Experimental|Exercise in Obese|Exercise in Obese
3109910|NCT01824160|Other|Repair of RV-PA Conduit Disruption|Covered stenting of RV-PA conduit injury
3109911|NCT01824147||CABG Patients|Patients undergoing surgery for coronary revascularization.
3109912|NCT01824134|Active Comparator|Klean & Klear|aloe vera gel
3109913|NCT01824134|Active Comparator|The Skin Gel|aloe vera gel
3109914|NCT01824121|Active Comparator|immediate stem cell therapy|patients will undergo active intervention i.e. they will be given stem cell therapy immediately. After 6 months they will undergo a sham procedure.
3109915|NCT01824121|Sham Comparator|delayed stem cell therapy|patients allocated to delayed stem cell therapy will undergo a sham procedure (incannulation of the femoral vein and infusion of saline solution). They will receive stem cell therapy after 6 months
3109916|NCT01824108|Active Comparator|control group: Lumbar discectomy|Lumbar discectomy alone
3109917|NCT01824108|Experimental|Treatment group: lumbar discectomy + Wallis implant|lumbar discectomy combined with Wallis interspinous dynamic stability system
3109918|NCT01824095|Placebo Comparator|placebo|Acute phase (1st treatment through Week 4): Placebo. 2 capsules 3 x day. Chronic phase (Weeks 5-16): Placebo. 1 capsule 3 x day.
3109919|NCT01824095|Experimental|dietary supplement|"Acute phase (1st treatment through Week 4): Ligaplex 1. Ligaplex 1 supplies nutrients to support connective tissue and reduce inflammation. The protocol is commonly used in chiropractic practice and suggested by Standard Process: 2 capsules 3 x day.~Chronic phase (Weeks 5-16): Glucosamine Synergy. This supplement maintains connective tissue and joint health. The protocol is commonly used in chiropractic practice and suggested by Standard Process: 1 capsule 3 x day."
3109920|NCT01824082|Experimental|Ropivacaine 0.5%|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects assigned this treatment for their initial infusion will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment: normal saline.
3109921|NCT01824082|Placebo Comparator|Normal saline (salt water) infusion|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of normal saline placebo fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects assigned this treatment for their initial infusion will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment: ropivacaine 0.5%.
3109922|NCT01824069|Experimental|Autologous mesenchymal stem cells|Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight in a dosis
3109923|NCT01824056|Experimental|18F-DTBZ for Parkinson's Disease|This study will compare the brain uptake of 18F- DTBZ in 40 patients with PD, 40 patients with MSA, 20 patients with CBD, and 20 patients with PSP . Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
3109924|NCT01824043|Experimental|vitreous hemorrhage group|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
3109925|NCT01824030|Active Comparator|FFR guided PCI arm|Patients with angiographic intermediate coronary artery stenosis randomized to FFR assessment. PCI performed only if FFR ≤ 0.80
3109926|NCT01824030|Active Comparator|OCT guided PCI arm|"Patients with angiographic intermediate coronary artery stenosis randomized to OCT. PCI will be performed if:~percentage area stenosis ≥75 %~percentage area stenosis between 50 and 75% and minimal lumen area <2.5 mm2~percentage area stenosis between 50 and 75% and major plaque ulceration"
3109927|NCT01824017|Other|Blood Draw|Data will be collected at patients' usual follow-up intervals for monitoring their metabolic conditions (i.e., T2D, hyperlipidemia, hypertriglyceridemia, etc.), which will be at 3 or 6 month intervals with a +/- 30 day window. Standard treatment surveillance measures such as hemoglobin A1c, LDL, and triglyceride levels will be performed as the standard of care for patients with MsY. Blood samples for these tests will be drawn while subjects are fasting
3109928|NCT01824004|Experimental|S-1,chemoradiotherapy, adjuvant treatment|Pts with radically D2 resected adenocarcinoma of the stomach or GEJ in AJCC stage Ib-IV (M0) were eligible for this study. Pts were treated with S-1 (40-60 mg depending on BSA) b.i.d. for 3 wks, and cisplatin (60 mg/m²) iv on day 1, followed by a 2-wk rest period, within a 5-wk cycle. Subsequently, radiotherapy (RT) started which consisted of 25 fractions of 1.8 Gy to a total dose of 45 Gy in 5 wks (5 fractions/wk). On RT days, S-1 (40-60 mg depending on BSA ) b.i.d., 5 days/wk was given. One month after the completion of RT, two 5-wk cycles of S-1/ciplatin chemotherapy were given.
3109929|NCT01823991|Experimental|COGNUTRIN (VITABLUE and n-3 fatty acids)|Participants will be provided with two bottles containing Lovaza (or placebo) and VitaBlue (or placebo). Participants will be asked to take 1 tablet of Lovaza (or placebo) two times a day and 1 tablet of VitaBlue (or placebo) three times a day.
3109930|NCT01823991|Placebo Comparator|Placebo Administration|Participants will be provided with two bottles containing Lovaza (or placebo) and VitaBlue (or placebo). Participants will be asked to take 1 tablet of Lovaza (or placebo) two times a day and 1 tablet of VitaBlue (or placebo) three times a day.
3109931|NCT01823978|Experimental|BPX-201|BPX-201 vaccine plus AP1903
3109932|NCT01823965|Experimental|ranibizumab|
3109933|NCT01823952||Males|Adult 18-65
3109934|NCT01823939|Other|Males / Females (Healthy)|Part A: This initial part of the study will be conducted in adult Bangladeshi healthy volunteers (4 males, 4 females) to assess the pharmacokinetics, safety, and tolerability of single doses of iOWH032. Participants will be admitted to the Clinical Trial Unit (CTU) of icddr,b (located at a 10 minute drive from the icddr,b main campus) the day prior to dosing and remain for 48 hours after dosing, unless treatment and/or follow-up of an adverse event (AE) require longer in-unit observation or treatment.
3109935|NCT01823939|Other|Males (Patient)|Part B: Patients will be eligible for the study if they have clinically severe dehydration and meet all other inclusion and exclusion criteria. Upon signing consent, they will be admitted to the Research Ward of the Dhaka Hospital of icddr,b.
3109936|NCT01823926|Active Comparator|Control Group|Noninvasive ventilation + jet nebulizer
3109937|NCT01823926|Experimental|Experimental Group|Noninvasive ventilation + vibrating mesh nebulizer
3109938|NCT01823913|Experimental|Test and reference formulations|Test formulation and reference formulation given orally 14 days apart in a fasted state
3109939|NCT01823900|Experimental|Test and reference formulations|Test formulation and reference formulation given orally 7 days apart in a fasted state
3109940|NCT01823887|Experimental|Left Sided Stimulation|Left cervical Vagus Nerve Stimulation (VNS)
3109941|NCT01823887|Experimental|Right Sided Stimulation|Right Cervical Vagus Nerve Stimulation (VNS)
3109942|NCT01823874|Experimental|ID virtual reality distraction|virtual reality distraction
3109943|NCT01823874|Experimental|HMD virtual reality distraction|virtual reality distraction
3109944|NCT01823861|Experimental|Mobile phone-based intervention|Standard care plus automated voice message to support post-abortion contraception use every two weeks for total of three months and direct follow up phone call by family planning counsellor depending on response to voice message.
3109945|NCT01823861|No Intervention|Standard care|Face-to-face post-abortion family planning (PAFP) counselling, follow-up at one or two weeks, clinic phone number, existing 'Hotline' phone number.
3109946|NCT01823848|Active Comparator|Sodium phosphate enema|Administration of sodium phosphate (fleets) enema for functional constipation in children ages 4-12 years Age 4-5: 33ml per rectum Age 5-12: 66ml per rectum
3109947|NCT01823848|Active Comparator|Normal saline enema|Administration of normal saline enema for functional constipation in children ages 4-12 years Admininstered as 10ml/kg with maximum of 700ml
3109948|NCT01823848|Experimental|Mineral oil enema|Administration of mineral oil enema for functional constipation in children ages 4-12 years Administered as 66ml per rectum
3109949|NCT01823835|Experimental|GDC-0810 + Palbociclib and/or an LHRH Agonist|The starting dose for Cohort C1 dose escalation of GDC-0810 will be 400 mg per day on Days 1 to 28 of a 28-day schedule, taken together with 125 mg palbociclib administered on Days 1 to 21 of a 28-day schedule. Dose escalation will be performed in Cohort C1. In Cohort D1, GDC-0810 600 mg will be administered orally on Days 1 to 28 of a 28-day schedule and an LHRH agonist administered monthly. Treatments will continue until disease progression, unacceptable toxicity, or withdrawal of consent (up to 3 years).
3109950|NCT01823835|Experimental|GDC-0810 Single Agent|During dose escalation (Phase I), GDC-0810 will be administered orally once daily in ascending-dose levels with a starting dose of 100 milligrams (mg) once daily. During dose expansion (Phase IIa), GDC-0810 will be administered at the MTD or RP2D define in dose escalation part of the study. Treatments will continue until disease progression, unacceptable toxicity, or withdrawal of consent (up to 3 years).
3109951|NCT01823822|Experimental|Oral protein supplement (Tested product)|
3109952|NCT01823822|Active Comparator|Iso-caloric supplement (Control product)|
3109953|NCT01823809|Other|Imaging arm|There is one study arm only. The imaging modalities will be performed in all patients.
3109954|NCT01823796||Healthy women.|35 healthy women. Control group.
3109955|NCT01823796||Fibromyalgia women group|35 women with fibromyalgia were measured at baseline of the observational study.
3109956|NCT01823783|Other|DMD infant|Muscle biopsy
3109957|NCT01823783|Other|Control infant|Muscle biopsy (during lower limb operation surgery for pure orthopedic causes)
3109958|NCT01823770|Active Comparator|Rotigotine|Patients randomized to rotigotine who will be treated with rotigotine patchs
3109959|NCT01823770|Placebo Comparator|Placebo|Patients randomized on the placebo group who will be treated with placebo patchs
3109960|NCT01823770|No Intervention|Control group|Volunteers matched on sex, age and BMI with RLS patients who will not receive treatment(no treatment)
3109961|NCT01823757||Non-pharmaceutical care|Veterans do not receiving pharmaceutical care
3109962|NCT01823757||Pharmaceutical care|Veterans receiving pharmaceutical care
3109963|NCT01823744|Experimental|micronutrient supplementation|"All the enrolled subjects will recieve orally, onca a day, during school days a chocolate bar including vitamins and minerals.~The micronitrient supplementation will be consumed over 6 weeks, 5 days/week."
3109964|NCT01823705|Experimental|Gastric Electrical Stimulation (GES)|Gastric Electrical Stimulation (GES) therapy for the treatment of obesity.
3109965|NCT01823692|Other|Distal Radius Fracture|after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
3109966|NCT01823679|Experimental|Capecitabine 1000 mg/m²|"Participants will receive oral capecitabine twice-a-day (BID) as 500 mg/m² doses on days 1 to 14.~Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3109967|NCT01823666||Mild cognitive impairment|People with cognitive complaint will be recruited. Who can be diagnosed as mild cognitive impairment will be enrolled according to the MCI criteria.
3109968|NCT01823666||Control|Normal cognition.
3109969|NCT01823653|Experimental|Treated Thigh|Subjects randomly received treatment of either the left or right thigh with the Liposonix System (Model 2)
3109970|NCT01823640|Experimental|Placebo-HRV|inoculation with placebo followed by inoculation with HRV
3109971|NCT01823640|Experimental|HRV-HRV|inoculation with HRV followed by a second inoculation with HRV
3109972|NCT01823627|Other|Spirometry with reversibility test|Spirometry with reversibility test
3109973|NCT01823614||Naïve patients, >500|The group contains patients who have not any ARV therapy experience and the level of CD4 count is more than 500 cells per mm3
3109974|NCT01823614||Naïve patients, 350-500|The group contains patients who have not any ARV therapy experience and the level of CD4 count is between 350 and 500 cells per mm3
3109975|NCT01823614||Naïve patients, <350|The group contains patients who have not any ARV therapy experience and the level of CD4 count is less than 350 cells per mm3
3109976|NCT01823614||ARVT <6 months|The group contains patients who have ARVT experience and obtain ART treatment less than 6 months
3109977|NCT01823614||ARVT from 6 months to 3 years|The group contains patients who have ARVT experience and obtain ART treatment from 6 months to 3 years
3109978|NCT01823614||ARVT >3 years|The group contains patients who have ARVT experience and obtain ART treatment more than 3 years
3109979|NCT01823601|Active Comparator|Seminars in Health|This group of volunteers will attend to seminars in health. Each seminar will last about 120 minutes, a similar period of time used for training experimental group.
3109980|NCT01823601|Experimental|Behavioral Management Program|"Behavioral Management Program consists in to teach to the volunteers procedures which involve autogenic muscle relaxation, progressive self-focus meditation and cognitive-behavioral training to change thoughts, beliefs and behavior in order to control emotions. This program will consist in 10 weekly sessions of about 120 minutes each."
3109981|NCT01823588|No Intervention|Usual care|Educational program and usual cardiovascular prevention.
3109982|NCT01823588|Experimental|Nurse-led reminder through email|In addition to usual care and educational program, the intervention group will also receive email alerts and phone calls from the nurse-care manager (NCM)
3109983|NCT01823575|Experimental|Silicone-covered metallic ureteral stent|Deployment of a silicone-covered metallic ureteral stent for malignant ureteral obstruction and compare the results with placement of a double-J stent in terms of primary patency rate at 3 month follow-up (primary end point)
3109984|NCT01823575|Active Comparator|Double-J stent|Placement of a double-J stent for malignant ureteral obstruction and compare these results to deployment of a silicone-covered metallic stent in terms of primary patency rate at 3 month follow-up.
3109985|NCT01823562|Active Comparator|Arm I (regular diet)|Patients follow a regular diet for 4-6 weeks and then undergo prostatectomy.
3109986|NCT01823562|Active Comparator|Arm II (low polyphenol diet)|Patients follow a low polyphenol diet for 4-6 weeks and then undergo prostatectomy.
3109987|NCT01823562|Active Comparator|Arm III (low ellagitannin diet)|Patients follow a low ellagitannin diet for 4-6 weeks and then undergo prostatectomy.
3109988|NCT01823562|Experimental|Arm IV (lower-dose lyophilized black raspberry gummy)|Patients follow a low ellagitannin diet and receive lower-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
3109989|NCT01823562|Experimental|Arm V (higher-dose black raspberry gummy)|Patients follow a low ellagitannin diet and receive higher-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
3109990|NCT01823562|Experimental|Arm VI (lower-dose black raspberry confection)|Patients follow a low ellagitannin diet and receive lower-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.
3109991|NCT01823562|Experimental|Arm VII (higher-dose black raspberry confection)|Patients follow a low ellagitannin diet and receive higher-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.
3109992|NCT01823536|Experimental|MenACWY-CRM (≥7-≤10 years of age)|Subjects, who had previously received 2 injections of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 2-5 years of age, were administered 1 injection of the same vaccine at 7-10 years of age.
3109993|NCT01823536|Experimental|MenACWY-CRM_1 (≥7-≤10 years of age)|Subjects, who had previously received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 2-5 years of age, were administered 1 injection of the same vaccine at 7-10 years of age.
3109994|NCT01823536|Experimental|Vaccine naive (≥7-≤10 years of age)|Vaccine naive subjects, age-matched to the ≥7-≤10 years of age groups, received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
3110196|NCT01822249|Active Comparator|EPI-743 15 mg/kg|Subjects in this arm will receive EPI-743 at a dose of 15 mg/kg three times daily
3109995|NCT01823536|Experimental|MenACWY-CRM_1 (≥11-≤15 years of age)|Subjects, who had previously received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 7-10 years of age, were administered 1 injection of the same vaccine at 11-15 years of age.
3109996|NCT01823536|Experimental|Vaccine naive (≥11-≤15 years of age)|Vaccine naive subjects, age-matched to the ≥11-≤15 years of age group, received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
3109997|NCT01823523|Active Comparator|Cefazolin, Cephalexin, Clindamycin|"Group will be receiving 1 day of IV cefazolin or clindamycin followed by 2 days of oral cephalexin or clindamycin~Clindamycin will be used in patients with allergy"
3109998|NCT01823523|Placebo Comparator|cefazolin, clindamycin, placebo|"Group will receive 1 day IV cefazolin, or clindamycin followed by 2 days of oral placebo~clindamycin will be used if patient has allergy"
3109999|NCT01823510|Experimental|Ticagrelor + Aspirin|Loading-dose plus daily-dosing for 5-7 days.
3110000|NCT01823510|Active Comparator|Clopidogrel + Aspirin|Loading-dose plus daily-dosing for 5-7 days.
3110001|NCT01823497|Active Comparator|Parent/Nurse Controlled Analgesia|Parent/Nurse Controlled Analgesia will be the method of morphine delivery.
3110002|NCT01823497|Active Comparator|Continuous Opioid Infusion|Continuous Opioid Infusion will be the method used to deliver morphine to group 2
3110003|NCT01823484|Experimental|AN 69 ST hemofilter|Use AN 69 ST hemofilter during CRRT
3110004|NCT01823484|Active Comparator|AN 69 hemofilter|Use AN 69 hemofilter during CRRT
3110005|NCT01823471|Experimental|I-scan first group|After the caecum is reached patients will be first examined with high definition i-scan endoscopy. Each colonic segment will be investigated in a back to back fashion, during the second pass white light will be used.
3110006|NCT01823471|Active Comparator|White light first group|After the caecum is reached patients will be first examined with high definition white light endoscopy. Each colonic segment will be investigated in a back to back fashion, during the second pass i-scan will be used.
3110007|NCT01823458|Experimental|Lottery Insurance|All participants receive a one time, $10 payment for attending the first exercise class of the 12 week session. Participants in the 'Lottery Insurance' arm receive a lottery ticket valued at $20 for attending either a Monday or Tuesday exercise class. They have the option to insure their lottery ticket by attending a second exercise class during the week on either Wednesday or Thursday. If they do not attend the second class, they have a 90% chance of winning the weekly lottery. This sequence is repeated each week over the 12 week exercise session.
3110008|NCT01823458|Experimental|Standard Lottery|All participants receive a one time, $10 payment for attending the first exercise class of the 12 week session. Subjects in the 'Standard Lottery' arm receive a lottery ticket valued at $20 for attending either a Monday or Tuesday exercise class. They also receive the expected value of the insurance ($2) for attending a second exercise class during the week on either Wednesday or Thursday. They have a 90% chance of winning the weekly lottery. This sequence is repeated each week over the 12 week exercise session.
3110009|NCT01823445|Experimental|Xylitol disk|Daily use of 8 disks containing 0.5 grams xylitol each for two weeks. The disks adhere to gum tissue with a food grade adhesive backing and slowly dissolve. The disks are applied one on each side of the mouth in the morning after breakfast, again at midday, and four are applied, two on each side, at bedtime.
3110010|NCT01823432||BAV Cohort|Patients with bicuspid or unicuspid aortic valves, regardless of surgical status.
3110011|NCT01823419||7-9 year olds|Typically developing 7- to 9-year-olds will be enrolled and tested.
3110012|NCT01823406|Experimental|Type 1 Diabetes no complications.|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
3110013|NCT01823406|Experimental|Type 1 Diabetes with microalbuminuria|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
3110014|NCT01823406|Experimental|Type 1 Diabetes with advanced complications.|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
3110015|NCT01823406|Experimental|Aged and sex matched healthy control volunteers|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
3110016|NCT01823393|Experimental|Heparin|injection of unfractionated heparin (50 IU / kg)
3110017|NCT01823393|Placebo Comparator|NaCl|without heparin
3110018|NCT01823380|Other|Amyotrophic lateral sclerosis|Blood test
3110019|NCT01823367|Experimental|Lifestyle counseling mom only|This intervention, delivered to groups of mothers only, builds upon the evidence-based curriculum used in the Diabetes Prevention Program (DPP) and incorporates into the curriculum detailed education regarding ways to help their children adopt healthier lifestyle behaviors.
3110020|NCT01823367|Experimental|Lifestyle counseling mom and child|The second intervention is delivered to both mothers and children in separate groups using the same parent Diabetes Prevention Program (DPP) curriculum, but adds a group program for children that directly teach these children strategies for eating better and increasing physical activity.
3110021|NCT01823354|Other|Patients|Polysomnography, Assessment of executive functions, Clinical scales, Medical consultation
3110022|NCT01823354|Other|Controls|Polysomnography, Assessment of executive functions, Clinical scales Medical consultation
3110313|NCT01821300||Down syndrome|Our goal is to enroll 155 subjects with Down syndrome, and to compare their data to our control group.
3110023|NCT01823341|Active Comparator|Pump suspension algorithm|The pump suspension algorithm will be running actively on the study laptop during the night and suspend the pump if the algorithm predicts hypoglycemia.
3110024|NCT01823341|No Intervention|Standard of Care|The control algorithm will run passively and not suspend the patient's pump.
3110025|NCT01823328|Active Comparator|Ketamine|Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
3110026|NCT01823328|Active Comparator|Etomidate|Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
3110027|NCT01823315|Experimental|MTX Single-dose chemotherapy|Methotrexate (MTX) 0.4mg/(kg·d) intramuscularly (IM) on days 1-5; If β-hCG level can not drop to 1/10 of the origin level during the following 3 weeks, additional course is administered at 2-week intervals, after the first normal hCG value has been recorded.
3110028|NCT01823315|Experimental|MTX/Act-d Single-dose chemotherapy|Act-d 0.6mg/m(2), IV, on day1,2; MTX 100mg/m(2), IV, on day1 (after Act-d); MTX 200mg/m(2), IVgtt, on day1 (after MTX, 500ml NS, >4h); If β-hCG level can not drop to 1/10 of the origin level during the following 3 weeks, additional course is administered at 2-week intervals, after the first normal hCG value has been recorded.
3110029|NCT01823315|Active Comparator|MTX multiple courses chemotherapy|"MTX 0.4mg/(kg·d) intramuscularly (IM) on days 1-5, 2-week intervals;~1 cycle of chemotherapy should be given after the first normal hCG level."
3110030|NCT01823302|Other|nutritional counseling|nutritional counseling
3110031|NCT01823302|Other|nutritional counseling and milk-based supplement|nutritional counseling plus oral milk-based nutrition supplement
3110032|NCT01823289|Experimental|Itraconazole Sequential Therapy|
3110033|NCT01823276|Active Comparator|Tyrosine-Containing Bar|150 mg/kg dose of tyrosine per administration, administered twice
3110034|NCT01823276|Placebo Comparator|Placebo Bar|0 mg/kg dose of tyrosine per administration, administered twice
3110035|NCT01823263|Experimental|Partial sleep deprivation|Partial sleep deprivation: participants will have a 4-h sleep opportunity before a 'Blood Sample' will be taken, and the 'Memory tasks', 'Working memory function task' and 'Portion size task' will be performed. This will be followed by an 'Interference task', followed by repeated blood sampling and an 'Intake task'.
3110036|NCT01823263|Experimental|Normal sleep|Normal sleep: participants will have an 8-h sleep opportunity before a 'Blood Sample' will be taken, and the 'Memory tasks', 'Working memory function task' and 'Portion size task' will be performed. This will be followed by an 'Interference task', followed with repeated blood sampling and an 'Intake task'.
3110037|NCT01823250|Experimental|CIFFTA|Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA)involves four months of intervention. Adolescents and families receive one family therapy session per week and an additional session which is either a psycho-educational session for the adolescent and/or parents, or an individual therapy session with the adolescent. There is a total of 2 sessions per week.
3110038|NCT01823250|Active Comparator|Traditional Family Therapy (TFT)|The Traditional Family Therapy condition consists of once per week family therapy based on Structural Family Theory and a didactic group intervention once per week in which HIV/STI risk is discussed.
3110039|NCT01823237|Active Comparator|rTMS|rTMS condition, rTMS will be applied at 0.1-0.5 Hz frequency at a subthreshold intensity
3110040|NCT01823237|Placebo Comparator|rTMS sham|Placebo condition will use a sham coil and apply a very small magnetic stimulus
3110041|NCT01823224|Experimental|Group 1|"Group 1 will receive IV acetaminophen 1000mg plus 2 oral capsules sugar pills 1 hour prior to surgical incision and 4 hours after initial dose, for a total of two doses of acetaminophen totaling or equaling 2000mg"
3110042|NCT01823224|Experimental|Group 2|"Group 2 will receive an IV salt water infusion plus 2 capsules of oral acetaminophen 1 hour prior to surgical incision and 4 hours after initial dose, for a total of two doses totaling or equaling 2000mg."
3110043|NCT01823211||ischaemic cardiomyopathy|EP (Electrophysiology) study,magnetic resonance with LGE (Late gadolinium enhancement), ICD implantation
3110044|NCT01823211||non-ischaemic cardiomyopathy|EP study,magnetic resonance imaging with LGE, ICD implantation
3110045|NCT01823198|Experimental|+ Chemotherapy + NK Cell infusion + Stem Cell Transplant|"Busulfan test dose of 32 mg/m2 within 2 weeks of the preparative regimen. Fludarabine 40 mg/m2 by vein on Day -13 to Day -10. Busulfan adjusted dose determined to achieve systemic exposure represented by an average daily AUC of 6000 µMol-min ± 5% for the entire 4-day treatment period on Day -13 to Day -10. Patients over age 60 and/or with performance status =2 receive and AUC of 4000 microM x min for each dose. Alloreactive NK infusion on Day -8. Alloreactive NK cell infusion given at one of 4 dose levels based on the number of NK cells (CD3-,CD 56+ cells)/kg recipient body weight. Dose levels are: 10^6, 10^7, 3 x 10^7, 10^8. Interleukin-2 0.5 million units subcutaneously on Day -8 to Day -4. Hematopoietic stem cell infusion on Day 0."
3110046|NCT01823185|Active Comparator|Clopidogrel|CYP2C19 genotyping will be carried out at the end of the study period. Clopidogrel will be used for treatment for one year according to local protocol. Patients will receive clopidogrel 75 mg per day.
3110047|NCT01823185|Experimental|Ticagrelor or prasugrel|Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) according to local protocol.
3110048|NCT01823172|Experimental|Methylene Blue|1% Methylene Blue - 1 ml. Methylene blue dye injection of sentinel lymph node
3110049|NCT01823159|Active Comparator|Retigabine|Administration of a single dose of 400 mg retigabine, two hours before the measures
3110050|NCT01823159|Placebo Comparator|placebo|Randomized administration of a single dose of placebo, two hours before the measures.
3110051|NCT01823146|Experimental|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
3110052|NCT01823146|Placebo Comparator|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
3110053|NCT01823133|Experimental|gemigliptin only|Multiple administrations of gemigliptin
3110054|NCT01823133|Experimental|rosuvastatin only|Multiple administrations of rosuvastatin
3110055|NCT01823133|Experimental|gemigliptin and rosuvastatin|Multiple administrations of gemigliptin and rosuvastatin
3110087|NCT01822925|Placebo Comparator|Placebo|Placebo (same formulation as DA-9801 but without the active ingredients) will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this tablet for 12 weeks.
3110056|NCT01823120|No Intervention|No text messages|Patients in the non-intervention group will not receive any text messages. However, they will also receive the routine outpatient follow-up arrangements associated with attendance at an ED with self-harm including the provision of a contact phone number for the Samaritans.
3110057|NCT01823120|Experimental|Supportive and interactive text messages|We will deliver daily supportive and informative text messages for one month followed by one supportive and informative text message every other day the second month and then one weekly text message the third month to patients in the intervention group after they have been discharged from the ED following an episode of self-harm. Supportive text messages will mainly target relieving the patients of mood symptoms and providing them with strategies for dealing with suicidal thoughts while the informative ones will provide patients with a dedicated mobile phone number through which they can receive interactive support from the Samaritans. The text messages will encourage participants to text the Samaritans in times of crisis. Please see appendix I for examples of the relevant text messages.
3110058|NCT01823107|Experimental|Meso BioMatrix Device|All subjects will have the Meso BioMatrix device implanted along with a tissue expander during the first stage of breast reconstruction. During the second stage of breast reconstruction, the tissue expander is replaced with a breast implant.
3110059|NCT01823094||Variability of measurements|variability of CTP measurements will be determined by repeating the CTP examination, and comparing the resultant blood flow estimates
3110060|NCT01823094||Treatment induced effects|The magnitude of treatment induced effects will be assessed by comparing tumor blood flow estimates before and after treatment
3110061|NCT01823081|Active Comparator|Intravitreal bevacizumab (Avastin)|Dosage: 1.25 mg/0.05 ml Frequency: 3 consecutive injections every 4 weeks
3110062|NCT01823081|Active Comparator|Combined intravitreal fasudil and bevacizumab (Avastin)|Dosage: bevacizumab 1.25 mg/0.05 ml + fasudil 0.025mg/0.05ml Frequency: 3 consecutive injections every 4 weeks
3110063|NCT01823068|Experimental|Vandetanib treatment arm|Vandetanib 300 mg once daily orally
3110064|NCT01823055|Experimental|Surgery|Transvaginal suture capturing mesh device
3110065|NCT01823042|Experimental|enteral nutrition+azathioprine|Patients is fasting and receive enteral nutrition and azathioprine treatment.
3110066|NCT01823042|Experimental|azathioprine|Patients have regular diet and receive only azathioprine treatment.
3110067|NCT01823029|Experimental|erythropoietin,injection of iron and enteral nutrition|The patients receive treatment of erythropoietin,injection of iron and enteral nutrition.
3110068|NCT01823029|Experimental|erythropoietin and enteral nutrition.|The patients receive treatment of erythropoietin and enteral nutrition.
3110069|NCT01823016|Placebo Comparator|Placebo|
3110070|NCT01823016|Experimental|JNJ-38518168|
3110071|NCT01823003|Experimental|A. 34 Gy in a single fraction|34 Gy by single fraction Risk-adapted radiation dose.
3110072|NCT01823003|Experimental|B. 54Gy (18Gy/fr. x 3 fractions)|54Gy administered in 3 fraction of 18 Gy, risk adapted radiation dose
3110073|NCT01823003|Experimental|C. 50Gy (12 x 5 fr.s)|54Gy administered in 5 fraction of 12 Gy, risk adapted radiation dose
3110074|NCT01823003|Experimental|D. 60Gy (7.5Gy x 8fr.)|60 Gy administered in 8 fraction of 7.5 Gy, risk adapted radiation dose
3110075|NCT01822990||Atherosclerotic patients|Male patients with intermittent claudication.
3110076|NCT01822990||Control subjects|healthy male subjects with normal results on vascular examination and no cardiovascular risk factors, who are not in receipt of any pharmacological treatment, matched by age within two years with peripheral arterial disease patients
3110077|NCT01822977|No Intervention|Proton pump inhibitor|"We will recruit 10 healthy adult individuals and 5 adult patients with an initial episode of CDI cared for at Mayo Clinic in Arizona. A baseline stool sample will be collected from the healthy individuals. They will then be given a PPI, omeprazole 20 mg, to be taken once (n=5) or twice (n=5) daily for 1 month. Stool samples will be collected after 1 week and again after 1 month. A final stool sample will be collected 1 month after stopping the omeprazole.~A stool sample will be collected from the CDI subjects before treatment of the infection and again 2 months after treatment to avoid enrolling those at risk for relapse (which most commonly occurs during the first 2 months after treatment)."
3110078|NCT01822964|Active Comparator|targeted brain cooling|In these 15 pts, targeted brain cooling (tympanic temperature of 33°C) will be applied during the TAVI intervention by the use of the RhinoChill device (Benechill Inc, San Diego cA)
3110079|NCT01822964|Placebo Comparator|no use of targeted brain cooling|In these 15 pts, no cooling techniques will be applied and current clinical practice as to maintenance of normothermia will be followed during these TAVI interventions
3110080|NCT01822951|Experimental|Cerebrolysin Verum|"Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). For the infusion 2x10 ml Cerebrolysin (215.2 mg/ml) is diluted with 80 ml 0.9% NaCl (saline) to a total volume of 100 ml, i.v.~Placebo for donepezil: 1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o."
3110081|NCT01822951|Active Comparator|Donepezil Verum|"5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Placebo for Cerebrolysin: 100 ml 0.9% NaCl (saline), i.v. infusion. Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly)."
3110082|NCT01822938|Experimental|effects of a incentive program for physical activity|The aim of the study is the assessment of the effects of a incentive program for physical activity on people following/with stroke
3110083|NCT01822938|No Intervention|control group|No intervention
3110084|NCT01822925|Experimental|DA-9801 300mg|DA-9801 will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
3110085|NCT01822925|Experimental|DA-9801 600mg|DA-9801 will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
3110086|NCT01822925|Experimental|DA-9801 900mg|DA-9801 will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
3110152|NCT01822535|No Intervention|No Drug: AB Controls|AB Controls: Matched for age and gender to subjects with tetraplegia. Exposure of up to 2 hours in a cool room.
3110088|NCT01822912|Active Comparator|Heart Failure Disease Management Program|Patients will receive personalized care to include medication titration, daily weights, symptom and activity assessment, documentation of ejection fraction, patient and caregiver education,dietary surveillance, discharge instructions and follow up visit within 7 days of SNF discharge
3110089|NCT01822912|Placebo Comparator|Heart Failure Usual Care|SNF patients with HF will receive usual care
3110090|NCT01822899|Experimental|Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS|Subjects will receive UMEC/ VI 62.5/25 mcg, one inhalation administered once-daily in the morning via the NDPI and one placebo ACCUHALER/DISKUS administered as one inhalation each morning and evening.
3110091|NCT01822899|Active Comparator|Fluticasone propionate/Salmeterol + placebo NDPI|Subjects will receive FSC 500/50 mcg, administered as one inhalation each morning and evening via ACCUHALER/DISKUS + placebo administered once daily in the morning via NDPI.
3110092|NCT01822886|Experimental|Romidepsin, Gemcitabine|Romidepsin 12 mg/m2 d.1,8, 15 + Gemcitabine 800 mg/m2 d.1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 d. 1, 15 to PD
3110093|NCT01822873||Normal|
3110094|NCT01822873||Age-related macular degeneration|
3110095|NCT01822860|Placebo Comparator|Placebo|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
3110096|NCT01822860|Experimental|Chlorthalidone 12.5 mg|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
3110097|NCT01822860|Active Comparator|Hydrochlorothiazide 25 mg|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
3110098|NCT01822847||catheterization|patients undergoing elective heart catheterization
3110099|NCT01822834||Non-CF Bronchiectasis Patients with or without NTM|Patients over the age of 18 with non-CF Bronchiectasis with or without Nontuberculosis Mycobacteria (NTM).
3110100|NCT01822834||Nontuberculosis Mycobacteria (NTM)|Patients over the age of 18 with Nontuberculosis Mycobacteria (NTM)
3110101|NCT01822821|Experimental|IV Acetaminophen|Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
3110102|NCT01822821|Placebo Comparator|Placebo|Patients will receive up to four doses of IV placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
3110103|NCT01822808|Active Comparator|Hydralazine|24 week course of Hydralazine 25mg 3 times daily for 4 weeks, thereafter uptitrating to 50mg hydralazine 3 times daily up to week 24. Those assigned to the Hydralazine control arm will receive the same number of identical placebo tablets.
3110104|NCT01822808|Active Comparator|Isosorbide dinitrate|24 week course of Isosorbide dinitrate 10mg 3 times daily for 4 weeks, thereafter uptitrating to 20mg isosorbide dinitrate 3 times daily up to week 24. Those assigned to the Isosorbide dinitrate control arm will receive the same number of identical placebo tablets.
3110105|NCT01822795|Experimental|Lung volume reduction coïl treatment|Lung volume reduction coïl treatment,added to usual medical treatment and follow up after the intervention
3110106|NCT01822795|Other|Regular Medical Treatment|No intervention, just a follow up under usual medical treatment
3110107|NCT01822782||Cases|"The study population consists of all consecutive women meeting inclusion/exclusion criteria and delivering at the Nîmes University Hospital, France during an inclusion period of 6 months. Cases are classified as those with a vaginal lesion due to delivery."
3110108|NCT01822782||Controls|"The study population consists of all consecutive women meeting inclusion/exclusion criteria and delivering at the Nîmes University Hospital, France during an inclusion period of 6 months. Controls are classified as those without a vaginal lesion due to delivery."
3110109|NCT01822769|Experimental|Cardiopulmonary rehabilitation|The subjects will attend 2 sessions each week for 12 weeks. Each session will be approximately 2 hours in duration, consisting of both exercise (aerobic and strength,~60 minutes) and education. In addition, subjects will be directed to participate in 3 weekly ~40 minute home exercise training sessions, personalized to their level of aerobic conditioning.
3110110|NCT01822769|Other|Standard of care|Subjects randomized to standard of care will not be enrolled in a rehabilitation program, but may receive any other clinically indicated exercise training or other intervention (e.g., an exercise prescription).
3110111|NCT01822756|Experimental|Regimen A -ruxolitinib, gemcitabine|Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food. The morning dose of RUX was to be taken before the chemotherapy infusion, Gemcitabine IV, on days when they were given together (Days 1, 8, and 15 of each cycle).
3110112|NCT01822756|Experimental|Regimen B-ruxolitinib, gemcitabine, nab-paclitaxel, filgrastim|"Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food.~Gemcitabine was provided as open-label, commercial product and was administered intravenously (IV) over 30 minutes on Days 1, 8, and 15 of each 28-day cycle. Reduced doses of gemcitabine administered IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle could also be explored.~nab-Paclitaxel, as open-label, commercial product, was administered IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle."
3110113|NCT01822743|Experimental|Osteopathic manipulative treatment|Osteopathic compression of pterygopalatine node
3110114|NCT01822743|Sham Comparator|Sham comparator|sham Osteopathic pterygopalatine node compression
3110115|NCT01822730|Experimental|paliperidone|paliperidone arm,6mg/pill,6-12mg/day,non-forced titration method.last2-4weeks.
3110116|NCT01822730|Active Comparator|.Risperidone|Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks
3110117|NCT01822717|Experimental|Nonvisual foot inspection|Instruction for nonvisual foot inspection included in comprehensive diabetes self-management education
3110118|NCT01822717|Active Comparator|Usual Care for foot inspection|Usual instruction for foot care included in comprehensive diabetes self-management education
3110119|NCT01822704|Active Comparator|Control|This group will undergo three 45-minute exercise sessions per week for 10 weeks. No whole body vibration will be given.
3110120|NCT01822704|Experimental|Low intensity vibration|This group will receive three 45-minute whole body vibration training sessions for 10 consecutive weeks. The vibration will be of low intensity (frequency: 20 Hertz, amplitude: 1mm).
3110194|NCT01822262|Experimental|gallbladder reservation|Patients in trial group all took minimally invasive cholecystolithotomy with gallbladder reservation
3110121|NCT01822704|Experimental|High intensity vibration|This group will receive three 45-minute whole body vibration training sessions per week for 10 consecutive weeks.The vibration will be of higher intensity than the low intensity vibration group (frequency: 30 Hertz, amplitude: 1mm).
3110122|NCT01822691|Experimental|INCB024360 Treatment|Participants were treated with 600 mg orally, twice a day for 16 weeks, unless clear evidence of disease progression or toxicity was evident.
3110123|NCT01822678|Experimental|Group 1|Group 1: Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
3110124|NCT01822678|Experimental|Group 2|Group 2: Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
3110125|NCT01822678|Placebo Comparator|Group 3|Group 3: Placebo (change in daily number of tablets administered, according to clinical response).
3110126|NCT01822665|Active Comparator|Paracetamol Tablet|Paracetamol 500 mg tablet, 2 tablets administered 4 times a day (QID) with water.
3110127|NCT01822665|Active Comparator|Ibuprofen Tablet|Ibuprofen 400 mg tablet, 2 tablets administered three times a day (TID) with water
3110128|NCT01822665|Placebo Comparator|Placebo Tablet|Placebo tablets, 2 tablets QID administered with water.
3110129|NCT01822665|Active Comparator|Ibuprofen Capsule|Ibuprofen 400 mg liquid gel capsules, 2 tablets, TID administered with water
3110130|NCT01822652|Experimental|iC9-GD2 T Cells - fresh - CLOSED|The cells will be given IV over 5-10 minutes. There is a possibility for additional doses of iC9-GD2 T cells.
3110131|NCT01822652|Experimental|iC9-GD2 T Cells - frozen - CLOSED|The cells will be given IV over 5-10 minutes. There is a possibility for additional doses of iC9-GD2 T cells.
3110132|NCT01822652|Experimental|iC9-GD2 T cells,Cytoxan,Fludara,Keytruda|Fresh T cells will be given IV over 5-10 mins. There is a possibility for additional doses of iC9-GD2 T cells.
3110133|NCT01822639|Experimental|Sequence 1|Subjects in this arm will receive Treatment A in period 1 and Treatment B in period 2. Treatment A is co-administration of 5mg amlodipine tablet and 20 mg enalapril maleate tablet. Treatment B (GSK2944404) is fixed dose combination tablet of 5 mg amlodipine and 20 mg enalapril.
3110134|NCT01822639|Experimental|Sequence 2|Subjects in this arm will receive Treatment B in period 1 and Treatment A in period 2. Treatment A is co-administration of 5mg amlodipine tablet and 20 mg enalapril maleate tablet. Treatment B (GSK2944404) is fixed dose combination tablet of 5 mg amlodipine and 20 mg enalapril.
3110135|NCT01822626|Experimental|motivational counseling|
3110136|NCT01822626|No Intervention|Usual Care|
3110137|NCT01822613|Experimental|LJM716-BYL719 arm|approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the LJM716-BYL719 combination arm to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).
3110138|NCT01822613|Active Comparator|Paclitaxel, Docetaxel or Irinotecan arm|approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the Paclitaxel, Docetaxel or Irinotecan arm (physician's choice arm) to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the LJM716-BYL719 combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).
3110139|NCT01822600|Experimental|Normal albumin group|"Based on the serum albumin level at enrollment, the patients were assigned into the normal albumin group if their serum albumin ≥ 30 g/L.~Patients in this group receive intravenous omeprazole treatment."
3110140|NCT01822600|Experimental|Intervention group|"Based on the serum albumin level at enrollment, the patients were assigned into an intervention group if their serum albumin < 30 g/L.~Patients in this group receive both Human albumin and intravenous omeprazole."
3110141|NCT01822600|Experimental|Cohort control group|"The study also included 29 patients with peptic ulcer bleeding and with hypoalbuminemia (serum albumin level < 30 g/L), but without receiving albumin supply from our previous study to serve as the cohort control group.~Patients in this group receive intravenous omeprazole treatment."
3110142|NCT01822587|Placebo Comparator|Placebo|Administered once orally following cue exposure on each of the first two days of testing.
3110143|NCT01822587|Active Comparator|Propranolol 40mg|Administered once orally following cue exposure on each of the first two days of testing.
3110144|NCT01822587|Active Comparator|Propranolol, 80mg|Administered once orally following cue exposure on each of the first two days of testing.
3110145|NCT01822574|Active Comparator|Cutting Guide Technique|The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
3110146|NCT01822574|Active Comparator|Haptic Feedback Technique|It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
3110147|NCT01822574|Active Comparator|Four Quadrant Technique|Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
3110148|NCT01822561|Experimental|Eplerenone|All patients in this study will receive Eplerenone 50mg once daily for 4 weeks.
3110149|NCT01822548|Experimental|Vildagliptin & metformin|Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
3110150|NCT01822548|Active Comparator|Glibenclamide & metformin|Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
3110151|NCT01822535|No Intervention|No Drug: Tetraplegia|"Tetraplegia: Lesion level T1 and above, American Spinal Injury Association (ASIA) impairment levels A and B, ages 18-68 years.~Exposure of up to 2 hours in a cool room."
3110195|NCT01822262|Experimental|laparoscopiccholecystectomy|Patients in control group all received LC.
3110153|NCT01822535|Experimental|Drug (midodrine): Tetraplegia|Persons with tetraplegia who completed Visit 1 (no drug). Participants are administered midodrine hydrochloride (10 mg tablet) by a physician before exposure of up to 2 hours in a cool room. (Visit 2)
3110154|NCT01822522|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3110155|NCT01822509|Experimental|Treatment (ipilimumab, nivolumab)|See Detailed Description.
3110156|NCT01822496|Experimental|Arm I (erlotinib hydrochloride, concurrent chemoradiation)|Patients receive erlotinib hydrochloride PO QD for up to 12 weeks. Patients who have had no response (partial or complete) after 6 weeks undergo concurrent chemoradiation therapy immediately. After 2 weeks of completion of induction therapy, patients receive chemoradiation.
3110157|NCT01822496|Active Comparator|Arm II (chemoradiation, EGFR TK Mutation Cohort)|Patients receive concurrent chemotherapy with thoracic radiation therapy beginning on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.
3110158|NCT01822496|Experimental|Arm III (crizotinib, concurrent chemoradiation)|Patients receive crizotinib PO BID for up to 12 weeks. Patients who have had no response (partial or complete) after 6 weeks undergo concurrent chemoradiation therapy immediately. After 2 weeks of completion of induction therapy, patients receive chemoradiation.
3110159|NCT01822496|Active Comparator|Arm IV (chemoradiation, ALK Tran L Cohort)|Patients receive concurrent chemotherapy with thoracic radiation therapy beginning on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.
3110160|NCT01822483|Experimental|Mycophenolate sodium|Arm1(Conversion):MPA AUC below 30mcg*h ml-1 - MPS+Calcineurin inhibitor+prednisone
3110161|NCT01822483|Active Comparator|Mycophenolate mofetil|Arm2(Maintained):MPA AUC between 30 to 60 mg*h ml-1 or above 60 mg - MMF+Calcineurin inhibitor+prednisone
3110162|NCT01822470||Study group|a. Study Subjects will be recruited from patients who are already undergoing upper enteroscopy and aspiration for diagnosis of SIBO.
3110163|NCT01822470||Control group|b. Control Subjects will be recruited from patients who are already undergoing a double balloon enteroscopy or upper enteroscopy for another medical reason
3110164|NCT01822457|Experimental|Nike FuelBand (NFB)|Patients will receive a Nike Fuel Band to encourage exercise.
3110165|NCT01822457|No Intervention|control|Standard follow-up
3110166|NCT01822444||Intent-to-treat population with aCRC or mCRC|Advanced Colorectal Cancer with planned treatment with a aCRC or mCRC and who fulfil all inclusion and exclusion criteria
3110167|NCT01822431||Patients with type 1 diabetes mellitus|Metaiodobenzylguanidine scintigraphy, Autonomic function tests, Pupillometry, Holter monitoring
3110168|NCT01822431||Healthy controls|Autonomic function tests, Pupillometry, Holter monitoring
3110169|NCT01822418|Experimental|Treatment|Open-label treatment with agomelatine 25 mg/day (or 50 mg/day after week 3).
3110170|NCT01822405|Active Comparator|Pentoxifylline + Tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Tocopherol 1000 mg/day oral during 6 months
3110171|NCT01822405|Experimental|pentoxifylline + tocopherol + Hyperbaric Oxygen Therapy|
3110172|NCT01822392|Active Comparator|Online treatment, High therapist contact|Participants receive online Parent Management Training (interactive).
3110173|NCT01822392|Experimental|Online treatment, Low therapist contact|Participants receive online Parent Management Training (recorded).
3110174|NCT01822379|Experimental|Cell transplantation|All patients will undergo transplantation of two distinct vitiligo lesions. One lesion will receive cells prepared with trypsin. The other lesion will receive cells prepared with dispase.
3110175|NCT01822366|No Intervention|Usual Care Comparison Condition|Half of the participating children/guardian dyads will receive no intervention (usual care) to serve as a control.
3110176|NCT01822366|Experimental|Trauma-focused CBT group therapy|Half of the participating children/guardian dyads will receive the 12-week Trauma-focused Cognitive Behavioral Therapy (TF-CBT) group treatment.
3110177|NCT01822353|Experimental|Milk allergy|Dietary supplement, milk in increasing dosages, delivered daily and orally.
3110178|NCT01822353|Experimental|Egg allergy|Dietary supplement, egg protein given in increasing dosages, delivered daily and orally.
3110179|NCT01822353|Experimental|Nut allergy|Dietary supplement, nut cream including nut allergens, delivered in increasing dosages, daily and orally.
3110180|NCT01822340|Experimental|Cohort 1|Once weekly HM10560A
3110181|NCT01822340|Experimental|Cohort 2|Once weekly HM10560A
3110182|NCT01822340|Experimental|Cohort 3|Once weekly HM10560A
3110183|NCT01822340|Experimental|Cohort 4|Biweekly HM10560A
3110184|NCT01822340|Active Comparator|Cohort 5|Once daily Genotropin
3110185|NCT01822327|Experimental|Contingent Vouchers Unmatched|CRA therapy plus Voucher incentives contingent on cocaine abstinence with monetary values set at usual monetary values across all patients.
3110186|NCT01822327|Experimental|Contingent Vouchers, Matched|CRA therapy plus Vouchers contingent on cocaine abstinence, with more severe patients receiving twice the usual voucher monetary values.
3110187|NCT01822327|Active Comparator|Non-Contingent Vouchers control|CRA therapy plus Vouchers earned independent of drug use
3110188|NCT01822314|Active Comparator|Paclitaxel|"Paclitaxel will be given on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles.~AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles"
3110189|NCT01822314|Experimental|Abraxane|"Abraxane will be given at the dosage of 125 mg/m2 on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles.~AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles"
3110190|NCT01822301|Experimental|Repeat Facial fat grafting|
3110191|NCT01822288|Experimental|Tibolone group|Tibolone (2.5 mg per day)for 12 consecutive weeks. Tibolone should be paid by patient herself, and does not cover by Taiwan Government health insurance.
3110192|NCT01822288|Active Comparator|Conventional hormone therapy group|Estradiol valerate (E2V) 1mg & medroxyprogesterone acetate (MPA) 2.5 mg per day for 12 consecutive weeks, and this drug is paid by Taiwan Government health care insurance.
3110193|NCT01822275|Other|Low Dose WBRT|Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by either 6 or a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
3110197|NCT01822249|Placebo Comparator|Placebo|Subjects in this arm will receive placebo at a volume equivalent to the volume of EPI-743 they would receive if in active group based on their weight
3110198|NCT01822236|Experimental|Craniosacral Therapy Program|A program of 10 craniosacral therapy techniques
3110199|NCT01822236|Active Comparator|One technique of craniosacral therapy|Decompression L5-S1.
3110200|NCT01822223|Experimental|Laser-ablated dental implant-abutments|Laser-ablated dental implant abutments will be attached to surgically placed dental implants.
3110201|NCT01822223|Active Comparator|Smooth implant-abutments|Smooth dental implant-abutments will be attached to surgically placed dental implants.
3110202|NCT01822210|Experimental|Botox|Injection of Botox in the tumor and surrounding stomach wall.
3110203|NCT01822197|Experimental|Phototherapy|Bright light phototherapy will be administered for 30 minutes daily over one week in the morning (Days 0-7)
3110204|NCT01822184||No treatment|Observational non-treatment study
3110205|NCT01822171|Experimental|Discharge counseling and MTM follow-up|"At the time of hospital discharge the subject will receive:~Discharge medication counseling from a pharmacist~Home medication if needed~Approximately 7 days after hospital discharge the subject have a Follow-up visit at Medication Therapy Management clinic."
3110206|NCT01822158|Experimental|vaginal delivery debrief checklist|Utilization of a Vaginal Delivery Debrief Checklist after vaginal deliveries for a period of three months, by team members who have consented to be a part of this study and who are present at vaginal deliveries. The Vaginal Delivery Debrief checklist consists of 2 levels. The first level includes a list of 6 key elements, such as APGAR scores,estimated blood loss, perineal repair, etc. The second level,or extended debrief, occurs whenever unanticipated outcomes, such as low APGAR scores, postpartum hemorrhage or a difficult delivery occurs. Team members complete the checklist after each delivery they attend.
3110207|NCT01822145||ICD recipients|ICD recipients with documented cardiac arrest or ventricular arrhythmias
3110208|NCT01822132|Experimental|Extended release naltrexone|One dose of intramuscular injection of 380mg extended-release naltrexone.
3110209|NCT01822132|Placebo Comparator|Placebo|One dose of intramuscular injection of placebo.
3110210|NCT01822119|Experimental|Baha Attract System|"This transcutaneous solution is based on a magnet coupling using magnets on both side of the skin;~One implant magnet~One external magnet on which a sound processor is attached, i.e. the Sound Processor magnet (SP magnet)"
3110211|NCT01822106|Active Comparator|Omeprazole|Omeprazole at a rate of 20mg once per day
3110212|NCT01822106|Experimental|Wu-Chu-Yu Tang|Wu-Chu-Yu Tang at a rate of 3.0 g three times per day
3110213|NCT01822093|Experimental|Cytovir-ADV|Adenovirus-specific T-cells
3110214|NCT01822080|Experimental|Dienogest|50% of the participants will be randomized to this arm and will receive 2 mg dienogest (DNG) once daily by mouth from 0-52 weeks
3110215|NCT01822080|Placebo Comparator|Placebo|50% of the participants will be randomized to this arm and will receive placebo once daily by mouth from 0-24 weeks then switch to 2 mg dienogest (DNG) once daily by mouth from 25-52 weeks
3110216|NCT01822067||Normal weight- Non Maternal obesity|Full-term neonates at 2 weeks of age born to normal weight mothers
3110217|NCT01822067||Obese- Obese Mothers|Full-term neonates at two weeks of age born of obese mothers
3110218|NCT01822054||Normal weight|
3110219|NCT01822054||Obese|
3110220|NCT01822041|Active Comparator|Part A - 14C labeled ARN-509|Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an intravenous (i.v.) microdose of 100 μg (9.25 kBq, 250 nCi) 14C-ARN-509
3110221|NCT01822041|Active Comparator|Part B: 14C labeled ARN-509|Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an oral dose of 240 mg ARN-509 with 37 kBq (1000 nCi) of 14C-ARN-509
3110222|NCT01822028|Placebo Comparator|Treatment A|"Treatment A: Florastor® 500 mg twice per day from Day 1 to Day 16 of the treatment period, and Zavesca® 100 mg three times per day from Day 3 to Day 16.~For Period 2, subjects will receive the alternate dosing regimen."
3110223|NCT01822028|Experimental|Treatment B|"Treatment B: Florastor® 500 mg twice per day from Day 1 to Day 16 of the treatment period, and Zavesca® 100 mg three times per day from Day 3 to Day 16.~For Period 2, subjects will receive the alternate dosing regimen."
3110224|NCT01822015|Experimental|Treatment (sirolimus, idarubicin, cytarabine)|Patients receive sirolimus PO QD on days 1-10, idarubicin IV over 3-5 minutes on days 4-6, and cytarabine IV continuously over 24 hours on days 4-10.
3110225|NCT01822002|Active Comparator|Canalith repositionig maneuver; Epley maneuver group|Patients with PC-BPPV will be randomly assigned to Epley maneuver or Semont maneuver.
3110226|NCT01822002|Active Comparator|Canalith repositioning maneuver : Semont maneuver group|Patients with PC-BPPV will be randomly assigned to Epley maneuver or Semont maneuver group.
3110227|NCT01821989|Active Comparator|Low Dose|Lactoferrin,dose of 100 mg/day.
3110228|NCT01821989|Experimental|High Dose|Lactoferrin, dose of 150 mg/kg/ twice daily.
3110229|NCT01821989|Placebo Comparator|Control|Receive placebo in form of distilled water.
3110230|NCT01821976|Active Comparator|Ertl Procedure|Patients randomized to the Ertl Procedure Arm will receive an amputation very similar to the Burgess Procedure, except the surgeon will perform an additional step to make the cut end of the tibia bone heal to the cut end of the fibula bone with a bone bridge. This bone bridge connects the two bones together.
3110231|NCT01821976|Active Comparator|Burgess Procedure|Patients randomized to the Burgess Procedure Arm will receive a below the knee amputation where the bone is cut and skin and muscle from the back of the leg are rotated to cover the cut end of your bone. This provides good soft tissue padding to the bone and a good shape to the leg for later fitting of your prosthesis.
3110232|NCT01821963|Experimental|Pegylated Interferon Alfa 2a + Ribavirin + Telaprevir|Triple combination with Telaprevir, PegIFN alfa-2a and Ribavirin administered for 12 weeks, followed by dual therapy with PegIFN alfa-2a and Ribavirin. Dual therapy continued for 48 weeks of total duration of therapy, as standard of care treatment for cirrhotic patients, or until day of transplantation, whichever comes first. Starting doses for standard of care pegylated interferon (PegIFN) alfa-2a 180 mcg subcutaneously once weekly, for ribavirin (RBV) 1,000 mg orally daily (< 75 kg) and 1,200 mg orally daily (≥ 75 kg), and for telaprevir 750 mg taken orally 3 times a day.
3110314|NCT01821300||Control|Our goal is to enroll 105 typically developing controls, who are matched to the Down syndrome group by age, sex, race, ethnicity, and BMI-z score.
3110233|NCT01821950|No Intervention|Physical education as usual|Physical education curriculum established by the school, including competitive sports, aerobic and anaerobic activities, balance and coordination skills. Yoga is not a component of the curriculum.
3110234|NCT01821950|Experimental|Yoga during physical education|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
3110235|NCT01821937|Experimental|faldaprevir(high dose)|10 subjects (approximate sex ration: 1:1) will be assigned to trial by single and multiple dose.
3110236|NCT01821937|Experimental|Faldaprevir(low dose)|10 subjects (approximate sex ration: 1:1) will be assigned to trial by single and multiple dose.
3110237|NCT01821911|Experimental|Zagreb2-1-1|Injection on day 0、7、21
3110238|NCT01821911|Active Comparator|Essen|Injection on day 0、3、7、14、28
3110239|NCT01821898|Active Comparator|Positive for food allergy: Group A|Oral Budesonide
3110240|NCT01821898|Active Comparator|Positive for food allergy: Group B|Elimination diet
3110241|NCT01821885|Experimental|Spirometry and a brief advice to quit smoking|"Intervention group:~The intervention consists of completing a questionnaire and undergo spirometry with bronchodilator test by a trained nurse. Later, the patients receives a brief advice to quit smoking and a report of the spirometry results by their family doctor."
3110242|NCT01821885|Active Comparator|Brief advice to quit smoking|"Control group:~Patients in the control group complete a questionnaire by a nurse and then receive a brief advice to quit smoking by their family doctor."
3110243|NCT01821872|Active Comparator|Sampling at approx 15 minutes|Plasma and CSF samples to be taken at 15 minutes post administration of intravenous paracetamol
3110244|NCT01821872|Active Comparator|Sampling at approx 30 minutes|Plasma and CSF samples to be taken at 30 minutes post administration of intravenous paracetamol
3110245|NCT01821872|Active Comparator|Sampling at approx 120minutes|Plasma and CSF samples to be taken at 120 minutes post administration of intravenous paracetamol
3110246|NCT01821859|Experimental|Abraxane/Bevacizumab|"Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.~Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion."
3110247|NCT01821846||Liraglutide|
3110248|NCT01821833|Experimental|Arm I (Omega-3 fatty acid)|"Four Omega-3 fatty acid capsules (at 1 gram/capsule) are administered orally daily.~The capsules may be administered either once daily or as 2 capsules two times daily."
3110249|NCT01821833|Placebo Comparator|Arm II (placebo)|"Four placebo capsules (at 1 gram microcrystalline cellulose/capsule) are administered orally daily.~The capsules may be administered either once daily or as 2 capsules two times daily."
3110250|NCT01821820|Experimental|Pistachios|Pistachio treatment (3 oz/d) for two weeks; 3 oz pistachio nuts and water (1.5 oz. before, and 1.5 oz during) cycling 75 km.
3110251|NCT01821820|No Intervention|No pistachios|No pistachios for two weeks, or before and during 75 km cycling.
3110252|NCT01821807||26 gauge quincke|Patients (n=150) will be treated with 26 gauge quincke spinal needle for spinal anesthesia for cesarean section.
3110253|NCT01821807||26 gauge atraucan|Patients (n=110) will be treated with 26 gauge atraucan spinal needle for spinal anesthesia for cesarean section.
3110254|NCT01821781|Experimental|Preparative|
3110255|NCT01821768|No Intervention|Arm 1: No sentinal lymph node biopsy|Patients will receive no additional axillary surgery which is experimental.
3110256|NCT01821768|Active Comparator|Arm 2: Sentinel lymph node biopsy|Patients will receive standard of care sentinel lymph node biopsy
3110257|NCT01821755|Experimental|Behavioral: Foster parent intervention|Foster parents receive a foster parent intervention consisting of 10 individual home visits and three group sessions. Duration of the intervention is four months
3110258|NCT01821755|No Intervention|Control|waiting-list control group who receive care-as-usual
3110259|NCT01821742||Children requiring fluid bolus on PICU|
3110260|NCT01821729|Experimental|Experimental Arm|FOLFIRINOX, Losartan, Proton Beam Radiation Therapy
3110261|NCT01821716|Experimental|1|"Three concentrations of Dermatophagoides pteronyssinus allergen extract (10, 1, 0.1 mg/ml)~Positive control (10 mg/ml histamine dihydrochloride)~Negative control (glycerinated phenol saline solution)"
3110262|NCT01821703|Experimental|LY3045697|Escalating dose (0.1 milligrams [mg] up to 100 mg) of LY3045697 administered once daily, orally, for 8 days in 2 of 3 dosing periods
3110263|NCT01821703|Active Comparator|Spironolactone|25 mg spironolactone administered once daily, orally, for 8 days in up to 1 of 3 dosing periods
3110264|NCT01821703|Placebo Comparator|Placebo|Placebo matching LY3045697 administered once daily, orally for 8 days in up to 1 of 3 dosing periods
3110265|NCT01821690|Experimental|Buspirone Treatment|starting at 15 mg/day and ending at 60 mg/day as prescribed
3110266|NCT01821690|Placebo Comparator|Buspirone Placebo|placebo tablets as prescribed
3110267|NCT01821677|Experimental|Low Dose Danazol|Low Dose Danazol
3110268|NCT01821677|Placebo Comparator|Placebo|Placebo
3110269|NCT01821664||Prosthetic vascular graft implantation, follow up|
3110270|NCT01821651|Experimental|HeartNavigator|Group with HeartNavigator-Software
3110271|NCT01821651|Active Comparator|Control|Control-group without HeartNavigator-Software
3110272|NCT01821651|Experimental|EchoNav|Group with EchoNav-Software
3110273|NCT01821651|Active Comparator|Conrol|Control-group without EchoNav-Software
3110274|NCT01821638||Older adults with heart failure|Older adults with heart failure
3110275|NCT01821625|Experimental|Thrombocytopenic (Low Platelet) Patients|"All study patients will undergo intervention in this study.~The intervention will be a lead-in with eltrombopag and antiviral triple therapy (interferon, ribavirin and boceprevir)."
3110315|NCT01821287||CHD Infants|Infants with a single ventricle (Congenital Heart Disease) CHD admitted to Cincinnati Children's Hospital Medical Center (CCHMC) for neonatal medical management or surgical palliation
3110316|NCT01821287||Normal Controls|Healthy newborns (full-term infants with no known medical problems) recruited from Cincinnati Children's Hospital Medical Center (CCHMC) and private practices
3112040|NCT01809470|Experimental|Call of Duty|Playing the video game 'Call of duty' for 1 hour
3110276|NCT01821612|Other|mFOLFIRINOX, chemoradiation, surgery and gemcitabine|"Each patient will receive mFOLFIRINOX therapy administered every other week for a total of 4 cycles. Each treatment cycle is a total of 14 days. This treatment program consists of four drugs (oxaliplatin 85 mg/m^2 IV over 2 hours on day 1 followed by irinotecan 180 mg/m^2 IV over 90 minutes on day 1 followed by, leucovorin 400 mg/m^2 IV over 2 hours on day 1 followed by 5-FU 2400 mg/m^2 IV over 46-48 hours).~Two to six weeks following treatment with the mFOLFIRINOX, if the tumor has not spread to other parts of the body then the patient will receive capecitabine 825 mg/m^2, twice daily for 28 days along with radiation therapy. Patients will have surgery within 4-10 weeks of the last dose of chemoradiation if the tumor has gotten smaller or stayed the same.~Within 6-8 weeks following surgery, patients will receive gemcitabine for 2 cycles (1 cycle is 28 days). Gemcitabine will be given IV on days 1, 8 and 15 of every 28 day cycle."
3110277|NCT01821599|Active Comparator|Conventional group|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction
3110278|NCT01821599|Experimental|Accelerated group|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction
3110279|NCT01821586|Experimental|Modified ORS-1|Modified ORS -1 will be assigned to the enrolled particfipants according to the randomization schedule.
3110280|NCT01821586|Experimental|Modified ORS-2 (ReSoMal)|Modified ORS -2 (ReSoMal) will be assigned to the enrolled particfipants according to the randomization schedule.
3110281|NCT01821586|Experimental|Modified ORS-3 (Benefibre)|Modified ORS -3 (Benefibre) will be assigned to the enrolled particfipants according to the randomization schedule.
3110282|NCT01821573|Experimental|Botox Injection|Patients treated by botulinum toxin.
3110283|NCT01821573|Placebo Comparator|Saline Solution|Patients treated with saline solution.
3110284|NCT01821560|Placebo Comparator|Sugar pill|Placebo-treated subjects will follow the identical schedule as Baclofen subjects.
3110285|NCT01821560|Active Comparator|Baclofen|Baclofen will be dispensed in pill form. Baclofen will be prescribed at 20 mg 4 times per day. Each baclofen pill will be 10 mg. Thus, 2 pills will be taken at each scheduled dose for a total of 8 pills a day over a period of 8 weeks. In this way, the titration schedule, taper and potential dose reductions can be managed.
3110286|NCT01821534||All Participants|Healthy volunteers. No treatment (intervention) was administered.
3110287|NCT01821521|Experimental|AGSPT_L20|tablet, q.d.
3110288|NCT01821521|Active Comparator|Pantoloc 40mg|tablet, q.d.
3110289|NCT01821508|Active Comparator|Clinical treatment|Best and most modern clinical treatment of type 2 diabetes mellitus.
3110290|NCT01821508|Active Comparator|Roux-En-Y gastric bypass surgery|"A metabolic surgery consists of any surgical procedure in which there is any anatomical alteration in the gastrointestinal tract by means of a diversion of food passage, resulting in improved metabolic control in patients with type 2 diabetes mellitus [SCHULMAN, 2009]."
3110291|NCT01821495|No Intervention|B|After accepting concurrent radiotherapy and chemotherapy, patients will just regularly follow up.
3110292|NCT01821495|Experimental|A|After accepting concurrent radiotherapy and chemotherapy, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK)treatment.
3110293|NCT01821482|Experimental|A|After complete resection or TACE, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK) (every 4 weeks)
3110294|NCT01821482|No Intervention|B|After complete resection or TACE, Patient only regularly follow up
3110295|NCT01821469|Experimental|psychoeducation|psychoeducation (12 weeks)
3110296|NCT01821456||Antiinfectives|To analyze the efficacy of antiinfectives at high risk patients
3110297|NCT01821443|Experimental|Stereotactic Radiosurgery (SRS)|Stereotactic radiosurgery technique via Gamma Knife® Perfexion™ radiosurgical system
3110298|NCT01821430|Experimental|Pregabalin|Pregabalin 400mg / Day
3110299|NCT01821430|Placebo Comparator|Placebo Control|Placebo Tablet
3110300|NCT01821417|Experimental|Microtextured dental implant|Randomized for microtextured dental implant treatment
3110301|NCT01821417|Active Comparator|Dental implant|Randomized dental implant treatment with machined-collar implants
3110302|NCT01821404|Placebo Comparator|Placebo|Similar capsules as in the atorvastatin arm, but including no active ingredient. Used daily for 3-5 weeks before prostatectomy
3110303|NCT01821404|Experimental|Atorvastatin|Atorvastatin capsules orally, 80 mg daily for 3-5 weeks before prostatectomy
3110304|NCT01821391|Experimental|NDL-PDT/c-PDT|Metvix natural daylight photodynamic therapy and Metvix conventional photodynamic therapy
3110305|NCT01821391|Experimental|NDL-PDT/placebo c-PDT|Metvix natural daylight photodynamic therapy and Metvix-placebo conventional photodynamic therapy
3110306|NCT01821378|Experimental|Lurasidone 20 mg|Lurasidone 20 mg once daily
3110307|NCT01821378|Experimental|Lurasidone 80 mg|Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2
3110308|NCT01821378|Placebo Comparator|Placebo|Placebo Comparator 20 or 80 mg once daily
3110309|NCT01821352|Active Comparator|Erchonia Obesity Laser|The Erchonia® Obesity Laser is made up of 10 independent 17 milliWatts (mW), 532 nanometer (nm) green laser diodes, each diode positioned 120 degrees apart from the next with each titled at a 30 degree angle. The Erchonia® Obesity Laser is a pulsed wave variable frequency device.
3110310|NCT01821352|Placebo Comparator|Placebo Laser|Laser device emitting sham green light that has no therapeutic effect.
3110311|NCT01821313|Experimental|Moderate exercise|The subject will participate in a 6-week exercise intervention, 3 days per week on a cycle ergometer. The moderate exercise group will begin with a five-minute warm-up, cycling at 50-55% of the subject's maximal heart rate as determined by the initial fitness assessment. Following the warm-up, the moderate group will cycle for 30 minutes at 65-70% of maximal heart rate. The subject will then complete a 5-minute cool-down at 50-55% of maximal heart rate. Heart rate will be measured via individual heart rate monitors.
3110312|NCT01821313|Active Comparator|High Intensity Interval Exercise (HIIE)|The subject will participate in a 6-week exercise intervention, 3 days per week on a cycle ergometer. The subjects in the HIIE group will begin with a five-minute warm-up at 50-55% of the subject's maximal heart rate as determined by the initial fitness assessment. Following the warm-up, the HIIE group will perform 10, two-minute exercise bouts at 90-95% of maximal heart rate, with one minute of active recovery at 55% of maximal heart rate between each interval for a total of 30 minutes. They will complete the test with a 5-minute cool-down at 50-55% of maximal heart rate. Heart rate will be measured via individual heart rate monitors.
3110317|NCT01821274|Experimental|topical Diltiazem Hydrochloride 2% Cream|0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.
3110318|NCT01821274|Placebo Comparator|Vehicle Cream|0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.
3110319|NCT01821274|Active Comparator|0.2% sodium lauryl sulfate (SLS)|0.2 mL applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a positive control.
3110320|NCT01821274|Placebo Comparator|0.9% saline|0.2 mL, applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a negative control.
3110321|NCT01821248|Experimental|Gemcitabine, Cisplatin, S-1|1000mg/m2/day1, 25mg/m2/day1, 100mg/body/day1-7
3110322|NCT01821235|Experimental|Neurontin® (gabapentin) batch A|
3110323|NCT01821235|Experimental|Neurontin® (gabapentin) batch B|
3110324|NCT01821235|Experimental|Gabasandoz® (gabapentin) batch A|
3110325|NCT01821235|Experimental|Gabasandoz® (gabapentin) batch B|
3110326|NCT01821222|Experimental|Wired mothers intervention|The wired mothers' intervention consisted of two components: an automated short messaging service (SMS) system providing wired mothers with unidirectional text messaging and a mobile phone voucher system providing the possibility of direct two-way communication between wired mothers and their primary health care providers. While only women with registered phone numbers received text messages, all women in the intervention group were given mobile phone vouchers to contact their local primary health care provider.
3110327|NCT01821222|No Intervention|Control|The control group received standard care
3110328|NCT01821209|No Intervention|Control|Standard robot assisted radical prostatectomy
3110329|NCT01821209|Experimental|Sling|Placement of sling at time of robot assisted radical prostatectomy
3110330|NCT01821196|Experimental|biopsy|Additional biopsies by means endoscopy, 5 from tumor tissue, 5 from adjacent normal mucosa per patient.
3110331|NCT01821183||hip rotators muscle strength|
3110332|NCT01821183||control group|no intervention
3110333|NCT01821170|Experimental|Cognitive remediation|
3110334|NCT01821170|Active Comparator|Supportive psychotherapy|
3110335|NCT01821170|Active Comparator|Methylphenidate|
3110336|NCT01821157|Active Comparator|Flapless|Flapless: Gingivectomy and osteoplasty, as necessary, will be performed without flap elevation.
3110337|NCT01821157|Active Comparator|Open-flap|Gingivectomy and osteoplasty, as necessary, will be performed with flap elevation
3110338|NCT01821144|Other|Control|No salt awareness education
3110339|NCT01821144|Experimental|Salt reduction|Salt reduction
3110340|NCT01821131|Experimental|30g ground flaxseed per day|consume 1 muffin containing 30g ground flaxseed every day for 4 weeks
3110341|NCT01821131|Experimental|20g ground flaxseed per day|consume 1 muffin containing 20g ground flaxseed every day for 4 weeks
3110342|NCT01821131|Placebo Comparator|0g ground flaxseed per day|consume 1 muffin containing 0g ground flaxseed every day for 4 weeks
3110343|NCT01821118|Experimental|1|
3110344|NCT01821118|Placebo Comparator|2|
3110345|NCT01821105|Experimental|Preoperative PET and CT Scans|Patients undergo preoperative whole-body PET scans and CT scans of the abdomen and pelvis. Patients then receive fluoro-deoxyglucose (FDG)IV 60-90 minutes prior to surgery and undergo intraoperative CT scans using a handheld probe and computer navigation system.
3110346|NCT01821092|Active Comparator|standard implant, switching platform|osseointegrated implant insertion and abutment connection Implants inserted in healed ridge, prosthetic connection with switching platform
3110347|NCT01821092|Active Comparator|immediate implant, switching platform|osseointegrated implant insertion and abutment connection Implants inserted in immediate post-extraction sites, prosthetic connection with switching platform
3110348|NCT01821079|Experimental|PF-05175157 PIC in fed state|200 mg single dose of PF-05175157 administered as PIC in the fed state (following a standard high fat meal).
3110349|NCT01821079|Experimental|PF-05175157 tablet in fed state|200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).
3110350|NCT01821079|Experimental|PF-05175157 tablet in fed state (repeat)|200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).
3110351|NCT01821079|Experimental|PF-05175157 tablet in fasted state|200 mg single dose of PF-05175157 administered as tablet formulation in the fasted state (following at least a 10 hour fast).
3110352|NCT01821066|Experimental|Two-Period Fixed-Sequence Arm|This arm is comprised of two treatment periods in fixed sequence. Period 1 is 7 days long, while Period 2 is 28 days long. In Period 1 the subjects receive a single 125 mg oral dose of PD-0332991 on Day 1. In Period 2 the subjects receive 4 daily 60 mg oral doses of tamoxifen (Days 1-4), followed by 23 daily 20 mg oral doses of tamoxifen (Days 5-27). On Day 22 of Period 2 the subjects receive a second 125 mg oral dose of PD-0332991.
3110353|NCT01821053||pregestational type 1 diabetes|It is an observational study. No intervention is made.
3110354|NCT01821040|Experimental|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
3110355|NCT01821040|Active Comparator|Prednisone IR|Prednisone IR 15mg daily start dose (immediate release) administered in the morning
3110356|NCT01821027|Experimental|Canagliflozin + simvastatin|Each volunteer will receive a single dose of simvastatin on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 2 through 6. On Day 7 volunteers will receive a single dose of simvastatin in combination with a single dose of canagliflozin.
3110357|NCT01821014|Experimental|Telemedicine First|Patients whose first physician visit during the clinic was using videoconference, a form of telemedicine, and whose second physician visit during the clinic was with a physician in-person.
3110358|NCT01821014|Experimental|Telemedicine Second|"Patients whose first physician visit during the clinic was with a physician in-person, and whose second physician visit during the clinic was using videoconference, a form of telemedicine. This is the reverse order of visits of the Telemedicine fist arm."
3110359|NCT01821014|Active Comparator|Two physician visits|Patients who had two sequential visits with different in-person physicians.
3110399|NCT01820702|Active Comparator|defined training programme|
3110400|NCT01820702|No Intervention|Control|
3110360|NCT01821001|Experimental|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
3110361|NCT01820988||Sarcopenic vs. non-sarcopenic|Participants are classified as sarcopenic/non-sarcopenic according to the criteria of the European Working Group of Sarcopenia in Older People (EWGSOP).
3110362|NCT01820975|Experimental|High protein intake|High protein intake: large bolus of protein in teh diet the day before testing
3110363|NCT01820975|Placebo Comparator|No protein intake|No protein in the diet the day before testing
3110364|NCT01820962|Active Comparator|A: heparin (Heparin LEO)|After each use, the central venous catheter lumen will be flushed with 10 ml 0.9% NaCl and then locked with heparin 5000 IU/ml(standard treatment)using a volume exactly equivalent to the internal volume noted on each catheter.
3110365|NCT01820962|Experimental|B: concentrated citrate (Citralock)|locking the central venous catheter with concentrated citrate after each use
3110366|NCT01820949||Control cohort|Standard care before implementation (pre-implementation)
3110367|NCT01820949||PBM cohort|After implementation of PBM program (post-implementation)
3110368|NCT01820936|Experimental|Treatment A: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water 30 minutes after completing a high-fat breakfast
3110369|NCT01820936|Experimental|Treatment B: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water after fasting for at least 10 hours and 30 minutes before starting a high-fat breakfast
3110370|NCT01820936|Experimental|Treatment C: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water 2 hours after completing a high-fat breakfast
3110371|NCT01820936|Experimental|Treatment D: PCI-32765|420 mg capsules administered with 240 mL noncarbonated water after fasting at least 10 hours
3110372|NCT01820936|Experimental|Treatment E: PCI-32765|840 mg capsules administered with 240mL noncarbonated water 30 minutes after completing a high-fat breakfast
3110373|NCT01820923|Experimental|Brain stimulation|"Brain stimulation will consist of 4 types of intervention:~real transcranial direct current stimulation (two weeks, five days a week)~a week of wash-out~Sham transcranial direct current stimulation (two weeks, five days a week)~two weeks of wash-out~real repetitive transcranial magnetic stimulation (two weeks, four days a week)~a week of wash-out~Sham repetitive transcranial magnetic stimulation (two weeks, three days a week)~Stimulations will be counterbalanced between patients."
3110374|NCT01820910|Experimental|Doxycycline|
3110375|NCT01820897|Experimental|Fosfomycin-Trometamol, Sulfamethoxazole trimethoprim, placebo|Fosfomycin-Trometamol 3 grams every 10 days for 6 months Plus Sulfamethoxazole trimethoprim 800/160 mg monday, wednesday and friday for 6 months Plus Placebo of Sulfamethoxazole trimethoprim Tuesday,thursday, saturday and sunday for 6 months.
3110376|NCT01820897|Active Comparator|Sulfamethoxazole trimethoprim, placebo|Sulfamethoxazole trimethoprim 800/160 mg every day for 6 months plus Placebo of Fosfomicyn-trometamol every 10 days for 6 months
3110377|NCT01820884|Experimental|Total Hysterectomy (TH)|Patients may receive total hysterectomy (TH) and bilateral pelvic and para-aortic lymph node dissection (BPLND).
3110378|NCT01820884|Active Comparator|TH and bilateral salpingo-oophorectomy (TH/BSO)|Patients may receive total hysterectomy, bilateral salpingo-oophorectomy (BSO) and bilateral pelvic and para-aortic lymph node dissection.
3110379|NCT01820871|Experimental|application arm|"The patients of application arm have the smartphone application (android) for management of type 2 DM.~The application contains action plans and alarm system for each situation of serum fasting glucose, blood pressure, body weight, exercise amount, calori intake, medication, etc."
3110380|NCT01820871|Active Comparator|conventional arm|The patients of conventional arm have the booklet for management of type 2 DM. The application contains general medical guideline and knowledge for management of type 2 DM such as,exercise amount, calori intake, medication, etc.
3110381|NCT01820858|Experimental|Adjuvant Chemotherapy|Paclitaxel: 175 mg/m(2) intravenously (IV); followed by Paraplatin (Carboplatin Injection) AUC=5 IV. 3-6 cycles as necessary.
3110382|NCT01820858|Active Comparator|Adjuvant Radiotherapy|"Histopathological grade G3 and <50% myometrial invasion: Vaginal brachytherapy 5Gy, 3 times;~Histopathological grade G3 and vascular space involvement: Pelvic radiation 45-50 Gy;~≥50% myometrial invasion: Pelvic radiation 50 Gy + Vaginal brachytherapy 5Gy, 2-4 times."
3110383|NCT01820845||Cohort of children with scoliosis surgery|
3110384|NCT01820832|Experimental|Calcitriol|General treatments (such as blood pressure control, lipid lowering, and so on) plus Calcitriol 0.5 ug/BIW for 24 weeks.
3110385|NCT01820832|No Intervention|Control|General treatments.
3110386|NCT01820819||Registered or not on the transplantation national waiting list|
3110387|NCT01820806|Experimental|[14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of [14C] GLPG0634 on one occasion
3110388|NCT01820793|Experimental|cefoxitin|this study is centered on women with pyelonephritis without severity symptoms due to ESBL-producing E. coli.
3110389|NCT01820780|Experimental|intensive disease management|Planned consultations with HF specialist including biological test at weeks 1, 2 and 4; in addition to usual care.
3110390|NCT01820780|Active Comparator|usual disease management|usual care according to guidelines; including first medical consultation and biological test within the 4-week time following discharge.
3110391|NCT01820767|Experimental|Paricalcitol|SUBGROUP 1 (G1): Paricalcitol oral dosis triphosphoinositide mgc/100, 3 days a week.
3110392|NCT01820767|Active Comparator|Paricalcitol, Atorvastatin|SUBGROUP 2 (G2): Paricalcitol (same dosis than G1) + Atorvastatin (1 daily dosis 20 mg)
3110393|NCT01820767|Active Comparator|Atorvastatin|SUBGROUP 3 (G3): Atorvastatin (same G2 dosis)
3110394|NCT01820754|Experimental|Ipilimumab|Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery) Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses
3110395|NCT01820728|Experimental|DA-3801 injection|Recominant human follicle stimulating hormone 75 IU/day is injected for 14 days
3110396|NCT01820728|Active Comparator|Gonal-F®|75 IU/day is injected for 14 days
3110397|NCT01820715|Experimental|600㎍ of DA-3030 Injection|600㎍ of DA-3030 is injected once a day, for 5 continuous days.
3110398|NCT01820715|Placebo Comparator|Placebo|Placebo(a salin drip) is injected once a day, for 5 continuous days.
3110403|NCT01820663|Experimental|Modified Atkins Diet|Patients will receive a 14 day menu consisting of the Modified Atkins diet, a low-carbohydrate, high protein, high fat diet.
3110404|NCT01820663|Placebo Comparator|Control Diet|Patients will receive a diet (e.g. regular, low cholesterol, diabetic) determined by the attending physician.
3110405|NCT01820637|Experimental|Test device arm (DES SFA)|Patients in this arm will receive the study device: the Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)
3110406|NCT01820624|Experimental|Treatment (tretinoin, lithium carbonate)|Patients receive tretinoin PO every 12 hours on days 1-7 and 15-21 and lithium carbonate PO TID on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3110407|NCT01820611||With Bonemaster HA|100 patients using Arcos Revision Stem System with BoneMaster Hydroxyapatite
3110408|NCT01820611||Without BoneMaster HA|100 patients using Arcos Revision Stem System without BoneMaster Hydroxyapatite
3110409|NCT01820598|Other|m-NMES first|Multisite electrostimulator first (Visit 1) and conventional electrostimulator then (Visit 2)
3110410|NCT01820598|Other|c-NMES first|Conventional electrostimulator first (Visit 1) and multisite electrostimulator then (Visit 2)
3110411|NCT01820585|Placebo Comparator|Placebo|Tablets
3110412|NCT01820585|Active Comparator|ESL 400 mg|Eslicarbazepine acetate (BIA 2-093) tablets
3110413|NCT01820585|Active Comparator|ESL 800 mg|Eslicarbazepine acetate (BIA 2-093) tablets
3110414|NCT01820585|Active Comparator|ESL 1200 mg|Eslicarbazepine acetate (BIA 2-093) tablets
3110415|NCT01820572|Experimental|Belatacept|Belatacept 5 mg/kg intravenous 30 minute infusion on Days 1, 15, 29, 43, 57 then every 28 days for 24 months
3110416|NCT01820572|Active Comparator|CNI|"Tacrolimus 4-11 ng/mL tablet orally according to package insert for 24 months~Cyclosporine 50-250 ng/mL tablet orally according to package insert for 24 months"
3110417|NCT01820559|Active Comparator|ESL 1200 mg|eslicarbazepine acetate 1200 mg
3110418|NCT01820559|Active Comparator|ESL 800 mg|eslicarbazepine acetate 800 mg
3110419|NCT01820559|Placebo Comparator|Placebo|Placebo tablets
3110420|NCT01820533||smokers|
3110421|NCT01820520|Experimental|Double staining with brilliant blue G during vitrectomy|
3110422|NCT01820507|Experimental|High Flow Conditioned Oxygen Therapy|Intervention: The Optiflow(R) device supplies oxygen in controlled concentrations and at high flow (from 10 to 70 liters/min) through special nasal cannulae. The device also humidifies the gases mixtures up to 100% relative humidity.
3110423|NCT01820507|Active Comparator|Standard Oxygen Therapy|The standard way of oxygen supply after extubation is either by nasal cannulae at flow between 1 and 5 liters/min or by mask with controlled oxygen concentration from 24% to 50%.
3110424|NCT01820494|Experimental|Experimental Infant Formula|Complete amino acid-based infant formula
3110425|NCT01820481|Experimental|Treatment 1|
3110426|NCT01820481|Experimental|Treatment 2|
3110427|NCT01820481|Experimental|Treatment 3|
3110428|NCT01820481|Placebo Comparator|Placebo|
3110429|NCT01820468|Experimental|Adapted critical time intervention team|Community-based team will help facilitate early inpatient discharge and re-entry into the community.
3110430|NCT01820468|No Intervention|Regular inpatient care|
3110431|NCT01820455|Active Comparator|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal Mupirocin ointment daily for 5 days
3110432|NCT01820455|Placebo Comparator|Soap baths, Lubricating jelly|Soap and water baths with lubricating jelly to each nare daily for 5 days
3110433|NCT01820442|Active Comparator|Lofexidine Titration in Buprenorphine Maintained Subjects|Buprenorphine maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID (4 tablets QID) or to the highest level tolerated. Following this initial titration attempt, all subjects will have their buprenorphine dose reduced by 50% and lofexidine titration efforts will resume.
3110434|NCT01820442|Placebo Comparator|Placebo Titration in Buprenorphine Maintained Subjects|Buprenorphine maintained subjects will be titrated on placebo tablets in ascending doses of 1 tablet starting with 2 tablets (e.g., Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) to mimic titration for subjects randomized to lofexidine.
3110435|NCT01820429||First 48 hours|Patients in the first 48 hours of non ST-elevation acute coronary syndromes.
3110436|NCT01820429||3 months after discharge|Patients with 3 months after hospital discharge for non ST-elevation acute coronary syndromes.
3110437|NCT01820416|Experimental|Low-Level Laser Therapy|Low-level laser applied for approximately 4 minutes to the area around the pinna, the back of the neck, and the top of the head.
3110438|NCT01820416|Placebo Comparator|Disabled Laser|Low-level laser device with laser diodes disabled. Also applied for approximately 4 minutes to the area around the pinna, the back of the neck, and the top of the head.
3110439|NCT01820416|No Intervention|Control|Visit laboratory using same schedule as experiment and placebo. No Low-level laser or any treatment applied. Used to assess normal test-retest variability.
3110440|NCT01820403|Experimental|portion size small|400 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
3110441|NCT01820403|Experimental|portion size medium|800 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
3110442|NCT01820403|Experimental|portion size large|1600 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
3110443|NCT01820403|No Intervention|control|no box lunch provided to participants.
3110444|NCT01820377|Experimental|Aboriginal Youth Mentorship Program|High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4 students, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s act as the intervention group.
3110445|NCT01820377|No Intervention|Control Group|This group acts as a control, and are not apart of the Aboriginal Youth Mentorship Program
3110446|NCT01820364|Experimental|LGX818 single agent|Patients had to have written documentation of a BRAFV600 mutation, which was to have been obtained locally on a fresh tumor biopsy (preferred) or on the most recent archival tumor sample available.
3110447|NCT01820338|Experimental|Behavioral Family Intervention|Child and Parent attend intervention including nutrition and physical activity education, plus behavioral strategies to facilitate behavior and weight status change
3110448|NCT01820338|Experimental|Behavioral Parent-Only Intervention|Only parents attend intervention including nutrition and physical activity education, plus behavioral strategies to facilitate behavior and weight status change
3110449|NCT01820338|Active Comparator|Education Control|Child and parent attend intervention that includes only nutrition and physical activity education; no instruction or assistance in the use of behavioral strategies are included in this condition
3110450|NCT01820325|Experimental|Buparlisib + Carboplatin + Paclitaxel|Carboplatin and paclitaxel plus buparlisib for up to 6 cycles, followed by blinded buparlisib maintenance
3110451|NCT01820325|Placebo Comparator|Placebo + Carboplatin + Paclitaxel|Carboplatin and paclitaxel plus buparlisib-matching placebo for up to 6 cycles, followed by blinded placebo maintenance
3110452|NCT01820299|Experimental|Grape Seed Extract and Vitamin D|All patients will take Grape Seed Extract from Day 1 to Day 21. All patients will take Grape Seed Extract and Vitamin D together from Day 22 until Day 64. For all patients on the study, patients will take Vitamin D once a day at a dose of 4000IU.
3110453|NCT01820286|Experimental|Positive psychology intervention|4-week positive psychology intervention of 1 positive psychology exercise per week. Exercises will include 1) recalling 3 good events, 2) writing a letter of thankfulness, 3) using a personal strength, 4) envisioning a best possible future.
3110454|NCT01820286|Active Comparator|Recollection intervention|4-week recollection intervention of 1 recollection exercise per week. Exercises will include recalling events related to 1) daily activities, 2) health, 3) social life, 4) morning and evening.
3110455|NCT01820260|Other|Part 1: Ingenol mebutate gel|Open-label, dose escalation, 2 or 3 days treatment
3110456|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel X dose for 3 days treatment|X dose for 3 days treatment
3110457|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel X dose for 2 days treatment|X dose for 2 days treatment
3110458|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel Y dose for 3 days treatment|Y dose for 3 days treatment
3110459|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel Y dose for 2 days treatment|Y dose for 2 days treatment
3110460|NCT01820260|Placebo Comparator|Part 2: Placebo for 3 days treatment|Placebo for 3 days treatment
3110461|NCT01820260|Placebo Comparator|Part 2: Placebo for 2 days treatment|Placebo for 2 days treatment
3110462|NCT01820247|Experimental|enteral nutrition|The patients receive treatment of enteral nutrition only.
3110463|NCT01820247|Experimental|tripterygium glycosides|The patients receive treatment of tripterygium glycosides only.
3110464|NCT01820247|Experimental|tripterygium glycosides and enteral nutrition|The patients receive treatment of tripterygium glycosides and enteral nutrition.
3110465|NCT01820234|Other|In-person dermatology evaluation|Health care modality
3110466|NCT01820234|Other|Store-and-forward teledermatology evaluation|Health care modality
3110467|NCT01820221|Active Comparator|Arm 1: Skin closure with suture|Subjects in this group will be randomized to suture for skin closure with computer generated random card draw.
3110468|NCT01820221|Active Comparator|Arm 2: Skin closure with staples|Subjects randomized to skin closure with staples with computer generated random card draw.
3110469|NCT01820208|Placebo Comparator|Placebo|Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
3110470|NCT01820208|Experimental|G-CSF|G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
3110471|NCT01820195|Active Comparator|Intravenous N Acetyl Cystein|1200 mg IV N- Acetyl Cystein half an hour before contrast administration. This group will also take oral placebo
3110472|NCT01820195|Placebo Comparator|Placebo|Patients on both oral placebo and IV placebo just like patients on oral and IV N-acetyl cystein groups in regard of dose and timing.
3110473|NCT01820195|Active Comparator|Oral N Acetyl Cystein|Patients on 600 mg oral N-Acetyl Cystein bid started at the day before contrast exposure and continue until the next day of contrast exposure.These patients will also take IV placebo
3110474|NCT01820182|Experimental|capsocam capsula|capsocam capsula readings
3110475|NCT01820169|Experimental|Single arm|
3110476|NCT01820156|Experimental|HRP-PSG|First performance three nights of HRP and following one night of laboratory PSG
3110477|NCT01820156|Experimental|PSG-HRP|First perform laboratory PSG and following three nights of HRP
3110478|NCT01820143|Experimental|Treatment sequence ADBC|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
3110479|NCT01820143|Experimental|Treatment sequence BACD|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
3110480|NCT01820143|Experimental|Treatment sequence CBDA|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
3110481|NCT01820143|Experimental|Treatment sequence DCAB|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
3110482|NCT01820130|Experimental|Spinal Cord Stimulation system therapy|St Jude Medical EON mini rechargeable system
3110483|NCT01820117||Hodgkin lymphoma|"Participants previously treated at St. Jude Children's Research Hospital with thoracic radiation therapy for Hodgkin lymphoma.~Interventions: Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Comprehensive Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, and Ophthalmology Examination."
3110484|NCT01820117||Normal control|"A group of healthy individuals matched for age, sex and race.~Interventions: Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Comprehensive Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, and Ophthalmology Examination."
3110485|NCT01820104|Placebo Comparator|Placebo|oral sitagliptin 100 mg on day 6 after administration of placebo (30 mg per day) for 6 days
3110486|NCT01820104|Experimental|Combination of lansoprazole and sitagliptin|oral sitagliptin 100 mg on day 6 after administration of lansoprazole (30 mg per day) for 6 days
3110487|NCT01820091|Experimental|Cohort 1 - Fusilev - 20 doses|"5 mg/m2 QID (6 hours apart) starting on Days 2 and 16 (24 hours after Folotyn dose) for a total of 20 doses in a 28-day cycle~Days 2 and 16: 4 doses/day~Days 3 and 17: 4 doses/day~Days 4 and 18: 2 doses/day~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
3110488|NCT01820091|Experimental|Cohort 2 - Fusilev - 12 doses|"5 mg/m2 BID 8 hours apart on Days 2, 3, 4, 16, 17, and 18 for a total of 12 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
3110489|NCT01820091|Experimental|Cohort 3 - Fusilev - 8 doses|"5 mg/m2 BID 8 hours apart on Days 2, 3, 16, and 17 for a total of 8 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
3110490|NCT01820091|Experimental|Cohort 4 - Fusilev - 4 doses|"5 mg/m2 BID 8 hours apart on Days 2 and 16 for a total of 4 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
3110491|NCT01820091|Experimental|Cohort 5 - Fusilev - 2 doses|"5 mg/m2 once on Days 2 and 16 for a total of 2 doses in a 28-day cycle~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
3110492|NCT01820078|Experimental|Paricalcitol, Daily treatment, CKD|Experimental Arm
3110493|NCT01820078|Other|Daily treatment for CKD|Comparator Arm
3110494|NCT01820065||Patients undergoing phacoemulsification|Patients undergoing phacoemulsification for age-related cataract with implantation of a single-piece Acrysof IOL (SN60AT)
3110495|NCT01820052|Active Comparator|Oral Iron|Patient will receive 230 mg of oral elemental iron daily for 3 months
3110496|NCT01820052|Placebo Comparator|Oral Placebo|Oral Placebo tablets will be administered daily for 3 months
3110497|NCT01820039|Experimental|FertiScreen|all patients between 18 and 38 years, consulting their general practitioner for infertility will be asked to use FertiScreen.
3110498|NCT01820026|Experimental|Imipenem & Vancomycin & Azithromycin|"Tienam combined with vancomycin (1g/12 h) for Spontaneous bacterial peritonitis, cholangitis, sepsis without evidence of a source of infections.~Tienam combined with vancomycin (1g/12 h)and azythromycin (500 mg/24 h)for pneumonia"
3110499|NCT01820026|Active Comparator|Cefotaxime & Amoxicillin & Azithromycin|Cefotaxime IV(2g/12 h): for Spontaneous bacterial peritonitis, cholangitis, sepsis without evidence of specific site of infection Amoxicillin/clavulanic acid (2,2 g/8 h)or Ciprofloxacin (500 mg/12 h: urinary tract infections Amoxicillin/clavulanic acid (2,2 g/8 h)and azithromycin (500 mg/24 h): pneumonia Amoxicillin/clavulanic acid (2,2 g/8 h)for skin or soft tissue infection
3110500|NCT01820013|Experimental|Customised Orthoses|Customised Dynamic Elastomeric Fabric Orthoses (DEFO)
3110501|NCT01820013|Active Comparator|Rigid 'off the shelf' pelvic support|Serola Sacroiliac Belt.
3110502|NCT01820000|Experimental|Diffusion Weighted Imaging with MRI scans|Subjects will undergo a MRI (magnetic resonance imaging) scan where DWI (diffusion weighted imaging) will be performed. Subjects will not receive contrast during this sequence, but will receive contrast as standard MRI protocol.
3110503|NCT01819987|Active Comparator|Mailing information|Participants in the mailing information group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
3110504|NCT01819987|Experimental|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
3110505|NCT01819974|No Intervention|Control|The normal procedure at the ward
3110506|NCT01819974|Active Comparator|Stratified medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist in patients with highest medication error risk
3110507|NCT01819961|Experimental|MCT/LCT|Structural Fat Emulsion Injection 250ml per day, for 7 days
3110508|NCT01819961|Experimental|MCT/LCT and fish oil|Structural Fat Emulsion Injection 250ml and fish oil 100ml for 7 days.
3110509|NCT01819948|Experimental|single-arm|Two capsules in the morning, one at night, every day for a month, taken with a glass of water.
3110510|NCT01819935||linezolid (Zyvox)|
3110511|NCT01819935||Vancomycin|
3110512|NCT01819922|Experimental|PF-05175157|
3110513|NCT01819922|Placebo Comparator|Placebo|
3110514|NCT01819909|Experimental|Postoperative Jackins Exercise Protocol|Jackin's exercises were initially designed for patients with difficulty performing forward elevation. The patient initially is positioned supine to perform shoulder flexion. When the patient can actively elevate in the supine position, one to two pounds of weight is placed in the patients hand and the patient is asked to repeat the maneuver of supine active elevation. When the patient can do this with little difficulty, the head of the bed is elevated approximately 20 degrees from the supine position and the sequence is repeated. Once the patient is able to perform flexion in this elevated head position, the inclination of the patient is increased in 20 degree increments until the patient is able to perform upright sitting shoulder flexion.
3110515|NCT01819909|Experimental|Postoperative Pulleys Exercise Protocol|Pulleys have been used in postoperative shoulder rehabilitation to improve passive as well as active range of motion and develop strength.
3110516|NCT01819896||pacemakers and defibrillators|
3110517|NCT01819883||Active Acromegaly|All study subjects with acromegaly will be studied twice - once during the active stage of their disease (pre-treatment) and a second time: 3 months after treatment of acromegaly. Controls will be studied at one time point.
3110518|NCT01819883||Healthy controls|
3110519|NCT01819870|Experimental|Dilatrend SR capsule 32mg|
3110524|NCT01819844|Experimental|Closed-loop blood glucose control|Type 1 diabetes, Type 2 diabetes, total daily dose (TDD) of insulin that is > 1 u/kg or > 2 u/kg.
3110525|NCT01819831|Experimental|Preoperative proton radiation|Patients will receive 50 Gray equivalents (GyE) in 25 fractions with proton therapy, followed by surgery 4-8 weeks after completion of radiation.
3110526|NCT01819818||Paliperidone palmitate|
3110527|NCT01819805||Patients taking tramadol hydrochloride and acetaminophen|
3110528|NCT01819792|Other|patient with Acute Myeloïd Leukemia|
3110529|NCT01819779|Active Comparator|Exforge tab. 10/160mg|"amlodipine besylate (10mg as amlodipine)~valsartan 160mg"
3110530|NCT01819779|Experimental|Lodivixx tab. 5/160mg|"S-amlodipine nicotinate (5mg as S-amlodipine)~valsartan 160mg"
3110531|NCT01819766||IBD or PSC|Subjects will be men and women, 18 to 84 years of age, inclusive, who are at increased risk of developing colorectal cancer.
3110532|NCT01819753|Active Comparator|Single access|It was performed only single access standard PCNL in this group.
3110533|NCT01819753|Active Comparator|Multiple access|It was performed multiple access standard PCNL in this group
3110534|NCT01819740||patients with suspected prostate cancer|
3110535|NCT01819727|Active Comparator|BMN 165, 20mg/day|Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and > 900 μmol/L).
3110536|NCT01819727|Active Comparator|BMN 165, 40mg/day|Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and > 900 μmol/L).
3110537|NCT01819714|Experimental|Study population|Patients hospitalized at the Serre-Cavalier centre and who have Alzheimer's-type neurodegenerative disease (see inclusion criteria).
3110538|NCT01819701|Placebo Comparator|Placebo|starch
3110539|NCT01819701|Experimental|LC and Coenzyme Q10|L-carnitine: 1000 mg/d and 2000 mg/d Coenzyme Q10: 150 mg/d and 300 mg/d
3110540|NCT01819675|Experimental|High frequency (10Hz) rTMS|<high frequency rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 10Hz; Number of total stimuli: 750; Coil orientation: tangential to scalp
3110541|NCT01819675|Experimental|Low frequency (1Hz) rTMS|<low frequency rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1200; Coil orientation: tangential to the scalp
3110542|NCT01819675|Sham Comparator|Sham rTMS|<Sham rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1200; Coil orientation: perpendicular to scalp
3110543|NCT01819662|Placebo Comparator|Standard management|No echocardiogram
3110544|NCT01819662|Active Comparator|Enhanced standard management|Echocardiogram performed, with results to GP
3110545|NCT01819662|Active Comparator|Optimised heart failure management|Echocardiogram, followed by referral to comprehensive heart failure program for those with left ventricular dysfunction
3110546|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 100 mcg/d|
3110547|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 200 mcg/d|
3110548|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 300 mcg/d|
3110549|NCT01819649|Placebo Comparator|Yeast tablet|
3110550|NCT01819636|Experimental|Sparkling highly mineral bicarbonated sodium water|1.25 liter a day of sparkling highly mineral bicarbonated sodium water
3110551|NCT01819636|Placebo Comparator|Sparkling low mineralized water|1.25 liter a day of sparkling low mineralized water
3110552|NCT01819623|Experimental|Non-pharmacological therapy|This group will be supervised nonpharmacologic therapy
3110553|NCT01819623|No Intervention|Control|This group will receive the standard treatment for mild cognitive impairment
3110554|NCT01819610|Experimental|SPRIX|Subjects will be administered open label SPRIX according to subject weight.
3110555|NCT01819597|Other|EDAS surgery|EDAS surgery is an established form of indirect revascularization. The study arm in this study will receive EDAS surgery
3110556|NCT01819584||Patients below 15 years old|
3110557|NCT01819584||Patients above 15 years old|
3110558|NCT01819571|Experimental|Normal diastolic function group|
3110559|NCT01819571|Active Comparator|Diastolic dysfunction group|
3110560|NCT01819558|Experimental|immune therapy|6 administration every 2 weeks of intra-muscular 200 micrograms of protein recwt1-A10+AS01B at week 1, 3, 5, 7, 9 and 11.
3110561|NCT01819545||Alzheimer's disease|no intervention
3110562|NCT01819545||Mild cognitive impairment|no intervention
3110563|NCT01819545||Normal aging|no intervention
3110564|NCT01819532|Active Comparator|Immediate umbilical cord clamping|The umbilical cord will be clamped immediately after delivery.
3110565|NCT01819532|Experimental|Cord milking group|"The umbilical cord will be milked in direction towards neonate 4 times over the course of 10 minutes."
3110566|NCT01819519|No Intervention|Standard Prenatal Care|Participants will receive standard prenatal care from the time they are screened for CMV to delivery. This includes a CMV brochure.
3110567|NCT01819519|Experimental|Educational Intervention|This group will be approached during a routine prenatal visit and will receive a 5-10 minute educational intervention (CMV prevention video, preventive information, weekly text messages/emails as reminders for hygiene behaviors, developmental calendar with hygiene reminders).
3110568|NCT01819506|Experimental|Targeted Task Practice|"Targeted task practice is defined as a therapy program aimed at patient-specific upper extremity motor impairment levels and systematically progressed to assure an ongoing just right match between task-difficulty and patient-ability."
3110569|NCT01819506|Active Comparator|Non-Targeted Task Practice|Non-targeted task practice is a standard of care treatment consisting of task practice with no guidance from the measurement framework to systematically address specific upper extremity motor impairment levels or progress rehabilitation therapy.
3110608|NCT01819272|Active Comparator|2000 mg XR|2000 mg extended-release metformin once daily in the evening
3110609|NCT01819272|Placebo Comparator|Placebo|Placebo once daily in the morning
3110570|NCT01819493|Active Comparator|Standard Family-Based intervention|"Families randomized to the Standard Family-based Intervention will receive three-month family YMCA memberships, one orientation training session, access to available equipment and programming at the YMCA, and receive diabetes educational materials from the Power to Prevent curriculum via email. Based on our previous experience with AA adults, the investigators anticipate that all families will have access to email either at home or at work. Educational materials will be mailed to families without access to email. The study will also maintain contact with participants by sending holiday and birthday cards, as well as postcard reminders of scheduled data collection visits."
3110571|NCT01819493|Experimental|Lifestyle Intervention|"The lifestyle intervention for adults will involve a dietary weight loss program and an increase in caloric expenditure through moderate PA. Parents will be encouraged to decrease caloric intake in a sound manner to produce a total weight loss of 5%. The PA component will be to promote an increase in family home-based activity.~Children. The study will promote healthy eating behaviors, rather than restrictive eating plans with caloric restrictions."
3110572|NCT01819480|Experimental|Transoral robotic surgery|Transoral robotic surgery
3110573|NCT01819467|Active Comparator|Treatment Group|Patients in this group will receive Seprafilm onto the uterine incision and the anterior midline of the uterus.
3110574|NCT01819467|No Intervention|Control Group|This arm will be known as the control/no intervention group. This group will not receive Seprafilm or any other adhesion barrier method
3110575|NCT01819454|Experimental|pH monitoring sinusitis no polyps|30 patients with chronic rhinosinusitis without nasal polyposis, without asthma bronchiale or ASA syndrome
3110576|NCT01819454|Experimental|pH monitoring sinusitis with polyp|30 patients with chronic rhinosinusitis with nasal polyposis, without asthma bronchiale or ASA syndrome
3110577|NCT01819454|Experimental|pH monitoring sinusitis, polyps, asthma|30 patients with chronic rhinosinusitis with nasal polyposis and with asthma bronchiale and/or ASA syndrome
3110578|NCT01819441|Sham Comparator|Normal Azelnidipine/Perindopril|Systole blood pressure controlled between 130 mmHg~140 mmHg(with or without hydrochlorothiazide).
3110579|NCT01819441|Experimental|Intensive Azelnidipine/Perindopril|Systole blood pressure controlled below 130 mmHg(with or without hydrochlorothiazide).
3110580|NCT01819428|Experimental|NOV120101 (Poziotinib)|Single arm study with NOV120101(poziotinib)12mg PO daily administration
3110581|NCT01819415|No Intervention|Naive|Patients starting on intravitreal anti-VEGF treatment, not receiving Omega-3 supplements. They serve as wet-AMD controls.
3110582|NCT01819415|Active Comparator|Anti-VEGF plus AREDS-1 supplementation.|Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-1 plus Lutein supplementation formula.
3110583|NCT01819415|Experimental|Anti-VEGF plus AREDS-2|Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-2 supplementation formula, that includes Omega-3 metabolites (DHA and EPA).
3110584|NCT01819415|No Intervention|Control|Patients undergoing vitrectomy surgery for epiretinal membrane or macular hole had their vitreous samples to serve as controls.
3110585|NCT01819402|Active Comparator|Active Comparator: 1|up to 30 mg pioglitazone, tablet, orally, once daily
3110586|NCT01819402|Sham Comparator|Sham Comparator: 1|up to 4 mg/day glimepiride, tablet, orally, once daily
3110587|NCT01819389|Experimental|Imatinib and nilotinib combination|All patients will receive treatment as follows: imatinib 100 mg tablets, 200 mg daily for 6 months; and nilotinib 150 mg capsule, 300 mg daily for 6 months.
3110588|NCT01819376|Experimental|Intervention: Facebook updates|The experimental group will be encouraged to update their Facebook status regarding healthy lifestyle decisions at least once a day.
3110589|NCT01819376|No Intervention|Control: No Facebook|This group will be encouraged not to share their healthy lifestyle decisions on Facebook.
3110590|NCT01819363||Study group|Patients with Malignant pleural effusion according to inclusion and exclusion criteria.
3110591|NCT01819350|Experimental|G4 and G5|Application of antibiotic group of pediatric medicines and control group (sucrose 10 %)on dental biofilm.
3110592|NCT01819350|Experimental|G1, G2 and G3|Application of Nutritional, Respiratory and Endocrine groups medicines pediatric on dental biofilm
3110593|NCT01819324|Experimental|Targeting the Teachable Moment|Receiving Targeting the Teachable Moment Intervention materials (focusing on health behaviors and issues specific to breast cancer survivors) every other week for 4 months
3110594|NCT01819324|Active Comparator|Standardized Lifestyle Management|Receiving Standardized Lifestyle Management materials (focusing mostly on health behaviors) every other week for 4 months
3110595|NCT01819324|No Intervention|Usual Care|Receiving SLM materials at the end of the 7 months
3110596|NCT01819311|Experimental|Attention Bias Modification|Attention Bias Modification is a computer-based attention training program
3110597|NCT01819311|Placebo Comparator|Placebo Attention Task|The Placebo Attention Task uses the same computer-based format and stimuli as the Attention Bias Modification Task, but does not train attention toward or away from stimuli.
3110598|NCT01819298||bacteria colonization in CAT less 20|the incidence of sputum potential pathogenic microoragnism in patients with CAT scores less than 20
3110599|NCT01819298||the PPM in change of CAT >2|the change of potential pathogenic microorganism in CAT difference more than 2 while follow-up
3110600|NCT01819298||the change of CAT<=2|the change of potential pathogenic microorganism in CAT difference less than or equal to 2 while follow-up
3110601|NCT01819298||PPM in CAT>=20|the incidence of sputum potential pathogenic microoragnism in patients with CAT scores more than or equal to 20
3110602|NCT01819285|Active Comparator|Immediate Endocrine Therapy|Immediate Endocrine Therapy. Orchiectomy or LHRH Agonist Therapy plus (initially) Antiandrogen Therapy. Buserelin (BSRL); Cyproterone acetate (Androcur) (CPTR), Cyproterone acetate (Androcur)(NSC-81430). Treatment initiated within 1 month of randomization.
3110603|NCT01819285|Experimental|Delayed Endocrine Therapy|Orchiectomy or LHRH Therapy plus (initially) Antiandrogen Therapy. BSRL; CPTR. Treatment delayed until onset of symptoms.
3110604|NCT01819272|Experimental|600 mg DR|600 mg delayed-release metformin once daily in the morning
3110605|NCT01819272|Experimental|800 mg DR|800 mg delayed-release metformin once daily in the morning
3110606|NCT01819272|Experimental|1000 mg DR|1000 mg delayed-release metformin once daily in the morning
3110607|NCT01819272|Active Comparator|1000 mg XR|1000 mg extended-release metformin once daily in the evening
3110610|NCT01819259|Active Comparator|ADHD Nonsmokers|All participants will be non-smokers defined as never having smoked an entire cigarette and no tobacco use in the past 3 years. The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
3110611|NCT01819259|Active Comparator|Non-ADHD Nonsmokers|All participants will be non-smokers defined as never having smoked an entire cigarette and no tobacco use in the past 3 years. The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
3110612|NCT01819246|Active Comparator|Pheresis Treatment Arm|
3110613|NCT01819246|Sham Comparator|Control Arm|
3110614|NCT01819233|Experimental|Behavioral dietary intervention|Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet. Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy). Patients undergo radiation therapy QD 5 days a week for 6 weeks.
3110615|NCT01819220|Active Comparator|amlodipine/valsartan|
3110616|NCT01819220|Experimental|hydrochlorothiazide/telmisartan|
3110617|NCT01819207|Experimental|TEG group|
3110618|NCT01819194|Experimental|senofilcon A|Acuvvue Oasys with Hydaclear Plus with 38% water.
3110619|NCT01819155|Experimental|adjTIV|Children randomized to receive adjTIV
3110620|NCT01819155|Experimental|TIV|Children randomized to receive TIV
3110621|NCT01819155|Placebo Comparator|Placebo|Children randomized to receive Placebo
3110622|NCT01819142|Experimental|AutoloGel|Subjects will be treated with AutoloGel on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All patients will receive Autologel treatment
3110623|NCT01819129|Experimental|Faster-acting insulin aspart (FIAsp)|Meal time faster-acting insulin aspart is given in combination with once daily insulin glargine and metformin in a basal-bolus regimen. Insulin glargine and metformin treatment are open labelled background medication.
3110624|NCT01819129|Active Comparator|Insulin aspart|Meal time insulin aspart is given in combination with once daily insulin glargine and metformin in a basal-bolus regimen. Insulin glargine and metformin treatment are open labelled background medication.
3110625|NCT01819103||Acute myocardial infarction|Drug Adherence
3110626|NCT01819090|Active Comparator|No ventilation switch control|Neuromuscular patients non invasively ventilated in a stable state at the time of the study testing an usual (with no ventilation switch control) Elysee 150 ventilator while speaking
3110627|NCT01819090|Active Comparator|Ventilation switch control|Neuromuscular patients non invasively ventilated in a stable state at the time of the study testing an Elysee 150 ventilator with a ventilation switch control allowing them to control ventilation while speaking
3110628|NCT01819077||TMMR|Patients with cervical cancer Stages IB - IIA treated with TMMR and tLNE
3110629|NCT01819064||Children less than 5Kg.|This group consists of children who are ASA physical status I and II, less than 2 years of age and scheduled for elective surgical procedure and weigh less than 5Kg will receive atropine 5 mcg/kg IV during sevoflurane anesthesia.
3110630|NCT01819064||Children weighing 5Kg to 15Kg|This group consists of children who are ASA physical status I and II, less than 2 years of age and scheduled for elective surgical procedure and weigh between 5Kg and 15Kg will receive atropine 5 mcg/kg IV during sevoflurane anesthesia.
3110631|NCT01819051|Experimental|Plasma|Apply plasma to great toenail for up to 20 minutes, 1X/week for 3 weeks
3110632|NCT01819038|Experimental|High NGAL and early RRT|NGAL level > 400 ng/ml and start continuous renal replacement therapy early
3110633|NCT01819038|Experimental|High NGAL and late RRT|NGAL > 400 ng/ml and start continuous renal replacement therapy late
3110634|NCT01819038|Active Comparator|Low NGAL|NGAL < 400 ng/ml and starting continuous renal replacement therapy follow with absolute indication
3110635|NCT01819025|Experimental|4 face-to-face and smartphone-app|Four face-to-face therapy sessions and smartphone app as a complement and support to the four sessions.
3110636|NCT01819025|Active Comparator|TAU|10 sessions of face-to-face therapy, full behavioral activation
3110637|NCT01819012|Experimental|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
3110638|NCT01819012|Experimental|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
3110639|NCT01819012|Experimental|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
3110640|NCT01818999|Experimental|arm one|IXABEPILONE and STEREOTACTIC BODY RADIATION THERAPY (SBRT)
3110641|NCT01818986|Experimental|arm one|Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR)
3110642|NCT01818973|Experimental|Single Arm|"Neoadjuvant chemotherapy with XELOX: Xeloda, po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning; Oxaliplatin, iv, 130mg/m2, day 1; and Bevacizumab, iv, 7.5 mg/kg, day 1, during the first cycle (each cycle has 3 weeks).~Followed by chemoradiotherapy, 50 Gy/25 fractions during 5 weeks plus 2 cycles XELOX and Bevacizumab: Xeloda, po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning; Oxaliplatin, iv, 100mg/m2, day 1; and Bevacizumab, iv, 7.5 mg/kg, day 1.~6-7 weeks from the last radiation therapy, Total Mesorectal Excision (TME) surgery will be performed.~3-4 weeks after operation, 3 cycles XELOX (the same as the neoadjuvant chemotherapy) and 2 cycles Xeloda (po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning) will be administered."
3110643|NCT01818960|Active Comparator|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
3110644|NCT01818960|Active Comparator|IRA-PCI|IRA only PCI with planned staging for non-IRA lesions
3110645|NCT01818947||Gefitinib|
3110646|NCT01818934|Active Comparator|expert clinical exam only|all babies assigned to this group had expert clinical examination only, no hip ultrasound
3110647|NCT01818934|Active Comparator|selective hip ultrasound screening|all children classified at increased risk, based on clinical findings and/or risk factors (breech presentation, family history, foot deformity)received a hip ultrasound at birth, in addition to expert clinical screening
3110648|NCT01818934|Active Comparator|universal hip ultrasound screening|All newborns assigned to this arm received hip ultrasound at birth in addition to expert clinical examination
3110715|NCT01818414|Experimental|Misoprostol|Misoprostol 400 mcg buccal 3 hours prior to D&E as an adjunct to same-day Dilapan-S.
3110649|NCT01818921|Placebo Comparator|ZGN-440 sterile diluent|Subjects will receive placebo twice weekly subcutaneous injections for up to 6 weeks.
3110650|NCT01818921|Experimental|1.2 mg ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
3110651|NCT01818921|Experimental|1.8 mg ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
3110652|NCT01818908|Experimental|DA-EPOCH|"Infused agents:~Etoposide 50 mg/m2/day CI24h d1-d4; Doxorubicin 10 mg/m2/day CI24h d1-d4; Vincristine 0.4mg/m2/day CI24h d1-d4;~Bolus agents:~Rituximab(B-NHL) 375 mg/m2/day IV d0; Cyclophosphamide 750 mg/m2/day IV d5 ; Prednisone 60 mg/m2/bid oral or IV d1-d5;~The details of dose adjustment are described in ref 1.~If enrolled patient was histologically confirmed CD20+ B cell lymphoma, standard dose of rituximab will be recommend to combined with DA-EPOCH regimen."
3110653|NCT01818895||Withdrawal of mechanical ventilation|
3110654|NCT01818882|Active Comparator|Standard care|"Patients randomized to this arm will receive standard care.~Intervention: Standard care."
3110655|NCT01818882|Experimental|Standard care + ultrasound|"Patients randomized to this arm will receive standard care + pleuropulmonary ultrasound.~Intervention: Standard care + ultrasound"
3110656|NCT01818869|Experimental|AZD8848|Subjects will participate in 1 of 3 groups and receive multiple doses of AZD8848 or matching placebo In each group 6 subjects will receive AZD8848 and 2 subjects will receive matching placebo.
3110657|NCT01818869|Placebo Comparator|Placebo to match AZD8848|Subjects will participate in 1 of 3 groups and receive multiple doses of AZD8848 or matching placebo. In each group 6 subjects will receive AZD8848 and 2 subjects will receive matching placebo.
3110658|NCT01818856|Experimental|Telaprevir interactions|"Telaprevir 750 mg/8h or 1125 mg/12h (+ pegIFN alfa and ribavirin) plus Atazanavir/ritonavir 300/100 mg/24. Pharmacokinetic profile on day 0.~Intervention: Ritonavir will be withdrawn and the atazanavir dose increased to 200 mg/12h for days 1 to 7. On day 8: a morning dose of Telaprevir (750 mg or 1125 mg) plus Atazanavir 200 mg. Pharmacokinetic profile for 12 hours"
3110659|NCT01818843|Experimental|Safety and Adverse Reaction in CO|Inhaled Carbon Monoxide
3110660|NCT01818830||SIRS group|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
3110661|NCT01818830||sepsis|SIRS+infection
3110662|NCT01818830||normal control|For the healthy control outpatients, possibilities of acute or past chronic diseases were excluded. Moreover, we made sure that the healthy control subjects had not been hospitalized or taken vitamin-based substitutive drugs in the last 12 months, and proved normal in physical checkups and lab examinations.
3110663|NCT01818817||TPVB group|In this group of patients thoracic paravertebral block is performed.
3110664|NCT01818817||GA group|In this group of patients general anesthesia is performed.
3110665|NCT01818804|Active Comparator|n-3PUFA|n-3 polyunsaturated fattyacids from fish oil
3110666|NCT01818804|Placebo Comparator|olive oil|Olive oil
3110667|NCT01818791|Active Comparator|Making Proud Choices alone|These sites will be trained in Making Proud Choices.
3110668|NCT01818791|Experimental|Making Proud Choices+Getting To Outcomes|These sites will receive training in Making Proud Choices and receive the Getting To Outcomes intervention.
3110669|NCT01818778|Experimental|Stimulation Group|Cognitive Stimulation Group: One-on-one (one volunteer visiting one resident at a time), stimulation-group residents and stimulation-group volunteers met 3 times each week, for 8 weeks, to work through a variety of memory, reasoning, and selective attention exercises. Each visit was 20 minutes in length.
3110670|NCT01818778|Active Comparator|Control Group|"Standard Friendly Visit: Control-group residents and control-group volunteers, one-on-one, met for 8 weeks, 3 times each week, for friendly visits. Each visit was 20 minutes in length."
3110671|NCT01818765|Experimental|Procedure|"Pre-procedure speckle-tracking echocardiography assessment of latest activation~Trans-ventricular-septal placement of LV pacing lead~Acute response assessment"
3110672|NCT01818752|Experimental|Carfilzomib, Melphalan, Prednisone|Participants received carfilzomib administered in combination with melphalan and prednisone for nine 42-day cycles. Carfilzomib was administered as an intravenous (IV) infusion on days 1, 2, 8, 9, 22, 23, 29, and 30 of each 42-day cycle. The carfilzomib dose was at 20 mg/m² on cycle 1, days 1 and 2 followed by 36 mg/m² thereafter. On days 1 to 4, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².
3110673|NCT01818752|Active Comparator|Bortezomib, Melphalan, Prednisone|Participants received bortezomib in combination with melphalan and prednisone for nine 42-day cycles. Bortezomib was administered either IV or subcutaneously at 1.3 mg/m² during cycles 1 to 4 on days 1, 4, 8, 11, 22, 25, 29, and 32 followed by 1.3 mg/m² during cycles 5 to 9 on days 1, 8, 22, and 29. On days 1 to 4 of each cycle, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².
3110674|NCT01818739|Experimental|sentinel lymph node detection|Patients undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue and sentinel lymph node biopsy.
3110675|NCT01818726|Active Comparator|Conventional treatment arm|10 Adult (aged above 18) transfusion-dependent patients with AA and serum ferritin < 1000 mg/L undergoing treatment programs of immunosuppressive treatment (Cyclosporine A)
3110676|NCT01818726|Experimental|Exjade treatment arm|15 transfusion-dependent adult (aged above 18) patients with AA and serum ferritin ≥ 1000 mg/L undergoing treatment programs of immunosuppressive treatment (Cyclosporine A) and Exjade
3110677|NCT01818713|Experimental|2B3-101|A single dose of 2B3-101 (a glutathione (GSH) pegylated liposomal doxorubicin hydrochloride formulation) will be administrated intravenously once per cycle. To minimize the risk of infusion reactions, 5% of the total dose of 2B3-101 (in mg) will be administrated over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes
3110712|NCT01818440|Experimental|B|Patients will have the procedure performed using the 3-D Roadmap software.With the 3DRoadmap, images from a Cone-Beam CT are analyzed. Software shows the vessels supplying the tumor and the plan is displayed on top of fluoroscopy
3110713|NCT01818427|Experimental|plasma|infusion of 2 units of plasma
3110714|NCT01818427|No Intervention|standard air medical care|control group
3110678|NCT01818700|Other|Single arm-Norspan patch (Buprenorphine)|This trial is single arm with Norspan patch. Treatment with NORSPAN Ò will be started from 5 μg/h (1 patch a week) for 2 weeks, and proper titration (up-titration) will be allowed at visit 2(wk 2) and at visit 3(wk 4) according to the investigator's decision. The up-titration will be considered by investigator's judgement as follows; (1) if the rescue medication was used more than 2 times per day, on average or (2) based on the daily average NRS(Numeric Rating Scale), if the NRS was changed to worsen since the previous visit, (3) Investigator's judgement by considering any titration needed situation (e.g. dose, frequency of rescue medication).
3110679|NCT01818687|Experimental|MCI-196 (Flexible dose)|MCI-196 BSA eq 3g, 6g, 9g, 12g or 15g
3110680|NCT01818674|Experimental|Group A|The Microclinic Group A is the group receiving the Microclinic Social Network Behavioral Health Program in microclinic groups (groups of 2-8 friends or family members).
3110681|NCT01818674|Active Comparator|Group B|The group B receives a modified Microclinic Behavioral Health Program with limited social network components (education curriculum in a classroom)
3110682|NCT01818674|Other|Group C controls|These are considered the control group who are receiving standard care. Subjects in this group will only have risk factor measurements obtained through clinic screenings only; they will not participate in program activities.
3110683|NCT01818661|Experimental|Tau positron emission tomography (PET)|All subjects will receive Tau PET scan on approximately day 1 or day 2 of study to assess Tau burden in the brain.
3110684|NCT01818648|Experimental|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
3110685|NCT01818648|Placebo Comparator|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
3110686|NCT01818622|Experimental|Patient-group blue-blockers|N= 21 Blue-blocking goggles/screens from 6 p.m. to 08 a.m. in addition to treatment as usual (TAU). The goggles may be taken of when going to bed and turning of the light. For consenting patients who are unable to use goggles according to the protocol blue-blocking screens covering light-sources will be used.
3110687|NCT01818622|Placebo Comparator|Patient group clear-lensed goggles|N= 21 (Patient group) clear-lensed goggles from 06 p.m. to 08 a.m. in addition to TAU.
3110688|NCT01818622|Experimental|Non-bipolar control-group blue-blockers|N= 42 For baseline day 1-7: Actiwatch Spectrum worn at the wrist of dominant hand, day 8-14 continued wearing of Actiwatch spectrum + blue-blocking goggles from 6 p.m. to 08 a.m. In addition to selfreport forms described in the outcome section self report forms Horne-Ostberg Morningness-Eveningness Questionaire (HOMEQ)and Seasonal Pattern Assessment Questionaire (SPAQ).
3110689|NCT01818609|Experimental|Step Reduction|"Step reduction:~Take less than 1500 steps/d~No disease"
3110690|NCT01818596|Experimental|E/C/F/TAF|Participants will receive E/C/F/TAF for 144 weeks.
3110691|NCT01818583|Experimental|Potassium|Potassium chloride infusion at a rate of 15 mmol/h (60 mmol KCl in 1000 ml of 5% glucose with a concentration of 0.05 mmol/mL, flow rate 265 mL/h). If the serum Mg ≤0.8 mmol/L, MgSO4 infusion (0.5 mmol/kg/24 hours in 1000 mL NaCl 0.9% corresponding to an infusion rate of approximately 42 mL/hour) will also be administered.
3110692|NCT01818583|Placebo Comparator|Placebo|5% glucose (flow rate 265 ml/h) as placebo infusion.
3110693|NCT01818570|Placebo Comparator|Placebo solution|A 100 ml placebo solution will be administered through an esophageal probe. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with placebo in one out of three visit days.
3110694|NCT01818570|Active Comparator|PPC-5650|"PPC‐5650 is a asic-sensing ion channel-1a antagonist that can block the acid-sensing ion channels, leading to a reduction in the pain signal under up-regulated conditions. A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered through an esophageal probe to assess local effects. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with PPC-5650 in one out of three visit days."
3110695|NCT01818557|No Intervention|Every day blood glucose testing|Patients will test their blood glucose values 4 times every day
3110696|NCT01818557|Experimental|Every other day blood glucose testing|Patients will test their blood glucose 4 times every other day
3110697|NCT01818544|Experimental|BAY85-8501|
3110698|NCT01818544|Placebo Comparator|Placebo|
3110699|NCT01818531|Experimental|Adductor canal block|Patients in this arm will receive an adductor canal block prior to undergoing a medial compartment knee arthroplasty.
3110700|NCT01818531|Active Comparator|Lumbar plexus block|Patients in this arm will receive a lumbar plexus block prior to undergoing a medial compartment knee arthroplasty.
3110701|NCT01818518||Preterm Labor|Group who goes into labor prior to 32 weeks of gestation
3110702|NCT01818518||Prelabor rupture of membranes|Group who have prelabor rupture of membranes are those who break their bag of water prior to 32 weeks gestation in the absence of labor.
3110703|NCT01818518||Premature birth before 32 weeks gestation|Premature birth before 32 weeks gestation not including PTL or PROM
3110704|NCT01818505||Gouty arthritis|Patient with gouty arthritis
3110705|NCT01818505||Asymptomatic hyperuricemia|Patient with asymptomatic hyperuricemia
3110706|NCT01818505||OA without hyperuricemia|Patient of osteoarthritis but without hyperuricemia and gout
3110707|NCT01818492|Experimental|NI-0501|
3110708|NCT01818479|Experimental|All participants|
3110709|NCT01818453|Active Comparator|Computerized self-help program for depression|Participants will have access to a computerized self-help program for depression, called deprexis, for 8 weeks.
3110710|NCT01818453|No Intervention|Wait List Control|"Participants randomly assigned to a wait list control condition will wait 8 weeks after assignment before they can access the deprexis program."
3110711|NCT01818440|Active Comparator|A|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method
3110716|NCT01818414|Placebo Comparator|Folic Acid|Folic acid 4 mg buccally 3 hours prior to D&E as an adjunct to same-day Dilapan-S
3110717|NCT01818401|Other|Control group|The control group will be constituted of patients with the prosthesis GMK ® without the ancillary MyKnee ® LBS.
3110718|NCT01818401|Other|Matched patient|The treated group will consist of patients which the GMK ® prosthesis with ancillary ® MyKnee LBS.
3110719|NCT01818388||IVTM system, therapeutic hypothermia|Induced therapeutic hypothermia post cardiac arrest
3110720|NCT01818375|Experimental|Goal Directed Fluid Therapy (GDFT)|"During surgery, patients in the Goal Directed Fluid Therapy (GDFT) will receive:~maintenance infusion of intravenous infusion of ringer lactate at a rate of 1.5 ml/Kg/hr to compensate insensible blood loss and fluid shift during surgery as recommended by perioperative fluid management guidelines for patients undergoing surgery with an enhanced recovery program and receiving a GDFT approach;~intraoperative intravenous boluses of colloids (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride-Voluven) guided by an algorithm based on Esophageal Doppler (ED) estimation of the stroke volume (SV) provided by the manufacture, and also used in other clinical trials."
3110721|NCT01818375|Active Comparator|Standard Fluid Therapy|During surgery, patients will receive a maintenance infusion of intravenous infusion of ringer lactate as recommended by international guidelines and anesthesia text-books (Standard Fluid Therapy). In the Standard Fluid Therapy arm, the Esophageal Doppler (ED) monitor will be turned away from the anesthesia care provider, and the screen will be covered with an opaque card. The ED variables will be collected by an independent research personnel. Hemodynamic variables triggering extra fluid administration (Ringer Lactate or Voluven) will be decided based on the clinical judgment of the anesthetist in charge and will include: urinary output less than 0.5/ml/kg/hr, an increase in heart rate more than 20% above baseline or more than 110 beats/min, a decrease in mean systolic blood pressure less than 20% below baseline or less than 90 mmHg and intraoperative blood loss. Boluses of 200 ml of intravenous fluid will be administered until the above targets will be restored
3110722|NCT01818362|Experimental|Group 2|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 52 weeks later.
3110723|NCT01818362|Experimental|Group 3|MVA NP+M1 1.5 x 10⁸pfu followed by ChAdOx1 NP+M1 2.5 x 10¹⁰vp 8 weeks later.
3110724|NCT01818362|Experimental|Group 4|MVA NP+M1 1.5 x 10⁸pfu followed by ChAdOx1 NP+M1 2.5 x 10¹⁰vp 52 weeks later.
3110725|NCT01818362|Experimental|Group 1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 8 weeks later.
3110726|NCT01818362|Experimental|Group 5|ChAdOx1 NP+M1 2.5 x 10¹⁰vp
3110727|NCT01818362|Experimental|Group 6|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 8 weeks later.
3110728|NCT01818349|Active Comparator|isokinetic lower-limb training|3 times/week for 6 weeks
3110729|NCT01818349|Placebo Comparator|isokinetic uppe-limb training|3 times/week for 6 weeks
3110730|NCT01818336|Experimental|all subjects|"Intervention: Penicillin skin test kit~Subjects with negative intradermal tests will be given single oral amoxicillin challenge dose and followed for 72 hours for IgE dependent reactions."
3110731|NCT01818323|Experimental|Intra-tumoral T4 immunotherapy|
3110732|NCT01818310|Experimental|Group A: Intramuscular|"Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
3110733|NCT01818310|Experimental|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
3110734|NCT01818310|Experimental|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
3110735|NCT01818310|Other|Group D: Control-standard treatment|Group D: Control Group Study subjects in Group D will receive a standard treatment for NO-option CLI.
3110736|NCT01818297|Active Comparator|Treatment|Treatment settings of Medtronic PrimeAdvanced® neurostimulator system implant
3110737|NCT01818297|Other|Control|Control settings of Medtronic PrimeAdvanced® neurostimulator system implant
3110738|NCT01818284|Experimental|Filgrastim + Plerixafor|"Each donor receives Filgrastim 5 µg/kg subcutaneously in the morning daily for 4 days. The dose of Filgrastim based on the donor's actual body weight. Donors will continue Filgrastim until completion of apheresis. Each donor receives Plerixafor 240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization. The dose-volume of Plerixafor based on the donor's actual body weight. Apheresis procedure to start the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor. The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.~The apheresis procedure may continue beyond day 1 until the target dose of 4x106 cluster of differentiation 34 (CD34+) cells/kg (recipient's weight) is obtained."
3110739|NCT01818271|Active Comparator|conventional physical Therapy|will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises
3110740|NCT01818271|Experimental|community-based group rehabilitation|"Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:~Advanced dynamic tasks, including stepping and other transitional tasks to treadmill & over ground walking) with use of various inexpensive exercise assistive equipment such as mini-exercise stepper or elliptical machines.~Treadmill walking exercise program."
3110741|NCT01818258|Active Comparator|Severe Malnutrition|ZDV+3TC+LPV/r Zidovudine (ZDV, Retrovir®) 10 mg/ml oral syrup administered twice daily at WHO weight band dose for 48 weeks; Lamivudine (Epivir®, 3TC) 10 mg/ml for oral solution administered twice daily at WHO weight band dose for 48 weeks; Lopinavir/ritonavir (Kaletra®, LPV/r) 80/20 mg/ml oral solution administered twice daily at the WHO weight band dose for 48 weeks
3110742|NCT01818258|Active Comparator|Normal Nutrition/Mild Malnutrition|ZDV+3TC+LPV/r Zidovudine (ZDV, Retrovir®) 10 mg/ml oral syrup administered twice daily at WHO weight band dose for 48 weeks; Lamivudine (Epivir®, 3TC) 10 mg/ml for oral solution administered twice daily at WHO weight band dose for 48 weeks; Lopinavir/ritonavir (Kaletra®, LPV/r) 80/20 mg/ml oral solution administered twice daily at the WHO weight band dose for 48 weeks
3110743|NCT01818245|Experimental|LY2605541 - Cohort A (Arm)|Each healthy participant will receive 1 subcutaneous (SC) injection of 0.5 Units per kilogram (U/kg) of LY2605541 in the arm in 1 of 3 treatment periods.
3110744|NCT01818245|Experimental|LY2605541 - Cohort A (Thigh)|Each healthy participant will receive 1 SC injection of 0.5 U/kg of LY2605541 in the thigh in 1 of 3 treatment periods.
3110745|NCT01818245|Experimental|LY2605541 - Cohort A (Abdomen)|Each healthy participant will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall in 1 of 3 treatment periods.
3110746|NCT01818245|Experimental|LY2605541 - Cohort B (Abdomen)|Each elderly participant will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall.
3110747|NCT01818232|Experimental|[14C]-LX4211|400 mg LX4211 administered orally
3110748|NCT01818219|Experimental|Study|
3110749|NCT01818206|Experimental|Cystic fibrosis (CF) patients|Cystic fibrosis patients whom induced sputum is collected in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
3110750|NCT01818180|Experimental|Urell|
3110751|NCT01818180|Placebo Comparator|Placebo|
3110752|NCT01818167|Active Comparator|10% Benzoyl Peroxide Topical Body Wash|Subjects will use 10% benzoyl peroxide twice daily. The product will be applied to the affected areas, left on for 45 seconds, then rinsed off.
3110753|NCT01818167|Active Comparator|Provodine Topical Cream|Subjects will use Provodine Topical Cream twice daily. The product will be applied to the affected areas, left on for 45 seconds, then rinsed off.
3110754|NCT01818154|Experimental|Minimal Erythema Dose LED|A 2 x 2 cm section of skin will be exposed to LED light.
3110755|NCT01818154|Placebo Comparator|Minimal Erythema Dose narrow band UVB|A 2 x 2 cm section of skin will be exposed to narrow band UVB light.
3110756|NCT01818141|Active Comparator|Fidaxomicin|Fidaxomicin 200mg by mouth every 12 hours for 10 days
3110757|NCT01818141|Active Comparator|Vancomycin|Vancomycin 125mg by mouth every 6 hours for 10 days
3110758|NCT01818128|Active Comparator|Neutral shape of bronchial tip|
3110759|NCT01818128|Experimental|Bent shape of bronchial tip|
3110760|NCT01818115|Experimental|IOL placement with Hydrus Implant|Cataract extraction with intraocular lens (IOL) placement and Hydrus Implant
3110761|NCT01818115|Active Comparator|IOL placement only.|Cataract Extraction with IOL placement only.
3110762|NCT01818102|Experimental|Width 1000 HU/Level -450 HU|
3110763|NCT01818102|Active Comparator|Width 400 HU/Level 25 HU|
3110764|NCT01818089||Lung Sound Analyzer|Patient with pneumonia admitted to hospital will receive additional auscultation with lung sound analyzing stethoscope
3110765|NCT01818076|Experimental|Dose A|Dose A: Botulinum toxin type A
3110766|NCT01818063|Experimental|Arm 1 (paclitaxel, carboplatin)|Patients receive paclitaxel IV and carboplatin IV on day 1 (course 1 only) or day 2 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3110767|NCT01818063|Experimental|Arm 2 (veliparib, paclitaxel, carboplatin)|Patients receive veliparib PO BID on days 1-5. Patients also receive paclitaxel IV and carboplatin IV on day 3 (course 1 only) or day 4 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3110768|NCT01818050|Other|Wing stent arm|There is only one arm in this study. Intervention: checking liver function tests to evaluate stent patency
3110769|NCT01818037||Microphthalmos with congenital cataract|72 eyes of 36 patients with microphthalmos who underwent bilateral congenital cataract surgery between January 2003 and June 2008.
3110770|NCT01818024|Experimental|Part 1: Cohort 1a|Single IV dose of GSK2862277 as a continuous infusion over 2 hours.
3110771|NCT01818024|Experimental|Part 1: Cohort 1b|Single IV dose of GSK2862277 as a continuous infusion over 3 hours.
3110772|NCT01818024|Experimental|Part 1: Cohort 1c|Single IV dose of GSK2862277 as a continuous infusion over 3 hours.
3110773|NCT01818024|Experimental|Part 2: Cohort 2a GSK2862277|Single IV dose of GSK2862277 as a continuous infusion over 1 hour.
3110774|NCT01818024|Experimental|Part 2: Cohort 2a Placebo|Matching placebo will be administered as a continuous IV infusion over 1 hour.
3110775|NCT01818024|Experimental|Part 2: Cohort 2b GSK2862277|Single IH dose of GSK2862277.
3110776|NCT01818024|Experimental|Part 2: Cohort 2b Placebo|Matching placebo will be administered.
3110777|NCT01818024|Experimental|Part 3: Cohort 3a GSK2862277|IV dose of GSK2862277 (decided from Part 2) as a continuous infusion over 1 hour for daily 5 days.
3110778|NCT01818024|Experimental|Part 3: Cohort 3a Placebo|Matching placebo will be administered as IV infusion over 1 hour daily for 5 days.
3110779|NCT01818024|Experimental|Part 3: Cohort 3b GSK2862277|Repeat IH dose of GSK2862277 (decided from Part 2) daily for 5 days.
3110780|NCT01818024|Experimental|Part 3: Cohort 3b Placebo|Matching placebo will be administered as IH daily for 5 days.
3110781|NCT01818011|Experimental|Part A GSK1322322 single dose Arm|Subjects will receive single dose of one of the following 4 GSK1322322 treatments in 4 treatment periods (one per period) with an aqueous suspension of a low dose of GSK1322322F (stable isotope labeled drug substance) PO in a fed condition: 1500 mg (fit for purpose formulation), 1500 mg (intended commercial formulation), 1500 mg (over granulated formulation), and 2000 mg (intended commercial formulation)
3110782|NCT01818011|Experimental|Part B Cohort 1- GSK1322322 Oral Arm|Subjects in this part will receive single dose of GSK1322322 on Day 1 of each of the three treatment periods. Subjects in Cohort 1 will receive following GSK1322322 (intended commercial formulation) doses po in fed state: 1000 mg, 1500 mg and 2000 mg
3110783|NCT01818011|Experimental|Part B Cohort 2 -GSK1322322 IV Arm|Subjects in this part will receive single dose of GSK1322322 on Day 1 of each of the three treatment periods. Subjects in Part B Cohort 2 will receive following GSK1322322 IV fasted doses (one per period): 600 mg, 900 mg and 1200 mg
3110784|NCT01818011|Experimental|Part C GSK1322322 Arm|Subjects in this arm will receive repeat doses of GSK1322322 as following: GSK1322322 1200 mg IV fasted for 4 days twice a day (BID), followed by GSK1322322 2000 mg orally fed for 6 days BID
3110785|NCT01818011|Placebo Comparator|Part C Placebo Arm|Subjects in this arm will receive repeat doses of Placebo IV fasted for 4 days BID, followed by placebo po fed for 6 days BID
3110786|NCT01817998|Experimental|High Intensity Endurance Physical Exercise|High Intensity endurance physical exercise, intensity measured on Borg Scale with progression from Borg 10-13 (50% of maximum) to 17-18 (80 % of maximum). One hour of exercise twice weekly for 12 weeks supervised by physiotherapists.
3110787|NCT01817998|Active Comparator|Low Intensity Endurance Physical Exercise|Low Intensity endurance physical exercise, intensity measured on Borg Scale, Borg 10-13 (50% of maximum) with no progression in intensity. One hour of exercise twice weekly for 12 weeks supervised by physiotherapists.
3110788|NCT01817985|Experimental|Cohort 1|(N = 20 Moderately Impaired / Normal Hepatic Function) 100 mg GS-5816.
3110789|NCT01817985|Experimental|Cohort 2|(N = 20 Severely Impaired / Normal Hepatic Function) up to 100 mg GS-5816.
3110790|NCT01817972|Placebo Comparator|Certolizumab pegol-Placebo Azathioprine|Certolizumab pegol (Cimzia) 400mg Subcutaneous injection (per standard induction protocol) - which is at week 0, week 2, week4, week 6, then every 4 weeks until week 26. You will also be receiving Azathioprine placebo tablets at a dosage of 1.5mg per kilogram of body weight once a day for 26 weeks. They will be 50mg tablets. This is not active Azathioprine.
3110791|NCT01817972|Active Comparator|Certolizumab pegol plus Azathioprine|Certolizumab pegol (Cimzia) 400mg Subcutaneous injection (per standard induction protocol) - which is at week 0, week 2, week4, week 6, then every 4 weeks until week 26. You will also be receiving Azathioprine tablets at a dosage of 1.5mg per kilogram of body weight once a day for 26 weeks. They will be 50mg tablets.
3110792|NCT01817959|Experimental|Reparixin group|Continuous iv infusion
3110793|NCT01817959|Placebo Comparator|Placebo group|Continuous iv infusion
3110794|NCT01817946||Genetic testing|All participants determined eligible for the study will be placed into genetic testing arm.
3110795|NCT01817933|Experimental|Physical therapy|
3110796|NCT01817920|Experimental|integrated multidisciplinary fall prevention program|
3110797|NCT01817907|Placebo Comparator|Placebo|Subjects will receive a sugar pill during their placebo night sleep study.
3110798|NCT01817907|Active Comparator|Trazodone|Subjects will receive trazodone during their treatment night sleep study
3110799|NCT01817894|Other|split-face eflornithin vs. no treatment|Eflornithine cream 11.5 W/W% applied twice daily to one side of the face for six months
3110800|NCT01817868||Group 1|
3110801|NCT01817855|Experimental|1|"Groups 1-4 multiple ascending doses of AZD7624 Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.~COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 patients will receive matching placebo."
3110802|NCT01817855|Placebo Comparator|2|"Groups 1-4 multiple ascending doses of placebo Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.~COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 will receive matching placebo."
3110803|NCT01817842|Experimental|mEX support|Participants in this arm receive both standard DC Quitline Support and Mobile EX cessation support. Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
3110804|NCT01817842|Active Comparator|Device Control|Participants randomized to this arm receive standard DC Quitline Support plus the device control. Device control includes an identical device (i.e., mobile phone) to that provided to the intervention group, but participants do not receive any of the phone-based mEX support features. Those in the device control group receive their device at the 1-month time point - a design feature that allows a direct comparison of the mEX intervention to standard quitline services over the first month.
3110805|NCT01817829|Active Comparator|paracetamol|paracetamol 2 tablets1000mg PO.
3110806|NCT01817829|Placebo Comparator|placebo|placebo 2 tablets containing Starch PO
3110807|NCT01817816|Experimental|Botox_A|receiving Botulinum Toxin Type-A (Botox-A, Allergan) at both affected lower extremity (aLE) and upper extremity (aUE)
3110808|NCT01817816|Placebo Comparator|placebo_A|receiving placebo injection at both aLE & aUE ; receiving Botox-A at both aLE & aUE at 6-month.
3110809|NCT01817816|Experimental|Botox_B|receiving Botox-A injection at aLE and placebo injection (sterile normal saline) at aUE.
3110810|NCT01817816|Placebo Comparator|placebo_B|receiving placebo injection at both aLE & aUE ; receiving Botox-A only at aLE at 6-month.
3110811|NCT01817803|Active Comparator|1) Add furosemide/no spironolactone|
3110812|NCT01817803|Active Comparator|2) Add metolazone/no spironolactone|
3110813|NCT01817803|Active Comparator|3) Add furosemide/spironolactone|
3110814|NCT01817803|Active Comparator|4) Add metolazone/spironolactone|
3110815|NCT01817790|Experimental|Fluticasone propionate nasal spray|Fluticasone propionate nasal spray with strength per dose of 50 mcg/spray. Two sprays of study treatment per nostril to be administered in morning.
3110816|NCT01817790|Placebo Comparator|Placebo nasal spray|Two sprays of placebo per nostril to be administered in morning.
3110817|NCT01817777|Experimental|Metformin Small Pack Arm|All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin small pack arm will receive medication free of charge in a small pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.
3110818|NCT01817777|Experimental|Metformin Large Pack Arm|All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin large pack arm will receive medication free of charge in a large, monthly pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.
3110819|NCT01817764|Experimental|Umeclidinium/vilanterol Arm|The subjects will receive UMEC/VI 62.5/25 mcg, administered as one inhalation once-daily in the morning via the NDPI and placebo administered as one inhalation each morning and evening via ACCUHALER/DISKUS
3110820|NCT01817764|Active Comparator|Fluticasone propionate/salmeterol Arm|The subjects will receive FSC 250/50 mcg, administered as one inhalation each morning and evening via ACCUHALER/DISKUS and placebo administered once-daily in the morning via NDPI
3110821|NCT01817751|Experimental|Treatment (sorafenib tosylate, valproic acid, sildenafil)|"Patients receive sorafenib tosylate PO, valproic acid* PO, and sildenafil citrate PO BID for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~* NOTE: Patients not receiving antiepileptic therapy begin valproic acid 1 week prior to the first day of sorafenib tosylate and sildenafil citrate."
3110822|NCT01817738|Active Comparator|CV9104|CV9104 intradermal injection
3110823|NCT01817738|Placebo Comparator|Placebo|Placebo intradermal injection
3110824|NCT01817725|Experimental|Engerix-B|Engerix-B (20 μg/ml, GlaxoSmithKline) was administered at 0-2-4-6-8-10-12 months in dosage of 40μg for >20 years old and 20μg for < or =20 years old
3110825|NCT01817712|Other|1 Individual Placement and Support (IPS)|The IPS intervention must achieve a rating of >66 of a possible 75 points on the Supported Employment Fidelity Scale. The fidelity ratings are conducted by the National IPS Fidelity Monitor at biannual on-site monitoring visits.
3110826|NCT01817712|Active Comparator|VA Transitional Work Program (TWP)|TWP will adhere to a lower rating (less than or equal to 55 of a possible 75 points) on the Supported Employment Fidelity Scale rated by the National Fidelity Monitor. The TWP specialist participates in face-to-face supervision with the local Compensated Work Therapy (CWT) team according to the CWT manager's schedule.
3110827|NCT01817699|No Intervention|Low Hb target without cholecalciferol|Target Hemoglobin level: ≥9.5 and <10.5 g/dL
3110828|NCT01817699|Active Comparator|Low Hb target with cholecalciferol|Target Hemoglobin level: ≥9.5 and <10.5 g/dL Cholecalciferol: 1,000 IU/day
3110829|NCT01817699|Active Comparator|High Hb target without cholecalciferol|Target Hemoglobin level: ≥12.5 and <13.5 g/dL
3110830|NCT01817699|Experimental|High Hb target with cholecalciferol|Target Hemoglobin level: ≥12.5 and <13.5 g/dL Cholecalciferol: 1,000 IU/day
3110831|NCT01817686|Experimental|Comfort Default|ADs with pre-selected defaults that focus on providing comfort at end-of-life.
3110832|NCT01817686|Experimental|Life Extension Default|ADs with pre-selected defaults that focus on extending life.
3110833|NCT01817686|Experimental|Standard Default|ADs without pre-selected defaults.
3110834|NCT01817673|Experimental|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
3110835|NCT01817673|Placebo Comparator|placebo (dextrose)|20 g/d for 5 d followed by 5 g/d throughout the trial
3110836|NCT01817660|Active Comparator|Open Surgery|In this arm, patients randomized to open surgical repair of popliteal artery aneurysm (OPAR).
3110837|NCT01817660|Active Comparator|Endovascular Surgical repair (EPAR)|In this arm, patients randomized to endovascular repair of popliteal artery aneurysm (EPAR).
3110838|NCT01817647||PCT|Patients undergoing colorectal surgery with an anastomosis performed
3110839|NCT01817634|Experimental|Food supplement Intervention - Capsule Intervention|Omega 3 food supplement + Omega 3 capsule.
3110840|NCT01817634|Experimental|Food Supplement Intervention - Capsule Control|Omega 3 food supplement + Control Capsule.
3110841|NCT01817634|Experimental|Food Supplement Control - Capusle Intervention|Food supplement control + Omega 3 Capsule.
3110842|NCT01817634|Active Comparator|Food Supplement Control - Capsule Control|Food supplement control + Control Capsule.
3110843|NCT01817621|Experimental|Experimental Intervention|
3110844|NCT01817621|Active Comparator|TAU Condition|
3110845|NCT01817595|Active Comparator|BG Star (Conventional Meter)|25 patients will use the (conventional) BG star meter in which patients will upload their readings onto a computer and send in their readings via email.
3110846|NCT01817595|Active Comparator|IBG Star Group (iPhone)|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
3110847|NCT01817582|Experimental|Lotemax gel + Restasis|Loteprednol etabonate ophthalmic gel 0.5% and cyclosporine ophthalmic emulsion 0.05% administered one drop of each medication into each eye, two times a day (BID) for 12-weeks.
3110848|NCT01817582|Experimental|Lotemax Gel|Loteprednol etabonate ophthalmic gel 0.5% administered one drop of medication into each eye, two times a day (BID) for 12-weeks.
3110849|NCT01817582|Experimental|Restasis|Cyclosporine ophthalmic emulsion 0.05% administered one drop of medication into each eye, two times a day (BID) for 12-weeks.
3110850|NCT01817569||Byetta|
3110851|NCT01817556|Experimental|Stillen Tab.|administered three times daily for four weeks
3110852|NCT01817556|Active Comparator|Mucosta Tab.|administered three times daily for four weeks
3110853|NCT01817543|Experimental|AutoloGel|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Autologel treatment
3110854|NCT01817530|Placebo Comparator|Cohort 1: Placebo|Placebo for elagolix and placebo for E2/NETA twice daily (BID)
3110855|NCT01817530|Experimental|Cohort 1: Elagolix 300 mg BID|Elagolix 300 mg BID alone
3110856|NCT01817530|Experimental|Cohort 1: Elagolix 300 mg BID plus LD E2/NETA QD|Elagolix 300 mg BID plus low-dose (LD) E2/NETA once daily (QD)
3110857|NCT01817530|Experimental|Cohort 1: Elagolix 300 mg BID plus SD E2/NETA QD|Elagolix 300 mg BID plus standard-dose (SD) E2/NETA QD
3110858|NCT01817530|Placebo Comparator|Cohort 2: Placebo|Placebo for elagolix and E2/NETA QD
3110859|NCT01817530|Experimental|Cohort 2: Elagolix 600 mg QD|Elagolix 600 mg QD alone
3110860|NCT01817530|Experimental|Cohort 2: Elagolix 600 mg QD plus LD E2/NETA QD|Elagolix 600 mg QD plus LD E2/NETA QD
3110861|NCT01817530|Experimental|Cohort 2: Elagolix 600 mg QD plus SD E2/NETA QD|Elagolix 600 mg QD plus SD E2/NETA QD
3110862|NCT01817517|Experimental|Deep Brain Stimulation implant|Unblinded treatment arm, thalamic DBS for Tourette syndrome.
3110863|NCT01817504|Active Comparator|Study group|The study group corresponds to systematic transplantectomy under immunosuppressive therapy within two months after return to dialysis,
3110864|NCT01817504|Other|Control group|The control group corresponds to progressive reduction of immunosuppression without systematic transplantectomy after return to dialysis
3110865|NCT01817491|Active Comparator|Reduced Fat Vegan Diet|Plant based diet with as few added oils and fats as possible.
3110866|NCT01817491|Active Comparator|American Heart Association Diet|Diet emphasizing fruits, vegetables and whole grains but also low fat dairy, low fat meat and fish.
3110867|NCT01817478|Experimental|medical staff|
3110868|NCT01817465|Experimental|Motilione®|30 mg is administered with a tablet of placebo (Pantoline®)
3110869|NCT01817465|Active Comparator|Pantoline®|40mg is administered with a tablet of Motilitone®
3110870|NCT01817465|Active Comparator|Motilitone® and Pantoline®|Both drugs are administered at once
3110871|NCT01817452|Experimental|Arm A|Trastuzumab + Pertuzumab
3110872|NCT01817452|Active Comparator|Arm B|Trastuzumab + Pertuzumab + Paclitaxel
3110873|NCT01817439|Experimental|oral amiodarone, group A|oral amiodarone 400 mg three times a day for 2 days
3110874|NCT01817439|Experimental|IV amiodarone, Group B|"Amiodarone:~IV loading of 300 mg for 30 min in 100cc glucose 5% IV infusion with 900 mg/24h in 1000cc glucose 5%"
3110875|NCT01817426|Active Comparator|infliximab|Patients in this arm are randomized to continue IFX therapy at an unchanged dosage and frequency.
3110876|NCT01817426|Placebo Comparator|Placebo|Patients in this arm are randomized to receive matching placebo.
3110877|NCT01817413|Active Comparator|Apexification with MTA|"The control group will receive:~Visit 1: root canal dressing with calcium hydroxide Visit 2: apexification with mineral trioxide aggregate (MTA), followed by obturation of the root canal with gutta percha.~Treatment will be carried out over two visits, two weeks apart."
3110878|NCT01817413|Experimental|Pulp revascularisation|"The experimental group will receive:~Visit 1: root canal dressing with triple antibiotic paste Visit 2: pulp revascularisation procedure Treatment will be carried out over two visits, two weeks apart."
3110879|NCT01817400|Experimental|Microdialysis|"Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min."
3110880|NCT01817400|Experimental|Anti-inflammatory treatment|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa - Fish Oil 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
3110881|NCT01817400|Experimental|Insulin-lowering therapy|We will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
3110882|NCT01817387|Experimental|PRIME + CT|4 months use of PRIME mobile application on mobile device and 30 hours of cognitive training
3110883|NCT01817387|Experimental|Daily Goals + CT|4 months use of Daily Goals mobile application on mobile device and 30 hours of cognitive training
3110884|NCT01817374|Other|2D US grayscale plus quantitative VCEUS|"Patients with breast cancer receiving neoadjuvant chemotherapy will undergo a 2D grayscale imaging followed by quantitative VCEUS imaging:~prior to initiation of treatment (baseline);~at 14 (± 4 days) after initiation of neoadjuvant chemotherapy (early treatment);~at 28 days (± 4 days) after initiation of neoadjuvant chemotherapy (inter-regimen);~at completion of therapy prior to definitive surgery (usually 2-3 months after initiation of treatment). Each patient will undergo a total of four VCEUS examinations."
3110885|NCT01817348|Experimental|Lidocaine group|"1% lidocaine 5ml intra-articular injection to shoulder joint + physiotherapy three times weekly~Injection is performed if pain during intervention equals to or greater than 7cm in a 10-cm VAS scale.~Injection frequency is not greater than twice per week and total injection time is limited to 10 times in the whole course~In each week, patient will receive 3 times of PT with or without intra-articular lidocaine injection."
3110886|NCT01817348|Placebo Comparator|PT group|- Apply to every patient, each by the same physical therapist, 3 times weekly for 3 months or till the patients gain satisfactory results.
3110887|NCT01817335|Experimental|Supportive care (psycho-educational program)|Patients participate in a psycho-educational program focused on medical/symptom management and communication with a medical team, coping skills, self image, and relationships and communication for 1.5 hours once weekly for 6 weeks.
3110888|NCT01817322|Experimental|Myfortic® (Enteric-coated Mycophenolate Sodium)|reduced cyclosporine+steroids+standard dose of myfortic
3110889|NCT01817322|Active Comparator|Myfortic|Conventional Dose+cyclosporine+steroid+Reduced Dose of Myfortic
3110890|NCT01817309|Experimental|Study group|endotoxin assay in peritoneal dialysis effluent
3110891|NCT01817296|Experimental|Single arm|
3110892|NCT01817283|Placebo Comparator|placebo + cART|combined with antiretroviral therapy, the control group will take placebo 2 tabs tid per day lasting for 6 months and then switch to take Triplitode 2 tabs tid po for anther 6 months
3110893|NCT01817283|Experimental|Triptolide + cART|combined antiretroviral therapy, the experimental group will take Triptolide 2 tabs tid po per day for 12 months.
3110894|NCT01817270|Experimental|Live Attenuated Varicella Vaccine|use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
3110922|NCT01817075|Experimental|Arm I (CHG cleansing wipe)|Patients receive CHG cleansing with topical skin wipes QD for 90 days.
3110895|NCT01817257|Experimental|A: Continue treatment|Continue low molecular weight heparin (LMWH) at treatment dose according to body weight for further six months.
3110896|NCT01817257|No Intervention|B: Discontinue treatment|Discontinue low molecular weight heparin (LMWH) once patient has received six months treatment following index VTE case.
3110897|NCT01817244|Experimental|care management type 1|2-month care management
3110898|NCT01817244|Active Comparator|care management type 2|6-month care management
3110899|NCT01817231||breast cancer cases|breast cancer cases versus controls
3110900|NCT01817218|Experimental|PRP (Platelet Rich Plasma)|PRP treatment of vascular ulcers one a week PRP: a volume of 9-30 ml of blood will be collected from the patient (depending of the size of their ulcer) in sterile 4.5-ml tubes containing 3.8% sodium citrate, which will bind to the calcium ions, preventing clot formation we will add 50 μl of CaCl2 per ml liquid plasma. The extraction of the PRP fraction by sticking with a syringe and the adding of CaCl2 should be performed under sterile conditions.
3110901|NCT01817218|Active Comparator|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
3110902|NCT01817205|Other|TACE with Hyperthermia treatment|Interventions: TACE to all liver lesions and two sessions of systemic hyperthermia performed at 24 hours and 48 hours respectively after TACE.
3110903|NCT01817192|Active Comparator|Observation|Post-operative observation of stage I non-small cell lunger cancer with Radiographic Surveillance is a current standard of care. Patients identified as high-risk by the Pervenio™ Lung RS Assay will be randomized either to this arm or the Adjuvant Chemotherapy Arm.
3110904|NCT01817192|Active Comparator|Adjuvant Chemotherapy|Adjuvant Chemotherapy is a current standard of care for high-risk stage I non-small cell lung cancer. Patients identified as high-risk by the Pervenio™ Lung RS Assay will be randomized either to this arm or the Observation Arm.
3110905|NCT01817179|Experimental|FES neuroprosthesis to dorsiflexors on affected side|Participants will use FES neuroprosthesis to dorsiflexors on affected leg for 3 months at home.
3110906|NCT01817166|Placebo Comparator|Placebo|"Patients in this arm will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.~Intervention: Placebo Intervention: Imaging Intervention: Lumbar puncture Intervention: Blood sampling Intervention: Urine samples"
3110907|NCT01817166|Experimental|Vit D|"Patients in this arm will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.~Intervention: Vitamin D Intervention: Imaging Intervention: Lumbar puncture Intervention: Blood sampling Intervention: Urine samples"
3110908|NCT01817153|Placebo Comparator|placebo|10 mL normal saline iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H8, H14 and H20
3110909|NCT01817153|Active Comparator|hydrocortison|50 mg hydrocortison iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H12, H18 and H24
3110910|NCT01817127||Main Study|Women enrolled in this cohort of the study will collect their breast milk, infant urine and stool, and their urine and stool samples. Blood and saliva will be collected from these participants by study personnel.
3110911|NCT01817127||Gestational Diabetes Mellitus Cohort|Women who have been diagnosed with gestational diabetes mellitus, type 2 diabetes mellitus or impaired glucose tolerance will be enrolled in this cohort. Participants will be asked to report their fasting and postprandial blood glucose levels if they are monitoring these outcomes at home with a glucometer.
3110912|NCT01817127||Fresh Milk Cohort|Women enrolled in this cohort will provide fresh milk samples (stored in the refrigerator and picked up by study personnel within 1 hour of collection) for analysis of glycan composition and gene expression of glycan metabolizing enzymes of somatic cells in milk.
3110913|NCT01817127||RNA Milk Fat Cohort|Women enrolled in this cohort must have given birth to sons and will collect a fresh milk sample for transcriptomic analysis compared against non-human primate milk.
3110914|NCT01817127||Skin Study|This cohort includes mothers and their infants who will provide milk and infant stratum corneum cells to act as the control group for a different study designed to investigate skin function in premature infants.
3110915|NCT01817127||BMMI Project|Subjects enrolled in this cohort will be part of the control group for the BMMI Project.
3110916|NCT01817114|Experimental|Chronic Remote Ischemic Conditioning|Remote ischemic conditioning will be induced using an AutoRIC device (occluding arm bloodflow exactly like manual bloodpressure cuff). With the participant in a supine or seated upright position, the AutoRIC device will be placed on the right arm and will inflate to a pressure of 200mmHg for 5 minutes (ischemia). The device will then auto-deflate (reperfusion), completing one cycle of ischemia-reperfusion. A total of 4 inflation and deflation cycles will occur. This will be initiated at first medical contact just prior to the performance of primary PCI in eligible subjects (RIPerC), and then repeated daily for 28 days following MI.
3110917|NCT01817114|Sham Comparator|SHAM Remote Ischemic Conditioning|Sham conditioning will involve the AutoRIC device being placed on the right arm and will inflate to a pressure of 10mmHg for 5 minutes (ie. no limb ischemia will occur). The device will then auto-deflate, completing one cycle. A total of 4 inflation and deflation cycles will occur. This will be initiated at first medical contact just prior to the performance of primary PCI in eligible subjects (RIPerC), and then repeated daily for 28 days following MI.
3110918|NCT01817101|Active Comparator|Dietary Supplement capsule|One capsule at meals (3 each day) during 1 year with Omega-3 fatty acid supplementation
3110919|NCT01817101|Placebo Comparator|Empty gelatine capsule|One capsule at meals (3 each day during 1 year)
3110920|NCT01817088|Experimental|New targeting procedure without electrophysiology|Patients with the high precision procedure under general anesthesia alone without electrophysiological stimulation
3110921|NCT01817088|Active Comparator|Classical neurosurgical procedure|patients with a first step of electrode implantation under awake surgery with electrophysiological control followed by a second step under general anesthesia
3110996|NCT01816568|Active Comparator|Group 1|SILS appendectomy
3110923|NCT01817075|Active Comparator|Arm II (control)|Patients receive control cleansing with topical skin wipes QD for 90 days.
3110924|NCT01817062||Neonates|Neonates with very low birth weight and surgery therapy of acute abdomen
3110925|NCT01817049|Experimental|HAPA intervention|Coaches will receive a 3.5 hour HAPA-based coach education workshop prior to the start of the first study season.
3110926|NCT01817049|Placebo Comparator|Attention control|Coaches will receive a 3.5 hour workshop prior to the start of the first study season, consisting of innocuous sport nutrition and sport psychology information as an attention control.
3110927|NCT01817036|Placebo Comparator|Placebo|5 placebo pills per day, 16 weeks
3110928|NCT01817036|Experimental|400 IU|(4 placebo pills + 1 vitamin D pill) per day, 16 weeks
3110929|NCT01817036|Experimental|800 IU|(3 placebo pills + 2 vitamin D pills) per day, 16 weeks
3110930|NCT01817036|Experimental|1200 IU|(2 placebo pills + 3 vitamin D pills) per day, 16 weeks
3110931|NCT01817036|Experimental|2000 IU|5 vitamin D pills per day, 16 weeks
3110932|NCT01817023|Experimental|RT alone|SIB-IMRT was given to the patients with a regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
3110933|NCT01817023|Active Comparator|CCRT group|SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume and cisplatin 100mg/m2 was given at d1, d22,d43 during radiotherapy.
3110934|NCT01817010|Experimental|Multi-Component Rehabilitation (CMC)|The CMC group will receive a multi-component program focused on rehabilitation of the abdominal and core musculature, neuromuscular re-education through therapeutic exercise as well as hip and knee muscle strengthening beginning 2 weeks after THA.
3110935|NCT01817010|Active Comparator|Control (CON)|The CON group will participate in physical therapist recommended activities based on their home rehabilitation and then will complete the same CMC rehabilitation intervention beginning 10 weeks after THA.
3110936|NCT01816997|Placebo Comparator|Control|IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.
3110937|NCT01816997|Active Comparator|Pravastatin|The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
3110938|NCT01816997|Experimental|Rosuvastatin|The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
3110939|NCT01816984|Experimental|Arm I (one-week run-in period)|"Patients receive PI3K inhibitor BKM120 PO QD on days -7 to 0. Patients complete 1 week washout before dose escalation.~All patients receive PI3K inhibitor BKM120 PO QD on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3110940|NCT01816984|Experimental|Arm II (no one-week run-in period)|"Patients receive no treatment on days -7 to 0.~All patients receive PI3K inhibitor BKM120 PO QD on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3110941|NCT01816971|Experimental|Treatment (dexamethasone, carfilzomib, lenalidomide)|"INDUCTION THERAPY: Patients receive dexamethasone IV or PO QD on days 1, 8, 15 and 22; carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16; and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity..~TRANSPLANT: Patients undergo autologous stem cell transplant.~CONSOLIDATION THERAPY: Patients receive dexamethasone, carfilzomib, and lenalidomide as in induction. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive dexamethasone and lenalidomide as in induction therapy and carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Treatment repeats every 28 days for 10 courses in the absence of disease progression or unacceptable toxicity."
3110942|NCT01816958||chronic depression and/or pain|co-administration of TMS and infused ketamine for patients with chronic pain of psyche and/or soma
3110943|NCT01816945|Experimental|Access to MOMBA web-based application|Study will provide the subject with a smartphone, pay the data plan, and facilitate access to the web-based application for purposes of researching the acceptability of the application, the operating and functioning of it, and its impact on maternal mental health.
3110944|NCT01816945|No Intervention|Smartphone only|Study will provide the subject with a smartphone and pay the data plan. Weekly assessments are completed through internet survey links sent via text message.
3110945|NCT01816932|Experimental|Home Visit|20 participants will be randomized to receive a home visit for the insertion of their implantable birth control rather than the standard office visit.
3110946|NCT01816932|Placebo Comparator|Office Visit|20 participants will be randomized to receive an office visit (standard of care).
3110947|NCT01816919|Experimental|eNose breath samples|
3110948|NCT01816906|Active Comparator|MCP Insole|"The intervention is Footwear: MCP. MCP insoles are commonly used within Diabetic sandals in India."
3110949|NCT01816906|Active Comparator|PU insole|"The intervention is Footwear: PU. Insoles made of Polyurethane(PU) are given to the participants in the intervention arm."
3110950|NCT01816893|Sham Comparator|Euglycemic hyperinsulinemic clamp|participant undergoes a euglycemic hyperinsulinemic clamp
3110951|NCT01816893|Active Comparator|Hypoglycemic hyperinsulinemic clamp|participant undergoes a hypoglycemic hyperinsulinemic clamp
3110952|NCT01816880||Healthy Elderly|Age 90 and over Gender: Male and Female Enrolled in the Healthy Elderly (HEAL) study prior to enrollment in this sub-study Blood sample of approximately 20mL is drawn.
3110953|NCT01816867||Patients with a ventral hernia|
3110954|NCT01816854||Patients with PAD|
3110955|NCT01816841|Experimental|Diagnostic (COE and DVFE)- Arm I|Arm I - Patients undergo COE followed by DVFE. Patients with tissue abnormalities found by COE or DVFE undergo biopsy within 2 weeks.
3110956|NCT01816841|Experimental|Arm II - Comparison of surgical margins using COE vs. DVFE|Comparison of surgical margins using COE vs. DVFE
3110957|NCT01816828|Experimental|Immediate|In the immediate arm, participants will begin the 8 session group motivational interviewing intervention, Gay Poz Sex, within 2 weeks of randomization.
3110997|NCT01816568|Active Comparator|Group 2|Three port laparoscopic appendectomy
3112041|NCT01809457|Experimental|educational poster|poster display for 2 weeks in classrooms,
3110958|NCT01816828|Active Comparator|Wait List/Standard of Care|Participants in the wait list/standard of care group will be given active referrals to existing community resources available to HIV+ MSM. For ethical reasons, participants randomized to the control group will have the option to attend the Gay Poz Sex program after a 6-month wait period.
3110959|NCT01816815|Experimental|BAY1002670 [0.1mg]|0.1 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
3110960|NCT01816815|Experimental|BAY1002670 [0.5mg]|0.5 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
3110961|NCT01816815|Experimental|BAY1002670 [1.0mg]|1.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
3110962|NCT01816815|Experimental|BAY1002670 [2.0mg]|2.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
3110963|NCT01816815|Experimental|BAY1002670 [5.0mg]|5.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
3110964|NCT01816815|Placebo Comparator|Placebo|Placebo for BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
3110965|NCT01816802||In-vitro fertilization using Eeva|Patients undergoing in-vitro fertilization treatment who provide informed consent and use Eeva in their treatment cycle.
3110966|NCT01816789|Active Comparator|"Group A: age"|Group A: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle, until the end of gonadotropin administration) + 150 IU of rFSH (starting dose) if female age was ≤35 years or 225 IU of rFSH if female age was ≥ 36 years.
3110967|NCT01816789|Experimental|"Group B: nomogram"|Group B: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle until the end of gonadotropin administration) + individualized starting dose of rFSH on the basis of the nomogram.
3110968|NCT01816776|Experimental|Treatment Group|Subjects implanted with the remedē system device and randomized to the Treatment group will receive optimal medical therapy and have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the Therapy Initiation Visit (1 month post device implant).
3110969|NCT01816776|Other|Control group|Subjects implanted with the remedē system device and randomized to the Control group will receive optimal medical therapy through the 6-month Post-Therapy Initiation Visit. Control group subjects will have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the 6-month Post-Therapy Initiation Visit (7 months post device implant).
3110970|NCT01816763|Experimental|tablet based NRS pain now, followed by nurse pain screen|tablet-based patient self-report of the 'NRS pain now'
3110971|NCT01816763|Experimental|tablet based PEG, followed by nurse pain screen|tablet-based enhanced pain screening with the PEG (pain intensity, emotional, and functional pain interference)
3110972|NCT01816763|No Intervention|tablet based health reminder, followed by nurse pain screen|Unrelated health reminder on tablet followed by usual nursing staff documented pain screening with NRS pain now
3110973|NCT01816750|Experimental|Anatomical accuracy Cardiac GSI vs ICA|The identification and quantification of coronary artery stenoses using Cardiac in comparison to ICA.
3110974|NCT01816750|Experimental|Stress perfusion Cardiac GSI vs MPI-SPECT|Assessment of the functional impact of coronary stenoses using Cardiac GSI in comparison to MPI-SPECT
3110975|NCT01816750|Experimental|Delayed enhancement Cardiac GSI vs CMR|Assessment of abnormal myocardial tissue characteristics representing ischaemic or scarred tissue using Cardiac GSI in comparison to CMR.
3110976|NCT01816724||Men with nocturia|Men older than 60 years old suffering from nocturia (one or more voidings overnight) without exclusion criteria
3110977|NCT01816724||Women with nocturia|Women older than 60 years old suffering from nocturia (one or more voidings overnight) without exclusion criteria
3110978|NCT01816711||No hip fractures, Frail elderly|Controls: Frail elderly, without a hip fracture in the previous ten years.
3110979|NCT01816711||Hip fracture, Frail elderly|Cases: Frail elderly with a hip fracture.
3110980|NCT01816698|Active Comparator|Taurine|Interventions Drug: Taurine granule Arms: Group 1
3110981|NCT01816698|Placebo Comparator|Placebo|Interventions Drug: Placebo Arms: Group 2
3110982|NCT01816685|Experimental|CPAP|Patients in the CPAP group will be instructed to wear an autotitrating positive airway pressure (APAP) device any time they sleep prior to surgery and on postoperative days 0, 1, and 2.
3110983|NCT01816685|No Intervention|Routine Care|
3110984|NCT01816672|Active Comparator|AutoloGel|AutoloGel treatment
3110985|NCT01816672|Other|Usual and Customary Care|Standard of care
3110986|NCT01816659|Experimental|Metformin + Colon Surgery|Patients randomized to Metformin-ER 500 mg once daily for one week and then escalation to 1000 mg/day for the duration of the trial. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
3110987|NCT01816659|No Intervention|Colon Surgery Alone|Patients will not receive any study drug from the time of colonoscopy until surgery.
3110988|NCT01816646|Experimental|Cidofovir|Patients receive a single dose of 2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours. Probenecid 2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
3110989|NCT01816633|Experimental|AutoloGel|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive AutoloGel treatment.
3110990|NCT01816620|Experimental|Lenalidomide, dexamethasone|Lenalidomide 10mg qd d1-21 & dexamethasone 40mg qw d1,8,15,22
3110991|NCT01816607||Rectal cancer|
3110992|NCT01816594|Experimental|Trastuzumab + BKM120 + paclitaxel|BKM120 (oral, pan-class I PI3K inhibitor) in combination with trastuzumab and paclitaxel.
3110993|NCT01816594|Placebo Comparator|Trastuzumab + BKM120 placebo + paclitaxel|BKM120 placebo in combination with trastuzumab and paclitaxel
3110994|NCT01816581|Active Comparator|Targin/OxyNorm|Patients randomized to this study arm will receive Targin as basis pain medication and additional OxyNorm (Oxycodone), if requested by the patients.
3110995|NCT01816581|Active Comparator|PCA|Patients randomized to this group will receive a PCA pump with morphine. The basic rate is 0.3 mg/h. Patients will be allowed to administer 1 mg each five minutes after a vesting period of five minutes, if subjectively needed.
3110998|NCT01816555|Experimental|Vitamin D- Normal Level at Screening|Subjects will have surgery as their initial breast therapy. If subjects have a normal level of Vitamin D(25-hydroxyVit D 30-100ng/mL), they will be assigned to this group.
3110999|NCT01816555|Experimental|Vitamin D- Insufficient or Deficient Level at Screening|Subjects will have surgery as their initial breast therapy. If subjects are insufficient (25-hydroxy Vit D 21-29 ng/mL)or deficient (25-hydroxyVit D <20ng/mL) Vitamin D levels, they will be assigned to this group.
3111000|NCT01816542|Other|patch tests on healthy skin|
3111001|NCT01816529|Experimental|Topical Diltiazem Hydrochloride 2% Cream|0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
3111002|NCT01816529|Placebo Comparator|Vehicle Cream|0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
3111003|NCT01816529|Active Comparator|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
3111004|NCT01816529|Placebo Comparator|0.9% Saline|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
3111005|NCT01816516|Experimental|Healthy Babies|Participants receive the Healthy Babies curriculum via 6 in home lessons and 3 follow up telephone calls delivered by Extension paraprofessionals.
3111006|NCT01816516|Active Comparator|EFNEP|Participants receive the Expanded Food and Nutrition Education Program (EFNEP) curriculum via 6 in home lessons delivered by Extension paraprofessionals.
3111007|NCT01816503||Fentanyl matrix|
3111008|NCT01816477|Active Comparator|Thoracic epidural|Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
3111009|NCT01816477|Experimental|ON-Q soaker catheter system|"ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly."
3111010|NCT01816464|Experimental|Trivalent Influenza Vaccine|"The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus;~a B/Wisconsin/1/2010-like virus.~Dose: Single Dose 0.5 mL of TIV from pre-filled syringe."
3111011|NCT01816451|Experimental|interval|The running training for interval group were performed on a treadmill for a period of 14 weeks, with a frequency of three times a week, lasting 20-minutes per session thus completing 46 sessions of training. The intensity and volume of training both were adapted according to the recommendations of the American College of Sports Medicine. The interval training group intensities ranged between 84-87% of maximal heart rate (HRmax) (vigorous intensity), 88-93%HRmax (near maximum intensity) and 94-99% HRmax (maximum intensity).
3111012|NCT01816451|Experimental|continuous|The running training for continuous group were performed on a treadmill for a period of 14 weeks, with a frequency of three times a week, lasting 20-minutes per session thus completing 46 sessions of training. The intensity and volume of training both were adapted according to the recommendations of the American College of Sports Medicine.The continuous group ran at an intensity of ~87% of maximal heart rate (HRmax)
3111013|NCT01816451|No Intervention|control|The control group did not do the running training program. Control did their normal physical activities.
3111014|NCT01816438||dysplasia or colorectal lesion|300 patients
3111015|NCT01816425|Experimental|thermoplastic partial denture|The patients that need oral rehabilitation with partial denture will receive a thermoplastic partial denture as treatment
3111016|NCT01816425|Active Comparator|CoCr partial denture|The patients that need oral rehabilitation with partial denture will receive a CoCr partial denture as treatment
3111017|NCT01816412|Experimental|LDCB|Paclitaxel Coated Balloon
3111018|NCT01816412|Active Comparator|PTA|Standard Uncoated Balloon Angioplasty Catheter PTA Catheter
3111019|NCT01816399||Routine coronary angiography patients|
3111020|NCT01816386|Active Comparator|Acupuncture Regimen|Standard anaesthetic procedure plus press needle acupuncture
3111021|NCT01816386|No Intervention|Standard Treatment Control|"Standard anaesthetic procedure plus No treatment.~All standardized medication according to the perioperative anaesthetic guideline, Department of Anaesthesiology, University of Munich, will be allowed. In special:~According to the guidelines, anxiolysis will be performed intravenously according to the standard guidelines with opioid immediately prior to the induction of anaesthesia.~Intraoperative anaesthesia will be performed according to our in-house guidelines: on general recommendations and guidelines of the German society for anaesthesiology (DGAI). Opioids and propofol will be administered via TCI pumps according to the standard protocol.~It is allowed to treat the subject for pain with metamizol (4*1.25 g/day) and additional piritramide (PCA; 2 mg each 10 minutes; maximum dosage 30 mg/4 hours) .~Variation of this guideline based regimen are allowed if medically indicated."
3111022|NCT01816386|Active Comparator|Acupressure Regimen|Standard anaesthetic procedure plus press plaster acupressure
3111023|NCT01816373|Other|Vacuum Bell|Patients with pectus excavatum will be treated with the Vacuum Bell device
3111024|NCT01816360|Experimental|Aromatherapy group|20 sessions of olfactory aromatherapy using protocol.
3111025|NCT01816360|Experimental|Yogatherapy group|20 sessions of yogatherapy with aroma-placebo using protocol.
3111026|NCT01816360|Experimental|Aromatherapy-Yogatherapy group|20 sessions of yogatherapy with olfactory aromatherapy, using protocol.
3111027|NCT01816360|No Intervention|Control group|Control group in the waiting-list model (all volunteers were offered the treatment after the completion of data collection).
3111028|NCT01816347||Routine PCI patients|
3111029|NCT01816334|Active Comparator|methylprednisolone|administration of 60 mg of methylprednisolone at 8:00 am and 100 ml of 0.9 % sodium chloride (placebo) at 6:00 pm
3111030|NCT01816334|Active Comparator|Ketoprofen|administration of 100 mg of ketoprofen at 8:00 am and at 6:00 pm
3111031|NCT01816334|Placebo Comparator|sodium chloride|administration of 100 ml of 0.9% sodium chloride (placebo) at 8:00 am and at 6:00 pm
3111032|NCT01816321|Experimental|Corifollitropin alfa followed by hpHMG|
3111033|NCT01816321|Active Comparator|recombinant FSH|
3111034|NCT01816295|Placebo Comparator|Placebo Solution|Placebo Solution applied topically once daily for 12 weeks.
3111035|NCT01816295|Experimental|Testosterone Solution|Testosterone Solution 60 milligram (mg) applied topically once daily with possible titration down to 30 milligram per day (mg/day) or up to 120 mg/day for 12 weeks and optional extension for 24 weeks.
3111036|NCT01816282|Experimental|Evicel|
3111037|NCT01816282|No Intervention|Control|
3111038|NCT01816269||Patients with scaling and patients without scaling|No drug
3111039|NCT01816269||Helicobacter eradicated or non-eradicated|
3111040|NCT01816256|Other|Screening tests|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
3111041|NCT01816243|Experimental|Transdermal Therapeutic System (TTS)-fentanyl|Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. Oral morphine syrup is allowed to titrate the dose of TTS-fentanyl. The study duration will be 30 days after first patch application.
3111042|NCT01816230|Experimental|NiCord®|NiCord® is a stem/progenitor cell based product composed of ex vivo expanded allogeneic UCB cells.
3111043|NCT01816217|Experimental|Intubated patient|Adult intubated in Intensive Care Unit (ICU) with The McGrath Mac videolaryngoscope (intervention described)
3111044|NCT01816204|Experimental|Therapist assisted online treatment (TAO)|Students assigned to treatment with weekly online modules and weekly 10-15 minute video conference with counselor.
3111045|NCT01816204|Active Comparator|face-to-face individual therapy|weekly individual 50 minute psychotherapy sessions.
3111046|NCT01816191|Experimental|Diltiazem Hydrochloride|Topical cream and oral pill
3111047|NCT01816178|Experimental|communication training|Participants were instructed in the use of a voices output communication aid.
3111048|NCT01816165|Experimental|Acipimox|Drug: acipimox
3111049|NCT01816165|Placebo Comparator|Placebo|Drug: Placebo
3111050|NCT01816152|Active Comparator|Active Intervention|Light levels, primary and secondary measurements are obtained after a 4-week intervention period where active lighting is experienced by patients.
3111051|NCT01816152|Placebo Comparator|Inactive intervention|Light levels, primary and secondary measurements are obtained after a 4-week intervention period where an inactive lighting is experienced by patients
3111052|NCT01816139|Experimental|WC3011|Vaginal Cream, 0.015 mg estradiol/0.5 g vehicle administered daily for initial 14 days followed by twice weekly for 10 weeks
3111053|NCT01816139|Placebo Comparator|Vehicle|0.5 g Vehicle vaginal cream administered daily for initial 14 days followed by twice weekly for 10 weeks
3111054|NCT01816126||one-operator technique|
3111055|NCT01816126||two-operator technique|
3111056|NCT01816113|Experimental|Group 1|4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^9 vp intramuscularly
3111057|NCT01816113|Experimental|Group 2A|4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly
3111058|NCT01816113|Experimental|Group 2B|8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly and 1 dose MVA PvDBP 1 x 10^8 pfu 8 weeks later intramuscularly
3111059|NCT01816113|Experimental|Group 2C|8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly and 1 dose MVA PvDBP 2 x 10^8 pfu 8 weeks later intramuscularly
3111060|NCT01816100|Experimental|exercise session|"6 months weight resistance session, with before/after evaluations by MEG and DTI. Fifty minute exercise sessions, twice weekly will be done. Each session will rotate between 3 separate exercise protocols: Static weights, free weights and balance. Exercises will be done with each extremity independently. For consistency and convenience, the resistance training will be performed at Fast Forward Gym, Omaha, NE.~The primary outcome exercise data include strength and endurance"
3111061|NCT01816087|Experimental|brief assessment tool (BAT)|all participants will have a brief assessment tool (BAT) for the identification of geriatric syndromes performed by their general practitioner. Afterwards, all participants will have a full geriatric assessment performed by geriatricians
3111062|NCT01816074|Experimental|Maternal Medication then meds|The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to enhanced medication
3111063|NCT01816074|Experimental|BPT then continued beh tx|The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to enhanced behavioral treatment.
3111064|NCT01816074|Experimental|Maternal Medication then BPT|The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to combined treatment (adding Behavior Parent Training).
3111065|NCT01816074|Experimental|BPT then maternal medication|The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to active ADHD medication, Vyvanse.
3111066|NCT01816061|Experimental|Arm 1: Experimental|The COMPASS (Community Participation through Self-Efficacy Skills Development) program aims at developing and testing a novel patient-centered intervention framework that can be utilized as a platform for VA community re-integration comparative effectiveness research.
3111067|NCT01816061|Active Comparator|Arm 1: Control|"Fifty-five participants in the supported discharge, or control, group will not receive the intervention, but will receive phone calls to answer a short questionnaire and check in on their status.~Control"
3111140|NCT01815528|Experimental|Catumaxomab|Catumaxomab treatment followed by an established chemotherapy regimen
3111174|NCT01815294|Experimental|Treatment B: DOXIL/CAELYX (doxorubicin)|50 mg/m2 of doxorubicin manufactured at the new site of manufacturing (test product) administered by IV infusion over 90 minutes on Day 1
3111068|NCT01816048|Experimental|TAK-700|"TAK-700 will be administered at 300 mg orally (PO)twice daily (BID) continuously on 28-day treatment cycles.~The most common way of assessing bone metastasis is planar bone scintigraphy or single photon emission computed tomography (SPECT), though both lack high spatial resolution and thus make small metastases detection inaccurate. Positron emission tomography (PET) is a successful imaging modality with a higher resolution than SPECT, but has not been widely adopted in bone imaging. One of the most promising PET imaging agents for detection of bone metastasis is 18F-Sodium Fluoride (Fluorine F 18 Sodium Fluoride, or NaF). NaF uptake is characterized by high and rapid bone uptake accompanied by very rapid blood clearance, which results in a high bone-to-background ration in a short time."
3111069|NCT01816035|Experimental|Treatment (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving response may continue treatment.
3111070|NCT01816009|Experimental|6 weeks|the duration of antibiotic treatment will be six weeks.
3111071|NCT01816009|Active Comparator|12 weeks|the duration of antibiotic treatment will be 12 weeks.
3111072|NCT01815996||Pregnant Women|"Females between the age of 18-80 who are pregnant~One time blood draw to look at patient's DNA"
3111073|NCT01815996||Pulmonary Embolism Patients|"Male and Female patients that have suffered a pulmonary embolism within the past 48 hours~One time blood draw to look at patient's DNA"
3111074|NCT01815996||Myocardial Patients|"Male and Female patients who have myocardial infarction in the past 48 hours.~One time blood draw to look at patient's DNA"
3111075|NCT01815996||Autoimmune Patients|"Male and Female patients that have been diagnosed with an Autoimmune disease~One time blood draw to look at patient's DNA"
3111076|NCT01815996||Healthy Controls|"Self-declared healthy adults (men and women).~One time blood draw to look at patient's DNA"
3111077|NCT01815983|Experimental|Videolaryngoscopy review.|Video review.
3111078|NCT01815970|Experimental|Pulmonary Rehabilitation|8 weeks of Pulmonary Rehabilitation
3111079|NCT01815957|Experimental|Ranalozine|After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
3111080|NCT01815944|Active Comparator|0.75% Ropivacaine and normal saline|Ultrasound-guided supraclavicular block using 0.75% ropivacaine diluted with normal saline
3111081|NCT01815944|Experimental|0.75% ropivacaine and dextrose 5%|Ultrasound guided supraclavicular block using 0.75% ropivacaine diluted with dextrose 5%
3111082|NCT01815931||ED patients|
3111083|NCT01815918|Placebo Comparator|Placebo|Patients receive a saline placebo before surgery, 8 hours after the first dose and 16 hours after the first dose.
3111084|NCT01815918|Active Comparator|Treatment|Patients receive 3 100 mg of hydrocortisone: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
3111085|NCT01815905|Active Comparator|Traditional therapy|Traditional rehabilitation therapy
3111086|NCT01815905|Experimental|Mobile program|Mobile program for occupational and speech therapy
3111087|NCT01815892|Active Comparator|Withdrawal of Furosemide|The patient's Furosemide will be withdrawn
3111088|NCT01815892|Experimental|Administration of furosemide|The patient will receive furosemide 120 mgms daily
3111089|NCT01815879||Control Group|Retrospective review of clinical data on at least 1,000 evaluable US patients with 12+weeks follow up that were treated with 90Y resin microsphere radioembolization for metastatic colorectal liver metastases
3111090|NCT01815866||CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
3111091|NCT01815853|Experimental|Neoadjuvant Chemoradiotherapy|Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 D1; 21-days/cycle) following with D2 Gastrectomy and 3 cycles of Adjuvant XELOX Chemotherapy
3111092|NCT01815853|Active Comparator|Neoadjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 D1; 21-days/cycle) following with D2 Gastrectomy and 3 cycles of Adjuvant XELOX Chemotherapy
3111093|NCT01815840|Experimental|Vismodegib Intermittent Schedule|Vismodegib intermittent schedule of 12 weeks vismodegib followed by 8 weeks placebo, repeated 3 times with a final course of vismodegib (total 72 weeks), followed by 52 weeks treatment-free follow up
3111094|NCT01815840|Experimental|Vismodegib Induction Followed by Intermittent Schedule|Vismodegib beginning with 24 weeks induction followed by intermittent schedule 8 weeks placebo, 8 weeks vismodegib (total 72 weeks), followed by 52 weeks treatment-free follow up
3111095|NCT01815827|Active Comparator|Caucasian Healthy volunteers|
3111096|NCT01815827|Experimental|Japanese Healthy volunteers|
3111097|NCT01815814|Experimental|Rolfing After 3-Month Wait|The children in this arm receive the therapy (rolfing / myofascial structural integration) 3 months after they start the study.
3111098|NCT01815814|Other|Rolfing After 6-Month Wait|The children in this arm receive the therapy (rolfing / myofascial structural integration) 6 months after they start the study.
3111099|NCT01815801|Experimental|Ventilated group|Lungs were mechanically ventilated during subclavian vein catheterization.
3111100|NCT01815801|Active Comparator|Control group|Lungs were not mechanically ventilated during subclavian vein catheterization.
3111101|NCT01815788|Experimental|Teo first|"Mild and moderate presbycusis (20 to 50 dB average hearing loss at 500, 1000, 2000 Hz and 4000 Hz)~Patient 60 years of age and older,~No previous hearing aid"
3111102|NCT01815775|Experimental|Normal pressure hydrocephalus|Hydrocephalus patients planned for shunting surgery. They will undergo clinical and imaging examinations at day 1, 3 months and 1 year after their surgery.
3111141|NCT01815515|Experimental|18F-DCFBC|Participants with hormone-naive prostate cancer (HNPC) and castration-resistant prostate cancer (CRPC) with metastatic lesions detected on conventional imaging modalities (contrast-enhanced computed tomography [CECT] and bone scintigraphy [BS]) undergo PET imaging with 18F-DCFBC radiotracer.
3111103|NCT01815762|Active Comparator|active arm of the study|The number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. The US B-line score (BLS) will be measured before dialysis. In patients presenting moderate to severe lung congestion (≥15 BLS pre-dialysis) LUS measurements will be repeated once a week until the treatment goal was achieved (<15 BLS pre-dialysis) and once a month thereafter. monthly monitoring frequency will be adopted also in patients without pulmonary congestion (BLS <15). Patients without evidence of lung congestion at baseline who developed pulmonary congestion (≥ 15 BLS) during the trial will received the same treatment contemplated for those with lung congestion at baseline during the trial.
3111104|NCT01815762|No Intervention|Standard care arm|In the control arm of the study, the dry weight will be assessed only clinically.Patients in the control arm of the study will be followed up and managed strictly with standard criteria according to current recommendations (implying optimization of fluids volume control on the basis of clinical criteria and the use of carvedilol, ACE inhibitors/sartans whenever deemed necessary); the use of lung US / bioimpedance assistance was not allowed in these patients.
3111105|NCT01815749|Experimental|Treatment (genetically modified T cell infusion)|Patients undergo mobilization for autologous stem cell collection with cytoreductive chemotherapy and filgrastim and/or plerixafor per current standard operating policies. Patients undergo myeloablative conditioning regimen per institutional standards beginning day -7 followed by hematopoietic stem cell transplantation on day 0. Patients receive CD19-CAR-specific/truncated EGFR lentiviral vector-transduced autologous T cells IV on day 2 or 3 (may be delayed up to day 45 if the patient is not yet eligible). Patients who experience disease progression and have not experienced DLTs at greater than or equal to 100 days post HSCT will be allowed to receive an optional second T cell infusion.
3111106|NCT01815736|Experimental|E/C/F/TAF|Participants will switch to E/C/F/TAF FDC tablet for up to 96 weeks in the Randomized Phase, and may continue treatment with E/C/F/TAF in the open-label Extension Phase.
3111107|NCT01815736|Active Comparator|Stay on Baseline Treatment Regimen (SBR)|Participants will stay on their baseline FTC/tenofovir disoproxil fumarate (TDF)-containing regimen (either E/C/F/TDF, EFV/FTC/TDF, RTV+ATV+FTC/TDF, or COBI+ATV+FTC/TDF) for up to 96 weeks in the Randomized Phase, and may switch to E/C/F/TAF in the open-label Extension Phase.
3111108|NCT01815723|Experimental|FP187|500 mg FP187 daily (250 mg twice daily)
3111109|NCT01815723|Active Comparator|Dimethyl fumarate|720 mg Fumaderm® daily (240 mg three times daily)
3111110|NCT01815723|Placebo Comparator|Placebo|Matching FP187 and Fumaderm® placebo
3111111|NCT01815710||Vomiting & Diarrhea|Alberta Health Services Acute Childhood Vomiting & Diarrhea Pathway
3111112|NCT01815710||Pediatric Asthma Clinical Pathway|Pediatric Asthma Clinical Pathway
3111113|NCT01815697|Experimental|Enhanced External Counterpulsation|Men with benign prostatic hyperplasia receive 35- 36 hours Enhanced External Counterpulsation treatment
3111114|NCT01815697|No Intervention|Control|Men with benign prostatic hyperplasia without Enhanced External Counterpulsation treatment as control
3111115|NCT01815684|Experimental|ASP3652 Group 1|Dosed according to the following scheme: placebo, low dose, medium dose, high dose
3111116|NCT01815684|Experimental|ASP3652 Group 2|Dosed according to the following scheme: low dose, placebo, medium dose, high dose
3111117|NCT01815684|Experimental|ASP3652 Group 3|Dosed according to the following scheme: low dose, medium dose, placebo, high dose
3111118|NCT01815684|Experimental|ASP3652 Group 4|Dosed according to the following scheme: low dose, medium dose, high dose, placebo
3111119|NCT01815671|Other|Lateral horizontal body position|Subjects randomized to receive colonoscopy in the lateral horizontal position, This is the standard position. The other position - tilt down is the intervention
3111120|NCT01815671|Other|Lateral tilt down body position|Subjects randomized to receive colonoscopy in the lateral tilt down position
3111121|NCT01815658||Broken humerus shaft|Patients presenting with broken humerus shaft
3111122|NCT01815645|Active Comparator|Standard treatment Alone|Participants in the Standard Treatment Alone group will receive 12 weeks of the exact treatment provided by the Ambulatory service where the study is being conducted
3111123|NCT01815645|Experimental|ST+CM|Participants in the Standard treatment plus Contingency Management (ST+CM) group will receive 12 weeks of the exact treatment provided by the Ambulatory service where the study is being conducted plus CM.
3111124|NCT01815632|Experimental|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow (without myeloablation) on the day of bone marrow harvest. Infusion of autologous blood at one year post-harvest
3111125|NCT01815632|Experimental|Late infusion of autologous marrow|Intravenous infusion of autologous blood on the day of bone marrow harvest. Infusion of autologous bone marrow (without myeloablation) at one year post-harvest
3111126|NCT01815619|Experimental|on-site pathologist|On-site pathologist will read slides during the procedure and render a diagnosis
3111127|NCT01815619|Active Comparator|off-site|Off-site pathologist will determine diagnosis via cell block
3111128|NCT01815606|Active Comparator|19 Gauge needle biopsy|biopsy with 19 gauge needle
3111129|NCT01815606|Active Comparator|25 gauge needle biopsy|biopsy with 25 gauge needle
3111130|NCT01815593|Experimental|Enhanced External Counterpulsation|Men with erectile dysfunction receive Enhanced External Counterpulsation treatment
3111131|NCT01815593|No Intervention|Control|Men with erectile dysfunction without Enhanced External Counterpulsation treatment
3111132|NCT01815580|Active Comparator|Immediate ART (Atripla or Stribild)|Daily Atripla or Stribild will be provided to these patients for the duration of the study beginning at enrollment.
3111133|NCT01815580|Placebo Comparator|Deferred ART (Atripla or Stribild)|Daily Atripla or Stribild will be provided to these patients for the duration of the study beginning at 24 weeks.
3111134|NCT01815567||controlled hypertension|hypertension with medication controlled
3111135|NCT01815567||uncontrolled hypertension|non-controlled hypertension
3111136|NCT01815567||hypertensive urgency|hypertensive urgency no previous history or antihypertensives
3111137|NCT01815567||asymptomatic normotensive|asymptomatic normotensive control group
3111138|NCT01815554||DPS Cohort|All patients implanted with a DPS within the past 5 years at one of 6 collaborating sites will be included. Patients will be interviewed as they cross their 1st, 3rd, 5th or 7th anniversary with the DPS.
3111139|NCT01815541|Experimental|teicoplanin|this group receive the teicoplanin
3111142|NCT01815502|Experimental|Sildenafil|Sildenafil will be given an one time dose 30 to 90 minutes prior to catheterization. Sildenafil will be given at a dose 1 milligram per kilogram with a maximum of 20 milligrams. During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
3111143|NCT01815502|Placebo Comparator|Sugar Pill|Patients will be given a one time dose of sugar pill 30 to 90 minutes prior to catheterization.During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
3111144|NCT01815476|Other|RT Positioning Intervention: Supine|Patient will be treated in a supine position as per standard of care/control.
3111145|NCT01815476|Experimental|RT Positioning Intervention: Prone|Patient will be treated in the prone position.
3111146|NCT01815463||colorectal neoplasia|No interventions Record colorectal neoplasia
3111147|NCT01815450|Experimental|BLI1100|BLI1100 topical cream
3111148|NCT01815450|Experimental|BLI1100 - modified formulation|BLI1100 topical cream
3111149|NCT01815450|Placebo Comparator|Placebo|Topical cream
3111150|NCT01815437|Active Comparator|2000 IU Vitamin D3- Cholecalciferol|Take 2000 IU crystalline vitamin D3 once/day for 12 weeks.
3111151|NCT01815437|Active Comparator|2000 IU Vitamin D2- Ergocalciferol|Take 2000 IU crystalline vitamin D2 supplement once/day for 12 weeks.
3111152|NCT01815437|Experimental|2000 IU Mushroom Vitamin D2|Take 2000 IU vitamin D2 in a mushroom supplement once/day for 12 weeks
3111153|NCT01815437|Placebo Comparator|Mushroom Extract|Capsules with mushroom extract and no vitamin D. The intervention is mushroom extract.
3111154|NCT01815424|Placebo Comparator|Placebo BID|
3111155|NCT01815424|Experimental|5mg BID CP-690,550|
3111156|NCT01815424|Experimental|10mg BID CP-690,550|
3111157|NCT01815411|Experimental|Mushroom extract|The patients are given the mushroom extract (Andosan) in doses 30 mlx2 per day for 1 days. The experimental group is selected by randomisation.
3111158|NCT01815411|No Intervention|Control group|The control group is selected by randomisation.
3111159|NCT01815398|Active Comparator|Computer skills training|26 sessions conducted 2-3 times a week to train in computer skills related to the workforce.
3111160|NCT01815398|Experimental|Cognitive Remediation|26 sessions conducted 2-3 times a week of cognitive remediation
3111161|NCT01815372|Experimental|SPEDI|These are the patients that will be randomized to receive a SPEDI block of the sciatic and saphenous nerve with at single needle penetration of the skin
3111162|NCT01815372|Active Comparator|Popliteal sciatic and mid-femoral saphenous|These are the patients that will be randomized to the administration of a popliteal sciatic nerve block combined with a mid-femoral saphenous nerve block with two separate injections
3111163|NCT01815359|Experimental|Appendiceal, no chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the Colorectal Disease Management Team.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
3111164|NCT01815359|Experimental|Appendiceal, chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the Colorectal Disease Management Team.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
3111165|NCT01815359|Experimental|Colorectal, no chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the Colorectal Disease Management Team.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
3111166|NCT01815359|Experimental|Colorectal, chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the Colorectal Disease Management Team.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
3111167|NCT01815346|Experimental|Acupuncture Group - Twice a Week|Acupuncture 2 times a week for 6 weeks. Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.
3111168|NCT01815346|Experimental|Acupuncture Group - Three Times a Week|Acupuncture 3 times a week for 4 weeks. Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.
3111169|NCT01815333|Experimental|Feraheme|Magnetic resonance imaging (MRI) acquired prior to the injection of Feraheme® and repeated at approximately 48 hours and 72 hours from the time of injection (scan time). The scan time will be adjusted, as needed. The MRI scan prior to the Feraheme injection is the routine scan. The scans at 48 and 72 hours are investigational.
3111170|NCT01815320|Experimental|Contrast-enhanced ultrasound (CE-US)|Ce-US is performed by contrast agent infusion SonoVue. The acquisition protocol will consist of two different administrations of SonoVue, performed 10 minutes apart. In the first session, SonoVue microbubbles will be administered as a fast 1.5 ml bolus immediately followed by 5 ml saline solution. In the second session, max 2 vials (9.6 ml) of SonoVue will be infused at an infusion rate between 0.5 and 1.0 ml/min.
3111171|NCT01815307|Experimental|Gemcitabine group|1000mg/m2, day 1 every 2 weeks
3111172|NCT01815307|Experimental|S-1 group|80mg/m2/day, day 1-28, every 6 weeks
3111173|NCT01815294|Experimental|Treatment A: DOXIL/CAELYX (doxorubicin)|50 mg/m2 of doxorubicin manufactured at the current site of manufacturing administered by IV infusion over 90 minutes on Day 1
3111175|NCT01815281|Experimental|Foot Mechanical Stimulation|The FMS stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland).
3111176|NCT01815281|Sham Comparator|Footh Mechanical Stimulation|The sham stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland).
3111177|NCT01815268|Experimental|HD Vaccine (Residents) + Free Vaccine (Staff)|NH facilities randomized to receive high-dose trivalent influenza vaccine (Fluzone High-Dose) for the residents and provided free SD vaccine (Fluzone) for the staff.
3111178|NCT01815268|Experimental|HD Vaccine (Residents) + Usual Care (Staff)|NH facilities randomized to receive high-dose trivalent influenza vaccine (Fluzone High-Dose) for the residents and not provided free vaccine for the staff.
3111179|NCT01815268|Active Comparator|SD Vaccine (Residents) + Free Vaccine (Staff)|NH facilities randomized to receive standard dose influenza vaccine (Fluzone) for the residents and provided free standard dose vaccine (Fluzone) for the staff.
3111180|NCT01815268|Active Comparator|SD Vaccine (Residents) + Usual Care (Staff)|NH facilities randomized to receive standard dose influenza vaccine (Fluzone) for the residents and not provided free vaccine for the staff.
3111181|NCT01815255||tenofovir (TDF)|HIV-infected children who are currently on TDF-based regimen or are changing to TDF based on their clinical indication
3111182|NCT01815242|Experimental|Arm A|nab-Paclitaxel + gemcitabine
3111183|NCT01815242|Experimental|Arm B|nab-Paclitaxel + carboplatin
3111184|NCT01815229||tracheal lavages|"After the placement of the endotracheal tube (Hi-Lo™ Evac Mallinckrodt), tracheal lavages will be performed.~A simultaneous blood sample of approx 5cc, will be collected by venipuncture or by sampling from intravenous or arterial line if available. The same procedure for collection of tracheal sample and blood will be repeated at the end of the surgical procedure and immediately prior to removal of the ETT. A total of approx 10cc blood will be collected for research purposes."
3111185|NCT01815216|Experimental|Bariatric surgery|patients participating in the intervention group , i.e. assessing effects of bariatric surgery on: Brain activity in resting state Memory performance
3111186|NCT01815216|Active Comparator|Control|"Patients in the control group will not undergo surgery during study.~These patients will be examined twice:~9 weeks before the operation (i.e. clinical intervention to reduce body weight has not started).~after 4 weeks of low-calorie diet (which will be a week before their surgery, when patients are in a catabolic metabolism because they eat much less energy than is needed) to assess effect of acute weight loss on: Brain activity in resting state Memory performance"
3111187|NCT01815203|Experimental|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
3111188|NCT01815203|Placebo Comparator|Placebo|Administration of placebo (one gelatin capsule containing starch) with subsequent cognitive tasks and food test.
3111189|NCT01815190||IgA-positive vasculitis|Patients with immune complex vasculitis who show perivascular deposits of IgA
3111190|NCT01815190||IgA-negative vasculitis|Patients with immune complex vasculitis who show no perivascular deposits of IgA
3111191|NCT01815177|Experimental|Arthroscopic transosseous fixation|Patients with torn rotator cuff randomized to experimental treatment receive a complete arthroscopic transosseous cuff repair
3111192|NCT01815177|Other|Repair using suture anchors|Patients randomized to this arm receive an arthroscopic rotator cuff repair using suture anchors.
3111193|NCT01815164|Active Comparator|Hypnotherapy|Hypnotherapy
3111194|NCT01815164|Active Comparator|Educational intervention|Educational intervention
3111195|NCT01815138|Experimental|hCG given at time of GnRHa trigger|"Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger.~Placebo administered 35 hours after GnRH agonist trigger"
3111196|NCT01815138|Active Comparator|hCG given 35 hours after GnRHa trigger|"Placebo administered at the time of GnRH agonist trigger~Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger."
3111197|NCT01815125|Experimental|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
3111198|NCT01815125|Placebo Comparator|Placebo|The control group will receive a similar looking/ tasting pill of placebo.
3111199|NCT01815112|Experimental|Alzheimer|Alzheimer patients detected via conventional clinical and neuropsychological tests. They will undergo Magnetic resonance imaging and positron emission tomography examinations.
3111200|NCT01815112|Experimental|Vascular dementia|Vascular dementia patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.
3111201|NCT01815112|Experimental|Mild cognitive impairment (MCI)|Mild cognitive impairment (MCI) patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.
3111202|NCT01815112|Experimental|Healthy subjects (MRI)|Healthy subjects agreeing to undergo magnetic resonance imaging examination.
3111203|NCT01815112|Experimental|Healthy subjects (PET)|Cognitively healthy subjects. These subjects are people addressed in the nuclear medicine department for cancer-related positron emission tomography examination. If they agree, an extended neuropsychological test will assess that they do not suffer any cognitive disorder.
3111204|NCT01815099|Experimental|rTMS Treatment|Clinical participants will receive rTMS
3111205|NCT01815086|Experimental|124I-labeled anti-amyloid mAb 11-1F4|124I-labeled anti-amyloid mAb 11-1F4 will be infused on day 0. Two and 5 days later, PET/CT scans will be performed.
3111206|NCT01815073|Experimental|Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine|use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
3111207|NCT01815073|Experimental|Live Attenuated Varicella Vaccine|use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
3111208|NCT01815073|Experimental|Live Attenuated JE Vaccine|use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
3111209|NCT01815047|Experimental|200 IU Vitamin D3|A singular daily dose of 200 IU vitamin D3
3111210|NCT01815047|Experimental|2000 IU Vitamin D3|A singular daily dose of 2000 IU vitamin D3
3111211|NCT01815021|Experimental|amorphous calcium carbonate|50, 100 and 200 mg elemental calcium tablets, according to the doctor's decision
3111212|NCT01815021|Active Comparator|crystalline calcium supplements|Tablets, according to the doctor's decision
3111213|NCT01815008|Experimental|Clopidogrel|Clopidogrel 75 mg daily by mouth for 1 week then Clopidogrel 75 mg daily with aspirin 81 mg daily
3111214|NCT01814995|Experimental|Nutrition/Physical Activity Intervention|There will be four in-person group sessions (1/month), two including the participants' partners, and all with on-site child care. Sessions will include preparation of a healthy meal (hands-on) and discussions of mindful eating, balanced meals, portion sizes, and preparing food at home, under a dietitian's supervision. Sessions will also include a one-hour physical activity information/practice session with a kinesiologist. Participants will track daily step counts with a pedometer and aim to eventually reach more than 10,000 steps/day. They will also receive instruction and demonstration from a kinesiologist of some simple resistance exercises they may perform at home. Between sessions, participants will receive advice and support through a study-specific website and telephone calls.
3111215|NCT01814982|Experimental|Part 1: JNJ-17299425|JNJ-1729425 will be administered once as 1 milligram (10 milliliter of a 0.1 milligram/milliliter (mg/ml) solution) intravenous bolus injection over 2 minutes in central vein. In case of no toxicity or Intra cranial pressure response, dose will be increased to a maximum of 200 milligram (mg).
3111216|NCT01814982|Experimental|Part 2: JNJ-17299425|JNJ-1729425 will be repeated once at a dose (which is, determined by Investigator in Part 1) as intravenous bolus injection over 2 minutes in central vein.
3111217|NCT01814969|Experimental|Hyperfractionated Radiochemotherapy|"radiotherapy in rectal tumor area due to the placing of pelvic nodal groups to a total dose of 42 Gy, 1.5 Gy d fx 2 times a day; (gap between the factions min. 6-8h) - duration of treatment 2.5 weeks with simultaneous two cycles of chemotherapy according to the scheme: 5FU-325mg/m2 (bolus) on 1-3 and 16-18 (last 3 days of radiotherapy).~Surgical resection has to be done within 14 days or 5-6 weeks after the completion of hyperfractionated radiochemotherapy (HRTCT)."
3111218|NCT01814969|Active Comparator|Hyperfractionated Radiotherapy|"radiotherapy in rectal tumor area due to the placing of pelvic nodal groups to a total dose of 42 Gy, 1.5 Gy d fx 2 times a day; (gap between the factions min. 6-8h) - duration of treatment 2.5 weeks.~Surgical resection has to be done within 14 days or 5-6 weeks after the completion of hyperfractionated radiotherapy (HRT)."
3111219|NCT01814956|Experimental|1|i.v. lipid emulsion for parenteral nutrition
3111220|NCT01814956|Active Comparator|2|i.v. lipid emulsion for parenteral nutrition
3111221|NCT01814943||Patients with prescription for low dose ASA (75-300 mg/day)|
3111222|NCT01814930|No Intervention|Routine Care|Routine postpartum contraceptive counseling
3111223|NCT01814930|Experimental|Individual counseling|Brief standardized contraceptive counseling intervention
3111224|NCT01814917|Experimental|MCI-196 (Flexible dose)|MCI-196 BSA eq 3g, 6g, 9g, 12g or 15g
3111225|NCT01814917|Active Comparator|CBPB|Calcium-based P binder
3111226|NCT01814904|Experimental|MCI-196-L|MCI-196 BSA eq 3g
3111227|NCT01814904|Experimental|MCI-196-M|MCI-196 BSA eq 6g
3111228|NCT01814904|Experimental|MCI-196-H|MCI-196 BSA eq 9g
3111229|NCT01814904|Active Comparator|CBPB|Calcium-based P binder
3111230|NCT01814891|Experimental|Orange maize|"Children were fed orange maize and the intervention name was orange"
3111231|NCT01814891|Active Comparator|Blue vitamin A group|Received vitamin A in the form of retinyl palmitate in oil at the estimated average requirment.
3111232|NCT01814891|Placebo Comparator|White|Received oil only at the same volume as the vitamin A group
3111233|NCT01814878|Experimental|Tramadol Hydrochloride/Acetaminophen ER|Participants will be administered 2 oral tablets of extended release (ER) tramadol HCl (75 milligram [mg])/acetaminophen (650 mg) and 2 tablets of placebo matching to immediate release (IR) tramadol HCl/acetaminophen orally every 12 hours up to 36 hours, and 2 tablets of placebo matching to IR tramadol HCl/acetaminophen every 6 hours up to 42 hours.
3111234|NCT01814878|Active Comparator|Tramadol HCl/Acetaminophen IR|Participants will be administered 2 oral tablets of IR tramadol HCl (37.5 mg)/acetaminophen (325 mg) and 2 tablets of placebo matching to ER tramadol HCl/acetaminophen at 0, 12, 24 and 36 hours, and 2 tablets of IR tramadol HCl/acetaminophen at 6, 18, 30 and 42 hours.
3111235|NCT01814865|Experimental|Abiraterone Acetate + Prednisone|Abiraterone 1000mg PO OD + Prednisone 5mg PO OD x 2 weeks
3111236|NCT01814865|Active Comparator|Aromatase Inhibitor|Anastrozole 1mg PO OD x 2 weeks
3111237|NCT01814852|Experimental|Shockwaves|4 weekly sessions of low-intensity shockwave therapy
3111238|NCT01814852|Sham Comparator|Control Group|
3111239|NCT01814839|Active Comparator|ALN-TTRSC (revusiran)|
3111240|NCT01814839|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3111241|NCT01814826|Experimental|MLN4924 and azacitidine|
3111242|NCT01814813|Experimental|Arm 1, HSPPC-96 + concomitant bevacizumab|"HSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles), plus bevacizumab 10 mg/kg intravenous (IV) on day 1 of each cycle, until progression. HSPPC-96 should be administered at least 60 minutes prior to starting bevacizumab infusion. (1 cycle=14 days)~Note: If HSPPC-96 treatment has ended but there is no evidence of disease progression, the patient should continue to receive bevacizumab at the specified dose until progression."
3111243|NCT01814813|Experimental|Arm 2, HSPPC-96 with bevacizumab at progression|"HSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles). At progression: bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until further progression. (1 cycle = 14 days)~NOTE: It is possible that HSPPC-96 vaccination may end prior to evidence of progression. In this instance it is important to wait until there is confirmed evidence of progression before initiating treatment with bevacizumab.~Upon confirmation of progression the patient should initiate bevacizumab within 7-42 days from the last dose of vaccine."
3111244|NCT01814813|Active Comparator|Arm 3, Bevacizumab|Bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until progression. (1 cycle = 14 days)
3111245|NCT01814800|Experimental|RI-002 Treatment|Drug: RI-002 Dose: 300-800 mg/kg infusion Frequency: Once every 3 to 4 Weeks
3111277|NCT01814592|Active Comparator|coronally partial thickness flap|coronally partial thickness flap plus connective tissue for root coverage (subepithelial connective tissue graft)
3111278|NCT01814579|Experimental|V-Loc Vaginal Cuff Closure|Patients in this arm will receive vaginal cuff closure with unidirectional barbed suture at time of their robotic hysterectomy.
3111246|NCT01814787|Experimental|CHICA Type 2 Diabetes Module|Children treated at the two intervention clinic sites will have be treated using the CHICA system AND will be provided access to the newly developed CHICA Type 2 Diabetes Module. The CHICA Type 2 Diabetes Module will assist pediatricians in identification of those children 10 years of age or older who are at increased risk for type 2 diabetes, it will provide pediatric physicians guidelines to screen for type 2 diabetes, and it will coordinate the diagnosis and long-term management of the condition.
3111247|NCT01814787|No Intervention|Usual Care|Those patients who are assigned to the control group will have the CHICA system but will NOT be cared for using the CHICA Type 2 Diabetes Module. The CHICA system will notify the physician of the child's BMI percentile on the physician worksheet. However, the CHICA system will not ask for any additional information related to risk factors for type 2 diabetes on the pre-screening form, no advice will be provided to the physician on the physician worksheet, nor will just-in-time documents or automated reminder calls be made available. Identification of patients at risk for type 2 diabetes and care of those patients will occur through routine practices for that clinic.
3111248|NCT01814774||BOTOX®|Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
3111249|NCT01814774||Xeomin®|Retrospective chart review of doses of Xeomin® (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
3111250|NCT01814761||Pts with POAG or OH (Previously Treatment Naive)|Previously treatment naïve patients with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).
3111251|NCT01814761||Pts with POAG or OH (Switched Monotherapy)|Patients previously on another monotherapy treatment with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).
3111252|NCT01814748|Experimental|Omarigliptin 25 mg|Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
3111253|NCT01814748|Placebo Comparator|Placebo|Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
3111254|NCT01814735|Experimental|Brown rice|Brown Rice
3111255|NCT01814735|Active Comparator|White rice|White rice
3111256|NCT01814722||Raltegravir + 2 NRTIs|Raltegravir is an integrase inhibitor. Two Nucleoside Reverse Transcriptase Inhibitor (NRTIs)
3111257|NCT01814722||NNRTI + 2 NRTIs|Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) could include: delavirdine, efavirenz, etravirine, rilpivirine, nevirapine; and two NRTIs.
3111258|NCT01814722||PI + 2 NRTIs|Protease inhibitors (PI) could include: nelfinavir, lopinavir, saquinavir, tipranavir, atazanavir and darunavir; and two NRTIs.
3111259|NCT01814709|Experimental|Itraconazole Arm|
3111260|NCT01814709|Experimental|Rifampin Arm|
3111261|NCT01814696|No Intervention|Control|Subjects will continue to receive usual medical care from their doctor(s).
3111262|NCT01814696|Experimental|MedSentry System|Subjects will continue to receive usual medical care from their doctor(s). Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
3111263|NCT01814683|Experimental|Primaquine 7 day|Standard blood schizontocidal therapy plus 7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
3111264|NCT01814683|Placebo Comparator|Placebo controlled arm|Standard blood schizontocidal therapy plus 14 days placebo.
3111265|NCT01814683|Active Comparator|Primaquine 14 day|Standard blood schizontocidal therapy plus 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
3111266|NCT01814670|Experimental|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
3111267|NCT01814657|Placebo Comparator|Normal Saline|Conscious sedation and sterile normal saline (placebo) paracervical block
3111268|NCT01814657|Active Comparator|Lidocaine|Conscious sedation and Lidocaine hydrochloride 1% solution paracervical block
3111269|NCT01814644|Active Comparator|Standard Care|Individual assessment Lifestyle counseling
3111270|NCT01814644|Experimental|TRIMM Intervention|Individual assessment Lifestyle counseling Text messages
3111271|NCT01814631||Aloka|image quality and resolution
3111272|NCT01814618|No Intervention|Observation|These subjects did not have improved sense of smell after surgery and were randomized to this observation group or treatment group. These patients will be observed post-operatively but will not receive the trial medication.
3111273|NCT01814618|Experimental|Treatment|"These subjects did not have improved sense of smell after surgery and were randomized to this treatment group or the observation. These patients will be observed post-operatively and will receive a 3-month course of topical nasal steroids(budesonide respules).~Drug: Budesonide Respules~Other Names:~Pulmicort respules~Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months."
3111274|NCT01814605|Experimental|Subgluteal space group|"The patients in Subgluteal space group will receive sciatic block according to the approach described by Karmakar et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint will be designated with a marker and will be the site of needle entry.~A 50 to 90 mm 22 G insulated needle will be inserted at the midpoint previously designated and advanced under real time guidance in an out-of-plane approach until the needle reaches the subgluteal space."
3111275|NCT01814605|Active Comparator|Infragluteal space group|The patients in this group will receive sciatic bock according to the approach described by Chan et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. After skin and transducer preparation, a curved 5 MHz(megahertz) transducer will be placed over the subgluteal region in a transverse plane to scan the sciatic nerve. A 50 to 90 mm 22 G needle is used and advanced under real time guidance in an out-of-plane approach until the needle tip is adjacent o the nerve.
3111276|NCT01814592|Experimental|coronally mucosal thickness flap|coronally mucosal thickness flap plus connective tissue graft for root coverage (subepithelial connective tissue graft)
3111311|NCT01814332|Placebo Comparator|Placebo|Placebo compound treatment for comparison with IP
3111279|NCT01814579|Active Comparator|Vicryl Vaginal Cuff Closure|Patients enrolled in this arm will have their vaginal cuff closed with polyglactin 910 (Vicryl) at the time of their robotic hysterectomy.
3111280|NCT01814553|Experimental|Afatinib 40 mg + Loperamide (Cohort 1)|afatinib starting 40 mg daily; Cohort 1 will receive loperamide at first sign of diarrhea; Cohort 2 will receive loperamide starting C1D1.
3111281|NCT01814553|Experimental|Afatinib 40 mg + loperamide prophylactic (Cohort 2)|afatinib starting 40 mg daily; Cohort 1 will receive loperamide at first sign of diarrhea; Cohort 2 will receive loperamide starting C1D1.
3111282|NCT01814540|Placebo Comparator|Placebo Control, Glucose polymer|Treatment 1: Polycose Glucose Polymer Module powder (Abbott Nutrition, Abbott Park, Illinois 60064), fed as 25% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days.
3111283|NCT01814540|Experimental|Treatment 2: Low-Dose BMO|"Treatment 2: Bovine Milk Oligosaccharide (BMO) powder (Hilmar Ingredients, Hilmar, California 95324) Dosage: 25% of individual daily fiber intake, split into two daily servings Frequency: Two servings per day (for total of 25% dosage per day) Duration: 11 days, followed by a 2-week wash-out period~Fiber intake was 25% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days."
3111284|NCT01814540|Experimental|Treatment 3: High-Dose BMO|"Treatment 3: Bovine Milk Oligosaccharide (BMO) powder (Hilmar Ingredients, Hilmar, California 95324) Dosage: 35% of individual daily fiber intake, split into two daily servings Frequency: Two servings per day (for total of 25% dosage per day) Duration: 11 days, followed by a 2-week wash-out period~Fiber intake was 35% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days."
3111285|NCT01814527|Active Comparator|Docosahexaenoic acid|The experimental group will be given a standardized dose of omega-3 fatty acid containing 2200mg of DHA for 30 days after onset of concussion or longer for those with continued symptomatology. Brain Armor an over the counter DHA supplements that is independently tested and certified by the National Science Foundation Athletic Banned Substance Certified for Sport Program. The Docosahexaenoic acid supplement has 440mg of DHA per capsule and each subject will be given 5 capsules of Brain Armor once daily for a DHA dose of 2200mg/day.
3111286|NCT01814527|Placebo Comparator|Placebo|The placebo group will be given an equal amount of capsules.
3111287|NCT01814514|Active Comparator|Timolol-trusopt|Dosage:One drop/12hours,duration:3 months
3111288|NCT01814514|Placebo Comparator|placebo,Artificial tear|dosage:one drop/12 hours,duration:3 months
3111289|NCT01814501|Experimental|Treatment (panitumumab, combination chemotherapy)|5-Fluorouracil, irinotecan, and panitumumab
3111290|NCT01814488|Experimental|allogenic transplant|The experimental treatment consists in the application of a therapeutic strategy of allogeneic transplantation as a potential curative procedure in a population of patients with chemoresistant acute leukemias. Therapeutic intervention, namely the conditioning regimen as well as GVHD prophylaxis, are based on regimens currently in standard use in the context of allogeneic transplantation.
3111291|NCT01814475|Active Comparator|A: Fludarabine + Busulphan|Conventional conditioning regimen with Fludarabine and Busulphan (Busilvex)for allogeneic stem cell transplantation in myelofibrosis
3111292|NCT01814475|Experimental|B: Fludarabine + Thiotepa|Reduced-intensity conditioning with Fludarabine and Thiotepa for allogeneic stem cell transplantation in myelofibrosis
3111293|NCT01814462|Experimental|6 months CPAP|Application of continuous positive airway pressure (CPAP) therapy as established per routine clinical treatment. Home use of therapy for a period of 6 months.
3111294|NCT01814449||Hypoxic Group|Higher 18FMISO uptake (Target to background Ratio, TBR>1.2) in Primary breast cancer by 18FMISO PET/CT scan.Primary endocrine therapy Letrozole was given to the patients.
3111295|NCT01814449||Non-Hypoxic Group|Lower 18FMISO uptake (TBR<1.2)in primary breast cancer by 18FMISO PET/CT scan.Primary endocrine therapy letrozole was given to the patients.
3111296|NCT01814436|Experimental|scaffold-free SHED-derived pellet|
3111297|NCT01814423|Experimental|Chloroquine-base 50 mg|Chloroquine-base 10 mg/kg twice a day for 2 days and 5 mg/kg twice a day for another day.
3111298|NCT01814423|Active Comparator|Chloroquine-base 70 mg|Chloroquine-base 10 mg/kg twice a day for 2 days and 5 mg/kg twice a day for another 3 days.
3111299|NCT01814410|Placebo Comparator|intravenous ethanol placebo and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
3111300|NCT01814410|Active Comparator|intravenous ethanol 40% and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
3111301|NCT01814410|Active Comparator|intravenous ethanol 100% and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
3111302|NCT01814397||Women starting AI therapy|There is only a single cohort. Postmenopausal women with ER positive breast cancer who are starting treatment with anastrozole 1 mg daily, letrozole 2.5 mg daily, or exemestane 25 mg daily. Choice of therapy is at the discretion of the treating physician.
3111303|NCT01814384|Other|Control group|Control group will be constituted of patients with the prosthesis GMK ® without the ancillary MyKnee ® LBS.
3111304|NCT01814384|Other|Matched patient|Treated group will consist of patients which the GMK ® prosthesis with ancillary ® MyKnee LBS.
3111305|NCT01814371|Active Comparator|Individualized Approach|The decolonization regimen will be performed only by those household members who experienced SSTI in the prior year.
3111306|NCT01814371|Active Comparator|Household Approach|All members of the household will perform the decolonization regimen.
3111307|NCT01814358|Experimental|Whey protein|Subjects on this arm will receive whey protein
3111308|NCT01814358|Active Comparator|Gelatin protein|Subjects on this arm will consume gelatin protein
3111309|NCT01814358|No Intervention|Control arm|Subjects on this arm will receive no intervention
3111310|NCT01814332|Experimental|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
3111312|NCT01814319|Experimental|Probenecid|Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate therapy.
3111313|NCT01814319|Placebo Comparator|placebo|Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate (placebo) therapy.
3111314|NCT01814306|Active Comparator|Supreme|Supreme LMA
3111315|NCT01814306|Active Comparator|Proseal|Proseal LMA
3111316|NCT01814293|Active Comparator|Handheld humidifier|Study design is a nonblinded randomized controlled comparison study of pediatric patients presenting to the UCSF Emergency Department (ED) with upper respiratory infection (URI) symptoms for which the ED physician has recommended supportive care only (ie. non-prescription symptom relief). Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) & control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
3111317|NCT01814293|No Intervention|Control group|Subjects will manage cold symptoms with any desired supportive over the counter treatment, and complete surveys related to symptom scores and modalities used.
3111318|NCT01814280|Other|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
3111319|NCT01814267|Experimental|Telemedicine|care and follow-up through telemedicine.
3111320|NCT01814267|Active Comparator|Conventional care|care and follow-up through iterative diabetes physician consultations (conventional care and follow-up)
3111321|NCT01814254||Receiving hemodialysis|
3111322|NCT01814241|Experimental|Open label peanut OIT|Open label orally ingested peanut flour with maintenance dose of 1450mg
3111323|NCT01814228|Experimental|right atrium ganglionated plexi transcatheter ablation|right atrium ganglionated plexi transcatheter ablation
3111324|NCT01814215|Experimental|Healthy Lifestyles Group|The Experimental Arm will receive the Keys to Healthy Family Child Care Homes intervention to be delivered over 9 months in 3 modules (3 months/module). The intervention group will be asked to participate in 3 workshops on 3 content areas. Participants will be asked to meet with a coach 3 times in-person, as well 3-9 times by phone/email, over the course of the 9-months. Three content areas are designed to help providers:(1) modify their own weight-related behaviors so they can role model healthy behaviors for children in their care (Healthy You module), (2) create environments that support children's physical activity and healthy dietary intakes (Healthy Home module), and (3) adopt sound business practices that will help them sustain the changes introduced (Healthy Business module).
3111325|NCT01814215|Placebo Comparator|Healthy Business Group|The Control Arm will receive the Healthy Business Education and Coaching program to be delivered over 9 months in 3 modules (3 months/module). The control group will be asked to participate in 3 workshops and a similar number of coaching contacts about their business practices. The focus on business topics is relevant, but not directly related to physical activity or nutrition.
3111326|NCT01814202|Experimental|PTM202|PTM202 is a medical nutrition product
3111327|NCT01814202|Placebo Comparator|Placebo|The placebo is a placebo for PTM202, a food product that can not be distinguished from PTM202 by appearance, taste or odor
3111328|NCT01814189|Active Comparator|sumatriptan+promethazine (SPr)|The SPr group denote patients receiving oral sumatriptan (50 mg) plus oral promethazine (50 mg).
3111329|NCT01814189|Placebo Comparator|Sumatriptan+placebo (SP)|The SP group denote patients receiving oral sumatriptan (50 mg) plus tablet of placebo matched to promethazine.
3111330|NCT01814176|Active Comparator|Macintosh Direct Laryngoscope|2 main forces - a 'lifting' force to elevate the structures not in the line of sight and a force exerted by the user's wrist to counterbalance the torque effect of the tongue tissues on the blade
3111331|NCT01814176|Active Comparator|GlideScope Video Laryngoscope|The GlideScope has a 60º angulation anteriorly at the distal portion of the blade, allowing an anterior view of the larynx.
3111332|NCT01814163||Paclitaxel, carboplatin and bevacizumab|Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
3111333|NCT01814150||Oncology Institute, Meir Medical Center|Metastatic cancer patients treated with docetaxel at the Oncology Institute, Meir Medical Center
3111334|NCT01814137|Experimental|IDegAsp BID + IAsp OD|
3111335|NCT01814137|Experimental|IDeg OD + IAsp TID|
3111336|NCT01814124|Active Comparator|Advice and home exercise|All participants will be given a handout consisting of education about avoidance of certain activities as well as 3 stretches and 3 strengthening exercises to be performed as a home exercise program 2-3x/week
3111337|NCT01814124|Experimental|Manual Therapy Plus Exercise|"Participants in this group will be given the same handout consisting of education about avoidance of certain activities as well as 3 stretches and 3 strengthening exercises to be performed as a home exercise program 2-3x/week.~Participants in this group will also receive 12 individualized physical therapy treatment sessions (2x/week for 6 weeks) consisting of both manual therapy and exercise directed at the hip and surrounding areas based upon findings from the initial examination. Participants will also be given additional exercises to be performed at home as directed by the treating physical therapist"
3111338|NCT01814111|Experimental|renal sympathetic denervation|Perform renal angiogram immediately prior to renal sympathetic denervation procedure to confirm anatomic eligibility，The treatment catheter was introduced into each renal artery using a guiding catheter. Up to six ablations at 10 W for 1 min each were performed in both renal arteries. Treatments were delivered from the first distal main renal artery bifurcation to the ostium proximally and were spaced longitudinally and rotationally under fluoroscopic guidance. Catheter tip impedance and temperature were constantly monitored, and radio frequency energy delivery was regulated according to a predetermined algorithm. Visceral pain at the time of energy delivery was managed with intravenous analgetics and sedatives.
3111339|NCT01814111|No Intervention|Drug Treatment Group|All the patients in this group will take their baseline antihypertensive medication at the original doses, without any changes except when medically required. AAD treatment is consistent in both arms.
3112042|NCT01809457|No Intervention|control|no intervention, waiting for two weeks
3111340|NCT01814098|Experimental|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
3111341|NCT01814085|Experimental|Escitalopram|Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
3111342|NCT01814072|Experimental|Condition 1|1) Lifestyle Core; 2) 12 Telephone Coaching Sessions; 3) Report to Primary Care Physician
3111343|NCT01814072|Experimental|Condition 2|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendations to use meal replacements; 5) Buddy training via webinars
3111344|NCT01814072|Experimental|Condition 3|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages; 5) Buddy training via webinars
3111345|NCT01814072|Experimental|Condition 4|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages
3111346|NCT01814072|Experimental|Condition 5|1) Lifestyle Core; 2) 12 telephone sessions; 3) Buddy training via webinars
3111347|NCT01814072|Experimental|Condition 6|1) Lifestyle Core; 2) 12 telephone coaching sessions; 3) Recommendations to use meal replacements
3111348|NCT01814072|Experimental|Condition 7|1) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages
3111349|NCT01814072|Experimental|Condition 8|1) Lifestyle Core; 2) 12 telephone sessions; 3) Recommendation to use meal replacements; 4) Regular text messages, 5) Buddy training via webinars
3111350|NCT01814072|Experimental|Condition 9|1) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Report to Primary Care Physician
3111351|NCT01814072|Experimental|Condition 10|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Buddy training via webinars
3111352|NCT01814072|Experimental|Condition 11|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages; 5) Buddy training via webinars
3111353|NCT01814072|Experimental|Condition 12|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages
3111354|NCT01814072|Experimental|Condition 13|1) Lifestyle Core; 2) 24 telephone sessions; 3) Buddy training via webinars
3111355|NCT01814072|Experimental|Condition 14|1) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Recommendation to use meal replacements
3111356|NCT01814072|Experimental|Condition 15|1) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages
3111357|NCT01814072|Experimental|Condition 16|1) Lifestyle Core; 2) 24 telephone sessions; 3) Recommendation to use meal replacements; 4) Regular text messages, 5) Buddy training via webinars
3111358|NCT01814072|Experimental|Condition 17|1) Lifestyle Core; 2) 12 Telephone Coaching Sessions
3111359|NCT01814072|Experimental|Condition 18|1) Lifestyle Core; 2) 12 telephone sessions; 3) Recommendations to use meal replacements; 4) Buddy training via webinars
3111360|NCT01814072|Experimental|Condition 19|1) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages; 4) Buddy training via webinars
3111361|NCT01814072|Experimental|Condition 20|1) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages; 4) Recommendation to use meal replacements
3111362|NCT01814072|Experimental|Condition 21|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Buddy training via webinars
3111363|NCT01814072|Experimental|Condition 22|1) Lifestyle Core; 2) 12 telephone coaching sessions; 3) Report to Primary Care Physician; 4) Recommendations to use meal replacements
3111364|NCT01814072|Experimental|Condition 23|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages
3111365|NCT01814072|Experimental|Condition 24|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages, 6) Buddy training via webinars
3111366|NCT01814072|Experimental|Condition 25|1) Lifestyle Core; 2) 24 telephone coaching sessions
3111367|NCT01814072|Experimental|Condition 26|1) Lifestyle Core; 2) 24 telephone sessions; 3) Recommendation to use meal replacements; 4) Buddy training via webinars
3111368|NCT01814072|Experimental|Condition 27|1) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages; 4) Buddy training via webinars
3111369|NCT01814072|Experimental|Condition 28|1) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages; 4) Recommendation to use meal replacements
3111370|NCT01814072|Experimental|Condition 29|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Buddy training via webinars
3111371|NCT01814072|Experimental|Condition 30|1) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements
3111372|NCT01814072|Experimental|Condition 31|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages
3111373|NCT01814072|Experimental|Condition 32|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages, 6) Buddy training via webinars
3111374|NCT01814046|Experimental|cells + high dose aldesleukin|Patients receiving cells + high dose aldesleukin
3111375|NCT01814046|Experimental|cells and no high dose aldesleukin|Patients receiving cells and no high dose aldesleukin
3111376|NCT01814033|Experimental|LRU Pillow|Experimental: LRU Pillow
3111377|NCT01814033|Active Comparator|Control Group|Other: Control Group
3111378|NCT01814007|Experimental|Fat Reduction|
3111379|NCT01813994|Placebo Comparator|Control group|Without simvastatin
3111380|NCT01813994|Placebo Comparator|Statin group|With simvastatin
3111381|NCT01813981|Placebo Comparator|High roast coffee|110mg caffeine with 108 mg chlorogenic acid at start of study
3111382|NCT01813981|Active Comparator|Low roast coffee|110 mg caffeine with 235 mg chlorogenic acid at start of the study
3111383|NCT01813981|Placebo Comparator|Control|110 mg caffeine at start of study
3111384|NCT01813968|Experimental|Ischemic postconditioning|"Ischemic postconditioning via the cardioplegia line starting with 2 min of reperfusion followed by 2 min of ischemia x 3"
3111385|NCT01813968|No Intervention|Control|Standard operating technique
3111386|NCT01813955|Experimental|Papaverine|Patients will receive either Papaverine or placebo added to their current medical treatment. Then after one week, they will receive the other treatment (if it was placebo first, then it will be papaverine; if it was papaverine first, then it will be placebo)
3111387|NCT01813929|Experimental|Metformin|
3111388|NCT01813929|Placebo Comparator|Placebo|
3111389|NCT01813916|No Intervention|proteomic analysis|
3111390|NCT01813903|Experimental|Nutrition|Intensified dietary counseling and use of web application.
3111391|NCT01813903|Experimental|Flexible mind|Use of mobile applications.
3111392|NCT01813903|No Intervention|Normal maternity clinic visits|In control maternity clinics, nurses continue their usual counseling.
3111393|NCT01813890|Experimental|Tapentadol IR 50 mg|
3111394|NCT01813890|Experimental|Tapentadol IR 75 mg|
3111395|NCT01813890|Placebo Comparator|Placebo|
3111396|NCT01813877|No Intervention|Standard Diagnostics without PET|
3111397|NCT01813877|Experimental|Diagnostics with PET|All 18F-DOPA PET/CT studies will be interpreted qualitatively during a clinical readout session. Based on a previous study scans will be classified as positive if tumor regions defined on CT exhibited tracer uptake above the level of the contra-lateral caudate nucleus. Scans will be classified as negative if tumor 18F-FDOPA uptake is lower than that of the contra lateral caudate nucleus. Uptake at the level of the contra-lateral caudate will be considered equivocal for malignancy.
3111398|NCT01813864|Experimental|CASPAR Resource Guide|Treatment Enhanced/CASPAR-- All counselors in this study will receive a training and take part in the experimental arm of the study in Phase 2.
3111399|NCT01813851|No Intervention|control group|"Patients in the control group will receive:~Dietary counseling by a dietician and if necessary modification of the prescription of oral nutritional supplements or intradialytic parenteral nutrition to reach recommended targets according to the European Best Practice Guidelines on Nutrition (energy intake 30-40 kcal/kg of ideal weight/day, protein intake 1.1 g/kg of ideal weight/day"
3111400|NCT01813851|Experimental|activity group|"Patients in the group exercise will:~Dietary counseling by a dietician and if necessary modification of the prescription of oral nutritional supplements or intradialytic parenteral nutrition to reach recommended targets according to the European Best Practice Guidelines on Nutrition (energy intake 30-40 kcal/kg of ideal weight/day, protein intake 1.1 g/kg of ideal weight/day A program of physical activity consisting of progressive endurance and resistance training on a cycle ergometer, performed during the dialysis session under supervision and counseling by a qualified trainer"
3111401|NCT01813838|Experimental|ACADESINE 140mg/kg/d|3 patients will be included at the initial dose of Acadesine 140mg/kg/d
3111402|NCT01813838|Experimental|ACADESINE 210mg/kg/d|In absence of toxicity at the dose of 140mg/kg/d. There is a dose escalation of acadesine at the dose of 210mg/kg/d for 3 additionnal patients
3111403|NCT01813838|Experimental|ACADESINE 315mg/kg/d|In absence of toxicity at the dose of 210mg/kg/d. There is a dose escalation of acadesine at the dose of 315mg/kg/d for 3 additionnal patients
3111404|NCT01813825||Female >=45 years, negative margins, DCIS|
3111405|NCT01813812|Experimental|DA-6034 45mg|two tablets (of DA-6034 45mg) are administered for 2 continuous weeks, three times a day.
3111406|NCT01813812|Experimental|DA-6034 90mg|two tablets (of DA-6034 90mg) are administered for 2 continuous weeks, three times a day.
3111407|NCT01813812|Active Comparator|Rebamipide 300mg|two tablets (of Rebamipide 300mg) are administered for 2 continuous weeks, three times a day.
3111408|NCT01813799|Experimental|DA-9801 300mg|300mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
3111409|NCT01813799|Experimental|DA-9801 600mg|600mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
3111410|NCT01813799|Experimental|DA-9801 900mg|900mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
3111411|NCT01813799|Placebo Comparator|Placebo|Placebo is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
3111412|NCT01813786|Experimental|755nm Alexandrite Laser with Handpiece 2|Focusing energy on skin
3111413|NCT01813786|Experimental|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
3111414|NCT01813786|Experimental|755nm Alexandrite laser with handpiece 1|Focusing energy on skin
3111415|NCT01813773|Experimental|Group A - IAI every 4 weeks|Receives 5 injections of Intravitreal Aflibercept Injection (IAI) beginning Day 1, and then at weeks 4, 8, 12, and 16. Following the 5 initial injections, this group will continue to receive IAI every 4 weeks, beginning week 20, through week 48.
3111416|NCT01813773|Experimental|Group B - IAI every 8 weeks|Receives 5 injections of Intravitreal Aflibercept Injection (IAI) beginning Day 1, and then at weeks 4, 8, 12, and 16. Following the 5 initial injections, this group will receive IAI every 8 weeks, beginning week 24, through week 48.
3111417|NCT01813760|Experimental|Diode laser|Diode laser to treat peri-orbital and peri-oral wrinkles
3111418|NCT01813747|Experimental|1440 nm wavelength laser with hand piece|To assess the effectiveness of the 1440 nm wavelength laser with handpiece for skin tightening and laser lipolysis for the mandibular and sub-mandibular areas
3111419|NCT01813734|Experimental|Ponatinib Treatment Arm|Ponatinib 30 mg PO daily
3111420|NCT01813721||Group 1|All patients enrolled
3111421|NCT01813708|Experimental|Intensive Life-Style Counseling|16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
3111422|NCT01813708|Active Comparator|Collaborative Educational|16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
3111423|NCT01813695||Preemptive|Patients with genotype testing entered into electronic medical record for consideration and opioid administration postoperatively.
3111424|NCT01813695||Control|Genetic sample taken but withheld from electronic medical record.
3111633|NCT01812291|Experimental|Stepped Care Approach for Depression|"Step 1: Diabetes-Specific CBT (5 group sessions)~Step 2: Depression-Specific CBT (6 single sessions)~Step 3: Referral to Psychotherapist and/or Psychiatrist"
3111425|NCT01813682|No Intervention|control group|preterm infants of this group with iron-free TPN for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
3111426|NCT01813682|Experimental|treatment group1|preterm infants of this group with iron supplementation of 200μg/kg/d for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
3111427|NCT01813682|Experimental|treatment group2|preterm infants of this group with iron supplementation of 400μg/kg/d for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
3111428|NCT01813669|Experimental|Integrative Coping Group|"The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:~Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions"
3111429|NCT01813669|No Intervention|Waitlist Control|Participants in the waitlist condition will not receive any experimental intervention. They can continue any treatments as usual. The waitlist will be approximately 10-14 weeks in duration. At the end they will be offered the opportunity to participate in the intervention. If they elect to participate in the intervention, post-study data will also be collected from this group, approximately 13-weeks following the first group session.
3111430|NCT01813656|Experimental|Aripiprazole|Aripiprazole arm,5mg/pill,10mg/day.last12weeks.
3111431|NCT01813656|Placebo Comparator|Sugar pill|placebo arm,5mg/pill,10mg/day,last12weeks
3111432|NCT01813643|Experimental|Aripiprazole|Aripiprazole arm,5mg/pill,20-30mg/day,non-forced titration method.last2-4weeks.
3111433|NCT01813643|Active Comparator|Risperidone|Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks.
3111434|NCT01813630|Experimental|DA-3002|0.14 IU (0.045-0.050mg)/kg/day of DA-3002 is injected for 52 weeks by changing injecting areas
3111435|NCT01813630|Active Comparator|Genotropin®|0.14 IU (0.045-0.050mg)/kg/day of Genotropin is injected for 52 weeks by changing injecting areas
3111436|NCT01813617||Recent onset polymyositis and dermatomyositis|Patients in this cohort was diagnosed with polymyositis or dermatomyositis during 2003-2010 and was treated with corticosteroids and other immunosuppressive agents according to standard care. They were all diagnosed and treated at the Rheumatology Clinic, Karolinska University Hospital.
3111437|NCT01813604|Active Comparator|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
3111438|NCT01813604|Active Comparator|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
3111439|NCT01813604|Active Comparator|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
3111440|NCT01813604|Active Comparator|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
3111441|NCT01813604|Active Comparator|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
3111442|NCT01813591|Experimental|H.P. Acthar Gel 80IU|H.P. Acthar Gel of 80IU (1.0 ml)
3111443|NCT01813591|Experimental|H.P. Acthar Gel 40IU|H.P. Acthar Gel of 40IU (0.5 mL)
3111444|NCT01813578|Experimental|Intervention|An SSED study is an open-label design where the individual is his or her own control. All patients included received the same exercise intervention.
3111445|NCT01813565|Experimental|Additional instillation of hyaluronic acid/chondroitin sulfate|Transurethral resection of bladder ulcer + instillation of hyaluronic acid/chondroitin sulfate
3111446|NCT01813565|Active Comparator|Transurethral resection of bladder ulcer|Transurethral resection of bladder ulcer
3111447|NCT01813552|Experimental|Samatasvir + Ritonavir|Days 1, 9 and 13: Healthy Volunteers will take samatasvir in the mornings under fed or fasted conditions with water. Days 5-16: Healthy Volunteers will take ritonavir in the mornings under fasted or fed conditions with water.
3111448|NCT01813552|Experimental|Samatasvir + Omeprazole|Days 1, 9 and 13: Healthy Volunteers will take samatasvir in the mornings under fasted conditions with water or Coke. Days 5-16: Healthy Volunteers will take omeprazole in the mornings under fasted conditions with water or Coke.
3111449|NCT01813539|Experimental|Cohort 1|Dose level 1 : ARGX-110 intravenous administration every 3 weeks. No dose escalation.
3111450|NCT01813539|Experimental|Cohort 2|Dose level 2: ARGX-110 intravenous administration every 3 weeks. No dose escalation.
3111451|NCT01813539|Experimental|Cohort 3|Dose level 3: ARGX-110 intravenous administration every 3 weeks. No dose escalation.
3111452|NCT01813539|Experimental|Cohort 4|Dose level 4: ARGX-110 intravenous administration every 3 weeks. No dose escalation.
3111453|NCT01813539|Experimental|Cohort 5|CTCL patients treated with dose level as cohort 1 and 2.
3111454|NCT01813526|Experimental|Experimental Infant Formula|Experimental formula to be fed ad libitum.
3111455|NCT01813513|Experimental|Group A: IDX719 then IDX719/Simeprevir|Healthy participants take IDX719 150 mg once daily (QD) on Days 1-7 and IDX719 150 mg QD + simeprevir 150 mg QD on Days 8-14.
3111456|NCT01813513|Experimental|Group B: Simeprevir then IDX719/Simeprevir|Healthy participants take simeprevir 150 mg QD on Days 1-7 and IDX719 150 mg QD + simeprevir 150 mg QD on Days 8-14.
3111457|NCT01813513|Experimental|Group C: IDX719|Healthy participants take IDX719 150 mg QD on Days 1-14.
3111634|NCT01812291|Active Comparator|Treatment-as-usual|Standard Diabetes Education
3111458|NCT01813513|Experimental|Group D: IDX719/Simeprevir|Participants from Groups A and B will be asked to return for Group D. Participants take IDX719 and simeprevir QD on Days 1-7 to determine the impact of food on single-dose (on Day 1) and steady state (Day 7) PK.
3111459|NCT01813513|Experimental|Group E: High-Fat then Low-Fat PK|Participants from Group C will return to determine the PK of IDX719 after high-fat (Day 1) and low-fat (Day 7) meals (Days 2-6 are drug-free washout).
3111460|NCT01813513|Experimental|Group F: Low-Fat then High-Fat PK|Participants from Group C will return to determine the PK of IDX719 after low-fat (Day 1) and high-fat (Day 7) meals (Days 2-6 are drug-free washout).
3111461|NCT01813500||IBD Patients|Subjects with Crohn's Disease or Ulcerative colitis. IBD patients will be asked to provide a blood and stool sample.
3111462|NCT01813500||Control Subjects|Subjects without Crohn's Disease or Ulcerative Colitis. Controls will also be asked to provide a blood and stool sample.
3111463|NCT01813487|Other|HBsAg vaccine with Entecavir|
3111464|NCT01813474|Experimental|olaparib tablet monotherapy|olaparib tablet
3111465|NCT01813461|Experimental|14C-labeled prodrug isavuconazonium sulfate|single dose
3111466|NCT01813448|Experimental|Cohort 1: Fidaxomicin low dose in Japanese males|
3111467|NCT01813448|Experimental|Cohort 2: Fidaxomicin high dose in Japanese males|
3111468|NCT01813448|Experimental|Cohort 3: Fidaxomicin high dose in Caucasian males|
3111469|NCT01813448|Placebo Comparator|Matching Placebo in Caucasian males|
3111470|NCT01813448|Placebo Comparator|Matching Placebo in Japanese males|
3111471|NCT01813435|Experimental|Experimental treatment strategy|"All patients in the treatment group will receive acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy.~Dosage and frequency:~Ticagrelor: 90 mg b.i.d. ASA: of 75mg qd (- ≤ 100 mg qd)"
3111472|NCT01813435|Active Comparator|Reference treatment strategy|"Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy.~Dosage and frequency:~Brilique(Ticagrelor): 90 mg b.i.d. ASA: of 75mg qd (- ≤ 100 mg qd) Clopidogrel: 75 mg qd"
3111473|NCT01813422|Placebo Comparator|Placebo|Participants received placebo to evolocumab administered by subcutaneous injection once a month for 76 weeks.
3111474|NCT01813422|Experimental|Evolocumab|Participants received 420 mg evolocumab administered by subcutaneous injection once a month for 76 weeks.
3111475|NCT01813396|Experimental|joint mobilization/massage|"joint mobilization: End-range joint mobilization~massage: massage twice a week on the identified muscle(s) of the involved shoulder about 6 minutes for each muscle for 3 months. The techniques of massage include petrissage for 3 minutes and rolling for 3 minutes of soft tissues"
3111476|NCT01813396|Experimental|joint mobilization/shoulder physical activity guide|joint mobilization: End-range joint mobilization shoulder physical activity guide: shoulder physical activity guide is based on the appropriate cut off activity level identified in the predication rule
3111477|NCT01813383||HLA-DR3-DQ2 patients|Patients with HLA-DR3-DQ2 haplotype
3111478|NCT01813383||HLA-DR7-DQ2 patients|Patients with HLA-DR7-DQ2 haplotype
3111479|NCT01813370||Pts with prostate cancer|Patients who have progressed or hit their 36 month post treatment date between the closure of TAX3503 and the activation of this TAX3503 Registry protocol will be permitted on the study to capture their date of progression or their 36 month post treatment progression free date.
3111480|NCT01813357|Placebo Comparator|Placebo|sugar pill that is encapsulated so as to appear identical to the active agent
3111481|NCT01813357|Experimental|Rosuvastatin|Rosuvastatin 20mg daily
3111482|NCT01813331||Chronic Heart Failure Patients|Chronic Heart Failure patients older than 65 years, which accept to participate to the study and give their informed written consent and consecutively refer to the A.R.C.A Campania Cardiologists in the pertaining healthcare districts.
3111483|NCT01813318|Placebo Comparator|Placebo/sugar pill|Placebo will be dosed similar to acamprosate, in terms of dosage form, frequency and duration.
3111484|NCT01813318|Active Comparator|Acamprosate|"Acamprosate: The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.~Other Name: Campral"
3111485|NCT01813305|Active Comparator|CSTC1|CSTC1 (vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof), topical, two times daily
3111486|NCT01813305|Placebo Comparator|CSTC1 Matched vehicle|Matched vehicle, topical, two times daily
3111487|NCT01813279|Experimental|patients|
3111488|NCT01813266||Usual practice in screening for Hepatitis C virus.|Three clinics in this group will use this approach.
3111489|NCT01813266||USPTF risk factors to screen for chronic HCV infection.|3 internal medicine clinics will use this screening strategy.
3111490|NCT01813266||USPTF/CDC recommendations to screen for chronic HCV infection.|3 internal medicine clinics.
3111491|NCT01813253|Experimental|Irinotecan and nimotuzumab|Adminitration of irinotecan 150 mg/m2 IV once every 2 weeks and nimotuzumab 400 mg IV once weekly
3111492|NCT01813253|Active Comparator|Irinotecan|Administration of irinotecan 150 mg/m2 IV once every 2 weeks
3111493|NCT01813240|Experimental|Minocycline, Spinal Tumor patients, quality of life|
3111494|NCT01813240|Experimental|Minocycline, Trauma patuents, quality of life|
3111495|NCT01813240|Placebo Comparator|Placebo, Trauma patients, quality of life|
3111496|NCT01813240|Placebo Comparator|Placebo, Spinal cord tumors, quality of life|
3111497|NCT01813227|Experimental|Carfilzomib|Carfilzomib 20 mg/m2 on day 1, 2 then 56 mg/m2 days 8, 9 and 15, 16 over 30 minutes every 28 days. Dexamethasone 4 mg (8 mg if > 45 mg/m2) orally each day of carfilzomib therapy. If less than a partial remission (PR) after 4 cycles, add rituximab 375 mg/m2 on day 16 of each cycle. Patients who meet the criteria for progression prior to 4 cycles of therapy will have rituximab added to their treatment. For patients receiving rituximab, the carfilzomib dose will be decreased to 27 mg/m2. Patients will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.
3111498|NCT01813214|Experimental|Vemurafenib Monotherapy|Vemurafenib 960 mg po BID until unacceptable toxicity or progression of disease
3111635|NCT01812278|Experimental|ACT|Acceptance & Commitment Therapy
3111636|NCT01812278|Active Comparator|CBT|Cognitive Behavioral Therapy
3111499|NCT01813214|Experimental|Vemurafenib + Cobimetinib Combination Therapy|"Vemurafenib 960 mg po BID until unacceptable toxicity or progression of disease~Cobimetinib will be given 60mg QD for 21 days on, then 7 days off, in a 28-day treatment cycle."
3111500|NCT01813201|Active Comparator|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose)
3111501|NCT01813201|Placebo Comparator|Saline isotonic solution (Placebo)|Placebo (saline isotonic solution)administered at inclusion and every 12 weeks for 9 months (4 dose) (control group).
3111502|NCT01813188|Experimental|ABM seeded onto a porous TCP and DBM|ABM seeded onto a porous TCP and DBM
3111503|NCT01813188|Active Comparator|autologous bone graft|autologous bone graft
3111504|NCT01813175|Active Comparator|Intervention Group I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
3111505|NCT01813175|Active Comparator|Interventional Group II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
3111506|NCT01813175|Placebo Comparator|Control Group|Regular non-hydrolysed cow's milk based infant formula
3111507|NCT01813175|No Intervention|Reference Group|Exclusively breast-fed infants
3111508|NCT01813162|Active Comparator|Tenofovir 1% gel|Participants will vaginally insert 1 applicator of TFV gel twice a day for 7 days, with each dose inserted approximately 12 hours after the previous dose (for a total of 13 doses). Each applicator contains 4.4 gm of TFV 1% gel.
3111509|NCT01813162|Active Comparator|Vaginal product alone|"Participants will use their assigned vaginal product for 5 to 21 days depending on the dosing instructions for the particular product:~Terconazole 0.4% vaginal cream: once a day for seven days. 1 applicator (5 gm) of terconazole cream contains 20 mg terconazole.~Metronidazole gel: once a day for 5 days. 1 applicator (5 gm)of metronidazole gel contains 37.5 mg metronidazole.~Contraceptive IVR: insert ring and leave in place for 21 days; return to clinic for removal on day 21. The IVR contains two active components, etonogestrel (progestin) and ethinyl estradiol (estrogen)."
3111510|NCT01813162|Experimental|Vaginal product and Tenofovir 1% gel|"Tenofovir gel: Participants will vaginally insert 1 applicator of TFV gel twice a day for 7 days, with each dose inserted approximately 12 hours after the previous dose (for a total of 13 doses). Each applicator contains 4.4 gm of TFV 1% gel.~In addition, Participants will use their assigned vaginal product for 5 to 21 days depending on the dosing instructions for the particular product:~Terconazole 0.4% vaginal cream: once a day for seven days. 1 applicator (5 gm) of terconazole cream contains 20 mg terconazole.~Metronidazole gel: once a day for 5 days. 1 applicator (5 gm)of metronidazole gel contains 37.5 mg metronidazole.~Contraceptive IVR: insert ring and leave in place for 21 days; return to clinic for removal on day 21. The IVR contains two active components, etonogestrel (progestin) and ethinyl estradiol (estrogen). Use of TFV gel will begin on day 15 of IVR use."
3111511|NCT01813149|Experimental|phenylephrine and clonidine|Subjects will be injected with phenylephrine and clonidine at affected and unaffected sites.
3111512|NCT01813136|Active Comparator|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
3111513|NCT01813136|Experimental|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression"
3111514|NCT01813123|No Intervention|Control|
3111515|NCT01813123|Experimental|Intervention|RealTeen
3111516|NCT01813110|Placebo Comparator|Placebo|Identical olive oil capsules
3111517|NCT01813110|Experimental|Omega-3|4 g prescription omega-3 concentrate (4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks)
3111518|NCT01813097||combination iodine 125 seed implants|30 cases should be treated with iodine 125 seed implants 0.5 mc transperineal prostate implant +Zoladex 3.6mg im 1/28d (LHRH agonist, 3.6mg subcutaneous injection 1/4weeks).
3111519|NCT01813097||LHRH agonists|30 cases should be treated with Zoladex 3.6mg im 1/28d (LHRH agonist, 3.6mg subcutaneous injection 1/4weeks).
3111520|NCT01813084|Experimental|Part A: single dose escalation|
3111521|NCT01813084|Experimental|Part B: 14 day repeat dose escalation (healthy volunteers)|
3111522|NCT01813084|Experimental|Part C: 14 day repeat dose (asthma patients)|
3111523|NCT01813071|Experimental|Part A (Adults): Cohort A1|One oral dose of ~3x10^4 cfu WRSS1(10 participants) or placebo (3 participants)
3111524|NCT01813071|Experimental|Part A (Adults): Cohort A2|Three oral doses of ~3x10^5 cfu WRSS1(10 participants) or placebo (3 participants)
3111525|NCT01813071|Experimental|Part A (Adults): Cohort A3|Three oral doses of ~3x10^6 cfu WRSS1(10 participants) or placebo (3 participants)
3111526|NCT01813071|Experimental|Part B (Children): Cohort B1|One oral dose of ~3x10^3 cfu WRSS1(12 participants) or placebo (4 participants)
3111527|NCT01813071|Experimental|Part B (Children): Cohort B2|Three oral doses of ~3x10^4 cfu WRSS1(12 participants) or placebo (4 participants)
3111528|NCT01813071|Experimental|Part B (Children): Cohort B3|Three oral doses of ~3x10^5 cfu WRSS1(12 participants) or placebo (4 participants)
3111529|NCT01813071|Experimental|Part B (Children): Cohort B4|Three oral doses of ~3x10^6 cfu WRSS1(12 participants) or placebo (4 participants)
3111530|NCT01813058|Placebo Comparator|Placebo|Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery.
3111531|NCT01813058|Active Comparator|Tranexamic acid|Tranexamic acid 100 mg/ml; 50 mg/kg loading dose = 0.5 ml/kg LD given over 15 minutes and 10 mg/kg/hr = 0.1 ml/kg/hr infusion for the duration of the surgery.
3111532|NCT01813045||Chronic Coronary Occlusion group|"We will also recruit 10 patients with an angiographically documented chronic (>6 months) proximal coronary artery occlusion that has not been revascularised but has extensive collateral coronary blood flow.~We will perform CT-coronary angiogram, cardiac MRI scan and CT-PET scan."
3111637|NCT01812265|Experimental|PF-06305591 Dose 1|
3111638|NCT01812265|Experimental|PF-06305591 Dose 2|
3111533|NCT01813045||MI (non-revascularised)|"These patients (n=15) will undergo Cardiac MRI, CT-PET scan and CT-coronary angiogram scan 2 weeks following their myocardial infarction.~They will undergo a second CT-PET scan 9 weeks following their myocardial infarction.~They will undergo a second cardiac MRI scan 6 - 12 months following their myocardial infarction."
3111534|NCT01813045||MI (revascularised)|"These patients (n=15) will undergo Cardiac MRI, CT-PET scan and CT-coronary angiogram scan 2 weeks following their myocardial infarction.~They will undergo a second CT-PET scan 9 weeks following their myocardial infarction.~They will undergo a second cardiac MRI scan 6 - 12 months following their myocardial infarction."
3111535|NCT01813032||Firefighters|20 firefighters will attend for vascular assessments following a minimum of 48 hours off-duty.
3111536|NCT01813032||Police Officers|20 police officers will attend for vascular assessments following a minimum of 48 hours off-duty.
3111537|NCT01813019|Experimental|AFQ056|"Following baseline, approximately 60 patients who are considered eligible will be randomized to AFQ056 arm and will receive the dosing regimen of 4 weeks AFQ056 b.i.d up-titration period of 50 mg,100 mg, 150 mg and 200 mg , followed by 12 weeks AFQ056 200 mg fixed dose* and then a 3 week down-titration of 100 mg, 50 mg and 25 mg AFQ056 b.i.d)~*patients that do not tolerate 200 mg b.i.d may be down-titrated to 150 mg b.i.d."
3111538|NCT01813019|Placebo Comparator|Placebo|Following baseline, approximately 60 patients who are considered eligible will be randomized to Placebo arm and will receive the dosing regimen of 4 weeks Placebo b.i.d up-titration period of 50 mg,100 mg, 150 mg and 200 mg , followed by 12 weeks Placebo 200 mg fixed dose* and then a 3 week down-titration of 100 mg, 50 mg and 25 mg Placebo b.i.d) *patients that do not tolerate 200 matching placebo AFQ056 mg b.i.d may be down-titrated to 150 mg b.i.d.
3111539|NCT01813006|Active Comparator|Omega-3|Omega-3 fatty acids
3111540|NCT01813006|Placebo Comparator|Placebo|Placebo/olive oil
3111541|NCT01812993|No Intervention|Control|No ventilatory treatment; standard stroke care
3111542|NCT01812993|Experimental|Active|Non-invasive ventilatory treatment with auto-BPAP plus standard stroke care
3111543|NCT01812980|Experimental|Trivalent Inactivated Influenza Vaccine|"Single dose, intramuscular injection from a pre-filled syringe~WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
3111544|NCT01812941|Other|Burn: blood collection|Procedure: Blood draws as the intervention.
3111545|NCT01812941|Other|trauma: blood collection|blood to be collected at different time intervals. Blood draw as the intervention
3111546|NCT01812941|Other|healthy volunteers: blood collection|Blood draws as the intervention
3111547|NCT01812928|No Intervention|Gel only|This group will be given only intraurethral gel during flexible cystoscopy.
3111548|NCT01812928|Experimental|Diclofenac and Gel|This group will also receive intraurethral gel during cystoscopy but additionally diclofenac suppository will be given per rectally one hour before procedure as preemptive analgesia.
3111549|NCT01812915|Experimental|Cylindrical-shape cuff ETT (Group C)|Control group: Mallinckrodt HiLo(TM) endotracheal tube. Intracuff pressures of the tubes every 10 minutes, Adult patients under general anesthesia with Mallinckrodt Hi-Lo(TM) tube.
3111550|NCT01812915|Experimental|Tapered-shape cuff ETT (Group T)|Experimental group: Mallinckrodt TaperGuard(TM) endotracheal tube. Intracuff pressures of the tubes every 10 minutes, Adult patients under general anesthesia with Mallinckrodt TaperGuard(TM) tube.
3111551|NCT01812902|Experimental|Extended LND|Radical Prostatectomy with extended lymphadenectomy
3111552|NCT01812902|Active Comparator|Limited LND|Radical Prostatectomy with Limited lymphadenectomy
3111553|NCT01812889|Active Comparator|Part 2|10 women diagnosed with BV, 10 diagnosed with VVC will be randomized to receive either TOL-463 gel or TOL-463 ovules administered intravaginally once daily for 7 consecutive days
3111554|NCT01812889|Active Comparator|Part 1|20 Healthy women randomized, two-way crossover design will receive a single dose of TOL-463 gel and ovule intravaginally, separated by a minimum of 7 day washout period between administrations
3111555|NCT01812863|Experimental|Supraclavicular Nerve Block|Maximum dose of 5 mL of 0.25% bupivacaine, and we base the dose on a ml/ kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. Bupivacaine is given with 1:200,000 epinephrine
3111556|NCT01812863|Placebo Comparator|No Nerve Block|A band-aid will be placed on all patients where a supraclavicular nerve block would have been inserted, and parents will be asked to leave the band-aid on for 3 days to maintain the blindness to the treatment type by the patient.
3111557|NCT01812850||Invisalign®|All subjects in the study (estimation of 40 subjects) will be treated using the Invisalign® appliance.
3111558|NCT01812837|Experimental|20 minutes incubation - with pretreatment|
3111559|NCT01812837|Experimental|40 minutes incubation - with pretreatment|
3111560|NCT01812837|Experimental|60 minutes incubation - with pretreatment|
3111561|NCT01812837|Sham Comparator|60 minutes incubation - no pretreatment|
3111562|NCT01812824|Experimental|Intervention (Virtual Patient Advocate)|Participants assigned to the Intervention (Virtual Patient Advocate) arm will have access to the Virtual Patient Advocate system on-line for 6 months; they will be encouraged, but not required, to log on once a week.
3111563|NCT01812824|No Intervention|Control (Letter)|Participants in the Control (Letter) arm will take the online Preconception Risk Assessment at baseline, but not have access to the Virtual Patient Advocate system during the 6 month study period. They will be sent a list of the Preconception Risks identified through their answers to the Risk Assessment, which they can choose to share with their healthcare provider(s).
3111564|NCT01812798|Active Comparator|Peanut|"Double Blind Placebo Controlled Food Challenge 5 gram peanut challenge~17 doses of peanut will be administered. Dose will be increased every 20-30 minutes. All doses listed are in g of peanut flour.~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000"
3111565|NCT01812798|Placebo Comparator|Placebo|Double Blind Placebo Controlled Food Challenge (No peanut - placebo only)
3111566|NCT01812772|Experimental|Double J-stent with a long tether|Following ureteroscopy patients will have placed a double J-stent with a long tether.
3111567|NCT01812772|Active Comparator|Double J-stent without a long tether|Following ureteroscopy patients will have a double J-stent placed without a long tether
3111639|NCT01812265|Placebo Comparator|Placebo|
3111568|NCT01812759|Experimental|Fentanyl Nasal Spray + Hydromorphone PCA|Fentanyl 100 mcg nasal spray administered plus hydromorphone PCA. All study patients receive demand dosing patient-controlled analgesia (PCA) with intravenous hydromorphone. Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
3111569|NCT01812759|Experimental|Placebo Nasal Spray + Hydromorphone PCA|Placebo nasal spray administered plus hydromorphone PCA . All study patients receive demand dosing patient-controlled analgesia (PCA) with intravenous hydromorphone. Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
3111570|NCT01812746|Experimental|BIND-014|
3111571|NCT01812720|Experimental|Treatment (carfilzomib, dexamethasone)|Patients receive carfilzomib IV over 30 minutes and dexamethasone PO on days 1, 2, 15, and 16. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3111572|NCT01812707|Placebo Comparator|Placebo|Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
3111573|NCT01812707|Experimental|Alirocumab 50 mg Q2W|Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
3111574|NCT01812707|Experimental|Alirocumab 75 mg Q2W|Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
3111575|NCT01812707|Placebo Comparator|Alirocumab 150 mg Q2W|Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
3111576|NCT01812694|Active Comparator|Enhanced standard of care|Standard prenatal care plus education
3111577|NCT01812694|Other|Intensive lifestyle intervention|Behavioral weight control
3111578|NCT01812681||Low vitamin D level|The premature infants with low cord blood vitamin D level
3111579|NCT01812681||Normal Vitamin D|The premature infants with normal vitamin D level
3111580|NCT01812668|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.
3111581|NCT01812655|Experimental|Virtual Reality|Virtual reality using a software program designed for burn patients during burn wound care
3111582|NCT01812655|Active Comparator|Passive distraction|watching a movie
3111583|NCT01812655|No Intervention|UC provided by the nurses|
3111584|NCT01812642|Experimental|JNJ-37822681 10 milligram|JNJ-37822681 oral capsule will be administered at a starting dose of 10 milligram (mg) twice daily for the first 3 days and thereafter dose will be titrated from Day 3 to Day 10 up to 80 mg per day and will be continued at same dose up to Day 14.
3111585|NCT01812642|Experimental|JNJ-37822681 20 milligram and placebo|JNJ-37822681 oral capsule will be administered at a starting dose of 20 mg once daily for the first 3 days and thereafter dose will be titrated from Day 3 to Day 10 up to 80 mg per day and will be continued at same dose up to Day 14. Matching Placebo will be administered orally in the evening for 14 days (12 hour post JNJ-37822681 administration).
3111586|NCT01812629|Experimental|Experimental Infant Formula|Complete peptide amino acid-based infant formula
3111587|NCT01812616|Experimental|Sativex and Dose-Intense Temozolomide|Patients will received Sativex and Dose-Intense Temozolomide in a double-blind manner
3111588|NCT01812616|Placebo Comparator|Placebo and Dose-Intense Temozolomide|Patients will received placebo and Dose-Intense Temozolomide and in double-blind manner
3111589|NCT01812603|Experimental|Sativex and Dose-Intense Temozolomide|Patients will received Sativex and Dose-Intense Temozolomide and in open-label manner
3111590|NCT01812590|No Intervention|Resting Trial|Pancreatic endocrine function will be determined the morning following a day where no exercise is performed
3111591|NCT01812590|Experimental|Exercise Trial|Pancreatic endocrine function will be determined the morning following a day where a 1-hour aerobic exercise is performed at 65% of pre-determined HRmax (maximal heart rate measured during an incremental work-load exercise test to volitional exhaustion)
3111592|NCT01812577||Thoracic paravertebral block (TPVB)|Twenty patients receiving thoracic paravertebral block at level of T7, before the interventistic procedure.
3111593|NCT01812577||Deep Sedation (DS)|Twenty patients receiving local and intravenous anesthesia during the procedure.
3111594|NCT01812564|Placebo Comparator|PPP|"Placebo: Platelet Poor Plasma~Under sterile conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PPP each, administered by a sports medicine physician (total 3 cc PPP).~Following the completion of the injections (treatment or control) physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
3111595|NCT01812564|Active Comparator|PRP|"Biological: Platelet Rich Plasma~Under sterile ultrasound conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PRP each, administered by a sports medicine physician (total 3 cc PRP).~Following the completion of the injections (treatment or control) physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
3111596|NCT01812564|No Intervention|Physiotherapy|"These patients will not receive an injection.~Following the inclusion physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
3111597|NCT01812551|Active Comparator|Alendronate|"128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).~65 subjects were randomized to this arm. Oral alendronate dose: 5 mg/day, if body weight ≤25 kg; 10 mg/day, if body weight >25 kg."
3111598|NCT01812551|Placebo Comparator|Placebo|"128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).~63 subjects were randomized to this arm. Oral placebo (inactive pills)."
3111599|NCT01812538|Placebo Comparator|Placebo|Placebo
3111600|NCT01812538|Experimental|Experimental 1|DIC075V 37.5 mg
3111601|NCT01812538|Experimental|Experimental 2|DIC075V 75 mg
3111602|NCT01812538|Active Comparator|Active control|Moxifloxacin hydrochloride 400 mg
3111603|NCT01812525|Active Comparator|NaCl 3% inhalations + standard therapy|"In this group, patients receive NaCl 3% inhalations ( 4ml QID) together with standard therapy.~Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed."
3111604|NCT01812525|Placebo Comparator|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
3111605|NCT01812512|Other|TIPS for HF Intervention HT Training-Charleston-Pre/Post|Group 1 (Charleston): In the proposed intervention, called Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF) , the observations from the previous RRP are used along with best practices from other studies of patient-centered communication in the VA , telephone coaching for chronic disease , problem-solving and counseling skills for telehealth nurse care managers , difficulties identified by patients working with the Health Buddy for telemonitoring , participation in provider-patient communication , essentials of patient education in heart failure process and content, and teach to goal theory to improve HF self-management for patients with low health literacy . Rather than an experimental trial, this implementation quasi-experimental pilot study examines pre- and post-training nurse practices and Veteran outcomes before and after communication skills training. The same intervention will then be delivered to Group 2 HT nurse care coordinators.
3111606|NCT01812512|Other|TIPS for HF Intervention HT Training-Columbia-Pre/Post|Group 2 (Columbia VAMC): To test the TIPS for HF educational intervention sufficiently in a sample not previously exposed to the information, the HT program at Dorn VA Medical Center in Columbia, South Carolina has volunteered to participate as a second study site. There are six nurse care coordinators who will be recruited; the larger number supports recruitment of a comparable number with 25 Veterans with HF to be recruited in the second site for a total of 50 Veterans. Both groups will use a purposeful sampling plan, beginning with an IRB-approved flyer for recruitment. The demographic make-up of the Charleston VAMC group is comparable Columbia HT group in age, race, and NYHA HF class. Also, consistent with an implementation quasi-experimental pilot study, the second site will examine pre-training and post-training nurse care coordinator communication practices and Veteran outcomes before and after communication skills training.
3111607|NCT01812486|Active Comparator|control arm|NID2Gy = 50 Gy Swallowing apparatus: standard dose
3111608|NCT01812486|Experimental|Experimental de escalated arm|NID2Gy = 40 Gy Swallowing apparatus: Dmax ≤ 60 Gy at 1 cm Dmax ≤ 50 Gy at 1.5 cm from the GTV or PSTB edge
3111609|NCT01812473||Patients admitted to the Intensive Care Unit|All patients admitted to the Intensive Care Unit, treated with voriconazole are eligible for the study.
3111610|NCT01812460|Experimental|Intervention-training-group|"The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times) The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every session of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoe as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.~The weight cuffs are handed over to the patients for self guided exercise during weekends"
3111611|NCT01812460|No Intervention|Control group|The patients randomized to the control group receive lung physiotherapy from day two of admittance. Lung physiotherapy consists of help to bring up sputum from the bronchi and lungs. The patients are instructed in breath exercises, use of Positiv Ekspiratory Pressure, breathing exercises, cough and pursed lip breathing. The patients are encouraged to spend as little time in bed as possible.
3111612|NCT01812447|Experimental|Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management.
3111613|NCT01812447|Experimental|Spiration Valve System, α-1|α-1 antitrypsin deficiency subjects will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management. There is no randomization for this group.
3111614|NCT01812447|Active Comparator|Medical Management|The control group for this study will receive medical management. This medical management group will be evaluated and followed in the same manner as the treatment group, but without having a bronchoscopic procedure.
3111615|NCT01812434|Experimental|Sildenafil|Patients will be randomized to sildenafil arm taken three times a day for 28 days and then crossed over to the alternate arm.
3111616|NCT01812434|Experimental|Placebo|Subject randomized to either Sildenafil or placebo arm
3111617|NCT01812421|Experimental|Ischemic Stroke or TIA (ISTIA) patients|
3111618|NCT01812395|Active Comparator|Ultrasonic Dissector Thyroidectomy|Thyroidectomy using harmonic focus (r) device
3111619|NCT01812395|Active Comparator|Classic thyroidectomy|Patients having conventional thyroidectomy
3111620|NCT01812382|Experimental|Microdialysis arm|Three microdialysis probes will be placed in the thigh of each subject prior to the start of the microdialysis procedure/infusion using a microdialysis device. All subjects will receive Sodium Chloride solution perfused for 30 minutes followed by Retapamulin perfusion for 90 minutes and then Saline perfusion will occur during the washout period.
3111621|NCT01812369|Experimental|GC|gemcitabine 1250 mg/m2 D1 and D8 cisplatine 70 mg/m2 D1 each cycle every 3 weeks, 4 cycles
3111622|NCT01812369|Active Comparator|MVAC-HD|Methotrexate 30 mg/m2 D1 Vinblastine 3 mg/m2 D2 Doxorubicine 30 mg/m2 D2 Cisplatine 70 mg/m2 D2 G-CSF D3 and D9 Each cycle every 2 weeks, 6 cycles
3111623|NCT01812356|Experimental|Argon gas probe|Cryomaze procedure using Argon gas probe
3111624|NCT01812356|Active Comparator|Nitrous oxide probe|Cryomaze procedure using Nitrous oxide probe
3111625|NCT01812343|Other|Exercise test|Ankle pressure Index measure before and after Maximal Exercise Tests
3111626|NCT01812330|Experimental|group 1|Group 1 will be administered with Clopidogrel 75mg daily until the end of the trial
3111627|NCT01812330|Experimental|group 2|Group 2 will be administered with Clopidogrel 150mg daily until the end of trial
3111628|NCT01812330|Experimental|group 3|Group 3 will be administered with Ticagrelor 90mg twice daily until the end of the trial
3111629|NCT01812317|Active Comparator|Real-fire training exercise|Subjects will undergo a 20 minute standardised training exercise in a fire simulation facility.
3111630|NCT01812317|Sham Comparator|Sedentary training session|Subjects will undergo a training exercise where they will remain sedentary for 20 mins in an ambient temperature.
3111631|NCT01812304|Experimental|hands-on training|probands perform predefined maneuvers to manage a vaginal breech hands-on after one instruction
3111632|NCT01812304|Active Comparator|frontal teaching|Probands perform predefined maneuvers to resolve a vaginal breech after forntal teaching
3111640|NCT01812252|Other|Arm A (decitabine or azacitidine)|Patients receive decitabine or azacitidine IV or SC per standard of care. Treatment repeats per standard of care, every 28 days for 4 courses of decitabine or 6 courses of azacitidine in the absence of disease progression or unacceptable toxicity.
3111641|NCT01812252|Other|Arm B (induction-like chemotherapy regimen)|Patients receive physician choice of standard of care or other experimental protocol using induction-like chemotherapy regimen. No one specific regimen is required. Several regimens are listed in the protocol for example only.
3111642|NCT01812239|Active Comparator|Vaginal Progesterone|Daily administration of Vaginal Progesterone (200mg) Gel between 20 weeks of pregnancy and 34 weeks of pregnancy.
3111643|NCT01812239|Placebo Comparator|Placebo|Daily vaginal administration of Placebo gel (Vanicream)between 20 weeks of pregnancy and 34 weeks of pregnancy.
3111644|NCT01812226||experimental group|This group will consist of men and women who received a liver transplant for alcohol-related liver disease.
3111645|NCT01812226||control group|This group will consist of men and women who had a liver transplant for reasons that are not alcohol-related.
3111646|NCT01812213|Experimental|[18F]NAV4694|Intravenous [18F]NAV4694 (8.1 mCi) administered once every 18 months
3111647|NCT01812200|Active Comparator|Dabigatran, Ticagrelor, ASA|Dabigatran 150mg td Ticagrelor 90 mg td ASA 100 mg od for 5 days
3111648|NCT01812200|Active Comparator|Rivaroxaban, Ticagrelor, ASA|Rivaroxaban 20 mg od Ticagrelor 90 mg td ASA 100 mg od for 5 days
3111649|NCT01812200|Active Comparator|Phenprocoumon, Ticagrelor, ASA|Phenprocoumon X mg to reach an INR of 2-3 on day 5 of triple therapy Ticagrelor 90 mg td ASA 100 mg od for 5 days
3111650|NCT01812187|Experimental|SHIFT Cognitive Behavioral Therapy|Service to Home for Individually-Focused Therapy (SHIFT), a Cognitive Behavioral Treatment for Substance Use Disorders
3111651|NCT01812174|Experimental|17mm On-X Aortic Heart Valve|Patients receiving the 17mm On-X aortic heart valve as a replacement for diseased native or prosthetic aortic heart valve.
3111652|NCT01812174|Experimental|23mm On-X Mitral Heart Valve|Patients receiving the 23mm On-X mitral heart valve as a replacement for diseased native or prosthetic mitral heart valve.
3111653|NCT01812161|Active Comparator|Acupuncture protocol 1|Acupuncture protocol 1：participants will receive treatment (acupuncture protocol 1, real acupuncture) twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
3111654|NCT01812161|Sham Comparator|Acupuncture protocol 2|Acupuncture protocol 2：participants will receive treatment (acupuncture protocol 2, sham acupuncture) twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
3111655|NCT01812148||Peritoneal Mesotheliomas|Cytoreductive surgery and HIPEC
3111656|NCT01812135|Experimental|Group 1: 400U EV71 vaccine without adjuvant|60 infants received 2 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant 28 days apart
3111657|NCT01812135|Experimental|Group 2: 400U EV71 vaccine without adjuvant|60 infants received 1 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant
3111658|NCT01812135|Experimental|Group 3: 400U EV71 vaccine with adjuvant|60 infants received 1 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant
3111659|NCT01812122|Experimental|Glimepiride|Starting with Glimepiride. After 3 month, switching to vildagliptin.
3111660|NCT01812122|Experimental|Vildagliptin|Starting with vildagliptin. After 3 month, switching to Glimepiride.
3111661|NCT01812109|Experimental|Hutchison Technologies Inspectra StO2 NIRS|Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy (NIRS) evaluation of acute scrotum per protocol
3111662|NCT01812096|Experimental|the pharmacokinetic of bortezomib|the pharmacokinetic and pharmacodynamic, and assessed safety and efficacy of subcutaneous administration of bortezomib
3111663|NCT01812096|Active Comparator|Intravenous|the pharmacokinetic and pharmacodynamic, and assessed safety and efficacy of intravenous administration of bortezomib
3111664|NCT01812070|Experimental|ACT|Acceptance & Commitment Therapy
3111665|NCT01812070|Active Comparator|CBT|Cognitive Behavioral Therapy
3111666|NCT01812057|Experimental|Dexamethasone|Dexamethasone 8 mg IV given intraoperatively as a one-time dose.
3111667|NCT01812057|Placebo Comparator|Placebo|Sodium chloride 0.9% (5 ml) given IV intraoperatively as a one time dose.
3111668|NCT01812044|Other|subtenons anesthetic and topical control|Group 1 (subtenons anesthetic and topical control): 0.5 cc of local anesthetic (preservative-free bupivacaine 0.75%) administered via a cannula subtenons through each surgical wound with 0.5 cc of Hypromellose 0.3% gel applied topically to each surgical wound at end of surgery
3111669|NCT01812044|Other|topical anesthetic and subtenons control|Group 2 (topical anesthetic and subtenons control): 0.5 cc of lidocaine 3.5% ophthalmic gel applied topically to each surgical wound and 0.5 cc of normal saline (NS) administered via a cannula subtenons through each surgical wound at end of surgery
3111670|NCT01812044|Other|topical control and subtenons control|Group 3 (topical control and subtenons control): 0.5 cc of topical Hypromellose 0.3% gel applied topically to each surgical wound and 0.5 cc of NS administered via a cannula subtenons through each surgical wound at end of surgery
3111671|NCT01812031|Experimental|Lung nodules|"Medical imaging intervention applied on patients included in the trial"
3111672|NCT01812018|Experimental|Endostar|Endostar, Gemcitabine, Docetaxel
3111673|NCT01812005|Experimental|Cohort A (alisertib, rituximab)|Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3111674|NCT01812005|Experimental|Cohort B (alisertib, rituximab)|Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3111747|NCT01811498|Experimental|SIACI of Bevacizumab|Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab
3111748|NCT01811485|Experimental|LMF237 50/250 mg|Patients took LMF237 50/250 mg twice daily for 14 weeks
3111675|NCT01811992|Experimental|Dose escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L|"This protocol is a dose escalation study of Ad-hCMV-TK and Ad-hCMV-Flt3L infused at the time of surgical resection followed by systemic oral administration of valacyclovir in addition to current standard of care with temozolomide and radiotherapy. Eligible subjects will be enrolled in six sequential dosing cohorts:~Cohort A= Ad-hCMV-TK: 1x1010 vp and Ad-hCMV-Flt3L: 1x109 vp~Cohort B= Ad-hCMV-TK: 1x1011 vp and Ad-hCMV-Flt3L: 1x109 vp~Cohort C= Ad-hCMV-TK: 1x1010 vp and Ad-hCMV-Flt3L: 1x1010 vp~Cohort D= Ad-hCMV-TK: 1x1011 vp and Ad-hCMV-Flt3L: 1x1010 vp~Cohort E= Ad-hCMV-TK: 1x1010 vp and Ad-hCMV-Flt3L: 1x1011 vp~Cohort F= Ad-hCMV-TK: 1x1011 vp and Ad-hCMV-Flt3L: 1x1011 vp~Subjects will be treated sequentially with a minimum of 21 days before treatment of new subjects within a cohort or before dose escalation. Once the Maximum Tolerated Dose (MTD) is determined, or after all subjects have been evaluated and found to tolerate the highest dose, the study will end."
3111676|NCT01811979|Active Comparator|oral sucrose solution|local anesthetic eye drops (Alcaine 0.5% drop) and a pacifier, plus 0.5 cc/kg of 24% sucrose, to relieve pain associated with eye examinations for retinopathy of prematurity will be given
3111677|NCT01811979|Placebo Comparator|steril water|steril water 0,5 cc/kg plus topical anesthetics (Alcaine %0.5 damla) before eye examination will be given
3111678|NCT01811966|Sham Comparator|Control|preoperative none substitution of i.v. fluids.
3111679|NCT01811966|Active Comparator|Volume|preoperative substitution of a defined amount of i.v. fluids (8 ml/kg RingerAcetate solution for 15 min prior to introduction of anesthesia).
3111680|NCT01811953|Experimental|1 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fasted conditions
3111681|NCT01811953|Experimental|2 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fed conditions
3111682|NCT01811953|Experimental|3 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fasted conditions
3111683|NCT01811953|Experimental|4 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fed conditions
3111684|NCT01811953|Experimental|5 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fed conditions
3111685|NCT01811953|Experimental|6 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fed conditions
3111686|NCT01811940|Experimental|Adderall-ER and Topiramate|Adderall-ER will be taken once per day in the morning or early afternoon since it may be activating. The dose is titrated to 60 mg per day or the maximum tolerated dose over two weeks and maintained for the duration of the study. Topiramate will be taken twice per day in the morning and the evening and titrated to 200mg/day or the maximum tolerated dose over the course of 6 weeks and maintained for the duration of the study.
3111687|NCT01811940|Placebo Comparator|Placebo|Placebo will be packaged in matching gelatin capsules similar to the pills in the active arm. Placebo will be taken as frequently and for the same duration as those taken in the active arm.
3111688|NCT01811927|Experimental|PRO-Kinetic Energy Stent|PRO-Kinetic Energy Stent
3111689|NCT01811914|Experimental|intraoperative TTE|TTE if a hemodynamic instability occurs
3111690|NCT01811901|Active Comparator|Intervention group (SITS-WATCH centers)|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
3111691|NCT01811901|No Intervention|Control group (non SITS-WATCH centers in SITS registry)|Centres that do not use 15-item list of suggested interventions aiming to reduce DNT.
3111692|NCT01811888||Patients with knee osteoarthritis|
3111693|NCT01811875|Experimental|Optivate 500IU|Optivate 500IU
3111694|NCT01811862|Experimental|Acupuncture|Acupuncture treatment once daily inpatient for 5 consecutive days starting at on the day after chemotherapy plus usual pre- and post-transplantation care.
3111695|NCT01811862|Sham Comparator|Sham acupuncture|Sham acupuncture once daily inpatient for 5 consecutive days starting at on the day after chemotherapy plus usual pre- and post-transplantation care.
3111696|NCT01811849|Experimental|BIOD-238|Subcutaneous injection
3111697|NCT01811849|Experimental|BIOD-250|Subcutaneous injection
3111698|NCT01811849|Active Comparator|Humalog|Subcutaneous injection
3111699|NCT01811836|Experimental|Resistant Starch|"Oral and intravenous zinc stable isotopes. Zinc: 67Zn (>97% enrichment),68Zn (>99% enrichment) and 70Zn (>95% enrichment) Days 1 and 38: children will be administered 40-75 μg of 67Zn through consumed food. At the end of these days, children will be given an intravenous injection of an accurately measured quantity of ~800 μg of 68Zn.~Days 3-35: resistant starch feeding -- which will be given to mothers and integrated into the food."
3111700|NCT01811823|Other|TIV|"Trivalent Inactivated Influenza Vaccine The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~A/California/7/2009 (H1N1)pdm-like virus~A/Victoria/361/2011 (H3N2)-like virus~B/Wisconsin/1/2010-like virus. (Yamagata lineage)"
3111701|NCT01811810|Other|xrt and long term ADT|Radiation therapy (XRT) and long term androgen deprivation therapy
3111702|NCT01811810|Other|xrt, chemotherapy and short term ADT|radiation therapy (XRT), chemotherapy and short term ADT
3111703|NCT01811797|Experimental|Low Intensity Shockwave treatment|4 weekly sessions of Low Intensity Shockwave treatment.
3111704|NCT01811797|Sham Comparator|Control group|
3111705|NCT01811784|Experimental|Use skirt on raw sap consumption|"Phase one: Test the effectiveness of a single message of do not drink raw sap."
3111706|NCT01811784|Experimental|Ask people not to drink sap|Test the effectiveness of a risk reduction approach, encouraging people to avoid drinking sap, if they do, they should only drink sap from skirt protected trees.
3111707|NCT01811784|No Intervention|Phase 1: Routine raw sap consumption among household members.|"Test the effectiveness of a single message of do not drink raw sap"
3111708|NCT01811784|No Intervention|Phase 2:|Raw sap consumption from skirt protected trees
3111709|NCT01811771|Active Comparator|Shanchol vaccine|Around 30,000 individuals will be vaccinated with two doses of oral cholera vaccine at least 14 days apart.All male and non-pregnant female residents above one year age will be targeted for vaccination.
3111710|NCT01811771|No Intervention|Non-intervention|No intervention will be given. Health education will be provided to the study participants.
3111805|NCT01811134|Experimental|PIPELINE flow diverter stent|flow diverter stent
3111711|NCT01811758|Experimental|Culturally Specific CBT|Culturally specific cognitive behavioral therapy. Group format, 8 sessions, approximately 90 minutes. Up to 8-weeks of transdermal nicotine patches. Focused on African Americans: smoking patterns, health outcomes, discrimination, stress, weight concerns, cultural beliefs and practices.
3111712|NCT01811758|Active Comparator|Standard CBT (control)|Standard cognitive behavioral therapy. Group format, 8 sessions, approximately 90 minutes each. Up to 8-weeks of transdermal nicotine patches. Traditional CBT, with no focus on race: smoking and health, benefits of quitting, weight control, relapse prevention, coping skills.
3111713|NCT01811745|Experimental|Jaques-Dalcroze eurhythmics training|Once-weekly 60-min Jaques-Dalcroze eurhythmics class, for 12 months.
3111714|NCT01811745|Active Comparator|Multicomponent exercise training|Once-weekly 60-min multicomponent exercise class supplemented by one 30-min home-based exercise session, for 12 months.
3111715|NCT01811732|Experimental|Delafloxacin plus placebo|Delafloxacin 300 mg IV every 12 hours for a minimum of 10 and up to a maximum of 28 doses
3111716|NCT01811732|Active Comparator|Vancomycin plus Aztreonam + placebo|Vancomycin 15 mg/kg IV plus two grams Aztreonam every 12 hours for a minimum of 10 and up to a maximum of 28 doses (Aztreonam was discontinued as soon as possible if a gram-negative organism was not identified in baseline cultures)
3111717|NCT01811719|Experimental|Enhanced NFP (NFP+)|"Enhanced NFP(NFP+)provides for the usual NFP services plus a three-prong experimental preventive intervention:~Structured and regularly occuring assessments for intimate partner violence (IPV);~McFarlane and Parker Brochure Driven Intervention for women experiencing IPV, including safety planning, referrals, and advocacy; and~Markman and Stanley Within My Reach Training which is a skills-based curriculum delivered to all participants focusing on improving relationship deicsions and outcomes."
3111718|NCT01811719|Active Comparator|NFP as usual|The Nurse Family Partnership is a well-known and widely used nurse home visit program developed by David Olds. It has been rigorously tested and replicated and is now considered a best practice.
3111719|NCT01811706|Experimental|Dalfampridine and then placebo|Participant first receive Dalfampridine at an oral dose of 10mg every 12 hours, for 4 weeks. After a washout period of 2 weeks, they then receive Placebo tablet orally every 12 hours, for a 4 weeks period.
3111720|NCT01811706|Experimental|Placebo, Then Dalfampridine|Participant first receive Placebo tablet orally every 12 hours, for a 4 weeks period. After a washout period of 2 weeks, they then receive Dalfampridine at an oral dose of 10mg every 12 hours, for 4 weeks.
3111721|NCT01811693|Experimental|Dose Tier 1|Glycerly Trinitrate (Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal
3111722|NCT01811693|Experimental|Dose Tier 2|Glycerly Trinitrate (Nitroglycerine) 10mg/24hour (0.4mg/hour) transdermal
3111723|NCT01811693|Experimental|Dose Tier 3|Glycerly Trinitrate (GTN, Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal plus a single metered dose 0.4mg of sublingual GTN
3111724|NCT01811680|Experimental|supervised treadmill training|Supervised treadmill training on variable sensing treadmill.
3111725|NCT01811667|Experimental|Sirolimus|Seric level between 10 to 15 ng/ml Pills for the adults and liquid for the children. Twice a day.
3111726|NCT01811654|No Intervention|Standard Care|Patients in this group will receive treatment per standard care. Standard Care is defined as consisting of physical therapy, activity modification (relative rest), and/or oral analgesic therapy. A specific physical therapy (PT) protocol will be implemented.
3111727|NCT01811654|Active Comparator|Intra-Articular Hyaluronic Acid-Euflexxa|Patients assigned to this group will receive treatment per standard care AND three (3) consecutive weekly injections of intra-articular hyaluronan (Euflexxa). Oral analgesics will be used at the lowest dose and for the shortest time possible to treat PFPS symptoms.
3111728|NCT01811641||maternal methyl-donors, infant epigenetics|women of reproductive age in rural Gambia, infants born to these women
3111729|NCT01811628||Questionnaire + Interview|Latinos and Hispanics who are smokers and recent quitters.
3111730|NCT01811615|Active Comparator|toothbrushing plus rinsing|0.06% CHX + 0.025% NaF plus toothbrushing and alcohol-containing mouth rinsing
3111731|NCT01811615|Experimental|alcohol-free experimental mouth rinse|0.06% CHX + 0.025% NaF plus toothbrushing
3111732|NCT01811615|Experimental|toothbrushing and rinsing|0.06% CHX + 0.03% CPC + 0.025% NaF, alcohol-free, mouth rinsing
3111733|NCT01811615|No Intervention|toothbrushing alone|negative control
3111734|NCT01811602|Other|Training|Pelvic floor muscle training delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction
3111735|NCT01811602|Other|Usual Care Control|Participants randomized to this arm will receive a 1-page educational pamphlet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
3111736|NCT01811589|Experimental|Thomale-Guide|Positioning of ventricular catheter with the Thomale-Guide instrument
3111737|NCT01811589|Other|Free-hand|Ventricular catheter placement without a guidance (free-hand)
3111738|NCT01811576|Active Comparator|recombinant human growth hormone|Daily subcutaneous dose
3111739|NCT01811576|Experimental|TV-1106|Titration dose levels of TV-1106
3111740|NCT01811563|Active Comparator|Stryker|Subjects will be receiving the Stryker Triathlon total knee replacement
3111741|NCT01811563|Active Comparator|Zimmer|Subjects will be receiving a Zimmer NexGen total knee replacement
3111742|NCT01811550||SHINE study subjects|Subjects enrolled in the SHINE trial who are not receiving intra-arterial therapy nor systemic anticoagulation; have no known moderate/severe hepatic insufficiency; have no known history of hypercoaguable or thrombotic condition; have INR =<1.5 (if known) at baseline and provide informed consent (self or LAR) will be enrolled in the I-SPOT study.
3111743|NCT01811537|Experimental|Experimental: premeasured Neochordae|Transthoracic echocardiography(TTE) is done for all patients. The new device will be setup using the TTE measurements.The artificial Chordae loops will be made at the operation room before starting the surgery. These loops will be attached to the respective papillary muscle's head and the free edge of respective prolapsed scallop.
3111744|NCT01811524||Glioma and meningioma patientsl|Glioma and meningioma patients of Tampere University Hospital during the study period
3111745|NCT01811511|Experimental|Chungkookjang|Chungkookjang(35g/day)
3111746|NCT01811511|Placebo Comparator|Placebo|Placebo(35g/day)
3111749|NCT01811485|Experimental|LMF237 50/500 mg|Patients took LMF237 50/500 mg (with a starting dose of LMF 237 50/250 mg for 2 weeks) twice daily for 14 weeks
3111750|NCT01811485|Placebo Comparator|Placebo|Patients took matching placebo of LMF237 (vildagliptin 50 mg) twice daily for 14 weeks
3111751|NCT01811472|Placebo Comparator|Placebo|Patients randomized to Placebo arm, received matching placebo to 5 mg, 10 mg and 20 mg pradigstat (LCQ908) once daily for 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
3111752|NCT01811472|Experimental|pradigastat (LCQ908) 5mg/10mg|Patients, randomized to pradigastat 5/10 mg, initially began with pradigastat (LCQ908) 5 mg once daily and then were up-titrated, if pradigastat (LCQ908) 5 mg once daily was tolerated, to pradigastat 10 mg once daily at Week 2. Total treatment duration was 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
3111753|NCT01811472|Experimental|pradigastat (LCQ908) 10mg/20mg|Patients, randomized to pradigastat 10/20 mg, initially began with pradigastat (LCQ908) 10 mg once daily and then were up-titrated, if pradigastat (LCQ908) 10 mg once daily was tolerated, to pradigastat 20 mg once daily at Week 2. Total treatment duration was 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
3111754|NCT01811459|Experimental|Quetiapine|Drug: Quetiapine 50-250 mg PO BID (5 levels of treatment) + IV Placebo Rescue IV haloperidol available.
3111755|NCT01811459|Experimental|Haloperidol|Drug: Haloperidol 1-5 mg BID (5 levels of treatment) + PO placebo Rescue IV haloperidol available.
3111756|NCT01811459|Placebo Comparator|Placebo|IV placebo + PO placebo Rescue IV haloperidol available.
3111757|NCT01811446|Experimental|Obese|Subjects with BMI > 30
3111758|NCT01811446|Experimental|COPD|Non-hospitalized COPD patients
3111759|NCT01811420|Experimental|CHEMOMECHANICAL CARIES REMOVAL|Dental caries removal using papain based gel
3111760|NCT01811420|Active Comparator|conventional method|Dental caries removal using rotatory instrument
3111761|NCT01811407|Other|Private/private|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Participants will be required to set a forward-looking commitment each week as to how many days during the following week they will meet their step count target. Commitment and results will be private.
3111762|NCT01811407|Experimental|Public/private|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Commitments are made as in the Private/Private condition. In addition, one Facebook announcement will be posted at the beginning of the week that says how many days the participant thinks they will meet their walking target the following week. An email will also be sent directly to 3 friends the participant chose with the same announcements.
3111763|NCT01811407|Experimental|Public/public|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Commitments will be made as in the Private/Private condition. In addition, one message will be posted to Facebook at the beginning of the week that says how many days the participant thinks they will meet their walking target the following week, and how they did on their previous weekly commitment. An email will also be sent directly to 3 friends the participant chose with the same announcements.
3111764|NCT01811394|Experimental|protons|16x4GyE protons
3111765|NCT01811394|Experimental|Carbon ions|16x4GyE carbon ions
3111766|NCT01811381|Experimental|Curcumin and aerobic exercise|For the first 6 months of the study, subjects will take 800 mg of curcumin (4 capsules x BID, p.o.) before meals. From six to 12 months after the beginning of the study, subjects will take curcumin (4 capsules BID before meals, total 800 mg/day) and also participate in an aerobic yoga exercise program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
3111767|NCT01811381|Placebo Comparator|Placebo vs non-aerobic yoga|For the first 6 months of the study, subjects will take Placebo (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Placebo (4 capsules x BID) and participate in a weekly non-aerobic yoga program (Attendance at 2 classes of 1 hour duration or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
3111768|NCT01811381|Active Comparator|Placebo vs Aerobic Yoga|For the first 6 months of the study, subjects will take Placebo (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Placebo (4 capsules x BID) and participate in a weekly aerobic yoga program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
3111769|NCT01811381|Active Comparator|Curcumin vs non aerobic yoga|For the first 6 months of the study, subjects will take 800 mg of curcumin (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Curcumin (4 capsules x BID, total 800 mg/day) and participate in a weekly non-aerobic yoga program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
3111770|NCT01811368|Experimental|Treatment (ibritumomab tiuxetan, allogeneic PBSCT)|"CONDITIONING REGIMEN: Patients receive rituximab IV on days -21 and 14, ibritumomab tiuxetan IV on day -14, TLI on days -11 to -7 and -4 to -1, and antithymocyte globulin IV over 4-6 hours on days -11 to -7. Patients also undergo TLI on days -11 to -7 and -4 to -1.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Patients receive cyclosporine PO BID or IV on days -3 to 56 with taper to 6 months and mycophenolate mofetil PO BID or IV on days 0-28."
3111771|NCT01811355|Active Comparator|Mexiletine|Mexiletine, capsule, 150mg, PO BID, 14 days
3111772|NCT01811355|Placebo Comparator|Placebo|Placebo, capsule, PO BID, 14 days
3111773|NCT01811342||Hemoglobin Measurement|Patients requiring intra-operative hemoglobin measurement.
3111774|NCT01811329|Active Comparator|Palm fat|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and protein powder.
3111806|NCT01811134|Active Comparator|Coils, with or without expendable stent|Coils
3111775|NCT01811329|Experimental|Palm fat + MFGM|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
3111776|NCT01811329|Active Comparator|Dairy fat|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain whipping cream, frozen fruit, glucose polymer, and protein powder.
3111777|NCT01811329|Experimental|Dairy fat + MFGM|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain whipping cream, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
3111778|NCT01811316|Active Comparator|Probiotics Lozenge (twice a day)|Subjects take their lozenge twice a day, one lozenge in the morning after brushing and one lozenge in the evening after brushing.
3111779|NCT01811316|Active Comparator|Probiotics Lozenge (once a day)|Subjects take their lozenge once a day, one lozenge at night after brushing.
3111780|NCT01811316|Placebo Comparator|Placebo Lozenge (once a day)|Subjects take their lozenge once a day, one lozenge at night after brushing.
3111781|NCT01811303|Experimental|D-fagomine|Measure the changes produced on the postprandial Glycaemic response to 50 g of sucrose containing 40 mg D-fagomine, in 200 ml water
3111782|NCT01811303|Placebo Comparator|Control|Sucrose 50 g without d-fagomine, in 200 ml water
3111783|NCT01811290||Gilenya Subjects|Gilenya therapy group subjects must have been treated with Gilenya a minimum of 3 months uninterrupted prior to screening visit, and approved by the principal investigator to continue on this agent.
3111784|NCT01811290||Controlled Therapy Group|Control therapy group subjects must have been consistently on an FDA approved disease modifying therapy other than Gilenya or off such therapy a minimum of 6 months prior to screening visit.
3111785|NCT01811277|Experimental|SOX sequential S-1|4-6 cycles of SOX followed by S-1 monotherapy until disease progression
3111786|NCT01811264|Experimental|Intervention|Participants will begin with a pre-visit structured interview to determine emotional and physical well-being, anxiety, depression, and self-efficacy. Then they will be helped through the Patient-Participation Aid (PPA) by the research assistant (RA). Then they will meet with their doctor while the visit is video-recorded. After they will complete a post-visit interview to see if there were any health decisions made, patients level of involvement, and doctor communication. Follow up phone interviews will be conducted at 1 week and 3 months to assess patients self-reported changes in well-being, anxiety, depression, and decision regret.
3111787|NCT01811264|No Intervention|Usual Care|Participants will begin with a pre-visit structured interview to determine emotional and physical well-being, anxiety, depression, and self-efficacy. They will have their doctor's visit video recorded. After they will complete a post-visit interview to see if there were any health decisions made, patients level of involvement, and doctor communication.Follow up phone interviews will be conducted at 1 week and 3 months to assess patients self-reported changes in well-being, anxiety, depression, and decision regret.
3111788|NCT01811251|Experimental|Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)|The aim of the study is to show a decrease in postoperative pain during the first postoperative mobilization surgery lumbar disc herniation through a co-analgesia with a single dose of dexamethasone, pregabalin, or a combination of these two products
3111789|NCT01811251|Placebo Comparator|Lactose (150mg), NaC1 0.9% (50ml)|The aim of the study is to show a decrease in postoperative pain during the first postoperative mobilization surgery lumbar disc herniation through a co-analgesia with a single dose of dexamethasone, pregabalin, or a combination of these two products
3111790|NCT01811238|Experimental|Oxycodone/Naloxone|Single-arm study
3111791|NCT01811225|No Intervention|Sample 1 - Pregnant Women|Females 18-35 years old, in stable physical/mental health with confirmed pregnancy, 16-36 weeks gestation
3111792|NCT01811225|Experimental|Sample 2 - Oral Contraceptive Users|Females, 18-35 years old, non-pregnant, using oral contraceptive for at least the last 3 months before enrollment.
3111793|NCT01811212|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3111794|NCT01811186|Other|Group A|Start oxycodone/naloxone 10/5mg b.i.d. titration->20/10mg b.i.d.->30/15mg b.i.d->40/20mg b.i.d.
3111795|NCT01811186|Other|Group B|Start oxycodone/naloxone 5/2.5mg b.i.d titration-> 10/5mg b.i.d.->20/10mg b.i.d.->30/15mg b.i.d->40/20mg b.i.d.
3111796|NCT01811173|Experimental|Nurse-physician comprehensive care|Comprehensive self management support and care coordination by a nurse-primary care physician team
3111797|NCT01811173|No Intervention|Usual care survey control group|Patients will receive usual primary care and asked to complete questionnaires on four time points throughout the study
3111798|NCT01811173|No Intervention|Usual care blinded control group|Patients will receive usual primary care.
3111799|NCT01811160|Experimental|Melatonin 5mg (extended release capsules)|Subjects received melatonin (extended release) 5mg nightly during the follow up period
3111800|NCT01811160|Placebo Comparator|Placebo|Subjects received a placebo capsule nightly during the eight week follow up period.
3111801|NCT01811147|Experimental|High Risk Depression|Interventions will include the prescribing of Selective serotonin reuptake inhibitor or Serotonin-norepinephrine reuptake inhibitor antidepressants, bupropion or other antidepressant.
3111802|NCT01811147|Experimental|Low Risk Depression|Interventions will include the prescribing of Selective serotonin reuptake inhibitor or Serotonin-norepinephrine reuptake inhibitor antidepressants, bupropion or other antidepressant..
3111803|NCT01811147|No Intervention|Healthy Control|There is no intervention, but rather phone follow ups conducted as check ins to determine the continued eligibility of the healthy control participant.
3111804|NCT01811147|No Intervention|Bipolar|Bipolar participants are checked in with via phone conversations every three months, and have the opportunity to be scheduled for non-study visits to manage their symptoms.
3111807|NCT01811121|Experimental|5-aminolévulinique acid (5-ALA)|5-aminolévulinique acid :microsurgical resection guided by fluorescence (CGF) in addition to the usual techniques of neuronavigation, after oral administration of 20mg/kg of 5-ALA 3-5 hours prior to surgical incision
3111808|NCT01811121|Placebo Comparator|Placebo|Laroscorbine :microsurgical excision guided solely by neuronavigation, after oral administration of a placebo 3 to 5 hours before the surgical incision
3111809|NCT01811108||Avastin regimens|Patients who have either received or who are going to receive chemotherapy plus Avastin (bevacizumab)
3111810|NCT01811095|Experimental|Training arm|"The training arm participates in the robotic suturing simulation curriculum, a proficiency curriculum that it is focused on the goal of achieving proficiency targets for five simulator tasks. Those six tasks are : Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2, and Suture sponge 3. The curriculum also includes a sixth task, Suturing Skills (Symbionix): Horizontal suturing defect. Participants are encouraged to complete this task ten times rather than to attain a certain score. Participants set their own hours about when and how much to train during the 5 week intervention period. They are instructed that approximately one hour per week over 5 weeks will be required to achieve the targets, on average."
3111811|NCT01811095|Placebo Comparator|Control|Participants in this group carry on with regular training (residents) or regular clinical work (attending surgeons) without robotic simulator training during the five week period when they are in the control group.
3111812|NCT01811082|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
3111813|NCT01811082|Active Comparator|Pantethine 600mg|Pantethine 600mg per day.
3111814|NCT01811056|No Intervention|In-Center Use of Mifepristone|Participants who choose to take mifepristone in the center
3111815|NCT01811056|Experimental|Out-of-Center Use of Mifepristone|Participants who choose to take the mifepristone outside of the center
3111816|NCT01811043|Experimental|Guided Meditation|Guided meditation is played via headphones during biopsy
3111817|NCT01811043|Active Comparator|Music|Music is played via headphones during biopsy
3111818|NCT01811043|Placebo Comparator|Supportive Dialogue|Supportive dialogue is provided during biopsy by the radiologist performing the procedure
3111819|NCT01811030|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
3111820|NCT01811017|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
3111821|NCT01811017|Experimental|Nanosecond 755nm Alexandrite Laser|Nanosecond 755nm Alexandrite Laser
3111822|NCT01811004|Experimental|Botox®|Botox®
3111823|NCT01811004|Experimental|miraDry®|miraDry®
3111824|NCT01811004|Experimental|Nd: YAG laser|Nd: YAG laser 1440nm
3111825|NCT01810991|Experimental|Nd:YAG Laser|Nd:YAG 1440nm Laser
3111826|NCT01810978|Active Comparator|Bifidobacterium lactis plus inulin|Bifidobacterium lactis plus inulin
3111827|NCT01810978|Placebo Comparator|maltodextrin|maltodextrin
3111828|NCT01810965|Experimental|Cohort|
3111829|NCT01810952|Experimental|Glargine/Lispro Insulin Arm|"Drug: Glargine insulin was administered per above.~Drug: Lispro insulin 0.2 unit/kg/day was administered per above. A coverage dose of 0.1 unit/kg/day of lispro for each 10 mg of prednisone or its equivalent was divided between 3 meals. The maximum starting coverage dose was 0.4 units/kg per day.~The prandial dose of lispro was increased by 10% if the pre-lunch, pre-dinner, or bedtime SG was between 141-200 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG is >200 mg/dL. The prandial dose of lispro was decreased by 10% if the pre-lunch, pre-dinner, or bedtime SG is between 70-89 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was less than 70 mg/dL.~Drug: prednisone or equivalent dose was determined by severity of exacerbation and clinician's judgement."
3111830|NCT01810952|Experimental|Glargine/Lispro/NPH Insulin Arm|"Drugs Glargine and Lispro insulin included similar starting doses of glargine and lispro.~Drug: A coverage dose of NPH insulin 0.1 unit/kg/day for each 10 mg of prednisone or its equivalent was given twice daily with the administration of the glucocorticoid. Maximum starting coverage dose was 0.4 units/kg per day. NPH dose was increased by 10% if the pre-lunch, pre-dinner, or bedtime SG is between 141-200 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was greater than 200 mg/dL. It was decreased by 10% if the pre-lunch, pre-dinner, or bedtime SG was between 70-89 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was less than 70 mg/dL.~Drug: the dose of prednisone or equivalent glucocorticoid was determined by severity of exacerbation and clinician's judgement."
3111831|NCT01810939|Active Comparator|Patiromer|Patiromer was administered twice a day as a powder mixed with water.
3111832|NCT01810939|Placebo Comparator|Placebo|Placebo was administered twice a day as a powder mixed with water.
3111833|NCT01810926|Experimental|MRD-Regimen&Polyclonal antibody|Patients MRD will be randomized to receive Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 & ATG-Fresenius S® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2
3111834|NCT01810926|Sham Comparator|MRD-Regimen|Patients receiving stem cell transplantation from a matched related donors (MRD) will be randomized to receive only Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²) + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 (total dose of 150 mg/m²) after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals (total dose of 8 mg/kg)+ Cyclosporine A iv at a starting dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL (In the absence of GvHD CSA will be tapered after day + 180 and stopped at 9-12 months) + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
3111867|NCT01810705|Experimental|GRASPA|"patients will receive one injection of GRASPA (100 IU/kg) after each course of low-dose cytarabine (see Arm Control)"
3111868|NCT01810705|No Intervention|Control|patients will receive successive courses of low intensive chemotherapy, as subcutaneous low-dose cytarabine 20mg twice daily for 10 days per course (from day 1 to day 10), each course occurring every 28 days, for a duration up to 24 months
3111869|NCT01810692||Group 1|
3111870|NCT01810692||Group 2|
3111871|NCT01810679|Experimental|Perceval S Aortic Heart Valve|Treatment with the Perceval S Aortic Heart Valve
3111835|NCT01810926|Experimental|MUD-Regimen & Rituximab|Patients MUD will be randomized to receive Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11 + ATG-Fresenius S ® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 & Rituximab in a single infusion of 200 mg/m2 on day -1
3111836|NCT01810926|Sham Comparator|MUD-Regimen|Patients MUD will be randomized to receive only Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11 + ATG-Fresenius S ® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2
3111837|NCT01810913|Experimental|Arm 1 (IMRT, cisplatin)|Patients undergo IMRT QD five days a week and receive cisplatin IV over 1-2 hours once weekly for 6 weeks.
3111838|NCT01810913|Experimental|Arm 2 (IMRT, docetaxel)|Patients undergo IMRT as in Arm I and receive docetaxel IV once weekly for 6 weeks.
3111839|NCT01810913|Experimental|Arm 3 (IMRT, docetaxel, cetuximab)|Patients receive cetuximab IV over 120 minutes on week 1 and over 60 minutes once weekly on weeks 2-7. Patients undergo IMRT as in Arm I and receive docetaxel once weekly for 6 weeks.
3111840|NCT01810900|Experimental|Protescal|Protescal is applied to this arm.
3111841|NCT01810900|No Intervention|non-treatment|
3111842|NCT01810887|Experimental|Ritonavir and darunavir|Ritonavir will be administered orally twice daily at a dose of 100 milligram (mg) from Day 1-5. Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 mg on Day 3.
3111843|NCT01810874|Active Comparator|Transperitoneal|Patients who where randomized to transperitoneal laparoscopic aortic lymphadenectomy.
3111844|NCT01810874|Experimental|Extraperitoneal|Patients who where randomized to extraperitoneal laparoscopic aortic lymphadenectomy.
3111845|NCT01810861||Serotype distribution (this is a non-interventional study)|Serotype distribution both in pediatrics and adults (this is a non interventional study)
3111846|NCT01810848|Active Comparator|Hylan G-F 20|Patients will receive a single injection of hylan G-F 20 6ml into affected knee. Injections will be performed under fluoroscopic guidance.
3111847|NCT01810848|Sham Comparator|Control|Patients will receive a single sham puncture into the affected knee. Sham punctures will be identical to the treatment injections in all other respects, including duration, use of sterile drapes, sterile preparation, and dimming of the lights. This procedure will include a 22g needle stick through the skin without violating the joint capsule or performing arthrocentesis.
3111848|NCT01810822||Genesis French-Belgium Study|Cross-sectional, multi-center, binational (Belgian and France) study designed to evaluate the genetic components of diabetic nephropathy. It is a cohort with 501 patients, including 279 individuals (55.7%) with diagnosis of diabetic nephropathy.
3111849|NCT01810822||GENEDIAB|Cross-sectional, multi-center, binational (Belgian and France) study designed to evaluate the genetic components of diabetic nephropathy. It is a cohort with 444 patients, including 310 individuals (69.8%) with diagnosis of diabetic nephropathy.
3111850|NCT01810822||Brazilian cohort|The cohort comprised 451 patients with type 1 diabetes for more than 10 years (56% women; aged 36 ± 11 years, mean ± SD) recruited in diabetes/endocrinology departments of three university hospitals in the cities of São Paulo (SP), Campinas (SP) and Porto Alegre (RS), Brazil.
3111851|NCT01810809|Active Comparator|Articular Lavage|Patients from Group Zero will receive articular lavage with saline injection
3111852|NCT01810809|Experimental|Group 1|Patients from Group 1 will receive articular lavage with saline injection and viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
3111853|NCT01810809|Experimental|Group 2|Patients from Group 2 will receive articular lavage with saline injection and viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
3111854|NCT01810809|Experimental|Group 3|Patients from Group 3 will receive articular lavage with saline injection and viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
3111855|NCT01810796|Experimental|Ranolazine treatment|Ranolazine 500-1000mg bid
3111856|NCT01810796|Placebo Comparator|Placebo|Placebo
3111857|NCT01810783|Experimental|Brexpiprazole|
3111858|NCT01810770|Experimental|Radium-223 dichloride|
3111859|NCT01810757|Active Comparator|Standard planning|Standard planning radiotherapy
3111860|NCT01810757|Experimental|Adaptive planning|Adaptive planning radiotherapy
3111861|NCT01810744|Other|metastatic colorectal cancer|Patients treated by bevacizumab will be follow up by capillaroscopy and blood pressure measurements.
3111862|NCT01810744|Other|glioblastoma|Patients treated by bevacizumab will be follow up by capillaroscopy and blood pressure measurements.
3111863|NCT01810731|Experimental|Quadrivalent Influenza Vaccine (QIV)|"15µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 0.5mL which is administered intramuscularly.~Administered as a single dose on the day of enrollment."
3111864|NCT01810731|Active Comparator|Inactivated Polio Vaccine|A sterile suspension of three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF1) and Type 3 (Saukett). This vaccine is prepared from types 1, 2 and 3 of poliomyelitis virus cultured on Vero cells, purified and then inactivated by formaldehyde and administered as a 0.5ml intramuscular or subcutaneous injection. A single dose of vaccine will be administered upon enrollment.
3111865|NCT01810731|Experimental|Double Dose QIV|"30µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 1.0mL which is administered intramuscularly.~Administered as a single dose on the day of enrollment."
3111866|NCT01810718|Experimental|Nilotinib|"3 patients (pts) will receive Nilotinib 200 mg daily dose. If no dose-limiting toxicity, the next 3 pts will be treated with next dose of Nilotinib 300 mg daily dose.~Doses will not be escalated beyond 600 or below 200 mg/die. The dose estimated as the MTD in phase I will be used for phase II."
3111872|NCT01810666|Experimental|Recombinant Factor VIII|
3111873|NCT01810653|Experimental|Macrogol (Transipeg)|
3111875|NCT01810640|No Intervention|Control|In this group a liver biopsy will not be performed. All management would be as per standard of practice
3111876|NCT01810640|Active Comparator|Percutaneous liver biopsy|In this group a percutaneous biopsy of the liver will be performed prior to organ recovery
3111877|NCT01810627||MVCT|Patients will receive an additional MVCT scan at their one month follow up visit.
3111878|NCT01810614|Experimental|ADPKD Diet|All study participants will follow their regular diet for 8 days. After that, they will be asked to follow the ADPKD diet for a total of 4 weeks.
3111879|NCT01810601|Experimental|Ultrasound guided embryo transfer|GnRh, HMG, HCG, Progesterone 45 patients had ultrasound guided embryo transfer during ICSI
3111880|NCT01810601|Placebo Comparator|clinical touch technique|GnRh, HMG, HCG, Progesterone 45 patients had embryo transfer using clinical touch technique during ICSI
3111881|NCT01810588|Experimental|All Patients|"Haplo-cord transplantation:~All subjects will receive a conditioning regimen of chemotherapy prior to stem cell transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past.~For the transplant component of treatment, subject will receive umblical cord blood. The study involves transplantation of unlicensed units of cord blood. Therefore, these are considered investigational products.~In addition to the umbilical cord blood unit, recipients will receive stem cells from a family member ( a haplo-identical donor). After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device."
3111882|NCT01810575|Active Comparator|WC3036-11F/Alprostadil in Vehicle 2.5%|Treatment A
3111883|NCT01810575|Experimental|WC3036-12F/Alprostadil in Vehicle 0.5%|Treatment B
3111884|NCT01810575|Placebo Comparator|WC3036-13P/Vehicle Only 0.5%|Treatment C
3111885|NCT01810562|Experimental|Specific treatment + std stroke care|Specific treatment in addition to standard stroke care
3111886|NCT01810562|No Intervention|Std stroke care|Patients receive only standard stroke treatment and no specific treatment.
3111887|NCT01810549|Active Comparator|Anakinra|Anakinra 100mg. Every subject will receive one subcutaneous injection of study drug once during the study, a total of one injection.
3111888|NCT01810549|Placebo Comparator|Placebo|Every study participant will receive a single subcutaneous injection of Placebo once during the study, a total of one injection.
3111889|NCT01810536|Experimental|Hi-flow nasal cannula|This group will receive supplemental oxygen by nasal cannula using the Optiflow system, with high flows of 100% humidified oxygen
3111890|NCT01810536|Active Comparator|Venturi mask|This group will receive supplemental oxygen by the current standard in our Institution: Venturi masks
3111891|NCT01810523|Experimental|Narrative|This arm will receive information regarding leg injuries and X-ray usage in narrative form in addition to standard of care discharge information.
3111892|NCT01810523|Placebo Comparator|Control|This arm will receive a blank piece of paper in addition to the standard of care discharge information.
3111893|NCT01810510|Experimental|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
3111894|NCT01810510|Experimental|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
3111895|NCT01810497|Active Comparator|Seven-day bandage use|Patients randomized and instructed to use of ear bandage 24h/day for seven days after otoplasty
3111896|NCT01810497|Active Comparator|Thirty-day bandage use|Patients randomized and instructed to use of ear bandage 24h/day for thirty days after otoplasty
3111897|NCT01810484|Active Comparator|Group 1|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with Ultherapy® treatment only; Treatment Area B will be treated with Ultherapy® treatment and CO2 laser treatment; Treatment Area C will be treated with CO2 laser treatment only"
3111898|NCT01810484|Active Comparator|Group 2|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with Ultherapy® treatment and CO2 laser treatment; Treatment Area B will be treated with CO2 laser treatment only; Treatment Area C will be treated with Ultherapy® treatment only"
3111899|NCT01810484|Active Comparator|Group 3|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with CO2 laser treatment only; Treatment Area B will be treated with Ultherapy® treatment only; Treatment Area C will be treated with Ultherapy® treatment and CO2 laser treatment"
3111900|NCT01810471|Experimental|ankle supports|
3111901|NCT01810458||AATD ZZ and Rare Alleles Group|Participants will get a history and physical (H&P) and have an intravenous catheter (IV) placed, for blood draws, at the screening and years 1-3 visits. An IV will also be placed at the liver biopsy visit(s) for the administration of medication. An abdominal ultrasound will be done at the screening and year 3 visits along with the completion of a liver questionnaire. Finally, participants will have a liver biopsy done, with the use of lidocaine, lorazepam, or midazolam and fentanyl, after the screening visit and potentially at the year 3 study visit, depending on the results of the first liver biopsy. Participants who experience pain after the liver biopsy may receive acetaminophen or oxycodone/acetaminophen. Any subject experiencing nausea may receive ondansetron.
3111902|NCT01810445||1|Patients undergoing a surgical bladder procedure in the main O.R.
3111903|NCT01810432|Experimental|Evacetrapib (Fasted)|130 milligram (mg) oral dose of evacetrapib once daily in a fasted state for 10 days.
3111904|NCT01810432|Experimental|Evacetrapib (Fed)|130 milligram (mg) oral dose of evacetrapib once daily following a high-fat breakfast for 10 days.
3112277|NCT01807858|Active Comparator|Bifidobacterium lactis|5 billion Bifidobacterium lactis
3111905|NCT01810419|Experimental|normal and various degrees splenomegaly|"Vscan Ultrasound (GE Healthcare, USA) Conventional Ultrasound (Ultrasonix) used to determine spleen size Crossover design, all subjects will be measured with both devices. half will have the handheld done first, then conventional half the Conventional done first, then handheld~Will complete questionaire for both:~Adequacy of image quality~What is best view obtained~Greatest Longitudinal Measure~Diagnosis~Diagnostic Certainty~Time to Complete exam"
3111906|NCT01810406|Experimental|Epidural Volume Extension|CSE with 10 ml EVE
3111907|NCT01810406|Active Comparator|No Epidural Volume Extension|CSE without EVE
3111908|NCT01810393|Experimental|Trastuzumab IV Then Trastuzumab SC|Participants will receive treatment with Trastuzumab IV for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab SC for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.
3111909|NCT01810393|Experimental|Trastuzumab SC Then Trastuzumab IV|Participants will receive treatment with Trastuzumab SC for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab IV for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.
3111910|NCT01810380|Placebo Comparator|Placebo|
3111911|NCT01810380|Experimental|Brexpiprazole|Patients randomised to brexpiprazole received 1mg/day on Day 1, 2mg/day on Day 2, 3mg/day on Day 3 (uptitration); the dose could be adjusted from Day 4 onwards to 2, 3, or 4mg/day to optimise the clinical effect and tolerability.
3111912|NCT01810380|Other|Quetiapine extended release|Active Reference. Patients randomised to quetiapine received 300mg/day on Day 1, 600mg/day on Days 2 and 3 (uptitration); the dose could be adjusted from Day 4 onwards to 400, 600, or 800mg/day to optimise the clinical effect and tolerability.
3111913|NCT01810367|Experimental|ABX Combined With Cisplatin|ABX，100mg/m2，d1、8、15，ivgtt,in 30 min，28day one cycle； cisplin 75mg/m2 d1 ivgtt
3111914|NCT01810367|Active Comparator|Gemcitabine Combined With Cisplatin|gemcitabine 1000mg/m2，d1、8；cisplatin 75mg/m2 d1 ivgtt,3 weeks one cycle.
3111915|NCT01810354|Experimental|Two grams cefazolin|Two grams of cefazolin will be given by intravenous bolus zero to 60 minutes prior to the start of the cesarean section.
3111916|NCT01810354|Active Comparator|Three grams cefazolin|Three grams of cefazolin will be given by intravenous bolus zero to 60 minutes prior to the start of the cesarean section.
3111917|NCT01810341||Development Group|In the Development Phase, analyses will be performed until the classification algorithm is finalized.
3111918|NCT01810341||Validation Group|The Validation Phase will assess the performance of the finalized classification algorithm in 300 subjects.
3111919|NCT01810328|Active Comparator|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
3111920|NCT01810328|Active Comparator|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
3111921|NCT01810315|No Intervention|Baseline|Premenopausal women will undergo baseline sampling in each the follicular and luteal phase. Postmenopausal women will undergo baseline sampling one time.
3111922|NCT01810315|Experimental|TFV 1% Gel|"Participants will vaginally insert 1 applicator of TFV gel followed by a 2nd applicator 2 hours later. Each applicator contains 4.4 gm of TFV 1% gel.~Premenopausal women will undergo sampling after TFV gel use in each the follicular and luteal phase. Postmenopausal women will undergo sampling after TFV gel use one time."
3111923|NCT01810315|Experimental|Estradiol Vaginal Cream|Post menopausal women only: Participants will insert 2 grams of estradiol cream into the vagina every night for 14 days and then one gram of estradiol cream into the vagina every other night
3111924|NCT01810315|Experimental|TFV 1% gel and estradiol cream|Postmenopausal women only: Participants will vaginally insert 1 applicator of TFV gel followed by a 2nd applicator 2 hours later. Each applicator contains 4.4 gm of TFV 1% gel. In addition, participants will one gram of estradiol cream into the vagina every other night.
3111925|NCT01810302|Experimental|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
3111926|NCT01810302|Placebo Comparator|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
3111927|NCT01810289|Experimental|MJAP Clinics|START
3111928|NCT01810276|Placebo Comparator|Saline|400 mL of Saline will be given intravenously over 2 hours once.
3111929|NCT01810276|Active Comparator|Platelets|2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
3111930|NCT01810263|Experimental|high protein supplement|high protein supplement given
3111931|NCT01810263|No Intervention|Control|no intervention
3111932|NCT01810250||Abdominal Aortic Aneurysm (Challenging anatomy)|Endovascular aneurysm repair
3111933|NCT01810237|Experimental|Dabigtran instead of LMWH for perioperative bridging.|
3111934|NCT01810224|Active Comparator|Angio-guided arm|In this arm will be included the patient randomized to a Angiography-guided surgical revascularization strategy.
3111935|NCT01810224|Experimental|FFR-guided arm|In this arm will be included the patient randomized to a FFR-guided surgical revascularization strategy.
3111936|NCT01810211|Experimental|Horizontal Adduction Stretch and Pendulums|"Horizontal Adduction Stretch- Individual standing with their operative scapula against a wall and rotating toward the side to be stretched to stabilize scapula and the operative arm is relaxed. The opposite hand is placed under the elbow of the involved extremity and assists the operative shoulder into horizontal adduction attempting to bring the hand to the opposite shoulder.~Pendulum -Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction."
3112278|NCT01807858|Active Comparator|İnulin|900 mg İnulin per day will be given
3112279|NCT01807858|Placebo Comparator|Maltodextrin|Maltodextrin
3111937|NCT01810211|Experimental|Modified Sleeper Stretch and Pendulum|"Modified Sleeper Stretch: Individual in supine with operative shoulder abducted to approximately 45 degrees and elbow at 90 degrees of flexion with neutral rotation of the glenohumeral joint. The individual then places other hand on the wrist of the involved extremity and passively moves the glenohumeral joint into internal rotation.~Pendulum Exercise: Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction."
3111938|NCT01810211|No Intervention|Pendulum Exercise|Pendulum Exercise: Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction.
3111939|NCT01810198|Active Comparator|Cardiac CT|Patients who undergo Cardiac CT (instead of Invasive Coronary Angiography)
3111940|NCT01810198|Active Comparator|Invasive Coronary Angiography|Patients did not undergo Cardiac CT, went straight to Invasive Coronary Angiography
3111941|NCT01810185|Experimental|Low dose naltrexone|Subjects in this arm will recieve low dose naltrexone (4.5 mg) daily for 12 weeks.
3111942|NCT01810185|Placebo Comparator|Placebo|Subjects in this arm will recieve a placebo daily for 12 weeks.
3111943|NCT01810172|Active Comparator|Dry suction pleural drainage system|The control group will have their chest tube connected to a dry suction pleural drainage system The intervention will be the dry suction pleural drainage system
3111944|NCT01810172|Experimental|Digital pleural drainage system|The experimental group will have their chest tube connected to a digital pleural drainage. The intervention will be the digital pleural drainage system.
3111945|NCT01810159|Experimental|ICC|Integrated collaborative care
3111946|NCT01810159|Active Comparator|E&R|Education and Resources--enhanced usual care
3111947|NCT01810146|No Intervention|Digestive functions investigations|Results from digestive functions investigations will be compared between patients eligible for bariatric surgery (BMI>40kg/m2) and volunteers (BMI between 20 and 25kg/m2).
3111948|NCT01810133||Anesthesia patients|All patients undergoing general anesthesia between January 2006 and December 2011 in Charité - University Berlin
3111949|NCT01810120|Experimental|TCR alfa beta depleted graft, infusion|The leukapheresis product will undergo TCR alfa beta negative selection following the standardized protocol.
3111950|NCT01810107||Children Examined with the OCT Probe|Children undergoing surgery will also have the Optical Coherence Tomography probe.
3111951|NCT01810107||Adults|Adults undergoing surgery will also have the Optical Coherence Tomography probe.
3111952|NCT01810094||Minimally invasive Approach|Patients with a thoracolumbar Fracture A3.1 to A 3.3 treated by fracture fixation by a minimally invasive approach
3111953|NCT01810081||cholecystectomy|cholecystectomy group: H.Pylori infection in gall bladder
3111954|NCT01810068|Sham Comparator|Placebo|patients who are undergoing diagnostic cystoscopy
3111955|NCT01810068|Active Comparator|HOLEP|Holmium laser enucleation of the prostate
3111956|NCT01810068|Active Comparator|monopolar TURP|Monopolar transurethral resection of the prostate
3111957|NCT01810068|Active Comparator|Bipolar TURP|Bipolar transurethral resection of the prostate
3111958|NCT01810042|Experimental|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity monthly 3 times for the 3 months then pro-re-nata (PRN) for following 3 months.
3111959|NCT01810029|Experimental|Cardiac Rehabilitation plus Transcendental Meditation|a standard validated cardiac rehabilitation program plus a standard validated stress reduction component, the Transcendental Meditation program
3111960|NCT01810029|Active Comparator|Cardiac Rehabilitation|This control is a standard Cardiac Rehabilitation without a stress reduction technique
3111961|NCT01810016|Experimental|Ipilimumab plus NY-ESO-1 OLP4 Vaccine with Montanide|Ipilimumab i.v. over 90 minutes followed by NY-ESO-1 OLP4 mixed with Poly-ICLC and Montanide ISA 51 VG s.c. every 3 weeks for 4 doses.
3111962|NCT01810016|Experimental|Ipilimumab plus NY-ESO-1 Protein Vaccine with Montanide|Ipilimumab i.v. over 90 minutes followed by NY-ESO-1 Protein mixed with Poly-ICLC and Montanide ISA 51 VG s.c. every 3 weeks for 4 doses.
3111963|NCT01810016|Experimental|Ipilimumab plus NY-ESO-1 OLP4 Vaccine without Montanide|Ipilimumab i.v. over 90 minutes followed by NY-ESO-1 OLP4 mixed with Poly-ICLC s.c. every 3 weeks for 4 doses.
3111964|NCT01810003|Experimental|High DHA|High DHA supplementation (3g/day)
3111965|NCT01810003|Experimental|High EPA|EPA supplementation (3g/day)
3111966|NCT01810003|Placebo Comparator|Placebo|Placebo (3g corn oil/day)
3111967|NCT01809990|Experimental|internet-delivered cognitive behavior therapy|Participants will be assigned to a 12 weeks internet-delivered cognitive behavior therapy program including therapist contact via an internet platform and telephone.
3111968|NCT01809977|Other|total removal|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
3111969|NCT01809977|Other|partial removal|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
3111970|NCT01809964|Experimental|Dose 1|ANT-1401
3111971|NCT01809964|Experimental|Dose 2|ANT-1401
3111972|NCT01809964|Placebo Comparator|Vehicle|Placebo Vehicle
3111973|NCT01809951||Isomil Advance with LCP|4 spoonful of Isomil Advance with LCP in 240 mL of water, 4 times a day
3111974|NCT01809938|Active Comparator|Black Tea|
3111975|NCT01809938|Active Comparator|Tea with Milk|
3111976|NCT01809925|Experimental|psyllium fiber 6.8g|Two (2) packets Metamucil Orange Sugar Free Fiber Singles (psyllium 6.8 g) thoroughly mixed in Ten (10) ounces of water. Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
3111977|NCT01809925|Placebo Comparator|placebo|One (1) level teaspoon of placebo product thoroughly mixed in Ten (10) ounces of water. Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
3112158|NCT01808690|Placebo Comparator|Metformin|Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
3111978|NCT01809912|Experimental|Greenstatin|"Cohort 1 : 6 mg/m2 Cohort 2 : 12 mg/m2 Cohort 3 : 24 mg/m2 Cohort 4 : 48 mg/m2 Cohort 5 : 96 mg/m2 Cohort 6 : 192 mg/m2 28 Day Course Subjects will receive MG1102 (Recombinant human apolipoprotein(a) Kringle V ) by IV administration on Day 0. If no DLTs are observed during the 6 days following the initial infusion, the same dose will be administered once daily for 5 consecutive days followed by a 2-day rest period three times (over 21 days), completing the course on Day 27.~Additional 21 Day Courses In the absence of a DLT, and in the case of stable disease or better, a subject may continue to receive MG1102 (Recombinant human apolipoprotein(a) Kringle V~) on a compassionate use basis at the same dose and regimen ."
3111979|NCT01809899|Experimental|Enhanced Consent Procedure|Participants in this group will receive an enhanced consent that will be an hour longer than usual.
3111980|NCT01809899|Active Comparator|Consent as Usual Procedure|Participants in this group will receive a normal consent procedure to the study
3111981|NCT01809886|Experimental|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC<2).
3111982|NCT01809886|Active Comparator|Neostigmina|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC<2).
3111983|NCT01809873|Experimental|Performance based incentives|Performance based incentives: The Incentive arm will receive monthly visits and external quality assurance of malaria diagnostic accuracy, identical to the comparison. Incentive arm will also receive quarterly incentives linked to performance of the facility around six indicators of appropriate malaria case management
3111984|NCT01809873|No Intervention|Comparison|The comparison arm will receive monthly visits and monthly external quality assurance of malaria diagnostic accuracy.
3111985|NCT01809860|Experimental|isavuconazole and sirolimus|Single dose of sirolimus on Days 1 and 26, isavuconazole 3 times a day (TID) for 2 days (Days 22 to 23) followed by once a day (QD) for 11 days
3111986|NCT01809847|Experimental|Ofatumumab|First dose of 300 mg Ofatumumab followed by seven weekly infusions of 2000 mg. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.
3111987|NCT01809834|Active Comparator|Etafilcon A|Each participant was randomized to wear the test lens in one eye and the control lens in the other simultaneously
3111988|NCT01809834|Experimental|Stenfilcon A|Each participant was randomized to wear the test lens in one eye and the control lens in the other simultaneously
3111989|NCT01809821|Experimental|Online Sleep Education|The sleep intervention is a multi-component online intervention consisting of sleep information and sleep hygiene education, along with behavioural and cognitive components.
3111990|NCT01809821|No Intervention|Usual CV care|Specialist nurses will administer the CV risk factor education intervention to participants in small groups over one hour.
3111991|NCT01809808||Acromegaly Subjects|People who have a biochemical diagnosis of acromegaly, and will or have already undergone surgery for acromegaly and will be taking medications for acromegaly . Subjects will undergo blood sampling, metabolic rate measurement, adipose tissue biopsy and total body magnetic resonance imaging before and over time after either surgery or medical therapy for acromegaly.
3111992|NCT01809808||Healthy Subjects|People who are not diagnosed with acromegaly, responding to flyer or by word of mouth for participation, without medical problems, not taking medications, and with a stable weight for 3 months prior to study. Subjects will undergo blood sampling, total body MRI and adipose tissue biopsy once.
3111993|NCT01809795|Experimental|Blueberry Smoothie|Participants in this group will receive a smoothie containing 1 1/2 cups of freeze-dried whole blueberries crushed into a powder.
3111994|NCT01809795|Sham Comparator|Sham Smoothie|Participants in this group will receive a smoothie that contains no blueberries.
3111995|NCT01809782||Study group:20 patients undergoing two stage liver-operation|Patients undergo two liver operations.First surgery: insitu-split for induction of proliferation in the remaining liver tissue; Second surgery: resection of the liver Tumor (4 cognitive measurements: Baseline, 7 days, 3 months and 1 year)
3111996|NCT01809782||Control group: 20 patients (ASA class II/III)|Relatives from study personel or patients from outpatient clinics from Charité in Berlin and surrounding area (4 cognitive measurements: Baseline, 7 days, 3 months and 1 year)
3111997|NCT01809769|Experimental|Mesenchymal stem cells low-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 1 x 10 E7 cells (3 ml), Frequency: 0,3 weeks.
3111998|NCT01809769|Experimental|Mesenchymal stem cells mid-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 2 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.
3111999|NCT01809769|Experimental|Mesenchymal stem cells high-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage:5 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.
3112000|NCT01809756|Active Comparator|Caphosol|
3112001|NCT01809756|No Intervention|No intervention|
3112002|NCT01809743|Active Comparator|Regadenoson central - peripheral|First bolus regadenoson administered central, second bolus administered peripheral
3112003|NCT01809743|Active Comparator|Regadenoson peripheral - central|First bolus regadenoson administered peripheral, second bolus administered central
3112004|NCT01809743|Active Comparator|Regadenoson central - central|First bolus regadenoson administered central, second bolus administered central
3112005|NCT01809743|Active Comparator|Regadenoson peripheral - peripheral|First bolus regadenoson administered peripheral, second bolus administered peripheral
3112006|NCT01809730||Cardiovascular risk|patients with CV disease
3112007|NCT01809717|Experimental|Weight Lifting Exercises|
3112008|NCT01809704||Normal|Normal results from clinical exam and free of ocular pathology.
3112009|NCT01809704||Glaucoma|Clinical exam results consistent with glaucoma and visual field defects consistent with glaucoma.
3112010|NCT01809704||Retina|Clinical exam results consistent with retina pathology
3112011|NCT01809691|Experimental|ADT + TAK-700|"LHRH agonist - given as approved for androgen deprivation at a dose necessary to maintain castrate levels and equivalent to 22.5 mg of Leuprolide IM every 3 months.~TAK-700, 300 mg, PO, twice daily"
3112012|NCT01809691|Active Comparator|ADT + Bicalutamide|"LHRH agonist - given as approved for androgen deprivation at a dose necessary to maintain castrate levels and equivalent to 22.5 mg of Leuprolide IM every 3 months.~Bicalutamide, 50 mg, PO, q daily"
3112013|NCT01809678|Experimental|Smoking Cessation plus Yoga|Twice weekly, 1-hour yoga classes delivered for 8 weeks combined with once-weekly, 1-hour cognitive-behavioral smoking cessation classes.
3112014|NCT01809678|Active Comparator|Smoking Cessation plus Wellness|Twice-weekly, 1-hour Wellness classes given on a variety of health topics twice weekly to match schedule of the yoga classes, plus 1-hour per week of cognitive-behavioral smoking cessation
3112015|NCT01809665||ICD/CRT-P therapy|Standard indication for ICD or triple-chamber pacemaker therapy
3112016|NCT01809652|Experimental|Remote Implant Support|Implant supported through remote implant support capability
3112017|NCT01809639|Experimental|Progesterone|400mg of oral micronized progesterone (Prometrium®) on days one, two, and three then 200mg on days four and five
3112018|NCT01809639|Placebo Comparator|Placebo|
3112019|NCT01809626|Experimental|Zolpidem (10 mg)|Oral administration of the drug zolpidem (Ambien)
3112020|NCT01809626|Placebo Comparator|Gelatin capsule|Oral administration of a placebo pill that is packaged identically to the active condition.
3112021|NCT01809613||Deep Brain Stimulation|Functional Magnetic Resonance Imaging (fMRI) will be performed to determine the areas of BOLD signal modulation with DBS.
3112022|NCT01809600||Patients with Burkitt's Lymphoma|should be diagnosed pathologically by WHO 2008 criteria
3112023|NCT01809587|Experimental|IQP-PO-101|Day 1 to Day 7 - 1 sachet to be mixed in 250ml of water and consumed twice a day Day 8 to Day 28 - 1 sachet to be mixed in 250ml of water and consumed once a day Day 28 to Day 42 - no investigational product intake (post treatment observation only)
3112024|NCT01809561||endometriosis|The study group will consist of women with suspected endometriosis facing surgical treatment
3112025|NCT01809561||no endometriosis|The control group will consist of healthy women facing gynecologic surgery for different indication
3112026|NCT01809548|Experimental|Early complementary feeding group|"Early intervention group:~Introduction of early complementary feedings between the 10th -12th week of gestation corrected for prematurity"
3112027|NCT01809548|Experimental|Late complementary feeding group:|"Late intervention group:~Introduction of late complementary feedings between the 16th and 18th week of life corrected for prematurity"
3112028|NCT01809535|Experimental|The Monthly EVL|Patients in the Monthly group were received EVL at 28-day treatment intervals.
3112029|NCT01809535|Active Comparator|The Biweekly EVL|Patients in the Biweekly group received repeating EVL every 2 weeks.
3112030|NCT01809522|Experimental|Posterior reconstruction of the musculofascial plate|These patients will receive reconstruction of the muscolofascial plate after radical prostatectomy. The reconstruction will be performed using two 3-0 Poliglecaprone sutures (on RB-1 needles) tied together, with each individual length being 12-15 cm. seven - Ten knots will be placed when tying the sutures to provide a bolster. The free edge of the remaining Denonvillier's fascia will be identified after the prostatectomy and approximated to the posterior aspect of the rhabdosphincter and the posterior median raphe using one arm of the continuous suture. As a rule, four passes will be taken from the right to the left and the suture is locked. The second layer of the reconstruction will be then performed with the other arm of the suture approximating the posterior lip of the bladder neck (full thickness) and the vesicoprostatic muscle to the posterior urethral edge and to the already reconstructed median raphe .This suture will be then tied to the end of the first suture arm.
3112031|NCT01809522|No Intervention|Standard radical prostectomy|
3112032|NCT01809496|Active Comparator|Informational counseling, patient only|The purpose of this experimental group is to evaluate the effectiveness of informational counseling alone. This type of counseling is considered the standard of care in audiologic practice. Patients in this will review this material in detail with a member of the study team for approximately 30 minutes at the second visit. Spouses in this experimental group will be will review material regarding VA services with a member of the study team for about 30 minutes.
3112033|NCT01809496|Experimental|Informational Counseling, couples|The purpose of this experimental group is to evaluate the influence of spousal involvement when receiving informational counseling. In this manner, both patients and spouses are presented with the same information regarding hearing loss and hearing aids. Couples in this experimental group will be given the same information that the patients in the first group were given. At the second visit, couples in this group will review this information together with a member of the research team for approximately 30 minutes.
3112034|NCT01809496|Experimental|Patient Centered Counseling,patient only|In order to assess the effects of enhanced patient-centered counseling (PCC), the patients assigned to this group will meet together with either Dr. Lewis or the Research Audiologist for approximately 30 minutes of counseling. In addition to the PCC techniques used in audiology, this counseling also will involve the core components of motivational interviewing. These principles and methods will be used to allow the patient to clearly express his/her expectations of, concerns about, and motivations for hearing-aid use. The spouses in this experimental group will be given information regarding VA services. This material will be reviewed with a member of the research team for about 30 minutes at the second visit.
3112035|NCT01809496|Experimental|Patient Centered Counseling, couples|In order to assess the influence of the spouse on the enhanced PCC process, the couples assigned to this group will meet together with either Dr. Lewis or the Research Audiologist for approximately 30 minutes of counseling. This counseling will be conducted with both the patient and the spouse together, giving both partners time to express their thoughts.
3112036|NCT01809483|Experimental|Bandage contact lens group|subject received antibiotic eye drops (combination of Polymyxin B, neomycin and gramicidin, q.i.d), and cycloplegic eye drops (tropicamide 0,5 %, q.d) and bandage contact lens. Bandage contact lenses maintained for 24 hours. Antibiotic eye drops were instilled without removing the contact lenses
3112037|NCT01809483|Active Comparator|Pressure patching group|Subject received antibiotic eye drops (combination of Polymyxin B, neomycin and gramicidin, q.i.d), and cycloplegic eye drops (tropicamide 0,5 %, q.d) and pressure patching. Pressure patching maintained for 24 hours and only opened for drug application. Subject and their families were educated on how to perform a good pressure patching
3112038|NCT01809470|Experimental|Watching TV|Watching TV (comedy, 'Friends') for 1 hour
3112039|NCT01809470|Experimental|FIFA2013|Playing the video game 'FIFA2013' for 1 hour
3112043|NCT01809444|Active Comparator|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks.
3112044|NCT01809444|Experimental|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg/d for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
3112045|NCT01809431|Experimental|intervention|Breastfeeding, progression to type 2 diabetes, nutrition, and exercise education, coping skills training, exercise training, a home-based exercise program and educational and motivational text messaging.
3112046|NCT01809431|No Intervention|Wait-listed control group|Wait-listed control group receive usual care delivered by their health care provider and after completion of their time in the study they are offered the intervention
3112047|NCT01809418|Experimental|keePAP|
3112048|NCT01809392|Experimental|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
3112049|NCT01809392|No Intervention|no decitabine|
3112050|NCT01809379|Experimental|intraperitoneal chemotherapy|Intraperitoneal chemotherapy with cisplatin at a dose of 7.5 mg/m2 body surface in a 150 ml NaCl 0.9% and doxorubicin at a dose of 1.5 mg/m2 body surface in a 50 ml NaCl 0.9% solution with a flow of 30 ml/min and a max upstream pressure of 200 psi.
3112051|NCT01809366|Experimental|seminal plasma insemination|seminal plasma insemination
3112052|NCT01809366|Placebo Comparator|culture medium insemination|culture medium insemination
3112053|NCT01809353|Experimental|Group A: JNJ-54452840 20 mg|Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose.
3112054|NCT01809353|Experimental|Group A: JNJ-54452840 80 mg|Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose.
3112055|NCT01809353|Experimental|Group A: JNJ-54452840 240 mg|Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose.
3112056|NCT01809353|Placebo Comparator|Group A: Placebo|Each participant will receive matching placebo as a single intravenous dose.
3112057|NCT01809353|Experimental|Group B: JNJ-54452840 20 mg|Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose.
3112058|NCT01809353|Experimental|Group B: JNJ-54452840 80 mg|Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose.
3112059|NCT01809353|Experimental|Group B: JNJ-54452840 240 mg|Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose.
3112060|NCT01809353|Placebo Comparator|Group B: Placebo|Each participant will receive matching placebo as a single intravenous dose.
3112061|NCT01809340|Experimental|Minocycline|Following a 12-day open-label treatment phase (involving ketamine and minocycline), responders may receive oral minocycline twice daily for up to 6 weeks in a blinded manner. In addition, non-responders may receive oral minocycline twice daily for up to 6 weeks in an open-label manner.
3112062|NCT01809340|Placebo Comparator|Placebo|Following a 12-day open-label treatment phase (involving ketamine and minocycline), responders may receive placebo twice daily for up to 6 weeks in a blinded manner
3112063|NCT01809340|Experimental|Ketamine and Minocycline|All patients will receive 6 IV infusions of ketamine and oral minocycline twice daily during a 12-day open-label treatment phase
3112064|NCT01809327|Experimental|Canagliflozin 100 mg|Participants will receive one 100 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.
3112065|NCT01809327|Experimental|Canagliflozin 300 mg|Participants will receive one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.
3112066|NCT01809327|Experimental|Metformin XR|Participants will receive metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.
3112067|NCT01809327|Experimental|Canagliflozin 100 mg + Metformin XR|Participants will receive one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.
3112068|NCT01809327|Experimental|Canagliflozin 300 mg + Metformin XR|Participants will receive one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.
3112069|NCT01809314||NeoRecormon in Symptomatic Anemia|Participants with symptomatic anemia who are receiving epoetin beta (NeoRecormon) according to standard of care and the Summary of Product Characteristics will be observed for 4 months. Treatment must be selected at the discretion of the prescriber prior to enrollment and will not be chosen by the Sponsor in this non-interventional study.
3112070|NCT01809301|Active Comparator|Niaspan|Single dose of one NIASPAN® 1000 mg Extended-Release Tablet following dinner
3112071|NCT01809301|Experimental|TRIA-662|Single dose of two TRIA-662, 500 mg Immediate-Release Tablets following dinner
3112072|NCT01809275|Experimental|QBECO|Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks
3112073|NCT01809275|Placebo Comparator|Placebo|Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks
3112074|NCT01809262|Experimental|olodaterol 2 mcg|solution for inhalation
3112075|NCT01809262|Experimental|olodaterol 5 mcg|solution for inhalation
3112076|NCT01809262|Experimental|olodaterol 10 mcg|solution for inhalation
3112077|NCT01809262|Experimental|olodaterol 20 mcg|solution for inhalation
3112078|NCT01809262|Experimental|olodaterol 40 mcg|solution for inhalation
3112079|NCT01809262|Placebo Comparator|placebo|solution for inhalation
3112080|NCT01809236|Experimental|0.5 mg Conbercept|patients will receive monthly intravitreal injections of Conbercept to month 3 (total 3 times) and then on an as needed (PRN) dosing schedule based on the pre-specified retreatment criteria till to month 9.
3112198|NCT01808443|Experimental|laser|laser, at most 4 times
3112081|NCT01809223|Experimental|conbercept treatment group|Subjects will receive conbercept injections at a dose of 0.5 mg/eye, once a month for first 3 months. In the next 6 months, the investigator will decide whether repeat injections are needed base on the monthly assessment results.
3112082|NCT01809223|Sham Comparator|sham injection group|Subjects will receive sham injections monthly for 3 months and will receive 0.5 mg/eye conbercept at month 4. The investigator will decide whether repeat injections are needed base on the monthly assessment results from month 5 to month 9.
3112083|NCT01809210|Experimental|Selumetinib+standard chemotherapy|Selumetinib plus gemcitabine; or pemetrexed and cisplatin or carboplatin
3112084|NCT01809197|Experimental|Air Optix/OFPM|Lotrafilcon B contact lenses (sphere, toric and multifocal), worn on a daily wear basis for 30 days, with OPTI-FREE MPDS lens care system
3112085|NCT01809197|Active Comparator|Acuvue Oasys/Habitual MPS|Senofilcon A contact lenses (sphere, toric and multifocal), worn on a daily wear basis for 30 days, with habitual MPS lens care system
3112086|NCT01809184|Experimental|Dose level 1|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
3112087|NCT01809184|Experimental|Dose level 2|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
3112088|NCT01809184|Experimental|Dose level 3|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
3112089|NCT01809184|Experimental|Dose level 4|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
3112090|NCT01809184|Experimental|Dose level 5|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
3112091|NCT01809184|Experimental|Dose level 6|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
3112092|NCT01809184|Experimental|Dose level 7|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
3112093|NCT01809171|Experimental|vitamin D3|1000 mg Ca2+/800IU vitamin D3 daily + 25 000IU vitamin D3 weekly during 6 months
3112094|NCT01809171|Placebo Comparator|Placebo|1000 mg Ca2+/ 800IU vitamin D3 daily + 25000IU placebo every week during 6 months
3112095|NCT01809158|Active Comparator|minocycline|Subjects randomized to the minocycline group will take 2 tablets per day, each 100mg of minocycline, for a total daily dose of 200mg of minocycline.
3112096|NCT01809158|Placebo Comparator|placebo|Subjects randomized to the placebo group will take 2 tablets of placebo (matched for minocycline) per day.
3112097|NCT01809145|Other|metal hypersensitivity|peripheral blood test for metal hypersensitivity (MELISA test)
3112098|NCT01809132|Experimental|Anakinra & Pentoxifylline & Zinc Sulfate|anakinra 100mg subcutaneous injection daily for 14 days pentoxifylline 400 mg orally three times daily for 28 day zinc sulfate 220 mg orally for 180 days
3112099|NCT01809132|Active Comparator|Methylprednisolone|methylprednisolone 32 mg orally daily for 28 days
3112100|NCT01809132|No Intervention|Observational|Individuals who choose not to participate in the interventional arm of the trial will be receive standard care and be observed for 6 months. They will be enrolled to have baseline and interval health information and laboratory results collected.
3112101|NCT01809119|Experimental|Laparoscopic Partial Nephrectomy|Patients with kidney neoplasms submitted to laparoscopic partial nephrectomy
3112102|NCT01809119|Active Comparator|Open Partial Nephrectomy|Patients with kidney neoplasms submitted to open partial nephrectomy
3112103|NCT01809106|Active Comparator|Morphine|
3112104|NCT01809106|Experimental|Oxycodone|
3112105|NCT01809106|Experimental|Buprenorphine|
3112106|NCT01809106|Experimental|Fentanyl|
3112107|NCT01809093||Blood draw|Blood (approximately equal to 3 to 4 tablespoons) will be drawn at the Wills Eye Institute, 1 time.
3112108|NCT01809067|Active Comparator|Lavender Aromatherapy Inhalers|Lavender Aromatherapy Inhalers
3112109|NCT01809067|No Intervention|No aromatherapy|No aromatherapy
3112110|NCT01809054|Active Comparator|Arixtra Arm|Arixtra (2.5 mg SQ/QD) subcutaneous injection daily for 2 weeks followed by aspirin 325 mg for 5 weeks
3112111|NCT01809054|Active Comparator|Pneumatic compression stockings arm|Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel) for 2 weeks with concomitant Aspirin 325 mg daily for 5 weeks.
3112112|NCT01809041|Experimental|Sevoflurane & remifentanil|sevoflurane at 0.5 to 1.5 minimum alveolar concentrations plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
3112113|NCT01809041|Active Comparator|propofol & remifentanil|propofol (50 - 150 µg/kg/min) and remifentanil (0.1 - 0.5 µg/kg/min)
3112114|NCT01809028|Active Comparator|EUS FNA with 2 passes|biopsy with 2 passes of the needle
3112115|NCT01809028|Active Comparator|EUS FNA with 4 passes|biopsy with 4 passes of the needle
3112116|NCT01809015||Cohort A: Regular medical care|Patients treated with vitamin K antagonists in regular medical care system
3112117|NCT01809015||Cohort B: Coagulation service|Patients with oral anticoagulation therapy in a telemedicine-based coagulation service
3112118|NCT01809002|Experimental|Processed Nerve Allograft|Processed Nerve Allograft
3112119|NCT01809002|Active Comparator|Collagen Nerve Cuff|
3112120|NCT01808976|Active Comparator|Evolution|This app is designed to be a cognitive training game that conditions the CCN. This is done by having participants play a multitasking game that targets their perceptual discrimination abilities, selective attention, and visuomotor tracking skills. At the first session, participants will be directed to an initial assessment of each of these cognitive control skills in a single task and dual-task setting (a total of 3 different diagnostics, described below). Each week, this diagnostic phase will reflect the training paradigm they will encounter for that week, as each week the perceptual and tracking challenges will increase.
3112121|NCT01808976|Experimental|Problem Solving Therapy|This app is based on the social problem solving protocol developed by Nezu and D'Zurilla . The app begins with explaining the PST steps. Participants are informed that they can learn each step one session at a time, or they can chose to learn all the steps at once. After each step completed, participants are asked if they want to continue onto the next step or save it for the next session, thus the app tailors itself to the users ability to absorb new information.
3112122|NCT01808976|Active Comparator|Basic health push app|This app provides daily suggestions for overcoming depressed mood and allows users to track their mood, using the 0-9 scale available for all three apps. In the first app session, participants are given a general education about depression and its known causes and consequences. Participants are told that to overcome mood problems, they must engage in one mood improvement strategy a day and that the app will suggest one to try each day.
3112123|NCT01808950|Experimental|0.06% Resiquimod Gel - A|"60 mg gel~Once daily prior to normal sleeping hours~5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation"
3112124|NCT01808950|Experimental|0.06% Resiquimod Gel - B|"100 mg gel~Once daily prior to normal sleeping hours~5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation"
3112125|NCT01808950|Experimental|0.06% Resiquimod Gel - C|"100 mg gel~Once daily prior to normal sleeping hours~5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation~The BCC will be pretreated. A shave biopsy (curettage or scraping off the tissue in a broad, superficial, tangential way) will be performed"
3112126|NCT01808937||Morphea|Those having the condition morphea or other synonymous diagnosis (such as localized scleroderma, linear scleroderma, Parry-Romberg syndrome, en coup de sabre)
3112127|NCT01808911|Active Comparator|Bras A|Steroid 1mg/kg/d and Cyclophosphamide 2mg/kg/d
3112128|NCT01808911|Experimental|Bras B|Steroid 1mg/kg/d and Rituximab 375 mg/m2 every week during four weeks
3112129|NCT01808898|Experimental|Local anaesthetic|2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
3112130|NCT01808898|Placebo Comparator|Saline|2mls of Normal Saline solution in a 5ml syringe
3112131|NCT01808885|Experimental|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
3112132|NCT01808885|Placebo Comparator|placebo|placebo (3 soft capsules, od) will be administered orally for 6 months
3112133|NCT01808872||Heart Failure|
3112134|NCT01808859|Experimental|Tourniquet|The Torniquet will be inflated to 100 mmHg over systolic pressure just before skin incision. The tourniquet will be deflated when the last stich/agraf is fixed
3112135|NCT01808859|No Intervention|No tourniquet|"The patients operated on in the non-tourniquet group will have the same surgery and surgical technique but without tourniquet~hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks."
3112136|NCT01808846||Lean Adolescents|Kids aged 12-17 with body mass index less than 25% and normal glucose tolerance test results
3112137|NCT01808846||Obese Insulin Sensitive|Obese Insulin Sensitive Adolescents aged 12-17 with BMI>95th% and whole body insulin sensitivity index > 3.
3112138|NCT01808846||Obese Insulin Resistant Adolscent|Obese Insulin Resistant Adolescents 12-17 with BMI> 95th% and WBISI<1.2.
3112139|NCT01808833||Frail patients|
3112140|NCT01808833||Non-frail patients|
3112141|NCT01808820|Experimental|Safety Pilot: DC Vaccine/Lysate|"Leukapheresis: Baseline, post-surgery;~Dendritic Cell Vaccine (DC Vaccine): Post-Leukapheresis, administered once weekly in dose-escalation scheme for 4 weeks;~Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 8, 12, 16 and 28;~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
3112142|NCT01808820|Experimental|Expansion Cohort: DC Vaccine/Lysate|"Leukapheresis: Baseline, post-surgery;~Dendritic Cell Vaccine (DC Vaccine): Post-Leukapheresis, administered once weekly in dose-escalation scheme for 4 weeks;~Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered every 4 weeks for a total of 4 doses;~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
3112143|NCT01808807||cesarean section rate after audit|cesarean section rate after audit
3112144|NCT01808794|Active Comparator|Mucograft|Placement of randomized membrane on half of subjects Mucograft
3112145|NCT01808794|Active Comparator|Dynamatrix|Placement of randomized membrane on half of subjects Dynamatrix Membrane Placement
3112146|NCT01808781|Experimental|Intervention group|Home exercise program plus walking program during 8-week period
3112147|NCT01808781|Active Comparator|Comparison group|Walking only program throughout the 8-week period.
3112148|NCT01808768|Experimental|Alcaftadine|subject on any ocular allergy ophthalmic treatment or no treatment will be started on Alcaftadine 0.25%(study drug)- 1 drop each eye daily for 1-2 weeks
3112149|NCT01808755|Experimental|D Mannose|1 gr. every 8 hours for 2 weeks, subsequently 1 gr. every 12 hours for 22 weeks
3112150|NCT01808755|Active Comparator|trimethoprim/sulfamethoxazole|intervention was a 5-days course of trimethoprim/sulfamethoxazole cp 160 mg/800 mg twice a day. Then one week of antibiotic every 4 weeks for the following 23 weeks
3112151|NCT01808742||Treatment|Treatment with CryoTouch III device
3112152|NCT01808729||FMD or CAD (as appropriate)|The study group will either have FMD, early onset CAD, or other rare/unusual vascular disorder. These differing disorders will be sub-groups within the overall study
3112153|NCT01808729||Healthy control subjects without vascular disease|Healthy controls will not exhibit signs, symptoms or other evidence of vascular disease.
3112154|NCT01808716|Active Comparator|Low-level laser therapy (LLLT) on muscle damage|Effects of low-level laser therapy (LLLT)on muscle damage
3112155|NCT01808716|Active Comparator|Low-level laser therapy (LLLT) placebo on muscle damage|Effects of low-level laser therapy (LLLT) placebo on muscle damage
3112156|NCT01808703|Experimental|Scaling and root planing plus PerioPatch|"All subjects in this group will receive scaling and root planing (full mouth during no more than 2 sessions within two weeks following the Baseline exam). Thereafter, PeriZone PerioPatch will be dispensed to subjects per randomization for administration over the trial period. Subjects will apply study patches (i.e., BID on Days 1, 28 and 42; QD on Days 2-6; Days 14-20, 29-30 and 43-44) to designated treatment sites (i.e., measuring 6 mm or more in pocket depth at Baseline)."
3112157|NCT01808703|Active Comparator|Scaling and root planing alone|Subjects in this group will receive only scaling and root planing (full mouth during no more than 2 sessions within two weeks following the Baseline exam).
3112199|NCT01808430||VATS for NSCLC patients|VATS for confirmed non-small cell lung cancer (NSCLC)
3112159|NCT01808690|Placebo Comparator|Placebo|Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.
3112160|NCT01808677||Thoracic Reirradiation Registry|Data collection on patients being treated with thoracic reirradiation with PBT or IMRT for NSCLC, with or without chemotherapy.
3112161|NCT01808664|Experimental|Standardized Patient Instructor Intervention|"Primary care physicians (PCPs) randomized to intervention will receive over a three month run-in period two visits by standardized patient instructors portraying: 1) a 48 year-old patient with low back pain for less than six-weeks and no red flags for immediate spinal imaging; and 2) a 50 year-old recently menopausal woman establishing care with concerns about osteoporosis risk."
3112162|NCT01808664|Active Comparator|Control|"In the latter half of visits with control PCPs, standardized patient instructors (SPIs) will share information regarding low back pain or bone health that are unrelated to diagnostic testing, but will not discuss patient-centered techniques or conduct training. The total duration of the control information sharing will be about one-third the SPI intervention to enhance patient-centeredness."
3112163|NCT01808651|Experimental|Fluoxetine|Flexible dosing of 20 to 40 milligrams (mg) administered orally, once daily, for approximately 52 weeks
3112164|NCT01808638|Other|Lead in safety period|Cohort of three subjects with non-pancreatic cancer for whom conventional treatment options have failed, will be treated. If one of the subjects in the safety cohort experiences an unacceptable toxicity, the safety cohort is expanded to six subjects.
3112165|NCT01808638|Experimental|Treatment arm 1|Subjects with advanced pancreatic cancer will be treated.
3112166|NCT01808638|Experimental|Treatment arm 2|Subjects with advanced pancreatic cancer will be treated.
3112167|NCT01808625|Other|HYPERBARIC OXYGEN STIMULATION|30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 atmospheres absolute(ATA).
3112168|NCT01808612|Experimental|20 mg Fluoxetine|20 milligrams (mg) fluoxetine (capsules) administered orally, once daily, for 6 weeks
3112169|NCT01808612|Experimental|40 mg Fluoxetine|40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks
3112170|NCT01808612|Placebo Comparator|Placebo|Placebo (capsules) administered orally, once daily, for 6 weeks
3112171|NCT01808599|Experimental|Chlorambucil, Rituximab i.v., Rituximab s.c.|"Chlorambucil 6 mg/m2 daily p.o for 42 consecutive days (weeks 1-6) in combination with intravenous Rituximab 375mg/m2 on days 1, 8, 15 and 22 (day 1 of weeks 1, 2, 3 and 4).~Starting from d56, (month 3) patients will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days (d1-14) every 28 days for 4 cycles in combination with subcutaneous Rituximab 1400mg on day 1 of each 28-day cycle. Therefore subcutaneous Rituximab 1400mg every two months for 2 years (in total 12 injections)."
3112172|NCT01808586|Experimental|Dexamethasone|Intra-articular corticosteroid number 2.
3112173|NCT01808586|Experimental|Betamethasone|Subjects will receive either betamethasone or dexamethasone injected into the cervical facet joints (levels determined by experienced physician).
3112174|NCT01808586|Active Comparator|Intramuscular injection|Subjects in this group will receive lidocaine injection directly into tender myofascial trigger points.
3112175|NCT01808586|Active Comparator|Home exercise|Subjects in this group will receive education and a pamphlet on a set of standardized home exercises for neck pain
3112176|NCT01808573|Experimental|neratinib plus capecitabine|
3112177|NCT01808573|Active Comparator|lapatinib plus capecitabine|
3112178|NCT01808560|Experimental|LipiFlow Pre-treatment|Subjects randomized to the LipiFlow Pre-Treatment group receive a 12-minute LipiFlow System treatment for MGD in both eyes one month prior to cataract surgery.
3112179|NCT01808560|No Intervention|Untreated Control|Subjects randomized to the untreated control group receive no MGD treatment prior to cataract surgery.
3112180|NCT01808560|Experimental|LipiFlow Post-treatment|Subjects in the untreated control group receive a 12-minute crossover treatment with the LipiFlow System in both eyes three months after cataract surgery.
3112181|NCT01808547|Experimental|ISV-303|
3112182|NCT01808547|Placebo Comparator|Durasite Vehicle|
3112183|NCT01808534|Experimental|Treatment (palifosfamide)|Patients receive palifosfamide IV over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3112184|NCT01808521|Experimental|N-acetylcysteine|IV administration of N-acetylcysteine (Acetadote) at 150mg/Kg loading bolus over 60 minutes followed by 150mg/Kg over 17 hours if loading dose was well tolerated.
3112185|NCT01808508|Active Comparator|Group 1- Continuous positive airway pressure (CPAP)|Group 1 will receive therapeutic CPAP for 4 months.
3112186|NCT01808508|Placebo Comparator|Group 2-Sham Continuous positive airway pressure (CPAP)|Group 2 are individuals with OSAS who will receive sham or placebo continuous positive airway pressure (CPAP) for 4 months.
3112187|NCT01808508|No Intervention|Group 3- No Intervention|Group 3 are individuals with normal breathing during sleep who will not receive any intervention and will be used as a control group.
3112188|NCT01808482|Experimental|Part A: GSK2618960|Subjects will receive ascending single dose in 3:1 ratio of active:placebo respectively in each dosing session.
3112189|NCT01808482|Placebo Comparator|Part A: Placebo|Subjects will receive ascending single dose in 3:1 ratio of active:placebo respectively in each dosing session
3112190|NCT01808482|Experimental|Part B: GSK2618960|Subjects will receive ascending repeat dose (dose decided from Part A) in 3:1 ratio of active:placebo respectively in each cohort.
3112191|NCT01808482|Placebo Comparator|Part B: Placebo|Subjects will receive ascending repeat dose (dose decided from Part A) in 3:1 ratio of active:placebo respectively in each cohort.
3112192|NCT01808482|Experimental|Part C: GSK2618960|Subjects will receive active treatments for 2 to 4 repeated doses (dose decided from Part A& B)
3112193|NCT01808469|Experimental|NI-0101|NI-0101 is an anti-Toll-like receptor monoclonal antibody.
3112194|NCT01808469|Placebo Comparator|Placebo|The placebo to be used for the proposed clinical trial is a sterile solution for intravenous infusion. The placebo is identical to the NI-0101 drug product but does not include the active substance.
3112195|NCT01808456|Experimental|High Dose Flu Vaccine|influenza trivalent inactive vaccine high dose. IM (intramuscular) injection one time administration
3112196|NCT01808456|Active Comparator|Flu Vaccine|influenza trivalent inactive vaccine IM injection one time administration
3112197|NCT01808443|Active Comparator|Cryotherapy|Cryotherapy, at most 4 times
3112200|NCT01808417|Experimental|Near Infrared Imaging|The intervention to be administered is the indocyanine green for NIR Lymphatic Mapping. All study subjects will receive this same intervention; there is only one arm.
3112201|NCT01808404|Experimental|Web-Based Guided Self-Help|The study is an open trial and all participants will be assigned to the same intervention arm.
3112202|NCT01808391||Clinical Follow-up Cohort|The clinical FU cohort comprises among patients who underwent clinical FU at 9, 12, and 24 months after index PCI those who arbitrarily underwent angiographic FU at 22 months (±60 days) after index PCI and those who did not undergo angiographic follow-up at all during the entire study period.
3112203|NCT01808391||Routine Angiographic Follow-up Cohort|The routine angiographic FU cohort comprises patients who underwent clinical FU at 9, 12, and 24 months after index PCI those who undergo angiographic FU at 10 months (±60 days) after index PCI.
3112204|NCT01808378|Experimental|Autologous Stem Cells|Autologous expanded adipose-derived stem cells
3112205|NCT01808365||Study cohort|
3112206|NCT01808352|Other|Daily PrEP + coordination of client centered svs|All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
3112207|NCT01808339|Experimental|FF AM dose|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects will receive FF 100 mcg in the morning (approximately 09:00) and placebo in the evening (approximately 21:00) for 14 days (+/- 2 days).
3112208|NCT01808339|Experimental|FF PM dose|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects will receive FF 100 mcg in the evening (approximately 21:00) and placebo in the morning (approximately 09:00) for 14 days (+/-2 days).
3112209|NCT01808339|Placebo Comparator|Placebo|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects in this arm will receive Placebo in the evening and morning (at approximately 09:00 and 21:00) for 14 days (+/- 2 days).
3112210|NCT01808326|Experimental|chlorambucil|chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
3112211|NCT01808313|Experimental|ambrisentan|ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
3112212|NCT01808300|Experimental|A-B-C|Drug will be administered to according to A-B-C sequence for 3 period.
3112213|NCT01808300|Experimental|A-C-B|Drug will be administered to according to A-C-B sequence for 3 period.
3112214|NCT01808300|Experimental|B-C-A|Drug will be administered to according to B-C-A sequence for 3 period.
3112215|NCT01808300|Experimental|B-A-C|Drug will be administered to according to B-A-C sequence for 3 period.
3112216|NCT01808300|Experimental|C-A-B|Drug will be administered to according to C-A-B sequence for 3 period.
3112217|NCT01808300|Experimental|C-B-A|Drug will be administered to according to C-B-A sequence for 3 period.
3112218|NCT01808287|Experimental|High risk population|SAPIEN 3 transcatheter heart valve was implanted in high risk patients
3112219|NCT01808287|Experimental|Intermediate risk population|SAPIEN 3 transcatheter heart valve was implanted in intermediate risk patients
3112220|NCT01808274|Experimental|TAVR|with CENTERA self-expanding valve
3112221|NCT01808261|Placebo Comparator|Placebo|Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
3112222|NCT01808261|Active Comparator|GSK249320 100/mg|Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
3112223|NCT01808248|Experimental|SOF+PEG+RBV|Participants will receive SOF+PEG+RBV for 12 weeks.
3112224|NCT01808235|Experimental|Oral health intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
3112225|NCT01808222|Experimental|FACBC|The patient will then receive a bolus of anti-[18F]FACBC injected IV over 1-2 minutes. The dosage will be approximately 10.0 mCi (3.70 x 108 Bq).
3112226|NCT01808209|Experimental|stenfilcon A|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
3112227|NCT01808209|Active Comparator|filcon II 3|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
3112228|NCT01808196|Experimental|EoE Only|Approximately 10 participants with EoE without a CTD will be enrolled, all of whom will receive the Losartan intervention.
3112229|NCT01808196|Experimental|EoE and CTD|Approximately 5 participants with EoE and CTD will be enrolled, all of whom will receive the Losartan intervention.
3112230|NCT01808183||supracondylar humerus fractures|All members of the study will have near Infrared spectroscopy pads placed on their injured and uninjured arms as a part of this study.
3112231|NCT01808170|Active Comparator|laparoscopic ovarian cystectomy|laparoscopic ovarian cystectomy will be performed on proliferative phase of menstrual cycle.Anti-mullerian hormone level measurement and estimation of antral follicle count will be done before surgery and will be repeated one month after surgery.
3112232|NCT01808170|Active Comparator|laparoscopic cyst deroofing|laparoscopic cyst deroofing will be performed on proliferative phase of menstrual cycle.Anti-mullerian hormone level measurement and estimation of antral follicle count will be done before surgery and will be repeated one month after surgery.
3112233|NCT01808157|Experimental|0.05% w/w CT327 ointment|Active
3112234|NCT01808157|Experimental|0.5% w/w CT327 ointment|Active
3112236|NCT01808144|Experimental|lesinurad 400 mg + febuxostat 80 mg|Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after implementation of protocol amendment 3, dated 07 October 2015.
3112237|NCT01808144|Experimental|lesinurad 200 mg + febuxostat 80 mg|
3112238|NCT01808131|Experimental|lesinurad 200 mg + allopurinol|
3112239|NCT01808131|Experimental|lesinurad 400 mg + allopurinol|Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after implementation of protocol amendment 4, dated 07 October 2015.
3112240|NCT01808118|Experimental|Double-Blind Adalimumab|40 mg every other week (eow), Weeks 28-68. Blinded adalimumab was discontinued in participants who met the criteria for flare.
3112241|NCT01808118|Experimental|Open-label (OL) Adalimumab|40 mg every other week (eow), Weeks 0-28. If participants flared during the double-blind period, they had an opportunity to receive at least 12 weeks of open-label adalimumab 40 mg eow.
3112242|NCT01808118|Placebo Comparator|Placebo|Placebo every other week (eow), Weeks 28-68. Placebo was discontinued in participants who met the criteria for flare.
3112243|NCT01808105|Other|Human Milk|Reference group, breast feeding ad libitum
3112244|NCT01808105|Active Comparator|Control Formula|Ready to feed infant formula, feed ad libitum
3112245|NCT01808105|Experimental|Experimental Formula 1|Ready to feed infant formula with human milk oligosaccharides, feed ad libitum
3112246|NCT01808105|Experimental|Experimental Formula 2|Ready to feed infant formula with human milk oligosaccharides, feed ad libitum
3112247|NCT01808092|Experimental|CAZ-AVI|Intra-Venous treatment
3112248|NCT01808092|Active Comparator|Meropenem|Intra-Venous treatment
3112249|NCT01808079||Ancillary-correlative (genetic markers of Wilms tumor)|Samples are analyzed for SNP profiling using real-time PCR and MLPA.
3112250|NCT01808066|Experimental|Play Groundskeeper|This study will employ design-based research models (Laurel, 2003) to the executive-functioning training game GroundsKeeper by CogCubed; we will assess the quality of digital designs for learning (Barab & Squire, 2004) using established qualitative data collection to analyze game play and player reaction over a three week period of time. We will assess the participants for their ability to stay engaged in play by observing their engagement in the game, time played, frequency of play, and the ability to complete a session over the course of three weeks while in school.
3112251|NCT01808053||Healthy older and independently living adults|The BodyGuardian remote health monitoring system will used by healthy older and independently living adults
3112252|NCT01808040|Experimental|1|"Tak700 (orteronel) dose escalation schedule:~1a 200 mg PO BID TAK700~1b 200mg PO BID TAK + glucocorticoid~1a 300mg PO BID TAK700 starting dose~1b 300 mg po BID + glucocorticoid 2a 400mg PO BID TAK700 2b 400 mg po BID + glucocorticoid"
3112253|NCT01808027||Acute myocardial infarction|patient with suspected acute coronary syndrome (ACS).
3112254|NCT01808014|Experimental|The addition of Nefopam|The addition of Nefopam for intravenous patient-controlled analgesia in patients with lumbar spinal surgery would reduce the side effects seen in monotherapy with opioid analgesia and result in effective pain management.
3112255|NCT01807988|Experimental|iCBT|Internetbased cognitive behavior therapy (iCBT) aimed att preventing relapse into major depression.
3112256|NCT01807988|No Intervention|Control group|The control group in the study will fill out questionnaires every month and will be interviewed every month to detect any relapses. They will also receive feedback on there self-reported symptoms.
3112257|NCT01807975|Experimental|post allogreffe patients|Functional evaluation of distal airway by forced oscillation technique : relevance earlier diagnostic of pulmonary syndrom of oblitérant bronchiolit in post allogreffe patients
3112258|NCT01807962|Active Comparator|rapidocain and bethametsaone|"Rapidocain and Bethametsaone :~Lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine Bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de bétaméthasone and 2mg/ml phosphate disodique de bétaméthasone)"
3112259|NCT01807962|Placebo Comparator|sterile saline|Placebo arm with 5ml of sterile saline (NaCl) solution
3112260|NCT01807949|Placebo Comparator|Placebo|Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.
3112261|NCT01807949|Experimental|LUM 600 mg qd/IVA 250 mg q12h|LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.
3112262|NCT01807949|Experimental|LUM 400 mg q12h/ IVA 250 mg q12h|LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.
3112263|NCT01807936|Experimental|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field lymphadenectomy
3112264|NCT01807936|No Intervention|Two -field lymphadenectomy|Thoracic-upper abdominal two -field lymphadenectomy
3112265|NCT01807923|Placebo Comparator|Placebo|Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.
3112266|NCT01807923|Experimental|LUM 600 mg qd/IVA 250 mg q12h|LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.
3112267|NCT01807923|Experimental|LUM 400 mg q12h/ IVA 250 mg q12h|LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.
3112268|NCT01807910|Experimental|Fructose|Participants will receive fructose (3g/kg/day) for 2 weeks.
3112269|NCT01807910|Active Comparator|Glucose|Participants will receive glucose (3g/kg/day) for 2 weeks.
3112270|NCT01807897|Experimental|CPAP|Nocturnal continuous positive airway pressure
3112271|NCT01807897|Experimental|NSO|Nocturnal supplemental oxygen
3112272|NCT01807897|Other|HLSE|Healthy lifestyle and sleep education control
3112273|NCT01807884|Experimental|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
3112274|NCT01807884|Placebo Comparator|Routine oral care|Oral suction followed by mouth care and tracheal suction
3112275|NCT01807871|Experimental|nicotine patch, experimental use|Participants will continue to use nicotine patch after they lapse and resume smoking as long as smoking is less than 75% of pre study levels.
3112276|NCT01807871|Active Comparator|nicotine patch, labeled use|Participants will discontinue using the nicotine patch when they resume smoking. This is the current FDA approved use of the nicotine patches.
3112280|NCT01807858|Active Comparator|Bifidobacterium lactis plus İnülin|5 billion active Bifidobacterium lactis plus 900 mg İnülin per day
3112281|NCT01807845|Active Comparator|Skimmilk VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80;
3112282|NCT01807845|Placebo Comparator|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk.
3112283|NCT01807845|Active Comparator|enriched skimmilk with VD|enriched skimmilk with VD
3112284|NCT01807832|Other|chronic cough|Capsaicine challenge in chronic cough patients
3112285|NCT01807819||Heart Failure|Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
3112286|NCT01807806|Experimental|Role-playing game|All eligible participants were invited to play the role playing game
3112287|NCT01807793|Active Comparator|Psychoeducation|Psychoeducation will include attending individual and group sessions.
3112288|NCT01807793|No Intervention|Care as usual|Receive care as usual
3112289|NCT01807780|Other|single arm :vaccinated|military personnel vaccinated with multiple vaccines and monitored about safety, immunogenicity and efficacy
3112290|NCT01807767|Experimental|Everolimus, Myfortic and Tacrolimus|"Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID"
3112291|NCT01807767|Other|Myfortic and Tacrolimus|Normal Care: Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
3112292|NCT01807754||Imaging scans for breast cancer screening|"To simulate the performance of the combination of three new breast imaging systems to digital mammography and hand-held ultrasound that are currently used to find and evaluate breast masses.~These three different systems make images of the breast in several ways to find breast masses and to distinguish normal and abnormal masses. This may result in less unnecessary call-backs from mammography."
3112293|NCT01807741|Experimental|Asenapine Group|Asenapine will be given beginning on day 0 at 5 mg bid. Dose will be increased to 10 mg bid if there is less than 50% decrease in MADRS score by week 2. Dose increases may be held if clinically indicated. Doses may be decreased at any time, if clinically indicated, by increments of 5 mg/day to a minimum of 5 mg qHS. Daily treatment with asenapine will be for 8 weeks.
3112294|NCT01807741|Active Comparator|Placebo Group|Sublingual tablets similar to the asenapine tablets.
3112295|NCT01807728|Experimental|Group 1 Training Program|
3112296|NCT01807728|Experimental|Group 2 Training Program|
3112297|NCT01807715||Study group|Women seeking first trimester surgical abortion
3112298|NCT01807702|Experimental|13C-pyruvate,13C-Lactate and dichloroacetate|During the first day of the subjects participation pyruvate will be given and blood, breath and buccal cell samples will be collected over a two hour period. On the last day DCA will be given.
3112299|NCT01807676|Active Comparator|ET View Double Lumen Tube|Patients assigned to the thisgroup will be intubated using the VivaSight-DL.
3112300|NCT01807676|Active Comparator|conventional Double Lumen Tube|Patients assigned to the first group will be intubated using conventional DLT (Bronchocath, left sided; Rüsch, Kernen, Germany).
3112301|NCT01807663|Experimental|healthy volunteers|Free breath monitoring. Correlation between two device for recording parameters of ventilation.
3112302|NCT01807663|Experimental|Chronic patient|Free breath monitoring. Number of pathological respiratory events (apneas, hypopneas, paradoxical breath) compared with the recording of the PtCO2 and the SpO2)
3112303|NCT01807663|Experimental|ACUTE PATIENT|Free breath monitoring. Number of pathological respiratory events (apneas, hypopneas, paradoxical breath) compared with the recording of the PtCO2 and the SpO2)
3112304|NCT01807650|Experimental|Oleogel-S10, non-adhesive wound dressing|A split-thickness skin graft (STSG) donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to Oleogel-S10 treatment and non-adhesive wound dressing (intra-individual comparison). Oleogel-S10 was administered (1 cm or 100 mg per cm2 wound area corresponding to thickness of about 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
3112305|NCT01807650|Other|Non-adhesive wound dressing only|A STSG donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days.
3112306|NCT01807637|Experimental|transcranial direct current stim|tDCS will be applied using a Life-Tech®, Iontophor PM Deluxe constant current stimulator with carbon rubber electrodes encased in saline (0.9% NaCl) soaked sponges that measure 5 x 5 cm (25cm2) for the anode and 5x7 for the cathode (35cm2). The anodal electrode will be placed over the lower extremity representation of primary motor cortex of the lesioned hemisphere. The cathodal electrode will be placed over the contralateral supraorbital region.
3112307|NCT01807637|Placebo Comparator|sham tDCS|Sham stimulation will be performed by turning the stimulator off after the initial sensory experience (30 seconds).
3112308|NCT01807624|Experimental|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
3112309|NCT01807611|Experimental|Transplant Recipients|"Participants undergo a preparative regimen of total lymphoid irradiation, fludarabine, cyclophosphamide, fludarabine, thiotepa, melphalan, and mycophenolate mofetil, followed by HPC,A infusion and TC-NK infusion. They also receive G-CSF and mesna.~Cells for infusion are prepared using the CliniMACS System."
3112310|NCT01807598|Experimental|Brentuximab vedotin|Subjects receive a 30-minute IV infusion of brentuximab vedotin once every 21 days for 8 courses, in the absence of disease progression or unacceptable toxicity.
3112311|NCT01807585|Experimental|VenaSeal SCS|Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA.
3112312|NCT01807585|Active Comparator|RFA (ClosureFast)|Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV). Heat is applied to the target vein using radiofrequency energy to ablate the target vein. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or RFA.
3112347|NCT01807299|Other|Sedentary|The sedentary group will be oriented not to make any type of physical training for three months.
3112313|NCT01807585|Experimental|Roll-in (VenaSeal SCS)|Prior to initiation of the randomized cohort at each site, a non-randomized cohort of 2 subjects per clinical site (roll-in phase) were enrolled and treated with VenalSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.
3112314|NCT01807572||obesity risk status|Lean adolescents at high-risk for obesity, by virtue of parental obesity, and lean adolescents at low-risk for obesity, by virtue of lean parents.
3112315|NCT01807546|Experimental|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
3112316|NCT01807533|Experimental|Family-centered intervention program|FCIP: family members were encouraged to present in all intervention sessions included 5 in-hospital intervention, 7 after-discharge interventions (0, 1, 2, 4, 6, 9, and 12 months of corrected age), and neonatal follow-up at 0, 1, 6, 12, 18, and 24 months of corrected age.
3112317|NCT01807533|Other|Usual care intervention program|UCP: family members were invited to present at least one session of the 5 in-hospital intervention session. Parents and infants in the UCP group received 7 after-discharge phone calls (0, 1, 2, 4, 6, 9, and 12 months of corrected age) and neonatal follow-up at 0, 1, 6, 12, 18, and 24 months of corrected age.
3112318|NCT01807520|Experimental|Secukinumab (AIN457) 150 mg|Participants assigned to secukinumab 150 mg were dosed weekly for five weeks, then once every four weeks up to and including Week 132. To maintain the blinding, patients received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment are administered by sub-cutaneous injections.
3112319|NCT01807520|Experimental|Secukinumab (AIN457) 300 mg|Participants assigned to secukinumab 300 mg were dosed weekly for five weeks, then once every four weeks up to and including Week 132. To maintain the blinding, patients received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment are administered by sub-cutaneous injections.
3112320|NCT01807520|Placebo Comparator|Placebo|Patients assigned to placebo were dosed weekly for five weeks, then at Week 8 and Week 12. At Week 16, placebo patients were randomized in a 1:1 ratio, to receive secukinumab either 150 mg or 300 mg and were dosed weekly for five weeks starting at Week 16, then once every four weeks up to and including Week 132. All doses of study treatment are administered by sub-cutaneous injections.
3112321|NCT01807507||Healthy Volunteers|
3112322|NCT01807494|Active Comparator|Posterior approach|Subjects in this group will total hip replacement performed with a posterior surgical approach and total hip replacement components.
3112323|NCT01807494|Active Comparator|Anterior Approach|Subjects in this group will have total hip replacement performed with a direct anterior surgical approach and total hip replacement components.
3112324|NCT01807481|Experimental|Mircera Arm|Once Monthly Mircera
3112325|NCT01807468|Experimental|HaploSC+NK|
3112326|NCT01807455|Experimental|Restylane Vital Lidocaine|
3112327|NCT01807442|Other|Optimal adherence|"Participants receive the qualitative interview and adherence intervention.~This arm includes participants with scores of greater than or equal to 15 on the Medical Outcomes Study Specific Adherence Scale. This scale ranges from a score of 3 (extremely low adherence to health behaviors) to a score of 18 (extremely high adherence to health behaviors). A score of greater than or equal to 15 suggests optimal adherence to health behaviors."
3112328|NCT01807442|Other|Sub-optimal adherence|"Participants receive the qualitative interview and adherence intervention.~This arm includes participants with scores of less than 15 on the Medical Outcomes Study Specific Adherence Scale. This scale ranges from a score of 3 (extremely low adherence to health behaviors) to a score of 18 (extremely high adherence to health behaviors). A score of less than 15 suggests sub-optimal adherence to health behaviors."
3112329|NCT01807429|Experimental|Ketamine-midazolam|300 to 500 mcg/kg ketamine plus 0.03 mg/kg midazolam
3112330|NCT01807429|Active Comparator|Morphine|0.05 to 0.1 mg/kg morphine
3112331|NCT01807416|Active Comparator|standard platform , standard abutment|implant insertion and abutment connection Osseointegrated implants with regular collar connected to standard designed prosthetic abutments
3112332|NCT01807416|Active Comparator|standard platform, flat abutment|implant insertion and abutment connection Osseointegrated implants with regular collar connected to flat designed prosthetic abutments
3112333|NCT01807416|Active Comparator|switching platform, standard abutment|implant insertion and abutment connection Osseointegrated implants with switched platform collar connected to standard designed prosthetic abutments
3112334|NCT01807416|Active Comparator|switching platform, flat abutment|implant insertion and abutment connection Osseointegrated implants with switched platform collar connected to flat designed prosthetic abutments
3112335|NCT01807403|Experimental|Deep brain stimulation of subthalamic nucleus|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.Stimulation of subthalamic nucleus
3112336|NCT01807403|Experimental|Deep brain stimulation of caudate nucleus|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker. Caudate nucleus stimulation
3112337|NCT01807403|Experimental|Deep brain stimulation of nucleus accumbens|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.Nucleus accumbens stimulation.
3112338|NCT01807377|Experimental|PF-05175157, Midazolam|Day 0: Midazolam 2 mg administered alone Days 1-14: 200 mg PF-05175157 administered BID Day 11: Midazolam and PF-05175157
3112339|NCT01807377|Experimental|Placebo, Midazolam|Day 0: Midazolam 2 mg administered alone Days 1-14: Placebo administered BID Day 11: Midazolam and Placebo
3112340|NCT01807364||Congenital adrenal hyperplasia|Patients > 18 yrs with classical or non classical CAH diagnosed during childhood
3112341|NCT01807364||controls|control patients
3112342|NCT01807338||saline|Saline administration to patients with idiopathic Parkinson's disease (PD) of moderate severity, who have previously been treated with sNN0031
3112343|NCT01807325||pancreas cysts and solid masses|patents referred for solid and cystic lesions of the pancreas who will have a biopsy for usual medical care.
3112344|NCT01807312|Experimental|CO2 insufflation|CO2 insufflations was applicated in routine colonoscopy examination with Endoscopic CO2 regulation unit and accessories
3112345|NCT01807312|Placebo Comparator|Air insufflation|Air insufflations is applicated in Routine Colonoscopy Examination
3112346|NCT01807299|Experimental|Physical Training|The training group will make physical exercise for three months (three times a week).
3112348|NCT01807299|Placebo Comparator|Placebo|The omega 3 group will receive 2g per day of mineral oil during 90 days treatment
3112349|NCT01807299|Experimental|Omega 3|The omega 3 group will receive 2g per day of fish oil during 90 days treatment
3112350|NCT01807286|Experimental|Pomalidomide + Melphalan + Dexamethasone|Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21. Melphalan 9 mg/m2 by mouth on days 1-4 of every 28-day cycle. Dexamethasone 40 mg/day by mouth on days 1-4. Questionnaires completed at different time points during study.
3112351|NCT01807273||Hemiplegic subjects|60 hemiplegic outpatients walking test
3112352|NCT01807260|Active Comparator|conventional Shock wave lithotripsy group|All procedures were performed under continu¬ous intravenous sedo-analgesia (using a combi-nation of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiply¬ing the largest length and width of the individual stones measured from the abdominal plain X-ray.
3112353|NCT01807260|Active Comparator|stepwise Shock wave lithotripsy group|All procedures were performed under continu¬ous intravenous sedo-analgesia (using a combi-nation of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave number was limited to a maximum of 3000 waves/session. In the stepwise group, the voltage was started at 10 kV and increased stepwise (every 250 shock waves) to 13 kV. The stone burden was defined as the stone area that was calculated by multiply¬ing the largest length and width of the individual stones measured from the abdominal plain X-ray.
3112354|NCT01807247||Hemiparetic|Intensive lower limbs muscles strengthening
3112355|NCT01807247||Spinal cord injury|Intensive lower limbs muscles strengthening
3112356|NCT01807247||Multiple sclerosis|Intensive lower limbs muscles strengthening
3112357|NCT01807234|Experimental|Ketorolac/Placebo|Ketorolac 31.5 mg single dose nasal spray and Placebo
3112358|NCT01807234|Experimental|Sumatriptan/Placebo|Sumatriptan 20 mg single dose nasal spray and placebo
3112359|NCT01807234|Placebo Comparator|Ketorolac Placebo/Sumatriptan placebo|single dose Ketorolac placebo, single dose Sumatriptan placebo
3112360|NCT01807221|Experimental|Finerenone(BAY94-8862)[2.5mg] + Placebo|Oral - 2.5mg once daily (OD) for 30 days. Potential up-titration to 5mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
3112361|NCT01807221|Experimental|Finerenone (BAY94-8862)[5mg] + Placebo|Oral - 5mg OD for 30 days. Potential up-titration to 10 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
3112362|NCT01807221|Experimental|Finerenone (BAY94-8862)[7.5mg] + Placebo|Oral - 7.5mg OD for 30 days. Potential up-titration to 15 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
3112363|NCT01807221|Experimental|Finerenone (BAY94-8862)[10mg] + Placebo|Oral - 10mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
3112364|NCT01807221|Experimental|Finerenone (BAY94-8862)[15mg] + Placebo|Oral - 15mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
3112365|NCT01807221|Active Comparator|Eplerenone [25 mg] + Placebo|Oral - 25mg every other day (EOD). Potential up-titration to 25mg OD after 30 days and 50mg OD after 60 days.Placebo OD for 90 days.
3112366|NCT01807208|Experimental|Educational tool|Patients randomized to the educational tool arm of the study will receive mailed educational materials at 1 week post hospital discharge and again at 3 months after discharge.
3112367|NCT01807208|No Intervention|Usual care|Patients in this arm of the study will receive usual care.
3112368|NCT01807195||the medical records of those in whom a contrast medium|
3112369|NCT01807182|Experimental|Treatment (TIL, combination chemotherapy, aldesleukin)|Patients receive cyclophosphamide IV on days -7 to -6 and fludarabine phosphate IV on days -5 to -1. Patients undergo TIL infusion over 30-60 minutes on day 0 and receive aldesleukin IV every 8 hours on days 1-5 for up to a maximum of 14 doses.
3112370|NCT01807169|Experimental|Colonic polypectomy or endoscopic mucosal resection|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
3112371|NCT01807156|Experimental|Tivozanib|Patients would receive Tivozanib 1.0 mg/day orally, 3 weeks on, one week off, for one cycle starting day 1. If no adverse event is encountered, patients will continue subsequent cycles of Tivozanib 1.5 mg/day orally; 3 weeks on/1 week off, dosing schedule. Patients will continue on treatment until disease progression, unacceptable toxicity, or patient withdrawal from the study.
3112372|NCT01807143||Correlative studies|Tissue samples are analyzed for translocations and deletions and analyzed using PCR or FISH.
3112373|NCT01807130|Placebo Comparator|Registry|Patients randomized to the registry arm will be followed per usual standard of care by their primary providers. Those providers may refer to subspecialty HF or electrophysiology care as they see fit.
3112374|NCT01807130|Experimental|Intervention|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology with recommendations to consider those therapies that are not in compliance with guidelines.
3112375|NCT01807117|Experimental|Diagnostic (PET-CT and PET-MRI)|Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
3112376|NCT01807104|Active Comparator|Anterior Approach Total Hip|Total hip arthroplasty performed through an anterior surgical approach. Compare results of total hip arthroplasty performed through either an Anterior or Posterior Surgical Approach
3112377|NCT01807104|Active Comparator|Posterior Approach Total Hip|The additional arm is the posterior approach total hip, which the Anterior Approach is being compared too. Compare results of total hip arthroplasty performed through either an Anterior or Posterior Surgical Approach.
3112378|NCT01807091|Experimental|Treatment (chemotherapy)|Patients receive outpatient induction chemotherapy.
3112379|NCT01807078|Active Comparator|Ezetimibe|Patients will receive for 6 months ezetimibe (10 mg/day)
3112380|NCT01807078|Active Comparator|Nutraceuticals|Patients will receive for 6 months a commercially available nutraceutical combined pill (1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
3112381|NCT01807065|Experimental|Arm A (sipuleucel-T)|Patients receive sipuleucel-T IV over 60 minutes days 22, 36, and 50.
3112382|NCT01807065|Experimental|Arm B (radiation therapy, sipuleucel-T)|Patients undergo external beam radiation therapy in weeks 1-2. Patients also receive sipuleucel-T as in Arm A.
3112383|NCT01807052||Observational|Tissue samples are analyzed for tumor factor expression levels by immunohistochemistry.
3112384|NCT01807039||patients after surgery with isolated proximal femur fracture|Patients between 18-110 years admitted to Faculty Hospital Brno with isolated injury of proximal femur (ICD dg. S72.0 a S72.1)who underwent surgery between 1.1. 2011 00:00 - 31.12. 2012 23:59 in Faculty hospital Brno (tertiary care university hospital).
3112385|NCT01807026|Experimental|Cohort A - LY2886721|Alzheimer's disease (AD) participants will receive a 70 mg single oral dose of LY2886721.
3112386|NCT01807026|Placebo Comparator|Cohort A - Placebo|AD participants will receive a single oral dose of placebo.
3112387|NCT01807026|Experimental|Cohort B - LY2886721|Healthy participants will receive a single 70 mg oral dose of LY2886721.
3112388|NCT01807026|Placebo Comparator|Cohort B - Placebo|Healthy participants will receive a single oral dose of placebo.
3112389|NCT01807026|Experimental|Cohort C - LY2886721|Healthy participants will receive a single oral ascending dose of LY2886721 in at least 2 of 3 study periods.
3112390|NCT01807026|Placebo Comparator|Cohort C - Placebo|Healthy participants will receive a single oral dose of placebo in up to 1 of 3 study periods.
3112391|NCT01807000|Experimental|Radiolabeled Prucalopride Succinate|
3112392|NCT01806987|Experimental|KITS Program|The KITS Program consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
3112393|NCT01806987|No Intervention|Services as usual|These include any services that the child and family might already be receiving in the community.
3112394|NCT01806974|Other|patient with parodontitis|Patient with rheumatoid arthritis and pparodontitis.
3112395|NCT01806974|Other|Patient without parodontitis|Patient with rheumatoid arthritis but periodontally healthy
3112396|NCT01806961||clearance at end of trial SP848-AK-1101|no trial medication during this follow-up trial
3112397|NCT01806948|Placebo Comparator|Control|Single dose of antiemetics. Specifically, Ramosetron 0.3 mg will be intravenously injected when surgery is ended. Additionally, placebo will be intravenously injected at 4 hours after surgery.
3112398|NCT01806948|Experimental|Experimental|Double dose of antiemetics. Specifically, Ramosetron 0.3 mg will be intravenously injected when surgery is ended. Additionally, Ramosetron 0.3 mg will be intravenously injected at 4 hours after surgery.
3112399|NCT01806935|Experimental|DC086|cream
3112400|NCT01806935|Placebo Comparator|placebo|
3112401|NCT01806922|Experimental|Yoga training, Tradiational physiotherapy|Experimental Group(20 people) receive tradiational physiotherapy(4 times in a week, every time 1 hour), and 8-weeks yoga training(2 time in a week, every time 1 hour)
3112402|NCT01806922|No Intervention|Tradiational physiotherapy|Control Group(20 people)only receive tradiational rehabiliation( 4 times in a week, every time 1 hour ) for 8 weeks.
3112403|NCT01806909|Other|Intranasal|Ad4-H5-VTN intranasal vaccine administered in cohorts of 3 at increasing dosages
3112404|NCT01806896|Experimental|20 mg Arm Cohort A|
3112405|NCT01806896|Placebo Comparator|Placebo Arm Cohort A|
3112406|NCT01806896|Experimental|5 mg Arm Cohort B|
3112407|NCT01806896|Placebo Comparator|Placebo Arm Cohort B|
3112408|NCT01806883|Experimental|Rehabilitation using Nintendo-Wii|30 patients will receive rehabilitation using Nintendo-Wii.
3112409|NCT01806883|Active Comparator|Traditional physiotherapy|30 patients will receive traditional physiotherapy.
3112410|NCT01806870|Experimental|Nutritional Supplements Zinc and SAMe|Each subject will receive 1600mg of SAMe per day Men subjects will receive 30mg Zinc Women subjects will receive 25mg Zinc
3112411|NCT01806857|Other|Nuedexta then Matching Placebo|Subjects in this arm will receive treatment with Nuedexta first for 28 days (±3 days) and then crossed over to receive treatment with matching placebo for 28 days (±3 days).
3112412|NCT01806857|Other|Matching Placebo then Nuedexta|Subjects in this arm will receive treatment with matching placebo first for 28 days (±3 days) and then crossed over to receive treatment with Nuedexta for 28 days (±3 days).
3112413|NCT01806818|Experimental|Eperisone 50mg BID|Administrate Eperisone 50mg tablet after the breakfast and dinner, and pacebo tablet after the lunch for 7 days
3112414|NCT01806818|Experimental|Epirisone 50mg TID|
3112415|NCT01806818|Placebo Comparator|Placebo comparator|
3112416|NCT01806805|Experimental|Zonegran|Zonegran / Placebo Zonisamide (Zonegran ®) and its placebo appear under the shape of virgin capsules of size 1. Each drug will be dispensed successively in a box containing blister packs of 14 capsules. For every period (A and B), box will contain 26 blister packs. A phase of progressive increase of doses by stages of 50 mg / week is planned before reaching the fixed dose of 300 in the daytime during 4 weeks. Then, a progressive diminution over two weeks is planned before the stop.
3112417|NCT01806805|Placebo Comparator|placebo|Placebo /Experimental Zonisamide (Zonegran ®) and its placebo appear under the shape of virgin capsules of size 1. Each drug will be dispensed successively in a box containing blister packs of 14 capsules. For every period (A and B), box will contain 26 blister packs. A phase of progressive increase of doses by stages of 50 mg / week is planned before reaching the fixed dose of 300 in the daytime during 4 weeks. Then, a progressive diminution over two weeks is planned before the stop.
3112418|NCT01806792|Experimental|Risendronate and Cholecalciferol combination|risedronate 150mg and cholecalciferol 30,000 IU 1 tablet + Placebo(for risedronate 150mg) 1 tablet by once a month.
3112419|NCT01806792|Active Comparator|Risedronate|risedronate 150mg 1 tablet + Placebo(for risedronate 150mg and cholecalciferol 30,000 IU) 1 tablet by once a month.
3112420|NCT01806779|Experimental|Chantix|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
3112421|NCT01806779|Experimental|Chantix + Zyban|For the first 3 days after being switched from NRT (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus Zyban at a dose of 150mg once per day. Subsequently, the dose of Chantix will be 1 mg twice per day and the dose of Zyban will be 150 mg twice per day for the remainder of the 12-week active treatment duration.
3112422|NCT01806766|Active Comparator|Ceramic on Ceramic|Ceramic on Ceramic bearing coupled side of a single patient undergoing bilateral total hip arthroplasty
3112423|NCT01806766|Active Comparator|Ceramic on HXPE|Ceramic on HIghly crosslinked polyethylene bearing coupled side of a single patient undergoing bilateral total hip arthroplasty
3112424|NCT01806753|Experimental|midazolam/propofol injection|Intermittent midazolam/propofol injection controlled by endoscopist
3112425|NCT01806753|Active Comparator|propofol infusion|Continuous propofol infusion with opioid administration
3112426|NCT01806740|Experimental|Meglumine Gadoterate|there is one single arm of patients (no comparative arm)
3112427|NCT01806727|Active Comparator|Diabetes Self Management (DSM)|Diabetes Self Management education, delivered in the clinics, using group-based visits and targeting improved control of hemoglobin A1c and related risk factors.
3112428|NCT01806727|Experimental|Community Lifestyle Weight Loss (LWL)|Participants with type 2 diabetes will be enrolled in a 12 month lifestyle intervention designed to achieve a mean >7% weight loss induced through caloric restriction and increased physical activity. The intervention will be delivered via supervised Community Health Workers (CHWs). Most meetings will be at a community location.
3112429|NCT01806714|Experimental|Text-based reminder for HPV vaccine/WCC|Parents of adolescents will receive text-based reminders if their adolescent is due for HPV vaccine (dose 1, 2 or 3) or well child care visit
3112430|NCT01806714|Active Comparator|Control arm|Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
3112431|NCT01806701|Experimental|Psychotherapy|Trauma-focused Cognitive Behavioral Therapy
3112432|NCT01806688|Experimental|Snack #1|gluten-free high protein snack
3112433|NCT01806688|Experimental|Snack #2|gluten-free high protein and high fibre snack
3112434|NCT01806688|Placebo Comparator|reference product #1|gluten-free snack with similar energy density, but 1/2 the protein as snack #1
3112435|NCT01806688|Placebo Comparator|reference product #2|gluten-free snack with similar energy density, but less protein and fibre than snack #2
3112436|NCT01806688|Placebo Comparator|non-caloric control #1|water
3112437|NCT01806688|Placebo Comparator|non-caloric control #2|water
3112438|NCT01806675|Experimental|Diagnostic (18F FPPRGD2 PET/CT or PET/MRI)|Patients undergo 18F FPPRGD2 PET/CT or PET/MRI imaging at baseline, 1 week, and 6 weeks (or standard of care follow-up) and 18F FDG PET/CT at baseline and 6 weeks (or standard of care follow-up) .
3112439|NCT01806662|Experimental|Treatment Arm (Ustekinumab first, Then Placebo)|Since there is a crossover design, each patient will be in the treatment arm for 16 weeks of the study.
3112440|NCT01806662|Placebo Comparator|Placebo Arm (Placebo first, Then Ustekinumab)|Since there is a crossover design, each patient will be in the placebo arm for 16 weeks of the study. If a patient begins in the placebo arm, they will switch over to the treatment arm at week 16.
3112441|NCT01806649|Experimental|BKM120|BKM120, starting at 100 mg oral once daily
3112442|NCT01806636||Treatment|Patients treated with PneumRx Coil System
3112443|NCT01806623|Experimental|Fluconazole|
3112444|NCT01806610|Experimental|BPS804|Single dose BPS804 administration.
3112445|NCT01806610|Placebo Comparator|Placebo|Single dose placebo administration.
3112446|NCT01806597|Experimental|secukinumab 150mg|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects assigned to secukinumab 150 mg were dosed weekly for the first five weeks, then every four weeks up to and including Week 128. To maintain blinding, subjects received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment were administered by sub-cutaneous injections.
3112447|NCT01806597|Experimental|secukinumab 300 mg|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects assigned to secukinumab 300 mg were dosed weekly for the first five weeks and then every four weeks up to and including Week 128. In order to maintain the blinding, subjects received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment were administered by sub-cutaneous injections.
3112448|NCT01806597|Placebo Comparator|Placebo|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects on placebo were dosed weekly for 5 weeks then once every 4 weeks. At Week 16, ppIGA responders continued to receive placebo weekly for 5 weeks starting at Week 16, then every 4 weeks up to and including Week 76 while ppIGA non-responders were randomized in a 1:1 ratio to secukinumab either 150 mg or 300mg weekly for 5 weeks, starting at Week 16, then every 4 weeks up to and including Week 128. At Week 80, subjects on placebo were either terminated their participation, if ppIGA responders, or randomized in a 1:1 ratio to secukinumab either 150 mg or 300 mg once every 4 weeks until Week 128 inclusive. All doses of study treatment were administered by sub-cutaneous injections.
3112449|NCT01806584|Active Comparator|SRM003|
3112450|NCT01806584|Other|Participating Site's standard practice|
3112451|NCT01806571|Experimental|Treatment (nilotinib, daunorubicin hydrochloride, cytarabine)|"INDUCTION THERAPY: Patients receive daunorubicin hydrochloride IV over 10 minutes on days 1-3, cytarabine IV continuously on days 1-7, and nilotinib PO BID on days 4-14. Patients achieving CR or CRi proceed to consolidation therapy. Patients not achieving a significant decrease in bone marrow recovery or CR/CRi upon bone marrow recovery receive another course of induction therapy.~CONSOLIDATION THERAPY: Patients receive cytarabine IV every 12 hours on days 1, 3, and 5, and nilotinib PO BID on days 4-14. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRi proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive nilotinib PO BID on days 1-84. Treatment repeats every 84 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
3112452|NCT01806558|Experimental|Women with lesion on MBI|Women with lesion on MBI
3112453|NCT01806545|Active Comparator|SRM003|One time implant (2 SRM003 pieces) on surgery day. Post-surgery, up to 26 weeks follow-up for assessment of efficacy/safety.
3112454|NCT01806545|Other|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure.
3112455|NCT01806532||18F-FDG PET-CT|A total of 10 patients with acute respiratory distress syndrome (ARDS) will be imaged with 2-18F-fluoro-2-deoxy-D-glucose (18F-FDG) and PET-CT scan.
3112456|NCT01806506|Experimental|Laparoscopic sleeve gastrectomy|The group of morbidly obese patients assigned to laparoscopic sleeve gastrectomy.
3112457|NCT01806506|Experimental|Roux-en-Y Gastric Bypass|The group of morbidly obese patients assigned to Roux-en-Y gastric bypass.
3112458|NCT01806493||obese subjects|One hundred and three overweight or obese subjects were included in the study: 74 women (aged 41.5±10 years) and 29 men (aged 43.8±8 years);
3112459|NCT01806480|Experimental|Person-centred proactive breastfeeding telephone support|Proactive breastfeeding telephone support initiated by the Breastfeeding Support Team (BST) at the NICU from which the infant is discharged. Daily phone calls from one member in the BST to the mother will be performed from day 1 until day 14 after discharge. In addition to this, the mother has the option to call someone in the BST during the same period (reactive). The telephone support will be conducted with a person-centered approach. Thus, the mother is enabled to talk about whatever feels important to her including the situation with the new infant at home and her breastfeeding. The feeding support team member should during the telephone support session: have an authentic presence, characterized by being there for the mother, having an empathic approach, taking time touching base, providing affirmation, being responsive, sharing the mother's experience and enabling a relationship.
3112460|NCT01806480|No Intervention|Person-centred reactive breastfeeding telephone support|The control group (and the intervention group) will be offered the possibility to person-centred reactive telephone support initiated by the mother who can phone the feeding support team from day 1 after discharge until day 14 after discharge, between 08.00-16.00 every day. Each NICU will set up a specific telephone number for their telephone support, and schedule the members in the BST for availability. The same level of person-centeredness will be provided in both reactive and proactive telephone support.
3112461|NCT01806467||critically ill patients|patients admitted to the medical-surgical ICU
3112462|NCT01806467||post-cardiac surgical patients|patients admitted to the post-cardiac surgical ICU
3112463|NCT01806454|Active Comparator|calcium A|tablets, 600mg per day,till birth
3112464|NCT01806454|Active Comparator|calcium B|tablets,1200mg per day,till birth
3112465|NCT01806441|Experimental|3-days high fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
3112466|NCT01806441|Active Comparator|3-days low fat diet|During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
3112467|NCT01806428||aPC treatment group|Septic patients with at least two sepsis-induced organ failures occurring within 48 hours of the onset of sepsis treated with activated protein C at 24 mcg/Kg/h for 96 hours
3112468|NCT01806428||Control group|Septic patients with at least two sepsis-induced organ failures occurring within 48 hours of the onset of sepsis not treated with activated protein C because of contraindications
3112469|NCT01806415|Experimental|Fenobam 50 mg|Treatment regimen 1: Fenobam [1-(3-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolidinylidine) urea hydrate], oral administration of one 50 mg gelatin capsule.
3112470|NCT01806415|Experimental|Fenobam 100 mg|Treatment regimen 2: Fenobam, oral administration of one 100 mg gelatin capsule.
3112471|NCT01806415|Experimental|Fenobam 150 mg|Treatment regimen 3: Fenobam, oral administration of one 150 mg gelatin capsule.
3112472|NCT01806415|Placebo Comparator|Placebo arm|Treatment regimen 4: Placebo (lactose), oral administration of one 150 mg gelatin capsule.
3112473|NCT01806402||Retina|Having clinical diagnosis of retina pathology
3112474|NCT01806402||Glaucoma|Having clinical diagnosis of glaucoma
3112475|NCT01806389||Buprenorphine|Buprenorphine maintained women at delivery of their infant
3112476|NCT01806376|Experimental|Subutinib Maleate capsules|Dose escalation will be dependent on any dose limiting toxicities
3112477|NCT01806363|Active Comparator|Part A: Telmisartan, Chlorthalidone + Telmisartan|telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally
3112478|NCT01806363|Active Comparator|Part B: Chlorthalidone, Chlorthalidone + Telmisartan|telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally
3112479|NCT01806350|Experimental|Arm I (PFMT)|Patients receive a handout describing behavioral management tips for urinary incontinence, including information and suggestions about optimal volume fluid intake, constipation management, measures to reduce urgency by spreading fluid intake, and avoiding caffeine and other bladder irritants that have proved effective in other intervention trials. Patients undergo PFMT over 20-30 minutes teaching them to contract the pelvic floor muscles correctly and receive feedback to avoid the contraction of abdominal, gluteal or adductor muscles. Patients are asked to perform 3 sets of 10 pelvic muscle contractions with a goal of holding the contraction for 5 seconds daily for 12 weeks and also receive a reminder phone call to address concerns and review the instructions at 4 weeks.
3112480|NCT01806350|Active Comparator|Arm II (usual care)|Patients receive usual care for urinary incontinence, with an option to join the training program after completion of study.
3112481|NCT01806337|Experimental|Alemtuzumab, antibody|alemtuzumab - anti CD 52 antibody administered as consolidation, total dose 133 mg
3112482|NCT01806324|Experimental|HL040XC(Atorvastatin+Losartan)|HL040XC lag time released combination drug
3112483|NCT01806324|Active Comparator|Losartan + Atorvastatin|Coadministration group
3112484|NCT01806311|Active Comparator|PartA: Candesartan, Candesartan + Amolodipine|Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
3112485|NCT01806311|Active Comparator|PartB: Amlodipine, Amlodipine+Candesartan|Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
3112486|NCT01806298|Experimental|Saizen®|
3112487|NCT01806285||Patients with Respiratory Symptoms|
3112528|NCT01805973|No Intervention|Control|Standard pre-operative care, no active intervention
3112555|NCT01805882|Experimental|D Retx: HCV GT-1, Re-Treatment, 12 wks Sofosbuvir, Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, 12 weeks in HCV genotype 1 subjects who failed HCV therapy in Arm B or Arm G or Arm H
3112488|NCT01806272|Experimental|Arm A|"Local use of rhGM-CSF + Compound Vitamin B12 solution: The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.~Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily~Radiotherapy: Intensity modulated radiation therapy(IMRT)~Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy."
3112489|NCT01806272|Active Comparator|Arm B|"Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily~Radiotherapy: Intensity modulated radiation therapy(IMRT)~Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy."
3112490|NCT01806259|Experimental|ketorolac 30 mg|Active drug to be compared with placebo
3112491|NCT01806259|Placebo Comparator|NaCl 0.9% 3mL|
3112492|NCT01806246|Experimental|integrative rehabilitation program|28 sessions during 12 months with focus on psychoeducation, activity planning, and thoughts and feelings connected to having a serious chronic disease. From week 13 to week 32 a training programme aiming at balancing heart rate variability.
3112493|NCT01806233|Experimental|Acupuncture|acupuncture
3112494|NCT01806233|Experimental|Rehabilitation|rehabilitation exercise
3112495|NCT01806220|Active Comparator|biopsy of retrocrycoid laryngeal mucosa|"During upper digestive endoscopy a biopsy specimen of the retrocrycoid laryngeal mucosa was obtained with a forceps introduced by the working channel of the scope.~Intervention: biopsy of retrocrycoid laryngeal mucosa"
3112496|NCT01806220|Active Comparator|biopsy of distal esophagus mucosa|"during upper digestive endoscopy a biopsy specimen of the distal esophageal mucosa was obtained~Intervention:biopsy of distal esophagus mucosa"
3112497|NCT01806207|Active Comparator|Durolane injection|Intraarticular injection of 3 ml Durolane.
3112498|NCT01806207|Placebo Comparator|Saline injection|Intraarticular injection of physiological sodium chloride (0.9% NaCl) solution pH 7.
3112499|NCT01806194|Active Comparator|Educational control arm|Control group receives 16 mailings of diabetes educational materials but no regular contact with community health workers
3112500|NCT01806194|Experimental|Lifestyle counseling|Small changes behavioral counseling and social support, delivered in 16 sessions by community health workers.
3112501|NCT01806181|Other|Cancer Treatment|
3112502|NCT01806168|Active Comparator|Low-frequency (1 Hz) rTMS|Low-frequency active stimulation over the right DLPFC on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
3112503|NCT01806168|Active Comparator|High-frequency (10 Hz) rTMS|High-frequency active stimulation over the right DLPFC on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
3112504|NCT01806168|Placebo Comparator|Sham rTMS|Sham stimulation over the right DLPFC on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
3112505|NCT01806155||Craniotomy|Patient undergoing major craniotomy
3112506|NCT01806142|Experimental|Medium-chain triglycerides|During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.
3112507|NCT01806142|Active Comparator|Corn oil|During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
3112508|NCT01806129|No Intervention|Arm A (no intervention)|Patients undergo usual standard practice related to reproductive health.
3112509|NCT01806129|Experimental|Arm B (reproductive health program)|Patients undergo reproductive health program comprising didactics, reproductive health assessment and navigating algorithm, and network development.
3112510|NCT01806116|Experimental|decitabine + transplantation|
3112511|NCT01806103|Experimental|Antimicrobial Stewardship Bundle|"An intervention bundle to reduce outpatient antibiotic use in children will include education, creation of and access to guidelines, and audit of and feedback on individual prescribing within the context of achievable benchmarks."
3112512|NCT01806103|No Intervention|Control|Control sites will be within strata to maintain balance of treatment arm within strata
3112513|NCT01806090|Active Comparator|Clopidogrel|Continue clopidogrel for 7 days prior to the endoscopic procedure
3112514|NCT01806090|Placebo Comparator|Placebo|Placebo daily for 7 days prior to the endoscopic procedure
3112515|NCT01806077|Experimental|PZ-128|
3112516|NCT01806064|Experimental|TRC105 and Axitinib|
3112517|NCT01806051|Experimental|PKU Participants (Arm 1)|"Subjects will be administered Kuvan once daily.~They will undergo several blood draws, including a 24-Hour Blood Assessment (at Study Visit #2 before the commencement of Kuvan), plasma Phe/Tyr draws (at Study Visits #3, 4, and 5), and another 24-Hour Blood Assessment (at Study Visit #6)."
3112518|NCT01806051|No Intervention|Control Group (Arm 2)|"Subjects allocated into this group will be healthy, non-PKU individuals that may be a relative (ex: sibling) of a PKU participant, but they don't have to be a blood relation.~These subjects will undergo a 24-Hour Blood Assessment (at Study Visit #2)."
3112519|NCT01806038|Experimental|RPh Counseling + Outpatient Dispensing|On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist.
3112520|NCT01806038|Active Comparator|Routine Med Dispensing + Counseling|At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
3112521|NCT01806025||Cystic Fibrosis Patients|Patients with Cystic Fibrosis with two known severe (class I and class II) mutations
3112522|NCT01806012|Experimental|Enseal|Tissue sealing with Enseal device
3112523|NCT01806012|Active Comparator|Supracervical hysterectomy using conventional instruments|Supracervical hysterectomy using conventional instruments
3112524|NCT01805999|Experimental|7 g Ispaghula|Volunteer will take 7 g of ispaghula 3 times daily for one week
3112525|NCT01805999|Placebo Comparator|7 g placebo|Volunteer will take 7 g of a placebo 3 times a day for one week
3112526|NCT01805999|Active Comparator|3.5g ispaghula + 3.5 g placebo|Volunteers will take 3.5 g of ispaghula with 3.5 g placebo 3 times daily for one week
3112527|NCT01805986||MS patient|
3112529|NCT01805973|Experimental|Exercise Training|"Supervised Exercise Training Programme Patients will be required to attend three 50 minute exercise sessions per week for 18 weeks. They will exercise in groups of 8-12 and will be supervised by an experienced exercise physiologist. Each session will comprise a 15 minute warm up, 30 minutes of moderate intensity aerobic exercise followed by a 10 minute cool down period.~The patients will have the option to choose from three different exercise programmes tailored to individuals of mixed abilities (and co-morbidities)."
3112530|NCT01805960|Experimental|Canakinumab|1 s.c. injection of canakinumab 150mg directly after cardioversion
3112531|NCT01805960|Placebo Comparator|Placebo|1 s.c. injection directly after cardioversion
3112532|NCT01805947||Lifestyle Modification|"All patients with chronic pain conditions participate in a 8-weeks structured group program. Detailed information on the mindfulness based program can be found in the publication by Paul, A. et al. An Integrative Day Care Clinic for chronically ill patients: Concept and case presentation in the European Journal of Integrative Medicine, 2012, 4(4):e455-e459."
3112533|NCT01805934|Active Comparator|Group RBLF|receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
3112534|NCT01805934|Active Comparator|Group RA|receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
3112535|NCT01805921|Experimental|Arm 1. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)|"Group 1A. Low dose prime PanAd3-RSV given by intra-muscular injection (IM) - low dose boost MVA-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 1B. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost MVA-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
3112536|NCT01805921|Experimental|Arm 2. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)|"Group 2A. Low dose prime PanAd3-RSV given by intra-muscular injection (IM) - low dose boost PanAd3-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 4 weeks.~Group 2B. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 4 weeks."
3112537|NCT01805921|Experimental|Arm 3. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)|"Group 3A. Low dose prime PanAd3-RSV given intra-nasally (IN) - low dose boost MVA-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 3B. High dose prime PanAd3-RSV given intra-nasally (IN) - high dose boost MVA-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
3112538|NCT01805921|Experimental|Arm 4. Prime PanAd3-RSV (IN), boost PanAd3-RSV (IM)|"Group 4A. Low dose prime PanAd3-RSV given intra-nasally (IN) - low dose boost PanAd3-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 4B. High dose prime PanAd3-RSV given intra-nasally (IN) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
3112539|NCT01805921|No Intervention|Arm 5. No vaccine|Group 5. Non-vaccinated control group. 6 volunteers, 60-75 years.
3112540|NCT01805921|Experimental|Arm 6. MVA-RSV (IM)|Group 6. Single high dose MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years.
3112541|NCT01805921|Experimental|Arm 7. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)|Group 7. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 4 weeks.
3112542|NCT01805921|Experimental|Arm 8. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)|Group 8. High dose prime PanAd3-RSV given intra-nasally - high dose boost MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 8 weeks.
3112543|NCT01805921|Experimental|Arm 9. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)|Group 9. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 8 weeks.
3112544|NCT01805908|Experimental|111In-Pertuzumab + SPECT-CT|Radiopharmaceutical 111In-labeled Pertuzumab given intravenously prior to SPECT-CT imaging.
3112545|NCT01805895|Experimental|Minocycline|This intervention arm will receive a total of 5 doses of Minocycline. Dose 1 of Minocycline will be 400mg IV within 12-hours of onset of symptoms. Dose 2 of Minocycline will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
3112546|NCT01805895|No Intervention|Control|This arm will not receive any minocycline. This arm will receive standard of care treatment.
3112547|NCT01805882|Experimental|A: HCV GT-1, tx naïve, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, for 12 weeks in HCV genotype 1, treatment naïve patients
3112548|NCT01805882|Experimental|B: HCV GT-1, tx naïve, 6 wks Sofosbuvir/Ledipasvir/GS-9669|Oral treatment with Sofosbuvir 400mg (GS-7977), Ledipasvir 90mg (GS-5885), GS-9669 500mg, once daily, for 6 weeks in HCV genotype 1, treatment naïve patients
3112549|NCT01805882|Experimental|C: HCV GT-1, tx naïve, 6 wks Sofosbuvir/Ledipasvir/GS-9451|Oral treatment with Sofosbuvir 400mg (GS-7977), Ledipasvir 90mg (GS-5885), GS-9451 80mg, once daily, for 6 weeks in HCV genotype 1, treatment naïve patients
3112550|NCT01805882|Experimental|D: HCV GT-1, tx-relapsed, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, for 12 weeks in HCV genotype 1, treatment-relapsed patients who previously received Sofosbuvir plus Ribavirin
3112551|NCT01805882|Experimental|E: HCV GT-4, tx naïve/expd, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, 12 weeks in HCV genotype 4 treatment naïve subjects and interferon treament experienced subjects
3112552|NCT01805882|Experimental|F: HCV GT-1, tx naïve/expd 6 wks Sofosbuvir/Ledipasvir/GS-9451|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) and GS-9451 80mg, once daily, 6 weeks in HCV genotype 1 treatment naïve and treatment experienced subjects with advanced liver disease
3112553|NCT01805882|Experimental|G: HCV GT-1, tx naïve, 4 wks Sofosbuvir, Ledipasvir, GS-9451|Oral Treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) with GS-9451 80mg, once daily, 4 weeks in HCV genotype 1 treatment naïve subjects with early stage liver disease
3112554|NCT01805882|Experimental|H: HCV GT-1, tx naïve, 4 wks Sofos/Ledip/GS-9451/GS-9669|Oral Treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) with GS-9451 80mg, and GS-9669 250mg, once daily, 4 weeks in HCV genotype 1 treatment naïve subjects with early stage liver disease
3112630|NCT01805401|Sham Comparator|Sham tDCS|
3112631|NCT01805388|Experimental|Regeneration Treatment Group|RTC with Triple Antibiotic Study Drug
3112556|NCT01805856|Experimental|Group A (intervention PIPC)|Patients in group A (intervention PIPC) were given AMP of 2g PIPC intravenously just after intubation. If the operation time was longer than 3 hours, additional infusion of same dose PIPC was done. After coming back to the patients' own room, one more infusion of same dose of same drug was done.
3112557|NCT01805856|Experimental|Group B (intervention CEZ)|Patients in Group B (intervention CEZ) were given AMP of 1g CEZ intravenously just after intubation. If the operation time was longer than 3 hours, additional infusion of same dose CEZ was done. After coming back to the patients' own room, one more infusion of same dose of same drug was done.
3112558|NCT01805856|No Intervention|Group C (without AMP)|Patients in Group C underwent surgery without any AMP.
3112559|NCT01805843||chronic meloid leukemia|echo, exercise echo, and if indicated, right heart catheter
3112560|NCT01805830|Experimental|MP513 group|
3112561|NCT01805830|Placebo Comparator|Placebo group|
3112562|NCT01805817|Experimental|Levonorgestrel releasing intrauterine device, contraception|LNG-IUS - Mirena ®,20μgr, once intrauterine insertion per 5 year, 1 year
3112563|NCT01805817|Experimental|YASMIN® (Drospirenone/Ethinyl Estradiol), contraception|oral, once a day, 1 year
3112564|NCT01805817|Experimental|Copper T 380 A , contraception|intrauterine device, once per 10 year, 1 year period
3112565|NCT01805804|Placebo Comparator|Placebo|Placebo pills to match valsartan tablets administered once daily
3112566|NCT01805804|Experimental|valsartan 80mg daily|Valsartan 80mg tablet once daily
3112567|NCT01805804|Experimental|valsartan 160mg daily|Valsartan 160mg tablet once daily
3112568|NCT01805791|Placebo Comparator|Placebo|Placebo, oral tablets, three times a day
3112569|NCT01805791|Experimental|1800 mg/day HMPL-004|1 600 mg HMPL-004 tablet, 2x400 mg placebo tablets taken 3 times a day
3112570|NCT01805791|Experimental|2400 mg/day|2 x 400 mg HMPL tablets, 1 x 600 mg placebo tablet, taken 3 times per day
3112571|NCT01805778||Acute Cohort|Patients newly diagnosed with cancer who will be receiving anthracycline chemotherapy
3112572|NCT01805778||Survivor Cohort|Survivors of childhood cancer who are at least 3 years or more from their last dose of anthracycline therapy.
3112573|NCT01805765|Active Comparator|Qing'E pills|9 g pills,twice a day for 12 weeks
3112574|NCT01805765|Placebo Comparator|Placebo|9 g pills,twice a day for 12 weeks
3112575|NCT01805752|Experimental|Integrated family-focused PMTCT arm|"Intervention package includes: 1) task-shifting to lower-cadre providers at PMTCT sites; 2) POC CD4+ cell count testing; (3) integrated mother-infant care; and (4) a prominent role for influential family members (male partners), working in close partnership with community-based health workers/volunteers.~Patients attending sites randomized to this arm will also receive group health education; opt-out HIV testing, same-day HIV test results; infant feeding counseling; HBC services; infant prophylaxis, early infant diagnosis, and linkage to family spacing services, if desired."
3112576|NCT01805752|No Intervention|Standard of care|Arm will receive standard of care activities, namely: group health education; opt-out HIV testing, same-day HIV test results; infant feeding counseling; HBC services; infant prophylaxis, early infant diagnosis, linkage to family spacing services, if desired.
3112577|NCT01805726|Placebo Comparator|Xylocain (C)|(C): Local anesthesia
3112578|NCT01805726|Active Comparator|Alfentanil Group + Xylocain (A)|Local anesthesia and Alfentanil
3112579|NCT01805726|Active Comparator|Dexmedetomidine Group + Xylocain (D)|Local anesthesia and dexmedetomidine
3112580|NCT01805713||CF Infant Cohort|Infants with CF followed for the first two years of life.
3112581|NCT01805713||CF Child/Adult Cohort|CF patients > 8 years of age followed during hospitalization for pulmonary exacerbation and when well for two years.
3112582|NCT01805700|Experimental|Regular caffeine enhanced energy drink|Regular caffeine enhanced energy drink (containing 240mg caffeine & 84g glucose) e.g. regular red bull cans (x3)
3112583|NCT01805700|Experimental|Diet Caffeine enhanced energy drink|Diet Caffeine enhanced energy drink ( containing 240mg of caffeine alone) e.g. Red Bull light)
3112584|NCT01805700|Active Comparator|Glucose drink|Glucose drink (containing 84g glucose alone)
3112585|NCT01805687|Other|Zileuton extended release|Oral, 1200 mg (2 x 600 mg tablets)
3112586|NCT01805674||isoflavones combined with magnolia|A food supplement containing soy isoflavones, lactobacillus sporogenous, Ca,vitamin D3, magnesium and magnolia extract will be administered once a day during 12 weeks.
3112587|NCT01805661|Active Comparator|Femoral With Tibial Nerve Block|Continuous femoral nerve block with catheter and selective tibial nerve block in the popliteal fossa
3112588|NCT01805661|Experimental|Canal Block and Capsular Injection|Adductor canal block with a continuous catheter and ultrasound guided posterior capsular injection with local anesthetic solution.
3112589|NCT01805648|Experimental|rhTPO|Active investigational product
3112590|NCT01805635||Children suspected of allergic diseases|Children suspected of allergic diseases No intervention
3112591|NCT01805622|Experimental|Passive Arm #1|Active Arm #1, 2; Passive Arm #1, 2 Community coalitions randomized to the Passive Arm #1-Web Access Without Technical Assistance will receive access to EPICS facilitator training materials and toolkits via the Research-Tested Intervention Programs (RTIPs) website and will not participate in monthly technical assistance teleconferences.
3112592|NCT01805622|Experimental|Passive Arm #2|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to the Passive Arm #2-Web Access With Technical Assistance will receive access to EPICS facilitator training materials and toolkits via the Research-Tested Intervention Programs (RTIPs) website and will participate in monthly technical assistance teleconferences.
3112593|NCT01805622|Active Comparator|Active Arm #1|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to Active Arm #1-In-Person Access Without Technical Assistance will receive training from intervention developers with access to facilitator training materials but will not participate in monthly technical assistance teleconferences.
3112594|NCT01805622|Active Comparator|Active Arm #2|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to Active Arm #2-In-Person Access with Technical Assistance will receive training from intervention developers with access to facilitator training materials and will participate in monthly technical assistance teleconferences.
3112632|NCT01805388|No Intervention|Control Non-study Drug Group|RTC on contralateral tooth with no study drug
3112595|NCT01805609|Experimental|Working with the Caregiving Family (WCF) training|This is a new training curriculum for inpatient oncology providers called Working with the Caregiving Family (WCF) training, a program designed to teach MSKCC inpatient staff to address family-level concerns during acute hospitalization. The WCF training will teach staff to recognize and inquire about areas of family distress that are likely to impact the caregiving process; to provide brief, supportive interventions, and/or to transition families to specialized support services when needed. We will provide staff with skills to address especially challenging family situations (e.g., noncompliance with medical care, conflict, poor communication) in collaborative and compassionate ways. We will teach clinicians to intervene and respond more effectively when problematic relationships develop within families or between families and larger systems (e.g., medical team, institutional programs).
3112596|NCT01805596|Experimental|clopidogrel-ticagrelor|21 days clopidogrel followed by 21 days ticagrelor
3112597|NCT01805596|Experimental|ticagrelor-clopidogrel|ticagrelor for 21 days followed by clopidogrel for 21 days
3112598|NCT01805583|Experimental|ACT|The ACT intervention consists of 6 manual-based face-to-face sessions and internet-based homework modules. The manual is based on the six core processes in the ACT-model: acceptance, mindfulness, defusion, self as context, values and committed action.
3112599|NCT01805583|Experimental|WPI|"This interventions aims at the facilitation of dialogue between the participant and the workplace through a series of steps consisting of individual interviews with the participant and his/her nearest supervisor and a so called convergence dialogue meeting in order to agree upon short- and long-term solutions."
3112600|NCT01805583|Experimental|ACT and WPI|"The study participants receive both ACT and WPI. The ACT intervention consists of 6 manual-based face-to-face sessions and internet-based homework modules. The manual is based on the six core processes in the ACT-model: acceptance, mindfulness, defusion, self as context, values and committed action. WPI aims at the facilitation of dialogue between the participant and the workplace through a series of steps consisting of individual interviews with the participant and his/her nearest supervisor and a so called convergence dialogue meeting in order to agree upon short- and long-term solutions."
3112601|NCT01805583|No Intervention|Control group|Treatment as usual (TAU) which means that the participant continues in ordinary health care and does not receive interventions other than the initial assessment.
3112602|NCT01805570|Active Comparator|Prasugrel loading dose|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI.
3112603|NCT01805570|Active Comparator|Ticagrelor loading dose|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI.
3112604|NCT01805557|Active Comparator|R-DHAP|R-DHAP x 2, restaging, mobilization and harvest of peripheral stem cell + R-DHAP x 2, restaging with PET evaluation
3112605|NCT01805557|Experimental|BR-DHAP|Bortezomib + R-DHAP x 2, restaging, mobilization and harvest of peripheral stem cell + Bortezomib + R-DHAP x 2, restaging with PET evaluation
3112606|NCT01805544||Rivaroxaban|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
3112607|NCT01805531||Rivaroxaban|
3112608|NCT01805518|Active Comparator|Scelectium Tortuosum|S Tortuosum
3112609|NCT01805518|Placebo Comparator|Sugar pill/placebo|Sugar pill/placebo
3112610|NCT01805505|Experimental|Transvaginal ultrasound-guided embryo transfer|Transvaginal ultrasound-guided transfer of two day-3 embryos
3112611|NCT01805505|Active Comparator|Transabdominal ultrasound-guided embryo transfer|Transabdominal ultrasound-guided transfer of two day-3 embryos
3112612|NCT01805492|Experimental|Intervention|Dr. Dean Ornish Program for Reversing Heart Disease
3112613|NCT01805492|No Intervention|Control|Non-intervention controls retrospectively matched to intervention participants
3112614|NCT01805479|Placebo Comparator|stretching-flexibility|This group will use a stretching and flexibility program designed to utilize minimal levels of aerobic capacity. It was chosen in place of a education-based control group due to the high level of personal interaction that is found in the active arm.
3112615|NCT01805479|Active Comparator|aerobic exercise group|aerobic activity targeting 60% peak heart rate for 12 weeks is the active group.
3112616|NCT01805466|Experimental|EVADO|"The E.V.A.D.O. system is made of the following components:~The ADMIRAL oxygenator, that requires low priming volumes (, has a limited contact surface and contains an accessory independent cardiotomy reservoir, allowing separation of pericardial suction blood.~The HARMONY Smart Suction System, which allows automatic regulation of a pumpless extracavity blood sucker, whose rates and pressures depend on whether suction is required for blood/air surfaces (skimming), or for fluids (pooled).~Paediatric circuits with 3/8 tubing for both arterial and venous lines."
3112617|NCT01805466|Active Comparator|Conventional CPB|conventional cardiopulmonary by-pass (CPB) system
3112618|NCT01805453|Active Comparator|Arm A: Losartan|Arm A: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan 50mg*2/day until the halting for any reason
3112619|NCT01805453|Placebo Comparator|Arm B: Placebo|Arm B: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
3112620|NCT01805440|Active Comparator|Uridine|Subjects randomized to this study arm will receive uridine 500 mg twice daily by mouth for 6 weeks.
3112621|NCT01805440|Placebo Comparator|Placebo|Subjects randomized to this arm of the study will receive placebo 500 mg twice daily by mouth for 6 weeks.
3112622|NCT01805440|No Intervention|Healthy Comparison|Subjects are not randomized, and do not receive any treatment intervention.
3112623|NCT01805427||patients treated with efavirenz|HIV-infected on stable HAART regimen with efavirenz
3112624|NCT01805427||patients treated with atazanavir|HIV-infected patients on stable HAART regimen with atazanavir
3112625|NCT01805427||patients treated with darunavir|HIV-infected patients on stable HAART regimen with darunavir
3112626|NCT01805414|Experimental|Intervention Breakfast|40-45g carbs (300-350 kcal)
3112627|NCT01805414|Active Comparator|Control Breakfast|These patients received the usual hospital breakfast which contained 40-45 g carbs.
3112628|NCT01805401|Experimental|Left OFC Group|Anode applied to the left OFC and cathode applied to the right OFC
3112629|NCT01805401|Experimental|Right OFC Group|Anode applied to the right OFC and cathode applied to the left OFC
3112633|NCT01805362|Active Comparator|MORNING|patients continue to take their treatments (RAS blockers and diuretics) on awaking
3112634|NCT01805362|Experimental|EVENING|Patients take their treatments(RAS blockers and diurectics)at bedtime
3112635|NCT01805349|Other|X-Rays|patients with digital arthrosis and hip/knee arthrosis will practice hand X-rays
3112636|NCT01805336|Other|Arm A|"Inclusion : cognitive complaint,fatigue, anxiety an depression questionnaires.~Assessment 1 : attentional function by traditional tests + executive function by virtual reality tests.~One week later, Assessment 2 : attentional function by virtual reality tests + executive function by traditional tests."
3112637|NCT01805336|Other|Arm B|"Inclusion : cognitive complaint,fatigue, anxiety an depression questionnaires.~Assessment 1 : attentional function by virtual reality tests + executive function by traditional tests.~One week later, Assessment 2 : attentional function by traditional tests + executive function by virtual reality tests."
3112638|NCT01805323||All Participants|Patients with macular edema previously treated with dexamethasone intravitreal implant (OZURDEX®) according to general clinical practice.
3112639|NCT01805310|Other|Bowel Preparation|Women randomized to the bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one. They will also be placed on a clear liquid diet on preoperative day number one.
3112640|NCT01805310|Other|No bowel preparation|Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
3112641|NCT01805297|Active Comparator|Vitrectomy with Aflibercept Injection|Preoperative 2.0mg intravitreal aflibercept and vitrectomy with intraoperative 2.0mg intravitreal aflibercept injection.
3112642|NCT01805297|Active Comparator|Standard Vitrectomy|Preoperative 2.0mg intravitreal aflibercept and standard of care vitrectomy.
3112643|NCT01805284|Experimental|Linezolid|
3112644|NCT01805271|Experimental|Everolimus|1 or 2 tablets/day (i.e.5 or 10mg/day )
3112645|NCT01805271|Placebo Comparator|Placebo|1 or 2 tablets/day
3112646|NCT01805258|Experimental|Intervention 2: Nevirapine|HIV and Tuberculosis co-infected patients on standard dose nevirapine (Intervention) based ART and Rifampicin based ATT.
3112647|NCT01805258|Active Comparator|Intervention 2: Efavirenz|HIV and Tuberculosis co-infected patients on standard dose Efavirenz(Intervention)based ART and Rifampicin based ATT.
3112648|NCT01805245|Experimental|Mindfulness Based Stress Reduction|
3112649|NCT01805245|Active Comparator|Health Education Control|
3112650|NCT01805232|Experimental|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
3112651|NCT01805232|Active Comparator|quinine|quinine infusion 80 mg/kg every 8 hours
3112652|NCT01805219||healthy subjects|
3112653|NCT01805206|Experimental|iFABP Monitored|Subjects monitored for urinary iFABP content during the first 4-12 days of life. Enteral feedings administered when iFABP levels are normal during the first four days of life or, if elevated during the first four days of life, have normalized for five days.
3112654|NCT01805193||Suspected coronary heart disease|
3112655|NCT01805180|Other|Arm 1: Spectra Optia followed by COBE Spectra|Controlled evaluation of Granulocyte/Polymorphonuclear Cell Collection on the Spectra Optia device followed by the COBE Spectra device.
3112656|NCT01805180|Other|Arm 2: COBE Spectra followed by Spectra Optia|Controlled evaluation of Granulocyte/Polymorphonuclear Cell Collection on the COBE Spectra device followed by Spectra Optia.
3112657|NCT01805167|Other|subjects with a cochlear implant|
3112658|NCT01805154||CRT patients|Patients who have received any market approved St Jude Medical CRT-D or CRT-P device
3112659|NCT01805128|Experimental|schizophrenia|child with a DSM-IV diagnosis of schizophrenia
3112660|NCT01805128|Experimental|autism spectrum disorder|child with a DSM-IV diagnosis of autism spectrum disorder
3112661|NCT01805128|Experimental|Healthy|child having no DSM-IV diagnosis of schizophrenia spectrum disorder or autism
3112662|NCT01805115|Experimental|Oral misoprostol|The oral group (misoprostol 400 ug) self-administered the medications orally 8-10 h before surgery.
3112663|NCT01805115|Experimental|Sublingual misoprostol|The sublingual group (misoprostol 400 ug) self-administered the medications sublingually 8-10 h before surgery.
3112664|NCT01805115|Experimental|Vaginal misoprostol|The vaginal group (misoprostol 400 ug) self-administered the medications vaginally 8-10 h before surgery.
3112665|NCT01805115|Experimental|Control|The no-misoprostol group did not administer the medication of misoprostol before the procedure
3112666|NCT01805102||maternal serum|measurement by immunoassay
3112667|NCT01805089|Active Comparator|Melatonin 3 mg|Taken orally, once per day, at/around 9:00pm
3112668|NCT01805089|Placebo Comparator|Placebo|Taken orally, once per day, at/around 9:00pm
3112669|NCT01805076|Other|Arm 1 (control)|Patients undergo a clinical breast examination and mammography with ultrasound of the breast and regional nodes followed by breast conserving surgery.
3112670|NCT01805076|Experimental|Arm 2 (experimental)|Patients undergo a clinical breast examination, mammography with ultrasound of breast and regional nodes and breast MRI followed by breast conserving surgery or mastectomy.
3112671|NCT01805063||Fire suppression|Firefighters will attend for vascular assessments following a night shift where they have performed fire suppression
3112672|NCT01805063||Non-fire emergency duty|Firefighters will attend for vascular assessments following a night shift where they have had an emergency response without fire suppression eg. road traffic collision.
3112673|NCT01805063||Sedentary shift|Firefighters will attend for vascular assessments following a night shift where they have remained sedentary throughout the shift.
3112674|NCT01805050||New Technique|All patients who underwent surgical repair of the anterior instability due an HAGL lesion.
3112675|NCT01805037|Experimental|Treatment (brentuximab vedotin, rituximab)|"INDUCTION: Patients receive brentuximab vedotin IV over 30 minutes once weekly for 3 weeks and rituximab IV once weekly for 4 weeks. Patients unable to achieve CR may receive additional optional consolidation therapy identical to induction therapy.~MAINTENANCE THERAPY: Patients receive brentuximab vedotin IV once every 3 weeks and rituximab IV once every 6 weeks. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
3112676|NCT01805024|Experimental|Omigapil|
3112677|NCT01805011||50 healthy mothers|
3112678|NCT01804998|Experimental|Laparoscopic Sentinel Node Biopsy|Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in this arm
3112679|NCT01804998|Active Comparator|Laparoscopy Assisted Gastrectomy|Conventional procedure is laparoscopy assisted gastrectomy in early gastric cancer patient.
3112680|NCT01804985|Experimental|De-escalated Treatment|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months
3112681|NCT01804972|Active Comparator|Verbal and written infomation|Verbal and written information:Patients will receive both verbal information and written patient information leaflets
3112682|NCT01804972|Experimental|Verbal and electronic information|Patient will receive both verbal information and a web address to access patient information electronically
3112683|NCT01804959|Placebo Comparator|Active vs Placebo|In phase I, subjects will be randomized into either the Vivomixx probiotics or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotics (4 sachets/ day or 1800 billion bacteria/day) or placebo (4 placebo sachets/day) for the first 60 days.
3112684|NCT01804959|Active Comparator|60 days of Active vs 120 days of Active|In phase II, subjects from both arms in phase I will receive Vivomixx probiotics 4 sachets/ day for another 60 days. Comparison will be made between the arm receiving 60 days of Vivomixx probiotics vs 120 days of Vivomixx probiotics
3112685|NCT01804946|Experimental|Ergoferon (1 tablet 3 times a day)|1 tablet per 1 intake: on day 1 of the treatment 8 tablets (1 tablet every 30 minutes for the first 2 hours, then 1 tablet 3 times a day with equal intervals starting on the same day. From day 2 to day 5 1 tablet TID.
3112686|NCT01804946|Active Comparator|Oseltamivir(Tamiflu): 75 mg two times a day.|Oseltamivir for 5 days (75 mg b.i.d.).
3112687|NCT01804933|No Intervention|conventional neuromuscular blockade|No rocuronium will be administered intraoperatively unless there is surgeons' complain or patients movement
3112688|NCT01804933|Active Comparator|optimal neuromuscular blockade|Rocuronium dose will be infused to maintain depth of NMB at TOF count 1 intraoperatively
3112689|NCT01804933|Experimental|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1~2 intraoperatively
3112690|NCT01804920|Experimental|D-serine adjuvant treatment|"Random assignment, parallel group, double blind, placebo controlled 8 weeks trial.~First arm: D-serine adjuvant treatment, up to 4 g/day Second arm: Placebo adjuvant treatment"
3112691|NCT01804920|Placebo Comparator|Placebo adjuvant treatment|"Random assignment, parallel group, double blind, placebo controlled 8 weeks trial.~First arm: D-serine adjuvant treatment, up to 4 g/day Second arm: Placebo adjuvant treatment"
3112692|NCT01804907|Experimental|CBT|Cognitive Behavioral Therapy
3112693|NCT01804907|Sham Comparator|Behavioral Modification|Standard sleep hygiene education/desensitization therapy
3112694|NCT01804894||athletes with lower extremity injury|athletes who were injured during one season of play
3112695|NCT01804881|Experimental|Lifestyle counseling|Group program using Craving Change(tm) material was the intervention for dietary counseling, 6 group sessions
3112696|NCT01804881|Placebo Comparator|Wait list control|Wait list, offered group program using Craving Change(tm) material at end of study
3112697|NCT01804868|Experimental|case vignette tutorial|The web tutorial composed of 4 case vignettes.
3112698|NCT01804868|Active Comparator|passive web presentation on research regulation|The presentation will be a web-based voice commented video presentation on research regulation.
3112699|NCT01804855|Active Comparator|W82GO|Usual face-to-face care as per the W82GO multidisciplinary treatment intervention (phase 1 for 6 weeks and phase 2 for 46 weeks).
3112700|NCT01804855|Experimental|Smartphone|Usual care for Phase 1 of treatment. Treatment during Phase 2 of intervention using the Reactivate smartphone application only.
3112701|NCT01804842|Active Comparator|500 mg Met DR BID|Two doses of 500 mg metformin delayed-release
3112702|NCT01804842|Experimental|1000 mg Met DR qAM|One dose of 1000 mg metformin delayed-release in the morning
3112703|NCT01804842|Experimental|1000 mg Met DR qPM|One dose of 1000 mg metformin delayed-release in the evening
3112704|NCT01804829|No Intervention|Observational Control|Subjects who attain HCV RNA <100 IU/ml and are randomized to the control arm will receive standard post-transplant immunosuppressant therapy and be followed for a 34 week period.
3112705|NCT01804829|Experimental|Civacir® 10% at 200 mg/kg dose|Subjects who attain HCV RNA <100 IU/ml and are randomized to the Civacir 200 mg/kg treatment arm will receive Civacir® before liver transplant, followed by 15 infusions over a 10 week regimen, with standard post-transplant immunosuppressant therapy. Civacir® treated subjects will be followed up to 34 weeks post-transplant.
3112706|NCT01804829|Experimental|Civacir® 10% at 300 mg/kg dose|Subjects who attain HCV RNA <100 IU/ml and are randomized to the Civacir® 300 mg/kg treatment arm will receive Civacir® before liver transplant, followed by 15 infusions over a 10 week regimen, with standard post-transplant immunosuppressant therapy. Civacir® treated subjects will be followed up to 34 weeks post-transplant.
3112707|NCT01804816|Experimental|Acupuncture|Acupuncture needles
3112708|NCT01804816|Placebo Comparator|No Acupuncture|"no acupuncture treatment"
3112709|NCT01804803|Experimental|T-SMBG|This group will perform SMBG using a smartphone-connected glucometer implemented with a software for real-time collection and transmission of measured glucose values to the remote server. SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS). A specific algorithm incorporated into the DSS will allow the patients to self-calculate the dose of basal insulin to be administered according to the measured fasting blood glucose levels for consecutive periods of three days. Glucose data and analyses will be made accessible to the patients and medical staff anytime and anywhere via the web. Patients will be also assisted by the diabetes medical team located at or connected with a call center 24-hours/day, 7 days/week.
3112710|NCT01804803|Active Comparator|SMBG|This group will perform SMBG using a regular glucometer and will report glucose data on paper charts (or download data from the glucometer onto the PC) at the planned study visits. Patients will not receive feed-back on their glucose levels nor instructions on how to potentially modify their drug therapy except when undergoing medical visits at the planned intervals. Patients, finally, will not be assisted by the diabetes team/call center.
3112783|NCT01804270|Active Comparator|Part 1 Active|Blinded, active repetitive transcranial magnetic stimulation
3112711|NCT01804790|Active Comparator|Arm A : Radiotherapy + capecitabine|Chemoradiotherapy 5 weeks (50 Gy, 2 Gy/session ; 25 fractions) + capecitabine 800 mg/m2 twice daily 5 days/7, excluding weekends), then 6-8 weeks after chemoradiation, surgery with total mesorectal excision (TME), followed by adjuvant chemotherapy for 6 months, either mFolfox6 or capecitabine, depending on ypTNM and the center's choice.
3112712|NCT01804790|Experimental|Arm B : Chemotherapy then radiochemotherapy|"Drug: Chemotherapy mFolfirinox~Investigational arm: Neoadjuvant CT mFolfirinox, 6 cycles (ca. 3 months; each cycle = 2 weeks):~oxaliplatin: 85 mg/m2 in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m2 simultaneously in 2 hours at D1 during the irinotecan infusion 5FU : 2400 mg/m2 continuous infusion during 48 hours (1200 mg/m2 at D1 and D2), every 14 days during 2 months (4 cycles).~Then followed by 5 weeks of chemoradiotherapy 50 Gy (2 Gy/session, , 5 sessions per week) + capecitabine 800mg/m2 twice daily 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, followed by 3 months of adjuvant chemotherapy, either mFolfox6 or capecitabine depending on ypTNM and center's choice."
3112713|NCT01804777|Experimental|Amiloride 10 mg, 20 mg, and diet|Amiloride 10 mg for 14 days and diet. Then dose titrated up at day 14 to 20 mg, and diet.
3112714|NCT01804777|Active Comparator|HCTZ 12.5 mg, 25 mg and diet|HCTZ 12.5 mg for 14 days and diet. Then dose titrated up at day 14 to 25 mg, and diet
3112715|NCT01804738|No Intervention|Glucose|Glucose anhydrous 50g dissolved in 250ml water
3112716|NCT01804738|Active Comparator|Jasmine rice|50g available carbohydrate portion
3112717|NCT01804738|Active Comparator|Parboiled basmati rice|50g available carbohydrate portion
3112718|NCT01804712|Experimental|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
3112719|NCT01804699||Proband|Probands - Participants diagnosed with ARVC according to the 2010 Task Force Criteria
3112720|NCT01804699||Family|First Degree Family member (blood related mother, father, sister, brother, child) of the proband
3112721|NCT01804686|Experimental|PCI-32765 (Ibrutinib)|
3112722|NCT01804673|Experimental|Fentanyl-ITS|
3112723|NCT01804660||25 healthy volunteers|No study treatments administered
3112724|NCT01804647||33 RRMS patients|No study treatments administered
3112725|NCT01804647||9 PPMS patients|No study treatments administered
3112726|NCT01804647||12 SPMS patients|No study treatments administered
3112727|NCT01804647||4 CIS patients|No study treatments administered
3112728|NCT01804634|Experimental|Reducued intesity conditioning|Given our promising results with low rates of GVHD and TRM using non-myeloablative haploidentical BMT in hematologic malignancies, we will use this backbone for very high risk solid tumors in order to maximize a graft versus tumor effect with allogeneic T cells and NK cells for patients with poor prognosis. We will modify our current regimen to include a reduced intensity dose of melphalan as an additional chemotherapeutic agent in the preparative regimen, as melphalan has commonly been incorporated into the myeloablative preparative regimens for solid tumors because of its tolerable side effect profile and anti-tumor efficacy.84 Sirolimus will be given post- transplant because of the potential for its additional anti-tumor benefit.
3112729|NCT01804621|Experimental|Exercise|Participant received health newsletter with targeted articles about exercise behavior.
3112730|NCT01804621|Experimental|Fruit & Vegetable|Participant received health newsletter with targeted articles about fruit & vegetable consumption.
3112731|NCT01804621|Experimental|Colorectal Cancer Screening|Participant received health newsletter with targeted articles about colorectal cancer screening.
3112732|NCT01804621|Experimental|Mammography|Participant received health newsletter with targeted articles about mammography screening.
3112733|NCT01804608|Experimental|Sensorimotor|Sensorimotor, this arm will receive sensorimotor and hip muscle strengthening.
3112734|NCT01804608|Active Comparator|Strength|Strength, this arm will receive only hip muscle strengthening.
3112735|NCT01804595|Experimental|Sunscreen|To reduce barriers to obtaining sunscreen and serve as cues to action, this group will be mailed during the months of May through September, a supply of SPF30 sunscreen lotion (known to prevent sun burning and skin cancer). The mailing will consist of large bottles of sunscreen and a small bottle that can be refilled and attached to their huge key rings that hang off of their belts.
3112736|NCT01804595|Experimental|Text Message Reminders|"As cues to action, this group will receive 60 cellular telephone text-messages on three random mornings per week during the month of May, June, July, August, and September when UV rays are the highest. Using an internet text-messaging service, the messages will be computer generated and sent to Operating Engineers and contain information about weather conditions and various reminders (e.g., Put on sunscreen today or Wow, it's a hot one, you know what to do!)."
3112737|NCT01804595|Experimental|Sunscreen and Text Message Reminders|Just as multimodal interventions such as surgery and radiation can be used to treat skin cancer, multimodal behavioral interventions may reduce sun burning and prevent skin cancer. To determine if the combination of these interventional components results in improvements above and beyond the individual parts, both sunscreen and text messaging interventions will be provided in addition to education.
3112738|NCT01804595|Active Comparator|Education|A 30-minute, picture enhanced power point presentation will be offered to all Operating Engineers during their annual safety trainings. The content of the power point presentation will include information on incidence and prevalence of skin cancer especially among outdoor workers, types of skin cancers and skin cancer risk, sunburn, Sun Protection Factor (SPF), sun protection behaviors including sunscreen use, correct application of sunscreen, types of products, and the new Food and Drug Administration (FDA) labeling of sunscreen products. In addition, other sun protection behaviors such as wearing hats, sunglasses, using shade, etc., will be discussed.
3112739|NCT01804582|Experimental|Family Navigator Consultation|"This group of parents will be contacted by a Family Navigator to assist them in accessing psychosocial resources based on their child and family needs. Components of this intervention are the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
3112784|NCT01804270|Sham Comparator|Part 1 Sham|Blinded, sham repetitive transcranial magnetic stimulation
3112740|NCT01804582|No Intervention|Usual Care|No specific study intervention is provided to this group of parents. This control group will received the usual care that they have been receiving from their child's providers.
3112741|NCT01804569|Experimental|moxa|moxibustion treatment 3 times a week for 3 weeks
3112742|NCT01804556|Other|Myofascial trigger point injection|Myofascial trigger point injection on gastrocnemius muscle
3112743|NCT01804543||Angina, Heart Disease|ranolazine 500 mg twice daily for 1 week, then 1000 mg twice daily for 3 weeks
3112744|NCT01804530|Experimental|PLX7486-TsOH, Dose escalation and RP2D|Part 1: Open-label, sequential PLX7486-TsOH single-agent dose escalation in approximately 60 patients with solid tumors.
3112745|NCT01804517||Physician based approach|Patients will be managed as usual at the clinic without the intervention of the nurse.
3112746|NCT01804517||Physician and nurse|Patients will be managed with the help of the nurse for education and follow-up.
3112747|NCT01804504|No Intervention|Control|"Food Frequency Questionnaire(FFQ) and KAP Questionnaire will be carried out before and after the trial to evaluate changes in calorie and nutrients intake, dietary structure, and KAP scores.~Physical examination and biochemical examination before and after the trial."
3112748|NCT01804504|Experimental|Nutrition education|"FFQ and KAP Questionnaire will be carried out before and after the trial to evaluate changes in calorie and nutrients intake, dietary structure, and KAP scores.~Physical examination and biochemical examination before and after the trial.~Do nutrition education"
3112749|NCT01804491||Control group|Healthy age matched control subjects
3112750|NCT01804491||Cheilectomy prospective group|"Patients with hallux rigidus treated by the surgery type cheilectomy"
3112751|NCT01804491||Arthrodesis prospective group|"Patients with hallux rigidus treated by the type of surgery arthrodesis"
3112752|NCT01804491||Mixed prospective group|"Patients with hallux rigidus treated by other type of surgery: Arthoplasty, joint resection (Keller-Brandes technique)"
3112753|NCT01804491||Cheilectomy retrospective group|Patients after cheilectomy due to hallux rigidus
3112754|NCT01804491||Arthrodesis retrospective group|Patients after arthrodesis of the metatarsophalageal joint due to hallux rigidus
3112755|NCT01804491||Mixed retrospective group|Patients after other types of surgery due to hallux rigidus: arthroplasty or resection of the first metatarso-phalangeal joint
3112756|NCT01804478|Experimental|Pneumatic Compression|Both diabetic and control subjects will undergo mild pneumatic compression while tissue oxygenation and blood flow are recorded with a non-invasive NIRS and PPG device
3112757|NCT01804465|Experimental|Immediate IpilimumabTreatment|Arm 1 (Immediate Treatment) Ipilimumab Q3wks x 4 started 1 day following the final dose of SipT.
3112758|NCT01804465|Experimental|Delayed IpilimumabTreatment|Arm 2 (Delayed Treatment) Ipilimumab Q3wks x 4 started 3 weeks following the final dose of SipT.
3112759|NCT01804452||Subjects with a diagnosis of PSP or CBD|
3112760|NCT01804439||CALIBER Healthy Cohort|We will report findings from the CALIBER (CArdiovascular disease research using Linked BEspoke studies and Electronic Records) collaboration where we linked primary care data (from the General Practice Research Database [GPRD]) to three further sources of electronic health records: the Myocardial Ischemia National Audit Project registry (MINAP),cause specific discharge data from Hospital Episodes Statistics (HES) and cause specific mortality from the Office for National Statistics (ONS).
3112761|NCT01804426||Trauma Exposed participants|18-50 years old men and women who have been brought to the ER after being involved or witnessing a life threatening event (or an event which was perceived as such).
3112762|NCT01804413|Active Comparator|Pegvisomant-glucagon test|To compare the combined pegvisomant with the glucagon test to the insulin tolerance test and the glucagon test in diagnosing adult growth hormone and cortisol insufficiency.
3112763|NCT01804413|Active Comparator|Insulin tolerance test|To compare the combined pegvisomant with the glucagon test to the insulin tolerance test and the glucagon test in diagnosing adult growth hormone and cortisol insufficiency.
3112764|NCT01804400|Experimental|QAW039 + Montelukast|
3112765|NCT01804400|Experimental|QAW039 Once a day (q.d.)|
3112766|NCT01804400|Experimental|QAW039 Twice a day (b.i.d.)|
3112767|NCT01804400|Active Comparator|Montelukast|
3112768|NCT01804400|Placebo Comparator|Placebo|
3112769|NCT01804387|Active Comparator|Telbivudine plus adefovir|study drugs
3112770|NCT01804387|Active Comparator|Lamivudine plus adefovir|standard drugs
3112771|NCT01804374|Experimental|sorafenib and everolimus|This is an open label study: all patients will be treated with sorafenib 400 mg twice a day in combination with everolimus 5mg per day
3112772|NCT01804361|Experimental|Haporine-S|Moderate to severe dry patients administered with with Haporine-S
3112773|NCT01804361|Active Comparator|Restasis, Cyclosporine 0.05%|Moderate to severe dry eye patients with Restasis(cyclosporine 0.05%)
3112774|NCT01804348|Experimental|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
3112775|NCT01804335|Experimental|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
3112776|NCT01804322|Active Comparator|Usual care|usual care according to the practice of participating Epilepsy Centers
3112777|NCT01804322|Experimental|Standardized educational plan|"The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:~The cause and nature of the adverse event and/or drug interaction~The tolerability profile of each drug present in the schedule~The clinical manifestations associated with the current drug interactions~Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule~The reasons for and the potential benefits of the suggested treatment change~An encouragement to withdraw any potentially interfering or contraindicated drug"
3112778|NCT01804309||Early breast cancer patients|Clinical stage T1-2 N0M0 primary unilateral invasive breast cancer patients
3112779|NCT01804296|Experimental|Part 2 Acute|Open-label, active repetitive transcranial magnetic stimulation
3112780|NCT01804296|Experimental|Part 2 Maintenance|Open-label, active repetitive transcranial magnetic stimulation
3112781|NCT01804283|Sham Comparator|CON|Patients undergoing double valve replacement (aortic and mitral).
3112782|NCT01804283|Experimental|IPO|Patients undergoing double valve replacement (aortic and mitral) with ischemic postconditioning.
3112785|NCT01804257|Experimental|Digital Health Feedback System (DHFS)|Ingestion Sensor, Wearable Sensor
3112786|NCT01804244|Experimental|TMC278|All participants will receive a single-dose of TMC278 (1 25-mg tablet [27.5 mg as the hydrochloride salt]) after an overnight fast (going without food) of at least 10 hours before eating a standard breakfast. Study drug will be taken within 10 minutes after completion of a standardized breakfast.
3112787|NCT01804231|Other|18F-FCH PET/MRI imaging|Patients eligible for the study will have an 18F-FCH PET/MRI in addition to standard of care clinical assessment and imaging (CT and bone scan)
3112788|NCT01804218|Placebo Comparator|Placebo|Placebo
3112789|NCT01804218|Experimental|Active, nadolol|Active
3112790|NCT01804205|Experimental|Magnesium sulfate group|In the magnesium group, patients received MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h.
3112791|NCT01804205|Placebo Comparator|Control group|Controls received 100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h.
3112792|NCT01804192|Experimental|Acu-TENS to LI4 and LI11|"Acu-TENS Group (Experimental Group), subjects received TENS over right L14 and LI11.~Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV."
3112793|NCT01804192|Active Comparator|Control group|"Control Acu-TENS Group (Control Group), subjects received TENS over tips of bilateral knee caps.~Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV."
3112794|NCT01804192|Placebo Comparator|Placebo group|Placebo Acu-TENS Group (Placebo Group), subjects received the same protocol as the Acu-TENS group and TENS was applied over right LI4 and LI11 that covered with non-conducting plastics (with the same dimension as the TENS electrodes) Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV.
3112795|NCT01804179|Active Comparator|Standard Intervention (SI)|"At Baseline Visit, Participants in the standard intervention (SI) condition will get: I-FOBT kit and Screen for Life brochure, a mailed reminder card at two weeks post-intervention to remind them about FOBT testing and follow up assessments at 12 months."
3112796|NCT01804179|Experimental|CARES Intervention|Colorectal Cancer Awareness, Research, Education and Screening (CARES). At Baseline Visit, Participants in the CARES intervention will receive: I-FOBT kit, a newly developed DVD and booklet, and a mailed reminder card at two weeks post-intervention to remind them about FOBT testing, and follow-up assessments at 12 months.
3112797|NCT01804166|Other|IBD patients with HSTCL|Subjects with Inflammatory Bowel Disease with a diagnosis of Hepatosplenic T-cell lymphoma
3112798|NCT01804153|Experimental|Autologous expanded stem cells|Adipose-derived expanded stem cells
3112799|NCT01804140||Cohort|
3112800|NCT01804127|Experimental|R-CHOP|rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
3112801|NCT01804114|Active Comparator|Local anesthetic continuous infusion|Pain management following hernia repair
3112802|NCT01804114|Placebo Comparator|Placebo continuous infusion|Placebo pain management following hernia repair
3112803|NCT01804101|Experimental|Arm I (lower-dose liposomal cytarabine-daunorubicin CPX-351)|"INDUCTION/RE-INDUCTION: Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRp continue on to consolidation.~CONSOLIDATION: Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1 and 3. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity."
3112804|NCT01804101|Experimental|Arm II (closed to accrual effective 4/21/14)|"INDUCTION/RE-INDUCTION: Patients receive higher-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRp continue on to consolidation.~CONSOLIDATION: Patients receive higher-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1 and 3. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity."
3112805|NCT01804088|Experimental|Stent|
3112806|NCT01804075|Active Comparator|methadone|"Methadone (1 mg/mL) administered orally every 4 hours. The following is a dosing guide:~NAS Score Methadone 8-12 0.05 mg/kg/dose >=13 0.1 mg/kg/dose~Maximum dose of methadone will be 0.2 mg/kg/dose. (NeoFax)~Additional doses, 0.05 mg/kg, may be given every 4 hours as needed and added to the next 24 hour's doses divided every 4 hours, until NAS scores are consistently <8 for 48 hours.~If the maximum dose of methadone is reached and if withdrawal is not controlled, the infant will be started on clonazepam (0.005 mg/kg/dose q 12h) per current treatment."
3112807|NCT01804075|Active Comparator|morphine|"Morphine (1 mg/mL) administered orally every 4 hours. The following is a dosing guide:~NAS Score Morphine 8-12 0.05 mg/kg/dose >=13 0.1 mg/kg/dose~Maximum dose of morphine will be 0.2 mg/kg/dose. (NeoFax)~Additional doses, 0.05 mg/kg, may be given every 4 hours as needed and added to the next 24 hour's doses divided every 6 hours, until NAS scores are consistently <8 for 48 hours.~If the maximum dose of morphine is reached and if withdrawal is not controlled, the infant will be started on clonazepam (0.005 mg/kg/dose q 12h) per current treatment."
3112808|NCT01804062||no treatment|no treatment, prospective observational
3112809|NCT01804049|Placebo Comparator|Placebo|60 participants will be randomized to placebo pills.
3112810|NCT01804049|Active Comparator|Metformin|60 enrolled participants will be randomized to metformin.
3112811|NCT01804036|Active Comparator|Zolpidem (Ambien) Treatment|A three week treatment of Zolpidem
3112812|NCT01804036|Experimental|Mind-Body Bridging|An awareness training program using mindfulness-based techniques.
3112813|NCT01804023||Healthy women|
3112814|NCT01804010|Active Comparator|Ivabradine|Single and repeated oral administrations of 3 doses of ivabradine
3112815|NCT01804010|Placebo Comparator|Placebo|Placebo administration
3112816|NCT01803997|Other|STRIDE|12 cooking classes offered over 6 weeks (approximately 2 classes/week)
3112817|NCT01803997|Other|SPARK|12 physical activity classes offered over 6 weeks (approximately 2 classes/week)
3112818|NCT01803984||Patient with migraine with aura|Patients with a clearly defined migraine (as per IHS criteria) with aura, who are aged 30 and older and are able to fluently speak French.
3112819|NCT01803984||Patient with migraine without aura|patients with a clearly defined migraine (as per IHS criteria) without aura who are aged 30 and older, are able to fluently speak French, and who are willing to participate
3112820|NCT01803971|Experimental|vascular access in out-of-hospital cardiac arrest patients|Obtention of vascular access according to the current strategy, ie after one unsuccessful attempt to obtain a peripheral venous access, use of an intra osseous device
3112821|NCT01803958|Experimental|partial breast irradiation|38.5 Gy total in 10 fractions (3.85 Gy per fraction), twice a day with an interval of at least 6 hours between the two fractions, for five consecutive working days
3112822|NCT01803958|Active Comparator|whole breast irradiation|50.0 Gy in 25 fractions (2 Gy per fraction), once a day for 5 days in the week, or other biologically equivalent schedule
3112823|NCT01803945|Placebo Comparator|Placebo Group|Sequential cohorts of eight patients with PD will be administered ascending oral doses of AVE8112 (n=6) or placebo (n=2) once a day for 14 days. Patients will be assessed in clinic for 30 hours following the initial oral dose of AVE8112 or placebo
3112824|NCT01803945|Active Comparator|AVE8112|Sequential cohorts of eight patients with PD will be administered ascending oral doses of AVE8112 (n=6) or placebo (n=2) once a day for 14 days. Dosing for subsequent cohorts will only proceed, and the dose level selected, after the safety and tolerability of the previous cohort has been reviewed. Doses are planned to be 1.0, 2.0, 3.0, and 4.0 mg once a day for 14 days. These are planned treatments, but doses may be modified based on safety review of previous cohort(s). In addition, cohorts may be added to reconfirm a previously administered dose, and/or a titration strategy may be employed to reach a desired dose. Patients will be assessed in clinic for 30 hours following the initial oral dose of AVE8112 or placebo
3112825|NCT01803932|Experimental|Behavioral intervention|Male-focused group violence prevention intervention
3112826|NCT01803932|No Intervention|Control communities|Communities in which male-focused group prevention activities will not be conducted
3112827|NCT01803919|Experimental|Silver Alloy-Coated Urinary Catheters|Bactiguard® Infection Protection coating consists of noble metals such as gold, palladium and silver. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.
3112828|NCT01803919|Other|Conventional Urinary Catheter|Conventional or standard urinary catheters are those commonly used in each study center, most of them made of silicone or silicone-latex. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.
3112829|NCT01803906||Mitochondrial disease|Patients with known or suspected DNA mutations that affect mitochondrial function. Patients with suspected mitochondrial disorders
3112830|NCT01803893||Embryo culture media|measurement using immunoassay
3112831|NCT01803893||maternal serum|measurement by immunoassay
3112832|NCT01803880|Active Comparator|Mechanical Debridement|Mechanical shaver removes areas of damaged tissue
3112833|NCT01803880|Active Comparator|RF-based Debridement|Electrical energy removes areas of damaged tissue (Coblation®)
3112834|NCT01803867|Placebo Comparator|rHIgM22|"Cohorts 1-5: In each dosing cohort, the first 2 eligible patients will be enrolled and randomized 1:1 to receive rHIgM22 or placebo, and monitored for safety for a minimum of 7 days before the remaining 8 patients in the cohort are randomized (7 active: 1 placebo) and dosed.~Expanded Cohort: Upon establishment of a Maximally Tolerated Dose (MTD), a new group of 21 patients will be enrolled in an Expansion Cohort. Randomly assigned in a 1:1:1 ratio to 1 of 3 treatment groups: placebo, Investigational Product (IP) at MTD, or IP at one full dose level lower than MTD."
3112835|NCT01803854||Gulf War Era Veterans|All Veterans who served in the uniformed services during 1990-1991 who signed consent forms, completed a survey, and provided a blood sample are included in the cohort.
3112836|NCT01803841|Active Comparator|Transradial access|Coronary angiography and intervention via radial artery approach
3112837|NCT01803841|Active Comparator|Transfemoral access|Coronary angiography and intervention via femoral artery approach
3112838|NCT01803828|Active Comparator|1|Tadalafil 5 mg
3112839|NCT01803828|Placebo Comparator|2|Placebo 5 mg
3112840|NCT01803802|Placebo Comparator|Time management|Writing prompts oriented towards objective recounting of previous day
3112841|NCT01803802|Experimental|Sexual schema writing|Expressive writing prompts oriented towards beliefs about sexuality
3112842|NCT01803802|Active Comparator|Trauma writing|Expressive writing prompts oriented towards processing traumatic experiences
3112843|NCT01803789|Active Comparator|Single Kirschner Wire|Antegrade intramedullary fixation of with a single Kirschner wire.
3112844|NCT01803789|Active Comparator|Double Kirschner Wire|Antegrade intramedullary fixation with double Kirschner wire.
3112845|NCT01803776|Experimental|lifestyle counseling|
3112846|NCT01803763|Active Comparator|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
3112847|NCT01803763|Placebo Comparator|Placebo|Fixed dose of Placebo is subcutaneously administered in total 4 monthly doses
3112848|NCT01803750||Primary Care Providers|Conduct and analyze in-depth, semi-structured interviews with community-based primary care providers serving large Latino populations and Form a community-based participatory committee.
3112849|NCT01803737|Active Comparator|Standard Behavioral Weight Loss Intervention (SBWL)|Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
3112850|NCT01803737|Experimental|Campaign Intervention (CI)|Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
3112851|NCT01803711|Experimental|Desvenlafaxine + Omega 3 FA supplement|Desvenlafaxine 50mg/day & Omega 3 FA supplement (range 2.4 gm/day - 4.8 gm day) over a 12 week period
3112852|NCT01803711|Active Comparator|Desvenlafaxine + Placebo (for Omega 3 FA supplement)|Desvenlafaxine 50mg/day & Placebo (for Omega 3 FA supplement) over a 12 week period
3112853|NCT01803698|Experimental|Training in the use of IOM charts|"Training family physicians to regularly refer to the Institute of Medicine guideline trajectories and provide feedback about GWG (training in the use of IOM charts) during routine prenatal visits."
3112854|NCT01803698|No Intervention|Usual care|Family physicians providing usual prenatal care.
3112855|NCT01803685||Surgical treatment|Surgical resection of intracranial arteriovenous malformations.
3112856|NCT01803685||Stereotaxic radiosurgery|Deliver a relatively high dose of focused radiation precisely to the arteriovenous malformations.
3112857|NCT01803685||Endovascular treatment|Deliver embolic materials to the feeding arteries or the nidus by microcatheters
3112858|NCT01803685||Comprehensive treatment|Use two or three methods ( Surgical treatment stereotaxic radiosurgery endovascular treatment ) to cure the intracranial arteriovenous malformations
3112859|NCT01803685||Conservative treatment|Patients refused to any of the treatment above
3112860|NCT01803672|Experimental|health talk and adventure-based training|Participate will join a four-day integrated health education and adventure-based training programme, which contains education talks, workshop and adventure-based training activities. The programme will be implemented on four different days within six months in a day camp training centre. The integrated programme will be implemented in small group with maximum 15 participants in one group. Health education talks and workshop will be implemented in between adventure-based training activities in day camp centre, which will be conducted by healthcare professionals working in a local university.
3112861|NCT01803672|Placebo Comparator|Placebo Control|Participants will receive an amount of time and attention that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
3112862|NCT01803659|Experimental|b-carotene|600 ug RAE/d as b-carotene, 6 d/wk for 3 weeks
3112863|NCT01803659|Active Comparator|retinyl palmitate|600 ug retinol equivalent/d, 6 d/wk for 3 weeks
3112864|NCT01803659|Placebo Comparator|placebo (corn oil)|0 ug RAE/d as corn oil
3112865|NCT01803646|Experimental|AM-101 injection|AM-101
3112866|NCT01803646|Placebo Comparator|Placebo injection|Placebo
3112867|NCT01803633|Experimental|Cheese|Cheese sandwich plus supplemental beverage will deliver 40% of each participants' energy expenditure and will be made up of 50% of energy as fat, 35% of energy as carbohydrate and 15% of energy as protein. The sandwich will contain medium cheddar cheese and whole wheat bread. The supplemental beverage will contain fruit sorbet, glucose polymer, protein powder, high oleic sunflower oil, high polyunsaturated fatty acids (PUFA) sunflower oil, and canola oil.
3112868|NCT01803633|Active Comparator|Vegan cheese|Non-dairy cheese alternative sandwich plus supplemental beverage will deliver 40% of each participants' energy expenditure and will be made up of 50% of energy as fat, 35% of energy as carbohydrate and 15% of energy as protein. The sandwich will contain vegan cheese and whole wheat bread. The supplemental beverage will contain fruit sorbet, glucose polymer, protein powder, cream of tartar, high oleic sunflower oil, high PUFA sunflower oil, and palm oil.
3112869|NCT01803607|Experimental|Odanacatib 50 mg|Participants will receive odanacatib 50 mg once weekly for 24 months. Additionally, all participants will receive weekly supplementation with 5600 international units (IU) of Vitamin D3 and, if required, will be provided with an open-label daily calcium supplement of 500 mg (sourced locally as calcium carbonate or calcium citrate) to ensure a total daily intake (from both dietary and supplemental sources) of approximately 1200 mg of elemental calcium.
3112870|NCT01803607|Placebo Comparator|Placebo|Participants will receive dose-matched placebo to odanacatib once weekly for 24 months. Additionally, all participants will receive weekly supplementation with 5600 IU Vitamin D3 and, if required, will be provided with an open-label daily calcium supplement of 500 mg (sourced locally as calcium carbonate or calcium citrate) to ensure a total daily intake (from both dietary and supplemental sources) of approximately 1200 mg of elemental calcium.
3112871|NCT01803594|Placebo Comparator|Control Shake|Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder.
3112872|NCT01803594|Active Comparator|PC700, Krill Oil, and Lutein|"Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water.~Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 = dairy lipids (Fonterra brand)"
3112936|NCT01803243|No Intervention|Control|A sample of 15 healthy controls from a simultaneously conducted study (UKBB-Spine-1315-1) will be used for comparative purposes.
3112937|NCT01803230|Placebo Comparator|placebo|placebo (dextrose)
3112938|NCT01803230|Experimental|creatine|creatine supplementation
3112873|NCT01803594|Active Comparator|PC700, Krill Oil, Lutein, and Niacin|"Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water. Nicotinic acid was added to each shake prior to consumption at a doses 5mg/kg of body weight.~Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 (Fonterra); Nicotinic acid (Natures Way)"
3112874|NCT01803581|Experimental|X92001327|the X92001327 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
3112875|NCT01803581|Active Comparator|RID shampoo|The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
3112876|NCT01803568|Experimental|Exercise in normoglycaemic individuals|
3112877|NCT01803568|Experimental|Exercise in hyperglycaemic individuals|
3112878|NCT01803555|Experimental|Budesonide/Formoterol SPIROMAX®|2 inhalations of BF Spiromax at a dosage of 160/4.5 mcg and 2 inhalations of SYMBICORT placebo administered twice daily (AM and PM) during the 12-week treatment period.
3112879|NCT01803555|Active Comparator|SYMBICORT® TURBOHALER®|2 inhalations of SYMBICORT TURBOHALER at a dosage of 200/6 mcg and 2 inhalations of placebo SPIROMAX administered twice daily (AM and PM) during the 12-week treatment period.
3112880|NCT01803542|Experimental|SBRT|High dose of radiation will be used to treat tumours.
3112881|NCT01803529|Experimental|heat-pack with massage|deep friction massage and standard heat-pack given a maximum of 8 treatments
3112882|NCT01803529|Active Comparator|heatpack only|standard heat-pack given a maximum of 8 treatments
3112883|NCT01803516||Breast cancer survivors with radiation-induced Telangiectasias|A quality of life assessment will also be completed by the patient using the Skindex-16 and a subscale of the BREAST-Q Breast Conserving Module questionnaire.
3112884|NCT01803503|Active Comparator|Docetaxel|Docetaxel 75mg/m2 day 1, every 3 weeks. Patients will be treated for a maximum of 6 cycles of chemotherapy in the absence of tumor progression or unacceptable toxicities.
3112885|NCT01803503|Experimental|Docetaxel + Sunitinib|"Docetaxel 75mg/m2 day 1, every 3 weeks, preceded by 7 days of sunitinib 12.5mg orally daily during each cycle.~Patients will be treated for a maximum of 6 cycles of chemotherapy in the absence of tumor progression or unacceptable toxicities."
3112886|NCT01803477|Active Comparator|Picato® 0.05% gel|once daily for two consecutive days
3112887|NCT01803477|Experimental|ingenol mebutate vehicle formulation 1|once daily for two consecutive days
3112888|NCT01803477|Experimental|ingenol mebutate vehicle formulation 2|once daily for two consecutive days
3112889|NCT01803477|Experimental|ingenol mebutate vehicle formulation 3|once daily for two consecutive days
3112890|NCT01803464|Experimental|Botox plus low-magnitude vibration|Cerebral palsy and Botox + vibration
3112891|NCT01803464|Experimental|Botox|Cerebral palsy and Botox
3112892|NCT01803464|No Intervention|Cerebral palsy control|Cerebral palsy without treatment
3112893|NCT01803464|No Intervention|Typically developing control|Typically developing
3112894|NCT01803451|Experimental|hyperglycemic clamp-Meal tolerance test|these studies are to evaluate the effect of exendin-9 on insulin secretion before and after meal ingestion in patients after bariatric surgeries compared to non-surgical controls
3112895|NCT01803451|Experimental|Labeled meal tolerance test|The effect of GLP-1 receptor blockade on glucose tolerance and glucose kinetics are evaluated in the group patients with bariatric surgery vs. nonsurgical using exendin-9-39 infusion during one of the the 2-day dual tracer studies of meal tolerance test
3112896|NCT01803438|Active Comparator|AADs|AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
3112897|NCT01803438|Experimental|Cryoablation procedure|electrical pulmonary veins isolation performed with cryoballoon ablation system
3112898|NCT01803425||Synflorix™ cohort|Only those subjects to whom Synflorix™ will be administered as per normal clinical practice, according to the locally approved PI, will be included in the study.
3112899|NCT01803412|Experimental|Alternate Intravenous Dosing Arm|Subjects will receive drisapersen as a regimen of 3 mg/kg over 1 hr IV weekly throughout the duration of participation.
3112900|NCT01803412|Experimental|Primary continuous Dosing Arm|Subjects will receive drisapersen 6 mg/kg as SC injection(s) once a week, continuously throughout their duration of participation.
3112901|NCT01803412|Experimental|Alternate Intermittent Dosing Arm|Subjects will receive drisapersen intermittently, as a regimen of 6 mg/kg as SC injection(s) once a week for 8 weeks followed by 4 weeks of no dosing, throughout their duration of participation.
3112902|NCT01803399|Experimental|GSK1322322 1200 mg Arm|Each subject will receive a single dose of GSK1322322 1200 mg IV over 60 minutes on Day 1 of one of the 4 treatment periods
3112903|NCT01803399|Experimental|GSK1322322 3000 mg Arm|Each subject will receive a single dose of GSK1322322 3000 mg IV over 60 minutes on Day 1 of one of the 4 treatment periods
3112904|NCT01803399|Placebo Comparator|Placebo Arm|Each subject will receive a single dose of GSK1322322 Placebo IV over 60 minutes on Day 1 of one of the 4 treatment periods
3112905|NCT01803399|Active Comparator|Moxifloxacin 400 mg Arm|Each subject will receive a single dose of moxifloxacin 400 mg administered orally on Day 1 of one of the 4 treatment periods
3112906|NCT01803386||ALS Subjects|EIM measurements will be taken on two upper and two lower extremity muscles with several different electrode arrays. The ALSFRS-R will also be administered. Subcutaneous fat measurement will also be performed on all four muscles using skinfold calipers.
3112907|NCT01803386||Healthy Subjects|EIM measurements will be taken on two upper and two lower extremity muscles with several different electrode arrays. Subcutaneous fat measurement will also be performed on all four muscles using skinfold calipers.
3112908|NCT01803373|Experimental|Treatment Sequence ABC|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
3112939|NCT01803217|Experimental|mode switch to atrial pacing|
3112940|NCT01803217|Active Comparator|atrioventricular hysteresis function|
3112909|NCT01803373|Experimental|Treatment Sequence ACB|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
3112910|NCT01803373|Experimental|Treatment Sequence BAC|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
3112911|NCT01803373|Experimental|Treatment Sequence BCA|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
3112912|NCT01803373|Experimental|Treatment Sequence CBA|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
3112913|NCT01803373|Experimental|Treatment Sequence CAB|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
3112914|NCT01803360|Experimental|Neridronate|Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
3112915|NCT01803360|Placebo Comparator|Placebo|Saline solution for infusion: 4 intravenous administrations in a course of 10 days treatment
3112916|NCT01803347|Experimental|ASC + fibrin glue|Intervention: drug: ASC + fibrin glue Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 100 million ASCs plus fibrin glue plus a deep curettage and closure of the internal orifice and evaluated after 16 weeks. If needed a second dose of 100 million ASCs plus fibrin glue will be applied then.
3112917|NCT01803347|Active Comparator|Fibrin glue|Intervention: fibrin glue Fibrin glue: Subjects will be treated with a dose fibrin glue plus a deep curettage and closure of the internal orifice, and evaluated after 16 weeks. If needed a second dose of fibrin glue will be applied then.
3112918|NCT01803334|Experimental|Marking abdomen|If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.
3112919|NCT01803334|No Intervention|Control|If she is randomized to the control group, then she will undergo traditional preoperative counseling by the same team without marking the abdomen.
3112920|NCT01803321|Experimental|Cohort 1|Dose 1
3112921|NCT01803321|Experimental|Cohort 2|Dose 2
3112922|NCT01803308|Experimental|Experimental Part A|"Experimental: Part A: Part A will use a single ascending dose protocol in small, open-label cohorts to determine the starting dose for Part B in the potentially therapeutic range.~Intervention: SB9200"
3112923|NCT01803308|Experimental|Experimental Part B|"Experimental: Part B: Part B will use a multiple ascending dose protocol to further explore the safety, tolerability, pharmacokinetics and pharmacodynamics of SB9200 over 7-14 days of dosing.~Intervention: SB9200 and Placebo"
3112924|NCT01803295|Experimental|40 mg MMC gel|"Device: TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 60 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter.~Other Name: MMC Gel"
3112925|NCT01803295|Active Comparator|Standard of care MMC mixed with water|40 mg MMC mixed with 40cc water. Six weekly intravesical instillations of 40 mg of MMC mixed with 40 cc of water will be instilled using catheter
3112926|NCT01803295|Experimental|80 mg MMC gel|"Device: TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 60 cc of TC-3 gel mixed with 80 mg MMC will be instilled using catheter.~Other Name: MMC Gel"
3112927|NCT01803282|Experimental|Andecaliximab|Participants will receive andecaliximab by intravenous (IV) infusion over approximately 30 minutes every 2 weeks on Days 1 and 15 of each 28-day treatment cycle or every 3 weeks on Day 1 of each 21-day treatment cycle (NSCLC group only).
3112928|NCT01803282|Experimental|Andecaliximab with chemotherapy|"Participants will receive andecaliximab by IV infusion every 2-3 weeks in combination with chemotherapy as follows:~Pancreatic adenocarcinoma, esophagogastric adenocarcinoma, CRC, and breast cancer: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle~Non Small Cell Lung Carcinoma (NSCLC): Administered intravenously on Day 1 of each 21-day treatment cycle~In Part B, andecaliximab will be given in combination with one of the following chemotherapy regimens:~Pancreatic adenocarcinoma: gemcitabine and nab-paclitaxel~NSCLC:~lung adenocarcinoma: carboplatin and pemetrexed~lung squamous cell carcinoma: carboplatin and paclitaxel~Esophagogastric adenocarcinoma: mFOLFOX6 (leucovorin+oxaliplatin+5-FU)~First-line colorectal cancer (CRC): mFOLFOX6 and bevacizumab~Second-line colorectal cancer: FOLFIRI (leucovorin+irinotecan+5-FU) and bevacizumab~Breast cancer: Paclitaxel"
3112929|NCT01803269|Active Comparator|Arm A (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3112930|NCT01803269|Experimental|Arm B (CRLX101)|Patients receive cyclodextrin-based polymer-camptothecin CRLX10 cyclodextr1 IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3112931|NCT01803256||Scoliosis patients:|15 patients with adolescent idiopathic scoliosis.
3112932|NCT01803256||Control subjects:|15 adolescent healthy control subjects
3112933|NCT01803243|Experimental|Leg length correction|The shorter leg in a sample of 15 patients with structural leg length inequality will be corrected by either a shoe insole or a modified shoe with sole lift.
3112934|NCT01803243|Experimental|Control of foot position 1|The foot position in in a sample of 15 patients with hemiplegic cerebral palsy will be controlled by an ankle foot orthosis.
3112935|NCT01803243|Experimental|Control of foot position 2|The foot position in in a sample of 15 patients with diplegic cerebral palsy will be controlled by an ankle foot orthosis.
3112941|NCT01803204|Experimental|Booklet - Preoperative Educational|This group received the booklet in the preoperative consult, they will monitoring during the postoperative phase
3112942|NCT01803204|No Intervention|Control|This group don't received booklet, they will be monitored during the postoperative period to control
3112943|NCT01803191|Experimental|Fosfomycin 3 g|Unique oral dosis of 3 g of fosfomycin 1hour before of biopsy
3112944|NCT01803191|Active Comparator|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg before biopsy
3112945|NCT01803178|Active Comparator|Plant Sterols|Plant Sterols
3112946|NCT01803178|Placebo Comparator|Placebo Product|Placebo Product
3112947|NCT01803165||Single shot femoral and sciatic nerve block|Prospective patient study group who present for infrainguinal bypass grafting and will receive single shot femoral and sub gluteal sciatic nerve blocks.
3112948|NCT01803165||Retrospective study group|Retrospective chart review will be performed and data collected on patients who have undergone infrainguinal bypass grafting under general anesthesia and without the use of regional or neuraxial anesthesia.
3112949|NCT01803152|Experimental|Part 1-DC Vaccine/Lysate|"Leukapheresis: Baseline, post-surgery;~Dendritic Cells Vaccine (DC Vaccine): Post-Leukapheresis, administered once weekly in dose-escalation scheme for 4 weeks;~Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 8, 12, 16 and 20;~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
3112950|NCT01803152|Active Comparator|Part 2-Gemcitabine/DC Vaccine/Lysate|"Leukapheresis: Baseline, post-surgery;~Gemcitabine: Post-Leukapheresis, administered once weekly for 3 weeks;~Dendritic Cells Vaccine (DC Vaccine): Post-Gemcitabine therapy, Recommended Phase 2 Dose (RP2D) administered once weekly for 4 weeks;~Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 12, 16, 20 and 32;~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
3112951|NCT01803139|Active Comparator|Standard breast radiotherapy|The treatment is planned using 2D wedges optimisation on the central CT-planning slice.
3112952|NCT01803139|Experimental|Breast IMRT|The treatment is planned 3D IMRT optimisation using all CT-planning slices.
3112953|NCT01803126||atherosclerosis|No treatment.
3112954|NCT01803100||Hospitalized inpatients|Inpatients newly admitted into freshly-cleaned rooms.
3112955|NCT01803087|Active Comparator|CHF 1535 100/6 pMDI (Foster®) TEST 1|Adolescents CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
3112956|NCT01803087|Active Comparator|CHF 1535 100/6 pMDI (Foster®) AeroChamber Plus™ (TEST 2).|CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ spacer device in adolescents (TEST 2)
3112957|NCT01803087|Active Comparator|(Qvar®: BDP 400 µg)+(Atimos®: formoterol 24 µg)|BDP 100 µg pMDI, 4 puffs (Qvar®, total dose: BDP 400 µg) + formoterol fumarate 6 µg pMDI, 4 puffs (Atimos®, total dose: formoterol 24 µg)
3112958|NCT01803087|Active Comparator|CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI|Adults CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
3112959|NCT01803074|Experimental|Part A-Group 1: BMS-955176 (5 mg) or Placebo|"BMS-955176 5 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
3112960|NCT01803074|Experimental|Part A-Group 2: BMS-955176 (10 mg) or Placebo|"BMS-955176 10 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
3112961|NCT01803074|Experimental|Part A-Group 3: BMS-955176 (20 mg) or Placebo|"BMS-955176 20 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
3112962|NCT01803074|Experimental|Part A-Group 4: BMS-955176 (40 mg) or Placebo|"BMS-955176 40 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
3112963|NCT01803074|Experimental|Part B-Group 5: BMS-955176 + Atazanavir|"BMS-955176 40 mg solution by mouth once daily for 28 days~Atazanavir 2 x 200 mg capsules by mouth once daily for 28 days"
3112964|NCT01803074|Experimental|Part B-Group 6: BMS-955176 + Atazanavir + Ritonavir|"BMS-955176 40 mg solution by mouth once daily for 28 days~Atazanavir 1 x 300 mg capsules by mouth once daily for 28 days~Ritonavir 1 x 100 mg tablet by mouth once daily for 28 days"
3112965|NCT01803074|Experimental|Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine|"Atazanavir 1 x 300 mg capsule by mouth once daily for 28 days~Ritonavir 1 x 100 mg tablet by mouth once daily for 28 days~Tenofovir 1 x 300 mg tablet by mouth once daily for 28 days~Emtricitabine 1 x 200 mg capsule once daily for 28 days"
3112966|NCT01803074|Experimental|Part C-Group 8: BMS-955176 (40 mg) or Placebo|"BMS-955176 40 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
3112967|NCT01803074|Experimental|Part A-Group 9: BMS-955176 (80 mg) or Placebo|"BMS-955176 80 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
3112968|NCT01803074|Experimental|Part A-Group 10: BMS-955176 (120 mg) or Placebo|"BMS-955176 120 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
3112969|NCT01803074|Experimental|Part A-Group 11 (Optional): BMS-955176 (≤120 mg) or Placebo|"BMS-955176 ≤120 mg solution by mouth once daily for 14 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 14 days"
3112970|NCT01803074|Experimental|Part B-Group 12: BMS-955176 (80 mg) + Atazanavir|"BMS-955176 80 mg solution by mouth once daily for 28 days~Atazanavir 2 x 200 mg capsules by mouth once daily for 28 days"
3112971|NCT01803074|Experimental|Part C-Group 13: BMS-955176 (120 mg) or Placebo|"BMS-955176 120 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
3112972|NCT01803061|Experimental|WebCan|Provides computerized PRO to the treating physician at the point of care
3112973|NCT01803061|No Intervention|Usual care|
3112974|NCT01803048||TBI|30 individuals who will be tested at two weeks post-TBI; 30 individuals who will be tested at one month post-TBI; 30 individuals who will be tested at three months post-TBI; 30 individuals who will be tested at six months post-TBI; 30 individuals who will be tested at 12 months post-TBI.
3112975|NCT01803048||Healthy Control|30 healthy individuals with no history of TBI
3112976|NCT01803035|Experimental|1 % LTX-109|LTX-109 topical gel in 1 % strength
3112977|NCT01803035|Experimental|2 % LTX-109|LTX-109 topical gel in 2 % strength
3112978|NCT01803035|Placebo Comparator|Placebo|Placebo gel, containing all ingredients except LTX-109
3112979|NCT01803022||Low Molecular Weight Heparin|
3112980|NCT01803009|Experimental|One arm|View CRC RAT and view presentation regarding risk of advanced adenoma
3112981|NCT01802996|Experimental|Arm I|Magnesium Isoglycyrrhizinate Injection 200mg IV on days 1-5
3112982|NCT01802996|No Intervention|Arm II|Only chemotherapy
3112983|NCT01802970|Experimental|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m^2 Intravenous on day 1,8 &15 of a 28 day cycle), or capecitabine (1000mg/m^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m^2 intravenous on day 1 & 8 of a 21 day cycle), or vinorelbine (25mg/m^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
3112984|NCT01802957|Other|St. Paul and Networked Health Centers|An uncontrolled before and after design with baseline and follow-up cross sectional measurements will be used at the overall site level (St. Paul Hospital and the 8 associated HCs). There will be no control unit.
3112985|NCT01802944|Experimental|10 IU BID|10 IU BID Intranasal Insulin
3112986|NCT01802944|Experimental|20 IU BID|20 IU BID Intranasal Insulin
3112987|NCT01802944|Experimental|PLACEBOS|Saline nasal solution used as placebo
3112988|NCT01802931|Active Comparator|Session 1 or Session 2|Single dose sessions without ketoconazole co-administration
3112989|NCT01802931|Active Comparator|Co-dose Session|Single dose session with ketoconazole co-administration
3112990|NCT01802918|Experimental|Cohort 1|Subject in this cohort will be randomized to one of the four following treatment sequences (1 treatment per visit): ABCD, BACD, BCAD, or BCDA. Where A=Placebo, B= GSK2838232 5mg, C=GSK2838232 10mg, and D=GSK2838232 20mg
3112991|NCT01802918|Experimental|Cohort 2|Subject in this cohort will be randomized to one of the four following treatment sequences (1 treatment per visit): EGHJ, FEHJ, FGIJ, or FGHK. Where E=Placebo, F= GSK2838232 50mg, G= GSK2838232 100mg, H= GSK2838232 50mg + food, I= Placebo + food, J= GSK2838232 10mg + RTV, K= placebo + RTV.
3112992|NCT01802905|Experimental|Sequenced patients|Patients enrolled on the study who have successful sequencing of their cancers will be closely monitored for: what chemotherapy agents are next used, what response and toxicity do they have, is there any early sign of response detected on PET-CT, overall did the genomic information change treatment decision-making.
3112993|NCT01802892|Experimental|Ronacaleret 100 mg|Subjects will receive ronacaleret (100 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
3112994|NCT01802892|Experimental|Ronacaleret 400 mg|Subjects will receive ronacaleret (400 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
3112995|NCT01802879|Experimental|Panobinostat|single agent panobinostat, starting with last assigned dose and regimen patient received in parent study
3112996|NCT01802866|Experimental|ACU-4429 2.5 mg|2.5 mg tablet
3112997|NCT01802866|Experimental|ACU-4429 5 mg|5 mg tablet
3112998|NCT01802866|Experimental|ACU-4429 10 mg|10 mg tablet
3112999|NCT01802866|Placebo Comparator|Placebo|Includes identical tablets with only inactive ingredients (0 mg).
3113000|NCT01802853|Experimental|A: RO6811135 s.c.|
3113001|NCT01802853|Active Comparator|B: RO6811135 i.v.|
3113002|NCT01802840|Placebo Comparator|biscuits without soy fiber|biscuits without soy fiber
3113003|NCT01802840|Experimental|biscuits supplemented with soy fiber|biscuits supplemented with soy fiber
3113004|NCT01802827||VAT patients|Patients developing Ventilator Associated Tracheobronchitis
3113005|NCT01802827||VAP|Patients presenting ventilator associated pneumonia
3113006|NCT01802827||No ventilator associated infection|patients who do not present ventilator associated infection during their stay in ICU
3113007|NCT01802814|No Intervention|SR-A|Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized not to receive epratuzumab.
3113008|NCT01802814|Active Comparator|SR-A + Epratuzumab|Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized to receive epratuzumab.
3113009|NCT01802814|No Intervention|SR-B|Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized not to receive epratuzumab.
3113010|NCT01802814|Active Comparator|SR-B + Epratuzumab|Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized to receive epratuzumab.
3113011|NCT01802801||1|
3113012|NCT01802788||Cohort A|"Patients implanted with a Portico valve bearing the CE mark (implanted after St Jude Medical declared the device compliant with all applicable essential requirements within the European union and marketed the device bearing the CE mark.)"
3113013|NCT01802788||Cohort B|Patients implanted with a Portico valve as part of an Investigational Device study.
3113014|NCT01802775|Experimental|edoxaban/aspirin|Open label edoxaban will be provided. Subjects randomized to this treatment arm will receive edoxaban 60 mg once daily (QD) (two 30 mg tablets) for a total of approximately 3 months on a background of aspirin 100 mg QD.
3113015|NCT01802775|Active Comparator|clopidogrel/aspirin|Open label clopidogrel will be provided. Subjects randomized to this treatment arm will receive clopidogrel 75 mg QD (one 75 mg tablet) for a total of approximately 3 months on a background of aspirin 100 mg QD. A loading dose of clopidogrel 300 mg (four 75mg tablets) will be given to subjects as the first dose as early as possible after adequate hemostasis (i.e., within 4 hours of hemostasis).
3113016|NCT01802762|Other|NeMo Patch and NeMo Probe|TBI and SAH patients, one arm
3113069|NCT01802411|Placebo Comparator|Placebo|Single total administration of 266 mg (approximately 88 mg to each of three nerve segments) of 6.6 mL volume each for a total of 20 mL
3113102|NCT01802164|No Intervention|2|Conventional abdominal wall closure without mesh implantation
3113017|NCT01802749|Active Comparator|chemotherapy|"Combination chemotherapy with ONE of the following regimens:~PLD-C: Pegylated liposomal doxorubicin 30 mg/m2 + Carboplatin AUC (area under curve) 5 on day 1 every 4 weeks;~GEM-C: Gemcitabine 1000 mg/m2 on day 1, 8 every 21 + Carboplatin AUC of 4 on day 1 every 21 days;~PAC-C: Paclitaxel 175 mg/m2 on day 1, every 21 + Carboplatin AUC of 5 on day 1 every 21 days."
3113018|NCT01802749|Experimental|Chemotherapy and bevacizumab|"Combination chemotherapy AND bevacizumab with ONE of the following regimens:~PLD-C: Pegylated liposomal doxorubicin 30 mg/m2 + Carboplatin AUC 5 on day 1 every 4 weeks and Bevacizumab 10 mg/kg i.v. on Day 1 every 2 weeks;~GEM-C: Gemcitabine 1000 mg/m2 on day 1, 8 every 21 + Carboplatin AUC of 4 on day 1 every 21 days AND Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks;L~PAC-C: Paclitaxel 175 mg/m2 on day 1, every 21 + Carboplatin AUC of 5 on day 1 every 21 days AND Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks.~Patients whose disease has not progressed after the initial six cycles of combination treatment will continue bevacizumab, at 15 mg/kg every 3 weeks until disease progression,unacceptable toxicity or patient withdrawn."
3113019|NCT01802736|Active Comparator|Standard Positive Prevention Counselling|"Standard positive prevention counseling which includes alcohol reduction and sexual risk behavior counseling provided in the clinic by the clinic medical counselors on the day of enrollment and at month 3 visit.~Although there is awareness of the need to engage and include PLWHA in HIV prevention, there are little practical efforts devoted towards this engagement even in developed countries. One of the major reasons is the lack of a well-defined standard positive prevention package that needs to be delivered to PLWHA. The approach proposed by Kennedy et al modified to suit the local setting and involves a simpler understandable classification of the goals, interventions and expected outcomes of the treatment."
3113020|NCT01802736|Experimental|Alcohol Motivational intervention counselling plus SPP|
3113021|NCT01802723|Experimental|LIPO-202, Low|Drug: salmeterol xinafoate
3113022|NCT01802723|Experimental|LIPO-202, Mid|Drug: salmeterol xinafoate
3113023|NCT01802723|Experimental|LIPO-202, High|Drug: salmeterol xinafoate
3113024|NCT01802723|Experimental|LIPO-202, Placebo|Drug: Placebo
3113025|NCT01802710|Experimental|Psychological support|Ten weekly sessions, which the first 8 were in group and the last 2 were individuals. It consists on a) an informational session; b) Beck's cognitive-behavioural therapy; and c) proressive-muscle relaxation according to Jacobson
3113026|NCT01802710|Active Comparator|No psychological support|Patients of this group only received the conventional medical treatment, not receiving any psychological support
3113027|NCT01802697|Experimental|IdeS|Intravenous infusion
3113028|NCT01802697|Placebo Comparator|PBS Buffer|Intravenous infusion
3113029|NCT01802684|Experimental|OPTIMOX-aflibercept|"Induction therapy (sequence #1)~Regimen : aflibercept + modified FOLFOX7~Duration : 6 cycles (3 months) Maintenance after induction (sequence #2) First phase (sequence #2A)~Regimen : aflibercept + fluoropyrimidine (simplifed LV5FU2 or capecitabine)~Duration : 6 cycles (3 months) Second phase (sequence #2B)~Regimen : aflibercept +/- fluoropyrimidine (simplifed LV5FU2 or capecitabine) according to eligibility criteria for chemotherapy-free interval)~Duration : until PD or limiting toxicity Reintroduction (sequence #3)~Regimen : aflibercept + modified FOLFOX7~Duration : 6 cycles (3 months) Maintenance after reintroduction (sequence #4)~Regimen : aflibercept + fluoropyrimidine~Duration : until PD or limiting toxicity"
3113030|NCT01802671|Experimental|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways: a web tool named TEO (Emotional Therapy Online) and SMS that will send to the patients' mobile phone with reminders and reinforcements.
3113031|NCT01802671|Active Comparator|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment and information
3113032|NCT01802671|Experimental|cognitive behavioural therapy (CBT)|Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT.
3113033|NCT01802658|Active Comparator|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times over two years.
3113034|NCT01802658|Placebo Comparator|NACL|NACl 100 ml IV. 3 infusions. Administration 3 times over two years.
3113035|NCT01802645|Active Comparator|Cetuximab/FOLFIRI|"Cetuximab 250 mg/m² (1 h) weekly Irinotecan 180 mg/m² (1 h)*, d-l Folinic acid 400 mg/m² (2 h), 5-FU 400 mg/m² (Bolus), 5-FU 2400 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
3113036|NCT01802645|Experimental|Cetuximab/FOLFOXIRI|"Cetuximab 250 mg/m² (1 h) weekly Irinotecan 125 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
3113037|NCT01802645|Active Comparator|FOLFOXIRI|"Irinotecan 165 mg/m² (1 h)*, Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
3113038|NCT01802645|Experimental|Bevacizumab/FOLFOXIRI|"Bevacizumab 5 mg/kg (30-90 min i.v.), Irinotecan 165 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
3113039|NCT01802632|Experimental|Daily dose of AZD9291|Daily oral dose of AZD9291
3113040|NCT01802619|Placebo Comparator|inhaled nitrogen|Using an Inovent (Ikaria Inc, N.J., USA) or volumetrically-calibrated flowmeters, pure nitrogen (placebo) is mixed with pure O2 or air. During CPB the gas mixture is delivered through the extracorporeal oxygenator, after CPB the NO is delivered through the inspiratory limb of the anesthetic or ventilator circuit.
3113041|NCT01802619|Experimental|inhaled nitric oxide|Using an Inovent (Ikaria Inc, N.J., USA) or volumetrically-calibrated flowmeters, 800 ppm NO gas is mixed with pure O2 or air to obtain a final concentration of 80 ppm NO. During CPB the gas mixture is delivered through the extracorporeal oxygenator, after CPB the gas is delivered through the inspiratory limb of the anesthetic or ventilator circuit. NO, NO2 and O2 and methemoglobin levels are monitored by an unblinded observer.
3113042|NCT01802593|Experimental|Immunomodulator therapy 26 weeks|IFX 5mg/kg for 76 weeks, continuing immunomodulator for 6 months from first infusion
3113043|NCT01802593|Experimental|Immunomodulator therapy 2 weeks|IFX 5mg/kg induction for 76 weeks, discontinuing immunomodulator on day of second infusion( after 14 days).
3113070|NCT01802398||No treatment|Observational cohort study of older (age≥60 years) adults who present to an emergency department with syncope (otherwise known as fainting)
3113071|NCT01802385|Placebo Comparator|Placebo|Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day).
3113044|NCT01802580|Experimental|Intervention - internet reminder survey|Treatment phase is 12 months. During the intervention, each subject will receive fluocinonide 0.05% ointment, a standard treatment for psoriasis. If their psoriasis could be suitably treated with fluocinonide, then they will be asked to participate in the study. At the initial study visit, fluocinonide will be dispensed in a small jar with a MEMS® electronic monitoring cap attached. Subjects will be asked to apply the medication twice daily. They will be asked to the entire affected area, excluding face and genitals. Subjects will be instructed to apply the smallest amount of study medication sufficient to cover the affected areas. At the end of the treatment phase, subjects will have a feedback session with specific results of adherence behavior revealed. They will receive weekly surveys via internet to complete.
3113045|NCT01802580|Experimental|Standard of care, no internet survey|Standard treatment for psoriasis. If it is felt that their psoriasis could be suitably treated with fluocinonide, then they will be asked to participate in the study. At the initial study visit, fluocinonide will be dispensed to the subjects in a small jar with a MEMS® electronic monitoring cap attached. Subjects will be asked to apply the medication twice daily. All subjects will be assigned to treatment with topical fluocinonide to the entire affected area, excluding face and genitals. Subjects will be instructed to apply the smallest amount of study medication sufficient to cover the affected areas. At the end of the treatment phase, subjects will have a feedback session with specific results of adherence behavior revealed.
3113046|NCT01802567|Experimental|Guided Therapy- Pediatric Gene Analysis Platform|A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
3113047|NCT01802554|Experimental|Pleasant Events Program (PEP)|The Pleasant Events Program (PEP) is a Behavioral Activation (BA) treatment for depression. Participants receive 4 weekly sessions of face-to-face therapy (60 minutes each) to increase caregiver participation in pleasurable activities. Two additional phone sessions focus on continued behavioral activation for caregivers as well as problem-solving barriers to activation.
3113048|NCT01802554|Active Comparator|Information-Support (IS)|Participants in the Information-Support (IS) control condition were provided with a resource manual consisting of topics commonly covered in support groups or information packets provided by community agencies. Topics included problem-solving and communication skills, cognitive reframing and behavioral management, self-care help, caregiver fact sheets on a range of social and mental health issues, placement information, financial and legal issues, and lists of local organizations and community resources available. Each IS session allowed caregivers to select issue(s) from the resource manual to discuss. The therapist covered the material based on the caregivers' needs. When requested by the caregiver, supportive psychotherapy was also provided.
3113049|NCT01802541|Experimental|DAG oil|
3113050|NCT01802541|Placebo Comparator|TAG oil|
3113051|NCT01802528||Obturator externus muscle injection|patients were treated with obturator externus injection
3113052|NCT01802515|Active Comparator|Atomoxetine, low dose|1 capsule containing 40mg of atomoxetine by mouth everyday for 8 weeks followed by 1 week of daily placebo capsules.
3113053|NCT01802515|Active Comparator|Atomoxetine, high dose|One capsule containing 80mg of atomoxetine by mouth everyday for 8 weeks, followed by 1 week of daily 40mg atomoxetine capsules
3113054|NCT01802515|Placebo Comparator|Placebo (sugar pill)|1 placebo capsule by mouth everyday for 8 weeks of treatment invention followed by one week of placebo capsule during study medication taper.
3113055|NCT01802502|Active Comparator|Rifampicin 600 mg|Subjects in this arm receive 600 mg rifampicin intravenously
3113056|NCT01802502|Experimental|rifampicin 750 mg|Subjects in this arm receive 750 mg rifampicin orally
3113057|NCT01802502|Experimental|rifampicin 900 mg|Subjects in this arm receive rifampicin 900 mg orally
3113058|NCT01802489|Active Comparator|Amiloride|Amiloride capsules 10mg once per day for 5 months
3113059|NCT01802489|Placebo Comparator|Placebo|Placebo capsules one per day for 5 months
3113060|NCT01802476|Other|Fixed Sequence Crossover Arm|This study arm consists of a fixed sequence crossover where study subjects will receive Treatment A and following a washout of no less than 10 days will then receive Treatment B. The drug class is a CDK4/6 inhibitor.
3113061|NCT01802463||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
3113062|NCT01802463||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
3113063|NCT01802463||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
3113064|NCT01802450|Experimental|Dasatinib (Sprycel)|Dasatinib (Sprycel): 100 mg QD administered orally as continuous daily dosing (CDD)until disease progression or adverse events that, by protocol definition or Investigator judgment, would preclude further treatment with dasatinib
3113065|NCT01802437|Experimental|Interpersonal Psychotherapy|Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.
3113066|NCT01802437|Other|Fluoxetine|The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. The medication will be taken as a daily pill.
3113067|NCT01802424|Experimental|The Friends program|Youth with increased levels of anxiety are thought to regulate their fear by recognizing bodily cues, learning relaxation, regulating thoughts and feelings and expose themselves to situations and objects that activate their anxiety.
3113068|NCT01802411|Active Comparator|Liposome bupivacaine|Single total administration of 266 mg (approximately 88 mg to each of three nerve segments) of 6.6 mL volume each for a total of 20 mL.
3113072|NCT01802385|Experimental|Sertraline 400mg|Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day plus adjunctive sertraline therapy at 400mg/day for 2 weeks, then 200mg for 12 weeks, and then tapered over 3 weeks.
3113073|NCT01802372|Active Comparator|WHO CVD Risk Assessment package|Arm#1 (Intervention Group): Provided Ghana's National Health Insurance and the WHO CVD Risk Assessment package for 12 months.
3113074|NCT01802372|Sham Comparator|Health Insurance only|Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline,and usual care.
3113075|NCT01802359||Mirodenafil|
3113076|NCT01802346|Experimental|Arm I (low-calorie diet)|Patients eat a special low-calorie diet during 3 days prior to chemotherapy, during the 12 weeks of chemotherapy, and 2 days after chemotherapy. Patients are provided with all meals and all food to be consumed and maintain a diary of the food consumed and appropriate amounts.
3113077|NCT01802346|Active Comparator|Arm II (normal diet)|Patients eat a normal diet and receive dietary advice which may include consultation with a nutritionist. Patients maintain a diary of the food consumed and appropriate amounts.
3113078|NCT01802333|Experimental|Arm I (standard dose cytarabine, daunorubicin hydrochloride)|"INDUCTION/RE-INDUCTION: Patients receive standard dose cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 15. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.~CONSOLIDATION: Patients receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5.~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy."
3113079|NCT01802333|Experimental|Arm II (high-dose cytarabine, idarubicin)|"INDUCTION/RE-INDUCTION: Patients receive high dose cytarabine IV continuously on days 1-4 and idarubicin IV over 15 minutes on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.~CONSOLIDATION: Patients receive cytarabine IV continuously on days 1-3 and idarubicin IV over 15 minutes on days 1-2.~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy."
3113080|NCT01802333|Experimental|Arm III (vorinostat, high-dose cytarabine, idarubicin)|"INDUCTION/RE-INDUCTIONI: Patients receive vorinostat PO TID on days 1-3, high-dose cytarabine IV continuously on days 4-7, and idarubicin IV over 15 minutes on days 4-6. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.~CONSOLIDATION: Patients receive vorinostat PO TID on days 1-3, cytarabine IV continuously on days 4-6, and idarubicin IV over 15 minutes on days 4-5.~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy. (Permanently closed to accrual, effective 6/2/2015) Patients previously randomized to Arm III may continue treatment with or without vorinostat."
3113081|NCT01802320|Experimental|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 orally (PO) on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
3113082|NCT01802307|Experimental|Focal Therapy|
3113083|NCT01802294|Experimental|Parenting Program|12-week group-based parenting program (Sinovuyo Caring Family Programme) delivered in weekly sessions. Program is manualized.
3113084|NCT01802294|No Intervention|Wait-list control|Wait-list control group. Program delivered 3 months after posttest.
3113085|NCT01802281|Active Comparator|Hysteropexy|Uphold® LITE
3113086|NCT01802281|Active Comparator|Hysterectomy and USLS|Vaginal hysterectomy and uterosacral ligament suspension (USLS)
3113087|NCT01802268|Active Comparator|Sirolimus|Conversion from Tacrolimus to Sirolimus
3113088|NCT01802268|Active Comparator|Tacrolimus|Maintenance on tacrolimus
3113089|NCT01802255|Experimental|Inhalatory sedation|Sevoflurane given via AnaConDa for sedation minimum 48 hours
3113090|NCT01802255|Active Comparator|Intravenous sedation|Midazolam given intravenously for sedation minimum 48 hours
3113091|NCT01802242|Experimental|Active Radiation Treatment (Cohort 2)|
3113092|NCT01802242|Other|Prior Radiation Treatment (Control Cohort)|Patients who received 78Gy RT to the prostate gland 3‐4.5 years prior to enrollment. This group will not be receiving any active treatment
3113093|NCT01802229|Active Comparator|Suture|Umbilical port-site closure with simple suture of the fascia.
3113094|NCT01802229|Experimental|Prophylactic mesh|Umbilical port-site closure with mesh placement
3113095|NCT01802216|No Intervention|Control/Delayed Treatment|Baseline panoramic x-ray (Panorex) and complete oral examinations at every visit. Rescue scaling and root planing only to sites of periodontal disease progression (since prior examination) of greater than 3mm. Subjects will be informed of their assignment to the delayed treatment group and provided referral list of local dentists should patient not feel comfortable waiting until end of study for full intensive periodontal disease treatment. Written and verbal instruction in oral hygiene. Provision of oral hygiene supplies.
3113096|NCT01802216|Active Comparator|Intensive periodontal disease treatment|Baseline panoramic x-ray (Panorex) and complete oral examinations at every visit. Intensive periodontal disease treatment to include administration of local anesthetic to up to two quadrants for scaling and root planing with ultrasonic and hand instruments. Minocycline will be applied to any sites with probing depth >=5mm. Hopeless teeth in scaled quadrants will be extracted. Written and verbal instruction in oral hygiene. Provision of oral hygiene supplies.
3113097|NCT01802203||truFreeze spray cryotherapy|truFreeze Spray Cryotherapy administered as routine clinical care
3113098|NCT01802190||Deafness patients|Deafness patients
3113099|NCT01802177|Experimental|UVB excimer light|Patches of alopecia will be treated twice weekly with UVB excimer light. Only one half of a single alopecia areata patch will be treated. In order to treat the same half during each visit, a transparent sheet will be marked, using a marking pen, to delineate the borders of the treatment area with a central dividing line. The other half will be covered and used as a control. Treatments will be given randomly (by sealed envelope randomization method) into one of the two halves in different patients but will be given into the same half in each patient in all treatment sessions. Only one investigator will know the intervention each half has received. A total of 23 treatments will be given over 12 weeks.
3113100|NCT01802177|No Intervention|No treatment (covered)|
3113101|NCT01802164|Experimental|1|Conventional abdominal wall closure with mesh implantation
3113103|NCT01802151|Placebo Comparator|Placebo|Placebo (starch, magnesium stearate, citric acid) capsules once daily for 4 weeks.
3113104|NCT01802151|Experimental|B. subtilis R0179 (10 billion CFU)|"B. subtilis R0179 (approximately 10 billion CFU/capsule) once daily for 4 weeks.~* CFU (Colony Forming Unit)"
3113105|NCT01802151|Experimental|B. subtilis R0179 (1 billion CFU)|B. subtilis R0179 (approximately 1 billion CFU/capsule) once daily for 4 weeks.
3113106|NCT01802151|Experimental|B. subtilis R0179 (0.1 billion CFU)|B. subtilis R0179 (approximately 0.1 billion CFU/capsule) once daily for 4 weeks.
3113107|NCT01802138|Experimental|Activated T-lymphocyte|"This was designed as a single-center, single group clinical trial, and subjects include patients with refractory refractory/relapsed neuroblastoma.~If subjects agree to participate in the clinical trial by signing a written consent, only appropriate subjects, who meet the criteria on the examinations and tests, will undergo this clinical trial. To participate in the clinical trial, subject's blood of more than 60 ml should be withdrawn to make a study drug at least 3 weeks before administration. Subjects should visit to hospital according to the protocol and receive a study drug. Therapeutic response rate, overall survival rate, time to progression should be investigated."
3113108|NCT01802125||Basic science (SNP array analysis)|Tissue samples are analyzed using laboratory biomarker analysis for LOH and SNP array profiling using microarray and immunohistochemistry.
3113109|NCT01802112|Placebo Comparator|Maltodextrins|15 grams of maltodextrins per day dissolved in water during 21 days
3113110|NCT01802112|Experimental|Resistant maltodextrins|15 grams of resistant maltodextrins per day, dissolved in water during 21 days
3113111|NCT01802099|Other|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
3113112|NCT01802099|Other|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
3113113|NCT01802086|Active Comparator|Emla-cream|Dose: 1 g Emla-cream, 1 hour.
3113114|NCT01802086|Placebo Comparator|Miniderm cream|Dose: 1 g Miniderm-cream, 1 hour.
3113115|NCT01802073|Experimental|Oral Vancomycin|1) For children who weight < or = 30 kg, the vancomycin dose will be 50 mg/kg/day given orally 3 times per day for the 1st month and continue with the same dose for subsequent months if the clinical laboratory studies improved and are normal. If the laboratory studies are not normal the dose will be increased to 75 mg/kg/day given orally 3 times per day for the 2nd month and 100mg/kg/day given orally 3 times per day the 3rd month. If the laboratory studies do not improve by the end of the 3rd month since starting the vancomycin, the vancomycin will be stopped and the child will not continue the study. 2) For adults and children who weigh >30 kg, the vancomycin dose will be 500 mg given orally 3 times per day for the 1st month and continue with this dose if the clinical laboratory studies improve and are normal. If the laboratory studies are not normal the dose will be increased to 750 mg 3 times per day for the 2nd month and 1000 mg 3 times per day the 3rd month.
3113116|NCT01802047|Experimental|Electric Pump Modality|Each mother follows all 3 electric pump modalities in a randomized order.
3113117|NCT01802034||Native, Renal Tissue Preservation Group|Subjects who have a renal biopsy and the tissue is possessed and maintained by the RENAL AID repository.
3113118|NCT01802034||Native, Non-tissue Preservation Group|"Subjects who have had a renal biopsy but the tissue is not held by RENAL AID repository; and/or~Subjects with diabetes and renal disease who have not had a renal biopsy."
3113119|NCT01802034||Transplant Nephropathy Group|"Subjects who have had a renal transplant and require a transplant biopsy for either surveillance or for-cause indications."
3113120|NCT01802021|Experimental|Qingshu-Yiqi-Tang+standard therapy|"Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy, maximal for 6 months.~1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD."
3113121|NCT01802021|No Intervention|1st line doublet chemotherapy|1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD.
3113122|NCT01802008|Active Comparator|3-minute withdrawal time|"For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist."
3113123|NCT01802008|Active Comparator|6-minute withdrawal time|"For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist."
3113124|NCT01801969||Rehabilitation service|"Centralized or Decentralized rehabilitation~Size of municipality"
3113125|NCT01801956|Active Comparator|Motivational interviewing|A one hour motivational interview
3113126|NCT01801956|Experimental|Physical activity|Four motivational interviews, free membership of a sport club, virtual arena to upload training data from a GPS-watch
3113127|NCT01801943|Experimental|Cognitive Remediation Therapy Group|30 minute Cognitive Remediation Therapy and 60 minute Healthy Living Class three time per week
3113128|NCT01801943|Experimental|Walking Intervention Group|60 minutes of walking and 30 minutes of reading stimulation three times a week
3113129|NCT01801943|Experimental|Combination Group|30 minutes of Cognitive Remediation therapy and 60 minutes of walking three times a week
3113130|NCT01801943|Experimental|Healthy Living Group|60 minute Healthy Living Class and 30 minutes of reading stimulation three times a week.
3113131|NCT01801930|Experimental|Dose level 1|
3113132|NCT01801930|Experimental|Dose level 2|
3113133|NCT01801930|Experimental|Dose level 3|
3113134|NCT01801930|Experimental|Dose level 4|
3113135|NCT01801917|Placebo Comparator|Placebo|5 placebo tablets daily during non-titration phase
3113136|NCT01801917|Experimental|BAF312 2mg|1 tablet of BAF312 2 mg + 4 tablets of Placebo daily during non-titration phase
3113137|NCT01801917|Experimental|BAF312 10 mg|5 tablets of BAF312 2 mg daily during non-titration phase
3113138|NCT01801904|Experimental|Panitumumab|
3113291|NCT01800695|Experimental|Arm B|ABT-414 in combination with temozolomide
3113139|NCT01801891|Active Comparator|Control group|Patients randomised to the control group will, in addition to their routine compression bandaging, be given muscle stimulators for home use and instructed to apply 3x 30 minute sessions of comfortable electrical stimulation daily for 12 weeks. The stimulators given to the control group will be set to provide minimal stimulation resulting in no visible muscular contraction.
3113140|NCT01801891|Experimental|VASGARD stimulator|Patients randomised to this group, in addition to their routine treatment with compression bandaging, will be given muscle stimulators for home use and instructed to apply 3x 30 minute sessions of comfortable electrical stimulation daily for 12 weeks. The intervention group stimulators will be capable of causing muscular contraction with a maximum force ranging from 30-40% of voluntary contractions.
3113141|NCT01801878|Experimental|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
3113142|NCT01801878|Active Comparator|Normal saline|Normal saline inject to the half of irradiated breast
3113143|NCT01801865|Experimental|MRI for Neonates|MRI
3113144|NCT01801852|Experimental|NKT cells|NKT cells treatment plus regular treatment
3113145|NCT01801839||SIRS,sepsis,normal|"SIRS~(1) temperature > 38 centigrade or < 36 centigrade; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000/μL or < 4000/μL , or > 10% immature cells.~sepsis~SIRS + infection.~normal~not SIRS and have no infection."
3113146|NCT01801826||Treatment|Treatment with CryoTouch IV device
3113147|NCT01801813||Neurosurgery for brain tumor patients|Collecting pre-operative and per-operative data, neuro-radiological data and post-operative complications
3113148|NCT01801800||Aneurysmal subarachnoid haemorrhage|Speckle-tracking images in Echocardiography
3113149|NCT01801787|Experimental|verum tDCS|left-hemispheric tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3
3113150|NCT01801787|Sham Comparator|sham tDCS|left-hemispheric sham tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3
3113151|NCT01801774|Placebo Comparator|Dexamethasone|Dexamethasone 0.1%/Tobramycin 0.3% eye drop 4 times per day for 28 days
3113152|NCT01801774|Active Comparator|Triamcinolone|Subtenon 20-mg Triamcinolone injection
3113153|NCT01801761||develop group|previous COPD study
3113154|NCT01801761||validation group|consecutive COPD patients from outpatient clinics
3113155|NCT01801748|Experimental|oral wheat challenge|
3113156|NCT01801735|Experimental|Meloxicam Test Capsules|One Capsule QD
3113157|NCT01801722||NT-proBNP,ejection fraction ,COPD stage.|The group comprised 25 women (47%) and 28 men (53%). The mean age was 75.4 years (SD 7.9), 76.3 (SD 7.6) for men and 74.4 (SD 8.2) for women.
3113158|NCT01801709|Experimental|AAVrh.10cuARSA|intracerebral administration of AAVrh.10cuARSA at 12 sites in the white matter of both brain hemispheres.
3113159|NCT01801696|Experimental|Parent massage tx group|Children in this group receive the parent-delivered massage intervention right after randomization.
3113160|NCT01801696|Experimental|Parent massage wait-list control group|Children in this group receive the parent-delivered massage intervention 5 months after randomization.
3113161|NCT01801683|Other|Intervention: PEARLS (evidence based reports)|Intervention was modified academic detailing method, performed by sixth-year medical students/academic detailers.Each mentor chose two patients from real life who represented diagnostic, therapeutic or prognostic challenge. The students formed an answerable question, using PICO, and wrote report according to PEARLS.
3113162|NCT01801683|No Intervention|Control group of GPs|GPs not mentors who do not receive academic detailing intervention using PICO/PEARLS.
3113163|NCT01801670||MF patients for blood & biopsy|Participants who are cared for at Boston Medical Center will first be assessed by physicians of the CTCL multi-specialty clinic if vorinostat, administered per standard of care, is an appropriate therapy for their CTCL. The decision to invite patients to participate in this study is (1) separate from the above described clinical decision to utilize vorinostat, and (2) will be offered subsequent to the clinical decision to utilize vorinostat. Vorinostat (Zolinza) will be administered as follows: each subject will receive each month for the first 3 months (cycle 1 to 3) 3 capsules of vorinostat 100 mg po daily. For months 4-6 (cycles 4 to 6), subjects will receive each month for 4 capsules of vorinostat 100 mg po daily.
3113164|NCT01801657||Bronchiectasis,stable|A patient was defined as stable if there was no exacerbation for the previous 4 wk
3113165|NCT01801657||Bronchiectasis,exacerbations|Bronchiectasis exacerbations were defined by subjective and persistent(>24 h) deterioration in at least three respiratory symptoms, including cough, dyspnea, hemoptysis, increased sputum purulence or volume, chest pain (with or without fever), radiographic deterioration, systemic disturbances, or changes in chest auscultation
3113166|NCT01801644|Experimental|gemcitabine plus cisplatin|gemcitabine plus cisplatin: 3 cycles of gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion and cisplatin 70 mg/m2 on day 1 as an 2 hour infusion will be applied
3113167|NCT01801631|Experimental|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
3113168|NCT01801631|Other|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
3113169|NCT01801605|Active Comparator|on|active session
3113170|NCT01801605|Placebo Comparator|off|fictive session
3113171|NCT01801566|Active Comparator|Conventional implant loading protocol|Single implant-retained mandibular overdenture
3113172|NCT01801566|Experimental|Immediate loading implant protocol|Single implant-retained mandibular overdenture
3113173|NCT01801553|Active Comparator|spinal manipulation intervention group|Spinal manipulation: 3 sessions within one week of true lumbopelvic manipulation
3113174|NCT01801553|Sham Comparator|Spinal manipulation control group|Sham spinal manipulation: 3 sessions within one week of sham lumbopelvic manipulation
3113175|NCT01801540|Experimental|0% arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
3113292|NCT01800695|Experimental|Arm C|ABT-414 monotherapy
3113176|NCT01801540|Other|5 % arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
3113177|NCT01801540|Other|10 % arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
3113178|NCT01801540|Other|0 % arabinose meal Starch|A meal containing two bons with butter and cheese, The and water
3113179|NCT01801540|Other|5 % arabinose meal starch|A meal containing two bons with butter and cheese, The and water
3113180|NCT01801540|Other|10 % arabinose meal starch|A meal containing two bons with butter and cheese, The and water
3113181|NCT01801527|Experimental|Telerehabilitation group|
3113182|NCT01801527|No Intervention|Control group|Information about usual care
3113183|NCT01801501||Critical Care Patients|Patients admitted in Critical Care Unit with diagnosis of severe sepsis/septic shock
3113184|NCT01801488||AVM Patients|Patients receiving surgical intervention for an intracranial arterial-venous malformation.
3113185|NCT01801488||Ruptured Aneurysm|Patients receiving surgical intervention for a ruptured intracranial aneurysm.
3113186|NCT01801488||Unruptured Aneurysm|Patients receiving surgical intervention for an unruptured intracranial aneurysm.
3113187|NCT01801475|Active Comparator|Pregnant women|Full term pregnant women scheduled for Cesarean section and will be given Ondansetron as standard-of-care prior to surgery.
3113188|NCT01801475|Active Comparator|Non-pregnant women|Non-pregnant women scheduled for surgery at Stanford who will be given Ondansetron prior to their surgery as standard-of-care.
3113189|NCT01801475|No Intervention|Neonates|"Babies of the pregnant women enrolled in the study; no ondansetron is given to babies in this Aim 1 of the study."
3113190|NCT01801462|Experimental|Simulation-based ultrasound training|The initial training is provided on a high-fidelity Virtual-Reality (VR) simulator (Scantrainer, Medaphor). The VR simulator provides images obtained from real patients and haptic feedback from the ultrasound probe. The basic gynecologic and advanced gynecologic modules are selected for training purposes. When all modules are passed on the VR simulator, the participants receive 30 minutes of training on the low-fidelity simulator (BluePhantom) to allow participants to review the functions, they just trained, using real ultrasound equipment.
3113191|NCT01801462|No Intervention|Control|Participants randomized to the control group receive traditional clinical introduction locally in the departments. This may include observation and supervised practice and the different types of clinical training provided by each department are gathered through the department's head of education and registered.
3113192|NCT01801449|Experimental|Rilonacept Treatment|Rilonacept loading dose of 4.4 mg/kg/week followed by maintenance dose of 2.2 mg/kg/week. Total duration of the study 24 months. Maintenance dose could be escalated to 4.4 mg/kg/week or further to 6.6 mg/kg/week for 3 months only.
3113193|NCT01801436|Experimental|Bortezomib|Bortezomib 1.3 milligram (mg) per meter square (m^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
3113194|NCT01801423|Experimental|Hydroxyurea|Study investigators propose to enroll 60 children with SCA and an elevated TCD measurement between 5 and 12 years of age in this one arm feasibility study of hydroxyurea therapy, with follow-up of at least 12 months per subject. The study intervention will include HU to begin at ~ 20 mg/kg/day(range 17.5 - 26 mg/kg/day). No dose escalation will occur. Given the success of the first year of enrollment and the favorable response of TCD measurement after 3 months on HU therapy, the study investigators have participants as an internal pilot. The definitive phase III trial will now compare low dose HU therapy to the result of no treatment arm from the STOP Trial.
3113195|NCT01801410|Active Comparator|Misoprostol|Group 2 will be induced using oral misoprostol tablets (25 mcg) every 2 hours for a maximum of 12 doses or until active labour commences. In primigravid women, if contractions have not commenced after 2 doses, the dosage may be increased to 50mcg every 2 hours. Once in labour (regular painful contractions with a cervical dilatation of at least 4cm) no more misoprostol will be used and artificial membrane rupture and/or oxytocin infusion will be used as clinically indicated. If labour has still not commenced after 24 hours, they will be deemed to have a 'failed induction' and the decision on further management will be made by the clinical team (their choice could include the use of repeat misoprostol, Foley catheter, dinoprostone, caesarean section or delay as deemed appropriate).
3113196|NCT01801410|Active Comparator|Foley Catheter|Group 1 will undergo induction using a transcervical Foley catheter (silicone, size 18F with 30ml balloon) which will remain until active labour starts, the Foley catheter falls out, or 12 hours have elapsed. If the Foley catheter falls out within 12h, membranes will be ruptured and/or oxytocin infusion started. If the Foley catheter does not fall out within 12h, it will be removed at 12h and oxytocin commenced with an artificial rupture of membrane when possible. If labour has still not commenced after 24 hours, they will be deemed to have a 'failed induction' and the decision on further management will be made by the clinical team (their choice could include the use of misoprostol, repeat Foley catheter, dinoprostone, caesarean section or delay as deemed appropriate).
3113197|NCT01801397|Other|Teriparatide|one arm study. All patients receive teriparatide
3113198|NCT01801384|Experimental|Original contingent vouchers schedule|Women will receive an abstinence-contingent voucher-based incentives intervention (Contingency Management) for smoking cessation and relapse prevention.
3113199|NCT01801384|Experimental|Revised contingent vouchers schedule|Women receive abstinence-contingent voucher-based incentives (Contingency Management) intervention designed to further increase cessation and relapse prevention rates.
3113200|NCT01801384|Sham Comparator|Non-contingent vouchers schedule|This serves as a control condition wherein women earn incentives independent of smoking status.
3113201|NCT01801371|Experimental|68Ga-BNOTA-PRGD2|In patients in suspicion of glioma, single bolus of nearly 111 MBq 68Ga-BNOTA-PRGD2 will be intravenously injected 30 minutes before brain PET/CT to determine 68Ga-BNOTA-PRGD2 uptake in tumor and brain.
3113202|NCT01801358|Experimental|Arm A|AEB071 and MEK162 combined
3113203|NCT01801358|Experimental|Arm B|MEK162 alone
3113204|NCT01801345|Other|Rested|Subjects will perform the scenario, once during a normal workday (rested)
3113205|NCT01801345|Active Comparator|Fatigued|Subjects will perform the scenario after working a 12-24 hour overnight shift (fatigued).
3113206|NCT01801332|Experimental|intensive arm|Corticosteroïds (Methylprednisolone 32 mg/d) for 28 days + intensive enteral nutrition by feeding tube for 14 days
3113207|NCT01801332|Active Comparator|control arm|"Corticosteroïds (Methylprednisolone 32 mg/d) for 28 days +  classical  oral alimentation for 14 days"
3113208|NCT01801319|Active Comparator|Stimulation|Libra Deep Brain Stimulation System is implanted and activated post implantation
3113209|NCT01801319|Sham Comparator|No Stimulation|The Libra DBS System is implanted and not activated
3113210|NCT01801306|Other|NeMoProbe|The NeMo System is used for intracranial pressure (ICP) and brain temperature monitoring, as well as the determination of the brain tissue oxygenation saturation (SbtO2) and cerebral blood flow. The sensors for NIRS are implemented into a conventional brain tissue probe for ICP monitoring (NeMo Probe).
3113211|NCT01801293|Experimental|Intervention Arm|One-time single dose of 50 mg radiolabeled GS-5806 administered orally in 3 capsules in the morning.
3113212|NCT01801280|Active Comparator|Mycophenolate mofetil (C)|Mycophenolate mofetil (C) tablet twice a day every 12 hours for two weeks.
3113213|NCT01801280|Other|Mycophenolate mofetil+Pantoprazole (C + P)|"Mycophenolate mofetil (C) tablet twice a day every 12 hours for two weeks.~Pantoprazole 40mg tablet (P) once a day in the morning for two weeks."
3113214|NCT01801280|Other|Mycophenolate sodium (M)|Mycophenolate sodium (M) tablet twice a day every 12 hours for two weeks.
3113215|NCT01801280|Other|Mycophenolate sodium+Pantoprazole (M+ P)|Mycophenolate sodium (M) tablet twice a day every 12 hours for two weeks. Pantoprazole 40mg tablet (P) once a day in the morning for two weeks.
3113216|NCT01801267|Experimental|Endoscopic third ventriculostomy (ETV)|Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV).
3113217|NCT01801267|Active Comparator|Ventricular shunt|Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision.
3113218|NCT01801254|Experimental|STRIDES|Brain-computer interface training protocol designed to up-regulate specific types of neural activity in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
3113219|NCT01801254|Sham Comparator|Sham Control|Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior. Stimuli used and durations of training sessions for this protocol are identical to those used in the treatment condition.
3113220|NCT01801228|Experimental|Eplerenone|oral daily treatment with doses 100 to 400 mg
3113221|NCT01801228|Active Comparator|Spironolactone|oral daily treatment with doses 100 to 400 mg
3113222|NCT01801202|Experimental|Hair removal|hair removal treatment using 805nm LightSheer Duet HS handpiece
3113223|NCT01801189|Experimental|Pregabalin|Single, 300 mg pre-operative oral dose of Pregabalin.
3113224|NCT01801189|Placebo Comparator|Sugar Pill|Single, placebo pre-operative dose.
3113225|NCT01801176|Experimental|Initial monitoring group|
3113226|NCT01801163|Experimental|Sorafenib plus Stereotactic Radiotherapy|Single agent Sorafenib x 2 weeks followed by Stereotactic Radiotherapy, then Sorafenib until disease progression.
3113227|NCT01801150|No Intervention|lifestyle and diabetes treatment|Counseil about lifestyle and current diabetes treatment
3113228|NCT01801150|Experimental|CPAP nasal treatment|Continuous positive airway pressure (CPAP) nasal during the night and current diabetes treatment. Device
3113229|NCT01801137|Experimental|Afinitor|Treatment by Afinitor 10 mg per day
3113230|NCT01801124|Experimental|EXPAREL|undiluted EXPAREL 266 mg
3113231|NCT01801111|Experimental|RO5424802|
3113232|NCT01801085||FOLFOX4|Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
3113233|NCT01801085||XELOX|Capecitabine (Xeloda) 1000 mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hrs d1 Q3w x 8 cycles
3113234|NCT01801072|Active Comparator|Levetiracetam|500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days.
3113235|NCT01801072|No Intervention|No levetiracetam|No levetiracetam
3113236|NCT01801059|Active Comparator|Arm I education CRC and CRC screening|Educational intervention: Patients receive CRC and CRC screening information from an educational video and received a brochure focused on healthy hints to prevent CRC. Questionnaire administration prior to and after the intervention.
3113237|NCT01801059|Experimental|Arm II education and patient activation intervention|Educational intervention administered: Patients receive patient activation intervention comprising CRC and CRC screening information and communication skills training intervention by educational video and brochure, and they also receive a brochure focused on healthy hints to prevent CRC. Questionnaire administration prior to and after the intervention.
3113238|NCT01801046|Experimental|Treatment (chemotherapy, G-PBSC)|INDUCTION CHEMOTHERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-3 and cytarabine IV on days 1-7. HMMACT: Patients receive G-PBSC on day 9.
3113239|NCT01801020|Experimental|temperature measuremts|A temporal artery measurement will be taken from two points a strait line across the forehead and an additional measurement behind the earlobe. In addition tympanic temperature will be measured.
3113240|NCT01801007|Other|Flow Re-Direction Endoluminal Device|
3113241|NCT01800994||asthma, COPD|patients with asthma and COPD treated with inhalation devices
3113242|NCT01800981||Debrase|Patients previously treated with Debrase for burn debridement
3113243|NCT01800981||Standard of Care|Patients previously treated with local Standard of Care for burn debridement
3113244|NCT01800968|Active Comparator|Liraglutide|Increasing dose from 0.6mg, 1.2mg to 1.8mg SQ daily.
3113245|NCT01800968|Placebo Comparator|Placebo|Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg SQ daily.
3113246|NCT01800955|Experimental|resistive capacitive diathermy|in the resistive capacitive diathermy protocol patients are administered the resistive capacitive diathermy treatment for a thirty minutes session, three times per week for a total of ten sessions
3113247|NCT01800955|Sham Comparator|sham placebo group|"The sham treatment is administered with the resistive capacitive diathermy device set on on but not active (not supplying energy) with the same type of application, the same frequency and duration of experimental diathermy group"
3113248|NCT01800942|Placebo Comparator|Placebo|"830 women will be recruited into the study and randomised in a ratio of 1:1 per study arm to receive either Azithromycin or placebo.~A single dose of Azithromycin 2g or Placebo will be given orally to pregnant women in labour."
3113439|NCT01799694|Experimental|Autologous Expanded Stem Cells|Inject of Autologous Adipose-derived expanded stem cells
3113249|NCT01800942|Experimental|Azithromycin|"830 women will be recruited into the study and randomised in a ratio of 1:1 per study arm to receive either Azithromycin or placebo.~A single dose of Azithromycin 2g or Placebo will be given orally to pregnant women in labour."
3113250|NCT01800929|Experimental|N6|The N6 system comprises an investigational sound processor, remote assistant and fitting software
3113251|NCT01800929|Active Comparator|N5|The current commercially-available cochlear implant system Performance of N5 will be compared to performance with N6 using a within-subject design.
3113252|NCT01800916|Experimental|Treatment sequence 1|"The subjects randomised to Treatment sequence 1 are going to test~Coloplast Adhesive baseplate A (A)~Coloplast Adhesive baseplate B (B)~SenSura 1-piece (S)~The subjects test the three test products in a randomised order: ABS; BSA; SAB"
3113253|NCT01800916|Experimental|Treatment sequence 2|"The subjects randomised to Treatment sequence 2 are going to test~Coloplast Adhesive baseplate B (B)~Coloplast Adhesive baseplate C (C)~SenSura 1-piece (S)~The subjects test the three test products in a randomised order: CBS; BSC; SCB"
3113254|NCT01800916|Experimental|Treatment sequence 3|"The subjects randomised to Treatment sequence 3 are going to test~Coloplast Adhesive baseplate A (A)~Coloplast Adhesive baseplate B (C)~SenSura 1-piece (S)~The subjects test the three test products in a randomised order: ACS; CSA; SAC"
3113255|NCT01800903|Active Comparator|Sequence 1|SpeediCath catheter then ZN-D catheter then ZN-C catheter
3113256|NCT01800903|Experimental|Sequence 2|SpeediCath catheter then ZN-C catheter then ZN-D catheter
3113257|NCT01800903|Experimental|Sequence 3|ZN-D catheter then SpeediCath catheter then ZN-C catheter
3113258|NCT01800903|Experimental|Sequence 4|ZN-D catheter then ZN-C catheter then SpeediCath catheter
3113259|NCT01800903|Experimental|Sequence 5|ZN-C catheter then SpeediCath catheter then ZN-D catheter
3113260|NCT01800903|Experimental|Sequence 6|ZN-C catheter then ZN-D catheter then SpeediCath catheter
3113261|NCT01800890|Other|Treatment sequence 1|"Subjects randomised to Treatment sequence 1 will test three different products:~Coloplast A~Coloplast B~SenSura Click~The subjects test the three test products in a randomized order: ABS; BSA, SAB"
3113262|NCT01800890|Experimental|Treatment sequence 2|"Subjects randomised to Treatment sequence 2 will test three different products:~Coloplast C (C)~Coloplast B (B)~SenSura Click (S)~The subjects test the three test products in a randomized order: CBS; BSC, SCB"
3113263|NCT01800890|Experimental|Treatment sequence 3|"Subjects randomised to Treatment sequence 3 will test three different products:~Coloplast A (A)~Coloplast C (C)~SenSura Click (S)~The subjects test the three test products in a randomized order: ACS; CSA, SAC"
3113264|NCT01800877|Other|Liberal Approach|In the liberal approach group, we will titrate vasopressors to maintain mean arterial pressures between 75 and 80 mmHg.
3113265|NCT01800877|Other|Restrictive Approach|We will titrate vasopressors to maintain mean arterial pressures between 60 and 65 mmHg.
3113266|NCT01800864|Other|Normal|Normal weight subjects
3113267|NCT01800864|Other|Over weight /obese subjects|Overweight and obese subjects
3113268|NCT01800851|Experimental|no weight gain|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
3113269|NCT01800851|Experimental|weight gain|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
3113270|NCT01800851|Other|lean body mass|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
3113271|NCT01800838|Experimental|Treatment (silicon phthalocyanine 4 and PDT)|Patients receive silicon phthalocyanine 4 topically and then undergo PDT.
3113272|NCT01800825|Active Comparator|Clindamycin|Clindamycin 300mg orally twice daily for five days
3113273|NCT01800825|Placebo Comparator|placebo|This will be an identical placebot
3113274|NCT01800799|Experimental|UTI (WBC>10 per high power field)|"Antimicrobial agent (Baktar 800mg h.s.)~Anti-inflammatory agent (Celecoxib 200mg QD)"
3113275|NCT01800799|Experimental|Recurrent UTI|"Antimicrobial agent (Baktar 800mg h.s.)~Anti-inflammatory agent (Celecoxib 200mg QD)"
3113276|NCT01800799|No Intervention|Normal control|Normal control
3113277|NCT01800786|Active Comparator|OSA-CPAP group|OSA patient will use CPAP for 3 months
3113278|NCT01800786|No Intervention|OSA -no CPAP|newly diagnosed OSA patient will not wear CPAP for 3 months
3113279|NCT01800773|Experimental|Written Exposure Therapy|Written exposure treatment is a 5 session treatment in which participants write about their trauma event in a specified manner.
3113280|NCT01800773|Active Comparator|Cognitive Processing Therapy|cognitive processing therapy will be included as the evidence-based treatment for PTSD in this study.
3113281|NCT01800760|Experimental|No groups|
3113282|NCT01800747|Active Comparator|Direct antibiotic treatment|The doctor gives to parents an antibiotic prescription for their son's respiratory infection which he should start immediately.
3113283|NCT01800747|No Intervention|No antibiotic treatment|The doctor does not give to parents an antibiotic prescription for their son's respiratory infection.
3113284|NCT01800747|Experimental|Delayed antibiotic prescription|The doctor gives to parents an antibiotic prescription for their son's respiratory infection with the advice to use it if needed, in case of worsening of symptoms or not improve.
3113285|NCT01800734|Other|Clamp-Mixed Meal Arm|Twenty adults patients with type 1 diabetes, regularly attending the Division of Endocrinology and Metabolic Diseases of University of Verona School of Medicine, using continuous subcutaneous fast insulin analogue infusion (CSII) through a permanent pump and on subcutaneous glucose sensing will be enrolled.
3113286|NCT01800721|Experimental|Experimental Condition SNAP|"Behavioral Intervention SNAP HIV training and peer outreach~Participants learn skills for sexual health and peer outreach which includes talking with network members about HIV testing and prevention."
3113287|NCT01800721|Active Comparator|SNAP Control Condition|"SNAP Control~Participants receive information on HIV/STDs as well as healthy eating and nutrition instruction."
3113288|NCT01800708|Active Comparator|Triamcinolone acetonide|The study group will receive an intraoperative intracameral injection of triamcinolone acetonide
3113289|NCT01800708|Active Comparator|Prednisolone syrup|The control group will receive prednisolone syrup postoperatively
3113290|NCT01800695|Experimental|Arm A|ABT-414 in combination with radiation and temozolomide
3113293|NCT01800682|Experimental|Tramodol Extended-release (ER), 25 milligram (mg)|Tramodol ER, 25 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
3113294|NCT01800682|Experimental|Tramodol ER, 50 mg|Tramodol ER, 50 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
3113295|NCT01800682|Experimental|Tramodol ER, 100 mg|Tramodol ER, 100 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
3113296|NCT01800669|Experimental|Intervention|Use of the complete CHICA MLP module in routine clinical care. The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
3113297|NCT01800669|Active Comparator|Control|CHICA without the MLP module. This version includes a module that screens families for medical-legal issue but does not provide additional guidance or referrals to resolve them.
3113298|NCT01800656|Experimental|Ligate and let go|"Subjects are submitted to endoloop-assisted ligate and let go colorectal polypectomy."
3113299|NCT01800656|Active Comparator|Snare polypectomy|Subjects are submitted to endoloop-assisted snare colorectal polypectomy
3113300|NCT01800643|Other|Orally Busulfan PK|Evaluate the Pharmacokinetics of orally busulfan
3113301|NCT01800643|Other|Intravenously Busulfan PK|Evaluate the Pharmacokinetics of intravenously busulfan
3113302|NCT01800630|Experimental|Gemcitabine HCl Oral Formulation (D07001-F4)|Subjects will receive a single 5-mg (nontherapeutic) dose of gemcitabine (Gemzar®) via an IV push and then treated with Gemcitabine HCl Oral Formulation (D07001-F4)according to assigned cohort (2 mg to 80 mg) on Day 1, 3, 5, 8, 10, and 12 of 4 21-day cycles study treatment period.
3113303|NCT01800617|Experimental|Liothyronine, Sodium|
3113304|NCT01800604|Experimental|Pain Self-Management Arm #1|Pain Self-Management Intervention #1
3113305|NCT01800604|Experimental|Pain Self-Management Arm #2|Pain Self-Management Intervention #2
3113306|NCT01800604|Experimental|Pain Self-Management Arm #3|Pain Self-Management Intervention #3
3113307|NCT01800604|Experimental|Pain Self-Management Arm #4|Pain Self-Management Intervention #4
3113308|NCT01800591|No Intervention|Control Arm|No other financial incentive other than for enrollment, 6-month weigh in, and completion.
3113309|NCT01800591|Experimental|Delayed gratification|In addition to the standard enrollment, 6-month, and completion incentives, if the subject loses 5% of their initial weight by the end of the study, they will receive an annual discount (distributed across bi-weekly pay periods) for 12 months beginning after the 12-month study ends. Their premium will return to normal price after this 12-month discount ends.
3113310|NCT01800591|Experimental|Immediate gratification|In addition to the standard enrollment, 6-month, and completion incentives, the subject will be told that they can weigh in again any time before the study ends when they think they have lost 5% of their initial body weight. If they did meet their 5% goal, they will begin receiving a bi-weekly premium discount during the next pay period for a total duration of 12 months. Subjects that do not meet the 5% cut off during a weigh in are allowed to re-weigh themselves as many times as they like although they are encouraged to do so when they think they have met their target weight. Their premium goes back to normal price after this 12-month discount ends.
3113311|NCT01800591|Experimental|Financial incentive with frequent feedback|In addition to the standard enrollment, 6-month, and completion incentives, the subject will be asked to weigh in on the IncentaHEALTH scales everyday they are at work. These subjects will participate in a daily lottery with the possibility of winning the same amount as the discount in Arms 2 and 3 over the course of the study. The subject can choose to select or be designated a two digit number that ranges from 00 to 99. Each day a lottery will be held and the subject will be given a 1% chance of matching both digits or an 18% chance of matching one digit. In order to get the lottery winnings, the subject must meet a weight goal that consistently decreases to accumulate to a 5% weight loss by the 6 month mark. After 6 months, the subject will receive the lottery winnings if they maintain that target weight (initial weight minus 5%) until the end of the 12-month study.
3113312|NCT01800578||Bispectral Index Group|
3113313|NCT01800565|Other|pubertal progression|A collection of first voided urine sample for the measurement of LH.
3113314|NCT01800539|Experimental|Provider Education Model (PEM)|condition wherein providers will receive specially structured training during their typical home visits based by Kennedy Krieger Institute (KKI) staff
3113315|NCT01800539|No Intervention|Treatment-as-Usual (TAU)|condition wherein providers continue with their existing practices
3113316|NCT01800526|Experimental|Oral N-acetylcysteine (NAC)|Eligible subjects who did not participate in Intravenous NAC or subjects who are at least 4 weeks after participation in Intravenous NAC, will be given Oral NAC at a dose of 2400mg daily, in two equally divided doses, for 4 weeks. Subjects will have blood drawn prior to beginning the phase and weekly for 4 weeks. At each visit interim medical events and adverse events will be collected.
3113317|NCT01800526|Experimental|Intravenous N-acetylcysteine (NAC)|"For part 1, Eligible subjects who did not participate in Oral NAC or subjects at least 4 weeks after oral NAC will receive IV NAC 150 mg/kg over 8 hours. At least four weeks after the first infusion, the subject will receive IV NAC 300 mg/kg over 8 hours.~For part 2, Eligible subjects with sickle cell disease and hospitalization for VOC within the past 2 years, who now present in VOC will be enrolled. Subjects will receive IV NAC 75 mg/kg over 1 hour every 6 hours for 5 days or discharge, whichever occurs earlier."
3113318|NCT01800513|Experimental|Endometrial Biopsy|Subjects will have a vaginal speculum placed and visualization of the cervix will be obtained. The cervix will be cleaned with betadine (or hibiclens for those with an iodine allergy). Those randomized to the treatment arm (endometrial biopsy) will have an endometrial pipelle (Endocell, Wallach, Orange, Connecticut) inserted gently through the cervix into the uterus. Two passes will be performed with the pipelle catheter. For each pass the catheter will be rotated and scraped 4 times, once in each quadrant.
3113319|NCT01800513|Sham Comparator|Control|Those randomized to the control group will have a small cotton swab placed gently into the cervix. No tissue will be obtained with this method. The randomization to a placebo control is necessary to prove that any positive effects seen are due to the biopsy and not just random chance.
3113320|NCT01800500|Experimental|Arm I (fixed rate ST product prices)|Participants purchase ST products using a fixed rate of product prices once weekly and record their consumption of ST products and cigarettes smoked daily for 3 weeks
3113321|NCT01800500|Experimental|Arm II (escalating ST product prices)|Participants purchase ST products using escalating product prices once weekly and record their consumption of ST products and cigarettes smoked daily for 3 weeks.
3113322|NCT01800487|Active Comparator|silymarin|Silymarin 140 mg three times a day for 4 weeks
3113323|NCT01800487|Placebo Comparator|placebo|"Placeo~1 tab three times a day for 4 weeks"
3113324|NCT01800461|Experimental|OPC-Stroke, Usual care|OPC-Stroke - 10 weekly sessions of goal setting followed by problem solving process
3113325|NCT01800461|Other|Usual care|Usual care - Follow-up by physician and possible receipt of home care services
3113326|NCT01800435|Active Comparator|aPCC, aPCC + TXA|aPCC 75IU/kg i.v aPCC 75IU/kg i.v +TXA 20mg/kg
3113327|NCT01800435|Active Comparator|rFVIIa, rFVIIa + TXA|rFVIIa 90 µg/kg i.v rFVIIa 90 µg/kg i.v + TXA 20 mg/kg
3113328|NCT01800422|Experimental|Arm I (telapristone acetate)|Patients receive telapristone acetate orally once daily for 2-10 weeks and then undergo surgical resection.
3113329|NCT01800422|Placebo Comparator|Arm II (placebo)|Patients receive placebo orally once daily for 2-10 weeks and then undergo surgical resection.
3113330|NCT01800409|Experimental|AFES training|Participants will take part in AFES training sessions five times per week (Mon-Fri) for a total of 8 weeks During these sessions participants will receive AFES for 40 minutes. Training sessions are designed to strengthen the participants abdominal muscles in order to improve respiratory function
3113331|NCT01800409|No Intervention|Control period|Four week control period. The order of the control and training periods will be randomised for each participant.
3113332|NCT01800396|Placebo Comparator|Milk protein|Milk powder, twice daily at breakfast and dinner.
3113333|NCT01800396|Experimental|Milk protein rich in phospholipids|Milk powder, twice daily at breakfast and dinner.
3113334|NCT01800383||Control|No Axis I psychiatric disorder and no trauma exposure
3113335|NCT01800383||Trauma-Exposed Normal Control|History of trauma exposure and subthreshold PTSD symptoms.
3113336|NCT01800383||PTSD|Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of PTSD as determined by the Structured Clinical Interview for DSM-IV-Text Revised
3113337|NCT01800370|Experimental|Hyperglycemia|Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine. Includes blood draws and fasting requirements.
3113338|NCT01800370|Placebo Comparator|Saline|Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine. Includes blood draws and fasting requirements.
3113339|NCT01800370|Experimental|Exercise|"Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.~Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds.~Includes blood draws and fasting requirements."
3113340|NCT01800357|Experimental|mildronate|infusion of mildronate
3113341|NCT01800357|Placebo Comparator|placebo|infusion of placebo mildronate
3113342|NCT01800344|Active Comparator|The laryngeal mask airway-ClassicTM (LMA)|The LMA is a large foreign body that exerts pressure on the pharyngeal mucosa. High LMA intracuff pressures may reduce pharyngeal mucosal perfusion and lead to throat discomfort.
3113343|NCT01800344|Active Comparator|The AES Ultra CPVTM LMA (Ultra)|Ultra is a new supraglottic airway with anatomical features and insertion technique virtually identical to the LMA-ClassicTM. The cuff and the shaft are made of silicone with a built-in CPV pilot balloon valve which provides continuous monitoring of the intracuff pressure. The CPV cuff pressure indicator has 3 zones indicated by color: yellow corresponds to pressure < 50 cm H2O; green 60 cm H2O; and red >70 cm H2O
3113344|NCT01800331|Experimental|Text2bHealthy|The intervention arm receives the Text2bHealthy program on a PDA
3113345|NCT01800331|No Intervention|Control group|The control group will complete a paper dairy to keep track of their lifestyle behaviours
3113346|NCT01800318|Experimental|Sham NESAP with 24% oral sucrose|"Sham NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. However, the Empi Select TENS unit will not be turned on. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~Infant will receive 1 ml of 24% oral sucrose solution given along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
3113347|NCT01800318|Experimental|NESAP with oral water|"NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. 10 minutes before the heel stick, the Empi Select TENS unit will be turned on with settings 3.5mA, 10 Hz. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~Infant will receive 1 ml of sterile water given via oral syringe along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given"
3113348|NCT01800318|Experimental|NESAP with 24% oral sucrose|"NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. The Empi Select TENS unit will be turned on ten minutes before the heel stick at settings 3.5 mA, 10 Hz. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~Infant will receive 1 ml of 24% oral sucrose solution given along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
3113349|NCT01800318|Placebo Comparator|Sham NESAP with oral water|"Sham NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. However, the Empi Select TENS unit will not be turned on. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~Infant will receive 1 ml of sterile water given via oral syringe along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
3113350|NCT01800305|Experimental|Pegylated rhEPO|Subcutaneous single-dose administration of 0.5mcg/kg, 1.0mcg/kg, 1.6 mcg/kg, 2.4 mcg/kg, 3.2 mcg/kg，3.2mcg/kg, 4.2mcg/kg, 5.5 mcg/kg, 7.2 mcg/kg, 9.3 mcg/kg (in dose-escalation, if the previous dose is confirmed to be safe.started with the second 3.2mcg/kg dose,Every subject takes Niferex 150mg every day, from day 1 to day 20. ) of the test drug (Pegylated rhEPO)
3113351|NCT01800305|Active Comparator|EPIAO®|Subcutaneous six-dose administration of 50IU/kg or 150IU/kg, as randomization, of the comparator drug(EPIAO®) at day 1, 3, 5, 8, 10, 12.
3113480|NCT01799356|Placebo Comparator|Ofloxacin Group|Treatment at uPID with Ofloxacin plus metronidazole
3113352|NCT01800292|Experimental|sildenafil therapy|Subjects will have 2D-Echocardiogram measuring left ventricular strain and strain rate using speckle tracking techniques, have 6 minute walk test, World Health Organization functional class (I-IV)assignment, and BNP lab result at baseline and at 3 months. Subjects will be started on sildenafil at 20 mg by mouth three times per day at the baseline visit. Each individual will serve as his/her own control.
3113353|NCT01800279|Active Comparator|Deontology Therapy|The patients in the control group will port a deprogramming occlusal splint to sleep every night, an average of 8 hours per day, for 12 weeks of the treatment.
3113354|NCT01800279|Experimental|Physiotherapy Protocol|The physiotherapy protocol involves the application of kinesitherapy techniques and a myofascial therapy protocol. This protocol will be administered twice a week for 12 weeks.
3113355|NCT01800266|Experimental|Symptom and Fidelity Monitoring (SFM)|Half of the study clinicians will be randomized to this supervision condition of TF-CBT.
3113356|NCT01800266|Experimental|SFM + Behavioral Rehearsal|Half of the study clinicians will be randomized to this supervision condition of TF-CBT.
3113357|NCT01800253|Experimental|Total sleep deprivation|Participants will be required to stay up for the entire night before 'Blood Samples' and 'Tissue samples' will be taken and the 'Portion Size Task' and 'Inhibitory task' will be performed. This will then be followed by the 'Oral glucose tolerance test' with additional 'Blood Samples' to be taken as described for that test.
3113358|NCT01800253|Experimental|Sleep|Participants will have an 8-h sleep opportunity before 'Blood Samples' and 'Tissue samples' will be taken and 'Portion Size Task' and 'Inhibitory task' will be performed. This will be followed by the 'Oral glucose tolerance test' with additional 'Blood Samples' to be taken as described for that test.
3113359|NCT01800214||Alzheimer's disease (AD)|
3113360|NCT01800214||Vascular Cognitive Disorders (VCD)|
3113361|NCT01800214||Lewy Body Disease (LBD)|
3113362|NCT01800214||Frontotemporal Dementia (FTD)|Behavioral-variant Frontotemporal Dementia (bvFTD) Language-variant Frontoemporal Dementia including Semantic dementia (SD) and Progressive non-fluent aphasia (PNFA) Corticobasal degeneration (CBD) Progressive supranuclear palsy (PSP)
3113363|NCT01800214||Mild Cognitive Impairment (MCI)|
3113364|NCT01800214||Cognitively Normal (CN)|
3113365|NCT01800201|No Intervention|Control|The control group will have their claims data analyzed for a 12 month period. We will be examining these data for hospital admissions, new vascular events (AMI, stroke, acute coronary syndrome admission), or repeat or new cardiovascular procedures.
3113366|NCT01800201|Experimental|Intervention|"The intervention group (1) will use the GlowCaps, a remote monitoring and reminder pill bottle; (2) will be assigned an engagement advisor from the study team; (3) asked to provide the study team with names and contact information of up to 3 family members or friends as support partners for medication adherence. The study team will contact these people in order listed until 1 agrees to serve in this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on medication adherence; and (5) will determine their preferences for Way to Health platform communication methods during the study.~The group receiving the program intervention will also have their claims data analyzed for the 12 months post-enrollment."
3113367|NCT01800188||Dialysis|Patients with dialysis dependent ESRD and normal fasting glucose will undergo a meal test during a hemodialysis and hemodiafiltration session. A meal test without dialysis is optional.
3113368|NCT01800175|Experimental|Formulation C|Two formulations of the OTX Punctum Plug will be evaluated in this trial. The difference in formulations is the time required for degradation of the PEG hydrogel. The persistence of OTX Punctum Plug (Formulation C) is anticipated to be slightly shorter than the persistence of OTX Punctum Plug (Formulation D).
3113369|NCT01800175|Experimental|Formulation D|Two formulations of the OTX Punctum Plug will be evaluated in this trial. The difference in formulations is the time required for degradation of the PEG hydrogel. The persistence of OTX Punctum Plug (Formulation C) is anticipated to be slightly shorter than the persistence of OTX Punctum Plug (Formulation D).
3113370|NCT01800162|Active Comparator|Uterine evacuation, then MTX for some|Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
3113371|NCT01800162|Active Comparator|Empiric treatment with MTX for all|Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
3113372|NCT01800162|Active Comparator|Expectant Management|Subjects will have their PPUL expectantly managed using serum hCG monitoring.
3113373|NCT01800149|Active Comparator|BBM+collagen|Ridge Augmentation After tooth extraction, edentulous sockets will be filled with BioOss Collagen and covered with Bio-Gide
3113374|NCT01800149|Active Comparator|BBM granules|Ridge Augmentation After tooth extraction, edentulous sockets will be filled with Bio-Oss Granules, 0-25-1 mm, and covered with Bio-Gide
3113375|NCT01800136|Experimental|rTMS; tDCS|
3113376|NCT01800123||Acute poisoning|Consecutive acute drug self poisoned patients admitted in the ED.
3113377|NCT01800110|Experimental|2|label I- 200 cc pomegranate juice once daily for 6 weeks post partum. label II- control group, no placebo is givening.
3113378|NCT01800097|Placebo Comparator|placebo|placebo
3113379|NCT01800097|Active Comparator|Modafinil|Modafinil
3113380|NCT01800084|Experimental|Patients undergoing SPECT-CT|"The patients in this study are scheduled for a SPECT-CT at the Nîmes University Hospital as part of their normal care regimen.~Intervention: Device: Asir Image Acquisition"
3113381|NCT01800058||Circulating prostatic tumor cells in the peripheral blood|"Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):~prior to any treatment;~following AD and prior to RT; and~following the end of RT (1-3 months afterwards).~The quantification of CTC in blood samples will be done with the CellSearch® system."
3113382|NCT01800045|Experimental|Pitolisant|Pitolisant at 5, 10, 20 or 40mg
3113383|NCT01800045|Placebo Comparator|Placebo|Capsules of placebo containing lactose
3113384|NCT01800032||Plexiform Neurofibroma|NF1 associated plexiform neurofibroma
3113385|NCT01800032||Optic Glioma|NF1 associated optic glioma
3113515|NCT01799109|Experimental|nebulized ms|magnesium sulfate 150mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
3113386|NCT01800019|Active Comparator|NRT arm|"Drug: Nicotine Replacement Therapy (Nico-Derm® and Nicorette®)~Dose: 7mg - 42mg depending on # of cigarettes smoked per day at study baseline, and withdrawal symptoms.~Mode of Administration: Transdermal Patch~Duration of Treatment: up to 24 Weeks~Additionally, participants will be provided with a supply of short-acting nicotine gum in order to supplement their long acting NRT patch regimen.~Individuals who smoke their first cigarette more than 30 minutes after waking are advised to use the 2 mg NRT gum. Participants who smoke their first cigarette within 30 minutes of waking will be advised to use the 4 mg NRT gum. Both NRT gum dosages will be recommended for use on an ad lib basis to address cravings and/or withdrawal symptoms, up to a maximum of 12 pieces of NRT gum per day."
3113387|NCT01800019|Active Comparator|NRT and HIV Tailored Quit Smoking Counseling|"Drug: Nicotine Replacement Therapy (Nico-Derm®)~Dose: 7mg - 42mg depending on # of cigarettes smoked per day at study randomization and withdrawal symptoms.~Mode of Administration: Transdermal Patch~Duration of Treatment: up to 24 Weeks~HIV tailored Smoking Cessation Counseling: The counseling consists of face-to-face sessions with a trained smoking cessation counselor at the start of the study, on your chosen quit date, and then at weeks 4, 8, 12 and 24; supportive telephone calls if needed."
3113388|NCT01800019|Active Comparator|Varenicline (VR) Arm|"Drug: Varenicline (Champix®)~Doses: 0.5 mg once daily for 3 days(i.e.day 1-3 of the week prior to quit date) 0.5 mg twice daily for 4 days i.e. day 4-7) and 1 mg twice daily for the remainder of the treatment period~Mode of Administration: Oral~Duration of Treatment: 24 Weeks (+ 1 Week of Dose Escalation, total of 25 weeks)"
3113389|NCT01800019|Active Comparator|Varenicline (VR) and HIV Tailored Quit Smoking Counseling|"Drug: Varenicline (Champix®)~0.5 mg once daily for 3 days(i.e.day 1-3 of the week prior to quit date) 0.5 mg twice daily for 4 days i.e. day 4-7) and 1 mg twice daily for the remainder of the treatment period~Mode of Administration: Oral~Duration of Treatment: 24 Weeks (+ 1 Week of Dose Escalation, total of 25 weeks)~Intervention: HIV tailored Smoking Cessation Counseling: The counseling consists of face-to-face sessions with a trained smoking cessation counselor at the start of the study, on your chosen quit date, and then at weeks 4, 8, 12 and 24; supportive telephone calls if needed."
3113390|NCT01800006||Group 1|
3113391|NCT01799993|Experimental|Amikacin inhale (BAY41-6551)|Participants received 400 mg (3.2 mL) aerosolized Amikacin (BAY41-6551) solution every 12 hours via Pulmonary Drug Delivery System (PDDS) Clinical from Day 1 to Day 10.
3113392|NCT01799993|Placebo Comparator|Placebo|Participants received 3.2 mL aerosolized placebo solution every 12 hours via PDDS Clinical from Day 1 to Day 10.
3113393|NCT01799980||Cervical mediastinoscopy|This group will undergo cervical mediastinoscopy before surgery to stage their lung cancer (procedure decided by the surgeon).
3113394|NCT01799980||Endo-bronchial ultrasound|This group will undergo endobronchial ultrasound before surgery to stage their lung cancer (procedure decided by the surgeon).
3113395|NCT01799954|Other|NYVAC Prime / NYVAC + AIDSVAX® B/E Boost vs. Placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a NYVAC vaccine prime and NYVAC + AIDSVAX® B/E boost. Twenty participants will get vaccines and 4 will get only placebos.
3113396|NCT01799954|Other|NYVAC + AIDSVAX® B/E Prime / Boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of priming and boosting with the vaccines NYVAC + AIDSVAX® B/E. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 1 to see if the priming makes a difference in the body's immune response.
3113397|NCT01799954|Other|DNA prime + NYVAC + AIDSVAX® B/E Boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a DNA vaccine priming and NYVAC + AIDSVAX® B/E boosting. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 4 to see if the priming makes a difference in the body's immune response.
3113398|NCT01799954|Other|DNA+AIDSVAX® B/E prime / NYVAC+AIDSVAX® B/E boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a DNA vaccine + AIDSVAX® B/E priming and NYVAC + AIDSVAX® B/E boosting. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 3 to see if the priming makes a difference in the body's immune response.
3113399|NCT01799941|Other|Nuedexta (DM 20 mg/Q 10 mg)|Single Arm, Open Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
3113400|NCT01799915||REM sleep behavior disorder, RBD|Patients that have rapid eye movement sleep behavior disorder.
3113401|NCT01799915||multiple system atrophy|is a neurodegenerative disorder charaterized by abnormal alpha-synuclein deposition in the cytoplasm of oligodendroglial cells in the CNS, and typically sparing peripheral autonomic nerves.
3113402|NCT01799915||Pure Autonomic failure|A neurodegenerative disorder characterized by loss of peripheral noradrenergic fibers, with low levels of plasma norepinephine.
3113403|NCT01799915||Parkinson disease|A degenerative disorder of the central nervous system that leads to termors, difficulty walking, movement and coordination.
3113404|NCT01799915||Dementia with Lewy bodies|A neurodegenerative disorder similar to PAF and PD with the accumulation of Alpha-synuclein in the CNS however DLB patients develop dementia.
3113405|NCT01799902||Male subjects with LUT predominant storage symptoms (OAB)|male subjects with Overactive Bladder Syndrome (OAB) being treated with solifenacin in monotherapy or combination
3113406|NCT01799889|Experimental|Entospletinib LPL/WM, SLL, MZL|Participants with LPL/WM, SLL, and MZL will receive entospletinib 800 mg (Amendment 1-7) or 400 mg (Amendment 8 - spray-dried dispersion (SDD) tablet) twice daily.
3113407|NCT01799889|Experimental|Entospletinib FL|Participants with FL will receive entospletinib 800 mg (Amendment 1-7) or 400 mg (Amendment 8 - SDD tablet) twice daily.
3113408|NCT01799889|Experimental|Entospletinib DLBCL|Participants with DLBCL will receive entospletinib 800 mg (Amendment 1-7) or 400 mg (Amendment 8 - SDD tablet) twice daily.
3113409|NCT01799889|Experimental|Entospletinib MCL|Participants with MCL will receive entospletinib 800 mg (Amendment 1-7) or 400 mg (Amendment 8 - SDD tablet) twice daily.
3113410|NCT01799889|Experimental|Entospletinib CLL|Participants with CLL will receive entospletinib 800 mg (Amendment 1-7) or 400 mg (Amendment 8 - SDD tablet) twice daily.
3113411|NCT01799889|Experimental|Entospletinib SDD CLL Prior BTK Exposure|Participants with CLL who have previously been treated with a bruton tyrosine kinase (BTK) inhibitor and now have progressive disease will receive entospletinib SDD 400 mg twice daily.
3113516|NCT01799096|Experimental|Sucrose|Receives sucrose
3113412|NCT01799889|Experimental|Entospletinib SDD CLL Prior PI3K Exposure|Participants with CLL who have previously been treated with a phosphatidylinositol 3-kinase (P13K) inhibitor and now have progressive disease will receive entospletinib SDD 400 mg twice daily.
3113413|NCT01799889|Experimental|Entospletinib SDD CLL Dose Ranging|Participants with CLL who are B-cell receptor (BCR) inhibitor treatment-naive will be randomized to receive 100, 200, or 400 mg of entospletinib SDD twice daily.
3113414|NCT01799876|Experimental|Autologous Cell|Regenerative cells obtained from autologous fat are administered in the knee at microfracture site.
3113415|NCT01799876|Sham Comparator|Control|Standard arthroscopy with sham lipoplasty procedure (no fat cells harvested).
3113416|NCT01799863|Experimental|Ketorolac trometamol 0.45%|Ketorolac trometamol 0.45% associated with carboxymethylcellulose eye drops (Acular CMC®, Allergan, Irvine, USA) qid for 7 days.
3113417|NCT01799863|Placebo Comparator|Artificial tears|Preservative free artificial tears (Optive UD®, Allergan, Irvine, USA) qid for 7 days.
3113418|NCT01799850|Active Comparator|Actos|Actos 30 mg daily
3113419|NCT01799850|Placebo Comparator|placebo|double blind placebo controlled
3113420|NCT01799837|Other|Healthy Controls|Posttraumatic stress disorder (PTSD) is a potentially debilitating anxiety disorder triggered when a person is exposed to a traumatic event that is beyond what is experienced in everyday life. A traumatic event may include an interpersonal event like physical or sexual assault, exposure to a disaster or accidents, combat or witnessing a traumatic event. Some symptoms of PTSD include not being able to sleep, nightmares, flashbacks of the event and having problems with memory or not being able to focus. You are being asked to volunteer because you are either 1) a normal healthy volunteer or 2) a deployed veteran or non-deployed veteran who is diagnosed with PTSD. We anticipate enrolling 16 subjects; 8 veterans with PTSD and 8 healthy volunteers without PTSD.
3113421|NCT01799837|Other|Veterans with PTSD|Posttraumatic stress disorder (PTSD) is a potentially debilitating anxiety disorder triggered when a person is exposed to a traumatic event that is beyond what is experienced in everyday life. A traumatic event may include an interpersonal event like physical or sexual assault, exposure to a disaster or accidents, combat or witnessing a traumatic event. Some symptoms of PTSD include not being able to sleep, nightmares, flashbacks of the event and having problems with memory or not being able to focus. You are being asked to volunteer because you are either 1) a normal healthy volunteer or 2) a deployed veteran or non-deployed veteran who is diagnosed with PTSD. We anticipate enrolling 16 subjects; 8 veterans with PTSD and 8 healthy volunteers without PTSD.
3113422|NCT01799824|Experimental|Active|ANT-1403
3113423|NCT01799824|Placebo Comparator|Vehicle|Vehicle
3113424|NCT01799811||CLI patient's needing open bypass|Patients presenting with Rutherford Class 5 or 6 CLI that are being evaluated for open peripheral arterial revascularization.
3113425|NCT01799798|Experimental|Denosumab subcutaneously|
3113426|NCT01799785|Experimental|Aerobic exercise|Supervised aerobic training 3 times per week for 8 weeks (30-60 minute sessions)
3113427|NCT01799785|Placebo Comparator|Usual care group|These patients will continue with their normal daily activity and will not be provided with supervised aerobic exercise training during the study period.
3113428|NCT01799772|Experimental|Comprehensive behavioral intervention|"It will involve regular contacts over 6 month period. It will include 2 weekly contacts for weeks 1-6, weekly contacts for weeks 7-8, bi-weekly contact for months 3-4, and monthly contact for months 5-6. There is a combination of 20 individual and group-based sessions.~It is a combination of 4 components: a) Evidence-based exercise program, b) Physical activity promotion, c) Healthy nutrition guidance, and d) Self-management."
3113429|NCT01799772|Active Comparator|Standard of Care Exercise Program (SCE)|The SCE will be delivered by a physical therapist. It represents the typical rehabilitation after TKA surgery. It is expected to provide small and short-lived functional improvement. Subjects will participate in 12 supervised sessions (2 x/week, for 6 weeks). The SCE consists of: a) lower extremity range of motion and stretching exercises, b) lower extremity strengthening exercises of moderate intensity, and d) endurance exercises using treadmill.
3113430|NCT01799759|Experimental|Online intervention for parent and child|Children complete 8 online modules of Project FUN Parents complete 6 modules of Project FUN for Parents
3113431|NCT01799759|Other|Instruments only|The waiting list control group only completes instruments and body composition, fitness measures
3113432|NCT01799733|Active Comparator|LWT+AM BWL|Late-wake therapy in combination with morning bright white light
3113433|NCT01799733|Placebo Comparator|EWT+PM BWL|Early-wake therapy in combination with evening bright white light
3113434|NCT01799720|Experimental|Less oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet. Follow-up 30 days
3113435|NCT01799720|Experimental|More oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 2 took 2 capsules/day of one of the most oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
3113436|NCT01799720|Experimental|Hypercholesterolemic diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 3 only took diet and no capsules. Follow-up 30 days
3113437|NCT01799707|Experimental|vision restoration training|Vision restoration training (VRT): visual stimuli repetitively presented to stimulate areas of residual vision. The training consists of luminance increment stimuli similar to perimetry and the task isa simple detection task (pressing a key whenever a target stimulus was detected).
3113438|NCT01799707|Placebo Comparator|Discrimination training|Discrimination training. Here, the stimulus is a line segment (bar) which is always presented within the central ±5° visual field in one of four possible random orientations: horizontal, vertical, oblique to the right or oblique to the left. If the patient has visual field defects in this central area, 80% of the stimuli are presented in the intact part of the training region. The task is to identify the orientation of the line segment and press, as fast as possible, one of 4 assigned buttons on the keyboard.
3113440|NCT01799681|Experimental|EXPERIMENTAL|a 4-week indoor and 4-week outdoor balance training with stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice
3113441|NCT01799681|Active Comparator|CONTROL|an eight-week training on upper limb stretching and strengthening, hand agility exercise, knot tying and Chinese calligraphy
3113442|NCT01799642||Cystic Fibrosis Patients|Participants with Cystic Fibrosis
3113443|NCT01799642||Healthy Controls|Participants who do not have cystic fibrosis and are otherwise healthy.
3113444|NCT01799629|Experimental|Intervention|Intervention group will receive the glycerin suppository
3113445|NCT01799629|No Intervention|Control|Normal care
3113446|NCT01799616|Experimental|Pamidronate|In total, 48 patients will need to be recruited. These patients will be randomly assigned to one of the two groups, with each group comprising 24 patients: one group will be given pamidronate and the other placebo
3113447|NCT01799616|Other|Placebo|In total, 48 patients will need to be recruited. These patients will be randomly assigned to one of the two groups, with each group comprising 24 patients: one group will be given pamidronate and the other placebo
3113448|NCT01799603|Experimental|TMC435 in fasted then fed condition|Participants under fasting condition will be administered with TMC435, 100 milligram (mg) as oral capsule on Day 1 of first treatment period and then will be administered with TMC435, 100 mg oral capsule on Day 1 under fed condition of second treatment period (after washout period of 9 days, between the two treatment periods).
3113449|NCT01799603|Experimental|TMC435 in fed then fasted condition|Participants under fed condition will be administered with TMC435, 100 milligram (mg) as oral capsule on Day 1 of first treatment period and then will be administered with TMC435, 100 mg oral capsule on Day 1 under fasting condition of second treatment period (after washout period of 9 days, between the two treatment periods).
3113450|NCT01799590|Experimental|Topiramate|
3113451|NCT01799577||Gynecologist|Gynecologist can use laparoscopic surgery.
3113452|NCT01799564|Experimental|Micropulse|Micropulse laser will be applied to the inferior hemiretina next to the area of atrophy in a randomly selected eye in 1, 2 or 3 occasions
3113453|NCT01799564|No Intervention|Control|The fellow eye does not receive any treatment
3113454|NCT01799551|Active Comparator|Ca CBT|Experimental arm will receive brief version of Culturally adapted CBT for depression. This is based on our previous work in which we adapted CBT for depression in Pakistan
3113455|NCT01799551|No Intervention|Treatment As Usual|Patients in this arm will get only Treatment As Usual, which normally includes regular follow up and medicines.
3113456|NCT01799525|Experimental|Hypercapnia|Intervention: SAH patients are subjected to gradual hypercapnia by reduction of respiratory volume in one trial session every day. PaCO2 is raised from normocapnia to 50 mmHg for 10 - 15 minutes and 60 mmHg for 10 - 15 minutes.
3113457|NCT01799512|Experimental|real-time continuous glucose monitoring|"real-time continuous glucose monitoring: Use will be made of the online real-time (RT) monitoring facility of the GlucoDay® (a continuous glucose monitoring (CGM)system). This will allow immediate adaptation of the insulin dose in order to maintain values within an optimal range.~The same IV insulin infusion protocol will be used in the experimental and the active comparator group (adapted Yale protocol).~When glycaemic changes of >25 mg/dl per 30 minutes are observed from the RT-CGM - GlucoDay data, this will be checked by measuring arterial blood glucose and the insulin infusion rate will be adapted according to the adapted Yale protocol."
3113458|NCT01799512|Active Comparator|blinded continuous glucose monitoring|"In the active comparator group the same continuous glucose monitoring device (GlucoDay) will be used in a blinded fashion. Glucose data will be analysed retrospectively.~IV insulin infusion will be adapted according to arterial blood glucose values, using the adapted Yale protocol."
3113459|NCT01799499|Experimental|Group A: 20 mg MMC mixed with 60cc TC-3|Group A: 20 mg MMC mixed with 60cc TC-3 hydrogel. (n=8)
3113460|NCT01799499|Experimental|• Group B: 40 mg MMC mixed with 60cc TC-3|• Group B: 40 mg MMC mixed with 60cc TC-3 hydrogel (n=8)
3113461|NCT01799499|Experimental|• Group C: 80 mg MMC mixed with 60cc TC-3 hydrogel (n=8)|• Group C: 80 mg MMC mixed with 60cc TC-3 hydrogel (n=8)
3113462|NCT01799486|Experimental|Telbivudine|Telbivudine,600mg/d,oral,100patients,2 years.
3113463|NCT01799486|Experimental|Adefovir|Adefovir,10mg/d,oral,100 patients,2years.
3113464|NCT01799486|Experimental|Enecavir|Enecavir,0.5mg/d,oral,100 patients,2 year
3113465|NCT01799460||CR/CTR group|The complete remission group treated by the Comprehensive Treatment Regimen
3113466|NCT01799460||NR/CTR group|The non-remission group treated by the Comprehensive Treatment Regimen
3113467|NCT01799460||CR/IA group|The complete remission group treated by Immunosuppressive Agents
3113468|NCT01799460||NR/IA group|The non-remission group treated by Immunosuppressive Agents.
3113469|NCT01799447|Other|Early intervention|Early intervention. Quasiexperimental study. Inclusion of 150 first times families in intervention and matched with 150 families from control group.
3113470|NCT01799434|Experimental|Exercise|All participants had to run 20min on their individual anaerobic threshold
3113471|NCT01799421||Non-haematologic cancer|
3113472|NCT01799408||betamethasone|Patients who had intra-articular injection of betamethasone
3113473|NCT01799408||Hyaluronic acid|Patients who had intra-articular injection of hyaluronic acid
3113474|NCT01799395||Lung Cancer|All patients with advanced lung cancer candidate for chemotherapy or chemotherapy + radiation therapy will be enrolled and followed-up for 1 year clinically and radiologically (Chest CT) to verify whether or not central airway obstruction is present at the time of diagnosis or occurs in the year following diagnosis (or in the life span from diagnosis and death in patients who die before 1 year of diagnosis). Furthermore, predictor variables possibly associated with central airway obstruction will be studied.
3113475|NCT01799382|Experimental|EBUS-TBNA + Rapid on-site evaluation|Patients in this arm will undergo rapid-on site evaluation of samples obtained with EBUS-TBNA
3113476|NCT01799382|Active Comparator|EBUS-TBNA|Patients in this arm will undergo EBUS-TBNA without rapid on-site evaluation
3113477|NCT01799369|No Intervention|Control|Routine post-operative care
3113478|NCT01799369|Experimental|Intervention|Post-operative care influenced by the Surgical Apgar Score
3113479|NCT01799356|Active Comparator|moxifloxacin Group|Treatment at uPID with moxifloxacin
3113481|NCT01799343|Experimental|Immersion into water|Normal healthy singleton pregnant women. The case serves as its own control. Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion (Baseline), during immersion (Immersion) and after immersion (Post-immersion).
3113482|NCT01799330|Experimental|Group 1:Active TCEMS|Transcutaneous Electrical Muscle Stimulation (TCEMS): Group 1 will undergo TCEMS using an Omnistim FX-2 with two surface patch electrodes (8 x 6 cm) applied to each quadriceps, hamstring and calf muscles. The knee angle will remain at 90 degrees during simultaneous muscle stimulation to prevent joint movement. Electrical stimulation will be performed for 20 minutes on each limb, 3 days/week for 8 continuous weeks on an outpatient basis. The stimulator will be set to generate brief bursts of electrical impulses at 50Hz lasting 200 ms every 1500 ms. Muscles will be stimulated with an asymmetrical square wave pulse with an initial intensity set to create a visible contraction ranging from 55 mA to 120 mA.
3113483|NCT01799330|Placebo Comparator|Group 2: Sham TCEMS|Patients randomized to Group 2 (Sham TCEMS) will receive the identical set-up for active TCEMS except they will receive a minimal electrical stimulus that does not produce a motor response.
3113484|NCT01799317|Active Comparator|Treatment with vitamin D2|Vitamin D2 50,000u titrated to serum 25(OH)D values given orally once a month in addition to standard of care: Doxercalciferol escalating doses beginning at 2.5 mcg given orally thrice weekly. Sevelamer Carbonate 800 mg (1600- 4800 mg) given orally with each meal
3113485|NCT01799317|No Intervention|Standard of Care|Standard of Care: Doxercalciferol escalating doses beginning at 2.5 mcg given orally thrice weekly. Sevelamer Carbonate 800 mg (1600- 4800 mg) given orally with each meal
3113486|NCT01799304|Experimental|no distractor control group|postural control and locomotion of CP children without attentional distractor and without additional cognitive task (control condition)
3113487|NCT01799304|Experimental|visual and sound attentional distractors|postural control and locomotion of CP children with visual and sound attentional distractors (video film).
3113488|NCT01799304|Experimental|sound attentional distractor alone|postural control and locomotion of CP children with sound attentional distractor alone (sound track of the video film).
3113489|NCT01799304|Experimental|additional cognitive task|postural control and locomotion of CP children with an additional cognitive task (adapted Stroop task with animals)
3113490|NCT01799291|Other|Treatment: Decision Making Tutorial|A brief presentation on mood disorders (i.e., Control condition) combined with the intervention (i.e., Treatment condition): a 20-minute training on decision-making errors and cognitive de-biasing strategies.
3113491|NCT01799291|No Intervention|Control|A brief presentation about mood disorders.
3113492|NCT01799278|Experimental|All Patients|MLN8237 at 50 mg twice daily for 7 days repeated every 21 days. Therapy will continue until disease progression, unacceptable toxicity as a result of MLN8237, or withdrawal of patient consent.
3113493|NCT01799265|Active Comparator|Transcend followed by REMstar|The patient will receive treatment with Transcend during the first night sleep study, followed by treatment with the REMstar on the second night.
3113494|NCT01799265|Active Comparator|REMstar followed by Transcend|The patient will receive treatment with REMstar during the first night sleep study followed by treatment with Transcend on the second night.
3113495|NCT01799252||Doxy|Women who are prescribed a seven-day regimen of doxycycline following medical abortion
3113496|NCT01799252||No Doxy|Women who are not prescribed antibiotics following medical abortion
3113497|NCT01799239|Experimental|First Test product; then SenSura|"The subject in this arm first test the Test product The test product is a newly developed ostomy appliance with a new top film. Due to company confidentiality the product is not described in further details.~After cross-over the subject test SenSura which is CE-marked and commerical available."
3113498|NCT01799239|Active Comparator|First SenSura, Then Test product|"The subject in this arm first test SenSura which is CE-marked and commerical available.~After cross-over the subject test the Test product The test product is a newly developed ostomy appliance with a new top film. Due to company confidentiality the product is not described in further details."
3113499|NCT01799226|Active Comparator|Toothpaste without Triclosan|This arm will use a toothpaste that does not contain triclosan
3113500|NCT01799226|Experimental|Triclosan|This arm will use colgate total which contains triclosan
3113501|NCT01799213|Experimental|Active Treatment|Eligible subjects will be randomized to Meloxicam 15 mg po QD vs placebo
3113502|NCT01799213|Placebo Comparator|Placebo|Eligible subjects will be randomized to Meloxicam 15 mg po QD vs placebo
3113503|NCT01799187|Experimental|revascularization|revascularization is is an alternative new treatment of immature permanent teeth with necrotic pulp. The use of triple antibiotic paste is followed by Induction of bleeding from the apical root during this intervention.
3113504|NCT01799187|Active Comparator|apexification|apexification is a traditional therapy of immature permanent teeth with necrotic pulp.calcium hydroxide is served as medication to induce the developing of root .
3113505|NCT01799174|Active Comparator|UVA-1 Phototherapy|Receive medium dose UVA-1 (70 J/cm2) 3x/week for 10 weeks
3113506|NCT01799174|Sham Comparator|Placebo|"Receive sham UVA1 phototherapy (0 J/cm2) 3x/week for 10 weeks"
3113507|NCT01799161|Active Comparator|DS-1|6 week course of gp96 Vaccine: >= 4 x 10^7 cells twice monthly on Day 1. Up to 3 courses, 9 vaccinations.
3113508|NCT01799161|Active Comparator|DS-2|6 week course of gp96 Vaccine: >= 2 x 10^7 cells weekly on Day 1. Up to 3 courses, 18 vaccinations.
3113509|NCT01799161|Active Comparator|DS-3|6 week course of gp96 Vaccine: >= 1 x 10^7 cells twice weekly on Days 1 and 4. Up to 3 courses, 36 vaccinations.
3113510|NCT01799148||Particulate air pollutants|Cohort of consecutive patients admitted with diagnosis of acute coronary syndrome in the cardiology unit of a tertiary hospital, which will quantify the exposure of particulate air pollutants 24 hours a day 7 days earlier prior to admission.
3113511|NCT01799135|Experimental|Experimental Arm|DCE-MRI scan (4 scans total); Stereotactic Body Radiation Therapy; 4D-CT scan
3113512|NCT01799122|Active Comparator|Precise sling vs TVT-O sling|
3113513|NCT01799109|Experimental|nebulization ms and albuterol|magnesium sulfate 150mg & albuterol 2.5mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
3113514|NCT01799109|Active Comparator|nebulized albuterol|albuterol 2.5mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
3113517|NCT01799096|Placebo Comparator|Aspartame|Receives Aspartame sweetened drinks
3113518|NCT01799083|Experimental|Decitabine|A continuous 5-day treatment of lower dose decitabine within 4-6 weeks is regarded as a treatment cycle, transfusion of auto-CIK cells or chemotherapy regimen may be used for patients.
3113519|NCT01799070||CHS|
3113520|NCT01799057|Experimental|Metformin|Metformin at a maximum dose of 1000mg twice daily for 16-18 weeks (i.e. maximum of 2000mg per day).
3113521|NCT01799057|Placebo Comparator|Placebo|Matching placebo twice daily for 16-18 weeks.
3113522|NCT01799044|Experimental|Irreversible electroporation|Single arm study: Irreversible electroporation of colorectal liver metastasis
3113523|NCT01799031|Experimental|Arm I (WISE)|Patients receive access to the WISE web-based educational intervention to help BCS manage their symptoms, identify ergonomic workplace problems and risks, and implement ergonomic modifications. Patients also receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
3113524|NCT01799031|Active Comparator|Arm II (control)|Patients receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
3113525|NCT01799018||SAH Patients|Patients admitted with the diagnosis of aneurismal subarachnoid hemorrhage (SAH) and cerebral angiogram negative SAH who would need to have the external ventricular drain (EVD) placed for the management of hydrocephalus.
3113526|NCT01799018||Control Patients|Patients with non-hemorrhagic brain pathology such as posterior fossa tumor or stroke who will have the CSF sampling for diagnostic or therapeutic purposes.
3113527|NCT01799005|Active Comparator|flavanol rich intervention|Ingestion of 410mg flavanols twice a day for 30 days
3113528|NCT01799005|Placebo Comparator|flavanol free intervention|Ingestion of a macro and micro nutrients matched flavanol free drink
3113529|NCT01798992|No Intervention|Non-failing control|Patients with normal ejection fraction who underwent a single myocardial biopsy and received no β-blocker therapy
3113530|NCT01798992|Active Comparator|Metoprolol succinate|Idiopathic dilated cardiomyopathy patients randomized to metoprolol succinate titrated to a goal of 200 mg by mouth daily for 18 months
3113531|NCT01798992|Active Comparator|Metoprolol succinate + doxazosin|Idiopathic dilated cardiomyopathy patients who were randomized to receive metoprolol succinate and doxazosin titrated to a goal of 200 mg and 8 mg by mouth daily for 18 months
3113532|NCT01798992|Active Comparator|Carvedilol|Idiopathic dilated cardiomyopathy patients who were randomized to receive carvedilol titrated to a goal of 25 mg by mouth twice daily for 18 months
3113533|NCT01798979|Experimental|Midazolam and GLPG0634|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8) and multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
3113534|NCT01798966|Experimental|SENSIMED Triggerfish|Sensimed Triggerfish device will be worn by each subject for 24h
3113535|NCT01798953||UC/PSC with IPAA|Patients with ulcerative colitis and primary sclerosing cholangitis reconstructed with ileal pouch-anal anastomosis
3113536|NCT01798953||UC with IPAA|Patients with ulcerative colitis reconstructed with ileal pouch-anal anastomosis.
3113537|NCT01798953||UC/PSC with IRA|Patients with ulcerative colitis and primary sclerosing cholangitis reconstructed with ileorectal anastomosis.
3113538|NCT01798953||UC with IRA|Patients with ulcerative colitis reconstructed with ileorectal anastomosis.
3113539|NCT01798927|Other|Ankle foot orthosis fitting|All participants will receive ankle foot orthosis or orthoses. Outcomes will be compared to pre-bracing findings.
3113540|NCT01798901|Experimental|Treatment (HDAC inhibitor AR-42, decitabine)|"INDUCTION THERAPY: Patients receive HDAC inhibitor AR-42 PO daily on days 1, 3, and 5 or 1, 3, 4, 5 and decitabine IV over 1 hour on days 6-15. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients achieving CR or CRi receive HDAC inhibitor AR-42 as in Induction Therapy and decitabine IV over 1 hour on days 6-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3113541|NCT01798875|Active Comparator|Metformin|oral metformin at a dose of 850mg twice daily
3113542|NCT01798875|Active Comparator|Oral contraceptive|oral contraceptive containing 35ug of ethynylestradiol and 2mg of cyproterone acetate (21 day regimen)
3113543|NCT01798862|Experimental|Endometrial injury by hysteroscopy or pipelle sapling|Endometrial Sampling by pipelle or hysteroscopy performed once between 6th to 10th day in the cycle prior to the fresh IVF/ ICSI cycle.
3113544|NCT01798862|Active Comparator|COH for IVF without hysteroscopy or pipelle sampling|Procedure: COH for IVF Both GnRH agonists (long, starting at day 2 or 21) with triptorelin acetate 0.1 mg (Gonapeptyl daily) and antagonists with ganirelix 0.25mg (Orgalutran) or cetrorelix 0.25mg (Cetrotide) protocols will be used; for ovarian stimulation both recombinant FSH ( Puregon) and human menopausal gonadotrophin ( Menopur) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the Hcg triggering and for luteal phase support 600 mg progesterone tablets ( Utrogestan) will be applied.
3113545|NCT01798849|Experimental|Panel A-Healthy|Within each of the 5 rising dose treatment periods, 6 participants will be randomly assigned to receive a single oral dose of MK-8892, and 2 will be randomly assigned to receive a single oral dose of matching placebo according to a computer-generated allocation schedule. Dosing periods will alternate with Panel B.
3113546|NCT01798849|Experimental|Panel B-Healthy|Within each of the 4 rising dose treatment periods, 6 participants will be randomly assigned to receive a single oral dose of MK-8892, and 2 will be randomly assigned to receive a single oral dose of matching placebo according to a computer-generated allocation schedule. Dosing periods will alternate with Panel A.
3113547|NCT01798849|Experimental|Panel C-Mild/Moderate Hypertension|Within each of the 5 rising dose treatment periods, 6 participants will be randomly assigned to receive a single oral dose of MK-8892, and 2 will be randomly assigned to receive a single oral dose of matching placebo according to a computer-generated allocation schedule. Dosages will be determined by the results of Panels A and B.
3113548|NCT01798836|Experimental|Oestradiol and ultrashort GnRH agonist/antagonist protocol|Women will begin pretreatment with 4 mg/day of 17 β-estradiol before the combination of GnRH ultashort agonist and antagonist protocol
3113549|NCT01798836|Active Comparator|GnRH agonist or antagonist protocol.|Women will undergo either a conventional short or long GnRH agonist or an antagonist protocol during COH for IVF
3113550|NCT01798823||EIB+A+|"children with EIB and asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
3113551|NCT01798823||EIB+A-|"children with EIB without asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
3113552|NCT01798823||EIB-A+|"children without EIB and asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
3113553|NCT01798823||EIB-A-|"children without EIB without asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
3113554|NCT01798810|Experimental|Supplemental Perioperative Oxygen (80% FiO2)|After intubation, patients in the Treatment Group will receive intraoperative inspired oxygen set at 80 percent (FiO2 of 0.80). Post-extubation, patients in the treatment arm will be placed on high flow non-re-breather mask at 15L/min for up to 2 hours postoperatively and then transitioned to nasal cannula, which will be weaned as tolerated.
3113555|NCT01798810|No Intervention|Control (30% FiO2)|After intubation, patients in the control arm will receive typical standard of care intraoperative inspired oxygen of 30 percent (FiO2 of 0.30). Post-extubation, patients in the control arm of the study will be placed on a nasal cannula at 4L/min to maintain SaO2≥92% as determined by pulse oximetry. This will be maintained for up to 2 hours and then weaned as tolerated.
3113556|NCT01798797||no treatment|non-randomized, all subjects who have been implanted with an ICD or CRT-D for at least 3 months
3113557|NCT01798784|No Intervention|Control Arm|Arm 1 will be the Control arm, in which participants receive an electronic pill container and are provided with daily reminders to take their medication but are not enrolled in the sweepstakes.
3113558|NCT01798784|Experimental|Sweepstakes Incentive 1|Arm 2 will be a sweepstakes incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication.
3113559|NCT01798784|Experimental|Sweepstake Incentive 2|Arm 3 will be a sweepstake incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which monetary prizes may be awarded if participants take their medication prior to receiving a reminder.
3113560|NCT01798784|Experimental|Sweepstake Incentive 3|Arm 4 will be a sweepstake incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which each participant maintains an account that will accumulate money based on their medication adherence throughout the study.
3113561|NCT01798771|Other|Control arm|5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.
3113562|NCT01798771|Other|Interventional arm|5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.
3113563|NCT01798745|Experimental|Cohort A: JNJ-54452840 20 mg|Each patient will receive 20 mg of JNJ-54452840 as a single dose.
3113564|NCT01798745|Experimental|Cohort A: JNJ-54452840 80 mg|Each patient will receive 80 mg of JNJ-54452840 as a single dose.
3113565|NCT01798745|Experimental|Cohort A: JNJ-54452840 160 mg|Each patient will receive 160 mg of JNJ-54452840 as a single dose.
3113566|NCT01798745|Placebo Comparator|Cohort A: Placebo|Each patient will receive matching placebo as a single dose.
3113567|NCT01798745|Experimental|Cohort B: JNJ-54452840 <= 240 mg|Each patient will receive JNJ-54452840 at a dose of less than or equal to 240 mg as a single dose (dose determined by the Data Monitoring Committee).
3113568|NCT01798745|Placebo Comparator|Cohort B: Placebo|Each patient will receive matching placebo as a single dose.
3113569|NCT01798745|Experimental|Cohort C: JNJ-54452840 for 3 days|Each patient will receive JNJ-54452840 once daily for 3 days at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
3113570|NCT01798745|Placebo Comparator|Cohort C: Placebo|Each patient will receive matching placebo once daily for 3 days.
3113571|NCT01798745|Experimental|Cohort D: JNJ-54452840 for 5 days|Each patient will receive JNJ-54452840 once daily for 5 days at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
3113572|NCT01798745|Placebo Comparator|Cohort D: Placebo|Each patient will receive matching placebo once daily for 5 days.
3113573|NCT01798745|Experimental|Cohort E: JNJ-54452840 weekly|Each patient will receive JNJ-54452840 once weekly on Days 1, 8, 15, and 22 at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
3113574|NCT01798745|Placebo Comparator|Cohort E: Placebo|Each patient will receive matching placebo once weekly on Days 1, 8, 15, and 22.
3113575|NCT01798745|Experimental|Cohort F: JNJ-54452840 multiple dose|Each patient will receive JNJ-54452840 once daily (for 3 or 5 days) or once weekly (up to Day 22) as determined by the Data Monitoring Committee and as explored in Cohorts C, D, and E (daily dose not exceeding 240 mg).
3113576|NCT01798745|Placebo Comparator|Cohort F: Placebo|Each patient will receive matching placebo once daily (for 3 or 5 days) or once weekly (up to Day 22).
3113577|NCT01798732|Experimental|Selective laser trabeculoplasty (Tango Laser, Ellex)|Patients treated with selective laser trabeculoplasty (Tango Laser, Ellex, Minneapolis, USA)
3113578|NCT01798719|Placebo Comparator|Diet: Dietary Advice|Some general dietary advice about healthy dietary components, servings size and frequency of servings
3113579|NCT01798719|Experimental|Low glycemic index Mediterranean Diet|Low glycemic index Mediterranean Diet prescription with indication about type of foods than can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
3113580|NCT01798706|Experimental|Lixisenatide|Lixisenatide 10 mcg once daily (QD) for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
3113581|NCT01798706|Placebo Comparator|Placebo|Placebo (matched to lixisenatide) QD for 24 Weeks.
3113582|NCT01798693|Placebo Comparator|Placebo (maltodextrin)|Maltodextrin
3113583|NCT01798693|Active Comparator|Multi-Nutrient Blend|Blend of vitamins, minerals, and amino acids, given twice daily
3113584|NCT01798680|Experimental|Vitamin D3 (cholecalciferol)|
3113585|NCT01798680|Placebo Comparator|Placebo|
3113586|NCT01798667|Placebo Comparator|Placebo|PO administration
3113587|NCT01798667|Experimental|DA-8031 dose 1|PO administration
3113588|NCT01798667|Experimental|DA-8031 dose 2|PO administration
3113589|NCT01798667|Experimental|DA-8031 dose 3|PO administration
3113590|NCT01798654||Antithrombotic agents|
3113676|NCT01798095|Active Comparator|PPD Standard|Determine equivalent specificity for new material compared to standard material.
3113591|NCT01798641|Experimental|Open Shunt|The programmable valve, MIETHKE proGAV® / MIETHKE proSA®, will be open at this time. The adjustment is done in the out-patient clinic.
3113592|NCT01798641|Placebo Comparator|Closed Shunt|The programmable valve, MIETHKE proGAV® / MIETHKE proSA®, will be closed during this time. The adjustment is done in the out-patient clinic.
3113593|NCT01798628|Experimental|Sequence ABC|
3113594|NCT01798628|Experimental|Sequence ACB|
3113595|NCT01798628|Experimental|Sequence BAC|
3113596|NCT01798628|Experimental|Sequence BCA|
3113597|NCT01798628|Experimental|Sequence CAB|
3113598|NCT01798628|Experimental|Sequence CBA|
3113599|NCT01798602|Experimental|Rosuvastatin|"Rosuvastatin 40 mg via nasogastric tube then 20 mg po or via nasogastric tube daily for 14 days or until hospital discharge Placebo is identical capsule with no active drug~Both are crushed for administration"
3113600|NCT01798602|Placebo Comparator|Placebo|Identical drug vehicle with no active agent
3113601|NCT01798589|Experimental|Ethylenediamine dihydrochloride|Ethylenediamine dihydrochloride in methylcellulose 50 mcg/cm2 Ethylenediamine dihydrochloride in polyvinylpyrrolidone 50 mcg/cm2 Methylcellulose (negative control 1) Polyvinylpyrrolidone (negative control 2)
3113602|NCT01798576||Pegylated interferon alfa-2a|Participants with chronic hepatitis C with previous treatment failure received combination therapy with pegylated interferon alfa-2a plus ribavirin or treatment regimens containing direct-acting anti-viral (DAAs)
3113603|NCT01798563||Tremor Dominant PD|Volunteers with predominantly tremor-related motor symptoms of PD
3113604|NCT01798563||Postural Instability & Gait Difficulty PD|Volunteers with primarily walking & balance-related motor symptoms of PD.
3113605|NCT01798563||Healthy Controls|Healthy volunteers consisting of people of same age as PD volunteers, w/o a diagnosis of PD.
3113606|NCT01798550|Experimental|Reduced Dose (0.8 mg/kg)|Enoxaparin 0.8 mg/kg (using total body weight) twice daily
3113607|NCT01798550|Active Comparator|Standard Dose (1 mg/kg)|Enoxaparin 1 mg/kg (using total body weight) twice daily
3113608|NCT01798537|Experimental|Neomycin Colistin Nystatin Vancomycin|"All participating study arm patients will receive SDD from admission to discharge according to the following plan:~ENTERAL MEDICATION (via feeding tube) x 4 times daily:~375 mg Neomycin 100 mg Colistin Sulphate~1 million units Nystatin * 250 mg Vancomycin *~Nystatin will be prescribed only if there is a positive sputum or urine culture for yeast or candida Vancomycin will be prescribed only in case of a positive screen or culture for MRSA"
3113609|NCT01798537|No Intervention|Control|No SDD given for 1 year Screening performed as in intervention arm
3113610|NCT01798524||Kidney allograft recipients|
3113611|NCT01798511|Experimental|Nasogastric Tube Feeding|Patients who are to have NTF will receive enteral nutrition within 6 hours after randomisation via a nasogastric tube placed into the stomach. A commercially available low fat semi-elemental feed (Peptisorb®, Nutricia Clinical NZ) will be used. The caloric target will be 2000 kcal per day. Enteral tube feeding will be commenced at a rate of 30 mL/h and increased gradually until 100 mL/h over 24-48 h.
3113612|NCT01798511|Active Comparator|Conventional Nutritional Management|Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case enteral tube feeding will be introduced) or the signs of AP mitigate,in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced.
3113613|NCT01798498|Experimental|Princess® VOLUME|"Injection of Princess® VOLUME into the deep dermis or subcutis of both nasolabial folds.~A touch-up treatment may be performed at Day 14 if correction is not complete after the first injection.~The injected volumes will be estimated by the investigator and depend on the depth of the nasolabial folds"
3113614|NCT01798485|Experimental|Ganetespib and Docetaxel|Ganetespib (150 mg/m^2) and docetaxel (75 mg/m^2) were administered as separate 1-hour IV infusions on Day 1 of each 3-week treatment cycle. Administration of ganetespib preceded the administration of docetaxel. Ganetespib was administered again on Day 15 of each cycle.
3113615|NCT01798485|Active Comparator|Docetaxel|Docetaxel (75 mg/m^2) was administered on Day 1 of a 3-week treatment cycle by 1-hour IV infusion.
3113616|NCT01798472|Experimental|uncemented hemiarthroplasty|Patients aged 80 or older with displaced femoral neck fracture treated with an uncemented hemiarthroplasty
3113617|NCT01798472|Experimental|reverse hybrid total hip arthroplasty|Patients aged between 65 and 79 years treated with an reverse hybrid arthroplasty.
3113618|NCT01798472|Active Comparator|cemented hemiarthroplasty|Patients aged 80 or older with displaced femoral neck fracture treated with an cemented hemiarthroplasty
3113619|NCT01798472|Active Comparator|cemented total hip arthroplasty|Patients aged between 65 and 79 years treated with an cemented total hip arthroplasty.
3113620|NCT01798459|Active Comparator|Methylphenidate|Methylphenidate 0.3 mg/kg per os is given before performing a continuous performance test.
3113621|NCT01798459|Placebo Comparator|Placebo|Placebo is given before performing a continuous performance test.
3113622|NCT01798446|Experimental|Axitinib|This is a single arm study. Axitinib arm is the only arm who receive axitinib.
3113623|NCT01798433|Experimental|One stent technique alone|One stent technique alone for non-true LM bifurcation
3113624|NCT01798433|Experimental|One stent technique + Elective FKB|One stent technique + Elective FKB for non-true LM bifurcation
3113625|NCT01798433|Experimental|Provisional approach|Provisional approach for true LM bifurcation
3113626|NCT01798433|Experimental|Elective 2-stent|Elective 2-stent for true LM bifurcation
3113627|NCT01798420||Corticosteroid|
3113628|NCT01798420||non-corticosteroid group|
3113629|NCT01798407|Experimental|Activa Tremor Control Sys (DBS Implant)|all subjects will receive bilateral surgical implantation of DBS system. Those who respond at 12 months will enter a randomized, staggered withdrawal phase.
3113630|NCT01798407|Experimental|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
3113677|NCT01798082|No Intervention|Standard counseling|
3113631|NCT01798394|Active Comparator|Progesterone|Take micronized natural progesterone capsule by mouth, twice daily (approximately at 8 am and 8 pm) for four weeks beginning on postpartum day 4.
3113632|NCT01798394|Placebo Comparator|Placebo|Take placebo capsule by mouth, twice daily (approximately at 8 am and 8 pm) for 4 weeks beginning on postpartum day 4.
3113633|NCT01798381|Active Comparator|Essential fatty acids|Omega-3
3113634|NCT01798381|Placebo Comparator|Placebo|
3113635|NCT01798368|Experimental|PBASE system 2.0|
3113636|NCT01798355|Experimental|Cognitive Behavioral Therapy|
3113637|NCT01798355|Active Comparator|Treatment as usual|
3113638|NCT01798342|Active Comparator|Maltodextrin|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin
3113639|NCT01798342|Experimental|Glutamine|The same volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of glutamine
3113640|NCT01798329|Active Comparator|Probiotic|Probiotic VSL#3 for 15 weeks, dosage variations according to the weight
3113641|NCT01798329|Placebo Comparator|Placebo|subjects treated with placebo for 15 weeks
3113642|NCT01798316|Active Comparator|IV Acetaminophen|IV Acetaminophen administered on admission to post-anesthesia care unit
3113643|NCT01798316|Active Comparator|Standard of care|Standard of care pain management regimen including opioids administered on admission to post-anesthesia care unit
3113644|NCT01798303|Experimental|LY2940094|40 mg LY2940094 oral tablet, QD for 8 weeks
3113645|NCT01798303|Placebo Comparator|Placebo|Identically matched placebo oral tablet, QD for 8 weeks
3113646|NCT01798290|Experimental|Behavioral: narrative medicine: reading workshop|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading patients' diaries or nurses'diaries. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
3113647|NCT01798290|Active Comparator|Behavioral: critical reading|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading literature. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
3113648|NCT01798277|Active Comparator|Catheter Ablation|Radiofrequency ablation procedure
3113649|NCT01798277|Active Comparator|Medical therapy|Antiarrhythmic drug therapy will include amiodarone or sotalol. Which antiarrhythmic drug will prescribed per patient depends on the observing physician.
3113650|NCT01798264|Experimental|10 mcg./day|ITCA 650 (exenatide in DUROS)
3113651|NCT01798264|Experimental|20 mcg/day|ITCA 650 (exenatide in DUROS)
3113652|NCT01798264|Experimental|40 mcg/day|ITCA 650 (exenatide in DUROS)
3113653|NCT01798264|Experimental|80 mcg/day|ITCA 650 (exenatide in DUROS)
3113654|NCT01798251|Experimental|XELOX-X|"XELOX: Oxaliplatin: 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine: 850mg/m^2 bid, days 1-14, every 3 weeks and maximum 4 cycles, or progression/intolerance.~X Maintenance: Capecitabine 850mg/m^2 bid, days 1-14, every 3 weeks after 4 cycles XELOX regimen, until progression/intolerance."
3113655|NCT01798251|Active Comparator|XELOX|XELOX: Oxaliplatin 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine 850mg/m^2 bid, days 1-14, every 3 weeks, until progression/intolerance.
3113656|NCT01798238|Placebo Comparator|Placebo group|
3113657|NCT01798238|Experimental|MP-513 group|
3113658|NCT01798225|Placebo Comparator|Control|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) pills.
3113659|NCT01798225|Experimental|Doxycycline|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Doxycycline 100mg x 14 pills)
3113660|NCT01798212|Other|full thickness gastroplication|
3113661|NCT01798199|Experimental|Alzheimer disease|
3113662|NCT01798186|Experimental|Cannabis 5% THC, No Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 5% THC and in a room with no ventilation.
3113663|NCT01798186|Experimental|Cannabis 11% THC, No Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 11% THC and in a room with no ventilation.
3113664|NCT01798186|Experimental|Cannabis 11% THC, Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 11% THC in a room with active ventilation.
3113665|NCT01798173|Experimental|Cases: cirrhotic patients with hepatocellular carcinoma|
3113666|NCT01798173|Active Comparator|Controls: cirrhotic patients without hepatocellular carcinoma|
3113667|NCT01798160|Active Comparator|DEB TACE|Drug eluting Beads (DC Beads) loaded with Doxorubicin
3113668|NCT01798160|Experimental|SIRT|Selective Internal Radiation Therapy using Yttrium 90 loaded resin beads (Sir Spheres)
3113669|NCT01798147|Active Comparator|DEB TACE|Drug eluting Beads (DC Beads) loaded with Doxorubicin
3113670|NCT01798147|Experimental|SIRT|Selective Internal Radiotherapy using Yttrium 90 loaded resin beads (Sir Spheres)
3113671|NCT01798134|Other|DEB-TACE|"Transarterial Chemoembolization with TANDEM™ - DOX Microspheres (DEB-TACE)~Treatment: Lobes; Dosing: TANDEM™/Doxorubicin; Second Treatment:TANDEM™/Doxorubicin"
3113672|NCT01798121|Experimental|Aplisol|To compare new PPD to reference standard material
3113673|NCT01798121|Placebo Comparator|Reference standard|Response of standard material
3113674|NCT01798108|Experimental|Radium-223 dichloride|The study had 2 parts. Part 1a was designed with single injections of Radium-223 given to cohorts of 5 patients for each of 5 pre-defined dose levels. Part 1b was designed to retreat and fractionate the dose of Radium-223 in multiple injections.Based on the revised correction factor by calibration, recalculations verified that the single injection doses administered in the part 1a were : 46, 93, 163, 213 and 250 kBq/kg b.w. Two re-treated patients (dose group 6) received a second dose that resulted in a total dose of 250 kBq/kg b.w. The fractionated doses were 1/5 and ½ of the highest dose in part1b (i.e. 250kBq so 5 x 50 and 2 x 125 kBq/kg b.w. respectively).
3113675|NCT01798095|Experimental|Aplisol|To confirm the response of PPD materials
3113678|NCT01798082|Experimental|Standard counseling, pelvic organ prolapse decision aid|In addition to standard counseling at the time of the initial new patient visit, the patients randomized to the experimental arm will recieve a pelvic organ prolapse decision aid prior to their initial visit.
3113679|NCT01798069|Experimental|Behavioral intervention|Students allocated to the experimental arm will follow 5 sessions in Class-led instruction of reflexive writing workshops. They will be divided into 12 sub-groups of 8 students. They will write their stories about their own experiences or the experiences of their family / patient.
3113680|NCT01798069|Active Comparator|behavoral intervention|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading medical publication workshops. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
3113681|NCT01798056|Experimental|GSK1437173A Group|Subjects received the first dose of GSK 1437173A at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of GSK 1437173A vaccine was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.
3113682|NCT01798056|Placebo Comparator|Placebo Group|Subjects received the first dose of placebo at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of placebo was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.
3113683|NCT01798043|Experimental|Septal RV lead with >50% pacing (B1)|Cardiac MRI with pacemaker stimulation
3113684|NCT01798043|Experimental|Septal RV lead with <50% pacing (B2)|Cardiac MRI with and without pacemaker stimulation
3113685|NCT01798043|Experimental|Apical RV lead with >50% pacing (A1)|Cardiac MRI with pacemaker stimulation
3113686|NCT01798043|Experimental|Apical RV lead with <50% pacing (A2)|Cardiac MRI with and without pacemaker stimulation
3113687|NCT01798030||Vitamin D|Specimen analysis
3113688|NCT01798017|Experimental|Mifepristone-misoprostol|Women will receive 200mg oral mifepristone followed in 24-48h by 800mcg buccal misoprostol
3113689|NCT01798004|Experimental|Treatment (induction therapy, consolidation therapy, ASCT)|"INDUCTION THERAPY:~COURSES 1-2: Patients receive cyclophosphamide IV over 15-30 minutes and topotecan hydrochloride IV over 30 minutes on days 1-5. Treatment repeats every 3 weeks for 2 courses.~COURSES 3 AND 5: Patients receive cisplatin IV over 1 hour on days 1-4 and etoposide IV over 1-2 hours on days 1-3. Treatment repeats every 3 weeks for 2 courses.~COURSE 4: Patients receive cyclophosphamide IV over 1-6 hours on days 1-2, vincristine sulfate IV over 1 minute on days 1-3, and doxorubicin hydrochloride IV over 24 hours on days 1-3. Treatment repeats every 3 weeks for 1 course.~Treatment continues in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Beginning 4-8 weeks following the 5th course of induction therapy, patients receive busulfan IV over 3 hours on days -6 to -3 and melphalan IV on day -1. Patients undergo ASCT on day 0.~Some patients also undergo EBRT after induction and consolidation."
3113690|NCT01797991|Active Comparator|Group A (dexamethasone per os)|"Dexamethasone 20 mg per os 12 hours and 6 hours before paclitaxel (form: opaque white capsules)~Matching placebo for dexamethasone IV (NaCl 0,9%) 30 minutes before paclitaxel"
3113691|NCT01797991|Experimental|Group B (dexamethasone IV)|"Dexamethasone 20 mg IV 30 minutes before paclitaxel~Matching placebo for dexamethasone per os (lactose capsule) 12 hours and 6 hours before paclitaxel (form: opaque white capsules)"
3113692|NCT01797978|Experimental|Intravenous methylene blue administration|2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion for 6hrs
3113693|NCT01797978|Placebo Comparator|Placebo|Normal saline administration instead of methylene blue
3113694|NCT01797965|Experimental|BIIB019|BIIB019 150 mg subcutaneous (SC) every 4 weeks
3113695|NCT01797952|Active Comparator|Lactobacillus CD 2 lozenges|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
3113696|NCT01797952|Placebo Comparator|Placebo lozenges|The placebo is a mix of sugars and salts used as excipients in the active formulation
3113697|NCT01797939||Erosive reflux disease (ERD)|
3113698|NCT01797939||Non-erovise reflux disease (NERD)|
3113699|NCT01797939||Functional heartburn (FH)|
3113700|NCT01797926|Experimental|Group 1 (5 mg amlodipine and 50 mg losartan)|Subjects in Group 1 will be randomized to receive a single dose FDC 5/50 mg tablet and also separate single tablets each of reference treatment 5 mg amlodipine and 50 mg losartan. The reference treatment will be replicated in a three sequence, three period design
3113701|NCT01797926|Experimental|Group 2 (5 mg amlodipine and 100 mg losartan)|Subjects in Group 2 will be randomized to receive a single dose FDC 5/100 mg; and also separate single tablets each of reference treatment 5 mg amlodipine and 100 mg losartan. The reference treatment will be replicated in a three sequence, three period design
3113702|NCT01797913|Experimental|gemcitabine|
3113703|NCT01797900|Experimental|Inductive + concurrent chemotherapy|Inductive chemotherapy :paclitaxel 175mg/m2 d1+ cisplatin 80mg/m2d1, every 21 days for two cycles concurrent chemotherapy:cisplatin 80mg/m2 on week 1, 4, 7 radiotherapy: IMRT
3113704|NCT01797900|Active Comparator|concurrent + adjuvant chemotherapy|concurrent chemotherapy: cisplatin 80 mg/m2, on week 1, 4, 7 adjuvant chemotherapy: paclitaxel 175mg/m2 + cisplatin 75mg/m2, every 21 days for 4 cycles radiotherapy: IMRT
3113705|NCT01797887|Experimental|Ayurveda|Ayurveda Diet and Lifestyle Counseling
3113706|NCT01797887|Active Comparator|Conventional|Standard Conventional Diet and Lifestyle Counseling
3113707|NCT01797874|Experimental|Pazopanib|pazopanib maintenance after 4 cycles of etoposide/platinum in SCLC
3113708|NCT01797874|Placebo Comparator|placebo|placebo after 4 cycles of etoposide/platinum chemotherapy in SCLC
3113767|NCT01797445|Active Comparator|E/C/F/TDF|E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks
3114224|NCT01794286|Experimental|Intervention Group|Trigger alerts + provider bulletins
3113709|NCT01797861|Active Comparator|Half-dose photodynamic therapy (PDT)|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne ®) is administered, with an infusion time of 10 minutes. At 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~If there still is subretinal fluid on OCT scan at Evaluation Visit 1 (6-8 weeks after Treatment Visit 1 / the first treatment with half-dose PDT), a second treatment with half-dose PDT will be performed (Treatment Visit 2)."
3113710|NCT01797861|Active Comparator|Micropulse laser (ML) treatment|"ML treatment with an 810 nm diode laser will be performed of the areas identified on mid-phase ICG angiography. Multiple laser spots will be applied, covering the leakage area on mid-phase ICG angiography. The area(s) that has to be treated is determined based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT scan and hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein angiogram.~If there still is subretinal fluid on OCT scan at Evaluation Visit 1 (6-8 weeks after Treatment Visit 1 / the first ML treatment), a second ML treatment will be performed (Treatment Visit 2)."
3113711|NCT01797848|Experimental|pegIFNα 2a + Ribavirin + Placebo|"pegIFNα 2a 180 µg, Solution for injection, Subcutaneous, Once weekly, 48 weeks~Ribavirin 200 mg Tablets, by mouth, 400-600mg AM, 600 mg PM, 48 weeks~Placebo 0 mg Tablets, by mouth, Once daily, 24 weeks"
3113712|NCT01797848|Experimental|pegIFNα 2a + Ribavirin + Daclatasvir|"pegIFNα 2a 180 µg, Solution for injection, Subcutaneous, Once weekly, 24 or 48 weeks depending on response~Ribavirin 1000-1200 mg Tablets, by mouth, 400-600mg AM, 600 mg PM, 24 or 48 weeks depending on response~Daclatasvir 60 mg Tablets, by mouth, Once daily, 24 weeks"
3113713|NCT01797835|Placebo Comparator|Usual Care|Youth in usual care will receive screening for alcohol and drug use. Those youth who are at risk will have a chance to talk to their provider about their use. They will also receive an informational brochure.
3113714|NCT01797835|Experimental|CHAT brief MI intervention|Youth in CHAT will receive screening for alcohol and drug use. Those youth who are at risk will have a chance to talk to their provider about their use. In addition, these youth will CHAT. CHAT is a brief motivational intervention that takes places in the primary care setting. It is a 15-20 minute intervention for adolescents age 12-18 focused on discussing alcohol and drug use. They will also receive a booster call one month later to check in on how they are doing.
3113715|NCT01797822|Other|Dexamethasone, artificial tears|Dexamethasone 0.01% ophthalmic solution four times a day for two weeks in both eyes Artificial tears four times a day for two weeks in both eyes
3113716|NCT01797809||Group 1|
3113717|NCT01797796|Experimental|PF-06305591|
3113718|NCT01797796|Placebo Comparator|Placebo|
3113719|NCT01797783|Experimental|DAILIES® AquaComfort Plus® Multifocal|Nelfilcon A multifocal contact lens with comfort additive worn for 30 days on a daily wear, daily disposable basis
3113720|NCT01797783|Active Comparator|Focus® DAILIES® Progressives|Nelfilcon A multifocal contact lens worn for 30 days on a daily wear, daily disposable basis
3113721|NCT01797770||Mechanical bowel preperation|mechanical bowel preparation with polyethylene glycol one day prior to surgery
3113722|NCT01797757|Active Comparator|Fish oil enriched with EPA + ORLISTAT|"The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.~The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days."
3113723|NCT01797757|Active Comparator|MAG-EPA|The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
3113724|NCT01797757|Active Comparator|MAG-EPA + ORLISTAT|"The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.~The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days."
3113725|NCT01797757|Active Comparator|Fish oil enriched with EPA|The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
3113726|NCT01797744|Experimental|Vestibular rehabiliation|Vestibular rehabiliation
3113727|NCT01797744|No Intervention|Control group|Usual rehabilitation whitout additional vestibular exercises
3113728|NCT01797731|Active Comparator|Conventional System|Conventional tibial extramedullary alignment system used by surgeon during surgery.
3113729|NCT01797731|Experimental|KneeAlign System|Digital hand-held surgical navigation system for tibial component placement used by surgeon during surgery.
3113730|NCT01797718|Active Comparator|Testosterone|~1mg/kg every 4 weeks for 6 months
3113731|NCT01797718|Active Comparator|Letrozole|2.5mg daily for 6 months
3113732|NCT01797705|Experimental|All subjects|All subjects underwent a sleep study with DeVilbiss AutoAdjust CPAP with revised algorithm simultaneously with hand-scored PSG.
3113733|NCT01797692|Other|geriatric assessment|geriatric assessment
3113734|NCT01797679|Other|Strength Training|"The strength group include progressive strength training and neuromuscular exercises. The inclusion will be performed 2-3 times a week for 12 weeks.~Intervention: Other: Strength training"
3113735|NCT01797679|Experimental|Aerobic exercise|The aerobic exercise group will cycle on an ergometer bicycle 2-3 times a week for 12 weeks on moderate loading. The loading will be controlled by a heart rate monitor and is defined as 85% of maximal heart rate.
3113736|NCT01797679|No Intervention|Control Group|The control group will do as usual.
3113737|NCT01797653|Placebo Comparator|Placebo CPAP|patients established on CPAP therapy, who are randomized to the placebo comparator, will use a CPAP device with subtherapeutic pressure during two weeks.
3113738|NCT01797653|Active Comparator|therapeutic CPAP|patients who are randomized to the active comparator, will continue with CPAP treatment with therapeutic pressure during two weeks
3113739|NCT01797601|Active Comparator|Human Insulin|Nasal spray
3113740|NCT01797601|Placebo Comparator|Placebo solution|Nasal spray
3113942|NCT01796171|Experimental|Part A, Arm 2: without pre-dosing|Betalutin, 15 MBq/kg b.w. in escalated doses without pre-dosing.
3113741|NCT01797588|Active Comparator|adductor-canal block and periarticular infiltration|Adductor-canal block,performed prior to surgery using ultra sound guidance by an anesthetist, with a total of 30mL of 0.33% ropivacaine injected into the area surrounding the saphenous nerve. Periarticular infiltration, performed intra-operatively by the surgeon, involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee.
3113742|NCT01797588|Active Comparator|adductor-canal block|The adductor-canal block only group will receive an adductor-canal block prior to surgery in the block room using ultra sound guidance by an anesthetist. After the adductor-canal is located a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve. Participants will also receive 110mL of normal saline administered as follows: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
3113743|NCT01797588|Active Comparator|periarticular infusion group|Periarticular infiltration,performed intra-operatively,involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. It will be administered as follows: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
3113744|NCT01797575|Active Comparator|Aspirin|research subject will be taking aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
3113745|NCT01797575|Active Comparator|N-acetyl-cysteine|research subject will be taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
3113746|NCT01797575|Active Comparator|Aspirin and NAC|research subject will be taking aspirin 1000mg (2 capsules of 500mg) every morning and NAC 1000mg (2 capsules of 500mg) two times a day in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations.
3113747|NCT01797575|Placebo Comparator|Sugar Pill|research subject will be taking 4 capsules of matching sugar pill( placebo) in the morning and 2 capsules of matching placebo in the evenings in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
3113748|NCT01797562|Experimental|T.R.U.E. Test Panel 3.2|T.R.U.E. Test Panel allergens; Gold sodium thiosulfate, Hydrocortisone-17-butyrate, Bacitracin, Parthenolide, Methyldibromoglutaronitrile, Disperse blue 106, and Bronopol
3113749|NCT01797549||History of having sustained TBI|Males and females between 18 and 60 years who have a diagnosis of TBI
3113750|NCT01797549||Control group|Control group with no history of TBI or concussion. Gender and age matched non-TBI volunteers
3113751|NCT01797536|Experimental|Mild Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with mild hepatic insufficiency, defined as a score of 5 to 6 on the Child-Pugh scale
3113752|NCT01797536|Experimental|Moderate Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with moderate hepatic insufficiency, defined as a score of 7 to 9 on the Child-Pugh scale
3113753|NCT01797536|Experimental|Severe Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with severe hepatic insufficiency, defined as a score of 10 to 15 on the Child-Pugh scale
3113754|NCT01797536|Experimental|Healthy Participants|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants matched to the mean of all hepatic insufficiency participants for age, gender, and weight
3113755|NCT01797523|Experimental|Letrozole + Metformin + RAD001|"Patients have a 7-10 day lead in period where they take Metformin alone. The starting dose of Metformin 500 mg by mouth daily for 4 days and then increased to 500 mg by mouth twice a day. Everolimus and Letrozole added and considered the start of Cycle #1.~Everolimus administered by mouth as once daily dose of 10 mg. Letrozole 2.5 mg tablet by mouth once daily. The oral dose of Everolimus should be taken together with the daily dose of Letrozole 2.5mg."
3113756|NCT01797510|Experimental|Coaching|Interventional web based coaching study
3113757|NCT01797510|No Intervention|Usual Care|
3113758|NCT01797497|Experimental|Care plan and coaching group|In the intervention group, parents complete a referral care plan with their children's physicians and receive a brief coaching session about how to exchange information with specialists. Outcome data are collected from parents before and after the specialist visit.
3113759|NCT01797497|No Intervention|Preintervention group|In the preintervention group, no care plan is used and no coaching takes place. Outcome data are collected from parents before and after the specialist visit.
3113760|NCT01797484|Active Comparator|Ranolazine|Ranolazine 500mg bid orally 7 days Ranolazine 750mg bid orally 35 days
3113761|NCT01797484|No Intervention|No additional medication|No additional medication - control group
3113762|NCT01797471|Experimental|LEAD RT|"Lattice Extreme Ablative Dose (LEAD) Radiation Therapy (RT) on Day 1 at dose of 18 Gy followed by;~Conventionally fractionated radiation therapy beginning on day 2 at 2 Gy per fraction for 30 fractions for a total dose of 60 Gy;~Conventional Platinum Chemotherapy Doublet at discretion of treating physician beginning on day 2."
3113763|NCT01797458|Experimental|Hall Technique|This technique uses preformed Stainless Steel Crowns (SSCs) to restore carious primary molars. Local anaesthesia, caries removal or tooth preparation are not required.
3113764|NCT01797458|Experimental|Non-Restorative Caries Treatment|This is a less operative approach, here carious lesions are opened removing the overhanging enamel and making the cavity accessible for biofilm removal. No carious dentine will be removed from the pulpal wall and no local anaesthesia will be placed. Fluoride varnish (Duraphat ®) will be applied to the cavity. Parents/children will be trained to clean the cavity by brushing using a buccolingual technique.
3113765|NCT01797458|Active Comparator|Conventional Restoration|This technique corresponds to the conventional way of treating cavitated carious lesions involving complete caries removal, use of local anaesthesia (when needed), and a compomer (Dyract ®) restoration. Cotton wool roll isolation and continuous aspiration will be used.
3113766|NCT01797445|Experimental|E/C/F/TAF|E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks
3113768|NCT01797432|Experimental|Combined IL Kenalog and Restylane|Injection of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on whole scalp and Restylane on half of scalp
3113769|NCT01797419|Experimental|GS-5806|Single dose, oral liquid, .5 mL/kg
3113770|NCT01797419|Placebo Comparator|Placebo|Single dose, oral liquid, .5 mL/kg
3113771|NCT01797406|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
3113772|NCT01797406|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .All the patients were examined without sedation during the whole procedure.
3113773|NCT01797393|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
3113774|NCT01797393|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .The mucosa was observed by inflating the bowel with air while withdrawing the colonoscope.All the patients were examined without sedation during the whole procedure.
3113775|NCT01797393|Experimental|" Air assisted water colonoscopy"|" Air assisted water injection colonoscopy: Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.All the patients were examined without sedation during the whole procedure."
3113776|NCT01797380|Placebo Comparator|Sugar Pill|Placebo
3113777|NCT01797380|Active Comparator|Active Drug|Escitalopram tablet, 10mg, daily, 9 weeks.
3113778|NCT01797354|Experimental|Cognitive-behavioral therapy and hypnosis group|Patients will receive (in groups of 6) fifteen 120-min sessions of group therapy including cognitive-behavioral techniques and hypnosis.
3113779|NCT01797354|Active Comparator|Support group|Patients will receive (in groups of 6) fifteen 120-min support group session.
3113780|NCT01797341|Experimental|Prograf arm|"patients will self-administer tacrolimus in the form of Prograf (twice daily administration.~Dosage will be adjusted to maintain trough serum levels of 5-15 μg/ml. Maximum daily dose of 20 mg once per day."
3113781|NCT01797341|Experimental|Advagraf Arm|patients will self-administer tacrolimus in the form of Advagraf (once daily dosing) Dosage will be adjusted to maintain trough serum levels of 5-15 μg/ml. Maximum daily dose of 20 mg once per day.
3113782|NCT01797328|Active Comparator|cold provocation|cold arm
3113783|NCT01797328|Active Comparator|to avoid feeling cold|warm arm
3113784|NCT01797315|Active Comparator|Sirolimus|Patients who meet all inclusion criteria will be included into the study and randomised. If converted to Sirolimus (SRL), patients will take SRL according to the investigator's instructions and medication label, once daily preferably 4 hours after calcineurin-inhibitor medication or in case without calcineurin-inhibitor co-medication in the morning. The dose of SRL will be correlated to the former immunosuppressive therapy according to the study's conversion protocol.
3113785|NCT01797315|No Intervention|Standard therapy|Patients who will not receive SRL stay on their previous immunosuppressive therapy including one or more of the following drugs: azathioprine, cyclosporine, tacrolimus, mycophenolate-sodium and steroids.
3113786|NCT01797302|Active Comparator|Vitamin D3 2000 IU|Vitamin D3 2000 IU tablet once daily by mouth for 6 months
3113787|NCT01797302|Active Comparator|Vitamin D3 1000 IU|Vitamin D3 1000 IU tablet by mouth once daily for 6 months
3113788|NCT01797302|Placebo Comparator|Vitamin D3 600 IU|Vitamin D3 600 IU tablet by mouth once daily for 6 months
3113789|NCT01797289|Experimental|First episode of loss of consciousness|
3113790|NCT01797263|Experimental|Yoga|A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
3113791|NCT01797263|Active Comparator|Structured Exercise|A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
3113792|NCT01797237|Experimental|Stable intertrochanteric fracture|The type of intertrochanteric fracture was below A2.1 (with A2.1) according to the AO/ATO classification.
3113793|NCT01797237|Experimental|Unstable intertrochanteric fracture|The type of intertrochanteric fracture was above A2.1 (without A2.1) according to the AO/ATO classification.
3113794|NCT01797224||Cohort 1 - Exposed Cohort|Pregnant women with a current diagnosis of an approved indication who have used Cimzia (certolizumab pegol) in the first trimester of pregnancy for any length of time from the date of conception.
3113795|NCT01797224||Cohort 2 - Diseased Comparison Cohort|Pregnant women with a current diagnosis of a Cimzia approved indication who have not used Cimzia (certolizumab pegol) during the current pregnancy.
3113796|NCT01797224||Cohort 3 - Non-Diseased Comparison Cohort|Pregnant women without a current diagnosis of an autoimmune disease and who have not used Cimzia (certolizumab pegol) at any time in pregnancy, nor have they been exposed to any known human teratogen during pregnancy.
3114338|NCT01793584|Active Comparator|Abdominal hysterectomy|Total Abdominal Hysterectomy
3113797|NCT01797224||Group 4 -Cimzia Registry, Not Qualified for the Cohort Study|Women who have used Cimzia (certolizumab pegol) for any length of time following the first day of the last menstrual period until the end of pregnancy who do not qualify for the prospective cohort study.
3113798|NCT01797211|Experimental|diet group A|Mediterranean diet+olive oil
3113799|NCT01797211|Experimental|Diet Group B|Mediterranean diet+not-fried fish
3113800|NCT01797211|Experimental|Diet Group C|Mediterranean diet+nuts
3113801|NCT01797198|Experimental|gemfibrozil + ASP3652|Multiple doses of gemfibrozil and single dose of ASP3652
3113802|NCT01797198|Experimental|ASP3652 + repaglinide|Multiple doses of ASP3652 and the single dose of repaglinide
3113803|NCT01797185|Experimental|SPARC1104|
3113804|NCT01797172|Experimental|Percutaneous Cervical Nucleoplasty|Percutaneous Cervical Nucleoplasty
3113805|NCT01797172|Active Comparator|Pulsed Radio Frequency|Pulsed Radio Frequency treatment
3113806|NCT01797159|Experimental|Hippocampal-sparing PCI|Hippocampal-sparing PCI 25 Gy in 10 fractions
3113807|NCT01797146|Active Comparator|CARE|All patients in the intervention wards will receive the Catheter Reminder and Evaluation (CARE) intervention.
3113808|NCT01797146|No Intervention|Control|All patients in the control wards will receive usual care without the CARE intervention.
3113809|NCT01797133|Active Comparator|Fellow arm|Patients in this arm will receive the ID fellow-based antibiotic pre-authorization intervention.
3113810|NCT01797133|Active Comparator|Pharmacist arm|Patients in this arm will receive the pharmacist-based antibiotic pre-authorization intervention.
3113811|NCT01797120|Active Comparator|Fulvestrant & Everolimus|Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus everolimus daily x 12 cycles.
3113812|NCT01797120|Placebo Comparator|Fulvestrant & Placebo|Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus placebo daily x 12 cycles.
3113813|NCT01797107|Experimental|Treatment eye|Azasite (azithromycin ophthalmic 1%) twice a day for 2 days followed by nightly for 4 weeks
3113814|NCT01797107|Placebo Comparator|Durasite|Vehicle of Azasite used as placebo
3113815|NCT01797094|Experimental|Botulinum toxin Type A (44U)|44 units (U) botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
3113816|NCT01797094|Experimental|Botulinum toxin Type A (32U)|32 units (U) botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
3113817|NCT01797081|Experimental|Botulinum toxin Type A (24U)|24 units (U) botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
3113818|NCT01797081|Experimental|Botulinum toxin Type A (12U)|12U botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
3113819|NCT01797081|Other|Placebo/Botulinum toxin Type A (24U)|Placebo (normal saline) one treatment injected into bilateral Crow's Feet Line areas on Day 1 and subsequent treatments if applicable until day 180. Botulinum toxin Type A (24U) injected into bilateral Crow's Feet Line areas at any additional treatments from day 180 onward. Based on retreatment criteria participants were eligible for up to 5 treatment cycles (2 Placebo + 3 botulinum toxin type A).
3113820|NCT01797081|Other|Placebo/Botulinum toxin Type A (12U)|Placebo (normal saline) one treatment injected into bilateral Crow's Feet Line areas on Day 1 and subsequent treatments if applicable until day 180. Botulinum toxin Type A (12U) injected into bilateral Crow's Feet Line areas at any additional treatments from day 180 onward. Based on retreatment criteria participants were eligible for up to 5 treatment cycles (2 Placebo + 3 botulinum toxin type A).
3113821|NCT01797068|Experimental|Patient Navigator|Patients in the experimental group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH).
3113822|NCT01797068|Active Comparator|Standard of Care|Patients in the active comparator group will experience the usual intake process in the ED setting.
3113823|NCT01797055|Experimental|human apotransferrin|intravenous apotransferrin every 4-8 weeks
3113824|NCT01797042|Active Comparator|Fructose 9%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
3113825|NCT01797042|Active Comparator|Glucose 9%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
3113826|NCT01797042|Active Comparator|High fructose corn syrup 18%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
3113827|NCT01797042|Active Comparator|Sucrose 18%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
3113828|NCT01797029|Experimental|Vaccine|
3113829|NCT01797029|Placebo Comparator|Placebo|
3113830|NCT01797003|Active Comparator|Opening wedge HTO|Opening wedge high tibial osteotomy using Puddu plate
3113831|NCT01797003|Active Comparator|Closing wedge HTO|Closing wedge high tibial osteotomy using cramp fixation
3113832|NCT01796990|Active Comparator|REF group|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
3113861|NCT01796795|Placebo Comparator|vehicle gel|The vehicle gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
3113902|NCT01796496|Experimental|Manipulative Therapy Techniques|Manipulative Therapy Techniques involve three techniques on lumbar and sacral areas. This protocol will be administered one a week for 3 weeks.
3113833|NCT01796990|Other|ACT group|"The ACT group gets the same procedure as the REF group. In addition, they will participate the ACT based program. The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
3113834|NCT01796977|Active Comparator|OxyGenesys Dissolved Oxygen Dressing|OxyGenesys Dissolved Oxygen Dressing is a closed-cell foam wound dressing enriched with gaseous and dissolved oxygen for use in the management of wounds.
3113835|NCT01796977|Placebo Comparator|Standard Gauze Dressing|A sterile 4x4 covered by an adhesive Tegaderm will serve as the comparator for this study.
3113836|NCT01796964|Experimental|ESBA1008|ESBA1008 solution, 7 intravitreal (IVT) injections, as specified in protocol
3113837|NCT01796964|Active Comparator|EYLEA|Aflibercept, 8 intravitreal (IVT) injections, as specified in protocol
3113838|NCT01796951|Experimental|Celecoxib, aspirin, followed by aspirin/celecoxib|Celecoxib 200 mg twice daily x3 days, aspirin 325 mg daily x10 days, celecoxib 200 mb twice daily + aspirin 325 mg daily x 3 days
3113839|NCT01796938|Experimental|Group 1: Healthy subjects|Single dose of 100 mg Lacosamide
3113840|NCT01796938|Experimental|Group 2: Subjects with mild renal insufficiency|Single dose of 100 mg Lacosamide
3113841|NCT01796938|Experimental|Group 3: Subjects with moderate renal insufficiency|Single dose of 100 mg Lacosamide
3113842|NCT01796938|Experimental|Group 4: Subjects with severe renal insufficiency|Single dose of 100 mg Lacosamide
3113843|NCT01796938|Experimental|Group 5: Subjects with end stage renal insufficiency|Single dose of 100 mg Lacosamide
3113844|NCT01796925|Experimental|aura6000 THN Therapy|The aura6000 THN system will be implanted and activated for nightly therapy during sleep.
3113845|NCT01796912|Active Comparator|Lipoprotein Apheresis|Three months of weekly lipoprotein apheresis
3113846|NCT01796912|Sham Comparator|Sham Apheresis|Three months of weekly sham apheresis
3113847|NCT01796899|Other|Brivaracetam 10 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 10 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 10 mg~Form: Oral tablet~Frequency: Once daily~Duration: 1 day"
3113848|NCT01796899|Other|Brivaracetam 50 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 50 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 50 mg~Form: Oral tablet~Frequency: Once daily~Duration: 1 day"
3113849|NCT01796899|Other|Brivaracetam 75 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 75 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 75 mg~Form: Oral tablet~Frequency: Once daily~Duration: 1 day"
3113850|NCT01796899|Other|Brivaracetam 100 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 100 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 100 mg~Form: Oral tablet~Frequency: Once daily~Duration: 1 day"
3113851|NCT01796899|Other|10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of 10 mL of BRV intravenous bolus injection (10 mg/mL) will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 100 mg (10 mg/mL)~Form: Intravenous bolus injection~Frequency: Once daily~Duration: 1 day"
3113852|NCT01796886|Experimental|patient's neurological status|
3113853|NCT01796860|Other|AFO|All persons in the study will be fit with the same AFO (Tamarack joint with adjustable check strap).
3113854|NCT01796847||PTEN, hyperglycemia|
3113855|NCT01796834|Experimental|Mindfulness-Based Stress Reduction|Subjects attend a community based Mindfulness-Based Stress Reduction course.
3113856|NCT01796821|Placebo Comparator|Vehicle gel|vehicle gel is used as a control group. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
3113857|NCT01796821|Active Comparator|SR-T100 gel with 1.0 % SM|SR-T100 contains 1.0% SM. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
3113858|NCT01796821|Active Comparator|SR-T100 gel with 2.3% SM|SR-T100 contains 2.3% SM. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
3113859|NCT01796808|Other|Pathway A|"Screening visit followed by pedal fat grafting procedure with local anesthetic and visits at:~1 week~Post op study visit 2 (1 month)~Post op study visit 3 (2 month)~Post op study visit 4 (6 month)~Post op study visit 5 (12 month)~Crossover to standard podiatry visits~Study visit 6 (18 months)~Study visit 7 (24 months)"
3113860|NCT01796808|Other|Pathway B|"Screening visit followed by:~Study visit 1 (6months)~Study Visit 2 (12 months)~Crossover to Pathway A~pedal fat grafting procedure and local anesthetic and visits at:~1 week~Post op study visit 2 (1 month post procedure)~Post op study visit 3 (2 month post procedure)~Post op study visit 4 (6 month post procedure)~Post op study visit 5 (12 month post procedure)"
3113862|NCT01796795|Active Comparator|SR-T100 gel with 1.0% of SM|SR-T100 contains 1.0% SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
3113863|NCT01796795|Active Comparator|SR-T100 gel with 2.3% of SM|SR-T100 contains 2.3%SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
3113864|NCT01796782|Active Comparator|Xeloda|Subjects will receive Xeloda until progression
3113865|NCT01796782|Experimental|QYHJ Granules|patients will receive QYHJ Granules until progression
3113866|NCT01796769|Experimental|Conventional|
3113867|NCT01796769|Active Comparator|Telemedicine|
3113868|NCT01796756|Experimental|Handover program|Standardized handover program Dedicated place and time Template Face-to-face communication Evidence-based education session Feedback and audit
3113869|NCT01796756|No Intervention|Usual handover practice|
3113870|NCT01796743||Controls|Age and gender matched controls ('control' group) with acute MI with similar degree of troponin elevation who are managed based solely on the basis of clinical or angiographic data alone.
3113871|NCT01796743||Cardiac MRI|Hospitalized patients with acute MI with a clinically-indicated CMR ordered will be enrolled. Data for T2 mapping will be added to the clinically prescribed cardiac MRI scan.
3113872|NCT01796730|Experimental|sequence I|10mg (21 days) -washout (7 days) - bambuterol 5mg (21 days) -washout (7 days) -placebo (21 days)
3113873|NCT01796730|Experimental|sequence II|bambuterol 5mg (21 days) -washout (7 days) - placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days)
3113874|NCT01796730|Experimental|sequence III|placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days) - washout (7 days) - bambuterol 5mg (21 days)
3113875|NCT01796717|Active Comparator|C Group|Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
3113876|NCT01796717|Experimental|E Group|Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
3113877|NCT01796704||healthy and mild heart failure|diversity of patients
3113878|NCT01796691||Standard therapy|Antiplatelet therapy following coronary stenting without platelet function testing
3113879|NCT01796691||Optimized antiplatelet therapy|"Platelet function testing and according to a test and treat strategy improve the antiplatelet therapy in low-responder.~Treatment adjustments were done as published before - see BOCLA-Plan manuscript. (Reference: Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 Jan 12;9:3.)"
3113880|NCT01796678|Experimental|Arginine|100 mg/kg T.I.D 3x a day IV or PO
3113881|NCT01796678|Placebo Comparator|Placebo|Saline or sugar pill
3113882|NCT01796665|Experimental|Test product|Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% applied to the affected areas of the face once daily.
3113883|NCT01796665|Active Comparator|Reference product|Acanya Gel applied to the affected areas of the face once daily.
3113884|NCT01796665|Placebo Comparator|Placebo product|Placebo of the Test product applied to the affected areas of the face once daily.
3113885|NCT01796652||Home and hospital treatment groups|Patients were randomized into either home or hospital groups after a brief hospitalization(≤24 hours. Hospital patients were followed 5 days in hospital.Home patients were visited on 2nd,3rd and 5th days by a staff nurse and the vital signs, symptoms, and general condition were recorded and transmitted back to the attending physician. On the 7th, 14th and 30th days, the home and hospital group patients were requested to return for a follow-up clinic visit at Bezmialem, at which time an assessment of their symptoms, physical examination, and laboratory evaluation was conducted.
3113886|NCT01796639||kidney transplantation patients with living-donor grafts|
3113887|NCT01796626|Experimental|Wrinkle treatment|Wrinkle treatment with ResurFX 1565nm module
3113888|NCT01796626|Experimental|Striae treatment|Striae treatment with the REsurFX 1565nm module
3113889|NCT01796613|Active Comparator|Vaginal Ring - intermittent regimen|3 weeks ring use followed by one week of no ring use to allow menstruation
3113890|NCT01796613|Active Comparator|Vaginal Ring - continuous regimen|3 weeks of ring use with no off period. The next ring is immediately inserted after the previous one
3113891|NCT01796600|Experimental|Conventional and a cone-beam scanner 5G|The patients will have a conventional scanner, a reference examination, and a cone-beam scanner Newtom 5G just after the conventional scanner
3113892|NCT01796587||LoFric Origo|
3113893|NCT01796574|Experimental|Ketogenic diet|Patients will receive the ketogenic diet as a formula delivered via feeding tube. Once able to tolerate food by mouth, patients will be switched to a modified Atkins diet.
3113894|NCT01796561|Active Comparator|Olive leaf extract liquid|20ml of polyphenol-rich olive leaf extract liquid to be consumed daily for 6 weeks
3113895|NCT01796561|Placebo Comparator|Placebo liquid|20ml of polyphenol-free placebo liquid (containing water, glycerin, flavours, colours and aromas) to be consumed daily for 6 weeks
3113896|NCT01796548|Experimental|Oxybutynin Extended-Release|Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
3113897|NCT01796535||PerX360º System™|Patients treated with PerX360º System™
3113898|NCT01796522|Active Comparator|Nifedipine (60 mg / day orally)|The name of this arm is Nifedipine. These Prolonged release tablets(Oros) presents a release system for 24h, acting as an osmotic pump releasing the nifedipine through an orifice in the tablet produced by laser technology.The Nifedipine tablet 60mg administered once daily to week 34 of gestation.
3113899|NCT01796522|Active Comparator|Progesterone 200 mg / day vaginally|The name of this arm is Progesterone. Soft gelatin capsule vaginal use, used in clinical practice as maintenance tocolytic therapy after episode of threatened preterm labor. The 200mg capsule administered once daily to week 34 of gestation. The patients assigned to this arm will begin treatment while the patient assigned to the arm of nifedipine.
3113900|NCT01796509|Experimental|multidisciplinary follow-up|
3113901|NCT01796509|No Intervention|no follow-up|
3114339|NCT01793571|Experimental|TAP block|20 ml Levobupivacaine 0,5%
3113903|NCT01796496|Active Comparator|Functional Technique|Manipulative Therapy Technique involves one technique on lumbar area. This protocol will be administered one a week for 3 weeks.
3113904|NCT01796483|Active Comparator|healthy Volunteers|
3113905|NCT01796483|Experimental|Patients|
3113906|NCT01796470|Experimental|Entospletinib + idelalisib|"Entospletinib plus idelalisib at one of 4 dose combinations (400 mg/100 mg; 600 mg/100 mg; 800 mg/100 mg; 800 mg/150 mg).~After discontinuation of entospletinib+idelalisib combination therapy, and following a washout period, participants may continue to receive entospletinib 400 mg monotherapy."
3113907|NCT01796444|Active Comparator|Axillary Lymph Node Dissection|After sentinel lymph node biopsy, surgery for standard axillary lymph node dissection. Pathological evaluation (include intraoperative pathological examination) is performed routinely. All women were to receive whole-breast opposing tangential-field radiation therapy. Adjuvant systemic therapy was determined by the treating physician.
3113908|NCT01796444|Experimental|Non-Axillary Lymph Node Dissection|After sentinel lymph node biopsy, no surgery of axillary lymph node In this study, the absence of surgery is the experimental arm (non-inferiority trial). Pathological evaluation (include intraoperative pathological examination) is performed routinely. All women were to receive whole-breast opposing tangential-field radiation therapy. Adjuvant systemic therapy was determined by the treating physician.
3113909|NCT01796431|Experimental|Eviplera®|Participants will take Eviplera every day for 14 days. Levels of the active ingredients, Tenofovir disoproxil fumarate, emtricitabine, rilpivirine hydrochloride will be measured in in blood after the drug intake has been stopped in order to understand how long these drugs persist in the blood.
3113910|NCT01796418|Experimental|Beraprost sodium|Beraprost sodium 0.02 mg capsule by mouth every 12 hours for 12 weeks
3113911|NCT01796418|Placebo Comparator|Placebo|Placebo capsule by mouth every 12 hours for 12 weeks
3113912|NCT01796405|Experimental|Low-Risk|Multifocal or Low-Risk Multi System Clofarabine, Low Dose, Two Cycles
3113913|NCT01796405|Experimental|High-Risk|High-risk Multi System Clofarabine, Standard Dose, Two Cycles
3113914|NCT01796392|Experimental|EBV and Optimal Medical Management|This study arm will undergo EBV treatment along with optimal medical management, including smoking cessation program, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
3113915|NCT01796392|Other|Optimal Medical Management|This study arm will receive maximal medical management, including smoking cessation program support if necessary, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
3113916|NCT01796379|Experimental|High Intensity Interval Training|
3113917|NCT01796379|Other|Moderate Training|Regular exercise training offered as usual care to all heart transplant recipients.
3113918|NCT01796366|Experimental|Insulin 338 + placebo|
3113919|NCT01796366|Active Comparator|Insulin glargine + placebo|
3113920|NCT01796353|Experimental|sexual rehabilitation|exercise plus psycho-education
3113921|NCT01796353|Active Comparator|usual care|usual care
3113922|NCT01796340|Experimental|Food cue exposure|
3113923|NCT01796340|Active Comparator|Psycho-education|
3113924|NCT01796327|Experimental|Treatment|Dacomitinib will be administered as a single oral dose and as an intravenous infusion
3113925|NCT01796314|Experimental|Group A : intervention|"85 dyads patient/caregiver in witch the patient suffers from mild to moderately severe Alzheimer's disease patients (MMSE 11 to 26), and lives at home with a caregiver"
3113926|NCT01796314|No Intervention|Group B : Control|There si no associated intervention
3113927|NCT01796301|Experimental|Romosozumab|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
3113928|NCT01796301|Active Comparator|Teriparatide|Participants received 20 μg/day teriparatide administered by subcutaneous injection for 12 months.
3113929|NCT01796288|Experimental|Erlotinib & simultaneous radiotherapy|patients started simultaneously radiotherapy for all gross tumors
3113930|NCT01796288|Other|Erlotinib & no radiotherapy|patients received no radiotherapy for all gross tumors
3113931|NCT01796275|Experimental|Group A|Subjects will have a core session intervention and booster intervention; questionnaire evaluation is conducted at baseline, post-session, pre-booster and 3 month after core session.
3113932|NCT01796275|Experimental|Group B|Subjects will only have a core session intervention; Questionnaire evaluation are conducted at baseline (T1-baseline), post-session (T2), 4 weeks after core session (T3) and 3 month after core session (T4).
3113933|NCT01796275|Other|Group C|Group C is a waiting list control, only questionnaire evaluations can be conducted at T1-baseline, T3- tea gathering and T4- 3 month after baseline evaluation; when finish T4 evaluation, the core session and booster can be optionally conducted subsequently.
3113934|NCT01796262|Placebo Comparator|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
3113935|NCT01796262|Active Comparator|docosahexaenoic acid|DHA Richoil 250 mg pearl (DMF srl): b.i.d. for six months
3113936|NCT01796236|Active Comparator|Minimally invasive surgery and BA400|This arm involves no softtissue reduction around the BA400 implant.
3113937|NCT01796236|Active Comparator|Traditional surgery and BA300|This arm involves traditional soft tissue reduction around the BA300 implant
3113938|NCT01796223|Experimental|Feedback|Feedback system included in psychotherapy
3113939|NCT01796223|Active Comparator|control|Psychotherapy as usual
3113940|NCT01796197|Experimental|Treatment Arm|"Run in phase: Trastuzumab IV 4 mg/kg, Pertuzumab IV 840 mg Pre-op phase: Trastuzumab IV 2 mg/kg weekly, Paclitaxel 80 mg/m2 IV weekly x 16 doses. Starting Day 21 (week 4) continue trastuzumab and paclitaxel as above and add Pertuzumab 420 mg IV every 3 weeks during 16 doses of paclitaxel administration. After completing 16 doses of Paclitaxel, Trastuzumab (6 mg/kg IV) and Pertuzumab 420 mg IV may be continued every 3 weeks until surgery~Modified Radical Mastectomy~Post-Operative Treatment:~Option 1: Adriamycin 60 mg/m2 IV and Cyclophosphamide 600 mg/m2 IV every 2-3 weeks x 4 cycles. Followed by Trastuzumab 8 mg/kg and Pertuzumab 840 IV load; followed by Trastuzumab 6 mg/kg every and Pertuzumab 420 mg IV every 3 weeks to complete 12 months of HER2-directed therapy~Option 2: Continue Trastuzumab 6 mg/kg and Pertuzumab 420 mg every 3 weeks to complete 12 months of HER2-directed therapy~Radiation Therapy"
3113941|NCT01796171|Experimental|Part A, Arm 1: with lilotomab pre-dosing|Betalutin, 10 MBq/kg b.w. in escalated doses with lilotomab pre-dosing.
3113943|NCT01796171|Experimental|Part A, Arm 3: with rituximab pre-dosing|Betalutin, 15 MBq/kg b.w. in escalated doses with rituximab pre-dosing.
3113944|NCT01796171|Experimental|Part A, Arm 4: with higher dose lilotomab pre-dosing|Betalutin, 15 MBq/kg b.w. in escalated doses with a higher dose lilotomab pre-dosing regimen.
3113945|NCT01796171|Experimental|Part A, Arm 5: with intermediate dose lilotomab pre-dosing|Betalutin, 20 MBq/kg b.w. with an intermediate dose lilotomab pre-dosing regimen.
3113946|NCT01796171|Experimental|Part B|Betalutin, 15 MBq/kg b.w. with 40mg lilotomab compared to Betalutin, 20 MBq/kg b.w. with 100mg/m2 lilotomab
3113947|NCT01796158|Experimental|cASBI+cMET|Participants will complete the computerized alcohol screening and brief intervention (cASBI)protocol at the time of an office visit and also complete the 2-session computerized Motivational Enhancement Therapy intervention (cMET).
3113948|NCT01796158|Active Comparator|cASBI|Participants will complete the computerized screening and brief intervention protocol at the time of a primary care office visit.
3113949|NCT01796145|Experimental|TACE|
3113950|NCT01796145|Experimental|Systemic Therapy|
3113951|NCT01796132|No Intervention|Control|Pregnant and/or nursing mothers not taking a SSRI or SNRI antidepressant are recruited in a non-exposed group (Control or no SSRI/SNRI). Control group participates only in the sub-studies related to neonatal adaptation, neurodevelopment, growth and early mother-infant relationship.
3113952|NCT01796132|Experimental|SSRI/SNRI exposure|Pregnant and/or nursing mothers under SSRI or SNRI treatment are recruited in an exposed group (SSRI/SNRI exposure). Drug regimen including dosage, frequency and duration is not modified by the study.
3113953|NCT01796119|Experimental|Ridge Splitting|"Dental implants placed using ridge splitting technique. To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length."
3113954|NCT01796119|Active Comparator|Implants placed using drilling technique|"Dental implants placed in the ridge with sufficient thickness using drilling technique.~To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length."
3113955|NCT01796106|Experimental|Icon|The study clinician will provide Icon treatment to all study participants randomized to study arm 1 after the radiograph and visual exam.
3113956|NCT01796106|Active Comparator|control|The study clinician will provide oral hygiene instruction and topical fluoridation therapy (Duraphat fluoride varnish) to all study participants randomized to study arm 2 after the radiograph and visual exam.
3113957|NCT01796093||Digoxin cross-over ivabradine|Digoxin 0,125 mg once a day 5 days per week during 3 months. Ivabradine, 7,5 mg b.id. during 3 months.
3113958|NCT01796080|Active Comparator|Mueller manoeuvre|Mueller manoeuvre lasting for 20 seconds
3113959|NCT01796080|Active Comparator|Inspiratory threshold|One continuous inspiration through an inspiratory threshold load for 20 seconds
3113960|NCT01796080|Active Comparator|Expiratory apnoea|Expiratory apnoea (without respiratory effort) lasting for 20 seconds
3113961|NCT01796080|Sham Comparator|Steady state normal breathing|Steady state normal breathing for 20 seconds
3113962|NCT01796067|Experimental|Mot. & Fam. Weight Loss + Online Interv.|Participants are randomized to motivational and family weight loss program plus the online intervention.
3113963|NCT01796067|Experimental|Mot. & Fam. Weight Loss + Online Control|Participants are randomized to motivational and family weight loss intervention and then the online control program.
3113964|NCT01796067|Experimental|Basic Health Educ. & Online Interv.|Participants are randomized to the basic health education program and then the online intervention program.
3113965|NCT01796067|Active Comparator|Basic Health Educ. & Online Control|Participants are randomized to the basic health education program and then to the online control program.
3113966|NCT01796054|Experimental|Stress Free Now with group support|Randomized participants have access to online stress reduction program, Stress Free Now. Participants will log in to online program, read daily lessons and practice therapeutic exercises. They will also attend weekly group support session during 6-week program
3113967|NCT01796054|Experimental|Stress Free Now|Randomized participants have access to online stress reduction program, Stress Free Now, for 6 weeks. Participants will log into online program, read daily lessons and practice therapeutic exercises.
3113968|NCT01796054|No Intervention|Control|Randomized participants do not have access to online stress reduction program, Stress Free Now, nor do they attend weekly group support sessions.
3113969|NCT01796041|Experimental|IV Injection of ICG|
3113970|NCT01796028|Placebo Comparator|Arm A : TAXOTERE® + Metformin placebo|Docetaxel (TAXOTERE®) will be administered at 75 mg/m2. Metformin (or placebo) is formulated into 850 mg tablets for oral administration and is to be dispensed twice a day on a continuous daily dosing schedule
3113971|NCT01796028|Experimental|Arm B : TAXOTERE® + Metformin|Docetaxel (TAXOTERE®) will be administered at 75 mg/m2. Metformin is formulated into 850 mg tablets for oral administration and is to be dispensed twice a day on a continuous daily dosing schedule
3113972|NCT01796015|Other|For the 97 patients|"day 0: ultrasound of ONSD (= 4 measurements: 1 transverse and 1 sagittal for each eye) + transcranial Doppler at T-15 (15 minutes before ICP measurement), within 1h following ICP measurement, and one more measurement is to be done if significant ICP variations are noticed (variation over 15 mmHg during at least 5 minutes)~day 1: ONSD ultrasound + transcranial Doppler in the morning and one more measurement is to be done if significant ICP variations are noticed (variation over 15 mmHg during at least 5 minutes)~days 2 and 3 : same as day 1~when leaving the intensive care unit: Pediatric Overall Performance Category (POPC) scale"
3113973|NCT01796015|Other|For the control group|one single ONSD in addition to their usual care (4 measurements: 1 transverse and 1 sagittal for each eye) in the morning in absence of painful sensation
3114000|NCT01795781||Patients receiving a new anticoagulant|Patients are receiving dabigatran for atrial fibrillation or rivaroxaban for osteoarthritis of hip or knee undergoing total hip or knee replacement respectively
3113974|NCT01796015|Other|For the learning curve|minimum 15 ONSD ultrasounds will be performed by each of the 15 intensive care doctor or interns expected. One ONSD ultrasound corresponds to 2 measurements: 1 transverse and 1 sagittal. Each volunteer will have maximum 30 ONSD ultrasound measures over a 1 month period.
3113975|NCT01796002|Experimental|Romidepsin + CHOP|"Patients in experimental arm receive romidepsin plus CHOP (Ro-CHOP) administered in 3 week cycles for 6 cycles.~Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks."
3113976|NCT01796002|Active Comparator|CHOP|Patients in control Arm receive cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles.
3113977|NCT01795989|Experimental|Child 1.5T MRI Coils|Pediatric Elbow Coil
3113978|NCT01795976|Experimental|NY-ESO-1 T cells|"NY-ESO-1 T cells are T cells engineered to target the tumour antigen NY-ESO-1. Autologous T cells are obtained from eligible patients who have NY-ESO-1 positive tumours and who are Human Leukocyte Antigen serotype A serotype group (HLA2) positive. The T cells undergo lentiviral transduction with NY-ESO-1 specific nucleic acid under Good Manufacturing Practice (GMP) conditions. The patient will then undergo preconditioning chemotherapy with a regime of cyclophosphamide 60mg/kg/day day -7 and -6 followed by fludarabine 25mg/m2 day -5 to -1. They will receive autologous NY-ESO-1 T cells on day 0 and following on from that they will receive up to 14 doses of intravenous IL-2 at a dose of 100000 units per kg.."
3113979|NCT01795963|Placebo Comparator|Placebo Control|Participants in the control condition will view a presentation that teaches inert information about anxiety, depression, and relationships such as definitions, prevalence rates, common problems associated with these conditions and available forms of treatment. This presentation was used initially in Cuckrowicz & Joiner (2007) and has since been shown to be effective as a placebo in two previous ePREP studies (Braithwaite & Fincham, 2007; Braithwaite & Fincham, 2008). This presentation is identical to the ePREP intervention in its set up, the only difference being, there is no information included in this presentation that teaches specific skills or strategies for improving relationships, depression or anxiety.
3113980|NCT01795963|Active Comparator|ePREP|The ePREP intervention teaches individuals how to recognize and combat dynamic risk factors that lead to relationship distress.
3113981|NCT01795950|Experimental|0.5 M PLX-PAD|0.5 million (M) PLX-PAD cells per kg body weight
3113982|NCT01795950|Experimental|1 M PLX-PAD|1.0 million (M) PLX-PAD cells per kg body weight
3113983|NCT01795950|Experimental|2 M PLX-PAD|2.0 million (M) PLX-PAD cells per kg body weight
3113984|NCT01795937|Experimental|Part 1: Faldaprevir + Itraconazole|Interaction of Faldaprevir and Itraconazole
3113985|NCT01795937|Experimental|Part 2:Faldaprevir+Rosuvastatin+Atorvast|Interaction of Faldaprevir, Rosuvastatin and Atorvastatin
3113986|NCT01795924|Experimental|PD-616 plus low-dose Cytarabine|Patients will receive low-dose cytarabine (20 mg/m2) subcutaneously (SC) once daily (QD), followed by a 1-hour intravenous (IV) infusion of PD-616 for 5 consecutive days during Week 1 (D1 to D5) and Week 2 (D8 to D12) of a 28-day treatment cycle. Cytarabine is to be administered approximately 30 minutes before PD-616. In Phase 1 part, the starting dose of PD-616 is 0.0875 mg/m2, with sequential increments of 0.0375 mg/m2, to 0.125, and 0.1625 mg/m2. The dose of PD-616 to be administered in Phase 2 part will be the maximum tolerated dose (MTD)determined from Phase 1 part of the study.
3113987|NCT01795911|Experimental|Substudy C: Pegylated Interferon Lambda+Ribasphere+Daclatasvir|"Pegylated Interferon Lambda 180 μg Solution, Subcutaneous Once weekly for 12 weeks;~Ribasphere 1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing ≥ 75 kg oral tablets per day [subjects should take either 400 mg for subjects < 75 kg or 600 mg ≥ 75 kg in the morning with food and 600 mg in the evening with food] for 12 weeks;~Daclatasvir 60 mg oral tablet Once daily for 12 weeks"
3113988|NCT01795898|Experimental|Fentanyl transdermal patch|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
3113989|NCT01795885|Experimental|16 and Pregnant|"Participants in this arm will be asked to watch an approximately 45-minute commercial-free episode of the show 16 and Pregnant once a week for 4 weeks."
3113990|NCT01795872|Other|Several diagnostic procedures|
3113991|NCT01795859|Experimental|SD-809 ER Tablets|SD-809 ER tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white). All are administered three times a day, with the 6 mg final dose is placebo.
3113992|NCT01795859|Experimental|SD-809 Tablets|SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white). All are administered three times a day, with the 6 mg final dose is placebo.
3113993|NCT01795846||monosensitized allergic rhinitis, asthma|adult patients with moderate/severe perennial allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites
3113994|NCT01795846||polysensitized allergic rhinitis, asthma|adult patients with moderate/severe perennial allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites or sensitized to at least 2 different allergens including house dust mites.
3113995|NCT01795833|Experimental|Text Messages|Short text messages related to healthy lifestyle will be sent to half the subjects three times per week, in addition to one off 'one-to-one structured education' during the study period.
3113996|NCT01795833|No Intervention|Control|Half of the subjects who has received only one off 'one-to-one structured education about healthy lifestyle during the study period
3113997|NCT01795820|Other|Group 1 (no loading)|Patients allocated to this group will not receive a loading dose of ticagrelor. In other words, clopidogrel 75 mg/die will be administered until the day before the pharmacological shift (study start), while ticagrelor 90 mg bis in die will be administered from the day of the pharmacological shift on.
3113998|NCT01795820|Other|Group 2 (loading)|Patients allocated to this group will receive a loading dose of ticagrelor. In other words, clopidogrel 75 mg/die will be administered until the day before the pharmacological shift (study start). On the very day of the pharmacological shift, patients allocated in Group 2 will receive Ticagrelor 180 mg (loading dose) on the morning and Ticagrelor 90 mg on the evening, while ticagrelor 90 mg bis in die will be administered from the day after the pharmacological shift on.
3113999|NCT01795794|Experimental|LOSEC|"LOSEC will be given 20 mg X 1/day for 6 months and then for the next 6 months the same group will be the control group of herself."
3114001|NCT01795768|Experimental|Single Treatment Arm|16-24 patients per tumour group will be treated with AZD4547 administered 80mg twice daily, 2 weeks on, 1 week off in 21 days cycles.
3114002|NCT01795755|Experimental|Treat as usual + Horse assisted therapy ( HAT)|Treatment as usual means mentalization based inpatient treatment. Horse assisted therapy(HAT) is a structured program of 12 X 90 minute sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists.
3114003|NCT01795755|Active Comparator|Treatment as usual|Treatment as usual means mentalization based inpatient treatment.
3114004|NCT01795742|Active Comparator|Electric Nebulizer|Pulmo-Aide Model 5650D
3114005|NCT01795742|Experimental|Human-Powered Nebulizer|Human-Powered
3114006|NCT01795729|Experimental|1: Coronary stent+optimal medical therapy|Coronary stent on top of optimal medical therapy
3114007|NCT01795729|Active Comparator|2: Optimal medical therapy|Optimal medical therapy
3114008|NCT01795716|Experimental|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
3114009|NCT01795716|Active Comparator|Glivec|Single and multiple oral Glivec 400mg qd
3114010|NCT01795703|Experimental|Abiraterone|Abiraterone 1000 milligram (mg) oral tablets will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
3114011|NCT01795677|Experimental|RUXOLOTINIB|Ruxolotinib : patient with donor HSCT 4 months later patients without donor: ruxolotinib alone
3114012|NCT01795664|Active Comparator|Seretide Evohaler|"Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Seretide Evohaler, Allen & Hanburys, UK)~Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg"
3114013|NCT01795664|Experimental|Salmeterol xinafoate and Fluticasone propionate HFA pMDI|"Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Cipla Ltd., India)~Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg"
3114014|NCT01795651||Take-Home message|
3114015|NCT01795638|Active Comparator|Sodium chloride|Sodium chloride 1 meq/kg (0.4 ml/kg of 2.5meq/ml formulation for injection)q6hrs on days of life 7-35. Intervention was given enterally if feedings were at least 100 ml/kg/day; otherwise medication was diluted in equal amounts of dextrose 5% water and administered intravenously.
3114016|NCT01795638|Placebo Comparator|sterile water|Sterile water, 0.4 ml/kg q6hrs on days of life 7-35. Placebo is given enterally when infant is tolerating at least 100 ml/kg/day; otherwise the product is diluted in equal amounts of dextrose 5% water and administered intravenously.
3114017|NCT01795612|Other|Arm A|6-month ETP, during adjuvant or neoadjuvant therapy
3114018|NCT01795612|Other|Arm B|6-month ETP, after adjuvant or neoadjuvant therapy
3114019|NCT01795612|Other|Arm C|12-monthETP, during and after adjuvant or neoadjuvant treatment
3114020|NCT01795599|Experimental|mifepristone/misoprostol|
3114021|NCT01795599|Active Comparator|misoprostol|
3114022|NCT01795599|Active Comparator|mifepristone|
3114023|NCT01795586|Experimental|Dose Escalation|Every patient will receive eribulin and carboplatin. Each cycle is 21 days (or 3 weeks). Eribulin and carboplatin will be given intravenously on days 1 and 8 of each cycle.
3114024|NCT01795573|Other|Cultured Treg cells|Co-culturing of recipient dendritic cells and donor Treg cells given prior to allogeneic stem cell transplant
3114025|NCT01795547|Experimental|Aripiprazole and aripiprazole once-monthly|
3114026|NCT01795547|Active Comparator|Paliperidone and paliperidone palmitate|
3114027|NCT01795534|Experimental|Beetroot shot then placebo shot|"Intervention: Participants will first consume a Beetroot shot: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate) (Beet It, James White Drinks Ltd, Ipswich, UK).~Following a four day wash out, participants will then consume a Nitrate-depleted beetroot shot: 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate)(Beet It, James White Drinks Ltd, Ipswich, UK)"
3114028|NCT01795534|Placebo Comparator|Placebo shot then beetroot shot|"Intervention: Participants will first consume a Nitrate-depleted beetroot shot: 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate)(Beet It, James White Drinks Ltd, Ipswich, UK).~Following a four day wash out, participants will then consume a Beetroot shot: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate) (Beet It, James White Drinks Ltd, Ipswich, UK)."
3114029|NCT01795521|Experimental|Stereotactic Body Radiotherapy (SBRT)|All eligible patients will be offered Stereotactic Body Radiotherapy using Four-dimensional computed tomography (4D-CT) planning (as a minimum), delivering a dose of 60 Gy in 8 fractions of 7.5 Gy on alternate days over a planned treatment time of 2.5 weeks
3114030|NCT01795508|Experimental|PMTO|Parent Management Training Oregon
3114031|NCT01795508|Active Comparator|TAU|Other kinds of family treatment
3114032|NCT01795495|Active Comparator|Remifentanil|This arm will receive remifentanil alone as is the current practice.
3114033|NCT01795495|Experimental|Remifentanil plus methadone|This arm will receive the current analgesic remifentanil plus and adjunct dose of methadone hydrochloride.
3114034|NCT01795495|Experimental|Remifentanil plus magnesium|This arm will receive the current analgesic remifentanil plus an adjunct dose of magnesium sulfate.
3114035|NCT01795482|Experimental|Group 2, Prewarming only before general anaesthesia|Active forced-air warming for 15 min after completion of epidural anaesthesia / before start of general anaesthesia. Continued active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
3114036|NCT01795482|Experimental|Group 3, Prewarming before epidural and general anaesthesia|Active forced-air warming for 15 min before start of epidural anaesthesia and for 15 min after completion of epidural anaesthesia / before start of general anaesthesia. Continued active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
3114037|NCT01795482|No Intervention|Group 1, control group|No active warming before start of epidural or general anaesthesia, active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
3114038|NCT01795469|Experimental|Abdominal and LE compression|Zoex compression garment during tilt testing (all straps)
3114039|NCT01795469|Experimental|abdominal compression only|Zoex compression garment use during tilt table testing (straps 4 and 5 fastened around thighs and abdomen)
3114040|NCT01795469|Experimental|Lower extremity compression only|Zoex compression garment use during tilt table testing (straps 1-4, lower extremity and thighs, fastened)
3114041|NCT01795443|Active Comparator|Healthy volunteers 1|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - high vibration; Intervention: Measures - low vibration;"
3114042|NCT01795443|Active Comparator|Healthy volunteers 2|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - low vibration; Intervention: Measures - high vibration;"
3114043|NCT01795443|Active Comparator|Healthy volunteers 3|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - no vibration; Intervention: Measures - low vibration;"
3114044|NCT01795443|Active Comparator|Healthy volunteers 4|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - low vibration; Intervention: Measures - no vibration;"
3114045|NCT01795443|Active Comparator|Healthy volunteers 5|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - no vibration; Intervention: Measures - high vibration;"
3114046|NCT01795443|Active Comparator|Healthy volunteers 6|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - high vibration; Intervention: Measures - no vibration;"
3114047|NCT01795443|Experimental|Back pain patients 1|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - high vibration; Intervention: Measures - low vibration;"
3114048|NCT01795443|Experimental|Back pain patients 2|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - low vibration; Intervention: Measures - high vibration;"
3114049|NCT01795443|Experimental|Back pain patients 3|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - no vibration; Intervention: Measures - low vibration;"
3114050|NCT01795443|Experimental|Back pain patients 4|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - low vibration; Intervention: Measures - no vibration;"
3114051|NCT01795443|Experimental|Back pain patients 5|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - no vibration; Intervention: Measures - high vibration;"
3114052|NCT01795443|Experimental|Back pain patients 6|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - high vibration; Intervention: Measures - no vibration;"
3114053|NCT01795430|Experimental|Treatment (radiation therapy/chemotherapy, stem cell infusion)|"BLOCK I: Patients receive etoposide IV over 1-2 hours and ifosfamide IV over 1 hour on days 1-5. Patients also undergo WB-MRI-guided intensity-modulated radiation therapy BID, 5 days a week, for approximately 4 weeks. Patients may also undergo 4 fractions of SRT QOD, 3-8 fractions of SBRT QOD, or 10 fractions of 3D RT daily to sites of metastatic disease.~BLOCK II: Patients receive high-dose chemotherapy comprising topotecan hydrochloride IV continuously over 24 hours on days -8 to -4, busulfan IV over 2 hours every 6 hours on days -8 to -4, and melphalan IV over 30 minutes on days -3 and -2. Patients undergo autologous peripheral blood or bone marrow stem cell infusion on day 0."
3114054|NCT01795417|Experimental|XP200 device RF treatments|Every subject in the study will undergo 4 treatments and will be followed up for 6 months with photoraphic 3 evaluations: before treatment, 3 and 6 months follow-up. Photographs will be scored on a Fitzpatrick scale by 3 blinded evaluators.
3114055|NCT01795404|Experimental|Inquiry Based Stress Reduction (IBSR) Program|During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts. Through the use of self-inquiry practices participants are taught to increase awareness of their thoughts and feelings, to observe their emotional and physical responses during situations perceived by them as stressful, and allow their mind to return to its true, peaceful, creative nature. Through the process of self-inquiry, participants take an active role in investigating their stressful thoughts, and by this regulating their stress and managing symptoms and emotions, thus enabling them to cope better with the distress related to the possibility of cancer.
3114056|NCT01795404|No Intervention|Control group|Waited-list control
3114057|NCT01795391||Tegaderm HP|Patients whose intravasculare devices dressings are made exclusevely with Tegaderm HP dressings.
3114058|NCT01795391||Advanced|Patients whose intravasculare devices dressings are made exclusevely with Advanced dressings
3114059|NCT01795365|Active Comparator|Epstein + (group I)|"Epstein + (Group I) PSA <10 ng/ml; Gleason 3+3=6; Number of positive biopsies ≤3/12;~% of tumor biopsy invasion <50% or ≤3mm; mp MRI negative; c-rTNM T1-T2a N0 M0"
3114060|NCT01795365|Experimental|Epstein - (group II)|"Epstein - (Group II) PSA <15 ng/ml; Gleason score max 3+4; Number of positive biopsies ≤5/12~% of tumor biopsy invasion <50% and ≤8mm; mp MRI positive; T1-T2c N0 M0"
3114061|NCT01795339|Experimental|AZD3293|Part 1: Up to 6 sequential cohorts of healthy elderly subjects are planned, with multiple ascending doses, starting with 5 mg (subject to confirmation by the Safety Review Committee) Part 2: Up to 16 mild-to-moderate AD patients administered one to up to 3 dosage levels of AZD3293
3114062|NCT01795339|Placebo Comparator|Placebo|Part 1: Placebo given (2 subjects in each cohort) Part 2: Placebo given (up to 4 subjects)
3114063|NCT01795326||Germany|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
3114064|NCT01795326||United Kingdom|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
3114065|NCT01795326||Spain|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
3114066|NCT01795326||Hungary|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
3114067|NCT01795326||Netherlands|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
3114068|NCT01795326||Sweden|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
3114069|NCT01795326||Romania|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
3114070|NCT01795326||Italy|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
3114071|NCT01795313|Experimental|HLA-A2 restricted tumor antigen vaccine|This is a single-arm study of a HLA-A2 restricted tumor antigen peptide vaccine, administered in conjunction with imiquimod
3114072|NCT01795300|Experimental|Carbon Ion Radiotherapy|Treatment Schedule Carbon Ion Radiation Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
3114073|NCT01795300|Experimental|Proton Therapy|Treatment Schedule Proton Radiation Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
3114074|NCT01795300|Experimental|Hypofractionated Photon Therapy|Treatment Schedule Photon Radiation 3 Gy E Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
3114075|NCT01795300|Active Comparator|Conventional Photon Radiotherapy|Treatment Schedule Photon Radiation 1.8 Gy E Total Dose 57.6 Gy Gy E, 32 fractions, 1.8 Gy E single dose
3114076|NCT01795287|Active Comparator|Spinal anesthesia|Spinal anesthesia
3114077|NCT01795287|Active Comparator|General anesthesia|General anesthesia with fentanyl, propofol and rocuronium and sevoflurane
3114078|NCT01795274|Experimental|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
3114079|NCT01795261||Lifestyle counseling|Prevention of mother to child transmission of HIV
3114080|NCT01795261||Lifestyle counseling Male|male partners and PMTCT completion rate among HIV-infected pregnant women.
3114081|NCT01795248|Experimental|Liraglutide|1.8 mg liraglutide, subcutaneous, once-daily for five years
3114082|NCT01795248|Placebo Comparator|Placebo|Placebo, subcutaneous, once-daily for one year
3114083|NCT01795248|No Intervention|Control|Control without previous GDM.
3114084|NCT01795235|Other|Saline s.c. injection and placebo tablet|Saline s.c. injection and one placebo tablet (preceded by one placebo tablet per day at 0900h for two days before admission).
3114085|NCT01795235|Other|glucagon s.c. injection and placebo tablet|1 mg glucagon s.c. injection and one placebo tablet (preceded by one placebo tablet per day at 0900h for two days before admission).
3114086|NCT01795235|Other|Saline s.c. injection and atenolol tablet|Saline s.c. injection and 100 mg atenolol tablet
3114087|NCT01795235|Other|glucagon s.c. injection and atenolol tablet|1 mg glucagon s.c. injection and 100 mg atenolol tablet
3114088|NCT01795222|Active Comparator|Oral Midazolam|Midazolam oral syrup 1mg/Kg twenty minutes before starting the procedure
3114089|NCT01795222|Placebo Comparator|placebo|placebo oral syrup twenty minutes before starting the procedure
3114090|NCT01795209|Experimental|Ranibizumab group|Patients will receive three monthly injections of 0.5 mg of Lucentis (0.05 ml), followed by retreatment/rescue laser as needed.
3114091|NCT01795209|Sham Comparator|Standard of care group|Patients will receive three monthly sham injections, followed by retreatment/rescue laser as needed.
3114092|NCT01795183|Experimental|Amisulpride|Patients are treated with Amisulpride referring to the dosage and usage section in Chinese Solian® PI. Amisulpride dosage is adjusted based on individual response and reaches the sufficiency within 1 week
3114093|NCT01795170||Test Group|Patients receiving a lysine restricted diet adjunct to pyridoxine therapy will be considered as participants in the 'exposure'/test group
3114094|NCT01795170||Control Group|Patients on pyridoxine mono-therapy will be participants in the 'control' group
3114095|NCT01795157|Experimental|CCADSS|questionnaire completed using i-Pad
3114096|NCT01795157|Active Comparator|pen-paper|Questionnaire completed using pen and paper
3114097|NCT01795144|Active Comparator|Healthy controls|"Healthy controls will be matched (age, gender, BMI) to monogenic diabetes subjects. Healthy controls will participate in the following:~OGTT~IGI~IGI with GLP-1 infusion~OGTT with Exendin 9-39 infusion"
3114098|NCT01795144|Experimental|Monogenic diabetes|"Monogenic diabetes subjects will be matched (age, gender, BMI) to healthy controls. Monogenic diabetes subjects will participate in the following:~OGTT~IGI~IGI with GLP-1 infusion~OGTT with Exendin 9-39 infusion"
3114099|NCT01795131|Active Comparator|Vitamin B12|Supplementation group (N=60) that will receive 250 µg of vitamin B12 in addition to 60 mg of Fe and 400µg of folate.
3114100|NCT01795131|Placebo Comparator|Placebo|Placebo group (N=60) that will receive placebo tablets and 60 mg of Fe and 400µg of folate daily.
3114101|NCT01795092|No Intervention|Control|Those in the control group do not obtain a dermatology evaluation and will be assessed and treated by their primary care provider. We will perform a chart review two weeks after presentation to assess for admission versus discharge home from clinic and outcome.
3114102|NCT01795092|Experimental|Dermatology consultation|Patients randomized to the treatment group will obtain a dermatology evaluation at the primary care physician's office and will be sent to the Emergency Department (ED) or discharged home with outpatient dermatology follow-up in 2-3 days to assess their condition. Patients who are evaluated by a dermatologist and require hospitalization will have their transition to the ED managed by the dermatologist. Patients who are admitted after the initial outpatient discharge or at the follow-up visit will be considered treatment failures. A medical record review will be performed for patients in the treatment group two weeks after initial evaluation at the internal medicine clinic.
3114103|NCT01795079|Experimental|Active tDCS|Subjects will undergo 20 minutes active tDCS.
3114104|NCT01795079|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham stimulation.
3114105|NCT01795066|Experimental|EUS-FNB with 25-gauge|
3114106|NCT01795053|Experimental|playtraining|playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and intensity and thereby reduce ADHD symptoms
3114107|NCT01795053|Placebo Comparator|open play session|the open play sessions are conducted in the same rooms, by the same staff and in the same time frame as the experimental sessions. The therapist plays with the child without structuring the sitauation through behavioral tecniques. The play situation is designed to be ineresting and comfortable for the child.
3114108|NCT01795040|Experimental|omega-3/omega-6 fatty acids (PUFAs)|Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
3114109|NCT01795040|Placebo Comparator|placebo without PUFAs|Placebo without PUFAs
3114110|NCT01795027|Experimental|S-1 plus Oxaliplatin|6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
3114111|NCT01795027|Active Comparator|S-1 single|S-1 40~60mg twice daily for 14 days in 3 weeks for totally 16 courses after D2 resection
3114112|NCT01795014||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an IOP above 21 mmHg that could suggest possible glaucoma suspects.
3114113|NCT01795014||Primary open-angle Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
3114114|NCT01795014||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
3114115|NCT01795001||late-onset FECD|tissue samples from patients with late-onset Fuchs' endothelial corneal dystrophy (FECD)
3114116|NCT01795001||normal control|tissue samples from patients with normal corneas
3114117|NCT01795001||non-FECD edematous control|tissue samples from patients with corneal edema but without FECD
3114118|NCT01794988|Experimental|Group Cognitive Behavioral Therapy|Participants will undergo 11 weeks of group cognitive behavioral therapy (CBT) and a pre- and post-intervention MRI brain scan.
3114119|NCT01794988|Active Comparator|Pain Education|Participants will receive 11 weeks of pain education and a pre- and post-intervention MRI brain scan.
3114120|NCT01794988|Experimental|Therapeutic Interactive Voice Response|Four months of therapeutic interactive voice response (TIVR).
3114121|NCT01794988|Active Comparator|No TIVR|Control - no intervention
3114122|NCT01794975|Active Comparator|Ketamine|Ketamine will be administered intravenously using a pseudo steady state infusion approach with a target plasma concentration of 300 ng/ml starting 15 minutes before the PET scan and continued throughout the scan.
3114123|NCT01794975|Active Comparator|Atomoxetine and the cold pressor test|An oral dose of approximately 1.2 mg/kg (range, 1.12-1.26 mg/kg) of atomoxetine is administered 1 h before the PET scans. A cold pressor test is employed as a physiological noradrenergic stimulus. The subject's foot is placed in a 8 °C water basin for the duration of the PET scan.
3114124|NCT01794975|Placebo Comparator|Placebo|Placebo capsules are given to mimic the atomoxetine treatment at each treatment visit except the atomoxetine visit. A baseline PET scan with [11C]ORM-13070 will be performed for all subjects with the placebo treatment only.
3114125|NCT01794962|Experimental|Manual therapy and exercises|Manual therapy treatment: spinal manipulation, Soft tissue treatment, muscle energy techniques. Exercises: stabilisation exercises, Mckenzie exercises and general muscle exercises.
3114126|NCT01794962|Experimental|Cognitive Functional Therapy|An in depth interview, including investigating the patients beliefs on back pain, fear towards movement, anxiety and distress, using reflecting questions. The physical part consists of specific and functional exercises related to the patients functional complaints.And general physical activity for 30 mins 3-4 times weekly.
3114127|NCT01794949|Experimental|Non-diabetic patients receiving the Resolute stent|Non-diabetic patients presenting with Acute Coronary Syndrome (ACS), receiving the Resolute stent.
3114128|NCT01794949|Experimental|Diabetic patients receiving the Resolute stent|Non-insulin dependent diabetes mellitus (NIDDM) patients presenting with Acute Coronary Syndrome (ACS), receiving the Resolute stent.
3114164|NCT01794689|Placebo Comparator|Saline Placebo|Participants randomized to receive the saline placebo will receive the injection via IV bolus over 30 seconds during each experimental quantitative sensory testing session.
3114165|NCT01794676||Family 1|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
3114166|NCT01794676||Family 2|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
3114167|NCT01794676||Family 3|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
3114168|NCT01794663|Experimental|OPN-305|
3114129|NCT01794936|Experimental|VTI Probe|During robotic-assisted laparoscopic prostatectomy, the VTI Doppler probe (test) will utilized to measure blood blow within the neurovascular bundles. This is to be completed after the bladder neck and seminal vesicles are identified and dissected. To use the probe, the assistant surgeon will place the Doppler probe within the abdomen and systematically move it cephalad along the lateral prostate pedicles to identify NVB vessels. The Doppler flow in these regions will be quantified as arterial (strong) flow, venous (minimal) flow or no flow. The procedures will proceed by dissecting the lateral margin of prostate step by step up to the gland's apex. Blood loss and the time required to identify and dissect the NVB will be recorded.
3114130|NCT01794936|No Intervention|Non-Probe|Patients randomized to not receive probe evaluation.
3114131|NCT01794923|Experimental|Ibuprofen 5% topical gel BID|IBU BID (Treatment A)
3114132|NCT01794923|Placebo Comparator|Placebo topical gel BID|Placebo BID (Treatment B)
3114133|NCT01794923|Experimental|Ibuprofen 5% topical gel TID|IBU TID (Treatment C)
3114134|NCT01794923|Placebo Comparator|Placebo topical gel TID|Placebo TID (Treatment D)
3114135|NCT01794910|Experimental|Plevic floor muscle therapy|The pelvic floor muscle therapy to women with vaginal or cesarean deliveries involved perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions.
3114136|NCT01794910|No Intervention|Controll group|Women with vaginal or cesarean deliveries did not did not undergo muscle training
3114137|NCT01794897|Experimental|Valacyclovir treatment|Drug: Experimental: Valacyclovir treatment. Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either Valacyclovir (VAV) or placebo (PLA) group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
3114138|NCT01794897|Placebo Comparator|Placebo|Placebo comparator: Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
3114139|NCT01794884|Experimental|Glutamine|20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg)(volume ratio=1:5).Intravenous injection twice (24 hours、1 hour before operation).
3114140|NCT01794884|Placebo Comparator|Ringer's solution|Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation).
3114141|NCT01794858|Experimental|Therapeutic Hypothermia|"Primary - Organ specific outcome at 28 days Logistic Organ Dysfunction Score (LOD) will be compared before and after TH. Change in LOD will reflect LOD day 4 minus LOD day 1 (Ehrmann, Can J Anesth 2006).~Secondary~Lab values: D-Dimer, IL-6, CRP~APACHE II Scores Day 1 and after TH (day 4)~Length of stay in the ICU and hospital~Prevalence of infections~28-day mortality~Hypothermia-related side effects: cardiac arrhythmia, electrolyte balance, hyperglycemia, bleeding, acute pancreatitis"
3114142|NCT01794845|Experimental|Erbitux, Taxotere, LD Fractionated RT|Erbitux, Taxotere and Low Dose Fractionated Radiation Therapy (LDFRT)
3114143|NCT01794832||Elderly with severe aortic stenosis|Patients with severe symptomatic aortic stenosis referred for consideration of surgical aortic valve replacement
3114144|NCT01794819|Experimental|C-reactive protein test|"The C-reactive protein test was performed in the intervention group at both the first and second consultations.~The Afinion test system (Axis Shield) was used, which provides results within 5 minutes and before treatment was determined. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L."
3114145|NCT01794806|Experimental|Tooth extraction and grafting|Tooth extraction and grafting with allograft
3114146|NCT01794806|Sham Comparator|Tooth extraction|Tooth extraction
3114147|NCT01794793|Experimental|Pasireotide|Pasireotide subcutaneous or Long Acting Release
3114148|NCT01794780|Experimental|Group 1|Group 1
3114149|NCT01794780|Experimental|Group 2|Group 2
3114150|NCT01794780|Experimental|Group 3|Group 3
3114151|NCT01794780|Experimental|Group 4|Group 4
3114152|NCT01794780|Experimental|Group 5|Group 5
3114153|NCT01794767|Active Comparator|0,9% NaCl flush|for children enrolled in this group, the nurse will perform the flushing of peripheral venous catheter using flush-solution as a bolus with saline 0.9% NaCl in the amount (ml) needed to fill the entire circuit of the catheter. The flushing will be performed routinely at the end of each fleboclisis
3114154|NCT01794767|Experimental|Heparin 50U/ml|for children enrolled in this group, the nurse will perform the washing of peripheral venous catheter using flush-solution as a bolus with heparin 50U/ml in the amount (ml) needed to fill the entire circuit of the catheter. The washing will be performed routinely at the end of each fleboclis
3114155|NCT01794754|Other|Control|Care as usual
3114156|NCT01794754|Experimental|Occupational therapy|Occupational therapy
3114157|NCT01794741|Active Comparator|Dymista nasal spray|azelastine 137mcg per spray/fluticasone propionate 50mcg per spray one spray per nostril twice a day for three months
3114158|NCT01794741|Active Comparator|fluticasone propionate nasal spray|fluticasone propionate nasal spray 50mcg per spray per nostril twice a day
3114159|NCT01794728||Elderly inpatients with heart failure|A single cohort group of elderly patients hospitalized for heart failure.
3114160|NCT01794715|Experimental|Ultrasound performed by nurses|Examinations including ultrasound examinations
3114161|NCT01794715|Active Comparator|Ultrasound not performed|Examinations not including ultrasound examinations, otherwise active
3114162|NCT01794702|Experimental|Clofarabine + Cytarabine + Decitabine + Idarubicin|"Phase I - Decitabine 20 mg/m2 by vein over approximately 1 hour daily for 5 days (days 1-5) Idarubicin 10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 6-8) Cytarabine 1 g/m2 by vein over approximately 2 hours daily for 5 days (days 6-10)~Phase II - Clofarabine 15 mg/m2 by vein over approximately 1 hour daily (number of days selected based on Phase I portion).~Decitabine 20 mg/m2 by vein over approximately 1 hour daily for 5 days (days 1-5) Idarubicin 10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 6-8) Cytarabine 1 g/m2 by vein over approximately 2 hours daily for 5 days (days 6-10)"
3114163|NCT01794689|Experimental|Morphine|Participants randomized to receive Morphine will receive the injection (0.08mg/kg) via IV bolus over 30 seconds during each experimental quantitative sensory testing session.
3114170|NCT01794650|Other|Meal composition|Changing the glycaemic index of the meals consumed after exercise and before sleep. (High GI - High GI, Low GI - Low GI, High GI - Low GI, Low GI - High GI).
3114171|NCT01794637||the end-stage liver disease patients|the end-stage liver disease scheduled for liver transplantation
3114172|NCT01794624|Active Comparator|Cognitive Therapy|Cognitive Therapy for Catastrophizing
3114173|NCT01794624|Active Comparator|Behavioral Therapy|Behavioral Therapy for Sleep Continuity Disturbance
3114174|NCT01794624|No Intervention|TMJD Education|6-sessions of TMJD disease education/support control
3114175|NCT01794611|Experimental|Laryngoscopy|Patients will be intubated by an experienced anesthesiologists. Anesthesiologist first uses Macintosh laryngoscope then KingsVision videolaryngoscope and lastly C-MAC videolaryngoscope to intubate patients. Cormack-Lehane scores, the time from the start of laryngoscopy to visualization of the vocal cords and the time from the visualization of the vocals from the successful intubation will be recorded. The success of the intubation will be assessed with bilateral chest auscultation. If visualization of the vocal cords or placing of the endotracheal tube was not successful after 60 seconds with a particular laryngoscope, it will be left out and patient will be ventilated for 1 minutes and then pass to other laryngoscopes.
3114176|NCT01794598|Experimental|Educational materials|Receiving educational materials of depression care
3114177|NCT01794598|Sham Comparator|No educational materials|Receiving an envelope but no inclusion of educational materials of depression care
3114178|NCT01794585|Experimental|Virtual Reality Based Exercise|
3114179|NCT01794585|Active Comparator|Standard Exercise|
3114180|NCT01794572|Experimental|Total BM irradiation dose|"Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are determined according to a 3x3 modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.~For Every patients:~Drug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.~Autologous Peripheral Stem Cell Rescue : are re-infused in the central line on day 0 after adequate premedication."
3114181|NCT01794559|Experimental|Informed by PEER Interactive Report|"The PEER Interactive Report -This study is prospective in nature. For subjects in the experimental group, the treating physician will follow the guidance of the subject's PEER Interactive Report as regards sensitivity to on-label medications and classes of medication.~The subjects will be washed out of all current medications prior to having an EEG, which is necessary to generate the PEER Interactive Report. The wash out period for outpatients is no longer than 14 days.~The subjects will be followed for 6 months after the initial treatment, or until the patient has achieved maximum medical improvement (MMI). The patient will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health."
3114182|NCT01794559|No Intervention|No Report|This study is prospective in nature. Subjects in the control group will be treated according to treatment as usual and best judgment of the treating physician. PEER Interactive Report is not provided to the investigator. The subjects will be followed for 6 months after the initial treatment, or until the patient has achieved maximum medical improvement (MMI). The patient will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health.
3114183|NCT01794546|Experimental|Immediate Telehealth|"The immediate intervention group will receive the telehealth intervention during the first 6 months of the study timeline."
3114184|NCT01794546|Active Comparator|Wait List Control|"The wait list control group will receive the telehealth intervention during months 6 through 12 of the study timeline."
3114185|NCT01794533|Placebo Comparator|Lidocaine with Epinephrine+ Normal saline|
3114186|NCT01794533|Active Comparator|Lidocaine with Epinephrine + fentanyl|
3114187|NCT01794520|Experimental|ABT-199 Safety Expansion Cohort|
3114188|NCT01794520|Experimental|Phase 2 Cohort|Venetoclax-Dexamethasone Combination Expansion
3114189|NCT01794520|Experimental|Venetoclax-Dexamethasone Combination|
3114190|NCT01794520|Experimental|ABT-199 Dose Escalation Cohorts|
3114191|NCT01794507|Experimental|ABT-199 + BTZ/Dex Dose Escalation Cohorts|Evaluate the safety and pharmacokinetics profile of ABT-199 administered with standard therapy bortezomib and dexamethasone in a dose escalation scheme in approximately 54 subjects.
3114192|NCT01794507|Experimental|ABT-199 + BTZ/Dex Safety Expansion Cohort|Safety expansion cohort to further evaluate recommended phase two dose (RPTD) of ABT-199 administered with standard therapy bortezomib and dexamethasone in approximately 12 subjects.
3114193|NCT01794494||Open surgical group|Bypass surgery for critical limb ischemia
3114194|NCT01794494||Endovascular treatment|Endovascular recanalization for critical limb ischemia
3114195|NCT01794481|No Intervention|Usual Care|Participants allocated to usual care will receive their usual treatment program which will include dietician counseling as needed. As part of standardized care, participants will not be encouraged to begin a new exercise program(patients needing physical therapy at time of enrollment will be excluded.
3114196|NCT01794481|Experimental|Resistance Exercise Training|"If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.~There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique."
3114197|NCT01794468|Experimental|study group-Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor
3114198|NCT01794455|Experimental|Phase 1: Sertraline|Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
3114199|NCT01794455|Experimental|Phase 2: Candesartan|For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.
3114200|NCT01794442||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
3114201|NCT01794442||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
3114202|NCT01794442||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
3114203|NCT01794429|Placebo Comparator|Placebo|Subcutaneum injection of placebo once-weekly for 3 months
3114204|NCT01794429|Active Comparator|exenatide|Subcutaneum injection of exenatide once-weekly for 3 months
3114205|NCT01794416|Active Comparator|Thoracoscopic epicardial ablation|"Patients were treated with video-assisted thoracoscopy under general anesthesia. PVI was performed from the epicardial side with a bipolar RF ablation clamp (AtriCure). At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. An additional application was made in the interatrial Waterston groove in the right side to isolate the ganglionic plexi from the atria. On the left side, the ligament of Marshal was cut, but no additional ablation of ganglionic plexi was pursued.~The RevealXT (implantable loop recorder) was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check."
3114206|NCT01794416|Active Comparator|Endocardial catheter ablation|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster). The RevealXT (implantable loop recorder) was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
3114207|NCT01794403|Active Comparator|Extended Hypofractionation (EHRT)|"Extended Hypofractionation Radiotherapy: A total dose of 70.2 Gy, 26 fractions, 2.7 Gy to the Planning Target Volume (PTV).~Expanded Prostate Cancer Index Composite SF-12 (EPIC SF-12) quality of life questionnaire;~International Prostate Symptom Score (IPSS) quality of life questionnaire;~Memorial Anxiety Scale for Prostate Cancer patients (MAX-PC) quality of life questionnaire;~OPTIONAL: Ultrasound-guided biopsy, blood and urine samples for correlative studies."
3114208|NCT01794403|Experimental|Accelerated Hypofractionation (AHRT)|"Accelerated Hypofractionation Radiotherapy: A total dose of 36.25 Gy, 5 fractions, 7.25 Gy each to the Planning Target Volume (PTV);~Expanded Prostate Cancer Index Composite SF-12 (EPIC SF-12) quality of life questionnaire;~International Prostate Symptom Score (IPSS) quality of life questionnaire;~Memorial Anxiety Scale for Prostate Cancer patients (MAX-PC) quality of life questionnaire;~OPTIONAL: Ultrasound-guided biopsy, blood and urine samples for correlative studies."
3114209|NCT01794390||Turbuhaler and MDI patients (Arm 1)|Patients (Diskus naive) will be randomised to receive training on the PulmoJet© device followed by Diskus, or vice versa
3114210|NCT01794390||Diskus patients (Arm 2)|Patients (Turbuhaler naive) will be randomised to receive training on the PulmoJet© device followed by Turbohaler, or vice versa
3114211|NCT01794377|Active Comparator|40 of an endurance training|Endurance training at 50% of VO2 peak measured by indirect calorimetry. Dietary Supplement: supplementation in fruits and vegetables.
3114212|NCT01794377|Experimental|30 minutes of a high intensity training|"This arm consist of an interval strength training for 30 min on bicycle ergometer (which include strengthening exercises in an high intensity interval training).~Dietary Supplement: supplementation in fruits and vegetables."
3114213|NCT01794364|Experimental|Experimental: Cohort A|Each subjects in Cohort A will receive 2 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-06291874 will be administered in Period 4 in the fed state.
3114214|NCT01794351|Experimental|Placebo then resveratrol|Participants in this arm (decided according to Latin square) first received placebo and then resveratrol, on seperate days, with a 7-14 day wash-out period between visits.
3114215|NCT01794351|Experimental|Resveratrol then placebo|Participants in this arm (decided according to Latin square) first received resveratrol and then placebo, on seperate days, with a 7-14 day wash-out period between visits
3114216|NCT01794338|Experimental|Bio-A Arm|"Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm bites from the fascial edge and a 1cm walk between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected."
3114217|NCT01794338|Active Comparator|Strattice Arm|"Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm bites from the fascial edge and a 1cm walk between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected.."
3114218|NCT01794325|Active Comparator|Trans-radial access|Coronary angiography performed through trans-radial access
3114219|NCT01794325|Active Comparator|Trans-femoral access|Coronary angiography performed through trans-femoral access
3114220|NCT01794312|Experimental|T4020|One drop 4 times per week
3114221|NCT01794312|Placebo Comparator|Vehicle|One drop 4 times per week
3114222|NCT01794299|Experimental|ATIR|
3114223|NCT01794286|Active Comparator|Control Group|Trigger alerts only
3114225|NCT01794273|Experimental|ephedrine|This is a randomised trial comparing ephedrine and phenylephrine as used for accidental hypotension occurring during carotid surgery, on cerebral perfusion, assessed by near-infrared spectroscopy (NIRS).
3114226|NCT01794273|Experimental|phenylephrine|This is a randomised trial comparing ephedrine and phenylephrine as used for accidental hypotension occurring during carotid surgery, on cerebral perfusion, assessed by near-infrared spectroscopy (NIRS).
3114227|NCT01794260|Placebo Comparator|Placebo cream|Placebo cream
3114228|NCT01794260|Experimental|Plai cream|Cream from Zingiber cassumunar Roxb. extract
3114229|NCT01794247|Experimental|Intrathecal magnesium|Intrathecal magnesium sulfate 15% 0,5 mL (75 mg) is added to lidocaine 5% 1 mL (50 mg)as anesthetic adjuvant
3114230|NCT01794247|Active Comparator|Intrathecal fentanyl|Intrathecal fentanyl 0.5 mL (25 micrograms)is added to lidocaine 5% 1 ML (50 mg) as anesthetic adjuvant
3114231|NCT01794234||Cohort|
3114232|NCT01794221|Active Comparator|Stitches only|Stitches only closing circumcision wound
3114233|NCT01794221|Experimental|Stitches and skin adhesive|application of 2-octyl cyanoacrylate skin adhesive.
3114234|NCT01794208|Experimental|treatment 1|FSH-GEX(TM)
3114235|NCT01794208|Experimental|treatment 2|FSH-GEX(TM)
3114236|NCT01794208|Experimental|treatment 3|FSH-GEX(TM)
3114237|NCT01794208|Experimental|treatment 4|FSH-GEX(TM)
3114238|NCT01794208|Experimental|treatment 5|FSH-GEX(TM)
3114239|NCT01794208|Active Comparator|treatment 6|Gonal-f(R)
3114240|NCT01794195|Experimental|apathetic patients with Parkinson's disease|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
3114241|NCT01794195|Experimental|non apathetic paired patients|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
3114242|NCT01794195|Experimental|healthy paired control|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
3114243|NCT01794182|Placebo Comparator|Matching Placebo|Subjects will receive matching placebo.
3114244|NCT01794182|Experimental|RP-1127 (Glyburide for Injection)|Subjects will receive the active agent, RP-1127 (Glyburide for Injection)
3114245|NCT01794169|Experimental|Azacitidine|Azacitidine 75mg/m2/d subcutaneously once daily for 5 days given every 5:th week for 8 cycles.
3114246|NCT01794169|Active Comparator|DA|"Two courses of DA in accordance with the Swedish National treatment program (reduced doses):~In case one induction course was given:~First consolidation course: daunorubicin 45 mg/m2 x 1 (iv infusion) day 1-3 and cytarabine 1000 mg/m2 x 2 (iv infusion) day 1-4.~Second consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.~In case two induction courses were given:~First consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.~Second consolidation course: cytarabine 200mg x 2 (fixed dose sc injection) day 1-5."
3114247|NCT01794156|Active Comparator|Cognitive behavior therapy|"The cognitive-behavioral model is presented and individualized.~Cognitive correction: beliefs are addressed by explaining their roles in maintaining cognitive biases. Next, clients are trained to identify and to challenge their key beliefs~Exposure and response prevention (ERP) using imaginal and in vivo exposure and to both over and covert neutralization is implemented according to hierarchies developed following the individual assessment. Extended periods of exposure permits emotional discomfort to dissipate.~Combined phase: continues ERP while making explicit links to the cognitive targets.~Relapse prevention included a written individualized guide to encourage the maintenance of treatment gains. Self-directed ERP continues."
3114248|NCT01794156|Active Comparator|Mindfulness-based stress reduction (MBSR)|The entire intervention is based on systematic and intensive training in MBSR following Santorelli and Kabat-Zinn and their applications to everyday life. The program is divided in 8 consecutive blocks with daily homework in mindfulness-based stress reduction skills. The main activity of MBSR is a cognitive and intervention-based process characterized by self-regulation of attention to the present moment and an open and accepting orientation towards one's experience.
3114249|NCT01794156|Experimental|Inference-based therapy|"The inference-based therapy will be delivered in 10-step~The client will:~learn that the compulsions, anxiety and discomfort are driven by an initial obsessional doubt~learn why this doubt is 100% irrelevant here and now~learn the inferential confusion process~have to recognize that the doubt originates from him/her~have to identify/describe the narrative leading him/her to the doubt~have to identify the cross-over point when he/she leaves reality~learn to be aware of the reasoning devices~learn how personal themes dictate the idiosyncratic nature of the person's obsession~explore and reinforced an alternative self-view~be trained to use properly his/her senses in the face of obsessional triggers situations"
3114250|NCT01794143|Active Comparator|Sulfonylurea (glimepiride)|Sulfonylurea
3114251|NCT01794143|Active Comparator|DPP-4 inhibitor|DPP-4 inhibitor (sitagliptin)
3114252|NCT01794143|Active Comparator|GLP-1 receptor agonist|GLP-1 receptor agonist (liraglutide)
3114253|NCT01794143|Active Comparator|Insulin (glargine)|Insulin (glargine), Lantus
3114254|NCT01794117|Experimental|A|An initial dose of anakinra 100 mg/day will beadministered daily via self-administered subcutaneousinjection. If pustule formation persists at this dose,anakinra dose may be escalated up to 200 mg/dayinjected subcutaneously daily at week 4
3114255|NCT01794104|Experimental|1|Open-label Phase I trial evaluating weekly administration of LMP400, on days 1, 8, and 15, in 28-day cycles.
3114256|NCT01794091|Experimental|Eplerenone|In a subgroup of 50 patients, 25 will be randomized to eplerenone to assess effects on fibrotic index pre- and post-6 months of therapy.
3114257|NCT01794091|Placebo Comparator|Sugar pill|
3114258|NCT01794078|Placebo Comparator|Control|Oral placebo, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
3114259|NCT01794078|Experimental|Aminophylline 400 mg|Oral aminophylline 400 mg, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
3114260|NCT01794078|Experimental|ambrisentan 5 mg|Oral ambrisentan 5 mg, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
3114261|NCT01794078|Experimental|Combined aminophylline 400 mg and ambrisentan 5 mg|Oral combined aminophylline 400 mg and ambrisentan 5 mg, administered as single doses during simulated altitude episodes Cycle 1 and Cycle 2
3114262|NCT01794065||Cypher|100 patients who have received a Cypher stent during their coronary intervention
3114263|NCT01794065||Taxus Express|100 patients who have received a Taxus Express stent during their coronary intervention
3114264|NCT01794065||Endeavor|100 patients who have received an Endeavor stent during their coronary intervention
3114265|NCT01794065||Promus/Xience V|100 patients who have received a Promus/Xience V stent during their coronary intervention
3114266|NCT01794065||Promus Element|100 patients who have received a Taxus Element stent during their coronary intervention
3114267|NCT01794052|Experimental|DSS enabled health care delivery model|Evidence based, DSS enabled, health care delivery model
3114268|NCT01794039|Experimental|Arm A (lenalidomide, dexamethasone)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may crossover to arm B.
3114269|NCT01794039|Experimental|Arm B (pomalidomide, dexamethasone)|Patients receive pomalidomide PO daily on days 1-21 and dexamethasone as in arm A. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3114270|NCT01794026|Experimental|diffusion MRI|histopathology of lymph nodes diagnosed by diffusion weighted magnetic resonance imaging
3114271|NCT01794013|Active Comparator|Parent trianing|The parent training group will learn about DIR/ Floortime™ model approach through one on one coaching for 1 hour at the beginning of the study, the end of 1st and 3th month and through 2 hours DVD lecture and a pocket book.
3114272|NCT01794013|Active Comparator|Routine care|The children in the control group will continue their standard routine care.
3114273|NCT01794000|Experimental|Prasugrel|Participants will be titrated from initial daily dose of 0.08 milligram per kilogram (mg/kg) of orally administered prasugrel monotherapy at randomization to a dose that will achieve a P2Y12 reaction units (PRU) level of 231 to 136, as measured by VerifyNow instrument. This corresponds to a range of platelet inhibition of approximately 30% to 60%. The maximum possible dose allowed is 0.12 mg/kg daily, not to exceed 10 mg daily.
3114274|NCT01794000|Placebo Comparator|Placebo|Participants in this treatment group will receive daily orally administered placebo and will follow visit schedule identical to that in the active treatment group.
3114275|NCT01793987|No Intervention|control: shaver|
3114276|NCT01793987|Experimental|Coblation polypectomy|
3114277|NCT01793974||Latent Autoimmune Diabetes in Adult|Individuals who meet criteria for Latent Autoimmune Diabetes in Adult
3114278|NCT01793974||Without Latent Autoimmune Diabetes in Adult|Individuals who do not meet criteria for Latent Autoimmune Diabetes in Adult
3114279|NCT01793961|Other|"Cannabis Arm"|patient addicted to cannabis
3114280|NCT01793961|Other|"Tobacco Arm"|patient addicted to tobacco
3114281|NCT01793961|Other|"Healthy volunteers"|no smokers
3114282|NCT01793948|Experimental|Arm I (metformin hydrochloride)|Patients receive metformin hydrochloride by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3114283|NCT01793948|Placebo Comparator|Arm II (placebo)|Patients receive placebo by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3114284|NCT01793935|Experimental|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera
3114285|NCT01793935|Placebo Comparator|Placebo|Placebo
3114286|NCT01793922|Active Comparator|PD|pneumodilation
3114287|NCT01793922|Active Comparator|POEM|peroral endoscopic myotomy
3114288|NCT01793909|Other|Single Leg Exercise|Supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
3114289|NCT01793896|Sham Comparator|control period|control period with no intervention. Comparison of parameters at entrance and one month later without any intervention
3114290|NCT01793896|Experimental|Diet group|Mediterranean diet prescription during 3 months
3114291|NCT01793896|Experimental|Exercise group|Subjects will be trained 3 times a week during 3 months
3114292|NCT01793896|Experimental|Diet + Exercise|Both a dietary prescription plus exercise training during 3 months
3114293|NCT01793883|Active Comparator|40 mg Laninamivir Octanoate DPI|40 mg Laninamivir Octanoate and matching placebo
3114294|NCT01793883|Active Comparator|80 mg Laninamivir Octanoate DPI|80 mg Laninamivir
3114295|NCT01793883|Placebo Comparator|Placebo|Matching Placebo
3114296|NCT01793870|Experimental|Treatment A (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 milligram [mg]) as a 1 x 25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
3114297|NCT01793870|Experimental|Treatment B (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 mg) as a 1 x 25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
3114298|NCT01793870|Experimental|Treatment C (33.75 mg total maximum dose)|Single oral dose of carvedilol (31.25 mg) as a 1 x 25 mg immediate release tablet, a 1 x 6.25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
3114299|NCT01793870|Experimental|Treatment D (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 mg) as a 1 x 25 mg x immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fed conditions.
3114300|NCT01793857||Study Group|Approximately 1300 primary caregivers of at least one child aged 6 months to less than 30 months who were interviewed during a clinic visit in Panama.
3114337|NCT01793584|Active Comparator|Laparoscopic hysterectomy|Total laparoscopic hysterectomy, laparoscopic assisted vaginal hysterectomy
3114301|NCT01793844||A (R-CHOP21)|"CHOP combined with Rituximab regimen（R-CHOP21）~Treatment Arm A(R-CHOP21): Rituximab 375mg/m2 for injection on day1; cyclophosphamide(C), 750mg/m2 for injection on day2; doxorubicin(H), 50mg/m2 for injection on day2; and Vincristine(O), 1.4mg/m2 for injection on day2, prednisone(P) 60mg/m2 orally on days 2 to 6. The therapy was repeated every 21 days for a total of 6 cycles."
3114302|NCT01793844||B (CHOP14)|Biweekly CHOP regimen （CHOP14） Treatment Arm B (CHOP14): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50mg/m2 for injection on day1; and Vincristine(O), 1.4 mg/m2 for injection on day1, prednisone(P) 60mg/m2 orally on days 1 to 5. The therapy was repeated every 14 days for a total of 6 cycles.PS: G-CSF 1.0-2ug/kg/ d for subcutaneous injections will be administered on day 6 for a total use of 6-8 days.
3114303|NCT01793844||C （R-CHOP14)|Biweekly CHOP combined with Rituximab regimen（R-CHOP14） Treatment Arm C (R-CHOP14): Rituximab 375mg/m2 for injection on day1; cyclophosphamide(C), 750mg/m2 for injection on day2; doxorubicin(H), 50mg/m2 for injection on day2; and Vincristine(O), 1.4mg/m2 for injection on day2, prednisone(P),60mg/m2 orally on days 2 to 6. The therapy was repeated every 14 days for a total of 6 cycles.PS: G-CSF 1.0-2ug/kg/ d for subcutaneous injections will be administered on day 7 for a total use of 6-8 days patients with bulky disease or extranodal lesion wil be received radiotherapy after finishing the chemotherapy.
3114304|NCT01793831|Experimental|Fecal microbiota transplantation|Standard fecal microbiota transplantation, once.
3114305|NCT01793831|Sham Comparator|Traditional treatments, eg. 5-ASA|Traditional treatments according to associated guidelines, including 5-ASA, immunomodulatory therapy, corticoids, antibody
3114306|NCT01793818|Placebo Comparator|Group 1 Phase I/II|Three injections with no active principle
3114307|NCT01793818|Active Comparator|Group 2 Phase I/II|Three injections of Tat Oyi vaccine containing 11 µg of active principle
3114308|NCT01793818|Active Comparator|Group 3 Phase I/II|Three injections Tat Oyi vaccine containing 33 µg of active principle
3114309|NCT01793818|Active Comparator|Group 4 Phase I/II|Three injections Tat Oyi vaccine containing 99 µg of active principle
3114310|NCT01793805||Metastatic Colorectal Cancer Patients|
3114311|NCT01793792|Other|Device: LVIS|"The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.~Device: LVIS™ and LVIS™ Jr. MicroVention Low-profile Visualized Intraluminal Support Device"
3114312|NCT01793779|Placebo Comparator|Control|Placebo supplement given prior to exercise and two times per day following exercise
3114313|NCT01793779|Experimental|cold water immersion|Placebo supplement to be give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
3114314|NCT01793779|Experimental|HMB-FA|beta-hydroxy-beta-methylbutyrate free acid supplement to be give prior to exercise and two times per day following exercise
3114315|NCT01793779|Experimental|cold water immersion group + HMB-FA|beta-hydroxy-beta-methylbutyrate free acid supplement give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
3114316|NCT01793766|Experimental|Brain modulation|10 sessions of brain modulation with Eldith/Neuroconn transcranial Direct Current Stimulation device
3114317|NCT01793766|Placebo Comparator|Placebo (sham modulation)|10 placebo sessions where no brain modulation takes place
3114318|NCT01793753||Propofol|Chronically constipated children ages 2-6 years who will receive anesthesia for anorectal manometry including propofol per standard of care
3114319|NCT01793740|Experimental|Cogmed|These children are enrolled in the Cogmed intervention.
3114320|NCT01793740|No Intervention|Waitlist|These children are enrolled in a waitlist condition, after which they will be offered the opportunity to complete the intervention.
3114321|NCT01793727|Experimental|Glidescope intubation|Comparison of direct laryngoscopy and Glidescope videolaryngoscopy
3114322|NCT01793701|Experimental|Dose escalation study|This is a dose escalation study of IMRT for women with locally advanced cervical cancer. Three dose levels will be investigated, (although, the first dose level is considered to be the equivalent to a standard pelvic dose with parametrial boost). Before moving to the next dose level it must be confirmed by the Chief Investigator that the Maximum Administrable Dose (MAD) has not been met in the previous dose level (see section 6.3). If MAD is reached before dose level 3 the study will stop. All patients enrolled on the study will undergo the same procedures at the same time points, regardless of the dose level they are being given (see section 5).
3114323|NCT01793688||Sulbactam Sodium/Ampicillin Sodium|Patients with the following disease who received high doses of UNASYN (exceeding 6 g per day) by intravenous injection or intravenous drip infusion from the first dosing date or the second dosing date: Pneumonia, Lung Abscess, Peritonitis.
3114324|NCT01793675||haploidentical transplant|transplant with haploidentical donor
3114325|NCT01793662|Active Comparator|Open aortobifemoral bypass|Patients with aortoiliac occlusive disease (only, TASC Type D lesions) shall be randomized to either laparoscopic aortobifemoral bypass or open aortobifemoral bypass operation.
3114326|NCT01793662|Experimental|Laparoscopic aortobifemoral bypass|Patients with aortoiliac occlusive disease (only, TASC Type D lesions) shall be randomized to either laparoscopic aortobifemoral bypass or open aortobifemoral bypass operation.
3114327|NCT01793649|Experimental|Cross-Over Sequence 1|85 μg GS-5737 in 2.8% saline or 2.8% saline alone (blinded)
3114328|NCT01793649|Experimental|Cross-Over Sequence 2|2.8% saline alone or 85 μg GS-5737 in 2.8% saline (blinded)
3114329|NCT01793636|Experimental|AZD2014|AZD2014- tablets, starting dose 50mg BD everyday, until disease progression or untolerable toxicity
3114330|NCT01793636|Active Comparator|Everolimus|Everolimus- tablets, starting dose 10mg OD everyday until disease progression or untolerable toxicity
3114331|NCT01793623||nonemergent heart surgery, atrial tissue|patients undergoing non-emergent heart surgery
3114332|NCT01793610|Active Comparator|Comparator-dose MDMA and Psychotherapy|Participants receive initial doses of comparator-dose MDMA during each of two experimental sessions.
3114333|NCT01793610|Experimental|Active Dose 1 MDMA and Psychotherapy|Participants receive and initial dose of Active Dose 1 MDMA during each of two experimental sessions.
3114334|NCT01793610|Experimental|Active Dose 2 MDMA and Psychotherapy|Participants receive and initial dose of Active Dose 2 MDMA during each of two experimental sessions.
3114335|NCT01793597||clopidogrel|previous treatment with clopidogrel
3114336|NCT01793597||ticagrelor|previous treatment with ticagrelor
3114340|NCT01793571|Active Comparator|Local wound infiltration|20 ml levobupivacaine 0,5%
3114341|NCT01793558|No Intervention|Control; passive insulation|The mothers will receive passive temperature insulation by a cotton blanket (standard procedure) after start of the spinal anaesthesia for cesarean section. The newborn will be bonded on the mothers chest under the cotton blanket (also passive insulation without active warming) for 20 min after birth (bonding period).
3114342|NCT01793558|Experimental|Active Warming|The mothers will receive active warming by a forced-air warming blanket after start of the spinal anaesthesia for cesarean section. The newborn will be bonded on the mothers chest under the warming blanket for 20 min after birth (bonding period).
3114343|NCT01793519|Active Comparator|Anti-tumor necrosis factor agent|Anti-TNF agent - etanercept, infliximab, adalimumab - administered parentally at standard dosage and frequencies
3114344|NCT01793519|Placebo Comparator|Placebo|Administered appropriately to active comparator
3114345|NCT01793506||PID|Any subject having testing done to evaluate the immune system is eligible for this study. This will include patients with known PIDs as well as patients evaluated for a suspected immunodeficiency.
3114346|NCT01793493|Experimental|Cognitive stimulation|
3114347|NCT01793493|Active Comparator|Sanitary education|
3114348|NCT01793480|Experimental|patient-controlled dose of methadone|The titration will be done on the patient's request (patient-controlled dose of methadone), with no overlapping with the previous opioid treatment, under the investigator's supervision.
3114349|NCT01793480|Experimental|fixed-dose of methadone|The titration will be done with fixed-dose of methadone, on a progressive switch with overlapping with the previous opioid treatment, to avoid withdrawal syndrome when the opioid is discontinued.
3114350|NCT01793454|Active Comparator|40% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen 40% during the surgery.
3114351|NCT01793454|Active Comparator|80% oxygen|Patients in this group will be ventilated with a fraction of inspired oxygen 80% during the surgery.
3114352|NCT01793441|Placebo Comparator|Placebo|Participants will receive placebo matching to RG7314 in each stage (Stage I, II, III and IV) for 12 weeks.
3114353|NCT01793441|Experimental|RG7314|Participants will receive RG7314 orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
3114354|NCT01793428||Injured patient admitted in vital emergency unit|
3114355|NCT01793415|Active Comparator|IodoCarb (r)|3 g iodinated activated charcoal, IodoCarb(r), daily for 28 +-2 days.
3114356|NCT01793415|Placebo Comparator|Placebo|3 g of non-iodinated activated charcoal daily for 28+-2 days.
3114357|NCT01793402||Preterm infants born at or less than 32 weeks gestation|
3114358|NCT01793389|Active Comparator|Subepithelial connective tissue graft|Soft tissue harvested from palatum of the subjects.
3114359|NCT01793389|Experimental|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
3114360|NCT01793363|Experimental|tracheotomized patients|
3114361|NCT01793350|Active Comparator|BC-DN-01 topically applied cream, DPN|4g topically applied BC-DN-01 cream applied twice daily to each leg and foot, for 12 weeks
3114362|NCT01793350|Placebo Comparator|Placebo topically applied cream, DPN|4g topically applied cream applied twice daily to each leg and foot, for 12 weeks
3114363|NCT01793337|Other|Cold first|temperature is measured in cold (-20°C) environment first, and warm (23°C) environment afterwards
3114364|NCT01793337|Other|Warm first|temperature is measured in warm (23°C) environment first, and cold (-20°C) environment afterwards
3114365|NCT01793324||GER|All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel® or Seroquel® XR seen by general practitioners and psychiatrists in Germany based upon patient encounters recorded in IMS Disease Analyzer during the calendar period 13 February 2012 - 31 August 2012
3114366|NCT01793324||UK|All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel® or Seroquel® XR seen by general practitioners in the United Kingdom based upon patient encounters recorded in IMS Disease Analyzer during the calendar period from 11 January 2012 - 31 July 2012
3114367|NCT01793311|Sham Comparator|Group1: Decaffeinated coffee|contains 0.5-2 mg of caffeine
3114368|NCT01793311|Active Comparator|Group2: regular dose coffee|contains 91.8 mg of caffeine
3114369|NCT01793311|Active Comparator|Group3: high dose coffee|contains 144 mg of caffeine
3114370|NCT01793298|Experimental|Healthy Subjects - ASM-024 Single Administration|Single administration of ascending doses of ASM-024
3114371|NCT01793298|Placebo Comparator|Healthy Subjects - Placebo|Single administration of placebo
3114372|NCT01793298|Experimental|Healthy Subjects - ASM-024 Repeat Administration|Repeat administration of ascending doses of ASM-024
3114373|NCT01793298|Placebo Comparator|Healthy Subjects - Placebo Repeat Administration|Repeat administration of ascending doses of placebo
3114374|NCT01793298|Experimental|Subjects with Asthma|Repeat administration of ascending doses of ASM-024 or placebo in a crossover fashion
3114375|NCT01793272|Other|Pentoxifylline|effect of pentoxifylline on ICSI outcome
3114376|NCT01793259|Other|prefilled pen then prefilled syringe|weekly methotrexate injection with a prefilled pen during 3 weeks and subsequently with the prefilled syringe the last 3 weeks
3114377|NCT01793259|Other|prefilled syringe then prefilled pen|weekly methotrexate injection with a prefilled syringe during 3 weeks and subsequently with the prefilled pen the last 3 weeks
3114378|NCT01793246||pCLE for Discrete lung lesions|Patients undergoing bronchoscopy for the diagnosis of a lesion with probe based laser endomicroscopy (pCLE) imaging before biopsy
3114379|NCT01793246||pCLE for acute lung transplant rejection|Patients undergoing bronchoscopy for the detection of acute rejection of lung transplant with probe based laser endomicroscopy (pCLE) imaging before biopsy
3114380|NCT01793233||Ancillary-Correlative (menstrual diary, biomarker analysis)|Patients complete a menstrual diary to document vaginal bleeding and undergo blood sample collections at baseline, the 3rd course of chemotherapy, at the end of chemotherapy, and at 6 and 12 months post-treatment.
3114381|NCT01793220|Experimental|SMS Reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
3114449|NCT01792700|Active Comparator|MEA|MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.)
3114382|NCT01793220|No Intervention|No SMS Reminders|The service user will not be sent text message reminders prior to each appointment at their Psychosis Community Service
3114383|NCT01793207||Normal|Subjects who had a normal colonoscopic examination (No polyps, masses or any evidence of colorectal neoplasia)
3114384|NCT01793207||colorectal cancer|Patients with endoscopic and histopathological evidence of colorectal cancer
3114385|NCT01793207||Adenoma|Patients with colorectal adenomas only detected on colonoscopy
3114386|NCT01793207||Hyperplastic polyps|Patients with hyperplastic polyps detected on colonoscopy.
3114387|NCT01793194|No Intervention|No Stocking Use|For pregnant women randomized to the no stocking use group, no compression stockings will be worn.
3114388|NCT01793194|Experimental|Compression Stocking Use|Patients who are randomized to the stocking use group (Treatment Subgroup A) will be formally measured for their stockings by a certified stocking fitter, given (at no charge) two pair of 20-30mmg Hg maternity pantyhose compression stockings, and will undergo a brief tutorial regarding how to put the stockings on. Each patient will be instructed to wear the stockings on a daily basis, during the day.
3114389|NCT01793181||CRVO patients|Patients with a newly diagnosed CRVO. Maximum duration 3 months.
3114390|NCT01793181||Control patients|Controls matched for age,gender, month of onset from the Central Bureau of Statistics Sweden
3114391|NCT01793155|Experimental|Inspiratory muscle training|Inspiratory muscle training for two weeks following surgery
3114392|NCT01793155|Placebo Comparator|Standard physiotherapy|Breathing exercises, cough/hugh, advice on early and active mobilization
3114393|NCT01793142||Viviant treatment group|Viviant treatment group
3114394|NCT01793129|Experimental|Whole-body Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours
3114395|NCT01793129|Placebo Comparator|Normothermia|Control group (with esophageal temperature at or near 37.0°C) for 72 hours
3114396|NCT01793090|Active Comparator|EPI-743|"EPI- 743 in capsule or formulation comprised of USP/NF (United States Pharmacopeia and The National Formulary)Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.~Dose: 100mg or 200 mg tid for 12 months, to be continued if clinically effective"
3114397|NCT01793090|Placebo Comparator|Placebo supplementation|placebo in the same formulation as the active comparator will be administered to patients, assigned to this arm in a randomized design
3114398|NCT01793077||Prostate Cancer patients|
3114399|NCT01793064|Experimental|Adaptive Intervention Group (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
3114400|NCT01793064|Active Comparator|Static Intervention group (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
3114401|NCT01793051|Experimental|Minocycline|"Minocycline 200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance chemotherapy for MM.~Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit."
3114402|NCT01793051|Placebo Comparator|Placebo|"Placebo 200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).~Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit."
3114403|NCT01793038|Active Comparator|CC-plus uFSH|clomiphene citrate 50 mg tablets twice/day for cycle days 3-7 plus daily IM injection of 37.5 IU HP uFSH for days 3-12
3114404|NCT01793038|Experimental|Aromataze inhibitor plus uFSH|Aromataze inhibitor (litrezole )2.5 mg twice daily for cycle days 3-7 plus daily IM injection of uFSH 37.5 IU for cycle days 3-12
3114405|NCT01793025|Experimental|ATAC Therapy|
3114406|NCT01793012||critically ill intensive care patients|Treatment with one or more of the following antibiotics: piperacillin/tazobactam, cefepime, meropenem, ciprofloxacin, linezolid, colistin
3114407|NCT01792999|No Intervention|Non-contrast KBCT|About 187 subjects, who had diagnostic imaging of the breast including mammography and were categorized as Breast Imaging-Reporting and Data System(BIRADS) scores 1, 2, 3, 4, or 5, received KBCT imaging without contrast injection.
3114408|NCT01792999|Experimental|Contrast-enhanced KBCT|About 231 subjects, who had diagnostic imaging of the breast including mammography and were scheduled for biopsy or surgery, received contrast-enhanced KBCT imaging of the affected breast before biopsy or surgery.
3114409|NCT01792986|Other|water-only 24-hour fasting once per week for 6 weeks|
3114410|NCT01792960||familial hypertrophic cardiomyopathy|familial hypertrophic cardiomyopathy patients and their relatives
3114411|NCT01792947|Active Comparator|Diet|Diet 1200 Kcal during 3 months
3114412|NCT01792947|Experimental|PENS associated to diet|Percutaneous electroneurostimulation of dermatome T6 associated to diet 1200 Kcal
3114413|NCT01792934|Active Comparator|XELOX or FOLFOX regimen|XELOX or FOLFOX regimen
3114414|NCT01792934|Experimental|XELOX or FOLFOX regimen and maximal tumor debulking|XELOX or FOLFOX regimen and maximal tumor debulking including Surgery, radiofrequency ablation (RFA), transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI)-TACE) or stereotactic body radiation therapy (SBRT).
3114415|NCT01792921||control waitlist|
3114416|NCT01792908|Experimental|KT group|The KT group received ankle KT on the lateral ligament in the non-dominant leg and a recommendation guide. The Kinesio tape procedure was carried out by the same certified athletic therapist to ensure consistency throughout the study.
3114417|NCT01792908|No Intervention|Control group|Any intervention has been applied. Using another kind of tape or a different KT application for control group may increase cutaneous information, undermining our goal.
3114418|NCT01792895|Active Comparator|Manipulation group|This Technique will be applied over four sessions, during two weeks
3114419|NCT01792895|Active Comparator|Mobilisation|This treatment will be applied on cervical spine during four sessions, over two weeks
3114420|NCT01792895|Active Comparator|Mobilization with movement|This Technique will be applied over four sessions, during two weeks
3114421|NCT01792882||Cancer Subjects|
3114897|NCT01789567|Other|Engager™ aortic valve|Implantation of the Medtronic Engager™ bioprosthesis via direct aortic approach
3114422|NCT01792856|Experimental|intervention group|Subjects are scheduled to receive a 6-month group-based recovery-oriented coaching program. This is a structured, manualised treatment program based on life coaching principles with cognitive-behavioural and solution-focused elements incorporated. It guides subjects to undergo an active, yet stepwise change process by stimulating motivation, setting achievable goals, generation of action plans via collaborative exploration, fostering self-regulatory capacity, and provision of autonomy-supportive treatment environment and peer support. Subjects' perceived competence, sense of control, self-management skills and hence functioning will be improved via successful experiences and positive feelings generated after attainment of self-initiated goals. Cognitive-behavioural techniques such as self-monitoring, activity scheduling and behavioural modification will be employed.
3114423|NCT01792856|Experimental|control group|Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
3114424|NCT01792843||Parkinson's disease|Patients with Parkinson's disease according to international criteria
3114425|NCT01792830|No Intervention|Control HbA1c < 7%|Subjects not requiring coronary artery bypass graft surgery (CABG), with no history of diabetes with HbA1c <7% not requiring subcutaneous insulin in the hospital will be discharged on no antidiabetic therapy.
3114426|NCT01792830|Active Comparator|Diabetic/ Metformin and 50-Glargine HbA1c 7%- 9%|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of basal (glargine) insulin at 50% of total daily hospital dose.
3114427|NCT01792830|Active Comparator|Diabetic/ Metformin and 80-Glargine HbA1c 7%-9%%|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c 7%- 9% will be discharged on oral metformin and a single dose of basal (glargine) insulin at 80% of total daily hospital dose or with basal bolus regimen at same inpatient total daily insulin dose.
3114428|NCT01792830|Active Comparator|No diabetes/ Metformin only|Subjects requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1c <7% and persistent hyperglycemia requiring subcutaneous (SC) insulin therapy in the hospital will be discharged on oral metformin.
3114429|NCT01792830|Active Comparator|Diabetic/antidiabetic regimen|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c <7% will be discharged on their same outpatient antidiabetic regimen. Subjects will receive one of the three treatment options based on their blood glucose levels: Metformin alone, both metformin and glargine insulin or glargine alone.
3114430|NCT01792830|Active Comparator|No diabetes/ Insulin only|Subjects requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1c <7% and persistent hyperglycemia will be given subcutaneous (SC) insulin therapy in the hospital.
3114431|NCT01792830|Active Comparator|Diabetes/Insulin only|Subjects requiring coronary artery bypass graft surgery (CABG) with an admission HbA1c >9% and persistent hyperglycemia will be given basal insulin (glargine) once daily, at the same time of the day and rapid-acting insulin (glulisine) before meals.
3114432|NCT01792817|Sham Comparator|Sham GammaCore device|The Sham GammaCore device looks and operates like the Active GammaCore device, but does not deliver a therapeutic stimulation treatment.
3114433|NCT01792817|Experimental|GammaCore Device|Non-Invasive Vagus Nerve Stimulator
3114434|NCT01792804|Experimental|Orally administered antibiotic|First choice (MRSA and MSSA): trimethoprim-sulfamethoxazole, or Second choice (MSSA): clindamycin, or Second choice (MRSA): linezolid administered for 7-9 days
3114435|NCT01792804|Experimental|Intravenously administered antibiotic|First choice (MSSA): flucloxacillin [Spain: cloxacillin], or cefazolin or Second choice (MSSA): vancomycin, or First choice (MRSA): vancomycin, or Second choice (MRSA): daptomycin administered for 7-9 days
3114436|NCT01792791||Single Arm|
3114437|NCT01792778|Active Comparator|ViaValve Safety IV Catheter|Catheter insertion using the ViaValve Safety IV Catheter.
3114438|NCT01792778|Active Comparator|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|Catheter insertion using the Insyte Autoguard BC Shielded IV Catheter
3114439|NCT01792765|No Intervention|Control Arm|This arm will undergo ureteroscopy using conventional fluoroscopy to guide the procedure and visualize scope position, safety wire status, etc.
3114440|NCT01792765|Experimental|Ultrasound guidance|This arm will have intraoperative ultrasound guidance to determine safety wire position and for scope guidance.
3114441|NCT01792752|Experimental|Enhanced HIV Care Access and Retention Intervention|Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. The neighborhoods will receive the intervention at different times throughout the study period, but once the intervention is initiated in a neighborhood it will continue being implemented in that neighborhood until the end of the study period.
3114442|NCT01792752|No Intervention|Control / Neighborhood(s) not receiving the intervention|The neighborhood(s) not receiving the intervention will act as a control while the intervention is initiated and implemented in other neighborhoods. All neighborhoods will receive the intervention but at different times throughout the study period. Once the intervention is initiated in a neighborhood, that neighborhood will continue receiving the intervention until the end of the study period.
3114443|NCT01792739|Experimental|Kadit B|Probiotic Lactobacillus casei variety rhamnosus granules
3114444|NCT01792739|Placebo Comparator|Kadit A|Placebo
3114445|NCT01792726|Experimental|TARGIT|The experimental policy is to give targeted intra-operative radiotherapy (TARGIT-Boost) in a single dose to substitute for the usual boost dose, in addition to whole breast external beam radiotherapy delivered according to local treatment guidelines.
3114446|NCT01792726|Active Comparator|External beam radiotherapy boost|The conventional policy is to receive radiation boost to the tumour bed delivered by external beam radiotherapy (EBRT) in addition to whole breast external beam radiotherapy delivered according to local treatment guidelines.
3114447|NCT01792713|Active Comparator|Sertaconazole 2% cream|2x daily treatment with Sertaconazole 2% cream for 4 weeks, 2 weeks follow-up
3114448|NCT01792713|Placebo Comparator|Placebo Arm|2x daily treatment with Placebo cream for 4 weeks, 2 weeks follow-up
3114450|NCT01792700|Active Comparator|EBMT|EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d)
3114451|NCT01792687|Experimental|Treatment|ARN-509 when combined with the approved dose of abiraterone acetate (1,000 mg daily) plus prednisone (5 mg daily).
3114452|NCT01792674|Experimental|In situ simulation|'In situ simulation' which is training in the actual patient care unit, in this situation the labour suite and operation theatre
3114453|NCT01792674|Active Comparator|Off site simulation|The control group will receive the same training 'off site simulation', i.e., in training rooms away from the actual patient care unit.
3114454|NCT01792661|Active Comparator|MyChart|The control group receives standard Cleveland Clinic care and has access to MyChart which is the standard Cleveland Clinic electronic PHR.
3114455|NCT01792661|Active Comparator|Enhanced MyChart|The enhanced PHR functionality adds the ability to securely receive and review CKD-education related messages to the existing features available to all PHR users. The CKD-educational related messages can be automatically delivered at pre-defined intervals and customized for each individual patient at their discretion and convenience.
3114456|NCT01792661|Active Comparator|Patient Navigator|A tracking log is kept by the Patient Navigator of each interaction regarding type of encounter, length of encounter, barriers addressed, and actions that occurred, adapting what is in use for the NIH-funded Patient Navigator program.
3114457|NCT01792661|Active Comparator|Patient Navigator and Enhanced MyChart|Combines patient self empowerment, regarding their CKD, with the Enhanced MyChart along with the aid and direction of a Patient Navigator.
3114458|NCT01792648|Active Comparator|Standard Reference Diet|
3114459|NCT01792648|Experimental|Almond Supplemented Diet|
3114460|NCT01792648|Active Comparator|Low Carbohydrate Reference Diet|
3114461|NCT01792635|No Intervention|Part A (Pilot Study)|
3114462|NCT01792635|Experimental|Monotherapy (Part B)|
3114463|NCT01792622||Phase I Patient Interviews|Indepth interviews will be completed with approximately 15 patients.
3114464|NCT01792622||Phase II Patient Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I
3114465|NCT01792609|Active Comparator|Maximum Number of Screws|Once enrolled and consented, patients with Lenke 1A curves will be randomized to a high- or low-density screw cohort. The high-density pattern will be designated as ≥ 1.8 implants per level fused. The low density pattern will be ≤ 1.4 screws per level fused. At least 75% of the implants must be pedicle screws for both cohorts.
3114466|NCT01792609|Active Comparator|Minimum Number of Screws|Once enrolled and consented, patients with Lenke 1A curves will be randomized to a high- or low-density screw cohort. The high-density pattern will be designated as ≥ 1.8 implants per level fused. The low density pattern will be ≤ 1.4 screws per level fused. At least 75% of the implants must be pedicle screws for both cohorts.
3114467|NCT01792596|Other|pasta|1. Plain pasta
3114468|NCT01792596|Other|pasta with protein|Pasta with protein
3114469|NCT01792596|Other|pasta with fiber|Pasta with Fiber
3114470|NCT01792583||Prospective Cohort|"Any woman who is pregnant, and was exposed to at least one dose of armodafinil or modafinil within 6 weeks prior to conception and/or during pregnancy~The condition of the fetus has not been assessed through prenatal testing such as targeted ultrasound and amniocentesis.~Eligible patients may include those where the condition of the fetus was already assessed as normal through early prenatal testing to determine the gestational age or viability within 10 weeks or less from registration."
3114471|NCT01792583||Retrospective Cohort|"Any woman who is pregnant, and was exposed to at least one dose of armodafinil or modafinil within 6 weeks prior to conception and/or during pregnancy~The condition of the fetus has been assessed through prenatal testing such as targeted ultrasound or amniocentesis."
3114472|NCT01792570|Experimental|RPV + DRV/r|switch to RPV + DRV/r
3114473|NCT01792570|Active Comparator|continue the PI/r-containing HAART.|continue the PI/r-containing HAART
3114474|NCT01792557|Active Comparator|Phenol|Crystallized Phenol Group
3114475|NCT01792557|Active Comparator|Limberg|Limberg Flap Group
3114476|NCT01792557|Active Comparator|Modified Limberg|Modified Limberg Flap Group
3114477|NCT01792557|Active Comparator|Karydakis|Karydakis Flap Group
3114478|NCT01792544|Experimental|Statement|A statement is added to the echocardiography report describing if and when a follow-up echocardiogram is recommended. The statement may be positive (e.g. follow-up recommended in 6 months) or negative (e.g. no follow-up recommended).
3114479|NCT01792544|Experimental|No Statement|No statement is added to the echocardiography report
3114480|NCT01792531|Experimental|Treatment focus - Parenting vs lifestyle|To determine the effectiveness of two obesity treatment interventions: 1) parent training group (n=90) and 2) standard treatment with focus on lifestyle (n=90). The two treatment conditions will be evaluated with respect to child weight status (BMI SDS; primary outcome), psychosocial and metabolic health, lifestyle choices, and family functioning (secondary outcomes). This design will allow us to assess whether a program targeting only parents and focusing on parenting practices will result in better outcomes than treatment as usual emphasizing lifestyle changes.
3114481|NCT01792531|Experimental|Length of treatment|To understand the influence of treatment duration by comparing the effectiveness of two obesity treatment interventions: the parent training group administered for 12 wks only (n=45) and the parent training group with booster sessions which include additional booster sessions at 8-week intervals for the following year (n=45). Thus we will randomize families to either a group with booster sessions or without. This design will allow us to evaluate if prolonged care is necessary to maintain intervention effects, or if a 12-week program is equally effective.
3114482|NCT01792518|Experimental|linagliptin 5mg|linagliptin 5 mg once daily
3114483|NCT01792518|Placebo Comparator|placebo|matching placebo for linagliptin dose once daily
3114484|NCT01792505|Experimental|Biological/Vaccine|
3114485|NCT01792479|Experimental|Arm A: BIND-014 every 3 weeks|
3114486|NCT01792479|Experimental|Arm B: BIND-014 weekly|
3114487|NCT01792466|Experimental|Transpacnreatic sphincterotomy|In patients randomized to TPS, a transpancreatic sphincterotomy will be performed with the sphincterotome superficially in the pancreatic duct over a wire.
3115073|NCT01788150|Experimental|Svelte Drug-Eluting Coronary Stent|Coronary Stenting
3114488|NCT01792466|No Intervention|Double wire without sphincterotomy|In patients randomized to the DWT group, the PD wire will be left in place, the catheter removed and then reinserted next to the PD wire with a second wire to attempt CBD cannluation
3114489|NCT01792453|Experimental|240 mL water drink|Volunteers will be asked to drink 240 mL water drink
3114490|NCT01792440||non-cystic fibrosis bronchiectasis|patients with non-cystic fibrosis bronchiectasis will be evaluated cross-sectionally
3114491|NCT01792440||healthy control subjects|healthy control subjects will be evaluated cross-sectionally
3114492|NCT01792414|Active Comparator|Active TES|Active TES
3114493|NCT01792414|Sham Comparator|Sham TES|Sham TES
3114494|NCT01792401|Placebo Comparator|Placebo|Patients on enteral feeding in intensive care units are administered a placebo
3114495|NCT01792401|Active Comparator|Probiotics|Patients on enteral feeding in intensive care unit are given a probiotic
3114496|NCT01792388|Placebo Comparator|Soya Bean oil|
3114497|NCT01792388|Active Comparator|Vitamin D|
3114498|NCT01792375|Active Comparator|Concurrent membrane sweeping with Dinoprostone|
3114499|NCT01792375|Active Comparator|Dinoprostone|
3114500|NCT01792362|Experimental|AMH|obese PCOS patients who underwent weight loss diet
3114501|NCT01792349|Experimental|STARFISH intervention|STARFISH is a smartphone-based programme designed as a behavioural intervention to encourage the user to become more physically active
3114502|NCT01792349|No Intervention|Control group|A smartphone application will record levels of physical activity, but subjects will not have access to daily step count or to the STARFISH application.
3114503|NCT01792323|Experimental|1 bolus of insulin lispro with short bolus duration|Subcutaneous administration of insulin lispro as a bolus of 15 IU over a period of 30 seconds
3114504|NCT01792323|Experimental|1 bolus of insulin lispro with long bolus duration|Subcutaneous administration of insulin lispro as a bolus of 15 IU over a period of 10 minutes
3114505|NCT01792310|Experimental|Dose Cohort 1|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 7 dose cohorts of up to 6 patients have been performed in the dose escalation phase. The starting dose cohort received 250 mg twice daily.
3114506|NCT01792310|Experimental|Dose Cohort 2|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 500 mg twice daily
3114507|NCT01792310|Experimental|Dose Cohort 3|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 1g twice daily
3114508|NCT01792310|Experimental|2-OHOA Dose Cohort 4|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 2g twice daily
3114509|NCT01792310|Experimental|2-OHOA Dose Cohort 5|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 4g twice daily
3114510|NCT01792310|Experimental|2-OHOA Dose Cohort 6|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 4g three times daily
3114511|NCT01792310|Experimental|2-OHOA Dose Cohort 7|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 8g twice daily
3114512|NCT01792310|Experimental|2-OHOA Dose Expansion cohort. Glioma|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA) at the MTD: 4g three times daily. Up to 10 patients with malignant glioma.
3114513|NCT01792310|Experimental|2-OHOA Dose Expansion cohort. Non-glioma|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA) at the MTD: 4g three times daily. Up to 10 patients with other advanced solid tumours that are suitable for biopsy.
3114514|NCT01792297|Experimental|Bovine Colostrum|60 g/d bovine colostrum in powder form to be mixed with drinks. The dose will be spread out 3 times per day (20 g per dose)
3114515|NCT01792297|Active Comparator|Whey protein|60 g/d whey protein powder mixed into drinks. It is to be divided into 3 daily doses (20 g per dose)
3114516|NCT01792284|Experimental|LY2605541 Fixed Time Dosing|"Participant-specific dose of LY2605541 administered subcutaneously (SQ) at approximately the same time every evening for 12 weeks in the Lead-in Period and in Randomization Period 1 or Randomization Period 2.~Participant-specific dose of insulin lispro SQ when >20% of calories were consumed (pre-meal).~Insulin dose and adjustments to insulin dose were determined by insulin algorithms based on self-monitored blood glucose (SMBG). Target glucose values were as follows:~Preprandial and bedtime BG between 71 and 130 milligrams/deciliter (mg/dL) Insulin adjustment and glucose correction between 71 and 100 mg/dL."
3114517|NCT01792284|Experimental|LY2605541 Variable Time Dosing|"Participant-specific dose of LY2605541 administered SQ on a variable time schedule (8- and 40-hour dosing intervals) for 12 weeks in Randomization Period 1 or Randomization Period 2. Dosing schedules were to remain approximately the same throughout the 12 weeks.~Participant-specific dose of insulin lispro SQ when >20% of calories were consumed (pre-meal).~Insulin dose and adjustments to insulin dose were determined by insulin algorithms based on SMBG. Target glucose values were as follows:~Preprandial and bedtime BG between 71 and 130 mg/dL Insulin adjustment and glucose correction between 71 and 100 mg/dL."
3114518|NCT01792271|Placebo Comparator|AB: 7% HS home tx, then 0.12% NaCl|"Inhaled Inhaled 7% HS (hypertonic saline) home treatment' , then 0.12% sodium chloride solution home treatment.~The intervention consists of the subject receiving both concentrations of inhaled sodium chloride solution, each during a different home treatment periods. Subjects randomized to order AB will receive inhaled 7% NaCl (sodium chloride solution) mist during the first home treatment period, then 0.12% NaCL during the second home treatment period."
3114519|NCT01792271|Placebo Comparator|BA: 0.12% NaCl home tx, then 7% HS|Subjects randomized to order BA will receive inhaled 0.12% NaCl mist during the first home treatment period, then Inhaled 7% HS home treatment during the second home treatment period.
3114520|NCT01792258||critical ill patients|The investigator will enroll all the critical ill patients undergoing percutaneous tracheostomy performed in ICU
3114521|NCT01792245|Active Comparator|NB-UVB|This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA. For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB. Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly. Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
3114560|NCT01791946|Experimental|Treatment Group A (Post-Surgery)|Subjects enrolled in this arm will first have eye alignment corrective surgery and then complete six weeks of the investigational binocular treatment training.
3114561|NCT01791946|Experimental|Treatment Group B (Pre-Surgery)|Subjects enrolled in this arm will first complete six weeks of the investigational binocular treatment training and then have eye alignment corrective surgery.
3114522|NCT01792245|Active Comparator|Topical PUVA|This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA. For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB. Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly. Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
3114523|NCT01792232|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by subject specific allergen placed in lung
3114524|NCT01792232|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by subject specific allergen placed in lung
3114525|NCT01792232|Active Comparator|Filtered air control|Exposure for 2 hours to filtered air followed by subject saline placed in lung
3114526|NCT01792232|Active Comparator|Diesel exhaust control|Exposure for 2 hours to diesel exhaust followed by saline placed in lung
3114527|NCT01792219|Experimental|interprofessioal education module|an interprofessional education module will be given to learn to collaborate interprofessionally.
3114528|NCT01792206|Active Comparator|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
3114529|NCT01792206|Placebo Comparator|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
3114530|NCT01792193||Parkinson's disease|Patients with Parkinson's disease
3114531|NCT01792193||Control|Healthy controls
3114532|NCT01792180|No Intervention|Control group|No intervention besides weekly telephone calls from the computerized falls telephone system
3114533|NCT01792180|Experimental|Intervention group|Weekly use of the mobility feedback device, use of instruction book with every day exercises, use of activity diary in intervention group.
3114534|NCT01792167|Experimental|Second Step|Second Step Curriculum
3114535|NCT01792167|No Intervention|Stories of Us|Stories of Us was provided to schools
3114536|NCT01792115|Active Comparator|Vit E 200 IU/d|Subjects randomized to vitamin E
3114537|NCT01792115|Active Comparator|Vitamin E 400|Subjects randomized to vitamin E
3114538|NCT01792115|Active Comparator|Vitamin E 800|Subjects randomized to vitamin E
3114539|NCT01792102|Experimental|Carfilzomib and Dexamethasone|"Phase 1: Carfilzomib will be administered at an escalating dose with dexamethasone administered at 8mg.~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: Carfilzomib and dexamethasone will be administered in the same fashion as the previous treatment cycles, but only on days 1, 2, 15, and 16."
3114540|NCT01792089||non-obese healthy subjects|subjects with BMI<25 and no known disease
3114541|NCT01792089||post-gastric bypass|post-obese subjects 12-18 months after Roux-en-Y gastric bypass
3114542|NCT01792089||matched control subjects|Nonobese, healthy subjects of similar age, weight, and gender ratio, than post-bypass subjects
3114543|NCT01792063|Active Comparator|Sevoflurane A|Generic sevoflurane
3114544|NCT01792063|Active Comparator|Sevoflurane B|Orginal sevoflurane
3114545|NCT01792050|Placebo Comparator|Arm 1A: Docetaxel + Placebo|Arm 1A: Docetaxel 75 mg/m^2 IV given every 3 weeks (on day 8 of 21 day cycle), plus placebo PO BID (days 1-14 of 21 day cycle).
3114546|NCT01792050|Experimental|Arm 1B: Docetaxel + Indoximod|Arm 1B: Docetaxel 75 mg/m^2 IV given every 3 weeks (on day 8 of 21 day cycle), plus Indoximod 1200 mg PO BID (days 1-14 of 21 day cycle).
3114547|NCT01792050|Placebo Comparator|Arm 2A: Paclitaxel + Placebo|Arm 2A: Paclitaxel 80 mg/m^2 IV given weekly x3 followed by a week of rest (28 day cycle), plus placebo PO BID (days 1-21 of 28 day cycle).
3114548|NCT01792050|Experimental|Arm 2B: Paclitaxel + Indoximod|Arm 2B: Paclitaxel 80 mg/m^2 IV given weekly x3 followed by a week of rest (28 day cycle), plus Indoximod 1200 mg PO BID (days 1-21 of 28 day cycle).
3114549|NCT01792037|Active Comparator|Etomidate|After taking of the blood samples, patients in Group I will be intubated with 0.3 mg/kg etomidate iv. Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired.
3114550|NCT01792037|Active Comparator|etomidate, steroid|After taking of the blood samples, patients in Group II will be intubated with 0.3 mg/kg etomidate iv following a 2mg/kg methylprednisolone iv Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired.
3114551|NCT01792037|Active Comparator|midazolam|"After taking of the blood samples, patients in Group III will be intubated with 0.01 mg/kg midazolam iv. Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.~Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired."
3114552|NCT01792024|Experimental|Treatment (LITT)|Patients undergo Magnetic Resonance imaging (MR) guided laser thermal therapy with Visualase Thermal Therapy device.
3114553|NCT01792011|Experimental|PVI|A new non-invasive device (Radical-7 pulse oximeter monitor, Masimo Corp.) has been introduced that continuously detects changes in the plethysmograph waveform and computes a Plethysmography Variability Index (PVI) reflecting alteration in preload and fluid management.
3114554|NCT01791998|Experimental|Treatment (MR-thermal image guided LITT)|Patients undergo MR-thermal image guided LITT over 1 hour.
3114555|NCT01791985|Experimental|Single arm study|"NSAI (anastrozole (1mg) or letrozole (2.5mg)), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off."
3114556|NCT01791972|Experimental|Albuterol Spiromax / Placebo Spiromax|Albuterol Spiromax, 180 mcg (2 inhalations of 90 mcg/inhalation), single dose on Day 1. Placebo Spiromax (2 inhalations), single dose on approximately Day 7.
3114557|NCT01791972|Experimental|Placebo Spiromax / Albuterol Spiromax|Placebo Spiromax, (2 inhalations), single dose on Day 1. Albuterol Spiromax 180 mcg (2 inhalations of 90 mcg/inhalation), single dose on approximately Day 7.
3114558|NCT01791959|Active Comparator|Synbiotic|2 synbiotic capsules for 28 weeks
3114559|NCT01791959|Placebo Comparator|maltodexterin|two capsules per day for 28 weeks
3114562|NCT01791946|Sham Comparator|Sham Treatment|Subjects enrolled in this arm will first complete six weeks of the sham binocular treatment and then undergo eye alignment corrective surgery.
3114563|NCT01791933||CAM treatment|
3114564|NCT01791920|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A
3114565|NCT01791920|Experimental|Botulinum toxin type A (Botulax®)|Botulinum toxin type A
3114566|NCT01791907|Experimental|Structured education in carbohydrate counting|A structured education in carbohydrate counting, a course inspired by the DAFNE program (Dose Adjustment For Normal Eating)
3114567|NCT01791907|Experimental|Structured education in healthy food choices and low GI|"A new, structured education for heart healthy food choices and low glycemic index in type 1 diabetes. The education is called My Wellness-LADDER (Lifelong Adult Diet & Diabetes Education Resource) and it is specifically designed to provide high long-term adherence through improved empowerment and transformative life style change."
3114568|NCT01791907|No Intervention|Regular routine|
3114569|NCT01791894|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3114570|NCT01791881|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®)
3114571|NCT01791881|Experimental|Botulinum toxin type A(Hugeltox)|Botulinum toxin type A(Hugeltox)
3114572|NCT01791868|Experimental|Intravenous sodium valproate|"Intravenous sodium valproate:~30 mg/kg during 15 min then 1 mg/kg/h during 12 h"
3114573|NCT01791868|Placebo Comparator|Intravenous Placebo|"Intravenous Placebo:~NaCl 0,9 % during 15 min at first then during 12 h."
3114574|NCT01791855|Experimental|Healthy Volunteers|
3114575|NCT01791855|Experimental|Mild Renal Impairment|
3114576|NCT01791855|Experimental|Moderate renal impairment|
3114577|NCT01791855|Experimental|Severe renal impairment|
3114578|NCT01791842|Experimental|Tocilizumab first, then placebo|one IV infusion per month of Tocilizumab for 6 months followed by 1 infusion per month of placebo, for 6 months.
3114579|NCT01791842|Experimental|Placebo first, then Tocilizumab|one IV infusion per month of Placebo for 6 months followed by 1 infusion per month of Tocilizumab, for 6 months.
3114580|NCT01791829||Luminal A with other Clinical Criteria|BCS postulated to be at low risk for IBTR following Endocrine Therapy
3114581|NCT01791816|Experimental|Phenylephrine and L-Ng-monomethyl Arginine (L-NMMA)|
3114582|NCT01791803|Experimental|Hypnotherapy|Patients admitted with a cardiopulmonary illness received a 90 minute free hypnotherapy session within 2 weeks of discharge, and a standardized tape for smoking cessation and relaxation for continued use after the session. They also received self-help brochures, and counseling during hospitalization and by telephone at 1,2,4,8 and 12 weeks after discharge.
3114583|NCT01791803|Experimental|Nicotine Replacement Therapy|Patients recieved a free one month supply of Nicotine replacement therapy to include patches and Gum, lozenges or sprays. Patients also received self-help brochures, and counseling during hospitalization and by telephone at 1,2,4,8 and 12 weeks after hospitalization.
3114584|NCT01791803|Experimental|Hypnotherapy and Nicotine replacement|The group received similar hypnotherapy session and tape, similar brochure and counseling protocol, as well as free nicotine replacement supplies for a month after discharge.
3114585|NCT01791803|No Intervention|Self-Quit group|Patients were given brief counseling during hospitalization and will not be contacted until 26 weeks after hospitalization.
3114586|NCT01791790|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
3114587|NCT01791790|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
3114588|NCT01791777|Experimental|Purveyor|"The purveyor arm will include SafeCare Coaching that is conducted by a Training Specialists from the National SafeCare Training and Research Center (NSTRC), a GSU (Georgia State University)-Center that conducts training and research on the SafeCare model."
3114589|NCT01791777|Experimental|Local|"The the local are will receive SafeCare Coaching that is provided by a staff member who works for the local social service agency."
3114590|NCT01791751|Experimental|Clomifene Citrate|Clomifene Citrate 50 mg
3114591|NCT01791751|No Intervention|Control|No intervention
3114592|NCT01791738|Experimental|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
3114593|NCT01791738|No Intervention|Standard total hip arthroplasty|Each surgeon will use their standard methods of pre-operative planning using pre-operative x-rays, and complete the procedure using standard surgical instruments for total hip arthroplasty.
3114594|NCT01791725|Experimental|ELND005 BID|ELND005 250 mg BID
3114595|NCT01791725|Experimental|ELND005 QD|ELND005 250 mg QD
3114596|NCT01791725|Placebo Comparator|Placebo|Placebo BID
3114597|NCT01791712|Experimental|On-line hemodiafiltration|On-line hemodiafiltration is a type of renal replacement therapy that was assigned as the intervention to compare with the control arm
3114598|NCT01791712|Active Comparator|High-flux hemodialysis (control)|The standard high-flux hemodialysis is the routine renal replacement therapy in sepsis-related acute kidney injury patients and is assigned as the intervention for the control group.
3114599|NCT01791699|Placebo Comparator|Control group|"The patients of the control group will undergo standard ablation procedure (pulmonary vein isolation) and will receive placebo, starting one week before scheduled ablation.~Optimal antihypertensive treatment will be prescribed, with adequate follow-up to ensure good control of hypertension (goal <= 140/90)."
3114600|NCT01791699|Active Comparator|Moxonidine group|"Patients of the active treatment group will receive moxonidine in a starting dose of 0.2 mg daily. The first dose will be administered 1 week before scheduled ablation. 3 weeks after the first dose the daily dose will be increased to 0.4 mg, if the lower dose is well tolerated.~Optimal antihypertensive treatment, in addition to moxonidine, will be prescribed, if needed, with adequate follow-up to ensure good control of hypertension (goal <= 140/90)."
3114671|NCT01791114|Experimental|Exercise|Subjects between 18 and 35 years old will be asked to participate in two trials: a) Exercise, i.e. four times for 10 min- at 85% VO2max (maximal oxygen consumption). with 15-min breaks between each bout b) and two weeks later rest.
3114601|NCT01791686|Experimental|Dense Deposit Disease|"► Induction Period~Patients will receive CDX-1135 as an IV infusion twice weekly (Mon-Thur or Tues-Fri). There will be two doses of 5 mg/kg, with intrapatient dose-escalation in 5 mg/kg increments up to a maximum dose of 30 mg/kg. This period may last up to 8 weeks.~► Maintenance Period~The starting dose for CDX-1135 Maintenance will be the same dose level as the last dose during the Induction Period; however, the Maintenance Period allows for dose decrease to 2 mg/kg, which is lower than the starting dose in the Induction Period.~Patients will receive CDX-1135 as an IV infusion twice weekly (Mon-Thur or Tues-Fri) for up to a total of 26 weeks."
3114602|NCT01791673|Experimental|Ultrasound Glaucoma treatment|Cyclocoagulation using High Intensity Focused Ultrasound (HIFU)
3114603|NCT01791660|Experimental|Zeltiq Coolsculpting System|non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
3114604|NCT01791647|Active Comparator|myo-inositol|1500 mg/day myoinositol
3114605|NCT01791647|Active Comparator|metformin|1500 mg/day of metformin
3114606|NCT01791634|Experimental|proximal open wedge osteotomy with LPS system|Proximal open wedge osteotomy with Low profile plate and screws
3114607|NCT01791634|Active Comparator|proximal wedge osteotomy|Proximal wedge osteotomy procedure
3114608|NCT01791621|Experimental|Elimination/Challenge Diet|Once non-IgE mediated food allergy testing has been administered, study participants will follow food choices according to a pre-specified elimination diet for three weeks (Elimination phase). After the Elimination phase, study participants will introduce one food every three days (Challenge phase)and monitor their symptoms. Eight different foods will be introduced in the Challenge phase of the study.
3114609|NCT01791608|Active Comparator|Zinc sulphate|Preschool children healthy enrolled in FAN Foundation of Medellin, which will be supplied with zinc sulphate
3114610|NCT01791608|Experimental|Zinc Amino Acid Chelate|Preschool children healthy enrolled in FAN Foundation of Medellin , which will be supplied with zinc amino acid chelate
3114611|NCT01791608|Placebo Comparator|Milk without fortification|Milk without zinc
3114612|NCT01791556|No Intervention|Standard of Care|clinical (World Health Organization staging) and immunological (CD4 count) monitoring every 6 months with confirmatory or targeted viral load monitoring based upon Kenya Ministry of Health and World Health Organization guidelines
3114613|NCT01791556|Experimental|HIV-1 viral load testing|viral load in addition to clinical (World Health Organization staging) and immunological (CD4 count) monitoring every 6 months
3114614|NCT01791543|Experimental|Intramural Needle Catheter Ablation|Ablation of Ventricular Tachycardia with Intramural Needle Ablation Catheter
3114615|NCT01791530||MV>48h|10-20 consecutive admissions with a predictive duration of intubation and mechanical ventilation > 48h.
3114616|NCT01791517|Other|Lens A (senofilcon A)|Subjects randomized to Lens A will be further randomized to 1 of 12 unique solution sequences; each subject will receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
3114617|NCT01791517|Other|Lens B (galyfilcon A)|Subjects randomized to Lens B will be further randomized to 1 of 12 unique solution sequences; each subject will receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
3114618|NCT01791517|Other|Lens C (etafilcon A)|Subjects randomized to Lens C will be further randomized to 1 of 12 unique solution sequences; each subject will l receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
3114619|NCT01791504|Experimental|TissuGlu Surgical Adhesive|Standard wound closure techniques plus TissuGlu and no drains.
3114620|NCT01791504|No Intervention|Control - Standard of Care|Standard wound closure techniques with drains.
3114621|NCT01791491|Experimental|Belatacept|
3114622|NCT01791478|Experimental|Treatment (PI3K inhibitor BYL719, letrozole)|Patients receive PI3K inhibitor BYL719 PO QD and letrozole PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3114623|NCT01791465|Experimental|Bydureon treatment|Treatment for 16 weeks with extended-release Exenatide (Bydureon)
3114624|NCT01791452||NAFLD|
3114625|NCT01791439|Experimental|Lidocaine|Patients in this arm will have gauze soaked with lidocaine applied to the peritonsillar pillars.
3114626|NCT01791439|Placebo Comparator|Saline|Application of saline to the glossopharyngeal nerve.
3114627|NCT01791426|Experimental|Artelac Rebalance|Artelac Rebalance ophthalmic solution contains 0.15% hyaluronic acid, is unpreserved and presented in single dose units with a fill volume of 0.5 mL.
3114628|NCT01791426|Active Comparator|Vismed|Vismed ophthalmic solution, contains 0.18% sodium hyaluronate, is unpreserved and presented in single dose units with a fill volume of 0.3 mL.
3114629|NCT01791413|Active Comparator|depot medroxyprogesterone acetate|
3114630|NCT01791413|No Intervention|No depot medroxyprogesterone acetate|
3114631|NCT01791400|Other|sumatriptan|Patients who underwent 6 mg sumatriptan subcutaneous one time
3114632|NCT01791400|Other|Metoclopramide|Patients who underwent 20 mg Metoclopramide intravenous one time
3114633|NCT01791387|Experimental|Dovitinib|Dovitinib 500 mg taken orally once daily 5 days on / 2 days off, until disease progression
3114634|NCT01791374|Experimental|Rilotumumab Monotherapy|Cohort 1A: Rilotumumab 10 mg/kg IV Q2W Cohort 1B: Rilotumumab 20 mg/kg IV Q2W Cohort 1C (if needed): Rilotumumab 15 mg/kg IV Q2W
3114635|NCT01791374|Experimental|Rilotumumab plus CX|Cohort 2A: Rilotumumab 15 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W Cohort 2B (if needed): Rilotumumab 10 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W
3114636|NCT01791361||Round 1|50 oncologists participate in Round 1. At least 3 medical records will be reviewed per oncologist
3114637|NCT01791361||Round 2|50 oncologists will participate in Round 2. At least 3 medical records will be reviewed per oncologist. Round 2 will occur approximately 12 months after Round 1
3114638|NCT01791361||Round 3|50 oncologists will participate in Round 3. At least 3 medical records will be reviewed per oncologist. Round 3 will occur approximately 24 months after Round 1
3114639|NCT01791348|Other|d2 test of attention|
3114640|NCT01791335||COPD patients receiving NIV|
3114672|NCT01791101|Experimental|Eltrombopag|Eltrombopag 50 mg/daily.
3115074|NCT01788150|Active Comparator|Medtronic Resolute Integrity Drug-Eluting Stent|Coronary Stenting
3114641|NCT01791309|Experimental|combination panitumumab and vemurafenib|This will be a pilot study of the combination panitumumab and vemurafenib in patients with metastatic colorectal cancer with a BRAF V600E mutation. Patients participating in this study must have BRAF V600E mutated metastatic colorectal cancer and not previously received treatment with an anti-EGFR targeting antibody (cetuximab or panitumumab).
3114642|NCT01791296|Experimental|Dexmedetomidine|Dexmedetomidine 0.2-0.7 mcg/kg/hr from 21:30 to 6:00
3114643|NCT01791296|Placebo Comparator|Placebo|Normal Saline 0.2-0.7 mcg/kg/hr from 21:30 to 6:00
3114644|NCT01791283||Healthy volunteers|Healthy volounteers with no previous medical history, age between 20-40. Both male and female. Subjects are provided extensive information about the study and the obligations and expectations included. All subjects sign a witnessed informed consent before inclusion.
3114645|NCT01791270||OSA versus Control subjects.|sleep apnea-hypopnea syndrome and control
3114646|NCT01791270||OSA patients before and after treatment, CPAP|Continuous positive pressure CPAP
3114647|NCT01791257||SAH with DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
3114648|NCT01791257||SAH without DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
3114649|NCT01791257||Neurological healthy controls|12 patients (ASA 1) undergoing spinal anesthesia for orthopedic surgery have 2 ml of cerebrospinal fluid drawn preceding injection of local analgetic.
3114650|NCT01791244|Active Comparator|Technical support for the RebiSmart™ device|Subjects will be administered Rebif® by the RebiSmart™ device at a dose of either 22 or 44 microgram (mcg) subcutaneously (SC) 3 times a week in accordance to the summary of product characteristics (SPC) along with technical support for RebiSmart.
3114651|NCT01791244|Experimental|Subject support program (MinSupport Plus)|Subjects will be administered Rebif® by the RebiSmart™ device at a dose of either 22 or 44 mcg SC 3 times a week in accordance to the SPC along with subject support program MinSupport Plus which includes technical support for RebiSmart™ device, personal coaching regarding treatment and understanding of the disease, lifestyle guide and web support.
3114652|NCT01791231|Experimental|Radiolabeled 14C-canagliflozin|Each volunteer will receive a single dose of radiolabelled 14C-canagliflozin (14C-JNJ-28431754) on Day 1.
3114653|NCT01791218|Experimental|CABG, AVR or CABG+AVR and PVI|Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis (AVR) or combination (CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation (PVI) in CBP prior to occlusion and CABG
3114654|NCT01791218|Active Comparator|CABG, AVR or CABG+AVR|Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis(AVR) or combination(CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. No operative procedures for the treatment of atrial fibrillation
3114655|NCT01791205||Monotherapy|Eligible participants who received any biologic drug as a monotherapy in the 12 months prior to the study entry will be observed for Phase I. Participants who were enrolled in Phase I and received tocilizumab (TCZ) as a monotherapy will be observed for 18 months from the first infusion of TCZ in Phase II, where TCZ was prescribed according to the approved product information, local treatment guidelines and/or routine clinical practice.
3114656|NCT01791205||Combination Therapy|Eligible participants who received any biologic drug in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the 12 months prior to study entry will be observed for Phase I.
3114657|NCT01791192|Experimental|FTY720|Fingolimod
3114658|NCT01791192|Active Comparator|Oral Corticosteroid|Oral Corticosteroid
3114659|NCT01791179|Experimental|Substance Abuse Treatment Group|
3114660|NCT01791166|Experimental|Pulmonary transplant|
3114661|NCT01791153|Experimental|Part 1: Tocilizumab qw + 26 weeks prednisone taper|Participants will receive tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
3114662|NCT01791153|Experimental|Part 1: Tocilizumab q2w + 26 weeks prednisone taper|Participants will receive tocilizumab at a dose of 162 mg as SC injection q2w (and tocilizumab placebo q2w starting from Week 2) up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
3114663|NCT01791153|Placebo Comparator|Part 1: Placebo + 26 weeks prednisone taper|Participants will receive tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
3114664|NCT01791153|Placebo Comparator|Part 1: Placebo + 52 weeks prednisone taper|Participants will receive tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to a protocol-defined schedule. Participants will receive prednisone tapering oral daily doses for 52 weeks.
3114665|NCT01791153|Experimental|Part 2: Open-Label Tocilizumab qw|Participants without sustained remission at Week 52 will receive open-label tocilizumab at a dose of 162 mg as SC injection qw and/or corticosteroids and/or methotrexate at the discretion of the investigator for a maximum of 104 weeks.
3114666|NCT01791140||Cohort|
3114667|NCT01791127||Pacemaker Therapy|Patients with a market-released BIOTRONIK pacemaker system including one or two Siello S leads.
3114668|NCT01791114|Experimental|Cold water consumption|Subjects will participate in two trials as part of this protocol: a) cold water (4 °C) consumption and b) tepid (36 °C) water consumption
3114669|NCT01791114|Experimental|Meal consumption|Subjects will participate in two trials as part of this protocol: a) High calorie meal consumption and two weeks later b) no meal consumption.
3114670|NCT01791114|Experimental|Cold exposure|Participants will complete three studies: a) cold exposure study (above their individually determined shivering threshold ~ 16°C); b) Cold exposure plus 0.5mg/kg up to 40mg propranolol at the beginning of the metabolic study and again after 4-6 hrs; c) thermoneutral conditions (26 - 28°C).
3114673|NCT01791088|Experimental|Treatment (sirolimus)|Patients receive sirolimus PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3114674|NCT01791075|Active Comparator|Tan Endoglide|Patients assigned to this arm will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide.
3114675|NCT01791075|Active Comparator|Endosaver/serter|Patients assigned to this arm will have their endothelial donor graft injected into the anterior chamber using the Endosaver/serter injector.
3114676|NCT01791062|Experimental|HYTOP®|
3114677|NCT01791049|Experimental|Active|Single escalating doses of TD-1607, administered intravenously
3114678|NCT01791049|Placebo Comparator|Placebo|Placebo
3114679|NCT01791036|Experimental|Adductor Canal Block Group|Adductor Canal Block
3114680|NCT01791036|Active Comparator|Femoral Nerve Block Group|Femoral Nerve Block
3114681|NCT01791023|Experimental|Physical exercise|Physical exercise
3114682|NCT01791010|Experimental|Inspiratory muscle training|Inspiratory muscle training for 8 weeks using a device that provides a linear resistance in the inspiratory phase. 7 days a week. 8 sets of 2 minutes twice a day. Intensity was at 40% of Maximal Inspiratory Pressure.
3114683|NCT01791010|Sham Comparator|Training sham|Training sham for 8 weeks using a device without provides resistance. 7 days a week. 8 sets of 2 minutes twice a day. Intensity was canceled.
3114684|NCT01790997|Experimental|Treatment I|1 tablet of DLBS1033 490 mg thrice daily, after meal
3114685|NCT01790997|Active Comparator|Treatment II|1 tablet of aspirin 80 mg once daily, after meal
3114686|NCT01790997|Active Comparator|Treatment III|1 tablet of clopidogrel 75 mg once daily, after meal
3114687|NCT01790984|Experimental|High sugar low starch diet|A high sugar, low starch diet was provided by the exchange of two thirds of the participants daily intake of carbohydrate. This was achieved by exchanging foods with low sugar to starch content, with foods containing a high sugar to starch content to reach a target ratio of starch to sugar of 1:1.2
3114688|NCT01790984|Experimental|Low sugar high starch diet|A high sugar, low starch diet was provided by the exchange of two thirds of the participants daily intake of carbohydrate. This was achieved by exchanging foods with a high sugar to starch content, with foods containing a low sugar to starch content to reach a target ratio of starch to sugar of 5:1
3114689|NCT01790971|Active Comparator|Intrathecal morphine|100μg of morphine will be added to the intrathecal mixture.
3114690|NCT01790971|Active Comparator|No Intrathecal morphine|Morphine will not be added to the intrathecal mixture.
3114691|NCT01790945||No treatment Study|Population of subjects will have been diagnosed with mild NPDR, Moderate NPDR, Severe NPDR, PDR and DME
3114692|NCT01790932|Experimental|BKM120 Treatment Arm|100 mg capsule for oral use, taken once daily
3114693|NCT01790919|Experimental|Cognitive Therapy plus Cognitive Support|Cognitive therapy for depression with cognitive support added
3114694|NCT01790919|Active Comparator|Cognitive therapy|Cognitive therapy for depression
3114695|NCT01790906|Active Comparator|RSD+Conventional therapy|We will recruit 100 randomised CHF patients who meet the inclusion criteria.First undergo renal artery angiography procedure to confirm anatomy.If renal artery meet the inclusion criteria,give the renal sympathetic denervation.At the same time, we will use conventional therapy to protect cardiac function.then we will conduct a clinic follow-up and a telephone follow-up.
3114696|NCT01790906|Placebo Comparator|Conventional therapy|We also will recruit 100 randomised CHF patients who meet the inclusion criteria.there are no significant differences in age,gender,race,past medical history,personal history and so on between the two groups.In this group we will use therapy just like the RSD+Conventional therapy group.we will conduct a clinic and a telephone follow-up.
3114697|NCT01790893|Experimental|intravitreal aflibercept injection|Group A -Monthly intravitreal aflibercept injection for 3 months (Baseline, Months 1 and 2), then mandatory every 2 months intravitreal aflibercept injection (Months 4,6, 8 and 10)for 12 months. Monthly visits with evaluations for as needed intravitreal aflibercept injection.
3114698|NCT01790893|Experimental|intravitreal aflibercept|Group B- One intravitreal aflibercept injection at Baseline, then monthly visits with evaluations for as needed dosing of intravitreal aflibercept injection for 12 months.
3114699|NCT01790880|Active Comparator|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system, for 90 minutes per day, 6 days per week for 6 weeks.
3114700|NCT01790880|Experimental|ORLA + Writing|"Practice on ORLA + writing computer program, 90 minutes per day, 6 days per week, for 6 weeks."
3114701|NCT01790854|Experimental|Prasugrel dose 5 mg/day|225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 5 mg/day of prasugrel for 12 months
3114702|NCT01790854|Active Comparator|Prasugrel dose 10 mg/day|225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 10 mg/day of prasugrel for 12 months
3114703|NCT01790841||ICD system with DF4 connection|Iforia/Ilesto ICD with DF4 connection and Linox smart DF4 lead/ Protego
3114704|NCT01790841||ICD system with DF-1 connection|Ilesto/Iforia ICD with DF-1 connection
3114705|NCT01790828||Xyntha group|Xyntha will be administered according to physician's discretion.
3114706|NCT01790802|Experimental|Active laser|Twelve 2RT nanosecond laser shots in two arcs of 6 shots superiorly and 6 shots inferiorly, inside the retinal vascular arcades at an approximate distance from the fovea of 3000 microns, with approximately one laser spot diameter between them.
3114707|NCT01790802|Sham Comparator|Sham laser procedure|The maximum illumination button on hte 2RT laser will be briefly pressed by the operating physician at each of the 12 locations where and when the laser would normally be applied. The laser remains in standby mode preventing accidental laser firing.
3114708|NCT01790789|Experimental|Stress reduction program|
3114709|NCT01790789|Other|Attention control|
3114710|NCT01790776|Active Comparator|Conventional urethrography|Current golden standard.
3114711|NCT01790776|Experimental|Sono-urethrography|Experimental urethrography, which could be followed by conventional urethrography if the results are inconclusive.
3114712|NCT01790763|Active Comparator|Keramatrix|Keramatrix
3114713|NCT01790763|Active Comparator|Mepilex|Mepilex
3114784|NCT01790321|Placebo Comparator|Filtered water|Pump water purified by the LSF-filtering device
3114785|NCT01790321|Experimental|Zinc water|Pump water purified and zinc-fortified by the LSF-filtering device
3114714|NCT01790750|Other|PES first, then FFES|A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
3114715|NCT01790737|Active Comparator|A|Cyclophosphamide plus filgrastim
3114716|NCT01790737|Active Comparator|B|Filgrastim
3114717|NCT01790724|Experimental|Walking exercise|Participants will be instructed in safe walking exercise. They will participate in an eight week, tapered, on-site program. Participants will also attend group workshops where they will learn self-regulatory skills such as goal-setting, self-monitoring, barrier trouble-shooting, rewarding, and relapse prevention and recovery.
3114718|NCT01790724|Active Comparator|Metabolic health education|Participants will complete an eight-week online metabolic health education course. Topics will include glucose control, insulin, weight management, nutrition, physical activity, eye/kidney/foot health, stress reduction, and doctor-patient communication.
3114719|NCT01790711|Experimental|FMT by endoscopy|Once, fresh or frozen bacteria
3114720|NCT01790685|Other|CRVO|Central Retinal Vein Occlusion
3114721|NCT01790685|Other|BRVO|Branch Retinal Vein Occlusion
3114722|NCT01790672|Placebo Comparator|Water|Lemon-flavored water. 293 ml in pilot A, 147 ml in pilot B, 235 ml in pilot C, 147 ml in the definitive study.
3114723|NCT01790672|Active Comparator|Alcoholized wine|"Wine 13º in pilot A (293 ml), B (147 ml) and the definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and 15 g of ethanol in the definitive study.~Wine 8º in pilot C (235 ml). Corresponding to 15 g of ethanol."
3114724|NCT01790672|Placebo Comparator|De-alcoholized wine|Wine 0º. Pilot A: 293ml; pilot B: 147 ml; pilot C: 235 ml; definitive study: 147 ml. Corresponding to 0 g of ethanol.
3114725|NCT01790672|Active Comparator|Ethanol|"Ethanol 13º in pilot A (293 ml), B (147 ml) and definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and in the definitive study.~Ethanol 8º in pilot C (235 ml). Corresponding to 15 g of ethanol.~Ethanol was administered as a single dose of Vodka Absolut (40º) diluted in lemon-flavored water."
3114726|NCT01790659|Experimental|WR 279,396|(Paromomycin and Gentamicin Topical Cream)
3114727|NCT01790659|Experimental|Paromomycin|Paromomycin alone
3114728|NCT01790646||patients undergoing general anesthesia|every elective patient undergoing general anesthesia for neurosurgical procedures with endotracheal intubation
3114729|NCT01790633|Active Comparator|Standard testing with ELISA|HBV, HCV, and HIV infection status determined by enzyme-linked immuno-assay (ELISA).
3114730|NCT01790633|Experimental|Rapid testing|HBV, HCV, and HIV infection status determined by a rapid test
3114731|NCT01790620|Experimental|CVVHD-ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVHD with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVHD. No citrate anticoagulation will be used.
3114732|NCT01790620|Active Comparator|CVVH-ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVH with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVH. No citrate anticoagulation will be used.
3114733|NCT01790607|Experimental|Subjects with moderate chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
3114734|NCT01790607|Experimental|Healthy subjects matched to moderate hepatic impaired subjects|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
3114735|NCT01790607|Experimental|Subjects with mild chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
3114736|NCT01790607|Experimental|Healthy subjects matched to mild hepatic impaired subjects|Single IV bolus of NO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
3114737|NCT01790607|Experimental|Subjects with severe chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
3114738|NCT01790594|Active Comparator|Immunosuppression without Belatacept|"Induction: 5 day course of methylprednisolone or equivalent;~Induction: Anti-thymocyte Globulin (Rabbit);~Maintenance Immunosuppression: Tacrolimus (or generic). The site investigator will identify a starting tacrolimus dose at his or her discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. Tacrolimus dosing will be initiated on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed, then adjusted to target trough levels of 8-12 ng/ml during the first 24 weeks post-transplant, then adjusted to target trough levels of 5-8 ng/ml thereafter.~Maintenance Immunosuppression: Mycophenolate mofetil (or Myfortic (mycophenolate sodium), or generic)."
3114739|NCT01790594|Experimental|Immunosuppression Including Belatacept|"Induction: 5 day course of methylprednisolone or equivalent;~Induction: Anti-thymocyte Globulin (Rabbit);~Maintenance Immunosuppression: Belatacept~Maintenance Immunosuppression: Tacrolimus (or generic)- The site investigator will identify a starting tacrolimus dose at his or her discretion, in order to achieve the target trough levels no later than 5 days post-transplantation. Tacrolimus dosing will be initiated on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed. The dosage will be adjusted to achieve the following therapeutic trough levels: 5-8 ng/ml during the first 24 weeks post-transplant and then 3-5 ng/ml until day 280 (week 40). Subjects may be withdrawn if they meet all the criteria defined below.~Maintenance Immunosuppression: Mycophenolate mofetil (or Myfortic (mycophenolate sodium), or generic)."
3114740|NCT01790581|Active Comparator|Balance Training|
3114741|NCT01790581|Experimental|Balance Training w/ STARS|
3114742|NCT01790568|Experimental|Vorinostat|Vorinostat, in combination with standard of care medications tacrolimus and methotrexate, for GVHD prophylaxis after unrelated donor stem cell transplant.
3114743|NCT01790555|Experimental|Namisol|The study medication is given from the day before surgery (day -1: 5 mg in the afternoon and in the evening) up to the fifth day after surgery (day 0 to +5: 5 mg four times daily).
3114786|NCT01790308|Active Comparator|CSII|continuous subcutaneous insulin infusion for 2-4 weeks
3114744|NCT01790555|Other|Diazepam/Placebo|"The study medication is given from the day before surgery (day -1: 5 mg in the afternoon and in the evening) up to the fifth day after surgery (day 0 to +5: 5 mg four times daily).~Before surgery, diazepam is used as an active comparator, to aid in blinding. After surgery, an inactive placebo is used as an inactive comparator."
3114745|NCT01790542|Other|A|Iron fortified cereal
3114746|NCT01790542|Other|B|Iron fortified cereal with fruit
3114747|NCT01790542|Other|C|Meat
3114748|NCT01790529|Experimental|Early Prophylaxis|Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)
3114749|NCT01790529|Active Comparator|Late Prophylaxis|Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)
3114750|NCT01790516|Experimental|Cisplatin|Cisplatin
3114751|NCT01790516|Experimental|Cetuximab|cetuximab
3114752|NCT01790503|Experimental|Phase 1b dose escalation - 800mg/day PLX3397 cohort|800mg/day PLX3397, Radiation Therapy, and Temozolomide
3114753|NCT01790503|Experimental|Phase 1b dose escalation - 1000mg/day PLX3397|1000mg/day PLX3397, Radiation Therapy, and Temozolomide
3114754|NCT01790503|Experimental|Phase 2 - Recommended phase 2 dose of PLX3397|Recommended phase 2 dose of PLX3397, Radiation therapy, and Temozolomide
3114755|NCT01790503|Experimental|Phase 1b dose escalation - 600 mg/day PLX3397 cohort|600 mg/day PLX3397, Radiation Therapy, and Temozolomide
3114756|NCT01790490|Experimental|K1|Ketamine 0.41 mg/kg infused over 52 min (K1)
3114757|NCT01790490|Experimental|K2|Ketamine 0.71 mg/kg infused over 52 min (K2)
3114758|NCT01790490|Experimental|LZP|Lorazepam 2 mg infused over 52 minutes (LZP)
3114759|NCT01790477|Experimental|Auricular Acupuncture|Use of auricular acupuncture in bilateral ears
3114760|NCT01790477|No Intervention|Control|
3114761|NCT01790464|Placebo Comparator|NS gauze|Standard airway anesthesia with 20 ml of aerosolized 2% lidocaine and peritonsillar instillation of gauze soaked in normal saline (Control Group)
3114762|NCT01790464|Active Comparator|Lidocaine gauze|20 ml of aerosolized 2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
3114763|NCT01790451|Active Comparator|peripheral ablation|an ablation of the peripheral area of the prostate
3114764|NCT01790451|Active Comparator|More central ablation|an ablation, more centrally, in proximity of the urethra
3114765|NCT01790438|Experimental|LY2605541|Administered by subcutaneous (SC) injection once daily in the morning or at bedtime. Initial dose is 10 units (or less for some of the participants in Korea) and is adjusted weekly based on Fasting Blood Glucose (FBG). LY2605541 will be given alone or in combination with up to 3 pre-study oral antihyperglycemic medications [OAM(s)] whose use is not excluded in combination with insulin. Treatment may last up to 26 weeks.
3114766|NCT01790438|Active Comparator|Human Insulin NPH|Administered by SC injection once daily at bedtime. Initial dose is 10 units (or less for some of the participants in Korea) and is adjusted weekly based on FBG. Human insulin NPH will be used alone or in combination with up to 3 pre-study OAM(s) whose use is not excluded in combination with insulin. Treatment may last up to 26 weeks. Some participants who are unable to achieve glycemic control after at least 12 weeks of treatment with a single injection of NPH may be asked to add a second injection prior to the morning meal.
3114767|NCT01790425|Experimental|water colonoscopy|The water (study) method: Warm water (body temperature) will be infused into colon to open the lumen for water infusion colonoscopy. Higher rate of complete colonoscopy will be achieved.
3114768|NCT01790425|Active Comparator|Air Colonoscopy|The air (conventional) method: Air is pumped gently (insufflation) into the colon will be used to open the inside space of the colon and aid in colonoscope insertion
3114769|NCT01790412|Experimental|Exercise group|"Three sessions per week:~Supervised exercise program"
3114770|NCT01790412|No Intervention|Control|Sedentary pregnant women
3114771|NCT01790399|Experimental|Identification of sentinel node(s)|
3114772|NCT01790386||Surgical Patients Group|Patients undergoing cardiovascular surgery and cardiology procedures
3114773|NCT01790386||Reference Ranges Group|Healthy volunteer subjects for determination of normal hemostasis parameter results
3114774|NCT01790373|Experimental|Suubi+Adherence|"Suubi+Adherence intervention arm provides:~Matched savings accounts/child development accounts (CDAs) for the adolescents held in a local bank.~Financial education and workshops on asset-building, future planning, and protection from risks~Mentorship from a young adult/near-peer~Family-based microenterprise development training~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
3114775|NCT01790373|Active Comparator|Bolstered Standard of Care|"Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
3114776|NCT01790360|Active Comparator|Patient Navigation (PN)|Behavioral Intervention: 'Patient Navigation (PN) Intervention' participants will receive support from navigators in choosing a provider and remembering to attend appointments
3114777|NCT01790360|Experimental|Financial Incentives (FI)|Behavioral Intervention: 'Financial Incentives (FI) Intervention' participants will receive gift cards and money for attending clinic visits
3114778|NCT01790347|Experimental|Exercise group|
3114779|NCT01790347|No Intervention|Control group|Sedentary pregnant women
3114780|NCT01790334||Spontenous Ventilation (Group S)|ultrasonography of Right internal jugular vein
3114781|NCT01790334||Pressure control Ventilation (Group P)|ultrasonography of Right internal jugular vein
3114782|NCT01790334||Volume control ventilation (Group V)|ultrasonography of Right internal jugular vein
3114783|NCT01790321|No Intervention|Pump water|Untreated pump water (pump water recognised as improved water source by WHO)
3114787|NCT01790308|Active Comparator|Liraglutide|continuous subcutaneous insulin infusion for 2-4 weeks combined with combined with Liraglutide 0.6mg/d for 2-4 weeks and 1.2mg/d for next 9 weeks
3114788|NCT01790295|Experimental|Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)|Ruxolitinib (INC424) tablets will be started 62 days (day -67) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
3114789|NCT01790282|Experimental|estradiole - progesterone arm|Cases are given estradiole valerate 2mg 3 times /day from day of ovum pick up until the time of pregnancy test two weeks together with daily IM injection of 100 progesterone starting . Single intramuscular 0.1 mg decapeptyl are given on day of transfer
3114790|NCT01790282|Active Comparator|Progesterone only arm|Patient are given 100 mg progesterone daily starting on day of pickup plus single dose of decapeptyl 0.1 mg on day of embryo transfer
3114791|NCT01790269||fingolimod treated patients|Indication for on-label treatment with fingolimod (Gilenya®) according to the current approval
3114792|NCT01790256|Active Comparator|Cereve Sleep System at 14-16 degrees C.|Active
3114793|NCT01790256|Active Comparator|Cereve Sleep System at 30 degrees C|Active
3114794|NCT01790243|Experimental|Lutonix Drug Coated Balloon|Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
3114795|NCT01790230|No Intervention|Standard of Care|Standard of Care Arm - subjects treated by routine manner
3114796|NCT01790230|Experimental|LifeSeal™ Kit|LifeSeal™ Kit Arm - subjects treated with the LifeSeal™ Kit device + Standard of Care treatment
3114797|NCT01790217||Cohort|
3114798|NCT01790204|Experimental|Watercress Juice|The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
3114799|NCT01790191|Experimental|RE group|Repeated consumption of artichoke purée. This group was exposed to basic artichoke puree from Exposure 1 to 10 (E1 to E10)
3114800|NCT01790191|Active Comparator|FFL group|Repeated consumption of artichoke purée. This group (Flavor-flavor learning group) was exposed to sweet artichoke puree from Exposure 1 to 10 (E1 to E10).
3114801|NCT01790191|Active Comparator|FNL group|Repeated consumption of artichoke purée. This group (Flavor-nutrient learning group) was exposed to fat, energy-dense artichoke puree from Exposure 1 to 10 (E1 to E10).
3114802|NCT01790178|Experimental|Ultrasound Guided Biopsy|Ultrasound guided biopsy will be used in all patients.
3114803|NCT01790178|No Intervention|Non-Ultrasound Guided Group|The control group will have non-ultrasound guided biopsies performed, which is the current standard of care.
3114804|NCT01790165|Experimental|TDT067|Active treatment
3114805|NCT01790165|Placebo Comparator|Placebo|Placebo
3114806|NCT01790152||Ancillary-Correlative (laboratory biomarker analysis)|Patients complete a diagnostic symptom checklist, undergo a physical exam, echocardiogram, collection of serum for biomarker testing, and a 6 minute walk test, and complete quality of life, family history, physical activity, and smoking questionnaires.
3114807|NCT01790139|No Intervention|Control|Control group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte and fecal/fluid tagging. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte.
3114808|NCT01790139|Experimental|Intervention-Oral Simethicone|Intervention group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte, fecal/fluid tagging, and oral administration of simethicone. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte. As the interventional procedure in this intervention group, 10 mL of simethicone is administered orally immediately following the administration of iohexol.
3114809|NCT01790126|Active Comparator|ARN-509|ARN-509 Tablets, 240 mg/day administered orally
3114810|NCT01790126|Active Comparator|LHRH agonist + ARN-509|Choice of LHRHa per investigator discretion/site practice guidelines (e.g, Eligard®, Zoladex®, Lupron Depot®, Trelstar®) and ARN-509 Tablets, 240 mg/day administered orally
3114811|NCT01790126|Active Comparator|LHRH agonist|Choice of LHRHa per investigator discretion/site practice guidelines (e.g., Eligard®, Zoladex®, Lupron Depot®, Trelstar®).
3114812|NCT01790113|Active Comparator|Univer™ II|Univers™ II Total Shoulder Replacement
3114813|NCT01790113|Experimental|Eclipse™|Eclipse™ Total Shoulder Replacement
3114814|NCT01790100|Experimental|VX-135 low dose in combination with ribavirin|12 weeks of VX-135 in combination with ribavirin
3114815|NCT01790100|Experimental|VX-135 high dose in combination with ribavirin|
3114816|NCT01790087|Experimental|ANX-188 Therapeutic dose level|IV administration. 100 mg/kg for one hour followed by 30 mg/kg/hour for five hours
3114817|NCT01790087|Experimental|ANX-188 Supratherapeutic dose|IV administration. 300 mg/kg for one hour followed by 200 mg/kg/hr for five hours
3114818|NCT01790087|Placebo Comparator|Saline|IV administration. Six hour infusion.
3114819|NCT01790087|Active Comparator|Moxifloxacin|Oral tablet. 400 mg.
3114820|NCT01790074|Experimental|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
3114821|NCT01790074|Placebo Comparator|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
3114822|NCT01790061|Experimental|Standardized FMT|endoscopy Tubing Once or repeat
3114824|NCT01790048|Experimental|Whey permeate RUSF|75 kcal/kg/day (314 k Joules (kJ)/kg/day) of whey RUSF. Whey RUSF contains whey permeate, Whey Permeate (WPC) 80 (contains at least 80% protein), peanut paste, sugar, soy oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier. Whey permeate RUSF will be locally produced and will undergo quality assurance and safety testing for aflatoxin and microbial contamination at the Malawi Bureau of Standards and Eurofins Scientific Inc., Des Moines, Iowa, USA.
3114825|NCT01790048|Active Comparator|Soy Protein RUSF|75 kcal/kg/day (314 kJ/kg/day) of whey RUSF. Soy RUSF contains extruded soy flour, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate (Roche, Mumbai, India). Soy RUSF has no protein from animal sources. Soy RUSF will be locally produced and will undergo quality assurance and safety testing for aflatoxin and microbial contamination at the Malawi Bureau of Standards and Eurofins Scientific Inc., Des Moines, Iowa, USA.
3114826|NCT01790035|Experimental|LGG|LGG (containing 10^10 viable bacteria) taken by mouth twice daily beginning at baseline (but starting at least 3 days prior to the start of radiation) and continue during RT and for the 2 weeks following RT.
3114827|NCT01790035|Experimental|Placebo|Placebo taken by mouth twice daily beginning at baseline (but starting at least 3 days prior to the start of radiation) and continue during RT and for the 2 weeks following RT.
3114828|NCT01790035|No Intervention|No intervention|Patients who prefer not to receive LGG will not be randomized and will receive standard of care RT. These patients will serve as a non-intervention comparator cohort to the first 20 patients and will have specimens collected but will not receive the placebo.
3114829|NCT01790022|Experimental|Methylprednisolone 500 mg|Methylprednisolone 500 mg administered intravenously at baseline
3114830|NCT01790009|Active Comparator|Flavanol Rich drink|Flavanol-rich drink containing 800 mg/75 Kg of Body Weight (BW)
3114831|NCT01790009|Active Comparator|Flavanol rich drink|Flavanol Intervention drink 400 mg/75 Kg BW
3114832|NCT01790009|Active Comparator|Acetaminophen|2 tabletsx500 mg
3114833|NCT01789996|Active Comparator|Alternative six minute walk test|"Subjects will be given the following instructions~walk as fast as they can in 6 minutes~walk as normally as they can in 6 minutes~walk leisurely as they can in 6 minutes. Pts will serve as their own controls."
3114834|NCT01789996|Placebo Comparator|Standard six minute walk test|"Subjects will be given the following instruction~1. walk as far as they can in 6 minutes"
3114835|NCT01789983||Breast Cancer Patients 60+|Breast Cancer Patients age 60 and older who have histologically confirmed stage I, II or III disease.
3114836|NCT01789983||Lung Cancer Patients 60+|Lung Cancer Patients age 60 and above who have stage I, II or III disease
3114837|NCT01789983||Colon Cancer Patients 60+|Colon cancer patients age 60 and above who have stage II or III disease.
3114838|NCT01789970|Placebo Comparator|Placebo|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the treatment period, participants were administered placebo tablets twice a day that matched the dosage deemed successful for managing their pain during the titration period. A step-wise, double-blind schedule to tamper off active drug was implemented during the first 2 weeks of the 12-week, double-blind, placebo-controlled treatment period to reduce the risk of withdrawal effects in participants randomly assigned to placebo.
3114839|NCT01789970|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the 12-week, double-blind, placebo-controlled treatment period, participants randomly assigned to hydrocodone ER were administered tablets twice a day at the dosage deemed successful for managing their pain during the titration period.
3114840|NCT01789957|Experimental|Open-label AC2993|
3114841|NCT01789944|Experimental|Provide Treatment|Peers provide treatment to 2nd generation following receipt of the intervention.
3114842|NCT01789944|Experimental|Treatment Only|Peers receive treatment and return for a 6-month follow-up
3114843|NCT01789931|Experimental|Research arm|"The participants will undergo an examination day in which they will complete VO2max test to evaluate their aerobic fitness. Afterwards they'll undergo 3 heat tolerance test (HTT) days: without CB protective clothing, with CB protective clothing, and with work clothes. During the tests, a Lifebeam sensor will be attached to their skin."
3114844|NCT01789918|Experimental|Percutaneous renal denervation|PARADISE percutaneous renal denervation
3114845|NCT01789905||Tigecycline (Tygacil)|Subjects who are treated with tigecycline
3114846|NCT01789892|Experimental|Diagnostic (methylprednisolone and FDG PET/CT scan)|Within 1-14 days of undergoing standard FDG PET/CT scan, patients receive methylprednisolone IV and then undergo a second FDG PET/CT scan.
3114847|NCT01789879|Active Comparator|Control group (no current ART)|Levonorgestrel subdermal implant in subjects not yet receiving ART (control group)
3114848|NCT01789879|Active Comparator|NVP-based ART group|Levonorgestrel subdermal implant in subjects receiving nevirapine-based ART
3114849|NCT01789879|Active Comparator|EFV-based ART group|Levonorgestrel subdermal implant in subjects receiving efavirenz-based ART
3114850|NCT01789853|Experimental|Intensive Walking|High intensity walking training in variable context for 8 weeks
3114851|NCT01789853|Active Comparator|Conventional Physical Therapy|Regular physical therapy for 8 weeks
3114852|NCT01789840|Experimental|Prostate artery emoblization (PAE)|Prostate artery embolization using Embosphere Microspheres
3114853|NCT01789840|Active Comparator|Transurethral resection of the prostate (TURP)|Transurethral Resection of the Prostate (TURP)
3114854|NCT01789827|Experimental|Cohort I (scintigraphy prior to immunotherapy and 12 weeks)|Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab or pembrolizumab and at 12 weeks.
3114855|NCT01789827|Experimental|Cohort II (scintograpy prior to immunotherapy, 3-4, 12 weeks)|Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab or pembrolizumab, at 3-4 weeks, and at 12 weeks.
3114856|NCT01789814|Active Comparator|Prasugrel|Prasugrel oral loading dose of 60 mg administered preceding cardiac intervention
3114857|NCT01789814|Active Comparator|Clopidogrel|Clopidogrel oral loading dose of 600 mg administered preceding cardiac intervention
3114858|NCT01789801|Active Comparator|Palpation only|"Patients randomized to this arm will have radial artery puncture via palpation of arteries.~Intervention: RAP palpation only"
3114859|NCT01789801|Experimental|Ultrasound guidance|"Patients randomized to this arm will have radial artery puncture with ultrasound guidance for artery localisation.~Intervention: RAP with ultrasound guidance"
3114860|NCT01789788|Placebo Comparator|Placebo|
3114861|NCT01789788|Experimental|RO6811135|
3114862|NCT01789775|Placebo Comparator|CD07805/47 gel Placebo|Placebo
3114863|NCT01789775|Experimental|CD07805/47 gel|Intervention: Drug: CD07805/47 gel
3114864|NCT01789762|Active Comparator|Historical control arm|Patients transfused with platelet concentrates re-suspended in autologous plasma
3114865|NCT01789762|Active Comparator|Control arm|Patients transfused with platelets prepared in additive solution
3114866|NCT01789762|Experimental|Experimental arm|Patients transfused with platelets treated by pathogen reduction process
3114867|NCT01789749|Active Comparator|No Coagulation Arm|Patients do not receive Snare Tip Soft Coagulation to the edge of the endoscopic resection defect
3114868|NCT01789749|Experimental|Coagulation Arm|Patients to receive Snare Tip Soft Coagulation to the edge of the endoscopic resection defect
3114869|NCT01789736|Experimental|PG286|PG286 Ophthalmic Solution q.d. O.U.
3114870|NCT01789736|Experimental|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5% q.d. O.U.
3114871|NCT01789736|Active Comparator|Travoprost 0.004%|Travoprost 0.004% q.d. O.U.
3114872|NCT01789723|Experimental|Cohort 1: Fusilev - 10 doses|"Fusilev: 5 mg/m2 QID, starting on Day 2 (24 ± 3 hours after Folotyn dose) for a total of 10 doses Day 2: 4 doses Day 3: 4 doses Day 4: 2 doses.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
3114873|NCT01789723|Experimental|Cohort 2: Fusilev - 6 doses|"Fusilev: 5 mg/m2 BID, on Days 2 (24 ± 3 hours after Folotyn dose), 3, and 4.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
3114874|NCT01789723|Experimental|Cohort 3: Fusilev - 4 doses|"5 mg/m2 BID, on Days 2 (24 ± 3 hours after Folotyn dose) and 3.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
3114875|NCT01789723|Experimental|Cohort 4: Fusilev - 2 doses|"5 mg/m2 BID, on Day 2 (24 ± 3 hours after Folotyn dose.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
3114876|NCT01789723|Experimental|Cohort 5: Fusilev - 1 dose|"Fusilev: 5 mg/m2 once on Day 2.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
3114877|NCT01789710|Experimental|Active Contingency Management|All participants are assigned to a single arm, active contingency management. In this arm, participants are provided monetary rewards for remaining abstinent from smoking.
3114878|NCT01789697|Experimental|Receives text messages/emails|Will receive text messages and emails periodically from the surgeon from Day 1 (day after discharge) through day 21.
3114879|NCT01789697|No Intervention|Does not receive text messages/emails|Will not receive text messages and emails periodically from the surgeon from Day 1 (day after discharge) through day 21.
3114880|NCT01789684|Experimental|Active Provider Intervention|Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve 1) appropriate referral of breast cancer patients at risk for HBOC to genetic counseling in the community cancer center setting and 2) pre-surgical referral among newly diagnosed patients. They will also receive the National Comprehensive Cancer Network (NCCN) guidelines and Commission on Cancer definition of qualified genetics professional.
3114881|NCT01789684|No Intervention|Passive Provider Intervention|Participating Sites assigned to the passive intervention cluster will only receive the National Comprehensive Cancer Network (NCCN) guidelines and Commission on Cancer definition of qualified genetics professional.
3114882|NCT01789671|Experimental|Peer Interventionist|Families randomized to this family-based behavioral intervention arm will receive 20 weeks of family-based behavioral pediatric overweight intervention delivered by parents who previously received this treatment (PEER). This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
3114883|NCT01789671|Active Comparator|Professional Interventionist|Families randomized to this family-based behavioral intervention arm will receive 20 weeks of family-based behavioral pediatric overweight intervention delivered by behavioral specialists(PROFESSIONAL). This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
3114884|NCT01789658|Experimental|Cryotherapy|Cryotherapy during conditioning treatment with chemotherapy prior to HSCT
3114885|NCT01789658|No Intervention|Control|Standard oral Care. No Cryotherapy during conditioning treatment prior to HSCT
3114886|NCT01789645|Experimental|Conservative group|The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
3114887|NCT01789645|Active Comparator|Surgical group|The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
3114888|NCT01789619||Extended release tacrolimus (Advagraf®)|
3114889|NCT01789606|Experimental|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|
3114890|NCT01789593|Other|Hypoglycaemia / euglycaemia clamp|
3114891|NCT01789593|Other|Euglycaemia clamp / hypoglycaemia|
3114892|NCT01789580|No Intervention|Control group|The participants play on their preferred online gambling site (experimental gambling session) without gambling moderator.
3114893|NCT01789580|Experimental|Bonus group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : bonus (with different modalities of the moderator).
3114894|NCT01789580|Experimental|Auto-exclusion group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : auto-exclusion.
3114895|NCT01789580|Experimental|Auto- limitation group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : auto- limitation(with different modalities of the moderator).
3114896|NCT01789580|Experimental|Information group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : information (with different modalities of the moderator).
3115254|NCT01786837|Experimental|Treatment|FMS will be administered for 5 weeks
3114898|NCT01789554|Experimental|MLS dispatch for bystander CPR|When an alarm call of a suspected OHCA suspected is received by the EMS dispatch operator a Mobile positioning system (MPS) is activated. The MPS uses the mobile phone network to geographically locate all lay volunteers connected to a tailored mobile phone service called mobile life saver (MLS). The MPS then locates all lay volunteers within a pre defined radius from the suspected OHACA an alerts them with a computer generated voice call and an sms containing data about were about were the suspected OHCA is located. A map is also sent in order to make route finding easy.
3114899|NCT01789554|No Intervention|NO MLS dispatch for bystander CPR|No activation of mobile positioning system to locate and recruit lay responders to nearby OHCAs
3114900|NCT01789541||Atrial fibrillation|Patients with atrial fibrillation undergoing ablation
3114901|NCT01789541||AV-nodal reentry tachycardia|Patients with AV-Nodal Reentry Tachycardia undergoing ablation
3114902|NCT01789528|Experimental|CAZ-AVI or CXL|"Cohort 1: CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) by intravenous infusion given over 2 hours, every 8 hours~Cohort 2: CXL (600 mg ceftaroline fosamil and 600 mg avibactam)"
3114903|NCT01789515||rectal cancer|Low Anterior Resection for Rectal Cancer
3114904|NCT01789502|Active Comparator|Plastic stents|Plastic stents are inserted by ERCP
3114905|NCT01789502|Experimental|Fully covered metal stents|Fully covered metal stents are inserted by ERCP
3114906|NCT01789489|Active Comparator|3 dimensional sonohysterography|3 dimensional sonohysterography
3114907|NCT01789489|Active Comparator|Standard hysteroscopy|Standard hysteroscopy
3114908|NCT01789476|Experimental|CR845|Peripheral kappa opioid receptor agonist
3114909|NCT01789476|Placebo Comparator|Placebo|Matched placebo
3114910|NCT01789463|Active Comparator|Self rehabilitation|Self rehabilitation
3114911|NCT01789463|Experimental|Self rehabilitation plus physiotherapy|Self rehabilitation plus physiotherapy
3114912|NCT01789450|Experimental|Section of Periareolar Dermis|Section of Periareolar Dermis
3114913|NCT01789437|Active Comparator|Dexamethasone Intravitreal Implant|
3114914|NCT01789411||ATHEROREMO-IVUS cohort|Drawing blood samples. Coronary intravascular ultrasound imaging. Coronary near-infrared spectroscopy.
3114915|NCT01789398|Experimental|BF2.649 (pitolisant)|BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules
3114916|NCT01789398|Placebo Comparator|placebo|Placebo of BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules
3114917|NCT01789385|Other|dexmedetomidine|Precedex 200 mcg 2ml
3114918|NCT01789359|Other|anthocyanin-free diet|Maintain anthocyanin-free diet throughout study. Day 1 to day 30, consume daily 250 ml single strength blueberry juice containing 229 mg anthocyanins, taken either as 1 morning dose or 1/3 dose morning, 1/3 mid-day and 1/3 evening. At d 31-38 continue anthocyanin-free diet. On d 39 consume daily dose.
3114919|NCT01789346|Other|532nm KTP laser|Cutera ExcelV 532nm KTP laser
3114920|NCT01789346|Active Comparator|595nm PDL|Cynosure Cynergy 595nm pulsed-dye laser
3114921|NCT01789333|Experimental|9 mw/cm2 at 10 minutes group|30 patients will be treated with UVA light source at 9 mw/cm2 at 10 minutes. Drug: Riboflavin Dose:1 drop every 2 to 3 minutes for 15 to 20 minutes
3114922|NCT01789320|Experimental|triamcinolone acetonide (Triesence®)|TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) in a total volume of 100 uL administered via microneedle directly to the suprachoroidal space (SCS)
3114923|NCT01789307|Active Comparator|corn syrup solids|corn syrup solids oral ingestion
3114924|NCT01789307|Experimental|sucrose|sucrose oral ingestion
3114925|NCT01789294|Experimental|Mesalamine|A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects
3114926|NCT01789294|No Intervention|Observation|A close clinical observation without therapy was taken in control patients, whom parents were alerted to refer immediately if symptoms persisted or get worse.
3114927|NCT01789294|Experimental|DIET|Dietetic avoidance of cow's milk and egg, plus foods eventually detected by skin tests, was prescribed by Pediatric Allergologists
3114928|NCT01789281|Experimental|Everolimus|Patients who are receiving everolimus in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study that has reached its study objectives, are not progressing on the current study treatment as defined by the parent protocol and are unable to access everolimus treatment outside of a clinical trial will be allowed to enroll. If patients are receiving treatment of everolimus in combination with other approved therapies, they can participate in the roll-over study, but it is not intended for combination with unapproved or experimental treatments. Patients who meet all inclusion and none of the exclusion criteria will be treated with the same daily everolimus dose they are receiving in the parent protocol until disease progression (as defined in the parent protocol), unacceptable toxicity develops, consent withdrawl, protocol non-compliance, the investigator feels it is no longer in the patient's best interest to continue therapy, or the patient's death.
3114929|NCT01789268|Other|Full-Term Healthy Infants (> /=37 weeks gestational age)|130 male and female term infants born at a gestational age of 37 0/7 to 41 6/7 weeks (Healthy comparator) will be observed for sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity
3114930|NCT01789268|Other|Preterm Infants (<36 weeks gestational age)|150 male and female preterm infants born at gestational age 23 0/7 to 35 6/7 weeks will be observed for sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity
3114931|NCT01789255|Experimental|Supportive care (vorinostat, tacrolimus, methotrexate)|Patients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180.Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.
3114932|NCT01789242|Experimental|Carfilzomib|All eligible subjects will receive the study intervention of Carfilzomib. Patients with suboptimal hematologic responses (<VGPR after 4 cycles) will have Dexamethasone added to their treatment.
3114933|NCT01789229||Malignant tumors|"Patients who have one of the Neoplasms stated above under conditions."
3114934|NCT01789229||Benign controls|Patients with a benign tumor or an inflammatory disease - to be matched by age.
3114935|NCT01789229||Healthy controls|People/patients who have no known disease at time of sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.
3114936|NCT01789216|Placebo Comparator|Placebo|Standard pain management + preoperative oral placebo + perioperative intravenous placebo & oral placebo. This group will serve as the control group. Patients will take an oral placebo pill twice daily for the first 14 days of the trial. A perioperative protocol will include an oral dose of placebo immediately prior to surgery and twice daily for 48 hours following any surgery, in addition to an intravenous dose of placebo immediately prior to surgery and every 6 hours for 48 hours following surgery. The oral protocol will be suspended while the patient is receiving medication from the perioperative protocol.
3114937|NCT01789216|Active Comparator|NSAID|Standard pain management + preoperative oral meloxicam + perioperative intravenous ketorolac & oral placebo. In addition to standard of care pain management, patients randomized to the NSAID group will receive an oral 7.5 mg dose of Meloxicam twice daily, to be initiated on enrollment and continued for 14 days or through definitive fixation, whichever comes first. The proposed dosing schedule represents the maximal safe dose of an adult population. Patients will receive intravenous (IV) ketorolac dosing surrounding all operative procedures leading up to and including the definitive fixation. The oral protocol will be suspended while the patient is receiving medication from the perioperative protocol. The proposed dosing schedule of 30 mg IV every 6 hours for the first 48 hours following procedure represents the maximal generally accepted safe dose of ketorolac currently in use for orthopedic surgery.
3114938|NCT01789216|Active Comparator|Gabapentinoid|Standard pain management + preoperative pregabalin + perioperative intravenous placebo & oral pregabalin. In addition to standard of care pain management, patients randomized to the pregabalin group will receive an oral 75mg dose of pregabalin twice daily, to be initiated on enrollment and continued for 14 days or through definitive fixation, whichever comes first.
3114939|NCT01789203|Active Comparator|Ciprofloxacin|Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
3114940|NCT01789203|Placebo Comparator|Placebo|Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
3114941|NCT01789190||Group S (sedentary)|Group S included patients that did not perform any physical activity at the moment of onset, continuing with the same habits during the subsequent observational period.
3114942|NCT01789190||Group A (active)|The inclusion criteria for group distribution took in account the principles of the American College of Sports Medicine, considering as active physical activity to practice a moderate-vigorous exercise during 1h, 5 days or more/week. In this context, a sedentary or less active person should be a person that practices any or less than 5h weekly
3114943|NCT01789177|Experimental|Modified incentive spirometry|Patients will be given a disposable incentive spirometer postoperatively and instructed to use the spirometer every hour while awake.
3114944|NCT01789177|Active Comparator|Postoperative chest physiotherapy|Patients will be given standard postoperative chest physiotherapy, according to hospital protocol, but will not receive incentive spirometers.
3114945|NCT01789164||Healthy group|Healthy group with no history of TBI or concussion. Gender matched non-TBI volunteers
3114946|NCT01789164||TBI group|Males and females between 18 and 60 years who have a diagnosis of TBI and are symptomatic with DSM-IV Research Criteria for Post-Concussional Disorder (see below), gender matched non-TBI volunteers
3114947|NCT01789138|Experimental|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention: see 'Interventions' for more details.
3114948|NCT01789138|No Intervention|Adherence counseling, standard of care|Standard of care: Antiretroviral therapy adherence is discussed with patient (study participant) according to usual practice in the medical institution no special protocol followed.
3114949|NCT01789125|Active Comparator|Smoking Termination and Anxiety Reduction Treatment|Cognitive-behavioral treatment program that blends smoking cessation and anxiety reduction treatment strategies
3114950|NCT01789125|Active Comparator|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
3114951|NCT01789112|Experimental|CCM aggregate|Taking of 10 blood samples
3114952|NCT01789099|Experimental|UV1 synthetic peptide vaccine and GM-CSF|GM-CSF (Leukine) followed by UV1 peptide vaccine with escalating concentrations (100, 300 and 700 microgram) will be injected intradermally in the lower abdomen.
3114953|NCT01789086|Experimental|Liraglutide|
3114954|NCT01789086|Placebo Comparator|Placebo|
3114955|NCT01789073|Experimental|Oral Impact, Nestlé Health Science|Oral Impact-arm receives the intervention the last 7 days prior to surgery
3114956|NCT01789073|No Intervention|Control|The control-arm receives no intervention but is treated according to the standard procedures
3114957|NCT01789060||p-AKT|p-AKT immunohistochemical staining,high p-AKT expression (upper quartile), low p-AKT expression (lower 3 quartiles)
3114958|NCT01789047|Active Comparator|Topiramate|Topiramate as adjunct to amantadine.
3114959|NCT01789047|Placebo Comparator|Placebo (sugar pill)|Placebo
3114960|NCT01789008|Other|Transient elastography|evaluation of fibrosis stage by transient elastography
3114961|NCT01789008|Active Comparator|liver biopsie|evaluation of fibrosis stage by liver biopsie
3114962|NCT01788995||Cohort|
3114963|NCT01788982|Experimental|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
3114964|NCT01788982|Placebo Comparator|Placebo|Placebo should be administered orally at a dose of 200 mg twice daily. Cross-over to nintedanib is allowed after progression.
3114965|NCT01788969|Experimental|Gait Training with Lexapro|Gait training 2 weeks, gait training 4 weeks (3 X week) with Lexapro (10mg SSRI), wash out period of 1 week, gait training, for 4 weeks with placebo (10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
3114966|NCT01788969|Active Comparator|Gait Training with Placebo|Gait training 2 weeks, gait training for 4 weeks (3X week) with Placebo (10 mg), wash out period of 1 week, gait training for 4 weeks with Lexapro(10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
3114967|NCT01788956||ICU Patients|80 subjects (male and female)
3114968|NCT01788943||Slow metabolizers|Individuals with an NMR <0.26 will be classified as slow metabolizers.
3114969|NCT01788943||Normal metabolizers|Participants with an NMR >= 0.26 will be classified as normal metabolizers.
3114970|NCT01788930|Active Comparator|CPAP|"This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.~Other Name: positive airway pressure"
3114971|NCT01788930|Placebo Comparator|Sham-CPAP|This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.
3114972|NCT01788917|Active Comparator|linseed oil|
3114973|NCT01788904||Patients with acute mesenteric ischemia|Patients with acute mesenteric ischemia meeting the in-/exclusion criteria
3114974|NCT01788891||second-line pediatric cohort|Asian HIV-positive children <18 years old who are receiving HIV care at one of the participating TREAT Asia Pediatric HIV Observational Database (TApHOD) sites that have been identified for TASER-P participation will be monitored for treatment failure of second-line ART
3114975|NCT01788878|Experimental|Questionnaires|completion of questionnaires
3114976|NCT01788865|Experimental|cSEMS|Patients with malignant ureteral obstruction have cSEMS(Covered self-expandable dual-layered metal stent) implant
3114977|NCT01788852||Perinatally HIV-infected adolescents|Perinatally HIV-infected adolescents
3114978|NCT01788852||behaviorally HIV-infected adolescents|behaviorally HIV-infected adolescents
3114979|NCT01788852||HIV negative adolescents|HIV negative adolescents
3114980|NCT01788839||women with breast cancer|This study is a prospective, observational, longitudinal study assessing the prevalence of sexual dysfunction and distress in premenopausal and postmenopausal women with breast cancer. This study will also evaluate the severity, time course, and predictors of sexual dysfunction. Breast cancer patients and survivors will be administered surveys of comprehensive questionnaires related to sexual function. In the case that participants miss the follow up questionnaires, study staff may contact the patient by phone to request and record the patients‟ responses. The study staff may also mail the missed questionnaires to each patient.
3114981|NCT01788839||women with lymphoma|This study is a prospective, observational, longitudinal study assessing the prevalence of sexual dysfunction and distress in premenopausal and postmenopausal women with Diffuse Large B-cell Lymphoma or Hodgkin's Lymphoma. This study will also evaluate the severity, time course, and predictors of sexual dysfunction. Lymphoma patients and survivors will be administered surveys of comprehensive questionnaires related to sexual function. In the case that participants miss the follow up questionnaires, study staff may contact the patient by phone to request and record the patients‟ responses. The study staff may also mail the missed questionnaires to each patient.
3114982|NCT01788826|Experimental|Prophylactic Mesh|Use of a prefascial polypropylene mesh when closing midline laparotomy
3114983|NCT01788826|Experimental|No prophylactic mesh closure|In this arm the laparotomy of the patients are closed with a running absorbable suture without a mesh
3114984|NCT01788813|Experimental|GSK2245035 Arm|Subjects participating prior to 2014 will receive i.n GSK2245035 80 ng once weekly for 8 weeks (each dose will be split between the two nostrils). Subjects participating in 2014 will receive i.n GSK2245035 20 ng once weekly for 8 weeks (each dose will be split between the two nostrils).
3114985|NCT01788813|Placebo Comparator|Placebo Arm|Subjects will receive i.n placebo once weekly for 8 weeks (each dose will be split between the two nostrils)
3114986|NCT01788800|Experimental|Exercise training|"Cognitive Behavioural Therapy (CBT)~+ Exercise training 3 times/week, 30 minutes on a treadmill, 70% maximal oxygen uptake (VO2max), 8 weeks"
3114987|NCT01788800|Active Comparator|Movements|"Cognitive Behavioural Therapy (CBT)~+ Low intensity physical activity without cardiovascular activation, 3 times/week, 30 minutes, 8 weeks"
3114988|NCT01788787||Texas Quitline|Patients interested in smoking cessation treatment by calling the Texas Quitline.
3114989|NCT01788787||Training Providers|Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians).
3114990|NCT01788774|Other|Risperidone ISM 50mg|Three different single doses will be evaluated
3114991|NCT01788774|Other|Risperidone ISM 75mg|Three different single doses will be evaluated
3114992|NCT01788774|Other|Risperidone ISM 100mg|Three different single doses will be evaluated
3114993|NCT01788761|Experimental|Probiotic Supplemented Group|500,000,0000 cells of Lactobacillus GG (utilizing either Culturelle for Kids or Kids Culturelle preparation) and 500,000,000 cells of Bifidobacterium Infantis (utilizing Align capsule) diluted in 3 ml breastmilk/formula and administered enterally from first day of enteral feeds until term gestation/discharge/transfer/death (whichever occurs first) every day infant is receives enteral feedings
3114994|NCT01788761|Sham Comparator|Control Group|3 ml enteral feeding of breastmilk/formula administered once daily in addition to regularly prescribed enteral feedings from day of first feeding until term gestation/discharge/transfer/death (which ever occurs first) and administered every day that infant receives enteral feedings
3114995|NCT01788748|Active Comparator|bipolar radiofrequency and infrared|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only bipolar radiofrequency potentiated by infrared, 3 treatments one month apart.
3114996|NCT01788748|Active Comparator|fractional bipolar radiofrequency|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only fractional bipolar radiofrequency , 3 treatments one month apart.
3114997|NCT01788748|Active Comparator|combined treatment|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive first bipolar radiofrequency potentiated by infrared, followed in the same session by fractional bipolar radiofrequency, 3 treatments one month apart.
3114998|NCT01788722||Group 1|
3114999|NCT01788709|Active Comparator|A|Fortrans (split dose) + Mentholyptus drops
3115000|NCT01788709|Active Comparator|B|MoviPrep (split dose)
3115001|NCT01788696|Active Comparator|Group A - Early Imaging|Group A will receive SPECT imaging 3 times during the study. The first scan will take place prior to the initiation of any treatment, followed by scans at week 26 and week 52.
3115002|NCT01788696|Active Comparator|Group B - Delayed Imaging|Group B will receive SPECT imaging 2 times during the study. Group B will not have the first scan (prior to the initiation of any treatment). Scan will take place at week 26 and week 52.
3115003|NCT01788683|Active Comparator|Regenexx SD|Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged tendon.
3115004|NCT01788683|Active Comparator|Exercise Therapy|Subjects will be instructed in a set of appropriate rotator cuff strengthening exercises and given an instructional hand-out to take home.
3115005|NCT01788670|Placebo Comparator|Water|Lemon-flavoured water (150 ml)
3115006|NCT01788670|Active Comparator|Ethanol high dose|The high dose corresponds to 30 g of ethanol in pilot cohort 1, to 12 g of ethanol in pilot cohort 2 and to 42 g of ethanol in pilot cohort 3. For the definitive study the high dose corresponds to 30 g of ethanol. Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
3115007|NCT01788670|Active Comparator|Ethanol low dose|The low dose corresponds to 18 g of ethanol in pilot cohort 1, to 6 g of ethanol in pilot cohort 2 and to 24 g of ethanol in pilot cohort 3. For the definitive study the low dose corresponds to 18 g of ethanol. Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
3115008|NCT01788657|Experimental|Standard internet-based cognitive behavior therapy|Standard internet-based cognitive behavior therapy for depression with a written treatment material consisting of 60000 words (textmaterial only).
3115009|NCT01788657|Experimental|Condensed internet-based cognitive behavior therapy|Condensed internet-based cognitive behavior therapy for depression with a written treatment material consisting of 30000 words (available as text or audio).
3115010|NCT01788644||No treatment (observational study)|
3115011|NCT01788631|Active Comparator|Regadenoson Arm|1.44 mcg/kg/hour infused over 48 hours
3115012|NCT01788631|Placebo Comparator|Placebo Arm|Placebo infused over 48 hours
3115013|NCT01788618|Other|Experimental group|Cognitive exams at T0 and T3. Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
3115014|NCT01788618|Other|The control group 1 (Homework)|Cognitive exams at T0 and T3. These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
3115015|NCT01788618|Other|Control group 2 ( telephone follow)|Cognitive exams at T0 and T3. These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
3115016|NCT01788605|Experimental|ramosetron|
3115017|NCT01788592||Drug eluting stent|Patients who receiving drug eluting stents
3115018|NCT01788579|Experimental|Multimedia WINGS|A one-hour session of a self-paced multimedia IPV screening, brief intervention and referral service delivered on a computer.
3115019|NCT01788579|Active Comparator|Caseworker Delivered WINGS|A one-hour session of IPV screening, brief intervention and referral service delivered by a case manager.
3115020|NCT01788566|Experimental|Gemcitabine + Cisplatin + Necitumumab|"Necitumumab administered intravenously (IV) 800 milligram (mg) on Days 1 and 8 of each 3-week cycle.~Gemcitabine administered IV at 1250 milligram per square meter (mg/m^2) on Days 1 and 8 of each 3 week cycle for a maximum of 6 cycles.~Cisplatin administered IV at 75 mg/m^2 on Day 1 of each 3 week cycle for a maximum of 6 cycles."
3115021|NCT01788553||patients with generalized anxiety disorder|
3115022|NCT01788540|Experimental|Intralipid|"IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.~the intralipid infusion is then repeated within the one week of positive pregnancy test and every 2 weeks till end of first trimester"
3115023|NCT01788540|No Intervention|Control|No intervention
3115024|NCT01788527|Experimental|CGM|Continuous Glucose Monitoring
3115025|NCT01788527|No Intervention|HGM|Standard of care, Home Glucose Monitoring
3115026|NCT01788514|Other|Videogame|Subject will play educational videogame
3115027|NCT01788501|Experimental|Tacrolimus/Methotrexate|"Tacrolimus D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to therapeutic drug monitoring(TDM) (10-20ng/ml)~Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push"
3115028|NCT01788501|Active Comparator|Cyclosporine/Methotrexate|"Cyclosporine D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)~Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push"
3115029|NCT01788488|No Intervention|Standard Therapy|
3115030|NCT01788488|Experimental|Procalcitonin-guided therapy|Procalcitonin levels will be measured to determine when it is appropriate to discontinue antibiotic therapy.
3115031|NCT01788475|Active Comparator|Ozurdex implant up to every 3 months|"Ozurdex (Dexamethasone) 0.7 mg implant will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.~Re-implantation of Ozurdex may occur at any time > 3 months following last injection in group 1 if any of the following conditions are met:~Increase of > 50 microns from the best previous CRT measurement~Recurrence of intraretinal cystic edema~Persistent intraretinal cystic edema"
3115032|NCT01788475|Active Comparator|Ozurdex implant up to every 6 months|"Ozurdex (Dexamethasone) 0.7 mg implant will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.~Re-implantation of Ozurdex may occur at any time >6 months following last injection in group 2 if any of the following conditions are met:~Increase of > 50 microns from the best previous CRT measurement~Recurrence of intraretinal cystic edema~Persistent intraretinal cystic edema"
3115069|NCT01788189|Experimental|Lenalidomide|"The LeMLAR protocol:~Lenalidomide 25 mg p.o., days 1 - 21; Methotrexate 30 - 60 - 90 - 120 - 150 mg/m² i.v. bolus, days 1, 8, 15; Leucovorin 4 x 45 mg p.o. (every 6 hrs), days 2, 9, 16; Cytarabine (Ara-C) 75 - 150 - 225 - 300 - 375 mg/m² i.v. bolus, days 1, 8, 15; Rituximab 375 mg/m² i.v. infusion, day 1.~28-day cycles, maximum 6 cycles, definition of dose-limiting toxicity in cycles 1 and 2, intra-patient dose escalation after cycles 2 and 4 in case of absence of dose-limiting toxicity in previous cycles"
3115070|NCT01788176|Placebo Comparator|Saline|One single intravenous infusion of 100ml of saline (placebo control group).
3115033|NCT01788475|Sham Comparator|Sham Implant|"Sham Procedure will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit. Also, at 13 months, patients in the sham group will be eligible for Ozurdex (Dexamethasone) 0.7 mg implantation if initial inclusion/exclusion criteria are met. These patients would follow re-implantation guidelines of group 2.~Sham implantation may occur at any time > 6 months following last sham injection in group 3 if any of the following conditions are met:~Increase of > 50 microns from the best previous CRT measurement~Recurrence of intraretinal cystic edema~Persistent intraretinal cystic edema"
3115034|NCT01788462||HIV and Lipodystrophy|The study population will consist of HIV patients with lipodystrophy who receive Tesamorelin (Egrifta).
3115035|NCT01788436|Experimental|Group 1: Patients with schizophrenia|
3115036|NCT01788436|Active Comparator|Group 2: Young healthy volunteers|
3115037|NCT01788436|Experimental|Group 3: Elderly healthy volunteers|
3115038|NCT01788423|Experimental|Audiologist-Based|Audiologist selects hearing aid for patient
3115039|NCT01788423|Experimental|Consumer Decides|Consumer selects hearing aid
3115040|NCT01788423|Placebo Comparator|Placebo|Patient fitted with hearing aid that is acoustically transparent.
3115041|NCT01788423|Experimental|Customer decides with limited inclusion/exclusion criteria|Consumer selects hearing aid with limited inclusion/exclusion criteria to closely simulate an actual over the counter dispensary.
3115042|NCT01788410||Cryoablation under image guidance|Patients with facet joint disease, or compressed or damaged nerve roots causing pain in the head, neck or spine. Procedures performed with MRI Seednet Cryotherapy System (Galil Medical).
3115043|NCT01788397|Experimental|Physical activity|Physical activity 2-4 times pr. day
3115044|NCT01788397|No Intervention|Control group|No intervention in the control group
3115045|NCT01788384|Active Comparator|Acanya|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% gel (Valeant Pharmaceuticals, North America)
3115046|NCT01788384|Experimental|Clindamycin Phosphate / Benzoyl Peroxide|Clindamycin Phosphate / Benzoyl Peroxide Gel, 1.2%/2.5%
3115047|NCT01788384|Placebo Comparator|Vehicle Gel|Placebo (Vehicle Gel)of the test product (Watson Laboratories, Inc.)
3115048|NCT01788371|No Intervention|No antiviral arm|provide standard of care to mothers and standard immunoprophylaxis to their infants
3115049|NCT01788371|Experimental|Lamivudine|lamivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants
3115050|NCT01788371|Experimental|Telbivudine|Telbivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants
3115051|NCT01788358|Experimental|Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)|Subjects received nifedipine gastrointestinal therapeutic system (GITS) / candesartan cilexetil fixed dose combination (FDC) (BAY98-7106) tablet orally, once daily in the morning of Visit 1 (Week 0) for 28 or 52 weeks. The starting dose (30/8 milligram [mg] or 30/16 mg) was determined based on local practice and clinical judgment by the investigator. Based on the experience of symptomatic and asymptomatic hypotension, peripheral edema or significant tolerability, the doses were up-titrated to the highest target dose (60/32 mg).
3115052|NCT01788345|Experimental|non-invasive ventilation|
3115053|NCT01788332|Active Comparator|Olaparib|3 100mg tablets to be administered twice a day with approximately 240ml of water.
3115054|NCT01788332|Placebo Comparator|Placebo|3 100mg tablets to be administered twice a day with approximately 240ml of water.
3115055|NCT01788319|Experimental|lasertrabeculoplasty|
3115056|NCT01788306|Active Comparator|Intervention (OOPEN+BBCC)|Study intervention, overdose prevention, education, intervention, brief behavioral change counseling, take-home naloxone, referral to local available resources.
3115057|NCT01788306|No Intervention|Control|Standard of care, referral to local available resources.
3115058|NCT01788293|Active Comparator|Intervention group|Intervention group will receive hydroxyethylstarch 6% bolus in order to minimize and maintain PVI below 14 %.
3115059|NCT01788293|No Intervention|Control group|Control group will receive fluid at the discretion of the anesthetist
3115060|NCT01788280|Experimental|All participants|All enrolled participants
3115061|NCT01788267|Experimental|Healthy volunteers|Volunteers realize a HR-pQCT scanner
3115062|NCT01788267|Experimental|Cystic Fibrosis patient|Patients realize a HR-pQCT scanner
3115063|NCT01788254|Experimental|Drug cocktail|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
3115064|NCT01788241||CAG and CT group|CAG group = patients included based on coronary angiography screening; CT group = patients included based on computed tomography screening
3115065|NCT01788228|Experimental|Influenza A (H5N1) Virus monovalent vaccine 18-64 Years Group|Subjects 18-64 years of age received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm at Day 0 and dominant arm at Day 21.
3115066|NCT01788228|Experimental|Influenza A (H5N1) Virus monovalent vaccine > 64 Years Group|Subjects >64 years of age received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm at Day 0 and dominant arm at Day 21.
3115067|NCT01788215|Active Comparator|Doxycycline|Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
3115068|NCT01788215|Placebo Comparator|Sugar Pill|The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
3115071|NCT01788176|Active Comparator|Zoledronic acid|one single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
3115072|NCT01788163|Other|Locally advanced/metastatic NSCLC pats.|Patients with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy)
3115075|NCT01788137|Active Comparator|CHOP|CHOP regimen Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles.
3115076|NCT01788137|Active Comparator|c-ATT regimen|c-ATT regimen Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
3115077|NCT01788124||Metal Speculum|exam with metal speculum
3115078|NCT01788124||Plastic Speculum|exam with plastic speculum
3115079|NCT01788111|Experimental|Low back exercises 1|Specific low back extensor exercises in special training bench
3115080|NCT01788111|Active Comparator|Low back exercise 2|Traditional low back exercises.
3115081|NCT01788098||Rheumatoid Arthritis|Patients with rheumatoid arthritis
3115082|NCT01788098||Healthy controls|Healthy control subjects
3115083|NCT01788085|Experimental|pH monitoring procedure|Bravo pH monitoring procedure
3115084|NCT01788072|Active Comparator|Intranasal Oxytocin|
3115085|NCT01788072|Placebo Comparator|Placebo|
3115086|NCT01788059|Experimental|mesenchymal stem cell|stem cells drived from iliac bone marrow with centrifuge and ficoll method then inject to non union site 2-3 ml with approximately 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion site of the bone fracture under fluoroscopic gide and general or spinal anesthesia as deemed appropriate by the anesthetist.
3115087|NCT01788046|Placebo Comparator|Placebo|Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
3115088|NCT01788046|Experimental|Etelcalcetide|Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW for 26 weeks.
3115089|NCT01788033|Active Comparator|XOMA 052|0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
3115090|NCT01788033|Placebo Comparator|Placebo|0.3 mg/kg placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
3115091|NCT01788020|Experimental|DRC+Bortezomib|"Induction experimental arm (Arm B):~Cycle 1-6:~Bortezomib 1.6 mg/m2 s.c. Day 1,8,15 Dexamethasone 20 mg p.o. Day 1 Rituximab 375 mg/m2 i.v. Day 1 Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5 Repeat day 29."
3115092|NCT01788020|Active Comparator|DRC|"Induction standard arm (Arm A)~Cycle 1-6:~Dexamethasone 20 mg p.o. Day 1 Rituximab 375 mg/m2 i.v. Day 1 Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5 Repeat day 29."
3115093|NCT01788007|Experimental|Imiquimod Topical Cream 3.75%|Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.)
3115094|NCT01788007|Placebo Comparator|Vehicle Topical Cream|Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.)
3115095|NCT01788007|Active Comparator|Zyclara® (imiquimod) Topical Cream 3.75%|Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.)
3115096|NCT01787994|Experimental|Cohort 1|"Cohort 1: HIV‐1‐positive women and men ≥18 years with a CD4 count > 350 cells/mm3, HIV‐1‐RNA levels undetectable by ultrasensitive HIV PCR Abbott assay. Subjects with HIV‐1 RNA < 400 copies/mL are also eligible; however, the HIV‐1 RNA must be < 50 copies/mL within 60 days prior to study entry based on the Abbott assay. Subjects with intermittent isolated episodes of detectable low level viremia (> 50 but <1,000 copies RNA/mL; blips) will be eligible.~There should be at least 2 documented HIV‐1 RNA assays, one drawn >3 months before study entry, one drawn <3 months before study entry. Subjects should be on HAART (no changes to treatment within 4 weeks of study entry) for at least 3 months.~Cohort 1 subjects will receive a single dose of MazF-T cells."
3115097|NCT01787994|Experimental|Cohort 2|"Cohort 2: HIV-1-positive men and women ≥18 years with a CD4 count > 450 cells/mm3, having well controlled HIV replication on HAART. The subjects should have a CD4 nadir ≥200 cells/mm3. Subjects in Cohort 2 will participate in a 16 week analytical treatment interruption beginning 2 weeks after T cell infusion.~Cohort 2 subjects will receive a single dose of MazF-T cells."
3115098|NCT01787968||TcI, TcII|TcI: T. cruzi seropositive mothers from countries where TcI predominates, or/and with TcI genotyping TcII: T. cruzi seropositive mothers from countries where TcII (non-TcI) predominates, or/and with TcII (non-TcI) genotyping
3115099|NCT01787955|Experimental|Braun anastomosis group|
3115100|NCT01787955|Active Comparator|conventional group|conventional Pylorus preserving pancreaticoduodenectomy
3115101|NCT01787942|Active Comparator|Blepharoplasty|"Participants under this group will undergo blepharoplasty from the oculoplastic clinic. These patients will form the case group of the cross-sectional study, and will be on follow-up for the prospective study."
3115102|NCT01787942|Placebo Comparator|Control|"Participants under this group will be recruited from the general ophthalmology clinic. These patients are cleared to have no lid disturbances in terms of function or anatomy, and will serve as the control group of the cross-sectional study."
3115103|NCT01787929|Other|Cemented hemiarthroplasty|hemiarthroplasty surgery with cement for displaced femoral neck fractures
3115104|NCT01787929|Other|Uncemented hemiarthroplasty|hemiarthroplasty surgery without cement is a surgery for displaced femoral neck fractures
3115105|NCT01787916|Experimental|Liraglutide|Liraglutide, s.c., 1.8 mg, die, 24 weeks
3115106|NCT01787916|Placebo Comparator|Placebo|Liraglutide placebo (visually identical to study drug) will be given s.c. 1.8 mg for 24 weeks
3115107|NCT01787903|Active Comparator|Real-time continuous glucose monitor|16 weeks use of a real-time continuous glucose monitor
3115108|NCT01787903|Placebo Comparator|Continuous glucose monitor|16 weeks use of a (blinded, retrospective) continuous glucose monitor
3115109|NCT01787877||Stroke patients reporting to the ER|
3115110|NCT01787864||Cross-Sectional Post-Ablation|"The cross-sectional arm will consist of patients who have undergone ablative therapy for Barrett's Esophagus (BE) and have had at least one clear pathology report with no evidence of Barrett's Esophagus (BE) since their first ablation.~Cross-sectional participants will receive one-time study biopsies during a routine care follow-up endoscopy."
3115148|NCT01787591|Experimental|Acute Soy Milk Ingestion|Participants will ingest 1 cup of soy milk with 15 mg deuterium-labeled alpha-tocopherol.
3115255|NCT01786837|Sham Comparator|Sham|FMS at 5% intensity for 5 weeks
3115111|NCT01787864||Prospective Longitudinal Pre-Ablation|"Concurrently enrolled will be a prospective longitudinal arm which will consist of patients prior to their first ablation procedure. The prospective cohort will be followed for 12 months or longer if Barrett's Esophagus (BE) is not yet clear 6 months after the initial treatment.~Prospective longitudinal participants will receive biopsies prior to ablation therapy and 6 and 12 months after the initial treatment. If Barrett's Esophagus (BE) is not yet clear at 6 months, biopsies will be taken at the first endoscopy after Barrett's Esophagus (BE) clearance and again at the next clinically scheduled follow-up visit."
3115112|NCT01787851|Active Comparator|Triheptanoin oil|The standard dose of triheptanoin oil for adults is 1-2gm/kg/24 hours. For purposes of this study, we will administer 0.25mg/kg four-times per day. The liquid study drug will be mixed into sugar-free, low fat yogurt, pudding or nutritional supplement shake, depending on patient preference.
3115113|NCT01787851|Placebo Comparator|Simple sugar|0.25mg/kg of sugar syrup will be mixed into sugar-free, low fat yogurt, pudding or nutritional supplement shake four-times per day before meals.
3115114|NCT01787838|Other|health education, audit and feedback|Focused health education for staff and patients.
3115115|NCT01787825|Other|PillCam SB2 then CapsoCam SV-1|PillCam SB2 capsule then CapsoCam SV-1 capsule
3115116|NCT01787825|Other|CapsoCam SV-1 then PillCam SB2|CapsoCam SV-1 capsule then PillCam SB2 capsule
3115117|NCT01787799|Experimental|SYNERGY Stent System|SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System)
3115118|NCT01787786||Irritable Bowel Disease|Infliximab administered according to current FDA and EMS approved doses and intervals.
3115119|NCT01787773|Experimental|Veniti Inferior Vena Cava Filter|
3115120|NCT01787760|Experimental|Test Soft Contact Lens B|Lenses will be worn in a daily disposable modality
3115121|NCT01787760|Experimental|Test Soft Contact Lens C|Lenses will be worn in a daily disposable modality
3115122|NCT01787760|Active Comparator|Spectacle Lenses|Control spectacle lenses worn daily.
3115123|NCT01787747|Experimental|Cohorts A and C|Single dose (D1) followed by twice daily dosing for 7 days
3115124|NCT01787747|Experimental|Cohorts B and D|Single dose (D1) followed by twice daily dosing for 7 days
3115125|NCT01787747|Experimental|Cohorts E and F|Single dose (D1) followed by twice daily dosing for 7 days
3115126|NCT01787747|Experimental|Cohorts G and I|Single dose (D1) followed by twice daily dosing for 7 days
3115127|NCT01787747|Experimental|Cohorts H and J|Single dose (D1) followed by twice daily dosing for 7 days
3115128|NCT01787721|Experimental|Ankle manipulation|Treatment will consist of manipulation of the tibiotalar joint intended to produce anterior to posterior glide of the tibia on the talus
3115129|NCT01787721|Sham Comparator|Sham manipulation|Sham manipulative procedure of the tibiotalar joint.
3115130|NCT01787708|Active Comparator|Low intensity red laser|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
3115131|NCT01787708|Active Comparator|High intensity red light|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
3115132|NCT01787708|No Intervention|No treatment1 (covered)|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
3115133|NCT01787708|No Intervention|No treatment2 (covered)|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
3115134|NCT01787695|No Intervention|No treatment (covered)|
3115135|NCT01787695|Active Comparator|UVA1|
3115136|NCT01787682|Experimental|Boost High Protein|Boost high protein with added spirulina
3115137|NCT01787669|Active Comparator|Avastin (bevacizumab)|Intravitreal Avastin loading doses followed by as prn for remainder of 6 months according to defined retreatment criteria
3115138|NCT01787669|Active Comparator|Ozurdex (dexamethasone)|single dose at baseline and repeat dose when required according to defined re-treatment criteria
3115139|NCT01787643|Experimental|Standing desk|Installation of standing desk
3115140|NCT01787630|Experimental|Hyaluronic acid|Hyaluronic acid will be injected in the space between the prostate and rectum prior to radiotherapy to perform a dorsal movement of rectum.
3115141|NCT01787617|Placebo Comparator|Control Group|We will randomly assign 52 individuals to a no exercise healthy living group.
3115142|NCT01787617|Experimental|Aerobic Plus Resistance Training Group|We will randomly assign 52 individuals to an aerobic plus resistance training group.
3115143|NCT01787604|Active Comparator|Aortic Root Reimplantation Procedure|Aortic Root Reimplantation Procedure
3115144|NCT01787604|Active Comparator|Aortic Valve Reimplantation Procedure|Aortic Valve Reimplantation Procedure
3115145|NCT01787591|Experimental|Acute Fat-Free Milk Ingestion|Participants will ingest 1 cup of fat-free milk with 15 mg deuterium-labeled alpha-tocopherol.
3115146|NCT01787591|Experimental|Acute Low-Fat Milk Ingestion|Participants will ingest 1 cup of low-fat milk with 15 mg deuterium-labeled alpha-tocopherol.
3115147|NCT01787591|Experimental|Acute Full-Fat Milk Ingestion|Participants will ingest 1 cup of full-fat milk with 15 mg deuterium-labeled alpha-tocopherol.
3115293|NCT01786629|Experimental|SUPREP Bowel Prep Kit|SUPREP Bowel Prep Kit
3115149|NCT01787578|Experimental|Sobetirome|Subjects will receive oral doses of sobetirome. All subjects will start with a 50 mcg dose, once-daily for 14 days. If this dose proves safe and well tolerated, subjects will receive a 100 mcg dose once-daily for an additional 14 days.
3115150|NCT01787565||painPREMIER cohort|
3115151|NCT01787565||Control cohort|
3115152|NCT01787552|Experimental|LDE225 + INC424|LDE225 and INC424 in combination
3115153|NCT01787539|Experimental|Complete Perioperative Chemotherapy|"Preoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Surgery: total or subtotal gastrectomy with D2 lymph node dissection. The surgical resection will be conducted 4-6 weeks after preoperative chemotherapy.~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery with the same regimen as in the preoperative part."
3115154|NCT01787539|No Intervention|Preoperative Chemotherapy|"Preoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Surgery: total or subtotal gastrectomy with D2 lymph node dissection. The surgical resection will be conducted 4-6 weeks after preoperative chemotherapy.~Patients with tumor regression grade 0, 1, 2 randomized to preoperative chemotherapy will not undergo postoperative chemotherapy and will be followed-up."
3115155|NCT01787526|Active Comparator|Oral Iron|oral iron in a corresponding dose of 10g (assuming an absorption of 10%, 100 capsules a 100mg iron each) taken over 8-12 weeks
3115156|NCT01787526|Experimental|Intravenous high dose iron|high dose intravenous iron (ferric carboxymaltose, 1000mg)
3115157|NCT01787513|Experimental|CBM Version A + iCBT|CBM Version A is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
3115158|NCT01787513|Placebo Comparator|CBM Version B (Control) + iCBT|CBM Version B (Control) is an Internet-based intervention taking place over 1 week (identical to CBM Version A without the putative active components) followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
3115159|NCT01787500|Experimental|Vemurafenib + Cetuximab + Irinotecan|"Phase I Dose Escalation: All groups treated. Starting dose of Vemurafenib 480 mg by mouth twice daily of a 14 Day cycle. Cetuximab 500 mg/m2 by vein every 2 weeks on Day 1 of each 14 Day cycle. Irinotecan 180 mg/m2 by vein every 2 weeks on Day 1 of each 14 Day cycle.~Dose Expansion Groups: Once the maximum tolerated dose has been defined, patients enrolled in two expansion cohorts. One group will have up to 18 participants with BRAF mutant, KRAS wild type colorectal cancer. The other group will have up to 18 participants with BRAF mutant, KRAS wild type solid tumor cancers. Starting dose of Vemurafenib is maximum tolerated dose from Dose Escalation Group. Cetuximab and Irinotecan dosages and administration remain the same."
3115160|NCT01787500|Experimental|Dose Expansion Group - Colorectal Cancer|Dose Expansion Groups: Once the maximum tolerated dose has been defined, patients enrolled in two expansion cohorts. One group will have up to 18 participants with BRAF mutant, KRAS wild type colorectal cancer. Starting dose of Vemurafenib is maximum tolerated dose from Dose Escalation Group. Cetuximab 500 mg/m2 by vein every 2 weeks on Day 1 of each 14 Day cycle. Irinotecan 180 mg/m2 by vein every 2 weeks on Day 1 of each 14 Day cycle.
3115161|NCT01787500|Experimental|Dose Expansion Group - Solid Cancers|Once the maximum tolerated dose has been defined, patients enrolled in two expansion cohorts. This group will have up to 18 participants with BRAF mutant, KRAS wild type solid cancers. Starting dose of Vemurafenib is maximum tolerated dose from Dose Escalation Group. Cetuximab 500 mg/m2 by vein every 2 weeks on Day 1 of each 14 Day cycle. Irinotecan 180 mg/m2 by vein every 2 weeks on Day 1 of each 14 Day cycle.
3115162|NCT01787487|Experimental|MF patients|Myelofibrosis (MF) patients receive 4 weeks (28 days) of therapy (1 standard cycle). RUX given orally, alone at a dose of 5 mg orally twice daily for 3 cycles, then AZA subcutaneously (SC) 25 mg/sq.m. starting on cycle 4 with increase to 50 mg/sq.m. after 2 cycles (i.e., concomitantly with cycle 6).
3115163|NCT01787487|Experimental|MDS/MPN patients|Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) receive 4 weeks (28 days) of therapy (1 standard cycle). RUX given orally, alone at a dose of 5 mg orally twice daily for 3 cycles, then AZA subcutaneously (SC) 25 mg/sq.m. starting on cycle 4 with increase to 50 mg/sq.m. after 2 cycles (i.e., concomitantly with cycle 6).
3115164|NCT01787474|Experimental|Natural Killer (NK) Cells + Chemotherapy|"Starting on Day -7, G-CSF daily by vein until post nadir of absolute neutrophil counts (ANC) are equal or over 1000. Day -6 to Day -2 Fludarabine administrated by vein at 30 mg/m^2. Four hours later Cytarabine administrated by vein at 2 g/m^2. Natural killer (NK) cell infusion Days 0 to 14 for 6 doses total. The first group of participants receive lowest dose level. Each new group receives a higher dose than the group before it, if no intolerable side effects were seen. This will continue for up to 6 dose levels or until the highest tolerable dose of NK cells is found. One (1) to 10 participants will be treated in each dose level.~NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema."
3115165|NCT01787461|Experimental|Imedeen|Imedeen is the study product
3115166|NCT01787461|Placebo Comparator|Placebo|
3115167|NCT01787448|Experimental|Ibuprofen 5% topical gel|
3115168|NCT01787448|Experimental|Topical gel vehicle|
3115169|NCT01787448|Active Comparator|Sodium lauryl sulfate 0.1%|
3115170|NCT01787448|Sham Comparator|Sodium chloride solution 0.9% (saline)|
3115171|NCT01787435||All women exposed to PPI at any time during pregnancy|Exposure to PPI defined as presence of at least one prescription of a PPI any time between last menstrual period and delievry date
3115172|NCT01787435||All women exposed to H2RA at any time during pregnancy|Exposure to H2RA defined as presence of at least one prescription of H2RA any time between last menstrual period and delivery date
3115173|NCT01787435||Pregnant women with no recorded use of acid suppressing drugs|Pregnant women with no recorded use of acid suppressing drugs at any time during pregnancy
3115174|NCT01787422|Experimental|Telemedicine Visit|Patients who are seen by use of an off-site telemedicine physician.
3115175|NCT01787422|Active Comparator|Traditional Visit|Patients who are seen in followup with a traditional in-office visit.
3115176|NCT01787409|Experimental|Treatment (cholecalciferol)|Vitamin D sufficient patients receive no intervention. Vitamin D insufficient patients receive cholecalciferol PO once weekly for 12 weeks and then once monthly for a total of 36 months.
3115177|NCT01787396|Experimental|Arm1|Gemigliptin 50mg + Metformin Once daily with dinner
3115178|NCT01787396|Experimental|Arm 2|Gemigliptin 50mg + Placebo(Metformin)Once daily with dinner
3115179|NCT01787396|Experimental|Arm3|Metformin+ Placebo(Gemigliptin 50mg)Once daily with dinner
3115180|NCT01787383|Active Comparator|Ingenol mebutate gel 0.05 %|
3115181|NCT01787383|Active Comparator|Ingenol mebutate gel 0.015 %|
3115182|NCT01787370||Patients undergoing coronary angiography|Consecutive patients referred for coronary angiography for the suspect of coronary artery disease
3115183|NCT01787357|Experimental|Sequence 1 (ADBC)|Each volunteer will receive Treatment A on Day 1 of Treatment Period 1, followed by Treatment D on Day 1 of Treatment Period 2, followed by Teatment B on Day 1 of Treatment Period 3, and followed by Treatment C on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
3115184|NCT01787357|Experimental|Sequence 2 (BACD)|Each volunteer will receive Treatment B on Day 1 of Treatment Period 1, followed by Treatment A on Day 1 of Treatment Period 2, followed by Treatment C on Day 1 of Treatment Period 3, and followed by Treatment D on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
3115185|NCT01787357|Experimental|Sequence 3 (CBDA)|Each volunteer will receive Treatment C on Day 1 of Treatment Period 1, followed by Treatment B on Day 1 of Treatment Period 2, followed by Treatment D on Day 1 of Treatment Period 3, and followed by Treatment A on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
3115186|NCT01787357|Experimental|Sequence 4 (DCAB)|Each volunteer will receive Treatment D on Day 1 of Treatment Period 1, followed by Treatment C on Day 1 of Treatment Period 2, followed by Treatment A on Day 1 of Treatment Period 3, and followed by Treatment B on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
3115187|NCT01787344|Experimental|Botulinum toxin type A (Botulax®)|Botulinum toxin type A (Botulax®)
3115188|NCT01787344|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®)
3115189|NCT01787331|Experimental|Treatment (itraconazole)|Patients receive itraconazole PO BID in the absence of disease progression or unacceptable toxicity.
3115190|NCT01787318|Experimental|ePID closed loop system using Insupatch|Insupatch activated at mealtimes
3115191|NCT01787318|Active Comparator|ePID closed loop system without InsuPatch|InsuPatch will not be activated at mealtimes
3115192|NCT01787292|Experimental|Motor coordination training|Finger movement coordination training using sequenced finger movements of varying pressure.
3115193|NCT01787292|Experimental|Exercise - cycling|3 bouts of 45 minutes weekly on a cycle ergometer. HR will be kept at 75% of age-related maximum
3115194|NCT01787292|Active Comparator|Waiting period|12 week enrollment waiting period after which treatment arms will begin
3115195|NCT01787292|Experimental|Long-term exercise - cycling|6 month self-monitored training phase during which time participants will exercise according to prescribed regimen (cycling)
3115196|NCT01787279|Experimental|Peginterferon alpha-2a, 180 mcg/48 weeks|Eligible participants with HI3vAg (a type of Hepatitis B surface antigen) negative chronic hepatitis B will be administered peginterferon alpha-2a (PEGASYS), 40kD, 180 micrograms (mcg) subcutaneously once weekly for 48 weeks. The untreated Follow-up will be for 24 weeks.
3115197|NCT01787266||1|pregnant women
3115198|NCT01787253||Irritable bowel syndrome (IBS)|
3115199|NCT01787253||Healthy controls|
3115200|NCT01787253||Microscopic Colitis (MC)|
3115201|NCT01787253||Irritable bowel disease (IBD)|
3115202|NCT01787240|Placebo Comparator|Placebo|After a screening visit, the patient will undergo a baseline assessment and will be randomized to escitalopram 10mg or placebo.
3115203|NCT01787240|Experimental|Escitalopram 10mg|After a screening visit, the patient will undergo a baseline assessment and will be randomized to escitalopram 10mg or placebo.
3115204|NCT01787227||Blinded, Pre-selected Arm|For targets that exhibit lower prevalence rates in the intended use population, banked, pre-selected, positive clinical specimens will be tested.
3115205|NCT01787227||Blinded, Prospective Arm|Diagnostic accuracy for the more prevalent targets will be evaluated in prospectively collected, de-identified, left-over, clinical specimens accrued during the 2012/2013 flu season.
3115206|NCT01787214|Active Comparator|Full dose|full dose of walnuts (20% energy needs)
3115207|NCT01787214|Active Comparator|Half-dose|Half dose of walnuts (10% of energy needs)
3115208|NCT01787214|Other|Control|Walnut free meals
3115209|NCT01787188|Experimental|Meloxicam Test Capsules low dose QD|Meloxicam Test Capsules low dose QD
3115210|NCT01787188|Experimental|Meloxicam Test Capsules high dose QD|Meloxicam Test Capsules high dose QD
3115211|NCT01787188|Placebo Comparator|Placebo Capsule QD|Placebo Capsule QD
3115212|NCT01787175|Experimental|Integrated Medication Manager|Experienced providers that participated in the EHR simulations. Half of the providers were assigned to use the new Integrated Medication Manager (intervention) during the simulation. The other half were assigned the VA's CPRS to use (standard EHR). Providers were randomly assigned which system to use.
3115213|NCT01787175|No Intervention|Standard EHR|Experienced providers that participated in the EHR simulations. Half of the providers were assigned to use the new Integrated Medication Manager (intervention) during the simulation. The other half were assigned the VA's CPRS to use (standard EHR). Providers were randomly assigned which system to use.
3115214|NCT01787162||myeloproliferative disorders|Echocardiography, spiroergometry, cardiac catheterization
3115215|NCT01787149|Placebo Comparator|Placebo|DMARDs alone
3115216|NCT01787149|Experimental|ENIA11|ENIA11 25 mg
3115217|NCT01787123|Placebo Comparator|Control: standard management|Standard management for patient suffering from aneurysmal subarachnoid haemorrhage
3115251|NCT01786889|Experimental|Patient with angiosarcoma of the liver|Blood and urine collections, questionnaire and telephone interview
3115218|NCT01787123|Active Comparator|Intervention: standard management AND Cerebrolysin|Standard management for aneurysmal subarachnoid hemorrhage and a 14-day administration of intravenous Cerebrolysin
3115219|NCT01787110|No Intervention|No oxygen|"For patients randomised to withholding oxygen treatment~no oxygen is administered at any time as long as the oxygen saturation is ≥90% on pulse oximeter (repetitive checks are performed)~all patients receive standard acute coronary syndrome treatment including reperfusion strategies~observation duration 12 hours"
3115220|NCT01787110|Active Comparator|Oxygen|"For patients randomised to oxygen therapy:~6 L/min of oxygen delivered by oxymask® started immediately after inclusion of the ambulance service or in the emergency department given continuously for 6-12 hours (at least 6 hours)~all patients receive standard acute coronary syndrome treatment including reperfusion strategies"
3115221|NCT01787097|Experimental|Symbicort®, Formoterol, Budesonide|"All Patients will receive randomly one-off dose of the following treatments:~Formoterol (FORM) total dose 24ug: is a LABA chosen at a higher clinical dose to determine whether this treatment can achieve an effective treatment response on GR in sputum cells compare to treatments 2 and 3.~Symbicort® total dose 400ug/12ug: is a combination of FORM (6ug) and ICS (Budesonide, (BUD) 200ug) at a lower-dose to determine whether this combination can have an effect on GR in sputum cells compare to treatment 4, 1 and 3.~Symbicort® total dose 800ug/24ug: is a combination FORM (12ug) and BUD (400ug) at a higher-dose, chosen to compare the effect on GR with treatment 4 and 1~BUD total dose 800ug: is an intermediate dose of ICS chosen for comparison with treatments 2 and 3 on GR."
3115222|NCT01787084||Inoperable Patients Alternative Access|Non-femoral delivery (or alternative access) in patients iwht severe symptomatic native aortic valve stenosis who have been determined by a cardiac surgeon to be inoperable for open aortic valve replacement and in whom existing co-morbidities would not preclude the expected benefit from correction of the aortic stenosis
3115223|NCT01787071||one group|Patients receiving fluid challebnge
3115224|NCT01787058||Dubai Cares beneficiary|Pupils who attend a school that has benefitted from a water, sanitation and hygiene intervention as part of the Dubai Cares program.
3115225|NCT01787058||Control|Pupils who attend a school of the same size and location as a school that benefitted from a water, sanitation and hygiene (WASH) intervention through the Dubai Cares program, but which has not benefitted from that program or any other WASH program since 2009.
3115226|NCT01787045|Experimental|Intervention Group|"Early and Active Physical Therapy will be performed by physiotherapist twice a day. During first week patients will be positioned in chair or bed and performed cycle-ergometer exercise during 30 min.~Our physiotherapy protocol will be continued until Intensive Care Unit (ICU) discharge."
3115227|NCT01787045|Other|Control Group|Routinary Passive Range of Motion will be performed by physiotherapist 20 min and twice a day until ICU discharge.
3115228|NCT01787032|Experimental|Period 3: BI 113608+Voriconazole|tablets with 240 ml water
3115229|NCT01787032|Experimental|Period 2: BI 113608+Ketoconazole|tablets with 240 ml water
3115230|NCT01787032|Experimental|Period 1: BI 113608|tablets with 240 ml water
3115231|NCT01787019|Experimental|30 weeks|initiation of oral feedings at 30 weeks
3115232|NCT01787019|Active Comparator|33 weeks|initiation of oral feedings at 33 weeks
3115233|NCT01787006|Experimental|Cetuximab, Cisplatin, 5-FU, Radiotherapy|"Cetuximab: Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total, IV~5-FU: 1000mg/m2 per day as continuous infusion on day 8-11 and 36-39, 750mg/m2/day as continuous infusion on day 71-74 and 99-102~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle (day 8-11, 36-39, 71-74 and 99-102)~radiotherapy: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery."
3115234|NCT01787006|Active Comparator|Cisplatin, 5-FU, Radiotherapy|"5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 and 29-32, 750mg/m2/day as continuous infusion on day 64-67 and 92-95~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle (day 1-4, 29-32, 64-67 and 92-95)~radiotherapy: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery."
3115235|NCT01786993|Experimental|Multi-point pacing arm|MultiPoint Pacing
3115236|NCT01786993|Active Comparator|Biventricular arm|Traditional Biventricular Pacing
3115237|NCT01786980||liver cancer, Radical hepatic resection|
3115238|NCT01786967|Experimental|Fesoterodine Fumarate|Participants will receive 4 mg of study drug for first 2 weeks, and then 8 mg of study drugs for 2 weeks.
3115239|NCT01786954|Experimental|Icare then Goldmann then Tonopen|Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation. Patients receive Icare first and then are randomized to receive Tonopen followed by Goldmann OR Goldmann followed by Tonopen. This arm is Icare then Goldmann then Tonopen.
3115240|NCT01786954|Experimental|Icare then Tonopen then Goldmann|Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation. Patients receive Icare first and then are randomized to receive Tonopen followed by Goldmann OR Goldmann followed by Tonopen. This arm is Icare then Tonopen then Goldmann.
3115241|NCT01786941|No Intervention|Lean Group|Healthy Controls - no intervention
3115242|NCT01786941|Other|Pre-Diabetes Group|Pre-Diabetes Group will undergo a 6-mo Aerobic and Resistance combined exercise training intervention
3115243|NCT01786941|Other|Gastric Bypass Group|Non-diabetic patients intending to undergo Gastric Bypass surgery
3115244|NCT01786928|Experimental|resistance training|resistance training of the upper and lower limbs, two series of 80% of repetition maximum test
3115245|NCT01786928|No Intervention|Control|Traditional Respiratory Therapy for bronchial hygiene
3115246|NCT01786915|Experimental|Bendavia 10mg|Bendavia capsule, 10mg, once daily for 7 days
3115247|NCT01786915|Placebo Comparator|Placebo|Placebo (matching), once daily for 7 days
3115248|NCT01786915|Experimental|Bendavia 50mg|Bendavia capsule, 50mg, once daily for 7 days
3115249|NCT01786902|Experimental|DA-3002 Treatment group|1.11 IU(0.37mg)/kg bodyweight of DA-3002 per week given by subcutaneous injections (six or seven times per week)
3115250|NCT01786902|No Intervention|Non-treatment control group|Height be measured with no treatment
3115256|NCT01786824|Experimental|Bicarbonate|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy containing sodium bicarbonate.~Intervention: Hydration strategy using sodium bicarbonate Intervention: Coronarography"
3115257|NCT01786824|Active Comparator|Saline|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy using sodium chloride solution.~Intervention: Hydration strategy using saline Intervention: Coronarography"
3115258|NCT01786824|Experimental|Bicar + L-Carnitine|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy containing sodium bicarbonate. They will also receive an oral L-carnitine solution on days -1, 0, 1 to 7.~Intervention: Hydration strategy using sodium bicarbonate Intervention: L-carnitine Intervention: Coronarography"
3115259|NCT01786824|Experimental|Saline + L-carnitine|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy using sodium chloride solution. They will also receive an oral L-carnitine solution on days -1, 0, 1 to 7.~Intervention: Hydration strategy using saline Intervention: L-carnitine Intervention: Coronarography"
3115260|NCT01786811|Experimental|Trained Clinicians|Clinicians randomized into this group will receive training in using the Serious Illness Conversation Guide with their patients. Patients of these clinicians will also be in the intervention arm.
3115261|NCT01786811|No Intervention|Non-trained Clinicians|Clinicians randomized into this group will not receive training in using the Serious Illness Conversation Guide with their patients. They will provide usual care. Patients of these clinicians will also be in the control arm.
3115262|NCT01786811|No Intervention|Non-volunteer Clinicians|These clinicians do not agree to participate in the study. They will continue to provide usual care. Their patients will be invited to participate and be followed.
3115263|NCT01786798|Other|Transvaginal sonography|
3115264|NCT01786785||Stroke Patients|Subjects between 2 and 17 years of age with a confirmed arterial ischemic stroke.
3115265|NCT01786785||Controls|Age and Gender Matched Controls
3115266|NCT01786772|Experimental|Cryotherapy and compression|Cryotherapy and intermittent pneumatic compression will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. Circumferential intermittent pneumatic compression to the knee joint (5 to 50 mm Hg) will be applied in conjunction with cryotherapy. The duration of intervention will be 20 minutes.
3115267|NCT01786772|Active Comparator|Cryotherapy|Cryotherapy will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. The duration of intervention will be 20 minutes.
3115268|NCT01786759|Active Comparator|LCT lipid emulsion|the LCT lipid emulsion is Intralipid
3115269|NCT01786759|Experimental|Olive oil lipid emulsion|the olive oil lipid emulsion is ClinOleic
3115270|NCT01786746|Experimental|Psychotherapy|Psychotherapy arm that consists of a randomization into 12 session manualized cognitive behavioral therapy or culturally adapted cognitive behavioral therapy for Chinese Americans.
3115271|NCT01786733|Experimental|Behavioral Activation|Behavioral Activation + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at increased activation towards goals and personal values and decreased avoidance behaviors.
3115272|NCT01786733|Active Comparator|Supportive Therapy|Supportive Therapy + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at providing psychological non-directive support.
3115273|NCT01786720||Prior Triple Therapy|Patients prescribed triple therapy prior to initial date of COPD diagnosis
3115274|NCT01786720||Triple therapy at COPD diagnosis|Patients prescribed triple therapy on date of initial COPD diagnosis
3115275|NCT01786720||Triple therapy after COPD diagnosis|Patients prescribed triple therapy after initial date of COPD diagnosis
3115276|NCT01786707|Experimental|Autologous SC and HOT|Autologous stem cells and hyperbaric oxygen therapy
3115277|NCT01786707|Active Comparator|Control group|Patients in a control group will continue with standard medical treatment (Insulin and Metformin)
3115278|NCT01786694|Experimental|cma microdialysis catheter placement|At the end of the surgery the cma microdialysis catheter is placed near the anastomosis
3115279|NCT01786681|Experimental|Positive pressure before surgery|Subjects treated with positive pressure in the BiPAP mode (Bi-Level Positive Airway Pressure) for one hour before bariatric surgery.
3115280|NCT01786681|Experimental|Positive pressure during the surgery|Individuals treated with 10 cm H2O of PEEP (Positive End Expiratory Pressure) during the surgical procedure.
3115281|NCT01786681|Experimental|Positive pressure after surgery|Subjects treated with positive pressure in the BiPAP mode (Bi-Level Positive Airway Pressure) for one hour after bariatric surgery.
3115282|NCT01786681|No Intervention|Control|Individuals treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
3115283|NCT01786668|Experimental|Tofacitinib 2 mg|
3115284|NCT01786668|Experimental|Tofacitinib 5 mg|
3115285|NCT01786668|Experimental|Tofacitinib 10 mg|
3115286|NCT01786668|Placebo Comparator|Placebo|
3115287|NCT01786655|Experimental|Neosaxitoxin in saline|Subjects receive only one injection of NeoSTX in saline on the back of one calf (test side). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5mcg, 10mcg, 15mcg, 20mcg, 30mcg, and 40mcg NeoSTX.
3115288|NCT01786655|Experimental|Neosaxitoxin + bupivacaine 0.2%|Subjects receive only one injection of NeoSTX in combination with 0.2% bupivacaine on the back of one calf (test side). Subjects receive NeoSTX in bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg NeoSTX.
3115289|NCT01786655|Experimental|Neosaxitoxin + bupivacaine 0.2% + epinephrine 5mcg/ml|Subjects receive one injection of NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml on the back of one calf (test side). Subjects receive NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
3115290|NCT01786655|Placebo Comparator|Saline placebo|Subjects receive one injection of saline on the back of one calf (test side).
3115291|NCT01786642||conscious|bronchoscopy without sedative drugs
3115292|NCT01786642||conscious sedation|bronchoscopy under midazolam
3115294|NCT01786629|Active Comparator|FDA approved bowel preparation|FDA approved bowel preparation containing electrolytes
3115295|NCT01786616||Formoterol|12 mcg BID for four weeks
3115296|NCT01786603|Experimental|Rasagiline|Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
3115297|NCT01786603|Placebo Comparator|Placebo|Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
3115298|NCT01786590|Experimental|EBUS-TBNA|
3115299|NCT01786577|Active Comparator|Surgery|80 patients will undergo total knee replacement surgery; two Magnetic Resonance Imaging scans; cognitive assessment testing.
3115300|NCT01786577|Active Comparator|Non-Surgery|80 non-surgery participants will be included as part of the control group; two Magnetic Resonance Imaging scans; cognitive assessment testing.
3115301|NCT01786551|Experimental|Eplerenone|Eplerenone 50 mg daily for 14 days
3115302|NCT01786538|Experimental|Regorafenib/FOLFOX|
3115303|NCT01786538|Active Comparator|Placebo/FOLFOX|
3115304|NCT01786525|Experimental|House Calls only|60-minute educational intervention in patient's home which will be delivered by a health educator.
3115305|NCT01786525|Active Comparator|House Calls + Web-Based Decision Support|Home based intervention plus web-based patient-centered decision support program that will be offered to participants following the home based intervention.
3115306|NCT01786525|No Intervention|Control|100 patients on the Organ Transplant Tracking Record who are not receiving the study intervention
3115307|NCT01786512|Experimental|Omecamtiv mecarbil|
3115308|NCT01786512|Placebo Comparator|Placebo|
3115309|NCT01786499|Other|Relaxation Response Training|
3115310|NCT01786486||Delivery system entry|
3115311|NCT01786473|Experimental|Testogel 1% 5g QD|
3115312|NCT01786473|Placebo Comparator|Placebo gel 5g QD|
3115313|NCT01786460||Healthy Volunteers|
3115314|NCT01786447||Traumatic Brain Injury|Patients who present to the health care facility with mild or moderate traumatic brain injury (Glasgow Coma Scale 9-15) within 4 hours of injury
3115315|NCT01786447||Orthopedic Control|Patients who present to the health care facility with isolated extracranial orthopedic injury within 4 hours of injury
3115316|NCT01786434|Experimental|Routine medication arm|Fentanyl is given routinely to all patients before the procedure
3115317|NCT01786434|Active Comparator|Fentanyl on-demand arm|Fentanyl is given during the procedure if the patient experiences pain
3115318|NCT01786421||General population|Healthy volunteers,patients with hyperlipidemia,a known medical history of cardiovascular diseases or type 2 diabetes mellitus.
3115319|NCT01786408|Experimental|TAP20-C|Single Use Integrated Capillary Blood Collection System
3115320|NCT01786408|Active Comparator|SAFE-T-FILL CAPILLARY SYSTEM|Single Use Capillary Blood Collection System
3115321|NCT01786395|Experimental|- UF-021|UF-021 is experimental code for isopropyl unoprostone
3115322|NCT01786395|Placebo Comparator|- Placebo|
3115323|NCT01786382|Experimental|midazolam|potential effects of PPI-668 on midazolam pharmacokinetics
3115324|NCT01786382|Experimental|omeprazole|potential effects of PPI-668 on omeprazole pharmacokinetics
3115325|NCT01786382|Experimental|telaprevir|potential effects of PPI-668 on telaprevir pharmacokinetics
3115326|NCT01786369||Admitted Patients with Acute Psychosis|Patients 18 years of age or older with a documented diagnosis of schizophrenia, schizoaffective disorder, or bipolar 1 disorder who are admitted to an inpatient psychiatric unit at Zucker Hillside Hospital for a psychotic compensations. Patients must have been in the outpatient setting for at least one month prior to admission on a regimen including risperidone, olanzapine, quetiapine, paliperidone or aripiprazole.
3115327|NCT01786356|Other|HOYA iMics Y-60H|eyes with implanted intraocular lens HOYA iMics Y-60H
3115328|NCT01786356|Other|B&L MI60|eyes with implanted intraocular lens B&L MI60
3115329|NCT01786343|Experimental|Decitabine - 5 Day Regimen|Decitabine 20 mg/m2 by vein daily for 5 days.
3115330|NCT01786343|Experimental|Decitabine - 10 Day Regimen|Decitabine 20 mg/m2 by vein daily for 10 days.
3115331|NCT01786330|Experimental|Intervention|Group receives elastic abdominal binders after surgery. Binder used is Procare manufactured by DJO, LLC. Binders are to be worn for 24 hours after surgery.
3115332|NCT01786330|Active Comparator|Control|Group receives standard of care
3115333|NCT01786317||Fecal incontience|Patient with fecal incotinence who will be explored using high resoltuion manometry
3115334|NCT01786317||Healthy controls|Healthy volunteers who will be explored using high resoltuion manometry
3115335|NCT01786304||Fecal incontinence|Patient with fecal incontinence and referred for a treatment with sacral nerve stimulation
3115336|NCT01786291||CPAP compliant|CPAP (continuous positive airway pressure) compliant patients
3115337|NCT01786291||CPAP non-compliant|patients who did not use CPAP therapy
3115338|NCT01786278|Experimental|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
3115339|NCT01786278|Other|Endoscopic Stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
3115340|NCT01786265|Experimental|Group A: LHRH Alone|"Group A LHRH Alone Group: Participants receive standard of care hormonal therapy. The study doctor will decide what hormone therapy participants receive. Participants already started on a 3-monthly injection schedule (Lupron 22.5 mg or Zoladex 10.8 mg) will also be allowed to enter the trial. The day of injection will coincide with Day 1 of treatment.~Crossover Study Phase:~Participants who experience a PSA progression or objective evidence of progressive disease eligible for the crossover phase. Participants who had received LHRH agonist alone treated with the combination of LHRH agonist and abiraterone acetate plus prednisone for eight months. Participants who received the combination therapy will receive LHRH agonist alone."
3115385|NCT01786018|Experimental|1|"Thiotepa 5 mg/kg/day on days -7, -6 (Total Dose 10 mg/kg)~Busulfan (i.v.) 3.2 mg/kg on days -5,-4,-3 (Total Dose 9.6 mg/kg)~Fludarabin: 50 mg/m2/day on days -5,-4,-3 (Total Dose 150 mg/m2)"
3115386|NCT01786005|Sham Comparator|Sham|Imitation of stimulation.
3115341|NCT01786265|Experimental|Group B: LHRH + Abiraterone Acetate + Prednisone|"Group B LHRH + Abiraterone Acetate + Prednisone Group: Participants receive standard of care hormone therapy as in Group A. Abiraterone acetate given at a dose of 4 tablets (250 mg each) by mouth each day. Prednisone given at a dose of 5 mg by mouth daily.~Crossover Study Phase:~Participants who experience a PSA progression or objective evidence of progressive disease eligible for the crossover phase. Participants who had received LHRH agonist alone treated with the combination of LHRH agonist and abiraterone acetate plus prednisone for eight months. Participants who received the combination therapy will receive LHRH agonist alone."
3115342|NCT01786252|Experimental|Drug: human chorionic gonadotropin (hCG)|"Drug: human chorionic gonadotropin (hCG). A single intrauterine infusion of 500IU hCG dissolved in IVF media (Global-trademark) will be administered to participants in the experimental group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic where a uterine lavage and an endometrial biopsy will be performed to obtain a sample of uterine secretory proteins and endometrial tissue, respectively, for research analysis."
3115343|NCT01786252|Placebo Comparator|"IVF media (Global-trademark)"|Placebo Comparator for hCG. A single intrauterine infusion of IVF media without hCG will be administered to participants in the control group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic and a sample of uterine secretory proteins and endometrial tissue, will be obtained via uterine lavage and endometrial biopsy, respectively, for research analysis.
3115344|NCT01786239|Experimental|Omega-3 capsules & Risperidone|Subjects will take 1 capsule in the morning and 1 capsule in the evening. Each capsule contains 370 mg EPA and 200 mg DHA as well as 2 mg/g tocopherol. The study dose will start on day 1 and remain the same throughout the study.
3115345|NCT01786239|Other|Placebo & Risperidone|Subjects will take 1 capsule in the morning and 1 capsule in the evening.The placebo is a soybean/corn blend (each capsule contains 1000 mg). The study dose will start on day 1 and remain the same throughout the study.
3115346|NCT01786226|Experimental|Mifepristone 2.5 mg daily for three months|Experimental: 1
3115347|NCT01786226|Experimental|Mifepristone 5 mg daily for three months|Experimental: 2
3115348|NCT01786213||Colonoscopist A|
3115349|NCT01786213||Colonoscopist B|
3115350|NCT01786213||Colonoscopist C|
3115351|NCT01786213||Colonoscopist D|
3115352|NCT01786213||Colonoscopist E|
3115353|NCT01786213||Colonoscopist F|
3115354|NCT01786213||Colonoscopist G|
3115355|NCT01786213||Colonoscopist H|
3115356|NCT01786213||Colonoscopist I|
3115357|NCT01786213||Colonoscopist J|
3115358|NCT01786200|Active Comparator|Aspirin|20 patients randomised to aspirin 75mg PO once daily
3115359|NCT01786200|Active Comparator|Ibuprofen|20 patients randomised to ibuprofen 400mg PO three times daily
3115360|NCT01786200|No Intervention|Control|20 patients randomised to receive no treatment
3115361|NCT01786187|Active Comparator|Symptom Experience Group|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive planned, structured, weekly telephone visits to report the experience of symptoms and health-related quality of life information.
3115362|NCT01786187|Experimental|Light Physical Activity Group|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light physical activity program to help manage a specific symptom related to cancer and cancer treatment.
3115363|NCT01786174|Experimental|Gilenya (fingolimod)|0.5mg Gilenya (fingolimod) orally once daily for 28 days +/- 3 days
3115364|NCT01786174|Placebo Comparator|Placebo|0.5mg placebo (sugar pill) orally once daily for 28 days +/- 3 days
3115365|NCT01786161|Experimental|Vancomycin with continuous infusion|24 hours continuous infusion
3115366|NCT01786161|Active Comparator|Vancomycin with intermittent dose interval|infusion rate 1000mg/hr
3115367|NCT01786148|Active Comparator|Educational music mobile app|A prerecorded program of songs on various topics in a mobile phone application (app). It is designed to provide education about non-health related topics and will be equivalent in length to the intervention app.
3115368|NCT01786148|Experimental|Live Network mobile phone App|The LN is a prerecorded mobile phone application (app). It employs a radio talk show format in which a Disc Jockey entertains HIV medication-, adherence-, and self-management-related questions and comments from callers and poses them to expert care providers, whose responses to these questions are augmented by songs that shed additional light on these issues.
3115369|NCT01786135|Experimental|SGN-CD19A|SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
3115370|NCT01786122|Experimental|Exercise group|supervised exercise program education program on healthy habits Pharmacological treatment and selfcare encouragement
3115371|NCT01786122|No Intervention|control group|Pharmacological treatment and selfcare encouragement.
3115372|NCT01786109|Experimental|Dronabinol 2.5 mg|One dose of dronabinol 2.5 mg was taken orally with water.
3115373|NCT01786109|Experimental|Dronabinol 5 mg|One dose of dronabinol 5 mg was taken orally with water.
3115374|NCT01786109|Placebo Comparator|Placebo|One dose of placebo was taken orally with water.
3115375|NCT01786096|Experimental|SGN-CD19A|SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
3115376|NCT01786083|Experimental|Lifestyle counseling|Application of Problem Solving Technique
3115377|NCT01786083|No Intervention|No counseling|Usual care by caregiver
3115378|NCT01786070|Active Comparator|Budesonide|Budesonide : 1 mg/4ml every 12 hrs for 48 hrs
3115379|NCT01786070|Placebo Comparator|Placebo|Normal saline at an equivalent volume (4 ml every 12 hrs for 48 hrs)
3115380|NCT01786057|Active Comparator|Extracorporeal shock wave therapy 1|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
3115381|NCT01786057|Placebo Comparator|Extracorporeal shock wave therapy 2|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
3115382|NCT01786044|Experimental|MasterMed|MasterMed, an online interactive educational program
3115383|NCT01786044|Placebo Comparator|Usual care|Access to an online patient portal
3115384|NCT01786031|Experimental|experimental|metastasis biopsy
3115387|NCT01786005|Experimental|High-frequency stimulation|High-frequency stimulation
3115388|NCT01786005|Experimental|TBS Theta burst stimulation|TBS Theta burst stimulation
3115389|NCT01786005|Experimental|Low-frequency stimulation|Low-frequency stimulation
3115390|NCT01785992|Other|Irosustat (Single arm study)|Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or the development of unacceptable toxicities.
3115391|NCT01785979|Experimental|Prednisone induction - chloroquine|0.5 mg/Kg daily of prednisone for 4 weeks after randomization, 0.25 mg daily for weeks 5-6, 0.15 mg daily for week 7 and 2.5 mg daily for week 8 and chloroquine at a fixed dose (300 mg base per week) for months 1-12
3115392|NCT01785979|Active Comparator|chloroquine|chloroquine at a fixed dose (300 mg base per week) for months 1-12
3115393|NCT01785966|Experimental|Daily checklist and clinician prompting|Checklist during multidisciplinary daily visits + clinician prompting + audit & feedback
3115394|NCT01785966|No Intervention|Usual care|Usual care
3115395|NCT01785953||1|
3115396|NCT01785940|Experimental|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
3115397|NCT01785927|Other|ABCD|ABCD A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
3115398|NCT01785927|Other|BCDA|BCDA A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
3115399|NCT01785927|Other|CDAB|CDAB A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
3115400|NCT01785927|Other|DABC|DABC A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
3115401|NCT01785914||1|
3115402|NCT01785901||Target subject population 1500|Asthma patients who have already received the treatment of budesonide/formoterol by physicians' determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China
3115403|NCT01785888||Locally advanced/metastatic NSCLC pts.|Patients(pts.) with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy)
3115404|NCT01785875|Experimental|Etelcalcetide|Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.
3115405|NCT01785862|Experimental|Drug|V0498, Ibuprofen 25 mg
3115406|NCT01785862|Placebo Comparator|Placebo|Placebo
3115407|NCT01785849|Experimental|Etelcalcetide|Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session three times a week, for 26 weeks.
3115408|NCT01785849|Placebo Comparator|Placebo|Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
3115409|NCT01785836|Experimental|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
3115410|NCT01785836|Experimental|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
3115411|NCT01785836|Experimental|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
3115412|NCT01785836|Active Comparator|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
3115413|NCT01785823|Experimental|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr
3115414|NCT01785823|Active Comparator|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the decremental rates of 6.0 ml/hr (D6-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr,
3115415|NCT01785823|Active Comparator|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at at the decremental rates of 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr,
3115416|NCT01785810|Experimental|Single Arm|
3115417|NCT01785797|No Intervention|Control: burr hole drainage only|Burr hole drainage of chronic subdural hematoma under general or local anesthesia without the subsequent placement of a subdural drain.
3115418|NCT01785797|Experimental|Intervention: silicon subdural drain|Placement of a silicon subdural drain after burr hole drainage of a chronic subdural hematoma.
3115419|NCT01785784|Experimental|burn patients|
3115420|NCT01785771|Experimental|ITCA 650|
3115421|NCT01785758|Experimental|Renal Group|Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade
3115422|NCT01785758|Active Comparator|Control group|Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade
3115423|NCT01785745|Active Comparator|Traditional therapeutic exercise|The traditional exercise protocol contains mainly strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance.
3115424|NCT01785745|Experimental|Neurocognitive therapeutic exercise|The neurocognitive exercise protocol contains ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture).
3115425|NCT01785732|Active Comparator|Renal denervation|Patients are randomized to renal denervation
3115426|NCT01785732|No Intervention|Optimization of medical therapy|Antihypertensive treatment is optimized
3115485|NCT01785355|Experimental|Dental treatment|Assessment of the clinical state of the patient. Professional prophylaxis and removal of calculus. Extraction of hopeless teeth.Education of patient for oral hygiene. Periodic reevaluation.
3115427|NCT01785719|Experimental|Overweight Women|Regardless of reproductive history, each participant will be provided with six months of the commercial weight loss program, Nutrisystem® D. Nutrisystem® D is a portion-controlled, low calorie, and low glycemic index meal delivery system that provides 1250-1500 kcal/day. It has been proven to help overweight adults achieve real and sustainable weight loss results. When meals and snacks are consumed as instructed, average weight loss is 1-2 lbs per week or 15-20% body weight by the end of six months. Nutrisystem® D offers a balanced meal plan that is consistent with the nutrition recommendations of the USDA for Americans and American Diabetes Association. Each participant will be encouraged to take a daily multivitamin to help meet her micronutrient needs on the program.
3115428|NCT01785693|Other|NaC1|The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption.
3115429|NCT01785693|Other|Levobupivacaine + clonidine|The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption.
3115430|NCT01785680|Active Comparator|Current protocol|These treatment arm is the standard care for moderate malnutrition. This includes a fortified cereal supplement treatment until the child reaches MUAC of above 12.5. Currently, MAM and SAM are treated separately, overseen by different agencies. Breastfeeding is often overlooked.
3115431|NCT01785680|Experimental|Integrated Protocol|Integrated protocol for treatment of children with MAM and SAM in humanitarian emergencies has the potential to result in a more streamlined, cost-effective program, higher recovery, and higher program coverage, allowing easier access to malnourished children, thus curing more children of malnutrition and preventing its lifelong effects.
3115432|NCT01785667||Young Danish adults with type 1 diabetes|This is an observational study with no interventions.
3115433|NCT01785654||reventilation collapse|
3115434|NCT01785641|Experimental|ceftazidime+ciprofloxacin|2 synergistic antibiotics(ceftazidime IP and ciprofloxacin po for gram negative bacterial peritonitis)
3115435|NCT01785641|Active Comparator|ceftazidime monotherapy|ceftazidime IP for gram negative bacterial peritonitis
3115436|NCT01785641|Experimental|cefazolin+gentamicin|cefazolin IP and gentamicin IP for gram positive bacterial peritonitis
3115437|NCT01785641|Active Comparator|cefazolin monotherapy|cefazolin IP for gram positive bacterial peritonitis
3115438|NCT01785628|Experimental|Sarcosine capsule|Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.
3115439|NCT01785628|Placebo Comparator|Placebo capsule|Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.
3115440|NCT01785615|Experimental|Atorvastatin|44 women randomized to 80 mg atorvastatin for 6weeks
3115441|NCT01785615|Placebo Comparator|sugar pill|44 women randomized to placebo for 6 weeks
3115442|NCT01785602|Experimental|QAW039|Participants received QAW039 450 mg daily by mouth.
3115443|NCT01785602|Placebo Comparator|Placebo|Participants received matching placebo to QAW039.
3115444|NCT01785589|Other|coronary angiography-FFR-CZT|Patients who were referred to our cardiology department for stress-rest CZT SPECT for known or suspected CAD and submitted for a clinical reason to invasive coronary angiography within 2 month of the SPECT studies. for these patients, A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
3115445|NCT01785576|Experimental|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
3115446|NCT01785576|No Intervention|Treatment as Usual|The treatment as usual group will complete all assessements and will not receive the psychosocial couple based intervention.
3115447|NCT01785563|Experimental|Nasal NIV-NAVA|Infants will be transitioned from their current mode of ventilation to nasal NIV-NAVA. If patients are currently on nasal NIV-NAVA an increase in the NAVA level will be utilized for the intervention.
3115448|NCT01785550||Control Group|No intervention to be performed.
3115449|NCT01785550||Ultrasound Group|All will receive nerve and muscle ultrasound.
3115450|NCT01785537||E-cigarettes only|Smokers of e-cigarettes containing nicotine only (non smoking traditional cigarettes and inhaling at least 50 puffs per week since six or more months). This group will be further split in the secondary analyses: never or former smokers of traditional cigarettes
3115451|NCT01785537||Traditional cigarettes only|Smokers of traditional cigarettes only (smokers of at least one traditional cigarette per day since six or more months). This group will be further split in the secondary analyses: recent and older smokers.
3115452|NCT01785537||Mixed group|Smokers of both electronic and traditional cigarettes (at least one per day since six or more months). This group will be further split in the secondary analyses: mixed smokers who quit and who did not quit traditional cigarette smoking during follow-up
3115453|NCT01785524|Experimental|BR Juice (Beet-It Stamina Shot) & Supervised Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of beetroot juice and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
3115486|NCT01785342||Indeterminate Pulmonary Nodule|The goal will be accomplished by recruiting 500 smokers with indeterminate pulmonary nodules (0.7cm - 3.0cm) on chest CT who will undergo fiberoptic bronchoscopy and will be followed for 2 years until a final diagnosis is made. Biosample and imaging collection will be done.
3115550|NCT01784965|Placebo Comparator|placebo|Both groups receive dietary weight loss intervention In addition one group received liraglutide and one group received placebo
3115454|NCT01785524|Placebo Comparator|BR Juice Placebo and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot; Placebo) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of placebo beverage and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot (Placebo) 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
3115455|NCT01785511|Sham Comparator|Sham UVA|sham exposure will be provided by covering the UVA lamps with space blanket.
3115456|NCT01785511|Experimental|UVA Radiation|Patients will be exposed to UVA radiation for 20 minutes
3115457|NCT01785498|No Intervention|Control Group|Receive standard clinical care and supports.
3115458|NCT01785498|Experimental|Supplementary resources|Receive standard care and supports plus supplementary resources developed for the intervention.
3115459|NCT01785485||Primary care patients|Primary care patients who are members of UAIHC.
3115460|NCT01785472|Experimental|LCZ696 200 mg|Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.
3115461|NCT01785472|Experimental|LCZ696 400 mg|Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.
3115462|NCT01785472|Active Comparator|Olmesartan 20 mg|Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.
3115463|NCT01785459|Active Comparator|standard care|intravenous Prochlorperazine
3115464|NCT01785459|Experimental|treatment|0.5% bupivacaine
3115465|NCT01785446|Active Comparator|P 1|"In this group patients were aged from 20 to 45. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
3115466|NCT01785446|Active Comparator|P 2|"In this group patients were aged from 46 to 65. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
3115467|NCT01785446|Active Comparator|P 3|"In this group patients were aged from 66 to 85. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
3115468|NCT01785446|Active Comparator|D|"In this group patients were aged from 46to 65. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Dexmedetomidine infusion is started at induction,a bolus dose of 0.5 µg/kg is given over the first hour which is followed by infusion of 0.4 µg/kg/hr.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
3115469|NCT01785433|Experimental|Treatment ABCD|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day"
3115470|NCT01785433|Experimental|Treatment BDAC|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day"
3115471|NCT01785433|Experimental|Treatment CADB|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day"
3115472|NCT01785433|Experimental|Treatment DCBA|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day"
3115473|NCT01785420|Experimental|Drug Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
3115474|NCT01785420|Placebo Comparator|Control|A 90 minute intravenous infusion of saline as placebo
3115475|NCT01785407|Active Comparator|80 mg FeSO4|
3115476|NCT01785407|Active Comparator|40 mg FeSO4|40 mg FeSO4
3115477|NCT01785407|Active Comparator|160 mg FeSO4|
3115478|NCT01785407|Active Comparator|240 mg FeSO4|
3115479|NCT01785394|Active Comparator|5 grass allergen extract|30 patients will receive the active component 5 grass allergen extract daily during the active pollen season (February-July)
3115480|NCT01785394|Placebo Comparator|Placebo|30 patients will receive placebo
3115481|NCT01785381|No Intervention|usual care|usual care
3115482|NCT01785381|Other|Added value of coordinator|Added value of coordinator
3115483|NCT01785368|Other|Before guideline implementation|"This study population consists of all patients for whom a participating ER doctor requests an imaging exam during the observation period BEFORE the implementation of the referral guidelines.~[This study is composed of (1) a period of observation for 1 month BEFORE the implementation of the referral guidelines, followed by (2) the implementation of the referral guidelines, then (3) a 5-6 month washout period, and finally (4) a 1 month observational period AFTER the implementation of the referral guidelines.]~Intervention: Baseline observation"
3115484|NCT01785368|Other|After guideline implementation|"This study population consists of all patients for whom a participating ER doctor requests an imaging exam during the observation period AFTER the implementation of the referral guideline.~[This study is composed of (1) a period of observation for 1 month BEFORE the implementation of the referral guidelines, followed by (2) the implementation of the referral guidelines, then (3) a 5-6 month washout period, and finally (4) a 1 month observational period AFTER the implementation of the referral guidelines.]~Intervention: Implementation of guidelines"
3115487|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose A|"alirocumab SAR236553 (REGN727) - Dose A - Injection in healthy subjects through subcutaneous administration in the abdomen.~alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)"
3115488|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose B|alirocumab SAR236553 (REGN727) - Dose B - Injection in healthy subjects through subcutaneous administration in the upper arm.
3115489|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose C|alirocumab SAR236553 (REGN727) - Dose C - Injection in healthy subjects through subcutaneous administration in the thigh.
3115490|NCT01785316|Experimental|IHP|Isolated Hepatic Perfusion
3115491|NCT01785316|No Intervention|BAC|Best alternative care
3115492|NCT01785303|Active Comparator|Model A|Model A consists of a 4 session CBT-I in phase I and CPAP for OSA in Phase II.
3115493|NCT01785303|Active Comparator|Model B|Model B consists of 4 weeks of monitoring using sleep diaries in Phase I. Phase II consists of concurrent initiation of CBT-I and CPAP for OSA.
3115494|NCT01785303|Other|Model C|Model C consists of 4 weeks of monitoring with sleep diaries in Phase I. Phase II consists of CPAP for OSA.
3115495|NCT01785290|Experimental|Haloperidol 1mg/q8h|Prophylactic haloperidol of 1 mg/q8h i.v.
3115496|NCT01785290|Experimental|Haloperidol 2mg/q8h|Prophylactic haloperidol 2mg/q8h i.v.
3115497|NCT01785290|Placebo Comparator|Sodium chloride 0.9%|Placebo (Sodium chloride 0.9%) three times a day
3115498|NCT01785277||SCIM scores for patients with SCI|All patients with SCI included in the study
3115499|NCT01785264|Active Comparator|Open surgery|Treatment is divided into three arms, and patients between 18 and 60 years of age sustaining first time achilles tendon ruptures will be invited to participate. All three groups will have identical rehabilitation protocol. Open surgical repair is done through a 10 cm longitudinal incision, through the fascia curries and the paratenon. After necessary revision of the injure site, the tendons ends is sutured with a double layer, three knot, Krakow whip suture technique. 5 to 10 degrees of overcorrection compared to the uninjured side is endeavored. The paratenon is sewn as much as possible back over the injure site and suture material. The fascia is sutured and then continuous lying mattress skin suture.
3115500|NCT01785264|Active Comparator|Non-operative treatment|Non-operative treatment starts with casting the ankle in equinus position. The rest of the treatment from there on will be identical to the two other arms: Minimal invasive and open surgery. Casting lasts for 2 weeks for all three arms.
3115501|NCT01785264|Active Comparator|Mini-invasive surgery|Patients allocated to mini-invasive treatment will (as patients treated with open surgery) be operated within 7 days from injury with the technique developed by Dr Amlang and Prof Zwipp in Dresden. Patients in all three arms will have an active, early weight bearing rehabilitation protocol.
3115502|NCT01785251|Experimental|NMES|Application of neuromuscular electrical stimulation to the calf muscles of the patient in order to elicit contraction of the calf muscle pump and thus, eject venous blood proximally.
3115503|NCT01785238|Experimental|cases with neonatal acute renal failure in preterm|
3115504|NCT01785238|Other|controls without neonatal acute renal failure in preterm|
3115505|NCT01785225|Experimental|modified commercial drape Tegaderm (R)|
3115506|NCT01785212|Other|Stapler-hepatectomy|The liver parenchyma is crushed with a Pean clamp and subsequently divided using Covidien Endo-Gia™ Ultra Handle Short Staplers and Endo Gia™ TRI staple 60 mm or 45 mm AVM/AMT loading units (Covidien). Hepatic veins and portal pedicles clamped and suture ligated.
3115507|NCT01785212|Other|CUSA-hepatectomy|The liver parenchyma is divided along the transection line by CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO) and bipolar forceps in a two surgeon technique. Vessels of less than 2 mm in diameter are coagulated with bipolar forceps. The remaining vessels are clipped or ligated. Hepatic veins and portal pedicles clamped and suture ligated.
3115508|NCT01785199|Placebo Comparator|normal (AHI < 5)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
3115509|NCT01785199|Active Comparator|mild OSA (AHI between 5 and 15)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
3115510|NCT01785199|Active Comparator|moderate OSA (AHI between 15 and 30)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
3115511|NCT01785199|Active Comparator|severe OSA (AHI > 30)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
3115512|NCT01785186|Experimental|Arm 1 (R35)|Arm 1 (R35): HR35ZE isoniazid, rifampicin 35 mg/kg, pyrazinamide, ethambutol
3115513|NCT01785186|Experimental|HRZQ|Arm 2 (Q): HRZQ isoniazid, rifampicin standard, pyrazinamide, SQ109 300 mg
3115514|NCT01785186|Experimental|HR20ZQ|Arm 3 (R20Q): HR20ZQ isoniazid, rifampicin 20 mg/kg, pyrazinamide, SQ109 300 mg
3115515|NCT01785186|Experimental|HR20ZM|Arm 4 (R20M): HR20ZM isoniazid, rifampicin 20 mg/kg, pyrazinamide, moxifloxacin 400 mg
3115516|NCT01785186|Active Comparator|HRZE|HRZE: Isoniazid, rifampicin standard, pyrazinamide, ethambutol
3115517|NCT01785173|Experimental|Endoscopic-guided gauze pledgetting|All patients in the study group receive endoscopic-guided gauze pledgetting (EGGP) nasal anesthesia. Each patient will receive an anterior rhinoscopy to select the most patent meatus for gauze pledegetting by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up the acute angle between the shorter leg and hypotenuse of a right-angled gauze strip (already soaked with anesthesia/decongestant) and retract back just into the biopsy channel. When the transnasal endoscope tip is set in the nasal vestibule, the preloaded biopsy forceps is protruded slowly into the desired meatus under endoscope monitoring. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
3115548|NCT01784978|Experimental|Rotational arm|Alternating cycles of treatment with sunitinib and everolimus; repeating cycles of 24 weeks of treatment consisting of 12 weeks of sunitinib 4weeks on 2 weeks off, 50 mg pd followed by 12 weeks of everolimus 10 mg per day 11 weeks on 1 week off in patients with metastatic clear cell renal cancer.
3115549|NCT01784978|Active Comparator|Sequential arm|The comparative arm will be the standard regimen of sunitinib (50 mg pd 4/2) until progression, followed thereafter by everolimus (10 mg per day continuously, 11/1) until progression.
3115588|NCT01784744||ASD Control|Patients aged 5 to 17 diagnosed with ASD.
3115518|NCT01785173|Active Comparator|Cotton-tipped applicator pledgetting|"Another randomized group of patients will receive cotton-tipped applicator gauze pledgetting (CTGP) method of nasal anesthesia. Two cotton-tippled applicators help determine the following: (a) right or left side, (b) inferior or middle nasal meatus (INM or MNM) and (c) the need of local epinephrine. The investigators apply gently in parallel two sterile 3 x 1/10, double-ended, plastic shaft cotton-tipped applicators, pretreated with minimal amount of 2% viscous lidocaine plus 4% liquid lidocaine, to lubricate and anesthetize the more patent meatus One cotton-tipped applicator is re-used to deliver a triangular gauze strip to the selected meatus during the gauze pledgetting procedure."
3115519|NCT01785160|Active Comparator|Raltegravir|coated tablets, oral administration with 240 ml water
3115520|NCT01785160|Experimental|Raltegravir + Faldaprevir|coated tablets and soft gelatine capsule, oral administration with 240 ml water
3115521|NCT01785147|Experimental|BP1.4979 3mg|BP1.4979 3mg during 3 months
3115522|NCT01785147|Experimental|BP1.4979 10mg|BP1.4979 10mg during 3 months
3115523|NCT01785147|Experimental|BP1.4979 15mg|BP1.4979 15mg during 3 months
3115524|NCT01785147|Placebo Comparator|Placebo|Placebo during 3 months
3115525|NCT01785134|Sham Comparator|Control|Gastric bypass operation without omentectomy.
3115526|NCT01785134|Active Comparator|Omentectomy|Gastric bypass operation in conjunction with removal of greater omentum
3115527|NCT01785121|Active Comparator|Control Group|Patients who are randomized to the MSO group will get a protocoled exercise advice from a member of the HF team (nurse, cardiologist or physiotherapist). During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their current activity.
3115528|NCT01785121|Experimental|Wii Group|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
3115529|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20µg, Vitamin D and Ibuprofen|"GAD-Alum (Diamyd) 20 µg given twice with one month interval~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450~Ibuprofen, 400 mg/day, from Day 1 to Day 90"
3115530|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20µg and Vitamin D|"GAD-Alum (Diamyd) 20 µg given twice with one month interval~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450"
3115531|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20 µg x 2 and Vitamin D|"GAD-Alum (Diamyd) 20 µg X 2 given twice with one month interval~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450"
3115532|NCT01785108|Placebo Comparator|Placebo|
3115533|NCT01785095|Experimental|FSH|FSH (Follicle stimulation hormone, 75 IU/vial) will be administered to women according to their need and response assessed by the Investigator.
3115534|NCT01785082|Experimental|LiMAx-group|Intravenous pre- and post-surgical injection of 0.4% 13-C-Methacetin solution. Dosage is adapted due to body weight (2 mg/kg). A LiMAx-test of >150 µg/kg/h would correspond to a general ward indication.
3115535|NCT01785082|No Intervention|control group|Control group without intervention. Post-surgical management as defined prior to surgery following well-established clinical standards.
3115536|NCT01785056|Experimental|Privigen|Privigen is a ready-to-use, sterile, 10% protein liquid preparation of polyvalent human immunoglobulin G (IgG) for intravenous administration. Subjects will be given 2 g/kg/month of IVIGfor 6 months. Each dose will be split into 2 to 4 infusions on consecutive days to achieve the total monthly dose.
3115537|NCT01785056|Placebo Comparator|Placebo (Albuminar-5)|Albuminar-5 is a sterile solution of albumin obtained from large pools of adult human venous plasma and used as the placebo in this study. Albuminar-5 will be administered by the intravenous route and each dose will be split into 2 to 4 infusions on consecutive days to achieve the total monthly dose.
3115538|NCT01785043|Experimental|Liraglutide|Liraglutide will be administered once a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given independently of meals and preferably at the same each day. The starting dose will be 0.6 mg. After one week, the dose will be increased to 1.2 mg, and then it will be increased to 1.8 mg one week later to achieve better control of blood glucose. When Liraglutide is added to existing treatment containing metformin, as it is our scenario, the dose of metformin does not have to be changed.
3115539|NCT01785043|Active Comparator|Sitagliptin|"Sitagliptin will be administered once daily at a 100 mg dose. When Sitagliptin is used in combination with metformin, as it is our scenario, the dose of metformin should be maintained. If a dose of Sitagliptin is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.~Sitagliptin will be used daily during the study period of 12 weeks."
3115540|NCT01785030|Experimental|50% Nitrous oxide|
3115541|NCT01785017||Chidren with critical asthma|Pre- and post-SCAMP
3115542|NCT01785004|Active Comparator|Vitamin D + fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
3115543|NCT01785004|Active Comparator|Vitamin D + fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
3115544|NCT01785004|Active Comparator|Vitamin D placebo + fish oil|Vitamin D placebo and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
3115545|NCT01785004|Placebo Comparator|Vitamin D placebo + fish oil placebo|Vitamin D placebo and fish oil placebo
3115546|NCT01784991|Active Comparator|1mg + 1mg Hydromorphone|Patient will receive 1 mg of hydromorphone for pain at timepoint 0. After 15 minutes, patients will be asked if the still need pain medication. If yes, patients will immediately receive 1mg hydromorphone. Patients will be under continuous monitoring for respiratory depression via capnometer. At 60 minutes, pain will be re-assessed for a second time. If needed, physician will give additional pain meds per their discretion.
3115547|NCT01784991|Active Comparator|Usual Care Group|"Patient will receive pain medicine per doctor's discretion at timepoint 0. After 15 minutes, patients will be asked if they still need pain medication. If yes, physicians will not be notified and patient will continue to have pain managed as deemed necessary by physician per usual care. Patients will be under continuous monitoring for respiratory depression via capnometer. At 60 minutes, pain will be re-assessed for a second time. If needed, physician will give additional pain meds per their discretion."
3115551|NCT01784965|Active Comparator|liraglutide|Both groups receive dietary weight loss intervention In addition one group received liraglutide and one group received placebo
3115552|NCT01784952|Experimental|Whole grains and lequmes|
3115553|NCT01784952|Placebo Comparator|refined rice|
3115554|NCT01784939||HEPFER cohort|"male, aged 18 and over, hereditary hemochromatosis C282Y homozygous diagnosed and followed in the service of Liver Diseases, University Hospital of Rennes~- Maintenance therapy with phlebotomy for at least 1 year with stable iron stock on the basis of at least four previous plasma ferritin < 50μg / L"
3115555|NCT01784926|Other|IOL repositioning|Operation method: Intraocular lens repositioning by scleral suturing
3115556|NCT01784926|Other|IOL exchange|Operation method: Intraocular lens exchange with retropupillary iris-claw lens
3115557|NCT01784913|Experimental|UV1 synthetic peptide vaccine and GM-CSF|GM-CSF (Leukine) followed by UV1 peptide vaccine with escalating concentrations (100, 300 and 700 microgram) will be injected intradermally at the same injection in the lower abdomen.
3115558|NCT01784900|Experimental|Schema B (140µg)|"D0 : 20 μg of catumaxomab~D2 : 40 μg~D4 : 80 μg"
3115559|NCT01784900|Experimental|Schema A (100µg)|"D0 : 10 μg of catumaxomab~D2 : 30 μg~D4 : 60 μg"
3115560|NCT01784887|Active Comparator|Bioelectric Dressing|SOC + Bioelectric Dressing
3115561|NCT01784887|No Intervention|SOC|Standard of Care
3115562|NCT01784874|Experimental|Purified Vero Rabies Vaccine Group|Participants will receive the Purified Vero Rabies Vaccine (VRVg) Serum Free
3115563|NCT01784874|Experimental|Imovax® Rabies Vaccine Group|Participants will receive the Imovax® Rabies
3115564|NCT01784861|Experimental|Dose Level 0|"X-82 100 mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~Everolimus and X-82 should be taken at the same time every day~28 days =1 cycle"
3115565|NCT01784861|Experimental|Dose Level 1|"X-82 150 mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~Everolimus and X-82 should be taken at the same time every day~28 days =1 cycle"
3115566|NCT01784861|Experimental|Dose Level 2|"X-82 200 mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~Everolimus and X-82 should be taken at the same time every day~28 days =1 cycle"
3115567|NCT01784861|Experimental|Phase II Dose|"X-82 (dose determined by Phase I portion to be 300 mg) mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~28 days =1 cycle"
3115568|NCT01784861|Experimental|Dose Level 3|"X-82 300 mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~Everolimus and X-82 should be taken at the same time every day~28 days =1 cycle"
3115569|NCT01784861|Experimental|Dose Level 4|"Everolimus 10mg by mouth once daily for each cycle MUST BE TAKEN FIRST~X-82 400 mg by mouth once daily 2 HOURS AFTER everolimus dose~28 days =1 cycle"
3115570|NCT01784861|Experimental|PK Expansion Renal Cell Carcinoma - Group A|"Everolimus 10 mg by mouth once daily for each cycle (MUST BE TAKEN FIRST)~X-82 (dose determined by Phase I portion to be 300 mg) mg by mouth once daily 2 HOURS AFTER everolimus dose~28 days =1 cycle"
3115571|NCT01784861|Experimental|PK Expansion Renal Cell Carcinoma - Group B|"Everolimus 10 mg by mouth once daily for each cycle (MUST BE TAKEN FIRST)~X-82 (dose determined by Phase I portion to be 300 mg) mg by mouth once daily 4 HOURS AFTER everolimus dose~28 days =1 cycle"
3115572|NCT01784861|Experimental|PK Expansion Renal Cell Carcinoma - Group C|"Everolimus 10 mg by mouth once daily for each cycle~X-82 (dose determined by Phase I portion to be 300 mg) mg by mouth once daily~Everolimus and X-82 MUST BE TAKEN AT THE SAME TIME~28 days =1 cycle"
3115573|NCT01784848|Experimental|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity.
3115574|NCT01784848|Active Comparator|Clinical treatment|Optimized clinical treatment including medical management of hypertension.
3115575|NCT01784835|Other|control|patients under standard medical care
3115576|NCT01784835|Experimental|OMT|patients under usual medical care plus osteopathic treatment
3115577|NCT01784822||Zenapro™ Hybrid Hernia Repair Device|Device to be used to reinforce or bridge the abdominal wall for the repair of ventral hernias.
3115578|NCT01784809|Experimental|Multimedia HIV/STI prevention|Multimedia WORTH is a 4-session group based gender specific HIV and drug abuse prevention intervention.
3115579|NCT01784809|Active Comparator|Traditional HIV/STI prevention|Traditional WORTH is a 4-session group-based HIV/STI and drug abuse prevention intervention that covers the same content as Multimedia WORTH without the use of interactive videos, computerized assessments, and other audiovisual tools.
3115580|NCT01784809|Placebo Comparator|Wellness Promotion|Wellness Promotion is a 4-session group based intervention that aims to improve diet, physical fitness and well-being which is designed as an attentional control condition.
3115581|NCT01784796|Experimental|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction program
3115582|NCT01784796|Active Comparator|Health education program|8 week Health Education program
3115583|NCT01784783|Experimental|HOPE Intervention|"Pregnant women and their male partners will receive home-based couple HIV testing and counseling and partner education 1-2 weeks after enrollment. The intervention will include educational messages concerning socio-behavioral, condom-based, and treatment-oriented approaches to prevention of horizontal and vertical HIV transmission, based on the status of each of the partners. The couple will also be educated about the importance of facility delivery, exclusive breastfeeding, family planning, and post-partum contraception.~During the HOPE Intervention, the purpose and design of the study will be explained to male partners. Men will be asked to provide written informed consent for study participation. Provided they consent, men will complete a questionnaire asking for sociodemographic characteristics, medical and sexual history, behavioral data and information on prior HIV testing and counseling."
3115584|NCT01784783|Experimental|INVITE Intervention|Pregnant women will be tested and encouraged to bring their male partners to the antenatal clinic for testing. Women will receive a clinic invitation to give to their male partners to attend the next visit for couple HIV counseling and testing. The couples will also be offered the relevant components of the intervention at the final study visit, 6 months postpartum.
3115585|NCT01784770||Azithromycin IV|Subjects who are treated with Azithromycin IV for Legionnaires' disease
3115586|NCT01784757|Experimental|ODM-201 Tablet A|ODM-201 tablet A in fed and fasted states plus ODM-201 capsule in fed state in randomised order.
3115587|NCT01784757|Experimental|ODM-201 Tablet B|ODM-201 Tablet B in fed and fasted states plus ODM-201 capsule in fed state in randomised order.
3115589|NCT01784744||ASD Case|Patients diagnosed with ASD aged 5 to 17 with a history of amelioration of symptoms during febrile episodes.
3115590|NCT01784731||Patients|
3115591|NCT01784705|Experimental|Transcranial bright light therapy|
3115592|NCT01784705|Placebo Comparator|Transcranial placebo treatment|
3115593|NCT01784692|Placebo Comparator|Placebo|10 participants will be randomized to take 1 capsule of placebo daily.
3115594|NCT01784692|Experimental|Immulina 200 mg/day|10 participants will be randomized to take 200 mg/day of Immulina.
3115595|NCT01784692|Experimental|Immulina 400 mg/day|10 participants will be randomized to take 400 mg/day of Immulina.
3115596|NCT01784692|Experimental|Immulina 800 mg/day|10 participants will be randomized to take 800 mg/day of Immulina.
3115597|NCT01784679||Natural History Prospective Observational Group|
3115598|NCT01784679||Online Registry Patient Reported Group|
3115599|NCT01784666|Experimental|Isradipine-Isradipine|Subjects will receive isradipine in phase 1 (4 weeks) and phase 2 (4 weeks)
3115600|NCT01784666|Experimental|Placebo -> Isradipine|Placebo non-responders after the 1st 4 weeks will be re-randomized 1:1 to placebo or isradipine for the next 4 weeks
3115601|NCT01784666|Placebo Comparator|Placebo-Placebo|Placebo nonresponders for the 1st 4 weeks will be re-randomized 1:1 to placebo or isradipine for the subsequent 4 weeks
3115602|NCT01784653|No Intervention|Treatment as Usual|Patients will receive the usual care from the treatment program
3115603|NCT01784653|Experimental|iMET|Participants will complete a self-guided computerized Motivational Enhancement Therapy
3115604|NCT01784653|Experimental|MET|Clinician-delivered Motivational Enhancement Therapy
3115605|NCT01784640|Experimental|Treatment (Hsp90 inhibitor AUY922, pemetrexed disodium)|Patients receive Hsp90 inhibitor AUY922 IV over 60 minutes weekly and pemetrexed disodium IV over 15 minutes every 3 weeks. Courses repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.
3115606|NCT01784627|No Intervention|Treatment at Usual|Participants in this group will receive treatment as usual (TAU) from their provider, which may or may not include screening and brief advice regarding alcohol use.
3115607|NCT01784627|Experimental|c-ASBI|Participants in this group will receive the computerized alcohol screening and brief intervention (c-ASBI).
3115608|NCT01784614|Experimental|0.1 milligrams (mg) LY2624803|Single dose of 0.1 mg LY2624803 administered orally in up to 2 of 4 treatment periods
3115609|NCT01784614|Experimental|1.0 mg LY2624803|Single dose of 1.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
3115610|NCT01784614|Experimental|3.0 mg LY2624803|Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
3115611|NCT01784614|Experimental|6.0 mg LY2624803|Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
3115612|NCT01784614|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to 1 of 4 treatment periods
3115613|NCT01784601||Control Group|We will be including all patients undergoing shoulder surgery not scheduled for a nerve block.
3115614|NCT01784601||Study Group|We will be including all patients undergoing shoulder surgery scheduled for a nerve block.
3115615|NCT01784588|Active Comparator|Solyx Single Incision Sling System|Solyx Single Incision Sling System
3115616|NCT01784588|Active Comparator|Obtryx II Sling System|Obtryx II Sling System
3115617|NCT01784575|Experimental|Patient Navigator Intervention|The Patient Navigator Intervention arm will have two 20 minute interactive sessions with a patient navigator in which they will learn about quality measures and view scores on the Massachusetts Health Quality Partner's website.
3115618|NCT01784575|Active Comparator|Control|The control arm will receive an information pamphlet about health care quality.
3115619|NCT01784549|Active Comparator|Cisplatin Docetaxel|- Cisplatin + Docetaxel day 1 q 21 days for 3 cycles
3115620|NCT01784549|Experimental|Gefitinib Pemetrexed Vinorelbine Gemcitabine|"Gefitinib day for 8 wks;~Pemetrexed day 1 q 21 days for 3 cycles;~Docetaxel day 1 + Vinorelbine days 1,8 q 21 days for 3 cycles;~Docetaxel days 1,8 + Gemcitabine days 1,8 q 21 days for 3 cycles;~Cisplatin + Docetaxel day 1 q 21 days for 3 cycles;~Cisplatin day 1+ Gemcitabine days 1,8 q 21 days for 3 cycles;"
3115621|NCT01784536|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
3115622|NCT01784523|No Intervention|Standard treatment|patients randomized to standard treatment will not receive hydroxychloroquine.
3115623|NCT01784523|Experimental|Hydroxychloroquine|Patients will be randomized to receive standard of care or standard of care + hydroxychloroquine. Dose will be weight-adjusted: 200 mg daily for patients weighing <60kg; and 400 mg daily (200 mg twice a day)for patients weighing >60kg.
3115624|NCT01784510|Active Comparator|2 cm|
3115625|NCT01784510|Experimental|6 cm|
3115626|NCT01784497||Recipients of Living Donor Liver Transplantation|Patients who will undergo Living Donor Liver Transplantation (LDLT) In Ain Shams Center For Organ Transplantation (ASCOT) .
3115627|NCT01784484||patients with abnormal liver enzymnes|
3115628|NCT01784471|Experimental|Magic foot shoe|Magic Foot™ will be dispensed to all subjects. Shoes will be activated at the clinic for 30 minutes. Subjects will self-use and activate the shoes at home daily for 30 days.
3115629|NCT01784458||intra-abdominal hypertension(IAH)|IAH group : patients developing IAH non-IAH group : patients without IAH
3115630|NCT01784445|Experimental|Ceftazidime plus placebo|Procedure/Surgery: ERCP Each patient will receive: Ceftazidime 2 g i.v. once daily 30 minutes prior to procedure and glycerin suppository as placebo
3115631|NCT01784445|Active Comparator|Diclophenac sodium plus placebo|Procedure/Surgery:ERCP Each patient will receive 100 mg Diclophenac suppositories, once daily immediately prior to procedure plus 100 ml of saline as placebo
3115632|NCT01784432|Active Comparator|Low-level laser therapy and training|Effects of low-level laser therapy on muscle performance during physical strength training and gene expression of muscle tissue.
3115633|NCT01784432|Active Comparator|Training without low-level laser therapy|Effects of physical strength training without low-level laser therapy on muscle performance and gene expression of muscle tissue
3115634|NCT01784419|Experimental|ivacaftor-placebo|The ivacaftor-placebo arm receives a 2 week course of ivacaftor 150 mg twice daily followed by a 2 week washout period followed by a 2 week placebo course.
3115712|NCT01783964|Experimental|[14C]-Elacytarabine Microdose|intravenous (IV) administration of one dose of elacytarabine
3115635|NCT01784419|Experimental|placebo-ivacaftor|The placebo-ivacaftor arm receives a 2 week placebo course followed by a 2 week washout period followed by a 2 week course of ivacaftor 150 mg twice daily.
3115636|NCT01784406|Experimental|Autonomy-supportive counselling|"2-4 autonomy-supportive conversations with an experienced nurse, educated both theoretically and practically in the method Guided Self-Determination that includes specific reflection sheets and use of advanced communication; in addition to standard care."
3115637|NCT01784406|No Intervention|Control|Standard of care.
3115638|NCT01784380||the case group|
3115639|NCT01784380||the control group|
3115640|NCT01784380||the treatment group|Patients of the treatment group recieved drugs,then we observed drugs' treatment effect.
3115641|NCT01784367|Experimental|ECLA-group|Treatment with a pump driven, venovenous extracorporeal lung assist
3115642|NCT01784354|Placebo Comparator|Education|target education toward Raynaud's
3115643|NCT01784354|Active Comparator|Acupressure|acupressure- dilatation
3115644|NCT01784354|Active Comparator|Acupressure relaxation|acupressure relaxation protocol
3115645|NCT01784328|Other|Use of a bowel irrigation system|Open label. No placebo use in this study. All volunteers will trial the bowel irrigation system. Eligible volunteers will be those patients who have failed conventional supportive bowel care.
3115646|NCT01784315||Chloroquine, primaquine and ACT|"Standard dose of Chloroquine( 10mg/kg on day 0 and 5mg/kg on day1 and day2) and Primaquine(0.25mg/kg for 14 days).~Artemisinin combination therapies (ACT) of 4 tablets on 0,8,24,36,48 and 60 hours will be used for Chloroquine resistant P.vivax infection"
3115647|NCT01784302|Active Comparator|Maalox Plus extra|Subjects will receive doses of raltegravir 400 mg and maalox plus extra
3115648|NCT01784302|Active Comparator|Multivitamin|Subjects will receive doses of raltegravir 400 mg along with a multivitamin tablet
3115649|NCT01784302|Active Comparator|Sodium bicarbonate|Subjects will receive doses of raltegravir 400 mg along with sodium bicarbonate
3115650|NCT01784289||normal|Patients with no overweight and no type 2 diabetes
3115651|NCT01784289||lipodystrophy|patients with a lipodystrophy, most are diabetics
3115652|NCT01784289||obese non diabetics|Patients with obesity (BMI <30kg/m2), without diabetes
3115653|NCT01784289||obese diabetics|Patients with obesity (BMI <30 kg/m2), with diabetes
3115654|NCT01784276|No Intervention|Control|Children assigned to Group A (control group) received usual care and therefore had no intervention before or during the return visit.
3115655|NCT01784276|Experimental|Video peer modeling|Video peer modeling (at home, the child watched a DVD recording of a typically developing child undergoing a dental visit);
3115656|NCT01784276|Experimental|Video goggles or portable DVD only|Video goggles/DVD (during the dental visit, the child watched their favorite movie using sunglass style video eyewear, or portable DVD player);
3115657|NCT01784276|Experimental|Video peer modeling plus video goggles|Video peer modeling plus video goggles/DVD. At home, the child watched a DVD recording of a typically developing child undergoing a dental visit; During the dental visit, the child watched their favorite movie using sunglass style video eyewear, or portable DVD player.
3115658|NCT01784263|Experimental|Individual Cognitive Behavioral Therapy|
3115659|NCT01784263|Active Comparator|Standard Community Treatment|
3115660|NCT01784250|Experimental|Propanolol|Propranolol 40mg tablets, one tablet administered 1 hour before surgery
3115661|NCT01784250|Placebo Comparator|Placebo|Placebo tablets, one tablet administered 1 hour before surgery
3115662|NCT01784250|Experimental|Clonidine|clonidine 150mcg tablets, one tablet administered 1 hour before surgery
3115663|NCT01784237|Experimental|Anterior meatuscopy|All patients in the study group receive anterior meatoscopy whereas patients in the control group perform a sniff test to select the most patent nostril for nasal anesthesia and transnasal endoscopic insertion.
3115664|NCT01784237|Active Comparator|Nasal sniff test|A sniff test for nasal patency is a common method before ultrathin transnasal esophago-gastro-duodenoscopy (UT-EGD) to select the right or left nostril for insertion.
3115665|NCT01784224|Experimental|Speaking Valves|"All participants will either have a Blom tracheotomy tube in place or have their current tracheotomy tube changed to a Blom tracheotomy tube to allow for use of both the Blom low profile voice inner cannula and the Passy-Muir one-way speaking valves.~The Blom low profile voice inner cannula and Passy-Muir speaking valves will be provided to participants in a random order. All valves will be placed by the PI. Duration of data collection trials will range from 10 to 30 minutes."
3115666|NCT01784211|Experimental|LY2605541 (Part A)|0.5 units per kilogram (U/kg) LY2605541 subcutaneously (SQ) once daily for 15 days. Participants will remain on their regular physician-prescribed mealtime insulin. Part A involves 3 clamp procedures on Days 8, 11 and 14.
3115667|NCT01784211|Active Comparator|Glargine (Part A)|0.5 U/kg insulin glargine SQ once daily for 15 days. Participants will remain on their regular physician-prescribed mealtime insulin. Part A involves 3 clamp procedures on Days 8, 11 and 14.
3115668|NCT01784211|Experimental|LY2605541 + Exercise (Part B)|0.5 U/kg LY2605541 SQ once daily for 6 days. Exercise challenge on Day 17 or 20. Participants will remain on their regular physician-prescribed mealtime insulin.
3115669|NCT01784211|Experimental|LY2605541 (Part B)|0.5 U/kg LY2605541 SQ once daily for 6 days. Participants will remain on their regular physician-prescribed mealtime insulin.
3115670|NCT01784211|Active Comparator|Glargine + Exercise (Part B)|0.5 U/kg insulin glargine SQ once daily for 6 days. Exercise challenge on Day 17 or 20. Participants will remain on regular physician-prescribed mealtime insulin.
3115671|NCT01784211|Active Comparator|Glargine (Part B)|0.5 U/kg insulin glargine SQ once daily for 6 days. Participants will remain on regular physician-prescribed mealtime insulin.
3115672|NCT01784198|Experimental|Protein Intake|Dietary supplement:Protein intake
3115673|NCT01784185|Experimental|virtual bronchoscopy guided transbronchial needle aspiration|virtual bronchoscopy guided transbronchial needle aspiration (VB-TBNA)(experimental method) and EBUS-TBNA (reference method) are performed in the same diagnostic session
3115674|NCT01784172|Experimental|electroacupuncture group|"Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward. Bilateral B L35 are given acupuncture of 50～60mm to outward and upward. The electric stimulator is applied to bilateral BL33 and BL35.~Every session lasts for 30 min per day. The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all."
3115675|NCT01784172|Experimental|sham electroacupuncture group|"Bilateral sham BL33 and sham BL35 are given sham electroacupuncture with no current output.~Every session lasts for 30 min per day. The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all."
3115676|NCT01784159|Placebo Comparator|Placebo|Placebo 1tb / day/ 7days
3115677|NCT01784159|Active Comparator|Aspirin|Intervention aspirin 200 mg/day for 7 days
3115678|NCT01784146|Placebo Comparator|Oxygen|
3115679|NCT01784146|Experimental|PEEP + Heliox|
3115680|NCT01784146|Experimental|Oxygen + PEEP|
3115681|NCT01784146|Active Comparator|Heliox|
3115682|NCT01784133|Active Comparator|omiganan mid dose|omiganan mid dose once daily application for 12 weeks
3115683|NCT01784133|Active Comparator|omiganan high dose|omiganan high dose once daily application for 12 weeks
3115684|NCT01784133|Placebo Comparator|Vehicle group|Vehicle once daily application for 12 weeks
3115685|NCT01784133|Active Comparator|omiganan low dose|omiganan low dose once daily application for 12 weeks
3115686|NCT01784120|Experimental|doxotubicin/Genexol-PM|
3115687|NCT01784107|Experimental|Belotecan and Ifosfamide|
3115688|NCT01784094||Low back pain subjects|Subjects with chronic or recurrent low back pain
3115689|NCT01784094||No low back pain subjects|Subjects who are generally healthy with no low back pain
3115690|NCT01784081||palliative care with iPC3|Palliative care with decision aids will be administered at each palliative care visit.
3115691|NCT01784068|Experimental|Nilotinib followed by treatment-free|Patients who have received a minimum of 2 years of first line nilotinib treatment and with pre-screen PCR results in ≥ MR4.5 will enter the consolidation phase of the study (52 weeks - nilotinib 300 mg BID). Patients with Minimal Residual Disease (MRD) at the end of this phase will enter the Treatment-Free Remission (TFR) phase where no treatment is given. Non eligible patients will enter the continuation phase of the study. Patients with MRD at the end of the continuation phase will enter the TFR-2 phase of the study where no treatment is given. Non eligible patients will enter the prolonged continuation phase of the study. If at any time during TFR or TFR-2 the patient loses MMR, nilotinib treatment will be immediately re-initiated (nilotinib 300 mg BID).
3115692|NCT01784042|Placebo Comparator|No dietary energy restriction plus Placebo|No dietary energy restriction plus Placebo
3115693|NCT01784042|Placebo Comparator|Dietary energy restriction plus placebo|Dietary energy restriction plus placebo
3115694|NCT01784042|Experimental|Lovaza|Lovaza only
3115695|NCT01784042|Experimental|Dietary energy restriction plus Lovaza|Dietary energy restriction plus Lovaza
3115696|NCT01784029|Experimental|Low Dose|"VItamin D3 1,000 IU~1 x day, 8 weeks"
3115697|NCT01784029|Experimental|Weekly High Dose|"Vitamin D3 50,000 IU~1x week, 8 weeks"
3115698|NCT01784029|Experimental|Daily High Dose|"Vitamin D3 5,000 IU~1x day, 8 weeks"
3115699|NCT01784016|Experimental|Healthy Smokers|Healthy smokers aged 18-50 years reporting average cigarette consumption of 15 or more cigarettes/day for the past year, providing an expired breath carbon monoxide reading exceeding 10 ppm at screening.
3115700|NCT01784016|Experimental|Healthy Nonsmokers|Healthy nonsmoking controls aged 18-50 reporting consumption of <100 cigarettes in their lifetime, none in the last 6 months, providing an exhaled breath carbon monoxide reading of < 9 ppm at screening.
3115701|NCT01784003||Non-amputee|People without an amputation will be recruited to participate in the study.
3115702|NCT01784003||Below the knee amputee|People with a unilateral transtibial amputation will be recruited to participate in the study.
3115703|NCT01783990||Active|"Blood and urine specimens, and questionnaires related to the child's health status.~Liver Spleen Scan~Abdominal Ultrasound~Brain MRI/MRA~Cardiac Echocardiogram/Pulmonary Function Testing~Transcranial Doppler~Neuropsychology Testing (Vineland, WISC-IV, Connor CPT II and Peds QOL)"
3115704|NCT01783990||Passive|Information from usual clinical care of sickle cell disease. We will collect information from routine tests ordered by the child's clinical sickle cell doctors.
3115705|NCT01783977|Experimental|Part A: Group 1: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) in the same deltoid at Days 0, 14, and 28.
3115706|NCT01783977|Experimental|Part B: Group 2: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0, 14, and 28. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 84.
3115707|NCT01783977|Placebo Comparator|Part B: Group 2: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0, 14, and 28. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 84.
3115708|NCT01783977|Experimental|Part B: Group 3: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0 and 28. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 84.
3115709|NCT01783977|Placebo Comparator|Part B: Group 3: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0 and 28. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 84.
3115710|NCT01783977|Experimental|Part B: Group 4: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0, 28, and 56. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 140.
3115711|NCT01783977|Placebo Comparator|Part B: Group 4: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0, 28, and 56. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 140.
3115713|NCT01783951|Experimental|DC-CIK plus S-1 based chemotherapy|Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone. Meanwhile those patients will receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
3115714|NCT01783951|Active Comparator|S-1 based chemotherapy|Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone.Cycles were repeated every 21 days. Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
3115715|NCT01783938|Experimental|Cohort A: Nivolumab followed by Ipilimumab|"Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1.~Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period."
3115716|NCT01783938|Experimental|Cohort B: Ipilimumab followed by Nivolumab|"Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period.~Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1."
3115717|NCT01783925||Group 1|
3115718|NCT01783912|Experimental|Cognitive/Motivational Intervention Group|"This arm of the project will address the following questions:~After completion of experimental individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Active Control group?~After completion of experimental individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Motivated Smokers Comparison group?"
3115719|NCT01783912|Active Comparator|Attention Control Group|"This arm of the project will address the following question:~After completion of control individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate that those who are in the experimental treatment group?~After completion of control individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Cognitive/Motivational Intervention Group?"
3115720|NCT01783912|No Intervention|Motivated Smokers Comparison Group|"This arm of the project will address the following question:~Do participants in the Motivated Smokers Comparison group (identified as motivated to quit upon recruitment) utilize the quit line services at the same, greater or lesser rate than those who are in the Motivated Smokers Comparison group?~Do participants in the Motivated Smokers Comparison group (identified as motivated to quit upon recruitment) utilize the quit line services at the same, greater or lesser rate than those who are in the Active Control group?~Participants will not receive any intervention but will be consented and enrolled into this group and assessed for utilization of the tobacco quit line services."
3115721|NCT01783899|Experimental|Hemospray Group|"Hemospray device consists of a syringe containing the Hemospray powder (21 g per syringe), a delivery catheter that will be inserted into the working channel of the endoscope, and an introducer handle with a built-in carbon dioxide canister to propel the Hemospray powder out of the catheter.~In addition to Hemospray device any other required endoscopic accessories can be used during the procedure."
3115722|NCT01783886|Experimental|Intravitreal Aflibercept Injection 2Q4|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF [vascular endothelial growth factor] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.
3115723|NCT01783886|Experimental|Intravitreal Aflibercept Injection 2Q8|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.
3115724|NCT01783886|Active Comparator|Macular Laser Photocoagulation|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.
3115725|NCT01783873|Placebo Comparator|Placebo|
3115726|NCT01783873|Active Comparator|flour allergen extract or quaternary ammonium compound|
3115727|NCT01783860|Experimental|Oral Azithromycin|Two 250 mg capsules (500 mg) of Azithromycin for the first day and 250mg/day for the next 4 days.
3115728|NCT01783860|Active Comparator|Doxycycline|Oral doxycycline 100mg capsule every 12 hours for one month
3115729|NCT01783847|Experimental|Recombinant human erythropoietin (EPO)|20,000 unit per day of EPO, Intravenous infusion for three sequential days.
3115730|NCT01783847|Active Comparator|Methylprednisolone|1 gram per day intravenous injection of Methylprednisolone for 3 days. If vision improved, it will be followed by oral steroid 1 mg/kg/day for 11 days
3115731|NCT01783847|No Intervention|Observation|No any treatment will be given
3115732|NCT01783834|Active Comparator|pemetrexed|pemetrexed
3115733|NCT01783834|Active Comparator|gefitinib|gefitinib
3115734|NCT01783821|Experimental|Budesonide and Formoterol|Subjects randomized to this arm will receive combined standard aerosolized doses of budesonide (0.5 mg) and formoterol (20 mcg) twice daily, with at least 6 hours between doses, for 5 days for a total of 10 doses or until hospital discharge or death, with the first dose administered as soon as possible following randomization but not later than 4 hours.
3115735|NCT01783821|Placebo Comparator|Placebo|Subjects randomized to this arm will receive normal saline, the quantity, appearance and timing of the doses the same as the intervention arm.
3115736|NCT01783808|Experimental|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
3115737|NCT01783808|No Intervention|Control group|The control group will not get supplemental oxygen during physical activity but they will get the same physical activity intervention as the intervention group.
3115738|NCT01783795|Other|Genetic Analysis|Genetic Analysis
3115739|NCT01783782|Experimental|DIET|Group A followed the standard regime consisting of a clear liquid diet for 12 hours on the day before CE, followed by an overnight fast.
3115772|NCT01783574|Placebo Comparator|Placebo|Placebo cream will appear identical to the testosterone cream and will be applied to skin for 8 weeks.
3115740|NCT01783782|Experimental|HIGH PEG|Group B received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of polyethylene glycol 4000 solution with simethicon solution the evening before the examination, followed always by an overnight fast.
3115741|NCT01783782|Experimental|LOW PEG|Group C, defined as a low volume regime, received 25 mL/Kg (up to 1Lt/die) of polyethylene glycol 4000 solution with simethicon solution the evening before the examination, followed by an overnight fast.
3115742|NCT01783782|Experimental|SIMETHICONE|Group D received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion.
3115743|NCT01783782|Experimental|SIMETH+PEG|Group E received 25 mL/Kg (up to 1 Lt/die) of polyethylene glycol 4000 solution with simethicon solution followed by an overnight fast plus 20mL oral simethicone and 200mL water 30 minutes before capsule ingestion.
3115744|NCT01783769|No Intervention|Normal O.R. Traffic|"This Normal O.R. Traffic protocol follows the national standards of care."
3115745|NCT01783769|Active Comparator|"Low O.R. Traffic"|"This protocol will restrict personnel movement thru the operating room to a bare minimum of personnel traffic."
3115746|NCT01783756|Experimental|Treatment (lapatinib ditosylate, everolimus, capecitabine)|Patients receive lapatinib ditosylate PO QD and everolimus PO QD on days 1-21, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.
3115747|NCT01783743|Experimental|Intervention arm|"Community treatment assistants (CTA ) will receive usual training, including the basic background of trachoma/trichiasis recognition, drug administration, and azithromycin dosing.~In addition to the usual training, these CTA's will also receive an additional modest half day training for TT case recognition which is called the TT training program and TT Screening Card to help them identify TT cases and refer them for surgery."
3115748|NCT01783743|No Intervention|Usual Assessment arm|Community treatment assistants will receive only usual training, including the basic background of trachoma/trichiasis recognition, drug administration, and azithromycin dosing.
3115749|NCT01783730||Participants with high rheumatoid arthritis disease activity|Participants who received adalimumab treatment
3115750|NCT01783717|Experimental|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
3115751|NCT01783704|Experimental|PUSH and Nutrition|PUSH is a specific multi-component intervention based on improving specific precursors to community ambulation. The intervention addresses endurance with continuous upright exercise for 20 min.; function by improving fast walking, standing from a chair, and stair negotiation; muscle performance by exercising to enhance lower extremity strength; and balance by performing unilateral activities and activities with decreased base of support. Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive up to three visits a week, on non-consecutive days, for 16 weeks. Visits take place in the participant's place of residence. Participants also receive the nutritional intervention for the duration of the 16-week study.
3115752|NCT01783704|Experimental|PULSE and Nutrition|PULSE is a non-specific multi-component intervention in which participants will receive flexibility exercises, active range of motion (AROM) for the upper and lower extremities, breathing exercises, and transcutaneous electrical nerve stimulation (TENS). Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive up to three visits a week, on non-consecutive days, for 16 weeks. Visits will take place in the participant's place of residence. Participants will also receive the nutritional intervention for the duration of the 16-week study.
3115753|NCT01783691|Experimental|NKTT120|
3115754|NCT01783678|Experimental|Genotype 2 treatment-naive|Treatment-naive (TN) participants with HIV-1 and genotype 2 HCV coinfection will receive sofosbuvir plus RBV for 12 weeks.
3115755|NCT01783678|Experimental|Genotype 2/3 treatment-experienced|Treatment-experienced (TE) participants with HIV-1 and genotype 2 or 3 HCV co-infection will receive sofosbuvir plus RBV for 24 weeks.
3115756|NCT01783678|Experimental|Genotype 1/3/4 treatment-naive|Treatment naive (TN) participants with HIV-1 and genotype 1, 3, or 4 HCV co-infection will receive sofosbuvir plus RBV for 24 weeks.
3115757|NCT01783665|Experimental|Aerobic Exercise|3x/week supervised moderate intensity aerobic exercise on recumbent stepper
3115758|NCT01783665|Active Comparator|Home exercise program|Walking and stretching exercises performed 3x/week for 30 minutes at intensity considered non-aerobic
3115759|NCT01783652|Experimental|Intervention group|Study participants in the intervention group will be given access to an anti-depression website and have four telephone follow-up within the 1-year study period.
3115760|NCT01783652|No Intervention|Control group|Study participants in the control group will not received any depression-related service other than an interactive anti-smoking website provided by the University of Hong Kong.
3115761|NCT01783639|Experimental|Arm 1|"Device: WIRION™ Embolic Protection System~Interventions: Carotid Artery Stent"
3115762|NCT01783626|Sham Comparator|Evodial|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
3115763|NCT01783626|Experimental|Evodial+ Condition B1|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
3115764|NCT01783626|Experimental|Evodial+ Condition B2|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
3115765|NCT01783626|Experimental|Evodial+ Condition C|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
3115766|NCT01783613|Experimental|Docosahexaenoic acid administration|50 patients will receive docosahexaenoic acid
3115767|NCT01783613|Placebo Comparator|placebo|50 patients will receive placebo
3115768|NCT01783600|Other|NanoCross .014 balloon catheter|NanoCross .014 balloon catheter
3115769|NCT01783587|Experimental|High Risk Group|Dose escalation of afatinib + docetaxel + radiation therapy
3115770|NCT01783587|Experimental|Intermediate Risk Group|Dose escalation of afatinib + radiation therapy
3115771|NCT01783574|Active Comparator|Testosterone|Testosterone cream will be applied to skin for 8 weeks. Starting dose is 10 mg daily and will be titrated based on blood levels.
3115857|NCT01783015|Placebo Comparator|Group D|Subjects who are mAb ADA negative
3115773|NCT01783561|Active Comparator|early caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 15 minutes within the first 2 hours of life. If the infant is in the early caffeine group, the blinded drug will be IV caffeine citrate 20mg/kg in the first 2 hours and placebo at 12 hours of life.
3115774|NCT01783561|Placebo Comparator|Routine caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. If the infant is in the routine caffeine group, the blinded drug will be placebo in the DR and IV caffeine citrate 20mg/kg at 12 hours of life.
3115775|NCT01783548|Experimental|BDP Nasal Aerosol 80 mcg/day|BDP nasal aerosol: 80 mcg dose once daily in the morning. Participants/parents administer 40 mcg BDP (one spray per nostril) during the 12-week Treatment Period.
3115776|NCT01783548|Placebo Comparator|Placebo Nasal Aerosol|Placebo nasal aerosol: Participants/parents administer placebo (no medication) (one spray per nostril) once daily in the morning during the 12-week Treatment Period.
3115777|NCT01783535|Experimental|Stratum A|"Participants with early bilateral or unilateral (unifocal or multifocal) retinoblastoma (R-E I-III, IC A-B; R-E IV with IC A or B; or IC C with limited sub-retinal seeding), and participants with bilateral disease in whom the advanced eye has been enucleated upfront (without any high risk histopathology) and the remaining eye has early stage disease (as defined above).~Interventions (see detailed description): vincristine, carboplatin, topotecan, filgrastim or PEG-filgrastim, and focal therapy, including cryotherapy, laser photocoagulation, thermo-therapy, plaque radiotherapy."
3115778|NCT01783535|Experimental|Stratum B|"Participants considered candidates for conservative management including those:~Participants with bilateral retinoblastoma who have R-E IV-V and IC D in one eye~Participants with advanced unilateral (unifocal or multifocal) retinoblastoma (R-E IV-V and IC D-E) who demonstrate foveal sparing by the tumor during EUA. Due to foveal sparing, these patients have potential for vision preservation.~Interventions (see Detailed Description): vincristine, topotecan, carboplatin, etoposide, filgrastim or PEG-filgrastim and focal therapy, including cryotherapy, laser photocoagulation, thermo-therapy, plaque radiotherapy."
3115779|NCT01783535|Experimental|Stratum C|"Participants with advanced (R-E IV-V and IC D-E) unilateral retinoblastoma who require upfront enucleation. Participants will be assessed and treated by low, intermediate or high risk.~Interventions (see Detailed Description): vincristine, cyclophosphamide, MESNA, doxorubicin, etoposide, enucleation, carboplatin, filgrastim or PEG-filgrastim, enucleation"
3115780|NCT01783535|Experimental|Stratum D|"Participants with bilateral retinoblastoma who may require upfront enucleation for one eye due to advanced disease (R-E IV-V and IC E).~Interventions (see Detailed Description): vincristine, carboplatin, topotecan, etoposide, enucleation, filgrastim or PEG-filgrastim, focal therapy, including cryotherapy, laser photocoagulation, thermotherapy (and thermo-chemotherapy) and episcleral plaque brachytherapy, and external beam radiation or proton beam radiation in select cases."
3115781|NCT01783522|Experimental|Arm I (preventative nutritional supplementation)|Patients receive glutamine PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
3115782|NCT01783522|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
3115783|NCT01783509||LGMD|Patients with GENETICALLY CONFIRMED limb girdle muscular dystrophy
3115784|NCT01783496|Active Comparator|Framed Tip|Treatment with Thermage CPT Framed Tip
3115785|NCT01783496|Experimental|Pattern Tip|Treatment with the Thermage CPT Pattern Tip
3115786|NCT01783496|Experimental|Pattern Tip Group 2|Treatment with the Thermage CPT Pattern tip
3115787|NCT01783496|Experimental|Total Tip|Treatment with the Thermage CPT Total tip
3115788|NCT01783496|Experimental|Framed and Patterned Tip|Split face treatment with the Thermage CPT Framed and Patterned tips
3115789|NCT01783496|Experimental|Total and Patterned Tip|Split face treatment with the Thermage CPT Total and Patterned tips
3115790|NCT01783483|Active Comparator|Suture Wire|The closure technique should be per surgeon and institutional preference, with documentation of the wiring technique including the wiring configuration and number of wires used. A minimum of 6 wires that cross the midline sternotomy should be used (e.g. 6 simple wires, 3 double wires, 3 figure of 8 wires, etc.).
3115791|NCT01783483|Experimental|SternaLock Blu closure system|"Patients will receive treatment option for sternal closure with the SternaLock Blue closure system at a minimum of 2 X plates on the sternal body and 1 L plate (or equivalent) on the manubrium. This technique is the standard configuration for this study, and is intended to ensure that at least 3 plates are used to achieve adequate fixation and stability, while allowing for variations in the plating configuration as a result of patient anatomy and surgeon preference. Various Sternal Blu plates may be used on the manubrium as described below, as can an additional plate on the sternal body."
3115792|NCT01783470|Experimental|beta3-adrenergic receptor agonist|single dose. Each subject was randomized to receive placebo at one visit and then the beta3-adrenergic receptor agonist on another study day.
3115793|NCT01783457|Experimental|Individual psychoeducation|Usual treatment + individual psychoeducational intervention (14 sessions). The psychoeducational programme consists of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.
3115794|NCT01783457|Active Comparator|Control|Usual treatment
3115795|NCT01783444|Experimental|Capecitabine Monotherapy|100 patients will be randomized to the Capecitabine monotherapy arm (1250mg/m2 twice daily) orally for two weeks, followed by a one week rest period in 3-weeks cycles.
3115796|NCT01783444|Experimental|Everolimus Monotherapy|100 patients will be randomized to this arm and will received Everolimus (10mg daily).
3115797|NCT01783444|Active Comparator|Everolimus with Exemestane|100 patients will be randomized to the control arm of this study, everolimus (10mg daily) with exemestane (25mg daily).
3115829|NCT01783223||Intoxicated patients|patients in the Emergency Department who appear to be intoxicated with ethanol.
3115830|NCT01783210|Experimental|TLC(Therapeutic Lifestyle Changes) group|"Intervention: Specific Therapeutic Lifestyle Changes program in pregnancy. TLC Program includes a diet (with a specific amount of calories and macronutrients) and a mild physical activity."
3115798|NCT01783431|Experimental|Leukapheresis and Poly-ICLC|Screening tests will be conducted to determine whether or not subjects can participate in this study. If subjects are eligible and choose to participate, they will have a procedure called leukapheresis. The leukapheresis product that is collected from you will be taken to a special lab at MUSC where it will undergo a process that will grow additional dendritic cells under controlled conditions in the lab. These cells will be given together with Poly-ICLC therapy when you begin study treatment. Some days you will receive both Poly-ICLC and dendritic cells, but on other days you will receive the Poly-ICLC by itself. After study treatment, subjects may be asked to return to MUSC approximately every 3 months for the first 2 years, then every 6 months thereafter for follow up procedures.
3115799|NCT01783418|Experimental|Mindfulness intervention|
3115800|NCT01783418|Active Comparator|Wait-list control|
3115801|NCT01783405||Cases|FH heterozygous
3115802|NCT01783405||Controls|Parents of FH heterozygotes with FH
3115803|NCT01783392|Active Comparator|Unilateral Posterior Tibial Nerve Stimulation|Transcutaneous posterior tibial nerve stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior tibial nerve and sets the stimulation intensity to a comfortable level.
3115804|NCT01783392|Active Comparator|Bilateral Posterior Tibial Nerve Stimulation|Transcutaneous posterior tibial nerve stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior tibial nerve on both legs and sets the stimulation intensity to a comfortable level.
3115805|NCT01783392|Active Comparator|Shoulder stimulation|Stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode and the anode electrodes on the lateral side of the left shoulder.
3115806|NCT01783379||ICU patient on micafungin|ICU patients with an invasive fungal infection on micafungin treatment
3115807|NCT01783366|No Intervention|CONTROL|In the control group (Group A) inserting the lubricated NG tube through the nostril, at that time head maintained in the neutral position.
3115808|NCT01783366|Active Comparator|tube-exchanger|The tube-exchanger group (Group B) made use of tube-exchanger G36402 (CAEC, [cook medical, Bloomington, IN]) as a stylet that was lubricated and inserted within 20-F NGT until the tip of the tube-exchanger was at the tip of the NGT
3115809|NCT01783353|Placebo Comparator|Corn starch pill|Two (2) corn starch pills will be taken three (3) times a day for 60 days.
3115810|NCT01783353|Experimental|Zinc gluconate|Two (2) zinc gluconate 50 mg capsules will be taken three (3) times a day for 60 days.
3115811|NCT01783340|Active Comparator|CQ and falciparum immunization|"This arm will receive chloroquine prophylaxis, a placebo during immunizations and three times 5 infected mosquito-bites (immunizations). Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Placebo capsules daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
3115812|NCT01783340|Experimental|CQ/AZM and falciparum immunization|"This arm will receive chloroquine and azithromycin prophylaxis and three times 5 infected mosquito-bites (immunizations).~Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
3115813|NCT01783340|Placebo Comparator|CQ and AZM control|"This arm will receive chloroquine and azithromycin prophylaxis and three times 5 uninfected mosquito-bites during immunization. Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
3115814|NCT01783327|Experimental|Teens-Connect|The Teens-Connect Program is an internet-based program that combines Managing Diabetes and TEENCOPE.
3115815|NCT01783327|Active Comparator|Planet D|Planet D is an internet program developed by the American Diabetes Association for children and adolescents with diabetes.
3115816|NCT01783314|Active Comparator|Normal liver function|Control group. Subjects will obtain MRI of liver.
3115817|NCT01783314|Experimental|Hepatitis C|Subjects with hepatitis C. Subjects will obtain both MRI of liver and limited CT of liver.
3115818|NCT01783301|Active Comparator|Antral follicle count|"Start dose of recombinant Follicle-Stimulating Hormone (rFSH) based on AFC guide~AFC < 6 on both ovary: 375 IU FSH~6<AFC <=15 on both ovary: 225 IU FSH~AFC> 15 on both ovary: 150 IU FSH"
3115819|NCT01783301|Active Comparator|Anti-Mullerian Hormone|"Start dose of FSH based on AMH guide~AMH < 5 pmol/L or < 0.7ng/ml: 375 IU FSH~AMH 5 to < 15 pmol/L or 0.7 to 2.1ng/ml: 225 IU FSH~AMH ≥ 15 pmol/L or > 2.1ng/ml: 150 IU FSH"
3115820|NCT01783288|Other|All participants|"All participants will be administered all procedures as described previously.~Interventions:~Autonomic Function Testing, Posture Study ,Measurement of Total Blood Volume ,Exercise Capacity Test"
3115821|NCT01783275|Experimental|Aerobic Exercise|12 weeks of aerobic exercise
3115822|NCT01783275|No Intervention|Control|12 weeks with no change in diet or exercise habits (weight maintenance).
3115823|NCT01783262|Active Comparator|Extracorporeal shock wave therapy|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
3115824|NCT01783262|Placebo Comparator|sham extracorporeal shock wave therapy|The second grouop of patients received 0.04 mJ/mm2, 2400 pulses once a week for 4 weeks.
3115825|NCT01783249|No Intervention|Control|Usual care monitoring
3115826|NCT01783249|Other|Exercise using stationary cycling|Stationary cycling exercise program
3115827|NCT01783236|Placebo Comparator|Saline Placebo|Subjects will receive a saline placebo infusion administered over 15 minutes every 6 hours for 24 hours.
3115828|NCT01783236|Active Comparator|IV Acetaminophen|Subjects will receive an infusion of 1 g of intravenous acetaminophen administered over 15 minutes every 6 hours for 24 hours with a maximum dose of 4 grams.
3115831|NCT01783210|Other|Control group|"Intervention: Dietary and behavioral counselling in pregnancy. The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake."
3115832|NCT01783197|Experimental|Paclitaxel and carboplain plus selumetinib|"Cohort 1: Standard Chemotherapy (paclitaxel and carboplatin) plus selumetinib~If you are registered to Cohort 1, you will receive two commonly-used chemotherapy drugs called paclitaxel and carboplatin, plus you will be given the experimental drug selumetinib."
3115833|NCT01783197|Experimental|pemetrexed and cisplain plus selumetinib|"Cohort 2: Standard Chemotherapy (pemetrexed and cisplatin) plus selumetinib (cohort closed)~If you are registered to Cohort 2, you will receive two commonly-used chemotherapy drugs called pemetrexed and cisplatin, plus you will be given the experimental drug selumetinib."
3115834|NCT01783197|Experimental|pemetrexed plus selumetinib|"Cohort 3: Standard Chemotherapy (pemetrexed) plus selumetinib (cohort closed)~If you are registered to Cohort 3, you will receive one commonly-used chemotherapy drug called pemetrexed, plus you will be given the experimental drug selumetinib."
3115835|NCT01783171|Experimental|Arm A (dinaciclib, Akt inhibitor MK2206)|"Patients receive dinaciclib IV over 2 hours on day 1 of course 1.~After day 1, all patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15 and dinaciclib IV over 2 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3115836|NCT01783171|Experimental|Arm B (Akt inhibitor MK2206, dinaciclib)|"Patients receive Akt inhibitor MK2206 PO on day 1 of course 1.~After day 1, all patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15 and dinaciclib IV over 2 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3115837|NCT01783158||Diagnostic group|A total of 132 patients with HNSCC were enrolled in this study. The patients underwent esophagoscopy and chromoendoscopy. The most frequent primary tumors were oropharyngeal (49/132), tumors of the oral cavity (36/132) and larynx (35/132). The majority of subjects (107/132 patients, 81.1%) had advanced HNSCC carcinomas (stages III and IV). Multiple LVLs were discovered in 24 subjects (18.2%), and no LVLs in 108 (81.8%) subjects. Fifty-five LVL biopsy specimens were obtained and assessed. Squamous cell carcinomas were detected in two patients, peptic esophagitis in 11 patients, gastric heterotopic mucosa in two patients, hyperplasia in two patients, and low- and high-grade dysplasia in three patients.
3115838|NCT01783145||Patients|Patients with disseminated TC who have finished their chemotherapy, if needed followed by surgery, and who are in complete remission and currently in active follow-up.
3115839|NCT01783132|Other|Budesonide|Asthma treated patient with Budesonide for 1 year, 4 different dosage according to measurement of exhaled NO done with NIOX MINO.
3115840|NCT01783132|No Intervention|Standard of care|Asthma treated patient with standard of care during 1 year. Exhaled NO measurement will be done 4 times/year, and compared afterwards with the Budesonide group.
3115841|NCT01783119|Experimental|Aloe Vera|Consume 200 ml of aloe vera gel per day over a period of three months
3115842|NCT01783119|Placebo Comparator|water|Consume 200 ml of placebo per day over a period of three months
3115843|NCT01783106|Active Comparator|budesonide|Oral Budesonide 9mg per day for 8 weeks followed by 6mg per day for 2 weeks and subsequent 3mg per day over a further 2 weeks
3115844|NCT01783106|Experimental|Ciprofloxacine, doxycycline and hydroxychloroquine|Oral Ciprofloxacin 500mg bd plus Doxycycline 100mg bd and Hydroxychloroquine 200mg tds followed by a further 20 weeks continued therapy with Doxycycline 100mg bd and Hydroxychloroquine 200mg tds
3115845|NCT01783093||Sickle cell and pulmonary hypertension|
3115846|NCT01783080|Experimental|Behavioral Activation for Return to Work|BA is a manualized psychotherapy with comparable efficacy to cognitive behavioral treatment and antidepressant medication for acute treatment of depression. In this study, BA's focus was shifted to target work dysfunction by activating the patient into employment-related goals. BA-W consisted of 12 50-minute weekly sessions. Conceptualizing work dysfunction as a product of avoidance patterns and low levels of positive reinforcement, the treatment addressed maladaptive coping strategies such as avoidance as maintaining work dysfunction beyond remission of symptoms. Rather than broadly activating patients, activity scheduling focused on tasks such as sending out resumes, calling for job interviews, and networking to meet potential employers.
3115847|NCT01783067|Experimental|Iron and zinc biofortified pearl millet|Participants in the experimental arm consume pearl millet which has been biofortified with iron and zinc.
3115848|NCT01783067|Active Comparator|Pearl millet|Participants in the control arm consume non-biofortified pearl millet.
3115849|NCT01783054|Experimental|chemotherapy, surgery, genetic expression|"All patients enrolled on study will start study treatment on a chemotherapy treatment regimen of Gemcitabine and abraxane. Treatment will be given on days 1, 8 and 15 of each cycle for 2 cycles over the course of 12 weeks.~Patients will move on to surgery, 4-8 weeks after chemotherapy treatment. Patients must be recovered from any adverse effects of the chemotherapy before proceeding with surgery.~As part of this study, tissue samples will be collect from each patient at the time of surgery for gene expression testing"
3115850|NCT01783041|Placebo Comparator|5% dextrose|Infants randomized to the placebo group will receive 5% dextrose intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of placebo (5% Dextrose) will be given to the study patients.
3115851|NCT01783041|Experimental|L-carnitine|Infants randomized to the study group will receive L-carnitine intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
3115852|NCT01783028|Experimental|Community Health Worker support|home visits from community health workers providing education and support for self-management of asthma, assessment of the home for environmental triggers, resources for asthma control, and assistance in effective communication with medical providers
3115853|NCT01783028|No Intervention|the usual care control group|Usual care is defined as services received by participants in the absence of the intervention plus information about community resources that support asthma self-management (such as classes and support groups) and educational pamphlets
3115854|NCT01783015|Experimental|Group A|Subjects who are mAb ADA positive
3115855|NCT01783015|Experimental|Group B|Subjects who are mAb ADA negative
3115856|NCT01783015|Placebo Comparator|Group C|Subjects who are mAb ADA positive
3115858|NCT01783002|Experimental|Primary hyperparathyroidism|Subjects with biochemical evidence, including elevated serum calcium and PTH levels, of primary hyperparathyroidism. All patients will undergo 11C-methionine PET/CT, SPECT-CT and 18F-FDG PET/CT scanning.
3115859|NCT01782989|Experimental|ORACEA®|40mg doxycycline
3115860|NCT01782989|Placebo Comparator|Placebo|
3115861|NCT01782976|Experimental|Cilengitide + Bevacizumab|Cilengitide administered intravenously at 2000 mg twice weekly, while Bevacizumab administered intravenously at 10 mg/kg every other week. Each cycle of therapy will be 4 weeks long.
3115862|NCT01782963|Experimental|Treatment Arm|"Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age)~Consolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15"
3115863|NCT01782950|Other|anti-tuberculosis drugs|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide tablets 3 to 5 tablets once daily for 2 months followed by Rifampicin, Isoniazid 3 to 5 tablets once daily for 4 months
3115864|NCT01782937|Experimental|KHK4827|
3115865|NCT01782924|Experimental|KHK4827 140mg SC|
3115866|NCT01782924|Experimental|KHK4827 210mg SC|
3115867|NCT01782911|Experimental|Resveratrol|Patients will be given 2 g of resveratrol a day from the onset of menses until ovarian pick-up.
3115868|NCT01782911|Placebo Comparator|Control|Patients will be given pills lacking medication from the onset of menses until the ovum pick-up.
3115869|NCT01782898|Active Comparator|Esmolol|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
3115870|NCT01782898|Placebo Comparator|.9 normal saline|.9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
3115871|NCT01782885|Active Comparator|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts.
3115872|NCT01782885|Experimental|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks
3115873|NCT01782872|Active Comparator|Interscalene Block (ISB) - 0.375% Ropivacaine + additives|
3115874|NCT01782872|Active Comparator|Interscalene Block (ISB) - 0.2% Ropivacaine + additives|
3115875|NCT01782872|Active Comparator|Interscalene Block (ISB) - 0.1% Ropivacaine + additives|
3115876|NCT01782872|Active Comparator|Interscalene Block (ISB) - Systemic Control|
3115877|NCT01782859|Placebo Comparator|Placebo|Control group
3115878|NCT01782859|Active Comparator|Prednisone/hydrocortisone|"Steroid group will receive the following:~20 mg prednisone pill to be taken in the morning of surgery prior to arrival to the hospital~100 mg hydrocortisone IV 8 hours after first dose of prednisone followed by 3. Second and last dose of 100 mg hydrocortisone IV"
3115879|NCT01782846|Active Comparator|Ixprim®|2 capsules of Ixprim® given orally (1000 mg Paracetamol + 75 mg Tramadol)
3115880|NCT01782846|Active Comparator|Dafalgan Codeine®|Two capsules of Dafalgan Codeine® given orally (1000 mg Paracetamol + 46.8 mg Codeine)
3115881|NCT01782833||Pletaal|
3115882|NCT01782820||dexamethasone late|dexamethasone during induction of anesthesia
3115883|NCT01782820||no dexamethasone|no dexamethasone during measurements
3115884|NCT01782820||dexamethasone early|dexamethasone before induction of anesthesia
3115885|NCT01782807|No Intervention|Hysterectomy|Hysterectomy without oophorectomy or salpingectomy
3115886|NCT01782807|Experimental|Hysterctomy with salpingectomy or fimbriectomy|Salpingectomy or Fimbriectomy
3115887|NCT01782794||Cohort A|Children aged 12-15 months at the time of the study. Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort.
3115888|NCT01782794||Cohort B|Children aged 24-27 months at the time of the study. Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort.
3115889|NCT01782781|Placebo Comparator|Group P|"Group P (Placebo) receives a local infiltration of saline in the operating field and ketorolac iv.~In Group P the injectant consists of saline, total volume 156 mL. This is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. Ketorolac 30 mg (1 mL) is also injected iv."
3115890|NCT01782781|Active Comparator|Group A|"Group A (Active) receives a local infiltration of ropivacaine, ketorolac and epinephrine in the operating field and saline iv.~Drug: ropivacaine, ketorelac and epinephrine~In Group A the injectant mixture consists of ropivacaine 300 mg mixed with 30 mg ketorolac and 0.5 mg epinephrine, total volume 156 mL. This mixture is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. One mL saline is also injected iv."
3115891|NCT01782768|Experimental|Effect of different NPPV mode on NRD|13 hypercapnic recovering AECOPD patients were placed on different mode of noninvasive positive pressure ventilation(NPPV,such as the PAV or PSV mode) randomly.For each mode, three levels (PA-, PA, PA+or PS-, PS, PS+), ) of support were applied.PS and PA are set for the patient's comfort . On the basis of these two levels, 25% increase and reduction assisted level of pressure were set both for PS and PA (PA-, PA+or PS-, PS+). At each level, the patients were ventilated at least 20 minutes until the breathing was stable.
3115892|NCT01782755|Active Comparator|Lactobacillus rhamnosus GG|Patients allocated to the intervention group will receive 1x1010 colony forming units (CFU) of Lactobacillus rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule suspended in sterile water, administered through a nasogastric, nasoduodenal, percutaneous gastrostomy or percutaneous jejunal tube twice daily while patients are mechanically ventilated until 24 hours of spontaneous breathing. The first dose will be within 48 hours of intubation.
3115893|NCT01782755|Placebo Comparator|Placebo|Patients allocated to the placebo group will receive a capsule identical in appearance to the L. rhamnosus GG capsule, but containing microcrystalline cellulose. The placebo will also be suspended in sterile water and similarly administered twice a day. When suspended in water, the placebo has identical appearance and consistency as the probiotic. The placebo will be prepared by the manufacturer of L. rhamnosus GG, Culturelle, and has been used successfully in a recent RCT in the ICU population
3116022|NCT01781910|Experimental|Branch Chain Amino Acid supplement|A drink supplement containing 1.22 grams of branched chain amino acids, plus glucose.
3115894|NCT01782742|Active Comparator|Bexarotene treatment Arm|"75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.~Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)"
3115895|NCT01782742|Placebo Comparator|Placebo|"1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.~Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)"
3115896|NCT01782729|Experimental|Tacrolimus ointment (pediatric)|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
3115897|NCT01782716||ASA|
3115898|NCT01782716||ASA+Euroscore|
3115899|NCT01782703||Control|Healthy subjects with no history of atopy (atopic dermatitis, asthma, or allergic rhinitis) from 0 months to 17 years of age that are age and sex matched to our atopic dermatitis subjects.
3115900|NCT01782703||Atopic Dermatitis|Children with atopic dermatitis from 0 months to 17 years of age.
3115901|NCT01782703||Control with Atopy history|Healthy subjects from 0 months to 17 years of age with history of asthma, food allergies, or allergic rhinitis, but no atopic dermatitis or with positive family history of atopy
3115902|NCT01782690||Erlotinib plus Gemcitabine|Patients with metastatic pancreatic cancer, who were planned to receive combination therapy of erlotinib and gemcitabine based on the investigator's assessment.
3115903|NCT01782677|Experimental|Bilateral Surgical Resection of Carotid Bodies|Patients undergoing Bilateral Surgical Resection of Carotid Bodies.
3115904|NCT01782664|Experimental|100 mg GSK2586184|Subjects will be randomized to 100 mg GSK2586184 twice daily for up to 84 days
3115905|NCT01782664|Experimental|200 mg GSK2586184|Subjects will be randomized to 200 mg GSK2586184 twice daily for up to 84 days
3115906|NCT01782664|Experimental|400 mg GSK2586184|Subjects will be randomized to 400 mg GSK2586184 twice daily for up to 84 days
3115907|NCT01782664|Placebo Comparator|Placebo|Subjects will be randomized to receive Placebo twice daily for up to 84 days
3115908|NCT01782664|Experimental|400 mg GSK2586184 (Cohort B)|Subjects will take 400 mg GSK2586184 twice daily for up to 84 days
3115909|NCT01782651||HER2+ metastatic breast cancer patients treated with lapatinib|HER2+ metastatic breast cancer patients treated with lapatinib plus capecitabine
3115910|NCT01782638|Experimental|deep brain stimulation with high frequency|The primary purpose of this study is to compare the effect of deep brain stimulation with high frequency vs low frequency on gait of patients whatever the electrodes placement (STN ou Forel fields) and whatever the medication condition (with or without treatment).
3115911|NCT01782638|Other|low frequency on gait of patients|The primary purpose of this study is to compare the effect of deep brain stimulation with high frequency vs low frequency on gait of patients whatever the electrodes placement (STN ou Forel fields) and whatever the medication condition (with or without treatment).
3115912|NCT01782625|Experimental|dive to 122 feet, no exercise|Subjects will undergo a simulated dive to a maximum depth of 122 feet of seawater with no exercise at depth
3115913|NCT01782625|Experimental|dive to 158 feet, no exercise|Subjects will undergo a simulated dive to a maximum depth of 154 feet of seawater with no exercise at depth
3115914|NCT01782625|Experimental|dive to 122 feet, exercise|Subjects will undergo a simulated dive to a maximum depth of 122 feet of seawater with exercise at depth
3115915|NCT01782625|Experimental|dive to 158 feet, exercise|Subjects will undergo a simulated dive to a maximum depth of 154 feet of seawater with exercise at depth.
3115916|NCT01782612|Active Comparator|General Ansethesia|Subjects undergoing Total uni-Hip Replacement will receive standard General Anesthesia with Laryngeal Mask Airway and Multimodal analgesic techniques
3115917|NCT01782612|Experimental|Peripheral Nerve Blocks|Subjects undergoing Total uni-Hip Replacement will receive Lumbar plexus block and Sciatic nerve block with 0.4% Ropivacaine and Multimodal analgesic techniques
3115918|NCT01782599|Experimental|Dual nicotine patch and electronic cigarette|Nicotine patch and the electronic cigarette will be administered.
3115919|NCT01782573|Active Comparator|Chlorhexidine gluconate ( CHG )|(i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
3115920|NCT01782573|Active Comparator|0.9% Sodium Chloride ( N/S )|(i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
3115921|NCT01782560|Placebo Comparator|Placebo|Two different placebo formulations will be created which will designed to be identical in appearance, taste, and consistency to the two study medications.
3115922|NCT01782560|Active Comparator|Omeprazole|Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. 2 mg/kg/day omeprazole.
3115923|NCT01782547|Experimental|Telehealth Intervention|Telehealth intervention - 6 months
3115924|NCT01782547|Active Comparator|Usual care|Usual care control with comparable frequency of contact
3115925|NCT01782534||aortic dissection|aortic dissection
3115926|NCT01782521|No Intervention|Primer|Metal brackets bonded with primer
3115927|NCT01782521|Experimental|No primer|Metal brackets bonded without primer
3115928|NCT01782508|Experimental|imatinib|Participants will take 400mg tablets once daily for one year
3115929|NCT01782508|Active Comparator|inteferon|Participants will receive Interferon 1500wiu/m2 d1-5for 4 weeks followed by 900wiu IH TIW for 11 months
3115930|NCT01782495|Experimental|Arm A|Liver transplant recipients with HCV genotype 1 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
3116049|NCT01781715|Experimental|Multivessel stenting|This group comprises the patients who undergo a one-time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions
3115931|NCT01782495|Experimental|Arm B|Liver transplant recipients with HCV genotype 1a or genotype 1b (dependent on prior treatment experience and response) infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
3115932|NCT01782495|Experimental|Arm C|Liver transplant receipts with HCV genotype 1b infection who were treatment naïve or prior responders to interferon treatment without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 24 weeks.
3115933|NCT01782495|Experimental|Arm D|Liver transplant recipients with HCV genotype 1a infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (dosed 1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
3115934|NCT01782495|Experimental|Arm E|Liver transplant recipients with HCV genotype 1b infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
3115935|NCT01782495|Experimental|Arm F|Liver transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
3115936|NCT01782495|Experimental|Arm G|Liver transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.
3115937|NCT01782495|Experimental|Arm H|Renal transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
3115938|NCT01782495|Experimental|Arm I|Renal transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.
3115939|NCT01782495|Experimental|Arm J|Liver transplant recipients with HCV genotype 4 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
3115940|NCT01782495|Experimental|Arm K|Liver transplant recipients with HCV genotype 4 infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
3115941|NCT01782482|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn on a daily wear basis for 7 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
3115942|NCT01782482|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color worn on a daily wear basis for 7 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
3115943|NCT01782469||Rheumatoid Arthritis (RA) participants|Male or female participants at least 18 years of age with diagnosis of RA
3115944|NCT01782456|Experimental|Study Oral Nutritional Supplement|2 servings per day of a complete and balanced, ready-to-drink oral nutritional supplement with a new protein blend.
3115945|NCT01782443|Experimental|Experimental Treatment Arm|Ziv-aflibercept IV every 2 weeks, 4 mg/kg
3115946|NCT01782430|Experimental|Standard oxygenation|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
3115947|NCT01782430|Experimental|High flow nasal oxygen therapy|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
3115948|NCT01782430|Other|invasive ventilation (VNI)|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
3115949|NCT01782417|Other|Patient and provider intervention|participants will receive a patient and provider intervention
3115950|NCT01782404|Experimental|Chlorhexidine|
3115951|NCT01782391|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
3115952|NCT01782391|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
3115953|NCT01782378|Active Comparator|Real LED Treatment Series First|Participants in this group first receive a series of 15 real LED treatments with the helmet and intranasal devices containing the real LEDs. At 1 week following the last real LED treatment, these participants then receive a series of 15 sham LED treatments with the helmet and intranasal devices containing the sham LEDs.
3115954|NCT01782378|Sham Comparator|Sham LED Treatment Series First|Participants in this group first receive a series of 15 sham LED treatments with the helmet and intranasal devices containing the sham LEDs. At 1 week following the last sham LED treatment, these participants then receive a series of 15 real LED treatments with the helmet and intranasal devices containing the real LEDs.
3115955|NCT01782365|Experimental|0,75 Hz stimulation|transcranial slow oscilliating stimulation (tSOS)during periods of SWS
3115956|NCT01782365|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of SWS
3115957|NCT01782352|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
3115958|NCT01782352|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
3115959|NCT01782352|Placebo Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~fish oil placebo"
3115960|NCT01782352|Active Comparator|Vitamin D + fish oil|"Vitamin D (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
3116050|NCT01781715|Active Comparator|Staged revascularization|This group comprises the patients who undergo PCI of only the culprit lesion and staged nonculprit PCI at a later date (3-15 days)
3115961|NCT01782339|Experimental|Combination Chemotherapy|"4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle."
3115962|NCT01782326|Experimental|QVA149|QVA149 (110/50 μg) once daily
3115963|NCT01782326|Active Comparator|Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)|Salmeterol/fluticasone (50/500μg) b.i.d
3115964|NCT01782313|Experimental|Treatment (tivozanib)|Patients receive tivozanib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3115965|NCT01782300|Experimental|TV003 Vaccine|Participants will receive an injection of the TV003 vaccine at study entry and Day 360.
3115966|NCT01782300|Placebo Comparator|Placebo Vaccine|Participants will receive an injection of the placebo vaccine at study entry and Day 360.
3115967|NCT01782287|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic stem cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
3115968|NCT01782287|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic stem cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
3115969|NCT01782274|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
3115970|NCT01782274|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
3115971|NCT01782261|Experimental|Liraglutide|Liraglutide subcutaneous injection every day. first week 0.6mg, week 2-4 1.2mg.
3115972|NCT01782261|Active Comparator|Saxagliptin|Saxagliptin 5mg tablet by mouth every day for 4 weeks
3115973|NCT01782248|Other|Alzheimer disease|Patients with Alzheimer disease
3115974|NCT01782248|Other|Fronto-temporal lobar dementia|Patients with Fronto-temporal lobar dementia
3115975|NCT01782248|Other|Control|Control group
3115976|NCT01782235|Experimental|Tocilizumab arm|Tocilizumab arm will receive tocilizumab.
3115977|NCT01782235|Placebo Comparator|Placebo arm|Placebo arm will receive placebo.
3115978|NCT01782222|Experimental|Rotigotine, high dose|Rotigotine, transdermal patches, maximal 16 mg / 24 hours for patients with advanced Parkinson's Disease and 8 mg / 24 hours for those with early Parkinson's Disease
3115979|NCT01782222|Experimental|Rotigotine, low dose|Rotigotine, transdermal patches, optimal dose, maximal 8 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours for those with early Parkinson's Disease
3115980|NCT01782222|Placebo Comparator|Placebo|Placebo transdermal patches
3115981|NCT01782196|Experimental|Type A Pouch followed by Type B pouch|Enhanced one piece drainable pouch with Type A mouldable adhesive for Stage 1 and 2 followed by pouch with Type B mouldable adhesive for Stage 3
3115982|NCT01782196|Experimental|Type B Pouch followed by Type A pouch|Enhanced one piece drainable pouch with Type B mouldable adhesive for Stage 1 and 2 followed by pouch with Type A mouldable adhesive for Stage 3
3115983|NCT01782183|Experimental|Thermal camera by Flir HM series|all patients in both study and control groups will undergo thermal camera photo of the tonsils by Flir HM series
3115984|NCT01782170|Active Comparator|Iocide Oral Rinse|Iocide Oral Rinse once daily 30 second rinse for 24 weeks
3115985|NCT01782170|Placebo Comparator|Placebo Control|Once daily 30 second rinse for 24 weeks
3115986|NCT01782157||Prompt intervention|The prompt intervention group will receive context-aware text, audio, and video prompts to initiate specified activities of daily living.
3115987|NCT01782157||No prompt intervention|The no prompt intervention will not receive any prompts to initiate activities of daily living.
3115988|NCT01782144|Active Comparator|NutriSystem|weekly behavior group weight loss education
3115989|NCT01782144|Placebo Comparator|Education|monthly behavior group weight loss education
3116020|NCT01781923|Experimental|Cognitive Remediation|"12 week computer-based cognitive remediation program aimed to improve working memory, processing speed, and verbal learning/memory.~40 week small group social skills training sessions aimed to improve social skills and cognition."
3116021|NCT01781923|No Intervention|Control|No intervention
3116051|NCT01781702|Experimental|Pelubiprofen 30 mg|Pelubiprofen 30 mg, tid
3115990|NCT01782131|Experimental|Posaconazole|Participants will start therapy with a posaconazole loading dose of 300 mg intravenously (IV) twice per day (BID) on Day 1, and then will receive posaconazole IV 300 mg once per day (QD) starting on Day 2 until clinically stable when participants will transition to oral therapy with posaconazole 300 mg tablets QD for up to a total of 12 weeks of treatment. Participants with renal insufficiency or without central venous catheter access may start study treatment with a loading dose of oral posaconazole 300 mg tablets BID on Day 1, and then 300 mg QD for up to a total of 12 weeks of treatment.
3115991|NCT01782131|Active Comparator|Voriconazole|Participants will start therapy with a voriconazole loading dose of 6 mg/kg of body weight IV BID on Day 1, and then will receive voriconazole IV 4 mg/kg of body weight IV BID starting on Day 2 until clinically stable when participants will transition to oral therapy with voriconazole 200 mg capsules BID for up to a total of 12 weeks of treatment. Participants with renal insufficiency or without central venous catheter access may start study treatment with a loading dose of oral voriconazole 300 mg capsules BID on Day 1, and then 200 mg BID for up to a total of 12 weeks of treatment.
3115992|NCT01782118|Experimental|Lactobacillus GG|Lactobacillus GG given for six weeks two times per day.
3115993|NCT01782118|Placebo Comparator|Placebo|Placebo two times per day for six weeks
3115994|NCT01782105|Active Comparator|Control group|In addition to the usual monitoring of pregnancy, this group will receive information about the recommended weight gain during pregnancy and an evaluation about of their nutritional and physical activity habits.
3115995|NCT01782105|Experimental|Intervention group|"This group will receive a regular monitoring by health professionals (nutritionist and kinesiologist) who will ensure nutritional changes and physical activity necessary to secure the adoption of a healthy lifestyle and could participate to a physical activity group session once a week until week 36 of gestation.~The intervention include:~A nutritional counseling every 2 weeks by a nutritionist until week 36 of gestation; a physical activity group session once a week lead by a kinesiologist until week 36 of gestation; 2 sessions of physical activity counseling (weeks 12 and 24)."
3115996|NCT01782092||Chiropractic & Diabetes|All subjects will also receive chiropractic care and receive spinal adjustments as indicated by Basic and Intermediate Activator Methods Protocols, which uses a combination of provocative tests designed to elicit a relative change in leg length in the presence of subluxation. Special shoes designed for improved accuracy of leg length analysis will be used for all visits. The patients will be analyzed two times per week for the first month followed by once per week for the remainder of the study. The Activator Methods protocol will be followed for all visits by all doctors in accordance with the guidelines set forth by Activator Methods International, Ltd. The first four visits will be limited to Basic Protocol to allow the patients to become accustomed to the process.
3115997|NCT01782079|Experimental|L. brevis|
3115998|NCT01782066|Experimental|Menveo, dose escalating|
3115999|NCT01782066|Experimental|Nimenrix, dose escalating|
3116000|NCT01782053|Experimental|Control condition|Current packaging with warning on side replaced with one of 9 mandated warning statements
3116001|NCT01782053|Experimental|Text plus picture|Revised packaging with half of front and back of pack showing FDA proposed warning including image.
3116002|NCT01782053|Experimental|Picture plus additional warning text|Same as text plus picture but containing additional text elaborating on the basis for the warning.
3116003|NCT01782040|No Intervention|Control Group|Control Group didn't receive any treatment and it was evaluated at the same time and the same way of interventions group
3116004|NCT01782040|Experimental|Auriculotherapy group|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.It was used 6 points: Kidney, Liver, Stomach, Brain Stem, Ovary and Uterus point with semi-permanent needles one time per week for 8 sessions
3116005|NCT01782027|Experimental|3H-cholesterol|
3116006|NCT01782014|Experimental|Water Insufflation|Colonoscopy using water insufflation
3116007|NCT01782014|Active Comparator|Carbon dioxide insufflation|Colonoscopy using carbon dioxide insufflation
3116008|NCT01782014|Active Comparator|Air insufflation|Colonoscopy using air insufflation
3116009|NCT01782001|Experimental|Vitamin A and zinc|combination of vitamin A and zinc supplements
3116010|NCT01782001|Active Comparator|Vitamin A and placebo|vitamin A with placebo
3116011|NCT01781988|Experimental|A.individual therapy|Carboplatin was administrated at an area under the plasma concentration time curve (AUC) of 5 on day 1 every 21 days, while gemcitabine was administrated at a dose of 1250 mg/m2 on day 1 and 8 and pemetrexed was administrated at a dose of 500 mg/m2 on day 1.
3116012|NCT01781988|Experimental|B. non-individualized therapy|Carboplatin was administrated at an area under the plasma concentration time curve (AUC) of 5 on day 1 every 21 days, while gemcitabine was administrated at a dose of 1250 mg/m2 on day 1 and 8 and pemetrexed was administrated at a dose of 500 mg/m2 on day 1.
3116013|NCT01781975|Experimental|Imatinib Mesylate|400 mg imatinib given once daily basis.
3116014|NCT01781975|Placebo Comparator|Placebo|Placebo given once daily basis.
3116015|NCT01781962||All Participants|Open-Angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) patients.
3116016|NCT01781949|Other|A: Nontargeted rapid HIV screening|Eligible patients randomized to this arm will be offered rapid HIV screening without assessment of risk. HIV testing will occur on a 24-hour basis as part of routine ED care.
3116017|NCT01781949|Other|B: Enhanced targeted rapid HIV screening|Eligible patients randomized to this arm will be asked to answer questions regarding HIV risk using the Denver HIV Risk Score (DHRS), an empirically-developed clinical prediction instrument for assessing HIV risk, to identify patients at increased risk for HIV infection. Patients identified as being at increased risk for HIV infection will be offered rapid HIV testing. HIV testing will occur on a 24-hour basis as part of routine ED care.
3116018|NCT01781949|Other|C: Traditional targeted rapid HIV screening|Eligible patients randomized to this arm will be asked to answer questions related to HIV risk using a traditional behavioral risk screening tool to identify patients at increased risk for HIV infection. Patients identified as being at increased risk for HIV infection will be offered rapid HIV testing. HIV testing will occur on a 24-hour basis as part of routine ED care.
3116019|NCT01781936|Experimental|Low dose FA-i (Fluocinolone Acetonide insert)|Each FA-i contains 180 µg FA (Fluocinolone Acetonide) designed to be released over 15 - 30 months.
3116052|NCT01781702|Active Comparator|Celebrex 200 mg|Celebrex 200 mg, tid
3116023|NCT01781910|Placebo Comparator|Placebo supplement|The placebo was formulated to match both the taste and color of the test supplement. Crystal Light Lemonade powder (Kraft Foods, Northfield, IL, USA) was mixed with 5.6g of powdered dextrose (Now Foods, Bloomingdale, IL, USA) to match the amount of dextrose present in the BCAA supplement.
3116024|NCT01781897|Active Comparator|mosapride|mosapride
3116025|NCT01781897|Experimental|Electro-acupuncture|Electro-acupuncture
3116026|NCT01781897|Sham Comparator|mosapride + sham acupuncture|mosapride + sham acupuncture
3116027|NCT01781884|Active Comparator|Gamma Aminobutyric Acid (GABA)|GABA will be given 50mg/kg/Day, thrice daily for 52 weeks
3116028|NCT01781884|Active Comparator|Gamma Aminobutyric Acid GABA)|GABA will be given 100mg/kg/Day, thrice daily for 52 weeks.
3116029|NCT01781884|Placebo Comparator|placebo|placebo will be given thrice daily for 52 weeks
3116030|NCT01781871|Experimental|Prevenar13|68 kidney transplant patients vaccinated with Prevenar13 as they enter the transplant waiting list. Pre- and postvaccination serotype specific ELISA and OPA measured. Revaccination at 6 months after the transplantation with Prevenar13, again pre- and postvaccination serotype specific ELISA and OPA measured
3116031|NCT01781871|Active Comparator|Pneumovax|68 kidney transplant patients vaccinated with Pneumovax as they enter the transplant waiting list, serotype specific ELISA and OPA measured before and after the vaccination. At six and seven months after transplantation ELISA and OPA measured parallel to the experimental group
3116032|NCT01781871|Experimental|liver Prevenar13|30 liver transplant patients vaccinated with Prevenar13 once they enter the transplant waiting list. Serotype specific ELISA and OPA measured before and after the vaccination. Revaccinated with Prevenar13 at 6 months after the transplantation. ELISa and OPA measured pre- and postvaccination.
3116033|NCT01781871|Active Comparator|liver Pneumovax|30 liver transplant patients vaccinated with Pneumovax once they enter the transplant waiting list. Serotype specific ELISA and OPA measured pre- and postvaccination. At 6 and 7 months posttransplant ELISA and OPA measured parallel to the experimental group.
3116034|NCT01781858||pulmonary embolism|Consecutive outpatients and inpatients with first episode of acute pulmonary embolism
3116035|NCT01781845|Experimental|ARFI-SVI Ultrasound|Ultrasound scan using acoustic radiation force impulse-shear wave velocity imaging in the characterization of pediatric hydronephrosis. This is a non-invasive scan that uses sound waves to create the images.
3116036|NCT01781832|Experimental|(ARFI)-Derived Shear Wave Velocities|"This is an ultrasound-based new technique using Acoustic Radiation Force Impulse (ARFI). Shear Wave speeds are derived using ARFI.~During ultrasound scanning a sound wave is sent towards tissue. The tissue's movement in response to the wave is measured in Shear Wave Velocity, which can estimate tissue stiffness. This technique may help detect bladder wall thickness and fibrosis (thickening) in the urinary bladder of pediatric patients."
3116037|NCT01781819|Experimental|ARFI SVI ultrasound imaging|Acoustic Radiation Force Impulse (ARFI) Shear Wave Velocity Imaging (SVI) ultrasound imaging
3116038|NCT01781806|Active Comparator|Cohort H (PrEP)|"Participants in the H cohort will be provided with a CPP, including daily oral emtricitabine/tenofovir-based PrEP.~High Risk Cohort Criteria (one or more of the following has to be met):~No condom use during anal intercourse with ≥3 male sex partners who are HIV-positive or of unknown HIV status during the last three months.~STD diagnosis during the last 12 months.~Previous PEP use during the last 12 months (* see exclusion criteria)~Has at least one HIV infected sexual partner for ≥4 weeks."
3116039|NCT01781806|Active Comparator|Cohort LM (PEP)|Participants who do not meet criteria for High Risk (Cohort H) will be assigned to the LM (low moderate) cohort and will receive a customized prevention package based on baseline assessments (in the same manner as the Cohort H Participants). In addition, they will receive education on the availability and use of post-exposure prophylaxis.
3116040|NCT01781793|Placebo Comparator|Fibrotic ILD Patients, Room Air|Fibrotic ILD patients will breathe room air (21% oxygen) during a constant work rate exercise test
3116041|NCT01781793|Active Comparator|Fibrotic ILD Patients, Hyperoxia|Fibrotic ILD patients will breathe hyperoxia (60% oxygen) during a constant work rate exercise test
3116042|NCT01781780|Active Comparator|General Nutrition Recommendations|Participants will be provided with a free USDA nutrition pamphlet describing general good nutrition habits. They will also receive an instruction handout to emphasize some of the points in the dietary guidelines in the handout. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the suggestions as best they can into their daily life.
3116043|NCT01781780|Experimental|Breakfast Recommendation|Participants randomized to the breakfast group will be instructed to consume breakfast before 10:00 a.m. every day, and will be asked to not eat again until after 11:00 a.m. Participants will be counseled on what a healthy breakfast is using an instruction handout. No specific restrictions will be given on types of foods that can be consumed for the breakfast meal. They will be instructed to keep track of their breakfast consumption (yes/no) using a calendar diary that will be provided to them. Participants will also be provided with a free USDA nutrition pamphlet describing general good nutrition habits. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the recommendations into their daily life as much as they can.
3116044|NCT01781780|Experimental|No Breakfast Recommendation|Participants randomized to the no breakfast group will receive a detailed handout with instructions to not consume any calories before 11:00 a.m. every day. Only water or 0 calorie beverages may be consumed from the time of waking until 11:00 a.m. They will be instructed to keep track of their breakfast consumption (yes/no) using a calendar diary that will be provided to them. Participants will also provided with a free USDA nutrition pamphlet describing general good nutrition habits. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the recommendations into their daily life as much as they can.
3116045|NCT01781754||Diabetic patients|Un balanced diabetic patients
3116046|NCT01781741|Experimental|Treatment (TEMLA and SBRT)|Patients undergo TEMLA to remove the mediastinal lymph nodes followed by a single fraction of SBRT to the primary tumor (unless VATS procedure done) and mediastinal lymph node beds (if positive on TEMLA), with or without minimally invasive surgery.
3116047|NCT01781728|Active Comparator|RT naive|
3116048|NCT01781728|Active Comparator|Previous RT|
3116240|NCT01780363||controls|frequency of mevalonate kinase gene frequency
3116053|NCT01781689|Experimental|Functional Electric Stimulation|perform arm cranking with functional electrical stimulation
3116054|NCT01781689|Sham Comparator|traditional rehabilitation program|Receive traditional rehabilitation programs
3116055|NCT01781689|No Intervention|Health|with no motor function impairment
3116056|NCT01781663|Experimental|KAM2904 Face Cream and KAM3008 Body Lotion|A group treated with KAM2904 Face Cream and KAM3008 Body Lotion
3116057|NCT01781663|Sham Comparator|petrolatum-based moisturizer|control group
3116058|NCT01781650|Active Comparator|Air insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
3116059|NCT01781650|Experimental|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
3116060|NCT01781650|Experimental|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
3116061|NCT01781637|Experimental|omalizumab group|Patients will receive omalizumab.
3116062|NCT01781637|Placebo Comparator|placebo|Patients will receive placebo.
3116063|NCT01781624|Experimental|Study Oral Nutritional Supplement|2 containers a day of a high calorie, complete, balanced, ready-to-drink oral nutritional supplement with a new protein blend.
3116064|NCT01781611|Experimental|extended release dipyridamole/aspirin|extended release dipyridamole 200mg/aspirin 25mg twice daily for 24 weeks
3116065|NCT01781611|Active Comparator|aspirin|half a tablet of a 81mg aspirin twice daily for 24 weeks
3116066|NCT01781598||Patients treated with Patient specific instruments in TKA|
3116067|NCT01781585||sustained low-efficiency dialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
3116068|NCT01781585||continuous veno-venous hemofiltration|Patients were randomized to receive CVVH or SLED and the next day on the other.
3116069|NCT01781572|Experimental|Phase Ib|The phase Ib is the dose escalation part where successive cohorts of 3-6 newly enrolled patients receiving various dose pairs considering the recommendation from an adaptive BLRM incorporating the EWOC principle until MTD(s)/RP2D is defined. Patients with either measurable or evaluable disease will be eligible. If multiple alternate dosing schedules are explored in parallel, the allocation of patients will proceed in an alternating fashion. Approximately 40 patients are expected to be treated during the phase Ib part of the study.
3116070|NCT01781572|Experimental|Phase II|The Phase II part will begin once the MTD(s)/RP2D have been determined in the Phase Ib in order to assess antitumor activity of the LEE011and MEK162 combination. Data from enrolled patients will also be used to better characterize the safety, tolerability and PK profile of the two agents. Patients enrolled in the Phase II part of the study are required to have measurable disease. Approximately 40 patients will be treated in this part.
3116071|NCT01781559|Experimental|phenolic acid + maltodextrin|phenolic acid + maltodextrin;
3116072|NCT01781559|Placebo Comparator|Maltodextrin|Maltodextrin
3116073|NCT01781559|Active Comparator|flavanol + maltodextrin|flavanol + maltodextrin
3116074|NCT01781546|Experimental|drug-eluting balloon (DEB)|Patients treated with drug-eluting balloon (DEB). Provisional stenting with BMS is permitted in case of a flow-limiting dissection or significant recoil (>30% in main branch and >50% side-branch), Includes both stable CAD and ACS patients.
3116075|NCT01781546|Active Comparator|bare-metal stent (BMS)|Patients treated with bare-metal stent (BMS). Includes both stable CAD and ACS patients.
3116076|NCT01781533|Experimental|algorithm|
3116077|NCT01781520|Experimental|S-1 plus DC-CIK|"Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or greater, respectively, for 14 consecutive days, followed by a 7-day rest, repeated every 3 weeks.~DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition aphaeresis, and then cultured DC-CIK cells were infused back to the patients on days 15, 17, and 19 of 21-day cycles."
3116078|NCT01781520|Active Comparator|DC-CIK alone|DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition aphaeresis, and then cultured DC-CIK cells were infused back to the patients on days 15, 17, and 19 of 21-day cycles.
3116079|NCT01781520|Active Comparator|S-1 alone|Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or greater, respectively, for 14 consecutive days, followed by a 7-day rest, repeated every 3 weeks.
3116080|NCT01781520|Active Comparator|Best supportive care|
3116081|NCT01781507|Experimental|Cetirizine|Cetirizine 10 mg orally once a day
3116082|NCT01781507|Placebo Comparator|Sugar pill|This will be the placebo arm
3116083|NCT01781494|Active Comparator|Immobilization|Immobilization followed by protected range of motion
3116084|NCT01781494|Experimental|Immediate range of motion|Immediate motion after anterior submuscular ulnar nerve transposition
3116085|NCT01781481||Children and youth with IBD|Children/youth (ages 8-17) with confirmed diagnoses of IBD.
3116086|NCT01781468|Experimental|Arm I|Patients receive 150 mg armodafinil orally every day in the morning for 8 weeks.
3116087|NCT01781468|Placebo Comparator|Arm II|Patients receive placebo orally every day in the morning for 8 weeks.
3116088|NCT01781468|Experimental|Arm III|Patients receive 250 mg armodafinil orally every day in the morning for 8 weeks.
3116089|NCT01781455|Experimental|BBI503|
3116090|NCT01781442||Patient Arm- temsirolimus|
3116091|NCT01781429|Experimental|BVD-523|
3116092|NCT01781416||1|
3116093|NCT01781403|Experimental|Capecitabine, Temozolomide, Radiotherapy|"The total dose of radiotherapy will be 50.4 Gy, with a daily dose of 1.8 Gy administered on 5 days of each week, comprising a total of 45 Gy to the whole pelvis, followed by a 5.4 Gy boost to the primary tumor.~The doses and schedules for capecitabine will be fixed, with only temozolomide being prescribed using a dose-escalation schedule. Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break)."
3116094|NCT01781390|Experimental|12.5M Mesenchymal Precursor Cells (MPC)|12.5M Mesenchymal Precursor Cell (MPC) administered via IC infusion
3116095|NCT01781390|Experimental|25M Mesenchymal Precursor Cells (MPC)|25M Mesenchymal Precursor Cell (MPC) administered via IC infusion
3116096|NCT01781390|Placebo Comparator|Placebo|Placebo via IC infusion
3116097|NCT01781377|Experimental|PROPOFOL|PROPOFOL SINGLE BOLUS 10 mg + 1mg/kg/hr INFUSION AT UMBILICAL CORD RESECTION
3116098|NCT01781377|Experimental|METOCLOPRAMIDE|METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION
3116099|NCT01781377|Experimental|PROPOFOL & METOCLOPRAMIDE|PROPOFOL SINGLE BOLUS of 10 mg + 1mg/kg/hr INFUSION AND METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION
3116100|NCT01781377|Placebo Comparator|PLACEBO|SALINE INFUSION
3116101|NCT01781364|Experimental|Cognitive Training|Brain Fitness Training, Posit Science SF
3116102|NCT01781351|Experimental|taping the ankle|
3116103|NCT01781338|Experimental|Induction Therapy|The kind of induction therapy is dependent on the respective sub-protocol.
3116104|NCT01781325|Active Comparator|IBEHR|IBEHR
3116105|NCT01781325|No Intervention|Standard therapy|written instructions
3116106|NCT01781312|Experimental|ProTectis|
3116107|NCT01781312|Experimental|Gastrus|
3116108|NCT01781299|Active Comparator|AlloDerm RTU|Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement.
3116109|NCT01781299|Active Comparator|SurgiMend PRS|Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement.
3116110|NCT01781286|Active Comparator|High Protein|Higher Protein Soy-based Snacks
3116111|NCT01781286|Active Comparator|Low Protein|Typical, Low Protein Snacks
3116112|NCT01781286|No Intervention|No Snack|No Snack
3116113|NCT01781273|Placebo Comparator|Cranberry juice alone|500 mL of cranberry juice
3116114|NCT01781273|Experimental|BAC 0.5 g/L|Cranberry juice with ethanol to rise BAC to 0.5 g/L
3116115|NCT01781273|Experimental|BAC 0.65 g/L|Cranberry juice with ethanol to rise BAC to 0.65 g/L
3116116|NCT01781273|Experimental|BAC 0.8 g/L|Cranberry juice with ethanol to rise BAC to 0.8 g/L
3116117|NCT01781260||Young. Fit. Minor neurosurgical operation. Prone position.|18-65 year old patients, without serious medical co-morbidities (assessed as ASA I/II status) who are having minor to moderate severity neurosurgical operations in the prone position.
3116118|NCT01781247|Experimental|Intervention group|Patients in the intervention group will participate in one single counseling session of 45 minutes (the minimal behavioral intervention) that targets specific MI-triggered traumatic reactions.
3116119|NCT01781247|Active Comparator|Control group|Patients in the control group will participate in one single counseling session of 45 minutes (the control intervention) that targets more general information about the role of psychological stress in coronary heart disease.
3116120|NCT01781234|Experimental|Intranasal Insulin|Intranasal Insulin
3116121|NCT01781234|Placebo Comparator|Placebo|Placebo
3116122|NCT01781221|Active Comparator|Alpha-Bio's GRAFT Natural Bovine Bone|two different bone substitutes commonly used in dental procedures.
3116123|NCT01781221|Active Comparator|Bio-Oss xenograft|two different bone substitutes commonly used in dental procedures.
3116124|NCT01781208|Experimental|Ultrasound-based Acoustic Radiation Force Imaging|The liver was scanned using ultrasound and ultrasound-based acoustic radiation force impulse imaging technique (ARFI).
3116125|NCT01781195||Advagraf-based immunosuppression|50 patients after liver transplantation (25 with a MELD-score ≤20 and 25 patients with a MELD-score >20) under CNI-based immunosuppression with Advagraf
3116126|NCT01781169|Experimental|Obese group|Oral supplementation of vitamin D (cholecalciferol), 50000 IU/wk for 8 weeks.
3116127|NCT01781169|Experimental|Normal-weight group|Oral supplementation of vitamin D (cholecalciferol), 50000 IU/wk for 8 weeks.
3116128|NCT01781143|Experimental|Perform echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
3116129|NCT01781130|Placebo Comparator|Percutaneous release alone|The patients who perform percutaneous release of trigger finger only
3116130|NCT01781130|Experimental|Percutaneous release + Steroid injection|Steroid local injection after percutaneous release of trigger finger
3116131|NCT01781117|Experimental|HoLEP group|Holmium Laser Enucleation of the Prostate (HoLEP)
3116132|NCT01781104|Active Comparator|RM-131|
3116133|NCT01781104|Placebo Comparator|Placebo|
3116134|NCT01781091|Experimental|FULLY CLOSED-LOOP VENTILATION|IntelliVent-ASV automatic mode
3116135|NCT01781091|Active Comparator|Conventional modes ventilation|Conventional modes
3116136|NCT01781078|Experimental|MRI Group|Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant.
3116137|NCT01781078|Experimental|Control Group|Those subjects randomized to the Control Group will not undergo s study-specific MRI scan. All follow-up time requirements are the same for the two groups.
3116138|NCT01781065|Experimental|transcranial direct current stimulation|Anodal stimulation on motor cortex
3116139|NCT01781065|Sham Comparator|Sham transcranial direct current stimulation|Turn off after 10 s of stimulation
3116140|NCT01781052||Group 1|
3116141|NCT01781026|Experimental|Vemurafenib Administration|Vemurafenib 960 mg orally, twice per day
3116142|NCT01781013|Experimental|Technology-supported care|This arm consists of Clinic Resource Management (CRM) clinics and serves as our intervention arm where the tested technology is implemented. Our overarching aim in these comparisons is to assess the potential effects of technology-facilitated depression symptom monitoring, relapse prevention, and medication adjustments and to examine depression care receipt and symptom improvement, patient/provider acceptance, and cost.
3116143|NCT01781013|No Intervention|Supported-Care|This arm consists of CRM (Clinic Resource Management) clinics and serves as one of the two control arms in the study.
3116144|NCT01781013|No Intervention|Usual Care|This arm consists of non-CRM (Clinic Resource Management) clinics and serves as one of the two control arms in the study.
3116145|NCT01781000|Experimental|Auditiory verbal discrimination training|Brain Fitness & Brain Training- Posit Science
3116146|NCT01781000|Experimental|Facial affect discrimination training|Behavioral: Facial Affect Training- FAT
3116147|NCT01781000|Active Comparator|Treatment as usual|standard treatment/rehabilitation protocol of schizophrenia ward
3116148|NCT01780987|Experimental|Apixaban|
3116149|NCT01780987|Active Comparator|UFH/Warfarin|
3116150|NCT01780974|Placebo Comparator|Placebo|Three placebo oil capsules per day (2 caps morning, 1 cap evening) + 2 placebo LA capsules per day. Capsules will be taken with food or a meal.
3116151|NCT01780974|Experimental|Lipoic acid plus omega-3 fatty acids|Three 1-gram fish oil concentrate capsules per day (2 caps morning, 1 cap evening) containing a daily dose of 675 mg docosahexaenoic acid (DHA) and 975 mg eicosapentaenoic acid (EPA) plus 2 LA capsules per day with a daily dose of 600 mg. Capsules will be taken with food or a meal.
3116152|NCT01780948|Placebo Comparator|everolimus|Everolimus administration with adjusted dose to target C trough (C0) level between 3-12 ng/mL
3116153|NCT01780948|Experimental|everolimus with atorvastatin 20 mg|"Co-administration of everolimus and atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.~Atorvastatin 20 mg/day (fixed dose)"
3116154|NCT01780935|Experimental|RBZ 0.5 mg: VA only (Group I)|RBZ 0.5 mg: Visual Acuity (VA) only (Group I) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA) loss due to neovascular (wet) age-related macular degeneration (nAMD)
3116155|NCT01780935|Experimental|RBZ 0.5 mg: VA and/or OCT (Group II)|RBZ 0.5 mg: VA and/or OCT (Group II) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA)loss due to neovascular (wet) age-related macular degeneration (nAMD) and/or signs of wet AMD disease activity on optical coherence tomography (OCT).
3116156|NCT01780922|Active Comparator|Low Calorie Cranberry Juice Cocktail|Beverage containing cranberry: one dose of 15.2 ounces consumed within 15 minutes
3116157|NCT01780922|Active Comparator|Cranberry Extract Beverage|Beverage containing cranberry: one dose of 15.2 ounces consumed within 15 minutes
3116158|NCT01780922|Placebo Comparator|Non-Cranberry Beverage|Beverage absent cranberry: one dose of 15.2 ounces consumed within 15 minutes
3116159|NCT01780909|Experimental|Paromomycin Sulfate Fasted State|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state. Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. • After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
3116160|NCT01780909|Experimental|Paromomycin Sulfate Fed State|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fed state. Fed state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. When you arrive at the hospital for the clinical trial, you will receive an Ensure Plus Shake, after the gastrointestinal catheters are placed. 20 minutes after the intake of the shake, you will receive the a glass of water, where Gabbroral is in dissolved. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
3116161|NCT01780909|Experimental|Paromomycin Sulfate w/ Domperidone|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state, in addition of the intake of Motilium® (API: domperidone 10 mg). Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. 20 minutes for the intake of the medicine, you will take 2 tablets of Motilium®, which stimulates the gastric emptying. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
3116162|NCT01780909|Experimental|Paromomycin Sulfate w/ Loperamide HCl|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state, in addition of the intake of Imodium® (API: loperamide HCl 2 mg). Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. 20 minutes for the intake of the medicine, you will take 2 tablets of Imodium®, which has an inhibited effect on the intestine. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
3116163|NCT01780896||Study Group|
3116164|NCT01780883|Placebo Comparator|Placebo|5 tablets of placebo once a day, an hour before falling asleep, for 6 weeks.
3116165|NCT01780883|Experimental|2 mg melatonin|1 tablet of 2mg melatonin and 4 tablets of its placebo once a day, an hour before falling asleep, for 6 weeks.
3116166|NCT01780883|Experimental|4 mg melatonin|2 tablets of 2mg melatonin and 3 tablets of its placebo once a day, an hour before falling asleep, for 6 weeks.
3116167|NCT01780883|Experimental|10 mg melatonin|5 tablets of 2mg melatonin once a day, an hour before falling asleep, for 6 weeks.
3116168|NCT01780870|No Intervention|Control Group|Obese, otherwise healthy people who are not receiving any nutritional,surgical or behavioral therapy
3116169|NCT01780870|Active Comparator|Weight loss group|Full Meal replacement Protocol
3116170|NCT01780857||PPP patients|Patients with palmoplantar pustulosis who have had blood and tissue samples taken.
3116171|NCT01780857||Healthy controls|Patients without palmoplantar pustulosis or any inflammatory skin condition who have had blood and tissue samples taken.
3116172|NCT01780844|Active Comparator|Standard of Care|Basiliximab induction + Tacrolimus + MMF + Corticosteroids
3116173|NCT01780844|Experimental|CNI avoidance|Basiliximab induction + ASKP1240 + MMF + Corticosteroids
3116174|NCT01780844|Experimental|CNI minimization-MMF avoidance|Basiliximab induction + ASKP1240 + Tacrolimus + Corticosteroids
3116175|NCT01780831|Experimental|Cohort 1|Cohort 1 will enroll HIV-1-exposed full-term infants (aged 48 hours or less). Infants will receive a single dose of RAL within 48 hours of birth and a second dose of RAL on Day 7 to 10 of life.
3116176|NCT01780831|Experimental|Cohort 2|Cohort 2 will enroll HIV-1-exposed full-term infants (aged 60 hours or less). RAL-naïve infants will receive RAL daily starting within 48 hours of birth and RAL-exposed infants will receive RAL daily starting between 12 and 60 hours of birth. Both the RAL-naïve and RAL-exposed infants will receive RAL for 6 weeks.
3116177|NCT01780818|Active Comparator|Air insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
3116178|NCT01780818|Experimental|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
3116179|NCT01780818|Experimental|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
3116180|NCT01780805||Young adult alcohol drinkers|Young adults between the ages of 21-25 who regularly drink alcohol
3116181|NCT01780792|Experimental|Dance Dance Revolution game play|Dance Dance Revolution video game play
3116182|NCT01780792|No Intervention|control|individuals continue usual care for 8 weeks
3116183|NCT01780779||Osteosarcoma|"All patients with Osteosarcoma), proven by surgical biopsy and histopathology.~All included patients will be treated by chemotherapy (EURAMOS protocol)~An MRI will be performed before, during and post-treatment"
3116184|NCT01780779||Ewing Sarcoma|"All patients with proven diagnosis of Ewing sarcoma, proven by surgical biopsy and histopathology.~All included patients will be treated by chemotherapy (EURO-EWING protocol)~An MRI will be performed in all included patients before, during and after the chemotherapy"
3116185|NCT01780766||Indolent myeloma patient|
3116186|NCT01780766||Symptomatic Myeloma patient|
3116187|NCT01780753|Experimental|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
3116188|NCT01780740|Experimental|Atorvastatin|Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
3116189|NCT01780740|Placebo Comparator|Sugar pill|Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included.
3116190|NCT01780727|No Intervention|Standard Hemodynamic Management (SHEM)|use of standard hemodynamic management
3116191|NCT01780727|Experimental|EGHEM|use of echocardiography guided hemodynamic management to control fluid and drug therapy.
3116192|NCT01780714|Active Comparator|Conventional cigarettes (CC)|Smokers are continuing to smoke exclusively their usual own brand of CC, for 5 days, ad libitum, under highly controlled conditions
3116193|NCT01780714|Experimental|Tobacco Heating System 2.1 (THS 2.1)|Smokers are switching to the exclusive and ad-libitum use of THS 2.1 for 5 days, under highly controlled conditions
3116194|NCT01780701||High risk prostate cancer patients|Men who have been recently diagnosed with high risk prostate cancer (Gleason score 7 and above) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center.
3116195|NCT01780701||Low risk prostate cancer patients|Men who have been recently diagnosed with low risk prostate cancer (Gleason score 7 [3+4] and below) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center.
3116196|NCT01780688|Active Comparator|smoking conventional cigarettes (CC)|After a 1-day nicotine deprivation, subjects are smoking one single cigarette (usual own brand) on one day and then smoking ad libitum on the subsequent day
3116197|NCT01780688|Experimental|using the Tobacco Heating System 2.1 (THS 2.1)|After a 1-day nicotine deprivation, subjects are puffing one single tobacco stick using the THS 2.1 on one day and then puffing ad libitum on the subsequent day
3116198|NCT01780675|Active Comparator|Prophylactic Cranial Irradiation|Radiation. Prophylactic Cranial Irradiation: 10 times 2.5 Gy (total 25 Gy)
3116199|NCT01780675|Experimental|Hippocampal Avoidance PCI|Radiation. Hippocampal Avoidance PCI. 10 times 2.5 Gy (total 25 Gy).
3116200|NCT01780662|Experimental|Treatment (brentuximab vedotin, gemcitabine hydrochloride)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 15 more courses in the absence of disease progression or unacceptable toxicity. Patients with CR after any course may go off protocol therapy for stem cell transplant.
3116201|NCT01780649|Experimental|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI)
3116202|NCT01780649|Active Comparator|ICSI|Intracytoplasmic sperm injection (ICSI)
3116203|NCT01780636|Experimental|Botulinum toxin (Botox) injection|All patients will be given the active Botox injection and thus this study will remain open-label and non-randomized as this is a pilot study to determine initial efficacy.
3116204|NCT01780623|Experimental|Bright White Light|Bright white light exposure every morning for 30 minutes for 28 consecutive days
3116205|NCT01780623|Active Comparator|Dim Red Light|Dim red light exposure every morning for 30 minutes for 28 consecutive days
3116241|NCT01780363||Behçet patients|frequency of mevalonate kinase gene mutations
3116206|NCT01780610|Other|group OI-A|Patients with irregular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited , who should not be elder than 40 and had more than 3 frozen embryos.They will be randomized to receive the Letrozole and human chorionic gonadotrophin ovulation induced cycles.
3116207|NCT01780610|Other|group HRT-B|Patients with irregular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited, who should not be elder than 40 and had more than 3 frozen embryos will be randomized to receive the estradiol and progesterone replacement therapy cycles.
3116208|NCT01780597||Organ Donors (declared Brainstem-Dead)|This group of subjects is defined as those who have previously expressed their future wish to organ donation and who have suffered events leading to declaration of brainstem-death. Furthermore these subjects will have had their hearts declined for heart transplantation on the basis of poor function.
3116209|NCT01780584|Active Comparator|Oral T3 low dose & placebo|Oral T3 low dose administer through nasogastric tube 0.5 mcg/kg (max 10 mcg) starting on induction of anesthesia and then every 24 hours alternating with placebo, which was given 12 hours after the first dose of oral T3 and then every 24 hours until 60 hours post anesthesia induction (3 doses oral T3, 3 doses placebo)
3116210|NCT01780584|Placebo Comparator|Placebo|Placebo (saccharin lactic) administer through nasogastric tube, given starting on induction of anesthesia and then every 12 hours until 60 hours post-anesthesia induction (6 doses total)
3116211|NCT01780584|Experimental|Oral T3 high dose|Oral T3 high dose administer through nasogastric tube 0.5 mcg/kg (max 10 mcg) q12h starting on induction of anesthesia until 60 hours post-anesthesia (6 doses oral T3)
3116212|NCT01780571|No Intervention|Control group|Neutral pressure breathing after 2 min preoxygenation
3116213|NCT01780571|Active Comparator|Active group|CPAP 5cm H2O + PSV 5cm H2O breathing after 2 min preoxygenation
3116214|NCT01780558|Other|group NC-A|Patients with regular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited, who should not be elder than 40 and had more than 3 frozen embryos.They will be randomized to receive the natural cycles.
3116215|NCT01780558|Other|group HRT-B|Patients with regular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospitalwill be recruited , who should not be elder than 40 and had more than 3 frozen embryos will be randomized to receive the estradiol and progesterone replacement therapy cycles.
3116216|NCT01780545|Experimental|Experimental Arm: Arm A|Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle.
3116217|NCT01780545|Active Comparator|Control Arm: Arm B|Docetaxel (75 mg/M2) will be administered IV on day 1 of each 21 day cycle for a maximum of 10 cycles.
3116218|NCT01780532|Experimental|Photo Acoustic Imaging|An exploratory, single armed, pilot study designed to evaluate the feasibility of Photo Acoustic Imaging (PAI) in a clinical setting.
3116219|NCT01780519|Other|L/VL APOE e3/e4 carrier|long and very long poly - T variants of TOMM40 and APOE e3/e4 carrier
3116220|NCT01780519|Other|L/S APOE e3/e4 carrier|long and short poly - T variants of TOMM40 and APOE e3/e4 carrier
3116221|NCT01780519|Other|S/VL APOE e3/e3 carrier|short and Very long poly - T variants of TOMM40 and APOE e3/e3 carrier
3116222|NCT01780519|Other|VL/VL APOE e3/e3 carrier|Very long poly - T variants of TOMM40 and APOE e3/e3 carrier
3116223|NCT01780519|Other|S/S APOE e3/e3 carrier|short poly - T variants of TOMM40 and APOE e3/e3 carrier
3116224|NCT01780506|Experimental|E/C/F/TAF|E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks
3116225|NCT01780506|Active Comparator|E/C/F/TDF|E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks
3116226|NCT01780493|Other|Direct Nipple Ureteroneocystostomy|
3116227|NCT01780480|Experimental|Dynamic Chinese herbal granule formula|Based on standard medical care, after evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a combination therapy of a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules, including 3 gram of Huangqi(Astragalus root), 2 gram of Renshen(ginseng), 2.5 gram of Danggui(Angelica sinensis), 2 gram of Danshen(Salvia miltiorrhiza), 2 gram of Dilong(Geosaurus), 3 gram of Chishao(Radix Paeoniae Rubra), 2 gram of Honghua(Safflower), 2 gram of Chuanxiong(Rhizoma Chuanxiong), 2 gram of Sanqi(Radix Notoginseng), 3 gram of Shudihuang(Radix Rehmanniae Preparata). The Chinese herbal granule formula could be weekly changed according to differentiation of Zhenghou.
3116228|NCT01780480|Placebo Comparator|Placebo|The process is the same as the experimental arm, except that the matched placebo granules should be in turn of Chinese herbal granules.
3116229|NCT01780467|Experimental|patients with and without treatment by L dopa)|to study the role of dopamine in the loss aversion phenomenon by comparing brain activity in parkinsonian patient with and without treatment with L Dopa, when they are exposed to mixed (gain/loss) gambles using money.
3116230|NCT01780467|Other|healthy paired control|to highlight the role of a dopamine depletion by comparing patient without treatment vs healthy paired control.
3116231|NCT01780454|Experimental|Combined Bone Marrow and Kidney Transplantation|Conditioning regimen consisting of Rituximab, MEDI-507, Total Body Irradiation, Thymic Irradiation followed by simultaneous bone marrow and kidney transplantation
3116232|NCT01780441||Tuberous Sclerosis Complex (TSC)|Tuberous Sclerosis Complex
3116233|NCT01780428|Experimental|CL-108|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg)
3116234|NCT01780428|Active Comparator|Norco|Commercial product containing hydrocodone 7.5 mg. acetaminophen 325 mg
3116235|NCT01780428|Placebo Comparator|Placebo|CL-108 formulation without API
3116236|NCT01780415||Bastovit|all the patients that have supernumerary embryos to vitrify at blastocyst stage
3116237|NCT01780402|Experimental|Hand feeding intervention delivery|Trained Research Feeding Assistants (TRFA), blind to the study outcomes, will assist enrolled PWDs with all three meals for two days using a pre-specified hand feeding technique. Videotaping will occur for two enrolled PWD during the six day time frame to promote efficiency. Coding of the video will be done by a trained Data Technician after meals have been recorded to determine frequency of aversive feeding behaviors, calculate meal intake, and time spent assisting with the meal.
3116238|NCT01780389|Experimental|Milnacipran|Open-label flexibly dosed milnacipran
3116239|NCT01780376|Experimental|WBV group|whole-body vibration (WBV) group
3116242|NCT01780350|Experimental|ResQGARD ITD|Subjects receive a ResQGARD ITD.
3116243|NCT01780337|Active Comparator|Oxytocin|Patients will be administered an intranasal dose of the study drug, 20 IU oxytocin. Repeat electrophysiologic measurements will be assessed at 15 minutes and 30 minutes after administration of the study medication/placebo. During the waiting periods in between the electrophysiologic measurements, we will continue with the standard protocol for an AF ablation, including transseptal puncture and left atrial mapping, performed prior to initiation of general anesthesia and actual delivery of ablation lesions. This 'preablation' period normally takes 45 minutes to one hour.
3116244|NCT01780337|Placebo Comparator|Saline|Patients will be administered an intranasal dose of saline. Repeat electrophysiologic measurements will be assessed at 15 minutes and 30 minutes after administration of the study medication/placebo. During the waiting periods in between the electrophysiologic measurements, we will continue with the standard protocol for an AF ablation, including transseptal puncture and left atrial mapping, performed prior to initiation of general anesthesia and actual delivery of ablation lesions. This 'preablation' period normally takes 45 minutes to one hour.
3116245|NCT01780324|No Intervention|No lidocaine|This group will have urinary catheterization without lidocaine (per standard procedure)
3116246|NCT01780324|Experimental|Lidocaine|The Intervention is the application of intraurethral lidocaine 5 minutes prior to urethral catheterization.
3116247|NCT01780311|Active Comparator|Antiarrhythmic drugs|Flecainide or Propafenone or Sotalol (oral, standard dosage)
3116248|NCT01780311|Experimental|ABLATION|Catheter Ablation
3116249|NCT01780298||Group 1: COPD GOLD Stage 1-2|Sixty subjects with a clinical diagnosis of COPD, according to the GOLD guidelines (Stages 1-2), who are current smokers with at least a 10 pack-year smoking history.
3116250|NCT01780298||Group 2: Current Cigarette Smokers|Sixty subjects who are current smokers with at least a 10 pack-year smoking history and matched to the COPD cases by ethnicity, gender and age (within 5 years).
3116251|NCT01780298||Group 3: Ex-Smokers|Sixty subjects who are ex-smokers with at least a 10 pack-year smoking history who have not smoked for at least one year and matched to the COPD cases by ethnicity, gender and age (within 5 years).
3116252|NCT01780298||Group 4: Never Smokers|Sixty subjects who have never smoked (non-smokers) and matched to the COPD cases by ethnicity, gender and age (within 5 years).
3116253|NCT01780285|Active Comparator|Nitinol-framed PTFE mesh hiatal repair|Nitinol-framed lightweight PTFE mesh for hiatal repair
3116254|NCT01780285|Active Comparator|Lightweight mesh hiatal repair|Partially absorbable lightweight mesh for hiatal repair
3116255|NCT01780272|Other|Normoglycaemia followed by hypoglycaemia|
3116256|NCT01780272|Other|Hypoglycaemia followed by normoglycaemia|
3116257|NCT01780259|Experimental|Cohort 1: Treatment A|Participants will receive 1 spray of esketamine solution in each nostril once (total dose: 28 mg).
3116258|NCT01780259|Experimental|Cohort 1: Treatment B|Participants will receive 1 spray of esketamine solution in each nostril twice, with 5 minutes interval (total dose: 56 mg).
3116259|NCT01780259|Experimental|Cohort 1: Treatment C|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 5 minutes interval between each repeated sprays (total dose 84 mg).
3116260|NCT01780259|Experimental|Cohort 1: Treatment D|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 10 minutes interval between each repeated sprays (total dose 84 mg).
3116261|NCT01780259|Experimental|Cohort 2: Treatment D|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 10 minutes interval between each repeated sprays (total dose 84 mg).
3116262|NCT01780259|Experimental|Cohort 3: Treatment E|Participants will receive 1 spray of esketamine solution in each nostril, 4 times with 10 minutes interval between each repeated sprays (total dose: 112 mg). Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution.
3116263|NCT01780259|Experimental|Cohort 3: Treatment F|Participants will receive 1 spray of placebo solution in each nostril, 4 times with 10 minutes interval between each repeated sprays (total dose: 112 mg). Single 0.25-mg oral dose of triazolam will be administered 5 minutes before the first intranasal spray of placebo solution.
3116264|NCT01780246|Experimental|nusinersen|
3116265|NCT01780233|Experimental|Fentanyl 400 µg sublingual spray + naltrexone 50 mg|Patients received a single administration of 400 µg of fentanyl spray sublingually + naltrexone hydrochloride 50 mg orally.
3116266|NCT01780233|Active Comparator|Actiq® 400 µg transmucosally + naltrexone 50 mg|Patients received a single administration of 400 µg of Actiq® transmucosally + naltrexone hydrochloride 50 mg orally.
3116267|NCT01780233|Active Comparator|Fentanyl citrate injection 100 µg iv + naltrexone 50 mg|Patients received a single administration of 100 µg of fentanyl citrate intravenously + naltrexone hydrochloride 50 mg orally.
3116268|NCT01780220|Experimental|abiraterone|Abiraterone acetate (three dose levels in phase I) + prednisone (10mg/day)+LHRH + Radiotherapy
3116269|NCT01780207|No Intervention|OSA without PFO|
3116270|NCT01780207|Other|OSA with PFO|PFO closure
3116271|NCT01780194||Lumbar fusion group|
3116272|NCT01780194||Conservative treatment group|
3116273|NCT01780181||TCM plus chemotherapy|TCM:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang, four packages,twice a day, three months; Chemotherapy : Intravenous drug use, treated with single-agent chemotherapy :DOC、NVB、GEM.Each cycle was 21-days. Cycles were repeated until disease progression, unacceptable toxicity, or chemotherapy taboo;
3116274|NCT01780181||Placebo plus chemotherapy|TCM Placebo: oral granules,YangYinFang orYiQiFang or YiQiYangYinFang, 10% of the original dose,four packages,twice a day ,three months; Chemotherapy : Intravenous drug use, treated with single-agent chemotherapy :DOC、NVB、GEM.Each cycle was 21-days. Cycles were repeated until disease progression, unacceptable toxicity, or chemotherapy taboo;
3116275|NCT01780168||Inborn errors of metabolism/mitochondrial disease|Patients with inborn errors of metabolism including those with mitochondrial disease
3116276|NCT01780129|Experimental|Polydatin Injectable (HW6)|10ml(2 ampoules) diluted in 500ml of 0.9% NaCl solution for i.v. infusion over 2 hours; once daily for 5 consecutive days
3116277|NCT01780129|Placebo Comparator|HW6 blank dummy (0.9%NaCl)|10ml (2 ampoules) diluted in 500ml of 0.9% NaCl solution for i.v. infusion over 2 hours; once daily for 5 consecutive days
3116374|NCT01779388|Experimental|Bronchoscopy guided by electromagnetic navigation|Bronchoscopy guided by ENG followed by fluoroscopy
3116278|NCT01780116|Experimental|Medicaiton adherence therapy|"Adherence therapy, consisting of six, 2-hour sessions over 3 months, in three phases:~Engaging patients: assessing needs and concerns in medication adherence;~Reviewing strengths and barriers and developing coping strategies; and~Rationalizing beliefs and concerns and preventing relapse."
3116279|NCT01780116|No Intervention|Routine community care|Routine Community psychiatric nursing services provided by the Community Psychiatric Nurses in the practice field
3116280|NCT01780090|Experimental|iPad software|Student participants will use specialized, iPad software under the direction of the SLP, 1 time a week over the course of 2 months.
3116281|NCT01780077|Experimental|RXI-109|
3116282|NCT01780077|Placebo Comparator|Placebo|
3116283|NCT01780064|Placebo Comparator|Standard group|routine monitoring with questionnaires
3116284|NCT01780064|Active Comparator|Interviews with psychologist|Patients have interviews with a psychologist (at cure one of chemotherapy treatment,at cure six of chemotherapy treatment, at last radiotherapy session, and three months after the end of radiotherapy) and questionnaires
3116285|NCT01780051|Experimental|Sequence A|
3116286|NCT01780051|Experimental|Sequence B|
3116287|NCT01780038|Experimental|Receipt of Genetic Results|Receipt of Genetic Results indicates that participants have received the results of genotyping for RS1051730
3116288|NCT01780038|Active Comparator|No results given|Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
3116289|NCT01780025||Mixed hearing loss|
3116290|NCT01780012|Experimental|Intervention|Osteoporosis prevention program: Women will receive oral and written information and advices on osteoporosis, a letter and a leaflet on osteoporosis management to give to their family physician, and phone call reminders.
3116291|NCT01780012|No Intervention|Control|Control women will receive usual post-fracture care without information
3116292|NCT01779999||PICC-carrying patients|All patients carrying a peripherally inserted central catheter in our service
3116293|NCT01779973|Experimental|Remote Observed Dosing|Compliance with dosage observations of suboxone doses using remote observed dosing 4 days per week and 1 weekly in-office visit.
3116294|NCT01779960||Londrina|20 patients with moderate-severe COPD from State University of Londrina, Brazi
3116295|NCT01779960||Leuven|20 patients with moderate-severe COPD from Catholic University of Leuven, Belgium
3116296|NCT01779947|Experimental|Estradiol Vaginal Insert 10 mcg|Estradiol Vaginal Insert 10 mcg - Test Product
3116297|NCT01779947|Active Comparator|Vagifem Tablets 10 mcg|Vagifem® (Estradiol Vaginal Tablets) 10 mcg - Reference Listed Drug
3116298|NCT01779947|Placebo Comparator|Placebo|Placebo for the test product Estradiol Vaginal Tablets 10 mcg
3116299|NCT01779921||FVII|
3116300|NCT01779908|Experimental|Vitamin D supplementation|5000 IU of vitamin D3 for 6 months
3116301|NCT01779908|Placebo Comparator|Placebo|Placebo pill for 6 months
3116302|NCT01779895|Active Comparator|NCC2461|probiotic blended in maltodextrin powder to be taken daily
3116303|NCT01779895|Placebo Comparator|Placebo|maltodextrin
3116304|NCT01779882|Active Comparator|BU-CY|Group A (standard group): conditioning regimen with Busulfan (BU) followed by Cyclophosphamide (CY)
3116305|NCT01779882|Experimental|CY-BU|Group B (experimental group): conditioning regimen with Cyclophosphamide (CY) followed by Busulfan (BU)
3116306|NCT01779869|Experimental|Single group assignment - imaging|All patients will undergo PET-MR myocardial perfusion imaging during rapid intravenous administration of 0.4 mg regadenoson.
3116307|NCT01779856|Other|REVEAL Insertable Cardiac Monitor (ICM)|Monitoring of cardiac arrhythmic events and the relationship between such events and the characteristics.
3116308|NCT01779843|Experimental|Treatment|"Induction: 100 mg/m2/day Cytarabine intravenous, days 1-7 of induction cycle. 12 mg/m2/day Idarubicin intravenous, days 1-3. Alisertib orally, twice a day for one week starting on day 8, dose escalation-starting dose 10 mg PO BID.~Consolidation: Cytarabine 3 g/m2 by IV infusion over 3 hours given every 12 hours on Days 1, 3 and 5 (subjects younger than age 60) or Cytarabine 2 g/m2 per day by IV infusion over 3 hours on days 1-5 (subjects at or older than age 60)"
3116309|NCT01779830|Experimental|0.3 mg LY2624803|Single dose of 0.3 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
3116310|NCT01779830|Experimental|3.0 mg LY2624803|Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
3116311|NCT01779830|Experimental|6.0 mg LY2624803|Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
3116312|NCT01779830|Active Comparator|10 mg Zolpidem|Single dose of 10 mg zolpidem administered orally in up to 1 of 4 treatment periods.
3116313|NCT01779830|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to 1 of 4 treatment periods.
3116314|NCT01779817|Other|child born to hyperthyroid mother during pregnancy|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
3116315|NCT01779817|Other|child born to euthyroid mother during pregnancy|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
3116316|NCT01779804||Patients with foot and ankle injury|After baseline data is obtained a cohort of patients with acute foot and ankle injuries will have OFAR applied
3116317|NCT01779791|Experimental|PCI-32765 (Ibrutinib)|
3116318|NCT01779765|Experimental|PHGG|2.5gr per day for the first week and then 5gr per day for 11 weeks.
3116319|NCT01779765|Placebo Comparator|Maltodextrin|2.5gr per day for the first week and then 5gr per day for 11 weeks.
3116320|NCT01779739|No Intervention|No perineorrhaphy|Subjects will not have a perineorrhaphy procedure added to the vaginal prolapse repair
3116321|NCT01779739|Active Comparator|Perineorrhaphy|Subjects will have a perineorrhaphy added to the vaginal repair of prolapse
3116322|NCT01779726|Experimental|CT scan before chest physician|CT scan before chest physician
3116323|NCT01779726|Active Comparator|Usual diagnostic workup|Usual diagnostic workup
3116375|NCT01779375|Active Comparator|Metformin alone|Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).
3116489|NCT01778465|Experimental|Low salicylate diet|Patients are to follow a low salicylate diet for one week.
3116324|NCT01779713||Vasospastic patients|Any patient send to the neuro-anesthesia intensive care unit in the 48 hours following an aneurismal sub-arachnoid hemorrhage and treated in the 96 first hours (embolization or surgery) and developing a vasospasm during the first 12 days after the bleeding; aged more than 18; of Caucasian origin; affiliated to a social care service; having (or one of is related if he is comatose) given its informed consent
3116325|NCT01779713||Control patients|Any patient send to the neuro-anesthesia intensive care unit in the 48 hours following an aneurismal sub-arachnoid hemorrhage and treated in the 96 first hours (embolization or surgery) not developing a vasospasm during the first 12 days after the bleeding; aged more than 18; of Caucasian origin; affiliated to a social care service; having (or one of is related if he is comatose) given its informed consent
3116326|NCT01779700|Active Comparator|Fingolimod|0.5mg of fingolimod, oral administration, daily, for 8 weeks.
3116327|NCT01779700|Placebo Comparator|placebo|placebo, oral administration, daily, for 8 weeks.
3116328|NCT01779687|Active Comparator|raltegravir alone|Raltegravir 400 mg BID for 7 days
3116329|NCT01779687|Active Comparator|Atorvastatin alone|Atorvastatin 20 mg QD for 7 days
3116330|NCT01779687|Experimental|Raltegravir + atorvastatin|Raltegravir 400 mg BID + Atorvastatin 20 mg QD for 7 days
3116331|NCT01779661|Active Comparator|Infant Aquatics|
3116332|NCT01779661|Active Comparator|Infant Massage|Infant Massage
3116333|NCT01779648|Active Comparator|Simultaneous compression+Fixed refill time|Simultaneous bilateral compression with fixed venous refill time through the whole duration of pneumatic compression
3116334|NCT01779648|Active Comparator|Alternate compression+Adjusted refill time|alternate bilateral compression with adjusted venous refill time which would change several times during pneumatic compression
3116335|NCT01779635|Active Comparator|oXiris as first filter|Start off the first CRRT circuit with oXiris, then cross-over to M150, then oXiris, then back to M150
3116336|NCT01779635|Other|M150 as first filter|Patients in M150 arm will start off with M150 as first filter for CRRT, then cross-over to oXiris after the former clots, then back to M150, then to oXiris.
3116337|NCT01779622|Experimental|1|Healthy volunteers are ingesting a mixed meal either rapidly or slowly
3116338|NCT01779609|Experimental|Bosentan + Exercise|2x/day 62.5 mg Bosentan for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Bosentan for 4 weeks alongside 3x/week supervised exercise
3116339|NCT01779609|Placebo Comparator|Placebo + Exercise|2x/day 62.5 mg Placebo for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Placebo for 4 weeks alongside 3x/week supervised exercise
3116340|NCT01779609|Other|Exercise|3x/week supervised exercise for 8 weeks
3116341|NCT01779596|Experimental|Bosentan|Single dose of Bosentan (125 mg)
3116342|NCT01779596|Placebo Comparator|Placebo|Single dose of placebo (125 mg)
3116343|NCT01779583||Advanced gastric cancer patients|Treatment näive advanced gastric cancer patients candidates to first-line chemotherapy
3116344|NCT01779583||Control group|Healthy adult volunteers without a cancer diagnosis
3116345|NCT01779570|Experimental|Macrolide treatment|Azithromycin 500 mg daily for 5 days
3116346|NCT01779570|No Intervention|No macrolide treatment|No azithromycin
3116347|NCT01779557|Experimental|Huaren peritoneal dialysate|Huaren Peritoneal dialysate CAPD 3-5 times/d
3116348|NCT01779557|Active Comparator|Baxter Peritoneal Dialysate|Baxter Peritoneal dialysate CAPD 3-5 times/d
3116349|NCT01779544|Active Comparator|Brief intervention only|Brief intervention, an educational model, consists of information
3116350|NCT01779544|Active Comparator|Exercise group|Brief educational intervention combined with exercise therapy
3116351|NCT01779531||pCR，XT|
3116352|NCT01779505|Experimental|GS-4774 at 10 yeast units (YU)|10 YU of GS-4774 given either weekly or monthly
3116353|NCT01779505|Experimental|GS-4774 at 40 YU|40 YU of GS-4774 given either weekly or monthly
3116354|NCT01779505|Experimental|GS-4774 at 80YU|80 YU of GS-4774 given either weekly or monthly
3116355|NCT01779492|Experimental|GL2907|Oxycodone HCl 20mg
3116356|NCT01779492|Active Comparator|Oxycontine CR 10mg|Oxycodone HCl 10mg
3116357|NCT01779479|Experimental|Cabacitaxel|
3116358|NCT01779479|Active Comparator|Paclitaxel|
3116359|NCT01779466|Experimental|Experimental A|
3116360|NCT01779466|Experimental|Experimental B|
3116361|NCT01779466|Placebo Comparator|Placebo|
3116362|NCT01779453|Experimental|ETC-1002|ETC-1002 treatment group, oral once daily
3116363|NCT01779453|Placebo Comparator|Placebo|Placebo treatment group, oral once daily
3116364|NCT01779440|Other|Electronic Decision Support System|The Electronic Decision Support System is a web-based computer program designed to motivate, educate, and engage people with severe mental illness into evidence-based smoking cessation treatment.
3116365|NCT01779440|Placebo Comparator|Control Computer Program|A computer program aimed to educate people about smoking cessation treatment.
3116366|NCT01779427|Experimental|AIM Intervention|
3116367|NCT01779427|Experimental|Wait List Control|Participants are in the Wait List Control group for 10 weeks and then they will participate in the AIM Intervention
3116368|NCT01779414|No Intervention|Enhanced Usual Care|Participants in this arm of the study will receive a standard, usual care psychological risk assessment by a social worker and then recommended to a mental health referral.
3116369|NCT01779414|Experimental|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
3116370|NCT01779401|Active Comparator|Clopidogrel + Aspirit|A Standard antiplatelet therapy control group： Clopidogrel 75mg Qd + Aspirin 100mg Qd
3116371|NCT01779401|Active Comparator|Clopidogrel + Aspirin|B Double-dosage Clopidogrel group： Clopidogrel 150mg Qd + Aspirin 100mg Qd
3116372|NCT01779401|Active Comparator|Clopidogrel + Aspirin + Cilostazol|C triple antiplatelet therapy group： Cilostazol 100mg Bid + Aspirin 100mg Qd + Clopidogrel 75mg Qd
3116373|NCT01779388|Other|Bronchoscopy guided by fluoroscopy|Bronchoscopy guided by fluoroscopy followed by ENG
3116376|NCT01779375|Active Comparator|Glargine followed by Metformin|Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 85-95 mg/dl, followed by metformin (titrated up to 2000 mg/day) for 9 months.
3116377|NCT01779362|Active Comparator|Metformin alone|Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day). Participants randomized to the metformin-alone arm will be blinded to treatment.
3116378|NCT01779362|Active Comparator|Glargine followed by Metformin|Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 80-90 mg/dl, followed by open-label metformin (titrated up to 2000 mg/day) for 9 months.
3116379|NCT01779362|Placebo Comparator|Placebo|Placebo - masked to metformin-alone. Placebo will be titrated to the maximum number of tablets equivalent to maximum dose of metformin.
3116380|NCT01779362|Active Comparator|Liraglutide + Metformin|Liraglutide + open-label Metformin. Liraglutide will be titrated to the maximum dose tolerated (up to 1.8 mg/day) after which metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).
3116381|NCT01779349|Experimental|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
3116382|NCT01779336|Experimental|PL225B|Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design.
3116383|NCT01779323||Pre and Post Sling Pelvic MRI|Cohort: Measure change in hypermobility of urethra after transobturator sling surgery via pelvic MRI.
3116384|NCT01779310||Alzheimer's disease|Outpatients with clinically significant cognitive impairment per judgment of the participating physicians are enrolled.
3116385|NCT01779284|Active Comparator|Travoprost/Timolol therapy|Enrolled patients will be treated for 3 months with travoprost/timolol drops administered once in the evening. Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
3116386|NCT01779284|Active Comparator|Latanoprost/Timolol therapy|Enrolled patients will be treated for 3 months with travoprost/timolol drops administered once in the evening. 24-hour pressure monitoring will be carried out for this drug after 3 months of chronic dosing. All patients will be crossed over to therapy for 3 months with latanoprost/timolol fixed combination drops administered once in the evening. Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
3116387|NCT01779271|Experimental|Pelubiprofen|
3116388|NCT01779271|Active Comparator|Loxoprofen|
3116389|NCT01779258|Other|Group 2|Active control arm, Locatop@, Locapred@
3116390|NCT01779258|Other|Group 3|Absence of emollient treatment, Locatop@, Locapred@
3116391|NCT01779258|Experimental|Group 1|"glycerol, paraffin (liquid and white soft), Locatop@~, Locapred@"
3116392|NCT01779245|Placebo Comparator|Control|A chocolate milkshake with a normal calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 400 mg calcium per serving).
3116393|NCT01779245|Experimental|High-Calcium|A chocolate milkshake with a high calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 1400 mg calcium per serving).
3116394|NCT01779232|Placebo Comparator|control|patients treated with placebo for at least 4 months before IVF attempt
3116395|NCT01779232|Active Comparator|danazol|patients treated with danazol (100mg/day)for at least 4 months before IVF attempt
3116396|NCT01779219|Active Comparator|iMRI-guided|Intervention: iMRI-guided brain tumour biopsy. The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet imager will be used in all cases. After the patient's positioning, the preoperative reference examination is routinely carried out. The entry point, target and optimal biopsy trajectory are then defined by the operator on the basis of the obtained iMRI images. Serial tissue samples are collected. Following each operation, a control iMRI (T1-weighted, axial, 4 mm scan examination) is routinely performed to confirm and document the proper targeting and to exclude postoperative hyperacute intraparenchymal bleeding.
3116397|NCT01779219|Active Comparator|non-iMRI|Intervention: Stereotactic frameless brain tumour biopsy. A frameless STx biopsy is performed for each patient from the control group with the use of a neuronavigation system. The entry point, target and optimal biopsy trajectory are defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
3116398|NCT01779206|Active Comparator|Anthracycline - Taxane|Study sites can choose between either Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q3w OR Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q2w for anthracycline treatment and between either 4 x Docetaxel (100mg/m²) q3w OR 12 x Paclitaxel (80mg/m²) q1w for taxane treatment.
3116399|NCT01779206|Experimental|Taxane - Anthracycline|Study sites can choose between either Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q3w OR Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q2w for anthracycline treatment and between either 4 x Docetaxel (100mg/m²) q3w OR 12 x Paclitaxel (80mg/m²) q1w for taxane treatment.
3116400|NCT01779193|Experimental|latic acid bacteria and cranberry|oral latic acid bacteria and cranberry capsule (dose of 2 * 10^9 cfu per capsule), one pill daily
3116401|NCT01779193|Active Comparator|cranberry|oral cranberry capsule without lactic acid bacteria, one pill daily
3116402|NCT01779193|Placebo Comparator|placebo|placebo without lactic acid bacteria and cranberry, one pill daily
3116403|NCT01779167|Experimental|All Patients|Daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in patients with previously treated WM
3116404|NCT01779154||eosinophilic gastrointestinal disorders|Individuals with a diagnosis of EGID including: eosinophilic esophagitis, eosinophilic gastritis, eosinophilic enteritis, eosinophilic colitis
3116405|NCT01779141||CSII, including SAP|The devices to be used in the study are the Paradigm REAL-Time (722) insulin pump, including the sensor augmented Paradigm® Veo (754) system (insulin pump + Enlite sensor + MiniLink transmitter);
3116406|NCT01779128|Experimental|Experimental Arm|PET/CT Scan MR-PET Scan
3116407|NCT01779102|Experimental|0.1 µg C-Tb|The C-Tb agent is given alone to volunteers in the RIGHT or LEFT forearm according to a double blind randomisation scheme
3116408|NCT01779102|Active Comparator|2 T.U Tuberculin PPD RT 23 SSI|The 2 T.U Tuberculin PPD RT 23 SSI agent is given alone to volunteers in the RIGHT or LEFT forearm according to a double blind randomisation scheme
3116409|NCT01779102|Experimental|0.1 µg C-Tb / 2 T.U Tuberculin PPD|The C-Tb and 2 T.U Tuberculin PPD RT 23 SSI agents are given concomitantly to volunteers in the RIGHT and LEFT forearms according to a double blind randomisation scheme
3116410|NCT01779089|Experimental|Minocycline|Minocycline 100 mg po bid for 6 months
3116411|NCT01779089|Placebo Comparator|Placebo|Placebo one tablet po bid
3116412|NCT01779076|Experimental|100% oxygen during extubation|In this arm the intervention will consist of 100 % oxygen.
3116413|NCT01779076|Experimental|30% oxygen during extubation|In this arm the intervention will consist of 30 % oxygen.
3116414|NCT01779063|Experimental|web based multimedia intervention|interactive,web based multimedia intervention
3116415|NCT01779063|Active Comparator|education booklet|printed educational booklet
3116416|NCT01779050|Active Comparator|Arm I (definitive therapy)|"Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:~doxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~docetaxel plus cyclophosphamide~single-agent paclitaxel~docetaxel plus carboplatin~fluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel"
3116417|NCT01779050|Experimental|Arm II (definitive therapy, trastuzumab)|"Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:~doxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~docetaxel plus cyclophosphamide~single-agent paclitaxel~docetaxel plus carboplatin~fluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~Patients will also receive trastuzumab IV over 30-90 minutes for 52 weeks starting such that there is a minimum of 8 weeks of overlap with the standard of care chemotherapy. Trastuzumab may be given weekly, every 2 weeks, or every 3 weeks while overlapping with standard of care chemotherapy. Trastuzumab will be given every 3 weeks after all standard of care chemotherapy has concluded. Treatment continues in the absence of disease progression or unacceptable toxicity."
3116418|NCT01779037||Inpatient Rehabilitation Patients|
3116419|NCT01779024|Experimental|ASA/Ghrelin|Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the first ASA visit; Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the second ASA visit.
3116420|NCT01779024|Placebo Comparator|ASA/Placebo|Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the first ASA visit; Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the second ASA visit
3116421|NCT01779024|Experimental|fMRI/Ghrelin|Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the first fMRI visit; Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the second fMRI visit.
3116422|NCT01779024|Placebo Comparator|fMRI/Placebo|Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the first fMRI visit; Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the second fMRI visit
3116423|NCT01779011||A cohort post amputation|Those patients undergoing either traumatic amputation or surgical amputation of limb
3116424|NCT01779011||A cohort post limb conserving surgery|Patients whose surgical management involved conservation of their injured limb
3116425|NCT01778998|Active Comparator|MICS-group|
3116426|NCT01778998|Active Comparator|SICS-group|
3116427|NCT01778998|Active Comparator|SICS pre-cut|
3116428|NCT01778998|Active Comparator|SICS stab-incision|
3116429|NCT01778985|Experimental|Premarin|Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
3116430|NCT01778985|Placebo Comparator|Placebo|Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
3116431|NCT01778972|Experimental|Otago home training programme|"Otago home exercise programme was designed specifically to prevent fall. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.~The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist."
3116432|NCT01778972|Experimental|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
3116433|NCT01778972|No Intervention|Control grop|Participants are instructed to live their ordinary lives.
3116434|NCT01778959|Active Comparator|standard OVD|
3116435|NCT01778959|Active Comparator|Iris hooks|
3116436|NCT01778959|Active Comparator|Malyugin Ring|
3116437|NCT01778959|Active Comparator|OVD|
3116438|NCT01778946|Experimental|Nicotine|"Low Dose Nicotine (7mg) Moderate Dose Nicotine (14mg)~All participants in study will begin with the 7mg patch, titrating from 2 hours/day to a full 16 hours/day over the course of the first 7 days (based on individual tolerance).~Day 7 - Day 28 of the study, participants will apply a new nicotine patch daily. Depending on tolerance, some participants may increase to the moderate dose (14mg) patch.~All participants will apply a new patch daily for a total of 28 days (1 month)"
3116439|NCT01778933|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
3116440|NCT01778920|Experimental|IV Injection of EC17|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
3116441|NCT01778907|No Intervention|Normal genotype- control (NG-C)|In the external control group, an advice for dose adaptation based on patients serum drug levels will be given to the physician according to current daily practice. Allocation to this arm is not based on randomization.
3116442|NCT01778907|No Intervention|Deviating genotype -control (DG-C)|In the internal control group, an advice for dose adaptation based on patients serum drug levels will be given to the physician according to current daily practice
3116443|NCT01778907|Experimental|Deviating genotype (DG-I)|In the intervention group, genotype information accompanied by a drug dosing advice will be given to the treating physician. Blood level of the drug will be communicated by a dedicated research team to the treating physician according to daily practice.
3116444|NCT01778894||Healthy Control|Healthy controls with no history of heart disease or heart failure. Subjects will undergo a medical history review and 1 echocardiograph procedure.
3116445|NCT01778894||>Grade 2 Diastolic Dysfunction|Diastolic Heart Failure, > Grade II (NYHA functional class) and/or > Grade II Diastolic Dysfunction as evaluated by echocardiography
3116446|NCT01778881|Experimental|Massage + Exercise|Massage and stretching exercises
3116447|NCT01778881|Experimental|Relaxation +Imagination|Relaxation and Imagination therapies
3116448|NCT01778881|Experimental|Dental treatment|Reconstruction with composite resin
3116449|NCT01778881|Experimental|Massage + Exercise + Relaxation + Imagination|Massage, stretching exercises, relaxation and imagination
3116450|NCT01778868||Overweight and obese individuals|
3116451|NCT01778868||Normal weight individuals|
3116452|NCT01778855|Active Comparator|Normothermia|IV t-PA and normothermia
3116453|NCT01778855|Active Comparator|Hypothermia|IV t-PA and hypothermia
3116454|NCT01778842|Experimental|Prasugrel low dose|Patient will be randomized to this intervention will receive prasugrel 5 mg and after 15 days and 30 days we will control the responsivness of the study drug.
3116455|NCT01778842|Experimental|Clopidogrel standard dose|Patient will be randomized to this intervention will receive clopidogrel 75 mg and after 15 days and 30 days we will control the responsivness of the study drug.
3116456|NCT01778829|Active Comparator|CPAP ventilation mode|Once the patient is extubated, CPAP ventilation mode is inmediately administered in order to prevent reintubation
3116457|NCT01778829|Experimental|NIPPV ventilation mode|NIPPV: Non Invasive Ventilation mode is administered inmediately after extubation to prevent reintubation
3116458|NCT01778803|Experimental|defactinib (VS-6063) plus paclitaxel|Oral defactinib (VS-6063) administered twice daily, in combination with intravenous paclitaxel administered on Days 1, 8, and 15 of a 28 day cycle.
3116459|NCT01778790|Sham Comparator|Sham Stimulation for 8 weeks|Implantation of internal pulse generator (IPG), Sham Stimulation
3116460|NCT01778790|Active Comparator|Stimulation for 8 weeks|Implantation of IPG and active stimulation
3116461|NCT01778777|Experimental|UniverseReverse|Cohort get an universe reverse prosthesis
3116462|NCT01778764||retrospective cohort|retrospective follow-up of patients treated since 2006
3116463|NCT01778764||prospective cohort|patients treated over a 5-year period from January 15, 2013 to December 31, 2017 and followed for at least one year thereafter
3116464|NCT01778751|No Intervention|Control|Veterans will receive diabetes educational materials and management per their primary provider
3116465|NCT01778751|Experimental|Intervention|Veterans randomized to the intervention arm will be enrolled in the HT program, provided with standard telemonitoring equipment by HT nursing staff (current HT practice at DVAMC is use of the Health Buddy 3 device for patients with landline phones and the Cardiocom Interactive Voice Response System for patients with cell phones), and will receive the study intervention for 6 months. Veterans without depressive symptoms on baseline PHQ-9 assessment (PHQ-9 < 10) will not initially be entered into the depressive symptom management component of the intervention, but will be monitored for new symptoms throughout the intervention.
3116466|NCT01778738|Experimental|Sleeve gastrectomy|Sleeve gastrectomy.
3116467|NCT01778738|Experimental|Gastric bypass|Gastric bypass surgery.
3116468|NCT01778738|No Intervention|Control group|This is an extra control group without diabetes. All subjects are morbidly obese patients recruited from the Morbid Obesity Centre.
3116469|NCT01778712|Experimental|Intervention|Multi-level intervention
3116470|NCT01778699|Experimental|Lozenges with Lactobacillus brevis CD2|During the treatment phases subjects will use 2 lozenges a day.
3116471|NCT01778699|Placebo Comparator|Lozenges|During the treatment phases subjects will use 2 lozenges a day.
3116472|NCT01778686|Experimental|Citalopram and Pindolol|"Citalopram intravenous infusion starting 30 min before scanning, 40 mg/h for 1 hour.~Pindolol peroral administration starting 3 days before scanning:~Day 1: 2.5 mg 3 times daily, day 2: 5 mg 3 times daily, day 3: 7.5 mg 3 times daily, Day 4 (scan day) 7.5 mg morning and noon."
3116473|NCT01778686|Placebo Comparator|Placebo|"Placebo for pindolol: sugar tablets that resembles pindolol~Placebo for ATD: amino acid drink balanced formula (containing tryptophan)~Placebo for Seropram: NaCl infusion"
3116474|NCT01778686|Experimental|Acute tryptophan depletion|Amino acid drink without tryptophan. Ingested 4-5 hours prior to PET scanning.
3116475|NCT01778673||Distal radius fractures Sundsvall Hospital|
3116476|NCT01778673||Distal radius fractures Östersund Hospital.|
3116477|NCT01778660|Active Comparator|Standard Counselling|Patients in this arm are randomised to standard counselling.
3116478|NCT01778660|Experimental|Mnemonic Counselling|Patients in this arm are randomised to counselling with the aid of a mnemonic.
3116479|NCT01778647|Experimental|Stimulants plus Lovaza|Usual dose of stimulant plus Lovaza (prescription Omega-3 fatty acids) at a dose of 1800 mg daily.
3116480|NCT01778647|Placebo Comparator|Stimulants plus placebo|Usual dose of stimulants plus placebo(corn oil), which will be given to the patients by MMC's pharmacy.
3116481|NCT01778634|Placebo Comparator|Placebo (5% dextrose)|Placebo
3116482|NCT01778634|Experimental|Azithromycin|Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
3116483|NCT01778621|Experimental|Acupuncture (Hwato®)|30-40 minutes acupuncture at certain acupoints that chosen according to traditional Chinese medicine and included LIV3,SP6,SP8,ST36,SP10,ST29,LI14,Ren 04;starting at follicular phase of the cycle till 2 days before oocyte picked up.
3116484|NCT01778621|No Intervention|No acupuncture|No intervention was done for this group of patients.
3116485|NCT01778569||Patients|Patients diagnosed with psoriasis
3116486|NCT01778556|Experimental|Leptin naive|Studied for 5 days without metreleptin, then 14 days while taking metreleptin
3116487|NCT01778556|Experimental|On-leptin|Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal
3116488|NCT01778530|Experimental|TRC105 for Recurrent Glioblastoma|
3116562|NCT01778023|Active Comparator|hGH: 6 month un-treatment + 6 month treatment|
3116490|NCT01778465|No Intervention|Normal diet|Patients are to continue with a normal diet for one week. There is then cross-over after one week for a further week into the intervention group.
3116491|NCT01778452|Active Comparator|Natural cycle|Natural cycle endometrial biopsy, lh+7
3116492|NCT01778452|Experimental|Antagonist cycle + endometrial priming.|Antagonist cycle + endometrial priming for egg donation program. endometrial biopsy, p4+5
3116493|NCT01778452|Experimental|Agonist cycle + endometrial priming.|Agonist cycle + endometrial priming for egg donation program endometrial biopsy, p4+5
3116494|NCT01778439|Experimental|OMP-52M51|
3116495|NCT01778426||Patients with Medtronic neurostimulator|Patients suffering from chronic neuropathic pain syndrome implanted (first implant or replacements) with a Medtronic neurostimulator.
3116496|NCT01778413|Experimental|ATRIPLA three times a week.|Atripla (600 mg/200 mg/245 mg) three times a week.
3116497|NCT01778413|Active Comparator|ATRIPLA one time a day.|Atripla (600 mg/200 mg/245 mg) one time a day.
3116498|NCT01778400|Experimental|Radiofrequency ablation|Treatment with radiofrequency ablation for the thyroid lesions and compare the results with ethanol ablation in terms of volume reduction at 6-month follow-up (primary end point).
3116499|NCT01778400|Active Comparator|Ethanol|Treatment of predominantly cystic nodule with ethanol ablation and compare these results to radiofrequency ablation in terms of volume reduction at 6-month follow-up.
3116500|NCT01778387|Active Comparator|Laparoscopic ventral hernia repair|Laparoscopic repair: Pneumoperitoneum was performed to 12 mmHg. Herniary contents and sac are reduced releasing adhesions with diathermy or harmonic scalpel. Defects are repaired with a polytetrafluoroethylene (PTFE) patch (Dual Mesh; W.L Gore and Associates, FlagstaV, AZ USA) with double crown fixation as technique of Carbajo et al, ensuring exceed 3 cm edge of defect, using 5mm tackers (Protack, Autosuture; Tyco Healthcare, USA), reducing intrabdominal pressure to 8 mmHg. All operations were performed by experienced surgeons, over than 40 laparoscopic ventral hernia repairs.
3116501|NCT01778387|Placebo Comparator|Open ventral hernia repair|Open repair: Incision was made over hernia defect, reducing herniary contents by opening sac if it is necessary. We made 4 cm soft tissue flaps around edge of defect depending on available healthy fascial tissue. Chevrel technique with fascial closure using anterior rectus sheath with continuous and absorbable suture and placement of polypropylene mesh (Parietene standart polypropylene mesh, Covidien, Norwalk, CT) in an onlay position fixed with polypropylene suture.
3116502|NCT01778374|Experimental|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
3116503|NCT01778374|Experimental|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
3116504|NCT01778361||HIV positive|
3116505|NCT01778361||HIV negative|
3116506|NCT01778348|Experimental|Overnight closed-loop combined with CGM|Glucose level is controlled by the automated closed loop glucose control system. After initial training with the closed-loop system devices, subjects will use the closed-loop system overnight at home for a total duration of 12 weeks.
3116507|NCT01778348|Active Comparator|Real-time CGM alone|The subjects will use the study CGM alone at home for the period of 12 weeks. Glucose level will be controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
3116508|NCT01778335|No Intervention|Control|Control arm subjects will receive best medical care.
3116509|NCT01778335|Experimental|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
3116510|NCT01778322||Index Embolization Cohort|WEB Aneurysm Embolization System
3116511|NCT01778309|Experimental|n-acetylcysteine/placebo supplementation|n-acetylcysteine supplementation, orally in three daily dosages, at 20 mg/kg/day, daily for eight days after exercise placebo, orally in three daily dosages, content: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder.
3116512|NCT01778296|Experimental|Surgical flap|The neurocutaneous island flap is based on the dorsal branch of the digital nerve
3116513|NCT01778283|Experimental|Acetate-free solution first|Acetate-free solution first : hemodialysis 4 hours with Acetate-free solution (Acetate 0 mEq/L Citrate 2 mEq/L) at the first session after enrollment, and then switch to Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the next 4-hr hemodialysis session
3116514|NCT01778283|Active Comparator|Acetate-based solution first|Acetate-based solution first : hemodialysis 4 hours with Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the first session after enrollment, and then switch to Acetate-free solution (Acetate 2 mEq/L Citrate 2 mEq/L) at the next 4-hr hemodialysis session
3116515|NCT01778270|Other|non invasive sensor pleural drainage|feasibility data will be collected with thorax impedance measurements via body bioimpedance sensor in Ohm before and after pleura drainage, via impedance cardiography stroke volume and cardiac output will be calculated and also respiratory parameters determined via capnograph as carbon dioxide (CO2) in %/ml exhaled volume before and after pleura drainage. Additionally heart sound analysis via electronic stethoscope will be compared to standard methods.
3116516|NCT01778270|Other|non invasive sensor healthy control|"the same measurements as in arm 1: feasibility data will be collected with thorax impedance measurements via body bioimpedance sensor before and after pleura drainage in Ohm, via impedance cardiography stroke volume and cardiac output will be calculated and also respiratory parameters determined via capnograph as carbon dioxide (CO2) in %/ml exhaled volume once in 25 healthy controls.~Additionally heart sound analysis via electronic stethoscope will be compared to standard methods."
3116517|NCT01778257|Experimental|Mate extracts group|Mate extract(3150 mg/day)for 12 weeks
3116518|NCT01778257|Placebo Comparator|Placebo group|Placebo (3150 mg/day) for 12 weeks
3116519|NCT01778244|Experimental|metformin|metformin
3116520|NCT01778244|Placebo Comparator|placebo|placebo
3116521|NCT01778231|Experimental|Vitamin Supplement|1 capsule of Nutrof Total made by Laboratories Thea for 16 weeks
3116522|NCT01778231|Placebo Comparator|Inert oil capsule|1 capsule daily for 16 weeks
3116523|NCT01778218|Experimental|99mTc-EC-DG|99mTc-EC-DG injection followed by SPECT imaging during a cardiac rest study (Visit 1) and an exercise/regadenoson study (Visit 2)
3116524|NCT01778205||Pregnant women|Pregnant women with confirmed viable fetus at first prenatal check-up at <12 gestational weeks
3116525|NCT01778192|Active Comparator|Same day PEG|group 1 (same day PEG, N=50) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
3116526|NCT01778192|Active Comparator|split PEG|group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
3116527|NCT01778192|Active Comparator|SPMC 2|group 3 (SPMC 2, N=50) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
3116528|NCT01778192|Active Comparator|SPMC 3|group 4 (SPMC 3, N=50) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
3116529|NCT01778179|Active Comparator|Group 1|"Subjects (group 1) will be treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.Then, at week 2, all the subjects will have the solar lentigines treated by cryotherapy (CRY-AC3® device).~Post-procedure phase (From week 2 up to Week 13 - Visit ) - Topical antibiotic treatment phase (from week 2 up to Week 5 - visit 2 up to visit 3): At week 2, all the subjects will start to apply a topical antibiotic (Neomycin/Nebacetin® ointment) for the next 3 weeks.~- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5): The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
3116530|NCT01778179|Placebo Comparator|Group 2|"Subjects (group 2) will be treated daily for their solar lentigines only with sumscreen for 2 weeks.Then, at week 2, all the subjects will have the solar lentigines will be treated by cryotherapy (CRY-AC3® device).~Post-procedure phase (From week 2 up to Week 13 - Visit )~- Topical antibiotic treatment phase (from week 2 up to Week 5 - visit 2 up to visit 3): At week 2, all the subjects will start to apply a topical antibiotic (Neomycin/Nebacetin® ointment) for the next 3 weeks."
3116531|NCT01778166|Active Comparator|Standard early enteral nutrition|There would be 100 patients in this group
3116532|NCT01778166|Experimental|Immuno-enhanced early enteral nutrition|There would 100 patients in this group
3116533|NCT01778153|Experimental|Equinox Personal Coaching|Participants assigned the Coached group will receive up to 36 sessions about three times a week, consisting of both strength and aerobic exercises, through a program designed by Equinox Fitness Centers.
3116534|NCT01778153|No Intervention|Self-directed exercise training|Participants in the Self-directed group will receive general exercise training advice as any member of the fitness club would, and will record the details of their exercise in log sheets. They will be asked to continue their usual exercise routine.
3116535|NCT01778140|Experimental|Patient-specific reminder|Intervention: Patient-specific computerized reminder. The physicians assigned to this arm will use the patient-specific CDSS on CPOE. The patient-specific reminder is designed as a real-time CDSS implemented on CPOE to monitor physician's contrast-enhanced image study orders. Computerized pop-up reminders provide the patient-specific CIN risk profile and optimal decision options which are generated when patients with high risk or with unknown risk of CIN are encountered.
3116536|NCT01778140|Active Comparator|Non-patient-specific reminder|Intervention: Non-patient-specific Computerized reminder. The physicians assigned to this arm will use the Non-patient-specific reminders through CPOE. Non-patient-specific reminders always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
3116537|NCT01778140|No Intervention|Control Arm|The physicians assigned to this arm will not use and any computerized reminder.
3116538|NCT01778127|Experimental|Group A: Minimal Rewards|Participants use an activity monitor and the interactive website. They will receive minimal rewards based on their physical activity levels.
3116539|NCT01778127|Experimental|Group B: Immediate Incentives|"Participants use an activity monitor and the interactive website.~In addition to minimal rewards, participants will receive immediate incentives as they move from one level to the other on the website."
3116540|NCT01778127|Experimental|Group C: Control|Participants in the control group will receive an activity monitor and educational materials, but will not have access to the interactive website. No rewards will be offered for their participation.
3116541|NCT01778114|Placebo Comparator|Placebo + orange juice without vitamin D|Placebo + orange juice without vitamin D
3116542|NCT01778114|Experimental|Placebo + 1000 IU vitamin D3 in OJ|Vitamin D3 in orange juice
3116543|NCT01778114|Experimental|Placebo + 1000 IU vitamin D2 in OJ|Vitamin D2 in orange juice
3116544|NCT01778114|Active Comparator|1000 IU vitamin D3 + placebo OJ|1000 IU vitamin D3 + placebo OJ
3116545|NCT01778114|Active Comparator|1000 IU vitamin D2 + placebo OJ|1000 IU vitamin D2 + placebo OJ
3116546|NCT01778101|Experimental|lansoprazole|lansoprazole 1mg/kg twice a day for 14days
3116547|NCT01778088|Other|Single Group|I-131-CLR1404 Injection
3116548|NCT01778075|Experimental|Treatment sequence AB|Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER
3116549|NCT01778075|Experimental|Treatment sequence BA|Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER
3116550|NCT01778062|Experimental|Indacaterol|Indacaterol 150 µg once daily
3116551|NCT01778062|Placebo Comparator|Placebo|Placebo once daily
3116552|NCT01778049|Experimental|Empagliflozin 10 mg dose|Empagliflozin open label treatment period
3116553|NCT01778049|Experimental|Placebo add on 10 mg dose|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo add on run-in
3116554|NCT01778049|Experimental|Empagliflozin/Linagliptin 25/5 mg Dose|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
3116555|NCT01778049|Experimental|Empagliflozin/Linagliptin 10/5 mg Dose.|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
3116556|NCT01778049|Experimental|Empagliflozin/Linagliptin 10/5 mg Dose|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
3116557|NCT01778049|Experimental|Empagliflozin 25 mg dose|Empagliflozin open label treatment period
3116558|NCT01778049|Experimental|Empagliflozin/Linagliptin 25/5 mg Dose.|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
3116559|NCT01778049|Experimental|Placebo add on 25 mg dose|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo add on run-in
3116560|NCT01778036||Neck pain patients following physiotherapy treatment|Neck pain patients will follow physiotherapy treatment in primary health care.
3116561|NCT01778023|Experimental|hGH:12months treatment|
3116563|NCT01778010|Placebo Comparator|Modafinil 0mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (0 mg/day) for 15 days, and underwent a dose response of cocaine.
3116564|NCT01778010|Experimental|Modafinil 200mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (200 mg/day) for 15 days, and underwent a dose response of cocaine.
3116565|NCT01778010|Experimental|Modafinil 400mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (400 mg/day) for 15 days, and underwent a dose response of cocaine.
3116566|NCT01777997|Experimental|FTC/RPV/TDF|"Step 1: From entry through week 12, the participants received no study treatment. From week 12 through week 60, the participants received one fixed dose combination emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) tablet daily.~Step 2 (Optional): From week 60 through week 108, the participants either received one FTC/RPV/TDF tablet daily or no study treatment."
3116567|NCT01777971||Patients with cirrhosis|Male and female subjects who have cirrhosis of the liver and diuretic-resistant ascites (based on International Ascites Clib criteria) and have been evaluated and approved to have a large-volume paracentesis as part of standard of care treatment.
3116568|NCT01777958||Cohort|
3116569|NCT01777945||Participants Receiving Capecitabine/Docetaxel|Participants received capecitabine and docetaxel according to individualized physician-prescribed regimens.
3116570|NCT01777932||Cohort|
3116571|NCT01777919|Experimental|Temozolomide+Disulfiram/copper|"Disulfiram/copper combination will be started on the 5th postoperative day and before the initiation of the standard radiochemotherapy (fractionated irradiation with a total dose of 60 Gy with concomitant 75 mg/m2 body surface temozolomide each day, including weekends, during irradiation). After completion of the radiation therapy patients will receive maintenance temozolomide 150-200 mg/m2 body surface on Days 1-5 every 28 days for 6 months. Daily administration of disulfiram and copper will take place for the whole study period.~NOTE: Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
3116572|NCT01777906||Fluticasone|Fluticasone nasal spray will be given 2 sprays twice a day for 6 weeks.
3116573|NCT01777906||Dexamethasone sodium phosphate 0.032%|Dexamethasone 0.032% nasal spray will be given at a dose of 2 sprays twice a day for 6 weeks.
3116574|NCT01777893|Experimental|HP-HI|High protein/ high intensity physical activity
3116575|NCT01777893|Experimental|HP-MI|High protein/ moderate intensity physical activity
3116576|NCT01777893|Experimental|MP-HI|Moderate protein/ high intensity physical activity
3116577|NCT01777893|Experimental|MP-MI|Moderate protein/ moderate intensity physical activity
3116578|NCT01777867||Healthy Volunteers|Subjects in this arm were healthy volunteers. Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
3116579|NCT01777867||Non-erosive reflux disease with reflux|Subjects enrolled in this arm had non-erosive reflux disease with reflux (heartburn) for at least 6 of the preceding 12 months. Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
3116580|NCT01777867||Non-erosive reflux disease without reflux|Subjects enrolled in this arm had non-erosive reflux disease with normal levels of reflux (heartburn). Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
3116581|NCT01777854|Active Comparator|Omeprazole|"Yes. Omeprazole (generic) will be used. Children >20 kg will be given 20 mg PO daily for 4 weeks prior to tonsillectomy. This is the normal standard pediatric dosing for reflux.~Omeprazole is authorized to treat reflux in children. The study focuses on laryngopharyngeal reflux that possibly contributes to post tonsillectomy pain."
3116582|NCT01777854|Placebo Comparator|Sugar pill|The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look.
3116583|NCT01777841|Other|Electronic Care plan delivery|
3116584|NCT01777828||Transcatheter Aortic Valve Implantation|FRANCE TAVI registry aims to identify all patients with a change of valves implanted catheter meets the selection criteria of the technical accepting the scheduled evaluations in the context of this disease and who have agreed to participate in the study .
3116585|NCT01777815|Experimental|Implanting ePTFE sutures|Implanting ePTFE sutures as artificial neochordae using the NeoChord DS1000 Artificial Chordae Delivery System
3116586|NCT01777802||Prostate Cancer|Patients with prostate cancer will be treated with SBRT, IMRT or brachytherapy
3116587|NCT01777802||Breast Cancer|Patients with breast cancer will be treated with SBRT, IMRT or brachytherapy
3116588|NCT01777802||Lung Cancer|Patients with lung cancer will be treated with SBRT, IMRT or brachytherapy
3116589|NCT01777802||Melanoma Cancer|Patients with melanoma cancer will be treated with SBRT, IMRT or brachytherapy
3116590|NCT01777776|Experimental|Phase Ib|Phase Ib will randomize 18 patients with BRAF mutant melanoma, who are naïve or who have progressed on prior therapy to evaluate the safety and tolerability of the combination of LEE011 and LGX818.
3116591|NCT01777776|Experimental|Phase II arm 1a|Phase II arm 1a will randomize 60 patients that are naïve to prior BRAF inhibitor therapy to LGX818+LEE011 to evaluate the effect of adding LEE011 to a BRAFi in this population.
3116592|NCT01777776|Experimental|Phase II arm 1b|Phase II arm 1b will randomize 30 patients to LGX818. Single agent anti-tumor activity of LGX818 is comparable to other BRAFi that are either approved or in clinical trials. This single agent anti-tumor activity will be compared to that of the combination (LEE011 + LGX818) in the BRAFi naïve patient population.
3116593|NCT01777776|Experimental|Phase II arm 2|Phase II arm 2 will evaluate a single arm LEE011+LGX818 in 40 patients resistant to prior BRAF inhibitor therapy. Single agent LGX818 has shown limited activity in patients with melanoma who have failed prior BRAF inhibitor treatment; the contribution of LEE011 in this combination will be evaluated.
3116594|NCT01777763|Experimental|Posaconazole 200 mg|Posaconazole 200 mg (two 100 mg tablets) twice daily (BID) on Day 1 followed by 200 mg (two 100 mg tablets) once daily (QD) for up to 28 days
3116595|NCT01777763|Experimental|Posaconazole 300 mg|Posaconazole 300 mg (three 100 mg tablets) BID on Day 1 followed by 300 mg (three 100 mg tablets) QD for up to 28 days
3116596|NCT01777750|Active Comparator|Pre- and perinterventional hypothermia|Cooling will be initiated by the application of cooling pads in the out-of-hospital setting followed by an infusion of 1000-2000ml of cold saline. In the cath lab a endovascular cooling catheter will be placed into the inferior vena cava via a femoral vein to achieve a core temperature of <35°C prior to revascularization.
3116598|NCT01777737|Experimental|Cotrimoxazole|Sulfamethoxazole 400 mg. + trimethoprim 80 mg. weight-adjusted
3116599|NCT01777737|Placebo Comparator|Placebo|Identical capsules to cotrimoxazole
3116600|NCT01777724|Experimental|Intervention|The intervention is a combination of Triple P Discussion Groups and Stress Control
3116601|NCT01777724|No Intervention|Control|Waitlist control. Participants allocated to the waitlist control will be able to access the intervention after post-intervention equivalent measures have been completed.
3116602|NCT01777711|Active Comparator|Couple condition|Couples randomized to the couple condition will undergo the experimental manipulations and both partners will complete all study measures. Both members of the couple will be given body mass index (BMI) based on measurements taken during the intervention. Both will complete three surveys on paper and do some prompted planning and goal-setting together regarding weight loss through healthier eating and physical activity.
3116603|NCT01777711|Active Comparator|Individual Condition|Couples randomized to the individual condition will be stratified on gender and one partner, chosen at random, will undergo the experimental manipulations and complete all study surveys while the other will not (heretofore called the active partner vs. the passive partner). The active partner will receive BMI feedback based on measurements taken during the intervention appointment, complete three surveys, and verbally state some goals and plans for weight loss to the passive partner. The passive partner will not complete any study materials or participate in the intervention during the session.
3116604|NCT01777685|Other|sulpiride 50 mg|
3116605|NCT01777672|Active Comparator|Dietary and oral hygiene recommendations|Patients in this group will receive recommendations from their healthcare providers about bolus volume and viscosity adaptation for fluids, dietary and nutritional adjustments (liquids and solids) of bolus volume and viscosity/texture. Before leaving each hospital they will also learn basic rehabilitation strategies for OD including swallow postures, compensatory manoeuvres and oropharyngeal rehabilitation exercises and oral hygiene to follow at home.
3116606|NCT01777672|Experimental|oral TRPV1 agonist|Patients will receive the same recommendations as the control group and also recommendation for the administration of a TRPV1 agonist (natural capsaicin) supplement (5 mL bolus before each meal), 3 meals/day, 5 days/week for 2 consecutive weeks.
3116607|NCT01777672|Experimental|pharyngeal electrical stimulation|Treatment in this group will also include the same measures as in the control group, plus neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during one week, done at the same center.
3116608|NCT01777672|Experimental|transcutaneous electrical stimulation|Treatment in this group will be the same as the control group plus trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
3116609|NCT01777659|Experimental|TENS CABG|Eligible patients will be randomized to a transcutaneous electrical nerve stimulation program (TENS; n = 20) or to placebo-TENS (P-TENS; n = 18). All patients were followed by their own physicians, received routine nursing assistance, and were visited daily by one of the investigators, but P-TENS group will be not exposed to any specific electrical stimulation or motor physical intervention.
3116610|NCT01777659|Placebo Comparator|P-TENS CABG|Patients will be treated with placebo-TENS (P-TENS) condition for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). P-TENS device underwent modifications in its internal programming: the control capacitor of the time constant was changed and the active time between pulses was modified from 330 milliseconds to 33 seconds, in order to prevent an analgesic effect (33).
3116611|NCT01777646|Experimental|MSC-NTF|
3116612|NCT01777633|Experimental|re-irradiation|re-irradiation for progressive DIPG in children
3116613|NCT01777620|Active Comparator|BOTOX®|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
3116614|NCT01777620|Placebo Comparator|Placebo|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
3116615|NCT01777607|Experimental|Intervention|
3116616|NCT01777594|Experimental|G-202 (Mipsagargin)|G-202 (mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
3116617|NCT01777581|Experimental|milnacipran|Milnacipran, flexibly dosed
3116618|NCT01777581|Placebo Comparator|Sugar pill (placebo)|Placebo
3116619|NCT01777568||30% oxygen|Inspired oxygen will be maintained at 30%.
3116620|NCT01777568||80% oxygen|Inspired oxygen will be maintained at 80%.
3116621|NCT01777555|Experimental|CVT-301|CVT-301 at Dose Level 1 for 1st 14 days of treatment then increased to Dose level 2 for last 14 days of treatment.
3116622|NCT01777555|Placebo Comparator|Inhaled Placebo|Subjects randomized to receive placebo in a 1:1 randomization scheme
3116623|NCT01777542|Active Comparator|Treatment Period 1|One half of subjects will be randomly assigned to receive Recombinant Human Insulin Growth Factor 1 (rhIGF-1) , and the other half of subjects will be randomly assigned to receive placebo.
3116624|NCT01777542|Placebo Comparator|Treatment Period 2|Subjects that initially received Recombinant Human Insulin Growth Factor 1 (rhIGF-1) will now receive placebo, and subjects that initially received placebo will now receive Recombinant Human Insulin Growth Factor 1 (rhIGF-1).
3116625|NCT01777529|Experimental|Multidose|Multidose from MMR Vaccine produced by Bio-Manguinhos/Fiocruz
3116626|NCT01777529|Active Comparator|Singledose|Singledose from MMR (GSK-TV), produced by GlaxoSmithKline
3116627|NCT01777516||healthy volunteers|1 group with no treatment : They provide the blank plasma to be used at in vitro study.
3116628|NCT01777503|Experimental|prasugrel|prasugrel 60 mg loading dose, followed by 5 mg once daily until the end of follow-up
3116629|NCT01777503|Active Comparator|clopidogrel|Clopidogrel 300 mg loading dose followed by 75 mg once day until the end of follow-up
3116630|NCT01777490|Active Comparator|Arm 1: Control|Caregivers in the control arm will be referred to the VA Caregiver Support Program (usual care), as a resource for them as they care for the patient in the home. The patient of each caregiver will also be enrolled and contact will be limited to assessments.
3116631|NCT01777490|Experimental|Arm 2: HI FIVES|Caregivers will take part in three phone training sessions and will attend four group training sessions at the VA. They will also be given the option of participating in 2 booster phone training sessions post-group sessions. Caregivers will be asked to provide one in-person (baseline) and three phone assessments (3, 9, and 15 months). Patients will also be enrolled and contact will be limited to assessments
3116632|NCT01777477|Experimental|Chloroquin in addition to Gemcitabine|Gemcitabine 1000 mg/m2 i.v. at days 1, 8, 15 of every 28-day cycle. Chloroquine 100 mg, 200 mg or 300 mg (according to dose level) p.o. at days 2, 9, 16 of every 28-day cycle.
3116633|NCT01777464|Experimental|patients|patients allergic to house dust mite receive sham solution for 5 minutes on first visit and histamine (16mg/ml) for 5 minutes on second visit
3116634|NCT01777464|Sham Comparator|healthy controls|healthy controls receive sham solution for 5 minutes on first visit and histamine (16mg/ml) for 5 minutes on second visit
3116635|NCT01777451||Neurofibromatosis 1|"All patients diagnosed with neurofibromatosis type 1. GROUP 1:ADDITIONAL IMAGING OR SURGERY There will be patients with high-risk neurofibromas (potential malignant). These patients will underwent additional examinations or surgery (outside this study). Follow-up MRI within 2 years (study MRI )~GROUP 2:~No suspicious lesions at MRI. Follow-up within 2 years(Study MRI)."
3116636|NCT01777438||control group|a control group of AR patients who visited the ear nose and throat (ENT) department of the University Hospitals Leuven in the same time period
3116637|NCT01777438||patients having SCIT|patients who started immunotherapy at the Department of Allergology of the University Hospitals Leuven between November 2007 and February 2010.
3116638|NCT01777425||rhinosinusitis patients|patients having undergone endoscopic sinus surgery (ESS) for bilateral inflammatory sinonasal disease from January 2008 until December 2010.
3116639|NCT01777412|Experimental|Bevacizumab|Bevacizumab 10 mg/kg intravenous infusion at onset of exacerbation and, if needed, a second time during the plasma exchange phase.
3116640|NCT01777386|Active Comparator|preexpanded flap|Fourteen patients were treated with fifteen '' preexpanded perforator flap surgery '' interventions. The last six cases were evaluated in terms of perforator artery diameter before and after expansion process. The preexpanded flap donor sites' perforator artery diameters were also compared with their anatomic equivalents located in the symmetric side of the body.
3116641|NCT01777386|No Intervention|control side|In six of the 14 patients, perforator artery diameter of the nonexpanded symmetric anatomical side of the body (equivalent to the expanded site)were measured.
3116642|NCT01777373||Idiopathic pulmonary fibrosis (IPF)|Idiopathic pulmonary fibrosis (IPF)
3116643|NCT01777373||Control|Control
3116644|NCT01777373||Non-IPF interstitial lung disease (ILD)|Non-IPF interstitial lung disease (ILD)
3116645|NCT01777373||Uncharacterized ILD|Uncharacterized ILD
3116646|NCT01777360|Experimental|THERMOPLASTY|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY
3116647|NCT01777347|Experimental|3% Saline|Nebulized 3% Saline
3116648|NCT01777347|Placebo Comparator|0.9% Normal Saline|Nebulized 0.9% normal saline
3116649|NCT01777334|Experimental|Umeclidinium/Vilanterol|Long-acting muscarinic antagonist (LAMA)/Long-acting Beta agonist (LABA)
3116650|NCT01777334|Active Comparator|Tiotropium|Long-acting muscarinic antagonist (LAMA)
3116651|NCT01777321|Experimental|SC HZ/su Group|Subjects will receive HZ/su vaccine administered SC on a 0,2-month schedule.
3116652|NCT01777321|Active Comparator|IM HZ/su Group|Subjects will receive HZ/su vaccine administered IM on a 0,2-month schedule.
3116653|NCT01777308|Experimental|Menitorix Group|"Subjects who were primed with Menitorix™ (Hib-MenC-TT) + Priorix™ (MMR) vaccines in the primary study HIB-MENC-TT-016 (NCT00326118) received one dose of Nimenrix™ (MenACWY-TT) booster vaccine at Month 72 post primary vaccination (booster visit 1).~The MenACWY-TT vaccine was administered intramuscularly (IM) in the deltoid region of the non-dominant arm."
3116654|NCT01777308|Experimental|Meningitec + Hiberix Group|"Subjects who were primed with Meningitec™ (MCC) + Hiberix™ (Hib) + Priorix™ (MMR) vaccine in the primary study HIB-MENC-TT-016 (NCT00326118) received one dose of Nimenrix™ (MenACWY-TT) booster vaccine at Month 72 post primary vaccination (booster visit 1).~The MenACWY-TT vaccine was administered intramuscularly (IM) in the deltoid region of the non-dominant arm."
3116655|NCT01777295|Experimental|HBsAg/AS Group|Subjects in this group received 1 dose of Placebo at Day -30 followed by 2 doses of HBsAg/AS, at Day 0 and Day 30.
3116656|NCT01777295|Active Comparator|Engerix-B Group|Subjects in this group received 1 dose of Placebo at Day -30 followed by 3 doses of Engerix-B at Day 0, Day 30 and Day 180.
3116657|NCT01777282|Active Comparator|Albiglutide + Sulfonylurea|Albiglutide in combination with background sulfonylurea
3116658|NCT01777282|Active Comparator|Albiglutide + Biguanide|Albiglutide in combination with background biguanide
3116659|NCT01777282|Active Comparator|Albiglutide + Glinide|Albiglutide in combination with background glinide
3116660|NCT01777282|Active Comparator|Albiglutide + Thiazolidinedione|Albiglutide in combination with background thiazolidinedione
3116661|NCT01777282|Active Comparator|Albiglutide + Alpha-glucosidase inhibitor|Albiglutide in combination with background alpha-glucosidase inhibitor
3116662|NCT01777269|Experimental|Duodart|Fixed dose combination of dutasteride 0.5mg and tamsulosin 0.4mg. A capsule once daily during 12 months
3116663|NCT01777269|Placebo Comparator|Sugar Pill|A capsule once daily during 12 months
3116664|NCT01777256|Experimental|GSK2586184 50 mg Arm|Subjects in the GSK2586184 50 mg Arm will receive twice daily dose of GSK2586184 50 mg 1 x 50 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal
3116665|NCT01777256|Experimental|GSK2586184 100 mg Arm|Subjects in the GSK2586184 100 mg Arm will receive twice daily dose of GSK2586184 100 mg (2 x 50 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
3116666|NCT01777256|Experimental|GSK2586184 200 mg Arm|Subjects in the GSK2586184 200 mg Arm will receive twice daily dose of GSK2586184 200 mg (1 x 200 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
3116667|NCT01777256|Experimental|GSK2586184 400 mg Arm|Subjects in the GSK2586184 400 mg Arm will receive twice daily dose of GSK2586184 400 mg (2 x 200 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
3116668|NCT01777256|Placebo Comparator|Placebo|Subjects in the placebo arm will receive twice daily dose of 2 matching placebo tablets orally up to 12 weeks; taken with food, immediately following a meal.
3116708|NCT01777009|Active Comparator|Patellar Lateral Retraction|Patients randomized to the Patellar Lateral Retraction arm of the study were surgically exposed by laterally retracting the patella during their Primary Total Knee Replacement Surgery.
3116669|NCT01777243|Experimental|Part A Arm|Two subjects in Part A will receive starting dose level of GSK2398852 as 5 milligram (mg) [approximately equivalent to 0.1 mg/kilogram (kg)]. The next escalation dose levels in two subjects each are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg. GSK2315698 will be administered at variable dosed until the concentration of the SAP mAb has fallen below 100 ng/mL.
3116670|NCT01777243|Experimental|Part B Arm|The precise selection of numbers of subjects and dose levels in Part B will be informed by the results from Part A.
3116671|NCT01777230||All patients|Alle subjects included retain in one cohort.
3116672|NCT01777217|Active Comparator|solifenacin succinate|Solifenacin succinate, 5mg or 10 mg once daily
3116673|NCT01777217|Placebo Comparator|Placebo|Drug: Placebo oral
3116674|NCT01777204||Tacrolimus|Influence of tacrolimus on gastrointestinal transit and motility in renal transplant recipients.
3116675|NCT01777204||Cyclosporine|Influence of cyclosporine on gastrointestinal transit and motility in renal transplant recipients.
3116676|NCT01777204||Mycophenolate mofetil|Influence of mycophenolate mofetil on gastrointestinal transit and motility in renal transplant recipients.
3116677|NCT01777204||Mycophenolate sodium|Influence of mycophenolate sodium on gastrointestinal transit and motility in renal transplant recipients.
3116678|NCT01777204||Everolimus|Influence of everolimus on gastrointestinal transit and motility in renal transplant recipients.
3116679|NCT01777204||Sirolimus|influence of sirolimus on gastrointestinal transit and motility in renal transplant recipients.
3116680|NCT01777204||Without immunosuppression|Gastrointestinal transit and motility in healthy volunteers.
3116681|NCT01777191|Experimental|80 mg Ixekizumab Auto-Injector|Ixekizumab administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection every 2 weeks (Q2W) at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection every 4 weeks (Q4W).
3116682|NCT01777191|Experimental|80 mg Ixekizumab Prefilled Syringe|Ixekizumab administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection Q2W at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection Q4W.
3116683|NCT01777178|Experimental|Low bicarbonate dialysis|
3116684|NCT01777165|Experimental|Arm 1 ABT-719 lower dose|
3116685|NCT01777165|Experimental|Arm 2 ABT-719 intermediate dose|
3116686|NCT01777165|Experimental|Arm 3 ABT-719 higher dose|
3116687|NCT01777165|Placebo Comparator|Arm 4 placebo|
3116688|NCT01777152|Active Comparator|CHOP|cyclophosphamide, doxorubicin, vincristine, and prednisone
3116689|NCT01777152|Experimental|A+CHP|brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone
3116690|NCT01777139|Experimental|Retigabine IR|All subjects will initially receive a starting dose of retigabine IR at 900 mg/day and after the first week of the OLE study, the dose of retigabine IR may be increased or decreased in increments or decrements of decrements of 150 mg/day on weekly basis based on efficacy and tolerability. The overall daily dose of retigabine IR must be maintained between a minimum dose of 600 mg/day and a maximum dose of 1200 mg/day.
3116691|NCT01777126|Active Comparator|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
3116692|NCT01777126|Experimental|Oral Nutrition Protocol (ONP) group|Oral intake was increased progressively with oral fluids and easily digestible food, independent of bowel movements. The corresponding energy content from the meals and oral fluids were calculated. Fortimel Jucy®, 200 ml containing 300 kcal, was used as the formulary energy sip. Extra fluids, up to two liter per day, were given intravenously, at the discretion of the treating physician. If the patient tolerated the ONP well, the oral intake was considered equal in terms of calories as the corresponding oral meal in the ONP. From the sixth day, the patient was allowed to eat at will. Only if oral intake remained insufficient after 5 days, which was left to the opinion of the treating physician, PN could be initiated in this group.
3116693|NCT01777113|Experimental|High Intensity Aerobic training|The subjects will perform a high intensity treadmill training
3116694|NCT01777113|Experimental|High Intensity Strength Training|The subjects will perform and high intensity training on the same leg horizontal press.
3116695|NCT01777113|Active Comparator|Mixed Training|Conventional training consisted of group mobility, balance and stretching exercises.
3116696|NCT01777100|Experimental|sufentanil|Anesthetic induction with IV sufentanil at 0.5 mcg.kg-1 and analgesic maintenance with IV remifentanil at 0.1 to 0.3 mcg.kg-1.min-1 on demand target-controlled infusion
3116697|NCT01777100|No Intervention|remifentanil|Anesthetic induction with target-controlled infusion IV remifentanil at 0.5 mcg.kg-1.min-1 in 5 minutes followed by analgesic maintenance on demand of IV target-controlled infusion remifentanil at 0.1 to 0.3 mcg.kg-1.min-1.
3116698|NCT01777087|Experimental|Healthy normal volunteers|Healthy normal volunteers
3116699|NCT01777074||Generalist physicians Cohort|
3116700|NCT01777074||Paediatricians Cohort|
3116701|NCT01777048|Experimental|Omega-3 Fatty Acids|1g of Omega-3 per day [400mg DHA & 600mg EPA] for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner
3116702|NCT01777048|Placebo Comparator|Omega-3 Placebo|1g of Omega-3 Placebo per day for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner
3116703|NCT01777035|Experimental|Early physical therapy(PT) occupational therapy (OT)|Early PT OT assessments begin on first day of study. Therapy delivered by a team consisting of physical and occupational therapists and coordinated with daily sedative interruption
3116704|NCT01777035|No Intervention|standard care|PT OT delivered as ordered by the primary ICU team
3116705|NCT01777022|No Intervention|Current treatment|Current education and management protocols will be followed
3116706|NCT01777022|Other|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
3116707|NCT01777009|Experimental|Patellar Eversion|Patients randomized to the Patellar Eversion arm of the study were surgically exposed by everting the patella during their Primary Total Knee Replacement Surgery.
3116709|NCT01776970|Experimental|Sativex|Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml)
3116711|NCT01776957||IUD|Repeat abortion rate in women receiving IUDs immediately post-abortion
3116712|NCT01776944||Obese children|
3116713|NCT01776931|Experimental|Lysine intake|Dietary supplement:lysine intake
3116714|NCT01776918||Metabolic Disease- Phenylketonuria|
3116715|NCT01776918||Mitochondrial disorder|
3116716|NCT01776905||Healthy control subjects|Characterize the baseline PA signals produced by the in vivo PAFC prototype device in healthy volunteers or Develop Standard Curves for the ex vivo CTC assays.
3116717|NCT01776905||Advanced-Stage Melanoma|To validate the in vivo PAFC method of melanoma CTC detection, we will use the PAFC-based prototype device to noninvasively determine CTC concentrations in the blood of subjects who have advanced-stage (Stage III or Stage IV)melanoma, and we will also use current ex vivo methods to determine the CTC concentration in samples of blood drawn from the same subjects.
3116718|NCT01776905||Early-Stage Melanoma|To determine whether in vivo PAFC can detect melanoma CTCs at concentrations below the detection limits of the ex vivo methods, we will use the PAFC-based prototype device to noninvasively detect CTCs in the blood of subjects who have early-stage (Stages I or II) melanoma, and we will also use current ex vivo methods to detect CTCs in samples of blood drawn from the same subjects.
3116719|NCT01776892|Experimental|Collagenase and needle aponeurotomy|"Participants in this arm of the study will be treated once with needle aponeurotomy and up to 3 times at 4 week intervals with collagenase injection.~Affected Dupuytren's cords will be treated with 1-3 collagenase clostridium histolyticum injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained."
3116720|NCT01776892|Active Comparator|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained. Participant feedback is obtained throughout the procedure to prevent digital nerve or flexor tendon injury. Participants are asked to report Tinel's sign which indicates that the needle is in close proximity to the digital nerve and to report pain with needle advancement which indicates proximity to the flexor tendon.
3116721|NCT01776892|Active Comparator|Collagenase injection|Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections. Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent.
3116722|NCT01776879||early & advanced PD 1st degree relatives|no intervention is performed in the study
3116723|NCT01776879||recording speech and voice|no intervention(s) will be administered
3116724|NCT01776879||speech intelligibility|no intervention(s) will be administered
3116725|NCT01776866|Other|Coronary Angiography|"Patient first undergo standard coronary angiography(SA) of either left or right coronary system followed by dual-axis rotational coronary angiography(DARCA). The SA protocol consist of six different projections (right anterior oblique (RAO)-caudal, RAO-cranial (CRA), left anterior oblique (LAO)-CRA, LAO-caudal (CAU), antero-posterior (AP)-CRA and AP-CAU) for left coronary artery (LCA) and two projections (LAO and AP-cranial) for right coronary artery (RCA).~The DARCA protocol consist of two coronary acquisitions specified by the protocol: one for LCA (Swing LCA CRA 35 5.8s), another for RCA (Swing RCA AP 4.0s)."
3116726|NCT01776853|Placebo Comparator|Glucose|40g glucose in 500ml water flavoured with lime juice
3116727|NCT01776853|Experimental|Fructose|40g fructose in 500ml water flavoured with lime juice
3116728|NCT01776853|Experimental|Fructans|40g fructans in 500ml water flavoured with lime juice
3116729|NCT01776840|Placebo Comparator|Treatment Arm A|
3116730|NCT01776840|Experimental|Treatment Arm B|
3116731|NCT01776801|Experimental|Hydrocephalus|Patients suffering of hydrocephalus (cognitive impairment, gait disturbance, urinary incontinence and enlargement of the ventricles) require for clinical purpose infusion studies i.e. injection of mock cerebrospinal fluid (CSF) in the sub arachnoid space to artificially increase ICP. We aim at using infusion studies as a indirect tool to assess whether a moderate increase in ICP has any influence on haemodynamics.
3116732|NCT01776788|Experimental|insulin lispro injection, exenatide injection|
3116733|NCT01776788|Active Comparator|insulin lispro injection|
3116734|NCT01776775|Active Comparator|abdominal binder|use of postoperative abdominal binder 30 days after the hernia repair
3116735|NCT01776775|No Intervention|No abdominal binder|No intervention
3116736|NCT01776762|Experimental|Individual nutritional therapy|Individual nutritional therapy provided by registered dietician by means of three Home-visits
3116737|NCT01776762|No Intervention|Standard Follow-home programme|Standard Follow-home programme without individual nutritional therapy
3116738|NCT01776749|No Intervention|no SubQ|No subcutaneous leads due to adequate low back stimulation by only SCS. Patient not randomised
3116739|NCT01776749|Active Comparator|SubQ ON|Subcutaneous stimulation on
3116740|NCT01776749|Sham Comparator|SubQ OFF|subcutaneous leads implanted, but no stimulation
3116741|NCT01776736|Experimental|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
3116742|NCT01776723|Experimental|I: Dose Escalation - Ruxolitinib|"Phase I: Dose Escalation. In Phase I, participants will be allocated to dose levels starting at 10 mg/d (twice a day [BID] dosing) according to the rolling six Phase I design."
3116743|NCT01776723|Experimental|II: Maximum Tolerated Dose - Ruxolitinib|Phase II: Treatment at Maximum Tolerated Dose (MTD).
3116798|NCT01776398||1.1 HEALTHY SUBJECTS|Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population.
3116843|NCT01776099|Placebo Comparator|soluble non-fermentable fibers|5 grams of soluble non-fermentable fibers, three times a day with the main meals, duration: 4 weeks
3116744|NCT01776710|Experimental|Structured education|The structured education intervention will comprise a 3-hour education workshop delivered by two trained facilitators and a follow-up telephone call 2 weeks later. The aims of the education programme are to enhance patients' understanding of peripheral arterial disease and intermittent claudication, and to support patients in increasing their daily walking activity. Key behaviour change techniques that will be incorporated will include goal setting, action planning, barrier identification/problem solving, prompt review of behavioural goals, prompt self-monitoring of behaviour, and instructions on how to perform the behaviour.
3116745|NCT01776710|No Intervention|Standard care control|Standard care will consist of general advice to increase walking and an information sheet on peripheral arterial disease, plus a consultation with a Consultant Vascular Surgeon.
3116746|NCT01776697|Active Comparator|pelubiprofen (30mg) tablet IR TID, fasting|
3116747|NCT01776697|Active Comparator|pelubiprofen (30mg) tablet IR TID, fed|
3116748|NCT01776697|Experimental|pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD|
3116749|NCT01776684|Experimental|EGFR positive arm|Patients with NSCLC harboring activating EGFR mutation (deletion in exon 19, L858R mutation in exon 21)
3116750|NCT01776671|Other|Gralise|Efficacy of Gralise
3116751|NCT01776658|Experimental|SYL1001 eye drops dose A|Ocular topical administration of SYL1001 eye drops dose A
3116752|NCT01776658|Placebo Comparator|Placebo|Ocular topical administration of placebo eye drops
3116753|NCT01776645|Experimental|Compassion cultivation training|
3116754|NCT01776632|Experimental|Physical activity|Latinas exposed to multi-level Fe en Acción intervention promoting physical activity.
3116755|NCT01776632|Active Comparator|Cancer prevention|Latinas exposed to Fe en Acción intervention on general topics related to cancer prevention and control.
3116756|NCT01776619|Experimental|Multiple Dose: Cohort 1|
3116757|NCT01776619|Experimental|Multiple Dose: Cohort 2|
3116758|NCT01776619|Experimental|Multiple Dose: Cohort 3|
3116759|NCT01776619|Experimental|Multiple Dose: Cohort 4|
3116760|NCT01776619|Experimental|Relative Bioavilability: Cohort 1|
3116761|NCT01776606|Active Comparator|Dose A|Dose A: Botulinum toxin type A
3116762|NCT01776606|Placebo Comparator|Dose B|Dose B: Placebo
3116763|NCT01776593||Lower urinary tract symptoms|
3116764|NCT01776580||Lower urinary tract symptoms|Women with lower urinary tract symptoms
3116765|NCT01776567|Active Comparator|Cobalt Chromium Everolimus-eluting stent (Xience Prime)|Cobalt Chromium Everolimus-eluting stent (Xience Prime)
3116766|NCT01776567|Active Comparator|Platinum Chromium Everolimus-eluting stent (Promus Element)|Platinum Chromium Everolimus-eluting stent (Promus Element)
3116767|NCT01776554|Experimental|aH5N1c-High dose|
3116768|NCT01776554|Experimental|aH5N1c-Low dose|
3116769|NCT01776541|Experimental|aH5N1c-High Dose|Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.
3116770|NCT01776541|Experimental|aH5N1c-Low dose|Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.
3116771|NCT01776528|Experimental|Cohort 1 SAD|NGM282 Dose 1 vs Placebo
3116772|NCT01776528|Experimental|Cohort 2 SAD|NGM282 Dose 2 vs Placebo
3116773|NCT01776528|Experimental|Cohort 3 SAD|NGM282 Dose 3 vs Placebo
3116774|NCT01776528|Experimental|Cohort 4 SAD|NGM282 Dose 4 vs Placebo
3116775|NCT01776528|Experimental|Cohort 5 SAD|NGM282 Dose 5 vs Placebo
3116776|NCT01776528|Experimental|Cohort 6 SAD|NGM282 Dose 6 vs Placebo
3116777|NCT01776528|Experimental|Cohort 7 MAD|NGM282 Dose 1 vs Placebo
3116778|NCT01776528|Experimental|Cohort 8 MAD|NGM282 Dose 2 vs Placebo
3116779|NCT01776528|Experimental|Cohort 9 MAD|NGM282 Dose 3 vs Placebo
3116780|NCT01776528|Experimental|Cohort 10 MAD|NGM282 Dose 4 vs Placebo
3116781|NCT01776528|Experimental|Cohort 11 MAD|NGM282 Dose 5 vs Placebo
3116782|NCT01776528|Experimental|Cohort 12 MAD|NGM282 Dose 6 vs Placebo
3116783|NCT01776515|Active Comparator|Tramadol hydrochloride/Acetaminophen Tab.|
3116784|NCT01776515|Experimental|Tramadol hydrochloride/Acetaminophen SR Tab.|
3116785|NCT01776502||Patients with Hyperparathyroidism|The cohort of patients is made of patients with primary mild hyperparathyroidism and who have received a surgery at Nantes, Angers, Limoges or Marseille University Hospitals
3116786|NCT01776489||food allergic|positive reaction during DBPCFC
3116787|NCT01776489||Non-food allergic|no reaction during DBPCFC
3116788|NCT01776476|Placebo Comparator|Placebo|normal saline of equivalent volume to the experimental drug infusion administered as a continuous infusion over 24 hours for up to 7 days or ICU discharge, whichever comes first.
3116789|NCT01776476|Experimental|Glutamine|Glutamine dipeptide 0.5 gm/kg/day will be administered as a continuous infusion over 24 hours for up to 7 days or ICU discharge, whichever comes first.
3116790|NCT01776463|Experimental|Z-360|1)Single dose study (60, 120, 240, 480, 720mg), 2)Food effect study(120mg), 3)Multiple doses study(120, 240mg (BID))
3116791|NCT01776463|Placebo Comparator|Placebo|1)Single dose study, 2)Multiple doses study
3116792|NCT01776437|Experimental|Treatment A|Period 1: fasted control → Period 2: fed control
3116793|NCT01776437|Experimental|Treatment B|Period 1: fed control → Period 2: fasted control
3116794|NCT01776424|Experimental|Rivaroxaban [2.5mg] + Aspirin|Rivaroxaban 2.5 mg twice daily and Aspirin 100 mg once daily. (Long-term open-label extension was added to make rivaroxaban 2.5 mg twice daily + aspirin 100 mg once daily available to COMPASS trial subjects until the rivaroxaban treatment is commercially available for this indication or for approximately 3 years from regulatory approval of the long term open label extension in a country, whichever comes first.)
3116795|NCT01776424|Experimental|Rivaroxaban [5mg] + Placebo(1)|Rivaroxaban 5 mg twice daily and Aspirin Placebo once daily
3116796|NCT01776424|Active Comparator|Aspirin + Placebo(2)|Rivaroxaban Placebo twice daily and Aspirin 100 mg once daily
3116797|NCT01776411|Experimental|Single Arm|Drug: forodesine hydrochloride 600 mg / body/day (3 x 100 mg capsules twice daily)
3116842|NCT01776099|Placebo Comparator|pure palatinose|5 grams of palatinose, three times a day with the main meals, duration: 4 weeks
3116799|NCT01776398||1.2 SUBJECTS WITH LUNG DISEASE|Defined by those having lung disease or symptoms of lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population)
3116800|NCT01776398||2. WCMC/NYPH CLINICAL PATIENTS|"Subjects may be recruited if subjects fit inclusion/exclusion criteria and are deemed eligible to participate as long as informed consent is given. Sample collection will occur during a separate study visit.~WCMC/NYPH clinical patients will not undergo any additional procedures listed in this protocol as part of this research study."
3116801|NCT01776398||3. PCNY CLINICAL PATIENTS|Subjects may be recruited if subjects fit inclusion/exclusion criteria and are deemed eligible to participate as long as informed consent is given. Sample collection will occur during a separate study visit. Clinical patients seen at the Pulmonary Consultants of New York will only undergo the nasal sample collection and may be asked to have a blood draw of about 2 teaspoons (9ml).
3116802|NCT01776385|Experimental|Group patients|Patients with Malignant Pleural Mesothelioma (all stages)
3116803|NCT01776385|Placebo Comparator|Control group|Patients with pneumothorax or of benign tumor of the thyroid
3116804|NCT01776372|Active Comparator|Digital thoracic drainage system|Medela Thopaz Thoracic Drainage System
3116805|NCT01776372|Active Comparator|Non-digital thoracic drainage system|Atrium Express Dry Seal Chest Drain
3116806|NCT01776359|Active Comparator|High Protein|High Protein
3116807|NCT01776359|Placebo Comparator|Low Protein|Low Protein
3116808|NCT01776346||Barrett's Esophagus/Esophageal Adenocarcinoma|Patients who have Barrett's esophagus or esophageal adenocarcinoma.
3116809|NCT01776346||Healthy control|
3116810|NCT01776333|No Intervention|usual care|
3116811|NCT01776333|Experimental|video arm|video decision aid intervention
3116812|NCT01776320|Experimental|VITAROS|VITAROS (Alprostadil) 330 ug PRN (as needed) transdermal topical 4-8 weeks
3116813|NCT01776307|Experimental|BBI608 in combination with cetuximab|
3116814|NCT01776307|Experimental|BBI608 in combination with panitumumab|
3116815|NCT01776307|Experimental|BBI608 in combination with capecitabine|
3116816|NCT01776294||prehypertensives|students will be classified as prehypertensives as per the JNC-7 (Joint National Commission) guidelines based on their Blood Pressure measurement
3116817|NCT01776294||normotensives|students will be classed as normotensives based on their BP measurement as per JNC-7 guidelines (systolic <120 AND diastolic <80)
3116818|NCT01776281|Experimental|Kangaroo Mother Care|Other than routine clinical care per hospital policy. Infants will receive skin-to-skin contact for minimum one hour daily during hospital stay and at home till one month.
3116819|NCT01776281|Active Comparator|Standard Care|Routine incubator or cot care with breastfeeding support from nurses as per policy.
3116820|NCT01776268|Experimental|Oral priming|Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
3116821|NCT01776268|No Intervention|No oral priming|No oral priming
3116822|NCT01776255|Experimental|Healthy Children, Strong Families (first)|Healthy Children, Strong Families intervention (first). This is a series of monthly educational tool kits mailed to primary caregivers for use with the participating child. This arm crosses over to receive the Child Safety in Year 2.
3116823|NCT01776255|Active Comparator|Child Safety (first)|A series of 12 monthly newsletters and providing education on child safety mailed to primary caregivers. This Arm crosses over to receive the Healthy Children, Strong Families intervention in Year 2.
3116824|NCT01776229|Experimental|Behavioral|Exposure, Relaxation, & Rescripting Therapy-Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
3116825|NCT01776229|No Intervention|Waitlist Control|All potential participants will be evaluated and some will be randomly placed in the control group, following the five-week treatment phase, participants in the control group will be re-evaluated and offered the treatment
3116826|NCT01776216|Experimental|Dairy diet|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy into their everyday diet.
3116827|NCT01776216|Placebo Comparator|Control diet|During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products into their everyday diet.
3116828|NCT01776203|Active Comparator|medroxyprogesterone acetate|
3116829|NCT01776203|No Intervention|control|
3116830|NCT01776190|Experimental|UVA1 treatment|Low-dose UVA1 will be applied to active cutaneous lupus lesions three times a week for 10 weeks.
3116831|NCT01776177||Continue Therapy Group|Patients who continued to recieve Omalizumab therapy beyond 6 month period
3116832|NCT01776177||Discontinued Therapy group|Patients who discontinued Omalizumab therapy prior to 6 month period from the start of therapy
3116833|NCT01776164||Patient with FRDA|Patients affected by Friedreich's ataxia
3116834|NCT01776164||Healthy controls|Healthy volunteers age- and gender-matched with no neurological disease identified.
3116835|NCT01776138||Bladder Cancer Patients|Patients diagnoses with bladder cancer who are eligible to undergo treatment.
3116836|NCT01776125||Dystrophic Scolisis and NF1|Patients with NF1 diagnosed with dystrophic scoliosis that have been clinically treated will be asked for a cheek swab for genetic testing
3116837|NCT01776125||Non-dystrophic scoliosis and NF1|NF1 patients with non-dystrophic scoliosis that have been treated clinically. will be asked for a cheek swab for genetic testing
3116838|NCT01776112|Experimental|SZ-Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
3116839|NCT01776112|Placebo Comparator|SZ-TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table soccer in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
3116840|NCT01776112|Experimental|HC-Exercise|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
3116841|NCT01776099|Active Comparator|pure galactose|5 grams of galactose, three times a day with the main meals, duration: 4 weeks
3116844|NCT01776099|Active Comparator|non-soluble non-fermentable fibers|5 grams of non-soluble non-fermentable fibers, three times a day with each main meal, duration: 4 weeks
3116845|NCT01776086|Other|Normal patients|for patients with normal score on neurological testing with Folstein Mini-Mental Status Exam will then take the Scenes Task
3116846|NCT01776073|Experimental|Patient navigation|In addition to receiving the standard of care, these patients will be connected with a patient navigator who will provide personalized assistance with regard to completion of the pre-waitlisting process
3116847|NCT01776073|No Intervention|Standard of Care|These patients will receive the standard of care, which includes assistance from the current Emory Transplant Center team of social workers, physicians, and other support staff with regard to completion of the pre-waitlisting process
3116848|NCT01776047|Active Comparator|Exforge® 10/160 (Amlodipine besylate 10mg / Valsartan 160mg)|Exforge® 10/160
3116849|NCT01776047|Experimental|G-0081 (Amlodipine orotate 10mg / Valsratan 160mg)|G-0081
3116850|NCT01776034|Experimental|SystemCHANGE Group Lifestyle counseling|"The SystemCHANGE™ intervention will be delivered over a six-month period involving 12 face-to-face group sessions (1.5 hours each) held weekly for three months, followed by three monthly booster calls. Intervention groups include up to 10 patients, and family is encouraged to attend. Intervention sessions consist of 30-min of behavior change activities and 60-min focused on healthy behaviors."
3116851|NCT01776034|Active Comparator|Phone Lifestyle Counseling|Participants will receive pamphlets that contain information on healthy eating, physical activity, sleep, and symptom management, and will be followed-up with telephone calls.
3116852|NCT01776021|Active Comparator|cranberry juice|cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
3116853|NCT01776021|Placebo Comparator|Placebo|placebo beverage at a dose of one 8 oz. beverage per day for six months
3116854|NCT01776008|Experimental|Treatment (MK2206, anastrozole, goserelin acetate)|Patients receive Akt inhibitor MK-2206 PO on days 2, 9, 16, and 23; anastrozole PO daily on days 1-28; and goserelin acetate SC on day 1 (premenopausal patients only). Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3116855|NCT01775995|Experimental|Meditation-CBT|Participants receiving the meditation-CBT intervention, in addition to usual care for CLBP and opioid therapy management.
3116856|NCT01775995|Other|Wait-list Control|Participants receiving usual care for CLBP and opioid therapy management.
3116857|NCT01775982||Study population|"See inclusion and exclusion criteria.~Intervention: Psychiatric evaluation Intervention: Geriatric evaluation~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
3116858|NCT01775969|No Intervention|Standard of Care|Written discharge instructions only
3116859|NCT01775969|Experimental|Text Message|Written discharge instructions plus a text message with antibiotic prescription instructions
3116860|NCT01775969|Experimental|Voicemail|Written discharge instructions plus a voicemail with antibiotic prescription instructions
3116861|NCT01775930|Experimental|Carfilzomib|Patients receive Carfilzomib at dose of 20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
3116862|NCT01775904|Experimental|LY2886721 Capsule|Reference formulation. A single oral dose of 70 mg LY2886721 in a capsule given with water and without a meal in one of four periods.
3116863|NCT01775904|Experimental|LY2886721 - ODT (no water, fasting)|A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given without water and without a meal in one of four periods.
3116864|NCT01775904|Experimental|LY2886721 - ODT (water, fasting)|A single oral dose of 70 mg LY2886721 in an ODT given with water and without a meal in one of four periods.
3116865|NCT01775904|Experimental|LY2886721 - ODT (water, fed)|A single oral dose of a 70 mg LY2886721 in an ODT given with water and after a high-fat breakfast in one of four periods.
3116866|NCT01775891|Active Comparator|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
3116867|NCT01775891|Placebo Comparator|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
3116868|NCT01775878|No Intervention|Usual Care|This arm received usual care from the diabetes care managers
3116869|NCT01775878|Experimental|Telemonitoring Device|Patients in this arm received a telemonitoring device installed in their homes
3116870|NCT01775865|Experimental|Salsalate|Salsalate capsule 1.5 g/day twice per day by mouth for 4 weeks
3116871|NCT01775865|Placebo Comparator|Placebo|Placebo capsule twice per day by mouth for 4 weeks
3116872|NCT01775865|No Intervention|Young Control|No intervention; Baseline measurements only
3116873|NCT01775852|Active Comparator|ACT-IM|The ACT-IM arm is a brief, one-day intervention that includes two components: 1) Illness Management for Migraine and, 2) Acceptance and Commitment Therapy for emotional difficulties that go along with, or are exacerbated by migraine.
3116874|NCT01775852|No Intervention|Waitlist/Treatment as Usual|The Waitlist/Treatment as Usual (WL/TAU)condition completes the same assessments as the active treatment group but does not undergo the active treatment (workshop) until after the 12-week follow-up visit. At that point, the WL/TAU participants are given the opportunity to join a treatment workshop.
3116875|NCT01775839|Experimental|Aspirin+Clopidogrel/Digoxin(oral)|Aspirin: Day 1 ~ Day 59(~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55
3116876|NCT01775839|Experimental|Aspirin+Clopidogrel/Digoxin(IV)|Aspirin: Day 1 ~ Day 59(~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55
3116877|NCT01775826||Child and adolescent|6-17 years of age
3116878|NCT01775826||Adult|18-55 years of age
3116879|NCT01775826||Older adults|65-85 years of age
3116880|NCT01775813|Experimental|Metformin|Dosage form: Metformin 1000 mg tablets Dosage: 1000 mg by mouth twice daily Duration: From early puberty (Tanner 3-4) until puberty completion (Tanner 5), approximately 3 years
3116881|NCT01775813|Placebo Comparator|Sugar pill|Dosage form: Stamped placebo pill to look like the 1000 mg metformin pill Dosage: 1 pill taken orally twice daily Duration: From early puberty (Tanner 3-4) until puberty completion (Tanner 5), approximately 3 years
3116882|NCT01775800|Experimental|Treatment modification|Patients in this arm will be treated to different targets of blood pressure, parathyroid hormone and serum phosphorus.
3116883|NCT01775800|No Intervention|Usual care|Patients will receive the usual hemodialysis care with no modifications
3116884|NCT01775787|Other|Tobacco Flavor/ Tobacco & Menthol Flavor|"Subjects randomized to Tobacco Flavor group 7-10 days, then crossed over to Tobacco and Menthol Flavor for 7-10 days.~Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor (18mg/mL nicotine)"
3116885|NCT01775787|Other|Tobacco & Menthol Flavor/Tobacco Flavor|"Subjects randomized to Tobacco and Menthol Flavor for 7-10 days,then crossed over to Tobacco Flavor for 7-10 days.~Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor (18mg/mL nicotine)"
3116886|NCT01775774|Experimental|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|A dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 1, 5 and 10 million cells/kg predicted body weight (PBW). Proceed from lower dose to next higher dose if no safety concerns for each cohort.
3116887|NCT01775761|Experimental|Period 1: 960 mg tafamidis (Vyndaqel)|
3116888|NCT01775761|Experimental|Period 2: 400 mg moxifloxacin|400 mg moxifloxacin
3116889|NCT01775761|Experimental|Period 3: Placebo|
3116890|NCT01775748|Other|Active First|Active Concord Grape Juice 12 oz per day Placebo Grape Juice 12 oz per day
3116891|NCT01775748|Other|Placebo First|Placebo Grape Juice 12 oz per day Active Concord Grape Juice 12 oz per day
3116892|NCT01775735|Experimental|Treatment Group A|The treatment device is an occipital nerve stimulator, specifically the BSC Precision™ ONS System
3116893|NCT01775735|Active Comparator|Treatment Group B|The treatment device is on occipital nerve stimulator, specifically the BSC Precision™ ONS System
3116894|NCT01775722|Other|Pulsed Dye Laser|port wine stain treatment using Pulse Dye Laser
3116895|NCT01775722|Experimental|Bipolar Radiofrequency&Pulsed Dye Laser|Port wine stain using Combined Bipolar Radiofrequency&Pulsed Dye Laser
3116896|NCT01775709|Experimental|PE tube with Duckbill Valve|PE tube with Duckbill Valve
3116897|NCT01775696||sporadic AD|80 sporadic AD patients (40 at the stage of MCI, 40 at the stage of mild or moderate dementia)
3116898|NCT01775696||familial forms of AD|15 familial forms of AD caused by APP, PSEN1 or PSEN2 mutations
3116899|NCT01775696||asymptomatic relatives|30 asymptomatic relatives to familial AD patients
3116900|NCT01775696||controls|40 controls
3116901|NCT01775696||genetic FTD|5 genetic forms of FTD
3116902|NCT01775683||Group A - chronically homeless|Men and women, greater than or equal to age 18 years, English-speaking, who are currently homeless and/or housed in an emergency shelter or housing facility for chronically homeless individuals ≥ 6 months.
3116903|NCT01775683||Group B - control/formerly homeless|Men and women, greater than or equal to 18 years, English-speaking who are not homeless ≥4 times in the last 3 years and currently living in stable housing ≥ 6 months and in the last 3 years, has been homeless ≤ 1 month
3116904|NCT01775670|Experimental|Off-the-Shelf Splint|Subjects in this arm will be managed with off-the-shelf splints for TMC arthrosis.
3116905|NCT01775670|Active Comparator|OT Splint|Subjects in this arm will be managed with a custom-made splint made by the Massachusetts General Hospital Occupational Therapists.
3116906|NCT01775657|Experimental|Air leak present - Analogue|Patients randomized to Pleur Evac (Analogue drainage) monitoring system, air leak present.
3116907|NCT01775657|Active Comparator|Air leak absent - Analogue (Pleur Evac)|Patients randomized to Pleur Evac (Analogue drainage) monitoring system, no air leak present
3116908|NCT01775657|Experimental|Air leak present - Digital (Thopaz)|Patients with an air leak present, randomized to Thopaz (digital drainage) monitoring system.
3116909|NCT01775657|Active Comparator|Air leak absent - Digital (Thopaz)|Patients randomized to digital system, no air leak present.
3116910|NCT01775644||Metastatic Colorectal Cancer Participants|"Administration of treatment will be as used in normal daily routine under local labelling in 4 subgroups- participants with liver and/or lung metastases, potentially resectable after a response to a systemic therapy and clinically operable; participants with tumor related symptoms, risks for complications or fast progression for whom quick proliferation control is needed; asymptomatic participants (indolent tumor) without the option of a metastases resection (no pressure for remission) for whom the aim of the therapy is proliferation control and participants without classification."
3116911|NCT01775631|Experimental|Arm -1 - Urelumab + Rituximab|"Urelumab (BMS-663513) flat dose intravenous infusion on specified days~Rituximab intravenous flat dose infusion on specified days"
3116912|NCT01775631|Experimental|Arm 1 - Urelumab + Rituximab|"Urelumab (BMS-663513) flat dose intravenous infusion on specified days~Rituximab intravenous flat dose infusion on specified days"
3116913|NCT01775618|Experimental|BAY94-9027|Patients will receive BAY94-9027 intravenous prophylaxis injection in the main study.
3116914|NCT01775618|Experimental|Expansion group (Part 2)|Patients in expansion group will receive BAY94-9027 intravenous prophylaxis injection in study part 2 .
3116915|NCT01775605|Active Comparator|Synera|Synera Pain Patch
3116916|NCT01775605|No Intervention|No patch control|No intervention group
3116917|NCT01775605|Sham Comparator|Control|Sham
3116918|NCT01775592|Other|Arterakin|"Number of DHA- PPQ (Arterakin™) tablets per day at 0hour, 8hours, 24hours, 48hours (according to age): 2 - 3 years:0.5, 0.5, 0.5, 0.5 3 - < 8 years: 1.0, 1.0, 1.0, 1.0 8 - < 15 years:1.5, 1.5, 1.5, 1.5~≥ 15 years:2.0, 2.0, 2.0, 2.0"
3116919|NCT01775579|Experimental|Crestor tablet 20 mg|Crestor tablet 20 mg single--->wash out---->Glucophage SR tablet 750 mg single---->washout--->Glucophage SR tablet 750 mg, Crestor tablet 20 mg both
3116920|NCT01775579|Experimental|Glucophage SR tablet 750 mg and Crestor tablet 20 mg both|Glucophage SR tablet 750 mg, Crestor tablet 20 mg both--->wash out---->Glucophage SR tablet 750 mg single------>washout--->Crestor tablet 20 mg single
3116921|NCT01775579|Experimental|Glucophage SR tablet 750 mg|Glucophage SR tablet 750 mg single --->wash out---->Crestor tablet 20 mg single---->washout--->Glucophage SR tablet 750 mg, Crestor tablet 20 mg both
3116922|NCT01775566||Eperisone SR tablet 75mg, Myonal 50mg|Eperisone SR tablet 75mg Myonal 50mg
3116923|NCT01775553|Experimental|Carfilzomib|All patients will receive Carfilzomib
3116924|NCT01775540|Experimental|Systane Ultra|Artificial tear Eyedrop, 1 drop used four times a day (QID) for 4 weeks
3116925|NCT01775540|Placebo Comparator|Saline solution|Saline solution Eyedrop, 1 drop used QID for 4 weeks
3116926|NCT01775540|Active Comparator|Maxidex|Steroid eyedrop, 1 drop QID for 4 weeks
3116927|NCT01775527|Other|blood test|
3116928|NCT01775514||Participants With Cancer|Participants from Turkey with non-small cell lung, colon cancer, breast cancer, gastric cancer and malignant melanoma will be included.
3116929|NCT01775501|Experimental|Experimental Treatment Arm|FOLFOX (Leucovorin, Fluorouracil and Oxaliplatin) + Sorafenib Sorafenib: orally, twice daily FOLFOX: injected via portacath once every two weeks
3116930|NCT01775488|Experimental|Vortx Rx - Histotripsy BPH Device|The Vortx Rx, is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.
3116931|NCT01775475|Active Comparator|Arm I (CHOP)|Patients receive CHOP chemotherapy comprising cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3116932|NCT01775475|Experimental|Arm II (oral chemotherapy)|Patients receive lomustine PO QD on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3116933|NCT01775462|Experimental|EDI200, 3mg/kg|Five doses of EDI200 given at 3 mg/kg twice weekly
3116934|NCT01775462|Experimental|EDI200, 10 mg/kg|Five doses of EDI200 given at 10 mg/kg twice weekly
3116935|NCT01775449|Experimental|polyamines depleted diet|• in the group with a polyamines depleted diet : 2-4 cans per day of Polydol® (oral alimentation without polyamines), associated to predefined menus low in polyamines, according to the chemotherapy cycle and for 107 days
3116936|NCT01775449|Other|normal polyamines containing diet|• in the control group with a normal polyamines containing diet: 1 can per day of Polydol® associated with predefined menus with normal average in polyamines and for 107 days.
3116937|NCT01775436|Active Comparator|Healthy Living Control|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Developmental History: Goal: To take a non-medical developmental history. The Research Assistant (RA)-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention."
3116938|NCT01775436|Experimental|FAmily-CEntered Advance Care Planning|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care & prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have."
3116939|NCT01775423|Experimental|BBI608|
3116940|NCT01775410|Experimental|Interventional|Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries
3116941|NCT01775397|Experimental|Fidaxomicin|Fidaxomicin with alternating matching placebo
3116942|NCT01775397|Active Comparator|Vancomycin|
3116943|NCT01775384|Experimental|Nutrasorb|Soy protein powder sorbed with polyphenols from blueberries and green tea extract
3116944|NCT01775384|Placebo Comparator|Placebo|Soy protein isolate powder without polyphenols (with food coloring)
3116945|NCT01775371|Experimental|Patient Controlled Analgesia|PCA (loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes)
3116946|NCT01775371|Active Comparator|Usual Care|Usual opioid analgesia determined by the provider
3116947|NCT01775358|Experimental|ALRN-5281 0.015 mg/kg|Dosage-0.015 mg/kg
3116948|NCT01775358|Experimental|ALRN-5281 0.05 mg/kg|Dosage- 0.05 mg/kg
3116949|NCT01775358|Experimental|ALRN-5281 0.15 mg/kg|Dosage- 0.15 mg/kg
3116950|NCT01775358|Placebo Comparator|Placebo 0.015 mg/kg|Dosage- 0.015 mg/kg
3116951|NCT01775358|Placebo Comparator|Placebo 0.05 mg/kg|Dosage- 0.05 mg/kg
3116952|NCT01775358|Placebo Comparator|Placebo 0.15 mg/kg|Dosage - 0.15 mg/kg
3116953|NCT01775345|Experimental|Isotonic exercises + ST|"This group will realize 20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a maximum repetition (MR)(MR is the maximum resistance that a muscle can conquer).~Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR."
3116954|NCT01775345|Experimental|Isokinetic exercises + ST|This group will realize 20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
3116955|NCT01775345|Experimental|Isotonic and isokinetic exercises + ST|This group will realize 20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
3116956|NCT01775332|Experimental|Educational Intervention|Educational Intervention - Access to educational materials provided (i.e. website, videos, brochure)
3116957|NCT01775332|No Intervention|No Intervention/Use of Own Resources|No educational materials are provided to participants, but they can use their own resources
3116958|NCT01775319|Active Comparator|Biofortified wheat|Biofortified wheat
3116959|NCT01775319|Placebo Comparator|Control wheat|Control wheat with low level of Zn
3116960|NCT01775319|Active Comparator|Fortified wheat|Wheat fortified before consumption
3116961|NCT01775293|Experimental|Non-absorbable polypropylene mesh|"2 step procedures~first step is insertion of Non-absorbable polypropylene mesh under the facial skin~second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step"
3116962|NCT01775280|Experimental|Radioembolization|Radioembolization using Yttrium-90 microspheres using a transarterial approach
3116963|NCT01775267|Experimental|ALPPS|Patients undergo Liver partition and portal vein ligation to induce hypertrophy of the future liver remnant
3116964|NCT01775267|Active Comparator|PVO|Patient undergo portal vein embolization or ligation
3116965|NCT01775254||Open Resection Group|Colon cancer survivors who undergo open surgical resection of their colon cancers.
3116966|NCT01775254||Laparoscopic Resection Group|Colon cancer survivors who undergo laparoscopic resection of their colon cancer
3116967|NCT01775254||Robotic Resection Group|Colon cancer survivors who undergo robotic resection of their colon cancer.
3116968|NCT01775228|No Intervention|Regular follow up care|No intervention group - received routine follow up care following discharge from hospital after cardiac surgery (no peer support intervention).
3116969|NCT01775228|Active Comparator|Peer Support intervention|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
3116970|NCT01775215||A - Symptomatic severe AS|Patients with symptomatic severe aortic stenosis (AS) as per ESC guidelines, requiring aortic valve replacement.
3116971|NCT01775215||B - Asymptomatic moderate to severe AS|Asymptomatic patients with moderate to severe aortic stenosis (AS) as per ESC guidelines ,with Left Ventricular ejection fraction >50%, not yet requiring aortic valve replacement.
3116972|NCT01775189|Placebo Comparator|Treatment A|
3116973|NCT01775189|Experimental|Treatment B|
3116974|NCT01775189|Placebo Comparator|Treatment C|
3116975|NCT01775189|Active Comparator|Treatment D|
3116976|NCT01775176|No Intervention|Control|Control subjects recieve no intervention for diet, exercise or metformin and are asked to adhere to usual behaviors throughout the trial.
3116977|NCT01775176|Experimental|Metformin|1000mg BID
3116978|NCT01775176|Experimental|Dietary Restriction|25% dietary restriction
3116979|NCT01775176|Experimental|Exercise|10 kcal/kg/week in exercise energy expenditure. 3 x resistance training sessions per week (8 exercises)
3116980|NCT01775163||Self Directed Exercise|Participants randomized to the self-directed group will receive information on physical activity recommendations and guidelines on nutrition aimed at promoting weight loss. Participants will not be given a specific exercise recommendation in terms of weekly energy expenditure.
3116981|NCT01775163||Low Intensity Exercise|Individuals assigned to the low dose exercise group will be required to expend 8 calories per kg of body weight per week in structured aerobic exercise on a treadmill or stationary bicycle. The exercise intensity will be maintained at 65% of VO2peak. The caloric goal of each session will be calculated by dividing the weekly caloric expenditure goal by participant selected exercise frequency (i.e., 3, 4 or 5 times per week). The training program consists of a 3-min warm-up at a progressively increasing intensity until the prescribed training intensity is reached. All exercise sessions are conducted at the PBRC Fitness Center and will be supervised by staff trained on the aspects of the study protocol.
3116982|NCT01775163||High Intensity Exercise|Individuals assigned to the low dose exercise group will be required to expend 20 calories per kg of body weight per week in structured aerobic exercise on a treadmill or stationary bicycle. The exercise intensity will be maintained at 65% of VO2peak. The caloric goal of each session will be calculated by dividing the weekly caloric expenditure goal by participant selected exercise frequency (i.e., 3, 4 or 5 times per week). The training program consists of a 3-min warm-up at a progressively increasing intensity until the prescribed training intensity is reached. All exercise sessions are conducted at the PBRC Fitness Center and will be supervised by staff trained on the aspects of the study protocol.
3116983|NCT01775150|Experimental|health education|health education via text messaging
3116984|NCT01775150|No Intervention|no health education|no health education via text messaging
3116985|NCT01775137|Experimental|TBM100|TIP 112 mg/b.i.d
3116986|NCT01775124|Experimental|Ranibizumab 0.5 mg monthly|Monthly intravitreal injections of ranibizumab 0.5 mg in the core treatment period and PRN intravitreal injections of the same dose guided by best-corrected visual acuity (BCVA) stabilization in the extension treatment period
3116987|NCT01775124|Experimental|Ranibizumab 0.5 mg pro re nata (PRN)|PRN intravitreal injections of ranibizumab 0.5 mg guided by best-corrected visual acuity (BCVA) stabilization in the 23 month treatment period
3116988|NCT01775111|Sham Comparator|Cognitive Training|Cognitive Training (riddles, skill games, ...) is performed twice a week in small groups
3116989|NCT01775111|Experimental|Strength Training|Progressive strength training is applied, meaning that the intensity is adjusted continuously in order to obtain a sufficient training stimulus. Exercises are chosen to involve the major muscle groups and are performed by using the own body weight or elastic bands.
3116990|NCT01775111|Experimental|Strength Training and Supplement|In addition to strength training as described above, participants receive a water-soluble dietary supplement 9x/week (FortiFit, Nutricia) consisting of 20.7 g of protein (56 En%, 19.7 g whey protein, 3 g leucine,> 10 g essential amino acids), 9.3 g carbohydrates (25 En%, 0.8 BE), 3.0 g fat (18 En%), 1.2 g fiber (2 En%), 800 IU (20μg) of vitamin D, 250mg calcium, vitamins B6 and B12, folic acid and magnesium.
3116991|NCT01775098|Experimental|Allopurinol|treatment with allopurinol
3116992|NCT01775098|Placebo Comparator|placebo|placebo comparator
3116993|NCT01775085|Experimental|Meaning-Centered Group for Breast Cancer Survivors (MCG-BCS)|
3116994|NCT01775085|Active Comparator|Discussion Group (DG)|
3116995|NCT01775072||Pts with solid tumors|Patients must have solid or hematologic cancer. for treatment on a . Patients must have undergone pathologic confirmation of their tumor at MSKCC and have either: 1) archival tissue available for analysis, 2) have fresh tissue collection planned as routine standard of care biopsy or part of a research biopsy under another clinical trial(or peripheral blood / bone marrow collection in the case of hematologic cancers) outside of the context of this protocol, or 3)archival tissue .available at an outside facility. For prospective genotyping tissue specimens from the primary site, a metastasis or recurrence will be used based upon the availability and quality of tissue.
3116996|NCT01775059|Experimental|Integrated sensor and infusion set.|
3116997|NCT01775046||DTA patients|160 patients presenting with a disease of descending thoracic aorta(DTA)with an indication for endovascular treatment with Valiant Thoracic Stent Graft with the Captivia Delivery System and who meet the inclusion/exclusion criteria are intended to participate in this non-interventional.
3116998|NCT01775033|Experimental|Multicomponent intervention|Hospitals in the experimental arm will receive a four-component intervention that integrates local education, community outreach, telemedicine and protocolized triage and transport
3116999|NCT01775033|No Intervention|Control|Hospitals in the control arm will receive usual care.
3117000|NCT01775020|Experimental|L-arginine|L-arginine
3117001|NCT01775007|Experimental|Normal Healthy Subjects|Brillouin Ocular Analyser
3117002|NCT01774994|Experimental|stable isotopes|stable isotope infusion for measurement of metabolism
3117003|NCT01774981|Placebo Comparator|Placebo (Part A)|Part A: Placebo administered by 60 minute Intravenous (IV) infusion at Week 1 and Week 4.
3117004|NCT01774981|Experimental|10 mg LY3016859 (Part A)|Part A: 10 milligram (mg) LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
3117005|NCT01774981|Experimental|100 mg LY3016859 (Part A)|Part A: 100 mg LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
3117006|NCT01774981|Experimental|750 mg LY3016859 (Part A)|Part A: 750 mg LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
3117007|NCT01774981|Placebo Comparator|Placebo (Part B)|Part B: Placebo administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
3117008|NCT01774981|Experimental|50 mg LY3016859 (Part B)|Part B: 50 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
3117009|NCT01774981|Experimental|250 mg LY3016859 (Part B)|Part B: 250 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
3117010|NCT01774981|Experimental|750 mg LY3016859 (Part B)|Part B: 750 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
3117011|NCT01774968|Experimental|Human Regular U-500 Insulin TID|Human Regular U-500 Insulin (U-500R) titrated based on blood glucose readings, administered subcutaneously (SC), three times a day (TID) for 24 weeks.
3117012|NCT01774968|Experimental|Human Regular U-500 Insulin BID|U-500R Insulin titrated based on blood glucose readings, administered SC, two times a day (BID) for 24 weeks.
3117013|NCT01774942|Experimental|All teeth out, full dentures, dental implants, blood draw|
3117014|NCT01774929|Experimental|Transdermal Therapeutic System (TTS)-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
3117015|NCT01774916|Other|patients|
3117016|NCT01774916|Other|volunter|
3117017|NCT01774903|Experimental|TTS-fentanyl|
3117018|NCT01774877|Experimental|Xinfeng capsule & placebo|"Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months~placebo(for leflunomide): 10 mg each time, 1 time a day, Oral,for3 months"
3117019|NCT01774877|Active Comparator|leflunomide & placebo|"leflunomide :10mg each time, one time a day, by mouth,for 3 months~placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for3 months"
3117020|NCT01774864|Experimental|DA-8159 dose 1|Udenafil
3117021|NCT01774864|Experimental|DA-8159 dose 2|Udenafil
3117022|NCT01774864|Placebo Comparator|Placebo|
3117023|NCT01774851|Experimental|Arm 1a|MM-111 + Paclitaxel + Trastuzumab
3117024|NCT01774851|Active Comparator|Arm 1b|Paclitaxel + Trastuzumab
3117025|NCT01774838|Experimental|Prasugrel|3 months treatment with 10 mg prasugrel
3117026|NCT01774838|Active Comparator|Clopidogrel|3 months treatment with clopidogrel 75 mg
3117027|NCT01774825|Active Comparator|IQP-CL-101|2 softgels twice a day
3117028|NCT01774825|Placebo Comparator|Placebo|2 softgels twice a day
3117029|NCT01774812|Active Comparator|Vitamin D Sequence 1|6 weeks - alfacalcidol 0.25mcg + placebo 3x per week, 12 week washout, 6 weeks - alfacalcidol 0.25mcg 3x per week + 50,000IU ergocalciferol 1x per week (placebo the 2 remaining days)
3117030|NCT01774812|Active Comparator|Vitamin D Treatment Sequence 2|6 weeks - alfacalcidol 0.25mcg 3x per week + 50,000IU ergocalciferol 1x per week (placebo the 2 remaining days), 12 week washout, 6 weeks - alfacalcidol 0.25mcg + placebo 3x per week
3117031|NCT01774799|Experimental|Advance care planning intervention|At baseline, health care proxies in the intervention arm will be shown a 12-minute Advance Care planning video that describes 3 levels of treatment in advanced dementia: comfort basic and intensive. After viewing the video, the proxies will be asked their preferred level of care for the resident and this choice will be communicated to the residents primary care team in a written form.
3117032|NCT01774799|Active Comparator|Usual care|Residents in control nursing homes with receive the usual advance care planning that occurs in their nursing home.
3117033|NCT01774786|Experimental|Pertuzumab + Trastuzumab + Chemotherapy|Participants will receive pertuzumab in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine [capecitabine or 5-fluorouracil]) for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive pertuzumab and trastuzumab until disease progression occurrence of unacceptable toxicity or withdrawal from the study for another reason.
3117034|NCT01774786|Placebo Comparator|Placebo + Trastuzumab + Chemotherapy|Participants will receive pertuzumab placebo in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine [capecitabine or 5-fluorouracil]) for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive pertuzumab placebo and trastuzumab until disease progression occurrence of unacceptable toxicity or withdrawal from the study for another reason.
3117035|NCT01774773|Experimental|Group A|E5501 5mg, then 20mg, then 40 mg, then 5mg
3117036|NCT01774773|Experimental|Group B|E5501 20mg, then 40mg, then 5 mg, then 5mg
3117037|NCT01774773|Experimental|Group C|E5501 40mg, then 5mg, then 20 mg, then 5mg
3117038|NCT01774760|Experimental|18F-EF5 PET/CT scan|
3117039|NCT01774747|Experimental|DSP-1053|DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
3117040|NCT01774747|Placebo Comparator|Placebo|Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
3117041|NCT01774734|Experimental|neck strength exerciser (NSE) group|Traditional physiotherapy 30 minutes per session for three times weekly + home-based NSE training 20 minutes daily
3117042|NCT01774734|Placebo Comparator|Physical therapy group|Traditional physiotherapy 30 minutes per session for three times weekly + home-based general neck exercise 20 minutes daily
3117043|NCT01774721|Experimental|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing.
3117044|NCT01774721|Active Comparator|gefitinib|Gefitinib is provided as 250 mg tablets, continuous oral daily dosing.
3117045|NCT01774708||Bed Exit|"Participants will be up to 60 ambulatory Budd Terrace residents.~Inclusion/Exclusion:~Inclusion:~Ambulatory patient able to leave the bed.~Willingness to consent and participate in a 30-night study~Exclusion:~Lack of capacity to consent, without an identifiable surrogate.~Terminal Prognosis~Unstable health, as determined by the principal investigator, medical doctor, or registered nurse."
3117046|NCT01774695|Other|Control and intervention|In the first study half of the subjects first served as controls for 12 weeks and then they went through the intervention. The other half only went through the intervention.
3117047|NCT01774682|Other|6-minute walk test|the 6-minute walk test is performed for each patient prior to the surgery and 6 months after by a specialist.
3117048|NCT01774669|Experimental|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each.
3117049|NCT01774669|Active Comparator|Conventional therapy|Patients in the control group (CG) will receive 16 therapy sessions (physiotherapy or occupational therapy) lasting for 45 minutes each.
3117050|NCT01774656|Experimental|HeartMate II plus Pharmacological Treat|"The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.~The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily."
3117051|NCT01774643||Pancreatic cancer with liver metastases|Tumor tissue biopsy, blood samples
3117052|NCT01774630|Experimental|Nilotinib|300 mg/twice a day
3117053|NCT01774617|Other|whole sample|
3117054|NCT01774604|Experimental|Indomethacin|Indomethacin 100 mg Per Rectum (PR) x 1 in peri-procedural period
3117055|NCT01774604|Placebo Comparator|Placebo|Placebo suppositories (#2)
3117056|NCT01774591|Active Comparator|azilsartan medoximil.|Subjects randomized to azilsartan medoximil arm will take 80 mg of azilsartan medoximil tablets by mouth each day.
3117057|NCT01774591|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will take 80 mg of placebo tablets by mouth each day
3117058|NCT01774578|Active Comparator|Arm 1: Docetaxel|"Arm 1: Docetaxel 75 mg/m^2 IV given every 3 weeks x 4 doses. If response or stable: Observe until disease progression.~First Progression: Gemcitabine 1250 mg/m^2/week for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity."
3117059|NCT01774578|Experimental|Arm 2a: HyperAcute®-Lung Immunotherapy (weekly)|"Arm 2a: 300 Million HAL cells given by intradermal injection weekly for 11 weeks and then every 2 months for 5 additional doses.~Up to 16 total immunizations of 300 million immunotherapy cells until disease progression or toxicity.~First Progression: Docetaxel 75 mg/m^2 IV given every 3 weeks or Gemcitabine 1250 mg/m^2 for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity and continue with HAL administration given every 2 weeks (not to exceed 16 total immunizations)."
3117060|NCT01774578|Experimental|Arm 2b: HyperAcute®-Lung Immunotherapy (biweekly)|"Arm 2b: 300 Million HAL cells given by intradermal injection biweekly for 6 doses and then every month for 10 additional doses.~Up to 16 total immunizations of 300 million immunotherapy cells until disease progression or toxicity.~First Progression: Docetaxel 75 mg/m^2 IV given every 3 weeks or Gemcitabine 1250 mg/m^2 for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity and continue with HAL administration given every 2 weeks (not to exceed 16 total immunizations)."
3117061|NCT01774565|Experimental|Fully Automated Closed-Loop Insulin Delivery|The control algorithm will automatically direct between meals and meal-related subcutaneous insulin delivery utilizing real-time continuous glucose monitoring (RT-CGM) data. The subcutaneous insulin pump will deliver insulin Aspart or similar. In phase 1, a once daily basal insulin analogue will also be given subcutaneously at 20% the patient's usual total daily dose.
3117062|NCT01774565|Active Comparator|Conventional insulin therapy|During the conventional therapy, subject's insulin dose and regimen on admission will be adjusted as necessary by the clinical team according to local centres' usual clinical practice. Subjects will have masked CGM sensors inserted during the study (CGM readings will be masked throughout the study).
3117063|NCT01774552||Port-wine stain|Photo Acoustic Microscopy and Optical Coherence tomography
3117064|NCT01774539||Physeal Injury - Distal Radius|Patients who suffer a physeal fracture of the distal radius will be scanned and compared to their healthy contralateral limb.
3117065|NCT01774513|Experimental|Procore Needle|
3117066|NCT01774487|Experimental|Pentoxifylline|"All newly-diagnosed biliary atresia patients fulfilling the study's inclusion criteria will receive oral pentoxifylline, 20 mg/kg/day divided in three doses for a total of 90 days.~The hospital pharmacy will create a 20 mg/ml oral pentoxifylline solution using 400 mg pentoxifylline tablets and established compounding recipes."
3117067|NCT01774474|Active Comparator|Non diabetics: bromfenac|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperatively
3117068|NCT01774474|Active Comparator|Non diabetics: dexamethasone|dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
3117069|NCT01774474|Active Comparator|Non diabetics: bromfenac & dexamethasone|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
3117070|NCT01774474|Active Comparator|Diabetics: eye drops|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
3117071|NCT01774474|Active Comparator|Diabetics: eye drops & TA|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~& a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA, Triesence/Vistrec)"
3117072|NCT01774474|Active Comparator|Diabetics: eye drops & bevacizumab|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~& a peroperative intravitreal injection of 1.25 mg bevacizumab (Avastin)"
3117073|NCT01774474|Active Comparator|Diabetics: eye drops, TA & bevacizumab|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative, dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~& a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA)~& a peroperative intravitreal injection of 1.25 mg bevacizumab"
3117074|NCT01774461|No Intervention|Sham RIC|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
3117075|NCT01774461|Active Comparator|Remote ischemic conditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
3117076|NCT01774448|No Intervention|Waitlist Control|Participants in the control group will undergo a non-intervention 8-week period while on the 'waitlist control' then will be crossed-over to the Mindfulness-Based Cognitive Therapy intervention.
3117077|NCT01774448|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy is an 8-week intervention, one session per week for 2 hours, where participants will learn and practice formal and informal mindfulness meditation, and participate in group discussion and inquiry.
3117078|NCT01774435|Experimental|EN3342|EN3342 (risperidone) subcutaneous implant
3117079|NCT01774422|Experimental|noninvasive ventilation alone|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~Noninvasive ventilation alone~Noninvasive ventilation associated with the DECAP CO2 device"
3117080|NCT01774422|Other|noninvasive ventilation associated with the DECAP CO2 device|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~Noninvasive ventilation alone~Noninvasive ventilation associated with the DECAP CO2 device"
3117081|NCT01774409|Experimental|Blood and tumor samples|
3117082|NCT01774396|Other|group 2|The intervention will be the injection of Emervel® Volume Lidocaine alone in the dorsa of one hand and Emervel® Deep Lidocaine alone in the dorsa of the contralateral hand.
3117083|NCT01774396|Experimental|group 1|EThe intervention will be the injection of mervel® Volume Lidocaine plus Emervel® Touch in the dorsa of one hand and Emervel® Deep Lidocaine plus Emervel® Touch in the dorsa of the contralateral hand
3117084|NCT01774370||Pradaxa group|
3117085|NCT01774344|Experimental|Regorafenib|160 mg orally (p.o.) every day (qd) for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC (Best Supportive Care)
3117086|NCT01774344|Placebo Comparator|Placebo|4 matching placebo tablets for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC
3117087|NCT01774331||Immunoglobulin Therapy|Immunoglobulin Therapy
3117088|NCT01774318|Other|preterm cohort|preterm infants born at medical university of vienna and born at gestational age 23+0 - 28+6 weeks of gestation intervention: aEEG and conventional EEG measurements will be performed every two weeks untill 36 weeks of gestation
3117089|NCT01774305|Experimental|dexmedetomidine|We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously, for 10 min) at time of muscle layer closing.
3117090|NCT01774305|Placebo Comparator|saline|We administrate the saline single bolus (0.25ml/kg,intravenously, for 10 min) at time of muscle layer closing.
3117091|NCT01774292|Active Comparator|Alkalized lidocaine|160 mg of 4% lidocaine (4 ml) in the endotracheal cuff and add bicarbonate 8,4% until appropriate seal.
3117092|NCT01774292|Placebo Comparator|Sterile saline|4 mL of sterile saline in the endotracheal cuff and add bicarbonate 8,4% until appropriate seal.
3117093|NCT01774279||anaplastic thyroid cancer|
3117094|NCT01774266||Molina - Chile|Molina is one of the counties with the highest mortality rate of gastric cancer in Chile. Molina has a population of 40.000 hab mostly rural. Half of the population lives in Molina city and the other half in the suburbs. Molina is located near the Mountain Andes.
3117095|NCT01774253|Experimental|Vismodegib|Vismodegib will be dosed at 150mg-300mg orally (max dose: 300mg) once a day on days 1 to 28 of a 28-day cycle. In the absence of unacceptable toxicity or disease progression, treatment may continue for as long as tolerated.
3117096|NCT01774240|No Intervention|before|no systematic approach
3117097|NCT01774240|Experimental|after|systematic screening and treatment of delirium
3117098|NCT01774227|Experimental|The pops-titration group|"The titration method uses power that is titrated according to the audible pop."
3117099|NCT01774227|Experimental|The slow-coagulation group|The slow-coagulation group utilize the low-energy using the Gaasterland's slow-coagulation technique
3117133|NCT01773980||Patient and Clinic Intervention|"The patient intervention consists of a single 90-minute interactive in-person session.~The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff."
3117100|NCT01774214|Experimental|A|"As this is a crossover trial, the study arms denote the order in which the two interventions are performed by the subject. In Arm A, subjects will perform the Push-Pull Technique of manual fluid resuscitation first, followed by the Disconnect-Reconnect Technique second. A washout period of at least 30 minutes between each of the two interventions will be observed."
3117101|NCT01774214|Experimental|B|"As this is a crossover trial, the study arms denote the order in which the two interventions are performed by the subject. In Arm B, subjects will perform the Disconnect-Reconnect Technique of manual fluid resuscitation first, followed by the Push-Pull Technique second. A washout period of at least 30 minutes between each of the two interventions will be observed."
3117102|NCT01774201|Experimental|Breathing exercises|Daily deep breathing exercises during two month
3117103|NCT01774201|No Intervention|Control|Control group
3117104|NCT01774188||Intraocular pressure, EECP, no glaucoma|To examine no glaucoma patients' intraocular pressure before and after the treatment of Enhanced Extracorporeal Counterpulsation. EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks
3117105|NCT01774188||intraocular pressure, EECP, glaucoma|To examine glaucoma patients' intraocular pressure before and after the treatment of Enhanced Extracorporeal Counterpulsation. EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks.
3117106|NCT01774175||Coolprep|A total of 2L A : NaCl 5.382g KCl 2.03g Sodium sulfate 15g Polyethylene glycol 3350 200.0g B : Ascorbic acid 9.4g Sodium ascorbate 11.8g
3117107|NCT01774175||Picolyte|Sodium picosulfate 30.0mg Magnesium citrate 10.5g + 36.0g
3117108|NCT01774162|Active Comparator|FNA for cytology|Fine needle aspiration using conventional FNA for cytology
3117109|NCT01774162|Experimental|FNB core biopsy for histology|Fine needle biopsy using ProCore needle for histology.
3117110|NCT01774149|Active Comparator|Delayed Diastat|Mobile phone application Few Touch Application (FTA) in the regular version, with Diastat turned on in week 12 post-enrollment.
3117111|NCT01774149|Experimental|Diastat|Few Touch Application with Diastat module turned on in week 4 post-enrollment.
3117112|NCT01774136|Experimental|Enhanced HIV and MCH training for CHW|The intervention includes two components: (1) a 2-week HIV/C-IMCI training for CCGs and their associated facilitators and supervisors, and (2) continuous support and supervision following the continuous quality improvement (CQI) framework, a low-technology approach to management and supervision of health programs.
3117113|NCT01774136|No Intervention|Standard of Care|
3117114|NCT01774123||Healthy|Healthy controls
3117115|NCT01774123||MS-ON|Multiple sclerosis with optic neuritis
3117116|NCT01774123||MS-NON|Multiple sclerosis without optic neuritis
3117117|NCT01774110|Experimental|early standardized task training|Persons in the experimental group will receive ESTT (early standardized task specific training) for gait treatment after stroke.
3117118|NCT01774097|Experimental|ALD-301|Participants will receive ALD-301 via intramuscular injection
3117119|NCT01774097|Placebo Comparator|Placebo (vehicle)|Participants will receive placebo (vehicle)via intramuscular injection
3117120|NCT01774084|Active Comparator|PreOp, NutriciaNordica AB|PreOp: 50 kcal/100 mL in the form of maltodextrin and fructose. One bottle of 800 ml to be ingested at bedtime, and at midnight by the latest, and another bottle with 400 ml approximately 2 hours before surgery started.
3117121|NCT01774084|Placebo Comparator|Water|Water: One bottle of 800 ml to be ingested at bedtime, and at midnight by the latest, and another bottle with 400 ml approximately 2 hours before surgery started.
3117122|NCT01774071|Experimental|89Zr DFOMSTP2109A tracer Group 1|The first group of participants will include 6 participants whom will receive 10mg of 89Zr-DFO-MSTP2109A. A second group of 6 participants may receive twice the amount of antibody to determine if this results in better pictures of your tumors. Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2.
3117123|NCT01774071|Experimental|89Zr-DFO-MSTP2109A tracer Group 2|Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2. Group 2 will include up to 15 participants whom may receive a dose of up to 20mg.
3117124|NCT01774058|Experimental|Ilomedin, bloodflow volume, measurement,|Surgery was performed under general anesthesia via a longitudinal skin incision. After systemic administration of 5000 IU of unfractionated Heparin, the peripheral vessels were clamped. Following a longitudinal arteriotomy, thrombendarterectomy of the common femoral artery was performed in all cases, extending into the deep femoral artery and superficial femoral artery when necessary. At the end of the reconstruction, 3000 ng of iloprost (Ilomedin), diluted in 15ml saline solution, were administered into the common femoral artery. Distal to the injection site doppler flow measurement was performed at the common femoral artery prior to arteriotomy, prior to the intraarterial application of iloprost and 5 and 10 minutes afterwards, using the Sono TT FlowLab instrument. During the procedure, systemic arterial blood pressure was continuously documented using a pressure transducer connected to an intraarterial cannula placed in the radial artery of the forearm.
3117125|NCT01774045|Experimental|PDC-1421|Dosage form: 380mg PDC-1421 per Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days.
3117126|NCT01774045|Placebo Comparator|Placebo control|Dosage form: Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days.
3117127|NCT01774032|Experimental|Influenza Vaccine|One dose of the vaccine will be administered at a volume of 0.5 mL by intramuscular injection into the musculus deltoideus in the upper arm on Day 1 and 22.
3117128|NCT01774019|Active Comparator|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|Patients in this group will receive a fully covered or uncovered study SEMS (self-expanding metal stent)
3117129|NCT01774019|No Intervention|None (No Pre-Operative Biliary Drainage)|Patients in this group will not receive pre-operative biliary drainage with a study SEMS
3117130|NCT01774006||Group culture|Embryos cultured in groups of 2-10
3117131|NCT01774006||Individual culture|Embryos cultured individually
3117132|NCT01773993||Pregabalin|Subjects who are treated with pregabalin
3117134|NCT01773980||Patient Intervention Only|The patient intervention consists of a single 90-minute interactive in-person session.
3117135|NCT01773980||Clinic Intervention Only|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
3117136|NCT01773980||Neither Clinic nor Patient Intervention|Consists of no intervention
3117137|NCT01773967|Experimental|LGG|LGG 10^10 cfu PO bid x 5 days
3117138|NCT01773967|Placebo Comparator|Placebo|micro-crystalline cellulose PO bid x 5 days
3117139|NCT01773954|Experimental|Intravitreal Aflibercept Injection More|Patient receives treatment at baseline and week 4 visit. The first time extension criteria are met the follow-up interval will be increased by 4 weeks. Each time the extension criteria is met the interval will be extended by 2 weeks to a maximum of 16 weeks. If a patient is being followed at an 8 week interval but fails to meet extension criteria at a particular visit, treatment will be administered as usual and the follow up interval will be reduced to 4 weeks. If patient is being followed at 10-16 week interval but fails to meet extension criteria at a particular visit, treatment will be administered but the follow-up interval will be reduced by 2 week increments.
3117140|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 1|Vero cell-derived trivalent influenza vaccine (VCIV)
3117141|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 2|Vero cell-derived trivalent influenza vaccine (VCIV)
3117142|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 3|Vero cell-derived trivalent influenza vaccine (VCIV)
3117143|NCT01773928|Active Comparator|VCIV manufactured with current process (18-49 Years Old)|Vero cell-derived trivalent influenza vaccine (VCIV)
3117144|NCT01773928|Active Comparator|Fluzone® (18-49 Years Old)|Fluzone®, licensed trivalent influenza vaccine (TIV)
3117145|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 1|Vero cell-derived trivalent influenza vaccine (VCIV)
3117146|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 2|Vero cell-derived trivalent influenza vaccine (VCIV)
3117147|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 3|Vero cell-derived trivalent influenza vaccine (VCIV)
3117148|NCT01773928|Active Comparator|Fluzone® (≥50 Years Old)|Fluzone®, licensed trivalent influenza vaccine (TIV)
3117149|NCT01773915||AD patients|Subject fulfilling the McKhann criteria for clinical probable AD
3117150|NCT01773915||Healthy elder persons|Healthy controls with abscence of any cognitive disorder
3117151|NCT01773902|Experimental|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if <1500g b.w. or 4.0g/kg/d of enteral protein if >1500g b.w. until 1 week before discharge
3117152|NCT01773902|Experimental|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
3117153|NCT01773902|Active Comparator|Standard protein supplementation|Protein supplementation independent of individual breast milk content using a standard dose of a standard breast milk fortifier until 1 week before discharge
3117154|NCT01773889|Experimental|Denileukin Diftitox/SC Pegylated IFNα-2A|Administration of Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A
3117155|NCT01773876|Active Comparator|Micafungin|MYCAMINE 100 mg intravenous an injection of 24 hours
3117156|NCT01773876|Placebo Comparator|PLACEBO|0.9% sodium chlorides 100ml infusion
3117157|NCT01773850||Patients|Patients with a breast lesion undergoing surgical biopsy. All patients will undergo stationary Carbon Nanotube x-ray digital breast tomosynthesis imaging in addition to routine conventional digital mammography.
3117158|NCT01773837|Experimental|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
3117159|NCT01773837|Placebo Comparator|placebo|the same number of pills (p.o.) than methylphenidate for six days
3117160|NCT01773824|Other|No feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial).
3117161|NCT01773824|Experimental|Antibiotic prescription feedback|Physicians receive quarterly electronic feedback on their antibiotic prescriptions
3117162|NCT01773811|No Intervention|Control|Individuals will write objectively about the events of their day.
3117163|NCT01773811|Experimental|Narrative Writing: Trauma-Assigned|Trauma-assigned: Individuals will write about their most traumatic life experience and be instructed to continue to think about their writing topic in the weeks following writing.
3117164|NCT01773811|Active Comparator|Narrative Writing: Trauma-Spontaneous|Individuals will write about their most traumatic life experience but will not be given further instructions for processing. Any additional processing about their writing topic in the weeks following writing will be considered spontaneous.
3117165|NCT01773798|Experimental|IDegAsp 15|
3117166|NCT01773798|Experimental|IDegAsp|
3117167|NCT01773798|Experimental|IDeg|
3117168|NCT01773798|Active Comparator|IAsp|
3117169|NCT01773798|Experimental|IDeg + IAsp|
3117170|NCT01773785|Experimental|SPI-1620 & Docetaxel|"SPI-1620 11 μg/m2 will be given intravenously over 1 minute.~Docetaxel 75 mg/m2 infusion will be administered per standard of care 10 (±2) minutes after SPI-1620."
3117171|NCT01773772|Experimental|Progesterone|Subjects will take 25-50 mg oral micronized P or placebo at 1600 h and again at 2000 h. P dosing will be based on weight, with 25 mg administered to girls < 42kg and 50 mg given to those > or = 42 kg.
3117172|NCT01773772|Placebo Comparator|Placebo|Subjects will take placebo at 1600 h and again at 2000 h.
3117173|NCT01773759|Experimental|Intervention child care programs|Intervention child care programs will receive immunization outreach and education.
3117174|NCT01773759|No Intervention|Control child care programs|Control programs will receive no more than usual training regarding childhood immunization requirements.
3117214|NCT01773408|Experimental|Part 1: RO5503781|Participants will receive RO5503781 alone in escalating doses on Days 1 to 5 of each 28-day cycle until disease progression or unacceptable toxicity.
3117215|NCT01773408|Experimental|Part 2: RO5503781 + Cytarabine|Participants will receive RO5503781 in escalating doses on Days 1 to 5 and cytarabine on Days 1 to 6 of each 28-day cycle until disease progression or unacceptable toxicity.
3117313|NCT01772732|Experimental|Simotinib Treatment|"3+3 design, ascending multiple doses. Simotinib Hydrochloride: 100mg, 200mg, 300mg, 400mg, 500mg, bid, for 28 days"
3117175|NCT01773746|Active Comparator|Room Air|Neonatal Resuscitation using continuous positive airway pressure(CPAP) or positive pressure ventilation (PPV) will be provided with 21% oxygen. Infants will remain on 21% oxygen until they have a functioning oximeter when SpO2 will be managed as below. FiO2 will be increased by 10% increments when the infant's SpO2 is below the lower sat limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 seconds as often as is necessary to bring the SpO2 within the pre-specified range. The FiO2 will be decreased by 10% increments when the SpO2 is above the upper limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 second as often as is necessary to bring the SpO2 within the pre-specified range.
3117176|NCT01773746|Active Comparator|60% Group|Neonatal Resuscitation using CPAP or PPV will be provided with 60% oxygen. Infants will remain on 60% oxygen until they have a functioning oximeter at which time their SpO2 will be managed as described below FiO2 will be increased by 10% increments when the infant's SpO2 is below the lower sat limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 seconds as often as is necessary to bring the SpO2 within the pre-specified range. The FiO2 will be decreased by 10% increments when the SpO2 is above the upper limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 second as often as is necessary to bring the SpO2 within the pre-specified range.
3117177|NCT01773733||BMI ≥ 30|
3117178|NCT01773733||BMI ≥27 kg/m2 associated with DM2|
3117179|NCT01773707|Experimental|abatacept IV infusion|CTLA4-Ig (Abatacept) will be administered as 14 (30 minute) infusions over one year (3 infusions every other week the first month; monthly for the following 11 months)
3117180|NCT01773707|Placebo Comparator|Placebo|The placebo arm will receive 14 (30 minute) IV infusions (containing saline) given 3 times (every other week) the first month and monthly for the following 11 months.
3117181|NCT01773694|Active Comparator|Early Water Exposure|The Intervention group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.
3117182|NCT01773694|No Intervention|Standard Care|The Standard Care group will receive standard wound care instructions and verbal education by the staff to keep the dressing dry and intact for 48 hours.
3117183|NCT01773668|Experimental|Integrated sensor and infusion set|
3117184|NCT01773655||tissue|This is a protocol to obtain and/or analyze tumor and germline DNA specimens of patients with MPM, choroidal nevus, and UM.
3117185|NCT01773642|Experimental|Cognitive-behavioral intervention|A cognitive-behavioural intervention aimed at supporting caregivers through paediatric HIV diagnosis disclosure to the child in their care.
3117186|NCT01773642|No Intervention|Standard of Care|
3117187|NCT01773629|Experimental|Intervention|Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.
3117188|NCT01773629|Other|Control|"Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a perinatal depression champion for a timely formal diagnostic interview."
3117189|NCT01773616|Experimental|Rituximab|Rituximab, methyl prednisolone and mycophenolate mofetil
3117190|NCT01773616|Active Comparator|Oral prednisolone|Oral prednisolone, methyl prednisolone and mycophenolate mofetil
3117191|NCT01773603|No Intervention|Conventional incubation|Five-day embryo culture in conventional incubators
3117192|NCT01773603|Active Comparator|Embryoscope|Five-day embryo culture in embryoscope which is an incubator with a built-in camera
3117193|NCT01773590|Other|Asthmatics|Rhinovirus Infection
3117194|NCT01773590|Other|Healthy Volunteers|Rhinovirus Infection
3117195|NCT01773577||Physician Pract. Employee and Off. Staff|The office staff and providers and physician practices enrolled in the RHIO
3117196|NCT01773564|Active Comparator|Available current hospital dressing|Control group: depending on the type of dressing available at the hospital, either 3M™ HP Dressing or Smith & Nephew IV3000 ™
3117197|NCT01773564|Experimental|3M™ IV Advanced Securement dressing|New generation transparent dressing
3117198|NCT01773551||Optical Index of Breast Density|Breast Density
3117199|NCT01773538|Active Comparator|Anti cHE treatment arm|Of 150 included patients aprox. 44 regardless of CRT and PSE test outcome will be offered to enter randomisation and 3 months follow up. Half of 44 patients will receive both lactulose, rifaximin and branched chain aminoacids (Bramino) the other half placebo.
3117200|NCT01773538|Placebo Comparator|Placebo arm|The goal of this intervention is to investigate whether the CRT method can detect an expected treatment response after initiation of the 3 named drugs know to ameliorate HE symptoms including psychometric test results.
3117201|NCT01773512|Experimental|Rosuvastatin|All patients will be using rosuvastatin 40 mg
3117202|NCT01773499||Patient with Cellulitis|Patients with uncomplicated cellulitis treated as outpatients
3117203|NCT01773486|Active Comparator|Hesperidin|Subjects will receive oral hesperidin 500 mg/day
3117204|NCT01773486|Placebo Comparator|Placebo|subjects will receive matching placebo to hesperidin daily for 1 month
3117205|NCT01773473|Experimental|Insulin Lispro Mix25|Insulin Lispro Mix25 administered subcutaneously (SC) using prefilled pen twice daily for 26 weeks.
3117206|NCT01773473|Experimental|Insulin Lispro Mix50|Insulin Lispro Mix50 administered SC using prefilled pen twice daily for 26 weeks.
3117207|NCT01773460|Experimental|Everolimus|Everolimus is given beyond progress
3117208|NCT01773460|Placebo Comparator|Everolimus-placebo|Everolimus-placebo is given beyond progress
3117209|NCT01773447|Active Comparator|Set-back suture|Wound to be close by set-back suture technique.
3117210|NCT01773447|Active Comparator|Vertical mattress suture technique|Wound to be closed by vertical mattress technique.
3117211|NCT01773434|Experimental|MORAb-004|
3117212|NCT01773421|Experimental|Part A|
3117213|NCT01773421|Experimental|Part B|
3117216|NCT01773408|Experimental|Part3:RO5503781+Cytarabine+Anthracycline|Participants will receive RO5503781 on Days 1 to 5, cytarabine on Days 1 to 7, and anthracycline (daunorubicin or idarubicin) on Days 1 to 3 of each 28-day cycle until disease progression or unacceptable toxicity.
3117217|NCT01773408|Experimental|Part 4: Optimized RO5503781 + Cytarabine|Participants will receive optimized RO5503781 formulation on Days 1 to 5 and cytarabine on Days 1 to 6 of each 28-day cycle until disease progression or unacceptable toxicity.
3117218|NCT01773395|Active Comparator|GVAX|"GVAX vaccine~Participants in the GVAX vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD. GVAX arm participants meeting criteria to begin vaccinations will be administered the GVAX vaccine at established study time points."
3117219|NCT01773395|Placebo Comparator|Placebo|"Placebo vaccine~Participants in the Placebo vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD. Placebo vaccine arm participants meeting criteria to begin vaccinations will be administered the placebo vaccine at established study time points."
3117220|NCT01773382|No Intervention|control|standard treatment of IgA nephropathy including ACEI/ARB for blood pressure control (target BP <130/80 mmHg)
3117221|NCT01773382|Experimental|weight reduction|target weight reduction is 3-5% from baseline
3117222|NCT01773369|Experimental|Early treatment group|These children will undergo the intervention (i.e., early leg training) shortly after recruitment. Measures will be taken before, during and after the intervention.
3117223|NCT01773369|Experimental|Delayed treatment group|These children will undergo the intervention (delayed leg training) after a delay of ~3 months, during which outcome measures will be taken so that they can serve as a control for the early treatment group. Their intervention is identical to the Immediate treatment group.
3117224|NCT01773369|No Intervention|Control group|These children will be recruited close to the age of 4 years old, and will only undergo gait analysis and GMFM-66 scoring.
3117225|NCT01773369|Experimental|Parent training group|These children will undergo the intervention (i.e., parent leg training) shortly after recruitment. Parents will be trained to provide the intervention instead of a physical therapist. Measures will be taken before, during and after the intervention.
3117226|NCT01773356|Placebo Comparator|Placebo 0 mg/d|0 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers
3117227|NCT01773356|Active Comparator|Dihydrocapsiate 9 mg/d|9 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers
3117228|NCT01773343|Active Comparator|CO2 laser at 1 month interval|CO2 laser treatment of mild to severe acne scars at 1 month interval
3117229|NCT01773343|Active Comparator|CO2 laser at 3 monrths interval|CO2 laser treatment of mild to severe acne scars at 3 month intervals
3117230|NCT01773330|Experimental|esophageal manometry|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
3117231|NCT01773317|Experimental|Perturbation|Subjects complete the training protocol and peturbation training exercises
3117232|NCT01773317|Experimental|Control|Subjects will complete the training protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
3117233|NCT01773304|Experimental|Meal rich in dairy protein|
3117234|NCT01773304|Experimental|Meal rich in meat protein|
3117235|NCT01773291|Experimental|acupuncture|acupuncture on GV26 and 12 Well points
3117236|NCT01773291|Experimental|laser acupuncture|laser acupuncture on GV26 and 12 Well points
3117237|NCT01773291|Sham Comparator|control group|laser acupuncture without laser output in control group.
3117238|NCT01773278|Experimental|antioxidant effects on retinal function|Patients with SLOS will be treated with both cholesterol supplementation and antioxidants. Retinal function will be followed by serial electroretinogram (ERG) testing and pigmentary retinopathy will be followed by Serial Ophthalmologic exams under anesthesia
3117239|NCT01773278|Experimental|antioxidant effects on hearing|Patients with SLOS will be treated with cholesterol and antioxidant medication and their hearing will be followed by serial brainstem audiometry (ABR)
3117240|NCT01773278|Experimental|Antioxidant effect on Oxysterols|Patients with SLOS will be treated with antioxidants and cholesterol. Blood oxysterol levels will be measured. Future focus will be on being able to use oxysterol levels to regulate antioxidant doses, and to determine which particular antioxidants might have the most benefit in lowering oxysterols
3117241|NCT01773252|Experimental|TEE|Within patient comparison of TEE, FDS and a TCD from select study sites
3117242|NCT01773239|Experimental|TARA computer-based exercises|"TARA is a computerized social cognitive (SC) remediation program consisting of a set of specific SC exercises. The program creates a game-like experience where the participant is encouraged to earn points and in-game rewards to further advance in each 'game'. Participants perform tens to hundred of trials over the course of their session, with each trial providing auditory and visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each trial, the difficulty of the next trial is updated to ensure that within each session, the participant gets ~85% of trials correct. Summary screens including game metrics (points, levels) and exercise metrics (usage, progress) are shown to the participant at the end of each session.~Participants in the TARA computer-based exercises arm will complete baseline- assessments, 24 hours of TARA computer based-exercises, and repeat post-assessments."
3117243|NCT01773226|Experimental|"Autologous Protein Solution APS(TM)"|Patients who have been treated with a single, intra-articular injection.
3117244|NCT01773213|Other|Bladder dysfunction, ice-water-test|
3117245|NCT01773213|Other|Bladder dysfunction, warm water-test|
3117246|NCT01773200||Aneurysmal Subarachnoid Hemorrhage|Each consecutive patient suffering from aneurysmal subarachnoid hemorrhage
3117247|NCT01773187|Experimental|Pacritinib|Pacritinib 400 mg taken orally, once daily
3117314|NCT01772719|Experimental|Study Arm|Study Arm
3117386|NCT01772277||Control group|patients were scheduled to undergo Endoscopic dacryocystorhinostomy without intraoperative MMC
3117248|NCT01773187|Active Comparator|Best Available Therapy|BAT includes any physician-selected treatment for PMF, PPV-MF, or PET-MF with the exclusion of JAK inhibitors (inhibitors of Janus kinases). For example, BAT may include hydroxyurea, glucocorticoids, erythropoietic agents, immunomodulatory agents, mercaptopurine, danazol, interferons, cytarabine, melphalan, or other agents.
3117249|NCT01773174|Experimental|dabigatran etexilate|single dose treatment with dabigatran oral solution
3117250|NCT01773161||Cerebral palsy, post hip surgery|Children between the ages of 4-18 undergoing surgical treatment for hip subluxation or dislocation secondary to cerebral palsy.
3117251|NCT01773148|Experimental|Arstasis Access System (AXERA) placement|Placement of AXERA device in subjects undergoing common femoral artery access for PCI and/or PVI through a 5F or 6F introducer sheath.
3117252|NCT01773135||preterm group|pregnant healthy women aged from 17 to 35 who suffered from symptoms of threatened preterm labor in the form of Presence of uterine contractions (at least 4 in 20 minutes or 8 in 60 minutes), Cervical dilation > 1 and < 4 cm, and/or Cervical effacement ≥ 80%. collection of blood sample and tocolysis administration will be done this group will deliver preterm (before 37 weeks of gestation)
3117253|NCT01773135||full term group|pregnant healthy women aged from 17 to 35 who suffered from symptoms of threatened preterm labor in the form of Presence of uterine contractions (at least 4 in 20 minutes or 8 in 60 minutes), Cervical dilation > 1 and < 4 cm, and/or Cervical effacement ≥ 80%. collection of blood sample and tocolysis administration will be done this group will deliver full term (after 37 weeks of gestation)
3117254|NCT01773122|Experimental|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
3117255|NCT01773122|Experimental|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
3117256|NCT01773122|Experimental|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
3117257|NCT01773122|Active Comparator|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
3117258|NCT01773096|Experimental|Study group|Weight-based dose (0.15 mg/kg for patients less than 38 kg, 8 mg for patients weighing 38-62 kg, or 12 mg for patients weighing greater than 62 kg) of methylnaltrexone will be administered on post-operative day 3 and again, if indicated, on post-operative day 4. This group will also receive the standard bowel protocol beginning on postoperative day one as per protocol.
3117259|NCT01773096|Active Comparator|Institutional bowel protocol|Patient will receive institutional standard bowel protocol. Beginning on post-operative day one either miralx,docusate sodium or senna, on a weight-based dose. If no bowel movement in 72 hours, either oral bisacodyl or magnesium hydroxide, on a weight-based dosing, will be added.
3117260|NCT01773083|Experimental|unfractionated heparin|25.000 IU/5 ml, will be nebulized 4 hourly (i.e. 6 times daily)
3117261|NCT01773083|Placebo Comparator|placebo|Sterile sodium chloride (NaCl 0.9%, Pfizer), in 5 ml, will be nebulized every 4 hours (i.e. 6 times daily)
3117262|NCT01773070|Other|All Participants|Participants who received ABT-450, ABT-333 or ABT-267 at any dose level in an eligible prior AbbVie Phase 2 or 3 study for the treatment of chronic HCV, followed for up to 3 years post-treatment.
3117263|NCT01773057|Experimental|Active decision support|Regular NHGDoc domains plus NHGDoc domain heart failure
3117264|NCT01773057|No Intervention|Passive decision support|Regular NHGDoc domains
3117265|NCT01773044|Active Comparator|alkalinized lidocaine & lidocaine|
3117266|NCT01773044|Active Comparator|alkalinized lidocaine &Placebo|
3117267|NCT01773031||Autoimmune pancreatitis|Patients with autoimmune pancreatitis based on clinical and CT findings
3117268|NCT01773018|Experimental|Volitinib(HMPL-504)|"There are six dose cohorts,including 100, 200, 400, 600,800 and 1000 mg/day, HMPL-504 will be administered orally to patients once daily for each dose cohort.~An alternative dosing schedule of twice every day (BID) may be investigated if pharmacokinetic studies indicate faster than anticipated clearance of Volitinib(HMPL-504)."
3117269|NCT01773005|Sham Comparator|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
3117270|NCT01773005|Active Comparator|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
3117271|NCT01772992|No Intervention|Control group (iVCT)|Male couples randomized to the control group (iVCT) will each receive individual HIV counseling and testing, separately.These couples in the control group (iVCT) will return every 6 months, up to 18 months, for individual visits, in which they will have STI testing and repeat HIV testing. All follow-up visits will be conducted separately.
3117272|NCT01772992|Experimental|Experimental group (CVCTPLUS)|Male couples randomized to the experimental group (CVCTPLUS) will each receive HIV counseling and testing as a couple. These couple will return for two additional visits that members of the control arm do not get, for two one-hour sessions of the Partner-STEPS. Couples in the experimental group (CVCTPLUS) at 8 and 10 weeks after the initial enrollment. They will also return every 6 months, up to 18 months, for visits in which they will be seen as a couple, in which they will have STI testing and repeat HIV testing. All follow-up visits will be conducted for the couples together.
3117273|NCT01772979|Experimental|Trabectedin|"Trabectedin 1.3 mg/m2 q 21 days~Patients will receive trabectedin until disease progression or unacceptable toxicity"
3117274|NCT01772966|Experimental|Spinal manipulation|Participants will receive spinal manipulation delivered as segmental thrust to a specific site in the neck. They will receive three intervention sessions over 7-10 days.
3117275|NCT01772966|Sham Comparator|Control manipulation|Participants will receive spinal manipulation delivered as non-segmental thrust to the neck. They will receive three intervention sessions over 7-10 days.
3117309|NCT01772758|Experimental|Protocol 2: BH4 (20mg)|measurements at baseline and 3 hours following the single dose of 20mg/kg Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4).BH4 has been shown in past studies to increase NO bioavailability.
3117310|NCT01772758|No Intervention|Healthy Controls|baseline measurements were done with no intervention
3117276|NCT01772953|Experimental|treosulfan, fludarabine and low-dose TBI prep regimen|"Treosulfan: 10-14 g/m2/day IV over 120 minutes on days -6, -5 and -4. Treosulfan will be administered prior to fludarabine on days -6 to -4 to facilitate PK testing.~Fludarabine: 30 mg/m2 IV for patients > 10 kg (or 1 mg/kg IV for patients < 10 kg) once daily per institutional infusion standards on days -6 through -2 for a total dose of 150 mg/m2 (or 5 mg/kg).~A single fraction of 200 cGy TBI will be administered on day -1. Stem cell infusion on day 0"
3117277|NCT01772940|Active Comparator|nevirapine and tenofovir/emtricitabine|nevirapine 200 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
3117278|NCT01772940|Experimental|lopinavir/r and tenofovir/emtricitabine|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
3117279|NCT01772940|Active Comparator|Nevirapine and zidovudine/lamivudine|nevirapine 200 mg/zidovudine 300 mg/lamivudine 150 mg (fixed-dose combination) twice daily, per os for 96 weeks
3117280|NCT01772940|Experimental|Lopinavir/r and zidovudine/lamivudine|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg once daily combined with zidovudine 300 mg/lamivudine 150 mg once daily, per os for 96 weeks
3117281|NCT01772927||Very low birth weight infants,|Parenteral nutrition
3117282|NCT01772901|No Intervention|Control|Usual outpatient antenatal care consists of routine checking of the maternal and foetal health by either clinic midwives or obstetricians along with health education to promote a healthy pregnancy.
3117283|NCT01772901|Experimental|Influenza Vaccine Intervention|The intervention group will receive a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions.
3117284|NCT01772888||Patients with ALS|All subjects aged > 18 years, diagnosed with an ALS and included in the multidisciplinary follow-up of the HUG at time of diagnosis will be considered and included, if possible, at their first visit.
3117285|NCT01772888||Healthy age and gender-matched subjects|Controls matched for age and gender and dental status and without a medical history for neurological or otolaryngologic disease (1 control for 1 patient). They will be recruited among hospital staff and patients of the dental school.
3117286|NCT01772875|Active Comparator|lavage Isobetadine Dermicum solution|Patient will receive 1 bladder lavage daily with a solution of 5ml Isobetadine Dermicum in 100cc saline
3117287|NCT01772875|Active Comparator|lavage Acetic Acid solution|Patients will receive a daily bladder lavage during 5 consecutive days with a solution of 0.5% acetic acid in 100cc of saline
3117288|NCT01772875|Sham Comparator|lavage with saline|patients will receive during 5 consecutive days a bladder lavage with 100cc saline
3117289|NCT01772875|Active Comparator|lavage Urotainer Suby G|patients will receive during 5 consecutive days a bladder lavage with 100cc of Urotainer Suby G
3117290|NCT01772862|No Intervention|Only conventional supportive care|The children receive conventional supportive care with respect to physical training
3117291|NCT01772862|Experimental|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.~Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors"
3117292|NCT01772849|Experimental|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors"
3117293|NCT01772849|No Intervention|Standard educational programme|The children receive the standard of care with respect to education this include education in the hospitals school or at home without a class mate and no specific activity to secure continuous linkage with community school and class mates
3117294|NCT01772836|Placebo Comparator|Normal saline|Single and multiple dose of normal saline
3117295|NCT01772836|Experimental|Single dose IV of biapenem or RPX7009|Single dose IV infusion of biapenem or RPX7009
3117296|NCT01772836|Experimental|Single dose of biapenem or RPX7009|Single IV dose of biapenem or RPX7009 (for those on active drug, this will be the drug not given in the first IV treatment)
3117297|NCT01772836|Experimental|Biapenem and RPX7009 in combination|Single dose followed by a multiple dose of biapenem and RPX7009 in combination
3117298|NCT01772823|Experimental|3MV Behavioral Intervention Group|3MV Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
3117299|NCT01772823|Experimental|PCC Behavioral Intervention Group|PCC Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
3117300|NCT01772810|Experimental|Surgical implantation of human spinal cord stem cells|Surgical implantation of human spinal cord derived neural stem cells.
3117301|NCT01772797|Experimental|LDK378 and AUY922|
3117302|NCT01772784|Experimental|phenolic acids|Maltodextrine + Phenolic acids
3117303|NCT01772784|Placebo Comparator|placebo|Maltodextrine
3117304|NCT01772784|Experimental|phenolic acid|Maltodextrine + Phenolic acids
3117305|NCT01772784|Active Comparator|polyphenol|
3117306|NCT01772771||Cancer Patients|Patients with histologically or cytologically documented invasive cancer, sarcoma, or hematologic cancer
3117307|NCT01772758|Experimental|Protocol 1: AOC|measurements at baseline and 2 hours following the antioxidant cocktail that is comprised of over the counter vitamins (vitamin C 1000mg, vitamin E 600 IU, and alpha lipoic acid 600 mg) that will be given in two doses, 30 minutes apart.
3117308|NCT01772758|Experimental|Protocol 2: BH4 (5mg)|measurements at baseline and 3 hours following the single dose of 5mg/kg Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4).BH4 has been shown in past studies to increase NO bioavailability.
3117315|NCT01772706|Experimental|laser low-level energy functional|The material used will be a diode laser of 100 mW, with a wavelength of 658 nm. Application will be made after each radiotherapy session in an adapted room (low light intensity, possibility of ENT examination) on all grade superior or equal to 2 stomatitis injuries. The energetic dose delivered will be 4 J/cm2. The duration of the treatment for one will be determined by an abacus.
3117316|NCT01772706|Placebo Comparator|laser low-level energy nonfunctional|The procedure is identical to the one used in arm A but the laser will not be functional. The period of application will be around one minute.
3117317|NCT01772693|Experimental|ExAblate Transcranial MRgFUS|ExAblate Transcranial MR guided Focused Ultrasound
3117318|NCT01772693|Sham Comparator|Sham ExAblate Transcranial MRgFUS|Sham treatment with ExAblate MR guided Focused Ultrasound
3117319|NCT01772680|Experimental|Zinc Supplementation|25 mg elemental Zinc as Zn sulfate in capsule form taken daily for 3 months
3117320|NCT01772667|No Intervention|Usual care|Usual care during the whole study period without pulmonary rehabilitation. The patients will perform their normal daily life.
3117321|NCT01772667|Active Comparator|Inpatient Rehabilitation|3-week inpatient multimodal pulmonary rehabilitation program, including daily exercise training, breathing therapy, medical treatment and psychological support. In the following 3 month, the patients will perform their normal daily life.
3117322|NCT01772654|Experimental|Left Temporal Lobe Epilepsy Subjects|Arterial Spin Labeled (ASL) MRI sequence
3117323|NCT01772654|Active Comparator|Control Subjects|Arterial Spin Labeled (ASL) MRI sequence
3117324|NCT01772641|Experimental|Scheduled Gradual Reduction + Varenicline|Participants will be given the behavioral intervention of Scheduled Gradual Reduction along with the smoking cessation drug, Varenicline.
3117325|NCT01772641|Experimental|Scheduled Gradual Reduction + Placebo Drug|Participants will be given the behavioral intervention, SGR, along with a placebo drug matching the schedule of the VN group.
3117326|NCT01772641|Experimental|Basic Advice + Varenicline|Participants will be given basic advice about quitting smoking along with the smoking cessation drug Varenicline
3117327|NCT01772641|Placebo Comparator|Basic Advice + Placebo Drug|Participants will be given basic advice along with a placebo drug matching the schedule of the VN group.
3117328|NCT01772628|Experimental|Promoting parent-child communication|This is the arm in which all interventions of Promoting parent-child communication on selected sexual and reproductive health issues among young secondary school adolescents in Kampala and Wakiso Districts were implemented. The interventions included; classroom-based component, STI/HIV prevention education, parenting component and homework assignment component.
3117329|NCT01772628|No Intervention|Comparison|The 11 comparison schools did not receive any form of intervention. Instead the students continued with the official standard school curriculum and regular parent/guardian involvement in school activities. No homework assignments were given to the senior one students.
3117330|NCT01772615|Experimental|ciprofloxacin-EcN|
3117331|NCT01772615|Experimental|ciprofloxacin-placebo|
3117332|NCT01772615|Experimental|placebo-EcN|
3117333|NCT01772615|Placebo Comparator|placebo-placebo|
3117334|NCT01772589|Active Comparator|New saw blade|New saw blade
3117335|NCT01772589|Active Comparator|Reprocessed saw blade|Reprocessed saw blade
3117336|NCT01772576|Experimental|Reliance 4-Front|Single arm, all patients will be implanted with the Reliance 4-Front lead
3117337|NCT01772563|Experimental|volasertib + itraconazole|administration of volasertib alone and in combination with itraconazole
3117338|NCT01772550|Experimental|20 Gauge BD Nexiva Diffusics|During their routinely scheduled contrast-enhanced computed tomography procedure, subjects in this arm will receive IV contrast media injected via the fenestrated 20GA BD Nexiva Diffusics single port IV catheter (20GA x 1.00 inch).
3117339|NCT01772550|Active Comparator|18 Gauge Conventional Catheter|During their routinely scheduled contrast-enhanced computed tomography procedure, subjects in this arm will receive IV contrast media injected via the non-fenestrated 18GA Conventional Catheter (18 GA x 1.25 inch Smiths Medical Jelco® IV Catheter).
3117340|NCT01772550|Experimental|BD Nexiva Diffusics - Nonrandomized|Subjects whose veins were not suitable for an 18 GA IV Catheter were assigned to this non-randomized arm. During their routinely scheduled CECT procedure, subjects receive IV contrast medium injected via the fenestrated 20GA BD Nexiva Diffusics single port IV catheter (20GA x 1.00 inch)
3117341|NCT01772537|No Intervention|Open repair of thoracoabdominal aneurysms|These will be patients undergoing an open repair of thoracoabdominal aneurysms with or without cardiopulmonary bypass. The will be observational only.
3117342|NCT01772537|Active Comparator|Stent graft repair of thoracoabdominal aneurysms isoflurane|These patients are patients receiving repair of thoracoabdominal aneurysms using stent grafts. These patients will be randomized to receive isoflurane as their primary anesthetic.
3117343|NCT01772537|Active Comparator|Stent graft repair of thoracoabdominal aneurysms propofol|These patients are patients receiving repair of thoracoabdominal aneurysms using stent grafts. These patients will be randomized to receive propofol as their primary anesthetic.
3117344|NCT01772524|Experimental|ALD403|Single IV Dose on Day 0
3117345|NCT01772524|Placebo Comparator|Saline|Single IV infusion on Day 0
3117346|NCT01772511||Questionnaire|Patients will be asked by a member of the research team if they would like to participate in this study evaluating patients' comprehension of the informed consent for the oncology treatment study that they are participating in. Patients will be consented and will be told that, at their next clinical visit, they will be given the questionnaire to complete. They will be given the option to complete the questionnaire on site after being given the document or have the ability to mail the completed questionnaire into the research office once completed. If the questionnaire is not returned within 2-weeks, the participant will be approached again during their normal clinical visit and asked if they still wish to participate in this study.
3117347|NCT01772498|Experimental|Heart rate variability biofeedback|Heart rate variability biofeedback training administered in eight, individual, weekly, one hour sessions. There will also be 20 minutes a day of resonant frequency breathing to be conducted at home. This intervention involves teaching subjects how to breath at their resonant frequency in a relaxed, diaphramatic manner.
3117384|NCT01772290|Experimental|D: Fluconazole + Vismodegib|
3117385|NCT01772277||MMC group|patients were scheduled to undergo Endoscopic dacryocystorhinostomy with intraoperative MMC
3117348|NCT01772485|Experimental|Cognitive Training|Training group participants will engage in 30 hours of at-home online training on the novel neuroplasticity-based cognitive training program ('Rewired') in 30 minute sessions completed approximately 3-5 days per week, for a total training period lasting 12-20 weeks. Both visual and auditory exercise forms will be practiced daily. Level progression criteria will be flexibly set to assure that almost all individuals can reach them in a reasonable time. Training compliance and performance data (accuracies and reaction times) will be continuously monitored remotely, and analyzed over secure online servers to assure that subjects are completing their training as scheduled and to deal with any unexpected road-blocks in training.
3117349|NCT01772485|Active Comparator|Active Control|The active control group shall engage in an at-home computer game suite, as used in a prior cognitive training trial in a psychiatric population (Fisher et al., 2009), for the same number of hours as the training group to control for the effects of computer exposure and interaction, contact with clinical research personnel and monetary rewards. Compliance will be monitored via an online data portal.
3117350|NCT01772472|Active Comparator|Trastuzumab|
3117351|NCT01772472|Experimental|Trastuzumab emtansine|
3117352|NCT01772459||Paper/Paper|This group will complete paper questionnaires at baseline and two week follow up.
3117353|NCT01772459||Paper/Internet|This group will complete paper questionnaires at baseline and internet questionnaires at two week follow up.
3117354|NCT01772459||Internet/Paper|This group will complete internet questionnaires at baseline and paper questionnaires at two week follow up.
3117355|NCT01772459||Internet/Internet|This group will complete internet questionnaires at baseline and two week follow up.
3117356|NCT01772446|No Intervention|CONTROL GROUP|ROUTINE CLINICAL PRACTICE
3117357|NCT01772446|Experimental|SMS MESSAGING|SMS MESSAGES TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED HEMOGLOBIN
3117358|NCT01772433|Placebo Comparator|Phonophoresis Gel|The Phonophoresis gel will be used as placebo
3117359|NCT01772433|Experimental|Olive Oil|Olive oil will be used as a replacement to phonophoresis gel in this arm
3117360|NCT01772420|Experimental|Arm A (lenalidomide, eltrombopag olamine)|"Patients with baseline platelet counts >= 50,000 receive lenalidomide PO daily or QOD on days 1-21. If platelet counts fall below 50,000, patients discontinue lenalidomide and receive eltrombopag olamine PO daily or QOD until platelet count is maintained above 50,000 for 2 weeks. Patients then resume lenalidomide PO daily or QOD. If platelets fall below 50,000 again, patients receive eltrombopag olamine as before. When platelet counts are maintained above 50,000 for 2 weeks, patients resume lenalidomide concurrently with eltrombopag for all subsequent courses.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity."
3117361|NCT01772420|Experimental|Arm B (eltrombopag olamine, lenalidomide)|"Patients with baseline platelet counts < 50,000 receive eltrombopag olamine PO daily or QOD on days 1-28 until platelet count is maintained above 50,000 for 2 weeks. Patients then receive treatment as in Arm A.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity."
3117362|NCT01772407||1|laparoscopic surgery in right colon cancer operations
3117363|NCT01772407||2|open surgery in right colon cancer operations
3117364|NCT01772394|Active Comparator|Cognitive Remediation Therapy (CRT)|Active : CRT
3117365|NCT01772394|Sham Comparator|Sham Therapy (ST)|Sham : ST
3117366|NCT01772381|Experimental|Dexamethasone|Dexamethasone, im , 12 mg twice, 12 hrs apart, 48 hrs before elective cesarean section
3117367|NCT01772368|Experimental|FS MDPI 100/6.25 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 6.25 mcg salmeterol xinafoate.
3117368|NCT01772368|Experimental|FS MDPI 100/12.5mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 12.5 mcg salmeterol xinafoate.
3117369|NCT01772368|Experimental|FS MDPI 100/25|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 25 mcg salmeterol xinafoate.
3117370|NCT01772368|Experimental|FS MDPI 100/50|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate.
3117371|NCT01772368|Active Comparator|Fp MDPI 100 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate.
3117372|NCT01772368|Active Comparator|Advair Diskus 100/50 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate. This arm is the only arm which is open-label because the inhaler device was different than the MDPI used in the other treatment arms.
3117373|NCT01772355|Other|tissue core|semi automated core needle biopsy of the orbital tumors
3117374|NCT01772342|Experimental|Nocturnal Air Purification|"Hepa Filtration with PureNight~SHAM with PureNight"
3117375|NCT01772329|Experimental|4 weekly CT sessions - in person|4 weekly CT sessions; all will be 1-hr individual cognitive therapy sessions with the psychology staff (under the supervision of John Burns, PhD).
3117376|NCT01772329|Experimental|8 weekly CT sessions|"8 weekly CT sessions; 1st and 8th will be 1-hr individual cognitive therapy session with the psychology staff (under the supervision of John Burns, PhD). The intermediate CT sessions will be by telephone call or video/Skype. Our group will purchase and setup a web camera and headphone/microphone for the subjects in the CT groups that use Skype. The 1-hr CT protocol was adapted from Dr. Beverly E. Thorn's CT manual (Cognitive Therapy for Chronic Pain: A Step-by-Step Guide; Thorn, 2004; with the Client and Therapy Workbooks."
3117377|NCT01772329|Experimental|4 weekly CT sessions - Tele-video|"4 weekly CT sessions; 1st and 4th will be 1-hr individual cognitive therapy session with the psychology staff. The intermediate CT sessions will be by telephone call or video/Skype."
3117378|NCT01772329|Placebo Comparator|Routine care|Routine care; no CT sessions
3117379|NCT01772316|Experimental|Tocilizumab Subcutaneous (SC)|Participants received Tocilizumab 162 milligram (mg) given as 0.9 milliliter (mL) of a 180 milligram per milliliter (mg/mL) solution administered once a week (for participants entering from NCT01194414) or once every two weeks (for participants entering from NCT01232569) by SC injection and as a single fixed dose irrespective of body weight.
3117380|NCT01772303|Experimental|HO/03/03 10-40 micro gram|Topically treatment with HO/03/03 10-40µg once daily for up to 24 weeks. Subjects will receive treatment with HO/03/03 10µg at a dose of 1-4 vials (i.e. 10-40 µg/administration) daily depending on their wound size.
3117381|NCT01772290|Active Comparator|A: Vismodegib|
3117382|NCT01772290|Experimental|B: Rabeprazole + Vismodegib|
3117383|NCT01772290|Experimental|C: Itraconazole + Vismodegib|
3117390|NCT01772238|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3117391|NCT01772238|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3117392|NCT01772225||Deceased Group|Subjects in this group will include the deceased patients from each of the three countries.
3117393|NCT01772225||Living Group|Subjects in this group will include living patients aged 18 years or older from each of the three countries.
3117394|NCT01772212|Experimental|A(test)/B(reference)|Initial administration of test and crossover to reference
3117395|NCT01772212|Experimental|B(reference)/A(test)|Initial administration of reference and crossover to test
3117396|NCT01772199|Experimental|GSK239512 Arm|GSK239512 once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
3117397|NCT01772199|Placebo Comparator|Placebo Arm|Placebo once daily orally
3117398|NCT01772186|No Intervention|Without real-time somatosensory cue|Parkinson patients wear the somatosensory stimulation system but not receive the real-time somatosensory cue during freezing-of-gait episodes.
3117399|NCT01772186|Experimental|With real-time somatosensory cue|Parkinson patients wear the somatosensory stimulation system and receive the real-time somatosensory cue during freezing-of-gait episodes.
3117400|NCT01772173||subjects with diabetes developing hypertension|subjects with diabetes not developing hypertension
3117401|NCT01772160||HZ Group|Subjects presenting with an HZ episode.
3117402|NCT01772147|Experimental|Umeclidinium bromide|Long-acting muscarinic antagonist (LAMA)
3117403|NCT01772147|Active Comparator|Fluticasone propionate/Salmeterol|Inhaled corticosteroid (ICS)/Long-acting beta agonist (LABA)
3117404|NCT01772134|Experimental|Umeclidinium bromide 62.5 + Fluticasone propionate/Salmeterol|Long-acting muscarinic antagonist (LAMA), 62.5mcg plus Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
3117405|NCT01772134|Active Comparator|Umeclidinium bromide 125 + Fluticasone propionate/Salmeterol|Long-acting muscarinic antagonist (LAMA), 125mcg plus Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
3117406|NCT01772134|Placebo Comparator|Placebo + Fluticasone propionate/Salmeterol|Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
3117407|NCT01772121||HCV Cohort|A total of 1000 subjects were enrolled in the study and of that 500 subjects had a diagnosis of chronic HCV infection
3117408|NCT01772121||HBV Cohort|A total of 1000 subjects were enrolled in the study and of that 500 subjects had a diagnosis of chronic HBV infection
3117409|NCT01772108|Experimental|MitraClip Device|Subjects randomized to the Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.
3117410|NCT01772108|No Intervention|Control|Subjects randomized to the Control group will receive optimal standard of care therapy alone.
3117411|NCT01772095||Patients with Dementia|Patients diagnosed with dementia and evaluated by specific Alzheimer disease scales
3117412|NCT01772082|Active Comparator|Pedometer alone|pedometer
3117413|NCT01772082|Experimental|Pedometer plus website|pedometer and website
3117414|NCT01772056|Experimental|Fluticasone, cream|fluticasone propionate (FP) cream of 0.05%. The vehicle is:Base PFCO/W, Propyleneglycol and Water conservant.
3117415|NCT01772056|Placebo Comparator|Placebo, cream|Vehicle cream is composed by Base PFCO/W, Propyleneglycol and Water conservant.
3117416|NCT01772043||Duchenne muscular dystrophy|
3117417|NCT01772030|Other|Recurrent Atrial Fibrillation|
3117418|NCT01772017|Experimental|Device Treatment|Tongue Advancement Retainer Device
3117419|NCT01772004|Experimental|Avelumab|
3117420|NCT01771991|Experimental|Topical Sodermix Dismutase|Patients with measurable radiation induced fibrosis of the neck. Patients will be randomized to applying Topical Sodermix Dismutase in the form of Sodermix(SOD) to the area of neck skin fibrosis twice a day for 12 weeks.
3117421|NCT01771991|Placebo Comparator|Placebo group|Cetaphil cream
3117422|NCT01771978|Placebo Comparator|Arm1: control group|Received 250 ml of a 5% dextrose solution as placebo drug
3117423|NCT01771978|Experimental|Arm 2: diltiazem group|Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution
3117424|NCT01771978|Experimental|Arm 3: acetylcystein group|Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
3117425|NCT01771978|Experimental|Arm 4: diltiazem and acetylcystein group|"Received a combination of drug :~bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution and 150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution"
3117426|NCT01771965|No Intervention|Usual care|No intervention.
3117427|NCT01771965|Experimental|CB Intervention|Cognitive Behavioral one-on-one single session administered by phone
3117428|NCT01771952|Experimental|Synvisc-One™|Patients randomized into this group will receive a single 6cc dose of Synvisc-One™ under sterile conditions. After cutaneous numbing with vasocoolant spray, the superolateral aspect of the patellofemoral joint will be draped and prepared with betadine soaked sterile gauze using concentric circles around the injection site. A 22 gauge needle will be advanced into the patellofemoral joint using a superolateral approach. Subjects will be monitored for minimum 5 minutes post injection to evaluate for adverse events.
3117429|NCT01771952|Sham Comparator|Sham Treatment|Patients randomized into this group will receive, under sterile conditions, a sham injection. Sterile preparation and injection procedures will be exactly the same as described above except, nothing will be injected into the joint. This procedure will include a needle stick through the joint without arthrocentesis or injection.
3117430|NCT01771939|Experimental|idiopathic epiretinal membranes|Patients in first arm, with worse visual condition, treated with 25-G Vitrectomy and phacoemulsification (cataract intervention)
3117431|NCT01771939|Active Comparator|idiopathic epiretinal membrane|Patient in second arm, with better pre-operative condition, treated with phacoemulsification (cataract intervention) only
3117432|NCT01771926|Experimental|High Resistant Starch Potatoes|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
3117433|NCT01771926|Experimental|Low Resistant Starch Potatoes|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
3117434|NCT01771926|Placebo Comparator|Other Carbohydrate Source|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
3117435|NCT01771913|Sham Comparator|centrifuged fat graft|female patients who underwent breast reconstruction and present with volume insufficiency will undergo centrifuged fat graft for contour and volume refinements.
3117436|NCT01771913|Active Comparator|ADSCs enriched centrifuged fat graft|female patients who underwent breast reconstruction and present volume insufficiency will undergo ADSCs enriched fat grafting for volume and irregularity contour improvement
3117437|NCT01771900|Experimental|Heart Camp Group|
3117438|NCT01771900|Experimental|Attention Control Group|
3117439|NCT01771887|Experimental|education program|education program in 6 hours for groups of 10 people. The content will be divided into 2 sessions with an interval of 2 weeks, the duration of each session is 3 hours. Means active learning, teaching materials in Arabic accompany the content masterful discussions on flipcharts, situation analysis, computer-assisted presentation, demonstration, 150 photos of Lebanese dishes. After, patients receive a 10-page illustrated book, a logbook of diabetes control. 2 weeks after the second education session, each participant will receive 5 calls every 15 days in 2 months. During each call, the research assistant will ask the patient about diet, exercise and self-monitoring, medication and foot care and this according to a checklist.
3117440|NCT01771874|Experimental|MDMA, bupropion, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject. The four treatment conditions are placebo-placebo, bupropion-placebo, placebo-MDMA, and bupropion-MDMA.
3117441|NCT01771861||Seriously injured or potentially seriously injured patients|
3117442|NCT01771848|Experimental|Grp 1-10ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 1 (n=6): 2,500 PfSPZ administered IM in a volume of 10 µL in 2 sites (one injection of 10µL containing 1,250 PfSPZ in each deltoid)."
3117443|NCT01771848|Experimental|Grp 2-50ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 2 (n=6): 2,500 PfSPZ administered IM in a volume of 50 µL in 2 sites (one injection of 50µL containing 1,250 PfSPZ in each deltoid)."
3117444|NCT01771848|Experimental|Grp 3-250ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 3 (n=6): 2,500 PfSPZ administered IM in a volume of 250 µL in 2 sites (one injection of 250 µL containing 1,250 PfSPZ in each deltoid)."
3117445|NCT01771848|Experimental|Grp 4-50ul x 2; 25,000 PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 4 (n=6) (control group) 25,000 PfSPZ administered IM in a volume of 50 µL in 2 sites (one injection of 50 µL containing 12,500 PfSPZ in each deltoid)."
3117446|NCT01771848|Experimental|Grp 5-Optimal vol Part A x 2; 25,000 PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 5 (n=6) 25,000 PfSPZ administered IM in the optimum volume determined in Part A in 2 sites (one injection of the optimum volume containing 12,500 PfSPZ in each deltoid).~If the optimal volume in Part A is 50µL, then Group 5 will be modified to avoid duplication of regimens between groups 4 and 5. In this case, volunteers in group 5 will be administered a dose of 25,000 PfSPZ administered intradermally in four 10 µL injections. (Every volunteer will receive 4 ID injections of 6,250 PfSPZ in a volume of 10 µL each, with 2 injections in each arm respectively)."
3117447|NCT01771848|Experimental|Grp 6-Optimal vol Part A x 2; 125,000* PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 6 (n=6) 125,000 PfSPZ administered IM in the optimum volume determined in Part A in 2 sites (one injection of the optimum volume containing 62,500 PfSPZ in each deltoid) if the volume is 50 µL or 250 µL.~*If the optimal volume in Part A is 10 µL, then Group 6 will receive 100,000 PfSPZ (2 inoculations of 50,000 PfSPZ) instead of 125,000 PfSPZ."
3117448|NCT01771835||Diabetes patients|Patients with diabetes mellitus type I + II, without diabetic retinopathy
3117449|NCT01771822|Experimental|Ibuprofen 5% topical gel|
3117450|NCT01771822|Experimental|Topical gel vehicle|
3117451|NCT01771822|Active Comparator|Sodium lauryl sulfate 0.2%|
3117452|NCT01771822|Sham Comparator|Sodium chloride solution 0.9% (saline)|
3117453|NCT01771809|Experimental|Open-Label Treatment Period 1A|75mg PF-00547659 subcutaneously every 4 weeks for 72 weeks
3117454|NCT01771809|Experimental|Open-Label Treatment Period 1B|225mg PF-00547659 subcutaneously every 4 weeks for 72 weeks (Weeks 0-72)
3117455|NCT01771809|Experimental|Open-Label Treatment Period 2|75mg PF-00547659 subcutaneously every 4 weeks for 18 months (Weeks 76-144)
3117456|NCT01771796|Experimental|Aerobic and muscle resistance training|
3117457|NCT01771796|No Intervention|Usual care group|All patients (intervention and usual care group) are patients with lung cancer who underwent a resection surgery.
3117458|NCT01771783|Experimental|ACEI-ARB-RI|angiotensin converting enzyme inhibitor (ACEI) angiotensin receptor antagonist (ARB) renin inhibitor (RI)
3117459|NCT01771783|Experimental|ARB-RI-ACEI|ARB-RI-ACEI
3117460|NCT01771783|Experimental|RI-ACEI-ARB|RI-ACEI-ARB
3117461|NCT01771744||Morbidly obese patients|48 morbidly obese patients with revisional gastric bypass
3117462|NCT01771744||48 morbidly obese patients|with primary gastric bypass
3117463|NCT01771731|Experimental|Cannabis|Contents of 1 cannabis cigarette (4.7% THC/5.1% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.
3117464|NCT01771731|Placebo Comparator|Placebo|Contents of 1 placebo cigarette (0% THC/0% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.
3117465|NCT01771718||Human skin|Multiphoton microscopy imaging to collect information about changes in skin cells and fibrilar structure.
3117466|NCT01771705|Experimental|Dose adjust group (NFAT)|Within 2 weeks of a 6 month management biopsy, if eligibility is confirmed, NFAT dependent cytokines including IL-2, IFNg, and GMCSF at times C0 and C1.5 will be performed with the residual expression calculated based on the ratio of C1.5/C0 x 100%. If the average residual expression of the 3 cytokines is <15%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is > 80% the CNI daily dose will be increased by 15%.
3117467|NCT01771705|No Intervention|Standard of care group|A CNI trough level will be obtained. Adjustments of CNI will be based on target trough drug levels as per standard of care.
3117468|NCT01771692|Active Comparator|Conventional ligation|Modules ligated in a conventional manner (figure of 0)
3117469|NCT01771692|Active Comparator|Figure of 8 ligation|Modules ligated in a figure of 8 configuration
3117511|NCT01771367|Active Comparator|Agrippal|Participants receive one dose of Agrippal vaccine.
3117470|NCT01771679|Experimental|Allogeneic Mesenchymal Bone Marrow Cells|1550 nm Fraxel laser treatment (6-8 mJ, Level 2) to full face followed by IV infusion of Allogeneic Mesenchymal Bone Marrow Cells (0.5, 1.0, or 1.5 million cells/kg, up to 150 million cells)
3117471|NCT01771666|Experimental|ISB and ICG|"The dose of Isosulfan blue (ISB) dye and Indocyanine green (ICG) solution will be started.~(IC-GREEN) SPY Elite Imaging willbe used to capture the images of axillary cavity."
3117472|NCT01771653||Previously treated|Data from patients who were previously treated with Peg, interferon (IFN), alfa, and ribavirin
3117473|NCT01771653||Previously untreated|Records of patients who have never received anti-HCV treatment.
3117474|NCT01771640|Experimental|stem cell reciepient|The patients with ALS that underwent mesenchymal stem cell transplantation
3117475|NCT01771627|Experimental|Arm I (varenicline)|Patients undergo general smoking cessation counseling and receive varenicline PO QD on days 1-28. Courses repeat every 28 days for up to 12 weeks.
3117476|NCT01771627|Active Comparator|Arm II (nicotine patch)|Patients undergo general smoking cessation counseling and receive nicotine patch continuously for 12 weeks.
3117477|NCT01771614|Experimental|Normoglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
3117478|NCT01771614|Experimental|Steady-State Hyperglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. During this time, steady-state hyperglycemia (~10 mM) will be induced experimentally via a variable-rate intravenous infusion of 20% dextrose. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
3117479|NCT01771614|Experimental|Fluctuating Hyperglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. During this time, fluctuating hyperglycemia (~8-15 mM) will be induced by intravenously injecting 0.15 g/kg boluses of 20% dextrose every 30 minutes. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
3117480|NCT01771601||Near-infrared spectroscopy sensors|Term infants born by elective Caesarean section
3117481|NCT01771588|Experimental|New human milk fortifier|New human milk fortifier
3117482|NCT01771588|Active Comparator|Currently marketed fortifier|Currently marketed fortifier
3117483|NCT01771588|Experimental|New human milk fortifier with new Ca source|a subgroup of patients will receive the new milk fortifier containing a new source of calcium.
3117484|NCT01771575|Experimental|Treatment Arm|PoNS™ device
3117485|NCT01771575|Placebo Comparator|Placebo Arm|placebo device
3117486|NCT01771549||Group 1|Patients with breast cancer beginning chemotherapy with a dose-dense regimen including adriamycin without concurrent trastuzumab.
3117487|NCT01771549||Group 2|Patients receiving trastuzumab in the adjuvant, neo-adjuvant, or metastatic setting in a regimen not containing simultaneous adriamycin therapy.
3117488|NCT01771536|Active Comparator|PCI Choice decision|Decision Aid intervention is provided to clinician to share with patient
3117489|NCT01771536|No Intervention|Usual Care|
3117490|NCT01771523|Active Comparator|Group 1|thyroidectomy
3117491|NCT01771523|Active Comparator|Group 2|thyroidectomy use of drain
3117492|NCT01771497||Women undergoing neoadjuvant therapy|
3117493|NCT01771484|Experimental|Low Sodium Diet|participants will consume a diet (10 milliequivalent Na+/day)for 4-5 days prior to study day.
3117494|NCT01771484|Experimental|High sodium diet|Participants will consume a diet high in sodium (300 milliequivalent Na+/day) for 4-5 days prior to study intervention.
3117495|NCT01771471|Experimental|NuQu treatment|single administration
3117496|NCT01771471|Other|Saline|single administration
3117497|NCT01771458|Active Comparator|Standard chemotherapy|Treatment choice is based on Investigator decision.
3117498|NCT01771458|Experimental|Personalized treatment|"Targeted therapy based on the patient molecular profil (if there is at least one abnormality that could be targeted)~Elligible therapies in this trial are :~Imatinib Everolimus Vemurafenib Sorafenib Erlotinib Lapatinib Trastuzumab Dasatinib Tamoxifen (or letrozole if contra-indication) Abiraterone"
3117499|NCT01771445|Active Comparator|IL-1Ra|
3117500|NCT01771445|Placebo Comparator|Placebo|
3117501|NCT01771432|Active Comparator|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics.
3117502|NCT01771432|Other|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
3117503|NCT01771419|Experimental|loop-tip arm|The cannulation of CBD will be obtained using the loop-tip wire (Cook Medical inc.)
3117504|NCT01771419|Active Comparator|Control arm|The cannulation of CBD will be obtained with a Cook Medical sphincterotome CT-25 mm (tradictional technique)
3117505|NCT01771406|Experimental|Nebivolol then CPAP|8 weeks of Nebivolol treatment (5m/day), 6 weeks of washout, 8 weeks of CPAP and if the patient is still hypertensive 8 weeks of Nebivolol plus CPAP treatment
3117506|NCT01771406|Experimental|CPAP then Nebivolol|8 weeks of CPAP treatment, 6 weeks of washout, 8 weeks of Nebivolol and if the patient is still hypertensive 8 weeks of Nebivolol plus CPAP treatment
3117507|NCT01771393|Experimental|CBCT prior to MDCT|To avoid systematic bias in performance or image quality due to dilution of the contrast enhancement within the joint, the order of the CBCT and the MDCT will be randomized. This arm is composed of patients who will have the CBCT performed prior to the MDCT.
3117508|NCT01771393|Experimental|MDCT prior to CBCT|To avoid systematic bias in performance or image quality due to dilution of the contrast enhancement within the joint, the order of the CBCT and the MDCT will be randomized. This arm is composed of patients who will have the MDCT performed prior to the CBCT.
3117509|NCT01771380||Subjects with impaired glucose tolerance|
3117510|NCT01771367|Active Comparator|Fluad|Participants receive one dose of Fluad vaccine.
3117512|NCT01771367|Placebo Comparator|Placebo|Participants receive one dose of saline placebo.
3117513|NCT01771354|Placebo Comparator|Placebo|Placebo
3117514|NCT01771354|Active Comparator|Vaccine|Engerix B vaccine
3117515|NCT01771341|Placebo Comparator|Pressure support|
3117516|NCT01771341|Experimental|NAVA|
3117517|NCT01771328|Active Comparator|hydrocortisone|Treatment B ( Solu-Cortef) the initial standard dose of 10mg/m2/24hrs. Hydrocortisone infusate will be given as Solu-Cortef Act-o-Vial 50mg/ml, produced by Pfizer. Treatment will take 4 months.
3117518|NCT01771328|Active Comparator|cortisone acetate|Treatment A (Cortisone tbl.) is current treatment, i.e. glucocorticoid and mineralocorticoid replacement according to best clinical judgement. This treatment period will take 6 months.
3117519|NCT01771315|Experimental|telephone follow-up|Nurse led follow-up in form of consultation by telephone 4 days and 2weeks after discharge, respectively as a supplement to conventional admission course.
3117520|NCT01771315|No Intervention|Usual treatment|All patients follow conventional admission course which implies preoperative seminar and a discharge planning consultation on the day of discharge. The patients are discharged to home, referred to physiotherapy in the community and a scheduled follow-up by the surgeon after 3 month in the orthopedic outpatient clinic.
3117521|NCT01771302|Active Comparator|Bio-Oss|the xenograft is of bovine origin where the organic phase has been eliminated.
3117522|NCT01771302|Experimental|calcium phosphate ceramic|is a calcium phosphate biomaterial
3117523|NCT01771289|Experimental|chemoradiation|
3117524|NCT01771276|Experimental|Ultimate Anchor|Use of the g-Cath Suture Anchor Delivery Catheter and accessories in placing the ultimate number of anchors for weight loss.
3117525|NCT01771263|Other|iControl-RP|iControl-RP is a system which performs controlled delivery of both remifentanil and propofol infusions.
3117526|NCT01771250|Experimental|LY2605541|Stable dose of LY2605541 (0.2 - 0.8 units per kilogram [U/kg]) administered subcutaneously (SQ) once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.
3117527|NCT01771250|Active Comparator|Insulin Glargine|Stable dose of insulin glargine (0.2 - 0.8 U/kg) administered SQ once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.
3117528|NCT01771237|Experimental|MyPeeps Manualized Group Intervention|Highly interactive, HIV prevention skills-based group intervention in 6 sessions. Tailored to YMSM.
3117529|NCT01771237|Active Comparator|Standard Sexual Health Education|Educational group intervention focused on HIV and STI knowledge using a lecture-based format in 6 sessions. Non-tailored to YMSM.
3117530|NCT01771224|Experimental|palmitoleic acid|Palmitoleic acid: 720 mg/day for 56 days
3117531|NCT01771224|Placebo Comparator|Sugar pill|Sugar pill: 720 mg/day for 56 days
3117532|NCT01771211|Experimental|anodal tDCS|anodal tDCS will be administered for 20 minutes with 1 milliampere (1 mA) to the left inferior frontal gyrus
3117533|NCT01771211|Sham Comparator|sham tDCS|sham tDCS will be administered to the left inferior frontal gyrus
3117534|NCT01771198|Experimental|SIMVASTATIN 40mg|SIMVASTATIN tablet of 40mg once a day during 30 days. Single arm with pre and post treament assessment
3117535|NCT01771185|Active Comparator|Best medical treatment|Metformin 2 g/day; gliclazide 30 mg
3117536|NCT01771185|Active Comparator|Duodenal jejunal bypass plus sleeve gastrectomy|Duodenal jejunal bypass plus sleeve gastrectomy is a metabolic surgical procedure
3117537|NCT01771159|Experimental|Population|All subjects will undergo the implantation of the TBC.
3117538|NCT01771146|Other|Neoadjuvant FOLFIRINOX Regimen|Single arm, treated with neoadjuvant FOLFIRINOX prior to surgical resection
3117539|NCT01771133|No Intervention|Lifestyle and nutrition control group|The control arm will receive routine prenatal care in the prenatal clinic. They will receive regular phone calls and mailings, token gifts and some useful information from data collected in the study, such as physical activity, feedback on behavior throughout the study. To additionally promote adherence (since they will have less contact with study staff), we will include 2 pre-partum and 1 post-partum group sessions meant to increase bonding between participants and retention of control participants. These sessions will include general pregnancy information not related to our interventions.
3117540|NCT01771133|Active Comparator|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
3117541|NCT01771120||Asthma Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
3117542|NCT01771120||Rhinitis Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
3117543|NCT01771120||Asthma and Rhinitis Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
3117544|NCT01771120||Healthy Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
3117545|NCT01771107|Experimental|Treatment (brentuximab and combination chemotherapy)|Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3117546|NCT01771094|Placebo Comparator|Group 1 (placebo) - Water|This group will drink water in 1st trial
3117547|NCT01771094|Experimental|"Group 3 (Intervention) - Low Sucralose"|This group will drink Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage in 1st trial
3117548|NCT01771094|Experimental|"Group 2(Intervention)-High Sucralose"|This group will drink Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage in 1st trial
3117549|NCT01771081||Group1|
3117550|NCT01771068|No Intervention|Waiting list|
3117692|NCT01770041||Liver resection group|Patients undergoing liver resection and receiving paracetamol (observation of routine administration)
3117551|NCT01771068|Experimental|Parenting Discussion Group|Two-hour discussion group on child noncompliance. Groups were composed by a maximum of 10 parents and were facilitated by the principal researcher, who is an accredited practitioner. The groups were interactive and discussion based, and a power point presentation with embedded-video clips was used to aid the facilitator. The key points covered in the discussion group included reasons for disobedience, parenting traps, encouraging good behaviour, and managing disobedience. Parents also received a workbook that included the content covered in the discussion group and 2 follow up telephone calls to check how they were doing after the discussion groups.
3117552|NCT01771055|Experimental|Galactose|Galactose
3117553|NCT01771055|Placebo Comparator|Standard resuscitation|Standard surgical methods of controlling bleeding
3117554|NCT01771042|Experimental|Normal glucose tolerant|"Weight loss attained by 25% caloric restriction.~This arm will be both a glycemic and time control. Initially they will undergo a 4-month weight maintenance phase (acting as time control), followed by 4 month weight loss."
3117555|NCT01771042|Experimental|Impaired glucose tolerant|"Weight loss using 25% caloric restriction.~Impaired glucose tolerant subjects will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
3117556|NCT01771042|Experimental|Type 2 diabetic hyperinsulinemic|"Weight loss using 25% caloric restriction.~This group will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
3117557|NCT01771042|Experimental|Type 2 diabetic hypoinsulinemic|"Weight loss via 25% caloric restriction.~This group will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
3117558|NCT01771003|Placebo Comparator|Without CellAegis' autoRIC™ Device|patients will have a blood pressure cuff attached to their arm that will not inflate/deflate as in the active group
3117559|NCT01771003|Active Comparator|With CellAegis' autoRIC™ Device|Patients will have the CellAegis' autoRIC™ Device attached and it will inflate to 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles (while under general anesthetic)
3117560|NCT01770990|Active Comparator|Tel-PT without mail|Telephone-based psychotherapy (1 personal session, 8-10 telephone sessions, educational materials and monitoring questionnaires) without additional motivating letters.
3117561|NCT01770990|Experimental|Tel-PT including mail|Telephone-based psychotherapy (1 personal session, 8-10 telephone sessions, educational materials and monitoring questionnaires) with an additional motivating letter after every telephone session.
3117562|NCT01770977|Active Comparator|Effective Light-emitting diode therapy|Effects of light-emitting diode therapy on clinical, biochemical and biomechanical of muscle performance in athletes
3117563|NCT01770977|Placebo Comparator|Placebo light-emitting diode therapy|Effect of placebo light-emitting diode therapy on clinical, biochemical and biomechanical of muscle performance in athletes
3117564|NCT01770964|Other|Training Type A, pregabalin|Subjects randomized to receive pregabalin at a site that received training Type A
3117565|NCT01770964|Other|Training Type B, pregabalin|Subjects randomized to receive pregabalin at a site that received training Type B
3117566|NCT01770964|Other|Training Type A, placebo|Subjects randomized to receive placebo at a site that received training Type A
3117567|NCT01770964|Other|Training Type B, placebo|Subjects randomized to receive placebo at a site that received training Type B
3117568|NCT01770938|Active Comparator|Effective light-emitting diode therapy and training|Effects of effective light-emitting diode therapy therapy on muscle performance of young males submitted to physical strength training
3117569|NCT01770938|Placebo Comparator|Placebo light-emitting diode therapy and training|Effects of placebo light-emitting diode therapy on muscle performance of young males submitted to physical strength training
3117570|NCT01770925|Active Comparator|n-CPAP|"The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.~CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.~If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed."
3117571|NCT01770925|Active Comparator|n-BiPAP|"The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.~The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water)."
3117572|NCT01770925|Active Comparator|NIPPV|o The NIPPV group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water).
3117573|NCT01770912||Lactated Ringers|1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.
3117574|NCT01770912||Triamcinolone hexacetonide|1 cc of triamcinolone hexacetonide (5 mg) injected once after the TMJ rinsing procedure.
3117575|NCT01770899|Experimental|Montelukast|Montelukast 5mg capsules for 2-5 year old every 24h and 8mg capsules for 6-14 year olds every 24h.
3117576|NCT01770899|Placebo Comparator|Placebo|One placebo capsule given every 24h
3117577|NCT01770886|Active Comparator|UE2343|Oral capsule
3117578|NCT01770886|Placebo Comparator|Placebo|Oral capsule
3117579|NCT01770873|Experimental|Take Charge 2|Receipt of BBBS mentoring plus youth and parent violence prevention curriculum
3117580|NCT01770873|No Intervention|Control|Standard emergency room protocol followed
3117581|NCT01770860|Active Comparator|6660|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
3117620|NCT01770652|Experimental|Severe Renal Impairment|Severe impairment, defined as having an eGFR 15-19 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
3117621|NCT01770639||MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
3117582|NCT01770860|Active Comparator|4314|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
3117583|NCT01770860|Active Comparator|8336|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
3117584|NCT01770860|Placebo Comparator|4840|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
3117585|NCT01770860|No Intervention|0000|"Device: 0000~At each daily visit, designated study personnel will cut out the center pad of the bandage and apply only the adhesive tabs around the assigned wound site.~Other Names:~Sheer Strips~BAND-AID® with QuiltVent™ Pad Technology~Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site."
3117586|NCT01770847||Healthy controls|Healthy age matched controls
3117587|NCT01770847||Chronic kidney diease|Chronic kidney disease patients stage 2-4
3117588|NCT01770834||Cohort|
3117589|NCT01770821|Active Comparator|Standard physical training & standard nutrition|Standard of care
3117590|NCT01770821|Experimental|Tailored physical training and sipdrink|Tailored physical training and sipdrink (Protein nutridrink, 200 ml x 2)
3117591|NCT01770821|Experimental|Tailored physical training and standard nutrition.|Standard physical training provided by the hospital and standard hospital nutrition
3117592|NCT01770821|Experimental|Standard physical training and sip drink|Standard physical training provided by the hospital and sipdrink (Nutridrink protein, 200 ml x2)
3117593|NCT01770808|Experimental|AquaCal|AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg).
3117594|NCT01770808|Experimental|AquaPT|AquaPT are produced by Marigot Ltd. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract.
3117595|NCT01770808|Placebo Comparator|Placebo|Produced by Marigot Ltd
3117596|NCT01770795|Experimental|Genexol-PM/Gemcitabine|
3117597|NCT01770782|Other|Laser Scanner|Laser Scanner (Vivid 9i® - Konica Minolta)was used to digitize the study casts. After scanning the dental casts a 3D virtual dental casts was used to realize all measurements (pre-treatment, 4 months and 10 months).
3117598|NCT01770782|Other|SARME|Surgically Assisted rapid Maxillary Expansion -SARME was used for the treatment of transverse maxillary deficiency.This procedure is a combination of a surgical procedure and orthopedic expansion of the maxilla.
3117599|NCT01770769|Active Comparator|Internal fixation - standard treatment|Internal fixation with two parallel cancellous screws (Hip Pins(R)) Current standard treatment
3117600|NCT01770769|Experimental|Hemi - arthroplasty|cemented Hemi - arthroplasty (Exeter(R)) modular system V40 by Stryker. Refobacin cement.
3117601|NCT01770756|Experimental|Enhancing willpower using active skills|This group will use active tasks such as learning skills using hands to enhance willpower.
3117602|NCT01770756|Experimental|Enhancing willpower using passive tasks|This group will use passive tasks such as taking still postures to enhance willpower.
3117603|NCT01770743|Experimental|AV7909 (Day 0 and 14)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
3117604|NCT01770743|Experimental|AV7909 (Day 0 and 28)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
3117605|NCT01770743|Experimental|AV7909 (Day 0, 14, and 28)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
3117606|NCT01770743|Experimental|AV7909 Reduced Dose|Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
3117607|NCT01770743|Active Comparator|BioThrax|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
3117608|NCT01770730|Experimental|LAM plus standard care|Patients allocated to this study arm will receive urine LAM strip testing in addition to the standard TB diagnostic tools WHO approved and available at each site
3117609|NCT01770730|No Intervention|Standard care|Patients allocated to this study arm will receive standard TB diagnostics currently WHO approved and available at the study site
3117610|NCT01770717||Pressure Ulcer Formation|Assessment of Pressure Ulcer Formation using Spatial Frequency Domain Imaging
3117611|NCT01770704||Patients diagnosed with bipolar disorder I or II|
3117612|NCT01770691|Experimental|TIPI vaginal pessary|Each subject will use different SMD'S (Slightly modified designs) of the TIPI vaginal pessary. Not all subjects will use all types of SMD's
3117613|NCT01770678|Experimental|Constraint induced movement therapy (prolonged restraint)|Constraint induced movement therapy(prolonged restraint)consists of a combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb over a forty-two day period.
3117614|NCT01770678|Active Comparator|Constraint induced movement therapy(manual restraint)|Constraint induced movement therapy(manual restraint)consists of a combination of manual restraint of the unaffected upper limb and massed practice of the affected upper limb over a forty-two day period.
3117615|NCT01770665||Mesothelioma|
3117616|NCT01770665||all cancer types|
3117617|NCT01770652|Experimental|Normal renal function|Healthy volunteers, defined as having an estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
3117618|NCT01770652|Experimental|Mild Renal Impairment|Mild impairment, defined as having an eGFR 60-89 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
3117619|NCT01770652|Experimental|Moderate Renal Impairment|Mild impairment, defined as having an eGFR 30-59 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
3117622|NCT01770626|No Intervention|Single arm|evaluate the composition of a participant's body, diagnosed with a brain tumor (glioblastoma multiforme) as determined by bioelectrical impedance analysis
3117623|NCT01770613|Experimental|Stem Cells|ALLOGENEIC MESENCHYMAL BONE MARROW CELLS
3117624|NCT01770613|Placebo Comparator|Control|Lactated Ringer's Solution
3117625|NCT01770600|Active Comparator|Risperidone|Administer pill of risperidone 1 mg once a day by mouth for 5 days.
3117626|NCT01770600|Placebo Comparator|Placebo|Administer pill of placebo once a day by mouth for 5 days.
3117627|NCT01770587|Experimental|Behavioral Insomnia Treatment|Brief Behavioral Insomnia Treatment
3117628|NCT01770574|Experimental|ReproBone|calcaneal lengthening
3117629|NCT01770574|Active Comparator|Autologous bone graft|calcaneal lengthening
3117630|NCT01770561|Experimental|Integrated sensor and infusion set.|All subjects must have been previously diagnosed Type 1 Diabetics and being used to sensor augumented pumps
3117631|NCT01770548|Experimental|Autism|Analysis of the glutamate synapse in autism
3117632|NCT01770548|Other|Relative|Analysis of the glutamate synapse in autism
3117633|NCT01770548|Other|Major control|DNA collection
3117634|NCT01770548|Other|Minor control|auditory evoked potentials
3117635|NCT01770509|Active Comparator|Standard of care|Standard of care: Dressings +Compression garments
3117636|NCT01770509|Experimental|Application of NMBM|Daily application of NMBM
3117637|NCT01770496|No Intervention|No reminder / recall notice|No childhood vaccination reminder / recall notification sent. Stratified by age cohort of subjects: 7 month recall; 12 month reminder; 19 month recall
3117638|NCT01770496|Experimental|mailed reminder / recall notice|Childhood vaccination reminder / recall notification sent by postal mail. Stratified by age cohort of subjects: 7 month recall; 12 month reminder; 19 month recall
3117639|NCT01770483|Experimental|study group|Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months
3117640|NCT01770483|Active Comparator|control group|Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months
3117641|NCT01770470||Patients receiving chronic hemodialysis|Dialysis patients chewing chitosan-containing gum
3117642|NCT01770444|Experimental|Low-dose cardiac CT|Patients randomized to this group will be assessed by low-dose cardiac CT protocol.
3117643|NCT01770444|Other|Conventional cardiac CT|Patients randomized to this group will be assessed by conventional cardiac CT protocol.
3117644|NCT01770431|Experimental|Huaier Granule group|"Huaier Granule group; specifications: 20g / bag; manufacturer: Qidong Gaitianli Medicines Co., Ltd..~Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 96 weeks after surgery or until study termination. The subjects should not take any other anticancer drugs or immunomodulatory agents, except for Huaier Granule."
3117645|NCT01770431|No Intervention|Bank-control group|"Blank-control group, not taking Huaier Granule, other anticancer drugs, or immunomodulatory agents.~During the study, patients who need antiviral therapy, in both the test group and control group, can be treated according to the therapeutic principles."
3117646|NCT01770418|Experimental|Proton Radiotherapy with Chemotherapy|
3117647|NCT01770405||pancreatic cysts|Patient indicated for a first endoscopic ultrasound fine needle aspiration (EUS-FNA) for a pancreatic cyst,
3117648|NCT01770392|Active Comparator|Test|multiple doses of Rifampicin + single dose of Nintedanib
3117649|NCT01770392|Experimental|Reference|single dose of Nintedanib
3117650|NCT01770379|Experimental|Secukinumab 75 mg|Secukinumab 75 mg s.c.
3117651|NCT01770379|Experimental|Secukinumab 150 mg|Secukinumab 150 mg s.c.
3117652|NCT01770379|Placebo Comparator|Placebo|Placebo patients will be re-randomized 1:1 to secukinumab 75 or 150mg s.c. (non-responders at Week 16 will be re-assigned to new treatment at Week 16; responders at Week 16 will be re-assigned to new treatment at Week 24)
3117653|NCT01770366|Placebo Comparator|Usual Care|Patients will receive usual care from the post-surgical clinic team.
3117654|NCT01770366|Experimental|Intervention Condition|Intervention participants will receive the Weight and Exercise Lifestyle Support (WELS) intervention, which involves use of a wireless activity monitor and weight scale, as well as access to a patient portal website displaying data from these devices.
3117655|NCT01770353|Experimental|Pilot Phase: Ferumoxytol followed by MM-398 (CLOSED)|Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min on Days 1 and 15 of every 4 week cycle
3117656|NCT01770353|Experimental|Expansion Phase: Ferumoxytol followed by MM-398|Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min dose 1 on Days 1 and 15 of every 4 week cycle Cohort 1: ER and/or PR-positive BC Cohort 2: TNBC Cohort 3: BC with active brain metastasis
3117657|NCT01770340|Sham Comparator|Control group|Radical prostatectomy without implantation of allograft
3117658|NCT01770340|Experimental|Treatment group|Radical prostatectomy with implantation of allograft
3117659|NCT01770327|Placebo Comparator|Group 1 (placebo) - Water|This group will drink water in 1st trial
3117660|NCT01770327|Experimental|Group 2 (Intervention) - Milk|This group will drink Non-Fat Milk in 1st trial
3117661|NCT01770327|Experimental|Group 3 (Intervention) - Orange Juice|This group will drink Orange Juice in 1st trial
3117662|NCT01770327|Experimental|Group 4 (Intervention) - Iced Tea|This group will drink Iced Tea in 1st study
3117663|NCT01770314|Experimental|Experimental|Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
3117664|NCT01770314|No Intervention|Control|The control group is a waitlist control. Participants will be given access to painACTION after the intervention period and follow up assessments are completed.
3117690|NCT01770067|Experimental|Infection Prone Patients Prior to CIED|Administration of high-dose antibiotics (CIA-RNPT)
3117691|NCT01770054||obtention of a blood sample|all Atahualpa residents aged 40 years or more
3117665|NCT01770301|Active Comparator|A - Paclitaxel|patients will receive paclitaxel alone at the dose 80 mg/m² administered by intravenous injection at D1, D8 and D15 every 4 weeks for 6 cycles. Thereafter, patients will be followed-up with imaging exams every 12 weeks. At the time of confirmed progression, patients could receive bevacizumab 15 mg/kg every 3 weeks for 12 months following investigator's decision. In some cases, longer therapy may be allowed after discussion with the Principal Investigator/Sponsor
3117666|NCT01770301|Experimental|B - Paclitaxel + Bevacizumab followed by Bevacizumab|patients will receive paclitaxel at the dose 80 mg/m² administered by intravenous injection at D1, D8 and D15 every 4 weeks + Bevacizumab at the dose 10 mg/kg administered by intravenous injection every 2 weeks (D1 and D15) for 6 cycles. Thereafter, patients will receive IV injection of bevacizumab 15 mg/kg every 3 weeks for up to 1 year
3117667|NCT01770288|Experimental|Anaerobic Performance|
3117668|NCT01770275||patients with esophageal cancer|Patients with esophageal cancer who underwent esophagectomy
3117669|NCT01770262||Osteoporosis|Hospitalized subjects diagnosed with osteoporosis
3117670|NCT01770262||Healthy|
3117671|NCT01770249|Other|Per-oral Endoscopic Esophagomyotomy (POEM)|An endoscopic surgical procedure for achalasia; Per-oral Endoscopic Esophagomyotomy (POEM)will be performed. The POEM procedure will be performed in the operating room under general anesthesia and a scope will then be inserted into your mouth and down your throat and measurements will be taken. With the use of this lighted flexible scope the surgeon will make a small incision in the inner lining of your esophagus (throat), create a tunnel and then cut the muscle between the esophagus (throat) and the stomach. The initial little opening will be closed with a small clip. This procedure will allow easier passage of food into the stomach.
3117672|NCT01770236|Experimental|IV acetaminophen|Patients in this group will receive intraoperative intercostal block + IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)
3117673|NCT01770236|No Intervention|On-Q Pain Pump catheter|Patients in this group will receive the current standard care which includes an intraoperative intercostal block + On-Q Pain Pump catheter (continuous dosing).
3117674|NCT01770223|Experimental|Boceprevir + PegIFN-2b + RBV|All participants will start treatment with 4 weeks of PegIFN-2b subcutaneously, 1.5μg/kg per week + RBV capsules orally, at a weight-based dose between 800-1400 mg/day divided into two daily doses (double therapy). Participants without cirrhosis will then continue on the PegIFN-2b and RBV with the addition of boceprevir capsules orally, 800 mg three times per day for 32 weeks (triple therapy), and will transition back to double therapy for the final 12 weeks of treatment (48 total weeks of therapy). Participants with cirrhosis or documented as null responders will receive triple therapy for 44 weeks (48 total weeks of therapy).
3117675|NCT01770210||Cardiovascular events|Patients on atorvastatin treatment hospitalised due to cardiovascular events
3117676|NCT01770197||recombinant tissue plasminogen activator|Stroke patients with rt-PA treatment in the 3-4.5 hour time window were compared with those within 3h.
3117677|NCT01770197||rt-PA|One group of was treated with standard recombinant tissue plasminogen activator therapy in 3h and the other group of stroke patients was treated within 3-4.5h.
3117678|NCT01770184|Experimental|Intervention Group|The intervention group will receive the rehabilitation services and support that is recommended and provided in the current health care structure. The intervention group will also receive the Chronic Disease Self-Management Program (CDSMP). The CDSMP is an education program based on the concept of self-management. Self-management refers to the ability of an individual to manage the day-to-day responsibilities of living with a chronic condition. The CDSMP will be delivered in two and a half hour sessions, once a week, for six weeks, in group format.
3117679|NCT01770184|No Intervention|Usual Care Group|The usual care group for this study will receive the rehabilitation services and support that is recommended and provided in the current health care structure. No additional intervention will be provided to the usual care group within this study.
3117680|NCT01770171|Experimental|Carboplatin-paclitaxel-bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg every 3 weeks until disease progression
3117681|NCT01770171|Active Comparator|carboplatin-paclitaxel|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
3117682|NCT01770145|Experimental|APOKYN|"APOKYN (apomorphine hydrochloride injection) is used as needed to treat off-episode motor symptoms, such as muscle stiffness, slow movements, and difficulty starting movements, in people with advanced Parkinson's disease (PD).~In the study, subjects will complete an L-Dopa Baseline Period in which they record daily time to on following their regularly scheduled L-Dopa morning dose for 7 days. At the end of the baseline period, patients will start trimethobenzamide therapy during a minimum 3-Day Anti-Emetic Pretreatment Period. Patients determined to remain eligible at the end of the required Anti-Emetic Pretreatment Period will be initiated on APOKYN therapy by an investigator. Once the appropriate dose is identified by a study investigator, patients will inject APOKYN at their regularly scheduled levodopa morning dose time (levodopa will be delayed by 40 minutes) daily during a 7-day APOKYN Treatment Period and record time to on following the APOKYN injection."
3117683|NCT01770132|Experimental|porfimer sodium, EUS-PDT, gemcitabine|Patients receive porfimer sodium IV over 3-5 minutes on day 1 and undergo endoscopic ultrasonography-photodynamic therapy (EUS-PDT) on days 1, 3, 8, and 21. After completion of EUS-PDT, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 of courses 1 and 2 and on day 22 of courses 3 and 5. During courses 1-5, treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After course 5, treatment with gemcitabine hydrochloride repeats every 2 months in the absence of disease progression or unacceptable toxicity.
3117684|NCT01770119|Experimental|MMR vaccination|MMR vaccine to seronegative pediatric SOT recipients
3117685|NCT01770106|Experimental|Denosumab|Patients in this arm will receive subcutaneous injection of denosumab 60mg every 6 months (1 dose for the study period).
3117686|NCT01770106|Active Comparator|Standard treatment|Patients (n=20) in this arm will receive oral alendronate (Fosamax®)70mg once.
3117687|NCT01770093||Parents of Pediatric Inpatients|
3117688|NCT01770080|Active Comparator|Euminz®|Acute treatment (3 to 5 time topical use of Euminz® = 10%ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
3117689|NCT01770080|Placebo Comparator|Placebo|Acute treatment (3 to 5 time topical use of Placebo= 0,5% ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
3117693|NCT01770028||Intervention partners|Partners of pregnant women randomized to lifestyle intervention. Note: There is no intervention in partners of pregnant women.
3117694|NCT01770028||Standard care partners|Partners of pregnant women randomized to Standard Care. Note: There is no intervention in partners of pregnant women.
3117695|NCT01770015|Experimental|ventilated patient|"all patients underwent the same diagnostic test . cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization.~HLA DR antigen, cytokines (IL 6 and 10), B-glucan. fungi and bacteria endotracheal aspiration"
3117696|NCT01770002|Active Comparator|Everted suture technique|Technique that everts the skin; the edges will sit up against each other in a little peak, raised above the surrounding skin.
3117697|NCT01770002|Active Comparator|Non-everted suture technique|Surgical wound will be approximated such that the suture line is flat relative to the surrounding skin.
3117698|NCT01769989|Active Comparator|Eletrodermabrasion|The side treated with electrodermabrasion will be burned with an electric cautery machine to remove the outermost layer of skin as well as the lumps and bumps and a small area of surrounding skin.
3117699|NCT01769989|Active Comparator|Dermabrasion|The side treated with dermabrasion will be scraped with a sterile piece of sandpaper until the outermost layer of skin and lumps and bumps have been removed and a small layer of surround skin.
3117700|NCT01769976|Experimental|Daily energy restriction|25% reduction in daily energy intake
3117701|NCT01769976|Active Comparator|Energy balance diet|Diet provides 100% of energy requirements and is designed to achieve weight stability
3117702|NCT01769976|Experimental|Periodic fasting with weight loss|Fast 3 days per week, and consume 1.5 times usual amount of food on other days
3117703|NCT01769976|Experimental|Periodic fasting without weight loss|Fast 3 days per week, and consume double usual amount of food on other days
3117704|NCT01769963|Experimental|Dietary intervention|All participants will be fed a high AGE diet followed by a low AGE diet (single arm study)
3117705|NCT01769950|Experimental|Choline-PET arm|Every eligible patient will be scanned with Choline-PET at the time of diagnosis of prostate cancer. MRI will also be obtained as it is the current standard of care. CT scan will be obtained as part of the same procedure while procuring the Choline-PET scan with PET-CT dual imaging hardware.
3117706|NCT01769937|Experimental|H.P. Acthar Gel SQ injection|Patients will administer single dose (80 units) of Acthar subcutaneously every day for 10 days (with a possible 5 day dosing rescue).
3117707|NCT01769924||Live kidney donors|Nephrectomy
3117708|NCT01769924||Healthy controls|Who also meet criteria to donate a kidney
3117709|NCT01769911|Experimental|Treatment (gene modified peripheral blood cell transplant)|"CONDITIONING: Patients receive carmustine IV over 3 hours on day -7, cytarabine IV over 2 hours BID and etoposide IV over 2 hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2.~TRANSPLANTATION: Patients receive an autologous PBSC infusion and/or infusion of autologous transduced hematopoietic cells on day 0.~Beginning 28-120 days later, patients eligible for in vivo selection after detection of gene-marked cells receive O6-benzylguanine IV over 1 hour and carmustine IV over 3 hours on days 14, 28, and then monthly until completion of therapy. Patients achieving > 10% gene marking and CD4 count of >= 500 cells/uL receive up to 2 courses of structured treatment interruption without undergoing in vivo selection."
3117710|NCT01769898|Placebo Comparator|Placebo+formoterol-budesonide|"Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks.~Inhaled Formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks."
3117711|NCT01769898|Experimental|Theophylline+formoterol-budesonide|"Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks.~Inhaled formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks."
3117712|NCT01769885|Experimental|Treatment (tivozanib and surgery)|Patients receive tivozanib PO QD on days 1-21. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. 25 days after completion of tivozanib, patients undergo curative nephrectomy.
3117713|NCT01769872|Experimental|Autologous Adipose Tissue derived MSCs|
3117714|NCT01769846|Experimental|Early Mobilization protocol|Early Mobilization protocol: Patients in the treatment group additionally received a progressive cycling exercise session 7 days a week, until the last day of ICU stay, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH & Co. KG, Betzenweiler, Germany). Cycling exercise will be realized during 30 consecutive minutes, initially in continuos and passive (classified patients with RASS - 4) exercise, at a fixed pedaling rate of 20 cycles/min and after in actively (classified patients with RASS 0), with an exercise intensity of 3-5 on the Borg rate of perceived exertion scale.
3117715|NCT01769846|No Intervention|Control group|Group will undergo usual mobilization per standard ICU care. Conventional physical and respiratory therapy were provided by the ICU physical therapists twice daily, for approximately 30 min, 7 days per week. The protocol included vibrocompression maneuvers; lung hyperinflation by the mechanical ventilator; and tracheal aspiration, when necessary; as well as passive and active-assisted motor exercises for arms and legs, depending on the clinical course of patients.
3117716|NCT01769833|Active Comparator|PEG-interferon-alfa 2A|PEG-interferon-alfa 2A
3117717|NCT01769833|Placebo Comparator|Nucleosides|Nucleosides
3117718|NCT01769820|Active Comparator|Dexamethasone|Study 1, and study2(2 arms); Dexamethasone 1.5mg daily Study 3 (adaptive -7 arms): Dexamethasone of 0.4, 0.8, 1.0, 1.2, 1.5, and 1.8 mg total dose per day
3117719|NCT01769820|Placebo Comparator|Placebo|Placebo
3117720|NCT01769807|Experimental|CPAP treatment|67 consecutive male patients with OSA were recruited: 36 with mild-moderate OSA and 31 with severe OSA. Data were collected in all subjects at baseline and after 1 month of CPAP.
3117721|NCT01769794|Active Comparator|Western therapy & Placebo|Western therapy(oral care, skin care and reducing temperature) Placebo for JET(Jinlianqingre Effervescent Tablets )
3117722|NCT01769794|Experimental|Western therapy & JET|Jinlianqingre Effervescent Tablets plus western therapy
3117723|NCT01769781|Experimental|anastrazole|women with endometriosis recurrence will be treated with Leuprolide acetate 11,25mg plus anastrazole 1mg/day for three months
3117724|NCT01769781|Active Comparator|GnRH analog alone|women with endometriosis recurrence will be treated with leuprolide acetate 11.25mg
3117725|NCT01769768|Experimental|LDE225+Warfarin|At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the warfarin group.
3117804|NCT01769222|Experimental|Ipilimumab 25 mg|Participants receive ipilimumab intratumorally on Day 1
3117726|NCT01769768|Experimental|LDE225+Bupropion|At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the Bupropion group
3117727|NCT01769755|Experimental|Human Placenta-Derived Cells PDA001 Intravenous Infusion|Intravenous infusion of Human Placenta-Derived Cells PDA001 over the course of 2 hours.
3117728|NCT01769755|Placebo Comparator|Vehicle controlled placebo|Intravenous infusion of Vehicle Controlled Placebo over the course of 2 hours
3117729|NCT01769742|Experimental|Early mobility bundle|Delivery of early targeted physiotherapy to patients on the interventional wards; to comprise assessment and communication of mobility to ward staff and patient, provision of mobility aids, guidance and encouragement to patient and staff to allow patient to dress and mobilise independently if clinically safe to do so
3117730|NCT01769742|No Intervention|Usual care|Usual physiotherapy service only
3117731|NCT01769729|Experimental|PEPP + care management|"This 4-month collaborative psychotherapy, entitled Program for Emotional and Physical Pain (PEPP), will include 1 joint meetings with the behavioral health specialist (BHS), primary care provider (PCP), and patient, 10 psychotherapy sessions, and continued collaboration between the BHS and the PCP to assure a shared treatment plan.~Care management will include monthly calls with a depression care manager."
3117732|NCT01769729|Active Comparator|Care management alone|Care management will include monthly calls with a depression care manager.
3117733|NCT01769716|Experimental|Umbilical cord blood transplantation|Allogeneic umbilical cord blood will be administered intravenously or intraarterially under non-myeloablative immunosuppression. In case of autologous umbilical cord blood, immunosuppression is not required.
3117734|NCT01769703|Experimental|Dabigatran|
3117735|NCT01769690|Experimental|DBS stimulator setting alteration|
3117736|NCT01769677|Experimental|Treatment Group AB|"Subjects in this group will receive study drug in the following sequence:~Treatment A: two 45-mg hydrocodone bitartrate extended-release tablets (reference).~Treatment B: one 90-mg hydrocodone bitartrate extended-release tablet (test)."
3117737|NCT01769677|Experimental|Treatment Group BA|"Subjects in this group will receive study drug in the following sequence:~Treatment B: one 90-mg hydrocodone bitartrate extended-release tablet (test).~Treatment A: two 45-mg hydrocodone bitartrate extended-release tablets (reference)."
3117738|NCT01769664|Experimental|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.)
3117739|NCT01769664|Active Comparator|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel)
3117740|NCT01769664|Placebo Comparator|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.)
3117741|NCT01769651||Drug service users|Those patients who receive Methadone replacement therapy as part of their treatment plan. In addition, those drug user patients who have a first consultation session with their Addiction Nurses.
3117742|NCT01769638|Experimental|SPO1101|
3117743|NCT01769638|Experimental|SPO1101D|
3117744|NCT01769625|Placebo Comparator|placebo & cholecalciferol 400 IU|In this arm, the placebo is in place of celecoxib and the current RDA for cholecalciferol is used the control of the cholecalciferol higher dose.
3117745|NCT01769625|Active Comparator|placebo & cholecalciferol 2,000 IU|Placebo & cholecalciferol 2,000 IU
3117746|NCT01769625|Experimental|celecoxib 400mg & cholecalciferol 2,000 IU|celecoxib 400 mg & cholecalciferol2,000 IU
3117747|NCT01769612||CL Detect Rapid Test and Microsopy Samples|Samples taken to be evaluated in the CL Detect and Microscopy assays
3117748|NCT01769599||Grid Treatment|30 patients that were treated with laser grid treatment
3117749|NCT01769599||Avastin Treatment|patients that were treated with Avastin injections
3117750|NCT01769586|Active Comparator|Diphenhydramine|Increments of 25 mcg to maximum of 3 times (total 75 mcg)
3117751|NCT01769586|Active Comparator|Midazolam|1.5 mg increments up to 3 times (maximum 4.5 mg)
3117752|NCT01769573|Experimental|100 TCID50|RG-HRV16 dose of 100 TCID50 administered intranasally (0.25ml per nostril) one time.
3117753|NCT01769573|Experimental|1,000 TCID50|RG-HRV16 dose of 1,000 TCID50 administered intranasally (0.25ml per nostril) one time.
3117754|NCT01769573|Experimental|10,000 TCID50|RG-HRV16 dose of 10,000 TCID50 administered intranasally (0.25ml per nostril) one time.
3117755|NCT01769573|Placebo Comparator|Placebo|Diluent administered intranasally (0.25ml per nostril) one time.
3117756|NCT01769573|Experimental|500 TCID50|RG-HRV16 dose of 500 TCID50 administered intranasally (0.25ml per nostril) one time.
3117757|NCT01769560|No Intervention|Centers for Disease Control and Prevention (CDC) Fact Sheet|Participants will receive the CDC Fact sheet about HPV vaccination while they are taking the survey.
3117758|NCT01769560|Experimental|MeFirst Intervention|Participants will receive a tailored website regarding their own individualized risk for HPV and information about HPV Vaccination while they are taking the survey as opposed to receiving the CDC fact sheet. This tailored website is generated based on answers provided by each subject in the baseline survey.
3117759|NCT01769547|Experimental|Dovitinib|Dovitinib 500 mg PO OD (5 days on, 2 days off); Each cycle = 28 days
3117760|NCT01769521|Experimental|Triggerfish|Device: Sensimed Triggerfish
3117761|NCT01769508|Experimental|Combined Therapy|Combined Modality Treatment of Radiation therapy, 5-Fluorouracil, Oxaliplatin and Lapatinib followed by Surgery
3117762|NCT01769495|No Intervention|Control|Standard post ED care
3117763|NCT01769495|Experimental|2-3 day return appointment|Patients will receive further treatment in Geriatric Clinic 2-3 days post ED discharge.
3117764|NCT01769482|Experimental|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg or placebo po q d for 3 months.
3117765|NCT01769482|Placebo Comparator|Placebo|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg or placebo po q d for 3 months.
3117766|NCT01769469||Subjects Enrolled in ATN 110 or ATN 113|A subset of 100 participants who are enrolled in the ATN 110 or ATN 113 study will be recruited for participation in this study. There is no treatment or intervention for this study; however, all subjects will be on daily coformulated tenofovir/emtricitabine (TDF/FTC (Truvada®)) as part of the ATN 110 or ATN 113 study.
3117767|NCT01769456|Experimental|PCC Behavioral Intervention Group|PCC Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
3118370|NCT01765452|Active Comparator|Plavix with Astrix|75mg per day, 8weeks, PO 100mg per day, 8weeks, PO
3117768|NCT01769443|No Intervention|No Desensitization Therapy|Subject(s) randomized to no desensitization therapy pre-transplant.
3117769|NCT01769443|Experimental|Desensitization Therapy|"Subject(s) randomized to desensitization therapy pre-transplant.~Desensitization therapy regimen pre-transplant: Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib."
3117770|NCT01769430||Community acquired respiratory infection|Measurement of exhaled breath aerosol
3117771|NCT01769417|Placebo Comparator|Placebo|
3117772|NCT01769417|Active Comparator|MEDI4893|
3117773|NCT01769404|Experimental|LY2605541|Stable dose of LY2605541 (0.2 - 0.6 units per kilogram [U/kg]) administered subcutaneously (SQ) once daily for at least 14 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.
3117774|NCT01769404|Active Comparator|Insulin Glargine|Stable dose of insulin glargine (0.2 - 0.6 U/kg) administered SQ once daily for at least 14 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.
3117775|NCT01769391|Experimental|Necitumumab +Paclitaxel+Carboplatin|"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.~Paclitaxel 200 milligram per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.~Carboplatin Area Under the Curve (AUC)6 (mg•min/mL) administered IV on Day 1 of every 3 week cycle.~The combination of paclitaxel-carboplatin and necitumumab may continue for a maximum of 6 cycles. Necitumumab may continue until Progressive Disease (PD), toxicity requiring cessation, protocol noncompliance, or withdrawal of consent."
3117776|NCT01769391|Active Comparator|Paclitaxel + Carboplatin|Paclitaxel 200 mg/m² administered IV on Day 1 of every 3 week cycle. Carboplatin AUC=6 administered IV on Day 1 of every 3 week cycle. The combination of paclitaxel-carboplatin may continue for a maximum of 6 cycles. After completion of chemotherapy, participants will be followed until radiographic documentation of PD.
3117777|NCT01769378|Placebo Comparator|Placebo|Placebo administered subcutaneously (SQ) once weekly for 24 weeks added to the participant's prescribed glimepiride dose.
3117778|NCT01769378|Experimental|Dulaglutide|Dulaglutide 1.5 milligram (mg) administered SQ once weekly for 24 weeks added to the participant's prescribed glimepiride dose.
3117779|NCT01769365|Experimental|7-day quadruple therapy|"pantoprazole 40 mg twice daily for 7 days,~clarithromycin 500 mg twice daily for 7 days,~amoxicillin 1 g twice daily for 7 days,~metronidazole 500 mg twice daily for 7 days"
3117780|NCT01769365|Experimental|10-day sequential therapy|"pantoprazole 40 mg twice daily for 5 days and amoxicillin 1 g twice daily for 5 days, followed by~pantoprazole 40 mg twice daily for 5 days, clarithromycin 500 mg twice daily for 5 days, metronidazole 500 mg twice daily for 5 days."
3117781|NCT01769365|Active Comparator|7-day standard triple therapy|"pantoprazole 40 mg twice daily for 7 days,~clarithromycin 500 mg twice daily for 7 days,~amoxicillin 1 g twice daily for 7 days."
3117782|NCT01769352|Active Comparator|PredA q1h WA + Kelac qid|Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthlmic solution four times a day (qid)
3117783|NCT01769352|Active Comparator|PredA qid + Kelac qid|Prednisolone acetate (PredA) 1% ophthalmic solution four times a day (qid) and Ketorolac (Kelac) 0.5% ophthlmic solution four times a day (qid)
3117784|NCT01769339|Experimental|Miconazole plus Hydrocortisone|
3117785|NCT01769326|Experimental|MusicGlove Group|Subject participates in 3 weeks of exercising with the experimental device: MusicGlove at a minimum of 3 days per week, 1 hour per day with the exercise program
3117786|NCT01769326|Active Comparator|Control Group for Music Glove|Subject participates in 3 weeks of conventional hand exercise program, at a minimum of 3 days per week, 1 hour per day with the exercise program.
3117787|NCT01769326|Experimental|Resonating Arm Exerciser (RAE)|Subject participates in 3 weeks of exercising with the experimental device: RAE at a minimum of 3 days per week, 1 hour per day with the exercise program
3117788|NCT01769326|Active Comparator|Control Group for RAE|Subject participates in 3 weeks of conventional arm exercise program, at a minimum of 3 days per week, 1 hour per day with the exercise program.
3117789|NCT01769313|Experimental|Group A|In Group A the anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
3117790|NCT01769313|Active Comparator|Group B|Group B acts as a control group where the capsulotomy as well as the lens fragmentation is performed manually.
3117791|NCT01769300|No Intervention|Control practices|Practices that do not use the ADHD clinical decision support
3117792|NCT01769300|Experimental|Clinical decision support|Electronic health record-based clinical decision support for ADHD medication titration.
3117793|NCT01769287||Surgical operation|The study aims to recruit a total of 20 patients, 10 of whom have AF and 10 who do not.
3117794|NCT01769274|Experimental|PF-05089771 1600 mg|
3117795|NCT01769274|Placebo Comparator|Placebo comparator: matching placebo|Single oral dose of placebo for PF-05089771 1600 mg
3117796|NCT01769261|Experimental|Internet, eligible patients|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
3117797|NCT01769261|Active Comparator|Telephone, eligible patients|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge..
3117798|NCT01769261|Other|" Non eligible patients"|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
3117799|NCT01769248|Active Comparator|Fine needle aspiration|fine needle aspiration
3117800|NCT01769248|Active Comparator|Fine needle biopsy|Fine needle biopsy
3117801|NCT01769235|Experimental|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)
3117802|NCT01769235|Active Comparator|Acanya® Gel, 1.2%/2.5%|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)
3117803|NCT01769235|Placebo Comparator|Vehicle of test product|Vehicle of test product (Taro Pharmaceuticals Inc.)
3117805|NCT01769222|Experimental|Ipilimumab 25 mg and radiation therapy|Participants receive ipilimumab intratumorally on Day 1 and undergo local radiation therapy (10 Gy/fraction) within 48 hours for at least 3 fractions
3117806|NCT01769209|Experimental|Treatment (bortezomib, chemotherapy)|Patients receive bortezomib SC on days 1, 4, 8, and 11; doxorubicin hydrochloride IV on day 1; pegaspargase IV or IM on days 5 and 22; vincristine sulfate IV on days 1, 8, 15, and 22; dexamethasone PO daily on days 1-14; cytarabine IT on day 1 and methotrexate IT on day 15. Patients with central nervous system disease receive intrathecal treatment per investigator's discretion.
3117807|NCT01769196|Experimental|Simtuzumab|Participants will receive simtuzumab for up to 254 weeks.
3117808|NCT01769196|Placebo Comparator|Simtuzumab Placebo|Participants will receive simtuzumab placebo for up to 254 weeks.
3117809|NCT01769183|Experimental|Squalamine|Study eyes will be assigned to receive Squalamine. The dose will be one drop twice daily. If neovascularization fails to regress at week one or if neovascularization returns within the study, the dose will be increased to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Patients will continue administering study drug until week 20.
3117810|NCT01769170|Placebo Comparator|CMX001|placebo BIW
3117811|NCT01769170|Active Comparator|CMX001 100mg|100 mg CMX001 BIW
3117812|NCT01769157|Active Comparator|L-carnitine|L-carnitine 330mg, 3 tablet twice daily
3117813|NCT01769157|Placebo Comparator|Placebo|placebo drug, 3 tablet twice daily
3117814|NCT01769144|Active Comparator|Acticoat Absorbent|Acticoat Absorbent wound dressing
3117815|NCT01769144|Experimental|BCT wound dressing|wound dressing
3117816|NCT01769131||Allis|
3117817|NCT01769131||Tenaculum|
3117818|NCT01769118||Caffeine|caffeine will be given according to clinical judgment
3117819|NCT01769105|Active Comparator|Standard Lid Hygiene Regime|Patients receive detailed verbal and written instruction to perform lid hygiene twice daily
3117820|NCT01769105|Active Comparator|Lipiflow|Patients receive a singe Lipiflow-treatment
3117821|NCT01769092|Experimental|Fish Oil|Each capsule contains 625 mg of fish oil (100 mg EPA & 250 mg DHA). Participants will take 12 capsules per day over 6 months.
3117822|NCT01769092|Placebo Comparator|Safflower Oil|Each capsule will contain 625 mg of Safflower oil. Participants will take 12 capsules per day over 6 months.
3117823|NCT01769079|Active Comparator|oral nitrate|In nitrate group will be provided the same prescribed dose for this drug. One group remains on nitrate use and other on placebo (same number of pills) use.
3117824|NCT01769079|Placebo Comparator|Placebo|In the placebo group will be given the same dose and frequency prescribed nitrate.
3117825|NCT01769066|Experimental|Sequential Gefitinib With Pemetrexed/Platinum|Pemetrexed IV 500 mg/m2 ，DAY2 DDP IV 75mg/m2 ，DAY1 OR CAP IV AUC 5,DAY1 Gefitinib PO. 250mg DAY3-16
3117826|NCT01769066|Active Comparator|Pemetrexed/Platinum|Pemetrexed IV 500 mg/m2 ，DAY2 DDP IV 75mg/m2 ，DAY1 OR CAP IV AUC 5,DAY1
3117827|NCT01769053|Active Comparator|Variable Ventilation|Patients are ventilated with variable pressure support mode.
3117828|NCT01769053|No Intervention|Conventional (non-variable) Ventilation|Patients are ventilated with non-variable(conventional) pressure support ventilation mode.
3117829|NCT01769040|Experimental|Rifaximin|Rifaximin tablets for oral ingestion, 550 mg twice daily for 28 days.
3117830|NCT01769040|Placebo Comparator|Placebo tablets|Placebo tablets similar in shape and size to intervention treatment, 1 tablet twice daily for 28 days.
3117831|NCT01769027|Active Comparator|SSRI+AB|Intervention: sertraline+antibiotic (penicillin/azithromycin) 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day)and one antibiotic ( benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week ). Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
3117832|NCT01769027|Placebo Comparator|SSRI+placebo|Intervention: Sertraline+placebo 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and a placebo
3117833|NCT01769001|Experimental|1 mg/kg|PRX-102 1 mg/kg every 2 weeks
3117834|NCT01769001|Experimental|2 mg/kg|PRX-102 2 mg/kg every 2 weeks
3117835|NCT01769001|Experimental|0.2 mg/kg|PRX-102 0.2 mg/kg every 2 weeks
3117836|NCT01768988|Experimental|Group I|Conventional analgesic treatment + pregabalin.
3117837|NCT01768988|Placebo Comparator|Group II|Conventional analgesic treatment + placebo.
3117838|NCT01768975|Experimental|OLT1177 Gel|4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
3117839|NCT01768975|Placebo Comparator|Placebo gel|Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
3117840|NCT01768962|Active Comparator|Sequence A|2 weeks, 6 week washout, 2 weeks
3117841|NCT01768962|Active Comparator|Sequence B|2 weeks, 6 week washout, 2 weeks
3117842|NCT01768949|Other|Echocardiography|An echocardiography will be systematically realised in all the patients included in the study in order to evaluate whether any echocardiographic criterion exploring the right ventricle can predict the efficacy and/or safeness of recruitment maneuvers in patients suffering from acute respiratory distress syndrome.
3117843|NCT01768936||eliminated infectious abdominal focus|
3117844|NCT01768936||persisting/progressing infectious abdominal focus|
3117845|NCT01768923|Active Comparator|SDAI remission group|SDAI remission
3117846|NCT01768923|Active Comparator|Minimal disease activity group|Minimal disease activity remission
3117847|NCT01768910|Experimental|Healthy controls|Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures (e.g. bladder cooling, body warm or room temperature)of the filling liquid.
3117848|NCT01768910|Experimental|MS with OAB|Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
3117849|NCT01768910|Experimental|MS without OAB|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
3118034|NCT01767584|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
3117850|NCT01768910|Experimental|NNOAB|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus additional post-treatment fMRI scan 5 to 7 weeks after OAB treatment (such as antimuscarinics, intradetrusor injections of botulinum toxin type A)
3117851|NCT01768910|Experimental|SCI with neurogenic detrusor overactivity|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus 1 additional post-treatment fMRI scan 5 to 7 weeks after intradetrusor injections of botulinum toxin type A
3117852|NCT01768897|Experimental|Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)|"Patients receive CPI-613 IV over 2 hours on days 1-5, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 3, and mitoxantrone hydrochloride IV over 15 minutes after the 1st, 3rd, and 5th doses of cytarabine. Treatment repeats every 14 days for up to 2 courses* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients undergoing a second course of therapy receive CPI-613 IV over 2 hours on days 1-3, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 2, and mitoxantrone hydrochloride IV over 15 minutes after the 1st and 3rd doses of cytarabine."
3117853|NCT01768884|Experimental|Nitric oxide inhalation + standard treatment|Inhalation of 160 ppm gNO for 30 minutes, 5 times daily, for 5 consecutive days or until discharged, which occurs first.
3117854|NCT01768884|Placebo Comparator|Standard treatment|Standard treatment
3117855|NCT01768858||Chronic inflammatory diseases (RA, PsA, AS, PsO, CD, UC)|Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque psoriasis, Crohn´s disease and ulcerative colitis.
3117856|NCT01768845|Experimental|Transplant|After a preparative regimen the patient will receive an infusion of one or two umbilical cord blood unit(s) (UBC). The UBC unit(s) will be thawed according to methods of Rubinstein et al. If two products are used, they will be administered sequentially on the same day 1-6 hours apart. Tacrolimus and mycophenolate mofetil (MMF) will be used for GVHD prophylaxis. On day +30, +60, +100, +180, and +365 the chimeric status of patients will be interpreted by VNTR analysis. Immune reconstitution (Digeorge Panel) will also be checked at these time points.
3117857|NCT01768832|Experimental|Treadmill|40 individuals assigned to the Treadmill group will complete two one hour treadmill training sessions per week for 12 weeks.
3117858|NCT01768832|Experimental|Tango|40 individuals assigned to the Tango group will complete two one hour dance classes twice per week for 12 weeks.
3117859|NCT01768832|Active Comparator|Stretching|40 individuals assigned to Stretching will complete two one hour stretching classes per week for 12 weeks.
3117860|NCT01768819|Experimental|Intervention Group|Physical Activity
3117861|NCT01768819|No Intervention|Control Group|
3117862|NCT01768806|Experimental|P.L.A.Y. Project Intervention for Autism|Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
3117863|NCT01768806|Active Comparator|Special Education Pre-school|Special education pre-school services include 10-12 hours per week of special education preschool, occupational therapy, and speech and language therapy. No intensive intervention is provided.
3117864|NCT01768793|Experimental|Parents As Teachers + Lifestyle Int.|Participants assigned to this group will receive Parents As Teachers Plus (PAT+). This will be a diet and physical activity lifestyle intervention integrated within the standard Parents As Teachers home visiting curriculum. There will be a total of 28 home visits, delivered over 24 months (6 month prenatal phase and 18 month post-partum phase).
3117865|NCT01768793|Active Comparator|Standard Parents as Teachers (PAT)|Participants assigned to this group will receive the standard Parents As Teachers (PAT) home visiting curriculum, focusing on parenting and child development. There will be a total of 28 home visits, delivered over 24 months (6 month prenatal phase and 18 month post-partum phase).
3117866|NCT01768780|Experimental|sensory nerve block level of spinal anesthesia|This test group and the control group. Because within the group in two ways to check the level after spinal anesthesia will be.
3117867|NCT01768767|Experimental|Ketamine/Lithium|Participant will receive ketamine/lithium
3117868|NCT01768767|Active Comparator|Ketamine|Participant will receive ketamine
3117869|NCT01768767|Placebo Comparator|Placebo|Participant will receive placebo
3117870|NCT01768754||COPD patients|Usual and Fast Walking Speeds
3117871|NCT01768741|Active Comparator|Laparoscopic liver resection group|
3117872|NCT01768741|Active Comparator|Open liver resection|
3117873|NCT01768728|Active Comparator|Laparoscopic left hemihepatectomy group|Group of patients that are operated with laparoscopic left hemihepatectomy
3117874|NCT01768728|Active Comparator|Open left hemihepatectomy|Group of patients operated with open left hemihepatectomy
3117875|NCT01768715||Good response|Patients with severe alcoholic hepatitis and good response to therapy.
3117876|NCT01768715||Non transplant candidates|Patients with severe alcoholic hepatitis and poor response to therapy, that are not candidates to transplantation, according to the specified criteria.
3117877|NCT01768715||Transplant candidates|Patients with severe alcoholic hepatitis and poor response to therapy, that are candidates to transplantation, according to the specified criteria.
3117878|NCT01768702|Sham Comparator|Control|Sham, no injection
3117879|NCT01768702|Experimental|C3BS-CQR-1 Treated|Injection of C3BS-CQR-1
3117880|NCT01768689|No Intervention|Run-in period|First 3 months of study during which adherence will be measured for each consecutively included study subject, but no intervention will be performed. Patient will receive routine treatment for CML according to the physician discretion.
3117881|NCT01768689|Experimental|Adherence-encouraging period|"Months 4 to 9 of study during which adherence will be measured for each consecutively included study subject, while implementing adherence-encouraging interventions:~adherence-encouraging interventions - Group meetings~adherence-encouraging interventions - Individual meetings~adherence-encouraging interventions - Monthly phone calls~Patient will receive routine treatment for CML according to the physician discretion."
3117882|NCT01768676|Experimental|avanafil|100 mg
3117883|NCT01768676|Placebo Comparator|Placebo|placebo
3117884|NCT01768663|Experimental|Treatment Group (Cohort 1)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and ciprofloxacin through Day 21.
3117885|NCT01768663|Experimental|Treatment Group (Cohort 2)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and itraconazole through Day 21.
3117886|NCT01768663|Experimental|Treatment Group (Cohort 3)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and rifampin through Day 24.
3117887|NCT01768663|Experimental|Treatment Group (Cohort 4)|Subjects will take a single dose of lumacaftor in combination with ivacaftor on 3 occasions separated by 7 days.
3117888|NCT01768650|Experimental|Self-Management #2|Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
3117889|NCT01768650|Experimental|Self-Management #1|Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
3117890|NCT01768637|Experimental|Chronic Kidney Disease|Patients with pre-dialysis stages 4-5 Chronic Kidney Disease will receive open-label aspirin 81 mg once daily for 2 weeks, then 2 weeks of aspirin 81 mg plus clopidogrel 75 mg once daily.
3117891|NCT01768637|Active Comparator|Normal controls|Patients without Chronic Kidney Disease will receive open-label aspirin 81 mg once daily for 2 weeks, then 2 weeks of aspirin 81 mg plus clopidogrel 75 mg once daily.
3117892|NCT01768624||Stage 5 chronic kidney disease|Patients receiving home hemodialysis Patients receiving home peritoneal dialysis Patients receiving center-based hemodialysis Patients who had a pre-emptive kidney transplant Patients who planned for renal conservative care
3117893|NCT01768611||Withou Diabetic Nephropathy|Patients who have persistent normoalbuminuria (<30 mg/g creatinine or <20 μg/min).
3117894|NCT01768611||Incipient Nephropathy|Patients who have persistent microalbuminuria (30-300 mg/g creatinine or 20-200 μg/min).
3117895|NCT01768611||Overt Diabetic Nephropathy|Patients who have persistent macroalbuminuria (>300 mg/g creatinine or >200 µg/min), proteinuria (>500 mg/24 h) or renal replacement therapy.
3117896|NCT01768598||Fracture - Boys|Boys who have sustained a distal radius fracture
3117897|NCT01768598||Fracture - Girls|Girls who have sustained a distal radius fracture
3117898|NCT01768598||Non Fracture - Boys|Boys who have not sustained a distal radius fracture
3117899|NCT01768598||Non Fracture - Girls|Girls who have not sustained a distal radius fracture
3117900|NCT01768585|Active Comparator|Ivabradine|Drug: Ivabradine bid administration of 7.5mg ivabradine Other Name: Procoralan, I(f)-inhibitor
3117901|NCT01768585|Placebo Comparator|Placebo|Drug: Placebo bid placebo Other Name: Placebo control
3117902|NCT01768572|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) and placebo intravenous (IV) infusion once every 4 weeks (q4w) was added to one or a combination of the nonbiologic disease modifying antirheumatic drug (DMARD), hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
3117903|NCT01768572|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w and placebo IV infusion q4w was added to one or a combination of the nonbiologic DMARD, hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
3117904|NCT01768572|Active Comparator|Tocilizumab q4w|Tocilizumab 4 mg/kg or 8 mg/kg IV infusion q4w and placebo SC injection q2w was added to one or a combination of the nonbiologic DMARD, hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
3117905|NCT01768559|Experimental|Lixisenatide|Lixisenatide 10 mcg once daily (QD) for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to Week 26 on top of insulin glargine with or without metformin.
3117906|NCT01768559|Active Comparator|Insulin Glulisine QD|Insulin glulisine QD from randomization up to Week 26 on top of Insulin glargine with or without metformin.
3117907|NCT01768559|Active Comparator|Insulin Glulisine TID|Insulin glulisine thrice daily (TID) from randomization up to Week 26 on top of Insulin glargine with or without metformin.
3117908|NCT01768546|Experimental|Video on Demand (VOD)|Virtual Diabetes Prevention Program: All participants will view the 16 Comcast on Demand episodes, weigh themselves, and track their progress weekly. Participants in the VOD arm of the study received access to a paper tracker to track food and activity during the program.
3117909|NCT01768546|Experimental|Video on Demand Plus (VOD+)|Virtual Diabetes Prevention Program: All participants will view the 16 Comcast on Demand episodes, weigh themselves, and track their progress weekly. Participants in the VOD+ arm of the trial received access an interactive tracking and problem solving web portal offered by SparkPeople™ (Cincinnati, Ohio).
3117910|NCT01768533||Survey|A lifestyle survey was administered to primary-care givers or legal guardians who take their children 4-10 y/o to the pediatric well-child visits.
3117911|NCT01768520|Experimental|Entelon tab. 150mg|
3117912|NCT01768520|Active Comparator|Celebrex cap.|
3117913|NCT01768520|Placebo Comparator|Placebo|
3117914|NCT01768507|Placebo Comparator|Placebo|no medication
3117915|NCT01768507|Experimental|Resveratrol|Trans-resveratrol (Resveratrol - Terraternal®): 5 g (10 capsules) as single oral dose on day 1 of the investigation period.
3117916|NCT01768481|Experimental|Statin|Atorvastatin 10 mg every day for one year
3117917|NCT01768481|Placebo Comparator|Sugar pill|Same size, taste and size placebo tablet (manufactured by sponsor) given every day for one year.
3117918|NCT01768468|Experimental|LAYLA|Drug : LAYLA tablet/ bid
3117919|NCT01768468|Active Comparator|JOINS|Drug : JOINS tablet/ tid
3117920|NCT01768455|Experimental|Gemigliptin and Glimepiride|Multiple administrations of gemigliptin and single concomitant administration of gemigliptin and glimepiride
3117921|NCT01768455|Experimental|Glimepiride|Single administration of glimepiride
3117922|NCT01768429|Experimental|Fatty fish|Four fatty fish meals per week
3117923|NCT01768429|Experimental|Lean Fish|Four lean fish meals per week
3117924|NCT01768429|Experimental|Alpha-linolenic acid|10 g of alpha-linolenic acid daily from camelina sativa oil
3117925|NCT01768429|Experimental|Control diet|Limited fish and alpha-linolenic acid intake
3117926|NCT01768390|Experimental|5000 Test|Twice daily use of a toothpaste containing 5,000 ppm fluoride
3117927|NCT01768390|Active Comparator|1450 GCP|Twice daily use of a toothpaste containing 1,450 ppm fluoride
3117928|NCT01768377|Active Comparator|Intubation with sedation|Sedation with midazolam and analgesia with fentanyl
3117929|NCT01768377|Experimental|Intubation with Nerve block|Laryngeal plus supraglottic plus intratracheal nerve block plus sedation with midazolam
3117930|NCT01768364|Active Comparator|Antibiotics|will receive antibiotics
3117931|NCT01768364|Active Comparator|No antibiotics|will not receive antibiotics
3117932|NCT01768351|Active Comparator|Control|Patients receiving treatment for secondary hyperparathyroidism with calcitriol. The calcitriol dosage schedule provided for an initial dose of 0.5 mch every other day and titration was performed on the basis of the serum levels of intact PTH (iPTH) (target 150-300 pg/mL), Ca, P and Ca x P product as suggested by the US National Kidney Foundation Dialysis outcomes Quality Initiative (NKF-DOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.
3117933|NCT01768351|Experimental|Paricalcitol|Patients treated by Paricalcitol for hyperparathyroidism. The paricalcitol initial dose was 1 mcg/die, and titration was performed on the basis of the serum levels of iPTH, Ca, P and Ca x P product as suggested by the NKF-DOQI and KDIGO guidelines.
3117934|NCT01768338|Experimental|Ofatumumab combined with SB-485232|Otatumumab: 1000 mg IV for 4 weeks. SB-485232: escalating doses (3 ug/kg up to 30 ug/kg) for 8 weeks.
3117935|NCT01768325|Active Comparator|EUS-Guided biopsy needle (ProCore)|"Comparison of ProCore core biopsy needle to QuickCore core biopsy needle.Cook Medical core biopsy needle.~The number of needle passes requiring to acquire adequate specimen~Length of core tissue obtained~Diagnostic contribution of immunohistochemical staining~Rates of complications"
3117936|NCT01768325|Active Comparator|EUS-TCB needle (Quick-Core)|"Comparison of core biopsy needles.~The number of needle passes requiring to acquire adequate specimen~Length of core tissue obtained~Diagnostic contribution of immunohistochemical staining~Rates of complications"
3117937|NCT01768312|Active Comparator|Restasis eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
3117938|NCT01768312|Experimental|T-sporin eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
3117939|NCT01768299|Experimental|Mifepristone at home 24 hours before miso dosing starts|"All women will receive study packet one containing mifepristone to swallow at home on study day 1. They will be told to return to the hospital for induction and will be scheduled to return to the hospital 24 hours later. Upon their return, they will be hospitalized and receive another study packet containing a placebo. Simultaneously, they will receive one dose of 400 mcg buccal misoprostol. Women will remain hospitalized and receive repeated doses of 400 mcg buccal misoprostol every three hours.~Participants will receive up to eight doses of misoprostol (e.g. 3200 mcg misoprostol) over 24 hours. Misoprostol dosing will stop when both the fetus and placenta are expelled."
3117940|NCT01768299|Experimental|Mifepristone and first dose of misoprostol simultaneously.|"Will receive study packet one containing placebo to swallow at home on study day 1. They will be told to return to the hospital for induction and will be scheduled to return to the hospital 24 hours later. Upon their return, they will be hospitalized and receive another study packet containing mifepristone. Simultaneously they will receive one dose of 400 mcg buccal misoprostol. Women will remain hospitalized and receive repeated doses of 400 mcg buccal misoprostol every three hours.~Participants will receive up to eight doses of misoprostol (e.g. 3200 mcg misoprostol) over 24 hours. Misoprostol dosing will stop when both the fetus and placenta are expelled. The procedure will be considered complete once both the fetus and placenta are expelled."
3117941|NCT01768286|Experimental|LDV/SOF 12 Weeks|Participants will receive LDV/SOF FDC for 12 weeks.
3117942|NCT01768286|Experimental|LDV/SOF+RBV 12 Weeks|Participants will receive LDV/SOF FDC plus RBV for 12 weeks.
3117943|NCT01768286|Experimental|LDV/SOF 24 Weeks|Participants will receive LDV/SOF FDC for 24 weeks.
3117944|NCT01768286|Experimental|LDV/SOF+RBV 24 Weeks|Participants will receive LDV/SOF FDC plus RBV for 24 weeks.
3117945|NCT01768273|Experimental|Midazolam and 824|2 mg midazolam (oral syrup) Day 1 and Day 17. 400 mg PA-824 once daily Day 4 - 17.
3117946|NCT01768260|Active Comparator|Enhanced External conterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive modality for the treatment of ischemic cardiovascular disease. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole.
3117947|NCT01768260|Active Comparator|aspirin|The subjects with Anterior ischemic Optic Neuropathy received aspirin therapy.
3117948|NCT01768247|Experimental|HCG priming|Patients in this arm after 7-9 days of estrogen replacement they will receive a 150 international units (IU) HCG every day for 7 days concomitantly with the estradiol
3117949|NCT01768234|Experimental|Supplemental water|This arm receives up to 2 L of supplemental water during the course of the testing day.
3117950|NCT01768234|No Intervention|Control|No supplemental water provided
3117951|NCT01768221|Other|Caregiver intervention|
3117952|NCT01768208|Experimental|Saxagliptin|
3117953|NCT01768195|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of immunochemotherapy and/or chemotherapy, and will be continued until 12 months after completion of the immunochemotherapy and/or chemotherapy.
3118035|NCT01767571|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3118036|NCT01767571|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3117954|NCT01768182|Experimental|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.
3117955|NCT01768182|Placebo Comparator|Placebo|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.
3117956|NCT01768169||fish oil capsule|10 capsules per day will provide 2130 mg of EPA (1280 mg) and DHA (850 mg)
3117957|NCT01768156|Experimental|Study arm|
3117958|NCT01768143||Nurse Trainees|unexperienced endoscopy nurses
3117959|NCT01768143||Nurse Experts|Educated endoscopy Nurses
3117960|NCT01768117|Experimental|rLP2086|
3117961|NCT01768104|Experimental|ESTD|Endoscopic submucosal tunnel dissection (ESTD) for patients with upper gastrointestinal submucosal tumors (SMTs)
3117962|NCT01768104|Active Comparator|VATS|Video-assisted thoracoscopic surgery (VATS) for patients with upper gastrointestinal submucosal tumors (SMTs)
3117963|NCT01768091|Experimental|POEM|POEM for patients with esophageal achalasia
3117964|NCT01768091|Active Comparator|Pneumatic dilation|Pneumatic dilation for patients with esophageal achalasia
3117965|NCT01768078|Experimental|with corticoids|
3117966|NCT01768078|Other|without corticoids|
3117967|NCT01768065|Experimental|Nasal Expiratory Positive Airway Pressure Devices|Nasal Expiratory Positive Airway Pressure Device
3117968|NCT01768065|Sham Comparator|placebo sham|A sham device
3117969|NCT01768052||functional Near Infrared Spectroscopy|Noninvasive functional Near Infrared Spectroscopy (fNIRS) monitoring will take place during patients' clinical rTMS treatment sessions.
3117970|NCT01768039|Active Comparator|Vitamin D|treatment with weekly 50000IU vitamin D
3117971|NCT01768039|Placebo Comparator|Placebo|Treatment with placebo
3117972|NCT01768026||No treatment|Subjects diagnosed with Dystrophic Epidermolysis Bullosa
3117973|NCT01768013|Experimental|LEO 90105 Ointment|
3117974|NCT01768000|Experimental|Family Cognitive Adaptation Training|Participants in this group will receive the Family CAT manual and DVD
3117975|NCT01768000|No Intervention|Control group|Participants in this arm will support their family members as usual, and will not receive the Family CAT manual and DVD provided to those in the experimental arm of the study.
3117976|NCT01767987|Active Comparator|Ranolazine|Oral treatment Intervention: Drug: Ranolazine 1000 mg
3117977|NCT01767987|Placebo Comparator|Placebo|Oral treatment Intervention: Drug: Placebo
3117978|NCT01767974||Non-Small Cell Lung Cancer|Locally advanced stage IIIB or IV (metastatic) or Relapsed Non-Small Cell Lung Cancer
3117979|NCT01767961|Experimental|Diagnostic (modified barium swallow)|Patients undergo the modified barium swallow, comprising swallowing boluses of thin liquid barium, barium honey, barium pudding, and barium crackers while undergoing fluoroscopic imaging.
3117980|NCT01767948|Experimental|Patients with mild hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
3117981|NCT01767948|Experimental|Patients with moderate hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
3117982|NCT01767948|Experimental|Patients with severe hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
3117983|NCT01767948|Experimental|Patients with normal hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
3117984|NCT01767935|Experimental|Treatment (cryosurgery and radiation therapy)|Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3117985|NCT01767922|Experimental|Extramel 10 mg - 140 UI SOD|This arm receives daily one capsule Extramel 10 mg containing 140 UI of SOD.
3117986|NCT01767922|Placebo Comparator|Placebo - exipients only|This arm receives daily one capsule Placebo containing excipients only.
3117987|NCT01767909|Experimental|Insulin (Humulin® R U-100)|120 subjects will take two daily doses of INI (20 IU bid for a total daily dose of 40 IU) approximately 30 minutes after breakfast and dinner for 12 months. A 6-month open label period will follow in which all participants will receive INI.
3117988|NCT01767909|Placebo Comparator|Placebo|120 subjects will take two daily doses of placebo approximately 30 minutes after breakfast and dinner for 12 months. A 6-month open label period will follow in which all participants will receive INI.
3117989|NCT01767896|Experimental|ASP7374 group|cell-culture-derived vaccine group
3117990|NCT01767896|Active Comparator|TIV group|approved egg-derived TIV group
3117991|NCT01767883|Experimental|Facilitated Clinical Decision Support|"The primary care practices in this arm will receive:~CKD decision support algorithms added to their Clinical Decision Support~System Academic detailing concerning the rationale for the algorithms~On-going mentoring and practice facilitation"
3117992|NCT01767883|Active Comparator|Clinical Decision Support Only|"The primary care practices in this arm will receive:~CKD decision support algorithms added to their Clinical Decision Support System~Academic detailing concerning the rationale for the algorithms"
3117993|NCT01767870|Experimental|FIT-Sigmoidoscopy|This arm (FIT-Sigmoidoscopy) will take fecal immunochemical test (FIT) followed by sigmoidoscopy for evaluation of advanced colorectal adenoma detection rate. Immediately after sigmoidoscopy, a total colonoscopy will be performed as a standard method for advanced colorectal adenoma detection.
3117994|NCT01767870|Experimental|Colonoscopy|This arm (Colonoscopy) will take a total colonoscopy as a control group that will represent the efficacy of colonoscopy for advanced colorectal adenoma detection rate.
3117995|NCT01767857|Experimental|Xilonix|MABp1 administered IV every two weeks, plus best supportive care
3117996|NCT01767857|Placebo Comparator|Placebo|Placebo administered IV every two weeks, plus best supportive care
3117997|NCT01767844|Experimental|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
3117998|NCT01767844|Placebo Comparator|Fruit powder drink|A regular fruit flavoured powder that has no benefits
3117999|NCT01767831||Group A: CGM monitoring (1) vs Intervention|Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention. The 4 week intervention period will be followed by an additional CGM monitoring period (session 2). For those in Group A, we compare the data collection in CGM monitoring session 1 to the data collection in the intervention period.
3118000|NCT01767831||Group B: CGM monitoring (2) vs Intervention|Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention. The 4 week intervention period will be followed by an additional CGM monitoring period (session 2). For those in Group B, we compare the data collection in CGM monitoring session 2 to the data collection in the intervention period.
3118001|NCT01767818||Previously treated PD patients|220 subjects with PD treated and responsive to dopaminergic medication
3118002|NCT01767818||Previously untreated PD|20 subjects with de-novo, previously untreated PD confirmed by I-123 Ioflupane SPECT
3118003|NCT01767818||Healthy age-matched controls|46 age-matched healthy controls will be studied.
3118004|NCT01767805|Other|Type of incubator|Embryos are cultured in a standard incubator or a mini-incubator
3118005|NCT01767805|Other|Oxygen concentration|Embryos are cultured in an incubator with a gas mixture with 20% oxygen or with 5% oxygen
3118006|NCT01767792|Experimental|Bevacizumab|Follow participant for 2 years and assess hearing response rates
3118007|NCT01767779||seizure free infants with dx of TSC|infants that are seizure free at the time of the study enrollment and meets genetic or clinical diagnostic criteria for TSC
3118008|NCT01767779||Parents or family guardian of cohort 1|Parent or family guardian of infants that are seizure free at the time of the study enrollment and meets genetic or clinical diagnostic criteria for TSC.
3118009|NCT01767766|Experimental|TGR-1202|TGR-1202 Daily Oral Dose
3118010|NCT01767753|Experimental|Triggerfish|Device: Sensimed Triggerfish
3118011|NCT01767740|Experimental|ULTRABRAID PLUS SUTURE|ULTRABRAID Plus Suture manufactured by Smith & Nephew used in subjects undergoing rotator cuff repair.
3118012|NCT01767740|Active Comparator|ULTRABRAID SUTURE|ULTRABRAID Suture is a marketed suture manufactured by Smith & Nephew used in subjects undergoing rotator cuff repair.
3118013|NCT01767727|Other|Surgical flap|The dorsal homodigital island flaps is based on the dorsal branch of the digital artery, and is used for reconstruction of multiple finger defects.
3118014|NCT01767714|Experimental|G-CSF + plerixafor|Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive plerixafor in the evening up to a maximum of 4 doses.
3118015|NCT01767714|Placebo Comparator|G-CSF + Placebo|Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive placebo in the evening up to a maximum of 4 doses.
3118016|NCT01767701|Experimental|Raltegravir|All eligible patients will complete a 3 months observation period (no medications) followed by 3 months on treatment period. During the treatment period patients will be treated with open label raltegravir 400mg twice daily.
3118017|NCT01767688|Experimental|Moderate Hepatic Impairment Group|
3118018|NCT01767688|Experimental|Healthy Matched Control Group|
3118019|NCT01767675|Experimental|Secondary Cytoreductive Surgery with HIPEC|secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B). In some patients randomized to HIPEC at MSKCC only , peritoneal fluid and blood samples will be drawn before, during and after the HIPEC procedure.
3118020|NCT01767675|Experimental|Secondary Cytoreductive Surgery without HIPEC|secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B).
3118021|NCT01767662|Experimental|manipulation|home program for parents manipulation
3118022|NCT01767662|Placebo Comparator|observe|observation
3118023|NCT01767649||Caesarean|Normal pregnant women at term without complication during pregnancy and without inflammatory disorders
3118024|NCT01767649||Vaginal Delivery|Normal pregnant women at term without complication during pregnancy and without inflammatory disorders
3118025|NCT01767636|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3118026|NCT01767623|Active Comparator|Cohort 1: Participants with Normal Liver Function|Participants with normal liver function (according to National Cancer Institute [NCI] liver dysfunction criteria) will receive vemurafenib 960 mg BID from Day 1 until the morning dose on Day 20 and then from Day 27 onward until disease progression, safety-related treatment termination, withdrawal of consent, death, or a decision by the Sponsor to terminate the study, whichever occurs first.
3118027|NCT01767623|Experimental|Cohort 2: Participants with Severe Liver Dysfunction|Participants with severe liver dysfunction (according to NCI liver dysfunction criteria) will receive vemurafenib 720 mg BID from Day 1 until the morning dose on Day 20 and then from Day 27 onward until disease progression, safety-related treatment termination, withdrawal of consent, death, or a decision by the Sponsor to terminate the study, whichever occurs first.
3118028|NCT01767610|Experimental|micronized fenofibrate|
3118029|NCT01767610|Experimental|pitavastatin Ca|
3118030|NCT01767610|Experimental|micronized fenofibrate plus pitavastatin Ca|
3118031|NCT01767597|Active Comparator|ELISA testing|HBV infection status determined by enzyme-linked immuno-assay (ELISA)
3118032|NCT01767597|Experimental|Rapid testing|HBV infection status determined initially by a rapid test, then confirmed by enzyme-linked immuno-assay (ELISA).
3118033|NCT01767584|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
3118037|NCT01767558|Other|Ablation / MRI|"All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.~MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit."
3118038|NCT01767545|Active Comparator|Dexamethasone-implant (Group 1)|Group 1 included 38 patients (22 with CRVO and 16 with BRVO) and was treated with a dexamethasone-implant injection from the beginning.
3118039|NCT01767545|Active Comparator|Bevacizumab/Dexamethasone-implant (Group 2)|Group 2 included 26 patients (14 CRVO, 12 BRVO) and was treated with three consecutive injections of bevacizumab at a monthly interval, followed by a dexamethasone-implant injection four weeks after the last bevacizumab injection.
3118040|NCT01767532|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3118041|NCT01767532|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3118042|NCT01767519|Experimental|BOTOX®|Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.
3118043|NCT01767519|Active Comparator|solifenacin|Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.
3118044|NCT01767519|Placebo Comparator|placebo|Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.
3118045|NCT01767506|Experimental|Intervention|Communities will receive usual care, including annual mass drug administration with azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more. In addition, surveillance and treatment with azithromycin of newcomer and traveler families within 2 weeks of arrival to or return to the community.
3118046|NCT01767506|Active Comparator|Usual Care|Communities will receive usual care, including annual mass drug administration with azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
3118047|NCT01767493|Experimental|[18F]Florbetapir and PET imaging|Subjects will have a baseline scan and second scan within 1 month following the baseline PET scan
3118048|NCT01767480|Experimental|Higher-intensity RT group|All participants received a duration-matched intervention for 90-120 minutes/day, 5 days/week for 4 consecutive weeks. For the RT groups, they will receive RT training together with functional rehabilitation trainings. Within 1 training session, each patient in the higher-intensity RT group will use Bi-Manual-Tract to practice 400-600 repetitions of the mode 1 and 800-1000 repetitions of mode 2, totaling 1200-1600 repetitions, respectively for the forearm and the wrist movements. In addition, the patients will practice 100-200 repetitions in mode 3, if application.
3118049|NCT01767480|Experimental|Lower-intensity RT group|Patients in the lower-intensity RT received half the number of the repetitions per unit of time than patients in the higher-intensity RT group. Within 1 training session, patients in the lower-intensity RT group will practice 200-300 repetitions of the mode 1 and 400-500 repetitions of mode 2, totaling 600-800 repetitions, respectively for the forearm and the wrist movements. In addition, the patients will practice 50-100 repetitions in mode 3, if application.
3118050|NCT01767480|Active Comparator|Conventional rehabilitation (CR) group|The CR group will be designed to control for the duration of therapeutic activities. CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
3118051|NCT01767467|Experimental|Vaccine Group|Subjects will receive the candidate HZ vaccine (GSK 1437173A).
3118052|NCT01767467|Placebo Comparator|Placebo Group|Subjects will receive the placebo vaccine.
3118053|NCT01767454|Experimental|Doublet arm|Subjects will be started with dabrafenib 150 mg twice daily (BID) orally for 2 weeks (run-in). The doublet arm will comprise 2 cohorts. Cohort A1 (Dabrafenib 150 mg BID + ipilimumab). Cohort A-1 (Dabrafenib 100 mg BID +ipilimumab). Ipilimumab will be administered as 3 mg/kg every 3 weeks (Q3W) for a total of 4 infusions over approximately 12-16 weeks. Dabrafenib will be continued through combination with ipilimumab and post-ipilimumab until no longer of clinical benefit, in the opinion of the treating physician, or until unacceptable AE or death
3118054|NCT01767454|Experimental|Triplet arm|This arm will be initiated using dabrafenib and ipilimumab doses established in the doublet dose-finding. Subjects will be started with dabrafenib and trametinib orally for 2 weeks (run-in), followed by ipilimumab 3 mg/kg Q3W for a total of 4 infusions over approximately 12-16 weeks. The triplet arm will comprise 3 planned cohorts. Cohort B-1: Dabrafenib 100 mg BID + trametinib 1 mg once daily + ipilimumab, Cohort B1: Dabrafenib 150 mg BID + trametinib 1 mg once daily+ ipilimumab, Cohort B2: Dabrafenib 150 mg BID + trametinib 2 mg once daily + ipilimumab. Dabrafenib and trametinib wil be continued through combination with ipilimumab and post-ipilimumab until no longer of clinical benefit, in the opinion of the treating physician, or until unacceptable AE or death
3118055|NCT01767441||Roux-en-Y-gastric bypass|morbidly obese subjects undergoing gastric bypass surgery
3118056|NCT01767441||gastric banding|morbidly obese subjects undergoing laparoscopic adjustable gastric banding
3118057|NCT01767441||sleeve gastrectomy|morbidly obese subjects undergoing laparoscopic sleeve gastrectomy
3118058|NCT01767441||control group|morbidly obese subjects not undergoing bariatric surgery, on diet treatment
3118059|NCT01767428|Experimental|Experimental Paracetamol Tablet|Experimental paracetamol tablet (500 milligrams [mg]) administered with 240 milliliters (mL) of water.
3118060|NCT01767428|Active Comparator|Standard Paracetamol Tablet (500 mg)|Standard paracetamol tablet (500 mg) administered with 240 mL of water.
3118061|NCT01767415|Experimental|Indigo Carmine|Intraoperative stereotactic injection of Indigo Carmine
3118062|NCT01767402|Experimental|PhtD Group 1|Subjects will receive PhtD vaccine formulation 1 without any adjuvant.
3118063|NCT01767402|Experimental|PhtD Group 2|Subjects will receive adjuvanted PhtD vaccine formulation 2.
3118064|NCT01767402|Experimental|PhtD Group 3|Subjects will receive adjuvanted PhtD vaccine formulation 3.
3118065|NCT01767402|Experimental|PhtD Group 4|Subjects will receive adjuvanted PhtD vaccine formulation 4.
3118066|NCT01767402|Experimental|PhtD Group 5|Subjects will receive adjuvanted PhtD vaccine formulation 5.
3118067|NCT01767402|Active Comparator|23 PPV Group|Subjects will receive the Pneumovax 23TM vaccine and NaCl.
3118068|NCT01767389||Type 2 diabetes patients taking antidiabetic agents|Subjects should also have at least 1 claim of T2D diagnosis identified using ICD-9 codes 250.x0 or 250.x2 (excluding 250.x1 and/or 250.x3 - Type 1 diabetes and 648.0x - gestational diabetes).
3118069|NCT01767376|Experimental|Nimenrix+ Boostrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Nimenrix vaccine co-administered with one dose of Boostrix vaccine, at Month 0, administered by intramuscular injection into the deltoid muscle.
3118070|NCT01767376|Experimental|Nimenrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Nimenrix vaccine at Month 0 and one dose of Boostrix vaccine at Month 1. Both vaccines were administered by intramuscular injection into the deltoid muscle.
3118071|NCT01767376|Experimental|Boostrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Boostrix vaccine at Month 0 and one dose of Nimenrix vaccine at Month 1. Both vaccines were administered by intramuscular injection into the deltoid muscle.
3118072|NCT01767363||5-alpha reductase inhibitors with or without alpha-blockers|Men using 5-alpha reductase inhibitors with or without alpha-blockers over the course of the study period.
3118073|NCT01767363||Alpha-blockers|Men using alpha-blockers over the course of the study period.
3118074|NCT01767350||children with organ transplant|Subjects who received an solid organ transplant at our institution at the age of 0-19 yrs and who were subject to pharmacokinetic evaluation during their follow up. Additional blood withdrawal for DNA will be performed
3118075|NCT01767337|Experimental|injection of 0.1 mL saline|deliver from FluGen 101.2 device
3118076|NCT01767337|Experimental|injection of 0.25 mL saline|deliver from FluGen 101.2 device
3118077|NCT01767337|Experimental|Injection of 0.5 mL saline|deliver from FluGen 101.2 device
3118078|NCT01767324|Experimental|Injection to deltoid|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
3118079|NCT01767324|Experimental|Injection to forearm|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
3118080|NCT01767324|Experimental|Injection to thigh|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
3118081|NCT01767311|Experimental|BAN2401 2.5 mg/kg biweekly|2.5 mg/kg biweekly
3118082|NCT01767311|Experimental|BAN2401 5.0 mg/kg biweekly|5.0 mg/kg biweekly
3118083|NCT01767311|Experimental|BAN2401 10 mg/kg biweekly|10 mg/kg biweekly
3118084|NCT01767311|Experimental|BAN2401 5.0 mg/kg monthly|5.0 mg/kg monthly
3118085|NCT01767311|Experimental|BAN2401 10 mg/kg monthly|10 mg/kg monthly
3118086|NCT01767311|Placebo Comparator|Placebo|Matching placebo biweekly
3118087|NCT01767298|Other|Valsartan 320 mg alone|Valsartan alone
3118088|NCT01767298|Other|Hydrochlorothiazide 25 mg alone|Hydrochlorothiazide alone
3118089|NCT01767298|Other|Valsartan 320 mg + Hydrochlorothiazide 25 mg|Concomitant administration of valsartan 320 mg + Hydrochlorothiazide 25 mg
3118090|NCT01767298|Other|Valsartan / Hydrochlorothiazide 320 mg/25mg|Fixed dose combination of valsartan 320 mg + Hydrochlorothiazide 25 mg
3118091|NCT01767285|Experimental|Immediate Postpartum Etonogestrel Implant|Etonogestrel implant placed in the hospital after delivery, before discharge home.
3118092|NCT01767285|Active Comparator|Delayed postpartum etonogestrel implant|These subjects will have the etonogestrel implant placed at the 6 week postpartum visit.
3118093|NCT01767272|Other|fexofenadine 60 mg|First dose strength
3118094|NCT01767272|Other|fexofenadine 120 mg|Second dose strength
3118095|NCT01767272|Other|fexofenadine 180 mg|Third dose strength
3118096|NCT01767272|Other|fexofenadine 240 mg|Fourth dose strength
3118097|NCT01767272|Other|fexofenadine 360 mg|Fifth dose strength
3118098|NCT01767259|Other|Valsartan 160 mg alone|Valsartan alone
3118099|NCT01767259|Other|Hydrochlorothiazide 12.5 mg alone|Hydrochlorothiazide alone
3118100|NCT01767259|Other|Valsartan160 mg + Hydrochlorothiazide12.5 mg|Concomitant administration of valsartan 160 mg + Hydrochlorothiazide 12.5 mg
3118101|NCT01767259|Other|Valsartan / Hydrochlorothiazide 160 mg/12.5mg|Fixed dose combination of valsartan 160 mg + Hydrochlorothiazide 12.5 mg
3118102|NCT01767246|Experimental|PFS algorithm treatment|The Patellofemoral Syndrome algorithm is designed to determine what deficits a patient may have and addressing these sequentially. This subgrouping first assesses a patient fear avoidance beliefs, flexibility, body mechanics, and then strength and functional ability. The reason for sequential treatment is that there is evidence that without adequate flexibility a patient will be unable to perform exercises with proper body mechanics, and without proper mechanics strengthening and functional activity can cause increased stress on the patellofemoral joint. Progression through each specific subgroup is based on objective goals. Once the patient has met these goals they are progressed to the next treatment subgroup until discharge.
3118103|NCT01767246|Active Comparator|Multimodal Treatment|Patients randomized to the this treatment group will be treated in a manner consistent with a Multimodal treatment approach previously described in literature that has been found effective in treating Patellofemoral Syndrome (Lowry, 2008). Treatment consists of strengthening, flexibility and manual treatments aim to improve patients knee pain.
3118104|NCT01767233|Experimental|Pancreatic stenting|Pancreatic stenting versus observation
3118105|NCT01767220|Active Comparator|Strategy 1- endocardial ablation|VT substrate mapping and VT ablation are done only from endocardial.
3118106|NCT01767220|Active Comparator|Strategy 2 - endocardial and epicardial ablation|VT substrate mapping and ablation are done from endocardial and epicardial.
3118107|NCT01767207||screening for mental disorders|screening for mental disorders
3118371|NCT01765439|Experimental|CD resected|Patients with Crohn´s disease with the history of single resection (<60 cm) of distal leum.
3118108|NCT01767194|Experimental|Arm I (temozolomide, irinotecan hydrochloride, temsirolimus)|CLOSED TO ACCRUAL 06/17/2016 Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride IV over 90 minutes on days 1-5, and temsirolimus IV over 30 minutes on days 1 and 8.
3118109|NCT01767194|Experimental|Arm II (temozolomide, irinotecan hydrochloride, dinutuximab)|Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride over 90 minutes on days 1-5, dinutuximab IV over 10-20 hours on days 2-5, and sargramostim SC or IV over 2 hours on days 6-12.
3118110|NCT01767181|No Intervention|A|Control group without intervention
3118111|NCT01767181|Experimental|B|Intensive light therapy during the first half of the night shift
3118112|NCT01767181|Experimental|C|Exercise before the beginning of the night shift
3118113|NCT01767181|Experimental|D|Exercise after the end of the night shift
3118114|NCT01767155|Experimental|AEZS-108 / zoptarelin doxorubicin|267 mg/m^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles up to 9 cycles
3118115|NCT01767155|Active Comparator|doxorubicin/ standard chemotherapy|60 mg/m^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
3118116|NCT01767142|Experimental|Fat Reduction|
3118117|NCT01767129|Experimental|AVP-923-45|AVP-923-45 twice daily for 14 days
3118118|NCT01767129|Placebo Comparator|Placebo|Placebo twice a day for 14 days
3118119|NCT01767116|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3118120|NCT01767116|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks plus placebo RBV (twice daily) for 12 weeks
3118121|NCT01767103|Experimental|Normal Hepatic Function (healthy volunteers)|Healthy volunteers with normal hepatic function received a single 33 mg/kg dose of Ferriprox®.
3118122|NCT01767103|Experimental|Mild Hepatic Failure|Subjects with mild hepatic failure as defined by the Child-Pugh Class C: 5-6 points received a single 33 mg/kg dose of Ferriprox®.
3118123|NCT01767103|Experimental|Moderate Hepatic Failure|Subjects with moderate hepatic failure as defined by the Child-Pugh Class B: 7-9 points received a single 33 mg/kg dose of Ferriprox®.
3118124|NCT01767090|Placebo Comparator|Placebo|Applicable to first 12 week period; subjects in this arm will be randomized to one of the ASP1707 dose levels for the second 12 week period
3118125|NCT01767090|Experimental|ASP1707 lowest dose|
3118126|NCT01767090|Experimental|ASP1707 low dose|
3118127|NCT01767090|Experimental|ASP1707 medium dose|
3118128|NCT01767090|Experimental|ASP1707 high dose|
3118129|NCT01767090|Active Comparator|Leuprorelin acetate|
3118130|NCT01767077|Placebo Comparator|Butter oil|Daily intake of 40 g butter oil
3118131|NCT01767077|Active Comparator|Cream|Daily intake of 100 g cream (40%)
3118132|NCT01767064|Experimental|Posted commitment letter|The poster-sized (18x24 inches) commitment letter, written at the 8th grade reading-level and displayed in English and Spanish, emphasize clinician commitment to guidelines for appropriate antibiotic prescribing and explain why antibiotics are not appropriate in many cases. These letters, featuring clinician photographs and signatures, are displayed in clinician exam rooms for a 16-week period.
3118133|NCT01767064|No Intervention|Control|Usual care with no posted letters.
3118134|NCT01767051||Children born from mothers who are diagnosed with PCOS|Children at the age of 2.5-4 years or at the age of 6-8 years born from mothers who are diagnosed with PCOS at the University Medical Centre in Utrecht (UMCU) in the period 2004-2012 (n=891) will be asked to participate. Children who were born before the diagnosed PCOS of their mothers at the UMCU will be asked to participate too. All mothers have been diagnosed with PCOS according to standardised extensive diagnostic work-up and have given informed consent to be approached for future research purposes.
3118135|NCT01767051||Children who participated in the WHISTLER study|Children who participated in the WHISTLER 3 (11-163) and WHISTLER/Cardio study (10-194) in 2002-2012. The children were born from mothers with a regular cycle prior to conception who conceived naturally. The children were examined at the age of 2.5-4 years or at the age of 7-8 years. The data of the WHISTLER 3 and WHISTLER/Cardio study have already been collected.
3118136|NCT01767025|Experimental|Oxytocin|Oxytocin 24 IU (3 puffs) per nostril
3118137|NCT01767025|Placebo Comparator|Sea water|Sea water 3 puffs per nostril
3118138|NCT01767012|Active Comparator|Polylens EC-Y10-PAL (uncoated)|hydrophobic acrylic IOL (no coating) implantation during cataract surgery
3118139|NCT01767012|Active Comparator|Polylens EC-Y10H-PAL (coated)|hydrophobic acrylic heparin-coated IOL implantation during cataract surgery
3118140|NCT01766999||SpMetHb > 8%|hemoximetric MetHb measurements triggered
3118141|NCT01766973||Chronic back pain|Adults, >6months duration
3118142|NCT01766973||Control|Age and sex matched controls
3118143|NCT01766960|Experimental|Healthy volunteers|Subjects will be asked to fast overnight. Upon presentation, FibroScan procedure with CAP will be conducted and baseline and postprandial bile acid profile will be assessed. Then, intravenous morphine will be administered and the pharmacokinetic profile will be assessed over 8 hours.
3118144|NCT01766960|Experimental|Advanced nonalcoholic fatty liver disease patients|Subjects will be asked to fast overnight. Upon presentation, FibroScan procedure with CAP will be conducted and baseline and postprandial bile acid profile will be assessed. Then, intravenous morphine will be administered and the pharmacokinetic profile will be assessed over 8 hours.
3118145|NCT01766947|Experimental|Triggerfish|Device : Sensimed Triggerfish
3118146|NCT01766921|Experimental|aH5N1c - High dose|
3118147|NCT01766921|Experimental|aH5N1c - Low dose|
3118148|NCT01766908|Active Comparator|Cord Clamp 20 Seconds After Delivery|Intervention is cord clamp at 20 seconds following vaginal or cesarean delivery
3118149|NCT01766908|Active Comparator|Cord Clamp 40 seconds After Delivery|Timing of cord clamp at 40 seconds following vaginal or cesarean delivery.
3118150|NCT01766908|Active Comparator|Cord Clamp 60 seconds After Delivery|Intervention is timing of cord clamp at 60 seconds following vaginal or cesarean delivery
3118151|NCT01766895||uremic patients|blood sampling of viral hepatitis in uremic patients
3118372|NCT01765439|Experimental|UC unoperated|Patients with ulcerative colitis without history of gut resection.
3118152|NCT01766882|Experimental|Treatment|"Lower sodium intervention:~Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day~Lower dialysate sodium at 137 mmol/L.~Progressive Challenge to Post Dialysis Weight:~The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments."
3118153|NCT01766882|No Intervention|Control|Usual care in addition to Blood pressure monitoring and and Hydration status monitoring
3118154|NCT01766856||children undergoing myringoplasty/tympanoplasty|child having repair of eardrum because of hole in eardrum after tube extruded or after tube removal
3118155|NCT01766843|Active Comparator|Seretide Diskus and charcoal|Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal
3118156|NCT01766843|Active Comparator|Seretide Diskus|Single-dose of Seretide Diskus (50/500 mcg/inhalation)
3118157|NCT01766843|Experimental|SF Easyhaler and charcoal|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal
3118158|NCT01766843|Experimental|SF Easyhaler|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)
3118159|NCT01766830|Experimental|Phase 3 Diagnostic|A total of 10 RDTs will be assessed in the patients cohort for the respective target condition
3118160|NCT01766817|Experimental|Arm 1: BMS 986020, 600 mg. once daily|BMS-986020, 600 mg tablets, by mouth, once daily, 26 weeks
3118161|NCT01766817|Experimental|Arm 2: BMS-986020, 600 mg twice daily|BMS-986020, 600 mg tablets, by mouth, twice daily, 26 weeks
3118162|NCT01766817|Placebo Comparator|Arm 3: Placebo matching with BMS-986020|Placebo, 0 mg tablets, by mouth, twice daily, 26 weeks
3118163|NCT01766804|Experimental|Bovine colostrum|A daily supplement of bovine colostrum powder.
3118164|NCT01766804|Placebo Comparator|Placebo|A daily placebo supplement consisting of whole milk powder and whey protein.
3118165|NCT01766791|Experimental|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, > 75% 1 Repetition Maximum (1RM)
3118166|NCT01766791|Experimental|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - <75% 1RM
3118167|NCT01766791|Experimental|HIT-exercise with protein|High Intensity Resistance Exercise Training with protein supplementation
3118168|NCT01766791|Placebo Comparator|Control|No physical exercise intervention
3118169|NCT01766778|Active Comparator|LAF237 (vildagliptin) 50mg once daily (QD)|Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin
3118170|NCT01766778|Active Comparator|LAF237 (vildagliptin) 50mg twice daily (BID)|Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin
3118171|NCT01766765|Experimental|Early jejunostomy nutrition|
3118172|NCT01766765|Active Comparator|Early oral nutrition|
3118173|NCT01766752|Experimental|GlucoTab System|Investigational system: GlucoTab system supports the glycaemic management of non-critically ill patients with type two diabetes at the general ward.
3118174|NCT01766752|No Intervention|no intervention|standard care
3118175|NCT01766739|Experimental|GL-ONC1|This is an open-label, dose-escalating, non-randomized, single-center Phase I therapeutic study of GL-ONC1 originally administered intrapleurally as a single dose and now escalating to three consecutive daily doses in patients with a diagnosis (histologically or cytologically documented) of malignant pleural effusions.
3118176|NCT01766726||Healthy control subjects|Historical healthy control subjects matched to HIV+ patients on traditional cardiovascular risk factors will be studied at baseline with respect to arterial inflammation and coronary atherosclerotic plaque. Prospectively recruited healthy control subjects matched to HIV+ patients on traditional cardiovascular risk factors will be studied at baseline with respect to lipid and immune function.
3118177|NCT01766726||ART-naïve HIV+ patients starting QUAD/Stribild|ART-naïve HIV+ patients who are about to be started QUAD/Stribild by their treating clinicians will be studied at baseline and 6 months after initiating QUAD/Stribild therapy.
3118178|NCT01766713|Experimental|Ezetimibe|10 mg/day of Ezetimibe
3118179|NCT01766713|Placebo Comparator|Placebo|
3118180|NCT01766700|Experimental|No calorie beverages|2 no calorie beverages per day.
3118181|NCT01766700|Active Comparator|Water|2 water beverages per day.
3118182|NCT01766687|Experimental|Hydration|Participants randomized to the hydration-intervention group will be asked to drink 1.0 to 1.5 L of water per day (depending on sex and weight), in addition to usual consumed beverages, for 12 months.
3118183|NCT01766687|No Intervention|Control|
3118184|NCT01766674|Experimental|Kyphosis spinal exercises|Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
3118185|NCT01766674|No Intervention|Control|Control group will be enrolled in the usual care waitlist group
3118186|NCT01766661|Active Comparator|Coloanal anastomosis with ileostomy|Hand-sewn coloanal anastomosis protected by a loop ileostomy
3118187|NCT01766661|Experimental|Two stage Turnbull-Cutait anastomosis|Two staged coloanal anastomosis without protective ileostomy (Turnbull-Cutait procedure).
3118188|NCT01766648|Experimental|Far Cortical Locking screw fixation|Far Cortical Locking screw fixation
3118189|NCT01766648|Active Comparator|Standard locking screw fixation|Standard locking screw fixation
3118190|NCT01766609|Active Comparator|A: Triamcinolone acetonide|Injections will be given within one half of a single vitiligo patch. The concentration of triamcinolone acetonide (TA) that will be used initially is 2.5 mg/ml. Dilution will be done using a bacteriostatic normal saline. Each half will receive injections with either TA 2.5 mg/ml or normal saline as a control. Only one investigator will know the intervention each half has received. If the patient did not show any evidence of repigmentation during the 3rd visit (i.e. after two injection sessions with TA 2.5 mg/ml) , the concentration of TA will be increased to 5 mg/ml. A total of 4 injections will be given over 4 visits. The treatment will be repeated every 3 to 5 weeks for a total of 4 treatment sessions.
3118191|NCT01766609|Placebo Comparator|B: Normal saline|Bacteriostatic normal saline will injected into one half of the vitiligo patch.
3118192|NCT01766596|Other|3C cohort|
3118193|NCT01766583|Experimental|CC-292 + lenalidomide|Combination of CC-292 + lenalidomide
3118194|NCT01766570|Experimental|Phenol|Men and women who are assigned to a 6 weeks experimental period where they consume the rich polyphenol berries extract mix.
3118195|NCT01766570|Placebo Comparator|Control|Men and women who are assigned to a 6 weeks experimental period where they consume a placebo.
3118196|NCT01766557|Experimental|Semi-controlled intervention with fish protein diet|Women with polycystic ovarian syndrome who are assigned to a 12 weeks experimental diet containing cod as the protein source.
3118197|NCT01766557|Active Comparator|Semi-controlled intervention with other animal proteins|Women with polycystic ovarian syndrome who are assigned to a 12 week experimental diet containing beef, pork, veal, eggs and milk products (BPVEM) as protein sources.
3118198|NCT01766544|Active Comparator|Standard practice group (SPG)|Send a copy of the latest Canadian asthma and COPD guidelines to all PCPs.
3118199|NCT01766544|Active Comparator|Targeted Intervention Strategy (TISG)|interactive educational intervention, expert mentorship, practice-based tools. Consisting of 3 interactive sessions, 2 of which would be live meetings of 3h each and the third a one-hour teleconference.
3118200|NCT01766531|Experimental|Body bioelectrical impedance|comparison with four methods for assessing nutritional status. ; compare length of mechanical ventilation, length in ICU and energy expenditure rest between malnourished and non-malnourished patient
3118201|NCT01766518|Experimental|MY-REPT capsule|MY-REPT capsule: Mycophenolate mofetil, 250mg/cap, orally
3118202|NCT01766505|Experimental|Candemore tablet|Candemore tablet: candesartan cilexetil 8mg, 16mg, 32mg/tab, orally, 1 tablet once a day during 16 weeks
3118203|NCT01766505|Active Comparator|Cozzar tablet|Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks
3118204|NCT01766492||male (age > 18 y/o) with prostate cancer|Men received Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer
3118205|NCT01766479|Experimental|Family Degree-relatives of pts. with CRC|Consecutive patients admitted with CRC diagnosis (index case, IC) were prospectively evaluated. Following the systematic identification of ICs with inherited predispositions to CRC, ICs who agreed to contact their FDRs ≥40 years old were included. Available FDRs were invited to undergo non-cathartic CTC, with OC the following day.
3118206|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 180mg at 0.5 hr|On Day 1: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours. Ticagrelor (180 mg) was administered at 0.5 h after the initiation of cangrelor infusion.
3118207|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 90mg (7 doses)|"On Day 1: Following completion of cangrelor and ticagrelor dosing, patients were discharged and instructed to take 90 mg ticagrelor every 12 hours for 7 doses (12, 24, 36, 48, 60, 72, and 84 h).~On Day 5: 12 h post last ticagrelor dose (90 mg), patients received another open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours."
3118208|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 180mg at 1.5 hr|On Day 1: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours. Ticagrelor (180 mg) was administered at 1.5 h after the initiation of cangrelor infusion.
3118209|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 90mg (6 doses)|"On Day 1: Following completion of cangrelor and ticagrelor dosing, patients were discharged and instructed to take 90 mg ticagrelor every 12 hours for 6 doses (12, 24, 36, 48, 60, and 72 h).~On Day 5: 24 h post last ticagrelor dose (90 mg), patients received another open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours."
3118210|NCT01766453|No Intervention|Non exercise control|Non exercise control will undergo baseline testing and follow up testing but will not participate in an exercise intervention.
3118211|NCT01766453|Experimental|Standard Exercise|The standard exercise group will attend exercise sessions under the supervision of a Certified Personal Trainer. Intensity will increase every four weeks by 10% from 50-80% of maximal heart rate to ensure that exercise is progressive in nature. Participants will be provided with a heart rate monitor during their exercise sessions and have the option to perform the aerobic training on a treadmill, upright bike, elliptical machine or recumbent bike as long as heart rate is kept within the prescribed training intensity. Intensity, duration, resting and exercise heart rates will be recorded for each exercise session for the duration of the intervention to ensure compliance to the exercise program.
3118212|NCT01766453|Experimental|Bhangra Dance Exercise|Bhangra dance classes taught be a certified instructor progressing in difficulty over the 12 week period. Bhangra dance is an Indian folk dance that consists of jumping and kicking of a high intensity. This group will attend exercise sessions under the supervision of a Bhangra Dance Instructor. The intensity of bhangra dance will be tracked through heart rate monitors worn by participants.
3118213|NCT01766440|Experimental|Calcitriol 3 mcg/g ointment|Topical application every 12 hours for 14 consecutive days
3118214|NCT01766427||morning electroacupuncture with pills|
3118215|NCT01766427||afternoon EA with pills|
3118216|NCT01766427||no EA group with pills|
3118217|NCT01766414|Active Comparator|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion followed by administration of Endotoxin 2ng/kg
3118218|NCT01766414|Placebo Comparator|Placebo|Placebo (saline 0.9%) infusion followed by administration of Endotoxin 2ng/kg
3118219|NCT01766401|Placebo Comparator|Placebo|Matching placebo tablets, oral administration
3118220|NCT01766401|Experimental|Vilazadone|Vilazadone tablets, oral administration
3118221|NCT01766388||Pregnant women|Pregnant women of 13-22 weeks gestation
3118222|NCT01766375|Experimental|IDBUCY|"Idarubicin: 20mg/m2 a day, d-12 ~d-10, intravenous infusion for 1 hour. Busulfan: 4mg/Kg a day, oral administration, d-7 ~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7~d-4.~cyclophosphamide: 60mg/Kg a day, intravenous infusion, d-3~d-2."
3118223|NCT01766375|Active Comparator|BUCY|"Busulfan: 4mg/Kg a day, oral administration, d-7 ~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7~d-4.~Cyclophosphamide: 60mg/Kg a day, intravenous infusion, d-3~d-2."
3118224|NCT01766362|Experimental|A session|
3118225|NCT01766362|Other|Four sessions|Every session are spaced out of month
3118226|NCT01766349||esophagus cancer patients|Respiratory muscle performance will be followed in patients with esophagus cancer during CCRT or RT treatments.
3118227|NCT01766336|Experimental|Group 1 ELND005/ELND005|Patients who received ELND005 during Study AG201 will continue on the same maintenance dose for 36 weeks.
3118306|NCT01765816|Experimental|high intensity interval training|one interval training session with 1 x 4 and 4 x 4 minutes interval training at 90-95% of peak heart rate
3118228|NCT01766336|Experimental|Group 2 PLACEBO/ELND005|Patients who received placebo during Study AG201 will receive ELND005 at the same dosing regimen as the active group in Study AG201 for 36 weeks.
3118229|NCT01766323|Placebo Comparator|Arm Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
3118230|NCT01766323|Active Comparator|Arm-Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
3118231|NCT01766310|Placebo Comparator|placebo|placebo tablet in the same appearance and taste with folic acid orally once a day for 8 weeks of the study
3118232|NCT01766310|Experimental|folic acid|Folic acid tablet 5mg per day orally (5mg/tablet) once a day for 8 weeks of the study
3118233|NCT01766297|Experimental|Proton Radiotherapy|Proton Radiotherapy 4.0 Gy (RBE) x10 fractions to 40 Gy (RBE) Total Dose
3118234|NCT01766284|Experimental|Niris 1300e OCT imaging|OCT imaging of the cervix using Niris 1300e will include computer aided calculations for epithelial brightness.
3118235|NCT01766271|Experimental|Standard Risk Assessment (SRA) Only|
3118236|NCT01766271|Experimental|SRA plus Health Coaching|
3118237|NCT01766271|Experimental|SRA plus Genetic Testing|
3118238|NCT01766271|Experimental|SRA plus Health Coaching plus Genetic Testing|
3118239|NCT01766258|Active Comparator|Stalevo|levodopa/carbidopa/entacapone
3118240|NCT01766258|Experimental|ODM-101 65mg Carbidopa|levodopa/carbidopa/entacapone
3118241|NCT01766258|Experimental|ODM-101 105mg Carbidopa|levodopa/carbidopa/entacapone
3118242|NCT01766245|Experimental|Formulation A followed by Formulation B|
3118243|NCT01766245|Active Comparator|Formulation B followed by Formulation A|
3118244|NCT01766232||Obstructed nasolacrimal drainage group|This group of patients is clinically identified as having epiphora due to an obstruction of the lacrimal drainage system.
3118245|NCT01766232||Ectropion group|This group of patients is clinically determined to have functional epiphora due to ectropion and a patent lacrimal drainage system.
3118246|NCT01766219|Experimental|Treatment (6,8-bis[benzylthio]octanoic acid)|"Pre-cycle: Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5, 1 week prior to course 1.~Patients receive 6,8-bis(benzylthio)octanoic acid IVover 2 hours on days 1 and 4 of weeks 1-3. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive up to 4 more courses of treatment."
3118247|NCT01766206|Experimental|MenACWY-CRM|2 months to 55 years of age
3118248|NCT01766193||vaginal birth|women whose first child was born by spontaneous vaginal delivery
3118249|NCT01766193||cesarean section|women whose first child was born by cesarean section
3118250|NCT01766193||forceps|women whose first child was born by forceps extraction
3118251|NCT01766193||vacuum|women whose first child was born by vacuum extraction
3118252|NCT01766180|No Intervention|Placebo / Placebo|In this control group, subjects receives placebo supplement pills without Fruitflow or ResVida ingredients.
3118253|NCT01766180|Active Comparator|Fruitflow-II / Placebo|In this group subjects receive Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for resVida.
3118254|NCT01766180|Active Comparator|Placebo / resVida|In this group subjects receive resVida daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for Fruitflow-II.
3118255|NCT01766180|Active Comparator|Fruitflow-II / resVida|In this group subjects receive resVida and Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient.
3118256|NCT01766167|Experimental|MP-424|
3118257|NCT01766154|Experimental|Subjects with normal renal function given tirofiban|Subjects with normal renal function (CrCl >90 mL/min)
3118258|NCT01766154|Experimental|Subjects with moderate renal insufficiency given tirofiban|Subjects with moderate renal insufficiency (CrCl 30-59 mL/min)
3118259|NCT01766154|Experimental|Subjects with severe renal insufficiency given tirofiban|Subjects with severe renal insufficiency (CrCl <30 mL/min).
3118260|NCT01766141|No Intervention|Acute versus chronic low back pain|No manipulative intervention. Phlebotomy for inflammatory biomarker determinations to compare acute versus chronic at baseline.
3118261|NCT01766141|Experimental|Spinal manipulation (SMT)|Inflammatory biomarker determinations after a course of 6 SMT interventions over the period of 2 weeks; a single SMT per treatment.
3118262|NCT01766141|No Intervention|No treatment controls|Asymptomatic subjects. Biomarker determinations at time zero and again two weeks later.
3118263|NCT01766128|Active Comparator|Zonisamide|The patients in this arm are treated with zonisamide 50mg/d
3118264|NCT01766128|Placebo Comparator|Placebo|The patients in this arm are treated with placebo
3118265|NCT01766115|Experimental|Telaprevir|750 mg oral tablet of telaprevir will be given three times per day for 4 weeks within a five (5) day period from health care worker exposure.
3118266|NCT01766102|Active Comparator|Intra-operative Mammography|Intra-operative Specimen Mammography
3118267|NCT01766102|Active Comparator|Standard Mammography|Standard Specimen Mammography
3118268|NCT01766089|Active Comparator|Dexmedetomidine|dexmedetomidine intravenous infusion rate of 0.4 µg/kg/h
3118269|NCT01766089|Placebo Comparator|Remifentanil|remifentanil intravenous infusion rate of 0.1 µg/kg/min
3118270|NCT01766076|Experimental|atorvastatin, Lipitor®|"Intervention is be atorvastatin, Lipitor® (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.~Peripheral blood mononuclear cells (PBMC) will be collected for immune activation assays using flowcytometry"
3118271|NCT01766076|Placebo Comparator|Placebo|Intervention for the placebo comparator arm is Placebo 2 tablets daily for 12 weeks PBMC will be collected for immune activation assays using flowcytometry
3118272|NCT01766063||Group 1|
3118273|NCT01766050|Experimental|Arm: Inje Cocktail + Belatacept|"Inje Cocktail consisting of (200 mg Caffeine, 50 mg losartan tablet, 40 mg Omeprazole capsule, 30 mg Dextromethorphan capsule and 5 mg Midazolam oral syrup) administered on Days 1, 4, 7 and 11~Belatacept 10 mg/kg Intravenous (IV) solution, administered on Day 4"
3118274|NCT01766037|Experimental|Aspiration Therapy|Aspiration Therapy and Lifestyle Therapy
3118275|NCT01766037|Active Comparator|Lifestyle Therapy|Lifestyle Therapy only
3118307|NCT01765816|Active Comparator|moderate intensity training|45 minutes of moderate continuous training at 75% of maximal heart rate
3118276|NCT01766024|Experimental|BCD-033 → Rebif|Volunteers in this group initially will receive a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the reference drug Rebif® (interferon beta-1a) at a dose of 44 µg.
3118277|NCT01766024|Experimental|Rebif → BCD-033|Volunteers in this group initially will receive a single sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg.
3118278|NCT01766011|Experimental|study pre-term formula|Pre-term formula with a modified stabilizer system in 2 oz. ready to feed plastic bottles
3118279|NCT01765998|Experimental|Probiotic|To study the effect of probiotic on the ability to build endothelial progenitor stem cells and to study clinical recovery of patients with Crohn's Disease.
3118280|NCT01765998|Placebo Comparator|placebo|This will be the comparison group to the experimantal group that recives Probiotic.
3118281|NCT01765985|Experimental|Intercurrent PSORIAMED|5 minutes twice a day for 12 weeks
3118282|NCT01765985|Active Comparator|PLACEBO|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
3118283|NCT01765972|Other|Test 1/Spectacles/Test 2/Test 3|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 1 (etafilcon A with Lacreon), spectacles, TEST 2 (etafilcon A with Lacreon with print) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.
3118284|NCT01765972|Other|Test 2/Test 3/ Spectacles/Test 1|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 2 (etafilcon A with Lacreon with print), TEST 3 (etafilcon A with print), spectacles and TEST 1 (etafilcon A with Lacreon) in both eyes for 8 +/-1 hours.
3118285|NCT01765972|Other|Test 3/Test 1/ Test 2/ Spectacles|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 3 (etafilcon A with print), TEST 1 (etafilcon A with Lacreon), TEST 2 (etafilcon A with Lacreon with print) and spectacles in both eyes for 8 +/-1 hours.
3118286|NCT01765972|Other|Spectacles/Test 2/Test 1/Test 3|Subjects assigned randomly to this arm will wear the study lenses sequentially as spectacles, TEST 2 (etafilcon A with Lacreon with print), TEST 1 (etafilcon A with Lacreon) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.
3118287|NCT01765959|Active Comparator|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
3118288|NCT01765959|Active Comparator|Cognitive behavioral therapy (CBT)|"Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:~Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 How to solve problems, planning for the future"
3118289|NCT01765946|Experimental|Metformin|Metformin tablets 500 mg tid for 2 months
3118290|NCT01765946|Placebo Comparator|Placebo|Placebo tables tid for 2 months
3118291|NCT01765933|Experimental|DMAA|Single oral dose 25 mg DMAA
3118292|NCT01765920|Experimental|Ergoferon (5 ml 3 times a day)|
3118293|NCT01765920|Placebo Comparator|Placebo (5 ml 3 times a day)|
3118294|NCT01765907|Experimental|HIFU|
3118295|NCT01765894||Normal glucose tolerance subjects|Healthy controls. If any medication then paused 3 days prior to test days. BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description.
3118296|NCT01765894||DM2|"Type 2 diabetics in diet treatment or type 2 diabetics who have paused their oral medication for 3 whole days.~Insulin treatment is an exclusion criteria. If any other medication then paused 3 days prior to test days.~BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description."
3118297|NCT01765894||DM2 + Metformin|"Type 2 diabetics in metformin treatment. Insulin treatment is an exclusion criteria. If any other medication (besides from metformin) then paused 3 days prior to test days.~BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description"
3118298|NCT01765881|Experimental|Misoprostol|one 25 micrograms capsule all 4 hours by intravaginal route
3118299|NCT01765881|Active Comparator|Dinoprostone|one unique intravaginal sustained released of 10 milligrams
3118300|NCT01765868|Experimental|Single Arm Oral and IV Betrixaban|
3118301|NCT01765855|Experimental|Single Arm Oral Betrixaban|
3118302|NCT01765842|Active Comparator|Rituximab (1 cycle)|"1 cycle of Rituximab (4 i.v. infusions):~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2"
3118303|NCT01765842|Experimental|Rituximab (2 cycles)|"A second cycle of Rituximab~First cycle of Rituximab (4 i.v. infusions):~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2~Second cycle of Rituximab (4 i.v. infusions, 6 months later)"
3118304|NCT01765829|Active Comparator|Antipsychotic treatment|"Antipsychotic treatment according to common clinical practice~Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine, Pipotiazine, Flufenazine, Periciazine, Clozapine, Pimozide, Perfenazine, Sertindole, Levomepromazine, Amisulpride, Asenapine, Tiapride, Droperidol, Ziprasidone."
3118305|NCT01765829|Experimental|Discontinuation antipsychotic treatment|Dose reduction of antipsychotic treatment (25% every 4 weeks).
3118368|NCT01765465|Placebo Comparator|Placebo|Placebo treatment with 200mg PO tid, on postoperative 1 days to 3 months
3118308|NCT01765803|Experimental|Mellaril (thioridazine)|A single 50 gm dose of thioridizine (Mellaril) will be given orally at the beginning of the study
3118309|NCT01765790|Experimental|Malignant Solid Tumor (Arm 1)|"Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 5 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -> 2. Safety data review. If dose escalation permissible -> 3. Next dose group -> 4. Safety data review, etc.~Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s)."
3118310|NCT01765790|Experimental|Metastatic Adenocarcinoma of the Colon or Rectum (Arm 2)|"Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 3 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -> 2. Safety data review. If dose escalation permissible -> 3. Next dose group -> 4. Safety data review, etc.~Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s)."
3118311|NCT01765777|No Intervention|Control Group|Subjects in this arm continue with standard medical care
3118312|NCT01765777|Experimental|Osteopathic Manipulative Medicine Group|Subjects in this arm will receive an OMM intervention.
3118313|NCT01765777|Experimental|Phototherapy Group|Subjects in this arm will receive a phototherapy intervention.
3118314|NCT01765777|Experimental|OMM and Phototherapy Group|Subjects in this arm will receive both the OMM and phototherapy interventions.
3118315|NCT01765764|Experimental|Bimatoprost Solution BID|Bimatoprost solution twice a day (BID) in the morning and in the evening applied to each eyebrow for 7 months.
3118316|NCT01765764|Experimental|Bimatoprost Solution QD|Vehicle to bimatoprost solution in the morning and bimatoprost solution once a day (QD) in the evening applied to each eyebrow for 7 months.
3118317|NCT01765764|Placebo Comparator|Vehicle to Bimatoprost Solution BID|Vehicle to bimatoprost twice a day (BID) in the morning and the evening applied to each eyebrow for 7 months.
3118318|NCT01765751|Active Comparator|Manual Cervical Distraction High Force|Manual Cervical Distraction forces will be limited to greater than 50N in the high force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
3118319|NCT01765751|Active Comparator|Manual Cervical Distraction Medium Force|Manual Cervical Distraction forces will be limited to between 20N-50N in the medium force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
3118320|NCT01765751|Sham Comparator|Manual Cervical Distraction Low Force|Manual Cervical Distraction forces will be limited to less than 20N in the low force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
3118321|NCT01765738|Active Comparator|Antibiotic coated PICC|Cook Medical Spectrum Turbo-Ject Minocycline/Rifampin Power-Injectable PICC (5fr double lumen or 6fr triple lumen)
3118322|NCT01765738|Active Comparator|Non-antibiotic coated PICC|Bard Access PowerPICC Power Injection PICCs (6fr double lumen or 6fr. triple lumen)
3118323|NCT01765725|No Intervention|Control group|The control group will be offered to take part in the patient education group as soon as they have completed the last outcome evaluations
3118324|NCT01765725|Experimental|Patient education program|Patient education program
3118325|NCT01765712|Placebo Comparator|Control Group|Patients will be randomized into the treatment arm using a computer generated randomization table (simple randomization). Patients in the control arm of the study will undergo Anterior cruciate ligament reconstruction using Autologous bone patellar tendon bone autograft. At the end of the surgery, their graft donor site will have bone graft chips placed into the bony defect and the wound will be closed using sutures.
3118326|NCT01765712|Experimental|Platelet Rich Plasma|Patients randomized into the treatment arm of the study will undergo Anterior cruciate ligament reconstruction with Autologous bone patellar tendon bone autografts. At the start of the surgery,just after the administration of anesthesia, 10cc of blood will be withdrawn from the patients IV by the anesthesiologist. This sample will be spun down into 3-5cc of Platelet Rich Plasma which will be added to the patients bone graft chips and placed into the donor site at the end of the case.
3118327|NCT01765699||Primary knee arthroplasty|Patients with osteoarthritis of the knee undergoing primary knee arthroplasty
3118328|NCT01765686|Active Comparator|Harmonic|Harmonic scalpel uses ultrasound technology to coagulate and to cut tissues.
3118329|NCT01765686|Active Comparator|Small Jaw|Small Jaw device uses bipolar electrical energy and pressure to form a seal and a micro blade to divide the sealed tissues.
3118330|NCT01765673||Vibrotactile Stimulation in Dysphagia|A Vibrotactile stimulation device will be evaluated in patients with chronic moderate to severe dysphagia for more than 6 months post onset due to stroke or following radiation treatment for head and neck cancer to assess which frequency, mode, pressure characteristics are most helpful in increasing the rate of swallowing, increasing the urge to swallow, assisting with the initiation of swallowing and not affecting discomfort.
3118331|NCT01765660|Experimental|Non-mesenchymal stem cells|Non-mesenchymal stem cell group refers to treatment with other second line drugs
3118332|NCT01765660|Experimental|Mesenchymal stem cells|Mesenchymal stem cell group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)every two weeks, four times for a cycle
3118333|NCT01765647|Experimental|AGY|All participants will receive the same, open-label dose of AGY
3118334|NCT01765634|Experimental|Mesenchymal stem cells|Mesenchymal stem cell group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)each week, four times for a cycle
3118335|NCT01765634|Experimental|Non-mesenchymal stem cells|Non-mesenchymal stem cell group refers to treatment with other second line drugs
3118336|NCT01765621|Experimental|DDI+ and Pharmacogenetic data|DDI+ System and Pharmacogenetic data
3118337|NCT01765621|No Intervention|Standard Care|Control
3118369|NCT01765452|Experimental|Closone|75mg/100mg per day, 8weeks, PO
3118338|NCT01765608|Experimental|Zonisamide|Zonisamide (Zonegran®) 300 mg. Hard white capsule. The total length of zonisamide treatment will be 20 and 24 weeks ± 2 weeks including one or two 4 week titration phases in the placebo and zonisamide groups respectively. Dosing will be down titrated after finished study during 2-3 weeks.The maximum dose after titration will be administrated once daily. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
3118339|NCT01765608|Active Comparator|Placebo|Matched for Zonisamide. Hard white capsule. Manufactured by Eisai Inc. Placebo tablets will be administered according to a forced stepwise weekly titration scheme with weekly 1 tablet escalations from 1 to 3 tablets daily matching the Zonisamide (Zonegran ®) dosing regimen for a total duration of 4 weeks. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
3118340|NCT01765608|Active Comparator|nCPAP|Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S8 or S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed within the first 4 weeks of treatment initiation. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 24 weeks.
3118341|NCT01765595|Experimental|DDI+|DDI+ Incorporated in routine ambulatory practice
3118342|NCT01765595|No Intervention|Control|Standard care
3118343|NCT01765582|Experimental|Arm A: Concurrent FOLFOXIRI + Bevacizumab|Participants will receive concurrent FOLFOXIRI along with 5 mg/kg of bevacizumab with treatment cycle of 2 weeks during first 4 month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
3118344|NCT01765582|Experimental|Arm B: Sequential FOLFOXIRI + Bevacizumab|Participants will receive alternating 4-week administrations of FOLFOX/bevacizumab and folinic acid (leucovorin), 5-FU, and irinotecan (FOLFIRI) /Bevacizumab with a treatment cycle of 2 weeks during first 4-month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
3118345|NCT01765582|Experimental|Arm C: FOLFOX + Bevacizumab|Participants will receive FOLFOX along with 5 mg/kg of bevacizumab with treatment cycle of 2 weeks during first 4-month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
3118346|NCT01765569|Experimental|Vemurafenib + Digoxin|Single oral dose of digoxin 0.25 mg tablet on Day 1 in Period A, followed by vemurafenib 960 mg tablet orally BID from Day 8 to Day 28 in Period B, and then single oral dose of digoxin 0.25 mg on Day 29, and vemurafenib 960 mg orally BID from Day 29 to Day 35 in Period C.
3118347|NCT01765556|Experimental|Ketoconazole treatment|
3118348|NCT01765556|Experimental|Vemurafenib treatment|
3118349|NCT01765543|Experimental|Vemurafenib + Rifampin|There will be 3 intervention periods in the study: Period A (Days 1 to 7), Period B (Days 8 to 16), and Period C (Days 17 to 24). Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 milligrams (mg) as film-coated tablets orally alone on Day 1 (Period A); with rifampin (at a dose of 600 mg as capsules orally) on Day 17 (Period C); and rifampin alone at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 16 (Period B) and from Days 18 through 23 (Period C).
3118350|NCT01765530|Experimental|ETT cleaning manuver|Patients randomized to the treatment group will undergo an ETT cleaning maneuver with endOclear three times a day (every 8 hours) for the whole intubation period in addition to the standard of care.
3118351|NCT01765530|No Intervention|Standard of care|In the protocol no intervention is planned for the control group, which will therefore be treated with blind suctioning as per caregiver clinical decision.
3118352|NCT01765517|Experimental|Probiotics|Probitoics
3118353|NCT01765517|Placebo Comparator|Placebo|Placebo
3118354|NCT01765491|Experimental|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy.
3118355|NCT01765491|Active Comparator|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy.
3118356|NCT01765478|Experimental|Treatment A Period 2|40mg HM71224 single dose
3118357|NCT01765478|Experimental|Treatment B Period1|20mg HM71224 single dose
3118358|NCT01765478|Experimental|Treatment A Period1|10mg HM71224 single dose
3118359|NCT01765478|Experimental|Treatment B Period2|80mg HM71224 single dose
3118360|NCT01765478|Experimental|TreatmentA Period3|160mg HM71224 single dose
3118361|NCT01765478|Experimental|TreatmentB Period3|200mg HM71224 single dose
3118362|NCT01765478|Experimental|Food effect period1|active 4subjects + placebo 4subjects
3118363|NCT01765478|Experimental|Food effect period2|active 4subjects + placebo 4subjects
3118364|NCT01765478|Experimental|TreatmentC|HM71224 Xmg multiple dose for 14days
3118365|NCT01765478|Experimental|TreatmentD|HM71224 Ymg 14days multiple dose
3118366|NCT01765478|Experimental|TreatmentE|HM71224 Zmg 14days multiple dose
3118367|NCT01765465|Experimental|Rowachol|Rowachol treatment with 200mg PO tid, on postoperative 1 days to 3 months
3118373|NCT01765439|Experimental|UC IPAA|Patients with ulcerative colitis after proctocolectomy and ileal pouch-anal anastomosis(IPAA).
3118374|NCT01765439|Experimental|Healthy volunteers|Subjects without any sign of disease of the digestive tract.
3118375|NCT01765426|Experimental|Group 1: TDV using PharmaJet® Injector|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) [previously DENVax] one dose injection in arm 1 and placebo: phosphate buffered saline (PBS) one dose injection in arm 2, using needle-free PharmaJet® Injector, intradermal, on Day 0 and TDV, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
3118376|NCT01765426|Experimental|Group 2: TDV using PharmaJet® Injector|TDV injection, one dose in each arm, using needle-free PharmaJet® Injector, intradermal, on Day 0 and placebo: PBS, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
3118377|NCT01765426|Experimental|Group 3: TDV using Needle and Syringe|TDV one dose injection in arm 1 and placebo: PBS one dose injection in arm 2, using needle and syringe, intradermal, on Day 0 and TDV injection using needle and syringe, intradermal, one dose on Day 90.
3118378|NCT01765426|Experimental|Group 4: TDV using PharmaJet® Injector|TDV injection, one dose in each arm, using needle-free PharmaJet® Injector, intradermal, on Day 0 and TDV, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
3118379|NCT01765413|Experimental|Varilrix|Participants receive one dose of 'Varilrix' varicella-zoster vaccine.
3118380|NCT01765413|Experimental|Stamaril|Participants receive one dose of 'Stamaril' yellow fever vaccine.
3118381|NCT01765413|Placebo Comparator|Placebo|Participants receive one injection of placebo.
3118382|NCT01765400|Active Comparator|Prasugrel|Prasugrel 10 mg once daily for 2 weeks
3118383|NCT01765400|Active Comparator|Clopidogrel|Clopidogrel 75 mg once daily for 2 weeks
3118384|NCT01765387|Experimental|Spa therapy|A cycle of 3 Vichy shower and whirlpool baths are applied during 30-minutes period. Vichy sedative shower is applied for 90-120 sec to the sides of the trunk and the abdomen, avoiding as much as possible the gall bladder area, at a temperature of 36-38ºC. A short, partial jet spray followed the shower. A whirlpool bath is administered where subjects immersed the body until their clavicle level for a 10min period with a water temperature ranging 33.5-35.5 ºC. Aromatherapy application using lavender and chamomile oils is used in all Spa therapy sessions.
3118385|NCT01765387|No Intervention|Control group|"The control group perform a rest session in supine position in a room with neutral temperature condition with a same duration to Spa session. Participants of both groups are encouraged to drink water ad libitum to prevent dehydration."
3118386|NCT01765374|Experimental|rituximab|Only one arm; all patients are treated by rituximab (monotherapy or in combination with conventional DMARD)
3118387|NCT01765348|Experimental|Sentence combining|
3118388|NCT01765348|Active Comparator|Narrative based method|
3118389|NCT01765335|Experimental|NICaS system efficacy in HF patients|NICaS system efficacy in HF patients
3118390|NCT01765322|Experimental|Assisted hatching group (AH group)|The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK IVOS Analyzer,Hamilton Thorne Biosciences,USA).
3118391|NCT01765322|No Intervention|Control group|The subjects are going to undergo the same procedure except for the treatment of assisted hatching.
3118392|NCT01765309|Experimental|Bilateral mastectomy with reconstruction|The trial was a comparison between each breast in a single patient undergoing bilateral mastectomy with reconstruction
3118393|NCT01765296|Active Comparator|Celecoxib|Celecoxib 200 mg by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)
3118394|NCT01765296|Placebo Comparator|Placebo|Placebo capsule by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)
3118395|NCT01765296|Experimental|CG100649|CG100649 2 mg capsule by mouth, once a day for 6 weeks (Treatment Phase); CG100649 2 mg capsule by mouth, once a day for 18 weeks (Safety Phase)
3118396|NCT01765283|Experimental|Hepastem Low dose|12.5x106cells/kg
3118397|NCT01765283|Experimental|Hepastem Intermediate dose|50x106cells/kg
3118398|NCT01765283|Experimental|Hepastem High dose|200x106cells/kg
3118399|NCT01765270|Active Comparator|Saxagliptin|Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.
3118400|NCT01765270|Placebo Comparator|Placebo|Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.
3118401|NCT01765257|Experimental|rasagiline|Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France
3118402|NCT01765257|Placebo Comparator|placebo|Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France
3118403|NCT01765244|Experimental|Anterior lamellar nanostructured artificial human cornea|Anterior lamellar nanostructured artificial human cornea with allogenic from dead donor and cultured in its inside and allogeneic corneal epithelium cultured in its surface
3118404|NCT01765244|Active Comparator|Amniotic membrane transplantation|Amniotic membrane transplantation as conventional treatment of corneal trophic ulcers.
3118405|NCT01765231|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of antitumor therapy, and will be continued until at least 6 months after completion of antitumor therapy.
3118406|NCT01765231|Active Comparator|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
3118407|NCT01765218|Placebo Comparator|Placebo|Subjects will receive the standard of care intervention for HIE at our institution (whole body cooling for 72h followed by gradual rewarming)
3118408|NCT01765218|Active Comparator|Toprimate|In addition to whole body cooling, infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
3118409|NCT01765205||Newborns with Pulse oximetry|Up to 50 healthy newborn participants will receive 15 minutes of pulse oximetry to determine the effectiveness of measuring somatic oxygen saturation.
3118410|NCT01765205||CHD infant with pulse oximetry|Up to 10 infants diagnosed with congenital heart disease will receive 15 minutes of pulse oximetry using the INVOS Cerebral/Somatic Oximeter to determine the effectiveness of measuring somatic oxygen saturation.
3118411|NCT01765192|Experimental|Roflumilast plus montelukast, then placebo plus montelukast|Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks.
3118412|NCT01765192|Experimental|Placebo plus montelukast, then roflumilast plus montelukast|Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks.
3118413|NCT01765179|Experimental|Oral testosterone undecanoate|
3118414|NCT01765166|Experimental|Control(ChO)|Children receive traditional SSGRIN child treatment with no parent involvement
3118415|NCT01765166|Experimental|Parent attention control(PAC)|Children will participate in traditional SSGRIN treatment, and parents will participate in a weekly support group to meet with other parents regarding their child's peer relations and behavior. The support group will meet for a parallel amount of time (1 hour/week for 10 weeks) and be facilitated by two parents with no SSGRIN or Parent Guide experience. The PAC condition will reflect the social support functions of a parenting group, but no therapeutic skills training or other instructional materials will be provided.
3118416|NCT01765166|Experimental|Parent Guide-Home Study(PG-HS)|Children will receive traditional SSGRIN treatment, and parents will receive the Parent Guide to SSGRIN training by participating in the online Parent Guide Home Study (PG-HS) course. The PG-HS course will include all instructional content and materials for the in-person Parent Guide course, but parent will receive the training online.
3118417|NCT01765166|Experimental|Parent Guide(PG)|Children will receive traditional SSGRIN treatment and parents will receive parallel traditional in-person SSGRIN-Parent Guide treatment.
3118418|NCT01765153|Experimental|Endurance first|Participants to start with Endurance Training. Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training. Training was 5x/wk for 2 months, followed by a 2-month rest period. Participants then returned for training in the Precision Training 5x/wk for 2 months.Participants train to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto. This is followed by another 2-month rest. Measures of walking speed, distance, skill, confidence, as well as mood were obtained at least 3 times before any training, then monthly thereafter.
3118419|NCT01765153|Experimental|Precision first|Participants to start with Precision Training. Participants train to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto. Training was 5x/wk for 2 months, followed by a 2-month rest period. Participants then returned for Endurance Training 5x/wk for 2 months. Participants are trained to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training. followed by another 2-month rest. Measures of walking speed, distance, skill, confidence, as well as mood were obtained at least 3 times before any training, then monthly thereafter.
3118420|NCT01765127||Asenapine|Patients prescribed asenapine for any indication by a National Health Service (NHS) general practitioner (GP) in England.
3118421|NCT01765114|Experimental|PEG-Formulation|PEG-Formulation, applied twice daily during the treatment period (duration: 6 months)
3118422|NCT01765101|Experimental|customized insoles|"customized full-length lateral wedged shoe insoles~1 month and 3 months study the immediate, short-term and intermediate-term therapeutic effects"
3118423|NCT01765101|Placebo Comparator|ready made insoles|"ready-made full-length lateral wedged shoe insoles at 1 and 3 months~study the immediate, short-term and intermediate-term therapeutic effects"
3118424|NCT01765088|Active Comparator|temozolomide|Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide (150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles)
3118425|NCT01765088|Experimental|temozolomide +α-IFN|Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide plus α-IFN α-IFN：3mIU (3million) Day1,3,5 of each 28 day TMZ：150 mg/m^2 daily on Days 2-6 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles
3118426|NCT01765075||Patients undergoing cardiac ablation for permanent AF|
3118427|NCT01765062||Before Rapid Maxillary Expansion|T0
3118428|NCT01765062||3 months After Rapid Maxillary Expansion|T1
3118429|NCT01765062||One year After Rapid Maxillary Expansion|T2
3118430|NCT01765036|Experimental|SonoVue®|"Non randomised study~Sonovue 4,8 ml intravenous administration, in 1 bolus, during the EUS examination"
3118431|NCT01765023|Experimental|Part A|single administration : atorvastatin 40mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)
3118432|NCT01765023|Experimental|Part B|single administration : metformin XR 1000mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)
3118433|NCT01765010|Placebo Comparator|Placebo control|Placebo control
3118434|NCT01765010|Active Comparator|Cholecalciferol 1000IU|Cholecalciferol 1000IU qd for 8 weeks
3118435|NCT01765010|Experimental|alfacalcidol|alfacalcidol 0.5ug qd for 8 weeks
3118436|NCT01765010|Experimental|Calcitriol|Calcitriol 0.25ug qd for 8 weeks
3118437|NCT01764997|Experimental|Adalimumab Open Label run-in|Adalimumab 40 mg every 2 weeks (Q2W) for 16 weeks added to stable dose of MTX.
3118438|NCT01764997|Active Comparator|Etanercept + MTX (Randomized)|Etanercept 50 mg in combination with Placebo for sarilumab Q2W and etanercept 50 mg on alternating weeks for 24 weeks added to stable dose of MTX.
3118439|NCT01764997|Experimental|Sarilumab 150 mg + MTX (Randomized)|Sarilumab 150 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
3118440|NCT01764997|Experimental|Sarilumab 200 mg + MTX (Randomized)|Sarilumab 200 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
3118441|NCT01764997|Experimental|Sarilumab 150 mg + MTX Open Label Sub-study|Sarilumab 150 mg Q2W for 52 weeks added to stable dose of MTX.
3118442|NCT01764984|Experimental|Trabecular metal|Primary Total Knee Arthroplasty is performed with a non cemented trabecular metal tibial baseplate.
3118443|NCT01764984|Active Comparator|Titanium|Primary total knee arthroplasty is performed with cemented titanium traditional tibial base plate
3118444|NCT01764971||chronic itp and cerebral dysfunction|patients with chronic itp and had behavioral and or cognitive dysfunction
3118445|NCT01764971||chronic itp only|chronic ITP patients without cerebral dysfunction
3118446|NCT01764958||preterm infants and their mothers|"Inclusion criteria are: preterm infants born between 26-34 weeks of gestation, whose mothers speak and write Hebrew fluently. Exclusion criteria are: preterm infants who suffer from perinatal asphyxia, genetic or metabolic diseases, necrotizing colitis that requires operation, intra uterine growth retardation, deafness, retinopathy of prematurity (ROP) or major congenital defects.~Infants and their mothers will be recruited from child developmental centers and Pediatric Clinics of Maccabi. No intervention is included in the research."
3118447|NCT01764945|Experimental|1 BI 201335|low dose
3118448|NCT01764945|Experimental|2 BI 201335|high dose
3118449|NCT01764932|Other|Thoracic epidural catheter insertion|Fluoroscopic imaging. For patients undergoing thoracic epidural analgesia (TEA) with catheter placement for pain associated with thoracic or upper abdominal surgery
3118450|NCT01764919|Experimental|[124I]FIAU|Single intravenous injection of [124I]FIAU in patients with diabetic foot infection
3118451|NCT01764906|Experimental|Novosis|Bongros/rhBMP-2
3118452|NCT01764906|Active Comparator|Iliac crest bone graft|Iliac crest bone graft
3118453|NCT01764893|Active Comparator|PTNS and solifenacin|PTNS bladder neuromodulation weekly for 12 treatments; solifenacin 5 mg capsule daily for 15 weeks
3118454|NCT01764893|Placebo Comparator|PTNS and placebo|PTNS bladder neuromodulation weekly for 12 treatments; placebo 1 capsule daily for 15 weeks
3118455|NCT01764880|Experimental|SST0001 (Roneparstat)|"SST0001 once daily for 5 or 10 days in a cycle of 28 days. Starting dose 25 mg, to be escalated in subsequent cohorts.~Duration of treatment depending on toxicities observed or until documentation of disease progression or other discontinuation criteria are met."
3118456|NCT01764867|Active Comparator|Algorithm Guided Treatment (AGT)|Algorithm Guided Treatment (AGT) strategies include two steps. In the first step, participants will be randomly assigned to escitalopram (10-20mg/d) or mirtazapine (30-45mg/d) group. In the second step those non-remitted will be allocated into a set of different intervention groups including mirtazapine monotherapy (only for those taken escitalopram in the first step), escitalopram monotherapy (only for those taken mirtazapine in the first step), or combination therapies (i.e. escitalopram plus mirtazapine, escitalopram or mirtazapine plus either modified electroconvulsive therapy with 6-10 sessions or repetitive transcranial magnetic stimulation with 20 sessions respectively) according to intent-to-treat principle. Medication dosage in combination therapy has the same range as the first.
3118457|NCT01764867|Active Comparator|Treatment As Usual (TAU)|This control arm refers to routine antidepressant treatment strategies for participants. Any of the new-generation antidepressants including fluoxetine, citalopram, escitalopram, paroxetine, sertraline, fluvoxamine, venlafaxine, duloxetine, mirtazapine, bupropion, or trazodone, which are all available in Chinese psychiatric clinics, may be used for participants who are randomly assigned to this treatment arm based on clinician's expertise and clinical judgement. The dosage range of any of the above antidepressants depends on clinician's judgement. The follow-up period will last up to 6-12 weeks. During follow-ups, clinician can decide to continue current treatment or start a switch or combination strategy based on his/her own clinical judgement.
3118458|NCT01764854|Experimental|AZD1722|
3118459|NCT01764854|Placebo Comparator|Placebo|
3118460|NCT01764841|Experimental|Ciprofloxacin DPI 28 Days on/off (Cipro 28)|Participants received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).
3118461|NCT01764841|Experimental|Ciprofloxacin DPI 14 Days on/off (Cipro 14)|Participants received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).
3118462|NCT01764841|Placebo Comparator|Placebo 28 Days on/off (Placebo 28)|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).
3118463|NCT01764841|Placebo Comparator|Placebo 14 Days on/off (Placebo 14)|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).
3118464|NCT01764828|Experimental|Refametinib (BAY86-9766)+ Gemcitabine|Single dose of BAY86-9766 on Cycle 1 Day -17; twice daily dosing every day starting on day -14, start dose 50mg bid ( 30mg or 20mg are possible based on adverse events need) in addition with Gemcitabine intravenous on day 1,8 and 15 1000mg/m2
3118465|NCT01764815|Experimental|Directional lead|
3118466|NCT01764802|Active Comparator|Arm I (enhanced standard care)|Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding cancer treatments and sexuality delivered over two sessions.
3118467|NCT01764802|Experimental|Arm II (psychological intervention)|Patients participate in individual or group therapy over 1.5 hours weekly for 6 weeks, bi-weekly for 8 weeks, and monthly for 2 months and complete assessment interviews.
3118468|NCT01764789|Experimental|Supportive care (psychosocial intervention)|Patients participate in a multi-component intervention based on cognitive and behavioral principles comprising MBSR, an intervention to promote hopefulness, and a problem solving approach which navigates around obstacles or generates alternatives when goals become blocked. Additional topics may be covered as indicated by clinical need and patients goals. Biobehavioral components include addressing social and disease-specific quality of life, and pain education. Intensive treatment sessions continue weekly for 16 weeks followed by 2 biweekly and 2 monthly maintenance sessions.
3118469|NCT01764776|Experimental|LDE225|LDE225
3118470|NCT01764763||non epiaortic group|non epiaortic group ( n=1019)
3118471|NCT01764763||epiaortic group|epiaortic group ( n=1273)
3118472|NCT01764750|Experimental|Low Dose Intrasite Vancomycin|10 patients will be enrolled to receive low dose (see protocol) intrasite Vancomycin at the time of surgery. This will be the first group enrolled in the dose-escalation trial.
3118473|NCT01764750|Experimental|Mid-dose Intrasite Vancomycin|10 patients will be enrolled to receive mid-dose intrasite Vancomycin at the time of surgery.
3118474|NCT01764750|Experimental|High-dose Intrasite Vancomycin|10 patients will be enrolled to receive high-dose intrasite Vancomycin at the time of surgery.
3118475|NCT01764750|Active Comparator|Optimally-dosed IV Vancomycin|10 patients will be enrolled to receive optimally-dosed IV Vancomycin at the time of surgery and two doses post-operatively (standard peri-operative IV antibiotics)
3118476|NCT01764737|Experimental|VX15/2503|
3118477|NCT01764737|Experimental|Placebo|
3118478|NCT01764724||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is a online consumer monitor panel which answers surveys every 8-10 weeks about diet and health.
3118479|NCT01764711|Experimental|Low Salt Diet|Each participant will be asked to sit in a chair for 30 minutes prior to a blood draw. Then a small dose of cosyntropin is administered intravenous. Blood samples will be drawn again at 30 minutes and 60 minutes after the drug has been given.
3118480|NCT01764698|Experimental|CALM-SUD|Participants receive the adaptation of the Coordinated Anxiety Learning and Management (CALM) protocol that demonstrated effectiveness in a large primary care sample. CALM will be adapted for those with anxiety and substance use disorder comorbidity, and will consist of an orientation session and 6 group treatment sessions. These participants will also receive substance abuse treatment as usual at a community Intensive Outpatient Program.
3118481|NCT01764698|Active Comparator|Treatment as usual|Participants in this arm receive the standard Intensive Outpatient treatment for their substance use disorder at a community addictions treatment facility.
3118482|NCT01764685|Experimental|Topiramate + Medical Management|Topiramate titrated up to 150 mg/day over 5 weeks then maintained for 6 weeks + Medical Management sessions for 15-25 minutes per study visit
3118483|NCT01764685|Placebo Comparator|Placebo Pill + Medical Management|Sugar pill with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit
3118484|NCT01764672|Experimental|Attention Deficit Hyperactivity Disorder|Adult males with Attention Deficit Hyperactivity disorder will participate in a crossover design and receive both methylphenidate and placebo on two separate days.
3118485|NCT01764672|Experimental|Healthy adults|Healthy male adults will participate in a crossover design and receive both methylphenidate and placebo on two separate days.
3118486|NCT01764646|Experimental|9 days|Patients undergo extreme hypofractionated radiation therapy (Intensity modulated radiation therapy, Volumetric modulated arc therapy, Image guided radiation therapy) once a week over 28 days
3118487|NCT01764646|Experimental|28 days|Patients undergo extreme hypofractionated radiation therapy (Intensity modulated radiation therapy, Volumetric modulated arc therapy, Image guided radiation therapy) other 9 days.
3118488|NCT01764633|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference.
3118489|NCT01764633|Experimental|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference.
3118490|NCT01764620|Other|Control|In this session, the athletes will be evaluated before and after the fatigue protocol, without any taping application.
3118491|NCT01764620|Experimental|Kinesio taping|A kinesio taping technique for facilitating lower trapezius muscle function will be applied just before fatigue protocol and removed after in the end of the evaluation session.
3118492|NCT01764620|Sham Comparator|Sham|A similar technique, using the same tape, will be applied but without any tension (tension is considered to be the therapeutic effect). The tape will be applied just before the fatigue protocol and removed in the end of the session.
3118493|NCT01764607|Experimental|Sirolimus treatment|Patients will receive sirolimus 5 weeks prior to removal of squamous cell skin carcinoma. After the 5 weeks of treatment, nephrology will determine/manage each patient's immunosuppressant therapy.
3118494|NCT01764594|Experimental|CDP7657|"CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks"
3118495|NCT01764594|Placebo Comparator|Placebo|Placebo
3118496|NCT01764581|Experimental|Tacrolimus dose regulation|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL.
3118497|NCT01764581|No Intervention|Control|immunosuppressive therapy is managed either by standard practice at our center (Control)
3118498|NCT01764568|Experimental|Metacognitive Training for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will receive Metacognitive Training twice weekly for 8 weeks (16 sessions).
3118499|NCT01764568|Experimental|Cognitive Remediation for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will receive Cognitive Remediation treatment twice weekly for 8 weeks (16 sessions).
3118500|NCT01764568|No Intervention|Treatment as Usual for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will continue to receive treatment as usual (TAU) as defined by their health care team (i.e., medication, other therapies) while still taking part in baseline, midpoint, and end-point assessments.
3118501|NCT01764555|Experimental|normal weight patients|normal weight patients receiving acetaminophen 2 g instead of 1 g
3118502|NCT01764555|Experimental|mobidly obese patients|morbidly obese patients receiving acetaminophen 2 g instead of 1 g
3118503|NCT01764542|Other|Endoscopy and biopsy|Endoscopy with biopsy taken Endoscopy and biopsy Blood samples Questionnaire
3118504|NCT01764529||CCM Participants|"Have a confirmed diagnosis of familial CCM by DNA testing, or~Meet 2 of the 3 following criteria:~Clinical diagnosis of CCM~Evidence of multiple cavernous malformations on MRI~Someone in your immediate or extended family has a clinical diagnosis of CCM"
3118505|NCT01764516||Zinc level (micro gram per deciliter)|In all cases
3118506|NCT01764516||Selenium level (micro gram per deciliter)|In all cases
3118507|NCT01764516||Zinc level in male (micro gram per deciliter)|
3118508|NCT01764516||Selenium level in male (micro gram per deciliter)|
3118509|NCT01764516||Zinc level in Female (micro gram per decilitre)|
3118510|NCT01764516||Selenium level in Female (micro gram per decilitre)|
3118511|NCT01764477|Experimental|PRI-724 and Gemcitabine|This study will have one arm: all enrolled subjects will be treated with both PRI-724 and Gemcitabine.
3118512|NCT01764464|Other|Group A|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®). 10 day washout (no intervention). 14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
3118513|NCT01764464|Other|Group B|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo). 10 day washout (no intervention). 14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
3118514|NCT01764451|Experimental|Simvastatin|20-40 mg tablet taken daily by mouth. Month 1: 20 mg; Months 2 and 3: 40 mg.
3118515|NCT01764451|No Intervention|No Treatment|
3118516|NCT01764438||very early or early staged patients|Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious HCC by liver dynamic CT
3118517|NCT01764425|Active Comparator|P7435|Tablets for once daily oral administration, For SAD part of the study dose would be 10 mg for Cohort 1; Cohorts 2, 3, 4 and 5 will be dosed subsequently at 30 mg, 100 mg, 300 mg, 1000 mg respectively Dose for MAD and food effects part of the study would be based on SAD study results
3118518|NCT01764425|Placebo Comparator|Placebo|Placebo tablets for oral administration
3118519|NCT01764412||Healthy women|Non interventional
3118520|NCT01764399|Experimental|Care4U intervention|Care4U intervention with 6 weekly sessions focusing on physical activity, healthy eating, self-management, emotional responses.
3118521|NCT01764399|No Intervention|Information group|The information group receives 6 weekly socialization sessions.
3118522|NCT01764386|Experimental|NB + CLI|Naltrexone SR 32 mg/Bupropion SR 360 mg/day (NB) with comprehensive lifestyle intervention (CLI)
3118523|NCT01764386|Other|Usual Care|"Usual Care (self-directed lifestyle intervention)~Usual Care: Usual Care was a self-directed lifestyle intervention in which subjects were given calorie targets, instructions to increase exercise, and a pamphlet about weight loss by study site staff."
3118524|NCT01764373|Experimental|16-Week Exercise Program|Subjects to participate in 16-week3 supervised aerobic exercise 3 times per week. Exercise sessions to last between 30 and 60 minutes.
3118525|NCT01764360|Other|KS structured clinical care training|Eight primary care sites in Zimbabwe will be randomized at different timepoints to receive structured training for diagnosis and treatment of Kaposi sarcoma (KS)
3118526|NCT01764347|Experimental|Diagnostic (MRI-TRUS fusion image-guided biopsy)|Patients undergo robotic radical prostatectomy, followed by 3 MRI-TRUS fusion image-guided prostate biopsies.
3118527|NCT01764334|Active Comparator|Fractional flow reserve|"Fractional flow reserve - guided group:~The initial treatment decision and the coronary arteries for fractional flow reserve (FFR) measurement will be established and recorded before randomization. FFR will then be measured by the cardiologist immediately after randomization and the FFR result will used to guide treatment decisions based on a threshold of 0.80. An FFR ≤ 0.80 should result in a treatment decision for revascularization by PCI or CABG combined with optimal medical therapy and an FFR>0.80 should result in treatment with optimal medical therapy alone. Changes in treatment compared to the treatment plan prior to FFR disclosure will be recorded at the time."
3118528|NCT01764334|Placebo Comparator|Angiography-guided|FFR is measured by but not disclosed to the clinical team. Treatment decisions are therefore guided by angiography but not by FFR. The patient and the clinical team, including the cardiologists and nurses, will be blinded to FFR. The RadiAnalyzer Xpress (St Jude Medical) will be turned away from the clinical team who will not see the pressure wire data. FFR will not be displayed on any other monitor. Quality control checks, such as assessments of equalized pressure, will be done in the usual way, by the unblinded clinical research team. These steps will be followed for all FFR measurements. Adherence to the blinding protocol, including any non-protocol FFR disclosure at any time, will be prospectively recorded and blinding procedures will be monitored with site visits.
3118529|NCT01764321||Certolizumab Pegol treatment|Certolizumab Pegol in combination with at least one Disease Modifying Antirheumatic Drug (DMARD)
3118530|NCT01764321||Other Tumor Necrosis Factor TNF inhibitor treatment|Other subcutaneous (sc) Tumor Necrosis Factor (TNF) inhibitor (Adalimumab, Golimumab, Etanercept) in combination with at least one Disease Modifying Antirheumatic Drug (DMARD)
3118531|NCT01764308|Experimental|O3FA|Omega 3 Fatty Acid 1200mg twice a day for 24 weeks
3118532|NCT01764308|Placebo Comparator|Placebo|4 tablets twice a day for 24 weeks
3118533|NCT01764295|Experimental|DWJ1276|Once daily, administered orally, 8 week
3118534|NCT01764295|Active Comparator|Olmesartan|Once daily, administered orally, 8 week
3118535|NCT01764295|Active Comparator|Rosuvastatin|Once daily, administered orally, 8 week
3118536|NCT01764295|Placebo Comparator|Placebo|Once daily, administered orally, 8 week
3118537|NCT01764282|Experimental|Intervention|comprehensive intervention components
3118538|NCT01764282|No Intervention|Usual|According the National HIV Antiretroviral treatment Guideline, provide treatment referrals for those treatment-eligible HIV-positive patients.
3118539|NCT01764269|Other|inactivated influenza vaccine (IIV)|Patients whose provider chooses to administer to them inactivated influenza vaccine (IIV)
3118540|NCT01764269|Other|Live attenuated influenza vaccine (LAIV)|Patients whose provider chooses to administer to them Live attenuated influenza vaccine (LAIV)
3118541|NCT01764256|Experimental|P2-VP8 subunit rotavirus vaccine|3 doses of P2-VP8 subunit rotavirus vaccine 4 weeks apart
3118542|NCT01764256|Placebo Comparator|Placebo group|12 subjects receiving 3 intramuscular injections of placebo 4 weeks apart
3118543|NCT01764243|Experimental|MT-4666 Low Dose|low dose
3118544|NCT01764243|Experimental|MT-4666 High Dose|high dose
3118545|NCT01764243|Placebo Comparator|Placebo|placebo
3118546|NCT01764230|Experimental|case group|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
3118549|NCT01764178|Experimental|Livalo fixed combination drug|Livalo fixed combination drug(Pitavastatin + Valsartan)
3118550|NCT01764178|Active Comparator|Pitavastatin + Valsartan|Pitavastatin, Valsartan
3118551|NCT01764165|Active Comparator|oxygen|nocturnal oxygen of 2 L/min
3118552|NCT01764165|Experimental|High Flow of room air|Warm and humidified air at a rate of 20 L/min through a small nasal cannula (similar to oxygen cannula)
3118553|NCT01764152|Experimental|Nasopharyngeal sample|one will be taken nasopharyngeal all patients hospitalized for 24 hours with ILI in the last seven days.
3118554|NCT01764139||Knee pain patients with minimal knee changes|Male & no pregnant female age between 18-40 yrs.
3118555|NCT01764126|Active Comparator|Pneumococcal protein vaccine|Pneumococcal protein vaccine
3118556|NCT01764126|Placebo Comparator|Placebo|Placebo
3118557|NCT01764113|Experimental|Mindful Eating|Subjects and at least one of their parents will receive mindful eating based behavioral modification program
3118558|NCT01764113|Active Comparator|Standard Dietary Couseling|Subjects and their parents will receive standard nutritional counseling provided by a registered dietician
3118559|NCT01764100|Experimental|Mesenchymal Stromal Cells (MSC)|Intravenous injections for a dose of 1 ± 0.5 x 106 MSC/kg recipient body weight
3118560|NCT01764087|Experimental|KX2-391 and Paclitaxel|"The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. 3 or 6 subjects with solid tumor per dose group will likely be necessary to determine the MTD of KX2-391 in combination with weekly paclitaxel. With paclitaxel dose fixed at 80 mg/m2/weekly, KX2-391 treatment will be started at 20 mg dose once daily (QD)~The phase II portion of this trial has a design to determine the efficacy of KX2-391 when administered in combination with paclitaxel in 20 subjects with stomach cancer and 20 subjects with breast cancer"
3118561|NCT01764074|Experimental|Brief Sleep Intervention|Every participant in the study will complete a 3-session sleep intervention with a clinician to improve sleep problems such as insomnia or hypersomnia.
3118562|NCT01764048|Experimental|Fix protocol|"During 48 hours following surgery pain medications will be given as followed (listed in brackets are the generic names of each medication):~At patient arrival to the department: Intravenous Tramadol hydrochloride 100 milligrams + TAB. Paracetamol 500 milligrams + TAB. Diclofenac 100 milligrams~After 6 hours from patient arrival and every 6 hours: TAB. Zaldiar (Paracetamol 650 milligrams + Tramadol 75 milligrams).~After 12, 24 and 48 hours from patient arrival: TAB. Diclofenac 100 milligrams.~Rescue medication: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)as necessary up to 4 times per day.~The total amount of paracetamol is limited to 4 gr per day."
3118563|NCT01764048|Experimental|medications following demand protocol|The same combinations will be given as in the fixed protocol however only after patient request
3118564|NCT01764035|Active Comparator|Brief Supportive Psychotherapy (SP)|30 people will be randomized to receive Brief Supportive Psychotherapy.
3118565|NCT01764035|Experimental|Body Scan (BS) Meditation Intervention|30 people will be randomized receive the Body Scan Meditation Intervention.
3118566|NCT01764022|Experimental|BCD-022 (CISC BIOCAD)|BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BCD-022 at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).
3118567|NCT01764022|Active Comparator|Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)|In this arm patients will receive 6 courses of treatment with Herceptin in combination with paclitaxel. Patients will receive Herceptin at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).
3118568|NCT01764009|Experimental|Plasmid AMEP electrotransfer in muscle|
3118569|NCT01763996|Experimental|Sequence 1: Febuxostat 80 mg + Placebo|Febuxostat 80 mg, capsules, orally, once daily for 6 weeks in Period 1, followed by febuxostat placebo-matching capsules, orally, once daily for up to 6 weeks in Period 2.
3118570|NCT01763996|Experimental|Sequence 2: Placebo + Febuxostat 80 mg|Febuxostat placebo-matching capsules, orally, once daily for 6 weeks in Period 1, followed by febuxostat 80 mg, capsules, orally, once daily for up to 6 weeks in Period 2.
3118571|NCT01763983|Experimental|Aerobic Exercise|12-week structured and monitored aerobic exercise program
3118572|NCT01763983|Experimental|CBT and Aerobic Exercise|Combined 12-week individual Cognitive Behavioural Therapy and Exercise Program
3118573|NCT01763983|No Intervention|Waitlist Condition|12-week waitlist control condition, after which participants will have the chance to receive CBT group treatment.
3118574|NCT01763970|Experimental|Hypofractionated SBRT|800 delivered in 5 fractions every day to total dose of 4000
3118575|NCT01763957|Active Comparator|Pelvic Floor Muscle Training (PFMT)|
3118576|NCT01763957|Active Comparator|Paula Method|
3118577|NCT01763944|Active Comparator|Low carbohydrate, lifestyle counseling|The Low carbohydrate arm will receive counseling to follow a carbohydrate restriction diet (<20 grams per day) for 6 months.
3118578|NCT01763944|No Intervention|Control|The control arm will receive no dietary intervention.
3118579|NCT01763931|Experimental|Digoxin|Digoxin administration for 2 weeks prior to surgery.
3118580|NCT01763931|No Intervention|No drug administration prior to surgery|Group of participants who will not receive digoxin; however, tissue will be collected at time of definitive breast surgery.
3118581|NCT01763918|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for up to 12 weeks.
3118582|NCT01763918|Placebo Comparator|Placebo QM|Participants received placebo subcutaneous injection once every month (QM) for up to 12 weeks.
3118583|NCT01763918|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
3118584|NCT01763918|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
3118585|NCT01763905|Active Comparator|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
3118586|NCT01763905|Active Comparator|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
3118587|NCT01763905|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
3118588|NCT01763905|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
3118589|NCT01763892||Children admitted to hospital with a TBI|non-intervention study
3118590|NCT01763879|Active Comparator|The PCV-VCV group|The dependent lung will be ventilated with pressure controlled (PCV) followed by the volume-controlled ventilation (VCV)
3118591|NCT01763879|Active Comparator|The VCV-PCV group|The dependent lung will be ventilated with volume-controlled ventilation (VCV) followed by the pressure controlled (PCV)
3118592|NCT01763866|Placebo Comparator|A10 PBO Q2W|Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.
3118593|NCT01763866|Placebo Comparator|A10 PBO QM|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.
3118594|NCT01763866|Active Comparator|A10 EZE (Q2W)|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once a day for up to 12 weeks.
3118595|NCT01763866|Active Comparator|A10 EZE (QM)|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
3118596|NCT01763866|Experimental|A10 EvoMab Q2W|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
3118597|NCT01763866|Experimental|A10 EvoMab QM|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
3118598|NCT01763866|Placebo Comparator|A80 PBO Q2W|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
3118599|NCT01763866|Placebo Comparator|A80 PBO QM|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month and placebo tablets once a day for up to 12 weeks.
3118600|NCT01763866|Active Comparator|A80 EZE (Q2W)|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
3118601|NCT01763866|Active Comparator|A80 EZE (QM)|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
3118602|NCT01763866|Experimental|A80 EvoMab Q2W|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
3118603|NCT01763866|Experimental|A80 EvoMab QM|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
3118604|NCT01763866|Placebo Comparator|R5 PBO Q2W|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
3118605|NCT01763866|Placebo Comparator|R5 PBO QM|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
3118606|NCT01763866|Experimental|R5 EvoMab Q2W|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
3118607|NCT01763866|Experimental|R5 EvoMab QM|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
3118608|NCT01763866|Placebo Comparator|R40 PBO Q2W|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
3118609|NCT01763866|Placebo Comparator|R40 PBO QM|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
3118610|NCT01763866|Experimental|R40 EvoMab Q2W|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
3118611|NCT01763866|Experimental|R40 EvoMab QM|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
3118612|NCT01763866|Placebo Comparator|S40 PBO Q2W|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
3118613|NCT01763866|Placebo Comparator|S40 PBO QM|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
3118614|NCT01763866|Experimental|S40 EvoMab Q2W|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
3118615|NCT01763866|Experimental|S40 EvoMab QM|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
3118616|NCT01763853|Other|albumin|The main objective of our prospective double blind, randomized, controlled trial is to compare the rate of alveolar fluid clearance, a marker of alveolar edema fluid resorption, in 2 groups of patients with ARDS and suffering from hypovolemia: those treated with albumin and those treated with crystalloid (fluid challenge of 7 mL/kg over 15 minutes, that can be repeated 3 times if hypovolemia persists).
3118617|NCT01763853|Other|crystalloid|The main objective of our prospective double blind, randomized, controlled trial is to compare the rate of alveolar fluid clearance, a marker of alveolar edema fluid resorption, in 2 groups of patients with ARDS and suffering from hypovolemia: those treated with albumin and those treated with crystalloid (fluid challenge of 7 mL/kg over 15 minutes, that can be repeated 3 times if hypovolemia persists).
3118618|NCT01763840|Experimental|Contrast enhanced Ultrasound|Presence and grade of solid organ injury on contrast enhanced ultrasound
3118619|NCT01763827|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.
3118620|NCT01763827|Placebo Comparator|Placebo QM|Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.
3118621|NCT01763827|Active Comparator|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
3118622|NCT01763827|Active Comparator|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
3118623|NCT01763827|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
3118624|NCT01763827|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
3118625|NCT01763814|Active Comparator|Single shot femoral nerve block|A ultrasound probe will be used to identify the nerve, and correct needle placement.
3118626|NCT01763814|Active Comparator|Femoral nerve block non stimulating catheter|A ultrasound probe will be used to identify the nerve, and correct needle placement. The catheter will be placed with the nerve stimulator powered off.
3118627|NCT01763814|Active Comparator|Femoral nerve block stimulating catheter|A ultrasound probe will be used to identify the nerve, and correct needle placement. The catheter will be placed with the nerve stimulator powered on.
3118628|NCT01763801|Active Comparator|P-Max group|Includes cases in which the catheter tip was considered correctly positioned when the Maximal P wave was obtained
3118629|NCT01763801|Active Comparator|P-Submax group|Includes cases in which the catheter tip was considered correctly positioned when the Submaximal P wave was obtained
3118630|NCT01763788|Experimental|Necitumumab + Gem and Cis|"Phase 1b Dose Escalation: Necitumumab 800 milligram (mg) on Days 1 and 8 of every 21 day cycle, administered as an intravenous (IV) infusion. Gemcitabine (Gem) dose escalation of 1000 or 1250 milligram per square meter (mg/m^2) on Days 1 and 8 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles. Cisplatin (Cis) 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles.~Phase 2 Randomized: Necitumumab 800 mg on Days 1 and 8 of every 21 day cycle, administered as an IV infusion. Gemcitabine at fixed dose determined in Phase 1b (1000 or 1250 mg/m^2) on Days 1 and 8 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles. Cisplatin 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles."
3118631|NCT01763788|Active Comparator|Gemcitabine + Cisplatin|Phase 2 Randomized: Gemcitabine at fixed dose determined in Phase 1b (1000 to 1250 mg/m^2) on Day 1 and Day 8 of every 21 day cycle,administered as an IV infusion over approximately 30 minutes for a maximum of 4 cycles. Cisplatin 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 120 minutes for a maximum of 4 cycles .
3118632|NCT01763775|Experimental|Transtek 125X|Which measured by DUT (Transtek 125X): GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B.
3118633|NCT01763775|Experimental|Transtek 950D|Measured by Reference (Transtek 950D): GBF-950-D.
3118634|NCT01763762|Experimental|Electrical pudendal nerve stimulation|At a frequency of 2.5 Hz and an intensity (45~55 mA) as high as the patient can tolerate without discomfort; 60 minutes three times a week for a total of four weeks
3118635|NCT01763762|Active Comparator|PFM training with Transvaginal ES|"PFM training: EMG-biofeedback assisted PFMT was performed by specially trained therapists, 20 min three times a week for a total of four weeks. Patients conduct 30 maximal high intensity PFM contractions for 2-6 sec (with 2-6 sec rest), three sessions a day at home for a total of four weeks.~Transvaginal ES: At a current intensity of < 60 mA (as high as possible to get a contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-min periods of stimulation); 20 min three times a week for a total of four weeks."
3118636|NCT01763749|Experimental|Closone|75mg/100mg per day, 4weeks, PO
3118637|NCT01763749|Active Comparator|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
3118638|NCT01763736|Experimental|Music|Everyone enrolled with receive music sessions.
3118639|NCT01763723|Experimental|IPL after UV-exposure|8 UV-exposures followed by 3 weekly IPL exposures
3118640|NCT01763710|Active Comparator|Arm A|Paclitaxel 80 mg/m2 days 1, 8 and 15
3118641|NCT01763710|Experimental|Arm B|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
3118642|NCT01763710|Experimental|Arm C|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
3118643|NCT01763710|Experimental|Arm D|Nab-paclitaxel 150 mg/m2 days 1 and 15
3118644|NCT01763697|Active Comparator|Morhpine/Taste acuity|Taste acuity assessment after 1mg subcutaneous morphine injection
3118645|NCT01763697|Placebo Comparator|Placebo/Taste acuity|Taste acuity assessment after subcutaneous placebo injection
3118646|NCT01763697|Active Comparator|Morphine4/Taste acuity|Taste acuity assessment after 4mg subcutaneous morphine injection
3118647|NCT01763684|Active Comparator|Signature Custom Guides|Oxford Partial Knee implanted using Signature Custom Guides
3118648|NCT01763684|Active Comparator|Conventional Instrumentation|Oxford Partial Knee implanted using Conventional Instrumentation
3118649|NCT01763671|Active Comparator|Docetaxel|
3118650|NCT01763671|Experimental|Paclitaxel - Bevacizumab|
3118651|NCT01763658|Experimental|Antioxidant, drug therapy for ITP|interventional arm 1 and will receive antioxidant therapy (Antox tablets ( 1 tablet contains : Vit. A 2000 IU, Vit C 90 mg, Vit E 15 mg and selenium yeast 55 ug ) with the therapy selected for ITP tailored according to patient's presentation.For Antox tablets it will be given daily for 6 months.
3118652|NCT01763658|Active Comparator|drug therapy for ITP|drug therapy for ITP according to ASH, 2011 guidelines.
3118691|NCT01763333|Experimental|1 BI 1026706 single rising dose part|single rising doses of BI 1026706
3118692|NCT01763333|Experimental|2 BI 1026706 bioavailability part|bioavailability part of BI 1026706
3118653|NCT01763645|Experimental|BCD-021 (CISC BIOCAD)|BCD-021 is a product code for bevacizumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.
3118654|NCT01763645|Active Comparator|Avastin (F. Hoffmann-La Roche Ltd)|In this arm patients will receive 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.
3118655|NCT01763619|Experimental|Freedom Cervical Disc|
3118656|NCT01763606|Experimental|Enoxaparin|Patients assigned to enoxaparin.
3118657|NCT01763606|Experimental|Aspirin|Patients assigned to Aspirin.
3118658|NCT01763593||Aurosleek blades|Patients having cataract will undergo surgery by using Aurosleek blades
3118659|NCT01763580|Experimental|Tacrolimus with low-dose corticosteroid|Oral
3118660|NCT01763580|Active Comparator|High-dose corticosteroid alone|Oral
3118661|NCT01763541|Other|Testosterone|"To determine the effect of testosterone on the NP responses to acute and chronic salt loading.~One testosterone patch (Androderm 5 mg) applied to each male subject each day for 14 days.~Intervention: Leuprolide acetate and anastrozole"
3118662|NCT01763541|Other|Estradiol|"To determine the effect of estradiol on the NP responses to acute and chronic salt loading.~Two estradiol patches (Vivelle Dot 0.1mg) will be applied to each female subject twice-a-week for 2 weeks.~Intervention: leuprolide acetate"
3118663|NCT01763528|Active Comparator|nutrition intervention|high protein diet
3118664|NCT01763528|No Intervention|control group|control diet
3118665|NCT01763515|Experimental|Laterally wedged insoles|Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
3118666|NCT01763502|Experimental|FOOD|Food transfer linked to preschool enrollment
3118667|NCT01763502|Experimental|CASH|Cash transfer linked to preschool enrollment
3118668|NCT01763502|No Intervention|CTRL|No transfer linked to preschool enrollment
3118669|NCT01763489|Experimental|ASSIST tool group|Surgeons will assess the applicability of a trial using the ASSIST
3118670|NCT01763489|Active Comparator|Synopsis Group|Surgeons will assess the applicability of a trial using the synopsis presented in a case vignette
3118671|NCT01763476|Active Comparator|Paclitaxel-coated balloon angioplasty|Target lesion to be treated with paclitaxel-coated balloon
3118672|NCT01763476|Active Comparator|Atherectomy + paclitaxel-balloon|Target lesion to be treated with atherectomy (TurboHawk, ev3) and paclitaxel-coated balloon
3118673|NCT01763463||Patients with COPD who develop severe pneumonia|Patients with COPD who develop severe pneumonia
3118674|NCT01763463||Patients with COPD who do not develop severe pneumonia|Patients with COPD who do not develop severe pneumonia
3118675|NCT01763450|Experimental|Bevacizumab plus chemotherapy|"Bevacizumab:~7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;~Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;~Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:~Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;"
3118676|NCT01763437|No Intervention|Observation|30 patients will be randomized to observation alone. These patients will return 4 weeks (+/- 2 weeks) after their initial visit for lesion measurement and photographs.
3118677|NCT01763437|Experimental|Tetracycline|30 patients will be randomized to treatment with an intralesional injection of 0.05 mL of 2% tetracycline solution. These subjects will return 4 weeks (+/- 2 weeks) after treatment for lesion measurement and photographs.
3118678|NCT01763424|Active Comparator|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
3118679|NCT01763424|Experimental|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
3118680|NCT01763411||Multifocal Spheric Intraocular Lens (Restor SN60D3 IOL)|No Intervention: Multifocal Spheric IOL implantation
3118681|NCT01763411||Monofocal Spheric Intraocular Lens (AcrySof SN60AT IOL)|No Intervention: Monofocal Spheric IOL implantation
3118682|NCT01763411||Multifocal Aspheric Intraocular Lens (Tecnis ZMA00 IOL)|No intervention Multifocal IOL implantation
3118683|NCT01763411||Monofocal Aspheric Intraocular Lens (AcrySof SN60WF IOL)|No Intervention: Monofocal IOL implantation
3118684|NCT01763411||Multifocal Aspheric Intraocular Lens (Tecnis ZMB00 IOL)|No intervention Multifocal IOL implantation
3118685|NCT01763411||Multifocal Spheric Intraocular Lens (Restor SN6AD1 IOL)|No intervention Multifocal IOL implantation
3118686|NCT01763398||non-Hodgkin's lymphoma|Patients with non-Hodgkin's lymphoma, high risk group for neutropenic fever, treated by CHOP-like regimen and primary G-CSF prophylactic therapy
3118687|NCT01763385|Experimental|Erlotinib & secondary brain radiotherapy|Erlotinib until brain tumor progression, then given brain radiotherapy, and continued to take Erlotinib till extracranial lesions progression.
3118688|NCT01763385|Other|Erlotinib & concurrent brain radiotherapy|Erlotinib with concurrent brain radiotherapy, and continued to take Erlotinib after radiotherapy until recurrence or termination for other reasons
3118689|NCT01763346|Active Comparator|metformin|subjects receiving metformin
3118690|NCT01763346|Experimental|gastric banding|subjects receiving LAP-BAND
3118693|NCT01763320|Experimental|Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
3118694|NCT01763320|Active Comparator|medical group|all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
3118695|NCT01763307|Experimental|RECONVAL CREAM|half face treated with RECONVAL CREAM
3118696|NCT01763307|Placebo Comparator|PLACEBO|half face treated with PLACEBO cream
3118697|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min|Apply 1 session of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
3118698|NCT01763294|Active Comparator|Nicolet Endeavor CR: 60min|Apply 1 session of 2 milliampere intensity for 60 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
3118699|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min for 3 days|Apply 3 sessions of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
3118700|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min for 5 days|Apply 5 sessions of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
3118701|NCT01763294|Placebo Comparator|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
3118702|NCT01763281|Active Comparator|CRH|"100 microgram bolus of Cortisol Releasing Hormone intravenous injection given at a 20 minutes prior to Fructose drink during one of the two visits.~The placebo comparator will be 0.9% saline (1ml) bolus injection given intravenously at the same time point during one of the two visits"
3118703|NCT01763281|Placebo Comparator|Normal Saline (0.9%)|"100 microgram bolus of Cortisol Releasing Hormone intravenous injection given at a 20 minutes prior to Fructose drink during one of the two visits.~The placebo comparator will be 0.9% saline (1ml) bolus injection given intravenously at the same time point during one of the two visits"
3118704|NCT01763268|Experimental|Trivivac|Children who receive Trivivac vaccine
3118705|NCT01763255|Experimental|CD133 transplantation|The patients with cerebral palsy that underwent CD133 transplantation.
3118706|NCT01763255|No Intervention|Control|The patients with cerebral palsy that underwent regular observation.
3118707|NCT01763242|Active Comparator|EMAN|Electronic auditing via synchronised blood tests and monthly dosing ESA and Home delivery of ESA from Pharmacy if required
3118708|NCT01763242|No Intervention|Control|Standard Outpatient Care with usual blood tests and follow up, and varied ESA dosing and frequency times. Patients are responsible for collecting their own ESA from Pharmacy
3118709|NCT01763229|Experimental|transthoracic echocardiography|
3118710|NCT01763216|Experimental|Road Tour|Road Tour was designed to improve the efficiency and accuracy of visual information processing and the ability to perform complex visual attention tasks. It focuses on improving the speed and accuracy with which users identify and locate visual information using a divided attention format. Over time, the difficulty and complexity of each task is systematically increased as users attain specified performance criteria. Difficulty is increased by reducing visual stimuli duration, adding visual distracters, increasing similarity between target and distracter stimuli, and presenting visual targets over a broader spatial expanse.
3118711|NCT01763216|Sham Comparator|Boatload of Crosswords|Boatload of Crosswords offers the user a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also provides optional help features that the user may select, like filling in a letter or word to minimize frustration levels often associated with puzzle completion. Boatload of Crosswords was chosen for this study because it is computerized, it is very popular and easy to use, and many older adults enjoy doing crossword puzzles. Boatload of Crosswords, however, does not improve speed of processing because it does not focus on central discrimination and peripheral target location. Indeed, Boatload of Crosswords is not designed to train on any aspect of cognitive ability associated with visual speed of processing.
3118712|NCT01763203|Experimental|Care Management+Community Health Worker|Care management
3118713|NCT01763203|Active Comparator|Usual Care|Written materials
3118714|NCT01763190|Experimental|SAR302503|single treatment of 300 mg oral dose of SAR302503
3118715|NCT01763177|No Intervention|No oxygen|No given oxygen at post-anesthetic care unit
3118716|NCT01763177|Active Comparator|Oxygen|Oxygen nebulizer via face mask, Fraction of inspired oxygen (FiO2) 0.4, flow 8 liter per minute (LPM) for 30 minutes
3118717|NCT01763164|Experimental|MEK162|
3118718|NCT01763164|Active Comparator|Dacarbazine|
3118719|NCT01763151|Active Comparator|toric IOL|aspherical, toric acrylic IOL (Lentis L-312T, Oculentis, Germany)
3118720|NCT01763151|Active Comparator|IOL combined with opposite clear corneal incision (OCCI)|aspherical, acrylic IOL with OCCI
3118721|NCT01763138|Other|pamphlet and reminder|pictorial oral health pamphlet comprising of instructions on child's oral hygiene and feeding practices and a oral health education reminder phone call after a period of one month.
3118722|NCT01763138|Other|pamphlet only|oral health education pictorial pamphlet would be provided to mothers however there will be no reminder phone calls.
3118723|NCT01763138|No Intervention|control|no oral health education or reminder phone calls will be provided to mothers.
3118724|NCT01763125||Malignant tumors|"Patients who have one of the Neoplasms stated above under conditions. Blood samples will be taken."
3118725|NCT01763125||Benign controls|"Patients with a benign tumor or an inflammatory disease - to be matched by age and affected organ with a patient with a malignant disease.~Blood samples will be taken."
3118726|NCT01763125||Healthy controls|"People/patients who have no known disease at time of blood sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.~Blood samples will be taken."
3118727|NCT01763112|Placebo Comparator|Placebo group|This group will not do any specific training baseline and week 4 investigation will be done only
3118728|NCT01763112|Active Comparator|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
3118729|NCT01763099|Experimental|Mesenchymal stem cells|Mesenchymal stem cells group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)
3118730|NCT01763099|Experimental|Mesenchymal stem cells and cord blood|Mesenchymal stem cells and cord blood group refers to treatment with mesenchymal stem cells (at a dose of 1×10^6 cells/kg) and cord blood
3118731|NCT01763086|Experimental|Mesenchymal stem cells|Mesenchymal stem cells 1×10^6 cells/kg, intravenously
3118732|NCT01763073||Medical Students|Fourth-year students in accredited US medical schools who have applied to, but not yet been matched with, residency programs in obstetrics and gynecology.
3118733|NCT01763060||ECMO survivors|CT scan of the chest of all ECMO survivors after 2009/2010 pandemics Tests for cognitive function MRI of the brain Lung function
3118734|NCT01763047|Active Comparator|etafilcon A/lotrafilcon B|Subjects were randomized to one of two lens wear sequences. Subject randomized to this sequence first wore the etafilcon A lens and then wore the lotrafilcon B lens.
3118735|NCT01763047|Active Comparator|lotrafilcon B/etafilcon A|Subjects were randomized to one of two lens wear sequences. Subject randomized to this sequence first wore the lotrafilcon B lens and then wore the etafilcon A lens.
3118736|NCT01763034|Sham Comparator|limb ischemia|
3118737|NCT01763021|Experimental|PCI-32765 + Rifampin|Participants will recieve a single oral dose of PCI-32765 560 mg on Day 1 and Day 11 along with rifampin; and rifampin 600 mg from Day 4 to Day 13.
3118738|NCT01763008||Doripenem|Patients will be administered doripenem as per the dosing regimen given on product insert approved in Philippines.
3118739|NCT01762995|Experimental|Cohort 1|Subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive all four treatments (one per period) in a random order. Treatment A = single dose DTG 50 mg fasted. Treatment B = single dose DTG 50 mg + Calcium Carbonate 1200 mg fasted. Treatment C = single dose of DTG 50 mg + Calcium Carbonate 1200 mg fed. Treatment D = single dose DTG 50 mg 2 hours prior to single dose Calcium Carbonate 1200 mg fasted
3118740|NCT01762995|Experimental|Cohort 2|Subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive all four treatments (one per period) in a random order. Treatment A = single dose DTG 50 mg fasted. Treatment E = single dose DTG 50 mg + Ferrous Fumarate 324 mg fasted. Treatment F = single dose of DTG 50 mg + Ferrous Fumarate 324 mg fed. Treatment G = single dose DTG 50 mg 2 hours prior to single dose Ferrous Fumarate 324 mg fasted
3118741|NCT01762982|Experimental|Test|Benzalkonium chloride (0.13%) Disinfectant Spray water
3118742|NCT01762982|Active Comparator|Positive Control|Sodium lauryl sulfate (SLS) (0.3% weight by weight [w/w]) water solution
3118743|NCT01762982|Placebo Comparator|Negative Control 1|Normal saline water (0.9% weight by volume [w/v])
3118744|NCT01762982|Placebo Comparator|Negative Control 2|Empty Finn Chamber
3118745|NCT01762969|Experimental|Modified by molecular response|Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
3118746|NCT01762956|Experimental|Training group (TG)|The group of patients undergoing radiotherapy and submitted to pelvic floor muscles training.
3118747|NCT01762956|No Intervention|Control group(CG)|The group of patients undergoing radiotherapy only.
3118748|NCT01762943|Experimental|Women with Postpartum Depression (PPD)|4 monthly (intramuscular) IM injections of leuprolide acetate (Lupron) 3.75 mg; micronized estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day; progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day. Participants will also receive placebo.
3118749|NCT01762943|Experimental|Women without any psychiatric history (Control)|4 monthly (intramuscular) IM injections of leuprolide acetate (Lupron) 3.75 mg; micronized estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day; progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day. Participants will also receive placebo.
3118750|NCT01762930|Active Comparator|Shanchol stored at 2-8oC|Vaccines will be stored at 2-8oC before administration.
3118751|NCT01762930|Experimental|Shanchol stored at 25oC|Vaccines will be stored at 25oC for 14 days before administration.
3118752|NCT01762930|Experimental|Shanchol stored at 37oC|Vaccines will be stored at 37oC for 14 days before administration.
3118753|NCT01762930|Experimental|Shanchol stored at 42oC|Vaccines will be stored at 42oC for 14 days before administration.
3118754|NCT01762917||Obstruction|Patients suffering from pulmonary obstruction
3118755|NCT01762917||Restriction|Patients suffering from pulmonary restriction
3118756|NCT01762917||Controls|Pulmonary healthy controls
3118757|NCT01762904|Experimental|Whole group of 135 units of measurement|"The arm is composed of 135 units of measurement, it means, 540 determinations to test 2% chlorhexidine gluconate in 70% isopropyl alcohol and 1% triclosan in 70% isopropyl alcohol and two controls.~The principal unit of measurement it will be four determinations of bacterial counts in a subject for antiseptics and controls to test each of the application sites, and determination as to each separately sampling for each area for each antiseptic forearm. The same subject may be assessed up to three separate occasions provided only after a minimum period of two weeks between each determination.~Interventions:~Biological: Bacterial culture of the prepared skin's areas with two antiseptics and two controls~Other: Preparing skin's areas to be tested with two antiseptics and two controls"
3118758|NCT01762891|Experimental|Celecoxib|Celecoxib 200mg/day oral rout Intervention: celecoxib 200mg oral rout administered durng 15 days and followed by administration of rofecoxib 25mg/day during 15 days, placebo 15 days and acetaminophen 3g/day during 15 days.
3118759|NCT01762878|Experimental|GSK2269557 100 mcg arm|Each subject will receive 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 100 mcg in one of the 4 treatment periods.
3118760|NCT01762878|Experimental|GSK2269557 500 mcg arm|Each subject will undergo 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 500 mcg in one of the 4 treatment periods
3118761|NCT01762878|Experimental|GSK2269557 3000 mcg arm|Each subject will undergo 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 3000 mcg in one of the 4 treatment periods
3118827|NCT01762462|Experimental|SAR302503|single treatment with oral dose up to 300 mg of SAR302503
3118762|NCT01762878|Placebo Comparator|Placebo arm|The subjects will receive single dose of placebo in each treatment period of part A and repeat doses of placebo in Part B of the study.
3118763|NCT01762878|Experimental|Part B GSK2269557 arm|The selection of total daily doses of GSK2269557 for Part B will anticipated to be the maximum well tolerated dose selected from Part A. The subjects will receive GSK2269557 in ratio of 3:1.with placebo. If the dose selected for Part B is not well tolerated on repeat dosing the dose may be reduced during Part B or given as divided doses.
3118764|NCT01762852|Experimental|Belimumab Arm|Subjects will receive belimumab 10 mg/kg intravenous infusion [will last for 1 hour (hr)] on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks with frequency adjusted for subjects with >1000 mg/mmol uPCR (>10 g/24 hrs). All subjects will receive background supportive therapy throughout the study.
3118765|NCT01762852|Placebo Comparator|Placebo Arm|Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks with frequency adjusted for subjects with >1000 mg/mmol uPCR (>10 g/24 hrs). All subjects will receive background supportive therapy throughout the study.
3118766|NCT01762839|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
3118767|NCT01762839|Placebo Comparator|Placebo|IV placebo
3118768|NCT01762839|Active Comparator|Moxifloxacin|Subjects randomized to the open label Moxifloxacin treatment arm will only receive a moxifloxacin tablet and will not receive a placebo infusion.
3118769|NCT01762826||Placebo control|Diet pills of 400 mcg of acid folic daily
3118770|NCT01762826||D-chiro-inositol / Myo-inositol|Diet sachets 2000 mg myo-inositol and 250 mg d-chiro-inositol and 400 mcg folic acid daily
3118771|NCT01762826||D-chiro-inositol|Diet pills with 500 mg d-chiro-inositol and 400 mcg folic acid daily
3118772|NCT01762826||Myo-inositol|Diet sachets with 2000 mg myo-inositol and 200 mcg folic acid twice daily
3118773|NCT01762813||open and laparoscopic surgery|Patients with primary and or metastatic colorectal cancer (CRC) eligible for curative surgery will be included. Subcohorts may be based on either colon cancer, rectal cancer, metastatic cancer, surgery (laparoscopy or open), node negative and node positive disease, and molecular profiling.
3118774|NCT01762800|Experimental|fluticasone propionate/salmeterol|Randomised treatment at Visit 2
3118775|NCT01762800|Experimental|tiotropium bromide|Randomised treatment at Visit 2
3118776|NCT01762787|Active Comparator|Effect of Aspirin|Positive control as previously used in the cantharidin blister experimental model of inflammation
3118777|NCT01762787|Experimental|Effect of steroid - Prednisolone|Prednisolone selected as steroids should provide the most robust positive control anti-inflammatory therapy
3118778|NCT01762787|Experimental|Cantharidin exposure to optimise blister formation|Cantharidin exposure to optimise blister formation
3118779|NCT01762774|Experimental|Cohort 1|Healthy male subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 2 mg GSK2256294 capsules, Treatment B = 6 mg GSK2256294 capsules, Treatment C = 18 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
3118780|NCT01762774|Experimental|Cohort 2|Obese adult male smoker subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 15 mg GSK2256294 capsules, Treatment B = 40 mg GSK2256294 capsules, Treatment C = 100 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
3118781|NCT01762774|Experimental|Cohort 3|Obese adult male smoker subjects in Cohort 3 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 3 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2.
3118782|NCT01762774|Experimental|Cohort 4|Obese adult male smoker subjects in Cohort 4 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 4 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2 as well as safety and PK profile obtained in cohort 3.
3118783|NCT01762761|Experimental|Eltrombopag|Thrombopoietin- receptor (TPO-R) agonist
3118784|NCT01762761|Placebo Comparator|Placebo|Placebo
3118785|NCT01762748|Experimental|S. boulardii 200mg (Floratil®)|"The patients received S. boulardii every 8h during 30 days as an oral capsule formulation which contained 200 mg lyophilized S. boulardii-17 (Floratil®).~The patients enrolled in the study were evaluated immediately before the beginning of treatment, after a thirty-day period of treatment with probiotic and at the end of the second study month (after a thirty-day period without treatment with probiotic)."
3118786|NCT01762735|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
3118787|NCT01762735|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .All the patients were examined without sedation during the whole procedure.
3118788|NCT01762722|Experimental|Desaturation|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
3118789|NCT01762709|Active Comparator|The VT 4 ml/kg group|Use of tidal volume of 4 ml/kg during one lung ventilation
3118790|NCT01762709|Active Comparator|The VT 6 ml/kg group|Use of tidal volume of 6 ml/kg during one lung ventilation
3118791|NCT01762709|Experimental|The VT 8 ml/kg group|Use of tidal volume of 8 ml/kg during one lung ventilation
3118792|NCT01762696|Active Comparator|MET only|Motivational Enhancement Therapy only
3118793|NCT01762696|Experimental|MOMENT|The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
3118794|NCT01762670|Active Comparator|Metronidazole|Oral administration of metronidazole, 500 mg twice daily for 7 consecutive days
3118795|NCT01762670|Experimental|GoldenCare|GoldenCare administered intravaginally for at least 6 hours at night for 7 consecutive nights.
3118828|NCT01762449||Patients who received cyclophosphamide|Patients who received cyclophosphamide on the Scleroderma Lung Study
3118796|NCT01762657|Experimental|Oral CyclosporineA and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day in two divided dosages given with Lansoprazole dosed at 30 mg per day in two divided dosages for subjects aged 8-15 year and 60 mg per day for those aged 16-60.
3118797|NCT01762657|Placebo Comparator|Placebos|
3118798|NCT01762644|Experimental|Arm 1|Immune Tolerance and Proton Pump Inhibitor
3118799|NCT01762644|Active Comparator|Arm 2|Proton Pump Inhibitor
3118800|NCT01762618|Experimental|Cognitive Behavioral Therapy Group|14 therapy sessions, once a week for one and a half hours.
3118801|NCT01762618|No Intervention|Control Group|Social support for caregiver (through the social worker) as usual. The social worker gives information when they considered that there is a social economic risk or upon request by the caregiver.
3118802|NCT01762605|Experimental|Supportive Care|No casting or splinting, supportive care only by parents
3118803|NCT01762605|Active Comparator|Cast|Casting for 4 weeks
3118804|NCT01762592|Experimental|Iodine (124I) Girentuximab|Single infusion of radio labeled antibody: 30 mL will be infused using an infusion pump at a rate of 2mL/min over 15 minutes on study day 0.
3118805|NCT01762579|Active Comparator|wheat flour|wheat flour is administered blindly versus placebo for 15 days
3118806|NCT01762579|Placebo Comparator|Xylose|placebo will be administered blindly versus wheat flour for 15 days
3118807|NCT01762566|Active Comparator|wheat|wheat is administered blindly versus placebo in capsules once
3118808|NCT01762566|Placebo Comparator|xylose|placebo (xylose) will be administered blindly versus wheat in capsules once
3118809|NCT01762553|Experimental|intervention|The TEA intervention program will be implemented for the intervention group. The TEA intervention has three modules (healthy body & healthy mind, family interaction, and quality of life) logically connected to each other and implemented at three levels from individual, family to the community: 1) TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; 2) TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; 3) TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
3118810|NCT01762553|No Intervention|Control|In order to tease out the impact of the proposed intervention from the impact of attention in general, we will add limited activities to the control group condition. The differences between the intervention and control conditions consist in both contents and formats. For the control group, there will only be group sessions once a week for three weeks starting after baseline assessment. The content of the sessions for the control group will focus on basic care, health education and promotion, nutrition, personal and family hygiene. The Essential Care Package (ECP), a set of education materials originally developed by the World Health Organization (WHO) and supported by the Global Fund Project, will be used and explained in these group sessions. Health workers from villages in the control group will also visit participating families once a week for the initial three weeks and once a month for 12 months.
3118811|NCT01762540|Placebo Comparator|Calcium supplement|Capsule with tablet of calclium supplement
3118812|NCT01762540|Active Comparator|Glucocorticoids|Capsule with tablet of Prednisolone 37,5mg
3118813|NCT01762527|Experimental|ART|Online adaptive radiotherapy
3118814|NCT01762514|No Intervention|Program I|Patients with American Joint Cancer Committee/Union Internationale Contre le Cancer (UICC/AJCC) 2010 Stage I and II; Radiotherapy applied
3118815|NCT01762514|Experimental|Program II|Patients with UICC/AJCC 2010 Stage I and II; Radiotherapy applied; Amifostine every-other-day regimen
3118816|NCT01762514|Active Comparator|Program III|Patients with UICC/AJCC 2010 Stage I and II; Radiotherapy applied; Amifostine everyday regimen
3118817|NCT01762514|No Intervention|Program IV|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied
3118818|NCT01762514|Experimental|Program V|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied; Amifostine every-other-day regimen
3118819|NCT01762514|Active Comparator|Program VI|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied; Amifostine everyday regimen
3118820|NCT01762501|Experimental|Azilsartan|Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
3118821|NCT01762501|Active Comparator|Amlodipine|Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks
3118822|NCT01762488|Active Comparator|Renal denervation by ablation of the renal arteries|By femoral access, renal angiography is performed. The patient will be sedated. In case of acceptable renal artery anatomy allowing renal ablation, the patient will be randomized in the cath. lab. If randomized to active treatment, renal artery ablation will be carried out straight away.
3118823|NCT01762488|Sham Comparator|Control|By femoral access, renal angiography is performed. The patient will be sedated. In case of acceptable renal artery anatomy allowing renal ablation, the patient will be randomized in the cath. lab. If randomized to sham treatment, the procedure stops.
3118824|NCT01762475|Experimental|Experimental: Group 1--Symptomatic TBI|"Experimental Group, Group 1, will consist of twenty-four male and female adult participants who have persistent TBI symptoms lasting more than six months.~Participants in the experimental group will be randomized in a 1:1 ratio, assigned to group a or b.~Participants randomized into Group 1a will take placebo twice daily for 8 weeks, followed by 8 weeks of sildenafil 25 mg twice daily with a 2-week washout period between the two 8-week periods.~Participants randomized into Group 1b will take sildenafil 25 mg twice daily for 8 weeks, followed by 8 weeks of placebo twice daily with a 2-week washout period between the two treatment periods."
3118825|NCT01762475|Active Comparator|Active Comparator: Group 2--Healthy Controls|Group 2 will be comprised of twenty male and female adult participants who have never experienced a TBI or concussion to serve as age and gender-matched healthy controls. Participants in Group 2 will have a single visit to measure cerebrovascular reactivity before and after a single dose of sildenafil (50 mg by mouth).
3118826|NCT01762475|Active Comparator|Group 3--Recovered TBI|Group 3 will be comprised of twenty male and female adult participants who have experienced a TBI, have recovered, and are asymptomatic at the time of screening, to serve as age and gender-matched asymptomatic TBI controls. Participants in Group 3 will have a single visit to measure cerebrovascular reactivity before and after a single dose of sildenafil (50 mg by mouth).
3118829|NCT01762449||Patients who received placebo|Patients who received placebo on the Scleroderma Lung Study
3118830|NCT01762436|Experimental|bisoprolol|initially received 5 mg of bisoprolol (Concor®, Merck Serono, Darmstadt, Germany) once daily. The heart rate was assessed every two weeks. If the RHR was ≤65 bpm, a 2-week maintenance treatment was added during the final visit. If the target RHR was not achieved, the dose was changed as recommended in the study protocol. The maximal dose was 10 mg Qd for bisoprolol. The longest treatment period was 8 weeks. If the patient's RHR did not reach below 65 bpm at week 6, the treatment was ended at week 8.
3118831|NCT01762436|Active Comparator|atenolol|initially received 50 mg atenolol (Beijing Double-Crane Pharmaceutical Co., Ltd, Beijing, China) once daily. The heart rate was assessed every two weeks. If the RHR was ≤65 bpm, a 2-week maintenance treatment was added during the final visit. If the target RHR was not achieved, the dose was changed as recommended in the study protocol. The maximal dose was 100 mg Qd for atenolol. The longest treatment period was 8 weeks. If the patient's RHR did not reach below 65 bpm at week 6, the treatment was ended at week 8.
3118832|NCT01762423|Experimental|Active Device|"Device Placement:~Upon completion of the subjects' standard of care body contouring surgery, the device will be placed directly on the operative dressings within an unobtrusive binder with Velcro strips and will be activated before the subject leaves the OR. Subjects will then be educated on the functionality and interpretation of the user interface of the device. They will be educated on the application, removal, and return of the device.~Active Devices The device will be activated at the time of placement. The active devices are programmed to automatically deliver treatment. Each treatment duration is 15 minutes. The active device delivers treatment every 2 hours. A light will flash on the device when the PEMF begins and will continue to flash every second until the end of the treatment. Between treatments the device will be in sleep mode and the light will flash every 5 seconds."
3118833|NCT01762423|Sham Comparator|Sham Device|"Device Placement:~Upon completion of the subjects' standard of care body contouring surgery, the device will be placed directly on the operative dressings within an unobtrusive binder with velcro strips and will be activated before the subject leaves the OR. Subjects will then be educated on the functionality and interpretation of the user interface of the device. They will be educated on the application, removal, and return of the device.~Sham Devices The sham devices mirror the active device with the exception of the delivery of the PEMF. The sham device will be activated at the time of placement. A light will flash on the device when the SHAM PEMF begins and will continue to flash every second until the end each treatment interval. While in sleep mode the device will not deliver treatment and the light will flash every 5 seconds."
3118834|NCT01762410|Experimental|P7170|Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design.
3118835|NCT01762397|Experimental|PMK-S005|
3118836|NCT01762384|Active Comparator|LSC|procedure: laparoscopic sacral colpopexy.
3118837|NCT01762384|Active Comparator|Modified PFRS|procedure: modified pelvic floor reconstructive surgery with mesh.
3118838|NCT01762371|Experimental|K-Pat|Getting one time one hour of Khalifa's therapy for ACL injury treatment.
3118839|NCT01762358|Active Comparator|Standard Therapy|Standardized physiotherapy for 12 times (15 patients)
3118840|NCT01762358|Experimental|Standard + Khalifa|Initial one hour Khalifa therapy followed by twelve times standardized Physiotherapy (15 patients)
3118841|NCT01762345|Experimental|pessary device|pessary (disposable intra-vaginal device)
3118842|NCT01762332|Active Comparator|Low opioid level|Base level of remifentanil effect side concentration: 2ng/ml Stopped recruitment (May 2014)
3118843|NCT01762332|Active Comparator|High opioid level|Base level of remifentanil effect side concentration: 4ng/ml Stopped recruitment (May 2014)
3118844|NCT01762332|Other|chronic beta-blocker treatment|"Patients with chronic beta-blocker treatment prior to surgery and study. Will all be allocated to the high opioid level arm without randomization.~Continue recruitment."
3118845|NCT01762319|Experimental|Misoprostol|200 mcg Misoprostol SL 1 hour prior to fractional curettage
3118846|NCT01762319|Placebo Comparator|Vitamin B6|100 mg Vitamin B6 SL 1 hr prior to fractional curettage
3118847|NCT01762306|Experimental|Diclofenac Potassium|Diclofenac Potassium 50 mg PO 1 hour prior to fractional curettage
3118848|NCT01762306|Placebo Comparator|Folic Acid|Folic acid 5 mg PO 1 hour prior to fractional curettage
3118849|NCT01762293|Experimental|Famitinib|Famitinib 25 mg qd p.o. and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
3118850|NCT01762293|Placebo Comparator|Placebo|Placebo qd p.o., and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
3118851|NCT01762280|Experimental|Famitinib Malate|Famitinib either at 4,8,13,20,27,36 mg, p.o. once daily
3118852|NCT01762267|Active Comparator|diet intervention, DASH diet|intervention: nutrition intervention: DASH diet
3118853|NCT01762267|No Intervention|not intervention, control diet|control weight loss diet
3118854|NCT01762254|Active Comparator|incisionless laparoscopic colectomy|incisionless laparoscopic colectomy: Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
3118855|NCT01762254|Active Comparator|conventional laparoscopic colectomy|conventional laparoscopic colectomy: The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
3118856|NCT01762241|Experimental|Training using the Xbox Kinect system|12 weeks systematically home based training 3 times per week one hour at the time using the Xbox Kinect system.
3118857|NCT01762241|No Intervention|Control group|No systematically training/standard of care
3118858|NCT01762228|Active Comparator|Transcutaneus electrical stimulation|Sensorial transcutaneous electrical stimulation to the pharynx and larynx will be used 1 hour/day during 5 days/week for 2 weeks.
3118859|NCT01762228|Active Comparator|TRPV1 agonist|Sensorial stimulation of TRPV1 receptors into the oropharynx of patients will be used 3 times/day (before meals) during 5 days/week for 2 weeks.
3118860|NCT01762215|Experimental|PLM|Upon consenting to the study, participants will be asked to register an account on PatientsLikeMe; no personal identifiers will be required. As part of registration patients create a user name and password for the website and share their email with PatientsLikeMe. Participants will be asked to provide a set of demographic variables and to complete a survey assessing elements of self-management, disease knowledge, social support, and quality of life. Paticipants will then use the PatientsLikeMe website for 6 weeks as much as they wish. After 6 weeks the participants are asked to complete a second survey.
3118861|NCT01762202|Experimental|Study therapy|
3118862|NCT01762176|Active Comparator|Usual care group|Usual care
3118863|NCT01762176|Active Comparator|Intensive care group|Protocolized intensive treatment
3118864|NCT01762163|Experimental|Qizhitongluo Capsule|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night;the routine recovery training.~intervention treatment:the Capsules were administered orally, four capsules each time, three times a day after each meal（placebo was taken only after lunch, and Qizhitongluo Capsule was taken after breakfast and supper)for 12 weeks."
3118865|NCT01762163|Active Comparator|Naoxintong Capsule|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night; the routine recovery training.~intervention treatment:Naoxintong Capsule was administered orally, four capsules each time, three times a day after each meal for 12 weeks."
3118866|NCT01762163|Placebo Comparator|Placebo|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night and the routine recovery training.~intervention treatment:placebo capsule was administered orally four capsules each time, three times a day after each meal for 12 weeks."
3118867|NCT01762150|Experimental|sorafenib combined with chemotherapy|this trial is designed single arm. all the subjects enrolled will receive the experimental intervention,ie. sorafenib+gemcitabine+cisplatin.
3118868|NCT01762137|Active Comparator|Coiling|Coiling
3118869|NCT01762137|Active Comparator|Flow Diversion|Flow Diversion
3118870|NCT01762124|Experimental|Native Outflow Tract TPV|Implantation of the Native Outflow Tract TPV
3118871|NCT01762098||Recurrent miscarriages|
3118872|NCT01762098||Repeated embryo implantation failures|
3118873|NCT01762085|Placebo Comparator|healed DFU control arm|"clinic-specific usual best care"
3118874|NCT01762085|Experimental|healed DFU surgical intervention|"clinic-specific best care plus nerve decompression at 4 known sites of lower leg fibro-osseous entrapment"
3118875|NCT01762072|Placebo Comparator|vitaminB12|VitB12 group (VitB12, n=10) receives 8 weeks of treatment with daily oral doses of 1000 μg of vitamin B12 (one capsule)
3118876|NCT01762072|Experimental|Fish oil|Fish oil group (FO, n=10)receives 8 weeks of treatment with daily oral doses of 2g of fish oil in the form of two capsules of fish oil) .
3118877|NCT01762072|Experimental|Fish oil+vitaminB12|VitB12+Fish oil group (VitB12+FO, n=10) receives 8 weeks of treatment with daily oral doses of a combination of 1000 μg of vitamin B12 and 2g of fish oil
3118878|NCT01762059|Experimental|Bi-homonal Bionic Pancreas|Closed-loop blood glucose control with a bi-hormonal bionic endocrine pancreas designed by Edward Damiano and Firas El-Khatib of Boston University. The device will deliver insulin lispro (Humalog) and glucagon based on blood glucose levels estimated by a continuous glucose monitoring device (Dexcom G4 Platinum) and a proprietary dosing algorithm. Blood glucose control will be automated for 5 days during which volunteers will sleep in a hotel and roam freely in downtown Boston during the day. There will be no restrictions on diet or exercise.
3118879|NCT01762059|Active Comparator|Usual Care|Usual care for 5 days (insulin pump therapy according to usual practice), volunteers will sleep at home and maintain their usual schedule during the day, there will be no restrictions on diet or exercise, they will wear a blinded CGM
3118880|NCT01762046|Other|Glipizide and Metformin|On day 1, subjects will receive a single oral dose of glipizide 5 mg, and will have blood drawn at various time points for up to 240 minutes. During study days 2-7, the participants will fill out a dietary intake food record, including 3 weekdays and one weekend day. During days 6-8, the subject will receive a short-course metformin treatment of four 500-mg doses. On the morning of study day 8, 60 minutes after taking the fourth metformin dose, the subject will do a 75g Oral Glucose Tolerance Test. Blood draws will again be taken at time points for 120 minutes.
3118881|NCT01762033|Experimental|ASONEP|ASONEP will be administered by intravenous infusion over 90 minutes at 15 mg/kg once a week every 4 consecutive weeks per cycle
3118882|NCT01762020|Active Comparator|3M Cavilon No Sting Barrier Film|Two of four regions of the breast will be randomly chosen to receive 3M Cavilon No Sting Barrier Film treatment twice per week.
3118883|NCT01762020|Placebo Comparator|Standard preparations|Standard treatment
3118884|NCT01762007||6Mo-2Yr old penile hypospadias patients before operation|
3118885|NCT01762007||6Mo-2Yr old male patients without hypospadias|
3118886|NCT01762007||penile hypospadias patients under the age of 5 Yr|penile hypospadias patients under the age of 5 Yr who got tubularized incised plate operation at out institution at the age between 6Mo and 2Yr old and more than 1 Yr have passed
3118887|NCT01762007||2Yr-5Yr old male patients without hypospadias|
3118888|NCT01761994|Active Comparator|M100|heparin free CRRT group
3118889|NCT01761994|Experimental|HF1000|CRRT with nafamostat mesilate anticoagulation group
3118890|NCT01761968|Experimental|Givinostat|"Patients will continue at their last tolerable dose and treatment schedule of Givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.~If patients previously received Givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination."
3118891|NCT01761955|Experimental|High Dairy|Consuming four or more servings of dairy per day.
3118892|NCT01761955|Placebo Comparator|Control, Low Dairy|Participants consumed less than 2 servings of low fat dairy per day.
3118893|NCT01761942|Placebo Comparator|placebo ,anorexia nervosa|2x3 placebo capsules with olive oil
3118894|NCT01761942|Experimental|fatty acids preparation- eye-q|2 x 3 tablets of eye -q preparation daily ( 558 mg of EPA, 175 mg of DHA, 60 mg fo GLA).
3118998|NCT01761188|Experimental|Control Group|conventional stepwise ablation approach for persistent AF(CPVI + Lines +CFE) .
3118895|NCT01761929|Experimental|Stereotactic Body Radiation Therapy|All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
3118896|NCT01761916|Experimental|CLONIDINE|Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
3118897|NCT01761916|Active Comparator|CAPTOPRIL|Postpartum patients with very high blood pressure will be treated with oral CAPTOPRIL (25mg)
3118898|NCT01761903||Primary Focal Dystonia|Volunteers with primary focal dystonia
3118899|NCT01761903||Healthy Controls|'Healthy' volunteers, consisting of people of the same age as the PFD volunteers, w/o a diagnosis of PFD.
3118900|NCT01761890||CML patients|
3118901|NCT01761877|Experimental|Sulindac (Clinoril)|Women taking aromatase inhibitors for adjuvant therapy for their breast cancer will receive 150 mg of sulindac twice daily for 12 months. They will receive up to 4 MRI within 12 months.
3118902|NCT01761877|No Intervention|Observational|Women taking aromatase inhibitors for adjuvant therapy for their breast cancer will continue their treatment, and will be monitored with MRI and standard of care tests every 6 months for up to 12 months.
3118903|NCT01761864|Experimental|intervention group|academic detailing receiver
3118904|NCT01761864|No Intervention|control group|not receiving an academic detailing intervention
3118905|NCT01761851||Cases|Liver cirrhosis
3118906|NCT01761838|Experimental|SMT for low back pain patients|To investigate the effects of high velocity, low amplitude lumbopelvic spinal manipulative therapy on spinal stiffness and back muscle activity.
3118907|NCT01761838|Other|Asymptomatic arm|To investigate the sequential changes in spinal stiffness and back muscle activity of asymptomatic participants over time without any intervention. Participants of this arm can volunteer for an additional experimental pain protocol after their third visit (at 1 week) to investigate the effects of experimental pain on the changes of spinal stiffness and back muscle activity using a randomized crossover design (injecting 5% hypertonic saline or 0.9% isotonic saline to the interspinous ligaments at L3 to L5 levels in random order in two additional visits).
3118908|NCT01761838|Other|Low back pain participants without SMT|To investigate the temporal changes in lumbar disc diffusion within a 1-hour period without SMT
3118909|NCT01761825|Active Comparator|Ivabradine|Ivabradine 10 mg once
3118910|NCT01761825|Placebo Comparator|placebo|
3118911|NCT01761812|Experimental|Single arm study|
3118912|NCT01761799|Experimental|P3 Vaccine Promotion Package|The 5 obstetric practices randomized to the intervention arm will receive and implement all components of the evidence-based P3 vaccine promotion package at the beginning of the study.
3118913|NCT01761799|No Intervention|No P3 vaccine promotion package intervention|The 5 obstetric practices randomized to the control arm will not receive the comprehensive vaccine promotion package at the beginning of the study and will instead be instructed to continue their standard of care regarding influenza and Tdap vaccination of pregnant patients.
3118914|NCT01761786|No Intervention|Control group|CYP2C19 genotyping will be performed after end of study. Patients will be treated with prasugrel or ticagrelor, according to local protocol.
3118915|NCT01761786|Active Comparator|Intervention group|CYP2C19 genotyping will be performed <48h after PCI and antiplatelet treatment will be chosen based on genotyping results.
3118916|NCT01761773|Experimental|Group 1|Subjects with normal renal function: healthy normal adult subjects with an eGFR ≥ 90 mL/min/1.73m2.
3118917|NCT01761773|Experimental|Group 2|Subjects with mild renal impairment: adult subjects with a eCFR ≥ 90 mL/min/1.73m2.
3118918|NCT01761773|Experimental|Group 3|Moderate renal impairment: adult subjects with an eGFR between ≥30 - ≤ 59 mL/min/1.73m2.
3118919|NCT01761773|Experimental|Group 4|Severe renal impairment: adult subjects with an eGFR ≤ 29 mL/min/1.73m2, not on dialysis.
3118920|NCT01761760|Experimental|Contingent|"Patients will earn game-based incentives contingent on meeting carbon monoxide goals.~Behavioral: Videogame-based smoking cessation intervention"
3118921|NCT01761760|Active Comparator|Non-contingent|"Patients will earn game-based incentives independent of meeting carbon monoxide goals.~Behavioral: Videogame-based smoking cessation intervention"
3118922|NCT01761747|Experimental|Ponatinib Treatment Arm|Ponatinib taken by mouth daily
3118923|NCT01761734|Experimental|text message|receipt of text message
3118924|NCT01761734|No Intervention|usual care|usual care
3118925|NCT01761721||RAHL|Women suspected of endometrial cancer planned to be treated by robotic assisted laparoscopy hysterectomy
3118926|NCT01761708||umbilical, epigastric and trocar-site hernia|
3118927|NCT01761695||CML CP|Diagnosed as CML with chronic phase
3118928|NCT01761695||CML AP|Diagnosed as CML with accelerated phase
3118929|NCT01761695||CML BC|Diagnosed as CML with blast crisis
3118930|NCT01761695||CML other|Diagnosed as CML, which is not included in any of other category
3118931|NCT01761682||Ph-ALL|Diagnosed as ALL with Philadelphia-negative
3118932|NCT01761682||Ph+ALL|Diagnosed as ALL with Philadelphia-positive (including biphenotypic acute leukemia with Philadelphia-positive)
3118933|NCT01761682||Other ALL|Diagnosed as ALL of other type, including Burkitt leukemia
3118934|NCT01761669||healthy voulnters|
3118935|NCT01761656|Experimental|loading dose atorvastatin|For the arm of loading dose atorvastatin, patients will be treated with 80 mg atorvastatin 12 hours before PCI and 40 mg atorvastatin 2 hours before PCI and then 20mg/d after PCI.
3118936|NCT01761656|Active Comparator|conventional dose atorvastatin|For the arm of conventional dose atorvastatin, patients will be treated with 20 mg atorvastatin 12 hours before PCI and then 20mg/d after PCI.
3118937|NCT01761643|No Intervention|Standard of Care (SoC)|"This proposal will perform a study of potential methods to improve adherence and retention by evaluating standard procedures versus the use of the iTAB platform.~All subjects will receive SoC that will include health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psycho-social barriers, adherence counseling, and completion of a computer based survey."
3118994|NCT01761214|Active Comparator|Beta-lactamase inhibitor|In the present study, amoxicillin and amoxicillin clavulanate potassium compound are employed, based on the British Thoracic Society guideline for bronchietasis, as mainly determined by sputum microbiology during steady-state bronchiectasis.
3118938|NCT01761643|Active Comparator|SoC + iTab|"Subjects assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.~Subjects will have visits with the study coordinator to introduce the iTAB texting system.~Once the time is identified, the text reminder system is automated. Patients will confirm medication taking via text responses to the personalized reminders. If a participant does not respond on three consecutive occasions, a high alert message (chosen by the participant) will be sent. If the subject does not respond to this message, the study coordinator would initiate phone calls to contact the subject and explore barriers."
3118939|NCT01761630||Severe Asthma|"We will classify subjects as having severe asthma using the following stages:~Stage 1: Subjects must have asthma which requires treatment with high-dose inhaled corticosteroids plus a 2nd controller, or systemic corticosteroids with or without a 2nd controller to prevent it from becoming uncontrolled or which remains uncontrolled despite this therapy~Stage 2: Assess for uncontrolled asthma by any one of the following criteria:~Poor symptom control evidenced by an Asthma Control Questionnaire score consistently > 1.5 or an Asthma Control Test Score < 20 or not well controlled by NAEPP or GINA asthma treatment guidelines~Frequent severe exacerbations as reflected by ≥ 2 bursts of systemic corticosteroids (> 3 days each) in the previous 12 months~Serious exacerbations reflected by at least one hospitalization, ICU stay or mechanical ventilation in the previous 12 months~Presence of airflow limitation evidenced by FEV1 < 80% predicted (in the face of reduced FEV1/FVC)"
3118940|NCT01761630||Non-severe Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
3118941|NCT01761630||Healthy Control|"The purpose of the SARP Control Sub-study is to generate reference data for outcomes measured in biospecimens collected from asthmatic subjects enrolled in the SARP Longitudinal Protocol.~Seven healthy subjects between the ages of 18-65 will be enrolled."
3118942|NCT01761617|Active Comparator|Yoga Class Twice Per Week|Participants attend two hatha yoga classes each week for 12 weeks.
3118943|NCT01761617|Active Comparator|Yoga Class Once per Week|Participants attend one hatha yoga class each week for 12 weeks.
3118944|NCT01761604|Other|Nasal ganglion block for TN|Sphenopalatine ganglion block using the Tx360™ device
3118945|NCT01761591|Experimental|Acrobat|Device: PCI with Svelte Acrobat
3118946|NCT01761591|Active Comparator|Control BMS|Device: PCI with other BMS
3118947|NCT01761578|Experimental|ART18Z Bioresorbable stent|
3118948|NCT01761565|Experimental|Single dose of SUF NT 15 mcg then 40 doses of SUF NT 15 mcg|"Period 1: Single dose of SUF NT 15 mcg~Period 2: 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes"
3118949|NCT01761552|Experimental|Sugammadex (tradename Bridion)|
3118950|NCT01761552|Active Comparator|Traditional reversal or spontaneous recovery:|Atropine/Neostigmine: Atropine, 0.02 mg/ kg, and Neostigmine,0.05 mg/kg diluted in 100 ml Normal Saline and given over a 10 min drip. Reversal will be given only recommended if spontaneous recovery has occurred up to the reappearance of T2 (shallow blockade) following rocuronium induced blockade.
3118951|NCT01761539|Experimental|Aggressive Hydration|Receives Lactated Ringers solution at 3cc/kg/hr following an initial 20cc/kg bolus.
3118952|NCT01761539|Active Comparator|Moderate Hydration|Receives Lactated Ringers solution at 1.5cc/kg/hr following an initial 10cc/kg bolus.
3118953|NCT01761526|Experimental|Rotigotine in Healthy Japanese|"Rotigotine transdermal patch~Single dose application of 2 mg / 24 hours Rotigotine in Healthy Japanese subjects~Transdermal patch over 24 hours"
3118954|NCT01761526|Experimental|Rotigotine in Caucasian|"Rotigotine transdermal patch~Single-Dose application of 2 mg / 24 hours Rotigotine in healthy Caucasian subjects~Transdermal patch over 24 hours"
3118955|NCT01761513|Experimental|Sequence 1|
3118956|NCT01761513|Experimental|Sequence 2|
3118957|NCT01761513|Active Comparator|Sequence 3|
3118958|NCT01761513|Active Comparator|Sequence 4|
3118959|NCT01761500|Other|Modified BFM-90 protocol|Using the Modified BFM-90 protocol to treat Chinese children and adolescents with NHL
3118960|NCT01761487|Other|One arm only - Gentamicin and polymyxin E|All subjects will receive:Gentamicin and polymyxin E paste applied on buccal surface four times daily + gentamicin + polymyxin E PO + Strict contact precautions
3118961|NCT01761474||1. Carbon dioxide insufflation with BPS|Both midazolam (0.05 mg/kg body weight; 1 mg if age[70 or ASA class III-IV) and fentanyl (50 lg; 25 lg if age[70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, repeated doses of 10-20 mg propofol were administered to achieve a moderate level of sedation. Maintenance of sedation was also performed with repeated doses of 10-20 mg propofol.
3118962|NCT01761474||2. Carbon dioxide insufflation with Propofol|Sedation was induced by intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age[70 or ASA class III-IV), followed by repeated doses of 10-20 mg propofol to induce sedation. Repeated doses of 10-20 mg propofol were then administered to maintain adequate sedation, according to the desired sedation depth and patient risk profile.
3118963|NCT01761474||3. Air insufflation with BPS|Both midazolam (0.05 mg/kg body weight; 1 mg if age[70 or ASA class III-IV) and fentanyl (50 lg; 25 lg if age[70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, repeated doses of 10-20 mg propofol were administered to achieve a moderate level of sedation. Maintenance of sedation was also performed with repeated doses of 10-20 mg propofol.
3118964|NCT01761474||4. Air insufflation with Propofol|Sedation was induced by intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age[70 or ASA class III-IV), followed by repeated doses of 10-20 mg propofol to induce sedation. Repeated doses of 10-20 mg propofol were then administered to maintain adequate sedation, according to the desired sedation depth and patient risk profile.
3118965|NCT01761461|Experimental|Arm A|S-1 40-60mg BID (4weeks - 2weeks off) x 8 cycles
3118966|NCT01761461|Active Comparator|Arm B|{S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 week} x 8 cycles
3118967|NCT01761461|Active Comparator|Arm C|{S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 weeks} x 2 cycles → S-1 40mg BID (2weeks - 1week off - 2weeks)+ RT 45 Gy (5weeks) → Rest for 4 weeks → {S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 weeks} x 4 cycles
3118995|NCT01761201|Experimental|levofloxacin|Levofloxacin 500 mg daily for 9 months starting on the waiting list for liver transplant
3118996|NCT01761201|Active Comparator|Isoniazid|"Isoniazid 300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months"
3118968|NCT01761448|Experimental|Device Guided Exercise|Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities of patients.
3118969|NCT01761435|Experimental|Influenza vaccine, second administration after 5 weeks|Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first one.
3118970|NCT01761435|Active Comparator|Influenza vaccine|Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.
3118971|NCT01761422||SLE active flare|Patients who are having an active flare of their lupus confirmed by labs
3118972|NCT01761396|Experimental|CBT|Cognitive behavioral therapy
3118973|NCT01761396|Active Comparator|UC|Usual care
3118974|NCT01761383|Experimental|Nintendo Wii and Chronic Schizophrenia|Participants enrolled in the study will be provided with the Nintendo Wii console and Nintendo Wii Fit Plus video games to use for the duration of the study (6 months) with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life with the use of self report questionnaires and psychiatric assessment.
3118975|NCT01761370|Active Comparator|Treatment|AHA diet plus exercise with BIB placement
3118976|NCT01761370|Sham Comparator|Sham control|AHA diet plus exercise with sham BIB placement
3118977|NCT01761344|Experimental|Intraoperative measurement of cortisol|Intervention: During a routine procedure intraoperative cortisol is measured. Upon unsuccessful sampling, the sampling will be repeated.
3118978|NCT01761331|Active Comparator|Group A: Standardized acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. Intervention: Infants in the standardized acupuncture group get minimal acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.
3118979|NCT01761331|Active Comparator|Group B: Individualized acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. Infants in the individualized acupuncture group get acupuncture in points chosen by the acupuncturists according to symptoms: maximum 5 needles are inserted about 3 mm in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute.
3118980|NCT01761331|No Intervention|Group C: No acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. The nurse hold the infant´s hand and talks to it but no acupuncture is given.
3118981|NCT01761318|Active Comparator|Liraglutide|"Liraglutide: Solution for subcutaneous injection 6 mg/ml; Flexpen 3 ml.~Dose: s.c. 0,6 mg (0,1 mL) once daily. After 1 week, the dose will be increased to 1,2 mg (0,2 mL) once daily. If tolerated, after 1 week, dose will be increased to 1.8 mg (0,3 mL) once daily. In case of a hypoglycaemic episode, the dosage of oral blood glucose lowering medicaments will be adjusted first. If hypoglycaemia persists, Liraglutide / Liraglutide placebo will be adjusted on the basis of clinical parameters.~Duration: 26 weeks"
3118982|NCT01761318|Placebo Comparator|Liraglutide-placebo|"Liraglutide placebo: Solution for injection; Flexpen 3 ml.~Dosage: same as Liraglutide~Duration: 26 weeks"
3118983|NCT01761305|Experimental|Brace|Hypercorrective night-time brace worn 8 hours per night. A prescription of general physical activity will be provided at a dose of 60 minutes per day. Instructions regarding physical activity will be delivered during a one hour session.
3118984|NCT01761305|Experimental|Scoliosis specific exercises.|Scoliosis specific exercises. The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. An additional session will be provided every 6 months for the entirety of the study. A prescription of general physical activity will be provided at a dose of 60 minutes per day.
3118985|NCT01761305|Active Comparator|Self-mediated physical activity.|A prescription of general physical activity will be provided at a dose of 60 minutes per day. Instructions will be delivered during a 1 hour session.
3118986|NCT01761292|Experimental|Givinostat|Givinostat will be administered as 2 oral doses daily while the child is in fed state.
3118987|NCT01761266|Active Comparator|Lenvatinib|
3118988|NCT01761266|Active Comparator|Sorafenib|
3118989|NCT01761253||Assessing costs & cost-variability|Data for the approximately 15,000 patients who were continuously enrolled during the calendar years 2006 and 2007 in the Generations Plus/ Northern Manhattan Health Network and 226,000 members of a large self insured union trust fund from 2007-2010 will be combined. The data will include age, gender, length of plan enrollment, whether or not the patient is disabled, their diagnoses, and their use of medical and social services.
3118990|NCT01761240|Experimental|Study Drug|
3118991|NCT01761227|Experimental|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
3118992|NCT01761227|Placebo Comparator|Placebo|3 tablets per time, 3 times per day for 24 weeks. The placebo has similar smile and appearance as the Fufangdanshen Tablets
3118993|NCT01761214|Active Comparator|Fluroquinolones|The fluroquinolones employed in the present study are referred to as oral levofloxacin (500mg q.d.), moxifloxacin (400mg, q.d.) and ciprofloxacin (500mg, b.i.d.). All medications are administered based on the bronchiectasis guideline issued by British Thoracic Society.
3118997|NCT01761188|Experimental|STABLE-SR|CPVI plus electrophysiologic substrate ablation in the left atrium during sinus rhythm ( STABLE-SR)
3119083|NCT01760551||Patients assessed with AMA guide sixth edition|
3118999|NCT01761175|Active Comparator|Ultrasound-guided infraclavicular block|Ultrasound-guided single injection infraclavicular block
3119000|NCT01761175|Active Comparator|Ultrasound-guided axillary block|Ultrasound-guided double injection axillary block
3119001|NCT01761162||Pacemaker Therapy|Patients with a ProMRI Pacemaker System
3119002|NCT01761149|Active Comparator|Remifentanil (Low dose)|remifentanil(Low):dose of 0.2ug/kg/min. The dose of remifentanil is widely used intraoperatively clinically;
3119003|NCT01761149|Experimental|Remifentanil (High dose)|The high dose of remifentanil is 1.2ug/kg/min. The does is sometimes used in clinical practice.
3119004|NCT01761136|Active Comparator|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
3119005|NCT01761136|Experimental|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
3119006|NCT01761123|Experimental|VXA-A1.1|Intestinal Delivery
3119007|NCT01761110|No Intervention|Pre-intervention|Participants will be enrolled prior to the implementation of the community-based buprenorphine treatment (CBBT) intervention.
3119008|NCT01761110|Experimental|Post-intervention|Participants will be enrolled after implementing the community-based buprenorphine treatment (CBBT) intervention
3119009|NCT01761097|Active Comparator|Endocuff assisted colonoscopy|Endocuff attachment
3119010|NCT01761097|Placebo Comparator|Control standard colonoscopy|Standard colonoscopy
3119011|NCT01761084|Experimental|Exercise and behaviour change strategies|The exercise program will include strength training, balance training and cardiovascular exercise that is individually tailored to the participants' abilities. The physical therapist will also implement strategies to assist with behaviour change, such as documenting progress in a log, participating in action planning and coping planning, and using techniques in the spirit of motivational interviewing.
3119012|NCT01761084|No Intervention|General health or social discussion|Participants in the control group will receive equal attention, but will not be prescribed exercise, or participate in counselling about exercise. The physical therapist will discuss topics related to general health.
3119013|NCT01761071|Experimental|group KO|(ketorolac 0.5% in one eye, ofloxacin 0.3% in the other eye)
3119014|NCT01761071|Active Comparator|group DO|(diclofenac 0.1% in one eye, ofloxacin 0.3% in the other eye)
3119015|NCT01761058||Severe Asthma|Subjects with Severe Asthma (SARP protocol definition)
3119016|NCT01761058||Well controlled asthma|subjects with well controlled asthma
3119017|NCT01761045|Active Comparator|Soup 1|Consommé soup with Monosodium L-Glutamate (MSG)
3119018|NCT01761045|Active Comparator|Soup 2|Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
3119019|NCT01761045|Placebo Comparator|Soup 3|Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
3119020|NCT01761032||Infrequent tanners|Individuals who tan less than twice a week and do not meet modified DSM-IV criteria for tanning addiction.
3119021|NCT01761032||Compulsive Tanners|Individuals who tan more than 3 times per week in a tanning bed. Tanning must cause disruption in daily functioning. Must meet modified DSM-IV criteria for tanning addiction
3119022|NCT01761019|Other|Taclonex topical suspension|Taclonex topical suspension will be used daily to affected areas of skin with psoriasis for 12 weeks
3119023|NCT01760993|Experimental|SPD489|
3119024|NCT01760980|Experimental|Test product (B)|B: Subjects receive Exemestane 25 mg tablets under fasting conditions
3119025|NCT01760980|Active Comparator|Reference product (A)|A: Subjects receive Aromasin 25 mg tablets on two occasions under fasting conditions
3119026|NCT01760967|Active Comparator|Dexmedetomidine|administer dexmedetomidine (0.1-0.7ug/kg/h) from the beginning of ICU treatment
3119027|NCT01760967|Active Comparator|non-Dexmedetomidine|administer sedatives except Dexmedetomidine
3119028|NCT01760954|Experimental|Elagolix Dose 1|Elagolix dose 1 for 6 month treatment period.
3119029|NCT01760954|Experimental|Elagolix Dose 2|Elagolix dose 2 for 6 month treatment period.
3119030|NCT01760941|Experimental|Treatment (radiation therapy)|"This is a survey study to evaluate the feasibility and effectiveness of an affordable, $400 flat rate, same-day consultation, simulation, and delivery of a single fraction of palliative radiation therapy for patients with symptomatic bony metastatic disease who are currently enrolled in hospice. Treatment planning and delivery of palliative radiotherapy will utilize standard of care techniques. A physician survey of feasibility will be conducted on the treatment day. Patient surveys will conducted on the day of treatment and at 2 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, and 6 months after treatment."
3119031|NCT01760928||Asthma patients|all
3119032|NCT01760915||Severe asthma|Subjects with severe asthma (SARP protocol definition)
3119033|NCT01760915||Well controlled asthma|Subjects with well controlled asthma
3119034|NCT01760915||Normal control|Subjects that are healthy normals
3119035|NCT01760902|Experimental|Diet and Physical Activity|Participants convene weekly for 12 consecutive weeks and then once per month for 9 months. Each sessions is 90 minutes
3119036|NCT01760889|Experimental|SPD489 Low Dose Range|
3119037|NCT01760889|Experimental|SPD489 High Dose Range|
3119038|NCT01760889|Placebo Comparator|Placebo|
3119039|NCT01760876|Experimental|Biofreedom stent|Coronary intervention
3119040|NCT01760863|Experimental|Oral Antibiotics|Oral antibiotics for 3 months; recommendation for antibiotics will be made by an infectious disease specialist.
3119041|NCT01760863|No Intervention|No oral antibiotics|No oral antibiotics.
3119042|NCT01760850|Experimental|Arm I (Esperanza y Vida)|Participants engage in the Esperanza y Vida educational information session for breast and cervical cancer.
3119043|NCT01760850|Active Comparator|Arm II (control)|Participants engage in an educational information session for diabetes.
3119044|NCT01760837|Other|baked milk products, cow's milk allergy|to offer baked milk products to cow's milk allergic patients and to follow them for tolerance and if this intervention may have any impact on the natural history of milk allergy
3119045|NCT01760824|Experimental|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
3119046|NCT01760824|Active Comparator|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg aid, bismuth sub citrate 120mg aid and tetracycline 500mg qid, all for 10 days
3119047|NCT01760811|Other|Cetuximab ,neoadjuvant administration|Drug administration ,Cetuximab(merck Serono )given neoadjuvant ,3 courses prior surgery followed by post operatve radiation and Cetuximab
3119048|NCT01760798|Active Comparator|Daily Teriparatide group|This group will recieve 20µg of teriparatide by subcutaneous route daily at 8 pm for 1 year
3119049|NCT01760798|Experimental|Weekly Teriparatide group|This group will recieve 60µg of teriparatide by subcutaneous route weekly at 8pm on Sunday for 1 year
3119050|NCT01760785|Active Comparator|divalproex sodium|
3119051|NCT01760785|Placebo Comparator|sugar pill|
3119052|NCT01760772|Placebo Comparator|Saline|0.9% saline
3119053|NCT01760772|Experimental|Exendin-9 (Ex-9)|Bolus of Ex-9 (7,500 pmol/kg) followed by a continuous infusion at 750 pmol/kg/min
3119054|NCT01760772|Experimental|GLP-1|GLP-1 infusion at 0.3 pmol/kg/min
3119055|NCT01760759|Active Comparator|Usual care|Patients receive antiretroviral therapy.
3119056|NCT01760759|Experimental|Usual care plus cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
3119057|NCT01760759|Experimental|Usual care, reminders & contingency management for adherence|Patients receive reminders and reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
3119058|NCT01760746||PDR, Avastin/Lucentis, randomization, humour, inflamation|Patients will be randomized to receive pre-treatment with either bevacizumab or ranibizumab . Sample of aqueous humour will be taken before injection and before surgery.Both the patient and the treating physician will be masked to the identity of the study drug.
3119059|NCT01760720|No Intervention|control|Standard care
3119060|NCT01760720|Experimental|intervention|The MMT CARE intervention has 3 session/modules: 1) MMT protocol and procedures, understanding stigma and its impact; 2) effective communication with clients, introducing motivational interviewing; 3) application of motivational interviewing, motivating clients for behavior change. The intervention contents reflect challenges faced by service providers working at MMT clinics and the impact of these challenges on their clients. Sessions will occur once a week for three weeks, with each session featuring a different set of themes and relevant activities. Each session will be 90-100 minutes long and will be conducted with a group of 5 to 7 providers.
3119061|NCT01760707|Experimental|Exercise Training|aerobic exercise training
3119062|NCT01760707|Active Comparator|Control|
3119063|NCT01760694|Experimental|Resectable Patients|Surgery with Intraoperative Radiation Therapy (IORT). Radiation Therapy within 6-8 weeks after surgery followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery
3119064|NCT01760694|Experimental|Marginally Resectable Patients|2-3 cycles of neoadjuvant FOLFIRINOX then restaged, then undergo surgery with Intraoperative Radiation Therapy (IORT) within 2-4 weeks following chemotherapy. Then Radiation Therapy within 6-8 weeks followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery for a total of 2-4 cycles
3119065|NCT01760681|Experimental|H coil DTMS|20 daily deep TMS treatments
3119066|NCT01760681|Sham Comparator|inactive stimulation|20 daily sham deep TMS treatments
3119067|NCT01760668||Turner syndrome (TS)|TS verified by genotyping Age > 18 years awaiting operation due to aortic dilation
3119068|NCT01760668||Marfan syndrome (MS)|Females with MS verified clinically or by genotyping Age > 18 years awaiting operation due to aortic dilation
3119069|NCT01760668||Bicuspid aortic valve|females with bicuspid aortic valve Age > 18 years awaiting operation due to aortic dilation
3119070|NCT01760668||Controls|Men/females who died from conditions other than aortic dilation or dissection. Age 20-60 years.
3119071|NCT01760655|Experimental|Treatment (RIC and stem cell transplant)|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 60 minutes on days -15 to -12, thiotepa IV over 2 hours on days -15 to -13, donor lymphocyte infusion (DLI) on day -6, and cyclophosphamide IV over 2 hours on days -3 and -2. Patients also undergo TBI on day -10.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV on days -1 to 42 followed by taper and mycophenolate mofetil IV BID on days -1 to 28."
3119072|NCT01760642|Experimental|Midazolam|"period 1: midazolam 1 mg IV single dose administration. period 2: midazolam 1 mg IV single dose after ketoconazole 400 mg oral dosing for 3 days.~period 3: midazolam 2.5 mg IV single dose after rifampicin 600 mg oral dosing for 10 days."
3119073|NCT01760629|Experimental|Cooling arm|Whole body cooling to 33 to 34 C rectal temperature
3119074|NCT01760616|Experimental|Test group|Test group: Adjuvant therapy + Huaier Granule group.Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 144 weeks after surgery or until study termination Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment
3119075|NCT01760616|No Intervention|Control group: adjuvant therapy|Control group: adjuvant therapy Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment.
3119076|NCT01760603|Experimental|ISFF|The patients performed ischia spinous fascia fixation surgery.
3119077|NCT01760590|Experimental|Manual Manipulation|Patients will be randomized to receive a thrust manipulation
3119078|NCT01760590|Experimental|Manual Mobilization|Patients will be randomized to receive mobilization
3119079|NCT01760577|Experimental|The Botulinum Toxin A group|The Botulinum Toxin A group received intraarticular injections of 100 units of Botulinum Toxin A (Allergan, Inc, Irvine CA) reconstituted in 2 cc normal saline.
3119080|NCT01760577|Active Comparator|The hyaluronate group (Hyalgan, Italy)|The hyaluronate group received intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, molecular weight 500-730kDa, Fidia Pharmaceutical Corporation, Abano Terme, Italy) and subsequent 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise for 2 weeks .
3119081|NCT01760564|Experimental|Miglustat|miglustat 200mg tid
3119082|NCT01760551||Patients assessed with AMA guide fifth edition|
3119088|NCT01760512|Experimental|Robot-assisted surgery|Robot-assisted (da Vinci surgical system) gastric bypass
3119089|NCT01760512|Active Comparator|Conventional laparoscopy|Laparoscopic gastric bypass
3119090|NCT01760499|Experimental|Immunotherapy Followed by Surgery|PV-10 administration, adverse events assessment, surgery to remove melanoma tumors, follow-up visit.
3119091|NCT01760486|Active Comparator|Shape Up Rhode Island|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive periodic newsletters throughout the 12 month trial.
3119092|NCT01760486|Experimental|Shape Up Rhode Island + Professional Coach + Incentives|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive a professional weight loss coach and will be incentivized for submitting information to their coach and meeting weight goals.
3119093|NCT01760486|Experimental|Shape Up Rhode Island + Peer Coach + Incentives|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive a peer coach and will be incentivized for reporting to their coach and meeting weight goals.
3119094|NCT01760473|Experimental|Bup 8|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally.
3119095|NCT01760473|Experimental|Bup 16|Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally.
3119096|NCT01760473|Experimental|Bup/Nal 8/2|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 2 mg of Naloxone.
3119097|NCT01760473|Experimental|Bup/Nal 8/8|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 8 mg of Naloxone.
3119098|NCT01760473|Experimental|Bup/Nal 8/16|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 16 mg of Naloxone.
3119099|NCT01760473|Experimental|Bup/Nal 16/4|Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally with 4 mg of Naloxone.
3119100|NCT01760473|Active Comparator|Heroin|Intranasal challenge drug: 24 mg of heroin administered intranasally.
3119101|NCT01760473|Sham Comparator|Placebo|Intranasal challenge drug: Intranasal lactose powder.
3119102|NCT01760473|Active Comparator|Naloxone 4 mg|Intranasal challenge drug: Intranasal Naloxone 4mg.
3119103|NCT01760460|Experimental|Anacetrapib|Participants will receive 100-mg anacetrapib, orally, once-daily for 24 weeks. Participants will continue on once-daily 100-mg anacetrapib during 28 week open-label extension.
3119104|NCT01760460|Placebo Comparator|Placebo|Participants will receive placebo tablet, orally, once daily for 24 weeks. Participants will be switched to once-daily 100-mg anacetrapib during 28 week open-label extension.
3119105|NCT01760447|Experimental|Sitagliptin + Metformin XR FDC|Phase A: two sitagliptin + extended-release (XR) metformin fixed-dose combination (FDC) tablets (MK-0431A XR) orally daily (total daily dose: 100 mg sitagliptin and 1000, 1500 or 2000 mg metformin XR) plus two placebo to metformin XR tablets plus/minus background insulin for 20 weeks. Insulin glargine may be administered, or background insulin may be up-titrated as glycemic rescue therapy during Phase A of the study. Phase B: two sitagliptin + metformin XR FDC tablets orally daily (total daily dose: 100 mg sitagliptin and 1000, 1500 or 2000 mg metformin XR) plus two placebo to metformin XR tablets plus/minus background insulin for 34 weeks. Insulin glargine may be administered, or background insulin may be up-titrated during Phase B of the study depending on the participants' glucose and A1C levels.
3119106|NCT01760447|Placebo Comparator|Placebo to Sitagliptin + Metformin XR FDC|Phase A: two placebo to sitagliptin + metformin XR FDC tablets orally daily plus two metformin XR tablets (total daily dose: 1000, 1500 or 2000 mg) plus/minus background insulin for 20 weeks. Insulin glargine may be administered, or background insulin may be up-titrated as glycemic rescue therapy during Phase A of the study. Phase B: two placebo to sitagliptin + metformin XR FDC tablets orally daily plus two metformin XR tablets (total daily dose: 1000, 1500 or 2000 mg) plus/minus background insulin for 34 weeks. Insulin glargine may be administered, or background insulin may be up-titrated during Phase B of the study depending on the participants' glucose and A1C levels.
3119107|NCT01760434|Other|Long-Term Outcomes|Patients will be recruited who were diagnosed with adolescent idiopathic scoliosis prior to age 18 and before 1994 (minimum 20 year outcomes) with available xrays. Patients will be included who were treated with surgery, observation, or bracing. Patients will return for a one-time visit for new xrays, physical exam, health-related quality of life surveys, and pulmonary function testing.
3119108|NCT01760421|Experimental|Hydroxychloroquine|Receive treatment with hydroxychloroquine
3119109|NCT01760408||Home PN - pediatric|Pediatric patients (under 18) on Home PN
3119110|NCT01760408||Adult patients on Home PN|Adult patients on Home PN
3119111|NCT01760382||STEMI network Primary PCI patients|Patients with STEMI brought to the Hub Hospital by the STEMI network ambulance and treated by primary PCI.
3119112|NCT01760382||STEMI Hospital ED Primary PCI patients|Patients with STEMI who reached by themselves the Hub Hospital, where they were admitted for STEMI and tretated by Primary PCI
3119113|NCT01760356||Healthy Volunteers No treatment|This is set as reference a cohort of untreated healthy volunteers, over which will be measured the biomarkers to determine the baseline. Implies PBMC ex-vivo exposure to Tacrolimus prior all cell incubations to study ex-vivo PD in stimulated conditions with mitogens to identify potential genetic sources of interindividual variability in physiological conditions Number proposed 30.
3119114|NCT01760356||Liver Transplant Patients on Tacrolimus|"To explore PD/PG/PK relationships of TAC residual PD activities ex-vivo in stimulated and non-stimulated conditions in liver recipients.~The number proposed is 50."
3119115|NCT01760356||Waiting List for Liver Transplantation|"To study the ex-vivo PD response to TAC in stimulated and non-stimulated conditions and the potential genetic sources of PD variability in pathological conditions.~The number proposed is 12."
3119116|NCT01760356||Liver Transplant Patients on Cyclosporine|"To explore PD/PG/PK relationships of CsA residual PD activities ex-vivo in stimulated and non-stimulated conditions in liver recipients.~The number proposed is 10."
3119340|NCT01758744|Experimental|Treprostinil|Inhaled prostanoid therapy with Treprostinil
3119117|NCT01760356||Longitudinal Cohort|"Patients form the waiting list for liver transplantation will be enrolled and monitored at different times after transplantation to study the relationships between TAC PD and the clinical responses.~The number proposed is 20."
3119118|NCT01760343|Experimental|Berinert, then CSL830|A single intravenous dose of Berinert at 1500 units (1500 IU), followed by a single intravenous dose of CSL830 at 1500 IU.
3119119|NCT01760343|Experimental|CSL830, then Berinert|A single intravenous dose of CSL830 at 1500 IU, followed by a single intravenous dose of Berinert at 1500 IU.
3119120|NCT01760330|Active Comparator|IV acetaminophen|IV acetaminophen administered q 4 hrs. for a total of 24 hrs.
3119121|NCT01760330|Placebo Comparator|Placebo|Normal saline administered IV every 4 hrs. for a total of 24 hrs.
3119122|NCT01760317|Active Comparator|Midline|Midline Lumbar Epidural Steroid Injection
3119123|NCT01760317|Active Comparator|Parasagittal|Parasagittal Lumbar Epidural Steroid Injection
3119124|NCT01760304|Experimental|Budesonide / Formoterol|This is a crossover study, where every patient will receive in a blinded fashion either Budesonide/Formoterol (Symbicort ® ) or placebo
3119125|NCT01760304|Placebo Comparator|Placebo|This is a crossover study, where every patient will receive in a blinded fashion either Budesonide/Formoterol (Symbicort ® ) or placebo
3119126|NCT01760291|Experimental|WATCHMAN|WATCHMAN LAA Closure Technology
3119127|NCT01760278|Experimental|Study Arm|Subjects would receive recombinant Follicle Stimulating Hormone (rFSH) by S.C. injection 150 - 225 IU/day for 9 days. The embryos of subjects would be cultured by time-lapse imagery technique (embryoscope) and analysis would be done using patients receive rFSH (Gonembryo viewer equipped with latest software.
3119128|NCT01760278|Active Comparator|Control Arm|Subjects would receive recombinant Follicle Stimulating Hormone (rFSH) by S.C. injection 150 - 225 IU/day for 9 days. The embryos of subjects would be cultured in conventional culture environment and analysis would be done using established subjective morphological criteria.
3119129|NCT01760252|Experimental|CAPOXIRI Chemotherapy Regimen|"Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)~The proposed chemotherapy regimen CAPOXIRI is:~Capecitabine 1000mg/m2 p.o. bid on days 1-7~Oxaliplatin 85mg/m2 intravenously (IV) on day 1~Irinotecan 150mg/m2 IV on day 1"
3119130|NCT01760239|Experimental|Clincal Decision Support (CDS)|The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR during any visit to a family practice or pediatric clinic (including both preventive care and sick visits, excluding prenatal and postpartum visits). The algorithm will be embedded in the EHR. In most cases, when a normal BP <90% and <120/80 mm Hg is entered, no alerts will be triggered. In some cases, clinical staff may receive up to two alerts, either to measure height or to repeat a first elevated BP reading. In cases with confirmed elevated BP measures, providers will receive a single CDS message summarizing that patient's current BP status and recommending specific clinical actions.
3119131|NCT01760239|No Intervention|Control|Patients in this group will receive usual care from their clinic. The CDS tool will not be activated.
3119132|NCT01760226|Experimental|DA-EPOCH-R for DLBCL, PTLD & PMBCL|"Minimum of 6 cycles (cycle=3 weeks), possibly 8. Dosages of the drugs will be determined by the subject's weight and height for cycle 1. Thereafter, the dosages of some drugs will be adjusted up or down for the next cycle, dependent on the blood tests results.~DA-EPOCH-R for 2 cycles then two more cycles of DA-EPOCH-R. If complete response (CR), then DA-EPOCH-R for more 2 cycles. If no CR, DA-EPOCH-R for 4 more cycles."
3119133|NCT01760213|Experimental|Treatment|intervention delivered via internet
3119134|NCT01760213|No Intervention|Control|
3119135|NCT01760200||Drug eluting balloon angioplasty|Drug eluting balloon angioplasty
3119136|NCT01760200||Drug eluting stent group|Drug eluting stent intervention
3119137|NCT01760187|Experimental|Cohort 1|12 Japanese and 12 Caucasian subjects. 10 out of 12 will receive lomitapide and 2 will receive placebo.
3119138|NCT01760187|Experimental|Cohort 2|8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive lomitapide and 2 will receive placebo.
3119139|NCT01760187|Experimental|Cohort 3|8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive lomitapide and 2 will receive placebo.
3119140|NCT01760187|Experimental|Cohort 4|8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive lomitapide and 2 will receive placebo.
3119141|NCT01760174|Active Comparator|Bupivacain-infusion in epidural catheter|Bupivacain-infusion in epidural catheter and intermittent isotonic potassium chloride bolus in transversus abdominis plane catheter.
3119142|NCT01760174|Active Comparator|Ropivacaine bolus in transversus abdominis plane catheter|Intermittent ropivacaine bolus in bilateral transversus abdominis plane catheter and isotonic potassium chloride infusion in epidural catheter.
3119143|NCT01760161|Active Comparator|Ropivacain|Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
3119144|NCT01760161|Placebo Comparator|Isotonic potassium chloride|Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
3119145|NCT01760148||Interferon and ribavirin|All the patients followed the standard treatment protocol.
3119146|NCT01760135|Experimental|low calory|15kcal/kg caloric supplement
3119147|NCT01760135|Active Comparator|high calory|25kcal/kg
3119148|NCT01760122|Experimental|Ypeginterferon Alfa-2b|
3119149|NCT01760122|Active Comparator|Pegasys|
3119150|NCT01760109|Experimental|Piperacillin Sodium and Sulbactam Sodium|"Drug:xintemie 1.5-3.0g,iv,bid 7-14 days~serious infections 6.0-12.0g,iv,tid for 7-14 days"
3119151|NCT01760096|Experimental|Levamisole+cyclosporin A+Glucocorticoids|Levamisole+cyclosporin A+Glucocorticoids
3119152|NCT01760096|Active Comparator|cyclosporin A+Glucocorticoids|cyclosporin A+Glucocorticoids
3119153|NCT01760096|Active Comparator|Glucocorticoids|Glucocorticoids
3119154|NCT01760083|Active Comparator|Biolimus-eluting stent implantation|PCI of CTO using a Biomatrix drug-eluting stent system + optimal medical therapy.
3119155|NCT01760083|No Intervention|Medical therapy|Optimal medical therapy. Subsequent PCI only if symptoms of angina persist despite optimal medical therapy. At least 2 anti-anginal agents or the maximum tolerated anti-anginal therapy should be used before crossover. Medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate.
3119406|NCT01758276||Smokers in pregnancy|Women who report smoking in pregnancy
3119156|NCT01760070|Experimental|Hybrid knife|O-type Hybrid knife is used the whole ESD process except for minimum use of dual knife in border marking and initial mucosal cutting.
3119157|NCT01760070|Active Comparator|IT knife|IT knife is used the whole ESD process except for minimum use of dual knife in border marking and initial mucosal cutting.
3119158|NCT01760057|Placebo Comparator|Health promotion message|Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites
3119159|NCT01760057|Experimental|Combined Web-based HIV intervention|Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging
3119160|NCT01760044|Experimental|Tissue oxygenation monitoring|Tissue oxygenation monitoring
3119161|NCT01760031||Subjects with impaired renal function|Subjects with baseline impaired renal function undergoing cardiac catheterization with contrast-medium exposure
3119162|NCT01760018|Experimental|Desflurane group|
3119163|NCT01760018|Active Comparator|TIVA(total intravenous anesthesia) group|
3119164|NCT01760005|Experimental|Gantenerumab|
3119165|NCT01760005|Experimental|Solanezumab|
3119166|NCT01760005|Placebo Comparator|Matching placebo (Gantenerumab)|
3119167|NCT01760005|Placebo Comparator|Matching Placebo (Solanezumab)|
3119168|NCT01760005|Experimental|JNJ-54861911|
3119169|NCT01760005|Placebo Comparator|Matching Placebo (JNJ-54861911)|
3119170|NCT01759992|No Intervention|Control group|Usual care
3119171|NCT01759992|Experimental|Treatment group|Participants will breathe against a load ≥ 50% of their baseline MIP, after which loads will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.
3119172|NCT01759979|Experimental|Laser and mechanical lithotripsy|Bile duct stones with be treated with cholangioscopy guided laser therapy in addition to mechanical basket and balloon techniques.
3119173|NCT01759979|Active Comparator|Mechanical lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloon for removal of large stones.
3119174|NCT01759966||Heart transplant recipients|Patients receiving orthotopic heart transplant in the enrollment period
3119175|NCT01759966||Healthy controls|Healthy control subjects, having the same age and sex distribution as the heart transplant recipients
3119176|NCT01759953|Active Comparator|InsuOnline game|Playing the InsuOnline game, on the web, in the player´s own time and rhythm, until its end, as already described previously.
3119177|NCT01759953|Active Comparator|Traditional CME|Traditional learning session as used for Continuing Medical Education, on insulin therapy, including a short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
3119178|NCT01759940|Experimental|ropivacaine 0,375%|In the study group the intermediate cervical block will be performed by ultrasound guidance using 20ml ropivacaine 0,375%. Additionally 10ml prilocaine 1% will be used to infiltrate the perivascular tissue around the carotid artery. In the area of the expected incision the skin will also be infiltrated with 10ml prilocaine 1%.
3119179|NCT01759940|Active Comparator|ropivacaine 0,75%|In the control group the intermediate cervical block will be performed by ultrasound guidance using 20ml ropivacaine 0,75%. Additionally 10ml prilocaine 1% will be used to infiltrate the perivascular tissue around the carotid artery. In the area of the expected incision the skin will also be infiltrated with 10ml prilocaine 1%.
3119180|NCT01759927|No Intervention|Control condition|Physically inactive employees are measured on anthropometrics, fitness and psycho-social variables.
3119181|NCT01759927|Experimental|Physical Activity Coaching|Physically inactive employees receiving a 12-week behavioural support intervention grounded in self-determination theory.
3119182|NCT01759914||Potent topical steroid-treated|Patients treated with potent topical steroids
3119183|NCT01759914||Superpotent topical steroid-treated|Patients treated with superpotent topical steroids
3119184|NCT01759901|Experimental|Pringle|Intermittent vascular inflow occlusion applied during liver resection
3119185|NCT01759901|No Intervention|Non-Pringle|No vascular inflow occlusion applied during liver resection
3119186|NCT01759888|Experimental|18F-DTBZ for Parkinson's Disease|This study will compare the brain uptake of 18F- DTBZ in 60 PD patients, including 20 LRRK2 G2385R, 20 PARK6, and 20 idiopathic PD. Subjects will be evaluated sequentially with 18F-DTBZ during a 36 month period. 18F-DTBZ PET scans will be performed twice, at baseline, and 24 (21~27) months following the start of their participation in the study.
3119187|NCT01759875|Active Comparator|Ritonavir-boosted Atazanavir|
3119188|NCT01759875|Experimental|Ritonavir-boosted Atazanavir plus Rabeprazole|
3119189|NCT01759875|Experimental|Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine HCl|
3119190|NCT01759862|Experimental|Aminophylline|"Patients will receive aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.~Theophylline drug levels will be monitored daily for 4 days."
3119191|NCT01759862|Placebo Comparator|Control|"Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.~Drug levels will be monitored daily for 4 days."
3119192|NCT01759849||Allergen challenge|Determination of the effects of a β-chain monoclonal antibody (MAb) on the function of cells naturally activated by in vivo allergen exposure, from donors with allergen-induced asthma
3119193|NCT01759836|Experimental|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
3119194|NCT01759836|Placebo Comparator|Placebo|Placebo daily for 1 year
3119195|NCT01759823|Experimental|mesenchymal stem cell transplantation|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control.
3119196|NCT01759823|Sham Comparator|Control|vildagliptin+metformin+pioglitazone and on Insulin >0.4unit/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1
3119197|NCT01759823|Experimental|MNC's TRANSPLANTATION|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control.
3119198|NCT01759810|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
3119199|NCT01759810|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
3119200|NCT01759797|Experimental|stem cell reciepient|the patients with ALS who underwent intravenous injection of mesenchymal stem cell.
3119201|NCT01759784|Experimental|stem cell recipient|The patients who underwent mesenchymal stem cell transplantation.
3119202|NCT01759771|Experimental|Arm 1|4,000 IU of VD3 for one year
3119203|NCT01759771|Placebo Comparator|Arm 2|placebo for one year
3119204|NCT01759758|Active Comparator|Plaster Ulnar Gutter Splint|Patients will have their hand placed in a conventional Plaster ulnar gutter splint. This immobilizes all joints of the ring and small fingers and the wrist
3119205|NCT01759758|Experimental|Thermoplastic Splint|Patients will be fitted with a custom molded thermoplastic splint that stabilizes the metacarpals of the injured hand but does not immobilize any joints
3119206|NCT01759745||Blepharospasm|Blepharospasm, patient's group
3119207|NCT01759745||Control|Healthy control subjects
3119208|NCT01759732|Experimental|HAPLO|
3119209|NCT01759719||PtCr stent PCI treated patients|patients treated with PCI in whichat least 1 PtCr stent was used
3119210|NCT01759706|Experimental|Enhanced Recovery After Surgery (ERAS)|Patients treated with enhanced recovery after surgery protocol: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia with naropin + sufentanil, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV prophylaxis with ondansetron + dexamethasone, hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, postoperative mobilization program, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.
3119211|NCT01759706|Active Comparator|Standard perioperative care (Control)|Patients treated with standard care perioperative protocol: epidural analgesia with naropin + sufentanil, pre-anesthetic medication with diazepam, Preoperative bowel preparation with sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4
3119212|NCT01759693||Skin disease|Patients with urticaria or atopic dermatitis
3119213|NCT01759693||Control|Healthy volunteers
3119214|NCT01759680|Experimental|Whole Body Vibration Group|The whole body vibration group received 3 training sessions every week composed of 5 series of 15 seconds of vibrations at 30 Hz intensity.
3119215|NCT01759680|No Intervention|Control Group|The control group had a normal daily life for the whole study period
3119216|NCT01759667|Experimental|A standard mixed Meal|The standard mixed meal was composed of a chicken salad sandwich and 200ml of coconut water, totalling 260 kcal, distributed among carbohydrates (62%), proteins (12%) and lipids (26%).
3119217|NCT01759654|Experimental|AdimFlu-V|
3119218|NCT01759641||Hypotension-prone patients|The study group included all patients treated with standard HD prone to acute intradialytic hypotension.
3119219|NCT01759628|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
3119220|NCT01759628|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
3119221|NCT01759615|Experimental|Early enteral feeding|Early enteral feeding group received minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours followed by regular feeding with feed increments of 20ml/kg/day to reach 150 ml/kg.
3119222|NCT01759615|Active Comparator|Late enteral feeding|Late enteral feeding group was kept NPO for a period of 48 hours followed by minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours and thereafter received regular feeding with feed increments of 20ml/kg/day till full enteral feeds of 150 ml/kg/day were achieved
3119223|NCT01759602|Experimental|C1-esterase inhibitor (Cinryze)|This is a phase 1b open-label, interventional proof-of-concept study in patients with neuromyelitis optica (NMO) in which all subjects will receive 3 daily infusions of 2000 Units of intravenous CINRYZE at the onset of an NMO exacerbation in addition to standard of care high-dose steroids, plus an additional 2 infusions of 1000 Units of intravenous CINRYZE during a second treatment phase with plasma exchange, if necessary.
3119224|NCT01759589|Placebo Comparator|propofol (Group P)|The patients in Group P received 1 mg/kg propofol IV (over 15 sec) during anesthesia induction
3119225|NCT01759589|Active Comparator|remifentanil and propofol (Group R)|Patients in Group R received remifentanil 1 µg/kg IV (over 60 sec) and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
3119226|NCT01759589|Active Comparator|sevoflurane (Group S)|In Group S, sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered, at which time it was stopped.
3119227|NCT01759576|Experimental|Group 1 (normal kidney function)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
3119228|NCT01759576|Experimental|Group 2 (mild kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
3119229|NCT01759576|Experimental|Group 3 (moderate kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
3119230|NCT01759576|Experimental|Group 4 (severe kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
3119445|NCT01758055|Experimental|Autologous MSCs transplantation|intra bronchial injection, Autologous MSCs transplantation derived bone marrow, 60millions cells, once
3119231|NCT01759576|Experimental|Group 5 (hemodialysis)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1 following completion of hemodialysis. Approximately 10 days later, each volunteer will receive another single dose of canagliflozin before hemodialysis begins.
3119232|NCT01759563|Other|single arm study|
3119233|NCT01759550||LigaSure Device|In this prospective observational study, 60 patients scheduled to undergo a Roux-en-Y or gastric reduction procedure (sleeve gastrectomy or plication) will have hemostasis controlled with LigaSure Advance ™ Pistol Grip or LigaSure™ Blunt Tip, respectively. Both devices are regularly used at Duke in the Bariatric Surgery division. The surgeon will select which device is used. There will be no randomization. The device decision tree will be based upon the procedure. Cases that require enterotomy will utilize the AdvanceTM pistol grip. Cases which don't need enterotomy will utilize the 5 Blunt Tip. The LigaSure AdvanceTM pistol grip and LigaSureTM Blunt Tip are used exclusively with the Force TriadTM Energy platform. There is no simultaneous use.
3119234|NCT01759537|Experimental|Implants placed at sub-crestal position.|Ankylos dental endosseous implants-sub-crestal
3119235|NCT01759537|Active Comparator|Epi-crestal implants.|Ankylos dental endosseous implants-Epi-crestal
3119236|NCT01759524|Experimental|Group L|40 mls of 2% lidocaine + 1.5 mcg/kg will be drawn up by an attending anaesthetist to blind the operator. Patients in this group will receive an ultra sound guided sciatic nerve block , 3 cm proximal to the nerve bifurcation, with 25 mls of the above mentioned solution and an ultra sound guided saphenous nerve block in the midthigh just lateral to the profunda femoris artery with 15 mls of the above mentioned solution.
3119237|NCT01759524|Active Comparator|Group B|40 mls of 0.5% bupivacaine will be drawn up by an attending anaesthetist to blind the operator. Patients in this group will receive an ultra sound guided sciatic nerve block , 3 cm proximal to the nerve bifurcation, with 25 mls of the above mentioned solution and an ultra sound guided saphenous nerve block in the midthigh just lateral to the profunda femoris artery with 15 mls of the above mentioned solution.
3119238|NCT01759511|Experimental|Simtuzumab|Participants will receive simtuzumab.
3119239|NCT01759498|Experimental|HYDRO 2|Subjects in the second experimental group will follow the procedures of first experimental group with additional administration of hydrogen-rick packs 6 times per day for 20 minutes throughout the study.
3119240|NCT01759498|Active Comparator|ACTIVE|During the period of 2 weeks subjects will receive traditional treatment protocol after the soft-tissue injury, consisting of RICE protocol during the first 48 h (e.g. rest, ice packs for 20 minutes every 2 hours, compression with elastic bandage, elevation of the injured area above the level of the heart at all possible times) and sub-acute protocol thereafter (e.g. passive stretching 3 times per day for 90 sec, isometric strength exercise with 3 sets with 15 repetitions, 30 min of pain-free weight-bearing exercise).
3119241|NCT01759498|Experimental|HYDRO|Subjects in the first experimental group will follow the PLA procedures with additional administration of oral hydrogen-rich capsules (4 capsules three times per day) throughout the study.
3119242|NCT01759485|Active Comparator|Vitamin D|Supplementation of Vitamin D as add-on to the regular anti-psychotic treatment
3119243|NCT01759485|Placebo Comparator|Placebo|Placebo as oral drops once weekly as add-on to the regular anti-psychotic treatment
3119244|NCT01759472||montelukast，vitamin C pill|leukotriene receptor antagonist:(montelukast)，montelukast (10 mg, once per night)，56 days vitamin C pill:100mg，once per night，56 days
3119245|NCT01759472||montelukast, vitamin C pill|montelukast:10 mg, once per night，56 days vitamin C pill:100mg，once per night，56 days
3119246|NCT01759459|Experimental|Lidocaine|1% Lidocaine for injection, 0.50 mL administered one time intradermally in peripheral forearm
3119247|NCT01759459|Experimental|Buffered Lidocaine|"1% Buffered Lidocaine for injection, 0.50 mL administered one time intradermally in peripheral forearm~Buffered lidocaine is compounded by the following process:~2.3 mLs of 8.4% sodium bicarbonate is added to a vial of 1% lidocaine"
3119248|NCT01759459|Experimental|Bacteriostatic Normal Saline|Bacteriostatic Normal Saline for injection, 0.50 mL administered one time intradermally in peripheral forearm
3119249|NCT01759446|Placebo Comparator|Placebo|Placebo
3119250|NCT01759446|Active Comparator|Hydrocodone and Acetaminophen|Hydrocodone and Acetaminophen
3119251|NCT01759446|Active Comparator|Vycavert (hydrocodone and acetaminophen)|hydrocodone and acetaminophen
3119252|NCT01759446|Active Comparator|Hydrocodone/Acetaminophen with inactives|Hydrocodone/Acetaminophen with inactives
3119253|NCT01759446|Active Comparator|Hydrocodone/Acetaminophen plus placebo|Hydrocodone/Acetaminophen plus placebo
3119254|NCT01759420||IV Ondansetron|Adult emergency department patients receiving 4mg of IV ondansetron as part of their treatment plan.
3119255|NCT01759407|Active Comparator|Femoral Nerve Block|Ropivicaine 0.2% with epinephrine 1:200,000 will be used for patients between 10kg and up to 25kg in weight; ropivicaine 0.5% with epinephrine 1:200,000 will be used for patients greater than or equal to 25kg
3119256|NCT01759407|No Intervention|Standard Anesthetic Management|
3119257|NCT01759394|Experimental|Avatrombopag maleate 40 mg|
3119258|NCT01759381|No Intervention|No Negative Pressure Wound Therapy Device|This control group will not receive the negative pressure wound therapy device. Post operative dressings will be per the surgeon's standard routine.
3119259|NCT01759381|Experimental|NPWT Arm Therapy|This group will receive NPWT as opposed to the standard incisional dressing following complex spinal surgery.
3119260|NCT01759368|Active Comparator|Telemonitoring assisted self-care|Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring.
3119446|NCT01758042|Other|Haploidentical Bone Marrow/Kidney|Single Arm Study
3119261|NCT01759368|No Intervention|Control group|Control group received usual care that includes multidisciplinary care approach in which patients receive guidance and support for self-care. In the care of heart failure (HF) patients, the cardiac team plays a central role in monitoring and interpreting patient symptoms, optimizing medication and providing education. The cardiac team consists of two physicians, one specialized heart failure nurse and a physiotherapist who helps after a hospitalization period. As part of the care process, patients capable of carrying out self-care are identified and they are encouraged to regularly measure their blood pressure, heart rate and weight at home. So far, the information exchange between heart failure patients and care personnel has taken place during patients' visits to the clinic and by telephone. Systematic collection and exploitation of the self-measurement data has been difficult, since it depends on the patient's own activity
3119262|NCT01759355||Surgery|Participants undergoing surgical intervention will receive a PET/MR scan prior and following surgery for a total of two (2) scans.
3119263|NCT01759355||Chemoradiation|Participants undergoing chemoradiation intervention will receive a PET/MR scan prior, during, and following chemoradiation for a total of three (3) scans.
3119264|NCT01759342|Experimental|Comprehensive exercise program|Moderate to high intensity aerobic, resistance, flexibility, posture and balance exercise program
3119265|NCT01759342|Active Comparator|Usual care exercise|30 minutes/day of self selected mode and intensity of aerobic exercise
3119266|NCT01759329|Experimental|test coffee|test coffee
3119267|NCT01759329|Active Comparator|control coffee|control coffee
3119268|NCT01759316|Active Comparator|heliox|Heliox is use in this group
3119269|NCT01759316|Placebo Comparator|Placebo|Oxygen is used in this group
3119270|NCT01759303|Experimental|pazopanib|"For subjects > 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.~For subjects 16-17 years of age with a BSA < 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity."
3119271|NCT01759290||Absorb Bioresorbable Vascular Scaffold|Subjects receiving the Absorb Bioresorbable Vascular Scaffold
3119272|NCT01759277|Active Comparator|Control|Femoral perineural local anesthetic infusion
3119273|NCT01759277|Experimental|Experimental|Adductor canal perineural local anesthetic infusion
3119274|NCT01759264||Moderate-to-severe Crohn's disease|Adalimumab induction therapy participants with moderate-to-severe Crohn's Disease
3119275|NCT01759251||vestibular vertigo|Patients with vestibular vertigo of known or unknown origin, and for whom the physician has decided to prescribe betahistine dihydrochloride at dose 48 mg/day in accordance with locally approved label
3119276|NCT01759238|Experimental|Chemoradiation|Chemoradiation with different radiotherapy regimes (depending on location and size of irradiated lesions; e.g. conventional radiotherapy with a total dose of 35 Gy, delivered in 2.5Gy fractions for 14 days or intensity-modulated and image-guided radiotherapy with a total dose of 40 Gy, delivered in 4.0 Gy fractions for 10 days or 3-8 fractions with 8-15 Gy) combined with bevacizumab (7.5mg/kg day 1) and capecitabine (825mg/m2 bid on day 1-5, 8-12 and 15-19)
3119277|NCT01759225||Cardiovascular Disease Patients|
3119278|NCT01759212|Experimental|Stem cells implantation|Patients with end-stage heart failure due to ischemic cardiomyopathy will undergo combined cellular and mechanical support with implantation of off-the-shelf allogeneic mesenchymal stem cells and left ventricular assist device.
3119279|NCT01759199|Experimental|The six minute Stepper Test|Experimental : The six minute Stepper Test with a Conventional respiratory rehabilitation
3119280|NCT01759186||None interventional|
3119281|NCT01759173||college athletes|
3119282|NCT01759160|Active Comparator|Marsh|Marsh Plasma TCI with high initial target
3119283|NCT01759160|Active Comparator|Schnider|Schnider Plasma TCI with high initial target
3119284|NCT01759147|Experimental|Surgery|Surgical repair of acromioclavicular dislocation.
3119285|NCT01759134|Experimental|Post Discharge Formula|Babies will be given formula for first three months post discharge
3119286|NCT01759121|Active Comparator|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
3119287|NCT01759121|Experimental|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
3119288|NCT01759108|Experimental|Rebamipide|Patients will be randomized 1:1 to receive 300mg/d (100mg x3/day) of rebamipide for 12 weeks together with their usual therapy
3119289|NCT01759108|Placebo Comparator|Placebo|Patients will be randomized 1:1 to receive 300mg/d (100mg x3/day) of placebo for 12 weeks together with their usual therapy.
3119290|NCT01759095|No Intervention|Control|At hospital discharge, patients of the control group will receive usual care at their community pharmacy.
3119291|NCT01759095|Experimental|Electronic Multidrug Blister Pack|
3119292|NCT01759069|Experimental|treatment with microscope|treatment with microscope
3119293|NCT01759069|Experimental|treatment without microscope|treatment without microscope
3119294|NCT01759056|Active Comparator|AVX 470|AVX 470 0.2 g(Cohort 1), 1.6 g (Cohort 2) and 3.5 g (Cohort 3) will be administered daily for 28 days
3119295|NCT01759056|Placebo Comparator|Placebo|Placebo will be administered daily for 28 days as a comparator with AVX-470 (all dose groups)
3119296|NCT01759043|Experimental|guiding catheter|a single transradial guiding catheter for coronary angiography and intervention in patients with STEMI
3119297|NCT01759043|Active Comparator|Diagnostic catheter|Diagnostic catheter followed by guiding catheter selection for transradial primary PCI
3119298|NCT01759030|Active Comparator|MabThera (F. Hoffmann-La Roche Ltd.)|"Stage 1 (week 1 - week 24) MabThera will be administered at a dose of 1000 mg, IV (on day 1 and day 15).~Stage 2 (week 24 - 48) If the disease activity remains on Week 24 the patient will undergo the second randomization (1:1 ratio): if he/she randomised into group A then he/she recieves BCD-020 at a dose f 1000 mg, IV, once in 2 weeks, 2 infusions per course (on day 1 and day 15); if he/she if he/she randomised into group B then he/she continues to recieve MabThera at a dose f 1000 mg, IV, once in 2 weeks, 2 infusions per course (on day 1 and day 15).~MabThera/BCD-020 will be used in combination with methotrexate (irrespectively to study stage)."
3119299|NCT01759030|Experimental|BCD-020 (CJSC BIOCAD)|"Stage 1 (week 1-week 24) BCD-020 will be administered at a dose of 1000 mg, IV (on day 1 and day 15).~Stage 2 (week 24-48) If the disease activity remains on Week 24 the patient will undergo the second randomization (1:1 ratio): if he/she randomised into group A then he/she recieves MabThera at a dose f 1000 mg, IV, on day 1 and day 15; if he/she if he/she randomised into group B then he/she continues to recieve BCD-020 at a dose f 1000 mg, IV, on day 1 and day 15.~MabThera/BCD-020 will be used in combination with methotrexate (irrespectively to study stage)."
3119300|NCT01759017||Infliximab responders|Gastroenterologist's overall assessment (response) Decrease in Harvey-Bradshaw index score of 2 or more points (clinical response) Harvey-Bradshaw index score less than 5 (clinical remission) Maintenance of steroid-free remission No Crohn's-related hospitalizations or surgeries
3119301|NCT01759017||Infliximab non-responders|Gastroenterologist's overall assessment (no response) Decrease in Harvey-Bradshaw index score of 1 or 0 points, or increase in HBI (no response) Harvey-Bradshaw index score greater than or equal to 5 (no remission) Resumption of steroid treatment Crohn's-related hospitalization or surgery
3119302|NCT01759004|Active Comparator|patient with lipoedema|"Lipedema group:~diagnosed with lipedema following the criteria of Wold~women~age ≥ 18 years~clinimetrics: volume, muscle strength, physical condition, BMI"
3119303|NCT01759004|Active Comparator|patients with obesity|"Obesity group:~BMI ≥ 30~women~age ≥ 18 years~clinimetrics: volume, muscle strength, physical condition, BMI"
3119304|NCT01758991|Active Comparator|real tDCS|"patients will receive non-invasive and painless brain stimulation over the rain areas involved in swallowing.~tDCS will be applied during swallowing therapy, during 20 minutes"
3119305|NCT01758991|Placebo Comparator|sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
3119306|NCT01758978|Experimental|Treatment Group AB|"Subjects in this group will receive study drug in the following sequence:~Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference)~Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test)."
3119307|NCT01758978|Experimental|Treatment Group BA|"Subjects in this group will receive study drug in the following sequence:~Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test).~Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference)."
3119308|NCT01758965|Experimental|combination therapy of H2RA and surgicel|H2RA and surgicel
3119309|NCT01758965|Experimental|Monotherapy of PPI|PPI
3119310|NCT01758952||Beijing Chaoyang Hospital|2000 cases
3119311|NCT01758952||Peking University Hospital|2000 cases
3119312|NCT01758952||Zhongshan Hospital of Fudan University|2000 cases
3119313|NCT01758952||Tongji Hospital, Wuhan|2000 cases
3119314|NCT01758952||Tangdu Hospital, Xi'an|2000 cases
3119315|NCT01758952||The Prince Welsh Hospital|1000 cases
3119316|NCT01758939||Hepatitis C virus infected patients|
3119317|NCT01758926||Inflammatory bowel disease|Patients previously diagnosed as having IBD
3119318|NCT01758926||Health control|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
3119319|NCT01758913|Experimental|Ibuprofen|Infant who was assigned to ibuprofen, an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 hours respectively as a course was given.
3119320|NCT01758900|Active Comparator|Air insufflation regulator|Room air will be used for insufflation as the Active Comparator arm
3119321|NCT01758900|Experimental|CO2 insufflation regulator|Device: CO2 insufflation regulator
3119322|NCT01758887||Controls|Healthy control
3119323|NCT01758887||patients|clinical high risk subjects for psychosis
3119324|NCT01758874|No Intervention|Non phlebotomy group (control group)|"• This control group is the patients who had Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss. They were treated with conventional standard treatment including revascularization operative procedure if feasible, maximum medical treatment with anticoagulation (heparin, low molecular weight heparin, etc), acetylsalicylic acid, cilostazol, and prostaglandin E1, dextran, and pain analgesia with opioid, and finally major amputation.~We records all control arms' amputation, day to amputation, mortality, etc. We will compare amputation and mortality between control and treatment groups.~Non phlebotomy arm has no phlebotomy treatment."
3119325|NCT01758874|Experimental|PH (study group)|"The patients will be pre-amputation and have Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss.~Procedures for therapeutic phlebotomy~Inject heparin 5000 units to prevent blood clot during phlebotomy~Inject volume expander equivalent to 5% of blood volume~Remove 5% of whole blood~Monitor the vital sign of the patient during the phlebotomy~They were treated both phlebotomy and conventional standard management including surgery, medication, amputation, etc.~We will compare amputation and mortality between control and study groups."
3119326|NCT01758861|Experimental|EPO group|EPO group received 300 IU/kg of rHuEPO-alpha via intravenous bolus administration after induction of anesthesia.
3119327|NCT01758861|Placebo Comparator|Placebo group|Placebo group received normal saline via intravenous bolus administration after induction of anesthesia.
3119328|NCT01758835|Active Comparator|Splint 3 weeks|Removable ankle brace/splint
3119329|NCT01758835|Active Comparator|Cast 3 weeks|Below-the-knee cast (glass fiber)
3119330|NCT01758835|Active Comparator|Cast 6 weeks|Below-the-knee cast (glass fiber)
3119331|NCT01758822|Experimental|No Endotracheal suction|In the experimental group, endotracheal suction will not be performed during the initial steps of resuscitation of non-vigorous meconium stained neonate
3119332|NCT01758822|No Intervention|Endotracheal suction|In the No intervention group endotracheal suction will be performed during the initial steps of resuscitation of non - vigorous meconium stained neonate
3119333|NCT01758809|Active Comparator|Bupivacaine|
3119334|NCT01758809|Other|Intravenous Patient Controlled Analgesia|postoperative pain control with intravenous patient controlled analgesia
3119335|NCT01758796|Active Comparator|Non-operative treatment|Non-operative treatment: 6 weeks in a cast, 4 weeks partial weight bearing and last 2 weeks weight bearing as tolerated.
3119336|NCT01758796|Active Comparator|Operative treatment|ORIF, after care like in a non-operative treatment group.
3119337|NCT01758783|Placebo Comparator|placebo group|
3119341|NCT01758731|Experimental|Olaparib with C225 and Radiation Therapy|Patients will begin taking Olaparib at the assigned dose three days prior to their first Cetuximab infusion. Patients will receive an initial dose of Cetuximab, 400 mg/m², intravenously over 120 minutes on Day 1. The initial dose of C225 will precede the start of radiation by 5-7 days. All patients will receive RT to a total dose of 69.3 Gy in 33 fractions over 6½ weeks. Weekly C225 will be administered at 250 mg/m2 in combination with daily RT. Patients will be assigned to receive Olaparib (25, 50, 100 or 200 mg bid) in combination with RT and C225. Olaparib will be taken twice daily, beginning three days prior to first scheduled C225 infusion. A further dose level of 300mg or 400mg may be considered should the 200mg Olaparib dose be well tolerated in this C225/RT combination schedule.
3119342|NCT01758718|Active Comparator|Entropion with Down's syndrome|Eyelash resection surgery was performed for entropion with Down's syndrome
3119343|NCT01758705||Cohort 1|Cohort 1
3119344|NCT01758692||Able-bodied Controls|"10 controls between the ages of 18 and 65 of either gender; free of cardiovascular disease and/or medication.~An addition 40 controls ages 18-89 of either gender, will perform the non-invasive manipulations only."
3119345|NCT01758692||Spinal Cord Injury|"40 subjects to perform the pharmacological and non-invasive manipulations; between the ages of 18 and 65 years old in stable health for the last 6 months, non-smoker, and level of injury from C1 - S4 for over 1 year and an AIS classification of A, B, C. Free of arrhythmia, hypertension, cardiovascular disease, kidney disease, diabetes, neuropathies, neuromuscular disease, and sulfite allergies or hypersensitivity.~60 subjects to perform the non-invasive manipulations only; between 18-89 years of age in stable condition (>6 months), non-smoker. Level of injury from C1-S4 for over a year with a AIS classification of A, B, or C. No history of diabetes, autonomic neuropathy, parkinson's disease, or acute illness or infection. An additional 30 will perform the non-invasive testing before and after completion of an ambulatory training protocol."
3119346|NCT01758679|Experimental|Licartin，Licartin and CIK|Intravenous Licartin 27.75 M Bq(0.75 mCi)/kg Licartin and CIK
3119347|NCT01758666|Experimental|Methotrexate and Calcium folinate|
3119348|NCT01758653||Biorepository|Patients with acute CO poisoning. Blood collection for biorepository only, no study intervention.
3119349|NCT01758640|Active Comparator|Pregnant|Group of Pregnant patients who will receive either warfarin or phenindione according to the study design
3119350|NCT01758640|Active Comparator|Non Pregnant|Group Of Non Pregnant patients who will receive either warfarin or phenindione according to the study design
3119351|NCT01758627|No Intervention|Peritoneal dialysis group|
3119352|NCT01758627|Experimental|Conventional treatment group|medical treatment such as diuretics
3119353|NCT01758614|Experimental|bypass group|all the participants in this group will be performed EC-IC bypass surgery
3119354|NCT01758614|Active Comparator|medical group|all the participants in this group will be given medical therapy including aspirin 100mg per day or clopidogrel 75mg per day
3119355|NCT01758601|Experimental|Fish - no fish|The individuals randomized to this arm continued with their previous alimentary habits, avoiding any significant nutritional imbalance, and with an ingestion of 7 serves of hake (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain) per week for a period of 8 weeks. Then switched to previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood.
3119356|NCT01758601|Active Comparator|No fish - fish|Patients were on previous diet except for the avoidance of fish and any other seafood for 8 weeks. Afterwards they were changed to the same diet but with 7 serves of hake per week.
3119357|NCT01758588|No Intervention|Observation arm|Subjects will be monitored closely for disease progression, however will receive no intervention.
3119358|NCT01758588|Experimental|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered at a dose of 50 micrograms once a week for up to 3 years.
3119359|NCT01758575||antiangiogenic tyrosine kinase inhibitors|Sunitinib: 50 mg orally once daily Sorafenib: 400 mg orally twice daily Pazopanib: 800 mg orally once daily
3119360|NCT01758575||EGFR inhibitors|Cetuximab 250 mg/m2 intravenously, weekly Panitumumab 6 mg/Kg intravenously, every 2 weeks
3119361|NCT01758575||mTOR inhibitors|Everolimus 10 mg orally once daily
3119362|NCT01758575||BRAF inhibitor|Vemurafenib 960 mg orally twice daily
3119363|NCT01758575||anti-CTL4 antibody|Ipilimumab 3 mg/kg intravenously, every 3 weeks
3119364|NCT01758562|No Intervention|State-of-the-art mouth care|
3119365|NCT01758562|Active Comparator|Mouth rinse Caphosol|Mouth rinse,aqueous solution. Caphosol is a preparation comprising two separately packaged aqueous solutions, a phosphate solution and a calcium solution, which, when both solutions are combined in equal volumes, forms a solution supersaturated with respect to both calcium and phosphate ions.
3119366|NCT01758549|Experimental|Aggressive Intravenous Hydration Group|Patients randomized to the aggressive intravenous hydration group receive lactated ringers (LR) IV at 3 mL kg-1 hr-1 during the procedure, a 20cc/kg LR IV bolus immediately afterward, and LR IV at 3 mL kg-1 hr-1 for 8 hours following the procedure.
3119367|NCT01758549|Active Comparator|Standard Fluids Arm|Those in the control arm receive standard fluids defined as LR at 1.5 mL kg-1 hr-1 during the procedure and for 8 hours afterwards.
3119368|NCT01758536|Placebo Comparator|Placebo Pills|"12 g each time, twice daily.~3 months"
3119369|NCT01758536|Experimental|Huatuo Zaizao Pills|"12 g each time, twice daily.~3 months."
3119370|NCT01758523|Experimental|dutasteride|4 mg oral loading dose of dutasteride followed by 1 mg/day dutasteride for 12 weeks.
3119371|NCT01758523|Placebo Comparator|Sugar Pill|Placebo pills prepared to appear the same as active medication and taken in the same number as active medication for 12 weeks.
3119372|NCT01758510|Experimental|HYNR-CS-Allo|HYNR-CS-Allo inj. 2 times by intrathecal administration with 28 days interval.
3119373|NCT01758497|Active Comparator|Ropivacaine|US guided injections of 30 ml 0.5% ropivacaine (Fascia Iliaca Compartment Block)
3119374|NCT01758497|Sham Comparator|Saline|US guided injections of 30 ml 0.9% NaCl (Fascia Iliaca Compartment Block)
3119375|NCT01758484|Experimental|Supportive care (palliative care support)|Patients undergo palliative care support before transplantation and at least once monthly while they remain at the transplant center.
3119376|NCT01758471|Experimental|Acarbose|The minimum dosage of acarbose in this study is 100mg tid p.o.(oral) for 3 month. With this dosage, patients should have similar glycemic control with those using glipizide, that is FBG(fasting blood glucose)<7.0,PBG(postprandial blood glucose)<10.0
3119377|NCT01758471|Active Comparator|glipizide|There is no fixed dosage of glipizide to control hyperglycemia for patients in this group. As long as the targeted blood glucose concentration is reached, FBG< 7.0, PBG< 10.0, patients will have the least dosage of glipizide according to their glucose level.
3119378|NCT01758458|Experimental|Treatment (autologous T cells and aldesleukin)|"Patients undergo radiation therapy or recombinant interferon beta intralesional injection within day -3 to day -1.~Patients receive MCPyV TAg-specific polyclonal autologous CD8-positive T cell infusion IV on day 1 and aldesleukin SC every 12 hours on days 1-14. Treatment repeats at least every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~Patients with continued presence of detectable metastatic disease 8 weeks after the first infusion may repeat the treatment regimen including radiation therapy or recombinant interferon beta injection."
3119379|NCT01758445|Experimental|Proton Radiotherapy|Proton Radiotherapy
3119380|NCT01758432|Experimental|Module 1 (90 mg bolus)|90 mg PRT064445 given as a single IV
3119381|NCT01758432|Experimental|Module 1 (210 mg bolus)|210 mg PRT064445 given as a single IV bolus
3119382|NCT01758432|Experimental|Module 1 (420 mg bolus)|420 mg PRT064445 given as a single IV bolus
3119383|NCT01758432|Experimental|Module 1 (420 mg bolus + 180 mg infusion) 4 mg/min|600 mg PRT064445 given as follows: 420 mg IV over ~14 minutes (~30 mg/min), followed by a continuous infusion of 180 mg (4 mg/min over 45 minutes)
3119384|NCT01758432|Experimental|Module 1 (420 mg bolus + 180 mg bolus) 30mg/min|600 mg PRT064445 given as follows: up to 420 mg IV over ~14 minutes (~30 mg/min), followed by a second bolus of 180 mg IV over ~6 minutes (~30 mg/min), 45 minutes after completion of the bolus
3119385|NCT01758432|Experimental|Module 1 (420 mg bolus + 480 mg infusion) 4mg/min|900 mg PRT064445 given as follows: 420 mg IV, followed by a continuous infusion of 480 mg (4 mg/min over 120 minutes
3119386|NCT01758432|Placebo Comparator|Module 1 Placebo|Placebo administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.
3119387|NCT01758419||Tomotherapy|Breast cancer female s/p scheduled RT will be arranged to undergo Thallium-201 Myocardial Perfusion Study. The scheduled RT will be arranged by clinical judgments of radiation-oncologists. All of the patients will receive myocardial SPECT before and after the scheduled RT. Comparing the clinical follow-up data between different groups (left-sided s/p tomography, left-sided s/p conventional RT, and right-sided RT), respectively.
3119388|NCT01758406|Experimental|cardiac stem cell transplantation|The patients with heart failure that underwent cardiac stem cell transplantation.
3119389|NCT01758406|Placebo Comparator|Placebo|The patients with heart failure that underwent placebo injection.
3119390|NCT01758393|Experimental|Medium Dose|Patients are treated with prednisone or equivlent at doseage of 0.5-0.6 mg/kg/d (max 40mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.
3119391|NCT01758393|Experimental|High Dose|Patients are treated with prednisone or equivlent at doseage of 0.8-1.0 mg/kg/d (max 60mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.
3119392|NCT01758380|Experimental|Vildagliptin + placebo to Gliclazide|Vildagliptin tablets will be given at 50mg twice daily (bid). Placebo to Gliclazide capsules will be given at an equivalent dose to previous sulfonylurea in multiples of 80mg only (80-320 mg/day). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
3119393|NCT01758380|Active Comparator|Gliclazide + placebo to Vildagliptin|Gliclazide capsules will be given in multiples of 80 mg (80-320 mg/day) at a dose equivalent to previous sulfonylurea dose, unless at the investigator's discretion it could be up-titrated to the next available dose (if HbA1c is higher than 7.5%). Placebo to Vildagliptin tablets will be given at 50mg twice daily (bid). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
3119394|NCT01758367|Experimental|Decitabine+DLI|Patients with relapsed AML after Allo-HSCT will be treated with decitabine and DLI.
3119395|NCT01758354|Experimental|Pompe disease newborn screening|newborns will be tested if they were affected by Pompe disease
3119396|NCT01758341|Experimental|Malignant biliary obstruction|All patients who underwent endoscopic radiofrequency ablation with the HabibTM EndoHBP as a treatment for malignant biliary obstruction in Austria between November 2010 and December 2012.
3119397|NCT01758328|Experimental|Pts with Mutiple myeloma|Patients will undergo a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor. Hematopoietic stem cell donors for this trial will include individuals who are 10/10 HLA matched or one antigen or allele mismatched at the HLA-A, B, C, DRB1 or DQB1 locus, as defined by high resolution methods .Donors who are 8/10 HLA matched with an antigen or allele mismatched at HLA-DQB1 and at one other locus will also be eligible for the trial. The administration of WT1-specific cytotoxic T cells (WT1 CTLs) post transplantation is integrated to induce complete remissions in patients with residual disease and to decrease the rate of relapse following the allogeneic transplant.
3119398|NCT01758315|Experimental|Improvement Sessions|We will implement a context-sensitive collaborative improvement model that will emphasize training and in-office coaching by quality improvement, efficiency and safety experts, as well as shared learning methods to develop, test and implement changes in the following four key risk areas: medication management; test and lab results management; follow-up and referral management; and communication - within and between practices as well as with patients.
3119399|NCT01758315|No Intervention|Control|Control practices will not receive training or in-office coaching.
3119400|NCT01758302|Active Comparator|No physical task + Taste cookies|Participants in this arm do not engage in a physical activity task. They are asked to taste test chocolate chip cookies.
3119401|NCT01758302|Active Comparator|No physical task + Taste vegetable|Participant does not complete a physical activity. Asked to taste test raw celery or radishes.
3119402|NCT01758302|Active Comparator|Simple physical task + Taste vegetables|Participants are asked to complete a simple physical task and are asked to taste test raw celery or radishes.
3119403|NCT01758302|Active Comparator|Complex physical task + Taste vegetables|Participants complete a more complex physical task that is novel and challenging. They are asked to taste test raw celery or radishes.
3119404|NCT01758289||Paricalcitol IV|Eligible participants with diagnosis of chronic kidney disease stage V undergoing hemodialysis, treated with paricalcitol IV per routine clinical practice according to prescribing information approved in Venezuela and clinical criteria.
3119405|NCT01758276||Non smokers|Women who did not report smoking in pregnancy
3119407|NCT01758263||Metoprolol to Nebivolol|Patients with high blood pressure (hypertension) who were continuously treated with metoprolol for a minimum of 6 months prior to switching to nebivolol. Patients were then continuously treated with nebivolol for a minimum of 6 months.
3119408|NCT01758250||Systemic Sclerosis|Patients with SSc will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.
3119409|NCT01758250||GVHD|Patients with GVHD will have imaging studies performed at baseline and at 3, 6, 9, 12, 18 and 24 months.
3119410|NCT01758250||Undergoing HSCT|Patients who are about to undergo HSCT will have imaging studies performed at 1 week pre-transplantation, day 40 and 80 post transplantation and at 3 months, 6 months, 12 months 18 months and 24 months post-transplant.
3119411|NCT01758250||Controls|Healthy Controls and Controls with hematologic and solid organ malignancies and dermatitis will have imaging studies performed at a single point in time.
3119412|NCT01758250||Sickle cell disease|Patients with SCD will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.
3119413|NCT01758250||Cutaneous fibrosing disorder|Patients with active cutaneous fibrosing disorder will have imaging studies performed at a single point in time.
3119414|NCT01758237|Experimental|Superior Laser Peripheral Iridotomy|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser peripheral iridotomy was performed on the superior aspect of the iris in the eye being treated. This will be in the 11 to 1 o'clock position.
3119415|NCT01758237|Experimental|Temporal Laser Peripheral Iridotomy|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser peripheral iridotomy was performed on the temporal aspect of the iris in the eye being treated. The position will be in the 2 to 4 o'clock in the left eye and 8 to 10 o'clock in the right eye.
3119416|NCT01758224|Experimental|Functional Magnetic Stimulation|This group will receive magnetic stimulation of the respiratory (breathing) muscles that may improve the breathing function in subjects with MS. The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes).
3119417|NCT01758224|Active Comparator|Resistive Expiratory Muscle Training|Participants in this group will perform breathing exercises using a resistive breathing device. The training will take place in the FMS lab. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home.
3119418|NCT01758211|Experimental|fMRI guided resection of AVM|fMRI Navigation AVM resection in AVM patients
3119419|NCT01758211|Active Comparator|conventional AVM resection|conventional resection of AVM
3119420|NCT01758198|Experimental|Group 1: Abatacept + Methotrexate (MTX)|"Abatacept 10 mg/kg solution intravenous (IV) infusion, once monthly for 12 months~Methotrexate ≥6 mg/week for 12 months"
3119421|NCT01758198|Placebo Comparator|Group 2: Placebo matching with Abatacept + Methotrexate|"Placebo matching with Abatacept 0 mg/kg solution, intravenous (IV) infusion once monthly for 12 months~Methotrexate ≥6 mg/week for 12 months"
3119422|NCT01758185|Placebo Comparator|recombinant hepatitis b vaccine|0.5ml intramuscular
3119423|NCT01758185|Experimental|Aleph influenza vaccine|0.5ml intramuscular
3119424|NCT01758172|Active Comparator|Albumin|albumin was administered to reach CVP up to 7mmHg
3119425|NCT01758172|Experimental|6% hydroxyethyl starch 130/0.4|6% hydroxyethyl starch 130/0.4 was administered to reach CVP up to 7mmHg
3119426|NCT01758159|Experimental|CFR group|The children in this group will receive complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
3119427|NCT01758159|Experimental|Fe group|The children in this group will receive iron supplementation 2mg/kg/day of ferric Na EDTA (in the form of syrup) daily for 24 weeks duration.
3119428|NCT01758159|Experimental|CFR + Fe group|The children in this group will receive both local food-based complementary feeding according to CFR and Iron supplementation for 24 weeks duration
3119429|NCT01758159|Placebo Comparator|Control group|The children in this group will receive basic health services and placebo syrup.
3119430|NCT01758146|Experimental|Arm A- Letrozole|Aromatase inhibitor- letrozole 2.5mg once daily for 5 years
3119431|NCT01758146|Active Comparator|Arm B- Tamoxifen|Tamoxifen 20 mg once daily for 5 years
3119432|NCT01758133||Mothers exposed to medical clowns|Mothers of premature infants who have been exposed to medical clown activities
3119433|NCT01758133||Mothers not exposed to medical clown activity|
3119434|NCT01758120|Experimental|prednisone plus cyclophosphamide|prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day*6 months) plus cyclophosphamide(1g intravenous use,per 1 month*6months)
3119435|NCT01758120|Experimental|prednisone alone|prednisone alone: prednisone(0.5mg/kg/day*6 months)
3119436|NCT01758107|Experimental|Sirolimus with Prednisolone|Sirolimus with Prednisolone, and withdraw cyclosporine
3119437|NCT01758107|No Intervention|Sirolimus with Cyclosporine with Prednisolone|
3119438|NCT01758094||Hypogonadotropic hypogonadism patients|Treatment naive 25 patients with idiopathic hypogonadotrophic hypogonadism
3119439|NCT01758081|Active Comparator|vitamin D + fish oil|vitamin D3 + Omacor
3119440|NCT01758081|Active Comparator|vitamin D + fish oil placebo|vitamin D3 + fish oil placebo
3119441|NCT01758081|Active Comparator|vitamin D placebo + fish oil|vitamin D placebo + Omacor
3119442|NCT01758081|Placebo Comparator|vitamin D placebo + fish oil placebo|vitamin D placebo + fish oil placebo
3119443|NCT01758068|Experimental|Coconut Oil Application|The oil (coconut oil) was applied by the trained nurse to the entire body surface of infant except the face two times a day started as early as possible Four ml of coconut oil was applied using both hands of the caregiver in four strokes starting from the level of clavicles over the chest and abdomen till the groin, from the front of thighs, knee, leg and upto the sole, from above the shoulders over the arm and forearm till the palm continuing medially over the forearm and arm till the axilla and the final stroke was used for the back reaching over the back of the thighs till the heel. Just prior to the first application, and thereafter prior to the subsequent applications the TEWL was recorded using the portable closed chamber evaporimeter. The oil application was continued twice daily (every 12 hrs at the same time as the hour of birth e.g. 11 am and 11pm) till the completion of the seventh day (168 hrs of life)..
3119444|NCT01758068|No Intervention|No Oil Application|Babies in this group were not subjected to oil application. TEWL measurement was recorded every 12 hrs for the first week of life, at the same time as the hour of birth.
3119447|NCT01758029||Testosterone Undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
3119448|NCT01757990|Experimental|Stevioside extract|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the solution containing Stevioside extract. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
3119449|NCT01757990|Experimental|Rebauside extract|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the solution containing Rebaudioside extract. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
3119450|NCT01757990|Sham Comparator|Saccarosio|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
3119451|NCT01757977|Experimental|Vivasight DL|placement and intraoperative use of Vivasight DL double lumen endobronchial tube
3119452|NCT01757977|Active Comparator|standard DLT|placement and intraoperative use of a standard double lumen endotracheal tube.
3119453|NCT01757964|Experimental|Bacteriotherapy|Study stool recipient's will receive approximately 30 grams of processed donor stool through a tube into their stomach for the transplant.
3119454|NCT01757951|Active Comparator|Unimalleolar Fixation|Talocrural joint is stable after fixation of medial malleolus. Patient is randomized to unimalleolar fixation group.
3119455|NCT01757951|Active Comparator|Bimalleolar Fixation|Talocrural joint is stable after fixation of medial malleolus. Patient is randomized to bimalleolar fixation group.
3119456|NCT01757938|Experimental|Shang Ring Guided Circumcision|The Shang Ring (SR) (Wuhu Santa Medical Devices Technology Co Ltd, China) male circumcision performed by study surgeon (study PI). In both study groups, participants were cleaned with povidone iodine solution and draped in a sterile fashion. Local anesthesia was administered to the dorsal penile nerve and penile ring blocks using 3mg/kg of 1% lidocaine. The surgeon measured participants in the SR group to determine ring size. Patients for whom a suitable ring size was not available crossed over to the FG group, but remained in the SR group for intention to treat (ITT) analyses.
3119457|NCT01757938|Active Comparator|Forceps Guided Circumcision|Standard forceps guided adult male circumcision was performed. In both study groups, participants were cleaned with povidone iodine solution and draped in a sterile fashion. Local anesthesia was administered to the dorsal penile nerve and penile ring blocks using 3mg/kg of 1% lidocaine.
3119458|NCT01757925|Experimental|Active Gaming|Participants will receivce a weight management program plus active gaming device
3119459|NCT01757925|Active Comparator|Control Group|Participants will receive a weight management program without active gaming
3119460|NCT01757912|Experimental|Cuff pressure after positioning|The patient will be positioned in 16 distinct body positions. Immediately after correct positioning, the cuff pressure is measured.
3119461|NCT01757899|Active Comparator|Methylprednisolone Arm|"The patients in this arm will receive methylprednisolone, which is available in vials containing 125 mg/2mL after dilution, as it follows:~Day 0 Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day"
3119462|NCT01757899|Placebo Comparator|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc [methylprednisolone + diluting fluid], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
3119463|NCT01757886||ST-elevation acute coronary syndrome|ARTERY is a prospective, multicenter, which will include patients admitted with the diagnosis of ST-elevation acute coronary syndrome and thrombus aspiration is performed during primary angioplasty
3119464|NCT01757873|Experimental|Z160|375 mg BID
3119465|NCT01757873|Placebo Comparator|Placebo|matching placebo control
3119466|NCT01757860|Experimental|CARD-024|CARD-024 oral administered: 3, 9, 27 or 81 mcg.
3119467|NCT01757860|Placebo Comparator|Drug Carrier|Placebo: 20% ethanol:80% propylene glycol solution oral administered.
3119468|NCT01757847|Active Comparator|Brief MOVE-II active control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions to patient with overweight or obesity who have completed the VA San Diego MOVE program.
3119469|NCT01757847|Experimental|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), has been effective in reducing distress, increasing quality of life, and improving other indices of health in a wide range of conditions from depression to diabetes. The ACT protocol for this study focuses on reducing binge eating and distress and improving functioning in individual who are overweight or obese. The protocol focuses on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life. The protocol will be delivered in four 2-hour weekly group sessions to patients with overweight or obesity who have completed the VA San Diego MOVE program.
3119502|NCT01757561||Propofol-Abnormal|patients with preoperative SjvO2<55%,using the TIVA technology with propofol,
3119503|NCT01757561||Propofol-Normal|patients with preoperative SjvO2≥55%,using the TIVA technology with propofol,
3119504|NCT01757561||Sevoflurane-Abnormal|patients with preoperative SjvO2<55%,using the VIMA technology with sevoflurane,
3119470|NCT01757834|Experimental|SWUS Elastography|This is a noninvasive technique using focused ultrasonic beams (pushing beams.) Several pushing beams at increasing depths are transmitted to generate a quasi-plane shear wave frame that propagates throughout the imaging area. After generating the shear wave, an ultrafast imaging sequence is performed to acquire successive raw radiofrequency dots at a very high frame rate (up to 20,000 per second). A tissue elasticity assessment can be derived from shear wave propagation speed. A color-coded image is displayed; softer tissue in blue and stiffer tissue in red. Quantitative information is delivered by drawing regions of interest on the thyroid and surrounding tissues which is the Elasticity Index expressed in kilo-Pascal (kPa). Due to the lack of manual compression and known value of the strength of pushing beam, SWUS gives an objective number to stiffness within the nodule.
3119471|NCT01757821|Experimental|6-Hz Priming|real 6-Hz primed low-frequency rTMS
3119472|NCT01757821|Sham Comparator|Sham 6-Hz Priming|Sham 6-Hz Primed low-frequency rTMS
3119473|NCT01757821|Active Comparator|Real 1-Hz rTMS only|real 1-Hz rTMS only
3119474|NCT01757808|Experimental|Ranolazine|
3119475|NCT01757808|Placebo Comparator|Placebo|
3119476|NCT01757795|Experimental|SP-8203|Active arm
3119477|NCT01757795|Placebo Comparator|Placebo|Matching Placebo
3119478|NCT01757782|Active Comparator|Oral Sildenafil|In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses.
3119479|NCT01757782|Placebo Comparator|Distilled water|In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses.
3119480|NCT01757769|Experimental|Silodosin|Silodosin capsule 8 mg daily for 24 weeks
3119481|NCT01757756|Experimental|Arm Label Pf-05175157, placebo, midazolam|
3119482|NCT01757743||Interventional closure|Interventional catheterization closure
3119483|NCT01757743||Open Heart Surgery|Surgery for Atrial septal defect
3119484|NCT01757730||Altered Stiffness|Tissue stiffness will be evaluated in subjects those with disease conditions where stiffness changes from normal. These studies will be repeated for reproducibility.
3119485|NCT01757730||Healthy Volunteers|Tissue stiffness will be evaluated in normal subjects to determine the normal values. These studies will be repeated for reproducibility.
3119486|NCT01757717|Experimental|Ir-192 high dose rate (HDR)|This pilot study is an investigation into the use of Ir-192 high dose rate (HDR) afterloader-based brachytherapy with catheter placement using image-guided surgical navigation techniques for patients with painful/symptomatic metastatic or recurrent lesions in the spine and/or pelvis that have been maximally treated with external beam radiation therapy.
3119487|NCT01757704|Experimental|Open pleurae & conventional filling of heart|In this group both pleurae will be opened and the ventilator disconnected during cardiopulmonary bypass to ensure bilateral pulmonary collapse. However, after completion of the left heart procedure, the heart will be filled with blood actively from the heart-lung machine and manual de-airing performed in a conventional manner and de-airing monitored by intraoperative trans-esophageal echocardiography (TEE). After de-airing is complete and patient has been weaned off the cardiopulmonary bypass the residual air in the left heart will be quantitatively assessed by TEE and Trans-cranial Echo-Doppler (TCD) over a period of 10 minutes.
3119488|NCT01757704|Experimental|Intact pleurae & staged filling of heart|In this group both pleurae will be left intact and the ventilator disconnected during cardiopulmonary bypass. After completion of the left heart procedure, the heart will be filled with blood actively from the heart-lung machine in a staged manner after adequate cardiac contraction has been established. De-airing will be obtained by active cardiac contraction and staged mechanical ventilation and de-airing monitored by intraoperative trans-esophageal echocardiography (TEE). After de-airing is deemed complete and patient has been weaned off the cardiopulmonary bypass (CPB) the residual air in the left heart will be quantitatively assessed by TEE and Trans-cranial Echo-Doppler (TCD) over a period of 10 minutes.
3119489|NCT01757691|Experimental|Fingolimod 0.5mg/daily|Oral capsule dose was given once daily for 48 weeks
3119490|NCT01757691|Placebo Comparator|Placebo|Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48
3119491|NCT01757678|Other|Standard of care: FFR, ICA, cCTA, FFRct|(ICA) Invasive coronary angiography with (FFR) fractional flow reserve measurement in standard of care environment, and cCTA (computed coronary tomography angiography) and FFRct Analysis (fractional flow reserve computed tomography)
3119492|NCT01757665|Experimental|Bioprosthesis: Aortic Model 11000A/ Mitral Model 11000M|Aortic/Mitral valve replacement therapy
3119493|NCT01757639|Experimental|Treatment (ipilimumab)|"INDUCTION: Patients receive ipilimumab IV on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning 12 weeks after last dose of induction ipilimumab, patients receive ipilimumab IV on day 1. Treatment repeats every 12 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3119494|NCT01757626|Experimental|Hu3F8 with GM-CSF|The phase I single arm trial assesses escalating doses of iv hu3F8 (days 1, 3, 5) in the presence of sc GM-CSF (day -4 through 5). These 3 doses of hu3F8 and 10 days of GM-CSF constitute a treatment cycle. The expansion phase II single arm trial assesses the anti-NB activity of hu3F8+GM-CSF.in 3 groups of patients: Group 1 patients have primary refractory disease (no prior relapse but incomplete response to treatment) in BM as documented by histology and/or 123I-MIBG scan. Group 2 patients are in >2nd CR/VGPR and at high risk for another relapse. Group 3 patients have secondary refractory disease (prior relapse and incomplete response to retrieval therapy) in BM as documented by histology and/or 123I-MIBG scan. Ph II: Groups 1 & 3 pts can continue to get cycles every 1-2 months for up to 24 months from study enrollment or until they receive 4 cycles after CR is achieved.
3119495|NCT01757613|Active Comparator|AK 3012 a for topical use|
3119496|NCT01757613|Active Comparator|AK 3012 b for topical use|
3119497|NCT01757613|Active Comparator|AK 3012 c for topical use|
3119498|NCT01757600||Macular Hole|
3119499|NCT01757587|Active Comparator|Vildagliptin|
3119500|NCT01757587|Placebo Comparator|Placebo|
3119501|NCT01757574|Experimental|Alemtuzumab|Open label study of alemtuzumab
3119505|NCT01757561||Sevoflurane-Normal|patients with preoperative SjvO2≥55%,using the VIMA technology with sevoflurane,
3119506|NCT01757548|Experimental|open operation|high ligation of spermatic vein by open operation
3119507|NCT01757548|Experimental|microsurgery|high ligation of spermatic vein by microsurgery
3119508|NCT01757535|Experimental|Oral Azacitidine|300mg Oral Azacitidine for the first 14 days of each 28 days treatment cycle
3119509|NCT01757535|Placebo Comparator|Placebo|300 mg Placebo for the first 14 days of each 28 days treatment cycle
3119510|NCT01757522||ARDS group|Patients under mechanical ventilation since less than 24 hours at inclusion and presenting acute respiratory distress syndrome criteria.
3119511|NCT01757522||ALI group|Patients under mechanical ventilation and presenting acute lung injury criteria.
3119512|NCT01757522||Control Group|Patients under mechanical ventilation for a non-respiratory cause
3119513|NCT01757509|Other|Intervention group|Participants in this group will receive a set dancing intervention along with their usual care.
3119514|NCT01757509|No Intervention|Control Group|The control group will continue with their usual medical regime, activities of daily living and exercise habits and at the end of the study participants in this group will be offered the set dancing intervention.
3119515|NCT01757496|Experimental|Cough Assist|These children will receive 2 Cough Assist sessions daily.
3119516|NCT01757496|No Intervention|Control group|These children receive standard care but no physiotherapy.
3119517|NCT01757483||Prescribers|
3119518|NCT01757470||Caprelsa Patient|All patients treated with Caprelsa in Canada and participating in the restricted distribution programme.
3119519|NCT01757470||Caprelsa Prescriber|All physicians having prescribed at least one dose of Caprelsa and registered as a certified prescriber of Caprelsa in Canada.
3119520|NCT01757457|Experimental|Intracoronary abciximab|Intracoronary administration of an abciximab bolus during primary PCI
3119521|NCT01757457|Active Comparator|Intravenous abciximab|Intravenous standard administration of an abciximab bolus during primary PCI
3119522|NCT01757444|Experimental|BiPAP - A40|BiPAP with AVAPS AE mode
3119523|NCT01757444|Active Comparator|BiPAP- ST|Patients receiving BiPAP- ST at home
3119524|NCT01757431|Other|ECULIZUMAB|
3119525|NCT01757418|Experimental|Immune Globulin Intravenous|IVIG used in the trial is the GAMUNEX brand, at doses up through 800 mg/kg in Phase 1 and at 400mg/kg in Phase 2.
3119526|NCT01757418|Placebo Comparator|Normal saline|An equivalent volume (weight-based)of normal saline
3119527|NCT01757405|Experimental|≤ 3 doses of 90 µg/kg rFVIIa BI|
3119528|NCT01757405|Experimental|One dose of 270 µg/kg rFVIIa BI|
3119529|NCT01757392|Experimental|Candin® 0.3 mL|Monthly intralesional injections of Candin® 0.3 ml until lesion resolves or up to 6 injections.
3119530|NCT01757379|Experimental|13C-labeled acetate|
3119531|NCT01757379|Experimental|13C-labeled propionate|
3119532|NCT01757379|Experimental|13C-labeled butyrate|
3119533|NCT01757379|Experimental|Inulin|
3119534|NCT01757366|Experimental|experimental|Ginsenoside Rg3 plus First-line Chemotherapy
3119535|NCT01757366|Active Comparator|Active Comparator|First-line Chemotherapy
3119536|NCT01757353|Active Comparator|Self-directed: Information only|Participants in this arm will complete a baseline assessment, followed by a 50-minute brief motivational interview (the Brief Alcohol Screening and Intervention for College Students; BASICS) 10-14 days after the initial assessment. Participants in this arm will complete follow-up assessments at approximately 3 and 9 months.
3119537|NCT01757353|Active Comparator|BASICS motivational interview|Participants in this arm will complete a baseline assessment, immediately after which they will be administered alcohol-related informational sheets. These participants will participate in follow-up assessment sessions at approximately 3 and 9 months.
3119538|NCT01757353|Experimental|BASICS plus normative enhancement motivational interview|Participants in this arm will complete a baseline assessment, followed by a 60-minute brief motivational interview (the Brief Alcohol Screening and Intervention for College Students, with a normative enhancement module) 10-14 days after the initial assessment. Participants in this arm will complete follow-up assessments at approximately 3 and 9 months.
3119539|NCT01757340|No Intervention|Weight maintenance|Weight maintenance with normal protein and leucine intake
3119540|NCT01757340|Active Comparator|Weight loss with normal protein intake|
3119541|NCT01757340|Experimental|Weight loss with leucine supplementation|
3119542|NCT01757327|Experimental|Arm I (erismodegib [LDE225])|400 mg daily and treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
3119543|NCT01757327|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily and treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
3119544|NCT01757314||CA 1 and 2 anethesia residents|palpation technique
3119545|NCT01757314||Ca1 and 2 residents|ultrasound guided technique
3119546|NCT01757301|Active Comparator|Assisted Symptom Management (ASM)|There will be 2 principal components to assisted symptom management (ASM): automated symptom monitoring, along with pain and mood self-management modules.
3119547|NCT01757301|Experimental|Comprehensive Symptom Management (CSM)|"This arm couples ASM with care management by a nurse-physician team, thus testing combined therapy vs. monotherapy (ASM only)."
3119548|NCT01757288|Active Comparator|PACLITAXEL|PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY
3119549|NCT01757288|Experimental|NAB-PACLITAXEL|NAB-PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY
3119550|NCT01757275|Experimental|Esomeprazole|
3119551|NCT01757275|Active Comparator|Cimetidine|
3119552|NCT01757262|Experimental|Ticagrelor|90 mg Ticagrelor
3119553|NCT01757262|Active Comparator|Clopidogrel|75mg Clopidogrel
3119554|NCT01757249|Experimental|Group 1 OCP|Combined oral contraceptive pill (OCP) (Microgynon 30) containing Levonorgestrel/Ethinylestradiol 150/30mcg. Taken orally on a continuous regime for 8 weeks, once a day.
3119555|NCT01757249|No Intervention|Group 2 Control|Control Group - no intervention
3119584|NCT01757015|Experimental|NVA237|NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening.
3119556|NCT01757236|Active Comparator|Treatment A|"IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained).~Patients with only a confirmed Gram-positive infection will continue the study and will receive standard of care antibiotic therapy including oral rifampin (10-15mg/kg every 12 hours) combined with either oral clindamycin (600 mg every 8 hours) or oral sulfamethoxazole and trimethoprim (800/160 mg every 8 hours) or oral fluoroquinolone (Ofloxacin 200 mg every 12 hours). The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks."
3119557|NCT01757236|Experimental|Treatment B|"IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained).~Patients with only a confirmed Gram-positive infection will continue the study and will receive oral linezolid (600mg every 12 hours) combined with oral rifampin (10-15mg/kg every 12 hours).~The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks."
3119558|NCT01757236|Experimental|Treatment C|IV linezolid (600 mg every 12 hours)and IV ceftriaxone (2g daily) until Day 2. Oral or IV rifampin (10-15 mg/kg every 12 hours) will be added 48 hours after initiating the study treatment. Treatment with the study drug will continue until Day 2 to 7 (until the susceptibility test results are obtained). Patients with only a confirmed Gram-positive infection will continue the study. Treatment with ceftriaxone will be discontinued and the patient will switch to oral linezolid and oral rifampin. The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 4 weeks.
3119559|NCT01757223|Experimental|Part A, Group 1 - 10^8 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^8 particle units.
3119560|NCT01757223|Experimental|Part A, Group 2 - 10^9 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^9 particle units.
3119561|NCT01757223|Experimental|Part A, Group 3 - 10^10 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^10 particle units.
3119562|NCT01757223|Experimental|Part B, Group 1 - AdVEGF-All6A+|Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 1 will receive AdVEGF-All6A+ at the highest tolerable dose determined in Part A.
3119563|NCT01757223|Experimental|Part B, Group 2 - AdNull placebo|Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 2 will receive AdNull, the placebo vector.
3119564|NCT01757197|Experimental|All Patients|Toclizumab will be administered on Day 0. The administration of tocilizumab will be every 2 weeks for a total of 8 doses.
3119565|NCT01757184|Experimental|SBC-102 [sebelipase alfa]|Every other week IV infusions of SBC-102
3119566|NCT01757184|Placebo Comparator|Placebo|Every other week infusions of placebo
3119567|NCT01757171|Experimental|Arm A (taxane naïve)|No prior Taxane treatment. Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks
3119568|NCT01757171|Experimental|Arm B (prior taxane therapy)|Subject previously treated with taxane. Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks
3119569|NCT01757158|Experimental|Cs-131 brachytherapy seeds|sub-lobar resection plus cesium-131 brachytherapy
3119570|NCT01757145|Experimental|Eltrombopag|"Eltrombopag will be given orally as a single daily dose. From day +1 after cord blood transplantation, start eltrombopag 100 mg/d. If primary end point not reached on day +14,then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d (maximal dose). If dose not tolerated, return to last tolerated dose.~Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets.~In case of decline of platelet count < 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks.~After 4 weeks we will re-attempt to hold the drug."
3119571|NCT01757132|Other|Implantable Miniature Telescope|Post approval study
3119572|NCT01757119|Experimental|Drug|
3119573|NCT01757106|Experimental|Drug: Xenon|gaseous anesthetic, dosage: 50-60% (v/v) in oxygen, continuous application during surgery
3119574|NCT01757106|Active Comparator|Drug: Sevoflurane|inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application during surgery
3119575|NCT01757093|Experimental|Automatic tube compensation plus CPAP|The patients is going to undergo trials of spontaneous breathing with automatic tube compensation plus continuous positive airway pressure and later a trial with continuous positive airway pressure. During 30 minutes.
3119576|NCT01757093|Active Comparator|Continuous Positive Airway Pressure|The patients is going to undergo a trial of spontaneous breathing with continuous positive airway pressure and later with automatic tube compensation plus continuous positive airway pressure, during 30 minutes each.
3119577|NCT01757080|Experimental|Diabetic-hypertensive elderly|Biochemical analysis and Cardiorespiratory performance assessment with ergospirometry test
3119578|NCT01757080|Active Comparator|Hypertensive elderly|Biochemical analysis and Cardiorespiratory performance assessment with ergospirometry test
3119579|NCT01757067|Active Comparator|ablation procedure vs medical therapy|PVC ablation vs medical therapy
3119580|NCT01757067|No Intervention|Compare 2 arms for safety, symptoms|Compare control of PVC's between 2 groups.
3119581|NCT01757054|Experimental|Probiotic group|
3119582|NCT01757054|No Intervention|Control group|This is a non-supplemented control group that will follow the same dietary and medication restrictions. The purpose of this group is to ensure results are due to supplementation and not due to random dietary exposure.
3119583|NCT01757015|Placebo Comparator|Placebo|Placebo to NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening
3119720|NCT01756118|Experimental|BEZ235|
3120859|NCT01748344|Experimental|Experimental 1|High dose ONO-4053
3119585|NCT01757002|Experimental|Tailored asthma management program|Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.
3119586|NCT01757002|Active Comparator|Control|Teens in the control group will receive generic, web-based asthma education.
3119587|NCT01756989|Experimental|Thalidomide, etoposide, celecoxib|Single arm study,phase II
3119588|NCT01756976||Investigational Device|The 510k cleared OrthoPAT Advance will be used in this standard of care arm.
3119589|NCT01756976||Control Group|The commercially available OrthoPAT will be used in this arm. This is an observational trial and there is no intervention.
3119590|NCT01756963||IBD-SL cohort|
3119591|NCT01756950|Experimental|Cohort 1 - CR8020|2 mg/kg CR8020
3119592|NCT01756950|Placebo Comparator|Cohort 1 - Placebo|5% dextrose in water
3119593|NCT01756950|Experimental|Cohort 2 - CR8020|5 mg/kg CR8020
3119594|NCT01756950|Placebo Comparator|Cohort 2 - Placebo|5% dextrose in water
3119595|NCT01756950|Experimental|Cohort 3 - CR8020|15 mg/kg CR8020
3119596|NCT01756950|Placebo Comparator|Cohort 3 - Placebo|5% dextrose in water
3119597|NCT01756950|Experimental|Cohort 4 - CR8020|30 mg/kg CR8020
3119598|NCT01756950|Placebo Comparator|Cohort 4 - Placebo|5% dextrose in water
3119599|NCT01756950|Experimental|Cohort 5 - CR8020|50 mg/kg CR8020
3119600|NCT01756950|Placebo Comparator|Cohort 5 - Placebo|5% dextrose in water
3119601|NCT01756950|Experimental|Cohort 6 - CR8020|30 mg/kg CR8020
3119602|NCT01756950|Placebo Comparator|Cohort 6 - Placebo|5% dextrose in water
3119603|NCT01756937|Active Comparator|Imotun|300.03mg/cap,orally, 1 capsule once daily for 24 weeks
3119604|NCT01756937|Placebo Comparator|Placebo|1 capsule once daily for 24 weeks
3119605|NCT01756924|Experimental|CEM-102 plus Rifampin|
3119606|NCT01756924|Active Comparator|Standard of Care|
3119607|NCT01756911|Experimental|Thotaco-abdominal aneurysm|MFM
3119608|NCT01756898|Experimental|Low dose ASB17061|Oral administration of low dose ASB17061 taken once daily for 28 consecutive days.
3119609|NCT01756898|Experimental|Middle dose ASB17061|Oral administration of middle dose ASB17061 taken once daily for 28 consecutive days.
3119610|NCT01756898|Experimental|High dose ASB17061|Oral administration of high dose ASB17061 taken once daily for 28 consecutive days.
3119611|NCT01756898|Placebo Comparator|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
3119612|NCT01756885|Active Comparator|Standard Varenicline Treatment|"12 weeks of active varenicline + 12 weeks of placebo + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Days 85-168: Placebo - 1.0mg twice daily orally"
3119613|NCT01756885|Experimental|Extended Varenicline Treatment|"24 weeks of active varenicline + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-168: 1.0mg twice daily orally"
3119614|NCT01756872||Ovarian reserve study participants|Measurements of ovarian reserve for women attending the Oxford Fertility Unit having their first IVF/IVF-ICSI cycle.
3119615|NCT01756859||Patients with HVPG measurements|Patients having HVPG measurements for clinical reasons will be recruited to undergo research MRI scan.
3119616|NCT01756846|Other|usual care|Daily practice of the cardiologist or attending emergency doctor, in order to diagnose a patient with chest pain. In this period attending doctors assess the risk of a patient with chest pain, based on his/hers experience and various criteria (for example described in European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, without a formal risk score).
3119617|NCT01756846|Other|use of HEART risk score|see intervention
3119618|NCT01756833|Active Comparator|Doxycycline|100 mg capsules, twice a day, for a period of two years.
3119619|NCT01756833|Placebo Comparator|Placebo|100 mg capsules, twice a day, for a period of two years.
3119620|NCT01756820|Active Comparator|Single-portal Endoscopic Carpal Tunnel Release (Microaire®)|Single-portal Endoscopic Carpal Tunnel Release (Microaire®) will be used, according to the endoscopic technique described by Agee at al.
3119621|NCT01756820|Active Comparator|Knifelight®|A mini-open technique will be performed, using the Knifelight® (Stryker).
3119622|NCT01756807|Experimental|The Combo Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
3119623|NCT01756794|Other|Transplantation of alcoholic hepatitis|Patients of this arm will be selected for early liver transplantation for severe alcoholic hepatitis not responding to medical therapy. Selection process will be based on a specific algorithm and follow-up time will be 2 years
3119624|NCT01756794|Other|Transplantation for alcoholic cirrhosis|Patients of this arm will be selected for liver transplantation for alcoholic cirrhosis using an abstinence period of 6 months. Outcome of these patients will be compared to that of patients transplanted for severe alcoholic hepatitis.
3119625|NCT01756781|Experimental|Sequence 1|Subjects randomized to Sequence 1 will receive Treatment A followed by Treatment B. Treatment A is a single 2 mg oral dose of midazolam alone. Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991 and a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
3119626|NCT01756781|Experimental|Sequence 2|Subjects randomized to Sequence 2 will receive Treatment B followed by Treatment A with a washout of no less than 14 days in between.Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991 and a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose. There will be a minimum washout of 14 days prior to beginning Treatment A. Treatment A is a single 2 mg oral dose of midazolam alone.
3119627|NCT01756768|Experimental|Radio-labeled Dose Arm|
3119628|NCT01756755|No Intervention|Control|Treat with severe sepsis / septic shock practice guideline
3135435|NCT01651026||rectal cancer|
3119629|NCT01756755|Experimental|PMX HP|Treat with severe sepsis / septic shock practice guideline Treat with PMX-20R Hemoperfusion [Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood].
3119630|NCT01756742|Experimental|Respiratory physiotherapy|54 people according to the inclusion criteria were recruited to have a respiratory physiotherapy treatment added to their medical intervention.
3119631|NCT01756742|Placebo Comparator|Conservative treatment|49 people were recruited in this group. These participants received conservative medical treatment intervention
3119632|NCT01756729|Active Comparator|Best Standard of Care|Patients recruited to the BSC group will be treated according to the BSC practiced at each center.
3119633|NCT01756729|Experimental|NovoTTF-100A (monotherapy)|Patients will be treated continuously with the NovoTTF-100A device. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
3119634|NCT01756716|Experimental|MT-3995 Low group|
3119635|NCT01756716|Experimental|MT-3995 High group|
3119636|NCT01756716|Placebo Comparator|Placebo group|
3119637|NCT01756703|Experimental|MT-3995 Low group|
3119638|NCT01756703|Experimental|MT-3995 High group|
3119639|NCT01756703|Placebo Comparator|Placebo group|
3119640|NCT01756664|Placebo Comparator|Control|Vaseline has been used on the first day after laser treatment
3119641|NCT01756664|Active Comparator|Sunscreen|Sunscreen has been used on the first day after laser treatment
3119642|NCT01756651|Experimental|Intranasal Fentanyl 100mcg|fentanyl pectin nasal spray 100mcg
3119643|NCT01756651|Experimental|Intranasal Fentanyl 200mcg|fentanyl pectin nasal spray 200mcg
3119644|NCT01756638|Experimental|Abiraterone plus Prednisolone|Abiraterone 1000 milligram (mg) oral tablets will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
3119645|NCT01756625||First line WT KRAS mCRC|
3119646|NCT01756612||Chronic Kidney Disease Participants|Participants for whom the treating physician has decided to initiate treatment with MIRCERA for medical reasons prior to study start, will be observed for 9 months.
3119647|NCT01756599|Experimental|leukaemia during childhood or adolescence|
3119648|NCT01756586|Active Comparator|Control|Plain bupivacaine
3119649|NCT01756586|Experimental|Experimental|Bupivacaine with Dexamethasone
3119650|NCT01756573|Active Comparator|Bupivacaine|Control
3119651|NCT01756573|Experimental|Bupivacaine with Dexamethasone|Dexamethasone will be mixed with bupivacaine
3119652|NCT01756573|Active Comparator|Intravenous Dexamethasone|Dexamethasone will be given intravenously
3119653|NCT01756560|Active Comparator|control|in this group, plain bupivacaine will be used to block femoral and sciatic nerve
3119654|NCT01756560|Experimental|Dexamethasone|Bupivacaine mixed with dexamethasone will be used to block femoral and sciatic nerve
3119655|NCT01756547|Experimental|Potassium citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age.
3119656|NCT01756547|Placebo Comparator|Placebo|Oral solution 30ml, that contains distilled water and simple syrup, in the same dose like the active treatment 0,3ml/kg/day.
3119657|NCT01756534|No Intervention|CONVENTIONAL HEMOSTASIS|patients for whom conventional surgical procedures (i. e., ligatures and bipolar electrocautery alone) were used to achieve hemostasis
3119658|NCT01756534|Active Comparator|SURGICEL|patients will receive an oxidized cellulose patch (Surgicel®) in addition to conventional surgical procedures (i. e., ligatures and bipolar electrocautery alone)
3119659|NCT01756521|Experimental|Moxifloxacin 400mg|moxifloxacin 400mg
3119660|NCT01756521|Experimental|Moxifloxacin 800mg|moxifloxacin 800mg
3119661|NCT01756521|Placebo Comparator|Placebo(No treatment)|Only drink water
3119662|NCT01756508|Experimental|eculizumab|Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
3119663|NCT01756508|No Intervention|control|No intervention will be applied instead eculizumab infusion
3119664|NCT01756495|Experimental|Losmapimod 7.5 mg|Each subject will receive losmapimod 7.5 mg BID orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
3119665|NCT01756495|Experimental|Losmapimod 20 mg|Each subject will receive losmapimod 20 mg QD orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
3119666|NCT01756495|Active Comparator|Moxifloxacin 400 mg|Each subject will receive moxifloxacin 400 mg orally on Day 5, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
3119667|NCT01756495|Placebo Comparator|Placebo|Each subject will receive losmapimod matched placebo and moxifloxacin placebo orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
3119668|NCT01756482|Experimental|GS-5806|GS-5806, powder for oral solution
3119669|NCT01756482|Placebo Comparator|Sugar powder for oral solution in juice|Sugar powder for oral solution
3119670|NCT01756469|No Intervention|Control|non-alcohol related information about nutrition
3119671|NCT01756469|Active Comparator|Intervention|Behavioral Intervention for Alcohol Use
3119672|NCT01756456|Experimental|rhNGF 10µg/ml|rhNGF 10 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only
3119673|NCT01756456|Experimental|rhNGF 20 µg/ml|rhNGF 20 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only
3119674|NCT01756456|Placebo Comparator|Vehicle|Placebo eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only
3119675|NCT01756443|Active Comparator|Premixed group|Patients will receive sciatic nerve block with premixed 7.5 mls of 2% lidocaine/adrenaline and 7.5 mls of 0.5% bupivacaine followed by an interval of 90 seconds with an injection of same amount of both drugs.
3119676|NCT01756443|Experimental|Sequential Group|Patients will receive a sciatic nerve block with 15 mls of 2% lidocaine/adrenaline followed by an interval of 90 seconds with 15 mls of 0.5% bupivacaine.
3119677|NCT01756430|Experimental|Carvedilol SR 32mg, 64mg|•Carvedilol SR 32mg QD for first 4 weeks and Carvedilol SR 64mg QD for following 4 weeks.
3119678|NCT01756430|Active Comparator|Carvedilol IR 25mg|•Carvedilol IR 25mg QD for first 4 weeks and Carvedilol IR 25mg BID for following 4 weeks.
3119679|NCT01756417|Experimental|Metformin + canagliflozin (JNJ-28431754)|Each volunteer will receive a single dose of metformin on Day 1 followed by canagliflozin (JNJ-28431754) once daily on Days 4 to 7. On Day 8, volunteers will receive a single dose of canagliflozin in combination with a single dose of metformin.
3119680|NCT01756404|Experimental|Cohort 1|Each volunteer will receive a total daily dose of 30 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
3119681|NCT01756404|Experimental|Cohort 2|Each volunteer will receive a total daily dose of 100 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
3119682|NCT01756404|Experimental|Cohort 3|Each volunteer will receive a total daily dose of 300 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
3119683|NCT01756404|Experimental|Cohort 4|Each volunteer will receive a total daily dose of 600 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
3119684|NCT01756404|Experimental|Cohort 5|Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) twice daily (600 mg total daily dose) or placebo (inactive medication) twice daily on Days 1 through 14.
3119685|NCT01756378|Experimental|Muligan mobilization with movement|"Interventions are:~medial glide mobilization with movement lateral glide mobilization with movement rotation mobilization with movement dorsal glide with active knee flexion"
3119686|NCT01756378|Active Comparator|traditional physical therapy program|Infra-red, stretching exercises, strengthening exercises,
3119687|NCT01756365|Experimental|CECA|
3119688|NCT01756352|Experimental|GBM Avastin receiving 18F-FET|Recurrent GBM patients receiving Avastin, imaged twice with 18F-FET PET before and approximately 8 weeks after receiving Avastin
3119689|NCT01756339|Experimental|Solithromycin|Solithromycin 800 mg orally (PO) on Day 1 followed by 400 mg PO daily on Days 2 through 5, followed by placebo on Days 6 and 7
3119690|NCT01756339|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg PO daily on Day 1 through Day 7
3119691|NCT01756326|Experimental|PREOB® Implantation|Each patient will undergo a single administration of PREOB® into the non-union site, under local or loco-regional anesthesia.
3119692|NCT01756326|Active Comparator|Bone Autograft|Each patient will be treated by Bone Autograft according to standard-of-care procedure of the investigating site.
3119693|NCT01756313|Experimental|Laser+Methylaminolevulinat|It's a single arm. Intervention as described in the detailed description.
3119694|NCT01756300|Experimental|Resistant Hypertension|The catheter-based (device: Celsius® ThermoCool® RD) renal denervation will serve to treat resistant hypertension.
3119695|NCT01756287|Experimental|Standardized Chinese ocular exercise|The participants are trained with standardized Chinese ocular exercise which contains accurate positions of acupuncture points and appropriate pressure on the points.
3119696|NCT01756287|Sham Comparator|Nonstandardized ocular exercise|The participants are trained with nonstandardized ocular exercise performed on wrong positions where no acupuncture points at all.
3119697|NCT01756287|No Intervention|Eye closure|The participants are told to close eyes and don't do ocular exercise at all.
3119698|NCT01756274|Experimental|Neonates 'Left-over' Blood Samples|Blood samples used in this study were 'left-over samples'. The blood samples were from heel sticks of neonates, collected (into a tube) and sent to the laboratory. Two left-over samples could be obtained from a single neonate. Laboratory professionals tested the BG concentration using three Bayer Blood Glucose Monitoring Systems (BGMS): Contour® NEXT BGMS, Contour® PLUS BGMS, and Contour® Next EZ BGMS.
3119699|NCT01756261||Group 1|
3119700|NCT01756248||Group 1|
3119701|NCT01756235||Participants with Rheumatoid Arthritis|Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.
3119702|NCT01756222||Bicuspid Aortic Valve Disease Patients|Patients with the diagnosis of BAV disease.
3119703|NCT01756196||Steroid Injection|Reactions associated with spinal steroid injection
3119704|NCT01756183|Experimental|S-1 + Paclitaxel Chemotherapy|"S-1: 60mg twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~Paclitaxel: 150 mg/m2, iv, 3h, at D1"
3119705|NCT01756170|Active Comparator|Arm 2|Patients receive radiotherapy alone as in arm 1.
3119706|NCT01756170|Experimental|Arm 1|Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area.
3119707|NCT01756157|Experimental|SC CINRYZE with rHuPH20 Dose Level 1 followed by Dose Level 2|SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks.
3119708|NCT01756157|Experimental|SC CINRYZE with rHuPH20 Dose Level 2 followed by Dose Level 1|SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks.
3119709|NCT01756144|Active Comparator|Autologous bone grafting|autologous bone of the iliac crest
3119710|NCT01756144|Experimental|rhBMP-2|Inductos, recombinant human bone morphogenetic protein
3119711|NCT01756131|Experimental|Cohort 1|100 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
3119712|NCT01756131|Experimental|Cohort 2|200 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
3119713|NCT01756131|Experimental|Cohort 3|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
3119714|NCT01756131|Experimental|Cohort 4|800 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
3119715|NCT01756131|Experimental|Cohort 5|100 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
3119716|NCT01756131|Experimental|Cohort 6|200 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
3119717|NCT01756131|Experimental|Cohort 7|400 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
3119718|NCT01756131|Experimental|Cohort 8|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
3119719|NCT01756131|Experimental|Cohort 9|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
3119721|NCT01756105|Experimental|treatment by Metformin plus insulin if needed|Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
3119722|NCT01756105|Active Comparator|treatment by insulin|Insulin therapy:If post meal (2 hours after meal) glycaemia is > to 120 mg/dl introduce Insulin rapid acting analog (Humalog*, Novorapid*) before the meal concerned and according to the weight. If weight is < 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is > 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH*, insulatard*) before sleeping : 5U if weight is < 80 kg - 6U if weight is > 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
3119723|NCT01756092|Experimental|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
3119724|NCT01756079|Experimental|PegIFN-2b + RBV+ boceprevir|Participants will receive PegIFN-2b (once weekly, 1.5 µg/kg subcutaneously) + RBV (capsules, orally, weight-based dose from 800-1400 mg/day divided into two daily doses) for 4 weeks and then will receive 44 additional weeks of treatment with PegIFN-2b (once weekly, 1.5 µg/kg subcutaneously) + RBV (capsules, orally, weight-based dose from 800-1400 mg/day divided into two daily doses) + boceprevir (capsules, orally, 800 mg three times per day).
3119725|NCT01756066|Active Comparator|A|Participant has 50% subsidy, i.e. gets a 50% discount off regular price of the program
3119726|NCT01756066|Experimental|B|Participant has 100% subsidy, i.e. program attendance is free
3119727|NCT01756066|Experimental|C|Participant has 80% subsidy; i.e. gets 80% discount off regular price of the program
3119728|NCT01756066|Experimental|D|Participant has 50% subsidy up front (i.e. pays 50%), with possibility for 100% subsidy based on attaining monthly participation goals
3119729|NCT01756053|Active Comparator|ABT-089|"During both 10-day study medication periods (Days 1-10 & Days 32-41), subjects will take 4 capsules daily. Administration of study medication will be double-blind and in counter-balanced order.~Those randomized to active ABT-089 during study medication period 1 will take four 10mg capsules daily (40mg daily) during the 10-day medication period. During study medication period 2, these subjects will take four capsules of the matched placebo capsules."
3119730|NCT01756053|Placebo Comparator|Placebo|"These are matched placebo capsules manufactured by the study drug supplier.~During both 10-day study medication periods (Days 1-10 & Days 32-41), subjects will take 4 capsules daily. Administration of study medication will be double-blind and in counter-balanced order.~Those randomized to matched placebo during study medication period 1 will take four capsules daily during the 10-day medication period. During study medication period 2, these subjects will take four 10mg capsules (40mg daily) of the active ABT-089 capsules."
3119731|NCT01756040|Other|Lactulose - rhamnose solution|Preterm Infants age 24-32 weeks gestation
3119732|NCT01756027|Active Comparator|Group A|Ulthera System providing one treatment per cheek
3119733|NCT01756027|Active Comparator|Group B|Ulthera System providing two treatments per cheek
3119734|NCT01756014||Controls|Age matched healthy subjects
3119735|NCT01756014||Mild DCM|Heart failure patients with dilated cardiomyopathy (DCM) with NYHA-functional class II
3119736|NCT01756014||Severe DCM|Heart failure patients with dilated cardiomyopathy (DCM) with NYHA-functional class III/IV
3119737|NCT01756001||Control Arm|Arm 1 will be the Control arm, in which subjects will be instructed to use the GlowCap for their chronic disease medication but will not be provided with any specific incentive for taking the medication or with any aid in remembering to do so.
3119738|NCT01756001||Reminder Arm|Arm 2 will be the Reminder arm with daily email, text message, or phone call reminders for intervention. Subjects will be told that to aid in daily adherence to the medication, they will be provided with reminders for the first three months of the study and possibly again later in the study. At the start of the study, subjects will be given the option to receive daily email reminders, text message reminders, or daily (automated) phone call reminders to take their pill, each at a time of day that they choose. The default setting will be for subjects to receive both text and email reminders at 8AM each day. Subjects will be instructed on how to change their settings if they would like to receive a different set of reminders at different points in time.
3119739|NCT01756001||Incentives Arm|Arm 3 will be the financial incentives arm, in which subjects will be paid for adherence. Their total earnings will be administered at the end of the experiment through the WTH platform.
3119740|NCT01756001||Incentives and Reminders Arm|Arm 4 will be the financial incentives and reminders arm, in which subjects will be paid for adherence. Their total earnings will be administered at the end of the experiment through the WTH platform. They will also receive daily email, text message, or phone call reminders for intervention. Subjects will be told that to aid in daily adherence to the medication, they will be provided with reminders for the first three months of the study and possibly again later in the study. At the start of the study, subjects will be given the option to receive daily email reminders, text message reminders, or daily (automated) phone call reminders to take their pill, each at a time of day that they choose. The default setting will be for subjects to receive both text and email reminders at 8AM each day. Subjects will be instructed on how to change their settings if they would like to receive a different set of reminders at different points in time.
3119741|NCT01755988|No Intervention|Usual care|
3119742|NCT01755988|Experimental|Educational website.|Educational website (in addition to usual care).
3119743|NCT01755988|Experimental|Website and interactive platform with telemonitoring.|Adjusted care pathway, including both the educational website and an interactive web-based platform with telemonitoring facilities. In this arm all routine consultations with heart failure nurses and general practitioner will be substituted by this combination of telemonitoring facilities connected to an interactive web-based platform plus the Dutch version of the European Society of Cardiology (ESC) website on heart failure.
3119785|NCT01755728|Active Comparator|Ibuprofen|If there is a PDA, that should be treated, and the infant is less than 2 weeks of age, we use ibuprofen, as this is the gold standard in literature.
3119834|NCT01755481|Experimental|Whey protein concentrate|Whey protein concentrate in an infant formula
3119916|NCT01754896|Experimental|Pick-up/Mail-back|Mailed invitation to pick up lab requisition and then kit. Mailing completed kits in for processing.
3119951|NCT01754675|Placebo Comparator|Movie|Watching a movie at the time that the favorite team is playing
3119744|NCT01755975|Experimental|Romidepsin and Lenalidomide|This will be a multicentered, open label, phase Ib/IIa trial of romidepsin and lenalidomide in patients with relapsed or refractory lymphomas or multiple myeloma. Lenalidomide will be provided in accordance with the Celgene Corporation's Revlimid REMS® program. Per standard Revlimid REMS® program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, and all research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the Revlimid REMS® program. Only enough lenalidomide for one cycle of therapy will be supplied to the patient each cycle.
3119745|NCT01755962|Experimental|Low Glycemic Load + Resistance Training|12-week intervention diet + resistance training (1 hour, 3 times per week)
3119746|NCT01755962|Experimental|High Glycemic Load + Resistance Training|12-week control diet + resistance training (1 hour, 3 times per week)
3119747|NCT01755962|Experimental|Low Glycemic Load|12-week intervention diet
3119748|NCT01755962|Other|High Glycemic Load|12-week control diet
3119749|NCT01755949|Active Comparator|Chronic atrial fibrillation, colchicine|Colchicine 0.6 mg PO BID
3119750|NCT01755949|Placebo Comparator|Chronic atrial fibrillation, placebo|Matching lacebo
3119751|NCT01755949|Active Comparator|Pre-ablation, sinus rhythm, colchicine|Colchicine 0.6 mg PO BID
3119752|NCT01755949|Placebo Comparator|Pre-ablation, sinus rhythm, placebo|Matching placebo
3119753|NCT01755949|Active Comparator|Pre-ablation, AF, colchicine|Colchicine 0.6 mg PO BID
3119754|NCT01755949|Placebo Comparator|Pre-ablation, AF, placebo|Matching placebo
3119755|NCT01755936||Controls|Patients will undergo cardiac magnetic resonance imaging, echocardiography and 72 hour holter monitoring
3119756|NCT01755936||Aortic Stenosis patients|All patients who agreed to study will undergo cardiac magnetic resonance imaging, echocardiography and 72 hour holter monitoring
3119757|NCT01755923|Experimental|Gefitinib|Gefitinib (Iressa) 250mg once per day until progression disease or intolerant side effects
3119758|NCT01755923|Active Comparator|Docetaxel|Docetaxel 75mg/m2,d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
3119759|NCT01755910||Left thoaracic paravertebral block|Surgery in the left breast under left thoracic paravertebral block and HRV
3119760|NCT01755910||Right thoracic paravertebral block and HRV|Surgery in the right breast under right thoracic paravertebral block and HRV
3119761|NCT01755897|Experimental|Adjuvant Chemotherapy (Arm A)|Paclitaxel (T): 135-175 mg/m(2) intravenously (IV) on day 1, administrated intravenously over 3 hours; followed by cisplatin 75-85 mg/m(2) IV on day 2 and 3. Patients received at least 3 cycles at 4-week intervals beginning 2-3 weeks after surgery. 3-6 cycles as necessary.
3119762|NCT01755897|Active Comparator|Concurrent radiochemotherapy, CCRT (Arm B)|Pelvic RT is delivered using IMRT technique, 45～50.4 Gy/4～7 weeks, brachytherapy will been given as necessary. Cisplatin 35 mg/m(2) IV once a week. Total treatment time is 6-7 weeks.
3119763|NCT01755884|Experimental|Wheat oral immunotherapy|Well-cooked wheat spaghetti is given daily to the patients starting from a minimal dosage (0,0003 g of wheat protein) and increasing the dosing in every 1-2 weeks until a dosage corresponding the size of one meal.
3119764|NCT01755871|Experimental|Fingolimod|Gilenya 0,5mg per day, oral
3119765|NCT01755858|Experimental|Bendavia|Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.
3119766|NCT01755858|Placebo Comparator|Placebo|Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.
3119767|NCT01755845|Experimental|Arm 1|Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area. After completion of chemoradiotherapy, patients receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
3119768|NCT01755845|Active Comparator|Arm 2|Patients receive chemoradiotherapy as in arm 1.
3119769|NCT01755832||Pool exercise group|Patients with inflammatory rheumatic disease
3119770|NCT01755819|Other|Biocomposite interference screw|Thirty patients treated with ACL reconstruction and graft fixation is performed using Biocomposite interference screw on tibial and femoral side. Patients are randomized to one of the two study arms.
3119771|NCT01755819|Other|Extracortical ACL Tightrope fixation|Thirty patients treated with ACL reconstruction and graft fixation is performed using extracortical ACL Tightrope fixation on tibial and femoral side. Patients are randomized to one of the two study arms.
3119772|NCT01755806||aortic root dimension change|those without aortic valve calcification
3119773|NCT01755806||aortic root dimension change, aortic valve calcium score|those with aortic valve calcification
3119774|NCT01755780||Left interscalene block|Left interscalene block on hypotension and bradycardia during beach chair positioning
3119775|NCT01755780||Right interscalene block|Right interscalene block on hypotension and bradycardia during beach chair positioning
3119776|NCT01755767|Experimental|Tivantinib 240 mg BID Cohort|The tivantinib dosage of 240 mg tablets administered by mouth twice daily (BID), once in the morning and once in the evening, with food, for a total daily dose of 480 mg.
3119777|NCT01755767|Experimental|Tivantinib 120 mg BID Cohort|Tivantinib 120 mg is administered by oral tablet BID, once in the morning and once in the evening, with food, for a total daily dose of 240 mg (amended dosing group; primary analysis group).
3119778|NCT01755767|Placebo Comparator|Placebo Matching 240 mg BID Cohort|Matching placebo is administered by oral tablet(s) BID, once in the morning and once in the evening, with food.
3119779|NCT01755767|Placebo Comparator|Placebo Matching 120 mg BID Cohort|Matching placebo is administered by oral tablet(s) BID, once in the morning and once in the evening, with food.
3119780|NCT01755754|Experimental|Silicone Elastomer Vaginal Ring|Silicone Elastomer Vaginal Ring
3119781|NCT01755754|Experimental|Female Condom|This trial will test the performance of female condoms when used concurrently with a placebo vaginal ring
3119782|NCT01755741|Experimental|Placebo Vaginal Ring|Placebo vaginal ring with condom use
3119783|NCT01755741|Other|Condom|Male condoms during vaginal intercourse in presence and absence of the vaginal ring.
3119784|NCT01755728|No Intervention|No known PDA|For all infants, we do echo cardiogram study only if they are suspected of having PDA, due to sings and symptoms. Hence, we do not do echo cardiogram study to most of the infants.
3119786|NCT01755728|Active Comparator|Surgical closure of PDA|Infants with symptomatic PDA, who had to be treated, but could not be treated by ibuprofen, either due to age (> 2 weeks) or due ibuprofen contraindications (thrombocytopenia or renal failure), whose could not be treated by paracetamol (either because of parents' refuse or because they were on nothing per os protocol due to other disease), for whom surgery was the treatment of choice to close the arterial duct.
3119787|NCT01755728|Experimental|Paracetamol|Infants with symptomatic PDA who could not be treated with ibuprofen, and their parents agreed and they could be treated with paracetamol.
3119788|NCT01755728|No Intervention|DA closed spontaneously|Infants with PDA, who did not get any treatment for it, and the duct was closed spontaneously.
3119789|NCT01755715|No Intervention|Control group|Insertion of IUD at 2-4 weeks after abortion.
3119790|NCT01755715|Experimental|Immediate IUD insertion|Insertion of IUD immediately (at the same day to 3 days) after expulsion of placenta.
3119791|NCT01755702|Placebo Comparator|Arm 1|Placebo
3119792|NCT01755702|Active Comparator|Arm 2|paracetamol marketed forumulation
3119793|NCT01755702|Active Comparator|Arm 3|ibuprofen marketed formulation
3119794|NCT01755702|Experimental|Arm 4|experimental paracetamol + caffeine formulation
3119795|NCT01755689|Experimental|Nimenrix+Cervarix (1,2,7-Month) Group|Subjects in this group received 1 dose of Nimenrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 1, Month 2 and Month 7. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
3119796|NCT01755689|Experimental|Nimenrix+Cervarix (0,1,6-Month) Group|Subjects in this group received 1 dose of Nimenrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
3119797|NCT01755689|Experimental|Cervarix Group|Subjects in this group received 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6, administered intramuscularly (IM) in the deltoid region of the arm.
3119798|NCT01755689|Experimental|Nimenrix+Cervarix+Boostrix Group|Subjects in this group received 1 dose each of Nimenrix and Boostrix vaccines at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. All vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
3119799|NCT01755689|Experimental|Boostrix+Cervarix Group|Subjects in this group received 1 dose of Boostrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
3119800|NCT01755676|Experimental|Orlistat 60 mg|
3119801|NCT01755676|Placebo Comparator|Placebo|
3119802|NCT01755663|Experimental|Ivabradine|Patients will recieved ivabradine(5) 1 tab bid pc for 3 day and the day of CT, and recieve placebo of metoprolol
3119803|NCT01755663|Active Comparator|metoprolol|Metoprolol (100) 1/2 tab bid pc for 3 day and the day of CT coronary , and placebo of ivabradine
3119804|NCT01755650|Experimental|D-18F FPM|
3119805|NCT01755650|Experimental|L-18F FPM|
3119806|NCT01755637|Experimental|Albendazole tablet (Aqua Based)|Albendazole tablets 400 milligram (mg) manufactured under aqua based solvent condition taken orally with 200 millilitre (mL) of water as single dose treatment.
3119807|NCT01755637|Active Comparator|Albendazole tablet (Alcohol Based)|Albendazole tablets 400 mg manufactured under ethanol based solvent condition taken orally with 200 mL of water as single dose treatment.
3119808|NCT01755624|Experimental|NovoTTF-100A device|Patients will be treated continuously with the NovoTTF-100A device. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
3119809|NCT01755624|Active Comparator|Best Standard of Care|Patients will be treated as the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain.
3119810|NCT01755611|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3119811|NCT01755611|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3119812|NCT01755598|Experimental|Vaccine group|Subjects will receive 2 doses of the candidate tuberculosis vaccine (Day 0 and Day 30).
3119813|NCT01755598|Placebo Comparator|Control group|Subjects will receive 2 doses of placebo (Day 0 and Day 30).
3119814|NCT01755585||C/T-RT group|Chemotherapy (C/T) is applied in the morning. After 2-4 hrs, radiotherapy (RT) is delivered (according to the clinical practice)
3119815|NCT01755585||RT-C/T group|Radiotherapy (RT) is delivered in the morning. After 2-4 hrs, chemotherapy (C/T) is applied (according to the clinical practice).
3119816|NCT01755572|Experimental|Liraglutide|Liraglutide 0.6mg for 7 days, liraglutide 1.2mg for 7 days, liraglutide 1.8mg for 7 days
3119817|NCT01755572|Placebo Comparator|Placebo|Placebo 0.6mg sc for 3 weeks, Placebo 1.2mg sc for 3 weeks, Placebo 1.8mg for 3 weeks.
3119818|NCT01755559|Other|Artesunate-amodiaquine|Efficacy estimates at 95%
3119819|NCT01755559|Other|Dihydroartemisinin-piperaquine|Efficacy estimates at 95%
3119820|NCT01755559|Other|Artemether-lumefantrine|Efficacy estimates at 95%
3119821|NCT01755546|Experimental|EN3409|Buprenorphine HCI Buccal File at doses ranging from 300-900 mcg twice daily
3119822|NCT01755533|Experimental|Rural curriculum|Receive rural version of curriculum
3119823|NCT01755533|Experimental|Classic curriculum|Receive classic version of curriculum
3119824|NCT01755533|No Intervention|Control|Continue normal prevention activities
3119825|NCT01755520|Experimental|Ticagrelor|Intervention: Drug: Ticagrelor verum + Aspirin placebo
3119826|NCT01755520|Active Comparator|Aspirin|Intervention: Drug: Aspirin verum + Ticagrelor placebo
3119827|NCT01755507|Experimental|B|norUDCA
3119828|NCT01755507|Experimental|C|norUDCA
3119829|NCT01755507|Placebo Comparator|placebo|Placebo
3119830|NCT01755507|Experimental|A|norUDCA
3119831|NCT01755494|Experimental|Lower dose|co-administration of a single oral dose of a 5 mg saxagliptin tablet and a 500 mg metformin XR (Glucophage XR®) tablet vs. single FDC tablet consisting of 5 mg saxagliptin and 500 mg metformin XR (Kombiglyze XR)
3119832|NCT01755494|Experimental|Higher dose|co-administration of a single oral dose of a 5 mg saxagliptin tablet and two (2) 500 mg metformin XR (Glucophage XR®) tablets vs. Single FDC tablet consisting of 5 mg saxagliptin and 1000 mg metformin XR (Kombiglyze XR)
3119833|NCT01755481|Experimental|Probiotics F19|F19 in an infant formula
3119835|NCT01755468|Active Comparator|Continuous metformin|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy. Metformin will be initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months).
3119836|NCT01755468|Experimental|Intermittent insulin therapy|After a 3-week course of intensive insulin therapy, participants will receive intermittent intensive insulin therapy for 2 weeks every 3 months. The 2-week course of insulin therapy will be repeated at 3-, 6-, 9-, 12-, 15-,18- and 21-months, with final outcome measurement performed at 24-months
3119837|NCT01755455|Active Comparator|Ferrous sulfate 325mg|Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks
3119838|NCT01755455|Placebo Comparator|Placebo|Identical-appearing tablet taken by mouth daily for 6 weeks
3119839|NCT01755442|Active Comparator|AMG 151|
3119840|NCT01755442|Placebo Comparator|Placebo|
3119841|NCT01755416|Placebo Comparator|Closed loop with sensor and Insulin|subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
3119842|NCT01755416|Active Comparator|Closed loop with sensor, Insulin and Liraglutide|Subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner, on Day 1.
3119843|NCT01755403|Other|Benznidazole|
3119844|NCT01755390|Experimental|Cabazitaxel|"IV escalation part:~XRP6258 administered as a 1-hour IV infusion on Days 1, 8, 15 and 22 of each 5-week cycle until evidence of disease progression, unacceptable toxicity or patient's withdrawal.~Oral bioavailability part:~XRP6258 administered at the dose of 8.4 mg/m² as an oral administration on Day 1 Cycle 1 and as a weekly 1-hour i.v. infusion at the subsequent weeks of treatment. Patients receiving oral administration at Day 1, Cycle 1 are to fast for 12 hours before and 4 hours after administration."
3119845|NCT01755377||No Chagas Disease|Participants with no Chagas Disease will be evaluated as a Control Group
3119846|NCT01755377||Chagas Disease|Participants diagnosed with Chagas Disease will be followed-up as a Case Group
3119847|NCT01755364|Experimental|AdimFlu-V|
3119848|NCT01755338|Active Comparator|Methylprednisolone|Methylprednisolone i.v. 15mg/kg x 1 intraoperative Aortic Valve Replacement
3119849|NCT01755338|Placebo Comparator|Placebo (NaCl)|Placebo i.v., x1, intraoperative Aortic Valve Replacement
3119850|NCT01755325|Experimental|Compound realgar natural indigo Tablet|"Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd"
3119851|NCT01755325|Placebo Comparator|placebo|"placebo tablet,65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib 0.4g qd"
3119852|NCT01755312|Experimental|medication reminder|medication reminder
3119853|NCT01755312|Placebo Comparator|Placebo|Placebo
3119854|NCT01755299|Active Comparator|Active ingredient|"Regular 5-hour Energy"
3119855|NCT01755299|Active Comparator|Active ingredient-2|"5-hour Energy Decaf"
3119856|NCT01755299|Active Comparator|Active ingredient-3|Compounded caffeine product 135 mg/2 ounces
3119857|NCT01755299|Placebo Comparator|Placebo|Flavored placebo
3119858|NCT01755286|Experimental|4 mg OTO-201|
3119859|NCT01755286|Experimental|12 mg OTO-201|
3119860|NCT01755286|Placebo Comparator|Vehicle for OTO-201|
3119861|NCT01755286|Sham Comparator|Sham|
3119862|NCT01755273|No Intervention|Standard pancreaticoduodenectomy|Cases receiving pancreaticoduodenectomy with standard enteral bypass
3119863|NCT01755260|No Intervention|oral intake|The patients at this arm were allowed to take food through mouth
3119864|NCT01755247|Placebo Comparator|Topical Gel Vehicle|Once daily application of topical gel vehicle to forehead for 3 days
3119865|NCT01755247|Active Comparator|8% NVN1000 Topical Gel|Once daily application of 8% NVN1000 Topical Gel to the forehead for 3 days
3119866|NCT01755247|Active Comparator|8% NVN1000 Topical Gel and moisturizer|Once daily application of 8% NVN1000 Topical Gel to the forehead, followed 15 minutes later by application of a commercially available moisturizer
3119867|NCT01755234|Active Comparator|Sevoflurane|Sevoflurane administered by inhalation (laryngeal mask airway or endotracheal tube)
3119868|NCT01755234|Active Comparator|Propofol|Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
3119869|NCT01755221|Other|Single-center prospective evaluation of the Restech pH probe|"Restech pH probe placement at initial clinic visit; Subject returns 24 hours later for probe removal~Proton pump inhibitor (PPI) therapy; Subject starts PPI medication (omeprazole 40mg once daily) and returns for follow-up visit 8-12 weeks later~Optional second pH probe placement at follow up visit; Subject returns 24 hours later for probe removal; Subject continues PPI medication for 2 more weeks"
3119870|NCT01755208|Experimental|Diagnostic (light-scattering spectroscopy)|Patients undergo light-scattering spectroscopy of the breast in addition to standard of care as it relates to screening for breast cancer or treatment of breast cancer.
3119871|NCT01755195|Experimental|1|60 mg tablets orally once a day in a 28-day cycle.
3119872|NCT01755182|Active Comparator|Pharmacologic therapy|Patients in this arm receive systemic pharmacologic therapy alone
3119873|NCT01755182|Experimental|TAE and pharmacologic therapy|Patients in this arm receive systemic pharmacologic therapy and TAE
3119874|NCT01755169|Experimental|Ketamine 0.25 mg/kg/dose|A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
3119875|NCT01755169|Experimental|Ketamine 0.5 mg/kg/dose|A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
3119876|NCT01755169|Experimental|Ketamine 1 mg/kg/dose|A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
3119877|NCT01755169|Placebo Comparator|Placebo|
3119878|NCT01755156|Experimental|Omarigliptin (Phase A) → Omarigliptin (Phase B)|Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks. Participants will continue pre-study metformin throughout the duration of the study. If necessary, rescue therapy may be initiated (open-label glimepiride during Phase A and insulin glargine during Phase B).
3120860|NCT01748344|Active Comparator|Cetirizine|10mg Cetirizine
3119879|NCT01755156|Placebo Comparator|Placebo to omarigliptin (Phase A) → Glimepiride (Phase B)|Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks. Participants will continue pre-study metformin throughout the duration of the study. If necessary, rescue therapy may be initiated (open-label glimepiride during Phase A and insulin glargine during Phase B).
3119880|NCT01755143|Experimental|MRI Group|Subjects randomized to the Magnetic Resonance Imaging group will undergo a series of MRI scans at the 9-12 week visit post-implant.
3119881|NCT01755143|Sham Comparator|Control Group|Subjects randomized to the control group will not undergo a series of MRI scans but will come into the study office for a one hour waiting period at the 9-12 week post-implant visit.
3119882|NCT01755130|Experimental|LOUIS-3D Imaging Procedure|"Part I Years 1-4: Years 1-4 to develop and calibrate the LOUIS-3D machine. The subject of this project is to successfully obtain diagnostic imaging of breast tumors with new imaging technology, laser Optoacoustic Tomography system.~Part 2 Year 5: Goal of part 2 to estimate and compare the false positive rate of LOUIS-3D compared to standard of care ultrasound. Patients will have had a positive standard of care ultrasound requiring a biopsy (gold standard). The LOUIS-3D images will be obtained within 7 days of the standard of care ultrasound."
3119883|NCT01755117|Active Comparator|TKR, sciatic, femoral, obturator|TKR surgery under ultrasound guided sciatic nerve block plus femoral nerve block plus obturator nerve block
3119884|NCT01755117|Active Comparator|TKR sciatic nerve block, posterior lumbar plexus block|TKR surgery under ultrasound guided sciatic nerve block plus posterior lumbar plexus block
3119885|NCT01755104|Experimental|Stablor|dietary supplement Stablor
3119886|NCT01755104|Placebo Comparator|Placebo|dietary supplement Placebo
3119887|NCT01755091|Placebo Comparator|Sugar Pill|Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
3119888|NCT01755091|Experimental|2.5 mg/day|Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
3119889|NCT01755091|Experimental|10 mg/day|Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation
3119890|NCT01755078|Experimental|Sevelamer HCl|Sevelamer HCl regular treatment 1-3 tablets TID
3119891|NCT01755078|Active Comparator|Calcium-based binder|Calcium-based phosphate binder (either CaCO3 or Ca acetate) administered 1-3 tablets TID
3119892|NCT01755065||Teenager laparoscopic patients|
3119893|NCT01755039||Patients with invasive out-of-hospital ventilation|
3119894|NCT01755026|Active Comparator|2 gram dose of cefazolin|2 gram dose of pre-operative cefazolin
3119895|NCT01755026|Experimental|4 gram Dose|4 gram dose of pre-operative prophylaxis
3119896|NCT01755013|Experimental|PDT Group|Subjects who receive Photodynamic therapy with plastic optic diffuser.
3119897|NCT01755000|Other|Aim 1: Hemodynamically Healthy Patients|"Nurse 1 will perform an USCOM scan and record values of Vpk and SV on the clinical data sheet.~Nurse 2 will perform the USCOM second scan within five minutes of Nurse 1's scan and record the values of Vpk and SV on the clinical data sheet.~Nurse 1 and 2 will be blinded to each other's scans by using separate clinical data forms"
3119898|NCT01755000|Other|Aim 2: Hemodynamically Unstable Patients|"Nurse 1 will perform an USCOM scan and record values of Vpk and SV on the clinical data sheet.~Nurse 2 will also be notified of the hypotensive event, will then perform the USCOM second scan within five minutes of PI's scan and record the values of Vpk and SV on the clinical data sheet.~The two USCOM scans will be completed within 10 minutes of the hypotensive episode.~Nurse 1 and Nurse 2 will be blinded to each other's scans by using separate clinical data forms."
3119899|NCT01755000|Other|Aim 3: Hemodynamically Unstable Patients + Fluid Bolus|"At the time that an enrolled patient meets one of the following criteria; SBP drops below 95 mmHg or MAP drops below 65 mmHg the PI will be notified to PI to perform the USCOM scan and record the Vpk, SV, systolic blood pressure and mean arterial pressure on the clinical data sheet within 10 minutes of the hypotensive episode, prior to the patient receiving a fluid bolus (fluid bolus is part of standard of care).~The USCOM scan will then be repeated within 5 minutes after fluid bolus delivery.~Before the hemodynamically unstable patient receives subsequent fluid boluses (multiple boluses are common standard of care), the PI will perform an USCOM scan. Then within 5 minutes after the delivered fluid bolus, the PI will perform another USCOM scan. This will continue, until no further boluses are prescribed."
3119900|NCT01754987|Experimental|Ascorbic Acid + Sorafenib|"Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate~Dosage:~Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)"
3119901|NCT01754987|Other|Sorafenib alone|Sorafenib: taken daily (oral)
3119902|NCT01754974|Experimental|Peginterferon Lambda-1a + Ribavirin|Peginterferon Lambda-1a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks
3119903|NCT01754974|Active Comparator|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks
3119904|NCT01754961|Placebo Comparator|Placebo|Placebo will be given on Day 1 orally
3119905|NCT01754961|Active Comparator|Vitamin D|Administration of 500,000 IU Vitamin D orally on Day 1
3119906|NCT01754935|Experimental|VX-509 100 mg qd Arm|
3119907|NCT01754935|Experimental|VX-509 200 mg qd Arm|
3119908|NCT01754935|Experimental|VX-509 300 mg qd Arm|
3119909|NCT01754935|Placebo Comparator|Placebo Arm|
3119910|NCT01754922||Exposed|Veterans deployed to OEF/OIF/OND and environmentally exposed to high levels of particulate matter
3119911|NCT01754922||Control|OEF/OIF/OND Veterans deployed to regions other than Southwest Asia
3119912|NCT01754909|Active Comparator|enalapril|Use of enalapril in subjects undergoing radiotherapy for lung cancer.
3119913|NCT01754909|Placebo Comparator|placebo|Use of placebo in subjects undergoing radiotherapy for lung cancer
3119914|NCT01754896|Experimental|Mail-out/Mail-back|Mailing of FIT kit directly to patient. Mailing completed kits in for processing.
3119915|NCT01754896|Experimental|Mail-out/Drop-off|Mailing of FIT kit directly to patient. Dropping completed kits at lab for processing.
3120861|NCT01748344|Experimental|Experimental 2|Low dose ONO-4053
3119917|NCT01754896|Experimental|Pick-up/Drop-off|Mailed invitation to pick up lab requisition and then kit. Dropping completed kits at lab for processing.
3119918|NCT01754883|Experimental|Lithium Augmentation|Open-label trial - active treatment
3119919|NCT01754870|Experimental|Bendamustine + Rituximab-->Rituximab and Lenalidomide|"Induction chemoimmunotherapy:~Bendamustine 70 mg/m2 IV days 1 & 2 every 28 days X 6 cycles~Rituximab 500 mg/m2 IV day 1 every 28 days X 6 cycles (375 mg/m2 IV cycle 1 only, day 1 or 2)~Maintenance phase:~Rituximab 375 mg/m2 IV on day 1 of every odd-numbered 28 day cycle for a maximum of 12 doses during the maintenance phase.~Lenalidomide 5 mg orally daily on days 1-28 of each 28-day cycle for 24 cycles (maintenance cycles 1-24); dose escalation to 10 mg orally daily will be allowed at the start of cycle 2 or at the start of any subsequent cycle in subjects with acceptable toxicities needed to escalate the dose of lenalidomide to 10 mg/day."
3119920|NCT01754857|Experimental|Bendamustine, rituximab, lenalidomide|"INDUCTION: Bendamustine 90mg/m2 IV D1&2 and rituximab IV D1 (up to day 5 of course 1) every 28 days for 6 cycles. Patients with objective response move to maintenance therapy. Patients with objective response after 4 courses are eligible to for maintenance therapy if ongoing induction therapy is associated w/unacceptable toxicity.~MAINTENANCE: At 6-12 wks post induction therapy, patients receive rituximab IV on day 1 of odd-numbered cycles for 24 cycles; lenalidomide 5mg PO daily on days 1-21 of each cycle (28 day cycles). Dose escalation to 10mg daily on days 1-21 allowed at start of cycle 2 or at start of subsequent cycles in subjects w/acceptable toxicities. Lenalidomide dose escalation only allowed at start of a new cycle up to a max dose of 10 mg/day on days 1- 21. Subjects entering maintenance with CrCl ≥40 & <60mL/min will begin dosing at 5mg every other day on days 1-21. Patients with excessive toxicity from lenalidomide may continue maintenance therapy with rituximab alone."
3119921|NCT01754844|Experimental|Group 1-5, single ascending dose AZD7624|Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo.
3119922|NCT01754844|Placebo Comparator|Placebo|Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo.
3119923|NCT01754831|Other|Fluoride varnish|Topical fluoride
3119924|NCT01754818|Placebo Comparator|Placebo|Placebo, oral capsule, no active study drug, single dose
3119925|NCT01754818|Experimental|Bendavia 10mg|Bendavia, oral capsule, 10mg, single dose
3119926|NCT01754818|Experimental|Bendavia 50mg|Bendavia, oral capsule, 50mg, single dose
3119927|NCT01754818|Experimental|Bendavia 100mg|Bendavia, oral capsule, 100mg, single dose
3119928|NCT01754805|Experimental|ASP015K and methotrexate|
3119929|NCT01754792|Experimental|Normal fasting glucose subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
3119930|NCT01754792|Experimental|Impaired fasting glucose subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
3119931|NCT01754792|Experimental|Diabetic subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
3119932|NCT01754779|Placebo Comparator|Calcium Phosphate stone formers without hypercalciuria|Each subject will undergo 3 phases, the order of which will be randomized by a simple randomization scheme. The 3 phases will be Placebo, Citric Acid, and Potassium Citrate. Each phase will be 1 week in duration, during which subjects will take assigned study medications. A 1-week washout period is imposed between phases.
3119933|NCT01754779|Placebo Comparator|Calcium Phosphate stone formers with hypercalciuria|Each hypercalciuric CaP stone former will undergo 3 phases, the order of which will be randomized by a simple randomization scheme.
3119934|NCT01754766|Experimental|AGN-229666 Dose A|One drop of AGN-229666 Dose A into each eye on Day 1 and Day 15.
3119935|NCT01754766|Experimental|AGN-229666 Dose B|One drop of AGN-229666 Dose B into each eye on Day 1 and Day 15.
3119936|NCT01754766|Placebo Comparator|vehicle of AGN-229666|One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
3119937|NCT01754753|Active Comparator|Telephone friendship groups|"Participants allocated to telephone friendship groups will take part in 12 weekly group telephone discussions. The participant will be called, by a trained Age UK Sheffield volunteer, in their own home. The group discussions will take place for about an hour each week and involve between 6-8 participants. Participants will be introduced to weekly group calls by the volunteer who will call each participant individually for around 20 minutes each week for up to six weeks before the group is established.~The group may have a particular focus or talk about different topics each week. The individual participants are joined together through a teleconferencing system (provided by Community Network)."
3119938|NCT01754753|No Intervention|Usual health and social care|Participants allocated to the control arm will not receive any research intervention. However, they will participate in the research by completing questionnaires about their health and wellbeing.
3119939|NCT01754740|Experimental|Study Group|19 patients whom received topical medication of urea 10%
3119940|NCT01754740|Placebo Comparator|Control Group|19 patients whom received placebo
3119941|NCT01754727||Participants with Ankylosing Spondylitis (AS)|Participants with ankylosing spondylitis treated with adalimumab in routine clinical practice.
3119942|NCT01754714|Experimental|1000 mg SAMe (S-adenosyl-L-methionine)|
3119943|NCT01754714|Experimental|1500 mg SAMe|
3119944|NCT01754714|Experimental|2000 mg SAMe|
3119945|NCT01754714|No Intervention|No treatment|
3119946|NCT01754701|Experimental|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
3119947|NCT01754701|Experimental|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
3119948|NCT01754688||Jaundice infants|Bilirubin Induced Neurologic Dysfunction II score
3119949|NCT01754688||Non-jaundiced infants|Bilirubin Induced Neurologic Dysfunction II score
3119950|NCT01754675|Experimental|Soccer|Watching the soccer match at the time that the favorite team is playing
3119952|NCT01754662|Experimental|Soy protein with isoflavones and cocoa|Soy protein with isoflavones and cocoa bars. 2 bars daily for 8 weeks.
3119953|NCT01754662|Experimental|Soy protein alone with cocoa|Soy protein alone with cocoa with no isoflavones. 2 bars daily for 8 weeks.
3119954|NCT01754662|Experimental|Soy protein with soy isoflavones|Soy protein with isoflavones bar. 2 bars daily for 8 weeks.
3119955|NCT01754662|Experimental|Soy protein alone|Soy protein alone without soy isoflavone or cocoa polyphenol. 2 bars daily for 8 weeks.
3119956|NCT01754662|Placebo Comparator|Placebo|Placebo bar without soy protein, isoflavones or cocoa polyphenols. 2 bars daily for 8 weeks
3119957|NCT01754649|Active Comparator|misoprostol vaginal 200 mcg|The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
3119958|NCT01754649|Placebo Comparator|placebo|The placebo group will receive two doses of placebo vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
3119959|NCT01754636||Elderly patients|patients aged 65 years old or older : no intervention
3119960|NCT01754636||"Young patients"|patients aged 18-64 years (added by amendment n°3 -02/2014) : no intervention
3119961|NCT01754623|Experimental|Chemotherapy Followed by Radiation Treatment|"Gemcitabine, Taxotere, Xeloda (GTX): 21 day cycle x 3 Gemcitabine 750mg/m^2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m^2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m^2 on days 1-14 Radiation: stereotactic body radiation therapy stereotactic body radiation therapy (SBRT).~After radiation, participants will be re-evaluated for surgery."
3119962|NCT01754610||Families participating in SFCR|Families who have experienced multiple traumas and high stress related to poverty
3119963|NCT01754597|Experimental|Peptide Natriurétique de type B|Peptide Natriurétique de type B
3119964|NCT01754571|Experimental|CBT treatment|
3119965|NCT01754558|Experimental|Ajust sling|The sling a a new device for stress urinary incontinence. The sling is ajustable and is not penetrating the skin, i.e. is only attached to the obturator membrane
3119966|NCT01754558|Experimental|TVT/TVT-O, polypropylne slings|TVT/TVT-O system. These two systems is wellknown and used for treatment of stress urinary incontinence. The sling penetrate the skin in order to secure adjustment.
3119967|NCT01754545|Experimental|Octaplas infusion and placebo (group 1)|Active treatment with randomly assigned 400 ml octaplas intravenously 2-3 times a week and 400 ml placebo (for octaplas)intravenously 2-3 times a week over two weeks.
3119968|NCT01754545|Experimental|Octaplas infusion and placebo (group 2)|Active treatment with randomly assigned 400 ml octaplas intravenously once and 400 ml placebo (for octaplas)intravenously twice in two separate intervention weeks
3119969|NCT01754532||Schizophrenia patients|
3119970|NCT01754519|Experimental|Treatment (radiation therapy)|Patients undergo wide local excision breast surgery and SFRT over 60-100 minutes once negative margins are obtained.
3119971|NCT01754506|Experimental|EPA+DHA|EPA+DHA (fish oil)
3119972|NCT01754506|Placebo Comparator|Placebo|mineral oil
3119973|NCT01754493|Experimental|Treatment with Duloxetine|Patients will receive open treatment with Duloxetine
3119974|NCT01754480|Experimental|Fibrin Sealant Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
3119975|NCT01754480|Active Comparator|Surgicel®|Surgicel® is a sterile, absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
3119976|NCT01754467|Experimental|NEAT!|Participants will use the NEAT! smartphone application and accelerometer over a 1 month period.
3119977|NCT01754454|Experimental|Human Umbilical Cord Derived MSC|"Human Umbilical Cord Derived MSC:~Patients who receive standard of care plus treatment with ex vivo cultured adult human Umbilical Cord Derived Mesenchymal Stem Cells"
3119978|NCT01754415|No Intervention|control|Do exercise at home with video program designed by our team.
3119979|NCT01754415|Experimental|hydraulic resistance circuit training|Intervention:12 weeks resistance training
3119980|NCT01754402|Experimental|Cohort 1: benda 120mg + pom 3mg|"Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days~Bendamustine: once intravenous (IV) dosing on day 1, every 28 days~Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
3119981|NCT01754402|Experimental|Cohort 2: benda 120mg + pom 4mg|"Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days~Bendamustine: once intravenous (IV) dosing on day 1, every 28 days~Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
3119982|NCT01754402|Experimental|Expansion|"Pomalidomide 3mg: once daily oral (PO) dosing on days 1-21, every 28 days~Bendamustine 120 mg: once intravenous (IV) dosing on day 1, every 28 days~Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
3119983|NCT01754389|Active Comparator|Arm A (Standard of Care)|Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously on days 1, 3, 6 and 11 post-transplant
3119984|NCT01754389|Experimental|Arm B (Experimental)|Bortezomib intravenously 1, 4 and 7 days post-transplant Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously 1,3,6 and 11 days post-transplant
3119985|NCT01754389|Experimental|Arm C (Experimental)|Bortezomib intravenously 1,4 and 7 days post-transplant Sirolimus, intravenously and orally, Day -3 through 3-6 months post-transplant Tacrolimus, intravenously and orally, Day -3 through 3-6 months post-transplant
3119986|NCT01754376|Experimental|Treatment Arm|"Oral vemurafenib 960 milligrams twice a day plus intravenous aldesleukin 600,000 IU/kg every eight hours to tolerance (maximum 14 doses) over five days on days 15-19 of cycle 1 and on days 1-5 of cycle 2. (A cycle is 28 days)~The first course of treatment will consist of three 28-day cycles (12 weeks): 2 weeks of lead-in vemurafenib plus 3 weeks on IL-2 plus 7 weeks wait.~A second course may be given at the discretion of the investigator, if there is evidence of tumor stability or regression."
3119987|NCT01754363|Experimental|Attune Primary Total Knee Replacement|"Subjects will receive one of the following Attune total knee implants:~Cruciate retaining fixed bearing (CR FB) Cruciate retaining rotating platform (CR RP) Posterior stabilized fixed bearing (PS FB) Posterior stabilized rotating platform (PS RP)"
3119988|NCT01754350|Experimental|ketogenic diet and transient fasting|Calorie-restricted, ketogenic diet and transient fasting during reirradiation
3119989|NCT01754350|Active Comparator|standard nutrition|nutrition according to recommendations of the German society for nutrition during reirradiation
3119990|NCT01754337|Active Comparator|Single-hormone closed-loop system|In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels.
3119991|NCT01754337|Active Comparator|Dual-hormone closed-loop system|In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels.
3119992|NCT01754337|Active Comparator|Insulin pump therapy|Patient's conventional treatment will be implemented.
3119993|NCT01754324||Methadone|All infants requiring pharmacological treatment of their NAS symptoms are treated with a standardized protocol utilizing oral methadone. This treatment protocol has been the standard of care for infants with NAS at our institution for many years. Infants enrolled in this study will have blood samples drawn at predetermined times in order to obtain information regarding the pharmacokinetics of oral methadone in this population.
3119994|NCT01754311||HTLV-1 infected patients|HAM/TSP patients and HTLV-1 Asymtomatic patients
3119995|NCT01754311||control|Blood donors
3119996|NCT01754298|Active Comparator|Retro-articular drilling|Retro-articular drilling goes through the cortical margin of the affected condyle, thereby sparing the articular surface and physes.
3119997|NCT01754298|Active Comparator|Trans-articular drilling|Trans-articular drilling penetrates the articular cartilage through multiple sites to create subchondral penetrations.
3119998|NCT01754285|Experimental|LF-PB 10 mg|2 IM injections = placebo + 10 mg
3119999|NCT01754285|Experimental|LF-PB 20 mg|2 IM injections = placebo + 20 mg
3120000|NCT01754285|Experimental|LF-PB 30 mg|2 IM injections = 10 mg + 20 mg
3120001|NCT01754285|Placebo Comparator|Placebo|2 IM injections of placebo
3120002|NCT01754272||FOLFIRI + Aflibercept|Non-interventional study. No drugs administered. In this arm 612 patients from the VELOUR trial
3120003|NCT01754272||FOLFIRI + Placebo|Non-interventional study. 614 patients from the FOLFIRI + placebo arm in the VELOUR trial.
3120004|NCT01754259|Experimental|Ranolazine|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
3120005|NCT01754259|Placebo Comparator|Placebo|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
3120006|NCT01754246|Experimental|Alexandrite Laser for Skin Toning|755 nm Alexandrite Laser for Skin Toning
3120007|NCT01754246|Experimental|Alexandrite Laser for Pigmented Lesions|755nm Alexandrite Laser for Epidermal Pigmented Lesions
3120008|NCT01754233|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
3120009|NCT01754220|Active Comparator|Montelukast|Montelukast tablets: adults - 10 mg, children - 5mg taken daily for two weeks
3120010|NCT01754207|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
3120011|NCT01754207|Experimental|755nm Alexandrite Laser with CAP Array|755nm Alexandrite Laser with CAP Array
3120012|NCT01754194||Procedure Type 1|Gastric Sleeve Resection
3120013|NCT01754194||Procedure Type 2|Roux-en-Y Gastric Bypass
3120014|NCT01754181|Experimental|Proposed treatment by Diabeloop algorithm|the insulin dose is calculated by the algorithm based on the usual treatment of the patient, the ratio I / C, the intensity of physical activity and blood glucose sensor.
3120015|NCT01754181|No Intervention|usual treatment|
3120016|NCT01754155|Other|Vitamin E Polyethylene and RSA|All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.
3120017|NCT01754142||Type 2 diabetes mellitus subjects initiating Kombiglyze XR|Patients with diagnosis of type 2 diabetes mellitus initiating Kombiglyze XR treatment within the approved indications will be enrolled
3120018|NCT01754129||Participants with Parkinson's disease|Participants with advanced levodopa-responsive Parkinson's disease and severe motor fluctuations and hyper-/dyskinesia who were prescribed and treated in accordance with the local levodopa/carbidopa intestinal gel product label
3120019|NCT01754116|Experimental|Lead In Period GSK1265744 30 mg + midazolam 3mg|During the lead-in period, a group of 12 subjects will receive a midazolam probe (on Day -29 and Day -14) to examine the potential of GSK265744 to inhibit or induce cytochrome P450 (CYP)3A activity. On Day -28, subjects will begin a 14 day oral dose of GSK265744 30 mg. to be taken once daily from Day-28 to Day -14. Subjects will begin a wash out period from Day -14 to Day -1 and be randomized to GSK1265744 LAP on Day 1
3120020|NCT01754116|Experimental|Lead in Period GSK1265744 30mg|On Day -28, subjects will begin a 14 day oral dose lead-in period. Subjects will be dispensed a 14 day supply of 30mg oral GSK1265744 to be taken once daily from Day-28 to Day -15. Subjects will begin a wash out period from Day -14 to Day -1 and be randomized to GSK1265744 LAP on Day 1
3120021|NCT01754116|Experimental|Treatment A|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400 mg GSK1265744 (Nanomilled 200 nm) LAP intramuscular suspension injection
3120022|NCT01754116|Experimental|Treatment B|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400mg GSK1265744 (Nanomilled 1 micro m) LAP intramuscular suspension injection
3120023|NCT01754116|Experimental|Treatment C|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400 mg GSK1265744 (Dry milling and homogenization 5 micro m) LAP intramuscular suspension injection
3120024|NCT01754103|Experimental|Functional Connectivity MRI|Functional Connectivity will be measured by MRI, we will perform one T1WI run as well as three resting state bold based runs. Bold runs parameters: TE 30ms, TR 3000ms, flip angle 90º, gap 0mm, 124 time points, voxel size 3mm, duration 6min18s each, FOV 240x240x141.
3120025|NCT01754090|Active Comparator|Usual care|"Receives two interventions:~Online screening and feedback.~Online booklet."
3120026|NCT01754090|Experimental|Extended follow-up|"Receives two interventions:~Online screening and feedback.~Online multi session follow-up."
3120862|NCT01748344|Placebo Comparator|Placebo|Placebo
3120027|NCT01754077|Experimental|Thirty Million Words Project|The participants in the intervention group receive the LENA linguistic feedback reports intervention and the home visiting educational session intervention. Participants in this arm complete the same assessments as participants in the control group.
3120028|NCT01754077|Other|Control Group|The control group receives the Childhood Nutrition Education intervention. Participants in this group completed the same assessments as the treatment group. Following participation in the control group, eligible families were offered the opportunity to continue into the experimental group.
3120029|NCT01754064||Cardiac Rhythm Management device|Implanted with implantable defibrillator or pacemaker system
3120030|NCT01754051||Treatment by the PC 400 coils|Patients enrolled in this study must be those treated according to the cleared indication for the PC 400 System in the Instructions for Use.
3120031|NCT01754038||Integrative Medicine Clinic Attendees|All patients attending a participating Integrative Medicine clinic for clinical services will be invited to participate in the PRIMIER Registry
3120032|NCT01754025||Cancer patients with T790M|Have a diagnosis of cancer of any type. Have an EGFR T790M mutation identified on either genotyping of their cancer at diagnosis OR on quantitative plasma genotyping with evidence of high level (>40% allelic fraction) EGFR T790M. OR another EGFR mutation previously reported as germline detected on tumor genotyping of their cancer.
3120033|NCT01754025||Relatives of Carriers|Have a relative known to carry a germline EGFR mutation (either T790M or other novel germline EGFR mutation)
3120034|NCT01754025||Individuals known to be carriers|Have a known germline EGFR mutation (either T790M or other novel germline EGFR mutation)
3120035|NCT01754012|Experimental|Dietary Intervention|This group will follow for a year the NU-AGE whole diet approach elderly-specific and will be supplemented with 10micrograms per day of Vitamin D (cholecalciferol) from MCOHealth.
3120036|NCT01754012|No Intervention|Control Group|This group will follow the habitual diet.
3120037|NCT01753999|Active Comparator|Standard CPAP|Use of a standard CPAP (continuous positive airway pressure) device with constant pressure for 4 weeks to improve breathing during sleep
3120038|NCT01753999|Active Comparator|CPAP - Flex|Use of CPAP-Flex (continuous positive airway pressure) device with decreased pressure during expiration for 4 weeks to improve breathing during sleep
3120039|NCT01753986|Experimental|Brief Alcohol Intervention plus Standard Batterer intervention|Brief Alcohol Intervention plus 40 hours of Standard Batterer intervention
3120040|NCT01753986|Placebo Comparator|General Health Improvement plus Standard batterer intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer intervention
3120041|NCT01753960||Control group|Anesthesiologists without access to data from a continuous noninvasive hemoglobin monitoring device during surgery.
3120042|NCT01753960||SpHb group|Anesthesiologists with access to data from a continuous noninvasive hemoglobin monitoring device during surgery.
3120043|NCT01753947|Experimental|Deliberate Practice|Residents in the deliberate practice group received individualized feedback at the end of the initial assessment case. The staff surgeon supervising the case completed 3 previously validated technical skills assessment forms.
3120044|NCT01753947|No Intervention|Conventional Feedback|Residents in the control group received informal feedback as they performed the initial laparoscopic cholecystectomy in the operating room. This was left up to the discretion of the staff surgeon supervising the operation. This corresponds to the routine teaching and feedback practices that occur during conventional surgical residency training
3120045|NCT01753921||DKA Group|Subjects who presented in diabetic ketoacidosis.
3120046|NCT01753921||Healthy control|Control subjects without diabetes.
3120047|NCT01753908|Experimental|Arm I (broccoli sprout extract)|Patients receive broccoli sprout extract PO QD on days 1-14 immediately prior to surgery.
3120048|NCT01753908|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-14 immediately prior to surgery.
3120049|NCT01753882|Experimental|Gait Training with Lexapro|Gait training 2 weeks, gait training for 4 weeks (3X week) with Lexapro (10 mg SSRI), wash out period of 1 week, gait training for 4 weeks with placebo (10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
3120050|NCT01753882|Active Comparator|Gait Training with Placebo|Gait training 2 weeks, gait training for 4 weeks (3X week) with Placebo (10 mg), wash out period of 1 week, gait training for 4 weeks with Lexapro(10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
3120051|NCT01753869|Active Comparator|ACTs after HTS inhalation:|ACTs after HTS inhalation: Patients will take a bronchodilator (Salbutamol, 2 puffs) wait 15 minutes, and then take a single inhalation (4 mls) of 7% HTS (Nebusal™) via updraft nebulizer (Portex) (approximately 20 minutes) immediately followed by an airways clearance session of 10 supervised cycles of Active Cycle of Breathing Technique (ACBT) using the acapella® (approximately 20 minutes).
3120052|NCT01753869|Active Comparator|ACTs during HTS inhalation|ACTs during HTS inhalation: Patients take a bronchodilator (Salbutamol, 2 puffs), wait 15 minutes, and then take a single inhalation (4mls) of 7% HTS (Nebusal™) through the acapella® duet (with portex updraft nebulizer attached) device. During inhalation, an airways clearance session of 10 supervised cycles of ACBT using the acapella® will be carried out (approximately 20 minutes).
3120053|NCT01753856|Experimental|Teriparatide|"20 micrograms (µg) teriparatide administered subcutaneously (SC) once every day for 6 months.~Demeclocycline (DEM): Beginning 18 days prior to randomization: Days 1, 2, 3 and 16, 17, 18: 150 milligrams (mg) DEM will be taken orally every 6 hours; Days 4 to15: DEM will not be administered.~Tetracycline (TET): Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.~Calcium: Approximately 1000 milligrams per day (mg/day) administered orally.~Vitamin D: Approximately 800 to 1200 International Units per day (IU/day) administered orally."
3120054|NCT01753856|Active Comparator|Denosumab|"60 mg denosumab administered SC once in 6 months.~DEM: Beginning 18 days prior to randomization: Days 1, 2, 3 and 16, 17, 18: 150 mg DEM will be taken orally every 6 hours; Days 4 to 15: DEM will not be administered.~TET: Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.~Calcium: Approximately 1000 mg/day administered orally.~Vitamin D: Approximately 800 to 1200 IU/day administered orally."
3120055|NCT01753843|Active Comparator|early cord clamping|cord clamping within 20 sec
3120056|NCT01753843|Experimental|brief delay in cord clamping|cord clamping delayed by 30 to 60 seconds
3120057|NCT01753830|Experimental|Durolane|Single intraarticular injection of Durolane
3120058|NCT01753830|Placebo Comparator|PBS|Single intraarticular injection of PBS
3120059|NCT01753817||Study cohort|Cohort of patients who have previously undergone transradial catheterization with the use of a 7F vascular sheath
3120060|NCT01753804||Study participants|All participants will follow the same protocol, including muscle strength and function testing, and blood and urine collection, for a maximum of 7 visits over 3 years.
3120061|NCT01753791|Experimental|Cohort 1|
3120062|NCT01753791|Experimental|Cohort 2|
3120063|NCT01753791|Experimental|Cohort 3|
3120064|NCT01753791|Experimental|Cohort 4|
3120065|NCT01753778|Experimental|Treatment|Treatment with Cryo-Touch III Device at Day 0
3120066|NCT01753765|Experimental|Treatment|Study treatment with Cryo-Touch III device at Day 0.
3120067|NCT01753752|Experimental|Chitosan-N-acetylcystein|Instillation into the study eye
3120068|NCT01753752|Placebo Comparator|Placebo|Instillation into the fellow eye
3120069|NCT01753739|Experimental|Bepotastine besilate Concentration 1|Bepotastine besilate nasal spray, BID for 14 days.
3120070|NCT01753739|Active Comparator|Placebo|Placebo nasal spray BID for 14 days
3120071|NCT01753739|Experimental|Bepotastine besilate Concentration 2|Bepotastine besilate nasal spray, BID for 14 days.
3120072|NCT01753739|Experimental|Bepotastine besilate Concentration 3|Bepotastine besilate nasal spray, BID for 14 days.
3120073|NCT01753739|Experimental|Bepotastine besilate Concentration 4|Bepotastine besilate nasal spray, BID for 14 days.
3120074|NCT01753726|Experimental|Experimental group|43 people are recruited in order to the inclusion criteria for the study. They are healthy people. A diaphragm stretching technique was employed in this experimental group.
3120075|NCT01753726|Placebo Comparator|Placebo group|37 healthy people were recruited in order to the inclusion criteria.
3120076|NCT01753713|Experimental|Anti-angiogenic Therapy Naive Patients|Patients who have progressed without anti-angiogenic therapy. Patients receive dovitinib orally (PO) 5 days a week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3120077|NCT01753713|Experimental|Anti-angiogenic Therapy Patients|Patients who have progressed on anti-angiogenic therapy. Patients receive dovitinib orally (PO) 5 days a week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3120078|NCT01753700|Experimental|UHT treated milk|1,5 L of 1,5% UHT milk pr day for 3 weeks (21days)
3120079|NCT01753700|Placebo Comparator|Paseurised milk|1,5 L 1,5% pasteurised milk pr day for 3 weeks (21 days)
3120080|NCT01753687|Other|50 patients with dry eye syndrome|
3120081|NCT01753674|Experimental|TA-65|TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
3120082|NCT01753674|Placebo Comparator|Placebo|Placebo will be provided to volunteers for 12 weeks, 2 pills per day of 8 mg each.
3120083|NCT01753661|Experimental|Project ASPIRE Treatment Condition|The Project ASPIRE Treatment condition will receive the Project ASPIRE intervention program which includes the linguistic feedback reports and the multimedia education sessions. This group will complete the same assessments as the control group.
3120084|NCT01753661|Active Comparator|EI-As-Usual Condition|As an ethical decision, eligible participants may roll over to the experimental group after satisfactory completion of this treatment.
3120085|NCT01753648|Experimental|hypertensive retinopathy|30 patients with hypertensive retinopathy stage 2 or 3
3120086|NCT01753648|Experimental|healthy controls|30 healthy age- and sex-matched controls
3120087|NCT01753635|Experimental|Baska mask|In this arm the Baska mask will be used as the airway management device
3120088|NCT01753635|Active Comparator|single use laryngeal mask airway device (LMA)|in this arm a single use LMA device will be used for airway management.
3120089|NCT01753622|No Intervention|Control group|Sedentary Obese and overweight pregnant women
3120090|NCT01753622|Experimental|Exercise group|Physical exercise program
3120091|NCT01753609|Experimental|Tulip capsule|swallowing Tulip capsule for up to 29 days
3120092|NCT01753596|Experimental|30 healthy subjects|Subjects will receive 1 drop of Genteal HA eye drops in one randomly chosen eye, the other eye will receive placebo
3120093|NCT01753596|Experimental|30 patients with dry eye syndrome|Patients will receive 1 drop of Genteal HA eye drops in one randomly chosen eye, the other eye will receive placebo
3120094|NCT01753583|Experimental|10 patients with corneal abrasions|
3120095|NCT01753583|Experimental|10 patients with corneal infiltrates|
3120096|NCT01753570|Experimental|MP-424(+RBV+IFN), Genotype1|
3120097|NCT01753570|Experimental|RBV+IFN, Genotype1|
3120098|NCT01753570|Experimental|MP-424(+RBV+IFN), Genotype2|
3120099|NCT01753557|Experimental|Treatment-Naive|
3120100|NCT01753557|Experimental|Treatment-Relapsed|
3120101|NCT01753531||Flu Symptoms|
3120102|NCT01753518|Active Comparator|Subcuticular suture|Subcuticular suture has been used for many years to close skin incisions.
3120103|NCT01753518|Active Comparator|Subcuticular staple|Subcuticular staples are a newer modality than suture, but are currently an accepted and widely used skin closure technique.
3120104|NCT01753505|Experimental|MDCTA|
3120105|NCT01753492|Experimental|Ologen implantation (single arm)|Ologen implantation as an adjunctive to trabeculectomy
3120106|NCT01753479|Experimental|Test subject|
3120107|NCT01753466|Experimental|Hydration|Participants who are randomized to the hydration-intervention group will be asked to consume 1.0 to 1.5 L water per day, depending on sex and weight, in addition to usual consumed beverages, for 6 weeks
3120108|NCT01753466|No Intervention|Control|
3120109|NCT01753453|Active Comparator|G-CSF alone|Patients will receive G-CSF for 5 consecutive days
3120110|NCT01753453|Experimental|G-CSF plus plerixafor|Patients will receive G-CSF for 4 consecutive days, then receive plerixafor before the 5th dose of G-CSF
3120111|NCT01753440|Active Comparator|Stem cells implantation|Patients with severe coronary artery disease with ischemic cardiomyopathy managed with concomitant coronary artery bypass grafting and intramyocardial administration of allogeneic mensenchymal stem cells.
3120974|NCT01747564|Experimental|mirabegron group|
3120112|NCT01753414|Other|Surgery|Complete resection, i.e., removal of the primary tumor with at least a 2 cm margin together with nodal dissection/sampling
3120113|NCT01753414|Experimental|Sterotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy (SBRT) given every other day 11 Gy in 5 fractions to a total dose of 55 Gy in 10-15 days with an inter-fraction interval of 2-3 days
3120114|NCT01753401|Experimental|0.5 mL Acthar|H.P. Acthar Gel 40 U (0.5 mL) daily
3120115|NCT01753401|Placebo Comparator|0.5 mL Placebo|Placebo (0.5 mL) daily
3120116|NCT01753401|Experimental|1.0 mL Acthar|H.P. Acthar Gel 80 U (1.0 mL) every other day
3120117|NCT01753401|Placebo Comparator|1.0 mL Placebo|Placebo (1.0 mL) every other day
3120118|NCT01753388|Experimental|Treatment by the Liberty Stent|
3120119|NCT01753375|Active Comparator|Vitamin D3|Administered orally on weekly basis
3120120|NCT01753375|Placebo Comparator|Placebo|To be administered orally on weekly basis
3120121|NCT01753362|Placebo Comparator|placebo|subcutaneous daily injection
3120122|NCT01753362|Active Comparator|liraglutide|subcutaneous daily injection
3120123|NCT01753349||Idiopathic cervical dystonia|Adults subjects from Hospitals, Private Practices suffering idiopathic cervical dystonia.
3120124|NCT01753336|Experimental|Dysport®|Dysport®, up to 500 units (U)/vial using 2mL dilution
3120125|NCT01753323|Experimental|Part 1 - Cohort 1: P. vivax: KAF156 400mg QD|Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.
3120126|NCT01753323|Experimental|Part 1 - Cohort 2: P. falciparum: KAF156 400mg QD|Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.
3120127|NCT01753323|Experimental|Part 2 - Cohort 3: P. falciparum: KAF156 800mg single dose|Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.
3120128|NCT01753310|Active Comparator|Dysport®|Dysport® (intramuscular injection), between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
3120129|NCT01753310|Placebo Comparator|Placebo|Placebo, up to 2mL
3120130|NCT01753297|Active Comparator|Triptorelin, 11.25 mg|Triptorelin, powder and solvent for suspension (prolonged released form)
3120131|NCT01753297|No Intervention|Active surveillance|Active surveillance after radical prostatectomy (RP)
3120132|NCT01753271|Experimental|Thoracic Mobilization|thoracic mobilization in addition to shoulder mobilization plus exercise
3120133|NCT01753271|Active Comparator|exercise only|shoulder mobilization plus exercise alone
3120134|NCT01753258||Definite diagnosis of dyspareunia|Patients who report dyspareunia, and whose dyspareunia was evaluated prior to delivery by a caregiver experienced with sexual pain disorders, with definite diagnosis.
3120135|NCT01753258||No definite diagnosis of dyspareunia|"Patients who report dyspareunia but were not evaluated prior to delivery or were evaluated inappropriately (i.e. yeast infection without cultures, inflammation and other vague definitions)."
3120136|NCT01753258||Patients without dyspareunia|Patients without dyspareunia- those who report non painful sexual intercourse. This group of patients will be used as a control group.
3120137|NCT01753245||Non-Metabolic Syndrome|Patients without Metabolic Syndrome criteria (OMS).
3120138|NCT01753245||Metabolic Syndrome|Patients with Metabolic Syndrome criteria (OMS).
3120139|NCT01753232||DALI-adsorber, hypercholesterolemia|Patients suffering from familial hypercholesterolemia treated at least twice a month with the DALI-system
3120140|NCT01753232||MONET-Filter, hypercholesterolemia|Patients suffering from familial hypercholesterolemia treated with the MONET-Lipoprotein filter
3120141|NCT01753219|Experimental|Onstep|Participants in this group will have a inguinal hernia repair ad modum Onstep.
3120142|NCT01753219|Active Comparator|Lichtenstein|Participants in this group will receive a inguinal hernia repair ad modum Lichtenstein.
3120143|NCT01753193|Experimental|MEDI-546|MEDI-546, IV q4wks for 104 weeks
3120144|NCT01753180|Experimental|collagenase|
3120145|NCT01753180|Placebo Comparator|saline|
3120146|NCT01753167|Experimental|MCMV5322A/MCMV3068A|Participants will receive a total of four doses of study drug administered by intravenous infusion: at the time of transplantation (Day 1), and at Days 8, 29, and 57. MCMV5322A/MCMV3068A will be tested in this study at 10 milligrams per kilogram (mg/kg) of each component antibody. Thus, at each dose, 10 mg/kg of MCMV5322A and 10 mg/kg of MCMV3068A will be tested (20 mg/kg total).
3120147|NCT01753167|Placebo Comparator|Placebo|Participants will receive a total of four doses of placebo matched with MCMV5322A/MCMV3068A administered by intravenous infusion: at the time of transplantation (Day 1), and at Days 8, 29, and 57.
3120148|NCT01753154|Experimental|Solution B (balance PD solution)|Treatment 8 weeks with solution B (balance PD solution), next 8 weeks with solution A (conventional PD solution)
3120149|NCT01753154|Active Comparator|Solution A (conventional PD solution)|Treatment 8 weeks with solution A (conventional PD solution), next 8 weeks with solution B (balance PD solution)
3120150|NCT01753141|Experimental|Active|Cognitive Behavioral Therapy for smoking cessation plus anxiety sensitivity reduction.
3120151|NCT01753141|Active Comparator|Control|Cognitive Behavioral Therapy for smoking cessation.
3120152|NCT01753128|Active Comparator|imipramine|
3120153|NCT01753115|Experimental|BioThrax + Ciprofloxacin PK|"BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.~Ciprofloxacin: 500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48)."
3120154|NCT01753115|Experimental|BioThrax + Ciprofloxacin no PK|"BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.~Ciprofloxacin: 500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48)."
3120155|NCT01753115|Experimental|BioThrax only|BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.
3120156|NCT01753102|Experimental|Estradiol|Intravaginal self-administration of study medication once daily for 14 days.
3120157|NCT01753102|Active Comparator|Reference: Estradiol|Intravaginal self-administration of study medication once daily for 14 days.
3120158|NCT01753102|Placebo Comparator|Placebo|Intravaginal self-administration of study medication once daily for 14 days.
3120159|NCT01753089|Other|WDVAX|Treatment
3120160|NCT01753076|Experimental|Ozanezumab IV|Administered by IV route. Treatment period - 48 Weeks
3120161|NCT01753076|Placebo Comparator|Placebo|Normal saline by IV route. Treatment period - 48 weeks
3120162|NCT01753063|Experimental|Patient Expectations|At the family's initial visit to the pediatric weight management program/clinic each parent/guardian and adolescent (if age 12 yrs. or older) will complete the survey tool. At 3 months, families will be asked to complete a follow up survey. This will be fielded at a visit for those returning to clinic or by phone/mail for those not returning.
3120163|NCT01753050|No Intervention|Standard care|No specific hemodynamic optimization measures
3120164|NCT01753050|Experimental|Hemodynamic optimization|Hemodynamic optimization by stroke volume monitoring
3120165|NCT01753037|Active Comparator|DHEA Group|Oral administration of a capsule containing 130 mg of dehydroepiandrosterone (DHEA) for 5 days.
3120166|NCT01753037|Placebo Comparator|Placebo Group|Oral administration of an identical capsule containing placebo for 5 days.
3120167|NCT01753024||Sepsis-PEST|septic patients with enteral nutrition and pancreatic enzyme supplementation therapy
3120168|NCT01753024||Sepsis-NPEST|Septic patients with enteral nutrition only
3120169|NCT01753024||DM-PEST|Diabetic patients with enteral nutrition and pancreatic enzyme supplementation therapy
3120170|NCT01753024||DM-NPEST|Diabetic patients with enteral nutrition only
3120171|NCT01753024||PCAS-PEST|Patients suffering from cardiac arrest receive both enteral nutrition and pancreatic enzyme supplementation therapy
3120172|NCT01753024||PCAS-NPEST|Patients suffering from cardiac arrest receive enteral nutrition only
3120173|NCT01753024||ARF-PEST|Patients with acute renal failure receive both enteral nutrition and pancreatic enzyme supplementation therapy
3120174|NCT01753024||ARF-NPEST|Patients with acute renal failure receive enteral nutrition only
3120175|NCT01753011||Stress Urinary Incontinence|Stress Urinary Incontinence
3120176|NCT01752998|Active Comparator|TOPPS Intervention|Individuals randomized into this arm will receive 7 individual sessions of the Treating Opioid Patients' Pain and Sadness (TOPPS) intervention, designed to reduce symptoms of pain and depression.
3120177|NCT01752998|Placebo Comparator|Health Education|Individuals randomized into this arm will receive 7 individual sessions on general health education.
3120178|NCT01752985|Experimental|Arm A: BMS-813160 150 mg & Placebo matching with BMS-813160|BMS-813160 150 mg capsules by mouth in AM and Placebo matching with BMS-813160 in PM for 12 weeks
3120179|NCT01752985|Experimental|Arm B: BMS-813160 300 mg|BMS-813160 300 mg capsules by mouth twice daily for 12 weeks
3120180|NCT01752985|Placebo Comparator|Arm C: Placebo matching with BMS-813160|Placebo matching with BMS-813160 0 mg capsules by mouth twice daily for 12 weeks
3120181|NCT01752972|Experimental|Palmer arsenical keratosis|Spirulina 10 g/day orally for 12 weeks
3120182|NCT01752972|Active Comparator|Arsenic exposed controls|Spirulina 10 g/day orally for 12 weeks
3120183|NCT01752972|Active Comparator|Heathy volunteers|Spirulina 10 g/day orally for 12 weeks
3120184|NCT01752959|Active Comparator|Remifentanyl|Group R 0.1-0.3 mic/kg/ min remifentanil infusion other names: Ultiva
3120185|NCT01752959|Experimental|esmolol|Grup E 500 micg/kg/min lading dose after 50-500 μcg/kg/dk esmolol infusion
3120186|NCT01752933|Experimental|SGI-110|SGI-110 administered subcutaneously daily on Days 1 - 5 every 28 days
3120187|NCT01752920|Experimental|ARQ 087|"Subjects will receive ARQ 087 orally at dose levels specified for their respective dose cohorts on a 28-day schedule.~Subjects will receive treatment with ARQ 087 until progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria is documented."
3120188|NCT01752907|Experimental|General Education DVD|Participants received chemotherapy and pegfilgrastim administered as a single subcutaneous injection dose of 6 mg 24 to 72 hours after chemotherapy. Participants were required to watch a general chemotherapy side effects education DVD on 2 separate visits to the clinic prior to the first administration of pegfilgrastim in cycle 1.
3120189|NCT01752907|Experimental|Bone Pain Education DVD|Participants received chemotherapy and pegfilgrastim administered as a single subcutaneous injection dose of 6 mg 24 to 72 hours after chemotherapy. Participants were required to watch a bone pain education DVD on 2 separate visits to the clinic prior to the first administration of pegfilgrastim in cycle 1.
3120190|NCT01752894|Active Comparator|Angio guided PCI|
3120191|NCT01752894|Experimental|OCT-guided PCI|
3120192|NCT01752894|Active Comparator|BES|
3120193|NCT01752894|Experimental|EES|
3120194|NCT01752894|Active Comparator|Keep dual antiplatelet therapy (DAPT)|Study subjects will be allocated into this arm with non-randomization method
3120195|NCT01752894|Active Comparator|Discontinue Dual antiplatelet therapy (DAPT)|Study subjects will be allocated into this arm with non-randomization method
3120196|NCT01752881|Experimental|AdimFlu-S|
3120197|NCT01752868|Experimental|supplement|
3120198|NCT01752868|No Intervention|control|
3120199|NCT01752855|Experimental|New formulation of adalimumab 40 mg every other week|New formulation adalimumab 40 mg every other week
3120200|NCT01752842|Experimental|Fenofibrate|One fenofibrate 160 mg capsule per day for 12 weeks
3120201|NCT01752842|Placebo Comparator|Placebo for fenofibrate|One inert sugar pill per day for 12 weeks
3120202|NCT01752816|Active Comparator|endurance training|40 min bicycle or treadmill training at 60% maximal oxygen uptake
3120203|NCT01752816|Experimental|Strength following endurance training|20 minutes bicycle or treadmill training at 60% maximal oxygen uptake followed by 20 minutes stength training increasing from 15RM to 10RM
3120204|NCT01752803|Experimental|probiotic|subjects in this arm will receive probiotic supplementation for 12 weeks.
3120205|NCT01752803|Placebo Comparator|placebo|subjects in this arm will receive placebo in identical sachets similar to probiotics which only differs in the codes mentioned on the label of sachets.
3120206|NCT01752790|Experimental|Top-down|patients randomized on top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus azathioprine (2 mg/Kg per os/day). During maintaining phase, patients will receive subsequent infusions of infliximab (5 mg/kg every 8 weeks), starting 8 weeks after the end of the induction phase (week 14). At 12 motnhs patients will stop azathioprine and continue infliximab (5 mg/kg every 8 weeks)
3120295|NCT01752127|Active Comparator|DM arms|comparison of two different stents(Xience prime and Resolute integrity)
3120296|NCT01752127|Active Comparator|Small vessel arms|comparison of two different stents(Xience prime and Resolute integrity)
3120207|NCT01752790|Active Comparator|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day). Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop).
3120208|NCT01752777|Experimental|Infectiousness Risk Reduction|Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
3120209|NCT01752777|Sham Comparator|General Health Improvement|Participants in this condition receive education conducted in one office session followed by 4 cell-phone-based sessions. The education sessions focus on raising awareness of health services and health improvement strategies.
3120210|NCT01752764|Experimental|Test product|Test product: Salad with high dosage fat
3120211|NCT01752764|Other|Control product|Control product: Salad with low dosage fat
3120212|NCT01752751||Cancer Patients Age 65 or above|Cancer patients age 65 years or above with a diagnosis of head and neck cancer or lung cancer with radiotherapy or chemoradiotherapy planned as part of curative standard treatment.
3120213|NCT01752725|Experimental|BiCision Arm|Coagulation with BiCision
3120214|NCT01752725|Active Comparator|Ultracision Arm|Coagulation with Ultracision
3120215|NCT01752712|Experimental|CBSST + oxytocin|Cognitive Behavioral Social Skills Training with adjunct oxytocin nasal spray treatment. Participants will receive 80 IU/day of oxytocin administered intranasally in two doses (40 IU morning and evening).
3120216|NCT01752712|Placebo Comparator|CBSST + placebo|Cognitive Behavioral Social Skills Training with placebo nasal spray. The placebo nasal spray bottles will be matched in appearance to the oxytocin nasal spray bottles and similarly administered intranasally in two doses (morning and evening).
3120217|NCT01752699|Experimental|Methadone|in this arm patients will take methadone 5mg.
3120218|NCT01752699|Experimental|Placebo|in this arm patients will take placebo pills.
3120219|NCT01752686|Experimental|carboplatin chemotherapy|At the time of post neo-adjuvant period, the patients will be assigned to each treatment group in a 1:1 ratio i.e. carboplatin AUC 6 group vs. observation group. Six cycles of carboplatin (AUC=6) on the first day of every 21 days.
3120220|NCT01752686|No Intervention|Observation arm|In this observation arm, patients should be follow up with regular interval without treatment.
3120221|NCT01752673|Experimental|Visualized pulmonary embolism computer task model|This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.
3120222|NCT01752673|Active Comparator|Didactic review pulmonary embolism lecture|This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
3120223|NCT01752660|Experimental|Endurance training|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
3120224|NCT01752660|Active Comparator|Standard care|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center
3120225|NCT01752647|Experimental|Low dose computed tomography|Patients will have one baseline LDCT scan.
3120226|NCT01752634|Experimental|Secukinumab (AIN457) 150 mg s.c.|Group 2 - Secukinumab 150 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4.
3120227|NCT01752634|Experimental|Secukinumab (AIN457) 75 mg s.c.|Group 1- Secukinumab 75 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4.
3120228|NCT01752634|Placebo Comparator|Placebo s.c.|Group 4 - Placebo at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4
3120229|NCT01752634|Experimental|Secukinumab (AIN457) 300 mg s.c.|Group 3 - Secukinumab 300 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4
3120230|NCT01752621||acromegaly|patients with acromegaly
3120231|NCT01752621||comparison population|matched background population
3120232|NCT01752608|Experimental|eCBT Mood|Electronic cognitive behavioral therapy application running on the iPhone and iPod Touch.
3120233|NCT01752608|No Intervention|Mood Tracker|Mood monitoring application running on the iPhone and iPod Touch
3120234|NCT01752595|No Intervention|Standard|Subjects randomized to this group will receive standard, usual care with no intervention.
3120235|NCT01752595|Active Comparator|Preference Based Music Intervention|Subjects randomized to this arm will receive an iPod player and an activity monitoring device. The iPod will be loaded with patient indicated music preferences that is synched to the patients pace prescription. Subjects will be asked to use their iPod player during off-site exercise periods.
3120236|NCT01752595|Active Comparator|Preference Based Rhythmic Auditory Stimulation Music|Subjects randomized to this arm will receive an iPod player and an activity monitoring device. The iPod will be loaded with patient indicated music preferences that is synched to the patients pace prescription. Subjects will be asked to use their iPod player during off-site exercise periods. Rhythmic Auditory Stimulation (accentuation of beats, frequencies) will be added to the music subliminally.
3120237|NCT01752582|Other|BuMA stent|"This study will enroll a total of 70 patients in Fuwai Hospital.All patients will be randomly assigned two groups(in a 1:1 ratio).~BuMA stent Arm:About 35 patients will undergoing implantation of BuMA stent.All of the patients will receive 6 months dual antiplatelet therapy and they will be followed (at the outpatient clinic) for up to 2 years. The follow-up visits will be conducted at 3 months(including angiographic/OCT investigation), 6 months, 1 and 2 years post PCI,in order to observe the Primary Endpoint and Secondary Endpoints."
3120238|NCT01752582|Other|EXCEL stent|"This study will enroll a total of 70 patients in Fuwai Hospital.All patients will be randomly assigned two groups(in a 1:1 ratio).~EXCEL stent Arm:About 35 patients will undergoing implantation of EXCEL stent.All of the patients will receive 6 months dual antiplatelet therapy and they will be followed (at the outpatient clinic) for up to 2 years. The follow-up visits will be conducted at 3 months(including angiographic/OCT investigation), 6 months, 1 and 2 years post PCI,in order to observe the Primary Endpoint and Secondary Endpoints."
3120297|NCT01752075||REVLIMID|Taiwanese patients treated with REVLIMID
3121574|NCT01743612|Experimental|Healthy subjects|18 years old or more
3120239|NCT01752569|Experimental|Selumetinib treatment|Phase I is a dose-finding study to discover the maximum tolerated dose of selumetinib in combination with HAART. Phase II will consider the efficacy of selumetinib for treating Kaposi's sarcoma at the recommended phase II dose discovered in phase I.
3120240|NCT01752556|Active Comparator|Hospital diagnosis|diagnosis of Sleep Apnea and therapeutic decision will perform according to polysomnography
3120241|NCT01752556|Experimental|Home diagnosis|diagnosis of Sleep Apnea and therapeutic decision will be perform according to home respiratory polygraphy
3120242|NCT01752543|Active Comparator|Conivaptan|10 patients will be randomized to conivaptan treatment
3120243|NCT01752543|Placebo Comparator|Dextrose|10 patients will receive placebo treatment (dextrose)
3120244|NCT01752530|Experimental|Computer program C8 + treatment as usual|Computer program C 8 + treatment as usual. Subjects in the intervention group will be playing a special computer program C8 for 40 min a day, 6 times a week for 8 weeks in addition to treatment as usual.
3120245|NCT01752530|Other|Treatment as usual|Treatment as usual at the clinic
3120246|NCT01752517||refractory SCLC|NI group vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days; every 3 weeks; up to the maximum cycles (total:6);
3120247|NCT01752504|Experimental|Intervention group|Community members who become engaged in the coalitions and in the broader mobilization effort. A subset of community members..
3120248|NCT01752491|Experimental|15g Ascorbate|"During radiation therapy:~Radiation: 61.2 Gray (1.8 Gray / fraction / day), 5 days/week, for approximately 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once daily, every day, until radiation is completed.~Ascorbate: 15 g administered by IV three times a week until 1 month after radiation is completed (approximately 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
3120249|NCT01752491|Experimental|25g Ascorbate|"If the 15g arm is tolerated, the study opens the 25g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 25 g administered by IV three times/wk until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
3120250|NCT01752491|Experimental|50g arm|"If the 25g arm is tolerated, the study opens the 50g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 50 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
3120251|NCT01752491|Experimental|62.5g|"If the 50g arm is tolerated, the study opens the 62.5g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 62.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
3120252|NCT01752491|Experimental|75g Ascorbate|"If the 62.5g arm is tolerated, the study opens the 75g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 75 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
3120253|NCT01752491|Experimental|87.5g Ascorbate|"If the 75g arm is tolerated, the study opens the 87.5g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 87.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
3120254|NCT01752465|Active Comparator|Standard Care|Patients in the standard care group will receive standard clinical care from their attending psychiatrist, including pharmacotherapy and education. Study assessments will be done at baseline, and once a month thereafter at Months 1, 2, 3, and 6.
3120255|NCT01752465|Experimental|Health Coaching|Patients in the Health Coaching group will receive both Health Coaching, and standard care. In addition to routine clinical appointments, patients receiving Health Coaching will attend Health Coaching sessions twice a month during Months 1, 2, and 3, and once a month during Months 4, 5, and 6. Study assessments will be conducted at baseline, and once a month thereafter during Health Coaching sessions at Months 1, 2, 3, and 6.
3120256|NCT01752439|Experimental|Anodal transcranial direct current stimulation|Anodal transcranial direct current stimulation
3120257|NCT01752439|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation
3120258|NCT01752439|No Intervention|Control group|
3120259|NCT01752426|Experimental|Heavy Water + PCI-32765|Subjects given 50ml 70% 2H2O (Heavy Water) 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks (labeling phase). Subjects given first dose in clinic. Subjects then given individual doses of 2H2O to consume at home; after the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765. PCI-32765 administered with 8 ounces (~240mL) of water at a dose of 420 mg (3 x 140mg capsules) orally once daily and continued daily. Treatment duration is 12 cycles, with each cycle consisting of 28 days.
3120260|NCT01752413|Experimental|Ferrous gluconate 325mg|Those found iron depleted by ferritin measure will receive 325 mg Ferrous gluconate twice a day for 100 days. They will be deferred as a whole blood donor for 120 days until completion of iron therapy. They will receive standard dietary counseling.
3120261|NCT01752413|Active Comparator|Nutrition counseling|For those consenting to this study but who demonstrate adequate ferritin levels (>20 micrograms/L female, >30 micrograms/L males), they will not receive oral iron or additional deferral period but will be allowed to donate after the standard 56 days. They will receive standard counseling about iron rich foods. Rate and frequency of subsequent donations will be tracked and compared to those receiving iron supplementation.
3120262|NCT01752400|Experimental|AUY922|Via intravenous infusion on Days 1, 8 and 15 of each 21 day cycle (once per week). Infusion lasts approximately 60 minutes
3120263|NCT01752374||Palonosetron group|Patient recieving Palonosetron/granisetron and ramosetron
3120264|NCT01752374||Granisetron group|
3120265|NCT01752374||Ramosetron group|
3120266|NCT01752361||Ulcerative Colitis|
3120267|NCT01752348|Placebo Comparator|Placebo (isotonic saline)|Endotoxin + isotonic saline. Reference for model of acute inflammatory illness
3120268|NCT01752348|Experimental|Acipimox + Placebo (isotonic saline)|Endotoxin + Acipimox + Placebo (isotonic saline). Intervention: blockage of endogenous lipolysis.
3120269|NCT01752348|Experimental|Acipimox + free fatty acids|Endotoxin + Acipimox + free fatty acids. Intervention: free fatty acids
3120270|NCT01752348|Experimental|Acipimox + 3-hydroxybutyrate|Endotoxin + Acipimox + 3-hydroxybutyrate. Intervention: 3-hydroxybutyrate
3120271|NCT01752335|Other|tocilizumab|"All the patients are treated with tocilizumab before inclusion. The doses, frequency and duration are in acordance with the Summary of Characteristics of the Product authorised by EMA.~Usually 8mg/kg (not minor than 480 mg), once each 4 weeks."
3120272|NCT01752322|Experimental|Lidocaine plaster|Topical hydrogel plaster
3120273|NCT01752322|Placebo Comparator|Placebo plaster|Topical hydrogel plaster
3120274|NCT01752309||Rheumatoid Arthritis, ultrasound, persistence disease activity|Patients diagnosed with early Rheumatoid Arthritis will be assessed three times in one year with ultrasound to evaluate the predictive value of ultrasound.
3120275|NCT01752283|Experimental|Hypnosis and local anesthesia|video-assisted thyroidectomy under hypnosis and local anesthesia.
3120276|NCT01752283|Active Comparator|General anesthesia|Video-assisted thyroidectomy under general anesthesia
3120277|NCT01752270|Experimental|diane-35|Diane-35 pretreatment from the third day of menstrual cycle
3120278|NCT01752270|No Intervention|blank control|
3120279|NCT01752257|Other|EF5 Hypoxia|EF5 administered at 21mg/kg
3120280|NCT01752244|Experimental|Alfacalcidol|Alfacalcidol
3120281|NCT01752244|Placebo Comparator|Placebo|Corn oil pearl Capsules 1 gram: were given to the intervention group once a day for 8 weeks
3120282|NCT01752231||DCE-MRI (dynamic contrast-enhanced MRI)|Patients undergo DCE-MRI over approximately 30-60 minutes consisting of an anatomical scout image to localize the region of interest, a set of pre-injection scans to calibrate the dynamic image set, a dynamic image set during which contrast agent will be injected, and a set of post-injection scans to calibrate the DCE-MRI database.
3120283|NCT01752218|Experimental|Arcuate Incision|Study arm will consist of patients who show cataract and corneal astigmatism.
3120284|NCT01752205|Active Comparator|Chemoradiotherapy|The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV ，dosing schedule: 45mg/m2/w.
3120285|NCT01752205|Experimental|Erlotinib and chemoradiotherapy|The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV (45mg/m2/w) and erlotinib PO QD.
3120286|NCT01752192|Experimental|Telerehabilitation programme|Telerehabilitation programme: Each patient will use a telehealth monitor and measure blood pressure, pulse and weight once or twice a week over a 3 months periods with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital step-counter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with healthcare professionals. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound. The patients are randomised in block of different sizes to follow rehabilitation from hospital, healthcare center or a callcenter.
3120287|NCT01752192|No Intervention|Control group traditional rehabilitation|The control group of heart patients follow traditional rehabilitation activities for a period of 3 months.The patients are randomised in block of different sizes to follow rehabilitation from hospital, healthcare center or a callcenter.
3120288|NCT01752179|Experimental|kinesio tape|kinesio Tape : Width 5cm ,Length 35cm Y shape
3120289|NCT01752179|No Intervention|Control group|without using Kinesio tape
3120290|NCT01752166||Blood culture|Subjects have had a blood culture ordered, per routine standard of care
3120291|NCT01752153|Experimental|Silymarin (Legalon)|Patients who were unable or unwilling to use desferrioxamine or had stopped desferrioxamine treatment for at least 6 months, were received only silymarin.
3120292|NCT01752153|Experimental|Combined therapy (Deaferrioxamine+Silymarin (Legalon)|In combined therapy group, patients continued desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy) was added to desferrioxamine regimen at the dose of 140 mg, taken orally, three times a day, 7 days a week.
3120293|NCT01752140|Active Comparator|10-core prostate biopsy protocol group|Ultrasound guided prostate biopsy with extraction of 10 cores
3120294|NCT01752140|Active Comparator|Vienna nomogram prostate biopsy protocol group|Ultrasound guided prostate biopsy performed according to the Vienna nomogram
3120510|NCT01750645||Intervention Group|
3120511|NCT01750645||Control Group|
3120298|NCT01752049|Active Comparator|Topical timolol maleate|"Drug: • Topical timolol maleate 0.5% drops~Topical timolol maleate 0.5% drops~Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~Study drops will be applied to 3 cutaneous telangiectasias per patient telangiectasia per patient)."
3120299|NCT01752049|Placebo Comparator|Placebo|"placebo saline drops~-Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to one cutaneous telangiectasias per patient."
3120300|NCT01752036|Experimental|Stereotactic Radiotherapy (SRS)|Stereotactic radiosurgery (SRS) 600 cGy x 5 fractions
3120301|NCT01752023|Experimental|Cisplatin + Gemcitabine with SUBATM-itraconazole|SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.
3120302|NCT01752023|Active Comparator|Cisplatin + Gemcitabine|Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.
3120303|NCT01752010|Active Comparator|Acupuncture Treatment|Traditional Chinese acupuncture.
3120304|NCT01752010|Active Comparator|Tennant™ Biomodulator Treatment|
3120305|NCT01752010|Active Comparator|Transcutaneous electrical nerve stimulation (TENS) Treatment|
3120306|NCT01751997|Active Comparator|Transplants from 8/8-matched unrelated|Participants will receive transplants from 8/8-matched unrelated donors using myeloablative or reduced-intensity conditioning according to age or comorbidity.
3120307|NCT01751997|Experimental|Transplants from family-mismatched/haploidentical donors|Participants will receive FMT using a reduced intensity conditioning regimens.
3120308|NCT01751984|Experimental|ETC-1002|ETC-1002 treatment, once daily oral
3120309|NCT01751984|Placebo Comparator|Placebo|Placebo treatment, once daily oral
3120310|NCT01751971|Active Comparator|Inspired Oxygen First|Participants breathe air with additional inspired oxygen (40%) for 1 night during an overnight sleep study (15 L/min via venturi mask). 1 week later participants will crossover to Sham (sham comparator).
3120311|NCT01751971|Sham Comparator|Sham First|Participants breathe air without additional inspired oxygen for 1 night during sleep (15 L/min via Venturi mask). 1 week later participants will crossover to Inspire Oxygen (active intervention).
3120312|NCT01751958|Experimental|Epidural Steroid injection|Group-Epidural Steroid injection (Intermittent)
3120313|NCT01751958|Experimental|Epidural Steroid Injection2|Group-injection under angiography (continuous)
3120314|NCT01751945|Experimental|EmONC package|"The EmONC package consists of:~Maternal and neonatal health pack(clean delivery kit, emollient, chlorhexidine, sms messages) for safe motherhood and newborn wellbeing.~Enhanced trainings of community-level health care providers to provide effective maternal and neonatal health services and referral of complicated cases to health facilities and creation of linkages amongst health care providers.~Community mobilisation"
3120315|NCT01751945|No Intervention|Standard of care|Standard care as per national policy
3120316|NCT01751932|Experimental|CGM Monitoring|Fitting of Dexcom G4 Platinum CGM monitor and Medtronic Enlite CGM monitor
3120317|NCT01751919|Other|Group 1 (RT)|"Period 1: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)~Period 2: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)"
3120318|NCT01751919|Other|Group 2 (TR)|"Period 1: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)~Period 2: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)"
3120319|NCT01751906|Experimental|Absorb BVS|Subjects receiving Absorb BVS
3120320|NCT01751906|Active Comparator|XIENCE|Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
3120321|NCT01751893|Experimental|Henna arm|Based on the treatment protocol for this study the patients will receive the henna treatment for 5 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna mixture (paste) (40gr natural henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 2 hours and then the mixture will be rinsed with fresh water.
3120322|NCT01751893|Placebo Comparator|Placebo|Based on the treatment protocol for this study the patients in this arm will receive the henna placebo treatment for 5 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna placebo mixture (paste) (40gr placebo henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 2 hours and then the mixture will be rinsed with fresh water.
3120323|NCT01751880|Experimental|Exercise Group|
3120324|NCT01751867|Experimental|3-Day Dose schedule|Decitabine will be administered at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3 hour period, repeated every 8 hours for 3 consecutive days. Cycles will be repeated every 6 weeks.
3120325|NCT01751867|Experimental|5-Day Dose schedule|Decitabine will be administered at a dose of 20 mg/m2 as a intravenous infusion within 1 hour, once daily for 5 consecutive days. Cycles will be repeated every 4 weeks.
3120326|NCT01751854|Experimental|SSRI|SSRI alone or with training
3120327|NCT01751854|Placebo Comparator|Placebo|Placebo alone or with training
3120328|NCT01751841||Spinal fusion patients with MIS surgery|Spinal fusion patients for whom Silicate-Substituted Calcium Phosphate Ceramic has been used as the Bone Graft
3120329|NCT01751828|Experimental|Sertraline|Open-label sertraline, 8 week trial, dosing from 50mg to 200mg daily.
3120330|NCT01751815|Experimental|Acu-TENS|
3120331|NCT01751815|Sham Comparator|Placebo-TENS|
3120332|NCT01751802|Experimental|Ecopipam|Active substance being tested, orally once a day at bedtime
3120333|NCT01751802|Placebo Comparator|Placebo|Inactive substance being tested, orally once a day at bedtime
3120334|NCT01751789|Active Comparator|Linkage|Participants will receive Suboxone during their inpatient detoxication and be given outpatient appointments to continue Suboxone treatment after completing inpatient detoxification
3120335|NCT01751789|Placebo Comparator|Detoxification|Participants will receive Suboxone to detoxify from opioids and the standard treatment offered by the inpatient detoxification program
3120336|NCT01751776|Experimental|BI 655064 Part 1|3 different doses plus placebo in healthy volunteers
3120337|NCT01751776|Experimental|BI 655064 Part 2|2 different doses plus placebo in rheumatoid arthritis patients
3120338|NCT01751763||Group 1|
3120339|NCT01751750|Other|Grape|
3120512|NCT01750632|Experimental|Orchiectomy|The patients undergo subcapsular orchiectomy
3120340|NCT01751737|Experimental|Prostate Cancer Imaging|"Subjects will receive multi-sequence Magnetic Resonance Imaging (MRI) of the prostate and pelvis. This scan will take approximately 90 minutes.~In addition, a 18F-Choline PET/CT(Positron emission tomography/computed tomography) scan of the abdomen and pelvis is performed. This scan will take about 30 minutes. Subjects may receive an additional 30 minute scan, if needed.~Patients participating in an active surveillance program at the University of Michigan may receive yearly imaging followed by a prostate biopsy procedure."
3120341|NCT01751724|Experimental|Caffeine Arm|Subjects randomized to this arm will receive blinded Caffeine citrate.
3120342|NCT01751724|Placebo Comparator|Placebo Arm|Subjects randomized to this arm will receive blinded Placebo (equivalent volume of normal saline).
3120343|NCT01751698|Active Comparator|JASP-EMT|JASP-EMT (Joint Attention, Symbolic Play and Enhanced Milieu Teaching) focuses on creating a context for joint engagement within naturally occurring child-led play routines. There is evidence of the effects of these interventions with children with ASD, and pilot data showing effects with minimally verbal children.
3120344|NCT01751698|Active Comparator|DTT|CORE-DTT (discrete trial training for core features of ASD) emphasizes didactic adult-led instruction and is considered the current evidenced-based 'standard of care' for children with autism (NRC, 2001).
3120345|NCT01751685|Experimental|Kyphosis-specific spinal exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
3120346|NCT01751685|Placebo Comparator|Control|Usual care control group will meet once a month for educational lectures on various topics. At the end of 6 months, each control group participant will get a one-on-one session with the physical therapist who was leading the intervention classes.
3120347|NCT01751672|Active Comparator|SBIRT|Screening, Brief Intervention, and Referral to Treatment
3120348|NCT01751672|Experimental|SBIRT+|Expanded Screening, Brief Intervention, and Referral to Treatment
3120349|NCT01751659||Phase I|"Semi-structured face-to-face or telephone interviews of 10 ATN-affiliated clinicians.~The total duration of Phase 1 is expected to last approximately nine months, including data analysis."
3120350|NCT01751659||Phase II|"Development of a new theory-based survey instrument and cognitive interview testing of this survey with approximately five clinicians (of those who participated in Phase 1).~The total duration of Phase 2 is expected to last approximately three months, including qualitative analysis of the interviews and modification of the survey."
3120351|NCT01751659||Phase III|"Administration of the newly developed survey to approximately 60 ATN-affiliated clinicians.~The total duration of Phase 3 will last approximately six to nine months."
3120352|NCT01751646|Experimental|Group A: Vitamin D3 50,000 IU|Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
3120353|NCT01751646|Placebo Comparator|Group B: Vitamin D3 placebo|Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
3120354|NCT01751633||Surgical treatment|"Surgical treatment according to one of the following:~Posterior open approach~Posterior minimally-invasive surgery (MIS) approach The choice of the approach will be left upon the surgeon's discretion"
3120355|NCT01751633||Conservative treatment|Conservative treatment according to hospital's standard of care
3120356|NCT01751620|Experimental|Project ACCEPT|Participants randomized to the intervention (Project ACCEPT) arm.
3120357|NCT01751620|Active Comparator|HEALTH|Participants randomized to the comparison (HEALTH) arm.
3120358|NCT01751607||genetic variants|AFib patients with or without the genetic variants
3120359|NCT01751594|Active Comparator|H4L Comparison Intervention|
3120360|NCT01751594|Experimental|MOVE Intervention|
3120361|NCT01751581|Active Comparator|Habitual Sleep|Women sleep 8 h/night throughout the study phase
3120362|NCT01751581|Experimental|Short Sleep|Women sleep 4 h/night throughout the study phase
3120363|NCT01751568|Experimental|4 Weeks to Less than 12 Years of Age|Participants will receive chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) twice daily, in addition to two NRTIs to treat HIV and a rifampicin-containing regimen to treat TB. Participants will be enrolled into the study into three cohorts: Cohort I: 2 years of age to less than 6 years of age, Cohort II: 6 years of age to less than 12 years of age, and Cohort III: 4 weeks of age to less than 2 years of age. After a study visit at Day 5 to 8, a fourth ARV medication will be added to the regimen.
3120364|NCT01751555|Experimental|TDF/3TC/EFV Treatment HIV/HBV Co-infection|TDF+3TC+EFV treatment regimen in Adults with HIV/HBV Coinfection
3120365|NCT01751542|Experimental|Mindfulness + residential treatment|Mindfulness and Acceptance Group Therapy + residential treatment
3120366|NCT01751542|Active Comparator|Residential Treatment|Residential treatment alone
3120367|NCT01751529|Experimental|Contrast-enhanced Ultrasound|
3120368|NCT01751503|Active Comparator|Interosseous route of TPTT|The investigators will have two groups of patients, one who had their tendon transfer using the extra membranous route and other group which had their tendon transfer through the interosseous route. Patients will be randomized to either groups before the surgery and both the patients and the assessors will be blinded to the technique used. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors.
3120369|NCT01751503|Active Comparator|Extra membranous route of TPTT|Extramembranous or circumtibial route of Tibialis Posterior tendon transfer.Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
3120370|NCT01751490|Active Comparator|physiotherapy alone|patients undergoing physiotherapy only
3121575|NCT01743599||Diabetic men|
3120371|NCT01751490|Active Comparator|surgery and physiotherpay|patients receiving surgical treatment followed by physiotherapy
3120372|NCT01751477||Probiotics (Infloran)|Very low birth weight Infants receiving 2 capsules/d Infloran starting in the first week of life
3120373|NCT01751477||Control|Very low birth weight Infants who did not receive Infloran (historical cohort)
3120374|NCT01751464|Experimental|WrapAround Care|
3120375|NCT01751451|Experimental|Abiraterone acetate|"Group 1~Abiraterone acetate 1000 mg daily x 8 months~Prednisone 5 mg once daily x 8 months"
3120376|NCT01751451|Experimental|Abiraterone acetate and Degarelix|"Group 2~Abiraterone acetate 1000 mg daily x 8 months~Prednisone 5 mg once daily x 8 months~Degarelix subcutaneous depot injection q 1 month x 8 months"
3120377|NCT01751451|Experimental|Degarelix|"Group 3~• Degarelix subcutaneous depot injection q 1 month x 8 months"
3120378|NCT01751438|Experimental|Best Systemic Therapy (BST)|Group 1 will continue to receive best systemic therapy (BST). Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete. Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
3120379|NCT01751438|Experimental|Best Systemic Therapy (BST) + Surgery or Radiation Therapy|Group 2 will receive best systemic therapy (BST) in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice. Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete. Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
3120380|NCT01751425|Experimental|Ruxolitinib + TKI|"Phase I Dose Escalation Group: Ruxolitinib starting dose level 5 mg orally, twice daily. Patients continue receiving commercially available TKIs (IM, NIL or DAS) at dose they had been receiving during the last 6 months.~Phase II Dose Expansion Group: Ruxolitinib starting dose level MTD from Phase I Dose Escalation Group. Patients continue receiving commercially available TKIs (IM, NIL or DAS) at dose they had been receiving during the last 6 months.~Once MTD is defined for imatinib in the phase I portion of the study the phase 2 portion of the study will start with imatinib only. The phase I portion of the study with dasatinib and nilotinib will open once MTD is defined for the imatinib-based combination."
3120381|NCT01751412|Experimental|Proton Radiation|Delivered daily (Monday-Friday) for two to five weeks.
3120382|NCT01751399|Experimental|LY2605541-Normal Hepatic Function|Participants will receive a single subcutaneous (SC) dose of 0.075 milligram per kilogram (mg/kg) LY2605541
3120383|NCT01751399|Experimental|LY2605541-Mild Hepatic Impairment|Participants will receive a single SC dose of 0.075 mg/kg LY2605541
3120384|NCT01751399|Experimental|LY2605541-Moderate Hepatic Impairment|Participants will receive a single SC dose of 0.075 mg/kg LY2605541
3120385|NCT01751399|Experimental|LY2605541-Severe Hepatic Impairment|Participants will receive a single SC dose of 0.075 mg/kg LY2605541
3120386|NCT01751386|Experimental|Baclofen|Baclofen 10 mg t.i.d.
3120387|NCT01751386|Placebo Comparator|Placebo|Placebo t.i.d.
3120388|NCT01751373|Active Comparator|Standard Therapy|Coupling focal BoNT-A injections with a therapy program comprising of functional tasks.
3120389|NCT01751373|Experimental|Optimal Muscle Activation Therapy|Coupling focal BoNT-A injections with a motor training program that focuses on developing and maintaining activation patterns in the muscle treated with BoNT-A.
3120390|NCT01751360|Experimental|SYR-472 100mg|SYR-472 100mg
3120391|NCT01751347|Active Comparator|Lidocaine|Subjects randomized to this treatment arm will receive lidocaine during their elective hand surgery.
3120392|NCT01751347|Experimental|Bupivacaine|Subjects randomized to this treatment arm will receive bupivacaine during their elective hand surgery.
3120393|NCT01751334|Experimental|Mobile Bearing|Mobile bearing total knee arthroplasty
3120394|NCT01751334|Active Comparator|Fixed Bearing|Fixed Bearing total knee arthroplasty
3120395|NCT01751321|Other|sitagliptin, metformin, placebo|"group- 25 patients will take sitagliptin 50 mg and metformin 1000 mg twice in a day~group- 25 patients will take placebo 50 mg and metformin 1000 mg twice in a day"
3120396|NCT01751308|Experimental|Phase 1: Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression (DP) or discontinuation due to adverse event (AE) or death (from any cause).
3120397|NCT01751308|Experimental|Phase 1: Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
3120398|NCT01751308|Experimental|Phase 1: Cabazitaxel 30 mg/m^2|Cabazitaxel 30 mg/m^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
3120399|NCT01751308|Experimental|Phase 1: Cabazitaxel 35 mg/m^2|Cabazitaxel 35 mg/m^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
3120400|NCT01751308|Experimental|Phase 2: Cabazitaxel 30 mg/m^2|Cabazitaxel at the maximum tolerated dose (MTD) as determined in phase 1 (30 mg/m^2) IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
3120401|NCT01751295|Active Comparator|atorvastatin|PCI with atorvastatin pre-treatment group
3120402|NCT01751295|No Intervention|control|PCI without atorvastatin pre-treatment group
3120403|NCT01751282|Placebo Comparator|Standard therapy and control saline spray|Conventional standard therapy and control saline spray
3120404|NCT01751282|Sham Comparator|standard therapy and fibrin spray|Conventional standard therapy and fibrin spray
3120405|NCT01751282|Experimental|Conventional standard therapy and MSCs|Conventional Standard Therapy and MSCs (autologous bone marrow-derived mesenchymal stem cells) in fibrin spray.
3120406|NCT01751269|Experimental|Ascending Single and Multiple dose of RPX7009|Ascending Single and Multiple dose of RPX7009
3120407|NCT01751269|Placebo Comparator|Normal Saline|Ascending Single and multiple dose of normal saline.
3120408|NCT01751256|Experimental|Continuous wound infiltration|Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
3121576|NCT01743599||Non-diabetic men|
3120409|NCT01751256|No Intervention|Control|Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
3120410|NCT01751243|Placebo Comparator|Group 0|Haploidentical transplantation of hematopoietic progenitors
3120411|NCT01751243|Experimental|Group 1|Allo-depleted lymphocyte infusion dose: 1x105 CD3/Kg
3120412|NCT01751243|Experimental|Group 2|Allo-depleted lymphocyte infusion dose: 3x105 CD3/Kg
3120413|NCT01751243|Experimental|Group 3|Allo-depleted lymphocyte infusion dose: 5x105 CD3/Kg
3120414|NCT01751243|Experimental|Group 4|Allo-depleted lymphocyte infusion dose: 1x106 CD3/Kg
3120415|NCT01751243|Experimental|Group 5|Allo-depleted lymphocyte infusion dose: 3x106 CD3/Kg
3120416|NCT01751230|Experimental|WIC E-Moms|If picked for this group, you will receive a personalized diet and exercise plan to help you lose the weight you gained during your pregnancy. All information will be given to you using a SmartPhone, such as an iPhone. You can use your own phone or one can be loaned to you for the study. You will also be loaned a scale so you can weigh yourself at home. You will also get advice and services from your WIC clinic.
3120417|NCT01751230|No Intervention|WIC Moms|You will get advice and services for nutrition and weight management after pregnancy from your WIC clinic.
3120418|NCT01751217|Experimental|Funct Family Tx/Video Teleconf (FFT-V)|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. Adolescents and parents assigned to the FFT-V condition will receive a Verizon netbook laptop computer equipped with the Microsoft Windows 7 operating system, webcam, and VTC software for use in the family home. The VTC software is designed to stream live video between therapists and participants, to record video, and to store recorded videos as digital mpeg files. All family sessions will take place via video teleconference.
3120419|NCT01751217|Experimental|Functional Family Tx|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. Families in the FFT condition will not be provided with the laptop and internet access described above. Instead, adolescents and parents in this condition will receive the FFT intervention face-to-face from an FFT therapist who will travel to the family home for each session.
3120420|NCT01751217|Active Comparator|Services as Usual|The main CYFD service provider for adjudicated youth in both Sandoval and Valencia counties is Youth Development Incorporated (YDI) which is a private not-for-profit youth service organization serving adolescents in New Mexico . YDI provides an array of services for youth including tutoring, after-school activities, gang intervention, school drop-out prevention, family counseling services, an emergency teen shelter, parenting skills training, youth leadership development, community corrections services, GED studies, substance abuse and AIDS education, etc. The YDI juvenile corrections services include intensive supervision, educational and employment assistance, community service, victim restitution, and institutional transition services.
3120421|NCT01751204|Active Comparator|Calcium tablet|250 mg calcium/tablet
3120422|NCT01751204|Experimental|Calcium ion water (250mg)|250 mg calcium in 200 ml water
3120423|NCT01751204|Experimental|Calcium ion water (125mg)|125 mg calcium in 200 ml water
3120424|NCT01751191||Training set-chronic response to propranolol|
3120425|NCT01751191||Validation set-chronic response to propranolol|
3120426|NCT01751191||Acute response to propranolol|
3120427|NCT01751178|Active Comparator|Mouthwash with Alcohol|rinse with 10ml 0.2% w/v Chlorhexidine Digluconate Mouthwash with alcohol for 1 timed minute twice daily for 6 weeks following brushing with a full brush head of standard toothpaste for 1 timed minute.
3120428|NCT01751178|Active Comparator|Mouthwash without Alcohol|rinse with 10ml 0.2% w/v Chlorhexidine Digluconate Mouthwash without alcohol for 1 timed minute twice daily for 6 weeks following brushing with a full brush head of standard toothpaste for 1 timed minute.
3120429|NCT01751165|Experimental|HZ/su-0,2 Group|Subjects will receive HZ/su vaccine on a 0,2-month schedule.
3120430|NCT01751165|Experimental|HZ/su-0,6 Group|Subjects will receive HZ/su vaccine on a 0,6-month schedule.
3120431|NCT01751165|Experimental|HZ/su-0,12 Group|Subjects will receive HZ/su vaccine on a 0,12-month schedule.
3120432|NCT01751152|Experimental|NNC0114-0006|
3120433|NCT01751152|Placebo Comparator|Placebo|
3120434|NCT01751139|Other|Study cohort|Subjects 6 months of age and older who live in the selected study sites in Brazil.
3120435|NCT01751126|Experimental|Ciclosporin|One drop of ciclosporin (NOVA22007) 1 mg/ml 4 times a day as monotherapy (morning, noon, afternoon and evening).
3120436|NCT01751126|Experimental|Ciclosporin/Placebo|One drop of ciclosporin (NOVA22007) 1 mg/ml twice a day and one drop of placebo twice a day (active study treatment morning and evening and placebo noon and afternoon) as monotherapy.
3120437|NCT01751126|Placebo Comparator|Placebo|One drop of placebo 4 times a day as monotherapy (morning, noon, afternoon and evening).
3120438|NCT01751113|Active Comparator|fluticasone propionate/salmeterol|250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
3120439|NCT01751113|Active Comparator|tiotropium bromide|18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
3120440|NCT01751113|Active Comparator|fluticasone propionate/salmeterol plus tiotropium bromide|250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
3120441|NCT01751100|Active Comparator|HIV Test Offer|Group 1 (Control) is the current standard of care in HIV testing. A trained counselor provides required information to obtain informed consent for HIV testing and provides rapid HIV testing on site.
3120442|NCT01751100|Experimental|General Health Screen Offer|In Group 2 (Intervention), a free general health screening is offered that may include a blood pressure check, blood glucose measurement, a Hepatitis C (HCV) test, and an HIV test.
3120443|NCT01751087|Other|Osmotic dilators + placebo (vit c) + placebo (vit B12)|Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
3120444|NCT01751087|Active Comparator|Osmotic dilators + placebo (vit c) + misoprostol|Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
3120445|NCT01751087|Active Comparator|Osmotic dilators + mifepristone + placebo (vit B12)|Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
3120446|NCT01751074|Experimental|Part A|All subjects will be of Caucasian descent and will receive single dose of Rosuvastatin 10 mg for 1 day (Day 1) during treatment period 1, then will receive Darapladib 160 mg once daily (QD) for 10 days (Day 5 to 14) in treatment period 2. Immediately following this, all subjects will receive the combination of Darapladib 160 mg and Rosuvastatin 10 mg for 1 day (Day 15) and continued Darapladib dosing of 160 mg QD for additional 3 days (Days 16 to 18) in treatment period 2.
3120447|NCT01751074|Experimental|Part B|The decision to initiate Part B will be made by the GSK study team based on an evaluation of data from Part A. Part B will consist of a cohort of healthy subjects of Far-East Asian descent and will be conducted similar to Part A.
3120448|NCT01751061|Experimental|Decision aid|Web-based decision aid (decision support tool) provided to surrogate decision maker
3120449|NCT01751061|Active Comparator|Usual care|usual care in an intensive care unit setting
3120450|NCT01751048|Experimental|Group #1|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE)
3120451|NCT01751048|Experimental|Group #2|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 10 mcg Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE)
3120452|NCT01751048|Experimental|Group #3|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + Stable oil-in-water Emulsion (SE)
3120453|NCT01751035|Placebo Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU) will be defined as it already exists within the community child advocacy centers. This could include individual and/or group therapy using a variety of treatment models.
3120454|NCT01751035|Experimental|RRFT|RRFT is an acronym for an experimental intervention named Risk Reduction through Family Therapy. Please see intervention description for more detail about the model.
3120455|NCT01751022|Experimental|Attain Performa LV Lead (Models 4298, 4398, 4598)|N/A: single arm study, separate analysis for each lead model (total of 3).
3120456|NCT01751009|Experimental|Vitamin A supplements|Sprinkles with Vitamin A
3120457|NCT01751009|Active Comparator|Sprinkles without Vitamin A|Made of other micronutrients without Vitamin A
3120458|NCT01750996|No Intervention|Usual Care control (Parenting tips)|Participants randomized to usual care will have access to a brief information website containing brief parenting tips but will not receive Strongest Families Intervention
3120459|NCT01750996|Experimental|Strongest Families|Strongest Families intervention
3120460|NCT01750983|Experimental|Ipilimumab + Lenalidomide|"Dose Escalation Group Ipilimumab Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Escalation Group Lenalidomide Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab and Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Groups."
3120461|NCT01750970|Experimental|Resection under blue light|
3120462|NCT01750970|Active Comparator|Resection under white light|
3120463|NCT01750957|Placebo Comparator|Placebo|
3120464|NCT01750957|Experimental|RO4917523 Dose A|
3120465|NCT01750957|Experimental|RO4917523 Dose B|
3120466|NCT01750944|Experimental|Healthy Volunteers 1|"The study population consists of adult, healthy volunteers randomized into two identical groups.~Intervention: ankle first"
3120467|NCT01750944|Experimental|Healthy Volunteers 2|"The study population consists of adult, healthy volunteers randomized into two identical groups.~Intervention: toe first"
3120468|NCT01750931|Other|Meloxicam GSK 15mg|A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fed condition
3120469|NCT01750931|Other|Mobic 15mg|A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fed condition
3120470|NCT01750918|Experimental|Part 1: Dabrafenib and Panitumumab|In Part 1 subjects will be assigned to escalation cohort of the doublet of dabrafenib and panitumumab based on the monotherapy doses of dabrafenib (150 milligrams [mg] twice daily) and panitumumab (6 milligrams per kilogram [mg/kg] every-2-week [Q2W]). Dose escalation will follow a 3+3 dose escalation procedure. If the initial combination dose of dabrafenib and panitumumab in Cohort 1 (starting dose) is not tolerable, lower dose combination(s) may be evaluated.
3120471|NCT01750918|Experimental|Part 1: Dabrafenib, Trametinib and Panitumumab|In Part 1 after the dabrafenib/panitumumab combination dose is defined, subsequent cohorts will evaluate the addition of trametinib based on a panitumumab dose that is one dose level lower than the dabrafenib/panitumumab dose defined in Cohort 1. Trametinib starting at 1.5 mg once daily will be added to the combination of dabrafenib and panitumumab. Dose escalation will follow a 3+3 dose escalation procedure until the full monotherapy doses of all agents are evaluated or the maximum tolerated dose is determined.
3120472|NCT01750918|Experimental|Part 2: Dabrafenib and panitumumab|In Part 2, subjects will be assigned to expansion cohorts at a selected dose of dabrafenib in combination with panitumumab
3120473|NCT01750918|Experimental|Part 2: Dabrafenib, Trametinib and Panitumumab|In Part 2, subjects will be assigned to expansion cohorts at selected dose of trametinib plus dabrafenib in combination with panitumumab.
3120474|NCT01750918|Experimental|Part 3a: Dabrafenib and Panitumumab|Subjects will be randomized to receive dabrafenib plus panitumumab. Dose levels for dabrafenib, and panitumumab in Part 3 will be chosen based on emerging PK, PD, and tolerability data from Part 1 and Part 2.
3120475|NCT01750918|Experimental|Part 3b: Dabrafenib, Trametinib and Panitumumab|Subjects will be randomized to receive study treatment as dabrafenib plus trametinib plus panitumumab. Dose levels for dabrafenib, trametinib and panitumumab in Part 3 will be chosen based on emerging PK, PD, and tolerability data from Part 1 and Part 2.
3120476|NCT01750918|Experimental|Part 3c: Chemotherapy comparator|Subjects will be randomized to receive chemotherapy comparator. The chemotherapy comparator will consist of a standard chemotherapy regimen with or without the addition of a biological agent, based on local practice preferences. The available chemotherapy regimens includes 5-fluorouracil-based chemotherapy
3120810|NCT01748656|Active Comparator|AVAPS|AVAPS mode(BIPAP-A30-PHILIPS-RESPIRONICS)1 night
3120477|NCT01750918|Experimental|Part 4a: Trametinib and Panitumumab|Subject will be administered starting dose of Trametinib 2 mg once daily and Panitumumab 6mg/kg Q2W. If the initial combination dose of trametinib and panitumumab in Cohort 1 (starting dose) is not tolerable, the lower dose combination defined in de-escalation cohorts (Cohort -1A, -1B and/or -1C) may be evaluated. Cohort -1A: Trametinib 1.5 mg once daily and Panitumumab 6 mg/kg Q2W; Cohort -1B: Trametinib 2 mg once daily and Panitumumab 4.8 mg/kg Q2W; Cohort-1C: Trametinib 1.5 mg once daily and Panitumumab 4.8 mg/kg Q2W
3120478|NCT01750918|Experimental|Part 4b: Trametinib and Panitumumab|In Part 4B cohort expansion, subjects will be assigned to expansion cohorts at a selected dose of trametinib in combination with panitumumab. Enrollment in expansion cohorts will be initiated once dose escalation for the trametinib /panitumumab combination has been completed. Subjects with advanced/metastatic CRC with either a BRAF-mutation (Cohort 1E) or who developed secondary resistance to prior anti-EGFR therapy (Cohort 2E).
3120479|NCT01750905|Active Comparator|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
3120480|NCT01750905|Placebo Comparator|Placebo|Placebo: Vehicle (D5W) SQ
3120481|NCT01750892|Active Comparator|Group 1: Control|Group 1 will be the control group. They will complete questionnaires but will otherwise receive usual care from their Primary Care Provider (PCP). At the end of the study period they will be given the Study Materials for participating.
3120482|NCT01750892|Experimental|Group 3: Group Intervention|Group 3 (Group Intervention) will receive the Study Materials at the beginning of the study and will also be invited to attend two REACH for Independence group sessions.
3120483|NCT01750892|Experimental|Group 4: Full Intervention|Group 4 (Full Intervention) will receive the Study Materials at the beginning of the study, will be invited to attend the REACH for Independence group sessions, and will be invited to a Transition Consult with an MD and social worker.
3120484|NCT01750892|Experimental|Group 2: Basic Intervention|Group 2 (Basic Intervention) will receive the Study Materials at the beginning of the study but will otherwise continue with their usual PCP care.
3120485|NCT01750879|Active Comparator|Peanut Flour|Oral Immunotherapy with peanut flour.
3120486|NCT01750879|Placebo Comparator|Oat Flour|Oral Immunotherapy with oat flour.
3120487|NCT01750866|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. Treatment will continue until disease progression, intolerable side effects, or a maximum of 10 cycles of therapy.
3120488|NCT01750853|Experimental|Group 1|"Period 1: 0.1 milligrams (mg) LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 1 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 3: 10 mg LY3045697 administered once orally or matching placebo administered once orally."
3120489|NCT01750853|Experimental|Group 2|"Period 1: 0.3 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 3 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 3: 30 mg LY3045697 administered once orally or matching placebo administered once orally."
3120490|NCT01750853|Experimental|Group 3|"Period 1: 100 mg of LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 300 mg of LY3045697 administered once orally or matching placebo administered once orally (via split delivery over a 15-minute period)."
3120491|NCT01750840||Stimulation Group|All patients will receive either the Biomet® EBI Bone Healing System, Biomet OrthoPak® Non-invasive Bone Growth Stimulator System or Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator Systems.
3120492|NCT01750827|Experimental|SB-659032|Single dose open label
3120493|NCT01750814|Active Comparator|GC FLU inj.|Influneza vaccine, single-dose vial
3120494|NCT01750814|Experimental|GC3102C|Influneza vaccine, multi-dose vial
3120495|NCT01750801|Active Comparator|Propolis|alcohol-free mouthwash containing 5% green propolis (MGP 5%) on the control of plaque and gingivitis.
3120496|NCT01750801|Active Comparator|chlorhexidine|chlorhexidine used on the control of plaque and gingivitis.
3120497|NCT01750788||Group 1|
3120498|NCT01750775|Experimental|Shensong Yangxin capsule|Shensong Yangxin capsule 4 granules t.i.d. by mouth for 8weeks
3120499|NCT01750775|Placebo Comparator|placebo Capsule|placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
3120500|NCT01750762|Experimental|Lenalidomide|Dose escalation. Starting dose is 10 mg/day for 3 weeks followed by 1 week off (1 cycle). Subject will receive a total of 3 cycles.
3120501|NCT01750749|Experimental|Autologous BMDC implantation at the venous ulcer|Autologous BMDC implantation at the venous ulcer in conjunction with SOC treatment (advanced wound management plus pressure therapy)
3120502|NCT01750736|Experimental|Augmented Exercise and Manual Therapy|Subjects will receive manual therapy according to clinical guidelines followed by instruction in a specific exercise to augment the specific manual treatment provided.
3120503|NCT01750736|Active Comparator|General Exercise and Manual Therapy|Subjects will receive manual therapy according to clinical guidelines followed by instruction in a general neck range of motion exercise.
3120504|NCT01750723|Active Comparator|Acetazolamide|Acetazolamide 1 g in 10 ml saline, i.v. infusion
3120505|NCT01750723|Placebo Comparator|Saline|Saline, 10 ml i.v. infusion
3120506|NCT01750697|Experimental|Rituximab|
3120507|NCT01750684|Placebo Comparator|Saline|Patients randomized (1:1) to the placebo arm will receive an initial intravenous infusion of saline for 30 minutes within a pre-specified time window (12, 9, 6 hours post-injury). Patients will receive 5 additional infusions of the same dose and duration at 6 -hour intervals.
3120508|NCT01750684|Active Comparator|AC105|Patients randomized (1:1) to the active drug arm will receive an initial intravenous infusion of AC105 for 30 minutes within a pre-specified time window (12, 9, 6 hours post-injury). Patients will receive 5 additional infusions of the same dose and duration at 6 -hour intervals.
3120509|NCT01750658||COPD|"COPD patients admitted in any of the participating ECOS hospitals due to a COPD exacerbation.~- External factors. The episodes of COPD exacerbations are associated to exogenous factors (pollution, change of ambient temperature, humidity, infections). The prevalence of environmental contamination and infections is higher than expected.~- Endogenous factors. These factors (hyperinflation, pulmonary embolism, cardiac dysfunction, mucus hypersecretion) are present in a proportion higher than expected~- During exacerbations of COPD serum markers of inflammation and autoimmunity are high relative to baseline in COPD and decrease progressively during the follow-up, after controlling the acute episode"
3120513|NCT01750619||Mucosal tumors of the colon|Patients who received endoscopic treatment for noninvasive mucosal tumors of the colon.
3120514|NCT01750619||Nonampullary tumors of the duodenum|Patients who received endoscopic treatment for noninvasive mucosal tumors of the duodenum.
3120515|NCT01750619||Ampullary tumors|Patients who received endoscopic treatment for noninvasive ampullary tumors.
3120516|NCT01750606||pre-THA|Patients who are planned but have not yet received a total hip arthroplasty. No intervention or treatment - blood draw only to be used as a surrogate baseline for metal ion exposure.
3120517|NCT01750606||Metal-on-Poly|Patients receiving a Biomet metal on poly hip implanted between January 1, 2003 and December 31, 2006.
3120518|NCT01750606||M2a Magnum hip|Patients receiving a Biomet M2a Magnum hip implanted between January 1, 2006 and January 1, 2011.
3120519|NCT01750606||M2a38 hip|Patients receiving a Biomet metal on metal M2a38 hip implanted between January 1, 2004 and December 31, 2006.
3120520|NCT01750606||M2a Ringloc hip|Patients receiving a Biomet M2a Ringloc metal on metal hip implanted between January 1, 2002 and December 31, 2004.
3120521|NCT01750606||M2a Taperloc hip|Patients receiving a Biomet M2a Taperloc metal on metal hip implanted between January 1, 2002 and December 31, 2003.
3120522|NCT01750593|Experimental|radiofrequency ablation of thyroid nodule|Under ultrasonography the thyroid nodules will be ablated by radiofrequency ablation
3120523|NCT01750580|Experimental|Arm 1: Lirilumab + Ipilimumab|Lirilumab and Ipilimumab on specific days
3120524|NCT01750567|Experimental|Metformin (Glucophage)|The starting dose of metformin will be 500 mg po daily for one week. The dose can be escalated to 500 mg twice a day after one week, and further escalated to the final dose of 1000 mg twice a day in week 3 if the medication is tolerated without adverse side effects (refer to holding parameters described in section 9.3.3). All doses should be administered with food to decrease gastrointestinal upset.
3120525|NCT01750554|Experimental|bupivacaine digital nerve block|Patients undergoing spine surgery will have a 50/50 chance of being randomized to receive a bupivacaine 0.25% (2 milliliters total) intermediate-acting digital nerve block.
3120526|NCT01750554|No Intervention|No bupivacaine digital nerve block|Patients undergoing spine surgery will have a 50/50 chance of being randomized to not receive a bupivacaine 0.25% (2 milliliters total) intermediate-acting digital nerve block.
3120527|NCT01750541|Active Comparator|Haloperidol|Haloperidol 5mg intramuscular injection
3120528|NCT01750541|Active Comparator|Valproate|Valproate single Infusion; 400 mg (weigh<60 kg), 500 mg (weight>60 Kg)
3120529|NCT01750528||Ankylosing spondylitis|patients aged 18 years or more who meet the 1984 modified New York criteria
3120530|NCT01750528||Control|age- (± 3 years) and gender-matched volunteers who do not have inflammatory arthropathy.
3120531|NCT01750515|Experimental|Intervention group - acupuncture treatment|
3120532|NCT01750515|No Intervention|Control group|
3120533|NCT01750502||coronary-artery-disease group|Participants, who are diagnosed as coronary-artery-disease which including acute coronary syndromes and stable ischemic heart disease, will receive at least one stent.
3120534|NCT01750502||non-coronary-artery-disease group|Participants, who are diagnosed as non-coronary-artery-disease without acute coronary syndromes and stable ischemic heart disease, will not receive stent.
3120535|NCT01750489|No Intervention|COPD|
3120536|NCT01750489|Experimental|COPD with non-invasive ventilation (NIV)|Starting non-invasive ventilation with the patient's own device during registration of MSNA.
3120537|NCT01750489|No Intervention|Healthy control subjects|
3120538|NCT01750476||Depo-Provera|Women who choose to initiate Depo-Provera
3120539|NCT01750476||Mirena|Women who choose to initiate Mirena (intrauterine device)
3120540|NCT01750476||Oral contraception|Women who choose to initiate oral contraception
3120541|NCT01750463||Arm A|"Critically ill pediatric patients admitted to PICU requiring hemoglobin monitoring.~Patients admitted to PICU requiring hemoglobin monitoring will have a reading total hemoglobin (SpHb) assessment done with the Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor,prior to standard laboratory blood draw and hemoglobin analysis."
3120542|NCT01750450||Elective left heart cath|Patients undergoing elective left heart catheterization will be consented for this study
3120543|NCT01750437|Experimental|YH1885L 33.3 mg|TID, Subject takes it for 4 week.
3120544|NCT01750437|Experimental|YH1885L 50mg|BID, Subject takes it for 4 week.
3120545|NCT01750437|Experimental|YH1885L 66.6 mg|TID, Subject takes it for 4 week.
3120546|NCT01750437|Experimental|YH1885L 100mg|BID, Subject takes it for 4 week.
3120547|NCT01750437|Active Comparator|Esomeprazole 20mg|QD, Subject takes it for 4 week.
3120548|NCT01750424|Experimental|Fat Grafted|The experimental arm of the study will be composed of 15 patients who undergo autologous fat grafting into the site of the facial reconstructive scar at 3 months post-operatively. A small amount of fat will be removed near the umbilicus through a cannula using local anesthetic and a small, 2-3mm incision just barely large enough for the cannula to pass. That fat will be injected directly under the scar site in those patients using a similar cannula, local anesthetic, and small, 2-3mm incision. No sutures will be required at either the donor or injection site. Patients will subsequently return to clinic for 3-D photographic assessment at 3, 6 and 12 months post-fat grafting. The images generated at each session will be provided to a group of assessors for evaluation. They will either use the Manchester Scar Scale or the modified Manchester Scar Scale depending on whether they are within the health care profession.
3120549|NCT01750424|Placebo Comparator|Non-fat grafted|The control arm will be composed of 15 patients who undergo no intervention. These patients will be identified at 3 months post-operatively from their facial reconstruction. They will undergo no fat-grafting but will be followed up with the same frequency as the experimental group, at 3 months, 6 months, and 12 months after their initial 3 month post-surgical follow-up. 3-D images will be taken at each appointment and will be distributed to all assessors. Assessors will use either the Manchester Scar Scale or a modified Manchester Scar Scale to evaluate the appearance of the scar at each time point.
3120550|NCT01750411||Asthma|Severe Asthma Not severe Asthma
3120620|NCT01749930|Experimental|BOL-303259-X|BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
3120621|NCT01749930|Active Comparator|Timolol|Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).
3121577|NCT01743586|No Intervention|Control|
3120551|NCT01750398|Experimental|ADT plus IV testosterone|"Men with castration-resistant prostate cancer will initiate androgen deprivation therapy (ADT) with an LHRH agonist (e.g. goserelin or leuprolide) for a total of 6 months. After this initial lead-in castration phase, patients will receive intermittent intramuscular testosterone cypionate or testosterone enanthate (T) at a dose of 400 mg while continuing on ADT."
3120552|NCT01750385|Active Comparator|no antibiotic prophylaxis|These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
3120553|NCT01750385|Active Comparator|second-generation cephalosporin|These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
3120554|NCT01750372||Persons with lower limb amputation|Persons with amputation below the hip and at or above the ankle
3120555|NCT01750359|Active Comparator|curcumin|
3120556|NCT01750359|Placebo Comparator|placebo|
3120557|NCT01750346|Active Comparator|0.05% AH-8|Participants in the 0.05% AH-8 arm received the higher dose of the study drug, Acetyl Hexapeptide 8 (AH-8), which is sold under the brand name, Argireline.
3120558|NCT01750346|Active Comparator|0.025% AH-8|Participants in the 0.025% AH-8 arm received the lower dose of the study drug, Acetyl Hexapeptide 8 (AH-8), which is sold under the brand name, Argireline.
3120559|NCT01750346|Placebo Comparator|Placebo|Participants in the Placebo arm received the placebo.
3120560|NCT01750333||Lean children|
3120561|NCT01750333||Overweight Children (OW)|
3120562|NCT01750333||Obese children (Ob)|
3120563|NCT01750320|Experimental|Koning Breast CT - guided Biopsy|
3120564|NCT01750307|Experimental|Fatty acid supplementation|4 capsules to be taken daily
3120565|NCT01750307|Placebo Comparator|Medium Chain Triglyceride (MCT) oil softgel|4 capsules to be taken daily
3120566|NCT01750281|Experimental|Selumetinib 75 mg twice daily +Docetaxel 75 mg/m2|Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
3120567|NCT01750281|Experimental|Selumetinib 75 mg twice daily + Docetaxel 60 mg/m2|Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 60 mg/m2 intravenously administered on day 1 of each 21 day cycle.
3120568|NCT01750281|Experimental|Placebo twice daily + Docetaxel 75 mg/m2|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
3120569|NCT01750268|Experimental|Topiramate|Topiramate capsules daily - up to 300 mg
3120570|NCT01750268|Placebo Comparator|Placebo|Placebo capsules daily - up 300 mg
3120571|NCT01750255|Placebo Comparator|Control|The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life, adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
3120572|NCT01750255|Active Comparator|Pharmaceutical Care|Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by certain criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy (Depression- Mania Rating Scale, Clinical Global Assessment Scale,Quality of life, adherence to treatment.
3120573|NCT01750242||Parkinson's disease Subjects|Subjects with advanced Parkinson's Disease implanted with Medtronic DBS system in the subthalamic nucleus (STN).
3120574|NCT01750229|Sham Comparator|Sham|Frequency Setting - Sham
3120575|NCT01750229|Experimental|1200 Hz|Frequency Setting - 1200 Hz
3120576|NCT01750229|Experimental|3030 Hz|Frequency Setting - 3030 Hz
3120577|NCT01750229|Experimental|5882 Hz|Frequency Setting - 5882 Hz
3120578|NCT01750216||Cohort|
3120579|NCT01750203||No treatment|No cohort as this study is not using a treatment or intervention only swabs are being collected.
3120580|NCT01750190|Experimental|FG-4592 (Double-blind, Three times a week)|Weight-based starting doses of 70mg or 100mg; dose adjustments to hemoglobin levels are allowed during the study.
3120581|NCT01750190|Placebo Comparator|Placebo (Double-blind, Three times a week)|Weight-based starting doses of 70mg or 100mg; dose adjustments to hemoglobin levels are allowed during the study.
3120582|NCT01750177|Experimental|Television Viewing|Television viewing before mealtime
3120583|NCT01750177|Experimental|Video Game Playing|Video Game Playing before mealtime
3120584|NCT01750177|Experimental|Computer Use|Computer Use before mealtime
3120585|NCT01750177|Experimental|Sitting Quietly|Sitting Quietly before mealtime
3120586|NCT01750164||Invasive breast cancer with metastatic disease|
3120587|NCT01750151|Experimental|Glucose beverage|Glucose beverage
3120588|NCT01750151|Experimental|Control beverage and video game playing|Control beverage and video game playing
3120589|NCT01750151|Experimental|Glucose beverage and video game playing|Glucose beverage and video game playing
3120590|NCT01750151|Experimental|Control beverage|Control beverage
3120591|NCT01750138|Experimental|Glutamine|Glutamine powder given preoperatively for five days
3120592|NCT01750138|Active Comparator|Placebo|dextrose powder for 5 days pre-operatively
3120593|NCT01750125||Healthy subjects|In these health subjects we will measure ascending aortic blood flow with pulse wave Doppler and also record the raw audio of the Doppler signal
3120594|NCT01750112|Experimental|Macrolane VRF20|All subjects will receive treatment with Macrolane VRF20 to correct pectus excvatum deformity.
3120622|NCT01749917|Active Comparator|Control group|30 people are recruited in order to the inclusion criteria for the study. The study include subjects who can complete the assessment battery of tests at the beginning and end in order to perform the control intervention.
3137023|NCT01639053||Control Participants|
3120595|NCT01750099|Experimental|Combined spinal-epidural|After verification of being in the intrathecal space with free-flow of cerebral spinal fluid, 1 mL of 0.25% bupivicaine along with 20 mcg of fentanyl will be injected into the intrathecal space. Subsequently, a B/Braun Perifix FX closed tip multiorifice flexible epidural catheter will be threaded 4 cm into the epidural space. After obtaining a T6 dermatomal level of sensory blockade, a standard solution consisting of 0.125% bupivicaine with 2 mcg of fentanyl/mL of solution will be started at 10 mL/hour with a patient controlled epidural analgesia (PCEA) option of 8 mL every 45 minutes. If a patient requires redosing, 5-10 mL of 0.25% bupivicaine will be injected slowly through epidural catheter with a goal dermatome level of T6. No systemic opioids will be given.
3120596|NCT01750099|Placebo Comparator|Continuous lumbar epidural|After identifying the epidural space with the loss of resistance technique, a standard flexible epidural catheter will be threaded 4 cm into the epidural space. A standard test dose of 3 mL of 1.5% lidocaine with epinephrine 1:200,000 will be given through the catheter. If positive for vascular or intrathecal placement, procedure to be repeated at different interspace. If negative, catheter will be secured and slowly dosed with 5-10 mL of 0.25% bupivicaine through epidural catheter with a goal dermatome level of T6. After obtaining the dermatome level of sensory blockade, a standard solution consisting of 0.125% bupivicaine with 2 mcg of fentanyl/mL of solution will be started at 10 mL/hour with a PCEA option of 8 mL every 45 minutes. If a patient requires redosing, 5-10 mL of 0.25% bupivicaine will be injected slowly through epidural catheter with a goal dermatome level of T6. No systemic opioids will be given.
3120597|NCT01750086|Active Comparator|Denosumab 60mg subcutaneous injection|Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
3120598|NCT01750086|Active Comparator|Alendronate 70mg weekly x 8 weeks|Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
3120599|NCT01750073|Experimental|Treatment (chemotherapy, surgery, post-operative therapy)|See Detailed Description
3120600|NCT01750060|Active Comparator|Fentanyl citrate IV infusion & Naltrexone|Fentanyl citrate (equivalent to 80 mcg fentanyl)administered over 20 minutes by IV infusion every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
3120601|NCT01750060|Experimental|Fentanyl Study System (170 mcAmps) & Naltrexone|Two consecutive 40 mcg fentanyl doses each delivered over 10 minutes by the Study System (170 mcAmps) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
3120602|NCT01750060|Experimental|Fentanyl, Study System (140 mcAmp) & Naltrexone|Two consecutive 35 mcg fentanyl doses, each delivered over 10 minutes by the Study System (140 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
3120603|NCT01750060|Experimental|Fentanyl, Study System (200 mcAmp) & Naltrexone|Two consecutive 50 mcg fentanyl doses, each delivered over 10 minutes by the Study System (200 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
3120604|NCT01750060|Experimental|Fentanyl, Study System (230 mcAmp) & Naltrexone|Two consecutive 54 mcg fentanyl doses, each delivered over 10 minutes by the Study System (230 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
3120605|NCT01750034|Active Comparator|Closed method|Burn patients randomized to closed method of burn wound care.
3120606|NCT01750034|Experimental|Open method|Burn patients randomized to the open method of burn wound care.
3120607|NCT01750021|Experimental|High fat low carbohydrate diet|High fat low carbohydrate diet
3120608|NCT01750021|Experimental|Low fat high carbohydrate diet|Low fat high carbohydrate diet
3120609|NCT01750008|Other|Global Fibroid Ablation|Global Fibroid Ablation
3120610|NCT01750008|Other|Laparoscopic Myomectomy|Myomectomy via laparoscopy
3120611|NCT01749982|Placebo Comparator|Placebo|Placebo tablets
3120612|NCT01749982|Experimental|Choline bitartrate|Choline bitartrate 700 mg by mouth daily
3120613|NCT01749982|Experimental|Betaine|Betaine 1000 mg by mouth daily
3120614|NCT01749982|Experimental|Choline bitartrate + Betaine|Choline bitartrate 700 mg + Betaine 1000 mg daily
3120615|NCT01749969|Experimental|SAR650984 (isatuximab)|"SAR650984 (isatuximab) (escalating dose) plus lenalidomide 25 mg on Days 1 to 21 plus dexamethasone 40 mg on Days 1, 8, 15, 22 in 28-day cycles for all cohorts up to disease progression.~For Q2W cohorts: SAR650984 (isatuximab) on Days 1 and 15 of every cycle. For QW/Q2W cohorts: SAR650984 (isatuximab) on Days 1, 8, 15, and 22 of first cycle and Days 1 and 15 of every subsequent cycle."
3120616|NCT01749956|Experimental|FOLFOX6/Aflibercept/Radiation/Surgery|"Preoperative Chemoradiation: (6 weeks)~5-FU: 225 mg/m2 per day by intravenous continuous infusion (IVCI), Days 1 thru 42;~Radiation: 50.4 Gy (1.8 Gy/day or 28 fractions) Mon thru Fri, Weeks 1 thru 6;~Aflibercept: 4 mg/ kg, via IV infusion, Days 1 and 15.~Surgery at least 6 weeks after last day of aflibercept: Patients will undergo abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines.~Postoperative Chemotherapy and Aflibercept Treatments (four 28-day cycles):~Aflibercept (administered first): 4 mg/kg IV for approximately 1 hour (no more than 2 hours) on Days 1 and 15 of each cycle.~Modified FOLFOX6:~Leucovorin: 400 mg/m2 as a 2-hour infusion prior to 5-FU on Days 1 and 15 of each cycle.~Oxaliplatin: 85 mg/m2 IV as a 2-hour infusion prior to 5-FU on Days 1 and 15 of each cycle.~5-FU: 400-mg/m2 bolus for 2 to 4 minutes followed by 2400 mg/m2 for 46 hours on Days 1 and 15 of each cycle."
3120617|NCT01749943||EDSS Score 0-3.5|21 Subjects Total : 7 with normal to mildly limited walking
3120618|NCT01749943||EDSS Score 4.0-5.5|21 Subjects total: 7 subjects with moderately limited walking ability.
3120619|NCT01749943||EDSS Score 6.0-7.5|21 Subjects total: 7 subjects with severely limited walking ability
3120811|NCT01748656|Active Comparator|IVAPS|IVAPS mode(STELAR 150-RESMED)1 night
3120623|NCT01749917|Experimental|Exercise program group|30 people are recruited, diagnosed with Parkinson attending to the Parkinson Association of Granada aged between 40 and 65 years. No sex differences. The study include subjects who can complete the assessment battery of tests at the beginning and end.
3120624|NCT01749904|Experimental|BOL-303259-X|BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
3120625|NCT01749904|Active Comparator|Timolol|Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).
3120626|NCT01749891|Experimental|Arm 1.5 mg ALG - 1001|Arm 1.5 mg ALG- 1001 per 50ul
3120627|NCT01749891|Experimental|Arm 2.5 mg ALG -1001|Arm 2.5 mg ALG -1001 per 50ul
3120628|NCT01749891|Experimental|Arm 4.0 mg ALG -1001|Arm 3 4.0 mg ALG -1001 per 50ul
3120629|NCT01749878|Experimental|Group A: Cohorts 1 through 6|"Group A:~Cohorts 1 through 3 will receive REGN1500 subcutaneous (SC) or placebo Cohorts 4 through 6 will receive REGN1500 intravenous (IV) or placebo"
3120630|NCT01749878|Experimental|Group B|Group B will receive REGN1500 IV or placebo
3120631|NCT01749878|Experimental|Group C: Cohorts 1 and 2|"Group C:~Cohort 1 will receive REGN1500 SC or placebo Cohort 2 will receive REGN1500 IV or placebo"
3120632|NCT01749865|Experimental|A, CIK|Biological/Vaccine: Cytokine-Induced Killer Cells
3120633|NCT01749865|No Intervention|B, CONTROL|Regular follow up with no intervention
3120634|NCT01749852|Experimental|Polyphenol-rich Dark chocolate|Dark chocolate with 500 mg of polyphenols
3120635|NCT01749852|Placebo Comparator|Placebo Dark chocolate|This chocolate contains little or no polyphenols
3120636|NCT01749826|Experimental|Chronic Opioid Exposure|
3120637|NCT01749826|Experimental|Acute Opioid Exposure|
3120638|NCT01749800|Experimental|Cognitive test with/without GVS|Subjects with attention span deficits and no significant motor impairments undergo solely a cognitive test. The test is carried out in multiple trials. For some of the trials (randomly selected), subjects receive galvanic vestibular stimulation (GVS). For other trials, subjects received sham GVS. GVS is delivered using a device by A-M Systems.
3120639|NCT01749800|Active Comparator|Armeo Spring +GVS|Subjects with both attention span deficits and significant motor impairments undergo robot-assisted upper-limb rehabilitation in combination with galvanic vestibular stimulation (GVS). Robot-assisted training is carried out using the Armeo Spring system by Hocoma AG. GVS is delivered using a device by A-M Systems.
3120640|NCT01749800|Sham Comparator|Armeo Spring + sham GVS|Subjects with both attention span deficits and significant motor impairments undergo robot-assisted upper-limb rehabilitation in combination with sham GVS. Robot-assisted training is carried out using the Armeo Spring system by Hocoma AG. Sham stimulation is delivered by connecting the subject to a device by A-M Systems, but the device is not active.
3120641|NCT01749787|Experimental|1.5 mcg/kg|PRTX-100 at 1.5 mcg/kg administered via infusion once per week for 5 weeks
3120642|NCT01749787|Experimental|3.0 mcg/kg|PRTX-100 at 3.0 mcg/kg administered via infusion once per week for 5 weeks
3120643|NCT01749787|Experimental|6.0 mcg/kg|PRTX-100 at 6.0 mcg/kg administered via infusion once per week for 5 weeks
3120644|NCT01749787|Experimental|12.0 mcg/kg|PRTX-100 at 12.0 mcg/kg administered via infusion once per week for 5 weeks
3120645|NCT01749787|Experimental|240 mcg|PRTX-100 at 240 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter.
3120646|NCT01749787|Placebo Comparator|Placebo|Placebo administered via infusion once per week for 5 weeks
3120647|NCT01749787|Experimental|420 mcg|PRTX-100 at 420 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter.
3120648|NCT01749774|Experimental|Physical activity counseling|
3120649|NCT01749761|Placebo Comparator|Hemodialysis without biofeedback|Patients will be randomized to receive hemodialysis without biofeedback for a period of 8 weeks.
3120650|NCT01749761|Active Comparator|BioLogic RR biofeedback|Patients will receive 8 weeks of HD with BioLogic RR Blood pressure guided biofeedback.
3120651|NCT01749748|Other|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy for asymptomatic women breasts.
3120652|NCT01749735|Experimental|Armeo training with continuous tDCS|Subjects will receive 10 sessions of transcranial Direct Current Stimulation (tDCS)/Armeo training over 2 weeks. Training sessions will last for 40 minutes and will focus on repetitive tasks using the Armeo device that. To deliver the stimulation, the anode will be placed over the primary motor cortex (M1) of the affected hemisphere, while the cathode will be placed over the unaffected M1 area. Direct current will be transferred by a saline-soaked pair of surface sponge electrode (35cm2). Continuous stimulation will be delivered at an intensity of 1mA while the subject undergoes the 40-minute Armeo motor training sessions.
3120653|NCT01749735|Sham Comparator|Armeo training with sham tDCS|Subjects will receive the same number of 40-minute training sessions (i.e. 10 sessions) as the subjects in the experimental group. Training will take place over a period of two weeks as per the experimental group. Also, electrodes will be positioned on the scalp as per the experimental group. However, for sham transcranial Direct Current Stimulation (tDCS), the current will be delivered for only 30 seconds. The current intensity will be gradually increased and decreased to diminish its perception.
3120654|NCT01749722|Experimental|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
3120655|NCT01749709|Experimental|Instrumental music listening|Daily music listening
3120656|NCT01749709|Experimental|Vocal music listening|Daily music listening
3120657|NCT01749709|No Intervention|control|Standard rehabilitation
3120658|NCT01749696||Patients with pelvic organ prolapse|Patients, who were operated on because of pelvic organ prolapse.
3120659|NCT01749696||Patients without pelvic organ prolapse|Patients, who had hysterectomy due to other reasons than pelvic organ prolapse.
3120660|NCT01749670||Autism|Children ages 4-17 years old with DSM-IV defined autism spectrum disorder
3120661|NCT01749670||Control|Age- and gender-matched controls with typical neuropsychological developmental patterns
3120662|NCT01749657|Active Comparator|Off-the-shelf Device and shoe|subjects will wear an off-the-shelf orthotic device (AirLift PTTD Brace) and standard Edge shoe (Aetrex Co) for 12 weeks
3120663|NCT01749657|Experimental|Custom Device - standard and Shoe|subjects will wear a custom (standard) orthotic device (Arizona Co) and Edge shoes (Aetrex Co.) for 12 weeks.
3137359|NCT01636752|No Intervention|Control|
3120664|NCT01749657|Experimental|Custom Articulated device and Shoe|subjects will wear a custom articulated device (Arizona Co) and Edge shoe (Aetrex Co)for 12 weeks
3120665|NCT01749657|Experimental|Custom Extended Device and Shoe|subjects will wear a custom extended foot plate orthotic device (Arizona Co) and Edge shoe (Aetrex Co) for 12 weeks.
3120666|NCT01749644||CF patients with chronic pseudomonas infection|
3120667|NCT01749631||Difficult to Intubate (DTI) Participants|Male or non-pregnant females over 18 years of age with Mallampati score III or IV who were undergoing surgery using sevoflurane as the anesthetic agent as judged by the investigator and in compliance with the drug market authorization and approved product labeling.
3120668|NCT01749618|No Intervention|No education or feedback|Rheumatologists randomized to this treatment arm receive no additional education or feedback about their systematic assessments of patients
3120669|NCT01749618|Experimental|Education and Feedback|Rheumatologists randomized to receive education and feedback participate in six web conferences designed to improve their systematic assessments of their patients, and are given feedback about their performances
3120670|NCT01749605|Active Comparator|nitrofurantoin 100 mg|
3120671|NCT01749605|Active Comparator|Ciprofloxacin 250 mg|
3120672|NCT01749592|Experimental|Cochlear Implant|Surgical Implantation of a Cochlear Implant
3120673|NCT01749579|Experimental|Propofol|The patients will receive propofol for sedation in addition to fentanyl
3120674|NCT01749579|Active Comparator|Midazolam|The patients will receive midazolam for sedation in addition to fentanyl
3120675|NCT01749566|Active Comparator|Group A (standard maraviroc dosing)|maraviroc 300mg po bid x 7 days
3120676|NCT01749566|Active Comparator|Group B (reduced maraviroc dosing)|maraviroc 300mg po daily x 7 days
3120677|NCT01749566|No Intervention|Group C (no drug)|No additional drug
3120678|NCT01749553|Experimental|sleeper stretch|
3120679|NCT01749553|No Intervention|no intervention|
3120680|NCT01749540|Experimental|ACE 536|ACE-536 - 1 of 7 possible dose levels.
3120681|NCT01749527|Other|24-hour pad test|decreased activity
3120682|NCT01749514|Experimental|ACE-536|Subjects assigned to 1 of 7 possible dosing groups.
3120683|NCT01749501|Active Comparator|Rocuronium|0.6 mg/kg once
3120684|NCT01749501|Placebo Comparator|Placebo|Placebo
3120685|NCT01749488|No Intervention|Control intensive care wards|This is a randomized cluster trial. The centers randomized into this arm will serve as controls. No interventions will be implemented for these centers.
3120686|NCT01749488|Experimental|Experimental intensive care wards|"This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.~Intervention: Designated dietitian for the ward"
3120687|NCT01749475||midazolam|
3120688|NCT01749475||hypnosis|
3120689|NCT01749462||Oxis|
3120690|NCT01749449|Experimental|High protein 3 meals/day|35% protein intake eaten as 3 meals per day
3120691|NCT01749449|Experimental|High carbohydrate consumed 3 meals/day|High carbohydrate 3 meals/day
3120692|NCT01749449|Experimental|High protein consumed 6 meals/day|35% protein 6 meals/day
3120693|NCT01749436||Lung ultrasound imaging|Lung ultrasound imaging examinations performed during the perioperative period for the monitoring of atelectasis associated with laparoscopic surgery
3120694|NCT01749423||All participants|Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective review of medical records.
3120695|NCT01749410||All participants|Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective medical record review.
3120696|NCT01749397|Experimental|Treatment (veliparib and floxuridine)|Patients receive veliparib PO BID on days 1-10 and floxuridine IP on days 3-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3120697|NCT01749384|Experimental|Treatment (bevacizumab, tivantinib)|Patients receive bevacizumab IV over 30-90 minutes on days -15, 1, and 15 (day -15 of course 1 only) and tivantinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3120698|NCT01749371|Experimental|Early Vitamin E|Vitamin E is administered from Days 1-15 after the initial excision surgery after admission.
3120699|NCT01749371|Experimental|Delayed Vitamin E|Vitamin E is administered from Days 16-30 after the initial excision surgery after admission.
3120700|NCT01749358|Experimental|High Therapy Dose|Sixty total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
3120701|NCT01749358|Experimental|Moderate Therapy Dose|Thirty total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
3120702|NCT01749358|Experimental|Low Therapy Dose|Fifteen total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
3120703|NCT01749358|Other|Active Monitoring|This is an observation only group.
3120704|NCT01749332|Experimental|Pts having liver or colon surgery|Blood will be obtained from patients at the time of laparotomy for hepatic resection and/or hepatic arterial infusion pump placement, or pancreatic head resection . Blood will be drawn from a peripheral vein or artery (when an arterial catheter is present), the portal vein, and suprahepatic IVC and given to a research assistant and placed on ice followed by immediate processing. Total amount of blood drawn will not exceed fifty milliliters (50ml).
3120705|NCT01749319|Active Comparator|Oral Baclofen|
3120706|NCT01749319|Experimental|Intervenous baclofen|Crossover study that eacg subject is given both oral and intervenous baclofen
3120707|NCT01749306|Other|ABH001|ABH001 application plus wound care dressings.
3120708|NCT01749306|Other|Control|Control wound treatment
3120709|NCT01749293|Experimental|Haploidentical Transplant|All subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
3120809|NCT01748669|Active Comparator|Heathy volunteers|One soft capsule of garlic oil (10 mg) daily for 12 weeks
3120710|NCT01749280||Abdominal Aortic Aneurysms|Patients will be recruited from the outpatient AAA surveillance population at the vascular unit in the Royal Infirmary of Edinburgh.Potential participation in the study will be completely asymptomatic from their AAA.
3120711|NCT01749267|Experimental|partial caries removal|partial caries removal only at enamel dentin junction (EDJ) without carious tissue removal at the pulpal site
3120712|NCT01749254||Acute Coronary Syndrome|40 patients admitted with ACS (NSTEMI/STEMI) will be recruited undergo 18F NaF PET, 18F FDG and CTCA within 1 month of the event.
3120713|NCT01749254||Stable angina cohort|40 patients with previously diagnosed coronary artery disease and listed to undergo elective coronary angiogram will be recruited. VH-IVUS will be attempted in all patients. Selected patients will undergo PET scan after stent implantation.
3120714|NCT01749241|Experimental|Loteprednol etabonate ointment|This is the arm which contains loteprednol steroid
3120715|NCT01749241|Other|Vehicle Ointment|This arm contains vehicle only.
3120716|NCT01749228|Experimental|Etodolac Capsules USP 300 mg|Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India
3120717|NCT01749228|Active Comparator|Etodolac Capsules USP 300mg|Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA
3120718|NCT01749215|Experimental|Topiramate|Topiramate capsules daily - up to 300 mg
3120719|NCT01749215|Placebo Comparator|Placebo|Placebo capsules daily - up to 300 mg
3120720|NCT01749202|Placebo Comparator|Negative Control|
3120721|NCT01749202|Active Comparator|Positive Control|
3120722|NCT01749202|Experimental|Active|
3120723|NCT01749189|Placebo Comparator|Placebo|Placebo dry blended beverage (carbohydrate)
3120724|NCT01749189|Experimental|Blend|A dry blended beverage containing a protein blend of soy, whey and casein
3120725|NCT01749189|Active Comparator|Whey|A dry blended beverage containing Whey protein
3120726|NCT01749176|Experimental|SMS texting intervention|Behavioral text messages will be sent at random times throughout the week reagarding Healthy nutrition tips, benefits of physical activity, benefits of medication adherence and requests to check blood sugar and send back results.
3120727|NCT01749176|Placebo Comparator|Control-Usual Care|Participants will continue to receive their usual care in their primary care home. They will return at months 3 and 6 to conduct behavioral and laboratory assessments to compare results with the intervention group.
3120728|NCT01749163|Experimental|Control|Saline will be coninfused during the pancreatic clamp
3120729|NCT01749163|Experimental|GIP|GIP will be infused intravenously during the pancreatic clamp at 1.5 pmol/kg/min
3120730|NCT01749163|Experimental|GLP-1|GLP-1 will be infused intravenously during the pancreatic clamp at 0.5 pmol/kg/min
3120731|NCT01749150|Experimental|with cirrhosis|
3120732|NCT01749150|Experimental|without cirrhosis|
3120733|NCT01749137|Active Comparator|RM-493|Double blind RM-493 will be administered at a dose of 1mg/24hrs via subcutaneous infusion for 90 days.
3120734|NCT01749137|Placebo Comparator|Placebo|Double blind placebo will be administered via subcutaneous infusion for 90 days.
3120735|NCT01749124|Experimental|My Coach Connect|"To evaluate the feasibility and effectiveness of this telephone tool while engaging clients and providers in discussion groups and surveys to better understand how this tool impacts the care provided and their overall experience in healthcare. Clients will use this tool to leave voice messages and survey answers which their providers will have access to by logging in to a secure website. Providers will have access to audio recordings of the voice responses, transcribed text of the responses, as well as word clouds generated from the text. Word clouds are a method of displaying the content of text such that words that are used more frequently are displayed in a larger size than words used less frequently."
3120736|NCT01749111|Experimental|Arm A|Graft versus host disease prophylaxis will be done with cyclophosphamide 50 mg/kg on day +3 and day +4
3120737|NCT01749111|Active Comparator|Arm B|In this arm, patients will receive a combination of methotrexate and a calcineurin inhibitor as graft versus host disease prophylaxis
3120738|NCT01749098|Experimental|PF-04958242|PF-04958242 and ketamine
3120739|NCT01749098|Placebo Comparator|Placebo|Placebo and ketamine
3120740|NCT01749085|Experimental|Sequence 1|
3120741|NCT01749085|Experimental|Sequence 2|
3120742|NCT01749072|Other|Gefitinib|Gefitinib group Gefitinib (Iressa) 250mg once per day until progression disease or intolerant side effects
3120743|NCT01749072|Other|Vinorelbine-Ifosfamide|VI group Vinorelbine 25mg/m2 d1,d8;Ifosfamide 1.25g/m2 d1-d3(Usually Ifosfamide 2g d1-d3 with Mesna 400mg 0,4,8hours after Ifosfamide administration for 3 days);every 3 weeks;at least for 2-6 cycles depending on the progression disease or the patient's physical condition
3120744|NCT01749059||Congenital Heart Defect|
3120745|NCT01749046|Experimental|Remegal|Remegal 1500 mg
3120746|NCT01749046|Placebo Comparator|Placebo|Placebo
3120747|NCT01749033|Active Comparator|Group 1 classic|Group 1 Using the classic inserting technique and completely deflated LMA recommended in the LMA manual.
3120748|NCT01749033|Active Comparator|Group 2 pre inflated|Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA from the manufacturer
3120749|NCT01749033|Active Comparator|Group 3 ELLIA technique|Group 3 (ELLIA): Using the ELLIA technique.
3120750|NCT01749020|Experimental|Polyphenol-rich Dark chocolate|Dark chocolate with 500 mg of polyphenols
3120751|NCT01749020|Placebo Comparator|Placebo Dark chocolate|This chocolate contains little or no polyphenols
3120752|NCT01749007||Veterans with HIV/AIDS|
3120753|NCT01748994|Placebo Comparator|Placebo|Administration of placebo to upper- and lower-body obese women
3120754|NCT01748994|Active Comparator|Drug|Administration of pioglitazone to upper- and lower-body obese women
3120755|NCT01748981|Other|Physical training|Exercise intervention.
3120756|NCT01748981|Other|As usual|Controls
3120757|NCT01748968||Veterans with HIV/AIDS|Veterans with HIV/AIDS
3120758|NCT01748955|Active Comparator|Bupropion|Participants will receive bupropion XL for 8 weeks.
3120759|NCT01748955|Active Comparator|paroxetine CR|Participants will receive Paroxetine CR for 8 weeks.
3120760|NCT01748942|Experimental|Arm I (treatment)|Patients receive dexamethasone IV at the time of surgery and PO every 8 hours for up to 4 days following surgery.
3137698|NCT01634282|Experimental|OPC-262|
3120761|NCT01748942|Active Comparator|Arm II (control)|Patients receive dexamethasone IV at the time of surgery and placebo PO every 8 hours for up to 4 days following surgery.
3120762|NCT01748929|Experimental|Albendazole|single dose 400 mg tablet of albendazole
3120763|NCT01748929|Placebo Comparator|Placebo|Placebo Manufactured by Hersil Laboratories in Lima, Peru
3120764|NCT01748916|Experimental|Papaya-Carrot-Tomato|Test meals were consumed in the following order: 1. Papaya 2. Carrot 3. Tomato.
3120765|NCT01748916|Experimental|Papaya-Tomato-Carrot|Test meals were consumed in the following order: 1. Papaya 2. Tomato 3. Carrot
3120766|NCT01748916|Experimental|Tomato-Papaya-Carrot|Test meals were consumed in the following order: 1. Tomato 2. Papaya 3. Carrot
3120767|NCT01748916|Experimental|Tomato-Carrot-Papaya|Test meals were consumed in the following order: 1. Tomato 2. Carrot 3. Papaya
3120768|NCT01748916|Experimental|Carrot-Papaya-Tomato|Test meals were consumed in the following order: 1. Carrot 2. Papaya 3. Tomato
3120769|NCT01748916|Experimental|Carrot-Tomato-Papaya|Test meals were consumed in the following order: 1. Carrot 2. Tomato 3. Papaya
3120770|NCT01748903||Target 360°, 2D, Nano Coils|Subjects will undergo embolization using Target 360°, 2D, Nano Coils for the treatment of their intracranial aneurysm.
3120771|NCT01748890|Experimental|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
3120772|NCT01748877|Experimental|NXN-462|capsule, 200 mg, bi.d. 28-days
3120773|NCT01748877|Placebo Comparator|Placebo|capsule, b.i.d. 28-days
3120774|NCT01748864|Experimental|Single Arm - Healthy Volunteers|Etarfolatide (EC20)
3120775|NCT01748851|Experimental|XELOX|Capecitabine 1000mg/m2 bid D1-D14 Oxaliplatin 130mg/m2 + 5% Dextrose water (5DW) 500ml over 2hour D1 Q 2weeks
3120776|NCT01748851|Active Comparator|FOLFOX|Oxaliplatin 85mg/m2 + 5DW 500ml over 2hr D1 Leucovorin 400mg/m2 + 5DW 500ml over 2hr D1 5-Fluorouracil (5-FU) 400mg/m2 IV PUSH D1 5-FU 1200mg/m2 + 5DW 1 Liter over 22hr D1-D2 Q 2weeks
3120777|NCT01748838|Experimental|Part 1: CTX-4430|
3120778|NCT01748838|Placebo Comparator|Part 1: Placebo + Mannitol|
3120779|NCT01748838|Experimental|Part 2: CTX-4430|
3120780|NCT01748838|Placebo Comparator|Part 2: Placebo + Mannitol|
3120781|NCT01748825|Experimental|A|MK-1775 (AZD1775) administered orally for 5 doses each cycle, starting at 225 mg per dose approximately 12 hours apart
3120782|NCT01748825|Experimental|B|MK-1775 (AZD1775) administered orally for 5 doses for 2 weeks each cycle, starting at 200 mg per day
3120783|NCT01748799|Other|Sequence 1|Self-titrated placebo - Self-titrated Sativex - Fixed dose Sativex - Fixed dose placebo
3120784|NCT01748799|Other|Sequence 2|Fixed dose placebo - Fixed dose Sativex - Self-titrated Sativex - Self-titrated placebo
3120785|NCT01748799|Other|Sequence 3|Fixed dose placebo - Fixed dose Sativex - Self-titrated placebo - Self-titrated Sativex
3120786|NCT01748799|Other|Sequence 4|Fixed dose Sativex - Fixed dose placebo - Self-titrated placebo - Self-titrated Sativex
3120787|NCT01748799|Other|Sequence 5|Self-titrated Sativex - Self-titrated placebo - Fixed dose Sativex - Fixed dose placebo
3120788|NCT01748799|Other|Sequence 6|Self-titrated Sativex - Self-titrated placebo - Fixed dose placebo - Fixed dose Sativex
3120789|NCT01748799|Other|Sequence 7|Self-titrated placebo - Self-titrated Sativex - Fixed dose placebo - Fixed dose Sativex
3120790|NCT01748799|Other|Sequence 8|Fixed dose Sativex - Fixed dose placebo - Self-titrated Sativex - Self-titrated placebo
3120791|NCT01748786|Experimental|Mindfulness Emotion Regulation|12 on-line modules targeting social and emotional regulation through mindfulness training
3120792|NCT01748786|Placebo Comparator|Placebo|12 on-line modules providing information regarding health behaviors
3120793|NCT01748773|Experimental|Combination Therapy|Participants will receive combination therapy comprising of trastuzumab, oxaliplatin, capecitabine, and radiation.
3120794|NCT01748760|Experimental|CLASP-A intervention|Adolescent participants and parents will receive adjunctive psychosocial intervention.
3120795|NCT01748760|Active Comparator|Treatment as Usual|Adolescent participants and parents will not receive study intervention
3120796|NCT01748747|Experimental|Arm I (MART-1 antigen, Gag:267-274 peptide vaccine)|Patients receive MART-1 antigen and Gag:267-274 peptide vaccine emulsified in Montanide ISA 51 VG SC on day 1.
3120797|NCT01748747|Experimental|Arm II (MART-1 antigen, resiquimod, Montanide ISA 51 VG)|Patients receive MART-1 antigen emulsified in Montanide ISA 51 VG SC followed by resiquimod applied topically on day 1.
3120798|NCT01748747|Experimental|Arm III (MART-1 antigen, Gag:267-274 peptide, resiquimod)|Patients receive MART-1 antigen and Gag:267-274 peptide vaccine peptide vaccine emulsified in Montanide ISA 51 VG SC followed by resiquimod applied topically on day 1.
3120799|NCT01748734|Experimental|Supportive care (cognitive behavioral therapy)|Cognitive behavioral therapy comprising progressive muscle relaxation training, behavioral activation, seeking information as a coping strategy, enhancing social support, cognitive reappraisal, assertive communication, changing depressive core beliefs, goal setting and planning for maintenance, and maintenance over 1 hour once weekly sessions for 12-20 weeks, biweekly sessions for 4-6 weeks, and monthly sessions for 2-3 months for a total of 16-26 sessions.
3120800|NCT01748721|Experimental|Treatment (MORAb-004)|Patients receive anti-endosialin/TEM1 monoclonal antibody MORAb-004 IV on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
3120801|NCT01748708|Experimental|Magnetic seizure therapy|
3120802|NCT01748708|Active Comparator|Electroconvulsive therapy|
3120803|NCT01748695|Experimental|Placebo followed by V158866|Placebo once per day for 4 weeks followed by V158866 450mg once per day for 4 weeks
3120804|NCT01748695|Experimental|V158866 followed by Placebo|V158866 450mg once per day for 4 Weeks followed by Placebo once per day for 4 Weeks
3120805|NCT01748682|Experimental|Liquid Diet Group|The group followed a very low calorie liquid diet for two weeks
3120806|NCT01748682|Active Comparator|Control Group|The group followed a very low calorie diet of normal consistency for two weeks.
3120807|NCT01748669|Experimental|Patients of palmer arsenical keratosis|One soft capsule of garlic oil (10 mg) daily for 12 weeks
3120808|NCT01748669|Active Comparator|Arsenic exposed controls|One soft capsule of garlic oil (10 mg) daily for 12 weeks
3120812|NCT01748643|Experimental|Deep neuromuscular blockade, reversal with sugammadex|a continuous rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with Sugammadex 4mg/kg. Patients are extubated when the train of four ratio is > 0.9.
3120813|NCT01748643|Active Comparator|normal neuromuscular blockade, reversal with neostigmine|After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when TOF ratio > 0.9.
3120814|NCT01748630|Active Comparator|Dexmedetomidine, Midazolam|dexmedetomidine (group DEX); starting dose, 0.4 μg•kg-1•h-1,with intermittent fentanyl
3120815|NCT01748630|Active Comparator|Midazolam|midazolam (group MDZ); starting dose, 0.1 mg•kg-1•h-1
3120816|NCT01748617|Experimental|Pomegranate Juice|Acute ingestion of pomegranate juice with high fat meal.
3120817|NCT01748617|Placebo Comparator|Control|Acute ingestion of juice-free sweetened beverage with high fat meal.
3120818|NCT01748604|Active Comparator|Standard trimodality therapy with MLD|Manual Lymphatic Drainage (MLD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day.
3120819|NCT01748604|Experimental|Trimodality therapy with LPD|Pneumatic massage with Lymphapress-Plus(TM) device (LPD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day
3120820|NCT01748604|Experimental|Bimodality therapy without MLD|intermittent pneumatic compression (IPC) followed by multilayer, multicomponent bandages (MB) until next day.
3120821|NCT01748591||PICOPREP treatment|PICOPREP powder for oral solution according to standard clinical practice
3120822|NCT01748578|Active Comparator|EBI-005-1 5mg/mL|Healthy subjects will be randomized to EBI-005 5mg/mL vs. EBI-005-1 Placebo 3x/day
3120823|NCT01748578|Active Comparator|EBI-005-1 20 mg/mL|Healthy subjects will be randomized to EBI-005 20 mg/mL vs. EBI-005-1 Placebo 3x/day
3120824|NCT01748565||premature infants|Infants born prematurely between 23-0/7 and 27-6/7 weeks post-menstrual age with and without bronchopulmonary dysplasia
3120825|NCT01748552|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo administered to healthy participants in up to 1 of 3 study periods in Part A
3120826|NCT01748552|Experimental|LY2922083 (Part A)|Single ascending dose of LY2922083 (starting at 0.5 milligram [mg]) administered orally to healthy participants in up to 2 of 3 study periods in Part A
3120827|NCT01748552|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo administered to participants with type 2 diabetes mellitus (T2DM) in up to 1 of 3 study periods in Part B
3120828|NCT01748552|Experimental|LY2922083 (Part B)|Single ascending dose of LY2922083 administered orally to participants with T2DM in up to 2 of 3 study periods in Part B. Dose determined by Part A
3120829|NCT01748539|Experimental|KHK4827 70mg SC|
3120830|NCT01748539|Experimental|KHK4827 140mg SC|
3120831|NCT01748539|Experimental|KHK4827 210mg SC|
3120832|NCT01748539|Placebo Comparator|Placebo SC|
3120833|NCT01748526|Experimental|Treatment A|Each volunteer will receive a single 200 mg dose of canagliflozin (JNJ-28431754) on Day 1.
3120834|NCT01748526|Experimental|Treatment B|Each volunteer will receive a single 300 mg dose of canagliflozin (JNJ-28431754) on Day 1.
3120835|NCT01748513||preoperative venous return optimizing|Morbidly obese patients scheduled for bariatric surgery
3120836|NCT01748500|Experimental|Pantoprazole, Docetaxel, Prednisone|
3120837|NCT01748487|Experimental|OZURDEX|24 patients will receive an intravitreal injection of OZURDEX at the end of cataract surgery.
3120838|NCT01748474|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
3120839|NCT01748474|Placebo Comparator|Sham room air|Room air will be applied similarly to oxygen
3120840|NCT01748461|Active Comparator|Structured intervention|Supervised cycle ergometer program
3120841|NCT01748461|Active Comparator|Coach intervention|Non-supervised cycle ergometer program
3120842|NCT01748461|No Intervention|Control group|No cycle ergometer program
3120843|NCT01748448|Active Comparator|Vitamin D|Every month 100 000 units of Vitamin D in syringe oral dispenser is taken . Study duration is maximum 3,5 years or until relapse occurs
3120844|NCT01748448|Placebo Comparator|arachides oleum raffinatum|Every month 100 000 units of vitamin D in syringe Oral dispenser is taken. Study duration is maximum of 3.5 years or until relapse occurs
3120845|NCT01748435||Qutenza|Single treatment with QUTENZA (topical capsaicin 8%) transdermal patch
3120846|NCT01748422||Experimental: Qutenza|Single treatment with Qutenza (topical capsaicin8%) transdermal patch
3120847|NCT01748396|Experimental|Calcitriol + CaCO3|Calcitriol 0.25mcg 1cap daily for 8 weeks, and Calcium Carbonate 500mg 1tab 3 times daily for 8 weeks
3120848|NCT01748396|Active Comparator|Calcitriol|Calcitriol 0.25mcg 1cap daily for 8 weeks
3120849|NCT01748383|Experimental|Transplantation of BMMCs|Autologous BMCs aspiration and transplantation of these cells
3120850|NCT01748383|Experimental|Transplantation of CD 133+ cells|Autologous CD 133+ BMCs aspiration and transplantation of CD 133+ cells
3120851|NCT01748383|Active Comparator|stenting of IRA|The only stenting of IRA
3120852|NCT01748370|Experimental|Vitamin D hypogonadal|Vitamin D supplementation in hypogonadal men
3120853|NCT01748370|Experimental|Vitamin D eugonadal|Vitamin D supplementation in eugonadal men
3120854|NCT01748370|Placebo Comparator|Placebo hypogonadal|Vitamin D supplementation in hypogonadal men
3120855|NCT01748370|Placebo Comparator|Placebo eugonadal|Vitamin D supplementation in eugonadal men
3120856|NCT01748357||Tuberculosis group|Patients with confirmed pulmonary infection with M. tuberculosis. At least 50% of the subjects should be tested before therapy is started. Patients with treatment for tuberculosis >1 week are excluded.
3120857|NCT01748357||Inflammation group|Patients with another inflammatory disease of the lower respiratory tract, i.e. pneumonia, sarcoid or bronchial carcinoma. This group is required to detect VOC pattern caused by pulmonary inflammation.
3120858|NCT01748357||Healthy group|Healthy subjects without lung disease. These subjects should be recruited from outside the hospital / study site to avoid confounding VOC pattern caused by continuous exposure to the hospital environment.
3120863|NCT01748331|Other|Strict fluid restriction < 1 L/day|20 patients will be randomized to strict fluid restriction < 1 L/day
3120864|NCT01748331|Other|Moderate fluid restriction < 2.5 L/day|20 patients will be randomized to moderate fluid restriction < 2.5 L/day
3120865|NCT01748318|Experimental|NM Regional Honey|15 ml of NM Honey applied directly to wound
3120866|NCT01748318|Active Comparator|Bactrim DS|Standard of Care Oral Antibiotic
3120867|NCT01748305|Experimental|Moderate-to-vigorous intensity exercise|Moderate-to-vigorous intensity exercise three times per day for three weeks
3120868|NCT01748292|Active Comparator|Monthly IVT ranibizumab|Monthly intravitreal injections (IVT) ranibizumab for 24 months, not less than 21 days apart to not more than 35 days apart
3120869|NCT01748292|Experimental|Treat and Extend IVT ranibizumab|0.5 mg intravitreal injections (IVT) ranibizumab for 3 consecutive months followed by a treat and extend protocol in which follow-up intervals are increased when there is no clinical and SD-OCT evidence of disease activity by 2-week intervals and patients are treated at every visit. (Comparator arm)
3120870|NCT01748279|Active Comparator|Atorvastatin|40 mg of Atorvastatin once daily as add-on to Formoterol only 12 weeks therapy.
3120871|NCT01748279|Placebo Comparator|Lactose tablet|One tablet taken once a day as add-on treatment to Formoterol baseline 12 weeks therapy.
3120872|NCT01748266||microcirculatory reactivity|Patients were studied during the first 48 postoperative hours. Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
3120873|NCT01748253|Active Comparator|Telmisartan-amlodipine tablet administration group (morning)|
3120874|NCT01748253|Active Comparator|Telmisartan-amlodipine tablet administration group (bedtime)|
3120875|NCT01748240|Experimental|Azacitidine and oral vorinostat|"Patients who meet eligibility criteria will be administered vorinostat orally at 300mg two times daily for 7 days. AZA will be administered SC at 75 mg/m2/day x 7 consecutive days or at maximum tolerated dose if a dose reduction of AZA was needed before entering the trial with a minimum dose of 50mg/m2/d for 7 consecutive days.~Each cycle will last 28 days with AZA starting on day 1 of each cycle and vorinostat starting on day 3."
3120876|NCT01748227|Other|Peer-Coached Pain Self-Management|Participants (n=20) were assigned to a peer coach, who delivered self-management instruction one-on-one over a 4-month period.
3120877|NCT01748214||Nasal CPAP|Infants received nasal CPAP as standard of care.
3120878|NCT01748214||High Flow Nasal Cannual|Infants received high flow nasal cannula as standard of care.
3120879|NCT01748201|Experimental|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
3120880|NCT01748188|Active Comparator|Ultrasound + Exercises + Cryotherapy|Ultrasound of 1 Megahertz (MHz), intensity 2 W/cm2, 5 minutes, for 20 sessions.
3120881|NCT01748188|Experimental|Phonophoresis + Exercises + Cryotherapy|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
3120882|NCT01748188|Experimental|Iontophoresis + Exercices + Cryotherapy|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 milliamperes (mA), 20 minutes, for 20 sessions.
3120883|NCT01748175|Other|Longitudinal follow up|Patients will undergo a characterization phase, which includes a baseline evaluation (1 visit), and a steroid responsiveness evaluation (2 visits). The longitudinal phase will include 3 office visits (annually) over 36 months with bi-annual phone calls. During the study patients will answer questionnaires, perform lung function testing and provide blood, urine, sputum and exhaled breath condensate samples.
3120884|NCT01748162|Experimental|Inhaled steroids|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
3120885|NCT01748162|Active Comparator|Oral control|Patient and clinician observation with short term oral prednisolone as needed. Offered at 1mg/kg (body weight) daily dosing for symptomatic treatment on as needed basis for three days, but may be modified per managing physician's discretion.
3120886|NCT01748149|Experimental|Vemurafenib|"Vemurafenib should be swallowed whole with 8 oz (1 cup) of water. Pharmacokinetic studies will determine if vemurafenib can be crushed. If patients receiving crushed tablets are felt to receive adequate exposure, then they will be allowed to participate in the expansion cohort. [Patients approved to take crushed tablets should use a pill crusher and mix pill with 3-5 ml apple sauce]. If not, then only patients able to swallow whole pills will be eligible.~The patient will be requested to maintain a medication diary of each dose of medication. The medication diary will be returned to clinic staff at the end of each cycle."
3120887|NCT01748136|Other|Single Arm|CT Scan Arm
3120888|NCT01748123|Active Comparator|Chlorthalidone|25mg daily orally for 8 weeks
3120889|NCT01748123|Active Comparator|Hydrochlorothiazide|50mg daily orally for 8 weeks
3120890|NCT01748110|No Intervention|Local Control Group|This arm is for patients in the District of Columbia (DC), (Maryland) MD, (Virginia) VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to standard recommendations for fitness/health interventions prior to surgery.
3120891|NCT01748110|Experimental|Local TRIMM Group|This arm is for patients in the DC, MD, VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to receive daily text message reminder and prompts targeted to the patient's dietary, fitness and urologic goals and needs using the Tailored Rapid Interactive Mobile Messaging (TRIMM) method. Patients will receive these text messages from 4 weeks prior to surgery until 8 week after surgery
3120892|NCT01748110|Experimental|Local Intensive Group|This arm is for patients in the DC, MD, VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to undergo intensive in-person fitness interventions according to the Look AHEAD model. This will involve attendance at weekly support group meetings and personal monthly meetings with a health care provider/
3120893|NCT01748110|No Intervention|Distant Control Group|This arm is for geographically distant patients that are unable to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to standard recommendations for fitness/health interventions prior to surgery.
3120938|NCT01747798|Experimental|Treatment (auranofin)|Patients receive auranofin PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3120894|NCT01748110|Experimental|Distant TRIMM Group|This arm is for geographically distant patients that are unable to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to receive daily text message reminder and prompts targeted to the patient's dietary, fitness and urologic goals and needs using the Tailored Rapid Interactive Mobile Messaging (TRIMM) method. Patients will receive these text messages from 4 weeks prior to surgery until 8 week after surgery
3120895|NCT01748097|Experimental|IV bicarbonate 4.2% 20 cc|injecting 20cc 4.2% to a newly administered IV line
3120896|NCT01748097|Placebo Comparator|IV normal saline|injecting 20 cc normal saline to a newly administered IV line
3120897|NCT01748084|Placebo Comparator|NaCl|NaCl 500 ml IV day 1 and day 15 plus 100 mg methylprednisolone
3120898|NCT01748084|Experimental|Rituximab|Rituximab 1G IV day 1 and day 15 plus 100 mg methylprednisolone
3120899|NCT01748071||Sufentanil group|Grouped by intravenous injection of sufentanil at the time of anesthesia induction
3120900|NCT01748071||Fentanyl group|Grouped by intravenous injection of fentanyl at the time of anesthesia induction
3120901|NCT01748071||Saline group|Grouped by intravenous injection of saline before the time of anesthesia induction
3120902|NCT01748058|Experimental|Active video games|Exercise based on active video gaming
3120903|NCT01748058|No Intervention|Routine care|
3120904|NCT01748045|Experimental|inhaled Nitric Oxide|iNO to start at 20 parts per million (ppm) for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.
3120905|NCT01748045|Placebo Comparator|Nitrogen Gas|Placebo gas will be adjusted the same as study gas: to start at 20ppm for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.
3120906|NCT01748032|Other|Alternative Uses Training|In this task, subjects are asked to produce atypical and alternative uses for common daily objects.
3120907|NCT01748032|Other|Word Association Training|In this task, subjects are asked to generate the first word that comes to their mind, and thus, encourages more general and spontaneous divergent thinking.
3120908|NCT01748019|Experimental|ST1968|ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks
3120909|NCT01748006||Blood and urine samples|
3120910|NCT01747993|Experimental|tamsulosin|Tamsulosin (0.4 mg/j) (1 tablet / day for 6 days)
3120911|NCT01747993|Placebo Comparator|placebo|1 tablet / day for 6 days
3120912|NCT01747980|Experimental|PRX-112|250 mL of resuspended carrot cells administered orally in a vehicle
3120913|NCT01747967|Experimental|Meal test|Both new-onset T1D children and adults will be recruited and followed up through 4 meal tests at 0, 6, 12 , 18, 24 and 30 months.
3120914|NCT01747954|Experimental|Bag Squeezing|"20% increase in FiO2~Inflation pressure of 30 cm H2O + 10l O2/min~0.5 ml saline 0.9%~10 Manual Hyperinflation~10 vibrocompression~Aspiration Tracheal"
3120915|NCT01747954|Active Comparator|Thoracic vibrocompression|"20% increase in FiO2~0.5 ml saline~10 vibrocompression toracica on the right and left~Aspiration Tracheal"
3120916|NCT01747941|Experimental|Cohort 1|Single ascending oral doses in fasted conditions
3120917|NCT01747941|Experimental|Cohort 2|Single ascending oral doses in fasted conditions
3120918|NCT01747941|Experimental|Cohort 3|Single ascending oral doses in fed conditions
3120919|NCT01747928|Experimental|Group 1|
3120920|NCT01747915|Experimental|Study Drug Level 1|
3120921|NCT01747915|Experimental|Study Drug Level 2|
3120922|NCT01747915|Placebo Comparator|Placebo|
3120923|NCT01747902|Other|Biceps tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
3120924|NCT01747902|Other|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
3120925|NCT01747889|Experimental|Electronic system|patients managed with an electronic chest drainage system
3120926|NCT01747889|No Intervention|traditional system|patients managed with a traditional analogue chest drainage system
3120927|NCT01747876|Experimental|LEE011|
3120928|NCT01747863||Mild NE|Infants with evidence of a perinatal event and NE who do not qualify for therapeutic hypothermia.
3120929|NCT01747850|Experimental|Sativex|Intervention consist on Sativex Spray (Δ9-tetrahydrocannabinol/cannabidiol). Study subjects will be randomized in blocks of ten to one of the two groups (Sativex vs. placebo) in a double blind manner. There will be a gradual increase of the maximal allowed dose starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays per day at the end of week 2. There will be a total of 12 weeks of drug exposure. All participants will receive a combination of pharmacotherapy (Sativex or Placebo) associated with a weekly intervention of combined Motivational Enhancement/Cognitive Behavioral Therapy.
3120930|NCT01747850|Placebo Comparator|Placebo spray|Participants will receive a combination of Placebo spray associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy
3120931|NCT01747850|Experimental|Pilot Study|The first five subjects will be treatment-seekers that fit our inclusion/exclusion criteria and that will be treated open-label. These subjects will be instructed to use the Sativex Spray according to the induction schedule provided above. These first subjects will allow us to determine if our schedule for dosing is appropriate for the subsequent phase of the study.
3120932|NCT01747837|No Intervention|standard ICD implantation alone|These subjects will undergo standard ICD implantation alone (if not already present)
3120933|NCT01747837|Experimental|Boston Scientific Vessix Renal Denervation System|"These subjects will undergo standard ICD implantation (if not already present) plus renal sympathetic denervation.~Ablation arm"
3120934|NCT01747824||Agitation Group|Patients that are evaluated to have an altered mental status score greater than 1 will be enrolled in the Agitation Group.
3120935|NCT01747824||Pain Group|Patients that report severe pain secondary to a long bone fracture or dislocation and report a visual analog scale pain score greater than 7 will be enrolled in the Pain Group.
3120936|NCT01747811|Experimental|wavelength-1 bright light|30 minutes daily light exposure for 6 weeks
3120937|NCT01747811|Placebo Comparator|wavelength-2 bright light|30 minutes daily light exposure for 6 weeks
3154238|NCT01520012|Experimental|Sequence 5|
3120939|NCT01747785||Healthy controls|Individuals without history of cardiovascular disease and at least 18 years of age will take a baseline (at rest) cardiopulmonary exercise test (CPX) and have a cardiac echocardiogram to measure myocardial deformation. CPX and echocardiograms will be repeated during exercise sessions at 3 visits over a 12 week period.
3120940|NCT01747785||Patients at risk of heart failure|Individuals at risk of heart failure and a preserved ejection fraction of at least 50% will take a baseline (at rest) cardiopulmonary exercise test (CPX) and have a baseline cardiac echocardiogram to measure myocardial deformation. CPX and echocardiograms will be repeated during exercise sessions at 6 visits over a 12 week period. A cardiac rehabilitation exercise program will also occur over 12 weeks.
3120941|NCT01747772|Experimental|Shear Wave Sonoelastography for Fibrosis Assessment|Shear Wave sonoelastography (SWE) was performed in patients who were scheduled for a non-focal liver biopsy.
3120942|NCT01747759|Other|Kruskal-Wallis and qualitative parameters|The evaluations will take place at baseline, the day before surgery and 6 weeks post-surgery on knowledge and beliefs scores at each visit and on a satisfaction score on the last one. Quantitative data will be compared between groups by the Kruskal-Wallis and qualitative parameters via Fisher exact test
3120943|NCT01747759|Other|Fisher exact test|The evaluations will take place at baseline, the day before surgery and 6 weeks post-surgery on knowledge and beliefs scores at each visit and on a satisfaction score on the last one. Quantitative data will be compared between groups by the Kruskal-Wallis and qualitative parameters via Fisher exact test
3120944|NCT01747746|Active Comparator|Rivaroxaban|Anticoagulation with Rivaroxaban 20 mg daily with dinner for 30 days
3120945|NCT01747746|Other|Warfarin and Enoxaparin|Warfarin: 1-10 mg per Nomogram Enoxaparin weight based 1 mg/kg Q12 or 1.5 mg/kg/day Historic control
3120946|NCT01747733||Endoscopy patients|Patients undergoing endoscopy in the endoscopy unit in HUCH (Helsinki University Central Hospital).
3120947|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 1000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 1000 IU daily, for 12 months
3120948|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 2000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 2000 IU daily, for 12 months
3120949|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 3000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 3000 IU daily, for 12 months
3120950|NCT01747720|Placebo Comparator|Placebo|daily, for 12 months
3120951|NCT01747707|Experimental|docetaxel, cisplatin and S-1 (DCS)|All patients receive the combination therapy of docetaxel, cisplatin and S-1 for a maximum of 6 cycles. Docetaxel 60mg/m2 IV infusion over 1 hour on d1; Cisplatin 30mg/m2 IV infusion on d1,2; S-1 40mg orally twice a day for patients with the body surface area (BSA) less than 1.25m2, 50mg twice a day with the BSA between 1.25 and 1.5m2, 60mg twice a day with the BSA over 1.5m2.
3120952|NCT01747694|Experimental|Multi-respiratory muscle training|Patients will perform multi-repiratory muscle training programe for 12 weeks
3120953|NCT01747694|No Intervention|Diaphragmatic breathing|Patients will be taught diaphragmatic breathing technique routinely. To practice at home lasting 12 weeks
3120954|NCT01747681||Microfracture|Microfracture of articular chondral defect
3120955|NCT01747668|Placebo Comparator|Control Supplement|soft-gel placebo capsules, 2 capsules from the placebo bottle per day
3120956|NCT01747668|Experimental|Experimental Supplement A|soft-gel capsules; 1 capsule from the experimental bottle and 1 capsule from the placebo bottle per day
3120957|NCT01747668|Experimental|Experimental Supplement B|soft-gel capsules; 2 capsules from the experimental bottle per day
3120958|NCT01747655||Duodopa|Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)
3120959|NCT01747655||Standard of Care|Participants that return to oral or transdermal anti-parkinson's disease medications
3120960|NCT01747642|Active Comparator|Oncoxin|Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
3120961|NCT01747642|Active Comparator|Oncoxin & Suranix|Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
3120962|NCT01747642|No Intervention|Supportive treatment|Only supportive treatment. No chemotherapy, radoiotherapy, ablation or surgical intervention will be carried out.
3120963|NCT01747629|Placebo Comparator|Placebo MDPI|Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
3120964|NCT01747629|Experimental|Albuterol MDPI|Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.
3120965|NCT01747616|Experimental|12 subjects wearing soft contact lenses|The medical test device will be administered with the contact lenses inserted
3120966|NCT01747616|Experimental|12 subjects wearing rigid contact lenses|The medical test device will be administered with the contact lenses inserted
3120967|NCT01747616|Experimental|12 subjects with soft contact lenses|The medical test device will be administered before insertion of the contact lenses
3120968|NCT01747616|Experimental|12 subjects with rigid contact lenses|The medical test device will be administered before insertion of the contact lenses
3120969|NCT01747603|No Intervention|Current management of LPTB|The current pragmatic, but non-systematic, pattern of management of LPTB infants. Growth measurements, feeding histories/methods, illness history including emergent visits to clinicians, walk-in clinics and emergency departments and breast-feeding support clinics, and basic developmental milestones (as itemized in the Rourke Developmental screening tool) will be recorded by families and primary health care providers as itemized in the Memory Book at the assessments made at the discretion of the health care providers.
3120970|NCT01747603|Experimental|Specialized LPTB Clinic|Additional 6 specialized LPTB follow-up clinic visits attended by pediatricians and neonatologists. Detailed findings from physical examination, feeding histories/methods, illness history including emergent visits to clinicians, walk-in clinics and emergency departments and breast-feeding support clinics, basic developmental milestones (as itemized in the Rourke Developmental screening tool) and physician recommendations will be recorded at each appointment. These will be compared to those obtained from families and primary health care providers as itemized in the Memory Book.
3120971|NCT01747590|Experimental|Zolpidem, Alprazolam, Caffeine, and Placebo|The 4 medications are given in a counterbalanced design.
3120972|NCT01747577|Experimental|Solifenacin group|
3120973|NCT01747577|Placebo Comparator|Placebo group|
3120975|NCT01747551|Active Comparator|mFOLFOX6 + Ziv-aflibercept|Patients received mFOLFOX6 and ziv-aflibercept every 2 weeks. Ziv-aflibercept 4mg/kg was given via intravenous (IV) infusion over 1 hour. Immediately following this was administration of mFOLFOX6: oxaliplatin 85 mg/m2 IV and leucovorin 400 mg/m2 IV were given concurrently over 120 minutes, followed by fluorouracil 400 mg/m2 IV bolus injection and then fluorouracil 2,400 mg/m2 IV infusion over 46 hours. Patients continued on treatment until radiological or clinical progression, unacceptable toxicity, or death.
3120976|NCT01747551|Active Comparator|mFOLFOX6 + Placebo|Patients received mFOLFOX6 and placebo every 2 weeks. Placebo was given via intravenous (IV) infusion over 1 hour. Immediately following this was administration of mFOLFOX6: oxaliplatin 85 mg/m2 IV and leucovorin 400 mg/m2 IV were given concurrently over 120 minutes, followed by fluorouracil 400 mg/m2 IV bolus injection and then fluorouracil 2,400 mg/m2 IV infusion over 46 hours. Patients continued on treatment until radiological or clinical progression, unacceptable toxicity, or death.
3120977|NCT01747538|Placebo Comparator|Placebo|
3120978|NCT01747538|Experimental|Dose 1 gevokizumab|
3120979|NCT01747538|Experimental|Dose 2 gevokizumab|
3120980|NCT01747525||NIRS/IVUS of coronary artery|All patients will have an epicardial coronary artery stenosis of intermediate severity (>50% to <70% stenosis) (stenosis ≥20% - ≤70%) by invasive angiography in whom IVUS is planned to further clinical evaluation of lesion severity; or a severe epicardial coronary artery stenosis by invasive angiography and percutaneous coronary intervention (PCI) is planned for definitive treatment.
3120981|NCT01747512|Active Comparator|C-PERT|45 patients with cancer
3120982|NCT01747512|Active Comparator|G-PERT|65 patients with cancer
3120983|NCT01747499|Experimental|Cohort 1|"Conditioning treatment~Transplant on Day 0~15 mg/m2 azacitidine Days 7-11~15 mg/m2 azacitidine Days 35-39~15 mg/m2 azacitidine Days 63-67~15 mg/m2 azacitidine Days 91-95"
3120984|NCT01747499|Experimental|Cohort 2|"Conditioning treatment~Transplant on Day 0~30 mg/m2 azacitidine Days 7-11~30 mg/m2 azacitidine Days 35-39~30 mg/m2 azacitidine Days 63-67~30 mg/m2 azacitidine Days 91-95"
3120985|NCT01747499|Experimental|Cohort 3|"Conditioning treatment~Transplant on Day 0~37.5 mg/m2 azacitidine Days 7-11~37.5 mg/m2 azacitidine Days 35-39~37.5 mg/m2 azacitidine Days 63-67~37.5 mg/m2 azacitidine Days 91-95"
3120986|NCT01747499|Experimental|Cohort 4|"Conditioning treatment~Transplant on Day 0~45 mg/m2 azacitidine Days 7-11~45 mg/m2 azacitidine Days 35-39~45 mg/m2 azacitidine Days 63-67~45 mg/m2 azacitidine Days 91-95"
3120987|NCT01747499|Experimental|MTD Cohort|"Conditioning treatment~Transplant on Day 0~Dose determined in Phase I - azacitidine Days 7-11~Dose determined in Phase I - azacitidine Days 35-39~Dose determined in Phase I - azacitidine Days 63-67~Dose determined in Phase I - azacitidine Days 91-95"
3120988|NCT01747486|Experimental|Target dose of 1-5x10e8|Arm 1: Target dose of 1-5x10e8 CART-19 cells (calculated as range of 10-50% transduced cells in 1 x10e9 total cells)
3120989|NCT01747486|Experimental|Target dose of 1-5x10e7|Arm 2: Target dose of 1-5x10e7 CART-19 cells (calculated as the range of 10-50% transduced cells in 1 x10e8 total cells)
3120990|NCT01747447|Placebo Comparator|Vitamin D placebo + fish oil placebo|
3120991|NCT01747447|Active Comparator|Vitamin D placebo + fish oil|
3120992|NCT01747447|Active Comparator|Vitamin D + fish oil placebo|
3120993|NCT01747447|Active Comparator|Vitamin D + fish oil|
3120994|NCT01747408|Experimental|25% human albumin|Subjects will be entered into one of 4 increasing dosages of 25% human albumin sequentially. Once the first 20 subjects have been enrolled and the DSMB reviews data and approves moving to the next dosage tier patients will be entered into the following dosage tier.
3120995|NCT01747395|No Intervention|Control Group|No exercise group (sedentary)
3120996|NCT01747395|Experimental|Aerobic Exercise Training|Group undergoing isolate aerobic exercise training 3 times/week, during 40 minutes, for 04 mouths
3120997|NCT01747395|Experimental|Inspiratory Muscle Training|Group undergoing isolate inspiratory muscle training 7 times/week, during 30 minutes, for 04 mouths
3120998|NCT01747395|Experimental|Aerobic+Inspiratory Muscle Training|Group undergoing aerobic exercise training (3 times/week during 40 minutes) associate inspiratory muscle training (7 times/week during 30 minutes) for 04 mounths
3120999|NCT01747356|Experimental|Resolute stent treatment group|"All patients will receive Resolute stent implantation to cure severe coronary atherosclerotic lesions.~RESOLUTE stent system specification (eluted zotarolimus 1.6μg/mm2):~After stent implantation, each patient will be followed up at time point of 30-day, 6-month and 12-month.~Follow-up window:~Duration of hospital stay Follow-up 1: 30days after procedure (±7 days) Follow-up 2: 6-month after procedure (±30 days) Follow-up 3: 12-month after procedure (±30 days)"
3121000|NCT01747343|Experimental|Underwear/Differential Reinforcement|All subjects will wear underwear followed by wearing underwear while receiving differential reinforcement.
3121001|NCT01747330|Experimental|Creon micro, minimicrospheres|
3121002|NCT01747317|Experimental|Single arm study|Single arm study.The investigators will conduct computed tomography,angiography and FFR measurement during angiography in this single arm.
3121003|NCT01747304||Screening population|Healthy post-menopausal women attending bone mineral density screening clinic with leg/hip/groin pain/discomfort/weakness an has been on anti-resorptive therapy for at least 5 years.
3121004|NCT01747304||Comparator Group|Control group from Toronto CaMOS cohort willing to participate.
3121005|NCT01747304||AFF group|participants in the AFF Cohort study at UHN
3121006|NCT01747291||Atypical femur fracture cohort|
3121007|NCT01747278|No Intervention|Placebo|Patients were not treated with Trimethoprim/Sulfamethoxazole (TMP/SMX).
3121008|NCT01747278|Experimental|TMP/SMX|Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 80 mg/400 mg p.o. every day as PCP Prophylaxis.
3121009|NCT01747252|Experimental|RGC1|RGC containing the equivalent of 50 mg resveratrol
3121010|NCT01747252|Active Comparator|Resveratrol|The equivalent of 150 mg resveratrol
3121011|NCT01747252|Experimental|RGC2|RGC containing the equivalent of 150 mg resveratrol
3121012|NCT01747239|Experimental|Cabazitaxel|25 mg/m2 IV every three weeks
3121013|NCT01747226|Placebo Comparator|Fluoride rinse|A fluoride rinse with alcohol was chosen because its similarity in color and aroma to the active rinses. This anti-cavity rinse does not contain any active components and therefore it is not expected to have any anti-malodour activity.
3121186|NCT01746095|Placebo Comparator|Placebo inhalation powder|Matching placebo inhaled BID
3121014|NCT01747226|Active Comparator|Halita|Halita is a CHX-containing benchmark product that has proven to be clinically effective against halitosis (Roldan et al, 2003)
3121015|NCT01747226|Active Comparator|Meridol Halitosis|This study aims to confirm the effect of meridol®Halitosis(AmF/SnF2 and zinc) already observed in volunteers with morning bad breath (physiological)(Wigger-Alberti et al, 2010; Wilhelm et al, 2010)in patients with oral malodor (pathological).
3121016|NCT01747226|Sham Comparator|Water|To distinguish the masking effect caused by the formulations and the one caused by the rinsing itself.Only for short term evaluation (15') to not to compromise compliance of patients.
3121017|NCT01747187||Septic shock|
3121018|NCT01747174|Experimental|Std PCI + Intra-coronary (IC) Adenosine|IC Adenosine in to IRA (following thrombus aspiration) with further dose via guide catheter following coronary stent deployment.
3121019|NCT01747174|Experimental|Std PCI + IC Sodium Nitroprusside (SNP)|IC SNP in to IRA (following thrombus aspiration) with further dose via guide catheter following coronary stent deployment.
3121020|NCT01747174|Active Comparator|Std PCI|Standard PCI only
3121021|NCT01747161|Experimental|botulin toxin|botulin toxin
3121022|NCT01747161|Placebo Comparator|physiological water|physiological water
3121023|NCT01747135|Experimental|Open label|
3121024|NCT01747122|Experimental|Wound catheter|Wound catheter
3121025|NCT01747122|Active Comparator|Epidural|Standard epidural, pre-operative insertion, to be run for 48 hours
3121026|NCT01747109|Experimental|PREOXYFLOW|"Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction"
3121027|NCT01747109|Active Comparator|STANDARD FACE MASK|"Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. No specific trademark is requested by the protocol."
3121028|NCT01747083|Experimental|A|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mgx2tablets))under fasting condition
3121029|NCT01747083|Experimental|B|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mgx2tablets))under fed condition
3121030|NCT01747070|Active Comparator|tDCS and EAC sham|Subjects will receive 05 sessions of tDCS. The tDCS consist of application of current of 2 mA, the anode being placed in the motor cortex (M1) and the cathode in the supraorbital region, for 30 minutes,using electrodes with saline solution. The sham DIMST consist of the use of rubber electrodes placed in the same places that active treatment. Will use the same electrical apparatus, but without pass of current to the electrodes. The unit will be in front of the patient on with their lights blinking.
3121031|NCT01747070|Placebo Comparator|tDCS sham and EAC sham|The subjects will receive 05 sessions of tDCS sham and EAC sham. The sham tDCS be performed in the same way as the active, although the Electro device is turned off 30 seconds after the beginning of treatment, the session will have the same duration of 30 minutes. The EAC sham consists of placement of rubber electrodes in the same areas of active stimulation (beside the spinous processes of L1 to S2, muscles vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus). The electrodes are connected to the same device electro, for 30 minutes, but without passage of electrical stimulation to the patient. The device is kept on and in front of the patient, with the lights blinking.
3121032|NCT01747070|Active Comparator|tDCS sham and EAC|Subjects will receive 05 sessions of tDCS sham and EAC.The sham tDCS be performed in the same way as the active, although the Electro device is turned off 30 seconds after the beginning of treatment, the session will have the same duration of 30 minutes. The EAC consist of electrical stimulation with a frequency of 2 Hz for 30 min. The needles are placed beside the spinous processes of L1 to S2, with a depth of 3 cm and in the muscles: vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus.
3121033|NCT01747070|Experimental|tDCS and EAC|Subjects will receive 05 sessions of transcranial direct current stimulation(tDCS) and electroacupuncture(EAC). The tDCS consist of application of current of 2 mA, the anode being placed in the motor cortex (M1) and the cathode in the supraorbital region, for 30 minutes,using electrodes with saline. The electroacupuncture consist of electrical stimulation with a frequency of 2 Hz for 30 min. The needles are placed beside the spinous processes of L1 to S2, with a depth of 3 cm and in the muscles: vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus.
3121034|NCT01747057|Experimental|Dynamic guide resuscitation|This arm follows a resuscitation protocol based on dynamic-parameters-guided fluid management.
3121035|NCT01747057|Active Comparator|Standard resuscitation|This arm follows a common resuscitation protocol based on Surviving Sepsis Campaign recommendations.
3121036|NCT01747044|Active Comparator|Milnacipran|Milnacipran is an antidepressant known and used in major depressive disorder according to its marketing authorization but is also part of the molecules used in the treatment of chronic neuropathic pain and fibromyalgia according to the recommendations of the EULAR
3121037|NCT01747044|Placebo Comparator|Capsules of lactose|placebo over a period of 8 weeks to 24 weeks
3121038|NCT01747031|Experimental|Single arm study|Single arm study.The investigators will conducte computed tomography,angiography and FFR measurement during angiography in this single arm.
3121039|NCT01747018|Experimental|Platelet-rich Plasma|From all the patients who participated in the clinical trial, 27 ml of blood sample was collected with a 20-G needle from an antecubital vein so that the ratio of the blood and the anti-coagulant became 10:1. The collected blood samples were transferred to a prepared separation kit (Prosys PRP, Seoul, Korea) and underwent centrifugation at the speed of 3,000 RPM for three minutes. The buffy coat layer and the plasma of the upper portion of the layer were obtained and were transferred to a concentration kit (Prosys PRP, Seoul, Korea) using a 10-ml syringe. They again underwent centrifugation at the speed of 3,300 RPM for three minutes in order to obtain concentrated PRP. The injection area was sterilized aseptically and 3-4 cc of PRP were percutaneously injected into the knee joints.
3121040|NCT01747005||Conventional therapy|
3121072|NCT01746784|Placebo Comparator|Normal saline|Subjects randomized to placebo will receive normal saline administered intravenously using the same volume as the active drug group
3121073|NCT01746771|Experimental|HM781-36B, Paclitaxel, Trastuzumab|HM781-36B(Poziotinib): QD*2weeks/3weeks Paclitaxel: 175mg/m2 Trastuzumab(Herceptin): 8mg/kg
3155534|NCT01511185|No Intervention|Healthy|
3121041|NCT01747005||ERAS|Oral intake of solid food restriction 6 hours before surgery. Oral intake clear fluids restriction 2 hours before surgery. Intravenous 5% Dextrose-500 ml 1 hour before surgery. Intravenous dexamethasone -4mg before anesthesia. Combined spinal-epidural anesthesia. Intraoperatively 10 ml/kg intravenous of crystalloids. Paracetamol intravenous 1g. Early mobilization of patient. Oral solid food intake 4 hour postoperative. Postoperative continuous epidural analgesia.
3121042|NCT01746992|Experimental|pirarubicin|3 cycles of CTOP(cyclophosphamide,vincristin,pirarubicin and prednisone),3 cycles of ITE(ifosfamide, pirarubicin, etoposide)and 2 cycles of methotrexate
3121043|NCT01746992|Active Comparator|doxorubicin|8 cycles of CHOP regimen(cyclophosphamide,vincristin,doxorubicin and prednisone)
3121044|NCT01746979|Active Comparator|Gemcitabine plus TH-302|
3121045|NCT01746979|Placebo Comparator|Gemcitabine plus placebo|
3121046|NCT01746966||Rheumatoid Arthritis|20 patients age of 20-60 with Rheumatoid Arthritis according to ARA 1987 revised criteria and disease activity Disease Activity Score (DAS) 3-5
3121047|NCT01746966||Healthy controls participants|Healthy controls age of 20-60 according to conclusion of preventive medicine department
3121048|NCT01746940|Placebo Comparator|Group 1, Placebo Topical Solution|Group 1: Placebo group -Placebo solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. The subject will then exit the treatment portion of the trial and be followed for safety for seven days . All placebo subjects, regardless of Von Frey filament test results, will undergo Phase 1 recovery (i.e. at least 90 minutes after cotton pledget removal) and associated required study procedures (including the final 12 lead ECG). After a minimum of 24 hours from the time of study drug pledget removal, the subject may continue the procedure, and the treatment reverts to standard anesthetic management (suitable products at the discretion of the investigator). Alternatively, at the investigator's discretion, the diagnostic procedure or surgery may be delayed until study termination.
3121049|NCT01746940|Active Comparator|Group 2, Cocaine HCl 4% Topical Solution|Group 2: Cocaine HCI 4% Group - Cocaine HCl 4% topical solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. If a score of 0 is recorded, then the diagnostic procedure or surgery proceeds along with safety monitoring for at least 90 minutes after removal of the pledget(s). The subject will be followed for safety for seven days. The total amount of Cocaine HCl 4% topical solution used will be recorded.
3121050|NCT01746940|Active Comparator|Group 3, Cocaine HCl 10% Topical Solution|Group 3: Cocaine HCI 10% Group - Cocaine HCl 10% topical solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. If a score of 0 is recorded the application then proceed with the diagnostic procedure or surgery along with safety monitoring for at least 90 minutes post removal of pledgets, and, the subject will be followed for safety for at least seven days post solution application. The total amount of Cocaine HCl 10% topical solution used will be recorded.
3121051|NCT01746927||cricoid pressure|
3121052|NCT01746914||Lung transplantated patients|Patients undergone lung transplantation
3121053|NCT01746901|Placebo Comparator|Treatment A|
3121054|NCT01746901|Experimental|Treatment B|
3121055|NCT01746901|Experimental|Treatment C|
3121056|NCT01746901|Active Comparator|Treatment D|
3121057|NCT01746901|Experimental|Treatment E|
3121058|NCT01746901|Active Comparator|Treatment F|
3121059|NCT01746888||Older Adults|Adults 65 years and older who present to the Emergency Department.
3121060|NCT01746875|Experimental|Treatment|aflibercept intravitreal injections, 2.0 mg monthly x 3 doses, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; aflibercept intravitreal injections, 2.0 mg x 3 doses is repeated, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; verteporfin photo dynamic therapy.
3121061|NCT01746875|No Intervention|Observation|
3121062|NCT01746862|Experimental|Saizen Test Group|
3121063|NCT01746862|Active Comparator|Saizen Control Group|
3121064|NCT01746849|Experimental|palifermin with Lupron|All patients undergo total body irradiation (TBI) on days -9 to -6 & receive thiotepa intravenously (IV) over 2-4 hours on days -5 to -4, cyclophosphamide IV over 30-60 minutes on days -3 to -2, & anti-thymocyte globulin infused over 12 hours on days -3 to -2 Pts undergo T-cell depleted allogeneic hematopoietic stem cell transplant on day 0. Pts will receive a three month depot dose of Lupron 3-6 weeks prior to the start date of the pre-transplant conditioning regimen. Pts will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 & no more than 48 hours prior to the start of cytoreduction. Pts will receive three additional daily doses of palifermin the first approximately 6 hours after the stem cell infusion on day 0, followed by two daily doses given at 24 hour intervals on d+1 & d+2. Pts will receive a further 3-month depot injection of Lupron approximately 3 months (+/- one week) post the first dose.
3121065|NCT01746849|Experimental|palifermin with Degarelix|Participants on the degarelix arm will receive a loading dose of degarelix 240 mcg subcutaneous 4-14 days before the start of pre-transplant conditioning. All participants will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 and no more than 48 hours prior to the start of cytoreduction.
3121066|NCT01746836|Experimental|Ponatinib|Starting dose of Ponatinib: 30 mg by mouth once daily.
3121067|NCT01746823||Controls, Keratoconus|Sub group of Keratoconus to be treated with anti-inflammatory agents ie Cyclosporine-A
3121068|NCT01746810|Experimental|Stereotactic Body RT and IRGA|Patients undergo stereotactic body radiation therapy QD for a total of 5 fractions and then undergo IRGA (either radiofrequency ablation or microwave ablation) 1 week later.
3121069|NCT01746797||Women currently taking antidepressants|Women who have selected to stay on antidepressant medication while undergoing infertility treatment.
3121070|NCT01746797||Women not on antidepressants|Women who decided to discontinue their antidepressants while undergoing fertility treatments.
3121071|NCT01746784|Experimental|N6022|Subjects randomized to study drug will receive N6022 by intravenous infusion once per day for 7 days
3121578|NCT01743573|Experimental|yoga training|Yoga training
3121074|NCT01746758|Experimental|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
3121075|NCT01746758|No Intervention|Comparison arm|No intervention will be implemented in intervention arm. Data on reproductive health conditions and treatments and data on referrals from drug stores in this arm will be obtained directly from ministry of health registers filled and filed at the dispensary and health centres, plus a tailor-made form which is filled by the dispensary and health centre clinicians whenever they receive a patient in the eligible categories.
3121076|NCT01746745|Experimental|[C14]-LY2940680|Single 100 mg of LY2940680 containing 100 micro curies of radioactivity
3121077|NCT01746732|Experimental|Ortho-Cyclen|Ortho-Cyclen (35 microgram (mcg) ethinyl estradiol and 250 mcg norgestimate) administered orally, once daily (QD), for 28 days (lead-in period). Then, Ortho-Cyclen orally QD for 28 Days (Days 1 to 28) in one of two treatment periods.
3121078|NCT01746732|Experimental|Ortho-Cyclen + Evacetrapib|Ortho-Cyclen administered orally, QD, for 28 days (lead-in period). Then, Ortho-Cyclen orally QD for 28 Days (Days 1 to 28) and 130 mg evacetrapib orally, QD, for 21 days (Days 1 to 21) in one of two treatment periods.
3121079|NCT01746719|Experimental|Etodolac Capsules USP 300 mg|Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India
3121080|NCT01746719|Active Comparator|Etodolac Capsules USP 300mg|Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA
3121081|NCT01746706|Experimental|patients|
3121082|NCT01746706|Experimental|volunteers|
3121083|NCT01746693|Experimental|amblyopia ex anisometropia|20 male and female volunteers with amblyopia ex anisometropia
3121084|NCT01746693|Experimental|amblyopia ex strabismus|20 male and female volunteers with amblyopia ex strabismus
3121085|NCT01746693|Experimental|control subjects|20 healthy male and female control subjects
3121086|NCT01746680|Experimental|Tacrolimus with Methotrexate|Subjects have tacrolimus per oral once daily with methotrexate for 24weeks. Tacrolimus increased dosing regimen: 1mg for 0~4 weeks, 2mg for 4 weeks~8 weeks, 3mg for 8 weeks~24 weeks
3121087|NCT01746667|Experimental|Exposure in vivo|This treatment will consist of 10 sessions (twice a week) of exposure therapy based on the protocol used previously in exposure therapy for social anxiety disorder by Scholing & Emmelkamp (1993).
3121088|NCT01746667|Experimental|Virtual Reality Exposure Therapy|"This treatment consists of 10 sessions (twice a week) of exposure therapy by using virtual environments.~The difference between the exposure in vivo and virtual reality exposure therapy is the exposure component, which will be delivered in vivo in one condition and through the Head Mounted Display (HMD) in the other condition."
3121089|NCT01746667|No Intervention|Wait-list|Participants on the wait-list will be offered either exposure in vivo or in virtual reality after a waiting period of five weeks.
3121090|NCT01746654|Experimental|P128-0.1 mg|Three healthy adult volunteers will be enrolled to P128-0.1 mg single dose-cohort 1 (Part A) Three healthy adult volunteers will be enrolled to P128-0.1 mg multiple doses-Cohort 4 (Part B) Ten chronic kidney disease patients will be enrolled to P128-0.1 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-0.1 mg single dose (Part D)
3121091|NCT01746654|Experimental|P128-0.3 mg|Three healthy adult volunteers will be enrolled to P128-0.3 mg single dose-Cohort 2 (Part A) Three healthy adult volunteers will be enrolled to P128-0.3 mg multiple doses-Cohort 5 (Part B) Ten chronic kidney disease patients will be enrolled to P128-0.3 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-0.3 mg single dose (Part D)
3121092|NCT01746654|Experimental|P128-1.0 mg|Three healthy adult volunteers will be enrolled to P128-1.0 mg single dose-Cohort 3 (Part A) Three healthy adult volunteers will be enrolled to P128-1.0 mg multiple doses-Cohort 6 (Part B) Ten chronic kidney disease patients will be enrolled to P128 1.0 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-1.0 mg single dose (Part D)
3121093|NCT01746654|Placebo Comparator|Placebo|Three healthy adult volunteers will be enrolled to placebo single dose-Cohort 1-3 (Part A) Three healthy adult volunteers will be enrolled to placebo multiple doses-Cohort 4-6 (Part B) Ten chronic kidney disease patients will be enrolled to placebo multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to placebo single dose (Part D)
3121094|NCT01746641|Active Comparator|Remifentanil|"Remifentanil target controlled infusion effect site with Minto's pharmacokinetic model.~Start dose: 1 ng/mL. Titration: 0.5 ng/mL according to clinical criteria."
3121095|NCT01746641|Active Comparator|Propofol|"Propofol target controlled infusion effect site with Marsh's pharmacokinetic model.~Start dose: 1 mcg/mL. Titration: 0.5 mcg/mL according to clinical criteria."
3121096|NCT01746628|Placebo Comparator|Hysterectomy without FloSeal|Endometrial curettage Intrauterine foley balloon placement for 5 minutes Removal of intrauterine foley balloon Saline irrigation of uterine cavity Hysterectomy
3121097|NCT01746628|Active Comparator|Hysterectomy with FloSeal|Endometrial curettage FloSeal placement into uterine cavity Intrauterine foley balloon placement for 5 minutes Removal of intrauterine foley balloon Saline irrigation of uterine cavity Hysterectomy
3121098|NCT01746615|Experimental|30 Patients with BRVO in one eye|
3121099|NCT01746615|Experimental|30 healthy age and sex matched controls|
3121100|NCT01746602|Experimental|healthy subjects I|20 healthy subjects
3121101|NCT01746602|Experimental|healthy subjects II|20 healthy subjects
3121102|NCT01746602|Experimental|healthy subjects III|20 healthy subjects
3121103|NCT01746602|Experimental|healthy subjects IV|20 healthy subjects
3121104|NCT01746602|Experimental|healthy subjects V|20 healthy subjects
3121105|NCT01746602|No Intervention|healthy subjects VI|20 healthy subjects
3121106|NCT01746589|Other|myopic LASIK procedure|All subjects will receive bilateral myopic LASIK procedure using the 200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
3121107|NCT01746576|Other|All|All subjects will undergo spontaneous ventilation through an impedance threshold device and ScvO2 will be recorded before and after
3121108|NCT01746563|Experimental|Ranibizumab|Ranibizumab 0,05 mg intravitreal injection
3121109|NCT01746563|Active Comparator|Laser Therapy|Laser Therapy alone
3121155|NCT01746329|Placebo Comparator|Placebo|Oral intake of 75 grams of glucose in water
3121110|NCT01746550|Experimental|MD-12-001 Stent Arm|This study includes a single arm, the MD-12-001 Stent Arm.
3121111|NCT01746524|Experimental|ATTUNE Primary Total Knee Arthroplasty|"Subjects will receive one of the following total knee configurations:~Cruciate Retaining Fixed Bearing (CR FB) Posterior Stabilized Fixed Bearing (PS FB) Cruciate Retaining Rotating Platform (CR RP) Posterior Stabilized Rotating Platform (PS RP)"
3121112|NCT01746511|Active Comparator|Glycerin Suppository|"Based on our institution's protocol, infant will receive a glycerin shave within one hour of initiation of phototherapy and then every eight hours while under phototherapy.~Subjects will be block randomized (varying block sizes of 2 to 8). Babies in both groups will be fed according to NICU standard birth weight protocols. Stratified enrollment will occur with 2 separate groups:~Infants who are NPO (< 20 mL/kg/day of fluids enterally at the time of therapy) vs.~Those being enterally fed at least 20 mL/kg/day of total fluids at the time of therapy."
3121113|NCT01746511|Experimental|No Glycerin Suppository|"Infants will receive no scheduled glycerin suppositories, while under phototherapy (unless otherwise directed by attending physician).~Subjects will be block randomized (varying block sizes of 2 to 8). Babies in both groups will be fed according to NICU standard birth weight protocols. Stratified enrollment will occur with 2 separate groups:~Infants who are NPO (< 20 mL/kg/day of fluids enterally at the time of therapy) vs.~Those being enterally fed at least 20 mL/kg/day of total fluids at the time of therapy."
3121114|NCT01746498|Active Comparator|Group 1|11 patients We Applied real anodal tDCS on the left dorsolateral prefrontal cortex (DLPFC)20 minutes every day for 10 consecutive days.
3121115|NCT01746498|Active Comparator|Group 2|11 patients we applied cathodal tDCS on left DLPFC for 20 minutes every day for 10 consecutive days.
3121116|NCT01746498|Sham Comparator|Group 3|11 patients We applied sham stimulations(anodal tDCS) on the left DLPFC for few seconds the stop stimulations 2 mA every day for 10 days.
3121117|NCT01746485|Experimental|UT-15C|
3121118|NCT01746472|Experimental|2 - B-passive|
3121119|NCT01746472|Experimental|3 - B-active|
3121120|NCT01746472|Experimental|4 - B-active, B-passive|
3121121|NCT01746472|Experimental|6 - z, B-passive|
3121122|NCT01746472|Experimental|7 - z, B-active|
3121123|NCT01746472|Experimental|8 - z, B-active, B-passive|
3121124|NCT01746472|Experimental|10 - t, B-passive|
3121125|NCT01746472|Experimental|11 - t, B-active|
3121126|NCT01746472|Experimental|12 - t, B-active, B-passive|
3121127|NCT01746472|Experimental|14 - t, z|
3121128|NCT01746472|Experimental|15 - t, z, B-active|
3121129|NCT01746472|Experimental|16 - t, z, B-active, B-passive|
3121130|NCT01746459|Active Comparator|Low Low|Low Intensity, Low Frequency Reminder System
3121131|NCT01746459|Active Comparator|Low, High|Low Intensity, High Frequency Reminder System
3121132|NCT01746459|Active Comparator|High, Low|High Intensity, Low Frequency Reminder System
3121133|NCT01746459|Active Comparator|High, High|High Intensity, High Frequency Reminder System
3121134|NCT01746446|Experimental|Care team|Patients are offered the support and services of the care team.
3121135|NCT01746446|No Intervention|Usual Care|Patients receive usual care.
3121136|NCT01746433|Active Comparator|Hanging Triangle Bar|"The patients randomized to this group will use a hanging triangle bar for aid in sitting up exercises.~No particular brand of hanging bar is targeted."
3121137|NCT01746433|Experimental|Ergonome|"The patients randomized to this group will use the l'ERGONOME device for aid in sitting up exercises.~Commercial name of the device: SAM ERGONOM (TM)~Manufacturer: Medicatlantic groupe Winncare, Le Pas du Château, 85680 Saint-Paul-Mont-Penit"
3121138|NCT01746420|Placebo Comparator|Placebo Control|Dose A - sodium acetate buffer (0 mg rhPDGF-BB)
3121139|NCT01746420|Experimental|0.45 mg rhPDGF-BB|Dose B - sodium acetate buffer + 0.45 mg rhPDGF-BB
3121140|NCT01746420|Experimental|0.75 mg rhPDGF-BB|Dose C - sodium acetate buffer + 0.75 mg rhPDGF-BB
3121141|NCT01746420|Experimental|1.5 mg rhPDGF-BB|Dose D - sodium acetate buffer + 1.5 mg rhPDGF-BB
3121142|NCT01746420|Experimental|3.0 mg rhPDGF-BB|Dose E - sodium acetate buffer + 3.0 mg rhPDGF-BB
3121143|NCT01746394|Experimental|Parents as Teachers Enhanced|Participants in the Parents as Teachers Enhanced (PaTE) intervention arm will receive the enhanced diet and activity maternal, infant, and early childhood home visiting program
3121144|NCT01746394|Active Comparator|Parents as Teachers|Participants in the Parents as Teachers (PaT) control arm will receive the standard maternal, infant, and early childhood home visiting program
3121145|NCT01746381|Experimental|IVAPS mode of non-invasive ventilation|Patients with ALS randomized to this arm will be treated with non-invasive home ventilation using the Intelligent Volume-Assured Pressure Support (IVAPS) mode
3121146|NCT01746381|Active Comparator|BIST mode of non-invasive ventilation|Patients with ALS who are randomized to this arm will receive non-invasive home ventilation with the traditional bilevel non-invasive ventilation in spontaneous/timed (BIST) mode
3121147|NCT01746368|Experimental|Nurse-Supported Advance Care Planning Intervention|The Nurse-Supported Advance Care Planning Intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices.
3121148|NCT01746368|Active Comparator|Care-as-Usual|The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices. Subjects in this arm who desired information about risks, benefits, and alternatives of specific choices before randomization were scheduled for the Care-as-Usual session after they received that information from the Primary Care Provider.
3121149|NCT01746355|Active Comparator|rTMS-active|patients undergoing of rTMS real
3121150|NCT01746355|Sham Comparator|rTMS-Sham|patients undergoing to placebo rTMS
3121151|NCT01746342|Active Comparator|Effective CPAP|Continuous positive airway pressure: effective fixed level determined by polysomnographic titration
3121152|NCT01746342|Sham Comparator|Sham CPAP|Continuous positive airway pressure device modified by manufacturer to deliver minimal pressure
3121153|NCT01746329|Experimental|Tea|Oral intake of tea containing 75 grams of glucose
3121154|NCT01746329|Experimental|Beet root|Oral intake of beetroot juice containing 75 grams of glucose
3157831|NCT01495377|Experimental|Technetium|
3121156|NCT01746303|Experimental|Omega 3 and Blueberry powder|This group will receive omega-3 fatty acid and blueberry powder supplement for 24 weeks (6 months)
3121157|NCT01746303|Experimental|Omega-3 and placebo powder|This group will receive omega-3 fatty acid and placebo powder for 24 weeks (6 months)
3121158|NCT01746303|Experimental|Placebo oil and blueberry powder|This group will receive placebo oil and blueberry powder for 24 weeks (6 months).
3121159|NCT01746303|Placebo Comparator|Placebo oil and placebo powder|This group will receive placebo oil and placebo powder for 24 weeks (6 months)
3121160|NCT01746290|Experimental|PulsePoint notification|Conventional Emergency Dispatch PLUS The PulsePoint notification. In the event of a potential cardiac arrest identified by 911call-takers, data will be automatically pushed to PulsePoint smartphone application users within very close proximity to the emergency. This will be done in parallel with normal emergency dispatch of paramedics and fire fighters to the scene of the emergency. The activation radius around the emergency is somewhat variable, depending on phone signal strength, climate conditions and whether the phone is inside or outside, but is approximately 200-500 meters.
3121161|NCT01746290|No Intervention|Usual Care|Patients randomized to the control arm will receive conventional emergency medical dispatching procedures but no PulsePoint notification will be sent to nearby PulsePoint users.
3121162|NCT01746277|Other|combined group|combined group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
3121163|NCT01746277|Other|sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
3121164|NCT01746264|Experimental|Vitamin D3|Vitamin D3 supplementation at 100,000 IU once a month for 3 months
3121165|NCT01746251|Active Comparator|Concise Afatinib|Afatinib oral daily dose for 3 months
3121166|NCT01746251|Active Comparator|Prolonged Afatinib|Afatinib oral daily dose for 2 years
3121167|NCT01746238|Experimental|Treatment Arm|Bevacizumab, metronomic doxorubicin and radiation therapy
3121168|NCT01746225|Experimental|nab-Paclitaxel 150 mg/m2 days 1,15|Arm A: Induction nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 150 mg/m2 administered on days 1, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.
3121169|NCT01746225|Experimental|nab-Paclitaxel 100 mg/m2 days 1,8,15|Arm B: Induction nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 100 mg/m2 administered on days 1, 8, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.
3121170|NCT01746225|Experimental|nab-Paclitaxel 75 mg/m2 days 1,8,15,22|Arm C: Induction nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 75 mg/m2 administered on days 1, 8, 15, 22 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.
3121171|NCT01746212||Degenerative Disc Disease|Patients diagnosed with degenerative disc disease, meeting all eligibility requirements (please refer to inclusion/exclusion criteria), will be asked to participate in this study. A one-level or two-level anterior lumbar interbody fusion surgery using InQu Bone Graft Extender and Substitute, mixed with BMAC (bone marrow aspirate concentrate) as autograft, with Synthes Spinal Instrumentation will be recommended to the patient. If patients elect to proceed with surgery using the prescribed surgical components, they will be offered enrollment into the study. If the patient opts to use a different bone graft, or other spinal instrumentation, then the patient will not meet all inclusion criteria and will not be offered the opportunity to enroll in this study.
3121172|NCT01746199|Experimental|cotrimoxazole daily prophylaxis|cotrimoxazole daily prophylaxis
3121173|NCT01746199|Active Comparator|Intermittent Preventive sulphadoxine-pyrimethamine Treatment|Referent treatment given according WHO recommendations
3121174|NCT01746186||21-35 years of age|200 Men and 200 women: Ages 21-27 and Ages 28-35, BMI: 20-35,living in the Columbia, SC area.
3121175|NCT01746173|Experimental|CHOEP + High Dose Therapy + Auto SCT|Patients received 6 cycles of induction chemotherapy: Cyclophosphamide, Doxorubicin, Vincristine, Etoposide and Prednisone (CHOEP) (5 if previously received 1 cycle of CHOP). CHOP was given at standard doses, with a dose of etoposide of 100 mg/m2 intravenously (IV) or 200 mg/m2 orally added on days 1-3 of each cycle. Patients who did not achieve a partial (PR) or complete (CR) remission at restaging after either 3 or 6 cycles were taken off study. Responders after 6 cycles had stem cell (SC) mobilization using filgrastim and plerixafor (if necessary) within 4 weeks of the end of induction. SC mobilization, harvesting, and reinfusion were performed per standard institutional protocol. A minimum collection of 2x106 CD34+ cells/kg was required to proceed to autologous stem cell transplant. Conditioning was comprised of gemcitabine 2700 mg/m2 on days -8 and -3, IV busulfan 105 mg/m2 days -8 to -5, and melphalan 60 mg/m2 given daily on days -3 and -2 (per MD Andersen protocol).
3121176|NCT01746160|Experimental|C1 Implant|Patient having C1 implant installed.
3121177|NCT01746147||Patients with MDS and AML prior to allogeneic SCT|
3121178|NCT01746134||Cohort|
3121179|NCT01746121||Amelogenesis Imperfecta|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth
3121180|NCT01746121||healthy family members|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth
3121181|NCT01746108|Experimental|At-risk-Unprimed Group|Subjects who have not been previously vaccinated with any pneumococcal vaccine and are at an increased risk of pneumococcal infection.
3121182|NCT01746108|Experimental|At-risk-Primed Group|"Subjects who have been previously vaccinated~with at least one dose of a pneumococcal conjugate vaccine i.e. either Synflorix (10Pn-PD-DiT), Prevenar or Prevenar13.~with plain polysaccharide pneumococcal vaccine more than 2 years and less than 5 years before enrollment.~and are at an increased risk of pneumococcal infection."
3121183|NCT01746108|Active Comparator|Healthy-Unprimed Group|Subjects who have not been previously vaccinated with any pneumococcal vaccine and are healthy.
3121184|NCT01746108|Active Comparator|Healthy-Primed Group|Subjects who have been previously vaccinated with at least one dose of a pneumococcal vaccine and are healthy.
3121185|NCT01746095|Experimental|Vancomycin inhalation powder|32 or 64 mg twice daily (BID)
3121187|NCT01746082|Experimental|Subjects 18 - 64 years|100 (up to 120) subjects 18 - 64 years old receive two doses of monovalent inactivated influenza H3N2 variant (MIV), delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart.
3121188|NCT01746082|Experimental|Subjects > /= 65 years|100 (up to 120) subjects greater than or equal to 65 years old receive two doses of monovalent inactivated influenza H3N2 variant (MIV), delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart.
3121189|NCT01746069|Placebo Comparator|health advice|clinical practice routine
3121190|NCT01746069|Experimental|Quit smoking combined cessation programme|Health advice and support sms messages to patient's mobile phone + clinical routine practice
3121191|NCT01746056|Experimental|Heat Patch|
3121192|NCT01746043|Experimental|Armodafinil + Placebo|Armodafinil 150 mg by mouth once a day for 6 weeks. Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
3121193|NCT01746043|Experimental|Minocycline + Placebo|Minocycline 100 mg by mouth 2 times a day for 6 weeks. Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
3121194|NCT01746043|Experimental|Armodafinil + Minocycline|Armodafinil 150 mg by mouth once a day for 6 weeks. Minocycline 100 mg by mouth 2 times a day for 6 weeks.Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
3121195|NCT01746043|Placebo Comparator|Placebos|Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
3121196|NCT01746030||Questionnaires|No treatment
3121197|NCT01746017|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo administered to healthy participants in up to 1 of 4 study periods in Part A
3121198|NCT01746017|Experimental|LY2922470 (Part A)|Single ascending dose of LY2922470 (starting at 1 mg) administered orally to healthy participants in up to 3 of 4 study periods in Part A
3121199|NCT01746017|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo administered to participants with type 2 diabetes mellitus (T2DM) in up to 1 of 3 study periods in Part B
3121200|NCT01746017|Experimental|LY2922470 (Part B)|Single ascending dose of LY2922470 administered orally to participants with T2DM in up to 2 of 3 study periods in Part B. Dose determined by Part A
3121201|NCT01746004|Experimental|[^14C]-LY2157299|Single 150 mg oral dose of LY2157299 monohydrate containing 100 micro curies of [^14C] labeled drug
3121202|NCT01745991||Biliary Atresia undergoing Kasai op|Randomisation for the use of CoSeal at the time of Kasai and assessment at the time of Transplantation.
3121203|NCT01745978|Experimental|the knob-tipped knife|the knob-tipped knife using for precut papillotomy in difficult CBD cannulation
3121204|NCT01745978|Active Comparator|the needle knife|the needle knife using for precut papillotomy in difficult CBD cannulation
3121205|NCT01745965|Experimental|T-DM1|single agent T-DM1 for 12 weeks (3,6 mg/kg q3w)
3121206|NCT01745965|Experimental|T-DM1 + endocrine therapy|Single agent T-DM1 for 12 weeks (3,6 mg/kg q3w) with standard endocrine therapy (tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if no contraindications are present, in a standard daily dosage).
3121207|NCT01745965|Active Comparator|Trastuzumab + endocrine therapy|The control group will receive trastuzumab in 3-weekly schedule (8 mg/kg as loading dose and then 6 mg/kg q3w)with endocrine therapy tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if not contraindications are present, in a standard daily dosage).
3121208|NCT01745952|Experimental|figure-of-eight active rTMS coil|rTMS is administered using the figure-of-eight active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
3121209|NCT01745952|Experimental|round active rTMS coil|rTMS is administered using the round active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
3121210|NCT01745952|Sham Comparator|sham rTMS coil (figure-of-eight)|rTMS is administered using the figure-of-eight sham coil, over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
3121211|NCT01745939|Active Comparator|Lumbar manipulation|Patients will receive thrust joint manipulation to their lumbar spine in side lying
3121212|NCT01745939|Sham Comparator|Sham manipulation|Patients will receive oscillations into slight rotation, without cavitation, in side lying
3121213|NCT01745926||CPR|MECHANICAL CHEST COMPRESSION
3121214|NCT01745913|Experimental|Haplo-Cord SCT|The UCB unit must supply a minimum of 1.0 x107/kg pre-cryopreserved nucleated cell dose. The unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient. This may include 0-2 antigen mismatches at each A or B (at the antigen level) or DRB1 (at the allele level) loci. All typing will be done using molecular typing. Though molecular level typing will be available, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1
3121215|NCT01745913|Active Comparator|UCB SCT|For the standard arm, UCB units will be selected using the Minnesota strategy and the strategy followed in a recent CTN study.17;19Each unit must supply a minimum of 1.5 x107/kg pre-cryopreserved nucleated cell dose. Subjects must have two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient. This may include 0-2 antigen mismatches at each A or B (at the antigen level) or DRB1 (at the allele level) loci. All typing will be done using molecular typing. Though molecular level typing will be available, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1
3121216|NCT01745887|Active Comparator|EBI-005-2 5mg/ml|Administration: 3 times per day
3158548|NCT01490190|Experimental|NuvaRing|
3121217|NCT01745887|Active Comparator|EBI-005-2 20 mg/ml|Administration: 3 times per day
3121218|NCT01745887|Placebo Comparator|EBI-005-2 Placebo|Administration: 3 times per day
3121219|NCT01745861|Active Comparator|Lipidem® (BBraun)|Lipid emulsion containing medium chain triglycerides (MCT), long chain triglyceride (LCT) and Omega-3 fatty acid (fish oil)
3121220|NCT01745861|Placebo Comparator|Lipofundin® MCT/LCT 20%|Lipid emulsion containing medium and long chain triglycerides
3121221|NCT01745848|Experimental|Study Drug|Roflumilast 500 μcg, once daily, for 30 days
3121222|NCT01745835|Active Comparator|2L Coolprep®|
3121223|NCT01745835|Experimental|1L Coolprep® and Bisacodyl|
3121224|NCT01745822|Experimental|Tenofovir disoproxil fumarate|tenofovir disoproxil fumarate, 300 mg tablets
3121225|NCT01745822|Placebo Comparator|Placebo|matching placebo (of tenofovir disoproxil fumarate)
3121226|NCT01745809||Severe Asthmatics|Subjects with a pre-existing physician diagnosis of asthma with reversible airflow obstruction of at least 12%.
3121227|NCT01745809||Healthy non-smokers|Subjects will be never smokers or former smokers for the past year and less than 10 pack years lifetime with no history of asthma or any other lung disease.
3121228|NCT01745796||Intubated ICU patients|
3121229|NCT01745783|Experimental|Experimental|"Receive a single IV administration of cellular product (Bone marrow mesenchymal stem cells autologous) on Day 0 and placebo infusion on day + 180.~Dose: 1-2x10^6 cells/Kg"
3121230|NCT01745783|Placebo Comparator|Placebo Comparator|Receive a placebo infusion on day 0 and a single administration cellular product on day +180. Dose: 1-2x10^6 cells/Kg
3121231|NCT01745770|Experimental|A|
3121232|NCT01745770|Active Comparator|B|
3121233|NCT01745757||Cohort|first line treatment for metastatic breast cancer
3121234|NCT01745744|Experimental|Low dose|- Infusion of mesenchymal stem cells from adipose tissue: 0.5x106 cells / kg of patient weight.
3121235|NCT01745744|Experimental|High dose|- Infusion of mesenchymal stem cells from adipose tissue: 1x106 cells / kg of patient weight.
3121236|NCT01745744|No Intervention|Control|Conventional treatment
3121237|NCT01745731|Experimental|Experimental|Patients with hepatic space occupying lesion requiring an extended hepatic resection to those who were preoperatively performed a Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
3121238|NCT01745731|No Intervention|Control|Patients with hepatic space occupying lesion that require an extended liver resection that were performed preoperatively portal embolization of the affected segments.
3121239|NCT01745718|Other|MRI and targeted biopsies|All patients receive the same level/number of diagnostic procedures. They all undergo targeted biopsies which are compared to the cytological imprints.
3121240|NCT01745705|Experimental|Cervical Spine Manipulation|Subjects will lie supine on a treatment table and receive a high velocity low amplitude thrust joint manipulation to their cervical spine in rotation to each side of the neck.
3121241|NCT01745705|Sham Comparator|Manual Contact|Subjects will lie supine on a treatment table and have their suboccipital region gently cupped by the therapist for 30 seconds. No movement or force will be applied, just simple manual contact.
3121242|NCT01745692|Active Comparator|Intravenous rtPA|IV alteplase (rtPA) 0.9mg/kg (10% of dose as bolus followed by 90% as infusion over 1 hour, to a maximum dose of 90mg total) given within 4.5 hours of onset of stroke symptoms
3121243|NCT01745692|Experimental|Intravenous rtPA and Mechanical Thrombectomy|IV alteplase (rtPA) 0.9mg/kg (10% of dose as bolus followed by 90% as infusion over 1 hour, to a maximum dose of 90mg total) given within 4.5 hours of onset of stroke symptoms + additional mechanical thrombectomy procedure to commence within 90 minutes of start of IV rtPA infusion
3121244|NCT01745679|Experimental|Ceftriaxone treatment|ceftriaxone will be administered à high dose : > or equal to 75mg/kg/day or 4 gr/day
3121245|NCT01745666|Experimental|patients with KCNQ1 or KCNH2 mutation|
3121246|NCT01745666|Other|patients WITHOUT KCNQ1 or KCNH2 mutation (control group)|
3121247|NCT01745653|Experimental|Low level laser therapy|Low level laser (970nm) will be delivered on the mucous membrane in regard to the first molar teeth on which rings of the quadhelix have been settled.
3121248|NCT01745653|Sham Comparator|sham procedure|Same procedure than experimental arm except that the laser is not activated.
3121249|NCT01745653|No Intervention|no intervention|no intervention : Patient received the quadhelix with nothing else
3121250|NCT01745640|Experimental|POMALIDOMIDE and dexamethasone treatment|All patients will receive pomalidomide (4 mg/day per os) and dexamethasone (40/20 mg/wk per os) during 21 day/28 day cycle
3121251|NCT01745627|Experimental|Laser Treatment|
3121252|NCT01745614|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
3121253|NCT01745614|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
3121254|NCT01745601|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3121255|NCT01745601|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3121256|NCT01745588|Experimental|Clarithromycin + Pomalidomide + Dexamethasone + stem cell|All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28, pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28-day cycle. Patients randomized to auto-SCT will proceed within 28 days after completion of the 4th cycle of ClaPD to receive melphalan 140mg/m2 or 200mg/m2 (as per institutional guidelines) followed by hematopoietic cell infusion.
3121257|NCT01745588|Experimental|Clarithromycin + Pomalidomide + Dexamethasone Alone|All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28 pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28 day cycle. Patients assigned to ClaPD alone will receive 5 additional cycles of ClaPD.
3121258|NCT01745575|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3121259|NCT01745575|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3121260|NCT01745562|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3121261|NCT01745562|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3158549|NCT01490177|Experimental|One|
3121262|NCT01745549|Experimental|needle 4 mm gauge 33|Needle for insulin pen, 4 mm long and with a diameter of 33 gauge (the smaller needle)
3121263|NCT01745549|Active Comparator|needle 4 mm gauge 32|Needle for insulin pen, 4 mm long and with a diameter of 32 gauge
3121264|NCT01745536|Experimental|Vitrified oocytes using closed Cryotop®|Oocytes are vitrified/stored using a closed device
3121265|NCT01745536|Active Comparator|Vitrified oocytes using open Cryotop®|Oocytes are vitrified/stored using an open device
3121266|NCT01745523|Experimental|Vitrified oocytes using HPC+Trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
3121267|NCT01745523|Active Comparator|Vitrified oocytes using SSS+ Sucrose|Oocytes are vitrified using the SSS containing HSA and sucrose
3121268|NCT01745510|Experimental|DHA Group|"DHA Group will receive 75 milligrams of docosahexaenoic acid (DHA) per kilogram of their baseline weight.~They will receive one dose, administered by enteral feeding every 24 h during 14 days"
3121269|NCT01745510|Placebo Comparator|Control Group (Placebo)|"Control group will receive sunflower oil which is the excipient of the DHA in this study.~They will receive one dose every 24 h during 14 days."
3121270|NCT01745497|Experimental|Ferrous Sulfate|3mg/kg divided twice per day, 30 minutes before a meal or 2 hours after a meal
3121271|NCT01745497|Placebo Comparator|Placebo|Equivalent volume of liquid placebo administered twice daily, before a meal or 2 hours after a meal
3121272|NCT01745484|No Intervention|Arm 1|SPECT scan will be performed at baseline. Patients will receive radiotherapy according to standard CT-based plan with conventional dose-volume histogram
3121273|NCT01745471||PCOS group|12 women with Polycystic Ovary Syndrome (PCOS) as defined by NIH criteria
3121274|NCT01745471||Pear shapes|12 with an android pattern as defined by a waist-to-hip greater than 0.85
3121275|NCT01745471||Apple shapes|12 will have a gynoid pattern as defined by a waist-to-hip ratio less than 0.78
3121276|NCT01745458|Experimental|SB-659032|250 mg non-enteric coated SB-659032
3121277|NCT01745458|Placebo Comparator|Placebo|matched placebo QD for 14 days
3121278|NCT01745445|Experimental|radiotherapy alone arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; All patients will be radiated by external beam radiation, using 3-D conformal radiation technique.
3121279|NCT01745432|Experimental|ADBLOCK +laparoscopic surgery|Adhesion Barrier System is site-specific sprayable adhesion barrier gel administered on the surgical field to reduce risk of adhesion formation.
3121280|NCT01745432|No Intervention|laparoscopic surgery|Laparoscopic surgery only without use of adhesion barrier
3121281|NCT01745419||COPD Frequent Exacerbators|COPD patients having experienced at least two episodes of acute exacerbations in the former 12 months. (Acute exacerbations are defined as worsening symptoms requiring treatment with systemic steroids (oral or parenteral) or antibiotics, a visit to the emergency room, and/or admission to a hospital. Events separated by at least 21 days are considered as separate events of exacerbation.)
3121282|NCT01745419||COPD non- exacerbators|COPD patients who have not experienced exacerbations in the former 24 months. (Acute exacerbations are defined as worsening symptoms requiring treatment with systemic steroids (oral or parenteral) or antibiotics, a visit to the emergency room, and/or admission to a hospital. Events separated by at least 21 days are considered as separate events of exacerbation.)
3121283|NCT01745406||Doctor and nurse|
3121284|NCT01745406||Doctor without nurse|
3121285|NCT01745393|Experimental|Clinic Quality Improvement + Behavioral Counseling|This multilevel intervention includes advice and a referral from a pediatrician, behavioral counseling by study staff, and community systems navigation, all designed to reduce pediatric secondhand smoke exposure. Over the course of 12 weeks participants receive a home visit designed to orient them to the program and trained health counselors provide multiple individualized phone counseling sessions designed to build coping skills, urge management skills, and self-efficacy. Counseling also includes assistance with goal setting and navigation of local resources.
3121286|NCT01745393|Active Comparator|Clinic Quality Improvement + Attention Control|The attention control intervention parallels the format of the experimental group but focuses on family nutrition information. The intervention includes a home visit to orient the participant to the program and multiple phone counseling sessions conducted by a trained health counselor.
3121287|NCT01745380|Experimental|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 2 sprays will be administered at the start of the procedure, if anesthesia is insufficient, a third spray will be administered.
3121288|NCT01745380|Placebo Comparator|Placebo|Placebo - 2 sprays will be administered at the start of the procedure, if anesthesia is insufficient, a third spray will be administered.
3121289|NCT01745367|Active Comparator|Placebo in combination with paclitaxel|Placebo orally once daily on a 3 weeks on/1 week off schedule with 90 mg/m2 of paclitaxel administered intravenously 3 weeks on (Day 1, Day 8 and Day 15)/1 week off (4 weeks = 1 Cycle).
3121290|NCT01745367|Experimental|Tivozanib Hydrochloride in combination with paclitaxel|1.5 mg tivozanib hydrochloride orally once daily on a 3 weeks on/1 week off schedule with 90 mg/m2 of paclitaxel administered intravenously 3 weeks on (Day 1, Day 8 and Day 15)/1 week off (4 weeks = 1 Cycle).
3121291|NCT01745354|Experimental|SD-101 + Combined with Local Radiation|
3121292|NCT01745341||vitreoretinal surgery patients|Patients undergoing vitreoretinal surgery under monitored anesthesia care. They will be observed during surgery and no interventions will be administered.
3121293|NCT01745328|Active Comparator|LVX-AMX|subject is treated with LAV-AMX, then followed by placebo.
3121294|NCT01745328|Active Comparator|TCM treatment|subject is treated with TCM
3121295|NCT01745315|Active Comparator|LigaSure (advanced bipolar device)|Laparoscopic hysterectomy will be done with LigaSure in 15 patients.
3121296|NCT01745315|Active Comparator|Halo PKSforceps(advanced bipolar device)|Laparoscopic hysterectomy will be done with Halo PKS cutting forceps in 15 patients.
3121297|NCT01745315|Active Comparator|EnSeal (advanced bipolar device)|Laparoscopic hysterectomy will be done with EnSeal in 15 patients.
3121298|NCT01745302||TCM plus EGFR-TKIs|TCM:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang,four packages,twice a day, six months; EGFR-TKIs:oral tablet,Gefitinib 250mg daily or Erlotinib 150mg daily or Icotinib 125 mg three times a day ，until progression or unacceptable toxicity;
3121579|NCT01743573|No Intervention|control|no yoga training
3121299|NCT01745302||Placebo plus EGFR-TKIs|TCM Placebo:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang,four packages,twice a day ,six months; EGFR-TKIs:oral tablet,Gefitinib 250mg daily or Erlotinib 150mg daily or Icotinib 125 mg three times a day until progression or unacceptable toxicity;
3121300|NCT01745276|Experimental|Pin fixation|
3121301|NCT01745263|Active Comparator|VitD-Omega3-StrengthExercise|Vitamin D3 (2000 IU/d); Omega-3 fatty acids (1 g/d); Strength Home Exercise (3*30 minutes/week)
3121302|NCT01745263|Active Comparator|VitD-Omega3-FlexibilityExercise|Vitamin D3 (2000 IU/d); Omega-3 fatty acids (1 g/d); Flexibility Home Exercise (3*30 minutes/week)
3121303|NCT01745263|Active Comparator|Placebo-Omega3-StrengthExercise|Placebo Vitamin D3; Omega-3 fatty acids (1 g/d); Strength Home Exercise (3*30 minutes/week)
3121304|NCT01745263|Active Comparator|Placebo-Omega3-FlexibilityExercise|Placebo Vitamin D3; Omega-3 fatty acids (1 g/d); Flexibility Home Exercise (3*30 minutes/week)
3121305|NCT01745263|Active Comparator|VitD-Placebo-StrengthExercise|Vitamin D3 (2000 IU/d); Placebo Omega-3 fatty acids; Strength Home Exercise (3*30 minutes/week)
3121306|NCT01745263|Active Comparator|VitD-Placebo-FlexiblityExercise|Vitamin D3 (2000 IU/d); Placebo Omega-3 fatty acids; Flexibility Home Exercise (3*30 minutes/week)
3121307|NCT01745263|Active Comparator|Placebo-Placebo-StrengthExercise|Placebo Vitamin D3; Placebo Omega-3 fatty acids; Strength Home Exercise (3*30 minutes/week)
3121308|NCT01745263|Sham Comparator|Placebo-Placebo-FlexibilityExercise|Placebo Vitamin D3; Placebo Omega-3 fatty acids; Flexibility Home Exercise (3*30 minutes/week)
3121309|NCT01745250|Experimental|Emervel Lips|Emervel Lips
3121310|NCT01745250|Experimental|Juvederm Ultra Smile|Juvederm Ultra Smile
3121311|NCT01745224|Experimental|Revlite Q switched Nd:YAG laser|Revlite Q switched Nd:YAG laser 1064 nm
3121312|NCT01745224|Experimental|TriVantage Q switched Nd:YAG laser|TriVantage Q switched Nd:YAG laser 1064nm
3121313|NCT01745211|Experimental|755nm Alexandrite Laser|755nm Alexandrite laser (standard handpiece)
3121314|NCT01745211|Experimental|755nm Alexandrite laser with modified handpiec|Device: 755nm Alexandrite laser with modified handpiece
3121315|NCT01745198||Treatment Group|This group consists of patients diagnosed with homocysteinemia who have been treated with Cerefolin®/CerefolinNAC® in the past or are currently being treated with Cerefolin®/CerefolinNAC®.
3121316|NCT01745198||Non-Treatment Group|This group consists of patients not diagnosed with homocysteinemia who have no past or current treatment with Vitamin B12, Folate or Cerefolin®/CerefolinNAC®.
3121317|NCT01745185||Fabry disease switch group|Subjects will include individuals with Fabry disease who are switching from agalsidase alfa to agalsidase beta
3121318|NCT01745185||Control Group|Controls will include individuals with Fabry disease who have only received agalsidase beta as treatment in their lifetime.
3121319|NCT01745172|Experimental|Carotid body excision|Patients undergoing the carotid body excision to test the hypothesis that carotid body excision is sufficient to attain target blood pressure.
3121320|NCT01745159|Experimental|continued tacrolimus treatment|children with moderate/severe atopic dermatitis treated with tacrolimus ointment and continuing to apply tacrolimus ointment during disease control period.
3121321|NCT01745159|No Intervention|no additional treatment|children with moderate/severe atopic dermatitis treated with tacrolimus ointment and with no additional treatment during disease control period.
3121322|NCT01745146|Experimental|Anger Self-Management Training (ASMT)|8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
3121323|NCT01745146|Active Comparator|Personal Readjustment and Ed (PRE)|8-session, individual, psycho-educational intervention based on principles of education and personal readjustment. Significant other (friend or relative) invited to participate in 3 of 8 sessions
3121324|NCT01745133|Placebo Comparator|vehicle|clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
3121325|NCT01745133|Active Comparator|calcipotriene|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks x
3121326|NCT01745133|Active Comparator|calcipotriene + clobetasol propionate|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays for 8 weeks + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
3121327|NCT01745120|Experimental|LentiGlobin® BB305 Drug Product|
3121328|NCT01745107|No Intervention|surgery alone|No prophylactic postoperative radiation therapy,that is surgery alone is developed in this arm
3121329|NCT01745107|Experimental|surgery plus radiation|Prophylactic postoperative radiation therapy is developed in this arm
3121330|NCT01745094|Experimental|Concomitant Group|concomitant administration of mirabegron to solifenacin treated patients
3121331|NCT01745081|Experimental|Mannitol|Bolus mannitol 20% at skin incision
3121332|NCT01745081|Experimental|Hypertonic saline|Hypertonic saline 3% at skin incision
3121333|NCT01745068|No Intervention|Control group|
3121334|NCT01745068|Experimental|Integrated program|Participants will be involved in an integrated interorganisational fragility fracture prevention program, which combines both post-fracture management as well as fall prevention strategies. The intervention will last up to 18 months.
3121335|NCT01745055|Experimental|CP-690,550 (tofacitinib) 30 mg q12h|Individual dose of methotrexate with the addition of CP-690,550 30 mg q12h
3121336|NCT01745042||android postmenopausal women|Clinical exams
3121337|NCT01745042||gynoid postmenopausal women|Clinical exams
3121338|NCT01745029||Ulcerative Colitis|
3121339|NCT01745016|Placebo Comparator|Placebo|placebo
3121340|NCT01745016|Experimental|Beta-Alanine|beta-alanine
3121341|NCT01745003|Experimental|Fibromyalgia|Investigate biochemical, functional, and structural neuroimaging changes following non-invasive brain stimulation in patients with chronic widespread pain: fibromyalgia (FM). We will be using tDCS as intervention.
3121342|NCT01744990|Other|Interventional single arm|Single group of children undergoing the same investigations and follow up
3121373|NCT01744782|Experimental|RP103|From Day 1 and throughout the duration of participation, RP103 (Cysteamine Bitartrate Delayed-release Capsules) was administered every 12 hours (Q12H), supplied as 75 mg and 25 mg capsules.
3121690|NCT01742858||Adolescents|15-18 years old
3121343|NCT01744977|Experimental|Adherence Packaging Intervention Group|[MeadWestvaco Packaging Intervention Arm] At baseline, the intervention arm will receive instructions from the RA on obtaining medication refills and the first fill of their statin medication from the VA pharmacy. At this time, the pharmacist will provide counseling including 1) use of adherence packaging, 2) to only use statin medications from the adherence packaging 3) purpose of LDL-related medications 4) how to take the medications.
3121344|NCT01744977|No Intervention|Education Only Group|Control Arm patients will receive primary care and LDL management according to the discretion of their provider. At baseline, patients will receive similar written information on how to obtain medication refills and the importance of taking their cholesterol medications as prescribed. The 6-month interval was selected to maintain contact with patients.
3121345|NCT01744964|Placebo Comparator|Saline|Assessment of experimental pain models before and after treatment
3121346|NCT01744964|Active Comparator|Apomorphine|Assessment of experimental pain models before and after treatment
3121347|NCT01744951|Experimental|ADAPT|ADAPT is a manualized intervention with eight treatment modules designed as an early intervention for children, ages 5-14, who are being adopted from foster care and their adoptive parent/s.
3121348|NCT01744951|No Intervention|Care as usual|Children, ages 5-14, and their adoptive parent/s will receive care as usual in the treatment setting.
3121349|NCT01744938|No Intervention|early surgery|only receiving pancreaticoduodenectomy without preoperative biliary drainage
3121350|NCT01744938|Experimental|preoperative biliary drainage|percutaneous preoperative biliary drainage before pancreaticoduodenectomy guided by CT scan
3121351|NCT01744925|Active Comparator|Icotinib of routine dose|Icotinib: 125mg, oral administration, three times per day.
3121352|NCT01744925|Experimental|Icotinib of high dose|Icotinib: 375mg, oral administration, three times per day.
3121353|NCT01744912|Experimental|Ublituximab + Lenalidomide|"4 cohorts, with 3 - 6 patients per cohort, as follows:~Cohort 1: Ublituximab 450 mg + Lenalidomide 10 mg~Cohort 2: Ublituximab 450 mg + Lenalidomide 15 mg~Cohort 3: Ublituximab 600 mg + Lenalidomide 10 mg (escalation to 15 mg permitted after cycle 1)~Cohort 4: Ublituximab 900 mg + Lenalidomide 10 mg (escalation to 15 mg permitted after cycle 1)~Ublituximab is an IV infusion on days 1, 8, and 15 of cycles 1 & 2 followed by a planned maintenance with a single infusion on day 1 of cycles 3 thru 6.~Lenalidomide is taken orally on days 9 - 28 of cycle 1 followed by daily administration on Days 1 - 28 for cycles 2 thru 6. Non-hodgkins lymphoma patients may have up to a 7 day rest period (Days 21-28) in any cycle."
3121354|NCT01744899||Prolonged sitting|Includes individuals who spent an average of at least 6 hours a day sitting over the past year.
3121355|NCT01744899||Control|Includes individuals who spent 4 hours or less/day sitting over the past year.
3121356|NCT01744886|Active Comparator|lung surgery|"An initial baseline arterial blood gas (ABG) will be taken before anesthesia induction while breathing room air.~A second ABG will be taken on FIO2=0.5 during double lung ventilation. Then 3 ABG's will be consecutively determined each 15 min once OLV is initiated. PaO2/FIO2 is calculated on every ABG's measurement. If necessary, measures are taken to maintain oxygenation during one lung ventilation."
3121357|NCT01744886|Active Comparator|port-access cardiac surgery|"An initial baseline arterial blood gas (ABG) will be taken before anesthesia induction while breathing room air.~A second ABG will be taken on FIO2=0.5 during double lung ventilation. Then 3 ABG's will be consecutively determined each 15 min once OLV is initiated. PaO2/FIO2 is calculated on every ABG's measurement. In the port-access group, FIO2 is maintained on 1 after the stopping of the ECC, so PaO2 will become our only indicator for oxygenation. If necessary, measures are taken to maintain oxygenation during one lung ventilation."
3121358|NCT01744873|Experimental|Bisoprolol Fumarate Tablet 10 mg|Bisoprolol Fumarate Tablet 10 mg of M/s Ipca Laboratories Limited, India
3121359|NCT01744873|Active Comparator|Zebeta®|Zebeta® (Bisoprolol Fumarate) Tablets 10 mg of Duramed Pharmaceuticals Inc., USA
3121360|NCT01744860||"INCa molecular genetics laboratory in-house methods"|"BRAF V600 mutations were analysed using INCa (Institut National du Cancer [French National Cancer Institute]) molecular genetics laboratories using in-house methods"
3121361|NCT01744860||Cobas 4800 Mutation Test|BRAF V600 mutations were analysed using Cobas 4800 mutation test
3121362|NCT01744847|Active Comparator|DGT, Tracer Metro® Direct™ Wire Guide|Double guide wire technique was performed by Tracer Hybrid® Wire Guides and Tracer Metro® Direct™ Wire Guide
3121363|NCT01744847|Active Comparator|TPS, Tracer Hybrid® Wire Guides|trans pancreatic sphincterotomy was performed by Tracer Hybrid® Wire Guides
3121364|NCT01744834||18-year-old males|18-year-old males, representative random sample of the Dresden/Berlin (Germany) area, categorized as high and as low-risk drinkers respectively
3121365|NCT01744821|Active Comparator|Arm A: Vitamin D3 Group|Patients will take Vitamin D3 by mouth in the weeks prior to and including the morning of surgery. If blood test done at the start of the study shows that patients have a low (< or = 30 ng/ml) Vitamin D level, patients will be given two 25,000 IU Vitamin D3 Tablets (for a total of 50,000 IU) to take once a week until surgery. If baseline Vitamin D level is >30ng/ml, patients will be given on 2,000 IU Vitamin D3 tablet to take once a day until day of surgery.
3121366|NCT01744821|Placebo Comparator|Arm B: Placebo Group|Patients will take a placebo by mouth prior to and including the morning of surgery. If bloods tests done at the start of study show that the patients have a low (< or = 30 ng/ml) Vitamin D level, patients will be given 2 placebo tablets to take once a week until surgery. If baseline Vitamin D level is > 30 ng/ml, patients will be given on placebo tablet to take once a day until surgery.
3121367|NCT01744808|Active Comparator|EB-1020 SR1|Sustained release formulation
3121368|NCT01744808|Active Comparator|EB-1020 SR2|Sustained Release Formulation
3121369|NCT01744808|Active Comparator|EB-1020 SR3|Sustained Release Formulation
3121370|NCT01744808|Active Comparator|EB-1020 IR|Immediate Release Formulation
3121371|NCT01744808|Placebo Comparator|Placebo|Placebo Formulation
3121372|NCT01744795|Experimental|induced changes in hemodynamics|Twenty-five patients are planned enrolled. After induction of anesthesia, insertion of the PAC and the CardioQ probe, the patient are placed in the following successive positions: a) supine, b) head-down tilt, c) head-up tilt, d) supine, e) supine with phenylephrine administration f) pace heart rate 80 bpm, g) pace heart rate 110 bpm. CO are measured simultaneously using the CardioQ and thermodilution technique.
3121374|NCT01744769||Hypothyroidism for RAI|The group of patients who experience hypothyroidism after thyroid hormone withdrawal for radioactive iodine(RAI) therapy
3121375|NCT01744756|Experimental|Subconjunctival Bevacizumab|One aplication of subconjunctival Bevacizumab 0,5 ml
3121376|NCT01744743|Active Comparator|preconception|Participants will be included according to their first outpatient visiting time. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
3121377|NCT01744743|Active Comparator|early conception|Participants will be included according to their first outpatient visiting time before 15+6 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
3121378|NCT01744743|Placebo Comparator|late conception|Participants will be included according to their first outpatient visiting time after 16 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
3121379|NCT01744730|Active Comparator|Clindamycin IV-ages 2 to 11 Years Old (BMI 85-95th Percentile)|Clindamycin IV: Children ages 2 to 11 years old with BMI 85th to 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
3121380|NCT01744730|Active Comparator|Clindamycin IV-ages 2 to 11 Years Old (BMI Greater Than 95th)|Clindamycin IV: Children ages 2 to 11 years old with BMI greater than 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
3121381|NCT01744730|Active Comparator|Clinidamycin IV-ages 12 to 17 (BMI 85-95th Percentile)|Clindamycin IV: Children ages 12 to 17 years old with BMI 85th to 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
3121382|NCT01744730|Active Comparator|Clindamycin IV-ages 12 to 17 (BMI Greater Than 95th)|Clindamycin IV: Children ages 12 to 17 years old with BMI greater than 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
3121383|NCT01744717||Critically ill uncommunicative patients|Critically ill non-communicative patients, on mechanical ventilation
3121384|NCT01744704|Experimental|rhNGF 0.5 µg/mL Sentinel|1 x 35 µL drop 3 subjects
3121385|NCT01744704|Experimental|rhNGF 5 µg/mL Sentinel|1 x 35 µL drop 3 subjects
3121386|NCT01744704|Experimental|rhNGF 60 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
3121387|NCT01744704|Experimental|rhNGF 20 µg/mL Sentinel|1 x 35 µL drop 3 subjects
3121388|NCT01744704|Experimental|rhNGF 20 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
3121389|NCT01744704|Experimental|rhNGF 180 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
3121390|NCT01744704|Placebo Comparator|Placebo Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
3121391|NCT01744704|Experimental|rhNGF 20 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subject
3121392|NCT01744704|Experimental|rhNGF 20 µg/mL Part B cohort 0M|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 3 subjects
3121393|NCT01744704|Experimental|rhNGF 60 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
3121394|NCT01744704|Experimental|rhNGF 180 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
3121395|NCT01744704|Placebo Comparator|Placebo Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 10 subjects
3121396|NCT01744691|Experimental|ibrutinib|All subjects will receive ibrutnib 420 mg (3 x 140-mg capsules) orally once daily.
3121397|NCT01744678|Experimental|Access to experimental break room|"Subjects will visit the experimental break room 4 times per Orbit 1 shift:~first, prior to the beginning of the work shift~second, during an operationally feasible 20-min break during the 1st half of the work shift~third, once during an operationally feasible 20-min break during the 2nd half of the work shift~fourth, immediately after the end of the work shift~In the break room, subjects will be passively exposed to blue-wavelength enriched ceiling lights during all four visits for each work shift.~Also in the break room, subjects will perform 10-minutes of mild exercise during the first three visits to the break room during each work shift."
3121398|NCT01744665|Experimental|AMN107 2 years of consolidation|59 patients will be enrolled to the study. Patients who achieve MR4.5 on study will then be randomized to receive a total 2 years (Consolidation Phase) of additional nilotinib therapy. If MR4.5 is sustained during the Consolidation phase, patients will be eligible to stop taking niltoinib during the treatment-free remission (TFR) phase. No head to head comparison of the 2 arms will be performed. Each arm will be compared to historical data.
3121431|NCT01744431||No treatment|
3121432|NCT01744418|Experimental|HAVG graft|HAVG graft implantation to study participants.
3121477|NCT01744145|Active Comparator|Interventional 40-60|Interventional group aged 40-60
3121399|NCT01744652|Experimental|Arm A - Crizotinib + Dasatinib|"Arm A: Patients receive dose of crizotinib plus an increasing dose of dasatinib. All participants take dasatinib by mouth 1 time each day. Patients take this drug alone on Day 1 of Cycle 1, before the first day they receive the study drug combination. Final dose level in both arms (dose level number 5) is identical. In the case that both arms define dose level 5 as the MTD, then the expansion cohort for safety will include 10 patients with that dose. If two different MTDs on both arms defined, then both MTDs cohorts expanded with 10 patients and 20 patients included on the safety expansion analysis.~Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle.~Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle. Dasatinib Expansion Dose: MTD from dose escalation group."
3121400|NCT01744652|Experimental|Arm B - Dasatinib + Crizotinib|"Arm B: Patients receive dasatinib plus an increasing dose of crizotinib. All participants take dasatinib by mouth 1 time each day. Patients take this drug alone on Day 1 of Cycle 1, before the first day they receive the study drug combination. Final dose level in both arms (dose level number 5) is identical. In the case that both arms define dose level 5 as the MTD, then the expansion cohort for safety will include 10 patients with that dose. If two different MTDs on both arms defined, then both MTDs cohorts expanded with 10 patients and 20 patients included on the safety expansion analysis.~Dasatinib 140 mg by mouth daily in a 28 day cycle. Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle.~Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group."
3121401|NCT01744639|Experimental|HCC under treatment with radioablation|Assessment of nutritional status by anthropometry, bioelectrical impedance, blood sampling and application of psychometric hepatic encephalopathy score and critical flicker frequency, to assess the presence of hepatic encephalopathy.
3121402|NCT01744626|Experimental|CC-292 with Rituximab|Dose Escalation
3121403|NCT01744613||Group A|Will include patients with PRU values above the optimal cut-off value determined by ROC analysis
3121404|NCT01744613||Group B|Will include patients with PRU values below the optimal cut-off value determined by ROC analysis.
3121405|NCT01744600|Experimental|Music Therapy|Participants in the experimental group will receive one active individual music therapy session each week for 22 weeks. Each session will last thirty minutes.
3121406|NCT01744600|No Intervention|Control|Participants in the control group will receive normal, standard daily care for the 22 week period.
3121407|NCT01744587|Placebo Comparator|Placebo|Placebo qd (2# bid) for 3 years
3121408|NCT01744587|Experimental|Epigallocatechin Gallate (EGCG)|EGCG 600 mg qd (2# bid) for 3 years
3121409|NCT01744574|Placebo Comparator|Placebo|Placebo - subjects will take 200 mg twice daily, orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date. They will also receive smoking cessation behavioral counseling.
3121410|NCT01744574|Experimental|Progesterone|The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily, orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date. They will also receive smoking cessation behavioral counseling.
3121411|NCT01744561|Experimental|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
3121412|NCT01744561|No Intervention|Control|Keep activity level constant
3121413|NCT01744548|Experimental|tCBT treatment|Participants randomised to the tCBT treatment arm will receive 12 individual, 1-hour tCBT sessions based upon Barlow et al.'s (2011) Unifed Protocol for emotional disorders (UP).
3121414|NCT01744548|No Intervention|7-week delayed tCBT treatment|Participants randomised to the delayed-treatment arm will receive a brief telephone call and complete the Hospital Anxiety and Depression Scale (HADS) in order to monitor risk and symptom deterioration during the 7-week delayed treatment phase. They will also receive TAU (e.g. Community Mental Health Team appointments, case reviews, etc) during this time. At the end of 7 weeks, participants in the delayed-treatment arm will crossover into the treatment arm and receive the tCBT intervention. This arm will serve as a control condition in order to enable between-group comparisons.
3121415|NCT01744535|Active Comparator|Paper food diary|
3121416|NCT01744535|Active Comparator|Online food diary|
3121417|NCT01744535|Experimental|"My Meal Mate (smartphone application)"|"A smartphone application called My Meal Mate (MMM) designed to facilitate weight loss. The app allows system users to set a goal for weight loss and self monitor diet and activity in an electronic diary. Users can select foods from the large Weight Loss Resources food database. Instant nutritional feedback is provided along with weekly feedback by text message."
3121418|NCT01744522||Leech therapy|Patients receiving leech therapy in the outpatient clinic
3121419|NCT01744509|Other|Diagnosis of CRC|All the patients enrolled received all the 3 procedures: capsule colonoscopy; CT-colonography and optical colonoscopy.
3121420|NCT01744496|Experimental|Rotigotine|Rotigotine Transdermal Patches
3121421|NCT01744496|Placebo Comparator|Placebo|Placebo Transdermal Patches
3121422|NCT01744483|Active Comparator|PVC ETT|Polyvinylchloride cuff endotracheal tube
3121423|NCT01744483|Experimental|PUC ETT|Polyurethane cuff endotracheal tube
3121424|NCT01744483|Experimental|PUC-CASS ETT|Polyurethane cuff with continuous aspiration of subglottic secretions endotracheal tube
3121425|NCT01744470|Experimental|Group A - tacrolimus half-dose|"Immunosuppressive strategy with 50 % reduction of Advagraf® daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.~Drug: Tacrolimus targeted half-dose"
3121426|NCT01744470|Experimental|Group B - tacrolimus unchanged dose|Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf® and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose
3121427|NCT01744457|Other|20 patients with dry eye syndrome|Patients with dry eye syndrome defined as outlined in the inclusion and exclusion criteria
3121428|NCT01744457|Other|20 healthy control subjects|age- and sex-matched controls
3121429|NCT01744444|Experimental|Memantine first|
3121430|NCT01744444|Experimental|Gabapentin first|
3121433|NCT01744405||Lactating Women with Chagas disease|Women with Chagas disease who fulfill clinical criteria for treatment with nifurtimox, and who are also lactating
3121434|NCT01744392|Experimental|education intervention|The intervention provides a personalized Meducation calendar to all patients enrolled in the study (identified in package as Example Calendar). The Meducation Calendar will include medications for diabetes (sugar), high blood pressure, cholesterol, heart medications and blood thinning medications. The medication calendars contains the following for each medication 1) the name, 2) the time of day, including a pictorial display, it should be taken 3) the number of times each day to take the medication, and 4) the indication for the medication.
3121435|NCT01744379|Experimental|200 mg lesinurad|200 mg lesinurad or placebo fasted and fed
3121436|NCT01744379|Experimental|400 mg lesinurad|400 mg lesinurad or placebo fasted and fed
3121437|NCT01744379|Experimental|100 mg lesinurad|100 mg lesinurad or placebo fasted and fed
3121438|NCT01744379|Experimental|50 mg lesinurad|50 mg lesinurad or placebo fasted and fed
3121439|NCT01744379|Experimental|600 mg lesinurad|600 mg lesinurad or placebo fasted and fed
3121440|NCT01744366|Experimental|Degarelix|Degarelix 240/80 mg
3121441|NCT01744366|Active Comparator|Goserelin|Goserelin 3.6 mg
3121442|NCT01744353|Experimental|Dose level 1|Abraxane 125 mg/m2, day 1 Oxaliplatin 85 mg/m2, day 1 leucovorin 400 mg/m2, day 1 5-FU Infusion 1200 mg/m2/ days 2 days IV infusion
3121443|NCT01744353|Experimental|Dose level 2/ MTD|Abraxane 150 mg/m2, day 1 Oxaliplatin 85 mg/m2, day 1 leucovorin 400 mg/m2, day 1 5-FU Infusion 1200 mg/m2/ days 2 days IV infusion
3121444|NCT01744353|Experimental|Dose level 3|Abraxane 175 mg/m2, day 1 Oxaliplatin 85 mg/m2, day 1 leucovorin 400 mg/m2, day 1 5-FU Infusion 1200 mg/m2/ days 2 days IV infusion
3121445|NCT01744340|Experimental|head and neck|Cetuximab, 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly there after Eribulin Mesylate 1.4mg/m2
3121446|NCT01744340|Experimental|Colon- closed as of May 2014|"Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
3121447|NCT01744327||Chronic Plaque type psoriasis|Patients with plaque type psoriasis
3121448|NCT01744314|Experimental|drug|The treatment arm will receive 21 days of Indomethacin and Pantoprazole (gastrointestinal protective agent). The patients will receive Indomethacin 25mg three times a day and Pantoprozole 40mg once a day.
3121449|NCT01744314|Placebo Comparator|placebo|The placebo group will receive microcrystalline cellulose powder tablets to be taken as a control. The placebo will be dosed at the same intervals and duration as the treatment arm in this study.
3121450|NCT01744301||All patients newly prescribed PPI|All patients newly prescribed PPI
3121451|NCT01744301||All patients newly prescribed H2RA|All patients newly prescribed H2RA
3121452|NCT01744288|Experimental|1|Ticagrelor with Platelet transfusion
3121453|NCT01744288|Experimental|2|Ticagrelor without Platelet transfusion
3121454|NCT01744288|Active Comparator|3|Clopidogrel with Platelet transfusion
3121455|NCT01744288|Active Comparator|4|Clopidogrel without Platelet transfusion
3121456|NCT01744275|Placebo Comparator|Placebo|Placebo
3121457|NCT01744275|Experimental|Omega 3 fatty acids supplementation|Omega 3 fatty acids capsules
3121458|NCT01744262|Active Comparator|Inhalational anesthesia group|
3121459|NCT01744262|Experimental|Total intravenous anesthesia group|
3121460|NCT01744249|Experimental|Axitinib + Sandostatin LAR|Axitinib 5 mg BID + Sandostatin LAR 30mg/28 days
3121461|NCT01744249|Placebo Comparator|Placebo + Sandostatin LAR|Placebo BID + Sandostatin LAR 30mg/28 days
3121462|NCT01744236|Experimental|Liraglutide (main study, long-term intervention)|This arm (n=20) will receive liraglutide 1.8mg and sitagliptin-placebo during 12 weeks
3121463|NCT01744236|Experimental|Sitagliptin (main study, long-term intervention)|This arm (n=20) will receive sitagliptin 100mg and liraglutide-placebo during 12 weeks
3121464|NCT01744236|Placebo Comparator|Placebo (main study, long-term intervention)|This arm (n=20) will receive liraglutide-placebo and sitagliptin-placebo during 12 weeks
3121465|NCT01744236|Experimental|Exenatide (main study, acute intervention)|Prior to the 12-week intervention study, a GLP-1 receptor agonist (exenatide) will be administered intravenously (n=30).
3121466|NCT01744236|Placebo Comparator|Placebo (main study, acute intervention)|Prior to the 12-week intervention study, placebo will be administered intravenously (n=30).
3121467|NCT01744236|Other|Acute MRI intervention study|In a subset of 12 patients with type 2 diabetes, a crossover trial with acute infusion of exenatide and placebo is performed. This is done prior to the 12-week intervention study.
3121468|NCT01744236|Other|Pilot-study|In 10 healthy obese subjects, a crossover trial with acute infusion of exenatide, placebo and L-NMMA is performed.
3121469|NCT01744223|Experimental|BPX-501 and AP1903|BPX-501 and AP1903
3121470|NCT01744210||CHF|
3121471|NCT01744197|Experimental|Arm 1|First application: Synera patch; Second application: Placebo patch
3121472|NCT01744197|Experimental|Arm 2|First application: Placebo patch; Second application: Synera patch
3121473|NCT01744184|Active Comparator|Midazolam|"midazolam sedation combined with pharyngeal anaesthesia~Participants randomized to receive midazolam will have an intravenous cannula sited and, following the administration of xylocaine throat spray as above, will be put into the left lateral position. They will then be given up to 5mg midazolam as appropriate to achieve conscious sedation as for standard protocol in endoscopy."
3121474|NCT01744184|Experimental|Entonox|"Entonox combined with pharyngeal anaesthesia.~Pharyngeal anaesthesia, given as 8-16 sprays of xylocaine to the pharynx; 3 minutes will be given to allow the pharynx to become anaesthetized.~Participants randomized to receive Entonox will be given the 50:50 nitrous oxide:oxygen mix via a mouthpiece with a demand valve system, once in position for the procedure. Inhalations will be given for 3-5 minutes (or until the participant feels adequately sedated) measured using a stopwatch. Oxygen will be given at 2 litres per minute via nasal cannulae during the procedure, (standard care for sedated procedures). The endoscopist will then proceed to intubate the cricopharynx and perform the procedure in the standard manner."
3121475|NCT01744171|Experimental|Treatment (recombinant hsp110-gp100 chaperone complex vaccine)|Patients receive recombinant hsp110-gp100 chaperone complex vaccine ID on days 1, 15, and 43 in the absence of unacceptable toxicity.
3121476|NCT01744158||Children with cerebral palsy|No intervention applicable
3158671|NCT01489488|Experimental|Arm 5|
3121478|NCT01744145|Placebo Comparator|Control 40-60|Control group aged 40-60
3121479|NCT01744145|Active Comparator|Interventional 60 and above|Interventional group aged 60 and above
3121480|NCT01744145|Placebo Comparator|Control 60 and above|Control group aged 60 and above
3121481|NCT01744132|Experimental|Aim 3: Contract|Half of patients screened in the pharmacy are selected to a contract group, which encourages patients to review the results of the screen, share the results with their PCP, and schedule and attend a follow-up appointment with an ophthalmologist if the results are abnormal.
3121482|NCT01744132|No Intervention|Aim 3: Control|No contract is signed for half of the patients screened in Aim 3.
3121483|NCT01744119||Abdominal Aortic Aneurysm|
3121484|NCT01744106|Experimental|pseudoephedrine hydrochloride 30 mg tablets|Test product
3121485|NCT01744106|Placebo Comparator|placebo tablets|Placebo
3121486|NCT01744093|Active Comparator|Doxycycline|100 mg BID (orally) for 6 months
3121487|NCT01744093|Placebo Comparator|Placebo (sugar pill)|100 mg BID (orally) for 6 months
3121488|NCT01744080|Active Comparator|Early Surgery|
3121489|NCT01744080|Experimental|Regular Wait Time|
3121490|NCT01744067|Active Comparator|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day: Omacor 1 g 1 capsule by mouth 3 times a day for 44 weeks.
3121491|NCT01744067|Placebo Comparator|Placebo|Placebo: 1 capsule containing 1 g of olive oil by mouth 3 times a day for 44 weeks.
3121492|NCT01744054|Other|PET/MR or PET/CT|"Patients must have had radioembolization, within 72 hours of the PET/MR or PET/CT~Subjects will be asked to lie still within the scanner for up to 1.5 hours while images are acquired for the liver"
3121493|NCT01744041|Experimental|Dyadic Interpersonal Psychotherapy|Brief Interpersonal Psychotherapy during pregnancy followed by dyadic mother-infant psychotherapy for one year postpartum
3121494|NCT01744041|Active Comparator|Enhanced Treatment as Usual|Personalized referral to community resources for depression treatment
3121495|NCT01744028|Experimental|Remote patient monitoring|Remote patient monitoring system including the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) tool can use changes in daily scores over a certain threshold level to alert notification to the clinical site. The site will contact the patient in order to determine the clinical significance associated with the change in score, and to treat the patient based on clinical judgment and clinical practice.
3121496|NCT01744028|Experimental|Usual care|This group of patient will continue on their usual standard care as close to real life situation as possible.
3121497|NCT01744015|Experimental|Patient Decision Making Tool|Patients will be given an opportunity to use a decision making tool to assist in decision making of their care
3121498|NCT01744015|Active Comparator|Standard of care|Control group consisting of normal care
3121499|NCT01744002|Experimental|Shoulder Treatment with Neck Mobilization|The experiment group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and Unlateral Posterior Anterior Mobilization to the cervical spine; applied as 3 X 30 seconds, to each comparable (stiff or painful) segment.
3121500|NCT01744002|Active Comparator|Control Group|The control group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
3121501|NCT01743989|Active Comparator|arm 1|12 months of nilotinib consolidation (arm 1) plus 36 months of TFR phase
3121502|NCT01743989|Active Comparator|arm 2|24 months of nilotinib consolidation plus 24 months of TFR phase
3121503|NCT01743976|Experimental|Donepezil|donepezil 5 mg every day
3121504|NCT01743976|Placebo Comparator|Placebo|Placebo (sugar pill) every day
3121505|NCT01743963|Experimental|Decision Support Intervention|Clinical pharmacists mediated computerized decision support
3121506|NCT01743963|Active Comparator|Usual Care|Clinicians' typical approach for GID monitoring
3121507|NCT01743950|Active Comparator|Bevacizumab naive recurrent grade IV gliomas|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
3121508|NCT01743950|Active Comparator|Bevacuzumab exposed and refractive grade IV gliomas|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
3121509|NCT01743950|Active Comparator|Bevacizumab naive recurrent grade III gliomas|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
3121510|NCT01743950|Active Comparator|Bevacizumab exposed and refractive grade III gliomas|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
3121511|NCT01743937|Active Comparator|Ticagrelor|Coronary occlusion with balloon inflation
3121512|NCT01743937|Active Comparator|Clopidogrel|Coronary occlusion with balloon inflation
3121513|NCT01743924|Experimental|Raw|Broccoli,200 grams
3121514|NCT01743924|Experimental|cooked|Microwaved, 200 grams
3121515|NCT01743911|Placebo Comparator|sugar pill|Intervention: sugar pill
3121516|NCT01743911|Active Comparator|tadalafil|Intervention: tadalafil
3121517|NCT01743898||Experimental|Patient taking FDA approved dose of rivaroxaban
3121518|NCT01743898||Control Group|Patient not taking any form of anticoagulation
3121519|NCT01743885|Active Comparator|propanolol|Propanolol (Syprol:oral solution)
3121520|NCT01743885|Active Comparator|Acebutolol|Acebutolol (Sectral:oral solution)
3121521|NCT01743872|Active Comparator|Contrast Injection|Media #1: IV Contrast (Omnipaque 350) will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml) Intervention protocol will be followed per Cross-Reference Intervention.
3121522|NCT01743872|Active Comparator|Dextran Injection|Media #2: Dextran 40 Solution will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml. Intervention protocol will be followed per Cross-Reference Intervention.
3121571|NCT01743625|Placebo Comparator|Placebo|Matching tablet to COV155 without containing active ingredients, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.
3121572|NCT01743612|Experimental|Sclerodermic patients|patients with systemic sclerosis according to Leroy's classification
3121573|NCT01743612|Experimental|Primary Raynaud's phenomenon|without secondary disease
3121523|NCT01743872|Active Comparator|CO2 Injection|Media #3: Carbon Dioxide (CO2) will be injected with large volume hand injection syringe as per the usual protocol. This be done with particular attention to avoid air in the closed system. In addition to supine, there is also an option that the patient's distal limb may be elevated to improve the flow of CO2 during injection. The surgeon will also wait at least 2 minutes between each CO2 injection to allow any potentially trapped CO2 to dissolve. A range of 20-60 ml will be used with each hand injection based on the data from the initial 5-10 pilot patients. Intervention protocol will be followed per Cross-Reference Intervention.
3121524|NCT01743859|Experimental|Azacitidine|Patients will receive 7 days of azacitidine followed by.....
3121525|NCT01743859|Experimental|Lenalidomide|3 weeks of lenalidomide followed by.....
3121526|NCT01743859|Experimental|Off Therapy|2 weeks off therapy, for a maximum of 12 cycles as noted above.
3121527|NCT01743846||Major Surgery|Patients undergoing major surgery
3121528|NCT01743833|Active Comparator|Thoracic HVLAMT, Postive Message|Thoracic HVLAMT with a positive message given prior to the intervention.
3121529|NCT01743833|Active Comparator|Thoracic HVLATM, Neutral Message|Thoracic HVLAMT with a neutral message given prior to the intervention.
3121530|NCT01743833|Active Comparator|Scapular HVLATM, Positive Message|Scapular HVLAMT with a positive message given prior to the intervention.
3121531|NCT01743833|Active Comparator|Scapular HVLATM, Neutral Message|Scapular HVLAMT with a neutral message given prior to the intervention.
3121532|NCT01743820|Active Comparator|dihydroartemisinin-piperaquine only|dihydroartemisinin -piperaquine (DP) only
3121533|NCT01743820|Experimental|DP and 0.125 mg/kg primaquine|DP and single dose oral 0.125 mg/kg primaquine
3121534|NCT01743820|Experimental|DP and 0.5 mg/kg primaquine|DP and single dose oral 0.5 mg/kg primaquine
3121535|NCT01743820|Experimental|DP and 0.25 mg/kg primaquine|DP and a single dose oral 0.25 mg/kg primaquine
3121536|NCT01743820|Experimental|DP and 0.0625 mg/kg primaquine|DP and a single dose oral 0.0625 mg/kg primaquine
3121537|NCT01743807|Experimental|Dose Level 1|GNKG168 0.25 mg/kg/day on days 1 through 5
3121538|NCT01743807|Experimental|Dose Level 2|GNKG168 0.75 mg/kg/day on days 1 through 5
3121539|NCT01743807|Experimental|Dose Level 3|GNKG168 1.5 mg/kg/day on days 1 through 5
3121540|NCT01743807|Experimental|Dose Level 0|If dose level #1 is too toxic the study will back down to dose level 0. GNKG168 0.15 mg/kg/day on days 1 through 5.
3121541|NCT01743794|Experimental|ropivacaine 0.2%, wound infusion|
3121542|NCT01743794|Placebo Comparator|saline solution 0.9%, wound infusion|
3121543|NCT01743781|Experimental|intervention group|view a 10-minute informational video about comprehensive eye examination
3121544|NCT01743781|No Intervention|control group|No intervention
3121545|NCT01743768|Experimental|SB010|"The drug will be administered in phosphate-buffered saline solution, inhaled over 5 - 10 min, using inhalation device.~Administered dose: 10 mg hgd40 in 2 mL solution (5.0 mg/mL).~Initial dose on Day 1 (single-dose PK profile); once daily dose for 28 consecutive days (Days 1 to 28); last inhalation on Day 28 (steady state PK profile)."
3121546|NCT01743768|Placebo Comparator|Placebo|"The placebo (phosphate-buffered saline) is administered as a solution, inhaled over 5 - 10 min, using inhalation device.~Initial dose on Day 1 (single-dose PK profile); once daily dose for 28 consecutive days (Days 1 to 28); last inhalation on Day 28 (steady state PK profile)."
3121547|NCT01743755|Active Comparator|Dexamethasone|
3121548|NCT01743755|Placebo Comparator|Placebo|Placebo tablet, once daily for four consecutive days
3121549|NCT01743742|Experimental|Oral vitamin E, vitamin C|Single dose of vitamin E drops 200 IU within 6 hours of birth and vitamin C tablet 250 mg in pulverised form (2 doses at 24 hr interval) via infant feeding tube
3121550|NCT01743729|Experimental|Lifitegrast|Lifitegrast Ophthalmic Solution (5.0%)
3121551|NCT01743729|Placebo Comparator|Placebo|
3121552|NCT01743716||MDD Mothers|Adult women with a history of major depressive disorder (MDD) and a healthy adolescent daughter between the ages of 12-14
3121553|NCT01743716||Healthy Control Mothers|Adult women with no history of psychopathology and an adolescent daughter between the ages of 12-14
3121554|NCT01743716||High Risk Female Adolescents|Healthy female adolescents aged 12-14 with a mother in the MDD Mothers cohort
3121555|NCT01743716||Healthy Female Adolescents|Healthy female adolescents aged 12-14 with a mother in the Healthy Control Mothers cohort.
3121556|NCT01743703|Other|whole body MRI|diagnostic whole body MRI, and skeletal imaging following guidelines (whole body radiographic and scintigraphic screening)
3121557|NCT01743690|Active Comparator|fluocinolone, placebo|fluocinolone, placebo
3121558|NCT01743690|Experimental|fluocinolone, probiotic|fluocinolone, Probiotic lactobacilli reuteri
3121559|NCT01743690|Active Comparator|Nystatin, placebo|Nystatin, placebo
3121560|NCT01743690|Experimental|nystatin, probiotic|nystatin, Probiotic lactobacilli reuteri
3121561|NCT01743677|Experimental|CP-690,550 100 mg|
3121562|NCT01743677|Placebo Comparator|Placebo|
3121563|NCT01743677|Active Comparator|Moxifloxacin hydrochloride|
3121564|NCT01743664|Experimental|Eye Movement Desesitization Reprocessing|The EMDR protocol follows procedures and phases described by Shapiro (1996). This is a complex treatment that incorporates many different interventions in order to recall trauma-related memories and to subdue them. EMDR processing consists of attending to oscillatory stimulation presented in a visual, auditory or tactile modalities, such as moving the finger from side to side across the patient's visual field or presenting an alternating tapping on the hands alternatively. Eye movements are the most commonly used external stimulus, but if the patient has problems with this kind of stimulation, such as headaches or sensomotor deficits, the therapist chooses tapping as an alternative form of oscillatory stimulation with equivalent therapeutic efficacy.
3121565|NCT01743664|Active Comparator|relaxation|Relaxation sessions will include diaphragmatic breathing, progressive muscle relaxation, visualisation, and rapid relaxation.
3121566|NCT01743651|Placebo Comparator|Placebo|Placebo
3121567|NCT01743651|Active Comparator|Baclofen|Baclofen
3121568|NCT01743651|Experimental|Arbaclofen|Arbaclofen
3121569|NCT01743638|Experimental|MR-Guided Laser Ablation|
3121570|NCT01743625|Experimental|COV155|COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.
3164742|NCT01448538||Group 1|
3121580|NCT01743560|Experimental|RAD001 and Exemestane|Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive RAD001 at a dose of 10mg daily p.o. and exemestane 25mg daily p.o. for 48 weeks.
3121581|NCT01743547|No Intervention|No Intervention; Arm A; Control Group|24 subjects who declined yoga but agreed to data collection
3121582|NCT01743547|Active Comparator|Active Comparator; Arm B; Intervention Group|24 subjects participating in 8 weeks of Yoga and agreed to data collection
3121583|NCT01743534||Conservation of praxies and form plates|
3121584|NCT01743521|Experimental|Group A - 8 weeks total therapy|8 weeks total therapy of TPV/PEG-IFN/RBV if undetectable HCV RNA after 2 weeks of therapy
3121585|NCT01743521|Experimental|Group B - 12 weeks total therapy|12 weeks total therapy of TPV/PEG-IFN/RBV if undetectable HCV RNA after 4 weeks of therapy
3121586|NCT01743521|Experimental|Group C - 24 weeks total therapy|24 weeks total therapy - TPV/PEG-IFN/RBV for 12 weeks + PEG-IFN/RBV for 12 weeks if undetectable HCV RNA after 8 weeks of therapy
3121587|NCT01743508|Active Comparator|Misoprostol by physician|Misoprostol treatment by midwife
3121588|NCT01743508|Experimental|Misoprostol by midwife|Misoprostol treatment by midwife
3121589|NCT01743495|Other|Functional Services|The program consists of up to 10 home-based functional services sessions over 4 months.
3121590|NCT01743482|Experimental|Pazopanib|Patients will receive pazopanib at the dose of 800 mg/day orally until disease progression or evidence of unacceptable toxicity/side effects. The study will be performed according to Simon's two-stage optimal design.
3121591|NCT01743469|Experimental|Hepatocellular Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
3121592|NCT01743469|Experimental|Ovarian Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
3121593|NCT01743469|Experimental|Renal Cell Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
3121594|NCT01743469|Experimental|Gastric Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
3121595|NCT01743456|No Intervention|Current practice (BIS and rSO2 blinded)|
3121596|NCT01743456|Experimental|Targeted intra-operative depth of anaesthesia|
3121597|NCT01743443|Experimental|Sensitiviy|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
3121598|NCT01743430|Experimental|telerehabilitation|telerehabilitation via internet
3121599|NCT01743430|No Intervention|conventional|conventional therapy
3121600|NCT01743417|Experimental|Cognitive intervention|Children in this arm will receive computerised cognitive rehabilitation training for 24 sessions lasting 45 minutes. The Captain's log brain training software is programmed to increase in difficulty as child progresses through the training levels.
3121601|NCT01743417|Active Comparator|Active control|Children in this arm will receive 24 sessions of computerised cognitive rehabilitation training. Captain's log, the brain training software will not be programmed to increase in difficulty with each successive level in this arm.
3121602|NCT01743417|No Intervention|Passive control|No computer training or games will be provided to this group
3121603|NCT01743404|Active Comparator|Inflaminat|Inflaminat 500 mg tablet by mouth three times a day
3121604|NCT01743404|Placebo Comparator|Sugar pill|Placebo 500 mg tablet by mouth three times a day
3121605|NCT01743391|No Intervention|Control|Standard treatment
3121606|NCT01743391|Experimental|Intervention|Office-hysteroscopy with endometrial biopsy before standard treatment
3121607|NCT01743378|Experimental|TAP Block Ropivacaine 0,75 %|Bilateral Transversus Abdominis Plane Block with 2 x 20 ml Ropivacaine 0,75 %
3121608|NCT01743378|Placebo Comparator|TAP Block Saline 0,9 %|Bilateral Transversus abdominis plane block with 2 x 20 ml Saline 0,9 %
3121609|NCT01743365|Experimental|Cisplatin-5FU-Afatinib|"Cisplatin 75mg/m2 iv administered on Day 1, 5FU 750mg/m2 at 24-hour iv infusion on Days 1-4, Afatinib (BIBW-2992) 40mg per os on Days 3-5, 8-12, 15-19 of each cycle. Administration of Afatinib will start on Day 3 of each cycle with an administration interval on each weekend (Weekday on, Weekend off) for 21 days. The administration of the combination Cisplatin-5FU-Afatinib will be continued until disease progression, appearance of significant toxicity, completion of 6 cycles, or withdrawal of consent. At completion of 6 cycles of the combination, in the absence of disease progression, the administration of Afatinib as maintenance monotherapy will be continued until disease progression, appearance of significant toxicity, or withdrawal of consent at the weekday on-weekend off schedule."
3121610|NCT01743352||Hypertension patients|Local common carotid artery pulse wave velocity is compared in patients with hypertension and healthy volunteers.
3121611|NCT01743352||Healthy Volunteers|Local common carotid artery pulse wave velocity is compared in hypertension patients and healthy volunteers
3121612|NCT01743339|Active Comparator|Control|Control (brief check-in calls) and Cognitive Processing Therapy (12 individual weekly sessions)
3121613|NCT01743339|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia (4 individual therapy sessions over 5 weeks) and Cognitive Processing Therapy (12 individual weekly sessions)
3121614|NCT01743326|Experimental|RFD-group|Radio Frequency Denervation
3121615|NCT01743326|Active Comparator|Local Anesthesia-group|Local Anesthesia-group
3121616|NCT01743313||Hip and knee replacement recipients|"Hip and knee replacement recipients (with osteoarthritis) enrolled previously into Perioperative Hyperglycaemia in Primary Total Hip and Knee Replacement study (NCT01021826)."
3121617|NCT01743300|Active Comparator|Grapefruit juice arm|The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment
3121618|NCT01743300|Active Comparator|Orange juice|The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment.
3121619|NCT01743287|Experimental|Imotun capsule|Imotun capsule: 300.03mg/cap, orally, 1 capsule once a day during 24 weeks
3121620|NCT01743287|Placebo Comparator|Imotun capsule placebo|Imotun capsule Placebo: Placebo 1 capsule once a day during 24 weeks
3121621|NCT01743274|No Intervention|Control Group|"Randomization will be performed after initial coronary angiography, once the operator has identified the lesion responsible for the ACS. Patients will be randomly allocated to one of two groups. In the Control Group, the angioplasty procedure will be guided by traditional fluoroscopy alone.~In both groups, fractional flow reserve (FFR) will be measured at the end of the procedure, once the operator considers the result of the angioplasty to be optimal. The average of three consecutive FFR measures will be recorded."
3121622|NCT01743274|Experimental|Optical Coherence Tomography|"Randomization will be performed after initial coronary angiography, once the operator has identified the lesion responsible for the ACS. Patients will be randomly allocated to one of two groups.~In the OCT group, OCT will be performed to optimise the results of angioplasty. The procedure will be performed according to usual practice, with or without pre-dilation before implantation of one or more stents (drug-eluting or bare metal). In the OCT group, OCT will be performed after initial coronary angiography and at the end of the procedure and the operator will have the possibility to change procedural strategy according to the data immediately available on the OCT images, with the possibility of additional interventions (additional balloon inflations, addition stent implantation, use of GPIIb/IIIa inhibitors and/or thromboaspiration and/or rotational atherectomy)."
3121623|NCT01743261|Active Comparator|usual care|In this arm patients were managed according to the organization of the management model which took on the care of the patient. The organization of these models is characterized by one or two professional figures (physiatrists, neurologist), with hierarchical relationships, in spaces limited to a specific pathology; access is determined by clinical stability; the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas; the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty.
3121624|NCT01743261|Experimental|Graded intensive rehabilitation|"Instruments of governance are the diagnostic-therapeutic rehabilitation. pathways (DTRP), the Quality system and product standards.~Medical care process with result-oriented autonomy. Technology support of vital signs. Multidisciplinary intervention"
3121625|NCT01743235|Experimental|Placebo|30 subjects administered a placebo
3121626|NCT01743235|Experimental|Testosterone + Buspirone hydrochloride combination drug|30 subjects are given combination drug (0.25 mg Testosterone + 5 mg Buspirone hydrochloride)
3121627|NCT01743235|Experimental|Testosterone + Buspirone hydrochloride combinat|30 subjects are given combination drug (0.25 mg Testosterone + 10 mg Buspirone hydrochloride)
3121628|NCT01743235|Experimental|Testosterone + Buspirone Combination Drug|30 subjects are given combination drug (0.5 mg Testosterone + 5 mg Buspirone hydrochloride)
3121629|NCT01743235|Experimental|Testosterone +Buspirone Combination Drug|30 subjects are given combination drug (0.5 mg Testosterone + 10 mg Buspirone hydrochloride)
3121630|NCT01743235|Experimental|Testosterone|30 subjects are given 0.5 mg Testosterone
3121631|NCT01743235|Experimental|Buspirone|30 subjects are given 10 mg Buspirone hydrochloride
3121632|NCT01743222|Experimental|eASC|"eASC~First cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 2.5 millions of eASCs suspended in 0.25 ml of HTS per lymph node, total dose 5 millions of cells.~Second cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 5 millions of eASCs suspended in 0.5 ml of HTS per lymph node, total dose 10 millions of cells."
3121633|NCT01743222|Placebo Comparator|Placebo|"First cohort (2 volunteers): injection of 0.25 ml of Hypo Thermosol (HTS) per lymph node~Second cohort (2 volunteers): injection of 0.5 ml of Hypo Thermosol (HTS) per lymph node"
3121634|NCT01743196||Normal weight|Women with BMI 18.5 to 24.9 kg/m2
3121635|NCT01743196||Obese|Women with BMI > 30 kg/m2
3121636|NCT01743183|Experimental|threshold|Held inspiratory muscle strengthening for 5 weeks with Threshold, charging 30% of maximal inspiratory pressure, 7 days a week, one supervised and unsupervised 6.
3121637|NCT01743170|No Intervention|Control group|In the control group doctors will receive information on the self-measured blood pressure as recorded at home via a diary card.
3121638|NCT01743170|Experimental|Intervention group|In the intervention group, doctors will receive weekly reports via telemonitoring of self-measured blood pressure.
3121639|NCT01743157|Experimental|Biochemo + Bevacizumab then Ipilimumab|Single arm: Biochemotherapy with 4 cycles at 3 week intervals of Temozolamide 150mg/m2 x4, cisplatin 20mg/m2 x 4, vinblastine 1.2mg/m2 x 4, bevacizumab 7.5-15 mg/kg x 1, interferon 5mg/m2 x5 and aldesleukin 36,18,9, % 9 miu/day over 4 days each cycle; then ipilimumab 3mg/kg q 21 days x 4, then q 3 months x 8 for total 3 years.
3121640|NCT01743144|Active Comparator|Magnesium sulphate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
3121641|NCT01743144|Placebo Comparator|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
3121642|NCT01743131|Placebo Comparator|Arm A- Placebo|Arm A-standard GVHD prophylaxis with a calcineurin inhibitor, methotrexate and placebo
3121643|NCT01743131|Active Comparator|Arm B- Abatacept|Arm B-investigational prophylaxis with abatacept, a calcineurin inhibitor and methotrexate
3121644|NCT01743118|Experimental|Psoriasis Plaque Test|SPS4251 Ointment, 0.01%; SPS4251 Ointment, 0.1%; SPS4251 Ointment, 1%; SPS4251 Placebo, Daivonex® ointment
3121645|NCT01743105|Experimental|Study population|"The study population consists of patients treated for acute respiratory distress in the emergency department at the Nîmes University Hospital. See inclusion and exclusion criteria.~Interventions: Diaphragm excursion measures 1, Diaphragm excursion measures 2"
3121646|NCT01743092|Other|Tutorial Workbook|Tutorial Workbook Group only receives a Tutorial Workbook Group
3121647|NCT01743092|Experimental|Tutorial Workbook Group plus webinar|Tutorial Workbook Group plus webinar will receive in addition, a webinar as an additional resource.
3121648|NCT01743079|Experimental|Telbivudine|Mother receives telbivudine 600mg per day. Infant receives standard immunoprophylaxis
3121691|NCT01742858||Young adults I|19-24 years old
3121649|NCT01743079|Experimental|Lamivudine|Mother receives lamivudine 100mg per day. Infant receives standard immunoprophylaxis.
3121650|NCT01743079|No Intervention|No antiviral treatment|Mother receives no antiviral treatment. Infant receives standard immunoprophylaxis
3121651|NCT01743066|Experimental|Arsenicosis patients|Vitamin E (200 IU, caplet) daily orally for 20 weeks
3121652|NCT01743066|Active Comparator|Arsenic exposed controls|vitamin E (200 IU, caplet) daily orally for 20 weeks
3121653|NCT01743066|Active Comparator|Heathy volunteers|Vitamin E (200 IU, caplet) daily orally for 20 weeks
3121654|NCT01743053|Other|Control: Standard Care|The control group will receive standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa™ Clear).
3121655|NCT01743053|Experimental|ReCell|The ReCell group will receive ReCell in addition to standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa Clear).
3121656|NCT01743027|Experimental|AL-4943A|AL-4943A ophthalmic solution, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
3121657|NCT01743027|Active Comparator|PATADAY|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
3121658|NCT01743027|Active Comparator|PATANOL|Olopatadine hydrochloride ophthalmic solution, 0.1%, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
3121659|NCT01743027|Placebo Comparator|Vehicle|AL-4943A ophthalmic solution vehicle, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
3121660|NCT01743014|Active Comparator|ramipril|Ramipril 10 mg tablets. Each dose will be taken orally with water once daily.
3121661|NCT01743014|Active Comparator|clopidogrel and ramipril|clopidogrel 75mg tablet and ramipril 10mg. Each drug will be taken orally with water once daily
3121662|NCT01743001|Experimental|Macitentan|Subjects receive macitentan 10 mg oral tablet once daily
3121663|NCT01743001|Placebo Comparator|Placebo|Subjects receive macitentan-matching placebo oral tablet once daily
3121664|NCT01742988|Experimental|CUDC-907 - Continuous Once Daily|30-60 mg/day CUDC-907, orally administered continuous once daily in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
3121665|NCT01742988|Experimental|CUDC-907 - 2x/week|60-240 mg/day CUDC-907, orally administered twice weekly on Days 1, 4, 8, 11, 15, 18 in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
3121666|NCT01742988|Experimental|CUDC-907 - 3x/week|60-180 mg/day CUDC-907, orally administered thrice weekly on Days 1, 3, 5, 8, 10, 12, 15, 17, 19 in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
3121667|NCT01742988|Experimental|CUDC-907 - four days on/three days off|60-180 mg/day CUDC-907, orally administered four days on/three days off on Days 1-4, 8-11, and 15-18 in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
3121668|NCT01742988|Experimental|CUDC-907 - five days on/two days off|60-180 mg/day CUDC-907, orally administered five days on/two days off on Days 1-5, 8-12, and 15-19 in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
3121669|NCT01742988|Experimental|CUDC-907 - Expansion 5x/week|60 mg of CUDC-907 on the 5 days on/2 days off dosing schedule.
3121670|NCT01742988|Experimental|CUDC-907 - Expansion 3x/week|120 mg of CUDC-907 on the 3 days on/4 days off dosing schedule.
3121671|NCT01742988|Experimental|CUDC-907 - Combination Arm A|Combination Arm A will adminster CUDC-907 orally at the expansion 5/2 dose level (60 mg) plus rituximab given at 375 mg/m2 IV infusion. Rituximab will be administered on Day 1 of every cycle (21 days) for six cycles.
3121672|NCT01742988|Experimental|CUDC-907 - Combination Arm B|Combination Arm B will give CUDC-907 orally at the expansion TIW dose level (120 mg) plus rituximab given at 375 mg/m2 IV infusion. Rituximab will be adminstered on Day 1 of every cycle (21 days) for six cycles.
3121673|NCT01742988|Experimental|CUDC-907 - Biocomparability Arm|A lead-in dose of CUDC-907 at 60 mg mesylate on Day -4 followed by besylate dosing beginning on C1D1 according to the 5/2 dosing schedule. The starting besylate dose will be 30 mg.
3121674|NCT01742975|Experimental|Arm A: Applying Ifabond|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients.
3121675|NCT01742975|No Intervention|Arm B: without Ifabond|The synthetic adhesive solution Ifabond, will not be applied at the end of conventional breast cancer surgery in arm B patients.
3121676|NCT01742962||Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
3121677|NCT01742949|Active Comparator|Thermosmart|Subjects receive heated humidification
3121678|NCT01742949|Placebo Comparator|No humidification|Subjects use dry CPAP / APAP
3121679|NCT01742936|Experimental|Spinal fusion|Patients undergoing a posterior spinal fusion and having clotting factors checked by both hand held CoaguChek and Hospital Laboratory.
3121680|NCT01742936|Experimental|Cardiac bypass|Patients undergoing surgery requiring cardiopulmonary bypass and having clotting factors checked by both hand held CoaguChek and Hospital Laboratory.
3121681|NCT01742923|Placebo Comparator|Usual care|Usual care
3121682|NCT01742923|Experimental|Complex tailored intervention|"The interventions consists of 3 elements:~Medication review with recommendations focused on antihypertensives and statins and adherence to guidelines and patient´s adherence to medications~Consultation with a pharmacist using motivational interviewing techniques~Follow-up telephone calls one month and six months after inclusion"
3121683|NCT01742910|Other|Tecnis ZCB00|eyes with implantation of Tecnis ZCB00
3121684|NCT01742910|Other|Acrysof SA60AT|eyes with implantation of Acrysof SA60AT
3121685|NCT01742897|Experimental|TTS-fentanyl|Transdermal therapeutic system (TTS) fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
3121686|NCT01742884|Experimental|Thealoz|Treatment with Thealoz (Trehalose) 3% for 1 month
3121687|NCT01742884|Placebo Comparator|Treatment with Thealoz´s vehicle|Treatment with Thealoz´s vehicle for 1 month
3121688|NCT01742871||controls|Patient under anti-vitamin K with no haemorrhagic manifestations admitted for another reason to Emergency Adults
3121689|NCT01742871||kaskadil|Patient under anti-vitamin K with a serious bleeding event that required treatment in the emergency Adults. Is considered serious accident requiring the use of a reversion by PPSB (Kaskadil ®).
3121692|NCT01742858||Young adults II|25-30 years old
3121693|NCT01742845|Active Comparator|control group|landmark-based superficial cervical block is used. After insertion of the needle superficially below the skin, 20 to 30 ml of 4.75 mg/ml ropivacaine are injected fan-like in the subcutaneus plane.
3121694|NCT01742845|Experimental|echo group|ultrasound-guided intermediate cervical block was performed. The probe is placed perpendicular to the skin, in the horizontal plane at the C3-C4 level. Needle is inserted in-plane. 10 ml ropivacaine 4.75mg/ml are injected under ultrasound control, 5 ml injected when needle is withdrawn under ultrasound control, 5 ml in the subcutaneous plane.
3121695|NCT01742832|Active Comparator|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
3121696|NCT01742832|Placebo Comparator|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
3121697|NCT01742819||Advanced glaucoma|Patients with MD < -6 or visual field loss within the central 10 degrees of the visual field.
3121698|NCT01742806|No Intervention|control|not to use bio-absorbable felt(NEOVEIL®)
3121699|NCT01742806|Experimental|NEOVEIL®|To use bio-absorbable felt
3121700|NCT01742793|Experimental|Arm L: subjects with lymphoma|"The following dosing steps will be applied to the dose-escalation, phase-I component of the study for patients with lymphoma who are eligible to enter Arm L:~Dose Level Arm L Lenalidomide dose Oral Romidepsin Dose Intravenous~2 10mg D1-7, D15-21 6mg D1, 8, 15~1 10mg D1-7, D15-21 8mg D1, 8, 15~10mg D1-21 8mg D1, 8, 15 2 15mg D1-21 8mg D1, 8, 15 3 15mg D1-21 10mg D1, 8, 15 4 15mg D1-21 12mg D1, 8, 15 5 15mg D1-21 14mg D1, 8, 15 6 25mg D1-21 14mg D1, 8, 15~The first patient in arm L will be entered into the study at dosing level one."
3121701|NCT01742793|Experimental|Arm M: subjects with myeloma|"The following dosing steps will be applied to the dose-escalation, phase-I component of the study for patients with myeloma who are eligible to enter Arm M:~Dose Level Arm M Lenalidomide dose Oral Romidepsin Dose Intravenous Dexamethasone~2 15mg D1-7, D15-21 6mg D1, 8, 15 20mg D1,8,15,22~1 15mg D1-7, D15-21 8mg D1, D8, 15 20mg D1,8,15,22~15mg D1-21 8mg D1, 8, 15 20mg D1,8,15,22 2 25mg D1-21 8mg D1, 8, 15 20mg D1,8,15,22 3 25mg D1-21 10mg D1, 8, 15 20mg D1,8,15,22 4 25mg D1-21 12mg D1, 8, 15 20mg D1,8,15,22 5 25mg D1-21 14mg D1, 8, 15 20mg D1,8,15,22~The first patient in arm M will be entered into the study at dosing level one."
3121702|NCT01742780|Active Comparator|Standard Vidacare Site Identification Method|Palpate up the proximal humerus towards the anterior shoulder just above the surgical neck, to the greater tubercle of the proximal humerus. Insert the needle set perpendicular to skin with a slight downward angle at the most prominent aspect of greater tubercle to establish proximal humerus intraosseous vascular access.
3121703|NCT01742780|Active Comparator|Saussy Site Identification Method|Palpate the proximal humerus to locate the intertubercular groove; rotate the forearm medially and laterally to isolate the groove. Move one finger breadth laterally from the groove to the greater tubercle. Insert perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access.
3121704|NCT01742780|Active Comparator|Campbell Site Identification Method|"With the fingers on both hands fully extended similar to a karate chop, place one hand into the anterior joint space (acromioclavicular joint) of the patient. Place the second karate chop hand along the midline of the patient's lateral shoulder; touch the pinkie fingers over the superior aspect of the patient's shoulder. Overlap the thumbs on the patient's shoulder, which will be at the most prominent aspect of the greater tubercle. Insert the needle set perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access."
3121705|NCT01742780|Active Comparator|Davlantes Site Identification Method|"Using one hand, place the thumb on the acromioclavicular joint in the natural recess or pocket between the distal clavicle and the humeral head, wrapping the rest of the hand around the upper arm. The hand should be oriented such that the index finger and rest of the hand is at a 90-degree angle to the thumb. The webspace between the thumb and index finger will be approximately where the surgical neck of the humerus is; move one finger breadth (approximately 1 cm) superior. Insert perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access."
3121706|NCT01742767|Active Comparator|Cis (D1) + Pem (D1)|Cisplatinum 75 mg/m2 d 1 Pemetrexed 500 mg/m2 d 1 q d 21
3121707|NCT01742767|Experimental|CIS (D1+8) + Pem (D!)|Cisplatinum 40 mg/m2 d 1 + d 8 Pemetrexed 500 mg/m2 d 1 q d 21
3121708|NCT01742754|Experimental|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation by colonoscopic delivery of stool to the right colon.
3121709|NCT01742741|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs)system running in Control to Range (CTR) or in Safety Only mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct the hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
3121710|NCT01742741|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. Subjects will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
3121711|NCT01742728||Nagasaki|Sample collection
3121712|NCT01742728||Tokushima|Oxidative stress, cytokine
3121713|NCT01742728||Kanagawa|oxidative stress
3121780|NCT01742338|Experimental|High Dose Corticosteroids|Methylprednisolone 40 mg IV q8hrs x 3 days*, then prednisone 80 mg PO daily x 4 days, then prednisone 60 mg daily x 1 day, then prednisone 40 mg daily x 1 day, then prednisone 20 mg daily x 1 day, then stop. *If patient unable to receive IV medications, will give prednisone 40 mg PO bid for the first 3 days.
3121781|NCT01742325|Other|Lifestyle counseling|To test an intervention program (two 20-minute sessions of walking around the nurse's station daily, five days a cycle) to reduce the symptoms of fatigue and pain and increase quality of sleep.
3165906|NCT01440231|Experimental|Arm 3|
3121714|NCT01742715|Experimental|PEEP by Best oxygenation|"Set Positive End Expiratory Pressure (PEEP) at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg Ideal Body Weight (IBW). fraction of inspired oxygen (FiO2) is set to 60%.~Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with arterial blood gas (ABGs), and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% Partial Oxygen tension (PaO2) PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected."
3121715|NCT01742715|Experimental|PEEP by Best Compliance|"In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.~Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed."
3121716|NCT01742715|Experimental|PEEP by Esophageal pressure|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
3121717|NCT01742702||DYNAMIC|Subjects with primary or secondary hypertension and normotensive control subjects. In addition haemodynamic recordings to 50 subjects suffering from chronic fatigue syndrome will be performed.
3121718|NCT01742702||AERO-DYNAMIC (recordings completed)|Subjects who had voluntarily decided to participate in a professionally coached marathon school (Varala Sports Institute, Tampere) were given the chance for haemodynamic recordings before, during and after the training protocol.
3121719|NCT01742702||Liquorice (recordings completed)|Normotensive subjects, daily liquorice ingestion (daily glycyrrhizin dose 290-370 mg) for 2 weeks, haemodynamic measurements before and after the intervention.
3121720|NCT01742702||Milk polypeptides (recordings completed)|Daily ingestion of yoghurt containing small milk casein-derived polypeptides for 12 weeks versus placebo yoghurt.
3121721|NCT01742702||Bisoprolol (recordings completed)|Hypertensive subjects, bisoprolol 5 mg once daily versus placebo in a double-blind, cross-over protocol.
3121722|NCT01742702||Aortic stenosis|Subjects with aortic stenosis confirmed by echocardiography
3121723|NCT01742702||Methodological (recordings completed)|35 normotensive subjects who received research drugs (nitroglycerin, salbutamol, placebo resoriblet, placebo inhalation, L-arginine infusion, saline infusion) in a placebo-controlled, double-blinded manner
3121724|NCT01742689|Experimental|Desmopressin intranasal spray|Patients in this arm will receive 40 microgram desmopressin intranasal spray & 100 milligram indomethacin suppository
3121725|NCT01742689|Placebo Comparator|Placebo intranasal spray|Patients in this group will receive placebo nasal spray & 100 milligram indomethacin suppository
3121726|NCT01742676|Experimental|ADVAGRAF group|
3121727|NCT01742676|Active Comparator|PROGRAF group|
3121728|NCT01742663|Experimental|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.)
3121729|NCT01742663|Active Comparator|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)
3121730|NCT01742663|Placebo Comparator|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.)
3121731|NCT01742650|Active Comparator|Screw fixation|3,5mm fully threaded cortical screw transfixation of syndesmosis
3121732|NCT01742650|Active Comparator|TightRope|TightRope transfixation of syndesmosis
3121733|NCT01742637|Experimental|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)
3121734|NCT01742637|Active Comparator|Epiduo® Gel|Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)
3121735|NCT01742637|Placebo Comparator|Placebo|Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)
3121736|NCT01742624|Experimental|Advagraf group|
3121737|NCT01742624|Active Comparator|Prograf group|
3121738|NCT01742611|Experimental|ASP1585 group|
3121739|NCT01742598|Experimental|Portico Implant|
3121740|NCT01742585|Experimental|ASP1585 group|
3121741|NCT01742585|Placebo Comparator|placebo group|
3121742|NCT01742572|Experimental|Vegan|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
3121743|NCT01742572|Experimental|Vegetarian|A vegetarian diet is one that does not contain meat, fish, or poultry but does contain eggs and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
3121744|NCT01742572|Experimental|Pesco-Vegetarian|A pesco-vegetarian diet is one that does not contain meat or poultry but does contain fish and shellfish, eggs, and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
3121745|NCT01742572|Experimental|Semi-Vegetarian|A semi-vegetarian diet is one that contains all foods, including meat, poultry, fish and shellfish, eggs, and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. However, red meat is limited to one time per week and poultry is limited to 5 times per week or less. We will also ask you to keep foods low in fat and low in glycemic index.
3121746|NCT01742572|Active Comparator|Omnivorous|An omnivorous diet contains all food groups. However, as part of this study, we will ask participants in this group to keep foods low in fat and low in glycemic index. Participants in this group will not need to attend weekly meetings but will receive information via e-mail each week.
3121782|NCT01742312||oesophageal adenocarcinoma|DEXA scan cardio-pulmonary exercise testing (CPEX) muscle biopsy
3121783|NCT01742299|Experimental|STI571 (imatinib mesylate)|STI571
3121747|NCT01742559|Experimental|Anterior middle superior alveolar|The AMSA technique was performed in the test group according to Friedman & Hochman (1997). The needle was introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule was performed for one minute and 1.8 ml of anesthetic solution was administrated. This amount of anesthetic was divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes were expected for the beginning of the periodontal procedure.
3121748|NCT01742559|Active Comparator|Supraperiosteal technique|The supraperiosteal technique at the bottom of the vestibule was performed for one minute and 1.8 ml of anesthetic solution was administrated. This amount of anesthetic was divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes were expected for the beginning of the SRP procedure.
3121749|NCT01742546|Experimental|Therapeutic ultrasound combine TENS|"Use therapeutic ultrasound with simultaneous TENS for 10 minutes/session for 10 sessions/course.~The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius), this device has treatment head described by the manufacturers as having surface area as 5.8 cm2, ERA (Effective Radiating Area) of 5.0 cm2 and BNR (Beam Non-uniform Ratio) as max. 5.0. For electrotherapy unit which composes of 2 channels, output characteristics are constant current (CC) or constant voltage (CV), resolution of output signal is in steps of 0.2 mA and timer is limited to 30 minutes during ultrasound and combination therapy are operated."
3121750|NCT01742546|Sham Comparator|Therapeutic ultrasound with sham TENS|Use the same therapeutic ultrasound machine and place the electrode as experimental group but turn-off electrical current during treatment period
3121751|NCT01742533|Experimental|Group1 : HRT plus hUCMSCs treatment:|Participants will be given HRT plus human cord mesenchymal stem cells transplantation with a 12 menstrual Cycle follow-up.
3121752|NCT01742533|Experimental|Group 2: HRT plus hCBMNCs and hUCMSCs therapy|Participants will be given HRT plus combination of hCBMNCs together with hUCMSCs transplantation with a 12 menstrual Cycle follow-up.
3121753|NCT01742533|Experimental|Group3 : HRT plus hCBMNCs treatment:|Participants will be given HRT plus human cord blood mononuclear cells transplantation with a 12 menstrual Cycle follow-up.
3121754|NCT01742533|Experimental|Group 4:Hormone Replacement Therapy|Participants will be given conventional therapy only with a 12 menstrual Cycle follow-up.
3121755|NCT01742520|Active Comparator|Formula or Breast Milk|Breast milk or formula prior to every painful procedure.
3121756|NCT01742520|Active Comparator|Multiple doses of sucrose|Infants in this group will be treated with Sucrose 24% 0.5-1ml on the anterior pat of the tongue 1-3min prior to every invasive procedure
3121757|NCT01742507|Active Comparator|Medtronic Resolute Integrity Stent|Medtronic Resolute Integrity Stent
3121758|NCT01742507|Active Comparator|Biomatrix stent|Biomatrix stent
3121759|NCT01742494|Active Comparator|Water-jet POEM|POEM were performed by the use of Erbe Hybrid knife (WJ group)
3121760|NCT01742494|Active Comparator|Conventional POEM|POEM were performed by the conventional technique using injection and triangle tip knife (C group).
3121761|NCT01742481|Experimental|Education and empowerment program|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
3121762|NCT01742481|Placebo Comparator|self-guided empowerment and education|participants have information packet but receive no individualized support or assistance
3121763|NCT01742468|Experimental|Dietary supplement: n-3 LC-PUFA|Name: microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany; rich in docosahexaenoic acid (DHA); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
3121764|NCT01742468|Placebo Comparator|Dietary supplement: sunflower oil|Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
3121765|NCT01742442||Older cancer patients|Older cancer patients 70 years or older referred to specialist oncology outpatient clinics
3121766|NCT01742429|Experimental|Levofloxacin-bismuth therapy|14 day levoﬂoxacin and bismuth-containing therapy:PPI,bismuth, amoxicillin, levoﬂoxacin
3121767|NCT01742429|Active Comparator|classical quadruple therapy|14 day classical quadruple therapy:PPI,bismuth, metronidazole, tetracycline
3121768|NCT01742416|Experimental|Ultrasound|
3121769|NCT01742416|Active Comparator|Palpation Method|
3121770|NCT01742403|Experimental|R/T gating kV intrafraction monitoring|"Intervention: Recruitment will be performed in 2 phases:~Phase I will include the first 10 patients. All patients will be treated on a standard fractionation protocol with 40 fractions. This will allow 400 potential fractions to be auto-segmented in real time. Once Phase I is successfully completed we will aim to continue recruitment of a further 20 patients as Phase II. For this phase we will open recruitment to patients with lymph node positivity, hypofractionation (as per Department protocols) and intermittent imaging (imaging less frequently than every fraction)."
3121771|NCT01742390|Experimental|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
3121772|NCT01742390|Active Comparator|risperidone or paliperidone|Stay on risperidone (RIS) or paliperidone (PALI)
3121773|NCT01742377||Patients with GerdQ positive|Gerd Q positive was defined as score equal or more than eight.
3121774|NCT01742377||Patients with GerdQ negative|Gerd Q neegative was defined as score less than eight.
3121775|NCT01742377||Normal volunteers|Normal volunteers was defined as population without dyspeptic symptom.
3121776|NCT01742364|Experimental|Bioject Intradermal (ID) Pen|Intradermal administration of BCG vaccine via the Bioject ID Pen.
3121777|NCT01742364|Active Comparator|Needle and syringe|Intradermal administration of BCG vaccine via needle and syringe.
3121778|NCT01742351|Experimental|Guided internet-based cognitive behavior therapy (CBT)|
3121779|NCT01742338|Active Comparator|Low Dose Corticosteroids|"10 mg IV q8hrs x 3 days*, then prednisone 40 mg PO daily x 4 days, then prednisone 30 mg daily x 1 day, then prednisone 20 mg daily x 1 day, then prednisone 10 mg daily x 1 day, then stop.~*If patient unable to receive IV medications, will give prednisone 20 mg PO bid for the first 3 days."
3121784|NCT01742286|Experimental|LDK378|Single-agent LDK378
3121785|NCT01742273|No Intervention|standard treatment (usual care)|standard treatment (usual care)
3121786|NCT01742273|Experimental|Vitamin K1|Vitamin K1 (phylloquinone), thrice weekly p.o. (5mg)
3121787|NCT01742260|Experimental|Repair of cranial defect|Repair of cranial defects by tissue engineering
3121788|NCT01742247|Experimental|Physiogel, Laser therapy, Moisturizer|"Experimental: Physiogel treated & Non-treated~1 Palmitoylethanolamide, Physiogel 3 times a day for 2 weeks"
3121789|NCT01742234||Kidney Donors|People who will donate a kidney at the University of Minnesota, Mayo Clinic, or University of Alabama
3121790|NCT01742234||Lung Donors|People who will donate a lung at the Washington University School of Medicine or the University of Southern California
3121791|NCT01742221|Experimental|HemaMax|Single subcutaneous dose of HemaMax
3121792|NCT01742221|Placebo Comparator|Placebo|Single subcutaneous dose of Placebo
3121793|NCT01742208|Experimental|Treatment A|
3121794|NCT01742208|Placebo Comparator|LX4211 Placebo|
3121795|NCT01742208|Experimental|Pioneer|
3121796|NCT01742195|Other|Nasal EBUS insertion|Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the nose.
3121797|NCT01742195|Other|Oral EBUS insertion|Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the mouth.
3121798|NCT01742182|No Intervention|Control|
3121799|NCT01742182|No Intervention|PD patients without sleep problems|
3121800|NCT01742182|Active Comparator|PD patients with sleep problems|light exposure
3121801|NCT01742182|Placebo Comparator|PD patients with sleep problem|light exposure
3121802|NCT01742169|Experimental|Outreach and Reminder Intervention|Participants randomized to this arm will receive the Outreach and Reminder intervention.
3121803|NCT01742169|No Intervention|Usual Care|Patients assigned to this arm will receive usual care.
3121804|NCT01742156||Presence of coronary disease|All patients with or without coronary disease who are followed in coronary clinics or wards
3121805|NCT01742156||coronary disease|Is coronary disease associated with tortuosity of vessels Patients seen in cardiology clinics
3121806|NCT01742143||ICCAN|For those randomized into the ICCAN arm, the core of the intervention will be three ICCAN Access Facilitators who will assess needs and synchronize for each patient an individualized set of transdisciplinary services.
3121807|NCT01742143||Usual and Customary Group (U&C)|Participants in this group will receive the same written materials on social and economic resources as ICCAN group.
3121808|NCT01742130|Experimental|Sodium bicarbonate|Sodium Bicarbonate (154 mEq/L in dextrose and H2O) 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
3121809|NCT01742130|Active Comparator|Saline|Sodium Saline 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
3121810|NCT01742117|Active Comparator|Clopidogrel then Retrospective Genotyping|Clopidogrel 75 mg daily for 1 year after PCI. DNA samples at baseline to be frozen. At 12 months DNA will be genotyped to determine the *2 & *3 reduced function/wild type allele status.
3121811|NCT01742117|Active Comparator|Prospective Genotyping - Clopidogrel|Patients with the wild type CYP2C19 allele (based on prospective genotype testing) will be assigned to receive a clopidogrel 75mg tablet daily for 1 year following PCI.
3121812|NCT01742117|Active Comparator|Prospective Genotyping - Ticagrelor|Patients with the CYP2C19 heterozygous and homozygous *2 and *3 reduced function allele (based on prospective genotype testing) will be assigned to receive a ticagrelor 90 mg tablet twice per day for one year following PCI.
3121813|NCT01742091|Experimental|180 mg LY2541546 SC Q4W|180 milligram (mg) LY2541546 administered subcutaneous (SC) once every 4 weeks (Q4W) for 8 weeks. Placebo administered SC at Weeks 2 and 6 to maintain the blind.
3121814|NCT01742091|Experimental|270 mg LY2541546 SC Q2W|270 mg LY2541546 administered (SC) once every 2 weeks (Q2W) for 8 weeks.
3121815|NCT01742091|Experimental|270 mg LY2541546 SC Q4W|270 mg LY2541546 administered (SC) once every 4 weeks (Q4W) for 8 weeks. Placebo administered SC at Weeks 2 and 6 to maintain the blind.
3121816|NCT01742091|Experimental|540 mg LY2541546 IV Q4W|540 mg administered intravenous (IV) once every 4 weeks (Q4W) for 8 weeks. Placebo administered IV at Weeks 2 and 6 to maintain the blind.
3121817|NCT01742091|Experimental|750 mg LY2541546 IV Q2W|750 mg administered (IV) once every 2 weeks (Q2W) for 8 weeks.
3121818|NCT01742091|Placebo Comparator|Placebo Q2W|Placebo administered IV or SC once every 2 weeks for 8 weeks.
3121819|NCT01742078|Experimental|7.5 mg LY2541546 - IV|Single dose of 7.5 mg LY2541546 administered intravenously (IV)
3121820|NCT01742078|Experimental|25 mg LY2541546 - IV|Single dose of 25 mg LY2541546 administered IV
3121821|NCT01742078|Experimental|75 mg LY2541546 - IV|Single dose of 75 mg LY2541546 administered IV
3121822|NCT01742078|Experimental|225 mg LY2541546 - IV|Single dose of 225 mg LY2541546 administered IV
3121823|NCT01742078|Experimental|750 mg LY2541546 - IV|Single dose of 750 mg LY2541546 administered IV
3121824|NCT01742078|Experimental|150 mg LY2541546 - SC|Single dose of 150 mg LY2541546 administered subcutaneous (SC)
3121825|NCT01742078|Placebo Comparator|Placebo|Single dose of placebo administered IV or SC
3121826|NCT01742078|Experimental|225 mg LY2541546 - IV, OL|Single dose of 225 mg LY2541546 administered IV, open label (OL)
3121827|NCT01742078|Experimental|750 mg LY2541546 - IV, OL|Single dose of 750 mg LY2541546 administered IV, OL
3121828|NCT01742065|No Intervention|Usual Care|Clinics in usual care will go about clinic practices to complete recommended screening for colorectal cancer.
3121829|NCT01742065|Active Comparator|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to a PDSA (Plan Do Study Act) cycle to refine or improve their process.
3121830|NCT01742052|Experimental|MT-1303-Low|MT-1303-Low Dose
3121831|NCT01742052|Experimental|MT-1303-Middle|MT-1303-Middle Dose
3121832|NCT01742052|Experimental|MT-1303-High|MT-1303-High Dose
3121833|NCT01742052|Placebo Comparator|Placebo|Placebo
3121834|NCT01742039||b-blocker|
3121835|NCT01742039||amiodarone|
3121836|NCT01742039||atrial pacing|
3121837|NCT01742039||amiodarone plus atrial pacing|
3121838|NCT01742026||High Risk Oncohematological Patients|Detection Aspergillus PCR technique and Aspergillus AGA technique
3121839|NCT01742013|Placebo Comparator|Placebo|NaCl 0.9%, s.c., 4ml (2ml x 2), 3 times per a week, 6 weeks
3121840|NCT01742013|Experimental|GCJBP Laennec Inj.|GCJBP Laennec Injection,s.c., 4ml(2ml x 2)/day, 3 times per a week, 6 weeks
3121841|NCT01742000|Active Comparator|Karinat|Karinat 500 mg tablet by mouth three times a day
3121842|NCT01742000|Placebo Comparator|Sugar pill|Placebo 500 mg tablet by mouth three times a day
3121843|NCT01741987|Active Comparator|optive® eye drop|
3121844|NCT01741987|Placebo Comparator|fresh tears ® eye drop|
3121845|NCT01741974|Active Comparator|Karinat|Karinat 500 mg tablet by mouth three times a day
3121846|NCT01741974|Placebo Comparator|Sugar pill|Placebo tablet 500 mg by mouth three times a day
3121847|NCT01741961||glaucoma, surgery, Ahmed valve|Patients with uncontrolled glaucoma undergoing Ahmed glaucoma valve implantation for intraocular pressure reduction.
3121848|NCT01741948||First time users of hormonal contraceptive|
3121849|NCT01741922|Experimental|ASA evening&placebo morning|Patients will receive acetylsalicylic acid (100 mg)in the evening and placebo in the morning.
3121850|NCT01741922|Active Comparator|ASA morning&placebo evening|Patients will receive acetylsalicylic acid (100 mg) in the morning and placebo in the evening
3121851|NCT01741909|Experimental|Before, After|The intervention is educational
3121852|NCT01741896|Active Comparator|RIPC|Patients in the RIPC arm will undergo a period of upper limb ischaemic preconditioning before their contrast enhanced CT scan. The RIPC stimulus involves four cycles of ischaemia/reperfusion (5 minutes of blood pressure cuff induced upper limb ischaemia with 3 minutes reperfusion). This will start at a time of 30 - 40 minutes before the administration of contrast. The cuff is inflated to 15mmHg above systolic pressure at each inflation.
3121853|NCT01741896|No Intervention|Control arm|Patients in the control arm will undergo no extra intervention.
3121854|NCT01741883|No Intervention|Standard Medical Care and Information|Patients receive standard treatment protocol for breast cancer patients and additional oral and written information about adjuvant endocrine treatment.
3121855|NCT01741883|Experimental|Side effect prevention training (SEPT)|Patients receive standard medical care and a brief behavioral intervention that targets patients' response and coping expectations while starting with adjuvant endocrine treatment.
3121856|NCT01741883|Active Comparator|Attention Control group (ACG)|Patients receive standard medical care and a comparable amount of therapist´s attention (common and unspecific factors) to the intervention group without targeting patients´ expectations.
3121857|NCT01741870|Placebo Comparator|Control|No intervention was given. All subjects received routine care
3121858|NCT01741870|Active Comparator|Received nutrition supplement as needed|Subjects in this group received 50 g/day soy protein-based nutritional supplement (containing 9.5 g protein, 250 kcal energy and all essential micro-nutrients) whenever subjects BMI is below 24 and MNA score also below 24.
3121859|NCT01741857|Experimental|human umbilical cord derived MSC|human umbilical cord derived MSC transplantation for SLE
3121860|NCT01741844||Etravirine|Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking etravirine as per recommended doses.
3121861|NCT01741831||Darunavir|Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking darunavir as per recommended doses.
3121862|NCT01741818||Group B|CVP less than 8cmH2o
3121863|NCT01741805||Severe Asthma|Patients with severe asthma as specified under inclusion, exclusion criteria
3121864|NCT01741792|Experimental|Blinatumomab|By study design, two dose regimens were assessed in this study. In Stage 1, Cohort 1, participants received blinatumomab in a dose-escalating manner: 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during cycle 1. In Cohort 2, the next participants enrolled and received a constant dose of 112 µg/day blinatumomab. The dosing regimen with the more favorable benefit-risk profile was then selected for Stage 2, Cohort 3.
3121865|NCT01741779|Experimental|Hypocaloric diet|This arm involves 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
3121866|NCT01741779|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 wk.
3121867|NCT01741779|Experimental|Whole body vibration training & diet|Lower-body exercise training on a vibration platform and diet
3121868|NCT01741779|Experimental|Whole body vibration training|Lower-body exercises 3 times per wk for 12 wk in a vibration platform
3121869|NCT01741766|Experimental|Stretching Training|Whole body stretching exercises 3 times per wk for 8 weeks
3121870|NCT01741766|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 8 wk.
3121871|NCT01741753|Experimental|Treatment Arm|BKM120+Abiraterone+Prednisone
3121872|NCT01741740||retrospective surgical patients|consecutive elective umbilical hernia repair patients during two years from two hospitals,- retrospective id with prospective follow up
3121873|NCT01741727|Experimental|ABT-414|Subjects with solid tumors (Phase 1) and squamous non-small cell lung cancer (NSCLC) (Phase 2)
3121874|NCT01741714|Active Comparator|Chiropractic Spinal Manipulative Therapy|Active chiropractic spinal manipulative treatment
3121875|NCT01741714|Sham Comparator|Sham manipulation|Sham chiropractic manipulative therapy
3121876|NCT01741714|No Intervention|Control group|No intervention, follow headache diary
3121877|NCT01741701|Experimental|Oxaloacetate (OAA)|active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily
3121878|NCT01741701|Placebo Comparator|Placebo|placebo capsules that contain only 100 mg ascorbate, taken daily
3121879|NCT01741688||Tocilizumab|Participants with moderate to severe rheumatoid arthritis (RA), according to the American College of Rheumatology (ACR) criteria and the Disease Activity Score Based on 28 Joints (DAS28), in whom the attending physician has decided to start treatment with tocilizumab (according to the local label).
3121917|NCT01741428|Active Comparator|Intervention (INT1)|The participants will join a 5-days course at the Feiring Heart Clinic.
3122065|NCT01740596|Experimental|C-Pulse® System|C-Pulse® System Counterpulsation
3121880|NCT01741675|Experimental|Monetary incentive|The intervention group will receive a postal questionnaire together with a voucher worth €15 for the largest supermarket chain in Denmark. Non-responders will after three weeks receive a reminder together with another copy of the questionnaire. In both cases the questionnaire will be sent with a cover letter and a reply paid return envelope.
3121881|NCT01741675|Other|Control|The control group will only receive a postal questionnaire. Non-responders will after three weeks receive a reminder together with another copy of the questionnaire. In both cases the questionnaire will be sent with a cover letter and a reply paid return envelope.
3121882|NCT01741662|Other|group psychopathological|
3121883|NCT01741649|Experimental|Clorhexidine|Skin prior to the surgical incision will be cleaned for five minutes with Clorhexidine.
3121884|NCT01741649|Experimental|Povidone|Skin prior to surgical incision will be cleaned for five minutes with a povidine solution.
3121885|NCT01741636|Experimental|Supportive care (survivorship plan)|Patients undergo Survivorship Care Planning comprising disease surveillance, management of potential long-term and late effects, psycho-social-spiritual issues, and healthy living recommendations.
3121886|NCT01741623|Experimental|Bisoprolol Fumarate Tablet 10 mg|Bisoprolol Fumarate Tablet 10 mg of M/s Ipca Laboratories Limited, India
3121887|NCT01741623|Active Comparator|Zebeta®|Zebeta® (Bisoprolol Fumarate) Tablets 10 mg of Duramed Pharmaceuticals Inc., USA
3121888|NCT01741610|Placebo Comparator|No coloading (Group E)|Placebo comparator
3121889|NCT01741610|Active Comparator|Cristalloid (Lactated Ringer) Coloading|Cristalloid (Lactated Ringer's) Coloading (Group L)
3121890|NCT01741610|Active Comparator|Colloid (HES) coloading|Colloid (HES) coloading (Group C)
3121891|NCT01741597|Experimental|Diagnostic (DCE-MRI, tumor-homing peptide iRGD)|Patients undergo DCE-MRI on day 1 and undergo tumor-homing peptide iRGD DCE-MRI on day 2.
3121892|NCT01741584|Experimental|stationary bike exercise|6 months of exercise (60% of anaerobic threshold)
3121893|NCT01741584|Placebo Comparator|aerobic|6 months of exercise <30% anaerobic threshold
3121894|NCT01741571|Active Comparator|EBUS guided FNA with suction|"Device/procedure: lymph node tissue collection using fine needle aspiration with suction applied.~Four fine needle aspirations will be taken sequentially from each lymph node. Two with suction and two without suction applied."
3121895|NCT01741571|Experimental|EBUS guided FNA without suction|"Device/procedure: lymph node tissue collection using fine needle aspiration without suction applied.~Four fine needle aspirations will be taken sequentially from each lymph node. Two with suction and two without suction applied."
3121896|NCT01741558|Experimental|Methotrexate|Established treatment associated with methotrexate
3121897|NCT01741558|Placebo Comparator|Placebo (Riboflavin)|Established treatment associated with placebo (riboflavin sodium fosfate 0.1%). We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
3121898|NCT01741545|Experimental|Cohort A: Genotype-2,-3 (Lambda/RBV/DCV)|"Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 12 weeks~Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 12 weeks~Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks"
3121899|NCT01741545|Experimental|Cohort B: Genotype-1b,-4 (Lambda/RBV/DCV)|"Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 24 weeks~Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 24 weeks~Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks"
3121900|NCT01741532|Experimental|Deferiprone|Deferiprone 80 mg/mL oral solution will be administered twice daily for 18 months. An initial dose 5 mg/kg/day will be administered for 6 weeks. Dose will then be escalated to 10mg/kg BID and finally to 15 mg/kg BID.
3121901|NCT01741532|Placebo Comparator|Deferiprone matching placebo|A deferiprone matching placebo oral solution will be given twice daily for 18 months.
3121902|NCT01741519|Experimental|LDLL600|Landiolol hydrochloride, intravenous infusion of 10, 20 and 40 µg/kg/min for 2 h each followed by 18 h long-term infusion of best tolerated dose.
3121903|NCT01741519|Active Comparator|Brevibloc|Esmolol, intravenous infusion of 50, 100 and 200 µg/kg/min for 2 h each followed by 18 h long-term infusion of best tolerated dose.
3121904|NCT01741506|Experimental|Dalteparin (Fragmin®)|Dalteparin (Fragmin®) 5000 IU (International Unit) once daily
3121905|NCT01741506|No Intervention|No treatment|No treatment
3121906|NCT01741506|Other|Open surgery arm|Dalteparin (Fragmin®) 5000 IU once daily
3121907|NCT01741493|Experimental|Healthy Volunteers (ABT-494)|Multiple dosing of ABT-494 in healthy volunteers
3121908|NCT01741493|Experimental|Rheumatoid Arthritis Patients|Multiple dosing of ABT-494 in patients with rheumatoid arthritis
3121909|NCT01741493|Placebo Comparator|No treatment|Placebo administration in healthy volunteers and patients with rheumatoid arthritis
3121910|NCT01741493|Other|Healthy Volunteers (tofa)|Multiple dosing of tofacitinib in healthy volunteers
3121911|NCT01741480|Placebo Comparator|Routine care|General hospital ward patients will receive routine care.
3121912|NCT01741480|Experimental|Intervention arm|The intervention with early warning system monitoring is to have the rapid response team assess the patients real-time.
3121913|NCT01741467|Experimental|RT-CGM|Patients using the RT-CGM for the intervention portion of the study.
3121914|NCT01741454|Active Comparator|Tamsulosin plus placebo|Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
3121915|NCT01741454|Experimental|Tamsulosin plus Tolterodine ER|"Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.~Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity."
3121916|NCT01741441||WAR and MR patients|Consecutive patients with MR and WAR selected for laparoscopic total fundoplication (LTF) were included in a prospective clinical study. Gastroesophageal function was assessed by clinical validated questionnaires, upper endoscopy, esophageal manometry and 24-h impedance pH monitoring before and 12 and 60 months after LTF. Gastric scintigraphy was preoperatively performed in all patients.
3121918|NCT01741428|No Intervention|Control (KTR1)|The participants in the Control Group will receive care as usual at their local Doctors Office
3121919|NCT01741428|Active Comparator|Subgroup Intervention (INT2)|Subgroup of 200 participants from the (INT1)where multiple, known CVD risk factors are studied: Physical Activity, Physical Condition (O2-consumption), Quality of life, Biochemical markers (fasting Glucose, Insulin, Apo Lipoprotein A (ApoA), Apo Lipoprotein B (ApoB), micro-C reactive protein (CRP), Total-, LDL- and HDL-cholesterol, Triglycerides and HbA1C.
3121920|NCT01741428|No Intervention|Subgroup control (KTR2)|Subgroup of 200 participants from the (KTR1)where multiple, known CVD risk factors are studied: Physical Activity, Physical Condition (O2-consumption), Quality of life, Biochemical markers (fasting Glucose, Insulin, Apo Lipoprotein A (ApoA), Apo Lipoprotein B (ApoB), micro-C reactive protein (CRP), Total-, LDL- and HDL-cholesterol, Triglycerides and HbA1C.
3121921|NCT01741415|Experimental|SIDI|Skills for Improving Distress Intolerance treatment protocol: individual, manualized treatment aimed at improving distress intolerance
3121922|NCT01741415|Placebo Comparator|SC|supportive counseling; psychological placebo/talk therapy - aimed at controlling for non-specific therapeutic factors
3121923|NCT01741402|Experimental|Virtual Reality Training|The virtual reality training was done by experimental group with ten games of Nintendo Wii Fit.
3121924|NCT01741402|Active Comparator|Physical Therapy|The Control Group was trained by conventional Physical Therapy exercises.
3121925|NCT01741389|Placebo Comparator|Sleep only|Placebo given at night to tetraplegic individuals before going to sleep,
3121926|NCT01741389|Active Comparator|Melatonin|Melatonin given at night to tetraplegic individuals before going to sleep.
3121927|NCT01741376|Placebo Comparator|Placebo + Placebo|Two placebos are given for 84 days.
3121928|NCT01741376|Active Comparator|Progesterone + Placebo|Progesterone (200 mg twice daily) and a placebo are given
3121929|NCT01741363|Experimental|one-day sampling with one-year interval|FIT one-day sampling with one-year interval
3121930|NCT01741363|Active Comparator|one-day sampling with two-year interval|FIT one-day sampling with two-year interval
3121931|NCT01741363|Experimental|two-day sampling with one-year interval|FIT two-day sampling with one-year interval
3121932|NCT01741363|Experimental|two-day sampling with two-year interval|FIT two-day sampling with two-year interval
3121933|NCT01741363|Experimental|Hp stool antigen (HpSA)+FIT|HpSA for detection of upper gastrointestinal tract diseases and upper endoscopy for H. pylori carriers; HPSA combined with FIT
3121934|NCT01741350|Experimental|CHRP Group|Patients assigned to Community-friendly Health Recovery Program (CHRP) will receive a weekly HIV risk reduction group level intervention led by two facilitators trained and supervised by the PI, a licensed clinical psychologist. The CHRP intervention is a substantially shortened version of the comprehensive Holistic Health Recovery Program (HHRP)-based interventions that have been identified as demonstrating evidence of effectiveness in two randomized clinical trials. The CHRP, which includes four 50-minute groups (1 group per week), will contain only content that relates explicitly to drug- or sex-related HIV risk reduction. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
3121935|NCT01741350|Active Comparator|Control Condition|The time-and-attention-matched control condition for the proposed research will be a time and contact-matched, non-contaminating support group for individuals in recovery modeled after similar groups offered in the community. There will be no overlap between the content of the comparison intervention and experimental intervention although the basic structure will be the same. Thus, each participant will be asked to attend four 50-minute weekly group sessions led by two trained facilitators. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
3121936|NCT01741337|Experimental|Patients treated by ventilation|Adaptive servo-ventilation post-operative treatment for 6 months
3121937|NCT01741337|No Intervention|Patients not treated by ventilation|Patients not treated during 6 months by an adaptive servo-ventilation
3121938|NCT01741324|Experimental|Umeå, vitamin D 25 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
3121939|NCT01741324|Active Comparator|Umeå, vitamin D 10 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 10 microg vitamin D3 per dag.
3121940|NCT01741324|Active Comparator|Umeå, vitamin D 10 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per dag.
3121941|NCT01741324|Experimental|Malmö, vitamin D 25 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
3121942|NCT01741324|Experimental|Malmö, vitamin D 25 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
3121943|NCT01741324|Active Comparator|Malmö, vitamin D 10 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
3121944|NCT01741324|Active Comparator|Malmö, vitamin D 10 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
3121945|NCT01741324|Placebo Comparator|Malmö, placebo, dark skin,|Participants with dark skin will be randomized to a milk drink without added vitamin D (placebo).
3121946|NCT01741324|Placebo Comparator|Malmö, placebo, light skin|Participants with light skin will be randomized to a milk drink without added vitamin D (placebo).
3121947|NCT01741324|Experimental|Umeå, vitamin D 25 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
3121948|NCT01741311|Experimental|3H+ Group|3H+ (Holistic for HIV) group patients will receive the standard of drug treatment care (i.e., methadone maintenance treatment and case management) plus four weekly 60-minute HIV risk reduction groups, and a 60-minute booster session at 12 weeks, led by two facilitators trained and supervised by a licensed clinical psychologist. 3H+ is an HIV risk reduction and ART adherence intervention that provides coping skills training and is delivered in a group modality, addressing high risk drug- and sex-related HIV risk behaviors and ART adherence for opioid-dependent individuals living with HIV.
3121989|NCT01741051|Experimental|HEPA Filter|HEPA filter(s) placed in the participant's home from approximately 10 weeks gestation until birth.
3121990|NCT01741051|No Intervention|Control|
3122066|NCT01740596|No Intervention|Control Arm|Optimal Medical Therapy
3121949|NCT01741311|Active Comparator|HHRP+ Group|HHRP+ (Holistic Health Recovery Program) is comprised of 12 two-hour weekly manual-guided group sessions with comprehensive HIV risk reduction content that addresses the medical, emotional, and spiritual needs of opioid-dependent individuals living with HIV. Each session is designed to last 2 hours and is co-facilitated by two trained facilitators, who address potential motivational conflicts of HIV+ individuals by providing them with self-protective as well as altruistic reasons for examining and changing their HIV risk behaviors and improving adherence behavior. Material is presented using cognitive remediation strategies.
3121950|NCT01741298|Experimental|Lifestyle counseling|CHARMS Intervention Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
3121951|NCT01741285|Active Comparator|Fluticasone|Two weeks treatment with HFA-Fluticasone 250 microgram twice daily
3121952|NCT01741285|Active Comparator|Clenil|Two weeks treatment with HFA-Clenil 200 microgram 2 inhalations twice daily.
3121953|NCT01741285|Experimental|QVAR|Two weeks treatment with QVAR 2 times 100 microgram twice daily
3121954|NCT01741272|Active Comparator|Group A (Usual Care)|Will be immobilized in a sling for 6 weeks. Intervention: Procedure: Sling
3121955|NCT01741272|Experimental|Group B (Early ROM)|Will use the sling for comfort only. Intervention: Procedure: No sling
3121956|NCT01741259|Experimental|Meperidine PCEA|Epidural Meperidine (5mg/ml) bolus of 20 mg, lockout of 30 min, hourly limit of 50 mg.
3121957|NCT01741259|Experimental|Meperidine PCEA with basal|Epidural meperidine (5mg/ml) basal rate of 10 mg/hr, bolus 20 mg, lockout 30 min, hourly limit 40 mg
3121958|NCT01741246||Control|Headache-free subjects.
3121959|NCT01741246||Episodic migraine|Patients with less that 15 headache days per month that fulfill International Classification of Headache Disorders 2R (ICHD-2nd edition Revised)- criteria for Episodic Migraine.
3121960|NCT01741246||Chronic migraine|Patients that fulfill International Classification of Headache Disorders (ICHD)-2R criteria for chronic migraine (more than 15 days per month).
3121961|NCT01741233|Experimental|UV-B irraditation|VitDgen
3121962|NCT01741220||anesthetists|German-speaking intensive-care providers and anesthetists
3121963|NCT01741207|No Intervention|control|control This group is without N-acetylcystein : just receives standard treatment
3121964|NCT01741207|Active Comparator|N-acetylcystein|receive N-acetylcystein in addition to standard treatment Ampoule 200 mg/ml
3121965|NCT01741194|Experimental|AC-1204|Powder formulation (40 g) mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed. Each dosing unit of AC-1204 contains 20 g of the active ingredient, caprylic triglyceride.
3121966|NCT01741194|Placebo Comparator|Placebo|Placebo is an isocaloric formulation prepared to be virtually identical to AC-1204 in appearance, odor and taste. Powdered formulation is mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed.
3121967|NCT01741181|Active Comparator|Vitamin D supplementation|Vitamin D3 tablets (cholecalciferol)
3121968|NCT01741181|Placebo Comparator|Placebo pill|Placebo pill
3121969|NCT01741168|Active Comparator|TLSO|TLSO brace 8-10 weeks
3121970|NCT01741168|Experimental|No Orthosis|No Orthosis
3121971|NCT01741155|Experimental|SPI-1620 & Docetaxel|"Single Arm and Randomized Part:~SPI-1620: 11μg/m2 Docetaxel: 75 mg/m2"
3121972|NCT01741155|Active Comparator|Docetaxel|Randomized Part only Docetaxel: 75 mg/m2 on Day 1 in 3-week cycles
3121973|NCT01741142|Experimental|ABT-436|Subject receiving ABT-436
3121974|NCT01741142|Active Comparator|Escitalopram|Subject receiving escitalopram.
3121975|NCT01741142|Placebo Comparator|Placebo|Subject receiving placebo
3121976|NCT01741129|Active Comparator|Nasal Continuous Positive Airway Pressure (CPAP)|"After 2 hours evaluation:~Infants needed invasive MV (mechanic ventilation) or Required a fraction of inspired oxygen of >40% to maintain the targeted saturation of >88% to 92%.~Non-invasive surfactant treatment (Curosurf®) 100 mg/kg per dose"
3121977|NCT01741129|Active Comparator|Nasal Intermittent Mandatory Ventilation (IMV)|"After 2 hours evaluation:~Infants needed invasive MV or Required a fraction of inspired oxygen of >40% to maintain the targeted saturation of > 88% to 92%.~Non-invasive surfactant treatment (Curosurf®) 100 mg/kg per dose"
3121978|NCT01741116|Experimental|TKI258, inhibitor of RTKs|"Intervention: TKI258~Investigational drug, TKI258, will be administered to all of the patients after enrollments. Treatment will initially be administered as 28-day cycles as follows:~- Daily 500mg of TKI258 will be self-administered orally by the patient for 5 days, followed by 2 days of treatment off."
3121979|NCT01741103|Experimental|Sitagliptin|
3121980|NCT01741103|Placebo Comparator|Placebo|
3121981|NCT01741090|Experimental|MSC injection|This study is designed as single interventional arm without comparative arm. MSC injection means hepatic artery catheterizations and mesenchymal stem cell injection through catheter.
3121982|NCT01741077||pregnant women|pregnant women taking 1 mg folic acid;
3121983|NCT01741077||non-pregnant women|non-pregnant women taking 0mg folic acid;
3121984|NCT01741077||non-pregnant women 2|non-pregnant women taking 1 mg folic acid
3121985|NCT01741077||non-pregnant women 3|non-pregnant women taking 5 mg folic acid
3121986|NCT01741064||PTH below target iPTH in CKD|iPTH at one year post transplantation below target range of iPTH by stage of CKD (KDOQI-guidelines).
3121987|NCT01741064||iPTH within target range of iPTH in CKD|iPTH at one year post transplantation within target range of iPTH by stage of CKD (KDOQI-guidelines).
3121988|NCT01741064||iPTH above target range of iPTH in CKD|iPTH at one year post transplantation above target range of iPTH by stage of CKD (KDOQI-guidelines).
3122040|NCT01740778||Study Group 4|Aurora vs. Multiclix
3165907|NCT01440231|Experimental|Arm 4|
3121991|NCT01741038|Experimental|AlloStim® treatment|The treatment schedule includes: (1) the priming step with two ID AlloStim® injections (Days 0 and 3), an additional two ID injections followed by IV infusion of AlloStim® (Days 7 and 10); (2) the vaccination step with cryoablation of a single metastatic lesion followed by injection of AlloStim® into the ablated tumor and IV infusion of AlloStim® on protocol day 14, followed by IV infusion of AlloStim® on Day 17 (3) the activation step with an IV study drug infusion on Day 21 and (4) the booster step with IV booster infusions of AlloStim® on days 49 and 77. Additional booster infusions can be administered monthly at the discretion of the Investigator.
3121992|NCT01741038|Other|Physician's Choice (PC)|All subjects will be assigned Physician's Choice (PC) therapy. PC can consist of best supportive care (BSC) or any US-FDA-approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated.
3121993|NCT01741025|Experimental|iFuse Implant System|Surgical placement of iFuse implants in the affected SI joint
3121994|NCT01741025|Active Comparator|conservative management|Medications, physical therapy, information
3121995|NCT01741012|Experimental|Gardasil|0.5 ml single dose Gardasil vaccine given at three separate visits
3121996|NCT01740999|Experimental|silicone arthroplasty|silicone arthroplasty
3121997|NCT01740999|Active Comparator|arthrodesis|arthrodesis
3121998|NCT01740986|Experimental|SA09012 Low dose|
3121999|NCT01740986|Experimental|SA09012 High dose|
3122000|NCT01740986|Placebo Comparator|Placebo|
3122001|NCT01740973||SILC cholecystectomy|No intervention. 239 SILC having a prospective questionnaire and clinical follow-up, if the patient suspects an umbilical hernia.
3122002|NCT01740973||and conventional lap. cholecystectomy|no intervention.Patients are also mailed a prospective questionnaire and clinical follow-up, if the patient suspects an umbilical hernia.
3122003|NCT01740960|Active Comparator|delta-9-tetrahydrocannabinol|Subjects will be randomized to receive 3 doses Namisol® (3 mg, 5 mg, 6,5 mg)
3122004|NCT01740960|Placebo Comparator|Placebo|The control product is placebo, consisting of a tablet with similar appearance and taste of the test product.
3122005|NCT01740947|No Intervention|Standard treatment|Standard treatment for colorectal cancer
3122006|NCT01740947|Experimental|Selective decontamination of the digestive tract (SDD)|"Standard treatment + SDD perioperatively 4 times daily 10 ml of SDD suspension, consisting of 100mg colistin sulfate, 80mg tobramycin and 500mg of amphotericin B.~SDD treatment starts 3 days before surgery and is continued until at least 3 days postoperatively."
3122007|NCT01740934|Active Comparator|Anatabloc Cream|Twice daily use of active facial cream
3122008|NCT01740934|Placebo Comparator|Placebo Cream|Twice daily use of placebo facial cream
3122009|NCT01740921|Active Comparator|Liraglutide|Liraglutide (Victoza) daily injections
3122010|NCT01740921|Placebo Comparator|diet|reduction in calorie intake
3122011|NCT01740921|Placebo Comparator|Aspirin|Aspirin 300mg once daily
3122012|NCT01740908||Hyperbaric Oxygen Treatment|Six healthy adult individuals (18-65 yrs), with no current, ongoing infection or chronic disease will be recruited for this study. Treatment study subjects will undergo a daily exposure to 2.0 ATA, 100% Oxygen for 90 minutes over 5 days.
3122013|NCT01740908||Baseline|Two healthy study subjects with no current, ongoing infection or chronic disease will be rectuited to serve as a baseline group. Study subjects will not be exposed to HBO, but will have blood drawn at the same time as the treatment group.
3122014|NCT01740869|Experimental|Experimental: Patients|Children who will receive intrathecal autologous stem cells
3122015|NCT01740869|Other|Control/Crossover|We will evaluate with IDEA and CARS scales the control group for 6 months with the possibility to change arms after that time.
3122016|NCT01740856|Experimental|Rest three hours|Rest three hours
3122017|NCT01740856|Experimental|Rest five hours|Rest five hours
3122018|NCT01740843|Active Comparator|Low intensity anodal tDCS|tDCS will be administered for 10 min at 1mA
3122019|NCT01740843|Experimental|High intensity anodal tDCS|tDCS will be administered for 10 min at 2.5mA
3122020|NCT01740843|Sham Comparator|Sham tDCS|Sham will be administered for 10 min at 0 mA
3122021|NCT01740830|Active Comparator|Anodal tDCS|
3122022|NCT01740830|Sham Comparator|Sham tDCS|
3122023|NCT01740817|Experimental|Intralipid 20%, then saline|Participants first received lipid infusion of 30ml/h x48h. After a washout period of 4-6 weeks, they then received saline infusion of 30ml/h x48h.
3122024|NCT01740817|Experimental|Saline, then Intralipid|Participants first received saline infusion of 30ml/h x48h. After a washout period of 4-6 weeks, they then received lipid infusion of 30ml/h x48h.
3122025|NCT01740791|Experimental|Cohort 1|(N = 10, genotype 1a): up to 150 mg GS-5816 or placebo QD fasted for 3 days
3122026|NCT01740791|Experimental|Cohort 2|(N = 10, genotype 1a): up to 150 mg GS-5816 or placebo QD fasted for 3 days
3122027|NCT01740791|Experimental|Cohort 3|(N = 10, genotype 1a): up to 150 mg GS-5816 or placebo QD fasted for 3 days
3122028|NCT01740791|Experimental|Cohort 4|(N = 10, genotype 1a): up to 150 mg GS-5816 or placebo QD fasted for 3 days
3122029|NCT01740791|Experimental|Cohort 5|(N = 10, genotype 2): up to 400 mg GS-5816 or placebo QD fasted for 3 days
3122030|NCT01740791|Experimental|Cohort 6|(N = 10, genotype 2): up to 400 mg GS-5816 or placebo QD fasted for 3 days
3122031|NCT01740791|Experimental|Cohort 7|(N = 10, genotype 3): up to 400 mg GS-5816 or placebo QD fasted for 3 days
3122032|NCT01740791|Experimental|Cohort 8|(N = 10, genotype 4/5/6): up to 400 mg GS-5816 QD fasted for 3 days
3122033|NCT01740791|Experimental|Cohort 9|(N = 10, genotype 1a, 1b, 2, 3 or 4/5/6): up to 400 mg GS-5816 or placebo QD fasted for 3 days
3122034|NCT01740791|Experimental|Cohort 10|(N = 10, genotype 1a, 1b, 2, 3 or 4/5/6): up to 400 mg GS-5816 or placebo QD fasted for 3 days
3122035|NCT01740791|Experimental|Cohort 11|(N = 10, genotype 1a, 1b, 2, 3 or 4/5/6): up to 400 mg GS-5816 or placebo QD fasted for 3 days
3122036|NCT01740791|Experimental|Cohort 12|(N = 10, genotype 1a, 1b, 2, 3 or 4/5/6): up to 400 mg GS-5816 or placebo QD fasted for 3 days
3122037|NCT01740778||Study Group 1|Aurora vs. Microlet 2
3122038|NCT01740778||Study Group 2|Aurora vs. SoftClix
3122039|NCT01740778||Study Group 3|Aurora vs. One Touch Comfort
3122064|NCT01740609|Experimental|2.0|
3122041|NCT01740765|Experimental|Eucaloric Feeding|Subjects will complete an initial eucaloric feeding study day. During this study day, subjects will receive 100% of their calorie requirements. 24-hour energy expenditure will be measured.
3122042|NCT01740765|Experimental|Underfeeding|Following the eucaloric feeding study day, subjects will undergo the underfeeding and overfeeding arms in random order. During the underfeeding study arm, subjects will receive 50% of their calorie requirements (as determined during the initial eucaloric study day) for 3 days. 24-hour energy expenditure will be measured.
3122043|NCT01740765|Experimental|Overfeeding|Following the eucaloric feeding study day, subjects will undergo the underfeeding and overfeeding arms in random order. During the overfeeding study arm, subjects will receive 150% of their calorie requirements (as determined during the initial eucaloric study day) for 3 days. 24-hour energy expenditure will be measured.
3122044|NCT01740752|Experimental|UCAN+CBT|This condition includes 22 UCAN sessions and 22 CBT sessions, totaling 44 psychotherapy sessions. UCAN is a manualized, 22-session Cognitive Behavioral Couple Therapy (CBCT) intervention that engages the couple to target the core psychopathology of AN and address the uniquely challenging stress that AN places on intimate relationships. The CBT proposed for this study is a 22 session adaptation of the manualized intervention that has been employed successfully as an outpatient post-hospitalization therapy and in an National Institute of Mental Health multisite study of fluoxetine with elements from the CBT manual used in McIntosh et al (PubMed 15800147).
3122045|NCT01740752|Experimental|CBT|"In this condition, participants will receive a higher dose of individual CBT, with 44 total sessions. Our experience with patients in the pilot strongly suggests that a higher dose of CBT will allow for further, fruitful discussion and exploration of key individual issues and is unlikely to be experienced as diluted or a slow approach to treatment. Most of these patients have complicated histories, long-standing eating disorders, and complex comorbid conditions."
3122046|NCT01740739||Cardiac Risk|Patients, as part of their standard of care, who are recommended for and who complete a test resulting in a Coronary Calcium Score, lipid test, hs-CRP and MPO result.
3122047|NCT01740726|Experimental|Behavioral Activation|
3122048|NCT01740726|Active Comparator|Fluoxetine|
3122049|NCT01740713|Experimental|Deferiprone, dose level 1|single dose level of 8.3 mg/kg every 8 hours for a corresponding total daily dose of 25 mg/kg/day.
3122050|NCT01740713|Experimental|Deferiprone, dose level 2|single dose level of 16.7 mg/kg every 8 hours for a corresponding total daily dose of 50 mg/kg/day.
3122051|NCT01740713|Experimental|Deferiprone, dose level 3|single dose level of 33.3 mg/kg every 8 hours for a corresponding total daily dose of 100 mg/kg/day.
3122052|NCT01740700|Experimental|p-Branch®|
3122053|NCT01740687||Essure+NovaSure|The group of women relying on Essure micro-inserts for permanent birth control when NovaSure is performed following a successful Essure Confirmation Test
3122054|NCT01740674|Experimental|Electronic data collection|The group of participants who will complete questionnaires via the internet
3122055|NCT01740674|No Intervention|Paper data collection|The group of participants who will continue to complete paper based questionnaires, as has been the practice for this longitudinal study.
3122056|NCT01740661|Experimental|Cryotherapy|The subjects will be exposed to a cold (~ 12° C) water immersion tub at the umbilical level for 20 minutes.
3122057|NCT01740661|Placebo Comparator|Control|The subjects will be exposed to a non-cold (~ 26° C) water immersion tub at the umbilical level for 20 minutes.
3122058|NCT01740648|Experimental|Treatment (trametinib, fluorouracil, radiation, surgery)|"Patients receive trametinib PO (by mouth) QD (daily) on days -14 through -10 and 1-38 and fluorouracil IV continuously 5 days a week from days 1-38. Patients also undergo radiation therapy 5 days a week on days 1-33. Patients then undergo surgery 6-10 weeks later.~Patients achieving negative surgical margins after complete resection of tumor receive postoperative chemotherapy comprising leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46 hours on days 1 and 15 OR oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46 hours on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3122059|NCT01740635|Experimental|EPIC WheelS Training Program|The EPIC WheelS program includes a comprehensive, structured library of educational material and training activities, organized in a hierarchy from simple to complex. Experimental group subjects will attend 2 training sessions with an expert Trainer. The Trainer will individualize a structured home training program, delivered via a computer tablet, and subjects will train at home for 1 month.
3122060|NCT01740635|No Intervention|Cognitive games|To provide a comparable level of investigator attention, control group subjects will receive two 1-hour social visits. To control for Trainer bias, the experimental and control groups will have separate Trainers. During social visits, the Trainer will discuss subjects' current community activities and their experience using the wheelchair, and provide verbal information related to barriers encountered. Subjects will receive a computer tablet with cognitive stimulation games to account for activity and tablet device exposure. Participants in the extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week (total 75 minutes/week) and document these on a simple calendar-style form provided. To minimize attrition, control subjects will receive a DVD with a condensed MWC skills education program after the post-intervention data collection is complete.
3122061|NCT01740622|Experimental|Injury Intervention Group|In homes of children who are randomized to the injury intervention arm of the trial, a comprehensive survey of injury hazards in living spaces will be undertaken. In addition to quantifying hazards, the area of living spaces will be obtained to allow the determination of both the number and density (number of hazards per 100 sq.ft.) of injury hazards. If one or more injury hazards are identified, they will be removed and/or modified to reduce exposure and injury risk. The intervention is focused on areas in living spaces below 1-meter (~39 inches) in height from (the 75th percentile in height or eye-level for a 3-year old US male toddler) which might be easily reached or climbed on by children less than 4 years.
3122062|NCT01740622|No Intervention|Control Group|Participants who are assigned to the control group will have their medical claims examined related to injury in the home. Households in this control condition will also be provided with information sheets on child safety developed by the American Academy of Pediatrics, The Injury Prevention Program (TIPP). These age-based recommendations for child safety are provided as standard of care at many pediatric offices.
3122063|NCT01740609|Placebo Comparator|1. Placebo|Placebo
3122067|NCT01740583|Experimental|annuloplasty|All patients will receive treatment with the Mitralign Percutaneous Annuloplasty System (MPAS).
3122068|NCT01740570|Experimental|Cabazitaxel|"Cabazitaxel by vein on day 1 of each 3 week cycle.~Phase I: Up to 5 dose levels of cabazitaxel tested. Two (2) dose levels will be given over 60 minutes, and 3 will be given over 30 minutes. First group of participants receive the lowest dose level. Each new group receives a higher dose level of cabazitaxel than the group before it, if no intolerable side effects were seen.~Phase II: Cabazitaxel at the highest dose that was tolerated in Phase I."
3122069|NCT01740557|Experimental|CXCR2 + NGFR T-cells|Cytoxan administered intravenously (IV) at 60 mg/kg/day over approximately 2 hours on Days -7 and -6. Mesna 60 mg/kg administered IV over 24 hours on Days -7 and -6. Fludarabine infused at 25 mg/m2 IV daily over approximately 15-30 minutes on Days -5 to -1. On day 0, all patients receive up to 1.5x10^11 T cells (including both CXCR2 and NGFR transduced TIL). TIL infused as an inpatient by IV over approximately 15-60 minutes. Twelve (12) to sixteen (16) hours after completing T cell infusion, all patients receive high dose interleukin-2 (IL-2) on an inpatient basis at standard dose of 720,000 IU/kg as an intravenous bolus over an approximate 15 minute period every 8-16 hours for up to 15 doses on Days 1 to 5, as tolerated.
3122070|NCT01740544|Experimental|Cathodal tDCS in young study participants|Cathodal tDCS in young study participants
3122071|NCT01740544|Experimental|Cathodal tDCS in elderly study participants|Cathodal tDCS in elderly study participants
3122072|NCT01740544|Sham Comparator|Sham tDCS in young study participants|Sham tDCS in young study participants
3122073|NCT01740544|Sham Comparator|Sham tDCS in elderly study participants|Sham tDCS in elderly study participants
3122074|NCT01740531|Experimental|S-303 Treated Red Blood Cells (RBC)|Patients will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible patients are randomly assigned to receive Test RBCs followed by Control RBCs or Control RBCs followed by Test RBCs. Each patient will complete both treatment periods.
3122075|NCT01740531|Active Comparator|Conventional, untreated Red Blood Cells|Patients will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible patients are randomly assigned to receive Test RBCs followed by Control RBCs or Control RBCs followed by Test RBCs. Each patient will complete both treatment periods.
3122076|NCT01740518||PEG + ascorbic acid|Those who taken PEG 2L + ascorbic acid
3122077|NCT01740518||PEG 4L|Those who taken PEG 4L alone
3122078|NCT01740505|Experimental|Timing and Coordination|
3122079|NCT01740505|Experimental|Aerobic Walking|
3122080|NCT01740505|Active Comparator|Stretching and Relaxation|
3122081|NCT01740492|Experimental|LDK1: Low dose Ketamine (0.15mg/kg)|"Participants randomized to the first group, LDK1, will receive an intravenous injection of low dose ketamine (0.15mg/kg).~All participants, regardless of the group, will receive a dose of morphine(0.15mg/kg) at the same time the study drug is administered."
3122082|NCT01740492|Experimental|LDK2: Low dose Ketamine (0.3mg/kg)|"Participants randomized to the second group, LDK2, will receive an intravenous injection of low dose ketamine (0.3mg/kg).~All participants, regardless of the group, will receive a dose of morphine(0.15mg/kg) at the same time the study drug is administered."
3122083|NCT01740492|Placebo Comparator|0.9% Normal Saline|This group will receive a placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
3122084|NCT01740479|Active Comparator|Complete Revascularization Strategy|"Complete Revascularization Strategy (Staged Non-Culprit Lesion PCI plus Optimal Medical Therapy): Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions.~All patients, regardless of randomized treatment allocation will receive optimal medical therapy consisting of risk factor modification and use of evidence-based therapies (including low dose acetylsalicylic acid (ASA) and ticagrelor)."
3122085|NCT01740479|No Intervention|Optimal Medical Therapy Alone|"Culprit lesion only Revascularization Strategy (Optimal Medical Therapy Alone): No further revascularization of non-culprit lesions.~All patients, regardless of randomized treatment allocation will receive optimal medical therapy consisting of risk factor modification and use of evidence-based therapies (including low dose ASA and ticagrelor)."
3122086|NCT01740466||Ocular diseases|Observational
3122087|NCT01740453|No Intervention|Single (no catheter)|ropivacaine single injection : 5 mg/ml 15 ml
3122088|NCT01740453|Experimental|Continuous infusion|Single injection with continuous injection ropivacaine 2 mg/ml 8 ml/h
3122089|NCT01740440|Other|BMR Face treatment|BMR Face treatment used once a day for 12 weeks
3122090|NCT01740427|Experimental|PD-0332991 + Letrozole|PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
3122091|NCT01740427|Active Comparator|Placebo + Letrozole|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
3122092|NCT01740414|Active Comparator|MN-166 (formerly AV411) First|Participants who began 14-day maintenance on MN-166 (50 mg) first, before switching to Placebo maintenance.
3122093|NCT01740414|Placebo Comparator|Placebo First|Participants who began 14-day maintenance on Placebo first, before switching to MN-166 (50 mg) maintenance.
3122094|NCT01740401|Experimental|Cyclophosphamide, Ipilimumab|"Treatment:~Cyclophosphamide 300 mg/m2 po - Day 1 of Weeks 1, 4, 7, and 10, for a total of 4 doses; (premedication prior to each dose of Cyclophosphamide 8mg Zofran po, then prn)~Ipilimumab 10 mg/kg iv - Day 3 of Weeks 1, 4, 7, and 10 for a total of 4 doses Maintenance treatment will be given on Weeks 24, 36, and 48 Ipilimumab 10 mg/kg iv"
3122095|NCT01740388|Experimental|Besifloxacin|besifloxacin ophthalmic suspension 0.6% administered 2 times daily (BID) for 3 days to participants with a clinical diagnosis of bacterial conjunctivitis
3122096|NCT01740388|Placebo Comparator|Vehicle|vehicle of besifloxacin ophthalmic suspension administered 2 times daily (BID) for 3 days to participants with a clinical diagnosis of bacterial conjunctivitis
3122097|NCT01740375|No Intervention|Arm B: observation:|No additional treatment after concurrent chemoradiotherapy. However, esophagectomy will be considered as a salvage treatment for local recurrence during observation.
3122098|NCT01740375|Experimental|Arm A: esophagectomy|Esophagectomy will be performed preferentially within 8 weeks (maximum 12 weeks) after completion of concurrent chemoradiotherapy
3122099|NCT01740362|Other|Healthy volunteers|Healthy volunteers
3122100|NCT01740362|Experimental|Mild renal impairment|patients with mild (>50 and ≤80 mL/min) renal impairment
3122101|NCT01740362|Experimental|Moderate renal impairment|patients with moderate (≥30 and ≤50 mL/min) renal impairment
3122102|NCT01740362|Experimental|severe renal impairment|patients with severe (<30 mL/min) renal impairment
3122103|NCT01740349||30 children with UC|This prospective pilot study of 30 pediatric subjects, that are indicated for standard colonoscopy due to follow-up of ulcerative colitis (UC), examines the Given Diagnostic System and the PillCam Colon Capsule in comparison to standard colonoscopy.
3122104|NCT01740336|Experimental|A: Paclitaxel, GDC-0941|Participants will receive GDC-091 260 milligrams (mg) orally in repeated rounds of once daily (QD) dosing for 5 consecutive days followed by 2 consecutive days during which GDC-0941 will not be administered (5/7-day schedule). This 5/7-day schedule will be repeated weekly in each 28-day cycle until disease progression or intolerable toxicity. Participants will receive 90 milligrams per square meter (mg/m^2) intravenously (IV) weekly for 3 out of 4 weeks in every 28-day cycle.
3122105|NCT01740336|Placebo Comparator|B: Paclitaxel, Placebo|Participants will receive placebo matching to GDC-0941 on the 5/7-day schedule along with 90 mg/m^2 IV weekly for 3 out of 4 weeks in every 28-day cycle.
3122106|NCT01740323|Placebo Comparator|Placebo|Placebo
3122107|NCT01740323|Experimental|Curcumin|500 mg BID
3122108|NCT01740310|Experimental|High Elaboration Video Arm|Women randomized to this arm will be exposed to a handheld/electronic tablet device-based video with detailed vaccine-related information designed to invoke a high level of attention to the message and thought (elaboration) while processing information.
3122109|NCT01740310|Experimental|High Elaboration Interactive Tutorial Arm|Women will be exposed to a handheld/electronic tablet device-based intervention designed to invoke a high level of attention to the message and thought (elaboration) while processing information through an interactive question/answer format.
3122110|NCT01740310|Placebo Comparator|Low Elaboration / Control Arm|Women randomized to the control arm will be provided standard CDC vaccine information statements that will likely lead to low elaboration information processing.
3122111|NCT01740297|Experimental|Phase 1b: Talimogene Laherparepvec + Ipilimumab|Participants received talimogene laherparepvec at an initial dose of 10⁶ plaque-forming units (PFU)/mL injected into 1 or more skin, nodal, or subcutaneous tumors. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until complete response (CR), all injectable tumors had disappeared, confirmed disease progression per the modified immune-related response criteria (irRC), or intolerance of study treatment, whichever occurred first. Participants also received 3 mg/kg ipilimumab administered intravenously every 3 weeks for a total of 4 infusions starting at the time of the third dose of talimogene laherparepvec (week 6).
3122112|NCT01740297|Active Comparator|Phase 2: Ipilimumab|Participants received ipilimumab 3 mg/kg intravenously every 3 weeks for a total of 4 infusions starting at week 1.
3122113|NCT01740297|Experimental|Phase 2: Talimogene Laherparepvec + Ipilimumab|Participants received talimogene laherparepvec at an initial dose of 10⁶ PFU/mL injected into 1 or more skin, nodal, or subcutaneous tumors. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until CR, all injectable tumors had disappeared, confirmed disease progression per the modified irRC, or intolerance of study treatment, whichever occurred first. Participants also received 3 mg/kg ipilimumab intravenously every 3 weeks for a total of 4 infusions starting at the time of the third dose of talimogene laherparepvec (week 6).
3122114|NCT01740284|Active Comparator|Grazax + Aerius|1 tablet (oral lyophilisate ) on Day 14 and Day 28 of Grazax (Phleum Pratense grass pollen allergen extract) 75.000 SQ-T and 1 tablet (melting tablet)of Aerius (desloratidine) 2.5 mg
3122115|NCT01740284|Placebo Comparator|Grazax + Placebo|1 tablet (oral lyophilisate ) on Day 14 and Day 28 of Grazax (Phleum Pratense grass pollen allergen extract) 75.000 SQ-T and 1 tablet (melting tablet)of Aerius (Placebo)
3122116|NCT01740271|Experimental|Epirubicin|Following genetic analysis, depending on results, participants will receive either standard or increased epirubicin dosing for cycles 2 - 4.
3122117|NCT01740258|Experimental|Bevaczimab, Radiation Therapy, Temozolomide|"In Part A, newly-diagnosed patients with Grade 4 malignant gliomas will receive standard radiation therapy, daily Temodar 75mg/M for 6-8 weeks. Bevacizumab will be given concurrently with radiation therapy and Temodar, 10 mg/kg every two weeks.~If they are stable at the end of Part A, they will continue to Part B. In Part B patients will receive up to 12 cycles of bevacizumab and Temodar. Bevacizumab will be given on Days 1 and 15 of a 28-day cycle. Temodar will be 200 mg/meter squared daily for 5 days (days 1-5) of each cycle.~If they have not progressed, patients will start Part C. In Part C, patients will receive bevacizumab 10mg/kg approximately every 2 weeks or 15 mg/kg approximately every 3 weeks.~If patients progress during Part B or C, they will start Part D. In Part D, patients will receive bevacizumab-based therapy containing bevacizumab in combination with a chemotherapy and/or biologic agent, as determined by the Duke treating physician."
3122118|NCT01740245|Active Comparator|Chlorhexidine|
3122119|NCT01740245|Experimental|Polyhexamethylene biguanide|
3122120|NCT01740232|Active Comparator|Trephination|A 1 x 10 mm pricker are used for the trephination of the meniscus before normal meniscal repair.
3122121|NCT01740232|Placebo Comparator|Normal meniscal repair|standard operation. Normal meniscalrepair.
3122122|NCT01740219|Experimental|Capacity Enhancement|
3122123|NCT01740219|Experimental|Standard Dissemination|
3122124|NCT01740206|Active Comparator|Amphetamine and/or methylphenidate|Patients who took their amphetamine and/or methylphenidate the morning of surgery.
3122125|NCT01740206|Experimental|Hold stimulant medication|Patients who did not take their stimulant medication the morning of surgery.
3122126|NCT01740193|Active Comparator|TAP Block|
3122127|NCT01740193|Active Comparator|Ilioinguinal/iliohypogastric blockade|
3122128|NCT01740180||CLIPPERS patients|"The population concerned by this study consists of patients diagnosed according to CLIPPERS criteria (see inclusion and exclusion criteria).~Intervention: Data entry"
3122129|NCT01740167|Experimental|Lifestyle program|health promotion lifestyle program : individual counseling, once a month, total 3 times.
3122130|NCT01740154|Experimental|Supportive care (sunitinib malate, neuromuscular testing)|Patients receive sunitinib malate PO daily for 4 weeks. Patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28.
3122131|NCT01740141|Other|Plexus before surgery|Plexus brachialis before surgery
3122132|NCT01740141|Other|Plexus after surgery|Plexus brachialis performed after surgery
3122133|NCT01740128|Experimental|Multimodal then Treadmill training|Participants will undergo harness-supported multimodal balance training exercises while simultaneously performing skilled hand exercises. Following a washout period of at least 6 weeks, Participants will undergo body weight supported treadmill training using the Lokomat apparatus.
3122134|NCT01740128|Active Comparator|Treadmill then Multimodal training|Robotic body weight supported treadmill training will be applied using the Lokomat apparatus. Following a washout period of at least 6 weeks, Participants will undergo harness-supported balance training exercises while simultaneously performing skilled hand exercises.
3122135|NCT01740102|Experimental|RIPC|Remote ischemic preconditioning (RIPC) in the operating theatre after induction of anaesthesia and before surgery.
3122136|NCT01740102|No Intervention|No RIPC|Patients in the control group will not receive remote ischemic preconditioning before the surgery.
3122137|NCT01740089|Experimental|Algeron 1.5 μg/kg|Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight < 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight > 105 kg).
3122138|NCT01740089|Experimental|Algeron 2.0 μg/kg|Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight < 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight > 105 kg).
3122139|NCT01740089|Active Comparator|PegIntron|PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight < 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight > 105 kg).
3122140|NCT01740076|Experimental|soy nuts|25 g of soy nuts provided daily to the subjects and they were counseled to replace 25 g of protein in their therapeutic lifestyle change (TLC) diet with the soy. TLC diet consisted of 30% of energy from total fat (<7% saturated fat, 12% monounsaturated fat and 11% polyunsaturated fat), 15% from protein and 55% from carbohydrate; less than 200 mg of cholesterol per day and 1200 mg of calcium and 2 fatty fish meals per week. Those ingesting suboptimal dietary calcium were given calcium carbonate supplementation.
3122141|NCT01740076|Other|Therapeutic lifestyle change diet|Counseling on therapeutic lifestyle change diet consisting of 30% of energy from total fat (<7% saturated fat, 12% monounsaturated fat and 11% polyunsaturated fat), 15% from protein and 55% from carbohydrate; less than 200 mg of cholesterol per day and 1200 mg of calcium and 2 fatty fish meals per week. Those ingesting suboptimal dietary calcium were given calcium carbonate supplementation.
3122142|NCT01740063|Experimental|DAS181-F02 formulation|DAS181 10 mg dose for three days of the F02 formulation
3122143|NCT01740063|Experimental|DAS181-F04 formulation|DAS181 20 mg dose group for three days of the F04 formulation,
3122144|NCT01740063|Placebo Comparator|Placebo|placebo group
3122145|NCT01740050|Active Comparator|Roux- and Y bypas surgery (RYGB)|"One subject group will lose 10% of initial body weight using RYGB. RYGB is an operation that first divides the stomach into a small upper pouch and a much larger lower remnant pouch and then re-arranges the small intestine to connect to both, in this way bypassing part of the small intestine."
3122146|NCT01740050|Active Comparator|Laparoscopic adjustable gastric banding (LAGB)|One subject group will lose 10% of initial body weight using LAGB. With LAGB an inflatable band is placed around the upper part of the stomach to create a smaller stomach pouch. This slows and limits the amount of food that can be consumed at one time giving the opportunity for the sense of satiety to be met. It does not decrease gastric emptying time.
3122147|NCT01740050|Active Comparator|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
3122148|NCT01740037|Experimental|Specialized AF-clinic|Management of AF patients in specialized AF Clinics according to the principles of an integrated chronic care program (ICCP) performed by nurse specialists, supported by an ICT decision support tool based on professional guidelines (CardioConsult AF®) and supervised by a cardiologist. In addition, a web-based patient centered medication management tool (Medication Manager(TM)and tailored telemonitoring at an outpatient AF clinic. In addition, the intervention is based on identifying risk factors and potential problems in patients, and addressing needs through dynamic use of personalized education and adjustment of treatment.
3122149|NCT01740037|Active Comparator|Usual Care|Usual care provided by cardiologists at the regular outpatient clinic.
3122150|NCT01740024|Experimental|1 (Dose-Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations Positive control Negative control
3122151|NCT01740011|Experimental|Group A|Laparoscopic surgery with AirSeal CO2 pressure insufflation
3122152|NCT01740011|Active Comparator|Group S|Laparoscopic surgery with standard CO2 pressure insufflation
3122153|NCT01739998|Experimental|functional oil|Treatment consisted of consuming 5 ml of functional oil [olive oil (4 ml) with omega 3 fatty acids from fish oil (1 ml: 90% omega 3: 75-80% DHA and 10-15% EPA) Orange flavour] during the day by 8 weeks.
3122154|NCT01739998|Placebo Comparator|Placebo|Treatment consisted of consuming 5 ml of olive oil during the day by 8 weeks
3122155|NCT01739985|Active Comparator|Dexamethasone + ondansetron + Placebo|dexamethasone + ondansetron + Placebo
3122156|NCT01739985|Experimental|Dexamethasone + ondansetron + Droperidol|dexamethasone + ondansetron + Droperidol
3122157|NCT01739972|Active Comparator|Levothyroxine|Levothyroxine in the capsule form, once daily, appropriate dosage to keep TSH at the normal range.
3122158|NCT01739972|Active Comparator|Desiccated thyroid extract|Desiccated thyroid extract in capsule form, once daily, appropriate dosage to keep TSH in the normal range.
3122159|NCT01739959||Necrotizing fasciitis proven|Histological evidence of necrotizing fasciitis at initial surgical debridement
3122160|NCT01739959||Not necrotizing fasciitis|A composite of those with no histological tissue necrosis at initial surgical debridement, and those clinically judged not to be a necrotizing infection who therefore did not undergo surgery.
3122161|NCT01739946||Implanted subject|Subjects with Interstim implanted
3122162|NCT01739946||Controls|Subjects without Interstim implanted
3122163|NCT01739933|Active Comparator|Dexmedetomidine|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 5 mcg/mL dexmedetomidine. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr."
3122164|NCT01739933|Active Comparator|Propofol|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 10 mg/mL propofol. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the propofol group, dose will range from 5-50 mcg/kg/min."
3122165|NCT01739920|Experimental|Povidone-iodine|1 drop of povidone-iodine 5% will be instilled at time zero, 20-minute and 28-minute study period.
3122166|NCT01739920|Active Comparator|Povidone-iodine and Saline Solution|1 drop of saline solution 0.9% will be instilled at time zero and 20-minute. At 28-minute will be instilled 1 drop of Povidone-iodine 5%.
3122167|NCT01739907|Experimental|Iron-fortified dairy product|Consumption of an iron-fortified flavoured skimmed milk as part of the usual diet
3122168|NCT01739907|Experimental|Iron and vitamin D dairy product|Consumption of an iron and vitamin D fortified flavoured skimmed milk as part of the usual diet
3122169|NCT01739894|Experimental|IP Paclitaxel|Paclitaxel will be administered intraperitoneally at 40mg/m2 on Days 1 and 8 in a 21-day cycle in patients receiving intravenous oxaliplatin 100mg/m2 on Day 1 and capecitabine 1000mg/m2 twice daily on Days 1-14.
3122170|NCT01739855|Active Comparator|Calcium/Vitamin D|"All subjects will receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery as follows:~daily: 500 mg oral calcium (calcium carbonate) weekly: 16.000 IU oral vitamin D3 (calciferol)"
3122171|NCT01739855|No Intervention|No Calcium/Vitamin D|All subjects will not receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery.
3122172|NCT01739842|Active Comparator|Kudzu extract treatment|"Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session.~During the medication week, participants will take 2 capsules three times a day for a total dose of 3 grams of kudzu."
3122173|NCT01739842|Placebo Comparator|Placebo|"Placebo will be administered as a pretreatment 2 ½ hours before a drinking session.~During the medication week, participants will take 2 capsules three times a day."
3122174|NCT01739829|Experimental|DIABECELL group 1|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
3122175|NCT01739829|Experimental|DIABECELL group 2|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
3122176|NCT01739816|No Intervention|Control group|Patients get no intervention at study start, but only at study end after seven months.
3122177|NCT01739816|Active Comparator|Intervention group|At the beginning and at the end of the study, this group receives a pharmacist's led medication review focusing on daily medicines use (= Polymedication Check).
3122178|NCT01739816|Other|Observational arm|If participants after recruitment violate inclusion criteria (e.g. change from autonomous medication management to external home care) or insists on intervention despite being randomised to control group or patient condition forces pharmacist to provide a PMC.
3122179|NCT01739803|Experimental|Intervention Group|Behavioral contract intervention
3122180|NCT01739803|No Intervention|Control Group|No intervention
3122181|NCT01739790|Placebo Comparator|Sugar Pill|Identical placebo pills twice daily for 8 weeks Placebo pills manufactured to mimic appearance of intervention drug n-acetylcysteine and prescribed with identical frequency and duration.
3122182|NCT01739790|Active Comparator|N-Acetylcysteine|1800 mg twice daily for 8 weeks
3122183|NCT01739777|Experimental|ucMSC|Umbilical cord derived mesenchymal are injected intravenously to Patients.
3122184|NCT01739777|Placebo Comparator|Controls|Intravenous placebo solution are administrated to Patients.
3122185|NCT01739764|Other|Vemurafenib|Participants will receive oral vemurafenib at 960 mg BID, 720 mg BID, or 480 mg BID, depending on the last dose in the antecedent protocol until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator, death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the sponsor to terminate the study, whichever occurs first.
3122186|NCT01739751|No Intervention|Control Group|Patients without feedback of a pedometers, followed for 3 months
3122187|NCT01739751|Experimental|Pedometers|With a program of physical activity enhancement using pedometers as a feedback
3122188|NCT01739738||no Ureteral Stent - control group|non-stented volunteers to receive ultrasound for peristalsis changes detection
3122189|NCT01739738||Ureteral stent|patients who receive stent, and to receive ultrasound for peristalsis changes detection in their stented and non-stented ureter
3122190|NCT01739725|Experimental|Helical stent insertion|Study participants will receive the helical stent
3122191|NCT01739712|Experimental|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
3122192|NCT01739712|Sham Comparator|Fixed Sleep Duration|All youth in this condition are asked to maintain their baseline sleep duration.
3122193|NCT01739699|Experimental|Acetaminophen|Subjects will receive 1000mg of intravenous acetaminophen every 6 hours for 24 hours beginning with dural closure.
3122194|NCT01739699|Other|Placebo|Subjects will receive 100cc of normal saline every 6 hours for 24 hours beginning at dural closure.
3122227|NCT01739439|Experimental|Treatment (chemoradiation and radiosurgery)|Patients receive gemcitabine hydrochloride IV over 30 minutes once weekly and undergo hyperfractionated IMRT 5 days a week in weeks 1-3. Patients then undergo a single fraction of radiosurgery boost in week 5 and then receive gemcitabine hydrochloride IV over 30 minutes once weekly in weeks 6-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
3165908|NCT01440231|Experimental|Arm 5|
3122195|NCT01739686|Experimental|CASA Intervention|"The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~A social worker provides structured counseling targeting adjustment to illness and depression if present.~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone."
3122196|NCT01739686|No Intervention|Usual Care|Patients in the control group will continue to receive care at the discretion of their providers, which may include referral to cardiology, palliative care, or mental health. If patients self-report depression on baseline surveys, this information will be given to their provider, and patients will be given resources. Patients will have the same amount of interaction with research assistants as the intervention patients, completing questionnaires and participating in study visits at the same frequency.
3122197|NCT01739673|Experimental|Ultraviolet-A and riboflavin|
3122198|NCT01739660|Experimental|Pegloticase|Pegloticase 8 mg single intraveneous dose
3122199|NCT01739647|Experimental|AZD3293|Up to 11 sequential cohorts of healthy young and healthy elderly subjects are planned, with single ascending doses ranging from 1mg to a maximum of 1000mg
3122200|NCT01739647|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
3122201|NCT01739634|Experimental|Active Drug|After a 1 week run-in period CASAD will be administered TID for 1 week. Each dose will be 2 500mg CASAD capsules. Patients will be followed for two weeks post active drug administration.
3122202|NCT01739621|Experimental|Proellex 12 mg|Telapristone acetate, 1 vaginally inserted capsule, once a day, for 4 months
3122203|NCT01739621|Experimental|Proellex 24 mg|Telapristone acetate, 1 vaginally inserted capsule, twice a day, for 4 months
3122204|NCT01739608|Experimental|CT Colonography (CTC)|Invitation to screening. Subject who consent to participate in the study undergo to low dose CTC examination with limited bowel preparation.
3122205|NCT01739608|Active Comparator|Sigmoidoscopy (FS)|Invitation to screening. Subjects who consent to participate in the study undergo to FS.
3122206|NCT01739595|Experimental|Androxal 12.5 mg|Androxal (enclomiphene citrate), 12.5 mg oral capsules taken once daily
3122207|NCT01739595|Experimental|Androxal 25 mg|Androxal (enclomiphene citrate), 25 mg oral capsules taken once daily
3122208|NCT01739595|Placebo Comparator|Placebo|Placebo oral capsules taken one time daily
3122209|NCT01739582|Experimental|Androxal|Androxal (enclomiphene citrate) 12.5 mg, once daily, oral capsule. Subjects will be up-titrated to 25 mg if testosterone levels remain below 450 ng/dL at visit 2.
3122210|NCT01739569|Experimental|Dietary treatment|Dietary treatment with healthy lunch and snack meal during working hours
3122211|NCT01739569|No Intervention|Habitual meals|Dietary treatment with habitual diet
3122212|NCT01739556|Experimental|Intervention Arm|Antiplatelet regimen modification will be guided by assessment of the on-treatment platelet reactivity. Low responders to aspirin will receive 200 mg aspirin for 30 days. Low responders to clopidogrel will receive 180 mg ticagrelor for 1 year.
3122213|NCT01739556|No Intervention|Standard Treatment|Patients enrolled in the Standard Treatment arm will receive standard antiplatelet regimen including 100 mg aspirin and 75 mg clopidogrel without assessment of on-treatment platelet reactivity.
3122214|NCT01739543|Experimental|Investigational|Subject receives Hem-Avert Device.
3122215|NCT01739543|No Intervention|Control|Subject does not receive Hem-Avert Device.
3122216|NCT01739530|Experimental|Repaircell|allogenic differentiated adipocyte
3122217|NCT01739517|Experimental|Omegaven Therapy|After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
3122218|NCT01739504|Experimental|Autologous Adipose-derived Stromal Vascular Fraction infusion|Intervention: AD-SVF infusion directly into affected joints.
3122219|NCT01739491||Bendamustine hydrochloride|Adult Filipino patients with chronic lymphocytic leukemia will be taking bendamustine hydrochloride as per the dosing regimen given on product insert approved in Philippines.
3122220|NCT01739478|Experimental|Non-packing of abscess cavity|
3122221|NCT01739478|Other|Packing of abscess cavity|Current practice
3122222|NCT01739465|Active Comparator|Self expanding metallic stent （SEMS ）placement only|Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing
3122223|NCT01739465|Experimental|Endoscopic radiofrequency ablation plus SEMS|Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. The radiofrequency ablation (RFA) catheter (EMcision, London, United Kingdom) would be placed under fluoroscopic guidance across the biliary stricture. Radiofrequency energy will be delivered to the malignant site. After that,A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing
3122224|NCT01739465|Experimental|Photodynamic therapy plus SEMS|Photofrin is injected 3 days prior to laser activation of the agent.Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) will be carried out to determine the length and positon of the biliary malignant. Delivery Fiber used along with the laser system to activate the photosensitizing agent and induce tumor tissue necrosis. A self expanding metallic stent (SEMS) will be placed the site of biliary narrowing
3122225|NCT01739452||erythropoiesis-stimulating agents|Patients diagnosed with low-risk MDS according to IPSS (low or intermediate-1), treated with erythropoiesis-stimulating agents.
3122226|NCT01739452||Transfusion support|A control group of patients who received only transfusional support.
3122228|NCT01739426|Experimental|Study population|"The population is composed of patients with a confirmed Zenker's diverticulum.~Intervention: Repair w/LigaSure"
3122264|NCT01739192|Experimental|Arm 3|Naltrexone (50 mg) oral daily for approximately six (6) weeks.
3122229|NCT01739413|Active Comparator|General Anesthesia|Patients will receive general anesthesia alone followed by intravenous morphine for postoperative pain control. This techniques is safe and is standard procedure for colorectal surgery.
3122230|NCT01739413|Experimental|Epidural Anesthesia|Patients will receive general anesthesia plus epidural anesthesia followed by epidural analgesia for postoperative pain control. This techniques is safe and standard procedure for colorectal surgery.
3122231|NCT01739400|Experimental|Macitentan|Macitentan 10 mg tablet, once daily.
3122232|NCT01739387||Breath actuated inhaler (BAI)|Placebo. Two to nine puffs on one day only
3122233|NCT01739387||Flutiform® pMDI|Placebo. Two to nine puffs on one day only
3122234|NCT01739374|Experimental|Device - Reduced mesh implants|Patients treated with reduced mesh implants for POP reconstruction
3122235|NCT01739361|Experimental|Acetaminophen|Patients will receive acetaminophen at the dose of 1 gram by mouth or by enteral feeding tube every six hours for a total of 72 hours.
3122236|NCT01739361|Placebo Comparator|Placebo|Patients will receive placebo by mouth or by enteral feeding tube every six hours for 72 hours.
3122237|NCT01739348|Experimental|Arm A. Verubecestat 12 mg [Part I]; 12 mg [Part II]|[Part I] Verubecestat 12 mg once daily for 78 weeks in Study Part I (Base Study). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 12 mg once daily for an additional 260 weeks.
3122238|NCT01739348|Experimental|Arm B. Verubecestat 40 mg [Part I]; 40 mg [Part II]|[Part I] Verubecestat 40 mg once daily for 78 weeks in Study Part I (Base Study). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
3122239|NCT01739348|Experimental|Arm C. Verubecestat 60mg/40mg [Part I]; 40 mg [Part II]|[Part I] Verubecestat 60 mg once daily until the first IA in Study Part I (Base Study). Following IA, participants in this group were switched to Verubecestat 40 mg once daily, for the remainder of Study Part I (total dosing period: 78 weeks). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
3122240|NCT01739348|Placebo Comparator|Arm D. Placebo [Part I]; Verubecestat 40 mg [Part II]|[Part I] Placebo once daily for 78 weeks in Study Part I (Base Study). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
3122241|NCT01739335|Experimental|Mifepristone|'Mifepristone Oral Tablet [Korlym] (2 x 300mg =600 mg total, once daily, at bedtime) for 7 days
3122242|NCT01739335|Placebo Comparator|Placebo|Placebo Oral tablet (2 sugar pills, once daily, at bedtime) for 7 days
3122243|NCT01739322|Experimental|1|"Four concentrations of Platanus acerifolia allergen extract (10, 1, 0.1, 0.01 mg/ml)~Positive control (10 mg/ml histamine dihydrochloride)~Negative control (glycerinated phenol saline solution)"
3122244|NCT01739309|Experimental|LY2835219|200 milligram (mg) LY2835219 administered orally every 12 hours on days 1 through 28 of a 28-day cycle
3122245|NCT01739296|Experimental|Wedge|Lateral wedge insole with subtalar strapping Use of lateral wedge insoles with subtalar strapping for 5 to 10 hours daily
3122246|NCT01739296|Sham Comparator|Neutral|Neutral insole with subtalar strapping (sham) Use of neutral insoles with subtalar strapping for 5 to 10 hours daily
3122247|NCT01739283|Experimental|hyperglycemia|Hyperglycemic clamping
3122248|NCT01739283|Experimental|hypoglycemia|Hypoglycemic clamping
3122249|NCT01739270|Active Comparator|dexamethasone with levobupivacaine|25ml 0.5% levobupivacaine plus 4mg Dexamethasone are given for supraclavicular brachial plexus block for upper extremity surgery
3122250|NCT01739270|Active Comparator|levobupivacaine|25ml 0.5% levobupivacaine plus 1ml 0.9% saline are given for supraclavicular brachial plexus block for upper extremity surgery
3122251|NCT01739257|Experimental|Theater|"1-hour dramatic reading of The Most Massive Woman Wins"
3122252|NCT01739257|Active Comparator|Lecture|1-hour lecture on the medical management of obese patients
3122253|NCT01739244|Experimental|SYL040012 eye drops dose A|Ocular topical administration of SYL040012 eye drops dose A
3122254|NCT01739244|Experimental|SYL040012 eye drops dose B|Ocular topical administration of SYL040012 eye drops dose B
3122255|NCT01739244|Experimental|SYL040012 eye drops dose C|Ocular topical administration of SYL040012 eye drops dose C
3122256|NCT01739244|Placebo Comparator|Placebo|Ocular topical administration of placebo eye drops
3122257|NCT01739231|Experimental|Cohort 1|Three oral doses of ~10^10 cfu ACE527 (12 participants) or ~10^10 cfu ACE527 + 25 ug dmLT (12 participants) or placebo (6 participants)
3122258|NCT01739231|Experimental|Cohort 2|Three oral doses of ~10^10 cfu ACE527 (12 participants) or ~10^10 cfu ACE527 + 25 ug dmLT (12 participants) or placebo (6 participants)
3122259|NCT01739218|Experimental|Carboplatin + Paclitaxel + Bevacizumab|Participants will receive 4 cycles of neoadjuvant therapy prior to IDS and 22 cycles of adjuvant therapy before entering long-term follow-up. Each cycle will be 3 weeks in length. Carboplatin and paclitaxel will be administered during Cycles 1 to 8. Bevacizumab will be administered during both the neoadjuvant and the adjuvant treatment periods in Cycles 1 to 26 (no treatment in Cycles 4 and 5).
3122260|NCT01739218|Active Comparator|Carboplatin + Paclitaxel|Participants will receive 4 cycles of neoadjuvant therapy prior to IDS and 22 cycles of adjuvant therapy before entering long-term follow-up. Each cycle will be 3 weeks in length. Carboplatin and paclitaxel will be administered during Cycles 1 to 8. Bevacizumab will be administered only during the adjuvant treatment period in Cycles 6 to 26.
3122261|NCT01739205|Experimental|Lifestyle counseling|"CALM-D Intervention Session Topic Weekly~I Welcome to the CALM-D Program. Getting Started Being Active, Losing Weight and Managing Stress~I Negative Thoughts and Emotions~G Where's the Fat?/Three Ways to Eat Less Fat~G Taking Your Medications/Stress and You Bi weekly~G Move Those Muscles/Being Active: A Way of Life~G Challenging and Changing Negative Thoughts~G Healthy Eating~G Problem Solving Monthly~G Four Keys to Healthy Eating Out~G Social Support/Communication~G Take Charge of What's Around You/Tip the Calorie Balance~G The Slippery Slope of Lifestyle Change~G Jump Start Your Activity Plan~G Assertiveness/Make Social Cues Work for You.~G You Can Manage Stress~G Life Goals~G Ways to Stay Motivated Abbreviations: I = Individual session; G = Group session"
3122262|NCT01739192|Placebo Comparator|Arm 1|Placebo oral daily for approximately six (6) weeks.
3122263|NCT01739192|Experimental|Arm 2|Naltrexone (25 mg) oral daily for approximately six (6) weeks.
3122265|NCT01739179||1|VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter
3122266|NCT01739179||2|VP Shunt Surgery for open insertion of the peritoneal catheter
3122267|NCT01739166|Experimental|Practice-tailored intervention - Early/Phase 1|During the 6 month Intervention Phase the Practice Facilitator works with each practice to create changes that are tailored to their individual preferences and methods of operation. Sites randomized to Early/Phase 1 start their 6 month intervention immediately after randomization.
3122268|NCT01739166|Experimental|Practice-tailored intervention - Late/Phase 2|The Phase 2 group will start the practice-tailored intervention with the study facilitator 4 months post-randomization and continue through post-randomization month 10.
3122269|NCT01739153|Experimental|CARB diet|The CARB diet will be a low-fat diet where cheese is replaced by starchy carbohydrates and lean meat. The CARB diet will have the same protein content (15 E%) and quality as the CHEESE and MEAT diet but a lower fat content (approx. 25 E%) and a correspondingly higher carbohydrate content (approx. 60 E%).
3122270|NCT01739153|Experimental|CHEESE diet|The CHEESE diet will contain cheese in amounts corresponding to 120 g/day on a 10 MJ diet (approx. 1.8 MJ from cheese). A high dose of cheese is chosen to provoke effects within this short time frame. The cheese types used in this study will be Danbo (45+) and Cheddar (50+) which will be supplied in equal amounts. The CHEESE diet will have the same macronutrient composition as that of the average Danish diet (15 E% from protein, max 35 E% from fat, and max 15 E% from saturated fat).
3122271|NCT01739153|Experimental|MEAT diet|The MEAT diet will be a diet without dairy products. In this diet cheese is mainly replaced by high-fat mixed meat products to achieve saturated fat content and protein quality similar to that of the CHEESE diet. The MEAT diet will have the same macronutrient composition as that of the average Danish diet (15 E% from protein, max 35 E% from fat, and max 15 E% from saturated fat).
3122272|NCT01739140|Experimental|Yoga|Study Participants will receive: 12 weekly yoga classes, a book and a home practice audio recording.
3122273|NCT01739127||Aripiprazole|Participants receiving treatment with at least 10mg aripiprazole per day, as prescribed to them by their psychiatrists.
3122274|NCT01739127||Risperidone/Quetiapine|Participants receiving treatment with either risperidone or quetiapine, as prescribed to them by their psychiatrists.
3122275|NCT01739127||Control|Healthy participants who are not taking any antipsychotic medications.
3122276|NCT01739114|Experimental|"SI group"|"Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cm H2O.~After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cm H2O and PEEP of 5 cm H2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided."
3122277|NCT01739114|Active Comparator|IPPV group|"Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided."
3122278|NCT01739101|Experimental|Intervention group|The intervention group answered a baseline questionnaire in the waiting room and received the intervention (Reproductive Life Plan) in addition to standard care.
3122279|NCT01739101|No Intervention|Control group 1|The control group 1 answered a baseline questionnaire in the waiting room and received standard care.
3122280|NCT01739101|No Intervention|Control group 2|The control group 2 received standard care.
3122281|NCT01739088|Experimental|Remote ischemic preconditioning stimulus|The remote ischemic pre-conditioning arm of the study is the experimental one. Patients in this arm will receive a remote ischemic pre-conditioning stimulus at 24-48 hours pre-operatively, and again intra-operatively before CPB.
3122282|NCT01739088|Sham Comparator|Sham Ischemic Pre-conditioning|In the control (sham-RIPC) group the cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the the control group.
3122283|NCT01739062|Experimental|Genetic risk assessment|At least 40 SNP (single nucleotide polymorphisms)increase the risk of PCa. The individual risk of PCa accumulates with the increasing number of these genetic variants. The risk is doubled if patient has familial disposition as well. In retrospective studies, non-genetic risk-prediction models were compared to risk-prediction models containing both non-genetic factors and SNPs analyses. The genetic models had a significantly higher specificity than the non-genetic models. It has been argued that genetic PCa risk assessment could reduce the inexpedient use of PSA tests, saving it for patients at high risk of PCa.
3122284|NCT01739062|No Intervention|Familial disposition risk assessment|
3122285|NCT01739049|Experimental|Liraglutide and lifestyle counselling|"Liraglutide 0.6mg od for 1st week, then 1.2mg od for 2nd week then 1.8mg od until 12 weeks.~Diet and Exercise"
3122286|NCT01739049|Active Comparator|Lifestyle counselling|Diet and Exercise
3122287|NCT01739036|Active Comparator|Group 4|Unvaccinated control volunteers who undergo controlled human malaria infection.
3122288|NCT01739036|Active Comparator|Group 3|Controlled human malaria infection administered at an interval of approximately 8-12 months after the initial controlled human malaria infection that the volunteers received in the VAC045 clinical trial.
3122289|NCT01739036|Active Comparator|Group 2|Intramuscular administration of a mixture of ChAd63 ME-TRAP 5 x 1010 vp and ChAd63 CS 5 x 1010 vp and ChAd63 AMA1 5 x 1010 vp followed by intramuscular administration of a mixture of MVA ME-TRAP 1.33 x 108 pfu and MVA CS 1.33 x 108 pfu and MVA AMA1 1.33 x 108 pfu eight weeks later, followed by controlled human malaria infection 17-24 days later.
3122290|NCT01739036|Active Comparator|Group 1|Intramuscular administration of a mixture of ChAd63 ME-TRAP 5 x 1010 vp and ChAd63 CS 5 x 1010 vp, followed by intramuscular administration of a mixture of MVA ME-TRAP 2 x 108 pfu and MVA CS 2 x 108 pfu eight weeks later, followed by controlled human malaria infection 17-24 days later.
3122291|NCT01739023|Experimental|Autologous Human Schwann Cells|
3122292|NCT01738997|Experimental|Group A|Dilation 10 sec
3122293|NCT01738997|Active Comparator|Group B|Dilation 2 min
3122338|NCT01738737|Experimental|Active Laser|Application of active laser only during 24 sessions
3122339|NCT01738737|No Intervention|Control|Control group that will receive a small book with informations about knee osteoarthritis and postural orientation.
3122340|NCT01738724|Experimental|Dienogest|Dienogest 2mg pills daily during 6 months
3122294|NCT01738984|Experimental|MomZing Web Program|Features include selection one to three 10-minute videos demonstrating yoga, aerobics, and strengthening, specifically designed for mothers with infants 2 to 8 months of age. Women will sequence together videos personalized to their fitness level, preference for exercise type, and a choice to actively exercise with her baby or alone. Exercises with a baby will be tailored to the infant's weight and include interactions that promote cognitive development and mother-child bonding.
3122295|NCT01738984|Experimental|Standard exercise DVD|Exercise DVD that demonstrates yoga or strengthening exercises a mother can perform with her infant.
3122296|NCT01738971|No Intervention|control (standard care)|standard verbal and written advice on contraception from pharmacy
3122297|NCT01738971|Experimental|rapid access|rapid access to family planning service
3122298|NCT01738971|Experimental|progestogen only pill|one month progestogen only pill
3122299|NCT01738958|Active Comparator|Probiotic lactobacilli|L. reuteri, two times a day for 6 weeks
3122300|NCT01738958|Placebo Comparator|Placebo|Placebo tablets, two times a day for 6 weeks
3122301|NCT01738945|Other|Amlodipine|Amlodipine 10 mg/day for 12 weeks
3122302|NCT01738932||Patients|women with histologically verified endometriosis
3122303|NCT01738932||Controls|Healthy Danish blood donors
3122304|NCT01738919|Active Comparator|Non-subluxated - splinting|Conservative treatment with splinting for 6 weeks.
3122305|NCT01738919|Active Comparator|Non-subluxated - operation|Operative treatment with extension block technique
3122306|NCT01738906|Experimental|Alcohol placebo and MSF|175 mL orange juice with 31 g Fantomalt maltodextrin and modified sham feeding of 40 g butter cake
3122307|NCT01738906|Experimental|Alcohol and MSF|65 mL vodka with 135 mL orange juice (ca 20 g alcohol)and modified sham feeding of 40 g butter cake
3122308|NCT01738906|Experimental|Alcohol placebo and consumption|175 mL orange juice with 31 g maltodextrin and consumption of 40 g butter cake
3122309|NCT01738906|Experimental|Alcohol and consumption|65 mL vodka with 135 mL orange juice and consumption of 40 g butter cake
3122310|NCT01738906|Experimental|Alcohol placebo and control|175 mL orange juice with 31 g maltodextrin and no oral exposure to butter cake
3122311|NCT01738906|Experimental|Alcohol and control|65 mL vodka with 135 mL orange juice and no oral exposure to butter cake
3122312|NCT01738893|Experimental|A (test)/ B (reference)|initial administration of test and cross-over to reference
3122313|NCT01738893|Experimental|B (reference/ A (test)|initial administration of reference and cross-over to test
3122314|NCT01738880|Active Comparator|group C|intraoperative fluid management based on CVP
3122315|NCT01738880|Experimental|group S|intraoperative fluid management based on SVV
3122316|NCT01738867|Placebo Comparator|Treatment A|Subject will receive oral dose of matching placebo once daily for 5 days in one of the 3 treatment periods.
3122317|NCT01738867|Experimental|Treatment B|Subject will receive 25 mg orally once daily for the first two days and 50 mg once daily for 3 days in one of the 3 treatment periods.
3122318|NCT01738867|Experimental|Treatment C|Subject will receive 10 mg orally once daily for 5 days in one of the 3 treatment periods.
3122319|NCT01738854|Experimental|intra-cuff pressure 40 cmH2O|
3122320|NCT01738854|Active Comparator|intra-cuff pressure 60 cmH2O|
3122321|NCT01738854|Active Comparator|intra-cuff pressure 80 cmH2O|
3122322|NCT01738841||Cohort Group|Children aged 12 months to 12 years will receive Priorix-Tetra as prescribed by the physician.
3122323|NCT01738828||Subjects with CAD|
3122324|NCT01738828||Subjects without CAD|
3122325|NCT01738815|Experimental|valproic acid|Patients will be administered valproic acid (Depakote ER) for up to 30 days prior to tumor resection
3122326|NCT01738802|Experimental|Anti-oxidant and micronutrient|This group will take the anti-oxidant and micronutrient supplement.
3122327|NCT01738802|Placebo Comparator|Placebo|This group will take the placebo.
3122328|NCT01738776||Cases|Hip fracture patients participating in a randomised controlled trial (RCT) of orthogeriatric care (ClinicalTrials.gov NCT01009268)
3122329|NCT01738776||Controls|A group of voluntary elderly persons without a history of hip fracture, recruited specifically for this purpose
3122330|NCT01738763|Experimental|Low dose (2.5 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
3122331|NCT01738763|Experimental|Intermediate dose (4.0 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
3122332|NCT01738763|Experimental|High dose (6.0 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
3122333|NCT01738750|Experimental|Cost Information Included|Group of patients that will receive cost information for both the laparoscopic and open surgical procedures prior to choice of procedure.
3122334|NCT01738750|No Intervention|No Cost Information Included|Group of patients that will not receive cost information for the laparoscopic and open surgical procedures prior to choice of procedure.
3122335|NCT01738737|Experimental|Stretching|Seven stretching exercises for lower limbs during 24 sessions
3122336|NCT01738737|Experimental|Placebo laser + Stretching|application of placebo laser therapy during nine sessions plus stretching exercises during 24 sessions
3122337|NCT01738737|Experimental|Active laser + Stretching|application of active laser therapy during nine sessions plus stretching exercises during 24 sessions
3122341|NCT01738724|Experimental|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
3122342|NCT01738724|Active Comparator|Desogestrel|Desogestrel 75mcg pills daily during six months
3122343|NCT01738711|Active Comparator|Cognitive Behavioural Therapy|Patient in this arm receive 2-6 sessions of cognitive behavioural therapy
3122344|NCT01738711|Placebo Comparator|Written information on CBT|Patients in this arm do not receive sessions of CBT but receive written information on anxiety control as per standard practice
3122345|NCT01738698|Experimental|SPD489 40mg|
3122346|NCT01738698|Experimental|SPD489 100mg|
3122347|NCT01738698|Experimental|SPD489 160mg|
3122348|NCT01738698|Placebo Comparator|Placebo|
3122349|NCT01738685|Other|Control.|Nutritional Education.
3122350|NCT01738685|Other|Behavioral Intervention|Behavioral Intervention.
3122351|NCT01738672|Experimental|Nitrous Oxide|Parturients who request labor analgesia will be offered inhaled nitrous oxide for labor analgesia.
3122352|NCT01738659|Experimental|normal sodium diet (120 mmol/die)|active comparator: low sodium diet (80 mmol/die)
3122353|NCT01738646|Experimental|Vorinostat & Bevacizumab|Patients will be administered bevacizumab every 2 weeks and vorinostat will be taken on days 1-7 and 15-21 of each 28-day cycle at 400 mg per day.
3122354|NCT01738633|Experimental|nutritional + respirology counseling|patients will receive both nutritional and respirology counseling
3122355|NCT01738633|Experimental|nutritional counseling|patients will receive nutritional counseling alone
3122356|NCT01738633|Experimental|respirology counseling|patients will receive respirology counseling alone
3122357|NCT01738633|No Intervention|standard care|patients will receive standard care
3122358|NCT01738620|Experimental|psychological counseling+prevention of sleep disorders in ICU|patients will receive both psychological counseling and interventions to prevent sleep disorders during their ICU stay
3122359|NCT01738620|Experimental|psychological counseling|patients will receive psychological counseling
3122360|NCT01738620|Experimental|prevention of sleep disorders in ICU|interventions to prevent sleep disorders during their ICU stay
3122361|NCT01738620|No Intervention|standard care|patients will receive standard care
3122362|NCT01738607|Placebo Comparator|Placebo|"basic recipe for juice and muffin recipe~abbreviated PLB"
3122363|NCT01738607|Experimental|Carboxymethylcellulose|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated CMC"
3122364|NCT01738607|Experimental|Gum Arabic|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated GA"
3122365|NCT01738607|Experimental|Psyllium|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated as PSY"
3122366|NCT01738594|Experimental|Arm A (carfilzomib)|Patients receive carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16.
3122367|NCT01738594|Experimental|Arm B (carfilzomib, romidepsin)|Patients receive carfilzomib as in Arm A and romidepsin IV over 4 hours on days 1, 8, and 15.
3122368|NCT01738581|Experimental|rTMS + SMR, then rTMS + CTL|First phase of treatment: Repetitive transcranial magnetic stimulation (rTMS) and sensorimotor retraining (SMR). Second phase of treatment: rTMS and control treatment (CTL) (CTL therapy consisted of non-specific therapy that includes stretching, massage, range of motion).
3122369|NCT01738581|Experimental|rTMS + CTL, then rTMS + SMR|First phase of treatment: Repetitive transcranial magnetic stimulation (rTMS) with non-specific therapy that includes stretching, massage, range of motion. Second phase of treatment: rTMS and sensorimotor retraining (SMR).
3122370|NCT01738568|Experimental|Exercise|Aerobic exercise
3122371|NCT01738555|Experimental|amdoxovir 300 mg bid|in combination with zidovudine 300 mg bid and lopinavir/ritonavir (400 mg/100 mg bid) for 36 weeks.
3122372|NCT01738555|Experimental|amdoxovir 500 mg bid|in combination with zidovudine 300 mg bid and lopinavir/ritonavir (400 mg/100 mg bid) for 36 weeks.
3122373|NCT01738542|Experimental|Antiaggregants & Statins & Antihypertensives & Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks) plus Antiaggregant therapy (AAS 100mg/d or Clopidogrel 75mg/d), Statins and Antihypertensive therapy
3122374|NCT01738542|Active Comparator|Antiaggregants & Statins & Antihypertensives|Antiaggregant therapy (AAS 100 mg/d or Clopidogrel 75 mg/d), Statins, Antihypertensive therapy
3122375|NCT01738529|Active Comparator|CLE ileocolonoscopy on Crohn patients|Patients known with Crohn´s disease
3122376|NCT01738529|Sham Comparator|CLE ileocolonoscopy on control patients|CLE ileocolonoscopy on patients without known IBD
3122377|NCT01738516|Other|epileptic patients|Electroencephalography
3122378|NCT01738516|Other|Healthy Volunteers|Electroencephalography and additional experimental tasks
3122379|NCT01738503|Experimental|(8 mg) RBP-6000: 50 mg|Participants are stabilized by day -5 on Subutex 8 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 50 mg are given at 28 day intervals.
3122380|NCT01738503|Experimental|(12 mg) RBP-6000: 100 mg|Participants are stabilized by day -5 on Subutex 12 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 100 mg are given at 28 day intervals
3122381|NCT01738503|Experimental|(24 mg) RBP-6000: 200 mg|"Participants are stabilized by day -5 on Subutex 24 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 200 mg are given at 28 day intervals.~Participants who receive RBP-6000 containing 200 mg buprenorphine and reach Day 112 (and have received all 4 planned SC injections) have the option to participate in the Positron Emission Tomography (PET) Pilot substudy. In the PET Pilot sub-study participants remain on 200 mg SC injections at 28 day intervals for an additional 6-9 intervals until they complete an magnetic resonance imaging (MRI) and a PET scan and pharmacokinetic samples at week 1 and week 4 post injection."
3122382|NCT01738503|Experimental|(8 mg) RBP-6000: 100 mg|Participants are stabilized by day -5 on Subutex 8 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 100 mg are given at 28 day intervals.
3122449|NCT01738074|Experimental|trivalent rotavirus genetic reassortment vaccine|2ml of rotavirus genetic reassortment vaccine by mouth every month for three month
3165952|NCT01439971|Experimental|3|
3122383|NCT01738503|Experimental|(14 mg) RBP-6000: 200 mg|"Participants are stabilized by day -5 on Subutex 14 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 200 mg are given at 28 day intervals.~Participants who receive RBP-6000 containing 200 mg buprenorphine and reach Day 112 (and have received all 4 planned SC injections) have the option to participate in the Positron Emission Tomography (PET) Pilot substudy. In the PET Pilot sub-study participants remain on 200 mg SC injections at 28 day intervals for an additional 6-9 intervals until they complete an magnetic resonance imaging (MRI) and a PET scan and pharmacokinetic samples at week 1 and week 4 post injection."
3122384|NCT01738503|Experimental|(8-24 mg) RBP-6000: 300 mg|Participants are stabilized by day -5 on a Subutex between 8-24 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 300 mg are given at 28 day intervals.
3122385|NCT01738490|Other|Wide diameter implant|Bone anchored hearing implant For the wide diameter arm (test group), the Ponto wide implant (diameter 4,5mm, length 4mm) and abutment 6mm developed by Oticon Medical AB (Gothenburg, Sweden) will be installed.
3122386|NCT01738490|Other|Control group|Bone anchored hearing implant For the control group, the previous generation Ponto implant (diameter 3,75mm, length 4mm) and 6mm abutment (Oticon Medical AB, Gothenburg, Sweden) will be installed.
3122387|NCT01738477|Experimental|Boostrix Group 2|Healthy male of female subjects, aged 19 to 30 years of age at the time of booster vaccination, who were randomized to the Lot A, Lot B or Lot C groups in study NCT00109330, received a second dose of Boostrix in this study.
3122388|NCT01738477|Active Comparator|Boostrix Group 1|Healthy male of female subjects, aged 19 to 30 years of age at the time of booster vaccination, who received Massachusetts Public Health Biologic Laboratories combined tetanus and diphtheria vaccine in study NCT00109330, received the first dose of Boostrix in this study.
3122389|NCT01738464||Pelvic Pain|Interstitial Cystitis or Chronic Prostatitis/Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, and Overactive Bladder patients will be compared to Healthy and Depressed patients.
3122390|NCT01738464||Controls|Healthy patients will be used as controls to compare to patients diagnosed with Interstitial Cystitis, Chronic Prostatitis, Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, Overactive Bladder, and Depressed patients.
3122391|NCT01738464||Major Depression|Major Depression patients will be compared to Controls and Pelvic Pain cohorts.
3122392|NCT01738451|Experimental|Part 1(Cohort 1): GSK2118436 225 mg|GSK2118436 (3 capsules of 75 mg) will be administered orally at the dose of 225 mg BID from Day 1 to 7 (and single dose on Day 8) under fasted conditions, either 1 hour before or 2 hours after a meal.
3122393|NCT01738451|Experimental|Part 1(Cohort 2): GSK2118436 300 mg|GSK2118436 (4 capsules of 75 mg) will be administered orally at the dose of 300 mg BID from Day 1 to 7 (and single dose on Day 8) under fasted conditions, either 1 hour before or 2 hours after a meal. If 225 mg BID is not tolerated in Part 1 /Cohort 1, then Part 1/Cohort 2 will not be initiated and 150 mg BID will be used in Part 2.
3122394|NCT01738451|Experimental|Part 2: GSK2118436 300 mg (or highest tolerated dose)|Subjects will receive a single dose of GSK2118436/placebo (4 capsules of 75 mg/highest tolerated dose) orally on the first 2 days of the study followed by 2 doses daily for 6 days and a single dose on the 9th day. There will be 1 day when a placebo will be given. All doses will be administered under fasted conditions, either 1 hour before or 2 hours after a meal.
3122395|NCT01738438|Experimental|Cabozantinib|Cabozantinib was given at a dose of 60 mg orally once per day for 21 day cycles. Treatment continued in the absence of disease progression or unacceptable toxicity.
3122396|NCT01738425|Experimental|GIC-1001 oral tablets|GIC-1001; 125 mg oral tablets; Single ascending doses (SAD) from 125 mg to 1000 mg; multiple ascending dose (MAD) from 125 mg to 500 mg TID over 7 successive days
3122397|NCT01738425|Placebo Comparator|GIC-1001 matching placebo|Matching placebo, single or multiple dosing
3122398|NCT01738412||Study population|Stroke patients
3122399|NCT01738399|Experimental|Coffee|Subjects take 4 cups of coffee mix per day for 24 weeks
3122400|NCT01738399|Placebo Comparator|Placebo|Subjects take 4 cups of placebo per day for 24 weeks
3122401|NCT01738360|Experimental|Arsenic trioxide|Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day).
3122402|NCT01738347|Experimental|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
3122403|NCT01738334|Active Comparator|Healthy subjects|"The active control group of healthy individuals was subjected to the practice of meditation for eight weeks."
3122404|NCT01738334|No Intervention|Standby|The control group of participants (patients and healthy subjects) who was not practice anything for eight weeks.
3122405|NCT01738334|Experimental|Meditation|A Group of Patients with ADHD was participate of the meditation practices for eight weeks.
3122406|NCT01738321||Cardiac patients|Patients undergoing cardiac surgery
3122407|NCT01738321||Non-cardiac patients|Patients undergoing any surgery other than cardiac surgery
3122408|NCT01738308|Experimental|Healing Touch Treatment|"Healing Touch Treatment~When enter PACU + usual standard of care.~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,"
3122409|NCT01738308|Sham Comparator|Sham Healing Touch Treatment|Usual standard of post operative care plus a sham Heal Touch treatment upon entering the post anesthesia care unit. Treatment done by untrained study staff using same hand locations.
3122410|NCT01738308|No Intervention|Control- No treatment done|Usual standard of post operative care with no additional intervention
3122411|NCT01738295|Active Comparator|Donepezil|Donepezil administration. In this group Donepezil (Aricept pill, 5 mg) will be orally administrated 3h before each experiment (1 week intervals)
3122412|NCT01738295|Placebo Comparator|Lactose pill|Placebo administration. In this group, placebo (lactose pill) will be orally administrated 3h before each experiments (1 week intervals)
3122450|NCT01738074|Placebo Comparator|Placebo|2ml of placebo by mouth every month for three month
3122413|NCT01738282|Experimental|Baclofen|Baclofen 20mg tablet. Titration:increasing dosage regimen to reach the target dosage of 180 mg (9 tablets)in 7 weeks Maintenance period with a constant dosage during 17 weeks Progressive decrease and stop of study treatment in 2 weeks
3122414|NCT01738282|Placebo Comparator|Placebo|Placebo tablet Titration:increasing dosage regimen to reach the target dosage of 9 tablets in 7 weeks Maintenance period with a constant dosage during 17 weeks Progressive decrease and stop of study treatment in 2 weeks
3122415|NCT01738269||Apparently healthy subjects|
3122416|NCT01738269||Non-malignant conditions subjects|
3122417|NCT01738269||Malignant conditions subjects|
3122418|NCT01738256|Experimental|Face-to-Face|Group meetings face-to-face using intervention for wellbeing with ACT principles.
3122419|NCT01738256|Experimental|Mobile|Intervention for wellbeing via mobile phone application with ACT principles.
3122420|NCT01738256|Experimental|Internet|Intervention for wellbeing via Internet (Virtual Health Check and Coaching).
3122421|NCT01738256|Experimental|Control|Control group, no intervention.
3122422|NCT01738243|Experimental|Unilateral Upper Eyelid Retraction|"This arm will consist of participants with unilateral upper eye lid retraction secondary to thyroid eye disease (TED).~Patients enrolled will be randomized 1:1 to Hyaluronic Acid Gel Injection or Saline injection"
3122423|NCT01738243|Experimental|Bilateral Upper Eyelid Retraction|"This arm will consist of participants with bilateral upper eye lid retraction secondary to thyroid eye disease (TED).~Patients enrolled will be randomized 1:1 to Hyaluronic Acid Gel injection or Saline injection"
3122424|NCT01738217|Experimental|Fluobeam|
3122425|NCT01738204||Females with endometriosis|Females with a surgical diagnosis of endometriosis or who undergoing surgery for suspected endometriosis. At this time, we are only recruiting patients of Boston Children's Hospital and Brigham and Women's Hospital for this group.
3122426|NCT01738204||Females without surgical diagnosis of endometriosis|Females do not need to be patients of Boston Children's Hospital or Brigham and Women's Hospital.
3122427|NCT01738191|Active Comparator|Atomoxetine|The study drug target dose is Atomoxetine (ATM) 80 milligram (mg) per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
3122428|NCT01738191|Placebo Comparator|Placebo|Patients in the placebo arm will follow the same titration schedule as those in the active arm. Patients will titrate up to target dose by starting 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose to 80mg daily.
3122429|NCT01738178|Placebo Comparator|Control - Placebo|These participants will receive placebo tablets during the first 5 years
3122430|NCT01738178|Active Comparator|Caffeine group|This group of participants will receive caffeine tablets.
3122431|NCT01738165|Experimental|KineSpring System|Surgical intervention In this single arm study, the KineSpring System will be surgically implanted in up to 110 study patients.
3122432|NCT01738152|Experimental|HLA treatment|This is a single arm prospective longitudinal clinical trial investigating the feasibility of a hyaluronic acid (HLA) vaginal gel (HyaloGYN®; Cebert Pharmaceuticals, Inc.; Birmingham, Alabama) to improve estrogen deprivation vaginal and vulvar health symptoms in post-menopausal women with a history of hormone-receptor positive cancer with estrogen deprivation symptoms of vaginal dryness and discomfort.
3122433|NCT01738139|Experimental|Ipilimumab + Imatinib Mesylate|The dose escalation portion of this study will consist of an initial daily oral administration of imatinib mesylate 400 mg alone for 14 days. A single Ipilimumab treatment 1 mg/kg given on day 15 will be added to daily imatinib mesylate therapy. Dose escalation group first study cycle is 35 days. Each cycle after that is 21 days. Cycles repeated every 21 days for 4 cycles until disease progression or development of intolerable toxicities, and a post-treatment visit.
3122434|NCT01738139|Experimental|KIT Confirmed GIST - Expansion Cohort|"Expansion cohort uses the MTD determined by the dose escalation study to treat participants.~Cycles repeated every 21 days for 4 cycles until disease progression or development of intolerable toxicities, and a post-treatment visit."
3122435|NCT01738139|Experimental|Melanoma - Expansion Cohort|"Expansion cohort uses the MTD determined by the dose escalation study to treat participants.~Cycles repeated every 21 days for 4 cycles until disease progression or development of intolerable toxicities, and a post-treatment visit."
3122436|NCT01738139|Experimental|Other Uncategorized Solid Tumors - Expansion Cohort|"Expansion cohort uses the MTD determined by the dose escalation study to treat participants.~Cycles repeated every 21 days for 4 cycles until disease progression or development of intolerable toxicities, and a post-treatment visit."
3122437|NCT01738113|Experimental|open kinetic chain exercise|Open kinetic chain exercise
3122438|NCT01738113|Experimental|Closed Kinetic chain exercise|Closed kinetic chain exercise
3122439|NCT01738100|Experimental|Ticagrelor + Intracoronary Morphine|180 mg loading pre-PCI followed by 90 mg bid for 5 days. Intracoronary Morphine Sulfate 3 mg + Saline 3 ml mix.
3122440|NCT01738100|Experimental|Ticagrelor + Intracoronary Saline|180 mg loading pre-PCI followed by 90 mg bid for 5 days. Saline 3 ml intracoronary injection.
3122441|NCT01738100|Experimental|Clopidogrel + Intracoronary Morphine|600 mg loading pre-PCI followed by 75 mg qd for 5 days. Morphine Sulfate 3 mg + Saline 3 ml mix intracoronary injection.
3122442|NCT01738100|Active Comparator|Clopidogrel + Intracoronary Saline|600 mg loading pre-PCI followed by 75 mg qd for 5 days. Saline 3 ml intracoronary injection.
3122443|NCT01738087|Experimental|NEXThaler 100/6 mcg DPI|Single dose (4 inhalations)of NEXThaler 100/6 mcg DPI: total dose 400/24 mcg
3122444|NCT01738087|Experimental|NEXThaler 200/6 mcg DPI|Single dose (4 inhalations)of NEXThaler 200/6 mcg DPI: total dose: 800/24 mcg
3122445|NCT01738087|Placebo Comparator|NEXThaler placebo|Single dose (4 inhalations)
3122446|NCT01738087|Experimental|NEXThaler 100/6 mcg plus CB|Single dose (4 inhalations) NEXThaler 100/6 mcg administered with activated charcoal (Charcoal Block): total dose 400/24 mcg
3122447|NCT01738087|Experimental|NEXThaler 200/6 mcg plus CB|Single dose (4 inhalations) NEXThaler 200/6 mcg administered with activated charcoal (Charcoal Block): total dose 800/24 mcg
3122448|NCT01738087|Active Comparator|Flixotide Accuhaler 500 mcg|Single dose (2 inhalations) of fluticasone propionate
3122451|NCT01738061|No Intervention|reference group|They continued their daily routine.
3122452|NCT01738061|Experimental|Multidimensional lifestyle intervention|The multidimensional lifestyle intervention program received motivational activities to improve awareness of the impact of lifestyle on chronic diseases and the importance of self-health management.
3122453|NCT01738048||Mastectomy|Patients treated with mastectomy without reconstruction
3122454|NCT01738048||Reconstruction|Patients treated with mastectomy followed by reconstruction
3122455|NCT01738035|Experimental|NEFECON 8 mg/day|NEFECON 8 mg/day (2 active + 2 placebo capsules daily) for 9 months
3122456|NCT01738035|Experimental|NEFECON 16 mg/day|NEFECON 16 mg/day (4 active capsules daily) for 9 months
3122457|NCT01738035|Placebo Comparator|Placebo|Placebo (4 placebo capsules daily) for 9 months
3122458|NCT01738022|Experimental|Gas mixture administration|Subjects will breathe different gas mixtures with different densities and viscosity for brief periods in order to promote changes in peak inspiratory flow
3122459|NCT01738009|Experimental|Induction of flow limitation|Flow limitation will be induced by sustained reductions in continuous positive airway pressure during sleep
3122460|NCT01737996|Experimental|All patients|For the first 9 days patients receive BI 207127 low dose or high dose, then BI 207127 high dose with faldaprevir
3122461|NCT01737983|Experimental|Lactobacillus reuteri (LR) ATCC55730|The tested probiotic, Lactobacillus reuteri, was administered in 5 drops per day (10^10 colony-forming units) for 6 months
3122462|NCT01737983|Placebo Comparator|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation for 6 months During the test period, patients were not allowed to consume any other product that contained probiotics or prebiotics
3122463|NCT01737957|Experimental|Low-fluence|Low-fluence pan-retinal photocoagulation in a single session for proliferative diabetic retinopathy
3122464|NCT01737957|Active Comparator|Full-fluence|Full-fluence pan-retinal photocoagulation for proliferative diabetic retinopathy
3122465|NCT01737944|Experimental|10mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
3122466|NCT01737944|Experimental|15mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
3122467|NCT01737944|Experimental|20mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
3122468|NCT01737944|Experimental|25mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
3122469|NCT01737931|Experimental|Topical Steroid|Topical medication of steroid (Dexamethasone) to the application sites after the patch removal
3122470|NCT01737931|Experimental|Topical antihistamine|Topical medication of antihistamine(Diphenhydramine) to the application sites after the patch removal
3122471|NCT01737931|No Intervention|No-treatment|No treatment to the application sites after the patch removal
3122472|NCT01737918|Experimental|trans obturatorial tape (TOT)|placement of a sub-urethral tape
3122473|NCT01737918|Active Comparator|solifenacin|10 mg per day
3122474|NCT01737905|Experimental|Arm T|Experimental arm utilizing Epinephrine HFA-MDI (E004)
3122475|NCT01737905|Placebo Comparator|Arm P|Placebo comparator arm utilizing Placebo-HFA
3122476|NCT01737892|Experimental|Arm T-Epinephrine Inhalation Aerosol HFA|Experimental arm utilizing Epinephrine HFA-MDI (E004)
3122477|NCT01737892|Active Comparator|Arm C-Epinephrine Inhalation Aerosol CFC|Active comparator arm utilizing Epinephrine CFC-MDI
3122478|NCT01737879|Experimental|Peginesatide / Epoetin Alfa|Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks.
3122479|NCT01737866|Experimental|Group 1|End Stage Renal Diseas (ESRD) requiring hemodialysis
3122480|NCT01737866|Experimental|Group 2|Normal renal function (eGFR >or = 80mL/min/1.73m^2)
3122481|NCT01737866|Experimental|Group 3|Mild decrease in GFR (eGFR 60-79 mL/min/1.73m^2)
3122482|NCT01737866|Experimental|Group 4|Moderate decrease in GFR (eGFR 30-59 mL/min/1.73m^2)
3122483|NCT01737866|Experimental|Group 5|Severe decrease in GFR (eGFR 15-29 mL/min/1.73m^2)
3122484|NCT01737866|Experimental|Group 6|Normal renal function (eGFR >or = 80mL/min/1.73m^2)
3122485|NCT01737853||Ganfort's Group|"Ganfort® QD for patients under Krytantek®~For patients assigned to the Ganfort's group, instructions for applying one drop QD (8:00 PM ± 30 minutes)"
3122486|NCT01737853||Krytantek's Group|"Krytantek® BID for patients under Ganforti®~For patients assigned to the Krytantek's group, application schedule will be BID (8:00 AM ± 30 minutes and 8:00 PM ± 30 minutes)"
3122487|NCT01737840|Experimental|pantoprazole|Intravenous pantoprazole 40 mg flacon
3122488|NCT01737840|Active Comparator|ranitidine|Intravenous ranitidine 50 mg
3122489|NCT01737827|Experimental|INC280|The protocol consists of two independent parts (Dose-Determining Part and Dose Expansion Part). Approximately 6 patients will be treated with INC280 300 mg twice a day in the Dose-Determining Part. Approximately 50 patients will be treated with INC280 in the Dose Expansion Part. The dose for the Expansion Part can be lower, equal or higher than in the Dose-Determining Part will be determined after the Dose Determining Part at the dose decision analysis.
3122490|NCT01737814|Experimental|MST-188|MST-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
3122491|NCT01737814|Placebo Comparator|Saline|Saline administered as a continuous infusion for up to 49 hours
3122492|NCT01737801|Experimental|Lung function test|Lung function test
3122493|NCT01737788|Experimental|Therapeutic Trial|Therapeutic cervical cerclage with or without cervical occlusion in women presenting with short cervix (<25mm)
3122494|NCT01737788|Experimental|Prophylactic Trial|Prophylactic cervical cerclage with or without cervical occlusion in women with a history of cervical insufficiency
3122495|NCT01737775|Experimental|Abdominal laparoscopic surgery (C group)|
3122496|NCT01737775|Experimental|Abdominal surgery by laparotomy (L group)|
3122497|NCT01737775|Experimental|Head and neck surgery (O group)|
3122532|NCT01737541|Experimental|Fluoxetine|fluoxetine per os 20 mg daily
3165953|NCT01439971|Experimental|4|
3122498|NCT01737762|Experimental|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 solution) containing 0.5 x 106 cells per mL every 14 days.
3122499|NCT01737762|Placebo Comparator|Vehicle|Vehicle Control(fibrinogen solution & thrombin solution without cells)
3122500|NCT01737749||Patients undergoing cardiac surgery|
3122501|NCT01737736||Patients undergoing cartoid endarterectomy surgery|
3122502|NCT01737723||Study population|Stroke patients
3122503|NCT01737710|Experimental|92 Non-atopic controls vaccinated with Fluzone® Intradermal|Non-atopic controls who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
3122504|NCT01737710|Experimental|Moderate to severe AD vaccinated with Fluzone® Intradermal|92 moderate to severe atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
3122505|NCT01737710|Active Comparator|Moderate to severe AD vaccinated with Fluzone® (Intramuscular)|92 moderate to severe atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® (Intramuscular) influenza vaccine from 0.5 mL single dose vials.
3122506|NCT01737710|Active Comparator|Non-atopic controls vaccinated with Fluzone® (Intramuscular)|20 non-atopic controls who will receive a single dose of the seasonal 2012-2013 Fluzone® (Intramuscular) influenza vaccine from 0.5 mL single dose vials.
3122507|NCT01737710|Experimental|Mild AD participants vaccinated with Fluzone® Intradermal|20 mild atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
3122508|NCT01737697|Experimental|Zirconium silicate (acute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
3122509|NCT01737697|Placebo Comparator|Placebo|Placebo ( silicified microcrystalline cellulose) randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals.
3122510|NCT01737697|Experimental|Zirconium silicate (subacute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
3122511|NCT01737697|Placebo Comparator|Placebo (subacute phase)|Placebo (silicified microcrystalline cellulose) randomized to mimic doses of experimental drug administered once a day (qd) prior to the morning meal for 12 days.
3122512|NCT01737684|Experimental|Participants With Moderate Hepatic Insufficiency|Participants with moderate hepatic insufficiency will receive a single oral dose of vibegron 100 mg.
3122513|NCT01737684|Experimental|Healthy Matched Control Participants|Participants who are healthy will receive a single oral dose of vibegron 100 mg.
3122514|NCT01737684|Experimental|Participants With Mild Hepatic Insufficiency|Participants with mild hepatic insufficiency will receive a single oral dose of vibegron 100 mg.
3122515|NCT01737671|Experimental|Methotrexate Infusion|3 consecutive cycles of intraventricular methotrexate infusions into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle, each cycle is 4 consecutive daily doses of intraventricular methotrexate with minimum 2 weeks between cycles. If any serum methotrexate level is > 0.3 micromolar, then Leucovorin therapy administered (5 mg/square meter per dose) every 6 hours by vein or mouth.
3122516|NCT01737658|Other|Exercise Program upon enrollment|Subject will receive exercise intervention immediately upon enrollment to study
3122517|NCT01737658|Other|Exercise Program 6 months after enrollment|Subject will be enrolled into study and then receive exercise intervention 6 months after enrollment.
3122518|NCT01737645||obese patients|BMI (body mass index) more than or equal to 35 kg/m2 (weight in kilograms divided by the square of the height in metres)
3122519|NCT01737645||Thin patients|BMI less than or equal to 30 kg/m2
3122520|NCT01737632|Experimental|Multidimensional Family Therapy (MDFT)|MDFT is an intensive, in-home family-based drug abuse treatment for adolescent substance abusers. MDFT views family factors in their context -in terms of the network (individual, familial, peer, community) or multiplicity of influences on drug use and change.
3122521|NCT01737632|Other|Adolescent Residential Treatment|"The Adolescent Treatment Program (ATP) is a residential dual diagnosed substance abuse treatment program that is staff secure. It is based on a social learning approach which emphasizes positive reinforcement for appropriate coping behavior and social skills, and incorporates a levels system which allocates privileges and responsibilities according to the individual's behavioral capacities."
3122522|NCT01737619|Other|Sentinel Lymph Node Mapping|"PET/CT prior to surgery. Surgical approach as determined by the primary surgeon.~At time of surgery, an endometrial biopsy will be performed once the patient is under anesthesia. Intra-operative lymphatic mapping with blue dye, radioactive colloid, and/or indocyanine green will be performed. Sentinel lymph nodes will be removed and labeled as blue, green, and/or hot. These nodes will be processed separately."
3122523|NCT01737606|Experimental|echography|Fast Cerebral Pulsatility Imaging
3122524|NCT01737593|Active Comparator|Acetaminophen PR|Acetaminophen PR (20-40mg/kg) after induction of Anesthesia (acetaminophen is in suppository form and given rectally)
3122525|NCT01737593|Active Comparator|Acetaminophen PO-low dose|Acetaminophen PO (10mg/kg) 60-120min before start of BMT placement (acetaminophen is in syrup form and given by mouth)
3122526|NCT01737593|Active Comparator|Acetaminophen PO-high dose|Acetaminophen PO (20mg/kg) 60-120min before start of BMT placement (acetaminophen is in syrup form and given by mouth)
3122527|NCT01737580|Active Comparator|Intanza+resiquimod gel|Intanza 15mcg intradermal injection + resiquimod gel applied to the vaccination site immediately post vaccination.
3122528|NCT01737580|Placebo Comparator|Intanza + placebo gel|Intanza 15mcg intradermal injection + placebo gel applied to the vaccination site immediately post vaccination.
3122529|NCT01737567|Experimental|Bright Narrow Band Imaging|Use of B-NBI to detect colonic adenomas.
3122530|NCT01737567|Active Comparator|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
3122531|NCT01737554||Participants|"Participants include children with cancer and hematologic disorders who, as part of their standard clinical care, have a central venous access device (CVAD) used for infusion, withdrawal of blood, or hemodynamic monitoring.~Intervention: Catheter resistance monitoring"
3122533|NCT01737541|Placebo Comparator|Placebo|per os daily
3122534|NCT01737528||TAVR Patients|Will include all patients 18 years or over who undergo Transcatheter Aortic Valve Replacement (TAVR) for severe aortic stenosis. The sample size will include all patients entered into the Registry.
3122535|NCT01737515||Main group|Consecutive patients undergoing colorectal surgery for benign or malignant colorectal disease without any diversion from the standard of care
3122536|NCT01737502|Experimental|Treatment (auranofin and sirolimus)|Patients receive auranofin PO on days 1-28 and sirolimus PO on days 1-28 (days 8-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3122537|NCT01737489|Active Comparator|LACE ( Listening And Communication Enhancement )|use the commercially available auditory training program which is administered by computer as daily lessons.
3122538|NCT01737489|Active Comparator|NOOK (Electronic reader)|will use an electronic reader (NOOK device) to do speech tracking
3122539|NCT01737489|No Intervention|Control|
3122540|NCT01737476|Sham Comparator|control|control-sham
3122541|NCT01737476|Active Comparator|Deep TMS PFC Lt|Deep TMS PFC left
3122542|NCT01737476|Active Comparator|DEEP TMS PFC Rt|DEEP TMS PFC Rt
3122543|NCT01737476|Active Comparator|Superficial TMS PFC Lt|Superficial TMS PFC Lt
3122544|NCT01737476|Active Comparator|superficial TMS PFC Rt|superficial TMS PFC Rt
3122545|NCT01737463|Active Comparator|Group A|"Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope (JF-240, TJF-240, JF-260, TJF-260; Olympus Optical Co, Ltd, Tokyo, Japan).~A pancreatic duct stent was inserted immediately after the excision."
3122546|NCT01737463|Active Comparator|Group B|"Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope (JF-240, TJF-240, JF-260, TJF-260; Olympus Optical Co, Ltd, Tokyo, Japan).~A pancreatic duct stent was not inserted immediately after the excision."
3122547|NCT01737450|Experimental|BKM120|Full dose=100 mg/day (oral route) One study cycle equals 28 days. Patients will be treated until disease progression, unacceptable toxicity, or willingness to stop.
3122548|NCT01737437|Experimental|group L|10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
3122549|NCT01737437|Placebo Comparator|group C|0.9% normal saline was applied to trachea and laryngoscope blade in Group C.
3122550|NCT01737437|Experimental|group V|0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
3122551|NCT01737437|Experimental|group LV|10% Lidocaine was applied on laryngoscope blade and trachea.
3122552|NCT01737424|Placebo Comparator|Placebo|Placebo
3122553|NCT01737424|Experimental|LC28-0126|LC28-0126(IV)
3122554|NCT01737411|Active Comparator|solifenacin|10 mg solifenacin per day for three months
3122555|NCT01737411|Experimental|cesa/vasa|repair of USL
3122556|NCT01737398|Active Comparator|Inotersen|300 mg inotersen administered subcutaneously (SC) 3 times on alternate days in the first week and then once-weekly for 64 weeks
3122557|NCT01737398|Active Comparator|Placebo|Placebo administered SC 3 times on alternate days in the first week and then once-weekly for 64 weeks
3122558|NCT01737385||Type 1|One segment fracture
3122559|NCT01737385||Type 2|Two segment fracture
3122560|NCT01737385||Type 3|Three segment fracture
3122561|NCT01737385||Type 4|Four segment fracture
3122562|NCT01737372||Secondary Progressive MS (SPMS)|Secondary Progressive MS participants
3122563|NCT01737372||Clinically Isolated Syndrome (CIS)|Clinically isolated syndrome participants
3122564|NCT01737372||Healthy participants|No immunological or neurological illnesses.
3122565|NCT01737359|Experimental|amdoxovir 300 mg bid|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
3122566|NCT01737359|Experimental|amdoxovir 500 mg bid|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
3122567|NCT01737359|Active Comparator|tenofovir DF 300 mg qd|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
3122568|NCT01737346|Experimental|lomustine and procarbazine|1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
3122569|NCT01737320|Experimental|short-course|antibiotic treatment stopped on day 7 if the patient has been afebrile for 48 hours and clinically stable. Continued hospitalization will be left to the discretion of the treating physician. Antibiotics will be restarted if fever recurs in at least 2 consecutive measurements above 38 or in cases of clinically or microbiologically documented infections.
3122570|NCT01737320|Active Comparator|accepted prolonged antibiotic treatment|"antibiotic treatment continued for 14 days according to accepted hospital local guidelines. Duration of hospital stay will also be left to the discretion of the treating physician.~Type of empiric antibiotic treatment and later, specific antibiotic treatment, will be chosen by the treating physicians in consultation with the infectious diseases unit.~The decision on timing of switch to oral antibiotic therapy will also be left to the discretion of the treating physician."
3122571|NCT01737307|Experimental|Fluoride Varnish|Fluoride varnish was used once in this group. Fluoride varnish(NaF 5%,Sultan,USA)
3122572|NCT01737307|Experimental|Oral hygiene|Oral hygiene followed twice daily. No F varnish or CPP-ACP applied.
3122573|NCT01737307|Experimental|CPP-ACP|CPP-ACP paste (GC Tooth Mousse,Gc,USA)was applied by patients once daily. 3gr,for 42 days.
3122574|NCT01737294||Treatment with QUTENZA|Patients with Peripheral Neuropathic Pain
3122575|NCT01737281|Experimental|Proactive outreach|Proactive outreach to deliver 7 sessions of telephone counseling and nicotine replacement therapy.
3122576|NCT01737281|Active Comparator|Usual care|Usual smoking cessation care from clinical staff
3122577|NCT01737268|Experimental|FK949E Elderly Participants|After 2 days of dose-titration, elderly participants received either FK949E 150 mg or FK949E 300 mg once daily at bedtime from day 3 to week 52. Dose increase and reduction was allowed following dose increase or reduction guidelines and at the investigator's discretion. After which, participants went through a follow-up period of 1 week. For participants, who completed or discontinued treatment at FK949E 300 mg, a dose-tapering period was placed before proceeding to the follow-up period, and FK949E 150 mg was administered once daily for 1 week in this period.
3122907|NCT01735149|Experimental|Kochujang Pills|
3122578|NCT01737255||TP53 mutation carriers|Carriers of TP53 mutation not known to be low penetrance
3122579|NCT01737255||Population controls|Population controls will be sex and aged matched (+/- 5 years) to the TP53 mutation carrier group, with no personal history of cancer and no family history of cancer diagnosed under 50 years
3122580|NCT01737229|Experimental|Direct pulp capping/carious exposure|symptomatic (provoked pain) or asymptomatic mature or immature tooth that presented pulp exposure when scraping out carious lesions or performing cavity preparation.
3122581|NCT01737229|Experimental|Direct pulp capping/dental trauma|• Permanent mature or immature single-root tooth having suffered traumatic injury < 72 hours, with amelodentinal coronal fracture causing pulp exposure.
3122582|NCT01737229|Experimental|Repairing root canals/pulp chamber floor|"Iatrogenic perforation of the pulpal floor, with or without LEO.~Iatrogenic perforated root canals following post space preparation involving dentin matrix, with or without LEO.~Iatrogenic perforated root canals with stripping not involving dentin matrix, with or without LEO."
3122583|NCT01737229|Experimental|Retrograde endodontic surgery - adults|"Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, provided that a working coronal restoration is in place.~Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when orthograde retreatment does not offer a more favorable risk-benefit ratio than the surgery option"
3122584|NCT01737229|Experimental|Pulpotomy in primary molars - children (3 to 12 years )|"Molar presenting deep carious lesion without irreversible pulpal disease, as the molar has to stay on the dental arch for at least 3 years.~Pulp exposure during excision of a carious lesion on a temporary molar that does not present irreversible pulp disease. The molar has to stay of the dental arch for at least 3 years."
3122585|NCT01737229|Experimental|Apexification - children (7 to 18 years) + adults|"Permanent immature single-root tooth having suffered periodontal or dentoalveolar injury causing pulp necrosis with or without periapical disease (LEO) in children, teenagers or adult patients.~Permanent immature single-root tooth presenting pulp necrosis with or without periapical disease (LEO) in children.~Apical Root Resorption"
3122586|NCT01737216|Experimental|Zoledronic acid plus First-line chemotherapy|
3122587|NCT01737216|Active Comparator|First-line chemotherapy|
3122588|NCT01737203|Active Comparator|Viagra|Oral tablet of sildenafil citrate (Japanese commercial tablet: Viagra® tablet) 50 mg as a single oral dose under fasted conditions
3122589|NCT01737203|Experimental|ODT without water|Sildenafil ODT 50 mg without water as a single oral dose under fasted conditions
3122590|NCT01737203|Experimental|ODT with water|Sildenafil ODT 50 mg with water as a single oral dose under fasted conditions
3122591|NCT01737190|Experimental|PEEP guided by Esophageal pressure + Recruitment maneuver.|"Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.~A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed."
3122592|NCT01737177|Experimental|Bendamustina, Lenalidomide, Rituximab|1 arm for all patients
3122593|NCT01737164|Experimental|Aerobic Exercise - Older Subjects|Subjects aged 65 and higher will perform 16 weeks of moderate intensity exercise
3122594|NCT01737164|Experimental|Aerobic Exercise - Young Subjects|Subjects 18-30 years old will perform 16 weeks of moderate intensity exercise
3122595|NCT01737151|Active Comparator|Arm I (standard stereotactic body radiation therapy (SBRT)|Patients undergo standard daily fractions of SBRT over 7-8.5 weeks
3122596|NCT01737151|Experimental|Arm II (four fraction split-course SBRT)|Patients undergo 2 fractions of SBRT in weeks 1 and 4
3122597|NCT01737138|Active Comparator|RSD+Medicine|The investigators will recruit 50 randomised CKD patients who meet the inclusion criteria. First undergo renal artery angiography procedure to confirm anatomy. If renal artery meet the inclusion criteria, give the renal sympathetic denervation. At the same time, we will use optimal medication to protect renal function. Then we will conduct a clinic follow-up and a telephone follow-up e(Total 36 months).
3122598|NCT01737138|Placebo Comparator|Medicine|The investigators aslo will recruit 50 randomised CKD patients who meet the inclusion criteria. There are no significant differences in age, gender, race, past medical history,personal history and so on between the two groups. In this group we will use optimal medication just like the RSD+Medicine group. Third we will conduct a clinic and a telephone follow-up(Total 36 months).
3122599|NCT01737112|Experimental|99mTc-3PRGD2 SPECT/CT scanning|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and evaluation of lung cancer patients.
3122600|NCT01737099|Experimental|DHA-O|
3122601|NCT01737099|Active Comparator|Fish oil|
3122602|NCT01737099|Placebo Comparator|Placebo|
3122603|NCT01737086|Experimental|ORS with probiotic and zinc|Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate
3122604|NCT01737086|Placebo Comparator|Standard ORS|Standard oral rehydration solution
3122605|NCT01737073|Experimental|IVR self management|cognitive behavioral based self management training for chronic pain delivered by interactive voice response (IVR)
3122606|NCT01737073|Experimental|Opioid monitoring|monthly interactive voice response (IVR) monitoring of prescription opioid use with feedback to the prescribing physician
3122607|NCT01737073|Experimental|IVR self management plus opioid monitoring|Cognitive behavioral based self management training for chronic pain delivered by IVR plus monthly IVR monitoring of prescription opioid use with feedback to the prescribing physician
3122608|NCT01737073|Other|Enhanced usual care|Weekly automated wellness tips via IVR
3122609|NCT01737060|Active Comparator|Angular stable plate Philos|Open Reduction and Osteofixation with Philos plate and TiCron cerclages
3122610|NCT01737060|Experimental|Reverse Total Shoulder Artroplasty|Intervention group
3122638|NCT01736891|Experimental|Rasagiline|Rasagiline 0.5 mg by mouth every day for 2 weeks, then 1 mg by mouth every day for 12 weeks, then switch to 0.5mg by mouth every day for remainder of the study (approximately 16 weeks total)
3122611|NCT01737047||HIV positive over 50 years of age|"All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.~Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn"
3122612|NCT01737047||HIV positive under the age of 50|"All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.~Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn"
3122613|NCT01737047||HIV negative over the age of 50|All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.
3122614|NCT01737034|Experimental|low GI, low GI|low GI diet (semi starvation phase) followed by low GI diet in the refeeding phase
3122615|NCT01737034|Experimental|low GI, high GI|low GI diet (semi starvation phase) followed by high GI diet in the refeeding phase
3122616|NCT01737034|Experimental|high GI, low GI|high GI diet (semi starvation phase) followed by low GI diet in the refeeding phase
3122617|NCT01737034|Experimental|high GI, high GI|high GI diet (semi starvation phase) followed by high GI diet in the refeeding phase
3122618|NCT01737021|Experimental|Psycho-educational intervention|Psycho-education
3122619|NCT01737021|No Intervention|Treatment as usual|
3122620|NCT01737008|Experimental|Dacomitinib with Radiotherapy|Dacomitinib, 15mg to 45mg orally, once daily. Radiotherapy, once daily (Monday to Friday) over six weeks.One day on weeks 2 to 6 the participants will receive treatment twice daily (bid).
3122621|NCT01737008|Experimental|Dacomitinib and Chemoradiotherapy|Dacomitinib: 15mg to 45mg orally, once daily. Radiotherapy: Once daily (Monday to Friday) over seven weeks. Twice daily (bid) treatments may be introduced to compensate for treatment days missed due to statutory holidays, or machine maintenance. Cisplatin: 100mg/m2 intravenously; weeks 1, 4, and 7.
3122622|NCT01736995|Experimental|Motivational/Cog Beh Tx-Contingency Mgmt|The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior.
3122623|NCT01736995|Experimental|Functional Family Tx- Contingency Mgmt|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers to the family as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior.
3122624|NCT01736995|Experimental|Motivational/Cog Beh Tx|The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention.
3122625|NCT01736995|Experimental|Functional Family Tx|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills.
3122626|NCT01736982|Active Comparator|Standard of Care|transdermal nicotine replacement [21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)], breath sample monitoring, standard smoking cessation counseling
3122627|NCT01736982|Experimental|Standard of Care plus Contingency Management|Standard smoking cessation intervention plus contingency management
3122628|NCT01736969|Experimental|RD047-023|RD-047-023
3122629|NCT01736969|Active Comparator|Predicate Device|legally marketed predicate device
3122630|NCT01736956|Experimental|Fetal Aortic Valvuloplasty|Subjects will undergo fetal aortic valvuloplasty
3122631|NCT01736956|No Intervention|Control|Control group. Will receive standard prenatal and postnatal care.
3122632|NCT01736943|Experimental|Bortezomib + Doxil|Bortezomib will be given subcutaneously at 1.5mg/m2 on days 1, 4, 8 and 11 of a 3 week cycle. Doxil will be administered once every three weeks as a single intravenous infusion at a dose of 40 mg/m2 (day 4 of each cycle).
3122633|NCT01736930|Active Comparator|Predictive pump suspension algorithm|The study laptop will be running actively during the night and suspending the patient's pump if the algorithm predicts hypoglycemia based on the patient's continuous glucose sensor trend.
3122634|NCT01736930|No Intervention|Standard of Care|The control algorithm will run passively and not recommend suspensions or resumption to the patient's pump.
3122635|NCT01736917|Experimental|Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone|"Patients must have no nausea and/or vomiting for 24 hours and must not have used other anti-emetics for 72 hours prior to starting protocol treatment. Treatment must not start until this criteria is satisfied.~Any germ cell chemotherapy regimen utilizing Cisplatin (20mg/m2 x 5 days).~Acute emesis prophylaxis:~Any 5HT3 receptor antagonist may be used D1 - 5 or D1, 3 and 5 if palonosetron is used per institutional standards.~Dexamethasone 20mg PO (orally) daily, D1 and 2~Fosaprepitant 150mg IV on day 3~Delayed emesis prophylaxis:~Fosaprepitant 150mg IV on D5~Dexamethasone 4mg PO BID (twice a day) on D6, 7 and 8~PRN antiemetics allowed at the discretion of the treating investigator~No additional doses of 5HT3 receptor antagonist, dexamethasone, or fosaprepitant will be given during the acute or delayed treatment periods"
3122636|NCT01736904|Active Comparator|FOLFIRI|FOLFIRI regimen
3122637|NCT01736904|Experimental|wXELIRI regimen|wXELIRI
3122685|NCT01736605|Active Comparator|Massage|Daily massage for 20 minutes the first 3 days following surgery.
3122639|NCT01736891|Placebo Comparator|Placebo|placebo 0.5 mg by mouth every day for two weeks, then 1 mg by mouth every day for 12 weeks, then switch to 0.5mg by mouth every day for remainder of the study (approximately 16 weeks total)
3122640|NCT01736878|Experimental|Sorafenib tablets|Oral administration of Sorafenib tablets, 400 mg bid, until disease progression or unacceptable toxicity
3122641|NCT01736878|Placebo Comparator|Placebo tablets|Oral administration of Placebo tablets until disease progression, afterwards continuation with Sorafenib at the discretion of the investigator
3122642|NCT01736865|Placebo Comparator|placebo|One placebo pill daily for 1 year
3122643|NCT01736865|Active Comparator|cholecalciferol|One cholecalciferol pill daily for 1 year
3122644|NCT01736852|Experimental|CRB plus Pitocin|
3122645|NCT01736852|Active Comparator|Pitocin|
3122646|NCT01736839||CF adults colonized with Pseudomonas aeruginosa|
3122647|NCT01736826||Group P: pregnancy w/complications|"The patient is pregnant and has complications typical of placental vascular disease (preeclampsia, eclampsia, HELLP syndrome, retro-placental hematoma, in utero fetal death) or venous thromboembolism (deep vein thrombosis, pulmonary embolism).~100 patients will be included.~Interventions to be administered: Bloodwork, baseline"
3122648|NCT01736826||Group T1: Healthy volunteers|"Healthy volunteers with no history of chronic or neoplastic disease.~30 healthy volunteers will be included.~Interventions to be administered: Bloodwork, baseline"
3122649|NCT01736826||Group T2: Pregnancy, no complications|"Pregnant patients with no identifiable pregnancy complications, and no history of chronic or neoplastic disease.~50 pregnant volunteers will be included.~Interventions to be administered: Bloodwork, baseline"
3122650|NCT01736826||Group T1x: 15 Healthy volunteers|"15 Healthy volunteers selected from group T1 (the first 15). These patients will have 2 additional months of follow up.~Interventions to be administered: Blood work, Months 1 & 2"
3122651|NCT01736826||Group T2x: 15 Pregnancy, no complications|"15 patients selected from group T2 (the first 15); these patients will have 7 months of follow up during pregnancy.~Interventions to be administered: Bloodwork, Months -1 to -6"
3122652|NCT01736813||CCR5-inhibitor at 300 mg/bid|colorectal cancer patients with liver metastases (twelve patients treated with 300 mg/bid)
3122653|NCT01736800|Experimental|Temozolomide/Topotecan|Temozolomide pills are to be taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule. Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
3122654|NCT01736787|Experimental|Cauliflower Mushroom extract|
3122655|NCT01736787|Placebo Comparator|Placebo|
3122656|NCT01736774|Experimental|Usual care intervention|Primary care as required including medication
3122657|NCT01736774|Experimental|Physiotherapy treatment|Exercise and manipulative therapy
3122658|NCT01736761|Experimental|Darunavir, Ritonavir, Rilpivirine|Darunavir 800 mg once daily, Ritonavir 100 mg once daily and Rilpivirine 25 mg once daily
3122659|NCT01736748|Experimental|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
3122660|NCT01736748|Other|Traditional PA counseling|In this arm, while children will wear the same sensors as in the intervention arm, the intervention will not rely on data gathered using the wearable sensors. Rather, a traditional physical activity counseling strategy will be adopted in this control group.
3122661|NCT01736735|Experimental|CLP|CLP BID
3122662|NCT01736735|Placebo Comparator|Placebo|BID powder
3122663|NCT01736722|Experimental|MRI-guided laser induced thermal therapy|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
3122664|NCT01736709|Experimental|trivalent seasonal influenza vaccine|2012-2013 trivalent seasonal influenza vaccine in 60 infants with two-dose regimen, 21 days interval trivalent seasonal influenza vaccine in 60 adults and 60 old people with single-dose regimen
3122665|NCT01736696|Experimental|5 mg BID|5 mg BID for 13 days and once on Day 14
3122666|NCT01736696|Experimental|10 mg BID|10 mg BID for13 days and once on Day 14*
3122667|NCT01736696|Experimental|20 mg BID|20 mg BID for 13 days and once on Day 14
3122668|NCT01736696|Experimental|30 mg BID|30 mg BID for 13 days and once on Day 14
3122669|NCT01736696|Experimental|60 mg QD|60 mg QD for 14 days
3122670|NCT01736696|Experimental|50 mg BID|50 mg BID x 13 days and once on day 14
3122671|NCT01736683|Experimental|Sotatercept 0.1 mg/kg|Sotatercept 0.1 mg/kg
3122672|NCT01736683|Experimental|Sotatercept 0.3 mg/kg|Sotatercept 0.3 mg/kg
3122673|NCT01736683|Experimental|Sotatercept 0.5 mg/kg|Sotatercept 0.5 mg/kg
3122674|NCT01736683|Experimental|Sotatercept 1.0 mg/kg|Sotatercept 1.0 mg/kg
3122675|NCT01736683|Experimental|Sotatercept 1.5 mg/kg|Sotatercept 1.5 mg/kg
3122676|NCT01736683|Experimental|Sotatercept 2.0 mg/kg|Sotatercept 2.0 mg/kg
3122677|NCT01736670|Experimental|Acute Steroid Responsive dermatitis|10 patients with acute steroid-responsive dermatoses
3122678|NCT01736670|Experimental|Chronic Steroid Responsive Dermatits|10 patients with chronic steroid-responsive dermatoses
3122679|NCT01736670|Active Comparator|Control, Otherwise healthy|10 healthy controls
3122680|NCT01736657|Experimental|Red cell exchange in sickle cell|Open arm; Red cell blood exchange for patients with sickle cell disease
3122681|NCT01736644|Placebo Comparator|Electrocautery|Use of electrocautery in tourniquet and without tourniquet total knee replacement surgery.
3122682|NCT01736644|Active Comparator|Bipolar Sealer Aquamantys|Use of bipolar sealer Aquamantys in tourniquet and tourniquetless total knee replacement surgical procedures.
3122683|NCT01736631|Experimental|Cognitive behavioural therapy|Cognitive behavioural therapy for social phobia in people with bipolar disorder
3122684|NCT01736618||S-ICD System Implant Attempt|
3122686|NCT01736605|Active Comparator|Massage combined with meditation|Daily massage for 20 minutes combined with meditation the first 3 days following surgery.
3122687|NCT01736592|Other|Long Term Follow up|Long term follow up in all patients who received SAR422459 in previous study TDU13583
3122688|NCT01736579|Experimental|IGIV, 10% at 0.2 g/kg body weight|IGIV, 10% at 0.2 g/kg body weight every 2 weeks for up to 3 years, 6 months.
3122689|NCT01736579|Experimental|IGIV, 10% at 0.4 g/kg body weight|IGIV, 10% at 0.4 g/kg body weight every 2 weeks for up to 3 years, 6 months
3122690|NCT01736566|Experimental|"Standard of Care + Whole Genome Sequencing"|Doctors and their patients will receive a Genome Report and an Annotated Family History Report.
3122691|NCT01736566|Placebo Comparator|"Standard of Care Only"|Doctors and their patients will receive an Annotated Family History Report only.
3122692|NCT01736553||Infants with Spinal Muscular Atrophy|Infants diagnosed Spinal Muscular Atrophy
3122693|NCT01736553||Healthy controls|Healthy control infants
3122694|NCT01736540|Other|Magnetic Resonance Imaging (MRI)|All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.
3122695|NCT01736527|Experimental|LE Gel|A single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears.
3122696|NCT01736514|Experimental|febuxostat group|oral
3122697|NCT01736514|Active Comparator|allopurinol group|oral
3122698|NCT01736501|No Intervention|Baseline1-demographics|Baseline survey- demographics only
3122699|NCT01736501|Other|Baseline1 w/genetics|Genetics education, baseline interest in genome screening - 1
3122700|NCT01736501|Other|Baseline2-demographics|Baseline survey- demographics only
3122701|NCT01736501|Other|Baseline2 w/genetics|Genetics education, baseline interest in genome screening - 2
3122702|NCT01736488|Experimental|Fimasartan 60mg|60mg/day of Fimasartan will be oral administered for the study period (8 weeks)
3122703|NCT01736488|Active Comparator|Atenolol 50mg|50mg/day of Atenolol will be oral administered for the study period (8 weeks)
3122704|NCT01736475|Experimental|Prophylaxis|
3122705|NCT01736475|Experimental|On-demand|
3122706|NCT01736462|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%
3122707|NCT01736449|Placebo Comparator|Pterygium Excision Alone|
3122708|NCT01736449|Experimental|Pterygium Excision with Bevacizumab Injection|
3122709|NCT01736436|Experimental|100 mg APG101 weekly over 12 weeks|Single arm open label study. Patient receive 100 mg APG101 i.v. weekly over 12 weeks with a 6 monthly follow-up phase
3122710|NCT01736423|Experimental|Female Patients with D-IBS|
3122711|NCT01736410|Other|IHC method|
3122712|NCT01736410|Other|FISH method|
3122713|NCT01736397|Experimental|Ferric Citrate|Ferric citrate will be taken with or within one hour of meals or snacks. The starting dose of ferric citrate is 3 tablets/day and titrated by the subject's serum phosphorus results at each treatment visit.
3122714|NCT01736397|Placebo Comparator|Placebo|Placebo will be taken with or within one hour of meals or snacks. The starting dose of placebo is 3 tablets per day and titrated by the subject's serum phosphorus results at each treatment visit.
3122715|NCT01736384||Obesity|Gastric bypass surgery and non-obese controls undergoing cholecystectomy
3122716|NCT01736371|Sham Comparator|Total Intravenous Anesthesia|Only propofol infusion is used for maintenance of anesthesia keeping Bispectral Index (BIS) between 45-55.
3122717|NCT01736371|Active Comparator|1% Sevoflurane|1% Sevoflurane with propofol infusion is used for maintenance. BIS is kept between 45-55 by adjusting propofol infusion.
3122718|NCT01736371|Active Comparator|Sevoflurane|Only Sevoflurane is used for maintenance keeping BIS between 45-55
3122719|NCT01736358|Experimental|Intranasal Ketoralac|A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.
3122720|NCT01736358|Placebo Comparator|Placebo|A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.
3122721|NCT01736345||Telephone Disclosure|Telephone Disclosure: Participants randomized to telephone disclosure will be asked to provide a personal identifier that the participant will be asked at the time of their telephone disclosure to ensure their identity.
3122722|NCT01736345||In Person Disclosure|Individuals opting out of randomization but still willing to participate in the research will be placed in the self-select in-person arm.
3122723|NCT01736267|Experimental|Non-NF2 ABI surgery|All subjects will be part of a single arm involving placement of the Nucleus ABI541 Auditory Brainstem Implant (ABI) device. The Nucleus 24 was discontinued and is no longer available.
3122724|NCT01736254|Experimental|Gemfibrozil|Single oral dose of 600 milligrams (mg) gemfibrozil on Day 1
3122725|NCT01736254|Experimental|Evacetrapib|Oral doses of 130 mg of evacetrapib once a day (QD) for 10 days (Day 2 through Day 12)
3122726|NCT01736254|Experimental|Evacetrapib + Gemfibrozil|Oral doses of 600 mg gemfibrozil twice a day (BID) and 130 mg evacetrapib once a day (QD) for 10 days (Day 13 through Day 22). Single oral dose of 600 mg gemfibrozil on Day 23.
3122727|NCT01736241|Experimental|LY3053102|A single 2-, 7-, 20-, 50-, 150-, or 405-milligrams (mg) dose of LY3053102 was subcutaneously administered to newly randomized participants in 6 escalating dose level cohorts. The dose was escalated based on the safety results over at least a 7-day evaluation period postdose. The dose escalation occurred over 13 weeks proceeding according to tolerability at each dose level.
3122728|NCT01736241|Placebo Comparator|Placebo|A single dose of LY3053102-matching placebo was administered subcutaneously to 1 newly randomized participant in each LY3053102-dose level cohort over 13 weeks.
3122729|NCT01736228|Experimental|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
3122730|NCT01736215||Participants with cancer related anemia|Participants with cancer related anemia receiving chemotherapy will be observed for response to erythropoietin treatment.
3122731|NCT01736202|Active Comparator|Palm oil orally|oral fat load
3122732|NCT01736202|Active Comparator|Canola oil orally|Oral fat load
3122733|NCT01736202|Placebo Comparator|Water orally|oral water administration as control
3122734|NCT01736189||Humira|those with an exposure
3122735|NCT01736176|Experimental|Levodopa-Carbidopa Intestinal Gel|"Participants had the PEG-J tube placement procedure performed on Study Day 1 and, at the discretion of the investigator, began initiation and titration of LCIG infusion. Dosing was determined individually. The starting total daily dose of LCIG was based solely on the daily dose of the oral levodopa taken immediately prior to Study Day 1 and was adjusted to obtain the optimal clinical response for the individual participant.~Participants received treatment for up to 60 weeks; participants who completed their Week 60 visit before LCIG was commercially available had the option to extend their LCIG therapy, if in the opinion of the investigator, the participant would benefit from continued LCIG treatment."
3122736|NCT01736163||Thyrogen and 131I|Patients were previously treated with Thyrogen in conjunction with a high ablative activity of 131I.
3122737|NCT01736163||Thyroid Hormone Withdrawal and 131I|Patients were previously treated with Thyroid hormone withdrawal (THW) in conjunction with a high ablative activity of 131I.
3122738|NCT01736150|Experimental|Sevelamer carbonate|Subjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site.
3122739|NCT01736150|Placebo Comparator|Placebo|Subjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site.
3122740|NCT01736137||Chronic Heart failure group|All chronic heart failure group participants will perform two walk tests at the same day, with a heart rate monitor, and answer questionnaires about their perception of quality of life. Tests will be conducted on a single day, without follow up of patients. The six minute walk test will be performed according the American Thoracic Society Statement (2002).
3122741|NCT01736137||Control Group|All control group participants will perform two walk tests at the same day, with a heart rate monitor, and answer questionnaires about their perception of quality of life. Tests will be conducted on a single day, without follow up of patients. The six minute walk test will be performed according the American Thoracic Society Statement (2002).
3122742|NCT01736124|Experimental|Computerized Cognitive Training (CCT)|Randomly selected subjects perform a variety of computer games tailored to address their personal cognitive deficits.
3122743|NCT01736124|Active Comparator|Active control|Randomly selected subjects perform a variety of computer games that are engaging but not designed to enhance cognitive skills.
3122744|NCT01736111|Experimental|Personal feedback|"This arm will receive all intervention components of Active Comparator group, plus the following:~Text messages to prompt participant to reply with self-monitoring entries~Human coach uses system to send personalized text messages with feedback on self-monitoring entries"
3122745|NCT01736111|Active Comparator|One Way Text|"Printed handouts from the Aim for a Healthy Weight booklet, which is published by National Heart, Lung, and Blood Institute and is frequently included in control conditions in primary care-based weight loss studies.~Other handouts will discuss the use of prepackaged foods as well as setting goals for calorie intake, physical activity, and weight loss.~One to three text messages per week, based on topics from Aim for a Healthy Weight and other sources. The text messages will be pre-scheduled, automated, non-tailored, and one-way (no reply will be requested). The total dose of contact will be low because each text message is limited to 160 characters. The condition is comparable in intensity to control conditions in other weight loss trials in the primary care setting.~Usual medical care from the PCP.~Education on symptoms of hypoglycemia, hypotension, and cardiovascular disease, with instructions to contact their PCP in the event of those symptoms."
3122746|NCT01736098|Experimental|High Energy Flux|Energy Flux Exercise Intervention: 7kcal/kg/day at 5 days/week of energy expenditure and matching energy intake
3122747|NCT01736098|Experimental|Medium Energy Flux|Energy Flux Exercise Intervention: 3.5kcal/kg/day at 5 days/week of energy expenditure and matching energy intake
3122748|NCT01736098|No Intervention|Low Energy Flux|No Intervention: maintain normal lifestyle
3122749|NCT01736085|No Intervention|Material Group|Subjects will receive self-help materials
3122750|NCT01736085|Active Comparator|Materials plus Voucher|Subjects will receive self-help materials and a voucher for 2 week's worth of nicotine patches
3122751|NCT01736085|Active Comparator|Materials plus Patches|Subjects will receive self-help materials and a 2 week's worth of nicotine patches
3122752|NCT01736085|Active Comparator|Counseling|Subjects will receive up to 5 sessions of telephone counseling
3122753|NCT01736085|Active Comparator|Counseling plus Voucher|Subjects will receive up to 5 sessions of telephone counseling plus a voucher for 2 week's worth of nicotine patches.
3122754|NCT01736085|Active Comparator|Counseling plus Patches|Subjects will receive up to 5 sessions of telephone counseling plus 2 week's worth of nicotine patches.
3122755|NCT01736072|Active Comparator|Laparoscopic Resection of Rectal Cancer|Research Subjects will be randomized to Surgical Resection of Rectal Cancer by Standard Laparoscopic Surgery.
3122756|NCT01736072|Active Comparator|Robotic Resection of Rectal Cancer|Research Subjects will be randomized to Surgical Resection of Rectal Cancer by Robotic Assisted Laparoscopic Surgery.
3122757|NCT01736059|Experimental|Stem cell treated|
3122758|NCT01736046||Crohn's Disease patients|All patients referred for CT Enterography will be undergo both standard and low dose CT Enterography
3122759|NCT01736033|Placebo Comparator|Tamsulosin + Placebo|Tamsulosin 0.2mg + Placebo 5 mg daily until clinical progression
3122760|NCT01736033|Active Comparator|Tamsulosin + Finasteride|Tamsulosin 0.2mg + Finasteride 5 mg daily until clinical progression
3122761|NCT01736020|Placebo Comparator|Placebo|Placebo
3122762|NCT01736020|Experimental|Dexmedetomidine|Dexmedetomidine intravenous infusion during scan.
3122763|NCT01736020|Experimental|Propofol|Propofol intravenous infusion during scan.
3122764|NCT01736020|Experimental|Ketamine|Ketamine intravenous infusion during scan.
3122765|NCT01736020|Experimental|Nitrous Oxide|Nitrous Oxide inhalation during scan.
3122766|NCT01736007|Sham Comparator|Liquid light guide tip on laser|Excimer laser treatment with 308-nm excimer laser with guide tip applied to alopecia patch twice a week.
3122767|NCT01736007|Active Comparator|308-nm excimer laser to alopecia patch|Laser treatment with 308-nm excimer laser procedure to alopecia patch twice a week with increasing fluence as tolerated.
3122768|NCT01735994|Experimental|Healthy Weight Intervention|Eating Disorder Prevention Program
3122769|NCT01735994|Other|Brochure wait list|Brochure wait list control group
3122770|NCT01735981|Experimental|video game exercise|Video game exercise using Dance Dance Revolution
3122771|NCT01735981|Other|control|hand-held video game control
3122772|NCT01735968|Experimental|STI571 (imatinib mesylate) and BYL719|The study will comprise of 2 parts. A dose escalation and a dose expansion part. All patients in the dose escalation part will have a pharmacokinetic (PK) run-in period of 7 days receiving imatinib monotherapy. Patients will receive increasing doses of BYL719 (200, 300, 400 mg) in combination with 400mg imatinib daily until maximum tolerated dose (MTD) and rapid phase 2 dose (RP2D) is determined. Approximately 35 patients will enter the expansion phase.
3122773|NCT01735955|Experimental|AMN107 (nilotinib)|AMN107
3122774|NCT01735942|Experimental|Ingenol Mebutate|Ingenol Mebutate applied to one side of face with skin lesions
3122775|NCT01735942|Active Comparator|Cryotherapy|Cryotherapy applied to other side of face with skin lesions
3122776|NCT01735929|Experimental|Neck Liposuction and Ultrasound Treatment|Subject will receive neck liposuction and ultrasound treatment.
3122777|NCT01735929|Sham Comparator|Sham|Subject will receive sham treatment
3122778|NCT01735916|Active Comparator|CRT-P ON|CRT-P Implant CRT-P ON
3122779|NCT01735916|Placebo Comparator|CRT-P OFF|CRT-P Implant CRT-P OFF
3122780|NCT01735890|Experimental|CJ Amlodipine/Valsartan 10/160mg|
3122781|NCT01735890|Active Comparator|Novartis Exforge 10/160mg|
3122782|NCT01735877|Experimental|Mirror therapy|All eligible patients will be randomly allocated into 2 groups. Group 1 will be given Mirror therapy
3122783|NCT01735877|Sham Comparator|Control group|Group 2 will be given sham mirror therapy
3122784|NCT01735864|Active Comparator|Indirubin 200 μg/g|per gram of ointment contains 200 μg of indirubin
3122785|NCT01735864|Active Comparator|Indirubin 100 μg/g|per gram of ointment contains 100 μg of indirubin
3122786|NCT01735864|Active Comparator|Indirubin 50 μg/g|per gram of ointment contains 50 μg of indirubin
3122787|NCT01735864|Active Comparator|Indirubin 10 μg/g|per gram of ointment contains 10 μg of indirubin
3122788|NCT01735851|Active Comparator|Thoracic epidural analgesia|Group 1 will receive a catheter congruent TEA. The epidural space will be identified using the loss of resistance technique. After a test dose to rule out intravascular and intrathecal placement of the catheterthe initial block will be made with 0.25% bupivacaine 5 mL followed by 3 mL aliquots administered every 5 minutes to establish a block between T8 and T12. An infusion will be started at 8 mL/hour with 0.1 % bupivacaine with 10microgram/mL of dilaudid and continued for 72 hours. Additional nurse administered boluses of 5-10mL of the standard solution will be allowed via the epidural catheter every 6hourly for poor pain control followed by an increase in the basal infusion rate up to a maximum of 14mL/hr. Patients will be allowed to self administer additional boluses of 3mL of the standard infusate every 20minutes (PCEA)
3122789|NCT01735851|Experimental|Bilateral Paravertebral block|Group 2 will have bilateral PVB catheters inserted using the ultrasound with patients prone. A high-frequency linear probe will used to visualize the transverse process, pleura and the internal intercostal membrane. A 17 guage Tuohy needle will be inserted to puncture the internal intercostal membrane. Injection of local anesthetic will push the pleura away, which will be the end point of needle position. A curved pigtail catheter will be inserted and further 5mL of local anesthetic will be injected while observing further movement of pleura. A similar procedure will be done on the contralateral side at the same level. Infusion of 0.2% ropivacaine will be continued for the next 72 hours. They will also receive IVPCA and additional nurse administered boluses of 5-10mL of ropivacaine 0.2% in the PVB every 6 hourly to the side of maximal pain.
3122790|NCT01735825|Experimental|paclitaxel-coated balloon|Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter (iopomide coating)
3122791|NCT01735825|Active Comparator|drug eluting stent|Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus
3122792|NCT01735825|Other|seal-wing paclitaxel-eluting balloon catheter|"Observational, non-randomised arm:~Pts with ISR treated by seal-wing paclitaxel-eluting balloon catheter"
3122793|NCT01735812|Experimental|symptomatic UF|
3122794|NCT01735786||Treatment group|Subjects in this group will received Endoclot treatment immediately after EMR.
3122795|NCT01735786||Control group|Subjects in this group will not received any hemostasis treatment after EMR.
3122796|NCT01735773||Hemodialysis group|Patients on chronic hemodialysis program
3122797|NCT01735773||Peritoneal dialysis group|Patients on chronic peritoneal dialysis program
3122798|NCT01735773||Pre-dialysis group|Patients with chronic kidney disease stage-4
3122799|NCT01735773||Control group|Healthy volunteers
3122800|NCT01735760||Palpation|The group using palpation as primary attempt at localizing the cricothyroid membrane
3122801|NCT01735760||Ultrasonography|The group using ultrasound for their primary approach to localizing the cricothyroid membrane
3122802|NCT01735747|Experimental|Temozolomide, Nedaplatin, Vincristine, Radiotherapy|The newly diagnosed PCNSL patients will be given concurrent temozolomide (75mg/m2, orally) daily during WBRT. Then, the TNV regimen will be given after four weeks. TNV regimen consisted of temozolomide (200mg/m2 orally, days 1-5), nedaplatin (80mg/m2 i.v., day 1), vincristine (1.4mg/m2 i.v., day 1). Each cycle was 4 weeks and a maximum of six cycles were applied.
3122803|NCT01735734||Capillary malformation|
3122804|NCT01735721|Active Comparator|Open Sinus Lift with DFDBA|In each patient, one sinus was chosen at random and filled with DFDBA (Tissue Regeneration Corporation, Iran).
3122805|NCT01735721|Experimental|Open Sinus Lift with Algipore|The contra lateral sinus was filled with Algipore (Dentsply, USA).
3122806|NCT01735708|Placebo Comparator|Health Education|Participants in the Health Education arm will receive 7 individual sessions, each of which will focus on a different health education topic.
3122807|NCT01735708|Active Comparator|HIVPASS Intervention|Participants in the HIVPASS intervention arm will receive 7 individual sessions with the study interventionist, the first of which is a collaborative meeting with the PCP. Sessions will focus on pain interference and depression management.
3122808|NCT01735682|Experimental|Whole body vibration|This group will receive whole body vibration and conventional exercise training (1 hour per session, 3 sessions per week, for 8 consecutive weeks).
3122862|NCT01735422|Experimental|r-hLH (22000 IU)|
3122863|NCT01735422|Active Comparator|u-hCG (5000 IU)|
3122809|NCT01735682|Active Comparator|Conventional exercise|This group will receive convention exercise training (1 hour per session, 3 sessions per week, for 8 consecutive weeks).
3122810|NCT01735682|Active Comparator|Control|This group will have exercise training that involve only the upper limbs (about 30 minutes per session, 3 sessions per week, for 8 consecutive weeks).
3122811|NCT01735669|Experimental|Remifentanil|External cephalic version at term under Remifentanil perfusion
3122812|NCT01735669|Active Comparator|Nitrous oxide|External cephalic version at term under Nitrous oxide inhalation
3122813|NCT01735656|Experimental|DK-culotte & Resolute stents|Double kissing culotte technique for true bifurcation lesion with Resolute stents
3122814|NCT01735656|Active Comparator|DK-crush & Resolute stents|Double kissing crush technique for true bifurcation lesion with Resolute stents
3122815|NCT01735643|Experimental|interactive videogame intervention|
3122816|NCT01735643|Experimental|waiting group|
3122817|NCT01735630|Experimental|ELND005|ELND005 film coated tablets, BID for 12 weeks
3122818|NCT01735630|Placebo Comparator|Placebo|Matched placebo BID for 12 weeks
3122819|NCT01735617|Experimental|Hydrocortisone Modified Release Capsules|Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
3122820|NCT01735604|Experimental|anti-CD20-CAR T cell|Arm 1 Patients receive anti-CD20-CAR lentiviral vector-transduced autologous T cells with 41BB vector for 3-5 days in the absence of disease progression or unacceptable toxicity.
3122821|NCT01735591|Experimental|Probiotic|Capsules with 3x10^9 colony forming units (Lactococcus lactis PB 411 - 50%; Lactobacillus casei PB 121 - 25%; Lactobacillus acidophilus PB 111 - 12,5%; Bifidobacterium bifidum PB 211 - 12,5%). 1 capsule a day from inclusion until liver transplantation
3122822|NCT01735591|Placebo Comparator|Placebo|Placebo, 1 capsule a day from inclusion until the date of liver transplantation
3122823|NCT01735578||Premature infants with anemia|Inpatient premature infants at the University of Utah Neonatal Intensive Care Unit (NICU) with Hct < or = to 28 who are being fed and are stable.
3122824|NCT01735565||Post bone marrow transplant|Patients who are undergoing bone marrow transplant, as well as patients who have completed a bone marrow transplant within the previous year.
3122825|NCT01735552||Infants requiring PRBCs|Premature infants who require PRBCs for anemia that is not related to sepsis, surgery, NEC or immunologic abnormalities.
3122826|NCT01735539|Experimental|Old Bolus|15g EAA bolus
3122827|NCT01735539|Experimental|Old Arginine|15g EAA Bolus supplemented with 3g Arginine
3122828|NCT01735539|Experimental|Young Bolus|15g EAA bolus
3122829|NCT01735539|Experimental|Young Pulse|4 x 3.75g Mixed EAA Pulses
3122830|NCT01735539|Experimental|Old Pulse|4 x 3.75g Mixed EAA Pulses
3122831|NCT01735513|Experimental|Transaortic TAVI with EmbolX|"Subjects are randomized into this arm to receive a transaortic transcatheter aortic valve implantation with the use of the embolic protection device EmbolX"
3122832|NCT01735513|Active Comparator|Transaortic TAVI without EmbolX|"Subjects are randomized into this arm to receive a transaortic transcatheter aortic valve implantation without the use of the embolic protection device EmbolX"
3122833|NCT01735500||CAG without PCI|
3122834|NCT01735500||CAG with PCI|
3122835|NCT01735487|Active Comparator|Own Brand cigarette|Smoke Own Brand cigarette, 15 puff of cigarette.
3122836|NCT01735487|Experimental|One High 2,4% nicotine|Smoke electronic cigarette One High 2,4% nicotine for a day, 15 puff of e-cigarette.
3122837|NCT01735487|Experimental|Original 7,4 mg nicotine|Smoke electronic cigarette Original 7,4 mg nicotine for a day. 15 puff of e-cigarette.
3122838|NCT01735487|Placebo Comparator|Nicotine Free|Smoke electronic cigarette nicotine free (15 puff)
3122839|NCT01735487|Experimental|EGO 9mg|Smoke electronic cigarette EGO for a day (15 puff)
3122840|NCT01735474|Placebo Comparator|Placebo|30 people are recruited in order to the inclusion criteria for the study. Placebo controlled.
3122841|NCT01735474|Active Comparator|Manual technique|30 people are recruited in order to the inclusion criteria for the study. Experimental group.
3122842|NCT01735461|Experimental|Dietary supplement|Calcium Carbonate
3122843|NCT01735448||Aboriginal smoker, male, Adelaide|Focus group: Aboriginal smoker, male from Adelaide
3122844|NCT01735448||Aboriginal smoker, female, Adelaide|Focus group: Aboriginal smoker, female, from Adelaide
3122845|NCT01735448||Aboriginal ex/non-smoker, male, Adelaide|Focus group: Aboriginal ex/non-smoker, male, from Adelaide
3122846|NCT01735448||Aboriginal ex/non-smoker, female, Adelaide|Focus group: Aboriginal ex/non-smoker, female, from Adelaide
3122847|NCT01735448||Healthcare workers, Adelaide|Focus group: Healthcare workers who are based in Adelaide and work with Aboriginal patients
3122848|NCT01735448||Healthcare workers, Murray Bridge|Focus group: Healthcare workers who are based in Murray Bridge and work with Aboriginal patients
3122849|NCT01735448||Aboriginal smoker, male, Murray Bridge|Focus group: Aboriginal smoker, male, from Murray Bridge
3122850|NCT01735448||Aboriginal smoker, female, Murray Bridge|Focus group: Aboriginal smoker, female, from Murray Bridge
3122851|NCT01735448||Aboriginal ex/non-smoker, male, Murray Bridge|Focus group: Aboriginal ex/non-smoker, male, from Murray Bridge
3122852|NCT01735448||Aboriginal ex/non-smoker, female, Murray Bridge|Focus group: Aboriginal ex/non-smoker, female, from Murray Bridge
3122853|NCT01735448||Key community stakeholders|One-on-one interviews with 10 key Aboriginal community stakeholders
3122854|NCT01735448||Respiratory physicians|One-on-one interviews with 10 Respiratory physicians
3122855|NCT01735448||Consultants and General Practitioners|One-on-one interviews with 10 consultants and/or GP's
3122856|NCT01735435|No Intervention|Group 2 (Control group)|Group 2(Control group)-patients in this group received nutrition according to the standard hospital dietary regimen.
3122857|NCT01735435|Experimental|Group 1 (Indirect Calorimetry)|Group 1(Indirect Calorimetry)-The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.
3122858|NCT01735422|Experimental|r-hLH (825 International Units [IU])|
3122859|NCT01735422|Experimental|r-hLH (2750 IU)|
3122860|NCT01735422|Experimental|r-hLH (5500 IU)|
3122861|NCT01735422|Experimental|r-hLH (11000 IU)|
3122864|NCT01735409|Experimental|1-day regimen|ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
3122865|NCT01735409|Experimental|2-day regimen|ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
3122866|NCT01735409|Experimental|3-day regimen|ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
3122867|NCT01735396|Experimental|Abiraterone Acetate|Abiraterone acetate 1000mg orally daily until the time of disease progression, in the absence of prohibitive toxicities.
3122868|NCT01735383|Experimental|Etodolac Tablets USP 500mg|Etodolac Tablets USP 500 mg of Ipca Laboratories Limited, India
3122869|NCT01735383|Active Comparator|Etodolac Tablets USP 500 mg|Etodolac Tablets USP 500 mg of Taro Pharmaceutical Industries Ltd., USA
3122870|NCT01735370|Experimental|Etodolac Tablets USP 500mg|Etodolac Tablets USP 500 mg of Ipca Laboratories Limited, India
3122871|NCT01735370|Active Comparator|Etodolac Tablets USP 500 mg|Etodolac Tablets USP 500 mg of Taro Pharmaceutical Industries Ltd., USA
3122872|NCT01735357|Placebo Comparator|Olive oil (BP specification)|5g per day
3122873|NCT01735357|Experimental|DHA-rich oil|Fish oil supplement (total = 5g/day) providing 3.1g/day of DHA triacylglycerol, blended with olive oil
3122874|NCT01735357|Experimental|EPA-rich oil|Fish oil supplement (total = 5g/day) providing 2.9g/day of EPA triacylglycerol, blended with olive oil
3122875|NCT01735344|Experimental|Lisinopril Tablets 40 mg|Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India
3122876|NCT01735344|Active Comparator|Zestril® (Lisinopril) 40 mg Tablets|Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA
3122877|NCT01735331||VEGF level|VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss.
3122878|NCT01735331||control group|Patients with Abnormal Uterine Bleeding
3122879|NCT01735318|Experimental|Lisinopril Tablets 40 mg|Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India
3122880|NCT01735318|Active Comparator|Zestril® (Lisinopril) 40 mg Tablets|Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA
3122881|NCT01735305||Antiplatelet therapy|patients with coronary artery disease receiving any antiplatelet therapy, without any intervention by the investigators.
3122882|NCT01735279|Placebo Comparator|Placebo|The omega 3 group will receive 3g per day of mineral oil during 90 days treatment
3122883|NCT01735279|Experimental|Omega3|The omega 3 group will receive 3g per day of fish oil during 90 days treatment
3122884|NCT01735266|Active Comparator|Air colonoscopy|Air was insufflated during whole procedure of colonoscope insertion.
3122885|NCT01735266|Experimental|Whole-colon water exchange colonoscopy|The air pump was turned off before colonoscopy. During the whole procedure of the scope insertion, residual air in lumen was suctioned and 37°C (maintained with a water bath) water was infused with a peristaltic pump to obtain lumen visualization. Air was insufflated until cecum was reached or appendix opening was seen.
3122886|NCT01735266|Experimental|left-colon water exchange colonoscopy|In the left side of colon (including descending colon, sigmoid colon and rectum), water was infused instead of air to obtain lumen visualization as described above in whole-colon water exchange colonoscopy group.
3122887|NCT01735253|Experimental|gastric bypass, duodenojejunal bypass|
3122888|NCT01735240|Experimental|First AZD5069, then Ketoconazole + AZD5069|AZD5069 in first period (on 1 day) and in second period (after wash out) ketoconazole alone (on 2 days) then ketoconazole + AZD5069 (on 1 day), then again ketoconazole alone (on 2 days)
3122889|NCT01735227|Experimental|omeprazole group|omeprazole group:all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and taking omeprazole 20mg/d(1 month).on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization due to cardiovascular disease , bleeding events) .
3122890|NCT01735227|Experimental|pantoprazole group|pantoprazole group: all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term),taking pantoprazole 20mg/d(1 month).
3122891|NCT01735214||Patients with POAG or OHT|Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
3122892|NCT01735201|Experimental|AGN-199201 Dose A Once Daily|AGN-199201 Dose A applied once daily to the face for 28 days.
3122893|NCT01735201|Experimental|AGN-199201 Dose B Once Daily|AGN-199201 Dose B applied once daily to the face for 28 days.
3122894|NCT01735201|Experimental|AGN-199201 Dose C Once Daily|AGN-199201 Dose C applied once daily to the face for 28 days.
3122895|NCT01735201|Placebo Comparator|AGN-199201 Vehicle Once Daily|AGN-199201 Vehicle applied once daily to the face for 28 days.
3122896|NCT01735201|Experimental|AGN-199201 Dose A Twice Daily|AGN-199201 Dose A applied twice daily to the face for 28 days.
3122897|NCT01735201|Experimental|AGN-199201 Dose B Twice Daily|AGN-199201 Dose B applied twice daily to the face for 28 days.
3122898|NCT01735201|Experimental|AGN-199201 Dose C Twice Daily|AGN-199201 Dose C applied twice daily to the face for 28 days.
3122899|NCT01735201|Placebo Comparator|AGN-199201 Vehicle Twice Daily|AGN-199201 Vehicle applied twice daily to the face for 28 days.
3122900|NCT01735188||Living|
3122901|NCT01735188||Deceased|
3122902|NCT01735175|Active Comparator|Neulasta®|During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.
3122903|NCT01735175|Experimental|LA-EP2006|During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.
3122904|NCT01735162||Very high risk|Very high risk PICU patients are on mechanical ventilation and at least one inotrope or vasopressor at time of admission
3122905|NCT01735162||High Risk|High risk PICU patients have a history of transplantation (solid organ or bone marrow)
3122906|NCT01735162||Moderate risk|Moderate risk PICU patients are all other admissions to the ICU (may have either mechanical ventilation or inotropy/vasopressor use but not both). Cannot have a history of transplant. Minimum expected stay 48 hours.
3122908|NCT01735149|Placebo Comparator|Placebo|
3122909|NCT01735136|Experimental|InSan Bamboo Salt|
3122910|NCT01735136|Placebo Comparator|Placebo|
3122911|NCT01735123|Experimental|extensively hydrolyzed casein formula|The investigators plan to randomize 60 out of 120 infants to be weaned to an extensively hydrolyzed casein formula. Recruited mothers are encouraged to breast-feed. The dietary intervention will be applied until 9 months of age. The minimum exposure time to the study formula should be 90 days. Signs of beta-cell autoimmunity, i.e. diabetes-associated autoantibodies, will be monitored in the study participants, although the study will not have sufficient power to detect statistically significant differences in the seroconversion rate between the groups due to the limited number of infants randomized.
3122912|NCT01735123|Experimental|cow's milk based infant formula|The investigators plan to randomize 60 out of 120 infants to be weaned to a cow's milk based infant formula. Recruited mothers are encouraged to breast-feed. The dietary intervention will be applied until 9 months of age. The minimum exposure time to the study formula should be 90 days. Signs of beta-cell autoimmunity, i.e. diabetes-associated autoantibodies, will be monitored in the study participants, although the study will not have sufficient power to detect statistically significant differences in the seroconversion rate between the groups due to the limited number of infants randomized.
3122913|NCT01735110|Active Comparator|Femoral approach group|PCI through Femoral approach
3122914|NCT01735110|Experimental|radial approach group|PCI through radial approach
3122915|NCT01735097|Experimental|Arsenical keratosis (Study)|Vitamin E (200 mg, soft capsule) plus Nigella sativa (500 mg, soft capsule) twice daily, orally for 12 weeks
3122916|NCT01735097|Active Comparator|Arsenical keratosis (Control)|Vitamin E (200 mg, soft capsule) plus Placebo (refined oil in soft capsule with same size and color as that contains N sativa) twice daily, orally for 12 weeks
3122917|NCT01735084|Experimental|Prevenar13|The booster dose of Prevenar13 is 0.5 mL given intramuscularly only, with care to avoid injection into or near nerves and blood vessels. The preferred sites are anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in young children.
3122918|NCT01735084|Experimental|Synflorix|The booster vaccination schedule consists of one dose of 0.5 ml with an interval of at least 1 month between doses.
3122919|NCT01735071|Experimental|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
3122920|NCT01735071|Experimental|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1-6, bevacizumab given as 1 hour infusion will be followed by carboplatin area under curve 4 (AUC 4) and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
3122921|NCT01735058|Active Comparator|Sodium hyaluronate|Ultrasound guided injection of sodium hyaluronate
3122922|NCT01735058|Placebo Comparator|Normal saline|Ultrasound guided injection of normal saline
3122923|NCT01735045|Experimental|Test Group myopia control|Subjects wearing contact lenses made of LSH (mangofilcon A) Soft (hydrophilic) Contact Lens for myopia control
3122924|NCT01735045|Active Comparator|Myopia Control|Subjects wearing Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens for myopia control
3122925|NCT01735019|Experimental|group 1|administration of remifentanil with target-controlled infusion (TCI) system at a given concentration during anesthetic emergence
3122926|NCT01735006|Experimental|HPV vaccine|This dosage contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant
3122927|NCT01735006|Placebo Comparator|HEV vaccine|commercialized HEV vaccine which contains 30μg HEV antigen adsorbed in alum-adjuvant
3122928|NCT01734993|Experimental|Tocilizumab|Moderate to severe rheumatoid arthritis participants from France, who completed the Week 97 visit of the WA22762 LTE study and considered as responders (defined as having improvement in DAS28 of >1.2 points) will continue tocilizumab treatment within this local LTE study for a maximum of 156 weeks, or until SC TCZ becomes commercially available, whichever occurs first.
3122929|NCT01734980|Experimental|Endobronchial Ultrasound|EBUS-TBNA is a procedure that allows accurate sampling of mediastinal lymph nodes and peribronchial lesions
3122930|NCT01734967|Experimental|needle based CLE & EUS-FNA|The study will prospectively include patients referred to our department for EUS and EUS-FNA of suspected pancreatic masses during a 12 months period. The indication for this investigation will be based on the patient's clinical history and previous imaging studies (abdominal ultrasound, CT scan, MRI).
3122931|NCT01734954|Experimental|Sciatic nerve blockade at bifurcation|Ultrasound-guided block at the bifurcation of the sciatic nerve
3122932|NCT01734954|Experimental|Sciatic block 2 cm beyond bifurcation|Ultrasound-guided block of the sciatic nerve 2 cm beyond of the bifurcation
3122933|NCT01734941|Active Comparator|TSO 2500|2500 TSO every other week
3122934|NCT01734941|Active Comparator|7500 TSO|7500 TSO every other week
3122935|NCT01734941|Placebo Comparator|Placebo|placebo every other week.
3122936|NCT01734928|Experimental|Pomalidomide, Bortezomib and Low Dose Dexamethasone|4 mg of Pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1.3 mg/m2 of Bortezomib administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and Dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [> 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2,8, 9 of 21 days for cycles 9 and onward until disease progression.
3122937|NCT01734928|Active Comparator|Bortezomib and Low Dose Dexamethasone|1.3 mg/m2 of Bortezomib will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression along with Dexamethasone 20 mg/day [≤ 75 years old]or 10 mg/day [> 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
3122938|NCT01734915||NSCLC|Subjects with advanced NSCLC, will undergo blood draw
3165954|NCT01439971|Experimental|5|
3122939|NCT01734902|Experimental|1 Hyoscine butylbromide|drops, oral administration with 240 mL water
3122940|NCT01734902|Experimental|2 Hyoscine butylbromide|sugar coated tablets, oral administration with 240 mL water
3122941|NCT01734889|Experimental|Orfadin suspension|Drug: nitisinone, oral suspension
3122942|NCT01734876|Experimental|Tactile Touch|Tactile Touch is given to the active arm
3122943|NCT01734876|Active Comparator|Rest To Music|Rest to Music. Rest for 30-60 minutes, aroma therapy, quit music in the background, well temepered room, lying position
3122944|NCT01734863|Experimental|Radiotherapy Arm|"this study arm will take External Beam radiotherapy as follows :~Radiotherapy Technique: Conformal radiotherapy, Intensity modulated radiotherapy [IMRT] is allowed.~Radiotherapy Dose: 45 Gy/25 fractions/5 weeks (1.8 Gy/fraction). , the inclusion criteria are as following:~Age < 18 years old.~Non-metastatic Ewing Sarcoma patients who will undergo surgery and show poor histologic response to neo-adjuvant chemotherapy.~Negative surgical margins.~Patients show good safety profile and acceptable performance status."
3122945|NCT01734863|No Intervention|No Radiotherapy Arm|"this arm will not take radiotherapy and their inclusion criteria as following:~Age < 18 years old.~Non-metastatic Ewing Sarcoma patients who will undergo surgery and show poor histologic response to neo-adjuvant chemotherapy.~Negative surgical margins.~Patients show good safety profile and acceptable performance status."
3122946|NCT01734850|Experimental|No busulfan pre-conditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes without busulfan preconditioning
3122947|NCT01734850|Experimental|1 x 4mg/kg busulfan preconditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes, with single 4mg/kg busulfan dose administered as pre-conditioning for transplant
3122948|NCT01734850|Experimental|2 x 4mg/kg busulfan pre-conditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes, with two 4mg/kg busulfan doses administered as pre-conditioning for transplant
3122949|NCT01734824|Active Comparator|Teriparatide|daily subcutaneous injection of teriparatide 20µg for three months
3122950|NCT01734824|Placebo Comparator|Placebo Teriparatide|daily subcutaneous teriparatide placebo injection
3122951|NCT01734824|Active Comparator|Denosumab|one subcutaneous injection of denosumab
3122952|NCT01734824|Active Comparator|Placebo Denosumab|one subcutaneous injection of denosumab placebo
3122953|NCT01734811|Placebo Comparator|Placebo|The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation
3122954|NCT01734811|Experimental|Biological vaccine|The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation
3122955|NCT01734798|Experimental|Arm 1|post-operative radiotherapy will be done in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy Dose of Radiotherapy: 45 Gray Gy/30 fractions/3 weeks
3122956|NCT01734798|Experimental|Arm 2|adjuvant chemotherapy (gemcitabine and cisplatin) in addition to post operative radiotherapy in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
3122957|NCT01734798|Experimental|Arm 3|Adjuvant chemotherapy alone in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
3122958|NCT01734785|Active Comparator|Linagliptin|5 mg once daily
3122959|NCT01734785|Experimental|Empaglifozin + Linagliptin low dose|1 tablet once daily
3122960|NCT01734785|Experimental|Empagliflozin + Linagliptin high dose|1 tablet once daily
3122961|NCT01734772|Experimental|Reference (Part 1/A, Part 2/C)|multiple doses of dabigatran (alone)
3122962|NCT01734772|Experimental|Test 1 (Part 1/Treatment B)|concomitant administration of dabigatran and ticagrelor
3122963|NCT01734772|Experimental|Test 2 (Part 2/Treatment D)|staggered administration of ticagrelor and dabigatran
3122964|NCT01734759|Experimental|Taste Test|
3122965|NCT01734746|Experimental|sentinel node procedure|Injection of both blue dye and the radioactive isotope (technetium-99-m-labeled albumin nanocolloid) in the ligamentum ovarii proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), close to the ovary and just below the peritoneum.
3122966|NCT01734733|Experimental|NTCELL|
3122967|NCT01734720||common bile duct stone|Patients undergoing cholecystectomy
3122968|NCT01734707|Active Comparator|Allicor|Allicor 150 mg tablet by mouth two times a day
3122969|NCT01734707|Placebo Comparator|Sugar pill|Placebo tablet 150 mg by mouth two times a day
3122970|NCT01734694|Active Comparator|Vancomycin|
3122971|NCT01734694|Active Comparator|Comparator|
3122972|NCT01734681|Experimental|Treatment with G-202|G-202 will be administered by intravenous infusion over one hour on Days 1, 2 and 3 of a 28-day treatment cycle. The G-202 dose will be 40 mg/m2 on Day 1 and 66.8 mg/m2 on Days 2 and 3.
3122973|NCT01734655||All Participants|Participants will be asked to complete the MEQ, the Eating Inventory Questionnaire, The Mindful Attention Awareness Scale (MAAS), and the Neighborhood Environment Walkability Scale (NEWS). Participants will then be asked to sequentially respond to each of the 28 items and the response choices from the MEQ and briefly discuss their reaction to the items and response choices. Finally, participants will either participate in a focus group or an individual cognitive interview, giving them the opportunity to elaborate on their responses to the MEQ. The first 11 participants completed focus groups and the remaining 29 participants completed individual cognitive interviews.
3122974|NCT01734642||PATIENT HOSPITALIZED|ALL THE PATIENTS HOSPITALIZED IN THE INVOLVED UNITS WHO GAVE THEIR INFORMED CONSENT. PATIENTS HOSPITALIZED DURING THE WEEK-END WILL BE ENROLLED ON the next MONDAY
3122975|NCT01734629||Coronary CT Spirometry Cohort|Patients refereed to coronary CT enrolled in the study.
3122976|NCT01734616|No Intervention|Young|Young subjects to be controlled to older individuals with interventions
3122977|NCT01734616|No Intervention|Old|Older individuals to compare to young and other older intervention groups
3122978|NCT01734616|Experimental|Old Exercise|Older individuals studied after an intervention of 20 weeks fully-supervised resistance exercise training
3122979|NCT01734616|Experimental|Old Acute Cocoa|Older individuals studied with the addition of cocoa flavanols during their acute study
3122980|NCT01734616|Experimental|Old 7 Day Cocoa|Older individuals studied after 7 day supplementation of cocoa flavanols
3123197|NCT01733212|Placebo Comparator|Placebo|2 gm of placebo pill (A capsule)
3122981|NCT01734603|Active Comparator|conventional rehabilitation program|conventional rehabilitation program 20 patients are expected in this arm. Patients perform walking treadmill exercises with complete rest.
3122982|NCT01734603|Experimental|experimental rehabilitation program|experimental rehabilitation program 20 patients are expected in this arm. Patients perform walking treadmill exercises with active recovery (no stop walking).
3122983|NCT01734590|Experimental|Carbohydrate based food mix 1|Slowly digestible carbohydrate
3122984|NCT01734590|Experimental|Carbohydrate based food mix 2|Slowly digestible carbohydrate
3122985|NCT01734590|Active Comparator|Control carbohydrate based food|Rapidly digestible carbohydrate
3122986|NCT01734577|Active Comparator|Dry needling|Monofilament needles will be inserted into each subject's left multifidus muscle and stimulated mechanically for a local twitch response
3122987|NCT01734577|Sham Comparator|Sham needling|Monofilament tubes will be pressed into the left multifidus muscle and mechanically manipulated to give the sensation that needling is occuring.
3122988|NCT01734564|Experimental|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
3122989|NCT01734564|Experimental|Hiltonol, dendritic cells and radiation|Hiltonol, dendritic cells and radiation.
3122990|NCT01734551|Active Comparator|Morphine|Initial dose is 0.4mg/kg/day, divided every 3-4 hours, given PO with feeds. Drug is required until symptoms of withdrawal no longer cause the infant feeding, behavior, or elimination problems, up to 3 months.
3122991|NCT01734551|Active Comparator|Clonidine|Dose is started at 5 mcg/kg/day, given PO with feeds, divided every 3-4 hours. Drug is required until symptoms of withdrawal no longer cause the infant feeding, behavior, or elimination problems, up to 3 months.
3122992|NCT01734538|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories, Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
3122993|NCT01734538|Placebo Comparator|Placebo Capsule|Oral ingestion of 5 capsules of a placebo oil pill (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
3122994|NCT01734525|Experimental|One arm|Patients at risk will receive therapy with anidulafungin
3122995|NCT01734512|Experimental|Everolimus|Everolimus tablet will be taken daily by mouth with water. Twenty-eight days will constitute one course and subsequent courses will immediately follow with no break in the administration of the drug. Dosing is based on the BSA (body surface area) calculated at the beginning of each course of therapy. Patients will also be provided with a drug diary for everolimus. The maximum time on study is 24-months, but if there is no disease progression or adverse events, the patient may speak with a doctor about continuing the treatment off-study.
3122996|NCT01734499|Experimental|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. Quality of Life survey completed at 5 time points after informed consent."
3122997|NCT01734499|Active Comparator|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program, (2)Local support groups centered at community cancer centers, (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation.Quality of Life surveys completed at 5 time points after informed consent.
3122998|NCT01734486|Experimental|Low dose|
3122999|NCT01734486|Experimental|High dose|
3123000|NCT01734473|Experimental|Study day 1|Hydrolyzed casein protein. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
3123001|NCT01734473|Experimental|Study day 2|Hydrolyzed casein protein + carbohydrates. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
3123002|NCT01734473|Experimental|Study day 3|Hydrolyzed casein protein + leucine. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
3123003|NCT01734473|Experimental|Study day 4|Hydrolyzed casein protein + carbohydrates + leucine. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
3123004|NCT01734473|Experimental|Study Day 5|4 levels of hydrolyzed casein protein + carbohydrates
3123005|NCT01734460||third trimester pregnant women|no intervention
3123006|NCT01734447|Experimental|1.2, continuous treatment|
3123007|NCT01734447|Experimental|1.2, non-continuous treatment|
3123008|NCT01734447|Experimental|2.4, non-continuous treatment|
3123009|NCT01734434||Pregnant women|24 weeks or more of gestation
3123010|NCT01734421|Other|Control group|Habitual deshabituation in the control group following the guidelines of the primary health care institution.
3123011|NCT01734421|Active Comparator|Cell phone Aplication for Smarth Phone|Cell phone 6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation which includes mobile APPs application
3123012|NCT01734408|Experimental|alum-adjuvant 160U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 160U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.
3123013|NCT01734408|Placebo Comparator|placebo A|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.
3123014|NCT01734408|Experimental|alum-adjuvant 320U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 320U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 320U/0.5ml EV71 vaccines one year before.
3123015|NCT01734408|Placebo Comparator|placebo B|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 320U/0.5ml EV71 vaccines one year before.
3123016|NCT01734408|Experimental|alum-adjuvant 640U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 640U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 640U/0.5ml EV71 vaccines one year before.
3123017|NCT01734408|Placebo Comparator|placebo C|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 640U/0.5ml EV71 vaccines one year before.
3123018|NCT01734408|Experimental|adjuvant-free 640U /0.5ml EV71 vaccine|A booster dose of adjuvant-free 640U /0.5ml EV71 vaccine in 160 children whom had received two doses of adjuvant-free 640U/0.5ml EV71 vaccines one year before.
3123019|NCT01734408|Placebo Comparator|placebo D|A 0/0.5ml placebo in 80 children whom had received two doses of adjuvant-free 640U/0.5ml EV71 vaccines one year before.
3123198|NCT01733199|Experimental|BA-|Patient with no secondary behavioural addiction
3123020|NCT01734395||Galantamine|Patients will receive galantamine 8 mg/day for the first 4 weeks and the dose of galantamine will be increased up to 24 mg (if tolerable).
3123021|NCT01734382|Experimental|Tocilizumab (RoActemra/Actemra) Q2W|Participants will receive tocilizumab IV infusions of 12 mg/kg or 8 mg/kg Q2W up to 24 weeks or until occurrence of laboratory abnormalities.
3123022|NCT01734382|Experimental|Tocilizumab (RoActemra/Actemra) Q3W|Participants who meets eligibility criteria for Part 2 will receive tocilizumab IV infusions of 12 mg/kg or 8 mg/kg Q3W up to 52 weeks or until occurrence of neutropenia, thrombocytopenia, or liver enzyme abnormality.
3123023|NCT01734382|Experimental|Tocilizumab (RoActemra/Actemra) Q4W|Participants who completed 5 consecutive infusions of Q3W and had laboratory abnormality of neutropenia, thrombocytopenia or elevated liver enzymes, will receive tocilizumab IV infusions of 12 mg/kg or 8 mg/kg Q4W up to 12 weeks.
3123024|NCT01734356|Other|inherited arrhythmias|6 patient with inherited arrhythmias
3123025|NCT01734356|Other|valvulopathies|6 patient with valvulopathies
3123026|NCT01734356|Other|controle|8 healthy people for these pathologies
3123027|NCT01734343|Other|HOYA iMics Y-60H|eyes with implanted intraocular lens HOYA iMics Y-60H
3123028|NCT01734343|Other|PhysIOL microAY|eyes with implanted intraocular lens PhysIOL microAY
3123029|NCT01734330|Experimental|Cognitive behavior therapy|Cognitive behavior therapy for 6 weeks associated to nicotine replacement for 12 weeks
3123030|NCT01734330|Other|Nicotine replacement|Nicotine replacement for 12 weeks
3123031|NCT01734317|Experimental|Dressing|Mepilex Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
3123032|NCT01734304|Experimental|DC vaccination|DC vaccination
3123033|NCT01734291|Active Comparator|Family psychoeducation plus TAU|Family psychoeducational therapy in addition to treatment as usual for the patients.
3123034|NCT01734291|Placebo Comparator|Treatment as usual(TAU)|Treatment as usual administered by physician and counseling administered by nurse.
3123035|NCT01734278||Asenapine|Patients prescribed asenapine for any indication.
3123036|NCT01734265|Experimental|Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)|Depigoid 50%Grasses/ 50% Olea europaea (2.000 DPP/ml) The administration regimen will consist of a rush build-up regimen: 0.2 ml followed by 0.3 ml after 30 minutes if no adverse events occur a second maintenance dose of 0,5 ml 4 weeks later.
3123037|NCT01734265|Experimental|Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)|Depigoid 50%Grasses/ 50% Parietaria judaica(2.000 DPP/ml) The administration regimen will consist of a rush build-up regimen: 0.2 ml followed by 0.3 ml after 30 minutes if no adverse events occur a second maintenance dose of 0,5 ml 4 weeks later.
3123038|NCT01734252|No Intervention|Standard Treatment|If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be contin-ued and, if necessary increased. Hereby the maximum heparin dose is 1.500 IU per hour.
3123039|NCT01734252|Experimental|Treatment with Argatroban|If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be stopped and Argatroban will be given and adjusted until the target aPTT-range is achieved.
3123040|NCT01734239|Experimental|Pneumovax™ 23: Participants Between 2 and 49 Years|Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
3123041|NCT01734239|Experimental|Pneumovax™ 23: Participants >=50 Years|Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
3123042|NCT01734226|Experimental|Prunus Mume Extract|
3123043|NCT01734226|Placebo Comparator|Placebo|
3123044|NCT01734213|Experimental|Eriobotyra Japonica Lindley Extract|
3123045|NCT01734213|Placebo Comparator|Placebo|
3123046|NCT01734200|Experimental|Eriobotyra Japonica Lindley Extract|
3123047|NCT01734200|Placebo Comparator|Placebo|
3123048|NCT01734187|Experimental|Fermented Cinnamon Vine Powder|
3123049|NCT01734187|Placebo Comparator|Placebo|
3123050|NCT01734174||cardiac patients|Patients having elective coronary artery bypass grafting surgery, valve repair or replacement surgery, aortic repair or replacement surgery, or any combination of these surgeries will be recruited for this study to validate measurements of left ventricular volume and ejection fraction (a quantitative measure of general heart function) as assessed by 3-dimensional transesophageal echocardiography (3D TEE) as compared to 3-dimensional transthoracic echocardiography (3D TTE). Secondarily, we will also compare the 3D TEE assessment to the 2D TEE and TTE assessment, which is routinely performed simultaneously. Last, we will compare this assessment to a third method of quantification of cardiac function via a pulmonary artery catheter using thermodilution.
3123051|NCT01734161|Active Comparator|Dexamethasone|One dose of 8 mg of intravenous dexamethasone diluted in 50 ml of normal saline given as an infusion over 10 minutes.
3123052|NCT01734161|Placebo Comparator|Placebo|One dose of 50 ml of 0.9% normal saline that will be given as an infusion over 10 minutes.
3123053|NCT01734148|Experimental|Experimental group (RELAX TO SLEEP program)|
3123054|NCT01734148|No Intervention|Control group (Usual Care)|
3123055|NCT01734135|No Intervention|Usual Care|Usual care
3123056|NCT01734135|Experimental|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
3123057|NCT01734122||Essential Tremor|Patients with severe, medication-refractory Essential Tremor
3123058|NCT01734122||Parkinsonian Tremor|Patients with severe, medication-refractory, tremor-dominant Parkinsons
3123059|NCT01734109|Placebo Comparator|Standard of Care - Wound Care|Standard, acceptable local wound care management, consisting of topical treatments, chemical debriders, or light bedside debridement.
3123060|NCT01734109|Active Comparator|Quantum NPWT|Intervention with Quantum NPWT to Standard III/IV pressure ulcers for 12 weeks.
3123061|NCT01734109|Active Comparator|Quantum NPWT with Irrigation|NPWT with the Quantum device, with the addition of simultaneous irrigation using 0.25% acetic acid.
3123062|NCT01734096|Active Comparator|control group|healthy volunteer
3123063|NCT01734096|Active Comparator|obesity group|Patients with BMI >30 Kg/m2
3123064|NCT01734096|Active Comparator|white coat hypertension group|Patients with office blood pressure >140/90 mmHg and ambulatory daytime blood pressure <135/85 mmHg
3123065|NCT01734096|Active Comparator|Resistant hypertension|Patients with ambulatory blood pressure > 135/85 mm Hg (day) or >120/70 mm Hg (night) with 3 antihypertensive drugs with direct observance of drug taking.
3123066|NCT01734083|Experimental|Whole body vibration exercise|The experimental group will receive 2 sessions of whole body vibration exercise training and conventional exercise per week for a period of 9 weeks. The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration frequency and amplitude used will be 30 Hz and 1 mm, respectively.
3123067|NCT01734083|Active Comparator|Conventional exercise|This group will receive 2 sessions of conventional exercise training per week for a period of 9 weeks.
3123068|NCT01734070|Experimental|Cherry consumption|Volunteers will supplement their diets with 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories. We will prefer that the subjects split the cherries into three equal portions and consume one with each meal; however, this will not be mandatory.
3123069|NCT01734057|Experimental|combinant treatment group|120 enrolled patients are randomly picked up to take Rituximab in combination with rhTPO at the indicated dose.
3123070|NCT01734057|Active Comparator|single treatment group|120 enrolled patients are randomly picked up to take dexamethasone at the indicated dose.
3123071|NCT01734044|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take rhTPO in combination with dexamethasone at the indicated dose.
3123072|NCT01734044|Active Comparator|single treatment group|100 enrolled patients are randomly picked up to take dexamethasone at the indicated dose.
3123073|NCT01734018||Cohort|
3123074|NCT01734005|Experimental|Red Ginseng|
3123075|NCT01734005|Placebo Comparator|Placebo|
3123076|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
3123077|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
3123078|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 1.0%|R348 Ophthalmic Solution, 1.0%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
3123079|NCT01733992|Placebo Comparator|Placebo|Placebo, single (1 day) or multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
3123080|NCT01733979|Experimental|Heme-Iron Polypeptide|
3123081|NCT01733979|Placebo Comparator|Placebo|
3123082|NCT01733979|Active Comparator|Heme-Iron|
3123083|NCT01733979|Active Comparator|Organic Iron|
3123084|NCT01733966|Experimental|Secnidazol-Ciprofloxacin|2g(single dose) of Secnidazol associated with 1g(2 doses of 500mg)of Ciprofloxacin during 3 days
3123085|NCT01733966|Active Comparator|Amoxicillin-Clavulanic Acid|3g (3 doses of 1g) of Amoxicillin-Clavulanic acid during 10 days
3123086|NCT01733953|Experimental|Atorvastatin|6-Months Atorvastatin Therapy; 40mg oral, once daily
3123087|NCT01733953|Placebo Comparator|Sugar Pill (Placebo)|6-Months Placebo (sugar pill); oral, once daily
3123088|NCT01733940|Experimental|"Tegaderm CHG Dressing"|This arm is receiving a clorhexidine dressing for intravascular catheters.
3123089|NCT01733940|Active Comparator|"Tegaderm IV dressing"|Use of tegaderm iv dressings for intravascular catheters. Change each 7 days.
3123090|NCT01733927|Experimental|Rapid testing for HIV|The intervention consisted in administer an oral rapid test for HIV (OQA) to people that also had taken an ELISA test to compare their tests results. Group 1 consisted of 344 participants who did not know their HIV status; Group 2 consisted of 153 participants who were previously confirmed to be HIV positive. The participants were instructed to obtain their own oral fluid sample using the testing devices provide by the OQA rapid test kits. Project team members, certified to interpret OQA results, registered each test outcome on a data form using the same code number that the participant was assigned for the ELISA test.
3123091|NCT01733914|Experimental|Acupuncture|Experimental group
3123092|NCT01733914|Sham Comparator|Waiting list|Control group
3123093|NCT01733901|Active Comparator|RSD+PCI+Medicine|We will recruit 300 randomised CHD patients who meet the inclusion criteria. First undergo percutaneous coronary intervention, and then perform the renal artery angiography procedure to confirm anatomy. If renal artery meet the inclusion criteria, give the renal sympathetic denervation. After renal sympathetic denervation traditional secondary prevention of coronary heart disease is recommend. Finally we will conduct a clinic follow-up every six month and a telephone follow-up every three month(Total 24 months).
3123094|NCT01733901|Placebo Comparator|PCI+Medicine|We aslo will recruit 300 randomised CHD patients who meet the inclusion criteria. There are no significant differences in age, gender, race, past medical history,personal history and so on between the two groups. In this group we will perform percutaneous coronary intervention firstly, then give traditional secondary prevention of coronary heart disease just like the RSD+PCI+Medicine group. Third we will conduct a clinic follow-up every six month and a telephone follow-up every three month(Total 24 months).
3123095|NCT01733888|Active Comparator|Office Bleaching|
3123096|NCT01733888|Experimental|Resin Infiltration|
3123097|NCT01733888|Experimental|Resin Infiltration twice|
3123098|NCT01733888|Experimental|Office Bleaching + Resin Infiltration|
3123099|NCT01733875|Experimental|CC-220 0.03 mg|
3123100|NCT01733875|Experimental|CC-220 0.1 mg|
3123101|NCT01733875|Experimental|CC-220 0.3 mg|
3123102|NCT01733875|Experimental|CC-220 1 mg|
3123103|NCT01733875|Experimental|CC-220 2 mg|
3123104|NCT01733875|Experimental|Placebo|In each arm, 6 subjects will receive a dose of CC-220 and 2 subjects will receive placebo depending on the randomization schedule.
3123105|NCT01733875|Experimental|CC-220 4 mg|
3123106|NCT01733875|Experimental|CC-220 6 mg|
3123107|NCT01733875|Experimental|CC-220 1 mg (Part 2 only)|
3123108|NCT01733862||Group Japan|Children less than five years of age, hospitalized for RV GE or AGE and children with outpatient or emergency room visits for RV GE or AGE, between November 2007 and October 2016 (i.e., before and after the introduction of RV vaccination in Japan) in any of the selected hospitals.
3123109|NCT01733849||Group Bulgaria|Subjects in this group include infants/children from Bulgaria, less than five years of age with home visits by the GP/paediatrician for the treatment of AGE or brought to the GP/paediatrician for the treatment of AGE.
3123110|NCT01733849||Group Latvia|Subjects in this group include infants/children from Latvia, less than five years of age with home visits by the GP/paediatrician for the treatment of AGE or brought to the GP/paediatrician for the treatment of AGE.
3123111|NCT01733836|Experimental|Metformin|850mg BID
3123112|NCT01733836|Placebo Comparator|Placebo|
3123113|NCT01733823|Experimental|Group A|Performance scale 0-1, Charlson co-morbidity score=0 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
3123114|NCT01733823|Experimental|Group B|PS 0-1 Charlson=1 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
3123115|NCT01733823|Experimental|Group C|PS 0-1 Charlson >=2 Will start inclusion after Group A and B Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
3123116|NCT01733823|Experimental|Group D|PS 2, Charlson: Any Will start inclusion after Group C Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
3123117|NCT01733810|Experimental|Reflux Patients|Patients with reflux and a prior history of reflux esophagitis are being enrolled. The intervention is cessation of acid-suppressing medications.
3123118|NCT01733797|Experimental|Wooden spatula|
3123119|NCT01733797|Experimental|Therabite|
3123120|NCT01733784|Experimental|Viscoelastic properties of the airway|
3123121|NCT01733771||CAM with standard care|Symptomatic hospitalized people referred by the medical team to CAM treatments on top of standard of care
3123122|NCT01733771||Standard care only|Symptomatic patients who are referred to CAM treatments but are not interested in such treatments
3123123|NCT01733758|Experimental|Albiglutide 30 mg weekly|Subjects will be randomly assigned to double blind albiglutide 30 mg weekly treatment for 52 weeks
3123124|NCT01733758|Experimental|Albiglutide 50 mg weekly|Subjects will be randomly assigned to double blind albiglutide 50 mg weekly until Week 52
3123125|NCT01733758|Placebo Comparator|Placebo|Subjects will be randomly assigned to double blind matching albiglutide placebo administered weekly. Subjects will then cross-over to double-blind treatment with albiglutide 30 mg weekly at Week 24 until Week 52
3123126|NCT01733758|Active Comparator|Liraglutide 0.9 mg daily|Subjects will be randomly assigned to open-label liraglutide for 52 weeks
3123127|NCT01733745|Experimental|SYSTANE® Family|SYSTANE® Lid Wipes administered to treated eye(s) once a day; SYSTANE® BALANCE lubricant eye drops administered to treated eye(s), 1 drop 4 times a day; SYSTANE® Vitamins, 2 softgels ingested daily. Duration of treatment was 3 months.
3123128|NCT01733745|Active Comparator|Standard of Care|Microfiber towels (as warm compresses, with or without saline eye drops) warmed to the maximum comfortable temperature and placed over closed eyes for 8 minutes, 1 time a day. Duration of treatment was 3 months.
3123129|NCT01733732|Experimental|Systane Balance|SYSTANE® BALANCE Lubricant Eye Drops, 1 drop in each eye 4 times a day for 30 days
3123130|NCT01733732|Active Comparator|Systane Gel|SYSTANE® Gel, 1 drop in each eye 4 times a day for 30 days
3123131|NCT01733719|Active Comparator|ER plus RFA|Initial Endoscopic Resection of visible neoplasia/HGD in Barrett's esophagus followed by 4 x 2 monthly interventions (either ER of residual/metachronous visible lesions or RadioFrequency Ablation of 'flat' dysplastic or non-dysplastic Barrett's esophagus)
3123132|NCT01733719|Active Comparator|ER plus APC|Initial Endoscopic Resection of visible neoplasia/HGD in Barrett's esophagus followed by 4 x 2 monthly interventions (either ER of residual/metachronous visible lesions or Argon Plasma Coagulation of 'flat' dysplastic or non-dysplastic Barrett's esophagus)
3123133|NCT01733706|Active Comparator|Standard counseling|a psychologist will provide standard counseling
3123134|NCT01733706|Experimental|No nicotine electronic cigarette|patients will receive standard counseling as well as an electronic cigarette
3123135|NCT01733693|Experimental|Buprenorphine|Oral sublingual tablet, 8-32 mg per day, administered daily for duration of 4 months
3123136|NCT01733693|Active Comparator|Methadone|Oral sublingual tablet, 60-100 mg per day, administered daily for duration of 4 months
3123137|NCT01733680|Active Comparator|Amiloride|"Drug: Subjects will take 5mg qd Amiloride for 2 weeks, 10mg qd Amiloride for 3 weeks, 15 mg qd Amiloride for 3 weeks.~Behavioral: Each week subjects will complete the AISRS, BRIEF-A, and CGI."
3123138|NCT01733680|Placebo Comparator|Placebo|Drug: Subjects will take placebo for 8 weeks Behavioral: Each week subjects will complete questionnaires: AISRS, BRIEF-A, and CGI
3123139|NCT01733667|Experimental|MediENT|Right or left sinus cavity where MediENT will be place after randomization.
3123140|NCT01733667|Active Comparator|MeroPack|Right or left sinus cavity where MeroPack will be placed after randomization of MediENT is assigned.
3123141|NCT01733654|Active Comparator|RO4995819 5mg|RO4995819 5mgX6wks
3123142|NCT01733654|Active Comparator|RO4995819 15mg|RO4995819 15mg X 6 weeks
3123143|NCT01733654|Active Comparator|RO4995819 30mg|RO4995819 30mg X 6 weeks
3123144|NCT01733654|Placebo Comparator|Placebo|Placebo X 6 weeks
3123145|NCT01733615||Mucopolysaccharidosis IVA|Patients with the condition.
3123146|NCT01733602|Experimental|active tDCS and cognitive training|Transcranial direct current stimulation combined with cognitive training
3123147|NCT01733602|Active Comparator|sham tDCD and cognitive training|Sham transcranial direct current stimulation combined with cognitive training
3123148|NCT01733589|Experimental|Recombinant Human Endostatin|All patients received recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7. During week 2 through 8, patients received etoposide 50mg/m2 days 1-5 and cisplatin 50mg/m2 on day 1,8, every 4 weeks for two cycles with concurrent thoracic radiation at 60~66Gy in 30~33 fractions for 6~7 weeks.
3123149|NCT01733576|Sham Comparator|Sham HD-tDCS|
3123150|NCT01733576|Active Comparator|Active HD-tDCS 1|
3123151|NCT01733576|Active Comparator|Active HD-tDCS 2|
3123152|NCT01733576|Active Comparator|Active HD-tDCS 3|
3123153|NCT01733563|Experimental|fructose sweetened beverage|"Soft drink consumption:~Subjects have to drink a fructose sweetened beverage (3x 200ml per day, 13.3g fructose/100ml) during 7 weeks"
3123199|NCT01733199|Experimental|BA+/DDS-|Patients with secondary behavioural addiction, without dopamine dysregulation syndrome
3123154|NCT01733563|Experimental|glucose sweetened beverage|"Soft drink consumption:~Subjects have to drink a glucose sweetened beverage (3x 200ml per day, 13.3g glucose/100ml) during 7 weeks"
3123155|NCT01733563|Experimental|sucrose sweetened beverage|"Soft drink consumption:~Subjects have to drink a sucrose sweetened beverage (3x 200ml per day, 13.3g sucrose/100ml) during 7 weeks"
3123156|NCT01733563|Experimental|No change of eating habits|"No Soft drink consumption (no soft drink diet):~Subjects do not change their eating habits during 7 weeks"
3123157|NCT01733550||Glaucoma patients|Intraocular pressure is measured by Home iCare performed by the study nurse, by the patient it self and by Goldmann applanation tonometry.
3123158|NCT01733537|Experimental|Vest and Education|Motorcycle Taxi Drivers provided with a reflective, fluorescent vest and basic education about recommended measures to increase their visibility
3123159|NCT01733537|Other|Education Alone|Motorcycle Taxi Drivers provided with basic education about recommended measures to increase their visibility
3123160|NCT01733524|Sham Comparator|Picture of a fish|Participants will receive a picture of a betta fish.
3123161|NCT01733524|Active Comparator|Pet fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
3123162|NCT01733511||admitted to emergency department|
3123163|NCT01733511||patients admitted to surgical ward|
3123164|NCT01733485|Active Comparator|Aspirin|
3123165|NCT01733485|Active Comparator|Indomethacin|
3123166|NCT01733485|No Intervention|Control|
3123167|NCT01733472|Placebo Comparator|RA-arm|RA-arm: the patients in this arm will receive intrathecal anaesthesia consisting of bupivacaine 15 mg
3123168|NCT01733472|Experimental|GA-arm, remifentanil|GA-arm: patients in this arm will receive general anaesthesia consisting of Target Controlled Infusion (TCI) of remifentanil and propofol
3123169|NCT01733459|Experimental|Treatment I|1 DLBS3233 capsule 100 mg (once daily) and 1 placebo caplet of Metformin XR (twice daily)
3123170|NCT01733459|Active Comparator|Treatment II|1 Metformin XR caplet 750 mg (twice daily) and 1 placebo capsule of DLBS3233 (once daily)
3123171|NCT01733446|No Intervention|Standard anesthesia regimen|Positive pressure ventilation will be stopped at the same time infusions of anesthetic agents and spontaneous ventilation employed until emergence from anesthesia is observed. (This is standard protocol for everyday anesthesia management of this population.)
3123172|NCT01733446|Experimental|Continuation of High Frequency Jet Ventilation ( HFJV)|In Group B after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
3123173|NCT01733433|Experimental|taped ankle|Subjects will be taped in at the ankle for a series of exercises.
3123174|NCT01733420|Experimental|Biodentine|Pulpotomy using Biodentine as pulpotomy medicine.
3123175|NCT01733420|Active Comparator|White Mineral trioxide Aggregate (MTA)|Pulpotomy using white MTA as pulpotomy medicine.
3123176|NCT01733420|Active Comparator|Tempophore|Pulpotomy using Tempophore as pulpotomy medicine in a control group.
3123177|NCT01733407|Placebo Comparator|Sugar pill|Placebo arm
3123178|NCT01733407|Active Comparator|L-serine|amino acid supplementation with L-serine
3123179|NCT01733394|Experimental|Generic A - Generic B - Brand - Generic A - Brand - Generic B|Sequence 1
3123180|NCT01733394|Experimental|Generic B - Brand - Generic A - Generic B - Generic A - Brand|Sequence 2
3123181|NCT01733394|Experimental|Brand - Generic A - Generic B - Brand - Generic B- Generic A|Sequence 3
3123182|NCT01733381||Barefoot runners|This group of individuals will run in minimally shod foot ware. For the purposes of this study we have defined this to be Vibram Five Finger shoes. Participants will be runners who consistently run in these shoes at least 20 miles per week.
3123183|NCT01733381||Shoed runners|This group of individuals will run in normal running shoes. Participants will be runners who consistently run in regular running shoes (that are not considered by industry standards to be minimal shoes) at least 20 miles per week.
3123184|NCT01733355|Experimental|Tau diagnostic|[F18] T807
3123185|NCT01733342|Active Comparator|Celsite|patients received celsite chemoport implantation under local anesthesia
3123186|NCT01733342|Experimental|Humanport|patients received Humanport chemoport implantation under local anesthesia
3123187|NCT01733329|Experimental|Misoprostol|women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to 400 mcg misoprostol (2 tablets) (n=60) placed in buccal space after umbilical cord clamping by anesthesiologist. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.
3123188|NCT01733329|Placebo Comparator|Folic Acid|women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to 10 mg Folic acid (2 tablets) (n=60) placed in buccal space after umbilical cord clamping by anesthesiologist. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.
3123189|NCT01733316|Experimental|All Participants|"Cystagon® Phase: From Screening and during Months 1, 2, 3 participants receive their usual dose of Cystagon® every 6 hours (Q6H).~RP103 Phase: During Months 3.5, 4, 5, 6, 7 participants receive RP103 every 12 hours (Q12H).~Long Term Phase: On or after Month 7, for the remainder of study participants receive RP103 Q12H."
3123190|NCT01733303|Experimental|Exercise|Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality.
3123191|NCT01733290|Experimental|Botulinum toxin A|A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
3123192|NCT01733290|Placebo Comparator|Control arm-Normal saline instillation|Normal saline instillation
3123193|NCT01733277||With neuropathic pain (PainDETECT ≥ 13)|Magnetic Resonance Imaging (MRI)
3123194|NCT01733277||No neuropathic pain (PainDETECT<13)|Magnetic Resonance Imaging (MRI)
3123195|NCT01733238|Experimental|PNT2258|PNT2258 120 mg/m2 will be administered as a 2-hour intravenous infusion on days 1-5 of a 21-day cycle. Treatment may continue (unless there is disease progression or the occurrence of unacceptable toxicity) for a total of 6 cycles of therapy.
3123196|NCT01733212|Experimental|Ginger|2 gm powder of ginger filled in a capsule
3123200|NCT01733199|Experimental|BA+/DDS+|Patients with secondary behavioural addiction and dopamine dysregulation syndrome
3123201|NCT01733186|Experimental|CARTISTEM®|Drug name and ingredients: CARTISTEM [allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo cultured, combined with sodium hyaluronate] Dosage: Administer 0.5 mL of the combination product per cm^2 of the cartilage defect
3123202|NCT01733173||mass in posterior fossa, either benign or malignant|A pilot study will be performed. We will perform fMRI and DTI in children before and after surgery for posterior fossa brain tumors. Each subject will receive the standard of care for their brain tumors in terms of surgical resection, radiation therapy and/or chemotherapy.
3123203|NCT01733147|Placebo Comparator|Placebo|Subjects will be placed on 3 capsules a day of placebo (1200 mg of ethyl oleate 3 capsules a day) taken orally for six months. Subjects will take 2 capsules with breakfast and 1 capsule with their evening meal.
3123204|NCT01733147|Active Comparator|Omega-3 free fatty acids|Subjects will be placed on 3 capsules a day of Omega 3 free fatty acids taken orally for six months. Subjects will take 2 capsules with breakfast and 1 capsule with their evening meal. Active drug will consist of 1200 mg of a ω3 FFA preparation containing 675 mg EPA and 300 mg DHA.
3123205|NCT01733134|Experimental|Standard therapy plus Tolvaptan|Patient in the interventional group will receive tolvaptan in addition to standard therapy
3123206|NCT01733134|Placebo Comparator|Standard therapy plus placebo|
3123207|NCT01733121|Experimental|NBI-98854|Dose titration to determine a subject's optimal dose in the range of 25 to 75 mg NBI-98854. Dose titration is performed in increments of 25 mg. NBI-98854 administered as one (1) 25 mg capsule, two (2) 25 mg capsules, or one (1) 25 mg capsule and one (1) 50 mg capsule by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
3123208|NCT01733121|Placebo Comparator|Placebo|Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.
3123209|NCT01733108|Experimental|Canagliflozin (JNJ-28431754) + glyburide|Each volunteer will receive a single dose of glyburide on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of glyburide in combination with a single dose of canagliflozin.
3123210|NCT01733095|Experimental|ambrisentan|In all patients with clinically significant PoPH, ambrisentan will be administered orally using a low ascending dose regime (see below). Duration of treatment will be 12 months.
3123211|NCT01733082||Cohort|
3123212|NCT01733069||No treatment|
3123213|NCT01733056|Placebo Comparator|Healthy Volunteer|Healthy volunteers without skin disease that received administration of Fluzone
3123214|NCT01733056|Experimental|Azathioprine|Patients with skin diseases taking azathioprine that received administration of Fluzone
3123215|NCT01733056|Experimental|TNF alpha blocker|Patients with skin diseases taking azathioprine that received administration of Fluzone
3123216|NCT01733043|Experimental|Dexmedetomidine infusion|Dexmedetomidine 0.5 mcg/kg loading dose administered over 20 minutes, followed by 0.6 mcg/kg/hr infusion for 1 hour and 40 minutes
3123217|NCT01733043|Placebo Comparator|Placebo|Normal saline infusions will be administered over 4 hours at rates mimicking the DEX infusion rate
3123218|NCT01733030||250 mg Seromycin|Healthy adults who will receeve one administration of 250 mg of Seromycin prior to the start of the study.
3123219|NCT01733030||500 mg Seromycin|Healthy adults who will recieve one administration of 500 mg of Seromycin prior to the start of the study.
3123220|NCT01733030||Placebo|Healthy adults who will receive one administration of a placebo pill prior to the start of the study.
3123221|NCT01733017|Experimental|sodium reduction, omega-3, lycopene|combination of dietary sodium restriction with supplementation of omega-3 capsules and lycopene containing juices or foods
3123222|NCT01733017|Placebo Comparator|Control|Limited nutritional counseling, juice without lycopene, rice oil capsules
3123223|NCT01733004|Experimental|Arm A|MM-141 monotherapy
3123224|NCT01733004|Experimental|Arm B|MM-141 and Everolimus
3123225|NCT01733004|Experimental|Arm C|MM-141 and Abraxane and Gemcitabine
3123226|NCT01732991|Experimental|prostatic photo-vaporization|prostatic photo-vaporization (PVP) surgery with laser Greenlight
3123227|NCT01732978|Other|Babies|Any child born in the University Hospital of Saint Etienne (inborn) whatever its term birth, hospitalized in a neonatal unit at the time of registration (after 37 weeks of gestation for preterm infants) or maternity
3123228|NCT01732965|Placebo Comparator|NB-UVB phototherapy|NB-UVB alone
3123229|NCT01732965|Experimental|phototherapy and photochemotherapy|NB-UVB and PUVA
3123230|NCT01732952||regions,hospitals,age, gender, risk levels, comorbidity,|
3123231|NCT01732939||AT|Docetaxel 75 mg/m2, day 1 or paclitaxel 175mg/m2 day 1 plus Epirubicin 75 mg/m2, day 1 or doxorubicine 50mg/m2 day 1 for 6-8 cycles
3123232|NCT01732939||AT-NP|docetaxel 75mg/m2,day 1 or paclitaxel 175mg/m2,day 1 plus doxorubicine 50mg/m2,day 1 or epirubicin 75mg/m2, day 1,for3-4 cycles then switch to vinorelbine 25mg/m2, day 1 and day 8 plus cisplatinum 75mg/m2, day 1 for 3-4 cycles
3123233|NCT01732926|Experimental|Rituximab + Bendamustine + Idelalisib|Participants will receive rituximab + bendamustine + idelalisib.
3123234|NCT01732926|Experimental|Rituximab + Bendamustine + Placebo|Participants will receive rituximab + bendamustine + placebo.
3123235|NCT01732913|Experimental|Rituximab + idelalisib|Participants will receive rituximab + idelalisib.
3123236|NCT01732913|Placebo Comparator|Rituximab + Placebo|Participants will receive rituximab + placebo. Following confirmation of iNHL disease progression by the independent review committee and unblinding, participants may be eligible to receive open-label idelalisib 150 mg twice daily.
3123237|NCT01732900|Active Comparator|Morphology|Embryos selected for transfer will be based on morphology alone.
3123238|NCT01732900|Experimental|GemART assay|Embryos selected for transfer will be based upon morphology and GemART assay.
3123239|NCT01732887|Other|Immediate cognitive fitness training|"After the initial baseline evaluation, the immediate treatment group participants will receive individualized multi-domain cognitive training and standard of care. Cognitive training includes at least 1/2 hour per session, 3 days per week, throughout the 10 week interval. After 10 weeks of cognitive fitness training, participants in this group will switch to a 20 week no intervention period where they receive only standard of care treatment."
3123349|NCT01732198|Active Comparator|ActHIB and Prevnar 13|ActHIB at a dose of 0.5 ml IM
3171190|NCT01401933|Experimental|Linifanib|
3123240|NCT01732887|Other|Delayed cognitive fitness training|"After the initial baseline evaluation, the delayed cognitive fitness training group participants will receive only standard of care for 10 weeks (no intervention period). Starting in week 11, participants in this arm will receive individualized multi-domain cognitive training and standard of care. Cognitive training includes at least 1/2 hour per session, 3 days per week, throughout the 10 week interval. After 10 weeks of cognitive fitness training, participants will go for another 10 weeks with only standard of care treatment."
3123241|NCT01732874|Other|Expecta 200 mg|Breastfeeding mothers of pre-mature infants randomly assigned to 200 mg Expecta to be taken orally once a day. Expecta to be taken for approximately 8 weeks post-partum or a shorter time if infant is discharged sooner from NICU.
3123242|NCT01732874|Other|Expecta 1 Gram|Breastfeeding mothers of pre-mature infants randomly assigned to one Gram of Expecta to be taken orally once a day. Expecta to be taken for approximately 8 weeks post-partum or a shorter time if infant is discharged sooner from NICU.
3123243|NCT01732861|Experimental|CC-292 + Lenalidomide|
3123244|NCT01732848||Subjects treated with BMS-986094/INX-08189|Subjects who participated in a clinical trial in which at least 1 dose of BMS-986094/INX-08189 was administered
3123245|NCT01732848||Subjects treated with Placebo matching BMS-986094/INX-08189|Subjects who participated in a clinical trial in which at least 1 dose of Placebo matching BMS-986094/INX-08189 was administered
3123246|NCT01732835|Experimental|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
3123247|NCT01732822|Experimental|Ticagrelor|Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
3123248|NCT01732822|Active Comparator|Clopidogrel|Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
3123249|NCT01732809|Active Comparator|group A|Group A: Patients received 2units/0.02 mL of reconstituted ABO on the right side of the forehead and 2 units/0.02 mL of reconstituted ONA on the left side.
3123250|NCT01732809|Active Comparator|group B|Patients received 2units/0.02 mL of reconstituted ABO on the left side of the forehead and 2 units/0.02 mL of reconstituted ONA on the right side.
3123251|NCT01732796|Experimental|Allocated 24 weeks BI 207127 + BI 201335|24 weeks of BI 207127 and BI 201335 in combination with Ribavirin
3123252|NCT01732796|Experimental|Randomized 16 weeks BI 7127+BI1335 + RBV|16 weeks of BI 207127 and QD BI 201335 RBV, followed by additional 8 weeks of placebo BI 207127+ placebo BI 201335 in combination with placebo RBV
3123253|NCT01732796|Experimental|Randomized 24weeks BI 7127+ BI1335 + RBV|24 weeks of BI 207127and BI 201335 in combination with RBV
3123254|NCT01732783||Metastatic Colorectal Cancer|Participants with wild-type RAS metastatic colorectal cancer who were receiving panitumumab in combination with chemotherapy.
3123255|NCT01732770|Experimental|Denosumab 60 mg|Participants received denosumab 60 mg subcutaneous injection once every 6 months for 12 months and placebo to zoledronic acid by intravenous infusion on Day 1.
3123256|NCT01732770|Active Comparator|Zoledronic Acid 5 mg|Participants received zoledronic acid 5 mg by intravenous infusion on Day 1 and placebo to denosumab by subcutaneous injection on Day 1 and at Month 6.
3123257|NCT01732757|Active Comparator|Lastacaft®|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
3123258|NCT01732757|Active Comparator|Pataday™|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
3123259|NCT01732757|Placebo Comparator|Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)|One drop of Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
3123260|NCT01732744|Placebo Comparator|Physiological solution|"1)Negative Control: physiological solution, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
3123261|NCT01732744|Active Comparator|Sodium hypochlorite|"2)active Comparator 1: Sodium hypochlorite, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
3123262|NCT01732744|Active Comparator|Peroxide alkaline|"2)Active Comparator 2: Alkaline peroxide (Polident), for 5 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
3123263|NCT01732744|Experimental|Castor bean solution|"3)Experimental: castor bean solution, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
3123264|NCT01732731|Experimental|treadmill training|children will receive home-based treadmill training with supervision from a physical therapist
3123265|NCT01732731|No Intervention|no treadmill training|children will not receive treadmill training
3123266|NCT01732718|Experimental|Atorvastatin|Atorvastatin 40mg tablet once daily for 6 weeks
3123267|NCT01732718|Placebo Comparator|Placebo for atorvastatin|Placebo (for atorvastatin) 1 tablet once daily for 6 weeks
3123268|NCT01732705|Experimental|HIT (trained leg) DM|High intensity interval training for one leg (trained leg) (randomized) in patient with type 2 diabetes
3123269|NCT01732705|No Intervention|Control leg, DM|Control leg (untrained leg)in patient with type 2 diabetes
3123270|NCT01732705|Experimental|HIT (trained leg), Control subject|High intensity interval training for one leg (trained leg) (randomized) in control subject
3123271|NCT01732705|No Intervention|Control leg, Control subject|Control leg (untrained leg)in control subject
3123272|NCT01732692|Experimental|MOVIPREP (Morning-only dose)|MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), twice within same morning of colonoscopy.
3123273|NCT01732692|Other|MOVIPREP (Split-dose)|MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), once the evening before colonoscopy and once the morning of colonoscopy.
3123274|NCT01732679||stroke patients|specialized rehabilitation in a multidisciplinary team, Sunnaas International Network
3123275|NCT01732666|Placebo Comparator|group L|receives 100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
3123276|NCT01732666|Placebo Comparator|group H|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
3123277|NCT01732666|Experimental|group N|20mg of nefopam mixed in 100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
3123278|NCT01732653|Experimental|TT+VR|The training will consist of walking on the treadmill while negotiating obstacles in a virtual reality simulation.Training will be provided3 times a week for a duration of 6 weeks (total of 18 sessions).
3123279|NCT01732653|Active Comparator|TT alone|The training will consist of walking on the treadmill 3 times a week for a duration of 6 weeks (total of 18 sessions).
3123280|NCT01732640|Experimental|Study Arm|Eligible patients will begin with a 14-day lead-in period with afatinib alone. This will be followed immediately by 2 cycles of induction chemotherapy (IC) with carboplatin AUC 6 IV Day 1, paclitaxel 175mg/m2 IV Day 1, and oral afatinib as a continuous daily dosing. Each cycle is repeated every 21 days. After completion of 2 cycles of IC, patients will be assessed for response by CT/MRI and clinical exam. After the induction, all patients will receive Intensity Modulated Radiation Therapy (IMRT) with weekly cisplatin 40mg/m2 IV. Chemoradiotherapy (CRT) will begin 2-3 weeks after the completion of the second cycle of IC. The patients will be evaluated with a MRI or CT, and FDG PET approximately 12 weeks after completion of CRT.
3123281|NCT01732627|Experimental|MenACYW Vaccine Group|Participants who receive MenACYW conjugate vaccine
3123282|NCT01732627|Active Comparator|Menomune® A/C/Y/W 135 Vaccine Group|Participants will receive Menomune® A/C/Y/W 135 Vaccine
3123283|NCT01732614|Experimental|Topcon Endpoint Management Laser|
3123284|NCT01732601|Experimental|Intensive Outpatient CBT|Intensive CBT for both parents and adolescents as well as family sessions to increase communication.
3123285|NCT01732601|Active Comparator|Standard Care|Standard Treatment in the Community
3123286|NCT01732588|Active Comparator|Regimen A - 120mg OZ439 PIB|120mg single dose of OZ439 as powder in bottle (PIB) formulation
3123287|NCT01732588|Experimental|Regimen B - 120 mg OZ439 IR caplet|120 mg single dose of OZ439 immediate release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
3123288|NCT01732588|Experimental|Regimen C - 120 mg OZ439 caplet via Enterion capsule|120 mg single dose of OZ439 caplet formulation containing nanoparticulate, administered orally via the Enterion capsule and delivered to the proximal small bowel
3123289|NCT01732575|Experimental|Enrichment|Enrichment with meaning-generating activities
3123290|NCT01732575|No Intervention|Rehabilitation as usual|The ongoing, normal day center program.
3123291|NCT01732562|No Intervention|Control|Patient receives the standard of care.
3123292|NCT01732562|Experimental|Patient e-Learning educational tool|Patient receives the standard of care and access to patient e-Learning educational tool.
3123293|NCT01732549|Experimental|Tasquinimod|1 capsule daily, taken orally with water and food (0.25 mg initially then dose escalated to 0.5 mg or 1 mg per day) until disease progression or toxicity or patient's willingness to stop.
3123294|NCT01732549|Placebo Comparator|Placebo|1 capsule daily, taken orally with water and food until disease progression or toxicity or patient's willingness to stop.
3123295|NCT01732536|Experimental|S8 Sinus Implant|"In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses~Mometasone furoate nasal spray (200mcg) once daily"
3123296|NCT01732536|Sham Comparator|Control|"In-office bilateral sham procedure~Mometasone furoate nasal spray (200mcg) once daily"
3123297|NCT01732523||No treatment|No intervention
3123298|NCT01732510|Experimental|Part 1: MK-8226 0.3 mg/kg|MK-8226 administered intravenously (IV) at a weight-based dose every 2 weeks for a period of 12 weeks.
3123299|NCT01732510|Experimental|Part 1: MK-8226 1 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
3123300|NCT01732510|Experimental|Part 1: MK-8226 3 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
3123301|NCT01732510|Experimental|Part 1: MK-8226 10 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
3123302|NCT01732510|Placebo Comparator|Part 1: Placebo (pooled)|Dose-matched placebo administered IV every 2 weeks for a period of 12 weeks.
3123303|NCT01732510|Experimental|Part 2: MK-8226 3 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
3123304|NCT01732510|Placebo Comparator|Part 2: Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
3123305|NCT01732497|Experimental|Single Group miraDry Treatment|This is a single group study where each enrolled subject will receive active miraDry treatment in each axilla.
3123306|NCT01732484|Other|iMics1 NY-60|eyes with implantation of iMics1 NY-60 IOL
3123307|NCT01732484|Other|AcrySof SN60WF|eyes with implantation of AcrySof SN60WF IOL
3123308|NCT01732471|Experimental|Kuvan®|
3123309|NCT01732458|Experimental|Aprepitant Dose 1: Equivalent to 125 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 125 mg in adults on Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered intravenously (IV) immediately prior to anesthesia.
3123310|NCT01732458|Experimental|Aprepitant Dose 2: Equivalent to 40 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 40 mg in adults on Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered IV immediately prior to anesthesia.
3123311|NCT01732458|Experimental|Aprepitant Dose 3: Equivalent to 10 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 10 mg in adults Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered IV immediately prior to anesthesia.
3123312|NCT01732458|Active Comparator|Ondansetron|Pediatric participants in the control regimen are administered ondansetron IV on Day 1 immediately prior to induction of anesthesia plus a matching placebo dose to aprepitant as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia.
3123350|NCT01732185|Other|Patient|congenital cystic adenomatoid malformations
3123351|NCT01732172|Experimental|Patient Group|Patient with urethritis
3176439|NCT01364441|Experimental|E|
3123313|NCT01732445|Experimental|Supportive care (ruxolitinib phosphate and danazol)|Patients receive ruxolitinib phosphate PO BID and danazol PO TID on days 1-56. Treatment repeats every 56 days for 6 courses in the absence of disease progression or unacceptable toxicity. At the treating physician's discretion, patients may continue treatment past 6 courses if they are without disease progression.
3123314|NCT01732419|Experimental|Home-based training|"After the first three supervised training sessions in the hospitals, patients in the home-based training group are instructed to wear a heart rate monitor during exercise training at home. Prescribed exercise exists of two or three exercise sessions per week, of one hour at 70 - 85% of their maximum heart rate.~Once a week the heart rate data is uploaded and evaluated by an exercise specialist together with the patient by telephone."
3123315|NCT01732419|Active Comparator|Centre-based training|Patients in the centre-based training group will perform all trainings sessions under direct supervision of a physical therapist specialized in CR. Training sessions will be performed on an cycle ergometer, starting with a warm up phase of 5 min, followed by 50 min of cycling at 70-85% of the maximal HR and a cooling down period of 5 min. During the training period, physical therapists will record attendance, training duration and actual training intensity. After the 12-week training period patients receive individual advice from their physical therapist on physical activities.
3123316|NCT01732406||Acomegaly with Pegvisomant|Patients receiving pegvisomant monotherapy from own doctor to treat acromegaly.
3123317|NCT01732406||Acromegaly with somatostatin analog|Patients receiving somatostatin analog monotherapy from own doctor to treat acromegaly
3123318|NCT01732406||Active Acromegaly|Patients not on drugs for treatment of acromegaly
3123319|NCT01732393|Active Comparator|oral quercetin capsules|Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks
3123320|NCT01732393|Placebo Comparator|oral placebo capsules|Patients in the placebo group received two placebo capsules containing lactose .
3123321|NCT01732380|Active Comparator|Radiotherapy|Radiotherapy 2.0Gy/day, 5 times/week,6 weeks In Subjects With Inoperable esophageal cancer
3123322|NCT01732380|Experimental|Raltitrexed/Oxaliplatin Plus Radiotherapy|Raltitrexed 2.5mg/㎡ d1,Oxaliplatin 100mg/㎡ d1,q21d Plus Radiotherapy 2.0Gy/day, 5 times/week,6 weeks In Subjects With Inoperable esophageal cancer
3123323|NCT01732367|Active Comparator|Lamivudine plus adefovir|Continue lamivudine/adefovir add on treatment (standard treatment)
3123324|NCT01732367|Experimental|Tenofovir|Switch from lamivudine/adefovir add on treatment to tenofovir monotherapy
3123325|NCT01732341|Experimental|STENTYS self-apposing stent|Intervention to treat STEMI with the STENTYS self-apposing stent
3123326|NCT01732341|Active Comparator|VISION balloon-expandable stent|STEMI treatment with a VISION balloon-expandable stent
3123327|NCT01732328|Placebo Comparator|placebo|Inactive pill (microcrystalline cellulose and corn starch) taken daily
3123328|NCT01732328|Active Comparator|Calcium plus vitamin D|600mg of calcium and 200 international units (IU) vitamin D taken daily
3123329|NCT01732315|Experimental|Vaccination Email Reminder|This group of parents in the study will receive email notifications about due/overdue vaccines for their adolescents. Vaccination records will be reviewed to identify adolescent patients in both practices who are newly eligible for a vaccine and/or overdue for a vaccine at the start of every other month. Email notifications will then be sent to the parents of these children.
3123330|NCT01732315|No Intervention|Usual Care|This group of parents in the study will not receive email notifications about due/overdue vaccines for their adolescents.
3123331|NCT01732302|Experimental|Educational intervention|Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
3123332|NCT01732302|No Intervention|Delayed educational intervention|Primary health care centers in the delayed intervention group will receive the same intervention as described above with 9 months delay.
3123333|NCT01732289|Experimental|A|
3123334|NCT01732276|Experimental|gefitinib|gefitinib tablet 250mg/day by mouth until disease progression
3123335|NCT01732263|Experimental|SSP-004184 (Child-Pugh A Liver Impaired)|The Child-Pugh Score is a scoring system used to determine the prognosis with cirrhosis and need for liver transplantation. Scoring is based upon albumin, ascites, total bilirubin, prothrombin time, and encephalopathy. Each category is based on a scoring system of 1-3 with 3 being the worst and a total score range of 5-15. It is broken into categories A (score of 5-6), B (score of 7-9), and C (score of 10-15) with worsening from A to C for prognosis.
3123336|NCT01732263|Experimental|SSP-004184 (Child-Pugh B Liver Impaired)|
3123337|NCT01732263|Experimental|SSP-004184 (Child-Pugh C Liver Impaired)|
3123338|NCT01732263|Experimental|SSP-004184 (Matched Healthy Subjects)|
3123339|NCT01732250|Experimental|Colistin and Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function
3123340|NCT01732250|Active Comparator|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function
3123341|NCT01732237|Experimental|JNJ-42396302|Patients will receive JNJ-42396302 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
3123342|NCT01732237|Experimental|JNJ-42692507|Patients will receive JNJ-42692507 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
3123343|NCT01732237|Experimental|JNJ-53773187|Patients will receive JNJ-53773187 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
3123344|NCT01732224|Experimental|Tenofovir + Telbivudine|Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
3123345|NCT01732224|Active Comparator|Tenofovir|In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
3123346|NCT01732211|Experimental|PD 0360324|
3123347|NCT01732211|Placebo Comparator|Placebo|
3123348|NCT01732198|Experimental|NU300 and Prevnar 13|NU300 at a single dose of 0.5 mL IM
3123352|NCT01732172|Other|Control group|Subjects with no urethritis and no history urogenital infection
3123353|NCT01732159|Experimental|Administration of the checklist|Patients will be contacted by phone for administration of the checklist
3123354|NCT01732159|No Intervention|No contact by phone|Patients who will not be contacted by phone
3123355|NCT01732146|Active Comparator|Erythropoietin beta|1000 to 1500 U/kg/dose X 3 every 24 hours
3123356|NCT01732146|Placebo Comparator|Placebo|0.2 ml saline solution X 3 given every 24 hours
3123357|NCT01732133|Experimental|Measurement of arterial pressure|
3123358|NCT01732120|Experimental|Off-clamp partial nephrectomy|Partial nephrectomy will be performed without clamping of the renal blood vessels.
3123359|NCT01732120|No Intervention|Traditional partial nephrectomy|Partial nephrectomy will be performed with clamping of the renal blood vessels.
3123360|NCT01732107|Experimental|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule.
3123361|NCT01732094|Experimental|Corifollitropin Alfa + hMG|
3123362|NCT01732081||Patients with chronic hepatitis B virus infection|Patients chronically infected with hepatitis B virus (HBV), and followed in university hospital of Strasbourg, France
3123363|NCT01732068|Experimental|Corifollitropin alfa+hMG|
3123364|NCT01732055|Active Comparator|Partner-Assisted Interpersonal Psychotherapy|Partner-Assisted Interpersonal Psychotherapy is an 8-week series of psychotherapy sessions attended by the patient and her identified partner.
3123365|NCT01732055|Other|Treatment as Usual|Treatment prescribed for subjects by the UNC Perinatal Psychiatry clinic physicians according to the clinic algorithm.
3123366|NCT01732029|Other|Normobaric hypoxia chamber|Study subjects will be put into a hypoxic state by exposing them to normobaric hypoxia by administrating an air mix containing a reduced O2 concentration. This is achieved in a hypoxia chamber where O2 concentration is gradually reduced to simulate high altitude (about 4500 m).
3123367|NCT01732016|Other|Normobaric hypoxia chamber|Study subjects will be put into a hypoxic state by exposing them to normobaric (sea-level atmospheric pressure) hypoxia (low oxygen) by administrating an air mix containing a reduced O2 concentration. This is achieved in a hypoxia chamber where O2 concentration is gradually reduced to simulate high altitude (around 4500 m).
3123368|NCT01732003|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
3123369|NCT01732003|Placebo Comparator|Placebo Pill|Oral ingestion of 5 capsules of a placebo oil pill (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
3123370|NCT01731990|Experimental|Canakinumab (ACZ885)|Monthly subcutaneous doses of Canakinumab 150 mg/1 mL for 12 months
3123371|NCT01731990|Placebo Comparator|Placebo|Monthly subcutaneous doses of placebo of Canakinumab 150 mg/1 mL for 12 months
3123372|NCT01731977|Experimental|Strengths-based family psychoeducation|Family psychoeducation in addition to treatment as usual
3123373|NCT01731977|No Intervention|Waiting list|Treatment as usual
3123374|NCT01731964|Experimental|WA- NG Telescope Prothesis|Implantable Miniature Telescope for end stage AMD
3123375|NCT01731951|Experimental|Arm A|Myelofibrosis (MF) participants will receive Imetelstat, 9.4 milligram per kilogram (mg/kg), intravenously [IV] as 2 hour infusion, on Day 1 of every 21-day cycle as long as they derive clinical benefit or until study end.
3123376|NCT01731951|Experimental|Arm B|MF participants will receive Imetelstat, 9.4mg/kg, IV as 2 hour infusion, on Day 1, 8, 15 of Cycle 1, then Day 1 of each subsequent 21-day cycle as long as they derive clinical benefit or until study end.
3123377|NCT01731951|Experimental|Arm D|Blast phase MF participants will receive Imetelstat, 9.4mg/kg, IV as 2 hour infusion, on Day 1, 8, 15, 22 of every 28-day cycle as long as they derive clinical benefit or until study end.
3123378|NCT01731951|Experimental|Arm E|MF participants with spliceosome mutations or ring sideroblasts will receive Imetelstat, 7.5mg/kg, IV as 2 hour infusion, on Day 1 of every 28-day cycle as long as they derive clinical benefit or until study end.
3123379|NCT01731951|Experimental|Arm F|MF participants without spliceosome mutations or ring sideroblasts will receive Imetelstat, 9.4mg/kg on Day1 of every 28-day cycle as long as they derive clinical benefit or until study end.
3123380|NCT01731951|Experimental|Arm G|Myelodysplastic syndromes (MDS)/ myeloproliferative neoplasm (MPN) or MDS participants with spliceosome mutations or ring sideroblasts will receive Imetelstat, 7.5mg/kg on Day 1 of every 28-day cycle as long as they derive clinical benefit or until study end.
3123381|NCT01731938|Experimental|Fibrin Sealant (FS) Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
3123382|NCT01731938|Active Comparator|Surgicel®|Surgicel® is a sterile, absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
3123383|NCT01731925|Experimental|Sunitinib|Sunitinib 37.5 mg daily. Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
3123384|NCT01731925|Placebo Comparator|Placebo|Placebo (for sunitinib). Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
3123385|NCT01731912|Experimental|Treatment (degarelix acetate, EBRT)|Patients receive degarelix acetate SC on day 1. Treatment repeats every 4 weeks for up to 6 courses. Beginning at week 15, patients also undergo standard EBRT for 8.5 weeks.
3123386|NCT01731899||agomelatine|patients diagnosed of fibromyalgia and concomitant major depression receiving agomelatine for this later disease
3123387|NCT01731886|Active Comparator|Arm A|Subjects will receive the current standard of care treatment. Lenalidomide and dexamethasone for four 28-day cycles followed by steam cell collection and autologous peripheral blood stem cell transplant. After 90 days, start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
3123388|NCT01731886|Active Comparator|Arm B|Subjects will receive the new treatment that will be compared with the standard of care. Lenalidomide and dexamethasone for eight 28-day cycles. After four cycles your stem cells will be collected (stem cell collection). After an additional four cycles of lenalidomide (a total of 8 cycles), start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
3123389|NCT01731860|Experimental|Patients receiving PET/CT|Patients already scheduled for a clinically necessary PET/CT scan.
3186809|NCT01290861||healthy controls|
3123390|NCT01731847|Experimental|The combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
3123391|NCT01731834|Active Comparator|Aspiration of secretion|10 children are evaluated at rest, during and after aspiration technique secretion
3123392|NCT01731834|Experimental|Vibrocompression|10 children will be assessed at rest, during and after the maneuver vibrocompression
3123393|NCT01731821|Experimental|Nonstented stump-closed anastomosis|Nonstented stump-closed anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
3123394|NCT01731821|Active Comparator|Duct-to-mucosa anastomosis|Duct-to-mucosa technique is used for pancreaticojejunostomy after pancreaticoduodenectomy.
3123395|NCT01731808|No Intervention|Standard care|All participants received three specially-developed brochures with information regarding the diabetic foot condition. The brochures contained explanations to a) the cause and warning signs of diabetic foot ulcers, b) the precautions patients can take in their daily life, and c) helpful foot gymnastics to be practiced at home. The participants who were randomized in the control group received standard care. Standard care consisted of either physician-prescribed inpatient or outpatient wound care.
3123396|NCT01731808|Experimental|Nursing counseling|
3123397|NCT01731795|No Intervention|No dexamethasone|Patients will be treated with conventional treatment
3123398|NCT01731795|Active Comparator|Dexamethasone|Conventional treatment plus dexamethasone
3123399|NCT01731782|Active Comparator|bupivacaine|bupivacaine-0.5ml/kg of 25% bupivacaine for maximum of 30ml
3123400|NCT01731782|Placebo Comparator|normal saline|Normal saline placebo-0.5ml/kg of 0.9% normal saline (max of 30ml)to mimic bupivacaine
3123401|NCT01731769|Active Comparator|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
3123402|NCT01731769|Experimental|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
3123403|NCT01731756|Experimental|Palmer arsenical keratosis (study)|Leaf extract of A. indica plus salicylic acid (6%) in petroleum jelly base will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks
3123404|NCT01731756|Placebo Comparator|Palmer arsenical keratosis (control)|Salicylic acid (6%) in petroleum jelly base will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks
3123405|NCT01731743|Other|implantation of a trifocal IOL (AT LISA tri 839MP)|
3123406|NCT01731730|Placebo Comparator|Placebo (Vehicle) Injection|Single Intrathecal (spinal) administration of Placebo Injection just prior to intrathecal administration of spinal anesthetic for knee surgery
3123407|NCT01731730|Experimental|AYX1 Injection 110 mg|Single Intrathecal (spinal) administration of AYX1 Injection (110 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
3123408|NCT01731730|Experimental|AYX1 Injection 330 mg|Single Intrathecal (spinal) administration of AYX1 Injection (330 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
3123409|NCT01731717|Experimental|Stepped care intervention (SCM)|"Patients within the stepped care intervention are screened by general physician using the PHQ-9 (inclusion criterion: >4 points) and diagnosed according to International Classification of Diseases (ICD-10) criteria. Patients receive differentially intensive treatment according to depression severity.~Patients with mild depression receive:~Step I: Active monitoring or Step II: II.a. Bibliotherapy or II.b. Online self-help (Deprexis®) or II+: Telephone-based psychotherapy~Patients with moderate depression receive:~Step III: III.a. Outpatient psychotherapy or III.b. Psychopharmacological treatment~Patients with severe depression receive:~Step IV: Combined psychotherapy and psychopharmacological treatment, optionally in inpatient setting."
3123410|NCT01731717|Active Comparator|Control group: treatment as usual|Patients in the control group are screened by their general physician using the PHQ-D-9 depression scale. Patients included in the study then receive treatment as usual from general physician or other health service providers.
3123411|NCT01731704|Active Comparator|Stereotactic Radiosurgery (SRS)|Radiation Therapy: Radiosurgical (SRS) technique via Gamma Knife Perfexion radiosurgical system
3123412|NCT01731704|Active Comparator|Whole Brain Radiation Therapy (WBRT)|whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
3123413|NCT01731691|Experimental|α1 Proteinase Inhibitor in HIV disease|α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks
3123414|NCT01731691|Placebo Comparator|Placebo in HIV disease|Placebo (saline) weekly for 8 weeks
3123415|NCT01731691|No Intervention|Uninfected controls|Blood collection only for 8 weeks
3123416|NCT01731678|Experimental|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
3123417|NCT01731665||The Songpa-Kangdong cohort of IBD|Incident cases of IBD in the Songpa-Kangdong district, a well-defined administrative area in Seoul, the capital of Korea, beginning in 1986, when the first patient with IBD was diagnosed, until 2017. For the prevalent cases, the inhabitants with IBD at Dec 31, 2007 in the Songpa-Kangdong district are included.
3123418|NCT01731652|Experimental|TMX-101|TMX-101 0.4% (200 mg in 50 ml) instilled in the bladder once weekly for 6 weeks
3123419|NCT01731639|Experimental|MSOME|The samples will be evaluated under high magnification
3123420|NCT01731613|Active Comparator|Standard Fortification|receive human milk fortified with human milk fortifier(HMF) in the standard amount (4 packs /100 ml of HM) throughout the study
3124457|NCT01724775||CME surgery for colon cancer|
3123421|NCT01731613|Experimental|Adjustable fortification|encompasses increasing/decreasing the amount of human milk fortifier(HMF) and adding supplemental protein guided by periodic determinations of the protein concentration of human milk (PCHM), body weight, blood urea nitrogen(BUN)
3123422|NCT01731600|Experimental|N8-GP|
3123423|NCT01731587|Experimental|L-BLP25 plus Cyclophosphamide (CPA)|
3123424|NCT01731574|Active Comparator|Dapivirine Ring + Miconazole|Dapivirine Ring + miconazole
3123425|NCT01731574|Experimental|Dapivirine Ring|Dapivirine Ring
3123426|NCT01731561|Experimental|Rituximab infusion according biological parameters|Rituximab infusion based on ANCA and CD19 lymphocytes
3123427|NCT01731561|Active Comparator|Systematic rituximab infusion|Semestrial rituximab infusion until 18 months
3123428|NCT01731548|Experimental|study arm|"For patients who are randomized to study arm, (i.e. to irradiate the post-chemotherapy tumor extent) the clinical target volume-tumor (CTV-T) includes the post-chemotherapy gross tumor volume-tumor (GTV-T) with a margin of 0.8 cm.~Chemotherapy includes etoposide 100mg/m2 d1-d3 combine with cisplatin 80mg/m2 d1 at 21-day interval for 4 cycles.~Radiotherapy will be administered with cycle 3 chemotherapy（1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks）"
3123429|NCT01731548|Active Comparator|control arm|"For patients who are randomized to control arm, (i.e. to irradiate the pre-chemotherapy tumor extent) the clinical target volume-tumor (CTV-T) includes the pre-chemotherapy gross tumor volume-tumor (GTV-T) with a margin of 0.8 cm.~Chemotherapy includes etoposide 100mg/m2 d1-d3 combine with cisplatin 80mg/m2 d1 at 21-day interval for 4 cycles.~Radiotherapy will be administered with cycle 3 chemotherapy (1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks)."
3123430|NCT01731535||Prior bisphosphonate users|Patients with record of using bisphosphonate medication
3123431|NCT01731522|Experimental|EF condition|
3123432|NCT01731509|Active Comparator|Standard FETO|Group of fetus that undergo fetal endoscopic tracheal occlusion between 26 0/7 weeks and 28 6/7 weeks.
3123433|NCT01731509|Experimental|Early FETO|Group of fetus that undergo fetal endoscopic tracheal occlusion between 22 0/7 weeks and 24 6/7 weeks.
3123434|NCT01731496|Experimental|Telephone reminder|Telephone message reminder to parents of adolescents whose child is due for a 2nd or 3rd dose of HPV vaccine.
3123435|NCT01731496|Experimental|Text Message reminder|Text message reminder to parents of adolescents whose child is due for a 2nd or 3rd dose of HPV vaccine.
3123436|NCT01731496|No Intervention|Control: Telephone|
3123437|NCT01731496|No Intervention|Control: Text Message|
3123438|NCT01731470|Experimental|Liposomes|Liposomes
3123439|NCT01731457|Experimental|Etanercept|
3123440|NCT01731457|No Intervention|Control|
3123441|NCT01731444|Experimental|Phenylephrine|20 ug/cc
3123442|NCT01731444|Active Comparator|Epinephrine|1:1000000
3123443|NCT01731431|Active Comparator|Insulin|standard protocol of insulin treatment for gestational diabetes
3123444|NCT01731431|Experimental|Glyburide|initial dose 2.5 mg per day increased if necessary until 10mg twice a day if glycemia is not controlled
3123445|NCT01731418|Other|Treamtent-as-usual|Treatment-as-usual can be defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive psychotherapy.
3123446|NCT01731418|Experimental|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a standardized short-term approach based on the principles of cognitive behavioral exposure therapy and testimony therapy for the treatment of PTSD resulting from organized violence.
3123447|NCT01731405||Formats A,B,C; medicines Ritalin, Morphine Sulfate, Aranesp|All patients will see all 3 different formats of the Medication Guide prototypes. They will also see information for the same drugs, in the same order - Ritalin, Morphine Sulfate, and Aranesp. All participants see all the formats, the only thing that changes by participant is which format is in each medication. There will be 6 different randomized orders - A,B,C; A,C,B; B,C,A; B,A,C; C,A,B; C,B,A. So for example, A,B,C participants would see Ritalin in format A, Morphine Sulfate in format B, and Aranesp in format C.
3123448|NCT01731405||There is not another group|
3123449|NCT01731392|Experimental|Milk with Bifidobacteria|duration of the treatment is 5 months
3123450|NCT01731392|Active Comparator|Milk with non replicating lactobacilli|duration of the treatment is 5 months
3123451|NCT01731392|Placebo Comparator|Semi skimmed milk|duration of the treatment is 5 months
3123452|NCT01731379||Surgical resections|Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy, patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
3123453|NCT01731366|Placebo Comparator|Refined grain|Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
3123454|NCT01731366|Active Comparator|Whole grain|Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
3123455|NCT01731353||Emerging fungal infections|Web-based registry of invasive infections by emerging fungi
3123456|NCT01731340|Active Comparator|Supplemental Calcium|"750 mg Calcium Citrate per day~800 IU Vitamin D3 per day~Low Dietary Calcium (450 mg per day)"
3123457|NCT01731340|Active Comparator|Dietary Calcium|"400 IU Vitamin D3 per day~High Dietary Calcium (1200 mg per day)"
3123458|NCT01731340|No Intervention|Usual Diet|"400 IU Vitamin D3 per day~Unrestricted Dietary Calcium"
3123459|NCT01731327|Experimental|Experimental Treatment A|A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
3123460|NCT01731327|Experimental|Experimental Treatment B|A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
3123461|NCT01731301|Experimental|Ribavirin, peginterferon, boceprevir|The efficacy and safety of HCV treatment in patients with ESRD will be assessed with a maximal tolerated dose of ribavirin, peginterferon and boceprevir.
3123462|NCT01731288||vulvodynia|Women with vulvodynia
3123463|NCT01731288||control|Women without vulvar pain
3123464|NCT01731275|Experimental|E6011|
3123465|NCT01731275|Placebo Comparator|E6011 Matching Placebo|
3123466|NCT01731262||RA group|expression of Shh pathway associated factors from peripheral blood mononuclear cells or synovial tissues will be detected
3123725|NCT01729390|Experimental|Std ED and Std PS|100% energy density and 100% portion size
3123467|NCT01731262||control group|expression of Shh pathway associated factors from peripheral blood mononuclear cells or synovial tissues will be detected
3123468|NCT01731249|Placebo Comparator|Placebo|Placebo sublingual solution
3123469|NCT01731249|Experimental|Birch pollen allergen extract|Sublingual Solution of Birch pollen allergen extract 300IR once daily 5 months per year and during 2 years
3123470|NCT01731236|Active Comparator|Carnitine (No antibiotics, No aspirin)|L-Carnitine 500 mg capsule by mouth, twice daily for 2 months. No aspirin for 1 month prior to starting study and remains off aspirin during study.
3123471|NCT01731236|Active Comparator|Choline (No Antibiotics, No aspirin)|Choline 500 mg capsule by mouth, twice daily for 2 months. No aspirin for 1 month prior to starting study and remains off aspirin during study.
3123472|NCT01731236|Active Comparator|Antibiotics|"Antibiotics (Ciprofloxacin, Vancomycin, Metronidazole and Neomycin) Drug: Ciprofloxacin 500 mg, po, twice daily for 7 days (Other Names: Cipro)~Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)~Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)~Drug: Neomycin 1 gram, po, four times daily for 7 days (Other Names: Aminoglycoside)"
3123473|NCT01731236|Active Comparator|Choline and Aspirin|"Choline supplement 500 mg capsule by mouth, twice daily for 2 months Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study)~Other Names:~Ecotrin, Bufferin, Ascriptin, Fasprin, Norwich Aspirin, Durlaza, Bayer Genuine Aspirin, Genacote, Bayer, Halfprin, Aspirtab, Aspir Low, Aspir-Trin"
3123474|NCT01731236|Active Comparator|Carnitine and Aspirin|"Carnitine supplement 500 mg capsule by mouth, twice daily for 2 months Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Carnitine supplementation during study)~Other Names:~Ecotrin, Bufferin, Ascriptin, Fasprin, Norwich Aspirin, Durlaza, Bayer Genuine Aspirin, Genacote, Bayer, Halfprin, Aspirtab, Aspir Low, Aspir-Trin"
3123475|NCT01731223|Experimental|Group treatment for insomnia|Group treatment for insomnia.
3123476|NCT01731223|No Intervention|No intervention|Treatment as usual
3123477|NCT01731197|Experimental|Test ISP-10|10 grams of the test ISP will be consumed as a dry-blended beverage
3123478|NCT01731197|Experimental|Test ISP-20|20 grams of the test ISP will be consumed as a dry-blended beverage
3123479|NCT01731197|Active Comparator|Control ISP-10|10 grams of the control ISP will be consumed as a dry-blended beverage
3123480|NCT01731197|Active Comparator|Control ISP-20|20 grams of the control ISP will be consumed as a dry-blended beverage
3123481|NCT01731184|Experimental|Midazolam|Midazolam (Hypnovel) at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
3123482|NCT01731184|Placebo Comparator|Placebo|Placebo at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
3123483|NCT01731171|Experimental|Probiotic Supplement|The probiotic supplement compound will consist of capsules containing approximately 10^8 colony forming units of the probiotic organisms, LactobacillusGG and Bifidobacteria lactis strain Bb12. The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. The participant will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.
3123484|NCT01731171|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.
3123485|NCT01731158|Other|arm A|"sequential therapy with approved drugs~Avastin in combination with Roferon-A (first-line), Afinitor (second-line) and a TKI (third-line)"
3123486|NCT01731158|Other|arm B|"sequential therapy with approved drugs~Avastin in combination with Roferon-A (first-line), a TKI (second-line) and Afinitor (third-line)"
3123487|NCT01731145|Experimental|SNUMAP assessment|Uses SNUMAP motion sensing system to quantify tremor symptom.
3123488|NCT01731132||Group 1|
3123489|NCT01731119|Experimental|Flexible Dose Latuda©|Lurasidone (Latuda©)dose will be determined solely by the clinician in accordance with the best interests of each participant.
3123490|NCT01731093|Experimental|AT-001|AT-001
3123491|NCT01731093|Placebo Comparator|Placebo|Matching placebo.
3123492|NCT01731080||Pseudoxanthoma Elasticum|Patients with genetically and clincally proven PXE
3123493|NCT01731080||chronic kidney disease|Type 2 diabetic patients with mediacalcosis and matched to PXE patients for gender and age (+/- 5 yrs).
3123494|NCT01731080||Diabetes|patients with chronic kidney disease and matched to PXE patients for gender and age (+/- 5 yrs).
3123495|NCT01731067|Active Comparator|CYP1A2, 2B6, 2C9, 2C19, 3A4 inhibitors|Oral intake of fluvoxamine (50 mg per day during 2 days) and voriconazole (400 mg) before oral intake of the cocktail probe drugs
3123496|NCT01731067|Active Comparator|CYP2D6 and P-gp inhibitor|Oral intake of quinidine (200 mg) before oral intake of the cocktail probe drugs
3123497|NCT01731067|Active Comparator|CYPs and P-gp inducer|Oral intake of rifampicin (600 mg per day during 7 days) before oral intake of the cocktail probe drugs
3123498|NCT01731067|Experimental|Probe cocktail alone|"Oral intake of the cocktail probe drugs :~bupropion 25 mg~flurbiprofen 25 mg~omeprazole 5 mg~dextromethorphan 5 mg~midazolam 1 mg~fexofenadine 25mg~Caffeine (a cup of coffee)"
3123499|NCT01731041|Experimental|Ticagrelor 180mg|Patients randomized to this arm will be administered 180 mg of ticagrelor (experimental arm, loading dose).
3123500|NCT01731041|Active Comparator|Ticagrelor 90mg|Patients randomized to this arm will be administered 90 mg dose of ticagrelor (active comparator, standard dose).
3123501|NCT01731028||Somatropin|Children with growth hormone deficiency treated with somatropin as Zomacton® according to the marketing authorization
3123502|NCT01731015|Experimental|Normal Subject|Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures. The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system. No additional drug products, investigational or otherwise will be provided in this study.
3123544|NCT01730742|Experimental|Sleep|Sleep: participants had an 8-h sleep opportunity before a 'Blood Sample' was taken and the 'Neuroeconomics task' and 'Portion size task' were performed
3123726|NCT01729390|Experimental|Std ED and Inc PS|100% energy density and 133% portion size
3189295|NCT01273298|Experimental|Bisoprolol|
3123503|NCT01731015|Experimental|Subjects with Lung/or Airway Disease|Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures. The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system. No additional drug products, investigational or otherwise will be provided in this study.
3123504|NCT01731002|Experimental|AR-13324 Ophthalmic Solution 0.01%|1 drop to study eye once daily
3123505|NCT01731002|Experimental|AR-13324 Ophthalmic Solution 0.02%|1 drop to study eye once daily
3123506|NCT01731002|Active Comparator|Latanoprost Ophthalmic Solution 0.005%|1 drop to study eye once daily
3123507|NCT01730989|Experimental|Estromineral Serena Plus|"Estromineral Serena Plus is an association of soy isoflavones, Lactobacillus sporogenes, magnolia, chaste tree, Vitamin D3, calcium and magnesium.~1 tablet oad for 12 weeks"
3123508|NCT01730989|Active Comparator|Estromineral|"Estromineral is an association of soy isoflavones, Lactobacillus sporogenes, Vitamin D3, and calcium.~1 tablet oad for 12 weeks"
3123509|NCT01730976|Experimental|Vitamin D 2,000 I.U. daily|Study subjects will take 2,000 I.U. vitamin D daily for three months
3123510|NCT01730963||Pregnant, Preterm, In Labor|Gestation Age at or less than 36 weeks, clinically determined to be in labor
3123511|NCT01730963||Pregnant, Preterm, Nonlaboring|Gestation Age at or less than 36 weeks, clinically determined to not be in labor
3123512|NCT01730963||Pregnant, Term, Nonlaboring|Gestation Age more than 36 weeks, clinically determined to not be in labor
3123513|NCT01730950|Active Comparator|Arm I (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks.
3123514|NCT01730950|Experimental|Arm II (bevacizumab, IMRT or 3D-CRT)|Patients receive bevacizumab as patients in arm I and undergo radiation therapy using IMRT, 3D-CRT, or proton beam RT 5 days a week for 2 weeks.
3123515|NCT01730937|Experimental|Arm 1 (sorafenib tosylate)|Patients receive sorafenib tosylate orally PO BID on days 1-28. Treatment repeats every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
3123516|NCT01730937|Experimental|Arm 2 (SBRT and sorafenib tosylate)|Patients undergo SBRT every 24-72 hours for a total of 5 fractions over 5 to 15 days. Within 1-5 days post-SBRT, patients receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
3123517|NCT01730924|Other|Contact force available|
3123518|NCT01730924|Other|Contact force not available|
3123519|NCT01730911|No Intervention|ParaGard, paper diaries|Women who have chosen ParaGard IUDs as their contraception, and randomized to submit bleeding diaries on paper.
3123520|NCT01730911|Active Comparator|ParaGard, text message|Women who have chosen ParaGard IUDs as their contraception, and randomized to submit bleeding diaries via text message.
3123521|NCT01730911|No Intervention|Mirena, paper diaries|Women who have chosen Mirena IUDs as their contraception, and randomized to submit bleeding diaries on paper.
3123522|NCT01730911|Active Comparator|Mirena, text message|Women who have chosen Mirena IUDs as their contraception, and randomized to submit bleeding diaries via text message.
3123523|NCT01730898|Active Comparator|Control capsule|2 capsules
3123524|NCT01730898|Experimental|Experimental capsule|2 capsules
3123525|NCT01730885|Other|BGStar|Comparision
3123526|NCT01730872|Experimental|Prednisolone|Prednisolone Sodium Phosphate Ophthalmic Solution, 1%
3123527|NCT01730872|Placebo Comparator|Placebo|Tears Naturale II Ophthalmic Solution, 1%
3123528|NCT01730859|Experimental|Balance exrercise and ankle taping|"Balance Exercises:Balance exercises for 6 weeks, 3 sessions per week and each session was 40 minutes for training group.~Ankle taping: Ankle joint taping was performed for 6 weeks and was renewed three times a week."
3123529|NCT01730846|Experimental|Doxazosin 4mg/day|doxazosin 4mg/day
3123530|NCT01730846|Placebo Comparator|Placebo|placebo control
3123531|NCT01730846|Experimental|Doxazosin 8mg/day|doxazosin 8mg/day
3123532|NCT01730833|Experimental|Treatment (pertuzumab, trastuzumab, nab-paclitaxel)|Patients receive pertuzumab IV over 30-60 minutes on day 1, trastuzumab IV over 30-90 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3123533|NCT01730807|Experimental|IntellaTip XP MiFi|Patients with Atrial Flutter will receive ablation treatment with the IntellaTip MiFi XP catheter
3123534|NCT01730794|Other|Conventional Lung Protective Ventilation|In this group, patients will be ventilated in either volume A/C, pressure A/C, pressure support, pressure regulated volume control or volume support based on the discretion of the medical team with TV 4-8 ml/kg PBW range and PP or pressure (control or support) level <30 cmH2O.
3123535|NCT01730794|Other|NAVA Ventilation Group|In the NAVA group, NAVA level will be set initially at zero, then the maximum Edi will be determined as the average level over the next 3 to 5 breaths without ventilatory support or PEEP. The actual NAVA level will then be titrated by the clinician to achieve the following: 1) an Edi equal to approximately 50% of the maximum Edi, 2) an average tidal volume of between 4 to 8 ml/kg predicted body weight (PBW), and 3) an average respiratory rate between about 15 and 40 per minute. In addition, the trigger sensitivity should be set as sensitive as possible without causing auto-triggering and the maximum pressure limit in NAVA should be set at 40 cm H2O.
3123536|NCT01730781||Schizophrenia|Patients diagnosed with schizophrenia both on medication and off medication
3123537|NCT01730781||Cannabis dependence|Frequent users of cannabis
3123538|NCT01730781||Family history of alcoholism|Healthy volunteers with a first degree relative with alcoholism
3123539|NCT01730781||Prodrome for psychotic illness|Not meeting full criteria for psychotic illness but exhibiting prodromal symptoms
3123540|NCT01730781||Healthy Volunteers|Healthy volunteers with no current or past major medical or psychiatric history
3123541|NCT01730768|Experimental|AQW051 10 mg/day|Two 5mg AQW051 capsules will be taken orally daily by patients from Day 1 until Day 84.
3123542|NCT01730768|Placebo Comparator|Placebo to AQW051|Matching placebo administered orally.
3123543|NCT01730742|Experimental|Sleep deprivation|Total sleep deprivation: participants were required to stay up for the entire night before a 'Blood Sample' was taken and the 'Neuroeconomics task' and 'Portion size task' were performed
3123727|NCT01729390|Experimental|Inc ED and Inc PS|133% energy density and 133% portion size
3123545|NCT01730729|Experimental|Treatment (cabergoline)|Patients receive cabergoline oral (PO) twice weekly for weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3123546|NCT01730716|Experimental|Surgery|There will be 5 sequential cohorts (Groups A-E) with 3 subjects in each cohort. Each cohort will follow a dose escalation plan. New patients will be enrolled into each group. No control group is included. All patients will received spinal cord injections of HSSC.
3123547|NCT01730703||Adults ages 65 and older|
3123548|NCT01730677|Experimental|Lapatinib+Vinorelbine|lapatinib 1000mg, once daily vinorelbine 20mg/m2, D1 and D8, every 3 weeks
3123549|NCT01730677|No Intervention|Vinorelbine|vinorelbine 30mg/m2, D1 and D8, every 3 weeks
3123550|NCT01730664|Experimental|ertapenem|single dose ertapenem
3123551|NCT01730651|Experimental|Tomotherapy|"Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)~Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)"
3123552|NCT01730625|Experimental|ABMT + CBT|CBT and ABMT
3123553|NCT01730625|Other|CBT Alone|CBT alone (compare/control group)
3123554|NCT01730625|Placebo Comparator|ABMT placebo + CBT|ABMT placebo training and CBT
3123555|NCT01730599||PD patients|PD patients carriers of the G2019S mutation in the LRRK2 gene
3123556|NCT01730586|Experimental|Abraxane|Abraxane 220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
3123557|NCT01730573|Active Comparator|Interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
3123558|NCT01730573|Active Comparator|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
3123559|NCT01730560|Experimental|Arm 1:Treatment A|Treatment A (active) followed by treatment B (neutral)
3123560|NCT01730560|Experimental|Arm 2: Treatment B|Treatment B (neutral) followed by treatment A (active)
3123561|NCT01730547|Active Comparator|Early treatment with mesenchymal stem cells|
3123562|NCT01730547|Active Comparator|Delayed treatment with mesenchymal stem cells|
3123563|NCT01730534|Experimental|Dapagliflozin|Dapagliflozin + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
3123564|NCT01730534|Placebo Comparator|Placebo|Placebo + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
3123565|NCT01730521||Difference in Iron bioavailabilty exercise and resting phase|the subjects will act as their own control during the study
3123566|NCT01730508||Chronic Hepatitis B Participants|Hepatitis B e antigen (HBeAg) chronic hepatitis B (CHB) participants who received treatment with pegylated interferon alfa (peginterferon alfa) according to China labeling and China standard of care and were followed up to 1 year after treatment cessation.
3123567|NCT01730495|Experimental|Etanercept|
3123568|NCT01730482|Experimental|[14C] AT1001 Arm|Each subject will receive a single oral dose of 150 mg of [14C] AT1001 as an aqueous solution containing 1 μCi AT1001 on Study Day 1.
3123569|NCT01730469|Experimental|AT1001 150 mg|Each subject will receive a single oral dose of AT1001 150 mg administered orally with 240 mL room temperature water after at least a 4-hour fast
3123570|NCT01730456|Experimental|RoActemra/Actemra|
3123571|NCT01730443||On progesterone treatment|The group assigned to progesterone treatment.
3123572|NCT01730443||group assigned to placebo|The group that will not be receiving progesterone treatment
3123573|NCT01730430||Collection of CSF|"Those with Alzheimer's disease~Those with non-Alzheimer's disease dementia~Healthy elderly volunteers"
3123574|NCT01730417|Experimental|Radiation dosimetry|no carrier added metaiodobenzylguanidine
3123575|NCT01730404|Experimental|CHF6001|CHF6001 DPI (Dry Powder Inhaler) once daily
3123576|NCT01730404|Active Comparator|Roflumilast|Roflumilast, tablet, once daily
3123577|NCT01730404|Placebo Comparator|placebo|Placebo
3123578|NCT01730391||Study cohort|Subjects visiting the hospital with suspected bacterial meningitis in The Philippines and Vietnam.
3123579|NCT01730378|Experimental|Prepandrix Group|Subjects in this group received 2 doses of Prepandrix™ vaccine at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
3123580|NCT01730378|Active Comparator|Fluarix Group|Subjects in this group received 1 dose of Fluarix™ vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid region of non-dominant arm.
3123581|NCT01730365||Histological biopsy procedures|Patients with a suspicious lesion in lung or liver or breast who are planned for a standard core biopsy procedure. And patients planned for percutaneous RFA (Radiofrequency Ablation) of colorectal liver metastasis
3123582|NCT01730352|No Intervention|H. pylori no treatment|Observational group, with clinical and platelet count follow-up
3123583|NCT01730352|Experimental|H. pylori triple therapy|Triple therapy for H. pylori eradication: clarithromycin 15mg/kg, amoxicillin 50mg/kg, furazolidone 7mg/kg and/ or doxycycline 4,4mg/kg (all 2 times per day), with a proton pump inhibitor for 14 days.
3123584|NCT01730339|Active Comparator|Group 1|
3123585|NCT01730339|Active Comparator|Group 2|
3123586|NCT01730326|Experimental|Paracetamol|Paracetamol which will be given after randomization will be diluted in serum physiologic and will be given as intravenous rapid infusion.
3123587|NCT01730326|Active Comparator|Dexketoprofen|Dexketoprofen which will be given after randomization will be diluted in serum physiologic and will be given as intravenous rapid infusion.
3123588|NCT01730313|Experimental|Pyridoxine (B6)|Oral pyridoxine, 30- 50 mg/kg/day in one daily dose (powder form)for a period of four weeks followed by cross-over to Phenytoin arm for another four weeks
3123589|NCT01730313|Experimental|Phenytoin|Phenytoin Oral, 5 mg/kg/day in two equally divided doses(powder form)for a period of four weeks and then cross-over to Pyridoxine arm for another four weeks
3123590|NCT01730313|Experimental|Sodium Valproate|Sodium valproate oral, 10 - 15 mg/kg/day once daily powder form)for a period of four weeks and then cross-over to placebo arm for another four weeks
3123728|NCT01729390|Experimental|Inc ED and Std PS|133% energy density and 100% portion size
3124458|NCT01724775||non-CME surgery for colon cancer|
3123591|NCT01730313|Placebo Comparator|Placebo|Placebo will consist of an inert substance (e.g., gelatin) with an appearance similar to medication in similar dosage as the study arms for a period of 4 weeks and subsequent cross-over to Sodium Valproate arm
3123592|NCT01730287|Experimental|Control|No lining applied in group1.
3123593|NCT01730287|Experimental|CEM cement|CEM cement applied over remained caries in group4.
3123594|NCT01730287|Experimental|Mineral Trioxide Aggregate (MTA)|MTA applied over remained caries in group3.
3123595|NCT01730287|Experimental|Calcium Hydroxide|Calcium Hydroxide applied over remained caries in group2.
3123596|NCT01730274||patients|children operated on a cerebellar tumor
3123597|NCT01730274||healthy subjects|healthy volunteers
3123598|NCT01730261|Experimental|Online Emotional Regulation Treatment|Participants will receive 24 treatment sessions, with baseline, post-treatment screening and follow-up screening, and bi-weekly assessments
3123599|NCT01730248|Experimental|JAK Inhibitor Naive|Two treatment periods applicable to all patients; Treatment Period (6 cycles / 28 days per cycle) and Extension Period ( 6 or more cycles of 28 days, with visits every 28days for 6 cycles and then visits every 12 weeks) following the treatment period dependent on patient continued eligibility. Two Study Phases: Dose Escalation Phase to determine maximum tolerated dose (MTD) / Recommended Phase II dose (RPIID) & an Expansion Phase
3123600|NCT01730248|Experimental|Prior JAK Inhibitor|Two treatment periods applicable to all patients; Treatment Period (6 cycles / 28 days per cycle) and Extension Period (6 or more cycles of 28 days, with visits every 28 days for 6 cycles then visits every 12 weeks) following the treatment period dependent on patient continued eligibility. Two Study Phases: Dose Escalation Phase to determine MTD / RPIID & an Expansion Phase
3123601|NCT01730235||Case Group|Group receiving access to MyMediHealth web site.
3123602|NCT01730235||Control Group|Children completing baseline and week two measures, but without any additional intervention.
3123603|NCT01730222|Experimental|PAXG regimen|cisplatin at 30 mg/m2 on days 1 and 15, nab-paclitaxel at the RP2D on days 1 and 15, capecitabine at 1250 mg/ m2 days 1-28, gemcitabine at 800 mg/ m2 on days 1 and 15 every 4 weeks
3123604|NCT01730222|Active Comparator|gemcitabine + nab-paclitaxel|gemcitabine at 1000 mg/ m2 on days 1, 8 and 15 every 4 weeks + nab-paclitaxel at 125 mg/ m2 on days 1, 8 and 15 every 4 weeks
3123605|NCT01730209|Experimental|Everolimus|Everolimus once daily for 1 year, titration to trough levels of 5-10 ng/ml
3123606|NCT01730209|Placebo Comparator|Placebo|Placebo treatment for 1 year. Tablets will be identical to everolimus tablets.
3123607|NCT01730196|Experimental|Fit Body and Soul|Faith-based adaptation of the Group Life Style Program
3123608|NCT01730196|Active Comparator|Wellness education|A health education program developed from the list of topics provided by the Centers for Disease Control and Prevention (CDC) Guide to Community Prevention Services
3123609|NCT01730183|Experimental|Bone marrow derived stem cells|Autologous Bone Marrow derived Stem Cells(BMSC) transplanted intrathecally into patients with spinal cord injury.
3123610|NCT01730170||Pregnant Women without Epilepsy|Women in their first trimester of pregnancy who are not diagnosed with epilepsy
3123611|NCT01730170||Nonpregnant Women with Epilepsy|Women diagnosed with epilepsy and not currently pregnant.
3123612|NCT01730170||Pregnant Women with Epilepsy|Women in their first trimester of pregnancy and diagnosed with epilepsy
3123613|NCT01730157|Experimental|Treatment (yttrium Y 90 glass microspheres, ipilimumab)|Patients undergo radioembolization with yttrium Y 90 glass microspheres via hepatic arterial infusion on day 1. Beginning on day 29, patients also receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3123614|NCT01730118|Experimental|1/Part I dose escalation|AdHER DC vaccine administered at escalating doses
3123615|NCT01730118|Experimental|2/Part I dose expansion|AdHER DC vaccine administered at a next lower dose or the highest dose
3123616|NCT01730118|Experimental|3/Part II dose escalation|AdHER DC vaccine administered at Dose Level 1
3123617|NCT01730118|Experimental|4/Part II dose expansion|AdHER DC vaccine administered at Arm 1 MTD
3123618|NCT01730066|Experimental|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria preoperatively and given the same study product enterally postoperatively
3123619|NCT01730066|No Intervention|Control|No intervention.What has been the standard procedure so far
3123620|NCT01730053|Active Comparator|Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received rosuvastatin 20 mg over-encapsulated tablet orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablet orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
3123621|NCT01730053|Active Comparator|Ezetimibe 10 mg + Rosuvastatin 10 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
3123622|NCT01730053|Experimental|Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg SC injection Q2W, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
3123623|NCT01730053|Active Comparator|Rosuvastatin 40 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received rosuvastatin 40 mg over-encapsulated tablet orally QD, placebo for alirocumab Q2W SC injection, and placebo for ezetimibe QD over-encapsulated tablet orally added to stable LMT for 24 weeks.
3123624|NCT01730053|Active Comparator|Ezetimibe 10 mg + Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for alirocumab Q2W SC injection added to stable LMT for 24 weeks.
3123720|NCT01729416|Active Comparator|Air colonoscopy|The intervention will be colonoscopy using the traditional air method in patients who are randomized to have screening colonoscopy with air colonoscopy.
3123721|NCT01729403|Experimental|Aleglitazar|
3123625|NCT01730053|Experimental|Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg Q2W SC injection, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
3123626|NCT01730040|Active Comparator|Atorvastatin 40 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received atorvastatin 40 mg over-encapsulated tablets orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablets orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
3123627|NCT01730040|Active Comparator|Ezetimibe 10 mg + Atorvastatin 20 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
3123628|NCT01730040|Experimental|Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received Alirocumab 75 mg SC injection Q2W, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
3123629|NCT01730040|Active Comparator|Atorvastatin 80 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received Atorvastatin 80 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.
3123630|NCT01730040|Active Comparator|Rosuvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received rosuvastatin 40 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.
3123631|NCT01730040|Active Comparator|Ezetimibe 10 mg + Atorvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
3123632|NCT01730040|Experimental|Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received alirocumab 75 mg SC injection Q2W, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
3123633|NCT01730027|Experimental|ADC3680|ADC3680 oral once daily
3123634|NCT01730027|Placebo Comparator|Placebo|Placebo oral once daily
3123635|NCT01730027|Active Comparator|montelukast|montelukast oral once daily
3123636|NCT01730014|Experimental|Trial part 1|
3123637|NCT01730014|Experimental|Trial part 2, treatment A|
3123638|NCT01730014|Experimental|Trial part 2, treatment B|
3123639|NCT01730001|Active Comparator|Early Intubation|Early intubation is defined as prehospital intubation on the scene of the patient illness/injury, or where the EMS physician first meets the patient (e.g en route to hospital). Intubation includes drug assisted and/or rapid sequence intubation (RSI) with endotracheal tube.
3123640|NCT01730001|Active Comparator|Late intubation|Late intubation is defined as on-scene prehospital high-flow (> 10 L/min) supplemental oxygen by mask, assisted bag-mask-ventilation by EMS physician if required and stable recovery position during transport to hospital. Intubation should be done on arrival in the emergency department.
3123641|NCT01729988|Experimental|Carotid body excision|Patients undergoing the carotid body excision to test the hypothesis that carotid body excision is sufficient to attain target blood pressure.
3123642|NCT01729975||18-28 years old Non-pathologic|
3123643|NCT01729975||29-80 years old Non-Pathologic|
3123644|NCT01729975||29-80 years old pathologic corneal disease|
3123645|NCT01729962||Agreement Cohort|All subjects in the agreement portion of the study will have a single measurement performed with each device, the Nidek optical biometer, predicate device and ultrasound reference device. Each device will be operated by a different operator.
3123646|NCT01729962||Precision Cohort|All subjects in the precision portion of the study will each be paired with one Nidek optical biometer and with one predicate device for a total of three Nidek optical biometer/predicate device pairs. Each of the three device pairs will be designated one and only one operator. All subjects in the precision portion of the study will have their measurements repeated three times on each of three Nidek optical biometer and predicate device pairs.
3123647|NCT01729949|Active Comparator|Active Treatment Beverage|Strawberry powder and Blackcurrent extract
3123648|NCT01729949|Placebo Comparator|Placebo Treatment Beverage|Placebo Beverage
3123649|NCT01729936|Experimental|Sitting time Change Intervention|"Sitting time Change Intervention: recommendation to substitute Sitting time by doing the regular activities standing or walking.~Duration: 6 month. Frequency: 1 time each 15 days during the first 4 month and 1 time each month the last 2 months."
3123650|NCT01729936|No Intervention|Active Control|Control visits to the Primary Health Care Center
3123651|NCT01729923|Experimental|Treatment (capecitabine, celecoxib, radiation therapy)|"Patients proceed to surgery, radiation therapy with ADAPT therapy followed by maintenance ADAPT therapy, or ADAPT therapy. Eligible patients undergo surgical resection at baseline or upon achievement of resectable disease after radiation therapy.~RADIATION + ADAPT: Patients undergo radiation therapy 5 days per week and receive capecitabine PO BID and celecoxib PO BID 5 days per week during radiation.~ADAPT: Patients receive capecitabine PO BID on days 1-14 and celecoxib PO BID on days 1-21. Courses repeat every 21 days for up to 3 years in the absence of disease progression or unacceptable toxicity."
3123722|NCT01729403|Placebo Comparator|Placebo|
3123723|NCT01729390|Experimental|Std ED Control|100% energy density and 133% portion size
3123804|NCT01728896|No Intervention|Conventional management|
3123652|NCT01729910|Experimental|Parent education / behavioral counseling|Parents of children in the intervention group will be invited to participate in four group visits and two individual visits with their primary care provider as well as four follow-up phone calls with study personnel (project coordinator or registered dietician). Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls.
3123653|NCT01729910|Placebo Comparator|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
3123654|NCT01729897|Experimental|Etomidate & Fentanyl|"4 min before procedure: fentanyl 1 μg/kg (0.02 ml/kg), intravenous injection~After injection of fentanyl, etomidate was infused intravenously at rate of 200 ml/h for 30 seconds with unified injection pump, then after interval time of 30 seconds, infusion rate was altered to 500 ml/h and infusion was sustained until patients fell asleep.~Additional dose of etomidate would be administrated separately when duration of procedure was prolonged."
3123655|NCT01729897|Placebo Comparator|Propofol & Fentanyl|"4 min before procedure: fentanyl 1 g/kg (0.02 ml/kg), intravenous injection~After injection of fentanyl, propofol was infused intravenously at rate of 200 ml/h for 30 seconds with unified injection pump, then after interval time of 30 seconds, infusion rate was altered to 500 ml/h and infusion was sustained until patients fell asleep.~Additional dose of propofol would be administrated separately when duration of procedure was prolonged."
3123656|NCT01729884|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID once monthly for 3 months.
3123657|NCT01729871|Experimental|rivaroxaban|rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
3123658|NCT01729871|Experimental|vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
3123659|NCT01729858||Metal-Ceramic|Metal Ceramic prosthesis with press on veneer with different thicknesses, different diameters of curvature of gingival embrasure and connector heights.
3123660|NCT01729858||Ceramic-Ceramic|Zirconia computer aided design and computer milled cores with press on veneers with different thicknesses, gingival embrasure diameters and connector heights.
3123661|NCT01729845|Experimental|Treatment (decitabine, MEC)|"Patients receive decitabine IV on days -9 to -5 (dose level 1), days -11 to -5 (dose level 2), or days -14 to -5 (dose level 3).~INDUCTION THERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-5, etoposide IV on days 1-5, and cytarabine IV on days 1-5. Patients achieving CR or CR with CRp may receive up to 2 courses of induction therapy and up to 2 courses of consolidation therapy."
3123662|NCT01729832|Experimental|Supportive care (image-guided breast reconstruction)|Patients undergo DIEP flap breast reconstruction using the StealthStation navigation system.
3123663|NCT01729819|Experimental|Combination|Tolterodine tartrate extended release capsules + Desmopressin orally disintegrating tablets
3123664|NCT01729819|Active Comparator|Tolterodine|Tolterodine tartrate extended release capsules + Placebo orally disintegrating tablets
3123665|NCT01729806|Experimental|Arm A (ipilimumab and rituximab)|Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 1, 4, 7, and 10. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
3123666|NCT01729806|Experimental|Arm B (ipilimumab and rituximab)|Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 3, 6, 9, and 12. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
3123667|NCT01729793|Active Comparator|Digestive Enzyme #2|A proprietary blend of dietary supplement enzymes in a capsule
3123668|NCT01729793|Placebo Comparator|Placebo|Capsule identical to active arm containing only microcrystalline cellulose
3123669|NCT01729780|Sham Comparator|Sham EEG-NF|Subjects who will undergo sham EEG-NF.
3123670|NCT01729780|Active Comparator|True EEG-NF|Subjects who will undergo true EEG-NF training in order to lessen their anxiety symptoms.
3123671|NCT01729767|Experimental|Acyclovir|Acyclovir 400 mg tablets by mouth 5 times a day for the first month, 3 times a day for next 10 days, and 2 times a day for the last 10 days.
3123672|NCT01729767|Placebo Comparator|Placebo|Placebo tablets by mouth 5 times a day for the first month, 3 times a day for next 10 days, and 2 times a day for the last 10 days.
3123673|NCT01729754|Experimental|Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg subcutaneously (SC) on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo (PBO) twice weekly until Week 12 and once weekly from Week 12 to Week 28.
3123674|NCT01729754|Experimental|Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg SC on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo twice weekly until Week 12 and once weekly from Week 12 to Week 28.
3123675|NCT01729754|Placebo Comparator|Placebo|Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive tildrakizumab 200 mg or tildrakizumab 100 mg on Weeks 12, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244.
3123676|NCT01729754|Active Comparator|Etanercept 50 mg|Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants who don't achieve PASI-75, receive tildrakizumab 200 mg after Week 28 (Weeks 32, 36 and 48) and, optionally, every 12 weeks thereafter until Week 244.
3123677|NCT01729741|No Intervention|No drain|No drain was inserted after Thyroid surgery
3123678|NCT01729741|Experimental|Drain|A drain was inserted after thyroid surgery
3123679|NCT01729728|Experimental|Tapentadol|
3123680|NCT01729715|Experimental|Internet|Internet site that offers parents tips on promoting sleep in infants and toddlers
3123681|NCT01729715|Experimental|DVD|DVD that offers parents tips on promoting sleep in infants and toddlers
3123682|NCT01729715|No Intervention|No treatment|
3123683|NCT01729702|Other|single group - consecutive patients|
3123724|NCT01729390|Experimental|Inc ED Control|133% energy density and 133% portion size
3191412|NCT01259154||RFITT+UPPP|
3123684|NCT01729689|Experimental|Supportive care (cognitive behavioral therapy)|Participants undergo cognitive behavioral therapy over 1 hour once weekly for a total of 6 sessions. Sessions are tailored to patient and caregiver cognitions and approach and avoidance behaviors.
3123685|NCT01729676||Group A|Degarelix or gonadotrophin releasing hormone (GnRH) agonist for treatment of prostate cancer according to physicians current practice
3123686|NCT01729663|Active Comparator|Interferon alpha 2 b|Interferon alpha 2b treatment will consist of s.c. injection of 10 MU (5 t/w) for four weeks and then 5 MU (3t/w) for 23 months.
3123687|NCT01729663|Experimental|CSF470 vaccine, BCG, Molgramostim|"CSF470 vaccine, BCG, Molgramostim~CSF-470 treatment will consist of four vaccine doses id injection (three weeks apart), then one dose every two months for the first year and them every three months for the second year.~Each vaccine consist of a mixture of 17,6.106 melanoma cells , from four melanoma cell lines, not genetically modified and lethally irradiated. As adjuvant BCG (120 µg prot) the first day and rhGM-CSF (Molgramostim 400 µg, fractionated in four days doses) will be used."
3123688|NCT01729650|Experimental|Physical and diet educational group|group educational PA program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks), carried out by mental health nurses.
3123689|NCT01729650|No Intervention|Usual clinical care|
3123690|NCT01729611||Scleroderma|60 patients with scleroderma - 30 with and 30 without Pulmonary Arterial Hypertension
3123691|NCT01729611||Cirrhosis|60 patients with cirrhosis - 30 with and 30 without Pulmonary Arteria Hypertension
3123692|NCT01729598|Experimental|Valproic Acid|Valproic acid 250 mg or 500mg by mouth twice daily.
3123693|NCT01729598|Placebo Comparator|Placebo|Placebo capsule by mouth twice daily.
3123694|NCT01729585|No Intervention|control group|control group
3123695|NCT01729585|Active Comparator|Massage therapy|Treatment group receives pre-determined massage therapy protocol x 5 over 10-12 weeks. massage therapy protocol includes a blend of Swedish strokes and myofascial trigger point therapy. Initially, dosing will be more frequent. Treatments will be spaced out to determine the ability of the body to maintain a more efficient musculoskeletal system, especially related to respiratory and postural efforts. Each session will end with resting hands and relaxation strokes to signal the end of the session. This protocol invites increased mobility in the musculoskeletal system. The ultimate goal is to return connective tissue (including muscles and fascia) to a more relaxed and neutral state, thus allowing expansion and ease of movement of the areas of the musculoskeletal system being worked.
3123696|NCT01729572|Experimental|Experimental: Tele-medicine monitoring|Tele-medicine monitoring of medication adherence will be given to the study group as an add-on to routine out-patient treatment
3123697|NCT01729572|No Intervention|No Intervention: Control Rutine out-patient treatment|routine out-patient treatment will be given to the control group
3123698|NCT01729559|Experimental|5000 Units unfractionated Heparin Q 8 hr|Low Dose Unfractionated Heparin (5000 Units) given every eight hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service.
3123699|NCT01729559|Active Comparator|30mg enoxaparin Q12 hr|Randomly assigned trauma patients to receive Low Molecular Weight Heparin (30mg enoxaparin) given subcutaneously every twelve hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service.
3123700|NCT01729533|Active Comparator|ICSI|In this arm, patients will be provided with standard intracytoplasmic sperm injection (ICSI), in which sperm selection is performed under an overall magnification of x400.
3123701|NCT01729533|Experimental|IMSI|In this arm, patients will be provided with a modified intracytoplasmic sperm injection (ICSI) procedure, the IMSI, in which sperm selection is performed under an overall magnification of x6600.
3123702|NCT01729520|Experimental|Knee extension strength training|
3123703|NCT01729507|Active Comparator|Treatment with tDCS|This group will receive 7x verum treatment with tDSC. All participants receive standardised behavioural therapy ('The smoke-free programme')
3123704|NCT01729507|Placebo Comparator|7x sham treatment|This group will receive 7x sham treatment. All participants will receive standardised behavioural therapy ('The smoke-free programme')
3123705|NCT01729494|Experimental|Group A|Alemtuzumab + belatacept + mycophenolate mofetil /Enteric coated mycophenolate sodium + early cessation of steroids
3123706|NCT01729494|Experimental|Group B|Rabbit antithymocyte globulin + belatacept + mycophenolate mofetil /Enteric coated (EC) mycophenolate sodium + early cessation of steroids
3123707|NCT01729494|Active Comparator|Group C|Rabbit antithymocyte globulin + tacrolimus + mycophenolate mofetil /Enteric coated (EC) mycophenolate sodium + early cessation of steroids
3123708|NCT01729481|Experimental|RASH positive|"Run-In-Phase during 4 weeks:~Gemcitabine 1000 mg/m², weekly Erlotinib 100 mg, weekly~Thereafter Treatment in patients with RASH-positve outcome after 4 weeks."
3123709|NCT01729481|Active Comparator|RASH-negative|"Run-In-Phase during 4 weeks:~Gemcitabine 1000 mg/m², weekly Erlotinib 100 mg, weekly~RASH-negative patients quit treatment with Gemcitabine + Erlotinib and continue treatment with FOLFIRINOX:~Oxaliplatin 85mg/m2 Irinotecan 180 mg/m2 Folinic acid 400 mg/m2 5-FU 400 mg/m2 bolus iv 5-FU 2400 mg/m2 46-hours continous infusion"
3123710|NCT01729468|Experimental|Aspirin|Aspirin 160 mg per day
3123711|NCT01729468|Placebo Comparator|Placebo|Placebo 160 mg per day
3123712|NCT01729455||With BENLYSTA|SLE treatment including BENLYSTA at baseline
3123713|NCT01729455||Without BENLYSTA|SLE treatment without BENLYSTA at baseline
3123714|NCT01729442|Other|Patients referred for first-line prostate HIFU ablation|10 patients
3123715|NCT01729442|Other|Patients referred for first-line HIFU hemi-ablation|10 patients
3123716|NCT01729442|Other|Patients referred for salvage HIFU after radiotherapy|10 patients
3123717|NCT01729429|Active Comparator|General Adolescent Vaccine Brochure|Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
3123718|NCT01729429|Experimental|HPV brochure, recall, reminders|"HPV-vaccine specific brochure mailed before clinic visit~Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine~Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses"
3123719|NCT01729416|Experimental|Water Exchange Colonoscopy|The intervention will be water exchange colonoscopy in patients who are randomized to have screening colonoscopy with water exchange colonoscopy.
3123729|NCT01729377||Suicidal older persons and their families|Suicidal older persons and their families will be interviewed
3123730|NCT01729364|Experimental|crystalloid|crystalloid fluid administration, Ringer-acetat 20ml/kg under 30 minutes
3123731|NCT01729364|Experimental|colloid|colloidal fluids administration, HES 6% (130/0,4) 7ml/kg under 30 minutes
3123732|NCT01729351||IPDI EF HFA-BDP|Patients initiating inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
3123733|NCT01729351||IPDI FP|Patients initiating inhaled corticosteroid therapy as FP via pMDI at the index date
3123734|NCT01729351||IPDI NEF HFA-BDP|Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
3123735|NCT01729351||IPDA EF HFA-BDP|Patients increasing inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
3123736|NCT01729351||IPDA FP|Patients increasing inhaled corticosteroid therapy as FP MDI at the index date
3123737|NCT01729351||IPDA NEF HFA-BDP|Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
3123738|NCT01729338|Experimental|Velcade, cyclophosphamide, Revlimid|"INDUCTION (28-day cycles for 8 cycles):~VELCADE 1.3 mg/m2 subcutaneously (SC) days 1, 8 and 15~Cyclophosphamide 300 mg/m2 orally (PO) days 1, 8 and 15~Dexamethasone 40 mg PO days 1,8 and 15~MAINTENANCE (28-day alternating cycles until stopped for toxicity, relapse or death):~Odd cycles (9, 11, 13, etc.) lenalidomide 10 mg PO days 1-21~Even cycles (10, 12, 14, etc.) VELCADE 1.3 mg/m2 SC days 1, 15"
3123739|NCT01729325|Experimental|Preventive Narrative Exposure Therapy|Treatment with Pre-NET before deployment in peace-keeping mission
3123740|NCT01729325|No Intervention|No treatment control|
3123741|NCT01729299|Placebo Comparator|saline|Saline: 0.9% saline solution
3123742|NCT01729299|Experimental|ghrelin and exendin (9-39)|Ghrelin+Ex-9: Combination of ghrelin and Ex-9,
3123743|NCT01729299|Experimental|Exendin (9-39)|Exendin (9-39) (25 µg/kg) bolus over 1 min followed by a continuous infusion of 2.5 µg/kg/min
3123744|NCT01729299|Experimental|ghrelin|synthetic human Acyl Ghrelin (0.28 μg/kg) bolus over 1 min followed by 2 μg/kg/h continuous infusion,
3123745|NCT01729286|Active Comparator|PriMatrix Moist Wound Therapy|sharp debridement, Primatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
3123746|NCT01729286|Other|Standard of Care Moist Wound Therapy|sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
3123747|NCT01729273|Experimental|Diet and Exercise Intervention|"Tests will include EndoPAT analysis to assess endothelial function, applanation tonometry to assess arterial stiffness, carotid artery imaging to assess the wall thickness of the carotid arteries, exercise testing to assess the physical exercise capacity of these children and blood work to evaluate the lipid profile and inflammation status (CRP).~The Home Exercise Program will be 3 days a week for 12 weeks and participants will connect with the trainer to perform 45-60 minutes of a combination of strength training and aerobic activity via Skype. The Dietary Approaches to Stop Hypertension(DASH) eating pattern will be prescribed to all participants in the treatment group and specific strategies to achieve goals will be discussed weekly by the participant over the phone."
3123748|NCT01729260|Experimental|mebendazole|
3123749|NCT01729247||FeNO|Participants with asthma will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit.
3123750|NCT01729234|Experimental|Nitrate|150µmol /Kg bodyweight /day
3123751|NCT01729234|Placebo Comparator|PLacebo|150µmol /Kg bodyweight /day
3123752|NCT01729221||HCV infected patients treated by stem cell therap|Hepatitis C virus infected patients treated by stem cell therapy
3123753|NCT01729221||HCV infected patients treated by standared line of care|Hepatitis C virus infected patients treated by standared line of care
3123754|NCT01729208|Experimental|Dual Focus Soft Contact Lens|Dual Focus Soft Contact Lens
3123755|NCT01729208|Placebo Comparator|Single Vision Soft Contact Lens|Single Vision Soft Contact Lens
3123756|NCT01729195|Experimental|Single-arm|The syndesmosis injury of the patients will be fixed with a ciprofloxacin containing bioabsorbable PLGA bone screw or a stainless steel metal screw
3123757|NCT01729182||Nexium|
3123758|NCT01729169||Sarcoidosis patients|Patients with biopsy proven sarcoidosis suspected of having cardiac sarcoidosis
3123759|NCT01729156|Other|Healthy controls|Healthy controls receiving 1000 mg metformin twice daily for 3 months
3123760|NCT01729156|Placebo Comparator|Placebo|Placebo
3123761|NCT01729156|Active Comparator|Metformin|"Metformin Sandoz, 1000 mg twice daily for 3 months"
3123762|NCT01729143|Active Comparator|Black pepper|During the black pepper study day, subjects consumed 1.5g of black pepper (0.5g/meal) in 60.8g of vegetable juice. Black pepper was consumed was a meal on each occasion. 24-hour energy expenditure and substrate utilization will be measured.
3123763|NCT01729143|Placebo Comparator|No pepper control|During the no pepper control study day, subjects consumed an identical menu without black pepper. 60.8g of vegetable juice (vehicle) was consumed at each of the three study meals. 24-hour energy expenditure and substrate utilization will be measured.
3123764|NCT01729130||Group 1 Pancreas/kidney transplant|Group 1 of patients with End Stage Renal Disease (ESRD) and Diabetes Mellitis who will receive a pancreas and kidney transplant. An adipose tissue biopsy and blood samples are collected at time of transplant surgery. A repeat adipose tissue needle biopsy and blood samples are collected between 3-12 months post transplant.
3123765|NCT01729130||Group 2 DM with kidney transplant|Group 2 are patient with DM and ESRD and who will receive only a kidney transplant.
3123766|NCT01729130||Group 3 No DM and kidney transplant|Group 3 will be patients who do not have DM but do have the diagnosis of ESRD and will receive only a kidney transplant.
3123767|NCT01729117|Other|Meal Replacement|Meal Replacements will be provided to participants randomized to the MR group
3123768|NCT01729117|Other|Standard Care|Standard Care participants will receive standard care but no meal replacements
3123805|NCT01728883||Diagnosed DR/DME requiring treatment|Patients diagnosed as diabetic retinopathy(DR) and/or diabetic macular edema (DME) and requiring treatment at the time they are recruited into the Study. Patients will be home vision monitoring using myVisionTrack®.
3123874|NCT01728454|Experimental|Proellex 6 mg|proellex 6 mg, oral, capsules, once a day for 18 weeks
3123769|NCT01729104|Experimental|Phase I: Carfilzomib + Lenalidomide + Rituximab|Phase I: Four primary dose levels of carfilzomib plus lenalidomide (carfilzomib 20 mg/27 mg + lenalidomide 20 mg, carfilzomib 20 mg/36 mg + lenalidomide 20 mg, carfilzomib 20mg/45 mg + lenalidomide 20 mg, carfilzomib 20 mg/56 mg + lenalidomide 20 mg,) evaluated with a fixed dose of rituximab (375 mg/m2 weekly for 4 weeks). Alternate dose levels using 15 mg of lenalidomide in combination with carfilzomib and rituximab evaluated if MTD is exceeded with 20 mg of lenalidomide.
3123770|NCT01729104|Experimental|Phase II: Mantle Cell Lymphoma Group|"Phase II: Patients enrolled at recommended dose level (MTD) of Carfilzomib established in Phase I of the study.~Phase II Lenalidomide Dose: 20 mg by vein on Days 1-21 of each cycle.~Phase II Rituximab Dose: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months."
3123771|NCT01729104|Experimental|Phase II: Follicular, Marginal Zone, DLBCL Group|"Group consists of : Patients with follicular lymphoma (FL) grade 1 - 3, marginal zone lymphoma (MZL), or non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL).~Phase II: Patients enrolled at recommended dose level (MTD) of Carfilzomib established in Phase I of the study.~Phase II Lenalidomide Dose: 20 mg by vein on Days 1-21 of each cycle.~Phase II Rituximab Dose: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months."
3123772|NCT01729091|Experimental|Chemotherapy + NK and Stem Cell Infusions|"Part I Dose Escalation: From Day -8 to Day -2, lenalidomide 10 mg by mouth daily. On Day -7, high-dose melphalan 200 mg/m^2 by vein. On D-5 NK cell given by vein. On Day 0, autologous stem cell infusion minimum cell dose of 1 x 10^8 cells/kg. G-CSF 5 mcg/kg/day subcutaneously beginning on Day 0, and continuing until evidence of an absolute neutrophil count (ANC) of 0.5 * 109/L per 3 consecutive days.~Elotuzumab 10 mg/kg to be given on day -15 (out-patient) and day -8 (in-patient). Dexamethasone 28 mg by mouth 3 to 24 hours before Elotuzumab infusion plus 8 mg by vein 45 to 90 minutes prior to infusion.~Part I Dose Expansion: Additional 18 high-risk patients treated."
3123773|NCT01729078|Experimental|high fat ( MUFA) diet|intervention using high fat diet.
3123774|NCT01729078|Experimental|high carb/high fiber|diet using high carb-high fiber with dry beans
3123775|NCT01729078|Experimental|high carb/low fat|Habitual diet
3123776|NCT01729065|No Intervention|Home Program|Participants perform home program only.
3123777|NCT01729065|Experimental|Physical Therapy Intervention|Physical therapy intervention provided for first 12 weeks following surgery.
3123778|NCT01729052|Experimental|Acupuncture and standard treatment|"Acupuncture at Neiguan (Pericardium-6) bilaterally with Seirin needles no 3 (0.20x15 mm) to a depth of approximately 7 mm will be performed on the children immediately after induction of anaesthesia and removed before they are fully awake.~Standard treatment: general anaesthesia"
3123779|NCT01729052|No Intervention|Standard treatment|General anaesthesia
3123780|NCT01729039|Experimental|gaze stability|standard balance rehabilitation plus vestibular-specific exercises
3123781|NCT01729039|Placebo Comparator|control|standard balance rehabilitation plus placebo eye exercises
3123782|NCT01729026|Experimental|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help of a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
3123783|NCT01729026|Active Comparator|Wait-list, Then Adoption after 3 Months|After 3 months on a wait-list, Veterans will choose a dog from the San Antonio Humane Society with the help of a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
3123784|NCT01729013||subjects previously given placebo|
3123785|NCT01729013||subjects previously given vitamin D|
3123786|NCT01729000|No Intervention|Hand hygiene|All staff that have interaction with subjects will perform hand hygiene with all patient contact and before all contact with the intravenous line.
3123787|NCT01729000|Experimental|Hand hygiene plus gloving|All staff that have interaction with subjects will perform hand hygiene and wear gloves with all patient contact and before all contact with the intravenous line.
3123788|NCT01728987|Active Comparator|cholecalciferol|vitamin d (cholecalciferol) will be given as a capsule of 20.000 Iu twice a week
3123789|NCT01728987|Placebo Comparator|placebo|the placebo capsules are looking identical to the vitamin d capsules and contain medium chain triglycerides and arachis oil
3123790|NCT01728974|Experimental|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
3123791|NCT01728961|Active Comparator|ARM A: AL + NVP -based ARV treatment|AL given to children who test positive for malaria and are already taking NVP as prescribed by their healthcare provider
3123792|NCT01728961|Active Comparator|ARM B: AL with No ARV treatment|AL given to children who do not meet national guidelines for beginning ARV treatment
3123793|NCT01728948||Group 1|
3123794|NCT01728935|Other|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
3123795|NCT01728922|Active Comparator|Healthy control - 5,000 IU vitamin D|13 healthy controls will be administered 5,000 IU vitamin D. Primary outcome and safety outcome measures will be assessed.
3123796|NCT01728922|Active Comparator|Healthy control - 10,000 IU vitamin D|13 healthy controls will be administered 10,000 IU vitamin D. Primary outcome and safety outcome measures will be assessed.
3123797|NCT01728922|Placebo Comparator|CIS - placebo|15 patients will be administered placebo and all outcome measures will be assessed.
3123798|NCT01728922|Active Comparator|CIS - 5,000 IU vitamin D|15 patients will be administered 5,000 IU vitamin D and all outcomes will be assessed.
3123799|NCT01728922|Active Comparator|CIS - 10,000 IU vitamin D|15 patients will be administered 10,000 IU of vitamin D and all outcome measures assessed.
3123800|NCT01728922|Placebo Comparator|Healthy control - placebo|13 control participants who will be administered placebo. These will be assessed for the primary outcome and safety outcomes only.
3123801|NCT01728909|Experimental|Oxytocin|40 IU Oxytocin
3123802|NCT01728909|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
3123803|NCT01728896|Experimental|Patient-controlled oral refeeding|Patients will be allowed to drink and eat hospital food freely as tolerated.
3191413|NCT01259154||UPPP|
3123806|NCT01728870|Experimental|Unique Diet+Partial Enteral Nutrition|"Unique Diet+Partial Enteral Nutrition (PEN): This group will receive as follows:~Weeks 1-6: 50% of dietary needs from PEN (Modulen, Nestle) and 50% from a limited whole food diet.~Weeks 7-12: 25% of dietary needs from PEN (Modulen, Nestle) and 75% from a limited whole food diet."
3123807|NCT01728870|Active Comparator|Exclusive Enteral Nutrition (Modulen)|"Exclusive Enteral Nutrition(EEN): This group will receive as follows:~Weeks 1-6: EEN(100% of dietary needs from Modulen) Weeks 7-12: 25% of dietary needs from Modulen and 75% from a free diet."
3123808|NCT01728857|Experimental|Fat Reduction|
3123809|NCT01728818|Experimental|Arm A|
3123810|NCT01728818|Active Comparator|Arm B|
3123811|NCT01728805|Experimental|KW-0761|anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)
3123812|NCT01728805|Active Comparator|Vorinostat|vorinostat 400 mg once daily
3123813|NCT01728792|Experimental|Group 1: TDV SC_2 Doses Day 0|Takeda's Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous (SC) injection, one dose in each arm, Day 0 using a needle/syringe.
3123814|NCT01728792|Experimental|Group 2: TDV IM_2 Doses Day 0|TDV, 0.5 mL, intramuscular (IM) injection, one dose in each arm, Day 0 using a needle/syringe.
3123815|NCT01728792|Experimental|Group 3: TDV IM_2 Doses Days 0 and 90|TDV, 0.5 mL, IM injection, one dose on Day 0 and one dose on Day 90 using a needle/syringe.
3123816|NCT01728792|Experimental|Group 4: TDV SC_2 Doses Day 0|TDV, 0.5 mL, SC injection, one dose in each arm, Day 0 using the PharmaJet Stratis™ device.
3123817|NCT01728792|Experimental|Group 5: TDV IM_2 Doses Day 0|TDV, 0.5 mL, IM injection, one dose in each arm, Day 0 using the PharmaJet Stratis™ device.
3123818|NCT01728779|Experimental|Nelfinavir w/Stereotactic Body Radiation Therapy (SBRT)|Patients with metastatic lesions of the lung, liver, or bone will be candidates for treatment. Within three weeks of the initial treatment planning, a 15 Gy dose (per lesion site) of SBRT will be administered. Prior to SBRT, patients will initiate Nelfinavir oral therapy twice daily for 7 days. Once SBRT is completed, the patient will repeat the same Nelfinavir therapy for an additional 7 days for a total of 14 days of treatment.
3123819|NCT01728766||Infants under-6 months and their mothers|Small for gestational age at delivery. Post-term Infant, Not Heavy-for-dates.
3123820|NCT01728753|Placebo Comparator|Placebo|Placebo
3123821|NCT01728753|Experimental|T-705 A|Favipiravir regimen 1: 1200 mg 3x daily (TID) on Day 1, then 600 mg TID on Days 2-5
3123822|NCT01728753|Experimental|T-705 B|Favipiravir regimen 2: 2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5
3123823|NCT01728753|Experimental|T-705 C|Favipiravir regimen 3: 1800 mg BID on Day 1, then 800 mg BID for Days 2-5
3123824|NCT01728740|Experimental|Acarbose/Metformin FDC|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Acarbose/Metformin FDC; Day 1: oral sucrose load plus single dose of 1 tablet Acarbose/Metformin FDC (containing 50 mg Acarbose and 500 mg Metformin)
3123825|NCT01728740|Active Comparator|Acarbose+Metformin|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without loose combination of Acarbose and Metformin; Day 1: oral sucrose load plus single dose of 1 tablet each of a loose combination of Acarbose 50 mg and Metformin 500 mg
3123826|NCT01728740|Active Comparator|Acarbose|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without comedication; Day 1: oral sucrose load plus single dose of 1 tablet Acarbose 50 mg
3123827|NCT01728740|Active Comparator|Metformin|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without comedication; Day 1: oral sucrose load plus single dose of 1 tablet Metformin 500 mg
3123828|NCT01728727|Active Comparator|conventional|conventional treatment & antiviral treatment
3123829|NCT01728727|Experimental|UC-MSC transplantation|Participants will receive umbilical cord derived mesenchymal stem cell treatment at day 1 and conventional treatment and antiviral treatment through the one year study visit. Participants will then be followed until one years study visit
3123830|NCT01728714||Adults over 18 years old|Adults over 18 years old, with type 2 diabetes, HbA1c <= 8,5%, treated with oral antidiabetics at least for 6 months submitted to an educational programme during 1 year
3123831|NCT01728714||Adults with HbA1c <= 8,5%|Adults over 18 years old, with type 2 diabetes, HbA1c <= 8,5%, treated with oral antidiabetics at least for 6 months followed according to normal clinical practice during 1 year
3123832|NCT01728701|Experimental|Grp 1: 75,000 PfSPZ Challenge, 3 immunizations|Grp 1 (10 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 1 gets 6 ID injections of PfSPZ Challenge (total 75,000 PfSPZ NF54 strain), on days 8, 36 & 64 (immunizations 1, 2 & 3). 33 days after last dose of CQ, Grp 1 will have CHMI by bites of 5 mosquitoes infected with Pf NF54 strain.
3123833|NCT01728701|Placebo Comparator|Grp 2: Normal Saline (NS)|Grp 2 (5 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 2 gets ID injections of normal saline, on days 8, 36 & 64 (immunizations 1, 2 & 3). 33 days after last dose of CQ, Grp 2 will have CHMI by bites of 5 mosquitoes infected with Pf NF54 strain.
3123834|NCT01728701|Experimental|Grp 3: 75,000 PfSPZ Challenge, 3/4 immunizations|Grp 3 (10 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 3 gets 6 ID injections of PfSPZ Challenge (total 75,000 PfSPZ NF54 strain), on days 8, 36 & 64 (immunizations 1, 2 & 3). Grp 3 outcome is dependent on results of Grp 1. If ≥75% of Grp 1 are protected against homologous Pf CHMI, Grp 3 will have CHMI by bites of 5 mosquitoes infected with heterologous Pf NF135.C10 strain 75 days after last dose of CQ. If <75% of Grp 1 are protected against homologous Pf CHMI, Grp 3 will receive 1 additional immunization (immunization 4), consisting of 6 ID injections on the same day of 75,000 PfSPZ Challenge, at day 162. In this 4th immunization period CQ will be administered for another 6 weeks starting at day 154. Finally, 33 days after last dose of CQ, Grp 3 will have homologous Pf CHMI by bites of 5 PfSPZ-infected mosquitoes.
3123868|NCT01728493||Part 2:|"newly diagnosed hypertensive patients with primary aldosteronism~newly diagnosed hypertensive patients with essential hypertension"
3123869|NCT01728493||Part 3:|"newly diagnosed hypertensive patients with normokalemic primary aldosteronism~newly diagnosed hypertensive patients with essential hypertension"
3123870|NCT01728480|Experimental|Treatment (entolimod, IMRT, cisplatin)|Patients undergo IMRT 5 times per week for 7 weeks, receive cisplatin IV once weekly for 7 weeks, and entolimod SC on days 1, 8, 15, 22, 29, 36, and 43.
3123871|NCT01728467|Experimental|RVX000222, 200 mg daily|
3123872|NCT01728467|Placebo Comparator|Placebo|
3123835|NCT01728701|Placebo Comparator|Grp 4: Normal Saline (NS)|Grp 4 (5 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 wks(98 days). In this time, Grp 4 gets ID injections of NS, on days 8, 36 & 64 (immunizations 1, 2 & 3). Grp 4 outcome is dependent on results of Grp 1. If ≥75% of Grp 1 are protected against homologous Pf CHMI, Grp 4 will have CHMI by bites of 5 mosquitoes infected with heterologous Pf NF135.C10 strain 75 days after last dose of CQ. If <75% of Grp 1 are protected against homologous Pf CHMI, Grp 4 will receive 1 additional immunization (immunization 4), consisting of ID injections of NS, at day 162. In this 4th immunization period CQ will be administered for another 6 weeks starting at day 154. Finally, 33 days after last dose of CQ, Grp 4 will have homologous Pf CHMI by bites of 5 PfSPZ-infected mosquitoes.
3123836|NCT01728688|Active Comparator|Conventional|conventional treatment & antiviral treatment
3123837|NCT01728688|Experimental|conventional & PBSC transplantation|After three days G-CSF mobilization, Patients randomized to the intervention arm will receive autologous PBSCs transplantation at day1, and receive conventional treatment and antiviral treatment through the one year study visit and followed until one years study visit.
3123838|NCT01728675|Experimental|Young group|Participants will underwent two isokinetic eccentric exercise sessions
3123839|NCT01728675|Experimental|Elderly group|Participants will underwent two isokinetic eccentric exercise sessions
3123840|NCT01728662|Experimental|ELVR Procedure|A single subsegmental AeriSeal System treatment consists of the administration of 10 mL Foam Sealant administered through a standard fiberoptic bronchoscope via an administration syringe and bronchoscopic catheter into the target area of damaged lung
3123841|NCT01728649|No Intervention|Normothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using current FDA approved devices. After which patient will be started on normothermia attempting to keep core body temp between 38 and 36.5 degrees centigrade. Patients will also undergo blood draws for biomarkers before reperfusion is achieved the immediately, 6 hours then 24 hours after reperfusion.
3123842|NCT01728649|Experimental|Mild Hypothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using current FDA cleared device. Patient will also have a Quattro catheter placed in the femoral vein and temperature brought to 33 degrees centigrade as quickly as possible. They will stay in mild hypothermia for 12 hours and then be rewarmed very slowly. Patients will also undergo blood draws for biomarkers before reperfusion is achieved the immediately, 6 hours then 24 hours after reperfusion.
3123843|NCT01728636|Experimental|Tranexamic Acid|Tranexamic acid 10mg/kg loading dose given pre-incision and 1mg/kg/hr infusion throughout intraoperative period
3123844|NCT01728636|Placebo Comparator|Placebo|Normal saline placebo loading dose 0.5ml/kg and infusion at 0.5ml/kg/hr throughout operative course
3123845|NCT01728623|Experimental|E7080|
3123846|NCT01728610|Active Comparator|Active high|Probiotic, high dose
3123847|NCT01728610|Active Comparator|Active low|Probiotic, low dose
3123848|NCT01728610|Placebo Comparator|Placebo|Placebo
3123849|NCT01728597||healthy volunteers|MR compliant volunteers with no history of cardiovascular diseases
3123850|NCT01728584|Experimental|Standard NMB and Standard Insufflation Pressure|Treatment condition for this arm is Standard NMB (depth of blockade at a targeted Train of Four [TOF] ratio of 10%)/Standard insufflation pressure (starting pressure of 12 mmHg).
3123851|NCT01728584|Experimental|Standard NMB and Low Insufflation Pressure|Treatment condition for this arm is Standard NMB (depth of blockade at a targeted TOF ratio of 10%)/Low insufflation pressure (starting pressure of 8 mmHg).
3123852|NCT01728584|Experimental|Deep NMB and Standard Insufflation Pressure|Treatment condition for this arm is Deep NMB (depth of blockade of 1-2 PTCs)/Standard insufflation pressure (starting pressure of 12 mmHg).
3123853|NCT01728584|Experimental|Deep NMB and Low Insufflation Pressure|Treatment condition for this arm is Deep NMB (depth of blockade of 1-2 PTCs)/Low insufflation pressure (starting pressure of 8 mmHg).
3123854|NCT01728571|Active Comparator|Vitamin D + fish oil|Dietary Supplement: vitamin D3 Drug: omega-3 fatty acids (fish oil)
3123855|NCT01728571|Active Comparator|Vitamin D + fish oil placebo|Dietary Supplement: vitamin D3 Dietary Supplement: Fish oil placebo
3123856|NCT01728571|Active Comparator|Vitamin D placebo + fish oil|Drug: omega-3 fatty acids (fish oil) Dietary Supplement: Vitamin D3 placebo
3123857|NCT01728571|Placebo Comparator|Vitamin D placebo + fish oil placebo|Dietary Supplement: Vitamin D3 placebo Dietary Supplement: Fish oil placebo
3123858|NCT01728558|Other|Early Goal Directed Sedation|"Early Goal Directed Sedation process of care involves:~Early delivery of proposed intervention, shortly after initiating mechanical ventilation;~Effective analgesia provided simultaneously and early (analgesia first).~Regular and frequent assessment of patient wakefulness/sedative state;~Avoidance of benzodiazepines and minimisation of use of propofol;~Reduced overall sedation depth with targeted light sedation; Patients randomised to the EGDS arm will receive a sedative infusion of Dexmedetomidine withor without minimal propofol in order to maintain a RASS of -2 to +1.~Dexmedetomidine infusion will be continued until sedation is no longer clinically indicated up to a maximum of 28 days after enrolment."
3123859|NCT01728558|Active Comparator|Standard care Sedation Arm|Patients randomised to the standard care sedation arm will receive process of care sedation directed by the treating clinician. Based on the information from our observational study and the EGDS Pilot trial, most patients in this group are likely to receive midazolam and /or propofol. These agents will be infused to achieve the default target of Light sedation (RASS -2 to +1) whenever clinically appropriate and as specified by the treating clinician. The use remifentanil or dexmedetomidine for initial and maintenance sedation will be precluded.
3123860|NCT01728532|Active Comparator|Pulp Canal Sealer (Kerr)|zinc oxide eugenol sealer
3123861|NCT01728532|Experimental|PA0903|type C implant according to ISO 7405:2008 and ISO 10993 guidelines.
3123862|NCT01728519|Experimental|AllerT SC|AllerT subcutaneous injections
3123863|NCT01728519|Placebo Comparator|Placebo SC|placebo subcutaneous injections
3123864|NCT01728519|Experimental|AllerT ID|AllerT intra-dermal injections
3123865|NCT01728519|Placebo Comparator|Placebo ID|placebo intra-dermal injections
3123866|NCT01728506|Experimental|Weight Loss & Exercise|Single arm intervention of a 24 week weight loss and exercise intervention.
3123867|NCT01728493||Part 1|- newly diagnosed hypertensive patients in general practice
3123873|NCT01728454|Placebo Comparator|Placebo|Parallel placebo arm oral, capsules, once a day for 18 weeks
3123875|NCT01728454|Experimental|Proellex 12 mg|proellex 12 mg, oral, capsules, once a day for 18 weeks
3123876|NCT01728441|Experimental|Paclitaxel Eluting Stent|Patients randomized to treatment with paclitaxel eluting stent will receive the Zilver® PTX® stent.Primary stenting should be performed covering the full lesion. Post-dilatation is at the investigator's discretion.
3123877|NCT01728441|Active Comparator|Paclitaxel Eluting Balloon|For patients randomized to treatment with drug eluting balloon (DEB), angioplasty (ballooning) should be performed covering the full lesion.
3123878|NCT01728415|Experimental|A: Exercise|High intensity interval exercise training (3 x 3 minutes of intensity abow 85% og Heart rate peak)
3123879|NCT01728415|Active Comparator|B: Execise|Moderate continuous exercise training
3123880|NCT01728415|No Intervention|C: Controll|Usual care without exercise training
3123881|NCT01728402||Blood Draw|
3123882|NCT01728389|Experimental|Intrabone transplantation|Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
3123883|NCT01728376|Experimental|Daptomycin - 12 to 17 year olds|Participants ages 12-17 years old were administered daptomycin 7 mg/kg infused once daily, intravenously (IV), over 30 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
3123884|NCT01728376|Active Comparator|Comparator - 12 to 17 year olds|Participants ages 12-17 years old received IV vancomycin or semi-synthetic penicillin or first-generation cephalosporins or clindamycin, given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
3123885|NCT01728376|Experimental|Daptomycin - 7 to 11 year olds|Participants ages 7 to 11 years old were administered daptomycin 9 mg/kg, infused once daily, IV over 30 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
3123886|NCT01728376|Experimental|Daptomycin - 1 to 6 year olds|Participants ages 1 to 6 years old were administered daptomycin 12 mg/kg, infused once daily, IV over 60 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
3123887|NCT01728376|Active Comparator|Comparator - 7 to 11 year olds|Participants ages 7-11 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
3123888|NCT01728376|Active Comparator|Comparator - 1 to 6 year olds|Participants ages 1-6 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
3123889|NCT01728363|Experimental|Ticarcillin-clavulanate antibiotic|"Cohort Gestational Age (GA) Postnatal Age (PNA) Dose~<30 weeks <14 days: 75 mg/kg Q12 hrs x 6 doses~<30 weeks ≥14 days-45 days 75 mg/kg Q 8 hours x 6 doses~<30 weeks >45 days-90 days 75 mg/kg Q 6 hours x 6 doses~Brand name is Timentin. This drug is an antibiotic used to treat a wide variety of bacterial infections. It is a combination of two drugs & both treat bacterial infections. Ticarcillin is a penicillin-type antibiotic that stops bacterial growth & clavulanate potassium is an enzyme inhibitor that helps the ticarcillin work better."
3123890|NCT01728363|Experimental|Rifampin generic antibiotic|"Cohort GA PNA Dose~<32 weeks <14 days 10 mg/kg Q 24 hours x 4 doses~<32 weeks ≥14 days-120 days 15 mg/kg Q 24 hours x 4 doses~≥32 weeks <14 days 15 mg/kg Q 24 hours x 4 doses~≥32 weeks ≥14 days-120 days 20 mg/kg Q 24 hours x 4 doses~The brand name is Rifadin, Rimatane. This drug is an antibiotic and a first line antituberculotic and unlabeled use for infections caused by staphylococcus aureus & staphylococcus epidermis."
3123891|NCT01728363|Experimental|Clindamycin Generic Antibiotic|"Cohort GA PNA Dose~<30 weeks <14 days 10 mg/kg Q 12 hours x 6 doses~<30 weeks ≥14 days-45 days 10 mg/kg Q 8 hours x 6 doses~<30 weeks >45 days-120 days 10 mg/kg Q 6 hours x 6 doses~The brand name is Cleocin. This drug is an antibiotic used to treat a wide variety of bacterial infections and serious infections."
3123892|NCT01728350|Experimental|Treatment|Participants in this arm will participate in a novel structured volunteering intervention called HOPE - Helping Others through Purpose and Engagement. This intervention involves orientation, training, volunteer placement assistance, and problem solving and support.
3123893|NCT01728350|No Intervention|Control|Participants who are randomized to the control arm will be offered the HOPE intervention at the conclusion of study.
3123894|NCT01728337|Active Comparator|Xeomin and Dysport|Xeomin® was injected on the right side of the forehead and Dysport® was injected on the left side of the forehead.
3123895|NCT01728324|Experimental|Randomised 24-week arm|BI 207127 in combination with FDV and RBV for 24 weeks (randomised)
3123896|NCT01728324|Experimental|Randomised 16-week arm|BI 207127-placebo, FDV-placebo and RBV-placebo for 8 weeks followed by BI 207127 in combination with FDV and RBV for 16 weeks (randomised)
3123897|NCT01728324|Experimental|Allocated 24-week arm|BI 207127 in combination with FDV and RBV for 24 weeks (allocated to patients with compensated cirrhosis)
3123898|NCT01728311|Experimental|Arm 1|
3123899|NCT01728298|Active Comparator|SLITone ULTRA low dose|SLITone ULTRA HDM immunotherapy
3123900|NCT01728298|Active Comparator|SLITone ULTRA medium dose|SLITone ULTRA HDM immunotherapy
3123901|NCT01728298|Active Comparator|SLITone ULTRA high dose|SLITone ULTRA HDM immunotherapy
3123902|NCT01728285|Active Comparator|Electronic compliance device|Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX®) using an electronic compliance device (Memozax®)
3123903|NCT01728285|No Intervention|No electronic compliance device|Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX®) without any electronic compliance device (Memozax®)
3124292|NCT01725594|Experimental|Cohort A4, Dose Level 4: CAT 2003 or placebo fasting|Single dose
3123904|NCT01728272|Experimental|blood concentration of metoprolol|how does off-pump miniperfusion and perfusion CABG influence the absorption of metoprolol after CABG
3123905|NCT01728259|Experimental|Treatment (pomalidomide, bortezomib, and dexamethasone)|Patients receive pomalidomide PO on days 1-21; bortezomib IV or SC on days 1, 8, and 15; and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3123906|NCT01728246|Experimental|Tramadol/Paracetamol (APAP)|
3123907|NCT01728246|Active Comparator|Non-Tramadol/APAP|
3123908|NCT01728233|Experimental|Dacomitinib (PF-00299804)|PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
3123909|NCT01728220|Active Comparator|Inhaled NO @ 0.003 mg/kg/ ideal body weight (IBW)/hr (Part A)|Inhaled NO using 3.0 mg/L [2440 ppm] NO minicylinder
3123910|NCT01728220|Active Comparator|Inhaled NO @ 0.010 mg/kg/IBW/hr (Part A)|Inhaled NO using 3.0 mg/L [2440 ppm] NO minicylinder
3123911|NCT01728220|Active Comparator|Inhaled NO @ 0.015 mg/kg/IBW/hr (Part A)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder
3123912|NCT01728220|Placebo Comparator|Placebo random @ 0.003, 0.010 or 0.015 mg/kg/IBW/hr (Part A)|Placebo using 99.999% N2 minicylinder
3123913|NCT01728220|Active Comparator|Inhaled NO @ 0.030 mg/kg IBW/hr (Part B)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder
3123914|NCT01728220|Active Comparator|Inhaled NO @ 0.075 mg/kg IBW/hr (Part B)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder
3123915|NCT01728220|Active Comparator|Placebo random @ 0.030 or 0.075 mg/kg/IBW (Part B)|Placebo using 99.999% N2 minicylinder
3123916|NCT01728207|Experimental|IMMU-114|IMMU-114 will be administered subcutaneously (under the skin) once or twice weekly for 3 weeks followed by one week of rest. Treatment cycles will continue until disease worsening or toxicity. Various dose levels will be studied.
3123917|NCT01728194|Experimental|Escitalopram|Target dose 20mg for 12 weeks
3123918|NCT01728181|Experimental|Phase I|Will receive Tivozanib and Erlotinib treatment.
3123919|NCT01728181|Other|Phase II Group 1 (Standard of Care)|"Group 1: VeriStrat® predicts the chance of no benefit from erlotinib~• The patient will get standard-of- care"
3123920|NCT01728181|Active Comparator|Phase II Group 2 (arm 1)|"Group 2: VeriStrat® predicts the chance of benefit from Erlotinib~• Arm 1: Patient will get the study drugs Erlotinib and Tivozanib"
3123921|NCT01728181|Placebo Comparator|Phase II Group 2 (arm 2)|"Group 2: VeriStrat® predicts the chance of benefit from Erlotinib~• Arm 2: Patient will get the study drug erlotinib and placebo"
3123922|NCT01728168||Atopic|Subjects with either documented allergy, neurodermatitis, allergic asthma, allergic rhinitis, and/or a positive atopic score based on the criteria of Erlangen (>10 points).
3123923|NCT01728168||Non-atopic|Subjects without atopy.
3123924|NCT01728155|No Intervention|Group1|initial observation (chemotherapy is only given if there is subsequent progression)
3123925|NCT01728155|Active Comparator|Group 1: chemotherapy|chemotherapy and surgery
3123926|NCT01728155|Experimental|Group 2|chemotherapy and surgery
3123927|NCT01728155|Experimental|Group 3|chemotherapy and surgery
3123928|NCT01728155|No Intervention|Group 4|Observation
3123929|NCT01728155|Experimental|Group 5|chemotherapy
3123930|NCT01728155|Experimental|Group 6|chemotherapy and surgery
3123931|NCT01728155|Experimental|Group 7|chemotherapy and surgery
3123932|NCT01728155|Experimental|Group 8|chemotherapy, surgery, radiotherapy and 13 cis-retinoic acid
3123933|NCT01728155|Experimental|Group 9|chemotherapy, surgery, radiotherapy and 13 cis-retinoic acid
3123934|NCT01728155|Experimental|Group 10|chemotherapy, surgery,
3123935|NCT01728142|Active Comparator|Non-concussed|Control group; individuals assigned to this group will be either healthy volunteers or individuals sustaining an injury that does not involve concussion. Participants will take both the ANAM and DANA Brief twice at minimum.
3123936|NCT01728142|Experimental|Concussed|Individuals who have been diagnosed with a concussion by a clinician. Participants will take both the DANA and ANAM twice at minimum.
3123937|NCT01728129|Experimental|Concussed|Subjects who are diagnosed with a concussion by a clinician will be assessed with the MACE and DANA Rapid every 24 hours for up to 72 hours post-injury.
3123938|NCT01728129|Active Comparator|Non-concussed|Subjects will have been exposed to a potentially concussive event but be clinically evaluated and found not to have sustained a concussion. Control subjects from this arm will take both the MACE and DANA Rapid twice: once within 24 hours of potentially concussive event, and again on the day of return to duty.
3123939|NCT01728116|Experimental|Device (EndoBarrier)|Device for glycemic control
3123940|NCT01728116|Sham Comparator|Sham Procedure|sham procedure
3123941|NCT01728103||No Treatment|
3123942|NCT01728090|Experimental|Hand sanitizer|"Intervention classrooms received alcohol-based hand sanitizer and a programme educational.~Characteristics of the hydroalcoholic gel (ALCO ALOE GEL): chlorhexidine digluconate at 20% solution, phenoxyethanol 1%, benzalkonium chloride 0.%. aloe Barbadensis 5%, Renat ethyl alcohol 70%, excipients c.s.p. 100 ml. Alcohol of between 65 - 70% degrees, pondus Hydrogenium (pH) = 7-7,5."
3123943|NCT01728090|No Intervention|Control|No hand sanitizer or educational programme were used
3123944|NCT01728077|Experimental|Brivaracetam|At Entry Visit (EV), subjects will start on the individualized Brivaracetam (BRV) dose that they had reached at the completion of the previous study. Dose adjustments of the Investigational Medicinal Product (IMP) are allowed at any time based on the clinical judgment of the investigator. The BRV dose can be increased or decreased in increments of 50 mg/day based on the individual subject's seizure control and/or tolerability; however, the BRV dose should not exceed 200 mg/day during the study and must always be administered as a symmetrical morning and evening dose. Upon completion or early discontinuation from this study, there will be a Down-Titration Period in steps of 50 mg/day on a weekly basis until 20 mg/day for 1 week is reached, followed by a Post-Treatment Period (between 2 and 4 weeks) during which the subject will not receive study drug. No down-Titration Period will be applicable if subjects are continued on BRV after they complete this study.
3123945|NCT01728064|Placebo Comparator|Placebo|Placebo capsules three times daily
3123946|NCT01728064|Active Comparator|EPI-743 400 mg|EPI-743 at a dose of 400 mg three times daily
3123947|NCT01728064|Active Comparator|EPI-743 200 mg|EPI-743 at a dose of 200 mg three times daily
3123948|NCT01728038|Experimental|Cessation Counseling|Parental smokers will be given a brief cessation intervention consisting of counseling, nicotine replacement therapy and Quitline connection.
3123949|NCT01728025|Experimental|Ranolazine|Ranolazine 500-1000 mg twice a day as tolerated
3123950|NCT01728012||eGFR >=60ml/min/1.73m2|Patients with an estimated glomerular filtration rate of >=60 ml/min/1.73m2.
3123951|NCT01728012||eGFR 45-60ml/min/1.73m2|Patients with estimated glomerular filtration rate >=45 ml/min/1.73m2 and <60ml/min/1.73m2.
3123952|NCT01727999||TPO responder|Patients with therapeutic response to TPO
3123953|NCT01727999||TPO non-responder|Patients not responding to TPO agonists
3123954|NCT01727986|Experimental|RoActemra/Actemra|
3123955|NCT01727973|Experimental|Doxycycline|Tablets Doxycycline 50 mg PO per day for 12 weeks
3123956|NCT01727960||Korean Male Adolescents|students from two academic high schools
3123957|NCT01727947|Experimental|MSOME|Couples in which the sperm cells were analysed through MSOME
3123958|NCT01727934|Experimental|Miravirsen sodium|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg then 4 every other week doses at 5 mg/kg.
3123959|NCT01727921|Active Comparator|22 gauge ProCore needle biopsy|EUS-guided pancreatic or peripancreatic mass biopsy with 22 gauge ProCore biopsy needle.
3123960|NCT01727921|Active Comparator|25 gauge ProCore needle biopsy|EUS-guided pancreatic or peripancreatic mass biopsy with 25 gauge ProCore biopsy needle.
3123961|NCT01727908|No Intervention|Endoscopy without staining of the mucosa|
3123962|NCT01727908|Experimental|Endoscopy with staining of the mucosa.|
3123963|NCT01727895|Experimental|Beta-glucan|Commercial available Beta-glucan derived from bakers yeast (S. Cerevisiae): Glucan #300® produced by Transferpoint, Columbia, United States. 2 capsules of 500mg Glucan #300®, daily, for seven days.
3123964|NCT01727895|No Intervention|Control group|
3123965|NCT01727882|Experimental|Daily Assessments & Brief Feedback|Daily assessments during 30 days after parole and a feedback intervention based on these daily assessments.
3123966|NCT01727882|Active Comparator|Daily assessments|Daily assessments during 30 days after parole.
3123967|NCT01727869|Experimental|Cohort 1|Dosing regimen 1: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
3123968|NCT01727869|Experimental|Cohort 2|Dosing regimen 2: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
3123969|NCT01727869|Experimental|Cohort 3|Dosing regimen 3: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
3123970|NCT01727856||Rehabilitation Measurement Tool|This single arm consists of all subjects which will interact with the tool under invstigation.
3123971|NCT01727843|Experimental|tranexamic acid|3000mg/mL tranexamic acid in saline applied directly to the wound at the end of the surgical procedure.
3123972|NCT01727843|Placebo Comparator|saline|3000mg/mL saline applied directly to the wound at the end of the surgical procedure
3123973|NCT01727817|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in Control to Range (CTR) or in Safety Only mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct for hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
3123974|NCT01727817|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. Subjects will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
3123975|NCT01727804|Experimental|Laser|
3123976|NCT01727791|Experimental|open label|
3123977|NCT01727778|Experimental|Antibody treatment|Intravenous infusion of the anti-GRP78 monoclonal IgM antibody PAT-SM6 group 1: 0.3mg/kg Group 2: 1.0mg/kg Group 3: 3mg/kg Group 4: 6mg/kg
3123978|NCT01727765|Experimental|Experimental|6 weeks of inspiratory muscle training, 6 days per week. The intensity of training will be equivalent to up to 50% of pre-training maximal inspiratory mouth pressure and will be adapted weekly to reflect the improvement in inspiratory muscle strength
3123979|NCT01727765|Sham Comparator|Sham Comparator|6 weeks of sham inspiratory muscle training, 6 days per week. The intensity of training will be equivalent to 5% of pre-training inspiratory mouth pressure throughout the 6 week period.
3123980|NCT01727752|Active Comparator|Surgical decompression|Surgical decompression
3123981|NCT01727752|Active Comparator|coflex Interlaminar Technology|Surgical decompression followed by implantation of coflex Interlaminar Technology.
3123982|NCT01727739|Active Comparator|PLLA bioscrew|poly-L-lactic acid bioscrew
3123983|NCT01727739|Active Comparator|PLLA+TCP bioscrew|poly-l-lactic acid with beta tricalcium phosphate bioscrew
3123984|NCT01727726|Placebo Comparator|Placebo + ADT|Matching Placebo and assigned ADT
3123985|NCT01727726|Experimental|Brexpiprazole + ADT|Brexpiprazole, flexible dose and assigned ADT
3123986|NCT01727726|Active Comparator|Seroquel XR + ADT|Seroquel XR, flexible dose and assigned ADT
3123987|NCT01727713|Experimental|Aripiprazole|Aripiprazole Immediate Release Once-Daily
3123988|NCT01727700|Placebo Comparator|Placebo|Matching Placebo Once-Daily
3123989|NCT01727700|Experimental|Aripiprazole 5 mg or 10 mg|Aripiprazole 5 mg or 10 mg Immediate Release Once-Daily
3123990|NCT01727700|Experimental|Aripiprazole 10 mg or 20 mg|Aripiprazole 10 mg 20 mg Immediate Release Once-Daily
3123991|NCT01727687|Experimental|Patients with Parkinson's disease|Using simulated traffic scene system to help patients with Parkinson's disease improve crossing road behaviors.
3123992|NCT01727661||type 1 diabetes mellitus|"exercise testing with near-infrared spectroscopy~lung function testing~quality of life"
3123993|NCT01727661||healthy controls|"exercise testing with near-infrared spectroscopy~lung function testing~quality of life"
3124105|NCT01726816|Experimental|Probucol 250mg/day|Probucol 250mg group: probucol 250mg 2 tablets, 16 weeks
3192151|NCT01253876|Experimental|Caw's milk|
3123994|NCT01727648|Experimental|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
3123995|NCT01727648|Experimental|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
3123996|NCT01727648|Experimental|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
3123997|NCT01727648|Active Comparator|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
3123998|NCT01727635|Experimental|counseling|body-mind-spirit group therapy
3123999|NCT01727622|Other|Diagnostic Imaging|ASL-MRI and FDG-PET will be compared for ability to discriminate between Control subjects and adults with Mild Cognitive Impairment (prodromal AD). A lumbar puncture will be obtained in a proportion of the participants.
3124000|NCT01727609|Active Comparator|Slower milk feed increment|Increase milk feeds by 18 ml/kg/day until on full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
3124001|NCT01727609|Experimental|Faster milk feed increment|Increase milk feeds by 30 ml/kg/day until on full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
3124002|NCT01727596|Experimental|1|
3124003|NCT01727583|Active Comparator|Lipid 1|Meal intake
3124004|NCT01727583|Placebo Comparator|Lipid-free|Maltodextrine + proteins
3124005|NCT01727583|Active Comparator|Lipid 2|Meal intake
3124006|NCT01727583|Active Comparator|Lipid 3|Meal intake
3124007|NCT01727583|Active Comparator|Lipid 4|meal intake
3124008|NCT01727570|No Intervention|Nutrition Counselling|Patients will be asked to fill out a three day record of all food and drink consumed. Patients will be given an appointment with the nutritionist approximately 4 weeks before surgery to go over their regular diet and advice will be given on how to improve the nutritional quality of their diet
3124009|NCT01727570|Active Comparator|Nutrition Supplementation|Patients will be asked to fill out a three day record of all food and drink consumed. An appointment with the nutritionist will be given approximately 4 weeks before surgery to go over their regular diet and advice will be given on how to improve the nutritional quality of the diet. Patients will also be given a supply of nutritional supplements to take orally (by mouth) every day. These supplements include a whey protein isolate (Immunocal®, Immunotec Inc), omega-3 fatty acids from fish oil, and vitamins/minerals.
3124010|NCT01727557|Active Comparator|Local anesthesia|
3124011|NCT01727557|Active Comparator|regional anesthesia|
3124012|NCT01727544|Active Comparator|Surgical Group|patients will undergo a primary transmastoid and tegmen mini-craniotomy cartilage cap occlusion surgery.
3124013|NCT01727544|No Intervention|Non Surgical Group|patients meet the same criteria but will elect not to undergo surgery
3124014|NCT01727531|Experimental|CQ Arm|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks.
3124015|NCT01727518||Reference Population|No Intervention
3124016|NCT01727505|Active Comparator|Sequence A: Conventional-Volume Guarantee|This is a crossover study. Infants will be assigned to one of two sequences. Sequence A consists of a 24-hour period during which the infant receives conventional mechanical ventilation followed by a second 24 hour period during which the infant receives volume guarantee ventilation.
3124017|NCT01727505|Active Comparator|Sequence B: Volume Guarantee-Conventional|This is a crossover study. Infants will be assigned to one of two sequences. Sequence B consists of a 24-hour period during which the infant receives volume guarantee ventilation followed by a second 24 hour period during which the infant receives conventional mechanical ventilation.
3124018|NCT01727492|Placebo Comparator|sugar pill|
3124019|NCT01727492|Active Comparator|Antioxidantia|Dosage: 600mg n-acetylcystein and 200mg magnesium intake: 1 hour before leisure noise exposure above 100dB of at least 30 minutes frequency: 4 separate events (2x placebo, 2x antioxidants)
3124020|NCT01727479|Experimental|Ribose|After each of the 3km time trial (3 in total), consumption of ribose incorporated in a sports drink.
3124021|NCT01727479|Placebo Comparator|Placebo|After each of the 3km time trial (3 in total), consumption of placebo incorporated in a sports drink.
3124022|NCT01727466|Experimental|Facing Your Fears|FYF is a group CBT approach to managing anxiety symptoms in children with high-functioning autism spectrum disorders and anxiety.
3124023|NCT01727453|Active Comparator|Bemiparin|Group 1 (low molecular weight heparin: bemiparin), which is the study group: after passing the bleeding episode, will receive low molecular weight heparin (bemiparin) in anticoagulant dose. Check should be made by measurement of anti-factor Xa.
3124024|NCT01727453|Active Comparator|Warfarin|which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.
3124025|NCT01727427||Anticoagulants, aspirin|Parenteral or oral anticoagulants: heparin, fondaparinux, vitamin-K antagonists, direct thrombin inhibitors, direct factor Xa inhibitors; aspirin. Any dosage, frequency and duration
3124026|NCT01727414|Other|OROS-Methylphenidate and placebo for inattentive type pts|Children with ADHD-inattentive type. Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
3124027|NCT01727414|Other|OROS-Methylphenidate and placebo for combined type pts|Children with ADHD-combined type type. Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
3124028|NCT01727401|Experimental|Fondaparinux|Drug: fondaparinux once daily sc injections 2.5 mg if renal clearance of creatinine above 50 ml/min once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
3124029|NCT01727388|Experimental|lateral decubitus|The digital rectal examination is performed in lateral decubitus i.e. curled up position . The patient in left lateral decubitus if the examiner is right handed and right lateral decubitus if the examiner is left handed.
3124030|NCT01727388|Active Comparator|supine decubitus|The digital rectal examination is performed supine, spread legs, feet on the examination table. The examiner is in the patient's right side if he is right handed and in the patient's left side if he is left-handed.
3124031|NCT01727375|No Intervention|Standard light|In this arm patients receive standard lightening conditions
3124032|NCT01727375|Experimental|Ciradian light|In this arm patients receive artificial ceiling light (circadian light) at the bedside.
3124033|NCT01727362|Active Comparator|Usual care + acupuncture|
3124034|NCT01727362|Active Comparator|Usual care|
3124035|NCT01727349|Other|Type 2 diabetic subject|Subject with type 2 diabetes
3124036|NCT01727349|Other|healthy subject|Healthy subjet from family where there is the existence of the disease (type 2 diabetes) in two successive generations
3124037|NCT01727336|Experimental|Dalantercept plus axitinib|Subcutaneous (SC) injection of Dalantercept once every 3 weeks and Oral axitinib BID for continuous dosing.
3124038|NCT01727336|Active Comparator|Placebo plus axitinib|Subcutaneous injection of normal saline once every 3 weeks and oral BID for continuous dosing
3124039|NCT01727297|Other|REVEAL Implantable Cardiac Monitor|
3124040|NCT01727284|Other|MR-guided cryoablation (freezing of tissue and/or tumors)|
3124041|NCT01727271|Active Comparator|Tenofovir Monotherapy|Tenofovir 300 mg tablet, orally (PO) once daily for 8 weeks, then Tenofovir 300 mg tablet, PO, once daily for an additional 96 weeks (total treatment duration 104 weeks)
3124042|NCT01727271|Experimental|PegIFN-2b/Tenofovir Sequential Therapy|Tenofovir 300 mg tablet, PO, once daily for 8 weeks, then PegIFN-2b, 1.5 mcg/kg subcutaneously (SC), once weekly, for 24 weeks, then Tenofovir 300 mg tablet, PO, once daily for 72 weeks (total treatment duration 104 weeks)
3124043|NCT01727271|Experimental|Peg-IFN-2b + Tenofovir Combination Therapy|Tenofovir 300 mg tablet, PO once daily for 8 weeks, then pegIFN-2b, 1.5 mcg/kg SC once weekly and tenofovir 300 mg tablet, PO, once daily for 24 weeks, and then tenofovir 300 mg tablet, PO, once daily for 72 weeks (total treatment duration 104 weeks)
3124044|NCT01727258|Experimental|Mouth Rinse|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of Fluoride Toothpaste provided. Rinse with water after brushing teeth. Then rinse for 60 seconds with 10 mL of the experimental Mouth Rinse 12027-033 (KOX).
3124045|NCT01727258|Active Comparator|Fluoride Toothpaste|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of the Fluoride Toothpaste (NEG) provided.
3124046|NCT01727258|Active Comparator|Potassium Nitrate Toothpaste|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of the Potassium Nitrate Toothpaste (POS) provided.
3124047|NCT01727245|Other|Obese|Obese patients undergoing gastric by-pass surgery
3124048|NCT01727245|Other|Control group|Cholecystectomy and anti-reflux surgery
3124049|NCT01727232||Standard regimen|Patients received the standard regimen (i.e 4 weekly infusions of 375 mg/m2)of rituximab
3124050|NCT01727232||Rheumatoid arthritis regimen|Patients received the RA regimen (i.e two infusions of 1000 mg, 2 weeks apart) of rituximab
3124051|NCT01727206|Experimental|Tocilizumab|Tocilizumab 8 mg/kg intravenously every month for six months
3124052|NCT01727193|Active Comparator|Azathioprine|cholinesterase inhibitors+Glucocorticoid +Azathioprine
3124053|NCT01727193|Active Comparator|Leflunomide|cholinesterase inhibitors+glucocorticoid+Leflunomide
3124054|NCT01727180||Chronic kidney disease|
3124055|NCT01727167|Placebo Comparator|Control Group|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
3124056|NCT01727167|Experimental|CO group|This group will breath 200 ppm of CO for one hour per day over the course of the three days immediately prior to surgery.
3124057|NCT01727154||Sipuleucel-T|
3124058|NCT01727141|Experimental|QVA149|27.5/12.5 ug twice daily (b.i.d.) via Single Dose Dry Powder Inhaler (SDDPI)
3124059|NCT01727141|Active Comparator|QAB149|27.5 ug b.i.d.
3124060|NCT01727141|Active Comparator|NVA237|12.5 ug b.i.d.
3124061|NCT01727141|Placebo Comparator|Placebo|b.i.d
3124062|NCT01727128|Experimental|Mild Hepatic Impaired Group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - mildly hepatically impaired
3124063|NCT01727128|Experimental|Moderate Hepatic Impaired group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - moderately hepatically impaired
3124064|NCT01727128|Experimental|Severe Hepatic Impaired Group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - Severely hepatically impaired
3124065|NCT01727128|Experimental|Control Group|Matching healthy control subjects who do not have hepatic impairment and are matched to the hepatic impaired subjects by sex, age, gender and BMI
3124066|NCT01727115|Active Comparator|NUTRAMIGEN®|"Subjects are orally fed ad libitum (following guidelines printed on the labels).~Subjects will receive the Nutramigen® formula for a 4 week period~Then depending of the result of the challenge test we have the following possibilities:~If the test is positive: The children continue the formula Nutramigen®~If the test is negative: A Follow up formula is given~(Nan pro2) if child > 6 months~(Nan pro1) if child < 6 months"
3124067|NCT01727115|Experimental|ALTHERA®|"Subjects are orally fed ad libitum (following guidelines printed on the labels).~Subjects will receive the Althera® formula for a 4 week period~Then depending of the result of the challenge test we have the following possibilities:~If the test is positive: The children continue the formula Althera®~If the test is negative: A Follow up formula is given~(Nan pro2) if child > 6 months~(Nan pro1) if child < 6 months"
3124068|NCT01727089|Active Comparator|Arm I (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3124069|NCT01727089|Experimental|Arm II (bevacizumab, anti-endoglin monoclonal antibody TRC105)|Patients receive bevacizumab as in Arm I and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3124070|NCT01727076|Experimental|Treatment (recombinant interleukin-15)|Patients receive recombinant interleukin-15 SC daily on days 1-5 of weeks 1 and 2. Treatment repeats every 28 days (4 weeks) for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3124071|NCT01727063|Experimental|Cell Therapy|Intramyocardial injection of autologous bone marrow-derived cells
3124072|NCT01727063|No Intervention|Placebo|Saline injection
3124073|NCT01727050|Active Comparator|Mechanical stapling|
3124074|NCT01727050|Active Comparator|Fibrin sealant spray|
3124075|NCT01727037|Experimental|BIABI arm|Patients will undergo intrabullous autologous blood instillation
3124076|NCT01727024|Experimental|Indacaterol (QAB149) Breezhaler®|In period 1, participants received Indacaterol 150 mcg once daily via Breezhaler® device for 7 days, followed by a 7-day washout. In period 2, participants received Tiotropium 2.5 mcg, in 2 consecutive puffs, once daily via Respimat® device for 7 days.
3124077|NCT01727024|Active Comparator|Tiotropium Respimat®|In period 1, participants received Tiotropium 2.5 mcg, in 2 consecutive puffs, once daily via Respimat® device for 7 days, followed by a 7-day washout. In period 2, participants received Indacaterol 150 mcg once daily via Breezhaler® device for 7 days.
3124078|NCT01727011|Experimental|IPAS|Once the patient recorded in the trial, and after completion of a post-implant dosimetry scanner to analyze the dose distribution within the target volume and organs at risk, the patient is treated by irradiation and partial accelerated breast brachytherapy using high dose rate, delivering a total dose of 16 Gy in one fraction
3124079|NCT01726998|Experimental|Lokomat Group|
3124080|NCT01726998|Active Comparator|conventional gait training group|
3124081|NCT01726985||Patients hospitalized with CHF|Patients hospitalized with CHF Parameter Based Clinical Disposition
3124082|NCT01726959||Methotrexate|Methotrexate for rheumatic diseases, 2.5 - 25 mg weekly
3124083|NCT01726946|Experimental|VX-135 High Dose with ribavirin|12 weeks of a high dose of VX-135 in combination with ribavirin
3124084|NCT01726946|Experimental|VX-135 Low Dose with ribavirin|12 weeks of a low dose of VX-135 in combination with ribavirin
3124085|NCT01726933|Experimental|LAS41008|up to 6 tablets/ day for 16 weeks double blind treatment period, randomized gastric resistant tablet
3124086|NCT01726933|Placebo Comparator|Placebo|up to 6 tablets/ day for 16 weeks randomized, double blind gastric resistant tablet
3124087|NCT01726933|Active Comparator|LASW1835|double blind, randomized gastric resistant tablet up to 6 tablets/ day for 16 weeks
3124088|NCT01726920|Experimental|naratriptan + naproxen|Fixed-dose combination of naratriptan + naproxen
3124089|NCT01726920|Active Comparator|naratriptan|
3124090|NCT01726920|Active Comparator|naproxen|
3124091|NCT01726907|Experimental|Robotic SMG resection|Robot-assisted SMG resection
3124092|NCT01726907|Active Comparator|Endoscopic SMG resection|Endoscope-assisted SMG resection
3124093|NCT01726894|Experimental|Irreversible Electroporation|
3124094|NCT01726881|Experimental|Fresh Spinal Cord Injury patients|Spinal Cord Injury patients that are currently admitted to the rehabilitation unit with three weeks or less since injury that will over go several tests and will fill out several questionnaires.
3124095|NCT01726881|Experimental|Chronic Spinal Cord Injury patients|Spinal Cord Injury patients with one year or more since injury that will over go several tests and will fill out several questionnaires
3124096|NCT01726881|Active Comparator|Healthy volunteers|Healthy subjects that will over go several tests and will fill out several questionnaires
3124097|NCT01726868|Experimental|Liposorber LA-15 System|
3124098|NCT01726855||dorsal fascial flap|combined with standard modified Kessler technique and vascularized finger dorsal fascial flap pedicled with dorsal cutaneous branch of proper digital artery ,which is transported to finger palmar for placement of a mechanical barrier between flexor digitorum superficialis /profundus tendons.
3124099|NCT01726855||standard modified Kessler technique|
3124100|NCT01726842||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
3124101|NCT01726842||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~VA <20/40 and 2 logMAR lines difference in normal eye~Mild amblyopia (>20/40)~Moderate amblyopia (20/40 and <20/100)~Severe amblyopia (≥20/100 or worse)~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~Constant: >2 PD at near and or distance.~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~'hypermetropia' (≥3.5 D),~'myopia' (≥-4.0 D),~'astigmatism' (≥1.5 D).~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
3124102|NCT01726842||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
3124103|NCT01726829|Experimental|MD-Logic Artificial Pancreas (MDLAP) system|four consecutive outpatients overnight sessions at home under closed loop MD-Logic Artificial Pancreas (MDLAP) system
3124104|NCT01726829|Active Comparator|Standard treatment with sensor augmented pump therapy|four consecutive outpatients overnight sessions at home under standard treatment with sensor augmented pump therapy
3124577|NCT01724060||Gastric bypass|Patients due for gastric bypass surgery
3124106|NCT01726816|Experimental|Probucol 500mg/day|Probucol 500mg group: probucol 250mg 2 tablets, 16 weeks
3124107|NCT01726816|Placebo Comparator|Placebo|Placebo group: placebo 2 tablets, 16 weeks
3124108|NCT01726803|Active Comparator|Usual Care|Usual care arm will receive management as recommended by practice guidelines and directed by the primary care provider. The recommended stepped care approach is used with initial management of advice and education only and no referral to physical therapy during the initial 4 weeks.
3124109|NCT01726803|Experimental|Early Physical Therapy|The Early Physical Therapy arm will receive the same advice and education intervention received by the usual care group and will be referred to receive 4 sessions of physical therapy during the first 4 weeks. The physical therapy protocol involves spinal manipulation and exercise.
3124110|NCT01726777|Placebo Comparator|Control|30g normal cheddar cheese once per week
3124111|NCT01726777|Experimental|Vitamin D|30g cheddar cheese containing 28,000IU vitamin D once per week
3124112|NCT01726764|Experimental|Metformin|"7 days of pretreatment with metformin before full pharmacokinetics and other goals are investigated.~Minimum 1 week of washout after this period. 3 weeks of pretreatment with St John's Wort and the last 7 days metformin is ingested again, and the same effect parameters as described above is performed again"
3124113|NCT01726751|Other|Early off-stimulation (group B)|Late SCS treatment. After 2 weeks without SCS, randomization to either of two study arms: Group B starting with no SCS for a period of six weeks (A) followed by a period of active SCS (on-period for 6 weeks). Thereafter, free stimulation for 12 weeks, followed by a concluding 2 sweeks of no SCS.
3124114|NCT01726751|Other|Early on-stimulation (group A)|Early SCS treatment. After 2 weeks without SCS, randomization to either of two study arms: Group A starting with SCS for a period of six weeks (A) followed by a period of no SCS (off-period for 6 weeks). Thereafter, free stimulation for 12 weeks, followed by a concluding 2 sweeks of no SCS.
3124115|NCT01726738|Experimental|BRAF (dabrafenib) and MEK (trametinib) inhibitors|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
3124116|NCT01726725||hemifacial spasm, lateral spread, motor evoked potentials|EMG recordings from facial muscles of HFS patients during MVD surgery will be compared during total intravenous anesthesia (propofol), 0.5 MAC desflurane and 1.0 MAC desflurane
3124117|NCT01726712|No Intervention|Routine Care|
3124118|NCT01726712|Active Comparator|Supportive Contact|
3124119|NCT01726699||Cancer Diagnosis|
3124120|NCT01726686|Active Comparator|Ropivacaine in the pump|The intra-articular Continuous Infusion Pump is filled with Ropivacaine,10 mg/ml, set at 2 ml/hour for 48 hours postoperatively.
3124121|NCT01726686|Placebo Comparator|Placebo in the pump|The intra-articular Continuous Infusion Pump is filled with NaCl, set at 2 ml/hour for 48 hours postoperatively.
3124122|NCT01726673|Experimental|tDCS + robotic arm therapy|Transcranial Direct Current Stimulation (tDCS) 2mA for 20 minutes over the primary motor cortex (M1) in the affected hemisphere immediately followed by robotic arm therapy for 60 minutes, 3x per week for 12 weeks (36 sessions total)
3124123|NCT01726673|Placebo Comparator|tDCS sham + robotic arm therapy|Transcranial Direct Current Stimulation sham condition (0 mA) for 20 minutes over the primary motor cortex (M1) in the affected hemisphere immediately followed by robotic arm therapy for 60 minutes, 3x per week for 12 weeks (36 sessions total)
3124124|NCT01726660|Experimental|IMT Robotic Arm Therapy: Aim training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for aim training, 3x/week for 12 weeks.
3124125|NCT01726660|Experimental|IMT Robotic Arm Therapy: Smoothness Training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for smoothness training, 3x/week for 12 weeks.
3124126|NCT01726660|Experimental|IMT Robotic Arm Therapy: Impairment training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for whole-arm, impairment training, 3x/week for 12 weeks.
3124127|NCT01726660|Experimental|IMT Robotic Arm Therapy: Functional training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for whole arm, functional training, 3x/week for 12 weeks.
3124128|NCT01726647||No product is tested|No intervention
3124129|NCT01726634|Experimental|Elastic Tapping|
3124130|NCT01726621|Other|Insulin dependent diabetics|Subjects currently using an insulin pump transferred to use the Medtronic MiniMed 620G and 640G insulin pumps and Guardian Link transmitter
3124131|NCT01726608|Active Comparator|Radiofrequency neurotomy|Active Radiofrequency Neurotomy
3124132|NCT01726608|Placebo Comparator|Sham|Sham radiofrequency neurotomy
3124133|NCT01726595||severe sepsis|Patients with severe sepsis or septic shock
3124134|NCT01726595||non-infected critically ill|Patients with severe non-infectious systemic inflammatory response syndrome
3124135|NCT01726595||healthy|healthy volunteers
3124136|NCT01726582|Other|Pre surgery targeted chemo|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.~Arm A:~Targeted chemotherapy prior to surgery: 8 weeks targeted chemotherapy; restaging:~see link to protocol Figures A & C at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3124137|NCT01726582|Other|Pre surgery cXRT|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.~Arm B:~Before surgery: Chemoradiotherapy (cRXT); restaging:~see link to protocol Figure C and Figure A or B at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3124138|NCT01726582|Other|Pre surgery targeted chemo, then cXRT|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.~Arm C1:~Before surgery: 8 weeks targeted chemotherapy; restaging; chemoradiotherapy (cXRT); restaging~see link to protocol Figures B and C at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3124139|NCT01726582|Other|Pre surgery FOLFIRINOX, then cXRT|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.~Arm C2:~standard FOLFIRINOX chemotherapy prior to surgery: 8 weeks FOLFIRINOX (standard chemotherapy); restaging; standard chemoradiotherapy (cXRT); restaging:~see link at protocol Figures B and C at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3193471|NCT01244204|Experimental|Vitamin D|
3124140|NCT01726582|Other|After surgery targeted chemo, then cXRT|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm D1:~After surgery: 8 weeks targeted chemotherapy; restaging; chemoradiotherapy (cXRT); restaging:~see link to protocol Figures A and D at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3124141|NCT01726582|Other|After surgery Gemcitabine, then cXRT|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm D2:~Gemcitabine after surgery: 8 weeks standard Gemcitabine (chemotherapy); restaging; chemoradiotherapy (cXRT); restaging:~see link to protocol Figures A and D at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3124142|NCT01726582|Other|After surgery cXRT|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm E:~After surgery: chemoradiotherapy (cXRT); restaging:~see lint to protocol Figures A and D at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3124143|NCT01726582|Other|After surgery targeted chemo|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm F1:~Targeted chemotherapy after surgery: 8 weeks targeted chemotherapy; restaging; 8 weeks targeted chemotherapy; restaging:~see link to protocol Figure E and Figure A or B at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3124144|NCT01726582|Other|After surgery Gemcitabine|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm F2:~Gemcitabine after surgery : 8 weeks Gemcitabine (chemotherapy); restaging; 8 weeks Gemcitabine (chemotherapy); restaging:~see link to protocol Figure E and Figure A or B at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3124145|NCT01726582|Other|After surgery no additional treatment|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm G:~No additional therapy after surgery:~see link to protocol Figure E and Figure A or B at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3124146|NCT01726569|Experimental|film and trained counseling|Subjects will be asked to watch a 5-10 min film and participate in a 10-15 min pre-operative counseling session with a trained doctor/nurse. Subjects will also participate in a 5 min post-operative counseling session and follow up counseling after operation 1 week and 6 weeks
3124147|NCT01726569|Other|traditional counseling|Subjects will be participate or not participate in pre-operative counseling and/or post-operative counseling with a rural hospital's doctor/nurse.
3124148|NCT01726556|Active Comparator|Rigid thoracoscopy|Rigid thoracoscopy would be done using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany.
3124149|NCT01726556|Active Comparator|Semirigid thoracoscopy|The semirigid thoracoscope employed is a model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan.
3124150|NCT01726543|Active Comparator|Canaloplasty and phacoemulsification|
3124151|NCT01726543|Active Comparator|Non-penetrating deep sclerectomy and phacoemulsification|
3124152|NCT01726530|Active Comparator|Transdermal fentanyl patch|Transdermal fentanyl patch, 50 mcg/hour, was attached to the patient's chest wall at 10 pm the day before surgery
3124153|NCT01726530|Placebo Comparator|Placebo|Placebo patch was attached to the patient's chest wall at 10 pm the day before surgery
3124154|NCT01726517|Experimental|LDV/SOF 8 Weeks (TN)|Treatment-naive (TN) participants will be randomized to receive LDV/SOF for 8 weeks.
3124155|NCT01726517|Experimental|LDV/SOF+RBV 8 Weeks (TN)|Treatment-naive participants will be randomized to receive LDV/SOF plus RBV for 8 weeks.
3124156|NCT01726517|Experimental|LDV/SOF 12 Weeks (TN)|Treatment-naive participants will be randomized to receive LDV/SOF for 12 weeks.
3124157|NCT01726517|Experimental|LDV/SOF 12 Weeks (TE)|Treatment-experienced (TE) participants (had virologic failure following prior therapy with a protease-inhibitor [PI]+pegylated interferon [PEG]+RBV regimen) will be randomized to receive LDV/SOF for 12 weeks.
3124158|NCT01726517|Experimental|LDV/SOF+RBV 12 Weeks (TE)|Treatment-experienced participants (had virologic failure following prior therapy with a PI+PEG+RBV regimen) will be randomized to receive LDV/SOF plus RBV for 12 weeks.
3124159|NCT01726504|Experimental|electro-acupuncture|"The electric stimulator is applied to bilateral ST25andSP14 with dilatational wave10/50 Hz and electric current0.1-1.0mA.They are given acupuncture with 0.3×50mm or 0.35×75mm needles by inserting30-70mm and twirling lifting andthrusting 3 times.Dosage:The needle arrives the abdominal muscle layer(patients feel painful and acupuncturists feel touching hard).~Bilateral ST37 are given conventional acupuncture with 0.30mm×40mm needles by inserting 25-30mm and twirling lifting and thrusting for 3.Dosage:Local sour and heavy feeling is the appropriate dose.~Every session lasts for 30min/day.The participants are treated continuously for 8 weeks.During 8-week treatment the first 2 weeks,5 sessions per week,and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total."
3124160|NCT01726504|Sham Comparator|sham electro-acupuncture|"The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave, 10/50 Hz and electric current 0.5mA. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. The needle is inserted by 3mm-5mm (the needle can be vertically fixed on the skin).~Bilateral ST37 are given acupuncture with 3mm-5mm (the needle can be vertically fixed on the skin).~Length of Treatment and the treatment sessions are the same as treatment group."
3124161|NCT01726491||Insulin resistance epigenetics|"This experiment will use the Infinium methylation assay to perform epigenome mapping and define patterns of DNA methylation in skeletal muscle and whole blood tissue of metabolically well-characterized lean healthy, obese nondiabetic, and type 2 diabetic volunteers. We will test the hypotheses that~(1) There is an increased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation and altered methylation of promoters of genes coding for extracellular matrix and cytoskeletal proteins in insulin resistance, (2) The altered methylation patterns observed correspond to protein and mRNA expression changes, and (3) There are coordinated patterns of DNA methylation between the skeletal muscle and whole blood tissues in insulin resistance."
3124162|NCT01726491||Single bout of exercise|"This experiment will test the hypotheses in lean healthy, obese non-diabetic and type 2 diabetic volunteers that~Increased methylation of the PGC-1α promoter predicts a decreased response of this gene to a single bout of exercise, and~Altered methylation of promoters of nuclear encoded mitochondrial genes predicts a decreased response of this gene to a single bout of exercise."
3124198|NCT01726205|Placebo Comparator|placebo|Placebo drug and normal saline infusion
3124163|NCT01726491||Eight weeks of exercise|"This experiment will test the hypothesis in lean healthy, obese non-diabetic and type 2 diabetic volunteers that~There is decreased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation, and the altered methylation corresponds to protein and mRNA (messenger ribonucleic acid) expression changes,~There is altered methylation of genes involved in inflammation and cytoskeletal structure."
3124164|NCT01726478|Active Comparator|2.5 units oxytocin|Administration of 2.5 units of oxytocin intravenously after clamping of umbilical cord
3124165|NCT01726478|Placebo Comparator|10 units oxytocin|Administration of 10 units of oxytocin after clamping of umbilical cord
3124166|NCT01726465|Experimental|N-acetylcysteine|Patients were randomized to this arm will receive a bolus of N-acetylcysteine in an hour of 150 mg/kg after the beginning of the operation. After the bolus will start a 6-hour infusion of 50mg/kg/h of N-acetylcysteine.
3124167|NCT01726465|Experimental|Methylprednisolone|Patients were randomized to this arm will receive a bolus of methylprednisolone in an hour of 500 mg after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).
3124168|NCT01726465|Placebo Comparator|Placebo|Patients were randomized to this arm will receive placebo (Ringer's acetate) in an hour after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).
3124169|NCT01726452|Experimental|A (MAGIC)|MAGIC regimen: Arm A consists of 3 cycles of chemotherapy pre-surgery and a further 3 cycles of chemotherapy post-surgery. Each cycle of chemotherapy lasts 21 days/3 weeks. The drugs used in the MAGIC regimen include Epirubicin, Cisplatin and 5-Flourouracil/ Capecitabine
3124170|NCT01726452|Experimental|B (CROSS)|Arm B consists of the CROSS protocol, which includes a combination of chemotherapy and radiotherapy prior to surgery. The patient will receive 5 weeks of radiation therapy and 5 weekly cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 5 weeks as follows: days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31 inclusive. The chemotherapy and radiotherapy will run concurrently over a 5-week period. Chemotherapy is given by intravenous infusion on days 1, 8, 15, 22 and 29.
3124171|NCT01726439||CHB patients who are naive to NUC treatment|CHB patients who are naive to NUC at enrollment and be treated at hospitals at tier 2 cities in China
3124172|NCT01726426|Experimental|Patients of palmer arsenical keratosis|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
3124173|NCT01726426|Active Comparator|Arsenic exposed controls|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
3124174|NCT01726426|Active Comparator|Heathy volunteers|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
3124175|NCT01726413|Experimental|Test Arm|GRC17356 for daily administration
3124176|NCT01726413|Placebo Comparator|Placebo|Matching placebo for daily administration
3124177|NCT01726400||Interferon and ribavirin|Treatment with standard of care pegylated interferon alpha and ribavirin.
3124178|NCT01726387|Experimental|Psychosocial Counseling|A Counseling Assistant offers a low-threshold intervention (self-management support, counseling, active guidance). This nurse practitioner collaborates extensively with the general practitioner, re-adjusting the intervention in order to meet the patient's needs.
3124179|NCT01726387|Placebo Comparator|Usual Care|Depending on the conditions, patients get usual care of their general practitioner.
3124180|NCT01726374|Experimental|One cycle adjuvant BEP(500)|Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15
3124181|NCT01726361|Experimental|MTFC|Out of home placement in MTFC family program
3124182|NCT01726361|Active Comparator|TAU|Other kind of out of home placement
3124183|NCT01726348||Darunavir|Patients will be taking darunavir as per the dosing regimen given on product insert approved in Philippines.
3124184|NCT01726335|Experimental|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
3124185|NCT01726309||Stage IV CRC|
3124186|NCT01726309||Stage IV NSCLC|
3124187|NCT01726296|Experimental|Health services research (educational intervention)|Health care providers complete an educational intervention based on NCCN guidelines in CRC and NSCLC survivorship care comprising a power point presentation reviewing evidence and prompts for addressing survivorship care components; and an electronic paper copy sample survivorship care plan that can be adapted and distributed at each participating site.
3124188|NCT01726283||low risk subjects for developing post-operative ectasia|Patients undergoing vision correction surgery who are not at a higher risk for developing post-op ectasia
3124189|NCT01726283||Subjects at Risk for Ectasia|Patients undergoing vision correction surgery who are at a higher risk for developing post-operative ectasia
3124190|NCT01726270|Experimental|tamsulosin hydrochloride|patients will take drug for 8 weeks in this exploratory study
3124191|NCT01726257|Experimental|Nellix System|The Nellix EndoVascular Aneurysm Sealing System ( Nellix System ) will be implanted into patients with an infrarenal abdominal aortic aneurysm (AAA).
3124192|NCT01726244|No Intervention|Control group|Habitual Clinical Practice
3124193|NCT01726244|Experimental|Intervention Group|Multidisciplinary intervention consisting in controlling disease and stress associated to it, and modifying eating habits. A Nurse, nutritionist and a psychologist will be the responsible of these educational sessions. it will be three educational sessions. Patients with a BMI lower than 20 or bigger than 30 will be receive a closer follow up by nutritionist. In addition, patients with a score of 9 or more in the Patients Health Questionnaire-9 questionnaire will be also a closer follow up with the psychologist.
3124194|NCT01726218||Stroke patients|
3124195|NCT01726218||Healthy Control|
3124196|NCT01726205|Active Comparator|pregabalin|perioperative pregabalin starting the evening before surgery, and for five days postoperatively
3124197|NCT01726205|Active Comparator|pregabalin and continuous wound infusion|Pregabalin as previous group and continuous infusion of ropivacaine 0.2% via a wound catheter
3198966|NCT01205724|Experimental|B|
3124199|NCT01726192|Active Comparator|HLOC|Placement of a femoral catheter with the hydrolocalization technique
3124200|NCT01726192|Active Comparator|NS|Placement of a femoral neurostimulating catheter
3124201|NCT01726179|Experimental|Icon infiltration|Icon infiltration regarding instructions for use
3124202|NCT01726179|Active Comparator|control|conventional non invasive treatment
3124203|NCT01726166|Active Comparator|Suprapubic Aspiration|A trained physician or neonatal nurse practitioner utilizing U/S guidance at the bedside will perform the SPA. An U/S machine is readily available for use in each NICU.
3124204|NCT01726166|Active Comparator|Urinary Catheterization|"The infants will have the procedure done by NICU nurses who have been trained in performing this procedure.~If the randomly assigned infant passes urine spontaneously during a UC attempt after complete perineal cleansing and the urine is collected as a clean catch sample, then this infant will be analysed in the assigned group (intention to treat)."
3124205|NCT01726153|No Intervention|Web sites|Individuals assigned to this arm are given a list of websites where they can view additional information relating to condom use.
3124206|NCT01726153|Experimental|Condom-HIM|Individuals assigned to this arm must follow an on-line one session tailored intervention.
3124207|NCT01726140|Experimental|TREATMENT|Helmet CPAP
3124208|NCT01726140|Active Comparator|CONTROL|Venturi Mask
3124209|NCT01726127|Experimental|Broccoli and Brussels Sprouts|Subjects will consume broccoli or Brussels sprouts (40g daily) for 8 weeks.
3124210|NCT01726127|Experimental|Cruciferous Complete|Subjects will take Cruciferous CompleteTM supplements (2 capsules, 3 times daily) for 8 weeks.
3124211|NCT01726127|Placebo Comparator|Placebo|Subjects will take placebo capsules (2 capsules, 3 times daily) for 8 weeks.
3124212|NCT01726114|Experimental|Non-invasive Optical Glucose Monitor™|Test device
3124213|NCT01726088|Active Comparator|modafinil|Study participants randomized to the active arm of the study will take modafinil 100mg capsules orally each day for 4 weeks.
3124214|NCT01726088|Placebo Comparator|Sugar Pill|Study participants randomized to the placebo arm of the study will take matching capsules orally each day for 4 weeks.
3124215|NCT01726075|Experimental|COLIRIOBCN070660|COLIRIOBCN070660 Somatostatin 1mg/mL Eye drops, solution. One drop/eye administered twice a day.
3124216|NCT01726075|Placebo Comparator|Placebo|Placebo Eye drops, solution. One drop/eye administered twice a day.
3124217|NCT01726075|Experimental|Brimonidine|Brimonidine tartrate 2mg/mL One drop/eye administered twice a day.
3124218|NCT01726062|Experimental|Motivational Interviewing plus Incentives|
3124219|NCT01726062|Other|Conventional Care (CC)|
3124220|NCT01726049|Active Comparator|Sildenafil|Sildenafil orally 3 times 20mg for 2 weeks , followed by 3 times 60 mg for 10 weeks
3124221|NCT01726049|Placebo Comparator|Placebo|placebo orally 3 times 20mg tablets, followed by 3 times 60 mg for 10 weeks
3124222|NCT01726036|Active Comparator|Gomco Circumcision Clamp|Gomco circumcision clamp used for neonatal circumcision.
3124223|NCT01726036|Active Comparator|Mogen Circumcision Clamp|Mogen circumcision clamp used for neonatal circumcision.
3124224|NCT01726023|Experimental|Ceftazidime-Avibactam plus metronidazole|
3124225|NCT01726023|Active Comparator|Meropenem|
3124226|NCT01726010|Experimental|22-G Procore Needle|
3124227|NCT01725997|Active Comparator|Operative treatment|Operative treatment with hook plate.
3124228|NCT01725997|Active Comparator|Conservative treatment|Physiotherapy
3124229|NCT01725984||AdVance|Subjects previously implanted with the AdVance Male Sling
3124230|NCT01725984||AdVance XP|Subjects previously implanted with the AdVance XP male sling
3124231|NCT01725971||Control group|Group of nonsmokers individuals without respiratory disease.
3124232|NCT01725971||normal exam|subjects with silicosis , but with normal spirometric data
3124233|NCT01725971||mild obstruction|subjects with silicosis with mild obstruction in spirometric data
3124234|NCT01725971||moderate to severe obstruction|subjects with silicosis with moderate to severe obstruction in spirometric data
3124235|NCT01725958|Experimental|Dietary Supplement|"Treatment Regimen~-The Nutritional Supplement will be given for approximately 90 days in the form of 7 capsules and a powder to mix into liquids or foods for the first 15 days of program. Subjects will also drink a protein shake."
3124236|NCT01725945|No Intervention|Usual Care|Usual Care
3124237|NCT01725945|Experimental|DASH Intervention|Dietary Approaches to Stop Hypertension dietary pattern. Usual care in combination with a DASH intervention consisting of 8 group and 3 individual sessions over 3 months, followed by 3 monthly phone consultations.
3124238|NCT01725932|Experimental|Culturally adapted CBT based Self Help|Culturally sensitive cbt based self help intervention, which consists of 6 regular chapters and 2 additional chapters. The self help intervention involves family to improve compliance with the intervention
3124239|NCT01725932|No Intervention|Care As Usual|Control Group
3124240|NCT01725919|Experimental|Immediate CI therapy|
3124241|NCT01725919|Active Comparator|Delayed CI therapy|
3124242|NCT01725906|Active Comparator|Empirical therapy|selection of antibiotic according to medication history
3124243|NCT01725906|Experimental|Genotypic resistance guided therapy|selection of antibiotics according to genotypic resistance
3124244|NCT01725880||No treatment|Observation
3124245|NCT01725867|Experimental|PT program|manual myofascial release for craniomandibular system for 30~40 minutes chin-in exercise within 10 minutes and as home exercise self-care education twice per week for 8 weeks
3124246|NCT01725867|Active Comparator|Splint group|custom-made oral appliance: wear every night for 8 weeks, occasional drop is allowed self-care education
3124247|NCT01725854|Experimental|Relaxation Response Training|The Military tailored RR training program will consist of six weekly small group sessions which involve group presentations, in-group skill building exercises, and at-home assignments. Groups will contain 5-8 participants who are active-duty Soldiers enrolled in either Respect-MIL or the Interdisciplinary Pain Management Center (IPMC).
3124288|NCT01725607|Experimental|general anesthesia combined with TEA|general anesthesia combined with TEA (Group E)
3124289|NCT01725594|Experimental|Cohort A1, Dose Level 1: CAT 2003 or placebo fasting|Single dose
3124290|NCT01725594|Experimental|Cohort A2, Dose Level 2: CAT 2003 or placebo fasting|Single dose
3124248|NCT01725854|No Intervention|Standard of Care|Participants randomized to the control group will receive standard care through their providers at Respect-MIL or at the IPMC. Participants randomized to the control group will remain on the wait list for further standard care. After the collection of the final data point, these participants will also have the option to participate in an abbreviated, two-hour version of the RR training.
3124249|NCT01725828|Experimental|External Palpation group|External Palpation group will consist of 109 patients, who's CTM will be marked using traditional palpation technique of identifying the Cricothyroid membrane.
3124250|NCT01725828|Experimental|Ultrasound group|"Ultrasound group will consist of 114 patients, who's CTM will be marked using, ultrasonography to identify the CTM.~The Intervention by using the Ultrasound to determine the CTM."
3124251|NCT01725815|Experimental|HARP Intervention|
3124252|NCT01725815|No Intervention|No Intervention: Control|
3124253|NCT01725802|Experimental|levodopa and carbidopa|levodopa and carbidopa solution
3124254|NCT01725802|Placebo Comparator|placebo to levodopa and carbidopa|saline
3124255|NCT01725789|Experimental|Ferinject® Group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with 7g/dl≤Hb<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.
3124256|NCT01725789|Placebo Comparator|Placebo Group|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with 7g/dl≤Hb<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.
3124257|NCT01725776|Experimental|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg(as for the injectable solution)
3124258|NCT01725763|Other|suspected PH|60 minute Cardiac MRI
3124259|NCT01725750|Experimental|Bright White Light (BWL)|"Participants will self-administer bright white light daily using a Litebook® (The Litebook Company Ltd.). The Litebook is a small (6 x 5 x 1) and lightweight (8 oz.) box."
3124260|NCT01725750|Active Comparator|Dim Red Light (DRL)|Participants will self-administer dim red light daily using a device that appears identical to Bright White Light (BWL) Litebook but that uses red LEDs emitting DRL.
3124261|NCT01725737|Placebo Comparator|Placebo|
3124262|NCT01725737|Active Comparator|GlyTI-M|GlyTI-M: 0.03gm/kg/day
3124263|NCT01725724|Active Comparator|Allogeneic blood|Allogeneic blood transfusion. Patients in this group will receive allogeneic red cell transfusions.
3124264|NCT01725724|Experimental|Autologous blood|Autologous blood transfusion. Patients in this arm will receive per- and postoperatively collected autologous blood collected with the Sangvia Blood Collection System. If teh amount of autologous blood is too small for the clinical need, additional allogeneic blood will be transfused.
3124265|NCT01725711|Experimental|Implant System|
3124266|NCT01725698|Experimental|Stemcell|Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant
3124267|NCT01725685|Experimental|Treatment A - FF 400 microgram (mcg)|Subjects will be randomized to single dose of FF 400 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
3124268|NCT01725685|Experimental|Treatment B - UMEC 500 mcg|Subjects will be randomized to single dose of UMEC 125 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
3124269|NCT01725685|Experimental|Treatment C - FF/UMEC 400/500 mcg|Subjects will be randomized to single dose of FF/UMEC 100/125 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
3124270|NCT01725672|Active Comparator|Part A and B:Arm 1: 500 mg metformin XR / 1 mg glimepiride IR|In Part A and Part B of the study, subjects will receive single dose oral tablets of 500 mg metformin XR and 1 mg glimepiride IR on Day 1 of the respective period per randomized sequence
3124271|NCT01725672|Active Comparator|Part A and B:Arm 2: 1000 mg metformin XR / 2 mg glimepiride IR|In Part A and Part B of the study, subjects will receive single dose oral tablets of 1000 mg metformin XR and 2 mg glimepiride IR on Day 1 of the respective period per randomized sequence
3124272|NCT01725672|Experimental|Part A:Arm 3: 500 mg metformin XR and 1 mg glimepiride XR|In Part A of the study subjects will receive single oral dose of 500 mg metformin XR and 1 mg glimepiride XR (FDC1) film coated tablet containing release controlling polymers on Day 1 of the respective period per randomized sequence
3124273|NCT01725672|Experimental|Part A:Arm 4: 1000 mg metformin XR and 2 mg glimepiride XR|In Part A of the study subjects will receive single oral dose of 1000 mg metformin XR and 2 mg glimepiride XR (FDC1) film coated tablet containing release controlling polymers on Day 1 of the respective period per randomized sequence
3124274|NCT01725672|Experimental|Part B:Arm 5: 500 mg metformin XR and 1 mg glimepiride XR|In Part B of the study subjects will receive single oral dose of 500 mg metformin XR and 1 mg glimepiride XR (FDC3) tablet coated with release controlling polymers on Day 1 of the respective period per randomized sequence
3124275|NCT01725672|Experimental|Part B:Arm 6: 1000 mg metformin XR and 2 mg glimepiride XR|In Part B of the study subjects will receive single oral dose of 1000 mg metformin XR and 2 mg glimepiride XR (FDC4) tablet coated with release controlling polymers on Day 1 of the respective period per randomized sequence
3124276|NCT01725659|Experimental|Motor Learning|subjects are provided with intensive motor learning training of the upper limb
3124277|NCT01725659|Experimental|Robotics and Motor Learning|subject are provided with intensive motor learning and robotics training of the upper limb
3124278|NCT01725659|Experimental|Motor learning and FES|subjects are provided with intensive motor learning and surface FES (Functional Electrical Stimulation) of the upper limb
3124279|NCT01725646|Active Comparator|Omacor® 4 g|Subjects in this group will take 4 g of Omacor® everyday.
3124280|NCT01725646|Active Comparator|Omacor® 2 g|Subjects in this group will take 2 g of Omacor® and 2 g of placebo everyday.
3124281|NCT01725646|Placebo Comparator|Placebo|Subjects in this group will take 4 g of placebo everyday.
3124282|NCT01725633|Other|Progressive Stretching Group|
3124283|NCT01725633|Experimental|Nonlinear Aerobic Training|
3124284|NCT01725620|Experimental|Group 1|Enbrel, LBEC0101
3124285|NCT01725620|Experimental|Group 2|LBEC0101, Enbrel
3124286|NCT01725607|No Intervention|the control group (Group C)|general anesthesia
3124287|NCT01725607|Experimental|general anesthesia combined with dexmedetomidine infusion|general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
3124291|NCT01725594|Experimental|Cohort A3, Dose Level 3: CAT 2003 or placebo fasting|Single dose
3124293|NCT01725594|Experimental|Cohort A5, Dose Level 5: CAT 2003 or placebo fasting|Single dose
3124294|NCT01725594|Experimental|Cohort A2: Dose Level 2: CAT 2003 or placebo fed|Single dose
3124295|NCT01725594|Experimental|Cohort A3: Dose level 3:CAT 2003 or placebo fed|Single dose
3124296|NCT01725594|Experimental|Cohort B1: Dose level 6: CAT 2003 or placebo|Multiple dose for 14 days
3124297|NCT01725594|Experimental|Cohort B2: Dose level 7: CAT 2003 or placebo|Multiple dose for 14 days
3124298|NCT01725594|Experimental|Cohort B3: Dose level 8: CAT 2003 or placebo|Multiple dose for 14 days
3124299|NCT01725594|Experimental|Cohort B4: Dose level 9: CAT 2003 or placebo|Multiple dose for 14 days
3124300|NCT01725581||Inexperienced students|Final year medical students at the end of the Obstetrics and Gynaecology placement
3124301|NCT01725581||Experienced students|Final year medical students at the end of the Obstetrics and Gynaecology placement
3124302|NCT01725581||Junior Doctors|Pre Royal College of Obstetric and Gynaecology registered junior doctors with experience in Obstetrics and Gynaecology
3124303|NCT01725568||Implantable cardiac monitor diagnostics|Patients has standard indication for implantable cardiac monitor diagnostic.
3124304|NCT01725555|Experimental|Fasted treatment|
3124305|NCT01725555|Experimental|Fed treatment|
3124306|NCT01725542|Experimental|Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a|"Lead-in Phase: day 0 to week 4 PegInterferon alpha-2a + Ribavirin~Quadruple therapy: week 4 to week 28 Asunaprevir + Daclatasvir + PegInterferon alpha-2a + Ribavirin"
3124307|NCT01725529|Experimental|TMC435 150 mg|Patients will receive 12 weeks TMC435 150 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue to receive treatment with PegIFNα-2a and RBV until Week 48.
3124308|NCT01725529|Experimental|TMC435 100 mg|Patients will receive 12 weeks TMC435 100 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue PegIFNα-2a and RBV until Week 48.
3124309|NCT01725529|Placebo Comparator|Control|Patients will receive placebo once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV) for 48 weeks.
3124310|NCT01725516|Experimental|Myofascial release technique|
3124311|NCT01725503|Experimental|Creatine and amino acid supplement|
3124312|NCT01725490|Experimental|metformin 500mg daily (arm A)|
3124313|NCT01725490|Experimental|metformin 1500mg daily (arm B)|
3124314|NCT01725490|Placebo Comparator|an identical- appearing placebo (arm C)|
3124315|NCT01725477|Experimental|Dye& normal saline/ 20ml methylene blue +50 ml normal saline|first arm:20 ml methylene blue washing with50 ml normal saline
3124316|NCT01725477|Active Comparator|injection of 20ml metheylen blue|20 ml methylene blue injected without washing
3124317|NCT01725464|Experimental|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
3124318|NCT01725451|Experimental|Testosterone Unshaved|No deodorant or antiperspirant: Single 30 mg dose of testosterone applied topically to each unshaved axilla in 1 of 6 treatment periods.
3124319|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Spray|Deodorant spray applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
3124320|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Antiperspirant Spray|Deodorant antiperspirant combination spray applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
3124321|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Antiperspirant Stick|Deodorant antiperspirant combination stick applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
3124322|NCT01725451|Experimental|Testosterone Shaved|No deodorant or antiperspirant: Single 30 mg dose of testosterone applied topically to each shaved axilla in 1 of 6 treatment periods.
3124323|NCT01725451|Experimental|Testosterone Shaved + Deodorant Antiperspirant Spray|Deodorant antiperspirant combination spray applied to shaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
3124324|NCT01725438|Experimental|Pregnant women accepting an invasive prenatal diagnosis|Pregnant women accepting an invasive prenatal diagnosis and a sample blood (non invasive diagnosis)
3124325|NCT01725425|Experimental|Control|Participants will receive equal amounts of foods.
3124326|NCT01725425|Experimental|Increase Portion Size|Participants will receive increased portion sizes.
3124327|NCT01725425|Experimental|Decrease Portion Sizes|Participants will receive decreased portion sizes.
3124328|NCT01725425|Experimental|Mixed Portion Sizes|Participants will receive mixed portion sizes.
3124329|NCT01725412|Experimental|Thiamine Supplementation|
3124330|NCT01725412|Placebo Comparator|Placebo|
3124331|NCT01725399|Placebo Comparator|Water|Water will be given as the study subject's first oral intake after emergence from general anesthesia.
3124332|NCT01725399|Experimental|Apple Juice|Apple juice will be given as the study subject's first oral intake after emergence from general anesthesia.
3124333|NCT01725386||Monotherapy|Capecitabine as monotherapy according to prescribing information and normal clinical practice.
3124334|NCT01725386||Combination Therapy|Capecitabine as part of combination therapy according to prescribing information and normal clinical practice.
3124335|NCT01725373||Angioplasty of left main|"Patients with:~stable or unstable angina and/or documented ischemia~de novo ≥50% stenosis in the left main stem referred for angioplasty"
3124336|NCT01725360|Experimental|montelukast|A leukotriene receptor antagonist (LTRA, montelukast) is added to a basic treatment of inhaled corticosteroids (ICS) + long-acting betamimetics (LABA) in well-controlled patients with asthma.
3124337|NCT01725347||African American Girls|-25% of sample is African American Girls
3124338|NCT01725347||African American Boys|-25% of sample is African American Boys
3124339|NCT01725347||Hispanic American Girls|-25% of sample is Hispanic American Girls
3124340|NCT01725347||Hispanic American Boys|-25% of sample is Hispanic American Boys
3124341|NCT01725334|Experimental|Nucleus Accumbens/Ventral Striatum (NAcc/VS) Stimulation|The first 3 patients will have the DBS device target the NAcc/VS, which has been found to be hypoactive in patients with primarily negative symptoms.
3124342|NCT01725334|Experimental|Ventral Tegmental Area (VTA) Stimulation|For 3 patients, the DBS device will target the VTA, which has been found to be hypoactive in patients with primarily negative symptoms.
3124343|NCT01725321||Narrow band imaging|Colonoscopy with new narrow band imaging
3124344|NCT01725308|Placebo Comparator|Placebo|Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
3124345|NCT01725308|Experimental|FK949E 150 mg|After 2 days of up-titration, participants who received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
3124346|NCT01725308|Experimental|FK949E 300 mg|After 4 days of up-titration, participants who received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
3124347|NCT01725308|Experimental|Placebo / FK949E|Participants received placebo administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive placebo for 4 weeks, followed by a 1-week dose adjustment period, and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
3124348|NCT01725308|Experimental|FK949E 150 mg / FK949E|After 2 days of up-titration, participants received FK949E 150 mg administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive FK949E 150 mg for 4 weeks followed by a 1-week dose-adjustment period and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
3124349|NCT01725308|Experimental|FK949E 300 mg / FK949E|After 4 days of up-titration, participants received FK949E 300 mg administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive FK949E 300 mg for 4 weeks followed by a 1-week dose-adjustment period and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
3124350|NCT01725295|Experimental|NST|A form of physical therapy to relieve symptoms of fibromyalgia
3124351|NCT01725295|Active Comparator|Hydrotherapy|An alternate form of physical therapy to relieve symptoms of fibromyalgia
3124352|NCT01725282|Placebo Comparator|Placebo|Participants received matching placebo tablets once daily before bedtime for 7 weeks.
3124353|NCT01725282|Experimental|Quetiapine 50 mg|Participants received quetiapine extended release (XR) 50 mg tablets once daily before bedtime for 7 weeks.
3124354|NCT01725282|Experimental|Quetiapine 150 mg|After 2 days of up-titration, participants received quetiapine XR 150 mg tablets once daily before bedtime for 6 weeks followed by quetiapine XR 50 mg tablets once daily for 1 week.
3124355|NCT01725282|Experimental|Quetiapine 300 mg|After 4 days of up-titration, participants received quetiapine XR 300 mg tablets once daily before bedtime for 6 weeks followed by quetiapine XR 150 mg tablets once daily for 1 week.
3124356|NCT01725269|Experimental|80mg AIR001, nebulized four times daily|AIR001, 80 mg into nebulizer
3124357|NCT01725269|Experimental|46 mg AIR001, nebulized four times daily|AIR001, 46 mg into nebulizer
3124358|NCT01725269|Experimental|80mg AIR001, nebulized once daily|AIR001, 80 mg into nebulizer
3124359|NCT01725256|Experimental|80mg AIR001 four times daily|80mg AIR001 nebulized four times daily for 16 weeks
3124360|NCT01725256|Experimental|46mg AIR001 four times daily|46mg AIR001 nebulized four times daily for 16 weeks
3124361|NCT01725256|Experimental|80mg AIR001 once daily|80mg AIR001 nebulized once daily for 16 weeks
3124362|NCT01725243|Active Comparator|Carbetocin 10mcg|Carbetocin 10mcg IV, once following delivery.
3124363|NCT01725243|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg IV, once following delivery.
3124364|NCT01725243|Active Comparator|Carbetocin 40mcg|Carbetocin 40mcg IV, once following delivery.
3124365|NCT01725243|Active Comparator|Carbetocin 60mcg|Carbetocin 60mcg IV, once following delivery.
3124366|NCT01725243|Active Comparator|Carbetocin 80mcg|Carbetocin 80mcg IV, once following delivery.
3124367|NCT01725243|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg IV, once following delivery.
3124368|NCT01725243|Active Comparator|Carbetocin 120mcg|Carbetocin 120mcg IV, once following delivery.
3124369|NCT01725243|Active Comparator|Carbetocin 140mcg|Carbetocin 140mcg IV, once following delivery.
3124370|NCT01725230|Experimental|Rosuvastatin|Single, oral dose of rosuvastatin 20mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of rosuvastatin 20 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily
3124405|NCT01725087|Experimental|Medium Dose GRT6005|Once daily GRT6005 medium dose oral administration for 12 weeks with a titration period of 2 weeks.
3198967|NCT01205724|Experimental|C|
3124371|NCT01725230|Experimental|Simvastatin|Single, oral dose of simvastatin 40 mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of simvastatin 40 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily
3124372|NCT01725217|Experimental|MenACWY-CRM|MenACWY-CRM
3124373|NCT01725204|Experimental|Dasatinib + PegIFN|Dasatinib 100mg OD for three months single drug, with subsequent addition of PegIFN 15 μg/ week for 3 months. If well tolerated (less than grade 2 non-hematological or grade 3 hematological AE) the dose should be increased to 25μg weekly for the remaining 9 months on combination treatment. Thereafter dasatinib will be given as monotherapy. Patients will be followed for 24 months totally.
3124374|NCT01725191|Experimental|Treatment (tivantinib)|Patients receive tivantinib PO BID on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3124375|NCT01725178|No Intervention|Standard care|No intervention besides usual care
3124376|NCT01725178|Active Comparator|Cognitive and physical training|Patients will undergo the comprehensive program of cognitive and physical training.
3124377|NCT01725165|Experimental|Local Consolidation Therapy (LCT)|Patients receive local consolidation therapy (LCT) after induction chemotherapy. LCT is radiation, surgery, or both. If assigned to the LCT group, the study doctor will decide if patient has radiation alone, surgery alone, or radiation combined with surgery.
3124378|NCT01725165|Active Comparator|No Local Consolidation Therapy (LCT)|Patients randomized to the no LCT arm receive maintenance therapy (switch or continuation), or surveillance, based on physician choice after induction chemotherapy. Pemetrexed, bevacizumab, crizotinib (for ALK-mutation positive patients) or erlotinib are recommended as acceptable maintenance agents but other agents may be used at physician discretion.
3124379|NCT01725152|Experimental|Ganaxolone|3 mg/kg up to 12 mg/kg, with maximum of 1500 mg/day
3124380|NCT01725152|Placebo Comparator|Placebo|non active
3124381|NCT01725139|Experimental|Cohort 1-GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 (0.25 mg twice daily [bid]) or placebo for approximately 8 days (7 to 10 days dosing)
3124382|NCT01725139|Placebo Comparator|Cohort 1-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing)
3124383|NCT01725139|Experimental|Cohort 2-GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 1 and which could be escalated or deescalated or repeated from Cohort 1 dosing.
3124384|NCT01725139|Placebo Comparator|Cohort 2-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
3124385|NCT01725139|Experimental|Cohort 3- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 2 and which could be escalated or deescalated or repeated from Cohort 2 dosing.
3124386|NCT01725139|Placebo Comparator|Cohort 3-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
3124387|NCT01725139|Experimental|Cohort 4- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 3 and which could be escalated or deescalated or repeated from Cohort 3 dosing.
3124388|NCT01725139|Placebo Comparator|Cohort 4- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
3124389|NCT01725139|Experimental|Cohort 5- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 4 and which could be escalated or deescalated or repeated from Cohort 4 dosing.
3124390|NCT01725139|Placebo Comparator|Cohort 5- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
3124391|NCT01725139|Experimental|Cohort 6- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 4 and which could be escalated or deescalated or repeated from Cohort 5 dosing.
3124392|NCT01725139|Placebo Comparator|Cohort 6- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
3124393|NCT01725126|Experimental|Part A - GSK2890457|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
3124394|NCT01725126|Experimental|Part B - GSK2890457 + Liraglutide|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
3124395|NCT01725126|Experimental|Part C - GSK2890457 + Metformin|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
3124396|NCT01725126|Placebo Comparator|Part A - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
3124397|NCT01725126|Placebo Comparator|Part B - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
3124398|NCT01725126|Placebo Comparator|Part C - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
3124399|NCT01725113|Experimental|Calcitriol|Patients will be converted from paricalcitol to calcitriol according to published package inserts which describe a 10mcg:3mcg ratio.
3124400|NCT01725113|Active Comparator|Paricalcitol|Continuation of intravenous paricalcitol that patient was originally on at the time of recruitment.
3124401|NCT01725100|Experimental|Treatment A: GSK1120212B (Standard DMSO content)|Subjects will receive Treatment A in Period 1 or 2 as single oral dose on Day 1 of Period 1 or 2 in fasting condition with water.
3124402|NCT01725100|Experimental|Treatment B: GSK1120212B (Lower DMSO content)|Subjects will receive Treatment B in Period 1 or 2 as single oral dose on Day 1 of Period 1 or 2 in fasting condition with water.
3124403|NCT01725087|Placebo Comparator|Matching Placebo|Twice daily oral administration of matching placebo for 14 weeks
3124404|NCT01725087|Experimental|Low Dose GRT6005|Once daily GRT6005 low dose oral administration for 12 weeks with a titration period of 2 weeks.
3124406|NCT01725087|Experimental|High Dose GRT6005|Once daily GRT6005 high dose oral administration for 12 weeks with a titration period of 2 weeks.
3124407|NCT01725087|Active Comparator|Tapentadol|Twice daily oral administration of Tapentadol for 12 weeks with a titration period of 2 weeks.
3124408|NCT01725074|Experimental|"Case Management CM CHD"|The intervention consists of a biweekly telephone or personal contact by trained case managers over the first 6-months and monthly contact over the second 6-months to assess well-being, everyday life (positive, neutral and negative daily events), and to inquire after health and personal problems on which basis the case manager offers practical or emotional support or a referral to the general practitioner if deemed necessary. During the contacts also medical control measures like blood pressure or weight are taken, and other study outcome measures like need for medical treatment.
3124409|NCT01725074|Experimental|Social Interaction|Identical as the CM CHD group, but with exclusion of medical control measures.
3124410|NCT01725074|No Intervention|Control Group|Patients assigned to the control group received usual care (no additional contact/support) and therefore stays under the standard supervision of the general practitioner i.e. as participant in the normal disease management program for CHD (quarterly check-ups).
3124411|NCT01725048|Active Comparator|Mirtazapine|Treatment with oral mirtazapine, dosed once daily, for 9 weeks, with starting dose of 7.5 milligrams (mg) daily up to 30mg daily.
3124412|NCT01725048|Active Comparator|Citalopram|Treatment with Citalopram, once daily, for 9 weeks, with dosages starting at 10mg once daily to 40mg once daily.
3124413|NCT01725035||Fatty liver|
3124414|NCT01725035||Non Fatty liver|
3124415|NCT01725022|Experimental|Home Care|This is the arm for patients who receive their transplant care in their homes.
3124416|NCT01725022|No Intervention|Hospital Care|Standard of care for stem cell transplant recipients where the aftercare is done in hospital.
3124417|NCT01725022|No Intervention|Clinic Care|Standard of care for stem cell transplant recipients who live at home but receive aftercare in the daily outpatient clinic.
3124418|NCT01725009|Experimental|Levetiracetam IV infusions in Japanese|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Japanese subjects
3124419|NCT01725009|Experimental|Levetiracetam IV infusions in Caucasian|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Caucasian subjects
3124420|NCT01724983|Experimental|ketamine|patients will receive ketamine at induction
3124421|NCT01724983|Active Comparator|fentanyl|patients will receive fentanyl at induction
3124422|NCT01724970|Experimental|PLMA|ProSeal
3124423|NCT01724970|Experimental|SLMA|Supreme LMA
3124424|NCT01724957||Patients with coronary bifurcation lesions|Only one group will be studied. The patient will be a slef-reference.
3124425|NCT01724944|Experimental|Systematic Lymphadenectomy|
3124426|NCT01724931|Placebo Comparator|Placebo|Placebo once weekly
3124427|NCT01724931|Experimental|3 mg LD-Aminopterin|3 mg LD-aminopterin once weekly
3124428|NCT01724931|Experimental|1 mg LD-aminopterin|1 mg LD-aminopterin once weekly
3124429|NCT01724918|Other|100 mg IV|100 mg IV lacosamide infused over 30 minutes
3124430|NCT01724918|Other|200 mg IV|200 mg IV lacosamide infused over 30 minutes
3124431|NCT01724918|Other|400 mg IV|400 mg IV lacosamide infused over 30 minutes
3124432|NCT01724905|Experimental|Modified Stop Light Diet|
3124433|NCT01724905|Active Comparator|Recommended Care for Weight Reduction|
3124434|NCT01724892|Active Comparator|Loteprednol etabonate|Topical Loteprednol etabonate eye drop 0.5%, 4 times a day, 3 weeks
3124435|NCT01724892|Active Comparator|Dexamethasone|Topical Dexamethasone eye drop 0.1%, 4 times a day, 3 weeks
3124436|NCT01724879|Experimental|Dasatinib and chemotherapy|Dasatinib, QD p.o. administration, day 1 to EOS
3124437|NCT01724866|Experimental|Single-dose HM10460A (45 μg/kg)|Single-dose HM10460A (45 μg/kg) should be administered on Day 2 of each cycle, approximately 24 hours (±2 hours) after TC chemotherapy.
3124438|NCT01724866|Experimental|Single-dose HM10460A (135 μg/kg)|Single-dose HM10460A (135 μg/kg) should be administered on Day 2 of each cycle, approximately 24 hours (±2 hours) after TC chemotherapy.
3124439|NCT01724866|Experimental|Single-dose HM10460A (270 μg/kg)|Single-dose HM10460A (270 μg/kg) should be administered on Day 2 of each cycle, approximately 24 hours (±2 hours) after TC chemotherapy.
3124440|NCT01724866|Active Comparator|Pegfilgrastim 6 mg|Pegfilgrastim (Neulasta®) is not to be administered between 14 days before or 24 hours after TC chemotherapy. Pegfilgrastim (Neulasta®) will be administered according to the manufacturer's Prescribing Information (6 mg subcutaneously once per chemotherapy cycle).
3124441|NCT01724853|Other|Surgery|Preferred surgery
3124442|NCT01724853|Other|Conservative|Conservative treatment
3124443|NCT01724840|Experimental|GraftJacket|GraftJAcket is used as interpositional material
3124444|NCT01724840|Active Comparator|Tendon Interposition|Flexor carpi radialis tendon is used as interpositional material
3124445|NCT01724827|Active Comparator|ceramic|Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)
3124446|NCT01724827|Active Comparator|composite|Nanohybrid composite resin (Lava Ultimate, 3M Espe)
3124447|NCT01724814|Experimental|Cohort S1|HM12460A Dose 1 (1.2 nmol/kg) or placebo
3124448|NCT01724814|Experimental|Cohort S2|HM12460A Dose 2 (2.4 nmol/kg) or Placebo
3124449|NCT01724814|Experimental|Cohort S3|HM12460A Dose 3 (4.8 nmol/kg) or Placebo
3124450|NCT01724814|Experimental|Cohort S4|HM12460A Dose 4 (9.6 nmol/kg) or Placebo
3124451|NCT01724814|Experimental|Cohort S5|HM12460A Dose 5 (14.4 nmol/kg) or Placebo
3124452|NCT01724814|Experimental|Cohort S6|HM12460A Dose 6 (19.2 nmol/kg) or Placebo
3124453|NCT01724801|Experimental|icotinib|icotinib administered orally at a dose of 125 mg 3 times daily
3124454|NCT01724801|Active Comparator|Whole brain irradiation|Whole brain irradiation 30Gy/3Gy/10 fractions plus concurrent or sequential chemotherapy for 4-6 cycles
3124455|NCT01724788|Experimental|Furosemide PO - IV|Oral furosemide allocated at the beginning of Period 1, then cross-over to IV furosemide (a minimum 7-day diuretic free washout period required between the two periods)
3124456|NCT01724788|Experimental|Furosemide IV - PO|IV furosemide allocated at the beginning of Period 1, then cross-over to oral furosemide (a minimum 7-day diuretic free washout period required between the two periods)
3200566|NCT01194336||Huperzine A: 100 ug|
3124459|NCT01724762|Experimental|Nursing orientation|Patients who received nursing orientation and read the informative manual concerning bed bath
3124460|NCT01724749||Healthy control subjects|"Age: 21 - 80 years~No prior history or symptoms of cardiovascular disease~The investigators aim to include equal numbers of females and males. Furthermore, the investigators aim to include patients in six different age strata: 21-30, 31-40, 41-50, 51-60, 61-70, 71-80."
3124461|NCT01724749||Subjects with cardiovascular disease|"Age: 21 - 80 years~HeartSCORE > 0%~Symptoms of angina pectoris~The investigators aim to include equal numbers of females and males. Furthermore, the investigators aim to include patients in six different age strata: 21-30, 31-40, 41-50, 51-60, 61-70, 71-80. Also, the investigators aim to include patients in 3 strata of HeartSCORE risk: low risk (1-4%), mild risk (5-9%) and high risk (> 9%)"
3124462|NCT01724736|Placebo Comparator|Placebo Comparator:|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
3124463|NCT01724736|Active Comparator|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
3124464|NCT01724723|Experimental|Entecavir group|Study treatment for only treatment group: entecavir (BARACLUDE®) 0.5 mg per day during and within 6 months after anti-tuberculous treatment.
3124465|NCT01724723|No Intervention|Control group|Not receiving entecavir (BARACLUDE®)
3124466|NCT01724710||chronic ulcer|1x1cm2 tissue from chronic ulcer wound
3124467|NCT01724710||normal skin|1x1x0.1 cm3 normal skin from graft
3124468|NCT01724697|Active Comparator|conventional treatment|conventional treatment & antivrial treatment.
3124469|NCT01724697|Experimental|BMSC transplantation|conventional treatment & antiviral treatment & autologous bone marrow stem cell transplantation via hepatic artery
3124470|NCT01724684|Other|Telehealth program|Telehealth program service
3124471|NCT01724684|Other|Usual care|Usual care service
3124472|NCT01724671||Cefatroline|Investigators will retrospectively capture patient cases that have been treated for MRSA with ceftaroline. Cases will only be included if the isolate was tested against vancomycin and ceftaroline
3124473|NCT01724671||Vancomycin|Investigators will retrospectively capture patient cases that were been treated for MRSA with Vancomycin.
3124474|NCT01724658|Experimental|Testosterone undecanoate|testosterone undecanoate 40 mg orally twice a week plus progynova 1mg oral daily
3124475|NCT01724658|Placebo Comparator|placebo|placebo twice a week with progynova 1 mg oral daily
3124476|NCT01724645|Experimental|Korean traditional diets|Korean traditional diets (calorie 2,100kcal) for 12weeks
3124477|NCT01724645|Active Comparator|Control group|"Control group : told to eat as usal diet) for 12weeks"
3124478|NCT01724632|Active Comparator|Group Treatment|Participants who are assigned to group treatment will attend group meetings weekly for the first 6 months, then every 2 weeks for 6 months, and then monthly for the final 6 months. Participants will be weighed individually at the start of each group meeting.
3124479|NCT01724632|Active Comparator|Individual Treatment|Participants who are assigned to individual treatment will attend one-on-one sessions with a weight loss counselor every month for 18 months.
3124480|NCT01724632|Experimental|Smartphone Treatment|Participants who are assigned to smartphone treatment will use a smartphone to learn and practice weight loss skills. They will also attend one-on-one sessions with a weight loss counselor every month for 18 months.
3124481|NCT01724619|Experimental|Healthy Volunteers|F-18] fluorinated dihydrotestosterone (FDHT) PET/CT
3124482|NCT01724619|Experimental|Prostate Cancer Patients|F-18] fluorinated dihydrotestosterone (FDHT) PET/CT
3124483|NCT01724606|Experimental|Radiotherapy with Sorafenib|This is a single institution, open label, prospective, phase I clinical trial using standard 3+3 design. Histologically confirmed metastatic adenocarcinoma of the breast with radiologic evidence of new and/or progressive brain metastases (BM) with a clinical indication for WBRT will be enrolled.
3124484|NCT01724593||Observational Cohort|No Intervention
3124485|NCT01724567|Experimental|Weight Loss|12 weeks of Low Calorie Diet to obtain a 10 - 15 % weight loss. Followed by 40 weeks on a weight maintenance diet and interval training 2 times a week.
3124486|NCT01724567|Experimental|Interval Training|12 weeks of interval training 3 times a week followed by 40 weeks of interval training 2 times a week.
3124487|NCT01724554|Experimental|Every Month Treatment|Patients will receive Intravitreal Aflibercept Injection (IAI) every month for the 12 month duration of the study.
3124488|NCT01724554|Experimental|Every Month, then Every Other Month|Patients will receive Intravitreal Aflibercept Injection (IAI) every month for the first 6 months, then every other month for the next 6 months. Retreatment criteria will allow for patients to be treated every month in the second 6 months if needed.
3124489|NCT01724528|Experimental|Febuxostat|Febuxostat for 7-9 days
3124490|NCT01724528|Active Comparator|Allopurinol|Allopurinol for 7-9 days
3124491|NCT01724515|Experimental|Obese Non-Diabetic Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
3124492|NCT01724515|Experimental|Type 2 Diabetic Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
3124493|NCT01724515|Experimental|Healthy Control Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
3124494|NCT01724502|Experimental|Obese Non-Diabetic Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
3124495|NCT01724502|Experimental|Type 2 Diabetic Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
3124496|NCT01724502|Experimental|Healthy Control Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
3124497|NCT01724489|Active Comparator|Growth Hormone|Growth Hormone is Genotropin, provided by Pfizer Inc. It is self administered daily for 18 months using a 5 mg injection pen device. Dose will be titrated based on IGF-1 levels.
3124498|NCT01724489|Placebo Comparator|Placebo|Placebo will be provided by Pfizer Inc. It will appear identical to active growth hormone and will be administered in the same manner.
3124499|NCT01724476|Active Comparator|folate with B12|Subjects randomized to the folate with B12 group will take 1 capsule of 400mcg per day of folate with B12.
3124578|NCT01724060||Gastric banding|Patients due for gastric banding
3124500|NCT01724476|Placebo Comparator|placebo|Subjects randomized to the placebo group will take 1 capsule of placebo per day.
3124501|NCT01724463||Electronically Screened Sepsis Patients|Patients between the ages 1 month and 18 years admitted to the hospital or presenting to the Emergency Department (ED) with clinical signs of Systemic Inflammatory Response Syndrome (SIRS) electronically screened for severe sepsis. Patients screened as positive will receive an evidence based goal directed severe sepsis management bundle.
3124502|NCT01724450|Active Comparator|Carvedilol|
3124503|NCT01724450|Placebo Comparator|Control|
3124504|NCT01724437|Active Comparator|Loss of pace capture|Pulmonary vein isolation: Ablation along the ablation line is continued until loss of pace capture along the ablation line is achieved
3124505|NCT01724437|Active Comparator|Conventional|Pulmonary vein isolation: Ablation is discontinued when electrical isolation of the pulmonary veins is achieved.
3124506|NCT01724424|Experimental|melatonin 20mg|2 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
3124507|NCT01724424|Experimental|melatonin 30mg|3 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
3124508|NCT01724424|Experimental|Melatonin 50mg|5 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
3124509|NCT01724424|Experimental|Melatonin 100mg|10 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
3124510|NCT01724411|Experimental|Resistant Starch 3|Resistant Starch Type 3:dose of 26g/day males and 22g/day female during 11 days of the maintenance period. (C ActiStar 11700, Tapioca Maltodextrin, Cargill, Belgium)
3124511|NCT01724411|No Intervention|Control Non- RS3|Non-Resistant Starch type 3 food items during 11 days of the maintenance period.
3124512|NCT01724398|Experimental|Conventional treatment|Participants will receive conventional treatment and then be followed until the week 48 study visit.
3124513|NCT01724398|Experimental|Conventional plus UC-MSC treatment|Participants will receive conventional treatment plus a dose of UC-MSC and then be followed until the week 48 study visit.
3124514|NCT01724398|Experimental|Conventional plus PE treatment|Participants will receive conventional treatment plus plasma exchange and then be followed until the week 48 study visit.
3124515|NCT01724398|Experimental|Conventional plus UC-MSC and PE therapy|Participants will receive conventional treatment plus umbilical cord mesenchymal stem cells transplantation combined with plasma exchange. Participants will then be followed until the week 48 study visit.
3124516|NCT01724385|Experimental|intravitreal bevacizumab injection|intravitreal injection of bevacizumab 1.25 mg
3124517|NCT01724372|Experimental|Antidepressant|Fluoxetine
3124518|NCT01724372|Active Comparator|Antipsychotic|Aripiprazole
3124519|NCT01724359|Experimental|Paliperidone ER|
3124520|NCT01724346|Other|Arm A Post-Chlorambucil Therapy Followup|Patients randomized to Chlorambucil in the parent study, PCYC-1115-CA, and have not progressed at the time of the parent study closure will be transferred to this Arm. Follow-up will continue until PD, unacceptable toxicity, or other reason for treatment discontinuation.
3124521|NCT01724346|Experimental|Arm B Ibrutinib|Patients randomized to Ibrutinib in the parent study PCYC-1115-CA who have not experienced PD at the time of parent study closure will be transferred to this Arm to continue on Ibrutinib treatment. Treatment will continue until PD, unacceptable toxicity, or other reasons for treatment discontinuation.
3124522|NCT01724346|Experimental|Arm C Second-line Ibrutinib|Patients who received Chlorambucil in the parent study PCYC-1115-CA and experienced PD are transferred to this Arm for Ibrutinib treatment. Treatment will continue until PD, unacceptable toxicity, or other reasons for treatment discontinuation.
3124523|NCT01724346|Other|Arm D Alternative Anticancer Therapy|At the investigator's discretion, alternative anticancer treatment is a therapeutic option for patients who experienced PD during Ibrutinib treatment or during or after Chlorambucil treatment. This Arm can also be considered if drug is discontinued for other reasons (eg., intolerability or adverse event [AE]) or prior to experiencing PD).
3124524|NCT01724333||Group 1- in active treatment|Questionnaires only
3124525|NCT01724333||Group 2 - 2-6 months post-treatment|Questionnaires only
3124526|NCT01724333||Group 3 - 6 mos-3yrs post-treatment|Questionnaires only
3124527|NCT01724333||Group 4 - Palliative treatment|Questionnaires only
3124528|NCT01724333||Group 5 - Referred to dentist/oral team|Questionnaires only
3124529|NCT01724320|Experimental|OTX008|Single-arm study of OTX008 given subcutaneously, daily without interruption to patients with advanced solid tumors. Starting dose: 65 mg/day.
3124530|NCT01724307|Active Comparator|Asthma positive to Methacholine Challenge Testing|Asthma diagnosis by positive Methacholine Challenge Testing
3124531|NCT01724307|Active Comparator|Asthma positive to Eucapnic voluntary hyperventilation testing|Asthma diagnosis by positive Eucapnic voluntary hyperventilation testing
3124532|NCT01724294||Cohort|
3124533|NCT01724281||pregnant women between 19-30 weeks gestational age|No intervention, only follow up
3124534|NCT01724268|Experimental|Pred + Meth|"Prednisolone : 10 mg daily~+ Methotrexate : 25 mg/ day~ARM 1 Treatment Arm"
3124535|NCT01724268|Active Comparator|Anti TNF + Meth|"Etanrcept: 50 mg; Adalimumab: 40 mg; Infliximab: 3mg/kg~+ Methotrexate 25 mg per day Control Arm"
3124536|NCT01724255||staple removal day 4 dressing removal day 1|early staple removal and early dressing removal
3124537|NCT01724255||staple removal day 4 dressing removal day 4|early staple removal and day 4 dressing removal
3124538|NCT01724255||staple removal day 7, dressing removal day 1|late staple removal and early dressing removal
3124539|NCT01724255||staple removal day 7, dressing removal day 7|late staple removal and late dressing removal
3124540|NCT01724255||staple removal day 7, dressing removal day 4|late staple removal and day 4 dressing removal
3124541|NCT01724242|Experimental|Vaginal DHEA|Vaginal DHEA 0.5%(6.5mg)inserted nightly
3124542|NCT01724242|Placebo Comparator|Placebo|
3124579|NCT01724060||Sleeve gastrectomy|Patients due for sleeve gastrectomy
3124580|NCT01724060||Endobarrier|Patients due to undergo endoscopic Endobarrier insertion
3200567|NCT01194336||Huperzine A: 200 ug|
3124543|NCT01724229|Other|treatment with OTC drug products|"Body Wash & Shampoo applied directly to the skin or cloth; soiled area gently wiped clean. No rinsing necessary.~Moisture Barrier Cream: Once area cleansed and dried thoroughly, a thin coat is gently applied to the area of the skin exposed to moisture twice daily for two weeks or as directed by doctor.~2-in-1 Cleanser: applied directly to the skin or a cloth and skin gently wiped clean. No rinsing necessary.~Antifungal Cream: Once reddened area cleansed and dried thoroughly a thin layer is applied over the affected area twice daily for two weeks or as directed by doctor."
3124544|NCT01724216|Experimental|pulse sequence software|The central aim of this study is to acquire a set of images and associated technical and clinical information to facilitate regulatory submission of the pulse sequences being studied by GEHC. Segment 1 allows to collect a minimum of 10 subjects then evaluate if additional scans/enrollment needed Segment 2 will allow an additional 90 subjects if data needed
3124545|NCT01724203|Active Comparator|Lactobacillus rhamnosus|Formula containing 1 million CFU/g Lactobacillus rhamnosus HN001 (trademarked DR20) at least three times daily for 12 weeks.
3124546|NCT01724203|Active Comparator|Bifidobacterium animalis subsp. lactis|Formula containing 1 million CFU/g Bifidobacterium animalis subsp. lactis HN019 (trademarked DR10) at least three times daily for 12 weeks.
3124547|NCT01724203|Placebo Comparator|Placebo|Placebo formula without probiotics at least three times daily for 12 weeks.
3124548|NCT01724190|Active Comparator|Vitamin D|Subjects will receive oral vitamin D supplementation, 3000 IU daily over the course of 9 months.
3124549|NCT01724190|Placebo Comparator|Placebo|Subjects will receive a placebo solution daily over the course of 9 months.
3124550|NCT01724177|Experimental|Lenalidomide|Lenalidomide 25mg by mouth (PO) daily until progressive disease or unacceptable toxicity
3124551|NCT01724164|Experimental|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
3124552|NCT01724164|Experimental|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
3124553|NCT01724164|Active Comparator|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
3124554|NCT01724164|Experimental|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
3124555|NCT01724164|Placebo Comparator|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
3124556|NCT01724151||Healthy adults|Healthy adults, over 45 years old
3124557|NCT01724151||Mild cognitive impairment|subjects with mild cognitive impairment
3124558|NCT01724151||Alzheimer's disease|subjects with Alzheimer's disease
3124559|NCT01724138|Experimental|Deferasirox|The study will provide PK, safety, tolerability and efficacy data collected during 48 weeks of treatment with deferasirox in Chinese pediatric patients with transfusion dependent -thalassemia major, aged 2 to <6 years at enrollment. The target patient pool consists of 20 patients with evidence of iron overload measured by serum ferritin level at the start of study. Patients will start their deferasirox treatment with a dose of 20 mg/kg/day. Serum ferritin will be monitored every month and the dose of deferasirox will be adjusted if necessary every 3 months based on the trends in serum ferritin. Other possible dose adjustments will be based on the patient's safety assessments.
3124560|NCT01724125|Experimental|Case|Assigned a Personal Electronic Health Record
3124561|NCT01724125|Active Comparator|Control: Usual Care|Assigned to control arm, continued to receive care as usual in community. Was issued information on community health resources, but did not use research study personal health record.
3124562|NCT01724112|Experimental|LY2940094|40 mg administered orally as 1 capsule QD for 8 weeks.
3124563|NCT01724112|Placebo Comparator|Placebo|Administered orally as 1 capsule QD for 8 weeks.
3124564|NCT01724099|Experimental|Euiiyin-tang|powder type, 3 times per day before the meal, 12 weeks total
3124565|NCT01724099|Placebo Comparator|Placebo|powder type, 3 times per day before the meal, 12 weeks total
3124566|NCT01724086|Experimental|Panel 1|10 chronic HCV genotype 1a (GT1a) infected treatment-naive patients/prior relapsers who will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose ritonavir and ribavirin.
3124567|NCT01724086|Experimental|Panel 2 Arm 1|10 chronic HCV GT1b infected treatment-naive patients/ prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir and ribavirin.
3124568|NCT01724086|Experimental|Panel 2 Arm 2|10 chronic HCV GT1b infected treatment-naive patients/ prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir.
3124569|NCT01724086|Experimental|Panel 3 - Arm 1|8 chronic HCV GT1a infected treatment naïve patients/prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir + ribavirin.
3124570|NCT01724086|Experimental|Panel 3 - Arm 2|8 chronically HCV GT1b infected treatment naïve patients/prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir.
3124571|NCT01724086|Experimental|Panel 4 - Arm 1|20 chronic HCV GT1a or GT1b infected treatment-naive patients/ prior relapsers will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose RTV + GSK2336805 (30 mg once daily)
3124572|NCT01724086|Experimental|Panel 4 - Arm 2|20 chronic HCV GT1a or GT1b infected treatment-naive patients/ prior relapsers will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose RTV + GSK2336805 (60 mg once daily)
3124573|NCT01724073|Experimental|Leafy vegetable-fish sauce|one meal per day, 6 days a week, with leafy vegetable-fish sauce + tô, a local cereal-based paste
3124574|NCT01724073|Experimental|Leafy vegetable-fish/liver sauce|one meal per day, 6 days a week, 5 days with leafy vegetable-fish sauce + tô, 1 day with leafy vegetable-liver sauce + tô
3124575|NCT01724073|Experimental|Misola|one meal per day, 6 days a week, with gruel prepared with the fortified Misola flour
3124576|NCT01724073|No Intervention|no test food|control group receiving no test food
3124581|NCT01724060||Exenatide|Patients due to be commenced on Exenatide
3124582|NCT01724060||Liraglutide|Patients due to be commenced on Liraglutide
3124583|NCT01724060||Lifestyle|Patients due to be commenced on a lifestyle intervention programme
3124584|NCT01724060||Elective surgery or endoscopy|Patients due to have non bariatric surgery (i.e. cholecystectomy) or an elective diagnostic endoscopy
3124585|NCT01724047|Experimental|Playground Intervention|Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed 2) Waitlist treatment, where the training will begin the following school year. The initial delivery will occur for 30 minutes three times for a period of two to three weeks, then 30 minutes two times for a period of two weeks, then 30 minutes once a week for up to 16 sessions, within a period of 3 months, then a 30 minute follow up will occur 3 months later. A systematic fading of intervention using performance feedback, coaching, and consultation. Outcome measures will be administered at entry, end of treatment, and 3-month follow-up. Entry diagnostic, exit and follow up assessments will last 1.5- 2 hours and participants will be assessed after school or in their homes.
3124586|NCT01724047|Experimental|STAT Intervention|Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. The intervention will be over a period of 6 weeks, with baseline, treatment, and a follow up visit totaling 18 weeks at the school site. Each visit is approximately 30 minutes. A systematic fading of intervention using performance feedback, coaching, and consultation. Outcome measures will be administered at entry, end of treatment. Entry diagnostic, exit and follow up assessments will last 1.5- 2 hours and participants will be assessed after school or in their homes.
3124587|NCT01724047|No Intervention|Playground Waitlist Control|Waitlist Control
3124588|NCT01724047|No Intervention|STAT Waitlist Control|Waitlist Control
3124589|NCT01724034|Experimental|Daily Lung Ultrasound|"If there is no lung sliding - evaluation for pneumothorax or mainstream intubation.~If lung ultrasound shows normal pattern - search for reversible airway obstruction or venous embolism. If the patient has COPD, non invasive ventilation must be used as mode of discontinuing mechanical ventilation.~If lung ultrasound shows intersticial syndrome - evaluate the need to negativate hydric balance before the next spontaneous breathing trial.~If findings are asymmetrical - search for new or uncontrolled infection. If there is simple pleural effusion - researchers should determine a negativation of hydric balance or perform thoracocentesis.~If there are signs of complicated pleural effusion - a new image technique should be performed as evaluated by the surgical team."
3124590|NCT01724034|No Intervention|Control Group|
3124591|NCT01724021|Experimental|Arm A|Participants in Arm A received one cycle of rituximab 375 mg/m^2 intravenously (IV), then three cycles of rituximab 1400mg subcutaneously (SC), followed by four cycles of rituximab 375 mg/m^2 IV in combination with a standard chemotherapy of cyclophosphamide, hydroxydaunorubicin, Oncovin, prednisone/prednisolone (CHOP), cyclophosphamide, vincristine, prednisone/prednisolone (CVP), or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
3124592|NCT01724021|Experimental|Arm B|Participants in Arm B received four cycles of rituximab 375 mg/m^2 IV followed by four cycles of rituximab 1400mg SC in combination with a standard chemotherapy of CHOP, CVP, or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
3124593|NCT01723995|Experimental|low-level laser on nipples|Application of laser light from the device in direct contact with the nipple injury, equipment connected and set up at a dose of 5J/cm2 (Epoint = 0.2J/cm2) for both groups, three consecutive doses of 5J/cm2 (ETotal = 0.6J/cm2) along the entire length of the injury.
3124594|NCT01723995|Placebo Comparator|low-level laser off on nipples|Laser with modified standard operation - shutdown of InGaAIP semiconductor diode and installation of a visible red light emitting diode with optical power of 0mW (LED - Light Emitting Diode - maximum power with standard nozzle).
3124595|NCT01723982|Experimental|A. FE 200440|Barusiban (FE 200440) Solution for Injection for Subcutaneous use
3124596|NCT01723982|Placebo Comparator|B. Placebo|Placebo Solution for Injection for Subcutaneous use
3124597|NCT01723969||Colo-rectal cancer|Tumour markers testing in patients with advanced or metastatic colo-rectal cancer
3124598|NCT01723956|Active Comparator|Arm B|LEEP treatment of CIN 2/3 cervical lesion in HIV positive women (standard of Care)
3124599|NCT01723956|Experimental|Arm A|Cryotherapy treatment of CIN 2/3 cervical lesions
3124600|NCT01723943|Active Comparator|Arm I (educational booklet)|"Participants receive the What's Happening to the Woman I Love? booklet, which focuses on ways to understand and deal with marital communication and relationship issues arising from breast cancer diagnosis."
3124601|NCT01723943|Experimental|Arm II (Helping Her Heal program)|"Participants undergo the Helping Her Heal educational counseling program comprising 5 1-hour sessions 2 weeks apart.~SESSION I: Participants learn stress management skills and discover ways stress affects themselves and their partner.~SESSION II: Participants practice attentive listening and reduce the tendency to try to distract patients from talking about sad or difficult aspects of the cancer experience.~SESSION III: Patients learn to help their spouse talk when she is quiet or withdrawn, to add to their understanding of what she is thinking and feeling, and to add to their ways of supporting her during especially difficult times with the cancer.~SESSION IV: Participants learn strategies for physically reconnecting with spouses.~SESSION V: Participants review skills from prior sessions, identify strategies he or she will continue to use to manage their personal stress, and identify ways to maintain connection and support."
3124602|NCT01723917|Experimental|PhytoSERM 50 mg tablet|Dietary supplement: PhytoSERM tablet to be taken once per day for 12 weeks
3124603|NCT01723917|Experimental|PhytoSERM 100 mg tablet|Dietary supplement: PhytoSERM tablet to be taken once per day for 12 weeks
3124604|NCT01723917|Placebo Comparator|Placebo tablet|Dietary supplement: placebo tablet to be taken once per day for 12 weeks
3124707|NCT01723215|Active Comparator|Active ABMT8|Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
3124852|NCT01722266|Active Comparator|Liraglutide 1.2mg|Daily injections
3124605|NCT01723904|Experimental|Rotigotine|"- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.~Duration of the Titration Period: Between 1 week and 5 weeks.~- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.~Duration of the Maintenance Period: Between 3 weeks and 7 weeks."
3124606|NCT01723891|Active Comparator|Surfolase capsule & HT-002-01|
3124607|NCT01723891|Active Comparator|HT-002-01 & Surfolase capsule|
3124608|NCT01723878||Cohort|
3124609|NCT01723865||Conventional|Patients with heart failure having an ICD-CRT implanted, followed by conventional visits.
3124610|NCT01723865||Remote Monitoring|Patients with heart failure having an ICD-CRT implanted, followed by remote monitoring.
3124611|NCT01723852|Active Comparator|Vitamin D supplement|Vitamin D supplement according to national guidelines (10 ug/day) from 2 weeks to 2 years of age
3124612|NCT01723852|Active Comparator|Vitamin D supplement at 30 ug/day|Vitamin D supplement at 30 ug/day from 2 weeks to 2 years of age
3124613|NCT01723839|Other|FCR with Lenalidomide|Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide - 19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity. If there are at least 5 CRs after 4 cycles of FCR plus lenalidomide the study will accrue an additional 35 subjects.
3124614|NCT01723826|Experimental|Crenezumab|Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
3124615|NCT01723813|Experimental|Group 1 : peptides + GM-CT-01 IV|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2 plus Galectin-3 inhibitor: GM-CT-01 systemic injections
3124616|NCT01723813|Experimental|Group 2 : peptides + GM-CT-01 IV+PT|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2 plus Galectin-3 inhibitor: GM-CT-01 systemic injections and Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration
3124617|NCT01723800|Experimental|Treatment (pemetrexed, carboplatin, PI3K inhibitor BKM120)|Patients receive pemetrexed disodium IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1, and PI3K inhibitor BKM120 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may receive courses of PI3K inhibitor BKM120 alone or PI3K inhibitor BKM120 and pemetrexed disodium after 4-6 courses with carboplatin in the absence of unacceptable toxicity or disease progression.
3124618|NCT01723787||Infantile Spasms|Participants retrospectively identified to have been treated with ACTH according to FDA-approved protocol for Infantile Spasms
3124619|NCT01723787||biological parents|Biological parents of participants retrospectively identified to have been treated with ACTH according to FDA-approved protocol for Infantile Spasms
3124620|NCT01723774|Experimental|Arm 1: PIK3CA Wild Type Cohort|"Tumor biopsy for testing/research at baseline and Cycle 1 Day 15~Cycle 0 is 28 days of anastrozole PO daily and, if premenopausal, goserelin SC every 28 days.~Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)~Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.~Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
3124621|NCT01723774|Experimental|Arm 2: PIK3CA Mutant Type Cohort|"Tumor biopsy for testing/research at baseline and Cycle 1 Day 15~Cycle 0 is 28 days of anastrozole PO daily and, if premenopausal, goserelin SC every 28 days.~Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)~Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.~Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
3124622|NCT01723774|Experimental|Arm 3: Endocrine Resistant Cohort|"Tumor biopsy for testing/research at baseline and Cycle 1 Day 15~Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)~Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.~Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
3124623|NCT01723748|Active Comparator|surgery treated|"10 patients with well-controlled acromegaly for at least 6 months after surgery alone.~Stimulated with genotropin"
3124624|NCT01723748|Active Comparator|SA treated|10 patients with well-controlled acromegaly for at least 6 months after SA treatment Stimulated with genotropin
3124625|NCT01723735|Experimental|Alirocumab + Ezetimibe Placebo|Subcutaneous (SC) injections of alirocumab added to oral administration of ezetimibe placebo
3124626|NCT01723735|Experimental|Alirocumab + Ezetimibe|Subcutaneous (SC) injections of alirocumab added to oral administration of ezetimibe
3124627|NCT01723735|Experimental|Alirocumab + Fenofibrate|Subcutaneous (SC) injections of alirocumab added to oral administration of fenofibrate
3124708|NCT01723215|Active Comparator|Active ABMT4|Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
3124709|NCT01723215|No Intervention|Control|Control: will not receive any intervention
3124710|NCT01723215|Placebo Comparator|Placebo|Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns
3124628|NCT01723722|Active Comparator|1 (Phenobarbital and Methadone)|"The following is a dosing guide for methadone:~The neonatal concentration is 1 mg/ml of methadone. It is administered orally every 12 hours.~For the first 24 hours, doses will be prescribed every 6 hours using a sliding scale in response to the last NAS score:~NAS Score Methadone dose 8-11 0.05 mg/kg/dose 12-15 0.1 mg/kg/dose~≥16 0.15 mg/kg/dose~Maximum dose of methadone will be 0.15 mg/kg/dose.~After the first 24 hours of treatment, the total methadone dose will be summed and that dose divided into two doses, given 12 hours apart. For the following 24 hours, additional doses may be given every 6 hours as needed and added to the next 24 hour's doses divided every 12 hours, until NAS scores are consistently <8 for 48 hours.~If at any pointthe maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the dDTO arm."
3124629|NCT01723722|Active Comparator|2 (Phenobarbital and Diluted Deodorized Tincture of Opium)|"The following is a dosing guide for dDTO:~The neonatal concentration is 1:24 dilution for a concentration of 0.4%, equivalent to 0.4 mg/ml of morphine. It is administered orally every 4 hours.~The starting dose will be determined using a sliding scale in response to the last NAS score before starting.~NAS Score Starting dDTO dose 8-11 0.4 mg/kg/day 12-15 0.6 mg/kg/day~≥16 0.8 mg/kg/day~The maximum dose of DTO will be 0.8 mg/kg/day.~After the first 24 hours of treatment, if the NAS scores are still ≥8, the dose will be increased to the next level.~If at any point the maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the methadone arm."
3124630|NCT01723696|Placebo Comparator|placebo tablet+prenatal vitamin|A daily placebo tablet
3124631|NCT01723696|Active Comparator|Vitamin C +prenatal vitamin|
3124632|NCT01723683|Experimental|MISTCPAP group|MISTCPAP group: Surfactant will be instillated via the Angio-Cath without endotracheal intubation and followed by CPAP.
3124633|NCT01723683|Active Comparator|INSURE group|INSURE group: The procedure of surfactant treatment should be according to the conventional surfactant treatment which involves intubation, surfactant divided to 4 liquors to inject into 4 positions followed by amubagging and then extubation to CPAP.
3124634|NCT01723670|Experimental|CHF 5074 1x|oral tablet, multidose
3124635|NCT01723670|Experimental|CHF 5074 2x|oral tablet, multidose
3124636|NCT01723670|Placebo Comparator|Placebo|placebo, oral tablet, multidose
3124637|NCT01723657|Other|Risk-adapted postremission treatment.|Ara-C, G-CSF, Autologous peripheral blood stem cell transplantation, Allogeneic matched related or unrelated donor transplant, G-CSF Priming, CD34+ selection, Myeloablative or reduced intensity conditioning, Mylotarg purging before autologous PBSC transplantation.
3124638|NCT01723644|Other|PCT guidance|"Group of patient  Procalcitonin  where the initiation and the stop of the antibiotic treatment are made according to a strategy guided by the PCT"
3124639|NCT01723644|Other|clinical reassessment|Group of patient where the initiation and the stop of the antibiotic treatment make following on clinical criteria and paraclinic not including the PCT.
3124640|NCT01723631|Other|Relapsing Multiple Sclerosis- group 1|Definite multiple sclerosis according to the McDonald criteria, relapsing Patient innocent of thorough treatment or treatment immunomodulator stopped for at least 6 months.
3124641|NCT01723631|Other|Relapsing Multiple Sclerosis- group 2|Multiple sclerosis defined according to the criteria of McDonald, relapsing Patient under treatment immunomodulator for at least 6 months.
3124642|NCT01723631|Other|secondary progressive multiple sclerosis- Group 3|Multiple sclerosis defined according to the criteria of McDonald, secondary progressive multiple sclerosis
3124643|NCT01723631|Other|primary progressive multiple sclerosis- group 4|Multiple sclerosis defined according to the criteria of McDonald, primary progressive multiple sclerosis
3124644|NCT01723631|Other|control 1|healthy volunteers
3124645|NCT01723631|Other|Control 2|Patients with central or peripheral neurological non-inflammatory, non-autoimmune.
3124646|NCT01723631|Other|Control 3|Patients having an autoimmune pathology
3124647|NCT01723618|Experimental|CRD007 10 mg|CRD007, 10 mg tablet, single dose
3124648|NCT01723618|Experimental|CRD007 25 mg|CRD007, 25 mg tablet, single dose
3124649|NCT01723618|Experimental|CRD007 40 mg|CRD007, 40 mg tablet, single dose
3124650|NCT01723605|Experimental|insitu repair|insitu repair of the uterine incision during caeserean section
3124651|NCT01723605|Active Comparator|exteriorisation of the uretus|uterine closure during caeserian section with exteriorisation of the uterus
3124652|NCT01723592|Placebo Comparator|Placebo|30 participants in this group receive a oral lactose placebo
3124653|NCT01723592|Active Comparator|Probiotics|"30 participants in this group receiving oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains belonging to the species:~L.rhamnosus/ LbV96 (DSM 22560)~L.jensenii /LbV 116 (DSM 22567)~L.crispatus/ Lbv88 (DSM 22566)~L.gasseri /LbV 150N (DSM 22583)"
3124654|NCT01723579|Experimental|NOMAC-E2 2.5 mg/1.5 mg|Participants will receive combined oral contraceptive NOMAC-E2 2.5 mg/1.5 mg tablet for 13 consecutive 28-day cycles. Each 28-day cycle with consist of 24 active tablets and 4 placebo tablets taken at approximately the same time each day.
3124655|NCT01723553|Experimental|PiB positron emission tomography (PET)|All subjects will receive PET imaging with C-11 PiB on approximately day 1 or day 2 of study to determine if they have beta-amyloid deposits in their brains.
3124656|NCT01723540|Experimental|Minilaparotomy cholecystectomy with ultrasonic scissors|Minilaparotomy vs laparoscopy
3124657|NCT01723540|Active Comparator|Laparoscopic cholecystectomy|Minilaparotomy vs laparoscopy
3124658|NCT01723527|Experimental|Therapeutic Workplace|Participants assigned to this condition will receive the standard services and requirements for diversion as described for the usual care group, and will also be eligible to attend the three-phase Therapeutic Workplace (TW) intervention. All phases of this intervention include employment-based drug abstinence reinforcement contingencies. Under these contingencies, participants can work and earn wages or wage subsidies contingent upon drug abstinence as verified by urinalysis. Phase 1 of the TW intervention is expected to increase cocaine abstinence and to prepare participants for employment. Phase 2 of the TW intervention is expected to maintain abstinence while participants are employed in an onsite model workplace. Phase 3 is designed to increase employment in community jobs and to maintain abstinence while participants are employed in offsite community workplaces.
3124787|NCT01722669|Active Comparator|isoquercetin|Single dose of isoquercetin with or without ascorbic acid
3200568|NCT01194336||Donepezil: 2.5 mg|
3124659|NCT01723527|Active Comparator|Diversion to treatment (Usual Care)|Participants in this condition will be offered the standard treatment services available in community methadone and buprenorphine programs, including medication (methadone or buprenorphine, respectively), counseling services, HIV testing, and case management. All services will be provided in the treatment clinics. There are a number of clinics within easy walking distance from the research site, and others throughout the city that are reachable by public transportation from the research site. In addition, all participants will receive referrals to the Re-Entry Center, a One-Stop Career Center tailored to the needs of offenders, at all intake and monthly assessments. As mentioned in detail above, participants will be required by the court to stay enrolled in treatment for 90 days. It is important to note that all diverted individuals will receive these services and requirements, independent of whether they agree to participate in the pilot study.
3124660|NCT01723514|Active Comparator|AMG 334 Treatment A|3 dose levels administered as multiple SC doses in healthy subjects and migraine patients
3124661|NCT01723514|Placebo Comparator|AMG 334 Treatment B|3 dose levels administered as multiple SC doses in healthy subjects and migraine patients
3124662|NCT01723501|Placebo Comparator|sterile water|sterile water wipes
3124663|NCT01723501|Experimental|0.25% chlorhexidine|0.44% chlorhexidine digluconate wipes which will release 0.25% free chlorhexidine
3124664|NCT01723488|Experimental|Tau diagnostic|Experimental: Tau diagnostic [F18] T808
3124665|NCT01723475|Experimental|BAY2010112 (s.c.)|
3124666|NCT01723475|Experimental|BAY2010112 (c.i.v.)|
3124667|NCT01723436|No Intervention|DLST Only|Surrogates will complete the Stroop test then answer the hypothetical life sustaining therapy (LST)
3124668|NCT01723436|Experimental|Contemplate only|Surrogates will contemplate each of the 3 scenarios but not make any decisions, then complete the Stroop test and answer the hypothetical LST question
3124669|NCT01723436|Experimental|Decide with advice|Surrogates will make decisions on 4 scenarios with physician advice, then complete the Stroop test and answer the hypothetical LST question. Within this arm, surrogates will receive two positive recommendations (i.e. to go ahead with the intervention) and two negative recommendations (i.e. to decline the intervention). These positive and negative recommendations will be randomly assigned upon study enrollment. With four hypothetical scenarios, there are six possible options for recommendation variations.
3124670|NCT01723436|Experimental|Decide without advice|Surrogates will make decisions on 4 scenarios without physician advice, then complete the Stroop test and the hypothetical LST question.
3124671|NCT01723423||Expander/Implant|Patients receiving expander/implant breast reconstruction procedures.
3124672|NCT01723423||Lat Dorsi|Patients receiving latissimus dorsi breast reconstructions with or without implant.
3124673|NCT01723423||PTRAM|Patients receiving pedicle transverse rectus abdominis musculocutaneous (PTRAM)breast reconstruction.
3124674|NCT01723423||FTRAM|Patients receiving free transverse rectus abdominis musculocutaneous (FTRAM.)
3124675|NCT01723423||DIEP|Patients receiving deep inferior epigastric perforator (DIEP) breast reconstructions.
3124676|NCT01723423||SIEA|Patients receiving superficial inferior epigastric artery (SIEA)breast reconstruction.
3124677|NCT01723423||S-GAP|Patients receiving superior gluteal artery perforator breast reconstruction.
3124678|NCT01723423||I-GAP|Patients receiving inferior gluteal artery perforator breast reconstruction.
3124679|NCT01723410|Experimental|Writing condition|Subjects will be asked to write about other individuals in their lives.
3124680|NCT01723410|Placebo Comparator|Writing|Subjects will be asked to write about places or objects in their lives.
3124681|NCT01723397|Active Comparator|Nasaleze spray|"Nasaleze spray 1 puff via spray device in each nostril 3 times daily for 1 week followed by allergen challenge"
3124682|NCT01723397|Placebo Comparator|Placebo spray|"Placebo spray 1 puff via spray device in each nostril 3 times daily for 1 week followed by allergen challenge"
3124683|NCT01723384|Active Comparator|Naltrexone|Intermittent oral naltrexone to be taken on an as-needed basis for 8 weeks.
3124684|NCT01723384|Placebo Comparator|Placebo|Intermittent oral placebo to be taken on an as-needed basis for 8 weeks
3124685|NCT01723371|Experimental|Carvedilol|
3124686|NCT01723358|Experimental|Neuromuscular electrical stimulation (NMES)|
3124687|NCT01723345|Active Comparator|omega 3|receive omega 3 in addition to standard treatment
3124688|NCT01723345|No Intervention|control|just receive standard treatment
3124689|NCT01723332|Experimental|Intervention|Clinical based educational and self management intervention.
3124690|NCT01723332|No Intervention|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies.
3124691|NCT01723319|Experimental|1|deep TMS treatment
3124692|NCT01723319|Sham Comparator|2|inactive treatment
3124693|NCT01723306|Experimental|2nd Generation Designer T Cells|All participants will receive gene modified T cells, with concomitant IL2 for 30 days post infusion.
3124694|NCT01723293|No Intervention|Control|Sedentary pregnant women
3124695|NCT01723293|Experimental|Exercise group|
3124696|NCT01723280||80% oxygen group|
3124697|NCT01723280||30% oxygen group|
3124698|NCT01723267|Active Comparator|3D follicles assessment|During IVF treatment all ultrasound examinations will use 3D- SonoAVC technology. Timing of hCG injection and oocyte collection will be based on follicle volume and 3D-volume based diameter.
3124699|NCT01723267|Active Comparator|2D follicles assessment|During IVF treatment all ultrasound examinations will use standard 2D ultrasound. Timing of hCG injection and oocyte collection will be based on follicle diameter.
3124700|NCT01723254|Experimental|PF-06444753|
3124701|NCT01723254|Experimental|PF-06444752|
3124702|NCT01723254|Placebo Comparator|Placebo|Intramuscular
3124703|NCT01723241|Experimental|XAF5|
3124704|NCT01723241|Placebo Comparator|Placebo|
3124705|NCT01723228|Experimental|Rasagiline 1.0 mg/day|Rasagiline 1 mg oral tablets once daily for 24 weeks
3124706|NCT01723228|Placebo Comparator|Placebo|Placebo oral tablets once daily for 24 weeks
3124788|NCT01722656|Other|Aflibercept|All subjects will receive aflibercept
3200569|NCT01194336||Donepezil: 5 mg|
3124711|NCT01723202|Experimental|Arm A: GSK2118436|Patients receive dabrafenib orally 2 twice a day on days 1-28. Patients with disease progression may cross over to arm II.
3124712|NCT01723202|Experimental|Arm B: GSK2118436 and GSK1120212|Patients receive dabrafenib orally twice a day and trametinib orally once a day on days 1-28.
3124713|NCT01723202|Other|Correlative Studies|Tumor pharmacodynamics (PD) evaluation,BRAF mutation quantification in circulating plasma DNA,Tumor mutation screening/Mechanisms of Drug Resistance,Predictive Markers of Response (Archival Tumor Block),Pharmacokinetics(PK,Pharmacogenetics (PGx)
3124714|NCT01723189||Central Apnoeas Patients|• 30 patients diagnosed with TIA / ischemic stroke within 7 days of admission and evidence at polysomnography of central apnoea (central apnoea index> 10 / h, or Cheyne-Stokes breathing for more than 30% of total sleep time or mixed apneas with central apnoeas> 50% of total apneas)
3124715|NCT01723189||Obstructive apnoea patients|• 30 patients diagnosed with TIA / ischemic stroke within 7 days of admission and evidence at polysomnography of obstructive sleep apnea (apnea-hypopnea index> 20 / h)
3124716|NCT01723189||No SDB patients|• 30 patients diagnosed with TIA / stroke within 7 days of admission and no evidence of sleep respiratory disorders at polysomnography
3124717|NCT01723189||Healthy controls|• 30 healthy controls matched for age, sex, race and BMI.
3124718|NCT01723176||Patients in Cardiopulmonary Failure|patients in cardiopulmonary failure
3124719|NCT01723163|Experimental|Arm 1|Abstinence Reinforcement Therapy (ART)
3124720|NCT01723163|Other|Arm 2|Telephone Counseling
3124721|NCT01723150|Experimental|Oral antibiotics|The intervention arm switched to oral antibiotics to complete 4 weeks of therapy. Oral antibiotics will be ciprofloxacin (or trimethoprim/sulfamethoxazole if the isolate is resistant).
3124722|NCT01723150|Active Comparator|Intravenous antibiotics|The active comparator arm continues intravenous antibiotics to complete 4 weeks of therapy. Intravenous antibiotics will be ceftriaxone (or ertapenem if the isolate is resistant).
3124723|NCT01723137||In pain|Patients who report pain greater than or equal to 3 out of 10 are eligible for this study.
3124724|NCT01723124|Experimental|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
3124725|NCT01723111||Peritoneal dialysis|start PD
3124726|NCT01723111||Hemodialysis|start HD
3124727|NCT01723098|No Intervention|Control|Sedentary pregnant women
3124728|NCT01723098|Experimental|Exercise group|
3124729|NCT01723085||Open myomectomy|All patients belong to the same group Description includes the surgical technique
3124730|NCT01723072|Experimental|1 Omalizumab|omalizumab once a month via subcutaneous injection.
3124731|NCT01723072|Placebo Comparator|2 Placebo|placebo of omalizumab once a month via subcutaneous injection
3124732|NCT01723059|Other|Standard triple therapy|Gold standard for management of H pylori is amoxicillin 1 gm twice daily, clarithromycin 500 mg twice daily, and omeprazole 20 mg twice daily for 10 days.
3124733|NCT01723059|Active Comparator|Sequential Therapy|Amoxicillin 1 gm twice daily and omeprazole 20 mg twice daily for 5 days followed by metronidazole 500 mg twice daily, clarithromycin 500 mg twice daily, and omeprazole 20 mg twice daily for 5 days.
3124734|NCT01723046|Experimental|Training with the device|Training with new upper limb robot assisted therapy device
3124735|NCT01723046|No Intervention|Control group|The control group is treated with conventional therapy.
3124736|NCT01723033||EEG acquisition|15 PTSD patients and 15 OCD patients who will, while wearing a net of electrodes for EEG acquisition on their heads, perform three error detection tasks.
3124737|NCT01723033||Control|Previously collected healthy student's data
3124738|NCT01723020|Experimental|AMG 232|AMG 232 is an anti-cancer agent.
3124739|NCT01723007|Experimental|Other: Apple|Women were supplemented with apples. Sixteen women were asked to ingest three apple daily between meals ( approximately 120g kcal) between meals (breakfast, lunch and dinner).
3124740|NCT01723007|Active Comparator|Other: oatmeal cookies|A another group with nineteen women were asked to ingest three oatmeal cookies a day, approximately 60g and similar caloric content to experimental group (approximately 120 kcal) between meals (breakfast, lunch and dinner).
3124741|NCT01723007|Active Comparator|Other: Pear|Women were supplemented with pear. Sixteen women were asked to ingest daily three pears (approximately 120 kcal) between meals daily (breakfast, lunch and dinner).
3124742|NCT01722994|Experimental|Group 1 Punch Biopsy Wound with chromic gut suture|One of two absorbable sutures is used to close punch wounds.
3124743|NCT01722994|Experimental|Group 2 Punch Biopsy Wound with PDS|This is one of two absorbable sutures used to close punch biopsy wounds.
3124744|NCT01722981|Active Comparator|Direct laryngoscopy|Performing percutaneous tracheostomy as accepted in our institute: By placing the tube higher up near the vocal cords by direct laryngoscopy. In the second stage tracheal perforation by a needle will be carried out by palpation of the anatomical placement of the neck.
3124745|NCT01722981|Active Comparator|Real time sonography|"Percutaneous tracheostomy will be guided by real time sonography (with the visualization of the needle path) using acoustic shadows of the cricoid and the tracheal rings.~In both methods, in order to identify the anatomic location of the needle prick- after passing the guide wire, the front elevation will be verified by optical means, which will be drawn out immediately afterwards."
3124746|NCT01722981|Active Comparator|Bronchoscopy|Percutaneous tracheostomy will be guided by bronchoscopy. Initially, the tube will be placed according to the desired height observed by the bronchoscope, phase two will be tracheal perforation by a needle under trans illumination and real-time view on the income of the needle and the passage of the guide wire.
3124747|NCT01722968|Active Comparator|Arm A|Arm A and feasibility phase: Bevacizumab 15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly.
3124748|NCT01722968|Active Comparator|Arm B|Arm B: Paclitaxel 80mg/m2 iv weekly.
3124749|NCT01722955|Experimental|Pre-warmed fluids|Pre-warmed fluids will be prepared for 8hous in 41℃ set hot cabinet.
3124750|NCT01722955|Experimental|Room temperature fluids|Room temperature fluids will be stored at ambient temperature.
3124853|NCT01722266|Active Comparator|Liraglutide 0.6 mg|Daily injection
3125068|NCT01720784|Placebo Comparator|Placebo|
3124751|NCT01722942|Active Comparator|ICD group|ICD implantation will be performed according to the Institution protocol of each participating center; single-chamber devices are preferred and programming should prioritize the patient's own pace, avoiding ventricular stimulation.
3124752|NCT01722942|Active Comparator|Amiodarone Group|"Patients randomized for this group will receive amiodarone hydrochloride (once a day) according to the following regimen:~Initial oral loading dose of 600 mg/day for 10 days on an outpatient basis;~After the loading period, an oral dose between 200 and 400 mg/day should be maintained until study termination. The determination of the optimal maintenance dose will be left at the discretion of each investigator; this dose may be based on the therapeutic response on 24-hour Holter monitoring, resting heart rate (HR), side effects, prolonged corrected QT interval (QTc), etc. Dose adjustments will be allowed throughout the study period provided the maintenance dose is kept between 200 and 400 mg/day. If the patient cannot tolerate the minimum 200 mg/day dose, amiodarone should be discontinued permanently and treatment should be considered interrupted."
3124753|NCT01722929|Experimental|Skin sensor on surgery side|Skin sensor will be placed on the side that had surgery. This is split-body, interventional, parallel-design study. All participants will have the skin sensor measured twice on their bodies: on the side with surgery and a contralateral, control site of the body.
3124754|NCT01722929|Active Comparator|Skin sensor on non-surgery side|Skin sensor will be placed on the contralateral side from surgery site.This is split-body, interventional, parallel-design study. All participants will have the skin sensor measured twice on their bodies: on the side with surgery and a contralateral, control site of the body.
3124755|NCT01722916|Experimental|Dose of Hyaluronidase|
3124756|NCT01722903||Stage IV colorectal cancer|CTCs will be drawn during liver and/or lung metastasectomy for colorectal cancer
3124757|NCT01722890||Cohort 1|TNM stage II-IV breast cancer patients with highly trastuzumab-sensitive tumours.
3124758|NCT01722890||Cohort 2(Control Group)|TNM stage II-IV breast cancer patients with trastuzumab-refractory disease.
3124759|NCT01722877|Experimental|JetStream Atherectomy|Jetstream NAVITUS System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic disease and thrombus in peripheral vasculature.
3124760|NCT01722864|Experimental|COV155|COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 10 to 35 days.
3124761|NCT01722851||Newly diagnosed breast cancer patients|All newly diagnosed breast cancer patients who are scheduled to undergo neoadjuvant chemotherapy will be recruited and enrolled into this study at the time of diagnosis, pending gaining informed consent.
3124762|NCT01722851||Recurrent breast cancer patients|All patients with a history of breast cancer who represent with disease recurrence or progression, and are commencing up-front hormonal therapy or chemotherapy, will also be recruited and enrolled.
3124763|NCT01722838|Experimental|B-ME intervention|Men will receive behavioral HIV prevention intervention, B-ME.
3124764|NCT01722838|No Intervention|Control Arm|Men in this arm will receive monthly text or telephone voice messages relaying general health messages.
3124765|NCT01722825|Experimental|LY2157299|80 up to 150 milligrams of LY2157299 administered orally, twice daily for 14 days, followed by 14 days with no study drug (2 weeks on/2 weeks off schedule) for at least two 28 day cycles. Participants receiving clinical benefit may continue receiving treatment until discontinuation criterion is met.
3124766|NCT01722812|Other|Placebo (left) / Cromoglicate (right)|Placebo (on a lesion on left bodyside), Cromoglicate (on a lesion on right bodyside)
3124767|NCT01722812|Other|Placebo (right) / Cromoglicate (left)|Placebo (on a lesion on right bodyside), Cromoglicate (on a lesion on left bodyside)
3124768|NCT01722799|Experimental|Drug elluting Balloon (DEB)|Is a coronary dilating device with Paclitaxel ® drug delivery, for dilatation and provisional spot bare metal stenting (BMS).
3124769|NCT01722799|Active Comparator|Drug elluting coronary stent (DES)|The Resolute Integrity Zotarolimus-Eluting Coronary Stent System is indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length ≤ 27 mm in native coronary arteries with reference vessel diameters of 2.25 mm to 4.20 mm.
3124770|NCT01722786||DOA|"Expected number of patients estimated by study duration~N= 90 patients treated with direct oral anticoagulants (DOA) with acute bleeding~N= 40 patients treated with direct oral anticoagulants (DOA) with urgent surgical intervention"
3124771|NCT01722786||VKA|"Expected number of patients estimated by study duration~N= 90 treated with vitamin K antagonists (VKA) with acute bleeding~N= 40 patients treated with vitamin K antagonists (VKA) with urgent surgical intervention"
3124772|NCT01722773|Active Comparator|Bipap|Bipap
3124773|NCT01722773|No Intervention|Standard of care|No intervention
3124774|NCT01722760||Term and preterm infants|Term and preterm infants
3124775|NCT01722747|Experimental|Intervention Condition|Tobacco Free Teachers, Tobacco Free Society (TFT/TFS)
3124776|NCT01722747|No Intervention|Delayed Intervention Control condition|Receives abbreviated 3-month delayed intervention after final data collection time point
3124777|NCT01722734|No Intervention|Control|Patients in the control arm only got a generic health message at the end of the study.
3124778|NCT01722734|Active Comparator|Short Message|Patients in this arm receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals.
3124779|NCT01722734|Active Comparator|Long message|Patients in this arm receive six long text message reminders (reminders including justification for why patients should finish medication) within 60 hours of treatment initiation at 12 hour intervals.
3124780|NCT01722708|Experimental|clindamycin|
3124781|NCT01722708|Experimental|metronidazole|
3124782|NCT01722695|Other|Revaclear followed by FX|
3124783|NCT01722695|Other|FX followed by Revaclear|
3124784|NCT01722682|Active Comparator|A: intraportal islet infusion|Patients will received islet into the liver through the portal venous circulation (standard procedure)
3124785|NCT01722682|Experimental|B: intra BM islet infusion|Patients will received an intra BM islet infusion at the level of the iliac crest. The direct intra BM administration will be performed following the same procedures that our institution utilizes for administration of cord-blood cells in patients with acute leukemia (Lancet Oncol. 2008;9:831). The procedure is easy and reproducible: a standard needle for BM aspiration is inserted in the iliac crest and cells are gently infused.
3124786|NCT01722669|Experimental|Quercetin|Single dose of quercetin with or without ascorbic acid
3124789|NCT01722643|Experimental|MAxIM|This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
3124790|NCT01722643|Active Comparator|Usual Care|Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment—quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
3124791|NCT01722630|No Intervention|control|Patients received intravenously saline solution at 5 ml/Kg/h
3124792|NCT01722630|Experimental|dopamine|Patients received intravenously saline solution at 5 ml/Kg/h and dopamine at 3 mcg/Kg/min
3124793|NCT01722630|No Intervention|crystalloids|Patients received intravenously saline solution at 10 ml/Kg/h
3124794|NCT01722617|No Intervention|DAS 28|Patients in this group will be asked to fill basic questionnaires, but without the FLARE questionnaires.
3124795|NCT01722617|Active Comparator|DAS 28 + FLARE questionnaires|Patients in this group will be asked to fill basic questionnaires and FLARE questionnaires.
3124796|NCT01722617|Active Comparator|DAS 28+FLARE + information to doctor|Patients in this group will fill basic and FLARE questionnaires which then will be transmitted to physician.
3124797|NCT01722604|Active Comparator|Azopt 1% ophthalmic suspension|Ophthalmic suspension
3124798|NCT01722604|Experimental|Brinzolamide 1% ophthalmic suspension|ophthalmic suspension
3124799|NCT01722591|Experimental|Cardiapex device|Use of the Cardiapex device in the context of transapical TAVI procedures
3124800|NCT01722578|Experimental|L-ornithine L-aspartate|L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
3124801|NCT01722578|Placebo Comparator|Placebo (sterile water)|Placebo (sterile water, 6 ampuoles of 10 ml each) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
3124802|NCT01722565|Experimental|Mesh Group|Patients receiving conventional sigmoid end colostomy plus a preperitoneal lightweight mesh Physiomesh® by laparoscopic procedure
3124803|NCT01722565|No Intervention|Control Group|Patients receiving conventional sigmoid end colostomy by laparoscopic procedure, without mesh
3124804|NCT01722552|Experimental|adherence feedback|Intervention subjects will receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time (as indicated by lack of a Wisepill opening). They will then participate in monthly interactive counseling sessions using summaries of their previous month's behavior. Patients whose mean adherence in the previous month was <95% will be required to have a counseling session, while those with higher adherence will be given the option to have a counseling session.
3124805|NCT01722552|Active Comparator|standard of care|Control subjects will use the electronic monitoring devices just like the intervention arm, but will receive standard of care. They will not receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time, and they will not have access to the summaries of their previous month's behavior for use in interactive counseling sessions, though they will be encouraged to engage in counseling.
3124806|NCT01722539|Experimental|Sulfadoxine-Pyrimethamine|"Sulfadoxine-Pyrimethamine every Four months Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more; Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
3124807|NCT01722539|Experimental|Sulfadoxine-Pyrimethamine+Piperaquine|"Sulfadoxine-Pyrimethamine every 4 months Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more; Piperaquine every four months Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.~Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
3124808|NCT01722539|Active Comparator|Control|"Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
3124809|NCT01722526|Experimental|Recombinant human acid sphingomyelinase|Participants will receive rhASM of an initial dose of 0.1 mg/kg, followed by several dose escalations, as tolerated, up to 3.0 mg/kg. All doses are given 2 weeks apart.
3124810|NCT01722513|Experimental|Alprostadil, Control|Alprostadil interventions: Alprostadil 40 ug + 1cc/kg/hr normal salin 6 hour before and after angiography AND Control interventions:Normal salin 1cc/kg/hr before and after angiography
3124811|NCT01722500||10 year old children|500 children with mean age 10.5 years from each of 12 countries
3124849|NCT01722279||Bariatric surgery patients, at least 5 years post-surgery|Survey participants had bariatric surgery at the St. Vincent Bariatric Center of Excellence at least 5 years before completing survey.
3124850|NCT01722266|Placebo Comparator|Placebo|Daily Injection
3124812|NCT01722487|Experimental|Ibrutinib|Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
3124813|NCT01722487|Active Comparator|Chlorambucil|Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle.The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
3124814|NCT01722474|Experimental|ASI Device|Study Participants will attend the research clinic one time (one visit) for the vascular testing. Each instrument/assessment will be run sequentially starting with the Arterial Stiffness Screening Device, then followed by SphygmoCor system, which will then be followed by the CR-2000 CV Profiler, then finally the VP-1000.
3124815|NCT01722461|Experimental|Active treatment|Ulthera System treatment
3124816|NCT01722461|Sham Comparator|Sham treatment|Ulthera System delivering no ultrasound energy
3124817|NCT01722448|Experimental|Choline|Phosphatidyl choline
3124818|NCT01722448|Placebo Comparator|Placebo|Vegetable oil
3124819|NCT01722435||OST completers|Patients who are likely to complete OST during the next 12 or 18 months
3124820|NCT01722422|Placebo Comparator|normoxia and isotonic saline|Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with isotonic saline during 3 days.
3124821|NCT01722422|Active Comparator|normoxia and 3% hypertonic saline|Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with 3% hypertonic saline during 3 days.
3124822|NCT01722422|Active Comparator|hyperoxia and isotonic saline|"Administration of oxygen with FiO2 = 100% during the first 24 hours and after switch oxygen administration to usual care.~Fluid resuscitation if needed with isotonic saline during 3 days."
3124823|NCT01722422|Active Comparator|hyperoxia and 3% hypertonic saline|"Administration of oxygen with FiO2 = 100% during the first 24 hours and after switch oxygen administration to usual care.~Fluid resuscitation if needed with 3% hypertonic saline during 3 days."
3124824|NCT01722409|No Intervention|sevoflurane and saline infusion|After induction of general anesthesia, Group S received a placebo infusion of normal saline.
3124825|NCT01722409|Experimental|sevoflurane and 0.5 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
3124826|NCT01722409|Experimental|sevoflurane and 1 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
3124827|NCT01722396|Experimental|Vitamin D|
3124828|NCT01722383||Chronic kidney disease|Stages 3-5 chronic kidney disease (pre-dialysis)
3124829|NCT01722370|Placebo Comparator|Medical air equivalent|Oxygen-nitrogen mix equivalent to medical air when inhaled from a cylinder at 2l/min
3124830|NCT01722370|Experimental|Oxygen|Ambulatory oxygen delivered at 2l/min on any activity performed by the patient, using a blinded cylinder
3124831|NCT01722357|Experimental|Pedometer + Exercise Counseling|
3124832|NCT01722357|Experimental|Pedometer|
3124833|NCT01722357|No Intervention|Usual Care|"Self-help information provided on physical activity (WIN:Weight Control Network Active At Any Size provided by National Institute of Diabetes and Digestive and Kidney Diseases, 2006)."
3124834|NCT01722344|Experimental|Individual Placement and Support (IPS)|
3124835|NCT01722344|Experimental|IPS plus|Individual Placement and Support plus cognitive remediation and work-related social skills training
3124836|NCT01722344|No Intervention|Standard intervention|
3124837|NCT01722331|Experimental|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered subcutaneously (SC) once a week at Weeks 0 and 4 and then every 12 weeks.
3124838|NCT01722331|Experimental|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC once a week at Weeks 0 and 4 and then every 12 weeks.
3124839|NCT01722331|Placebo Comparator|Placebo|Matching placebo administered SC once a week at Weeks 0 and 4.
3124840|NCT01722318|Active Comparator|Plecanatide 0.3mg|Plecanatide 0.3mg, one tablet by mouth daily for 12 weeks
3124841|NCT01722318|Active Comparator|Plecanatide 1.0mg|Plecanatide 1.0mg one tablet by mouth daily for 12 weeks
3124842|NCT01722318|Active Comparator|Plecanatide 3.0mg|Plecanatide 3.0mg, one tablet by mouth daily for 12 weeks
3124843|NCT01722318|Active Comparator|Plecanatide 9.0mg|Plecanatide 9.0mg, one tablet by mouth daily for 12 weeks
3124844|NCT01722318|Placebo Comparator|Placebo|Placebo, one tablet by mouth daily for 12 weeks
3124845|NCT01722305|Experimental|Treatment (pomalidomide, dexamethasone)|Patients receive pomalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 of courses 1 and 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3124846|NCT01722292|Experimental|Phase 1b: LY2940680 + C + E|"Phase 1b Dose Escalation: Cycles 1-6 (21 day cycles) LY2940680 administered orally, once daily at escalating doses (100 milligrams [mg] up to 400 mg) in combination with etoposide (E) 100 milligram per square meter (mg/m^2) administered by intravenous (IV) infusion on days 1, 2, 3 of each cycle and carboplatin (C) Area Under the Curve [AUC] 5 (mg•min/mL) administered by IV infusion on day 1 each cycle.~Phase 1b Maintenance: Cycles 7+ (21 day cycles) LY2940680 administered orally, once daily at the same dose as induction. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation."
3124847|NCT01722292|Placebo Comparator|Phase 2: Placebo + C + E|"Induction: Cycles 1-6 (21 day cycles) Placebo administered orally once daily in combination with etoposide 100 mg/m2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle.~Maintenance: Cycles 7+ (21 day cycles) Placebo administered orally once daily. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation."
3124848|NCT01722292|Experimental|Phase 2: LY2940680 + C+ E|"Induction: Cycles 1-6 (21 day cycles) LY2940680 (dose to be determined in Phase 1b portion) administered orally once daily in combination with etoposide 100 mg/m^2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle.~Maintenance: Cycles 7+ (21 day cycles). LY2940680 (dose to be determined in Phase 1 portion) administered orally once daily."
3124851|NCT01722266|Active Comparator|Liraglutide 1.8mg|Daily Injection
3124854|NCT01722253||placebo, electroacupuncture|"Electroacupuncture before and after surgery (40min and 60 min respectively) with frequency 2 Hz, and 'frequency scanning mode'.~Placebo electroacupuncture, in which the needles are secured (without penetrating the skin) and connected to the electrical device, which is not functional."
3124855|NCT01722240|Active Comparator|Liraglutide 1.8mg|Daily Injection
3124856|NCT01722240|Placebo Comparator|Placebo|Daily Injection
3124857|NCT01722227|Active Comparator|Liraglutide 0.6mg|Daily Injection
3124858|NCT01722227|Placebo Comparator|Placebo|Daily Injection
3124859|NCT01722214|Experimental|Group Adalimumab|A total of 53 patients with moderate to severe psoriasis will randomized in the adalimumab group. At Day 0 patients will receive adalimumab. It will be administered sub-cutaneously as described in the Canadian product monograph (80mg followed by 40mg at Week 1 and 40mg every other week). At Week 16, all patients will received two injections of placebo. As of Week 17, patients randomized to the adalimumab group will receive 40 mg adalimumab every other week until Week 51.
3124860|NCT01722214|Placebo Comparator|Placebo Group|A total of 53 patients with moderate to severe psoriasis will be randomized in the placebo group. At Day 0 these patients will receive the placebo. It will be administered sub-cutaneously as described in the Canadian product monograph of adalimumab. At Week 16, all these patients will received two injections of adalimumab. As of Week 17, patients randomized to the placebo group will receive 40 mg adalimumab every other week until Week 67.
3124861|NCT01722201|Experimental|Risperidone Tablet 1 mg|Risperidone Tablet 1 mg of M/s Ipca Laboratories Limited, India
3124862|NCT01722201|Active Comparator|Risperdal®|Risperdal® (Risperidone) Tablet 1 mg of Janssen Pharmaceutica Products, USA
3124863|NCT01722188||Optim Leads|
3124864|NCT01722175|Experimental|Arm I (ALPPS)|Patients undergo Associating Liver Partition with Portal Vein Ligation (ALPPS) step 1 surgery on day 0 and step 2 surgery 7-14 days later, based on patient's liver size.
3124865|NCT01722175|Active Comparator|Arm II (PVO)|Patients undergo portal vein occlusion (PVO) step 1 on day 0 and step 2 surgery 6-8 weeks later, based on patient's liver size.
3124866|NCT01722162|Experimental|Arm A: (start levocetirizine after bevacizumab/capecitabine)|"Bevacizumab IV 5 mg/kg on Days 1 each 2-week cycle.~Capecitabine PO 850 mg/m2 twice a day on Days 1-7 of each 2 week cycle.~Levocetirizine PO 5 mg daily before bed starting on Day 8 of Cycle 1. 5 mg daily before bed Days 1-4 of each cycle starting with cycle 2."
3124867|NCT01722162|Experimental|Arm B: (start levocetirizine before bevacizumab/capecitabine)|"Bevacizumab IV 5 mg/kg on Days 1 each 2-week cycle.~Capecitabine PO 850 mg/m2 twice a day on Days 1-7 of each 2 week cycle.~Levocetirizine PO 5 mg daily starting 7 days prior to initiation of bevacizumab and capecitabine therapy. 5 mg daily Days 1-14 starting with cycle 2."
3124868|NCT01722149|Experimental|Adoptive Transfer of re-directed T cells|Adoptive Transfer of re-directed FAP specific T cells in the pleural effusion
3124869|NCT01722136|Experimental|Low Dosage|Exercise dose of 8kcal/kg/week
3124870|NCT01722136|Experimental|High Dosage|Exercise dose 14kcal/kg/week
3124871|NCT01722123|No Intervention|DLST Only|Patients will complete the Stroop test then answer the hypothetical life sustaining therapy (LST)
3124872|NCT01722123|Experimental|Contemplate only|Patients will contemplate each of the 3 scenarios but not make any decisions, then complete the Stroop test and answer the hypothetical LST question
3124873|NCT01722123|Experimental|Decide with advice|Patients will make decisions on 4 scenarios with physician advice, then complete the Stroop test and answer the hypothetical LST question. Within this arm, patients will receive two positive recommendations (i.e. to go ahead with the intervention) and two negative recommendations (i.e. to decline the intervention). These positive and negative recommendations will be randomly assigned upon study enrollment. With four hypothetical scenarios, there are six possible options for recommendation variations.
3124874|NCT01722123|Experimental|Decide without advice|Patients will make decisions on 4 scenarios without physician advice, then complete the Stroop test and the hypothetical LST question.
3124875|NCT01722110|Experimental|Indomethacin Extended-Release Capsules USP 75 mg|Indomethacin Extended-Release Capsules USP 75 mg of Ipca Laboratories Limited, India
3124876|NCT01722110|Active Comparator|Indomethacin Extended Release Capsules USP 75 mg|Indomethacin Extended Release Capsules USP 75 mg of Epic Pharma, USA.
3124877|NCT01722097|Active Comparator|Deep neuromuscular blockade|Drug: Rocuronium Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h Other Name: Esmeron
3124878|NCT01722097|Placebo Comparator|Moderate neuromuscular blockade|Drug: Rocuronium Intravenous use: 0,3 mg/kg followed by NaCl-infusion Other Name: Esmeron
3124879|NCT01722084|Experimental|Community-eùbedded reproductive health interventions|Members of communities that belonged to the intervention arm were exposed to complex interventions addressing different target groups (adolescents, parents, authorities and health providers) and focusing on various behaviours that were related to communication about sexuality, information seeking, access to health care and safe sexual intercourse.
3124880|NCT01722084|No Intervention|Community members without intervention|
3124881|NCT01722071|Placebo Comparator|Placebo|Each participant will be studied using fMRI following self-administration of placebo.
3124882|NCT01722071|Experimental|Oxytocin|Each participant will be studied using fMRI following self-administration of oxytocin.
3124883|NCT01722058|Experimental|peptide application|
3124884|NCT01722045|Experimental|Open label IAI|
3124885|NCT01722032|Experimental|Treatment|"The intervention centers' menus were modified to include more fresh fruit, fresh vegetables, low-fat (1%) or skim milk, water, less juice, and less simple carbohydrate snacks. The centers were also encouraged to incorporate fresh fruits and vegetables as often as possible for snack and meal time.~Physical Activity. Physical activity was promoted for at least 60 minutes per day. TV viewing, watching movies and playing computer games were logged and limited to 30 minutes or less per day. Schools adopted Best-Practice Policies."
3124886|NCT01722032|No Intervention|Control|Those schools randomized to the control arm received a safety curriculum and some child care center locations received an attention control consisting of three visits from the University of Miami Safety Van which provided parents and teachers with home, car and child seat safety information. The control group received all the same pre-post measures as the intervention arms. They also received the same incentives as the intervention arms to foster involvement and ensure retention/reduce loss to follow up.
3124887|NCT01722019|Active Comparator|radiofrequency ablation with VNUS closure fast|Radiofrequency ablation will be performed with VNUS closure fast.
3124888|NCT01722019|Experimental|laser ablation and Tulip fiber|Laser ablation with a 1470 nm wave length in combination with a new fiber, the Tulip fiber.
3124889|NCT01722006||Pairing group|Paired, high reward, oral methamphetamine (20 mg) vs placebo Paired, low reward, oral methamphetamine (20 mg) vs placebo Paired, no reward, oral methamphetamine (20 mg) vs placebo Unpaired, oral methamphetamine (20 mg) vs placebo
3124890|NCT01721993|Experimental|T121E01F|
3124891|NCT01721993|Active Comparator|zoledronic acid IV|
3124892|NCT01721980|Other|50 mg GLPG0974 or placebo|50 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
3124893|NCT01721980|Other|100 mg GLPG0974 or placebo|100 mg GLPG0974 dose as oral capsule or placebo oral capsule, daily for 14 days
3124894|NCT01721980|Other|200 mg GLPG0974 or placebo|200 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
3124895|NCT01721980|Other|400 mg GLPG0974 or placebo|400 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
3124896|NCT01721967|Experimental|Ranolazine|Ranolazine, 500 mg for 60 days
3124897|NCT01721954|Active Comparator|Control Arm|Systemic chemotherapy with FOLFOX6m plus or minus bevacizumab repeated every two weeks until evidence of treatment failure.
3124898|NCT01721954|Experimental|Experimental Arm|Systemic chemotherapy with FOLFOX6m plus or minus bevacizumab plus SIR-Spheres microspheres.
3124899|NCT01721941|Experimental|Phase I dose level -1|TH-302 25mg; Doxorubicin 50mg
3124900|NCT01721941|Experimental|Phase I Dose level 1|TH-302 50mg; doxorubicin 50mg
3124901|NCT01721941|Experimental|Phase I Dose level 2|TH-302 100mg; doxorubicin 50mg
3124902|NCT01721941|Experimental|Phase 1 Dose level 3|TH-302 150mg; Doxorubicin 50mg
3124903|NCT01721928||ICU patients with AKI|ICU patients with AKI treated with continuous venovenous hemodialysis
3124904|NCT01721928||ICU patients without AKI|ICU patients without AKI defined as RIFLE group O and R
3124905|NCT01721915|Experimental|Vitamin D supplementation|The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)
3124906|NCT01721915|Placebo Comparator|Placebo|the placebo group will receive oily drops without vitD
3124907|NCT01721902|Active Comparator|Autologous CD133+ Bone Marrow Stem Cells|Intra-myocardial injection of autologous CD133+ cells in suspension.
3124908|NCT01721902|Placebo Comparator|Carrier Solution|Intra-myocardial inception of carrier solution.
3124909|NCT01721889||Radiostereometric analysis - Intact fusion|Clinically fused per classical radiographic assessment (≤ 2 degrees angular motion and evidence of bone bridging)
3124910|NCT01721889||Radiostereometric analysis - Symptomatic pseudoarthrosis|Definitive clinical evidence of pseudarthrosis (not fused, ˃ 2 degrees angular motion or absence of bone bridge) and scheduled for surgical exploration
3124911|NCT01721889||Radiostereometric analysis - Asymptomatic pseudoarthrosis|Definitive clinical evidence of pseudarthrosis without scheduled surgical exploration.
3124912|NCT01721876|Experimental|Volasertib + low dose cytarabine|
3124913|NCT01721876|Placebo Comparator|PLACEBO + low dose cytarabine|
3124914|NCT01721863|Experimental|Exercise training|Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
3124915|NCT01721863|No Intervention|control group|Control group conducted the usual care
3124916|NCT01721850|Active Comparator|control formula|infants are fed a commercial stage 1 infant formula during the first 4 months of life, according to protocol
3124917|NCT01721850|Experimental|intervention formula 1 group|infants are fed hydrolyzed infant formula containing pre- and probiotics during the first 4 months of life, according to protocol
3124918|NCT01721850|Experimental|intervention formula 2 group|infants are fed hydrolyzed infant formula containing pre- and probiotics during the first 4 months of life, according to protocol
3124919|NCT01721837||Atrial fibrillation and mild to moderate renal impairment|
3124920|NCT01721824|Experimental|IPS-MA|"The IPS-MA method consists of five basic services for the participants. 1)Individual mentor support, based on psychiatric knowledge. 2)Coordination by the mentor of activities, internal as well as from external providers. 3)Career counseling aimed at people with mental illnesses. 4)Impartial help to clarify private economy. 5) Contact to employers to help participants obtain jobs, and keep them.~Participants will receive the IPS-MA method in addition to treatment as usual."
3124921|NCT01721824|No Intervention|Control group|"Participants randomised to the control group will receive treatment as usual only. This means the standard support offered by the social- and health services in Denmark."
3124922|NCT01721811|Experimental|Healthy|Healthy study participanats
3124923|NCT01721811|Experimental|Diabetes|Patients with diabetes
3124924|NCT01721798|Active Comparator|Copper T-380a IUD|Copper T-380a IUD
3124925|NCT01721798|Active Comparator|Mirena Levonorgestrel IUD|Mirena levonorgestrel IUD
3124926|NCT01721785||Primary staging group I|"All patients will be treated according to standard practice of the concerning hospital.~Patients in group I are patients that will be stratified for direct surgery (TME) or a short-course of radiotherapy (5x5 Gy) followed by immediate TME.~Group I will undergo only a staging MRI, including gadofosveset-enhanced MRI."
3124927|NCT01721785||Restaging group II|"All patients will be treated according to standard practice of the concerning hospital.~Patients in group II are patients that will be stratified for a long course of chemoradiotherapy.~Group II will undergo a staging MRI, a re-staging MRI and a optional sigmoidoscopy as part of restaging. MRI includes diffusion-weighted imaging and gadofosveset-enhanced MRI."
3124928|NCT01721772|Experimental|Nivolumab, 3 mg/kg|Participants received nivolumab, 3 mg/kg, solution administered Intravenously (IV) every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion. Eligible participants may switch to nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
3124961|NCT01721512||Formula-fed infants|"Mother is exclusively feeding infant formula milk less than or equal to 6 weeks of birth and has no prospect of breastfeeding.~Mother consents to her infant receiving trial infant formula for 12 months"
3200570|NCT01194336||Galantamine: 4 mg|
3124929|NCT01721772|Active Comparator|Dacarbazine, 1000 mg/m^2|Participants received dacarbazine, 1000 mg/m^2, solution administered IV every 3 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion. Eligible participants may cross-over to nivolumab open label treatment, either 3 mg/kg every 2 weeks or 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
3124930|NCT01721759|Experimental|Nivolumab, 3 mg/kg|Participants received nivolumab, 3 mg/kg, intravenously over 60 minutes every 2 weeks (on Day 1 of each cycle) until disease progression, discontinuation due to toxicity, withdrawal of consent, or end of study. Every 2-week treatment period was considered to be a cycle.
3124931|NCT01721746|Experimental|BMS-936558 3 mg/kg (IV)|BMS-936558 3 mg/kg solution for injection by intravenous (IV), every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3124932|NCT01721746|Active Comparator|Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)|"Dacarbazine: 1000mg/m2, Powder for IV solution, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~Carboplatin: Area under the concentration-time curve (AUC) 6, solution for injection, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~Paclitaxel: 175 mg/ m2, solution for injection, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends"
3124933|NCT01721733|Placebo Comparator|Placebo|Each patient will receive a volume of placebo based on weight
3124934|NCT01721733|Active Comparator|EPI-743 15 mg/kg|Each subjects dose will be based on their weight. 15 mg/kg with a maximum dose of 200 mg per dose, t.i.d., will be administered in this treatment arm.
3124935|NCT01721733|Active Comparator|EPI-743 5 mg/kg|Each subjects dose will be based on their weight. 5 mg/kg with a maximum dose of 100 mg per dose, t.i.d., will be administered in this treatment arm.
3124936|NCT01721707|Experimental|Latanoprost+Brinzolamide combination|Latanoprost 0.005%(50 mg/ml)+brinzolamide 1%(10mg/ml) eye drops
3124937|NCT01721707|Active Comparator|Latanoprost|Latanoprost 0.005% (50 mg / ml)
3124938|NCT01721694|Experimental|azithromycin 1.5%/Loteprednol 0,5% + placebo|fixed combination of azithromycin 1.5% / Loteprednol 0,5% eye drops + placebo eye drops
3124939|NCT01721694|Active Comparator|azithromycin 1.5% + Loteprednol 0,5% (separately)|azithromycin 1.5% + Loteprednol 0,5% eye drops (separately)
3124940|NCT01721681|Experimental|FACTOR X|"At the Baseline Visit, eligible children will receive a bolus dose of 50 IU/kg FACTOR X. After the Baseline Visit, children will be treated with FACTOR X prophylactically for a period of 6 months (26 weeks).~A dosing regimen of 40-50 IU/kg twice a week is recommended, but is not mandatory. Each dose of FACTOR X must not exceed 60 IU/kg."
3124941|NCT01721668|Experimental|MSR - Music Supported Rehabilitation|Behavioral: Music Supported Rehabilitation
3124942|NCT01721668|Active Comparator|CU/ET|Experimental: CU/ET (Conventional Upper Extremity Therapy)
3124943|NCT01721655|Active Comparator|Spironolactone|Oral spironolactone suspension dosed at 3 mg/kg/day will be administered once-daily to the patients assigned to the treatment arm.
3124944|NCT01721655|Placebo Comparator|Placebo suspension|An oral placebo suspension dosed at 3 mg/kg/day administered once-daily will be given to patients in the placebo arm.
3124945|NCT01721642|Experimental|Apica Cardiovascular ASC Device|Access, stabilisation and closure with the Apica Cardiovascular ASC Device
3124946|NCT01721629|Other|Sudden wean of nasal CPAP|The CPAP is taken off at the morning ward round. If the discontinuation of the CPAP fails according to prespecified failure criteria, CPAP is recommenced and continued for at least 24 hours. Then a new evaluation takes place and if the infant again meets the inclusion criteria another attempt of sudden wean can be undertaken. Infants are considered successfully weaned if they are off CPAP for three days.
3124947|NCT01721629|Other|Gradual wean of nasal CPAP pressure|The reduction of the CPAP pressure begins at the morning ward round and the pressure is reduced in steps with 1 cmH2O maximum once a day. Each time the pressure is to be reduced the infant needs to be evaluated according to the inclusion criteria and only if these are still met, will the pressure be reduced. When a CPAP pressure at 4 cmH2O is reached the infant is treated with this pressure for 24 hours and then the CPAP is discontinued. Infants are considered successfully weaned if they are off CPAP for three days.
3124948|NCT01721616|Active Comparator|Cefazolin|single antibiotic
3124949|NCT01721616|Active Comparator|Cefazolin + Azitrhromycin|double antibiotic
3124950|NCT01721603|Experimental|Dabrafenib + Trametinib + gamma knife radiosurgery|
3124951|NCT01721590|Placebo Comparator|Control|Placebo，3 capsules/time，3times/day for 1 year
3124952|NCT01721590|Experimental|Tongxinluo|Tongxinluo 3 capsules/time 3times/day for 1 year
3124953|NCT01721577|Experimental|AXL1717|In the first phase, 10-20 patients will be enrolled and treated with 300-520 mg BID of AXL1717 for 28 days. The primary endpoint of the first phase is to determine the recommended Phase 2 dose (RP2D) of AXL1717 and to assess the safety and toxicity of AXL1717. The study has a 3+3 design and the first cohort will be treated with 400 mg AXL1717 BID for 28 days repeated in up to 5 cycles. The highest dose level without DLT or with maximally one DLT out of 6 patients will be the RP2D. Non-progressing patients may be treated for a total of five 28-day cycles (24 weeks).
3124954|NCT01721564|Experimental|Bosentan|62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
3124955|NCT01721551|Experimental|Exercise training|HD patients will receive a 9 months intradialytic exercise training program
3124956|NCT01721551|Placebo Comparator|No exercise|HD patients will not participate in any type of systematic exercise training
3124957|NCT01721538|Experimental|Therapy arm|Non-drug therapeutic weight reduction program (15 weeks)
3124958|NCT01721538|Placebo Comparator|Control arm|Lecture on healthy nutrition (1 hour)
3124959|NCT01721525|Experimental|afatinib, ribavirin, and weekly carboplatin/paclitaxel|This will be a single institution phase I study with an expansion cohort. Up to 2 dose levels of daily afatinib will be studied: 30 mg/day and 40 mg/day. The doses of ribavirin, carboplatin, and paclitaxel are fixed. A standard 3 + 3 phase I dose escalation design will be used.
3124960|NCT01721512||Breast-fed infants|80 infants of mothers who plan to exclusively breastfeed for at least 6 months.
3125069|NCT01720784|Experimental|Low dose (1.5 g DF)|
3125070|NCT01720784|Experimental|High dose (2.25 gDF)|
3200571|NCT01194336||Galantamine: 8 mg|
3124962|NCT01721499|Experimental|Mindfulness intervention|"The mindfulness intervention consists of weekly group format mindfulness instruction and skills development, weekly individual therapy sessions, and 6 nutritional sessions.~The control group receives 6 nutritional sessions only."
3124963|NCT01721499|Active Comparator|Nutrition Control Group|The control group receives 6 nutritional counseling sessions.
3124964|NCT01721486|Experimental|Study Group|IV acetaminophen 15 mg/kg (up to 1000 mg) administered intraoperatively over a 15 minute infusion.
3124965|NCT01721486|Active Comparator|Control Group|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30 minutes) prior to induction of anesthesia in the pre-operative area.
3124966|NCT01721473||cigarette smokers|Smokers with or without certain drug use comorbidities
3124967|NCT01721460|Experimental|Dexmedetomidine during MER|The study is performed in patients undergoing DBS electrode implantation to their STN for the treatment of parkinson's disease. Microelectrode recording (MER) is performed as part of STN electrode implantation surgery, to increase the precision of the stimulating electrode placement. The study includes administration of dexmedetomidine while recording electrical activity at a single location to evaluate the effects of this drug on the MER.
3124968|NCT01721447|Experimental|Echo arm|Subjects with atrial fibrillation who are undergoing a TEE procedure will be assessed using Optison echocardiography contrast agent
3124969|NCT01721434|Experimental|Levosimendan|Levosimendan 0.2 ug/kg/min intravenous for a single 7 hours.
3124970|NCT01721434|Placebo Comparator|Placebo|Similar coloured placebo intravenous for a single 7 hours
3124971|NCT01721421|Experimental|Extended Treatment time|Extended treatment time of 6 hours
3124972|NCT01721421|Active Comparator|standard treatment time|Standard Treatment time of 4 hours
3124973|NCT01721408|Experimental|Group A|
3124974|NCT01721408|Active Comparator|Group B|
3124975|NCT01721395|Placebo Comparator|Colored, Flavored water|The placebo will be colored to approximate the reddish amber color of the agave syrup. The placebo will use the same flavoring used in the agave syrup. The placebo will be created in a GMP facility
3124976|NCT01721395|Experimental|Agave Syrup|The formulation of pasteurized agave syrup consists of pasteurized agave syrup and natural flavoring.
3124977|NCT01721395|Sham Comparator|Air-filled oral syringe|Air-filled oral syringe to match experimental and placebo arm
3124978|NCT01721382|Experimental|Sitagliptin|Treatment with sitagliptin
3124979|NCT01721356||Healthy individuals|Healthy individuals ranging in age, race, ethnicity, socioeconomic status, and years of education
3124980|NCT01721343|Experimental|Arm I (enhanced usual care)|Patients undergo enhanced usual care comprising telephonic monitoring, monthly status reports, and an oncology care team for 6 months.
3124981|NCT01721343|Experimental|Arm II (enhanced usual care, RCM)|Patients undergo enhanced usual care as in Arm I and participate in an individualized conditioning program delivered by a local physical therapist and coordinated by the RCM for 6 months.
3124982|NCT01721343|Experimental|Arm III (enhanced usual, RCM, PCM)|Patients undergo enhanced usual care as in Arm I, participate in an individualized conditioning program coordinated by the RCM as in Arm II, and receive optimized pain management through a PCM for 6 months.
3124983|NCT01721330|Active Comparator|Naltrexone|Active Naltrexone administered twice daily up to a maximum total dose of 100mg/day.
3124984|NCT01721330|Placebo Comparator|Placebo|Naltrexone-masked placebo administered twice daily up to a maximum total dose of 100mg/day.
3124985|NCT01721317|Experimental|Titration Phase: Ezogabine/Retigabine 300 mg|Subjects receive Ezogabine/Retigabine 300 mg equally divided TID over Wk 1
3124986|NCT01721317|Placebo Comparator|Titration Phase: Placebo 300 mg|Subjects receive matching Placebo
3124987|NCT01721317|Experimental|Titration Phase: Ezogabine/Retigabine 450 mg|Subjects receive Ezogabine/Retigabine 450 mg equally divided TID over Wk 2
3124988|NCT01721317|Placebo Comparator|Titration Phase: Placebo 450 mg|Subjects receive matching Placebo
3124989|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 600 mg|Subjects receive Ezogabine/Retigabine 600 mg equally divided (200 mg TID) over Wk 3 or until they achieve their optimal tolerated dose as assessed by the Investigator
3124990|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 600 mg|Subjects receive matching Placebo
3124991|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 750 mg|Subjects receive Ezogabine/Retigabine 750 mg equally or unequally divided TID over Wk 4 or until they achieve their optimal tolerated dose as assessed by the Investigator
3124992|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 750 mg|Subjects receive matching Placebo
3124993|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 900 mg|Subjects receive Ezogabine/Retigabine 900 mg equally or unequally divided TID over Wk 5 or until they achieve their optimal tolerated dose as assessed by the Investigator
3124994|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 900 mg|Subjects receive matching Placebo
3124995|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 1050 mg|Subjects receive Ezogabine/Retigabine 1050 mg equally or unequally divided TID over Wk 6 or until they achieve their optimal tolerated dose as assessed by the Investigator
3124996|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 1050 mg|Subjects receive matching Placebo
3124997|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 1200 mg|Subjects receive Ezogabine/Retigabine 1200 mg equally divided (400 mg TID) over Wk 7 or until they achieve their optimal tolerated dose as assessed by the Investigator
3124998|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 1200 mg|Subjects receive matching Placebo
3124999|NCT01721317|Experimental|Maintenance Phase:Ezogabine/Retigabine|Subjects receive Ezogabine/Retigabine at the daily dose achieved (equally or unequally divided TID) at the end of the Dose-Optimization Phase for 8 Weeks (600 mg, 750 mg, 900 mg, 1050 mg, or 1200 mg)
3125000|NCT01721317|Placebo Comparator|Maintenance Phase: Placebo|Subjects receive matching Placebo
3125001|NCT01721304|Experimental|Adaptive Conjoint Analysis|Computerized survey to elicit preferences
3125002|NCT01721304|No Intervention|Usual care|Patients are counseled by their physician as usual
3125067|NCT01720797|Other|Non Micro-osteoperforation|Prior to intervention a swish of 5cc of chlorhexidine for one minute, twice, will take place. Chlorhexidine rinses are to begin twice a day for a week.
3200572|NCT01194336||Placebo|
3125003|NCT01721291|Experimental|SALBUTAMOL 1.5 MICRONS|DOSAGE FORM- SALBUTAMOL INHALED VIA RESEARCH NEBULISER;DOSAGE- 30 MICROGRAMS, ONCE SINGLE INHALATION ONLY; FREQUENCY- AT THREE VISITS (ONE VISIT INHALE SLOWY, ANOTHER VISIT INHALE FAST, ANOTHER VISIT INHALE SLOW AT 15 MICROGRAMS)
3125004|NCT01721291|Experimental|SALBUTAMOL 3 MICRONS|DOSAGE FORM- SALBUTAMOL INHALED VIA RESEARCH NEBULISER;DOSAGE- 30 MICROGRAMS, ONCE SINGLE INHALATION ONLY; FREQUENCY- AT THREE VISITS (ONE VISIT INHALE SLOWY, ANOTHER VISIT INHALE FAST, ANOTHER VISIT INHALE SLOW AT 15 MICROGRAMS)
3125005|NCT01721291|Experimental|SALBUTAMOL 6 MICRONS|DOSAGE FORM- SALBUTAMOL INHALED VIA RESEARCH NEBULISER;DOSAGE- 30 MICROGRAMS, ONCE SINGLE INHALATION ONLY; FREQUENCY- AT THREE VISITS (ONE VISIT INHALE SLOWY, ANOTHER VISIT INHALE FAST, ANOTHER VISIT INHALE SLOW AT 15 MICROGRAMS)
3125006|NCT01721291|Active Comparator|SALBUTAMOL 200 MICROGRAMS|DOSAGE FORM- SALBUTAMOL INHALED VIA METERED DOSE INHLAER;DOSAGE- 200 MICROGRAMS, ONCE SINGLE INHALATION ONLY; FREQUENCY- AT ONE VISIT INHALE SLOWY)
3125007|NCT01721239|No Intervention|Control group|No intervention
3125008|NCT01721239|Experimental|Standardized Followup program|Standardized written information, patient photos and three follow-up consultations.
3125009|NCT01721226|Sham Comparator|Control Arm|Participants in the Control Arm will receive standard discharge services according to the standards of care for that facility. In addition, participants in this arm will view an educational video on opiate overdose prevention. Study participants in the Control Arm will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
3125010|NCT01721226|Experimental|CARE tool and cell phone/text messaging|The Intervention Arm will complete the CARE tool device, a technology based HIV-counseling tool, and will receive text message reminders about HIV medical appointments and the importance of taking HIV medications. Study participants in this arm will be followed after release/study enrollment, just like participants in the Control Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
3125011|NCT01721213||Patients using Trobalt™|Use of Trobalt™ current use or at least one prescription filled within the previous three months.
3125012|NCT01721213||Physicians prescribing AEDs|Physicians (neurologists) who prescribed AEDs at least once in the three months prior to the survey.
3125013|NCT01721213||Physicians Prescribing Trobalt™|Physicians (neurologists) who have had experience of prescribing Trobalt™ specifically, from among those who have prescribed AEDs at least once in the three months prior to the survey.
3125014|NCT01721200|Other|Decision Support Tool|This study will examine the efficacy of a web-based educational decision support tool.
3125015|NCT01721200|Other|Usual Care|Usual Care Group will receive their biologic drug teaching from their rheumatologist.
3125016|NCT01721187||Low disinhibition|fMRI during fed and fasted states
3125017|NCT01721187||High disinhibition|fMRI during fed and fasted states
3125018|NCT01721174|Active Comparator|SEMS only|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. An uncovered self expanding metallic stent (SEMS) would be inserted to bypass the site of narrowing (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea)
3125019|NCT01721174|Active Comparator|EBRFA and SEMS|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. The radiofrequency ablation (EBRFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter with energy delivered by an RFA generator would be used to apply RFA to the entire length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. Patients would undergo 2 sessions of EBRFA 2 weeks apart. A plastic stent would be inserted in between the 2 sessions. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after the second EBRFA.
3125020|NCT01721161|Experimental|BIIB033|Participants will receive BIIB033 once every 4 weeks for 20 weeks (a total of 6 doses).
3125021|NCT01721161|Placebo Comparator|Placebo|Participants will receive Placebo via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
3125022|NCT01721148|Other|Cohort Dose Escalation|open label dose escalation study of ASLAN002 administered orally on a once daily schedule to subjects with advanced or metastatic solid tumours, who have either progressed on standard therapy or for whom standard therapy is not known
3125023|NCT01721135|Experimental|GSK2190915 100mg|GSK2190915 100mg on days 1-5; moxifloxacin placebo on day 5
3125024|NCT01721135|Experimental|GSK2190915 1000mg|GSK2190915 1000mg on days 1-5; moxifloxacin placebo on day 5
3125025|NCT01721135|Active Comparator|moxifloxacin 400mg|placebo tablet on days 1-5; moxifloxacin 400mg on day 5
3125026|NCT01721135|Placebo Comparator|placebo|placebo tablet on days 1-5; moxifloxacin placebo on day 5
3125027|NCT01721109|Experimental|EVG/COBI/FTC/TDF|Participants will receive treatment for 48 weeks and then had the option to enter an Extension Phase to receive EVG/COBI/FTC/TDF until 1) the age of 18, 2) EVG/COBI/FTC/TDF becomes commercially available in the country the participant is enrolled, or 3) Gilead elects to terminate the development of EVG/COBI/FTC/TDF in that country.
3125028|NCT01721096||XIENCE PRIME - Long Length (LL)|Long Lesion Arm patients (n=323) are treated by at least one Long Size stent (28, 33 and 38 mm length).There are no significant difference between both the groups with respect to patient background, ischemic status, risk factors and medical history, numbers of target lesions and the lesion types, target lesion treatment, number of stents implanted, and target lesion characteristics other than lesion lengths.
3125029|NCT01721096||XIENCE PRIME - Core Size|Core Size Arm patients (n=213) are treated with small size stent (8, 12, 15, 18 and 23 mm length). There are no significant difference between both the groups with respect to patient background, ischemic status, risk factors and medical history, numbers of target lesions and the lesion types, target lesion treatment, number of stents implanted, and target lesion characteristics other than lesion lengths.
3125030|NCT01721083|Experimental|Z-Track immunization|Subject receives Intramuscular injection by z-track method during flu vaccination given by employee health Registered Nurse into deltoid muscle.
3125031|NCT01721083|Active Comparator|Bunch immunization|Subject receives Intramuscular injection by bunch method during flu vaccination given by employee health Registered Nurse into deltoid muscle.
3125032|NCT01721070|Experimental|SUF NT 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually. Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil.
3125033|NCT01721070|Experimental|Ketoconazole 400 mg, SUF NT 15 mcg|"Ketoconazole 400 mg administered once daily for three days. One dose of SUF NT 15 mcg was co-administered sublingually with the third (last) ketoconazole dose.~Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil."
3125034|NCT01721057|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.~Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study."
3125035|NCT01721057|Experimental|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
3125036|NCT01721057|Experimental|Baricitinib 4 mg|"Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
3125037|NCT01721044|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.~Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study."
3125038|NCT01721044|Experimental|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
3125039|NCT01721044|Experimental|Baricitinib 4 mg|"Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
3125040|NCT01721031|Experimental|DPNB|Patients receive DPNB 30min before extubation at the end of operation.
3125041|NCT01721031|Active Comparator|Tramadol|Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
3125042|NCT01721018|Experimental|HSV1716|Single Arm Phase I/II study of intra-pleural HSV1716 administration.
3125043|NCT01721005|Other|pulse palpation education|The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model
3125044|NCT01720992|Experimental|Group A|A theory-based action planning toolkit will be distributed to Group A participants.
3125045|NCT01720992|Other|Group B|Group B is a wait list control
3125046|NCT01720979||Patients with traumatic injuries|Children that were admitted to the hospital after traumatic injuries to body parts below the clavicles (traumatic control injury) and children that were admitted to the hospital after traumatic brain injury as diagnosed by a physician (TBI).
3125047|NCT01720966||Laparoscopy|Patients who will undergo liver resection who have a laparoscopically performed colorectal resection in history. Assignment to cohort is on intention to treat of the primary operation.
3125048|NCT01720966||Laparotomy|Patients who will undergo liver resection who have an open colorectal resection in history. Assignment to cohort is on intention to treat of the primary operation.
3125049|NCT01720953||Healthy control subjects|Matched healthy control subjects will be assessed at 6 month intervals to compare changes in DNA methylation, BDNF serum levels, salivary cortisol levels, and neuropsychological test performance. Healthy control subjects will within the 1-year study period also undergo continuous assessment for comparative changes in symptoms of dissociation, depression, and personality dysfunction.
3125050|NCT01720940|Experimental|continuous vancomycin infusion|
3125051|NCT01720940|Active Comparator|intermittent vancomycin infusion|vancomycin in this arm will be administered as intermittent infusion
3125052|NCT01720927||Acute Pharyngitis|Subjects presenting with acute pharyngitis
3125053|NCT01720914||Critically ill patient|
3125054|NCT01720901|Experimental|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
3125055|NCT01720888|No Intervention|Maximal medical therapy|Maximal medical therapy which comprises of optimal pharmacological therapy
3125056|NCT01720888|Experimental|Maximal medical therapy and BM-MSCs|Autologous Bone marrrow-derived mesenchymal stem cells implantation
3125057|NCT01720875|Experimental|Vorinostat Velcade Dexamethasone (VVD)|"Up to 8 cycles of VVD followed by vorinostat maintenance until disease progression.~Cycles 1-8 (21-day cycle)~Velcade: 1.3mg/m2 (subcutaneous) on days 1, 4, 8 and 11~Dexamethasone: 20 mg (PO) on days 1, 2, 4, 5, 8, 9, 11 and 12~Vorinostat: 400mg (PO) on days 1-4, 8-11, 15-18 Maintenance (28-day cycle)~Vorinostat: 400mg PO on 1-4 and 15-18"
3125058|NCT01720862||Episodic migraineurs|Those with migraines >2 and < 12 times per month.
3125059|NCT01720862||Chronic migraineurs|Those with migraines greater than 14 days per month.
3125060|NCT01720862||Controls|Those without headaches other than occasional hangover, cold, flu headaches.
3125061|NCT01720849||Fampyra group|
3125062|NCT01720836|Experimental|Stage IA or I/II NSCLC|Resection or radiotherapy without adjuvant chemotherapy followed by 3 cycles of vaccine + PolyICLC.
3125063|NCT01720836|Experimental|Stage IB/II/IIIA|Resection and adjuvant chemotherapy followed by 3 cycles of vaccine + PolyICLC.
3125064|NCT01720836|Experimental|Stage IIIA or IIIB|Concomitant chemo-irradiation followed by 3 cycles of vaccine + PolyICLC.
3125065|NCT01720823|Experimental|home polysomnography and standard polysomnography|home polysomnography (GETEMED) and standard polysomnography (BRAINNETII) are both carried out in children during 1 night.
3125066|NCT01720797|Experimental|Micro-osteoperforation|Minimally invasive micro-osteoperforation (PROPEL™) procedure used to achieve rapid orthodontic tooth movement. Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice. Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice, will take place. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
3125071|NCT01720771|Active Comparator|Probiotic tablet|a tablet with three probiotic streptococci strains (S. uberis KJ2, S. oralis KJ3 and S. rattus JH145) at a concentration of 3x108 CFU
3125072|NCT01720771|Placebo Comparator|Sugar pill|The same tablet but without active probiotic bacteria
3125073|NCT01720745||EUS FNA|Patients undergoing endoscopic ultrasound for solid mass lesions with a 22 G needle at University of Minnesota Medical center and Aurora St.Luke's Medical Center, Milwaukee, WI
3125074|NCT01720732|Experimental|Lifeline NET|Lifeline-NET (Short Version of NET)
3125075|NCT01720732|No Intervention|TAU|Treatment as Usual
3125076|NCT01720719|Active Comparator|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
3125077|NCT01720719|Experimental|Atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
3125078|NCT01720706|Experimental|Acute|The RFA Loosely wound thermal coil electrode will be inserted directly or percutaneously into the lesion, depending on the imaging modality (US or CT guidance) and deployed with same method as previously described in the 'delayed group'. Energy will be delivered using the single timed heating cycle. Treatment will be monitored with B mode US. Once the cycle is completed, the probe will be removed and the planned surgery will continue with partial or radical nephrectomy.
3125079|NCT01720706|Experimental|Delayed|Using an electrically insulated 12ga introducer with trocar is inserted percutaneously into the renal tumor. The needle tip will be placed 20mm from the center of the target. The trocar is removed and co-axially (i.e. within the introducer), a core biopsy of the lesion is performed with a 14-18 gauge needle. The radiofrequency applicator with a 14ga cannula containing the RFA Loosely wound thermal coil electrode is then optimally positioned and locked into the introducer. On approximately day 6-10, a partial or radical nephrectomy will be performed in the usual way.
3125080|NCT01720693|Experimental|hypoperfusion|Hypoperfusion of the renal artery
3125081|NCT01720667|Experimental|Intravenous levetiracetam|Intravenous levetiracetam 40 to 60 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
3125082|NCT01720667|Active Comparator|Intravenous phenobarbital|Intravenous phenobarbital 20 to 40 mg/kg load. 1.5 mg/kg 8 hourly maintenance
3125083|NCT01720654|No Intervention|Control|Standardized partner notification counseling.
3125084|NCT01720654|Experimental|EPT|Standardized partner notification counseling and provision of 5 partner treatment (EPT) packets.
3125085|NCT01720641|No Intervention|Control|Standardized partner notification counseling
3125086|NCT01720641|Experimental|Internet Notification|Standardized partner notification counseling and referral to internet-based partner referral website.
3125087|NCT01720641|Experimental|Referral Card|Standardized partner notification counseling and provision of 5 printed partner referral cards.
3125088|NCT01720641|Experimental|Internet and Referral Card|Standardized partner notification counseling and referral to internet-based partner referral website and provision of 5 printed partner referral cards.
3125089|NCT01720628||Behçet's patients|Serum levels of angiogenin, bFGF, VEGF levels in Behçet's patients with ocular involvement group, without ocular involvement group and control group
3125090|NCT01720615|No Intervention|Propofol or Sevoflurane|General anesthesia
3125091|NCT01720602|Experimental|Treatment (vorinostat, AI therapy)|Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
3125092|NCT01720589|Experimental|Melt (test oil)|Participants will consume a muffin containing 20 g of dietary fat provided by the test oil and their energy expenditure will be measure post-prandially for 6 hours. At the end of the measurement period, participants will consume a cookie containing 10 g of fat provided by the test oil and their food intake at an ad libitum meal will be measured 1 hour later.
3125093|NCT01720589|Active Comparator|Corn oil (control)|Participants will consume a muffin containing 20 g of dietary fat provided by the control oil and their energy expenditure will be measure post-prandially for 6 hours. At the end of the measurement period, participants will consume a cookie containing 10 g of fat provided by the control oil and their food intake at an ad libitum meal will be measured 1 hour later.
3125094|NCT01720576|Experimental|Cohort 1|Dose 1 of REGN1033 (SAR391786) or Placebo
3125095|NCT01720576|Experimental|Cohort 2|Dose 2 of REGN1033 (SAR391786) or Placebo
3125096|NCT01720576|Experimental|Cohort 3|Dose 3 of REGN1033 (SAR391786) or Placebo
3125097|NCT01720563|Placebo Comparator|Control|Placebo
3125098|NCT01720563|Experimental|Treatment|Astragalus polysaccharides 500 mg
3125099|NCT01720550|Experimental|PG2 High Dose|Astragalus Polysaccharides 500 mg
3125100|NCT01720550|Experimental|PG2 Low Dose|Astragalus Polysaccharides 250 mg
3125101|NCT01720537|Experimental|Cohort 1|
3125102|NCT01720537|Experimental|Cohort 2|
3125103|NCT01720537|Experimental|Cohort 3|
3125104|NCT01720537|Experimental|Cohort 4|
3125105|NCT01720537|Experimental|Cohort 5|
3125106|NCT01720537|Experimental|Cohort 6|
3125107|NCT01720524|Placebo Comparator|placebo|iv placebo of normal saline or 10% dextrose
3125108|NCT01720524|Experimental|sildenafil|Active study drug
3125109|NCT01720511|Experimental|Purple Rice|Twice a day given purple rice with 5mg of resveratrol.
3125110|NCT01720511|Active Comparator|Brown RIce|Plain Purple rice given twice a day
3125111|NCT01720498|Experimental|Male|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
3125112|NCT01720498|Experimental|Female|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
3125113|NCT01720485|Experimental|Desloratadine + Prednisolone|"The patients will take 2 tablets three times a day, as follows:~Morning: 1 tablet of the test medication(Desloratadine 5 mg + Prednisolone 20 mg) + 1 tablet of placebo control medication.~Afternoon: 1 tablet of placebo test medication + 1 tablet of placebo control medication.~Night: 1 tablet of placebo test medication + 1 tablet of placebo control medication."
3125165|NCT01720121|No Intervention|Control group|The control group received the guidelines orientation provide by nursing team
3125166|NCT01720121|Experimental|Guidelines printed group|The patient received the informative material in details about the cardiac catheterization provide by the researchers
3125114|NCT01720485|Active Comparator|Dexchlorpheniramine + Betamethasone|"The patients will take 2 tablets three times a day, as follows:~Morning: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.~Afternoon: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.~Night: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication."
3125115|NCT01720472||Community, Physical Performance|
3125116|NCT01720459|Active Comparator|Micronized trans-resveratrol|Micronized trans-resveratrol
3125117|NCT01720459|Placebo Comparator|Placebo|
3125118|NCT01720446|Experimental|Semaglutide 0.5 mg|
3125119|NCT01720446|Experimental|Semaglutide 1.0 mg|
3125120|NCT01720446|Placebo Comparator|Semaglutide placebo 0.5 mg|
3125121|NCT01720446|Placebo Comparator|Semaglutide placebo 1.0 mg|
3125122|NCT01720433|Experimental|intervention|In the intervention group, in addition to the above, the patient was placed in the Trendelenburg position (30°) and a pulmonary recruitment maneuver utilized, consisting of two manual inflations to a maximum pressure of 60 cm H2O. This was performed by the Anaesthetist, who held each positive pressure inflation for five seconds, with the valves on the operative ports fully open.
3125123|NCT01720433|No Intervention|control arm|In the control group residual carbon dioxide pneumo-peritoneum was evacuated at the end of the procedure by passively allowing the abdomen to decompress by opening the operative ports.
3125124|NCT01720420|Experimental|Mandible|NobelReplace CC NobelProcera Implant Bar Titanium Overdenture (lab-made)
3125125|NCT01720420|Experimental|Maxilla|NobelReplace CC NobelProcera Implant Bar Titanium Overdenture (lab-made)
3125126|NCT01720407|Experimental|Imiquimod|
3125127|NCT01720407|Placebo Comparator|Placebo|
3125128|NCT01720394|Experimental|Cervical ripening balloon|primary treatment with the cervical ripening balloon on day 1. removal of the balloon latest after 12 h. If no progression of labor (Bishop Score ≥ 9 and/or cervical opening ≥ 3 cm) continuing of standard treatment using dinoprostone vaginal-inserts on day 2 and if necessary on day 3.
3125129|NCT01720394|Active Comparator|Propess|Primary treatment using dinoprostone-vaginal-inserts on day 1-3 if no progression of labor (Bishop Score ≥ 9 and/or cervical dilatation ≥ 3 cm)
3125130|NCT01720368||1st Group of 50 patients|
3125131|NCT01720368||2nd Group of 50 patients|
3125132|NCT01720342||Aortic valve stenosis, aortic valve insufficiency|Patients with aortic valve insufficiency and/or aortic valve stenosis who require AVR.
3125133|NCT01720329|Active Comparator|Probiotics|Participants randomized to probiotics will receive 2 capsules supplemented with 10 billion cfu of Lactobacillus rhamnosus GG on a daily basis for six months
3125134|NCT01720329|Placebo Comparator|Probiotic placebo|Participants randomized to placebo will receive 2 capsules of matching placebo on a daily basis for six months
3125135|NCT01720316|Active Comparator|glycine|Glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks Double-blind
3125136|NCT01720316|Placebo Comparator|Placebo|placebo, TID dosing, 6 weeks Double-blind
3125137|NCT01720316|Active Comparator|glycine, open-label|glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks
3125138|NCT01720303|Experimental|Rep + NPH|
3125139|NCT01720303|Active Comparator|Premixed insulin/NPH|
3125140|NCT01720290|Experimental|Rep|
3125141|NCT01720290|Active Comparator|Met|
3125142|NCT01720290|Active Comparator|Rep + met|
3125143|NCT01720277|Experimental|HD Fluzone Vaccine|NH facilities randomized to receive high dose trivalent influenza vaccine (HD Fluzone) for the residents.
3125144|NCT01720277|Active Comparator|SD Fluzone Vaccine|NH facilities randomized to standard dose trivalent influenza vaccine (SD Fluzone) for the residents.
3125145|NCT01720264|Experimental|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
3125146|NCT01720251|Placebo Comparator|placebo|SC injections of placebo
3125147|NCT01720251|Experimental|AllerT low dose|SC injections of AllerT 25 or 50 micrograms
3125148|NCT01720251|Experimental|AllerT full dose|SC injections of AllerT 50-100 micrograms
3125149|NCT01720238||Group 1|Entecavir Therapy
3125150|NCT01720238||Group 2|Lamivudine plus Adefovir Dipivoxil Therapy
3125151|NCT01720225|Experimental|Decitabine|Patients randomized to receive Decitabine 20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
3125152|NCT01720225|Experimental|Azacitidine|Patients randomized to receive Azacitidine 75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
3125153|NCT01720212|Experimental|Single dose group|
3125154|NCT01720212|Experimental|Multiple dose group|
3125155|NCT01720199|Experimental|Intervention group|Preadolescents allocated to the Diario della Salute (DDS) intervention.
3125156|NCT01720199|No Intervention|Control group|
3125157|NCT01720186|Experimental|SPI Medical device|SPI medical device used during PET/CT 4D imaging in a synchronized mode centered on the thorax.
3125158|NCT01720186|Active Comparator|reference medical device : RPM|Reference medical device (RPM) used simultaneously during PET/CT 4D imaging in a synchronized mode centered on the thorax.
3125159|NCT01720173|Experimental|Treatment (dalantercept)|Patients receive dalantercept SC on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3125160|NCT01720160|Experimental|Device Group|Barostim Neo system
3125161|NCT01720160|Active Comparator|Medical Management Group|Medical management therapy only
3125162|NCT01720147|Experimental|Quercetin - Dietary Supplement|"Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 1500 mg/day, for 4 months (16 weeks). Pharmacokinetics (PK) data will be analyzed after each cohort of 3 patients and will be used to optimize the dosing schedule (if required) for subsequent patients.~An expansion cohort has been added to the study protocol. Up to 20 patients may be enrolled. The dose utilized will be the same as the max weight adjusted dose that showed biological activity in our last cohort of patients (subjects #10-12 from above)."
3125163|NCT01720134||after legislation 1st july 2003|2003-2006
3125164|NCT01720134||before legislation 1st july 2003|1999-2003
3125484|NCT01717976|Experimental|Intervention|primary care based nurse telephone support
3125167|NCT01720121|Experimental|Guidelines digital video disc group|Guidelines digital video disc group: The patient received the informative provide by digital video disc in details about the cardiac catheterization
3125168|NCT01720108|Active Comparator|rivaroxaban|rivaroxaban 10mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients
3125169|NCT01720108|Experimental|ASA|ASA 81mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients
3125170|NCT01720095|Experimental|Niaspan|these are the first episode psychosis patients that are randomized to receive niaspan
3125171|NCT01720095|No Intervention|healthy control|this is the group of healthy controls for cognitive outcome measures
3125172|NCT01720095|No Intervention|first episode control group|first episode psychosis patients who are randomized to no intervention
3125173|NCT01720082|Active Comparator|Single incision laparoscopic appendectomy|Acute appendicitis with surgical indication
3125174|NCT01720082|Active Comparator|Multiport Laparoscopic appendectomy|Acute appendicitis with surgical indication
3125175|NCT01720069|Active Comparator|Dose 1 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
3125176|NCT01720069|Active Comparator|Dose 2 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
3125177|NCT01720069|Active Comparator|Dose 3 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
3125178|NCT01720056|Active Comparator|Verapamil|Verapamil 2.5 mg/mL injection sc intralesionally
3125179|NCT01720056|Active Comparator|Kenalog 10|Kenalog 10 mg/mL injection sc intralesionally
3125180|NCT01720043|Experimental|All participants|All participants enrolled
3125181|NCT01720030|Placebo Comparator|Conventional therapy|Standard of care as protocolized locally
3125182|NCT01720030|Experimental|Levosimendan|The experimental group receives standard treatment supplemented by levosimendan (0.2 µg/kg/min) for 24 hours within 36 hrs following onset of AKI.
3125183|NCT01720017|Active Comparator|Inservice Training Only|Inservice training will include review of a product information handout and a video demonstration. Specific attention will be given to (1) describing each system component and its operation, (2) attaching the wireless camera head and coordinating channel selection with the monitor, (3) turning on the Airtraq Avant light and device preparation for use, (4) Airtraq Avant insertion into the patient's mouth and advancement into the hypopharynx (deep in the throat) to obtain a view of the vocal cords, (5) use of standard lift and rotation movements to optimize the vocal cord view, (6) tracheal tube advancement through the vocal cords tracheal intubation, (7) standard methods for confirmation of correct tracheal tube placement, (8) tracheal tube removal from the Airtraq Avant and the Airtraq Avant removal from the patient's mouth, and (9) disposal of the disposable blade and cleaning of the reusable optics insert.
3125184|NCT01720017|Experimental|Inservice and Manikin Training|Study subjects in this group will receive the standard inservice training described above, as well as, preclinical manikin training on use of the Airtraq Avant and Wireless Monitor System in simulated difficult airway conditions (swollen tongue and cervical collar). During the preclinical manikin training, each subject will perform 10 intubations. Performance characteristics including attempts for successful Airtraq Avant insertion, glottic view obtained, ease of insertion, ease of tracheal intubation, time required for tracheal intubation, and attempts for successful tracheal intubation will be recorded for each intubation.
3125185|NCT01720004|Experimental|Repeated Use of Hands-and-Knees|The intervention was repeated use of hands-and-knees position during labour. Participants were asked to try it for at least 15 minutes every hour, from randomization until delivery. They were not required to use it for delivery.
3125186|NCT01720004|No Intervention|Usual care|Participants were asked to refrain from using hands-and-knees position at any time from randomization to delivery. They were free to use any other position.
3125187|NCT01719991|Experimental|Nurse case management and self-management support|The first component of the intervention is the monitoring offered under the case management process. The second component of the intervention consists of group meetings (10-12 people) for self-management support in accordance with the stanford model. A sample of patients in each of the four FMGs (n = 126) will be recruited. These patients will receive the intervention for six months.
3125188|NCT01719991|No Intervention|Control group|Patients in the control group (n = 121) will receive the usual care for six months and then the same intervention as the experimental group for the next five months (waiting list control group).
3125189|NCT01719978|Active Comparator|Hyaluronidase|Lower Third Molar Extraction -- 3.6mL 2% Mepivacaine with 1:100,000 epinephrine + Hyaluronidase
3125190|NCT01719978|Placebo Comparator|Placebo|Lower Third Molar Extraction -- Anesthetic: 3.6 mL of the LA 2% HCl mepivacaine with 1:100,000 epinephrine + Placebo (0.9% saline)
3125191|NCT01719965||Health Workers|"Worked in SMRU for at least 6 months~Clinic assistants, medics or home visitors"
3125192|NCT01719965||Researchers|"Worked in SMRU for at least 6 months~Physician or scientist"
3125193|NCT01719965||CAB members|- Member of the CAB for at least 3 months
3125194|NCT01719965||Community members|- Lived in the border area (area served by SMRU or Mae Sot) for at least 6 months
3125195|NCT01719965||Research subjects|- Participants who are currently enrolled in an SMRU study
3125196|NCT01719952|Experimental|Carbetocin|Carbetocin 100 µg, given as an intravenous bolus over 30 seconds others names are: duratocin, pabal
3125197|NCT01719952|Active Comparator|Oxytocin|Other names are Pitocin, syntocinon given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
3125198|NCT01719926|Experimental|Capecitabine/Oxaliplatin|Patients receiving Capecitabine/Oxaliplatin chemotherapy
3125199|NCT01719926|Experimental|Cisplatin + Xeloda(Capecitabine) or Gemcitabine|Patients receiving Cisplatin regimen
3125200|NCT01719913|Active Comparator|Low gluten|Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
3125201|NCT01719913|Placebo Comparator|High gluten|Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
3125202|NCT01719900|Experimental|Pulse Fibre|The intervention group will receive a biscuit containing 5g/serving of yellow pea fibre to be eaten 3 times per day approximately 30 minutes prior to their 3 largest meals.
3200674|NCT01193582|Experimental|Group 2|
3125203|NCT01719900|Placebo Comparator|Control|The placebo group will receive a biscuit an isocaloric control biscuit that is similar in taste and texture and without pulse fibre to be eaten 3 times per day approximately 30 minutes prior to their 3 largest meals.
3125204|NCT01719887|Active Comparator|Conservative treatment|Conservative treatment with functional brace and physiotherapy.
3125205|NCT01719887|Experimental|Operative treatment|Operative treatment with open reduction and internal fixation with 4,5mm locking compression plate. Physiotherapy at 3 and 9 wks.
3125206|NCT01719874|Experimental|TCN-032|single-dose, administered intravenously
3125207|NCT01719874|Placebo Comparator|Placebo (saline)|single-dose, administered intravenously
3125208|NCT01719861|Experimental|Desipramine HCl|Desipramine is a tricyclic antidepressant (TCA).
3125209|NCT01719848||Preoperative airway examination|patients undergoing general anesthesia for any surgery
3125210|NCT01719835|Experimental|Chemotherapy GEM-P|Gemcitabine, Methylprednisolone, Cisplatin
3125211|NCT01719835|Active Comparator|Chemotherapy CHOP|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone
3125212|NCT01719822|No Intervention|Usual Care|Standard 8-week pulmonary rehabilitation programme with 2 supervised sessions per week and a written home exercise plan/diary.
3125213|NCT01719822|Experimental|Intervention|Standard 8-week pulmonary rehabilitation programme with 2 supervised sessions per week. In addition they will receive a pedometer with a daily step count target set by a physiotherapist and a written home exercise plan/diary.
3125214|NCT01719796|Experimental|Bilateral TAP catheter|Ultrasonography guided bilateral TAP catheter insertion.
3125215|NCT01719796|No Intervention|No TAP catheter|
3125216|NCT01719783|Experimental|LAIV H5N2|Two doses of live monovalent influenza vaccine A/17/turkey/Turkey/05/133 ( live monovalent (LAIV H5N2) given intranasally
3125217|NCT01719783|Placebo Comparator|Placebo|two doses of placebo solution intranasal
3125218|NCT01719770|Active Comparator|Rocuronium|Continuous infusion of rocuronium with 0,25mg/kg (blinded) for 29 hours after initiation of mild therapeutic hypothermia
3125219|NCT01719770|Placebo Comparator|Placebo|Continuous infusion of sodium-chloride (placebo) and rocuronium bolus (0,25mg/kg)in case of shivering episode (blinded)
3125220|NCT01719757|Experimental|Oxycodone/naloxone|Trade name is Targin. Oxycodone (10mg)/naloxone (5mg) or Oxycodone (20mg)/naloxone (10mg) tablets. Twice daily per oral. Dose adjustment and asymmetric dose are allowed up to 80/40mg per day
3125221|NCT01719744|Experimental|ENMD-2076|ENMD-2076 capsules, 275 mg once daily, by mouth.
3125222|NCT01719731|Placebo Comparator|Non-Education|This group will not receive the psychosocial education.
3125223|NCT01719731|Active Comparator|Education|This group will receive the psychosocial education
3125224|NCT01719718|Active Comparator|Closure|
3125225|NCT01719718|Sham Comparator|Non-Closure|
3125226|NCT01719705|Placebo Comparator|Placebo|receive two identical placebo capsules
3125227|NCT01719705|Active Comparator|Pregabalin 150 mg group|one capsule of pregabalin 150 mg
3125228|NCT01719705|Active Comparator|Pregabalin 300 mg group|two capsules of pregabalin 150 mg
3125229|NCT01719692|Experimental|Rituximab A group|375mg/m2 for once
3125230|NCT01719692|Active Comparator|Rituximab B group|100mg/week for four weeks
3125231|NCT01719679|Experimental|School Located Vaccine (SLV) Program|A vaccine program carried out by a community vaccinator will be conducted in a limited number of participating schools. The program will be open to the students enrolled at the participating schools
3125232|NCT01719679|No Intervention|no School Located Vaccine (SLV) Program|Schools that are part of the non-intervention arm of the study will not have a school-located vaccine program.
3125233|NCT01719666|Other|isolated MPFL reconstruction|
3125234|NCT01719666|Experimental|MPFL reconstruction and Lateral retinaculum release|
3125235|NCT01719653|Active Comparator|MiraLAX 306 g (Day-Prior)|MiraLAX 306 g and Gatorade 64 oz (1/2 gallon) consumed the day-prior to the colonoscopy as follows: Miralax 51 g at 12 noon; Gatorade 64 oz mixed with Miralax 255 g from about 6 PM to 9 PM
3125236|NCT01719653|Experimental|MiraLAX 357 g (Day-Prior)|MiraLAX 357 g and Gatorade 64 oz (1/2 gallon) consumed the day-prior to the colonoscopy as follows: Miralax 68 g at 12 noon; Gatorade 64 oz mixed with Miralax 289 g from about 6 PM to 9 PM.
3125237|NCT01719653|Experimental|MiraLAX 306 g (Split-Dose)|MiraLAX 306 g and Gatorade 64 oz (1/2 gallon) consumed as a split-dose as follows: Gatorade 32oz mixed with Miralax 153 g from about 6 PM to 8 PM the day prior to the colonoscopy; Gatorade 32oz mixed with Miralax 153 g from about 2-4 hours prior to the colonoscopy.
3125238|NCT01719653|Active Comparator|MoviPrep (Split-Dose)|MoviPrep consumed as a split-dose as follows: MoviPrep 1 liter consumed from about 6 PM to 7 PM the day prior to the colonoscopy followed by 0.5 liter of clear liquids; MoviPrep 1 liter consumed from 3-4 hours prior to the colonoscopy followed by 0.5 liter of clear liquids.
3125239|NCT01719653|Active Comparator|SUPREP (Split-Dose)|SUPREP consumed as a split-dose as follows: SUPREP 16 oz consumed from about 6 PM to 7 PM the day prior to the colonoscopy followed by 32 oz of clear liquids; SUPREP 16 oz consumed from 3-4 hours prior to the colonoscopy followed by 32 oz of clear liquids.
3125240|NCT01719640|Experimental|BMMSC+BMMNC|infusion of BMMSC+BMMNC and insulin injection
3125241|NCT01719640|Active Comparator|BMMNC|infusion of BMMNC and insulin injection
3125242|NCT01719640|Active Comparator|Insulin|insulin injection
3125243|NCT01719627|Experimental|MVC 300 mg|MVC 300 mg in unique dose
3125244|NCT01719627|Active Comparator|TVD 300/200 QD|TVD 300/200 QD during 7 days.
3125245|NCT01719627|Experimental|Maraviroc 600mg|MVC 600mg in unique dose
3125246|NCT01719614|Experimental|Rilpivirine+Metformin|All participants will receive study medications in two sessions in a fixed, sequential order as a session 1 (a single dose of metformin on Day 1) followed by washout period (period when no treatment is received) of 4 days and then session 2 (rilpivirine on Day 5 to Day 17 with a single dose of metformin on Day 15).
3125247|NCT01719601||Immediate release tapentadol|Patients will be taking immediate release tapentadol hydrochloride as per the product insert approved in Philippines.
3125248|NCT01719588||Prolonged release tapentadol|Patients will be taking prolonged release tapentadol hydrochloride as per the product insert approved in Philippines.
3125446|NCT01718210|Experimental|GM-CSF medium|patient's embryos are incubated after fertilization with mediun supplemented with GM-CSF
3125249|NCT01719575|Other|Motilitone|take motilitone 30mg three times daily for the first week After 7 day wash-out period, take placebo three times daily for the second week
3125250|NCT01719575|Other|Placebo|take placebo three times daily for the first week After 7 day wash-out period, take motilitone 30mg three times daily for the second week
3125251|NCT01719562|Experimental|Diagnostic (MRI)|Patients undergo MRI scans for LV function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
3125252|NCT01719549|Experimental|Dovitinib|
3125253|NCT01719536|Experimental|Icotinib|Icotinib 125mg is administered orally three times per day.
3125254|NCT01719536|Active Comparator|Chemotherapy|Patients in this arm will receive pemetrexed/cisplatin for 4 cycles, of who don't progress will receive maintenance treatment with pemetrexed.
3125255|NCT01719523|Experimental|EPI-743|EPI-743- Participants will receive 200mg three times a day of EPI-743 for 2 weeks and then receive 300mg of EPI-743 for an additional 2 weeks.
3125256|NCT01719510|Other|Positive Group B Streptococcus vaginal sample|"At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.~For all women included will be achieved in the delivery room:~a blood sample to the mother and a sampling of umbilical cord blood. Newborns will have a search for GBS (standard culture) in the stools and the pharynx.~For mothers, the collection of milk when breastfeeding."
3125257|NCT01719497||Alcohol|Subjects diagnosed with alcohol dependence
3125258|NCT01719497||Obese|Subjects diagnosed with obesity
3125259|NCT01719497||High Stress|Subjects diagnosed with high stress
3125260|NCT01719497||Healthy|Subjects deemed medically healthy
3125261|NCT01719484||Healthy|Subjects deemed to be medically healthy
3125262|NCT01719484||Obese|Subjects deemed to be medically obese
3125263|NCT01719471||Smokers|Nicotine dependent individuals otherwise medically healthy
3125264|NCT01719471||Healthy|Medically healthy individuals who do not smoke
3125265|NCT01719458||Alcohol|Subjects diagnosed with alcohol dependence
3125266|NCT01719458||Obese|Subjects diagnosed with obesity
3125267|NCT01719458||Healthy|Subjects deemed to be medically healthy
3125268|NCT01719445||RFPM/Paper and Pen Method|
3125269|NCT01719432||Obese patients|
3125270|NCT01719432||Non-obese patients|
3125271|NCT01719419|Experimental|Placebo|Fatty food intake on the day the Modified sham feeding technique with placebo compared to the day modified sham feeding with orlistat.
3125272|NCT01719419|Experimental|Orlistat|Fatty food intake on the day of the modified sham feeding technique with orlistat compared to the day with placebo.
3125273|NCT01719406|Experimental|Intervention, behavioral lifestyle education|Pregnant women will participate in 20 educational sessions designed to promote daily exercise, vegetable and fruit intake, maintain a diet that is relatively lower in fat and rich in whole grains.
3125274|NCT01719406|No Intervention|Control|Standard medical care
3125275|NCT01719380|Experimental|LGX818 + cetuximab|
3125276|NCT01719380|Experimental|LGX818 + BYL719 + cetuximab|
3125277|NCT01719367|Experimental|Atenolol|Patients will undergo a standardized, graded exercise protocol before ank after receiving a dose of oral atenolol.
3125278|NCT01719354|Experimental|Community Health center|Aftercare in a community Health center
3125279|NCT01719354|Active Comparator|Control|AFtercare as usual in hospital/Mental health centers of District Psychiatric Service (DPS.
3125280|NCT01719328|Experimental|Vinyasa yoga|Group administered 60 minute vinyasa yoga classes delivered twice weekly for 8 weeks
3125281|NCT01719315||MDD with Hypersomnia|Participants with Major Depressive Disorder and co-morbid hypersomnia
3125282|NCT01719315||MDD without hypersomnia|Participants with Major Depressive Disorder but without co-morbid hypersomnia
3125283|NCT01719315||BPAD with hypersomnia|Participants with Bipolar Affective Disorder and co-morbid hypersomnia
3125284|NCT01719315||BPAD without hypersomnia|Participants with Bipolar Affective Disorder without co-morbid hypersomnia
3125285|NCT01719315||Primary Hypersomnia|Patients with primary hypersomnia (idiopathic hypersomnia)
3125286|NCT01719315||Primary Insomnia|Patients with primary insomnia
3125287|NCT01719315||Narcolepsy|Subjects with narcolepsy
3125288|NCT01719315||Healthy Controls|healthy participants
3125289|NCT01719302|Experimental|cohort 1|
3125290|NCT01719289|Experimental|PROGRAVIDA|All women in this arm receive a stepped-care program for depression based on psycho-education and problem solving techniques.
3125291|NCT01719289|No Intervention|Treatment as usual|Primary health care professionals in charge of prenatal care are notified by the research team about all women with depression receiving pre-natal care and included in the trial. Primary health care professionals decide how to treat these women without any interference from the research team.
3125292|NCT01719276|Active Comparator|Graded Activity|Exercise treadmill, Strengthening of the lower limbs and trunk
3125293|NCT01719276|Active Comparator|Supervised exercises|Stretching, Strengthening, Motor Control
3125294|NCT01719263|Experimental|Treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System and Optimal Medical Therapy
3125295|NCT01719263|Active Comparator|Optimal Medical Therapy|Patients will be treated according to Optimal Medical Therapy
3125296|NCT01719250|Experimental|Treatment (buparlisib)|Patients receive buparlisib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3125297|NCT01719237|Active Comparator|Ropivacine and Cholroprocaine mixture|20 ml's of 1% ropivacaine + 10 ml's of 3% 2-chloroprocaine + 0.1 ml of 1 mg/ml epinephrine
3125298|NCT01719237|Sham Comparator|Ropivacine only|30 ml syringe with either 20 ml's of 1% ropivacaine + 10 ml's of normal saline + 0.1 ml of 1mg/ml epinephrine
3125299|NCT01719224|Active Comparator|Elevated body position|We collect data about the apnea- hypopnea index, obstructive and central apneas, as well as oxygen, by comparing supine to 45 degrees elevated body position.
3125300|NCT01719224|Active Comparator|supine body position|We collect data about the apnea- hypopnea index, obstructive and central apneas, as well as oxygen, by comparing supine to 45 degrees elevated body position.
3125419|NCT01718418|Experimental|+ ind.CHO + prebiotics|test meal: intrinsic indigestible carbohydrates in combination with a combined probiotic supplement.
3125301|NCT01719185|Experimental|Phentermine and B12|Those in the experimental group will take 37.5 mg of phentermine daily as well as receive 1000 mg intramuscular injections of B12 weekly.
3125302|NCT01719185|Active Comparator|Phentermine|Those in the control group will take phentermine 37.5 mg daily as well as receive 1000 mg intramuscular injections of saline weekly.
3125303|NCT01719172|Experimental|Veriset™ Hemostatic Patch|Topical hemostat
3125304|NCT01719159|Experimental|Rituximab|Rituximab, 25 mg, is administrated intrathecal three times one week apart
3125305|NCT01719146||UofL Subjects|Subjects undergoing Specimen Collection at University Kidney Center, University of Louisville, Louisville, KY
3125306|NCT01719146||Duke Subjects|Subjects undergoing Specimen Collection at Duke University, Durham, NC
3125307|NCT01719146||WNERTA Subjects|Subject undergoing Specimen Collection at Western New England Renal and Transplant Associates, Springfield, MA
3125308|NCT01719133|Other|All subjects|placebo histamine T1 T2 T3 T4 T5 T1-T2-T3 T4-T5
3125309|NCT01719120|Experimental|Self-help CBT with tel. consultation|Self-help CBT with tel. consultation (SHTC)group will receive telephone consultation provided by the investigator in addition to self-help cognitive-behavioral therapy once per week for 6 consecutive weeks.During the consultation, the investigator will answer questions about the treatment content, monitor whether the subjects read the assigned materials and comply with the tasks and procedures, and provide encouragement and support.
3125310|NCT01719120|Experimental|Self-help CBT|The subjects will receive self-help cognitive-behavioral therapy (SH)once per week for 6 consecutive weeks.
3125311|NCT01719120|No Intervention|Waiting-list control (WL)|Subjects in this group will not receive any kind of treatment during the waiting period. They will receive the treatment identical to the self-help group within 3 months from the baseline.
3125312|NCT01719107|Active Comparator|L. reuteri DSM 17938 chewable tablets|The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri DSM 17938 is 1x108 live bacteria (CFU)/tablet.
3125313|NCT01719107|Placebo Comparator|Placebo chewable tablets|The placebo study product consists of an identical formulation in all respects except that the live bacteria are excluded.
3125314|NCT01719094||Childhood Cancer Surviviors|
3125315|NCT01719094||Adolescent/young adults with no cancer history|
3125316|NCT01719094||Newly diagnosed cancer patients|
3125317|NCT01719081|Experimental|Ultrasound Guided SIJ Injection|Needle placement will be performed under US guidance. Fluoroscopy will be used to confirm needle placement prior to medication injection.
3125318|NCT01719081|Active Comparator|Xray Guided SIJ Injection|Needle placement will be performed under fluoroscopy.
3125319|NCT01719068||Workers exposed to asbestos|
3125320|NCT01719055||Precision Plus|Subjects permanently implanted with a Boston Scientific Precision Plus neurostimulation system
3125321|NCT01719055||Alternative Boston Scientific systems|Subjects permanently implanted with other Boston Scientific neurostimulation systems
3125322|NCT01719042|Active Comparator|Zofran (8mg)|Participant will take Zofran (8mg) once per day before taking their antibiotic regimen
3125323|NCT01719042|Active Comparator|Ensure|Subject will drink a can of Ensure before taking their antibiotic regimen
3125324|NCT01719029|Experimental|Conventional Diet|Low carbohydrate/higher fat diet: 40% carbohydrate, 45% fat, 15% protein
3125325|NCT01719029|Experimental|Complex Carbohydrate Diet|High complex carbohydrate/lower fat diet: 60% complex carbohydrate, 25% fat, 15% protein
3125326|NCT01719016||Cardiac PET, Coronary catheterization|"Cardiac PET scan:~Injection of N-13 Ammonia radionuclide. 2 doses of 10 milliCuries and 20 milliCuries each.~Injection of Lexiscan.~Coronary catheterization:~Pressure and flow readings using Combowire~Injection of Adenosine."
3125327|NCT01719003|Experimental|Empagliflozin low dose qd|Empagliflozin low dose once daily
3125328|NCT01719003|Experimental|Empagliflozin high dose qd|Empagliflozin high dose once daily
3125329|NCT01719003|Experimental|OL empa high dose + met 1000 mg bid|Open label empagliflozin high dose split twice daily + metformin 1000 mg twice daily - Patients are no longer enrolled into this arm because of change in the inclusion criteria in protocol version 2.0 all patients are now enrolled into remaining double-blind arms. Patients already enrolled in the open-label arm according to protocol version 1.0 can complete the study.
3125330|NCT01719003|Experimental|Empagliflozin low dose + met 500 mg bid|Empagliflozin low dose split twice daily + metformin 500 mg twice daily
3125331|NCT01719003|Experimental|Empagliflozin low dose + met 1000 mg bid|Empagliflozin low dose split twice daily + metformin 1000 mg twice daily
3125332|NCT01719003|Experimental|Empagliflozin high dose + met 500 mg bid|Empagliflozin high dose split twice daily + metformin 500 mg twice daily
3125333|NCT01719003|Experimental|Empagliflozin high dose + met 1000mg bid|Empagliflozin high dose split twice daily + metformin 1000 mg twice daily
3125334|NCT01719003|Experimental|Metformin 500 mg bid|Metformin 500 mg twice daily
3125335|NCT01719003|Experimental|Metformin 1000 mg bid|Metformin 1000 mg twice daily
3125336|NCT01718990||Patients with Idiopathic Pulmonary Fibrosis (IPF)|Sixty patients with IPF will be included in this prospective cohort;15 IPF patients per year for years 1-4.
3125337|NCT01718990||Healthy Volunteers|Sixty normal controls will be recruited from volunteers.
3125338|NCT01718977|Experimental|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
3125485|NCT01717976|No Intervention|Control|usual care
3125339|NCT01718977|Active Comparator|Arm Cycle Ergometry Training|"Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.~The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session."
3125340|NCT01718964|Other|A|Cortisol 20 mg /Placebo Mannitol
3125341|NCT01718964|Other|B|Placebo Mannitol/Cortisol 20mg
3125342|NCT01718951|Active Comparator|golimumab|golimumab 50mg subcutaneous every 4 weeks
3125343|NCT01718951|Active Comparator|pamidronate|Pamidronate (60mg) intravenously every 4 weeks
3125344|NCT01718938|Experimental|Sequence 1|3-way crossover of velusetrag or placebo
3125345|NCT01718938|Experimental|Sequence 2|3-way crossover of velusetrag or placebo
3125346|NCT01718938|Experimental|Sequence 3|3-way crossover of velusetrag or placebo
3125347|NCT01718938|Experimental|Sequence 4|3-way crossover of velusetrag or placebo
3125348|NCT01718925||Inflammatory Bowel Disease|Ulcerative Colitis and Crohns's disease patients will be recruited from sqeduled outpatient follow-up
3125349|NCT01718925||Irritable Bowel Syndrome|Irritable Bowel patients will be recruited from sqeduled outpatient follow-up
3125350|NCT01718925||Rheumatoid Arthritis|Rheumatoid Arthritis patients will be recruited from sqeduled outpatient follow-up
3125351|NCT01718925||Diabetes Mellitus|Diabetes mellitus patients will be recruited from sqeduled outpatient follow-up
3125352|NCT01718912|Other|Metronidazole-nystatin oral rinse, regular oral hygiene|Week 1: daily brushing with suction brush. Week two: daily brushing with a mixture of metronidazole-nystatin suspension.
3125353|NCT01718899|Experimental|PVX-410, .4 mg dose|Approximately 3 patients will receive 6, bi-weekly, subcutaneous injections of a .4 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
3125354|NCT01718899|Experimental|PVX-410, .8 mg dose|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
3125355|NCT01718899|Experimental|PVX-410 plus lenalidomide|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will also receive 3 cycles of lenalidomide. Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
3125356|NCT01718886||Obalon Gastric Balloon|Patients received 1-3 Obalon Gastric Balloons over a period of 12 weeks
3125357|NCT01718873|Experimental|bevacizumab before chemotherapy|Bevacizumab administered 4 days before each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)
3125358|NCT01718873|Active Comparator|bevacizumab with chemotherapy|Bevacizumab administered on the first day of each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)
3125359|NCT01718860||Postoperative Residual Paralysis|Patients with train-of-four ratio less than 0.9 measured in the postanesthesia care unit
3125360|NCT01718860||No Postoperative Residual Paralysis|Patients with train-of-four ratio greater than 0.9 measured in the postanesthesia care unit
3125361|NCT01718847|Experimental|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
3125362|NCT01718834|Active Comparator|prophylactic vaccine|6 monthly doses each of 648 ug of prophylactic vaccine subcutaneously injected to healthy volunteers
3125363|NCT01718834|Active Comparator|therapeutic vaccine|6 monthly doses each of 648 ug subcutaneously injected to chronic HCV patients
3125364|NCT01718821||Advanced upper GI cancer patients|Upper GI cancers include: esophageal cancer, gastric cancer, ampulla vater cancer, pancreatic cancer and cholangiocarcinoma.
3125365|NCT01718808|Active Comparator|Arm A: Cetuximab|Cetuximab 500 mg/m2 every 2 weeks
3125366|NCT01718808|Active Comparator|Arm B: Cetuximab and Capecitabine|"Cetuximab 500 mg/m2 every 2 weeks plus Capecitabine 1000 mg/m2 (*) bid d1-14 every 3 weeks~* 750 mg/m2 if creatinine-clearance 30-50 ml/min"
3125367|NCT01718795|Active Comparator|Bag-valve mask ventilation|"Bag-valve mask ventilation during CPR, i.e. traditional ventilation during CPR. Airway management with bag-valve mask ventilation and efficient ventilation: yes or no?~Intervention is Bag-valve mask ventilation during CPR"
3125368|NCT01718795|Active Comparator|Laryngeal Tube|"Laryngeal Tube Ventilation during CPR, i.e. the alternative ventilation technique to be compared to the traditional technique. Airway management with laryngeal tube and efficient ventilation: yes or no?~Intervention is Ventilation through laryngeal tube during CPR"
3125369|NCT01718782|Active Comparator|laryngeal mask Ambu AuraOnce|laryngeal mask Ambu AuraOnce
3125370|NCT01718782|Active Comparator|laryngeal mask LMA Supreme|laryngeal mask LMA Supreme
3125371|NCT01718769|Active Comparator|STAMP using|100 boys and girls aged 1 to 6, attending Clalit Health Care Services Pediatric Centers, will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
3125372|NCT01718769|Placebo Comparator|No STAMP using|150 files shall be reviewed in the beginning of the research and after 6 months in order to estimate the change in medical staff's attention to nutritional status, by way of noting relevant diagnoses, reference to nutritional status- related tests and recording of anthropometric measurements.
3125373|NCT01718756|Placebo Comparator|Placebo|The placebo group received 12 hourly boluses of 0.9% saline, followed by a constant infusion for 48 hrs after surgery.
3125374|NCT01718756|Active Comparator|Scheduled|They received a 12 hourly boluses of lornoxicam followed by a constant infusion of 0.9% saline, for 48 hrs after surgery
3125375|NCT01718756|Active Comparator|Continuous infusion|They received boluses of lornoxicam 0.8 mg/mL before induction of anaesthesia followed by a 12 hourly boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery.
3125376|NCT01718743|Experimental|Lenalidomide + MLN9708|Lenalidomide 10 mg by mouth every day in a 28 day cycle. After three months, the dose may be increased to 15 mg/day at discretion of physician. MLN9708 3 mg by mouth on days 1, 8, 15 in a 28 day cycle. Questionnaire completion on Day 1 of Cycle 1, 2 and beyond.
3125377|NCT01718730||Mild depression|Subjects with mild, but clinically significant depression
3125378|NCT01718730||Moderate to Severe MDD|Subjects with moderate to severe major depressive disorder who have not yet initiated treatment with an SSRI
3125379|NCT01718730||MDD with response to SSRI|Subjects with moderate to severe major depressive disorder that has responded to an SSRI
3125380|NCT01718730||MDD without response to SSRI|Subjects with moderate to severe major depressive disorder which has not responded to treatment with an SSRI
3125381|NCT01718717|Active Comparator|6 days TEA|Postoperative analgesia for the first six postoperative days with TEA and daily monitoring for arrhythmia
3125382|NCT01718717|Active Comparator|3 days TEA and 3 days intravenous morphine|Postoperative analgesia for the first three postoperative days with TEA followed for the next three days with intravenous morphine, and daily monitoring for arrhythmia
3125383|NCT01718704|Experimental|Viberect device|Men in this group will begin using the Viberect device 3 days after Foley catheter removal after surgery on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting.
3125384|NCT01718704|No Intervention|No Viberect|Men in this group will not be provided with the Viberect device
3125385|NCT01718691|Experimental|SyB L-0501＋rituximab|
3125386|NCT01718678|Active Comparator|Melatonin|Melatonin, Tablet, 3 mg, once, one month
3125387|NCT01718678|Placebo Comparator|Placebo|Placebo, tablet
3125388|NCT01718652|Experimental|Canagliflozin + cyclosporine|Each volunteer will receive canagliflozin (JNJ-28431754) once daily on Days 1 through 8 with a single dose of cyclosporine on Day 7.
3125389|NCT01718639|Active Comparator|IQP-LH-101 tablet|4 chewable tablets to be chewed thoroughly before swallowing
3125390|NCT01718639|Active Comparator|IQP-LH-101 liquid|2 liquid sachets to be emptied into the mouth and consumed.
3125391|NCT01718639|Placebo Comparator|Placebo|1 tablet to be swallowed with water.
3125392|NCT01718626|Active Comparator|S1+Docetaxel|
3125393|NCT01718626|Experimental|S1+Docetaxel followed by S1|
3125394|NCT01718613|Active Comparator|Norepinephrine|
3125395|NCT01718613|Active Comparator|Vasopressin|
3125396|NCT01718600||Neuroimaging Correlates|Carotid revascularization can significantly reduce the risk of stroke in patients with severe carotid stenosis; however, it has been associated with cognitive decline in 25% of the older adults who undergo the procedure. Neuroimaging techniques that characterize white matter integrity and regional hypoperfusion have the potential to provide sensitive brain structure indicators that may be associated with memory decline following revascularization procedures. In this proposal, we hope to determine the risk factors and cognitive effect of microembolization following carotid revascularization procedures.
3125397|NCT01718587|Experimental|stem cell transplantation therapy|umbilical cord mesenchyma stem cell transplantation through interventional procedures do in liver cirrhosis patients.
3125398|NCT01718587|Active Comparator|antiviral therapy|"Antiviral therapy: lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).~Supportive therapy are allowed to use on patients not including intravenous infusions of plasma or albumin."
3125399|NCT01718574|Experimental|Self-help book|
3125400|NCT01718574|No Intervention|Usual Care Control|
3125401|NCT01718561|No Intervention|Control|Usual clinical airway evaluation and usual registration in Danish Anaesthesia Database (without SARI registration)
3125402|NCT01718561|Experimental|SARI|Registration of Modified SARI score and predictors for difficult mask ventilation in Danish Anaesthesia Database
3125403|NCT01718548|Active Comparator|CS and Lingzhi|CS liquid (each dosage is a bottle of liquid containing 30 ml: comprising 75% of CS, 6% Lingzhi, 6% shitake, 5% bamboo shoot, 2% honey, 0.1% potassium sorbet and 5.9% pure water) and Lingzhi capsule (each capsule contains 620mg of: 52.42% Lingzhi, 28.23% CS, and 19.35% soy gel ) ; one quarter bottle of CS to be ingested twice a day, and the Lingzhi capsule to be taken once a day, both for a period of 28 days.
3125404|NCT01718548|Placebo Comparator|Placebo|Liquid tea ingested twice a day and flour-filled capsules ingested once a day over a period of 28 days
3125405|NCT01718535||CYP2C19 Genotyping|
3125406|NCT01718509|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
3125407|NCT01718509|Placebo Comparator|Placebo|
3125408|NCT01718496|Active Comparator|Morphine|Patient with advance COPD who will randomly receive single dose oral Morphine
3125409|NCT01718496|Placebo Comparator|Placebo|patient with advanced COPD who will receive Placebo
3125410|NCT01718483|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
3125411|NCT01718483|Placebo Comparator|Placebo|
3125412|NCT01718470|Active Comparator|Endotracheal tube|At the end of surgery, emerge from anesthesia with the ETT still in place
3125413|NCT01718470|Active Comparator|Laryngeal mask|At the end of surgery,emerge from anesthesia after ETT had been replaced by an LMA.
3125414|NCT01718457|Experimental|Endobarrier device insertion|
3125415|NCT01718444|Experimental|Group A (No PIES)|"Subjects randomized to this group will receive clomiphene citrate (CC) without using progestin throughout their treatment course.~CC 50 mg oral for 5 days (Days 3-7)~If no ovulation, CC 100 mg for 5 days (Days 12-16)~If no ovulation, CC 150 mg for 5 days (Day 21-25)~Exit study if no response to 150 mg CC, or if no pregnancy after 5 ovulatory cycles"
3125416|NCT01718444|Active Comparator|Group B (PIES Group)|"Women randomized to this group will receive progestin to induce endometrial shedding before starting any doses of clomiphene citrate (CC)~Progestin 10 mg oral for 10 days to induce endometrial shedding (PIES)~CC 50 mg oral for 5 days (Day 3-7)~If no ovulation, progestin 10 mg for 10 days to induce endometrial shedding (starting on CD28) and CC 100 mg x 5 days, starting on day 3 of induced menses~If no ovulation, progestin 10 mg for 10 days to induce endometrial shedding, and CC 150 mg for 5 days~Exit study if no response to 150 mg CC, or if no pregnancy after 5 ovulatory cycles"
3125417|NCT01718431|Experimental|indigestible carbohydrates|test meal: indigestible carbohydrates
3125418|NCT01718431|Experimental|reference|reference meal: no indigestible carbohydrates
3200675|NCT01193582|Experimental|Group 3|
3125420|NCT01718418|Experimental|+ ind.CHO - prebiotics|test meal: intrinsic indigestible carbohydrates in combination with placebo probiotic supplement.
3125421|NCT01718418|Experimental|- ind.CHO - prebiotics|reference: no ind. carbohydrates and no probiotic supplement
3125422|NCT01718405|Experimental|Exercise Group|Each individual subject will give a blood sample for genetic analysis and undertake an exercise session and a rest session as a control. Cognitive function will be tested before and after each session.
3125423|NCT01718392|Experimental|Training|24 weeks combined exercise programme (supervised)
3125424|NCT01718392|No Intervention|Control|sedentary/habitual lifestyle
3125425|NCT01718379|Experimental|Arm A|"Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses.~Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.~Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.~The patients will be followed every 3 months for 12 months"
3125426|NCT01718379|Experimental|Arm B|"Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses combined with weekly subcutaneous injections of Epoetin beta (60,000 Units/w).~Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.~Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.~The patients will be followed every 3 months for 12 months"
3125427|NCT01718366|Experimental|ferritin level >300ng/ml and < 1000ng/ml|"Patients will be included in 2 groups according to the ferritin level at time of inclusion.~Patients with the ferritin level >300ng/ml and < 1000ng/ml, will be included in Group 1.~Interventions: Deferasirox, Vitamin D (100000/week) and Azacitidine (75 mg/kg/day Day1 today 7)~5 patients in each cohort: Cohort 1: Deferasirox: 5mg/kg/d Cohort 2: Deferasirox: 10mg/kg/d Cohort 3: Deferasirox: 15mg/kg/d"
3125428|NCT01718366|Experimental|ferritin level > 1000ng/ml|"Patients will be included in 2 groups according to the ferritin level at time of inclusion.~Patients with the ferritin level > 1000ng/ml, will be included in Group 2. Intervention: Deferasirox, Vitamin D (100000/week) and Azacitidine (75 mg/kg/day Day1 today 7)~5 patients in each cohort: Cohort 1: Deferasirox: 10mg/kg/d Cohort 2: Deferasirox: 15mg/kg/d Cohort 3: Deferasirox: 20mg/kg/d"
3125429|NCT01718353|Experimental|Docetaxel + Prednisone (Treatment A)|Docetaxel 75 mg/m^2 intravenous (IV) infusion on Day 1 of Cycle 1 and every 3 weeks (q3w) thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily. Participants with <30% PSA reduction from baseline at the end of Cycle 4 switched to Cabazitaxel 25mg/m^2 IV infusion on Day 1 of Cycle 5 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), death, unacceptable toxicity or participant's refusal of further study treatment. Participants with ≥30% PSA reduction from baseline at the end of Cycle 4, continued on the same treatment which they received before switching until DP, death, unacceptable toxicity or participant's refusal of further study treatment.
3125430|NCT01718353|Experimental|Cabazitaxel + Prednisone (Treatment B)|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of Cycle 1 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily. Participants with <30% PSA reduction from baseline at the end of Cycle 4 switched to Docetaxel 75mg/m^2 IV infusion on Day 1 of Cycle 5 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, death, unacceptable toxicity or participant's refusal of further study treatment. Participants with ≥30% PSA reduction from baseline at the end of Cycle 4, continued on the same treatment which they received before switching until DP, death, unacceptable toxicity or participant's refusal of further study treatment.
3125431|NCT01718340|Experimental|Metformin|The patients with PCO and hyper insulinemia will be subdivided into two groups, one group will continue metformin 500 mg three times per day from the start of induction of ovulation till the end of pregnancy, the other group will stop the drug once pregnancy test become positive
3125432|NCT01718327|Experimental|open label, single arm|single arm: sunitinib until progresion or unacceptable toxicity
3125433|NCT01718314|Experimental|Sublingual Misoprostol & Lidocaine placebo|Misoprostol 200 µg sublingually single dose and Lidocaine spray placebo
3125434|NCT01718314|Experimental|Lidocaine Pump Spray & Misoprostol placebo|Lidocaine Pump spray, 6 sprays to cervix (60 mg totally) and sublingual misoprotol placebo
3125435|NCT01718301|Experimental|boceprevir + ribavirin + peginterferon|boceprevir 800 mg three times a day (v.o.) in combination with peginterferon (alfa-2b or alfa-2a) and ribavirin
3125436|NCT01718288|Experimental|iloprost + standard treat.(aspirin)|1B - patients unsuitable to surgical or endovascular vascular therapy: treatment with iloprost intravenous infusions for 10 days every 3 months, in addition to conventional treatment
3125437|NCT01718288|Active Comparator|Standard Treatment (aspirin....)|"1A - patients unsuitable to surgical or endovascular vascular therapy: conventional treatment~Conventional Treatments:correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin / low molecular weight heparin, hemorheological / vasodilators such as pentoxifylline / buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids"
3125438|NCT01718288|Experimental|Vascular surgery patients + iloprost|2B - patients suitable to vascular surgical or endovascular therapy: treatment with intravenous infusions iloprost for 10 days every 3 months, in addition to conventional treatment
3125439|NCT01718288|Active Comparator|Vasc. Surg.+ standard treat. (aspirin..)|2A - patients suitable to vascular surgical or endovascular therapy + standard treatment (aspirin...)
3125440|NCT01718275||Non-operative Group|Patients and caregivers who agree to receive non-operative management with antibiotics alone
3125441|NCT01718275||Surgery Group|Patients and caregivers who decide to undergo appendectomy that permit us to track their standard treatment course
3125442|NCT01718249|Other|deep brain stimulation|
3125443|NCT01718236|Experimental|Rocuronium + sugammadex|Intubation after rocuronium administration and reversal of blockade after administration of sugammadex
3125444|NCT01718236|Experimental|Succinylcholine + Neostigmine|Intubation after succinylcholine administration, neuromuscular block is than maintained by rocuronium administration and reversal of block is by neostigmine + atropine administration
3125445|NCT01718223|Experimental|Treatment (interstitial photodynamic therapy using temoporfin)|Patients receive temoporfin IV over at least 6 minutes on day 1 and undergo interstitial photodynamic therapy on day 3. Within 4-6 weeks, patients undergo surgical resection.
3125447|NCT01718210|Placebo Comparator|CONTROL|50 women with recurrent implantation failure (at leat three previous IVF attempts failed with at least 8 good embryos transferred in uterus)that the obtained with IVF are incubated with a standard medium for IVF, and utilized as control group.
3125448|NCT01718197||Mild-to-Moderate Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
3125449|NCT01718197||Severe Asthma|"Major Criteria: (1 required)~Treatment with oral corticosteroids for at least 6 of the previous 12 months~Treatment with high-dose inhaled corticosteroids (ICS) for at least 10 of the previous 12 months~Minor Criteria: (2 required)~Daily treatment with an asthma controller medication in addition to ICS, or~Asthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis, or~Persistent airway obstruction with baseline FEV1 <80% predicted, or~≥ 1 urgent visits for asthma in the previous 12 months, or~≥ 3 systemic corticosteroid bursts in the previous 12 months, or~Prompt deterioration with a reduction in oral or inhaled corticosteroid dose, or~A near-fatal asthma event (i.e., intubation) in the past"
3125450|NCT01718197||Healthy Controls|Those without asthma or other chronic lung disease.
3125451|NCT01718184|Experimental|Sulcoflex|Sulcoflex intraocular lens implantation
3125452|NCT01718171||Group I, Group II, Group III, Group IV|Values and results of the Systemic Inflammatory Response and C-reactive protein to appendicitis
3125453|NCT01718158|Experimental|Peginterferon Lambda-1a + Ribavirin + Daclatasvir|"Peginterferon Lambda-1a 180 µg solution for subcutaneous injection, once a week for 24 Weeks~Ribavirin 200 mg tablets [1000-1200 mg total daily dose: subjects should take either 400 mg (2 tablets for subjects < 75 kg) or 600 mg (3 tablets for subjects ≥ 75 kg) in the morning with food and 600 mg (3 tablets) in the evening with food] by mouth, twice daily, for 24 weeks~Daclatasvir 60 mg tablets by mouth, once a day for 12 weeks"
3125454|NCT01718158|Experimental|Peginterferon Alfa-2a + Ribavirin + Telaprevir|"Peginterferon Alfa-2a 180 µg solution for subcutaneous injection, once a week for 24 to 48 weeks depending on response~Ribavirin 200 mg tablets [1000-1200 mg total daily dose: subjects should take either 400 mg (2 tablets for subjects < 75 kg) or 600 mg (3 tablets for subjects ≥ 75 kg) in the morning with food and 600 mg (3 tablets) in the evening with food] by mouth, twice daily, for 24 to 48 weeks depending on response~Telaprevir 375 mg tablets [2250 mg total daily dose: subjects should take 750 mg (two 375 mg tablets) orally three times a day, approximately 7-9 hours apart) for 12 weeks"
3125455|NCT01718145|Experimental|Arm 1: Daclatasvir + Asunaprevir|"Daclatasvir 60 mg tablets by mouth once daily and Asunaprevir 200 mg capsules by mouth twice daily for 24 weeks~- Naive cohort"
3125456|NCT01718145|Active Comparator|Arm 2: Telaprevir + pegIFNα-2b + Ribavirin|"Telaprevir 750 mg tablets by mouth three times daily, pegIFNα-2b 1.5 μg/kg solution by Subcutaneous weekly & Ribavirin 600- 1000 mg Capsules by mouth twice daily for 24 Weeks~- Naive cohort"
3125457|NCT01718145|Experimental|Arm 3: Daclatasvir + Asunaprevir|"Daclatasvir 60 mg tablets by mouth once daily and Asunaprevir 200 mg capsules by mouth twice daily for 24 weeks~- Relapser cohort"
3125458|NCT01718132||postoperative patients|
3125459|NCT01718119|Experimental|DA-3803|subjects treated with DA-3803(r-hCG)
3125460|NCT01718119|Active Comparator|Ovidrel|subjects treated with Ovidrel(r-hCG)
3125461|NCT01718106|Active Comparator|Single long bioabsorbable polymer DES|Patients with long coronary stenosis treated by a single long bioabsorbable polymer DES
3125462|NCT01718106|Active Comparator|Two bioabsorbable polymer DES in overlapping|patients with long coronary artery stenosis tretaed by 2 bioabsorbable polymer DES with minimal overlapping
3125463|NCT01718093|Active Comparator|Insulin plus sitagliptin|The subjects continued their usual insulin regimen throughout the study. Sitagliptin was started and continued at 50 mg orally twice daily
3125464|NCT01718093|Active Comparator|Insulin plus metformin|The subjects continued their usual insulin regimen throughout the study. Metformin was started at 500 mg orally daily. The dose was increased over a 2 week period up to 2,000 mg per day as tolerated.
3125465|NCT01718093|Active Comparator|Insulin plus sitagliptin and metformin|The subjects continued their usual insulin regimen throughout the study. Sitagliptin was started and continued at 50 mg orally twice daily. Metformin was started at 500 mg orally daily. The dose was increased over a 2 week period up to 2,000 mg per day as tolerated.
3125466|NCT01718080||Group A|Healthy lean children before puberty
3125467|NCT01718080||Group B|Otherwise healthy overweight children before puberty
3125468|NCT01718080||Group C|Healthy lean adolescents in mid to late puberty
3125469|NCT01718080||Group D|Otherwise healthy overweight adolescents in mid to late puberty
3125470|NCT01718067|Experimental|Vakum|VAKÜM system (Free Aspire, MPR, Legnano-I) added to the conventional manual ELTGOL technique
3125471|NCT01718067|Active Comparator|Control|conventional manual ELTGOL technique
3125472|NCT01718054|Active Comparator|vascular|In this intervention period children will receive a vascular ready-to-use supplementary food with added L-Arginine & L-Citrulline plus daily chloroquine
3125473|NCT01718054|Active Comparator|regular|In this intervention period children will receive a regular ready-to-use supplementary food plus weekly dose of chloroquine
3125474|NCT01718041|Experimental|VRS-317|Active treatment arm
3125475|NCT01718028|Experimental|SYSTANE® BALANCE|Propylene glycol 0.6% ocular emulsion, 1 drop in each eye 4 times a day for 30 days
3125476|NCT01718028|Active Comparator|LARMABAK®|Sodium chloride 0.9% saline solution, 1 drop in each eye 4 times a day for 30 days
3125477|NCT01718015||Patients with diabetic polyneuropathy|
3125478|NCT01718015||Patients with diabetes without peripheral nerve disorder|
3125479|NCT01718015||Patients with polyneuropathies not due to diabetes|
3125480|NCT01718015||Patients not suffering from diabetes or nerve disease|Control subjects
3125481|NCT01718015||Patients with unspecified nerve disease|
3125482|NCT01718002|Other|Educational video on oral hygiene|The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
3125483|NCT01717989||Cohort|Patients with end-stage renal disease (ESRD) treated at small dialysis organizations (SDOs).
3125486|NCT01717963|Experimental|Naltrexone intramuscular suspension|Extended release naltrexone injections 380mg
3125487|NCT01717963|Active Comparator|Buprenorphine-naloxone|Flexible oral dose 4-24 mg daily
3125488|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel®|
3125489|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel® plus 2.5 µg GLA-AF|
3125490|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel® plus 5.0 µg GLA-AF|
3125491|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel®|
3125492|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel® plus 2.5 µg GLA-AF|
3125493|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel® plus 5.0 µg GLA-AF|
3125494|NCT01717937||PVOCT|Subjects will receive fluorescein angiography (FA) as part of their normal clinical evaluation and will undergo phase variance optical coherence tomography (PV-OCT) as the study intervention. This involves having subjects undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images.
3125495|NCT01717924|Active Comparator|peri-operative chemotherapy|Neoadjuvant chemotherapy with 3 cycles of Epirubicin/Cisplatin/5 fluoro-uracil (oral or intra-veinous) Surgery within 3 and 6 weeks after the end of neoadjuvant chemotherapy Adjuvant chemotherapy with 3 cycles of the same chemotherapy within 6 and 12 weeks after surgery
3125496|NCT01717924|Experimental|surgery first with adjuvant chemotherapy|Surgery first Adjuvant chemotherapy with 3 cycles of Epirubicin/Cisplatin/5FU within 6 and 12 weeks after surgery No neoadjuvant chemotherapy
3125497|NCT01717911|Active Comparator|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
3125498|NCT01717911|Experimental|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was <70mg /dl, discontinued the study if blood glucose was still <70mg/dl under sitagliptin 50mg per day.
3125499|NCT01717911|Experimental|Insulin|In the insulin therapy group (Insulin glargine), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Daily dose was administrated before breakfast.
3125500|NCT01717898|Experimental|Abiraterone/prednisone + BEZ235|In Phase I, a dose escalation of BEZ235 will be performed using a standard 3 + 3 design to determine the maximum tolerated dose (MTD) of BEZ235 given in combination with continuous fixed doses of Abiraterone Acetate and prednisone. This BEZ235 dose will be used in the phase II portion of the study.
3125501|NCT01717885||HIV+children on LPV/r|HIV+ children who are stabilized on a LPV/r based ART regimen
3125502|NCT01717885||HIV+ children on nevirapine|HIV+ children who are stabilized on an nevirapine based ART regimen
3125503|NCT01717885||HIV+ children on efavirenz|HIV+ children who are stabilized on an efavirenz based ART regimen
3125504|NCT01717885||HIV+ pregnant women on LPV/r|HIV+ pregnant women who are stabilized on an LPV/r based ART regimen
3125505|NCT01717885||HIV+ pregnant women on NVP|HIV+ pregnant women who are stabilized on an nevirapine based ART regimen
3125506|NCT01717885||HIV+ pregnant women on EFV|HIV+ pregnant women stabilized on an efavirenz based ART regimen
3125507|NCT01717885||HIV negative children|HIV negative children that will serve as a control for HIV positive children on either a LPV/r, NVP or EFV based ART regimen and will be compared to HIV negative non-pregnant adults
3125508|NCT01717885||HIV negative adults|HIV negative adults that will serve as a control for comparing results to HIV negative children and HIV negative pregnant women
3125509|NCT01717885||HIV negative pregnant women|HIV negative pregnant women who will serve as a control for HIV positive pregnant women on either a LPV/r, NVP or EFV based ART regimen and will be compared to HIV negative non-pregnant adults
3125510|NCT01717872|Active Comparator|Macintosh laryngoscope blade|A photo of the larynx will be taken with the Macintosh laryngoscope blade lifting and not lifting the epiglottis. The view of the larynx will be assessed using the Percent of Glottic Opening (POGO) score by a blinded assessor.
3125511|NCT01717872|Active Comparator|Miller laryngoscope blade|A photo of the larynx will be taken with the Miller laryngoscope blade lifting and not lifting the epiglottis. The view of the larynx will be assessed using the percent of glottic opening score by a blinded assessor.
3125512|NCT01717859|Other|Tocilizumab|All subjects will receive tocilizumab.
3125513|NCT01717846|Experimental|Arm 1|Orencia Group is for RA patients who have not received any other biologic treatment, including abatacept previously, and whose doctor has determined that it is appropriate to treat their RA with Abatacept. If you are in Group 1, you will receive the study drug, Abatacept, given in an intravenous (IV - injected into a vein) as well as subcutaneous form. Abatacept, given in an intravenous injection is approved by the FDA for the treatment of RA.
3125514|NCT01717846|Other|Arm 2 or group 2|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
3125515|NCT01717833|Experimental|NEMS group|
3125516|NCT01717833|Sham Comparator|Sham group|
3125517|NCT01717820|Experimental|Freeze-dried whole-grape powder|Freeze-dried whole-grape powder (46g/day)will be provided to participants for 12 weeks.
3125518|NCT01717807||lung cancer; advanced pancreatic cancer|
3125519|NCT01717794|Active Comparator|Standard bipolar electrosurgery|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with standard bipolar electrosurgery.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope.~Two additional 5 mm ports are placed under direct visualization. One more 5-mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
3125572|NCT01717599|Experimental|Diclofenac group|
3125573|NCT01717599|Placebo Comparator|Placebo(normal saline) group|
3125574|NCT01717586|Active Comparator|Pravastatin Group|Pregnant women at high-risk for preeclampsia who are taking pravastatin during their pregnancy.
3126555|NCT01710956|Experimental|Arm 2 (with once-daily TRT)|
3125520|NCT01717794|Experimental|Thunderbeat technology|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with Thunderbeat technology: using Thunderbeat technique, surgeons can avoid changing instruments during surgery since Thunderbeat combines bipolar energy for haemostasis and ultrasound for dissection and cut.~Thunderbeat is used to coagulate the fallopian tubes, to coagulate and divide the round ligaments, to seal ovarian pedicles, to open the anterior and posteriors leaves of the broad ligaments peritoneum, to develop the paravesical and pararectal spaces, to seal uterine arteries and uterine pedicles, to incise the bladder peritoneum, to dissect the bladder, to develop rectovaginal septum, to cut parametria, and to divide the uterosacral ligaments. Thunderbeat is also used to perform the pelvic lymphadenectomy and, if necessary, the para-aortic lymphadenectomy."
3125521|NCT01717781|Experimental|Thunderbeat|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with Thunderbeat technology: using Thunderbeat technique, surgeons can avoid changing instruments during surgery since Thunderbeat combines bipolar energy for haemostasis and ultrasound for dissection and cut.~Thunderbeat is used to divide the round ligaments, to seal ovarian pedicles, to open the anterior and posteriors leaves of the broad ligaments peritoneum, to incise the bladder peritoneum, to develop the paravesical and pararectal spaces, to seal uterine arteries and uterine pedicles, to dissect the bladder and develop rectovaginal septum, to unroof the ureter, to cut parametria, and to divide the uterosacral ligaments. Monopolar hook is used in the culdotomy. Thunderbeat is also used to perform pelvic lymphadenectomy."
3125522|NCT01717781|Active Comparator|Standard|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with standard bipolar electrosurgery.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope.~Two additional 5 mm ports are placed under direct visualization. One more 5-mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
3125523|NCT01717768|Experimental|Part 1: 120 mg BID|Oral TSX-002 120 mg BID (total dose = 240 mg/day) for a duration of 15 days
3125524|NCT01717768|Experimental|Part 1: 240 mg BID|Oral TSX-002 240 mg BID (total dose = 480 mg/day) for a duration of 15 days
3125525|NCT01717768|Experimental|Part 2: 120 mg BID|Single cohort, open-label, nonrandomized oral TSX 002 120 mg BID (total dose = 240 mg/day) for a duration of 15 days
3125526|NCT01717768|Experimental|Part 3: A-B-C 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
3125527|NCT01717768|Experimental|Part 3: B-C-A 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
3125528|NCT01717768|Experimental|Part 3: C-A-B 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
3125529|NCT01717768|Experimental|Part 4 Cohort 1: 60 mg BID/ 60 mg TID|Oral TSX-002 60 mg BID for 15 days then 60 mg TID for 15 days
3125530|NCT01717768|Experimental|Part 4 Cohort 2: 90 mg BID/ 90 mg TID|Oral TSX-002 90 mg BID for 15 days then 90 mg TID for 15 days
3125531|NCT01717768|Experimental|Part 4 Cohort 3: 180 mg QD|Oral TSX-002 180 mg once daily (QD) for 15 days
3125532|NCT01717768|Experimental|Part 4 Cohort 4: 120 mg BID|Oral TSX-002 120 mg BID for 15 days
3125533|NCT01717755|No Intervention|Best medical management.|"Best medical management consists of the standard of care of patients with acute ischemic stroke according to existing local protocols and guidelines, and may include IV thrombolysis.~If treated with IVT as part of BMM, IVT should be started within 4.5 hours of estimated time of BAO."
3125534|NCT01717755|Experimental|Additional intra-arterial treatment.|Best medical management followed by intra-arterial treatment and best medical management
3125535|NCT01717742|Active Comparator|tPA and placebo|
3125536|NCT01717742|Experimental|tPA and DNase|
3125537|NCT01717729|Experimental|RFA-125I group|The combination RFA and 125I (RFA-125I) (n = 68; 42 men, 26 women; mean age, 50.7 years; age range, 29-73 years) In this group, patients were accepted not only radiofrequency ablation (RFA) but also iodine-125.
3125538|NCT01717729|Active Comparator|RFA-only group|(n = 68; 47 men, 21 women; mean age, 48.9 years; age range, 30-74 years) In tis group,the patient were just peformed radiofrequency ablation alnoe.
3125539|NCT01717716|Experimental|Calorie-free control|Calorie-free control
3125540|NCT01717716|Experimental|HFCS-55 drink|HFCS-55 drink
3125541|NCT01717716|Experimental|Glucose drink|Glucose drink
3125542|NCT01717716|Experimental|Sucrose drink|Sucrose drink
3125543|NCT01717703|Experimental|Water Control|Water Control
3125544|NCT01717703|Experimental|Fruit drink|Fruit drink
3125545|NCT01717703|Experimental|Cola|Cola
3125546|NCT01717703|Experimental|1% chocolate milk|1% chocolate milk
3125547|NCT01717690|Active Comparator|CHG antiseptic body cleanser|"One randomly selected intervention unit in Complex Continuing Care program where all patients (MRSA-positive and MRSA-negative) will be bathed daily with an antiseptic body cleanser (CHG).~Only MRSA-negative patients at enrollment will be included in the study analysis, and only their outcomes (MRSA status and time to conversion) will be analyzed.~Antiseptic body cleanser - 2% Chlorhexidine Gluconate in a non-alcohol and non-alkaline base, delivered to skin surface through the bath cloths impregnated with this antiseptic solution."
3125548|NCT01717690|No Intervention|Non-antiseptic body cleanser|"Two control units in Complex Continuing Care program where all patients (MRSA-positive and MRSA-negative) will be bathed daily with a non-antiseptic body cleanser (Comfort Bath ®).~Only MRSA-negative patients at enrollment will be included in the study analysis, and only their outcomes (MRSA status and time to conversion) will be analyzed."
3125549|NCT01717677|Experimental|radical prostatectomy|Procedure/Surgery: radical prostatectomy
3125550|NCT01717677|Experimental|percutaneous radiation therapy|Radiation: percutaneous radiation therapy
3125551|NCT01717677|Experimental|permanent seed implantation|Radiation: permanent seed implantation
3125552|NCT01717677|Experimental|Active Surveillance|Procedure/Surgery: Active Surveillance
3125553|NCT01717664|Experimental|RHB-104|5 RHB-104 capsules administered orally BID
3125554|NCT01717651||CPM device|a CPM (continuous passive motion) device attached to one of your legs intermittently over the next three days.
3125555|NCT01717638|Experimental|B+R246_12_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3125556|NCT01717638|Experimental|B+R246_18_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3125557|NCT01717638|Experimental|B+R246_24_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3125558|NCT01717638|Experimental|B246_12_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3125559|NCT01717638|Experimental|B246_18_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3125560|NCT01717638|Experimental|B246_24_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3125561|NCT01717638|Experimental|B+R234_12_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3125562|NCT01717638|Experimental|B+R234_18_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3125563|NCT01717638|Experimental|B+R234_24_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3125564|NCT01717638|Experimental|B12 14_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 12 and14 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3125565|NCT01717638|Experimental|B18 20_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 18 & 20 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3125566|NCT01717638|Experimental|B24 26_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 24 & 26 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3125567|NCT01717638|Experimental|B48_50|Newly recruited 4 year old naive subjects who received 2 catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine, two months apart, in the present study.
3125568|NCT01717625|Experimental|Montelukast|"montelukast sodium~dosage~< 1000g : 0.5 mg/D QD~1000g~1500g : 1.0 mg/D QD~1500g~2000g : 1.5 mg/D QD~> 2000g : 2mg/D QD~medication period : to discharge or GA 36wks"
3125569|NCT01717625|No Intervention|Control|Standard treatment of BPD and preterm infants
3125570|NCT01717612|Active Comparator|Histoacryl group|the injected agents consisted of n-butyl-2-cyanoacrylate (Histoacryl; B.Braun, Melsungen AG, Germany) 0.5ml mixed with 1.5 ml Lipiodol ultra-fluide (Guerbet, Bois Cedex, France). The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
3125571|NCT01717612|Experimental|thrombin group|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
3125575|NCT01717586|Placebo Comparator|Control Group|Pregnant women who are at high-risk for developing preeclampsia who are taking a placebo during their pregnancy.
3125576|NCT01717573|Active Comparator|Deferred stenting|During primary PCI in STEMI, when TIMI 3 flow has been re-established with guide-wire, aspiration thrombectomy and/or balloon angioplasty, stenting is then deferred for a period of 4-16 hours following reperfusion. During this time, patients remain in the Coronary Care Unit and will receive intravenous tirofiban and subcutaneous low molecular weight heparin (enoxaparin 1 mg/kg)
3125577|NCT01717573|Sham Comparator|Conventional treatment|Conventional treatment in STEMI, with immediate stenting
3125578|NCT01717560|Experimental|Collaborative multidisciplinary integrated care|Collaborative, multidisciplinary, integrated care for hepatitis C
3125579|NCT01717547|Experimental|Yoga|Yoga-based treatment - manualized group treatment - classes will be held twice per week for approximately 85 minutes for a period of eight weeks.
3125580|NCT01717534|Experimental|Heat-treated lactobacilli|"One sachets (1 gram of content) will be consumed once a day, and will be suspended in a provided milk powder to be reconstituted with water.~The duration of the treatment is 5 months."
3125581|NCT01717534|Placebo Comparator|Maltodextrin|"One sachets (1 gram of content) will be consumed once a day, and will be suspended in a provided milk powder to be reconstituted with water.~The duration of the treatment is 5 months."
3125582|NCT01717521||Cases|
3125583|NCT01717508|Other|Cognitive Behavioral Therapy|12 weekly sessions of cognitive behavioral therapy
3125584|NCT01717508|No Intervention|Healthy Controls|
3125585|NCT01717495||Implantation Procedures|Patients submitted to initial pacemaker or ICD implantation
3125586|NCT01717495||Reoperation Procedures|Patients submitted to pacemaker or implantable cardioverter-defibrillator generator replacements, upgrade procedures and lead extraction
3125587|NCT01717482|Active Comparator|Metformin|Metformin 850mg BID
3125588|NCT01717482|Placebo Comparator|Observation|Standard of Care Observation
3125589|NCT01717469|Active Comparator|RV Pacing|Right ventricular pacing
3125590|NCT01717469|Experimental|LV Pacing|Left ventricular pacing through coronary sinus tributaries
3125591|NCT01717456|Active Comparator|Educational-Medical-Behavioral|Educational-Medical-Behavioral intervention includes education, fiber supplements [Metamucil 1-4 packets (3.4-13.6 g)/day], laxatives or anti-diarrheals [Miralax 1-2 packets (17-34 g)/day or Imodium 0.5-2 tablets (1-4 mg)/day], pelvic floor muscle exercises [100 10-second squeezes/day], tips on how to prevent fecal incontinence, daily diary, and protective pads or garments [as needed].
3125592|NCT01717456|Placebo Comparator|Standard Care|Standard care includes fiber supplements 1-4 packets (3.4-13.6 g)/day], daily diary, and protective pads or garments [as needed].
3125593|NCT01717443||Women, renal disease, transplantation|Women with end-stage renal disease, whose eligibility for renal transplantation is assessed
3125594|NCT01717430||Corticosteroid injection|Consecutive patients receiving initial or repeated sacroiliac joint or single or multi-level epidural corticosteroid injections as part of their management plan for SI joint, neck, back, or radicular pain. Injections will be performed using 0.5 mL bupivacaine 0.25% and 15 mg dexamethasone sodium phosphate.
3125595|NCT01717404|Experimental|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
3125596|NCT01717391|Experimental|Fluorothymidine F 18 PET/CT|Fluorothymidine F 18 (FLT) PET/CT imaging ordered pre-radiation therapy, during weeks 1 and 2 of radiation therapy, and then at 1 month and 12 months after radiation therapy. The FLT PET/CT imaging ordered pre-radiation therapy is used for bone marrow sparing IMRT radiation therapy.
3125597|NCT01717378||Potential research participants|UCSF Registry represents a single recruitment pool of individuals who have consented to be contacted about future studies for which they may be eligible based on self-reported health information.
3125598|NCT01717365||OTs|Occupational therapists
3125599|NCT01717352|Active Comparator|Weight Loss Education|Provides participants with important information about weight control and healthy eating prior to treatment to prepare participants for participation in a weight loss program and enhance outcomes.
3125600|NCT01717352|Active Comparator|Sleep and Eating Routine|Establish a consistent sleep and eating routine prior to treatment to prepare participants for participation in a weight loss program and enhance outcomes.
3125601|NCT01717339|Other|Normal Subjects|Non-OSA (Obstructive sleep apnea) patients
3125602|NCT01717339|Other|OSA subjects|(Obstructive sleep apnea) OSA subjects
3125603|NCT01717326|Experimental|A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk|GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally once daily (QD) for 12 weeks, Elbasvir 20 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally twice daily (BID) for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3125604|NCT01717326|Experimental|A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally BID for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3125605|NCT01717326|Experimental|A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1b only participants receive Grazoprevr 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
3125606|NCT01717326|Experimental|B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3125607|NCT01717326|Experimental|B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3125608|NCT01717326|Experimental|B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
3125680|NCT01716936||MAGEC Implant|All patients implanted with the MAGEC System will be reviewed for inclusion into this retrospective study.
3125609|NCT01717326|Experimental|B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant
3125610|NCT01717326|Experimental|B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
3125611|NCT01717326|Experimental|B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3125612|NCT01717326|Experimental|B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
3125613|NCT01717326|Experimental|B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3125614|NCT01717326|Experimental|B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
3125615|NCT01717326|Experimental|B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3125616|NCT01717326|Experimental|B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
3125617|NCT01717326|Experimental|B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3125618|NCT01717326|Experimental|B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
3125619|NCT01717326|Experimental|C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, and RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight.
3125620|NCT01717326|Experimental|C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk|GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks and Elbasvir 50 mg capsule orally QD for 8 weeks
3125621|NCT01717326|Experimental|D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT3 participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, and RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3125622|NCT01717326|Experimental|D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk|GT3 participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, and RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3125623|NCT01717313|Experimental|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week for 24 weeks (Phase A) followed by omarigliptin 25 mg administered orally once a week plus placebo to metformin daily (Phase B). Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria during Phase A, but was otherwise prohibited. Open-label glimepiride daily may be initiated as glycemic rescue therapy during Phase B.
3125624|NCT01717313|Placebo Comparator|Placebo to Omarigliptin|Placebo to omarigliptin administered orally once a week for 24 weeks (Phase A) followed by placebo to omarigliptin administered orally once a week plus metformin daily for an additional 30 weeks (Phase B). Open-label metformin was to be initiated for participants meeting protocol-specified glycemic criteria during Phase A, but was otherwise prohibited. Open-label glimepiride daily may be initiated as glycemic rescue therapy during Phase B.
3125625|NCT01717300|Experimental|Anacetrapib 100 mg|
3125626|NCT01717300|Experimental|Anacetrapib 25 mg|
3125627|NCT01717300|Placebo Comparator|Placebo|
3125628|NCT01717287|Experimental|Raltegravir Film-coated Tablet|Raltegravir film-coated tablet 400 mg administered orally twice-daily, in combination with other anti-retroviral therapy for 24 weeks
3125629|NCT01717287|Experimental|Raltegravir Chewable Tablet|Raltegravir chewable tablet weight-based dose up to 300 mg administered orally twice-daily, in combination with other anti-retroviral therapy for 24 weeks
3125630|NCT01717274|Experimental|Hot saline irrigation|Hot saline is prepared by first placing 2 litres of sterile normal saline (0.9%) into a basin (IntraTemp Therma BasinTM) that is wrapped in a sterile disposable drape (IntraTemp Therma Basin DrapeTM). The basin is then placed in a medical grade warmer (IntraTemp Fluid Warming SystemTM). The warmer is set to heat the saline up to a temperature of 50 degrees Celsius. An external digital thermometer is placed in the saline at all times to ensure that the temperature is between 45-50 degrees.
3125631|NCT01717274|No Intervention|Room temperature saline irrigation|Room temperature saline is prepared in the same manner as the experimental arm except that the warmer is switched off and the temperature of the saline in the basin is left to equilibrate to the temperature of the operating room.
3125632|NCT01717261|Experimental|Single Pre-Operative Radiation Therapy|
3125633|NCT01717248|Experimental|GCS-100|GCS-100 will be administered once weekly by a ten minutes injection.
3125634|NCT01717235|Experimental|Test Product|Drug: Ropinirole Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fasting conditions
3125635|NCT01717235|Experimental|Reference Product|REQUIP XL Tablets (containing Ropinirole hydrochloride CR 2mg Tablets)under fasting conditions
3125636|NCT01717222|Active Comparator|Intraperitoneal (IP) group|Patients will receive 100 ml of 0.2% Lignocaine as intraperitoneal lignocaine irrigation in the gall bladder fossa along with a placebo of normal saline of volume equivalent to 1.5 mg/kg of intravenous lignocaine at induction and normal saline of volume equivalent to 2 mg/kg/hour of intravenous lignocaine as continuous infusion until one hour postoperatively to ensure blinding
3128346|NCT01699282|Active Comparator|control group|
3125637|NCT01717222|Active Comparator|Intravenous (IV) group|Patients will receive 1.5mg/kg of intravenous lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lignocaine until one hour after surgery and 100 ml of saline intraperitoneally as placebo to ensure blinding.
3125638|NCT01717209|Experimental|Combined nitric oxide and prostacyclin|iNO (20 ppm continuously) and iPGI2 (0.05 micrograms/kg/min continuously)
3125639|NCT01717196|Experimental|DIFFERENT VOLUME ASPIRATION BIOPSY|The needle system was in all cases the 22 gauge EUS-FNA (Expect needle). After the puncture the stylet was removed, and we performed three punctures with a 22 G needle with both volume aspiration 10 and 20 cc and without syringe for each lesion. The sequence of different volume aspiration Biopsy/ FNA (10cc, 20cc, no aspiration) was randomly assigned by sealed envelope system.
3125640|NCT01717183|Experimental|URGO 310 3113 dressing - new|flexible, conformable, non-adhesive and non-occlusive lipido-colloid matrix that does not adhere to the wound.
3125641|NCT01717183|Placebo Comparator|URGO 310 3113 dressing|flexible, conformable, non-adhesive and non-occlusive lipido-colloid matrix that does not adhere to the wound.
3125642|NCT01717170|Experimental|Tocilizumab (4 mg/kg)|Tocilizumab (4 mg/kg) as an intravenous infusion over 1 hour at day 0, 30, 60, 90, 120, and 150.
3125643|NCT01717170|Experimental|Tocilizumab (8 mg/kg)|Tocilizumab (8 mg/kg) as an intravenous infusion over 1 hour at day 0, 30, 60, 90, 120, and 150.
3125644|NCT01717157|Experimental|Treatment sequence 1 (AEBD)|
3125645|NCT01717157|Experimental|Treatment sequence 2 (BACE)|
3125646|NCT01717157|Experimental|Treatment sequence 3 (CBDA)|
3125647|NCT01717157|Experimental|Treatment sequence 4 (EDAC)|
3125648|NCT01717157|Experimental|Treatment sequence 5 (DECA)|
3125649|NCT01717157|Experimental|Treatment sequence 6 (EADB)|
3125650|NCT01717157|Experimental|Treatment sequence 7 (ABEC)|
3125651|NCT01717157|Experimental|Treatment sequence 8 (BCAD)|
3125652|NCT01717144|No Intervention|traditional medical care|patients benefiting of a traditional medical care
3125653|NCT01717144|Experimental|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
3125654|NCT01717131|Active Comparator|Surgery for standard axillary node dissection|Standard axillary dissection
3125655|NCT01717131|Experimental|No axillary lymph node dissection|No surgery of axillary lymph node In this study, the absence of surgery is the experimental arm (non-inferiority trial)
3125656|NCT01717118|Active Comparator|Tetravalent Vaccine|"Month 2 visit: May be scheduled on the appropriate month +/- 3 weeks.~Month 6, 21, 60 and 61 visit (vaccination scheme 0, 2, 6): May be programmed on the appropriate month +/- 4 weeks.~Month 7 and 61 visit (vaccination scheme 0, 6, 60): The time interval between the month 6/60 visit and the month 7/61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination"
3125657|NCT01717118|Active Comparator|Bivalent Vaccine|"Month 1 visit: May be scheduled 21 to 62 days after the Day 0 visit.~Month 6 visit: May be scheduled 161 to 216 days after the Day 0 visit.~Month 6 visit: The time interval between the month 6 visit and the month 7 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination.~Month 21, 60 and 61 visit (vaccination scheme 0, 1, 6): May be scheduled on the appropriate month +/- 4 weeks.~Month 61 (vaccination scheme 0, 6, 60) The time interval between the month 60 visit and the month 61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination"
3125658|NCT01717105||metastatic non-small cell lung cancer|Only epidermal growth factor receptor (EGFR) M+ patients will be eligible for the study assessments
3125659|NCT01717092||Consecutive patients with acute PE|
3125660|NCT01717079|Active Comparator|Effective arm|Effective coil
3125661|NCT01717079|Placebo Comparator|Placebo arm|Placebo coil
3125662|NCT01717066|Experimental|the ginsenoside Rg3|320 HCCs,the ginsenoside Rg3 capsule,4-8 weeks after surgery, will be taken, 2 capsules, BID, 8 weeks as one cycle, continue taking it until the tumor recurs or until the end date of the study for patients without recurrence
3125663|NCT01717066|Placebo Comparator|the placebo|160 HCCs as control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group
3125664|NCT01717053|Experimental|Abiraterone acetate|Abiraterone Acetate, Radiotherapy and Short Term Androgen Deprivation. Prednisone will be prescribed concurrently with Abiraterone acetate.
3125665|NCT01717040|Experimental|Pioglitazone|
3125666|NCT01717040|Placebo Comparator|Placebo|
3125667|NCT01717027|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3125668|NCT01717027|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3125669|NCT01717027|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3125670|NCT01717027|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3125671|NCT01717014|Experimental|Covidien Radial Reload Stapler with Tri-Staple Technology|Covidien Radial Reload Stapler with Tri-Staple Technology in open low anterior resection or anterior proctosigmoidectomy
3125672|NCT01717001||ConforMIS|Patients with ConforMIS implants
3125673|NCT01717001||Standard Total Knee Implant|Patients implanted with standard total knee implant
3125674|NCT01716988||Micafungin|
3125675|NCT01716975|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day -14 through Day 182
3125676|NCT01716975|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
3125677|NCT01716975|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
3125678|NCT01716962||ARDS with acute circulatory failure|acute respiratory distress syndrome with acute circulatory failure with infusion of 6% tetrastarch for a total of 500ml
3125679|NCT01716949|Experimental|HyRec|Radiotherapy, Hyperthermia, 5-Fluorouracil (may be replaced by Capecitabine), Capecitabine (may be replaced by 5-Fluorouracil), Oxaliplatin
3128347|NCT01699269|Other|brain tumor|
3125681|NCT01716923|Experimental|S-303 Treated Red Blood Cells|Patients receive S-303 treated red blood cells (RBCs).
3125682|NCT01716923|Active Comparator|Conventional, untreated Red Blood Cells|Patients receive conventional, untreated red blood cells (RBCs).
3125683|NCT01716910|Placebo Comparator|Maltodextrin|'Combination of Lactobacillus acidophilus NCFM and cellobiose', Sachet, 5 g/day
3125684|NCT01716910|Active Comparator|Synbiotic|'Combination of Lactobacillus acidophilus NCFM and cellobiose', Sachet, 5 g/day + 10e9 CFU
3125685|NCT01716897|Other|50 mg E2609 capsule formulation in fasted state|50 mg E2609 capsule formulation
3125686|NCT01716897|Other|50 mg E2609 tablet formulation in fasted state|50 mg E2609 tablet formulation in fasted state
3125687|NCT01716897|Other|50 mg tablet formulation in fed state|50 mg E2609 tablet formulation in fed state
3125688|NCT01716871|Active Comparator|cryotherapy using Cold pack®|"patients with lateral ankle sprain who have been randomized in the cold packs® group.~Application of cryotherapy with Cold pack® or ice-cubes pack in the sprained ankle during 20 minutes 4 times a day, 3 days long."
3125689|NCT01716871|Active Comparator|cryotherapy using Neurocryostimulation|"Patient with lateral ankle sprain randomized in the neurocryostimulation group.~Application of neurocryostimulation with Duo-cryo® device during 1 minute on the sprained ankle, 2 times a day, 3 days long"
3125690|NCT01716858|Experimental|A single-arm study|
3125691|NCT01716845||Development group 1|
3125692|NCT01716845||Development group 2|
3125693|NCT01716845||Development group 3|
3125694|NCT01716845||Validation group|
3125695|NCT01716832|Experimental|Mindfulness walking|
3125696|NCT01716832|No Intervention|No intervention (waiting list)|
3125697|NCT01716819|Other|Abdominal obesity|"Single arm, follow up cohort in patient with abdominal obesity. No comparator: description of interventions :~Composition of body mass by Dual x-ray absorptiometry Pulse wave velocity Electrocardiogram Urine sample Blood sample (and biological collection) Assessment of sleep apnea syndrome Glucose tolerance test Echocardiography Echotracking cardiac and abdominal magnetic resonance imaging Ambulatory blood pressure monitoring"
3125698|NCT01716806|Experimental|Brentuximab Vedotin|
3125699|NCT01716806|Experimental|Brentuximab Vedotin + Dacarbazine|
3125700|NCT01716806|Experimental|Brentuximab Vedotin + Bendamustine|
3125701|NCT01716806|Experimental|Brentuximab Vedotin + Nivolumab|
3125702|NCT01716793|Other|Risk-adapted postremission treatment|Ara-C, autologous transplantation, Allogeneic HLA-identical sibling transplantation depending on risk factors (cytogenetics, courses to CR)and availability of an HLA-identical sibling, CD34+ selection.
3125703|NCT01716780|No Intervention|Routine care|"Patients allocated to the control group will undergo their 'usual care'; they will be given pain medication when they specifically request it or when their oncology doctor/ nurse or GP considers it appropriate to prescribe it, either at the oncology clinic visit or at any time during the course of the study."
3125704|NCT01716780|Experimental|Intervention|"Patients allocated to the intervention group will be reviewed by the pain/palliative care team and will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care."
3125705|NCT01716767|Experimental|Menthol|Biofreeze topical gel containing 3.5% menthol
3125706|NCT01716767|Placebo Comparator|Placebo|Topical gel containing a menthol scent, but no active menthol
3125707|NCT01716754|Experimental|QGE031 240 mg every 2 weeks (q2w)|Participants received QGE031 240 mg subcutaneously (s.c.) q2w for 16 weeks.
3125708|NCT01716754|Experimental|QGE031 240 mg q4w|Participants received QGE031 240 mg s.c. q4w for 16 weeks.
3125709|NCT01716754|Experimental|QGE031 180 mg q2w|Participants received QGE031 180 mg s.c. q2w for 16 weeks.
3125710|NCT01716754|Experimental|QGE031 120 mg q2w|Participants received QGE031 120 mg s.c. q2w for 16 weeks.
3125711|NCT01716754|Experimental|QGE031 36 mg q2w|Participants received QGE031 36 mg s.c. q2w for 16 weeks.
3125712|NCT01716754|Experimental|QGE031 12 mg q2w|Participants received QGE031 12 mg s.c. q2w for 16 weeks.
3125713|NCT01716754|Active Comparator|Omalizumab (as per locally approved dosing table)|Participants received omalizumab as per locally approved dosing table s.c. q2w or q4w for 16 weeks.
3125714|NCT01716754|Placebo Comparator|Placebo to QGE031 240 mg q2w|Participants received matching placebo to QGE031 240 mg s.c. q2w for 16 weeks.
3125715|NCT01716754|Placebo Comparator|Placebo to QGE031 240 mg q4w|Participants received placebo to QGE031 240 mg s.c. q2w for 16 weeks.
3125716|NCT01716754|Placebo Comparator|Placebo to QGE031 180 mg q2w|Participants received QGE031 180 mg s.c. q2w for 16 weeks.
3125717|NCT01716754|Placebo Comparator|Placebo to QGE031 120 mg q2w|Participants received QGE031 120 mg s.c. q2w for 16 weeks.
3125718|NCT01716754|Placebo Comparator|Placebo to QGE031 36 mg q2w|Participants received QGE031 36 mg s.c. q2w for 16 weeks.
3125719|NCT01716754|Placebo Comparator|Placebo to QGE031 12 mg q2w|Participants received QGE031 12 mg s.c. q2w for 16 weeks.
3125720|NCT01716754|Placebo Comparator|Placebo to omalizumab|Participants received placebo to omalizumab s.c. q2w or q4w for 16 weeks.
3125721|NCT01716741|Other|Enzyme analysis|Patients invited for evaluation will undergo glucocerebrosidase enzyme analysis
3125722|NCT01716728|No Intervention|Enzyme analysis|Patients invited for evaluation will undergo lysosomal acid lipase enzyme analysis
3125723|NCT01716715|Experimental|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28.
3125724|NCT01716715|Experimental|Arm II (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
3125725|NCT01716702|Experimental|Couples Prostate Cancer Support Group|"The participants in the support group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.~Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks)."
3125726|NCT01716702|No Intervention|Wait-List Control|Participants will be asked to complete questionnaires at three time points: 1)week 1 2) week 7, and 3) week 13.
3125727|NCT01716689|Experimental|Patients with advanced sarcoma|
3125728|NCT01716676|Active Comparator|Standard CPAP follow-up|
3125729|NCT01716676|Experimental|Telemedicine CPAP follow-up|
3125730|NCT01716663||Experimental: Catheter Ablation|These patients have drug refractory recurrent symptomatic paroxysmal AF, are 18 years and older, and are able and willing to provide written informed consent to participate in the study and comply with study requirements.
3125731|NCT01716650||Saphenous nerve block|Data collection after saphenous nerve block placement
3125732|NCT01716637|Active Comparator|Etanercept|25 mg administered weekly for 6 weeks
3125733|NCT01716637|Active Comparator|Nutritional Supplements|Nutritional supplements administered daily for 6 weeks in each period as well as an additional 12 weeks following visit 15.
3125734|NCT01716624|Active Comparator|Oxybutynin|
3125735|NCT01716624|Experimental|Botulinum Toxin A injection|
3125736|NCT01716611|Active Comparator|Tolvaptan group|Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days
3125737|NCT01716611|Placebo Comparator|Placebo group|Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days
3125738|NCT01716598|Experimental|Treatment|Targeted Lung Denervation Therapy (TLD Therapy)
3125739|NCT01716585|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3125740|NCT01716585|Experimental|Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3125741|NCT01716572|Active Comparator|gastric lavage|gastric lavage by nasogastric tube with 1 liter saline before the endoscopy
3125742|NCT01716572|Active Comparator|erythromycin|administration of 250mgr of erythromycin before the endoscopy
3125743|NCT01716559||Cohort|
3125744|NCT01716546|Experimental|1|Panitumumab plus DCF
3125745|NCT01716533|Other|Recurrence group|Subjects who experience recurrence of CDI after clinical response to antibiotic treatment to treat the initial CDI episode.
3125746|NCT01716533|Other|Sustained response group|Subjects who do not experience recurrence of CDI after clinical response to the antibiotic treatment to treat the initial CDI episode.
3125747|NCT01716520|Experimental|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
3125748|NCT01716520|Experimental|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
3125749|NCT01716520|Experimental|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
3125750|NCT01716507|Other|20 gauge pars plana vitrectomy|20 gauge pars plana vitrectomy for retinal detachment repair
3125751|NCT01716507|Other|23 gauge pars plana vitrectomy|23 gauge pars plana vitrectomy for retinal detachment repair
3125752|NCT01716494||Severe Asthma|Subjects with severe asthma (SARP protocol definition)
3125753|NCT01716494||Well controlled asthma|Subjects with well controlled asthma
3125754|NCT01716494||Normal control|Subjects that are healthy normals
3125755|NCT01716481|Experimental|Mesenchymal stem cell treatment|
3125756|NCT01716481|No Intervention|Standard treatment|
3125757|NCT01716468|Other|Advanced or metastatic cancer|Patients chosen must be diagnosed with advanced or metastatic cancer of the following tumor types (colorectal, prostate, brain, breast, pancreatic, hepatobiliary, melanoma, sarcoma, non-small cell /small cell lung, genitourinary cancers).All participants will be assigned to a ketogenic diet. There are no randomization to other separate arms since this is a safety and feasibility study.
3125758|NCT01716455|Experimental|SSP-004184 (Mild Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
3125759|NCT01716455|Experimental|SSP-004184 (Moderate Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
3125760|NCT01716455|Experimental|SSP-004184 (Severe Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
3125761|NCT01716455|Experimental|SSP-004184 (End Stage Renal Disease)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
3125762|NCT01716455|Experimental|SSP-004184 (Healthy Elderly Subjects)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
3125763|NCT01716455|Experimental|SSP-004184 (Matched Healthy Subjects)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1. Healthy subjects matched to renally impaired subjects in arms 1 through 4. (Note: One healthy subject can match more than one renally impaired subject.)
3125764|NCT01716442|Active Comparator|steroid-resistant|Steroid-resistant group: n=27 , enroll all for treatment
3125765|NCT01716442|Active Comparator|steroid-dependent-rituximab|steroid-responsive group: n=38
3125766|NCT01716442|Placebo Comparator|steroid-dependent-placebo|steroid-responsive group: n=23
3125767|NCT01716429|Active Comparator|Low Calorie|Participants in this arm will be instructed on how to reduce their caloric intake and follow a low calorie diet
3125768|NCT01716429|Experimental|Vegan diet|Participants in this arm will follow a very low fat diet (~10% kcals from fat) and also a diet that has a low glycemic index and is free of animal products (vegan)
3125769|NCT01716416|Experimental|Dose Level 1|"Pazopanib 200 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
3125770|NCT01716416|Experimental|Dose Level 2|"Pazopanib 400 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
3125771|NCT01716416|Experimental|Dose Level 3|"Pazopanib 600 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
3125772|NCT01716416|Experimental|Dose Level 4|"Pazopanib 800 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
3125773|NCT01716416|Experimental|Part 2 Dose|"Pazopanib (dose to be determined in Part 1 of study) mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
3125774|NCT01716403||HCV tritherapy and anemia|HCV-genotype 1 infected patients
3125775|NCT01716390|Active Comparator|Drink that contains plant stanols|Dietary supplement: Plant stanol
3125776|NCT01716390|Placebo Comparator|Placebo drink|Dietary supplement: Placebo
3128495|NCT01698112|No Intervention|Flaxseed control|
3125777|NCT01716377|Placebo Comparator|Placebo|37.5mg QD 1 week 75mg QD 1 week 150mg QD 8 weeks 75mg QD 1 week 37.5mg QD 1 week
3125778|NCT01716377|Active Comparator|Venlafaxine|37.5mg QD 1 week 75mg QD 1 week 150mg QD 8 weeks 75mg QD 1 week 37.5mg QD 1 week
3125779|NCT01716364|Experimental|Anti-LeY- scFv-CD28-ζ vector.|Anti-LeY- scFv-CD28-ζ vector, a non-pathogenic, replication-incompetent retroviral vector specifically designed for this study and produced by EUFETS under GMP-conditions.
3125780|NCT01716351|Experimental|Adapted Yoga Intervention Group|Patients received the Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients and a call from a cardiac research nurse once monthly for five months.
3125781|NCT01716351|No Intervention|Control|Patients received usual care and a call from a cardiac research nurse once monthly for five months to control for attention.
3125782|NCT01716338|Active Comparator|Glyburide|1.5 mg (lowest dose) by mouth every day with breakfast for 7 days
3125783|NCT01716338|Placebo Comparator|Sugar Pill (Capsule)|Matching placebo capsule by mouth every day with breakfast for 7 days
3125784|NCT01716325|Experimental|Weight loss - ICT support|Weight loss - ICT support
3125785|NCT01716325|Other|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
3125786|NCT01716286|Experimental|yoghurt type|low fat yoghurt vs. essence yoghurt
3125787|NCT01716273|Experimental|Chronic & Acute infected wounds|Wound will be cleaned with normal saline or tap water and Granulated sugar will be applied directly to the wound and covered with an absorbent pad and held in place with a bandage and tape.
3125788|NCT01716273|Active Comparator|Chronic and Acute infected wounds|Wound will be cleaned with normal saline or tap water and an appropriate debridement dressing (Aquacel or Sorbsan) is applied to the wound and secured with a bandage and surgical tape.
3125789|NCT01716260||Chloroquine and Primaquine|Chloroquine (CQ)10mg/kg for day 1, 2 and 5mg/kg for day 3 Primaquine (PQ)0.25mg/kg/day for 14 days
3125790|NCT01716247|Experimental|pts at risk for breast cancer|Women at increased risk for breast cancer who are being referred for screening MRI will be offered and consented for CESM at the same time. The 2 examinations will be performed on the same day when at all possible and if not we will make every attempt to perform CESM before MRI. Patients with outside MRI performed within 30 days and of adequate quality will also be eligible for CESM.
3125791|NCT01716234|Experimental|POS 12 BID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
3125792|NCT01716234|Experimental|POS 12 BID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
3125793|NCT01716234|Experimental|POS 18 BID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
3125794|NCT01716234|Experimental|POS 18 BID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
3125795|NCT01716234|Experimental|POS 18 TID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
3125796|NCT01716234|Experimental|POS 18 TID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
3125797|NCT01716234|Experimental|POS 12 TID 3 months to <2 Years|Participants aged 3 months to <2 years received posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
3125798|NCT01716221|Experimental|Bupropion & Citalopram|100mg Bupropion & 20mg Citalopram taken orally one time per day or 100mg Bupropion & 10mg Citalopram taken orally one time per day or 50mg Bupropion & 20mg Citalopram taken orally one time per day 0r 50mg Bupropion & 10mg Citalopram taken orally one time per day
3125799|NCT01716221|Active Comparator|Bupropion & Placebo|100mg Bupropion & Placebo taken orally one time per day or 50mg Bupropion & Placebo taken orally one time per day
3125800|NCT01716221|Active Comparator|Placebo & Citalopram|Placebo & 20mg Citalopram taken orally one time per day or Placebo & 10mg Citalopram taken orally one time per day
3125801|NCT01716221|Placebo Comparator|Placebo & Placebo|Placebo & Placebo taken orally one time per day
3125802|NCT01716208|Experimental|Ofatumumab + Fresh Frozen Plasma|Ofatumumab will be infused intravenously on day 1 (300 mg initial dose), followed one week later by 2000 mg weekly for 7 doses, followed 4 weeks later by 2000 mg every 4 weeks for 4 doses. Two units (approximately 200 or 250 ml) of FFP will be administered prior to ofatumumab(with the exception of the first dose). A unit of fresh frozen plasma is approximately 250ml (or half a pint).
3125803|NCT01716195|Experimental|6 weeks of Radiotherapy|Paclitaxel + Carboplatin (2 cycles) IV followed by Radiation Therapy (6 weeks) + Paclitaxel IV
3125804|NCT01716195|Experimental|5 weeks of Radiotherapy|Paclitaxel 175 mg/m2 + Carboplatin area under curve (AUC) 6 (2 cycles) IV followed by Radiation Therapy (5 weeks) + Paclitaxel 175 mg/m2 IV
3125805|NCT01716182||transacral lumbar interbody fusion procedure|
3125806|NCT01716182||transforaminal lumbar interbody fusion procedure (TLIF)|
3125807|NCT01716169|Experimental|Helicoll|"Helicoll will be applied to one chronic wound (approximately 6 months or more duration).~Wound designations of control or Helicoll were placed in a sealed envelope prior to study start. When a subject was enrolled, wounds were identified as A or B. Then the envelope was opened which designated whether A or B would receive control or Helicoll."
3125808|NCT01716156|Experimental|Grazoprevir 100 mg + RBV 12 Weeks|Grazoprevir 100 mg tablet once per day by mouth for 12 weeks and RBV capsules twice per day by mouth at a total daily dose from 800 to 1400 mg based on participant weight for 12 weeks. Participants with detectable HCV RNA at TW4 received an additional 12 weeks of study therapy for a total of 24 weeks of treatment.
3125809|NCT01716156|Experimental|Grazoprevir 100 mg + RBV 24 Weeks|Grazoprevir 100 mg tablet once per day by mouth for 24 weeks and RBV capsules twice per day by mouth at a total daily dose from 800 to 1400 mg based on participant weight for 24 weeks.
3125810|NCT01716143|Other|catheter ablation|
3125811|NCT01716130||IM vaccine in the past 3 years|Those subjects that received the Fluzone ID influenza vaccine, and reported having received the IM influenza vaccine in the past three years.
3125812|NCT01716130||no IM vaccine in the past 3 years|Patients that received the Fluzone ID vaccine and reported not receiving the IM influenza vaccine in the past 3 years.
3125813|NCT01716130||vaccine administrators|Those experienced vaccine administrators that administered the Fluzone ID vaccine, and were then surveyed concerning safety and overall satisfaction with the ID vaccine in comparison to the IM vaccine.
3125814|NCT01716117|Experimental|Surpass Flow Diverter|The objective of this study is to determine the safety and effectiveness of the Surpass Flow Diverter (Surpass System) in the endovascular treatment of large or giant wide-necked intracranial aneurysms in the internal carotid artery up to the terminus.
3125815|NCT01716104|Experimental|Afalaza (2 tablets twice a day)|
3125816|NCT01716104|Placebo Comparator|Placebo (2 tablets twice a day)|
3125817|NCT01716091||saline irrigation|irrigation group:saline irrigation after uterine wall closed control group:no irrigation after uterine wall closed
3125818|NCT01716052|Active Comparator|Ibuprofen|Pfizer 200 mg caplets (Advil)
3125819|NCT01716052|Placebo Comparator|Placebo|Lactulose
3125820|NCT01716039|Active Comparator|MTX 12.5|Receive once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX and/or placebo in addition to doses of adalimumab
3125821|NCT01716039|Active Comparator|MTX 25 mg|Once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX in addition to doses of adalimumab
3125822|NCT01716039|Placebo Comparator|Placebo|Once weekly oral dosing with placebo (n=20) two weeks prior to the initiation of adalimumab. Subjects will receive 18 weekly doses of placebo in addition to doses of adalimumab
3125823|NCT01716026|Active Comparator|3 Month Load with 9 month p.r.n.|3 Monthly bevacizumab injections with 9 p.r.n. monthly doses if patient meets the treatment criteria for each monthly visit
3125824|NCT01716026|Experimental|Single Dose Load Phase|Single dose treatment with bevacizumab, followed by 2 sham injections if conditions are met in the months 2 and 3, and followed with bevacizumab monthly p.r.n. as per protocol
3125825|NCT01716013|Experimental|BondEase|Topical Skin Adhesive
3125826|NCT01716013|Active Comparator|CWCD|Conventional Wound Closure Devices (CWCD) including: sutures, staples, or adhesive strips
3125827|NCT01716000|Experimental|2 mL vaginal gel|2 mL gel inserted vaginally for completion of vaginal gel imaging and computer aided self interview.
3125828|NCT01716000|Experimental|4 mL vaginal gel|4 mL gel inserted vaginally for completion of vaginal gel imaging and computer aided self interview.
3125829|NCT01715987||Tenofovir Disoproxil Fumarate|Patients who are taking Tenofovir Disoproxil Fumarate.
3125830|NCT01715987||Entecavir|Patients who are taking Entecavir.
3125831|NCT01715974|Placebo Comparator|CONTROL|patients with recurrent implantation failure treated with PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test
3125832|NCT01715974|Experimental|G-CSF group|patients with recurrent implantation failure treated with G-CSF (60 micrograms/day) from the day of embryo transfer through the day of beta hCG test
3125833|NCT01715961|Other|anthropometric measurement|"The muscle area assessed by CT scan imaging at a lumbar vertebral landmark (L3) at the time of diagnosis, at the end of treatment, at 12 and 18 months~anthropometric measures (weight, height, BMI, brachial and calf circumference) and MNA (mini nutritional assessment)~albuminemia, transthyretin, orosomucoid, CRP~functional test to attest the muscular strength: hand grip test, unipodal test, up and go test~hematological and non-hematological chemotherapy toxicities of cycle 1 and cycle 2~OS and PFS at 18 and 24 months~GCB and ABC phenotypes determined by immunohistochemistry and transcriptome analysis"
3125834|NCT01715948|Experimental|CROS hearing aid|The CROS uses two hearing aids that fit behind each ear. The hearing aid fitted with a retainer earhook on the side of the poor ear houses a microphone and a transmitter. The hearing aid fitted on the normal ear side houses a receiver that is connected to a slim tube and open ear tip. The CROS does not amplify sound but rather transmits sound from the side of the unaidable ear to the contralateral ear, overcoming the head shadow effect that presents with SSD.
3125835|NCT01715948|Experimental|Bone-anchored hearing device (BAHD)|The BAHD (such as the Baha by Cochlear or Bone-Bridge by MED-EL) also helps to alleviate the negative effect of head shadow and the difficulty with speech perception in noise that present with SSD. Also known as an osseointegrated aural prosthesis, the BAHD is implanted in individuals with SSD to stimulate the ear with the normal cochlea. The BAHD requires that a titanium screw be surgically implanted in the temporal bone on the side of the poor ear. This titanium screw is connected to a percutaneous abutment. An electromechanical sound processor (external transducer) is coupled onto the abutment and can be removed when necessary. Sound can now be routed to the better ear by transcranial bone conduction.
3125836|NCT01715935|Experimental|everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
3125837|NCT01715922|Other|oral treatment|"Drug: Fluconazole and flucytosine~Induction treatment for 2 weeks:~Fluconazole (1600mg/j) + flucytosine (100 mg/kg/j) lumbar punctures to control intracranial pressure Consolidation treatment for 8 weeks: fluconazole (800 mg/j)"
3125838|NCT01715909|Experimental|Oseltamivir: Standard dose|Participants will receive standard dose of oseltamivir capsules or suspension orally for 5 to maximum of 20 days depending on weight. Infants <1 year of age will receive oseltamivir at a dose of 3 milligrams per kilogram (mg/kg).
3125839|NCT01715909|Experimental|Oseltamivir: Triple dose|Participants will receive three times the standard dose of oseltamivir capsules or suspension orally for 5 to maximum of 20 days depending on weight and age. Infants <1 year will receive standard dose at 3 mg/kg.
3125840|NCT01715896|Experimental|Golimumab 50 mg alternating with Placebo|Participants received alternating doses of golimumab 50 milligram (mg) (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
3125841|NCT01715896|Experimental|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
3125894|NCT01715532|Active Comparator|TACE|Patients in this arm will receive transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment.
3125842|NCT01715883|Experimental|Sodium Nitrite|"Sodium Nitrite will be administered at three time points:~At the time of organ procurement, a pre-prepared syringe of sodium nitrite will be added to each of the 2.8 liter bags of Perfadex solution to flush the donor lungs.~At the time of transplant just prior to reperfusion of lungs, the donor lungs are flushed with a cold pneumoplegia solution after the bronchial (1st) anastomosis and with warm pneumoplegia solution after the portal vein (3rd, last) anastomosis. The drug will be added to pneumoplegia solution just prior to both the flushes.~Sodium Nitrite will be delivered intravenously to the recipient immediately prior to lung reperfusion as a single infusion at rate of 4 mL/min for the first 30 min, followed by 2.2 mL/min for the next 60 min."
3125843|NCT01715870||"Population of the Epidemiological study on AMD."|
3125844|NCT01715857||Chinese Patients Requiring Surgery with Sevoflurane Anesthesia|Participants who were scheduled for surgery requiring sevoflurane anesthesia with endotracheal intubation or laryngeal mask airway (LMA) per approved product information of sevoflurane in China
3125845|NCT01715844|Active Comparator|L-citrulline|3-gr/day of L-citrulline effervescent powder mix
3125846|NCT01715844|Placebo Comparator|Placebo|3 gr of Placebo/day matching L-citrulline effervescent powder
3125847|NCT01715831|Experimental|Tocilizumab|Participants will receive tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 104 weeks. The maximum single dose administered to any participant will be of 800 mg of tocilizumab. Participants may also receive disease-modifying anti-rheumatic drugs (DMARDs) in addition to the tocilizumab treatment in any visit, at the investigator discretion, according to the local prescription information and participant's tolerance.
3125848|NCT01715818|Experimental|Aleglitazar|
3125849|NCT01715818|Placebo Comparator|Placebo|
3125850|NCT01715805|Experimental|Cariprazine|Cariprazine, 1.5 milligrams to 4.5 milligrams per day, oral administration.
3125851|NCT01715805|Placebo Comparator|Placebo|Dose-matched placebo, onec per day, oral administration
3125852|NCT01715792||Group 1|Subject defined as acceptable in the CPRD GOLD with at least one solid organ transplant rejection reported during the overall study period (01 September to 31 October 2010).
3125853|NCT01715779||Patients who experienced a thromboembolic event|Patients who experienced a thromboembolic event during participation in the ENABLE clinical trials.
3125854|NCT01715753|Active Comparator|Weight Loss Control|Diet counseling and group education lessons. Subjects follow a calorie-reduction diet for a weight loss of ≥10%.
3125855|NCT01715753|Experimental|Weight Loss-High Protein|Protein supplementation. Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of protein, including substantial amounts of supplemental protein provided as lean beef. Intakes of > 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
3125856|NCT01715740|Experimental|Chinese herbal medicine (CHM)|Subject in CHM group will receive CHM capsules, 8 capsules (4 gm) four times a day, total 16 gm a day, combined with levocetiricine 1PC once a day for 1 month.
3125857|NCT01715740|Placebo Comparator|Control|Subjects in control group will receive the placebo capsules, which has the similar look, smell and taste. The dosage, frequency and duration are the same as CHM group, in which 8 placebo capsule (4gm) 4 times a day, total 16 gm a day, combined with levocetiricine 1PC once a day, for 1 month.
3125858|NCT01715727||Parkinson's Disease for follow-up|"Patients should fulfill the National Institute of Neurological Disorders and Stroke in USA ( NINDS ) Diagnostic Criteria for Parkinson Disease(37) for probable‟ PD, except for the age of onset.~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent.~Early to moderate stage defined as Hohen and Yahr stage 1-3,"
3125859|NCT01715727||Parkinsons‟s Disease with severity match|"Parkinsons‟s Disease with severity match: 30 subjects~Patients should fulfill the National Institute of Neurological Disorders and Stroke in USA ( NINDS ) Diagnostic Criteria for Parkinson Disease(37) for probable‟ PD, except for the age of onset.~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent.~Severity matched with PSP (subjects = 15)/MSA (subjects= 15), the severity was judged by Hohen and Yahr stage"
3125860|NCT01715727||Healthy age matched controls|"Healthy age matched controls: subjects = 112~Healthy subjects without a clinically significant abnormal laboratory values, and/or clinically significant or unstable medical or psychiatric illness.~Able to understand and provide signed informed consent.~Age range and gender matched with Parkinsons‟s Disease for follow up."
3125861|NCT01715727||Parkinson Plus Syndrome Group M|"MSA Patients should fulfill the NINDS Consensus statement for the clinical diagnosis of probable MSA~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent"
3125862|NCT01715727||Parkinson Plus Syndrome Group P|"PSP Patients should fulfill the NINDS-SPSP and Litvan criteria(4) for probable PSP~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent."
3125863|NCT01715714|Active Comparator|Statin Recapture Therapy|Oral statin reload of patients at 12 and 2 hours before CABG using the maximal dose of the chronically prescribed statin* on admission. (*simvastatin 80 mg, atorvastatin 80 mg, fluvastatin 80 mg or pravastatin 40 mg)
3125864|NCT01715714|Placebo Comparator|Placebo|Placebo given orally 12 hrs and 2 hrs before CABG
3125865|NCT01715701|Experimental|Paravertebral nerve blockade|A multilevel thoracic paravertebral nerve block will be performed by the anaesthesiologist prior to the induction of general anesthesia. Prior to the block, the anaesthesiologist will locate and mark each level and then, infiltrate the skin with lidocaine 2% (0.5-1 mL). Subsequently, using a Tuohy needle 22G, 5 mL of ropivacaine 0.5% will be injected at each level between T4 and T8. At the end of surgery, before skin closure, a multilevel intercostal nerve block will be performed by the surgeon using 5 mL of saline at each level between T4-T8. A PCA device will be installed upon arrival in the recovery room.
3125866|NCT01715701|Active Comparator|Intercostal nerve blockade|Prior to the induction of general anaesthesia, a paravertebral block will be simulated by measuring, marking the patient's skin and applying mild pressure at each level (T4-T8). To preserve the blind, the anaesthesiologist will also infiltrate the skin with lidocaine 2% (0.5-1 mL). A multilevel intercostal nerve block will be performed by the surgeon at the end of surgery before skin closure. Five mL of ropivacaine 0.5% will be injected at each level between T4 and T8. A PCA device will be installed upon arrival in the recovery room.
3200676|NCT01193582|Experimental|Group 4|
3125867|NCT01715701|Active Comparator|Patient Controlled Analgesia (PCA)|Prior to the induction of general anaesthesia, a paravertebral block will be simulated by measuring, marking the patient's skin and applying mild pressure at each level (T4-T8). To preserve the blind, the anaesthesiologist will infiltrate the skin with lidocaine 2% (0.5-1 mL). At the end of surgery, before skin closure, a multilevel intercostal nerve block will be performed by the surgeon using 5 mL of saline at each level between T4-T8. A PCA device will be installed upon arrival in the recovery room.
3125868|NCT01715688|Active Comparator|Alkalinized lidocaine|"The endotracheal tube cuff will be pre-filled at least 90 minutes before intubation with alkalinized lidocaine. Endotracheal tube cuff will be emptied before intubation and then re-filled with the same mixture following intubation to secure the position of the endotracheal tube. (cuff will be inflated until there is no air leak around the tube).~During emergence, when the expired fraction of desflurane reaches 0.2 MAC, the patient will be asked to open his eyes every 30 seconds. Any coughing effort before 0.2 MAC will be considered as a treatment failure and the patient will be treated according to the attending anaesthesiologist."
3125869|NCT01715688|Placebo Comparator|Saline|"The endotracheal tube cuff will be pre-filled at least 90 minutes before intubation with saline. Endotracheal tube cuff will be emptied before intubation and then re-filled with the same mixture following intubation to secure the position of the endotracheal tube. (cuff will be inflated until there is no air leak around the tube).~During emergence, when the expired fraction of desflurane reaches 0.2 MAC, the patient will be asked to open his eyes every 30 seconds. Any coughing effort before 0.2 MAC will be considered as a treatment failure and the patient will be treated according to the attending anaesthesiologist."
3125870|NCT01715675|Active Comparator|plant stanol|
3125871|NCT01715675|Placebo Comparator|control|
3125872|NCT01715662|Experimental|Wii.n.Walk|Subjects (n=12) in the experimental arm (Wii.n.Walk) will be trained using the Wii Fit for 40-minute sessions, 3 times a week for a period of 4 weeks. Subjects will stand on the Wii Fit balance board and interact with the games through weight shifting or using the Wii remote controller. The intervention protocol includes: 1) Yoga (static single and double leg exercises), 2) Balance games (lateral and poster/anterior weight shifting exercises in standing), 3) Aerobics (running on spot and step class), and 4) Strength training (dynamic single and double leg exercises). The sessions will start in the clinic with a group of 3 participants and will graduate to individualized in-home training starting from week 2. For the in-clinic training sessions, a trained research assistant will administer the intervention and will provide external cueing and correction of the pose if the participants use unsafe technique.
3125873|NCT01715662|Placebo Comparator|Control|Subjects (n=12) in the control arm will play cognitive computer games using Wii Big Brain for the same frequency and duration as the Wii.n.Walk arm. The sessions will start in the clinic with a group of 3 participants and will graduate to individualized in-home training starting from week 2. For the in-clinic sessions, a research assistant will administer the intervention and will provide supervision. Wii Big Brain is a low-cost commercially available gaming software to improve cognitive function.
3125874|NCT01715649|No Intervention|Control-usual care|Nurse care coordination in a telephonic diabetes disease management program
3125875|NCT01715649|Experimental|Intervention paired testing and remote monitoring|Telehealth remote patient monitoring, structured blood glucose and usual care Paired testing-weekly remote monitoring Data analysis Virtual visits in EHR
3125876|NCT01715636|Other|Eviplera|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg, one tablet, once daily, taken with food, for 28 days
3125877|NCT01715623||Children with HSP|children with Purpura of Henoch-Schönlein with or without renal complication
3125878|NCT01715623||healthy volunteers|healthy volunteers without allergy
3125879|NCT01715623||subjects with allergy|subjects with peanut allergy or hymenoptera venom allergy
3125880|NCT01715623||lymphoma|lymphoma-proliferation with chromosome 14 translocation
3125881|NCT01715610|Active Comparator|Antibiotic Clavulin or Clindamycin|Patient's in this arm are randomized by random-number generator to receive antibiotics. This is for a 7 day course of antibiotics. Those that are allergic to penicillin will receive clindamycin. Randomization occurs after knowledge of the patient's allergy status.
3125882|NCT01715610|Placebo Comparator|Placebo|Patient's randomized to this arm post-drainage will receive placebo and not receive antibiotics
3125883|NCT01715597|Experimental|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 2hours before the operation
3125884|NCT01715597|Placebo Comparator|Control|Normal saline 500ml IV infusion for 2hour
3125885|NCT01715584|Other|Angiotensin Converting Enzyme Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients exposed to Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)will make up this arm.~Preoperative Exposure to any of the following Angiotensin Converting Enzyme Inhibitors Enalapril (Vasotec/Renitec) Ramipril (Altace/Prilace/Ramace/Ramiwin/Triatec/Tritace) Quinapril (Accupril) Perindopril (Coversyl/Aceon) Lisinopril (Listril/Lopril/Novatec/Prinivil/Zestril) Benazepril (Lotensin) Imidapril (Tanatril) Zofenopril (Zofecard) Trandolapril (Mavik/Odrik/Gopten) Fosinopril (Fositen/Monopril)"
3125886|NCT01715584|Other|Angiotensin Receptor Blocker Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients exposed to Angiotensin Receptor Blocking Agents (ARBs).~Preoperative Exposure to any of the following Angiotensin II Receptor Blocking Agents Losartan(Cozaar) Candesartan (Atacand) Valsartan (Diovan) Irbesartan (Avapro) Telmisartan (Micardis) Eprosartan (Teveten) Olemisartan (Benicar) Azilsartan (Edarbi)"
3125887|NCT01715584|Other|Non ACE/ARB Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients not exposed to angiotensin converting enzyme inhibitors or Angiotensin receptor blocking agents will be put into this arm."
3125888|NCT01715571|Experimental|men with mild to moderate ED|Participants in this arm have documented mild to moderate ED of organic etiology and will be given the Viberect device for 4 weeks of daily home use in preparation for sexual activity. Men will be asked to use the device and attempt sexual intercourse at least 3 times weekly
3125889|NCT01715558||RYTHMIQ study group|
3125890|NCT01715558||Historical control from OPTI-MIND|
3125891|NCT01715545||day-3 poor quality embryos|
3125892|NCT01715545||developmental stage|day3 poor quality embryos day4 morular day-5/6 blastocyst
3125893|NCT01715532|Experimental|Huachansu + TACE|Patients in this arm will receive Huachansu tablets each 3 and 3 times a day orally, as well as transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment.
3125895|NCT01715519|Experimental|Treatment (Viibryd)|10 mg/day 1 to 7; 20 mg/day 8 to 14; 40 mg/day week 3 to end week 12. Subjects will then be tapered off vilazodone as follows: 20 mg/day week 13, 10 mg/day, week 14 and no medication during week 15.
3125896|NCT01715519|Placebo Comparator|Placebo|will be compared to the treatment group (viibryd)
3125897|NCT01715506|Experimental|Educational intervention|Educational intervention with two days of lecture/course for the whole staff in the selected department in each nursing home and six monthly sessions of counselling in smaller groups
3125898|NCT01715493|Experimental|Lysozyme 90 mg|
3125899|NCT01715493|Placebo Comparator|Placebo|
3125900|NCT01715480|Experimental|Broccoli sprout homogenate ingestion|Subjects will ingest broccoli sprout homogenate in the form of a shake.
3125901|NCT01715441|Active Comparator|Irinotecan monotherapy|Intravenous infusion irinotecan 180 mg/m2 over 90 minutes (D1=D15) with cross over to irinotecan and sorafenib combination at progression.
3125902|NCT01715441|Active Comparator|Sorafenib monotherapy|Oral sorafenib 400 mg twice daily (total dose 800 mg/day) with cross over to irinotecan and sorafenib combination at progression
3125903|NCT01715441|Experimental|Sorafenib and irinotecan combination|"Intravenous infusion irinotecan 120 mg/m2 over 90 minutes (D1=D15) at Cycle 1, 150 mg/m² at C2 if no diarrhea > grade 1 and no other toxicity > grade 2, and 180 mg/m² at C3 in the same conditions~Oral sorafenib 400 mg twice daily (total dose 800 mg/day) from C1. 1 cycle = 15 days and 1 course = 4 weeks."
3125904|NCT01715428||Liraglutide|administration of liraglutide at 1.2 mg/daily
3125905|NCT01715415|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3125906|NCT01715415|Experimental|Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3125907|NCT01715402||operated patients|this cohort includes patients who underwent a liver surgery whatever the pathology and whatever the surgical procedure
3125908|NCT01715389|Experimental|Intervention|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
3125909|NCT01715389|No Intervention|Control|The control group will be signed up for MyChart but not use the MyAsthma Patient Portal. This group will be referred to asthma educational content on the CHOP website, complete study measures and otherwise, receive standard care.
3125910|NCT01715376||Integrative Chinese and western medicine|Integrative Chinese and western medicine group treat with western medical therapy for CHD refering to the 'Chronic stable angina pectoris diagnosis and treatment guide'which is published by Chinese society of Cardiology, Chinese Medical Association in March, 2007, including the anti-ischemia treatment(nitric acid ester,β-blocker,calcium antagonist,ACEI), anti platelet therapy(aspirin and/or clopidogrel) and other statins.TCM should be confirmed by the physicians, according to the syndrome differentiation and the treat plan recommended in this study.
3125911|NCT01715376||Western medicine|western medical therapy for CHD can refer to the 'Chronic stable angina pectoris diagnosis and treatment guide'which is published by Chinese society of Cardiology, Chinese Medical Association in March, 2007, including the anti-ischemia treatment(nitric acid ester,β-blocker,calcium antagonist,ACEI), anti platelet therapy(aspirin and/or clopidogrel) and other statins.
3125912|NCT01715363|Experimental|FOLFOX + surgery + FOLFOX|"Systemic chemotherapy (modified FOLFOX 4) 48 hours before surgery~resection of the colorectal tumor during surgery~Resumption of FOLFOX within the month after surgery (post operative administration of 4 course of treatment and assessment of the response)"
3125913|NCT01715350|Placebo Comparator|Placebo group|"• Drug : Placebo 2 tablet~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
3125914|NCT01715350|Experimental|Dose group 1|"Drug : Placebo 1 tablet + Study drug 1 tablet~Study drug(650-mg PM012 tablet)~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
3125915|NCT01715350|Experimental|Dose group 2|"Drug : Study drug 2 tablet~Study drug (650-mg PM012 tablet)~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
3125916|NCT01715337|Other|pulmonary rehabilitation|
3125917|NCT01715324|Experimental|Growth Hormon|The participants randomized in the control group will be prescribed a regular antagonist IVF cycle with dose appropriate stimulation medication and will receive 2.5 mg of Adjuvant Growth Hormon (Saizen) daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering.
3125918|NCT01715324|No Intervention|Control|The participants randomized in the control group will be prescribed a regular antagonist IVF cycle with dose appropriate stimulation medication without Adjuvant Growth Hormon (Saizen).
3125919|NCT01715311|Experimental|Indacaterol|Indacaterol once daily
3125920|NCT01715311|Placebo Comparator|Placebo|Placebo for indacaterol and placebo for tiotropium once daily
3125921|NCT01715311|Active Comparator|Tiotropium|Tiotropium
3125922|NCT01715298|Experimental|NVA237|NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
3125923|NCT01715298|Placebo Comparator|Placebo|Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
3125924|NCT01715285|Experimental|Abiraterone acetate + Prednisone + ADT|Participants will receive abiraterone acetate tablet at a total dose of 1000 milligram (mg) along with 5 mg capsule of prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of androgen deprivation therapy (ADT) will be administered.
3126001|NCT01714739|Experimental|Part 1|Dose Escalation and Initial Signal Detection in Multiple Solid Tumors - Nivolumab with Lirilumab
3203918|NCT01170520|Experimental|rTMS|
3125925|NCT01715285|Placebo Comparator|Placebo + Androgen Deprivation Therapy (ADT)|Participants will receive placebo matched to abiraterone acetate and prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of ADT will be administered.
3125926|NCT01715272|Active Comparator|Fleet enema|This group will receive Fleet enema as their treatment
3125927|NCT01715272|Experimental|TF037|This group will receive TF037 as their treatment
3125928|NCT01715259|Experimental|Abiraterone acetate|
3125929|NCT01715246|Placebo Comparator|Starter infant formula without HMO|Volumes of feed depend on age, weight and appetite.
3125930|NCT01715246|Active Comparator|Starter infant formula with 2 HMOs|Volumes of feeds depend on age, weight and appetite
3125931|NCT01715246|No Intervention|Breasfed reference group|
3125932|NCT01715233|Active Comparator|Arm A|CHFR Methylated Group
3125933|NCT01715233|Active Comparator|Arm B|CHFR Unmethylated Group
3125934|NCT01715220|Active Comparator|Sublingual nitroglycerine|Sublingual nitroglycerine followed by pain assessment and if necessary second dose of sublingual nitroglycerine
3125935|NCT01715220|Placebo Comparator|placebo|sublingual placebo followed by pain assessment and if necessary second dose of sublingual placebo
3125936|NCT01715207|Experimental|Atenolol & Aliskiren|Atenolol tablet and Aliskiren 150mg or 300mg tablet by mouth per day for 6month
3125937|NCT01715207|Other|Atenolol|Atenolol tablet(Negative controls, Open-label)
3125938|NCT01715194|Active Comparator|Telemedicine intervention|"In the telemedicine intervention arm, a telemetry device is instructed and attached to the CPAP. Patients are instructed to use CPAP every night. Data of the CPAP are downloaded to the internet once daily. On week days, a nurse is checking the downloaded data three times per week. The nurse contacts the patient if~CPAP was used <4h/ night for 2 consecutive night~the median leakage was above 0.4 L/sec on 2 consecutive nights The nurse informs the patient of the problem observed, asks for explanations and gives advice on possibilities to solve the problem. The common problems and the respective solutions are discussed according to the ELF facts sheet (Dry mouth/throat, nasal congestion, skin irritation, conjunctivitis, headache, loss of benefits, appendix 1). The patient is encouraged to use CPAP every night. In the case of regular use and acceptable leakage, a congratulatory message is sent to the patient via sms or e-mail (for procedural rules, see appendix 4)."
3125939|NCT01715194|No Intervention|Control (without telemedicine)|In the control arm, no device is attached to the CPAP machine, but data stored in the CPAP machine are collected at the follow-up visit after 1 month of CPAP use.
3125940|NCT01715181|No Intervention|Usual care|Individuals will receive usual care
3125941|NCT01715181|Experimental|Volunteer visits|Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
3125942|NCT01715168|Active Comparator|DOXIL/CAELYX or Doxorubicin Hydrochloride (Lipspome)|Current Standard of care and/or reference product in Europe (Caelyx) and US (Doxorubicin Hydrochloride (Liposome) and Doxil)
3125943|NCT01715168|Experimental|ATI-0918|Investigational drug arm which will be compared to Doxil/Caelyx and Hydrochloride Doxorubicin (Liposome) arms for bioequivalence analysis
3125944|NCT01715155||Female patients diagnosed with metastatic breast cancer|Patients newly diagnosed with metastatic breast cancer, either De Novo or having progressed from a non-metastatic stage.
3125945|NCT01715142|Experimental|Gemcitabine+Abraxane|Chemotherapy combining gemcitabine and Abraxane during 4 weeks (1 cycle) before surgery (cohort 1: resectable patients) and during at least 8 weeks (2 cycles or more in case of response of stable disease) (cohort 2: locally advanced and metastatic patients)
3125946|NCT01715129|Experimental|11.25mg|11.25mg, SC on Day 1 and Day 92
3125947|NCT01715116|Experimental|Enhanced ICD programming|
3125948|NCT01715103|Other|Healthy women volunteers|Healthy women volunteers with vaginal swabs by washing and cytobrush
3125949|NCT01715103|Other|HIV-1 infected women|HIV-1 infected women with vaginal swabs by washing and cytobrush
3125950|NCT01715090|Experimental|Web-based insulin titration|An online web-based insulin titration algorithm to guide patients in self-titration
3125951|NCT01715090|No Intervention|Standard care|
3125952|NCT01715077|Experimental|Ipilimumab|The recommended induction dose of ipilimumab is 3 mg/kg administered intravenously over a 90-minute period every 3 weeks for a total of four doses, as guided by laboratory tests and patient assessment.
3125953|NCT01715064|No Intervention|Control|non-exercise control consisting of movie watching.
3125954|NCT01715064|Experimental|Exercise|1 hour of moderate intensity exercise.
3125955|NCT01715051|Active Comparator|D-serine|Participants randomized to D-serine will receive 500 mg tablets of D-serine based on the participant's weight in addition to weekly cognitive behavioral therapy (CBT). The number of capsules prescribed will be based on the target ~60 mg/kg per day dose. In practice, the mg/kg daily dose will range between approximately 55 mg/kg and 65 mg/kg. Dosing will be bid.
3125956|NCT01715051|Placebo Comparator|Placebo|The number of placebo capsules prescribed to a study participant per day will be based on the participant's weight and will be bid dosing to match the dosing of D-serine.
3125957|NCT01715038|Experimental|Comprehensive|"Comprehensive LNS: LNS-PLW provided daily to mothers during pregnancy and postpartum lactation (a total of at least 11 months, starting by 20 weeks gestation and ending at 6 months post-partum) and LNS developed for infants and young children (LNS-child) provided daily to their infants (beginning at 6 months of age for a period of 18 months i.e., from 6-24 months of age)."
3125958|NCT01715038|Experimental|Child-only LNS|"Child-only LNS: Daily LNS-child supplementation of the child starting at 6 months of age and ending at 24 months of age (18 months total). Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum."
3125959|NCT01715038|Experimental|Child-only MNP|"Child-only MNP: Daily MNP supplementation of the child starting at 6 months of age and ending at 24 months of age (18 months total). Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum."
3125960|NCT01715038|Active Comparator|Control: IFA|Control: No additional nutrient supplementation for the child will be provided through the study, but the regular nutrition education and visits provided by the program frontline staff will continue. Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum.
3126002|NCT01714739|Experimental|Part 2 and 3: Cohort Expansion|In platinum-refractory recurrent or metastatic SCCHN - Nivolumab with or without Lirilumab
3125961|NCT01715025|Experimental|E2/Nomac|Women with demonstrated HMB at baseline will be assigned to 3 cycles of a E2/Nomac combined pill 1 daily for 24 days followed by 1 placebo pill daily for 4 days per cycle.
3125962|NCT01715012|Experimental|ACCS|ACCS sprayed to the skin graft and donor site
3125963|NCT01715012|Placebo Comparator|Saline|Saline (placebo)sprayed to the skin graft and donor site
3125964|NCT01714999|Experimental|Bursectomy: Vienna|At the Department of Trauma Surgery, Medical University of Vienna, bursectomy is considered the gold standard in case of traumatic laceration of the OB or PB bursa.
3125965|NCT01714999|Experimental|Bursal reconstruction: Munich|At the Department of Trauma Surgery, Medical University of Munich, the treatment regime is a primary bursa-preserving therapy.
3125966|NCT01714986|Active Comparator|Affect School|Psychological group education intervention
3125967|NCT01714986|Active Comparator|Body Awareness Therapy|Physiotherapeutic psychosomatic intervention
3125968|NCT01714973|Experimental|ACCS|There will be 3 treatment cohorts of 10 patients each. The area of the breast will be divided into two, roughly equal parts, medial and lateral. The patient will be randomized before the first treatment to receive ACCS and saline, one to the medial segment and the other to the lateral segment. The randomization scheme will be equal in each of three cohorts. The first cohort will receive ACCS and saline beginning with the first radiation treatment, the second cohort will receive ACCS and saline beginning with the onset of erythema from the breast irradiation, the third cohort will receive ACCS and saline beginning with the onset of skin ulceration from the breast irradiation.
3125969|NCT01714960|Experimental|Healthy volunteers low dose|MRZ-99030 eye drops (5mg/mL), 1-3 drops three times per day, duration: 16 days.
3125970|NCT01714960|Experimental|Healthy volunteers high dose|MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days.
3125971|NCT01714960|Experimental|Glaucoma patients|MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days.
3125972|NCT01714960|Placebo Comparator|Placebo|Placebo eye drops, 1-3 drops three times per day, duration: 16 days.
3125973|NCT01714947|Experimental|alisertib|"Part A: Patients will receive a single dose of 35-mg [14C]-alisertib oral solution containing 80 - 100 μCi of total radioactivity (1.19 - 1.48 mCi/mmol). The estimated duration is approximately 10 days during which time the patient will remain at the clinical facility. The maximum number of days that a patient may remain in confinement is expected to be between 11 to 17 days.~Part B: Eligible patients from Part A may continue into Part B which will begin immediately after or within 2 weeks of the patient completing Part A (ie, when the patient has met the criteria to be discharged from the clinic). Patients will receive alisertib tablets administered orally at a dose of 50 mg twice daily for 7 days in 21-day cycles."
3125974|NCT01714934||IPF|IPF patients diagnosed according to clinical and radiological findings
3125975|NCT01714934||NON IPF|Other interstitial lung diseases such as sarcoidosis or hypersensitivity pneumonitis diagnosed as per clinical and radiological findings
3125976|NCT01714921||Smart shock technology|
3125977|NCT01714908|Experimental|Erlotinib w Concurrent Radiotherapy|erlotinib 150mg oral daily up to 2 years concurrent radiotherapy total dose 60-66 Gray (Gy) in 2 Gray (Gy) fractions. One fraction per day, and 5 fractions per week.
3125978|NCT01714908|Active Comparator|etoposide/cis-platin (EP) w Concurrent Radiotherapy|etoposide 50mg/m2 on D1-5 and D29-33 cis-platin 50mg/m2 on D1, D8, D29 and D36 concurrent radiotherapy total 60-66 Gray (Gy) in 2 Gray (Gy) fractions. One fraction per day, 5 fractions per week.
3125979|NCT01714895|Other|High plasma insulin-Low plasma insulin|Seven out of the 14 subjects recruited in the study have been randomized to receive on the first study day a High insulin glucose clamp and on the second day a Low insulin glucose clamp (sequence 'AB')
3125980|NCT01714895|Other|Low plasma insulin-High plasma insulin|Seven out of the 14 subjects recruited in the study have been randomized to receive on the first study day a Low insulin glucose clamp and on the second day a High insulin glucose clamp (sequence 'BA')
3125981|NCT01714882|Experimental|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
3125982|NCT01714882|Active Comparator|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
3125983|NCT01714869|Other|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
3125984|NCT01714856|Experimental|Test Product|Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fed conditions
3125985|NCT01714856|Experimental|Reference Product|Single oral dose of REQUIP XL Tablets 2mg under fed conditions
3125986|NCT01714843|Experimental|ASP0456 lowest dose group|
3125987|NCT01714843|Experimental|ASP0456 low dose group|
3125988|NCT01714843|Experimental|ASP0456 middle dose group|
3125989|NCT01714843|Experimental|ASP0456 high dose group|
3125990|NCT01714843|Placebo Comparator|placebo group|
3125991|NCT01714830|Sham Comparator|sham group|the same protocol is applied but with the probe being turned off.
3125992|NCT01714830|Sham Comparator|treatment group|patients will be treated by ESWT once a week for 4 weeks
3125993|NCT01714817|Experimental|BMS-188667 + Mycophenolate mofetil + Prednisone|BMS-188667 30 mg/kg injection by intravenous on Days 1,15, 29, and 57, followed by a weight-tiered dose approximating 10mg/kg injection by intravenous every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 weeks
3125994|NCT01714817|Placebo Comparator|Placebo + Mycophenolate mofetil + Prednisone|Placebo matching with BMS-188667 injection by intravenous on Days 1,15, 29, and 57, followed by every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 Weeks
3125995|NCT01714804|Experimental|Prospective|Accell Evo3
3125996|NCT01714791|Active Comparator|Usual care|Patients following the outpatient cardiac rehabilitation program.
3125997|NCT01714791|Experimental|Usual care and Osteopathic treatment|Patients following the outpatient cardiac rehabilitation program and receiving osteopathic treatment.
3125998|NCT01714778||e-Cigarette|Smokers attempting to quit with behavioural support and e-Cigarettes.
3125999|NCT01714765|Other|Dovitinib and Everolimus|No Arms
3126000|NCT01714752|Experimental|exercise|Patients perform exercise and pression measure is performed
3126045|NCT01714479|Placebo Comparator|Load Carriage - Control|Load Carriage - with a calorie-free placebo
3126003|NCT01714739|Experimental|Part 4: Cohort Expansion|Additional Signal Detection in Solid Tumors - Nivolumab with Lirilumab
3126004|NCT01714739|Experimental|Part 5 and 6|Safety Lead-In and Additional Signal Detection in Solid Tumors -- Nivolumab Plus Ipilimumab with Lirilumab
3126005|NCT01714726|Experimental|1|MEDI2070 iv infusion
3126006|NCT01714726|Placebo Comparator|2|placebo iv infusion
3126007|NCT01714726|Experimental|open-label|MEDI2070 sc injection; open-label arm is available for all subjects upon completion of first placebo-controlled treatment period
3126008|NCT01714713|Experimental|EVP-6124 low dose|low dose Tablet, Once Daily, Day 1 through Day 182
3126009|NCT01714713|Experimental|EVP-6124, high dose|high dose Tablet, Once Daily, Day 1 through Day 182
3126010|NCT01714700|Active Comparator|High protein diet, Resistance exercise|High protein diet, Resistance exercise total calories 2400 Kcal/day, 55% carbohydrate, 30% protein, and 15% fat
3126011|NCT01714700|Placebo Comparator|Standard diet, Resistance exercise|total calories 2400 Kcal/day, 60% carbohydrate, 15% protein, and 25% fat; ST group
3126012|NCT01714687|Active Comparator|balloon sinus dilation|Balloon sinus dilation will be conducted in-office under local anesthesia.
3126013|NCT01714687|Active Comparator|medical therapy|Medical therapy as needed per subject's specific disease and as determined by the investigators' clinical judgment.
3126014|NCT01714674|Placebo Comparator|Placebo beverage|the impact of placebo (no active substance) on exercise-induced cTnT release
3126015|NCT01714674|Active Comparator|Dietary nitrate beverage|The impact of dietary nitrate (active substance) on exercise-induced cTnT release
3126016|NCT01714661|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
3126017|NCT01714661|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
3126018|NCT01714661|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day -14 through Day 182
3126019|NCT01714648|Experimental|OHSS high risk patients|Triptorelin 0.2 mg
3126020|NCT01714635|Experimental|Tecnis Multifocal Intraocular lens #1|A low diopter add multifocal intraocular lens
3126021|NCT01714635|Experimental|Tecnis Multifocal Intraocular Lens #2|A low diopter add multifocal intraocular lens
3126022|NCT01714635|Active Comparator|Monofocal Intraocular Lens|Commercially available monofocal intraocular lens (IOL)
3126023|NCT01714622||metabolic syndrome|gastric cancer patients with metabolic syndrome
3126024|NCT01714622||metabolic disease|gastric cancer patients with metabolic disease
3126025|NCT01714622||normal|gastric cancer patients without metabolic syndrome or metabolic disease
3126026|NCT01714609|Placebo Comparator|Placebo|Subjects randomized to placebo will take two tablets of placebo by mouth twice daily.
3126027|NCT01714609|Experimental|Sorafenib|Subjects randomized to Sorafenib will take Sorafenib 400 mg by mouth twice daily.
3126028|NCT01714596|Active Comparator|Oral Antibiotic|Oral Antibiotic Arm; Participants assigned to this group will receive oral antibiotics as prescribed by their treating physician.
3126029|NCT01714596|Active Comparator|IV Antibiotic|Participants assigned to this group will receive intravenous (IV) antibiotics as prescribed by their treating physician.
3126030|NCT01714583||High PEEP|Cohort of participants with positive end-expiratory pressure (PEEP) greater than or equal to 12cm.
3126031|NCT01714583||Low PEEP|Cohort of participants with positive end-expiratory pressure (PEEP) less than 12cm.
3126032|NCT01714570|Experimental|piperacillin/tazobactam|
3126033|NCT01714570|Active Comparator|imipenem/cilastatin|
3126034|NCT01714557|No Intervention|No prophylaxis|
3126035|NCT01714557|Active Comparator|piperacillin|
3126036|NCT01714557|Experimental|piperacillin/tazobactam|
3126037|NCT01714544|Experimental|Cloderm Cream|Cloderm (clocortolone pivalate) Cream 0.1%, twice daily for 28 days
3126038|NCT01714531|Experimental|Telephone-Based Goal Management Training|The GMT intervention targets cognitive deficits in executive functioning that impact a person's ability to carry out daily tasks. Participants learn how to recognize and stop absentmindedness and automatic pilot and how to reduce daily errors and 'slips' through goal setting. The telephone-based GMT condition includes 7 sessions delivered over the phone for 10 weeks.
3126039|NCT01714531|Active Comparator|Telephone-Based Attention-Control|The attention group receives an educational intervention that is matched to the GMT intervention in terms of session length and contact with the study therapist. The telephone-based attention condition includes 7 sessions delivered over 10 weeks. Sessions address education on brain function and cognitive principles of memory, attention, language, perception, and motor skills. Education on stress reduction, sleep hygiene, energy management, exercise, communication, and nutrition are also provided
3126040|NCT01714531|No Intervention|Usual Care Control|Participants in the control group will receive usual care as determined by the treating surgeon. Usual care may include referral to a physical therapist, occupational therapist, psychiatrist, and/or psychologist and utilization of health services will be recorded during follow-up assessments.
3126041|NCT01714518||ILD diagnosis|Patients subjected to Cryobiopsy and/or VATS for diagnosis of interstitial lung disease
3126042|NCT01714505|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in Control to Range (CTR) or in Safety Only mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct for hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
3126043|NCT01714505|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. The subject will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
3126044|NCT01714492||Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|subjects implanted with the Sigma Posterior Stabilizing Rotating Platform TKA including a polyethylene insert with 4 beads
3126046|NCT01714479|Experimental|Load Carriage - leucine-enriched nutrition supplement|Load Carriage with leucine-enriched amino acid supplementation
3126047|NCT01714479|Placebo Comparator|Conventional Exercise - Control|Conventional Exercise with a calorie-free placebo
3126048|NCT01714479|Active Comparator|Conventional Exercise - Leucine-enriched Nutrition Supplement|Conventional Exercise with leucine-enriched Amino Acid supplementation
3126049|NCT01714466|Experimental|Part A, arm 1|Evening dose of TF048. Morning dose of TF043
3126050|NCT01714466|Experimental|Part A, arm 2|Evening dose of TF043. Morning dose of TF048
3126051|NCT01714466|Experimental|Part A, arm 3|Evening dose of TF047. Morning dose of TF043
3126052|NCT01714466|Active Comparator|Part A, arm 4|MOVIPREP (Both evening and morning dose)
3126053|NCT01714466|Experimental|Part B, arm 1|IMP selected based on the optimal dosing sequence and volume identified from Part A
3126054|NCT01714466|Experimental|Part B, arm 2|IMP as used in Part B, arm 1, with a differing amount of additional clear fluid being consumed
3126055|NCT01714466|Active Comparator|Part B, arm 3|IMP as used in Part B, arm 1, except for a reduced amount of ascorbate
3126056|NCT01714466|Experimental|Part B, arm 4|MOVIPREP used in both evening and morning dose
3126057|NCT01714440||Transplant Recipients Cohort|Main Study Cohort: Kidney (or kidney-pancreas) transplant recipients. Enrollment for this cohort is closed.
3126058|NCT01714440||Transplant Donors Cohort|Main Study Cohort: The kidney donor for transplant recipients in this study. Enrollment for this cohort is closed.
3126059|NCT01714440||Activity&mRNA Expression Substudy Cohort|A subset of subjects enrolled in the main study who will receive tacrolimus, cyclosporine or mycophenolate as part of maintenance immunosuppression therapy. This group has a prospective observational cohort design. Enrollment into the Activity and messenger ribonucleic acid (mRNA) Expression Cohort, occurring concurrently with enrollment of the rest of the study, will continue until either the required sample size of 600 is achieved or the protocol team terminates enrollment. Participants in the Activity and mRNA Expression Cohort have additional blood draws up to 2 weeks prior to transplant, at week 1, Month 3 and Month 6 post-transplant.
3126060|NCT01714427|Active Comparator|Dexamethasone|
3126061|NCT01714427|Placebo Comparator|Sterile isotonic saline|
3126062|NCT01714414|Experimental|FZD 600mg twice daily|FZD 3 tablets (600mg) twice daily / 3TC 1 tablet (150mg) twice daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
3126063|NCT01714414|Experimental|FZD 800mg once daily|FZD 4 tablets (800mg) once daily / 3TC 2 tablets (150mg) once daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
3126064|NCT01714414|Experimental|FZD 1200mg once daily|FZD 6 tablets (1200mg) once daily / 3TC 2 tablets (150mg) once daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
3126065|NCT01714414|Active Comparator|AZT twice daily|1 tablet Combivir(AZT 300mg/3TC 150mg) twice daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
3126066|NCT01714401|Active Comparator|Salbutamol 2,5 mg|
3126067|NCT01714401|Active Comparator|Salbutamol 5mg|
3126068|NCT01714401|Active Comparator|Ipratropium 0.5|
3126069|NCT01714388|Experimental|Remifentanil, Vagotonic response|1 microgram/kg remifentanil given iv over at least 30 sec. at the beginning of induction of general anaesthesia
3126070|NCT01714375|Active Comparator|QuietDose device VOLUNTARY|"This group of employees will voluntarily use the QuietDose units in place of their regular hearing protection, which may be either ear plugs or ear muffs."
3126071|NCT01714375|No Intervention|No QuietDose device|"This group of employees will not use the QuietDose units and maintain use of their regular hearing protection which may be either ear plugs or ear muffs."
3126072|NCT01714375|Active Comparator|QuietDose Device REQUIRED|"This group of employees will be required to use the QuietDose units in place of their regular hearing protection, which may be either ear plugs or ear muffs."
3126073|NCT01714349|Experimental|Nerve Transfer|Surgical - Nerve transfers for patients with stable cervical spinal cord injuries
3126074|NCT01714336|Placebo Comparator|placebo|Normal saline will be administered intravenously in two doses of 15 mg/kg each administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
3126075|NCT01714336|Active Comparator|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg each administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
3126076|NCT01714323|Other|Standard care|At discharge, the participant receives the standard care provided by the hospital. This consists of a handout with information to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
3126077|NCT01714323|Experimental|Sustained Care|A 3-month program after hospital discharge with these 2 components: (1) Free Medication and (2) Interactive Voice Response (IVR) Triage to Telephone Counseling.
3126078|NCT01714310|Experimental|Adjunctive fluoxetine|Participants previously titrated with open-label lisdexamfetamine randomized to adjunctive fluoxetine at end of study week 4.
3126079|NCT01714310|Placebo Comparator|Adjunctive placebo|Participants previously titrated with open-label lisdexamfetamine randomized to adjunctive placebo at end of study week 4.
3126080|NCT01714310|Other|Open Lisdexamfetamine Titration|All participants initially titrated with open-label lisdexamfetamine from baseline to end of study week 4.
3126081|NCT01714297|Active Comparator|dalteparin 5000IU s.c.|5000IU dalteparin s.c. injected the evening before cemented total hip arthroplasty
3126082|NCT01714297|Placebo Comparator|saline|Syringes of Saline with the same volume as in the dalteparin injections are injected the evenings before total hip arthroplasty. Dalteparin 5000IU are injected 6 hours after surgery and the concomitant 33 days
3126083|NCT01714284|Experimental|Diet and Exercise|
3126084|NCT01714284|Sham Comparator|Informative|
3126142|NCT01713868|Other|Safe Sleep Edu and Safe Sleep mHealth|Participants will receive Safe Sleep Nursery Education and Safe Sleep Mobile Health messaging
3126143|NCT01713868|Other|Breastfeed Edu and Breastfeed mHealth|Participants will receive Breastfeeding Nursery Education and Breastfeeding Mobile Health messaging
3126144|NCT01713842|Experimental|TCZ|Tocilizumab at week 0, week 4 and week 8 8mg/kg at each perfusion
3127119|NCT01707407|Experimental|Pomalidomide plus Ketoconazole plus Fluvoxamine|
3126085|NCT01714271|Experimental|Home environs-based lifestyle counseling|Home environs-based lifestyle counseling Involves Spanish-speaking community health workers interacting with intervention subjects in home visits and phone calls - 12 contacts overall. The counseling focuses on promoting subject adherence to the Dietary Guidelines for Americans (DGA) and the Physical Activity Guidelines for Americans (PAGA) with special attention devoted to changing the home environment to make it optimally supportive of the lifestyle choices consistent with the DGA and PAGA. Study participants will also be provided 4 group education sessions that will be devoted to improving subject adherence to the DGA and PAGA.
3126086|NCT01714271|Experimental|Cancer early detection|Cancer Early Detection Spanish-speaking health educators will interact with study participants via a home visit and four telephone calls. The focus of the health education will be on practical strategies to detect cancer early to help prevent death from cancer. Cancer sites of interest will be: breast, cervical, skin, colon, prostate and testicular cancers. In addition, study participants will be provided two group education classes that will focus on the basics of the cancer process and why early detection and intervention can be life-saving.
3126087|NCT01714258|Experimental|non invasive cardiac output measure|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients 20 times, throughout a period of about 45 min
3126088|NCT01714232|Experimental|Study Staff Test BGMSs|All testing and lancing were performed by the study staff; subjects did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using five Blood Glucose Monitoring Systems (BGMS): Contour® PLUS BGMS; OneTouch® SelectSimple™ BGMS; Accu-Chek® Performa BGMS; Accu-Chek® Active BGMS; Freestyle Freedom® BGMS.
3126089|NCT01714219|Experimental|Posterior reconstruction|"New posterior reconstruction, which entails opposition of the median dorsal fibrous raphe solely to the posterior counterpart of the detrusor apron~Vesicourethral anastomosis using the van Velthoven method~Anterior reconstruction, which involved opposing the anterior detrusor apron to the remaining puboprostatic ligaments and dorsal vascular complex"
3126090|NCT01714219|No Intervention|No posterior reconstruction|"No posterior reconstruction~Vesicourethral anastomosis using the van Velthoven method~Anterior reconstruction, which involved opposing the anterior detrusor apron to the remaining puboprostatic ligaments and dorsal vascular complex"
3126091|NCT01714206|Active Comparator|Treatment A|Each volunteer will receive digoxin once daily on Days 1 through 7.
3126092|NCT01714206|Experimental|Treatment B|Each volunteer will receive digoxin once daily on Days 1 through 7 in combination with canagliflozin (JNJ-28431754) once daily on Days 1 through 7.
3126093|NCT01714193|Experimental|Canagliflozin + oral contraceptive|Each volunteer will receive a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel in combination with a single dose of canagliflozin.
3126094|NCT01714180||Obese Patients|
3126095|NCT01714180||Non-obese Patients|
3126096|NCT01714167|Active Comparator|intracerebral stem cell transplantation|Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient plus conventional treatment include rehabilitation
3126097|NCT01714167|No Intervention|conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
3126098|NCT01714154|Experimental|A: setrobuvir|
3126099|NCT01714154|Experimental|B: setrobuvir + DNV/r|
3126100|NCT01714141|Experimental|Multi-component, technology based intervention|2 tailored, computer-delivered motivational interviewing sessions targeting adherence to asthma control medications + tailored text messaged reminders to take medications between sessions.
3126101|NCT01714141|Active Comparator|Asthma education active control|Control condition consists of active control matched to intervention for delivery-method and time-- 2 sessions of computer-delivered asthma education + daily text messaged facts about asthma.
3126102|NCT01714128|Other|Optional Diagnostic Imaging|Optional diagnostic imaging FES-PET/CT imaging
3126103|NCT01714102|Placebo Comparator|Placebo|Placebo for 30 days
3126104|NCT01714102|Active Comparator|Resveratrol|1000 mg PO BID for 30 days
3126105|NCT01714089|Experimental|RNS60 125 ml|125 ml of RNS60 administered weekly by IV infusion
3126106|NCT01714089|Experimental|RNS60 250 ml|250 ml of RNS60 administered weekly by IV infusion
3126107|NCT01714089|Active Comparator|Interferon beta-1a|Weekly dose of 30 mcg Interferon beta-1a (Avonex) administered by intramuscular injection.
3126108|NCT01714076||cohort isolation|patients with bronchiolitis are cohorted together irrespective of viral agent diagnosed, thus respiratory syncytial virus (RSV)-positive patient stay in the same room as RSV-negative patients
3126109|NCT01714063||Age 5-6.5|Group 1 will consist of 16 children aged 5-6.5 years
3126110|NCT01714063||Aged 6.6- 8 years|Group 2 will consist of 16 children aged 6.6- 8 years
3126111|NCT01714050|Experimental|Cognitive-Behavioral Therapy (CBT)|"The CBT is a SAD-tailored version of Beck et al.'s (1979) cognitive therapy for depression called Coping with the Seasons (Rohan, 2008). The rationale addresses environmental changes, thoughts, and behaviors in SAD onset and maintenance. It seeks to change behaviors and thoughts to improve coping with winter. Behaviors that promote enjoyment in the winter are increased. Negative thoughts that interfere with self-esteem and negative thoughts about winter are identified and addressed. A relapse-prevention component addresses early identification of negative anticipatory thoughts about winter and SAD-related behavior changes, using the CBT skills learned to cope with subsequent winter seasons, and development of a personalized relapse-prevention plan. The CBT sessions are administered twice a week over 6 weeks (total of 12 sessions) with 4-8 participants per group. The CBT is led by one of three licensed Ph.D.-level psychologists working on the project."
3126145|NCT01713829|Experimental|Cranberry Beverage|Cranberry Beverage is provided in an 8 oz daily beverage consumed once daily for 12 weeks
3126146|NCT01713829|Placebo Comparator|Placebo Beverage|The placebo beverage looks like the active arm and is given in the same way but contains no active ingredient.
3126147|NCT01713816||Elderly control|Healthy elderly subjects age and gender matched to the AD cohort, predominantly male
3126148|NCT01713803|Placebo Comparator|Sugar pill|
3126149|NCT01713803|Experimental|buprenorphine and nalaxone|
3127120|NCT01707407|Experimental|Pomalidomide plus Carbamazepine|
3126112|NCT01714050|Experimental|Light Therapy (LT)|LT will be initiated at 30-minutes in the morning at home, first thing upon awakening, using a light box with an ultraviolet shield that emits 10,000-lux of white fluorescent light. After the first week, an M.D. light therapy consultant will recommend individually-tailored, clinical adjustments to the duration and timing of light use to maximize response and reduce any reported side effects. For each of the 6-weeks of LT, LT participants will complete a Light Therapy Side Effects Questionnaire to assess side effects attributed to LT. Participants will keep daily LT compliance diaries to record the timing and duration of LT. After the 6-weeks of monitoring, participants may choose to continue using the light box through April. We will offer LT participants who wish to use light therapy in the next fall/winter season access to our light boxes if they agree to followup with a physician or other qualified professional for monitoring and side effects management.
3126113|NCT01714037|Experimental|Cisplatin, Pemetrexed, Debio 0932|Cisplatin, Pemetrexed, Debio 0932
3126114|NCT01714037|Experimental|Cisplatin, Gemcitabine, Debio 0932|Cisplatin, Gemcitabine, Debio 0932
3126115|NCT01714037|Experimental|Docetaxel, Debio 0932|Docetaxel, Debio 0932
3126116|NCT01714024|Experimental|Healthy Volunteers|Subjects who are non-diabetic, with no history of smoking within the past two years and no metabolic bone disease diagnosis.
3126117|NCT01714024|Experimental|Diabetic Subjects|Subjects must have Type 2 diabetes mellitus as diagnosed by a physician or in medication history. The condition must be currently diagnosed and treated by medications and/or insulin.
3126118|NCT01714024|Experimental|Osteopenic Subjects|Subjects must be diagnosed with osteoporosis or osteopenia and must be currently under the care of a physician and treatment with oral bisphosphonates
3126119|NCT01714011|Active Comparator|Ziprasidone|Ziprasidone is a psychotropic agent with chemical name: 5-[2-[4-(1,2-benzisothiazole-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one.Ziprasidone is a potent antagonist of both serotonin 5-HT2A and dopamine D2 receptors, although its affinity for 5-HT2A receptors is about 10 times higher than for D2 receptors.
3126120|NCT01714011|Active Comparator|Aripiprazole|Aripiprazole is a psychotropic drug that is available as tablets for oral administration. Aripiprazole is 7-[ 4-[ 4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3-4-dihydrocarbostyril. Aripiprazole exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors, moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha 1-adrenergic and histamine H1 receptors and moderate affinity for serotonin reuptake site (Ki = 98nM).
3126121|NCT01713998|Active Comparator|Group A|Subjects will receive an increased density Ulthera System Treatment over the full face but with the energy turned down to the second highest level of four possible energy settings on one side of the face.
3126122|NCT01713998|Active Comparator|Group B|Subjects will receive an increased density guideline Ulthera System Treatment over the full face but with the energy turned down to the lowest level of four possible energy settings on one side of the face.
3126123|NCT01713998|Active Comparator|Group C|Subjects will receive an increased density guideline Ulthera System Treatment over the full face with the exception that a 4 MHz transducer will be used on the upper face in place of a7 MHz transducer, with the energy turned down to the lowest level of four possible energy settings.
3126124|NCT01713985|Active Comparator|Group A|Ulthera System Treatment Right, Thermage Left
3126125|NCT01713985|Active Comparator|Group B|Ulthera System Treatment Left, Thermage Right
3126126|NCT01713972|Experimental|Treatment (dabrafenib, pazopanib hydrochloride)|Patients receive dabrafenib PO BID on days 1-28 (once daily on day 1 and BID on days 3-28 of course 1), and pazopanib hydrochloride PO QD on days 1-28 (days 2-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3126127|NCT01713972|Other|Correlative Studies|"Pharmacokinetic studies: Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~Tumor genotyping: Archival tumor blocks or unstained slides~BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
3126128|NCT01713959|Experimental|Group A - Split Body Treatment|Active treatment of one axilla with the Ulthera System Treatment; Sham treatment of one axilla.
3126129|NCT01713959|Active Comparator|Group B: Ulthera System Treatment w lido|Subjects receive a bilateral Ulthera System Treatment, with one axilla receiving a subcutaneous lidocaine injection.
3126130|NCT01713946|Experimental|Everolimus low trough|everolimus titrated to 3 to 7 ng/mL
3126131|NCT01713946|Experimental|Everolimus high trough|everolimus titrated to 9 to 15 ng/mL
3126132|NCT01713946|Placebo Comparator|Placebo|Placebo
3126133|NCT01713933|Experimental|Ultherapy™ treatment|Each enrolled subject will receive a bilateral Ultherapy™ treatment of the upper arms
3126134|NCT01713920|Experimental|SEVIKAR|Subjects who are eligible for the inclusion and exclusion criteria will be treated with Sevikar 5/20mg for 4 weeks. If subjects fail to reach the SBP threshold of SeSBP≥ 140mmHg after 4-week treatment, they will receive Sevikar 5/40mg for 4 weeks. At the end of 4-week treatment, subjects who fail to reach SBP threshold will receive Sevikar 10/40mg for 4 weeks. Subjects who can reach SBP threshold will continue to treat with current dose until 12 weeks.
3126135|NCT01713907|Experimental|Ulthera® treatment|All enrolled subjects will receive one full face and neck Ulthera® treatment.
3126136|NCT01713894|Other|Decision Aid|In this arm of the study, parents will be counseled using a decision aid.
3126137|NCT01713894|Other|Standard|In this arm of the study, parents will be counseled using current standard methods.
3126138|NCT01713881||post-registry|"Registry Group:~Select 500 consecutive patients from the polyp registry who were found to have a tubular adenoma on a colonoscopy done between 2007-2008 from the polyp registry.~Quantify the completion rate and time between index and surveillance colonoscopy after the establishment of the polyp surveillance program (2006-2013)."
3126139|NCT01713881||pre-registry|Pre-registry Group: Select 380 consecutive patients who were found to have a tubular adenoma on a colonoscopy done between April 2004-Nov 2006.
3126140|NCT01713868|Other|Safe Sleep Edu and Breastfeeding mHealth|Participants will receive Safe Sleep Nursery Education and Breastfeeding Mobile Health messaging
3126141|NCT01713868|Other|Breastfeeding Edu and Safe Sleep mHealth|Participants will receive the Breastfeeding Nursery Education and the Safe Sleep Mobile Health messaging
3126218|NCT01713361|Active Comparator|Enoxaparin|Enoxaparin (40mg)
3205812|NCT01156363|Experimental|Single Arm|
3126150|NCT01713790|Experimental|Training group|T0 - Intervention program 3x/ week over 10 weeks: Stochastic resonance whole-body vibration + Exergame + leg press - T1
3126151|NCT01713777|Experimental|"Lamotrigine Generic A/Generic B"|"Crossover trial. Each arm will receive generic A for two periods and generic B for two periods."
3126152|NCT01713777|Experimental|"Lamotrigine Generic B/Generic A"|"Crossover trial. Each participant will have two periods of generic A and two periods of generic B"
3126153|NCT01713764|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate diet: carbohydrate intake 10-50 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
3126154|NCT01713764|Active Comparator|American Diabetes Association Diet|"Participants in the American Diabetes Association (ADA) diet group will receive standard ADA advice. The diet includes high-fiber foods (such as vegetables, fruits, whole grains, and legumes), low-fat dairy products, fresh fish, and foods low in saturated fat.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
3126155|NCT01713751|Active Comparator|Interrupted suturing Group|Includes women who have their skin closed with interrupted mattress stitches using non-absorbable polypropylene [Prolene®]
3126156|NCT01713751|Active Comparator|Subcuticular suturing Group|Includes women who have their skin closed with subcuticular stitches using non-absorbable polypropylene [Prolene®].
3126157|NCT01713738|Experimental|rituximab|
3126158|NCT01713725|Active Comparator|Omalizumab 300 mg|"Subcutaneous route~300 mg dose (independent from total IgE, weight or high)"
3126159|NCT01713725|Placebo Comparator|Placebo|"Saline serum~Subcutaneous route~0.6 ml saline serum with same volume as an active treatment"
3126160|NCT01713712|No Intervention|Routine Obstetric Care|
3126161|NCT01713712|Experimental|Nutritional Counseling|Patients will receive an initial 90 minute nutritional consult followed by 60 minute follow up consults every 2 weeks to monitor weight gain and nutritional status.
3126162|NCT01713699|Other|diagnostic|Using extra CSF material received by clinically indicated lumbar punctures to determine the sensitivity and specificity of CTCs in CSF (5ml CSF). Standard material of 5 ml CSF for cytology and 2 ml CSF for cell count and chemistry is being regularly used and processed.
3126163|NCT01713686|Experimental|Ulthera System Treatment|A single triple-depth Ulthera System treatment of the decolletage delivering treatment at 4.5mm, 3.0mm and 1.5mm depths.
3126164|NCT01713673|Experimental|Active Treatment|Subjects receive Ulthera System Treatments according to the pre-defined Ulthera® System energy settings.
3126165|NCT01713673|Sham Comparator|Sham Treatment|Subjects will receive Sham treatments using the Ulthera® System with the energy set to 0.00 Joules.
3126166|NCT01713660|Other|FS Corneal Incisions|
3126167|NCT01713647|Experimental|LOSANET AM PLUS (10/100/12.5 mg) of PHARMALINE, Lebanon|"Subjects will be fasted overnight and receive one tablet by mouth in accordance with randomization table, and blood samples will be taken at specified intervals over 3 days~intervention: Drug: LOSANET AM PLUS Amlodipine/ Losartan/Hydrochlorothiazide Other Name: NA"
3126168|NCT01713647|Active Comparator|NORVASC & HYZAAR (100/12.5 mg)|"Subjects will be fasted overnight and receive one tablet of Norvasc &HYZAAR by mouth in accordance with randomization table, and blood samples will be taken over 3 days~intervention: Drug: LOSANET AM PLUS Amlodipine/ Losartan/Hydrochlorothiazide Other Name: NA"
3126169|NCT01713634|Experimental|Low Apro/K Diet|Subjects consume a prescribed diet for 4 days with a low ratio of animal protein to potassium (0.3-0.6 g/mEq).
3126170|NCT01713634|Experimental|High Apro/K Diet|Subjects consume a prescribed diet that has a high ratio of animal protein to potassium (1.0-1.3 g/mEq) for 4 days.
3126171|NCT01713621|Experimental|OZ439 100mg|Single dose of 100mg of OZ439 administered as an oral suspension
3126172|NCT01713621|Experimental|OZ439 500mg|Single dose of 500mg of OZ439 administered as an oral suspension
3126173|NCT01713608|Experimental|OZ439 Dose level 1 (300mg)|• Cohort 1 (12 subjects: 8 Active [A] and 4 on Placebo [P]) Active dose will consist of 300mg OZ439 drinking solution administered once daily for 3 days
3126174|NCT01713608|Experimental|OZ439 Dose level 2|• Cohort 2 (12 subjects: 8 A, 4P). Subjects on active will receive X amount of OZ439 (dose level to be determined based on safety and tolerability of previous dose level) drinking solution once daily for 3 days
3126175|NCT01713608|Experimental|OZ439 dose level 3|Cohort 3 (12 subjects: 8 A, 4P). Subjects on active will receive X amount of OZ439 (dose level to be determined based on safety and tolerability of previous dose level) drinking solution once daily for 3 days
3126176|NCT01713595|Experimental|Hypertonic Saline Aerosol|a single 5ml dose of 7% Saline aerosol
3126177|NCT01713582|Experimental|Acute Leukemia Participants|Participants with AML or ALL receive OTX015/MK-8628 at a starting dose of 10 mg, orally (PO) once per day (QD) continuously for 21 days per cycle.
3126178|NCT01713582|Experimental|Hematologic Malignancy Participants|Participants with DLBCL or MM receive OTX015/MK-8628 at a starting dose of 10 mg, PO QD continuously for 21 days per cycle.
3126179|NCT01713569|Active Comparator|Subject 1|Ulthera treatment will be administered to both pre-auricular regions using a 4 MHz, 4.5mm depth transducer at 1.2 Joules and 30 Watts on the Left side versus 0.9 Joules and 30 Watts on the Right side.
3126180|NCT01713569|Active Comparator|Subject 2|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm depth transducer at 1.05 Joules and 25 Watts on the Left side versus 0.75 Joules and 25 Watts on the Right side.
3126297|NCT01712854|Placebo Comparator|Budesonide only|Budesonide 80 mcg (Entocort EC) only
3129358|NCT01692145|Placebo Comparator|Placebo|
3126181|NCT01713569|Active Comparator|Subject 3|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm depth transducer at 0.45 Joules and 15 Watts on the Left side versus 0.35 Joules and 14 Watts on the Right side.
3126182|NCT01713569|Active Comparator|Subject 4|Ulthera treatment will be administered to both pre-auricular regions using a 10 MHz, 1.5mm depth transducer at 0.25 Joules and 5 Watts on the Left side versus 0.18 Joules and 5 Watts on the Right side.
3126183|NCT01713569|Active Comparator|Subject 5|Ulthera treatment will be administered to both pre-auricular regions using a 4 MHz, 4.5mm depth transducer at 0.9 Joules and 30 Watts on the Left side versus 7 MHz, 4.5mm 0.9 Joules and 25 Watts on the Right side.
3126184|NCT01713569|Active Comparator|Subject 6|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm transducer at 0.35 and 14 Watts, and a 4 MHz, 4.5mm depth transducer at 0.9 Joules and 30 Watts on the Left side versus a 7 MHz, 3.0mm depth and 4.5mm depth transducer at 2.0 Joules and 40 Watts on the Right side.
3126185|NCT01713556|Experimental|Propranolol + reactivation|they have a script-driven mental imagery of the traumatic event white drug
3126186|NCT01713556|Placebo Comparator|Placebo + reactivation|They have a script-driven mental imagery of the traumatic event with placebo
3126187|NCT01713543|Experimental|Intervention Group|The intervention consists of a tailored physical therapy focused on progressive strength, balance and gait training for a period of 3 months.
3126188|NCT01713543|No Intervention|Control Group|Usual care by physician.
3126189|NCT01713530|Experimental|IDegAsp BID+/-OADs|
3126190|NCT01713530|Experimental|IDeg OD plus IAsp +/-OADs|
3126191|NCT01713517|Active Comparator|Universal coverage of Long Lasting Insecticidal Nets (LLIN)|Distribution of long lasting insecticidal nets to all community members in the study arm allowing for at least one net per 2 persons
3126192|NCT01713517|Experimental|LLIN Plus Indoor Residual Spraying|Distribution of long lasting insecticidal nets to all community members in the study arm allowing for at least one net per 2 persons plus indoor residual spraying with insecticide of interior walls of all houses twice yearly.
3126193|NCT01713504|Experimental|Hypereosinophilic syndrome unexplained|
3126194|NCT01713504|Active Comparator|Hypereosinophilic syndrome explained|
3126195|NCT01713504|Sham Comparator|Normal rate of eosinophilic|
3126196|NCT01713491||Cognitively normal|Patients with IQCODE score of 52 or less
3126197|NCT01713491||Cognitively impaired - no dementia|IQCODE score 53 - 63
3126198|NCT01713491||Demented|IQCODE score 64 or more
3126199|NCT01713478|Experimental|cirrhotic patients|"Study will include 50 cirrhotic patients, divided in 2 subgroups: 25 with alcoholic cirrhosis, and 25 with viral cirrhosis~Routine blood samples~Electrocardiogram (12 leads)~Specific biomarkers: proBNP, troponin, myocardial fibrosis (β cross laps and procollagen type-1 amino terminal), and markers of inflammation (PCR-hs, IL1, IL6, IL 10, TNFα); oxidative stress: carbonyl in plasmatic proteins, and the antioxidant capacity of plasma.~Comprehensive Echocardiography"
3126200|NCT01713478|Active Comparator|normal controls|50 normals subjects with the same procedures as cirrhotic patients: echocardiography, ECG, biomarkers
3126201|NCT01713465|Experimental|1 CBMP|CBMP: Computer based Metabolic syndrome program
3126202|NCT01713452|Active Comparator|Purse string closure|Patients undergo a purse string closure of their old stoma site.
3126203|NCT01713452|Active Comparator|Primary closure|Patients have their stoma sites close primarily with staples.
3126204|NCT01713439|Experimental|Injection of allogeneic neuroblastoma cells|Retrovirally transduced allogeneic neuroblastoma cell lines secreting the human interleukin-2 and lymphotactin genes are frozen and, when needed, are thawed, mixed and irradiated. Relapsed or refractory patients are then treated with a course of four injections of their gene-modified tumor cells according to the following schedule: The first two injections will be given at week 1 and week 2. Patients will then have a two-week rest and the remaining two injections will be given at week 4 and week 5. A complete evaluation for evidence of toxicity and response will be performed at week 8 after a 3 week rest. At the 8 week evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received.
3126205|NCT01713426|Experimental|Qutenza|Cutaneous patch
3126206|NCT01713426|Active Comparator|Pregabalin|Oral capsule
3126207|NCT01713413|Active Comparator|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
3126208|NCT01713413|Active Comparator|nasal cannula|Using first the conventional nasal cannula and 24 h later the Oxymizer
3126209|NCT01713400|Experimental|Ustekinumab|Ustekinumab, Tacrolimus and Sirolimus. Ustekinumab: 45 mg for adults who weight 100 kg or less; 90 mg for adults who weight greater than 100 kg. Tacrolimus: Level determined according to Blood and Marrow Transplant (BMT) Program standard operating procedures. Sirolimus: The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program.
3126210|NCT01713400|Placebo Comparator|Placebo|Placebo, Tacrolimus, and Sirolimus. Placebo: Identical volume to that of ustekinumab. Tacrolimus: Level determined according to Blood and Marrow Transplant (BMT) Program standard operating procedures. Sirolimus: The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program.
3126211|NCT01713387|Experimental|gemcitabine , S-1|Level-2 Gem 800mg/msq, S-1 50mg/msq Level-1 Gem 800mg/msq, S-1 65mg/msq Level 1 Gem 1000mg/msq, S-1 65mg/msq Level 2 Gem 800mg/msq, S-1 80mg/msq
3126212|NCT01713374|Active Comparator|Myogenic activation|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of myogenic activation
3126213|NCT01713374|Active Comparator|Cold pressure test|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of cold pressure test
3126214|NCT01713374|Active Comparator|mental stress|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of mental stress
3126215|NCT01713374|Active Comparator|Control|Control visit - no intervention performed - subjects will undergo endothelial function measurement twice at a distance of 45 minutes
3126216|NCT01713361|Experimental|ISIS-FXIRx Dose 2|Group B: ISIS-FXIRx Dose #2
3126217|NCT01713361|Experimental|ISIS-FXIRx Dose 3|Group C: ISIS-FXIRx Dose #3
3206400|NCT01152606||Cohort|
3126219|NCT01713348|Experimental|CGM - intervention arm|Following a 14 day masked (baseline) period using the FreeStyle Navigator subjects will wear an unmasked FreeStyle Navigator with the glucose alarms switched off.
3126220|NCT01713348|Active Comparator|SMBG - Control arm|Following a 14 day masked ( baseline) period using the FreeStyle Navigator subjects will manage their blood glucose with a standard SMBG and use a FreeStyle Navigator masked for a 14 day period at the end of the study.
3126221|NCT01713322|Experimental|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
3126222|NCT01713322|Other|No pain management education|Control - parents receive general information about childhood immunization.
3126223|NCT01713309|Active Comparator|Filgrastim|Filgrastim 300 microgr/day subcutaneously for 7 days
3126224|NCT01713309|Placebo Comparator|NaCl 0.9%|Corresponding placebo once daily, subcutaneously for 7 days
3126225|NCT01713296|Experimental|Pazopanib|
3126226|NCT01713283|Experimental|SOF+RBV 12 Weeks|Treatment-naive and treatment-experienced participants will receive SOF+RBV for 12 weeks.
3126227|NCT01713283|Experimental|SOF+RBV 24 Weeks|Treatment-naive and treatment-experienced participants will receive SOF+RBV for 24 weeks.
3126228|NCT01713270|Experimental|renal sympathetic denervation|Contrast renal angiography was performed to localize and assess the renal arteries. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter was introduced into each renal artery. This was then maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 60 seconds each were performed in both renal arteries. After renal sympathetic denervation, patients with persistent AF accepted direct-current cardioversion immediately.
3126229|NCT01713270|Active Comparator|drug therapy|Patients in the drug treatment group will be followed-up at 3, 6, 9 and 12 months after randomization. All the patients in this group will take their baseline antihypertensive medication at the original doses, without any changes except when medically required. Antiarrhythmic drugs treatment is consistent in both arms.
3126230|NCT01713257|Experimental|Immunoenhancing diet|Immunoenhancing diet feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
3126231|NCT01713257|Active Comparator|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
3126232|NCT01713244|Active Comparator|Hepatectomy|Using Hepatectomy for the treatment of advanced HCC
3126233|NCT01713244|Experimental|RFA assisted Hepatectomy|Ablating the liver tissue around the tumor before hepatectomy.
3126234|NCT01713231|Active Comparator|standard-dose vitamin D|one group of 30 participants will be randomized to receive vitamin D3 at a dose of 400 international units per day ('standard-dose group').
3126235|NCT01713231|Experimental|high-dose vitamin D|One group of 30 participants will be randomized to receive vitamin D3 at a dose of 2000 international units per day ('high-dose group').
3126236|NCT01713218|Experimental|Gemcitabine+Vismodegib|Neoadjuvant chemotherapy combining gemcitabine and Vismodegib during 4 weeks before surgery
3126237|NCT01713192||Cardiac surgery|
3126238|NCT01713179|Experimental|ambroxol|"Ambroxol hydrochloride (Mucopect®, trans-4[2-amino-3.5-dibrombenzylamino]-cyclohexanhydro-chloride, 60 mg, Boehringer Ingelheim) was administered orally to subjects in the ambroxol group immediately after initial examination (10 AM).~one dose for one day"
3126239|NCT01713179|No Intervention|control|
3126240|NCT01713166|Active Comparator|Plasmalyte solution|Plasmalyte solution infusion to meet the fluid requirements.
3126241|NCT01713166|Experimental|Hextend|6% Hetastarch administeration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
3126242|NCT01713153|Experimental|Misoprostol|600 mcg oral misoprostol administered during the third stage of labor
3126243|NCT01713153|Experimental|UnijectTM|10 IU oxytocin delivered IM with UnijectTM during he third stage of labor
3126244|NCT01713140|Experimental|1 strength training set performed until contraction failure|Knee extensions until contraction failure will be performed, using a relative loading of 10 repetition maximum (RM).
3126245|NCT01713127|Placebo Comparator|Placebo|5% dextrose infusion for 72 hours during ventilator care start within 48 hours after birth
3126246|NCT01713127|Active Comparator|remifentanil|0.1mcg/kg/min remifentanil infusion for 72 hours during ventilator care start within 48 hours after birth
3126247|NCT01713114|Experimental|Low carbohydrate|
3126248|NCT01713114|Experimental|Moderate carbohydrate|
3126249|NCT01713114|Experimental|Higher Carbohydrate|
3126250|NCT01713114|Placebo Comparator|Meal Skipping|
3126251|NCT01713101|Experimental|Early intravenous tranexamic acid administration|"Early intraveous administration of tranexamic acid~(1g IV bolus over 10 minutes followed by 1g slow infusion over 8 hours"
3126252|NCT01713101|Placebo Comparator|Placebo group|Normal saline (placebo) administration instead of tranexamic acid solution
3126253|NCT01713088|Experimental|Multisystemic therapy|MST is a family- and community-based intervention that establishes close contact with families to understand and deal with the factors that cause the young person's antisocial behaviour. The intervention targets the individual's adjustment, family relationships, school functioning and peer group affiliations. Therapists help caretakers develop skills to intervene and operate changes in important domains such as young person's individual adjustment, their family relationships, school functioning, and peer group affiliations.
3126254|NCT01713088|Active Comparator|YOT (usual services)|YOT intervention consisted of services currently available to young offenders in accordance with the Youth Justice Board National Standards.These services included supporting the young person to re-engage with education, with substance misuse problems and anger management; training them in social problem-solving skills; and programs to decrease vehicle-crime, violent-offending and knife crime. The treatments were delivered by professional social workers, specialist therapists or probation officers.
3126255|NCT01713075||Symbicort|
3126256|NCT01713062||Vitelene|Plasmacup DC® with Vitelene® inlay manufactured by UHMWPE-XE (Ultra High Molecular Weight Polyethylene highly cross-linked with 0.1% Vitamin E) in combination with one of four different Aesculap® stems (Bicontact®, TRJ®, Metha®, Excia®)
3126257|NCT01713062||XLPE|Plasmacup DC® with a standard polyethylene inlay manufactured by UHMWPE-X (Ultra High Molecular Weight Polyethylene highly cross-linked) in combination with one of four different Aesculap® stems (Bicontact®, TRJ®, Metha®, Excia®)
3126258|NCT01713049|Other|18F-FLT|18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound.
3126259|NCT01713036|Experimental|Pimasertib|
3126260|NCT01713023|Experimental|Glucose solution|Solution containing 75g of glucose diluted in 200 mL of water
3126261|NCT01713023|Experimental|Fructose solution|Solution containing 75g of fructose diluted in 200 mL of water
3126262|NCT01712997|Experimental|Combination therapy|combine inhaled iloprost, 10μg, 4-6times/day with bosentan,125mg,po,bid.
3126263|NCT01712997|Active Comparator|monotherapy|Bosentan,125mg,po,bid.
3126264|NCT01712984|Experimental|QIV ID Vaccine Group|Participants will receive the intradermal quadrivalent influenza vaccine
3126265|NCT01712984|Active Comparator|TIV ID1 Vaccine Group|Participants will receive the trivalent influenza vaccine containing the B strain from the primary (Yamagata) lineage
3126266|NCT01712984|Active Comparator|TIV ID2 Group|Participants will receive the intradermal trivalent influenza vaccine containing B strain from the alternate (Victoria) lineage
3126267|NCT01712971||OPD|standard open pancreaticoduodenectomy
3126268|NCT01712971||LPD|laparoscopic pancreaticoduodenectomy
3126269|NCT01712945|Experimental|Palifermin (and Alemtuzumab)|Palifermin (Kepivance®), at the maximum identified tolerated dose will be administered by intravenous bolus on days -5, -4. -3 prior to, and on days 8, 9 and 10 after each cycle of alemtuzumab, then again on 3 consecutive days at month 1 and month 3 after each cycle of alemtuzumab. Patients will be observed for adverse reactions for at least 1 to 2 hours following each bolus dose. Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
3126270|NCT01712945|Placebo Comparator|Placebo (and Alemtuzumab)|Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
3126271|NCT01712919|Experimental|cetuximab|Patients will be given intensity-modulated radiotherapy,2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin,and weekly cetuximab during radiation therapy.
3126272|NCT01712906|Experimental|3.50±0.25logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 adults aged 16-59 years old on day 0.
3126273|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 adults aged 16-59 years old on day 0.
3126274|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 adults aged 16-59 years old on day 0.
3126275|NCT01712906|Placebo Comparator|0 logCCID50/ml in adults|0 logCCID50/ml in 18 adults aged 16-59 years old on day 0.
3126276|NCT01712906|Experimental|3.50±0.25logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 children aged 5-15 years old on day 0.
3126277|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 children aged 5-15 years old on day 0.
3126278|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 children aged 5-15 years old on day 0.
3126279|NCT01712906|Placebo Comparator|0 logCCID50/ml in children (5-15 years old)|0 logCCID50/ml in 18 children aged 5-15 years old on day 0.
3126280|NCT01712906|Experimental|3.50±0.25logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 children aged 2-4 years old on day 0.
3126281|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 children aged 2-4 years old on day 0.
3126282|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 children aged 2-4 years old on day 0.
3126283|NCT01712906|Placebo Comparator|0 logCCID50/ml in children (2-4 years old)|0 logCCID50/ml in 18 children aged 2-4 years old on day 0.
3126284|NCT01712906|Active Comparator|Attenuated Mumps vaccine in children (2-4 years old)|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in 18 children aged 2-4 years old on day 0.
3126285|NCT01712906|Experimental|3.50±0.25logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 infants aged 8-23 months old on day 0.
3126286|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 infants aged 8-23 months old on day 0.
3126287|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 infants aged 8-23 months old on day 0.
3126288|NCT01712906|Placebo Comparator|0 logCCID50/ml in infants|0 logCCID50/ml in 18 infants aged 8-23 months old on day 0.
3126289|NCT01712906|Active Comparator|Attenuated Mumps vaccine in infants|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in 18 infants aged 8-23 months old on day 0.
3126290|NCT01712893|Experimental|Zoladex combined with chemotherapy|After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the test group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,all patients will receive Tamoxifen after chemotherapy
3126291|NCT01712893|Active Comparator|Zoladex after chemotherapy|After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the control group should use Zoladex 3.6mg once a month up to 2-3 years after chemotherapy,all patients will receive Tamoxifen after chemotherapy
3126292|NCT01712880|Active Comparator|open debridement with modular exchange|
3126293|NCT01712880|Active Comparator|one stage exchange|
3126294|NCT01712867|Experimental|Phytosterol esters of omega-3|4 capsules/day for 12 weeks
3126295|NCT01712867|Active Comparator|Omega-3 acid ethyl esters|4 capsules/day for 12 weeks
3126296|NCT01712854|Experimental|Symbicort|A combination of budesonide + long acting beta agonist (Symbicort): Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
3126298|NCT01712841||Severe NEAMD|Presence of definite central or noncentral geographic atrophy within 3000 microns of the foveal center
3126299|NCT01712841||Moderate/Intermediate NEAMD|Presence of large drusen (>125µ) and pigmentary changes without geographic atrophy
3126300|NCT01712841||Mild/Early NEAMD|Presence of small or medium drusen without geographic atrophy
3126301|NCT01712828|Experimental|Lenalidomide plus Quinidine|
3126302|NCT01712828|Experimental|Lenalidomide plusTemsirolimus and Diphenhydramine|
3126303|NCT01712815|Experimental|Diagnostic (fluorine F 18-clevudine PET/CT)|Patients receive fluorine F18-clevudine IV over 1 minute and then undergo PET/CT scan at baseline. Patients with HER2+ breast cancer also undergo fluorine F 18-clevudine PET/CT scan 2-3 weeks after the first course of treatment and after completion of treatment.
3126304|NCT01712802|Experimental|Denture Adhesives: Cream|Parallel arm that receives application of Cream denture adhesives.
3126305|NCT01712802|Experimental|Denture Adhesives: Powder|Parallel arm that receives application of powder denture adhesive.
3126306|NCT01712802|Placebo Comparator|control|Parallel arm that receive placebo.
3126307|NCT01712789|Experimental|Pomalidomide plus Dexamethasone|Pomalidomide 4mg by mouth (PO) daily days 1 through 21 of a 28 day cycle and dexamethasone 40mg/day PO for those ≤75 years of age or 20mg/day for those greater than 75 years of age on Days 1, 8, 15 and 22 of a 28 day cycle.
3126308|NCT01712776|Active Comparator|Vapocoolant (Pain Ease Medium Stream )|Application of Vapocoolant (Pain Ease Medium Stream) for 4-10 seconds onto venipuncture site.
3126309|NCT01712776|Placebo Comparator|Nature's Tears Sterile Water|Application of sterile water stream (nature's tears) for 4-10 seconds onto the venipuncture site.
3126310|NCT01712763|Experimental|Degarelix|50 women will be treated with degarelix 80mg in one administration
3126311|NCT01712763|Active Comparator|Goserelin|goserelin 3.6mg monthly for three months
3126312|NCT01712750||VOT on bypass|
3126313|NCT01712737|Experimental|Snack foods: raisins|children were given ad libitum access to raisins for 15 min
3126314|NCT01712737|Experimental|Snack foods: grapes|children were given ad libitum access to grapes for 15 min
3126315|NCT01712737|Experimental|Snack foods: a mix of almonds with raisins|children were given ad libitum access to a mix of almonds with raisins for 15 min
3126316|NCT01712737|Experimental|Water control|children were given ad libitum access to water
3126317|NCT01712724|Active Comparator|Aerobic Training|Walking, elliptical, stationary recumbent or upright cycling will be the modes of AT prescribed depending on individual ability and access to equipment when away from the Centre. Treadmill or overground walking will be considered for those who can sustain high enough speeds and durations to achieve aerobic benefit. Cycle ergometer exercise (upright or recumbent) will be prescribed to patients in addition to walking when stroke-related deficits preclude a sufficient walking speed. The AT group will complete AT 5 d∙wk-1.
3126318|NCT01712724|Experimental|Combined Resistance and Aerobic Training|The AT+RT group will complete AT 3 d∙wk-1 + RT 2 d∙wk-1.The RT exercises will be task specific, incorporating muscle actions that are performed during daily activities. Resistance will be provided by hand-held dumbbells, exercise bands (wrist/ankle attachments), or patients' body weight. A weight load equivalent to 50-60% of 1 repetition maximum will be prescribed on the non-affected limb. On the hemiparetic limb ≥50% of 1 repetition maximum and/or a resistance rated as 13-14 on the Rating of Perceived Exertion scale on the last repetition of the set will be prescribed
3126319|NCT01712711|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
3126320|NCT01712711|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
3126321|NCT01712698||Cervical spinal cord injury|Those patients with an acute cervical spinal cord injury evaluated with DTI MRI
3126322|NCT01712685|Experimental|Renal Cell Carcinoma|
3126323|NCT01712659|Experimental|1|Ruxolitinib 20 mg orally twice daily
3126324|NCT01712620|Experimental|Group A|
3126325|NCT01712620|Placebo Comparator|Group B|
3126326|NCT01712607|Experimental|Warm-Up|Surgery after warm-up task Preoperative Warm-Up training
3126327|NCT01712607|No Intervention|No Warm-up|Surgery without warm-up exercise
3126328|NCT01712594|Active Comparator|Closed Loop Procedure AB|Closed loop procedure with normal calibration first followed by closed loop procedure B with calibration error induced.
3126329|NCT01712594|Active Comparator|Closed loop Procedure BA|Closed loop procedure with an induced calibration error first followed by closed loop procedure with normal calibration.
3126330|NCT01712581|Experimental|Healthy volunters|175 Healthy volunters in the cohorte divided in 7 groups of age: 18-19 years old (ratio M/F: 1/1) 20-24 years old (ratio M/F: 1/1) 25-29 years old (ratio M/F: 1/1) 30-39 years old (ratio M/F: 1/1) 40-49 years old (ratio M/F: 1/1) 50-59 years old (ratio M/F: 1/1) 60-69 years old (ratio M/F: 1/1)
3126331|NCT01712568|Experimental|Test Product|Drug: Ropinirole Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fasting conditions
3126332|NCT01712568|Experimental|Reference Product|Drug: Ropinirole REQUIP XL Tablets (Ropinirole hydrochloride CR 2mg)commercial formulation under fasting conditions
3126333|NCT01712555|Experimental|fat grafting with PRP to anophthalmic orbits|There is only one arm to this study. People with orbital atrophy and loss of an eye are to be injected with autologous fat mixed with autologous PRP (platelet rich plasma) and observed for at least one year for evidence of retention of the injected fat
3126334|NCT01712529|Experimental|Supervised physical exercise|Walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
3126335|NCT01712529|No Intervention|No supervised physical exercise|No intervention for 16 weeks
3126336|NCT01712516|Experimental|QVA149|27.5/12.5 ug twice daily (b.i.d.) Single Dose Dry Powder Inhaler (SDDPI
3126337|NCT01712516|Active Comparator|QAB149|27.5 ug b.i.d.
3126338|NCT01712516|Active Comparator|NVA237|12.5 ug b.i.d.
3126339|NCT01712516|Placebo Comparator|Placebo|b.i.d.
3126340|NCT01712503|Experimental|Toric intraocular lens|TFlex Lens (623T)
3126341|NCT01712503|Placebo Comparator|Monofocal intraocular lens|Superflex Aspheric Lens (920H)/Cflex Aspheric Lens (970C)
3127156|NCT01707186||Group 2A|Established phase, requiring a change in treatment
3126342|NCT01712490|Experimental|A + AVD|A+AVD consists of brentuximab vedotin (ADCETRIS®) 1.2 mg/kg plus doxorubicin 25 mg/m2, vinblastine 6 mg/m2, and dacarbazine (DTIC) 375 mg/m2
3126343|NCT01712490|Active Comparator|ABVD|ABVD consists of doxorubicin 25 mg/m2, bleomycin 10 units/m2, vinblastine 6 mg/m2, and dacarbazine (DTIC) 375 mg/m2
3126344|NCT01712477|Active Comparator|Intravenous sedation with propofol|Traumatic brain injured patient, already requiring sedation. Intervention is sedation with intravenous propofol during mechanical ventilation
3126345|NCT01712477|Active Comparator|Intravenous sedation with midazolam|Patients with traumatic brain injury requiring mechinical ventilation. Intervention is intravenous midazolam for sedation at variable doses to achieve adequite sedation levels
3126346|NCT01712464|Other|Cross over Oxytocin and Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
3126347|NCT01712464|Other|Cross over Placebo and Oxytocin|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
3126348|NCT01712451|Experimental|LIPO-102, Low|
3126349|NCT01712451|Experimental|LIPO-102, Mid|
3126350|NCT01712451|Experimental|LIPO-102, High|
3126351|NCT01712451|Experimental|LIPO-102; Placebo|
3126352|NCT01712451|Experimental|salmeterol xinafoate|
3126353|NCT01712438|Experimental|Human cl rhFVIII|
3126354|NCT01712425|Experimental|0-24 week prime/boost regimen (ARM A)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly, 0-24 week prime/boost regimen
3126355|NCT01712425|Experimental|0-8 week prime/boost regimen (ARM B)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly, 0-8 week prime/boost regimen
3126356|NCT01712425|No Intervention|Arm A control (ARM C)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm A.
3126357|NCT01712425|No Intervention|Arm B control (ARM D)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm B.
3126358|NCT01712412|Experimental|IW-9179|Oral IW-9179 taken daily for two weeks
3126359|NCT01712412|Placebo Comparator|Placebo|Oral placebo taken daily for two weeks
3126360|NCT01712399|Experimental|Mavrilimumab 100 mg|Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years.
3126361|NCT01712386|Experimental|COPD|
3126362|NCT01712373|Active Comparator|Ginseng|Ginseng, tablet, 250 mg, twice, 3 months
3126363|NCT01712373|Placebo Comparator|Placebo|Placebo, tablet
3126364|NCT01712360|Experimental|NAFT500 (pediatric)|Topical once a day for two weeks
3126365|NCT01712360|Experimental|NAFT600 (pediatric)|Topical once a day for two weeks
3126366|NCT01712360|Experimental|NAFT500 (adult)|Topical once a day for two weeks
3126367|NCT01712360|Experimental|NAFT600 (adult)|Topical once a day for two weeks
3126368|NCT01712347||mCRC Participants|mCRC participant will receive bevacizumab as per approved label with the approved first-line fluoropyrimidine based chemotherapy, as per physician discretion. The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
3126369|NCT01712334|Experimental|eRapid Nebulizer|Dornase alfa (Pulmozyme®) inhaled once daily by the Pari eRapid nebulizer for 2 weeks.
3126370|NCT01712334|Active Comparator|Jet Nebulizer|Dornase alfa (Pulmozyme®) inhaled once daily by the Pari LC Plus jet nebulizer for 2 weeks.
3126371|NCT01712321|Experimental|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth for up to 12 weeks
3126372|NCT01712321|Placebo Comparator|Placebo|Placebo to match Vilazodone 20mg or 40mg, taken once daily by mouth for up to 12 weeks
3126373|NCT01712308|Experimental|Sotatercept (higher dose) Group|Patients treated with 1.0 mg/kg dose subcutaneously on Day 1 every 3 weeks. If there is at least one responder out of 5 treated patients, this cohort will be expanded with an additional 15 subjects.
3126374|NCT01712308|Experimental|Sotatercept (lower dose) Group|Patients treated with 0.75 mg/kg dose subcutaneously on Day 1 every 3 weeks. If there is at least one responder out of 5 treated patients, this cohort will be expanded with an additional 15 subjects.
3126375|NCT01712308|Experimental|Myelofibrosis on Treatment with Ruxolitinib Group|Participants already on therapy with ruxolitinib (for at least for 6 months, and on stable dose for last 2 months, receive 0.75 mg/kg dose of sotatercept subcutaneously every 3 weeks. If there is at least one responder out of 5 treated patients, this cohort will be expanded with an additional 15 subjects.
3126376|NCT01712295|Experimental|17% Salicylate with Ethyl Pyruvate|Subjects with plantar wart(s) will apply the product to warts twice a day for up to 16 weeks.
3126377|NCT01712295|Active Comparator|17% salicylate|subjects will apply 17% salicylate (standard of care treatment) to plantar skin wart(s) twice a day for up to 16 weeks
3126378|NCT01712282|Experimental|High dose training|2 x 30 minutes/day on a weight-bearing treadmill
3126379|NCT01712269|Experimental|Weight-loss (bariatric) surgery|All subjects enrolled will undergo bariatric surgery to assist weight-loss
3126380|NCT01712256|Experimental|Re-boosting with Vacc-4x|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) at day 1 and day 15.
3126381|NCT01712243|Active Comparator|Dim light|15 minutes of very dim (<1 lux) light during the night
3126382|NCT01712243|Active Comparator|Room light|15 minutes of normal room light (~100 lux) during the night
3126383|NCT01712243|Experimental|Colored light|15 minutes of colored light during the night
3126384|NCT01712230|Placebo Comparator|Placebo|Monthly placebo injections for 6 months
3126385|NCT01712230|Active Comparator|GnRH agonist|Monthly GnRH agonist injections for 6 months
3126386|NCT01712230|Active Comparator|GnRH agonist + exercise|Monthly GnRH agonist injections for 6 months plus supervised cardiovascular exercise intervention
3126434|NCT01711892|Active Comparator|Soccer Training|12 weeks of soccer training. (2 times per week for the first 8 weeks and 3 times per week in the last 4 weeks. Training will consist of 15 minutes warm-up and 2 x 15 minutes matches for the first 4 weeks and of 15 minutes warm-up and 3 x 15 minutes matches for the last 8 weeks). After 12 weeks assessments participants in the intervention group will continue bi-weekly supervised training for additional 20 weeks at the end of which tests will be repeated.
3207565|NCT01144143|Experimental|Infliximab|
3126387|NCT01712217|Experimental|AT13387 and Crizotinib|Part A is a single-arm, Phase 1, open-label, dose-escalation design in patients with NSCLC who have already been receiving crizotinib 250 mg by mouth (PO) twice daily (BID) for at least 8 weeks and are still tolerating treatment at that dose. Patients will continue treatment with crizotinib + escalating doses of AT13387 IV weekly for 3 weeks in a 4-week cycle. Each cohort will consist of at least 6 patients until the maximum tolerated dose (MTD) is reached. An additional 12 patients will be treated at the MTD level of AT13387 in combination with crizotinib to confirm the safety profile of the combination at that dose level.
3126388|NCT01712217|Active Comparator|Crizotinib versus crizotinib + AT13387|Part B is a Phase 2, open-label, randomized continuation design comparing crizotinib alone versus the combination of crizotinib + AT13387 at the MTD established in Part A. Part B will enroll 128 patients with NSCLC who have been treated with crizotinib for at least 8 weeks and are still tolerating treatment without evidence of disease progression.
3126389|NCT01712217|Active Comparator|AT13387 or AT13387 + crizotinib|Part C is an open-label, randomized, Phase 2, Simon's 2-stage design of AT13387 administered alone once weekly for 3 weeks (QW×3) or in combination with crizotinib at the MTD established in Part A.
3126390|NCT01712204|Placebo Comparator|Placebo|Placebo plus Febuxostat
3126391|NCT01712204|Experimental|AC-201|AC-201 plus Febuxostat
3126392|NCT01712191|Experimental|NUsurface Meniscus Implant|
3126393|NCT01712178|Experimental|New formulation of adalimumab 40 mg every other week|New formulation adalimumab 40 mg every other week
3126394|NCT01712178|Active Comparator|Current formulation adalimumab 40 mg every other week|Current formulation adalimumab 40 mg every other week
3126395|NCT01712165|Active Comparator|ANMUM Materna|75g milk powder in 400 ml water daily for 12 weeks.
3126396|NCT01712165|Placebo Comparator|Control|75g of milk powder in 400 ml water for 12 weeks.
3126397|NCT01712139|Active Comparator|Avalide|irbesartan 300 mg and hydrochlorothiazide 25 mg tablet
3126398|NCT01712139|Experimental|Irbesartan and Hydrochlolothiazide|300 mg irbesartan and 25 mg hydrochlorothiazide tablet
3126399|NCT01712126|Experimental|Irbesartan and Hydrochlorothiazide|300 mg and 25 mg tablet
3126400|NCT01712126|Active Comparator|Avalide|irbesartan 300 mg and hydrochlorothiazide 25 mg
3126401|NCT01712113|Experimental|irbesartan|300 mg tablet
3126402|NCT01712113|Active Comparator|Avapro|300 mg tablet
3126403|NCT01712100|Experimental|irbesartan|300 mg tablet
3126404|NCT01712100|Active Comparator|Avapro|300 mg tablet
3126405|NCT01712087||MedStream System Implants|All subjects presenting for a de novo programmable pump implant or replacement of an implantable, programmable infusion pump for the treatment of severe spasticity with intrathecal Baclofen.
3126406|NCT01712074|Experimental|30 mg QD of PF-05212377|
3126407|NCT01712074|Placebo Comparator|Placebo|
3126408|NCT01712061|Active Comparator|Arm 1 PF-04634817|
3126409|NCT01712061|Placebo Comparator|Arm 2 Placebo|
3126410|NCT01712048|Active Comparator|Submucosal Injection EMR|"For patients who are randomized to the submucosal injection arm polypectomy will be performed with selective saline injection to the layer of tissue underneath the polyp in order to create a safety cushion for resection."
3126411|NCT01712048|Active Comparator|Underwater EMR|"For patients who are randomized to the underwater arm polypectomy with water will be performed under full water emersion without the use of submucosal injection."
3126412|NCT01712035||Treatment-active NVAMD|Patients with NVAMD who have received treatment with an anti-VEGF agent (Avastin, Lucentis, Macugen, or Eylea) 6 weeks prior enrollment visit
3126413|NCT01712035||Treatment-naive NVAMD|Individuals who have not received any treatment for neovascular AMD in the study eye
3126414|NCT01712022||Dry Eye|clinical diagnosis of dry eye
3126415|NCT01712022||Contact Lens|routine wear of contact lens
3126416|NCT01712022||Normal|Not having history of dry eye or contact lens wear or corneal pathology or surgery
3126417|NCT01712009|Experimental|Prophylactic naproxen|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
3126418|NCT01712009|Experimental|Prophylactic loratadine|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic loratadine 10 mg once a day (QD) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
3126419|NCT01712009|Other|No prophylactic treatment|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis.
3126420|NCT01711996||UPJO|0-3 year old hydronephrosis patients without ureter dilatation who undergo pyeloplasty
3126421|NCT01711996||Hydronephrosis|0-3 year old hydronephrosis patients without ureter dilatation who does not meet the indication of pyeloplasty
3126422|NCT01711996||Normal|0-3 year old children without hydronephrosis
3126423|NCT01711983|Experimental|GORE® Septal Occluder|subjects who receive a GORE® Septal Occluder
3126424|NCT01711970|Experimental|VB-111|
3126425|NCT01711957||Liver disease and liver transplantation|Patient with end stage liver disease and/or primary liver tumor undergoing liver transplantation
3126426|NCT01711944|Experimental|Online PSST|An online version of Problem-Solving Skills Training (PSST) will be compared to standard (face-to-face) PSST
3126427|NCT01711944|Active Comparator|Face-to-Face PSST|This is an 8-session face-to-face Problem-Solving Skills Training intervention
3126428|NCT01711931|Active Comparator|Everolimus-eluting bioresorbable vascular scaffold stents|
3126429|NCT01711931|Active Comparator|Everolimus-eluting stent|
3126430|NCT01711931|Active Comparator|Biolimus-eluting stent|
3126431|NCT01711918|Experimental|Domperidone|Participants will received domperidone at a dose of 10mg given up to three times per day
3126432|NCT01711905|Experimental|Vitamin D3|cholecalciferol 20 µg per day for 12 weeks
3126433|NCT01711905|No Intervention|Placebo|Placebo for 12 weeks
3126435|NCT01711892|No Intervention|Control group|Usual care
3126436|NCT01711879|Active Comparator|Aflibercept with Laser|A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks
3127157|NCT01707186||Group 1|Early phase, stable treatment
3126437|NCT01711879|Experimental|Aflibercept|2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.
3126438|NCT01711866|Experimental|Rotigotine|"First application of Rotigotine patch for 24 hours on Day 1, followed by application of a new patch each day of the Treatment Period.~Subjects on lower doses switch from Pramipexole or Ropinirole to equivalence doses of Rotigotine on Day 1 of the 28 days Treatment Period. On Day 8 (Visit 3) the dose will be evaluated and potentially adjusted up to a maximum dose of 8 mg / 24 hours.~Subjects on higher doses switch from the equivalent dose to 8 mg / 24 hours Rotigotine of Pramipexole or Ropinirole to 8 mg / 24 hours Rotigotine on Day 1 and the remainder of the dose of Pramipexole or Ropinirole is to be switched on Day 8 of the 28 days Treatment Period. On Day 15 (Visit 4) the dose will be evaluated and potentially adjusted up to a maximum dose of 16 mg / 24 hours."
3126439|NCT01711853|Experimental|Dabigatran Etexilate|patient to receive a capsule containing 75 mg of dabigatran etexilate
3126440|NCT01711840||Symbicort|
3126441|NCT01711827|Experimental|Isavuconazole and Prednisone|Single dose of prednisone on Days 1 and 9, isavuconazole 3 times a day (TID) on Days 5-6, isavuconazole once a day (QD) on Days 7-10
3126442|NCT01711814|Experimental|ASP015K|Experimental
3126443|NCT01711801|Placebo Comparator|Part 1: Placebo|
3126444|NCT01711801|Experimental|Part 1: RO5545965|
3126445|NCT01711801|Experimental|Part 2: Food effect|
3126446|NCT01711788|Experimental|Intrabone umbilical cord blood tranplant|Intrabone infusion of umbilical cord blood stem cells
3126447|NCT01711775|Experimental|Aleglitazar|
3126448|NCT01711762|Experimental|GDC-0973 Single Arm|
3126449|NCT01711749|Active Comparator|Sequence 1|01 tablet, single dose, of Reference Product in period 1 and 01 tablet, single dose, of Test Product in period 2.
3126450|NCT01711749|Active Comparator|Sequence 2|01 tablet of Test Product in period 1, and 01 tablet, single dose, of Reference Product in period 2.
3126451|NCT01711736|Experimental|GSK2282512A Group|"Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.~Quadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects ≥ 12 months of age)."
3126452|NCT01711736|Active Comparator|Fluarix Group|"Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.~Fluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects ≥ 12 months of age)."
3126453|NCT01711723|Experimental|Renal Impaired Group|Subjects with renal impairment received darapladip 160 mg daily for 10 consecutive days.
3126454|NCT01711723|Experimental|Healthy Control Group|Healthy volunteers matching with renal impairment subjects for gender, age and BMI; received darapladip 160 mg daily for 10 consecutive days.
3126455|NCT01711710|Experimental|Cohesive Gel Breast Implant|Cohesive Silicone Gel-Filled Breast Implant
3126456|NCT01711697|Experimental|Treatment (radiation therapy, carboplatin, paclitaxel, SBRT)|Patients undergo radiation therapy daily and receive carboplatin and paclitaxel weekly for 4.5 weeks. Patients then undergo 2 boost SBRT treatments 2-3 days apart.
3126457|NCT01711684|Experimental|Diphenylcyclopropenone (DPCP)|Subjects will have DPCP in a topical gel formulation applied to their cutaneous metastatic lesions.
3126458|NCT01711671|Experimental|DKN-01 300mg|DKN-01 plus lenalidomide (Revlimid)/dexamethasone
3126459|NCT01711671|Experimental|DKN-01 600mg|DKN-01 plus lenalidomide (Revlimid)/dexamethasone
3126460|NCT01711671|Active Comparator|Standard of Care|Lenalidomide (Revlimid)/dexamethasone
3126461|NCT01711658|Placebo Comparator|Radiation therapy (IMRT) + cisplatin + placebo|Radiation therapy: Intensity Modulated Radiation Therapy (IMRT) + cisplatin + placebo
3126462|NCT01711658|Active Comparator|Radiation therapy (IMRT) + cisplatin + lapatinib|Radiation therapy: Intensity Modulated Radiation Therapy (IMRT) + cisplatin + lapatinib
3126463|NCT01711645|Experimental|Adacel® Tdap vaccine|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
3126464|NCT01711632|Experimental|Vemurafenib|Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days).
3126465|NCT01711619|Experimental|SQS plus OMM|subcutaneous nerve stimulation plus optimized medical management
3126466|NCT01711619|Active Comparator|OMM|optimized medical management
3126467|NCT01711606||unselected Fragile-X patients|
3126468|NCT01711593|Experimental|Allergic Asthmatic, Non-allergic non-asthmatics(HC)|Track 1: Adult subjects who are allergic asthmatics or non-allergic non-asthmatics(Healthy Controls) will not receive segmental allergen challenge to the lung but will have their blood drawn at 1 time point. Track 2: Adult subjects who are allergic asthmatics will receive segmental allergen challenge to the lung and have their blood drawn at 2 time points.
3126469|NCT01711580||Re-irradiation, high grade glioma|EORTC QLQ-C30 EORTC QLQ-BN20 Hopkins Verbal Learning Test-Revised (HVLT-R) Trail Making Test (TMT) Stroop color-word test Controlled oral word association test (COWA) Jamar hand dynamometer EORTC QLQ- FA13 Short Form health survey (SF-36)
3126470|NCT01711567|Active Comparator|entecavir|standard drugs
3126471|NCT01711567|Active Comparator|tenofovir|study drugs
3126472|NCT01711554|Experimental|Treatment (lenalidomide, dinutuximab, isotretinoin)|Patients receive lenalidomide PO QD on days 1-21, dinutuximab IV over 10 hours on days 8-11, and isotretinoin PO BID on days 15-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3126473|NCT01711541|Experimental|Arm I (veliparib, combination chemotherapy)|Patients receive veliparib PO BID on days 1-7, paclitaxel IV over 60 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then continue on to concomitant chemoradiotherapy.
3126474|NCT01711541|Experimental|Arm II (placebo, combination chemotherapy)|Patients receive placebo PO BID on days 1-7. Patients also receive paclitaxel and carboplatin as in Phase I. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Within 10 days from completion of course 2, patients begin concomitant chemoradiotherapy.
3126475|NCT01711528|Experimental|Schedule I (dinaciclib, bortezomib, dexamethasone)|Patients receive dinaciclib IV over 2 hours and bortezomib SC or IV (if patients do not tolerate SC injection) on days 1, 8, and 15 and dexamethasone PO QD on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3126476|NCT01711528|Experimental|Schedule II (dinaciclib, bortezomib, dexamethasone)|Patients receive dinaciclib IV over 2 hours on day 1; bortezomib SC on days 1 and 8; and dexamethasone PO QD on days 1, 2, 8, and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3126477|NCT01711515|Experimental|Treatment (cisplatin, radiation therapy, and ipilimumab)|Patients receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36, undergo extended beam radiation therapy 5 days a week for 6 weeks, and then undergo intracavitary brachytherapy for approximately 2 weeks. Within 2 weeks, patients receive ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks.
3126478|NCT01711502||Female patients diagosed with metastatic breast cancer|
3126479|NCT01711489|Experimental|isavuconazole and mycophenolate mofetil|Single dose of MMF on Day 1, isavuconazole three times daily (TID) on Days 9 and 10, isavuconazole once daily (QD) Days 11-16, a single dose of MMF on Day 13
3126480|NCT01711476|Active Comparator|Lifestyle counseling ARM 1|Arm 1 Breakfast Diet The arm 1 will be assigned to eat High calorie breakfast (800kcal) and reduced dinner (200 kcal) During 90 days from baseline to the end of the trial (day 90)
3126481|NCT01711476|Placebo Comparator|Lifestyle counseling ARM 2|Lean PCOS women in the Arm 2 will be assigned to do a dinner diet from day 0 to day 90 of the trial
3126482|NCT01711463|Experimental|FF/VI|50/25 mcg, 100/25 mcg or 200/25 mcg
3126483|NCT01711463|Placebo Comparator|Placebo|matching placebo
3126484|NCT01711450|Experimental|Paravertebral block|Paravertebral space will be needled and an anesthetic agent will be injected.
3126485|NCT01711450|Placebo Comparator|Control sham procedure|Paravertebral space will be needled, but only normal saline injected.
3126486|NCT01711437|Experimental|PEG-S|polyethylene glycol 4000 solution with simethicon
3126487|NCT01711437|Experimental|PEG-CS + Bisacodyl|PEG-CS is a new sulphate-free iso-osmotic formulation of PEG-4000 with citrates and simethicone
3126488|NCT01711437|Experimental|PEG-ASC|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid
3126489|NCT01711437|Experimental|picoprep|sodium picosulphate plus magnesium oxide and citric acid
3126490|NCT01711424||OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
3126491|NCT01711398|Experimental|IPP204106N|
3126492|NCT01711385|No Intervention|Standard practice|"Study patients are notified of their diagnostic test result within 72 hours. Those identified as potentially pre-diabetic or diabetic and randomized to the basic/control intervention, are informed that it is important to follow-up with their physician regarding their test results. They are contacted by phone once to schedule their 6-month recall visit."
3126493|NCT01711385|Experimental|Enhanced intervention|"Study patients are notified of their diagnostic test result within 72 hours. Those identified as potentially pre-diabetic or diabetic and randomized to the enhanced group, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results. They are given a letter to take to their physician and receive a call at month two and then again at month four if necessary to inquire if they have followed-up with their physician and encouragement to do so, if they have not, prior to their six month follow-up study visit."
3126494|NCT01711372|Experimental|Video Game Diagnostic Tool|Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD.
3126495|NCT01711359|Experimental|Baricitinib + MTX|Baricitinib 4 milligram (mg) administered orally once daily through Week 52. Participants received methotrexate (MTX) orally once weekly with dose ranging from 10 to 20 mg per week through Week 52. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
3126496|NCT01711359|Experimental|Baricitinib|Baricitinib 4 mg administered orally once daily through Week 52. Participants received MTX placebo orally once weekly through Week 52. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
3126497|NCT01711359|Active Comparator|MTX|MTX administered orally once weekly with dose ranging from 10 to 20 mg per week through Week 52. Participants also received baricitinib placebo orally once daily. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
3126498|NCT01711346|Experimental|S303 Red Blood Cells (RBCs)|Participants will be assigned to S303 Red Blood Cells (RBCs) and then to Conventional, Untreated Red Blood Cells (RBCs).
3126499|NCT01711346|Active Comparator|Conventional, Untreated Red Blood Cells (RBCs)|Participants will be assigned to Conventional, Untreated Red Blood Cells (RBCs) and then to S303 Red Blood Cells (RBCs).
3126500|NCT01711333|Experimental|Pletaal SR capsule|
3126501|NCT01711320|Placebo Comparator|Placebo|oral dose of Placebo combined with two dose of Metformin (OGTTs)
3126502|NCT01711320|Experimental|Omeprazole|oral dose of Omeprazole (80 mg) combined with two dose of Metformin (OGTTs)
3126503|NCT01711307|Experimental|non-operative|cast applied within 48 hours
3126504|NCT01711307|Active Comparator|operative|cast applied within 48 hours and surgery within 14 days
3126505|NCT01711294|Active Comparator|19 G Flex Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G Flex)
3126506|NCT01711294|Active Comparator|22 G Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (22 G)
3126507|NCT01711294|Active Comparator|19 G Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G)
3126508|NCT01711281|Experimental|Intracardiac Impedance Measurement|
3126509|NCT01711255||Multiple Sclerosis|Subjects who have been diagnosed with clinically definite or probable multiple sclerosis as defined and recorded by board certified neurologist.
3126510|NCT01711255||Healthy controls|Adults age 18 and older who have not been diagnosed with any neurological, endocrine, or other chronic health condition. They must also be free of any recent acute illness that can impact inflammation/clotting.
3126553|NCT01710969|Experimental|Group Intervention|behavioral - children receive the Coping Power program in a small group format (5-6 children per group)
3126554|NCT01710956|Experimental|Arm 1(with twice-daily TRT)|
3208891|NCT01134484|Experimental|VTD|
3126511|NCT01711242|Experimental|capecitabine/Oxaliplatin/radiotherapy|"sequence chemoradiotherapy following radical resection~sequence chemoradiotherapy two cycles of XELOX + concurrent chemoradiotherapy + two cycles of XELOX.~Postoperative radiotherapy regimen: Radiotherapy consisted of 4500 centigray of radiation at 180 centigray per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Concurrent chemotherapy regimen: capecitabine 825 mg/m² twice daily Postoperative chemotherapy regimen: see arm 2"
3126512|NCT01711242|Active Comparator|capecitabine/Oxaliplatin|"chemotherapy alone following radical resection~Drug: chemotherapy alone following radical resection Postoperative chemotherapy regimen: The XELOX regimen was administrated: Oxaliplatin, 130mg/m2/day on day1, i.v. 2h; Capecitabine 1000mg/m²/day twice daily d1-14; every 21 days repeated, for 4 cycles."
3126513|NCT01711229|Active Comparator|Group I: IV acetaminophen|Group I will receive 1 gram IV acetaminophen 15 minutes prior to going to the operating room for arthroscopic rotator cuff repair
3126514|NCT01711229|Active Comparator|group 2|Group 2 will receive 1.5grams of oral acetaminophen immediately prior to proceeding to the operation groom for arthroscopic rotator cuff surgery
3126515|NCT01711216||women received dydrogesterone for irregular menstrual cycle|Adult women received dydrogesterone for irregular menstrual cycle as per standard clinical practice of the treating physician
3126516|NCT01711203|Experimental|Motor Control|"Pilates-based exercise with verbal cues to facilitate motor control Plank progression, use of feedback tool VERBAL CUES FOR MOTOR CONTROL GROUP (could also include above cues) Maintain neutral spine Not too arched, not too flexed Remember your pilates position Inhale, exhale Let me hear your breath"
3126517|NCT01711203|Active Comparator|General strengthening|"Patient group that will receive active strengthening without specific verbal cueing to recruit deeper abdominal musculature. Core strengthening and lower quarter strengthening is the focus of this group.~Verbal cuing will include:~VERBAL CUEING FOR NON-MOTOR CONTROL GROUP~Keep your back straight Don't slouch Don't arch your back Don't let your body move Nothing should move but your arms tighten up your abs suck in your stomach feet shoulder-width apart, knees bent, shoulders back, hold your stomach tight Time will be kept the same as the intervention group."
3126518|NCT01711177|Sham Comparator|Normal control|Normal patient placebo
3126519|NCT01711177|Sham Comparator|Glaucoma suspect|Patients with elevated Intraocular pressure higher than 18 mmHg (placebo)
3126520|NCT01711177|Experimental|Newly diagnosed glaucoma|Treated with Travoprost (0.04%)
3126521|NCT01711164||patients|Chronic HCV patients who undergo antiviral therapy
3126522|NCT01711164||Healthy controls|healthy controls who are willing to give blood and liver tissue samples
3126523|NCT01711151||Idiopathic Pulmonary Fibrosis|Questionnaire evaluation
3126524|NCT01711151||Non Idiopathic Pulmonary Fibrosis|Questionnaire evaluation
3126525|NCT01711151||Sarciodosis|Questionnaire evaluation
3126526|NCT01711151||Healthy Controls|Questionnaire evaluation
3126527|NCT01711138||Intervention|Intervention group is geographically located near a built environment intervention (neighbourhood redevelopment).
3126528|NCT01711138||Comparison|Comparison group is not exposed to the built environment intervention according to their geographic location.
3126529|NCT01711125|Experimental|Arm 1|Baclofen low dose
3126530|NCT01711125|Experimental|Arm 2|Baclofen high dose
3126531|NCT01711125|Placebo Comparator|Arm 3|Placebo
3126532|NCT01711112|Experimental|docetaxel|Days 1 & 8 Docetaxel 35 mg/m2 IV
3126533|NCT01711099|Experimental|ESMR treated|
3126534|NCT01711086|Active Comparator|Inspiromatic followed by Aerolizer|volunteers will perform lung function pre and post Formoterol (a bronchodilator) inhalation. They will use either the Inspiromatic dry powder inhalers the delivery device. 3-60 days later participants will receive the same drug through the Aerolizer dry powder inhaler.
3126535|NCT01711086|Active Comparator|Aerolizer followed by Inspiromatic|volunteers will perform lung function pre and post Formoterol (a bronchodilator) inhalation. They will use either the Aerolizer dry powder inhalers the delivery device. 3-60 days later participants will receive the same drug through the Inspiromatic dry powder inhaler.
3126536|NCT01711073|Experimental|Mobilization with G-CSF plus Mozobil|Patients will receive G-CSF (Filgrastim) plus Mozobil (Plerixafor)
3126537|NCT01711060|Experimental|oxytocin|
3126538|NCT01711060|Experimental|balloon catheter|Dufour 1859H18
3126539|NCT01711047|Active Comparator|PVI + Linear ablation|Arm A: patients have PVI and roof and mitral isthmus lines
3126540|NCT01711047|Active Comparator|PVI + linear ablation + CFAE|Arm B: patients have PVI + roof and mitral isthmus lines and CFAE ablation
3126541|NCT01711034|Experimental|OPB-111077|"In escalation stage of study, treatment with a once daily dose of OPB-111077 during cycles 1 and 2 on day 1, followed by 2-day treatment free interval, and then resuming daily dosing on day 4 through day 28. For cycle 3 and beyond, OPB-111077 will be administered for 28 continuous days per cycle until MTD is reached.~In expansion portion of study, established dose of 250mg administered once daily for 28 consecutive days for each cycle. Patient in expansion are defined as those who meet eligibility criteria and have a diagnosed malignancy that is presumed to be susceptible to inhibition by OPB-111077"
3126542|NCT01711021|Active Comparator|d-Amphetamine Transdermal System|d-Amphetamine Transdermal System
3126543|NCT01711021|Placebo Comparator|Placebo patch|Placebo patch
3126544|NCT01711008|Placebo Comparator|No Breakfast|Water only
3126545|NCT01711008|Active Comparator|20g Cereal|20g Kelloggs Special K cereal with 83ml semi-skimmed milk
3126546|NCT01711008|Active Comparator|40g Cereal|40g Kelloggs Special K cereal with 166ml semi-skimmed milk
3126547|NCT01710995|Active Comparator|Zegerid 20mg capsule|Zegerid 20mg capsule (20mg omeprazole and 1100mg sodium carbonate
3126548|NCT01710995|Active Comparator|Zegerid 20mg powder for oral suspension|Zegerid 20mg powder for oral suspension (20mg omeprazole and 1680mg sodium bicarbonate)
3126549|NCT01710995|Active Comparator|Losec 20mg capsule|Losec 20mg capsule (20mg omeprazole)
3126550|NCT01710982|Active Comparator|TZP-101|TZP-101
3126551|NCT01710982|Placebo Comparator|Placebo|Placebo
3126552|NCT01710969|Experimental|Individual Intervention|behavioral - children receive the Coping Power program in an individual, face-to-face format
3208892|NCT01134484|Active Comparator|TD|
3126556|NCT01710943|Experimental|Web-based Cognitive Behavioral Treatment|"Participants who are randomly assigned to the treatment condition will receive the same standard care as those in the control condition and they will also receive access to the web-based CBT intervention. Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial."
3126557|NCT01710943|No Intervention|Treatment as Usual|TAU consists of the usual Veterans Integrated Service Network 2 (VISN) primary care services. As we have described, all of the participants will be recruited from patients presenting for treatment typically for physical complaints in primary care clinics in VA's VISN 2 (Upstate NY). VISN 2 officially practices a co-located, collaborative care model of integrated (behavioral health and physical health) in its primary care clinics. This integrated model has been implemented widely in both VA and non-VA primary care clinics in the United States .
3126558|NCT01710930|Experimental|Study of predictive factors|
3126559|NCT01710917||Targinact® (oxycodon/naloxon)|
3126560|NCT01710891|Active Comparator|Direct Laryngoscopy|Patients will undergo their first intubation attempt with direct laryngoscopy using the CMAC device without video assistance. The video monitor with be covered with a hood.
3126561|NCT01710891|Experimental|CMAC|Patients will undergo their first intubation attempt using the CMAC videolaryngoscope using video assistance
3126562|NCT01710878|Other|Intergard Synergy Graft|
3126563|NCT01710865|Experimental|Ultraseal Sealant|Both Ultraseal XT Hydro and Ultraseal XT Plus will be applied on patients.
3126564|NCT01710852|Experimental|Group A|ISIS CRP Rx followed by Placebo
3126565|NCT01710852|Experimental|Group B|Placebo followed by ISIS CRP Rx
3126566|NCT01710839|Experimental|Targeted Pan Retinal laser combined with 0.5mg ranibizumab|Cohort 1 (n=24), previously treated with at least 2 consecutive or more intravitreal injections of any anti-VEGF agent with persistent or recurrent macular edema will receive 6 loading doses of 0.5 mg ranibizumab followed by PRN treatment with ranibizumab 0.5 mg; after receiving the first loading dose of ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) based on 200° wide field angiography with possibility of a second session of TRP at M4/M7, if non-perfusion persists based on angiogram.The 200°wide field angiography will indicate areas of peripheral ischemia which will be selectively treated, preserving areas of more perfused retina.
3126567|NCT01710839|Active Comparator|Ranibizumab 0.5mg|Cohort 2 (n=6), previously treated with at least 2 consecutive or more intravitreal injections of any anti-VEGF agent with persistent or recurrent macular edema will receive 6 loading doses followed by PRN monthly treatment with ranibizumab 0.5 mg.
3126568|NCT01710826|Experimental|Genz-682452|This study will include three cohorts for doses of Genz-682452: Dose 1, Dose 2, Dose 3. Each cohort will include 12 participants, 9 of whom will be administered Genz-682452 and 3 will be administered placebo.
3126569|NCT01710826|Placebo Comparator|Placebo|Placebo comparator taken by participants randomized to the placebo arm in each of the three cohorts. Each cohort will include 12 participants, 9 of whom will be administered Genz-682452 and 3 will be administered placebo.
3126570|NCT01710813||pompe safety sub-registry|patients are selected from those who are enrolled in the Pompe Registry, and will be followed for safety evaluation in this sub-registry
3126571|NCT01710800|Placebo Comparator|Placebo arm|Patients will be randomized to receive either PPI or placebo and then undergo a 24 hour pH study with impedance to measure the number of reflux episodes
3126572|NCT01710800|Active Comparator|Esomeprazole|Patients were randomly assigned to receive 40 mg esomeprazole twice daily prior to undergoing a 24 hour pH study with impedance to measure the number of reflux episodes
3126573|NCT01710787|Experimental|Kovacaine Mist, 3 sprays unilateral|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
3126574|NCT01710787|Experimental|Tetracaine Only, 3 sprays unilateral|Tetracaine HCl 3%
3126575|NCT01710787|Placebo Comparator|Placebo, 3 sprays unilateral|Placebo
3126576|NCT01710774|No Intervention|Traditional follow-up|Traditional follow-up with standard consultations at the Section of Endocrinology. For some patients, this will include follow-up from nurses in the home care or general practice office related to wound care. However, this is not the standard procedure and will not take place in combination with telemedicine follow-up.
3126577|NCT01710774|Active Comparator|Telemedicine follow-up care|Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
3126578|NCT01710761|Active Comparator|Nitrate supplement with caffeine|
3126579|NCT01710761|Placebo Comparator|Placebo|
3126580|NCT01710748|Active Comparator|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
3126581|NCT01710748|Experimental|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
3126582|NCT01710735|Experimental|Dry needling (deep)|Subjects receive dry needle insertion deeper than 1,5cm below the skin of the Trapezius.
3126583|NCT01710735|Active Comparator|Dry needling (superficial)|Insertion of dry needle less than 1cm.
3126584|NCT01710722|Experimental|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
3126585|NCT01710722|Experimental|leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
3126586|NCT01710722|Experimental|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
3126587|NCT01710709|Experimental|Experimental|Aripiprazole, Intramuscular (IM) Depot
3126588|NCT01710696|Experimental|Individual dose|
3126589|NCT01710696|Experimental|Fixed dose|
3126590|NCT01710683||Control group|Median age 45 years, 18-63.
3126591|NCT01710683||Intervention group|Median age 46 years, 18-62.
3126592|NCT01710670|Experimental|Ethanol + Brivaracetam|Treatment A: Ethanol + Brivaracetam
3126593|NCT01710670|Experimental|Ethanol Placebo + Brivaracetam|Treatment B: Ethanol Placebo + Brivaracetam
3126594|NCT01710670|Experimental|Ethanol + Brivaracetam Placebo|Treatment C: Ethanol + Brivaracetam Placebo
3126595|NCT01710657|Placebo Comparator|Placebo|Matching placebo for 16 weeks.
3208893|NCT01134471|No Intervention|Control|
3126596|NCT01710657|Experimental|Lacosamide 200 mg/day|Lacosamide treatment of 200 mg/day (100 mg bid (twice daily)) for 16 weeks.
3126597|NCT01710657|Experimental|Lacosamide 400 mg/day|Lacosamide treatment of 400 mg/day (200 mg bid (twice daily)) for 16 weeks.
3126598|NCT01710644|Experimental|Burlulipase|Burlulipase orally, per meal
3126599|NCT01710644|Placebo Comparator|Placebo (Caramel in sterile water)|Placebo orally, per meal
3126600|NCT01710631|Experimental|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
3126601|NCT01710631|Placebo Comparator|placebo|placebo tablet
3126602|NCT01710605|Active Comparator|Standard|Treatment choices (hormonotherapy or chemotherapy) are done according to standard of each center based on clinical, radiological and biological information.
3126603|NCT01710605|Experimental|Circulating Tumor Cells|"Treatment choices (hormonotherapy or chemotherapy) are done according to the number of CTC / 7.5 ml of blood at baseline :~If <5 CTC : Hormonotherapy If 5 or more CTC : chemotherapy"
3126604|NCT01710592|Active Comparator|Epirubicin, Oxaliplatin, Capecitabine|"Epirubicin 50mg/m2 (day 1) bolus injection~Oxaliplatin 130mg/m2 (day 1) in 250mls of 5% dextrose. i.v. over 2 hours~Capecitabine 625mg/m2 (days 1-21) b.d. orally~8 x 3-weekly cycle"
3126605|NCT01710592|Active Comparator|Docetaxel, Oxaliplatin|"Docetaxel 20mg/m2 (days 1, 8 & 15)in 250mls of 5% dextrose. i.v. over 30mins (Dexamethasone 8mg i.v, Chlorpheniramine 10mg i.v,Ranitidine 50mg i.v. to be given 30 minutes prior to Docetaxel)~Oxaliplatin 85mg/m2 (days 1 & 15)in 250mls of 5% dextrose. i.v. over 2 hours~6 x 4-weekly cycle"
3126606|NCT01710579|Other|ARM 1 Healthy Volunteers|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
3126607|NCT01710579|Other|ARM 2: Patients with fecal incontinence|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
3126608|NCT01710579|Other|ARM 3 Patients with constipation|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
3126609|NCT01710566|Experimental|Group 1|600 mcg oral misoprostol
3126610|NCT01710566|Experimental|Group 2|10 IU oxytocin in Uniject
3126611|NCT01710553|Other|Metformin GSK 1000mg|open label, crossover, two period, two treatment, two sequence, single dose of Metformin 1000mg
3126612|NCT01710553|Other|Glucophage 1000mg|open label, crossover, two period, two treatment, two sequence, single dose of Glucophage 1000mg to asset bioequivalence
3126613|NCT01710540|Other|Metformin GSK 850mg|open label, crossover, two period, two treatment, two sequence, single dose of Metformin 850mg
3126614|NCT01710540|Other|Glucophage 850mg|open label, crossover, two period, two treatment, two sequence, single dose
3126615|NCT01710527|Other|Metformin 500mg|Cross over, two treatment, two period, two sequence, cross over, single dose
3126616|NCT01710527|Other|Glucophage 500mg|Cross over, two treatment, two period, two sequence, sigle dose
3126617|NCT01710514|Active Comparator|FE 999913 100 mg BID|FE 999913 100 mg vaginal tablet BID
3126618|NCT01710514|Active Comparator|FE 999913 100 mg TID|FE 999913 100 mg vaginal tablet TID
3126619|NCT01710501|Experimental|Grazoprevir 25 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 25 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by Response Guided Therapy (RGT). Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their Hepatitis C virus ribonucleic acid (HCV RNA) level at Treatment Week (TW) 4.
3126620|NCT01710501|Experimental|Grazoprevir 50 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 50 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.
3126621|NCT01710501|Experimental|Grazoprevir 100 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 100 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.
3126622|NCT01710488|Active Comparator|Levofloxacin 1 tablet 500 mg once a day|Levofloxacin 1 tablet 500 mg once a day for 7-10 days. It will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients
3126623|NCT01710488|Experimental|Prulifloxacin 1 tablet 600 mg once a day|Prulifloxacin 1 tablet 600 mg once a day for 7-10 days. It will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients
3126624|NCT01710462|Experimental|Pantoprazole + Domperidone|The combination of pantoprazole and domperidone provided for the study will be the new incremental formulation produced by Eurofarma. For this study will be used doses of capsules containing 20 mg pantoprazole, 20 mg of domperidone.
3126625|NCT01710462|Active Comparator|Pantozol® (Takeda)|The Pantozol® may be presented in boxes of coated tablets of 20 mg or 40 mg. For this study will be used 20 mg tablets.
3126626|NCT01710449|Experimental|Normal|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using either a disposable Mouthpiece without Bite blocks or Disposable oral-nasal (full Face) Non Invasive Ventilation with no Anti Asphyxia Vents no vent CAPA/NPPV Face mask and a standard Douglas Bag system.
3126627|NCT01710449|Experimental|Lung Disease|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using either a disposable Mouthpiece without Bite blocks or Disposable oral-nasal (full Face) Non Invasive Ventilation with no Anti Asphyxia Vents no vent CAPA/NPPV Face mask and a standard Douglas Bag system.
3126628|NCT01710436||Low dose - Wild genotype (LW)|75mg Qd > 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 wild genotype
3126629|NCT01710436||Low dose - Variant genotype (LV)|75mg Qd > 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 variant genotype
3126630|NCT01710436||High dose - Wild genotype (HW)|300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 wild genotype
3126631|NCT01710436||High dose - Variant genotype (HV)|300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 variant genotype
3126632|NCT01710423|Experimental|Immediate Intervention|Peer mentoring intervention ('Cooking with Friends')
3126633|NCT01710423|No Intervention|Delayed Entry Control|
3127271|NCT01706536|Experimental|EP 101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
3126634|NCT01710410|Experimental|DLPFC tDCS (left anode/right cathode)|Active transcranial Direct Current Stimulation (tDCS) administered to the left DLPFC. Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
3126635|NCT01710410|Experimental|DLPFC tDCS (left cathode/right anode)|Active transcranial Direct Current Stimulation (tDCS) administered to the right DLPFC. Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
3126636|NCT01710410|Sham Comparator|DLPFC tDCS|Sham transcranial Direct Current Stimulation (tDCS) delivered to the DLPFC. Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
3126637|NCT01710397|No Intervention|Standard group, non-pregnant adults|Comparison group (prospective enrollment)
3126638|NCT01710397|No Intervention|Standard group, pregnant women|Comparison group (retrospective record review)
3126639|NCT01710397|Experimental|Rapid group, non-pregnant adults|Rapid ART initiation
3126640|NCT01710397|Experimental|Rapid group, pregnant women|Rapid ART initiation
3126641|NCT01710384|Experimental|betamethasoneb, 34-36 weeks, preterm labor|betamethasone 12 mg 2 injections will be given 24-hours apart.
3126642|NCT01710384|No Intervention|preterm labor, 34-37 weeks|betamethasone 12 mg 2 injections will be given 24-hours apart.
3126643|NCT01710371|Experimental|Arginine Stimulation Testing|Establish the methodology for glucose enhanced arginine stimulation testing (AST).
3126644|NCT01710371|Experimental|PET Imaging|Determine if pancreatic PET-determined binding measures of 18F-AV-133 differ in up to 60 subjects determined to be at one of four stages of the natural history of Type 2 Diabetes: Healthy Overweight/obese Volunteers (HOV), Subjects with Pre-diabetes (PD) and Type 2 Diabetes mellitus (T2DM).
3126645|NCT01710358|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24 and placebo administered by subcutaneous (SC) injection every 2 weeks through Week 50.~At Week 24, participants were given baricitinib 4 milligram (mg) orally once daily through Week 52.~Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
3126646|NCT01710358|Experimental|Baricitinib|"Baricitinib 4 mg administered orally once daily through Week 52 and an adalimumab placebo SC injection every 2 weeks through Week 50.~Starting at Week 16, nonresponder participants originally randomized to baricitinib continued to receive baricitinib 4 mg administered orally once daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
3126647|NCT01710358|Active Comparator|Adalimumab|"Adalimumab 40 mg administered by SC injection every 2 weeks through Week 50 and baricitinib placebo orally once daily through Week 52.~Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
3126648|NCT01710345|Experimental|Sufentanil NanoTab 20 mcg|Sufentanil NanoTab 20 mcg as needed every 60 minutes for 12 hours
3126649|NCT01710345|Experimental|Sufentanil NanoTab 30 mcg|Sufentanil NanoTab 30 mcg as needed every 60 minutes for 12 hours
3126650|NCT01710345|Placebo Comparator|Placebo NanoTab|Placebo NanoTab as needed every 60 minutes for 12 hours
3126651|NCT01710332|Experimental|Intravitreal Aflibercept Injection (x4)|2 mg / Intravitreal / every 1 month x 3 months and at month 4 (Drug administered 4 times).
3126652|NCT01710332|Experimental|Intravitreal Aflibercept Injection (x6)|2 mg / Intravitreal / every 1 month x 6 months ((Drug administered 6 times).
3126653|NCT01710319||smoker with lung cancer|patients that smoke greater than 45 pack years or have end organ damage due to cigarette smoking and have lung cancer
3126654|NCT01710319||smoker without lung cancer|patients that smoke greater than 45 pack years or have end organ damage due to cigarette smoking and do not have lung cancer
3126655|NCT01710319||nonsmoker with lung cancer|patients that have smoked less than 100 cigarettes in their lifetime and have lung cancer
3126656|NCT01710319||nonsmoker without lung cancer|patients that have smoked less than 100 cigarettes in their lifetime and do not have lung cancer
3126657|NCT01710306|No Intervention|Semi-structured telephone interviews|Phase 1 semi-structured telephone interviews are to evaluate the participants' perceptions of and satisfaction with the revised web-based interface and to inform Phase 2 intervention to evaluate and test differences in VA initiation and use for those who screen positive for PTSD by randomly assigned route: 1) Study concierge nurse case manager (NCM) or 2) existing OEF/OIF/OND outreach.
3126658|NCT01710306|Experimental|Phase 2|Nurse care manager interventions with shared decision making compared to outreach as usual OEF/OIF/OND outreach.
3126659|NCT01710293|Experimental|Communication of Patients Lost to Follow-up to Providers|This intervention will consist of two related, continuous steps over at least a 12-month period. In the first step, the investigators will query the VA's Corporate Data Warehouse (CDW, a repository of near real-time patient data from all VA medical centers) weekly to identify possible lost to follow-up events in a pre-specified time period and for a random sample of about half of the providers at the investigators' study sites. These identified patient charts will be reviewed by Facility Recipients/Cancer Trackers at each site who will then communicate patients truly found to be lost to follow-up to the appropriate provider/care team.
3126660|NCT01710293|No Intervention|Usual Care|In the usual care group, providers will continue to use the existing notification system to receive abnormal test results in accordance with institutional norms, policies, and procedures. There are no formal patient-tracking programs currently at our study sites for all abnormal test results. The investigators will apply our computerized surveillance tools in the usual care arm only when the investigators are ready to conduct the final chart reviews on intervention patients and identify these patients in similar time periods as in the intervention arm. If persistent delays are found, the investigators will inform the patients' primary care providers.
3126661|NCT01710280|Active Comparator|Native palm olein|75 g native palm olein
3126662|NCT01710280|Experimental|Interesterified palm olein|75 g interesterified palm olein
3126663|NCT01710267||Observation group|This group includes all volunteers of this observation study.
3126664|NCT01710254|Experimental|Regadenoson MRI|Participants with AF receiving regadenoson stress MRI, using Gadobenate dimeglumine
3126665|NCT01710228|Placebo Comparator|Methylprednisolone placebo|"subjects will be randomized 1:1 to receive either:~Methylprednisolone placebo or~Methylprednisolone"
3126995|NCT01708278|Active Comparator|Quercetin 3-Cohort 3|Quercetin chew containing 2000 mg quercetin, 350 mg vitamin C and 10 mg niacin
3126666|NCT01710228|Experimental|methylprednisolone|"subjects will be randomized 1:1 to receive either:~Methylprednisolone placebo or~Methylprednisolone"
3126667|NCT01710215|No Intervention|Usual Care|"No outreach mailed invitations.~Ordering of colonoscopy or FIT for screening at the discretion of the primary provider.~Follow up of abnormal tests and results reporting to the patient at the discretion of primary and specialty providers."
3126668|NCT01710215|Experimental|FIT Screening Strategy|"Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).~Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow up."
3126669|NCT01710215|Experimental|Colon Screening Strategy|"Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.~Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow up."
3126670|NCT01710202||Placebo|Control group who will not receive hydrocortisone. Will act as a comparison group to the hydrocortisone group.
3126671|NCT01710202||Experimental: Hydrocortisone|Group will receive 20mg oral hydrocortisone
3126672|NCT01710189|Experimental|TicoVac immunisation - right deltoid muscle|IM immunisation right deltoid muscle
3126673|NCT01710189|Experimental|TicoVac immunisation - upper anterolateral thigh|IM: right upper anterolateral thigh
3126674|NCT01710176|Active Comparator|standard chemotherapy with full-dose epirubicin + ifosfamide|Standard arm foresees 3 cycles of preoperative chemotherapy, each cycle will be repeated every 21 days and includes: epirubicin 60 mg/m2/day, short infusion, days 1 and 2; ifosfamide 3 g/m2/day, days 1, 2, 3
3126675|NCT01710176|Experimental|histotype-tailored chemotherapy according to the histotype|gemcitabine+docetaxel for undifferentiated pleomorphic sarcoma, trabectedin for myxoid liposarcoma with hypercellularity, ifosfamide for synovial sarcoma, ifosfamide+etoposide for malignant peripheral nerve sheath tumor, gemcitabine+dacarbazine for leiomyosarcoma
3126676|NCT01710163|Experimental|Lithium|Potentiation of previous treatment (Quetiapine monotherapy) with Lithium (0.5 - 0.8 mEq/L)
3126677|NCT01710163|Experimental|Aripiprazole|Potentiation of previous treatment (Quetiapine monotherapy) with Aripiprazole (10 - 15 mg)
3126678|NCT01710150|Placebo Comparator|CTI ablation only|subjects undergoing cavo-tricuspid isthmus (CTI) ablation alone for Atrial flutter
3126679|NCT01710150|Active Comparator|CTI ablation and PVI.|subjects undergoing cavo-tricuspid isthmus (CTI) ablation for Atrial flutter and pulmonary vein isolation (PVI) for Atrial Fibrillation.
3126680|NCT01710137|Active Comparator|Varenicline|"12 weeks of active varenicline + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally"
3126681|NCT01710137|Placebo Comparator|Placebo|"12 weeks of placebo + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally"
3126682|NCT01710124|Experimental|Incentive|Subjects in this group will receive financial incentives for using grocery coupons to purchase healthy foods.
3126683|NCT01710124|No Intervention|No incentive|Subjects in this group will receive no financial incentives.
3126684|NCT01710111|Experimental|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
3126685|NCT01710111|No Intervention|Control Recipients|No face shield and no repeat hand hygiene measures
3126686|NCT01710098||Degarelix|adult male patients with advanced hormone dependent prostate cancer who receive 240 mg as a start dose and then monthly 80mg Firmagon® for one year
3126687|NCT01710085|Experimental|Diffusion weighted imaging, Recurrence|
3126688|NCT01710072|Experimental|aspirin|aspirin 81 mg po every day
3126689|NCT01710072|No Intervention|no aspirin|
3126690|NCT01710059|Experimental|Experimental: Intervention Group|"Experimental: Intervention Group~1) Asthma Supervision; 2) Mobile Phone with talking, texting, and data plan; 3) Inhaled Corticosteroid Mobile Phone Application to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated; and 4) Beta2-adrenergic agonist Mobile Phone Application to monitor real time patterns of use of beta2-adrenergic agonist medication for asthma."
3126691|NCT01710046|Experimental|Cohort 1|
3126692|NCT01710046|Experimental|Cohort 2|
3126693|NCT01710033|Placebo Comparator|Placebo|
3126694|NCT01710033|Experimental|CP-690,550 5 mg BID|
3126695|NCT01710033|Experimental|CP-690,550 15 mg BID|
3126696|NCT01710033|Experimental|CP-690,550 30 mg BID|
3126697|NCT01710020|Experimental|CP-690,550|
3126698|NCT01710007|Experimental|1PC002|2 mg 1PC002 once daily for 12 weeks.
3126699|NCT01710007|Active Comparator|Lipitor|10 mg atorvastatin once daily for 12 weeks.
3126700|NCT01709994|Active Comparator|aspirin|Aspirin dosage 100 mg/day
3126701|NCT01709994|No Intervention|standard medication|the patients will continue with standard medication
3126702|NCT01709981|Experimental|Colchicine|1.2mg colchicine 1 to 2 hours prior PCI, followed by 0.6mg one hour later
3126703|NCT01709981|Placebo Comparator|Placebo|Placebo 1-2 hours prior PCI, followed by placebo 1 hour later
3126704|NCT01709968|Experimental|MAGNOX 520®|MAGNOX 520® (un-organic granular magnesium complex, composed of Magnesium Oxide & Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks.
3126705|NCT01709968|Placebo Comparator|Similarly looking placebo.|Similarly looking placebo. Oral administration once daily for 4 weeks.
3126706|NCT01709955|Experimental|Gucomannan|
3126707|NCT01709955|Placebo Comparator|Placebo pill|
3126708|NCT01709942|Experimental|degarelix group|group of patients treated with long acting GnRH antagonist
3126709|NCT01709942|Active Comparator|Cetrorelix 0.25mg|patients treated with gonadotropin and Cetrorelix ina flexible GnRH antagonist protocol
3126710|NCT01709929|Experimental|Insulin detemir|
3126711|NCT01709916||Glaucoma patients|Glaucoma patients treated with eye drops to lower the IOP.
3126712|NCT01709903|Experimental|QVA149|QVA149 110/50 µg o.d., delivered via a single-dose dry powder inhaler (SDDPI), consisting of a fixed dose combination of indacaterol 110µg and NVA237 50µg
3126996|NCT01708278|Placebo Comparator|Sugar chew-Cohort 2|contains 350 mg of vitamin C and 10 mg niacin
3126713|NCT01709903|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol 500/50 µg b.i.d., delivered via a dry powder inhaler Accuhaler® device
3126714|NCT01709890||Airway catheter during sedation|
3126715|NCT01709877|Active Comparator|Traditional multiport laparoscopic cholecystectomy|Standard laparoscopic cholecystectomy performed by the traditional multiport technique
3126716|NCT01709877|Experimental|Single port laparoscopic cholecystectomy|Laparoscopic cholecystectomy performed using the reusable ENDOCONE system with dedicated curved coaxial instruments
3126717|NCT01709864|Experimental|NVA237|NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
3126718|NCT01709864|Placebo Comparator|Placebo|Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks.
3126719|NCT01709851||Type 1 Diabetes - vMD and sMD|Patients will undergo vascular (vMD) and subcutaneous microdialysis (sMD) using the GMD-system (GlucoMen(R)Day-system)
3126720|NCT01709851||Type 1 diabetes - vMD|Patients will undergo vascular microdialysis (vMD) using the GMD-system (GlucoMen(R)Day-system)
3126721|NCT01709838|Other|Deferasirox|one arm, deferasirox, LIC based dose titration
3126722|NCT01709825|Placebo Comparator|Sugar Pill|Sugar Pill will be taken as a capsule once daily for 6 weeks.
3126723|NCT01709825|Experimental|Probiotic- Bifidobacterium bifidum|Bifidobacterium bifidum (Supplement A) will be taken as a capsule once daily for 6 weeks.
3126724|NCT01709825|Experimental|Probiotic- Lactobacillus helveticus|Lactobacillus helveticus (Supplement B) will be taken as a capsule once daily for 6 weeks.
3126725|NCT01709825|Experimental|Probiotic- Bifidobacterium longum ss. Infantis R0033|Bifidobacterium longum ss. Infantis R0033 (Supplement C)will be taken as a capsule once daily for 6 weeks.
3126726|NCT01709812|Other|1 standard care|standard care
3126727|NCT01709812|Experimental|2 individualized PSP|individualized patient support program
3126728|NCT01709799|Experimental|Cognitive Training plus Exercise|"Physical exercise will be achieved using traditional methods of aerobic exercise. Participants may choose between walking on a treadmill or riding on a stationary bike (Choices include recumbent or traditional sit-up bike.)~Every 4th week, participants will add 80mins./day of Insight gaming for cognitive training."
3126729|NCT01709799|Active Comparator|Cognitive Training plus Exergames|"Physical exercise in this group will be achieved using the Nintendo Wii Sports Resort and Wii Sports video games. A standardized gaming plan will be used for all participants, with play starting at 15 mins. and increasing 5 mins each week after, up to a maximum of 40 play minutes.~Every 4th week, participants will add 80mins./day of Insight gaming for cognitive training."
3126730|NCT01709799|Active Comparator|Cognitive Training|Participants will complete 80 mins/day during the 4th, 8th, 12th and 16th weeks of the intervention.
3126731|NCT01709786||Patients with Suspected Hemorrhage|There is a single group of patients in this study -- those with suspected hemorrhage who satisfy the inclusion and exclusion criteria. The same set of measurements will be take from each patients and those measurements will be compared with one another to determine accuracy.
3126732|NCT01709773|Experimental|Focal treatment arm|
3126733|NCT01709760|Experimental|methotrexate & ENIA11|ENIA11 25 mg, sc twice weekly
3126734|NCT01709760|Active Comparator|methotrexate & Placebo|Placebo, sc twice weekly
3126735|NCT01709747|Experimental|Hydromorphone Hydrochloride|Hydromorphone hydrochloride for intrathecal administration, 12 months safety evaluation
3126736|NCT01709734|Experimental|Dose Confirmation|"Dose A - galeterone tablets once daily PO for three months + extension~Dose B - galeterone tablets once daily PO for three months + extension~Dose C - galeterone tablets once daily PO for three months + extension"
3126737|NCT01709734|Experimental|Dose Expansion|Single dose expansion (from part 1) of galeterone tablets once daily PO for three months + extension
3126738|NCT01709721|Experimental|Active|Subjects on hydromorphone hydrochloride for the duration of therapy.
3126739|NCT01709721|Active Comparator|Titrated off therapy|Subjects on control
3126740|NCT01709708|Active Comparator|Marcaine|Group A will receive treatment with 0.3 mL of 0.5% Marcaine delivered bilaterally with the Tx360™ device to the mucosa associated with the Sphenopalatine Ganglion (SPG)
3126741|NCT01709708|Placebo Comparator|Saline|Group B will receive saline placebo delivered bilaterally with the Tx360TM device to the mucosa associated with the SPG.
3126742|NCT01709695|Experimental|guanfacine hydrochloride XR|Flexible dose titration of guanfacine extended release (Intuniv; active medication). The medication is titrated in doses from 1 - 4 mg once daily
3126743|NCT01709695|Placebo Comparator|Placebo Group|Flexible dose titration of placebo
3126744|NCT01709682|Active Comparator|AAD therapy|Recurrent episodes were pharmacologically managed by conventional AAD therapy (propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure) according to AF management guidelines.
3126745|NCT01709682|Active Comparator|re-ablation procedure|"Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s.~The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity. Only in patients with induced left atrial flutter, additional RF ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs."
3126746|NCT01709669||Enrolling by invitation|
3126747|NCT01709656|Experimental|MSC plus NSAID|"human mesenchymal stem cells:1*10^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment, plus non-steroid anti-inflammatory drugs (NSAID: celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os).~Duration of treatment:24 weeks for follow up. collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
3126780|NCT01709435|Experimental|Treatment (cabozantinib S-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3126748|NCT01709656|Experimental|NSAID|"non-steroid anti-inflammatory drugs (NSAID: celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up;collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
3126749|NCT01709643|Other|High fat breakfast lean subjects|Subjects will consume a high fat breakfast, containing of sausage rolls. Energy content of the breakfast will be set to 50 % of the recommended daily calorie intake (BMR times 1.3).
3126750|NCT01709643|Other|High fat breakfast,obese subjects|Subjects will consume a high fat breakfast, containing of sausage rolls. Energy content of the breakfast will be set to 50 % of the recommended daily calorie intake (BMR times 1.3).
3126751|NCT01709643|Other|HF breakfast with protein,lean subjects|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls. The amount of added proteins will be calculated to assure that the total energy content from proteins in the breakfast equals 20 %,
3126752|NCT01709643|Other|HF breakfast with protein,obese subjects|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls. The amount of added proteins will be calculated to assure that the total energy content from proteins in the breakfast equals 20 %,
3126753|NCT01709630||Neonatal|Neonates born to pregnant women exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection.
3126754|NCT01709630||Maternal|Pregnant women exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection
3126755|NCT01709617|Experimental|Glucose-glucose|Glucose ingestion
3126756|NCT01709617|Active Comparator|Glucose-Fructose|glucose-fructose ingestion
3126757|NCT01709617|Active Comparator|disaccharide|Disaccharide ingestion
3126758|NCT01709604||continuous venovenous hemofiltration|Continuous venovenous hemofiltration(CVVH):blood access was achieved by placing a double lumen catheter in the femoral or internal jugular vein. Continuous diffusive solute transport is achieved by infusing a dialysis fluid that runs counter-current to blood at an ultrafiltration rate of 35 ml/h/Kg.
3126759|NCT01709604||Standardized therapy regimens|The standardized therapy regimens included reduce absorption, accelerate the elimination and prevent the complications in patients with paraquat poisoning.
3126760|NCT01709591|No Intervention|No Prenatal education|These subjects will be randomized to receive routine prenatal epidural class (control group).
3126761|NCT01709591|Active Comparator|Receives Prenatal Education|Subjects randomized to this group will receive educational video addressing the cultural and perceptions regarding the myths on epidural in either English or Spanish (Keeping an Open Mind: choices in Labor Anaglesia: an educational produce of the Society for Obstetric Anesthesia and perinatology)
3126762|NCT01709578|Placebo Comparator|Placebo q2w|Placebo matched to sarilumab once every 2 weeks (q2w) was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
3126763|NCT01709578|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
3126764|NCT01709578|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
3126765|NCT01709565||No hepatic dysfunction|No hepatic dysfunction, total plasma bilirubin ≤ 2.0 mg/dl
3126766|NCT01709565||Hepatic dysfunction|Hepatic dysfunction, total plasma bilirubin > 2.0 mg/dl
3126767|NCT01709552|Experimental|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
3126768|NCT01709552|Sham Comparator|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
3126769|NCT01709539|Experimental|Diagnostiskt Centrum|Investigation at the primary care center followed by further investigation at Diagnostiskt Centrum, Kristianstad General Hospital
3126770|NCT01709539|No Intervention|Existing diagnostic procedures|Investigation at the primary care center followed by further investigation at Helsingborg General Hospital
3126771|NCT01709526|Other|Improvement after psychiatric inpatient treatment|
3126772|NCT01709513|Other|Atorvastatin (statin rechallenge arm)|Atorvastatin 20 mg over-encapsulated tablets orally once daily (QD) for 24 weeks and placebo (for alirocumab) subcutaneous (SC) injection every two weeks (Q2W) for 24 weeks added to stable lipid-modifying therapy (LMT).
3126773|NCT01709513|Active Comparator|Ezetimibe|Ezetimibe 10 mg over-encapsulated tablets orally QD for 24 weeks and placebo (for alirocumab) SC injection Q2W for 24 weeks added to stable LMT.
3126774|NCT01709513|Experimental|Alirocumab 75 mg/ up to 150 mg|Alirocumab 75 mg SC injection Q2W for 24 weeks and placebo (for atorvastatin/ezetimibe) over-encapsulated tablets orally QD for 24 weeks added to stable LMT. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on cardiovascular risk.
3126775|NCT01709500|Experimental|Alirocumab 75 mg/up to 150 mg|Alirocumab 75 mg every two weeks (Q2W) added to stable dose of statin with or without LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL at Week 8.
3126776|NCT01709500|Placebo Comparator|Placebo|Placebo matched to alirocumab SC injection for 78-week treatment duration.
3126777|NCT01709487|Experimental|HIPEC surgery with chemotherapy|"3 courses of pre-operative chemotherapy: carboplatin AUC = 5 IV + paclitaxel 175 mg/m2 IV every 3 weeks~Debulking surgery~HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery~3 courses of post-operative chemotherapy: carboplatin AUC = 5 IV + paclitaxel 175 mg/m2 IV every 3 weeks"
3126778|NCT01709474|Experimental|Vitamin D3 6000 IU|6000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose is reduced to 4,000 IU/day. Note: Subjects weighing <40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
3126779|NCT01709474|Active Comparator|Vitamin D3 400 IU|400 IU/day of vitamin D3 by mouth daily.
3126948|NCT01708603|Placebo Comparator|Placebo|Administered by subcutaneous (SC) injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
3126781|NCT01709422|Active Comparator|Propofol|both midazolam (1mg if aged <= 70 years or 0.5mg in age >70 years) and meperidine 20 mg were given intravenously at the initiation of sedation, Thereafter, an initial bolus of propofol 20 mg intravenously. Sedation was maintained with repeated dose of 5 to 10 mg propofol.
3126782|NCT01709422|Active Comparator|Conventional|both midazolam 2 to 5 mg and meperidine 25 to 50 mg were given intravenously at the initiation of sedation. Sedation was maintained with repeated doses of 0.5 to 1.0 mg midazolam and 5 to 10 mg meperidine.
3126783|NCT01709409|Experimental|Curosurf (Group 1)|Surfactant(Curosurf in this arm) is given for treatment of RDS after the diagnosis has been made by the Neonatologist. The treatment dose for Curosurf® is 2.5 ml/kg (200mg/kg) for the first dose and 1.25 ml/kg (100mg/kg) for repeat doses, given by endotracheal method. There is a maximum of 3 doses in the study.
3126784|NCT01709409|Active Comparator|BLES (Group 2)|Surfactant(BLES in this arm) is given for treatment of RDS after the diagnosis has been made by the Neonatologist. For BLES the recommended dose is 5 ml/kg. given by endotracheal method. There is a maximum of 3 doses in the study.
3126785|NCT01709396|Experimental|18 cGY ED-TBI|18 cGY ED-TBI followed by an allogenic done marrow transplant
3126786|NCT01709383|Active Comparator|Transcranial Direct Current Stimulation|TDCS was applied bilaterally, with the anodal electrode on the left temple and cathodal electrode on the right. TDCS was applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period
3126787|NCT01709383|Sham Comparator|Sham Stimulation|Sham tDCS was applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
3126788|NCT01709370|Experimental|Letrozole plus PD 0332991|Drug: Letrozole 2.5mg/d for 16 weeks before surgery plus PD 0332991 (CDK-4/6 inhibitor) 125 mg/d for 3 out of 4 weeks in repeated cycles for 16 weeks before surgery
3126789|NCT01709357|Experimental|Muscle energy technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed the muscle energy technique of the upper trapezius muscle.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
3126790|NCT01709357|Experimental|Ischemic compression technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed ischemic compression technique on the latent trigger point.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
3126791|NCT01709357|Experimental|Passive stretching technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed the passive stretching of the upper trapezius muscle.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
3126792|NCT01709357|Sham Comparator|Sham technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, for the sham technique, the therapist only contacted with his hands the head and the shoulder of the subject, without executing any movement, for 30 seconds.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
3126793|NCT01709357|No Intervention|No intervention group|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next,the subject was lying for 30 seconds, without intervention.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
3126794|NCT01709344|Experimental|PS-OT|Problem-solving Occupational Therapy
3126795|NCT01709344|Other|Usual care|Access to all supportive and rehabilitative services available at DHMC
3126796|NCT01709331|Experimental|Corifollitropin alfa 150 μg + hCG|During a 16-week pretreatment phase, participants will receive twice-weekly subcutaneous (SC) injections of hCG 1500 or 3000 international units (IU). Eligible participants will then be enrolled in the combined treatment phase in which they will receive a single dose of corifollitropin alfa 150 μg by SC injection once every 2 weeks for 52 weeks. In addition, eligible participants will continue to receive twice-weekly hCG injections on the same schedule as the pretreatment phase.
3126797|NCT01709318|Experimental|NOMAC-E2 500/300|Participants will receive NOMAC-E2 500/300 for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3126798|NCT01709318|Experimental|NOMAC-E2 700/300|Participants will receive NOMAC-E2 700/300 for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3126799|NCT01709318|Experimental|NOMAC-E2 900/300|Participants will receive NOMAC-E2 900/300 for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3126800|NCT01709318|Experimental|ENG-E2 75/300|Participants will receive ENG-E2 75/300 for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3126801|NCT01709318|Experimental|ENG-E2 100/300|Participants will receive ENG-E2 100/300 for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3126997|NCT01708278|Placebo Comparator|Sugar Chew-Cohort 3|contains 350 mg of vitamin C and 10 mg niacin
3211277|NCT01117636|Experimental|Arm 1|
3126802|NCT01709318|Experimental|ENG-E2 125/300|Participants will receive ENG-E2 125/300 for three 28-day treatment periods, each treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3126803|NCT01709318|Active Comparator|NuvaRing® (ENG-EE 120/15)|Participants will receive NuvaRing® for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3126804|NCT01709305|Active Comparator|Metformin + Sitagliptin + Glimepiride|During Phase 2, participants receive up to 6 mg glimepiride daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
3126805|NCT01709305|Experimental|Metformin + Sitagliptin + Repaglinide|During Phase 2, participants receive up to 16 mg repaglinide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
3126806|NCT01709305|Experimental|Metformin + Sitagliptin + Acarbose|During Phase 2, participants receive 50-100 mg acarbose three times daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
3126807|NCT01709305|Experimental|Metformin + Sitagliptin + Gliclazide|During Phase 2, participants receive 30-120 mg gliclazide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
3126808|NCT01709292|Experimental|Vemurafenib - (Presurgery)|All Groups: Vemurafenib 960 mg by mouth 2 times a day for 56 days prior to surgery (patients not planned for surgical resection will have a core biopsy at day 56 +/- 7 days).
3126809|NCT01709292|Experimental|Vemurafenib (Post Surgery) - Group A|Vemurafenib 960 mg by mouth two times a day 2 weeks post-surgery, or if patients have not sufficiently recovered at that point, as soon as their condition permits. Patients in Group A restaged 8 weeks after resuming drug. If patients in Group A demonstrate either stable or regressing disease, they will continue on vemurafenib with restaging occurring every 8 weeks until no longer benefitting from the drug.
3126810|NCT01709292|No Intervention|Post Surgery - Group B|Post Surgery - Group B: Patients discontinue vemurafenib after surgery but will be restaged with CT neck 8 weeks after surgery.
3126811|NCT01709292|Experimental|Vemurafenib - Group C|Patients not scheduled for surgical resection undergo a CT scan and core biopsy at day 56, Vemurafenib 960 mg by mouth twice a day unless there is evidence of progressive disease on day 56 CT scan. Patients evaluated for resectability after each CT scan is performed. If scheduled for resection, patient continues vemurafenib until surgery and follows same treatment schema as patients in Groups A and B.
3126812|NCT01709279|Other|adipose tissue derived stromal cells|
3126813|NCT01709266|Experimental|Probiotics|Capsule containing 5x10E9 CFU probiotics. Twice daily for 2 weeks.
3126814|NCT01709266|Placebo Comparator|Placebo|Capsule containing carrier material powder of identical appearance. Twice daily for 2 weeks.
3126815|NCT01709253|Experimental|Arm 1|27pt/60CGE/20fx/5wks to PGTV(mon, tue, thu, fri; 4/wk)
3126816|NCT01709253|Experimental|Arm 2|27pt/54CGE/15fx/5wks to PGTV (mon, wed, fri; 3/wk)
3126817|NCT01709253|Experimental|Arm 3|27pt / 47CGE/10fx/5wk to PGTV(tue, thu;2/wk)
3126818|NCT01709253|Experimental|Arm 4|27pt/ 35CGE/ 5fx/2.5wk to PGTV(the, thu; 2/wk)
3126819|NCT01709240|Experimental|BioWeld1 System|
3126820|NCT01709227|Experimental|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output <1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output >1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
3126821|NCT01709227|Experimental|Peritoneal dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management will be directed by CICU attending and Nephrology service
3126822|NCT01709214|Experimental|GRT6005 Low-Dose Range|Once daily GRT6005, flexible dosing 200, 300 or 400 micrograms, oral administration for 15 weeks
3126823|NCT01709214|Experimental|GRT6005 High-Dose Range|Once daily GRT6005, flexible dosing 400, 600 or 800 micrograms, oral administration for 15 weeks
3126824|NCT01709214|Placebo Comparator|Placebo|Once daily GRT6005, flexible dosing 400, 600 or 800 micrograms, oral administration for 15 weeks
3126825|NCT01709214|Active Comparator|Oxycodone CR|Twice Daily Oxycodone CR, flexible dosing 10, 20, 30, 40 or 50 milligrams, oral administration for 15 weeks
3126826|NCT01709201|No Intervention|Treatment as Usual|Those in the Treatment as Usual group will not receive the brief intervention for substance use but will receive a brief health education brochure.
3126827|NCT01709201|Experimental|Brief Intervention|Those in the Brief Intervention group will receive a brief motivational intervention aimed at encouraging the participant to decrease their substance use.
3126828|NCT01709188|Experimental|Musical Dual Task Training|60 minute individual session once a week across 2 months for a total of 8 sessions.Each session will be led by a qualified music therapist. Within the Musical Dual Task Training session, participant will be asked to sing familiar songs, play simple percussive musical instruments such as paddle drums and shakers, sing while walking, and play instruments while walking.
3126829|NCT01709188|Active Comparator|Walking and Talking|60 minute individual session once a week across 2 months for a total of 8 sessions.Each session will be led by a qualified music therapist. Within the walking and talking session, participant will be asked to read a newspaper article prior to a walk and have a conversation with the music therapist based on the content of the news while walking.
3126830|NCT01709175|Experimental|Once-a-week Strength Training|After completing the introduction to strength training (two sessions in the first week), participants randomized to the once-a-week group will receive 12 additional weeks of progressive strength training. Participants will meet ONCE-A-WEEK to strength train in a supervised exercise group. The program includes nine exercises.
3126831|NCT01709175|Experimental|Twice-a-week Strength Training|After completing the introduction to strength training (two sessions in the first week), participants randomized to the twice-a-week group will receive 12 additional weeks of progressive strength training. Participants will meet TWICE-A-WEEK to strength train in a supervised exercise group. The program includes nine exercises.
3126832|NCT01709162|Experimental|Ipilimumab, 3 mg/kg|Participants received ipilimumab, 3 mg/kg, by intravenous infusion, every 3 weeks for a total of 4 doses or until disease progression, unacceptable toxicity, or withdrawal of consent
3126833|NCT01709162|Active Comparator|Chemotherapy|Participants received the investigator's choice of chemotherapy, administered per package instructions.
3126834|NCT01709149|Experimental|CK-2017357|125 mg tablets
3126835|NCT01709149|Placebo Comparator|Placebo|Placebo tablets
3126836|NCT01709136|Experimental|Sirolimus|
3126837|NCT01709123|Placebo Comparator|placebo|Placebo supplementation in pill form for 3 months following randomization after a placebo run-in period.
3126838|NCT01709123|Experimental|chromium niacinate|Chromium niacinate supplementation (200ug or 500ug/day) in pill form for 3 months following randomization after a placebo run-in period
3126839|NCT01709110|Experimental|Teriparatide|"Teriparatide 20 microgram (µg) administered by subcutaneous (SC) injection once daily for 24 months.~Placebo given orally once weekly for 24 months.~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment."
3126840|NCT01709110|Active Comparator|Risedronate|"Risedronate 35 milligram (mg) administered orally once weekly for 24 months.~Placebo given by SC injection once daily for 24 months.~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment."
3126841|NCT01709097||With Med-O-Wheel™|Kidney Transplant Recipient with Med-O-Wheel™
3126842|NCT01709097||With out Med-O-Wheel™|Kidney Transplant Recipient with out Med-O-Wheel™
3126843|NCT01709084|Experimental|Group 1|Patients will receive fixed dose combination (FDC) tablet of tenofovir disoproxil fumarate/emtricitabine/rilpivirine with a meal, until Week 48.
3126844|NCT01709084|Active Comparator|Group 2|Patients will receive FDC tablet of tenofovir disoproxil fumarate/emtricitabine /efavirenz on an empty stomach at bedtime, until Week 48.
3126845|NCT01709071|Experimental|Low dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
3126846|NCT01709071|Experimental|Low dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 2.5, 4, 8 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
3126847|NCT01709071|Experimental|Middle dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
3126848|NCT01709071|Experimental|Middle dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
3126849|NCT01709071|Experimental|High dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
3126850|NCT01709071|Experimental|High dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
3126851|NCT01709071|Active Comparator|Conventional IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose.~Infants receive three injections with an interval of 8 weeks between doses."
3126852|NCT01709058|Experimental|Intramuscular/paravertebral injections of Oxygen-Ozone|"This group will be treated with Intramuscular/paravertebral injections of Oxygen-Ozone twice a week for six weeks"
3126853|NCT01709058|Other|Simulated treatment|"The Simulated intramuscular/paravertebral injections will mimic the Oxygen-Ozone injections in the area to be treated by pricking the skin with the needle without drilling. These simulated injections will be performed twice a week for six weeks."
3126854|NCT01709045||Patients scheduled for CEA|All patients who are scheduled for carotid endarterectomy (CEA)
3126855|NCT01709032|Experimental|Deferasirox and deferiprone|
3126856|NCT01709019|Experimental|Group A|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
3126857|NCT01709019|Experimental|Group B|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
3126858|NCT01709019|Experimental|Group C|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
3126859|NCT01709019|Experimental|Group D|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
3126860|NCT01709019|Placebo Comparator|Group E|Placebo (Day 0 & Day 28); Seasonal TIV (Day 28)
3126861|NCT01709006|Other|Radiation therapy|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
3126862|NCT01708993|Active Comparator|Arm A: Pemetrexed and Reolysin (and safety run-in)|
3126863|NCT01708993|Active Comparator|Arm B: Pemetrexed|
3126864|NCT01708993|Active Comparator|Arm C: Docetaxel and Reolysin (and safety run-in)|
3126865|NCT01708993|Active Comparator|Arm D: Docetaxel|
3126866|NCT01708980|Experimental|Six different strength training exercises|Six different strength training exercises are investigated. Four repetitions of each exercise are performed with a relative loading of 10 RM.
3126867|NCT01708967|Experimental|Catheter-free method|"We explored success rate, side effects, and vital signs in patients with catether-free method.~Intervention: one-time spray of epinephrine (1cc) plus 4% lidocaine (4cc)"
3126868|NCT01708967|Experimental|Catheter insertion method|We explored success rate, side effects, and vital signs in patients with catether insertion method : use both spray and catheter
3126869|NCT01708954|Experimental|Arm A (erlotinib)|Patients receive erlotinib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3126998|NCT01708265|Active Comparator|Early mitral valve repair|Early mitral valve repair
3126870|NCT01708954|Experimental|Arm B (cabozantinib)|Patients receive cabozantinib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3126871|NCT01708954|Experimental|Arm C (erlotinib+cabozantinib)|Patients receive erlotinib as patients in Arm A and cabozantinib as patients in Arm B. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3126872|NCT01708954|Experimental|Arm Z (erlotinib+cabozantinib; step II)|Patients achieving disease progression in Arm A or Arm B may receive erlotinib and cabozantinib as patients in Arm C. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3126873|NCT01708941|Experimental|Arm A (higher dose ipilimumab, HDI)|"INDUCTION PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses and recombinant interferon alfa-2b IV over 20 minutes 5 days a week for 4 weeks and then SC 3 times weekly for 8 weeks.~MAINTENANCE PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24 and recombinant interferon alfa-2b SC 3 times weekly for 48 weeks."
3126874|NCT01708941|Experimental|Arm B (higher dose ipilimumab)|"INDUCTION PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses.~MAINTENANCE PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24."
3126875|NCT01708941|Experimental|Arm C (lower dose ipilimumab + HDI)|"INDUCTION PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses and recombinant interferon alfa-2b IV over 20 minutes 5 days a week for 4 weeks and then SC 3 times weekly for 8 weeks.~MAINTENANCE PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24 and recombinant interferon alfa-2b SC 3 times weekly for 48 weeks."
3126876|NCT01708941|Experimental|Arm D (lower dose ipilimumab)|"INDUCTION PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses.~MAINTENANCE PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24."
3126877|NCT01708928|Active Comparator|Group A|Subjects who have previous history of submentoplasty and or rhytidectomy
3126878|NCT01708928|Active Comparator|Group B|Subjects naïve to submentoplasty and or rhytidectomy
3126879|NCT01708915|Active Comparator|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
3126880|NCT01708915|Active Comparator|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
3126881|NCT01708915|Active Comparator|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
3126882|NCT01708915|Placebo Comparator|placebo|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
3126883|NCT01708902|Experimental|linagliptin2.5mg / metformin500mg BID|patient to receive a tablet containing linagliptin 2.5mg and metformin 500mg BID
3126884|NCT01708902|Experimental|linagliptin2.5mg / metformin1000mg BID|patient to receive a tablet containing linagliptin 2.5mg and metformin 1000mg BID
3126885|NCT01708902|Active Comparator|metformin 500mg BID|patient to receive a tablet containing metformin 500mg BID
3126886|NCT01708902|Active Comparator|metformin 1000mg BID|patient to receive a tablet containing metformin 1000mg BID
3126887|NCT01708902|Active Comparator|linagliptin 5 mg QD|patient to receive a tablet containing linagliptin 5mg once daily
3126888|NCT01708889|Experimental|Group 1: BMS-914143 (eGFR ≥ 80 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with normal renal function with eGFR ≥ 80 mL/min/1.73 m2
3126889|NCT01708889|Experimental|Group 2: BMS-914143 (eGFR 60 to 79 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with mild renal dysfunction with eGFR 60 to 79 mL/min/1.73 m2
3126890|NCT01708889|Experimental|Group 3: BMS-914143 (eGFR 30 to 59 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with moderate renal dysfunction with eGFR 30 to 59 mL/min/1.73 m2
3126891|NCT01708889|Experimental|Group 4: BMS-914143 (eGFR 15 to 29 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with severe renal dysfunction with eGFR 15 to 29 mL/min/1.73 m2
3126892|NCT01708889|Experimental|Group 5: BMS-914143 (eGFR < 15 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with end-stage renal dysfunction with eGFR < 15 mL/min/1.73 m2 (on hemodialysis [HD] or non-HD)
3126893|NCT01708876|Active Comparator|Artesunate-mefloquine|3 doses artesunate-mefloquine - daily over 3 days (dosage according to bodyweight - 4mg/kg and 8.3mg/kg respectively).
3126894|NCT01708876|Active Comparator|Chloroquine|4 doses chloroquine over 3 days - total dose 25mg/kg. 10mg/kg at 0 hours, 5mg/kg at 6-8, 24, 48 hours.
3126895|NCT01708863||Children with Hypoplastic Left Heart Syndrome (HLHS)|HLHS patients requiring Stage II Glenn surgery
3126896|NCT01708850|Other|Rivaroxaban|Rivaroxaban 15 mg po bid x 3 weeks, followed by rivaroxaban 20 mg po daily x 9 weeks. Then up to discretion of investigator to decide regarding further anticoagulation as study length is limited to 12 weeks.
3126897|NCT01708837|Other|deep anesthesia group|Propofol infusion rate is titrated to maintain the target BIS values in 30-45
3126898|NCT01708837|Other|light anesthesia group|Propofol infusion rate is titrated to maintain the target BIS values in 45-60
3126899|NCT01708824|Experimental|dietary|"Dietary intervention to meet the target of~1.<5 servings of red/processed meat weekly; <2 servings would be processed meat 2.2 servings of refined grains daily"
3126900|NCT01708824|Experimental|physical activity|"Physical activity intervention with the following targets:~General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);~Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)"
3126901|NCT01708824|Experimental|dietary and physical activity|Meeting both the dietary and physical activity targets
3126902|NCT01708824|No Intervention|usual care|Follow the general lifestyle advice in accordance with the recommendations of the Department of Health in Hong Kong available in the public domain
3126949|NCT01708590|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to placebo or continued treatment. Participants are retreated at return of disease.
3211278|NCT01117636|Active Comparator|Arm 2|
3126903|NCT01708798|Placebo Comparator|Placebo|"One tablet by mouth daily. If serum potassium level is <5.0 mmol/L at four weeks, increase to two tablets by mouth daily.~If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: one tablet by mouth every other day. If serum potassium level is <5.0 mmol/L at four weeks, increase to one tablet by mouth daily."
3126904|NCT01708798|Experimental|Eplerenone|"Eplerenone 25 mg tablet by mouth daily. If serum potassium level is <5.0 mmol/L at four weeks, increase to two 25 mg tablets by mouth daily.~If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: eplerenone 25 mg tablet by mouth every other day. If serum potassium level is <5.0 mmol/L at four weeks, increase to 25 mg tablet by mouth daily."
3126905|NCT01708785|Active Comparator|Single context|Subjects will be exposed to food cues in a single context.
3126906|NCT01708785|Experimental|Multiple contexts|Subjects will be exposed to food cues in multiple contexts.
3126907|NCT01708785|Active Comparator|8 treatment sessions|Subjects receive 8 treatment sessions.
3126908|NCT01708785|Experimental|16 treatment sessions|Subjects receive 16 treatment sessions
3126909|NCT01708772||Sepsis|Forty five patients developed septic complication during ICU stay (sepsis group).
3126910|NCT01708772||SIRS group|Forty five patients were critically ill without evidence of infectious organism (SIRS group).
3126911|NCT01708759||Sepsis|Forty patients developed septic complication during ICU stay (sepsis group).
3126912|NCT01708759||SIRS|Forty patients were critically ill without evidence of infectious organism (SIRS group).
3126913|NCT01708746||Enrolled subjects|
3126914|NCT01708746||Historic control|
3126915|NCT01708733|Placebo Comparator|KSY diluted|KSY diluted, 100mg decoction by mouth per day for 6 weeks
3126916|NCT01708733|Experimental|KSY|KSY, 100mg decoction by mouth per day for 6 weeks
3126917|NCT01708720|Experimental|Sabin-IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, and 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose
3126918|NCT01708720|Experimental|Adjuvanted Sabin-IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, and 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose, adjuvanted with 0.5 mg aluminium hydroxide
3126919|NCT01708720|Active Comparator|IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose
3126920|NCT01708707|Active Comparator|Oral morphine sulfate|Oral morphine sulfate 0.4 mg/kg/day morphine every 3-4 hours as needed for Finnegan scores suggestive of Neonatal Abstinence Syndrome Other Name: morphine
3126921|NCT01708707|Experimental|Buprenorphine|Sublingual Buprenorphine 15.9 µg/kg per day in 3 divided doses, titrated up or escalated down based upon standardized scoring for neonatal abstinence syndrome
3126922|NCT01708694|Placebo Comparator|Placebo Starch|Yogurt with about 45 g/day of placebo starch (amylopectin).
3126923|NCT01708694|Experimental|Experimental Starch|Yogurt with about 45 g/day of slowly digestible starch (amylose).
3126924|NCT01708681|Experimental|Lean seafood|Cross-over design, half of the subject will receive lean seafood in study period I and the other half in study period II
3126925|NCT01708681|Active Comparator|Meat, egg, milk|Cross-over design, half of the subject will receive meat, egg, milk in study period I and the other half in study period II
3126926|NCT01708668|Active Comparator|1|Epidural analgesia (EA) with continuous epidural infusion(CEI)
3126927|NCT01708668|Active Comparator|2|Combined spinal-epidural analgesia (CSEA) with continuous epidural infusion(CEI)
3126928|NCT01708668|Active Comparator|3|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)
3126929|NCT01708668|Active Comparator|4|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)
3126930|NCT01708668|Active Comparator|5|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)
3126931|NCT01708668|Active Comparator|6|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)
3126932|NCT01708668|Active Comparator|7|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)
3126933|NCT01708668|Active Comparator|8|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)
3126934|NCT01708655|Other|Sweat Evaporimeter measurement|"0.1 ml Carbachol, intraocular solution - diluted to 0.1 µg/ml in normal saline- dose 0.01 µg~0.2 ml Atropine sulphate, injection solution - diluted to 44 µg/ml in normal saline - dose 8.8 µg.~0.2 ml of the Beta cocktail injection solution diluted to 44 µg/ml atropine, 22 µg/ml isoproterenol and 4.6 mg/ml aminophylline in normal saline - dose:~4.4 µg Isoproterenol hydrochloride, injection solution~0.93 mg Aminophylline injection solution~8.8 µg Atropine, injection solution"
3126935|NCT01708642|Experimental|Adrenaline|Intraoperative low-dose adrenaline infusion
3126936|NCT01708642|Placebo Comparator|Placebo|Placebo: Isotonic Saline
3126937|NCT01708629|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
3126938|NCT01708629|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
3126939|NCT01708629|Active Comparator|ustekinumab|Administered by subcutaneous (SC) injection per the labeled dosing regimen.
3126940|NCT01708629|Placebo Comparator|Placebo|Administered by SC injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
3126941|NCT01708616|Placebo Comparator|Placebo + risperidone|
3126942|NCT01708616|Placebo Comparator|Placebo +placebo|
3126943|NCT01708616|Active Comparator|RO5285119 + placebo|
3126944|NCT01708616|Experimental|RO5285119 + risperidone|
3126945|NCT01708603|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
3126946|NCT01708603|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
3126947|NCT01708603|Active Comparator|ustekinumab|Administered by subcutaneous (SC) injection per the labeled dosing regimen.
3126950|NCT01708590|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to placebo or continued treatment. Participants are retreated at return of disease.
3126951|NCT01708590|Placebo Comparator|placebo|Administered by SC injection until week 12. At week 12 particpants are assigned to 210 mg brodalumab.
3126952|NCT01708577|Experimental|IPANEMA validation without water intake|The one group is restricted to the water intake during the Indoor phase during testing the IPANEMA measurement system. The other group is not restricted to the water intake.
3126953|NCT01708577|Experimental|IPANEMA validation with water intake|The one group is restricted to the water intake during the Indoor phase, the other group is not restricted to the water intake.
3126954|NCT01708564|Experimental|Cohort 1|10 patients administered a single low dose of rhFVIIa
3126955|NCT01708564|Experimental|Cohort 2|10 patients administered a single intermediate dose of rhFVIIa
3126956|NCT01708564|Experimental|Cohort 3|10 patients administered a single high dose of rhFVIIa
3126957|NCT01708551|Active Comparator|Group A|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments; dual depth treatment at 4.5mm and 3.0mm.
3126958|NCT01708551|Active Comparator|Group B|Subjects who were non-responders to a prior Ultherapy™ treatment for hyperhidrosis will receive bilateral Ulthera System treatments; dual depth treatment at 4.5mm and 3.0mm.
3126959|NCT01708551|Active Comparator|Group C|Subjects will receive one double-density Ulthera System treatment; dual depth treatment at 4.5mm and 3.0mm.
3126960|NCT01708551|Active Comparator|Group D|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments at 2.0mm treatment depth and standard energy level.
3126961|NCT01708551|Active Comparator|Group E|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments at 2.0mm treatment depth and adjusted energy level.
3126962|NCT01708538|Active Comparator|Epithelium on|Epi not removed during CXL treatment
3126963|NCT01708538|Active Comparator|Epithelium off|Epi removed before CXL treatment
3126964|NCT01708525|Experimental|Ultherapy®-treated tissue|Heavy water labeled tissue receiving an Ulthera® System Treatment
3126965|NCT01708512|Experimental|Ultherapy™ study treatment|Each subject will receive a customized, high-density, vectored Ulthera System Treatment.
3126966|NCT01708499|Experimental|Study treatment|All enrolled subjects will receive one Ulthera System Treatment.
3126967|NCT01708486||Adolescents' with asthma using inhalation devices|Asthmatic adolescents will record their opinion for their inhalation devices by replying to FSI-10 questionnaire
3126968|NCT01708473|Active Comparator|Advil with Ultherapy|Subjects randomized to this study arm will receive Advil prior to an Ulthera System Treatment.
3126969|NCT01708473|Active Comparator|Lortab with Ultherapy|Subjects randomized to this study arm will receive Lortab prior to an Ulthera System Treatment.
3126970|NCT01708460|Experimental|Ulthera-treated subjects|All enrolled subjects will receive one Ultherapy treatment to one side of the body in the lateral buttock region. Following study completion, subjects may elect to receive a balancing treatment to the other side of the body.
3126971|NCT01708447|Active Comparator|Topical anesthetic - L.M.X.4.® cream|Topical anesthetic cream, L.M.X.4.® cream, applied to one side of the face and neck prior to Ulthera System treatment.
3126972|NCT01708447|Placebo Comparator|Placebo cream|A placebo cream with similar consistency and color will be applied to the other side of the face and neck prior to Ulthera System treatment.
3126973|NCT01708434|Experimental|Ulthera® treatment of the knees|Bilateral treatment of the knees using the Ulthera® System
3126974|NCT01708408||community|
3126975|NCT01708395||Cohort 1|First 50 patients
3126976|NCT01708395||Cohort 2|2nd group of 50 patients
3126977|NCT01708382|Experimental|Ultherapy treatment on the elbows|All enrolled subjects will receive one Ultherapy treatment to the elbows.
3126978|NCT01708369|Active Comparator|Oseltamivir & Placebo|Oseltamivir 150 mg orally will be administered 15 minutes after subjects consume orange juice
3126979|NCT01708369|Experimental|Oseltamivir & Ethanol|Oseltamivir 150 mg and ethanol targeted to blood alcohol concentration 0.08 g/dl
3126980|NCT01708369|Active Comparator|Aspirin & Placebo|Aspirin 650 mg orally will be administered 15 minutes after subjects consume orange juice
3126981|NCT01708369|Experimental|Aspirin & Ethanol|Aspirin 650 mg and ethanol targeted to blood alcohol concentration 0.08 g/dl
3126982|NCT01708356|Experimental|Normal cycling|Cycling on a residential and downtown route (crossover design)
3126983|NCT01708343|Sham Comparator|Placebo-sham|Placebo-sham twice a week during four weeks
3126984|NCT01708343|Active Comparator|Lidocaine injection|Lidocaine 0.2-0.5 mL of 1% injected each time into the trigger point. Twice a week during four weeks
3126985|NCT01708343|Experimental|DIMMST|"DIMMST include the combination of trigger point deep dry needling (TrP-DDN) is combined with paraspinal deep intramuscular stimulation (PDIMS) and needle rotation (NR).~Twice a week during four weeks"
3126986|NCT01708330|Placebo Comparator|Placebo gel|Placebo gel applied topically to the cervix
3126987|NCT01708330|Experimental|Lidocaine gel|2% lidocaine gel applied topically to the cervix
3126988|NCT01708317|Other|ACASI|The group of patients that agreed to participate in the study and answer questions on our Audio-enhanced Computer-Assisted Self-Interview (ACASI)
3126989|NCT01708304|Other|RDAD|Exercise training for caregiver and care recipient. Behavior modification training for caregiver.
3126990|NCT01708291|Active Comparator|Mindfulness Based Stress reduction|attending 10 weekly sessions and comprised of an eight week mindfulness intervention program, and completing pre- and postevaluation measures on the first and last sessions
3126991|NCT01708291|Placebo Comparator|No Mindfulness based intervention|completing only re- and post-evaluation measures on the first and last sessions
3126992|NCT01708278|Placebo Comparator|Sugar chew-Cohort 1|contains 350 mg of vitamin C and 10 mg niacin
3126993|NCT01708278|Active Comparator|Quercetin 1-Cohort 1|Quercetin chew containing 500 mg quercetin, 350 mg vitamin C and 10 mg niacin
3126994|NCT01708278|Active Comparator|Quercetin 2-Cohort 2|Quercetin chew containing 1000 mg quercetin, 350 mg vitamin C and 10 mg niacin
3126999|NCT01708265|Active Comparator|Watchful waiting|Watchful waiting
3127000|NCT01708252|Experimental|Ulthera treatment group|All subjects will receive an Ulthera System Treatment
3127001|NCT01708239||Pregnant women|Pregnant women with suspected DVT assessed by the LEFt rule, D-dimer measurement and complete ultrasonography.
3127002|NCT01708226|Experimental|Attention Modification Program|Attention Modification Program
3127003|NCT01708213|Experimental|Dermal Filler - Aline HA|Single armed study
3127004|NCT01708200|Experimental|Memory Intervention|Two types of memory protocols (psychoeducational vs computerized) will be compared in a population of individuals with mental illness.
3127005|NCT01708187|Experimental|Clarix™1k graft|Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.
3127006|NCT01708187|No Intervention|Control arm without Clarix™1k graft|Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue.
3127007|NCT01708174|Experimental|Sonidegib (LDE225)|600 mg orally for adults and 500 mg/m2 orally for children
3127008|NCT01708174|Active Comparator|Temozolamide (TMZ)|150 to 200 mg/m2 for 5 sequential days every 4 weeks according to prescribing information until the study was amended to a single arm study.
3127009|NCT01708161|Experimental|BYL719 + AMG 479|For: Dose escalation phase/Phase II Expansion Phase. Cohorts of 3-6 patients were to be enrolled sequentially until an MTD or a recommended Phase II dose were defined. All patients were to receive the combination treatment. Sequential cohorts may receive different doses of the combination. In the Phase II expansion, all patients were to receive the same combination treatment.
3127010|NCT01708148|Active Comparator|Lactobacilli|30 Participants with verum
3127011|NCT01708148|Placebo Comparator|Placebo|30 Participants
3127012|NCT01708135|Other|Smartphone Arm|This is a feasibility trial and thus all participants in the study will be provided a smartphone app to assist them in preparing for bariatric surgery.
3127013|NCT01708122|Experimental|Fentanyl|Subjects will receive either 0.5mL or 1 mL of intranasal fentanyl (50mcg or 100mcg)
3127014|NCT01708122|Placebo Comparator|Placebo|Subjects will receive either 0.5mL or 1 mL of intranasal saline as placebo.
3127015|NCT01708109|Experimental|Biliary calculus remain|biliary calculus, less than or equal to 6 mm, remains
3127016|NCT01708109|Experimental|Biliary calculus removed|biliary calculus, less than or equal to 6 mm, removed
3127017|NCT01708096|Active Comparator|Modifast|treated with VLD Modifast 1000 kcal/day in 2 weeks before gastric by-pass,
3127018|NCT01708096|Placebo Comparator|Normal diet|normal diet 2 weeks before gastric by-pass surgery
3127019|NCT01708083||Type 2 Diabetes and BMI>35|Patients with type 2 diabetes and body mass index 35 or more.
3127020|NCT01708083||BMI>35|Patients undergoing surgery, gastric bypass or cholecystectomy, without diabetes type 2 and body mass index 35 or more
3127021|NCT01708083||BMI 18-27|Patients undergoing surgery, cholecystectomy or reflux, without type 2 diabetes and body mass index between 18-27
3127022|NCT01708070|Active Comparator|Asthma self-management experimental|The intervention will involve a self-management workbook, contracting to improve self-management behaviors, instruction in using of a peak flow meter, and follow-up discussions based on the workbook.
3127023|NCT01708070|Other|Asthma self-management control|The control state will involve a self-management workbook and contracting to improve self-management behaviors.
3127024|NCT01708057|Experimental|1|Single dose of AZD8683 50 µg
3127025|NCT01708057|Experimental|2|Single dose of AZD8683 150 µg
3127026|NCT01708057|Experimental|3|Single dose of AZD8683 300 µg
3127027|NCT01708057|Experimental|4|Single dose of AZD8683 900 µg
3127028|NCT01708057|Placebo Comparator|5|Single dose of placebo
3127029|NCT01708057|Active Comparator|6|Single dose of tiotropium 18 µg
3127030|NCT01708044|Experimental|Pramlintide 6 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 6 mcg for each unit of insulin.
3127031|NCT01708044|Experimental|Pramlintide 9 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 9 mcg for each unit of insulin.
3127032|NCT01708044|Experimental|Pramlintide 12 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 12 mcg for each unit of insulin.
3127033|NCT01708044|Placebo Comparator|Placebo|
3127034|NCT01708031|Experimental|stress inducing task|Normal subjects without history medication presently will be participated. Stress induced through stress inducing task (mental arithmetic task), the physiological signals collected before and during the task simultaneously. All the subjects will be participating only once in this MAT based study. Because, the stress will not be possible to induce when the subject is more familiar with the stress inducing task.
3127035|NCT01708018|No Intervention|Control group|Prior and post intervention period (on days 1 and 4) and final control (day 8): ultrasound examination of position of the fetus and amount of amniotic fluid. On these days plus weekly (until birth) questionnaires (QoL: SF-36, EQ-5D-5L, stress: PSS, psychological wellbeing: MDBF, current stress and pain: VAS). Survey concerning birth.
3127036|NCT01708018|Experimental|Intervention group|Prior and post intervention (days 1 and 4) and final control (day 8): ultrasound examination of position of the fetus and amount of amniotic fluid. On these days plus weekly (until birth) questionnaires (QoL: SF-36, EQ-5D-5L, stress: PSS, psychological wellbeing: MDBF, current stress and pain: VAS). After the second intervention(day 4): qualitative questionnaire for intervention-group only. Survey concerning birth.
3127037|NCT01708005|Active Comparator|Intervention|80 participants start the oral intake of Lecitone®Se-Vitamin D3 the day after inclusion and during 24 weeks
3127038|NCT01708005|Placebo Comparator|Placebo|"80 participants in this arm start the oral intake of placebo the day after inclusion and during 12 weeks.~Then, they start the oral intake of Lecitone®Se-Vitamin D3 12 weeks after inclusion until the 24th week."
3127039|NCT01707992|Experimental|Laquinimod Dose 0.6 mg|Two capsules, one containing 0.6 mg laquinimod and the other containing matching placebo, to be administered orally once daily during both Periods 1 and 2.
3127040|NCT01707992|Experimental|Laquinimod Dose 1.2 mg|"Two capsules containing 0.6 mg laquinimod to be administered orally once daily during both Periods 1 and 2.~NOTE- As of January 2016, this arm has been discontinued."
3213773|NCT01100281||Alzheimer's disease|
3127041|NCT01707992|Placebo Comparator|Placebo|Two capsules containing placebo (matching to the 0.6 mg) to be administered orally once daily during Period 1.
3127042|NCT01707979||Diabetic neuropathy|Male participants, type1 diabetic with diabetic neuropathy
3127043|NCT01707979||Diabetes without neuropathy|Male participants, type1 diabetic without diabetic neuropathy
3127044|NCT01707979||Non diabetic control|Male participants, control group non diabetic
3127045|NCT01707966|Experimental|Orteronel and best supportive care|Arm A: 300mg Orteronel twice daily and best supportive care until occurrence of an event.
3127046|NCT01707966|Placebo Comparator|Placebo and best supportive care|Arm B: Placebo twice daily and best supportive care until occurrence of an event.
3127047|NCT01707953|Experimental|Midodrine|Midodrine Hydrochloride (5mg) administered as capsule 5 and 23 hours after end of surgery.
3127048|NCT01707953|Placebo Comparator|Placebo|Placebo administered as capsule 5- and 23 hours after end of surgery.
3127049|NCT01707940|Experimental|BI 144807|subjects receive an oral single dose of BI 144807
3127050|NCT01707940|Experimental|BI 144807 plus Ketoconazole|subjects receive bid ketoconazole plus an oral single dose of BI 144807
3127051|NCT01707927||Trifecta|Degenerated aortic valve with indication for aortic valve replacement
3127052|NCT01707927||mosaic Ultra|Need a aortic valve replacement
3127053|NCT01707914|Experimental|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
3127054|NCT01707914|Placebo Comparator|Placebo|Consume 500 mL placebo/d (250 mL placebo twice daily)
3127055|NCT01707901|Experimental|ONO-8539|ONO-8539
3127056|NCT01707901|Placebo Comparator|Placebo|Placebo
3127057|NCT01707888||major lung resection|Patients undergo major lung resection by thoracoscopy/VATS.
3127058|NCT01707875||fetal ventricle brain asymmetry|
3127059|NCT01707849|Active Comparator|MMF arm|"MMF arm (n=20)~They will receive immunosuppression as stipulated by hospital protocol:~Tacrolimus (levels 8-10ng/mL) and Mycophenalate mofetil 1mg bid(levels 1-3ng/mL)."
3127060|NCT01707849|Experimental|EVL arm|"EVL arm (n=20):~Tacrolimus (levels 8-10ng/ml) + everolimus 1mg bid (levels 2-4 ng/mL)"
3127061|NCT01707836||Family|Families with a child with Neurofibromatosis Type 1 who has been diagnosed with a brain tumor.
3127062|NCT01707823|Experimental|Prevention (acetylsalicylic acid)|Patients receive acetylsalicylic acid PO for 7 days.
3127063|NCT01707810|Sham Comparator|Conventional method|In the conventional method IVC was clamped during the anhepatic phase and venous return was maintained by a portal femoral axillary venovenous bypass with a centrifugal pump. In these cases, IVC reconstruction was performed by end-to-end anastomosis above and below the liver.
3127064|NCT01707810|Experimental|Piggyback method|In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.
3127065|NCT01707797||Healthy children aged 9-15 months|Healthy children aged 12 months (± 3 months) at baseline stratified by Medicaid status and/or race/ethnicity to ensure a diverse representation. Each child will be paired with the primary caregiver, whom the investigators expect to most likely be the adult parent or legal guardian.
3127066|NCT01707784||Women with gestational diabetes|Women with gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
3127067|NCT01707784||Women without gestational diabetes|Women without gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
3127068|NCT01707771|Active Comparator|Roux-en-Y gastric bypass|Both sexes, age between 30 and 60 years, BMI =/> 35 kg/m2
3127069|NCT01707771|Active Comparator|diet and lifestyle modifications|Both sexes, age between 30 and 60 years, BMI =/> 35 kg/m2
3127070|NCT01707758||pancreatic cancer|This study will collect blood from 36 patients with known or suspected pancreatic cancer and from 12 healthy cancer-free subjects.
3127071|NCT01707745|Other|Avastin|Bevacizumab(Avastin) 0.75mg in 0.03 ml
3127072|NCT01707732|Active Comparator|Enoxaparin 40mg/ day|Enoxaparin administrated at the following dose : 40mg/ day
3127073|NCT01707732|Experimental|Enoxaparin 60 mg/day|Enoxaparin administrated at the following dose : 60 mg/day
3127074|NCT01707719||Alzheimer's disease|
3127075|NCT01707719||Non demented subjects|
3127076|NCT01707706|Experimental|Traditional Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, Neiguan PC6, Shenmen HT7, Sanyinjiao SP6, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (ITO ES160, Japan) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.4 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
3127077|NCT01707706|Active Comparator|Minimal Acupuncture|"Patients will be treated superficially at points away from classic acupoints. The points include bilateral Forearm [1 inch lateral to the middle point between HE3 and HE7] , Upper arm [1 inch lateral to LU 3 ], and Lower leg [0.5 inch dorsal to GB39]; for head, the non-acupoints include bilateral Head [middle point between GB8 and ST8], Forehead [middle point between ST8 and GB14], Neck [middle point between TB16 and SI17], and Ear [the point on the helix, inferior to the apex]. The points selected have been used in previous acupuncture studies as sham control. De qi is avoided during needling. The treatment procedure, electric-stimulation, frequency, duration and number of treatment sessions will be the same for the Traditional Acupuncture group."
3127114|NCT01707433||Diagnosis of hip disease|Diagnosed with spondyloepiphyseal dysplasia or multiple epiphyseal dysplasia or bilateral Legg-Calve-Perthes disease, or bilateral proximal femoral epiphyseal dysplasia
3127115|NCT01707420|Active Comparator|Gabapentin|gabapentin, 20 mg/kg, single dose, 60 min prior to surgery
3127116|NCT01707420|Placebo Comparator|liquid placebo|subjects randomized to the liquid placebo arm will receive a single dose elixir of 0.4 mL/kg given 60 min prior to surgery
3127117|NCT01707407|Experimental|Pomalidomide|
3127118|NCT01707407|Experimental|Pomalidomide plus Ketoconazole|
3215294|NCT01089998|Experimental|Arm 3|
3127078|NCT01707706|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the site 1 inch beside the acupoints in order to avoid the acupressure effect. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
3127079|NCT01707693|Experimental|Lifestyle Physical Activity Intervention|the women will be randomized to either the LPA Intervention (n=60) or Information/Attention Comparison (I/A, n=60) groups using a permuted block randomization scheme. Participants in both groups will be followed longitudinally with repeated assessments of LPA (accelerometer & LPA diary), stage of change, and self-efficacy at baseline and 3 and 6 months; and functional health and well-being (SF36) at baseline and 6 months.
3127080|NCT01707693|Active Comparator|Information/Attention Comparison|the women will be randomized to either the LPA Intervention (n=60) or Information/Attention Comparison (I/A, n=60) groups using a permuted block randomization scheme. Participants in both groups will be followed longitudinally with repeated assessments of LPA (accelerometer & LPA diary), stage of change, and self-efficacy at baseline and 3 and 6 months; and functional health and well-being (SF36) at baseline and 6 months.
3127081|NCT01707680||Dexmedetomidine|Here, patients to be included are those being sedated with dexmedetomidine as primary sedative.
3127082|NCT01707680||Propofol|Here, patients to be included are those being sedated with propofol as primary sedative.
3127083|NCT01707680||Midazolam|Here, patients to be included are those being sedated with midazolam as primary sedative
3127084|NCT01707667|Experimental|Prucalopride|
3127085|NCT01707667|Active Comparator|PEG 3350|
3127086|NCT01707654|Other|nerve graft|Simultaneous repair of the infected wound and digital nerve defect in the finger using a bipedicled nerve flap including nerve graft from the dorsal branch of the digital nerve.
3127087|NCT01707641|Active Comparator|CD#2|patients will be asked to melt slowly in the mouth 6 lozenges per day, containing Lactobacillus brevis CD2
3127088|NCT01707641|Active Comparator|bicarbonate sodium mouthwash|patients will be asked to wash their mouth with bicarbonate several times per day
3127089|NCT01707628|Active Comparator|Early group after rituximab|"Patients who received rituximab last dose 3-6 months before influenza vaccination will be the early group."
3127090|NCT01707628|Active Comparator|Late group after rituximab|"Patients who received rituximab last dose 9-12 months before influenza vaccination will be the late group."
3127091|NCT01707628|Active Comparator|Control group|Healthy individuals will be receive vaccination with influenza vaccine and will serve as controls.
3127092|NCT01707615|Other|control group|In the control group, all patients were enrolled in a lifestyle intervention
3127093|NCT01707615|Active Comparator|GSPE group|GSPE 240 mg/day (120mg bid) in addition to the same lifestyle intervention.
3127094|NCT01707602|Experimental|Arm A|Type Vaccine Name: INTANZA® 15 T Description : transcutaneous vaccination
3127095|NCT01707602|Active Comparator|Arm B|Type: Vaccine Name: INTANZA® 15ug Description : intradermal vaccination
3127096|NCT01707602|Active Comparator|Arm C|Type : Vaccine Name: Vaxigrip® Description :Intramuscular vaccination
3127097|NCT01707589|Experimental|Neonates admitted to the NICU|Neonates admitted to the NICU for a variety of medical reasons will be the cohort group. Those whose parents give informed consent will compose the subjects of the study
3127098|NCT01707576|Other|screening of adolescent mental suffering. Management|screening of adolescent mental suffering consultant to emergencies. Management and later monitoring
3127099|NCT01707563|Other|Marfan patients|Study participants were recruited between 11/2009 and 10/2011, among adult patients consulting in the Multidisciplinary Marfan Clinic of our University Hospital, and having a known mutation in the FBN1 gene. There, patients are evaluated by geneticists, rheumatologists, cardiologists, and ophthalmologists. Systematic slit-lamp examination, cardiac ultrasonography, and radiological investigations are also performed. A skin punch biopsy was used to establish a fibroblast cell culture. We determined mRNA levels for FBN1 and compared it to the clinical involvement.
3127100|NCT01707563|Other|control patients|Fibroblasts were obtained from non Marfan patients (cell bank). We determineed mRNA level for FBN1 for each allele.
3127101|NCT01707550||Cohort|
3127102|NCT01707537|Experimental|Euvichol|Euvichol is a homogeneous suspension of inactivated suitable strains of Vibrio cholera serogroup O1 and O139. Euvichol is Yellow to yellowish colour.
3127103|NCT01707524|Experimental|Trans-radial approach|Randomized left versus right radial artery approach
3127104|NCT01707524|No Intervention|Trans-femoral approach|Observational
3127105|NCT01707498|Experimental|Tetraplegic patients|Scanning device RoBIK Brain-Computer Interface
3127106|NCT01707498|Experimental|Healthy volunteers|RoBIK Brain-Computer Interface
3127107|NCT01707485|Experimental|Short course|amoxicillin. high-dose, 5 days
3127108|NCT01707485|Active Comparator|Standard therapy|amoxicillin, high-dose, 10 days
3127109|NCT01707472|Experimental|Simtuzumab in HIV Patients|HIV-infected participants will receive simtuzumab every 2 weeks for 24 weeks while continuing on standard therapy for HIV.
3127110|NCT01707472|Experimental|Simtuzumab in HCV Patients|HCV-infected participants will receive simtuzumab every 2 weeks for 24 weeks.
3127111|NCT01707472|Experimental|Simtuzumab in HIV/HCV Co-Infected Patients|HIV/HCV co-infected participants will receive simtuzumab every 2 weeks for 24 weeks while continuing on standard therapy for HIV.
3127112|NCT01707446|Active Comparator|Near-infrared reflectance spectroscopy|Bilateral NIRS (The INVOS® Cerebral/Somatic Oximeter)will be used to measure rSO2 intraoperatively and during the 24h postoperative period in the intensive care unit. In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established.
3127113|NCT01707446|No Intervention|Blinded Near-infrared reflectance spectroscopy|In the control group, the NIRS monitor screen will be electronically blinded, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in NIRS application and unaware of the study design.
3127121|NCT01707394|Experimental|Group 1: Apixaban (low dose)|"Apixaban capsule 0.1 mg by mouth or by nasogastric tube (NG) or gastronomy tube (G-tube) using a dosing syringe on the morning of Day 1~Group 1: Neonates to < 28 days of age"
3127122|NCT01707394|Experimental|Group 2A: Apixaban (low dose)|"Apixaban solution 2.43 mg/ m2 by mouth or by nasogastric tube (NG) or gastronomy tube (G-tube) using a dosing syringe on the morning of Day 1~Group 2A: 9 months to < 2 years"
3127123|NCT01707394|Experimental|Group 2B: Apixaban (low dose)|"Apixaban solution 1.08 mg/ m2 by mouth or by nasogastric tube (NG) or gastronomy tube (G-tube) using a dosing syringe on the morning of Day 1~Group 2B: 28 days to < 9 months"
3127124|NCT01707394|Experimental|Group 3: Apixaban (low dose)|"Apixaban solution 1.17 mg/ m2 by mouth or by nasogastric tube (NG) or gastronomy tube (G-tube) using a dosing syringe on the morning of Day 1~Group 3: 2 years to < 6 years"
3127125|NCT01707394|Experimental|Group 4: Apixaban (low dose)|"Apixaban solution 1.80 mg/ m2 by mouth or by nasogastric tube (NG) or gastronomy tube (G-tube) using a dosing syringe on the morning of Day 1~Group 4: 6 years to <12 years"
3127126|NCT01707394|Experimental|Group 5: Apixaban (low dose)|"Apixaban solution 2.19 mg/ m2 by mouth or by nasogastric tube (NG) or gastronomy tube (G-tube) using a dosing syringe on the morning of Day 1~Group 5: 12 years to <18 years"
3127127|NCT01707394|Experimental|Group 2AA: Apixaban (low dose)|"Apixaban solution 1.08 mg/ m2 by mouth or by nasogastric tube (NG) or gastronomy tube (G-tube) using a dosing syringe on the morning of Day 1~Group 2A: 9 months to < 2 years"
3127128|NCT01707381|Active Comparator|Timolol Maleate|Timolol maleate ophthalmic solution 0.5% administered 1 drop BID once in morning and once in the evening for 4 weeks.
3127129|NCT01707381|Experimental|BOL-303259-X|BOL-303259-X topical ophthalmic solution administered 1 drop QD in the evening for 4 weeks.
3127130|NCT01707368||all eligible patients|Daivobet® Gel once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
3127131|NCT01707355|Active Comparator|invention with poster|intervention - poster
3127132|NCT01707355|No Intervention|control|control - no poster
3127133|NCT01707342|Experimental|Simeprevir (TMC435)|Treatment A: single oral dose of simeprevir (TMC435) 50 mg; and Treatment B: single oral dose of simeprevir (TMC435) 150 mg. A single 10 minute intravenous infusion of [3H]-TMC435 (100 microcurie) 100 microgram will be followed 5 hours later after administration of Treatment A and Treatment B in Period 1 and Period 2, respectively.
3127134|NCT01707329|Active Comparator|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
3127135|NCT01707329|Experimental|Icotinib+Chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
3127136|NCT01707316|Experimental|Sequence 1: Treatment A-B-C|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
3127137|NCT01707316|Experimental|Sequence 2: Treatment B-C-A|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
3127138|NCT01707316|Experimental|Sequence 3: Treatment C-A-B|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
3127139|NCT01707303|Other|Usual Care|Usual hospital rehabilitative services
3127140|NCT01707303|Experimental|Early ICU Rehabilitation Strategy|Early ICU physical therapy will be applied in this arm
3127141|NCT01707290|Experimental|Ivacaftor|Participants who received Ivacaftor 150 milligram (mg) tablet and/or Placebo matched to Ivacaftor tablet orally, every 12 hours (q12h) in the previous study VX11-770-110 (Study 110; NCT01614457), VX12-770-111 (Study 111; NCT01614470) or VX12-770-113 (Study 113; NCT01685801); received Ivacaftor 150 mg tablet q12h in this VX12-770-112 (Study 112; NCT01707290) up to 104 weeks.
3127142|NCT01707290|No Intervention|Observational|Participants who received Ivacaftor 150 mg tablet and/or Placebo matched to Ivacaftor tablet, orally, q12h in the previous Study 110 (NCT01614457) or Study 111 (NCT01614470), were observed (did not receive study drug) in this Study 112 (NCT01707290) for up to 2 years.
3127143|NCT01707277|Experimental|Inspiratory muscle training|Inspiratory muscle training for improving maximum inspiratory pressure plus phrmacological treatment Pharmacological treatment (usual care)
3127144|NCT01707277|Active Comparator|Usual care|Pharmacological treatment
3127145|NCT01707264|Experimental|NEOD001|NEOD001 will be administered intravenously once every 28 days. The starting dose will be 0.5 mg/kg. Dose escalation will continue until the the maximum tolerated dose is determined for single agent NEOD001. Approximately 20 additional subjects will be treated with the maximum tolerated dose.
3127146|NCT01707251|Experimental|Intravenous Ibuprofen|800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
3127147|NCT01707251|Placebo Comparator|Saline|IV saline every 6 hours starting preoperatively (5 doses).
3127148|NCT01707238|Experimental|stenfilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
3127149|NCT01707238|Active Comparator|etafilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
3127150|NCT01707225|Experimental|Octreotide LAR Depot|Once enrolled in the study subjects will receive a monthly intra-muscular injection of 20mg of octreotide LAR at each study visit for 24 weeks and will be followed for a total of 36 weeks.
3127151|NCT01707212|Experimental|Pain management education|Education about pain management during infant immunization
3127152|NCT01707212|Other|No pain management education|Control - general information about immunization only
3127153|NCT01707199|Experimental|Artesunate + Sulphadoxine-pyrimethamine|"AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date."
3127154|NCT01707186||Group 1A|Early phase, requiring change in treatment
3127155|NCT01707186||Group 2|Established phase, stable treatment
3215295|NCT01089998|Experimental|Arm 4|
3127158|NCT01707173|Other|Standard Education|Control group participants will receive standard educational materials published by the CDC or American Academy of Pediatrics as an intervention along with a generic infant safety DVD
3127159|NCT01707173|Experimental|Tailored education|Parents/caregivers will receive educational materials tailored to their specific beliefs and barriers about infant supine sleep along with a DVD detailing standard guidelines along with specific solutions and facilitators to infant supine sleep as the intervention.
3127160|NCT01707160|Experimental|Treatment period 1|
3127161|NCT01707160|Active Comparator|Treatment period 2|
3127162|NCT01707147||Patients with T2DM|
3127163|NCT01707134|Experimental|insulin aspart|
3127164|NCT01707134|Active Comparator|human insulin|
3127165|NCT01707121||Surgical patients|Patients with planned surgery for breast cancer, colorectal cancer and gall bladder disease
3127166|NCT01707108|Experimental|Dental Implants|Rehabilitation of missing teeth with Dental Implant (MIS Technologies)
3127167|NCT01707095|Experimental|Bundling of cords|The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
3127168|NCT01707095|Experimental|Unbundling of cords|The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
3127169|NCT01707082|Experimental|Part A Cohort 1|
3127170|NCT01707082|Experimental|Part A Cohort 2|
3127171|NCT01707082|Experimental|Part A Cohort 3|
3127172|NCT01707082|Experimental|Part A Cohort 4|
3127173|NCT01707082|Experimental|Part A Cohort 5|
3127174|NCT01707082|Experimental|Part B Cohort 1|
3127175|NCT01707082|Experimental|Part B Cohort 2|
3127176|NCT01707069|Experimental|Group 1: 4mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who are skin test negative to Japanese Red Cedar pollen or Mountain Cedar pollen and have no reactive Cry J 2 antibodies.~Group 1: will receive 4mg of Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection (considered to be the optimal DNA vaccine dose based on historical clinical data from other DNA vaccine studies). The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) of a 4 mg dose at 14 day intervals."
3127177|NCT01707069|Experimental|Group 2: 2mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan, are Skin test positive to Japanese Red Cedar pollen or Mountain Cedar pollen and/or have reactive Cry J 2 antibodies, and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain Cedar season will receive a total of four half (2 mg) dose dosing regimen.~Group 2: will receive 2 mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection(considered ½ of the optimal plasmid vaccine dose based on historical clinical data from studies with other antigens). The dosing regimen for this group will be to receive three (3) additional 2 mg doses at 14 day intervals between doses (4 doses in total)."
3127178|NCT01707069|Experimental|Group 3: 4 mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan, are Skin test positive to Japanese Red Cedar pollen or Mountain Cedar pollen and/or have reactive Cry J 2 antibodies, and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain Cedar season will receive a total of four full (4 mg) dose dosing regimen.~Group 3: will receive 4 mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection (considered the optimal plasmid vaccine dose based on historical clinical data from studies with other antigens). The dosing regimen for this group will be to receive 3 additional 4 mg doses at 14 day intervals between doses (4 doses in total)."
3127179|NCT01707056|Active Comparator|Black coffee|Synthroid will be administered with 12 ounces of black coffee for a period of 6 weeks.
3127180|NCT01707056|Active Comparator|Coffee with Milk|Synthroid will be administered with 12 ounces of coffee and 2 ounces of 2% milk for a period of 6 weeks.
3127181|NCT01707056|Active Comparator|Black Tea|Synthroid will be administered with 12 ounces of black Lipton tea for a period of 6 weeks.
3127182|NCT01707056|Placebo Comparator|Water|Synthroid will be administered with 12 ounces of water for a period of 6 weeks.
3127183|NCT01707043|Active Comparator|Taclonex Ointment First|All subjects will use Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment once daily for three days to affected areas, then switch to Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension once daily to affected areas for three days
3127184|NCT01707043|Active Comparator|Taclonex Scalp Suspension first|All subjects will use Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension once daily to affected areas for three days, then switch to Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment once daily for three days to affected areas,
3127185|NCT01707030|Experimental|BAI Arm|Receiving a web-based brief intervention for alcohol problems
3127186|NCT01707030|Active Comparator|Usual Care|In usual care, Hepatitis C clinic staff will sometimes discuss alcohol use with patients, and this will be the experience of some of the controls
3127187|NCT01707017|Active Comparator|High-load strength training|
3127188|NCT01707017|Active Comparator|Low-load strength training|
3127189|NCT01707017|Active Comparator|Low-load + moderate-load strength training|
3127190|NCT01707004|Experimental|Treatment (donor bone marrow transplant)|"Beginning between days -29 and -22, patients receive decitabine IV over 1 hour daily for 10 days, fludarabine phosphate IV over 30 minutes on days -5 to -2, and busulfan IV over 3 hours on days -5 to -2.~PREPARATIVE REGIMEN: Patients undergo total-body irradiation BID on day -1.~TRANSPLANT: Patients undergo allogeneic bone marrow transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus PO BID or IV continuously on days 5-180, mycophenolate mofetil PO TID on days 5-35, and filgrastim SC beginning day 5 until ANC >= 1,000/mm^3 for 3 consecutive days."
3127191|NCT01706991||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
3127212|NCT01706874||Control|Periodontal prophylaxis (standard of care) versus control in rheumatoid arthritis patients
3127213|NCT01706861|Other|Celotres|Celotres following surgical removal of earlobe keloid.
3127214|NCT01706848|Active Comparator|Celotres|Scar halves randomized to treatment with device, opposite side treated per standard of care.
3127215|NCT01706848|Active Comparator|Standard surgical wound closure|Scar halves randomized to treatment with device, opposite side treated per standard of care.
3127192|NCT01706991||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~VA <20/40 and 2 logMAR lines difference in normal eye~Mild amblyopia (>20/40)~Moderate amblyopia (20/40 and <20/100)~Severe amblyopia (≥20/100 or worse)~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~Constant: >2 PD at near and or distance.~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~'hypermetropia' (≥3.5 D),~'myopia' (≥-4.0 D),~'astigmatism' (≥1.5 D).~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
3127193|NCT01706991||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
3127194|NCT01706978|Experimental|Soft Tissue Trephination|"Ten days prior to the standard rotator cuff repair, a trephination procedure will be carried out. The trephination procedure will take approximately 30 minutes to complete and will be carried out under local anesthesia. A needle will be placed through the skin over the shoulder and either into the bone or into the edge of the cuff tendon, depending on whether you are allocated to the bone trephination or soft tissue trephination groups. The needle will be used to make 6 small holes in either bone or the tendon in the shoulder in the area where the cuff is to be repaired."
3127195|NCT01706978|Active Comparator|Bone Trephination|"Ten days prior to the standard rotator cuff repair, a trephination procedure will be carried out. The trephination procedure will take approximately 30 minutes to complete and will be carried out under local anesthesia. A needle will be placed through the skin over the shoulder and either into the bone or into the edge of the cuff tendon, depending on whether you are allocated to the bone trephination or soft tissue trephination groups. The needle will be used to make 6 small holes in either bone or the tendon in the shoulder in the area where the cuff is to be repaired."
3127196|NCT01706965|Experimental|Kuvan|Kuvan once-daily dosing initiated with 10mg/kg for the first week followed by 20mg/kg for the remaining weeks of the study
3127197|NCT01706965|Active Comparator|Multivitamin|Daily multivitamin tablet
3127198|NCT01706952|Experimental|Cocaine|"Cocaine 4%. Three cotton neuropatties will be soaked with 4% cocaine. One neuropattie will be placed in the sphenoethmoidal recess, one in the middle meatus, and one in the anterior end of the middle turbinates on the side that the randomization has determined.~This intervention will be done before the beginning of the surgery, and will be left in the nose for 10 minutes, this will be done just once. After the 10 minutes, the neuropatties will be taken out of the nose."
3127199|NCT01706952|Active Comparator|Adrenaline|"Adrenaline 1/1.000 Three cotton neuropatties will be soaked with Adrenaline 1/1,000. One neuropattie will be placed in the sphenoethmoidal recess, one in the middle meatus, and one in the anterior end of the middle turbinates on the side that the randomization has determined.~This will be done before the beginning of the surgery, and will be left in the nose for 10 minutes, this will be done just once. After the 10 minutes, the neuropatties will be taken out of the nose."
3127200|NCT01706939|Experimental|Reduced Dose Radiation|Patients randomized to receive a reduced (5600 cGy) dose radiotherapy with weekly Carboplatin
3127201|NCT01706939|Active Comparator|Standard Dose Radiation|Patients randomized to receive a standard (7000 cGy) dose radiotherapy with carboplatin
3127202|NCT01706926|Placebo Comparator|Placebo|Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 milligram [mg] per week) through oral or parenteral route.
3127203|NCT01706926|Experimental|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
3127204|NCT01706926|Experimental|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
3127205|NCT01706926|Experimental|Mavrilimumab 150 mg|Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
3127206|NCT01706913|No Intervention|No consult|Those who are in the control group will follow internal medicine hospitalist recommendations alone which will include when and what type of post-discharge follow-up appointments the patient will have. We would like to emphasize that as part of the standard of care, patients in the control arm may still receive a dermatology consult if it is deemed necessary and/or requested. We will not prevent patients or the patient's team of caregivers from requesting a dermatology consultation during the course of hospitalization. A follow-up phone call will be performed two weeks after discharge for patients in the control group in order to confirm the patient's outcome. There will also be a medical record review one month after the patient's initial discharge from the hospital to assess for readmission
3127207|NCT01706913|Active Comparator|Dermatology Consult|The patients randomized to the treatment group will obtain a dermatology evaluation within 24 hours of being admitted to MGH for their cellulitis. The skin and lymph node exam performed by the dermatologist on patients in the treatment group will be documented in the LMR for the subjects' medical records. Patients who are readmitted for cellulitis within one month of being discharged from the hospital will be considered treatment failures. Patients in the treatment group will have a follow-up visit in dermatology clinic within two weeks after being discharged. There will also be a medical record review performed one month after the patient's initial discharge from the hospital to assess for readmission.
3127208|NCT01706900|Placebo Comparator|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
3127209|NCT01706900|Experimental|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
3127210|NCT01706887|Experimental|Diet Amiloride|One week Low Na diet (10 mmol/d) followed by ine week high Na diet (200 mmol/d) followed by 2 weeks administration of amiloride (10 mg the 1 st week and the 20mg).
3127211|NCT01706874||Periodontal prophylaxis|Periodontal prophylaxis (standard of care) versus control in rheumatoid arthritis patients.
3127270|NCT01706536|Placebo Comparator|EP-101 Placebo|EP-101 Placebo AM + EP-101 Placebo PM
3127216|NCT01706835|Experimental|Aldoxorubicin|Aldoxorubicin dosages of 230 mg/m2 or 350 mg/m2 will be given as a 30 minute infusion every 3 weeks for 8 cycles.
3127217|NCT01706822|Experimental|Covidien Radial Reload Stapler with Tri-Staple Technology|Covidien Radial Reload Stapler with Tri-Staple Technology in laparoscopic LAR or proctosigmoidectomy
3127218|NCT01706809||Biomarkeres|
3127219|NCT01706796|Experimental|PF-06273340 Oral Solution Fasted|
3127220|NCT01706796|Experimental|PF-06273340 Immediate Release Tablet Fasted|
3127221|NCT01706796|Experimental|PF-06273340 Modified Release (MR1) Tablet Fasted|
3127222|NCT01706796|Experimental|PF-06273340 Modified Release (MR2) Tablet Fasted|
3127223|NCT01706796|Experimental|PF-06273340 Modified Release (MR1) Tablet Fed|
3127224|NCT01706796|Experimental|PF-06273340 Modified Release (MR2) Tablet Fed|
3127225|NCT01706783|Experimental|NNC0195-0092 (somapacitan)|
3127226|NCT01706783|Active Comparator|Norditropin NordiFlex®|
3127227|NCT01706770|Experimental|enfilcon A|The test (experimental) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
3127228|NCT01706770|Active Comparator|galyfilcon A|The control (active comparator) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
3127229|NCT01706757|Experimental|with go-cart|conducts exercises with the help of a go-cart
3127230|NCT01706757|No Intervention|without go-cart|conduct exercises without go-cart
3127231|NCT01706744|Experimental|Intermediate care unit|Follow-up treatment and care in a intermediate care unit after discharge from hospital
3127232|NCT01706744|Active Comparator|Local health care 1|Discharge from hospital to usual care as provided by the local health and social care (Verdal)
3127233|NCT01706744|Active Comparator|Local health care 2|Discharge from hospital to usual care as provided by the local health and social care (Stjørdal)
3127234|NCT01706731|Active Comparator|TAU plus Cognitive-behavioral Therapy|Participants randomized to this group will receive treatment as usual plus cognitive behavioral therapy (CBT) provided by trained Buddhist monks.
3127235|NCT01706731|Sham Comparator|TAU plus routine counselling|Participants randomized into this group will receive treatment as usual (TAU) plus plus routine psychological support from non-CBT monks.
3127236|NCT01706718|Placebo Comparator|Control white bread|
3127237|NCT01706718|Experimental|Beetroot bread|
3127238|NCT01706705|Experimental|Brachytherapy Treatment Planning|"MRI-compatible intracavitary applicator inserted using ultrasound guidance to verify tandem placement in the uterus. Tandem and ovoids, tandem and cylinders, or tandem and ring chosen to accommodate patient's tumor and vaginal anatomy.~Computed tomography (CT) scan and a magnetic resonance imaging (MRI) scan performed after the implant is placed in the operating room. The CT scan should take about 20 minutes and the MRI about 45 minutes."
3127239|NCT01706692||Adalimumab|Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed
3127240|NCT01706692||Etanercept|Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed
3127241|NCT01706692||Infliximab|Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed
3127242|NCT01706692||Ustekinumab|Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
3127243|NCT01706692||Cyclosporine A|Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
3127244|NCT01706692||Fumaric acids|Intervention: Drug: conventional systemic: Fumaric acids, all dosages, frequencies and durations prescribed
3127245|NCT01706692||Methotrexate|Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
3127246|NCT01706692||Other anti-psoriatic systemic treatments|e.g.: Intervention: Drug: conventional systemic: Acitretin or Systemic phototherapy (PUVA), all dosages, frequencies and durations prescribed
3127247|NCT01706679|Active Comparator|Maximum therapeutic dose of ATX-101|ATX-101 10 mg/ml
3127248|NCT01706679|Active Comparator|Supratherapeutic dose of ATX-101|ATX-101 20 mg/ml
3127249|NCT01706679|Active Comparator|Moxifloxacin|moxifloxacin (400mg)
3127250|NCT01706679|Placebo Comparator|Placebo vehicle|placebo vehicle (PBS)
3127251|NCT01706666|Experimental|Arm A (bortezomib)|Patients receive bortezomib SC on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
3127252|NCT01706666|Experimental|Arm B (bortezomib, cyclophosphamide, dexamethasone)|Patients receive bortezomib SC as in Arm A, cyclophosphamide PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
3127253|NCT01706666|Experimental|Arm C (bortezomib, lenalidomide)|Patients receive bortezomib SC as in Arm A and lenalidomide PO QD on days 1-28.
3127254|NCT01706653|Active Comparator|Intervention 1|Polyphenol-enriched fruit-based drink - low
3127255|NCT01706653|Active Comparator|Intervention 2|Polyphenol-enriched fruit-based drink - medium
3127256|NCT01706653|Active Comparator|Intervention 3|Polyphenol-enriched fruit-based drink - high
3127257|NCT01706653|Placebo Comparator|Intervention 4|Very low polyphenol fruit based drink (control)
3127258|NCT01706627|Placebo Comparator|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
3127259|NCT01706627|Active Comparator|Drug: 10 mg Melatonin|10 mg melatonin gelatin capsule
3127260|NCT01706627|Active Comparator|Drug: 20 mg Melatonin|20 mg melatonin gelatin capsule
3127261|NCT01706601||Hemorrhoids|Patient with hemorrhoids
3127262|NCT01706588|Experimental|Diclofenac sodium 5 mg/mL|
3127263|NCT01706588|Experimental|Diclofenac sodium 12.5 mg/mL|
3127264|NCT01706588|Experimental|Diclofenac sodium 25 mg/mL|
3127265|NCT01706588|Experimental|Diclofenac sodium 50 mg/mL|
3127266|NCT01706588|Placebo Comparator|Placebo 1 mL|
3127267|NCT01706575|Experimental|Pegylated Interferon (Peginterferon) Alfa-2a|Participants receiving nucleos(t)ide analogues (NA) therapy with Hepatitis B surface Antigen (HBsAg) decline less than <0.5 log 10 international unit/milliliter (IU/ml) at baseline received peginterferon alfa-2a 180 microgram (mcg), subcutaneously (SC) once weekly for 48 weeks along with their NA therapy.
3127268|NCT01706562||Itraconazole|
3127269|NCT01706549||Posthysterectomy pain|Observational study on posthysterectomy pain
3215940|NCT01085695|Experimental|1|
3127272|NCT01706536|Experimental|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
3127273|NCT01706536|Experimental|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
3127274|NCT01706536|Experimental|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
3127275|NCT01706523|Experimental|STX209|Active treatment with STX209
3127276|NCT01706510|Experimental|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
3127277|NCT01706510|Active Comparator|Clopidogrel|Clopidogrel 600 mg Loading Dose followed by 75 mg Daily for 7 days ± 2 days
3127278|NCT01706484|Experimental|80 mg BNO 1016 und placebo|2 tablets (one containing 80 mg BNO 1016 and one placebo) by mouth 3 times daily
3127279|NCT01706484|Experimental|160 mg BNO 1016|2 tablets (each containing 80 mg BNO 1016) by mouth 3 times daily
3127280|NCT01706484|Placebo Comparator|placebo|2 tablets (each without BNO 1016) by mouth 3 times daily
3127281|NCT01706471|Experimental|Everolimus + Low dose CsA +PD|
3127282|NCT01706471|Active Comparator|Myfortic+ Standard CsA + PD|
3127283|NCT01706458|Active Comparator|sipuleucel-T|Patients receive sipuleucel-T IV on weeks 0, 2, and 4.
3127284|NCT01706458|Experimental|sipuleucel-T with DNA Vaccine|Patients receive sipuleucel-T as patients in arm I and pTVG-HP plasmid DNA vaccine ID on weeks 6, 8, 10, and 12, and then at 6 and 9 months.
3127285|NCT01706445|No Intervention|Control|
3127286|NCT01706445|Other|intervention|Exercise training
3127287|NCT01706432|Experimental|Treatment (radiation therapy)|Patients with metastases in the lung, liver, abdomen, and extremities undergo 10 fractions or less of hypofractionated radiation therapy and patients with brain metastases undergo a single fraction of stereotactic radiosurgery.
3127288|NCT01706419|No Intervention|no school meal|control group receiving no school meal
3127289|NCT01706419|Placebo Comparator|normal school meal|school meal without fortified rice, placebo group
3127290|NCT01706419|Experimental|cold extruded fortified rice|school meal with fortified rice using cold extrusion kernels
3127291|NCT01706419|Experimental|warm extrusion|school meal with fortified rice using warm extrusion kernels
3127292|NCT01706419|Experimental|hot extruded|school meal with fortified rice using hot extrusion kernels
3127293|NCT01706406|Experimental|1 treatment|"Women randomized into the treatment group will undergo pre-treatment testing (questionnaires and physiological assessment)within 14 days of beginning treatment"
3127294|NCT01706406|Other|2 waitlist|"Women randomized to the waitlist group will undergo initial testing (questionnaires and physiological testing) and receive no treatment until the next scheduled group (4 months). They will undergo pretreatment testing and treatment on the same schedule as women in the treatment group."
3127295|NCT01706393|Experimental|probiotics|"Probiotics supplementation group. Probiotics intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.~Probiotics is composed of Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium lactis, L. rhamnosus, B. longum and B. bifidum."
3127296|NCT01706393|Placebo Comparator|placebo|"Placebo group. Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.~Placebo is composed of starch.Probiotics and placebo were similar in appearance, taste."
3127297|NCT01706380|Experimental|Interactive voice response with personal feedback|Interactive voice response follows the client twice weekly for 3 months with respect to symptoms and substance use, in both arms. This intervention group also receives a personalized and automated feedback describing whether the symptom status of the patient is better, worse or equal, compared to the preceding follow-up.
3127298|NCT01706380|Active Comparator|Interactive voice response without personal feedback|This control group is also followed with identical interactive voice response follow-up, addressing symptoms and substance use, but without the personal feedback.
3127299|NCT01706367|Experimental|Low dose C diff vaccine|
3127300|NCT01706367|Experimental|Low dose C diff vaccine + adjuvant|
3127301|NCT01706367|Experimental|Mid dose C diff vaccine|
3127302|NCT01706367|Experimental|Mid dose C diff vaccine + adjuvant|
3127303|NCT01706367|Experimental|High dose C diff vaccine|
3127304|NCT01706367|Experimental|High dose C diff vaccine + adjuvant|
3127305|NCT01706354|Active Comparator|Local anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
3127306|NCT01706354|Experimental|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
3127307|NCT01706341|Active Comparator|acetate Ringer's solution|Administering acetate Ringer's solution that contains no glucose as an initial infusion A total infusion volume of acetate Ringer's solution is 1500ml
3127308|NCT01706341|Active Comparator|acetate Ringer's solution with 1% glucose|Administering the acetate Ringer's solution that contains 1% glucose as an initial infusion A total infusion volume of the acetate Ringer's solution containing 1% glucose is 1500ml (containing 15g of glucose)
3127309|NCT01706328|Experimental|FF/VI Inhalation Powder NDPI|Subjects randomized to the FF/VI 100/25 arm will take an active inhalation of study medication during their morning dosing from their NDPI and will have an inhalation of dummy medication (placebo) as their morning ACCUHALER/DISKUS dose and as their evening dose.
3127310|NCT01706328|Active Comparator|Fluticasone Propionate/Salmeterol Inhalation Powder|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg arm will have an active dose of medication during both their morning and evening treatments from the ACCUHALER/DISKUS and a dummy placebo dose in the morning from their NDPI.
3127311|NCT01706315|Experimental|Cohort 1 - GSK2140944 400 mg|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days
3127312|NCT01706315|Placebo Comparator|Cohort 1 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 BID or matching placebo for approximately 15 days
3215941|NCT01085695|Experimental|2|
3127313|NCT01706315|Experimental|Cohort 2 - GSK2140944 800 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 2 will be decided based on the safety and PK data from six subjects in Cohort 1
3127314|NCT01706315|Placebo Comparator|Cohort 2 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 BID or matching placebo for approximately 15 days
3127315|NCT01706315|Experimental|Cohort 3 - GSK2140944 1500 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 3 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 2
3127316|NCT01706315|Placebo Comparator|Cohort 3 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 bid or matching placebo for approximately 15 days
3127317|NCT01706315|Experimental|Cohort 4 - GSK2140944 2500 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 4 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 3
3127318|NCT01706315|Placebo Comparator|Cohort 4 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 bid or matching placebo for approximately 15 days
3127319|NCT01706315|Experimental|Cohort 5 - GSK2140944 TBD|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) TID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 5 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 4
3127320|NCT01706315|Placebo Comparator|Cohort 5 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 TID or matching placebo for approximately 15 days
3127321|NCT01706315|Experimental|Cohort 6 - GSK2140944 TBD|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) TID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 5 will be decided on the safety data and available PK data from at least 6 subjects dosed at the Cohort 5
3127322|NCT01706315|Placebo Comparator|Cohort 6 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 TID or matching placebo for approximately 15 days
3127323|NCT01706302||Cohort Group|
3127324|NCT01706289||diabetic mellitus screen|
3127325|NCT01706263|Experimental|MAXCLARITY II|MAXCLARITY II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam. Available over-the-counter.
3127326|NCT01706250|Experimental|MAXCLARITY II|MaxClarity II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam. Available over the counter. Each subject applies both arms (MaxClarity II and Proactiv) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
3127327|NCT01706250|Active Comparator|PROACTIV|Proactiv (2.5% BPO) Renewing Cleanser and Repairing Lotion and Revitalizing Toner. Available over the counter. Each subject applies both arms (MaxClarity II and Proactiv) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
3127328|NCT01706237|Experimental|Shield|A shield (similar to a contact lens) is placed on the eye after myopic LASIK procedure.
3127329|NCT01706224||Group A|Subjects in this group will be all physicians actively working at hospital centres in Spain.
3127330|NCT01706224||Group B|Subjects in this group will be all nurses actively working at hospital centres in Spain.
3127331|NCT01706224||Group C|Subjects in this group will be all ancillary nursing professionals actively working at hospital centres in Spain.
3127332|NCT01706224||Group D|Subjects in this group will be all midwives actively working at hospital centres in Spain.
3127333|NCT01706211|Experimental|BRL 49653C|Eligible patients may enter the study at visit 1 according to the inclusion/exclusion criteria. At the screening visit, patients will enter a single blind placebo run-in period to establish baseline characteristics. Patients must have been stable on sulphonylurea therapy for at least 2 months prior to the screening visit to be included. For the duration of the run-in period, patients will receive BRL 49653C placebo in addition to their constant dose of sulphonylurea. Patients eligible to enter the double-blind phase of the study will be randomized in equal numbers at visit 2, to one of two treatment groups (BRL 49653C 2 mg bid. or placebo bid). Patients will then continue to take their study medication arid the constant dose of sulphonylurea through visits 3 to 8 (weeks 4 to 24).
3127334|NCT01706211|Placebo Comparator|placebo|Eligible patients may enter the study at visit 1 according to the inclusion/exclusion criteria. At the screening visit, patients will enter a single blind placebo run-in period to establish baseline characteristics. Patients must have been stable on sulphonylurea therapy for at least 2 months prior to the screening visit to be included. For the duration of the run-in period, patients will receive BRL 49653C placebo in addition to their constant dose of sulphonylurea. Patients eligible to enter the double-blind phase of the study will be randomized in equal numbers at visit 2, to one of two treatment groups (BRL 49653C 2 mg bid. or placebo bid). Patients will then continue to take their study medication arid the constant dose of sulphonylurea through visits 3 to 8 (weeks 4 to 24).
3127335|NCT01706198|Experimental|FF/VI|fluticasone furoate (FF) + vilanterol (VI) once daily via a Novel Dry Powder Inhaler
3127336|NCT01706198|Active Comparator|ICS or ICS/LABA maintenance therapy|inhaled corticosteroid (ICS) alone or in combination with a long acting beta2-agonist (LABA)
3127337|NCT01706185||Cancer Group|
3127338|NCT01706172|Active Comparator|Dextrose 20 % Injection|Injecting 20 % Dextrose and 0.2 % lidocaine intra-articularly into the TM Joint
3127339|NCT01706172|Active Comparator|Sterile Water Injection|Injection of Sterile water in 0.2 % lidocaine intra-articularly into the TM joint
3127340|NCT01706159|Experimental|rFXIII|
3127341|NCT01706159|Active Comparator|Placebo|
3127342|NCT01706146|Other|Non-Coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
3127385|NCT01705795|Active Comparator|Mepolizumab|Mepolizumab 750 mg four times one month apart.
3127386|NCT01705795|Placebo Comparator|Placebo|Placebo (saline) four times one month apart
3127387|NCT01705782|No Intervention|Saline|Only saline is given.
3127343|NCT01706133|No Intervention|Basal phase|Integrated measurement of all variables involved impact and frequency of prior use of health services and specifically to the emergency room, service access, patient characteristics, features for the classification of frailty, cognitive impairment and depression, why consultation, triage scale level on admission to the service and to the service variables in terms of length of stay, diagnosis and medical management, and related services with internal consultants percentage of inpatients discharged or deceased, in further analysis the researchers undertake group estimating frequency of use and the identification of factors associated with the use of emergency departments and adverse events
3127344|NCT01706120|Other|First-line chemotherapy with bevacizumab|"Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks for up to 22 cycles~Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles~Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles"
3127345|NCT01706094|Experimental|lying flat head position|positioning the head of the bed at zero degrees during the first 48 hours from admission of patients with acute ischemic stroke Active Comparator: upright position of the head of the bed during 48 hours from admission of patients with acute ischemic stroke
3127346|NCT01706081|Experimental|Acupuncture|Patients in the acupuncture group will receive acupuncture treatment twice weekly for six consecutive weeks.
3127347|NCT01706081|Experimental|Wait-list|Patients in the wait-list control group will cross over and receive acupuncture twice weekly for 6 consecutive weeks.
3127348|NCT01706055||Group 1|
3127349|NCT01706042|Placebo Comparator|white bread|White bread (based on 35 g available carbohydrates)
3127350|NCT01706042|Active Comparator|Legume meal|Legumes are consumed as a late evening meal(based on 35 g available carbohydrates)
3127351|NCT01706016|Experimental|Patients with breast cancer smaller than 20mm|
3127352|NCT01706003||Migraine Headaches|People who suffer from Migraine Headaches who own a computer and have internet access
3127353|NCT01705990|Experimental|Group A: SeV-G(NP) followed by Ad35-GRIN|SeV-G(NP) (IN) at 2x10^7 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)
3127354|NCT01705990|Experimental|Group B: SeV-G(NP) followed by Ad35-GRIN|SeV-G(NP) (IN) at 2x10^8 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)
3127355|NCT01705990|Experimental|Group C: Ad35-GRIN followed by SeV-G(NP)|Ad35-GRIN (IM) at 1x10^10 vp at Month 0 followed by SeV-G(NP) (IN) at 2x10^8 CIU at Month 4. (Vaccine/Placebo = 12/4)
3127356|NCT01705990|Experimental|Group D: SeV-G(NP) only|SeV-G(NP) (IN) at 2x10^8 CIU at Month 0 and 4. (Vaccine/Placebo = 12/4)
3127357|NCT01705977|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period.
3127358|NCT01705977|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period.
3127359|NCT01705964|Experimental|IM epinephrine 1:1000|IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
3127360|NCT01705964|Sham Comparator|No intervention|A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
3127361|NCT01705951|Experimental|Group 1: Resistance Training/Nicotine Replacement|
3127362|NCT01705951|Experimental|Group 2: Resistance Training only|
3127363|NCT01705951|Experimental|Group 3: Nicotine Replacement Therapy only|
3127364|NCT01705951|No Intervention|Group 4: Control; no RT and no NRT|
3127365|NCT01705938|Active Comparator|Group 1|SP-333 0.1 mg & Placebo, one tablet by mouth, single dose
3127366|NCT01705938|Active Comparator|Group 2|SP-333 0.3 mg & Placebo, 3 tablets by mouth, single dose
3127367|NCT01705938|Active Comparator|Group 3|SP-333 1 mg & Placebo, one tablet by mouth, single dose
3127368|NCT01705938|Active Comparator|Group 4|SP-333 3 mg & Placebo, 3 tablets by mouth,single dose
3127369|NCT01705938|Active Comparator|Group 5|SP-333 10 mg & Placebo, 1 tablet by mouth, single dose
3127370|NCT01705938|Active Comparator|Group 6|SP-333 30 mg & Placebo, 3 tablets by mouth, single dose
3127371|NCT01705938|Active Comparator|Group 7|SP-333 60 mg & Placebo, 6 tablets by mouth, single dose
3127372|NCT01705912|Experimental|Training|Complete intervention i.e. basic intervention + individual training program.
3127373|NCT01705912|Active Comparator|Control|Basic intervention.
3127374|NCT01705899|Experimental|Subjects with preserved kidney function|Subjects with preserved renal function that have not previously received a kidney transplant will be treated with Human Pancreatic Islets (in the form of islets alone - IA).
3127375|NCT01705899|Experimental|Subjects with prior kidney transplant|Subjects with renal failure secondary to diabetes who have received a prior kidney transplant at least 6 months previously and have stable renal function on a steroid-free immunosuppressive regimen will receive Human Pancreatic Islets (in the form of islets after kidney - IAK).
3127376|NCT01705886||Knee Arthroplasty|"Patients undergoing knee replacement surgery. This may be a Total Knee Arthroplasty or MAKO® Robot Assisted Medial Knee Arthroplasty.~The MAKO® Robot Assisted surgeries use the RESTORIS Multicompartmental Knee System.~The total knee arthroplasty uses the Depuy Knee Replacement System or the Stryker® Knee Replacement System."
3127377|NCT01705873||LPV/r|LPV/r based HAART
3127378|NCT01705873||Efavirenz|EFV first line based HAART
3127379|NCT01705860||Assessment|All subjects will receive same assessments.
3127380|NCT01705847|Experimental|GS-9820|Participants will be sequentially enrolled at progressively higher dose levels to receive GS-9820 administered twice a day. Escalation will proceed to the maximum tolerated dose (MTD), defined as the highest tested dose associated with a rate of dose-limiting toxicities (DLT) of < 33% during the first 4 weeks of therapy.
3127381|NCT01705834||Arthritis patients|Patients with Rheumatoid Arthritis
3127382|NCT01705821||Skull Base Surgery Candidate|Patient with a skull base lesion will undergo use of standard surgical curette with force sensor built into shaft. 6-axis force and torque data will be collected during the surgical procedure.
3127383|NCT01705808|Experimental|Protein C concentrate|
3127384|NCT01705808|Placebo Comparator|Placebo|
3127388|NCT01705782|Placebo Comparator|+ Saline|Endotoxin is given + Placebo (Saline)
3127389|NCT01705782|Active Comparator|+ amino acids|Endotoxin is given + amino acids (intravenously)
3127390|NCT01705769|Experimental|RUTF-Centrally produced|Ready to Use Therapeutic Food-Centrally produced by an Indian company
3127391|NCT01705769|Experimental|RUTF-Locally produced|Ready to Use Therapeutic Food-Locally produced by the study team at each study site
3127392|NCT01705769|Active Comparator|High energy and micronutrient rich foods|High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
3127393|NCT01705756|Placebo Comparator|Vehicle|•Patients randomized to placebo will receive syringes identical to active drug (100 mg prefilled syringes for subcutaneous injection) filled with drug vehicle
3127394|NCT01705756|Experimental|Kineret (Anakinra)|Patients randomized to active drug will receive Kineret (Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
3127395|NCT01705743|Active Comparator|Group 1 Sevoflurane+Nitrous oxide|
3127396|NCT01705743|Active Comparator|Group 2 Sevoflurane|
3127397|NCT01705730||Cohort|
3127398|NCT01705717||cohort|
3127399|NCT01705704||Cohort|
3127400|NCT01705691|Active Comparator|Arm 1: Paclitaxel then AC|Paclitaxel 80 mg/m2 IV weekly for 12 doses followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles
3127401|NCT01705691|Experimental|Arm 2: Eribulin then AC|Eribulin 1.4 mg/m2 IV on days 1 and 8 of a 21-day cycle for 4 cycles, followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles
3127402|NCT01705678|Active Comparator|Krill oil|Krill oil will be compared to fish oil as an active comparator
3127403|NCT01705678|Active Comparator|Fish oil|Fish oil 500 mg of DHA/EPA
3127404|NCT01705665||Aspirated Coronary Thrombi During AMI|
3127405|NCT01705652|Experimental|Nexrutine Surgery Group|Surgery Group: Nexrutine 500mg by mouth, three times per day, given prior to surgery.
3127406|NCT01705652|Experimental|Nexrutine Radiation Group|Radiation Group: Nexrutine 500mg by mouth, three times per day, given prior to and during radiation treatment.
3127407|NCT01705639|Experimental|Melatonin|melatonin 4mg od for 3 months
3127408|NCT01705626||Observation|all adult patients at 18 years with small fiber polyneuropathy of undetermined etiology based on the normal results of laboratory data (CRP, glucose, electrolytes, urea, transaminases, TSH, immunoglobulins, vitamin B12, RF, ANA, antibodies against Lyme borrelia ; no anamnesis for carcinoma, no continuous alcohol consumption; no light-chain-amyloidosis; no anamnesis for heavy metal exposure
3127409|NCT01705600|Experimental|Pain Verbalization Repression Rules|This group will wear a bracelet with a set of rules which will restrict ones verbalization of pain complaints
3127410|NCT01705587|Experimental|Immediate teriparatide|Open label teriparatide given immediately following surgical repair of fracture
3127411|NCT01705587|Experimental|Delayed teriparatide|Open label teriparatide given six months following surgical repair of fracture
3127412|NCT01705574|Experimental|E/C/F/TDF|E/C/F/TDF + ATV placebo + RTV placebo + FTC/TDF placebo
3127413|NCT01705574|Active Comparator|ATV+RTV+FTC/TDF|ATV+RTV+FTC/TDF + E/C/F/TDF placebo
3127414|NCT01705574|Experimental|Open-Label Extension|Participants randomized to the E/C/F/TDF arm will continue to receive open-label E/C/F/TDF and participants randomized to the ATV+RTV+FTC/TDF arm will be rerandomized to receive elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or ATV+RTV+FTC/TDF.
3127415|NCT01705548|Experimental|Hypofractionated Radiosurgery|"HR (Hypofractionated Radiosurgery) delivered in 5 fractions, with a minimum of 2 and a maximum of 3 fractions being delivered per week, to patients with brain metastases or resection cavity greater than 3 cm and less than 6 cm.~Dose escalation will proceed according to the Escalation with Overdose Control (EWOC) method with a planned total enrollment of 24 patients, in 8 patient cohorts with 3 patients per cohort. A 4 month observation period will occur for each completed cohort prior to dose escalation, with a goal timeline for trial completion of 4 years from first patient enrollment."
3127416|NCT01705535|Experimental|Pelvic floor muscle exercises|Individual supervised pelvic floor muscle exercises. Standard information and guidance
3127417|NCT01705535|Active Comparator|Masage of the neck and back|Massage of the neck and back. Standard information and guidance
3127418|NCT01705522||IBD patients|patients with ulcerative colitis or crohn's disease, in remission
3127419|NCT01705509|Other|Ranolazine Treatment Arm|All patients who meet the criteria of ischemia will receive ranolazine after enrollment. The initial CPET will serve as the control. The second CPET after 30-days of therapy will serve as the therapy arm. CPET parameters will be assessed and compared both on and off therapy.
3127420|NCT01705496|Experimental|[124I]FIAU|Single dose study of [124I]FIAU in patients presenting with pain in a prosthetic knee or hip joint who will undergo PET-CT scanning.
3127421|NCT01705483|Experimental|Part 1: ASP9853 with docetaxel|2 docetaxel dose levels and starting dose of ASP9853 followed by escalation of ASP9853 with additional dose cohorts
3127422|NCT01705483|Experimental|Part 2: ASP9853 with paclitaxel|Starting dose for ASP9853 determined as one dose level below maximum tolerated dose (MTD) determined in Part 1, 2 paclitaxel dose levels and starting dose of ASP9853 followed by escalation of ASP9853 with additional dose cohorts
3127423|NCT01705470|Experimental|arm1|will receive 60 mg (6 ml) of intra-venous furosemide before administration of the blood transfusion (250-300 ml of packed cells).
3127424|NCT01705470|Experimental|arm2|will receive 6 ml of normal saline (NaCl 0.9%) before administration of the blood transfusion (250-300 ml of packed cells).
3127425|NCT01705457|Active Comparator|with Multiple Sclerosis, vitamin A|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type
3127426|NCT01705457|Placebo Comparator|with multiple sclerosis,placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type
3127427|NCT01705444|Other|Foley catheter and The Spanner Insertion|Quality of life questionnaire after using the Foley catheter and the Spanner
3127428|NCT01705431|Experimental|Support for students with EBD|
3127429|NCT01705431|No Intervention|Control|Participants continue with services as usual
3127430|NCT01705405|Experimental|medical device|medical device to acquire ultrasound and endoscopic images during surgery
3130072|NCT01687374|Experimental|Parathyroid hormone|
3127431|NCT01705392|Experimental|Bevacizumab plus propranolol|Bevacizumab 10mg/kg q2w plus propranolol 80 mg x 1
3127432|NCT01705392|Experimental|Bevacizumab plus enalapril|Bevacizumab 10mg/kg q2w plus enalapril 5 mg x 1
3127433|NCT01705392|Active Comparator|Dacarbazine|Dacarbazine 1000mg/m2 q3w
3127434|NCT01705379||MenACWY-CRM|2 years of age and older
3127435|NCT01705366||Knee Arthroplasty|"Patients undergoing total knee arthroplasty. This may be Non-MAKO® Robot Assisted Total Knee Arthroplasty or MAKO® Robot Assisted Medial Knee Arthroplasty or MAKO® Robot Assisted Medial and PF Knee Arthroplasty~The Non-MAKO® Robot Assisted Total Knee Arthroplasty uses the Depuy Knee Replacement System or the Stryker® Knee Replacement System. The MAKO® Robot Assisted Arthroplasty uses the RESTORIS Multicompartmental Knee System ."
3127436|NCT01705340|Experimental|Treatment (MK2206, lapatinib ditosylate, trastuzumab)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15; lapatinib ditosylate PO QD on days 1-21 or on days 1-3, 8-10, and 15-17; and trastuzumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3127437|NCT01705327||Parkinson's Disease Subjects|
3127438|NCT01705327||Healthy Control Subjects|
3127439|NCT01705314|Experimental|vitamin D supplements|children and adolescents that are randomized to the intervention will receive 7 mls of D-drops (14,000U/week of vitamin D) for eight months
3127440|NCT01705314|Placebo Comparator|vitamin D placebo|children and adolescents that are randomized to placebo will receive 7 mls of placebo drops for eight months
3127441|NCT01705301||Deep Brain Stimulation|Patient's undergoing the clinical procedure of Deep Brain Stimulation will have the experimental protocol that involves, after implantation of the DBS electrodes, a single electrochemical recording electrode, from the WINCS system, implanted along the same trajectory path as the electrophysiology and the DBS electrode
3127442|NCT01705288|Active Comparator|Control Group (Standard Laparotomy)|Patients undergoing standard anesthesia and standard exploratory laparotomy. Treatment will be per your surgeon's routine standards.
3127443|NCT01705288|Experimental|Rapid Recovery Group|"Protocol for rapid recovery laparotomy procedure involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), post-operative use of non-steroidal anti-inflammatory drugs, early eating after surgery, early walking, and certain goals for discharge from the hospital."
3127444|NCT01705275|Experimental|ONO-8539 BID|ONO-8539
3127445|NCT01705275|Placebo Comparator|Placebo BID|0mg
3127446|NCT01705262||u-65 M|Male patients under 65
3127447|NCT01705262||u-65 K|Female patients under 65 years old
3127448|NCT01705262||o-65 -K|Female patients over 65 years
3127449|NCT01705262||O-65 M|Male patients over 65 years
3127450|NCT01705249|Experimental|estradiol / norethisterone acetate|
3127451|NCT01705236|Other|longitudinal assessment|additional OCT assessments
3127452|NCT01705223|Experimental|group A|DNA vaccine prime at week 0,4,8 and rTV boost at week 16
3127453|NCT01705223|Experimental|group B|DNA vaccine prime at week 0,4,8 and rTV boost at week 24
3127454|NCT01705223|Experimental|group C|DNA vaccine prime at week 0,4,8 and rTV boost at week 32
3127455|NCT01705223|Experimental|group D|DNA vaccine prime with the addition of electroporation at week 0, 4, 8 and rTV boost at week 24
3127456|NCT01705210||Diabetes mellitus type 2 (DM2)|
3127457|NCT01705210||metabolic syndrome (MetS)|
3127458|NCT01705210||healthy controls|
3127459|NCT01705197|Active Comparator|Avanfil 100 or 200mg|All subjects, who are judged to be suitable to the clinical trial after 4-week free run-in period was completed, should be administered with Avanafil 100mg(study group) or placebo 100mg(control group) for the first 4 weeks after randomization. When there are no moderate to severe adverse events at the 4 weeks evaluation after administration, and when it is decided by the researcher that the effect of Avanafil or placebo 100mg against erectile dysfunction is insufficient, a dosage increase to 200mg is executed. For subjects with a sufficient improvement effect on ED at 100mg, no dosage increase is allowed, and the previous 100mg administration should be maintained until the termination of the study.
3127460|NCT01705197|Placebo Comparator|Placebo 100mg or 200mg|When there are no moderate to severe adverse events at the 4 weeks evaluation after administration, and when it is decided by the researcher that the effect of Avanafil or placebo 100mg against erectile dysfunction is insufficient, a dosage increase to 200mg is executed.
3127461|NCT01705184|Experimental|BUCiL|"Sequence 1 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab if disease control. If progression --> Sequence 2~Sequence 2 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab-pemetrexed if disease control"
3127462|NCT01705171||IBS patients with fructose intolerance|analysis of biopsies
3127463|NCT01705171||Control group: no IBS or fructose intolerance|analysis of biopsies
3127464|NCT01705158|Experimental|carboplatin and liposomal doxorubicin|carboplatin and liposomal doxorubicin in ovarian cancer in realapse
3127465|NCT01705145|Experimental|Ivacaftor|"Part A: Ivacaftor 50 milligram (mg) (for participants weighing less than [<] 14 kilograms [kg]) or 75 mg (for participants weighing greater than or equal to [>=] 14 kg) every 12 hours (q12h) from Day 1 through Day 3 and 1 morning dose on Day 4 during Part A of the study..~Part B: Ivacaftor 50 mg (for participants weighing <14 kg) or 75 mg (for participants weighing >=14 kg) q12h for 24 weeks during Part B of the study."
3127466|NCT01705119|Experimental|Mechanically Ventilated|
3127467|NCT01705106|Experimental|Treatment (capecitabine, celecoxib)|Patients receive celecoxib PO BID for 7 days (course 0) and then on days 1-21 of course 1 and all subsequent courses. Patients also receive capecitabine PO BID on days 1-14 beginning in course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3127468|NCT01705093|Experimental|Flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
3127469|NCT01705093|Placebo Comparator|macronutrient- matched control powder|50g macronutrient-matched control powder that will lack strawberry flavonoids
3127502|NCT01704898|Other|Stocrin 600 Reference-Efavirenz 600 Test|Stocrin 600 mg will be randomly assigned.
3127503|NCT01704885|Sham Comparator|Active Control Group|Children in the active control group will play with puzzles, a building toy, or color. The play facilitator will praise the child and interact at a similar rate to control for interaction with a caring adult.
3215942|NCT01085695|Experimental|3|
3127470|NCT01705080||A - EnligHTN for Severe Resistant HTN|"Office systolic Blood Pressure ≥160 mmHg~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~Patient has an estimated GFR ≥45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula"
3127471|NCT01705080||B - EnligHTN for Resistant HTN|"Office systolic Blood Pressure ≥140 mmHg~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~Patient has an estimated GFR ≥45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula"
3127472|NCT01705080||C - EnligHTN for Resistant HTN & CKD|"Office systolic Blood Pressure ≥140 mmHg~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~Patient has an estimated ≥15 GFR <45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula"
3127473|NCT01705067|Other|Journey II BCS TKA|Subjects having TKA with Journey II BCS Total Knee System
3127474|NCT01705054||Outpatient Coronary Artery Disease Patient|CAD patients being seen in a participating cardiology office for a scheduled clinic visit who agree to take the survey.
3127475|NCT01705041|Experimental|Diagnostics for All liver function test (LFT)|HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
3127476|NCT01705015|Experimental|UCFit plus direct feedback about exercise|Subjects assigned to higher feedback will be encouraged to look at the summary of daily data about pedaling and will be encouraged to progress activity - more repetitions per minute (RPM range from 10-60), more frequent sessions (up to 3 times daily), longer sessions (from 5-20 minutes), and exertion against larger forces (no resistance, mild, moderate) for the legs. These subjects will also be encouraged to carry out pedaling with the upper extremities once a day, if the arms are free of lines that could be damaged. Progression of leg exercises would be within the capability and motivation of each subject, but would not exceed increments of 10% from one day to the next in any one of these parameters. Graphical displays that can be used for feedback will be available at the patient's bedside. The staff, patient and family will be able to view these bar graphs.
3127477|NCT01705015|Placebo Comparator|UCFit plus encouraged exercise|These subjects will receive a graph of the total number of minutes cycled each day and the average RPMs. The coordinator will only encourage these subjects to try to increase their total cycling time. These bar graphs will not be posted, but will be left by the bedside.
3127478|NCT01705002|Experimental|Cohort A: Promitil 0.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
3127479|NCT01705002|Experimental|Cohort B: Promitil 1.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
3127480|NCT01705002|Experimental|Cohort C: Promitil 1.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
3127481|NCT01705002|Experimental|Cohort D: Promitil 2.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
3127482|NCT01705002|Experimental|Cohort E: Promitil 2.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
3127483|NCT01705002|Experimental|Cohort F: Promitil 3.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
3127484|NCT01705002|Experimental|Cohort G: Promitil 3.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
3127485|NCT01705002|Experimental|Cohort H: Promitil 4.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
3127486|NCT01705002|Experimental|Expanded Cohort|"Patients treated with the selected RP2D of PROMITIL (3 mg/kg) intravenously administered on their first cycle and reduced dose of 2 mg/kg from cycle 2 and onwards.~Only for mCRC patients."
3127487|NCT01705002|Experimental|Combination Cohort|"Patients treated with one cycle of 2.5mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21 followed by two cycles of 2.0 mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21, at four-week intervals.~Only for mCRC patients."
3127488|NCT01705002|Experimental|Triple combination Cohort|"Patients treated with one cycle of 2mg/kg Promitil I.v and 5 mg/kg Bevacizumab i.v on day 1 together with Capecitabine 1,000 mg bid p.o days 1-14 at four-week intervals.~Only for mCRC patients."
3127489|NCT01705002|Experimental|3 Weekly Cohort|"Patients treated with one cycle of 2mg/kg Promitil I.v and 7.5 mg/kg Bevacizumab i.v on day 1 together at three-week intervals.~Only for mCRC patients."
3127490|NCT01704989|Active Comparator|Laser pathway|Arm in which patients first randomised to receive SLT laser
3127491|NCT01704989|Active Comparator|Topical therapy|Arm in which patients first selected to receive drops (Prostagladin analogue as first-line)
3127492|NCT01704976|Experimental|Intervention|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (5 Hz, noise 4) - T1
3127493|NCT01704976|Sham Comparator|Sham group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (1 Hz, noise 1) - T1
3127494|NCT01704963|Experimental|PCI-32765|Patients will receive oral doses of PCI-32765 in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be given before administration of daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
3127495|NCT01704937|Experimental|Colonoscopy|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via colonoscopy"
3127496|NCT01704937|Experimental|Nasogastric Tube (NGT)|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via NGT"
3127497|NCT01704924|Active Comparator|Prevena|Incision with prevena device overlying
3127498|NCT01704924|Active Comparator|Standard of Care dressing|Prevena device is not used
3127499|NCT01704911|Experimental|Transradial Coronary Intervention|Transradial Coronary Intervention
3127500|NCT01704911|Experimental|Transfemoral Coronary Intervention|Transfemoral Coronary Intervention
3127501|NCT01704898|Other|Efavirenz 600 Test-Stocrin 600 Reference|Efavirenz 600 mg will be randomly assigned.
3127504|NCT01704885|Experimental|Play Intervention|"children in the play intervention group will be given 3 story stems that they are asked to play out with the goal of helping the main character feel better (see session scripts). The play facilitator will play with the child, modeling and praising use of positive coping skills. In the first session the play facilitator will focus on positive self-statements, in the second session the play facilitator will focus on problem-solving, and a combination of these two approaches will be used in the final session. The child will be allowed to make up a story about whatever they want before ending each session."
3127505|NCT01704872|Experimental|dose level finding ch14.18/CHO|A dose escalation design based on Phase I rules starting at 10 mg/m2/day ch14.18/CHO. This is 50% below the dose of ch14.18/SP2/0 used in a large cohort of patients. Dose escalation will be adapted to a modified Fibonacci series aiming at 10, 20 and 30 mg/m2 of ch14.18/CHO. Since this study is a bridging study aiming at a reassessment of the toxicity and determination of the pharmacokinetics of ch14.18/CHO, only a limited number of dose escalation steps (3) is implemented in the design.
3127506|NCT01704859|Placebo Comparator|Vitamin D placebo + fish oil placebo|
3127507|NCT01704859|Active Comparator|Vitamin D placebo + fish oil|
3127508|NCT01704859|Active Comparator|Vitamin D + fish oil placebo|
3127509|NCT01704859|Active Comparator|Vitamin D + fish oil|
3127510|NCT01704846|Experimental|Treatment sequence 1|Test - Reference - Reference - Test
3127511|NCT01704846|Experimental|Treatment sequence 2|Reference - Test - Test - Reference
3127512|NCT01704833|Experimental|Cognitive Behavioral Therapy|This group receives 15 weeks of Paranoia-Focused Cognitive Behavioral Therapy (PFCBT) in addition to standard care.
3127513|NCT01704833|No Intervention|Treatment as Usual|This group receives standard care only.
3127514|NCT01704820|Experimental|Retroflexion arm|Retroflexion arm: retroflexion in the cecum or proximal ascending colon and slow withdrawal to the hepatic flexure with removal of all visible colon polyps
3127515|NCT01704820|Placebo Comparator|Forward view arm|Colonoscope is slowly withdrawn from the proximal colon to the hepatic flexure and all visible colon polyps are removed.
3127516|NCT01704807|Active Comparator|Intervention, Custom Orthotics|Wearing custom foot orthotics
3127517|NCT01704807|Sham Comparator|Sham Foot Orthotic|Wearing sham or flat shoe insoles
3127518|NCT01704794|Active Comparator|Folic Acid + Paludrine +Jobelyn (500mg)|Folic acid 5mg given twice daily. Paludrine 50mg to 20mg daily. Jobelyn 500mg once daily.
3127519|NCT01704794|Active Comparator|Folic Acid + Paludrine +Jobelyn (250mg.)|Folic Acid 5mg daily Paludrine 20 - 40mg daily Jobelyn 250mg daily
3127520|NCT01704794|Active Comparator|Folic Acid + Paludrine + Jobelyn (2mg)|Folic Acid 5mg daily Paludrine 20 - 40mg daily Jobelyn 2mg daily
3127521|NCT01704781|Experimental|Part A: lenalidomide dose escalation|"All patient receive intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide in a dose escalation (3+3) design.~Dose level -1: 2.5 mg Lenalidomide (CC-5013) in the event Dose level 1 is non tolerated dose (NTD) Dose level 1(start): 5 mg Lenalidomide (CC-5013) Dose level 2: 10 mg Lenalidomide (CC-5013) Dose level 3: 25 mg Lenalidomide (CC-5013)"
3127522|NCT01704781|Experimental|Part B: lenalidomide|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) & lenalidomide (dose determined in Part A) two days prior to and at the day of immunization.
3127523|NCT01704781|Placebo Comparator|Part B: lenalidomide placebo|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) & lenalidomide placebo two days prior to and at the day of immunization.
3127524|NCT01704768|Experimental|COPE/Healthy Lifestyles TEEN Program|COPE is a manualized 15-session educational and cognitive-behavioral skills building program guided by Cognitive Behavioral Theory with physical activity as a component of each session.
3127525|NCT01704768|Placebo Comparator|Healthy Teens Attention Control Program|Healthy Teens is an attention control program that controls for the time spent with the adolescents in the COPE group is essential to determining the efficacy of the experimental program.
3127526|NCT01704755|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
3127527|NCT01704755|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 24 weeks
3127528|NCT01704742||No treatment|
3127529|NCT01704729|Other|group2|Cycloplegic subjective refraction by an experienced optometrist or ophthalmologist
3127530|NCT01704729|Other|group3|"Cycloplegic subjective refraction by a vision technician trained in the Zhongshan Ophthalmic Center's Rural Refractionist Program"
3127531|NCT01704729|Other|group4|Cycloplegic subjective refraction by an experienced optometrist or ophthalmologist
3127532|NCT01704729|Other|group1|Non-cycloplegic self-refraction using First Generation, Child-Specific fluid-filled adjustable spectacles and updated self-refraction protocol
3127533|NCT01704716|Experimental|R0: COJEC plus G-CSF|Patients randomised to G-CSF during induction treatment (Rapid COJEC) received a single daily subcutaneous injection of 5 microgram/kg/day G-CSF (filgrastim) beginning 24 hours after the last chemotherapy dose.
3127534|NCT01704716|Active Comparator|R0: COJEC|Induction treatment (COJEC) without filgrastim Patients randomised to Rapid COJEC alone will receive induction Treatment without G-CSF
3127535|NCT01704716|Active Comparator|R1: BuMel MAT|"The BuMel MAT regimen consists of oral administration of busulphan and the short i.v. infusion of melphalan.~In July 2007 (amendment 3) oral busulfan was changed to i.v. Busulfan (Busilvex)"
3127536|NCT01704716|Experimental|R1: CEM MAT|The CEM MAT regimen uses three drugs: the dose of Carboplatin must be based on renal function with a target area under the concentration versus time curve (AUC) of 16.4 mg/ml.min, etoposide 350 mg/m2/course and melphalan 210 mg/m2/course
3127537|NCT01704716|Active Comparator|R2: ch14.18/CHO|ch14.18/CHO is given at a dose of 20 mg/m2/day over five days every four weeks for five courses
3127538|NCT01704716|Experimental|R2: ch14.18/CHO plus Aldesleukin|Patients randomised to receive ch14.18/CHO plus Aldesleukin
3127633|NCT01704131||children > 6 months|children > 6 months of age
3127634|NCT01704131||children < 6 months|children < 6 months
3127539|NCT01704716|Active Comparator|R3: COJEC Induction|"Rapid COJEC induction treatment is applied over ten weeks; three different courses are given every ten days:~Course A (given on days 0 and 40): vincristine, carboplatin, and etoposide Course B (given on days 10, 30, 50, and 70): vincristine and cisplatin Course C (given on days 20 and 60): vincristine, etoposide, and cyclophosphamide"
3127540|NCT01704716|Experimental|R3: Modified N7|The modified N7 induction is a dose intense induction chemotherapy regimen including two putatively non cross-resistent drug combinations: high-dose cyclophosphamide plus doxorubicin/vincristine (CAV) and high-dose cisplatin/etoposide (P/E).
3127541|NCT01704716|Active Comparator|R4: cnt inf ch14.18/CHO|ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO
3127542|NCT01704716|Experimental|R4: cnt inf ch14.18/CHO plus Aldesleukin|"ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO.~In addition, Aldesleukin is given at a dose of 3 x 10e6 on days 1 to 5 and on days 9, 11, 13, 15, and 17 during ch14.18/CHO infusion"
3127543|NCT01704703|Experimental|Experimental|FOLFIRI + panitumumab
3127544|NCT01704690|Experimental|S-1 and Paclitaxel|Patients in these arm will receive combination treatment of S-1 and paclitaxel. S-1, 80-120mg po, bid, from day 1 to day 14 Paclitaxel, 175mg/m2, IV infusion on day 1 Repeated every 21 days
3127545|NCT01704690|Active Comparator|Paclitaxel and Cisplatin|"Patients in these arm will receive combination treatment of paclitaxel and cisplatin.~Paclitaxel, 175mg/m2, IV infusion on day 1 Cisplatin, 30 mg/m2, IV infusion on day 1 and day 2 Repeated every 21 days"
3127546|NCT01704690|Active Comparator|5-FU and Cisplatin|Patients in these arm will receive combination treatment of 5-FU and cisplatin. 5-FU, 2500mg/m2, continue iv infusion for 120 hours Cisplatin, 35 mg/m2, IV infusion on day 1 and day 2 Repeated every 21 days
3127547|NCT01704677|Experimental|Surgery|Replacement of the degenerative intervertebral lumbar disc with an artificial lumbar disc device (degeneration had to be restricted to the two lower levels (L4/L5 and/or L5/S1))
3127548|NCT01704677|Active Comparator|Multidiciplinary rehabilitation|
3127549|NCT01704664|Active Comparator|I - Nutritional therapy only during the postoperative period.|Postoperative nutritional therapy administered in group I will not include immunomodulating factors. Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb), starts 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will be increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition will be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
3127550|NCT01704664|Active Comparator|II - parenteral glutamine in postoperative time|The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
3127551|NCT01704664|Active Comparator|III - perioperative oral immunonutrition|Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they will be administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will be increased gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
3127552|NCT01704664|Active Comparator|IV - Perioperative parenteral immunonutrition|Nutritional therapy of group IV will be based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids will be administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will be started at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition will be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
3127553|NCT01704651|Experimental|Alvimopan|Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative. Drug was continued for duration of hospital stay, but did not exceed 7 days.
3127554|NCT01704651|Placebo Comparator|Placebo|Perioperative administration of placebo, at same dosing interval as study drug.
3127555|NCT01704638|Experimental|2677TT|Plasma kinetics of fluvoxamine and digoxin in this genotype
3127556|NCT01704638|Other|2677GG|plasma kinetics of fluvoxamine and digoxin in this genotype
3127557|NCT01704625|Experimental|Osteopathic Manipulative Treatment|The osteopathic treatment group will have performed on them 3 standardized osteopathic manipulative treatments. If at any time the patient is unable to tolerate a treatment secondary to pain that particular study will be stopped. If the patient's nurse enters the room with medication, the study will be stopped and patient will not be included in the study. At no time will the patient's medical treatment in the emergency department be delayed to perform OMT
3127558|NCT01704625|Sham Comparator|Sham Osteopathic Manipulative Treatment|The sham group will receive 3 sham treatments. If at any time the patient is unable to tolerate a treatment secondary to pain that particular study will be stopped. If the patient's nurse enters the room with medication, the study will be stopped and patient will not be included in the study. At no time will the patient's medical treatment in the emergency department be delayed to perform OMT.
3127559|NCT01704612|Active Comparator|Diabete group|Patient with type 2 diabete received 20 mL ropivacaine
3127560|NCT01704612|Sham Comparator|Control group|no diabete reveived 20 mL ropivacaine
3215943|NCT01085695|Active Comparator|4|
3127561|NCT01704599|Experimental|Humira then Humira plus 3 B vitamins|"Humira then Humira plus 3 B vitamins~The only arm: After 16 weeks on adalimumab, modulators of homocysteine (oral vitamin B12, oral vitamin B6 or pyridoxine, and oral folic acid) will be added to adalimumab therapy for an additional 12 weeks. At end of this therapy can stop or continue. Telephone call day 70 after formal end of in person study the investigators will assess general health of each subject."
3127562|NCT01704586|Active Comparator|Radioiodine|Standard procedures using only I-131. All patients in this arm will have assigned I-131 ablation, followed by periodic I-131 diagnostic re-evaluations after 4-6 months as needed.
3127563|NCT01704586|Active Comparator|I-124|I-124 PET/CT guided concept following ATA guideline recommendations after total thyroidectomy. Uptake outside of thyroid bed constitutes I-131 therapy for remnant ablation and metastasis therapy based on I-124 dosimetry. Remnant mass and/or metastasis mass will be estimated by a diagnostic CT scan simultaneously while doing PET at the optimum time point 2-3 days after administration of I-124. If there is no uptake outside of thyroid bed, no ablation will follow in stage I disease according to AJCC with the possibility of lymph node involvement but no distant metastasis and no microscopical residual disease (Patient age <45y: any T, any N, M0; Patient age 45y or older: T1, N0, M0). Periodic follow-up may include I-124 PET/CT when indicated to determine whether or not another I-131 therapy has to follow. Thyroglobuline increase also constitutes I-124 PET/CT imaging.
3127564|NCT01704573||NMR by abstinence status|"This study uses a mixed design with one between-subject factor (NMR: continuous variable) and one within-subject factor (session: 24 hours abstinent vs. smoking as usual) to examine NMR by abstinence status interactions on α4β2* nAChR availability using 2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine (2-[18F]FA) PET imaging.~Subjects will participate in two one-hour PET sessions: a) after smoking as usual (smoking exposure standardized) and b) the other following 24 hours of smoking abstinence.~All participants who complete both PET scans will also complete an anatomical MRI scan."
3127565|NCT01704560|Experimental|Coversheet to Informed Consent|Coversheet attached to Informed Consent.
3127566|NCT01704560|No Intervention|No Coversheet|Standard, full permission form, without the coversheet.
3127567|NCT01704534|Experimental|Ustekinumab|Ustekinumab 45 mg or 90 mg (dependent on patient's weight) administered on weeks 0-4-16-28
3127568|NCT01704521|Active Comparator|Lead-In|Kinetic assessment of response guided treatment per standard of care with PegInterferon + Ribavirin for 4 weeks followed by 12 weeks of PegInterferon + Ribavirin + Telaprevir followed by variable duration of PegInterferon + Ribavirin
3127569|NCT01704521|Active Comparator|No Lead-in|Kinetic assessment of response guided treatment per standard of care with PegInterferon + Ribavirin + Telaprevir for 12 weeks followed by variable duration of PegIntereron + Ribavirin
3127570|NCT01704508|Active Comparator|Artemether-lumefantrine|6-dose regime will be used:
3127571|NCT01704508|Active Comparator|Dihydroartemisinin-piperaquine|A 3 dose regime will be used
3127572|NCT01704495|Experimental|AZD5069 5 mg|AZD5069 oral capsules self-administered twice daily
3127573|NCT01704495|Experimental|AZD5069 15 mg|AZD5069 oral capsules self-administered twice daily
3127574|NCT01704495|Experimental|AZD5069 45 mg|AZD5069 oral capsules self-administered twice daily
3127575|NCT01704495|Placebo Comparator|Placebo|Placebo oral capsules self-administered twice daily
3127576|NCT01704482|Experimental|N-acetylcysteine|N-acetylcysteine bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
3127577|NCT01704482|Placebo Comparator|Glucose 5%|equivalent volume over the same period.
3127578|NCT01704469|Experimental|The local anesthetic injection group|
3127579|NCT01704456|Experimental|Mindfulness-based cognitive therapy (MBCT)|Women in the MBCT Group Treatment arm will receive the treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
3127580|NCT01704456|Experimental|Cognitive Behavioural Therapy (CBT)|Women in the CBT Group Treatment arm will receive the treatment in small group format (8-9 women). Each session will be 2.25 hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
3127581|NCT01704443|Experimental|Immediate treatment|Women in the Immediate treatment arm will receive the Group Psychoeducational treatment in the next available group. There will be 8-9 womenper group and each session will be 2.25 hours in duration and there will be 4, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
3127582|NCT01704443|Experimental|Waitlist Control- delayed treatment|Women in the Waitlist Control arm will receive no treatment for a period of approximately 8 weeks. After the waitlist period they will receive the same Group Psychoeducational treatment as the participants in the immediate treatment arm of the study.
3127583|NCT01704430|Experimental|Glutamine|Oral/enteral glutamine 0.5 g/kg satisfactory body weight per day (divided doses every 8 hours) starting 6 hours post-operatively
3127584|NCT01704430|Placebo Comparator|Maltodextrin|Oral/enteral maltodextrin 0.5 g/kg satisfactory body weight per day (divided doses every 8 hours) starting 6 hours post-operatively
3127585|NCT01704417|Experimental|IDeg followed by IGlar|
3127586|NCT01704417|Experimental|IGlar followed by IDeg|
3127587|NCT01704404|Experimental|Dose 1 TD-4208|22 µg
3127588|NCT01704404|Experimental|Dose 2 TD-4208|44 µg
3127589|NCT01704404|Experimental|Dose 3 TD-4208|88 µg
3127590|NCT01704404|Experimental|Dose 4 TD-4208|175 µg
3127591|NCT01704404|Experimental|Dose 5 TD-4208|350 µg
3127592|NCT01704404|Experimental|Dose 6 TD-4208|700 µg
3127593|NCT01704404|Placebo Comparator|Placebo|Placebo
3127594|NCT01704391||Aortic aneurysm patients|10 patients with a CT verified diagnosis of aortic aneurysm demanding open elective surgical correction with insertion of vascular prosthesis
3127803|NCT01703078|Experimental|Ingenol derivative concentration 2|once daily for two consecutive days
3127595|NCT01704391||Aortic occlusive disease patients|10 patients with CT verified aortic occlusive disease demanding open elective surgical correction with insertion of vascular prosthesis
3127596|NCT01704378|Experimental|BIAsp|
3127597|NCT01704365|Experimental|Group A|Low dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)
3127598|NCT01704365|Experimental|Group B|Low dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)
3127599|NCT01704365|Experimental|Group C|Low dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)
3127600|NCT01704365|Experimental|Group D|Low dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)
3127601|NCT01704365|Experimental|Group E|High dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)
3127602|NCT01704365|Experimental|Group F|High dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)
3127603|NCT01704365|Experimental|Group G|High dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)
3127604|NCT01704365|Experimental|Group H|High dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)
3127605|NCT01704365|Experimental|Group J|Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing] (Day 0 & Day 28)
3127606|NCT01704365|Placebo Comparator|Group K|Placebo (Day 0 and Day 28)
3127607|NCT01704352|Active Comparator|CBT-I|Cognitive behavioral therapy for insomnia (CBT-I) is a multicomponent treatment consisting of sleep restriction therapy, psychoeducation about sleep, stimulus control, stabilizing circadian rhythm and challenging beliefs and perception of sleep.
3127608|NCT01704352|No Intervention|Treatment as usual|Treatment as usual (TAU) consists of pharmacological and supportive psychosocial treatment according to the needs of the patient.
3127609|NCT01704339|Experimental|QUTENZA|Single treatment with QUTENZA (topical capsaicin 8%) transdermal patch
3127610|NCT01704313|Experimental|Interrupted|Interrupted suturing technique used around heel of anastomosis
3127611|NCT01704313|Active Comparator|Continuous|Continuous suturing technique used for the anastomosis
3127612|NCT01704300||CALIBER Healthy Cohort|We will report findings from the CALIBER (CArdiovascular disease research using Linked BEspoke studies and Electronic Records) collaboration where we linked primary care data (from the General Practice Research Database [GPRD]) to three further sources of electronic health records: the Myocardial Ischemia National Audit Project registry (MINAP),cause specific discharge data from Hospital Episodes Statistics (HES) and cause specific mortality from the Office for National Statistics (ONS).
3127613|NCT01704287|Experimental|Pembrolizumab 2 mg/kg|Participants initially received pembrolizumab 2 mg/kg intravenously (IV) Q3W. This dosing was discontinued with Amendment 03. With Amendment 03, all study participants will be treated with fixed-dose pembrolizumab 200 mg IV Q3W.
3127614|NCT01704287|Experimental|Pembrolizumab 10 mg/kg|Participants initially received pembrolizumab 10 mg/kg IV Q3W. This dosing was discontinued with Amendment 03. With Amendment 03, all study participants will be treated with fixed-dose pembrolizumab 200 mg IV Q3W.
3127615|NCT01704287|Active Comparator|Investigator-Choice Chemotherapy (ICC)|Participants received one of four possible chemotherapy regimens decided at the treating institution (carboplatin + paclitaxel, paclitaxel alone, dacarbazine, or temozolomide).
3127616|NCT01704287|Experimental|ICC→Pembrolizumab 2 mg/kg|Participants who were assigned to ICC, experienced confirmed progressive disease (PD) and met all crossover criteria at study treatment Week 12, had the opportunity to switch to receive pembrolizumab 2 mg/kg or 10 mg/kg in a double-blind fashion. Participants who qualified to switch to pembrolizumab, must have completed a washout period of ≥28 days from last dose of chemotherapy before receiving pembrolizumab. Participants received pembrolizumab 2 mg/kg IV Q3W. This dosing was discontinued with Amendment 03. With Amendment 03, all study participants will be treated with fixed-dose pembrolizumab 200 mg IV Q3W.
3127617|NCT01704287|Experimental|ICC→Pembrolizumab 10 mg/kg|Participants who were assigned to ICC, experienced confirmed PD and met all crossover criteria at study treatment Week 12, had the opportunity to switch to receive pembrolizumab 2 mg/kg or 10 mg/kg in a double-blind fashion. Participants who qualified to switch to pembrolizumab, must have completed a washout period of ≥28 days from last dose of chemotherapy before receiving pembrolizumab. Participants received pembrolizumab 10 mg/kg IV Q3W. This dosing was discontinued with Amendment 03. With Amendment 03, all study participants will be treated with fixed-dose pembrolizumab 200 mg IV Q3W.
3127618|NCT01704274|Placebo Comparator|Placebo|Placebo patch
3127619|NCT01704274|Experimental|Low dose GTN 0.0285 mg/hr|Low dose GTN
3127620|NCT01704274|Experimental|High Dose GTN 0.057 mg/hr|High Dose GTN
3127621|NCT01704261|Experimental|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once a week for 24 weeks. Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose >=4 mg per day) and metformin tablet(s) orally once or twice daily (total daily dose >=1500 mg per day).
3127622|NCT01704261|Placebo Comparator|Placebo|Matching placebo to omarigliptin capsule administered orally once a week for 24 weeks. Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose >=4 mg per day) and metformin tablet(s) orally once or twice daily (total daily dose >=1500 mg per day).
3127623|NCT01704248|Placebo Comparator|Routine self-instillation technique|The participants first use the Routine self-instillation technique for two weeks and then switch to the Eye Drop Guide technique for another two weeks.
3127624|NCT01704248|Experimental|Eye Drop Guide technique|The participants first use the Eye Drop Guide technique for two weeks and then switch to the Routine self-instillation technique for another two weeks.
3127625|NCT01704235||Primary health care providers|medical physicians and nurse practitioners
3127626|NCT01704222||Child in nursery|Children older than 3 months and less than 6 years kept in nurseries retained, regardless of the duration of custody of the child in the manger concerned.
3127627|NCT01704209|Experimental|Fibroblast Treatment|The fibroblast treatment will be randomly injected into one side of the face.
3127628|NCT01704209|Placebo Comparator|Vehicle|The vehicle will be injected randomly to the other side of the face.
3127629|NCT01704196|Active Comparator|Nepicastat|Nepicastat 120mg and 100mg riboflavin (once per day) for 11 weeks
3127630|NCT01704196|Placebo Comparator|Placebo|Placebo capsule containing 100mg riboflavin (once per day) for 11 weeks.
3127631|NCT01704170|Experimental|Renal Denervation Using Externally Focused Ultrasound Therapy|
3127632|NCT01704157|Other|Open Treatment|Treatment with Cryo-Touch III Device
3127635|NCT01704118|Experimental|I-gel|I-gel (Intersurgical Ltd, Wokingham, Berkshire, UK) is a disposable supraglottic airway device with a non-inflatable cuff in which part of that is fixed on glottis is made of thermoplastic elastomer, unlike other laryngeal masks
3127636|NCT01704118|Active Comparator|ProSeal Laryngeal mask|ProSeal laryngeal mask (PLMA) (LMA North America, Inc., San Diego, USA) is a modified type of LMA (larger and deeper bowl and enlarged and softer cuff) with gastric drainage tube.
3127637|NCT01704105|Active Comparator|Water Quality|100 clusters, approximately 1,000 newborns
3127638|NCT01704105|Active Comparator|Sanitation|100 clusters, approximately 1,000 newborns
3127639|NCT01704105|Active Comparator|Handwashing|100 clusters, approximately 1,000 newborns
3127640|NCT01704105|Active Comparator|Combined Water, Sanitation, and Handwashing|100 clusters, approximately 1,000 newborns
3127641|NCT01704105|Active Comparator|Nutrition|100 clusters, approximately 1,000 newborns
3127642|NCT01704105|Active Comparator|Nutrition + Combined Water, Sanitation, and Handwashing|100 clusters, approximately 1,000 newborns
3127643|NCT01704105|No Intervention|Active control arm|200 clusters, approximately 2,000 newborns. Village-level promoter will visit household and will strictly engage in recording the child's MUAC, which will also be conducted in all active comparator arms as well.
3127644|NCT01704105|No Intervention|Passive control arm|100 clusters, approximately 1,000 newborns. No intervention.
3127645|NCT01704092||Group High-dose|Dexmedetomidine loading dose 1μg/kg Dexmedetomidine maintenance dose 0.6μg/kg/h
3127646|NCT01704092||Group Low-dose|Dexmedetomidine loading dose 0.6μg/kg Dexmedetomidine maintenance dose 0.3μg/kg/h
3127647|NCT01704092||Group Control|Dexmedetomidine loading dose and Dexmedetomidine maintenance dose were placed with the same amount of 0.9% saline as placebo
3127648|NCT01704079|Active Comparator|CTAP101 30 μg capsules|1 CTAP101 30 μg capsule daily at bedtime for 12 weeks, with a possible increase to 2 CTAP101 30 μg capsules daily at bedtime for study duration, if needed (26 weeks total). Subjects not requiring a dose increase after 12 weeks would receive 1 CTAP101 30 μg capsule and one sugar pill (to CTAP101 30 μg capsule) for weeks 13-26.
3127649|NCT01704079|Placebo Comparator|Sugar pill to CTAP101 30 μg|1 sugar pill to CTAP101 30 μg capsule daily at bedtime for 12 weeks, with an increase to 2 sugar pills to CTAP101 30 μg capsules daily at bedtime for weeks 13-26.
3127650|NCT01704040|Experimental|Part 1: Healthy participants (CNTO 3157 + HRV-16)|
3127651|NCT01704040|Placebo Comparator|Part 1: Healthy participants (placebo + HRV-16)|
3127652|NCT01704040|Experimental|Part 2: Asthmatic patients (CNTO 3157 + HRV-16)|
3127653|NCT01704040|Placebo Comparator|Part 2: Asthmatic patients (placebo + HRV-16)|
3127654|NCT01704027|Experimental|Radiotherapy|Patient will receive a pelvic and prostatic simultaneous integrated boost intensity-modulated arctherapy (SIB-IMAT) in combination with three years of androgen deprivation
3127655|NCT01704014||α1-ARA Group|All patients on α1-ARA(α1-adrenergic receptor antagonists) medication who underwent cataract surgeries.
3127656|NCT01704014||Control Group|Age and sex-matched control subjects
3127657|NCT01704001|Experimental|Renal impairment grade 0|
3127658|NCT01704001|Experimental|Renal impairment grade 1|
3127659|NCT01704001|Experimental|Renal impairment grade 2|
3127660|NCT01704001|Experimental|Renal impairment grade 3|
3127661|NCT01703988|Experimental|Nusinersen 3 mg|3 mg nusinersen on Days 1, 29, 85, intrathecal (IT) injection
3127662|NCT01703988|Experimental|Nusinersen 6 mg|6 mg nusinersen on Days 1, 29, 85, IT injection
3127663|NCT01703988|Experimental|Nusinersen 9 mg|9 mg nusinersen on Days 1 and 85, IT injection
3127664|NCT01703988|Experimental|Nusinersen 12 mg|12 mg nusinersen on Days 1, 29, 85, IT injection
3127665|NCT01703975|No Intervention|Single training|Students training alone on the simulator
3127666|NCT01703975|Experimental|Training in pairs (Dyad Training)|Students training in pairs on the simulator
3127667|NCT01703962||Patients with IDH1 R132H or wild type IDH1/IDH2 glioma|
3127668|NCT01703949|Experimental|Arm A (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3127669|NCT01703949|Experimental|Arm B (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3127670|NCT01703936|Experimental|agricultural training program|Three to four month residential agriculture and life skills training program.
3127671|NCT01703936|No Intervention|Control group|
3127672|NCT01703923|Experimental|FP01 6mg or Placebo|FP01 6mg Oral
3127673|NCT01703923|Experimental|FP01 12mg or Placebo|FP01 12mg Oral
3127674|NCT01703910|Active Comparator|Arm A|Control treatment and will be treated with any of the schemes used in the study according to the discretion of the physician.
3127675|NCT01703910|Experimental|Arm B|Treatment guided by the gene expression profiles obtained from the CTC
3127676|NCT01703897||Obese patients|
3127677|NCT01703884|Experimental|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy women will be systematically evaluated with RDT for whether they have malaria parasites and treated effectively.
3127678|NCT01703884|No Intervention|SP|At ANC and labor wards for women in the control area, there will be no change from routine approaches.
3127679|NCT01703858|Active Comparator|1 BI 113608|powder in the bottle for oral solution, oral administration with 240 mL water
3127680|NCT01703858|Experimental|2 BI 113608|conventional tablet formulation
3127681|NCT01703858|Experimental|3 BI 113608|conventional tablet formulation, fed
3127682|NCT01703858|Experimental|4 BI 113608|conventional tablet after pantoprazole administration
3127683|NCT01703858|Experimental|5 BI 113608|conventional tablet formulation, fasted, 0:30 min before fat breakfast
3127684|NCT01703845|Experimental|Tiotropium + Olodaterol (high dose)|Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT
3127685|NCT01703845|Experimental|Tiotropium + Olodaterol (low dose)|Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT
3127686|NCT01703832|Experimental|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
3127687|NCT01703832|No Intervention|No intervention|no tablet intake and subjects will undergo the natural course
3127688|NCT01703819|Experimental|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
3127689|NCT01703819|Placebo Comparator|Placebo|6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
3127690|NCT01703806||Mitral regurgitation|Asymptomatic patients with severe degenerative mitral regurgitation
3127691|NCT01703793|Placebo Comparator|Vehicle|Vehicle (placebo) treatment, twice a week for four weeks.
3127692|NCT01703793|Experimental|Test Product 10156|Product 10156 treatment, twice a week for four weeks.
3127693|NCT01703793|Experimental|Test Product 49778|Product 49778 treatment, twice a week for four weeks.
3127694|NCT01703780||resistant hypertension|blood pressure remaining above goal (< 140/90 mm Hg for the general population and < 130/80 mm Hg for patients with diabetes or renal disease) despite using optimal doses of 3 antihypertensive agents of different classes(including a diuretic) for half to one year.
3127695|NCT01703780||controllable hypertension|blood pressure can reach 130/80 mm Hg or less in half year by use of optimal dose of less than 3 antihypertensive agents of different classes
3127696|NCT01703780||healthy control|"Age>50 years old~Blood pressure ≤ 120/80 mm Hg( 24-hour blood pressure monitor or home blood pressure measurement at 6-9 am and 5-8pm, twice)~No cardiovascular diseases: coronary artery disease(coronary angiography or CTA), cerebrovascular diseases(history, MRI-Lacunar brain stem), Carotid ultrasound~No peripheral angiopathy (ABI<0.9 or lower extremity vessels Doppler ultrasound)~No major cardiovascular risk factors:~Dyslipidemia~Diabetes~Smoke within one year"
3127697|NCT01703767||Gulf War 1 Veterans|Persian Gulf War 1 Veterans (GW1V) who are currently treated by a primary care physician at the VA Salt Lake City Health Care System. GW1V will assess their primary care satisfaction before and after their providers receive a Provider Education Workshop.
3127698|NCT01703754|Experimental|Ad-RTS-hIL-12 and veledimex|Experimental study drug monotherapy arm (A)
3127699|NCT01703754|Experimental|Ad-RTS-hIL-12 and Palifosfamide|Study drug combination therapy arm (C)
3127700|NCT01703741|Experimental|Testosterone gel (FE 999093)|Subjects received testosterone gel with initial dose as fixed on Day 56 (23 mg, 46 mg or 69 mg) during the 000023 study. The dose could further be down titrated based on serum testosterone levels at Day 90/91 of 000023 study. Testosterone gel was applied daily in morning using an applicator, to the shoulder/upper arm in a contralateral fashion for 6 months.
3127701|NCT01703728||Highly purified menotropin (HP-hMG) treatment|Cohort of women from 18 to 36 years old treated by HP-hMG for controlled ovarian stimulation (COS) for a first or second cycle of IVF / ICSI.
3127702|NCT01703715||Patients aged 65 years and over|All patients aged 65 years and over admitted to acutely to medical wards
3127703|NCT01703702|Experimental|Intervention|Subjects will receive florbetapir (18F) PET scans and physicians will have immediate access to PET scan results.
3127704|NCT01703702|Experimental|Control|Subjects will receive florbetapir (18F) PET scans but physicians will be blinded to PET scan results for 12 months
3127705|NCT01703689|Experimental|strong intervention group (SIG)|Nursing homes that received audit and feedback information on quality indicators and benefited of cooperative work meetings with hospital geriatricians
3127706|NCT01703689|Active Comparator|intervention group (LIG)|Nursing homes that only received audit and feedback information on quality indicators
3127707|NCT01703676||Patients|Klinefelter Patients
3127708|NCT01703676||Parents|Parents of Klinefelter Patients
3127709|NCT01703676||Controls M|Healthy Male Control with normal karyotype
3127710|NCT01703676||Controls F|Healthy female controls
3127711|NCT01703663|Experimental|EPAP|Provent Sleep Apnea Therapy.
3127712|NCT01703663|No Intervention|control|
3127713|NCT01703650||Resectable pancreas cancer|patients with resectable pancreas adenocarcinoma or neuroendocrine tumor underwent perfusion CT after intravenous iopromide administration
3127714|NCT01703650||Locally advanced Pancreas cancer|Patients with locally advanced pancreas cancer underwent perfusion CT after intravenous iopromide administration before and after chemotherapy.
3127715|NCT01703637|Experimental|Sitagliptin|Drug: sitagliptin sitagliptin 100mg tablet by mouth , once daily for 12 weeks
3127716|NCT01703637|Experimental|Vildagliptin|Drug: vildagliptin saxagliptin 50mg tablet by mouth , twice daily for 12 weeks
3127717|NCT01703637|Experimental|Saxagliptin|Drug: saxagliptin saxagliptin 5mg tablet by mouth , once daily for 12 weeks
3127718|NCT01703624|Experimental|glycopyrronium bromide 12.5mcg|glycopyrronium bromide 12.5mcg single dose via pressurised metered dose inhaler (pMDI)
3127719|NCT01703624|Experimental|glycopyrronium bromide 25mcg|glycopyrronium bromide 25mcg single dose via pressurised metered dose inhaler (pMDI)
3127720|NCT01703624|Experimental|glycopyrronium bromide 50mcg|glycopyrronium bromide 50mcg single dose via pressurised metered dose inhaler (pMDI)
3127721|NCT01703624|Experimental|glycopyrronium bromide 100mcg|glycopyrronium bromide 100mcg single dose via pressurised metered dose inhaler (pMDI)
3127722|NCT01703624|Placebo Comparator|placebo|placebo single dose via pressurised metered dose inhaler (pMDI)
3127723|NCT01703611|Experimental|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBPGN) (www.guidelines.gov)
3127724|NCT01703611|Active Comparator|Usual Nutrition Care|Visits for usual nutrition therapy (diet and lifestyle changes) provided by dietitians over a 12 month period.
3127725|NCT01703598|Experimental|DBS surgery|Single arm
3127726|NCT01703585||metastatic breast cancer|
3127727|NCT01703585||metastatic colorectal cancer|
3127728|NCT01703585||metastatic gynecological cancer|
3127729|NCT01703585||metastatic melanoma|
3127730|NCT01703572|Experimental|OMP-52M51|
3127731|NCT01703559|Active Comparator|Placebo|
3127732|NCT01703559|Active Comparator|0.5% Phentolamine|
3127733|NCT01703559|Active Comparator|1.0% Phentolamine|
3127804|NCT01703078|Experimental|Ingenol derivative concentration 3|once daily for two consecutive days
3127734|NCT01703546|Experimental|LAGB & LGCP|"All study patients will have the following surgical procedure: Laparoscopic Adjustable Gastric Banding and Gastric Plication (LAGB & LGCP).~The percent of Excess Body Weight Loss will be monitored at all post op visits."
3127735|NCT01703533|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
3127736|NCT01703533|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water for Injection
3127737|NCT01703520||Male Finasteride Users|Male finasteride users aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
3127738|NCT01703520||Male Finasteride Non-users|Country-matched male finasteride non-users aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
3127739|NCT01703520||Men with Breast Cancer|Breast cancer cases among men aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
3127740|NCT01703520||Men without Breast Cancer|Country- and age-matched controls: men without breast cancer aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
3127741|NCT01703507|Experimental|Arm A (Ipilimumab and Whole Brain Radiation Therapy)|Patients receive ipilimumab IV over 90 minutes once in weeks 1, 4, 7, and 10. Patients also undergo WBRT 5 days a week in weeks 1-2.
3127742|NCT01703507|Experimental|Arm B (Ipilimumab and Stereotactic Radiosurgery)|Patients receive ipilimumab IV over 90 minutes as in Arm A. Patients also undergo SRS on day 1 in week 1.
3127743|NCT01703494|Active Comparator|Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal Microbiota Transplant (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
3127744|NCT01703494|Sham Comparator|Sham Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute severe C. difficile infection, subjects will receive a 300 mL infusion of a sham (autotransfusion) fecal solution at colonoscopy.
3127745|NCT01703481|Experimental|Part 1|Dose Escalation, Part 1: Participants will be enrolled in sequential cohorts to determine recommended Phase 2 doses (RP2D).
3127746|NCT01703481|Experimental|Part 2|Dose Confirmation, Part 2: Tumor biopsy cohorts will confirm RP2D.
3127747|NCT01703481|Experimental|Part 3, Cohort A|First dose expansion, Part 3: Participants with squamous non-small cell lung cancer.
3127748|NCT01703481|Experimental|Part 3, Cohort B|First dose expansion, Part 3: Participants with small cell lung cancer.
3127749|NCT01703481|Experimental|Part 3, Cohort C|First dose expansion, Part 3: Participants with breast cancer.
3127750|NCT01703481|Experimental|Part 3, Cohort D|First dose expansion, Part 3: Participants with solid tumors (consisting of one of the following: gastric, head and neck, lung adenocarcinoma, urothelial, glioblastoma multiforme [GBM], ovarian or prostate).
3127751|NCT01703481|Experimental|Part 4, Cohort E|Second dose expansion, Part 4: Participants with non-small cell lung cancer.
3127752|NCT01703481|Experimental|Part 4, Cohort F|Second dose expansion, Part 4: Participants with solid tumors (consisting of one of the following: breast, urothelial, GBM).
3127753|NCT01703468|Active Comparator|Oxcarbazepine then Trileptal|600 mg suspension
3127754|NCT01703468|Active Comparator|Trileptal then Oxcarbazepine|600 mg suspension
3127755|NCT01703442||Ovarian cancer patients|Perioperative primary epithelial ovarian cancer patients
3127756|NCT01703429||Individuals with MS|
3127757|NCT01703416||1|
3127758|NCT01703390|Experimental|ERCC-1 low|modifiedFOLFOX6 + Cetuximab oxaliplatin 85 mg/m2 on day 1, 15 q d29 for 6 cycles folinic acid (FA) 400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus day 1 + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly
3127759|NCT01703390|Experimental|ERCC-1 high|FOLFIRI + Cetuximab irinotecan 180 mg/m² on day 1, 15 q d29 for 6 cycles folinic acid (FA)400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly
3127760|NCT01703364|Experimental|Lenalidomide/Fludarabine/Rituximab|"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
3127761|NCT01703351|Experimental|Drug: 0.5% ropivacaine|
3127762|NCT01703351|Active Comparator|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg|
3127763|NCT01703338||1|
3127764|NCT01703325|Active Comparator|triamcinolone injection (10 mg/ml)|"Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection"
3127765|NCT01703325|Active Comparator|Topical 0.05% clobetasol ointment|Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C Apply Topical 0.05% clobetasol propionate ointment on the nail fold twice daily for 6 months
3127766|NCT01703325|No Intervention|Controlled group|Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C Controlled group
3127767|NCT01703312|Experimental|QGE031|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses). Three dose levels of QGE031 will be offered during the study: low, medium, and high. Participants will be randomized to receive one of these dose levels for all dosing visits.
3127851|NCT01702727|Active Comparator|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
3127768|NCT01703312|Active Comparator|omalizumab|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses) or once every four weeks (total of three doses). The dose that a participant receives will depend upon the participant's body weight and IgE level; dosage will be determined based upon local omalizumab dosing charts.
3127769|NCT01703312|Placebo Comparator|placebo|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses).
3127770|NCT01703299||imipenem-treated patients|imipenem-treated patients
3127771|NCT01703299||ertapenem-treated patients|ertapenem-treated patients
3127772|NCT01703286|Experimental|Linagliptin 5mg|given once daily over 28 days
3127773|NCT01703286|Active Comparator|Glimepiride|given once daily in 1mg dosis over 7 days, following a titration step to 2mg and application for 21 days
3127774|NCT01703286|Placebo Comparator|Placebo|given once daily over 28 days
3127775|NCT01703273|Experimental|low key intervention|
3127776|NCT01703273|Active Comparator|routine care|
3127777|NCT01703260|Experimental|Roflumilast + pioglitazone|Roflumilast dose and pioglitazone dose, orally for up to 4 months
3127778|NCT01703260|Experimental|Roflumilast|Roflumilast dose and pioglitazone matching-placebo dose orally for up to 4 months.
3127779|NCT01703260|Experimental|Pioglitazone|Pioglitazone dose, orally and roflumilast matching-placebo dose, orally for up to 4 months
3127780|NCT01703247|Active Comparator|PVI+LL|Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.
3127781|NCT01703247|Active Comparator|PVI+GP|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
3127782|NCT01703234|Experimental|Ramipril|
3127783|NCT01703221|Experimental|Omarigliptin 25 mg (Phase A+B)|Omarigliptin 25 mg once weekly for 52 weeks (Phase A + B)
3127784|NCT01703221|Active Comparator|Sitagliptin (Phase A) switching to Omarigliptin (Phase B)|Sitagliptin 50 mg once daily for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)
3127785|NCT01703221|Placebo Comparator|Placebo (Phase A) switching to Omarigliptin (Phase B)|Placebo for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)
3127786|NCT01703208|Experimental|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
3127787|NCT01703208|Placebo Comparator|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
3127788|NCT01703195|Other|Diffusion Weighted Magnetic Resonance Imaging (DWMR)|Patients receive Magnetic Resonance Imaging (MRI) and Diffusion Weighted Magnetic Resonance Imaging (DWMR) imaging pre-treatment and 4-6 weeks post-treatment.
3127789|NCT01703182||leg amputation|Patients undergoing below-knee and above ankle amputation for vascular reasons will receive transcutaneous oximetry and transcutaneous carbon dioxide measurement
3127790|NCT01703169|Experimental|Eltrombopag|Single arm study. Dose Escalation.
3127791|NCT01703156|Experimental|Non-Stress Group|Medical therapy will be implemented and will include the following: aspirin, clopidogrel, b-blockers, and statins. The dosages of aspirin, b-blocker and statin will be left to the discretion of the treating physician. Statins will be initiated irrespective of LDL unless contraindicated. Clopidogrel will be taken for at least one month and ideally up to one year. Sublingual nitroglycerin will be provided to all patients. Other anti-ischemic medications including long-acting nitrates, calcium channel blockers, and ranolazine may be provided at the treating physicians' discretion. If a patient has contraindications to any medications, they will not be administered. If a statin contraindication exists, other cholesterol-lowering medications may be administered. Appendix 4 shows the detailed management of low risk ACS patients randomized to the non-stress group.
3127792|NCT01703156|Active Comparator|Stress Group|Medical therapy will be implemented and will include the following: aspirin, clopidogrel, b-blockers, and statins. Statins will be initiated irrespective of LDL unless contraindicated. Clopidogrel will be taken for at least one month and ideally up to one year. Sublingual nitroglycerin will be provided to all patients. Other anti-ischemic medications including long-acting nitrates, calcium channel blockers, and ranolazine may be provided at the treating physicians' discretion. If a statin contraindication exists, other cholesterol-lowering medications may be administered. All patients will undergo noninvasive stress testing. Results of individual stress tests will be reviewed by a cardiologist. Based on the myocardium deemed at risk and patient symptoms, further testing with angiography and revascularization using percutaneous techniques and/or coronary artery bypass grafting may be considered. Likewise, medical treatment may be adjusted.
3127793|NCT01703143|Experimental|Laser Ablation|Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
3127794|NCT01703130|Experimental|Local Anesthestic Dose|
3127795|NCT01703117|Experimental|age matched cohort 60-85 years old|24 subjects between the ages of 60-85 will receive riluzole
3127796|NCT01703117|Placebo Comparator|24 subjects between 60-85 years old|24 subjects between 60-85 will receive placebo
3127797|NCT01703104|Active Comparator|Paludrine + Folic Acid|This arm uses routine drugs, Paludrine + Folic Acid
3127798|NCT01703104|Active Comparator|Paludrine + Folic Acid + Jobelyn|This group uses Paludrine + Folic Acid + Jobelyn
3127799|NCT01703091|Experimental|Ramucirumab plus Docetaxel|Ramucirumab 10 milligram per kilogram (mg/kg) on Day 1 of every 21 day cycle, administered as an intravenous (IV) infusion over approximately 60 minutes. Docetaxel 60 milligram per square meter (mg/m2) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
3127800|NCT01703091|Placebo Comparator|Placebo plus Docetaxel|Placebo (administered at a volume equivalent to a dose of milligram per kilogram (mg/kg)) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes. Docetaxel 60 mg/m2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
3127801|NCT01703078|Active Comparator|Ingenol mebutate gel 0.05%|once daily for two consecutive days
3127802|NCT01703078|Experimental|Ingenol derivative concentration 1|once daily for two consecutive days
3127805|NCT01703065|Experimental|Cabozantinib in metastatic CRPC|Metastatic CRPC patients to receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
3127806|NCT01703065|Experimental|Cabozantinib in non-metastatic CRPC|Non-Metastatic CRPC patients to receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
3127807|NCT01703052|Experimental|CHF 6001 SD or placebo|Single administration of CHF 6001 dose levels 1 to 7 or placebo
3127808|NCT01703052|Experimental|CHF 6001 MD or placebo|Multiple administration of CHF 6001 dose levels 1 to 5 or placebo
3127809|NCT01703039|Experimental|sertraline + riluzole|sertraline 100 mg po daily and riluzole 50 mg po bid
3127810|NCT01703039|Active Comparator|sertraline + placebo|sertraline 100 mg po daily and placebo
3127811|NCT01703000|Experimental|NG PROMUS stent|Single-arm treatment group receiving interventional NG PROMUS study stent
3127812|NCT01702987|Placebo Comparator|Statin + placebo|9 patients taking statin medications and placebo.
3127813|NCT01702987|Active Comparator|Statin + ubiquinol|12 patients on statins and ubiquinol
3127814|NCT01702974|Active Comparator|Vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
3127815|NCT01702974|Placebo Comparator|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
3127816|NCT01702961|Other|BEAM+R: Autologous Stem Cell Transplant|Ara-C, VP-16, BCNU, Melphalan, Rituxan and Stem Cells
3127817|NCT01702922||1/Active Cancer Parents|Must have been in a partnership at the time child was diagnosed with cancer &amp; must have been diagnosed at least 3 months prior to enrollment on this study &amp; be currently receiving treatment
3127818|NCT01702922||2/Complete Cancer Parents|Must have been in a partnership at the time the child was diagnosed with cancer and the child has completed treatment at age 21 or younger (without evidence of disease) within the previous 3 years
3127819|NCT01702922||3/NF1 Parents|Must have been in a partnership at the time the child was diagnosed with NF1 and the child must have been diagnosed with NF1 at least 3 months prior to enrollment on this study.
3127820|NCT01702909|Experimental|Interleukin-2|Interleukin-2
3127821|NCT01702896|Experimental|Interleukin-2|Interleukin-2 will be used in this group
3127822|NCT01702883|No Intervention|Control|Randomization occurs after enrollment survey has been completed. This group will not receive the internet intervention for the twelve months. They will be asked to complete the final survey.
3127823|NCT01702883|Experimental|Intervention Group A|Randomization occurs after enrollment survey has been completed. Upon secondary randomization at week eight, this group will continue to receive weekly internet surveys for the entire twelve months. They will be asked to complete the final survey.
3127824|NCT01702883|Experimental|Intervention Group B|Randomization occurs after enrollment survey has been completed. This group will complete weekly internet surveys for eight weeks. Upon secondary randomization at week eight, this group will begin to receive monthly internet surveys. They will be asked to complete the final survey.
3127825|NCT01702883|Experimental|Intervention Group C|Randomization occurs after enrollment survey has been completed. This group will complete weekly internet surveys for eight weeks. Upon secondary randomization at week eight, the group will not receive any more internet surveys. They will be asked to complete the final survey.
3127826|NCT01702870||Suspected myositis|Participants with suspected myositis based on clinical criteria (Bohan and Peters criteria) referred for Magnetic resonance imaging
3127827|NCT01702870||Controls|Normal volunteers without myositis, who will undergo MR imaging to establish normal ranges of MR signal in health muscle
3127828|NCT01702857|Experimental|TDENV-PIV alum4|4 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
3127829|NCT01702857|Experimental|TDENV-PIV AS03B|1 µg TDENV-PIV with AS03B adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
3127830|NCT01702857|Placebo Comparator|Placebo|Phosphate buffered saline; 0.5 mL intramuscular injection at 0 and 28 days
3127831|NCT01702857|Experimental|TDENV-PIV alum1|1 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
3127832|NCT01702857|Experimental|TDENV-PIV AS01E|1 µg TDENV-PIV with AS01E adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
3127833|NCT01702844|Experimental|nab paclitaxel|Patients will receive nab-paclitaxel once weekly for 3 weeks of every 4 week cycle
3127834|NCT01702831|Experimental|BuMel + lenalidomide Maintenance|I.V. Busulfan + I.V. Melphalan for conditioning prior ASCT, followed by Lenalidomide maintenance at day 100 after ASCT.
3127835|NCT01702818||HSDD group|Women with a diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
3127836|NCT01702818||Control Group|Women without a diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
3127837|NCT01702805|Active Comparator|Low Threshold Transfusion|Transfusions will be administered using a lower threshold hemoglobin value. The low threshold values reflect more common practice, so this is considered the 'usual treatment' group
3127838|NCT01702805|Active Comparator|High Threshold Transfusion|Transfusions will be administered using a higher threshold hemoglobin value.
3127839|NCT01702792|Experimental|Tumor Vaccine|1 x 107 TCE tumor lysate in 0.5 ml Lactated Ringers Solution (approximately 1 mg of tumor lysate protein) and equivalent volume of adjuvant will be injected 2 weeks and 3 weeks (2 vaccinations) after surgery in the intradermal skin of the upper thigh. There will be 2 vaccine administrations and patients will be followed for 2 months after inguinal node removal for any possible vaccine/study-related toxicity.
3127840|NCT01702779|Other|optiflow|
3127841|NCT01702779|Other|O2|
3127842|NCT01702766|Active Comparator|Bifidobacterium animalis subsp. lactis|
3127843|NCT01702766|Placebo Comparator|Placebo|
3127844|NCT01702753|Active Comparator|Bifidobacterium animalis subsp. lactis|
3127845|NCT01702753|Placebo Comparator|Placebo|
3127846|NCT01702740|Experimental|Part A, 1 mg/kg CNTO 136|
3127847|NCT01702740|Experimental|Part A, 4 mg/kg CNTO 136|
3127848|NCT01702740|Experimental|Part A, 10 mg/kg CNTO 136|
3127849|NCT01702740|Experimental|Part B, 10 mg/kg CNTO 136/placebo|
3127850|NCT01702727|Experimental|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
3130194|NCT01686594|No Intervention|No maintenance treatment|observation
3127852|NCT01702727|Experimental|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
3127853|NCT01702714|Experimental|RO5083945 + carboplatin + paclitaxel|
3127854|NCT01702714|Experimental|RO5083945 + cisplatin +gemcitabine|
3127855|NCT01702701|Active Comparator|Montelukast|patients will receive 10 mg po montelukast daily for 12 weeks.
3127856|NCT01702701|Active Comparator|Fluticasone|patients will receive 440mcg fluticasone po bid for 12 weeks
3127857|NCT01702675|Experimental|ACH15 - 50mg capsule|ACH15 50mg capsule by mouth single dose (Group 1)
3127858|NCT01702675|Experimental|ACH15 - 250 mg capsule|ACH15 250mg capsule by mouth as single dose(Group 2)
3127859|NCT01702675|Experimental|ACH15 - 500mg capsule|ACH15 500mg capsule by mouth in a single dose(Group 3)
3127860|NCT01702675|Experimental|ACH15 - 1000 mg (two 500mg capsule)|ACH15 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)
3127861|NCT01702675|Experimental|ACH15 - 2000 mg (four 500 mg capsule)|ACH15 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)
3127862|NCT01702675|Experimental|ACH15 - 500 mg (twice a day for 7 days)|ACH15 500mg capsule by mouth twice a day for seven days (Group 6)
3127863|NCT01702675|Placebo Comparator|Placebo - 250 mg capsule|Placebo 250mg capsule by mouth single dose (Group 2)
3127864|NCT01702675|Placebo Comparator|Placebo - 500 mg capsule|Placebo 500mg capsule by mouth in a single dose(Group 3)
3127865|NCT01702675|Placebo Comparator|Placebo - 1000 mg (two 500mg capsule)|Placebo 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)
3127866|NCT01702675|Placebo Comparator|Placebo 2000 mg (four 500mg capsule)|Placebo 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)
3127867|NCT01702675|Placebo Comparator|Placebo - 500 mg (twice a day for 7 days)|Placebo 500mg capsule by mouth twice a day for seven days (Group 7)
3127868|NCT01702662|Experimental|Photopill treatment|Photopill treatment, 2 minutes per cm rectal mucosa (3cm) 10 times
3127869|NCT01702649|Experimental|RPX2003 (Biapenem)|Single and multiple dose of RPX2003 (Biapenem).
3127870|NCT01702649|Placebo Comparator|Normal Saline|Single and multiple doses of normal saline.
3127871|NCT01702636|Active Comparator|Tranexamic Acid|Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
3127872|NCT01702636|Placebo Comparator|Placebo|Intravenous placebo in 100 mL 0.9% NaCl over 10 minutes followed by 500 mL 0.9% NaCl infusion over 8 hours.
3127873|NCT01702623|Active Comparator|Oxcarbazepine first, then Trileptal|Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period)
3127874|NCT01702623|Active Comparator|Trileptal first, then Oxcarbazepine|Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period
3127875|NCT01702610|Experimental|Temozolomide, Accelerated Hypofractionated RT|Patient will receive two weeks of neo-adjuvant Temozolomide followed by Accelerated Hypofractionated RT for a total of 20 fractions for a total of 60Gy followed by Temozolomide for 12 cycles.
3127876|NCT01702597|Experimental|WBV|Patients will receive supervised physical therapy using a whole body vibration device (Galileo® Med M Plus, Novotec, Pforzheim, Germany) twice a week, 30 minutes per session, for 6 weeks.
3127877|NCT01702597|Active Comparator|Physiotherapy|Patient will receive the current gold standard treatment protocol: supervised physical therapy, twice a week, 30 minutes per session, for 6 weeks.
3127878|NCT01702584||stent assisted embolization|stent assisted embolization of intracranial aneurysm
3127879|NCT01702571|Experimental|Trastuzumab Emtansine (All Participants)|This cohort will enroll all participants with HER2 positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
3127880|NCT01702571|Experimental|Trastuzumab Emtansine (Asian Participants)|This cohort will enroll Asian race participants with HER2 positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
3127881|NCT01702558|Experimental|Phase I: Locally Advanced/Metastatic Gastric Cancer Cohort|Participants will receive a fixed dose of trastuzumab emtansine every 3 weeks. Capecitabine will be evaluated at different doses levels to determine the MTD. Treatment will continue until progression, withdrawal, death, physician decision, or study end.
3127882|NCT01702558|Experimental|Phase I: Metastatic Breast Cancer Cohort|Participants will receive a fixed dose of trastuzumab emtansine every 3 weeks. Capecitabine will be evaluated at different doses levels to determine the MTD. Treatment will continue until progression, withdrawal, death, physician decision, or study end.
3127883|NCT01702558|Active Comparator|Phase II: Kadcyla|Participants will be randomly assigned to receive trastuzumab emtansine until progression, withdrawal, death, physician decision, or study end.
3127884|NCT01702558|Experimental|Phase II: Kadcyla + Capecitabine|Participants will be randomly assigned to receive trastuzumab emtansine plus capecitabine until progression, withdrawal, death, physician decision, or study end.
3127885|NCT01702532|Experimental|Nicotine Mouth Film|mint nicotine mouth film, buccal administration
3127886|NCT01702532|Active Comparator|Nicotine Lozenge|nicotine lozenge, buccal administration
3127887|NCT01702519|Active Comparator|Reference|nicotine transdermal patch with the existing polyisobutylene adhesive
3127888|NCT01702519|Active Comparator|Treatement|nicotine transdermal patch with the alternate polyisobutylene adhesive
3127889|NCT01702506|Experimental|Fasted|Dacomitinib administered under fasted conditions
3127890|NCT01702506|Experimental|Fed|Dacomitinib administered under fed conditions
3127891|NCT01702506|Experimental|Antacid|Dacomitinib administered under antacid treatment
3127892|NCT01702493|Active Comparator|Part 1: Cap SRT2104|500 mg SRT2104 (in the form of two, 250 mg capsules) will be administered as a single oral dose in the fasting state
3127893|NCT01702493|Experimental|Part 1: Tab SRT2104 (slow release)|500 mg SRT2104 (in the form of two, 250 mg slow release tablets) will be administered as a single oral dose in the fasting state.
3127894|NCT01702493|Experimental|Part 1: Tab SRT2104 (intermediate release)|500 mg SRT2104 (in the form of two, 250 mg intermediate release tablets) will be administered as a single oral dose in the fasting state.
3127895|NCT01702493|Experimental|Part 1: Tab SRT2104 (fast release)|500 mg SRT2104 (in the form of two, 250 mg fast release tablets) will be administered as a single oral dose in the fasting state.
3127896|NCT01702493|Experimental|Part 2A: SRT2104 500 mg single-dose|500 mg SRT2104 (formulation selected from Part 1) will be administered as a single oral dose in the fed state.
3127897|NCT01702493|Experimental|Part 2B: SRT2104 single alternative dose|An alternative dose (other than 500 mg, but not to exceed 2000 mg) of SRT2104 (formulation selected from Part 1) will be administered as a single oral dose.
3127898|NCT01702493|Experimental|Part 2C: SRT2104 500 mg daily for 7 days|500 mg SRT2104 (formulation selected from Part 1) will be administered daily for 7 days.
3127899|NCT01702480|Experimental|Part 1: GSK2981710 10 gram (g)|Eight subjects will receive single dose of GSK2981710 in the form of 10 g medium-chain triglycerides (MCT) powder daily for 14 days.
3127900|NCT01702480|Experimental|Part 1: GSK2981710 20 g|Eight subjects will receive single dose of GSK2981710 in the form of 20 g MCT powder daily for 14 days.
3127901|NCT01702480|Experimental|Part 1: GSK2981710 30 g|Eight subjects will receive single dose of GSK2981710 in the form of 30 g MCT powder daily for 14 days.
3127902|NCT01702480|Experimental|Part 1: GSK2981710 40 g|Eight subjects will receive single dose of GSK2981710 in the form of 40 g MCT powder daily for 14 days.
3127903|NCT01702480|Placebo Comparator|Part 1: Placebo|Eight subjects will receive single dose of matching placebo daily for 14 days.
3127904|NCT01702480|Experimental|Part 2: GSK2981710 (dose to be decided from Part 1)|The subjects will receive single dose of GSK2981710 in the form of MCT powder (dose to be decided from Part 1) daily for 14 days.
3127905|NCT01702480|Placebo Comparator|Part 2: Placebo|The subjects will receive single dose of matching placebo daily for 14 days..
3127906|NCT01702467|Experimental|GSK2647544|The starting dose of GSK2647544 is 0.5 mg. The escalating doses to be administered will be determined based on study results from previous dose (s).
3127907|NCT01702467|Placebo Comparator|Placebo|Matching placebo
3127908|NCT01702454|Experimental|Fluarix Quadrivalent Primed Group|Subjects in this group were previously primed with 2 doses of Fluarix Quadrivalent vaccine in the primary study 115345 (NCT01439360) and received 1 dose of Fluarix Quadrivalent vaccine at Day 0 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.
3127909|NCT01702454|Experimental|Fluarix Quadrivalent Unprimed Group|Subjects in this group were unprimed in the primary study 115345 (NCT01439360) and received 2 doses of Fluarix Quadrivalent vaccine at Days 0 and 28 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.
3127910|NCT01702441|Experimental|AKB-9778|Up to 4 dose levels of subcutaneous AKB-9778 will be evaluated. Doses will be administered daily for 28 days.
3127911|NCT01702428|Experimental|INV_MMR_L1 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 1 (L1) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
3127912|NCT01702428|Experimental|INV_MMR_L2 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 2 (L2) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
3127913|NCT01702428|Experimental|INV_MMR_L3 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 3 (L3) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
3127914|NCT01702428|Active Comparator|COM_MMR Group|Subjects receive 1 dose of COM_MMR Lot 1 and Lot 2 co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively. Pooled analysis is conducted for this group.
3127915|NCT01702415|Placebo Comparator|Placebo|Placebo
3127916|NCT01702415|Experimental|Zoledronic acid|Active IMP
3127917|NCT01702402|Experimental|Intervention Arm|Intervention activities will include behaviour change communications on healthy timing and spacing of pregnancy, couples counselling, social networking and expansion of contraceptive options for postpartum women, including provision of oral contraceptive pills and condoms in the home.
3127918|NCT01702402|Other|Comparison|A comparison area received standard government health services.
3127919|NCT01702389|Experimental|Remifentanil|The study has only one arm. Same group of volunteers will receive remifentanil infusion with abrupt withdrawal, remifentanil infusion with gradual dose reduction and saline infusion at three separate trials.
3127920|NCT01702376|Experimental|Retosiban 100 mg|Each subject will be randomized to single dose of retosiban 100 mg in one of the four treatment sequences.
3127921|NCT01702376|Experimental|Retosiban 800 mg|Each subject will be randomized to single dose of retosiban 800 mg in one of the four treatment sequences
3127922|NCT01702376|Placebo Comparator|Placebo|Each subject will be randomized to single dose of matching placebo in one of the four treatment sequences
3127923|NCT01702376|Active Comparator|Moxifloxacin 400 mg|Each subject will be randomized to single dose of moxifloxacin 400 mg in one of the four treatment sequences
3127924|NCT01702363|Experimental|GSK573719|125mcg
3127925|NCT01702350|Experimental|Study Drug Formulation A|Enterric Coated Tablet Formulation of GSK2251052
3127926|NCT01702350|Experimental|Study Drug Formulation B|Modified Release Table Formulation of GSK2251052
3127927|NCT01702350|Experimental|Study Drug Formulation C|Enterric Coated Powder for Oral Suspension Formulation of GSK2251052
3127928|NCT01702350|Experimental|Study Drug Formulation D|Immidiate Release Table Formulation of GSK2251052
3127929|NCT01702350|Experimental|Study Drug Formulation E|Oral Solution Formulation of GSk2251052
3127930|NCT01702337||HPV-1 Group|Hypothetical group of women vaccinated with HPV-1 vaccine in Taiwan.
3127931|NCT01702337||HPV-2 Group|Hypothetical group of women vaccinated with HPV-2 vaccine in Taiwan.
3127932|NCT01702324|Experimental|DD-25|A concentration of 0.025% of topical DD-25 cream.
3127933|NCT01702311|Active Comparator|Bedtime supplementation|Patients in this arm will have acqhs (before meals and at bedtime) and 3 am blood glucose testing and will receive sliding scale insulin supplementation as needed.
3127934|NCT01702311|No Intervention|no bedtime supplementation|Patients in this arm will have ac (before meals), qhs (at bedtime) and 3 am blood glucose testing; however, subjects in this group will NOT receive sliding scale insulin bedtime supplementation.
3127935|NCT01702298|Experimental|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants will continue pre-study dose of metformin >=1000 mg per day.
3127936|NCT01702285|Experimental|CUDC-101|200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
3127937|NCT01702272||Dengue Virus|
3127938|NCT01702259|Experimental|Erchonia Scanner device (GLS)|The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
3127939|NCT01702259|Sham Comparator|Placebo device|Inactive Erchonia GLS device
3127940|NCT01702246|Experimental|simvastatin|Simvastatin (Zocor), 40mg tablet, 40mg orally once daily, for 3 months
3127941|NCT01702233|Experimental|Traumeel S inj.|Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
3127942|NCT01702233|Active Comparator|Fortecortin/Dexamethasone 8 mg inj|Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
3127943|NCT01702233|Placebo Comparator|Saline inj.|Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
3127944|NCT01702220|Experimental|CBT|
3127945|NCT01702220|Active Comparator|Enhanced Community Care (ECC)|
3127946|NCT01702207|Active Comparator|Once Daily Tacrolimus|Treatment Arm - Subjects are switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
3127947|NCT01702207|Active Comparator|Twice Daily Tacrolimus|Control Arm - Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
3127948|NCT01702194|Experimental|TD-1211 IV [C14]|TD-1211 IV [C14]
3127949|NCT01702194|Experimental|TD-1211 PO [C14]|TD-1211 PO [C14]
3127950|NCT01702181|Placebo Comparator|Placebo|Matching placebo.
3127951|NCT01702181|Active Comparator|Tacrolimus|Tacrolimus 0.1% ointment twice daily for 28 days.
3127952|NCT01702181|Experimental|OPA-15406|
3127953|NCT01702168||CBT Training|
3127954|NCT01702155|Experimental|DFP-10917|"7-day continuous infusion (in the vein): Starting dose 4 mg/m^2~14-day continuous infusion (in the vein): Starting dose 10 mg/m^2~Phase II Only: 6 mg/m^2 for the 14-day continuous infusion (in the vein)"
3127955|NCT01702142||NIATx Only|NIATx (Network for the Improvement of Addiction Treatment) organization change model only
3127956|NCT01702142||NIATx and Advancing Recovery|Organizational and system changes
3127957|NCT01702129|Experimental|anti-EGFR Immunoliposomes|anti-EGFR immunoliposomes loaded with doxorubicin. Dose escalating study. 3 patients per dose level. Dose levels: 5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2.
3127958|NCT01702116|Experimental|extralevator APR|"This is a modified and more extensive procedure that is used to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive."
3127959|NCT01702116|Active Comparator|standard APR|conventional abdominoperineal resection (APR)
3127960|NCT01702103|Experimental|Mometasone|Mometasone, nasal spray for 8 weeks, 2 actuations each nostril in the morning.
3127961|NCT01702103|Active Comparator|Nasonex®|Nasonex nasal spray for 8 weeks 2 actuations each nostril in the morning.
3127962|NCT01702090|Experimental|TMC114/ritonavir|
3127963|NCT01702077|Experimental|Neurofeedback first|Neurofeedback then sham feedback
3127964|NCT01702077|Experimental|Sham first|Sham feedback then neurofeedback
3127965|NCT01702064|Experimental|Nilotinib with Ruxolitinib|"The starting dose of ruxolitinib will be 5mg by mouth (PO) twice a day (BID) and will increase by 5 mg increments in each cohort, to a maximum dose of 15 mg PO BID. Nilotinib will be given at a dose ranging from 300 mg PO BID to 400 mg PO BID, depending on the participant's dose prior to enrollment on the trial.~Dose Level 1: Ruxolitinib 5 mg twice a day (BID); Nilotinib 300 mg or 400 mg BID.~Dose Level 2: Ruxolitinib 10 mg BID; Nilotinib 300 mg or 400 mg BID.~Dose Level 3: Ruxolitinib 15 mg BID; Nilotinib 300 mg or 400 mg BID."
3127966|NCT01702051||1|patients with chronic pancreatitis treated with total or subtotal pancreatectomy
3127967|NCT01702051||2|patients underwent completion pancreatectomy because of anastomotic leak after partial pancreatectomy
3127968|NCT01702051||3|patients underwent pancreatoduodenectomy in which pancreatic anastomosis was made impracticable by technical difficulties and/or high risk of leakage
3127969|NCT01702051||4|patients underwent extensive distal pancreatectomy for pancreatic lesions located at the neck
3127970|NCT01702038|Experimental|Rituximab|Participants will receive an intravenous infusion of rituximab on Days 0 and 14
3127971|NCT01702025|Placebo Comparator|Placebo|"Administer a single dose of placebo (yellow corn meal in a capsule, gelatin ) in Normoxic Conditions.~Following a minimum of 7 days a single dose placebo will be administered (yellow corn meal in a gelatin capsule) in Hypoxic conditions."
3127972|NCT01702025|Active Comparator|Aminophylline|"Administer a single dose of 400 mg Aminophylline (4-100 mg tablets) in Normoxic Conditions.~Following a minimum of 7 days administer a single dose of 400 mg Aminophylline (4-100 mg tablets) in Hypoxic conditions."
3128008|NCT01701752|Active Comparator|Group 3|Day 1: FP-01.1-Adjuvant + Placebo ; Day 29: FP-01.1-Adjuvant
3127973|NCT01702025|Active Comparator|Methazolamide|"Administer a single dose of 250 mg Methazolamide (10-25 mg tablets) in Normoxic Conditions.~Following a minimum of 7 days administer a single dose of 250 mg Methazolamide (10-25 mg tablets) in Hypoxic conditions."
3127974|NCT01702025|Active Comparator|Aminophylline+Methazolamide|"Administer a single dose of 400 mg Aminophylline (4-100 mg tablets) + 250 mg Methazolamide (10-25 mg tablets) in Normoxic Conditions.(Aminophylline+Methazolamide)~Following a minimum of 7 days administer a single dose of 400 mg Aminophylline (4-100 mg tablets) + 250 mg Methazolamide (10-25 mg tablets) in Hypoxic conditions."
3127975|NCT01702012|Experimental|Almased Meal Replacement Powder|Participants assigned to this arm will receive the Almased meal replacement powder and will be asked to replace one meal per day during the first 6 months of participation. During the second 6 months, participants will be allowed to choose whether to continue using the product to replace a meal or to use the product as a supplement prior to meals.
3127976|NCT01702012|Active Comparator|Lifestyle Intervention|Participants randomized to this group will receive 5 group sessions in the first two months of participation and 5 additional group sessions in the last two months. These group sessions will focus on lifestyle behavior changes for weight loss and management including goal-setting, calorie balance, general nutrition, and physical activity.
3127977|NCT01701999|Experimental|Vaccine|
3127978|NCT01701986|Experimental|Gemcitabine + Clofarabine + Busulfan|"Phase I Starting dose of Gemcitabine: 950 mg/m2 by vein on Days -6 and -4.~Phase II Starting dose of Gemcitabine: Maximum tolerated dose (MTD) from Phase I.~Phase I and Phase II dose of Clofarabine: 40 mg/m2 by vein on Days -6 to -3.~Phase I and Phase II dose of Busulfan: Busulfan will be administered at the dose calculated to achieve a systemic exposure dose of 4000 µMol-min in normal saline over three hours IV every twenty-four hours for four consecutive days (days -6 to -3), starting immediately after the completion of clofarabine. If not feasible to perform pharmacokinetic monitoring, patients receive fixed dose of 100 mg/m2/day for 4 days, which is expected to yield a median daily AUC of 4,000 µMol.min-1.~Stem cell infusion on Day 0."
3127979|NCT01701973|Other|Group A (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either LNMMA (L-N-Monomethyl-arginine) versus placebo."
3127980|NCT01701973|Other|Group B (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either pegvisomant versus placebo."
3127981|NCT01701973|Other|Group C (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either Exendin 9-39 versus placebo."
3127982|NCT01701960||Group 1|This cohort will be injected with 1% lidocaine with 1:100,000 of epinephrine into the nasal mucosa at the time of nasal surgery
3127983|NCT01701960||Group 2|This group will be injected with 1% lidocaine with 1:200,000 of epinephrine into the nasal mucosa at the start of nasal surgery.
3127984|NCT01701934|Experimental|Roflumilast|Roflumilast 500 mcg, once daily for 6 months
3127985|NCT01701934|Placebo Comparator|Placebo pill|Placebo pill, once daily for 6 months
3127986|NCT01701921|Experimental|Pregabalin 75|Pregabalin 75mg by mouth one hour before surgery
3127987|NCT01701921|Active Comparator|Pregabalin 150|Pregabalin 150mg by mouth one hour before surgery
3127988|NCT01701921|Placebo Comparator|Sugar pill|Placebo : Sugar pill manufactured to mimic pregabalin capsule by mouth one hour before surgery
3127989|NCT01701882|Experimental|tenofovir/emtricitabine/rilpivirine|A one pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily.
3127990|NCT01701869||NTHi positive|No intervention, this is an observational study
3127991|NCT01701869||NTHi negative|No intervention, this is an observational study
3127992|NCT01701869||Healthy Control|No intervention, this is an observational study
3127993|NCT01701856|Experimental|Interferon beta-1b|Interferon beta-1b 250 mcg s.c. every other day
3127994|NCT01701843|Other|Placebo (left) / Cromoglicate (right)|Placebo (on a lesion left bodyside), Cromoglicate (on a lesion on right bodyside)
3127995|NCT01701843|Other|Placebo (right) / Cromoglicate (left)|Placebo (on a lesion right bodyside), Cromoglicate (on a lesion on left bodyside)
3127996|NCT01701830||Case Group|Patients with chronic kidney disease of stage 3-4.
3127997|NCT01701830||Control group|30 healthy subject
3127998|NCT01701817||Patients with Atrial Fibrillation (AF)|(1) patients with new onset/first detected Atrial Fibrillation (AF) diagnosed within the 6 months preceding the baseline visit; or (2) patients with AF who had initiation or transition to a FXa (Factor Xa) inhibitor or a direct thrombin inhibitor within the preceding 3 months.
3127999|NCT01701804||integrative treatment|
3128000|NCT01701791|Experimental|Computerized Decision Support System (CDSS)|GPs will use a CDSS with treatment algorithms, supervision from a consultant psychiatrist, and despatch to patients of reminders via mobile texting or automatic mobile (or landline) phone calls to improve adherence to the treatment prescribed.
3128001|NCT01701791|No Intervention|Treatment as usual|GPs will provide TAU, will make their own decisions and will therefore not use the CDSS. Patients will not receive any reminders.
3128002|NCT01701778|Experimental|Caudal Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
3128003|NCT01701778|Experimental|Intravenous Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg~Anesthesia was induced and maintained with sevoflurane"
3128004|NCT01701778|Placebo Comparator|Placebo|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
3128005|NCT01701765||Patients in residential facilities|All patients staying in September 2010 in 23 medium-long term RFs of the St John of God Order in Northern Italy with a primary psychiatric diagnosis and younger than 65 years recruited.
3128006|NCT01701752|Active Comparator|Group 1|Day 1: FP-01.1 + Placebo ; Day 29: FP-01.1
3128007|NCT01701752|Active Comparator|Group 2|Day 1: FP-01.1 + TIV ; Day 29: FP-01.1
3131864|NCT01675518|Placebo Comparator|Part-1 placebo|
3128009|NCT01701752|Active Comparator|Group 4|Day 1: FP-01.1-Adjuvant + TIV ; Day 29: FP-01.1-Adjuvant
3128010|NCT01701752|Active Comparator|Group 5|Day 1: Adjuvant + TIV ; Day 29: Placebo
3128011|NCT01701752|Active Comparator|Group 6|Day 1: Placebo + TIV ; Day 29: Placebo
3128012|NCT01701739|Experimental|aleglitazar / digoxin|
3128013|NCT01701726|Experimental|Acupuncture|Two types of acupuncture are given, one is acupuncture at affected meridian points, the other is at non-affected. For the first type, We select the acupoints from the affected meridians.Patients in this group are divided into two subgroups according meridian syndrome differentiation(jue-yin style,yang-ming style).Patients pertaining to Jue-yin-style are treated with taichong (LR3), renying(ST9), taixi(KI3), neiguan(PC6) .Patients pertaining to Yang-ming-style: taichong(LR3), renying(ST9), zusanli(ST36), quchi(LI11). For the second,We select the acupoints from the non-affected meridians.Patients assigned into the non-affected meridian acupuncture group will be treated with Fengchi (GB20), waiguan(SJ5), yinlingquan(SP9), xuehai (SP10).
3128014|NCT01701726|Sham Comparator|Sham acupuncture|"we use sham acupoints:~The edge of the tibia (1-2cm lateral and horizontal to the zusanli (ST36))~Half way between the tip of the elbow and the axilla~On the ulnar side of the arm, half way between the epicondylus medialis of the humerus and the ulnar side of the wrist.~2cm superior to fu tu(LI18)"
3128015|NCT01701726|No Intervention|Waiting list|Participants who will be randomized into the waiting-list group will not receive any acupuncture treatment throughout 13-week observation period. At the end of trial, if the participant would like to be treated with acupuncture, it will be provided three times weekly for 6 weeks.
3128016|NCT01701713|Experimental|TDCS - DKI ED2011|TDCS with DKI ED2011 session is followed by a behavioral naming therapy with different cues
3128017|NCT01701713|Sham Comparator|Sham-TDCS|Sham-TDCS session is followed by a behavioral naming therapy with different cues
3128018|NCT01701700|Experimental|portable electronic magnifier|Use of a prescribed electronic magnifier plus existing optical aids for a period of 2 months
3128019|NCT01701700|Active Comparator|optical aids|Use of existing optical aids for 2 months
3128020|NCT01701687||Decompensated Alcoholic Cirrhosis|Recruited patients will have diagnosed liver cirrhosis (histological, radiological or accepted clinical parameters)admitted with an episode of decompensation. Patients must still be drinking hazardous alcohol quantities (>14 units for women, >21 units for men) at study enrollment
3128021|NCT01701674|Experimental|Combination Therapy|The combination of ipilimumab followed by lymphodepletion with chemotherapy, TIL infusion, and high dose IL-2.
3128022|NCT01701661|Active Comparator|conservative treatment|Compression stockings class II
3128023|NCT01701661|Active Comparator|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refloating trunk
3128024|NCT01701648|Active Comparator|1|
3128025|NCT01701635|Experimental|Disclosure intervention|In the disclosure intervention plus usual care arm the adherence and disclosure specialist will meet with caregiver at each clinic visit and provide information, education, disclosure skills, and support till disclosure occurs.
3128026|NCT01701635|Sham Comparator|Enhanced usual care|"In the enhanced usual care (control) arm the disclosure specialist will meet with caregiver at each clinic visit and provide them will general health education and no mention or effort will be made to improve disclosure skills of caregiver."
3128027|NCT01701622|Experimental|Allopurinol, febuxostat|Patients currently treated with allopurinol will be switched to febuxostat, and the blood pressure differences between the two arms will be compared.
3128028|NCT01701609|Experimental|Cognitive Remediation Therapy|CRT: Frontal/Executive Program. The program has a duration of 40 sessions, with two session for week. Is is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding in a context of learning without errors.
3128029|NCT01701596|Experimental|Rotational atherectomy (RA)|Immediate rotational atherectomy (RA) in the treatment with nondilatable calcified lesion complicated by coronary dissection
3128030|NCT01701596|Active Comparator|Delayed rotational atherectomy (RA)|Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
3128031|NCT01701583|Experimental|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
3128032|NCT01701570|Active Comparator|An Active Comparator exercise training intervention|The Active Comparator Groupwill participate in an exercise training intervention to distinguish the relative roles of objective factors (lactate level) and subjective factors (self-efficacy) in mediating pre-post change in RPE during low, moderate, and vigorous exercise.
3128033|NCT01701570|Placebo Comparator|A Placebo Attention Control|The placebo attention control group will receive monthly diabetes education and phone calls phone calls to monitor their blood glucose levels. Participants will receive an accelerometer to wear for one week.
3128034|NCT01701557|Active Comparator|slow fluid rate|bolus 10 ml/kg of NS followed by 1.25 times maintenance rate
3128035|NCT01701557|Active Comparator|Fast fluid rate|bolus 20 ml/kg of NS followed by 1.5 times maintenance rate
3128036|NCT01701544|Sham Comparator|NBM DBS Off|NBM DBS switched off
3128037|NCT01701544|Active Comparator|NBM DBS On|NBM DBS Switched On
3128038|NCT01701531|Experimental|RBCPF|Treatment intervention arm
3128039|NCT01701518|Other|Ozurdex|Intra-operative Ozurdex (biodegradable 0.7mg dexamethasone implant) post-vitrectomy for epiretinal membrane
3128040|NCT01701505|Experimental|Kovacaine Mist High Dose|400uL of Kovacaine Mist, as 2 sprays of 200uL.
3128041|NCT01701505|Experimental|Kovacaine Mist Mid Dose|200uL of Kovacaine Mist, as 2 sprays of 100uL.
3128042|NCT01701505|Experimental|Kovacaine Mist Low Dose|120uL of Kovacaine Mist, as 2 sprays of 60uL.
3128043|NCT01701492||Stem Cell Transplant Survivors|All participants enrolled on this study will complete a questionnaire and undergo neurocognitive evaluation.
3128044|NCT01701492||Normal control participants|Control participants in the community without a history of serious illness, matched on age, gender, race/ethnicity and socioeconomic status. They will complete a questionnaire and undergo neurocognitive evaluation.
3128077|NCT01701258|Active Comparator|MDD-amisulpride|Subjects without a history of child sexual abuse that are currently experiencing a major depressive episode are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
3128345|NCT01699282|Experimental|Group thorough VKA (antivitamin K)education|
3128045|NCT01701479|Experimental|dose schedule finding ch14.18/CHO|"Subcutaneous aldesleukin (IL-2) will be given at a dose of 6 x 106 IU/m2/day in two 5 day blocks (days 1-5 and 8-12).~A continuous infusion of ch14.18/CHO is started on day 8. The duration of the infusion is dependent on the assigned infusion schedule. The duration will range from 10 to 21 days. Three dose levels will be considered with respect to daily dose (7 mg/m2, 10 mg/m2, 15 mg/m2), which relates to total doses of 100 mg/m2,150 mg/m2 and 210 mg/m2.~Patients will receive isotretinoin (13-cis-RA) 160 mg/m²/day divided into two equal doses given orally twice a day for 14 days after the completion of the ch14.18/CHO infusion. The starting day is dependent on the duration of ch14.18/CHO infusion and may be either day 19, 23, 24 or 30."
3128046|NCT01701466|Experimental|Arm B: standard of care plus NeoVIDERM cream|Patients will apply NeoVIDERM cream to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. Patients will also perform standard of care skin treatment.
3128047|NCT01701466|Active Comparator|Arm A: standard skin care|Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatments. If they develop dry desquamation, they will be asked to apply Flamazine twice a day until dermatitis resolves.
3128048|NCT01701453|Experimental|6 months group|6 months duration of P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) treatment
3128049|NCT01701453|Experimental|12 months or longer group|12 months or longer duration of P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) treatment
3128050|NCT01701427||1|1. Healthy, un-operated, groin-hernia free, pain-free and medicinal free males
3128051|NCT01701414|Sham Comparator|Standard Care (SC)|The SC group will receive a sham injection of normal saline in order to blind both the participants and the treating physicians. A 7.5-MHz linear transducer will be placed on the side of the affected hip 1cm below the inguinal ligament. 1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice.
3128052|NCT01701414|Experimental|Femoral Nerve Block (FNB)|"Participants randomized to the second group, FNB group, will receive an Ultrasound (US) guided femoral nerve block using a Sonosite TitanTM (Sonosite, Inc., Bothell, WA) with a 7.5-MHz linear array transducer. Using this technique, 25ml of 0.5% bupivacaine will be injected along the nerve sheath. The femoral, obturator, and lateral cutaneous nerve are anesthetized with this technique (thus the name 3-in-1 femoral block is often used), providing maximum analgesia to the hip."
3128053|NCT01701401|Experimental|LDV/SOF 12 weeks|LDV/SOF administered for 12 weeks
3128054|NCT01701401|Experimental|LDV/SOF+RBV 12 weeks|LDV/SOF+RBV administered for 12 weeks.
3128055|NCT01701401|Experimental|LDV/SOF 24 weeks|LDV/SOF administered for 24 weeks
3128056|NCT01701401|Experimental|LDV/SOF+RBV 24 weeks|LDV/SOF+RBV administered for 24 weeks.
3128057|NCT01701388|Experimental|Ekso Safety and Efficacy|Observational study on the first time use of a robotic exoskeleton.
3128058|NCT01701375|Experimental|Arm 1|"PD 0332991 will be given orally days 1,2,3~Cytarabine (ara-C) will be given by continuous 72 hour intravenous infusion beginning on day 6~Mitoxantrone will be given over 2 hour infusion day 9, 12 hours after the completion of the ara-C infusion. The mitoxantrone dose may be reduced by 25-50% for patients who have received previous anthracyclines as determined by total previous anthracycline dose"
3128059|NCT01701362|Active Comparator|pregabalin|
3128060|NCT01701362|Placebo Comparator|placebo|
3128061|NCT01701349|Active Comparator|Fosbretabulin + paclitaxel + carboplatin|"Six 21 day cycles of:~Fosbretabulin (60 mg/m2) IV on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC 6) IV on Day 2"
3128062|NCT01701349|Placebo Comparator|Placebo + paclitaxel + carboplatin|"Six 21-day cycles of:~Placebo (formulated and packages to match fosbretabulin)on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC6) IV on Day 2"
3128063|NCT01701336|Experimental|Unique Arm|"Ad6NSmut~MVA-NSmut~15 subjects receiving 2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination"
3128064|NCT01701323|Experimental|Treatment (ex vivo expanded cord blood progenitors)|Patients receive filgrastim SC or IV on days 1-7, fludarabine phosphate IV QD over 30 minutes on days 2-6, cytarabine IV QD over 4 hours on days 2-6, and ex vivo-expanded cord blood progenitor cells IV over 30 minutes on day 8.
3128065|NCT01701310|Experimental|Ferric carboxymaltose|
3128066|NCT01701310|Active Comparator|Ferrous Sulphate|
3128067|NCT01701297|Active Comparator|Co-trimoxazole|Co-trimoxazole 960mg daily po
3128068|NCT01701297|Experimental|VSL#3 active|VSL#3 active 2 sachets/daily
3128069|NCT01701297|Placebo Comparator|VSL#3 placebo|VSL#3 placebo 2 sachets/daily
3128070|NCT01701284|Experimental|Right-Sided Low-Frequency rTMS|Participants will have rTMS administered at 1Hz to the right dorsolateral Prefrontal Cortex (dlPFC) once a day for 40 minutes, 5 days a week, for a total of six weeks.
3128071|NCT01701284|Experimental|Left-Sided High-Frequency rTMS|Participants will have rTMS administered at 10Hz to the left dorsolateral Prefrontal Cortex (dlPFC) once a day for 40 minutes, 5 days a week, for a total of six weeks.
3128072|NCT01701271|Experimental|Volunteers|20 volunteers both men and women with an age between 18 and 70 years suffering from Androgenetic Allopecia in several types apply on the scalp drops of the hair loss prevention lotion
3128073|NCT01701258|Active Comparator|CSA/MDD-amisulpride|Subjects experiencing a current episode of major depression (MDD) with a history of child sexual abuse (CSA) are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
3128074|NCT01701258|Placebo Comparator|CSA/MDD-placebo|Subjects experiencing a current episode of major depression (MDD) with a history of child sexual abuse (CSA) are randomized to receive a placebo during the fMRI session.
3128075|NCT01701258|Active Comparator|CSA/RES-amisulpride|Subjects with a history of child sexual abuse (CSA) without a current or past diagnosis of major depressive disorder (RES) are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
3128076|NCT01701258|Placebo Comparator|CSA/RES-placebo|Subjects with a history of child sexual abuse (CSA) without a current or past diagnosis of major depressive disorder (RES) are randomized to receive a placebo during the fMRI session.
3128160|NCT01700699||Sorafenib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Sorafenib
3131865|NCT01675518|Experimental|Part-2 fed|
3128078|NCT01701258|Placebo Comparator|MDD-placebo|Subjects without a history of child sexual abuse that are currently experiencing a major depressive episode are randomized to receive a placebo during the fMRI session.
3128079|NCT01701258|Active Comparator|Control-amisulpride|Subjects without a history of child sexual abuse and without a current or past diagnosis of major depressive episode are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
3128080|NCT01701258|Placebo Comparator|Control-placebo|Subjects without a history of child sexual abuse and without a current or past diagnosis of major depressive episode are randomized to receive a placebo during the fMRI session.
3128081|NCT01701245|No Intervention|Standard of care|No intervention, standard of care
3128082|NCT01701245|Active Comparator|GammaCore|Three stimulation treatments 2x/day 7 to 10 hours apart from one another. In addition, three stimulation treatments at the time of onset of symptoms of a headache attack.
3128083|NCT01701232|Active Comparator|MabThera|Reference rituximab at a dose of 375 mg/m2 intravenously once a week for four weeks (on days 1, 8, 15 and 22)
3128084|NCT01701232|Experimental|BCD-020|Proposed rituximab biosimilar at a dose of 375 mg/m2 intravenously once a week for four weeks (on days 1, 8, 15 and 22)
3128085|NCT01701219|Other|Cohort A|S. aureus on at least 1 blood culture within 72 hours of beginning study drug
3128086|NCT01701219|Other|Cohort B|MRSA on a baseline blood culture and on at least 1 additional blood culture after at least 72 hours of vancomycin and/or daptomycin treatment
3128087|NCT01701206|Experimental|HIV intervention Group|Experimental arm receives peer-led HIV information on social media
3128088|NCT01701206|No Intervention|Control arm|
3128089|NCT01701193|Placebo Comparator|Saline|1g/kg of body weight, 1 time intra-abdominal administration at time of surgery
3128090|NCT01701193|Experimental|Amino Acid|1g/kg of body weight, 1 time intra-abdominal administration at time of surgery
3128091|NCT01701180|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
3128092|NCT01701180|Placebo Comparator|Placebo|Intranasal application, sodium chloride solution, 3 puffs per nostril
3128093|NCT01701154||Pompe|Adults and children with Pompe disease.
3128094|NCT01701141||Individuals with MDD|Individuals with current MDD as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment.
3128095|NCT01701141||Healthy Controls|Individuals with no psychiatric diagnosis as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment
3128096|NCT01701128|Experimental|Speed TT|Walk on treadmill with progressive increases in speed
3128097|NCT01701128|Experimental|Mixed TT|Walk on treadmill with progressive increases in speed and incline
3128098|NCT01701128|Active Comparator|Control|Light-intensity exercise group, work flexibility and coordination
3128099|NCT01701115|Experimental|Low Dose (20 mL) Local Anesthetic|Intervention to be administered is a total volume of 20 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine.
3128100|NCT01701115|Active Comparator|Control Dose (40 mL) Local Anesthetic|Intervention to be administered is a total volume of 40 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine
3128101|NCT01701102|Active Comparator|Mepivacaine 37.5 mg|
3128102|NCT01701102|Active Comparator|Mepivacaine 30 mg plus fentanyl 10 µg|
3128103|NCT01701102|Active Comparator|Mepivacaine 27 mg plus fentanyl 10 µg|
3128104|NCT01701102|Active Comparator|Mepivacaine 24 mg plus fentanyl 10 µg|
3128105|NCT01701089|Experimental|RO4602522 Group 1|
3128106|NCT01701089|Experimental|RO4602522 Group 2|
3128107|NCT01701076|Experimental|Bendamustine|All patients are treated with bendamustine in combination with lenalidomide and dexamethasone for a maximum of 6 cycles.
3128108|NCT01701063|Experimental|Treatment-Naive or Prior Partial/Null Response|telaprevir + Peginterferon alfa-2b + Ribavirin
3128109|NCT01701050||Blood collection|Female patients 18 years or older with estrogen receptor (ER) positive, HER2 negative, progressive metastatic breast cancer after one or more lines of endocrine therapy (ET) who are initiating a new ET will be enrolled into the study. Patients must have immunohistochemistry (IHC) proven ER positive disease, IHC and/or fluorescence in-situ hybridization (FISH) proven HER2 negative disease, and an ECOG performance status of 0-2. Patients with brain metastases only or those who are progressing on fulvestrant are not eligible for the study.
3128110|NCT01701037|Experimental|Dabrafenib and Trametinib|Patients receive dabrafenib PO BID on days 1-28 adding trametinib on days 15-28 followed by surgery on days 28-30. Treatment continues in the absence of unacceptable toxicity.
3128111|NCT01701024|Active Comparator|ACYC|ACYC active, topically applied to the face for 12 weeks
3128112|NCT01701024|Placebo Comparator|ACYC vehicle|ACYC vehicle (placebo), topically applied to the face for 12 weeks
3128113|NCT01701011|Experimental|PRCI-monitoring|Coping intervention, Daily Record Keeping, Questionnaires
3128114|NCT01701011|No Intervention|Routine care control|Questionnaires
3128115|NCT01701011|No Intervention|Monitoring control|DRK and Questionnaires
3128116|NCT01700998|Placebo Comparator|Placebo|250 ml saline 0.9% for 24 hours in an infusion rate solution of 10.4 ml / hr for 3 days repeated during ICU stay if hypomagnesemia occurs.
3128117|NCT01700998|Experimental|Magnesium|48 mEq Magnesium diluted in 250 ml saline 0.9% for 24 hours in an infusion rate solution of 10.4 ml / hr. Therapy is continued for 3 days and repeated if hypomagnesemia occurs during ICU stay
3128118|NCT01700985|Experimental|122-0551|
3128119|NCT01700985|Placebo Comparator|Vehicle|
3128120|NCT01700972|Experimental|Imaging at 10-minute vs. 30-45-minutes|The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
3128121|NCT01700959|Active Comparator|Melatonin|Participants receive 3 mgs of time-release melatonin 1-2 hours prior to bedtime.
3128122|NCT01700959|Placebo Comparator|Placebo|Participants receive a placebo identical to the time-release melatonin and are instructed to take it 1-2 hours prior to bedtime.
3128161|NCT01700699||Axitinib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Axitinib
3128162|NCT01700699||Pazopanib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Pazopanib
3128123|NCT01700946|Active Comparator|Standard Risk|"Interventions: dexamethasone, vincristine sulfate, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, vinblastine, natural killer cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone~Cells for infusion are prepared using the CliniMACS System."
3128124|NCT01700946|Active Comparator|High Risk|"Interventions: dexamethasone, vincristine, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, natural killer cell infusion, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis, therapeutic hydrocortisone~Cells for infusion are prepared using the CliniMACS System."
3128125|NCT01700933|Active Comparator|High-dosage-group|
3128126|NCT01700933|Active Comparator|Low-dosage-group|
3128127|NCT01700920|Experimental|Mesenchymal Stem Cell|"Cell suspension mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They employ a minimum dose of 0.5 x 106 MSC / kg and a maximum of 1, 0x106 CSM / kg of patient weight.~Pharmaceutical form: Suspension cell Route of administration: local implant intraosseous injection with trocar in the femoral head."
3128128|NCT01700907|Active Comparator|group DES|The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.
3128129|NCT01700907|Active Comparator|group SEVO|The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
3128130|NCT01700894|Experimental|Walking Program + motivational interviewing calls|"The Women's Walking Program (WWP) core included a lifestyle PA prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every week for 5 weeks in the 1st 24 weeks and 1 3 months later) targeted to increase lifestyle PA in AA women.~Participant in the WWP plus motivational interviewing telephone call arm receives 11 motivational interviewing telephone calls from an interventionist, with two calls in between each of the group-visits. Motivational interviewing calls are tailored to the individual and intended to sustain intervention effects between group-visits"
3128131|NCT01700894|Experimental|Walking Program + automated calls|"The Women's Walking Program (WWP) core, including a lifestyle physical activity prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every 5 weeks during the first 24 weeks and 1 3 months later) targeted to increase lifestyle physical activity in African American women.~Participants in the WWP plus automated telephone call arm receive 11 automated calls with two calls sent between each group-visit. The automated calls are intended to supplement and sustain the intervention effects of the group-visits."
3128132|NCT01700894|Experimental|Walking Program|"The Women's Walking Program (WWP) core, including a lifestyle physical activity prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every 5 weeks during the first 24 weeks and 1 3 months later) targeted to increase lifestyle physical activity in African American women.~Participants in the WWP receive no telephone calls."
3128133|NCT01700881|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
3128134|NCT01700881|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
3128135|NCT01700868|Experimental|Vegan Group|Participants in the intervention group will follow a low-fat, vegan diet for 20 weeks, and will attend nutrition classes in the form of a weekly support group.
3128136|NCT01700868|Active Comparator|American Diabetes Association guidelines|Participants will follow ADA diet according to ADA regulations. This group will also receive weekly nutrition classes.
3128137|NCT01700855|Experimental|Electroacupuncture|Patients received electroacupuncture stimulation
3128138|NCT01700855|Sham Comparator|Non-electroacupuncture|Patients received sham electroacupuncture
3128139|NCT01700829|Active Comparator|Midazolam|0.02 mg/kg, I.V. (in the vein)
3128140|NCT01700829|Active Comparator|Ketamine|0.5 mg/kg, I.V. (in the vein)
3128141|NCT01700816|Experimental|Bright light therapy|2500 Lux gaze directed every morning from 8 am until 8:30 am
3128142|NCT01700816|Placebo Comparator|Sham light|<1000 Lux gaze directed every morning from 8 am until 8:30 am
3128143|NCT01700803|Experimental|Povidone Iodine 10%|Using Povidone Iodine 10% hand scrub before caesarian section
3128144|NCT01700803|Experimental|Povidone Iodine 7.5% hand scrub|Using Povidone Iodine 7.5% hand scrub before caesarian section
3128145|NCT01700790|Experimental|Lopinavir/ritonavir and ritonavir|Two tablets of twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 tablets of ritonavir 100 mg of twice daily given with rifampin 600 mg daily.
3128146|NCT01700777|Experimental|Intensive rehab group|"A group of children will beneficiate of HABIT-ILE treatment in an intensive way (camp) for 90h."
3128147|NCT01700777|Active Comparator|Regular treatment group|A group of children with hemiplegic cerebral palsy will beneficiate from conventional training at a regular frequency (1 to 6 hours / week) for 90hours.
3128148|NCT01700751|Experimental|Dose Level 0 (starting dose)|brentuximab vedotin 0.3mg/kg, given IV on Days 7, 28, 49 & 70
3128149|NCT01700751|Experimental|Dose Level 1|brentuximab vedotin 0.6mg/kg, given IV on Days 7, 28, 49 & 70
3128150|NCT01700751|Experimental|Dose Level 2|brentuximab vedotin 1.2mg/kg, given IV on Days 7, 28, 49 & 70
3128151|NCT01700751|Experimental|Dose Level 3|brentuximab vedotin 1.8mg/kg, given IV on Days 7, 28, 49 & 70
3128152|NCT01700751|No Intervention|Control Dose Level|The first 3 patients will not receive brentuximab vedotin.
3128153|NCT01700738|Experimental|gastric ring surgery|in this group a gastric ring will be put by surgery.
3128154|NCT01700738|Active Comparator|nutritional help|the usual treatment of obesity in France with nutritional care will be dispensed for this arm
3128155|NCT01700725|Experimental|Nasal Irrigation - Saline|nasal irrigation using saline plus routine care for symptoms of CRS and fatigue
3128156|NCT01700725|Experimental|Nasal Irrigation - Xylitol|Nasal Irrigation with Xylitol plus routine care for symptoms of CRS and fatigue
3128157|NCT01700725|No Intervention|Control Group|Control group subjects continue to use routine care only
3128158|NCT01700712|Active Comparator|L. reuteri (DSM 17938 and ATCC PTA 5289; 1x108 CFU|2 tablets a day for 2 weeks
3128159|NCT01700712|Placebo Comparator|Sugar pill|2 tablets a day for 2 weeks
3128163|NCT01700699||TKI|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with different type of tyrosine kinase inhibitor
3128164|NCT01700699||Motesanib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Motesanib
3128165|NCT01700699||Sunitinib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Sunitinib
3128166|NCT01700686||Obese subjects|Meal test and dexa scan
3128167|NCT01700673|Experimental|Myeloablative BMT|Azacitidine and sargramostim after myeloablative stem cell transplant
3128168|NCT01700673|Experimental|Non-myeloablative BMT|Azacitidine and sargramostim after non-myeloablative stem cell transplant
3128169|NCT01700673|Experimental|Standard consolidation|Azacitidine and sargramostim after standard consolidation
3128170|NCT01700660||VIO|Patients operated under VIO.
3128171|NCT01700660||Control|Patients operated without VIO.
3128172|NCT01700647||smoking controls|patients referred for bronchoscopy who have detailed axamination and do not have any dysplasia proven by bronchoscopy and laryngoscopy Breath test- sampling using ENose
3128173|NCT01700647||In Situ carcinoma larynx|Biopsy proven in situ carcinoma larynx proven by laryngoscopy and bronchoscopy Breath test- sampling using ENose
3128174|NCT01700647||Advanced Larynx Cancer|Biopsy proven stage 3/4 larynx cancer proven by laryngoscopy and bronchoscopy Breath test- sampling using ENose
3128175|NCT01700634||OA patients with HIGH central sensitization|Central sensitization will be defined by the presence of both spreading sensitization and temporal summation to repeated pressure pain stimulation (Arendt-Nielsen et al. 2010, Graven-Nielsen et al. 2010, Woolf 2010, Imamura et al. 2008, Nijs et al. 2010).
3128176|NCT01700634||OA patients with LOW central sensitization|
3128177|NCT01700634||Control subjects|
3128178|NCT01700621|Experimental|measles-rubella and rotavirus vaccines|receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine and one 1.0 ml dose of oral Rotarix vaccine at 9 months of age
3128179|NCT01700621|Active Comparator|measles-rubella vaccine|receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine at 9 months of age
3128180|NCT01700608||plerixafor treated patients|lymphoma and myeloma patients
3128181|NCT01700595|Experimental|new technical intervention|''new technical intervention'' represents the surgical procedure which is applied for the patients assigned to this group because of their certain characteristics. Namely, pediatric patients with broad axillary, anterior chest wall, mammary and neck scars are treated with this surgical approach.
3128182|NCT01700582||Patients with advanced lung cancer|Patients with advanced lung cancer
3128183|NCT01700569|Experimental|Folinic Acid|"Folinic acid is given orally every day during the radiation therapy (47 days), then 5 days at each of the 6 maintenance cycle of temozolomide. The dose is escalated in a 3x3 method and the levels are: 5mg, 10mg, 15mg, 30mg, 60mg."
3128184|NCT01700556|Active Comparator|Usual Care|"150 patient-caregivers will receive a light support in the form of paper brochures and 3 preventive home visits by a nurse"
3128185|NCT01700556|Experimental|UP Protocol|150 patient-caregivers provided with the systematic and comprehensive support of a case manager social worker and receiving 3 preventive home visits by a nurse
3128186|NCT01700556|Experimental|UP-TECH Protocol|150 patient-caregivers provided with the systematic and comprehensive support of a case manager social worker, receiving an intervention based on assistive technologies and 3 preventive home visits by a nurse
3128187|NCT01700543||1|Patients indicated for hemi or total shoulder arthroplasty with good bone stock who fulfill all inclusion and none of the exclusion criteria.
3128188|NCT01700530|Experimental|Statin|Statins (40mg/day)for an average of 12 weeks
3128189|NCT01700530|Experimental|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
3128190|NCT01700530|Active Comparator|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk) for 12 weeks
3128191|NCT01700517|Sham Comparator|control group|Spinal anesthesia with 0.5% isobaric bupivacaine, in isolation. Punctures in the femoral and popliteal areas were made to mask the femoral and sciatic block, respectively, with no infusion of any medication.
3128192|NCT01700517|Experimental|Femoral nerve block|In addition to the spinal anesthesia, block of the femoral nerve guided by ultrasonography (Nemio 17 - Toshiba Systems Co. - Japan) and neurosimulation (Stimuplex HNS 12 - Braun - Germany) with 1 Hz stimulus frequency, 1.2 to 0.5 mA energy. The technique used was femoral area puncture, at the level of the crural fold of skin, with a 0.5% (125mg) ropivacaine associated to 75 mcg of clonidine.
3128193|NCT01700517|Experimental|sciatic nerves block|In addition to the spinal anesthesia and femoral block, the anesthesia of the sciatic nerve at the top of the popliteal fossae was realized, also guided by ultrasonography (Nemio 17 - Toshiba Systems Co. - Japan) and neurosimulation (Stimuplex HNS 12 - Braun - Germany) with 1 Hz stimulus frequency, 1.2 to 0.5 mA energy. 0.5% ropivacaine was injected associated to 75mcg clonidine.
3128194|NCT01700504|Experimental|Gentamicin lavage|Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
3128195|NCT01700504|Active Comparator|Normal saline lavage|Patients undergoing 2 axillary lavages with 500ml of normal saline
3128196|NCT01700491|Active Comparator|Epidural Catheter 0.2% ropivacaine|Patients will receive an infusion of 0.2% ropivacaine at a range of 0-10 mL/hr through an epidural catheter. They will also receive an infusion of saline at a rate of 0-10 mL/hr through a paravertebral catheter.
3128197|NCT01700491|Active Comparator|Paravertebral Catheter 0.4% ropivacaine|Patients will receive an infusion of 0.4% ropivacaine at a range of 0-10mL/hr through a paravertebral catheter. They will also receive an infusion of saline at a range of 0-10mL/hr through an epidural catheter.
3128198|NCT01700478|Experimental|Misoprostol + vasopressin, Vasopressin|Misoprostol 400ug given rectally one hour before surgery.
3128199|NCT01700465||Hemodialysis|Patients undergoing hemodialysis
3128200|NCT01700452||patients suspected of having lung cancer|Subjects presenting with 0.8 - 3 cm solitary pulmonary nodules with high probability for malignance. The subject must be scheduled for a lung biopsy procedure to determine clinical diagnosis.
3128201|NCT01700439|Experimental|EDWARDS INTUITY valve|All subjects enrolled into the study are implanted with the EDWARDS INTUITY Valve System.
3128226|NCT01700231||Liver resection ,Liver Dysfunction|100 patients will be monitored perioperatively, in a subset of 40 patients hepatic venous pressure gradient will be monitored
3128202|NCT01700426|Active Comparator|iron|"Sixty-eight subjects found to have ID or IDA will be consented and randomized to one of the two treatment regimens (34 subjects per group). Liquid supplement preparations of iron (both groups), Vitamin E (test) and placebo (control) will be distributed by the research pharmacy at Children's Hospital Colorado.~A commercial ferrous sulfate solution (Fer-In-Sol, 15 mg elemental Fe/mL; Mead Johnson, Inc, Evansville, IN) will be distributed to all qualifying participants for the study by the research pharmacy at Children's Hospital Colorado. The volume of the suspension will be individualized by the pharmacy to the infant's weight, to maintain consistent iron dosing at 6 mg/kg/day."
3128203|NCT01700426|Active Comparator|iron 2|"Sixty-eight subjects found to have ID or IDA will be consented and randomized to one of the two treatment regimens (34 subjects per group). Liquid supplement preparations of iron (both groups), Vitamin E (test) and placebo (control) will be distributed by the research pharmacy at Children's Hospital Colorado.~A commercial ferrous sulfate solution (Fer-In-Sol, 15 mg elemental Fe/mL; Mead Johnson, Inc, Evansville, IN) will be distributed to all qualifying participants for the study by the research pharmacy at Children's Hospital Colorado. The volume of the suspension will be individualized by the pharmacy to the infant's weight, to maintain consistent iron dosing at 6 mg/kg/day."
3128204|NCT01700413|Experimental|Idarubicin|Cohort 1: Idarubicin 14 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day Cohort 2: Idarubicin 16 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day Cohort 3: Idarubicin 18 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day
3128205|NCT01700400|Experimental|Experimental Phase I Dose Escalation|"Pemetrexed: intravenous; 500 mg/m² for Dose Levels 1, 2 and 3~Carboplatin: intravenous; 5 AUC for Dose Level 1; 6 AUC for Dose Levels 2 and 3~Bevacizumab: intravenous; 15 mg/kg for Dose Levels 1, 2, and 3~Everolimus: oral, 2.5 mg/day for Dose Levels 1 and 2; 5.0 mg/day for Dose Level 3"
3128206|NCT01700387|Experimental|OnabotulinumtoxinA + Topiramate|"Subject will receive 155 U onabotulinumtoxinA injections at 31 sites every 3 months for 12 months and treat daily with topiramate. During the first month of the treatment period, subjects will titrate as follows:~Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
3128207|NCT01700387|Placebo Comparator|OnabotulinumtoxinA + Placebo|"Subject will receive 155 U onabotulinumtoxinA injections at 31 sites every 3 months for 12 months and treat daily with placebo. During the first month of the treatment period, subjects will titrate as follows:~Week 1: 1 tab qhs Week 2: 1 tab bid Week 3: 1 tab q am + 2 tabs qhs Week 4: 2 tabs bid"
3128208|NCT01700374||Women without Prepubertal Adversity|"At 8-17 weeks gestational age, 1,500 pregnant women will complete:~Adverse Childhood Events (ACE) Questionnaire;~Perceived Stress Scale (PSS);~A general health and demographic questionnaire.~All women who are screened will be asked if they would be willing to allow the study team to access their delivery report.~Women who report 0 or 1 adverse childhood experiences will be invited to continue in the study as part of the Women without Prepubertal Adversity cohort. We aim to have 125 women in this cohort."
3128209|NCT01700374||Women with Prepubertal Adversity|"At 8-17 weeks gestational age, 1,500 pregnant women will complete:~Adverse Childhood Events (ACE) Questionnaire;~Perceived Stress Scale (PSS);~A general health and demographic questionnaire.~All women who are screened will be asked if they would be willing to allow the study team to access their delivery report.~Women who report 2 or more adverse childhood experiences will be invited to continue in the study as part of the Women without Prepubertal Adversity cohort. We aim to have 125 women in this cohort."
3128210|NCT01700361||No treatment|This is an observational study. Women in this study are not receiving any treatments.
3128211|NCT01700348|Experimental|Airflosser|Use of Airflosser
3128212|NCT01700348|Active Comparator|Manual Floss|Normal Routine
3128213|NCT01700335|Experimental|SyB L-1101|"In Cohort 1, SyB L-1101 1200 mg/day group, Participants were administered 1200 mg/day of SyB L-1101 intravenously for 3 consecutive days, followed by 11-day observation period.~In Cohort 2, SyB L-1101 1800 mg/day group, Participants were administered 1800 mg/day of SyB L-1101 intravenously for 3 consecutive days, followed by 11-day observation period.~For both Cohorts, the treatment period of 14 days constitutes 1 cycle, and the treatment was allowed for up to 8 cycles."
3128214|NCT01700322|Active Comparator|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
3128215|NCT01700322|Active Comparator|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
3128216|NCT01700322|Active Comparator|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
3128217|NCT01700309|No Intervention|Control group|Treatment as usual
3128218|NCT01700309|Experimental|Young and Active|This arm will recieve web-based health counselling through the web-site Young and Active.
3128219|NCT01700296|No Intervention|Standard Care|"Standard Care: finishing treatment for AECOPD in hospital and after hospital discharge to further control by the GP. In case of severe symptoms and / or airway obstruction (measured by FEV1) refer patients for follow-up in lung clinic. The subjects are recorded with the same subjective, clinical, paraclinical and invasive parameters as the Best care group"
3128220|NCT01700296|Experimental|Best care|"Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:~10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)~Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters."
3128221|NCT01700283|Experimental|exercise education and walking program|
3128222|NCT01700283|No Intervention|maintain their daily activity|
3128223|NCT01700270|Experimental|dovitinib (TKI258)|dovitinib, 5 days on / 2 days off dose schedule
3128224|NCT01700257|Other|CT scan & Early CDT Lung test|Every study participant receives a CT scan & Early CDT-Lung test (biomarker blood test) for lung cancer screening purposes.
3128225|NCT01700244|Experimental|Pacemaker|
3128300|NCT01699620|Experimental|Linear incision|BAHA implant insertion with linear incision
3128227|NCT01700218|Other|telemonitoring|patients in the telemonitoring arm will record vital parameters (blood pressure, heart rate, body weight) and transmit these parameters together with wellbeing and daily dose of heart failure medication
3128228|NCT01700218|Other|control|patients in the control arm will not record any vital parameter
3128229|NCT01700205|Active Comparator|Type of Formula: CMF|infant is randomized to feed standard cow milk formula during first year of life
3128230|NCT01700205|Experimental|Type of Formula: EHF|infant is randomized to feed extensively hydrolyzed infant formula during first year of life
3128231|NCT01700192|Experimental|MK-8237|MK-8237 12 Development Units (DU) rapidly dissolving tablets administered sublingually once daily (q.d.).
3128232|NCT01700192|Placebo Comparator|Placebo|Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
3128233|NCT01700179|Experimental|ACH-0143102 plus ribavirin daily|ACH-0143102 225 mg loading dose on Day 1 followed by 75 mg maintenance dose on Days 2-84. Weight-based RBV(as per label) for Days 1-84.
3128234|NCT01700166|Experimental|Biologic; Cord Blood Stem Cells; Intravenous injection|Autologous Human Umbilical Cord Blood derived Stem Cell injection
3128235|NCT01700153|Experimental|Experimental: Robotic-assisted therapy|All patients will receive a similar classical rehabilitation as a basis. the 10 patients of this group will receive a supplement of robotic-assisted therapy.
3128236|NCT01700153|Active Comparator|Classical therapy|All patients will receive a similar classical rehabilitation as a basis. the 10 patients of this group will receive a supplement of classical rehabilitation.
3128237|NCT01700140|Experimental|SyB D-0701: high dose group|
3128238|NCT01700140|Experimental|SyB D-0701: low dose group|
3128239|NCT01700140|Placebo Comparator|placebo group|
3128240|NCT01700127|Other|Breastfeeding|Breastfeeding Encouraged
3128241|NCT01700127|Active Comparator|Breastfeeding Withheld|Breastfeeding Withheld
3128242|NCT01700088||Oxygen cannular|After lung resection surgery,every patient will received supplementary oxygen 5 L/minutes via oxygen cannular for 120 minutes
3128243|NCT01700075|Active Comparator|Conventional treatment|"Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day."
3128244|NCT01700075|Experimental|Weight loss treatment|Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
3128245|NCT01700062|Experimental|Medium calorie|
3128246|NCT01700062|Experimental|standard calorie|
3128247|NCT01700049|Experimental|Open Label oral vismodegib|This is a Phase 2B single-site, open-label, nonrandomized 24-week study of the efficacy and safety of vismodegib (150 mg PO daily) in subjects with high risk and/or locally advanced basal cell carcinoma. A total of 36 subjects with infiltrative/morpheaform, nodular, or superficial BCC will be enrolled in the study.
3128248|NCT01700036|Experimental|Treatment arm|Alpha-1-Antitrypsin (AAT) for the treatment of Steroid Refractory Acute Graft vs Host Disease.
3128249|NCT01700023||patients with leg-edema|patients with decompensated heart failure presenting with leg-edema
3128250|NCT01700010|Experimental|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
3128251|NCT01699997|Experimental|Oxytocin|Each treatment will consist of 10 insufflations (5/nostril alternating between nostrils) of OXT Spray, which contains approximately 40 international units (IU) of OXT
3128252|NCT01699997|Placebo Comparator|Placebo vial|Each treatment will consist of 10 insufflations (5/nostril alternating between nostrils) of placebo Spray, which contains all OXT Spray ingredients except for oxytocin.
3128253|NCT01699984||Hospitalized patients|All patients hospitalized in 4 inpatient facilities in Northern Italy during 4 index-months.
3128254|NCT01699971|Active Comparator|Lichtenstein|Hernia repair with lichtenstein propylene mesh
3128255|NCT01699958|Experimental|Problem-solving intervention|2 individual sessions teaching problem-solving skills with the use of videos, handouts, and worksheets.
3128256|NCT01699958|No Intervention|Control: Standard Care|Control arm participants will receive standard of care from their primary care provider.
3128257|NCT01699945||Verbal Autopsies|The study involves filling of verbal autopsies for still births and deaths in women of reproductive age group.
3128258|NCT01699932|Experimental|Arm 1|24-week treatment period: starting dose will be of 2/1000 mg or 4/2000 mg of glimepiride/metformin fixed combination (Amaryl M® ) depending on the previous treatment and dose. The Interventional medicinal product's dose will be increased every 2 weeks up to the maximum tolerated dose of 8/2000 mg of Amaryl M® , and adjusted throughout the 24-week treatment period according to fasting Self Monitored Plasma Glucose (SMPG) values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
3128259|NCT01699919|Active Comparator|intravenous lignocaine|Intravenous lignocaine will be given as a bolus of 1.5mg/kg at the time of intubation followed by an infusion at a rate of 1.5mg/kg/hr throughout surgery and till one hour post surgery.
3128260|NCT01699919|Placebo Comparator|normal saline|Normal saline will be given as a bolus at the time of intubation and saline infusion given to patients in the control group during the surgery and till one hour post surgery.
3128261|NCT01699906|Experimental|Dietary intervention|Diet regimen to induce weight loss
3128343|NCT01699295|Experimental|A+PAAC|Lessons delivered using A+PAAC
3128262|NCT01699893|Experimental|unique arm|"At V0: 1500 will be screened~At V1: 1000 subjects will be performed following samples: blood, nasal swab,stool. 500 subjects among 1000 will be performed one additional sample (Skin Biopsy)~At V2: only the 500 subjects having performing the skin biopsy at V1 will come at V2 to perform blood, nasal swab and stool samples"
3128263|NCT01699880||conventional high FiO2 bag reservoir facemask|this group of patients is intubated according to our current practice that requires the use of a high FiO2 nonrebreathing with bag reservoir facemask to ensure preoxygenation in patients requiring tracheal intubation. a small nasal catheter is inserted just before laryngoscopy to ensure a low oxygen flow to allow oxygenation during laryngoscopy.
3128264|NCT01699880||high flow nasal cannula oxygen|we wish to change our standard practice of preoxygenation and expand our use of high flow nasal cannula oxygen therapy to the tracheal intubation setting. Currently, used of high flow oxygen nasal cannula oxygen therapy to ensure oxygenation during intubation is limited to the patients already under high flow nasal cannula oxygen. the change of practice consists in the systematic use of high flow nasal cannula oxygen therapy in all patients requiring tracheal intubation in the ICU.
3128265|NCT01699854|Active Comparator|capsaicin patch|
3128266|NCT01699854|Placebo Comparator|placebo patch|
3128267|NCT01699841||HIV+ and HIV- mothers and their infants|
3128268|NCT01699828|Experimental|Buspirone 120 mg|Buspirone 120 mg (encapsulated).
3128269|NCT01699828|Experimental|Buspirone 60 mg|Buspirone 60 mg (encapsulated)
3128270|NCT01699828|Placebo Comparator|Placebo|Placebo (encapsulated)
3128271|NCT01699828|Experimental|Buspirone 30 mg|Buspirone 30 mg (encapsulated).
3128272|NCT01699815|Active Comparator|Preemptive group|The preemptive group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered within 60 minutes prior to incision. Each infusion will be administered over 15 minutes as recommended by manufacturer package insert.
3128273|NCT01699815|Active Comparator|Closure group|The closure group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered upon onset of skin closure.
3128274|NCT01699802|Experimental|Inhaled anaesthetic agent|The group where the investigators adds inhaled anaesthetic agent when using the anaesthetic gas reflector (AnaConda).
3128275|NCT01699789|Active Comparator|Resources for Services|The Resources for Services condition offers time-limited technical assistance to individual agencies, coupled with outreach from a community engagement specialty, to participate in structured reviews of components of the Quality Improvement Program Intervention as implemented by the Resources for Services Expert Team.
3128276|NCT01699789|Experimental|Community Engagement and Planning|The Community Engagement and Planning arm supported 4 months of planning for the Community Engagement and Planning Council consisting representatives of all assigned programs in biweekly 2 hour meetings to fit trainings in the Quality Improvement Program to the community and develop strategies across programs to collaborate as a network. The CEP Council developed a written plan for training and monitoring and supported implementation of the training plan. CEP sites were provided with enrolled client lists.
3128277|NCT01699776|Active Comparator|Ivabradine|Ivabradine, 7,5 mg b.id. by mouth for 14-16 weeks.
3128278|NCT01699776|Active Comparator|Digoxin|Digoxin 0.125 mg once a day, 5 times per week, for 12-14 weeks by mouth.
3128279|NCT01699763|Experimental|Subjects with and without Diabetes|All testing and lancing were performed by the study staff; Subjects with and without Diabetes did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using three Blood Glucose Monitoring Systems (BGMS): Contour® NEXT LINK BGMS; OneTouch® UltraLink® BGMS; Nova Max Link® BGMS.
3128280|NCT01699750|Experimental|Air Optix Aqua|Lotrafilcon B contact lenses with OFPM and BIOTRUE for 30 days each
3128281|NCT01699750|Active Comparator|Acuvue Oasys|Senofilcon A contact lenses with OFPM and BIOTRUE for 30 days each
3128282|NCT01699737|Experimental|JTT-851 Dose 1|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
3128283|NCT01699737|Experimental|JTT-851 Dose 2|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
3128284|NCT01699737|Experimental|JTT-851 Dose 3|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
3128285|NCT01699737|Active Comparator|Glimepiride Dose 1|Active Comparator Capsule and Placebo Tablets, administered once daily for 12 weeks
3128286|NCT01699737|Placebo Comparator|Placebo active & Placebo comparator|Placebo Tablets for study drug and Placebo Capsule for active comparator, administered once daily for 12 weeks
3128287|NCT01699724|Active Comparator|JZoloft|Oral tablet of sertraline hydrochloride (Japanese commercial tablet: JZoloft ® tablet) 50 mg as a single oral dose under fasted conditions
3128288|NCT01699724|Experimental|ODT without water|sertraline ODT 50 mg without water as a single oral dose under fasted conditions
3128289|NCT01699724|Experimental|ODT with water|sertraline ODT 50 mg with water as a single oral dose under fasted conditions
3128290|NCT01699711|Active Comparator|Dietary Supplement: Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
3128291|NCT01699711|Placebo Comparator|Placebo|No active treatment is given.
3128292|NCT01699698|Experimental|Test subject|
3128293|NCT01699685|Placebo Comparator|Sequence A|Patients will inhale QAB149 (capsule form in blister packs) + Placebo via Novartis Concept 1 SDDPI
3128294|NCT01699685|Active Comparator|Sequence B|Patients will inhale QAB149 plus NVA237 (capsule form in blister packs) via Novartis Concept 1 SDDPI
3128295|NCT01699672|Experimental|Group and Individual information|The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
3128296|NCT01699672|No Intervention|Individual information|Standard information about disease and treatment from doctor and nurse given at 2 occasions.
3128297|NCT01699646|Active Comparator|CTG + FBS|intrapartum surveillance with CTG+FBS
3128298|NCT01699646|Active Comparator|Neoventa S 21 ST-ANalysis of fetal heart|intrapartum surveillance with CTG + STAN
3128299|NCT01699620|Experimental|Dermatome|BAHA implant insertion with Dermatome technique
3128344|NCT01699295|Active Comparator|CON|Regular sedentary lessons
3128301|NCT01699607|Experimental|amphetamine|There is only one arm to the study. All subjects will receive amphetamine at 0.5mg/kg prior to the second PET scan.
3128302|NCT01699594|Experimental|Mannitol|This arm will assess the allergen induced change in airway responsiveness to mannitol bronchoprovocation.
3128303|NCT01699594|Active Comparator|Methacholine Chloride|This arm will assess the allergen induced change in airway responsiveness to methacholine bronchoprovocation.
3128304|NCT01699581|Experimental|Nestle Impact Advanced Recovery|"Nestle Impact Advanced Recovery~1 dose of Nestle Impact Advanced Recovery orally three times a day"
3128305|NCT01699568|Experimental|Vulcano Actives|Implants 4mm x 10mm Vulcano Actives (anodized surface)(AR Torque Vulcano actives), Conexão Sistemas de Prótese, Arujá, Brasil)will be placed on edentulous area in maxilla
3128306|NCT01699568|Active Comparator|Porous|Implants 4mm x 10mm Porous (dual acid-etched surface treatment)(AR Torque Porous, Conexão Sistemas de Prótese, Arujá, Brasil)will be placed on edentulous area in maxilla
3128307|NCT01699555|Experimental|GNbAC1|Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
3128308|NCT01699555|Placebo Comparator|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
3128309|NCT01699542|Active Comparator|Metal Stent|The WallFlex Biliary Fully Covered Esophageal Stent System is being evaluated for treatment of refractory anastomotic esophageal strictures.
3128310|NCT01699542|Active Comparator|Bougie Dilation|Esophageal Bougie Dilator commercially available devices used per Investigator preference are being evaluated for treatment of refractory anastomotic esophageal strictures.
3128311|NCT01699529|Experimental|Renal Denervation|
3128312|NCT01699516||Intestinal graft vs host disease|Patients with biopsy-proven intestinal acute GVHD in the setting of an allogenic transplant
3128313|NCT01699516||Control group|In the setting of an allogenic bone marrow transplant: patients with biopsy-proven stomach GVHD without intestinal symptoms and patients with neutropenic enterocolitis. Normal volunteers.
3128314|NCT01699503|No Intervention|No Screening|Subjects who are randomized into the non-screening arm will receive the usual standard of care.
3128315|NCT01699503|Experimental|Screening Group|Subjects who are randomized into the screening arm of the study will be screened by the MIS. Subjects with MIS score of less than 5 points will be referred to the Collaborative Dementia Care Program for a subsequent diagnostic assessment, counseling and management.
3128316|NCT01699490|Experimental|Fluoxetine + Valsartan|"The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.~Add-on treatment to 40 mg per day of valsartan"
3128317|NCT01699490|Active Comparator|Fluoxetine + Placebo|"The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.~Add-on treatment to placebo"
3128318|NCT01699477|Other|Trancranial MRg Focused Ultrasound for Neuropatic Pain|
3128319|NCT01699464|Experimental|AR-12286 Ophthalmic Solution 0.7%|AR-12286 Ophthalmic Solution 0.7%, both eyes
3128320|NCT01699464|Experimental|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5% both eyes
3128321|NCT01699464|Active Comparator|Timolol maleate ophthalmic solution 0.5%|Timolol maleate ophthalmic solution 0.5% both eyes
3128322|NCT01699438|Experimental|Mesalazine|
3128323|NCT01699438|Placebo Comparator|Placebo|
3128324|NCT01699425|Experimental|Ajust|Experimental group: surgery to treat stress urinary incontinence with the sling Ajust®
3128325|NCT01699425|Active Comparator|Classical transobturator tape|Control group: surgery to treat stress urinary incontinence with the Align® sling.
3128326|NCT01699412|Experimental|Dexamethasone|Patients under topical treatment with solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL
3128327|NCT01699412|Experimental|Clobetasol|Patients under topical treatment with solution of clobetasol 0.05% associated with nystatin 100,000 UI/mL
3128328|NCT01699399|Experimental|water immersion|infuse water during insertion phase of colonoscopy instead of air insufflation; remove the water during withdrawal phase.
3128329|NCT01699399|Experimental|water exchange|infuse and remove water during the insertion phase of colonoscopy. Air insufflation is used only in the withdrawal phase
3128330|NCT01699399|Active Comparator|air insufflation|standard colonoscopy using traditional air insufflation during insertion
3128331|NCT01699386|Active Comparator|Control Study Formula|protein hydrolysate formula
3128332|NCT01699386|Experimental|Experimental Study Formula|free-amino acid-based medical food
3128333|NCT01699373|Experimental|Ultrasound-assisted|Pre-procedural ultrasound scan performed
3128334|NCT01699373|No Intervention|Manual Palpation|
3128335|NCT01699360|Experimental|Cyclosporine A, Tacrolimus, Sirolimus|"Cyclosporine A：soft capsule,2-6mg/kg/d, the same twice daily dose at least five days.~Tacrolimus:capsule,0.15-0.3mg/kg/d, the same twice daily dose at least five days.~Sirolimus:tablet,2mg/d, once a day."
3128336|NCT01699347|Experimental|OK432|Intracystic injection of OK432 under US guiding
3128337|NCT01699334|Experimental|Psychoeducational video|
3128338|NCT01699334|Active Comparator|Relaxation video|
3128339|NCT01699321|Experimental|Your Move (physical activity)|The Your Move intervention is a multi-level, theory and evidence-based intervention that will include the following components: monthly handbills with community resources, newsletters, contests (shop and customer level), tailored health feedback report, and monthly phone calls from the research team.
3128340|NCT01699321|Other|Your Money (financial empowerment)|The Your Money program is an attention control intervention. Owners and barbers will receive 3 workshops that focus on financial health. Customers will receive monthly handbills and newsletters about different financial health topics.
3128341|NCT01699308|Experimental|Genotropin|10 persons with TBI and GHD will receive daily rhGH injections titrated to bring their GH levels into the normal range for one year. Treatment is initiated using rhGH (Genotropin) at an initial daily dose of 200mcg/day subcutaneously with a titration schedule calling for an increase in daily dosage by 200 mcg every two months until the target daily dose, 600 mcg/day, is achieved. The 10 GHD subjects will be assessed at baseline with EEG, fMRI and DTI and neuropsychological measures, again at 6 months, and a third time at 12 months.
3128342|NCT01699308|No Intervention|Control|5 demographically-matched TBI with normal GH subjects will be assessed at baseline (with EEG, fMRI and DTI, and neuropsychological measures) and at 12 months.
3128348|NCT01699256|Experimental|Enhanced strategy|Enhanced implementation strategy
3128349|NCT01699256|Active Comparator|Strategy as usual|Normal implementation strategy
3128350|NCT01699243||Epidural|subjects under epidural anesthesia
3128351|NCT01699230|Experimental|Omega 3 supplemented patients|To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
3128352|NCT01699230|No Intervention|Control group|
3128353|NCT01699204|Placebo Comparator|Filtered air with placebo|Exposure for 2 hours to filtered air and placebo tablets 3 times daily for 6 days
3128354|NCT01699204|Active Comparator|Diesel exhaust with placebo|Exposure for 2 hours to diesel exhaust and placebo tablets 3 times daily for 6 days
3128355|NCT01699204|Experimental|Diesel exhaust with N-acetylcysteine|Exposure for 2 hours to diesel exhaust and N-acetylcysteine tablets (600 mg) 3 times daily for 6 days
3128356|NCT01699191|Active Comparator|Probiotic Mixture|Probiotic mixture
3128357|NCT01699191|Placebo Comparator|Placebo|Placebo
3128358|NCT01699178|Experimental|Oral testosterone undecanoate|Oral testosterone undecanoate; continue dose from previous Phase III trial; 100-300 mg T (as TU), BID, for 12 months.
3128359|NCT01699178|Active Comparator|Transdermal testosterone gel (AndroGel)|Transdermal testosterone gel; continue dose from previous Phase III trial, 2.5-10 g/applied once daily for 12 months
3128360|NCT01699165|Sham Comparator|Placebo Nasal filter|Placebo treatment
3128361|NCT01699165|Active Comparator|Nasal Filter|Active treatment
3128362|NCT01699152|Experimental|TG02 citrate|TG02 citrate capsules given orally.
3128363|NCT01699139|Active Comparator|positional device|
3128364|NCT01699139|Sham Comparator|lumbar corset|
3128365|NCT01699126|Experimental|CPAP, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after CPAP on OSA
3128366|NCT01699126|Active Comparator|CPAP and statin, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after CPAP plus statin on OSA patients
3128367|NCT01699126|Active Comparator|OSA, statin, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after statin treatment on OSA
3128368|NCT01699126|No Intervention|Placebo|We will also measure the FMD, blood pressure and inflammation on patients with only life style modification as in all other patients
3128369|NCT01699100|Experimental|device|In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure > 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
3128370|NCT01699087|Experimental|PRK ALLEGRETTO|Photorefractive keratectomy (PRK) surgery using the ALLEGRETTO WAVE EYE-Q excimer laser system for myopic wavefront-optimized ablation
3128371|NCT01699074|Experimental|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
3128372|NCT01699074|Experimental|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
3128373|NCT01699074|Experimental|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
3128374|NCT01699074|Placebo Comparator|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
3128375|NCT01699074|Active Comparator|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
3128376|NCT01699061|Placebo Comparator|Placebo|Placebo tablet administered with a meal twice a day on Day 1
3128377|NCT01699061|Experimental|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
3128378|NCT01699048|Other|Hybrid group|Hybrid approach (Minimally invasive off-pump revascularization of the left anterior descending artery (LAD) with the left internal mammary artery (LIMA) bypass followed by consecutive percutaneous coronary intervention (PCI) in the rest of the arteries with drug eluting stents (DES) (Hybrid group, n=50)
3128379|NCT01699048|Other|PCI|Multi-vessel PCI with DES (MV-PCI group, n=50)
3128380|NCT01699048|Other|CABG|Coronary artery bypass graft (CABG) treatment (CABG group, n=50)
3128381|NCT01699035||stroke survivors|stroke survivors who have either returned to work, have thought about returning to work, or have tried to return to work
3128382|NCT01699022|Experimental|Injection Cyclofem|"Injection of Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.~Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection."
3128383|NCT01699009|Experimental|Vegan diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks.
3128384|NCT01699009|Placebo Comparator|Supplement group|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
3128385|NCT01698996|Active Comparator|No Packing|No Packing
3128386|NCT01698996|Experimental|Packing|Packing
3128387|NCT01698970|Experimental|1 = Tested product|
3128388|NCT01698970|Placebo Comparator|2 = Control product|
3128389|NCT01698957||UA Doppler Velocimetry|Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.
3128390|NCT01698944|Experimental|Somatropin|
3128391|NCT01698931|Experimental|Treatment period 1|
3128392|NCT01698931|Active Comparator|Treatment period 2|
3128393|NCT01698931|Placebo Comparator|Treatment period 3|
3128394|NCT01698918|Experimental|Everolimus + letrozole/exemestane|Enrolled patients will receive everolimus in combination with letrozole in the first line setting until disease progression, unacceptable toxicity or withdrawal of consent. Following disease progression in the first line setting, patients will be offered everolimus in combination with exemestane. Patients who discontinue treatment in the first line setting due to unacceptable toxicity or due to withdrawal of consent will not be offered everolimus plus exemestane. Those patients treated in the second line setting will continue treatment until disease progression, unacceptable toxicity or withdrawal of consent.
3128395|NCT01698905|Experimental|nilotinib|70 patients who maintain MR4.5 during the one year nilotinib consolidation phase will stop treatment when they enter the treatment-free remission (TFR) phase
3128396|NCT01698892|Experimental|I.V. sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation
3128397|NCT01698892|Active Comparator|sublingual sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
3128398|NCT01698879|Experimental|Single arm, two cohorts|Idarubicin, cytarabine, Mylotarg, G-CSF.
3128399|NCT01698866|Experimental|vaccin GenHevac B Pasteur|vaccin GenHevac B Pasteur (Suspension for injection in pre-filled syringe / 20 μg microgram(s)Per day). In total, 3 injections at M0, M1 and M6
3128400|NCT01698840|Experimental|Investigational Nutrition|Starting between post menstrual age (PMA) 34 0/7 to 38 6/7 weeks, infants in the Investigational Nutrition group will receive vitamin D drops that are added to transitional formula daily through hospital discharge and at home until the outpatient follow-up visit at 52 weeks PMA.
3128401|NCT01698840|Placebo Comparator|Routine Nutrition|Starting between post menstrual age (PMA) 34 0/7 to 38 6/7 weeks, infants in the Routine Nutrition group will receive placebo drops that are added to transitional formula daily through hospital discharge and at home until the outpatient follow-up visit at 52 weeks PMA.
3128402|NCT01698827||Kangaroo|"20 patients managed by Kangaroo gastrostomy tubes. Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
3128403|NCT01698827||Cook|"20 patients receiving Wilson Cook gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
3128404|NCT01698827||Silmag|"20 patients managed by Silmag gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
3128405|NCT01698827||Freka|"20 patients carrying Freka gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
3128406|NCT01698827||Bard|"20 patients using the Bard gastrostomy tube. Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
3128407|NCT01698814|Experimental|AL-4943A|AL-4943A Ophthalmic Solution, one drop instilled in both eyes once daily for up to 6 weeks
3128408|NCT01698814|Placebo Comparator|AL-4943A Vehicle|AL-4943A Ophthalmic Solution Vehicle, one drop instilled in both eyes once daily for up to 6 weeks
3128409|NCT01698801|Experimental|Lenalidomide plus dexamethasone|Lenalidomide plus low-dose dexamethasone
3128410|NCT01698788|Experimental|TPHM removal without ozurdex|Comparison of taut posterior hyaloid removal with (Group B)and without intraoperative ozurdex(Group A)
3128411|NCT01698788|Experimental|TPHM removal with ozurdex|Comparison of TPHM removal with (Group B) and without (Group A)Ozurdex
3128412|NCT01698775|Experimental|Omarigliptin (Phase A) → Omarigliptin (Phase B)|Phase A: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 24 weeks. Phase B: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 30 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24) will receive matching placebo to glipizide daily in a blinded manner during Phase B of the study (Week 24 through Week 54).
3128413|NCT01698775|Active Comparator|Placebo to omarigliptin (Phase A) → Glipizide (Phase B)|Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: matching placebo to omarigliptin orally once a week for 30 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24) will receive glipizide 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
3128414|NCT01698762||Osteoarthritis (OA)|"One OA group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One OA group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
3128415|NCT01698762||Osteoporosis (OP)|"One OP group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One OP group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
3128416|NCT01698762||Rheumatoid Arthritis (RA)|"One RA group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One RA group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
3128417|NCT01698749|Experimental|Ozurdex in diabetic macular edema|Intravitreal ozurdex given in patients with diabetic macular edema and patients followed up for change in central macular thickness and visual acuity over period of 6 months
3128418|NCT01698736|Active Comparator|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
3128419|NCT01698736|Experimental|Semiselective IA + membrane filtration|Semiselective immunoadsorption (GAM peptide adsorber) in combination with membrane filtration
3128420|NCT01698723|Active Comparator|Ribavirin|1000 mg (5 capsules)
3128421|NCT01698723|Placebo Comparator|Placebo|5 capsules of placebo
3128422|NCT01698710|Experimental|Albumin bound paclitaxel|Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
3128423|NCT01698697|Active Comparator|U100|
3128424|NCT01698697|Experimental|U200|
3128425|NCT01698684|Placebo Comparator|Placebo|
3128426|NCT01698684|Experimental|Avanafil 100 mg|
3128427|NCT01698684|Experimental|Avanafil 200 mg|
3128428|NCT01698671|Other|InterGard Synergy Vascular Graft|
3128429|NCT01698658|Experimental|Diagnostic (SoftVue ultrasound tomography)|Patients undergo ultrasound tomography using SoftVue. Some patients also undergo MRI of the breast.
3128430|NCT01698645||PecFent®|
3128431|NCT01698632||benign-looking adnexal masses|
3128432|NCT01698619||Climbers on Mount Aconcagua|The Cohort consists of volunteers climbing Mount Aconcagua.
3128433|NCT01698606|Active Comparator|Secondary lifestyle intervention arm|6-month wait list group. Second arm to receive multidisciplinary, family-centered lifestyle intervention with behavioral counseling, following of completion of main 6-month intervention for arm 1.
3224852|NCT01022164|Other|fibrin glue|
3128434|NCT01698606|Experimental|Primary lifestyle intervention arm|First arm to receive multidisciplinary, family-centered lifestyle intervention with behavioral counseling
3128435|NCT01698593|Active Comparator|Ring Finger Nerve Block|
3128436|NCT01698580|Active Comparator|usual care|The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
3128437|NCT01698580|Experimental|Multifactorial Falls Prevention Program|12 week intervention for 10 to 12 participants with sessions once a week, lasting for 2 hours, consisting of: On-site exercises (progressive body balance exercise program),Home-based exercise program, Educational and Behavioural sessions and management of modifiable risk factors.
3128438|NCT01698567|Active Comparator|Antithrombin III|"Product- Antithrombin III is derived from pooled human plasma~ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity [7], goal 120% activity[18], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)~a."
3128439|NCT01698567|Placebo Comparator|Placebo|placebo (normal saline)
3128440|NCT01698554|Experimental|bimatoprost formulation A solution|Bimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
3128441|NCT01698554|Active Comparator|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
3128442|NCT01698554|Placebo Comparator|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
3128443|NCT01698554|Placebo Comparator|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
3128444|NCT01698541|Experimental|Tacni|Tacrolimus administered as generic formulation Tacni in accordance with standard protocol at the transplant center
3128445|NCT01698541|Active Comparator|Prograf|Tacrolimus administered as Prograf in according to standard protocol at the transplant center
3128446|NCT01698528|Experimental|Intervention Group|The experimental arm will be provided with a tablet computer with a newly designed software to help manage his or her diabetes care. This arm will communicate with his or her provider through the tablet computer to initiate and titrate basal insulin dose based on the 303 protocol. The individuals in this arm will also track their glucose values and medication adherence using the tablet computer by documenting when medication was taken or insulin was injected.
3128447|NCT01698528|No Intervention|Control Group|The individuals in the control group will receive usual care from the study Clinic as they always have. These individuals will be tracking their diabetes in the same way they have been by communicating with their health care provider and his or her office via fax/phone/e-mail. These individuals will not be provided with a tablet computer.
3128448|NCT01698515||Anti-TNF subgroup|"anti - TNF subgroup~20 subjects with RA, who are starting TNF inhibitors based on the decision of their treating rheumatologist, will be recruited from the clinic. Patients will be starting commercially available anti-TNF agents that have already been authorized for insurance coverage. We are not requesting anti-TNFs or other drugs specifically for patients enrolled in this study from any pharmaceutical company. Patients will also continue on their background MTX and corticosteroids if they are taking these agents, and MTX will be required for patients taking Infliximab or Golimumab as per approved indication. No medications will be supplied through the study."
3128449|NCT01698502||Trained|Healthy, Endurance trained (Maximal oxygen uptake (VO2max), ml*min-1*kg-1>60), 20-30 year, BMI: 18,5-25kg/m2, males.
3128450|NCT01698502||Untrained|Healthy, sedentary (Maximal oxygen uptake (VO2max), ml*min-1*kg-1<50), 20-30 year, BMI: 18,5-25kg/m2, males.
3128451|NCT01698476|Active Comparator|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
3128452|NCT01698476|Placebo Comparator|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
3128453|NCT01698450|Other|Focused Ultrasound for Movement Disorders|
3128454|NCT01698437|Other|Transcranial MR-Guided Focused Ultrasound for Brain Tumors|
3128455|NCT01698398|Experimental|CF-LVAD pumpspeed.|Optimal pumpspeed setting of CF-LVAD during exercise on ergometric bicycle.
3128456|NCT01698385|Active Comparator|Lifestyle counseling|
3128457|NCT01698385|No Intervention|Control, just measurements|
3128458|NCT01698372|Experimental|Prevena device (Group A)|Group A will have the VAC Prevena portable device applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery.
3128459|NCT01698372|No Intervention|Conventional dressing (Group B)|Group B will have conventional dry dressing applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery.
3128460|NCT01698346|No Intervention|control|50 unvaccinated pregnant women
3128461|NCT01698346|Active Comparator|Pertussis vaccine (Boostrix®, GSK Biologicals, Rixensart)|50 pregnant women vaccinated with pertussis vaccine
3128462|NCT01698333|Experimental|122-0551|
3128463|NCT01698320|Placebo Comparator|Placebo MDPI-Albuterol MDPI|"During the 12-week double-blind period, participants take 2 inhalations of placebo MDPI (multi-dose dry powder inhaler), four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.~The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise."
3128491|NCT01698138|Active Comparator|Onabotulinumtoxin A|"30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, Allergan) in 30 ml of NaCl 0.9 %."
3128492|NCT01698125||Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
3128464|NCT01698320|Experimental|Albuterol MDPI-Albuterol MDPI|"During the 12-week double-blind period, participants take 2 inhalations of albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation, four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total daily dose of 720 micrograms per day.~The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise."
3128465|NCT01698307|Active Comparator|Enhanced Treatment Algorithm|The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.
3128466|NCT01698307|Other|Conventional Step-care Algorithm|Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Index (HBI).
3128467|NCT01698294|Experimental|Group I (flaxseed)|"Participants receive flaxseed PO daily for 6 weeks. After a usual diet washout period of 8 weeks, patients crossover to Group II."
3128468|NCT01698294|Active Comparator|Group II (usual diet)|"Participants maintain a usual diet for 6 weeks. After a usual diet washout period of 8 weeks, patients crossover to Group I."
3128469|NCT01698281|Experimental|Arm A: AEZS-108|Intervention: AEZS-108 (267 mg/m^2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle). Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone
3128470|NCT01698281|Active Comparator|Arm B: Standard (SCCC)|"commercially available standard single agent cytotoxic chemotherapy (SSCC): - doses below the recommended package insert at the discretion of treating oncologist;~- on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle)."
3128471|NCT01698268|Experimental|TAP Group|Enrolled subjects will receive a TAP block with 0.5cc/kg of 0.25% ropivacaine.
3128472|NCT01698268|Active Comparator|Local Infiltration Group|Enrolled subjects will receive will receive local infiltration of 0.5 cc/kg of 0.25% ropivacaine.
3128473|NCT01698255|Experimental|ENGAGE|"ENGAGE is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression. The steps of ENGAGE are:~basic social and physical engagement, which has been found to be a very effective depression strategy for most older adults;~the addition of strategies to address clinical features of depression interfering with treatment engagement, namely affect regulation, pessimism, and disorganization."
3128474|NCT01698255|Active Comparator|Standard of Care Psychotherapy|The comparison group for this study will be the current standard of care psychotherapy offered by Westchester Jewish Community Services (WJCS) therapists. This type of psychotherapy is often supportive or eclectic in nature. Therapists will focus on helping the subject to express feelings and focus on strengths and abilities in working through current difficulties and transitions. Therapists assigned to provide standard psychotherapy to eligible participants will receive training and supervision from WJCS staff consistent with agency practice.
3128475|NCT01698242|Experimental|Enhanced Training|The Enhanced Training intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. Randomization occurs at the PCP-level, that is, patients are assigned to the Enhanced Training group only if their PCP has been enrolled and randomized to this group. Descriptions of the intervention on the PCP-level and patient-level are provided in the intervention section.
3128476|NCT01698242|Active Comparator|Enhanced Education|The Enhanced Education intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention strategy revolves around providing nominal information through the mail. Randomization occurs at the PCP-level; that is, patients are assigned to the Enhanced Education group only if their PCP already has been enrolled and randomized to this group. Description of the intervention on the PCP-level and patient-level is provided in the intervention section.
3128477|NCT01698229||Group 1|Study cohort is comprised of healthy children, ages 2yrs - 8yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
3128478|NCT01698216||Consta Sustenna switching|The patients group who switched to paliperidone palmitate from risperidone long acting injection
3128479|NCT01698203|Experimental|ropivacaine|
3128480|NCT01698203|Placebo Comparator|placebo|
3128481|NCT01698190|Active Comparator|Fine needle aspiration (FNA)|Endoscopic ultrasound guided needle tissue acquisition: Tissue acquisition using a standard FNA needle
3128482|NCT01698190|Active Comparator|Fine needle biopsy (FNB)|Endoscopic ultrasound guided needle tissue acquisition: Tissue acquisition using a new Core needle (Procore; Fine Needle Biopsy).
3128483|NCT01698177|Active Comparator|Group A|This group will receive the influenza vaccine preoperatively.
3128484|NCT01698177|Active Comparator|Group B|Group B will receive the influenza vaccine postoperatively, prior to hospital discharge.
3128485|NCT01698177|No Intervention|Group C|Group C subjects have already received the seasonal flu vaccine.
3128486|NCT01698177|Placebo Comparator|Group D|Group D subjects have refused the vaccine, but agree to have serum titers drawn.
3128487|NCT01698164|Active Comparator|estradiol plus MPA|"1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 4mg medroxyprogesterone acetate, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.~estradiol valerate, 1mg*21/box medroxyprogesterone acetate, 2mg*100/bottle"
3128488|NCT01698164|Experimental|estradiol plus progesterone|"1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 200mg progesterone capsule, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.~estradiol valerate, 1mg*21/box progesterone capsule, 100mg*6/box"
3128489|NCT01698164|Experimental|Ximingting tablet|1 tablet of cimicifuga rhizoma extract, tid 100mg*15*2/box The anticipated duration is 2 years.
3128490|NCT01698138|Placebo Comparator|Placebo|30 transurethral injections, each of 1 ml solution containing NaCl.
3128493|NCT01698112|Experimental|Flaxseed High Dose|
3128494|NCT01698112|Experimental|Flaxseed Low Dose|
3128496|NCT01698086|Experimental|Experimental group|Participants who are randomized to the Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions (Figure 1). The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report.
3128497|NCT01698086|No Intervention|Wait-listed Control group|The Wait-listed Control group will not receive treatment; however, participants in the Wait-listed Control group will undergo the same outcome measurement plan as the Experimental group. If interested, participants from this group will be placed on a wait-list and will have the opportunity to receive instructions in how to perform the vestibular rehabilitation program following their completion of the study.
3128498|NCT01698073|Experimental|mCOL|mCircle of Life is a culturally-based HIV-prevention intervention designed for American Indian and Alaska Native 10-12 year-olds. It includes both online and facilitated material.
3128499|NCT01698073|Active Comparator|AS+|After-School Science Plus is a curriculum designed for youth to teach science and literacy using everyday materials. It helps youth see how science is a part of everyday life and provides role models of scientists who come from different backgrounds and ethnicities.
3128500|NCT01698060|Experimental|Intestinal Delivery|ND1.1
3128501|NCT01698047|Experimental|Resiliency Class|"Resiliency Classes (study group) Study participant randomized to the Resiliency classes will be offered and assigned a time and date to attend the classes. Each class will have up to 10 participants. Classes will be 90-120 minutes in duration and will be held weekly for six weeks. At the classes, participants will be offered a copy of the Resiliency Class Manual. And at each class, light snacks and refreshments will be offered.~The Resiliency Class manual covers the following topics:~Session 1 - What Affects Your Mood and Resilience; Session 2 - Pleasant Activities Can Help Improve Your Mood and Make You Resilient; Session 3 - What Gets In The Way of Pleasant Activities: Harmful Thoughts and How to Change Them; Session 4 - How to Increase Your Resilience Through Support from Others; Session 5 - My Personal Resiliency Plan: Goal Setting; Session 6 - Celebrate Your Resiliency: Graduation"
3128502|NCT01698047|Active Comparator|Case Management|Case management phone calls (control group) Study participants randomized to the case management phone calls will be told that they will receive two calls over two months by study staff to offer them referrals based on their perceived need for services to local health care, mental health, substance use, social services, child welfare, housing, and food. In addition, study participants in this arm of the study will be told that if the study determines that the resiliency classes are better at improving mood than the case management calls, they will receive a call to invite them to participate in resiliency classes for free at the B-RICH partner agencies.
3128503|NCT01698034|Experimental|Volunteering|Weekly volunteering with elementary school children in after school programs
3128504|NCT01698034|No Intervention|Control|Wait-list control
3128505|NCT01698008|Experimental|Mobile application use|The intervention group will be instructed to submit their blood glucose logs once a month with the use of a mobile application, Diabetes Doctor, to the provider who will make insulin regimen changes. All subjects will be evaluated once at initial, 3 month, and 6 month visits. They will receive HbA1c on each visit. After the initial 3 months have been completed a 15 question Diabetes Quality of Life survey will be completed by all patients from both groups. A Usability and Satisfaction of Diabetes Doctor survey will be given to those patients who used the mobile application. At the 3 month interval the control group will be given the opportunity to use the mobile application if desired. The study group will be given the opportunity to continue or discontinue the use of the mobile application. At the 6 month interval the Usability and Satisfaction of Diabetic Doctor survey and 15 question Diabetes Quality of Life survey will be administered to evaluate all mobile application users.
3128506|NCT01697995||Lexiscan-Echo echo subjects|No Intervention: Observational study
3128507|NCT01697995||Lexiscan-Echo control subjects|No intervention: observational study
3128508|NCT01697982|Experimental|Living with Hope Program|"Participants will receive the Living with Hope Program (LWHP). The LWHP involves viewing a short film and choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection."
3128509|NCT01697982|Experimental|LWH Film|Participants will viewing a short film entitled Living with Hope (LWH), which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope
3128510|NCT01697982|No Intervention|Usual Care|Participants in the usual care group will not receive an intervention. Data collection for outcome variables will be the same as the participants in the other arms.
3128511|NCT01697969|Experimental|Pataday|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop once daily in both eyes for 14 days
3128512|NCT01697956|Experimental|BDP Nasal Aerosol 80 mcg/day|BDP nasal aerosol: 80 mcg dose once daily in the morning. Participants/parents administer 40 mcg BDP (one spray per nostril) during the 42 day (6 week) Treatment Period.
3128513|NCT01697956|Placebo Comparator|Placebo Nasal Aerosol|Participants/parents administer placebo (no medication) (one spray per nostril) once daily in the morning during the 42 day (6 week) Treatment Period.
3128514|NCT01697943|Experimental|Roux-En-Y Pouch Reconstruction or Roux-En-Y Reconstruction|
3128515|NCT01697930|Experimental|[18F] 4-L-Fluoroglutamine (2S,4R)|This pilot, first in-human microdose PET trial of the positron-emitting agent [18F] 4-L-Fluoroglutamine (2S,4R) will be an open-label study. The [18F] 4-L-Fluoroglutamine (2S,4R) agent will be administered by bolus intravenous injection. In all study patients, the pharmacokinetics, metabolism, and biodistribution of [18F] 4-L-Fluoroglutamine (2S,4R) will be evaluated by non-invasive blood- and PET-based assays, at multiple time points (see Table 1,) during one day. Eligible patients optionally can participate in the study twice, on a separate date, receiving a second radiotracer microdose of [18F] 4-L-Fluoroglutamine (2S,4R), followed by non-invasive blood- and PET-based assays. At the discretion of the investigator, scan 3 can be waived.
3128516|NCT01697917|Other|Total Gastrectomy or Proximal Gastrectomy|
3128561|NCT01697592|Experimental|Omarigliptin 25 mg/α-GIs (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of α-glucosidase (α-GIs) inhibitors throughout the duration of the study.
3129044|NCT01694212|Experimental|Diclofenac|Patients with diabetic retinopathy having preoperative treatment with diclofenac
3128517|NCT01697904|Experimental|Low Oxygen Strategy|"Resuscitation was initiated with room air (21% O2) for LOX infants. Supplemental oxygen was given if 1) the heart rate (HR) was less than 100 bpm after 30 seconds of effective ventilation, 2) the lower limits of goal saturations were not met. Targeted goal Pre-ductal saturations after birth were derived by approximation of the interquartile values for healthy term infants as reported by Kamlin et al and Dawson et al.FiO2 was increased or decreased by 10% in 30 second intervals as needed. If HR < 60 bpm after 30 seconds of effective ventilation , FiO2 was increased to 100% until the heart rate was stabilized.~Targeted Pre-ductal SpO2 After birth~min 60%-65%~min 65%-70%~min 70%-75%~min 75%-80%~min 80%-85%~10 min 85%-94%"
3128518|NCT01697904|Active Comparator|Traditional Oxygen strategy ( TOX)|Resuscitation for TOX infants was started with 100% O2 and adjusted every 30 seconds by 10% to meet the target oxygen saturation range of 85-94%
3128519|NCT01697891|Experimental|ALTENS|Patients in this arm will be treated with Acupuncture-like Transcutaneous Electrical Nerve Stimulation using Codetron (Codetron ALTENS)
3128520|NCT01697878|Experimental|Randomization Group 1|CPAP first followed by standard of care
3128521|NCT01697878|Active Comparator|Randomization group 2|Standard of care followed by CPAP
3128522|NCT01697865|Active Comparator|Transfer group|The first surgical technique includes a concomitant latissimus and teres major transfer (transfer group).
3128523|NCT01697865|Active Comparator|Control group|The second technique does not include a concomitant latissimus and teres major transfer (control group).
3128524|NCT01697852|Experimental|LLIN plus IRS|LLIN by universal coverage campaign 2 rounds of indoor residual spraying with bendiocarb insecticide
3128525|NCT01697852|Active Comparator|LLIN only|LLIN by universal coverage campaign
3128526|NCT01697826|Active Comparator|ClinSupV3 -soft gelatin capsule|Soft gelatin capsule containing 100mg Clindamycin and 200mg clotrimazole administered per vaginally for 3 consecutive days
3128527|NCT01697826|Active Comparator|ClinSupV3ER- Extended release tablet|ER tablets containing 100mg clindamycin and 200mg clotrimazole administered per vaginally for 3 consecutive days.
3128528|NCT01697800|Placebo Comparator|Placebo|Placebo Capsules
3128529|NCT01697800|Active Comparator|Tadalafil|Tadalafil
3128530|NCT01697787|Other|Amodiaquine-Artesunate|ASAQ is produced by Sanofi-Aventis as CoarsucamTM and as artesunate-amodiaquine Winthrop®
3128531|NCT01697787|Other|Artemether-Lumefantrine|AL (tablets containing 20 mg of artemether and 120 mg of lumefantrine) is produced by Novartis
3128532|NCT01697761|Experimental|Treatment Group|treat by moxibustion and acupuncture
3128533|NCT01697761|Experimental|Control Group|treat by Sham acupuncture and moxibustion
3128534|NCT01697748|Placebo Comparator|Telfa pad dressing|Telfa pad dressing placed over Cesarean wound after skin closure; the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
3128535|NCT01697748|Active Comparator|Silver-impregnated dressing|Silver-impregnated dressing placed over Cesarean wound after skin closure; the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
3128536|NCT01697735|Experimental|Berberine;Atorvastatin or Rosuvastatin|Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily; Besides taking statins, Participants will receive 500mg berberine twice a day for 8 weeks.
3128537|NCT01697735|Active Comparator|Atorvastatin or Rosuvastatin|Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
3128538|NCT01697722||Step-up as FDC ICS/LABA|ICS asthma patients who increased therapy as FDC ICS/LABA (no increase in daily ICS dose).
3128539|NCT01697722||Step up as separate therapies|ICS asthma patients who increased therapy as ICS / LABA via separate pMDI and / or BAI inhalers (no increase in daily ICS dose).
3128540|NCT01697722||Qvar step-up|ICS asthma patients who increased therpy as extra-fine hydrofluoroalkane-beclometasone dipropionate
3128541|NCT01697709|Placebo Comparator|Placebo|Placebo medication
3128542|NCT01697709|Experimental|quetiapine|Quetiapine treatment
3128543|NCT01697696|Experimental|NVA237 dose 1|NVA237 dose 1
3128544|NCT01697696|Active Comparator|Long-acting beta 2-agonist (LABA)|QAB149
3128545|NCT01697683|Active Comparator|Probiotic Rhamnosus Lactobacilli|
3128546|NCT01697683|Placebo Comparator|Sugar pill|
3128547|NCT01697670|Experimental|Photodynamic therapy with Gliolan|Intervention: Laser light illumination with a cylindrical light diffuser (Model RD, Medlight SA) is performed 3 hours after administration of 15 mg/kg 5-aminolevulinic acid (5-ALA, Gliolan)
3128548|NCT01697657|Experimental|Detemir|
3128549|NCT01697657|Active Comparator|NPH|
3128550|NCT01697644|Experimental|Low dose|
3128551|NCT01697644|Experimental|High dose|
3128552|NCT01697631|Experimental|BIAsp|
3128553|NCT01697631|Experimental|Insulin aspart|
3128554|NCT01697618|Experimental|BIAsp 30|
3128555|NCT01697618|Active Comparator|BHI 30|
3128556|NCT01697605|Experimental|BGJ398|Eligible participants received oral BGJ398 once daily or twice daily. Patients may continue treatment with BGJ398 until the patient experiences unacceptable toxicity or progressive disease.
3128557|NCT01697592|Experimental|Omarigliptin 25 mg/Sulfonylureas (SUs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of SUs throughout the duration of the study.
3128558|NCT01697592|Experimental|Omarigliptin 25 mg/Glinides (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of glinides throughout the duration of the study.
3128559|NCT01697592|Experimental|Omarigliptin 25 mg/biguanides (BGs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of BGs throughout the duration of the study.
3128560|NCT01697592|Experimental|Omarigliptin 25 mg/Thiazolidinediones (TZDs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of TZDs throughout the duration of the study.
3128562|NCT01697592|Placebo Comparator|Placebo/SUs (Phase A) → Omarigliptin 25 mg/SUs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of SUs throughout the duration of the study.
3128563|NCT01697592|Placebo Comparator|Placebo/Glinides (Phase A) → Omarigliptin 25 mg/Gln. (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of glinides throughout the duration of the study.
3128564|NCT01697592|Placebo Comparator|Placebo/BGs (Phase A) → Omarigliptin 25 mg/BGs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of BGs throughout the duration of the study.
3128565|NCT01697592|Placebo Comparator|Placebo/TZDs (Phase A) → Omarigliptin 25 mg/TZDs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of TZDs throughout the duration of the study.
3128566|NCT01697592|Placebo Comparator|Placebo/α-GIs (Phase A) → Omarigliptin 25 mg/α-GIs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of α-GIs inhibitors throughout the duration of the study.
3128567|NCT01697579|Experimental|Fosaprepitant 5 mg/kg-Cycle 1|Participants were administered intravenous (IV) fosaprepitant at the following weight-adjusted doses: participants 4 months to <12 years old were administered 5 mg/kg (not to exceed 150 mg); participants 1 to <4 months old were administered 2.5 mg/kg; participants 0 to <1 month old were administered 1.25 mg/kg. Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
3128568|NCT01697579|Experimental|Fosaprepitant 3 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 150 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 3 mg/kg (not to exceed 150 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
3128569|NCT01697579|Experimental|Fosaprepitant 1.2 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 60 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 1.2 mg/kg (not to exceed 60 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
3128570|NCT01697579|Experimental|Fosaprepitant 0.4 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 20 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 0.4 mg/kg (not to exceed 20 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
3128571|NCT01697579|Placebo Comparator|Placebo Control-Cycle 1|Participants were administered IV normal saline at volume to match age and weight specific doses of fosaprepitant. Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
3128572|NCT01697579|Experimental|Fosaprepitant 5 mg/kg-Cycles 2-6|For optional Cycles 2-6, participants from the 5 mg/kg fosaprepitant arm in Cycle 1 were administered fosaprepitant 5 mg/kg IV (or age-adjusted equivalent). For Cycle 2, fosaprepitant was administered IV plus ondansetron with or without dexamethasone. For Cycles 3-6, fosaprepitant was administered IV plus a 5- hydroxytryptamine 3 (5-HT3) antagonist with or without dexamethasone. Participants 1 year or less were required to receive ondansetron in all cycles as the 5-HT3 antagonist.
3128573|NCT01697579|Experimental|Fosaprepitant 3 mg/kg-Cycles 2-6|For optional Cycles 2-6, participants from Cycle 1 fosaprepitant arms (3, 1.2, or 0.4 mg/kg) or Cycle 1 control arm were administered fosaprepitant 3 mg/kg IV (or age-adjusted equivalent). For Cycle 2, fosaprepitant was administered IV plus ondansetron with or without dexamethasone. For Cycles 3-6, fosaprepitant was administered IV plus a 5-HT3 antagonist with or without dexamethasone.
3128574|NCT01697566|Experimental|Metformin|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg."
3128575|NCT01697566|Experimental|Placebo + Lifestyle Intervention|Placebo taken by mouth twice daily for 4, 30 day cycles. Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
3128576|NCT01697566|Experimental|Metformin + Lifestyle Intervention|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg.~Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period."
3128577|NCT01697566|Placebo Comparator|Placebo|Placebo taken by mouth twice daily for 4, 30 day cycles.
3128578|NCT01697553|Experimental|Home automation pack coupled to teleassistance service|
3128579|NCT01697553|Active Comparator|Home without automation pack coupled to teleassistance service|
3128580|NCT01697527|Experimental|Treatment (gene and vaccine therapy)|"CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 30 minutes on days -4 to -1.~TRANSPLANT: Patients receive NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL IV on day 0. Patients also receive NY-ESO-1 (157-165) peptide pulsed dendritic cell vaccine therapy ID on days 1, 14, and 30 and aldesleukin SC BID on days 1-14. Patients may receive 3 additional doses of NY-ESO-1 (157-165) peptide pulsed dendritic cell vaccine therapy after day 90."
3128618|NCT01697215||Oral or nasal endotracheal intubation|Oral or nasal endotracheal intubation, anticipated to last at least 48 hours Adults that require ETT internal diameter sizes of 6.5 - 9.0 mm Subject must be at least 18 years old (no upper age limitation) English speaking patients/decision makers.
3128619|NCT01697202||no intervention|
3128581|NCT01697514|Experimental|Part A: LY2940680 (Dose Escalation)|LY2940680 administered orally once daily at escalating doses (92.5 milligrams per square meter [mg/m^2] up to 370 mg/m^2) for two 28 day cycles. Lower dose levels (23 mg/m^2 and 46 mg/m^2) may also be explored, if necessary. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
3128582|NCT01697514|Experimental|Part B: LY2940680 (Dose Confirmation)|LY2940680 administered orally once daily for two 28 day cycles. Dose based on Part A. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
3128583|NCT01697501|Experimental|Chronic hepatitis B patients|
3128584|NCT01697488||Cohort|Overall sample
3128585|NCT01697488||Subgroup|Patients aged >/= 70 years
3128586|NCT01697475|Experimental|Intervention Group|Motivational text messaging
3128587|NCT01697475|No Intervention|Control Group|Step count
3128588|NCT01697462||Cohort|
3128589|NCT01697449||Cohort|
3128590|NCT01697436|Experimental|Crossover Period 1|
3128591|NCT01697436|Experimental|Crossover Period 2|
3128592|NCT01697436|Experimental|Crossover Period 3|
3128593|NCT01697436|Experimental|Crossover Period 4|
3128594|NCT01697423|Experimental|platelet-rich plasma|
3128595|NCT01697423|Active Comparator|durolane|
3128596|NCT01697410|Experimental|terlipressin|
3128597|NCT01697410|Active Comparator|norepinephrine|
3128598|NCT01697384|Experimental|one histrelin acetate 50 mg implant|The test product was a histrelin acetate 50 mg hydrogel implant surgically placed subdermally into the inner aspect of the upper arm.
3128599|NCT01697371|Experimental|Proton Radiation|
3128600|NCT01697358|Active Comparator|SCS + OMM|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead plus an individual Optimal Medical Management (OMM) treatment plan
3128601|NCT01697358|Active Comparator|OMM alone|The investigator and subject will determine an individual Optimal Medical Management (OMM) treatment plan
3128602|NCT01697345|Experimental|Vaginal Testosterone|Testosterone USP micronized powder supplied by Medisca Pharmacy will be compounded by Precision Compounding pharmacy as testosterone 0.3% per 0.5 milliliters (mL) in pharmabase cream. The compounded testosterone vaginal cream will be supplied in pre-filled syringes and each 0.5 mL dose will deliver 300 mcg of testosterone daily. The cream will be applied to the vaginal opening once daily for four weeks (28 days).
3128603|NCT01697332|Experimental|Subjects with and without COPD|All subjects will inhale hyperpolarized 129Xe gas and then have a MRI scan performed to measure lung function.
3128604|NCT01697319|Experimental|BMN 110 at 2.0 mg/kg/week|Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 144 weeks.
3128605|NCT01697306|Active Comparator|Gemcitabine-arm|7-15 days after TUR patients received six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline. Maintenance consisted in monthly instillations up to 1 year
3128606|NCT01697306|Active Comparator|BCG-arm|7-15 days after TUR patients received an induction cycle of six weekly instillations of Connaught strain Bacillus Calmette-Guerin (BCG Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline. Maintenance consisted of 3 weekly instillations at 3, 6 and 12 months
3128607|NCT01697293|Experimental|Treatment (chemotherapy, surgery)|"COURSES A 1-12 (PHASE I & II): Patients receive triciribine phosphate IV over 60 minutes on days 1, 8, and 15, 29, 36, 43, 57, 64, and 71 and paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 79. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.~COURSES B 1-4 (PHASE II): Patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~SURGERY (PHASE II): Eligible patients undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy."
3128608|NCT01697280|Experimental|Educational messages only|EPI vaccinators/volunteers will educate mothers/care-providers of infants less than 12 months old months about the benefits of routine immunization
3128609|NCT01697280|Experimental|Immunization status verification only|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
3128610|NCT01697280|Experimental|Education and vaccine verification|EPI vaccinators/volunteers will educate mothers/care-providers of infants less than 12 months old months about the benefits of routine immunization, identify and record details of un/under-vaccinated children in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
3128611|NCT01697280|No Intervention|Status quo|No interventional activity will take place in this group. Therefore, the status quo (routine services) will be maintained during Polio NID
3128612|NCT01697267|Experimental|Rituximab Maintenance|Rituximab maintenance: 1g at 4, 8, 12, 16 & 20 months with standardised steroid taper
3128613|NCT01697267|Active Comparator|Azathioprine Maintenance|Azathioprine Maintenance: 2mg/kg/day with standardised steroid taper, from month 4 (randomisation) (200 mg maximum daily dose). Azathioprine withdrawn at month 27.
3128614|NCT01697241|Experimental|Supervised exercise and patient education|The entire duration of the intervention is 12 weeks, and consists of 24 sessions each lasting 60-70 minutes. Patients will receive two types of exercises, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX) in groups with progression guided by the patient's neuromuscular function (12 sessions). The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load (12 sessions).
3128615|NCT01697241|Other|Patient Education|The patient education program is designed to educate the patients about hip OA during 3 sessions of 90 min. duration
3128616|NCT01697228|Other|Immediate treatment group|This group will receive vitamin D supplementation for the first 6 months, then will be monitored off vitamin D for the next 6 months.
3128617|NCT01697228|Other|Delayed treatment group|This group will be monitored for the first 6 months, and then will be given vitamin D for the next 6 months.
3129045|NCT01694212|Placebo Comparator|Placebo|Control group having placebo treatment
3128620|NCT01697189|Experimental|Fatigue management training|Experimental group subjects participated in a single half-day fatigue management training session.
3128621|NCT01697189|No Intervention|No fatigue management training|The control group subjects did not participate in the fatigue management training.
3128622|NCT01697163||Iressa|Lung cancer patients with EGFR mutation
3128623|NCT01697150|Experimental|Control to Range Testing|Subjects will spend two nights in a non hospital setting while the DiAs Diabetes Assistant Wearable Artificial Pancreas Platform is remotely monitored from an adjacent room. DiAs Diabetes Assistant Wearable Artificial Pancreas Platform is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
3128624|NCT01697137|No Intervention|Usual Care|Following enrollment, participants will visit with their primary care provider per usual.
3128625|NCT01697137|Experimental|Participant Video and Provider Cueing|Participants will watch a video prior to meeting with their provider. Participants will then cue their providers to discuss organ donation with them.
3128626|NCT01697124|Experimental|SPARK-EC|SPARK-EC curriculum for preschoolers offered instruction and practice in a comprehensive program designed to promote motor development through increased physical activity.
3128627|NCT01697111|Experimental|Arm 1|
3128628|NCT01697111|Experimental|Arm 2|
3128629|NCT01697111|Active Comparator|Arm 3|
3128630|NCT01697098|Experimental|12 hours Dexamethasone|Those patient will be given 12 hours dexamethasone after randomization
3128631|NCT01697098|Experimental|24 hours Dexamethasone|Those patient will be give 24 hours dexamethasone after randomization
3128632|NCT01697085|Experimental|Sea buckthorn oil|3 g (6 capsules)/day for three months
3128633|NCT01697085|Placebo Comparator|Placebo oil|3 g (6 capsules)/day for three months
3128634|NCT01697072|Experimental|Rilotumumab|Rilotumumab (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
3128635|NCT01697072|Placebo Comparator|Placebo|Rilotumumab-placebo (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
3128636|NCT01697059|Experimental|Piperacillin + Amoxicillin|Piperacillin/Tazobactam (Zosyn®) 100 mg/kg, up to adult dose of 3 g, i.v. q 6 hours x 2 doses, followed by Ampicillin/Clavulanate (Augmentin®) 50 mg/kg/d p.o. in 3 divided doses for 1 week.
3128637|NCT01697046|Experimental|Isentress+Truvada|All participants will receive the intervention
3128638|NCT01697020|Experimental|Arm 1|Mercaptopurine 20mg/ml Oral Suspension
3128639|NCT01697020|Active Comparator|Arm 2|Mercaptopurine 50mg tablets
3128640|NCT01697007|Experimental|2 injections of DNA administered by Zetajet|This arm will receive 600 micrograms of HIVIS DNA given as 2 injections using the Zetajet device each injection will comprise of 0.1 ml at a concentration of 3mg/ml
3128641|NCT01697007|Experimental|2 injections DNA by Zetajet and electroporation|This arm will receive 600 micrograms of HIVIS DNA given as 2 injections using the Zetajet device each injection will comprise of 0.1 ml at a concentration of 3mg/ml followed by electroporation using the Derma Vax device.
3128642|NCT01697007|Experimental|1 injection DNA by Zetajet and electroporation|This arm will receive 600 micrograms of HIVIS DNA given in 1 injection using the Zetajet device the injection will comprise of 0.1 ml at a concentration of 6mg/ml followed by electroporation using the Derma Vax device.
3128643|NCT01696994|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
3128644|NCT01696994|Active Comparator|Ovarian Screening|Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.
3128645|NCT01696981|Active Comparator|Colorectal Screening|Participants undergo a colorectal examination with a flexible sigmoidoscope at baseline and year 5. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident colorectal cancers as all deaths that occur among both screened and control subjects during the trial.
3128646|NCT01696981|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
3128647|NCT01696968|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
3128648|NCT01696968|Active Comparator|Lung Screening|"Participants undergo a chest x-ray (one postero-anterior view) at baseline and annually for 2 years. Participants classified as smokers undergo an additional chest x-ray at year 3. Participants complete a BQF/M at baseline. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident lung cancers as all deaths that occur among both screened and control subjects during the trial."
3128649|NCT01696955|Experimental|Arm I (cetuximab and tivantinib)|Patients receive cetuximab IV over 60-120 minutes on days 1 and 15 and tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3128650|NCT01696955|Experimental|Arm II (cetuximab)|Patients receive cetuximab IV over 60-120 minutes on days 1 and 15. Patients who fail cetuximab as a single agent may receive single agent tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3128651|NCT01696942|Experimental|Cimzia treatment arm|Beginning at 4 weeks after surgery, patients would be randomly assigned using a pulled card method to receive certolizumab at a dose of 400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks thereafter up to 12 months after enrollment.
3128726|NCT01696487|No Intervention|NASH|Patients with confirmed non-alcoholic steatohepatitis (biopsy proven) will be compared at baseline with other arms.
3128652|NCT01696942|Active Comparator|Mesalamine treatment arm|Beginning at 4 weeks after surgery, patients would be randomly assigned to receive mesalamine 800 mg orally three times daily for twelve months following enrollment.
3128653|NCT01696929|Experimental|Tocilizumab|Following a screening evaluation, participants will receive two infusions of tocilizumab, one at baseline and another at week 4 of the study. All subjects will receive a 4 mg/kg infusion of tocilizumab, the recommended starting dose for adults with rheumatoid arthritis.
3128654|NCT01696916|Experimental|exercise testing|6-minute walking test with pCO2 and pO2 measurement
3128655|NCT01696903|No Intervention|Conventional anastomosis|"Conventional anastomosis: The pancreaticojejunostomy is carried out in a traditional way according to Cattell's duct-to-mucosa technique."
3128656|NCT01696903|Active Comparator|Novel anastomosis|Novel anastomosis: This the active comparator to the conventional anastomosis. A new pancreaticojejunostomy technique is used for the reconstruction. The pancreas is intubated into the jejunum.
3128657|NCT01696890|Active Comparator|integrated care|telemonitoring-assisted follow-up with intensive collaboration between general practitioner and specialized Heart failure clinic.
3128658|NCT01696890|Active Comparator|standard care|telemonitoring- assisted follow-up with usual care by general practitioner, without supervision of heart failure clinic
3128659|NCT01696877|Active Comparator|Arm A|In Arm A, an identical dose of degarelix acetate will be administered 14 (±3) days prior to surgery. A telephone follow-up interview (or an in-person clinic visit) to evaluate for adverse events will occur 28 (±21) days after prostatectomy. Patients will then be followed by their urologists according to standard institutional practices, but will require PSA evaluations every 3 (±1) months during year 1 and every 6 (±2) months during years 2-3.
3128660|NCT01696877|Experimental|Arm B|In Arm B, Cyclophosphamide will be given at a dose of 200 mg/m2 as a single intravenous infusion. 1 day later, prostate GVAX will be administered as five 0.8-mL intradermal injections of PC3 (2.5 × 108 cells) and five 0.5-mL intradermal injections of LNCaP (2.5 × 108 cells), for a total dose of 5 × 108 cells. On day 14, Degarelix acetate will be administered as three 80 mg subcutaneous injections, for a total dose of 240 mg. Prostate glands will be harvested 14 (±3) days later, at the time of radical prostatectomy, and prostate tissue will be examined for the primary endpoint.
3128661|NCT01696864|Experimental|stroke patients - hand|stroke patients with the ability to move their hand
3128662|NCT01696864|Experimental|stroke patient - arm|stroke patients with the ability to move their arms
3128663|NCT01696851||wheelchair rugby players with tetraplegia|
3128664|NCT01696851||other routine sport participants with tetraplegia|
3128665|NCT01696838|Experimental|EA group|Electroacupuncture group
3128666|NCT01696838|Experimental|MOX group|Herbs-partitioned moxibustion group
3128667|NCT01696825|Experimental|Diazepam Tablet, 5 mg, Vaginal|
3128668|NCT01696825|Experimental|Diazepam Suppository, 5 mg, Vaginal|
3128669|NCT01696825|Experimental|Diazepam Cream, 5 mg, Vaginal|
3128670|NCT01696825|Active Comparator|Diazepam Tablet, 5 Mg, Oral|
3128671|NCT01696812|Experimental|electrode position, STN DBS, Parkinson' disease|To determine the electrode positions with the relationship of the STN from the fused images of the preoperative MRI and the postoperative CT via web-site.
3128672|NCT01696799|Experimental|Econazole Nitrate Foam|Investigational Drug Product
3128673|NCT01696799|Placebo Comparator|Vehicle Foam|Vehicle Foam Comparator
3128674|NCT01696799|Active Comparator|Econazole Nitrate Cream|Active comparator cream product
3128675|NCT01696786|Experimental|Oocyte cryopreservation|
3128676|NCT01696773|Experimental|Tangerine tomato juice|Tangerine tomato juice will be fed
3128677|NCT01696773|Experimental|Red tomato juice|Red tomato juice will be fed
3128678|NCT01696760|Experimental|Arm I (acetylsalicylic acid and PCD)|Patients receive acetylsalicylic acid orally PO BID and wear PCD on days 1-28 after surgery.
3128679|NCT01696760|Experimental|Arm II (enoxaparin and PCD)|Patients receive enoxaparin subcutaneously SC QD and wear PCD on days 1-28 after surgery.
3128680|NCT01696747||Diabetic|participants with a primary etiology of diabetic gastroparesis
3128681|NCT01696747||Idiopathic|participants with a primary etiology of idiopathic gastroparesis
3128682|NCT01696747||Post-Nissen|participants with a primary etiology of post-Nissen fundoplication gastroparesis
3128683|NCT01696734|Experimental|Domperidone|Domperidone 10 mg 3 times a day at the onset of the study. The physician's decision to increase the dosage will be based on patient self-assessment of symptoms. The maximum dosage used in this study will be 80 mg per day (20 mg 4 times a day), and the minimum dosage will be 30 mg per day (10 mg 3 times a day). Questionnaire completion at baseline, 8 weeks after drug, 6 months, then every 6 months. At 2 weeks and 4 weeks(± 3 days) of treatment, the physician will contact the patient via telephone to assess whether or not a dosage increase is warranted.
3128684|NCT01696721||Pediatric Patients Treated with Protons|Proton Radiation Therapy
3128685|NCT01696708|Other|Patients|31-Phosphorus RMN Spectroscopy
3128686|NCT01696708|Other|Volunteers|31-Phosphorus RMN Spectroscopy
3128687|NCT01696695||Metastatic Colorectal Carcinoma (mCRC) Participants|Newly diagnosed mCRC participants, who will receive first line capecitabine based chemotherapy according to effective official Summary of Product Characteristics, will be observed. The choice of therapy is based exclusively on the medical decision of the treating physician before study enrollment. The study protocol does not enforce treatment initiation and also do not specify any treatment regimen.
3128688|NCT01696682|Experimental|Narrow Gastric Conduit|The group in which narrowed gastric conduit will be performed during minimally invasive esophagectomy
3128689|NCT01696682|Experimental|Wide Gastric Conduit|The group in which widened gastric conduit will be performed during minimally invasive esophagectomy
3128690|NCT01696669|Experimental|Chemotherapy + Surgery + Radiotherapy|"Standard risk patients: MP6 Treatment:~CHEMOTHERAPY: 2 cycles of vincristine-doxorubicin + dexrazoxane-cyclophosphamide, 1 cycle of ifosfamide-etoposide. SURGERY: Ideally within 21 days after chemotherapy.~CHEMOTHERAPY: 1 cycle of vincristine-doxorubicin + dexrazoxane-cyclophosphamide, 1 cycle of ifosfamide-etoposide.~RADIOTHERAPY: On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response <90%.~High risk patients:~CHEMOTHERAPY: Window phase with 2 cycles of gemcitabine + docetaxel. MP6 TREATMENT. CHEMOTHERAPY: Maintenance therapy for 1 year with gemcitabine + docetaxel."
3128691|NCT01696656||Intestinal insufficiency|Patients with variable categories of major intestinal resection due to benign diseases,suffering from intestinal insufficiency and maintained with home nutritional support. Only clinically stable and nonhospitalized subjects will be recruited.
3128692|NCT01696643|Experimental|CB-5945|0.25 milligrams (mg) CB-5945, administered orally, twice daily (BID) for 52 weeks
3128693|NCT01696643|Placebo Comparator|Placebo|Placebo, administered orally, BID for 52 weeks
3128694|NCT01696630|Active Comparator|Desflurane|Desflurane 6.5% (+/-0.5%) in association with a thoracic epidural analgesia in maintenance phase
3128695|NCT01696630|Experimental|Xenon|Xenon 60% (+/-5%) in association with a thoracic epidural analgesia in maintenance phase
3128696|NCT01696617|Experimental|Aripiprazole 8-week group|Adjunctive aripiprazole 8-week treatment
3128697|NCT01696617|Active Comparator|Aripiprazole 6-week group|Adjunctive aripiprazole 6-week treatment
3128698|NCT01696604|Experimental|Part A: Cohort 1-GSK2849466|The subjects will receive single planned dose of GSK284946 in ascending order (0.01, 0.03, 0.1, and 0.3 mg) in ratio of 3:1.with placebo within each of 4 treatment periods. The dose will not be allowed to exceed 30 mg over a 24-hour period.
3128699|NCT01696604|Experimental|Part A: Cohort 1-Placebo|The subjects will receive single dose of matching placebo in one of the 4 treatment periods.
3128700|NCT01696604|Experimental|Part A: Cohort 2-GSK2849466|The subjects will receive single planned dose of GSK284946 in ascending order (0.3, 1, 3, and 10 mg) in ratio of 3:1.with placebo within each of 4 treatment periods. The dose will not be allowed to exceed 30 mg over a 24-hour period in one of the 4 treatment periods.
3128701|NCT01696604|Experimental|Part A: Cohort 2-Placebo|The subjects will receive single dose of matching placebo in one of the 4 treatment periods.
3128702|NCT01696604|Experimental|Part B: Cohort 3-GSK2849466 (Repeat dose 1)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo.
3128703|NCT01696604|Experimental|Part B: Cohort 3-Placebo (Repeat dose 1)|The subjects will receive repeat dose of matching placebo.
3128704|NCT01696604|Experimental|Part B: Cohort 4-GSK2849466 (Repeat dose 2)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo. In Cohort 4 subjects will be dosed in the fasted state on Days 1 and 14 and in the fed state on Day 7.
3128705|NCT01696604|Experimental|Part B: Cohort 4-Placebo (Repeat dose 2)|The subjects will receive repeat doses of matching placebo.
3128706|NCT01696604|Experimental|Part B: Cohort 5-GSK2849466 (Repeat dose 3)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo
3128707|NCT01696604|Experimental|Part B: Cohort 5-Placebo (Repeat dose 3)|The subjects will receive repeat doses of matching placebo.
3128708|NCT01696591||NEUROSTEM®-AD|"A single administration of human umbilical cord blood-derived mesenchymal stem cells through a brain surgery~DOSE A - 250,000 cells per entry site, 3 million cells per brain; DOSE B - 500,000 cells per entry site, 6 million cells per brain"
3128709|NCT01696591||Control Group|"A group of subjects with comparable demographics (age and gender) and disease characteristics [Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB)] as the NEUROSTEM®-AD-treated group, but did not receive the treatment with NEUROSTEM®-AD and were continued on conventional therapy. Restrictions in the concurrent use of drug therapy are as follows:~Patients are, in principle, permitted to continue the drug therapy they were on prior to the enrollment, for the treatment of concurrent illnesses other than Dementia, such as hypertension, diabetes mellitus, or hyperlipidemia.~For drugs used in the treatment of dementia, behavior-modifying drugs can be added to the pharmacological regimen of a subject during the course of the study. However, adding a new cognitive enhancer, such as donepezil, memantine, galantamine, rivastigmine, is not permitted while dose adjustment is permitted given that the drug had been in use prior to the initiation of the study."
3128710|NCT01696578|Experimental|BF-CBT and group physiotherapy|Multivitamin+10 sessions of biofeedback supported cognitive behavioral therapy (BF-CBT) and 10 sessions of group physiotherapy
3128711|NCT01696578|Active Comparator|Waiting list|The waiting list group receives only multivitamin pills while being waiting and will receive the same intervention 3 months later
3128712|NCT01696565|Experimental|125 mg/day Treatment Arm|125 mg/day PG2 treatment continuously for 7 days
3128713|NCT01696565|Experimental|250 mg/day Treatment Arm|250 mg/day PG2 treatment continuously for 7 days
3128714|NCT01696565|Experimental|500 mg/day Treatment Arm|500 mg/day PG2 treatment continuously for 7 days
3128715|NCT01696552|Active Comparator|TKR with Positioning Guides (PSPG)|Use of PSPG (Signature, Materialise) in TKR (Vanguard Total Knee System, Biomet)
3128716|NCT01696552|Active Comparator|TKR with Conventional Technique|TKR (Vanguard Total Knee System, Biomet), Conventional Technique
3128717|NCT01696539|Experimental|Walking Intervention|Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
3128718|NCT01696539|Active Comparator|Standard of Care|Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
3128719|NCT01696526|Experimental|vitamin D fortified fish|Human volunteers receiving vitamin D fortified fish, 4 weeks
3128720|NCT01696526|Placebo Comparator|conventional fish|consumption of conventional fish , 4 weeks
3128721|NCT01696513|Experimental|Subcision & Suction|Standard treatment for acne scars followed by suction.
3128722|NCT01696513|Active Comparator|Subcision|Standard treatment for acne scars only
3128723|NCT01696500|Experimental|NPB-01|
3128724|NCT01696487|Experimental|Healthy Volunteers|Volunteers will be challenged with oral 150g Fructose per day for 28 days.
3128725|NCT01696487|No Intervention|NAFLD|Patients with confirmed fatty liver (imaging positive) will be compared at baseline with other arms.
3128727|NCT01696487|No Intervention|Hepatitis C genotype 1 (HCV-GT1)|Patients with confirmed hepatitis C genotype 1 will be compared at baseline with other arms and act as different liver disease control group
3128728|NCT01696474|Experimental|Bortezomib therapy|A single course of Bortezomib will be given at the dose of 1,3 mg/sqm iv on days 1, 4, 8, 11. Prophylaxis of HZ reactivation will be given with oral acyclovir at the dosage of 400 mg twice daily for one month after the end of Bortezomib.
3128729|NCT01696461|Experimental|Related donors receiving plerixafor|
3128730|NCT01696448|Experimental|Experimental Group|CAR-191: Berberine 200mg, Alpha-lipoic Acid 150mg, Picrorhiza 100mg each in a separate capsule, to be taken 3 times a day, 30 minutes before breakfast, lunch and dinner. Total 9 capsules per day.
3128731|NCT01696448|Placebo Comparator|Control Group|3 placebo capsules, to be taken 3 times a day, 30 minutes before breakfast, lunch and dinner. Total 9 capsules per day.
3128732|NCT01696435|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
3128733|NCT01696435|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
3128734|NCT01696435|Active Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~Fish oil placebo"
3128735|NCT01696435|Active Comparator|Vitamin D + fish oil|"Vitamin D3 (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
3128736|NCT01696422|Experimental|Step A: dengue lyophilized vaccine|Dengue 1,2,3,4 (attenuated) vaccine Two doses with a six-months interval, SC
3128737|NCT01696422|Active Comparator|Step A:dengue liquid vaccine|TetraVax-DV Vaccine - Admixture TV003 Two doses with a six-months interval, SC
3128738|NCT01696422|Placebo Comparator|Step A: Placebo|Placebo comparator Two doses with a six-months interval, SC
3128739|NCT01696422|Experimental|Step B: dengue lyophilized vaccine|Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC
3128740|NCT01696422|Placebo Comparator|Step B: Placebo|Placebo comparator Single dose, SC
3128741|NCT01696409||Arm A|400 IU vitamin D3 once a day for 2 months
3128742|NCT01696409||Arm B|2000 IU Vitamin D3 once/day for 2 months
3128743|NCT01696396|Experimental|Drug Dose Level 1|AMG 181 SC Injection
3128744|NCT01696396|Experimental|Drug Dose Level 2|AMG 181 SC Injection
3128745|NCT01696396|Experimental|Drug Dose Level 3|AMG 181 SC Injection
3128746|NCT01696396|Placebo Comparator|Placebo|Placebo SC injection
3128747|NCT01696383|Experimental|DuoTrav|One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
3128748|NCT01696370|Active Comparator|Trimetazidine|
3128749|NCT01696370|Placebo Comparator|Placebo capsule|
3128750|NCT01696357||Adolescents with asthma|Ages 13-17 with an asthma diagnosis-both symptomatic and non-symptomatic- and with currently prescribed asthma medication.
3128751|NCT01696357||Adolescents without asthma|Ages 13-17 without an asthma diagnosis and without any other respiratory condition that presents with asthma-like symptoms.
3128752|NCT01696344||Cohort 1|No additional ablation after AF termination(PVAI only)
3128753|NCT01696344||Cohort 2|Additional ablation of extra-PV triggers before and after isoproterenol-challenge after AF termination (PVAI + ablation of extra-PV triggers)
3128754|NCT01696331|Experimental|Text Message Reminder|
3128755|NCT01696318|No Intervention|Educational program|Educational Program with Professional Physical Education, Pharmacist and Nutritionist
3128756|NCT01696318|Experimental|Educational program and individual care|Educational program and individual care with professional Physical Education; Pharmacist and Nutritionist
3128757|NCT01696305|Experimental|Hyalobarrier|ACP200 (Auto-crosslinked polysaccharide:inner ester of hyaluronic acid) 30mg/ml*10ml/syringe and 5cm-cannula
3128758|NCT01696305|Active Comparator|Guardix-SG|Poloxamer/sodium alginate mixture 6g/syringe
3128759|NCT01696279|Experimental|Lanthanum Carbonate|
3128760|NCT01696279|Active Comparator|Calcium Carbonate|
3128761|NCT01696266||Insulin-treated patients with diabetes|
3128762|NCT01696253||Subjects at risk for Alport sydrome|
3128763|NCT01696253||Newly identified subjects with Alport syndrome|
3128764|NCT01696240|Placebo Comparator|Placebo|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
3128765|NCT01696240|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
3128766|NCT01696227||Nissle 1917|In vitro, Nissle 1917's ability to adversely affect the growth of uropathogens associated with urinary catheters and those with a known GI resevoir will be measured.
3128767|NCT01696214|Placebo Comparator|Ipratropium|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and be assigned to a 24 week treatment of ipratropium 2.5 mL, 0.02% 3 times daily via mini nebulizer with placebo theophylline and placebo montelukast.
3128768|NCT01696214|Placebo Comparator|Theophylline|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to theophylline 400 mg once a day for 24 weeks with placebo ipratropium and placebo montelukast.
3128769|NCT01696214|Placebo Comparator|Montelukast|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to montelukast 10 mg once a day for 24 weeks with placebo theophylline and placebo ipratropium.
3128770|NCT01696214|Placebo Comparator|fluticasone 250 mg/salmeterol 50mg|Participants will be assigned to inhaled fluticasone 250/salmeterol 50 twice a day for 24 weeks with placebo theophylline, placebo ipratropium, and placebo montelukast.
3128771|NCT01696201|No Intervention|Control group|Sedentary pregnant women
3128772|NCT01696201|Experimental|Exercise group|Exercise program
3128773|NCT01696188|Experimental|In-plane group|This group will receive an interscalene catheter placed with in-plane approach.
3128774|NCT01696188|Experimental|Out-of-plane group|This group will receive an interscalene catheter with an out-of-plan approach.
3131866|NCT01675518|Experimental|Part-2 fasted|
3128775|NCT01696175||PICU admittance|Children equipped with an arterial and a central venous catheter within 12 hours after admittance to a Dutch PICU
3128776|NCT01696162|Active Comparator|PDF exercise sheets|Participants in this arm will receive a PDF sheet of 6 exercises that are commonly administered for the treatment of anterior knee pain. They will be asked to perform the exercises three times a week for 6 weeks. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
3128777|NCT01696162|Active Comparator|Limited Exercise Videos|"Participants in this arm will receive the same six exercises as provided in the PDF sheet in arm 1 in a video format. They will be asked to perform the exercises three times per week for 6 weeks.~A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety."
3128778|NCT01696162|Experimental|Algorithm based Exercise Videos|Participants in this arm will be provided a 6 week regimen of exercise videos for their anterior knee pain. Following each exercise session, the participant will be asked for their input concerning each exercise. The algorithm will adjust the exercise regimen for the next session based on the participants input. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
3128779|NCT01696149|Experimental|electrical nerve stimulation|All subjects participated, randomly, in a 4 Hz transcutaneous electrical nerve stimulation session, a 110 Hz transcutaneous electrical nerve stimulation session, and a control (off-transcutaneous electrical nerve stimulation) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period
3128780|NCT01696136|Active Comparator|AF-Ablation with Multi-electrode catheter|Regular AF-ablation with a multi-electrode ablation catheter
3128781|NCT01696136|Active Comparator|AF-Ablation with single-tip electrode|Regular AF-ablation with a regular single-tip ablation catheter
3128782|NCT01696123|Experimental|MLC601|MLC601 (NeuroAid, Moleac Pte. Ltd, Singapore) (0.4 g per capsule) was prescribed as one capsule three times daily without an escalation dose.
3128783|NCT01696110|Experimental|Bivalirudin|Bivalirudin will be started in the cath lab, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; if ACT<225s 5min after bolus, an additional dose of 0.3mg/kg bolus should be given. After procedure, a prolonged infusion (1.75mg/kg per h) will be given for at least 30 min (totally no more than 4 h) followed by a reduced dose infusion (0.2mg/kg per h) up to 20 h.
3128784|NCT01696110|Active Comparator|Heparin monotherapy|100 IU/kg intravenous bolus. If ACT <225s 5 min after bolus injection, additional dose of heparin (20U/kg) will be given.
3128785|NCT01696110|Active Comparator|heparin plus tirofiban|heparin 60 IU/kg intravenous bolus and Tirofiban: 10μg/kg intravenous bolus followed by 0.15μg/kg per min infusion for up to 36h.
3128786|NCT01696097|Other|Dietary Counseling|Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure
3128787|NCT01696084|Experimental|Arm A (CPX-351)|Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with CPX-351. The number of inductions and consolidations a subject received depended on response.
3128788|NCT01696084|Active Comparator|Arm B (7+3)|Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7 + 3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received depended on response.
3128789|NCT01696071|Experimental|Treatment A|2 puffs of daily dose (5 mcg) in the evening and 2 puffs of matching placebo in the morning via Respimat inhaler
3128790|NCT01696071|Experimental|Treatment B|2 puffs of half daily dose (2.5 mcg) twice daily, in the evening and in the morning via Respimat inhaler
3128791|NCT01696058|Experimental|Olodaterol andTiotropium|2 puffs Olodaterol from Respimat and one capsule Tiotropium by Handihaler once daily in am, co-administered
3128792|NCT01696058|Other|Placebo and Tiotropium|2 puffs placebo inhalation solution from Respimat and one capsule Tiotropium by Handihaler once daily in am, co-administered
3128793|NCT01696045|Experimental|Ipilimumab 3 mg/kg|Ipilimumab (3 mg/kg) was administered intravenously (IV) over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
3128794|NCT01696045|Experimental|Ipilimumab 10 mg/kg|Ipilimumab (10 mg/kg) was administered intravenously (IV) over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
3128795|NCT01696032|Experimental|SGI-110 + Carboplatin|Part 1: Patients will be dosed with SGI-110 and carboplatin
3128796|NCT01696032|Experimental|SGI-110 + carboplatin or TC|Part 2: Patients will be randomized to receive SGI-110 and carboplatin or Treatment of Choice (TC). TC is at the discretion of the investigator and can be one of three standard of care treatments (topotecan, paclitaxel or pegylated liposomal doxorubicin).
3128797|NCT01696019|Experimental|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
3128798|NCT01696019|Active Comparator|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
3128799|NCT01696019|Active Comparator|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
3128800|NCT01696019|Placebo Comparator|Contact and testing only|The fourth group received no intervention. Contact was maintained by phone during the intervention period to reduce dropout. Participants were called four times during the 40 weeks intervention period by the study coordinator.
3128801|NCT01695993|No Intervention|Arm 1 - Standard Care Only|Patients will receive standard care only
3227334|NCT01004445|Experimental|Arm 2|
3128802|NCT01695993|Other|Arm 2 - Expectancy-neutral Arm|"Patients receive:~Expectancy-neutral handout~Expectancy-neutral MP3~Acupressure bands"
3128803|NCT01695993|Experimental|Arm 3 - Expectancy-enhancing Arm|"Patients receive:~Expectancy-enhancing handout~Expectancy-enhancing MP3~Acupressure bands"
3128804|NCT01695980|Experimental|LMA with modified retractor|LMA with modified retractor
3128805|NCT01695980|Active Comparator|ETT with non modified retractor|ETT with non modified retractor
3128806|NCT01695967|Experimental|Turbinate Cauterization|Turbinate Cauterization will be completed.
3128807|NCT01695967|No Intervention|control|no turbinate cauterization
3128808|NCT01695954|Experimental|Arm A: (Pitavastatin and Efavirenz)|Subjects assigned to Arm A will receive pitavastatin 2 mg at bedtime and efavirenz 600 mg at bedtime.
3128809|NCT01695954|Experimental|Arm B: (Pitavastatin and Ritonavir-boosted Darunavir)|Subjects assigned to Arm B will receive pitavastatin 2 mg daily and darunavir 800 mg with ritonavir 100 mg daily.
3128810|NCT01695941|Experimental|Treatment (alisertib, bortezomib, and rituximab)|"Patients receive alisertib PO BID on days 1-7; bortezomib SC on days 1, 8, and 15; and rituximab IV on day 1. Treatment repeats every 28 days* in the absence of disease progression or unacceptable toxicity.~Note: *After 8 courses, treatment with rituximab repeats once every 3 courses (12 weeks) in the absence of disease progression or unacceptable toxicity."
3128811|NCT01695928|Active Comparator|Extracorporeal shockwave therapy (ESWT)|Active treatment
3128812|NCT01695928|Placebo Comparator|ESWT Placebo|No extracoporeal shockwave therapy
3128813|NCT01695915||Healthy|Transabdominal ultrasound
3128814|NCT01695915||Constipated|Transabdominal ultrasound
3128815|NCT01695902|Experimental|Levosert-20|Levosert is a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG in a cylindrical-shaped reservoir. The reservoir is mounted on the vertical arm of a T-shaped plastic frame and is covered with a release rate controlling membrane.
3128816|NCT01695902|Active Comparator|Mirena®|Mirena® IUS, Bayer-Schering, a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG.
3128817|NCT01695876|Experimental|AMG 357|AMG 357 is a small molecule for treatment of inflammatory disease
3128818|NCT01695876|Placebo Comparator|Placebo|Matching placebo to AMG 357 containing no active drug
3128819|NCT01695863|Experimental|miralax|miralax with dulcolax and gatorade efficacy evaluated by colonoscopy and patient satisfaction evaluated by patient questionnaire
3128820|NCT01695863|Experimental|moviprep split dose|Efficacy of split dose moviprep on cleansing colon for colonoscopy and patient satisfaction with the regimen
3128821|NCT01695850|Experimental|MZRW|MZRW is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo).
3128822|NCT01695850|Active Comparator|Senna|Senna is a stimulant laxative which facilitates the passage of stools by altering intestinal electrolyte transport and increasing intestinal motor activity.
3128823|NCT01695850|Placebo Comparator|Placebo|Placebo MZRW and Placebo Senna
3128824|NCT01695837|Experimental|Group A-dietary counseling month 0-6|"Group A Visit #1 - Weight, height, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the primary care physician (PCP) reviewed the results of the fasting lipid panel and diet test with the patient; the PCP provide the patient with written educational materials and access to the counseling website. Weekly automatic emails sent to patient reminding to visit the counseling website~Visit #2 - Same as visit #1. Weekly automatic emails sent to patient reminding to visit the counseling website.~Visit #3 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the new fasting lipid panel and diet test with the patient."
3128825|NCT01695837|Other|Group B- Dietary counseling month 3-6|"Group B Visit #1: Weight, height, blood pressure and pulse were measured at the beginning of the visit. Follow up visit and lab order were scheduled for 3 months. No blood test or diet test results were reviewed with the patient.~Visit #2 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the two fasting lipid panels ; the PCP provide the patient with written educational materials and access to the counseling website. Weekly automatic emails sent to patient reminding to visit the counseling website~Visit #3 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the new fasting lipid panel and diet test with the patient."
3128826|NCT01695824|Active Comparator|LAA occluder|
3128827|NCT01695824|Active Comparator|Warfarin|
3128828|NCT01695811||FLAK|FLAK
3128829|NCT01695811||PKP|Retrospective
3128830|NCT01695798|No Intervention|Chronic malnourished bOPV|This arm will receive only bOPV
3128831|NCT01695798|Experimental|Malnourished IPV+bOPV|This arm will receive IPV and bOPV
3128832|NCT01695798|No Intervention|Normally nourished bOPV|This arm will receive only bOPV
3128833|NCT01695798|Experimental|Normally nourished IPV+bOPV|This arm will receive both IPV and bOPV
3128834|NCT01695785||Healthy weight|greater than or equal to the 5th to less than the 85th BMI percentile
3128835|NCT01695785||Obese|greater than or equal to the 95th BMI percentile
3128836|NCT01695772|Experimental|Bevacizumab|
3128837|NCT01695759|Experimental|Epoetin alpha|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
3128838|NCT01695759|Active Comparator|Eprex|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
3128877|NCT01695434||Healthy Controls MRI|Subjects who are otherwise healthy, without neurological disorders, will have a MRI.
3128878|NCT01695421|Experimental|Functional electrical stimulation|Burst modulated alternating rectified current with a 10 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts
3128959|NCT01694849|Experimental|GFT505 120mg|Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.
3128839|NCT01695746||C.E.R.A.|Participants with chronic renal anemia Stage III-IV, not on dialysis, will be administered Continuous Erythropoietin Receptor Activator (C.E.R.A.) according to routine clinical practice and will be followed up for the treatment duration of 24 weeks (6 months). Dosing and titration of C.E.R.A. treatment will be at the discretion of the investigator in accordance with local clinical practice or prescribing information. Dosing instructions as per the local label are - For correction of anemia: 0.6 microgram per kilogram (mcg/kg) of C.E.R.A. once every two weeks, and for Maintenance of hemoglobin (Hb) levels: Conversion to C.E.R.A. dose (120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks) depending on the previous weekly epoetin or darbepoetin dose.
3128840|NCT01695733|Experimental|Schedule A|Influenza vaccination on the first day of chemotherapy
3128841|NCT01695733|Experimental|Schedule B|Influenza vaccination 1 week (+/- 1 day) prior to chemotherapy
3128842|NCT01695720|Experimental|VisionScope Imaging (VSI) Exam|A VisionScope Imaging (VSI) Exam is diagnostic arthroscopic procedure. Through a natural or surgical opening, an endoscope is inserted through a cannula to illuminate and visualize the interior cavity of a joint.
3128843|NCT01695707|Placebo Comparator|Placebo|"Subjects randomized to placebo will receive opaque size 00 gelatin capsules containing 240mg lactose. As with the intervention group, 1 capsule will be taken by each day throughout the treatment period."
3128844|NCT01695707|Experimental|Pioglitazone|"Subjects randomized to pioglitazone will receive opaque size 00 gelatin capsules containing pioglitazone. For the first 3 weeks, capsules will contain 30 mg pioglitazone. For the remaining 9 weeks of the treatment period, capsules will contain 45 mg pioglitazone unless subjects are unable to tolerate this increased dose.~One capsule will be taken by each day throughout the treatment period."
3128845|NCT01695694|Active Comparator|community support group|
3128846|NCT01695694|Experimental|supporting positive and healthy relationships|
3128847|NCT01695681|Other|Dietary instruction|Gluten-free diet
3128848|NCT01695668|Experimental|Lotemax|Loteprednol Etabonate 0.5%
3128849|NCT01695668|Active Comparator|Restasis|Cyclosporine
3128850|NCT01695655||PKP|Subjects undergoing penetrating keratoplasty
3128851|NCT01695642||Microkeratome|mechanical microkeratome
3128852|NCT01695642||Intralase|femtosecond laser
3128853|NCT01695629||None to Mild|Subjects with Diabetes with none to mild peripheral neuropathy
3128854|NCT01695629||Severe|Subjects with diabetes with severe neuropathy
3128855|NCT01695616|Placebo Comparator|Placebo|Patients enrolled in this arm will take a tablet twice a day
3128856|NCT01695616|Active Comparator|Passiflora incarnata and isoflavona combination|Patients enrolled in this arm will take a tablet twice a day
3128857|NCT01695603|No Intervention|Standard mode of controlled ventilation|Each brain injured patient will be ventilated during two hours with a standard mode of controlled ventilation.
3128858|NCT01695603|Experimental|Intellivent arm|Each brain injured patient will be ventilated during two hours with an automated mode of ventilation, the Intellivent mode.
3128859|NCT01695590|Experimental|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle
3128860|NCT01695577|Experimental|Multidisciplinary evaluation and VR|Vestibular rehabilitation and balance training. Twice a week for eight weeks.Outcome measures and tests at baseline, after 8 weeks and 6 months after the injury.
3128861|NCT01695577|Active Comparator|Multidisciplinary evaluation and no VR|Multidisciplinary evaluation. Outcome measures and tests at baseline, after 8 weeks and 6 months after the injury.
3128862|NCT01695564||WATCHMAN|Patients that had the WATCHMAN device implanted
3128863|NCT01695564||LARIAT LAA Device|patients that had LARIAT LAA device implanted
3128864|NCT01695551||Ventricular Tachycardia|Participants in cohort will have implantable defibrillators in-situ and are undergoing ablation procedure for ventricular tachycardia.
3128865|NCT01695538|Experimental|Yoga|Participants will be asked to practice yoga 3 days per week, at a minimum and encouraged to practice 7 days per week, for 1 year.
3128866|NCT01695525|Experimental|Yoga|Participants will be asked to practice Yoga 3 times per week at a minimum, and daily at a maximum. Participants will receive training in different Yoga techniques including breathing exercises, postures and meditation. Participants will be asked to practice 1 hour Yoga sessions comprised of breathing exercises, postures and meditation.
3128867|NCT01695512||Immunocompromised Patients|Patients with acute leukemia undergoing induction chemotherapy or undergoing allogeneic stem cell transplantation
3128868|NCT01695512||Control Group|Patients underdoing bronchoscopy and diagnostic BAL without immunosuppression and without signs of infection (Sarcoidosis, Lung Cancer)
3128869|NCT01695499||Immunosuppressed ICU Patients with lung infiltrates|Immunosuppressed ICU Patients with lung infiltrates
3128870|NCT01695499||Control Group|BAL and blood aliquots of 20 immunocompetent pts (suffering from lung diseases) will be collected and tested identically as a control population.
3128871|NCT01695473|Experimental|Neoadjuvant BKM120|Twenty four men will receive 2 weeks of daily BKM120 prior to having radical prostatectomy
3128872|NCT01695460|Active Comparator|Vitamin D|"The active treatment consists of vitamin D and is given in tablets of the brand D3 Vitamin ®, supplied by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.~The tablets contain the vitamin D in the form of vitamin D3, also known as cholecalciferol.~D3 Vitamin ® consists of small white tablets, which are easy to swallow.~D3 Vitamin ® contains 25 micrograms vitamin D3 (colecalciferol) per tablet, equivalent to 1000 IU (International Units).~Tablet Excipients: Cellulose, dicalcium phosphate, magnesium stearate, silicon dioxide and talc. Vitamin D3 ® contains no gluten, soy, gelatin or other animal products."
3128873|NCT01695460|Placebo Comparator|Placebo|Placebo tablets to match D3 Vitamin ®, were produced. They are identical to the D3 Vitamin ® in appearance, ie small white tablets. These tablets do not have a therapeutic effect. Placebo tablets produced and delivered by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.
3128874|NCT01695447|Experimental|duct-to-mucosa|duct-to-mucosa technique is used for pancreaticojejunostomy after pancreaticoduodenectomy
3128875|NCT01695447|Active Comparator|invagination|invagination technique is used for pancreaticojejunostomy after pancreaticoduodenectomy
3128876|NCT01695434||Copaxone MRI|Patients with relapsing-remitting multiple sclerosis who take Copaxone will have a MRI.
3130031|NCT01687673|Experimental|Treatment|Combination temsirolimus plus sorafenib
3128879|NCT01695421|Experimental|Medium-frequency alternating current|Burst modulated alternating current with a 2500 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts
3128880|NCT01695421|Experimental|Burst-modulated alternating current|Burst modulated alternating current with a 4000 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts.
3128881|NCT01695421|Placebo Comparator|Placebo|Training with the intensity of 5 mA.
3128882|NCT01695395||Intellectual disabled adults without a mental disorder|
3128883|NCT01695395||Intellectual disabled adults with a mental disorder|
3128884|NCT01695382|Experimental|Navigation|Participants randomized to the control arm of the study will receive a packet of written materials that are appropriate linguistically and written for individuals with low health literacy. In addition they will have 5 navigator initiated home visits to review the educational materials and help patients and families address barriers to palliative care through education, advocacy, and activation.
3128885|NCT01695382|No Intervention|Control|Participants randomized to the control arm of the study will receive a packet of written materials that are appropriate linguistically and written for individuals with low health literacy.
3128886|NCT01695369|Active Comparator|Senofilcon A|Senofilcon A; Comfilcon A
3128887|NCT01695369|Experimental|Comfilcon A|Comfilcon A; Senofilcon A
3128888|NCT01695356|Active Comparator|290-400 nm sunscreen|"Sunscreen containing Mexoryl SX, Mexoryl XL, Titanium Dioxide, Octocrylene, Tinosorb S, Avobenzone, and Ethylhexyl triazone.~Fluid vehicle administered daily, from 8AM to 5PM every 3 hr, for 12 weeks."
3128889|NCT01695356|Experimental|290-800 nm sunscreen|"Sunscreen containing Benzophenone-3, Octinoxate, Octocrylene, Titanium Dioxide, Zinc Oxide, and iron oxide.~Fluid vehicle administered daily, from 8AM to 5PM every 3 hr, for 12 weeks."
3128890|NCT01695343|Experimental|KB001-A|KB001-A administered up to 5x intravenously (IV) at 10 mg/kg up to a maximum dose of 800 mg per dose.
3128891|NCT01695343|Placebo Comparator|Placebo Comparator|Placebo administered up to 5x intravenously
3128892|NCT01695330|Experimental|Subcutaneous bortezomib|
3128893|NCT01695317|Active Comparator|Acetyl-L-carnitine|Acetyl-L-carnitine tablets
3128894|NCT01695317|Placebo Comparator|Sugar pills|Glucose with lemon acid
3128895|NCT01695304|Experimental|Intervention Arm|Households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water.
3128896|NCT01695304|No Intervention|Control Arm|Households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
3128897|NCT01695291|Placebo Comparator|Placebo|Participants randomized to placebo will receive pills that are identical in appearance to the study drug but contain no active medication.
3128898|NCT01695291|Experimental|Minocycline Augmentation|Those randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline (minimum 50 mg/day and maximum 200 mg/day). After randomization, participants will receive child proofed bottles that contain enough study medication until the next visit with an additional 3 days coverage in case of scheduling issues. All participants will have a minocycline level drawn at week 12 to confirm treatment adherence. Minocycline is FDA-approved in those ages 8 and above for treatment of infections and acne and has a favorable risk-benefit profile.
3128899|NCT01695278|Active Comparator|Standard Care|Participants will receive standard care from physicians for monitoring and treating their diabetes. They are placed on a wait list to receive the intervention.
3128900|NCT01695278|Experimental|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
3128901|NCT01695265|Experimental|Exercie oronasal breathing (ONB)|Exercise protocol was walking on a treadmill for 10 minutes at a constant rate at 50% of VO2peak with oronasal breathing (ONB) (Without FeelBreathe device)
3128902|NCT01695265|Experimental|Exercie nasal breathing through the FB|Exercise protocol was walking on a treadmill for 10 minutes at a constant rate at 50% of VO2peak with nasal restriction using FeelBreathe device.
3128903|NCT01695252|No Intervention|S-Sup|Standard supervision
3128904|NCT01695252|Experimental|MEMOS|Patient informed clinical outcomes supervision
3128905|NCT01695239|Experimental|Ixekizumab Q2W|Administered by 80 milligram (mg) subcutaneous (SC) injection every 2 weeks (Q2W).
3128906|NCT01695239|Experimental|Ixekizumab Q4W|Administered by 80 mg SC injection every 4 weeks (Q4W).
3128907|NCT01695239|Placebo Comparator|Placebo|Placebo for ixekizumab and placebo for adalimumab administered by SC injection.
3128908|NCT01695239|Active Comparator|Adalimumab Q2W|Administered by 40 mg SC injection Q2W.
3128909|NCT01695226|Placebo Comparator|placebo|pre-operative placebo twice daily for two to three weeks
3128910|NCT01695226|Experimental|celecoxib|pre-operative celecoxib (400 mg) twice daily for two to three weeks
3128911|NCT01695213|Active Comparator|HA-Omnifit|Patients who receive a HA-Omnifit uncemented hip stem
3128912|NCT01695213|Active Comparator|Symax hip stem|Patients with the Symax uncemented hip stem
3128913|NCT01695200|Experimental|Omega-3 Fatty Acids|15ml omega-3 liquid form, twice a day for 12 weeks (Total daily dosage:840mg DHA and 192mg EPA)
3128914|NCT01695187|Experimental|NB-001 (0.3%)|NB-001 is an oil-in-water emulsion composed of nanometer-sized, positively charged droplets (average particle size = 180nm). NB-001 is composed of highly refined soybean oil, purified water, ethanol, edetate disodium dihydrate (EDTA) and two surfactants: polysorbate (Tween) 20 and cetylpyridinium chloride (CPC).
3128915|NCT01695187|Placebo Comparator|Vehicle|NB-001 is an oil-in-water emulsion composed of nanometer-sized, positively charged droplets (average particle size = 180nm). NB-001 is composed of highly refined soybean oil, purified water, ethanol, edetate disodium dihydrate (EDTA) and one surfactant: polysorbate (Tween) 20.
3128916|NCT01695174|Experimental|Xifaxan|Xifaxan 550 mg two times per day for three months
3128917|NCT01695161||mucopolysaccharidosis|mucopolysaccharidosis
3128918|NCT01695161||Fabry disease|Fabry disease
3128919|NCT01695161||healthy controls|healthy controls
3128920|NCT01695148|Active Comparator|White Maize Flour|Children will receive 2 meals a day (~200 g of white maize flour), 6 days a week for 6 months.
3128921|NCT01695148|Experimental|β-Carotene Biofortified Maize|Children will receive 2 meals a day (~200 g of beta-carotene biofortified maize flour), 6 days a week for 6 months.
3128922|NCT01695148|No Intervention|Non-Intervened|Children will receive no food for the duration of the study, but families in this group will receive an equivalent ration of food items at the end of the trial.
3128923|NCT01695135|Experimental|Abiraterone acetate plus prednisone|
3128924|NCT01695135|Experimental|Placebo plus prednisone|
3128925|NCT01695122|Experimental|valproic acid|
3128926|NCT01695109|Placebo Comparator|Placebo|
3128927|NCT01695109|Active Comparator|Liraglutide|
3128928|NCT01695096|Experimental|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
3128929|NCT01695096|Placebo Comparator|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to > 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
3128930|NCT01695070|Experimental|Melatonin|Women with IUGR will take 4mg prolonged release melatonin oral tablets twice daily. Treatment will occur as soon as the diagnosis of intrauterine growth restriction is made and the patient has been enrolled to this study until birth. The overall duration of treatment will vary due to the nature of intrauterine growth restriction.
3128931|NCT01695057|Experimental|Treatment (vorinostat and surgery)|Patients receive vorinostat 400 mg daily PO on days 1-21 followed by surgery within 14 days.
3128932|NCT01695044|Experimental|Arm 1: PSMA ADC|Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
3128933|NCT01695031|Experimental|Tailored asthma management program|Teens randomized to the experimental arm will receive 4 sessions of web-based, tailored asthma management
3128934|NCT01695031|Active Comparator|Generic web-based education|Teens in the control group will receive generic, web-based asthma education.
3128935|NCT01695018||p16 methylation positive|48 patients with mild or moderate oral epithelial dysplasia containing methylated p16.
3128936|NCT01695018||p16 methylation negative|104 patients with p16 mild or moderate oral epithelial dysplasia NOT containing methylated p16.
3128937|NCT01695005|Experimental|LY3039478 - Dose Escalation|Part A: LY3039478 administered orally three times per week (TIW) at escalating doses (2.5 milligrams [mg] to 100 mg) for two 28 day cycles. Participants receiving benefit may continue until disease progression
3128938|NCT01695005|Experimental|LY3039478 - Cohort Expansion|Part B, C, D and E: LY3039478 administered orally three times per week (TIW) at a fixed dose determined in Part A for two 28 day cycles. Participants receiving benefit may continue until disease progression.
3128939|NCT01695005|Experimental|Dose 1 LY3039478 + Prednisone|Part F1: LY3039478 administered orally TIW for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only (28 day cycles). Participants receiving benefit may continue until disease progression.
3128940|NCT01695005|Experimental|Dose 2 LY3039478 + Prednisone|Part F2: LY3039478 administered orally TIW (twice a week in cycle 1) for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only. Participants receiving benefit may continue until disease progression.
3128941|NCT01694992|Experimental|Early mobilization|The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after stroke, five times per week for 30 plus a time spent out of bed (sitting).
3128942|NCT01694992|No Intervention|Control|The Control Group will follow within the routines of the hospital as is usually done.
3128943|NCT01694979||Single group: pelvic floor and breathing|This is a single group with repeated measures during variable breathing effort
3128944|NCT01694966|Active Comparator|Methylene Blue MMX® 200mg|Oral dose, 8 Methylene Blue MMX® tablets over a 4hr schedule
3128945|NCT01694966|Active Comparator|Methylene Blue MMX® 100mg|Oral dose, 4 Methylene Blue MMX® tablets and 4 Placebo tablets over a 4hr schedule
3128946|NCT01694966|Placebo Comparator|Placebo|Oral dose, 8 Placebo tablets over a 4hr schedule
3128947|NCT01694953||Patients with MNGIE|Patients of all races of any gender who are at least 5 years of age with a defect in thymidine phosphorylase may participate in this natural history study.
3128948|NCT01694940||Mitochondrial Disease Patients|Patients with possible or known mitochondrial disorders. Patients who are known carriers of mitochondrial or nuclear DNA mutations involved in mitochondrial function.
3128949|NCT01694927|Experimental|Mesenchymal Stem cells|
3128950|NCT01694914|Experimental|Animal Compound Free Medium|Patients in this arm receive a corneal graft stored in organ culture in a animal compound free medium
3128951|NCT01694914|Active Comparator|organ culture medium containing 2% of fœtal calf serum|Patients in this arm receive a corneal graft stored in organ culture in a commercial organ culture medium containing 2% of fœtal calf serum
3128952|NCT01694901||SmartPilot® system|50 patients scheduled for elective surgery (general/abdominal surgery; traumatological/orthopedic surgery, gynecology, urology) in general anesthesia using the SmartPilot® system
3128953|NCT01694901||Standard arm|50 patients scheduled for elective surgery (general/abdominal surgery; traumatological/orthopedic surgery, gynecology, urology) in general anesthesia according to the standard operating procedures of the department, i.e. manually controlled clinical anesthesia and EEG-derived parameters of anesthetic depth
3128954|NCT01694888|Experimental|midwifery students|all midwifery students studying at last term (except one who was absent) (27) in Mashhad school of nursing and midwifery in April 2011
3128955|NCT01694875||No Treatment|
3128956|NCT01694862|Experimental|Integrated FP /PNC service delivery|Clinic or district identified as 'intervention' in which FP and PNC services are (theoretically) being provided together with HIV services (counselling, testing, treatment etc.) and in which the procedural intervention has been applied.
3128957|NCT01694862|No Intervention|Non-integrated FP/PNC service delivery|Clinic or district where FP and PNC services are not (theoretically) being provided together with HIV services, and in which no procedural intervention has been applied.
3128958|NCT01694849|Experimental|GFT505 80mg|Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.
3128960|NCT01694849|Placebo Comparator|Placebo|hard gelatin capsules, oral administration, 3 capsules per day before breakfast with a glass of water.
3128961|NCT01694836|Experimental|Depigoid Birch 5.000 DPP/ml|"Suspension for s.c. injection. Treatment schedule:~Build-up phase (1 day: 0,2 ml+0,3 ml at interval of 30 minutes)~Maintenance phase (3 years: 0,5 ml at intervals of 4-6 weeks)"
3128962|NCT01694836|Placebo Comparator|Placebo|"Suspension for s.c. injection. Treatment schedule:~Build-up phase (1 day: 0,2 ml+0,3 ml at interval of 30 minutes)~Maintenance phase (3 years: 0,5 ml at intervals of 4-6 weeks)"
3128963|NCT01694823|Experimental|CS-ACI|"Group/Cohort Label： pretherapy post-treatment~Group/Cohort Description ：The CS—ACI is used to prepare cell sheet and implant to the Cartilage defects.The arm of safety and efficacy are compared preoperative observation with postoperative observation."
3128964|NCT01694810|Experimental|2% NVN1000 Topical Gel|2% NVN1000 Topical Gel once daily for 4 weeks
3128965|NCT01694810|Experimental|4% NVN1000 Topical Gel|4% NVN1000 4% Topical Gel once daily for 4 weeks
3128966|NCT01694810|Placebo Comparator|Vehicle Topical Gel|Vehicle Topical Gel once daily for 4 weeks
3128967|NCT01694810|Experimental|8% NVN1000 Topical Gel|8% NVN1000 8% Topical Gel applied once daily for 4 weeks
3128968|NCT01694797|Experimental|Metoprolol Succinate ER Tablets, 50 mg|Metoprolol Succinate ER Tablets, 50 mg of Dr.Reddy's Laboratories Ltd
3128969|NCT01694797|Active Comparator|TOPROL-XL ER Tablets 50 mg|TOPROL-XL ER Tablets 50 mg of AstraZeneca
3128970|NCT01694784|Experimental|Quantitative|In the quantitative arm, we will present harms as absolute risks in the Quantitative Information Sheet. Compared with other risk formats, absolute risks have been shown to improve understanding relative to other common risk formats.
3128971|NCT01694784|Active Comparator|Qualitative|In the qualitative arm, we will describe harms using verbal descriptors (such as rare, uncommon, fairly common, and common) in the Qualitative Information Sheet.
3128972|NCT01694784|Experimental|Narrative|In the narrative arm, we will present harms using patient narratives (i.e. descriptions in which patients describe their experience with decision making about potentially harmful screening services)in the Narrative Information Sheet. To address concerns in the literature that characteristics of the narrator independently influence narrative effect, we will present narratives in paper format with a banner of culturally diverse age-appropriate pictures shown at the top.
3128973|NCT01694784|Experimental|Framed|In the framed arm, we will frame not screening with potentially harmful services as beneficial (i.e. use a gain frame). In the Framed Information Sheet, we will highlight the harms that could be avoided by not getting screened.
3128974|NCT01694771|Experimental|Olodaterol and Tiotropium|2 puffs olodaterol from Respimat and one capsule tiotropium from Handihaler once daily in am, co-administered
3128975|NCT01694771|Other|Placebo and Tiotropium|2 puffs placebo inhalation solution from Respimat and one capsule tiotropium from Handihaler once daily in am, co-administered
3128976|NCT01694758||Patients with diabetes type 2|
3128977|NCT01694732|Experimental|varenicline with counselling|Active varenicline associated with intensive smoking cessation counselling
3128978|NCT01694732|Placebo Comparator|Placebo with counselling|Placebo of varenicline associated with intensive smoking cessation counselling
3128979|NCT01694719|Experimental|Behavioral Activation + Cognitive Control Training|Participants will receive 5 sessions of behavioral activation therapy concurrent with 4 sessions of cognitive control training, a computerized intervention which targets cognitive control processes such as working memory and attention.
3128980|NCT01694719|Active Comparator|Behavioral Activation Therapy plus Control Task|Participants will receive 5 sessions of behavioral activation therapy and 4 sessions of a non-active, computerized control task.
3128981|NCT01694706|Experimental|Reference|faldaprevir medium, fasted
3128982|NCT01694706|Active Comparator|Test 1|faldaprevir medium, fed
3128983|NCT01694706|Active Comparator|Test 2|faldaprevir medium + omeprazole medium
3128984|NCT01694693||RA patients treated by Orencia|RA patients treated by Orencia according to usual practice from June 1st 2007
3128985|NCT01694680|Active Comparator|Lutein-enriched-egg beverage|Powder in sachets is provided and dissolved to prepare Lutein-enriched-egg beverage
3128986|NCT01694680|Placebo Comparator|Placebo|Powder in sachet to prepare beverage
3128987|NCT01694667|Active Comparator|Omega-3 Fatty Acids|Omega-3 Fatty Acids: Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA
3128988|NCT01694667|Placebo Comparator|Placebo|Placebo packets will have same orange-flavored pudding with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
3128989|NCT01694641|Experimental|time-lapse morphokinetic evaluation|"Embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse: upon fertilization embryos in a petri dish that allows individual assessment (Primo Vision Dish) are placed onto an automated time-lapse equipment in an incubator. The time-lapse equipment performs imaging in 10 minutes intervals. The software is presenting the up-to-date images and allows the operator to assess the time-lapse movie of the developmental history of the embryos to perform annotations and apply evaluation/selection algorithm. This morpho-kinetic TL algorithm (made up of standard moprhology as seen on time lapse and kinetci scores) is used for embryo selection, which actually describes the intervention."
3128990|NCT01694641|No Intervention|standard embryo monitoring|Upon fertilization embryos are observed once on days 1-3-5 by the embryologist to check for development. The single embryo for transfer is selected based on actual morphology as seen under light microscope.
3128991|NCT01694628|Experimental|CLIMB (COPD Lifestyle, Mood, and Behavior)|Counseling sessions for COPD and depression
3128992|NCT01694628|No Intervention|Control|Usual Care
3128993|NCT01694615|Active Comparator|Cryoprobe biopsy|All patients enrolled will undergo standard forceps biopsies followed by cryoprobe biopsies and results will be compared
3128994|NCT01694615|Active Comparator|Forceps Biopsy|All patients enrolled will undergo standard forceps biopsies followed by cryoprobe biopsies and results will be compared
3129043|NCT01694225|Experimental|bubble package for monthly prescription|use of bubble packaging for monthly prescription
3128995|NCT01694602||Newly Diagnosed NSCLC patients|In this study, newly diagnosed NSCLC patients who are not candidates for curative resection, will receive a (non-radioactive) oral dose of deuterated 3-methylhistidine (D-3MH).
3128996|NCT01694589|Experimental|LDE-225|LDE-225: dose - 800 mg, taken by mouth once daily for 2 weeks.
3128997|NCT01694576|Experimental|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients will receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
3128998|NCT01694576|No Intervention|Observation|Patients will be followed up without adjuvant chemotherapy after concurrent chemoradiation
3128999|NCT01694563||Atrial Fibrillation|Patients with non-paroxysmal atrial fibrillation (persistent or longstanding persistent)who are scheduled to undergo elective concomitant open, on-pump cardiac surgical procedure and the Maze IV ablation procedure. This single arm registry is designed to monitor the AtriCure Synergy Ablation System for continued safety and efficacy during the peri-procedural and long term phase during commercial use.
3129000|NCT01694550||Pacemaker mode programming|High grade AV-block
3129001|NCT01694537|Placebo Comparator|placebo|The comparison drug is placebo, which is made with same size and shape with study drug. DLBS1033 and placebo is produced by PT Dexa Medica. Placebo will taken 3 times 1 tablet per day for 7 days. Wash out period before enter another arm is 7 days.
3129002|NCT01694537|Experimental|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction. The drug will taken 3 times 490 mg per day for 7 days. Wash out period before enter another arm is 7 days.
3129003|NCT01694511|Active Comparator|Introductory conventional endoscopy|Conventional endoscopy followed by HRME+CVC after 30 days.
3129004|NCT01694511|Active Comparator|Introductory HRME+CVC|HRME+CVC followed by conventional endoscopy after 30 days.
3129005|NCT01694498|Active Comparator|A. Desmopressin 25 µg|1 orally disintegrating tablet every night during study period
3129006|NCT01694498|Active Comparator|B. Desmopressin 50 µg|1 orally disintegrating tablet every night during study period
3129007|NCT01694498|Placebo Comparator|C. Placebo|1 orally disintegrating tablet every night during study period
3129008|NCT01694485|Placebo Comparator|Placebo|Placebo delivered SC
3129009|NCT01694485|Experimental|Drug Dose level 1|Drug AMG 181 delivered SC
3129010|NCT01694485|Experimental|Drug Dose level 2|Drug AMG 181 delivered SC
3129011|NCT01694485|Experimental|Drug Dose level 3|Drug AMG 181 delivered SC
3129012|NCT01694485|Experimental|Drug Dose level 4|Drug AMG 181 delivered SC
3129013|NCT01694472|Experimental|MAGE-A4 TCR Gene-Modified T Cells|
3129014|NCT01694459|Active Comparator|Standard dose heparin|Bolus of 100 UI/Kg of heparin. Activated clotting time (ACT) > 300 sec. during the procedure
3129015|NCT01694459|Experimental|Low-dose heparin|Bolus of 50 UI/Kg heparin with a target ACT during the procedure of >200 sec.
3129016|NCT01694446|Experimental|Intraduodenal glucose or fructose|
3129017|NCT01694433|Experimental|Calcipotriene Cream|The Calcipotriene Cream will be supplied as 1g daily use individual tubes to be used 2x/day (once in the morning and once in the evening) for 12 weeks.
3129018|NCT01694433|Placebo Comparator|Placebo|The Placebo Cream will be supplied as 1g daily use individual tubes to be used 2x/day (once in the morning and once in the evening) for 12 weeks.
3129019|NCT01694420|Experimental|Quad FDC|FDC elvitegravir + cobicistat + tenofovir + emtricitabine STR once daily for 48 weeks
3129020|NCT01694407|Active Comparator|TFV Alone Vaginal Tablet|
3129021|NCT01694407|Active Comparator|Emtricitabine (FTC) Alone Vaginal Tablet|
3129022|NCT01694407|Active Comparator|TFV Combined with FTC Vaginal Tablet|
3129023|NCT01694407|Placebo Comparator|Placebo Vaginal Tablet|
3129024|NCT01694394||Cohort|Single arm cohort will receive a St. Jude Medical Implantable Cardiac Monitor (Confirm ICM model 2102) for continuous monitoring over the study follow-up period to determine incidence of sub-clinical atrial fibrillation.
3129025|NCT01694381||mutant pro-urokinase (M5) alone|
3129026|NCT01694381||Mutant pro-urokinase (M5) and its inhibitor, C1 inhibitor|
3129027|NCT01694355|Experimental|Vitamin D treatment|We assume that among postmenopausal women, Vitamin D treatment will improve bone mineralization and will cause a rapid increase in BMD.
3129028|NCT01694329||2006-2010 cohort|cohort of children born between 2006 and 2010, and living in Nunavik
3129029|NCT01694316|Active Comparator|Engaging in Computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
3129030|NCT01694316|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
3129031|NCT01694303|Active Comparator|Engaging computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
3129032|NCT01694303|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
3129033|NCT01694290|Experimental|Chemical Ice packs to neck, groin, axillae|Chemical ice packs will be changed out every 9 minutes
3129034|NCT01694290|Experimental|Chemical Ice Packs to cheeks, palms, soles|Chemical Ice packs will be changed out every 9 minutes
3129035|NCT01694290|No Intervention|no chemical ice packs|
3129036|NCT01694277|Experimental|Masitinib|masitinib at 12 mg/kg/day
3129037|NCT01694277|Active Comparator|Sunitinib|sunitinib at 50 mg/day
3129038|NCT01694264|Experimental|Experimental Group|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
3129039|NCT01694264|Placebo Comparator|Control Group|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
3129040|NCT01694238|Active Comparator|Cruciate incision|Cruciate incision in the abdominal wall fascia
3129041|NCT01694238|Experimental|Circular incision|Circular incision in the fascia
3129042|NCT01694238|Experimental|Mesh enforced cruciate incision|Mesh enforcement and then cruciate incision in the abdominal wall fascia
3130068|NCT01687387|Experimental|IPH2102 at 1 mg/kg|lirilumab (IPH2102/BMS986015) at 1 mg/kg
3129046|NCT01694199|Active Comparator|Active study device with PRFE|This study arm receives pulsed radiofrequency energy (PRFE) from an active test device.
3129047|NCT01694199|Sham Comparator|Sham study device with no PRFE|This study arm receives no pulsed radiofrequency energy (PRFE) from a sham test device.
3129048|NCT01694186|Sham Comparator|sham injection|sham injection
3129049|NCT01694186|Experimental|FAI insert|FAI insert (0.18 mg fluocinolone acetonide)
3129050|NCT01694173|Experimental|Stem cell therapy - SPD artery|Stem cells will be infused into the superior pancreaticoduodenal artery.
3129051|NCT01694173|Active Comparator|Stem cell therapy - splenic artery|Stem cells will be infused into the splenic artery.
3129052|NCT01694173|Active Comparator|Stem cell therapy-intravenous|Stem cells will be given intravenously.
3129053|NCT01694173|Placebo Comparator|Normal saline placebo -sham procedure|Sham procedure with infusion of normal saline.
3129054|NCT01694160|Experimental|Paricalcitol|Paricalcitol 2 ug/daily for 48 weeks
3129055|NCT01694160|No Intervention|no intervention|
3129056|NCT01694147||patients with sepsis related ALI/ARDS.|Consecutive septic patients with ALI/ARDS in medical intensive care units (ICUs) will be enrolled. EVLWI will be measured by PiCCO monitoring system.
3129057|NCT01694134|Active Comparator|Corticoids|A group of patients will receive an intradiscal injection of Hydrocortancyl.
3129058|NCT01694134|Sham Comparator|Local anaesthetic|A group of patients will receive an intradiscal injection of Lidocaine.
3129059|NCT01694121|Experimental|MEN Count|3 session HIV intervention including a) HIV risk reduction, inclusive of gender equity and healthy relationship counseling and b) case management support for stable employment and housing.
3129060|NCT01694121|Active Comparator|Comparison|An attention comparison program similar to the MEN Count intervention in structure (3 one-on-one sessions delivered over 60-90 days) but focused on stress reduction and healthy lifestyle.
3129061|NCT01694108|Experimental|BCG-vaccine (SSI)|"Children born to mothers, who have accepted to participate, will be randomised to either intervention group or to the control group at birth. Block‐randomisation stratified by hospital, gender and gestational age (≥37 weeks of gestation vs. < 37 weeks of gestation) will be performed electronically just before vaccination by the overall study electronic case report system (e‐crf).~Children randomised to the BCG vaccination group will receive an intradermal BCG vaccine (Statens Serum Institute CG vaccine in the standard dose 0.05 ml in the upper, lateral part of the arm of the child by a specially trained midwife or a study physician."
3129062|NCT01694108|No Intervention|No Intervention|Control children will be treated as usual, since no suitable placebo exists.
3129063|NCT01694095||Patients with geographic atrophy|
3129064|NCT01694082|Experimental|THRIVE replication|Participants in this condition receive THRIVE with a full list of direct and indirect protective behavioral strategies to reduce alcohol consumption.
3129065|NCT01694082|Experimental|THRIVE direct strategies|Participants in this condition receive THRIVE including a subset of protective behavioral strategies that are directly related to alcohol drinking.
3129066|NCT01694082|Experimental|THRIVE indirect strategies|Participants in this condition receive THRIVE including a subset of protective behavioral strategies that are indirectly related to alcohol drinking.
3129067|NCT01694082|Sham Comparator|Brief brochure and assessment control|Participants will answer the same survey questions as participants in the THRIVE conditions, but will receive a brief alcohol-related brochure with only didactic content rather than the intervention components received by participants randomized to THRIVE conditions.
3129068|NCT01694069|Active Comparator|Intermittent Infusion piperacillin-tazobactam|Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams), divided in four equal doses, administered over 30 minutes, four times a day
3129069|NCT01694069|Experimental|Continuous infusion piperacillin-tazobactam|Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams) as a continuous infusion over 24 hours, once daily
3129070|NCT01694056|Experimental|Soy protein diet|High mixed protein diet (20 en%) with 25gr of soy protein per day
3129071|NCT01694056|Active Comparator|Control diet|High mixed protein diet (20 en%)
3129072|NCT01694043|Experimental|Non-Food Related Commercials|Participants will watch a 30-minute Saturday Night Live television show with non-food related commercials embedded.
3129073|NCT01694043|Experimental|Healthy Food Commercials|Participants will watch a 30-minute Saturday Night Live television show with healthy food commercials embedded.
3129074|NCT01694043|Experimental|Unhealthy Food Commericlas|Participants will watch a 30-minute Saturday Night Live television show with unhealthy food commercials imbedded.
3129075|NCT01694030|Experimental|Neutral Condition|Participants in the neutral (control) condition of the attachment security priming experiment will be asked to spend time visualising neutral events (e.g., supermarket shopping)for 3-10 minutes at a time.
3129076|NCT01694030|Experimental|Secure condition|Participants in the attachment security priming condition will be asked to complete visualisation tasks where they think about a secure attachment figure for between 3 - 10 minutes.
3129077|NCT01694017|Active Comparator|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
3129078|NCT01694017|Active Comparator|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
3129079|NCT01694004|Experimental|Benzocaine Infusion into Duodenum|The investigator will conduct a study in 20 lean (BMI = 19-27 kg/m2) subjects involving intravenous (IV) and intraduodenal (ID) infusions of glucose tracers or amino acid traces and measurement of tracer rate of appearance in the plasma. An ID infusion of LCFA will allow the investigators to determine if LCFA can alter nutrient absorption and glucose and amino acid metabolism. Benzocaine will be added to the ID infusion of LCFA to inhibit nerve terminals in the duodenum thereby preventing gut-brain communication. Plasma levels of glucose and amino acid tracers, glucose oxidation (13CO2 breath test), gut hormones (CCK, GIP, PYY, GLP-1, ghrelin), and bioactive lipids (N-acyl phosphatidylethanolamines, NAPEs) will be measured during all infusion periods.
3129080|NCT01693991|Experimental|Meaning-Making intervention (MMi)|Patients in this arm will be receiving the Meaning-Making intervention (MMi) as per intervention manual (Lee, 2006).
3129185|NCT01693211|Active Comparator|Group B|The Capulorhexis and nuclear fragmentation are performed manually.
3129186|NCT01693185|Experimental|Remifentanil|remifentanil of 0.04 mcg/kg/min with placebo (for midazolam) and placebo (for meperidine)
3129081|NCT01693991|Placebo Comparator|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
3129082|NCT01693991|No Intervention|Control Group|Patients in this group will only be receiving treatment as usual.
3129083|NCT01693978|Experimental|Reinforced Prolonged Exposure (RPE)|All participants will be scheduled to attend a weekly Prolonged Exposure therapy session for 12 consecutive weeks, and followed for 12 additional weeks. RPE participants will receive voucher-based reinforcement contingent on attendance to scheduled Prolonged Exposure therapy sessions.
3129084|NCT01693978|Active Comparator|Standard Prolonged Exposure (SPE)|All participants will be scheduled to attend a weekly Prolonged Exposure therapy session for 12 consecutive weeks, and followed for 12 additional weeks.
3129085|NCT01693965|Other|sputum samples|
3129086|NCT01693952|Experimental|blood samples|
3129087|NCT01693939|Other|FS200 Femtosecond Laser|The LASIK flap will be created using the FS200 Femtosecond Laser
3129088|NCT01693926|Experimental|Acute physical activity intervention|25 min of moderate physical activity
3129089|NCT01693926|Placebo Comparator|Placebo|25 min of reading (instead of physical activity)
3129090|NCT01693913|Experimental|Cognitive-behavioral|Those participating in a cognitive behaviorally supported exercise and nutrition treatment will receive a cognitive behavioral exercise and nutrition over 50 weeks
3129091|NCT01693913|Active Comparator|Nurtition education|This arm will participate in nutrition and exercise education
3129092|NCT01693900|Experimental|Pre-operative Ultrasound FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under an ultrasound guidance device with an in-plane technique by a single study investigator, in the preoperative area.
3129093|NCT01693900|Active Comparator|Intra-operative FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room.
3129094|NCT01693887||empirical therapy|immediate initiation of antifungal therapy; Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid)
3129095|NCT01693887||preemptive therapy|Dynamic monitoring of fungal infection, initiation antifungal therapy when clinical diagnosis ( microbial + experiment +, G/GM, CT typical change ) approveled in two weeks Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid) If within two weeks without obtaining positive results, researchers determine whether initiation of antifungal therapy。
3129096|NCT01693874|Experimental|Mindfulness Based Stress Reduction|All participants in this arm receive Mindfulness Based Stress Reduction (MBSR).
3129097|NCT01693874|Active Comparator|control|All participants in this arm receive an attention control
3129098|NCT01693861||Patients|Patients with metastatic colorectal cancer treated with chemotherapy
3129099|NCT01693848||Patients|Patients with metastatic colorectal cancer scheduled for metastatic surgery
3129100|NCT01693848||Control patients|Patients with metastatic colorectal cancer scheduled for general anesthesia without metastatic surgery
3129101|NCT01693835||Patients|Patients with metastatic colorectal cancer
3129102|NCT01693835||Healthy subjects|Age and sec-matched healthy subjects
3129103|NCT01693822|Experimental|Axitinib|Axitinib - oral tablet twice daily until disease progression. Starting dose 5mg.
3129104|NCT01693809|Experimental|Caffeine|Caffeine 420mg, one time
3129105|NCT01693783|Experimental|Treatment (ipilimumab)|Patients receive ipilimumab IV over 90 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving objective response or stable disease continue to receive maintenance therapy comprising ipilimumab IV over 90 minutes once every 12 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
3129106|NCT01693770|Other|MRgFUS|High intensity focused ultrasound energy, delivered under the guidance of the MR images (MgFUS) allows for a predefined amount of energy to be delivered in the desired target (Metastasis). Bone readily absorbs focused ultrasound energy resulting in a thermo-related neurolysis of the periostium with consequent pain palliation. The amount of energy delivered can be modulated with the objective to penetrate cortical space and obtain necrosis of the metastasis thus preventing local recurrence.
3129107|NCT01693757||BPTB group|Bone-patellar tendon-bone
3129108|NCT01693757||STG group|Semitendinosus and gracilis tendon
3129109|NCT01693757||Control|Healthy
3129110|NCT01693744||Dialysis patients|Patients with stage 5 chronic kidney disease undergoing haemodialysis
3129111|NCT01693744||Chronic kidney disease patients|Stage 1-4 Chronic kidney disease patients
3129112|NCT01693744||Control group|Patients with normal renal functions
3129113|NCT01693731||Aromatase Inhibitor|Postmenopausal women with breast cancer taking Arimidex, Aromasin, or Femara
3129114|NCT01693731||No Treatment|Healthy volunteer postmenopausal women not taking Aromatase Inhibitors
3129115|NCT01693705||Tracheostomy Patients|Critical care patients with respiratory failure who were mechanically ventilated and who underwent tracheostomy
3129116|NCT01693705||Non-Tracheostomy Patients|Critical care patients with respiratory failure who were mechanically ventilated but did not undergo tracheostomy
3129117|NCT01693692|Experimental|TD-9855 Group 1|Group 1 to be dosed with TD-9855
3129118|NCT01693692|Experimental|TD-9855 Group 2|Group 2 to be dosed with TD-9855
3129119|NCT01693692|Placebo Comparator|Placebo|Group to be dosed with Placebo
3129120|NCT01693679|Experimental|antiviral drug|Telbivudine team,Telbivudine,600mg/d,oral,60 patients. non-Tebivudine team,Lamivudine,100mg/d,oral,20 patients.Adefovir,10mg/d,oral,20 patients.Enecavir,0.5mg/d,oral,20 patients.
3129187|NCT01693185|Active Comparator|midazolam and meperidine|a bolus midazolam of 0.03 mg/kg a bolus meperidine of 1.0 mg/kg placebo (for remifentanil)
3129188|NCT01693172|Active Comparator|early postoperative mobilization|Early postoperative supervised aerobic exercise, resistance and flexibility training
3129189|NCT01693172|No Intervention|Standard|Standard rehabilitation care
3132690|NCT01669915|Placebo Comparator|Vitamin D placebo + fish oil placebo|
3129121|NCT01693666|Experimental|Lifestyle intervention group|The LIFE program emphasizes improved nutritional quality, moderate physical activity, and weight maintenance (±10 lb) in obese pregnant women using a contingency management (CM) approach to reinforce behavior change. Participants will meet with the study dietitian and exercise physiologist every 2-4 weeks to develop and maintain individualized nutrition and physical activity plans, reinforced by CM. When the subject meets with the interventionists at their regular appointments, they will review the diet and exercise requirements, and provide vouchers earned as reinforcement from the previous study period. Diet requirements include at least 5 days of food logs each week. Exercise requirements include objective verification of up to 5 exercise sessions per week (as prescribed).
3129122|NCT01693666|No Intervention|Routine care group|Participants in the Routine Care (RC) control group will receive no additional intervention beyond standard of care.
3129123|NCT01693653|Active Comparator|Tocilizumab|tocilizumab infusion every 4 weeks over 3 months
3129124|NCT01693653|Placebo Comparator|Placebo|placebo infusion 0.9% sodium chloride every 4 weeks over 3 months
3129125|NCT01693640|Experimental|abatacept|
3129126|NCT01693627|Active Comparator|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
3129127|NCT01693627|Active Comparator|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
3129128|NCT01693627|Active Comparator|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
3129129|NCT01693627|Active Comparator|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
3129130|NCT01693614|Experimental|BKM120|
3129131|NCT01693601|Experimental|Panobinostat and Ruxolitinib|Combination of Panobinostat and Ruxolitinib
3129132|NCT01693588|Experimental|Pain Management Bundle|The Pain Management Bundle will be implemented for all postoperative neurosurgical patients admitted to nursing units at the University of Florida.
3129133|NCT01693575|Experimental|Pupil expansion with APX 100 device|Use of APX 100 device during standard phacoemulsification cataract extraction surgery in patients with small pupil diameter (<4.5 mm) or with documented intraoperative floppy iris syndrome in previous eye.
3129134|NCT01693562|Experimental|MEDI4736 Q2W|Evaluate MEDI4736 given every 2 weeks
3129135|NCT01693562|Experimental|MEDI4736 Q3W|Evaluate MEDI4736 given every 3 weeks
3129136|NCT01693562|Experimental|MEDI4736 Dose Expansion|At least 16 different types of solid tumors will be evaluated in the expansion phase
3129137|NCT01693562|Experimental|MEDI4736 Q4W|Evaluate MEDI4736 given every 4 weeks
3129138|NCT01693549|Experimental|Cabazitaxel|Cabazitaxel(XRP6258) will be administered on day 1 of each cycle, every 21 days, at a dose of 25 mg/m² by i.v. route in 1 hour. Treatment can be continued until patient's consent withdrawal, intolerable toxicity or documented disease progression.
3129139|NCT01693536|Experimental|Lifestyle counselling|"Three dietician visits focussed on education to find food with sodium less than 120mg/100gms.~Two physiotherapist visits focussed on teaching personalised sustainable practical exercise."
3129140|NCT01693536|No Intervention|Control|Control group was offered free skin cancer check and wait listed for the same lifestyle counselling after the six months of the study.
3129141|NCT01693523|Experimental|Minocycline|Minocycline 100 mg by mouth two times a day (200 mg/day). Initial Dose (starts on first day of run-in phase or chemotherapy). Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
3129142|NCT01693523|Placebo Comparator|Placebo|Matching placebo capsules by mouth twice a day. Initial Dose (starts on first day of run-in phase or chemotherapy). Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
3129143|NCT01693510|Experimental|Exercise and Nutrition Intervention|Nutrition intervention: The proposed nutrition plan is a high protein (25% energy) diet providing low fat dairy foods and individualized to energy needs. Dairy foods are accepted by women during pregnancy as a healthy choice (from pilot study) and in our recent birth cohort study, women consumed an average of 3 or more servings of dairy per day. Exercise intervention: Most previous studies and published guidance focus on aerobic exercise such as walking as it is the easiest physical activity to implement in pregnancy in terms of setting goals of steps and monitoring of adherence using accelerometer-type devices. Walking is also the most practical since women reduced moderate and vigorous physical activity during pregnancy but levels of walking were maintained.
3129144|NCT01693510|No Intervention|Usual Prenatal Care|Mothers in the Control Group will be followed by their primary care provider and have usual access to public health. In addition, women will have the opportunity to attend one focus group session exploring women's experiences with nutrition, exercise, and weight gain in pregnancy.
3129145|NCT01693497|Experimental|Dialogical exposure therapy|Psychotherapy based on a manual integrating Gestalt principles with cognitive-behavioral techniques.
3129146|NCT01693497|Active Comparator|Cognitive Processing Therapy|Cognitive Processing Therapy, a cognitive behavioral psychotherapy for PTSD patients. Based on a German manual adapted from Resick and Schnicke, 1993.
3129147|NCT01693484|Experimental|ICG administered|The ICG dose (10 mg/4cc per image capture) will be administered in its entirety via push injection through IV access established for standard surgical procedure, followed by 10 cc Normal Saline bolus. This ICG dose will be administered twice, 1X prior to anesthesia, and 1X after the tourniquet on operative extremity has been removed for at least 15 minutes.
3129148|NCT01693471||SEARCH Study Group|
3129149|NCT01693458|Experimental|Lifestyle counseling|Appreciative Inquiry Change Agents (CA) Program (NAMWEZA)
3129150|NCT01693458|Placebo Comparator|Control group|Since the design is a stepped-wedge randomized trial, those in the control group will eventually receive the intervention later in the study.
3129151|NCT01693445|Experimental|OIS (Oxaliplatin, Irinotecan, S-1)|"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~Oxaliplatin 85 mg/m²IV on day 1~Irinotecan 120 mg/m² IV on day 1~S-1 60 mg/m2/day PO on day 1-7 Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
3129152|NCT01693432|Experimental|DS (docetaxel+S-1)|"Treatment will be delivered as a 3-week cycle.~Docetaxel 60 mg/m²IV on day 1~S-1 80 mg/m2/day PO on day 1-14"
3129153|NCT01693419|Experimental|GES (Gemcitabine, Erlotinib, S-1)|"Treatment will be delivered as a 3-week cycle.~Gemcitabine 1000 mg/m² IV on day 1, 8~Erlotinib 100 mg/day PO on day 1~S-1 60 mg/m²/day PO on day 1-14"
3129154|NCT01693406||Normal Weight|Normal weight and normoglycemic women: Pre-pregnancy BMI between 18.5 - 24.9 kg/m2.
3129155|NCT01693406||Overweight/Obese|Overweight and normoglycemic women: Pre-pregnancy BMI between > 25 kg/m2.
3129156|NCT01693406||Gestational Diabetes|Women who develop gestational diabetes and return to normal glucose control after delivery.
3129157|NCT01693406||Type 2 Diabetes|Women who are overweight and have Type 2 Diabetes that was diagnosed before pregnancy: Pre-pregnancy BMI > 25 kg/m2.
3129158|NCT01693393|Other|Cyclosporine A|All patients will receive Cyclosporine A in a dose of 2mg/kg/BW daily for 16 weeks
3129159|NCT01693380|Experimental|Influenza vaccine|"Schoolchildren from 6 to 8 years received two intra-muscular doses of 0.5 ml of inactivated influenza vaccine, of the Southern Hemisphere, 2009.~Schoolchildren above 8 years received one intra-muscular dose of 0.5 ml of inactivated influenza vaccine, of the Southern Hemisphere, 2009."
3129160|NCT01693380|Sham Comparator|Control vaccine|"Schoolchildren received one intra-muscular dose of 0.5 ml of Meningococcal C conjugate vaccine.~Schoolchildren under nine years of age received also one intra-muscular dose of 0.5 ml of varicella vaccine one month after the Meningococcal C vaccine."
3129161|NCT01693367|Active Comparator|DLS 5.0 (Dynamic Locking Screws)|ORIF with DLS 5.0 (Dynamic Locking Screws)
3129162|NCT01693367|Active Comparator|SLS (Standard locking screw)|ORIF with SLS (Standard locking screw)
3129163|NCT01693354|Active Comparator|HF dialysis|HF (high-flux) dialysis is standard hemodialysis treatment performed by using a high permeability dialyzer instead of a low permeability one.
3129164|NCT01693354|Experimental|Mid-dilution HDF|Mid-dilution is a newly developed hemodiafiltration therapy able to allow a simultaneous pre- and post-dilution infusion.
3129165|NCT01693341|Active Comparator|Care-giver mediated training|Each patient and the caregiver of the intervention group received weekly home training and exercise counseling by a physical therapist about the caregiver mediated home exercise skill for stroke patient. The training program were progress weekly based on the patient's need.
3129166|NCT01693341|No Intervention|Standard-care|Maintain the inherent standard-care
3129167|NCT01693328||PecFent®|
3129168|NCT01693315|Experimental|Cohort 1 - AMA0076 Dose A (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo).
3129169|NCT01693315|Experimental|Cohort 2: AMA0076 Dose B (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo).
3129170|NCT01693315|Experimental|Cohort 3: AMA0076 Dose C (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo).
3129171|NCT01693315|Experimental|Cohort 4: AMA0076 Dose D (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo).
3129172|NCT01693302|Experimental|-20 minute insulin|Insulin for the meal is given 20 minutes prior to starting the meal.
3129173|NCT01693302|Experimental|0 minute insulin|Insulin for the meal is given immediately before starting to eat.
3129174|NCT01693302|Experimental|+20 minute insulin|Insulin is given 20 minutes after the start of the meal.
3129175|NCT01693289|Experimental|Metformin plus letrozole|metformin :850mg tablets twice daily for 6 months letrozole :5mg tablets twice daily form day 3to7 of cycle
3129176|NCT01693289|Experimental|ovarian drilling|bilateral diathermy ovarian drilling, four drills each ovary
3129177|NCT01693276|Experimental|Gemzar/Abraxane and Radiation Therapy|Patients will receive 2 cycles of gemcitabine and abraxane prior to the start of chemoradiation. Chemoradiation will commence 2 week after the completion of second cycle of gemcitabine/abraxane. Patients will receive an additional 2 cycles of gemcitabine and abraxane to start 2-4 weeks after the completion of chemoradiation. After the last two cycles of chemotherapy, if well tolerated with continued tumor response additional cycles of chemotherapy may be given.
3129178|NCT01693263||brachiocephalic fistula placed|Subjects are being asked to participate in this study because they have end-stage renal disease and they are undergoing dialysis, and their doctor has recommended that they will have brachiocephalic fistula placed for their dialysis access.
3129179|NCT01693263||Sub-study participants|As part of this study there is an additional sub-study. The researchers would like to collect more information about the vascular access from 50 subjects. For the purposes of this sub-study the following will take place: Intravenous Ultrasound (IVUS) and Hand Held Doppler
3129180|NCT01693250|Experimental|fitbit ultra|Adolescents in the intervention group will receive a Fitbit Ultra and will download an app to their smartphone. Participants will be asked to wear the Fitbit device and use the app every day for three months.
3129181|NCT01693250|Active Comparator|Pedometer|After completion of the baseline assessments, adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
3129182|NCT01693237|Active Comparator|Group psychotherapy|20 sessions of systemic and narrative group psychotherapy
3129183|NCT01693237|Experimental|Group psychotherapy with feedback|20 sessions of systemic and narrative group psychotherapy with session-to-session feedback to patient and therapist.
3129184|NCT01693211|Experimental|Group A|Capsulorhexis and pre-fragmentation of the nucleus are performed by the femtosecond laser.
3130069|NCT01687387|Experimental|IPH2102 at 0.1 mg/kg|lirilumab (IPH2102/BMS986015) at 0.1 mg/kg
3129190|NCT01693159|Experimental|ECA: Ethyl-2-cyanoacrate|Application of ethyl-2-cyanoacrylate (ECA) for painful cetuximab-induced rhagades
3129191|NCT01693159|Active Comparator|Standard treatment of the institution|Standard treatment of the institution to treat painful cetuximab-induced rhagades
3129192|NCT01693146|Active Comparator|Nasal insufflation of oxygen|Nasal insufflation of oxygen starting at at flow of 0.5 L/min.
3129193|NCT01693146|Active Comparator|Nasal oxygen insufflation with a TNI® 20 oxy device|Device: TNI®20 oxy Nasal insufflation at a constant high flow of 15 L/min with oxygen addition starting at 0.5 L/min
3129194|NCT01693133|Other|Control|Standard of Care: Moist Wound Therapy and Offloading
3129195|NCT01693133|Experimental|EpiFix plus Standard of Care|Weekly application of EpiFix (up to 12 week) and standard of care (moist wound therapy and offloading)
3129196|NCT01693120|Experimental|Ablation|Phased RF ablation
3129197|NCT01693107||Operator Blinded to Contact Force|Physicians performing the ablation will be blinded to the contact force data
3129198|NCT01693094|No Intervention|No decision aid|One cohort will not receive the decision aid, and instead will receive only a brochure as standard treatment.
3129199|NCT01693094|Active Comparator|Decision Aid|One cohort will receive a decision aid.
3129200|NCT01693081|Active Comparator|VR040/Aspirair® inhaler|VR040 was administered as an inhaled dry powder, in a dosage of 1.5, 2.3, 3.0 and 4.0mg, single dose given at each dose level.
3129201|NCT01693081|Placebo Comparator|Placebo|Placebo was administered as an inhaled dry powder, matching to active comparator at dosages of 1.5, 2.3, 3.0 and 4.0mg, single dose given at each dose level.
3129202|NCT01693068|Experimental|Pimasertib|
3129203|NCT01693068|Active Comparator|Dacarbazine|
3129204|NCT01693055|Experimental|UltheraTM|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
3129205|NCT01693042|Active Comparator|Single intracoronary cell application|Single intracoronary application of autologous bone marrow derived mononuclear cells
3129206|NCT01693042|Active Comparator|repeated (2 times) intracoronary cell application|2 times (interval 4 months) intracoronary application of autologous bone marrow derived mononuclear cells
3129207|NCT01693029|Experimental|HX575 epoetin alfa|HX575, recombinant human epoetin alfa
3129208|NCT01693029|Active Comparator|US-licensed epoetin alfa|US-licensed recombinant human epoetin alfa
3129209|NCT01693016|Other|inhalation group|20 children Taking blood samples and SpHb-measurement was made under inhalational anesthesia
3129210|NCT01693016|Other|non-inhalational|40 children Taking blood samples and SpHb measurements in awake and spontaneous breathing children.
3129211|NCT01693003|Experimental|Indacaterol first|"Indacaterol 150 µg d.o. during the first 3-week period followed by other 3-week period of tiotropium bromide 5 µg d.o. separated by a wash-out phase of at least 5 to 14 days between each treatment period"
3129212|NCT01693003|Experimental|Tiotropium first|"Tiotropium bromide 5 µg d.o. during the first 3-week period followed by other 3-week period of Indacaterol 150 µg d.o. separated by a wash-out phase of at least 5 to 14 days between each treatment period"
3129213|NCT01692990|Experimental|Fish oil|5 g/d in 10 capsules, providing 3.5 g of long-chain n-3 fatty acids
3129214|NCT01692990|Placebo Comparator|Soy bean oil|5 g/d in 10 capsules
3129215|NCT01692977|Experimental|Alzheimer disease patients|Alzheimer disease patients
3129216|NCT01692977|Active Comparator|control|healthy control subjects.
3129217|NCT01692951||Lung adenocarcinoma patients|Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung adenocarcinoma was based on pathologic analysis.
3129218|NCT01692951||Control matched to adenocarcinoma|Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
3129219|NCT01692951||Lung squamous cell carcinoma patients|Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung squamous cell carcinoma was based on pathologic analysis.
3129220|NCT01692951||Control matched to squamous cell|Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
3129221|NCT01692938||No Retinal Disease|
3129222|NCT01692938||Retinal Disease|
3129223|NCT01692925|Experimental|Lot A|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
3129224|NCT01692925|Experimental|Lot B|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
3129225|NCT01692925|Experimental|Lot C|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
3129226|NCT01692925|Experimental|Lot D|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
3129227|NCT01692912|Active Comparator|Intensive Care (IC)|Rheumatologists treating to target of DAS28<2.6
3129228|NCT01692912|No Intervention|Routine Care (RC)|Participants treated in the routine manner by their rheumatologist (not treated to the target of DAS28<2.6)
3129229|NCT01692899||Etanercept|Etanercept: administered as first line biotherapy in RA during the period of the study
3129230|NCT01692899||Adalimumab|Adalimumab: administered as first line biotherpy in RA during the period of the study
3129231|NCT01692899||Infliximab|Infliximab: administered as first line biotherpy in RA during the period of the study
3129232|NCT01692886|Active Comparator|7vPnC (3-, 4-, 5-, 12-Month)|
3129233|NCT01692886|Experimental|13vPnC (3-, 4-, 5-, 12-Month)|
3129234|NCT01692886|Experimental|13vPnC (2-, 4-, 6-, 12-Month)|
3129235|NCT01692886|Experimental|13vPnC (3-, 5-, 12-Month)|
3129236|NCT01692873|Experimental|suspected pancreatic tumor|Realization of pancreatic tumor biopsy and blood samples
3129237|NCT01692860|Experimental|High protein consumption|Intervention, energy restriction. This arm has a dietary protein intake of 1.5g/kg/d
3132691|NCT01669902||Cohort|
3129238|NCT01692860|Placebo Comparator|Normal protein consumption|Intervention, energy restriction. This arm has a dietary protein intake of .8g/kg/d
3129239|NCT01692847||RRT calls prior to IGS use|Patients who triggered ACT/RRT calls prior to the installation of the IGS (Intellivue Guardian System)
3129240|NCT01692847||RRT calls during IGS use|Patients who triggered ACT/RRT calls after the installation of IGS. All patients on the study ward receive the same care in both groups. The only difference is the system used to collect vital signs and to inform the staff about patient deteriorations. In Group 2, the IGS (FDA approved and CE marked) is the vital signs collection and information system.
3129241|NCT01692834|Active Comparator|Cyclosporine in Cremophor EL®|Dosing 5 mg/kg infused at a constant rate over 4 h with a syringe pump.
3129242|NCT01692834|Active Comparator|Cyclosporine in lipid emulsion|Dosing 5 mg/kg infused at a constant rate over 4 h with a syringe pump.
3129243|NCT01692821|Experimental|100% oxygen breathing|
3129244|NCT01692821|Experimental|15% oxygen in N2 breathing|
3129245|NCT01692821|Experimental|12% oxygen in N2 breathing|
3129246|NCT01692808|No Intervention|Exclusive Enteral Nutrition|This group is one of the non interventional group. As enteral nutrition is one of the usual therapy of Crohn disease at diagnosis.
3129247|NCT01692808|Experimental|EEN + Vitamin D3 3000 UI daily|Exclusive Enteral Nutrition + Vitamin D3 3000 UI daily for one month This arm will be one of the two experimental arms.
3129248|NCT01692808|No Intervention|Corticosteroïd|Corticosteroids (1mg/kg/day) associated with usual vitamin and calcium supplementation: vitamin D 800 IU of vitamin D3 + 1000 mg calcium per day) for one month
3129249|NCT01692808|Experimental|Corticosteroids + Vitamin D3 4000 UI|Corticosteroids (1mg/kg/day) associated with vitamin D3 4000 UI daily and calcium 1000 mg daily for one month
3129250|NCT01692808|Experimental|Vitamin D3 4000 UI|Vitamin D3 4000 UI /day . This arm is intended for those children in remission with or without immunosuppressant. Vitamin D will be administered in adjunction to usual therapy.
3129251|NCT01692795||MI patients|
3129252|NCT01692782|Experimental|SEP-225289 4mg|SEP-225289 4mg once daily taken as a combination of SEP-225289 2mg and placebo capsules to achieve 4mg QD doses
3129253|NCT01692782|Experimental|SEP-225289 8mg|SEP-225289 8mg once daily taken as a combination of SEP-225289 2mg and placebo to achieve 8mg QD doses
3129254|NCT01692782|Placebo Comparator|Placebo|4 capsules of placebo
3129255|NCT01692769|Active Comparator|Normal Saline|Patients will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
3129256|NCT01692769|Active Comparator|Ringer's Lactate|Patients will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
3129257|NCT01692756|Experimental|Kenalog or Placebo|Kenalog® (40mg) or saline placebo injection 1-2 days after ACL injury and 12-14 days later.
3129258|NCT01692756|Experimental|Kenalog then placebo|Subjects will initially receive 40mg injection of Kenalog® 1-2 days after injury and saline placebo at 12-14 days post injury.
3129259|NCT01692756|Experimental|Kenalog only|Subjects will receive two consecutive (40 mg) intra-articular injections of Kenalog®
3129260|NCT01692756|Placebo Comparator|Placebo|subjects will receive two consecutive intra-articular saline placebo injections at the same time periods.
3129261|NCT01692743|No Intervention|Standard of Care|Participants undergo usual follow up (routine and as needed office visits and telephone calls) and receive educational fact sheets from the Crohn's and Colitis Foundation of America.
3129262|NCT01692743|Experimental|Weekly Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
3129263|NCT01692743|Experimental|Home Monitoring Every Other Week|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
3129264|NCT01692730|Experimental|Enhanced Web Assisted Intervention|Enhanced Web Assisted Tobacco Intervention. An enhanced and highly interactive website for cessation.
3129265|NCT01692730|Active Comparator|Basic Web Assisted Intervention.|Basic Web Assisted Tobacco Intervention. A basic website for cessation comparable to those for general adult populations, including established evidence-based cessation information and features.
3129266|NCT01692717|Active Comparator|Atorvastatin|Citalor (Atorvastatin) - Pfizer
3129267|NCT01692717|Active Comparator|Hydrochlorothiazide + Losartan|Hyzaar (Hydrochlorothiazide + Losartan) - Merck Sharp & Dohme
3129268|NCT01692717|Experimental|Atorvastatin + Hydrochlorothiazide + Losartan|Polipílula (Atorvastatin + Hydrochlorothiazide + Losartan) - Lab Hypermarcas
3129269|NCT01692704|Experimental|HAI with FUDR & systemic cisplatin and gemcitabin|FUDR: 0.2mg/kg/day continuously i.a. for 14 days Cisplatin: 25mg/m2 i.v. Gemcitabin: different doses according to dose level 600, 800, or 1000 mg/m2 i.v.
3129270|NCT01692691|Experimental|Dacarbazine, carmustine, neulasta|Dacarbazine IV - Day 1; Carmustine IV - Day 2; Neulasta SC - Day 3
3129271|NCT01692678|Experimental|Trabectedin (Part 1 and Part 2)|Trabectedin will be administered at a dose of 1.5, 1.2 or 1.0 mg/m2 as a 24-hour intravenous infusion on Day 1 of each 21-day treatment cycle (ie, each treatment cycle being at least 21 days apart).
3129272|NCT01692678|Active Comparator|Dacarbazine (Part 2)|Dacarbazine will be administered at a dose of 1 g/m2 as a longer than 30-minute intravenous infusion on Day 1 of each 21-day treatment cycle (ie, each treatment cycle being at least 21 days apart).
3129273|NCT01692665||stage 3 or stage 4 meibomiang gland dysfunction patients|stage 3 or stage 4 meibomiang gland dysfunction patients
3129274|NCT01692652|Experimental|Lotemax with warm compress group|topical loteprednol etabonate (lotemax 0.5%) qid and warm compress & ocular massage (a minimum of four times, once or twice a daily) for 2months
3129275|NCT01692652|Active Comparator|warm compress only group|warm compress only group
3129324|NCT01692340|Experimental|Isotopically labeled lycopene|We will administer 10 mg of isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
3129276|NCT01692626|Experimental|Pimecrolimus on Left vs. Placebo on Right|Patients will apply a thin layer of the Pimecrolimus cream twice daily for four weeks (unless rash worsens sooner) to one half of face at the same time the are started on cetuximab. Patients will be provided with a placebo cream to apply to the other side of their face. The study coordinator will instruct the patient regarding which side of the face to apply the investigational cream. This will be randomly assigned by the study coordinator based on a randomization list generated by the biostatistics core and will only be known to the study coordinator.
3129277|NCT01692626|Experimental|Pimecrolimus on Right vs. Placebo on Left|Patients will apply a thin layer of the Pimecrolimus cream twice daily for four weeks (unless rash worsens sooner) to one half of face at the same time the are started on cetuximab. Patients will be provided with a placebo cream to apply to the other side of their face. The study coordinator will instruct the patient regarding which side of the face to apply the investigational cream. This will be randomly assigned by the study coordinator based on a randomization list generated by the biostatistics core and will only be known to the study coordinator.
3129278|NCT01692600||healthy volunteers|Age-matched with the patient group, with no oral pathologies and comorbidities
3129279|NCT01692600||Late oral radiation toxicity patients|Head-and-neck cancer patients who had undergone radiation therapy and developed late radiation side ffects
3129280|NCT01692587|No Intervention|Control|No changes in dietary group
3129281|NCT01692587|Experimental|Protein restrictive diet|reduced protein diet
3129282|NCT01692574|Experimental|Combined|Group cognitive-behavior therapy for depression combined with behavior modification for weight loss
3129283|NCT01692574|Active Comparator|GCBT-ND|Group cognitive-behavior therapy for depression combined with an alternative approach to weight loss
3129284|NCT01692574|Active Comparator|DSE|Behavior modification for weight loss combined with depression support and education.
3129285|NCT01692561||normaL|Healthy subjects without symptoms of dysautonomia.
3129286|NCT01692561||Neurocardiogenic syncope|Fainting due to sudden drop in blood pressure.
3129287|NCT01692561||Orthostatic hypotension|Sudden decrease in blood pressure while standing.
3129288|NCT01692561||Postural Orthostatic Tachycardic Syndrome|Increased heart rate when standing.
3129289|NCT01692548|Experimental|Neurofeedback|Neurofeedback: two sessions per week, 30 sessions total.
3129290|NCT01692548|No Intervention|Control|
3129291|NCT01692535|Experimental|GlideScope|intubation
3129292|NCT01692535|Experimental|Airtraq|intubation
3129293|NCT01692535|Experimental|McGrath MAC|intubation
3129294|NCT01692535|Experimental|King Vision|intubation
3129295|NCT01692535|Experimental|A.P. Advance|intubation
3129296|NCT01692535|Experimental|C-MAC|intubation
3129297|NCT01692522|Experimental|Ambu Aura-i|intubation
3129298|NCT01692522|Active Comparator|AirQ|intubation
3129299|NCT01692509||Patients requiring NIV|Patients requiring NIV because of acute respiratory failure
3129300|NCT01692496|Experimental|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
3129301|NCT01692483||Abiraterone acetate plus prednisone|
3129302|NCT01692470||rilpivirine hydrochloride|Patients will be taking 1 tablet of 25 mg rilpivirine hydrochloride is administered once daily orally in combination with other anti-retroviral (ARV) medications.
3129303|NCT01692457||Golimumab|Patients will be taking golimumab as per the dosing regimen given on product insert approved in Philippines.
3129304|NCT01692444||COPD|15 patients with COPD from 1 to 4 according to the GOLD 2011
3129305|NCT01692444||Non smoker Control|15 patients without COPD and no smoking history
3129306|NCT01692444||Smoker Control|15 patients without COPD but a smoking history
3129307|NCT01692431|Experimental|DHA|High fat meal containing DHA rich oil.
3129308|NCT01692431|Experimental|EPA|High fat meal containing EPA.
3129309|NCT01692431|Placebo Comparator|Control|High fat meal with no/negligable omega-3 fatty acid content.
3129310|NCT01692418|Experimental|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline) over a minimum of 15 minutes
3129311|NCT01692418|Placebo Comparator|Placebo|Normal saline will be administered as an i.v. infusion (100ml normal saline) over a minimum of 15 minutes
3129312|NCT01692405|No Intervention|Standard method|Standard method- shaking the biopsy needle into a formalin container.
3129313|NCT01692405|Active Comparator|Download onto a biopsy sponge pad|Samples will be downloaded by moving the needle notch on a biopsy sponge pad.
3129314|NCT01692405|Experimental|Dowloading the biopsy cores using NavigoBx system|Downloading the biopsy cores using NavigoBx™ system. The NaviGoBx™ device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.
3129315|NCT01692392||Pectus carinatum|Patients who have undergone surgical repair of pectus carinatum.
3129316|NCT01692379|Experimental|Endovascular treatment|Mechanical embolectomy with Solitaire FR device
3129317|NCT01692379|Active Comparator|Medical treatment|Medical treatment (standard of care in acute ischemic stroke)including intravenous thrombolysis
3129318|NCT01692366|Experimental|SAR302503 300mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 300mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
3129319|NCT01692366|Experimental|SAR302503 400 mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 400 mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
3129320|NCT01692366|Experimental|SAR302503 500 mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 500 mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
3129321|NCT01692353||Exclusive cigarette smokers (SMK)|Subject's usual brand (UB) of cigarettes
3129322|NCT01692353||Exclusive moist snuff consumers (MSC)|Subject's usual brand (UB) of moist snuff
3129323|NCT01692353||Non-tobacco consumers (NTC)|No use of tobacco or nicotine-containing products of any kind
3129357|NCT01692145|Experimental|KCT-0809 ophtalmic solution|
3129325|NCT01692340|Experimental|Isotopically labeled phytoene|We will administer 3.2 mg isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
3129326|NCT01692340|Experimental|Isotopically labeled phytofluene|We will administer 10 mg of isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
3129327|NCT01692327|Other|Obese Group|Obese group with fat overload intake.
3129328|NCT01692327|Other|Control Group|Control Group + fat overload intake
3129329|NCT01692327|Other|Glucose Intolerance|glucose intolerance + fat overload intake
3129330|NCT01692314|Experimental|Obese adolescents is being compared to control ones|Patients underwent to resistance training, three times a week, during three months.
3129331|NCT01692301|Experimental|LCZ696 (sacubitril/valsartan)|Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study.
3129332|NCT01692301|Active Comparator|Olmesartan|Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study.
3129333|NCT01692288|Experimental|Offered First Born® Program services|Family and first-born child are selected to be offered First Born® Program home visiting services.
3129334|NCT01692288|No Intervention|Not offered First Born® Program services|Family and first-born child are not selected to be offered First Born® Program home visiting services.
3129335|NCT01692275|Active Comparator|Medical Care + Chiropractic Care|Medical care plus chiropractic manipulative therapy
3129336|NCT01692275|Active Comparator|Conventional Medical Care Only|Conventional medical care only
3129337|NCT01692262|Experimental|Part A Group 1 Intermittent|Recruitment suspended and will not be re-opened. See intervention description below.
3129338|NCT01692262|Experimental|Part A Group 2 Intermittent|Recruitment complete. See intervention description below.
3129339|NCT01692262|Experimental|Part B|This part of the study will not be conducted following a review of data from Part A. See intervention description below.
3129340|NCT01692249|Experimental|immediate spa therapy|group (A) received immediate spa treatment, with 18 days of therapy over 3 weeks; The standardized shoulder therapy program was designed by experienced spa therapy physicians. Spa mineral water and treatments are approved and controlled by the French authorities. Spa treatment included: bubble buses at 36°C for 15 minutes, applications of mineral matured mud at 45°C to the shoulder for 20 minutes, mineral hydrojet sessions at 39°C for 7 minutes and general mobilization in a collective mineral water pool at 35°C for 20 minutes supervised by a registered physiotherapist.
3129341|NCT01692249|No Intervention|control group|in group (B), spa therapy was delayed for 6 months (control group).
3129342|NCT01692223||Unaffected Relatives|We will use a prospective, observational cohort design, we will invite a sample of individuals who have indicated willingness to be re-contacted for future studies (from existing protocols involving cancer survivors and their unaffected relatives employing mixed methods -qualitative interviews coupled with validated measures - to assess: the proportion of participants experiencing psychological distress from Whole genome/exome sequencing (WGS/WES) results.
3129343|NCT01692223||Pts with history of cancer|We will use a prospective, observational cohort design, we will invite a sample of individuals who have indicated willingness to be re-contacted for future studies (from existing protocols involving cancer survivors and their unaffected relatives employing mixed methods -qualitative interviews coupled with validated measures - to assess: the proportion of participants experiencing psychological distress from Whole genome/exome sequencing (WGS/WES) results.
3129344|NCT01692223||Participants whose genomes/exomes are not sequenced|We will also recruit an additional group of participants from the general public (with or without a cancer history) who have not had their genomes or exomes sequenced to participate in focus groups to inform us about their perceptions of the hypothetical utility of learning of incidental results from their genome or exomes. For our sampling purposes, this group of participants is referred to as the 'focus group participants (sample #3-hypothetical group)
3129345|NCT01692210||Blood Draw Pre and Post Surgery|Patients within the UT MD Anderson Cancer Center who are scheduled for breast cancer surgery.
3129346|NCT01692197|Experimental|E7070 + Idarubicin + Cytarabine|E7070 400 mg/m2 IV over 1 hour on day 1 and day 8 (+/- 2 days on Day 8 only) followed by, Idarubicin 8 mg/m2 IV over 1 hour daily for 3 days (days 9-11) and Cytarabine 1.0 g/m2 IV over 24 hours daily on day 9-12 (age <60 years) or days 9-11 (age > 60 years). Dexamethasone 10 mg IV daily for 3-4 days with cytarabine.
3129347|NCT01692184|Experimental|50 mg of AVL-292 and Placebo|50 mg AVL-292 (2 x 25 mg AVL-292 capsules and 6 placebo capsules) once daily for 7 days administered orally under fasted condition
3129348|NCT01692184|Experimental|100 mg of AVL-292 and Placebo|100 mg AVL-292 (4 x 25 mg AVL-292 capsules and 4 placebo capsules) once daily for 7 days administered orally under fasted condition
3129349|NCT01692184|Experimental|200 mg AVL-292|8 x 25 mg AVL-292 capsules orally once daily for 7 days under fasted condition
3129350|NCT01692184|Experimental|350 mg of AVL-292|350 mg AVL-292 (14 x 25 mg AVL-292 capsules) once daily for 7 days administered orally under fasted condition
3129351|NCT01692184|Placebo Comparator|Placebo - 8 capsules|8 placebo capsules once daily for 7 days administered orally under fasted condition
3129352|NCT01692184|Placebo Comparator|Placebo - 14 capsules|14 placebo capsules once daily for 7 days administered orally under fasted condition
3129353|NCT01692171|Experimental|Teste|Enoxalow (Heparin, Low-Molecular-Weight) - Blau Farmacêutica S/A.
3129354|NCT01692171|Active Comparator|Comparador|Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis
3129355|NCT01692158|Experimental|Teste|Enoxalow (Heparin, Low-Molecular-Weight) - Blau Farmacêutica S/A.
3129356|NCT01692158|Active Comparator|Comparador|Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis
3129360|NCT01692119|Experimental|regular, pharmacy-based intervention|providing medication in weekly dosing aids and regular contacts with the local pharmacy
3129361|NCT01692119|No Intervention|usual care|usual care
3129362|NCT01692106|Experimental|peroral endoscopic myotomy (POEM)|The Procedure: per oral endoscopic myotomy (POEM)will be performed on all patients in this single arm study.
3129363|NCT01692093|Experimental|KM110329|Participants will receive KM110329 for eight weeks. Participants will take 2 tablets by mouth with water two times a day after meals.
3129364|NCT01692093|Placebo Comparator|Control|Participants will receive placebo drug for eight weeks. Participants will take 2 tablets by mouth with water two times a day after meals.
3129365|NCT01692080||Asthma Screenings and Camps|Children, ages 5-17 years who participate in one of the asthma screenings or camps are eligible to participate in this study.
3129366|NCT01692067||D0|Not deployed
3129367|NCT01692067||D1|Deployed to combat-related regions once
3129368|NCT01692067||D2|Deployed to combat related regions more than once
3129369|NCT01692067||D3|Deployed outside of the continental US but not to combat related regions
3129370|NCT01692054||Alcohol intoxicated adolescents|Adolescents who were hospitalized due to acute alcohol intoxication
3129371|NCT01692054||Control group|adolescents who were hospitalized due to other medical conditions but not alcohol intoxication
3129372|NCT01692041|Active Comparator|Ivy leave|active therapy arm with Ivy leave 5 ml twice daily p.o. for four weeks
3129373|NCT01692041|Placebo Comparator|Placebo|Ivy leave placebo 5 ml twice daily p.o. for four weeks
3129374|NCT01692015|Experimental|Diet and nosebleed questionnaire|Participants will only be required to fill in two paper questionnaires, one on dietary history, and one on nosebleed severity.
3129375|NCT01692015|Experimental|Weighed food diary arm|Participants will be required to weigh their food for one week to generate a food dairy, and have a single blood test, in addition to filling in the two paper questionnaires, one on dietary history, and one on nosebleed severity.
3129376|NCT01692002|Placebo Comparator|Sodium chloride pill|Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test
3129377|NCT01692002|Experimental|Sodium propionate pill|Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test
3129378|NCT01691989|Experimental|aleglitazar|
3129379|NCT01691989|Experimental|placebo|
3129380|NCT01691976|No Intervention|Controls|Age-matched male patients with benign prostatic hyperplasia, otherwise healthy, as controls
3129381|NCT01691976|Active Comparator|LHRHa|Prostate cancer patients receiving androgen deprivation therapy by luteinising hormone releasing-hormone agonists (LHRHa)
3129382|NCT01691976|Experimental|Oestrogen|Prostate cancer patients recruited from the Prostate Adenocarcinoma TransCutaneous Hormones (PATCH) Trial, randomised to receive ADT via transdermal oestrogen patches.
3129383|NCT01691963|No Intervention|Control group|"In the control group, anaesthesia will be induced in the same way as mentioned above for the intervention group. Also in this group, intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula. The glottic view will be scored in this position using the Cormack and Lehane classification system. If correct laryngoscope positioning cannot be achieved with a size 3 blade, a size 4 blade will be used. Hereafter, the patient's trachea will be intubated once the optimal view of the larynx had been obtained. Intubation attempts will be scored in the same way as mentioned above for the intervention group."
3129384|NCT01691963|Experimental|Epiglottic downfolding|"Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.~The glottic view will be scored in both positions using the Cormack and Lehane classification system.~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position."
3129385|NCT01691950||Reconstruction|Those who have undergone limb reconstruction following lower limb trauma
3129386|NCT01691950||Prosthesis|Those who have undergone amputation and rehabilitation with a prosthesis following lower limb trauma
3129387|NCT01691950||Control|Healthy volunteers
3129388|NCT01691937|Experimental|PVB + PCA|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with sufentanil
3129389|NCT01691937|Placebo Comparator|Placebo PVB + PCA|Continuous Paravertebral Block with Saline and Patient-controlled analgesia with sufentanil
3129390|NCT01691924|Placebo Comparator|Placebo|Placebo capsules: solid microcrystalline cellulose c.s.p
3129391|NCT01691924|Experimental|PBF-509|The initial dose-escalation scheme includes the following eight doses: 10 mg, 20 mg, 40 mg,80 mg, 160 mg, 320 mg, 480 mg and 620 mg. This dose-escalation scheme has been built with the aim to reach the Minimum Intolerated Dose (MID), i.e. when investigator should stop escalating, and consequently the MTD.
3129392|NCT01691911|Experimental|Remote preconditioning|Preconditioning will be performed in the same manner as several previous trials. Immediately after induction of anaesthesia, a standard, CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
3129393|NCT01691911|No Intervention|Remote preconditioning control|Patients randomised to this group will receive routine pre-operative, peri-operative and post operative care.
3129418|NCT01691768|Active Comparator|Control|monthly 1% tenofovir gel provision and monitoring through CAPRISA research clinics
3129419|NCT01691755|Placebo Comparator|Placebo|
3129420|NCT01691755|Experimental|aleglitazar|
3129421|NCT01691742|Placebo Comparator|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
3132692|NCT01669889||Cohort|
3129394|NCT01691898|Experimental|Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab|For the first 2 cycles, RTX 375 milligrams per square meter (mg/m^2) will be given by intravenous (IV) infusion on Day 1 and pinatuzumab vedotin 2.4 milligrams per kilogram (mg/kg) will be administered by IV infusion on Day 2 to Arm A participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and pinatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop disease progression (PD) will be further treated with RTX 375 mg/m^2 followed by polatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
3129395|NCT01691898|Experimental|Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab|For the first 2 cycles, RTX 375 mg/m^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 2.4 mg/kg will be administered by IV infusion on Day 2 to Arm B participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop PD would be further treated with RTX 375 mg/m^2 followed by pinatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
3129396|NCT01691898|Experimental|Cohort C (FL): RTX + Polatuzumab|For the first 2 cycles, RTX 375 mg/m^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 1.8 mg/kg will be administered by IV infusion on Day 2 to Cohort C participants (with r/r FL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, PD, or withdrawal from study.
3129397|NCT01691898|Experimental|Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort E participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
3129398|NCT01691898|Experimental|Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort G participants (with r/r FL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort G participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
3129399|NCT01691898|Experimental|Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort H participants (with r/r DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort H participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
3129400|NCT01691885|Experimental|A/B|Placebo followed by Fluticasone Furoate Vilanterol Combination
3129401|NCT01691885|Placebo Comparator|B/A|Fluticasone Furoate Vilanterol Combination followed by Placebo
3129402|NCT01691872|Experimental|Japanese|Retigabine 300mg single-dose
3129403|NCT01691872|Experimental|Caucasian|Retigabine 300mg single-dose
3129404|NCT01691859|Experimental|Mepolizumab|Subjects will receive 100 mg of mepolizumab (in 1ml polypropylene syringe) injected subcutaneously (SC) approximately every 4 weeks.
3129405|NCT01691846|Experimental|aleglitazar|
3129406|NCT01691846|Placebo Comparator|placebo|
3129407|NCT01691833|Experimental|Vitamin D|Patients that are deficient in Vitamin D will be assigned to the randomized arm of the study. They will be randomly chosen to receive either the Vitamin D supplement or the placebo.
3129408|NCT01691833|Placebo Comparator|Placebo|Patients that are deficient in Vitamin D will be assigned to the randomized arm of the study. They will be randomly chosen to receive either the Vitamin D supplement or the placebo.
3129409|NCT01691820|Experimental|Group S+|CMV seropositive subjects at inclusion
3129410|NCT01691820|Experimental|Group S-|CMV seronegative subjects at inclusion
3129411|NCT01691807|Experimental|Arm A|bendamustine and ofatumumab treatment of NHL
3129412|NCT01691807|Experimental|Arm B|ofatumumab only treatment of NHL
3129413|NCT01691794|Active Comparator|Atazanavir, 150 mg + Ritonavir, 100 mg (weight:15 to <20 kg)|Participants with baseline weight of 15 to <20 kg received 150 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
3129414|NCT01691794|Active Comparator|Atazanavir, 200 mg + Ritonavir, 100 mg (weight: 20 to <40 kg)|Participants with baseline weight of 20 to <40 kg received 200 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 NRTIs for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
3129415|NCT01691794|Active Comparator|Atazanavir, 300 mg + Ritonavir, 100 mg (weight: ≥ 40 kg)|Participants with baseline weight ≥ 40 kg received 300 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 NRTIs for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
3129416|NCT01691781|Experimental|lisinopril|Lisinopril - open-label, 2.5-40mg daily
3129417|NCT01691768|Experimental|Intervention|1% tenofovir gel provision through a public sector family planning services with 2-3 monthly provision and monitoring and the use of QI methodology to promote reliable service delivery
3129422|NCT01691742|Active Comparator|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
3129423|NCT01691729|Other|Ostomy 1|3 Ostomy Accessory Devices with the order of wear being Investigative Ostomy AccessoryProduct/Ostomy Accessory Marketed Product #1/Ostomy Accessory Marketed Product #2
3129424|NCT01691729|Other|Ostomy 2|3 Ostomy Accessory Devices with the order of wear being Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #2/Ostomy Accessory Marketed Product #1
3129425|NCT01691729|Other|Ostomy 3|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #1/Ostomy Accessory Marketed Product #2/Investigative Ostomy Accessory Product
3129426|NCT01691729|Other|Ostomy 4|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #2/Ostomy Accessory Marketed Product #1/Investigative Ostomy Accessory Product
3129427|NCT01691729|Other|Ostomy 5|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #1/Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #2
3129428|NCT01691729|Other|Ostomy 6|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #2/Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #1
3129429|NCT01691716|Experimental|Tendoactive|Tendoactive dosage: 3 capsules per day
3129430|NCT01691716|Active Comparator|Eccentric training|Protocol published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
3129431|NCT01691716|Active Comparator|Tendoactive and eccentric training|Tendoactive dosage: 3 capsules per day. Eccentric training: protocol described by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
3129432|NCT01691703|Experimental|Videolaryngoscope and Bonfils|First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
3129433|NCT01691690|Experimental|IV Acetaminophen|Patients will receive pre-medication with oral midazolam Participants of this experimental arm of the study will receive Acetaminophen IV to evaluate opioid-sparing effect and pain score reduction..
3129434|NCT01691690|Placebo Comparator|Saline placebo infused intraoperatively|For this arm Morphine will be administered to manage pain.
3129435|NCT01691677|Experimental|beclomethasone dipropionate|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days
3129436|NCT01691677|Placebo Comparator|placebo|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days
3129437|NCT01691664|Active Comparator|Only radiation therapy|Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 50Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.
3129438|NCT01691664|Experimental|Radiation therapy plus DC-CIK cellular therapy|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 50Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~DC-CIK cellular therapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before radiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the radiation intermittent period."
3129439|NCT01691651|Active Comparator|Botulinum toxin type A|The group that will be subjected to the injection of botulinum toxin (subcutaneous injection of botulinum toxin type A).Subcutaneous botulinum toxin A injection will be performed in this group, (2.5 units per point application), at two points in a nasal and temporal extent of the orbicularis muscle.
3129440|NCT01691651|No Intervention|Control|The group that will not be subjected to any intervention.
3129441|NCT01691638||Periodontitis|
3129442|NCT01691638||Control|
3129443|NCT01691625|Experimental|concurrent chemoradiotherapy plus DC-CIK immunotherapy|patients will receive concurrent chemoradiotherapy plur DC-CIK immunotherapy
3129444|NCT01691625|Active Comparator|Concurrent chemoradiation only|patients will receive concurrent chemoradiotherapy only
3129445|NCT01691612|Experimental|D. pteronyssinus allergens|Single arm study exploring the role of Pin-1 enzyme in development of Asthma. Bronchoscopy before and 48 hours after installation of D. pteronyssinus allergens into the lung segments
3129446|NCT01691599||Tibia fractures|Patients with open and closed tibia fracture treated with internal fixation in India
3129447|NCT01691586|Experimental|Remote patient management|Remote patient management system + yearly in-clinic follow-up
3129448|NCT01691586|Other|In-Clinic follow-up|In-clinic follow-up according to standard practice (every 3-6 months)
3129449|NCT01691560|Experimental|5% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate with sodium monofluorophosphate containing 1500 parts per million fluoride (ppmF).
3129450|NCT01691560|Active Comparator|0% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
3129451|NCT01691560|Active Comparator|Sodium monofluorophosphate|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
3129452|NCT01691560|Active Comparator|Sodium fluoride|Dentifrice containing 1100 ppmF as sodium fluoride
3129453|NCT01691547|Experimental|UMEC/VI+FF|UMEC (500 µg)/VI(100 µg) (blended together) and FF (400 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
3129454|NCT01691547|Experimental|UMEC+VI|UMEC (500 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
3129455|NCT01691547|Experimental|FF+VI|FF (400 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
3129456|NCT01691547|Experimental|FF+UMEC|FF (400 µg) and UMEC (500 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
3129457|NCT01691534|Experimental|TMC207, PA-824, pyrazinamide and clofazimine (J-PA-Z-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus pyrazinamide 1500mg Days 1-14 plus clofazimine 300mg Days 1-3 and Clofazamine 100mg Days 4-14
3129458|NCT01691534|Experimental|TMC207, PA-824 and pyrazinamide (J-PA-Z)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus pyrazinamide 1500mg Days 1-14
3129459|NCT01691534|Experimental|TMC207, PA-824 and clofazimine (J-PA-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14
3129460|NCT01691534|Experimental|TMC207, pyrazinamide and clofazimine (J-Z-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus pyrazinamide 1500mg Days 1-14 plus clofazimine 300mg Days 1-3 and Clofazimine 100mg Days 4-14
3129461|NCT01691534|Experimental|pyrazinamide (Z)|pyrazinamide 1500mg Days 1-14
3129462|NCT01691534|Experimental|clofazimine (C)|Clofazimine 300mg Days 1-3 and Clofazimine 100mg Days 4-14
3129463|NCT01691534|Active Comparator|Rifafour|Rifafour e-275 mg dosed by weight
3129464|NCT01691521|Experimental|Mepolizumab IV|Mepolizumab 75 mg will be administered intravenously approximately every 4 weeks with the last dose at week 32. Subjects in the Mepolizumab IV arm will receive mepolizumab 75 mg intravenously and placebo SC once every 4 weeks with the last dose at Week 28 (total of 8 doses)
3129465|NCT01691521|Experimental|Mepolizumab SC|Subjects in the Mepolizumab SC arm will receive mepolizumab 100 mg SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
3129466|NCT01691521|Placebo Comparator|Placebo|Subjects in the Placebo arm will receive matching placebo SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
3129467|NCT01691508|Experimental|Mepolizumab|Mepolizumab 100 mg subcutaneous once every 4 weeks upto Week 20
3129468|NCT01691508|Experimental|Placebo|Placebo subcutaneous once every 4 weeks upto Week 20
3129469|NCT01691495||Superficial Vein Thrombosis (SVT)|A representative of geographical regions of patients with Superficial Vein Thrombosis (SVT) who live in several EU countries.
3129470|NCT01691482|Active Comparator|Albuterol/salbutamol followed by ipratropium|Subjects will recieve daily albuterol/salbutamol followed by ipratropium which will be adminstered one hour after adminstration of albuterol/salbutamol
3129471|NCT01691482|Active Comparator|Ipratropium followed by albuterol/salbutamol|Subjects will recieve daily ipratropium followed by albuterol/salbutamol which will be adminstered one hour after adminstration of ipratropium
3129472|NCT01691469|Experimental|Montelukast Sodium Oral Granules|Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited
3129473|NCT01691469|Active Comparator|SINGULAIR|(Montelukast sodium) Oral Granules 4mg of Merck Sharp & Dohme Ltd., USA
3129474|NCT01691456|Experimental|Montelukast Sodium Oral Granules|Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited
3129475|NCT01691456|Active Comparator|SINGULAIR|(Montelukast sodium) Oral Granules 4mg of Merck Sharp & Dohme Ltd., USA
3129476|NCT01691443|Experimental|Use of the glove|The subject wear the glove for the time of the trial
3129477|NCT01691430|Active Comparator|2 cranberry capsules|Experimental: 2 cranberry capsules
3129478|NCT01691430|Placebo Comparator|2 placebo capsules|Experimental: 2 placebo capsules qd
3129479|NCT01691417|Experimental|Pneumatic Sleeves|
3129480|NCT01691417|Experimental|Congestive Heart Failure Patients|
3129481|NCT01691404|Active Comparator|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
3129482|NCT01691404|Active Comparator|Quercetin|Subjects will be asked to consume supplements containing 160mg of quercetin-3-glucoside daily
3129483|NCT01691404|Placebo Comparator|Placebo|Subjects will be asked to consume capsules containing a placebo (cellulose) daily
3129484|NCT01691391||Advanced CRC, candidates for anti-EGFR antibody monotherapy|Patients with histopathologically confirmed advanced CRC with K-Ras wild type, aged ≥ 18 years, with a life expectancy of at least 12 weeks, who are candidates for anti-EGFR antibody monotherapy (3rd line palliative treatment).
3129485|NCT01691378|Experimental|WtoH|
3129486|NCT01691378|Other|Waitlist Control|
3129487|NCT01691365|Active Comparator|vitamins pills|antioxidant and B vitamins vitamins vitamin
3129488|NCT01691365|Placebo Comparator|pills|MICROCRYSTALLINE CELLULOSE
3129489|NCT01691352|Active Comparator|Wick|Patients with wick placed in their wound at the time of ostomy reversal
3129490|NCT01691352|Sham Comparator|No wick|patients with non-wicked dressing placed on their wound
3129491|NCT01691339|Experimental|Fluzone vaccine (Group 1)|Adults 18 to < 65 years of age randomized to receive one dose of Fluzone vaccine intramuscularly
3129492|NCT01691339|Experimental|Fluzone Intradermal vaccine (Group 2)|Adults 18 to < 65 years of age randomized to receive one dose of Fluzone Intradermal vaccine intradermally
3129493|NCT01691339|Experimental|Fluzone vaccine (Group 3)|Adults ≥ 65 years of age randomized to receive one dose of Fluzone vaccine intramuscularly
3129494|NCT01691339|Active Comparator|Fluzone High-Dose Vaccine (Group 4)|Adults ≥ 65 years of age randomized to receive one dose of Fluzone High-Dose vaccine intramuscularly
3129495|NCT01691326|Experimental|6 months to < 36 months of age group|Participants at 6 months to < 36 months of age at the time of enrollment will receive Influenza Virus Vaccine, No Preservative; Fluzone® (Pediatric Dose).
3129496|NCT01691326|Experimental|3 years to < 9 years of age group|Participants at 3 years to < 9 years of age at the time of enrollment will receive Influenza Virus Vaccine, No Preservative; Fluzone®.
3129497|NCT01691313|Experimental|vanoxerine 200mg|vanoxerine HCl 200mg single dose (2x 100 mg oral capsule)
3129498|NCT01691313|Placebo Comparator|placebo|placebo to match vanoxerine oral capsule
3129499|NCT01691313|Experimental|vanoxerine 300mg|vanoxerine HCl 300 mg single dose (3x 100mg oral capsules)
3129500|NCT01691313|Experimental|vanoxerine 400mg|vanoxerine HCl 400 mg single dose (4x 100 mg oral capsules)
3129501|NCT01691300|Experimental|ACT PET/CT|Dual-tracer ACT/FDG PET/CT and WB-DCE-MRI at baseline (pretreatment), post-induction and post-ASCT (if eligible)
3129631|NCT01690351|Experimental|PF-05089771 TS formulation fasted|Capsules TS formulation- fasted
3129502|NCT01691287|Experimental|Michael Method|14 group meeting, taking place once a week during 14 consecutive weeks
3129503|NCT01691274|Experimental|PF-04895162|
3129504|NCT01691274|Placebo Comparator|Placebo|
3129505|NCT01691261|Experimental|Treatment|PF-05206388 Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane
3129506|NCT01691248|Active Comparator|Fidaxomicin|200 mg Fidaxomicin tablet once daily for no longer than 40 days
3129507|NCT01691248|Placebo Comparator|Placebo|Placebo tablet once daily for no longer than 40 days
3129508|NCT01691235||Arm 1|Subjects in this arm will receive their medication (telaprevir, interferon and ribavirin) dispensed using the Simpill device. The study staff will have access to data from the device during therapy and will be able to give subjects feedback on adherence during the course of therapy. The study team will refill the device as the medication is needed. The device will be configured to remind a subject each time a dose is missed. Subjects in this study arm will receive a text message each time a dose of medication is missed. This message will only go to the telephone number specified by the subject and will not go to members of the study team.
3129509|NCT01691235||Arm 2|Subjects in this arm will receive their medication (telaprevir, interferon and ribavirin) as standard of care therapy where the SIMpill device will not be used.
3129510|NCT01691222|Other|Double lumen endotracheal tube tracheostomy|Tracheostomy with a dedicated double lumen endotracheal tube
3129511|NCT01691209|Experimental|Phoenix|Application over 29 days twice daily
3129512|NCT01691209|Active Comparator|Hydrocortison|Application over 29 days twice daily
3129513|NCT01691209|No Intervention|Untreated skin|Participants will be observed over 29 days without study treatment
3129514|NCT01691183||Study Subjects|Subjects with or without orbital disease that present to clinic for scheduled appointments.
3129515|NCT01691170|Active Comparator|Quadriceps Strengthening|
3129516|NCT01691170|Active Comparator|Stretching Hamstring|
3129517|NCT01691157|Active Comparator|Usual physiotherapy without exercise|Will receive 6 sessions of modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
3129518|NCT01691157|Experimental|Exercise|Will receive an evidence based exercise protocol but no other physiotherapeutic modalities
3129519|NCT01691144||recently treated patients|
3129520|NCT01691144||2-3 years after treatment|
3129521|NCT01691131|Other|Exercise training on land|High intensity exercise training on land.
3129522|NCT01691131|Other|Exercise training on water|High intensity exercise training on water.
3129523|NCT01691118|Active Comparator|Fimasartan|Fimasartan 60mg qd added on conventional antihypertensive treatment for 10 months.
3129524|NCT01691118|Placebo Comparator|Placebo|Conventional antihypetensive treatment
3129525|NCT01691105|No Intervention|Academic Detailing|Standard of care for patients who are smokers and admitted to the hospital.
3129526|NCT01691105|Experimental|Academic Detailing + Integrated Tobacco Order Set|Access to the Integrated Tobacco Order Set (ITOS) Nicotine Replacement Therapy with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center
3129527|NCT01691092|Experimental|Ketamine|All subjects will receive ketamine
3129528|NCT01691079|Placebo Comparator|placebo|placebo 2 puffs prior to exercise challenge
3129529|NCT01691079|Active Comparator|ipratropium bromide|ipratropium bromide HFA 2 puffs prior to exercise challenge
3129530|NCT01691066|Experimental|Infant Toddler Years PRT|Infant Toddler PRT in an evidence-based, manualized treatment for children with autism spectrum disorder that involves specific motivational behavioral procedures adapted to be developmentally appropriate for 12-15 month old infants who present with developmental delays.
3129531|NCT01691066|No Intervention|Community Treatment|Community Treatment includes the treatments offered by early intervention services (e.g., speech-language therapy, special education instruction).
3129532|NCT01691053|Active Comparator|Spironolactone|
3129533|NCT01691053|Placebo Comparator|Placebo|
3129534|NCT01691040|Experimental|Open-label pilot group|Twice weekly administration of NOX-H94
3129535|NCT01691027|Experimental|Visuo-motor training for low vision|All participants undergo training on scotoma awareness, Line and Circle Tracing and Video games
3129536|NCT01691014||adalimumab|
3129537|NCT01691014||Etanercept|
3129538|NCT01691014||infliximab|
3129539|NCT01691014||Certolizumab|
3129540|NCT01691001|Experimental|dexmedetomidine|
3129541|NCT01691001|Placebo Comparator|placebo group|normal saline
3129542|NCT01690988|Experimental|Ketamine (0.5 mg/kg)|Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
3129543|NCT01690988|Placebo Comparator|Normal saline (placebo)|Intravenous normal saline
3129544|NCT01690988|Experimental|Ketamine (1 mg/kg)|Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
3129545|NCT01690975|Placebo Comparator|Placebo|Placebo Control
3129546|NCT01690975|Experimental|Benzonatate|Benzonatate Active
3129547|NCT01690962|Experimental|Vegan diet and vitamin B12 supplement|The diet/supplement group will be asked to follow a low-fat, vegan diet for 20 weeks, and take a vitamin B12 supplement daily.
3129548|NCT01690962|Active Comparator|Vitamin B12 supplement|The supplement group will be asked to take a daily vitamin B12 supplement, and to make no changes to their current diet.
3129549|NCT01690949|Experimental|PUR118 low dose|
3129550|NCT01690949|Experimental|PUR118 mid dose|
3129551|NCT01690949|Experimental|PUR118 high dose|
3129552|NCT01690936|Experimental|Breakfast|Almonds (43g/day) were consumed with breakfast for four weeks.
3129553|NCT01690936|Experimental|Morning snack|Almonds (43g/day) were consumed alone as morning snacks for four weeks.
3129554|NCT01690936|Experimental|Lunch|Almonds (43g/day) were consumed with lunch for four weeks.
3227377|NCT01004120|Placebo Comparator|MDn|
3129555|NCT01690936|Experimental|Afternoon snack|Almonds (43g/day) were consumed alone as afternoon snacks for four weeks.
3129556|NCT01690936|No Intervention|Control no nuts|Avoided all nuts and seeds
3129557|NCT01690923|Experimental|Nasal Mask First, then Pillows Mask|"Nasal mask is used for 7 nights, then followed by Pillows mask for 7 nights.~[Nasal mask=Mirage Activa, Micro, FX; Pillows mask=Swift FX]"
3129558|NCT01690923|Experimental|Pillows Mask, then Nasal Mask|Pillows mask for 7 nights, then followed by Nasal mask is used for 7 nights. [Nasal mask=MMirage Activa, Micro, FX; Pillows mask=Swift FX]
3129559|NCT01690910|Active Comparator|Front Wheeled Walker|The Front Wheeled Walker is a standard walker that is used to assist patients while walking.
3129560|NCT01690910|Active Comparator|Rifton Gait Trainer|The Rifton Gait Trainer is used to assist patients while walking. It includes a harness to support the patient and prevent falls.
3129561|NCT01690897|Experimental|MBCT group|Women randomized into the MBCT group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the mindfulness-based treatment.
3129562|NCT01690897|Active Comparator|Support group|Women randomized into the support group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the sex therapy, education, and support treatment.
3129563|NCT01690884|Placebo Comparator|Placebo|To determine if there is an increase in adenosine interstitial levels in the forearm.
3129564|NCT01690884|Active Comparator|Dipyridamole|To determine if there is an increase in adenosine interstitial levels in the forearm.
3129565|NCT01690884|Experimental|Ticagrelor|To determine if there is an increase in adenosine interstitial levels in the forearm.
3129566|NCT01690871|Experimental|BEZ235|BEZ235 will be supplied in 200mg, 300mg and 400mg sachets packaged in boxes. Each box will contain only sachets of one strength.
3129567|NCT01690858||females with medical history of repeated foetal losses|The females can be pregnant
3129568|NCT01690858||females without medical history of repeated foetal losses|The females can be pregnant
3129569|NCT01690845|No Intervention|Control|Patients with severe HH will be treated with standard medical therapy (i.e. vasopressor support with norepinephrine in refractory hypotension = RR mean < 65 mmHg, positive inotropic support with dobutamine if the central venous oxygen saturation < 70%, renal replacement therapy in case of severe metabolic acidosis and/or renal failure, antibiotic treatment in case of suspected or proven infection, mechanical ventilation in case of severe hypoxemia or hypercapnia and/or GCS <= 8.
3129570|NCT01690845|Experimental|MARS-Group|20 patients will be allocated by randomization to the MARS arm. Additionally to standard medical therapy they will receive 4 MARS sessions on three consecutive days, MARS® therapy will be applied for at least 12 hours per session. Thereafter, MARS® treatment will be continued if the patient still has increasing aminotransferase levels, requires vasopressor support or suffers from cholestasis (defined as serum bilirubin levels > 5 mg/dL) for 3 sessions again. There will be a maximum of 7 MARS ® sessions per patient.
3129571|NCT01690832|Active Comparator|standard saline infusion|standard i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure.
3129572|NCT01690832|Active Comparator|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure.
3129573|NCT01690819|Active Comparator|Conventional Ventilatory Strategy|Conventional Ventilatory Strategy
3129574|NCT01690819|Experimental|Protective Ventilatory Strategy|Protective ventilatory strategy
3129575|NCT01690806||dexamethasone|Patients who receive dexamethasone (8 mg; Decadron; Merck Sharp & Dohme) intravenously 90 min before skin incision
3129576|NCT01690806||placebo|Patients who receive saline placebo intravenously 90 min before skin incision
3129577|NCT01690780|Active Comparator|Ibuprofen|
3129578|NCT01690780|Experimental|Oral morphine|
3129579|NCT01690767|Experimental|Topical and intraurethral 2% lidocaine|2% lidocaine gel will be applied for 5 minutes to the external urethral opening. This will be followed immediately by 2% lidocaine gel administration into the urethra using a 24 gauge angiocath for 5 minutes prior to catheterization for urine specimen collection. Children < 7 kg and > 7 kg will receive 1 cc and 1.5 cc, respectively.
3129580|NCT01690767|Active Comparator|Standard of care|According to standard nursing practice, the urethra will be catheterized without anaesthetic gel but using lubricant gel only. Intervention is Health Care Lubricating Jelly.
3129581|NCT01690754|No Intervention|Control|This arm will receive the regular standard of care given by TB clinics.
3129582|NCT01690754|Experimental|Interactive Reminders|Patients randomized to this arm will receive Interactive SMS reminders daily.
3129583|NCT01690741|Experimental|Nerofe|Nerofe administered intravenously 3x/week
3129584|NCT01690728|Active Comparator|Physical Activity|40 min exercise supervised by physiotherapists two times weekly in six month.
3129585|NCT01690728|No Intervention|Control Group|These participants follows the standard post surgery follow-up consisting of counseling by dietitians, nurses and doctors.
3129586|NCT01690715||Hepatocellular carcinoma underwent surgery|
3129587|NCT01690702|Active Comparator|dtEC-dtD|Epirubicin and Cyclophosphamide with a tailored dose 4 cycles q2w followed by one additional week followed by Docetaxel with a tailored dose 4 cycles q2w.
3129588|NCT01690702|Experimental|EnPC|Epirubicin 150mg/qm 3 cycles q2w followed by nabPaclitaxel 260-330mg/qm (to be determined in run-in-phase) 3 cycles q2w followed by Cyclophosphamide 2000mg/qm 3 cycles q2w
3129589|NCT01690689|Experimental|Surgery|Implant surgery
3129590|NCT01690676|Active Comparator|Epicatechin|The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
3129591|NCT01690676|Placebo Comparator|Microcrystalline cellulose|The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
3129592|NCT01690663|Placebo Comparator|Bupivacaine 0.25% mixed with 1ml normal saline|Bupivacaine 0.25% mixed with 1ml normal saline (placebo/control group)
3129593|NCT01690663|Active Comparator|Bupivacaine 0.25% with 1mg dexamethasone (1ml)|Bupivacaine 0.25% mixed with 1mg preservative free dexamethasone (1ml)
3133084|NCT01667198|Experimental|Train the leaders course|
3129594|NCT01690663|Active Comparator|Bupivacaine 0.25% mixed with 2mg dexamethasone|Bupivacaine 0.25% mixed with 2mg preservative free dexamethasone (1ml)
3129595|NCT01690663|Active Comparator|Bupivacaine 0.25% mixed with 4mg dexamethasone (1ml|Bupivacaine 0.25% mixed with 4mg preservative free dexamethasone (1ml
3129596|NCT01690650|Experimental|Oxygen + Cerebral NIRS|Induced changes in oxygen supply (100% vs. room air). Continuously monitoring of cerebral oxygen saturation.
3129597|NCT01690637|Active Comparator|Oseltamivir phosphate suspension|Participants assigned to the oseltamivir phosphate treatment arm will receive the appropriate weight-based dose of oseltamivir phosphate every 12 hours for 10 doses. For children 0-11 months of age, oseltamivir phosphate will be dosed as 3mg/kg/dose every 12 hours. For children 12 months and older, oseltamivir phosphate will be dosed as follows: 30 mg every 12 hours for children up to 15kg, 45mg every 12 hours for children greater than 15kg up to 23 kg, 60mg every 12 hours for children greater than 23 up to 40kg, and 75mg every 12 hours for children greater than 40kg.
3129598|NCT01690637|Placebo Comparator|Placebo|
3129599|NCT01690624|Experimental|Patients with relapsed or refractoryAML|Patients with acute myeloid leukemia who have relapsed after 1 prior treatment.
3129600|NCT01690611|Experimental|Walking & Visual Feedback|Individuals in this arm will walk on a treadmill while viewing real time visual feedback regarding their body motions and use the visual feedback to correct their body motions.
3129601|NCT01690611|Active Comparator|Walking & No Visual Feedback|Individuals in this arm will walk on a treadmill without viewing real time visual feedback regarding their body motion.
3129602|NCT01690598|Experimental|Veliparib and Topotecan|
3129603|NCT01690585|Experimental|Ferinject 1000 mg|Intravenous Administration of 1000 mg of ferinject Volume of infusion : 250 mL
3129604|NCT01690585|Placebo Comparator|Placebo|Intravenous administration of 250 ml of sodium chlorure 0.9 %
3129605|NCT01690572|Active Comparator|Paclitaxel coated balloon catheter|"Paclitaxel coated balloon catheter IN.PACT Falcon"
3129606|NCT01690572|Active Comparator|uncoated balloon catheter|"uncoated balloon catheter sprinter legend"
3129607|NCT01690559||Group 1|Patient treated with Ciproxan without dilution treatment in daily clinical practice
3129608|NCT01690546|Experimental|BUP/VLNXT to VIVITROL|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
3129609|NCT01690533||Group 1|
3129610|NCT01690520|Active Comparator|Arm I (standard of care)|"CONDITIONING REGIMEN: One of two possible conditioning regimens is chosen by the attending physician: Patients receive fludarabine phosphate IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6., and undergo high dose TBI BID on days -4 to -1 OR Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo middle intensity TBI QD on days -2 to -1.~TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclosporine IV over 1 hour BID (adults) or TID (children) or PO on days -3 to 100 with taper beginning on day 101. Patients also receive MMF IV TID a day on days 0-7 then may receive MMF PO TID. Patients remain on MMF TID for a minimum of 30 days, and then may begin a taper if there is no evidence of GVHD and are well-engrafted from one donor unit."
3129611|NCT01690520|Experimental|Arm II (experimental)|"CONDITIONING REGIMEN: Patients receive the conditioning regimen chosen by the attending physician as in Standard of Care Arm.~TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day 0. Patients also undergo infusion of ex vivo-expanded cord blood progenitor cell infusion at least 4 hours after completion of UCB transplant.~GVHD PROPHYLAXIS: Patients receive cyclosporine IV or PO and mycophenolate mofetil IV or PO as in Standard of Care Arm."
3129612|NCT01690507|Other|DCAG plus HLI|
3129613|NCT01690494|Experimental|PACT + TAU|4-session PACT delivered to both partners together + standard treatment of care services (TAU) delivered to the male participant
3129614|NCT01690494|Active Comparator|TAU|TAU control condition delivered to the male participant
3129615|NCT01690468|Experimental|Triciribine & Carboplatin|"Phase I/II: 25mg/m^2 Triciribine and Carboplatin AUC 4. Triciribine escalated to 30, 35, 45mg/m^2 if toxicities are not encountered.~Phase II: Recommended phase II dose of triciribine and carboplatin."
3129616|NCT01690455||Cohort|
3129617|NCT01690442|Experimental|Couples Based HIV/STI Risk Reduction Intervention (CHSR)|The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
3129618|NCT01690442|Active Comparator|Renaissance Wellness Promotion (WP)|This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
3129619|NCT01690429|Other|OSA Patients|
3129620|NCT01690416|Active Comparator|Ultrasound DNTP|the catheter will be placed using ultrasound and DNTT and Lidocaine as local anesthesia, by the same fellow as the one who performs the puncture with the traditional method
3129621|NCT01690416|Active Comparator|Traditional palpation technique|arteria cannulation by traditional palpation technique, using preprocedural lidocaine for anesthetic and palpation method by a fellow
3129622|NCT01690403|Experimental|cohort 1|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 1).
3129623|NCT01690403|Experimental|cohort 2|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 2).
3129624|NCT01690403|Experimental|cohort 3 (optional)|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 3).
3129625|NCT01690390|Active Comparator|Icotinib of Routine Dose|Oral Drug icotinib 125 mg three times per day
3129626|NCT01690390|Experimental|Icotinib of High Dose|Oral Drug icotinib 250 mg three times per day
3129627|NCT01690377|Experimental|1|PDC or myDC
3129628|NCT01690364|Experimental|Cisatracurium Group|MEP monitoring with continuous infusion of cisatracurium during general anesthesia
3129629|NCT01690364|Active Comparator|Vecuronium Group|MEP monitoring with continuous infusion of vecuronium during general anesthesia
3129630|NCT01690351|Experimental|PF-05089771 Oral Dispersion fasted|Oral dispersion TS formulation- fasted
3129632|NCT01690338|Active Comparator|Vecuronium Bromide|Patients who will be performed general anesthesia and tracheal intubation. Vecuronium will be used during surgery and tracheal extubation is scheduled when surgery is over.
3129633|NCT01690338|Active Comparator|cisatracurium|Patients who will be performed general anesthesia and tracheal intubation. Cisatracurium will be used during surgery and tracheal extubation is scheduled when surgery is over.
3129634|NCT01690338|Active Comparator|rocuronium|Patients who will be performed general anesthesia and tracheal intubation. Rocuronium will be used during surgery and tracheal extubation is scheduled when surgery is over.
3129635|NCT01690325|Experimental|Docetaxel, Avastin, Herceptin; adjuv. Epirubicin, Cyclophos.|Arm A: Neoadjuvant: 6 cycles of Docetaxel every 21 days together with 6 cycles of Avastin and Herceptin; Adjuvant: 4 cycles of Epirubicin and Cyclophosphamid every 21 days together with 12 cycles of Herceptin every 21 days.
3129636|NCT01690325|Experimental|Docetaxel, Avastin; adjuvant Epirubicin, Cyclophosphamid|Arm B: neoadjuvant: 6 cycles of Docetaxel and Avastin every 21 days. Adjuvant: 4 cycles of Epirubicin and Cyclophosphamid every 21 days.
3129637|NCT01690312|Experimental|1 (Dietary Supplement - Fish Oil)|"On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.~On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol."
3129638|NCT01690312|Experimental|2 (Placebo)|"On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.~On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol."
3129639|NCT01690299|Experimental|Apremilast 30 mg plus placebo injection|Apremilast 30 mg tablets orally twice a day (BID) plus once weekly (QW) evaluator/subject-blinded subcutaneous (SC) saline (placebo) injections
3129640|NCT01690299|Experimental|Etanercept 50 mg plus placebo tablet|Etanercept 50 mg evaluator/subject-blinded SC QW injections plus placebo tablets orally BID
3129641|NCT01690299|Placebo Comparator|Oral placebo tablets plus SC placebo injections|Identically matching placebo tablets and evaluator/subject-blinded SC injections
3129642|NCT01690286|Experimental|Group 1: JNJ-38518168 3 mg/ ketoconazole|
3129643|NCT01690286|Experimental|Group 2: JNJ-38518168 30 mg/ ketoconazole|
3129644|NCT01690286|Experimental|Group 3: JNJ-38518168 10 mg/ ketoconazole (optional)|
3129645|NCT01690273|No Intervention|ankylosing spondylitis control|control group
3129646|NCT01690273|Experimental|mobility exercise|mobility exercises
3129647|NCT01690273|Experimental|mobility and elastic resistance exercise|AS patients was submitted to a program mobility exercise plus elastic resistance exercises
3129648|NCT01690260|Experimental|Bone Morphogenetic Protein 2|Condition of bone healing will be evaluated at serial radiological examinations and by clinical results according to a standard score system.
3129649|NCT01690260|Experimental|Autologous bone graft|Condition of bone healing will be evaluated at serial radiological examinations after 1,2,3,4,5,6,9 and 12 months. Blood tests and urine samples will also be examined for monitoring the bone healing process.
3129650|NCT01690247|Experimental|Conventional plus UC-MSC|Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit
3129651|NCT01690247|Placebo Comparator|Conventional plus placebo|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.
3129652|NCT01690234|Experimental|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
3129653|NCT01690234|Active Comparator|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
3129654|NCT01690221|Experimental|VEN 307|diltiazem hydrochloride 2% cream
3129655|NCT01690221|Placebo Comparator|Placebo|Placebo Cream
3129656|NCT01690208|Experimental|EMERALD|Patients assigned to the EMERALD group will be invited to join the multi-component program which will last for 1 year. This program will be held on a 4-weekly basis for the first 3-4 months followed by a maintenance program involving 2-4 group activities every year. Between clinic visits, patients in this group will also receive telephone reminders from the staff and peer supporters to reinforce compliance and for social support.
3129657|NCT01690208|Active Comparator|Usual Care|"Irrespective of the assignment group, all patients will undergo a baseline comprehensive assessment using the JADE portal disease management system. All patients will also receive a 2-hour session on how to interpret their individualised JADE report and risk profiles, whilst the importance of achieving targets and optimizing self care will be reinforced.~Patients assigned to the UC group will be followed up in their usual clinic according to the 'standard' practice."
3129658|NCT01690195|Experimental|ABT-126|ABT-126 Open-label dose
3129659|NCT01690182|Experimental|Study test meal 1|High volume, high energy density test meal. Volunteers will be given 490 mL of a high energy test meal once in the morning
3129660|NCT01690182|Experimental|Study test meal 2|High volume, low energy density test meal. Volunteers will be given 490 mL of a high volume low energy density test meal once in the morning
3129661|NCT01690182|Experimental|Study test meal 3|A low volume, high energy test meal. Volunteers will be given 140 mL high energy density test meal once in the morning.
3129662|NCT01690169|Experimental|NNC0113-0987|
3129663|NCT01690169|Placebo Comparator|Placebo|
3130070|NCT01687387|Placebo Comparator|Placebo (Normal saline solution)|Normal saline solution
3129664|NCT01690156||Parallel Probe Position|Performing the simulated interscalene block with the ultrasound probe parallel to the shoulders of the person performing the block
3129665|NCT01690156||Perpendicular Probe Position|Performing the simulated interscalene block with the ultrasound probe perpendicular to the shoulders of the person performing the block
3129666|NCT01690143|Experimental|Carfilzomib + high dose melphalan|Single arm.
3129667|NCT01690130|Experimental|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual.The brain stimulation techniques could theoretically improve the efficacy of smoking cessation. Treatment was standardized at 100% magnetic field intensity relative to the participant's resting MT, at 10 pulses per second (10 Hz) for 5 seconds, with an intertrain interval of 10 seconds. Treatment session lasted for 15 minutes with 3000 pulses.
3129668|NCT01690130|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham-TMS procedures: After rMT determination and DLPFC cortex localization, participants were fitted with two electrodes on the scalp just below the hairline. Electrodes were connected to an Epix VT® Transcutaneous Electrical Nerve Stimulation Device (Empi; St. Paul, MN, USA)
3129669|NCT01690117|Experimental|GE-REACH-program|GE-REACH-program
3129670|NCT01690117|No Intervention|control group|usual care
3129671|NCT01690104|Active Comparator|Rifampicin|Rifampicin 600 mg daily
3129672|NCT01690104|Placebo Comparator|Placebo|Placebo daily
3129673|NCT01690091|Experimental|Metformin|500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening), duration: 3 months
3129674|NCT01690091|Placebo Comparator|Placebo|500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening), duration:3 months
3129675|NCT01690078||Cross sectional|Cross sectional study where subjects with PRS, micrognathia, or SGS will have a single study visit that will be scheduled within 14 days of a clinically indicated upper airway endoscopy. CT scans of the neck or maxillofacial CT will be obtained in all subjects. During upper airway endoscopy, airway measurements will be conducted. Cohort may include subjects who have previously undergone medical or surgical intervention for their airway obstruction, or who are currently undergoing multidisciplinary team management. The following data will be collected: clinical parameters, Obstructive Sleep Apnea (OSA)OSA-18 (quality of life) questionnaire, and lung function tests (subjects > 4 years of age). Clinically indicated swallowing studies and voice evaluations will be collected.
3129676|NCT01690078||Longitudinal|The prospective, longitudinal cohort arm of the study is designed to describe the effects of treatment on clinical and computational model endpoints. This is performed in a subset of subjects with PRS, micrognathia, or SGS who are scheduled for clinically indicated upper airway endoscopy and who are scheduled to complete a definitive treatment course which necessitates multiple endoscopic evaluations and follow-up imaging. Subjects will have an entry visit comparable to the cross-sectional entry visit. Longitudinal subjects will have up to 3 additional study visits over a 12 to 15-month period.
3129677|NCT01690078||Normal Control Data|Normal de-identified control data is retrospectively collected from clinically indicated CT scans of the neck and maxillofacial CT scans in children less than 18 years of age.
3129678|NCT01690065|Experimental|Nilotinib+AD induction|"Nilotinib plus AD induction chemotherapy~AD regimen : Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)~Nilotinib 400mg bid PO (continuous without interruption from D8 of induction chemotherapy)~Re-induction chemotherapy AD regimen : Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 5 days (D 1-5) plus Daunorubicin 45 mg/m2/day iv daily for 2 days (D 1-2)"
3129679|NCT01690052|Active Comparator|Cevimeline|Cevimeline vs Pilocarpine
3129680|NCT01690052|Active Comparator|Pilocarpine|Pilocarpine vs. Cevimeline
3129681|NCT01690039||All study participants|Furosemide-Fludrocortisone-Test and Ammonium chloride-Loading Test will be performed in renal stone patients.
3129682|NCT01690026|Other|Brief intervention|Motivational intervention based brief intervention
3129683|NCT01690026|Other|Standard intervention|Standard intervention condition
3129684|NCT01690013||Klinefelter|Men with Klinefelter syndrome
3129685|NCT01690013||Control|Men from the general population, matched by age, education and zipcode.
3129686|NCT01690000|Active Comparator|Melatonin1|1 mg melatonin nightly
3129687|NCT01690000|Active Comparator|Melatonin3|3 mg melatonin given nightly
3129688|NCT01690000|Active Comparator|Placebo|Identical placebo given nightly
3129689|NCT01689987|Experimental|Treatment (HCQ, sirolimus, cy/dex)|Patients receive hydroxychloroquine PO daily on days 1-28 (days 5-28 of course 1), sirolimus PO on days -2 to 4, and cyclophosphamide IV continuously and dexamethasone PO on days 1-4. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3129690|NCT01689974|Other|Arm A: Ipilimumab|Ipilimumab administered alone Day 4, 25, 46, and 67
3129691|NCT01689974|Other|Arm B: Ipilimumab and Radiation|Radiation Therapy and Ipilimumab. Radiation treatment is administered for 5 fractions (sessions) over 1 week. On Day 4 treatment with Ipilimumab begins and continues on Days 25, 46, and 67.
3129692|NCT01689961|Experimental|Nutrition+Exercise Intervention|"Structured + monitored nutrition and exercise intervention:~The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence"
3129693|NCT01689961|No Intervention|Usual Prenatal Care|Mothers in the Control Group will be followed by their primary care provider and have usual access to public health services. In addition, they will be asked to attend 2 focus group sessions exploring women's experiences with exercise, nutrition, and weight gain in pregnancy. Women will receive information about healthy pregnancy from Health Canada.
3129694|NCT01689948|Experimental|Home rehabilitation therapy|12 weekly sessions of Home rehabilitation therapy
3129695|NCT01689935|No Intervention|Control|No drug, no treatment
3227378|NCT01004120|Active Comparator|B-GOS|
3129696|NCT01689935|Active Comparator|ALA-PDT|Drug- topical 20% Aminolevulinic acid - ALA followed by red light irradiation - conventional photodynamic therapy -PDT
3129697|NCT01689935|Experimental|i-PDT|Drug - topical 20% Aminolevulinic acid - followed by inhibitory light during incubation time, then red light for photodynamic therapy
3129698|NCT01689935|Active Comparator|Red Light only|Red light only - no drug
3129699|NCT01689935|Active Comparator|Blue light only|Blue light only - no drug
3129700|NCT01689922||AlterG and Physical therapy|2) Standard postoperative rehabilitation program with addition of lower body positive pressure (LBPP) treadmill training
3129701|NCT01689922||Control group|1) Standard postoperative rehabilitation program
3129702|NCT01689909|Active Comparator|Zolpidem-CR|Zolpidem 6.25 or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
3129703|NCT01689909|Placebo Comparator|Placebo|Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
3129704|NCT01689896|Active Comparator|Testosterone Gel|Testosterone Gel
3129705|NCT01689896|Placebo Comparator|Placebo Gel|Placebo Gel
3129706|NCT01689883|Other|Current stimulator|The investigators have developed a device to deliver very small currents to the arm. The device will be used while subjects perform upper-limb movements using a device for upper-limb rehabilitation. Subjects will perform multiple trials of movement. During half of the trials, they will receive actual stimulation. During the other half, they will receive sham stimulation.
3129707|NCT01689870|Experimental|Phase 1 Cohort 1|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.1 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
3129708|NCT01689870|Experimental|Phase 1 Cohort 2|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.2 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
3129709|NCT01689870|Experimental|Phase 1 Cohort 3|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.4 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
3129710|NCT01689870|Experimental|Phase 2 Cohort 4|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered i.v. at the Phase 1 Maximum Tolerated Dose over 60 minutes only in the first week on Days 1, 3 and 5.
3129711|NCT01689857|Experimental|Scarclinic™ Thin|Scarclinic™ Thin
3129712|NCT01689857|Active Comparator|Scarclinic™ Normal|Scarclinic™ Normal
3129713|NCT01689844|Active Comparator|Behavioral, DASH Plus - Dietary advice|This group will receive DASH diet advice and guided ordering of fruits, vegetables, nuts and beans that are high in potassium from a local supermarket.
3129714|NCT01689844|Other|DASH - C|DASH C Group will receive brief DASH diet advice and will be able to make non- guided purchases of food products from the local supermarket.
3129715|NCT01689831|Experimental|Aplisol, potency determination|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.
3129716|NCT01689831|Active Comparator|Reference standard PPD-S2, reference|Reactivity of Aplisol compared to reference standard PPD-S2.
3129717|NCT01689818|Experimental|exercise training|exercise training program which included aerobic exercise for 3 times per week.
3129718|NCT01689818|No Intervention|control|lifestyle counseling
3129719|NCT01689805||Patients with atopic dermatitis|
3129720|NCT01689805||Non-atopic controls|
3129721|NCT01689792|Active Comparator|CitraFleet|Administration of CitraFleet
3129722|NCT01689792|Experimental|MOVIPREP|Administration of MOVIPREP
3129723|NCT01689779|Active Comparator|Cholecalciferol|A maximum of 40 patients will receive a one-time oral dose of 100,000 IU cholecalciferol 3-7 days before their scheduled elective surgery.
3129724|NCT01689779|Placebo Comparator|Placebo|A maximum of 40 patients will receive a one-time oral sugar pill 3-7 days before their scheduled elective surgery.
3129725|NCT01689766|Other|Technetium Tc 99m EC20|
3129726|NCT01689753|Experimental|TEGO® connector|The TEGO® connector is used during 3 consecutive hemodialyse. After each dialysis session, the dead space of the catheter is flushed with NaCl 0.9%.
3129727|NCT01689753|Active Comparator|Trisodium citrate|After each dialysis, the dead space of the catheter is filled with trisodium citrate 46.7% (Citralock®).
3129728|NCT01689740|Experimental|Lead in: 125 mg MDMA (Open Label) and psychotherapy|Open label: Participants receive initial dose of 125 mg MDMA possibly followed by a supplemental dose of 62.5 mg during two psychotherapy sessions scheduled 3-5 weeks apart.
3129729|NCT01689740|Placebo Comparator|Active placebo dose MDMA and psychotherapy|Participants receive initial doses of 25 mg MDMA during each of two experimental sessions.
3129730|NCT01689740|Experimental|Full dose MDMA and psychotherapy|Participant will receive full dose MDMA (125 mg NDMA( during two separate psychotherapy sessions.
3129731|NCT01689727|Other|Technetium Tc 99m EC20|
3129732|NCT01689714|Experimental|Tc 99m EC20|Patients received 2 intravenous (IV) injections: 1 mg of folic acid (to reduce the uptake of FolateScan in normal tissues), followed 1 to 3 minutes later by 0.1 mg of EC20 labeled with 15 to 25 mCi of technetium-99m (99mTc) over 30 seconds in a total injection volume of 1 to 2 mL.2 Each injection was given as a slow IV push via a free-flowing indwelling IV catheter in an upper extremity vein (i.e., in the antecubital fossa).
3129733|NCT01689701|Experimental|Hizikia Fusiformis extract|
3129734|NCT01689701|Placebo Comparator|Placebo|
3129735|NCT01689688||EES-XIENCE V|Groups who were treated with XIENCE V® everolimus eluting stent
3129736|NCT01689675|Experimental|Computer based pain management|The computer-based self-management program (CBSM) intervention will be administered over 8 sessions during the average 4 week period patients are receiving their standard on-site rehabilitation care. Patients will come to the center to receive their standard care and then interact with the computer for the 25-30 minute CBSM intervention. The primary goals of treatment include developing skills for managing acute injury and related pain including: reducing fear avoidance beliefs and catastrophizing, improving mood, increasing perceptions of control and self-efficacy, maintaining activity and reducing pain. Skills are presented and modeled by computer-based video during sessions, audio will be used to explain models and teach skills such as relaxation training.
3129737|NCT01689675|Active Comparator|Education control|The computer exposure will be administered over 8 sessions during the average 4-week period patients are receiving their standard on-site rehabilitation care. Patients will come to the center to receive their standard care and then interact with the computer for the 25-30 minute control condition. The primary goal of this condition is to provide a control for computer exposure. Briefly, the first session will concentrate on establishing the patient's ability to interact with the computer. The materials will provide general education regarding the injury and methods for preventing re-injury. This condition will not provide teaching and practice of specific pain management and coping management skills. This control computer education activity will equalize the computer exposure of the two groups and the duration of time devoted to injury care.
3129738|NCT01689662|Experimental|Tc 99m EC20|"Subjects will receive two intravenous injections 1-3 minutes apart:~1 mg of folic acid~1-2 mL injection of 0.1 mg of EC20 labeled with 15-25 mCi of technetium-99m"
3129739|NCT01689649|Experimental|Topiramate|For children: Children will start on topiramate with a dosage of 0.5mg/kg in the evening, followed by 0.5mg/kg/day weekly increments until an initial target dose of 3mg/kg/day is reached. The total daily topiramate dose for children may, not exceed 9mg/kg/day. For adult patients: Adult patients start on topiramate with a dosage of 25mg/day in the evening, followed by weekly increments of 25 mg/day until an initial target dose of 100mg/day is reached. The dose of topiramate may be increased to the optimal dose with weekly increments of 0.5mg/kg/day and of 25 mg/day for children and adults, respectively at the discretion of the investigator.
3129740|NCT01689636|Experimental|Single-center, open-label|"The study was designed as a single-center, open-label clinical study to evaluate the safety, pharmacokinetics, dosimetry and metabolism of Tc 99m EC20 in normal volunteers and in patients with known or suspected ovarian cancer.~Eight subjects were to be enrolled at one center: four normal subjects, four patients with ovarian cancer. Each subject was to receive a single injection of Tc 99m EC20 complex composed of 0.1 mg ligand (EC20) and 15 - 20 mCi of Tc 99m. Two (2) of the 4 normal subjects and 2 of the 4 patients were to receive an injection of 0.25-2.0 mg folic acid 1-2 minutes prior to the injection of Tc 99m EC20."
3129741|NCT01689623|Experimental|Panel I|Each participant will be administered a single oral 40-mg atorvastatin dose on Day 1 and Day 13. The participants will receive TMC435 once daily dose of 150 mg from Day 4 until Day 15.
3129742|NCT01689623|Experimental|Panel II|Each participant will be administered a single oral 40-mg simvastatin dose on Day 1 and Day 13. The participants will receive TMC435 once daily dose of 150 mg from Day 4 until Day 15.
3129743|NCT01689610||Adult female patients with MBC|This is an observational study, no interventions are specified
3129744|NCT01689597|Active Comparator|Low dose epidural morphine|One dose of 1.25 mg epidural morphine
3129745|NCT01689597|Active Comparator|High dose epidural morphine|One dose of 2.5 mg epidural morphine
3129746|NCT01689597|Placebo Comparator|Saline|One dose of 10 ml saline administered through an epidural catheter
3129747|NCT01689584|Other|Covar|
3129748|NCT01689571|Placebo Comparator|Placebo DPI|Placebo by inhalation for 9 days
3129749|NCT01689571|Experimental|CHF6001 DPI Dose 2|CHF6001 by inhalation for 9 days
3129750|NCT01689571|Experimental|CHF6001 DPI Dose1|CHF6001 by inhalation for 9 days
3129751|NCT01689558|Experimental|Recombine Endostatin|Induction chemotherapy:docetaxel 75mg/m2 iv in day 1 +Cisplatin 80mg/m2 iv in day 1 +human endostatin 7.5mg/m2 iv in day 8-21 and three weeks repeat and total two cycles Synchronous chemotherapy: cisplatin 80 mg/m2 points d1-2, 21days for a cycle, 2 cycles, the same day in radiation therapy. Synchronous chemotherapy in chemotherapy day one recombinant human vascular endothelial inhibin 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
3129752|NCT01689545|Experimental|Individual level|
3129753|NCT01689545|Experimental|Structural level|
3129754|NCT01689545|Experimental|Combined individual & structural level|
3129755|NCT01689545|Active Comparator|Standard of Care|
3129756|NCT01689532|Experimental|Sirukumab 100 mg|
3129757|NCT01689532|Experimental|Sirukumab 50 mg and Placebo|
3129758|NCT01689519|Active Comparator|Placebo + Vemurafenib|Participants will receive placebo orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 milligrams (mg) orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
3129759|NCT01689519|Experimental|Cobimetinib + Vemurafenib|Participants will receive cobimetinib 60 mg orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 mg orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
3129760|NCT01689506|Experimental|Volulyte|Volulyte 6%-supplemented arm: 6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (solution for infusion)
3129761|NCT01689506|Active Comparator|Human Serum Albumin|5% Albumin-supplemented arm: Human Serum Albumin (HSA 50g/L, solution for infusion)
3129762|NCT01689493|No Intervention|usual care|usual care arm, without SMS reminder
3129763|NCT01689493|Active Comparator|patient education and daily SMS|Multifaceted patient centered intervention including : collaborative care, patient education , and daily SMS.
3129764|NCT01689480||FSHD training|Only the patients who have participated to the FSHD1 study (NCT01116570) can be included in this study.
3129765|NCT01689467|Experimental|Fermented Velvet Antler extract|
3129766|NCT01689467|Placebo Comparator|Placebo|
3129767|NCT01689454||IVF treatment ISM1|Embryo culture in ISM1 medium
3129768|NCT01689454||IVF treatment EG|Embryo culture in EmbryoGen medium
3129769|NCT01689441|Experimental|Calcitriol|Calcitriol 2mcg IV x 1
3129770|NCT01689441|Placebo Comparator|Placebo|Normal saline 2cc IV x 1
3129771|NCT01689428||IVF treatment EmbryoGen|Embryo culture in EmbryoGen medium
3129772|NCT01689428||IVF treatment ISM1|Embryo culture in ISM1 medium
3129773|NCT01689402||Intracerebral Hemorrhage Patients|Patients admitted with acute intracerebral hemorrhage within 72 hours after symptom onset.Patients are included in the study for MRI studies
3129774|NCT01689389||Main study population|"All eligible patients receiving Quetiapine XR for the first time in the inclusion period regardless the diagnosed disease or the patients' age.~Patients aged 18 years and over and diagnosed with bipolar disorder or schizophrenia according to DSM-IV criteria will be followed during 12 months."
3227948|NCT00999986|No Intervention|placebo|
3129775|NCT01689389||Schizophrenia SoC sample|Patients would have to be prescribed for the first time with a new (not used during the preceding 3 months) atypical antipsychotic other than Quetiapine XR (irrespective this new atypical antipsychotic is preceded or not by another atypical antipsychotic).
3129776|NCT01689389||Bipolar SoC sample|Patients would have to be prescribed a new (not used during the preceding 3 months) antidepressant [N06A], antipsychotic (other than Quetiapine XR) [N05A] or mood stabilizer (including lithium [N05AN], valproate [N03AG01], and lamotrigine [N03AX09].
3129777|NCT01689363|Experimental|Arm H|Intradermal injection of Amphadase (hyaluronidase 150 USP units/mL)
3129778|NCT01689363|Active Comparator|Arm P|Intradermal injection of Histatrol (histamine base 0.1 mg/mL)
3129779|NCT01689363|Placebo Comparator|Arm N|Intradermal injection of saline (0.02 mL)
3129780|NCT01689350|No Intervention|Control Group|The cases in control group received traditional therapy that the initial dose of cyclophosphamide (CPA) was 0.2-0.6g/week injection according to clinical experience.
3129781|NCT01689350|Experimental|Experimental Group|Genetic: Genotype Detection To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM),with initial dose of CPA as 0.2g, 0.4g and 0.6g per week by injection, respectively.
3129782|NCT01689337|Experimental|Sprifermin (AS902330), 30 mcg|
3129783|NCT01689337|Experimental|Sprifermin (AS902330), 100 mcg|
3129784|NCT01689337|Placebo Comparator|Placebo|
3129785|NCT01689324|Experimental|Study Group|Participants will receive a single booster dose of Tdap vaccine (ADACEL®) on Day 0.
3129786|NCT01689311|Experimental|Treatment|All samples will undergo dose response treatment (increasing concentrations) of one of the four uterotonic drugs: oxytocin, ergonovine, prostaglandin F2alpha, or misoprostol.
3129787|NCT01689298|Active Comparator|No drug pre-treatment|A control sample from each patient (no uterotonic drug will be applied during pre-treatment) will be measured concurrently with samples pre-treated with oxytocin. Controls will undergo the same dose response of oxytocin or carbetocin after pre-treatment period as the groups given oxytocin for pre-treatment.
3129788|NCT01689298|Active Comparator|Drug pre-treatment|A sample from each patient will be pre-treated with oxytocin 10-5mol/L. These samples will undergo the same dose response of oxytocin or carbetocin after pre-treatment period as the groups given no drug for pre-treatment (controls).
3129789|NCT01689285|Active Comparator|valacyclovir tablet|Administration of 500 mg once daily on day 1 (group A) or on day 8 (group B)
3129790|NCT01689285|Experimental|valacyclovir oral solution|Administration of 500 mg once daily on day 1 (group B) or on day 8 (group A)
3129791|NCT01689272|Experimental|Kidney transplantation|Kidney transplantation from alive relative donor.
3129792|NCT01689259|Experimental|SL TNX-102 at 2.4 mg|1 x TNX-102 SL Tablets at 2.4 mg
3129793|NCT01689259|Experimental|SL TNX-102 at 4.8 mg|2 x TNX-102 SL Tablets at 2.4 mg
3129794|NCT01689259|Experimental|SL TNX-102-A at 2.4 mg|1 x TNX-102-A (without phosphate) SL Tablet at 2.4 mg
3129795|NCT01689259|Active Comparator|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine oral tablet
3129796|NCT01689246|Experimental|TRx0237 250 mg/day|
3129797|NCT01689246|Placebo Comparator|Placebo|
3129798|NCT01689246|Experimental|TRx0237 150 mg/day|
3129799|NCT01689233|Experimental|TRx0237 200 mg/day|
3129800|NCT01689233|Placebo Comparator|Placebo|
3129801|NCT01689220|Experimental|SP-02L|
3129802|NCT01689207|Experimental|Drug: A|Avibactam (AVI)
3129803|NCT01689207|Experimental|Drug: B|Aztreonam (ATM)
3129804|NCT01689207|Experimental|Drug: C|combination of Aztreonam-Avibactam (ATM-AVI)
3129805|NCT01689207|Placebo Comparator|Drug: D|Matching Placebo
3129806|NCT01689194|Experimental|genexolPM + cisplatin|
3129807|NCT01689181||chronic schizophrenic patients|
3129808|NCT01689181||healthy volunteers|
3129809|NCT01689168|Experimental|Counseling plus chiropractic adjustments|
3129810|NCT01689168|Active Comparator|Counseling alone|
3129811|NCT01689155||Study Group|Participants must have received Menactra Vaccine according to routine clinical practice.
3129812|NCT01689142|Experimental|New formulation of insulin glargine|once daily in the evening on-top of oral antihyperglycemic drug (OADs)
3129813|NCT01689142|Active Comparator|Lantus (insulin glargine)|once daily in the evening on-top of OADs
3129814|NCT01689129|Experimental|New formulation of insulin glargine|once daily in the evening on-top of mealtime insulin
3129815|NCT01689129|Active Comparator|Lantus (insulin glargine)|once daily in the evening on-top of mealtime insulin
3129816|NCT01689116|Experimental|Bardoxolone Methyl 20mg|
3129817|NCT01689116|Experimental|Bardoxolone Methyl 80mg|
3129818|NCT01689116|Placebo Comparator|Bardoxolone Methyl Placebo|
3129819|NCT01689116|Active Comparator|Moxifloxacin|
3129820|NCT01689103|Experimental|Alliance Feedback to Therapist|Alliance feedback provided to therapist
3129821|NCT01689103|Placebo Comparator|No alliance feedback to therapist|No alliance feedback provided to therapist
3129822|NCT01689090|Experimental|Hypoxia|Inhaling hypoxic gas mixture to induce hypoxemia during recordings of diameter changes of retinal vessels. Recording are performed during hypoxia alone and in combination with the associated interventions at two examination days.
3129823|NCT01689090|Experimental|Normoxia|Breathing atmospheric air during recordings of diameter changes of retinal vessels. Recording are performed during normoxia alone and in combination with the associated interventions at two examination days.
3129824|NCT01689077|Active Comparator|24 hours hypothermia|24 hours hypothermia
3129825|NCT01689077|Experimental|48 hours hypothermoa|48 hours hypothermia
3129872|NCT01688791|Experimental|Part A: Vintafolide TIW|Vintafolide, intravenously (IV) on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle. Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle. Paclitaxel, IV, at a dose of 175 mg/m^2, administered on Day 1 of each 21-day cycle
3129911|NCT01688479|Experimental|Calendula Weleda® cream (Weleda)|Calendula Officinalis (marigold plant) is applied twice daily on the skin in the radiated area during the entire treatment period and until the skin reaction subsided
3130071|NCT01687374|Placebo Comparator|Placebo|
3229069|NCT00992108|Experimental|Botulinum|
3129826|NCT01689064|Active Comparator|Posterior Septectomy|Patient will be randomized to a study arm. The patient will be blinded to the approach. The surgeon will have performed at least 10 procedures previous for each approach. The surgeon will maintain the following surgical practives: preservation of both middle turbinates, preservation of one superior turbinate (to minimize olfactory injury), elevation of a nasoseptal flap, the use of a combination of gelform, surgicel and nasapore dissolvable spacer placed within the surgical defect. These practices are all standard of care. Patient will start Neilmed high volume low pressure saline irrigation three times daily starting on post operative day five. Patients will receive prophylactic antibiotics for fourteen days post operatively.
3129827|NCT01689064|Experimental|Stamm Approach|Patient will be randomized a study arm. The patient will be blinded to the approach. The surgeon will have performed at least 10 procedures previous for each approach. The surgeon will maintain the following surgical practives: preservation of both middle turbinates, preservation of one superior turbinate (to minimize olfactory injury), elevation of a nasoseptal flap, the use of a combination of gelform, surgicel and nasapore dissolvable spacer placed within the surgical defect. These practices are all standard of care. Patient will start Neilmed high volume low pressure saline irrigation three times daily starting on post operative day five. Patients will receive prophylactic antibiotics for fourteen days post operatively.
3129828|NCT01689051|Active Comparator|Healthy subjects|
3129829|NCT01689051|Active Comparator|Patients with type 2 diabetes|
3129830|NCT01689038|Experimental|Tested product|
3129831|NCT01689025|Experimental|NNC0114-0006|
3129832|NCT01689025|Placebo Comparator|Placebo|
3129833|NCT01689012|Experimental|Facial Exercise|
3129834|NCT01688999|Experimental|Cabozantinib|Administered orally at a dose of 60 mg once dailyon each day of a 28-day cycle.
3129835|NCT01688973|Experimental|Arm I (tivantinib)|Patients receive tivantinib PO BID on days 1-28.
3129836|NCT01688973|Experimental|Arm II (tivantinib and erlotinib hydrochloride)|Patients receive tivantinib PO BID and erlotinib hydrochloride PO QD on days 1-28.
3129837|NCT01688960|Experimental|Cohort 1|
3129838|NCT01688960|Experimental|Cohort 2|
3129839|NCT01688960|Experimental|Cohort 3a|
3129840|NCT01688960|Experimental|Cohort 3b|
3129841|NCT01688960|Experimental|Cohort 4|
3129842|NCT01688947|Experimental|V116517 - 50 mg|V116517 50-mg tablets
3129843|NCT01688947|Experimental|V116517 - 30 mg|V116517 30-mg tablets
3129844|NCT01688947|Active Comparator|Pregabalin|Pregabalin capsules
3129845|NCT01688947|Placebo Comparator|Placebo|Placebo
3129846|NCT01688934|Experimental|V116517 - 50 mg|V116517 50-mg tablets
3129847|NCT01688934|Experimental|V116517 - 30 mg|V116517 30-mg tablets
3129848|NCT01688934|Active Comparator|Naproxen 500 mg|Naproxen 500-mg capsules
3129849|NCT01688934|Placebo Comparator|Placebo|Placebo
3129850|NCT01688921|Experimental|STRATIS Needle-Free|Patients assigned to this arm will receive AFLURIA vaccine administered using the Stratis needle-free injection device.
3129851|NCT01688921|Active Comparator|Needle-Syringe|Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
3129852|NCT01688908|No Intervention|Control Arm|Participants in this arm will not accept the endoscopic screening and only baseline and follow-up interview will be conducted in this arm.
3129853|NCT01688908|Experimental|Screening Arm|Participants in this arm will accept a baseline endoscopic screening, questionnaire investigation and follow-up interview. Subsequent re-examination and further medical services would be arranged among individuals who already have high-grade lesions found at baseline screening.
3129854|NCT01688895||Erythropoietic Protoporphyria (EPP)|Individuals with a documented diagnosis of EPP
3129855|NCT01688895||X-Linked Protoporphyria (XLP)|Individuals with a documented diagnosis of XLP
3129856|NCT01688895||Erythropoietic protoporphyria, unspecified|Individuals with clinical and/or biochemical diagnosis of an erythropoietic protoporphyria, but the specific type (EPP or XLP) has not been determined
3129857|NCT01688882|Experimental|QGE031|QGE031 240 mg Q2W s.c.
3129858|NCT01688882|Placebo Comparator|Placebo|Placebo to Match Q2W s.c.
3129859|NCT01688882|Experimental|Open Label QGE031|Open Label QGE031 Q2W s.c.
3129860|NCT01688869||Mild TBI|Patients who have been diagnosed with a mild brain injury.
3129861|NCT01688856|Experimental|Arm+Hand CCFES|Uses an electrical stimulator that activates the muscles of the paretic arm and hand in response to and with an intensity proportional to movement of the contralateral arm and hand. The finger and thumb extensors will be stimulated, as well as the elbow extensors. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 75 min of functional task practice twice a week in the laboratory for 12 weeks.
3129862|NCT01688856|Experimental|Hand CCFES|Uses an electrical stimulator that activates the muscles of the paretic hand in response to and with an intensity proportional to movement of the contralateral hand. The finger and thumb extensors will be stimulated. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 75 min of functional task practice twice a week in the laboratory for 12 weeks.
3129863|NCT01688856|Active Comparator|Arm+Hand Cyclic NMES|Uses an electrical stimulator which delivers stimulation automatically and repeatedly with preprogrammed timing and intensity. The finger and thumb extensors will be stimulated, as well as the elbow extensors. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 75 min of functional task practice twice a week in the laboratory for 12 weeks.
3129864|NCT01688843|Experimental|INGEVITY lead|INGEVITY lead implant
3129865|NCT01688830|Experimental|BI 655075|
3129866|NCT01688830|Placebo Comparator|Placebo|
3129867|NCT01688830|Experimental|BI 655075 with dabigatran|
3129868|NCT01688817|Other|Physician's counseling|
3129869|NCT01688817|Active Comparator|Information leaflet|
3129870|NCT01688804|Experimental|Behavioral intervention|Behavioral intervention to reduce sedentary time delivered via mobile smartphone
3129871|NCT01688791|Experimental|Part A: Vintafolide BIW|Vintafolide, intravenously (IV), on Days 1, 4, 8, and 11 of each 21-day cycle. Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle. Paclitaxel, IV, at a dose of 175 mg/m^2, administered on Day 1 of each 21-day cycle
3129873|NCT01688791|Experimental|Parts B & C: Vintafolide Single Dose & Weekly (QW)|Single dose, dose escalation, vintafolide (Part B) followed by 2 week observation. Those completing Part B will have the option to continue on to Part C (weekly dosing, dose finding, on Days 1, 8, and 15 in a 21-day cycle until disease progression or toxicity) unless they experience severe and/or persistent drug related toxicity.
3129874|NCT01688778|Experimental|Telemedicine|Monthly video consultations with a nurse as add-on to standard treatment.
3129875|NCT01688778|No Intervention|Standard treatment|Standard diabetes control at a Diabetes Clinic or GP
3129876|NCT01688765||First Episode Psychosis Patients|
3129877|NCT01688765||Healthy Controls|
3129878|NCT01688752||Sibling Controls|Healthy siblings of acute lymphoblastic leukemia (ALL) subjects frequency matched by age and sex.
3129879|NCT01688752||Acute Lymphoblastic Leukemia Survivors|Survivors of acute lymphoblastic leukemia (ALL) who recently completed therapy.
3129880|NCT01688739|Active Comparator|AMG 334 Treatment A|6 dose levels administered as single doses SC or IV in healthy subjects and migraine patients.
3129881|NCT01688739|Placebo Comparator|AMG 334 Treatment B|6 dose levels administered as single doses SC or IV in healthy subjects and migraine patients.
3129882|NCT01688726|Experimental|SYSTANE BALANCE|SYSTANE® BALANCE eyedrops, 1 drop 4 times a day for a continuous period of 1 month
3129883|NCT01688726|Active Comparator|Minims Saline|Minims® Saline 0.9% eyedrops, 1 drop 4 times a day for a continuous period of 1 month
3129884|NCT01688713|Experimental|Icotinib,Brain metastases|
3129885|NCT01688700|Experimental|Nimotuzumab plus chemotherapy|
3129886|NCT01688687||Superficial gastric neoplasia|Patients with superficial gastric neoplasia on diagnostic endoscopy, recieved both conventional endoscopic forcpes biopsies and pCLE. All patients were subject to endoscopic resection of the lesion.
3129887|NCT01688674|Placebo Comparator|Bolus arm|two hourly dextrose boluses administered via an intravenous cannula
3129888|NCT01688674|Experimental|infusion|10% dextrose infusion by burettes
3129889|NCT01688648|Experimental|Lidocaine group|a bolus dose of lidocaine 1.5 mg/kg after anesthetic induction with following lidocaine infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
3129890|NCT01688648|Experimental|Dexmedetomidine group|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 ~ 0.7 mcg/kg/hr during the surgery
3129891|NCT01688648|Experimental|Combined infusion group|Combined lidocaine and dexmedetomidine infusion with the dose specified in single infusion group
3129892|NCT01688648|No Intervention|Control group|The group without infusion of lidocaine or dexmedetomidine
3129893|NCT01688635|Experimental|LY2963016|Single 0.5 units per kilogram (U/kg) dose of LY2963016 administered subcutaneously, twice during the study
3129894|NCT01688635|Experimental|US-approved Lantus|Single 0.5 U/kg dose of US-approved Lantus administered subcutaneously, twice during the study
3129895|NCT01688622|Other|Exercise|obese women who are volunteers for the 3 months exercise programs
3129896|NCT01688609|Experimental|Treatment (lapatinib, trastuzumab, paclitaxel, surgery)|"Drug exposure: Patients receive lapatinib ditosylate PO QD and trastuzumab IV over 30-90 minutes once weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.~Preoperative therapy: Patients receive lapatinib ditosylate PO QD, trastuzumab IV over 30 minutes once weekly, and paclitaxel IV over 90 minutes once weekly for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo lumpectomy or mastectomy."
3129897|NCT01688596|No Intervention|No Treatment|"The No Treatment group includes patients undergoing laparoscopic hysterectomy without local infiltration of bupivacaine."
3129898|NCT01688596|Active Comparator|Bupivacaine|"The Bupivacaine Arm includes all patients who will receive bupivacaine injection on their trocar sites after the laparoscopic hysterectomy is completed. Bupivacaine (0.25%) will be injected through the closed incisions ensuring subcutaneous tissue, fascia, muscle and pre-peritoneal space of the trocar incision sites are infiltrated. All incisions 8 mm and greater are injected with 10 cc while all incisions 5 mm or less are infiltrated with 5 cc."
3129899|NCT01688583||Fentanyl matrix|
3129900|NCT01688570|Active Comparator|Duloxetine|Neuromuscular fatigue testing with duloxetine dose
3129901|NCT01688570|Active Comparator|Cyproheptadine|Neuromuscular fatigue testing with cyproheptadine dose
3129902|NCT01688570|Placebo Comparator|Placebo|Neuromuscular fatigue testing with placebo dose
3129903|NCT01688557|Experimental|Innovative colonoscopy|Innovative colonoscopy performed using narrow band imaging and dual focus function (NBI + Dual Focus).
3129904|NCT01688557|Active Comparator|Conventional colonoscopy|Conventional colonoscopy performed without innovative techniques assessed in this study.
3129905|NCT01688544|Experimental|Ilaprazole|"Before Ilaprazole dosing, 24 hours intragastric pH monitoring is performed as baseline value.~After 7 days dosing of Ilaprazole 10 mg, 24 hours intragastric pH monitoring, serum gastrin level check, and pharmacokinetic sampling is performed"
3129906|NCT01688531|Experimental|CD0271/CD1579, vehicle|
3129907|NCT01688518|Active Comparator|Synera® for 30min & Lidoderm® for 4 hours|Heated Lidocaine/Tetracaine (Synera®)applied to one forearm for either 30 minutes or 4 hours and a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.
3129908|NCT01688518|Active Comparator|Lidoderm® for 30min & Synera® for 4 hours|Heated Lidocaine/Tetracaine (Synera®)applied to one forearm for either 30 minutes or 4 hours and a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.
3129909|NCT01688505||Visit-to-visit BP variability|The highest, intermediate, and the lowest visit-to-visit BP variability (Tertile grouping)
3129910|NCT01688492|Experimental|ipilimumab|This multi-institution open label study has a Phase 1 and Phase 2 component. The Phase 1 dose escalation stage is to establish the tolerability of ipilimumab to be used in combination with the standard clinical dose of abiraterone acetate plus prednisone in chemotherapy and immunotherapy-naïve patients with progressive metastatic CRPC. Due to the overlapping potential hepatic toxicity between abiraterone and ipilimumab, a Lead in Therapy with abiraterone plus prednisone for 2 cycles will assess for adverse events related to the abiraterone plus prednisone. Patients, who tolerate well the Lead in therapy as defined by Grade 1 or less AEs, will pursue Combination Therapy. Patients with AEs Grade ≥ 2 after Lead in Therapy will be excluded and replaced. The Phase 2 stage will assess efficacy and confirm an acceptable safety profile of the recommended dose.
3129912|NCT01688479|Active Comparator|Essex® cream (Schering-Plough)|Essex cream is applied twice daily on the skin in the radiated area during the entire treatment period and until the skin reaction subsided
3129913|NCT01688466|Experimental|0.5 mg/day with Dose Escalation|0.5 mg/day with Dose Escalation by 0.5 mg/day increments every 2 weeks to a maximum of 2.0 mg/day
3129914|NCT01688466|Experimental|0.5 mg/day without Dose Escalation|0.5 mg/day without Dose Escalation
3129915|NCT01688453|Active Comparator|Group 1:|Socially advantaged overweight or obese adolescents are allocated to the standard care management.
3129916|NCT01688453|Experimental|Group 2|Socially less advantaged overweight or obese adolescents are allocated to the standard care management.
3129917|NCT01688453|Experimental|Group 3|Socially less advantaged overweight or obese adolescents are allocated to the strengthened care management.
3129918|NCT01688440|Experimental|#1 Respiratory Care Solution|Low sodium physiologically based airway care solution.
3129919|NCT01688427|Experimental|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper.
3129920|NCT01688427|Experimental|Standard DOVE intervention|The standard DOVE intervention has already been developed and tested (NR009093). The standard DOVE intervention is a brochure based 10 minute intervention that the home visitor reviews with the women. It consists of information about IPV, its effects on pregnancy and infant health, community resources and a plan for individual safety options. For the eMOCHA DOVE intervention, the DOVE 10 minute brochure intervention will be converted from the paper format to a visually colorful interactive presentation loaded into the home visitor device using the eMOCHA application. The format will be completely activated and implemented by the women. She uses small ear buds and a touch screen, so how she responds and interacts with the media enhanced eMOCHA DOVE intervention is private.
3129921|NCT01688414|Experimental|Diagnostic (fluorescence imaging, PAI)|Patients undergo fluorescence imaging and PAI during robot assisted laparoscopic surgery.
3129922|NCT01688388|Experimental|IORT Arm|Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure.
3129923|NCT01688375|Experimental|Ursodeoxycholic acid|Ursodeoxycholic acid administration UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
3129924|NCT01688362|Experimental|platelet-rich plasma protein (PRP)|Subjects in this group will receive 2 injections with PRP. Each injection separated by two weeks.
3129925|NCT01688362|Active Comparator|Corticosteroid|Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later.
3129926|NCT01688349|Experimental|Cushing group|AT biopsy during partial nephrectomy
3129927|NCT01688349|Other|Controls1|normal weight metabolic healthy patients having partial nephrectomy with small AT Biopsy.
3129928|NCT01688349|Other|Controls2|obese individuals already included and having biopsies of VAT and SCAT stocked.
3129929|NCT01688336|Experimental|FOLFIRINOX|FOLFIRINOX given to all subjects
3129930|NCT01688323||Elderly Chemorads|Elderly patients with Head and Neck Cancer who are Undergoing Chemotherapy
3129931|NCT01688310|Active Comparator|Open surgical circumcision|Open surgical techniques, which are commonly used for circumcision in Mozambique, require good surgical skills and minor complications are common.
3129932|NCT01688310|Experimental|Gomco clamp with tissue adhesive|Coupling removal of the foreskin with the Gomco clamp followed by wound sealing with tissue adhesive results in a procedure that can be performed by generalist doctors using the same technique in all age groups.
3129933|NCT01688297|Experimental|Low Dose VXA-A1.1 Oral Vaccine|Two doses of replication incompetent adenovirus vaccine given in an oral tablet formulation.
3129934|NCT01688297|Placebo Comparator|VXA Placebo Tablet|Oral tablets of the same size and number as the vaccine tablet doses. Placebo arms were included during enrollment of each of the experimental dose groups to maintain the double-blind study design.
3129935|NCT01688297|Experimental|Medium Dose VXA-A1.1 Oral Vaccine|Two doses of replication incompetent adenovirus vaccine given in an oral tablet
3129936|NCT01688297|Experimental|High Dose VXA-A1.1 Oral Vaccine|One dose of replication incompetent adenovirus given in an oral tablet dose. This dose was studied under protocol VXA02-003.
3129937|NCT01688284|Active Comparator|No treatment|patients with recurrent miscarriages
3129938|NCT01688284|Active Comparator|OFFICE HYSTEROSCOPY|Office hysteroscopic endometrial biopsy at the luteal phase of the menestrual cycle
3129939|NCT01688271||Anesthesiologists|
3129940|NCT01688245|No Intervention|Control|No SMS dialog
3129941|NCT01688245|Active Comparator|SMS Assessments|Weekly post-weekend drinking outcome assessments
3129942|NCT01688245|Experimental|SMS Assessments & Feedback|Weekly pre-weekend drinking intention & post-weekend drinking outcome assessments with personalized feedback and harm-reduction support
3129943|NCT01688206|Experimental|Vanucizumab|Participants will receive escalating doses of vanucizumab and fixed dose of vanucizumab, intravenously every 2 weeks.
3129944|NCT01688206|Experimental|Vanucizumab + Atezolizumab|Participants will receive fixed dose of vanucizumab along with atezolizumab, intravenously every 2 weeks.
3129945|NCT01688193||HCP 1004|
3129946|NCT01688193||Vimovo 500/20mg|
3129947|NCT01688167|Experimental|Intervention|Experimental condition clinics offer the MC and sexual risk reduction intervention: four group counseling sessions focused on male circumcision and sexual risk reduction.
3129948|NCT01688167|No Intervention|Standard of Care|"Male participants in the standard of care control condition CHCs will receive counseling per the VCT protocol guidelines. Participants will attend four video-based time-equivalent attention-control group sessions on endemic disease prevention strategies (e.g., TB, malaria, cholera, waterborne diseases). Female partners will be invited to participate in a similar four session program devoted to endemic disease risk reduction."
3129949|NCT01688167|No Intervention|Observational|"3 CHC sites will be randomly assigned as observation only; only aggregated clinic VCT and circumcision data will be collected."
3129950|NCT01688154|Active Comparator|Product 1|35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)
3129951|NCT01688154|Placebo Comparator|Control product|2 empty capsules
3129952|NCT01688141|No Intervention|Control|Usual care
3129953|NCT01688141|Active Comparator|Enhanced Management|Practices randomised to the intervention group will be offered an enhanced level of CKD disease management led by clinical nurse specialists based on an intervention previously piloted in high risk patients. Here, high risk patients identified will be invited to a CKD clinic for tailored management of bp and proteinuria and referral as needed.
3129954|NCT01688128|Experimental|Intervention_Control group|Phase I: U-SMART for 4 weeks (2 session/week); Washout: for 2 weeks; Phase II: No intervention for 4 weeks
3129955|NCT01688128|Experimental|Control_Intervention group|Phase I: No intervention for 4 weeks; Washout: for 2 weeks; Phase II: U-SMART for 4 weeks (2 session/week)
3129956|NCT01688115|Experimental|Procedure|
3129957|NCT01688115|Active Comparator|Standard Care|
3129958|NCT01688102|Active Comparator|Oral Vitamin D3|Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain <35 ng/ml, subjects will receive additional doses of oral vitamin D.
3129959|NCT01688102|Active Comparator|Ultraviolet Light|Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain <35 ng/ml, subjects will receive additional doses of narrow band UVB.
3129960|NCT01688089|Experimental|ODM-103|Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days
3129961|NCT01688089|Placebo Comparator|Placebo|Oral capsules given once daily for one day or three times daily for 7 days
3129962|NCT01688089|Active Comparator|entacapone + levodopa/carbidopa|entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day
3129963|NCT01688076|Experimental|Muscle contractions|Under supervision by study personnel, subjects be asked to make active muscle contractions for one hour after Botox injections. Subjects will return for follow-up visits.
3129964|NCT01688076|Active Comparator|No muscle contractions|Patients will be asked to not perform muscle contractions following Botox injections.
3129965|NCT01688063||Part A: 3 Arms|Subjects will be recruited and enrolled to fill one of three Arms. The first Arm will include 25 subjects who are scheduled to receive resurfacing or tightening procedures AS STANDARD OF CARE (CO2 resurfacing or tightening procedure (1 treatment), radiofrequency (2 tx), Fraxel ( 2 tx), or PDL. These subjects will have baseline elasticity measurements recorded on their face and right forearm before their procedures, and follow up measurements will be repeated 3 months following their last treatment. The second Arm will include 25 subjects who are not scheduled to receive any cosmetic procedures but who agree to return for repeated measurements 3 months following the first. Baseline elasticity measurements will be recorded from subjects' face and right forearm and subjects will return in 3 months for follow-up measurements. The third Arm will include the remaining 50 subjects; these subjects will have the elasticity measurements performed only once on their face and forearm.
3129966|NCT01688063||Part B|The study population in the second cohort will consist of 250 subjects who have a surgical scar >2 cm in length. Subjects enrolled will have three elasticity measurements performed in one study visit. Elasticity will be measured directly in the center of the scar, 3cm perpendicular to the center of the scar, and 3cm in line from one end of the scar (Appendix 2).
3129967|NCT01688050|Experimental|Endovascular Repair|
3129968|NCT01688037|Experimental|NBI-98854 50 mg|NBI-98854 50 mg administered as two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
3129969|NCT01688037|Experimental|NBI-98854 100 mg and 50 mg|NBI-98854 100 mg administered as two (2) 50 mg capsules taken every morning between 7:00am - 10:00am for 2 weeks. After 2 weeks, NBI-98854 50 mg administered by two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for remaining 4 weeks.
3129970|NCT01688037|Placebo Comparator|Placebo|Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.
3129971|NCT01688024|Experimental|Mitomycin C|Up to 10 mg administered during each standard of care endoscopic retrograde cholangiography. No more than five mitomycin C applications per every twelve months will be given.
3129972|NCT01688024|Placebo Comparator|Normal saline|Given during each standard of care endoscopic retrograde cholangiography. No more than five normal saline applications per every twelve months will be performed.
3129973|NCT01688011||Lower-Risk Myelodysplastic Syndromes (LR MDS)|Newly diagnosed lower risk MDS patients as determined by International Prognostic Scoring System (IPSS).
3129974|NCT01688011||Higher-Risk Myelodysplastic Syndromes (HR MDS)|Newly diagnosed higher risk MDS patients as determined by International Prognostic Scoring System (IPSS).
3129975|NCT01688011||Acute Myeloid Leukemia (AML)|Newly diagnosed AML patients (≥55 years old, excluding patients with acute promyelocytic leukemia (APL).
3129976|NCT01688011||Idiopathic Cytopenia of Undetermined Significance (ICUS)|Newly diagnosed ICUS patients as determined by clinical criteria defined by Valent et al. (Valent P, Horny H-P, Bennett JM et al. 2007. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leukemia Research. 31: 727-736. And further updated Valent P, Bennett JM et al. 2017. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 8(43): 73483-73500.)
3129977|NCT01687998|Experimental|Evacetrapib|Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants will also receive standard of care for high-risk vascular disease (HRVD).
3129978|NCT01687998|Placebo Comparator|Placebo|Placebo, tablet administered orally once daily for up to 4 years. Participants will also receive standard of care for HRVD.
3129979|NCT01687985|Experimental|BLI801 laxative - low dose|BLI801 laxative - oral solution
3129980|NCT01687985|Experimental|BLI801 laxative - high dose|BLI801 laxative - oral solution
3129981|NCT01687972|Active Comparator|Sutures|
3129982|NCT01687972|Active Comparator|Insorb Staples|
3129983|NCT01687959|Active Comparator|activity of peritoneal fibrinolysis|measurements of peritoneal fibrinolysis using tissue-type plasminogen activator and its specific activity, urokinase-type plasminogen activator, and plasminogen activator inhibitor type 1
3129984|NCT01687959|Active Comparator|surgical outcomes|surgical outcomes of laparoscopic cholecystectomy
3129985|NCT01687946||Pulmonary fibrosis in aged individuals|"Group A and B:~Patients with UIP (histologically and/or radiologically proven) providing informed consent. According to functional and radiological assessment, the disease may be either limited (Group A) or advanced (Group B). The patients are usually older than 55 years."
3231859|NCT00973011|Experimental|A|
3129986|NCT01687946||Pulmonary fibrosis and inflammation|"Groups C and D:~Patients with HP (histologically and radiologically proven) providing informed consent. According to functional and radiological assessment, the disease will be either acute or chronic. The patients will be significantly younger (mean > 10 years) than in groups A and B."
3129987|NCT01687946||Regular wound healing in lung|Patients receiving lung biopsy or bronchoscopy for reasons other that the study and volunteers providing informed consent. The group will consist of young (18-40 years) and old individuals (older than 55 years).
3129988|NCT01687933|Experimental|three-dimensional glasses (Virtual Reality glasses)|Women in case group used the glasses for 30 minutes
3129989|NCT01687933|Experimental|usual care|Women in control group did not use the glasses.
3129990|NCT01687920|Experimental|BAY94-8862 (1.25mg)|single dose BAY94-8862 IR tablet 1.25mg
3129991|NCT01687920|Experimental|BAY94-8862 (2.5mg)|single dose BAY94-8862 IR tablet 2.5mg
3129992|NCT01687920|Experimental|BAY94-8862 (5mg)|single dose BAY94-8862 IR tablet 5mg
3129993|NCT01687920|Experimental|BAY94-8862 (7.5mg)|single dose BAY94-8862 IR tablet 7.5mg
3129994|NCT01687920|Experimental|BAY94-8862 (10mg)|single dose BAY94-8862 IR tablet 10mg
3129995|NCT01687907|Active Comparator|Fear of childbirth, music|Patients referred to the motherhood out-patient clinic because of fear of childbirth. Advised to active music listening. Followed up by weekly and monthly diaries and three questionnaires (when recruiting, just after the delivery and 6 months after the delivery).
3129996|NCT01687907|No Intervention|Fear of childbirth, control|Patients referred to the motherhood out-patient clinic because of fear of childbirth. No intervention. Followed up by three questionnaires (when recruiting, just after the delivery and 6 months after the delivery).
3129997|NCT01687907|Active Comparator|Nulliparous, music|300 nulliparous women recruited from the ultrasound screening. Advised to active music listening. Three questionnaires like the other arms, weekly and monthly diaries like the other music group. Screening questionnaires about fear of childbirth.
3129998|NCT01687907|No Intervention|Nulliparous, control|300 nulliparous women recruited from ultrasound screening. No intervention. 3 Questionnaires as all the other groups. Screening questionnaire about fear of childbirth.
3129999|NCT01687894||Vasopressins & propofol|Administer vasopressin 0.05 or 0.07 IU/kg before sitting position during propofol anesthesia.
3130000|NCT01687894||Placebo & propofol|Administer saline 10 ml (placebo) 2 min before beach chair position during propofol anesthesia
3130001|NCT01687894||Vasopressins & sevoflurane|Administer vasopressin 0.05 or 0.07 IU/kg 2 min before beach chair position during sevoflurane anesthesia
3130002|NCT01687894||Placebo & sevoflurane|Placebo (saline 10 ml) for vasopressin is administered 2 min before beach chair position during sevoflurane anesthesia
3130003|NCT01687881|Sham Comparator|Sham Chiropractic|Sham Chiropractic manipulative therapy.
3130004|NCT01687881|No Intervention|Control group|No intervention: Control group.
3130005|NCT01687881|Active Comparator|Chiropractic Spinal Manipulative Therapy|Active intervention: Chiropractic Spinal Manipulative Therapy
3130006|NCT01687868|Experimental|dexmedetomidine continuous infusion|
3130007|NCT01687855||OSAHS group|Subjects that underwent night Ultrafast Magnetic Resonance Imaging with obtaining a series of midline sagittal images of the upper airway .
3130008|NCT01687855||normal group|Subjects that underwent night Ultrafast Magnetic Resonance Imaging with obtaining a series of midline sagittal images of the upper airway .
3130009|NCT01687842||Turner syndrome patients|Evaluation of 45,X Turner syndrome patients
3130010|NCT01687829||ILM-on group|patients were scheduled to undergo macular hole surgery without internal limiting membrane (ILM) peeling
3130011|NCT01687829||ILM-off group|patients were scheduled to undergo macular hole surgery with internal limiting membrane (ILM) peeling
3130012|NCT01687816||No interventions to be administered|Only a nasal swab is collected, no therapeutic interventions
3130013|NCT01687803|Experimental|Physical Activity|Physical activity intervention will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to ~60 min/day for 6 days/week (~360 minutes per week).
3130014|NCT01687803|Other|Control|The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
3130015|NCT01687790|Experimental|molecular breast imaging|
3130016|NCT01687777|Active Comparator|Mesenchymal stem cells (MSCs)|Mesenchymal stem cells with a collagen type I membrane (OrthoADAPT)
3130017|NCT01687777|Placebo Comparator|OrthADAPT|Membrane of collagen type I (OrthoADAPT)
3130018|NCT01687764|Experimental|CBGT+ABMT(active)|
3130019|NCT01687764|Experimental|CBGT+ABMT(placebo)|
3130020|NCT01687764|Experimental|PCI+ABMT(active)|
3130021|NCT01687764|Placebo Comparator|PCI+ABMT(placebo)|
3130022|NCT01687751|Experimental|Dexmedetomidine|Dexmedetomidine 0.2 to 1.1 mcg/kg/hr by continuous subcutaneous infusion for up to 10 days
3130023|NCT01687751|Active Comparator|Midazolam|Midazolam 10 to 100 mcg/kg/hr by continuous subcutaneous infusion for up to 10 days
3130024|NCT01687738|Experimental|Communication Intervention|Specially trained communicator addresses factual understanding and elicits other barriers to care
3130025|NCT01687738|Experimental|Real Time Registry and data feedback only|Patients are enrolled in registry and clinicians receive warnings about delayed or missed care.
3130026|NCT01687725||Renal denervation|Renal denervation using Symplicity Catheter system
3130027|NCT01687712|Experimental|AFOLIA|One subcutaneous injection of 225IU AFOLIA (follitropin alfa) per day (initial dose) for the first 5 days. From day 6 dose could be adjusted up (to a max of 450IU per day) or down (to a min of 75IU per day) in multiple increments of 37.5IU.
3130028|NCT01687712|Active Comparator|Gonal-f® RFF|One subcutaneous injection of 225IU Gonal-f® RFF (follitropin alfa) per day (initial dose) for the first 5 days. From day 6 dose could be adjusted up (to a max of 450IU per day) or down (to a min of 75IU per day) in multiple increments of 37.5IU.
3130029|NCT01687699|Experimental|spironolactone|
3130030|NCT01687686||All cohort|Initially healthy patients in General Practise Research Database (GPRD) meeting the inclusion criteria at any point between 1st January 2001 and 25th March 2010
3130032|NCT01687660|Experimental|acupoint-meridian group|Apply traditional acupuncture to prevent the migraine attack according to TCM theory
3130033|NCT01687660|Other|sham-acupoint group|sham-acupoint will be penetrated for migraine prophylaxis.
3130034|NCT01687660|No Intervention|waiting list|No acupuncture nor other methods will be conducted in this group.
3130035|NCT01687647|Other|Screening|Paired-design: low-dose CT scan, sputum sample and blood test will be performed on all subjects.
3130036|NCT01687634|Experimental|In-home Mentor Mother visits|Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.
3130037|NCT01687634|Experimental|Health Information Mailings|Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
3130038|NCT01687621||Neonates, 1 to 10 days old|Neonates between day 1-10 of life presenting to hospitals and community health centers in Southern Province, Zambia, with no prior diagnosis of omphalitis, whose guardian, aged 15 and above, is willing to allow their newborn to participate in the study.
3130039|NCT01687608|Experimental|AskBio009 Dose Escalation|Single Dose of a Self-Complementing Optimized Adeno-associated Virus (AAV) Serotype 8 Factor IX Gene Therapy
3130040|NCT01687595|Experimental|HerpV and QS-21|HerpV and QS-21
3130041|NCT01687595|Placebo Comparator|Placebo|
3130042|NCT01687582|Experimental|GLP-1 analog|Liraglutide, 0.6 to 1.8 mg per day or Exenatide, 5 to 10 µg twice a day.
3130043|NCT01687569|Placebo Comparator|Control Cracker|Base cracker snack
3130044|NCT01687569|Experimental|Experimental Cracker Snack 1|Cracker snack containing test ingredient 1
3130045|NCT01687569|Experimental|Experimental Cracker Snack 2|Cracker snack containing test ingredient 2
3130046|NCT01687556|Active Comparator|Topical EGCG 1%|Seventeen subjects were designated to use 1% EGCG .Since baseline visits, affected areas of randomly allocated half sides were treated with 1% solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol).
3130047|NCT01687556|Experimental|topical EGCG 5%|Eighteen subjects were designated to use 5% EGCG, to evaluate a dose-response relationship. Since baseline visits, affected areas of randomly allocated half sides were treated with 5% EGCG solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol).
3130048|NCT01687543|Experimental|Probiotics|Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water through a nasogastric tube. Patients randomized 1:1 between groups
3130049|NCT01687543|Placebo Comparator|Control|Patients will be given only the dissolved maltodextrin in water through the nasogastric tube. Patients randomized 1:1 between groups
3130050|NCT01687530|Experimental|AMCA bone membrane|AMCA Bone is manufactured from Polyethylene Glycol 400 and Ammonio Methacrylate copolymer type A (Eudragit RL 100) materials.
3130051|NCT01687517|Experimental|Patient|90 patients suffering from sarcoidosis
3130052|NCT01687517|Active Comparator|Volunteer|100 volunteers
3130053|NCT01687491|Active Comparator|Enoxa|ENOXA® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours
3130054|NCT01687491|Active Comparator|Lovenox|LOVENOX® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours
3130055|NCT01687478|Experimental|Olanzapine + Fluoxetine|"Olanzapine starting dose is 5 milligram (mg) (1 tablet). May titrate up to 10 mg (2 tablets), or 15 mg (3 tablets) administered once daily by mouth for 8 weeks.~Fluoxetine starting dose is 20 mg. May titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks."
3130056|NCT01687478|Placebo Comparator|Placebo + Fluoxetine|"Placebo matches the Olanzapine tablet for blinding.~Fluoxetine starting dose is 20 mg, then may titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks."
3130057|NCT01687465|Active Comparator|Argon laser trabeculoplasty|Up to the year 2005, the vast majority of ophthalmologists used Argon laser trabeculoplasty (ALT) as the mode of laser therapy. ALT is effective but its most significant problem is that its effectiveness decreases with re-treatment since the tissue it targets (the trabecular meshwork) is changed by the laser rendering repeat treatments less effective.
3130058|NCT01687465|Active Comparator|selective laser trabeculoplasty|Post 2005, a newer mode of laser therapy, selective laser trabeculoplasty (SLT) has emerged as the standard of care laser. There are many potential advantages to SLT but to date these advantages are only theoretical. The most important potential clinical advantage of SLT is that it causes less damage to the tissue it targets.
3130059|NCT01687452|Experimental|Groupe A|Infected by the HIV Innocents of antiretroviral treatment, with a viral plasmatique load > 1000 copies / ml
3130060|NCT01687452|Experimental|group B|Infected by the HIV whith antiretroviral treatment for at least 6 months,, with a viral plasmatique load > 40 copies / ml
3130061|NCT01687452|Placebo Comparator|group C|Healthy volunteers
3130062|NCT01687439|Experimental|Treatment|Eligible patients receive one cycle of Endostar monotherapy, two cycles of Endostar combined with chemotherapy (vinorelbine plus cisplatin) treatment, followed by Endostar plus radiotherapy treatment.
3130063|NCT01687426|Active Comparator|Brimonidine Tartrate 0.025%|
3130064|NCT01687426|Placebo Comparator|Vehicle|
3130065|NCT01687413|Experimental|Radiotherapy|"Patients undergo postoperative IMRT once daily, 5 days a week, for 6 weeks. The prescribed radiotherapy dose will be 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions).~Patients can consent to participate in either the randomized (physician chooses radiotherapy arm or radiotherapy & cisplatin arm) or non-randomized (patient chooses radiotherapy arm or radiotherapy & cisplatin arm) pathways"
3130066|NCT01687413|Active Comparator|Radiotherapy, cisplatin|"Patients undergo postoperative IMRT once daily, 5 days a week, for 6 weeks. The prescribed radiotherapy dose will be 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions)~Patients also receive cisplatin 40 mg/m2 IV on Days 1, 8, 15, 22, 29, and 36 of radiation therapy (6 doses for a total of 240 mg/m2).~Patients can consent to participate in either the randomized (physician chooses radiotherapy arm or radiotherapy & cisplatin arm) or non-randomized (patient chooses radiotherapy arm or radiotherapy & cisplatin arm) pathways"
3130067|NCT01687400|Experimental|Decitabine|Patients receive decitabine IV over 1 hour on days 1-10 of a 28-day cycle. Treatment continues for 2 cycles. Patients then receive decitabine IV over 1 hour on days 1-10, 1-5, or 1-3 (depending on response). Treatment continues in the absence of disease progression or unacceptable toxicity.
3130073|NCT01687361|Experimental|branched-chain amino acids (BCAA) supplementation|
3130074|NCT01687361|Placebo Comparator|PLACEBO|
3130075|NCT01687348|Experimental|lidocaine|lidocaine traitment
3130076|NCT01687335||cancerous patients|the patients benefiting from treatment by chemotherapy.
3130077|NCT01687322||total hip replacement, quality of life, functioning|
3130078|NCT01687309|Other|Cohort A fed session|GSK2586184 800mg single dose with food
3130079|NCT01687309|Other|Cohort A fasted session|GSK2586184 single dose without food
3130080|NCT01687309|Active Comparator|Cohort B active study medication|GSK2586184 800mg single and twice daily dose for 13 days
3130081|NCT01687309|Placebo Comparator|Cohort B placebo|Placebo-to-match single and twice daily dose for 13 days
3130082|NCT01687296|Experimental|fluticasone Nebules/placebo tablet|2×0.5mg/2ml twice daily neblulized/placebo tablet, oral, once daily
3130083|NCT01687296|Active Comparator|oral prednisone/placebo inhalation solution|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) / placebo inhalation solution nebulized twice daily
3130084|NCT01687283|Experimental|fluticasone propionate|1 mg BID inhalation via nebulizer
3130085|NCT01687283|Active Comparator|budesonide suspension|2 mg BID inhalation via nebulizer
3130086|NCT01687270|Experimental|SOF+RBV|Participants will receive sofosbuvir+RBV for 24 weeks.
3130087|NCT01687257|Experimental|SOF+RBV|Participants will receive SOF+RBV for 48 weeks.
3130088|NCT01687257|Experimental|Observation, then SOF+RBV|Participants will undergo 24 weeks of observation and then receive SOF+RBV for 48 additional weeks.
3130089|NCT01687244|Experimental|rAd-IFN Dose 1x10^11vps/ml|Subjects will be randomly assigned to one of two INSTILADRIN arms.
3130090|NCT01687244|Experimental|rAd-IFN dose 3x10^11 vps/ml|Subjects will be randomly assigned to one of two INSTILADRIN arms.
3130091|NCT01687231|No Intervention|Neutropenic Diet|This arm is the control and subjects will receive the standard of care neutropenic diet.
3130092|NCT01687231|Experimental|Non-neutropenic Diet|This arm is interventional and subjects will receive a non-neutropenic diet without restriction.
3130093|NCT01687218|Active Comparator|Group 1|Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
3130094|NCT01687218|Active Comparator|Group 2|Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
3130095|NCT01687218|Active Comparator|Group 3|Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks)
3130096|NCT01687218|Active Comparator|Group 4|Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
3130097|NCT01687218|Active Comparator|Group 5|Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
3130098|NCT01687218|Active Comparator|Group 6|Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks);followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks)
3130099|NCT01687205|Active Comparator|Group 1|Single Dose/BAT Cohort
3130100|NCT01687205|Active Comparator|Group 2|Multiple Dose Cohort
3130101|NCT01687192|Experimental|Girls and young womens receiving immunosuppressive treatment|
3130102|NCT01687179|Experimental|Rapamycin and Hydroxychloroquine|Subjects will take sirolimus at an initial dose of 2mg followed by dose adjustment to keep sirolimus trough levels between 5-15ng/ml consistent with the effective dose in the MILES trial. In addition to sirolimus subjects will receive hydroxychloroquine at 200 mg daily or twice a day for 6 months, depending on time of enrollment into the study, following a standard phase I dose escalation.
3130103|NCT01687166|Experimental|Blazer Open-Irrigated Ablation Catheter|Blazer Open-Irrigated Ablation Catheter and Ablation Catheter Cable used in conjunction with a compatible electroanatomic mapping system
3130104|NCT01687166|Active Comparator|FDA Approved Open-Irrigated Ablation Catheter|FDA approved Open-Irrigated Radiofrequency Ablation Catheter system and compatible electroanatomic mapping system for the treatment of paroxysmal atrial fibrillation.
3130105|NCT01687153||Traumatic Brain Injury (TBI)|65-100 Vietnam Veterans with Traumatic Brain Injury (TBI), but without PTSD, mild cognitive impairment (MCI)/dementia
3130106|NCT01687153||Post Traumatic Stress Disorder (PTSD)|65-100 Vietnam Veterans with PTSD, but without TBI, MCI/dementia
3130107|NCT01687153||Controls|65-100 Vietnam Veteran Controls without TBI or PTSD and comparable in age, gender, and education to the other cohorts
3130108|NCT01687153||TBI w/ MCI|65-100 Vietnam Veterans with TBI but without PTSD who meet the criteria for MCI but not dementia
3130109|NCT01687153||PTSD w/ MCI|65-100 Vietnam Veterans with PTSD but without TBI who meet the criteria for MCI but not dementia
3130110|NCT01687153||Controls w/ MCI|65-100 Vietnam Veteran Controls without TBI or PTSD who meet the criteria for MCI but not dementia, and are comparable in age, gender, and education to the other cohorts
3130111|NCT01687140|Placebo Comparator|Placebo|Participant takes one pill of placebo a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
3130112|NCT01687140|Active Comparator|DCS|Participant takes one pill of D-Cycloserine a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
3130155|NCT01686815||Olanzapine|Olanzapine-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
3130270|NCT01686152|Placebo Comparator|Vehicle|Vehicle of Test Product (Teva)
3232842|NCT00965666|Experimental|Open Label|
3130113|NCT01687127|Experimental|Folic acid supplementation|Folic acid will be given orally in form of tablets. A supplement of 1 mg will be taken daily for 12 weeks. Thereafter, a supplement of 5 mg will be taken daily for 12 weeks (i.e., until Week 24). At baseline, Week 12, and Week 24, subjects will receive a 9-hour primed constant infusion of amino acids in saline solution for quantification of kinetics of one-carbon metabolism.
3130114|NCT01687127|Experimental|5-MTHF supplementation|"The calcium salt of 5-methyltetrahydrofolate (5-MTHF; Brand name Metafolin) will be given orally in form of tablets. A supplement of 1 mg will be taken daily for 12 weeks. Thereafter, a supplement of 5 mg will be taken daily for 12 weeks (i.e., until Week 24). At baseline, Week 12, and Week 24, subjects will receive a 9-hour primed constant infusion of amino acids in saline solution for quantification of kinetics of one-carbon metabolism."
3130115|NCT01687114|Experimental|cranberry juice|27% cranberry juice
3130116|NCT01687101|Experimental|STOPAIN topical gel|STOPAIN gel which is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
3130117|NCT01687088||chronic migraineurs|At least 8 migraine days per week and headache at least 15 days per month.
3130118|NCT01687088||controls|No significant headache or disability as defined by migraine disability scale.
3130119|NCT01687075|Experimental|CR8|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
3130120|NCT01687062|Active Comparator|FeSO4 + high phytate|injera test meal 1 labeled with a 4 mg staple iron isotope tag
3130121|NCT01687062|Experimental|FeSO4 + medium phytate|injera test meal 2 labeled with a 4 mg staple iron isotope tag
3130122|NCT01687062|Experimental|FeSO4 + low phytate|injera test meal 3 labeled with a 4 mg staple iron isotope tag
3130123|NCT01687062|Experimental|FeSO4 + NaFeEDTA (1:1) + high phytate|injera test meal 4 labeled with a 4 mg staple iron isotope tag
3130124|NCT01687062|Experimental|FeSO4 + NaFeEDTA (1:3) + high phytate|injera test meal 5 labeled with a 4 mg staple iron isotope tag
3130125|NCT01687049|Experimental|red yeast rice (RYR)|Two RYR capsules three times daily for a minimum of 6 months
3130126|NCT01687036|Other|Cryoablation|Cryoablation
3130127|NCT01687023||Tai Chi|Healthy Tai Chi practitioners
3130128|NCT01686997|Active Comparator|Primairy long biliopancreatic limb RYGB|Roux limb 75 cm and Biliopancreatic Limb 150 cm
3130129|NCT01686997|Active Comparator|Redo Long biliopancreatic limb RYGB|Roux limb 75 cm and Biliopancreatic limb 150 cm
3130130|NCT01686997|Active Comparator|Primairy standard RYGB|Roux limb 150 cm and Biliopancreatic limb 75 cm
3130131|NCT01686997|Active Comparator|Redo standard RYGB|Roux limb 150 cm and Biliopancreatic limb 75 cm
3130132|NCT01686984|Experimental|Altered breath|The group where the investigators alter the inspiratory and expiratory aspects of a ventilated breath.
3130133|NCT01686971||questionaire|patients will receive a questionaire and speak to a nurse regarding their needs and/ or demands.
3130134|NCT01686958|Experimental|MR-Guided Transurethral US Ablation|MR-Guided Transurethral US Ablation of Prostate Tissue
3130135|NCT01686945|Experimental|Healthy - 20 mg|
3130136|NCT01686945|Experimental|Healthy - 40 mg|
3130137|NCT01686945|Experimental|Healthy - 60 mg|
3130138|NCT01686945|Experimental|T2D - 20/40/60 mg|
3130139|NCT01686932|Experimental|Vildagliptin followed by Sitagliptin|Period 1: vildagliptin 50mg BID for 8 weeks; followed by Washout then Period 2: sitagliptin 100mg QD for 8 weeks
3130140|NCT01686932|Experimental|Sitagliptin followed by Vildagliptin|Period 1: sitagliptin 100mg QD for 8 weeks; followed by Washout then Period 2: vildagliptin 50mg BID for 8 weeks
3130141|NCT01686919|Experimental|milk-free|morbidly obese patients with irritable bowel syndrome (IBS) eligible for gastric bypass surgery
3130142|NCT01686906|Experimental|Bowman layer graft implantation|
3130143|NCT01686893|Active Comparator|Standard Nasal Insufflation of oxygen|Standard Nasal Insufflation of oxygen
3130144|NCT01686893|Active Comparator|Nasal oxygen insufflation with a TNI 20 oxy device|Nasal oxygen insufflation with a TNI 20 oxy device
3130145|NCT01686880|Experimental|Preoperative aTARE|The patients in this arm will receive Sirsphere trans-arterial radioembolization before surgery
3130146|NCT01686867|Experimental|Commercially-made followed by locally-made improved cookstove|Following a four month run-in period using their traditional, open-fire cookstoves, the investigators will install a commercially-made improved, ventilated cookstove (Envirofit G-3300/G-3355) in each patient's kitchen. Four months later the investigators will install a locally-made improved, ventilated cookstove in each patient's kitchen. During each of the two periods, the investigators will request that the patient uses the improved, ventilated cookstove installed for that period.
3130147|NCT01686867|Experimental|Locally-made followed by commercially-made improved cookstove|Following a four month run-in period using their traditional, open-fire cookstoves, the investigators will install a locally-made improved, ventilated cookstove in each patient's kitchen. Four months later the investigators will install a commercially-made improved, ventilated cookstove (Envirofit G-3300/G-3355) in each patient's kitchen. During each of the two periods, the investigators will request that the patient uses the improved, ventilated cookstove installed for that period.
3130148|NCT01686854|Experimental|Cognitive Behavioral (B)|a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.
3130149|NCT01686854|Active Comparator|Prescriptive Diet (A)|prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
3130150|NCT01686841|Experimental|Fat Reduction|
3130151|NCT01686828|Experimental|Acyline & placebo gel & placebo pill|Acyline (300mcg/kg) + placebo transdermal gel + placebo pill daily
3130152|NCT01686828|Experimental|Acyline & Testosterone 1.25g & placebo pill|Acyline (300mcg/kg) + Testosterone gel (1.25g) daily + placebo pill daily
3130153|NCT01686828|Experimental|Acyline & Testosterone 5g & placebo pill|Acyline (300mcg/kg) + Testosterone gel (5g) daily + placebo pill daily
3130154|NCT01686828|Experimental|Acyline & Testosterone & Letrozole|Acyline (300mcg/kg) + Testosterone gel (5g) daily + letrozole (5mg) daily
3232843|NCT00965653|Experimental|1|
3130156|NCT01686815||Risperidone|Risperidone-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
3130157|NCT01686815||Iloperidone|Iloperidone-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
3130158|NCT01686802|Active Comparator|ibuprofen|ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 8 doses) from the time the patient is discharged from hospital as deemed by the physician to a maximum of 48 hours.
3130159|NCT01686802|Active Comparator|oral morphine|oral morphine 0.5 mg/kg (max 20 mg) every 6 hours as needed for pain (maximum 8 doses) from the time the patient is discharged from hospital as deemed by the physician to a maximum of 48 hours.
3130160|NCT01686789|Active Comparator|Pegylated interferon alpha-2a plus standard dose ribavirin|Pegylated interferon alpha-2a 180 mcg weekly plus standard dose ribavirin 100-1200 mg/day for 48 weeks
3130161|NCT01686789|Experimental|Pegylated interferon alpha-2a 180 mcgs adjusted dose ribavirin|Pegylated interferon alpha-2a 180 mcg weekly plus adjusted dose ribavirin for 48 weeks
3130162|NCT01686776|Active Comparator|123 I-HSA + 125 I-HSA|Healthy Volunteers, N=16
3130163|NCT01686776|Experimental|123 I- HSA + 125 I-HSA|Patients, planned for elective Major Abdominal Surgery, N=16
3130164|NCT01686776|Experimental|123-I-HSA+125 I-HSA|Patients, with a acute pancreatitis or cholecystitis, N=16
3130165|NCT01686763||subarachnoid hemorrhage disease|subarachnoid hemorrhage patients
3130166|NCT01686750|Experimental|Integrated care centers|"Integrated care centers will provide HIV prevention and treatment services to high risk populations of IDU or MSM in an accepting and supportive environment.~HIV voluntary counseling and testing & staging~Risk reduction services including free condoms, needle and syringe exchange, opiate substitution therapy~Substance abuse counseling~Sexually transmitted infection screening and treatment~Access to free antiretroviral therapy and adherence support~Peer community outreach"
3130167|NCT01686750|No Intervention|Standard services|In Standard Services sites, HIV testing, prevention, and treatment services will be available through standard venues. Government centers typically provide most HIV testing services and are the only source for free antiretroviral therapy. Non-governmental organizations typically provide prevention and risk reduction services.
3130168|NCT01686737|Experimental|Yoga|"Iyengar Yoga~12 weeks of Iyengar yoga~2 weekly sessions of 60 minutes"
3130169|NCT01686737|Active Comparator|Aerobic exercise|"Walking~12 weeks of walking~2 weekly sessions of 60 minutes"
3130170|NCT01686737|No Intervention|Usual Care|
3130171|NCT01686724|Other|Business as Usual (BAU)|This group receives services as usual in their schools. They will receive the intervention after follow-up measures are gathered.
3130172|NCT01686724|Experimental|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
3130173|NCT01686711|Experimental|SYR-322 25 mg , AD-4833 15 mg|
3130174|NCT01686711|Experimental|SYR-322 25 mg , AD-4833 30 mg|
3130175|NCT01686711|Placebo Comparator|SYR-322 25 mg , AD-4833 placebo|
3130176|NCT01686698|Active Comparator|VSL#3 (Original De Simone formulation)|VSL#3 (Original De Simone formulation) sachets containing 450 x 109 bacteria, 1 sachet every 12 hours during 3 months (n=20).
3130177|NCT01686698|Placebo Comparator|Placebo|Placebo sachets, 1 sachet every 12 hours during 3 months (n=20).
3130178|NCT01686672|Experimental|Web Intervention|BeInCharge has two components: an electronic diet tracker and a 7 session intervention. The 7 treatment sessions are designed to be completed over a 7 to 10 week period. Each treatment module includes both a nutrition education and child behavior management component. Treatment sessions should be completed every 7 to 10 days, while the electronic diet tracker requires daily input.
3130179|NCT01686672|No Intervention|Usual Care|Participants will receive usual care and be assessed at baseline and week 10 for study outcomes.
3130180|NCT01686659|Experimental|SpHb Arm|These are the patients whose primary anesthesiologists have been allocated to treat them while having access to data from a continuous noninvasive hemoglobin monitoring device
3130181|NCT01686659|No Intervention|Control Arm|These are the patients whose primary anesthesiologists have been allocated to treat them without having access to data from a continuous noninvasive hemoglobin monitoring device
3130182|NCT01686646|Active Comparator|highest dose Paracetamol + caffeine|highest dose of Paracetamol and caffeine
3130183|NCT01686646|Active Comparator|low-dose Paracetamol + caffeine|lowest dose of Paracetamol and caffeine
3130184|NCT01686646|Active Comparator|high dose paracetamol|highest dose paracetamol
3130185|NCT01686646|Active Comparator|low dose paracetamol|lowest dose paracetamol
3130186|NCT01686633|Experimental|Arm1: Fluticasone Furoate/ Vilanterol 200/25 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF/ VI 200/25 mcg once daily in the evening for 84 days.
3130187|NCT01686633|Experimental|Arm 2: Fluticasone Furoate/ Vilanterol 100/25 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF/ VI 100/25 mcg once daily in the evening for 84 days
3130188|NCT01686633|Experimental|Arm 3: Fluticasone Furoate 100 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF 100 mcg once daily in the evening for 84 days
3130189|NCT01686620|Experimental|BIOD-123|BIOD-123 used as prandial insulin
3130190|NCT01686620|Active Comparator|Lispro (Humalog)|Lispro (Humalog) used as prandial insulin
3130191|NCT01686607||1) parenteral micafungin users|patients who had been treated with parenteral micafungin
3130192|NCT01686607||2) other parenteral antifungal users|patients who had been treated with a parenteral antifungal agent (not micafungin)
3130193|NCT01686594|Active Comparator|PUVA maintenance treatment|Psoralen plus UVA (PUVA) treatment. The patients receive a standardized dose of oral 8-methoxypsoralen (Oxsoralen) 1 hour before UVA exposure
3130195|NCT01686581||Patients with Chronic Migraine Prescribed BOTOX®|Onabotulinumtoxin A (BOTOX®) administered according to physician prescription; all treatment decisions lie with the physician.
3130196|NCT01686568|Experimental|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
3130197|NCT01686568|Placebo Comparator|Placebo|Patients in this group will be supplemented with placebo capsules containing ethyl oleate.
3130198|NCT01686555|Experimental|Single Dose|Subjects enrolled in the Single Ascending Dose (SAD) part of the study will receive a single dose of study drug or placebo. (Groups 1, 2, 3, 4, 5 and 6).
3130199|NCT01686555|Experimental|Multiple Dose|Subjects enrolled in the Multiple Ascending Dose (MAD) part of the study will receive multiple doses of study drug or placebo. (Groups 7, 8, 9, 10 and 11)
3130200|NCT01686542|Experimental|CPVI+RSM group|Circumferential pulmonary vein isolation (CPVI) plus renal sympathetic modification for atrial fibrillation ablation.
3130201|NCT01686542|Active Comparator|CPVI group|Circumferential pulmonary vein isolation is done alone for atrial fibrillation.
3130202|NCT01686529|Experimental|One subconjunctival injection|Autoconjunctival grafting and one subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery
3130203|NCT01686529|Experimental|Two subconjuctival injections|Autoconjunctival grafting and subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery, with another injection 15 days after surgery
3130204|NCT01686529|Active Comparator|Conventional treatment|Autoconjunctival grafting without subconjuntival bevacizumab injection
3130205|NCT01686503|Experimental|2/5 dose intradermal IPV|Participants in this arm will receive 2/5 dose (0.2 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one-time dose intradermally using the NanoPass MicronJet 600 microneedle device
3130206|NCT01686503|Experimental|1/5 dose intradermal IPV|Participants in this study arm will receive 1/5 dose (0.1 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intradermally using the NanoPass MicronJet 600 microneedle device.
3130207|NCT01686503|Active Comparator|full dose intramuscular IPV|Participants in this study arm will receive the standard full dose (0.5 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.
3130208|NCT01686503|Active Comparator|2/5 dose intramuscular IPV|Participants in this study arm will receive 2/5 dose (0.2 mL) inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.
3130209|NCT01686490|Other|D.|The focus is evaluation of LifeSkills Video/Workbook for patients about to receive an AICD. Patients who now have received their AICD were given a video/workbook pre-implantation as an intervention to reduce their concerns/distress. After implantation, they will be asked what was and was not helpful about the materials they received.
3130210|NCT01686477|Active Comparator|Unfortified Human Donor Milk|Used to make up any shortfall in mother's own milk
3130211|NCT01686477|Active Comparator|Fortified Human Donor Milk|Used to make up any shortfall in mother's own milk
3130212|NCT01686477|Active Comparator|Preterm Formula|Used to make up any shortfall in mother's own milk
3130213|NCT01686464|Experimental|Magnetic - Oxygen|Magnetic and Oxygen Treatment for Bell's Palsy
3130214|NCT01686464|Active Comparator|prednisone - valacyclovir|prednisone and valacyclovir treatments for bell palsy
3130215|NCT01686451|Experimental|XueZhiKang|Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
3130216|NCT01686451|Active Comparator|Simvastatin|Participants will receive 20mg of simvastatin daily for 4 weeks.
3130217|NCT01686438|Experimental|CBT-I delivery by video teleconferencing|Groups of participants will receive a cognitive behavioral therapy for insomnia program delivered by a trained psychologist using video teleconferencing.
3130218|NCT01686438|Active Comparator|In-person CBT-I delivery|Groups of participants will receive a cognitive behavioral therapy for insomnia (CBT-I) program by meeting in-person with a trained psychologist.
3130219|NCT01686425|Active Comparator|Percutaneous Transhepatic cholangiography|
3130220|NCT01686425|Active Comparator|Endoscopic Ultrasound guided biliary drainage|
3130221|NCT01686412|Active Comparator|Healthy patients|
3130222|NCT01686412|Active Comparator|Oncology patients|
3130223|NCT01686399|Experimental|The study has a single arm|The study has one arm The whole population of the campus will be exposed to the intervention. the effectiveness will be assessed using a random selection twice - before and after the intervention
3130224|NCT01686386|Experimental|Dose escalation benda lena dexa|"Phase I: Participants will be treated in groups (cohorts) of three to six subjects per cohort, according to a modified Fibonacci design. The dose of Bendamustine and Lenalidomide (from 0 to 5) will be increased from one cohort to the next. Regardless of the treatment cohort, participants will receive treatment in cycles lasting 28 days. In the first phase of the study, the dose of B and L given with will be gradually escalated to reach the MTD.~Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days."
3130225|NCT01686373|Experimental|Activa Dose II Real tDCS|Actual delivery of electrical stimulation
3130226|NCT01686373|Placebo Comparator|Activa Dose II Sham tDCS|Sham delivery of electrical stimulation
3130227|NCT01686360|No Intervention|Control group 1: pre/post-test|Group receives pre and post test questions only.
3130228|NCT01686360|Experimental|Control group 2: tool and pre/post-test|Group receives decision tool without personalized information. (Behavioral: Decision Aid)
3130229|NCT01686360|Experimental|Gail score in a percentage format|Group receives Gail score in a percentage format. (Behavioral: Decision Aid)
3130230|NCT01686360|Experimental|Gail score in a frequency format|Group receives Gail score in a frequency format. (Behavioral: Decision Aid)
3130231|NCT01686360|Experimental|Frequency + Average 50 year old|Group receives Gail score in a frequency format as well as information about risk of breast cancer for the average 50 year old woman. (Behavioral: Decision Aid)
3130232|NCT01686360|Experimental|Frequency + Mammography Data|Group receives Gail score in a frequency format as well as information about the risks of mammography. (Behavioral: Decision Aid)
3130233|NCT01686360|Experimental|Frequency + Mortality Data|Group receives Gail score in a frequency format as well as information about mortality benefit of mammography. (Behavioral:Decision Aid)
3130312|NCT01685853|Active Comparator|PEG 4 litres split|Polyethylene glycol with electrolytes (PEG)
3133085|NCT01667198|Active Comparator|Audit and feedback|
3130234|NCT01686360|Experimental|Frequency + Avg 50 year old + Mamm Data + Mortality Data|Group receives Gail score in a frequency format as well as information about breast cancer risk for the average 50 year old woman, information about the risks of mammography, risk of breast cancer for the average 50 year old woman, and information about the mortality benefit associated with mammography. (Behavioral: Decision Aid)
3130235|NCT01686347|Other|fetal cardiac rhythm abnormally|patient at term, in spontanous labor with fetal cardiac rythm abnormally which occurs 30 minutes after the epidural analgesia induction
3130236|NCT01686347|Other|control group|patient at term, spontaneous labor, without any fetal cardiac rhythm abnormalies during the 30 minutes after the epidural analgesia induction
3130237|NCT01686334|Experimental|DC vaccine|Vaccination with autologous WT1 mRNA-electroporated DCs plus follow-up care. Patients receiving hypomethylating agents are allowed to continue this treatment in combination with DC vaccination.
3130238|NCT01686334|No Intervention|Control arm|Follow-up care. Patients receiving hypomethylating agents are allowed to continue this treatment during the follow-up care
3130239|NCT01686321|Experimental|Bendamustine and subcutaneous Rituximab|single-arm non randomized
3130240|NCT01686308|Active Comparator|Conventional Intra Ocular Lens (IOL)|Standard minimal incision cataract surgery by phacoemulsification and posterior intraocular lens implantation.
3130241|NCT01686308|Experimental|Yellow Intra Ocular Lens (IOL)|Standard minimal incision cataract surgery by phacoemulsification and posterior intraocular lens implantation.
3130242|NCT01686295|Experimental|iRestore Hair Rejuvenation System|Seventy six (76) subjects will be enrolled in the 24-week study; of which 38 will be male and 38 will be female using the iRestore hair growth device
3130243|NCT01686295|Sham Comparator|Sham Device Arm|This study arm will use a sham device consistent with the experimental device with 12 men and 12 women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
3130244|NCT01686282|Placebo Comparator|Placebo|8 weeks of freeze-dried blueberry powder taken in two doses of 22g each per day.
3130245|NCT01686282|Experimental|Blueberry|8 weeks of freeze-dried blueberry powder taken in two doses of 22g each per day.
3130246|NCT01686256|Experimental|Tc 99m EC20|A Phase 1, multi-center, open-label, single-treatment group, baseline-controlled (for safety) study designed to verify product safety, determine optimal imaging time, gather efficacy data for the radioactive drug product (Technetium Tc 99m EC20), and assay masses for presence of folate receptors, in women with suspected ovarian or endometrial cancer. Twelve subjects will be enrolled, with a minimum of five malignant cases, as determined by histopathological evaluation.
3130247|NCT01686243|Experimental|"echogenic 17G tuohy needles  Pajunk TuohySono"|Epidural will be placed with the aid of ultrasound and echogenic 17G Tuohy needles (Pajunk TuohySono).
3130248|NCT01686243|Placebo Comparator|standard epidural needles|Epidural will be placed in standard practice with standard needles.
3130249|NCT01686230|Experimental|acupoints on specific meridian|Acupuncture plus foundation treatment。 We Select specific acpupoints on the heart and pericardium meridian.
3130250|NCT01686230|Active Comparator|acupoints on the other meridian|Acupuncture plus foundation treatment。We choose the acupoints on the other meridian。
3130251|NCT01686230|Sham Comparator|sham acupoints|Acupuncture plus foundation treatment。We use sham acupoints。
3130252|NCT01686230|Other|waiting-list|wait for the treatment，Only basic treatment, We will not treat the participants until they complete all the observations.
3130253|NCT01686217|Experimental|Dose Group 1 Treatment A|Lowest per tablet dose of ASP015K Extended Release (ER) tablets under fasted conditions
3130254|NCT01686217|Active Comparator|Dose Group 1 Treatment B|Medium per tablet dose ASP015K Immediate Release (IR) tablets under fasted conditions for comparison to lowest dose ER fasted conditions
3130255|NCT01686217|Experimental|Dose Group 1 Treatment C|Lowest per tablet dose of ASP015K ER tablets under fed conditions
3130256|NCT01686217|Experimental|Dose Group 2 Treatment D|Medium per tablet dose of ASP015K ER tablets under fasted conditions
3130257|NCT01686217|Active Comparator|Dose Group 2 Treatment E|Medium per tablet dose of ASP015K IR tablets under fasted conditions for comparison to medium dose ER fasted conditions
3130258|NCT01686217|Experimental|Dose Group 2 Treatment F|Medium per tablet dose of ASP015K ER tablets under fed conditions
3130259|NCT01686217|Experimental|Dose Group 3 Treatment G|Highest per tablet dose of ASP015K ER tablets under fasted conditions
3130260|NCT01686217|Active Comparator|Dose Group 3 Treatment H|Medium per tablet dose of ASP015K IR tablets under fasted conditions for comparison to highest dose ER under fasted conditions
3130261|NCT01686217|Experimental|Dose Group 3 Treatment I|Highest dose of ASP015K ER tablets under fed conditions
3130262|NCT01686204|Active Comparator|Non-obese individuals|Daily consumption of 12 oz lowfat yogurt or soy pudding for 9 weeks.
3130263|NCT01686204|Experimental|Obese individuals|Consumption of 12 oz of soy pudding or low fat dairy yogurt daily for 9 weeks.
3130264|NCT01686191||Cardiac transplant recipients|
3130265|NCT01686178|Experimental|Anti-smoking social marketing campaign|"In prior research, a high risk subpopulation of young adults was identified in San Diego, CA: the hipster subculture. We developed a yearlong pilot social branding intervention to decrease smoking among this group, using social events and social leaders to promote a strong nonsmoking lifestyle. The intervention rationale is based on utilizing industry market research tools to define the target audience and directly countering tobacco industry lifestyle marketing strategies. We now propose to extend this intervention to three other cities (tailoring the intervention to a high-risk subpopulation of young adults in each city) and evaluate it in a multicenter quasi-experimental controlled trial."
3130266|NCT01686178|No Intervention|Control|Survey research data will be collected in control cities with the same schedule as data collection in the cities where the intervention is taking place.
3130267|NCT01686165|Experimental|Belinostat Yttrium Ibritumomab Tiuxetan|Patients receive belinostat IV over 30-60 minutes on days 1-5. Treatment with belinostat repeats every 21 days for 2 courses. Patients then receive rituximab IV on days 1 and either 7, 8, or 9, and yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
3130268|NCT01686152|Experimental|Investigational Test Product|Imiquimod Cream, 3.75% (Teva)
3130269|NCT01686152|Active Comparator|Reference Listed Drug|Zyclara® (imiquimod Cream), 3.75% (Medicis)
3232844|NCT00965653|Active Comparator|2|
3130271|NCT01686139|Experimental|ABDM-MSC|"The patient will receive multiple injections in one session during the study. The injections will take place in the chronic wound bed and in the third distal part of the treated shin (in the form of a ring).~Maximal amount of ABMD-MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight)."
3130272|NCT01686126|Experimental|Mirena + Metformin|Metformin tablets, 500mg twice daily orally, 6 months Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months
3130273|NCT01686126|Experimental|Mirena|Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months
3130274|NCT01686126|Experimental|Mirena + Weight Loss Intervention|Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months Weight Loss Intervention will be delivered via Weight Watchers
3130275|NCT01686113|Experimental|NEFA|Participants swish and spit 5 mL of an oleic acid solution everyday for 10 days.
3130276|NCT01686113|Active Comparator|Control|Participants swish and spit 5 mL of sucrose solution everyday for 10 days.
3130277|NCT01686100|Active Comparator|No touch vein grafts|The grafts were harvested with there surrounding tissues.
3130278|NCT01686100|Active Comparator|Conventional vein grafts.|The grafts were stripped from surrounding tissue.
3130279|NCT01686087|Active Comparator|Continuation of SRI|Patients who achieve minimal to mild OCD symptoms and are not currently depressed at end of preparatory phase will be randomized to stay on SRI. They will receive 45 minute EX/RP booster sessions once per month.
3130280|NCT01686087|Placebo Comparator|Replace SRI w/placebo|Patients who achieve minimal to mild OCD symptoms and are not currently depressed at end of preparatory phase will be randomized to gradual replacement with pill placebo. They will receive 45 minute EX/RP booster sessions once per month.
3130281|NCT01686074||Chronic fatigue syndrome|
3130282|NCT01686074||fibromyalgia|
3130283|NCT01686074||chronic fatigue syndrome + fibromyalgia|
3130284|NCT01686074||healthy sedentary control|
3130285|NCT01686061||Blepharospasm Survey Group|
3130286|NCT01686022||Pollen Allergy|Pollen allergy and control will have the same intervention, ie. Skin prick test and collect serum samples.Then measure the specificIgE, immunoblot, and ELISA inhibition
3130287|NCT01686009|Experimental|Intra-nasal ketamine|0.5 mg/kg ketamine intra-nasally; then 0.25 mg/kg repeat dose after 10 minutes if necessary
3130288|NCT01685996|Experimental|zonisamide|participants will receive zonisamide capsules (up to 300 mg) to take once a day.
3130289|NCT01685996|Placebo Comparator|Placebo|Participants will receive placebo capsules to take once a day
3130290|NCT01685983|Experimental|Abiraterone actetate and Prednisolone|
3130291|NCT01685970|Placebo Comparator|High volume Split-dose PEG|Patients who are scheduled afternoon colonoscopy ingest high volume split-dose PEG for bowel preparation
3130292|NCT01685970|Active Comparator|2 sachets of picosulfate|Patients who are scheduled afternoon colonoscopy ingest 2 sachets of picosulfate at the day of colonoscopy.
3130293|NCT01685957|Active Comparator|Standard dietary treatment (STD)|Dietary treatment - 6 individual sessions with a registered dietitian
3130294|NCT01685957|Experimental|"Ned i vaegt (NIV)"|Dietary treatment - 3 individual sessions and 3 group sessions. All sessions with a registered dietitian.
3130295|NCT01685957|Experimental|"Verdens bedste kur (VBK)"|Dietary treatment - 3 individual sessions and 3 group sessions. All sessions with a registered dietitian.
3130296|NCT01685944|Placebo Comparator|Placebo|
3130297|NCT01685944|Experimental|Live Pediococcus pentosaceus LP28|
3130298|NCT01685944|Experimental|Heat-killed Pediococcus pentosaceus LP28|
3130299|NCT01685931|Experimental|Paliperidone Palmitate|
3130300|NCT01685892|Experimental|Dose-Finding: Schedule A: Relapsed/Refractory CLL|All 4 cohorts will begin venetoclax administration after the ramp-up period of 5 weeks. In 4 cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before obinutuzumab. Schedule A will be explored prior to Schedule B.
3130301|NCT01685892|Experimental|Dose-Finding: Schedule B: Relapsed/Refractory CLL|In 4 cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after obinutuzumab. Schedule A will be explored prior to Schedule B.
3130302|NCT01685892|Experimental|Dose-Finding: Schedule A: Previously Untreated CLL|All 4 cohorts will begin venetoclax administration after the ramp-up period of 5 weeks. In 4 cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before obinutuzumab. Schedule A will be explored prior to Schedule B.
3130303|NCT01685892|Experimental|Dose-Finding: Schedule B: Previously Untreated CLL|In 4 cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after obinutuzumab. Schedule A will be explored prior to Schedule B.
3130304|NCT01685892|Experimental|Safety Expansion: Relapsed/Refractory CLL|In participants with relapsed/refractory CLL a recommended dose of venetoclax will be administered in combination with obinutuzumab in the safety expansion stage. Schedule A or B will be used for the expansion cohort after a review of available safety data from the dose finding stage.
3130305|NCT01685892|Experimental|Safety Expansion: Previously Untreated CLL|In participants with previously untreated CLL a recommended dose of venetoclax will be administered in combination with obinutuzumab in the safety expansion stage. Schedule A or B will be used for the expansion cohort after a review of available safety data from the dose finding stage.
3130306|NCT01685879|Experimental|High Amylose Rice 1|Test rice with high dietary fiber content
3130307|NCT01685879|Experimental|High Amylose Rice 2|Test rice with high dietary fiber content
3130308|NCT01685879|Placebo Comparator|Control Rice|Rice portion that contains 50 g carbohydrate.
3130309|NCT01685879|Placebo Comparator|Glucose beverage|Glucose beverage with 50 g carbohydrate
3130310|NCT01685866|Other|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
3130311|NCT01685866|No Intervention|no medical device|in the second arm, we use no medical device
3133086|NCT01667185||Pediatric subjects with diabetes mellitus|
3130313|NCT01685853|Experimental|Bisacodyl plus PEG-CS|Bisacodyl plus PEG-CS: Bisacodyl plus Polyethylene glycol with citrate and simethicone (PEG-CS)
3130314|NCT01685840|Experimental|Usual Care|Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.
3130315|NCT01685840|Experimental|Biomarker-Guided Care|Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.
3130316|NCT01685827|Active Comparator|NECT (Nifurtimox Eflornithine Combination Therapy)|"Nifurtimox tablets will be given orally three times a day, at the daily dose of 15 mg/kg/day, for 10 days.~Eflornithine (400 mg/kg/day) will be given twice daily for 7 days, as a 2-hour IV infusion."
3130317|NCT01685827|Experimental|Fexinidazole|"Fexinidazole, 600 mg tablets given by oral route, after the main daily meal (within 30 minutes from the start of the meal), at the daily dose of:~1 800 mg (3 tablets) once a day for 4 days,~Followed by 1 200 mg (2 tablets) once a day for 6 days. Total duration of treatment will be 10 days."
3130318|NCT01685814|Active Comparator|single stem cell transplant, 3-year lenalidomide maintenance|Arm A
3130319|NCT01685814|Experimental|tandem autologous transplant, lenalidomide maintenance|Arm B
3130320|NCT01685814|Active Comparator|allogeneic stem cell transplant, lenalidomide maintenance|Arm C
3130321|NCT01685814|Experimental|tandem autologous transplant|Arm D
3130322|NCT01685801|Experimental|Ivacaftor, Placebo, Ivacaftor, Placebo (IPIP)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
3130323|NCT01685801|Experimental|Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
3130324|NCT01685801|Experimental|Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
3130325|NCT01685801|Experimental|Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
3130326|NCT01685788||study participants|
3130327|NCT01685775|Experimental|Transvaginal/transumbilical cholecystectomy|Transvaginal/transumbilical group: we will use a 5 mm trocar in the umbilicus and a 10 mm trocar together with a 5 mm seizing forceps through the posterior vaginal vault to perform the cholecystectomy in the Zornig style
3130328|NCT01685775|Active Comparator|Needlescopic cholecystectomy|Needlescopic cholecystectomy with 3 trocars: we will use two 2-3 mm working trocars and one 10 mm optic trocar, its access is also used for extraction of the gallbladder
3130329|NCT01685762|Experimental|Metformin|Metformin once daily for 4 weeks (weeks 1-4) and then twice daily for 8 weeks (weeks 5-12).
3130330|NCT01685749||Enrolled participants|The targeted study population will include all people at Seal Beach who have been identified by the Seal Beach Lifeguards to have been stung by a jellyfish over the course of one year who are adults or children whose parent or guardian is present at the time of the injury. Children and pregnant women are included in the group.
3130331|NCT01685723|Experimental|Counseling group|"Subjects in this group will receive a face-to-face individualized brief advice based on risk communication for 15-30 minutes from the nurse counselors and a booster intervention (10-15 minutes) at 1 week.~Data collection will be conducted at 1 week, 1, 3, 6, 9, 12 months via telephone.Ten subjects from the intervention group who have not quitted will be invited for a process evaluation in the form of face-to-face interviews by research assistants at 12-month follow-up."
3130332|NCT01685723|Sham Comparator|General supporting|"Subjects in this group will receive standard care without risk communication.~Data collection will be conducted at 1 week, 1, 3, 6, 9, 12 months via telephone."
3130333|NCT01685710|Experimental|GTN patch|GTN patch 5mg, in situ 24hrs
3130334|NCT01685710|Placebo Comparator|Placebo patch|Placebo patch, in situ for 24hrs
3130335|NCT01685697|Active Comparator|Laerdal Mask|Mask ventilation with a Laerdal face mask
3130336|NCT01685697|Experimental|F&P Mask|Mask ventilation with a F&P face mask
3130337|NCT01685684|Experimental|Oxycodone DETERx|
3130338|NCT01685684|Placebo Comparator|Placebo|
3130339|NCT01685671|Active Comparator|NESP 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
3130340|NCT01685671|Experimental|CKD-11101 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
3130341|NCT01685658|Active Comparator|Ketaprofen|"Patients randomized to this arm will receive intravenous ketaprofen when treating renal colic.~Intervention: intravenous ketaprofen"
3130342|NCT01685658|Experimental|Paracetamol|"Patients randomized to this arm will receive intravenous paracetamol when treating renal colic.~Intervention: intravenous paracetamol"
3130343|NCT01685645|Experimental|Study population|"The study population consists of male and female patients admitted for programmed major knee surgery (arthroplasty) with a truncal analgesic block (femoral nerve block with a sciatic block) and operated under general anesthesia.~See inclusion and exclusion criteria.~Intervention: AlgiScan"
3130344|NCT01685632|Active Comparator|Surgery with IPCH|Patients having an IPCH (Intra Peritoneal Chemo Hyperthermia) during the surgery time
3130345|NCT01685632|Sham Comparator|patients without IPCH|Patients recused for the surgery due to intraoperative contraindication
3130346|NCT01685619||AML Cohort|This cohort is comprised of participants who have acute myelogenous leukemia (AML).
3130347|NCT01685619||MDS Cohort|This cohort is comprised of participants who have myelodysplastic syndrome (MDS).
3130348|NCT01685606|Experimental|cellular immunotherapy|A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor will be infused, irrespective of the number of CD34+ cells.
3130349|NCT01685593|Sham Comparator|regular bandage|no abdominal binder
3130350|NCT01685593|Experimental|abdominal binder|binder
3130351|NCT01685580|Experimental|Manufacturer VPAP ST|7 days minimum non-invasive ventilation at 2 levels of pressure (BPAP) to the intervention.
3130352|NCT01685580|No Intervention|No intervention|usual advice
3130353|NCT01685567|Experimental|MICHI NPS+f|The MICHI™ NPS+f is a flow reversal circuit consisting of two proprietary sheaths connected by standard surgical tubing. The sheaths each have a standard hemostasis valve and sidearm. An in-line flow regulator allows the clinician to modify to the flow through the circuit (either high flow or low flow) in addition to permitting temporary cessation of flow.
3130354|NCT01685554|Active Comparator|normothermic CPB|cardiopulmonary bypass with maintenance of normal body temperature
3130355|NCT01685554|Active Comparator|hypothermic CPB|cardiopulmonary bypass using mild hypothermia
3130356|NCT01685541|Experimental|Maximum AVS Content|AVS includes patient name, visit date, chief complaining, allergies, immunizations, vital signs, medications, problem list, lab order, physician contact information, referrals, instructions
3130357|NCT01685541|Experimental|Intermediate AVS content|AVS includes patient name, visit date, vital signs, medications, diagnosis, problem list, physician contact information, referrals, instructions
3130358|NCT01685541|Experimental|Minimum AVS content|AVS contains patient name, visit date, medications, diagnosis, physician contact information, referrals, instructions
3130359|NCT01685541|Active Comparator|Control Group (Usual AVS)|Content differed by clinic site
3130360|NCT01685528|Experimental|CBT|
3130361|NCT01685515|Experimental|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Tetrahydrouridine
3130362|NCT01685515|Placebo Comparator|Placebo|Placebo
3130363|NCT01685502||Group 1|Patients treated with Glucobay OD under practical manner
3130364|NCT01685489|Experimental|Docetaxel, PSK®|A 21-day lead-in oral PSK alone is followed by the addition of standard intravenous docetaxel at 75 mg/m2 evey 3 weeks for three cycles. After the third dose of docetaxel, study drug will be discontinued on day 14 to allow for a 7-day washout period before a fourth dose of docetaxel is administered.
3130365|NCT01685489|Placebo Comparator|Docetaxel, Placebo|A 21-day lead-in oral placebo alone is followed by the addition of standard intravenous docetaxel at 75 mg/m2 every 3 weeks for three cycles. After the third dose of docetaxel, the placebo will be discontinued on day 14 to allow for a 7-day washout period before a fourth dose of docetaxel is administered.
3130366|NCT01685476|Other|Intracranial pressure|
3130367|NCT01685463|Experimental|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive brain stimulation technology that can focally stimulate the brain of an awake individual. The brain stimulation techniques could theoretically improve the efficacy of smoking cessation.
3130368|NCT01685463|Placebo Comparator|Sham Transcranial Magnetic Stimulation|Sham-TMS procedures: After rTMS determination, participants were fitted with two electrodes on the scalp just below the hairline. Electrodes will be connected to an Epix VT Transcutaneous Electrical nerve stimulation device.
3130369|NCT01685450|Other|Intracranial pressure|
3130370|NCT01685437|Experimental|AA4500|collagenase clostridium histolyticum
3130371|NCT01685424||Etoricoxib Prescription (Period 1)|First Etoricoxib Prescription, Apr. 1, 2002 to Feb. 17, 2005
3130372|NCT01685424||Etoricoxib Prescription (Period 2)|First Etoricoxib Prescription, Feb. 18, 2005 to Dec. 31, 2015
3130373|NCT01685424||Repeat Etoricoxib Prescription|One prescription during the Period 1 and, at least, one etoricoxib prescription during Period 2.
3130374|NCT01685411|Experimental|Allogeneic Hematopoietic Stem Cell Transplant|Patients treated with Allopurinol, Keppra, Busulfan, Cyclophosphamide, Filgrastim, antithymocyte globulin, Tacrolimus, Mycophenolate mofetil and allogeneic hematopoietic stem cell transplant infusion.
3130375|NCT01685398|Placebo Comparator|normal saline|normal saline 1-2 drops put on the hemangioma lesion 4 times a day and rub over the entire lesion with a finger
3130376|NCT01685398|Experimental|0.5% timolol maleate eye drop|0.5% timolol maleate solution 1-2 drops put on the hemangioma lesion 4 times a day and rub over the entire lesion with a finger
3130377|NCT01685385|Active Comparator|Diagnostic intervention group A|Patients who will receive the BNP test
3130378|NCT01685385|No Intervention|Group B|Patients who will not receive the BNP test.
3130379|NCT01685372|Experimental|Fluzone High Dose|Fluzone High Dose 0.5 mL intramuscularly (IM) given once
3130380|NCT01685372|Active Comparator|Fluzone|Fluzone 0.5mL IM given once
3130381|NCT01685359|Experimental|Test Drug|Test Drug (Human Recombinant Epoetin alfa - Blau) dosage: 100 IU/kg intravenous administration
3130382|NCT01685359|Active Comparator|Eprex|Eprex (Janssen-Cilag, Epoetin alfa) dosage: 100 IU/kg intravenous administration
3130383|NCT01685346|Experimental|Biofeedback|biofeedback-mediated stress management (BFSM)
3130384|NCT01685333|Other|Group A|First Period: Test Drug (Epoetin Alfa) Second Period: Comparator Drug
3130385|NCT01685333|Other|Group B|First period: Comparator drug Second Period: Test drug (Epoetin alfa)
3130386|NCT01685320|Active Comparator|Direct laryngoscope|Includes cases in which the forces applied by Macintosh direct laryngoscope onto soft tissue of the pharynx during glottis visualization and intubation were measured.
3130387|NCT01685320|Active Comparator|Indirect laryngoscope|Includes cases in which the forces applied by GlideScope indirect laryngoscope onto soft tissue of the pharynx during glottis visualization and intubation were measured.
3130388|NCT01685307|Experimental|intense cooking process|Test meal: 150g of beef cooked at intense temperature. Beef proteins are intrinsically labelled with 15 N protein
3130389|NCT01685307|Experimental|mild cooking process|Test meal: 150 g of beef cooked at moderate intensity. Beef proteins are intrinsically labeled with 15N.
3130390|NCT01685294|No Intervention|Treatment as Usual (TAU)|Standard prison mental health treatment instead of the research groups, including individual therapy, medication, etc.
3233606|NCT00960258|Experimental|Arm 1|
3130391|NCT01685294|Experimental|Group Interpersonal Psychotherapy (IPT) for Depression + TAU|Participants will receive Group IPT for Depression + TAU.
3130392|NCT01685281|Active Comparator|Metadoxine (MG01CI) 1400 mg|single dose of Metadoxine (MG01CI) 1400 mg
3130393|NCT01685281|Active Comparator|Metadoxine (MG01CI) 700 mg|Single dose of Metadoxine (MG01CI) 700 mg
3130394|NCT01685281|Placebo Comparator|Placebo|Single dose of Placebo
3130395|NCT01685268|Experimental|Part A, Regimen 1|AT13387 given as a 1-hr IV infusion at a starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle, in combination with abiraterone acetate 1000 mg by mouth (PO) daily (QD) and prednisone or prednisolone 5 mg PO twice daily.
3130396|NCT01685268|Experimental|Part A, Regimen 2|At13387 administered as a 1-hr IV infusion at a starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle, in combination with abiraterone acetate 1000 mg by mouth (PO) daily (QD) and prednisone or prednisolone 5 mg PO twice daily.
3130397|NCT01685255|Active Comparator|INCB024360|Subjects randomized to Arm A (INCB024360) will take INCB024360 tablets at a dose of 600 mg BID, beginning on Day 1.
3130398|NCT01685255|Active Comparator|Tamoxifen|Subjects randomized to Arm B (tamoxifen) will take tamoxifen tablets at a dose of 20 mg BID, beginning on Day 1.
3130399|NCT01685242|Experimental|AC-170 0.24%|
3130400|NCT01685242|Placebo Comparator|AC-170 0%|
3130401|NCT01685229||Balloon Sinus Dilation|Subjects with chronic sinusitis electing to have a balloon sinus dilation
3130402|NCT01685229||Medical Management|Subjects with chronic sinusitis electing to continue with medical therapy
3130403|NCT01685216|Experimental|velaglucerase alfa|IV infusion, 60 U/kg, every other week for 1 year
3130404|NCT01685203|Experimental|Group 1|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants
3130405|NCT01685203|Experimental|Group 2|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve HCV GT1b-infected participants
3130406|NCT01685203|Experimental|Group 3|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, HCV GT1b-infected, pegylated-interferon/ribavirin (pegIFN/RBV) treatment null responder participants
3130407|NCT01685203|Experimental|Group 4|ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants
3130408|NCT01685203|Experimental|Group 5|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-experienced, HCV GT4-infected participants
3130409|NCT01685203|Experimental|Group 6|ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, HCV GT4-infected, pegylated-interferon/RBV (pegIFN/RBV) treatment-experienced participants
3130410|NCT01685203|Experimental|Group 7|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, treatment-naïve participants with compensated cirrhosis
3130411|NCT01685203|Experimental|Group 8|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, pegylated-interferon/RBV(pegIFN/RBV) treatment-experienced participants with compensated cirrhosis
3130412|NCT01685190|Active Comparator|Prostate Alone IMRT|Participants will receive standard prostate Intensity Modulated Radiotherapy (IMRT) of 74Gy in 37 fractions delivered over 7.5 weeks.
3130413|NCT01685190|Experimental|Prostate & Pelvis IMRT|Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
3130414|NCT01685177||SADI|Patients submitted to a second-step operation after a failed sleeve on which a single-anastomosis duodena-ileal bypass at 250 cm from the cecum is performed.
3130415|NCT01685164||LNG-IUS|Nulliparous women
3130416|NCT01685164||Cu-IUD|Nulliparous women
3130417|NCT01685151|Experimental|Ramelteon SL (Dose 1)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 12 months.
3130418|NCT01685151|Experimental|Ramelteon SL (Dose 2)|Ramelteon SL tablets, sublingual, once daily, at nigh time for up to 12 months
3130419|NCT01685151|Placebo Comparator|Placebo|Ramelteon SL placebo-matching tablets, sublingual, once daily, at night time for up to 12 months.
3130420|NCT01685138|Experimental|LDK378|Oral LDK378 750 mg once daily
3130421|NCT01685125|Active Comparator|Arm A (abiraterone acetate, prednisone)|Abiraterone acetate 1000 mg PO QD and Prednisone 5 mg PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3130422|NCT01685125|Experimental|Arm B (abiraterone acetate, prednisone, dasatinib)|Abiraterone acetate 1000 mg PO QD, Prednisone 5 mg PO BID, and dasatinib 100 mg PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3130423|NCT01685112||Conventional Group|Patients who developed refractory shock, but didn't received ECMO as salvage treatment
3130424|NCT01685112||ECMO group|Patient who have septic shock, and progreseed to have ECMO as salvage therapy
3130425|NCT01685099||Group with tuberculous pleurisy|
3130426|NCT01685099||Group with non-tuberculous pleurisy|
3130427|NCT01685086||Patients with severe chronic kidney disease|
3130428|NCT01685086||Patient with peritoneal dialysis|
3130429|NCT01685086||Patients with hemodialysis|
3130430|NCT01685073|Experimental|Zolpidem|Participants receive active zolpidem nightly in addition to psychosocial therapy during 12-week treatment of a cannabis use disorder
3130431|NCT01685073|Placebo Comparator|Placebo|Participants receive placebo medication during a 12-week psychosocial treatment for a cannabis use disorder
3130432|NCT01685060|Experimental|LDK378|Patients treated with ceritinib/LDK378 750 mg once-daily, fasted
3130433|NCT01685047||Merlin.net|Group 1 uses Merlin.net for remote monitoring, i.e. scheduled follow ups every 6 months in clinic, collection of ST Segment, ATP and Shock Therapy delivered alerts via Merlin.net.
3130434|NCT01685047||Non Merlin.net|"Group 2 will not use Merlin.net, i.e. scheduled follow ups every 3 months in clinic for alert review during device interrogation.~The use of Merlin.net will be per physician's preference."
3131501|NCT01677871|Experimental|9HLE|Isoniazid+ Levofloxacin+ Ethambutol for 9 months
3130435|NCT01685034|Experimental|Allergy Immunotherapy Group|There is only one active experimental group as this is a pilot study comparing clinical/histologic/endoscopic changes before and after treatment.
3130436|NCT01685021|Experimental|MOR00208 (formerly Xmab5574)|intravenous Infusion of MOR00208, Fc-optimized Anti-CD19 Antibody
3130437|NCT01685008|Experimental|MOR00208 (formerly Xmab5574)|intravenous Infusion of MOR00208, Fc-Optimized Anti-CD19 Antibody
3130438|NCT01684995|Active Comparator|Minimal|Brief physician advice to quit smoking plus nicotine patch
3130439|NCT01684995|Experimental|Tailored|
3130440|NCT01684982|Experimental|everolimus eluting stent|second generation drug eluting stent
3130441|NCT01684982|Active Comparator|sirolimus eluting stent|first generation drug eluting stent
3130442|NCT01684969|Active Comparator|intravenous haloperidol|intravenous haloperidol pharmacokinetics
3130443|NCT01684969|Placebo Comparator|Placebo|
3130444|NCT01684956|Experimental|Intradermal first|Intradermal injection experiment first, followed by subcutaneous injection experiment
3130445|NCT01684956|Experimental|Subcutaneous first|Subcutaneous injection experiment first, followed by intradermal injection experiment
3130446|NCT01684943|Experimental|Multiplex pharmacokinetic profiling|Multiplex pharmacokinetic profiling of regular human insulin, insulin aspart, insulin lispro, insulin glulisine, and regular human insulin
3130447|NCT01684943|Experimental|Continuous insulin monitoring|Continuous insulin monitoring of insulin lispro
3130448|NCT01684930|Experimental|BR Juice (Beet-It Stamina Shot) and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of beetroot juice and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
3130449|NCT01684930|Placebo Comparator|BR Juice Placebo and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot; Placebo) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of placebo beverage and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot (Placebo) 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
3130450|NCT01684917|Experimental|Life style advice|reduce energy intake by 20% less than estimated energy expenditure.
3130451|NCT01684917|Active Comparator|UK background diet|Diet where energy intake will be matched with estimated energy expenditure.
3130452|NCT01684917|Other|Metabolomic inquiry|This inquiry took place prior to the randomized controlled trial and include 50 volunteers who will then be asked to volunteers of the weight loss study. Were randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option.
3130453|NCT01684904|Experimental|Proton radiation|Proton radiation
3130454|NCT01684891|Experimental|RG1662|
3130455|NCT01684878|Experimental|Part 1: Pertuzumab + Topotecan|Participants received pertuzumab and topotecan in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.
3130456|NCT01684878|Experimental|Part 1: Pertuzumab + Paclitaxel|Participants received pertuzumab and paclitaxel in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.
3130457|NCT01684878|Experimental|Part 2: Pertuzumab+Chemotherapy|Participants received pertuzumab and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
3130458|NCT01684878|Placebo Comparator|Part 2: Placebo+Chemotherapy|Participants received pertuzumab matching placebo and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
3130459|NCT01684865||Non-Hodgkin's Lymphoma Participants|Participants initiated on rituximab maintenance therapy according to the standard of care and in line with the current summary of product characteristics will receive rituximab for maximum two years or until disease progression. Participants will be followed for one year after last dose of rituximab administered as maintenance.
3130460|NCT01684839|Other|new surgical treatment|Treatment of Painful Digital Neuroma Using A Pedicled Nerve Flap taken from the homolateral dorsal branch of the digital nerve.
3130461|NCT01684826|Experimental|ClarityIQ|Angiographic run with new algorithm and low dose (50% dose)
3130462|NCT01684826|Experimental|AlluraXper|Angiographic run with predecessor algorithm and dose (100% dose)
3130463|NCT01684813|Active Comparator|Clopidogrel|This group will receive after PCI the standard dose of clopidogrel, a daily dose of 75 mg.
3130464|NCT01684813|Experimental|Prasugrel|This group will receive after PCI a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by a daily dose of prasugrel (10 mg tablet).
3130465|NCT01684800|Active Comparator|A. Desmopressin 10 microgram|
3130466|NCT01684800|Active Comparator|B. Desmopressin 25 microgram|
3130467|NCT01684800|Placebo Comparator|C. Placebo|
3130468|NCT01684787|Experimental|1|Peginterferon alfa-2a + ribavirin in normal ALT
3130469|NCT01684787|Active Comparator|2|peginterferon alfa-2a + ribavirin in elevated ALT
3130470|NCT01684774||I. USG|Patients receiving Ultrasound-guided Ankle Block
3130471|NCT01684774||II. ALG|Patients receiving Anatomic Landmark-guided Ankle Block
3130472|NCT01684761|Experimental|Tcelna|30-45 x 10E6 total cells in 2 ml. Subjects receive two annual courses of 5 subcutaneous doses each year (at 0, 4, 8, 12 and 24 weeks).
3130473|NCT01684761|Placebo Comparator|Placebo|Tcelna inactive ingredients (without cells) totaling 2 ml per dose. Administered subcutaneously with same two year treatment regimen as experimental treatment arm.
3130589|NCT01683890||Simple hysterectomy group|Patients will undergo simple hysterectomy due to benign uterine disease.
3130474|NCT01684748|Experimental|Olmesartan Medoxomil first, then No Drug|During the First Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects receive additional daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), no drug will be administered to the subjects.
3130475|NCT01684748|Experimental|No Drug first, then Olmesartan Medoxomil|During the First Intervention (8 weeks), no drug will be administered to the subjects. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects then receive daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period.
3130476|NCT01684735||women with breast cancer and chemotherapy|women recently diagnosed with breast cancer and selected to start with neo-adjuvant chemotherapy (6 cycles) before surgery/therapy
3130477|NCT01684722|Active Comparator|Vitamin D + fish oil|Vitamin D and omega-3 fatty acids (fish oil)
3130478|NCT01684722|Active Comparator|Vitamin D + fish oil placebo|Vitamin D and fish oil placebo
3130479|NCT01684722|Active Comparator|Vitamin D placebo + fish oil|Vitamin D placebo and omega-3 fatty acids (fish oil)
3130480|NCT01684722|Placebo Comparator|Vitamin D placebo + fish oil placebo|Vitamin D placebo and fish oil placebo
3130481|NCT01684709|Experimental|Telemonitoring + self-management support|Automated assessment calls with follow-up by a Care Manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up.
3130482|NCT01684709|No Intervention|Usual Care|Usual Care
3130483|NCT01684696|Experimental|mHealth TLC|"The mhealth TLC group will meet with a nurse before each of 4 clinician visits and use the mHealth TLC on an iPad with an interactive 3-dimensional intervention that allows individuals to experience virtual visits with their clinicians. Key aspects of mHealthTLC include informational videos about lung cancer and LCS. Blame and self-blame will be addressed, information about the role of addiction, social/cultural factors, and tobacco industry influence on smoking behaviors will be highlighted. Patients will experience practiced interaction in ever increasing complex situations with avatars (i.e., receptionist, medical assistant, and clinician). A virtual coach will accompany the patient through the virtual visit and will provide information and coaching (as needed)."
3130484|NCT01684696|Active Comparator|Attention Control|Attention control group (ACG) - Patients assigned to the ACG will meet with a nurse and receive only the informational videos on an iPad before 4 clinician visits with assessments after each clinician visit. An effort will be made to match the intervention condition on salience, credibility, and contact time.
3130485|NCT01684683|Experimental|Theophylline|Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks
3130486|NCT01684683|Placebo Comparator|placebo|Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks
3130487|NCT01684670|Experimental|Behavioral speech treatment|
3130488|NCT01684657|Placebo Comparator|Placebo|This is the comparator. Placebo will be matched to color, taste, size, and smell.
3130489|NCT01684657|Experimental|Asenapine|This is an atypical antipsychotic that blocks dopamine and increases serotonin. The dosage will be from 2.5 to 10mg daily throughout the study.
3130490|NCT01684644|Experimental|New Forest Parenting Programme|The New Forest Parenting Programme is a parent training programme specifically developed to treat ADHD in preschool children. The programme is delivered as an 8 week intervention for individual parents and their child.
3130491|NCT01684644|Other|Treatment as Usual|Treatment as usual for preschool ADHD consists of psychoeducation groups for parents.
3130492|NCT01684631||Hip arthroplasty|Patients implanted with a PINNACLE® ULTAMET™ Metal-on-Metal implant for conventional total hip arthroplasty for the treatment of a severe hip disease or true femoral cervical fracture.
3130493|NCT01684618|Experimental|Cerebral NIRS oximetry + CPAP|Cerebral NIRS oximetry, using the INVOS Cerebral/Somatic Oximeter, and changes in regional cerebral oxygen saturation, rSO2, during induced changes in CPAP flow pressure
3130494|NCT01684605|Active Comparator|NESP 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
3130495|NCT01684605|Experimental|CKD-11101 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
3130496|NCT01684592|Active Comparator|Standard care|Standard care for smokers during pregnancy and referral to 24/7 quitline postpartum (passive)
3130497|NCT01684592|Experimental|Standard care plus PPCC|Standard care for smoking during pregnancy and proactive phone-based postpartum continuing care (PPCC) for 6 months postpartum
3130498|NCT01684579|Experimental|Exercise and psychosocial counseling|Patients will participate in a psychosocial counseling session, 1 day/week for 20 weeks. Patients will be invited to participate in a progressive aerobic and resistance exercise program designed to achieve moderate and then vigorous levels of exercise, 5 days/week for 20 weeks.
3130499|NCT01684566|Experimental|Standard-Of-Care + episil(R)|Standard-Of-Care plus episil® administered as three consecutive pump-strokes for a total volume of 0.45 mL applied 3 times daily and additionally, as needed
3130500|NCT01684566|Other|Standard-Of-Care|Oral hygiene procedures
3130501|NCT01684553|Experimental|Slow eating condition|The subjects were asked to eat their meal slowly during the slow eating condition
3130502|NCT01684553|Active Comparator|Fast eating condition|The subjects were asked to eat their meal quickly during the fast eating condition
3130503|NCT01684527||Children Suffering From Bronchiolitis|Respiratory secretions obtained from children suffering from Bronchiolitis
3130504|NCT01684527||Healthy Children|Respiratory secretions obtained from children with no respiratory infection
3130505|NCT01684514|Experimental|colitis, ulcerative|Enrolled patients will be examined by conventional colonoscopy and confocal laser endomicroscopy before and after initiation of topical treatment, respectively.
3130506|NCT01684514|Sham Comparator|Control group|A control group will be examined by conventional colonoscopy and confocal laser endomicroscopy.
3130507|NCT01684501||Amputees|Adults with history of traumatic unilateral transtibial amputation
3133087|NCT01667172|Other|point-of-care test for CRP|
3130508|NCT01684488|Active Comparator|Waitlist+EducAid|Immediately following enrollment, participants do not immediately receive any intervention. At 3 months, they are enrolled in EducAid educational programming for the 2012-2013 academic year.
3130509|NCT01684488|No Intervention|Waitlist|Participants do not receive any intervention throughout the trial period. Once the trial has concluded, participants are invited to enroll in EducAid educational programming for the 2013-2014 academic year.
3130510|NCT01684488|Experimental|YRI only|Immediately following enrollment, participants complete the YRI. They are then placed on a waitlist for the remainder of the trial. At the end of the trial, participants are invited to enroll in EducAid educational programming for the 2013-2014 academic year.
3130511|NCT01684488|Experimental|YRI+EducAid|Immediately following enrollment, participants complete the YRI. Participants are then immediately enrolled in EducAid educational programming for the 2012-2013 academic year.
3130512|NCT01684475|Experimental|Treatment with CJH1|
3130513|NCT01684462|Experimental|Human Serum Albumin 20|Human Serum Albumin 20% 100cc intravenously infused over 4~8h
3130514|NCT01684462|Placebo Comparator|0.9 % Normal saline|Treatment with same volume of normal saline
3130515|NCT01684449|Experimental|Phase 2: Experimental Arm|Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).
3130516|NCT01684436|Experimental|Punctal plug|Punctal plugs inserted into the study eye on Day 1.
3130517|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) tablet, OD, Age: 12 - <18|Subjects aged from 12 - <18 years were administered with age and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR (immediate-release) tablet once daily (OD) under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kilogram (kg) received a dose (equivalent to 20 milligram [mg] in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
3130518|NCT01684423|Active Comparator|Comparator, Age: 12 - <18 years|Subjects aged from 12 - <18 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
3130519|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) tablet, OD, Age: 6 - <12 years|Subjects aged from 6 - <12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kg received a dose (equivalent to 20 mg in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
3130520|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) suspension, BID, Age: 6 - <12 years|Subjects aged from 6 - <12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily (BID). Subjects with a body weight of 9 to less than 50 kg received a total daily dose (equivalent to 20 mg in adults) ranging from 6.4 to 15 mg and subjects with a body weight of greater than or equal to 50 kg received a total daily dose of 20 mg.
3130521|NCT01684423|Active Comparator|Comparator, Age: 6 - <12 years|Subjects aged from 6 - <12 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or INR-adjusted (vitamin K antagonist).
3130522|NCT01684410|Experimental|Alpha-1 HC 100 mg|100 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.
3130523|NCT01684410|Experimental|Alpha-1 HC 200 mg|200 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.
3130524|NCT01684410|Placebo Comparator|Placebo|Placebo inhaled daily via nebulizer for 3 weeks. Placebo (phosphate buffer saline with polysorbate).
3130525|NCT01684397|Experimental|Treatment (pazopanib hydrochloride and bevacizumab)|Patients receive pazopanib hydrochloride PO on days 1-28 and bevacizumab IV over 30-90 minutes on days 36 and 50. Courses repeat every 70 days in the absence of disease progression or unacceptable toxicity.
3130526|NCT01684384|Experimental|No treatment|CT-scans will be taken in the study. The EC of the University hospital antwerp considers this as an intervention.
3130527|NCT01684371||Blue Dotted Elmore Oil|Patients applied the above oil 3 times daily for four weeks and on the fifth week stopped the application completely for the flush out period before switching to Orange Dotted Elmore Oil
3130528|NCT01684371||Orange Dotted Elmore Oil|Patients give this oil applied it three times daily on the affected knees for four weeks and on the fifth week, stopped the application totally for the flush out period before switching to the Blue Dotted Elmore Oil.
3130529|NCT01684358|Experimental|Immediate implant|Sino-implant (II) inserted at enrollment visit
3130530|NCT01684358|Active Comparator|Delayed implant|Sino-implant (II) inserted at 3-month follow-up visit
3130531|NCT01684345|Placebo Comparator|Placebo|
3130532|NCT01684345|Experimental|Dose 1 gevokizumab|
3130533|NCT01684345|Experimental|Dose 2 gevokizumab|
3130534|NCT01684332|Experimental|High Sugar (HS)|Study of the postprandial effects after consuming 60g of strawberry jam with high sugar content
3130535|NCT01684332|Experimental|Low Sugar (LS)|Study of the postprandial effects after consuming 60g of strawberry jam with low sugar content
3130536|NCT01684332|Experimental|Low Sugar + Antioxidant (LSA)|Study of the postprandial effects after consuming 60g of strawberry jam with low sugar content and an antioxidant extract from strawberry pulp
3130537|NCT01684319|Placebo Comparator|Infant formula milk|Infant formula milk adapted to age of infant
3130538|NCT01684319|Active Comparator|Formula milk free of milk proteins|Milk-free formula milk adapted to age of infant
3130539|NCT01684306|Experimental|Placebo|Study subjects received, in a double blind fashion, a placebo pill identical to the drug.
3130540|NCT01684306|Experimental|Modafinil|"Modafinil (Provigil), a drug on the market since 1997, is employed for the treatment of narcolepsy and other sleep disorders. In recent years, modafinil has also been used off-label to treat cognitive dysfunction in psychiatric disorders such as schizophrenia and Attention Deficit/Hyperactivity Disorder (ADHD).~Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil."
3130541|NCT01684293|Experimental|Cognitive Rehabilitation|Occupational therapy-based cognitive rehabilitation
3130542|NCT01684293|Placebo Comparator|Psychoeducation/games|Psychoeducation/games
3130543|NCT01684280||gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
3130544|NCT01684267|Experimental|Healthy|Healthy individuals
3130545|NCT01684267|Experimental|Post-stroke|Chronic stroke survivors
3130546|NCT01684254||Children with Cerebral Palsy (CP)|
3130547|NCT01684241|Experimental|RBL001/RBL002 intranodal administration|"All participants will be treated with RBL001/RBL002 after allocation to one of the four escalating dose cohorts:~Cohort-1 50 µg RBL001 and 50 µg RBL002~Cohort-2 100 µg RBL001 and 100 µg RBL002~Cohort-3 300 µg RBL001 and 300 µg RBL002~Cohort-4 600 µg RBL001 and 600 µg RBL002"
3130548|NCT01684215|Experimental|Single-agent PD-0332991|Phase 1 Part 1
3130549|NCT01684215|Experimental|PD-0332991 in combination with letrozole|Phase 1 Part 2
3130550|NCT01684215|Experimental|PD-0332991 with letrozole|Phase 2
3130551|NCT01684202|Experimental|OPC-41061|
3130552|NCT01684189||Patient registry|Patients with newly diagnosed malignant hematological diseases will be enrolled into this registry
3130553|NCT01684176|Experimental|Complex tailored intervention|"The intervention consists of 3 elements:~Medication review with recommendations focused on antithrombotics and adherence to guidelines and patient´s adherence to medications.~Discharge consultation with an pharmacist using motivational interviewing techniques.~Follow-up telephone calls one week, two months and six months after discharge."
3130554|NCT01684176|Placebo Comparator|Usual care|Usual care
3130555|NCT01684163|Placebo Comparator|Placebo injection|Normal saline
3130556|NCT01684163|Experimental|GLYX-13, 5 mg/kg|Low dose of GLYX-13
3130557|NCT01684163|Experimental|GLYX-13, 10 mg/kg|High dose of GLYX-13
3130558|NCT01684150|Experimental|EPZ-5676 Extension cohort|
3130559|NCT01684137|Active Comparator|Joalis Bambi Bronchi & Joalis Bambi Analerg|10 days, 2 times per day 2,5/5 ml
3130560|NCT01684137|Placebo Comparator|Placebo & Placebo|10 days, 2 times per day 2,5/5 ml
3130561|NCT01684124|Placebo Comparator|standard care|normal treatment
3130562|NCT01684124|Active Comparator|conservative O2 therapy|a value of 90-92% O2 saturation will be targeted
3130563|NCT01684111|Experimental|BIBF 1120, Vinorelbine|"To determine the 'Maximum Tolerated Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle.~Under certain conditions the dose level will be escalated to 200mg bid in a second cohort."
3130564|NCT01684098|Other|Tc 99m EC20|
3130565|NCT01684085|Placebo Comparator|Encouragement to sleep|Encouraging explanation to sleep, rest and receiving Lorazepam 1mg in the first night post trauma
3130566|NCT01684085|Experimental|Encouragement to deprived sleep|Encouraging explanation to deprived sleep in the first night post trauma
3130567|NCT01684072|Experimental|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
3130568|NCT01684072|Active Comparator|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
3130569|NCT01684059||Single group|Single group: each participant receive same intervention (zinc sulfate) throughout study (non-randomized)
3130570|NCT01684046|Other|PureMoist - RevitaLens|Opti-Free® PureMoist® MPDS used first, followed by RevitaLens MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
3130571|NCT01684046|Other|RevitaLens - PureMoist|RevitaLens MPDS used first, followed by Opti-Free® PureMoist® MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
3130572|NCT01684033|Other|PureMoist - Biotrue|Opti-Free® PureMoist® MPDS used first, followed by Biotrue™ MPS. Each product used as indicated for 30 days with participant's habitual contact lenses.
3130573|NCT01684033|Other|Biotrue - PureMoist|Biotrue™ MPS used first, followed by Opti-Free® PureMoist® MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
3130574|NCT01684020|Experimental|ARTISS Human Fibrin Sealant|Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.
3130575|NCT01684020|No Intervention|Standard of Care|Fixation of the skin flap created during external rhinoplasty will use the standard of care
3130576|NCT01684007|Experimental|Bilateral|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
3130577|NCT01684007|Active Comparator|Contralateral|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0] and AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1, contralateral implantation
3130578|NCT01683994|Experimental|Phase 1|combination of cabozantinib, docetaxel and prednisone
3130579|NCT01683994|Active Comparator|PII/ Arm 1|docetaxel + prednisone only
3130580|NCT01683994|Active Comparator|PII/Arm 2|docetaxel+ prednisone + cabozantinib
3130581|NCT01683981|Experimental|L-Citrulline, Exercise Capacity|L-Citrulline malate, 1gr, oral, divided 3 times a day,for 2 weeks
3130582|NCT01683968||Sickle cell|Patient who are admitted with sickle cell crises
3130583|NCT01683955|Experimental|Tranexamic Acid|Topical tranexamic acid (2g/100mL) applied during unilateral total hip arthroplasty.
3130584|NCT01683955|Placebo Comparator|Placebo|100mL 0.9% NS, applied topically
3130585|NCT01683929|Active Comparator|Oral glucose tolerance test|The participants will consume a beverage containing 75 gram glucose During the meeting, the participants will drink the sweetened drink followed by blood work, at 0, 30, 60, 120, 180 minutes. Also, they will record their macronutrient\caloric consumption during the 24 hour following the test.
3130586|NCT01683929|Placebo Comparator|Artificial sweetner|"participants will consume a beverage containing 0.42 gram artificial sweetener (Aspartame) During each meeting, the participants will drink the sweetened drink followed by blood work, at 0, 30, 60, 120, 180 minutes.~Also, they will record their macronutrient\caloric consumption during the 24 hour following the test."
3130587|NCT01683903||Non coronary patients (NC)|Patient with myocardial infarction with non-coronary (NC) etiology
3130588|NCT01683903||Coronary patients (C)|Patients with myocardial infarction due to coronary disease
3134096|NCT01659892|Active Comparator|Montelukast|5 mg Chewable Tablet
3130590|NCT01683877|Experimental|FloSeal group|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
3130591|NCT01683877|Active Comparator|Electrocautery group|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
3130592|NCT01683864|Experimental|positive cytology with HIPEC|gastric cancer cytology positive with HIPEC Mytomycin and cisplatin intraoperative
3130593|NCT01683864|No Intervention|positive cytology without HIPEC|gastric cancer cytology positive without HIPEC
3130594|NCT01683864|No Intervention|negative cytology without HIPEC|gastric cancer with negative cytology
3130595|NCT01683838|Active Comparator|fampridine-SR 50mg/day|
3130596|NCT01683838|Placebo Comparator|Placebo|
3130597|NCT01683825|Experimental|F-18 florbetapir PET-Amyloid Subjects|Individuals with documented cardiac amyloidosis will undergo F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET).
3130598|NCT01683825|Other|F-18 florbetapir PET-Healthy Controls|Individuals without documented cardiac amyloidosis will undergo F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET).
3130599|NCT01683812|Experimental|Cranial Cup Arm|Single arm
3130600|NCT01683799|Experimental|Insomnia treatment|Cognitive Behavioral Therapy for Insomnia
3130601|NCT01683799|No Intervention|Control|
3130602|NCT01683786|Experimental|Pegintron + Riba for 36 wks in total|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day for 24 weeks (36 weeks in total HCV treatment)
3130603|NCT01683786|Active Comparator|Pegintron + Riba for 48 wks in total|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day for 36 weeks (48 weeks in total HCV treatment)
3130604|NCT01683773|Experimental|Group A|Two doses of AERAS-402 (1x10^11 vp intramuscular injection) followed by one dose of MVA85A (1x10^8 pfu intradermal injection)
3130605|NCT01683773|Experimental|Group B|One dose of AERAS-402 (1x10^11 vp intramuscular injection) followed by one dose of MVA85A (1x10^8 pfu intradermal injection)
3130606|NCT01683773|Experimental|Group C|Three doses of AERAS-402 (1x10^11 vp intramuscular injection)
3130607|NCT01683760|Experimental|Population PK|
3130608|NCT01683747|Experimental|Tranexamic acid|Study group receives enteral tranexamic acid in normal saline in addition to usual care.
3130609|NCT01683747|Placebo Comparator|Control group|Control group receives vehicle (normal saline) without study drug and usual care.
3130610|NCT01683734||Renal Function Observation|
3130611|NCT01683721||Winx|
3130612|NCT01683708||Symbiotic group|Jaundiced patients who have symbiotic therapy
3130613|NCT01683708||No Symbiotic therapy|Jaundiced patients who not have symbiotic therapy
3130614|NCT01683695|Active Comparator|AMG 557|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141 and Day 155.
3130615|NCT01683695|Placebo Comparator|AMG 557 Matching Placebo|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141 and Day 155.
3130616|NCT01683682|Experimental|BIBF 1120, Vinorelbine, Carboplatin|"To determine the 'Maximum Toleraetd Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle.~Under certain conditions the dose level will be escalated to 200mg bid in a second cohort."
3130617|NCT01683669|Other|Noisy-PSV 1|different levels of variable pressure support
3130618|NCT01683669|Other|Noisy-PSV 2|different levels of variable pressure support
3130619|NCT01683656|Active Comparator|ER Niacin/laropipant|ER niacin/laropiprant 1g/20 mg for the first 4 weeks and 2g/40mg from week 5 to the end of the study.
3130620|NCT01683656|Placebo Comparator|ER Niacin/laropipant Placebo|ER niacin/laropiprant placebo p.m.
3130621|NCT01683643|Experimental|SBIRT Group|Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Experimental subjects, in addition to their risk score and informational materials, will also receive a brief intervention and a referral to treatment appropriate to their risk score from trained health educators. The health educators will be provided by Homeless Health Care, Los Angeles.
3130622|NCT01683643|Active Comparator|Control Group|Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
3130623|NCT01683630||Confirmed influenza A and B cases|Cases of influenza A and B as diagnosed by PCR, viral culture or florescence microscopy
3130624|NCT01683617|Experimental|A treatment based on CBT and new technologies|Individuals will receive a treatment based on cognitive behavioral therapy and new technologies (virtual reality, virtual reality combined to biofeedback and mobile phones). Relaxation will be induced through the immersion in different virtual environments (e.g., lake) which will be customized with different pre-recorded audio narratives that describe the specific setting and that guide the execution of a series of relaxation exercises. During biofeedback exercises a wearable biosensor system will provide suggestions to the trainer based on the reactions of the participants, and the biosensor data will directly modify the virtual reality experience in real time.
3130625|NCT01683617|Active Comparator|Traditional treatment based on CBT|Participants will receive a treatment based on traditional cognitive behavioral therapy techniques for stress management, without the use of new technologies. Relaxation will be induced by guided imagery, through auditory narratives.
3130626|NCT01683604||Rheumatoid Arthritis (RA) Participants (All Groups)|Participants with severe RA were prescribed with tocilizumab in accordance with routine clinic practice, and were observed for 6 months.
3130627|NCT01683591||High-risk aspiration group|Among the consecutive stroke patients, categorized to high-risk group in the patient (1) was not on alert mentality (from drowsy to comatose mentality), (2) was not able to sit upright or control his/her head, and (3) failed to pass indirect water swallow test.
3130628|NCT01683591||Low-risk aspiration group|Patents without oropharyngeal neurologic signs
3130701|NCT01683019|Sham Comparator|Inactive Sham Treatment|Generate sound similar to active treatment, except that no magnetic field is generated.
3240217|NCT00912834||7|control group
3130629|NCT01683591||Intermediate-risk aspiration group|If any one of following was positive, categorized to intermediate-risk group; (1) dysarthria, (2) motor aphasia, (3) inability to close and open lips or (4) facial weakness, (5) tongue deviation or (6) uvula deviation, (7) loss of gag reflex, and (8) inability to cough voluntarily.
3130630|NCT01683578|Active Comparator|Variable Ventilation|Variable tidal volumes with mean at 8 mL/kg of predicted body weight
3130631|NCT01683578|No Intervention|Non-variable Ventilation|Conventional mechanical ventilation with tidal volume 8 mL/kg of predicted body weight
3130632|NCT01683565|Experimental|LCPUFA Oil Supplement|EPA + DHA + GLA + OA oil supplement
3130633|NCT01683565|Placebo Comparator|Canola Oil Placebo|
3130634|NCT01683552|Other|Aprepitant|Aprepitant is administered in patients ,affected by solid tumors treated with biological therapy, who did not receive any treatment for severe pruritus
3130635|NCT01683552|Other|Aprepitant after anti-itch standard therapy|Aprepitant will be administered in patient affected by severe itch resistant to standard treatment (steroids and/or antihistamines) administered for at least one week
3130636|NCT01683539|Experimental|The Thinking Skills for Work Program|The Thinking Skills for Work Program includes 5 components delivered by a Cognitive Specialist who works collaboratively with the consumer's Employment Specialist: a) assessing the consumer's strengths and weaknesses in cognitive functioning, and analysis of the contribution of cognitive impairments and other factors to job losses and difficulties obtaining a job; b) teaching coping strategies for dealing with cognitive challenges associated with job search or maintaining a job; c) computer cognitive training involving cognitive exercises with a commercially available software program, which is designed to improve the broad range of cognitive skills through a combination of practice and strategy coaching by the Cognitive Specialist; d) job search planning; and e) job support consultation.
3130637|NCT01683539|Active Comparator|The Cognitive Skills for Work Program|The Cognitive Skills for Work Program includes 4 components delivered by a Cognitive Specialist who works with the consumer's Employment Specialist: a) assessing the consumer's cognitive strengths and weaknesses their relation to job history b) teaching coping strategies for cognitive challenges associated with job search or maintenance c)job search planning, in which the consumer and the Cognitive and Employment Specialists help identify job leads based on the consumer's interests, and identify cognitive coping strategies and supports the consumer may need to succeed at the workplace; and d) job support consultation, in which the Cognitive and Employment Specialists consult with the consumer on additional cognitive coping strategies to enable the consumer to meet the demands of the job.
3130638|NCT01683526|Active Comparator|Direct laryngoscopy|Intubation will be done using direct laryngoscopy
3130639|NCT01683526|Active Comparator|Video laryngoscopy|Intubation will be done using video laryngoscopy
3130640|NCT01683513|No Intervention|humaan chorion gonadotropine|ovulation induction with 5000E hCG
3130641|NCT01683513|Active Comparator|GnRH agonist + 1500E hCG|ovulation induction with GnRH agonist and 1500E hCG one hour after egg retrieval
3130642|NCT01683500|Experimental|shock wave therapy|intervention: shock wave therapy with Modulith SLK (Storz)
3130643|NCT01683474|Experimental|Venus A-Valve|single arm with intervention that percutaneous implantation of the Venus MedTech Aortic Valve Prosthesis
3130644|NCT01683461|Experimental|Enhanced Counseling|Women in the intervention arm receive: (1) a standardized health education video before HIV pre-test counseling; (2) HIV pre- and post-test counseling sessions that prepare women for decisions related to testing, serostatus disclosure and anti-retroviral (ARV) prophylaxis and help women plan strategies for sexual risk behavior change; (3) two additional post-test counseling sessions postpartum focused on legal education and referral, partner testing, sexual risk behavior change and family planning decisions and; (4) an active referral system to post-test support groups run by a clinically trained staff psychologist and (5) an active referral system to legal services run by a lawyer at the clinic.
3130645|NCT01683461|Active Comparator|Standard of Care|Women in the control arm receive the standard of care in terms of HIV counseling and testing during pregnancy. The standard of care for HIV counseling adheres to guidelines provided by the US Centers for Disease Control and the World Health Organization. Women receive one individual pre-test counseling session immediately before they are tested for HIV, and one individual post-test counseling session the same day that they are tested.
3130646|NCT01683435|Experimental|hylauronin binding assay|HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
3130647|NCT01683422|Experimental|Proton Radiation|
3130648|NCT01683409|Placebo Comparator|Placebo|Administered orally, given as three placebo tablets in the morning and one placebo tablet in the evening for 24 weeks.
3130649|NCT01683409|Experimental|Baricitinib 0.75 mg/0.5 mg QD|Administered orally, 0.75 mg given as one 0.75 mg tablets and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
3130650|NCT01683409|Experimental|Baricitinib 0.75 mg/0.5 mg BID|Administered orally, 0.75 mg given as one 0.75 tablet and 2 placebo in the morning and one 0.75 mg tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one 0.5 mg tablet in the evening. Placebo tablets given to maintain blind.
3130651|NCT01683409|Experimental|Baricitinib 1.5 mg/1 mg|Administered orally, 1.5 mg given as two 0.75 mg tablets and 1 placebo tablet in the morning and one placebo tablet in the evening for 24 weeks or 1 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
3130652|NCT01683409|Experimental|Baricitinib 4 mg/2.75 mg|Administered orally, 4 mg given as one tablet and 2 placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 2.75 mg given as two 1 mg tablets and one 0.75 mg tablet in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
3130653|NCT01683396|Placebo Comparator|Placebo|
3130654|NCT01683396|Experimental|gevokizumab|
3130655|NCT01683383|Active Comparator|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
3130656|NCT01683383|Experimental|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
3130657|NCT01683370||Patients|Pediatric patients with cancer, receiving standard chemotherapy, and receiving standard supportive therapy in case of fever in neutropenia (FN) (No intervention for study purposes)
3130658|NCT01683357||Multiple Bilobar CLM|Patients selected for hepatectomy because carrier of multiple (> or = to 4), bilobar CLM
3130659|NCT01683331|Active Comparator|Insulin treatment for hyperglycemia|Table 1. NPH Insulin Titration Regimen for Patients in Group A Pre-dinner Capillary blood glucose NPH dose initiation (IU/day) NPH dose adjustment(IU/day) > 240 mg/dl 14 Increase by 4 > 180 mg/dl 12 Increase by 4 > 140 mg/dl 10 Increase by 4 > 120 mg/dl 0 Increase by 2 100 to 119 mg/dl 0 Maintain the dose 80 - <100 mg/dl 0 Decrease by 4 60 - <80 mg/dl 0 Decrease by 8 < 60 mg/dl 0 Give ½ of previous dose
3130660|NCT01683331|No Intervention|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation.
3130661|NCT01683318|Experimental|Treatment|Patients will undergo Thermal Pulsation treatment of Meibomian Gland Dysfunction using the TearScience System (Lipiflow).
3130662|NCT01683305||Subjects who have no mammographically detectable tumors|This group will be evaluated for marker presence in NAF. no drugs administered
3130663|NCT01683305||Subjects who have non-cancerous growths|This group will be evaluated to study whether marker(s) detected in NAF are also expressed in non-cancerous tumors. No drugs administered
3130664|NCT01683305||subjects who have cancerous growths|In this group, any markers detected in NAF could also be detected in tumor tissues. No drugs administered.
3130665|NCT01683292|Experimental|Inhaled VR040|Inhaled apomorphine, dry powder, VR040 at fine particle doses (FPD) of 0.2mg, 0.5mg and 0.8mg. A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
3130666|NCT01683292|Placebo Comparator|Placebo|Inhaled dry powder. A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
3130667|NCT01683279|Experimental|CAR+ T cells|Subjects will receive two days of cyclophosphamide for a total of 3g/m^2 followed several days later by a single dose of Autologous CD19 CAR+ EGFTt + T cells
3130668|NCT01683266|Experimental|HOE901-U300|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]).
3130669|NCT01683266|Active Comparator|Lantus|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
3130670|NCT01683253|Experimental|Levodopa/Carbidopa(200mg/50mg)|
3130671|NCT01683253|Experimental|Control A (dopaminergic agonist )|Parkinson patients treated with anti-Parkinson drug over 6 months.
3130672|NCT01683253|No Intervention|Control B (no drug)|Parkinson diseased patients not treated.
3130673|NCT01683240|Experimental|Frimberger cholangioscope|Patients with need for cholangioscopy due to gallstones or histological evaluation of strictures
3130674|NCT01683227|Experimental|Screening/motivational drug intervention|Screening and brief intervention counseling matched to patient's risk level delivered in the ER
3130675|NCT01683227|Placebo Comparator|Motivational placebo intervention|Screening and brief intervention for driving and traffic safety
3130676|NCT01683201|Experimental|Functional exercise class|Functional exercise class 45 mins twice weekly from week 12 to week 18
3130677|NCT01683201|Placebo Comparator|Usual Care Group|Usual Care
3130678|NCT01683188|Other|Cohort 1|Patients who have received less than 7 weeks vemurafenib dosing prior to treatment with HD IL-2
3130679|NCT01683188|Other|Cohort 2|Patients who have receive >7 weeks to 18 weeks vemurafenib dosing prior to treatment with HD IL-2
3130680|NCT01683175|Experimental|Arm 1|Erlotinib 150mg daily oral up to 2 years
3130681|NCT01683175|Active Comparator|Arm 2|NP Chemotherapy for 4 cycles
3130682|NCT01683162|Experimental|Olive oil lipid emulsion|the olive oil lipid emulsion is ClinOleic
3130683|NCT01683162|Experimental|MCT/LCT lipid emulsion|the MCT/LCT lipid emulsion is Lipofundin
3130684|NCT01683162|Experimental|LCT lipid emulsion|the LCT lipid emulsion is Intralipid
3130685|NCT01683149|Experimental|Combination Chemotherapy|"Combination Chemotherapy: Topotecan and Sorafenib. Participants will receive the treatment in cycles. Every cycle is 28 days long. For the first cycle participants will get the chemotherapy drugs:~Topotecan PO (by mouth) once daily on days 1-5 and days 8-12~Sorafenib PO (by mouth) twice daily (BID), continuously on days 2-28 of cycle one and days 1-28 on each additional cycle.~Level -1: Topotecan 1.0 mg/m^2: Sorafenib 100 mg/m^2 BID~Level -2: Topotecan 0.8 mg/m^2: Sorafenib 100 mg/m^2 BID~Level 1: Topotecan 1.0 mg/m^2: Sorafenib 150 mg/m^2 BID~Level 2: Topotecan 1.4 mg/m^2: Sorafenib 150 mg/m^2 BID~Level 3: Topotecan 1.4 mg/m^2: Sorafenib 200 mg/m^2 BID~Level 4: Topotecan 1.8 mg/m^2: Sorafenib 200 mg/m^2 BID"
3130686|NCT01683136|Experimental|Deep TMS treatment|
3130687|NCT01683136|Sham Comparator|inactive stimulation|
3130688|NCT01683097|No Intervention|Control|Questionnaire
3130689|NCT01683097|Experimental|Intervention|Standardized explanation followed by questionnaire
3130690|NCT01683084|Active Comparator|Telmisartan|One 40mg telmisartan pill given once daily for 24 months
3130691|NCT01683084|Placebo Comparator|Placebo|One 40mg placebo pill given once daily for 24 months
3130692|NCT01683071|Active Comparator|Group 1|EXPAREL 67 mg
3130693|NCT01683071|Active Comparator|Group 2|EXPAREL 133 mg
3130694|NCT01683071|Active Comparator|Group 3|EXPAREL 266 mg
3130695|NCT01683071|Placebo Comparator|Group 4|Placebo (preservative-free normal saline)
3130696|NCT01683058|Experimental|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg once monthly (every 28 days) for 24 weeks
3130697|NCT01683045|Experimental|The Estech COBRA® Surgical System|
3130698|NCT01683032|Experimental|Experimental: Healthy adults|Participants, aged 21-40 years, will be recruited through an advertisement posted at the University of Haifa (including the website of Haifa University).
3130699|NCT01683019|Active Comparator|Active Fixed Alpha Frequency Magnetic Stimulation|Sinusoidal magnetic field set to the subject's intrinsic alpha frequency (IAF).
3130700|NCT01683019|Active Comparator|Active Random Frequency Magnetic Stimulation|Magnetic field hops to random frequencies in the alpha band (8-13Hz), once per second.
3130842|NCT01682330||Control|
3241712|NCT00902135||Group 2|
3130702|NCT01683006|Active Comparator|Neuromuscular blocker group|"Continuous application of neuromuscular blockers during therapeutic hypothermia.~Bolus application of placebo in case of shivering."
3130703|NCT01683006|Placebo Comparator|Placebo group|"Continuous application of placebo during therapeutic hypothermia.~Bolus application of neuromuscular blockers in case of shivering."
3130704|NCT01682993|Active Comparator|Corneal Cross Linking|Patients will receive a standard corneal cross linking treatment
3130705|NCT01682993|Experimental|Corneal Cross Linking and Topo Laser|Patients will receive a topography guided laser treatment in combination with a standard corneal cross linking treatment in the same session.
3130706|NCT01682980|Experimental|Strength training|The strength group include progressive strength training and neuromuscular exercises. The inclusion will be performed 2-3 times a week for 12 weeks.
3130707|NCT01682980|Experimental|Aerobic exercise|The aerobic exercise group will cycle on an ergometer bicycle 2-3 times a week for 12 weeks on moderate loading. The loading will be controlled by a heart rate monitor and is defined as 75% of maximal heart rate (calculated with formula for maximal heart rate reserve).
3130708|NCT01682980|No Intervention|Control group|The control group will do as usual.
3130709|NCT01682967||Experimental group|Patients suffering from PDPH would form this group
3130710|NCT01682967||Control group - Epidural|Patients who received an epidural during labour but did not have symptoms of PDPH would form this reference group
3130711|NCT01682967||Control Group without Epidural analgesia|Patients in labour who did not receive an EDA would form this cohort of controls
3130712|NCT01682954|Experimental|Lifestyle counseling|Diabetes Prevention Program lifestyle intervention
3130713|NCT01682954|No Intervention|Usual Care|Usual care from primary care physician
3130714|NCT01682941|Active Comparator|Soy Bread Intervention|Arm I Soy Bread
3130715|NCT01682941|Experimental|Soy -Almond Bread Intervention|Arm II Soy-Almond Bread
3130716|NCT01682928|Active Comparator|IV/Oral Hydration and Bedrest|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs"
3130717|NCT01682928|Active Comparator|Hydrotherapy Group|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs~HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
3130718|NCT01682915||Group 1: ADHD+DAT1, Probands|30 ADHD probands with DAT1 variants
3130719|NCT01682915||Group 2: ADHD+DAT1, Unaffected sibling|30 same-sex unaffected siblings of Group 1
3130720|NCT01682915||Group 3: ADHD Drug‐naïve, Probands|30 ADHD probands without DAT1 gene variants, who were age-, sex-, and IQ-matched to Group 1
3130721|NCT01682915||Group 4: ADHD Drug‐naïve, unaffected sibling|30 same-sex unaffected siblings of Group 3
3130722|NCT01682915||Matched controls|30 age-, sex- and IQ-matched TD controls for each of 4 groups
3130723|NCT01682902|Experimental|Formulation 1|
3130724|NCT01682902|Experimental|Formulation 2|
3130725|NCT01682902|Active Comparator|Insulin aspart (NovoLog®)|
3130726|NCT01682889|Placebo Comparator|Placebo|NaCl 0.9% intravenously for 24 hours after induction of anaesthesia
3130727|NCT01682889|Active Comparator|Arginine|L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours after induction of anaesthesia
3130728|NCT01682876|Placebo Comparator|2 through 5 years (1 Vac) MenACWY-CRM 1|Subjects 2 through 5 years received one vaccination of MenACWY-CRM
3130729|NCT01682876|Active Comparator|2 through 5 years (2 Vac) MenACWY-CRM 2|Subjects 2 through 5 years received two vaccinations of MenACWY-CRM
3130730|NCT01682876|Placebo Comparator|6 through 10 years (1 Vac) MenACWY-CRM 3|Subjects 6 through 10 years received one vaccination of MenACWY-CRM
3130731|NCT01682876|Active Comparator|6 through 10 years (2 Vac) MenACWY-CRM 4|Subjects 6 through 10 years received two vaccinations of MenACWY-CRM
3130732|NCT01682863|Experimental|QVA149 dose 1|QVA149 27.5/12.5 μg capsules
3130733|NCT01682863|Experimental|QVA149 dose 2|QVA149 27.5/25 μg capsules
3130734|NCT01682863|Active Comparator|QAB149|QAB149 75 μg capsules
3130735|NCT01682850|Active Comparator|Intervention|The Intervention Arm will receive 10 sessions of Mindfulness Based Pulmonary Rehabilitation prior to lung surgery
3130736|NCT01682850|Placebo Comparator|Usual Care|The Usual Care Arm will receive the normal care that a patient with severe COPD having a lung surgery would receive.
3130737|NCT01682837|Experimental|KMgCit, KCit, KCl, Placebo|Participants who received study drug in the order: Potassium Magnesium Citrate (KMgCit) powder, Potassium Citrate (KCit) powder, Potassium Chloride (KCl) powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130738|NCT01682837|Experimental|KMgCit, KCit, Placebo, KCl|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Citrate powder, Placebo, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130739|NCT01682837|Experimental|KMgCit, KCl, KCit, Placebo|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Chloride powder, Potassium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130740|NCT01682837|Experimental|KMgCit, KCl, Placebo, KCit|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Chloride powder, Placebo, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130741|NCT01682837|Experimental|KMgCit, Placebo, KCit, KCl|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Placebo, Potassium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130742|NCT01682837|Experimental|KMgCit, Placebo, KCl, KCit|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Placebo, Potassium Chloride powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130743|NCT01682837|Experimental|KCit, KMgCit, KCl, Placebo|Participants who received study drug in the order: Potassium Citrate powder, Potassium Magnesium Citrate powder, Potassium Chloride powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130744|NCT01682837|Experimental|KCit, KMgCit, Placebo, KCl|Participants who received study drug in the order: Potassium Citrate powder, Potassium Magnesium Citrate powder, Placebo, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130745|NCT01682837|Experimental|KCit, KCl, KMgCit, Placebo|Participants who received study drug in the order: Potassium Citrate powder, Potassium Chloride powder, Potassium Magnesium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130746|NCT01682837|Experimental|KCit, KCl, Placebo, KMgCit|Participants who received study drug in the order: Potassium Citrate powder, Potassium Chloride powder, Placebo, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130747|NCT01682837|Experimental|KCit, Placebo, KMgCit, KCl|Participants who received study drug in the order: Potassium Citrate powder, Placebo, Potassium Magnesium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130748|NCT01682837|Experimental|KCit, Placebo, KCl, KMgCit|Participants who received study drug in the order: Potassium Citrate powder, Placebo, Potassium Chloride powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130749|NCT01682837|Experimental|KCl, KMgCit, KCit, Placebo|Participants who received study drug in the order: Potassium Chloride powder, Potassium Magnesium Citrate powder, Potassium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130750|NCT01682837|Experimental|KCl, KMgCit, Placebo, KCit|Participants who received study drug in the order: Potassium Chloride powder, Potassium Magnesium Citrate powder, Placebo, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130751|NCT01682837|Experimental|KCl, KCit, KMgCit, Placebo|Participants who received study drug in the order: Potassium Chloride powder, Potassium Citrate powder, Potassium Magnesium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130752|NCT01682837|Experimental|KCl, KCit, Placebo, KMgCit|Participants who received study drug in the order: Potassium Chloride powder, Potassium Citrate powder, Placebo, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130753|NCT01682837|Experimental|KCl, Placebo, KMgCit, KCit|Participants who received study drug in the order: Potassium Chloride powder, Placebo, Potassium Magnesium Citrate powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130754|NCT01682837|Experimental|KCl, Placebo, KCit, KMgCit|Participants who received study drug in the order: Potassium Chloride powder, Placebo, Potassium Citrate powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130755|NCT01682837|Experimental|Placebo, KMgCit, KCit, KCl|Participants who received study drug in the order: Placebo, Potassium Magnesium Citrate powder, Potassium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130756|NCT01682837|Experimental|Placebo, KMgCit, KCl, KCit|Participants who received study drug in the order: Placebo, Potassium Magnesium Citrate powder, Potassium Chloride powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130757|NCT01682837|Experimental|Placebo, KCit, KMgCit, KCl|Participants who received study drug in the order: Placebo, Potassium Citrate powder, Potassium Magnesium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130758|NCT01682837|Experimental|Placebo, KCit, KCl, KMgCit|Participants who received study drug in the order: Placebo, Potassium Citrate powder, Potassium Chloride powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130759|NCT01682837|Experimental|Placebo, KCl, KMgCit, KCit|Participants who received study drug in the order: Placebo, Potassium Chloride powder, Potassium Magnesium Citrate powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130760|NCT01682837|Experimental|Placebo, KCl, KCit, KMgCit|Participants who received study drug in the order: Placebo, Potassium Chloride powder, Potassium Citrate powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3130761|NCT01682824||Childhood Central Nervous System (CNS) Tumor Survivors|Questionnaire for Adolescent and young adult (AYA) survivors of childhood central nervous system (CNS) tumors in the United States (US).
3130762|NCT01682811|Experimental|Part 1|Levulan (5-aminolevulinic acid) uptake.
3130763|NCT01682811|Experimental|Part 2|Levulan (5-aminolevulinic acid) photodynamic therapy.
3130764|NCT01682798|Active Comparator|"Yili Chang Qing Pro-ABB yoghurt (Formula 1)"|"100g of Yili Chang Qing Pro-ABB yoghurt (Formula 1) will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
3130765|NCT01682798|Placebo Comparator|Placebo yoghurt|100g of placebo yoghurt (normal yoghurt) will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
3130766|NCT01682798|Active Comparator|"Yili Chang Qing Pro-ABB yoghurt (Formula 2)"|"100g of Yili Chang Qing Pro-ABB yoghurt (Formula 2) will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
3130767|NCT01682772|Experimental|Olaparib|Oral Olaparib at a dose of 400mg twice daily, continuously on a 28 day cycle
3130768|NCT01682759|Experimental|Omarigliptin|Participants will receive omarigliptin, 25 mg once weekly and placebo matching glimepiride once daily for up to 54 weeks.
3130769|NCT01682759|Active Comparator|Glimepiride|Participants will receive glimepiride titrated to a maximum of 6 mg, once daily, and placebo to omarigliptin, once weekly for up to 54 weeks.
3130770|NCT01682746|Experimental|Treatment|Photofrin (porfimer sodium) photodynamic therapy.
3130771|NCT01682733|Experimental|Botulinum toxin at injection site|All subjects will have gastroplasty performed using the Overstitch Endoscopic Suturing System. Botulinum toxin will be injected in every other suture site in half of the randomly patients selected.
3130772|NCT01682720|Placebo Comparator|Placebo 12 Weeks (GT2/3)|Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
3130773|NCT01682720|Experimental|SOF 12 Weeks (GT2/3)|Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
3130774|NCT01682720|Experimental|SOF 24 Weeks (GT3)|SOF 400 mg tablet once daily + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 24 weeks in participants with genotype 3 HCV infection.
3130775|NCT01682707|Active Comparator|Laryngoscopy|Laryngoscopy Track Light teaqueal intubation
3130776|NCT01682707|Active Comparator|Track Light|
3130777|NCT01682694|Experimental|Glucosamine and Chondroitin|Glucosamine and Chondroitin
3130778|NCT01682694|Placebo Comparator|Placebo|Inactive ingredients
3130779|NCT01682681||Topiramate|
3130780|NCT01682668|Experimental|Frequency of subthalamic stimulation|Comparison between healthy controls and PD patients
3130781|NCT01682642|Active Comparator|Zoladex|After surgical vaporization of endometriosis patients are treated with Zoladex for 3 months.
3130782|NCT01682642|No Intervention|vaporization only|Surgical vaporization of the endometriosis is done and patients start IVF without additional treatment.
3130783|NCT01682629|No Intervention|Non-Scripted Debriefing, Low Realism Simulation|A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. In this arm, novice instructors were provided the scenario learning objectives but NO SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing. The simulation scenario itself was conducted with an infant simulator. The low realism group had the simulator with the compressor turned off, thus eliminating the functionality of physical findings.
3130784|NCT01682629|Experimental|Scripted debriefing, Low Realism|In this arm, novice instructors were provided the scenario learning objectives WITH A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing USING THE SCRIPT. The lo realism group had the simulator with the compressor turned on, thus eliminating the functionality of physical findings.
3130785|NCT01682629|Experimental|non-Scripted Debriefing, High Realism Simulation|In this arm, novice instructors were provided the scenario learning objectives WITHOUT A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing WITHOUT USING THE SCRIPT. The hi realism group had the simulator with the compressor turned on, thus activating the functionality of physical findings.
3130786|NCT01682629|Experimental|Scripted Debriefing, High Realism Simulation|In this arm, novice instructors were provided the scenario learning objectives WITH A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing USING THE SCRIPT. The hi realism group had the simulator with the compressor turned on, thus activating the functionality of physical findings.
3130787|NCT01682616|Experimental|Arm 1|Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
3130788|NCT01682603|Experimental|Botulinum toxin A|BoNT-A (BOTOX 300U)
3130789|NCT01682590|Experimental|Early initiation of RRT|Start of RRT within a maximum of 12 hours after randomisation.
3130790|NCT01682590|Active Comparator|Deferred RRT|Start of RRT between 48 and 60 hours after randomisation.
3130791|NCT01682577|Experimental|Perindopril 4 mg tablets of PT Dexa Medica|"Group I (Test product): each tablet contains perindopril tert-butylamine salt 4 mg.~A single dose of perindopril tablet of PT Dexa Medica was given to each of study subjects."
3130792|NCT01682577|Active Comparator|Perindopril 4 mg tablets of Servier|"Group II (Reference product) : each tablet contains perindopril tert-butylamine salt 4 mg.~A single dose of perindopril (Prexum) tablets of Servier was given to each of study subjects."
3130793|NCT01682564|Experimental|Candemore tablet|"Candemore tablet~Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
3130794|NCT01682564|Active Comparator|Atacand tablet|"Atacand tablet~Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
3130795|NCT01682551|Experimental|Chinese Medicine|"The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day."
3130796|NCT01682551|Placebo Comparator|Acetazolamide|"If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang."
3130797|NCT01682538|Active Comparator|Orfadin capsules, fasting|Orfadin capsules, single dose, 30 mg
3130798|NCT01682538|Experimental|Orfadin suspension, fasting|Orfadin suspension 4 mg/mL, single dose 30 mg (7,5 mL)
3130799|NCT01682538|Experimental|Orfadin suspension, with food|Orfadin suspension 4mg/mL, single dose 30 mg (7,5 mL)
3130800|NCT01682525|Experimental|Ovarian tissue cryopreservation|The ovarian tissue is cryopreserved and stored at Boston IVF, which is an FDA compliant and American Association of Tissue Banks accredited long term storage facility for reproductive tissue.
3130801|NCT01682512|Experimental|Part I BI 695500 group|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
3134097|NCT01659892|Active Comparator|Singulair|5 mg Chewable Tablet
3130802|NCT01682512|Active Comparator|Part I Rituxan®|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
3130803|NCT01682512|Active Comparator|Part I MabThera®|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
3130804|NCT01682512|Experimental|Part II BI 695500 group|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
3130805|NCT01682512|Active Comparator|Part II rituximab group|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
3130806|NCT01682499|Experimental|Calcium and Magnesium Infusion|
3130807|NCT01682486|Experimental|BIP ETT, Bactigaurd coated endotracheal tube|
3130808|NCT01682486|Placebo Comparator|Standard ETT, un-coated endotracheal tube|
3130809|NCT01682473|Experimental|Arm 1: 5/2 Dosing|Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 5 days on drug and 2 days off drug.
3130810|NCT01682473|Experimental|Arm 2: 21/7 Dosing|Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 21 days on drug and 7 days off drug.
3130811|NCT01682460|Experimental|Refresh Tears Lubricant Eye Drops (Allergan)|Artificial tears eye drops QID for 1 month
3130812|NCT01682447|Experimental|Extensive Pulmonary Rehabilitation (ERP)|Participants in this group are measured on primary and secondary outcome measures before and after a 12 week extensive pulmonary rehabilitation program.
3130813|NCT01682447|No Intervention|Waiting List Control group|Participants in the waiting list control group are measured on primary and secondary outcome measures before and after waiting time for the extensive pulmonary rehabilitation program and start with this program after the second moment of measurement.
3130814|NCT01682434|Active Comparator|Wavefront-guided LASIK|One eye will be randomized to wavefront-guided treatment. The other receives conventional LASIK.
3130815|NCT01682434|Active Comparator|Conventional LASIK|One eye will receive wavefront-guided LASIK. The other eye receives conventional treatment.
3130816|NCT01682421|Experimental|Weak steroid|Initial treatment with dexamethasone 6x per day for two weeks, followed by Fluorometholone 4x per day for 2 months, 3x per day for 2 months, 2x per day for 2 months, and finally 1x per day continually during 2 years.
3130817|NCT01682421|Experimental|Potent steroid|Initially Dexamethasone 6x per day for 2 weeks followed by 4x per day for one month, 3x per day for one month, 2x per day for one month, and finally 1x per day for one month - giving a total of 4,5 months of steroid treatment.
3130818|NCT01682408|Active Comparator|Part A1|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), fed 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
3130819|NCT01682408|Active Comparator|Part A2|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference) 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed 150 mg ranitidine
3130820|NCT01682408|Active Comparator|Part B1|1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
3130821|NCT01682408|Active Comparator|Part B2|1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)
3130822|NCT01682408|Active Comparator|Part B3|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
3130823|NCT01682395|Active Comparator|G-SV Resection and colostomy|Gangrenous sigmoid volvulus patients randomized to undergo resection with colostomy and delayed anastomosis
3130824|NCT01682395|Experimental|G-SV Resection and anastomosis|Gangrenous sigmoid volvulus subjects randomized to undergo resection and anastomosis
3130825|NCT01682395|Active Comparator|NG-SV resection and anastomosis|Nongangrenous sigmoid volvulus subjects randomized to undergo resection and anastomosis
3130826|NCT01682395|Experimental|NG-SV mesosigmoidopexy|Nongangrenous sigmoid volvulus subjects randomized to undergo mesosigmoidopexy
3130827|NCT01682382||choroidal neovascular (CNV) AMD subjects|Subjects diagnosed with CNV (AREDS Grade 4b)
3130828|NCT01682382||dry AMD subjects|Subjects diagnosed with dry AMD (AREDS Grade 3)
3130829|NCT01682382||age-matched controls|Subjects without AMD (AREDS Grade 1)
3130830|NCT01682369|Other|Group 1 a - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Agrippal) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Agrippal)~V3-(Day V2+1)- Collect blood sample (up to 6.0 ml)~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
3130831|NCT01682369|Other|Group 1 b - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Agrippal) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Agrippal)~V3-(Day V2+3)- Collect blood sample (up to 6.0 ml)~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
3130832|NCT01682369|Other|Group 1 c - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Aggripal) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Aggripal)~V3-(Day V2+7)- Collect blood sample (up to 6.0 ml)~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
3130833|NCT01682369|Other|Group 2 a - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)~V3- V3(Day V2+1)- Collect blood sample (up to 6.0 ml)~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
3130834|NCT01682369|Other|Group 2 b - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)~V3- V3(Day V2+3)- Collect blood sample (up to 6.0 ml)~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
3130835|NCT01682369|Other|Group 2 c - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)~V3- V3(Day V2+7)- Collect blood sample (up to 6.0 ml)~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
3130836|NCT01682356|Placebo Comparator|BRJ crossover to placebo|Beetroot Juice without nitrate.s Patients will be studied before and after ingestion of beetroot juice
3130837|NCT01682356|Active Comparator|Beetroot Juice|Beetroot Juice with nitrates. Patients will be studied before and after ingestion of beetroot juice with nitrates
3130838|NCT01682343|Placebo Comparator|Placebo|Breakfast consisting of milk-based porridge with a normal calcium content.
3130839|NCT01682343|Experimental|High-Calcium|As control, but with a high-calcium content.
3130840|NCT01682330||Fitness|
3130841|NCT01682330||Whole-body vibration|
3130843|NCT01682317|Experimental|Three Meal|Participants in this condition will be instructed to limit their number of eating frequency to three meals per day.
3130844|NCT01682317|Experimental|Grazing|Participants in the increased eating frequency condition will be instructed to eat > 100 kcals every 2-3 hours.
3130845|NCT01682304||History of Preeclampsia|Chronic hypertension with history of preeclampsia Chronic hypertension without history of preeclampsia
3130846|NCT01682291|Active Comparator|Life-style modifications|"Lifestyle modifications will include:~Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)"
3130847|NCT01682291|Active Comparator|Dietary supplements|Life-style modifications along with a novel combination of dietary supplements that includes: Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
3130848|NCT01682278||Amalgam cohort|Patients with medically unexplained physical symptoms attributed to dental amalgam restorations which the patient wish to have removed.
3130849|NCT01682278||MUPS-cohort|Patients with medically unexplained physical symptoms without attribution to amalgam and no explicit wish to remove amalgam.
3130850|NCT01682278||Dental cohort|Healthy comparison group: Subjectively healthy without diagnosed chronic disease or prescribed medication.
3130851|NCT01682265|Experimental|Stretta procedure|"Patient randomized in Stretta procedure arm will be hospitalized to have endoscopy and esophagus will receive radiofrequency.~Control visits will then take place until Month 6. At this visit endoscopic control will take place."
3130852|NCT01682265|Sham Comparator|Sham procedure|"Patient randomized in Sham procedure arm will be hospitalized to have endoscopy. Material necessary to perform Stretta procedure will be inserted (like in Stretta procedure arm) BUT esophagus will not receive radiofrequency.~Control visits will then take place until Month 6. At this visit endoscopic control will take place."
3130853|NCT01682252||musculoskeletal tumors|all patients undergoing surgery for musculoskeletal tumors
3130854|NCT01682239|Experimental|RVAP lead|"Pacemaker lead implantation:~Pacemaker leads will be placed in specific predefined RA and RV sites according to randomization. In this arm pacemaker leads will be placed in the RV apex. The successful lead positioning at its target location will be verified by surface ECG and by fluoroscopy."
3130855|NCT01682239|Experimental|RVSP arm|"Pacemaker lead implantation:~Pacemaker leads will be placed in specific predefined RA and RV sites according to randomization. In this arm pacemaker leads will be placed in the RV septum. The successful lead positioning at its target location will be verified by surface ECG and by fluoroscopy."
3130856|NCT01682226|Experimental|A: standard risk group|This is a 2 arm phase 2 study to obtain an estimate of the speed of neutrophil recovery after myeloablative CBT with abrogation of prolonged cytopenia by infusion of haploidentical family member T-cell depleted PBSC in patients with high-risk or advanced hematologic malignancies.
3130857|NCT01682226|Experimental|B: high risk group|This is a 2 arm phase 2 study to obtain an estimate of the speed of neutrophil recovery after myeloablative CBT with abrogation of prolonged cytopenia by infusion of haploidentical family member T-cell depleted PBSC in patients with high-risk or advanced hematologic malignancies.
3130858|NCT01682213|Experimental|dabrafenib|This is a single institution phase II trial assessing the efficacy of adjuvant dabrafenib (GSK2118436) in patients with surgically resected AJCC stage IIIC melanoma characterized by a BRAFV600E/K mutation.
3130859|NCT01682200|Experimental|ProOxy, Effects and Side Effects in treating acne|Patients are instructed to clean the face with ProOxy facial cleanser and then spray on the face wet enough but not dripping twice daily (upon waking up and before bedtime) for 3 months.
3130860|NCT01682187|Experimental|LY2157299 (Part A)|Administered orally by tablet twice daily for two weeks followed by two weeks of no treatment for two 28-day cycles. Part A dose escalation will have starting dose of 40 mg/day and may increase up to 360 mg/day.
3130861|NCT01682187|Experimental|LY2157299 + Lomustine (Part B)|"LY21547299 will be administered orally by tablet twice daily for two weeks followed by two weeks of no treatment for two 28-day cycles. Part B dose expansion will have starting dose of 80 mg twice daily and may increase up to 150 mg twice daily.~Lomustine will be administered orally by capsule once on Day 7 of Cycle 1 after receiving LY2157299, and once after receiving LY2157299 on Day 21 of Cycles 2, 5, 8, 11, and every 4th cycle thereafter."
3130862|NCT01682174|Placebo Comparator|Control Test Drink|control drink
3130863|NCT01682174|Experimental|Experimental Test Drink|Experimental Drink
3130864|NCT01682161|Experimental|Group 1 (Immediate switch)|Paliperidone palmitate will be administered immediately after randomization and will be continued throughout the treatment phase.
3130865|NCT01682161|Experimental|Group 2 (Delayed switch)|Current oral antipsychotics will be continued until Week 8, and later on paliperidone palmitate will be administered.
3130866|NCT01682148|Active Comparator|Group 1|Current clinical practice technique and high-concentration dilution
3130867|NCT01682148|Experimental|Group 2|NMJ targeted technique and low-concentration dilution
3130868|NCT01682135|Experimental|Ramucirumab|Ramucirumab administered intravenously (IV) at escalating doses (6 milligrams per kilogram [mg/kg] up to 10 mg/kg) every 2‐3 weeks for 6 weeks (1 Cycle). Treatment may continue until discontinuation criterion is met.
3130869|NCT01682122||Newborns|Healthy newborns in Regular and Observation nurseries who are between 0-72 hrs of age. Infants with gestational age > or = 35weeks and birth weight > 2500g, who are hemodynamically stable, have no cardiorespiratory abnormalities and have no evidence of sepsis. If a blood culture was drawn due to the presence of maternal risk factors (e.g. maternal fever, prolonged rupture of membranes), patients will be included only if the blood culture result is negative and in case of intrapartum antibiotic treatment, ancillary blood tests (CBC with differential, CRP) are also within the normal range
3130870|NCT01682109|Experimental|new paediatric valacyclovir formulation|Newly developed formulation
3130871|NCT01682109|Active Comparator|reference valacyclovir formulation|Formulation derived from FDA label information
3130872|NCT01682096|Active Comparator|Computed coronary angiography (CTA)|Patients will undergo a MDCT as the initial diagnostic test to rule out Acute Coronary Syndrome
3130873|NCT01682096|Active Comparator|Exercise stress echocardiography|Patients will undergo exercise stress echocardiography as the initial diagnostic test to rule out acute coronary syndrome.
3130874|NCT01682083|Experimental|Dabrafenib and trametinib combination therapy|Subjects will receive dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.
3130875|NCT01682083|Placebo Comparator|Dabrafenib and trametinib placebos|Subjects will receive matching placebos orally for 12 months
3130876|NCT01682070|Placebo Comparator|SUBLIVAC FIX Phleum prat. 0 AUN/ml|
3130877|NCT01682070|Experimental|SUBLIVAC FIX Phleum prat. 3,333 AUN/ml|
3130878|NCT01682070|Experimental|SUBLIVAC FIX phleum prat. 10,000 AUN/ml|
3130879|NCT01682070|Experimental|SUBLIVAC FIX phleum prat. 20,000 AUN/ml|Evaluation of the SUBLIVAC FIX Phleum prat. 20,000 AUN/ml by an independent safety committee
3130880|NCT01682070|Experimental|SUBLIVAC FIX Phleum prat. 40,000 AUN/ml|Start of SUBLIVAC FIX Phleum prat. 40,000 AUN/ml arm depends on safety in the SUBLIVAC FIX Phleum prat. 20,000 AUN/ml arm evaluated by an independent safety committee
3130881|NCT01682057|Experimental|Group A|ROX Anastomic Coupler System (ACS) + continuing standard antihypertensive medications
3130882|NCT01682044|Experimental|Treatment (colony-stimulating factor and monoclonal antibody)|Patients receive pegfilgrastim SC followed by rituximab IV 3 days later in weeks 1, 3, 5, 7, 15, 23, 31, and 39. Treatment continues in the absence of disease progression or unacceptable toxicity.
3130883|NCT01682031|Placebo Comparator|Arm I (placebo, cisplatin, and radiotherapy)|Patients receive placebo PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin IV over 3 hours once in weeks 2, 5, and 8 and undergo radiotherapy 5 days a week in weeks 2-8.
3130884|NCT01682031|Experimental|Arm II (selenomethionine, cisplatin, and radiotherapy)|Patients receive selenomethionine PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin and undergo radiotherapy as in arm I.
3130885|NCT01682018|Experimental|intervention group|Patients that underwent dingle lung transplantation due to emphysema and developed native lung overinflation as demonstrated by chest CT and decline in pulmonary lung function tests (FEV1 ) shall undergo valves placement to the native lung
3130886|NCT01682005||Complete RV vaccination|Subjects had received 2 doses of Rotarix or 3 doses of Rotateq/mixed within the vaccination window and the observation time is from the end of the vaccination window (8 months old) to end of observation.
3130887|NCT01682005||Incomplete RV vaccination|Subjects received at least one vaccination but less than complete vaccination has been received within the vaccination window and the observation time from 8 months old (if still observed) to end of observation.
3130888|NCT01682005||Any RV vaccination before 8 months|Subjects received any vaccination within the vaccination window and the observation time from 6 weeks old to earliest of end of observation or 8 months old.
3130889|NCT01682005||Historical unvaccinated on/before 8 months old|Subjects did not receive any RV vaccination within the vaccination window and the observation time is from 6 weeks old (if still observed and on/before 12/31/06) to earliest of: 12/31/2006, end of observation, or 8 months old.
3130890|NCT01682005||Historical unvaccinated after 8 months old|Subjects did not receive any RV vaccination within the vaccination window and observation time is from 8 months old (if still observed and on/before 12/31/2006) to earliest of: 12/31/2006 or end of observation.
3130891|NCT01682005||Contemporary unvaccinated on/before 8 months old|Subjects did not receive any RV vaccination within the vaccination window and observation time is from 6 weeks old (if on/after 01/01/2007) to earliest of: end of observation, or 8 months old.
3130892|NCT01682005||Contemporary unvaccinated after 8 months old|Subjects did not receive any RV vaccination within the vaccination window observation time is from 8 months old (if on/after 01/01/2007) to end of observation.
3130893|NCT01681992|Experimental|Inv_MMR_Min Group|Subjects receive one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a minimum potency lot (Inv_MMR_Min), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
3130894|NCT01681992|Experimental|Inv_MMR_Med Group|Subjects receive one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a mid-range or medium potency lot (Inv_MMR_Med), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
3130895|NCT01681992|Active Comparator|Com_MMR Group|Subjects receive one dose of M-M-R II (Com_MMR) vaccine (Lot 1 or Lot 2), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose of Com_MMR vaccine (Lot 1 or Lot 2), for the second dose. Com_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
3130896|NCT01681979||Women with asthma during pregnancy|Women with asthma during pregnancy will be identified based on one of the following: 1) an asthma related medical code recorded anytime before the pregnancy start date and at least one prescription for an asthma medicine in the 6 months before the pregnancy start date or during pregnancy; 2) no asthma related medical code but at least 6 prescriptions for an asthma medicine in their record before the pregnancy start date, including one in the 6 months before the pregnancy start date or during pregnancy.
3130897|NCT01681966|Experimental|Application of PRF110- oily solution|Post operative application of new extended release PRF110- oily solution (Ropivacaine)
3130898|NCT01681953|Active Comparator|Lamazym|1 mg Lamazym/kg body weight
3130899|NCT01681953|Placebo Comparator|Placebo|Placebo is formulated as an isotonic phosphate buffer with glycine and mannitol
3130900|NCT01681940|Experimental|Lamazym|1 mg/kg body weight
3130933|NCT01681693|Experimental|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
3130901|NCT01681927||1.4kg wt gain 8AM -10 PM|Complete a questionnaire. Measure and record weight in AM and PM.Record for one week,number of times urinated after bedtime and before waking up.
3130902|NCT01681927||>1.4kg wt gain 8AM - 10PM no nocturia.|Complete a questionnaire. Measure and record weight in AM and PM.Record for one week,number of times urinated after bedtime and before waking up.
3130903|NCT01681927||> 1.4 kg wt gain 8AM -10PM with nocturia|Complete a questionnaire. Measure and record weight in AM and PM. Record the number of times and collect all urine passed overnight in separate containers for one week.Collection of blood and interstitial fluid samples, fluorescein dye angiography, and bioimpedance study.
3130904|NCT01681914||Anemia|Ambulatory, HIV-infected adult patients with hemoglobin <10 g/dL will be evaluated and managed in accordance with Mozambique's new anemia guideline for non-physician clinicians. The basic steps recommended by the guideline are: screen for danger signs and stabilize or admit if indicated; perform rapid malaria antigen test (and/or peripheral blood smear) and treat if indicated; evaluate for adverse drug reactions and manage per Mozambican national guidelines; consider nutritional deficiencies and intestinal parasites; evaluate response to therapy at <=1 month.
3130905|NCT01681914||Fever or History of Fever|Ambulatory, HIV-infected adult patients with measured axillary temperature >=37.5 C or history of fever within the past 24 hours will be evaluated and managed in accordance with Mozambique's new fever guideline for non-physician clinicians. The basic steps of the fever guideline are: screen for danger signs and stabilize or admit if indicated; perform rapid malaria antigen test (and/or peripheral smear) and treat if indicated; treat any other cause of fever identified through history and physical examination; re-evaluate at next scheduled clinical visit (sooner if worse or if not improving within 48 hours of initiating treatment). Although blood cultures are seldom performed in Mozambican health centers, venipuncture specimens will also be cultured for bacterial pathogens at the first study visit.
3130906|NCT01681914||Anemia and Fever/History of Fever|Patients who meet eligibility criteria for both the anemia and fever arms will be evaluated and managed using both the new Mozambican anemia guideline and the new Mozambican fever guideline, as above.
3130907|NCT01681901||Diagnostic (ultrasound)|Patients undergo breast ultrasound imaging.
3130908|NCT01681888|Experimental|Surface EMG Biofeedback|
3130909|NCT01681875|Experimental|0.8 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.8 (±0.15) mg nicotine with 9 (±1.5) mg tar (standard nicotine and tar yields of commercially-available cigarettes; control condition)"
3130910|NCT01681875|Experimental|0.26 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.26 (±0.06) mg nicotine with 9 (±1.5) mg tar"
3130911|NCT01681875|Experimental|0.12 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.12 (±0.03) mg nicotine with 9 (±1.5) mg tar"
3130912|NCT01681875|Experimental|0.07 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.07 (±0.02) mg nicotine with 9 (±1.5) mg tar"
3130913|NCT01681875|Experimental|0.03 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.03 (±0.01) mg nicotine with 9 (±1.5) mg tar"
3130914|NCT01681875|Experimental|0.04 mg nicotine with 13 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.04 (±0.02) mg nicotine with 13 (±2) mg tar"
3130915|NCT01681875|Other|Usual brand|"very low nicotine content cigarettes~Usual brand cigarettes (control condition)"
3130916|NCT01681862|Experimental|Personal Health Record|"Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan."
3130917|NCT01681849|Experimental|Paroxetine Group|Women who have experienced early childhood abuse and have PTSD will be randomized in a double blind fashion to receive paroxetine for a three month period followed by an open label phase of three months.
3130918|NCT01681849|Placebo Comparator|Placebo Group|Women who have experienced early childhood abuse and have PTSD will be randomized in a double blind fashion to receive placebo for a three month period followed by an open label phase of paroxetine for three months.
3130919|NCT01681849|Other|PTSD Negative|Women who have experienced early childhood abuse and do not have PTSD will serve as a control group and complete baseline assessments. They do not undergo intervention therefore they are assessed at baseline only.
3130920|NCT01681823|Experimental|PectaSol-C Modified Citrus Pectin (MCP)|Treatment with 4.8 grams PectaSol-C Modified Citrus Pectin three times a day, away from meals for six months.
3130921|NCT01681810|Experimental|14Nitrogen sodium nitrite|sodium nitrite 40 mg three times a day for 12 weeks
3130922|NCT01681797|Experimental|add-on fluorescence angiography|"The surgeon will prescribe the usual morphological assessment of the proposed flap:~CT angiography for an anterolateral thigh flap or an epigastric inferior flap~A Doppler ultrasonography for a fibula flap.~In addition to the usual radiological technique used to locate the perforating arteries, the patient will have a fluorescence angiography prior to surgery, another just after the end of surgery and then one every six hours during the next 4 days."
3130923|NCT01681771|Experimental|Cogntive behaviour therapy|Internet based Cognitive behaviour therapy during 9 weeks
3130924|NCT01681771|Active Comparator|Discussion group|Internet moderated discussion group during 9 weeks
3130925|NCT01681758|Active Comparator|PPV|use PPV to guide fluid therapy
3130926|NCT01681758|Placebo Comparator|standard care|fluids according to standard care
3130927|NCT01681745|Experimental|Treatment|
3130928|NCT01681732|Experimental|Personalized Care Plan|A personalized plan based on baseline clinic visit data
3130929|NCT01681732|Active Comparator|Control|This arm will be standard care
3130930|NCT01681719|Experimental|WBV and resistance|used both interventions
3130931|NCT01681719|Experimental|WBV & resistance sham|used the vibrating platform and sham for resistance training
3130932|NCT01681719|Experimental|Resistance & sham WBV|used resistance exercises and sham for vibrating platform
3131502|NCT01677871|Active Comparator|9RLE|Rifampicin + Levofloxacin+ Ethambutol for 9 months
3130934|NCT01681680|Other|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
3130935|NCT01681667|Active Comparator|ibuprofen|liquid ibuprofen 400mg compared to tablet ibuprofen 400mg
3130936|NCT01681667|Placebo Comparator|sugar pill or liquid|
3130937|NCT01681654|Experimental|Immediate Lifestyle Intervention - Maintenance Program|Patients will receive a 12-week lifestyle program during treatment. Patients will also receive maintenance support following the 12-week program.
3130938|NCT01681654|Experimental|Immediate Lifestyle Intervention - No Maintenance Program|Patients will begin the 12-week lifestyle intervention during treatment. Patients will not receive a maintenance support following the 12-week intervention.
3130939|NCT01681654|Experimental|Delayed Lifestyle Intervention - Maintenance Program|Patients will receive a 12-week lifestyle intervention program following treatment (12 weeks after diagnosis). Patients will then receive maintenance support following the 12-week program.
3130940|NCT01681654|Experimental|Delayed Lifestyle Intervention - No Maintenance Program|Patients will receive a 12-week lifestyle intervention program following treatment completion (12 weeks following diagnosis). Patients will not receive maintenance support following the 12-week program.
3130941|NCT01681641|Experimental|Lifestyle counseling|Patients and spouses in the intervention group are offered 3 targeted meetings with the DBS nurse, focusing on goal setting for each individual, following DBS, based on patients and spouses own expectations, challenges and goals for everyday life after DBS.
3130942|NCT01681641|No Intervention|Control group|Patients and spouses enrolled in a control group
3130943|NCT01681628|Experimental|Thought Field Therapy|Thought Field Therapy delivered by trained community leaders.
3130944|NCT01681628|Other|Wait list|"Delayed intervention.~No intervention prior to assessment after one week (pre-test 2). Then treated with Thought Field Therapy, and re-assessed after a further week (post-test)."
3130945|NCT01681615|Active Comparator|Acetylsalicylate|Acetylsalicylic Acid Eyedrops
3130946|NCT01681615|Placebo Comparator|isotonic NaCl|Saline Eyedrops
3130947|NCT01681602|Active Comparator|Intervention group|16 weeks of aerobic exercise
3130948|NCT01681602|No Intervention|Control group|Usual care.
3130949|NCT01681589|Sham Comparator|Control Group|The control group will receive sham-tDCS and computerized cognitive training also twice a week for 20 minutes for 6 weeks (12 training sessions).
3130950|NCT01681589|Experimental|Transcranial Direct Current Stimulator (TDCS)|The experimental group will receive active tDCS for 20 minutes and computerized cognitive training twice a week for 30 minutes for 6 weeks.
3130951|NCT01681589|Other|Healthy Control Group|Fifteen (15) healthy control subjects will participate.
3130952|NCT01681576|Experimental|LCZ696 followed by Valsartan|Period 1: LCZ696 400mg QD for 4 weeks then washout followed by Period 2: Valsartan 320mg QD for 4 weeks
3130953|NCT01681576|Experimental|Valsartan followed by LCZ696|Period 1: Valsartan 320mg QD for 4 weeks then washout followed by Period 2: LCZ696 400mg QD for 4 weeks
3130954|NCT01681563|Experimental|Pentostatin/Cyclophosphamide/Ofatumumab|Subjects will receive up to 6 cycles of pentostatin, cyclophosphamide, and ofatumumab given every 21 days (+/- 4 days).
3130955|NCT01681550|Other|Incretin theapy combined with insulin|
3130956|NCT01681537|Experimental|Treatment Arm|Lenalidomide and re-induction chemotherapy
3130957|NCT01681524|Experimental|Flurpiridaz F18|Open-label study of a single injection of flurpiridaz F18 for PET MPI compared to SPECT MPI in patients with suspected or known coronary artery disease referred for coronary cathertization
3130958|NCT01681511|Experimental|ICET™ TIC Foley Catheter|Route of Administration: Urinary Bladder Catheterization
3130959|NCT01681511|Active Comparator|BARD® LUBRI-SIL® IC Foley Catheter|Route of Administration: Urinary Bladder Catheterization
3130960|NCT01681498||Pregnancy|
3130961|NCT01681485||NSCL cancer patients|Surgery, chemotherapy and/or radiation therapy
3130962|NCT01681472|Active Comparator|Levoleucovorin 200 mg/m2|
3130963|NCT01681472|Active Comparator|Levoleucovorin 60 mg/m2|
3130964|NCT01681472|Experimental|6R-MTHF 200 mg/m2|
3130965|NCT01681472|Experimental|6R-MTHF 60 mg/m2|
3130966|NCT01681446|Active Comparator|interferon-alpha (IFN-alpha)|interferon-alpha is intramuscularly or subcutaneously injected at 30 μg three times a week or 50 μg twice a week for 18 months
3130967|NCT01681446|No Intervention|control|no anti-cancer interventions were assigned
3130968|NCT01681433|Experimental|Experimental: Arm A|OGX-427 + continuation of standard therapy with abiraterone acetate and prednisone
3130969|NCT01681433|Active Comparator|Control Arm: Arm B|Continuation of standard therapy with abiraterone acetate and prednisone
3130970|NCT01681420|Experimental|Approved Intervention Counseling|Approved blood donors randomized to intervention and choosing HIV counseling option with no donation.
3130971|NCT01681420|Experimental|Approved Intervention Donation|Approved blood donors randomized to intervention and choosing donation with no HIV counseling.
3130972|NCT01681420|Experimental|Deferred Intervention|Deferred blood donors randomized to intervention with HIV counseling.
3130973|NCT01681407||Depressed Patients|Patients: Group of patients that are diagnosed for having depression, and are suitable for SSRI treatment.
3130974|NCT01681407||Non-Depressed Controls|Controls: Volunteers that had clinical screening with no depression diagnosis.
3130975|NCT01681407||Patients Relatives|Patient Relatives (Optional group for later stage): First degree relatives with no depression diagnosis.
3130976|NCT01681394|Active Comparator|Product 1|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
3130977|NCT01681394|Placebo Comparator|Control product|250 g of chocolate cream
3130978|NCT01681381|Active Comparator|Firebird2® DES|Device:Firebird2® DES The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length.
3130979|NCT01681381|Experimental|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length.
3130980|NCT01681368|Experimental|Birinapant for Advanced Ovarian,Fallopian Tube & Peritoneal Ca|single arm
3130981|NCT01681355|Experimental|Intervention group|Healthy infants receiving standard cow's milk-based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition.
3130982|NCT01681329|Experimental|Cognitive-behavioral therapy with interpretation training|14 sessions of cognitive-behavioral therapy combined with computerized interpretation modification training
3130983|NCT01681329|Active Comparator|Cognitive-behavioral therapy with non-active training|14 sessions of cognitive-behavioral therapy combined with computerized non-active training
3130984|NCT01681316|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
3130985|NCT01681316|Placebo Comparator|Placebo|Based on the standard medical care, placebo was 40ml of 0.9% saline, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
3130986|NCT01681303|Experimental|AST-120 group|Administration of AST-120
3130987|NCT01681303|No Intervention|2|
3130988|NCT01681290|Experimental|CBX129801 High Dose|Solution for injection, 2.4 mg, weekly for 52 weeks
3130989|NCT01681290|Experimental|CBX129801 Low Dose|Solution for injection, 0.8 mg, weekly for 52 weeks
3130990|NCT01681290|Placebo Comparator|Placebo|Solution for injection, vehicle with no active, weekly for 52 weeks
3130991|NCT01681277|Experimental|BI 113608 high dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
3130992|NCT01681277|Experimental|BI 113608 low dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
3130993|NCT01681277|Experimental|BI 113608 medium dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
3130994|NCT01681277|Experimental|BI 113608 high dose qd|powder in the bottle for oral solution, oral administration with 240 ml water
3130995|NCT01681264|Active Comparator|Morphine:Placebo|
3130996|NCT01681264|Active Comparator|Morphine:Guanfacine 1mg|
3130997|NCT01681264|Active Comparator|Morphine:Guanfacine 2mg|
3130998|NCT01681264|Active Comparator|Placebo:Guanfacine 2mg|
3130999|NCT01681264|Placebo Comparator|Placebo:Placebo|
3131000|NCT01681251|Experimental|Intervention|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%
3131001|NCT01681251|Active Comparator|Control|Fluid titrated at the discretion of the attending anesthesiologist.
3131002|NCT01681238|Other|Protocol group 1|Using standard hemodynamic therapy
3131003|NCT01681238|Experimental|Protocol group 2|Using goal-directed therapy
3131004|NCT01681225|Experimental|EPVent|"The overall goals for the EPVent group (esophageal-pressure guided mechanical ventilation) are to employ an open-lung strategy that includes low tidal volumes and maintenance of a positive transpulmonary pressure at end-expiration [Ptpexp]. Fraction of inspired oxygen [FiO2] and transpulmonary pressure pressure during an expiratory hold will be changed to achieve values shown in one of the columns of a protocol-specified table to meet the oxygenation target."
3131005|NCT01681225|Active Comparator|Control|The overall goals for the Control group are similar to those for the EPVent group: to employ an open-lung strategy that includes low tidal volumes using an alternative high positive end-expiratory pressure [PEEP] strategy. The control group PEEP and tidal volume will be managed without reference to the esophageal pressure measurements, and instead will follow an empiric high PEEP mechanical ventilation strategy. PEEP and FiO2 will be raised or lowered to achieve the oxygenation target level specified in a study table.
3131006|NCT01681212|Experimental|Ipilimumab, 10 mg/kg + Dacarbazine, 850 mg/m^2|During the Induction Period, participants received ipilimumab, 10 mg/kg, as tolerated by intravenous (IV) infusion as 1 single dose during Weeks 1 (Day 1), 4, 7, and 10 for a total of 4 separate doses. During the Maintenance Phase, participants received ipilimumab, 10 mg/kg, as tolerated by IV infusion every 12 weeks, beginning at Week 24, until disease progression or unacceptable toxicity occurred or the patient withdrew consent. Participants also received dacarbazine, 850 mg/m^2, by IV infusion over 30 to 60 minutes, starting on Week 1 and repeated every 3 weeks until Week 22. Dacarbazine was dosed on the same day as ipilimumab, when applicable, after the ipilimumab dose.
3131007|NCT01681199|Experimental|Fluvastatin extended release tablet|Fluvastatin extended release tablet 80mg/day
3131008|NCT01681186|Experimental|LY2940680 (Part A)|Single escalating dose (50 mg up to 400 mg) of LY2940680 given once orally in up to 2 of 2 study periods
3131009|NCT01681186|Placebo Comparator|Placebo (Part A)|Placebo given once orally in up to 1 of 2 study periods
3131010|NCT01681186|Experimental|LY2940680 Capsule Fasted (Part B)|100 mg LY2940680 given once orally as a capsule (reference formulation) in fasted state in 1 of 4 study periods
3131011|NCT01681186|Experimental|LY2940680 Tablet Fasted (Part B)|100 mg LY2940680 given once orally as a tablet (test formulation) in fasted state in 1 of 4 study periods
3131012|NCT01681186|Experimental|LY2940680 Tablet Fed (Part B)|100 mg LY2940680 given once orally as a tablet (test formulation) following a standardized, high-fat breakfast in 1 of 4 study periods
3131013|NCT01681186|Experimental|LY2940680 Tablet Fasted + PPI (Part B)|30 mg lansoprazole (proton pump inhibitor [PPI]) given orally once daily for 7 days. One hour after last dose, 100 mg LY2940680 given orally once as a tablet (test formulation) in fasted state in 1 of 4 study periods
3131014|NCT01681173|Experimental|Drink enriched in fibers|7,5g enriched fiber drinks, BID
3131015|NCT01681173|Experimental|Placebo drink|Placebo drink, BID
3131016|NCT01681160|Experimental|MAGGOT THERAPY & conventional therapy T|Maggot therapy,ADMINISTERED TWO TIMES AS A NEW METHODS OF DRESSING in experimental group.conventional therapy ,administered two times in control group
3131017|NCT01681147|No Intervention|Group One|Standard postpartum care after a pregnancy with gestational diabetes
3131018|NCT01681147|Experimental|Group Two|"Standard postpartum care after a pregnancy with gestational diabetes~2 online nutrition and exercise education classes"
3131019|NCT01681147|Experimental|Group Three|"Standard postpartum care after a pregnancy with gestational diabetes~2 online nutrition and exercise education classes~Self monitoring of blood glucose levels"
3131020|NCT01681134|Experimental|Advagraf followed by Prograf|
3131021|NCT01681134|Experimental|Prograf followed by Advagraf|
3131022|NCT01681121|Experimental|ADX-N05|ADX-N05 to be taken once a day for 12 weeks
3131023|NCT01681121|Placebo Comparator|Placebo|Placebo to match ADX-N05 to be taken once a day for 12 weeks
3131024|NCT01681108|Other|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
3131025|NCT01681095|Experimental|Cardioplegia: Custodiol HTK Solution|"Custodiol HTK (histidine-tryptophan-ketoglutarate) cardioplegia: One liter of HTK solution (Custodiol; Koehler Chemi, Alsbach-Haenlien, Germany) contains the following components: 15 mmol/L sodium chloride, 9 mmol/L potassium chloride, 4 mmol/L magnesium chloride, 18 mmol/L histidine hydrochloride, 180 mmol/L histidine, 2 mmol/L tryptophan, 30 mmol/L mannitol, 0.015 mmol/L calcium chloride, 1 mmol/L potassium hydrogen 2-ketoglutarate, osmolarity 310 mOsm/kg, pH 7.02-7.20.~Custodiol-HTK was delivered to establish and maintain cardiac arrest. After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. Custodiol-HTK was delivered at a temperature of 4°C - 10°C."
3131026|NCT01681095|Active Comparator|Cold Blood Cardioplegia|"Cold Blood Cardioplegia: One liter of cold blood cardioplegic solution, mixed at a ratio of 4:1 per Beaumont standard of care (blood /cardioplegic solution), contains the following in a 500 cc bag of D5W (dextrose 5% in water): 50meq/L potassium chloride, 37.5 meq/L sodium bicarbonate and 7.5 meq/L magnesium sulfate.~After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional > 200 mL was administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 8°C."
3131027|NCT01681082|Experimental|Tai Chi Training|"Subjects will be recruited from the University of Wisconsin-Madison course, Introduction to Martial Arts: Tai Chi."
3131028|NCT01681082|No Intervention|Control|"Subjects will be recruited from the University of Wisconsin-Madison course Introduction to Psychology."
3131029|NCT01681069|Active Comparator|IQP-VV-102|2 tablets twice a day
3131030|NCT01681069|Placebo Comparator|Placebo|2 tablets twice a day
3131031|NCT01681056|Experimental|Autosuggestion|
3131032|NCT01681056|No Intervention|Standard medical theraphy|
3131033|NCT01681043|No Intervention|24 hour PSG under ordinary conditions|24 hour PSG in 46 patients under ordinary (routine) conditions
3131034|NCT01681043|Active Comparator|24 hours PSG under protocol 'Quiet in the room'|24 hour PSG in the same 46 patients with protocol 'Quiet in the room' from 10 p.m. til 6 a.m.
3131035|NCT01681030|Experimental|EVARREST™|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
3131036|NCT01681030|Active Comparator|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
3131037|NCT01681030|Active Comparator|Standard of Care|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
3131038|NCT01681017|Other|Facilities|Have appropriate staff trained in HBB and have HBB equipment provided
3131039|NCT01681017|Other|Master Trainers|Receive appropriate HBB training
3131040|NCT01681017|Other|Facilitators|Receive appropriate HBB training
3131041|NCT01681017|Other|Learners|Receive appropriate HBB training
3131042|NCT01681004|Experimental|iFuse Implant System|Surgical placement of iFuse implants in the affected SI joint
3131043|NCT01681004|Active Comparator|Non-Surgical Management|Medications, SI joint injection, physical therapy and RF ablation of SI joint
3131044|NCT01680991|Experimental|CLL: 1000 mg Obinutuzumab|Participants with chronic lymphocytic leukemia (CLL) will receive 1000 milligrams (mg) obinutuzumab as an intravenous (IV) infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. The first infusion on Cycle 1 Day 1 will be given over two days: Day 1 and Day 2. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
3131045|NCT01680991|Experimental|DLBCL: 1000 mg Obinutuzumab|Participants with diffuse large B-cell lymphoma (DLBCL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
3131046|NCT01680991|Experimental|FL: 1000 mg Obinutuzumab|Participants with follicular lymphoma (FL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
3131047|NCT01680978|Experimental|Aleglitazar|
3131048|NCT01680978|Placebo Comparator|Placebo|
3131049|NCT01680965|Experimental|Ofatumumab|"Phase I:~Escalating dose of ofatumumab~Phase II:~Maximum tolerated dose (MTD) of Ofatumumab"
3131050|NCT01680952|Active Comparator|A) TEST|
3131051|NCT01680952|Experimental|B) CONTROL|
3131052|NCT01680939|Experimental|Morphine|Receives morphine for post-surgical pain
3131053|NCT01680939|Experimental|Ibuprofen|Receives ibuprofen for post-surgical pain
3131054|NCT01680926|Experimental|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
3131055|NCT01680913|Experimental|Spinal with ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
3131056|NCT01680913|Active Comparator|Spinal by palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
3131057|NCT01680900|Experimental|experimental 1|vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks
3131058|NCT01680900|Placebo Comparator|placebo capsules (sugar pill)|Placebo capsules matched to the drug dose for 8 weeks
3131059|NCT01680887|Experimental|Varenicline|Oral 1.0 mg BID.
3131060|NCT01680887|Placebo Comparator|Placebo|Oral 1.0 mg BID.
3131061|NCT01680874|Experimental|Probiotic|"This arm will receive a probiotic combination which will consist of equal amounts of Lactobacillus acidophilus NCFM® (ATCC 700396), Lactobacillus paracasei Lpc-37 (ATCC SD5275), Bifidobacterium lactis Bi-07 (ATCC SC5220), and Bifidobacterium lactis Bl-04 (ATCC SD5219).~The probiotic will be taken orally, once a week, for 4 weeks."
3131062|NCT01680874|Placebo Comparator|Placebo|A placebo will be taken orally, once a day, for 4 weeks.
3131466|NCT01678105|Experimental|Dovitinib|Dovitinib 500 mg PO OD (5 days on, 2 days off); Each cycle = 28 days
3131063|NCT01680861|Experimental|Tacrolimus and Everolimus|"Patients in both arms will receive reduced tacrolimus dosing (rTd), 0.1 mg/kg PO divided in two daily doses - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.~Everolimus initiated within 24 hours post-transplant (i.e., immediately following randomization) at 0.75mg PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml."
3131064|NCT01680861|Active Comparator|Tacrolimus and Enteric-Coated Mycophenolate Sodium (EC-MPS)|"Patients in both arms will receive reduced tacrolimus dosing (rTd), 0.1 mg/kg PO divided in two daily doses - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.~EC-MPS will be initiated at 720 mg PO BID starting on the first post-operative day."
3131065|NCT01680835|Experimental|Study cohort|All patients enrolled in this study will be treated with the EverFlex™ Self-Expanding Peripheral Stent System.
3131066|NCT01680822||NTM patient|confirmed NTM patient
3131067|NCT01680809|Experimental|Compression stocking 15-20mmHg|Compression stocking 15-20mmHg
3131068|NCT01680809|Experimental|Compression stocking 20-30mmHg|Compression stocking 20-30mmHg
3131069|NCT01680796|Experimental|Active Treatment|"Dovitinib will be given at up to four different dose levels beginning with dose level 1 on a 5 days on/2 days off dosing schedule of each 21-day cycle.~Bortezomib will be given at two different dose levels intravenously on Days 1 and 8 of each 21-day cycle.~Dexamethasone will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle."
3131070|NCT01680783|Other|Usual Care|Patients who require noninvasive ventilation via Face mask for more than 8 hours will continue using noninvasive ventilation via facemask.
3131071|NCT01680783|Experimental|Non invasive ventilation via helmet|Patients requiring more than 8 hours of noninvasive ventilation via facemask will switch to non-invasive ventilation using a helmet instead of face mask for treatment of respiratory failure
3131072|NCT01680770||Hypotensive patients in shock|
3131073|NCT01680757|Experimental|LAA exclusion with LARIAT & Accessories|Permanent exclusion of the LAA using the LARIAT Suture Delivery Device and Accessories
3131074|NCT01680744|Experimental|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure > 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
3131075|NCT01680744|No Intervention|Standard Treatment|
3131076|NCT01680731||Forceps assisted vaginal delivery|Forceps assisted vaginal delivery within 1-5 years without any interval delivery
3131077|NCT01680731||Vacuum assisted vaginal delivery|Vacuum assisted vaginal delivery within 1-5 years without any interval delivery
3131078|NCT01680731||Elective cesarean delivery|Elective cesarean vaginal delivery within 1-5 years without any interval delivery done prior to labor
3131079|NCT01680731||Spontaneous vaginal delivery|Spontaneous vaginal delivery within 1-5 years without any interval delivery
3131080|NCT01680718|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
3131081|NCT01680718|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
3131082|NCT01680718|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010). Participants will self-administer 5 puffs per nostril.
3131083|NCT01680705|Active Comparator|Frequency: Once Daily|Patients will use high volume saline irrigation once daily post operatively.
3131084|NCT01680705|Active Comparator|Frequency: Twice Daily|Patients will use high volume saline irrigation twice daily post operatively.
3131085|NCT01680705|Active Comparator|Frequency: Three Times Daily|Patients will use high volume saline irrigation three times daily post operatively.
3131086|NCT01680692|Active Comparator|Continuous femoral and single shot sciatic nerve block|Will receive pre-operative continuous femoral catheter & post-operative single shot sciatic with both given an initial bolus of 30 mL (femoral) 0.5% Ropivicaine & 20mL (sciatic) 0.2% Ropivicaine. Following surgery the femoral infusion will be started, which will be running Ropivicaine 0.2 at 10cc/hr.
3131087|NCT01680692|Experimental|Continuous femoral and tibial peripheral nerve catheters|Patients will receive pre-operative continuous femoral catheter & post-operative continuous tibial catheter with an initial bolus of 30 mL 0.5% Ropivicaine (femoral) & 20mL 0.2% Ropivicaine (tibial), which will be followed by infusions post-operatively running at 10cc/hr.
3131088|NCT01680679|Experimental|Inactivated Trivalent Influenza Vaccine|Inactivated trivalent influenza vaccine (TIV), split virion
3131089|NCT01680679|Placebo Comparator|Inactivated Polio Vaccine|Inactivated poliovirus vaccine (IPV), trivalent
3131090|NCT01680679|No Intervention|Surveillance arm|Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members.
3131091|NCT01680666|Active Comparator|landmark guided|central line placement
3131092|NCT01680666|Active Comparator|ultrasound guided|central line placement
3131093|NCT01680653|Experimental|Mini-Glucagon and Remote Monitoring|"Subjects glucose data are remotely monitored at night using the University of Virginia (UVA) Diabetes Assistant (DiAs) Android Platform. Study staff intervenes with a fingerstick blood glucose measurement when sensor value falls below 70mg/dL. If fingerstick value is less than 70 mg/dL, hypoglycemic treatment is administered as below.~Administer mini-glucagon as treatment for nocturnal hypoglycemia. Administer 0.01 cc per number of years in age via insulin syringe, subcutaneously. This amounts to 1 unit per age, for example: an 8 year old gets 8 units glucagon."
3131131|NCT01680406|Experimental|Chloroquine and primaquine|"Chloroquine will be given in a weight-based dose to be administered once daily for three days.~Primaquine will be given beginning on day 2 of chloroquine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days."
3131574|NCT01677455|Experimental|HER2+ breast cancer|
3131094|NCT01680653|Other|Carbohydrates and Remote Monitoring|"Subjects glucose data are remotely monitored at night using the University of Virginia (UVA) Diabetes Assistant (DiAs) Android Platform. Study staff intervenes with a fingerstick blood glucose measurement when sensor value falls below 70mg/dL. If fingerstick value is less than 70 mg/dL, hypoglycemic treatment is administered as below.~Administration of carbohydrate per camp protocol to treat nocturnal hypoglycemia. Expected treatment is 15-45g."
3131095|NCT01680653|Other|Carbohydrates No Remote Monitoring|"Subjects wear a continuous glucose monitor for their own use, but they are not remotely monitored.~If hypoglycemia occurs and is acknowledged through standard camp protocol it will be treated with standard camp protocol administration of carbohydrates. Expected treatment is 15g-45g."
3131096|NCT01680653|Other|Mini-Glucagon and No Remote Monitoring|"Subjects wear a continuous glucose monitor for their own use, but they are not remotely monitored.~If hypoglycemia occurs and is acknowledged through standard camp protocol it will be treated with mini-glucagon.~Administer mini-glucagon as treatment for nocturnal hypoglycemia. Administer 0.01 cc per number of years in age via insulin syringe, subcutaneously. This amounts to 1 unit per age, for example: an 8 year old gets 8 units glucagon."
3131097|NCT01680640|Active Comparator|Synbiotic|Fructo-oligosachharide with a degree of polymerization < 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis BB-12 as minimum of 10 billion CFU/day (1 capsule a day).
3131098|NCT01680640|Placebo Comparator|Maltodextrin|4 grams of maltodextrin daily.
3131099|NCT01680627||ADOLESCENT|
3131100|NCT01680614||At Risk Adult Drinkers|CASI
3131101|NCT01680601|Experimental|RIPC group|Patients assigned to this arm will go through a remote ischaemic preconditioning (RIPC)protocol
3131102|NCT01680601|Placebo Comparator|Control|Patients assigned to this arm will not receive the intervention, however the protocol will be applied to a wooden block in order to maintain blinding to relatives and investigators.
3131103|NCT01680588|Experimental|[18F]NAV4694|Single intravenous injection of 8.1 millicuries of [18F]NAV4694
3131104|NCT01680575||Training cohort|This cohort is a prospective cohort to develop a risk prediction model. This cohort include patients who underwent staging operation or debulking operation for epithelial ovarian cancer and are planned to receive ajuvant chemotherapy with paclitaxel/carboplatin up to 6 cycles.
3131105|NCT01680575||Validation cohort|"This is a retrospective cohort for validation of a risk prediction model developed using training cohort.~This is consisted with 600 patients with epithelial ovarian cancer who received adjuvant chemotherapy with paclitaxel/carboplatin after staging operation or debulking operation."
3131106|NCT01680562||skin cancer|Skin cancer patients with scheduled tumor excision and subsequent histopathological analysis of the tumor.
3131107|NCT01680549|Active Comparator|Gabapentin|Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
3131108|NCT01680549|Placebo Comparator|Placebo|Placebo 600 mg po preoperatively and continued postoperatively 300 mg po q8hours X 3 days
3131109|NCT01680536|Experimental|Maraviroc, darunavir, ritonavir|Single-arm,assessing cerebrospinal fluid inflammatory markers after addition of maraviroc to patients stable on monotherapy darunavir/ritonavir
3131110|NCT01680523|Experimental|RH group|Radical hysterectomy followed by tailored adjuvant therapy
3131111|NCT01680523|Active Comparator|CCRT group|Primary concurrent chemoradiation therapy
3131112|NCT01680510|Experimental|Alga Dunaliella Bardawil 9-cis beta Carotene Rich Powder|50 patients will receive first the capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder and after 24 weeks of washout period will receive capsule containing placebo (Starch).
3131113|NCT01680510|Placebo Comparator|Placebo (Starch)|The other 50 Patients will receive first the placebo (Starch) capsules and after 24 weeks of washout period will receive capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder .
3131114|NCT01680497|Experimental|JUVÉDERM VOLIFT™|All subjects receiving treatment with JUVÉDERM VOLIFT™.
3131115|NCT01680484|Active Comparator|Bitter chocolate|50 grams Ülker Golden %70 bitter chocolate, İstanbul, Turkey
3131116|NCT01680484|Active Comparator|Orange juice|Ülker İçim Orange Juice 250 cc, İstanbul, Turkey
3131117|NCT01680484|No Intervention|Control|Sit and rest
3131118|NCT01680471|Experimental|Midazolam 0.03mg/kg|This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.
3131119|NCT01680471|Experimental|Midazolam 0.05mg/kg|This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.
3131120|NCT01680471|Placebo Comparator|Placebo|This group will be injected intravenous normal saline five minutes before the end of surgery.
3131121|NCT01680458||fluconazole|Infant Subjects who are treated with fluconazole
3131122|NCT01680432|Experimental|Probiotic cheese|The group received, for 30 days, was instructed to eat 30 g/day of probiotic fresh cheese enriched with Bifidobacterium lactis Bi-07.
3131123|NCT01680432|Placebo Comparator|Regular Cheese|The group placebo received, for 30 days, was instructed to consume 30g/day of regular fresh cheese.
3131124|NCT01680419|Experimental|Mission Reconnect only|Autonomous use of the Mission Reconnect multimedia instructional program at home.
3131125|NCT01680419|Active Comparator|PREP only|Participation in a standard PREP for Strong Bonds weekend retreat program.
3131126|NCT01680419|Active Comparator|PREP plus Mission Reconnect|Participation in a standard PREP for Strong Bonds weekend retreat followed by autonomous use of the Mission Reconnect multimedia instructional program at home.
3131127|NCT01680419|No Intervention|Wait-list control|No intervention, followed by delivery of the Mission Reconnect multimedia program materials for home use after the end of the study period.
3131128|NCT01680406|Active Comparator|Artemether-lumefantrine|Weight-based dose to be administered as fixed-dose combination twice daily for three days.
3131129|NCT01680406|Experimental|Artemether-lumefantrine and primaquine|"Artemether-lumefantrine will be given in a weight-based dose to be administered as fixed-dose combination twice daily for three days.~Primaquine will be given beginning on day 2 of artemether-lumefantrine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days."
3131130|NCT01680406|Active Comparator|Chloroquine|Chloroquine will be given in a weight-based dose to be administered once daily for three days.
3131467|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (500 mg/day)|Encapsulated Calcium
3131132|NCT01680393|Experimental|Sequential compression device|During arthroscopic shoulder surgery, an SCD device will be applied to the patients legs during surgery. Cerebral oxygenation and circulatory parameters will be recorded continuously throughout the surgery. Recordings will be hidden to the primary caregiver.
3131133|NCT01680393|Experimental|TED stockings|During arthroscopic shoulder surgery, TED stockings will be applied to the patients legs during surgery. Cerebral oxygenation and circulatory parameters will be recorded continuously throughout the surgery. Recordings will be hidden to the primary caregiver.
3131134|NCT01680393|No Intervention|Control|no stockings will be applied to the patients legs
3131135|NCT01680380||At-Home|Overnight sleep at home
3131136|NCT01680367|Experimental|Arm I (control)|Patients receive transparent film dressing (otolaryngology service) or Xeroform petroleum gel impregnated gauze dressing (surgical oncology service) after surgery.
3131137|NCT01680367|Experimental|Arm II (native collagen wound dressing)|Patients receive native collagen wound dressing after surgery.
3131138|NCT01680354|Active Comparator|ReLEx|One eye is treated with ReLEx the other with LASIK
3131139|NCT01680354|Active Comparator|LASIK|One eye is treated with ReLEx the other with LASIK
3131140|NCT01680341|Experimental|IDegAsp Simple|
3131141|NCT01680341|Experimental|IDegAsp Step wise|
3131142|NCT01680328|Other|Different injection speed and volume combinations|The study consists of 80 treatment arms in a cross-over design with 19 treatments and 19 periods. The 80 treatment arms will represent different orders of the 19 treatments and each treatment arm will be used for one subject. A subject not completing all treatments will be replaced by another subject using the same treatment arm.
3131143|NCT01680315|Experimental|Calorie information|"Low calorie yogurt~High calorie yogurt~with low calorie information sheet"
3131144|NCT01680315|Experimental|Calorie information (high)|"Low calorie yogurt~High calorie yogurt~High calorie information sheet"
3131145|NCT01680302|Experimental|High intensity exercise|High intensity exercise(Borg 16) in intervals.
3131146|NCT01680302|Experimental|Moderate intensity exercise|Moderate intensity exercise 3 times a week.
3131147|NCT01680302|Experimental|Control group|Exercise on their own. Follow current guidelines.
3131148|NCT01680289|Experimental|Three adhesive coats|Consecutive application of three one-bottle adhesive coats
3131149|NCT01680289|Active Comparator|Two adhesive coats|Consecutive application of two one-bottle adhesive coats
3131150|NCT01680276|Experimental|PBS based staff training|"The training, which will be supported by a treatment manual will comprise the following sections:~Functional Behavioural Assessment and formulation skills~• Brief Behavioural Assessment Tool for brief functional analyses~Primary Prevention~Secondary Prevention and Reactive Strategies~Periodic Service Review and Problem Solving~Developing individualised periodic service reviews~Trouble shooting"
3131151|NCT01680276|Other|Treatment as usual|Most community intellectual disability services provide a range of health interventions that include but are not limited to psychiatric assessment and management, nursing support, psychology, speech and language therapy, occupational therapy and counselling. There may be some variation in resources but service users with challenging behaviour are likely to receive a range of broadly defined behavioural management and pharmacological interventions. Staff is routinely supervised by their clinical managers weekly.
3131152|NCT01680263|Experimental|Kinesiotaping|"Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1 week interval"
3131153|NCT01680263|Active Comparator|NSAIDs/Physical therapy|treatment was done with NSAIDs and 10 sessions of daily physical therapy.
3131154|NCT01680250|Experimental|Sirolimus|Sirolimus administration group starting dose: 2mg/day target trough level: 4-10 ng/dL
3131155|NCT01680237|Active Comparator|Cognitive behavior therapy|"Identification of bodily sensations, cognitions and safety behaviors characteristic of the individual patient~Modification of dysfunctional beliefs and assumptions using socratic questioning and behavioral experiments~Exposure in-vivo~Relapse prevention"
3131156|NCT01680237|Active Comparator|Exposure in-vivo|"Preparation of a brief behavior analysis of the individual case and construction of a hierarchy of relevant (internal and external) phobic situations~Exposure with internal stimuli~Exposure with external stimuli~Relapse prevention~Remark: In this condition there is no active work with the patient`s catastrophic cognitions"
3131157|NCT01680224|Active Comparator|Healthy Weight|The main goal of the Healthy Weight intervention is to make small, sustainable changes to input and output on a weekly basis to achieve a balance between caloric intake and output. All sessions begin with a brief review of what was covered in the previous session, presentation of educational handouts, careful review of previous behavior change goals, and the development of healthy behavior change plans for the next session. Home exercises for all sessions consist of following individualized diet and exercise goals, and keeping a food and exercise log to determine areas for future healthy changes.
3131158|NCT01680224|Experimental|Project Health|Project Health adds dissonance-inducing activities, discussions, and homework activities to the Healthy Weight basic intervention. Each session begins with a verbal commitment to participate (to underscore the voluntary nature of participation), includes discussions of completed home practice assignments and in-session writing/sharing exercises (to create accountability), and concludes with home exercises (to increase level of effort). Completed home assignments are videotaped in subsequent sessions to increase accountability.
3131159|NCT01680224|Placebo Comparator|Control|"Some participants will be randomized to control condition whereby they will be given an psychoeducational video (Weight of the World)to view."
3131160|NCT01680211|Experimental|Salacia bark extract (SR-B-01) and TLC|Capsules containing 250mg of salacia bark extract,two times a day along with Therapeutic Lifestyle Change (TLC)
3131161|NCT01680211|Experimental|Sesame seeds extract (SI-S-01) and TLC|Capsules containing 250mg of sesame seed extract,two times a day along with Therapeutic Lifestyle Change (TLC)
3131162|NCT01680211|Experimental|Salacia leaf extract (SR-L-01) and TLC|Capsules containing 250mg of salacia leaf extract,two times a day along with Therapeutic Lifestyle Change (TLC)
3131163|NCT01680211|Placebo Comparator|Placebo and TLC|Capsules containing 250mg of placebo,two times a day along with Therapeutic Lifestyle Change (TLC)
3131164|NCT01680198|Placebo Comparator|Placebo|Placebo capsules daily for 12 weeks.
3131165|NCT01680198|Experimental|Paracalcitol|"see Intervention description for details."
3241713|NCT00902135||Group 3|
3131166|NCT01680185|Active Comparator|Sensor-augmented Insulin Pump|Continuous subcutaneous sensor-augmented insulin-pump therapy (SAPT) with an insulin pump from Medtronic (Paradigm® Velo) for a period of approximately 3 months post-transplantation.
3131167|NCT01680185|Active Comparator|Basal insulin|NPH insulin titration regimen, as specified in the IPT-NODAT study
3131168|NCT01680185|Active Comparator|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation
3131169|NCT01680172|Experimental|Ketamine|Single dose of ketamine (0.5 mg/kg)
3131170|NCT01680172|Placebo Comparator|Placebo|Single dose of placebo
3131171|NCT01680159|Experimental|TA-650|
3131172|NCT01680146|Active Comparator|PRO|Subjects will ingest 20 g of intrinsically labeled casein dissolved in water
3131173|NCT01680146|Experimental|PRO+FAT|Subjects will ingest 20 g of intrinsically labeled casein plus 26.7 g of anhydrous milk fat dissolved in water
3131174|NCT01680133||NGT|Normal glycaemic healthy control men, age between 45-65, BMI 25-35 kg/m2
3131175|NCT01680133||T2D|Type 2 diabetic men, age 45-65 yrs, BMI 25-35, diagnosed >5yrs and Hba1c 7-9%
3131176|NCT01680120|Experimental|Continuous spinal anaesthesia|
3131177|NCT01680107|Experimental|d-cycloserine|oral, capsule, 250 mg, once
3131178|NCT01680107|Placebo Comparator|sugar pill|oral, capsule, once
3131179|NCT01680094|Experimental|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
3131180|NCT01680081|Experimental|CT perfusion group|
3131181|NCT01680068|Experimental|Pars plana vitrectomy and postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
3131182|NCT01680055||AA-ATG|Acquired Aplastic Anemia Patients Treated with Antithymocyte Globulin plus Cyclosporine
3131183|NCT01680042|Active Comparator|phenytoin paste|this group receives phenytoin paste after oral biopsy
3131184|NCT01680042|Placebo Comparator|usual mucoadhesive paste|this group receives the usual mucoadhesive paste without phenytoin after oral biopsy
3131185|NCT01680029|Experimental|PBASE-system 2.0|
3131186|NCT01680016|Experimental|Zagreb(≥6 to ≤17 Years)|
3131187|NCT01680016|Experimental|Zagreb(≥51 Years)|
3131188|NCT01680016|Active Comparator|Essen(≥6 to ≤17 Years)|
3131189|NCT01680016|Active Comparator|Essen(≥51 Years)|
3131190|NCT01680003|Experimental|Hepar-P|Hepar-P: Two capsules (250mg x 2), three times daily, orally
3131191|NCT01680003|Placebo Comparator|Placebo for Hepar-P|Placebo: Two capsules, three times daily, orally
3131192|NCT01679990|Experimental|PLX-PAD Low dose|PLX-PAD double low doses
3131193|NCT01679990|Active Comparator|PLX-PAD high doses|PLX-PAD double high dose
3131194|NCT01679990|Placebo Comparator|Placebo|Double Placebo doses
3131195|NCT01679990|Experimental|PLX-PAD high dose +Placebo|High dose+Placebo
3131196|NCT01679977|Active Comparator|Legpress|"Subjects in the LP group train on a custom built, computer controlled, linear electric motor powered leg press device. The so called swinging vibrational-proprioceptive mode is used, which means that constant velocity of the pedals (0.3 m/s and 0.2 m/s for concentric and eccentric phase, respectively) are interrupted by short stops (every 8 mm), resulting in short force peaks appearing throughout the movement. Training load is progressively increased throughout the training."
3131197|NCT01679977|Active Comparator|E-Stim|ES training is performed with a custom-built battery-powered stimulator. The subject are seated over the edge of the therapeutic table with the trunk upright and lower legs freely swinging. Two conductive rubber electrodes covered by wet sponge are placed on the anterior thigh on each side of the body. The electrode pairs are connected to the independent channels of the stimulator and the left and the right thigh are stimulated in an alternative manner. Each repetition (i.e. ES evoked muscle contraction) is evoked by a 3.5 s train (60 Hz) of electrical pulses (rectangular, biphasic, width 0.6 ms). Consecutive contractions of the same thigh are separated by 4.5 s off intervals. Maximal tolerable intensity should be used and is monitored during the training sessions. In all the subjects this should induce a tetanic contraction of the stimulated muscles.
3131198|NCT01679977|No Intervention|Control|This group only perform the same measurements as the intervention groups and lives their live as usual in between.
3131199|NCT01679964|Other|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
3131200|NCT01679951|Placebo Comparator|Placebo|
3131201|NCT01679951|Experimental|JNJ-38518168 (3 mg/d)|
3131202|NCT01679951|Experimental|JNJ-38518168 (10 mg/d)|
3131203|NCT01679951|Experimental|JNJ-38518168 (30 mg/d)|
3131204|NCT01679938|Experimental|primary obesity prevention|"The intervention will involve four main components:~Training of child care providers.~Curriculum sessions for children.~Family outreach activities.~Maintenance activities."
3131205|NCT01679938|No Intervention|Control group|For the control group, usual care will be provided
3131206|NCT01679912|Experimental|1: phone to call center|recommendations to phone to the call center for all the patients who have an acute attack
3131207|NCT01679912|No Intervention|2: usual strategy|usual strategy. No intervention (patients does not change their practice)
3131208|NCT01679899|Experimental|Vildagliptin|Vildagliptin 50 mg bid for 12 months
3131209|NCT01679899|Active Comparator|Gliclazide MR|Gliclazide MR 60 or 120mg once a day for 12 months
3131210|NCT01679886|Experimental|Rubidium PET|Rubidium PET
3131211|NCT01679873|Placebo Comparator|Control group|Assess abstract not reporting funding sources or conflicts of interest
3131212|NCT01679873|Experimental|Funding sources|Assess one type of abstract in the randomized arm. Assess abstract reporting funding sources only.
3131213|NCT01679873|Experimental|Funding sources/Conflicts of Interests|Assess one type of abstract in the randomized arm. Assess abstract reporting funding sources and conflicts of interest
3131214|NCT01679860|Experimental|Clin A|Clin A. CHOP-Campath (CHOP-C) for 2 cycles , Hyper-C-Hidam for 2 cycles and auto-SCT (stem cell transplantation) or RIC allo-SCT in advanced stage PTCL pts ≥ 18 and ≤ 60 years
3131468|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (1000 mg/day)|Encapsulated Calcium
3131215|NCT01679860|Experimental|Clin B|Clin B: CHOP-Campath (CHOP-C) for 6 cycles . It is a combined immunochemotherapy approach in a subset of elderly pts aged > 60 ≤ 75 years
3131216|NCT01679834||Cohort|
3131217|NCT01679821||Dental students|Seventy dental students of State University of West of Paraná - UNIOESTE. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. A questionnaire and a clinical examination were employed.
3131218|NCT01679821||Removable partial denture|Seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous). Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary were not included in the research. A questionnaire and a clinical examination were employed.
3131219|NCT01679821||Double complete denture|Seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Patients wearing just one complete denture were not included in the research. A questionnaire and a clinical examination were employed.
3131220|NCT01679795|Experimental|Tibolone|patientes will use tibolone 2,5mg/day during 30 days
3131221|NCT01679795|Placebo Comparator|Placebo use|Patients will use placebo for 30 days
3131222|NCT01679782||COPD nocturnal desaturator|COPD patients who spend 30% of the nigth with a SaO2 < 90%.
3131223|NCT01679782||COPD no nocturnal desaturator|COPD patients who spend less than 30% of the night with a SaO2 < 90%
3131224|NCT01679782||control group|healthy sedentary subjects
3131225|NCT01679756|Experimental|Intracorporeal anastomosis|Laparoscopic right hemicolectomy for cancer. .For the IA group, colon, transverse mesocolon, ileum and terminal ileum mesentery will be resected intracorporeally through a 45 mm endoscopic linear stapler with vascular cartridge. Then, the linear stapler will inserted through two small enterotomies and a mechanical ileo-transverse, side-to-side isoperistaltic intracorporeal anastomosis performed using the vascular cartridge with six rows of closely placed staples. The enterotomies will be then closed using a double layered continuous intra corporeal manual suture with 3-0 Polyglactin 910. The mesenteric defects will be left open. The specimen will be placed in a protective plastic bag and then extracted through a Pfannestiel incision.
3131226|NCT01679756|Active Comparator|Extracorporeal anastomosis|"Laparoscopic right hemicolectomy for cancer. In the EA group, the bowel will be externalized by widening the incision of one of the trocars or by performing a mini-laparotomy at another location (subcostal, suprapubic) protected with a plastic sheet. The ileum and colon will be then resected through a 45 mm endoscopic linear stapler with vascular cartridge (staple height = 3.85 mm) and a side-to-side isoperistaltic mechanical anastomosis will be then performed using the same vascular cartridge. The enterotomies will be then closed using a double layered continuous manual suture using a 3-0 Polyglactin 910.~In both groups, a drain will not routinely inserted."
3131227|NCT01679743|Experimental|A|Breast Cancer Cohort
3131228|NCT01679743|Experimental|B|Non-Small Cell Lung Cancer Cohort
3131229|NCT01679730||irritable bowel syndrome patients|
3131230|NCT01679717|Active Comparator|Early mobilisation after CMC1-surgery|Mobilisation at two weeks after operation. The participants will wear a soft splint for six weeks.
3131231|NCT01679717|Other|Conservative treatment after CMC1-surgery|Current standard procedure: Mobilisation at six weeks after operation. The participants will wear a rigid splint for six weeks.
3131232|NCT01679704|Other|Food products|Ten food products will be given to all subjects
3131233|NCT01679691|No Intervention|Control group|Control group in whom no epidural anesthesia will be applied
3131234|NCT01679691|Active Comparator|Epidural Anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
3131235|NCT01679678|Experimental|PolyHeal 2|Negatively charged 5-micron polystyrene microspheres in Water For Injection
3131236|NCT01679678|Active Comparator|PolyHeal|Negatively charged 5-micron polystyrene microspheres suspended in Dulbecco's Modified Eagle's Medium (DMEM)
3131237|NCT01679665|Experimental|320U /0.5ml in children (from 2 to 5 years old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 48 children aged 2-5 years old on day 0,28
3131238|NCT01679665|Placebo Comparator|0/0.5ml placebo in children (from 2 to 5 years old)|0/0.5ml placebo in 24 children aged 2-5 years old on day 0, 28
3131239|NCT01679652|Experimental|Nebivolol|Tablet Nebivolol 5 mg (oral use) for 5 days
3131240|NCT01679652|Placebo Comparator|Placebo|Inactive placebo given as tablet for 5 days
3131241|NCT01679639|Experimental|Aleglitazar|
3131242|NCT01679613|Experimental|1 Nintedanib (Reference)|single dose, oral with 240 ml water
3131243|NCT01679613|Experimental|2 Nintedanib + Ketoconazole (Test)|Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
3131244|NCT01679613|Experimental|3 Nintedanib (Reference)|single dose, oral with 240 ml water
3131245|NCT01679613|Experimental|4 Nintedanib + Ketoconazole (Test)|Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
3131246|NCT01679600|Experimental|FC-RATE|Feedback-controlled robotics-assisted treadmill exercise
3131247|NCT01679600|Active Comparator|RATE|Robotics-assisted treadmill exercise
3131248|NCT01679587|Experimental|Molidustat, 80 mg|Subjects received a single oral dose of 80 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week.
3131249|NCT01679587|Experimental|Molidustat, 120 mg|Subjects received a single oral dose of 120 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week.
3131250|NCT01679587|Experimental|Molidustat, 40 mg|Subjects received a single oral dose of 40 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step.
3131251|NCT01679587|Experimental|Molidustat, 160 mg|Subjects received a single oral dose of 160 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step.
3131252|NCT01679574|Experimental|letrozole|Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
3131253|NCT01679574|Active Comparator|Metformin and clomiphene|".Drug: metformin (Cidophage®; CID,Cairo, Egypt) metformin 1500 daily for 3 months~Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation"
3242022|NCT00898859||5|COPD, smokers
3131254|NCT01679561|Experimental|intralipids|Two hundreds patients (group1) with abnormal NK activity results (NKa)will receive intralipids 20% i.v. (9 mg/mL total blood volume -corresponds to 2 mL of intralipids 20% diluted in 250 mL saline; or 18 mg/mL - corresponds to 4 mL of intralipids 20% diluted in 250 mL saline) infusions and their NKa will be tested periodically. The determination of NK cell function will be performed by flow cytometry using K562 cells as targets,then follow up of the patients by the Doppler of endometrial blood follow at the time of luteal phase,and the clinical pregnancy rate.Group(2)of 180 patients will receive placebo.
3131255|NCT01679548|Experimental|Single-port LAVH group|single-port laparoscopic assisted vaginal hysterectomy
3131256|NCT01679548|Active Comparator|Three-port LAVH group|three-port laparoscopic assisted vaginal hysterectomy
3131257|NCT01679535|Experimental|Intervention|nutrition and hygiene education by community health workers
3131258|NCT01679522|Experimental|Single-port surgery group|Single-port laparoscopic surgical staging including total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
3131259|NCT01679522|Active Comparator|Four-port surgery group|Four-port laparoscopic surgical staging including total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
3131260|NCT01679509|Experimental|Single-port surgery group|Single-port laparoscopic adnexal surgery
3131261|NCT01679509|Active Comparator|Three-port surgery group|Three-port laparoscopic adnexal surgery
3131262|NCT01679496|Experimental|Food items|Food items low in saturated fat and high in polyunsaturated fat
3131263|NCT01679496|Placebo Comparator|Control food items|Food items containing saturated fat and polyunsaturated fat according to a traditional Norwegian diet
3131264|NCT01679483|Experimental|FloSeal group|This group will undergo appropriate cancer surgery for each patient with pelvic lymph node dissection +/- para-aortic lymph node dissection. At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
3131265|NCT01679483|No Intervention|No FloSeal group|All surgical procedures of control group is the same with study group except that Floseal is not applicated in control group.
3131266|NCT01679457|Experimental|ACT-Focused ERP|One Session.
3131267|NCT01679457|Active Comparator|TAU-ERP|One Session.
3131268|NCT01679431||Patients with aortic stenosis|"Patients have every year: 1) an assessment of cardiometabolic risk profile with measure of body mass index, waist circumference and fasting blood sample and 2) a comprehensive Doppler-echocardiography exam.~Computed tomography and magnetic resonance imaging are performed every 2 years."
3131269|NCT01679418|Active Comparator|Drain placement (Group A)|Patients in group A received a wound drain after surgery.
3131270|NCT01679418|Sham Comparator|No-drain placement (group B)|Patients assigned to group B, did not receive a wound drain after surgery.
3131271|NCT01679405|Experimental|BIBW 2992 added to the standard therapy|"In part A the maximum tolerated dose (MTD) of oral BIBW 2992 administered continuously added to the standard therapy of Gemcitabine / Cisplatin (Gem/Cis) (administered together on day 1 and 8 of a three-week cycle) will be evaluated in a 2 step dose escalation.~In part B (phase Ib) of this study, the MTD cohort may be expanded up to 7 further patients and one or two additional study centers may be recruited.~During Part B dose adjustments, based on individual patient's tolerability, are possible. A dose increase of BIBW 2992 higher than 40 mg daily per os is not permitted."
3131272|NCT01679392|Experimental|Ropivacaine|Unilateral transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
3131273|NCT01679379|Active Comparator|Absorbable suture group|Include women who have their skin closed with subcuticular stitches using [Polyglactin 910 absorbable, synthetic, braided suture].
3131274|NCT01679379|Active Comparator|Non absorbable suture group|Include women who have their skin closed with subcuticular stitches using [Polypropylene non absorbable monofilament suture].
3131275|NCT01679366|No Intervention|Penicillin G|hospitalization of 30 patients given penicilline intraveniously for 72 hours
3131276|NCT01679366|Placebo Comparator|Placebo|30 hospitalized patients will be given placebo with a regular penicillin treatment
3131277|NCT01679366|Experimental|Probiotic|Probiotics will be given to 30 hospitalized patients with regular penicillin treatment
3131278|NCT01679353|Placebo Comparator|placebo group|normal saline 0.5ml
3131279|NCT01679353|Experimental|magnesum group|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.5mL added to ropivacaine 0.15% 1.0 ml/kg was administered to Group R , Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.
3131280|NCT01679340|Experimental|S-1+oxaliplatin|S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d oxaliplatin: 65mg/m2, D1,D8, 3weeks/cycle after 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.
3131281|NCT01679340|Active Comparator|S-1+cisplatin|S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d) cisplatin: 75mg/m2, D1, every 3 weeks After 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.
3131282|NCT01679327|Experimental|Bevacizumab plus chemotherapy（XELOX or FOLFOX）|Bevacizumab plus XELOX (Bevacizumab 7.5mg/kg d1;Xeloda 2g/m2 d1-14 divided into two times;Oxaliplatin 130mg/m2 d1;repeated in 21 days) Bevacizumab plus FOLFOX (Oxaliplatin 85mg/ m2 ivgtt d1;CF 200mg/ m2 ivgtt d1;Bevacizumab 5mg/kg ivgtt d1 5-FU 400mg /m2 ivgtt d1;5-FU 2400mg/m2 CIV 48h;repeated in 14 days)
3131283|NCT01679314|Active Comparator|Active AlphaCore device|AlphaCore active stimulation treatment
3131284|NCT01679314|Sham Comparator|Sham AlphaCore device|AlphaCore sham device
3131285|NCT01679301||Continuous dose oxygen first part of night|Users will be randomized to either receive oxygen via continuous dose or pulsed dose ('sleep' mode) for the first part of the night and will switch for the second part of the night.
3131286|NCT01679301||Pulse dose ('sleep mode') first part of night|Users will be randomized to either receive oxygen via continuous dose or pulsed dose ('sleep' mode) for the first part of the night and will switch for the second part of the night.
3131287|NCT01679288|Experimental|ultrasound arm|Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
3131469|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (1500 mg/day)|Encapsulated Calcium
3131288|NCT01679275|Other|measuring cerebral oxygenation|NIRS: Measurement of cerebral oxygenation using Near Infrared Spectroscopy (NIRS) during the pre-operative phase in neonates with congenital heart disease.
3131289|NCT01679262|Other|Optimal size of OPAs|
3131290|NCT01679249||Hemodialysis patients|Stable prevalent patients on 3-times-per-week hemodialysis
3131291|NCT01679236|Active Comparator|Mindfulness Training for Smokers|Mindfulness Training for Smokers (MTS) is a 7-week intervention that provides instruction in mindfulness very similar to the way it is taught in Mindfulnes-Based Stress Reduction. In addition MTS provides mindfulness training targeted to specific smoking relapse challenges. The MTS intervention was designed around a weekly curriculum that provides instruction to help participants learn practices including mindfulness meditation, mindful walking and mindful eating. MTS participants are instructed to practice meditation 30 minutes per day with a guided meditation CD.
3131292|NCT01679236|Active Comparator|Interactive Learning for Smokers|Interactive Learning for Smokers (ILS) is a 7-week intervention that provides a closely matched active control group for MTS, but with substantive education and skills training for smoking cessation. To this end, ILS combines elements of two smoking cessation programs, the American Lung Association, Freedom from Smoking program and The Mayo Clinic Nicotine Dependence Center program. ILS participants were asked to practice 30 minutes of silent non-directed walking per day throughout the intervention and were instructed to use non-directed walking for relaxation, stress reduction and as a strategy for managing urges and withdrawal symptoms.
3131293|NCT01679223||<40 years|subjects aged less than 40 years
3131294|NCT01679223||40-60 years|subjects aged 40-60years
3131295|NCT01679223||> 60 years|subjects aged greater than 60 years
3131296|NCT01679210|Experimental|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
3131297|NCT01679210|No Intervention|Health and Wellness|Standard of care group.
3131298|NCT01679197|Experimental|Treatment|Metreleptin
3131299|NCT01679158|Experimental|Continuous Horizontal row|Use the IOP system from USGI to install suture anchors running from the distal body into the proximal antrum
3131300|NCT01679158|Experimental|"Reduction in ring opening"|"Use the IOP system from USGI to install suture anchors to reduce the ring opening to the antrum"
3131301|NCT01679158|Experimental|Control Arm|Use the IOP system from USGI to install suture anchors in the Current V shape in distal body
3131302|NCT01679145||Alcohol- dependent patients|Detoxified alcohol- dependent patients in an inpatient setting
3131303|NCT01679145||Control group|Age- and gender matched healthy controls
3131304|NCT01679132|Experimental|Neo Baroreflex Activation Therapy System|Patients are randomized to receive Neo Baroreflex Activation Therapy System device plus optimal medical management.
3131305|NCT01679132|Active Comparator|Medical Management Arm|Patients are randomized to receive optimal medical management alone.
3131306|NCT01679119|Experimental|IO-R-CVP|Inotuzumab Ozogamicin plus Rituximab and CVP (Cyclophosphamide, vincristine & prednisolone).
3131307|NCT01679119|Active Comparator|Gem-R-CVP|Gemcitabine plus Rituximab and CVP (Cyclophosphamide, Vincristine and Prednisolone).
3131308|NCT01679106|Placebo Comparator|Fentanyl IV PCA and placebo TAP catheter|Patients will receive Fentanyl IV PCA and placebo TAP catheter.
3131309|NCT01679106|Active Comparator|TAP catheter with continuous infusion of Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine for up to 48 hours after surgery.
3131310|NCT01679093|Active Comparator|ONDANSETRON (OS)|patients receiving ondansetron at the beginning of the surgery to prevent postoperative nausea and vomiting (PONV); and paracetamol at the end of the surgery for postoperative analgesia.
3131311|NCT01679093|Active Comparator|DROPERIDOL (DRO)|patients receiving droperidol at the beginning of the surgery to prevent PONV; and paracetamol at the end of the surgey for postoperative analgesia.
3131312|NCT01679093|Active Comparator|DEXAMETHASONE (DEXA)|patients receiving dexamethasone at the beginning of the surgery to prevent PONV; and paracetamol at the end of the surgey for postoperative analgesia.
3131313|NCT01679080|Experimental|Zolendronic acid, 3 yr + placebo teriparatide, 2 yr|yearly intravenous infusion of 5mg active zoledronic acid in 3 yr
3131314|NCT01679080|Experimental|teriparatide 2 yr; active zol in 3rd yr|daily injection of one dose active teriparatide for two years, active zoledronic acid in year 3.
3131315|NCT01679080|Placebo Comparator|No active treatment|Observation in three years, no treatment
3131316|NCT01679067||HIV-GALT|
3131317|NCT01679054||EOX|Epirubicin + Oxaliplatin + Capecitabine (EOX) Epirubicin 50 mg/m2 iv bolus d1 q3w x 8 cycles Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hours d1 q3w x 8 cycles Capecitabine (Xeloda) 625 mg/m2 po bid x 6 months
3131318|NCT01679054||FOLFOX4|FOLFOX4 Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
3131319|NCT01679041|Experimental|Single Arm|Conditioning regimens with Alemtuzumab, Fludarabine, and Cyclophosphamide will be used for all patients.
3131320|NCT01679028|Placebo Comparator|Placebo Group A|150mg Placebo Single dose
3131321|NCT01679028|Experimental|T89 Group A|150mg T89 single dose
3131322|NCT01679028|Placebo Comparator|Placebo Group B|300mg placebo single dose
3131323|NCT01679028|Experimental|T89 Group B|300mg T89 single dose
3131324|NCT01679028|Placebo Comparator|Placebo Group C|225mg Placebo bid for 14 days
3131325|NCT01679028|Experimental|T89 Group C|225mg T89 bid for 14 days
3131326|NCT01679015||Dry Eyes, Eye Allergies|Patients with ocular allergies and those with dry eyes.
3131327|NCT01679002|Experimental|Group A|"BIA 2-093 900 mg once-daily period followed by BIA 2-093 450 mg twice-daily period followed by oxcarbazepine 450 mg twice-daily period~BIA 2-093 450 mg od - BIA 2-093 450 mg bid - OXC 900 mg bid"
3131328|NCT01679002|Experimental|Group B|"BIA 2-093 450 mg twice-daily period followed by oxcarbazepine 450 mg twice-daily period followed by BIA 2-093 900 mg once-daily period~BIA 2-093 450 mg bid - OXC 450 mg bid - BIA 2-093 900 mg od"
3131329|NCT01679002|Experimental|Group C|"oxcarbazepine 450 mg twice-daily period followed by BIA 2-093 900 mg once-daily period followed by BIA 2-093 450 mg twice-daily period~OXC 450 mg bid - BIA 2-093 900 mg od - BIA 2-093 450 mg bid"
3131330|NCT01678989||Patient group|Children with BD, (20 children) 12-18 year-old who agreed to participate in the study will be established.
3131331|NCT01678989||Risk group|Twenty healthy children of 12-18 years old who have mothers and/or fathers who previously assessed by an adult psychiatrist and diagnosed as BD according to DSM-IV diagnostic criteria, and who agreed to participate in the study. The age and gender of the groups will be matched.
3131332|NCT01678989||Healthy control group|Twenty participants between the ages of 12-18 who agree to participate in the study and whose family members do not have BD. The age and the gender of the groups will be matched.
3131333|NCT01678976|Experimental|Group 1 BIA 2-093 + Oxcarbazepine|Period 1 - Subjects recieved 900 mg of BIA 2-093 Period 2 - Subjects recieved 900 mg of oxcarbazepine
3131334|NCT01678976|Active Comparator|Group 2 Oxcarbazepine + BIA 2-093|Period 1 - Subjects recieved 900 mg of oxcarbazepine Period 2 - Subjects recieved 900 mg of BIA 2-093
3131335|NCT01678963|Experimental|Squalamine|Squalamine eye drop 0.2%
3131336|NCT01678963|Placebo Comparator|Vehicle Control|Eye drop vehicle control
3131337|NCT01678937||Control Group|"Ten Healthy individuals will have blood drawn (4 green top tubes(40 ml = 8 tsp.)) at one time point at Northwestern for control purposes. Blood will be drawn to conduct the following tests:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells), and~HLA microchimerism & HLA G."
3131338|NCT01678937||Monotherapy Group|"Monotherapy patients [cyclosporine (CyA) (10 patients), Tacrolimus (5 patients), mycophenolate mofetil (MMF) (10 patients), rapamycin (10 patients)]: Blood will be drawn at one time point (4 green top tubes (40 ml = 8 tsp.)) to conduct the following tests:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells), and~HLA microchimerism & HLA G."
3131339|NCT01678937||Conversion Group|Ten CNI monotherapy/dual therapy (CNI + MMF) patients pre-selected for conversion to rapamycin or wean to MMF monotherapy. Assays performed 2 weeks prior to conversion, 3-6 months following successful conversion. Liver function/drug levels monitored weekly during conversion until stable levels achieved. Patients converting from CNI monotherapy to rapamycin monotherapy (2-4 wks.): CNI discontinued when 2 therapeutic rapamycin levels (5-10) reached, graft function stable (clinical care protocol). MMF conversion: MMF dose slowly increased to 3 g/day (max.) while CNI therapy reduced by 1-2 mg/day (FK506) or 25-50 mg/day (CyA) monthly until CNI discontinued (1-6 months) (clinical care protocol). Monthly liver function/drug levels performed after successful conversion (standard of care).
3131340|NCT01678924|Experimental|AGN-214868 Dose 1|AGN-214868 Dose 1 given as injections into the area of pain on Day 1.
3131341|NCT01678924|Experimental|AGN-214868 Dose 2|AGN-214868 Dose 2 given as injections into the area of pain on Day 1.
3131342|NCT01678924|Placebo Comparator|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
3131343|NCT01678924|Experimental|AGN-214868 Dose 3|AGN-214868 Dose 3 given as injections into the area of pain on Day 1.
3131344|NCT01678911|Placebo Comparator|Placebo then Gralise|Subjects may receive a pill with no medicine (placebo) for phase 1. Subject washout, then cross over to Gralise in Phase 2.
3131345|NCT01678911|Active Comparator|Gralise then Placebo|Subjects recieve Gralise (a long acting gabapentinoid) for phase 1.Subject washout, then cross over to placebo in Phase 2.
3131346|NCT01678898|Experimental|0.2 mg/kg|PRX-102 0.2 mg/kg every 2 weeks
3131347|NCT01678898|Experimental|1 mg/kg|PRX-102 1 mg/kg every 2 weeks
3131348|NCT01678898|Experimental|2 mg/kg|PRX-102 2 mg/kg every 2 weeks
3131349|NCT01678885|Experimental|Sub-study 1, Dig Photo, Actical & IDEEA|During one week of the doubly labeled water (DLW), participants will use digital photography of foods. During the other week of the DLW phase, participants will wear the Intelligent Device for Energy Expenditure and Activity (IDEEA) monitor and Actical monitor. Whether the participants wear the monitors first or complete digital photography first will be randomozed. Participants who complete the first two weeks and have a BMI over 25kg/m2 will receive a partial supplement low-calorie diet (LCD) for 8 weeks. This diet plan is a 1000-1150 kcal/day diet that participants will complete in a free-living environment. All participants will return to follow-up at six and twelve months after they completed the LCD. Anthropometric and questionnaire data will be collected.
3131350|NCT01678885|Experimental|Sub-study 2 - Dig Photo & Sensewear|During one week of the doubly labeled water (DLW) period, participants will use digital photography of foods. During the other week of the DLW phase, participants will wear the Sensewear armband. Whether the participants wear the monitor first or complete digital photography first will be randomozed. Participants who complete the first two weeks and have a BMI over 25kg/m2 will receive a partial supplement low-calorie diet (LCD) for 8 weeks. This diet plan is a 1000-1150 kcal/day diet that participants will complete in a free-living environment. All participants will return to follow-up at six and twelve months after they completed the LCD. Anthropometric and questionnaire data will be collected.
3131351|NCT01678872|Other|Long Term Follow up|Long Term follow up of patients who received RetinoStat in a previous study.
3131352|NCT01678846|Experimental|Good School Toolkit|Schools in the intervention arm will receive the Good Schools Toolkit materials and implementation support.
3131353|NCT01678846|No Intervention|Control|Schools in this arm will receive the Good Schools Toolkit materials and some implementation support after the end of the trial.
3131354|NCT01678820|Experimental|Sitagliptin/Simvastatin FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC plus placebo to sitagliptin plus placebo to simvastatin administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of >=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
3131355|NCT01678820|Active Comparator|Sitagliptin|Sitagliptin 100 mg plus placebo to simvastatin plus placebo to sitagliptin/simvastatin FDC administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of >=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
3131462|NCT01678131|Experimental|Vaniprevir 600 mg|Participants received 600 mg vaniprevir only on days 1-7, and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
3243878|NCT00883649|Active Comparator|2|
3131356|NCT01678820|Active Comparator|Simvastatin|Simvastatin 40 mg plus placebo to sitagliptin plus placebo to sitagliptin/simvastatin FDC administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of >=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
3131357|NCT01678807|Experimental|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablet administered sublingually once daily for 28 days
3131358|NCT01678807|Experimental|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablet administered sublingually once daily for 28 days
3131359|NCT01678807|Placebo Comparator|Placebo|Placebo rapidly dissolving tablet administered sublingually once daily for 28 days
3131360|NCT01678794|Experimental|Candesartan|
3131361|NCT01678794|Placebo Comparator|Placebo|
3131362|NCT01678781||One patient group|Patients suffering from irritable bowel syndrome
3131363|NCT01678755|Experimental|ABT-126 Low Dose|ABT-126 Low Dose
3131364|NCT01678755|Experimental|ABT-126 High Dose|ABT-126 High Dose
3131365|NCT01678755|Placebo Comparator|Placebo|Placebo
3131366|NCT01678742|Experimental|High-protein diet|
3131367|NCT01678742|Active Comparator|Standard diet|
3131368|NCT01678716|Active Comparator|Essential Health Care (EHC) only|This arm is the basic comparison arm, which will receive the standard package of health services offered through BRAC's essential health care (basic antenatal care, basic counseling on health and nutrition through health worker home visits. In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm.
3131369|NCT01678716|Experimental|EHC + Micronutrient Powders|This arm will be based on the EHC platform but will also include EHC platform health workers promoting and selling the micronutrient powders.
3131370|NCT01678716|Experimental|EHC + BCC|This arm will have a behavior chance communications intervention to improve infant and young child feeding practices. The intervention will be delivered primarily by the frontline health workers who will visit mothers in their homes and counsel them on essential IYCF practices.
3131371|NCT01678716|Experimental|EHC + BCC + Micronutrient powders|This arm will contain both the behavior change communication and the micronutrient powder sales intervention.
3131372|NCT01678703|Active Comparator|Laminaria group|Patients in this group will have cervical preparation with laminaria MedGyn Products, Inc. USA overnight the day before the abortion
3131373|NCT01678703|Active Comparator|Misoprostol group|Patients in this group will have cervical preparation with vaginal Misoprostol 600 mcg overnight the day before the abortion
3131374|NCT01678690|Experimental|Gemcitabine HCl Oral Formulation|Subjects will be treated with Gemcitabine HCl Oral Formulation according to assigned cohort (2 mg or 5 mg or 10 mg) on Day 1 of the 7-day study treatment period
3131375|NCT01678677|Experimental|Group A|Subjects in this group will receive formulation 1 of NTHi vaccine.
3131376|NCT01678677|Experimental|Group B|Subjects in this group will receive formulation 2 of NTHi vaccine.
3131377|NCT01678677|Experimental|Group C|Subjects in this group will receive formulation 3 of NTHi vaccine.
3131378|NCT01678677|Experimental|Group D|Subjects in this group will receive formulation 4 of NTHi vaccine.
3131379|NCT01678677|Experimental|Group E|Subjects in this group will receive formulation 5 of NTHi vaccine and a placebo.
3131380|NCT01678677|Experimental|Group F|Subjects in this group will receive formulation 6 of NTHi vaccine and a placebo.
3131381|NCT01678677|Experimental|Group G|Subjects in this group will receive formulation 7 of NTHi vaccine and a placebo.
3131382|NCT01678677|Experimental|Group H|Subjects in this group will receive formulation 8 of NTHi vaccine and a placebo.
3131383|NCT01678677|Placebo Comparator|Group Placebo 1|Subjects in this group will receive placebo.
3131384|NCT01678677|Placebo Comparator|Group Placebo 2|Subjects in this group will receive placebo.
3131385|NCT01678664|Experimental|embolization or chemoembolization plus everolimus|After 2 sessions of embolization with microsphere of 100 to 500 µm or chemoembolization with 100 mg of doxorubicine and 10 ml of lipiodol, administered every day, 10 mg of everolimus during 24 months or until progression (hepatic and other site).
3131386|NCT01678651|Active Comparator|Human FSH|Human FSH
3131387|NCT01678651|Active Comparator|Recombinant FSH|Recombinant FSH
3131388|NCT01678638|Active Comparator|Early inguinal hernia (IH) repair|IH repair before NICU discharge
3131389|NCT01678638|Active Comparator|Late inguinal hernia (IH) repair|IH repair at 55-60 weeks post-menstrual age
3131390|NCT01678625||Acceleromyography group|Train-of-four ratio calculation (TOF-Watch-SX-Bluestar enterprise)
3131391|NCT01678625||Electromyography group|Train-of-four ratio calculation (T4-EMG)
3131392|NCT01678612|No Intervention|Non copper standard surfaced objects|Rooms assigned to standard surfaced objects
3131393|NCT01678612|Experimental|Copper-alloy surfaced objects|Rooms furnished with copper surfaced objects, i.e. bed rails, bed rail levers, IV poles, nurse workstation, clipboards, sink handles.
3131394|NCT01678599|Other|Benznidazol|This is a single arm, open label study; therefore, all subjects enrolled will receive benznidazol.
3131395|NCT01678586|Active Comparator|True Acupuncture|Pain subjects with radicular pain receiving 6, 30 minute acupuncture treatments.
3131396|NCT01678586|Sham Comparator|Sham Acupuncture|Pain subjects with radicular pain receiving 6, 30 minute sham acupuncture treatments.
3131397|NCT01678586|Active Comparator|Gabapentin|Pain subjects with radicular pain receiving gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.
3131398|NCT01678586|Sham Comparator|Sham Gabapentin|Pain subjects with radicular pain receiving sham gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.
3131399|NCT01678573|Experimental|Sequence 1: abiraterone acetate|"Randomly assigned participants in Sequence 1 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule ABC under fasted conditions."
3131465|NCT01678118||minority smokers|A single arm ABA design will be used to pilot a tobacco-focused patient navigation (TPN) intervention for low income, minority smokers.
3131400|NCT01678573|Experimental|Sequence 2: abiraterone acetate|"Randomly assigned participants in Sequence 2 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule BAC under fasted conditions."
3131401|NCT01678573|Experimental|Sequence 3: abiraterone acetate|"Randomly assigned participants in Sequence 3 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule CBA under fasted conditions."
3131402|NCT01678560|Active Comparator|Usual Care|These patients will be monitored on a 3-month, 6-month, 9-month and 12-month intervals with face-to-face visits. Adherence and efficacy data will only be assessed by the clinician at these intervals.
3131403|NCT01678560|Active Comparator|Wireless Care|These patients will be monitored using wireless modems as the method to obtain adherence and efficacy data.
3131404|NCT01678547|Experimental|Robot G-EO|Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling.
3131405|NCT01678547|Active Comparator|Treadmill Training|Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) consisting of a treatment cycle using the treadmill system device, according to individually tailored exercise scheduling.
3131406|NCT01678547|Active Comparator|Ground treatment|Ground Control Group (cCG): Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) of traditional lower limb physiotherapy treatment.
3131407|NCT01678534|Placebo Comparator|Placebo|In patients randomly assigned to the placebo arm will receive a intravenous solution (containing the vehicle) with the same appearance as the drug under investigation. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.
3131408|NCT01678534|Experimental|Allogeneic stem cells from adipose tissue|The experimental drug is a solution of mesenchymal stem cells from adipose tissue. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.Dose: 1 million units/kg
3131409|NCT01678521||Hypercholesterolemic patients|Hypercholesterolemic Patients with documented CAD and poor- or non responders or intolerant to pharmacological treatment (statins) on chronic LDL-apheresis treatment
3131410|NCT01678495|Experimental|Sonothrombolysis + microbubbles|"rtPA+ sonovue. SonoVue sulphur hexafluoride microbubbles 8 microlitres/ml Powder and solvent for dispersion for injection 1 vial containing 25 mg lyophilized powder to be reconstituted with 5 ml sodium chloride 9 mg/ml (0.9%) solution for injection~1 pre‐filled syringe containing sodium chloride 9 mg/ml (0.9%) solution for injection~1 Mini‐Spike Plus 6/8 (CE 0123) transfer system.~1 ml of the reconstituted dispersion contains 8 microlitres sulphur hexafluoride microbubbles."
3131411|NCT01678495|Active Comparator|Standard intravenous thrombolysis|Patients in thecontrol group will use thehelmetbut without U.S continuous U.S wave emission. Serial monitoring of the status ofrecanalizationaccording to theschedule set will be carried out according to theestablished schedule
3131412|NCT01678482|Experimental|lession count reduction post treatment|"A total of 50 subjects were included.~The majority are female (62 %)~At baseline the average number of lesions was 20.5±7.1, ranging from 6 to 36 lesions.~All subjects demonstrated a reduction in lesion count.~The average improvement after one month was 56.7%±8.9%, and remained similar also after 3 months 57.7%±9.4%.~The percent of responders (with at least 40% of reduction) was 94% after 1 month and 96% after 3 months~The Percent of responders is similar for males & females and similar for cheeks & front."
3131413|NCT01678469|Other|blood sample|
3131414|NCT01678443|Experimental|Treatment (yttrium-90 anti-CD45 monoclonal antibody BC8)|Patients receive indium-111 anti-CD45 monoclonal antibody BC8 IV on day -28 and (if necessary) day -21. Patients receive yttrium-90 anti-CD45 monoclonal antibody BC8 IV on day -28, -14, and -13. Patients then undergo autologous peripheral blood stem cell transplantation on day 0.
3131415|NCT01678430|Active Comparator|Ofatumumab-Chlorambucil|Ofatumumab cycle 1: 300mg iv day 1, 1000mg iv day 8; cycle 2 onwards: 1000mg iv day 1 Chlorambucil: 10mg/m2 po days 1-7
3131416|NCT01678430|Experimental|Ofatumumab-Bendamustine|Ofatumumab cycle 1: 300mg iv day 1, 1000mg iv day 8; cycle 2 onwards: 1000mg iv day 1 Bendamustine: 70mg/m2 iv days 1 and 2
3131417|NCT01678417|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
3131418|NCT01678404|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
3131419|NCT01678391|Experimental|Patients with common bile duct stones.|Common bile duct stone removal without fluoroscopy
3131420|NCT01678378|Experimental|SHARP Intervention|School health centers randomized to the SHARP Intervention will be trained to address adolescent relationship abuse with school health center clients.
3131421|NCT01678378|No Intervention|Control|School health centers randomized to Control will provide standard of care.
3131422|NCT01678365|Experimental|ceftriaxone and metronidazole for complicated appendicitis.|Children with complicated appendicitis treated with single daily dose of ceftriaxone and metronidazole.
3131423|NCT01678365|Active Comparator|Ampicillin, gentamicin, and metronidazole|Children with complicated appendicitis treated with ampicillin, gentamicin, and metronidazole
3131424|NCT01678352|Experimental|Cohort 1|Patients must have undergone surgery or biopsy alone (no postoperative radiation or chemotherapy) and have a baseline MRI scan (within 4 weeks of the first vaccine) that shows stable disease or regression (no progression from the initial surgery/biopsy).
3131425|NCT01678352|Experimental|Cohort 2|Patients received surgery or biopsy and radiation therapy (RT) (including fractionated external beam radiation therapy and/or stereotactic radiosurgery), which was completed ≥ 6 months prior to enrollment, and have a baseline MRI scan within 4 weeks prior to the first vaccine that shows stable disease or regression.
3131463|NCT01678131|Experimental|Vaniprevir 600 mg + Peg-IFN + RBV|Participants received 600 mg vaniprevir on Days 1-7; Peg-IFN alpha-2b once a week, RBV daily from Day 1 up to Day 21; and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
3131464|NCT01678131|Experimental|Vaniprevir 300 mg + Peg-IFN + RBV|Participants received 300 mg vaniprevir from Days 1-7; Peg-IFN alpha-2b once a week, RBV daily from Day 1 up to Day 21; and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
3135308|NCT01651832|Experimental|SCAN-Intervention|
3131426|NCT01678352|Experimental|Cohort 3|Patients with recurrent WHO grade 2 glioma may have received prior external beam radiotherapy and/or chemotherapy. Patients with stable WHO grade 2 glioma must have had prior chemotherapy (at least one cycle of Temozolomide or PCV-based chemotherapy). With regard to the prior therapy in Cohort 3, patients may have had treatment for no more than 2 prior relapses. Relapse is defined as progression following initial therapy (i.e. radiation +/- chemo if that was used as initial therapy) or observation of stable disease. The intent therefore is that patients may have had 3 prior therapies (initial therapy and treatment for 2 relapses). If the patient had a surgical resection for relapsed disease, and no anti-cancer therapy was instituted for up to 12 weeks, and the patient undergoes another surgical resection, this is considered as 1 relapse.
3131427|NCT01678339||1|
3131428|NCT01678326|Active Comparator|EUS-Rendezvous or direct intervention|EUS rendezvous or direct intervention involves: (1) using endoscopic-ultrasound technology to access the bile duct with a small needle and manipulate a wire across the biliary orifice and into the duodenum to be then retrieved endoscopically for ERCP (rendezvous ERCP), or (2) using endoscopic-ultrasound technology to directly puncture and perform intended biliary therapy
3131429|NCT01678326|Active Comparator|Advanced ERCP Biliary Access Techniques|Advanced ERCP techniques involve the following: precut access sphincterotomy and needle-knife fistulotomy. These are accepted techniques for biliary access in cases of difficult cannulation.
3131430|NCT01678313|Experimental|Study group|Doxazosin 4 mg daily plus celecoxib 200 mg every day (QD)
3131431|NCT01678313|Experimental|Control group|Doxazosin 4 mg every day (QD)
3131432|NCT01678287|Experimental|Arm 1 Non elderly receiving ASP1941|healthy subjects age 18 to 45 years receiving ASP1941
3131433|NCT01678287|Experimental|Arm 2 Non elderly receiving placebo|healthy subjects age 18 to 45 years receiving placebo
3131434|NCT01678287|Experimental|Arm 3 Elderly receiving ASP1941|healthy subjects age ≥ 65 years receiving ASP1941
3131435|NCT01678287|Experimental|Arm 4 Elderly receiving placebo|healthy subjects age ≥ 65 years receiving placebo
3131436|NCT01678274||Turner syndrome|Females with Turner syndrome
3131437|NCT01678274||Control group|age matched females acting as controls
3131438|NCT01678261||1a Turner syndrome 45,X|Blood from 50 persons with Turner syndrome an karyotype 45,X
3131439|NCT01678261||1b Controls for TS 45,X|50 healthy aged female controls matched to the TS 45,X cohort
3131440|NCT01678261||2a Turner syndrome 45,X mosaics|Blood from 50 persons with Turner syndrome an karyotype 45,X mosaics
3131441|NCT01678261||2b Controls for TS 45,X mosaics|50 healthy aged female controls matched to the TS 45,X mosaics cohort
3131442|NCT01678261||3a Paraffin embedded aortic tissue TS|3a Paraffin embedded samples of aortic tissue from 10 persons with TS
3131443|NCT01678261||3b Paraffin embedded aortic tissue from 10 controls|3b Paraffin embedded samples of aortic tissue from 10 controls who did not die from aortic aneurism
3131444|NCT01678261||4a 70 47,XXY men|4a Blood from 70 men with Klinefelter syndrome (47,XXY)
3131445|NCT01678261||4b 70 controls matching group 4a|4b 70 male controls matching group 4a with respect to age.
3131446|NCT01678261||5a 5 persons with double Y-syndrome|5a Blood from 5 persons with double Y-syndrome (47,XYY)
3131447|NCT01678261||5b 20 controls matching 5a|5b 20 healthy controls matching group 5a with respect to age
3131448|NCT01678261||6a 5 persons with triple X-syndrome|6a Blood from 5 persons with triple X-syndrome (47,XXX)
3131449|NCT01678261||6b 20 controls matching 6a|6b 20 healthy controls matching group 6a with respect to age.
3131450|NCT01678261||7 10 biological parents of cohort 1a.|7 Blood from 10 biological parents of individuals in cohort 1a
3131451|NCT01678235|Experimental|GLU_ASP|"Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.~First day: insulin glulisine~Second day: insulin aspart"
3131452|NCT01678235|Experimental|ASP_GLU|"Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.~First day: insulin aspart~Second day: insulin glulisine"
3131453|NCT01678209|Active Comparator|fMRI scans|Healthy Control Group: will receive initial evaluation, and 2 fMRI (functional magnetic resonance imaging) scans each 6-8 weeks apart
3131454|NCT01678209|Experimental|Atomoxetine arm|These subjects will receive initial evaluation and baseline fMRI scan, flexible dose titration with atomoxetine for 6-8 weeks, and fMRI postscan, with optional post study stabilization visits.
3131455|NCT01678209|Experimental|Methylphenidate arm|Subjects will receive initial evaluation, baseline fMRI scan, flexible dose titration with methylphenidate (Concerta) for 6-8 weeks, and fMRI scan post treatment.
3131456|NCT01678196|Experimental|VA-CRAFT|Family participants complete an on-line training course (VA-CRAFT) over a 3 month period
3131457|NCT01678196|Placebo Comparator|Control|Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
3131458|NCT01678183|Experimental|Monthly Incentive|Subjects in this arm will receive a cash incentive each month when they pick up their medications for diabetes, hypertension, and hypercholesterolemia at the pharmacy on time. The intervention is the cash incentive.
3131459|NCT01678183|Experimental|Monthly and Final Incentive|Subjects in this arm will receive a cash incentive each month when they pick up their medications for diabetes, hypertension and hypercholesterolemia at the pharmacy on time, as well as an additional financial incentive for each full percentage point of decrease in their hemoglobin A1c over the eight-month course of the study. The two cash incentives are the intervention.
3131460|NCT01678183|No Intervention|Control|These subjects will complete the enrollment process for the study but will be randomized to a group that receives usual care.
3131461|NCT01678157||Documented symptomatic paraesophageal hernia|"Documented symptomatic paraesophageal hernia.~Greater than 5 cm hiatal hernia on upper gastrointestinal study.~Evidence that the stomach or other viscera is present in the hernia and does not spontaneously reduce from the mediastinum.~Significant symptoms or signs of a paraesophageal hernia including but not limited to heartburn,dysphagia, chest pain, shortness of breath, postprandial abdominal pain, early satiety, odynophagia, or chronic anemia.~Consenting adult 19 years of age or older~Must be able to participate in follow-up evaluation.~Free of cognitive impairment"
3131470|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (500 mg/day)|Non-capsulated Calcium
3131471|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (1000 mg/day)|Non-capsulated Calcium
3131472|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (1500 mg/day)|Non-capsulated Calcium
3131473|NCT01678066||Bilateral cardiac output|This is a prospective, non-randomized study to collect data from two noninvasive FDA-approved cardiac output monitors simultaneously in pediatric patients under general anesthesia in the operating room from age 1 month old to 8 years old with all types of medical conditions. We will enroll 50 male and female pediatric patients who are having lower abdominal and lower extremity surgery in this study so that the additional 8 EKG leads placed on the patients do not interfere with the surgical site or patient positioning.
3131474|NCT01678053|Experimental|PPI and BOTOX|onabotulinumtoxinA (BOTOX), injection, 10 units, one time; omeprazole 40mg po bid (standard of care) for 3 months
3131475|NCT01678053|Other|Proton pump inhibitor only|omeprazole 40mg po bid for 3 months(standard of care)
3131476|NCT01678040||Cardiac Magnetic Resonance|"The CMR examinations will be performed in the cardiac MRI scanner (Siemens Avanto, 1.5 Tesla, Erlangen, Germany) at the Hospital for Sick Children. A brief echocardiogram will be performed using a GE Vivid 7 or Vivid E9 machine (General Electric Medical Systems, Wisconsin, USA) We will image from standard parasternal long axis and apical four-chamber before and after completed hydration."
3131477|NCT01678027|Placebo Comparator|Placebo|Placebo for LAC triple therapy
3131478|NCT01678027|Active Comparator|LAC triple therapy|PPI (Lansoprazole), Clarithromycin, Amoxicilline
3131479|NCT01678014|Experimental|Anorexia|Anorexia patients
3131480|NCT01678001|Active Comparator|Xeomin|Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
3131481|NCT01678001|Placebo Comparator|Placebo|Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
3131482|NCT01677988|Experimental|Chemotherapy, Chemoradiation, Surgery|Neoadjuvant Chemotherapy- Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles for 3 cycles with growth factor support Chemoradiation Surgical Resection
3131483|NCT01677975|Experimental|ultrasound, dynamic lymphscintigraphy|
3131484|NCT01677962|Experimental|dendritic cell and Poly-ICLC vaccination|Dendritic cell and Poly-ICLC vaccination will be administered directly into the tumor on Day 0 and Day 14 of Treatment Phase. Subjects will then have standard of care procedures along with injections of Poly-ICLC and dendritic cells for the remainder of the study.
3131485|NCT01677949|Experimental|ALL patients receiving transplant|Patients intent on receiving an allogeneic hematopoietic cell transplantation (allo-HCT) with the diagnosis of acute lymphoblastic leukemia (ALL) along with Clofarabine, Etoposide and Cyclophosphamide.
3131486|NCT01677949|Experimental|AML patients receiving transplant|Patients intent on receiving an allogeneic hematopoietic cell transplantation (allo-HCT) with the diagnosis of acute myeloid leukemia (AML) along with Clofarabine, Etoposide and Cyclophosphamide.
3131487|NCT01677936|Experimental|Raisin|Subjects randomized to the raisin treatment arm will consume raisins three times a day, prior to meals, and with a glass of water or non-caloric beverages (i.e. tea). Subjects will consume the raisins over a 12 week period.
3131488|NCT01677936|Active Comparator|Snack Group|Subjects randomized to the snack group will consume 100 calorie snack packs three times a day, before meals, and with water or other non-caloric beverages (i.e. tea). Subjects will consume the snack packs over a 12 week period.
3131489|NCT01677923|No Intervention|Control without Metformin|Conventional management of obesity including basic instructions on diet and physical activity
3131490|NCT01677923|Experimental|Control with Metformin|Conventional management of obesity including basic instructions on diet and physical activity plus Metformin treatment
3131491|NCT01677923|Experimental|Intervention with Metformin|Intensive physical activity course twice per week and monthly diet control by dietitian plus Metformin treatment.
3131492|NCT01677923|No Intervention|Intervention without Metformin|Intensive physical activity course twice per week and monthly diet control by dietitian
3131493|NCT01677910|Experimental|250 mg Telotristat Etiprate|Following a 3 to 4-week run-in period on stable-dose somatostatin analog (SSA) therapy (octreotide or lanreotide) participants were randomized to receive one 250 mg telotristat etiprate tablet plus one placebo-matching telotristat etiprate tablet administered three times daily for 12 Weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
3131494|NCT01677910|Experimental|500 mg Telotristat Etiprate|Following a 3 to 4-week run-in period on stable-dose SSA therapy (octreotide or lanreotide) participants were randomized to receive, one telotristat etiprate 250 mg plus one placebo-matching telotristat etiprate tablet administered 3 times daily for 1 week, followed by two telotristat etiprate (250 mg) tablets administered three times daily for 11 weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
3131495|NCT01677910|Placebo Comparator|Placebo|Following a 3 to 4-week run-in period on stable-dose SSA therapy (octreotide or lanreotide) participants were randomized to receive two placebo-matching telotristat etiprate tablets administered three times daily for 12 weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
3131496|NCT01677910|Experimental|Telotristat Etiprate Open-Label Extension|Patients previously assigned to 250 mg or 500 mg three times daily of telotristat etiprate were administered two 250 mg telotristat etiprate tablets three times daily in a 36 week open-label extension (OLE) period. Patients previously assigned to placebo were administered one 250 mg telotristat etiprate tablet plus one placebo-matching tablet three times daily for one week, followed by two 250 mg telotristat etiprate tablets three times daily for 35 weeks.
3131497|NCT01677897|Experimental|Metformin|Metformin 2x1000mg orally per day
3131498|NCT01677884|Experimental|Patients with metastatic CRC|
3131499|NCT01677871|Experimental|2HRZE/4HR|Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
3131500|NCT01677871|Active Comparator|2HRLE/4HR|Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
3244139|NCT00881842|Experimental|1|
3131503|NCT01677858|Experimental|Carfilzomib|"In phase 1 participants were assigned to one of four sequential dose-escalating cohorts to receive 45, 56, 70 or 88 mg/m² carfilzomib administered by intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle. Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15.~In phase 2 participants received carfilzomib at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study on days 1, 8 and 15 plus 40 mg dexamethasone IV or orally at the same schedule as used in the Phase 1 portion of the study.~Participants were treated until confirmed progressive disease, unacceptable toxicity, withdrew consent for further treatment, were lost to follow-up, died, or the sponsor closed the study."
3131504|NCT01677845|Experimental|Radiation Therapy|Radiation Therapy
3131505|NCT01677832||ADHD/Taiwan|
3131506|NCT01677832||Control/Taiwan|
3131507|NCT01677832||ADHD/Germany|
3131508|NCT01677832||Control/Germany|
3131509|NCT01677806|Experimental|Percutaneous vertebroplasty|
3131510|NCT01677806|Active Comparator|Conservative therapy|
3131511|NCT01677793||Child and adolescent population|
3131512|NCT01677780|Experimental|RO5045337|Participants will continue the most similar dose and formulation available (which does not exceed the MTD or the maximum safely administered dose for that formulation during Phase 1) and the same schedule of RO5045337 treatment that they were receiving at the time of transitioning from their respective parent clinical study protocols: NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296).
3131513|NCT01677767||Cohort|
3131514|NCT01677754|Placebo Comparator|Placebo|Participants will receive placebo as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
3131515|NCT01677754|Experimental|RO4602522 1 milligram (mg)|Participants will receive RO4602522 1 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
3131516|NCT01677754|Experimental|RO4602522 5 mg|Participants will receive RO4602522 5 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
3131517|NCT01677741|Experimental|Part 1: Dabrafenib treatment|Three subjects will receive a single dose of 3 mg/kg dabrafenib on Day 1 and repeat dose will begin from Day 2, evenly divided in two daily doses. Once all 3 subjects have been fully evaluated for the first 28 days (including Day 15 PK) and no DLTs are observed, a next subject will be enrolled at the next higher dose levels (i.e., dose escalation to 3.75 mg/kg [+1] and may be further to 4.5 mg/kg [+2] and so on). If all 3 subjects have not been fully evaluated for the first 28 days or 1 DLT occurred, the fourth subject will be enrolled at the same dose level. If 2 or more DLTs are observed, the next subject will be enrolled at the next lower dose level (i.e., de-escalated to 2.25 mg/kg [-1] and may be further to 1.5 mg/kg [-2]). Similarly, the process is repeated for the fifth and sixth subjects in a cohort. All subjects will receive treatment till end of study.
3131518|NCT01677741|Experimental|Part 2: Cohort 1 Low-Grade Gliomas with BRAF V600 mutations|Subjects with low-grade gliomas with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
3131519|NCT01677741|Experimental|Part 2: Cohort 2 High-Grade Gliomas with BRAF V600 mutations|Subjects with high-grade gliomas with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
3131520|NCT01677741|Experimental|Part 2: Cohort 3 LCH with BRAF V600 mutations|Subjects with LCH with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
3131521|NCT01677741|Experimental|Part 2: Cohort 4 Melanoma and PTC with BRAF V600 mutations|Subjects with other tumors with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
3131522|NCT01677728||arm A|patients received chemotherapy alone
3131523|NCT01677728||arm B|patients received target therapy combined with chemotherapy
3131524|NCT01677715|Active Comparator|"Yili Mei Yi Tian lactobacillus drink"|"100ml of Yili Mei Yi Tian active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention"
3131525|NCT01677715|Placebo Comparator|recombined milk drink contains no lactobacillus|100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
3131526|NCT01677702|Active Comparator|Yili Lactoferrin ShuHua Milk (lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
3131527|NCT01677702|Active Comparator|Yili Lactoferrin ShuHua Milk (lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
3131528|NCT01677702|Placebo Comparator|Recombined low-protein milk|Total 250mL placebo milk will be taken once per day at 10am daily during the 84 days intervention.
3131529|NCT01677689|Placebo Comparator|Control Group|Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal
3131530|NCT01677689|Experimental|Study Group|Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
3131531|NCT01677676|Active Comparator|Group 2|FP-01.1 (250µg/peptide)
3131532|NCT01677676|Active Comparator|Group 3|FP-01.1-Adjuvant (150µg/peptide / 10.8mg)
3131533|NCT01677676|Active Comparator|Group 4|FP-01.1-Adjuvant (250µg/peptide / 18mg)
3131534|NCT01677676|Active Comparator|Group 1|FP-01.1 (150µg/peptide)
3131535|NCT01677650|Active Comparator|Methadone 0.5 mg/kg|Methadone 0.5 mg/kg
3131536|NCT01677650|Experimental|Methadone 0.4 mg/kg|Methadone 0.4 mg/kg
3131537|NCT01677650|Active Comparator|Methadone 0.3 mg/kg|Methadone 0.3 mg/kg
3131538|NCT01677650|Active Comparator|Methadone 0.2 mg/kg|Methadone 0.2 mg/kg
3131539|NCT01677650|Active Comparator|Methadone 0.15 mg/kg|Methadone 0.15 mg/kg
3131540|NCT01677637||All measurements|Total measured population
3131541|NCT01677624|Experimental|E7040|
3131542|NCT01677611|Experimental|Resveratrol|Trans-resveratrol extract from Polygonum Cuspidatum (Mega Resveratrol, Danbury, USA) was used in the trial.Following the run-in period, subjects who were tolerant of the placebo would proceed to the treatment period. Subjects were given a starting dose of 500 mg daily of either resveratrol.The dose was increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia. Subjects were instructed to abstain from foods with high resveratrol content during the entire duration of the trial.
3131543|NCT01677611|Placebo Comparator|Placebo|All subjects underwent a 2-week run-in period during which placebo was administered. The placebo was manufactured so that it was not distinguishable by color, form, or taste from the active drug. Following the run-in period, subjects who were tolerant of the placebo would proceed to the treatment period. Subjects were given a starting dose of 500 mg daily of matching placebo and instructed to abstain from foods with high resveratrol content during the entire duration of the trial. The dose was increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia.
3131544|NCT01677598||Patients with plaque psoriasis|Patients with plaque psoriasis using ustekinumab in Asia-Pacific countries.
3131545|NCT01677572|Experimental|Low-dose #1 Aducanumab|Intravenous doses of low-dose level #1 Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 84 doses.
3131546|NCT01677572|Experimental|Low-dose #2 Aducanumab|Intravenous doses of low-dose level #2 Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 84 doses.
3131547|NCT01677572|Placebo Comparator|Placebo (low dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 84 doses.
3131548|NCT01677572|Experimental|Mid-dose Aducanumab|Intravenous doses of mid-dose Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 84 doses.
3131549|NCT01677572|Placebo Comparator|Placebo (mid dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 84 doses.
3131550|NCT01677572|Experimental|High-dose Aducanumab|Intravenous doses of high-dose Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 84 doses.
3131551|NCT01677572|Placebo Comparator|Placebo (high dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 84 doses.
3131552|NCT01677572|Experimental|Aducanumab Titration|Intravenous doses of Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 84 doses.
3131553|NCT01677572|Placebo Comparator|Placebo (Titration Group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 84 doses.
3131554|NCT01677559|Experimental|Dose Level 0|"MLN8237 20 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
3131555|NCT01677559|Experimental|Dose Level 1|"MLN8237 30 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
3131556|NCT01677559|Experimental|Dose Level 2|"MLN8237 40 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
3131557|NCT01677559|Experimental|Dose Level 3|"MLN8237 50 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
3131558|NCT01677559|Experimental|MTD Expansion Phase|"MLN8237 as determined during the dose escalation phase on Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
3131559|NCT01677546|Experimental|CSII+BC+CL|Patients using insulin pump (CSII) bolus calculator (BC) wirelessly connected with blood glucose meter Contour Link (CL)
3131560|NCT01677546|Experimental|CSII+BC|Patients using insulin pump (CSII) bolus calculator (BC) without wireless connection with blood glucose meter (CL)
3131561|NCT01677546|No Intervention|CSII (insulin pump only)|Patients using insulin pump (CSII) without BC and connection with CL
3131562|NCT01677533|Active Comparator|PM-Data|Team will receive data only.
3131563|NCT01677533|Experimental|PM-Support|Team will receive data and panel management support
3131564|NCT01677533|Experimental|PM-Education|Team will receive data, panel management support, and educational interventions.
3131565|NCT01677520||18-30 yrs, 31-50 yrs, 51-70 yrs|No intervention
3131566|NCT01677507|Experimental|timolol|To compare the variation in response to timolol between individuals
3131567|NCT01677507|Active Comparator|latanoprost|To compare the variation in response to latanoprost between individuals
3131568|NCT01677494||heart failure with preserved ejection fraction|- Inclusion Elevated BNP EF > 50%
3131569|NCT01677481||Femoral|Coronary angiography procedures performed using transfemoral access
3131570|NCT01677481||Left radial access|Coronary angiography procedures performed using left radial access site.
3131571|NCT01677481||Right radial Access|Coronary angiography procedures performed using Right radial access site.
3131572|NCT01677468|Experimental|Intermediate embolization|TACE with substatsis using gelfoam
3131573|NCT01677468|Active Comparator|Complete embolization|TACE with complete embolization using gelfoam
3131575|NCT01677455|Experimental|Triple negative breast cancer|Closed to enrollment
3131576|NCT01677455|Experimental|ER/PR+ Refractory to Prior Hormonal Treatment|
3131577|NCT01677442|Experimental|no-intubated group|Experimental: no-intubated thoracic epidural anesthesia Thoracic epidural anesthesia at the T5/T6 thoracic interspace
3131578|NCT01677442|Active Comparator|intubated group|Active Comparator:double-lumen endotracheal intubated anesthesia
3131579|NCT01677429|Experimental|VR movie + balance challenge|VR-based balance training
3131580|NCT01677429|Sham Comparator|still pictures from VR|Exposure to still pictures from the same VR scene but no balance challenge
3131581|NCT01677429|Active Comparator|Cognitive Behavioral Therapy|Standard CBT protocol for the treatment of panic disorder
3131582|NCT01677416||Rheumatoid Arthritis Group|RA with at least one year since diagnosis, asymptomatic feet, and age between 18 and 65 years
3131583|NCT01677416||Control group|Absence of known osteoarticular disease
3131584|NCT01677403|Active Comparator|Nebulised Tobramycin|Nebulised Tobramycin
3131585|NCT01677403|Placebo Comparator|Nebulised 0.9% Saline|Nebulised 0.9% Saline
3131586|NCT01677390|Experimental|Arm 1|SGN-75, everolimus
3131587|NCT01677377|Active Comparator|Risperidone Comparator, Subcu injection|Risperidone 2mg oral and RBP-7000 60mg injection
3131588|NCT01677377|Active Comparator|Risperidone Comparator, Subcutaneous|Risperidone 3mg oral and RBP-7000 90mg injection
3131589|NCT01677377|Active Comparator|Risperidone comparator, injection|Risperidone 4mg oral and RBP-7000 120mg injection
3131590|NCT01677364|Active Comparator|induction of labour|drug- infusion of 30U oxytocin diluted in 500ml normal saline given at rate of 3mU/min and subsequently dose increased 3mU/min every 45 min
3131591|NCT01677364|No Intervention|Spontaneous Labour|patients were allowed to go into spontaneous labour
3131592|NCT01677351|Active Comparator|group 2: clonidine 4mcg.kg|this group (group 2) will receive 4mcg.kg-1 of clonidine 20 minutes before surgery.
3131593|NCT01677351|Placebo Comparator|Group 1: sterile saline solution|this group (Group 1) will receive a sample injection of sterile saline solution 20 minutes before surgery
3131594|NCT01677338|Experimental|13C-uracil and 99mTc sulfur colloid|Subjects will consume the Semi-solid Test Meal containing 500 uCi 99mTc sulfur colloid and 100 mg of 13C-uracil.
3131595|NCT01677338|Experimental|99mTc sulfur colloid|Subjects will consume the Solid Test Meal containing 500 uCi 99mTc sulfur colloid.
3131596|NCT01677325|Experimental|Chinese herb|Chinese herb
3131597|NCT01677312|Active Comparator|19G FNA needle|Evaluate median number of passes to diagnosis (Diagnostic accuracy) and ability to procure histological samples using a 19G FNA needle when performing pancreatic biopsy.
3131598|NCT01677312|Active Comparator|25G FNA needle|Evaluate median number of passes to diagnosis (Diagnostic accuracy) and ability to procure histological samples using a 25G FNA needle when performing pancreatic biopsy.
3131599|NCT01677299|Active Comparator|1000 mg EFB0026 (metformin immediate-release)|BID
3131600|NCT01677299|Experimental|1000 mg EFB0027 (metformin delayed-release)|BID
3131601|NCT01677299|Experimental|500 mg EFB0027 (metformin delayed-release)|BID
3131602|NCT01677299|Experimental|500 mg EFB0026 + 1000 mg EFB0027|BID
3131603|NCT01677286|Experimental|doxycycline 100 mg po bid x 12 months|Open-label doxycycline 100 mg twice daily by mouth will be administered to subjects for 12 months.
3131604|NCT01677273|Active Comparator|Hydrolyzed casein|Hydrolyzed casein
3131605|NCT01677273|Active Comparator|Intact casein|Intact casein
3131606|NCT01677273|Active Comparator|Intact whey protein|Intact whey protein
3131607|NCT01677260|Experimental|Group I|500 mg metformin hydrochloride extended release caplet (PT Ferron Par Pharmaceuticals)
3131608|NCT01677260|Active Comparator|Group II|500 mg metformin hydrochloride prolonged release tablet (PT Merck Pharmaceuticals)
3131609|NCT01677247|Experimental|Group I (Test)|Test : glimepiride 4 mg tablet of PT Dexa Medica
3131610|NCT01677247|Active Comparator|Group II (Reference)|Reference : glimepiride (Amaryl) 4 mg tablet of PT Sanofi-Aventis, Indonesia
3131611|NCT01677234||Pregnant women|Pregnant women undergoing a cesarean section
3131612|NCT01677208|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
3131613|NCT01677208|Placebo Comparator|placebo|Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
3131614|NCT01677195|Active Comparator|ACCS100 High Dose|Participants will receive a total daily dose of 3 grams of ACCS100; 1 gram three times a day with meals.
3131615|NCT01677195|Active Comparator|ACCS100 Low Dose|Participants will receive a total daily dose of 1.5 grams of ACCS100; 500 mgs three times a day with meals.
3131616|NCT01677195|Placebo Comparator|Placebo|Participants will receive placebo capsules shown not to absorb mycotoxins three times a day with meals.
3131617|NCT01677182|Experimental|Ramelteon SL (Dose 1)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 6 weeks.
3131618|NCT01677182|Experimental|Ramelteon (Dose 2)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 6 weeks.
3131619|NCT01677182|Placebo Comparator|Placebo|Ramelteon SL placebo-matching tablets, sublingual, once daily, at night time for up to 6 weeks.
3131620|NCT01677169|Experimental|59 mL noni juice|Ingestion of 59 mL of Tahitian Noni® juice (mixture of noni juice and grape and blueberry juices) twice daily (118 mL daily total) for 30 days.
3131621|NCT01677169|Placebo Comparator|Placebo|Ingestion of 59 mL of placebo (mixture of grape and blueberry juices and natural cheese flavor) twice daily (118 mL daily total) for 30 days.
3131622|NCT01677169|Experimental|29.5 mL noni dose|Ingestion of 29.5 mL of Tahitian Noni® juice (mixture of noni juice and grape and blueberry juices) daily for 30 days.
3131623|NCT01677156||Receiving Corus CAD (ASGES)|Patients receiving Corus CAD (ASGES) to aid in the diagnosis of obstructive CAD
3131624|NCT01677143|Active Comparator|bupivacaine|Injection of 5 ml bupivacaine, 5mg/ml in each port site.
3131625|NCT01677143|Placebo Comparator|Placebo|Injection of 5 ml saline in each port site.
3131626|NCT01677104|Active Comparator|DPP-IV inhibitor|Linagliptin 5mg (Tradjenta) before microinjection of GLP-1 and its analogues
3131627|NCT01677104|Placebo Comparator|Placebo pill|One placebo tablet before microinjection
3131628|NCT01677091|Active Comparator|Control group|This group will benefit from conventional rehabilitation
3131629|NCT01677091|Experimental|Cervical vibration|This group will benefit from a daily 20 minutes session, with vibration of neck muscles during 10 minutes
3131630|NCT01677091|Experimental|Prism adaptation|This group will benefit from a daily 20 minutes session, with prism adaptation during 10 minutes
3131631|NCT01677091|Experimental|Cervical vibration + Prism adaptation|This group will receive a daily 30 minutes session, with cervical vibration during 10 minutes + prism adaptation during 10 minutes
3131632|NCT01677078|Experimental|Neuronavigation system|"10 sessions of rTMS coupled with a neuronavigation system~Description of 1 session of the rTMS protocol :~Frequency: 20Hz~Intensity: 110% of motor threshold~80 train of 2 seconds duration~10 seconds between two trains~3200 pulses~Devices :~rTMS: System Mag Pro (Magventure, Denmark)~Neuronavigation system: Syneika One (Syneika, France)"
3131633|NCT01677078|Sham Comparator|Standard localisation method|"10 sessions of rTMS with manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')~Description of 1 session of the rTMS protocol :~Frequency: 20Hz~Intensity: 110% of motor threshold~80 train of 2 seconds duration~10 seconds between two trains~3200 pulses~Devices :~- rTMS: System Mag Pro (Magventure, Denmark)"
3131634|NCT01677065||Treatment A|Controlled release oxycodone test formulation 40 mg
3131635|NCT01677065||Treatment B|Immediate release oxycodone reference drug 20 mg
3131636|NCT01677039|Active Comparator|Treatment A|
3131637|NCT01677039|Experimental|Treatment B|
3131638|NCT01677039|Experimental|Treatment C|
3131639|NCT01677013|No Intervention|Oral medication treatment|type 2 diabetics with only oral medications
3131640|NCT01677013|Experimental|Oral medication plus BMMCT|Collect mononuclear cells from bone marrow aspiration, administer to pancreas via selective catheterization to splenic artery.
3131641|NCT01677013|No Intervention|Oral medication plus insulin treatment|Type 2 diabetics who need insulin therapy with oral medications
3131642|NCT01677013|Experimental|Oral medication plus insulin plus BMMCT|Collect mononuclear cells from bone marrow aspiration, administer to pancreas via selective catheterization to splenic artery.
3131643|NCT01676987|Experimental|Fixed Combination of Budesonide and formoterol|Group 1 (experimental): Fixed Combination of Budesonide and formoterol
3131644|NCT01676987|Active Comparator|Budesonide|Group 2 (comparator): Budesonide
3131645|NCT01676974||Travelers|Travelers and their family members
3131646|NCT01676961|Experimental|Supportive care (romiplostim)|Patients receive romiplostim SC once weekly for up to 6 weeks. Patients achieving a platelet count > 50 x 10^9 then receive romiplostim once weekly during 1 course of chemotherapy and may continue for as long as benefit is seen..
3131647|NCT01676948|Experimental|Canakinumab - Cohort 1, 2mg|2 mg/kg q4wk (followed by taper to 1 mg/kg q4wk and drug discontinuation if appropriate)
3131648|NCT01676948|Experimental|Canakinumab - Cohort 1, 4mg|4 mg/kg q8wk (followed by taper to 4 mg/kg q12wk and drug discontinuation if appropriate)
3131649|NCT01676948|Experimental|Canakinumab - Cohort 2, 2mg|2 mg/kg q4wk (followed by taper to 1 mg/kg q4wk and drug discontinuation if appropriate)
3131650|NCT01676948|Experimental|Canakinumab - Cohort 2, 4mg|4 mg/kg q8wk (followed by taper to 4 mg/kg q12wk and drug discontinuation if appropriate)
3131651|NCT01676948|Experimental|Cohort 2 - canakinumab dose reduction|
3131652|NCT01676948|Experimental|Cohort 1 - canakinumab dose reduction|
3131653|NCT01676935|Experimental|ABT-126|ABT-126 Open-label dose
3131654|NCT01676922||Cohort|
3131655|NCT01676909|Experimental|Living Well|Living Well will be implemented as a 12 session small-group intervention (4-8 persons). Groups will meet weekly for 75 minutes for three months (12 sessions). There will be 3 booster sessions after the 12 sessions, once a month for 3 months.
3131656|NCT01676909|Active Comparator|Medical Illness Education and Support Group|The comparison condition will be a once-weekly support and education group focusing on living with a chronic medical condition. Each of the 12 sessions will follow a basic structure that includes a review of the material presented in the previous session, new education content and discussion.
3131657|NCT01676896|Experimental|Asthma in-school class|Provided in 16 15-minute sessions (4 hours total didactic time); scheduled 3 sessions/week. The content is provided by trained asthma educators. The Asthma Plan for Kids (AP-K) is a 7-step curriculum for children to use when responding to asthma symptoms. Skills practice with placebo metered dose inhaler (MDI) and peak expiratory flow (PEF) meters with PEF score interpretation. Topics include (a) identifying lung function, asthma warning signs, symptoms, and triggers; (b) learning skills to manage symptoms, including PEF meter score interpretation, communication with adults (e.g. teachers, coaches, family members), medication use and MDI technique; (c) evaluating asthma symptoms and the effectiveness of management; and (d) discussing how to stay active in a safe manner.
3131658|NCT01676896|Experimental|Asthma Day Camp|The asthma day camp is provided in a single day session (5.5 hours total) by trained camp staff. The same skills (i.e., placebo metered dose inhaler (MDI) and peak expiratory flow (PEF) meters) and topics [a) identifying lung function, asthma warning signs, symptoms, and triggers; (b) learning skills to manage symptoms, including PEF meter score interpretation, communication with adults (e.g. teachers, coaches, family members), medication use and MDI technique; (c) evaluating asthma symptoms and the effectiveness of management; and (d) discussing how to stay active in a safe manner] are covered as those in the asthma in-school classes.
3131659|NCT01676896|Sham Comparator|Health Promotion in-school class|The mock comparison follows the in-school format of 16 15-minute sessions; scheduled 3 sessions/week. The content is provided by trained health educators and includes skills practice (i.e., handwashing and brushing teeth) and health promotion topics of nutrition, healthy snacks, preventing colds, and safe exercise.
3131660|NCT01676883|Experimental|body composition assessment|Bioelectric impedance measurement pre- and post removal of calluses and corns (pedicure), then air-displacement plethysmography (gold standard)
3131661|NCT01676870|Experimental|1x4 aerobic interval training|1x4min aerobic interval training (1-AIT), 3 times a week
3131662|NCT01676870|Experimental|4x4 aerobic interval training|4x4min aerobic interval training (4-AIT), vigorously exercise according to today's guidelines, 3 times a week
3131823|NCT01675791|Experimental|ALK tree AIT 4 DU|1 AIT administered sublingually every day
3131663|NCT01676870|Active Comparator|traditional moderate training|traditional moderate training (CME), moderate exercise at least 30 min, 5 days a week or more, according to today's guidelines
3131664|NCT01676857||CP/CPPS group|The Study population will include patients diagnosed with CPPS (equal numbers of CPPS IIIa and CPPS IIIb) at least 18 years of age, recruited from Northwestern urology clinical site practices. All CPPS participants will be male and will have pelvic pain symptoms. Men who are at least 18 years of age and who had been seen by a physician for symptoms of CP/CPPS within the previous 2 years will comprise the patient population
3131665|NCT01676857||Control group|Adult male volunteers who are male, at least 18 years of age and meet inclusion and exclusion criteria
3131666|NCT01676844|Experimental|Oral thin film therapy|One or more oral thin films (OTFs) containing potassium acid phosphate administered to the inside cheek, tongue or palate at a dose of 0.5 mmol/kg body weight twice daily. Dosages will be rounded to the nearest 0.1 mM/kg. Where more than one OTF is required to achieve a dosage of 0.5mmol/kg, strips will be administered consecutively with time allowed between doses to allow for complete dissolving of the previous strip. Treatment will continue until the participant has received OTF therapy for 14 consecutive days.
3131667|NCT01676844|Active Comparator|Standard therapy|Standard oral phosphate supplementation as per NHS Greater Glasgow and Clyde Guidelines. An oral solution containing potassium acid phosphate (1 mmol/mL) will be administered at a dosage of 0.5 mM/kg body weight twice daily. Dosages will be rounded to the nearest 0.1 mM/kg. Standard therapy will continue until the participant has received treatment for 14 consecutive days.
3131668|NCT01676831|Experimental|topical resiquimod 0.06%|Topical resiquimod 0.06% will be applied in dosing frequencies that are periodically adjusted to tolerability. Dosing frequency will be 3 times a week. The dosing frequency may be adjusted (1,2,3,5,or 7times per week) based on the physician assessment of tolerability. Treatment will occur for 8 weeks followed by 4 weeks rest followed by another 8 weeks of treatment with 4 weeks rest. At 24 weeks a final evaluation will be performed. Those with a partial response at week 24 will have the option to continue therapy for up to another 12 weeks.
3131669|NCT01676831|Experimental|topical resiquimod 0.03%|Topical resiquimod 0.03% will be applied in dosing frequencies that are periodically adjusted to tolerability. Dosing frequency will begin 5 times a week. The dosing frequency may be adjusted (1,2,3,5,or 7times per week) based on the physician assessment of tolerability. Treatment will occur for 8 weeks followed by 4 weeks rest followed by another 8 weeks of treatment with 4 weeks rest. At 24 weeks a final evaluation will be performed. Those with a partial response at week 24 will have the option to continue therapy for up to another 12 weeks.
3131670|NCT01676818|Experimental|Eribulin mesylate|Eribulin mesylate 1.4 mg/m2 IV bolus over 2-5 minutes on days 1 and 8 every 21 days in the absence of disease progression or unacceptable toxicity.
3131671|NCT01676805||1|Known lymphoid malignancy or precursor disease to a lymphoid malignancy
3131672|NCT01676792|Experimental|Lesion reduction|
3131673|NCT01676779|Experimental|Arm A dendritic cell therapy|Arm-A, patients will receive Dendritic Cell therapy during one year following randomization.
3131674|NCT01676779|Experimental|Arm B Dendritic cell therapy|Arm-B, patients will initiate Dendritic Cell therapy only after documented recurrence of the melanoma that cannot be salvaged by local therapy.
3131675|NCT01676753|Experimental|Dinaciclib & Pembrolizumab Treatment|Dinaciclib is administered on days 1 and 8 of a 21-day cycle in combination with pembrolizumab administered on day 1 of each 21-day cycle.
3131676|NCT01676740|Placebo Comparator|Mild anemia, normal hematinics|Mild anemia, normal iron studies, serum folate and vitamin B12 levels - will receive placebo
3131677|NCT01676740|Experimental|Anemia, normal hematinics|Mild anemia, deficient iron, folate or vitamin B12 levels Iron supplement will be given
3131678|NCT01676740|Other|Deficeicnt hematinics|Iron supplement will be provided
3131679|NCT01676727||CoreValve aortic valve|Implantation of CoreValve aortic valve via direct aortic approach
3131680|NCT01676714|Experimental|Dovitinib|500 mg of dovitinib (5 capsules) once a day for 5 continuous days and stop for 2 days. Continue to take dovitinib capsules in this manner until until progression or unacceptable toxicity develops.
3131681|NCT01676701|Experimental|Tabalumab Auto-Injector|Tabalumab 180 milligram (mg) loading dose administered using auto-injectors at Week 0 as 2 subcutaneous (SC) injections (90 mg each), followed by a 90 mg SC injection every 2 weeks (Q2W) up to Week 12.
3131682|NCT01676701|Experimental|Tabalumab Prefilled Syringe|Tabalumab 180 mg loading dose administered using prefilled syringes at Week 0 as 2 SC injections (90 mg each), followed by a 90 mg SC injection Q2W up to Week 12.
3131683|NCT01676675|Experimental|7.5μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml in 30 adolescents aged 12-17 years old on day 0, 21
3131684|NCT01676675|Experimental|15μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml in 30 adolescents aged 12-17 years old on day0,21
3131685|NCT01676675|Experimental|30μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml in 30 adolescents aged 12-17 years old on day0,21
3131686|NCT01676675|Experimental|7.5μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
3131687|NCT01676675|Experimental|15μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
3131688|NCT01676675|Experimental|30μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
3131689|NCT01676675|Placebo Comparator|0/0.5ml in adolescents (12-17 years old)|0/0.5ml placebo in 30 adolescents aged 12-17 years old on day 0, 21
3131690|NCT01676675|Placebo Comparator|0/0.5ml in adults(18-60 years old)|0/0.5ml placebo in 30 adults aged 18-60 years old on day 0, 21
3131691|NCT01676662|Experimental|Treatment on Day 0|Subjects who are treated with the Solace Bladder Control System upon entry into the trial.
3131692|NCT01676662|Sham Comparator|Sham Treatment on Day 0|Patients who undergo a sham procedure upon entry into the trial, with treatment with the Solace Bladder Control System at 3 months after the sham procedure.
3131693|NCT01676649|Experimental|A|Arm A: Carboplatin (week 1, week 4, week 7, week 10, and week 13) Paclitaxel (week 1, week 4, week 7, week 10, and week 13) Ipilimumab (week 4, week 7, week 10, and week 13)
3131824|NCT01675791|Experimental|ALK tree AIT 7 DU|1 AIT administered sublingually every day
3131694|NCT01676649|Experimental|B|Carboplatin (week 1, week 4, week 7, week 10, and week 13) Paclitaxel (week 1, week 4, week 7, week 10, and week 13) Ipilimumab (week 5, week 8, week 11, and week 14)
3131695|NCT01676636||Pregnant Women|Women who are 13 to 30 weeks pregnant. Each participant will take all 4 different calcium vehicles and decide which one they prefer.
3131696|NCT01676623|Active Comparator|Comparison area, only standard government services|This intervention arm will receive the standard government services offered at CHCs all over Vietnam. In addition, participants in this arm will be exposed to the nationwide mass media campaign.
3131697|NCT01676623|Experimental|A&T Franchise|In this arm, the 20 CHCs will offer Alive & Thrive branded franchise services with enhanced quality of IYCF counseling through interpersonal contact between health workers at the commune level and clients who use the commune health services. In addition, the clients could also be exposed to the mass media campaign.
3131698|NCT01676610||Infants presenting to the Clinic|Infants presenting to the Bilal and Bhains Colony Health Center. Devices used to measure Pulse Oximetry (PO) include Rad-5v by Masimo, TuffSat by GE, N-65 by Nellcor, PRO2 by Conmed, and Lifebox by Acare.
3131699|NCT01676597|Experimental|rifaximin and pentoxifylline|Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
3131700|NCT01676597|Active Comparator|pentoxifylline and placebo|Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
3131701|NCT01676584|Placebo Comparator|Placebo|
3131702|NCT01676584|Experimental|RO6811135|
3131703|NCT01676571|Experimental|Lu AA21004|
3131704|NCT01676558|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
3131705|NCT01676545||Chronic Periodontitis|
3131706|NCT01676545||Control|
3131707|NCT01676532||Students attending SBHC|Students who attend the SBHC from either Sprucecourt Public School or any other participating schools.
3131708|NCT01676519||PCI|diabetic patients undergoing percutaneous coronary intervention
3131709|NCT01676493|Experimental|Codeine|Codeine Sulfate Oral Solution and Tablet
3131710|NCT01676480|Experimental|ADT group|
3131711|NCT01676480|Experimental|Control group|
3131712|NCT01676467||Smoking asthma on steroids|Smokers with persistent asthma on background steroid therapy
3131713|NCT01676467||Smoking asthma steroid naïve|Smokers with persistent asthma, steroid naive
3131714|NCT01676467||asthma on steroids|Non-Smokers with persistent asthma on background steroid therapy
3131715|NCT01676467||asthma, steroid naïve|Non-smokers with persistent asthma, steroid naive
3131716|NCT01676467||Healthy smoking|Healthy smoking control subjects
3131717|NCT01676467||Healthy non-smoking|Healthy non-smoking control subjects
3131718|NCT01676454||Vasopressin levels.|"Cohort will consist of subjects with a minor injury or injuries defined as:~no episodes of systolic blood pressure < 90 mmHg between occurrence of injury and admission;~no blood transfusion requirement;~base deficit < 5 mEq/L;~no requirement for mechanical ventilation other than transiently during orthopedic surgery."
3131719|NCT01676441|Experimental|Mesenchymal stem cell|Procedure: posterior cervical laminectomy and MSC transplantation. After laminectomy, 1.6X107 and 3.2 X107 Autologous MSCs is injected into the intramedullary and intrathecal space respectively
3131720|NCT01676428|Experimental|Radiotherapy|"The interventional treatment will be prescribed as a 2-tiered dose scheduled dependant of target size.~For lesions <5cm, a single fraction of 26 Gy will be prescribed. For lesions ≥5cm a fractionated course of 15Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
3131721|NCT01676415|Active Comparator|Prednisone|Oral steroid medication
3131722|NCT01676415|Active Comparator|Topical Mometasone|Topical steroid medication
3131723|NCT01676402|Experimental|Group 1: HA DNA + TIV ID|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV ID at Week 14±2 wks
3131724|NCT01676402|Experimental|Group 2: HA DNA + TIV IM|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV IM at Week 14±2 wks
3131725|NCT01676402|Experimental|Group 3: TIV ID + TIV ID|licensed 2012/13 TIV ID at Day 0 and licensed 2013/14 TIV ID at Week 44±2 weeks
3131726|NCT01676402|Experimental|Group 4: TIV IM + TIV IM|2012/13 licensed TIV IM at Day 0 and licensed 2013/14 TIV IM at Week 44±2 weeks
3131727|NCT01676402|Experimental|Group 5: (HA DNA and TIV ID) + TIV ID|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) and licensed 2012/13 TIV ID at Day 0 followed by licensed 2013/14 TIV ID at Week 44±2 weeks
3131728|NCT01676402|Experimental|Group 6: (HA DNA and TIV IM) + TIV IM|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) and licensed 2012/13 TIV IM at Day 0 followed by licensed 2013/14 TIV IM at Week 44±2 weeks
3131729|NCT01676389|Experimental|OMM Hands-On Treatment|The Osteopathic Manual Medicine (OMM) Hands-On Treatment group will be receiving an osteopathic structural exam along with 7 gentle, non-thrusting techniques during each treatment session that lasts 20-30 minutes. The Sham treatment group will be receiving only an osteopathic structural exam that will be slowed down in order to be a similar duration to the full treatment group session (approximately 20-30 minutes).
3131730|NCT01676389|Placebo Comparator|Sham OMM|Sham Osteopathic Manual Medicine (OMM)
3131731|NCT01676376|Active Comparator|eSVS Mesh treated saphenous vein graft|Each subject will be randomized to an eSVS Mesh treated SVG to the right or left coronary system.
3131732|NCT01676376|Sham Comparator|Control saphenous vein graft|Each subject will be randomized to an untreated (no eSVS Mesh) SVG to the right or left coronary system.
3131733|NCT01676376|Active Comparator|Single Vessel Treatment|Each subject with receive one SVG with eSVS Mesh either to the right or left coronary system.
3131734|NCT01676363|Experimental|Diflunisal|
3131735|NCT01676350|No Intervention|Standard of care|If you are assigned to this group, ultrasound-guided IV will be used to obtain vascular access.
3131736|NCT01676350|Experimental|'IO access using EZ-IO®|If you are assigned to this group, you will receive an IO line in the humeral head of the shoulder. IO lines are placed using an FDA-approved device called an EZ-IO®.
3131737|NCT01676337|No Intervention|Control|Patients randomized to the control arm will not receive text message reminder regarding their upcoming appointment.
3131825|NCT01675791|Experimental|ALK tree AIT 12 DU|1 AIT administered sublingually every day
3131915|NCT01675193|Other|Disinvestment protocol|No eye screening at 6-9 and 14-24 months
3131738|NCT01676337|Experimental|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
3131739|NCT01676324||Inflammatory Bowel Disease|Those with Inflammatory Bowel Disease (known) and those with no Inflammatory Bowel Disease (not previously diagnosed)
3131740|NCT01676311|Experimental|Huperzine A|Huperzine A will be administered to patients, titrating dose up from 100mcg/day to 600mcg per day over the course of 20 days - and remaining on the dose of 600mcg/day for the remainder of the drug phase (64 days) - for a total of 12 weeks on Huperzine A.
3131741|NCT01676311|Placebo Comparator|Placebo|Placebo will be administered to patients at the same frequency/intervals as the experimental arm (Huperzine-A).
3131742|NCT01676285|Active Comparator|Metoprolol succinate|Metoprolol succinate
3131743|NCT01676285|Placebo Comparator|Placebo|Placebo
3131744|NCT01676285|No Intervention|Follow up|Group without cirrhotic cardiomyopathy, only follow up without randomization.
3131745|NCT01676259|Active Comparator|Chemotherapy|Gemcitabine+nab-Paclitaxel
3131746|NCT01676259|Experimental|siG12D-LODER + chemotherapy|Eight siG12D-LODER+(Gemcitabine+nab-Paclitaxel)
3131747|NCT01676246|Active Comparator|flupirtine per os single dose|100 mg flupirtine per os, pharmacokinetics of flupirtine, induce delayed onset of muscle soreness (DOMS), electric pain measurement
3131748|NCT01676246|Active Comparator|flupirtine intravenous|100 mg flupirtine intravenous, pharmacokinetics of flupirtine, induce delayed onset of muscle soreness (DOMS), electric pain measurement
3131749|NCT01676246|Active Comparator|flupirtine per os steady state|400 mg flupirtine per os, pharmacokinetics of flupirtine, electric pain measurement
3131750|NCT01676233|Experimental|Sequence 1|Reference (insulin glargine) -Test1 (insulin glargine - new formulation), both dose will be adjusted individually to achieve the target glycemic goal
3131751|NCT01676233|Experimental|Sequence 2|Test1 - Reference , both dose will be adjusted individually to achieve the target glycemic goal
3131752|NCT01676220|Experimental|HOE901-U300|
3131753|NCT01676220|Active Comparator|Lantus|
3131754|NCT01676207||1|CAD
3131755|NCT01676207||2|no CAD
3131756|NCT01676194|Experimental|Intra-arterial administration of DC BeadsR|Intra-arterial administration of DC BeadsR, (1 vial of 100-300 µm) as selectively as possible loaded with doxorubicin (50 mg per procedure) and mixed with an equal volume of contrast medium. The first injection will be performed within 21 days following enlisting and repeated 1-2 times until LT (only if hypervascularized vital tumor tissue is again visible on CT Scan and if liver function remains within Child A stage) or until complete response
3131757|NCT01676194|No Intervention|Control|Usual care
3131758|NCT01676181|Active Comparator|Adenotonsillectomy|Total removal of tonsils and adenoids with cold steel
3131759|NCT01676181|Active Comparator|Adenotonsillotomy|Partial removal of tonsils with coblation and total removal of adenoids with cold steel
3131760|NCT01676168||hypertrophic scar|1x1cm2 hypertrophic scar of post-burn patients are taked by visiting staff when they accept scar-reconstructive surgery.
3131761|NCT01676168||normal skin|When the patient accept skin grafting surgery, visiting staff will take 1x1cm2 normal skin.
3131762|NCT01676155||Patient with active tuberculosis|
3131763|NCT01676155||Patients with diagnosis of latent tuberculosis infection|
3131764|NCT01676155||Patient without latent tuberculosis or active tuberculosis|
3131765|NCT01676142||Patients with NTM pulmonary infection|
3131766|NCT01676142||Patients with other pathogen related lung infection|
3131767|NCT01676142||Patient with NTM pulmonary colonization|
3131768|NCT01676129|Experimental|Nocipoint Therapy|"Nocipoint therapy (NT) follows rules of TENS stimulation in each session, all within the general FDA guidelines of TENS uses. The key points of Nocipoint Therapy include the following:~The stimulation pads are located at the skin surface location of the nociceptors of the muscle/tissue in pain (i.e., Nocipoint)~The intensity is set to induce C-fiber response during the stimulation~The duration of stimulation (about 1.5-4 minutes for each tissue stimulation)~Stimulations for different tissues (muscles, ligaments) are sequenced such that later stimulations will not cause re-injury of previously treated tissues.~Patient are instructed not to use the newly recovered muscle/tissue too much for an estimated rest period depending on his/her age."
3131769|NCT01676129|Active Comparator|Physical Therapy|"Patients in this group will be treated with comprehensive physical therapy program including typical electrical stimulation using a standard transcutaneous electrical nerve stimulation (TENS) device, manual myofascial release and postural correction exercise.~The application of TENS will follow general physical therapy guidelines, especially for TMD. Manual myofacial release will be applied on orofacial muscles and neck muscles.~TENS will serve both as a part of the standard of care and as placebo, as the same TENS device is used in both arms."
3131770|NCT01676116|Experimental|Insulin degludec/liraglutide + OADs|
3131771|NCT01676116|Active Comparator|Liraglutide or exenatide + OADs|
3131772|NCT01676103|Experimental|Tyrosine|Tyrosine supplementation (500 mg 2x daily) for 7 days
3131773|NCT01676103|Placebo Comparator|Sugar pill|Placebo sugar pills (2x daily) for 7 days
3131774|NCT01676077||Patients with a genetically confirmed dysferlinopathy|
3131775|NCT01676064|Active Comparator|liberal fluid group|during surgery 7 ml/kg/hr RL during first intraoperative hr, 5 ml/kg/hr for the subsequent hours.After surgery ( PACU) 1,5 ml/kg/hr;After operation ward on the day of surgery 1,5 ml/kg/hr; Postoperative day 1- 1,5 ml/kg/hr RL, oral fluids;Postoperative day 2-oral fluids and solid food according to surgical allowance.
3131776|NCT01676064|Active Comparator|restrictive fluid group|"during surgery-RL according to 4-2-1 4 ml/kg/hr for first 10 kg (=40ml/hr) then 2 ml/kg/hr for next 10 kg (=20ml/hr)then 1 ml/kg/hr for any kg over 20 kg of weight. This always gives 60ml/hr for first 20 kg then you add 1 ml/kg/hr for each kg over 20 kg.~After surgery (PACU):4-2-1 rule. After operation ward on the day of surgery 1,5 ml/kg/hr.Postoperative day 1:1,5 ml/kg/hr RL, oral fluids. Postoperative day 2:oral fluids and solid food according to surgical allowance."
3131777|NCT01676051||Chloraprep|
3131778|NCT01676051||Duraprep|
3131779|NCT01676051||Betadine only|
3131862|NCT01675518|Experimental|Part-1 dose 5|
3131863|NCT01675518|Experimental|Part-1 dose 6|
3131780|NCT01676038|Active Comparator|Pinless-Navigated Total Knee Arthroplasty|The patients underwent total knee arthroplasty using a Pinless-Navigated system that is designed to restore the mechanical alignment of the lower limb.
3131781|NCT01676038|Active Comparator|Conventional Total Knee Arthroplasty|The patients underwent total knee arthroplasty using conventional technique.
3131782|NCT01676025|Experimental|PRA|Persons who get PRA surgery.
3131783|NCT01676025|Experimental|LA|Persons who get LA surgery.
3131784|NCT01676012||five types of bronchoscopy|"Bronchoscopy will be performed in a standardized order using five different imaging modes.~Standard white light videobronchoscopy (WLB)~High Definition -Bronchoscopy~HD-bronchoscopy + surface enhancement (iScan-surface)~HD-bronchoscopy + tone enhancement (iScan-tone)~Auto Fluorescence Bronchoscopy (AFB - SAFE3000) in dual video mode"
3131785|NCT01675999|Experimental|1|"Perioperative simplified FOLFOX-4 chemotherapy~- Simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by simplified FOLFOX-4 (8 cycles)."
3131786|NCT01675999|Experimental|2|Perioperative FOLFOX4+Cetuximab chemotherapy Simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h)+ Cetuximab (IV 500 mg/m2 every 2 weeks) for 4 cycles followed by colectomy (3 to 5 weeks after), followed by simplified FOLFOX-4 + Cetuximab (8 cycles).
3131787|NCT01675999|Other|3|Surgery followed by FOLFOX4 chemotherapy No preoperative chemotherapy Colectomy (maximum 4 weeks after randomization) followed by simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h) for 12 cycles.
3131788|NCT01675986|Experimental|Pregabaline|Groups PREGABALINE : 150 mg de LYRICA®
3131789|NCT01675986|Experimental|Hydroxyzine|Groups HYDROXYZINE : 75 mg d'ATARAX®
3131790|NCT01675986|Placebo Comparator|Lactose|Groups placebo : 4 g de lactose
3131791|NCT01675973|Experimental|Subjects with severe renal impairment|Cohort B (subjects with severe RI): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.
3131792|NCT01675973|Experimental|Subjects with normal renal function|Cohort A (healthy subjects with normal renal function): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.
3131793|NCT01675960|Active Comparator|gabapentin|Neurotin
3131794|NCT01675960|Placebo Comparator|placebo|Glycerin based clear solution that is flavored similar to the commercial product
3131795|NCT01675947|Experimental|Sirolimus|Monthly 20 μL (440 μg) intravitreal injection of sirolimus
3131796|NCT01675947|Sham Comparator|Lidocaine|Monthly subconjunctival injection of 2% lidocaine
3131797|NCT01675934|Active Comparator|Adult colonoscope|Use of the adult colonoscope.
3131798|NCT01675934|Active Comparator|Pediatric colonoscope|Use of the pediatric colonoscope.
3131799|NCT01675921|No Intervention|Control|"Participants will continue to receive medical care from their doctor as usual.~Participants will have access to this study website at the start and at the end of the study."
3131800|NCT01675921|Experimental|Facebook group|"Participants will continue to receive medical care from their doctor as usual.~Participants will have access to the study website at all times throughout the study.~Participants will have access to the secret study group on Facebook for 12 months.~Participants will take the ACT survey once a month for 12 months."
3131801|NCT01675908|Active Comparator|Metal stent|Patients randomized to one cohort will undergo placement of fully covered self expandable metal stents. The rates (%) of stent dysfunction and complications will be evaluated.
3131802|NCT01675908|Active Comparator|Plastic Stent|At ERCP, a 10Fr plastic stent will be placed in the bile duct. The rates (%) of stent dysfunction and complications will be evaluated.
3131803|NCT01675895|Experimental|Group Levobupivacaine lidocaine|Group Levobupivacaine lidocaine Spinal anesthesia with 1.5 ml hyperbaric levobupivacaine (6.75 mg) + 0.3 ml 2 % lidocaine
3131804|NCT01675895|Active Comparator|Group Control|Group Control levobupivacaine spinal anesthesia with levobupivacaine (6.75 mg) + saline
3131805|NCT01675882|Experimental|Viaskin Peanut 50 mcg|
3131806|NCT01675882|Experimental|Viaskin Peanut 100 mcg|
3131807|NCT01675882|Experimental|Viaskin Peanut 250 mcg|
3131808|NCT01675882|Placebo Comparator|Viaskin Placebo|
3131809|NCT01675869|Experimental|ETAM group|Executive Function/Metacognitive Training Program: An 8-week program, which addresses major areas of deficit in ADHD; namely, attention (the ability to concentrate and focus), inhibition (the ability to control ones behaviors), and memory (the ability to remember information).
3131810|NCT01675869|Active Comparator|Attention Control|Attention control group: An 8-week program which provides education regarding several topics relevant for preschool children including nutrition, sleep, temperament, etc.
3131811|NCT01675856|Active Comparator|Urgent endoscopy|Oesophagogastroduodenoscopy done within 6hours of first GI specialists consultation
3131812|NCT01675856|Placebo Comparator|Early endoscopy|Oesophagogastroduodenoscopy done within 24hours of first GI specialists consultation
3131813|NCT01675843|Experimental|Group A|controlled ovarian hyperstimulation (COH) and intrauterine insemination (IUI)
3131814|NCT01675843|No Intervention|Group B|Controlled ovarian hyperstimulation (COH)+ Timed Intercourse (TI)
3131815|NCT01675830|Experimental|Head Retention Head Wrap device|All subjects recieved the experimental intervention with the Heat Retention Head Wrap device for during the rewarming phase of cardiopulmonary bypass surgery.
3131816|NCT01675804|Experimental|Computerized cognitive rehabilitation|-Computer-assisted cognitive rehabilitation (CACR): 20 Ninety-minute sessions of CACR.
3131817|NCT01675804|Placebo Comparator|Placebo CACR [PCACR]|-PCACR group simultaneously received 20 Ninety-minute sessions of Placebo CACR.
3131818|NCT01675804|Experimental|Ritalin|-2 to 3 doses of 10 mg Ritalin tablets per day during two months.
3131819|NCT01675791|Placebo Comparator|ALK tree AIT Placebo|1 AIT administered sublingually every day
3131820|NCT01675791|Experimental|ALK tree AIT 0.5 DU|1 AIT administered sublingually every day
3131821|NCT01675791|Experimental|ALK tree AIT 1 DU|1 AIT administered sublingually every day
3131822|NCT01675791|Experimental|ALK tree AIT 2 DU|1 AIT administered sublingually every day
3131826|NCT01675778|Other|Hydromorphone|Every enrolled patients will receive a fixed dose (1mg) of intravenous hydromorphone. Pain scale change, patients' satisfaction, requirements for additional pain medications, side effects and adverse events will be recorded at 15 and 30 minutes. Patients' weight and height will be measured. Age, gender, and race/ethnicity will also be recorded. Blood draw for genetic study will be performed.
3131827|NCT01675765|Experimental|Immunotherapy plus chemotherapy- CLOSED to enrollment|"Weeks 1 and 3: CRS-207 (1 × 10^9 CFU)~Weeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m^2) and cisplatin (75 mg/m^2)~Weeks 23 and 26: CRS-207~Maintenance Vaccinations: CRS-207 every 8 weeks (starting at Week 34) until disease progression"
3131828|NCT01675765|Experimental|Immunotherapy with cyclophosphamide plus chemotherapy|"Weeks 1 and 3: cyclophosphamide (200 mg/m^2), CRS-207 (1 × 10^9 CFU)~Weeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m^2) and cisplatin (75 mg/m^2)~Weeks 23 and 26: cyclophosphamide one day before CRS-207~Maintenance Vaccinations: cyclophosphamide one day before CRS-207 every 8 weeks (starting at Week 34) until disease progression"
3131829|NCT01675739|Active Comparator|No-SMS group|In No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy without SMS.
3131830|NCT01675739|Experimental|SMS group|Patients in SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled short message service(SMS)
3131831|NCT01675726|Other|quality of life|
3131832|NCT01675713|Experimental|Lifestyle intervention|10-14 weeks intensive lifestyle intervention
3131833|NCT01675713|No Intervention|Controls|No treatment, waiting list
3131834|NCT01675700|Experimental|Myofascial trigger point|Patients diagnosed with myofascial trigger points who will receive a nitroglycerin patch over the trigger point.
3131835|NCT01675687|Experimental|Internet|"Participants of this intervention group get follow up support via Internet.~They have access to new inputs biweekly consisting of~Thematic inputs and instructions (e.g. advice on shopping, cooking, regular exercise on daily routine, motivation and more)~assignments promoting self-awareness and introspection~spreadsheets promoting self-monitoring~News and updates (e.g. recipes, gymnastic classes, meetings of self support groups and more) will be available each month.~Tailored feedback of their behaviour will be given by documentation on spreadsheets."
3131836|NCT01675687|Experimental|Printed Manual|"Participants of this intervention group get follow up support via a printed manual.~The manual consist of all the same inputs as are available to the Internet follow up group.~Thematic inputs and instructions (e.g. advice on shopping, cooking, regular exercise on daily routine, motivation and more)~assignments promoting self-awareness and introspection~spreadsheets promoting self-monitoring~All inputs will be given at once at the beginning of the follow up intervention, only news and updates (e.g. recipes, gymnastic classes, meetings of self support groups and more) will be sent per mail each month.~There is no tailored feedback of their behaviour as the paper-pencil documentation on spreadsheets can't be monitored by the psychologists."
3131837|NCT01675674||Dried blood spot test for MPS|"For the prospective study, subjects will be drawn from all children (aged 6 months to 18 years) with a history of presenting to selected clinics (pediatric rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE highly suspicious symptom or at least TWO less suspicious symptoms that may be indicative of an MPS disorder (see inclusion criteria).~For the retrospective chart review, subjects will be drawn from all children who were 6 months to 18 years of age at the time of first presentation to selected clinics (pediatric rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE highly suspicious symptom or at least TWO less suspicious symptoms that may be indicative of an MPS disorder (see inclusion criteria)."
3131838|NCT01675661|Active Comparator|NAC plus CM|N-acetylcysteine (NAC) plus Contingency Management (CM)
3131839|NCT01675661|Placebo Comparator|Placebo plus CM|Placebo plus Contingency Management (CM)
3131840|NCT01675648|Experimental|Lofexidine & Diazepam Placebo|"Initial Lofexidine dosage starts from 0.8mg per day, it will be gradually increased by increments of 0.4 to 0.8mg per day up to a maximum of 2.2mg daily. After 3 peak dose days, the dosage will be gradually decreased by 0.2 to 0.6mg per day till to 0.2mg of the last lofexidine dosage in Day 10.~The Diazepam placebo will be administrated to the patients with the same frequency, time and number tablets of diazepam in the active comparator arm."
3131841|NCT01675648|Active Comparator|Diazepam & Lofexidine Placebo|"The initial dosage of Diazepam is 10 mg per day on Day 1&2, the dosage will be increased to 15 mg per day on Day 3&4, subsequently decreased to 10mg per day on Day 5, 5mg per day on Day 6&7, 2mg per day on Day 8&9&10.~The Lofexidine placebo will be administrated to the patients with the same frequency, time and number tablets of lofexidine in the experimental arm."
3131842|NCT01675635|Experimental|OxyNorm Capsules|To determine the efficacy and safety of OxyNorm Capsules.
3131843|NCT01675635|Active Comparator|Morphine tablet|To determine the efficacy and safety of Morphine tablet.
3131844|NCT01675622|Experimental|Oxycodone Capsules for cancer pain|
3131845|NCT01675622|Active Comparator|Morphine tablets for cancer pain|
3131846|NCT01675609|Placebo Comparator|Placebo|
3131847|NCT01675609|Experimental|Brimonidine Tartrate 0.025%|
3131848|NCT01675596|Experimental|Test|SAPIEN XT™ valve with the NovaFlex and NovaFlex+ delivery systems.
3131849|NCT01675583||Standard Care Group|Subjects who will undergo only standard wound care management.
3131850|NCT01675583||Hyperbaric Oxygen Therapy Group|Subjects who are selected for adjunctive hyperbaric oxygen therapy in addition to standard wound care intervention.
3131851|NCT01675570|Experimental|RX-10045 active arm|RX-10045 Opththalmic Solution, 0.09%
3131852|NCT01675570|Placebo Comparator|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution
3131853|NCT01675557|Active Comparator|Vitamin D2|a single oral dose of vitamin D2
3131854|NCT01675557|Placebo Comparator|Placebo|a single oral dose of a placebo
3131855|NCT01675557|Experimental|Vitamin D3|A single oral dose of vitamin D3
3131856|NCT01675544||Heart Failure Admission|Patients admitted for acute decompensated heart failure
3131857|NCT01675531|Experimental|Targin|Targin
3131858|NCT01675518|Experimental|Part-1 dose 1|
3131859|NCT01675518|Experimental|Part-1 dose 2|
3131860|NCT01675518|Experimental|Part-1 dose 3|
3131861|NCT01675518|Experimental|Part-1 dose 4|
3131867|NCT01675505||Patients|"Inclusion criteria:~Patients with first-diagnosed colon cancer. Age 18-60 y.o.~Exclusion criteria:~Metastatic colon cancer. Former psychiatric history. Substance use. Previous serious medical conditions."
3131868|NCT01675492|Experimental|wave-front guided LASIK|
3131869|NCT01675479|Experimental|wavefront-guided LASIK|
3131870|NCT01675466|Active Comparator|early laparoscopy|early laparoscopy, aiming to achieve this within 12 hours
3131871|NCT01675466|Placebo Comparator|active observation|"standard management - the wait and see approach with serial examinations and investigations as deemed necessary"
3131872|NCT01675453|Active Comparator|7.2% NaCl /hydroxyethyl starch 200/0.5|On-pump CABG. 7.2% NaCl plus 6% hydroxyethyl starch 200/0.5 solution (HyperHAES) 4 mL/kg for 30 min, IV (in the vein), once, starting after the first hemodynamic measurement is obtained (before the beginning of CPB)
3131873|NCT01675453|Placebo Comparator|0.9% NaCl|On-pump CABG. 0.9% NaCl (isotonic saline) 4 mL/kg for 30 min, IV (in the vein), once, starting after the first hemodynamic measurement is obtained (before the beginning of CPB)
3131874|NCT01675440||Severe (≥3-4+) Mitral Valve Regurgitation|Mitral valve regurgitation ≥3-4+
3131875|NCT01675440||Severe (≥3-4+) Tricuspid Valve Regurgitation|Tricuspid valve regurgitation ≥3-4+
3131876|NCT01675440||End Stage Renal Disease (ESRD)|End stage renal disease requiring renal replacement therapy or a creatinine clearance (CRCL) <20 cc/min, but not on dialysis
3131877|NCT01675440||Low Gradient Low Output Aortic Stenosis|Low gradient low output aortic stenosis
3131878|NCT01675440||Failed Bioprosthetic Surgical Aortic Valve|Stenosed, insufficient or combined bioprosthetic surgical aortic valve failure
3131879|NCT01675440||2 or More Conditions|2 or more of the listed conditions
3131880|NCT01675427|Experimental|Chronic hepatitis C patients|
3131881|NCT01675401|Experimental|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
3131882|NCT01675401|Other|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
3131883|NCT01675388|Experimental|Hypothermia|Hypothermia to 33.5 deg Centigrade
3131884|NCT01675375|Experimental|Eye shield|Eye shield place on post Laser Vision Correction eye
3131885|NCT01675362|Placebo Comparator|Control group|They will receive placebo
3131886|NCT01675362|Active Comparator|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
3131887|NCT01675362|Active Comparator|Calcium channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
3131888|NCT01675362|Active Comparator|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
3131889|NCT01675349|Experimental|Chenopodium album allergen extract|Four concentrations of Chenopodium album allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
3131890|NCT01675323||RLS Patients|Participants who have diagnosed RLS with diagnosis confirmed by study investigators.
3131891|NCT01675323||Healthy Controls|Participants without RLS who are generally healthy and matched for gender, age, educational level, and race to patients in the RLS group.
3131892|NCT01675310|Experimental|medical nutrition therapy + metformin|medical nutrition therapy plus trans-gestational metformin (850mg 2 times day)
3131893|NCT01675310|Active Comparator|medical nutrition therapy|medical nutrition therapy without trans-gestational metformin
3131894|NCT01675297|Experimental|Risendronate/Cholecalciferol combination|Experimental: Administer Risendronate/Cholecalciferol combination one tablet once a week for 12months.
3131895|NCT01675297|Active Comparator|Risedronate|Active comparator: Administer Risendronate one tablet once a week for 12months.
3131896|NCT01675284|Experimental|Low Dosage AT-301|7.5 µg hemagglutinin (HA)
3131897|NCT01675284|Experimental|Middle Dosage AT-301|15 µg hemagglutinin (HA)
3131898|NCT01675284|Experimental|High Dosage AT-301|30 µg hemagglutinin (HA)
3131899|NCT01675271|Active Comparator|individual exercise|individualized exercise program
3131900|NCT01675271|Active Comparator|general exercise|general exercise program
3131901|NCT01675271|No Intervention|control|No exercise and dietary counselling
3131902|NCT01675258||Control|Healthy adults above the age of 18 years
3131903|NCT01675258||Study|Adult patients above the age of 18 years with gastric, colorectal (including pre-cancer polyps) or pancreatic cancer
3131904|NCT01675245||Velcade|Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks.
3131905|NCT01675232|Active Comparator|Soak and smear|Application of hydrocortisone 2.5% ointment or triamcinolone acetonide 0.1% ointment immediately to wet skin once a day and dry skin once a day.
3131906|NCT01675232|Active Comparator|Dry smear|Application of hydrocortisone 2.5% ointment or triamcinolone acetonide 0.1% ointment to dry skin twice a day.
3131907|NCT01675219|Experimental|Group B|Blue light TUR-BT with no adjuvant instillations
3131908|NCT01675219|Active Comparator|Group A|White light TUR-BT with no adjuvant instillations
3131909|NCT01675219|Experimental|Group C|White light TUR-BT with six weekly optimized mitomycin-C instillations.
3131910|NCT01675219|Experimental|Group D|Blue light (PDD) TUR-BT with six weekly optimized mitomycin-C instillations.
3131911|NCT01675206|Active Comparator|360 µg Vit K2|Administration of 360 µg of Vitamin K2 thrice weekly
3131912|NCT01675206|Active Comparator|720 µg Vit K2|Administration of 720 µg of Vitamin K2 thrice weekly
3131913|NCT01675206|Active Comparator|1080 µg Vit K2|Administration of 1080 µg of Vitamin K2 thrice weekly
3131914|NCT01675193|No Intervention|Current screening protocol|Eye screening at age 1-2, 3-4, 6-9, 14-24, 36, 45 and 54-60 months
3245108|NCT00875017|No Intervention|Fasting|
3131916|NCT01675180|Other|Information|Women randomized to the intervention will recieve information and counseling on oral health care during pregnancy
3131917|NCT01675180|No Intervention|Control|
3131918|NCT01675167|Placebo Comparator|Placebo Buccal Film|Twice Daily Dosing
3131919|NCT01675167|Experimental|Buprenorphine HCl Buccal Film|Twice Daily Dosing
3131920|NCT01675154|Placebo Comparator|SLx-4090 placebo/Orlistat Placebo|"Slx-4090(placebo) is dosed as 4 tablets of 50 mg, three times per day with meals.~Orlistat (placebo) is dosed as 2 capsules of 60 mg, three times per day with meals."
3131921|NCT01675154|Active Comparator|Orlistat/placebo|Orlistat two capsules 60mg each, three times per day with meals. Placebo for SLx-4090, 4 tablets 50mg each, three times per day with meals.
3131922|NCT01675154|Active Comparator|Orlistat placebo /Slx-4090|Orlistat placebo 2 capsules, 60mg each three times per day with meals. Slx-4090 4 tablets, 50mg each. three times per day with meals.
3131923|NCT01675154|Active Comparator|Orlistat/SLx-4090|Orlistat, 2 capsules 60 mg each, three times per day with meals. SLx-4090 4 tablets 50mg each, three times per day with meals.
3131924|NCT01675141|Experimental|Lenalidomide Maintenance Therapy for Multiple Myeloma|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
3131925|NCT01675128|Experimental|Phase I Dose Level I|Irinotecan 160 mg/m^2 every other week; ISIS 183750 started 800 mg/every week will be administered intravenously on Cycle 1 Days 1, 3, 5, 8, 15 and 22 of a 28 day cycle, restaged every 8 weeks.
3131926|NCT01675128|Experimental|Phase I Dose Level II|Irinotecan 180 mg/m^2 every other week; ISIS 183750 1000 mg/every week will be administered intravenously on Cycle 1 Days 1, 3, 5, 8, 15 and 22 of a 28 day cycle, restaged every 8 weeks.
3131927|NCT01675128|Experimental|Phase II Dose Level I|Irinotecan 160 mg/m^2 every other week; ISIS 183750 1000mg every week will be administered as an intravenous infusion every week without break, i.e. Days 1, 8, 15 and 22 of a 28-day cycle. Patients will be re-staged every 8 weeks.
3131928|NCT01675115|Active Comparator|BNG-1 plus Aspirin|BNG-1 3 grams TID plus Aspirin 100mg QD for 4 weeks
3131929|NCT01675115|Sham Comparator|Aspirin|Aspirin 100mg QD for 4 weeks
3131930|NCT01675089|Experimental|Zoledronic acid|Intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement.
3131931|NCT01675089|No Intervention|Control|The control group will receive only vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
3131932|NCT01675076|Experimental|Continued NOAC|- Patients continue on their chronic dose of Dabigatran or Rivaroxaban or Apixaban throughout
3131933|NCT01675076|Active Comparator|Interrupted NOAC|"Interrupted Dabigatran:~Discontinue Dabigatran 1 day before surgery if GFR > 50 mL/min or discontinue 2 days before surgery if GFR 30-50 mL/min~Resume Dabigatran at next regular dose timing >or = 24 hours after the end of surgery~Interrupted Rivaroxaban:~Discontinue Rivaroxaban 1 full day before surgery~Resume Rivaroxaban at next regular dose timing >or = 24 hours after the end of surgery~Interrupted Apixaban:~Discontinue Apixaban 1 full day before surgery~Resume Apixaban at next regular dose timing >or = 24 hours after the end of surgery"
3131934|NCT01675063|Other|Retia Non-Invasive Sensors|Sensors will be placed on the patient and connected to an amplifier that produces a waveform for 8 hours post cardiac surgery.
3131935|NCT01675050|Experimental|Cyproheptadine first then Placebo|4 weeks of cyproheptadine or placebo with crossover to the other
3131936|NCT01675050|Experimental|Sugar Pill first then Cyprotheptadine|4 weeks of cyproheptadine or placebo with crossover to the other
3131937|NCT01675037||obstructive|obstructive hydrocephalus in children and adults with biological evaluation
3131938|NCT01675024|Experimental|Rotigotine, Period 1|In Period 1 (Day 1 to Day 3) all 24 subjects will receive only 1 dose 2 mg / 24 hours.
3131939|NCT01675024|Experimental|Rotigotine, Period 2|In Period 2 (Day 7 to Day 14) all 24 subjects will receive 2 mg / 24 hours for 3 days then 4 mg / 24 hours for 3 days.
3131940|NCT01675011|Experimental|Embozene® Microspheres|Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink.
3131941|NCT01675011|Active Comparator|Embosphere®|Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink.
3131942|NCT01674985|Experimental|Decitabine and cytarabine|induction therapy：decitabine 25mg/m2 daily for 4 days with cytarabine 150 mg/m2 daily for 7 days consolidation：decitabine 25mg/m2 daily for 4 days with cytarabine 2g/m2 q12h for 3 days
3131943|NCT01674972||NAFLD|Patients with biopsy proven NAFLD
3131944|NCT01674972||Control|Matched healthy control subjects
3131945|NCT01674959|Experimental|concurrent chemoradiation|"• Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative current chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks)."
3131946|NCT01674946|Placebo Comparator|ID saline|ID saline by feeding tube
3131947|NCT01674946|Active Comparator|ID saline + CDCA (5 mmol/L)|CDCA = chenodeoxycholic acid (primary bile acid)
3131948|NCT01674946|Active Comparator|ID + CDCA (15 mmol/L)|CDCA = chenodeoxycholic acid (primary bile acid)
3131949|NCT01674946|Active Comparator|ID saline + oleanolic acid (1 mmol/L)|
3131950|NCT01674946|Active Comparator|ID saline + CDCA (5 mmol/L) + oleic acid|
3131951|NCT01674946|Placebo Comparator|ID saline + oleic acid (20 mmol/L)|
3131952|NCT01674933|Active Comparator|treatment as usual|any treatment from the family dentist, plus the preventive intervention programme offered to nursery school children, including daily supervised toothbrushing
3131953|NCT01674933|Experimental|Duraphat® Fluoride Varnish|treatment as usual (ie any treatment from the family dentist, plus the preventive intervention programme offered to nursery school children, including daily supervised toothbrushing) plus up to 4 six-monthly applications of Duraphat Fluoride Varnish in the nursery school setting.
3132346|NCT01672307|Placebo Comparator|Placebo|Placebo is applied twice daily to the other eyebrow.
3131954|NCT01674920|Experimental|Choices|"The 3-month twelve-session intervention, Choices, included topics on nutrition, physical activity, and resiliency. Parents, boys and girls met separately. The sessions were developed for delivery by a family physician, two family medicine residents, and a nutritionist, who received training in positive psychology and resilience skills. All children were measured on the same dates, but children were randomly assigned to two cohorts, beginning 6 months apart, to facilitate statistical analysis by having one group experience normal growth on study prior to intervention."
3131955|NCT01674907||Cohort|
3131956|NCT01674894||Group 1|Women treated with Menopur
3131957|NCT01674894||Group 2|Women treated with Menopur and Bravelle
3131958|NCT01674881|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|This group will receive MBCT for 8 consecutive weeks.
3131959|NCT01674881|Other|Waitlist control group|This group is a waitlist control group.
3131960|NCT01674868|Experimental|Fluoxetine|Subjects will take 20 mg fluoxetine daily for 90 days after stroke
3131961|NCT01674868|Placebo Comparator|placebo|Subjects will take one pill daily for 90 days after stroke.
3131962|NCT01674855|Experimental|DA-3031|PEG-G-CSF
3131963|NCT01674855|Active Comparator|Leucostim®|G-CSF
3131964|NCT01674842|Experimental|Cisplatin + Radiation Therapy|Cisplatin concurrently with radiation therapy
3131965|NCT01674829|Experimental|Biological: MA09-hRPE Cellular therapy|"Biological: MA09-hRPE Cellular therapy~Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
3131966|NCT01674816|Active Comparator|Repeated Measurements of Knee Alignment and Kinematics|Patients in the Repeated Measurements Arm will have the kinematic measurement protocol repeated twice before and twice after the surgical procedure; the procedure itself will be performed with the traditional technique, i.e without guidance by the system.
3131967|NCT01674816|Active Comparator|Computer Guidance of Surgical Actions|Patients in the Computer Guidance of Surgical Actions Arm will have the kinematic measurement protocol performed only once before and once after the surgical procedure; the procedure itself will be performed with guidance by the system.
3131968|NCT01674803|Active Comparator|Orsiro|
3131969|NCT01674803|Active Comparator|Synergy|
3131970|NCT01674803|Active Comparator|Resolute Integrity|
3131971|NCT01674790|Experimental|AEROBIC group|6-week program of one 20-min session of aerobic training and one 20-min session of ROM exercise 5 days/week.
3131972|NCT01674790|Experimental|COGNITIVE group|6-week program of one 20-min session of cognitive training and one 20-min session of ROM exercise 5 days/week.
3131973|NCT01674790|Experimental|AEROBIC + COGNITIVE group|6-week program of one 20-min session of aerobic training and one 20-min session of cognitive training 5 days/week.
3131974|NCT01674790|Experimental|CONTROL group|6-week program of one 20-min session of ROM exercise and one 20-min session of unstructured mental activity 5 days/week.
3131975|NCT01674777|Experimental|under fasting condition group|Subjects will receive a single dose of ASP1941 under fasting condition
3131976|NCT01674777|Experimental|before meal group|Subjects will receive a single dose of ASP1941 before meal
3131977|NCT01674777|Experimental|after meal condition|Subjects will receive a single dose of ASP1941 after meal
3131978|NCT01674764||Early surgical intervention = Cohort 1|≤ 12 hours after the tSCI
3131979|NCT01674764||Late surgical intervention = Cohort 2|> 12 hours and < 14 days after the tSCI
3131980|NCT01674751|Experimental|Immediate intervention|Group begins the 4 week Pre-Ordering Program intervention immediately following a 4-wk baseline period.
3131981|NCT01674751|Other|Wait-listed control|Group begins the 4 week Pre-Ordering Program intervention following an 8-wk baseline period.
3131982|NCT01674738|Experimental|Pemetrexed, Cisplatin, Bevacizumab|Stratum A
3131983|NCT01674738|Experimental|Pemetrexed, Cisplatin, Bevazizumab|Stratum B:
3131984|NCT01674725|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3131985|NCT01674725|Experimental|ABT-450/r/ABT-267 and ABT-333|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks
3131986|NCT01674712|Experimental|Fenofibrate/simvastatin 145/20 mg|
3131987|NCT01674712|Active Comparator|Simvastatin 20 mg|
3131988|NCT01674712|Active Comparator|Fenofibrate 145 mg|
3131989|NCT01674712|Experimental|Fenofibrate/simvastatin 145/40 mg|
3131990|NCT01674712|Active Comparator|Simvastatin 40 mg|
3131991|NCT01674699||EXCOR|Pediatric candidates age 0 - 21 with severe isolated left ventricular or biventricular dysfunction who are candidates for cardiac transplant and require circulatory support may be treated using the EXCOR® Pediatric.
3131992|NCT01674686|Experimental|A|Sarpogrelate versus placebo
3131993|NCT01674686|Experimental|B|Atorvastatin 80mg versus no statin or simvastatin 20 mg if LDL > 130 mg/dl
3131994|NCT01674660||volume status|volume status:group1 over volume status,group2 normal volume status,group3 low volume status
3131995|NCT01674660||night blood pressure|night blood pressure：group1 nondipper,group2 dipper,group3 extreme dipper,group4 riser
3131996|NCT01674660||interdialysis weight gain|interdialysis weight gain:group1 >5% dry weight,group2 <5% dry weight
3131997|NCT01674647|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|A Direct Cardioversion Strategy can be performed only if sufficient anticoagulation is proven during the last 21 days prior to randomization and/or a transesophageal echocardiogram (TEE) is planned before cardioversion. Rivaroxaban will be given for 1-5 days before planned direct cardioversion. The run-in of 1-5 days is needed due to potential pretreatment with VKA. Treatment with rivaroxaban will be continued for 42 days after the cardioversion. A Delayed Cardioversion Strategy will be chosen if sufficient anticoagulation is not proven during the last 21 days prior to randomization and no TEE is planned. Rivaroxaban will be given for at least 21 (+4) days before the planned cardioversion, to a maximum of 56 (+4) days prior to planned cardioversion.
3132041|NCT01674374|Experimental|Arm I (SAMITAL)|Beginning as soon as symptoms arise during chemoradiotherapy, patients receive Vaccinium myrtillus extract/Macleaya cordata alkaloids/Echinacea angustifolia extract granules PO QID. Patients may continue to receive Vaccinium myrtillus extract/Macleaya cordata alkaloids/Echinacea angustifolia extract granules for up to 4 weeks after completion of radiation therapy for a maximum of 11 weeks.
3131998|NCT01674647|Active Comparator|Vitamin K antagonist (VKA)|A Direct Cardioversion Strategy can be performed only if sufficient anticoagulation is proven during the last 21 days prior to randomization and/or a transesophageal echocardiogram (TEE) is planned before cardioversion. VKA will be given for 1-5 days before planned direct cardioversion. The run-in of 1-5 days is needed due to potential pretreatment with VKA. Treatment with VKA will be continued for 42 days after the cardioversion. A Delayed Cardioversion Strategy will be chosen if sufficient anticoagulation is not proven during the last 21 days prior to randomization and no TEE is planned. VKA will be given for at least 21 (+4) days before the planned cardioversion, to a maximum of 56 (+4) days prior to planned cardioversion.
3131999|NCT01674634|Experimental|XIAFLEX / XIAPEX|AA4500 (collagenase clostridium histolyticum)
3132000|NCT01674621|Placebo Comparator|BA058 (abaloparatide) Transdermal Placebo (0 mcg)|BA058 (abaloparatide) Transdermal Microneedle Patch 0 mcg daily
3132001|NCT01674621|Experimental|BA058 (abaloparatide) Transdermal (50 mcg)|BA058 (abaloparatide)Transdermal Microneedle Patch - 50 mcg daily
3132002|NCT01674621|Experimental|BA058 (abaloparatide) Transdermal (100 mcg)|BA058 (abaloparatide) Transdermal Microneedle Patch - 100 mcg daily
3132003|NCT01674621|Experimental|BA058 (abaloparatide) Transdermal (150 mcg)|BA058 (abaloparatide) Transdermal Microneedle Patch - 150 mcg daily
3132004|NCT01674621|Active Comparator|BA058 (abaloparatide) Injection (80 mcg)|BA058 (abaloparatide-SC) Subcutaneous Injection - 80 mcg daily
3132005|NCT01674595|Experimental|Immunotherapy|AVANZ
3132006|NCT01674582|Other|MRI, Neuropsychological testing|
3132007|NCT01674569|Experimental|50 mg X-82 oral alternate days|50 mg X-82 oral on alternate days with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria for 24 weeks or until unacceptable toxicity develops
3132008|NCT01674569|Experimental|50 mg X-82 oral QD|50 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria.for 24 weeks or until unacceptable toxicity develops
3132009|NCT01674569|Experimental|100 mg X-82 oral alternate days|100 mg X-82 oral on alternate days with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria.for 24 weeks or until unacceptable toxicty develops
3132010|NCT01674569|Experimental|100 mg X-82 oral QD|100 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs
3132011|NCT01674569|Experimental|200 mg X-82 oral QD|200 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs
3132012|NCT01674569|Experimental|300 mg X-82 oral QD|300 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs.
3132013|NCT01674556|Experimental|Contrast-enhanced ultrasound (CEUS)|
3132014|NCT01674543|Experimental|Resistance training|
3132015|NCT01674543|Experimental|Concurrent training|
3132016|NCT01674543|Sham Comparator|Control Group|
3132017|NCT01674530|Experimental|Lubiprostone|Manufactured by Dr Reddy's Laboratories Ltd( 24 mcg administered for 7 days )
3132018|NCT01674530|Active Comparator|AMITIZA®|Manufactured by Sucampo Pharmaceuticals(24 mcg administered for 7 days)
3132019|NCT01674530|Placebo Comparator|Placebo|Manufactured by Dr Reddy's Laboratories Ltd ( 24 mcg adminstered for 7 days )
3132020|NCT01674517|Experimental|Montelukast sodium|Montelukast sodium chewable tablets 4mg and 5mg of Dr. Reddy's Laboratories Limited
3132021|NCT01674517|Active Comparator|SINGULAIR®|SINGULAIR®(containing Montelukast sodium) chewable tablets 4mg and 5mg of Merck Sharp & Dohme Ltd., USA
3132022|NCT01674504|Experimental|Montelukast sodium|Montelukast sodium chewable tablets 4mg and 5mg of Dr. Reddy's Laboratories Limited
3132023|NCT01674504|Active Comparator|SINGTJLAIR ®|SINGTJLAIR ® (containing Montelukast sodium)chewable tablets 5mg of Merck Sharp & Dohme Ltd., USA
3132024|NCT01674491|Experimental|4.5g/day black soy peptide|4.5 g/day, 8weeks
3132025|NCT01674491|Placebo Comparator|placebo|similar appearance to the black soy peptide tablet, 8 weeks
3132026|NCT01674478|Experimental|Microlipid and fish oil group|This group will be given early enteral lipid supplementation with Microlipid and fish oil.
3132027|NCT01674478|Active Comparator|Microlipid group|This group will be given early enteral lipid supplementation only with Microlipid.
3132028|NCT01674465||CNI-induced nephrotoxicity|Hypoxyprobe-1
3132029|NCT01674452|Experimental|home-based group|
3132030|NCT01674452|Active Comparator|supervised exercise group|
3132031|NCT01674452|No Intervention|control|Control group:no intervention
3132032|NCT01674439|Experimental|With supplementation of ADRC|Fat graft with supplementation of ADRC
3132033|NCT01674439|Active Comparator|Without supplementation of ADRC|Fat grafts without supplementation of ADRC
3132034|NCT01674426|Experimental|Cognitive behavior therapy|Cognitive behavior therapy consisting of 16 sessions over 20 weeks
3132035|NCT01674426|Placebo Comparator|observation|Subjects were called by telephone but were not given cognitive behavior therapy until the study phase was completed
3132036|NCT01674413|Placebo Comparator|Placebo/Step-Down|1 syringe of placebo SC q 2 weeks.
3132037|NCT01674413|Active Comparator|PRNLOAD Arm|160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38)
3132038|NCT01674413|Active Comparator|Maintenance Arm|Adalimumab 40 mg q 2 weeks.
3132039|NCT01674387|Experimental|acupuncture|30 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral Jiaji (EX-B2) of cervical positive reaction plane (taking two pairs). Besides, bilateral Jianzhongshu (SI15) and bilateral Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
3132040|NCT01674387|Other|comprehensive treatment|Other 30 patients (the matched group) receive the comprehensive treatment, including traction and low-frequency therapy. Each treatment 15 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
3132347|NCT01672294|Experimental|treatment|three facilitator-led end-of-life preparation and completion sessions with a facilitator with both patient and caregiver
3245964|NCT00868894|Placebo Comparator|3|
3132042|NCT01674374|Placebo Comparator|Arm II (placebo)|Beginning as soon as symptoms arise during chemoradiotherapy, patients receive placebo PO QID. Patients may continue to receive placebo for up to 4 weeks after completion of radiation therapy for a maximum of 11 weeks.
3132043|NCT01674361|Experimental|Bitopertin 30 mg|"Participants in Stratum 1 will receive bitopertin 30 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI.~Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 30 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI."
3132044|NCT01674361|Experimental|Bitopertin 10 mg|"Participants in Stratum 1 will receive bitopertin 10 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI.~Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 10 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI."
3132045|NCT01674361|Placebo Comparator|Placebo|Participants (both Stratum 1 and Stratum 2) will receive placebo from Day 1 to Week 16 in addition to their background therapy with an SSRI.
3132046|NCT01674348|Active Comparator|P2202|"Two treatment arms in Stage I- P2202 (1000 mg) and placebo~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo"
3132047|NCT01674348|Placebo Comparator|Placebo|"Two treatment arms in Stage I- P2202 (1000 mg) and placebo~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo"
3132048|NCT01674335|No Intervention|Delayed-Intervention|A total of 120 participants with fibromyalgia will be randomly assigned to one of four intervention groups (Operant Learning (OL), Energy Conservation (EC), delayed-OL and delayed-EC). The delayed groups will receive the AP intervention 3 months later and will serve as a Usual Care control group. All groups will continue to receive any concomitant interventions that they are receiving (pharmacological and non-pharmacological) at the time of enrollment.
3132049|NCT01674335|Active Comparator|Operant Learning|
3132050|NCT01674335|Active Comparator|Energy Conservation|
3132051|NCT01674322|Experimental|Ibrutinib|All participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
3132052|NCT01674309|Other|single arm study/ non randomized trial|FOLFORINOX
3132053|NCT01674296||Group 1 (2012-2013)|Monitoring of Dietary Intake, Physical Activity and Stress
3132054|NCT01674296||Group 2 (2013-2014)|Monitoring of Dietary Intake, Physical Activity and Stress
3132055|NCT01674283|Experimental|Glucagon|"The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of Glucagon.~The second recording is doing the same way 10 minutes after the Glucagon injection, just before the embryo transfer."
3132056|NCT01674283|Placebo Comparator|Sodium chloride 0.9%|"The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of the placebo.~The second recording is doing the same way 10 minutes after the placebo injection, just before the embryo transfer."
3132057|NCT01674270|Experimental|Degarelix|Degarelix Alone
3132058|NCT01674270|Experimental|Degarelix + Casodex|Degarelix and Casodex
3132059|NCT01674270|Active Comparator|LHRH Agonist + Casodex|LHRH Agonist and Casodex
3132060|NCT01674257||Carotid Endarterectomy|Patients due to undergo carotid endarterectomy for symptomatic carotid artery stenosis will undergo an 18F-Fluoride PET/CT, an 18F-Flurodeoxyglucose PET/CT and a USPIO (ferumoxytol)-enhanced MRI scan (2 MRI scans).
3132061|NCT01674244|Experimental|Integrative Exercise|Subjects will exercise for 12 weeks (3 times weekly, with each total workout being approximately 60 minutes in length). The exercise protocol will incorporate elements of mindfulness, cardiovascular strengthening, and controlled breathing.
3132062|NCT01674244|Active Comparator|Monitor Only Waitlist|Monitor Only Waitlist
3132063|NCT01674231|Active Comparator|Grape|Grapes in the form of a Freeze-dried Whole Grape Powder. 60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
3132064|NCT01674231|Placebo Comparator|Sugar|Grape Powder Placebo. 60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
3132065|NCT01674218|Experimental|Treatment E|PA-824 400 mg plus moxifloxacin 400 mg
3132066|NCT01674218|Active Comparator|Treatment D|PA-824 placebo plus moxifloxacin 400 mg
3132067|NCT01674218|Experimental|Treatment C|PA-824 1000 mg plus moxifloxacin placebo
3132068|NCT01674218|Experimental|Treatment B|PA-824 400 mg plus moxifloxacin placebo
3132069|NCT01674218|Placebo Comparator|Treatment A|PA-824 placebo and moxifloxacin placebo
3132070|NCT01674205|Experimental|Group 1 (Inpatient, H2N3 MO 2006/AA ca)|Participants will receive one dose of vaccine on Day 0, with 0.2 mL being delivered by Accuspray device (0.1 mL per nostril).
3132071|NCT01674205|Experimental|Group 2 (Inpatient, H9N2 G9/AA ca)|Participants will receive one dose of vaccine on Day 0, with 0.5 mL being delivered as nose drops (0.25 mL per nostril) using a sterile, needle-less tuberculin syringe.
3132072|NCT01674205|Experimental|Group 3 (Outpatient, seasonal LAIV [FluMist®])|2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)
3132073|NCT01674205|Placebo Comparator|Group 4 (Both inpatient and outpatient, placebo)|Participants will receive either the L-15 placebo delivered by nose drops or the FluMist® placebo delivered as a nasal spray.
3132074|NCT01674192|Experimental|prucalopride|single dose of 2 mg prucalopride
3132075|NCT01674179||ACR diagnosis of Fibromyalgia|
3132076|NCT01674179||Patients without Fibromyalgia|
3132077|NCT01674166|Experimental|prucalopride|single dose 0.03 mg/kg prucalopride open label
3132078|NCT01674153|Experimental|HD-Exercise-HDF|Prescribe intra-dialytic exercise of three bouts in 4 hours dialysis session.
3132079|NCT01674140|Placebo Comparator|Arm I|Patients receive an approved endocrine therapy comprising tamoxifen citrate*, goserelin acetate** or leuprolide acetate**, or an aromatase inhibitor (anastrozole, letrozole, or exemestane) for 2-5 years. Patients also receive a placebo PO daily for 1 year in the absence of disease progression or unacceptable toxicity.
3132080|NCT01674140|Experimental|Arm II|Patients receive an approved endocrine therapy regimen as in arm I. Patients also receive everolimus PO daily for 1 year in the absence of disease progression or unacceptable toxicity.
3132348|NCT01672294|Active Comparator|attention control|three facilitator led sessions of listening to a relaxation CD.
3132081|NCT01674127|Experimental|Methyldopa|In case group, 25 patients, under treatment, using Methyldopa for 7 days, received 500 mgs of Methyldopa in its oral form per day and in control group, participants received placebo for 7 days.
3132082|NCT01674127|Placebo Comparator|placebo|
3132083|NCT01674114|Experimental|TAP block|transversus abdominis plane block (TAP block). Ultrasound guided TAP-block at the end of surgery using 20 ml bupivacaine 0,25% with Adrenaline 5mcg/ml bilaterally by the anaesthesiologist, and 20 ml NaCl intracutaneously in the operating wound performed by the obstetrician
3132084|NCT01674114|Active Comparator|control|Ultrasound guided TAP block at the end of surgery with 20 ml NaCl bilaterally and 20 ml bupivacaine 0,25% with Adrenaline 5mcg/ml intracutaneously in the surgical wound(standard practice)
3132085|NCT01674101|Experimental|Physical Therapy|"The intervention group will receive PT 3 times per week for 60 minutes each session. The therapy sessions will include endurance, strengthening, and stretching exercises.~Exercise time and resistance will be progressed per individual's medical status and per participant's tolerance. All participants will be given a tailored home exercise program (HEP).~Participants will participate in PT 10 weeks prior to surgery and 10-12 weeks after surgery. Subjects will be seen by the physical therapist both when inpatient and outpatient. Patients will not be seen for PT if platelet count is less than 20,000mm3 and/or hemoglobin is less than 8g/dL."
3132086|NCT01674088||Irritable Bowel Syndrome|Subjects meeting Rome III criteria will be included as the group Irritable Bowel Syndrome
3132087|NCT01674088||Healthy Controls|Subjects not meeting Rome III criteria and meeting clinical definitions of general good health will be considered as Healthy Controls
3132088|NCT01674075||Healthy adult volunteers|Healthy adult volunteers will be administered a J-Tip to the dorsum of his/her hand.
3132089|NCT01674062|Experimental|Pertuzumab + Trastuzumab (Cohorts 1 and 2)|Females with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer will receive dual-agent treatment with pertuzumab and trastuzumab. Trastuzumab will be administered IV as 2 milligrams per kilogram (mg/kg) once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1. Pertuzumab will be administered IV at a loading dose of 840 mg followed by a standard dose of 420 mg every 3 weeks, beginning on Day 2 of Cycle 1. Thereafter, both medications will be administered on Day 1 of each 3-week cycle. Treatment will continue for a minimum of 8 cycles and may be extended until disease progression, intolerable toxicity, or death.
3132090|NCT01674062|Experimental|Pertuzumab +/- Trastuzumab (Cohort 3)|Females with HER2-positive metastatic breast cancer will receive single-agent treatment with pertuzumab. Pertuzumab will be administered IV at a loading dose of 840 mg followed by a standard dose of 420 mg every 3 weeks, administered on Day 1 of each 3-week cycle. Participants with documented disease progression may have trastuzumab added to the regimen, per the dosing schedule described for Cohorts 1 and 2, to receive dual-agent treatment until disease progression, intolerable toxicity, or death.
3132091|NCT01674049|Experimental|Exercise and Immediate Nutrition|40 min of circuit-style resistance exercise and 600g low-fat chocolate milk immediately after the exercise bout
3132092|NCT01674049|Active Comparator|Exercise and Nutrition 3 hours Post-Bout|40 min of circuit-style resistance exercise and 600g low-fat chocolate milk three hours after the exercise bout
3132093|NCT01674036|Experimental|Part 1 (GZFD00111/TDU12766): Genz-682452|Participants will receive a single oral dose of Genz-682452. Six ascending single doses and an optional seventh dose under fasted conditions will be used.
3132094|NCT01674036|Placebo Comparator|Part 1 (GZFD00111/TDU12766): Placebo|Participants will receive a single oral dose of placebo.
3132095|NCT01674036|Experimental|Part 2 (GZFD00211/FED12767): Genz-682452|Participants will receive two single doses of Genz-682452 separated by a 7-day wash-out period, one dose given under fed (standardized high-fat breakfast) and one under fasted conditions. The dose will be based on the blind review of the safety/tolerability/pharmacokinetic data of single dose level cohorts in Part 1.
3132096|NCT01674023||human vitreous, human blood serum, PCR|"human vitreous and blood serum sampling, PCR~1ml of human vitreous and 3ml of human blood serum of patients with various vitreoretinal diseases"
3132097|NCT01674010|Experimental|Lamotrigine or Valproic acid + ELND005|Lamotrigine or valproic acid plus ELND005 film coated tablets, 500mg BID for up to 48 weeks
3132098|NCT01674010|Placebo Comparator|Lamotrigine or Valproic acid + placebo|Lamotrigine or valproic acid plus matched placebo BID for up to 48 weeks
3132099|NCT01673997|Experimental|Metoprolol Succinate ER Tablets, 200 mg|Metoprolol Succinate ER Tablets, 200 mg of Dr.Reddy's Laboratories Ltd
3132100|NCT01673997|Active Comparator|TOPROL-XL ER Tablets 200 mg|TOPROL-XL ER Tablets 200 mg of AstraZeneca
3132101|NCT01673984|Experimental|Decapeptyl® SR 22.5mg (Triptorelin)|
3132102|NCT01673984|Active Comparator|Current 3-monthly LHRH agonist|One of the following: Decapeptyl® SR 11.25mg (Triptorelin), Prostap® 3 DCS 11.25mg, Zoladex® LA 10.8mg
3132103|NCT01673971||Natural History|
3132104|NCT01673971||Treatment|
3132105|NCT01673958|Experimental|Stair descending group|Stair descending exercise. Participants will carry out six weeks of stair descending training consisting of three exercise sessions per week.
3132106|NCT01673958|Experimental|Stair ascending group|Stair ascending exercise. Participants will carry out six weeks of stair descending training consisting of three exercise sessions per week.
3132107|NCT01673945|Active Comparator|EUS-FNA with the CLA-EUS|
3132108|NCT01673945|Experimental|EUS-FNA With the FV-EUS|
3132109|NCT01673932|Experimental|Group A - UCBMC Early Treatment Group|Group A subjects will receive transplant of UCBMC isolated from HLA-matched umbilical cord blood at Day 0.
3132110|NCT01673932|Experimental|Group B - UCBMC Delayed Treatment Group|Group B subject will partipate in 6 months observation and then receive the UCBMC transplant at month 6.
3132111|NCT01673919|Experimental|RoActemra/Actemra|
3132112|NCT01673906|Experimental|Diagnostic work up|The patients enrolled in the study (see below), with a consistent clinical suspicion of a primary duodenal-pancreatic NET.
3132113|NCT01673893||Readmission Results|The registry will record the use of the ClearWay™ Rx catheter during the index procedure, and assess whether or not the patient was readmitted within 30 days, related to the index procedure.
3132114|NCT01673880|Other|E2006 2.5 mg|
3132115|NCT01673880|Other|E2006 10mg|
3132116|NCT01673880|Other|E2006 25 mg|
3132349|NCT01672281|Experimental|vibrox training|
3132350|NCT01672281|Experimental|resistance training|
3132117|NCT01673867|Experimental|Arm A: Nivolumab|Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
3132118|NCT01673867|Active Comparator|Arm B: Docetaxel|Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
3132119|NCT01673854|Experimental|Vemurafenib, 960 mg + Ipilimumab, 10 mg/kg|Participants received vemurafenib, 960 mg, twice daily for 6 weeks (Vem1 Phase). After a washout period of 3-10 days, patients received ipilimumab, 10 mg/kg, every 3 weeks for a maximum of 4 doses. At Week 24, participants received ipilimumab, 10 mg/kg, every 12 weeks until disease progression or unacceptable toxicity. Patients who did not progress or have unacceptable toxicity in the Vem1 Phase were retreated with vemurafenib (Vem 2 Phase) at the last dose level identified at the end of the Vem1 Phase until disease progression or unacceptable toxicity.
3132120|NCT01673841||Relative + absolute cerebral oxygen saturation.|
3132121|NCT01673828|Experimental|Allopregnanolone|Allopregnanolone injection (intravenous solution) continuous infusion for 5 days
3132122|NCT01673828|Placebo Comparator|Placebo|Placebo injection (intravenous solution) continuous infusion for 5 days
3132123|NCT01673815|Experimental|1st: R eye video. 2nd: L eye no video|The right eye will be examined first with video, followed by the left eye without video.
3132124|NCT01673815|Experimental|1st: R eye no video. 2nd: L eye video|The right eye will be examined without video, followed by the left eye with video.
3132125|NCT01673815|Experimental|1st: L eye video. 2nd: R eye no video|The left eye will be examined first with video, followed by the right eye without video.
3132126|NCT01673815|Experimental|1st: L eye no video. 2nd: R eye video|The left eye will be examined first without video, followed by the right eye with video.
3132127|NCT01673802|Experimental|CT imaging|Patients will undergo a standard of care Gadoxetate (Eovist) MRI for cholangiocarcinoma. Patients will then be immediately placed on the CT scanner. Patients will undergo a dual energy CT of the abdomen with no additional contrast.
3132128|NCT01673789|Experimental|Stem Cell Educator|The collected lymphocytes are transferred into the device for exposure to CB-SCs, and other blood components are automatically returned to the patient. The Stem Cell Educator functions as part of a closed-loop system that circulates a patient's blood through a blood cell separator, briefly co-cultures the patient's lymphocytes with CB-SCs in vitro, and returns the educated lymphocytes to the patient's circulation. CB-SCs tightly attached to interior surfaces in the device, and only the CB-SC-educated autologous lymphocytes are returned to the subjects. The Stem Cell Educator therapy requires only two venipunctures with minimal pain, and does not introduce stem cells or reagents into patients.
3132129|NCT01673776|No Intervention|K group|commonly used therapy
3132130|NCT01673776|Experimental|M group|multimodal intervention
3132131|NCT01673763|Active Comparator|Stent|Stent insertion into the main pancreatic duct
3132132|NCT01673763|No Intervention|No stent|No stent insertion into the main pancreatic duct
3132133|NCT01673750||Participants|Participants will have documented HIV infection and are aware of their diagnosis. They will complete a one-time questionnaire.
3132134|NCT01673737|Experimental|Part A Monotherapy|Dose escalation of daily or twice daily SAR260301 within a 28-day cycle, followed by an expansion phase at the maximal tolerated dose
3132135|NCT01673737|Experimental|Part B Combination|Dose escalation of twice-daily SAR260301 within a 28-day cycle and in combination with 720 or 960 mg twice daily of Vemurafenib, followed by an expansion phase at the maximal tolerated dose of SAR260301 in combination
3132136|NCT01673724|Experimental|pramipexole|dosage form: tablet dosage: pramipexole 0.125/0.25/0.5/1mg frequency: tid duration: 24weeks
3132137|NCT01673724|Active Comparator|Bromocriptine|bromocriptine dosage form: white round tablet
3132138|NCT01673711||Basic Science (deuterated phenanthrene tetraol)|Patients receive deuterated phenanthrene tetraol PO and collect urine for 6 hours after dosing.
3132139|NCT01673698|Active Comparator|ReShape Duo Balloon|ReShape Duo Balloon
3132140|NCT01673698|Sham Comparator|Sham Comparator|Sham Comparator
3132141|NCT01673685|Placebo Comparator|Portable Oxygen Cylinder|Portable Oxygen Cylinder
3132142|NCT01673685|Active Comparator|Portable Oxygen Concentrator|Portable Oxygen Concentrator
3132143|NCT01673672|Placebo Comparator|Placebo|7 weekly/biweekly injections of a placebo buffer
3132144|NCT01673672|Experimental|CYT003 low dose|7 weekly/biweekly injections of CYT003 low dose
3132145|NCT01673672|Experimental|CYT003 medium dose|7 weekly/biweekly injections of CYT003 medium dose
3132146|NCT01673672|Experimental|CYT003 high dose|7 weekly/biweekly injections of CYT003 high dose
3132147|NCT01673659|Experimental|Test product|Mometasone furoate 50 mcg/actuation Nasal Spray
3132148|NCT01673659|Active Comparator|Reference product|Nasonex Nasal Spray
3132149|NCT01673659|Placebo Comparator|Placebo Nasal Spray|vehicle of the test product
3132150|NCT01673646|Experimental|SOM230LAR 20mg|10 enrolled patients will be randomized to 20mg pasireotide LAR.
3132151|NCT01673646|Experimental|SOM230LAR 40mg|10 enrolled patients will be randomized to 40mg pasireotide LAR.
3132152|NCT01673646|Experimental|SOM230LAR 60mg|10 enrolled patients will be randomized to 60mg pasireotide LAR.
3132153|NCT01673633||SSc|Sacroiliitis
3132154|NCT01673633||Rheumatoid arthritis|Sacroiliitis
3132155|NCT01673633||Healthy controls|Sacroiliitis
3132156|NCT01673620|Experimental|Montelukast 10 mg/loratadine 10 mg|Montelukast 10 mg/loratadine 10 mg combination tablet administered orally once daily for 2 weeks
3132157|NCT01673620|Placebo Comparator|Placebo|Matching placebo tablet administered orally once daily for 2 weeks
3132158|NCT01673594|Experimental|Naltrexone|Arm 1: Naltrexone + SODAS MPH
3132159|NCT01673594|Placebo Comparator|Placebo|Arm 2: Placebo + SODAS MPH
3132160|NCT01673581||Low risk prostate cancer|
3132351|NCT01672268|Active Comparator|Standard TAVI procedure|Patients without Cardiac CT measures before TAVI
3135436|NCT01651013||metastatic colorectal cancer|
3132161|NCT01673568|Active Comparator|abdominal binder|"The abdominal binder is worn from immediately after the operation and continuously for 7 days, night and day. The belts are standard elastic belts (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done before the operation by waist measurement according to the recommendation from the company."
3132162|NCT01673568|No Intervention|no abdominal binder|no abdominal binder
3132163|NCT01673555|Experimental|GSK1278863 5mg|GSK1278863 5mg
3132164|NCT01673555|Experimental|GSK1278863 100mg|GSK1278863 100mg
3132165|NCT01673555|Placebo Comparator|Placebo|Placebo
3132166|NCT01673542|Experimental|Lidocaine-Prilocaine 5%|
3132167|NCT01673542|Placebo Comparator|Dexeryl|
3132168|NCT01673529|Experimental|study population|All subjects will receive 1%, 3%, 5% (w/w) of SB705498 and a placebo comparator
3132169|NCT01673516|Active Comparator|group Co|"group Co receives intensive medical therapy utilizing integrated hemodynamic management calculated by impedance cardiography of The HOTMAN® System"
3132170|NCT01673516|Active Comparator|group RDN|"For patients who will be randomly assigned to undergo renal denervation by The SymplicityTM Renal Denervation System, the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Symplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm."
3132171|NCT01673503|Active Comparator|Carl Zeiss Meditech VisuMax laser - ReLEx flex|>30 patients will receive treatment for myopia with a VisuMax femtosecond laser from Carl Zeiss. The laser can cut with two different settings, called ReLEx flex and ReLEx smile. One eye will recieve ReLEx flex, and the other ReLEx smile
3132172|NCT01673503|Active Comparator|Carl Zeiss Meditech VisuMax laser - ReLEx smile|>30 patients will receive treatment for myopia with a VisuMax femtosecond laser from Carl Zeiss. The laser can cut with two different settings, called ReLEx flex and ReLEx smile. One eye will recieve ReLEx flex, and the other ReLEx smile
3132173|NCT01673490|Experimental|Combodart/Duodart|Single arm testing the efficacy/safety of the combinnation of Dutasteride/Tamsulosin
3132174|NCT01673464||High School Athletes|
3132175|NCT01673451|Placebo Comparator|Placebo comparator|
3132176|NCT01673451|Experimental|E2006|
3132177|NCT01673438|Experimental|Aldoxorubicin plus doxorubicin|Aldoxorubicin dosages of 175, 240, and 320 (doxorubicin equivalents of 130, 180, and 240 mg/m2) will be administered as a 30 minutes IVI on Day 1 of each cycle. In addition 35 mg/m2 of doxorubicin HCl will be administered as an IVI over > 3 minutes no later than 3 hours, but no more than 6 hours before the start of aldoxorubicin infusion.
3132178|NCT01673425|Experimental|Live Attenuated Influenza Vaccine|Single intervention study- all participants will receive LAIV instead of injectable flu vaccine.
3132179|NCT01673412|Experimental|interventional arm|Psychological tests
3132180|NCT01673399|Active Comparator|Atosiban|Patients receive a bolus injection of 6.75mg atosiban and following an atosibaninfusion at 18mg/u during 3 hours.
3132181|NCT01673399|Placebo Comparator|placebo|Patients receive a placebo bolus injection (NaCl 0.9%)and an infusion of NaCl 0.9% during 3 hours
3132182|NCT01673386|Experimental|Tivozanib Hydrochloride|1.5 mg oral tivozanib hydrochloride daily on a 3 weeks on/1 week off schedule for 12 weeks, followed by 50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks.
3132183|NCT01673386|Active Comparator|Sunitinib|50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks, followed by 1.5 mg oral tivozanib hydrochloride daily on a 3 weeks on/1 week off schedule for 12 weeks.
3132184|NCT01673373|Experimental|iCAST RX™ Stent Systen|All enrolled subjects will receive the iCAST RX™ Stent System
3132185|NCT01673360||Elevate PC|Subjects implanted with Elevate PC
3132186|NCT01673360||Mini Arc Pro|Subjects implanted with Mini Arc Pro
3132187|NCT01673360||RetroArc|Subjects implanted with RetroArc
3132188|NCT01673347|Experimental|MENISCAL ALLOGRAFT|The meniscal allograft is taken from the meniscal knee joint and implanted surgically in to the great toe.
3132189|NCT01673334|Experimental|Fine Needle Aspiration and Core Biospsy|Patients will undergo both FNA and core biopsy during EUS evaluation of a solid pancreatic tumor.
3132190|NCT01673321|Experimental|Non-fat Yogurt-Plain flavored|Protein to carbohydrate ratio: 2.30
3132191|NCT01673321|Experimental|Skim milk|Protein to carbohydrate ratio: 0.69
3132192|NCT01673321|Experimental|Non-fat Yogurt with honey-Plain flavored|Protein to carbohydrate ratio: 1.24
3132193|NCT01673321|Experimental|Orange juice|Protein to carbohydrate ratio: 0.07
3132194|NCT01673321|Experimental|Non-fat Yogurt-Strawberry flavored|Protein to carbohydrate ratio: 0.79
3132195|NCT01673308|Experimental|Treatment arm|Lenalidomide treatment arm
3132196|NCT01673295|Experimental|RTX group|Subjects will receive a RTX infusion (1g) at w0, w2, w24, w48 and w72.
3132197|NCT01673295|Active Comparator|Control group|Subjects will not receive RTX infusions and will be followed in standard of care
3132198|NCT01673282||Vimpat + Na Channel Blocking AED|Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs) to include at least 1 sodium channel blocking AED.
3132199|NCT01673282||Vimpat + Non-Na Channel Blocking AED|Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs), none of which is a sodium channel blocking AED.
3132200|NCT01673269|Experimental|ERCP with direct examination of the CBD|
3132201|NCT01673256||SJM Confirm ICM Observational Group|
3132202|NCT01673243||Cancer|Parents of children with cancer will complete a questionnaire.
3132203|NCT01673243||Sickle cell disease|Parents of children with sickle cell disease will complete a questionnaire.
3132204|NCT01673243||Survivors|Parents of survivors of childhood cancer will complete a questionnaire.
3132205|NCT01673230|Other|Ventricular dysfunction|cardiac surgery for ventricular dysfunction
3132352|NCT01672268|Experimental|Cardiac CT scan before TAVI procedure|patients with cardiac CT measures before TAVI
3245965|NCT00868894|Active Comparator|4|
3132206|NCT01673217|Experimental|Treatment (chemotherapy and vaccine therapy)|Patients receive decitabine IV over 3 hours on day 1, pegylated liposomal doxorubicin hydrochloride IV on day 8, and NY-ESO-1 peptide vaccine emulsified in incomplete Freund's adjuvant and sargramostim subcutaneously on day 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3132207|NCT01673204|Experimental|Calcitriol|Calcitriol
3132208|NCT01673204|Placebo Comparator|Placebo|Placebo
3132209|NCT01673191|Experimental|OZURDEX intraocular implant|OZURDEX (dexamethasone posterior segment drug delivery system (DEX PS DDS), 0.7 mg
3132210|NCT01673191|Active Comparator|Steroid plus NSAID eye drop combination therapy|NSAID eye drop: Acular LS Steriod eye drop: Pred Forte
3132211|NCT01673178|Placebo Comparator|Placebo Arm|
3132212|NCT01673178|Experimental|25 mg|
3132213|NCT01673178|Experimental|50 mg|
3132214|NCT01673178|Experimental|100 mg|
3132215|NCT01673178|Experimental|150 mg|
3132216|NCT01673165|Active Comparator|Specialized Formula|25 infants of mothers who do not have breast milk or do not want to use the skimming technique. These infants will receive our standard of care - specialized formula for the treatment of chylothorax
3132217|NCT01673165|Experimental|Skimmed mother's milk|25 infants of mothers who have breast milk and who also want to learn the skimming technique will be taught the technique. The infants will then receive the skimmed breast milk for the treatment of chylothorax
3132218|NCT01673152|Placebo Comparator|Maltodextrin|
3132219|NCT01673152|Experimental|Oligofructose|Orafti P95, Beneo-Orafti, Belgium,
3132220|NCT01673139|Experimental|Moderate exercise|Moderate exercise
3132221|NCT01673139|Experimental|Control|Control group
3132222|NCT01673139|Experimental|Interval exercise|interval exercise
3132223|NCT01673126|Active Comparator|Anodal tDCS|Patients received anodal tDCS (on DLPF cortex) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised)
3132224|NCT01673126|Sham Comparator|sham tDCS|Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
3132225|NCT01673113|Experimental|Cryolipolysis|All subjects were randomized to have either the left of right flank treated with single the Zeltiq CoolSculpting Device, which is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks. Sensory testing was done before and after the procedure.
3132226|NCT01673113|No Intervention|Control|All subjects were randomized to have either the left of right flank treated with single the Zeltiq CoolSculpting Device. The untreated flank served as the internal control for each subject.
3132227|NCT01673100|Experimental|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. These messages will be tips to help them engage in physical activity and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
3132228|NCT01673100|No Intervention|Atttention Control|Subjects in the attention control group will receive only general health messages on their study cell phone (not physical activity promoting messages). They also will receive any usual post-PCI procedure care that all get.
3132229|NCT01673087|Experimental|laboratory HPA probes|"All subjects will be studied with multiple probes of HPA axis function over the course of one to two months:~Metyrapone, oral, 750 mg, administered twice 3.5 hrs apart; Dexamethasone, oral, 1.5 mg administered once; oral, 0.25 mg administered once; Corticorelin ovine triflutate (CRH), intravenous, 100 mcg, administered once over 30 seconds; Cortrosyn (ACTH), intravenous, 250 mcg, administered once by bolus."
3132230|NCT01673061|Active Comparator|Lidocaine|Lidocaine injection will be used for anesthesia prior to incision and drainage. 2% Lidocaine with epinephrine will be injected into the abscess site. Amount injected will be per physician discretion.
3132231|NCT01673061|Active Comparator|Vapocoolant|Vapocoolant spray will be used for anesthesia prior to incision and drainage. The spray will be administered to the abscess site for a duration of 2 seconds, from a distance of 12 cm.
3132232|NCT01673048|Active Comparator|Femoral fracture, ESIN|"Prospectively all patients treated with the 3-nail-configuration for dislocated femoral shaft fractures were enrolled; 25 patients are planned, 18 could be enrolled Comparison will be with own previous data of patients treated with the classical 2-C-shaped ESIN-osteosynthesis"
3132233|NCT01673035|Experimental|internet-based CBT|Cognitive behavior therapy delivered via the internet: 12 weeks, therapist-guided
3132234|NCT01673035|Active Comparator|internet-based BSM|behavioral stress management delivered via the internet: 12 weeks, therapist-guided
3132235|NCT01673022|Experimental|IC Green Arm|One arm only: Receives IC Green for testing of study objective
3132236|NCT01673009|Experimental|Administration of Gleevec|Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
3132237|NCT01672996|Experimental|Arm 1 - Ioforminol 160mgI/mL|Single administration of Ioforminol 160mgI/mL given to the subject.
3132238|NCT01672996|Experimental|Arm 2 - Ioforminol 200mgI/mL|Given as a single administration to the subject
3132239|NCT01672996|Active Comparator|Arm 3 - Iopamidol 300mgI/mL|Given as a single administration to the subject
3132240|NCT01672983|Experimental|Arm 1|Participants with HCV GT1b received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
3132241|NCT01672983|Experimental|Arm 2|Participants with HCV GT1b received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
3132242|NCT01672983|Experimental|Arm 3|Participants with HCV GT1b received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 24 weeks.
3132243|NCT01672983|Experimental|Arm 4|Participants with HCV GT1b received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 24 weeks.
3132244|NCT01672983|Experimental|Arm 5|Participants with HCV GT2 received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
3132245|NCT01672983|Experimental|Arm 6|Participants with HCV GT2 received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
3132246|NCT01672970||Cohort|
3132353|NCT01672255|Active Comparator|Trial 1-SSRI|90 minute exercise baseline with 6 weeks treatment with SSRI (Prozac). Repeat 90 minute exercise after 6 week treatment.
3132247|NCT01672957||Renal Transplant Participants|Renal transplant participants who will be subjected to a combined immunosuppressive treatment containing mycophenolate mofetil, will be followed-up until the end of the study (after 12 months), or until the participant's death, withdrawal, or lost contact with the participant, whichever occurs first. The choice of treatment will be made prior to enrolment by the treating physician. The treatment will be administered according to applicable therapeutic protocol and Summary of Product Characteristics (SmPC).
3132248|NCT01672944|Experimental|TBCCN-developed educational materials|"Biobanking educational DVD and booklet kit developed by the Tampa Bay Community Network (TBCCN) Center. English kit is entitled Biobanking Hope for a Cancer Cure, and Spanish kit is entitled Biobanco: Una esperanza de cura para el cancer."
3132249|NCT01672944|Other|Control Group|"Biobanking educational Brochure developed by the National Cancer Institute. English brochure is entitled Providing your Tissue for Research: What you need to Know, Spanish brochure is entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
3132250|NCT01672931||BMI over 30|Women undergoing IVF with BMI over 30
3132251|NCT01672931||BMI 20-25|Women undergoing IVF treatments with BMI between 20-25
3132252|NCT01672892|Experimental|Intensity-Modulated Radiation Therapy|intensity-modulated radiation therapy (IMRT) to the pelvis of either 45 Gy or 50.4 Gy
3132253|NCT01672892|Active Comparator|Standard Radiation Therapy|Standard radiation therapy (4-field) to the pelvis of either 45 Gy or 50.4 Gy
3132254|NCT01672879|Experimental|SIM 200 mg|Participants will receive simtuzumab 200 mg for up to 240 weeks during the Randomized Phase. During the optional Open Label Phase, participants will receive simtuzumab 700 mg for up to an additional 240 weeks.
3132255|NCT01672879|Experimental|SIM 700 mg|Participants will receive simtuzumab 200 mg for up to 240 weeks during the Randomized Phase. During the optional Open Label Phase, participants will receive simtuzumab 700 mg for up to an additional 240 weeks.
3132256|NCT01672879|Placebo Comparator|Placebo|Participants will receive placebo to match simtuzumab for up to 240 weeks during the Randomized Phase. During the optional Open Label Phase, participants will receive simtuzumab 700 mg for up to an additional 240 weeks.
3132257|NCT01672866|Experimental|Simtuzumab 75 mg (Arm A)|During the Randomized Double-Blind Phase, participants will receive simtuzumab 75 mg once weekly for up to 240 weeks. During the optional Open Label Phase, participants will receive simtuzumab 125 mg for up to an additional 240 weeks.
3132258|NCT01672866|Experimental|Simtuzumab 125 mg (Arm B)|During the Randomized Double-Blind Phase, participants will receive simtuzumab 125 mg once weekly for up to 240 weeks. During the optional Open Label Phase, participants will receive simtuzumab 125 mg for up to an additional 240 weeks.
3132259|NCT01672866|Placebo Comparator|Placebo to match simtuzumab (Arm C)|During the Randomized Double-Blind Phase, participants will receive placebo to match simtuzumab once weekly for up to 240 weeks. During the optional Open Label Phase, participants will receive simtuzumab 125 mg for up to an additional 240 weeks.
3132260|NCT01672853|Experimental|Treatment Arm A|Subject will receive subcutaneous injections of 75 mg of Simtuzumab (GS-6624) weekly for 96 weeks.
3132261|NCT01672853|Experimental|Treatment Arm B|Subject will receive subcutaneous injections of 125 mg of Simtuzumab (GS-6624) weekly for 96 weeks.
3132262|NCT01672853|Placebo Comparator|Treatment Arm C|Subject will receive subcutaneous injections of placebo weekly for 96 weeks.
3132263|NCT01672840|Experimental|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
3132264|NCT01672840|Experimental|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
3132265|NCT01672827|Experimental|[18F]Flutemetamol|
3132266|NCT01672814|Active Comparator|Keraflex combined with Crosslinking|Vedera KXS microwave system used in conjunction with corneal collagen crosslinking performed with VibeX (Riboflavin ophthalmic solution)and the KXL UV System
3132267|NCT01672814|Active Comparator|Corneal collagen crosslinking alone|Corneal collagen crosslinking alone performed with VibeX (Riboflavin Ophthalmic Solution)and the KXL UV system
3132268|NCT01672801|Placebo Comparator|Placebo|All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Placebo comparator subjects will receive 8 total doses of liquid placebo orally 4 times a day for 8 total doses in pre-filled liquid placebo containing syringes
3132269|NCT01672801|Active Comparator|Nimodipine|All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Active comparator subjects will receive Nimodipine 30mg liquid orally 4 times a day for 8 total doses in pre-filled syringes
3132270|NCT01672788|Experimental|Test 1|fixed dose combination tablet
3132271|NCT01672788|Active Comparator|Reference 1|empagliflozin tablets and metformin tablet
3132272|NCT01672788|Experimental|Test 2|fixed dose combination tablet
3132273|NCT01672788|Active Comparator|Reference 2|empagliflozin tablet and metformin tablet
3132274|NCT01672775|Experimental|Cohort 1 AGS-16C3F highest dose|Renal Cell Carcinoma subjects with clear and non-clear histology
3132275|NCT01672775|Experimental|Cohort 0 AGS-16C3F higher dose|Renal Cell Carcinoma subjects with clear and non-clear histology
3132276|NCT01672775|Experimental|Cohort (-1) AGS-16C3F high dose|Renal Cell Carcinoma subjects with clear and non-clear histology
3132277|NCT01672775|Experimental|Cohort (-2) AGS-16C3F middle dose|Renal Cell Carcinoma subjects with clear and non-clear histology
3132278|NCT01672775|Experimental|Cohort (-3) AGS-16C3F low dose|Renal Cell Carcinoma subjects with clear and non-clear histology
3132279|NCT01672775|Experimental|Cohort (-4) AGS-16C3F lowest dose|Renal Cell Carcinoma subjects with clear and non-clear histology
3132280|NCT01672775|Experimental|AGS-16C3F in RCC Subjects with Clear Cell Histology|Expansion Cohort
3132281|NCT01672775|Experimental|AGS-16C3F in RCC Subjects with Papillary Histology|Expansion Cohort
3132282|NCT01672762|Experimental|ASP1941 group|oral
3132313|NCT01672567|Experimental|Control diet|Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
3132354|NCT01672255|Placebo Comparator|Trial 2-Placebo|90 minute exercise at baseline with 6 weeks treatment with placebo. Repeat 90 minute exercise after 6 weeks treatment of placebo.
3132283|NCT01672749||Spine based dual growing rod or VEPTR|Patients treated with the TROLLEY system will be compared with patients from the Chest Wall and Spine Deformity Study Group (CWSDSG) and the Growing Spine Study Group (GSSG) treated with a spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America). For each patient in the TROLLEY group a patient from each of the databases will be selected to be matched based on diagnosis, age, gender, and spine deformity classification.
3132284|NCT01672749||TROLLEY system|Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs). The TROLLEY system is CE marked at the time of the study conduct.
3132285|NCT01672736|Experimental|ASP7487, Velcade, Dexamethasone|ASP7487 administered orally 75, 100 and 150 mg) BID continuously for each cycle. Bortezomib administered at 1.3 mg/m2 twice weekly for the first 8 21 day cycles and once weekly beyond cycle 9 for 35 day cycles. Dexamethasone is administered on bortezomib administration days at 20 mg
3132286|NCT01672723|Experimental|Naltrexone|"Participants will take 4 doses of naltrexone over 4 days (25mg/day for days 1 and 2, 50mg/day for days 3 and 4) as well as 4 matched placebo pills for a total of 8 days. Capsules will be packaged into blister packs.~Participants will be asked to take the first drug, either naltrexone or placebo, once a day for three days prior to the first experimental session and when they arrive at the lab for the experimental procedure . After the first session, participants will take the second study drug for three days prior to the second experimental session and when they arrive for the second experimental procedure."
3132287|NCT01672723|Placebo Comparator|Placebi|"Participants will take 4 doses of naltrexone over 4 days (25mg/day for days 1 and 2, 50mg/day for days 3 and 4) as well as 4 matched placebo pills for a total of 8 days. Capsules will be packaged into blister packs.~Participants will be asked to take the first drug, either naltrexone or placebo, once a day for three days prior to the first experimental session and when they arrive at the lab for the experimental procedure . After the first session, participants will take the second study drug for three days prior to the second experimental session and when they arrive for the second experimental procedure."
3132288|NCT01672710|Experimental|niacin, exercise, sauna,|
3132289|NCT01672710|No Intervention|no intervention|
3132290|NCT01672697|Experimental|Physical & Behavioral Therapy Group|"Intervention Group: Randomized to Physical Therapy (PT)~2-week visit which includes: Demographic Data, Physical Exam, ehavioral Therapy (BT) handouts Functional questionnaires administered Physiologic measurements obtained~Follow-up Evaluation-6-week visit PT session #1 Functional questionnaires administered~Follow-up Evaluation-8-week visit PT session #2~Follow-up Evaluation-10-week visit PT session #3~Study Completion Visit-12-week visit Functional questionnaires administered PT session #4 Physiologic measurements Physical Exam~Long-term Follow-up-24-weeks Functional questionnaires administered by mail"
3132291|NCT01672697|No Intervention|Control Group|"Control Group:~Baseline Data obtained at 2-week visit Demographic Data General Physical Exam findings Functional questionnaires administered in person (FIQOL, FISI, SF-12, FSFI, UDI-6, IIQ-7) Physiologic measurements obtained (Vaginal EMG, Anal-rectal manometry)~Follow-up Evaluation at 6-week visit Functional questionnaires administered in person at patient's previously scheduled postpartum office visit with primary Ob/Gyn or by mail~Study Completion Visit at 12-week visit Functional questionnaires administered Physiologic measurements obtained Physical Exam findings~Long-term Follow-up at 24-weeks - Functional questionnaires administered by mail"
3132292|NCT01672684|Experimental|Arm I (experimental arm)|Participants complete at-home group video calling sessions for 1 1/2 hours once weekly for 8 weeks.
3132293|NCT01672684|Active Comparator|Arm II (control arm)|Participants receive an educational workbook journal.
3132294|NCT01672671|Experimental|Neoadjuvant platinum-based chemotherapy|Doxorubicin, Paclitaxel, Cisplatin
3132295|NCT01672658|Experimental|Sensory Kinectics Balance System|Subjects will be randomized in to one of two groups. The group that will receive training on the SKBS device along with traditional vestibular and balance training.
3132296|NCT01672658|Active Comparator|Traditional Vestibular Rehabilitation|Traditional vestibular rehabilitation will include VOT exercises that will work toward increasing the gain of the system as well as walking, balance re-training, and functional mobility.
3132297|NCT01672645|Experimental|PF-05402536|
3132298|NCT01672645|Experimental|PF-06413367|Intramuscular, multiple dose
3132299|NCT01672645|Placebo Comparator|Placebo|Intramuscular
3132300|NCT01672632|Experimental|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
3132301|NCT01672619||children with craniosynostosis|children with craniosynostosis aged 6 months to 13
3132302|NCT01672606|Experimental|Rocuronium|Intravenous infusion of rocuronium with the goal of TOF 0.70 and >0.90
3132303|NCT01672593|Experimental|PRFG treatment|As described in our previous study, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the autologous PRFG(platelet-rich fibrin glue) group and then frozen at -20°C for storage. Prior to application, frozen cryoprecipitate and thrombin stored were thawed in a 37°C water bath. Aminomethylbenzoic Acid (1ml: 1mg, Sigma-Aldrich, St Louis, MO) was added into the cryoprecipitate in the volume ratio of 1:10.
3132304|NCT01672593|Active Comparator|Bioseal treatment|The commercial fibrin sealants used in the study were purchased from Guangzhou Bioseal Biotech Co. Ltd, Guangzhou, China. Upon application, two components, fibrinogen and thrombin, were placed separately in two syringes which were joined by a Y-shaped connector. The trunk of the Y-shaped connecter was connected to a single lumen catheter.
3132305|NCT01672580|Active Comparator|Random-Cloro|exposure to water chlorination
3132306|NCT01672580|Active Comparator|Random-Vitamin|exposure to vitamin use
3132307|NCT01672580|Experimental|Indegree-Cloro|high in-degree, exposure to water chlorination
3132308|NCT01672580|Experimental|Indegree-Vitamin|high in-degree, exposure to vitamin use
3132309|NCT01672580|Experimental|Nominated-Cloro|nominated by random, exposure to water chlorination
3132310|NCT01672580|Experimental|Nominated-Vitamin|nominated by random, exposure to vitamin use
3132311|NCT01672567|Experimental|Egg supplementation|Daily consumption of 2 eggs for breakfast for 6 weeks
3132312|NCT01672567|Experimental|Egg substitute|Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
3132345|NCT01672307|Experimental|Minoxidil lotion 2%|Minoxidil lotion 2% is applied twice daily to one eyebrow.
3135794|NCT01648192|Experimental|20 mg|Losmapimod for single dose
3132314|NCT01672554|Other|Seroquel XR|Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
3132315|NCT01672541|Experimental|Dating Matters Comprehensive Approach|Schools randomly assigned to the comprehensive approach will: implement 6th, 7th, and 8th grade student curricula in English to all the students in these grades; offer parent programs for parents of 6th, 7th, and 8th graders;implement a communications campaign involving brand ambassadors, a text message campaign, and social media campaign;encourage all educators to take an online training about teen dating violence for educators;be supported in assessing and informing local school or community policies relevant to teen dating violence.
3132316|NCT01672541|Active Comparator|Standard of Care Safe Dates Approach|Schools randomly assigned to the standard of care approach will implement Safe Dates as it is published in their schools 8th grade classes.
3132317|NCT01672528||Cardiac arrhythmia patients|Patients with cardiac arrhythmias consented to and awaiting a cardiac ablation procedure or post ablation.
3132318|NCT01672515|Experimental|RIPC group|RIPC treatment was performed by the inflating tourniquets to 200mmHg on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days.
3132319|NCT01672515|Sham Comparator|Control group|RIPC sham was performed by the inflating tourniquets to 60mmHg on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days.
3132320|NCT01672502|Experimental|Intervention|Firefighters in this group will receive at the beginning of the study an introduction to the study, sleep education, sleep disorder screening survey, health survey, increased sleep opportunities at their fire department, followed later by physiological monitoring of a portion of the firefighters, and then finally an 'end of year' survey at the end of the study.
3132321|NCT01672502|Active Comparator|Control|Firefighters in this group will only receive an introduction to the study and a health survey, followed later by physiological monitoring of a portion of the firefighters, and then at the end of the study will receive the sleep disorders screening survey, sleep education (Intervention group received screening survey and education much earlier at the beginning of the study), and an 'end of year' survey. None of these firefighters will receive the increased sleep opportunities as the Intervention group will.
3132322|NCT01672476|Placebo Comparator|Placebo|1 capsule/day of placebo will be orally administered for the study period (8 weeks)
3132323|NCT01672476|Active Comparator|Valsartan 80mg|(As reference group) 80mg/day of Valsartan will be orally administered for the study period (8 weeks)
3132324|NCT01672476|Experimental|Fimasartan 30mg|30mg/day of Fimasartan will be orally administered for the study period (8 weeks)
3132325|NCT01672463|Experimental|All patients|All participants enrolled in this study
3132326|NCT01672450|Experimental|All patients|All participants in this study will receive the same treatment.
3132327|NCT01672437|Experimental|Birth and parent preparation|"The following subjects will be covered in the sessions:~Session 1 (25 weeks gestation):~Common challenges in the transition to parenthood and in the relationship~Couple communication~Session 2 (33 weeks gestation):~Expectations in relation to birth~The normal course of labour~Obstetric intervention~Pain relief,coping strategies~Partner support~Session 3 (35 weeks gestation):~Feeding a newborn~Interpreting the newborn's signs, symptoms and behaviour~Taking care of a newborn~Mood swings, postnatal depressive symptomatology~Session 4 (5 weeks post-partum):~Birth experiences~Mood swings, postnatal depressive symptomatology~The first time at home with a newborn~Couplehood - partner support, communication, division of household tasks"
3132328|NCT01672437|No Intervention|control group|The control group are offered two lectures in an auditorium during pregnancy - one on breastfeeding and one on labour. This is standard care.
3132329|NCT01672424||Group P: High Protein Drink|Patients receiving the high protein drink with 30 grams of protein in 11 fluid ounces.
3132330|NCT01672424||Group C: Ice Chips|The control group consisting patient receiving 11 ounces of ice chips
3132331|NCT01672398|Experimental|Intervention Group|Telemonitoring plus self-management support
3132332|NCT01672398|No Intervention|Usual Care Group|Usual Care
3132333|NCT01672385|Experimental|Intervention Group|Telemonitoring plus self-management support
3132334|NCT01672385|No Intervention|Usual Care Group|Usual Care
3132335|NCT01672372|Placebo Comparator|Placebo Max Stress B|oil/water emulsion with food coloring to simulate actual product
3132336|NCT01672372|Experimental|Max Stress B|whole-nutrient natural source extract from probiotic colonies that contains vitamins B1, B2, B5, B6, B12, and folate, PABA, biotin, inositol, purified water and certified organic alcohol.
3132337|NCT01672359|Experimental|Ginkgo Synergy® and Choline|Ginkgo Synergy® (120 mg/day Ginkgo biloba leaf with 80 mg/day Ginkgo biloba whole extract combined with 40 mg/day Grape Seed extract) and Choline (700 mg choline/day)
3132338|NCT01672359|Experimental|OPC Synergy® and Catalyn|OPC Synergy® (100 mg/day of Grape Seed extract with 50 mg/day Green Tea extract (60% catechins)) and Catalyn® (1,248 IU/day of Vitamin D, 4,800 IU/day of Vitamin A, combined with vitamin C, thiamine, riboflavin, and vitamin B6)
3132339|NCT01672359|Placebo Comparator|Placebo|cellulose pills to simulate actual products
3132340|NCT01672346|Active Comparator|Arm I|PVAI with ablation of posterior wall contained within pulmonary veins using energy up to 30 watts and post-ablation adenosine challenge
3132341|NCT01672346|Active Comparator|Arm II|AF ablationPVAI with ablation of posterior wall contained within pulmonary veins using energy up to 40 watts and post-ablation adenosine challenge
3132342|NCT01672333|Experimental|Pathological Response|
3132343|NCT01672320||Phase II|An evaluation of long-term outcomes, patient reported outcomes, and radiographic analysis will be conducted prospectively on 500 patients
3132344|NCT01672320||Phase I|An analysis of post-operative component positioning will be evaluated for 500 patients, retrospectively.
3135795|NCT01648192|Placebo Comparator|Placebo|Placebo
3132355|NCT01672242|Experimental|HFNC|High Flow Nasal Cannula (HFNC) oxygen.
3132356|NCT01672242|Experimental|CPAP|Continuous Positive Airway Pressure (CPAP)
3132357|NCT01672229|Experimental|Dose-escalation|Bortezomib starting dose is 0.2 mg/m2 subcutaneously which will be given weekly with incremental increase of 0.2 mg/m2 every other week, if no improvement is seen, and no dose limiting toxicities are observed to the maximum dose of 1.6 mg/m2. Bortezomib will be administered in the outpatient clinic.
3132358|NCT01672216|Experimental|Triple Target Treatment|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
3132359|NCT01672216|Active Comparator|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
3132360|NCT01672203||PE peripheral with fibrinolysis|Patients with peripheral PE who received fibrinolysis therapy
3132361|NCT01672203||PE peripheral, no fibrinolysis|Patients with peripheral PE who did not receive fibrinolysis
3132362|NCT01672203||PE central with fibrinolysis|Patients with central PE who received fibrinolysis therapy
3132363|NCT01672203||PE central, no fibrinolysis|Patients with central PE who did not receive fibrinolysis
3132364|NCT01672190|Experimental|Yoga Therapy|Women in the Yoga Therapy Group will receive twice weekly yoga classes for 6 weeks.
3132365|NCT01672190|No Intervention|Control|Women in the Control Group will wait 6 weeks before receiving a gift certificate for yoga classes at an external yoga studio in the San Francisco Bay Area
3132366|NCT01672177|No Intervention|Control|Individuals in the control group will not receive any training.
3132367|NCT01672177|Experimental|Intervention|Individuals in the intervention group will receive two hour long weekly training sessions for seven to eight months. The content of the training focuses on health promotion, health seeking behaviours and chronic disease management.
3132368|NCT01672164||Liver Transplant Recipients|
3132369|NCT01672138|Active Comparator|Control|Pulmonary Vein Antrum Isolation alone
3132370|NCT01672138|Active Comparator|Study I|PVAI+ CFAE ablation
3132371|NCT01672138|Active Comparator|Study II|PVAI + CFAE + non-PV triggers ablation
3132372|NCT01672125||women who have completed treatments|women who have completed breast cancer treatments, with a diagnosis of unilateral arm lymphedema, in the intensive phase of lymphedema treatment
3132373|NCT01672125||women who have completed treatment in maintenance phase|women who have completed breast cancer treatment and are in the maintenance phase of lymph edema treatment
3132374|NCT01672125||healthy women|healthy women adjusted in age and BMI
3132375|NCT01672112|Other|Codeine|Oral Codeine 60mg 6hrly/prn
3132376|NCT01672112|Active Comparator|Oxycodone|Oral Oxycodone 5mg 6hrly/prn
3132377|NCT01672099|Active Comparator|nutrient enriched dairy|Yoghurt product which contains vitamin K2 and extra dairy nutrients; all in a concentration of 15% of the recommended allowed daily intake (RDI)
3132378|NCT01672099|Placebo Comparator|Basic dairy|2 basic yoghurt products
3132379|NCT01672086||Stelkast Surpass Patients|
3132380|NCT01672060|Experimental|Nurse-Family Partnership (NFP)|
3132381|NCT01672060|Active Comparator|Existing services|
3132382|NCT01672047|Experimental|Treament|Intervention Vitamin D2
3132383|NCT01672047|No Intervention|Control|Not take Vitamin D2
3132384|NCT01672034||Obese, BMI > 35|
3132385|NCT01672021|Other|PET/MRI|PET/MRI
3132386|NCT01672008|Experimental|NOX-100/Placebo|"After enrollment, subjects will be randomly assigned to one of the following treatment sequences in a 1:1 ratio.~Sequence A: NOX-100 treatment phase followed by Placebo treatment phase Sequence B: Placebo treatment phase followed by NOX-100 treatment phase"
3132387|NCT01672008|Experimental|Placebo/NOX-100|"After enrollment, subjects will be randomly assigned to one of the following treatment sequences in a 1:1 ratio.~Sequence A: NOX-100 treatment phase followed by Placebo treatment phase Sequence B: Placebo treatment phase followed by NOX-100 treatment phase"
3132388|NCT01671995|Experimental|Nurse monitored heart failure program|To assess whether a nurse monitored management programme at the hospital outpatient clinic would improve quality of life, as compared to standard primary health care.
3132389|NCT01671995|Active Comparator|Standard primary health care|To assess whether a nurse monitored management programme at the hospital outpatient clinic would improve quality of life, as compared to standard primary health care.
3132390|NCT01671982|Experimental|Tenofovir-containing HAART|
3132391|NCT01671969|Experimental|very low calorie diet|
3132392|NCT01671956|Experimental|Bertilimumab|Bertilimumab 10 mg/kg will be administered by IV infusion over 30 minutes
3132393|NCT01671956|Placebo Comparator|Placebo|Phosphate buffered saline (PBS) placebo will be administered by IV infusion over 30 minutes.
3132394|NCT01671943|Experimental|Breast carcinoma up to 2.0 cm|
3132395|NCT01671930||cardiac computed tomographic angiography|Patients refered for cardiac computed tomographic angiography by a cardiologist.
3132396|NCT01671917|Experimental|Educational and exercise program|
3132397|NCT01671917|Active Comparator|Usual care|
3132398|NCT01671904|Experimental|Dose-Finding: Schedule A (Optional): CLL|Optional study arm: In four cohorts of participants with relapsed/refractory or previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose bendamustine and obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before bendamustine and obinutuzumab. Schedule A will be explored prior to Schedule B.
3132431|NCT01671735|Experimental|VA DPP|Pre-Diabetic Participants eligible for VA DPP receive a curriculum based life-style intervention program tailored off of the original DPP but in a group format
3135932|NCT01647308|Active Comparator|ISIS-APOCIIIRX|
3132399|NCT01671904|Experimental|Dose-Finding: Schedule A: Previously Untreated CLL|In four cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose bendamustine and rituximab in the dose-finding stage. In Schedule A, venetoclax will be introduced before bendamustine and rituximab. Schedule A will be explored prior to Schedule B.
3132400|NCT01671904|Experimental|Dose-Finding: Schedule A: Relapsed/Refractory CLL|In four cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose bendamustine and rituximab in the dose-finding stage. In Schedule A, venetoclax will be introduced before bendamustine and rituximab. Schedule A will be explored prior to Schedule B.
3132401|NCT01671904|Experimental|Dose-Finding: Schedule B (Optional): CLL|Optional study arm: In four cohorts of participants with relapsed/refractory or previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose bendamustine and obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after bendamustine and obinutuzumab. Schedule A will be explored prior to Schedule B.
3132402|NCT01671904|Experimental|Dose-Finding: Schedule B: Previously Untreated CLL|In four cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose bendamustine and rituximab in the dose-finding stage. In Schedule B, venetoclax will be introduced after bendamustine and rituximab. Schedule A will be explored prior to Schedule B.
3132403|NCT01671904|Experimental|Dose-Finding: Schedule B: Relapsed/Refractory CLL|In four cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose bendamustine and rituximab in the dose-finding stage. In Schedule B, venetoclax will be introduced after bendamustine and rituximab. Schedule A will be explored prior to Schedule B.
3132404|NCT01671904|Experimental|Safety Expansion (Optional): Previously Untreated CLL|In participants with previously untreated CLL a recommended dose of venetoclax will be administered in combination with bendamustine and obinutuzumab in the safety expansion stage.
3132405|NCT01671904|Experimental|Safety Expansion: Previously Untreated CLL|In participants with previously untreated CLL a recommended dose of venetoclax will be administered in combination with bendamustine and rituximab in the safety expansion stage.
3132406|NCT01671904|Experimental|Safety Expansion: Relapsed/Refractory CLL|In participants with relapsed/refractory CLL a recommended dose of venetoclax will be administered in combination with bendamustine and rituximab in the safety expansion stage.
3132407|NCT01671891||rectal cancer with stage II-IV|rectal cancer with stage II-IV intervention: pelvic radiotherapy (45-55Gy) concurrent chemotherapy using capecitabine and oxaliplatin
3132408|NCT01671878|Other|Reference Glucose|Glucose standard
3132409|NCT01671878|Experimental|Test Food 1|Cereal
3132410|NCT01671878|Experimental|Test Food 2|Biscuit
3132411|NCT01671852|Active Comparator|Nasonex|The intervention group will receive mometasone nasal sprays at the dosage outlined below for 8 weeks. For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks.
3132412|NCT01671852|Placebo Comparator|Saline|The placebo group will receive saline nasal sprays for 8 weeks.
3132413|NCT01671839|Experimental|Subcutaneous tissue release|Device: Subcutaneous tissue release with the Cabochon System
3132414|NCT01671826||above 65 years old|
3132415|NCT01671813|Experimental|Brentuximab vedotin Treatment|Participants will have screening tests up to 4 weeks before study treatment and dosing for up to 48 weeks. Brentuximab vedotin will be given with a dose of 1.8 mg (per kilogram of participant's body weight) intravenously (an IV through their vein) every 21 days, over 30 minutes for 16 cycles. Follow-up assessments will be performed up to 104 weeks (2 years).
3132416|NCT01671800|Experimental|Botulinum Type B (Myobloc)|Each vial of active drug will contain 5000 unit/ml of Myobloc, with a total volume of 1 mL. The injections will be spaces 6 cm apart and will cover the entire area to be injected. Each site will receive a volume of 0.08 ml (400 units).
3132417|NCT01671800|Placebo Comparator|Saline solution|The volume to be injected will be calculated assuming the injectate is an active drug, and will therefore be an equivalent volume as an active drug (i.e. 0.08 mL per injection site with a 6 cm spacing interval)
3132418|NCT01671787|Experimental|GS-7340 8mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
3132419|NCT01671787|Experimental|GS-7340 25mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
3132420|NCT01671787|Experimental|GS-7340 40mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
3132421|NCT01671787|Experimental|GS-7340 120mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
3132422|NCT01671787|Experimental|Tenofovir disoproxil fumarate 300mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
3132423|NCT01671774|Experimental|IMAB362 + ZA|
3132424|NCT01671774|Experimental|IMAB362 + ZA + IL-2 (1 million IU)|
3132425|NCT01671774|Experimental|IMAB362 + ZA + IL-2 (3 million IU)|
3132426|NCT01671774|Active Comparator|IMAB362|
3132427|NCT01671761||young adults|19-24 years old
3132428|NCT01671761||adolescents|15-18 years old
3132429|NCT01671748|Active Comparator|Standard Care|Standard treatment for VLUs is administered once a week, i.e. compression bandaging and non-adherent dressing, with debridement if required.
3132430|NCT01671748|Experimental|MIST and Standard Care|MIST ultrasound therapy is applied for between 3 and 12 minutes (depending on wound size) 3 times a week in combination with standard treatment for VLUs of compression bandaging and non-adherent dressing change 3 times a week, with debridement as required.
3132915|NCT01668381||HCC patients|Hepatocellular carcinoma patients treated by radiofrequency ablation
3132432|NCT01671735|No Intervention|VA DPP-eligible MOVE!|Pre-Diabetic participants who screen and are eligible for VA DPP but bc of class being filled - have been assigned to MOVE!
3132433|NCT01671722|Experimental|Montelukast sodium tablets|Montelukast sodium tablets 10mg of Dr. Reddy's Laboratories Limited
3132434|NCT01671722|Active Comparator|SINGULAIR|(containing Montelukast sodium) tablets 10mg of Merck Sharp & Dohme Ltd., USA
3132435|NCT01671709|Experimental|Montelukast sodium tablets|Montelukast sodium tablets 10mg of Dr. Reddy's Laboratories Limited
3132436|NCT01671709|Active Comparator|SINGULAIR|(containing Montelukast sodium) tablets 10mg of Merck Sharp & Dohme Ltd., USA
3132437|NCT01671670|Experimental|acupuncture group|use traditional acupuncture to treat functional dyspepsia
3132438|NCT01671670|Sham Comparator|sham acupuncture group|use penetrating sham acupuncture to manage functional dyspepsia
3132439|NCT01671657||Eeva Test Group|Day 3 embryo transfers that used Eeva with morphology grading (Test Group).
3132440|NCT01671657||Matched case control group|Day 3 embryo transfers using morphology grading only (from concurrent Control Group).
3132441|NCT01671644||Eeva Test Group|Day 3 embryo transfers that used Eeva predictions with morphology grading.
3132442|NCT01671644||Matched case control group|Day 3 embryo transfers using morphology grading only (from a matched concurrent control group).
3132443|NCT01671631||Acute Coronary Syndrome|Patients with Acute Coronary Syndrome and multivessel coronary artery disease undergoing functional evaluation of non-culprit lesions.
3132444|NCT01671605||CKD not on dialysis|Patients with CKD not on dialysis (CKD III-IV)
3132445|NCT01671605||Controls|Controls with normal kidney function (Control)
3132446|NCT01671592|Experimental|Day 1 MRI with low dose vaccine|DC vaccine at 3 x 10e6 per course which consists of 3 daily intradermal doses per course with the MRI on day 1 of the course.
3132447|NCT01671592|Experimental|Day 3 MRI with low dose vaccine|DC vaccine at 3 x 10e6 per course which consists of 3 daily intradermal doses per course with the MRI on day 3 of the course.
3132448|NCT01671592|Experimental|Day 1 MRI with high dose vaccine|DC vaccine at 3 x 10e7 per course which consists of 3 daily intradermal doses per course with the MRI on day 1 of the course.
3132449|NCT01671592|Experimental|Day 3 MRI with high dose vaccine|DC vaccine at 3 x 10e7 per course which consists of 3 daily intradermal doses per course with the MRI on day 3 of the course.
3132450|NCT01671579|Other|Pediatric small bowel Crohn disease|Subjects with previously diagnosed PSBCD (pediatric small bowel Crohn disease)who are scheduled for a clinically MRE (magnetic resonance enterography)imaging exam.
3132451|NCT01671566|Experimental|Home based interval training|12 weeks home based interval training
3132452|NCT01671566|No Intervention|Control group|No structured exercise training.
3132453|NCT01671553|Experimental|Counseling group|Study participants in the intervention group were received an intensive smoking cessation telephone counselling with 2-weeks free and 6-weeks discount nicotine replacement therapy (NRT).
3132454|NCT01671553|No Intervention|Control group|Study participants in the control group were not received any quitting assistance other than the self-help materials provided by Hong Kong Council on Smoking and Health (COSH).
3132455|NCT01671540|Experimental|Intrapulmonary percussive ventilation|IPV is applied for 1 week (once a day) during the physical therapy treatment of the patient
3132456|NCT01671540|Active Comparator|standard airwy claerance regime|The standard treatment consists out of existing drainage techniques to remove secretion out of the lungs by means of breathing control exercises
3132457|NCT01671527||Cervical Dystonia: DBS Subjects|Subjects who have undergone or plan to undergo DBS surgery for cervical dystonia
3132458|NCT01671527||Cervical Dystonia: Control Subjects|Subjects who DO NOT plan to undergo DBS surgery for cervical dystonia
3132459|NCT01671527||Healthy Controls|Healthy control subjects who do not have dystonia.
3132460|NCT01671514|Experimental|Sedentary|The sedentary arm will be randomly assigned to either epicatechin-enriched dark chocolate or low-epicatechin dark chocolate as a placebo. Participants will take one square of chocolate per day for 90 days.
3132461|NCT01671514|Experimental|Heart failure/diabetes|The heart failure/diabetes arm will be randomly assigned to either epicatechin-enriched dark chocolate or low-epicatechin dark chocolate as a placebo. Participants will take one square of chocolate per day for 90 days.
3132462|NCT01671501|Experimental|Motivational Interviewing|The intervention consists of one 45-minute in-person session followed by two 20-minute telephone sessions.The first telephone MI session will occur approximately 10 days after the in-person session. The second call will occur 30 days after the first call. The same research clinician will conduct both the in-person session and phone sessions. The calls will include a review of material covered in the initial session, questions on alcohol use, open-ended questions regarding patients' current motivational level, and a review of the patient's initial goals regarding alcohol consumption and will last about 20 minutes. If after six months hazardous drinking is noted, three more motivational interviewing phone sessions will be delivered by the research clinician.
3132463|NCT01671501|Experimental|Email Feedback|Each participant will receive up to three detailed emails, (if participants respond to a first, initial email with information on alcohol use risks). The initial and subsequent emails will be brief in length, and will include specific information on hazardous drinking levels, standard drink size; as well as advice to reduce drinking to non-hazardous levels. Each email will conclude with contact numbers for patients to receive further information and assistance if needed, including information on how to easily access SU treatment; and will encourage participants to respond to the research clinician with questions. If after six months hazardous drinking is detected, up to 3 more detailed emails will be delivered to the participant.
3132464|NCT01671501|Other|Usual Care|Participants in this arm will receive routine primary care services only. Usual care in this health care setting may include alcohol screening, brief intervention and referral to treatment (SBIRT) delivered by usual care clinic staff
3132500|NCT01671228|Experimental|decision aid|The Yorkshire Dialysis Decision Aid (YoDDA). Delivered as a leaflet in clinic and a web resource outside the NHS.
3132501|NCT01671228|Experimental|Decision Aid + values task|The Yorkshire Dialysis Decision Aid (YoDDA) + values clarification questions. delivered as a leaflet in clinic and a web-based resource outside the NHS.
3132502|NCT01671228|Experimental|Decision Aid + patient stories|The Yorkshire Dialysis Decision Aid (YoDDA) + patient stories. Delivered as an web-based resource outside the NHS.
3132465|NCT01671488|Experimental|Treatment|"The first dose will be given 10-14 days prior to the initiation of chemoradiation.~Patient will then receive 5-FU: 1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days and Mitomycin: 10 mg/m2, day 1 and 29 with IMRT radiation: 54 Gy in 30 fractions at 1.8 Gy per fraction.~The 2-4th dosages of ADXS11-001 will not be until after completion of all chemoradiation. The second dosage of ADXS11-001 will not be administered until a minimum of 10 days after completion of chemoradiation. The subsequent third and fourth treatment with of ADXS11 will be administered at 28 day intervals."
3132466|NCT01671475|Experimental|Routine care plus microEEG|Subjects allocated to this group will undergo an EEG using microEEG device in addition to their routine care. The microEEG device will be used with commercially available electrodes in a headpiece configuration.
3132467|NCT01671475|No Intervention|Routine care only (control group)|Subjects allocated to the control group will receive routine care without microEEG. The treating physician may request a standard EEG, which will be performed by the hospital EEG laboratory, if available.
3132468|NCT01671449|Active Comparator|S-1 plus Cisplatin|"S-1: 40 mg/m2, twice daily, p.o., day 1-14 (see Table 6 for dose calculation of S-1 according to body surface area)~: If S-1 is started on the evening of day 1, last dose of S-1 will be administered at the morning of day 15.~Cisplatin: 60 mg/ m2/day, i.v., day 1~Every 3 weeks"
3132469|NCT01671449|Experimental|S-1 plus Oxaliplatin|"S-1: 40 mg/m2, twice daily, p.o., day 1-14 (see Table 6 for dose calculation of S-1 according to body surface area)~: If S-1 is started on the evening of day 1, last dose of S-1 will be administered at the morning of day 15.~Oxaliplatin: 130 mg/ m2/day, i.v., day 1~Every 3 weeks"
3132470|NCT01671436|Experimental|Central Meditation and Imagery Therapy|Intervention involved Central Meditation, may be characterized by a voluntary, regulated attentional set towards a specific stimulus or set of stimuli and visualization exercises utilized within CMIT, which primarily involves two types of thought experiments: 1) creating mental models of how a person fits into the larger world and universe according to evolutionary biology and modern cosmology, in order to gain a larger perspective on emotions and thought patterns, and 2) backcasting, the generation of a desirable future coupled with mental time travel back to the present to determine how to create that future with present-day actions.
3132471|NCT01671423|Active Comparator|Prednisone|In addition to standard care for cellulitis, subject will receive a single 60 mg dose of Prednisone orally during their initial visit.
3132472|NCT01671423|Placebo Comparator|Placebo|In addition to standard care for cellulitis, subjects will receive a single placebo pill to take during their initial visit.
3132473|NCT01671410|Experimental|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
3132474|NCT01671410|Active Comparator|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
3132475|NCT01671397|Experimental|Diet, exercise, sleep hygiene counseling|Subjects will meet with a dietitian and a physician and receive counseling on diet restriction, exercise goals, and good sleep hygiene. Subjects will identify goals in each domain and keep a calendar of the success with achieving these goals.
3132476|NCT01671397|Active Comparator|Diet and exercise counseling|Subjects will meet with a dietitian and a physician and receive counseling on calorie restriction and exercise. They will identify goals in each domain and keep a calendar to determine their success with achieving these goals.
3132477|NCT01671384|Active Comparator|Valproate, levocarnitine|"The patients will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)"
3132478|NCT01671384|Placebo Comparator|Placebo|"All patients will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)"
3132479|NCT01671371|Other|Immediate Ultrasound|A point-of-care ultrasound will be performed during the initial evaluation of the patient after randomization (Defined as Time 0)
3132480|NCT01671371|Other|Delayed Ultrasound|A point-of-care ultrasound will be performed by the provider at 60 min after initial randomization
3132481|NCT01671358||Isolation Rooms for MRSA|Rooms that currently have a patient in them that are in isolation status due to MRSA
3132482|NCT01671358||Non-isolation rooms|Rooms that have not been occupied by a patient in isolation due to MRSA for 14 days
3132483|NCT01671345|Active Comparator|Intervention|Patients randomized to the intervention will view the intervention video
3132484|NCT01671345|Placebo Comparator|Control|Patients randomized to control will view an informative video about nutrition and exercise of similar length
3132485|NCT01671332|Active Comparator|Docetaxel|
3132486|NCT01671332|Experimental|Docetaxel plus Suramin|
3132487|NCT01671319|Experimental|dose dense TC + pegfilgrastim|Docetaxel + Cyclophosphamide chemotherapy given every 2 weeks x 4 cycles plus pegfilgrastim given 24-48 hours post day 1 of each cycle
3132488|NCT01671306||Collateral, coronary disease|Patients are grouped into 2: Good and poor collateral development
3132489|NCT01671306||collateral|Patients are grouped into 2: Good and poor collateral development
3132490|NCT01671293|Experimental|Multicomponent remote care model|A remote intervention based on counseling (telephone-based).
3132491|NCT01671293|Active Comparator|Usual care|Usual care.
3132492|NCT01671280||Azithromycin IV|Subjects who are treated with Azithromycin IV
3132493|NCT01671267|Experimental|Strength training|Strength training of the shoulder, arm and hand muscles for 3 x 10 minutes a week.
3132494|NCT01671267|Active Comparator|Ergonomic|Receives counseling on workstation adjustment and optimal use of the work tools.
3132495|NCT01671254|Active Comparator|FishOil + placebo|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and placebo capsule
3132496|NCT01671254|Experimental|FishOil + CBE75|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and citrus bioflavonoids+vitamin E (CBE)(75 mg/capsule/day)
3132497|NCT01671254|Experimental|FishOil + CBE150|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and CBE (150 mg/capsule/day)
3132498|NCT01671241|Experimental|Total body polyethylene wrap (body plus head)|The entire body surface (body plus head) is covered by a polyethylene wrap
3132499|NCT01671241|Active Comparator|Polyethylene wrap (body)|A polyethylene wrap covers the patient's body up to the neck
3135933|NCT01647308|Placebo Comparator|Placebo|
3132503|NCT01671228|No Intervention|usual predialysis education|The consultations and information usually provided by the predialysis health professionals
3132504|NCT01671189|Experimental|SMS Appointment Reminders|150 patients will be randomly assigned to the intervention arm of the study and receive text reminders about their upcoming appointments.
3132505|NCT01671189|No Intervention|Existing Reminder Protocol|150 patients will be randomly assigned to the control arm of the study and will not receive SMS reminders about their upcoming appointments. They will, however, be subject to the clinics' existing reminder protocol (phone call reminders by either clinic personnel or computer machine).
3132506|NCT01671176|Other|Wide diameter bone anchored implant|Intervention: Implantation of a wide diameter bone anchored auditory implant either 3 or 4 mm in length, into the skull on the side of the ear where intervention is intended in order to restore hearing. In the case of a conductive or mixed hearing loss, that side is chosen. In patients with unilateral, profound sensori-neural hearing loss the implant is implanted on that side but the sound is transmitted to the side with the normal hearing ear via bone conduction stimulation.
3132507|NCT01671163||Subjects requiring fiducial placement|Endoscopic Ultrasound (EUS) for fiducial placement
3132508|NCT01671150|Placebo Comparator|Placebo control|half of the participants will receive a placebo control
3132509|NCT01671150|Active Comparator|Endotoxin (Inflammatory challenge)|
3132510|NCT01671137|Active Comparator|Lactobacillus Rhamnosus Strain GG|LGG (6 × 109 colony forming units)
3132511|NCT01671137|Placebo Comparator|Placebo|Placebo
3132512|NCT01671124||Soline capsule|Salvia divinorum, Lycium, Chenpi and Dihuang
3132513|NCT01671111|Experimental|SSP-004814AQ|
3132514|NCT01671098||Control|Healthy adults
3132515|NCT01671098||Balloon Sinuplasty|Patients who had balloon sinuplasty
3132516|NCT01671098||FESS-Uncinectomy|Patients who had FESS-Uncinectomy
3132517|NCT01671085|Experimental|1.0 mg/kg of LY3015014|1.0 milligrams per kilogram (mg/kg) of LY3015014 given subcutaneously (SQ) on 2 dosing occasions occurring 4 weeks apart (Q4W) (Days 1 and 29).
3132518|NCT01671085|Placebo Comparator|Placebo|0.9% sodium chloride injection given subcutaneously (SQ) (to match LY3015014) on 2 dosing occasions occurring 4 weeks apart (Q4W) (Days 1 and 29).
3132519|NCT01671072|Experimental|TissueGene-C|Single intra-articular injection to the damaged knee joint a dose of 1.8 x 10^7 cells
3132520|NCT01671072|Placebo Comparator|Normal Saline|Single intra-articular injection to the damaged knee joint at the same volume
3132521|NCT01671059||Tocilizumab|Participants with rheumatoid arthritis (RA) receiving tocilizumab either as combination therapy or monotherapy through routine clinical practice.
3132522|NCT01671046||Cohort|
3132523|NCT01671033|Experimental|Muscle Relaxation|The patients of this arm practice on-line muscle relaxation every day.They complete the Brief Symptom Rating Scale(BSRS), Family APGAR(APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Clinical Global Impression (CGI) were performed by well-trained clinicians.
3132524|NCT01671033|Experimental|Muscle Relaxation with Biofeedback|The patients of this arm practice on-line muscle relaxation with finger temperature biofeedback every day. They complete the Brief Symptom Rating Scale(BSRS), Family APGAR(APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Clinical Global Impression (CGI) were performed by well-trained clinicians.
3132525|NCT01671033|No Intervention|Waiting-List|The patients of this arm waited for four weeks. They complete the Brief Symptom Rating Scale(BSRS), Family APGAR (APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Impressions-Improvement(CGI) were performed by well-trained clinicians.
3132526|NCT01671020|Active Comparator|(R)(T)|Period 1: Fimasartan 60mg → Period 2: Fimasartan 30mg
3132527|NCT01671020|Active Comparator|(T)(R)|Period 1: Fimasartan 30mg → Period 2: Fimasartan 60mg
3132528|NCT01670994|Experimental|ALT-801|
3132529|NCT01670981|Experimental|ixmyelocel-T|Ixmyelocel-T delivered by catheter-based intramyocardial injection procedure.
3132530|NCT01670981|Placebo Comparator|Placebo|Placebo delivered by catheter-based intramyocardial injection procedure.
3132531|NCT01670955|Active Comparator|Jobelyn + Ferrous Sulphate + Folic Acid|Caps Jobelyn 250mg, 12 hourly + Ferrous Sulphate 600mg thrice daily + Folic Acid 5mg daily
3132532|NCT01670955|Active Comparator|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
3132533|NCT01670942||Traumatic Pneumothorax1|hypobaric chamber
3132534|NCT01670929|Active Comparator|Progesterone group|progesterone (400 mg pessary, once daily)
3132535|NCT01670929|Placebo Comparator|Placebo group|Placebo (pessary, once daily)
3132536|NCT01670916||Probiotics|Capsule with 1 x 10**9 Lactobacillus rhamnosus GG and 1 x 10**8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
3132537|NCT01670916||Control|Probiotics never given
3132538|NCT01670903||ARBs|Hypertensive patients treated with ARBs
3132539|NCT01670903||ACE inhibitors|Hypertensive patients treated with ACE inhibitors
3132540|NCT01670903||non ARB/ACE|Hypertensive patients treated with non ARBs or ACE inhibitors meds
3132541|NCT01670890|Active Comparator|TMZ group|patients were treated with TMZ alone
3132542|NCT01670890|Experimental|TMZ plus CDDP group|patients were treated with TMZ plus CDDP
3132543|NCT01670877|Experimental|Part I: met HER2- BC w/HER2 mutations|"Patients will receive neratinib PO daily on Days 1-28. Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~If a participant experiences disease progression following neratinib, trastuzumab may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days."
3132574|NCT01670656|Experimental|NOMAC-E2 900/300 mcg|NOMAC-E2 900/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3133515|NCT01664000|Experimental|Kevetrin|thioureidobutyronitrile intravenous once/week for 3 weeks/ cycle
3132544|NCT01670877|Experimental|Part II: met HER2- ER- BC w/HER2 mutations|"Patients will receive neratinib PO daily on Days 1-28. Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~If a participant experiences disease progression following neratinib, trastuzumab may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days."
3132545|NCT01670877|Experimental|Part II: met HER2- ER+ BC w/HER2 mutations, fulvestrant-naive|"Patients will receive neratinib PO daily on Days 1-28 and fulvestrant on Day 1 of each cycle (and C1D15). Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~If a participant experiences disease progression following neratinib, trastuzumab may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days."
3132546|NCT01670877|Experimental|Part II: met HER2- ER+ BC w/HER2 mutations, fulvestrant-tx|"Patients will receive neratinib PO daily on Days 1-28 and fulvestrant on Day 1 of each cycle (and C1D15). Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~If a participant experiences disease progression following neratinib, trastuzumab may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days."
3132547|NCT01670864|Experimental|Counseling group|Study participants in the counseling group will receive a brief on-site face-to-face smoking cessation counseling from our trained smoking cessation counselor on the study site after signing the consent form. They will receive advice on quitting smoking and specific warning about the hazardous effects of smoking on health. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week & 1-month will be made to the participants in this group.
3132548|NCT01670864|Experimental|SMS intervention group|Study participants in the SMS group will receive SMS text messages on smoking cessation advice and warning on the hazardous effects of smoking on health. The participants will receive a total of 16 tailored SMS messages after recruitment.
3132549|NCT01670864|No Intervention|Control group|Study participants in the control group will not receive any quitting assistance other than the self-help materials from the recruitment sites.
3132550|NCT01670851||Strattice|eLAPE
3132551|NCT01670838||subarachnoid haemorrhage|nontraumatic subarachnoid haemorrhage
3132552|NCT01670825|Experimental|Pulsed radiofrequency + local anesthetic injection|Local anesthetic injection plus pulsed radiofrequency over each affected occipital nerve
3132553|NCT01670825|Active Comparator|Corticosteroid injection + sham pulsed radiofrequency|"Injection with corticosteroid and local anesthetic over the occipital nerve(s)plus sham pulsed radiofrequency"
3132554|NCT01670812|Experimental|FFP+HDMP+Rituximab|Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5.
3132555|NCT01670799|Experimental|Ketorolac|"All patients will receive a single dose of IV ketorolac for pain management for the indication of post-operative pain control. Patients less than 65 years of age and in otherwise good health will receive a 30mg IV single dose. Patients 65 years of age or greater, or who have mild renal insufficiency or are of low weight (as per section 3.2) will receive a single 15 mg dose IV ketorolac.~In patients who have a clinical pain response and have no contraindications to multi-dose (every 6 hours over 24 hours), additional doses will be given per physician discretion based on clinical indication. Patients receiving 24 hour dosing will be eligible for sample time points after 24 hour dosing."
3132556|NCT01670786|Experimental|Iodopovidone 1%|The patients enrolled in this arm were submitted to pleurodesis with iodopovidone 1% administration into pleural cavity.
3132557|NCT01670786|Experimental|Iodopovidone 2%|The patients enrolled in this arm were submitted to pleurodesis with iodopovidone 2% administration into pleural cavity.
3132558|NCT01670773|Experimental|CAT-1004 Dose #1|Single dose #1
3132559|NCT01670773|Active Comparator|Salsalate + DHA|Single dose #2
3132560|NCT01670773|Placebo Comparator|Placebo|Single Dose #3
3132561|NCT01670760|Experimental|Zero-Heat-Flux|This is a single arm study. All patients will have deep tissue temperature monitored from the nasopharyngeal and lateral forehead sites simultaneously.
3132562|NCT01670747||ARDS|Sedated and mechanically ventilated patients admitted to ICU
3132563|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - mild hepatic function|Injection through subcutaneous (SC) administration in patients with mild hepatic function
3132564|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - moderate hepatic function|Injection through subcutaneous (SC) administration in patients with moderate hepatic function
3132565|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - normal hepatic function|Injection through subcutaneous (SC) administration in patients with normal hepatic function
3132566|NCT01670721|Experimental|Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)|Aflibercept 4 mg/kg intravenous (IV) infusion over 60 minutes followed by Irinotecan 180 mg/m^2 IV infusion over 90 minutes and Leucovorin 400 mg/m^2 IV infusion over 120 minutes at the same time followed by 5-FU 400 mg/m^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until DP, unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.
3132567|NCT01670708|Experimental|HOPE|Participation in HOPE program
3132568|NCT01670708|Active Comparator|Probation as Usual|Participation in probation as usual
3132569|NCT01670695||IgG4-RD|Patients with IgG4-RD, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis (Mikulicz disease and Küttner's tumor), inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions.
3132570|NCT01670682|Active Comparator|fascia fixation group|procedure: ischia spinous fascia fixation
3132571|NCT01670682|Active Comparator|mesh group|Procedure: Modified Pelvic Floor Reconstruction Surgery with mesh
3132572|NCT01670669|Active Comparator|prucalopride|0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
3132573|NCT01670656|Experimental|NOMAC-E2 700/300 mcg|NOMAC-E2 700/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3132688|NCT01669915|Active Comparator|Vitamin D + fish oil placebo|
3132575|NCT01670656|Experimental|ENG-E2 100/300 mcg|ENG-E2 100/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3132576|NCT01670656|Experimental|ENG-E2 125/300 mcg|ENG-E2 125/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3132577|NCT01670656|Placebo Comparator|Placebo|Placebo will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3132578|NCT01670643||Video camera magnifier|
3132579|NCT01670630|Active Comparator|Sheathed speculum|"Investigators will perform a vaginal speculum examination with either a sheathed or a standard (non sheathed speculum in a randomized comparison to estimate the degree of cervical visualization and subject pain perception."
3132580|NCT01670630|Active Comparator|Standard speculum examination|Investigators will perform a vaginal speculum examination with either a standard or a sheathed speculum in a randomized comparison to estimate the degree of cervical visualization and subject pain perception.
3132581|NCT01670617|Other|DeNovo NT Graft|DeNovo NT Graft stratified by lesion location - femur or patella
3132582|NCT01670604|Experimental|VOL group|patients will receive 6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)
3132583|NCT01670604|Experimental|TET group|patient will receive 6% HES 130/0.42 in a balanced electrolyte containing Na+140 mmol/L, Cl- 118 mmol/L, K +4 mmol/L, Ca++ 2.5 mmol/L, Mg++ 1 mmol/L, acetate- 24 mmol/L and malate-- 5 mmol/L
3132584|NCT01670591|Experimental|PS - Prevention in School|Teachers learn to use the core program components (defining and teaching school rules and the handling of rule breakings, principles of positive behavior support)with help from external consultants during approximately 1.5 years.
3132585|NCT01670591|No Intervention|Business as usual|
3132586|NCT01670578|Experimental|PRP Group|Patients (n=96) randomized to this group of treatment will receive 3 blinded knee intra-articular injections of autologous Platelet-Rich Plasma one week apart each other.
3132587|NCT01670578|Active Comparator|Hyaluronan Group|Patients (n=96) randomized to this group of treatment will receive 3 blinded knee intra-articular injections of hyaluronic acid ( Hyalubrix 30 mg/2ml, Fidia Farmaceutici Spa, Italy) one week apart each other.
3132588|NCT01670565|Experimental|Mycophenolate mofetil + Belimumab|All patients who enroll in this trial will FIRST receive mycophenolate mofetil (MMF, Cellcept), which is a drug commonly given to patients with scleroderma in clinical practice. This drug will be given at no cost to the patient. After the patient has been titrated to 2 grams of MMF per day, the patient will receive EITHER a 10 mg/kg belimumab (Benlysta) intravenous infusion OR a placebo (saline) infusion. This medication and infusion will of course be covered by the study.
3132589|NCT01670565|Placebo Comparator|Mycophenolate Mofetil + Saline (placebo)|In order to observe the difference between belimumab/MMF compared to MMF alone, half of the patients will receive a normal saline infusion that appears identical to the belimumab infusion.
3132590|NCT01670552|Experimental|Nimesulide + Pantoprazole|Nimesulide + Pantoprazole- 1 tablet each 12 hours for 14 days
3132591|NCT01670552|Active Comparator|Naproxen + Esomeprazole|Naproxen + Esomeprazole - 1 tablet each 12 hours for 14 days
3132592|NCT01670539|Experimental|Telemonitor|"In addition to routine care, the HomMed Telemonitor wireless telemonitoring system (intervention)will be used in the patient's home for 14 days to alert the clinical research nurse to changes in patients conditions in order to contact them to teach self-management. The Honeywell HomMed Genesis™ DM Remote Patient Care Monitor will be used to measure temperature, pulse, oxygen level,weight and blood pressure. The telemonitor will also ask for a YES or NO response to questions on symptoms such as difficulty breathing. Research nurses review the data daily and call the participant for 2 weeks, and continue to monitor outcomes for 2 months."
3132593|NCT01670539|No Intervention|Routine care for patients with lungCa|Traditional physician ordered post-hospital care for patients with lung CA in rural WV requires patients to make an outpatient office/ clinic visit two to three weeks after discharge;a few patients receive homecare service referrals. No attempt to change care - just monitor what is used and collect study data at Discharge, 2 weeks, one month and two months.
3132594|NCT01670526|Experimental|Rivastigmine|Rivastigmine transdermal patch
3132595|NCT01670526|Placebo Comparator|Placebo|Placebo
3132596|NCT01670513|Experimental|IDP-118 Low Strength|IDP-118 Low Strength
3132597|NCT01670513|Experimental|IDP-118 High Strength|IDP-118 High Strength
3132598|NCT01670500|Active Comparator|Doxorubicin-Cyclophosphamide|Doxorubicin q 2-3 wk x 4 Cyclophosphamide q 2-3 wk x 4
3132599|NCT01670500|Active Comparator|Cisplatin|Cisplatin q 3 wk x 4
3132600|NCT01670487|Active Comparator|Vapocoolant (Pain Ease Medium Stream)|Application of the stream steadily 4 to 10 seconds onto the cannulation site.
3132601|NCT01670487|Placebo Comparator|Nature's Tears|Apply sterile water (see manufacturer above) steadily 4-10 seconds onto the cannulation site.
3132602|NCT01670474|Experimental|fmDLC and rt-PA (2mg/2mL actilysis)|"Surface thrombogenicity of film-coated domain structured double lumen catheters (fmDLC) consisting of a novel reactive polyurethane copolymer coating will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
3132603|NCT01670474|Active Comparator|polyDLC and rt-PA (2mg/2mL actilysis)|"The same procedure will be assessed in the polyurethane double lumen catheter (polyDLC)as with the fmDLC. Indeed, surface thrombogenicity of polyDLC will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
3132604|NCT01670474|Active Comparator|siDLC and rt-PA (2mg/2mL actilysis)|"Same procedure as the previous catheters. Surface thrombogenicity of silicone double lumen catheter (siDLC) will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
3132689|NCT01669915|Active Comparator|Vitamin D placebo + fish oil|
3132605|NCT01670461|Experimental|FACE Advance Care Planning|FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
3132606|NCT01670461|Other|Standard of Care (SOC) Control|Standard of Care Control: Advance Directive Information Booklet plus Advance Directive Checklist.
3132607|NCT01670448|Active Comparator|PECBLOCK performed with bupivacaine|Active drug given through PECBLOCK in these patients.
3132608|NCT01670448|Placebo Comparator|PECBLOCK performed with NaCl 0.9%|Placebo drug given through PECBLOCK in these patients
3132609|NCT01670435||Group 1|
3132610|NCT01670409|Experimental|SMART combined with PF chemotherpay|SMART-base IMRT with concurrent and adjuvant chemotherapy(cisplatin and 5-fluorouracil)
3132611|NCT01670396||in-stent restenosis|
3132612|NCT01670396||non-in-stent restenosis|
3132613|NCT01670383||Postresuscitation group|Adults (age over 16 years old) who have survived from nontraumatic cardiac arrest and admitted to ICU.
3132614|NCT01670383||Sepsis group|Adults (age over 16 years old) who satisfy the sepsis criteria (SIRS>=2 and infection is suspected for a cause) and admitted to the ICU.
3132615|NCT01670370|Experimental|Rituximab+Gemcitabine+oxaliplatin (R-GemOx)|Rituximab: 375 mg/m2 IV day1, Gemcitabine 1g/m2 IV day 2, oxaliplatin 100mg/m2 IV day2(every 14 days)
3132616|NCT01670357|Experimental|DA-6034 Low dose|DA-6034 3%
3132617|NCT01670357|Experimental|DA-6034 High dose|DA-6034 5%
3132618|NCT01670357|Placebo Comparator|Placebo|DA-6034 Placebo
3132619|NCT01670344|Other|A|Treatment with investigational method (virtual implant positioning system)
3132620|NCT01670344|Other|B|Treatment with surgical standard of care
3132621|NCT01670331|Active Comparator|Psychological preparation|Patients undergo 3 seminar sessions with the bariatric psychologist prior to their surgery. These will aim to prepare them for the lifestyle changes that will occur / they will have to make after surgery
3132622|NCT01670331|No Intervention|Surgery as usual|Patients will proceed to surgery as usual. They will complete psychological assessment forms at their follow up clinic sessions.
3132623|NCT01670318|Experimental|platinum chromium everolimus-eluting stent|
3132624|NCT01670305|Experimental|Residual pocket - PDT|Photosensitizer plus diiodo laser
3132625|NCT01670305|Placebo Comparator|Residual pocket - Photosensitizer|Photosensitizer alone
3132626|NCT01670305|Active Comparator|Residual pocket - SRP|scaling and root planing alone
3132627|NCT01670305|Experimental|Furcation - PDT+SRP|Photosensitizer plus diiodo laser associated with scaling and root planing
3132628|NCT01670305|Active Comparator|Furcation - SRP|Photosensitizer associated with scaling and root planing
3132629|NCT01670292|Other|Experimental: HVLA-SM|Experimental High Velocity Low Amplitude Spinal Manipulation
3132630|NCT01670279|Experimental|Cohort 1|14 day titration phase and two fixed dose phases. The first fixed dose phase is 14 days with a daily dose of 2mg brexpiprazole/placebo. The second fixed dose phase is 14 days with a daily dose of 3 mg brexpiprazole/placebo.
3132631|NCT01670279|Experimental|Cohort 2|14 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.
3132632|NCT01670279|Experimental|Cohort 3|21 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.
3132633|NCT01670279|Placebo Comparator|Placebo|Placebo
3132634|NCT01670266|Experimental|Experimental Arm 1|Experimental Eye drops 3.0 µg/mL QD both eyes on Day 1, 5-18
3132635|NCT01670266|Experimental|Experimental Arm 2|Experimental Eye drops 10.0 µg/mL QD both eyes on Day 1, 5-18
3132636|NCT01670266|Experimental|Experimental Arm 3|Experimental Eye drop 30.0 µg/mL QD both eyes on day 1, 5-18
3132637|NCT01670266|Experimental|Experimental Arm 4|Experimental Eye drop, 2 sequence crossover Cohort [1 dose; 1-30 µg/mL]to be determined and placebo
3132638|NCT01670266|Placebo Comparator|Placebo Arm|Matched placebo eye drops dosed in same manner as ONO-9054
3132639|NCT01670253|No Intervention|Group 2|6 hours of total fast for all solid and liquid food / drinks
3132640|NCT01670253|Experimental|Group 1|"6 hour fast from all solid foods and milk beverages~2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)~Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like."
3132641|NCT01670240|Active Comparator|Adalimumab|Every second week, mg: 160-80-40-40-40-40 12 weeks in all
3132642|NCT01670240|Placebo Comparator|Placebo|Given as the active comparator, every second week
3132643|NCT01670227|Experimental|PARENTCORPS|ParentCorps is a school-based, family-focused universal intervention designed to attenuate the multiple risks associated with urban poverty, on children's health and development
3132644|NCT01670227|Other|Control Condition|No intervention
3132645|NCT01670214|Active Comparator|Pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions phase 1 treatment and added 6 sessions for phase 2 treatment (3 sessions per week)
3132646|NCT01670214|Placebo Comparator|pulsed electromagnetic field|patients are placed under off instrument while who is kept blind to know it for 6 sessions (3 sessions per week).
3132647|NCT01670201|Experimental|Mepilex Transfer Ag|Mepilex Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
3132648|NCT01670188|Active Comparator|Pneumatic SCD|Use of pneumatic SCD (VenaFlow System - DJO Global) on upper extremity with PICC line inserted.
3132649|NCT01670188|No Intervention|Non-SCD group|Standard care
3132650|NCT01670175|Experimental|Sirolimus, Cyclophosphamide, Topotecan|Sirolimus, Cyclophosphamide, Topotecan Patients accrued to dose levels in cohorts of 3 (3+3 design). Patients will receive daily oral sirolimus and cyclophosphamide days 1-21 in 28-day cycle, combined with oral topotecan given on days 1-14. Sirolimus will be dosed based on steady-state plasma trough concentrations.
3248250|NCT00852670|Placebo Comparator|B|
3132651|NCT01670162|Experimental|3 loading doses, then every 2 months|All patients will receive 3 monthly intravitreal aflibercept injections followed by mandatory dosing every 3 months. If needed, patients can be treated monthly.
3132652|NCT01670149|Placebo Comparator|Placebo|Identical looking tablet
3132653|NCT01670149|Active Comparator|Rifaximin , Xifaxanta™|2 weeks of Rifaximin 400mg thrice daily then 2 weeks of Rifaximin 200mg thrice daily Modified Xifaxanta™ (rifaximin film-coated tablet) manufactured by Alfa Wasermann (AW),
3132654|NCT01670136|No Intervention|sildenafil, standard of care|Infants receiving sildenafil as standard of care
3132655|NCT01670136|Other|sildenafil administered for study|1 dose of sildenafil administered for study
3132656|NCT01670123|Experimental|Mobile Phone Condition|This arm will involve daily self-monitoring with an electronic mobile device with responses to survey questions about mood status. Mood status reports are linked with personalized coping strategies.
3132657|NCT01670123|Placebo Comparator|Paper-and-pencil condition|This arm will complete a paper-and-pencil mood chart on a daily basis
3132658|NCT01670110|Active Comparator|Pasireotide LAR (SOM230)|Active Pasireotide LAR
3132659|NCT01670110|Placebo Comparator|placebo injection|
3132660|NCT01670097|Experimental|Dexamethasone|"Dexamethasone 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days. In the open label phase, patients assigned to either arm asked to take Dexamethasone 4 mg orally twice a day for 7 days. Patient to blow into spirometry machine 1 time a day to test lung function. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.~Participants randomized to either dexamethasone or placebo for 7 days in a blinded fashion; this will be followed by an open label phase in which patients in both arms would take dexamethasone for 7 days."
3132661|NCT01670097|Placebo Comparator|Placebo|"Two placebo capsules taken twice a day for 4 days, followed by one capsule twice a day for 3 days. Patient to blow into spirometry machine 1 time a day to test lung function. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.~Participants randomized to either dexamethasone or placebo for 7 days in a blinded fashion; this will be followed by an open label phase in which patients in both arms would take dexamethasone for 7 days."
3132662|NCT01670084|Experimental|Treatment (nilotinib, combination chemotherapy)|See Detailed Description
3132663|NCT01670071|Experimental|Paliperidone extended-release|
3132664|NCT01670071|Active Comparator|Risperidone immediate-release|
3132665|NCT01670058||Belatacept treated adult kidney-only transplant recipients|All adult kidney-only transplant recipients treated with Nulojix (Belatacept)
3132666|NCT01670058||CNIs at transplantation|
3132667|NCT01670045||Rheumatoid Arthritis Participants|Participants with moderate to severe rheumatoid arthritis (RA) according to the American College of Rheumatology (ACR) criteria and the Disease Activity Score based on 28 Joint Count (DAS28) who were on tocilizumab treatment within 8 weeks prior to start of study will receive tocilizumab in accordance with the licensed label recommendations, and will be observed for 6 months. The study is designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication is required.
3132668|NCT01670032|Experimental|CD07223 1.5 % Topical Gel BID|Drug: 1.5% CD07223 Topical Gel applied BID for 7 days
3132669|NCT01670032|Experimental|CD07223 1.5% Topical Gel TID|Drug: 1.5% CD07223 Topical Gel applied TID for 7 days
3132670|NCT01670032|Placebo Comparator|CD07223 vehicle gel BID|Drug: CD07223 Vehicle Topical Gel applied BID for 7 days
3132671|NCT01670032|Placebo Comparator|CD07223 vehicle gel TID|Drug: CD07223 Vehicle Topical Gel applied TID for 7 days
3132672|NCT01670019|Experimental|Asenapine 5-20 mg daily|Asenapine will be started at 5 mg BID. The asenapine dose can be increased to 15 mg daily and then to 20 mg daily, or reduced to 5 mg daily, depending on therapeutic response and tolerability
3132673|NCT01670019|Placebo Comparator|Placebo 1-4 tablets daily|Matched, blinded placebo tablets will be administered at doses from 1-4 tablets daily depending on therapeutic response and tolerability
3132674|NCT01669980|Experimental|Ceftaroline fosamil|
3132675|NCT01669980|Active Comparator|IV Ceftriaxone and Vancomycin|
3132676|NCT01669967|Placebo Comparator|Diphenhydramine(Benadryl)|
3132677|NCT01669967|Active Comparator|Lidocaine|
3132678|NCT01669954||Controls, females|Controls who are presumed HIV uninfected, females, aged 18 or above
3132679|NCT01669954||Controls, males|Controls presumed HIV uninfected, males, aged 18 or above
3132680|NCT01669954||HIV infected patients, males|HIV patients, males, aged 18 or above
3132681|NCT01669954||HIV patients,|HIV patients, females, aged 18 or above
3132682|NCT01669941|Experimental|IPTp-DP|At each ANC visit, women will be given treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
3132683|NCT01669941|Experimental|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if they test positive, will be treated with dihydroartemisinin-piperaquine (DP). Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
3132684|NCT01669941|Active Comparator|IPTp-SP|Treatment with a single dose of three tablets of sulfadoxine-pyrimethamine, each containing sulfadoxine (500 mg) and pyrimethamine (25 mg) at each FANC visit. This is the standard regimen.
3132685|NCT01669928|Active Comparator|Group B|Anti hypertensive medication in the evening (between 18.00 and 23.00)
3132686|NCT01669928|Active Comparator|Group A|Antihypertensive medication in the morning(between 06.00 and 11.00)
3132687|NCT01669915|Active Comparator|Vitamin D + fish oil|
3132693|NCT01669876|Active Comparator|Dietary Supplement: Anatabloc(R)|Study product, as mint-flavored lozenge (3 mg anatabine per lozenge) to be taken 2-3 times each day
3132694|NCT01669876|Placebo Comparator|Placebo|Placebo, as mint-flavored lozenge, to be taken 2-3 times each day
3132695|NCT01669863|Experimental|Use of ECMO in non-intubated patients|ECMO will be used in non-intubated patients with ARDS
3132696|NCT01669850|Experimental|Clipped anastomosis|A vascular clip device will be used to create the anastomosis during arteriovenous fistula creation.
3132697|NCT01669850|Active Comparator|Handsewn anastomosis|A handsewn technique will be used to create the anastomosis in arteriovenous fistula creation.
3132698|NCT01669837||Patient group|Administration of surgical tissue glue.
3132699|NCT01669824||Group 1|
3132700|NCT01669811|Experimental|D961H 20mg twice daily|Double-blinded
3132701|NCT01669811|Active Comparator|D961H 20mg once daily|Double-blinded
3132702|NCT01669798|Experimental|BIBF 1120|BIBF 1120 will be administered at a daily oral dose of 200 mg BID until disease progression or adverse effects prohibit further therapy.
3132703|NCT01669785|Active Comparator|Group C|"NUPRO Classic Prophy Paste~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains no Novamin or Fluoride..~Leave in contact for 60 seconds, rinse with water and expectorate."
3132704|NCT01669785|Experimental|Group A|"NUPRO Sensodyne Prophy Paste w/ Novamin~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains 15% Novamin. Does not contain Fluoride.~Leave in contact for 60 seconds, rinse with water and expectorate"
3132705|NCT01669785|Experimental|Group B|"NUPRO Sensodyne Prophy Paste w/ Novamin w/ Fluoride~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains 1.23% fluoride ion and 15% Novamin.~Leave in contact for 60 seconds, rinse with water and expectorate."
3132706|NCT01669772|Other|DA-9701 and placebo|Administer DA-9701 for 1week and assess the study outcomes. After 1 week of washout period, administer placebo for 1week and assess the outcomes again.
3132707|NCT01669772|Other|Placebo and DA-9701|Administer placebo for 1 week and study the outcome parameters. After 1 week of washout, administer DA-9701 for 1 week and assess the outcome parameters again.
3132708|NCT01669759||fatigue|
3132709|NCT01669746|Experimental|Treatment|
3132710|NCT01669733|Experimental|Live/Recorded Music Group|The music therapist will prepare a preferred song to be performed live in the preoperative room. Subjects in the live music group will listen to recorded music intraoperatively.
3132711|NCT01669733|Experimental|Recorded Music Group|Recorded music group will be given an iPod and headphones and will listen to a recorded version of a preferred song.
3132712|NCT01669733|Active Comparator|No Music (Standard of care)|The control group will receive standard of care and no music.
3132713|NCT01669720|Experimental|Aflibercept|Patients will be randomized 2:1, to receive Aflibercept,4mg/kg IV q2weeks until progression for a maximum of 2 years
3132714|NCT01669720|No Intervention|Observation|Patients will be randomized 2:1 to receive Aflibercept. Patients who are randomized to observation will be followed per the study table, but will receive no intervention.
3132715|NCT01669707|Experimental|Endostar -Continued Pumping into+GP|Endostar that is Continued Pumping into vein Combining With Gemcitabine -Cisplatin
3132716|NCT01669707|Active Comparator|Endostar -injecting into +GP|Endostar that is injecting into vein with Gemcitabine -Cisplatin
3132717|NCT01669694||Women with Pelvic Pain|Women with Pelvic Pain undergoing pelvic floor PT in the Beaumont Women's Urology Center
3132718|NCT01669681||Included in the cohort COBRA|
3132719|NCT01669668|Experimental|RFA|Patients undergo laparoscopic ultrasound followed by RFA.
3132720|NCT01669642|Experimental|Ketamine|participants who get the ketamine sedation will be enrolled. there is no control or comparison group.
3132721|NCT01669629|Experimental|Delefilcon A/ Etafilcon A|6-10 days of delefilcon A soft contact lens wear first, then 6-10 days of etafilcon A soft contact lens wear
3132722|NCT01669629|Experimental|Etafilcon A / Delefilcon A|6-10 days of etafilcon A soft contact lens wear first then 6-10 days of delefilcon A soft contact lens wear
3132723|NCT01669603|Experimental|Bifidobacterium animalis lactis Bl-04|Bifidobacterium animalis subspecies lactis Bl-04 as powder mixed into drink.
3132724|NCT01669603|Placebo Comparator|Placebo|Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
3132725|NCT01669590||old (60-75yr)|
3132726|NCT01669590||young (18-35y)|
3132727|NCT01669577||severe trauma patients|analysis of blood samples and clinical features
3132728|NCT01669564|Active Comparator|Activated Patients|Will use HIT patient feedback to activate patients.
3132729|NCT01669564|Other|Control patients|Patients will not receive HIT patient feedback.
3132730|NCT01669564|Other|Intervention Physicians|Will use HIT patient feedback to activate patients.
3132731|NCT01669564|Other|Control Physicians|Patients will not receive HIT patient feedback.
3132732|NCT01669551||Structural or Valvular Heart Disease|
3132733|NCT01669538|Experimental|Galantamine|"Galantamine hydrobromide-ER (extended release) is currently marketed for the treatment of Alzheimer's disease. The dosing regimen follows the FDA-approved guidelines. For the first week of study treatment, participants will take 8mg daily of galantamine-ER, preferably with food. 8mg is the lowest dose and this period is designed to introduce the medication into their system. After the initial week, participants will increase their daily dose to 16mg. They will remain on 16mg daily until the end of the treatment period for a total of 23 days on active study medication.~Galantamine will be purchased, encapsulated, and packaged into blister packs by the Investigational Drug Service at the University of Pennsylvania. Both active medication and placebo will look identical."
3132734|NCT01669538|Placebo Comparator|Placebo|"Participants assigned to the placebo (sugar pill) arm will take one capsule daily, preferably with food, for a total of 23 days. They will follow the same instructions and complete the same procedures as those in the active treatment.~Placebo ingredients (sucrose filler and gel capsules) will be purchased, encapsulated, and packaged into blister packs by the Investigational Drug Service at the University of Pennsylvania. Both active medication and placebo will look identical."
3132735|NCT01669525||No treatment|Singleton pregnancies presenting to the Genetic Counselor for Sequential Screening prior to 14 weeks gestation.
3133558|NCT01663675||Trisomy 21 (Down syndrome)|Trisomy 21 (Down syndrome)
3132736|NCT01669512|Active Comparator|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56 6 Volunteers
3132737|NCT01669512|Experimental|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56 8 Volunteers
3132738|NCT01669512|Experimental|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56 8 Volunteers
3132739|NCT01669499|Placebo Comparator|Placebo|Placebo on day 0-3
3132740|NCT01669499|Active Comparator|Dexamethasone acetate day 0|8 mg dexamethasone on day 0
3132741|NCT01669499|Active Comparator|Dexamethasone acetate day 0-3|8 mg dexamethasone on day 0-3
3132742|NCT01669486||ICU patients|All patients admitted to ICU for a minimal hospitalization of 24 hours, invasive mechanically ventilated, will be evaluated with CPOT and BPS scores, during nurses work, in particular before and after nurses manoeuvers.
3132743|NCT01669473|Experimental|Intervention Arm|"EHR Based Strategy to promote Safe and Appropriate Drug Use~Patients randomized to the intervention arm will be given (3) print tools to assist in safe and appropriate medication use. These include a Medreview, Medsheet,and Medlist."
3132744|NCT01669473|No Intervention|Standard Care Arm|The control group will receive regular standard care at the Clinic. They will not receive any print tools.
3132745|NCT01669460|Experimental|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink: two (250mL) cans per day for 28 days
3132746|NCT01669447|Experimental|ranibizumab|"Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment."
3132747|NCT01669434|Experimental|ACEI continuation|Patients in this arm will be randomized to continue their chronic angiotensin converting enzyme inhibitor without interruption preoperatively
3132748|NCT01669434|Experimental|ACEI omission|Patients randomized to this arm will be told to omit their final preoperative chronic angiotensin converting enzyme inhibitor dose.
3132749|NCT01669421|Experimental|Alpha-1 Antitrypsin (human)|Alpha-1 Antitrypsin (human) 120 mg per kg per week for 4 weeks
3132750|NCT01669408|Active Comparator|Cold infusions|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
3132751|NCT01669408|No Intervention|Control group|Best medical treatment following international stroke guidelines
3132752|NCT01669395|Experimental|Early homebased rehabilitation|After discharge from the hospital patients are offered a homebased rehabilitation program lasting 6 weeks.
3132753|NCT01669395|Experimental|control group: Ususal care|After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
3132754|NCT01669382|Active Comparator|Exo Seal system|Percutaneous coronary intervention
3132755|NCT01669382|Active Comparator|AngioSeal system|percutaneous coronary intervention
3132756|NCT01669369|Placebo Comparator|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
3132757|NCT01669369|Experimental|Lithium Carbonate|Patients in this arm take Lithium Carbonate twice a day with a dose of 20-25mg/kg/d.
3132758|NCT01669356|Experimental|PN supplement|Parenteral supplement with enteral nutrition for patients after esophagectomy
3132759|NCT01669356|Active Comparator|EN alone|Enteral nutrition alone for patients after esophagectomy
3132760|NCT01669343|Active Comparator|Part A letrozole 2.5 mg|letrozole 2.5 mg tablet,once daily for 28 days
3132761|NCT01669343|Experimental|Part B letrozole 5.0 mg|letrozole 2.5 mg tablet, two tablets,once daily for 28 days
3132762|NCT01669330|Active Comparator|Total fundoplication|Procedure: Laparoscopic Nissen fundoplication
3132763|NCT01669330|Active Comparator|Anterior partial fundoplication|Procedure: Laparoscopic anterior partial fundoplication
3132764|NCT01669317|Experimental|Cherry Juice Standardized|You will be given an 8-ounce glass of cherry juice to drink when you arrive at the Sleep Laboratory.
3132765|NCT01669317|Placebo Comparator|Artificial Cherry Juice|You will be given an 8-ounce glass of artificial cherry juice to drink when you arrive at the Sleep Laboratory.
3132766|NCT01669304|Experimental|Verapamil|Verapamil extended release oral tablets administered in a flexible dose format ranging from 120 mg to 360 mg daily, as determined by severity of headache and dizziness.
3132767|NCT01669304|Experimental|Sertraline|Sertraline oral tablets administered in a flexible dose format ranging from 25 mg to 150 mg daily depending on severity of headache and dizziness.
3132768|NCT01669291|Active Comparator|Bravelle & Menopur Agonist Long Protocol|Patients will use an LH agonist (Lupron) starting on day 18 of the oral contraceptive pill (OCP), 5 units b.i.d. followed by 5 units q.d. beginning on day one of stimulation medications. The 5 units q.d. dose will continue until the day of hCG administration.Patients will administer Bravelle and Menopur for ovarian stimulation.
3132769|NCT01669291|Active Comparator|Bravelle & Menopur Antagonist Protocol|Patients will complete standard dose of oral contraceptive pill (OCP) and will then administer GnRH antagonist (ganirelix acetate or cetrorelix acetate) 0.25 mg q.d. during the stimulation phase when the lead follicle size reaches 12mm. The antagonist will continue until the day of hCG administration. Patients will administer Bravelle and Menopur for ovarian stimulation.
3132770|NCT01669278|No Intervention|Traditional flexible nasopharyngolaryngoscopy|No sheath procedure
3132771|NCT01669278|Active Comparator|Sheath flexible nasopharyngolaryngoscopy|Flexible nasopharyngolaryngoscopy using endosheath
3132772|NCT01669265||OSNA|Patient cases with cT1-3, N0 early breast cancer, who previously had intraoperative sentinel lymph node (SLN) evaluation by one-step nucleic acid amplification (OSNA) assay with a complete axillary dissection.
3132773|NCT01669252|Experimental|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
3248608|NCT00850148|Experimental|Melles|
3132774|NCT01669239|Experimental|Liposomal Doxorubicin|"Six cycles of:~Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"
3132775|NCT01669226|Experimental|Regimen B, PEip and TCiv therapy|Weekly IP cisplatin plus etoposide followed by IV paclitaxel plus carboplatin or docetaxel plus carboplatin
3132776|NCT01669226|Active Comparator|Regimen A: Standard TCiv therapy|IV paclitaxel plus carboplatin or docetaxel plus carboplatin
3132777|NCT01669213|Active Comparator|ramosetron 0.3 mg|preparation of ramosetron 0.3 mg
3132778|NCT01669213|Active Comparator|ondansetron 8 mg|preparation of ondansetron 8mg
3132779|NCT01669213|Active Comparator|ondansetron 4 mg|preparation of ondansetron 4mg
3132780|NCT01669213|Placebo Comparator|non 5-HT3 receptor antagonist|preparation of normal saline 5 ml
3132781|NCT01669200|Placebo Comparator|Placebo Oil|Differential changes will be compared in the test group versus the control group at one month and six months with respect to BHB and insulin levels, and at six months with respect to cognitive scores.
3132782|NCT01669200|Experimental|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group versus the control group at one month and six months with respect to BHB and insulin levels, and at six months with respect to cognitive scores.
3132783|NCT01669187|Active Comparator|Education brochure|The control group will receive a standard education brochure which will be provided pre-operatively to the participants.
3132784|NCT01669187|Experimental|Live education and exercise instruction|The intervention group will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
3132785|NCT01669174|Experimental|BYM338|
3132786|NCT01669174|Placebo Comparator|Placebo|
3132787|NCT01669161|Experimental|VNS|VNS (vagus nerve stimulation) paired with rehabilitation as provided by the Vivistim System.
3132788|NCT01669161|Active Comparator|Rehab Only|Rehabilitation only (no implant, no VNS)
3132789|NCT01669148|Active Comparator|Conventional + Tomosynthesis|conventional (2D) imaging plus tomosynthesis (3D) imaging first then tomosynthesis alone 1 month later.
3132790|NCT01669148|Active Comparator|Tomosynthesis alone|tomosynthesis (3D) imaging alone first then conventional (2D) imaging plus tomosyntheis 1 month later.
3132791|NCT01669135|Other|Spinal Anesthesia with cerebral oxygen saturation monitoring|The cerebral oxygen saturation of the right and left frontal lobe as well as the thigh oxygen saturation are monitored during spinal anesthesia by means of the near-infrared spectroscopy. Hemodynamic variables were recorded at the same time points.
3132792|NCT01669122|Experimental|Prototype 1|4mg nicotine lozenge administered orally as a single dose treatment per subject
3132793|NCT01669122|Experimental|Prototype 2|4mg nicotine lozenge administered orally as a single dose treatment per subject
3132794|NCT01669122|Experimental|Prototype 3|4mg nicotine lozenge administered orally as a single dose treatment per subject
3132795|NCT01669122|Active Comparator|Reference Therapy|4mg nicotine lozenge (internationally marketed) to be administered orally as a single dose treatment per subject.
3132796|NCT01669109|Experimental|Hatha yoga|"10 weeks of Hatha yoga, designed for patients with colorectal cancer, as a group intervention~1 weekly class (90 minutes)"
3132797|NCT01669109|No Intervention|Usual care|Patients continue their self-directed usual care
3132798|NCT01669096|Experimental|TB Group|Subjects will receive two doses of TB vaccine
3132799|NCT01669083|Experimental|Cohort 1: GSK557296 10 mg|GSK557296 10 mg single dose on Day 1 followed by repeat dosing (4 times a day) on Days 2-6
3132800|NCT01669083|Experimental|Cohort 2: GSK557296 150 mg|GSK557296 150 mg as a single dose on Day 1 followed by repeat nominal dosing of the same dose (either 2, 3 or 4 times a day based on half-life demonstrated in treatment A) on Days 9-13
3132801|NCT01669083|Experimental|Cohort 3|This study had an adaptive design and additional cohorts may be added depending on the PK profiles of Cohort 1 and Cohort 2. Subjects in this optional Cohort 3 will receive GSK557296 (dose to be determined) as a single dose on Day 1 followed by repeat nominal dosing of the same dose (either 2, 3 or 4 times a day based on half-life demonstrated in Cohort 1 and Cohort 2) on Days 2-6
3132802|NCT01669083|Experimental|Cohort 4|This study had an adaptive design and additional cohorts may be added depending on the PK profiles of Cohort 1 and Cohort 1. Subjects in this optional Cohort 4 will receive GSK557296 (dose to be determined) by PK of prior doses, 10-150 mg single dose on Day 1 followed by repeat dosing (either 2, 3 or 4 times a day dependent on half-life demonstrated in prior groups) on Days 2-6
3132803|NCT01669070|Experimental|FF 50 mcg powder inhalation|Each subject will receive a single dose of 300 mcg FF (6 inhalations of 50 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 50 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
3132804|NCT01669070|Experimental|FF 100 mcg powder inhalation|Each subject will receive a single dose of 600 mcg FF (6 inhalations of 100 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 100 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
3132805|NCT01669070|Experimental|FF 200 mcg powder inhalation|Each subject will receive a single dose of 1200 mcg FF (6 inhalations of 200 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 200 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
3132806|NCT01669070|Experimental|FF 250 mcg IV|Each subject will receive a single dose of 250 mcg FF, administered as an IV infusion over 20 minutes on Day 1 of the respective period per randomization sequence.
3132807|NCT01669057||Congenital heart defect（CHD） group|
3132808|NCT01669057||Normal control group|
3132809|NCT01669044||dexmedetomidine,hemodynamics,injection|Group 1:when the patient can be roused after major abdominal surgery ，we will inject dexmedetomidine at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h for 6 to 24hours.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
3248609|NCT00850148|Experimental|Anwar|
3132810|NCT01669044||propofol,hemodynamics,injection|Group 2 :when the patient can be roused after major abdominal surgery ，we will inject propofol at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg.h for 6 to 24hours.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores
3132811|NCT01669031|No Intervention|Control Group|No practice tests are performed in this arm
3132812|NCT01669031|Experimental|Practice Program|"At the 3 study visits exposed to a training session (simulated visual field test on a computer).~Visit 1 they get 2 simulated tests tests per eye. At visits 2 and 3 they get 1 simulated test per eye. Each simulated test takes 3-15 minutes"
3132813|NCT01669018|Active Comparator|Lumbar ultrasound trident (LUT)|Lumbar plexus block using LUT technique
3132814|NCT01669018|Experimental|Supra Sacral Parallel Shift (SSPS)|Lumbar plexus block using SSPS technique
3132815|NCT01669005||Bone marrow transplant unit patients|hospitalized patients in the bone marrow transplant unit for an autologous or allogeneic hematopoietic stem cells transplantation or induction/consolidation chemotherapy
3132816|NCT01668992|Experimental|Family intervention|Families receive 12-week program on parenting skills, discipline methods and family communication.
3132817|NCT01668992|No Intervention|Waitlist control|Families are on a waitlist and receive the intervention only after the trial is complete.
3132818|NCT01668979||new system to detect Near Falls|the new system comprises of a treadmill and a virtual reality simulation that will be used to induce Near Falls in healthy older adults with a history of falls.
3132819|NCT01668966|Experimental|Tocilizumab|Participants will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenously (IV) every 4 weeks for up to 104 weeks.
3132820|NCT01668953|Experimental|Platelet Rich Plasma (PRP) Injection|Patients in this arm will receive a platelet rich plasma injection at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises.
3132821|NCT01668953|Active Comparator|Whole Blood Injection|Patients in this arm will receive a whole blood injection at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises.
3132822|NCT01668953|Active Comparator|Dry Needle Fenestration|Patients in this arm will receive 15-25 gentle strokes of dry needling (piercing of the tendon) at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.
3132823|NCT01668953|Placebo Comparator|Sham Injection|Patients in this arm will receive a sham injection, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.
3132824|NCT01668940|Experimental|Lillipops Iced Soothies (4 flavours)|"Initially, women will be given 1 multiflavour box of Lillipop samples minus the ginger flavour (4 flavours). Each box contains 24 freezies (20 mL each), 6 of each flavor. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 per day, and to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days). They can request an additional multiflavour box of freezies at each follow-up, as needed.~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
3132825|NCT01668940|Experimental|Lillipop Iced Soothies (Ginger flavour)|Initially, women will be given 1 Ginger flavor box of Lillipop samples. Each box contains 24 freezies (20 mL each). Each 20ml contains 80mg of dried ginger root. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 a day and to not have any other popsicles, freezies or other ginger products throughout the duration of the study (7 days). Due ginger's antiemetic property, a maximum daily dose is up to 1000mg/day of dried ginger root powder in pregnancy.They can request an additional box of freezies at each follow-up, as needed.All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol.
3132826|NCT01668940|Active Comparator|Mr. Freeze Freezies (4 flavours)|"Initially, women will be given 1 multiflavour box of Mr. Freeze samples. Each box contains 24 freezies (20 mL each), 6 of each flavor. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 per day, and to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days). They can request an additional multiflavour box of freezies at each follow-up, as needed.~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
3132827|NCT01668940|No Intervention|Natural Course Group|"Women will not receive any freezies and will be asked to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days).~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
3132828|NCT01668927|Experimental|tetracycline/furazolidone|one of the four empirical rescue therapies
3132829|NCT01668927|Experimental|amoxicillin/tetracycline|one of the four empirical rescue therapies
3132830|NCT01668927|Experimental|amoxicillin/furazolidone|one of the four empirical rescue therapies
3132831|NCT01668927|Active Comparator|tetracycline /metronidazole|Classical rescue therapy
3132832|NCT01668914|Experimental|clinically positive axillary nodes|3~18 hours before surgery, under ultrasonographic guidance, 0.5~1.0 mCi 99mTc-SC in sterile saline (total volume 0.2~2.0 mL) is injected intraparenchymally into 2 quadrants of breast. Subsequently, LSG is performed 0.5~1.0 hour before surgery. Methylthioninium was injected intraparenchymally. IM-SLNB is performed during the surgery and the IMSLNs were sent to histologic examination
3132833|NCT01668901|Experimental|warfarin|medication
3132834|NCT01668901|Active Comparator|aspirin|medication
3132835|NCT01668888||Apparently Helathy Subjects|
3132836|NCT01668875|Experimental|Treatment condition|In intervention period patients were received head-down 30 degree postural drainage position for 10 min.
3132837|NCT01668875|Experimental|Sham condition|In intervention period patients were received horizontal supine lying for 10 min.
3132838|NCT01668862|Other|Study arm A|Subjects will receive one injection of Autologous Human Platelet lysate in the lateral epicondyle space
3132839|NCT01668862|Other|Control Arm B|Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
3250983|NCT00833066|Experimental|gpASIT 25|
3132840|NCT01668849|Experimental|1 - Grape extract|Grape extract self-administered daily by mouth for 35 days during chemoradiation therapy.
3132841|NCT01668849|Active Comparator|2 - Lortab, Fentanyl patch, mouthwash|Standard oral mucositis therapy such as pain medication and anti-fungal mouth washes will be prescribed according to product labels.
3132842|NCT01668836|Experimental|men with resveratrol|12 men will receive a pill with 500mg of resveratrol daily for 30 days
3132843|NCT01668836|Experimental|women with resveratrol|12 women will receive a pill with 500mg of resveratrol daily for 30 days
3132844|NCT01668836|Active Comparator|men with caloric restriction|12 men will follow a 1000 calories per day diet for 30 days
3132845|NCT01668836|Active Comparator|women with caloric restriction|12 women will follow a 1000 calories per day diet for 30 days
3132846|NCT01668823|Experimental|Treatment (PDT using HPPH)|Patients receive HPPH IV over 1 hour on day 1. Patients then photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.
3132847|NCT01668810||Beijing region|include six hospitals
3132848|NCT01668810||Guangdong Province|include 3 hospitals
3132849|NCT01668810||Jiangsu province|include 3 hospitals
3132850|NCT01668810||Hebei province|include 6 hospitals
3132851|NCT01668810||Hubei Province|include 7 hospitals
3132852|NCT01668810||Shanxi province|include 3 hospitals
3132853|NCT01668810||Jiangxi province|include 3 hospitals
3132854|NCT01668810||Jilin province|include 6 hospitals
3132855|NCT01668810||Sichuan province|include 3 hospitals
3132856|NCT01668810||Shaanxi province|include 3 hospitals
3132857|NCT01668797|Placebo Comparator|Placebo|Placebo comparator for 52 weeks
3132858|NCT01668797|Experimental|Brexpiprazole (OPC-34712)|Brexpiprazole (OPC-34712) for 52 weeks
3132859|NCT01668784|Experimental|Arm 1: Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3132860|NCT01668784|Active Comparator|Arm 2: Everolimus|Everolimus 10 mg tablets by mouth daily until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3132861|NCT01668745|Experimental|Early measles vaccine|The intervention is about to administer an early standard dose of Edmonston-Zagreb (EZ) measles vaccine in addition to the conventional dose. As such children will be randomised to receive either an early measles vaccine at 4 months after DTP3 or not. Thereafter both groups of children will receive the recommended EZ measles vaccine at 9 months of age according to WHO policy.
3132862|NCT01668745|No Intervention|Control|
3132863|NCT01668732||community heroin addicts|
3132864|NCT01668719|Active Comparator|Arm I (bortezomib, lenalidomide, dexamethasone)|"INDUCTION: Patients receive bortezomib SC or IV on days 1, 4, 8, and 11; lenalidomide PO QD on days 1-14; and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity (patients who received a course of chemotherapy prior to registration will begin protocol treatment with course 2 and receive a total of 7 courses of protocol therapy).~MAINTENANCE: Patients receive bortezomib SC or IV on days 1, 8, and 15; lenalidomide PO QD on days 1-21; and dexamethasone PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3132865|NCT01668719|Experimental|Arm II (bortezomib, lenalidomide, dexamethasone, elotuzumab)|"INDUCTION: Patients receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Patients also receive elotuzumab IV on days 1, 8, and 15 of courses 1 and 2 and on days 1 and 11 of courses 3-8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Patients also receive elotuzumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3132866|NCT01668706||Methadone maintenance treatment (MMT)|
3132867|NCT01668706||Buprenorphine-Naloxone treatment (BNT)|
3132868|NCT01668706||Medication-free ex-addicts(MF)|
3132869|NCT01668706||Normal control (NC)|
3132870|NCT01668693|Active Comparator|RIF ERA Receptive 1|"With the receptive results from the first Endometrial Receptivity Array (ERA), the patients will undergo embryo transfer on Day 5 of Progesterone administration in the cycle following the ERA diagnosis."
3132871|NCT01668693|Experimental|RIF ERA Non Receptive|"The Non Receptive results of the ERA diagnotic tool will indicate how many more days of Progesterone are necesary in order to obtain the Receptive daignosis. A second ERA will take place to confirm receptivity and in the following cycle, the personalized embryo transfer will take place on the day predicted by this diagnostic tool."
3132872|NCT01668680|Experimental|LDM anti-angiogenic chemotherapy|LDM (Low Dose Metronomic) anti-angiogenic chemotherapy includes daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE.
3132873|NCT01668680|No Intervention|observation|observation only
3132874|NCT01668667|Active Comparator|GSK1838262 600 mg|Once-daily dose with food in the evening at approximately 5 PM
3132875|NCT01668667|Active Comparator|GSK1838262 450 mg|Once-daily dose with food in the evening at approximately 5 PM
3132876|NCT01668667|Active Comparator|GSK1838262 300 mg|Once-daily dose with food in the evening at approximately 5 PM
3132877|NCT01668667|Placebo Comparator|GSK1838262 placebo match|Once-daily dose with food in the evening at approximately 5 PM
3132878|NCT01668654|Experimental|retigabine/ezogabine|retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight
3132879|NCT01668641|Experimental|capsule, 30mg GLPG0634 once a day|3 capsules of 10 mg once a day
3132880|NCT01668641|Experimental|capsules, 75mg GLPG0634 once a day|3 capsules of 25mg once a day
3132881|NCT01668641|Experimental|capsules, 150mg GLPG0634 once a day|3 capsules of 50mg once a day
3132882|NCT01668641|Experimental|capsules, 300mg GLPG0634 once a day|3 capsules of 100mg once a day
3132883|NCT01668641|Placebo Comparator|capsules, placebo once a day|3 capsules placebo once a day
3132916|NCT01668368|Other|Esophageal balloon group|"Esophageal balloon will be inserted, and esophageal pressure will be measured in patients with acute respiratory failure.~Intervention - PEEP and Inspiratory pressure will be adjusted according to the measured esophageal pressure."
3133628|NCT01663129||Leukemia Patient Group|Acute Lymphoblastic Leukemia (ALL)
3132884|NCT01668628||Incident PD patients|First treatment for end stage of renal disease (ESRD) by any peritoneal dialysis modality within 30 days prior to or following enrollment (patients may be enrolled prior to commencing first treatment if there is clear indication that the treatment modality is continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dilaysis (APD) and they consent in advance to enter the study) and patients who don't have any experience of dialysis treatment before this study
3132885|NCT01668628||Prevalent PD patients|Prevalent peritoneal dialysis(PD) patients who are under peritoneal dialysis treatment more than 6 months
3132886|NCT01668628||Prevalent HD patients|Prevalent hemodialysis(HD) patients who are under hemodialysis treatment more than 6 months
3132887|NCT01668602|Experimental|Fast walking and FES|Fast treadmill walking with ankle electrical stimulation
3132888|NCT01668602|Active Comparator|Fast treadmill walking|Fast treadmill walking without electrical stimulation
3132889|NCT01668563|Active Comparator|Endovascular management|Endovascular treatment will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
3132890|NCT01668563|Active Comparator|Surgical management|Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
3132891|NCT01668537|Experimental|Group 1|LF formulation of IMVAMUNE® 2 doses of 1 x 10E8 TCID50, s.c., 4 weeks apart
3132892|NCT01668537|Experimental|Group 2|FD formulation of IMVAMUNE® 2 doses of 1 x 10E8 TCID50, s.c., 4 weeks apart
3132893|NCT01668524|Experimental|Single Arm: ATS907|Single-cohort, dose-escalation
3132894|NCT01668511|Experimental|Group 1|Randomized 7 drug/2 placebo by group
3132895|NCT01668511|Experimental|Group 2|Randomized 7 drug/2 placebo by group
3132896|NCT01668511|Experimental|Group 3|Randomized 7 drug/2 placebo by group
3132897|NCT01668511|Experimental|Group 4|Randomized 7 drug/2 placebo by group
3132898|NCT01668498|Experimental|Erythromycin|Experimental Arm (ARM A) skin- treatment: erythromycin cream 2% daily at bedtime doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2 skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks
3132899|NCT01668498|Active Comparator|Doxycyline|Standard Arm (ARM B) skin- treatment:doxycycline 100mg b.i.d. skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks
3132900|NCT01668485|Experimental|Islet transplant recipients|Hypoglycemic and euglycemic glucose clamp
3132901|NCT01668485|Placebo Comparator|Type 1 diabetic subjects|Hypoglycemic and euglycemic glucose clamp.
3132902|NCT01668485|Active Comparator|Non-diabetic subjects|Hypoglycemic and euglycemic glucose clamp
3132903|NCT01668459|Experimental|Cabazitaxel|6 cycles (3 weekly) of 25 mg/m^2 IV infusion
3132904|NCT01668459|Other|Best Supportive Care|Best supportive care including single agent chemotherapy as determined by the patient's study doctor
3132905|NCT01668446|Experimental|sildenafil|"One of two group to prepare the endometrium give estradiol by step up method with menstruation.~From first to fourth day of menstrual cycle, estradiol valerat tablet 2 mg daily From Fifth to eighth day of menstrual cycle, estradiol valerat tablet 4 mg daily From Ninth to twelfth day of menstrual , estradiol valerat tablet 6 mg daily The second group in addition to the above treatment protocol from First day of cycle until day of starting progesterone will be given sildenafil tablets(50 mg) daily."
3132906|NCT01668446|Experimental|Sildenafil and estradiol valerat|"One of two group to prepare the endometrium give estradiol by step up method with menstruation.~From first to fourth day of menstrual cycle, estradiol valerat tablet 2 mg daily From Fifth to eighth day of menstrual cycle, estradiol valerat tablet 4 mg daily From Ninth to twelfth day of menstrual , estradiol valerat tablet 6 mg daily The second group in addition to the above treatment protocol from First day of cycle until day of starting progesterone will be given sildenafil tablets(50 mg) daily."
3132907|NCT01668433|Active Comparator|G6PD Normal|Subjects will be given either primaquine, 45 mg single dose or methylene blue, 600 mg single dose with a washout period of 7 days then followed by either methylene blue, 600 mg single dose or primaquine, 45 mg single dose.
3132908|NCT01668433|Experimental|G6PD deficiency|Subjects will be given either primaquine, 45 mg single dose or methylene blue, 600 mg single dose with a washout period of 7 days then followed by either methylene blue, 600 mg single dose or primaquine, 45 mg single dose.
3132909|NCT01668420|Experimental|noxious thermal stimulation|Heat-pain:46-47°C and Cold-pain:2-3°C alternately (intervention) 3 times /week and total 24 TS while conventional rehabilitation program was given
3132910|NCT01668420|Active Comparator|thermal stimulation (innocuous)|Heat:40-41°C and Cold:23-24°C alternately (intervention) 3 times /week and total 24 TS while conventional rehabilitation program was given
3132911|NCT01668407|Experimental|Robot-Assisted Gait Training (RAGT)|Robot-Assisted Gait Training (RAGT): Subjects (at least 40) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.
3132912|NCT01668407|Active Comparator|Treadmill Gait Training (TT)|Treadmill Gait Training (TT): Subjects (at least 40) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.
3132913|NCT01668394|Active Comparator|Learning and coping arm|Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.
3132914|NCT01668394|Placebo Comparator|Control arm|Usual care. Teaching style: deductive.
3132989|NCT01667835|Experimental|Yoga Intervention|
3132917|NCT01668355|Experimental|SMI-PACT|Patient Aligned Care Team (PACT) medical home model to address the physical healthcare needs for individuals with serious mental illness
3132918|NCT01668355|No Intervention|Usual Care|Primary Care
3132919|NCT01668342|Experimental|SMS assessments & feedback|Daily symptom assessments of headaches, trouble ocncentrating and irritability/anxiety with self-care feedback based on response severity.
3132920|NCT01668342|No Intervention|Control|Standard of care
3132921|NCT01668316|Experimental|Weight loss|12 week weight loss program with biweekly meetings with a Registered Dietitian. Participants will be given a nutrition prescription and asked to record dietary intake online. Participants will be given a pedometer and record daily physical activity.
3132922|NCT01668316|No Intervention|Control|Participants asked to not change dietary and physical activity habits.
3132923|NCT01668303|Experimental|Miami Juvenile Drug Court-MDFT|Multidimensional family therapy (MDFT) is primarily a family-based approach (Liddle, 2002)which conducts individual sessions with the teen and parent[s] but not peer-group sessions.
3132924|NCT01668303|Other|Miami Juvenile Drug Court -TAU|The Treatment as Usual (TAU) condition is primarily a peer group-based and individual approach that uses cognitive-behavioral principles and interventions.
3132925|NCT01668290||Stress Echocardiography|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Stress Echocardiography.
3132926|NCT01668290||SPECT|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Single Photon Emission Computed Tomography (SPECT)
3132927|NCT01668290||CCTA|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Cardiac Computed Tomographic Angiography (CCTA)
3132928|NCT01668277|Experimental|3 ml/kg 7.2% NaCl|The test fluids 7.2% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
3132929|NCT01668277|Active Comparator|3 ml/kg 0.9% NaCl|The test fluids 0.9% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
3132930|NCT01668277|Active Comparator|20 ml/kg 0.9% NaCl|The test fluids 0.9% NaCl 20 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
3132931|NCT01668264|Experimental|Magnetic Resonance Imaging (MRI)|Subjects with congenital heart disease will undergo an echocardiograph, as well as an MRI.
3132932|NCT01668264|Experimental|Echocardiograph|Subjects with congenital heart disease will undergo an echocardiograph, as well as an MRI.
3132933|NCT01668251||Fetal ascertainment|Girls who are diagnosed with Turner syndrome because of concerns raised by an abnormal fetal ultrasound.
3132934|NCT01668251||Maternal ascertainment|Girls who are diagnosed with Turner syndrome because their mothers had an amniocentesis for a reason other than an abnormal fetal ultrasound concerning for Turner syndrome. For example an amniocentesis was done because of advanced maternal age or because of an abnormal triple screen or because another condition was being screened for such as trisomy 21.
3132935|NCT01668238||malignant tumor|Inpatients with malignant tumors of thyroid and breast
3132936|NCT01668238||benign tumor|Inpatients with benign tumors of thyroid and breast
3132937|NCT01668238||Healthy volunteers|Volunteers without thyroid or breast tumors
3132938|NCT01668225||G-CSF FIV nat|Patient following a natural In Vitro Fecondation cycle
3132939|NCT01668212||natural In Vitro Fertilization cycle|Patient doing following natural In Vitro fertilization cycle
3132940|NCT01668199|Experimental|14C TZP-101|
3132941|NCT01668186||Patients diagnosed with PBD|Collection of medical records and images (retrospective and prospective), Next-generation panel, Drug screening, and Consultation
3132942|NCT01668173|Experimental|AUY922|This is an open-label phase II trial to assess the efficacy of the HSP90 inhibitor, AUY922, in patients with PMF, post-PV MF, post-ET MF, and with PV/ET who are refractory to hydroxyurea, phlebotomy or anagrelide.
3132943|NCT01668160|Experimental|Revision Total Hip|patients recieving a revision total hip replacement will be assessed for implant stability and wear using RSA. Tantalum beads will be placed in the polyethylene and surrounding pelvic and femoral bone.
3132944|NCT01668147|Experimental|study arm|Session 1: Control (no pretreatment) - IV 10-14 mCi of [11C] desmethyl-loperamide (dLop) with PET/CT imaging Session 2: Pretreatment with oral ritonavir for 3 days followed by IV 10-14 mCi of [11C]dLop with PET/CT imaging Session 3: Pretreatment with oral efavirenz for 14 days followed by IV 10-14 mCi of [11C]dLop with PET/CT imaging
3132945|NCT01668134|Experimental|Stereotactic radiation|
3132946|NCT01668121|Experimental|Symbicort Turbohaler|Symbicort Turbohaler
3132947|NCT01668121|Active Comparator|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
3132948|NCT01668108||carcinoma, Paclitaxel onkovis (Paclitaxel)|treatment in mono- or combination therapy with Paclitaxel of breast-, non-small cell lung- and ovarial cancer.
3132949|NCT01668095||Ancillary-Correlative (biomarker analysis)|Immunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis.
3132950|NCT01668082|Experimental|surgical resection of a brain tumor|The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.
3132951|NCT01668069|Experimental|Ondansetron|study drug
3132952|NCT01668069|No Intervention|Doxylamine and Pyridoxine (vitamin B6)|other nausea treatment in use
3132990|NCT01667835|No Intervention|Control|
3132991|NCT01667822|Active Comparator|Continued guided self help CBT|Continued guided self help CBT. Participants will receive CBT through self-help books with minimal therapist contact (3 sessions in total).
3132992|NCT01667822|Experimental|CBT individual therapy|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
3133088|NCT01667159|Experimental|Integrated Cognitive Behavioral Therapy|Adolescents and their parent(s) will receive integrated cognitive behavioral therapy.
3132953|NCT01668056|Active Comparator|Control|Patients will be stimulated according to the conventional flexible GnRH antagonist protocol for IVF. Alfa follitropin (150IU a day) will be started on the third day of the menstrual cycle. Treatment monitoring will be done with transvaginal ultrasound scans and serum determinations of estradiol and progesterone 5 days after the start of gonadotropins and every each day thereafter. Once the leading follicle reaches 13 mm in mean diameter 0,25mg of cetrorelix acetate will be administered daily. Once at least two follicles reach 18mm or more in mean diameter 250 micrograms of choriogonadotropin alfa will be administered and 36 hours latter patients will undergo follicle aspiration for IVF. Embryos will be cryopreserved (vitrification) on the third or fifth day of development. Two months after women will undergo uterine preparation for embryo transfer.
3132954|NCT01668056|Experimental|Ovulation induction|Patients will be monitored with daily transvaginal ultrasound scans from the tenth day of the menstrual cycle on. When the dominant follicle reaches a mean diameter of 16mm or more, patients will receive 250 micrograms of choriogonadotropin alfa subcutaneously. Daily transvaginal ultrasound scans will be done starting two days after the administration of the medication until a cohort of ovarian follicles between 4-6 mm is seen (follicular wave emergence). From this point on patients will undergo the same stimulation protocol as Controls, i.e., flexible GnRH antagonist protocol.
3132955|NCT01668056|Experimental|Dominant follicle aspiration|Patients will be monitored with daily transvaginal ultrasound scans from the tenth day of the menstrual cycle on. When the dominant follicle reaches a mean diameter of 16mm or more, patients will then undergo aspiration of the dominant and all follicles greater than 10mm in mean diameter. aspiration will be transvaginal ultrasound guided and under sedation, as for oocyte retrieval. Oocytes eventually obtained at this first aspiration will not be used for IVF. Daily transvaginal ultrasound scans will be done starting the day after the follicular aspiration until a cohort of follicles between 4-6 mm is seen (follicular wave emergence). From this point on patients will undergo the same stimulation protocol as Controls, i.e., flexible GnRH antagonist protocol.
3132956|NCT01668043|Experimental|Antibody UB-421 Cohort 1|10 mg/kg BW, 8 weekly doses for 8-week treatment period
3132957|NCT01668043|Experimental|Antibody UB-421 Cohort 2|25 mg/kg BW, 4 biweekly doses for 8-week treatment period
3132958|NCT01668030|Experimental|Bacitracin on left, Enzymatic agent on right|Subjects were randomized to receive enzymatic agent on right side of face and bacitracin on left.
3132959|NCT01668030|Experimental|Bacitractin on right, enzymatic agent on left|Subjects were randomized to receive enzymatic agent on left side of face and bacitracin on right.
3132960|NCT01668017|Experimental|Part 1: Pimasertib 30mg in Solid Tumor|
3132961|NCT01668017|Experimental|Part 1: Pimasertib 45 mg in Solid Tumor|
3132962|NCT01668017|Experimental|Part 1: Pimasertib 60 mg in Solid Tumor|
3132963|NCT01668017|Experimental|Part 1: Pimasertib 30 mg in Hepatocellular Carcinoma (HCC)|
3132964|NCT01668017|Experimental|Part 1: Pimasertib 45 mg in HCC|
3132965|NCT01668004|Experimental|GLM 50 mg|GLM given subcutaneously at a dose of 50 mg once monthly for up to 12 months
3132966|NCT01667978|Experimental|PI|Study group with PI: atazanavir ritonavir
3132967|NCT01667978|Placebo Comparator|Control|o PI therapy, control group
3132968|NCT01667965||pts receiving palliative radiation therapy|The design of the study will be a prospective non-randomized cohort study with structured questionnaires administered to all enrolled patients at two or three time-points.
3132969|NCT01667952||Cancer Survivors|The purpose of this study is to establish a registry of survivors of cancer, tumors,or a related illness. The registry will include detailed family history and germline DNA. Ultimately, we hope to improve our understanding of genetic susceptibility to secondary malignant neoplasms and other late effects among survivors of cancer, tumors, or a related illness.
3132970|NCT01667939|Experimental|pregnancy diet|Healthy Eating Index (HEI) in supervised pregnancies
3132971|NCT01667939|No Intervention|unsupervised pregnancy|women attending the obstetrics unit who did not follow a supervised diet
3132972|NCT01667926|Experimental|Ketamine|Subject will receive 6 infusions of ketamine over three weeks.
3132973|NCT01667926|Placebo Comparator|Placebo|Subjects will receive 6 infusions of normal saline over 3 weeks.
3132974|NCT01667913|No Intervention|6 minutes walking test|
3132975|NCT01667900|Experimental|0.5 mg Dulaglutide (Part A-Healthy)|0.5 milligrams (mg) dulaglutide administered once subcutaneously (SQ) to healthy participants in 1 of 3 treatment periods
3132976|NCT01667900|Experimental|0.75 mg Dulaglutide (Part A-Healthy)|0.75 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods
3132977|NCT01667900|Experimental|1.5 mg Dulaglutide (Part A-Healthy)|1.5 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods
3132978|NCT01667900|Placebo Comparator|Placebo (Part A-Healthy)|Placebo administered once SQ to healthy participants in 1 of 3 treatment periods
3132979|NCT01667900|Experimental|0.5 mg Dulaglutide (Part B-T2DM)|0.5 mg dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM) once weekly SQ for 4 weeks
3132980|NCT01667900|Experimental|0.75 mg Dulaglutide (Part B-T2DM)|0.75 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks
3132981|NCT01667900|Experimental|1.5 mg Dulaglutide (Part B-T2DM)|1.5 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks
3132982|NCT01667900|Placebo Comparator|Placebo (Part B-T2DM)|Placebo administered to participants with T2DM once weekly SQ for 4 weeks
3132983|NCT01667887||Femur Fractures|Patients with Distal Femur Fractures
3132984|NCT01667874|No Intervention|No Collatamp sponge|Joint infection treated without the use of the Collatamp G sponge.
3132985|NCT01667874|Experimental|Collatamp G sponge|Use of Collatamp G Gentamicin impregnated sponge for the treatment of early total joint infections
3132986|NCT01667861||(Wind) musicians|Members of (professional) orchestras, especially wind instrument players.
3132987|NCT01667848|Experimental|group B: Insufflation with warm gas|Insufflation with warmed, humidified carbon dioxide insufflation during laparoscopic cholecystectomy using the optitherm® device attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
3132988|NCT01667848|Experimental|group A: Insufflation with cold gas|group A: Insufflation with cold gas during laparoscopic cholecystectomy, the use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A
3132993|NCT01667809|Active Comparator|Cognitive Behavior Therapy|As the trial will include several different common subclinical mental disorders, the cognitive behavior therapy used in the study will be based on the protocols with best empirical support. Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
3132994|NCT01667809|Experimental|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
3132995|NCT01667796|Experimental|Vitamin D3|Both those with MS and healthy controls will be given vitamin D3 5000 IU/day by mouth for 90 days.
3132996|NCT01667783|Active Comparator|Gastric Banding|Laparoscopic Adjustable Gastric Banding
3132997|NCT01667783|Active Comparator|Medical Weight Loss|Medical Weight Loss using a comprehensive lifestyle intervention consisting of diet (meal replacements), physical activity and behavioral techniques
3132998|NCT01667783|Active Comparator|Gastric Bypass|Roux-en-Y Gastric Bypass
3132999|NCT01667770|Active Comparator|surgery - autologous graft|surgical intervention: decompression of Chiari malformation by suboccipital craniectomy using autologous graft
3133000|NCT01667770|Active Comparator|surgery - non-autologous graft|surgical intervention: decompression of Chiari malformation by suboccipital craniectomy using using non-autologous graft
3133001|NCT01667757||low post DES FFR group (<0.9)|the patient with FFR values less than 0.9 after DES procedure
3133002|NCT01667757||high post DES FFR group (≥0.9)|the patient with FFR values greater than 0.9 after DES procedure
3133003|NCT01667744|Placebo Comparator|Placebo|Placebo pill
3133004|NCT01667731|Experimental|SOF+RBV 12 Weeks (GT 2/3, TN)|Treatment-naive (TN) participants coinfected with HIV-1 and genotype (GT) 2 or genotype 3 HCV infection will receive SOF+RBV for 12 weeks.
3133005|NCT01667731|Experimental|SOF+RBV 24 Weeks (GT 2/3, TE)|Treatment-experienced (TE) participants coinfected with HIV-1 and genotype 2 or genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
3133006|NCT01667731|Experimental|SOF+RBV 24 Weeks (GT 1, TN)|Treatment-naive (TN) participants coinfected with HIV-1 and genotype 1 HCV infection will receive SOF+RBV for 24 weeks.
3133007|NCT01667718|Active Comparator|Levofloxacin-triple therapy|Lansoprazole (Proton Pump Inhibitor), Levofloxacin, Amoxicillin
3133008|NCT01667718|Experimental|Levofloxacin-quadruple therapy|Lansoprazole (Proton Pump Inhibitor),Bismuth, Levofloxacin, Amoxicillin
3133009|NCT01667705||SkyCeiling during CT-Suite visit|Patients in the trial group are exposed to the SkyCeiling during their procedure.
3133010|NCT01667705||No SkyCeiling during CT-Suite visit|Patients in the trial group are not exposed to the SkyCeiling during their procedure.
3133011|NCT01667692|Experimental|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics. It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
3133012|NCT01667692|Experimental|clarithromycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
3133013|NCT01667679|Experimental|OPTINOSE SUMATRIPTAN and Placebo|20 mg OPTINOSE SUMATRIPTAN Powder Delivered Intranasally With the Bi-directional Device nasally and Placebo Tablet
3133014|NCT01667679|Active Comparator|100mg Sumatriptan and OPTINOSE Placebo|100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally
3133015|NCT01667666|Experimental|Nebulized HTS|The first 5 patients will receive 3% Nebulized hypertonic saline, the second 5 patients will receive 4.5% Nebulized hypertonic saline, the third group 6% Nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% Nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
3133016|NCT01667653|Experimental|Augmentin/Probiotic|Participants are provided in double blinded fashion probiotic to take with antibiotics
3133017|NCT01667653|Experimental|Augmentin/placebo|Participants are provided in double blinded fashion placebo to take with antibiotics
3133018|NCT01667640|Active Comparator|whole brain irradiation|whole brain irradiation with 40 Gy, with fixation mask, radiation of the entire brain, skull base and meninges
3133019|NCT01667640|Experimental|sector irradiation|irradiation of the resection margin plus 5 mm safety margin with 30 Gy in 5 fractions
3133020|NCT01667627|Active Comparator|BIO-25, Probiotic-mixture|Two capsules a day.
3133021|NCT01667627|Placebo Comparator|Placebo|Identical to the Bio-25 capsule: same taste, same colour, same appearance
3133022|NCT01667614|No Intervention|ACE/ARB|In 62 patients previously treated with enalapril (10-30 mg daily) + losartan (50-100 mg daily), this regimen was continued.
3133023|NCT01667614|Active Comparator|Spironolactone/ARB|spironolacone 25 mg tablets added to losartan
3133024|NCT01667601|Experimental|Mindfulness-based program|A structured, researcher-designed mindfulness-based psycho-education program (6 months), comprised of 12 bi-weekly, 2-hour group sessions (10-12 patients per group). The program was based on the psycho-education programs by Chien et al. (2010) and Lehman et al. (2004), as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn (1990).
3133025|NCT01667601|Other|Routine Care|Routine psychiatric outpatient care, including medication, psychiatric consultation in outpatient clinic, brief education by psychiatric nurses, financial and social welfare advices by social workers, and individual counseling by clinical psychologist.
3133083|NCT01667211|Experimental|albumin-bound paclitaxel plus nedaplatin|albumin-bound paclitaxel plus nedaplatin: Intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
3250984|NCT00833066|Experimental|gpASIT 100|
3133026|NCT01667601|Active Comparator|Psychoeducation group|"A psychoeducation group program (12 sessions, bi-weekly) based on Dr. Macpherson's Family Psychoeducation Program in 1996 and Chien and Bressington's one in 2014/15 will be used.~References:~Chien WT, Bressington D. A randomized controlled trial of a nurse-led structured psychosocial intervention program for people with first-onset mental illness in psychiatric outpatient clinics. Psychiatry Res 2015;229:277-86.~Macpherson R, Jerrom B, Hughes AA. controlled study of education about drug treatment in schizophrenia. Br J Psychiatry 1996;168:709-17."
3133027|NCT01667588||Pre-Dialysis|
3133028|NCT01667588||Dialysis|
3133029|NCT01667575|Experimental|10 day Quadruple Therapy|Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 10 days
3133030|NCT01667575|Active Comparator|10 day Triple therapy|Esomeprazole 20mg, Amoxicillin 1.0g,and Clarithromycin 500mg, twice a day, for ten days
3133031|NCT01667575|Active Comparator|14 day quadruple therapy|Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 14 days
3133032|NCT01667562|Experimental|Erlotinib|Erlotinib will be administered as a single daily oral dose of 150 milligrams until disease progression, death or unacceptable toxicity.
3133033|NCT01667549|Experimental|1M0.5|"Mothers will receive the intervention for 1 month beginning when their infant is 0.5 months old.~Intervention: Timing of Diet and Flavor Experience"
3133034|NCT01667549|Experimental|1M1.5|"Mothers will receive the intervention for 1 month beginning when their infant is 1.5 months old.~Intervention: Timing of Diet and Flavor Experience"
3133035|NCT01667549|Experimental|3M0.5|"Mothers will receive the intervention for 3 months beginning when their infant is 0.5 months old.~Intervention: Timing of Diet and Flavor Experience"
3133036|NCT01667549|No Intervention|Control|Mothers will not receive the intervention.
3133037|NCT01667536|Experimental|Drug: 99mTc-MIP-1404|20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
3133038|NCT01667523|Experimental|Capsaicin|
3133039|NCT01667523|Experimental|Cinnamaldehyde|
3133040|NCT01667523|Placebo Comparator|Placebo|Physiological saline
3133041|NCT01667510|Experimental|Cardio Mato|Soft gel capsule for oral use (Grade A Lyc-O-Mato, a tomato extracted lycopene)
3133042|NCT01667510|Placebo Comparator|Placebo|Soft gel capsule without test material, for oral use
3133043|NCT01667497|Experimental|Fampridine SR|Fampridine SR 10mg BID
3133044|NCT01667497|Placebo Comparator|Placebo|non-drug
3133045|NCT01667484|Placebo Comparator|Placebo|treatment group #1
3133046|NCT01667484|Active Comparator|Adderall XR 5mg|treatment group #2
3133047|NCT01667484|Active Comparator|Adderal XR 10mg|treatment group #3
3133048|NCT01667471|Experimental|RoActemra/Actemra|
3133049|NCT01667458||Cohort|
3133050|NCT01667445|Experimental|epimorph|single dose administration of 150mcg epimorph
3133051|NCT01667445|Active Comparator|spinal analgesia|spinal alone
3133052|NCT01667432||Peginterferon alfa-2a|Participants received peginterferon alfa-2a (PEGASYS®) 180 µg subcutaneously in the abdomen or thigh once weekly for 12 weeks.
3133053|NCT01667419|Experimental|Vemurafenib|Participants will receive vemurafenib tablets, 960 milligrams (mg) twice daily (BID) orally in 28-day cycles for up to 52 weeks.
3133054|NCT01667419|Placebo Comparator|Placebo|Participants will receive placebo tablets matching to vemurafenib, BID orally in 28-day cycles for up to 52 weeks.
3133055|NCT01667406|Experimental|kisspeptin|kisspeptin
3133056|NCT01667393|Experimental|IDEV SUPERA Stent|Following PTA of the target lesion, the SUPERA stent will be delivered to the treated segment.
3133057|NCT01667393|Active Comparator|Percutaneous Transluminal Angioplasty|The target lesion will be treated by PTA alone.
3133058|NCT01667380||Cohort|
3133059|NCT01667367|Placebo Comparator|Placebo|
3133060|NCT01667367|Experimental|RG1662|
3133061|NCT01667354|Experimental|Intervention Clinics|Providers in intervention clinics will receive a training followed by telephone coaching and follow-up visits for six months.
3133062|NCT01667354|No Intervention|Control Clinics|Control clinics will receive all intervention materials at the completion of the study.
3133063|NCT01667341|Experimental|Low Dose GEN-003 with Matrix M-2|10µg GEN-003, 50µg Matrix M-2 Adjuvant
3133064|NCT01667341|Experimental|Mid Dose GEN-003 with Matrix M-2|30µg GEN-003, 50µg Matrix M-2 Adjuvant
3133065|NCT01667341|Experimental|High Dose GEN-003 with Matrix M-2|100µg GEN-003, 50µg Matrix M-2 Adjuvant
3133066|NCT01667341|Experimental|Low Dose GEN-003 Only|10µg GEN-003
3133067|NCT01667341|Experimental|Mid Dose GEN-003 Only|30µg GEN-003
3133068|NCT01667341|Experimental|High Dose GEN-003 Only|100µg GEN-003
3133069|NCT01667341|Placebo Comparator|Placebo|0.5 mL phosphate buffered saline
3133070|NCT01667328|Experimental|Massage therapy|This group will received presurgical massage
3133071|NCT01667328|Placebo Comparator|Control|Standard of care with no massage
3133072|NCT01667315|Experimental|Bupivacaine|Bupivacaine 0,375%
3133073|NCT01667302|Experimental|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
3133074|NCT01667289|Active Comparator|Radiotherapy alone|Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
3133075|NCT01667289|Experimental|Concurrent chemoradiation|"Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy"
3133076|NCT01667263|Experimental|All-trans retinoic acid ＆Danazol|Danazol 400mg po and ATRA 10mg bid po
3133077|NCT01667263|Active Comparator|Danazol|Danazol 400mg po
3133078|NCT01667250|Active Comparator|GammaCore Active Device|Subjects will use an Active GammaCore Device
3133079|NCT01667250|Sham Comparator|GammaCore Sham Device|Subjects who treat with the gammacore sham device in Phase 2 will receive the active gammacore treatment during phase 3 (active treatment) of this study.
3133080|NCT01667237|Experimental|Pulmonary rehabilitation|
3133081|NCT01667224|Experimental|Actiponin|Actiponin(extract of Gynostema pentaphyllum, 450mg/day) for 12weeks
3133082|NCT01667224|Placebo Comparator|Placebo|Placebo(450mg/day) for 12weeks
3133089|NCT01667159|Active Comparator|Standard Care|Adolescents and their parent(s) will receive treatment as usual through a community intensive outpatient program.
3133090|NCT01667146|Experimental|PHARLAP ventilation group|PHARLAP mechanical ventilation strategy
3133091|NCT01667146|Active Comparator|Control group ventilation|Control group mechanical ventilation strategy
3133092|NCT01667133|Experimental|Phase 1 dose escalation|Phase 1
3133093|NCT01667133|Experimental|Phase 2 expansion|Phase 2
3133094|NCT01667120|Placebo Comparator|Placebo|Postoperative surgical neonates will receive an equivalent volume of 0.9% normal saline as placebo.
3133095|NCT01667120|Experimental|Ketorolac|Postoperative ketorolac 0.5mg/kg intravenously every 8 hrs for 72hrs will be administered.
3133096|NCT01667107|Experimental|Posaconazole - CF Participants|Posaconazole 400 mg oral solution twice daily administered with Calogen® to optimize absorption for a total of 6 weeks starting within 12 hours of leaving surgery, thereafter administered in the hospital or as an outpatient; the dose could be changed to posaconazole 200 mg 4 times per day if the participant is unable to meet the conditions for optimal absorption of posaconazole.
3133097|NCT01667107|Experimental|Posaconazole - Non-CF Participants|Posaconazole 400 mg oral solution twice daily administered with Calogen® to optimize absorption for a total of 6 weeks starting within 12 hours of leaving surgery, thereafter administered in the hospital or as an outpatient; the dose could be changed to posaconazole 200 mg 4 times per day if the participant is unable to meet the conditions for optimal absorption of posaconazole.
3133098|NCT01667094|Active Comparator|Intermittent, short infusion|"Infusion over 30 minutes of either:~Cefepime 1g q8/24 OR Ceftazidime 2g q8/24 OR Meropenem 1g q8/24 OR Piperacillin-Tazobactam 4.5g q8/24 OR Ticarcillin-clavulanate 3.1g q6/24~Antibiotic chosen by treating physician"
3133099|NCT01667094|Experimental|Continuous infusion|"Continuous infusion of either:~Cefepime 1.5g over 12h, q12/24 after initial loading dose of 500mg OR Ceftazidime 3g over 12h, q12/24 after initial loading dose 1g OR Meropenem 1.5g over 12h, q12/24 after initial loading dose 500mg OR Piperacillin-tazobactam 13.5g over 24h after initial loading dose 2.25g OR Ticarcillin-clavulanate 12.4g over 24h after initial loading dose 1.55g~Antibiotic chosen by treating physician"
3133100|NCT01667081||Grazoprevir|Participants who previously received grazoprevir as study treatment on a prior study.
3133101|NCT01667068||Regional Ruhrgebiets Cohort|HIV-positive patients in the German Ruhr-Region from out-patient clinics of hospitals and HIV-physicians pratices
3133102|NCT01667055||Patients with suspected drug allergy|Patients with a history of allergic reaction to penicillin/aminopenicillin
3133103|NCT01667042||Without Interstitial lung disease (ILD)|
3133104|NCT01667042||With Interstitial lung disease (ILD)|
3133105|NCT01667029|Experimental|sulfasalazine|1 g oral twice daily for 2 weeks
3133106|NCT01667029|Placebo Comparator|placebo|oral placebo pill twice daily for two weeks.
3133107|NCT01667016||Orsiro DES|
3133108|NCT01667003||Orsiro DES|
3133109|NCT01666990|Experimental|TwHF, lifestyle counseling|Participants will receive TwHF (20mg each time, 3 times per day, for 48 weeks) from Day 0 through the Week 48 study visit.
3133110|NCT01666990|Placebo Comparator|placebo, Lifestyle|Participants will receive placebo treatment (20mg each time, three times per day for 48 weeks) from Day 0 through the Week 48 study visit.
3133111|NCT01666977|Experimental|Arm A|Arm A: AMG 386 placebo IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
3133112|NCT01666977|Experimental|Arm B|Arm B: AMG 386 15 mg/kg IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
3133113|NCT01666977|Experimental|Arm C|Arm C: AMG 386 30 mg/kg IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
3133114|NCT01666964||3 months post-injury|Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 3 months prior to enrollment, 50% mild, 50% moderate and severe
3133115|NCT01666964||6 months post-injury|Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 6 months prior to enrollment, 50% mild, 50% moderate and severe
3133116|NCT01666951|Experimental|LCP-Tacro|LCP-Tacro Tablets, once daily (Veloxis Pharmaceuticals A/S, Horsholm, DK)
3133117|NCT01666951|Active Comparator|Prograf|Prograf Capsules, twice daily (Astellas Pharma US, Deerfield, IL)
3133118|NCT01666938|Experimental|Diabetes Education Group & Telephone counseling|This step was done for four months.
3133119|NCT01666938|Active Comparator|Telephone counseling about physical activity|This step was done for four months.
3133120|NCT01666925|Experimental|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
3133121|NCT01666925|Active Comparator|Rabies vaccine|2 x 2.5IU Verorab
3133122|NCT01666912|Active Comparator|6 week postpartum contraceptive implant|randomized to receive contraceptive implant at normal 6 week postpartum visit
3133123|NCT01666912|Experimental|Immediate postpartum contraceptive implant|randomized to receive contraceptive implant prior to leaving the hospital postpartum
3133124|NCT01666899|Experimental|Skin and blood vessel procedures|All patients will be placed into Arm 1. They will undergo punch biopsies of the breast skin at the time of mastectomy and at 2, 4, 6, 8 and 12 months after completion of radiation therapy. Three more biopsies will be taken at 3, 6, and 12 months after completion of reconstruction. Patients will also undergo skin blood flow studies with a laser imaging device prior to each biopsy procedure. Ultrasound studies of the chest vessels will be performed 4 times over the course of the study- once prior to radiation and at 2, 6 and 12 months after radiation.
3133125|NCT01666886|Experimental|Mandibular Advancement Device (MAD)|Mandibular advancement during therapy with a mandibular advancement device (MAD) in 90% of maximal protrusion
3133126|NCT01666873||total knee prosthesis|Patients that undergo a total knee prosthesis.
3133127|NCT01666860||Anterior Lumbar Interbody Fusion procedure|
3133128|NCT01666847|Experimental|Cord Milking|Infant receiving cord milking intervention before umbilical cord clamped.
3133129|NCT01666847|No Intervention|Immediate Cord Clamping|Infant whose umbilical cord is immediately clamped after delivery.
3133130|NCT01666821||early and intermediate-stage AMD|Follow-up observation was implemented in whose fundus examination show lesions in the early and intermediate-stage AMD
3133253|NCT01666041|Active Comparator|fenofibrate/omega|fenofibrate/omega
3133131|NCT01666808|Experimental|FACBC PET scan|A trial group in which anti-3-[18F]FACBC PET-CT is used to guide radiotherapy decisions and radiotherapy treatment volumes.
3133132|NCT01666808|Active Comparator|Radiation therapy|A control group whose treatment decisions will be made based on conventional imaging - bone scan and abdominopelvic CT and/or MR scan.
3133133|NCT01666795||IVIG therapy in ITP|IVIG therapy in untreated adults with severe ITP
3133134|NCT01666782|Experimental|High-Dose Influenza Vaccine|
3133135|NCT01666782|Active Comparator|Standard Trivalent Influenza Vaccine|
3133136|NCT01666769|Other|Treatment Dosing|Age group: 0 - <2y, Micafungin 8 mg/kg/day IV
3133137|NCT01666769|Other|Prophylaxis dosing|Age group: 0-<2y, Micafungin 4 mg/kg/day IV
3133138|NCT01666769|Other|Standard of care Dosing|Age group: 2-17.85 y, Micafungin standard of care dosing (decided by treating physician)
3133139|NCT01666756|Experimental|Treatment (Chinese herbal formulation PHY906 and sorafenib)|Patients receive Chinese herbal formulation PHY906 PO BID on days 1-4, 8-11, 15-18, 21-24 and sorafenib tosylate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3133140|NCT01666743|Experimental|Ceftaroline fosamil|IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
3133141|NCT01666730|Experimental|Treatment (metformin hydrochloride, FOLFOX)|Patients receive metformin hydrochloride PO BID on days 1-14 and FOLFOX therapy comprising leucovorin calcium IV over 120 minutes, fluorouracil IV continuously over 46 hours, and oxaliplatin IV over 120 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3133142|NCT01666717||Healthy controls (HC)|HC
3133143|NCT01666717||Inflammatory Bowel Disease (IBD) patients|Crohn's disease (CD), Ulcerative colitis (UC) and pouchitis
3133144|NCT01666704|Experimental|Treatment A: BMS-823778 (2mg)|
3133145|NCT01666704|Experimental|Treatment B: BMS-823778 (15mg)|
3133146|NCT01666704|Placebo Comparator|Treatment C: Placebo|
3133147|NCT01666691|Placebo Comparator|Placebo|ZGN-440 sterile diluent
3133148|NCT01666691|Experimental|0.3 mg Beloranib|0.3 mg ZGN-440 for injectable suspension
3133149|NCT01666691|Experimental|0.6 mg Beloranib|0.6 mg ZGN-440 for injectable suspension
3133150|NCT01666691|Experimental|1.2 mg Beloranib|1.2 mg ZGN-440 for injectable suspension
3133151|NCT01666691|Experimental|2.4 mg Beloranib|2.4 mg ZGN-440 for injectable suspension
3133152|NCT01666691|Experimental|3.2 mg Beloranib|3.2 mg ZGN-440 for injectable suspension
3133153|NCT01666678|Experimental|Arm 1|
3133154|NCT01666678|Active Comparator|Arm 2|
3133155|NCT01666678|Active Comparator|Arm 3|
3133156|NCT01666678|Experimental|Arm 4|
3133157|NCT01666665|Active Comparator|metformin|Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
3133158|NCT01666665|Placebo Comparator|Sugar pill|sugar pill up to 3 times per day for 12 months
3133159|NCT01666652|Experimental|TDENV-PIV alum4|4 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
3133160|NCT01666652|Experimental|TDENV-PIV AS01E1|1 µg TDENV-PIV with AS01E1 adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
3133161|NCT01666652|Experimental|TDENV-PIV AS03B1|1 µg TDENV-PIV with AS03B1 adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
3133162|NCT01666652|Placebo Comparator|Placebo|Phosphate buffered saline; 0.5 mL intramuscular injection at 0 and 28 days
3133163|NCT01666652|Experimental|TDENV-PIV alum1|1 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
3133164|NCT01666639|Active Comparator|Control Group|
3133165|NCT01666639|Experimental|Intervention Group|
3133166|NCT01666626||Crohn's Inpatients|Crohn's Inpatients, with clinical small bowel obstruction All undergo ultrasound stiffness imaging (USI) of distal affected ileum.
3133167|NCT01666626||Crohn's Outpatients|Crohn's Outpatients, starting anti-TNF therapy All undergo ultrasound stiffness imaging (USI) at week 0, 6, 14
3133168|NCT01666613|Experimental|1|AZD8683 iv
3133169|NCT01666613|Experimental|2|AZD8683 oral
3133170|NCT01666613|Experimental|3|AZD8683 inhalation New Dry Powder Inhaler
3133171|NCT01666613|Experimental|4|AZD8683 inhalation Turbuhaler™
3133172|NCT01666600|Experimental|BIBF 1120 + reirradiation|2 x minimal tolerated dose BIBF 1120 per day in combination with radiotherapy (2 Gy / fraction; 36 Gy in total)
3133173|NCT01666600|Active Comparator|reirradiation alone|radiotherapy (2 Gy / fraction; 36 Gy in total)
3133174|NCT01666587|No Intervention|control|Control trial to determine the impact of the ischemic injury on vascular function without intervention
3133175|NCT01666587|Experimental|Antioxidant load|Trial to determine the impact of an antioxidant load before the ischemic injury on vascular function recovery
3133176|NCT01666587|Experimental|Prostaglandin inhibition|Trial to determine the impact of a non-selective prostaglandin inhibitor before the ischemic injury on vascular function recovery
3133177|NCT01666587|Experimental|Combined|Trial to determine the impact of an antioxidant load and prostaglandin inhibitor before the ischemic injury on vascular function recovery
3133178|NCT01666574|Experimental|Test cereal 1, Oat-based|The purpose of this arm is to determine if a breakfast containing 250 kcal of Oat based cereal will cause people to eat less at lunch.
3133179|NCT01666574|Experimental|Test Cereal 2, Oat based|The purpose of this arm is to determine if a breakfast containing 250 kcal of Oat based ready-to-eat cereal will cause people to eat less at lunch.
3133180|NCT01666561|Experimental|Breakfast Test Cereal 1, Oat based|"Test cereal 1, Oat based breakfast cereal- you will be randomly presented with a breakfast consisting of either:~Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
3133181|NCT01666561|Experimental|Breakfast Test Cereal 2, Oat-based|"Test Cereal 2, Oat-based breakfast cereal. You will be randomly presented with a breakfast consisting of either:~Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat oat brand cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
3250985|NCT00833066|Experimental|gpASIT 400|
3133182|NCT01666561|Experimental|Ready-to-eat cereal|"Ready-to-eat cereal, Oat based breakfast cereal- you will be randomly presented with a breakfast consisting of either:~one Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
3133183|NCT01666535|Other|Influenza vaccination Timing #1|Influenza vaccination administered on the same day as infliximab administration (Day 0 to 4).
3133184|NCT01666535|Other|Influenza vaccination Timing #2|Influenza vaccination administered at the mid-point between infliximab infusions (Day 21 to 28)
3133185|NCT01666522|Experimental|Vitamin D|vitamin D-oral cholecalciferol 2000 IU/day for 4 months
3133186|NCT01666522|Active Comparator|Physical activity|A 3-day/week exercise programme lasting 60 minutes each day for 4 months was instigated.
3133187|NCT01666522|Experimental|Vitamin D and Physical activity|Vitamin D -oral cholecalciferol 2000 IU/day and Physical activity-60-minute 3-day/week exercise programme
3133188|NCT01666522|Placebo Comparator|Control|The control group was provided with health education using videotaped presentations, physician talks on topics concerning bone and muscle health.
3133189|NCT01666509|Experimental|Rossoseq™|Gel, topically applied twice daily
3133190|NCT01666509|Placebo Comparator|Vehicle|Gel, topically applied twice
3133191|NCT01666496|Experimental|Experimental Video Game|Participants will play the experimental videogame for 6 weeks. The intervention will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
3133192|NCT01666496|Other|Off the Shelf Video Game|Participants will play the off the shelf videogame for 6 weeks. The intervention be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
3133193|NCT01666483|Active Comparator|micro-laparoscopy|M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
3133194|NCT01666483|Active Comparator|laparoendoscopic single site surgery|LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip.Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
3133195|NCT01666470||Drug allergy patients|Patients with a history of drug allergy in Thailand
3133196|NCT01666457||Pre-SOFFI infants|Infants discharged from the NICU prior to the implementation of the SOFFI infant driven feeding program with NICU staff.
3133197|NCT01666457||Post SOFFI infants|Subject infants discharged from the NICU at least 6 months after the implementation of the SOFFI infant driven feeding program and
3133198|NCT01666444|Experimental|PLD 40 mg/m2 plus VTX-2337|The dosing schedule will be be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus VTX-2337 on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus VTX-2337 on Day 3 only, without additional doses of VTX-2337 on Days 10 and Day 17.
3133199|NCT01666444|Active Comparator|PLD 40 mg/m2 plus placebo|The dosing schedule will be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus placebo on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus placebo on Day 3 only.
3133200|NCT01666431|Other|Lapatinib|
3133201|NCT01666418|Other|Pazopanib/Paclitaxel|
3133202|NCT01666405|Experimental|Urgent(R) PC Neuromodulation System|Urgent(R) PC Neuromodulation System
3133203|NCT01666392|Experimental|Fish oil (Omega-3 fatty acid)|2 capsules/day of ProOmega providing 650mg EPA and 450mg DHA
3133204|NCT01666392|Placebo Comparator|Soybean oil|2 capsules/day
3133205|NCT01666379|Experimental|Fentanyl|
3133206|NCT01666379|Placebo Comparator|placebo|
3133207|NCT01666366|Active Comparator|In Situ Bilateral mammary grafting|Coronary artery bypass grafting: BITA in situ (LITA to the LAD and RITA to the marginal branches into the transverse sinus)
3133208|NCT01666366|Active Comparator|Y composite Bilateral mammary grafting|Coronary artery bypass grafting: BITA Y (LITA to the LAD and RITA to the marginal branches but anastomozed proximally to the LITA in a Y configuration
3133209|NCT01666353|Experimental|Therapeutic response for solid tumors|Adult patients, with documented metastatic melanoma, RCC or NSCLC, about to initiate any line of immune checkpoint blockade therapy will receive a FDG PET scan during mid treatment to check for change in disease.
3133210|NCT01666340|Experimental|high intensity aerobic training|Exercise intervention: High intensity group performing high intensity training where they are required to raise their heart rate several times during the workout and reach perceived exhaustion of 16 on a Borg scale
3133211|NCT01666340|Other|Moderate intensity training|Exercise intervention: Moderate intensity Group of people asked to perform moderate training where they exercise at a given intensity (moderate as per Borg scale) for a certain amount of time
3133212|NCT01666327|Experimental|MT-1303|
3133213|NCT01666314|Other|Placebo + Orteronel 200 mg (Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 (28 days) followed by orteronel 200 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
3133214|NCT01666314|Experimental|Orteronel 200 mg (Japan)|Orteronel 200 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 3 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
3133254|NCT01666041|Active Comparator|fenofibrate|fenofibrate
3133255|NCT01666028|Experimental|Closed Loop Glucose control|Subject's glucose level is controlled by the automated closed loop glucose control system
3133850|NCT01661660|Experimental|Predementia / MCI patients|Subjects at predementia stage or MCI stage
3133215|NCT01666314|Other|Placebo + Orteronel 300 mg (Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 300 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 2.8 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
3133216|NCT01666314|Experimental|Orteronel 300 mg (Japan)|Orteronel 300 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 2.8 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
3133217|NCT01666314|Other|Placebo + Orteronel 200 mg (Ex-Japan)|"Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 200 mg, tablets, orally, twice daily in 28 day cycles outside of Japan (Ex-Japan) for up to 3.1 years.~Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study."
3133218|NCT01666314|Experimental|Orteronel 200 mg (Ex-Japan)|Orteronel 200 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
3133219|NCT01666314|Other|Placebo + Orteronel 400 mg (Ex-Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 400 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
3133220|NCT01666314|Experimental|Orteronel 400 mg (Ex-Japan)|Orteronel 400 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
3133221|NCT01666301|Active Comparator|C.E.R.A.|C.E.R.A. every 4 and then every 2 weeks
3133222|NCT01666301|Active Comparator|Darbepoetin|Darbepoetin alfa every 4 and then every 2 weeks
3133223|NCT01666288||IT Anaphylaxis|Blood samples will be taken from patient that develop anaphylaxis to routine outpatient allergen or venom immunotherapy.
3133224|NCT01666275||Aspirin desensitization|This group of patients has AERD (aspirin exacerbated respiratory disease) and is undergoing aspirin desensitization.
3133225|NCT01666262|Experimental|A/17/CA/2009/38 (H1N1)|
3133226|NCT01666262|Placebo Comparator|Stabilizer|
3133227|NCT01666249|Experimental|Immunoglobulin Anti-RhD|Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).
3133228|NCT01666236|Other|Triple Therapy|"The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light [wavelength of 689 nm] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections"
3133229|NCT01666223|Experimental|Colesevelam|
3133230|NCT01666223|Experimental|Chenodeoxycholic acid|
3133231|NCT01666223|Experimental|Colesevelam + chenodeoxycholic acid|
3133232|NCT01666223|Experimental|Placebo|
3133233|NCT01666210|Active Comparator|Dexamethasone Punctum Plug|Sustained and tapered release of dexamethasone from hydrogel punctum plug following insertion over 30 days
3133234|NCT01666210|Placebo Comparator|Placebo Vehicle Punctum Plug|Placebo punctum plug insertion
3133235|NCT01666197|Experimental|diclofenac potassium 25 mg tablet|
3133236|NCT01666197|Placebo Comparator|placebo|
3133237|NCT01666158|Active Comparator|Exercise|Patients in this group will follow standard MUHC protocol of nutritional counseling and supplementation as needed in order to maintain caloric and protein requirements in the preoperative period. Additionally, these patients will be given a specific physical exercise program before and after surgery by kinesiologist.
3133238|NCT01666158|No Intervention|Standard nutrition counselling|Patients in this group will follow standard MUHC protocol of nutritional counseling and supplementation as needed in order to maintain caloric and protein requirements in the preoperative period. This group will receive general instructions on exercises (breathing, ankle rotation) to be done during hospital stay by kinesiologist.
3133239|NCT01666145|Experimental|Intraoperative Imaging|Laparoscopic microwave ablation surgery utilizing the Advanced Image Guidance system for needle placement.
3133240|NCT01666132|Experimental|Intramyocardial injection of BM cells|
3133241|NCT01666132|Experimental|Intramyocardial / intracoronary injection of BM cells|
3133242|NCT01666132|Other|control|
3133243|NCT01666119|Experimental|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone)will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
3133244|NCT01666106||Subjects with cancer and ONJ|Subjects with cancer and positively adjudicated ONJ
3133245|NCT01666093|Other|revascularization group|patients will revascularized after a conservative treatment failure of at least 4 weeks
3133246|NCT01666080|Other|Reduced Intensity Conditioning|Includes patients receiving a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using reduced intensity conditioning (RIC). Patients will receive busulfan, fludarabine, total body irradiation and stem cell transplant. Keppra will be given for seizure prophylaxis.
3133247|NCT01666067|Active Comparator|placebo|placebo
3133248|NCT01666067|Active Comparator|vytorin|vytorin
3133249|NCT01666067|Active Comparator|simvastatin|simvastatin
3133250|NCT01666054|Active Comparator|Proportional Assist Ventilation (PAV)|Proportional Assist Ventilation (PAV+ on the PB840 ventilator) will be used according to a weaning algorithm. If patients develop distress despite maximum levels of support on PAV+, they will be temporarily switched to assist control mode.
3133251|NCT01666054|Active Comparator|Pressure Support Ventilation (PSV)|Pressure Support Ventilation on the PV840 ventilator will be used according to a weaning algorithm. If patients develop distress despite maximal level of support on PSV, they will be temporarily switched to assist-control mode.
3133252|NCT01666041|Placebo Comparator|placebo|placebo
3133256|NCT01666028|Active Comparator|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
3133257|NCT01666015|Experimental|Exercise (EX)|This group will perform two phases of an EX program.
3133258|NCT01666015|Active Comparator|Standard Care|This group will follow the standard care without any EX prescription.
3133259|NCT01666002|Experimental|Treatment|"st visit: Patient will come into clinic for initial laser treatment with Nd:YAG 1064 nm laser fitted with special handpiece.~nd visit: 2 weeks after initial laser treatment, patient will be seen for second treatment with Nd:YAG 1064 nm laser fitted with special handpiece."
3133260|NCT01666002|No Intervention|Placebo|"st visit: For the control group, no treatment will be given.~nd visit: 2 weeks after initial visit, patient will be seen for second visit"
3133261|NCT01665989|Experimental|Group Lifestyle program|The group lifestyle program used in the IDOLc study is adapted from the first 6 months of the Look AHEAD program and will include 19 group sessions offered over a six month period. Each of 2 groups will contain up to 15 patients with type 2 diabetes and will last 1-1.5 hours. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. The program fosters the development of knowledge and lifestyle skills to change diet and exercise habits through use of goal setting, problem solving, stimulus control and other behavioral techniques that have resulted in weight loss, weight maintenance and improved glycemic control.
3133262|NCT01665989|Active Comparator|Usual Care|A research assistant will provide the usual care group participants with brief (~15-20 minutes) counseling which reviews an educational handout emphasizing that modest weight loss (5 - 10%) via caloric restriction and gradual adoption of moderate increases in daily physical activity (equivalent to brisk walking for 30 minutes daily) is safe and effective in managing diabetes; and refer them to Nutrition Services for follow up.
3133263|NCT01665976|Experimental|A: film coated tablets, fasted condition|
3133264|NCT01665976|Experimental|B: film coated tablets, fed condition|
3133265|NCT01665976|Experimental|C: hard gelatin capsules|
3133266|NCT01665976|Experimental|D: oral suspension|
3133267|NCT01665963|Active Comparator|TopClosure(c) Treated Wound|Pressure Bandage using the TopClosure(C) System
3133268|NCT01665963|Active Comparator|Traditional Wound Closure Treatment|Pressure Bandage
3133269|NCT01665950|Experimental|Simvastatin-Simvastatin|Subjects will receive simvastatin in phase 1 (4 weeks) and phase 2 (4 weeks)
3133270|NCT01665950|Experimental|Placebo->Simvastatin|Placebo non-responders after the 1st 4 weeks will be re-randomized 1:1 to placebo or simvastatin for the next 4 weeks
3133271|NCT01665950|Placebo Comparator|Placebo-Placebo|Placebo nonresponders for the 1st 4 weeks will be re-randomized 1:1 to placebo or simvastatin for the subsequent 4 weeks
3133272|NCT01665937|Experimental|STA-9090|Patients receiving STA-9090
3133273|NCT01665924|Experimental|40-50 years old|GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 40 and 50 years old
3133274|NCT01665924|Experimental|65-74 years old|GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 65 and 74 years old
3133275|NCT01665924|Experimental|75 years and older|GLPG0634 100mg capsule once a day for 10 days in healthy subjects of 75 years and older
3133276|NCT01665911|Other|Arm 1|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
3133277|NCT01665911|Other|Arm 2|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
3133278|NCT01665911|Other|Arm 3|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
3133279|NCT01665911|Other|Arm 4|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
3133280|NCT01665911|Active Comparator|Arm 5|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
3133281|NCT01665898|Active Comparator|Cold biopsy forceps|Cold biopsy forceps for removal of colon polyps
3133282|NCT01665898|Active Comparator|Cold Snare Biopsy|Cold snare biopsy for removal of colon polyps
3133283|NCT01665885|Active Comparator|Endovascular cooling|Endovascular cooling using the cooling device ZOLL Thermogard XP with ZOLL Quattro cooling catheter
3133284|NCT01665885|Active Comparator|Surface cooling|Surface cooling using the cooling device BARD/Medivance Arctic Sun 5000 with BARD/Medivance Arctic Gel Pads
3133285|NCT01665885|No Intervention|Control group|Best medical treatment following international stroke guidelines
3133286|NCT01665872|Experimental|Cognitive-Behavioral Group Therapy|8-session Cognitive-Behavioral intervention based on Munoz et al's Mother Baby Manual, modified to meet the needs of mothers of children of all ages residing in public housing in New Haven, CT. Intervention co-facilitated by mental health clinician and a Community Mental Health Ambassador (peer).
3133287|NCT01665872|Active Comparator|Standard of care - Cognitive-Behavioral Group Therapy|8-session Cognitive-Behavioral intervention based on Munoz et al's Mother Baby Manual, modified to meet the needs of mothers of children of all ages residing in public housing in New Haven, CT. Intervention administered by mental health clinician.
3133288|NCT01665859||Danish Ventral Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
3133289|NCT01665846|Experimental|Ferumoxotyol|Brain MRI will be performed before and 48 +/- 8 hours after ferumoxytol administration.
3133290|NCT01665820||Auscultate with mechanical stethoscope|Cardiologist & Medical Resident auscultate using mechanical stethoscope
3133291|NCT01665820||Auscultate with electronic stethoscope|Cardiologist & Medical Resident auscultate using electronic stethoscope
3133292|NCT01665807|Experimental|Nurse-administered IM|Nurse-administered intramuscular influenza vaccine (Vaxigrip, 0.5 mL)
3133293|NCT01665807|Experimental|Self-administered intradermal|Self-administered intradermal influenza vaccine (Intanza 0.1 mL)
3133404|NCT01665066|Experimental|EGO 9mg|Smoke electronic cigarette EGO for a day (15 puff)
3136130|NCT01645319||Hispanic - Medication Treatment Pathway|
3133294|NCT01665807|Active Comparator|Repeat self-administration intradermal|Self-administration of intradermal influenza vaccine (Intanza 0.1 mL) by participants who self-administered an intradermal vaccine in our 2010 study
3133295|NCT01665794|Experimental|PdC Group|Patients receive carfilzomib, pomalidomide, and dexamethasone at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
3133296|NCT01665794|Experimental|PdC + Dara Group|Patients receive carfilzomib, pomalidomide, dexamethasone, and daratumumab at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
3133297|NCT01665781|Experimental|Erythropoietin|Erythropoietin 10,000U, weekly, for 4 weeks Last dose: 1 week before departure (10days before high altitude)
3133298|NCT01665781|No Intervention|Control|No erythropoietin
3133299|NCT01665768|Experimental|Everolimus and Rituximab|After your body has fully recovered from the effects of the chemotherapy, you will receive everolimus daily for one year and IV rituximab four times during that year.
3133300|NCT01665755|Experimental|Precompression|Control arm
3133301|NCT01665755|Active Comparator|Upstroke Compression|Intervention arm
3133302|NCT01665742|Active Comparator|Anti-inflammatory supplement|"8-weeks of daily supplementation with:~1 x fruit juice fortified with fish oil, and 4 x film-coated tablets containing vitamin C, alpha-tocopherol, green tea extract and lycopene~in conjunction with a weight management programme"
3133303|NCT01665742|Placebo Comparator|Placebo supplement|"8 weeks of daily supplementation with:~1 x fruit juice fortified with high-oleic sunflower oil, and 4 x film-coated placebo tablets~in conjunction with a weight management programme"
3133304|NCT01665729||artery-artery embolus|There is no hypoperfusion ( contralateral compensatory is good )
3133305|NCT01665729||Hypoperfusion|Contralateral compensatory not sufficient
3133306|NCT01665729||Hypoperfusion and embolus amotic|Hypoperfusion and embolus amotic
3133307|NCT01665703|Experimental|FDG PET/MR|Participents will undergo a gadolinium enhanced FDG PET/MR study.
3133308|NCT01665690|Experimental|Intervention period|The study will include 23 WA state local health jurisdictions (LHJ). Each LHJ will be a randomized unit and a unit in which we will measure outcomes. (LHJs are governmental administrative units that usually correspond with a county.) Because this is a stepped-wedge randomized trial, the study will have two groups (intervention and control). However, each LHJ will be in both groups depending on the time period.
3133309|NCT01665690|No Intervention|Control Period|The study will include 23 WA state local health jurisdictions (LHJ). Each LHJ will be a randomized unit and a unit in which we will measure outcomes. (LHJs are governmental administrative units that usually correspond with a county.) Because this is a stepped-wedge randomized trial, the study will have two groups (intervention and control). However, each LHJ will be in both groups depending on the time period.
3133310|NCT01665677|Experimental|Atorvastatin calcium (Lipitor)|"Atorvastatin will be administered at a dose of 40 mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning.~Patients will receive atorvastatin until +180 days or until the patient develops grade II-IV acute GVHD, extensive chronic GVHD, or any grade 3-4 toxicity related to atorvastatin."
3133311|NCT01665677|Experimental|Unrelated Donor|"Atorvastatin will be administered at a dose of 40 mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning.~Patients will receive atorvastatin until +180 days or until the patient develops grade II-IV acute GVHD, extensive chronic GVHD, or any grade 3-4 toxicity related to atorvastatin."
3133312|NCT01665664|Other|Hypocaloric feeding group|intervention - Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
3133313|NCT01665664|No Intervention|Full energy feeding group|Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 100% of REE will be provided.
3133314|NCT01665651|Placebo Comparator|kidney Yin deficiency with placebo|chronic renal insufficiency patients with kidney Yin deficiency evaluated with traditional Chinese medicine will be given Zuogui granules placebo treatment besides basic treatment.
3133315|NCT01665651|Placebo Comparator|kidney Yang deficiency with placebo|chronic renal insufficiency patients with kidney Yang deficiency evaluated with traditional Chinese medicine will be given Yougui granules placebo treatment besides basic treatment.
3133316|NCT01665651|Experimental|kidney Yin deficiency with Zuogui|chronic renal insufficiency patients with kidney Yin deficiency evaluated with traditional Chinese medicine will be given Zuogui granules treatment besides basic treatment.
3133317|NCT01665651|Experimental|kidney Yang deficiency with Yougui|chronic renal insufficiency patients with kidney Yang deficiency evaluated with traditional Chinese medicine will be given Yougui granules treatment besides basic treatment.
3133318|NCT01665638|Experimental|Treatment Sequence Group AB|
3133319|NCT01665638|Experimental|Treatment Sequence Group BA|
3133320|NCT01665625|Experimental|regional interventional chemotherapy group|
3133321|NCT01665625|No Intervention|systemic chemotherapy|
3133322|NCT01665612|Experimental|MPDS1|Contact lens care solution
3133323|NCT01665612|Active Comparator|MPDS2|Contact lens care solution
3133324|NCT01665612|Active Comparator|MPDS3|Contact lens care solution
3133325|NCT01665599|Experimental|Testosterone gel (FE 999303)|"Subjects received a starting dose of 46 mg (two actuations) of testosterone gel (2%) daily in the morning. The dose was further titrated (increased or decreased - three actuations [69 mg] or single actuation [23 mg], respectively) based on serum testosterone concentrations.~Testosterone gel was applied using an applicator, to the shoulder/upper arm in a contralateral fashion."
3133326|NCT01665586|Placebo Comparator|Group C|: Spinal anesthesia with 6mg bupivacaine and intrathecal placebo(normal saline) added
3133327|NCT01665586|Active Comparator|Group F|: Spinal anesthesia with 6mg bupivacaine and intrathecal small dose of fentanyl(20micro gram)
3133328|NCT01665573|Active Comparator|PF-04457845|Acquisition of conditioning Administration of drug Extinction of conditioning
3133329|NCT01665573|Placebo Comparator|Placebo|Placebo
3133330|NCT01665560||Smokers--Currently Smoking|Individuals that are right handed, and not claustrophobic were recruited. This same group was used for the smoking-group and refrain from smoking was evaluated by CO2 evaluation. To be classified as smokers, they had to report smoking 3-10 cigarettes daily for at least the last year and have a carbon monoxide reading of CO >10 ppm.
3133331|NCT01665560||Non-Smoker|Healthy individuals meeting the inclusion criteria who claim to not smoke. This is confirmed w/ CO testing.
3133332|NCT01665547|Active Comparator|l-carnitine|adding 3gm l-carnitine from day 1 to day 12 of induced the menstrual cycle by 50 mg clomiphene
3133333|NCT01665534|Experimental|Effect of salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks. During the low salt intake period, patients received a 10-20 mmol sodium diet + placebo tablets for two weeks.
3133334|NCT01665521|Experimental|HEART Pathway|The HEART Pathway will be used for real time clinical decision making. Physicians will receive care recommendations according to the HEART Pathway, based on HEART score and serial cardiac biomarkers. This will help physicians identify low-risk patients for early discharge with no objective cardiac testing.
3133335|NCT01665521|No Intervention|Usual Care|Conventional Care cardiac testing. Patients will undergo cardiac testing as determined by their treating physicians.
3133336|NCT01665508|Experimental|Nebivolol|Testing will be performed at baseline (SAQ questionnaire, cardiopulmonary testing, resource utilization, metabolomics and vascular testing). This will be repeated on the same group of patients after 3 months of nebivolol treatment.
3133337|NCT01665495|No Intervention|Pericardiocentesis|Pericardial fluid drained by simple echo-guided pericardiocentesis
3133338|NCT01665495|Active Comparator|Extended pericardial drainage|Extended pericardial drainage will include pericardiocentesis followed by an intermittent pericardial catheter drainage. Pericardial drainage will be kept till daily fluid return<30ml
3133339|NCT01665482|Active Comparator|Saturated fat rich diet|
3133340|NCT01665482|Active Comparator|Monounsaturated fat rich diet|
3133341|NCT01665482|Active Comparator|Carbohydrate/ Low fat diet|
3133342|NCT01665469|Placebo Comparator|Placebo|Soft gel capsule without test material
3133343|NCT01665469|Experimental|Tomato extracted lycopene|Soft gel cups for oral use
3133344|NCT01665456||Cases (women with complications)|Cases are women aged 15-49 years who delivered within 12 months prior to data collection and had experienced obstetric complication(s) that either necessitated treatment or hospitalization in order to prevent the likelihood of death of the mother.
3133345|NCT01665456||Control (women who did not experience any complications)|Controls are women aged 15-49 years who delivered within 12 months prior to data collection. They did not have or develop any of the complications which cases experienced or suffered from.Although controls did not have complications, they were individually matched on the basis of age and location. The idea was to compare how many cases were exposed versus how many controls were exposed.
3133346|NCT01665430|Experimental|Tocilizumab|Participants will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenous infusion every 4 weeks up to 104 weeks.
3133347|NCT01665417|Experimental|Experimental Icotinib|Icotinib: 125mg, oral administration, three times per day.
3133348|NCT01665417|Active Comparator|Chemotherapy Regimen 1|Chemotherapy Regimen 1：Pemetrexe 500 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
3133349|NCT01665417|Active Comparator|Chemotherapy Regimen 2|Chemotherapy Regimen 2：Docetaxel 75 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
3133350|NCT01665404|Experimental|Dosing Period 1|
3133351|NCT01665404|Experimental|Dosing Period 2|
3133352|NCT01665391|Experimental|fresolimumab 1 mg/kg total body weight|
3133353|NCT01665391|Experimental|fresolimumab 4 mg/kg total body weight|
3133354|NCT01665391|Placebo Comparator|Placebo|
3133355|NCT01665378|Experimental|Multiple micronutrient - 1|"The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive:~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
3133356|NCT01665378|Active Comparator|Iron and folic acid - 1|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.
3133357|NCT01665378|Placebo Comparator|Folic Acid - 1|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.
3133358|NCT01665378|Experimental|Multiple Micronutrient - 2|"The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive:~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
3133359|NCT01665378|Active Comparator|Iron and Folic Acid - 2|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.
3133441|NCT01664793|No Intervention|Control Group Year 1|Control sites will not receive assistance with increasing influenza vaccination in Year 1, they will follow guidelines for usual care.
3133442|NCT01664780||Patients after liver transplantation|
3133360|NCT01665378|Placebo Comparator|Folic acid - 2|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.
3133361|NCT01665365|Experimental|1. Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention (intervention group).
3133362|NCT01665365|No Intervention|2.|Primary percutaneous coronary intervention (control group).
3133363|NCT01665352|Experimental|TTP054 400 mg|
3133364|NCT01665352|Experimental|TTP054 200 mg|
3133365|NCT01665352|Experimental|TTP054 800 mg|
3133366|NCT01665352|Placebo Comparator|Placebo|
3133367|NCT01665339|Experimental|preload|subjects in preload group consumed salad, yogurt and water 15 minutes before the main meal.
3133368|NCT01665339|Experimental|control|subjects in control group consumed salad and yogurt with meal.
3133369|NCT01665326||Infantile Pompe disease|Individuals with a confirmed diagnosis of Infantile Pompe disease
3133370|NCT01665313||participants|Full-time faculty with morning and afternoon outpatient clinics on the same day in SNUH
3133371|NCT01665274|Active Comparator|XELOX adjuvant group|"D2 resection~XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 6 cycles"
3133372|NCT01665274|Experimental|XELOX neoadjuvant|"XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 3 cycles chemotherapy before operation.~D2 resection~After operation:~CR/PR: XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 3 cycles chemotherapy after operation. SD/PD:,ST(Drug: S-1，40-75mg twice daily. d1-14 q3w Drug: Paclitaxel IV infusion 135mg/m2 d1; q3w) 3 cycles chemotherapy after operation."
3133373|NCT01665248|Other|stable angina pectoris or acute coronary syndrome|
3133374|NCT01665235|Active Comparator|amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
3133375|NCT01665235|Experimental|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
3133376|NCT01665222|Experimental|Morphine Sulfate 60mg Extended-release tablets|A single oral dose of Morphine Sulfate 60mg Extended-release tablets of Ohm Laboratories Inc.
3133377|NCT01665222|Active Comparator|MS Contin® 60 mg Controlled-release tablets|A single oral dose of MS Contin® 60 mg Controlled-release tablets of Purdue Pharma L.P.
3133378|NCT01665209|Experimental|Morphine Sulfate 60mg Extended-release tablets|A single oral dose of Morphine Sulfate 60mg Extended-release tablets of Ohm Laboratories Inc.
3133379|NCT01665209|Active Comparator|MS Contin® 60 mg Controlled-release tablets|A single oral dose of MS Contin® 60 mg Controlled-release tablets of Purdue Pharma L.P.
3133380|NCT01665196|Experimental|18F-FDG PET/CT scanning|18F-FDG PET/CT scanning will be performed in patients with IgG4RD to determine the pictorial characteristics and measure the standardized uptake values (SUVs) of the lesions and their response to treatment.
3133381|NCT01665183|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethylene glycol
3133382|NCT01665170|Placebo Comparator|Placebo|Placebo arm
3133383|NCT01665170|Active Comparator|Verum|Verum arm - Pascoflair 425mg
3133384|NCT01665157|Experimental|low-residue diet package (Enimaclin®)|Low-residue diet package with normal amount 2L PEG-ELS
3133385|NCT01665157|Placebo Comparator|Self-controlled diet|Self-controlled diet with normal amount of 2L PEG-ELS
3133386|NCT01665157|Experimental|Low-residue diet (Enimaclin®) package|Low-residue diet package with low volume 1.5L PEG-ELS
3133387|NCT01665144|Experimental|BAF312|1090 patients will be randomized to receive BAF312 during the trial for a maximum of approximately 3 years (Core Part). Patients who meet all inclusion and none of the exclusion criteria will be treated with BAF312 daily. Following the Core Part, eligible patients enter the Extension Part during which all receive open-label BAF312 for a maximum of 84 additional months.
3133388|NCT01665144|Placebo Comparator|Placebo|Matching Placebo administered orally during the Core Part of the trial. Following the Core Part, eligible patients enter the Extension Part during which all receive open-label BAF312 for a maximum of 84 additional months.
3133389|NCT01665131|Experimental|Subcutaneous ICD group|
3133390|NCT01665118|Experimental|Treated Thigh|Trusculpt (Radio Frequency) Device
3133391|NCT01665118|No Intervention|Untreated Contra-lateral Thigh|To be used as the self control in this split body study.
3133392|NCT01665105|Experimental|Zusanli Group|electroacupuncture at both Zusanli on the leg, and record simultaneously the pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
3133393|NCT01665105|Active Comparator|Yanlingquan Group|electroacupuncture at both Yanglingquan on the leg, and record simultaneously the pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
3133394|NCT01665105|Sham Comparator|Sham Group|acupuncture without electrical stimulation at non-acupoint on the leg, and record simultaneously pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
3133395|NCT01665092|Placebo Comparator|Control|Normal saline
3133396|NCT01665092|Experimental|Carnitine Low|Levo-Carnitine 6g
3133397|NCT01665092|Experimental|Carnitine Medium|Levo-Carnitine 12 g
3133398|NCT01665092|Experimental|Carnitine High|Levo-Carnitine 18 g
3133399|NCT01665079|Experimental|Propofol|14 obese patients(IMC>35 kg m-2) scheduled for laparoscopic bariatric surgery
3133400|NCT01665066|Active Comparator|Own Brand cigarette|Smoke Own Brand cigarette, 15 puff of cigarette.
3133401|NCT01665066|Experimental|One High 2,4% nicotine|Smoke electronic cigarette One High 2,4% nicotine for a day, 15 puff of e-cigarette.
3133402|NCT01665066|Experimental|Original 7,4 mg nicotine|Smoke electronic cigarette Original 7,4 mg nicotine for a day. 15 puff of e-cigarette.
3133403|NCT01665066|Placebo Comparator|Nicotine Free|Smoke electronic cigarette nicotine free (15 puff)
3136131|NCT01645319||Hispanic - Laser Surgery Treatment Pathway|
3133405|NCT01665053|Active Comparator|Promus Element Plus|PROMUS Element Plus is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
3133406|NCT01665053|Experimental|SYNERGY|SYNERGY is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).
3133407|NCT01665040|Experimental|Neurostimulation for chronic pain|Neurostimulation (spinal cord stimulation with or without peripheral nerve stimulation of the trunk) for chronic intractable pain of the trunk and/or limbs.
3133408|NCT01665027|Experimental|vacuum|Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head. He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers).
3133409|NCT01665027|Experimental|routine manual maneuvers for fetal head extraction|"Procedure/Surgery:~fetal head techniques like fundal pushing, pulling technique or reverse breech extraction"
3133410|NCT01665014|Experimental|Total marrow irradiation|Double autologous hematopoietic stem cell transplantation using TMI and HD-Mel
3133411|NCT01665001|Experimental|Multiagent induction-consolidation|Induction, consolidation, HSCT, maintenance for adults with newly diagnosed precursor lymphoid neoplasms
3133412|NCT01664988|Experimental|muscular relaxation|muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
3133413|NCT01664988|Experimental|breath control|include deep diaphragmatic breathing and decrease breath rate to 6-10/min
3133414|NCT01664988|Other|control|received routine care of clinic or health center and control their blood pressure weekly and use drugs if necessary
3133415|NCT01664975|Experimental|GDPT regimen|GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen
3133416|NCT01664975|Experimental|CHOP regimen|CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
3133417|NCT01664962||Patients|Women with severe Vulvodynia
3133418|NCT01664962||Healthy controls|Women without vulvodynia
3133419|NCT01664949|Experimental|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
3133420|NCT01664949|Active Comparator|OPTIVE™|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
3133421|NCT01664936||pts receiving a PET/CT scan with Metastatic LNs|This study seeks to optically image the Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I in a cohort of patients with primary tumor sites and from pathologic lymph nodes after routine 18F-FDG PET 31I radiotherapy and/or investigational study scans. We will include a subset of patients with normal lymph nodes during screening. This subset of patients will be imaged as a negative control for this study.
3133422|NCT01664923|Experimental|Enzalutamide|Enzalutamide 160 mg/day orally
3133423|NCT01664923|Active Comparator|Bicalutamide|50 mg/day orally
3133424|NCT01664910|Experimental|Inotuzumab Ozogamicin (CMC-544) + Chemotherapy|D-13, CMC-544 infused intravenously (IV) on Day -13. Starting dose per cohort: 0.6,1.2 or 1.8 mg/m2. Dose based on actual body weight. Fludarabine 30 mg/m2 IV followed by Bendamustine 130 mg/m2 IV on Days -5 to -3. Patients with CD20+ disease also receive Rituximab IV at 375 mg/m2 on Days -6, +1 and +8. Allogeneic stem cell transplantation on Day 0. Thymoglobulin 1 mg/kg administrated IV on Days -2 and -1 to patients receiving a matched unrelated donor (MUD). Tacrolimus on Day -2 administered at starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no GVHD is present.
3133425|NCT01664897|Experimental|Erlotinib|"Patients receive therapy with erlotinib administered orally as a continuous daily dose in 28-day cycles. Patients will continue therapy until clinically significant progression of the disease or unacceptable toxicity.~Erlotinib starting dose 150 mg by mouth, once daily in 28-day cycles."
3133426|NCT01664884||Bipolar Disorder Patients|Bipolar Disorder Patients, with age between 18 to 40 years old, at euthymic phase.
3133427|NCT01664884||Schizophrenia Patients|Schizophrenia Patients, with age between 18 to 40 years old, with minimum or none positive symptoms.
3133428|NCT01664871|Experimental|Levels of SIlver and Fluoride in Plasma|
3133429|NCT01664858|Active Comparator|3T CMR-guided management|Patient to be managed according to the results of 3T CMR imaging
3133430|NCT01664858|Active Comparator|SPECT-guided management|Patients to be managed according to the results of SPECT
3133431|NCT01664858|Active Comparator|NICE-guidelines based management|"Patients will be receive NICE-guidelines based management and will receive the imaging strategy specified by NICE according to their pre-test likelihood of having CHD.~10-29% - CT calcium score +/- CT coronary angiography; 30-60% - SPECT; 61-90% - X-Ray coronary angiography"
3133432|NCT01664845|Active Comparator|metformin, pegylated-IFN, ribavirin|metformin,pegylated-IFN and ribavirin
3133433|NCT01664845|Placebo Comparator|Pegylated-IFN and ribavirin|pegylated -IFN and ribavirin
3133434|NCT01664832|Experimental|S-nIMV|nIMV synchronized using abdominal pressure capsule sensor device
3133435|NCT01664832|Placebo Comparator|nIMV|non-synchronized nasal intermittent mandatory ventilation group
3133436|NCT01664819|Active Comparator|Antioxidant supplementation|Randomized to receive antioxidant supplementation (vitamin C, 500 mg; beta carotene, 15 mg; and alpha-tocopherol, 400 IU) three times per week for five years.
3133437|NCT01664819|Placebo Comparator|Placebo|Randomized to receive placebo three times per week for five years
3133438|NCT01664806|No Intervention|Coag mode 30 Watts Power|Elective laparoscopic cholecystectomy will be performed with 30 Watts power coag mode which is current standard of care.
3133439|NCT01664806|Experimental|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform Elective laparoscopic cholecystectomy. which is the experimental arm of the study's mode.
3133440|NCT01664793|Experimental|Intervention Group Year 1|The 4 Pillars Immunization Toolkit along with donated vaccines for early season vaccination, staff education and support.
3133443|NCT01664767|Experimental|Thermal water inhalation|Patients will perform 12 days of sulfur thermal water inhalation
3133444|NCT01664767|Placebo Comparator|Isotonic saline inhalation|Patients will perform 12 days of isotonic saline inhalation
3133445|NCT01664754|Experimental|Treatment (exemestane, pemetrexed disodium, and carboplatin)|Patients receive exemestane PO QD on days 1-28 and pemetrexed disodium IV over 15 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3133446|NCT01664741|Active Comparator|Nicotine patch - transdermal|21 mg nicotine patch
3133447|NCT01664741|Placebo Comparator|Placebo NRT|Matching placebo patch
3133448|NCT01664741|No Intervention|Healthy non-smoker comparison|Demographically-matched women and men who have never smoked
3133449|NCT01664728|Experimental|Abiraterone acetate|
3133450|NCT01664715|Active Comparator|150 Minutes per Week|Performs 150 minutes of physical activity per week.
3133451|NCT01664715|Active Comparator|225 Minutes per Week|Performs 225 minutes of physical activity per week.
3133452|NCT01664715|Active Comparator|300 Minutes per Week|Performs 300 minutes of physical activity per week.
3133453|NCT01664702|Experimental|Recommended dairy diet|Recommended servings of dairy products per day
3133454|NCT01664702|Experimental|Low dairy diet|One or fewer dairy servings per day
3133455|NCT01664689|Active Comparator|DiscoVisc|microcoaxial phacoemulsification performed with discovisc
3133456|NCT01664689|Active Comparator|Healon 5|microcoaxial phacoemulsification using healon 5
3133457|NCT01664689|Active Comparator|Celoftal|microcoaxial phacoemulsification using celoftal
3133458|NCT01664676|Experimental|Liraglutide|1.2 mg liraglutide sc. (single-dose)
3133459|NCT01664676|Placebo Comparator|Placebo-liraglutide|Placebo liraglutide sc. (single-dose)
3133460|NCT01664663|Active Comparator|Arm A:Standard radiochemotherapy|Radiotherapy with 2 Gy per fractions 5 fractions a week to 68 Gy to the planning target volume. Three courses of cisplatin 75 mg/m2 day 1and vinorelbine 25 mg/m2 day 1+8. Two courses concomitant with radiation.
3133461|NCT01664663|Experimental|Arm B Escalated radiochemotherapy|Radiotherapy with 2 Gy per fraction 5 or 6 times a week to 68-84 Gy to the planning target volume due to normal tissue tolerance constraints. Dose to lung tissue, esophagus and spinal cord will be considered. Three courses of cisplatin 75 mg/m2 day 1 and vinorelbine 25 mg/m2 day 1+8 will be given, two courses concomitant with radiation.
3133462|NCT01664650|Placebo Comparator|Lifestyle counseling|Placebo tablets. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
3133463|NCT01664650|Experimental|Genistein|Genistein 54 mg/day in 2 tablets for 12 months. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
3133464|NCT01664637|Experimental|TZP-102 three times a day|10 mg TZP-102 will be taken 30 minutes prior to each main meal for a total of three daily doses.
3133465|NCT01664637|Placebo Comparator|Placebo three times a day|Placebo will be taken 30 minutes prior to each main meal for a total of three daily doses.
3133466|NCT01664624|Experimental|Roflumilast + alogliptin|Roflumilast 500 μg, tablets, orally and alogliptin 25 mg, tablets, orally, once a day for 11 days.
3133467|NCT01664624|Experimental|Alogliptin alone|Placebo to roflumilast, tablets, orally and alogliptin, 25 mg, tablets, orally, once a day for 11 days.
3133468|NCT01664624|Experimental|Roflumilast alone|Roflumilast 500 μg, tablets, orally and placebo to alogliptin, tablets, orally, once a day, for 11 days.
3133469|NCT01664624|Active Comparator|Exenatide|Exenatide 5 μg subcutaneous injection twice a day for 11 days.
3133470|NCT01664611|Experimental|Treatment arm|Participants in this arm will receive remote ischaemic conditioning on a daily basis for 4 weeks post MI
3133471|NCT01664611|Sham Comparator|Sham arm|Participants in this arm will receive sham ischaemic conditioning on a daily basis for 4 weeks post MI
3133472|NCT01664598|Experimental|RoActemra/Actemra|
3133473|NCT01664585|Experimental|Training group|"The rationale and means for the exercise program are to~Motivate and teach participants for postural and motor control and strengthening exercises~Monitor and motivate to continue exercise training, and to increase their physical activity~Training is organised six times as a 60-min session during six months: two individually supervised sessions, and four following training sessions will be accomplished in groups of 10 participants guided by an experienced physical therapist. Three weekly similar home training sessions are recommended for participants. Information on amount of exercise sessions per week and repetitions of each exercise will be collected via exercise diary. To perform home training, a DVD and/or booklet will be provided to participants in the training group."
3133474|NCT01664585|Sham Comparator|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0), and the participants in this group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
3133475|NCT01664572||Healthy subjects|
3133476|NCT01664559|Placebo Comparator|Placebo with 1cc normal saline IM|If the patient is randomized to the placebo arm, they will receive 1cc of normal saline via the intramuscular route.
3133477|NCT01664559|Experimental|Toradol, 30mg in 1cc IM|If the patient is randomized to the toradol (ketorolac) arm, they will receive 30mg of toradol in a 1cc volume via the intramuscular route.
3133478|NCT01664546||Molecular blastocyst karyotype|Trophectoderm biopsy for genetic study by aCGH
3133479|NCT01664533||Erlotinib|Selection of the dose of erlotinib most suitable for each participant was left to the discretion of the physician, guided by the recommendation in the Summary of Product Characteristics. The recommended daily oral dose of erlotinib is 150 mg.
3133480|NCT01664520|Experimental|Dexmedetomine infusion|
3133481|NCT01664507|Active Comparator|conventional dose epinephrine|L-epinephrine (1:1000) 0.5 mL/kg (maximum 5mL) + normal saline : total 5mL
3133482|NCT01664507|Experimental|low dose epinephrine|L-epinephrine (1:1000) 0.1 mL/kg (maximum 1mL) + normal saline : total 5mL
3133483|NCT01664494||Capecitabine|Participants will receive capecitabine according to the label text as monotherapy (1250 mg/m^2 twice daily) or combination therapy (800 to 1000 mg/m^2 or 1250 mg/m^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
3133484|NCT01664260|Experimental|N-acetylcysteine + Escitalopram|The subjects with posttraumatic stress disorder, treated with N-acetylcysteine in addition to escitalopram
3133485|NCT01664260|Placebo Comparator|Placebo + Escitalopram|The subjects with posttraumatic stress disorder, treated with placebo in addition to escitalopram
3133486|NCT01664247|Experimental|IDeg + Lira|
3133487|NCT01664247|Experimental|Placebo + Lira|
3133488|NCT01664234|Experimental|laryngoscopy with simultaneous insufflation of oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
3133489|NCT01664234|Placebo Comparator|laryngoscopy without simultaneous oxygen insufflation|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
3133490|NCT01664221|Experimental|Eritromax|Eritromax (Epoetin alfa) intravenous administration, dose: 100 IU/kg
3133491|NCT01664221|Active Comparator|Eprex|Eprex (Epoetin alfa) intravenous administration: 100 IU/kg
3133492|NCT01664195|Other|Group A|Epoetin alfa Test drug in the first period and comparator drug in the second period.
3133493|NCT01664195|Other|Group B|Epoetin alfa Comparator Drug in the first period and test drug in the second period
3133494|NCT01664182|Experimental|Arm I (trebananib monotherapy)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3133495|NCT01664182|Experimental|Arm II (trebananib and anti-VEGF therapy)|Patients receive trebananib as in Arm I and either bevacizumab IV over 30-90 minutes on days 1, 15, and 29; pazopanib hydrochloride PO QD on days 1-42; sorafenib tosylate PO BID on days 1-42; or sunitinib malate PO QD on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3133496|NCT01664169||Single group|"The samples required for this study are stored in the CALGB Pathology Coordinating Office at The Ohio State University from patients enrolled on protocol CALGB-80303. No additional samples are required from patients.~The following markers are analyzed in EDTA plasma samples using the IMPACT a Roche proprietary multiplex ELISA platform: VEGF-A, VEGF-C, VEGF-R1, VEGF-R2, E-selectin, VEGF-R3, IL-8, bFGF, PDGF-C, ICAM-1, and PlGF."
3133497|NCT01664156|Experimental|Korean red ginseng|The patients will receive Korean red ginseng(Korean Red Ginseng Powder Capsule®; Korea Ginseng Corporation, Daejeon, Korea). Patients will be requested to take 6 capsules 2 times a day (1h after breakfast and dinner).
3133498|NCT01664156|Placebo Comparator|placebo|Placebo Korean red ginseng capsule contain cornstarch powder with the same color and taste as Korean red ginseng. Patients will be requested to take 6 capsules 2 times a day (1h after breakfast and dinner).
3133499|NCT01664143|Placebo Comparator|Placebo|
3133500|NCT01664143|Experimental|RO5508887|
3133501|NCT01664130|Experimental|Treatment (SBRT)|Patients undergo 5 fractions of prostate stereotactic body radiation therapy over 10-20 days with at least 40 hours between each fraction in the absence of disease progression or unacceptable toxicity.
3133502|NCT01664117||bDMARD Monotherapy|Patients with moderate to severe rheumatoid arthritis (RA) will be treated with bDMARD (biologic disease-modifying antirheumatic drug) monotherapy under routine clinical practice conditions at rheumatology clinics
3133503|NCT01664104||RA Participants|Participants with moderate or severe RA who are under tocilizumab treatment in routine clinical practice (in accordance with the local label) will be observed for 6 months from the start of treatment.
3133504|NCT01664078|Experimental|InCraft® - AAA stent graft system|Intervention: Endovascular AAA repair using the InCraft device
3133505|NCT01664065|Experimental|AZ drug: A|200 mg Ceftaroline fosamil 1h infusion
3133506|NCT01664065|Experimental|AZ drug: B|600 mg Ceftaroline fosamil 1h infusion
3133507|NCT01664052|Experimental|ESS505-A (Essure, BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert with minimal polyethylene terephthalate (PET) fibers (investigational device model ESS505-A) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement.
3133508|NCT01664052|Experimental|ESS 305/ESS 505 (Essure, BAY1454032/Essure, BAY1454033)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) and contralateral placement of the current commercially approved Essure device, model ESS305 followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
3133509|NCT01664039|Experimental|TRAVATAN|Travoprost 0.004% ophthalmic solution with Polyquad®, 1 drop to the study eye(s), once a day in the evening, for 6 months
3133510|NCT01664039|Active Comparator|LUMIGAN|Bimatoprost 0.01% ophthalmic solution with BAK, 1 drop to the study eye(s), once a day in the evening, for 6 months
3133511|NCT01664026|No Intervention|Control|Subjects assigned to the usual care group will receive general lifestyle recommendations as per their country standards of care.
3133512|NCT01664026|Experimental|Web|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
3133513|NCT01664026|Experimental|Web+|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
3133514|NCT01664013|Experimental|Neuronox|Neuronox® is a botulinum toxin type A (BoNT/A) product developed by Medytox Inc. (Medytox) of Korea. Neuronox® was first approved by the Korean Food and Drug Administration in 2006, and by Thai Food and Drug Administration in 2008.
3133516|NCT01663987|Active Comparator|18 mcg tiotropium|Patient to receive one tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
3133517|NCT01663987|Placebo Comparator|Placebo|Patient to receive one placebo capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler
3133518|NCT01663974||Bipolar disorder patients|
3133519|NCT01663961|Experimental|YM178 OCAS + digoxin|
3133520|NCT01663948||Patients with Plastic bronchitis|
3133521|NCT01663935|Other|Levodopa/carbidopa 4mg/kg/day|Treatment drug taken orally three times daily
3133522|NCT01663922|Experimental|St John's Wort, then Boceprevir|D 1-14 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 22-35 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 31-35 Boceprevir 800mg tds D 52-56 Boceprevir 800mg tds
3133523|NCT01663922|Experimental|Boceprevir, then St John's Wort|D 10-14 Boceprevir 800mg tds D 22-35 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 31-35 Boceprevir 800mg tds D 43-56 St. John's Wort 2 x 300mg (Ucalm(r)) QD
3133524|NCT01663909|No Intervention|Standard care|
3133525|NCT01663909|Experimental|Guided imagery|
3133526|NCT01663896||Single or multi vessel disease|
3133527|NCT01663883|Experimental|Healthy subjects|
3133528|NCT01663870||Breast Cancer Survivors|Patients in the LBJ General Hospital Cancer Survivorship Clinic.
3133529|NCT01663870||Clinic Stakeholders|Survivorship clinic stakeholders include clinic nurses, physicians, case managers, oncology patient navigators currently working with those in active treatment, information technology support professionals from the Harris County Hospital District (HCHD).
3133530|NCT01663857|Experimental|Phase 1b 200 mg LY2228820|"Induction: Cycles 1-6 (21 day cycles)- 200 milligrams (mg) LY2228820 administered orally every 12 hours on days 1-10. Gemcitabine 1000 milligrams per square meter (mg/m^2) administered intravenously (IV) over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (mg-min/ml) administered IV over 30 minutes on day 3.~Maintenance: Cycles 7+ (28 day cycles)- 300 mg LY2228820 administered orally every 12 hours on days 1-14."
3133531|NCT01663857|Experimental|Phase 1b 300 mg LY2228820|"Induction: Cycles 1-6 (21 day cycles)- 300 mg LY2228820 administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose AUC 4 administered IV over 30 minutes on day 3.~Maintenance: Cycles 7+ (28 day cycles)- 300 mg LY2228820 administered orally every 12 hours on days 1-14."
3133532|NCT01663857|Experimental|Phase 2 dose LY2228820|"Induction: Cycles 1-6 (21 day cycles)- Recommended Phase 2 dose of LY2228820 administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose AUC 4 administered IV over 30 minutes on day 3.~Maintenance: Cycles 7+ (28 day cycles)- 300 mg LY2228820 administered orally every 12 hours on days 1-14."
3133533|NCT01663857|Placebo Comparator|Phase 2 Placebo|"Induction: Cycles 1-6 (21 day cycles)- Placebo administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose AUC 4 administered IV over 30 minutes on day 3.~Maintenance: Cycle 7+ (28 day cycles)- Placebo administered orally on days 1-14 to maintain blind."
3133534|NCT01663844|Experimental|(Study 1) ICBT for insomnia and depression|
3133535|NCT01663844|Active Comparator|(Study 1) ICBT for depr. plus placebo insomnia intervention|
3133536|NCT01663844|Experimental|(Study 2) ICBT for insomnia with added support|
3133537|NCT01663844|Active Comparator|(Study 2) ICBT for insomnia with regular level of support|
3133538|NCT01663831|Experimental|Topical Repellent & LLIN|
3133539|NCT01663831|No Intervention|Long Lasting Insecticidal Nets|"Brand Name LLIN: Olyset Net~Active ingredient: permethrin"
3133540|NCT01663818|Experimental|Treatment group|Treatment with Tack-IT Endovascular Staple
3133541|NCT01663805|Active Comparator|Everolimus|SCD/ECD: BXB (2x20mg, D1 and D4) + EVL (3.0 -8.0ng/ml) + MYF (1440mg/d)+ Prednisone
3133542|NCT01663805|No Intervention|mycophenolate sodium|SCD/ECD: BXB (2x20mg, D1 and D4) + TAC + MYF (1440mg/d)+ Prednisone
3133543|NCT01663792|Placebo Comparator|Placebo|5 g/d placebo (maltodextrin)in 10 500-mg capsules for 1 month
3133544|NCT01663792|Experimental|Seaweed|Seaweed (Undaria pinnatifida) given orally in ten 500-mg capsules for 1 month
3133545|NCT01663792|Placebo Comparator|Placebo2|5 g/d placebo in 10 500-mg capsules for one month
3133546|NCT01663779|Experimental|Ultrasound radial artery catheter|Ultrasound guided radial artery catheterization.
3133547|NCT01663779|Active Comparator|Palpation based artery catheterization|Blind insertion of radial artery catheterization
3133548|NCT01663766|Experimental|Milatuzumab|Milatuzumab will be added to the standard GVHD reduced intensity consitioning and prophylaxis regimen of fludarabine, busulfan, tacrolimus and low-dose methotrexate.
3133549|NCT01663753|Experimental|18F-FDG-PET|The 18F-FDG-PET will be performed 8 weeks following completion of brachytherapy (date of inclusion)
3133550|NCT01663740|Experimental|Cohort A: Partcipants who Received Valganciclovir|Participants with donor positive (D+)/recipient negative (R-) cytomegalovirus (CMV) serology, who receive valganciclovir prophylaxis according to the local prescribing information, will be observed for spermatogenesis up to 52 weeks post-transplant.
3133551|NCT01663740|No Intervention|Cohort B: Untreated Participants|Participants with donor negative (D-)/R- CMV serology, who do not receive prophylaxis, will be observed for spermatogenesis up to 52 weeks post-transplant.
3133552|NCT01663727|Experimental|A|Paclitaxel + Bevacizumab [Avastin]
3133553|NCT01663727|Experimental|B|Paclitaxel + Placebo
3133554|NCT01663714|Experimental|open-label, single arm|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. CVP will be repeated every 21 days for a total of six cycles. tositumomab and iodine I 131 tositumomab will begin within 56 days following the first day of the sixth cycle of CVP. Patient will undergo two dosing phase for the tositumomab and iodine I 131 tositumomab therapy.
3133555|NCT01663701|Active Comparator|Usual care|Patients are managed according to admitting doctors' orders. Blood cultures are drawn in all patients. Antibiotics are specified by the admitting doctors.
3133556|NCT01663701|Experimental|Simplified Severe Sepsis Protocol|This protocol consists of an early aggressive fluid strategy, early blood cultures and antibiotics, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings. Antibiotics are specified by the admitting doctors.
3133557|NCT01663688||Normative Data Collection|
3133559|NCT01663662|Active Comparator|Tolvaptan Arm|"Tolvaptan 30 mg qd x 3 days and Low Dose Loop Continuous Infusion - Initial Dosing:~Furosemide - 10 mg/hr Bumentanide - 0.25 mg/hr Torsemide - 5 mg/hr"
3133560|NCT01663662|Placebo Comparator|Placebo|Placebo x 3 days and standard of care continuous infusion diuretic
3133561|NCT01663649|Experimental|Deprexis|Deprexis (Web-based intervention deprexis consists of ten online modules (plus one introductory and one summary module) representing different psychotherapeutic strategies with a strong focus on evidence-based cognitive-behavioral techniques (e.g. interpersonal skills). Each module lasts approximately 10-60 minutes (e.g. depending on the user´s reading speed). Modules are sequential and organized as simulated dialogues. Each module refers and builds upon previous one. The program is delivered at no cost to participants.)
3133562|NCT01663649|Active Comparator|Wait-list|Wait-list group (Subjects receive access to deprexis after six months)
3133563|NCT01663636||SMS Vaccine|Mothers will be sent an SMS message reminding them to come for their scheduled vaccines 1 week prior to the date of 2nd and 3rd doses
3133564|NCT01663636||SMS BF|Mothers will serve as a control, and will be sent a message to remind them to continue breastfeeding
3133565|NCT01663623|Placebo Comparator|Placebo plus azathioprine|Placebo IV plus oral azathioprine 2 mg/kg/day; placebo administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to receive treatment with belimumab in a 6-month open-label extension phase. Placebo patients who opt to participate in the extension will receive belimumab 10 mg/kg IV every 28 days plus oral azathioprine 2 mg/kg/day for an additional 6 months.
3133566|NCT01663623|Experimental|Belimumab 10 mg/kg plus azathioprine|Belimumab 10 mg/kg IV plus oral azathioprine 2 mg/kg/day; belimumab administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to continue treatment with belimumab in a 6-month open-label extension phase. Patients who opt to participate in the extension will continue to receive belimumab 10 mg/kg IV every 28 plus oral azathioprine 2 mg/kg/day days for an additional 6 months.
3133567|NCT01663610|Experimental|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
3133568|NCT01663610|No Intervention|Wait List Control (CONT)|Weekly registrations only. After 6 weeks the Internet-based course without therapist support well be offered (SelfSMART)
3133569|NCT01663597||Cohort 1|40 subjects with high grarde myopia ranging from -10 diopters to -4.01 diopters
3133570|NCT01663597||Cohort 2|40 subjects with moderate myopia ranging from -4 diopters to -1.01 diopter
3133571|NCT01663597||Cohort 3|40 subjects with emmetropia, -1 diopter to +1 diopter
3133572|NCT01663597||Cohort 4|40 subjects with hyperopia, +1.01 diopter and more
3133573|NCT01663558|Active Comparator|imiquimod|"i. Each subject will use an imiquimod anal suppository three times weekly (overnight on Monday, Wednesday, Friday) for 12 weeks.~ii. Each subject will be asked to abstain from receptive anal sex during therapy period (12 weeks).~iii. If local imiquimod adverse effects are severe, a 7-day period off of treatment will be permitted.~iv. During 12 week therapy period, each subject will be evaluated 2, 4, 8, and 12 weeks after starting therapy. At each visit, subject will complete a therapy questionnaire and undergo anal Pap, HRA with biopsies as indicated, and anal HPV testing.~v. After therapy completed (12 weeks), subject will enter 12 month observation period."
3133574|NCT01663558|Active Comparator|ablative|"i. Subject will be referred to colorectal surgeon, will complete a therapy questionnaire, and will be treated in accordance with treatment algorithm which is already in use.~ii. Subject will be asked to abstain from receptive anal sex for 12 weeks after ablative therapy.~iii. After therapy, subject will enter 12 month observation period."
3133575|NCT01663558|No Intervention|Observation|"i. Given lack of accepted guidelines and outcome data on dysplasia management, the study PI will thoroughly discuss risks and benefits of observation/monitoring and treatment of dysplasia.~ii. If treatment is chosen, subject will be randomized to 1) ablative group, or 2) imiquimod group and begin therapy. Observation subjects will continue observation visits (observation questionnaire, anal Pap, HRA with biopsies as indicated, and anal HPV testing) every 3 months for 12 months (4 additional study visits)."
3133576|NCT01663532|Experimental|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg, with allowed decrease to 300 mg for safety and return to 400 mg for efficacy if needed, every four weeks for 12 weeks
3133577|NCT01663532|Placebo Comparator|Placebo|Matching placebo
3133578|NCT01663519|Experimental|Prefabricated insoles|Prefabricated insoles with support in medial arch and metatarsal pad. A 2 mm top layer of cushioned material.
3133579|NCT01663519|Experimental|Custom made insoles 35 shore|Custom made insoles formed over an individual cast positive. 35 shore of hardness in material Ethyl Vinyl Acetate
3133580|NCT01663519|Experimental|55 shore Custom made insoles|Custom made insoles formed over an individual cast positive. 55 shore of hardness in material Ethyl Vinyl Acetate
3133581|NCT01663506||Cohort|
3133582|NCT01663493|Other|Fine needle aspiration needle|standard Beacon FNA needle
3133583|NCT01663493|Other|fine needle biopsy needle|SharkCore fine needle biopsy needle
3133584|NCT01663467|Active Comparator|Ginkgo biloba only|control group Ginexin-F 80mg tablet will be given twice a day for 6 months.
3133585|NCT01663467|Experimental|Ginkgo biloba + modified TRT|"experimental group modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.~Ginexin-F 80mg tablet will be given twice a day for 6 months."
3133586|NCT01663454|Experimental|Cogmed Robomemo working memory training|Participants will complete 25 sessions (5 weeks) of Cogmed Robomemo (Pearson assessment) working memory training
3133587|NCT01663441|Experimental|A1|"Patients in this treatment group will receive NL201(5μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201(7.5μg/kg).~Only for Dose-finding in Phase Ⅲa."
3133588|NCT01663441|Experimental|A2|"Patients in this treatment group will receive NL201(7.5μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201(5μg/kg).~Only for Dose-finding in Phase Ⅲa."
3133589|NCT01663441|Active Comparator|A|"Patients in this treatment group will receive NL201（optimal dosing dose）in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive rhIL-11(25μg/kg).~Only in Phase Ⅲb."
3133841|NCT01661699||Sleep apnea|Those suspected of sleep apnea and scheduled for polysomnography and treated with CPAP therapy.
3133590|NCT01663441|Active Comparator|B|"Patients in this treatment group will receive rhIL-11(25μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201（optimal dosing dose）.~Only in Phase Ⅲb."
3133591|NCT01663428|Experimental|Sup-ER Splint|Experimental group that will receive Sup-ER splint.
3133592|NCT01663428|Active Comparator|Control (Currently accepted treatment)|Control group that will receive the currently accepted treatment.
3133593|NCT01663415|Experimental|Enzalutamide|
3133594|NCT01663402|Experimental|Alirocumab|"Injection through subcutaneous (SC) administration~Alirocumab is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)"
3133595|NCT01663402|Placebo Comparator|Placebo|Injection through subcutaneous (SC) administration
3133596|NCT01663389|Experimental|GSK1322322 1000 mg IV|On Day 1 of Period 1, after an overnight fast, subjects will receive GSK1322322 1000 mg IV single dose (containing approximately 45.5 microcurie [μCi] radioactive 14C-GSK1322322) for intravenous infusion over 60 minutes.
3133597|NCT01663389|Experimental|GSK1322322 1200 mg Oral Solution|On Day 1 of Period 2, after an overnight fast, subjects will receive GSK1322322 1200 mg oral solution single dose (containing approximately 54.5 μCi radioactive 14C-GSK1322322).
3133598|NCT01663363|Experimental|wavefront-guided LASIK|LASIK correction of myopic refractive errors. Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System.
3133599|NCT01663350||All-risk pregnant women|All-risk pregnancies undergoing conventional forms of prenatal screening
3133600|NCT01663337|Active Comparator|Cognitive Processing Therapy (CPT)|
3133601|NCT01663337|Active Comparator|Relapse Prevention Therapy (RP)|
3133602|NCT01663337|No Intervention|Assessment Only (AO)|AO functions as a benchmark comparison condition. Consists of baseline assessment, daily interactive voice response (IVR) monitoring, and immediate post-test assessment. Not an active treatment
3133603|NCT01663324|Experimental|single site rTMS|"Low frequency temporoparietal transcranial magnetic stimulation~Intervention: Device: rTMS intervention 1"
3133604|NCT01663324|Experimental|multisite rTMS|"Combined high frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation~Intervention: Device: rTMS Intervention 2"
3133605|NCT01663311|Experimental|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
3133606|NCT01663311|Experimental|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
3133607|NCT01663298||Control group|Subjects must have never smoked and must be non-diabetic.
3133608|NCT01663298||Smoking group|Subjects must have had at least 5 pack-years of self-reported smoking history, must be currently smoking and must be non-diabetic.
3133609|NCT01663298||Diabetic group|Subjects must have type 2 diabetes. The condition must be diagnosed subjects must be treated by medications and/or insulin. A HbA1C test result either within past 3 months or performed in the first visit must be available. They must have never smoked.
3133610|NCT01663285|Experimental|Neoadjuvant Gemcitabine and Cisplatin|Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
3133611|NCT01663272|Experimental|cabozantinib with gemcitabine|The Study Treatment Period will consist of continued treatment during which time patients will receive cabozantinib and gemcitabine until either disease progression or the occurrence of unacceptable drug-related toxicity
3133612|NCT01663259|Experimental|Cetuximab|
3133613|NCT01663246|Active Comparator|Healthy Adults|Healthy adults over the age of 18, with no history of surgery to the salivary glands, or cancer therapy.
3133614|NCT01663246|Active Comparator|Radiation for Head and Neck Cancer|History of radiation therapy for head and neck cancer.
3133615|NCT01663233|Experimental|LCZ696 and amlodipine|Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (had an office msSBP ≥145 mmHg and <180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks.
3133616|NCT01663233|Active Comparator|Amlodipine|Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (had an office msSBP ≥145 mmHg and <180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks.
3133617|NCT01663220||obese individuals with type 2 diabetes mellitus|
3133618|NCT01663207||obese individuals with prediabetes|
3133619|NCT01663194||N/L ratio tertile 2|patients were divided in to the tertiles
3133620|NCT01663194||N/L ratio tertile 3|patients were divided in to the tertiles
3133621|NCT01663194||N/L ratio tertile 1|patients were divided in to the tertiles
3133622|NCT01663181||urogynecologic patients undergoing outpatient cystoscopy|
3133623|NCT01663181||urogynecologic patients undergoing outpatient-urodynamics|
3133624|NCT01663168|Active Comparator|Rifabutin three times a week|Rifabutin 150mg tablet three times a week (Mon-Wed-Fri) in combination with daily lopinavir/ritonavir taken as part of second-line ART for duration of TB treatment (24 weeks)
3133625|NCT01663168|Experimental|Rifabutin daily|Rifabutin 150mg tablet daily in combination with daily lopinavir/ritonavir taken as part of second-line ART for duration of TB treatment (24 weeks)
3133626|NCT01663155||all enrolled subjects|Intervention is chest x-ray and CT scan. The chest x-ray image is read first without computer aided detection (CAD) and then a second time with computer aided detection (CAD) the CT scan is read by one reader. Subjects are asked to contribute breath and blood samples.
3133627|NCT01663142||Patients who receive surgical resection for intestinal in CD|
3133629|NCT01663129||Rheumatic Disease Patient Group|"Juvenile Idiopathic Arthritis (JIA)~Systemic Lupus Erythematosis~Juvenile Dermatomyositis~Scleroderma~Overlap Syndromes~Sjogren's syndrome~Sarcoidosis~Systemic Vasculitis (excluding Kawasaki's disease and Henoch-Schonlein Purpura)~Systemic vasculitis as defined by the Chapel Hill Concensus Conference on Nomenclature. Other forms of systemic vasculitis, including Giant cell (temporal) arteritis, Takayasu's arteritis, Polyarteritis nodosa, Wegener's granulomatosis, Churg-Strauss syndrome, Microscopic polyangiitis, Essential cryoglobulinemic vasculitis, Cutaneous leukocytoclastic angiitis, Behcet's disease, Other vasculitis~Other rheumatic disease"
3133630|NCT01663129||Nephrotic Syndrome Patient Group|"Nephrotic syndrome will be classified according to the following categories:~Idiopathic nephrotic syndrome, without renal biopsy histology, presumed minimal change disease (MCD), Focal segmental glomerulosclerosis (FSGS), confirmed on biopsy, Minimal change disease, confirmed on biopsy Nephrotic syndrome with Henoch-Schonlein Purpura (HSP)."
3133631|NCT01663116|Experimental|Treatment|"first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
3133632|NCT01663116|Placebo Comparator|Placebo|Lactate Ringer´s solution
3133633|NCT01663103|Experimental|Rilonacept|12 weeks of treatment with rilonacept
3133634|NCT01663103|Placebo Comparator|Placebo|Twelve weeks of treatment with placebo
3133635|NCT01663090|Experimental|Nanoparticle enhanced MRI|
3133636|NCT01663077|Experimental|Clozapine|Clozapine tablet 150 mg at the day and 150 mg in the evening by mouth per day for 3 month
3133637|NCT01663064|Experimental|Endovascular|Endovascular treatment
3133638|NCT01663051||Stent|Stent
3133639|NCT01663038|Active Comparator|Clopidogrel and Aspirin|
3133640|NCT01663038|Experimental|Copidogrel|
3133641|NCT01663025|Experimental|Hand Reflexology|Participants in this condition will receive hand reflexology, performed by a trained reflexologist during their treatment. This will be in addition to usual standard care therefore the surgeon will speak to the participant occasionally to ensure they are comfortable.
3133642|NCT01663025|No Intervention|Control|Participants in condition will form the control group for the study. They will receive usual standard care during treatment which will involve the surgeon speaking to them occasionally to ensure that they are comfortable.
3133643|NCT01663012|Experimental|Drug: Etirinotecan pegol|145 mg/m2 dose
3133644|NCT01662999|Experimental|A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)|Treatment A: Saxagliptin 5mg, Tablet, Oral; Single dose Treatment B: Dapagliflozin 10mg, Tablet, Oral; single dose Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; single dose
3133645|NCT01662999|Experimental|A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin|Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
3133646|NCT01662999|Experimental|B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)|Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose. Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose
3133647|NCT01662999|Experimental|B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin|Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
3133648|NCT01662999|Experimental|C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin|Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
3133649|NCT01662999|Experimental|C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin|Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, Once daily, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
3133650|NCT01662986|Active Comparator|18 mcg tiotropium bromide|Patient to receive one tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
3133651|NCT01662986|Placebo Comparator|placebo|Patient to receive one placebo inhalation powder capsule daily (in the morning) via HandiHaler
3133652|NCT01662973|Experimental|Conventional plus UC-MSC treatment|"Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.~Participants will then be followed until the week 48 study visit."
3133653|NCT01662973|Placebo Comparator|Conventional plus placebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.
3133654|NCT01662960|Experimental|Visual feedback therapy #1|In both forms of visual feedback therapy, participants will practice making movements at home without full visual feedback of their low-functioning arm.
3133655|NCT01662960|Active Comparator|Visual feedback therapy #2|In both forms of visual feedback therapy, participants will practice making movements at home without full visual feedback of their low-functioning arm.
3133656|NCT01662947|Experimental|DUT Arm|"DUT: Transtek Wrist Blood Pressure Monitor TMB-1117~Measurement: Blood Pressure~Groups/Cohorts: DUT"
3133657|NCT01662947|Experimental|Reference Arm|"Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.~Measurement: Blood Pressure~Groups/Cohorts: Reference"
3133658|NCT01662934|Sham Comparator|Sham|Using not functioning device
3133659|NCT01662934|Experimental|Experimental|Using functioning device
3133660|NCT01662921|Active Comparator|NPH and insulin lispro|Patients diagnosed with diabetes during pregnancy will be randomized to long acting insulin NPH and short acting insulin lispro in a basal bolus regimen to treat post prandial hyperglycemia using a dosing schedule of 50% NPH calculated by the patients weight and gestational age and 50% lispro pending their last three SMPG average.
3133661|NCT01662921|Active Comparator|NPH and insulin glulisine|Patients with a diagnosis of diabetes during pregnancy will be randomized to using long acting insulin NPH and short acting insulin glulisine as treatment for post prandial hyperglycemia with a 50% NPH dosing schedule based on the weight and gestational age and 50% glulisine schedule based on their last three SMBG result average.
3133662|NCT01662908|Experimental|edoxaban tosylate|
3133663|NCT01662908|Active Comparator|heparin/warfarin|
3254367|NCT00809289|Placebo Comparator|Two|
3133664|NCT01662895|Active Comparator|Deferoxamine|Deferoxamine mesylate supplied in vials containing 2 gm of sterile, lyophilized, powdered deferoxamine mesylate. The drug will be reconstituted for injection, by dissolving in 20 ml of sterile water. The reconstituted drug will be further diluted in normal saline to achieve a final concentration of 7.5 mg per ml.
3133665|NCT01662895|Placebo Comparator|Normal Saline|0.9% sodium chloride
3133666|NCT01662882|Experimental|AD Subjects|
3133667|NCT01662882|Experimental|MCI|MCI (mild cognitive impairment)
3133668|NCT01662882|Experimental|Healthy Controls|
3133669|NCT01662869|Experimental|Onartuzumab+mFOLFOX6|Participants will receive onartuzumab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion + mFOLFOX6 (oxaliplatin, folinic acid, and 5-fluoruracil) regimen. Participants will receive a maximum of 12 cycles (each cycle is 14 days) of mFOLFOX6 with onartuzumab. Participants whose disease has not progressed after 12 cycles of mFOLFOX6 with onartuzumab will continue treatment with onartuzumab until disease progression, unacceptable toxicity, or death.
3133670|NCT01662869|Placebo Comparator|Placebo+mFOLFOX6|Participants will receive onartuzumab matching placebo + mFOLFOX6. Participants will receive a maximum of 12 cycles (each cycle is 14 days) of mFOLFOX6 with placebo. Participants whose disease has not progressed after 12 cycles of mFOLFOX6 with placebo will continue treatment with placebo until disease progression, unacceptable toxicity, or death.
3133671|NCT01662856|Experimental|Fibrin Sealant Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
3133672|NCT01662856|Active Comparator|Manual Compression|Direct manual compression of target bleeding site with gauze/laparotomy pads.
3133673|NCT01662843||BRIPPED scan|Patients presenting with undifferentiated shortness of breath who receive the ultrasound scan in addition to standard of care
3133674|NCT01662843||Control|Patients who only receive the standard of care for undifferentiated shortness of breath
3133675|NCT01662830||MWCC clients|This study will be a systematic retrospective chart review of clients participating in the Jump Start (5 & 1) Plan at three different MWCC locations in Texas during the years 2007 - 2010.
3133676|NCT01662817||Intervention|Intervention group primary care physician (PCP) receives one day training in depression screening guidelines and uses guidelines for six months
3133677|NCT01662817||Control|Control group PCP manages depression in the usual way for six months
3133678|NCT01662804|Experimental|hu3F8 and rIL-2|This phase I single arm trial assesses the toxicity of escalating doses of hu3F8 (day 1 and day 8) in the presence of 6 × 10^6 U rIL-2/m^2/d x 5 days sc (day 8 through day 12). These 2 doses of hu3F8 and 5 doses of rIL-2 constitute a treatment cycle.
3133679|NCT01662791|Experimental|Case Group|All individuals in the Case group (i.e., only the subjects who had lost weight) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO twice a day (BID) for 14 days. Subjects in the case group were in the study for 3 months.
3133680|NCT01662791|No Intervention|Control Group|This arm consisted of subjects with Parkinson's Disease who had not experienced significant weight loss. These patients were in the study for one day.
3133681|NCT01662778|Experimental|Monodisperse Fluticasone Propionate 1.5microns|50 micrograms of monodisperse Fluticasone Propionate delivered as 1.5 micrometers
3133682|NCT01662778|Experimental|Monodisperse Fluticasone Propionate 6.0 microns|50 micrograms of monodisperse Fluticasone Propionate delivered as 6.0 micrometers
3133683|NCT01662778|Placebo Comparator|Placebo STAG|No active drug, just solvent delivered from STAG
3133684|NCT01662778|Experimental|Metered dose inhaler of Fluticasone Propionate|Fluticasone Propionate Inhaled, Metered dose inhaler, 250 micrograms dose (total dose)
3133685|NCT01662765|Experimental|Surgery|"Circular incision 2-3 mm below the skin level in the umbilicus through the subcutaneous fat towards the linea alba. Dissection of the subcutaneous tissue within the umbilicus and its deep connection to preperitoneal fat through the linea alba. Excision of the umbilical complex containing pilonidal cyst 3 mm below the umbilical ostium.~Approximation of the subcutaneous tissue with a single purse-string absorbable suture. The specimen, including the umbilical complex (pilonidal cyst, and involved skin and subcutaneous tissue), was transferred to department of pathology for histopathological examination."
3133686|NCT01662765|Active Comparator|Conservative|"Conservative treatment described as follow:~Under local anesthesia, extracting all protruding hair, and curetting the granulation tissue and pilonidal cyst deep in the umbilicus.~postoperative management include antibiotic treatment with ampicilline plus sulbactam and ornidazole, shaving surrounding skin, washing twice daily, and keeping umbilicus dry."
3133687|NCT01662752|Other|Indocyanine green|Indocyanine green is used for intraoperative identification of sentinel lymph nodes in patients with early colonic cancer using near infrared laparoscopic imaging
3133688|NCT01662726|Experimental|Irosustat|Irosustat 40mg OD for a minimum of 2 weeks until follow up FLT-PET/CT. For those patients consented to a repeat tumour biopsy, treatment will be extended to that day before the procedure.
3133689|NCT01662713|Experimental|NMSC Imaging|Optical Frequency Domain Imaging (OFDI) will be used to look at non melanoma skin cancer (NMSC) lesion(s).
3133690|NCT01662700|Experimental|AS2|"Artesunate 2 mg/kg/day for 5 days Combine with~Primaquine 15 mg is given daily for 14 days.~Or primaquine 45 mg is given once a week for 8 weeks in G6PD deficiency patients."
3133691|NCT01662700|Active Comparator|Chloroquine|"CH25: Chloroquine 25 mg/kg: 15 mg base/kg on the first days (D0), followed by 5 mg base/kg daily on the second and third day (day1-2) (total 25 mg base/ kg).~Combine with~Primaquine 15 mg is given daily for 14 days.~Or primaquine 45 mg is given once a week for 8 weeks in G6PD deficiency patients."
3133692|NCT01662687|Experimental|Sancuso patch|
3133693|NCT01662687|Active Comparator|Kytril|
3133694|NCT01662674|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
3133695|NCT01662674|Experimental|C|Combination of gemigliptin50mg/metformin HCl extended release 1000mg
3133696|NCT01662661|Experimental|Arm AB|Treatment A: 200 mg dose of JNJ-47910382 formulated as a suspension followed by Treatment B: 200 mg JNJ-47910382 formulated as an uncoated tablet, administered on Day 1.
3133697|NCT01662661|Experimental|Arm BA|Treatment B: 200 mg JNJ-47910382 formulated as an uncoated tablet followed by Treatment A: 200 mg dose of JNJ-47910382 formulated as a suspension, administered on Day 1.
3133842|NCT01661686|Active Comparator|Insertion of a partially covered SEMS|
3256571|NCT00793676|Other|B= COPD|
3133698|NCT01662648|Experimental|Paliperidone ER: Lack of efficacy|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics for the main reason of lack of efficacy.
3133699|NCT01662648|Experimental|Paliperidone ER: Lack of tolerability, compliance or other|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics for the main reason of lack of tolerability, compliance or other reasons.
3133700|NCT01662635||ALK-BREAK APART|"We reviewed 230 consecutive cases of NSCLC that were retrieved from oncologic molecular laboratory and diagnostic pathology unit at the Instituto Nacional de Cancerologia, Mexico city, between 2011 and 2014. Samples were sent to the unit of pathological anatomy, a Pathologist confirmed the histologic diagnosis. The only inclusion criterion was the availability of tissue for biomarker studies. Clinical and pathologic details of these patients were included in a database, obtained from medical records.~For ALK fusion testing, we applied dual-color, break-apart FISH, RT-qPCR, and immunohistochemistry. Interpretation of the results was done in double-blind manner without knowing the results by other methods."
3133701|NCT01662622|Experimental|Sevoflurane|Anaesthesia was induced by 8% sevoflurane. Cisatracurium 0.15mg kg-1 was administered after loss of the lash reﬂex, then ventilated manually until the amplitude of T1 decreased to 0. Intubation was performed and switched to mechanical ventilation with a fresh gas flow 2L min-1. Gas concentrations were analysed using a gas analyser.The end-tidal concentration of carbon dioxide was maintained at 4.7kPa; an esophageal temperature probe was inserted and a warming unit was used if necessary to maintain normothermia (35.5°-38.5°). The surgical incision was performed at least 30min after tracheal intubation. When arterial blood pressure (MAP) decrease exceeding 20% of baseline values. Phenylephrine 0.1mg was administered intravenously if necessary to maintained MAP and recorded.
3133702|NCT01662609||Endoscopic Ultrasound (EUS) Participants|High-risk for Pancreatic Cancer: Patients with 2 or more relatives with pancreatic cancer and a first degree relationship with at least one of the relatives with pancreatic cancer.
3133703|NCT01662583|Experimental|Educational Text Message|Educational text message reminder
3133704|NCT01662583|Experimental|Plain Text Message|plain text message reminder
3133705|NCT01662583|Other|Written reminder only|written reminder at time of vaccination
3133706|NCT01662570|Active Comparator|Beverage Choice Lifestyle Modification|The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake.
3133707|NCT01662570|Other|Nutrition Education (NE)|This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included.
3133708|NCT01662557|Active Comparator|Family Behavior Modification|Family-based behavior modification with parent and child using goal setting, self monitoring, reinforcement, behavioral skills training, and tasting opportunities.
3133709|NCT01662557|Other|Minimal Nutrition Information|Weekly mailings emphasizing healthy eating guidelines for families.
3133710|NCT01662544|Experimental|HHFNC|Heated High Flow arm
3133711|NCT01662544|Active Comparator|Standard Nasal Cannula|Standard treatment
3133712|NCT01662531|Experimental|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) will be administered by IV infusion as routine weekly prophylaxis and episodic treatment for bleeding episodes.
3133713|NCT01662518|Experimental|DDS-25|Intravitreal injection of DDS-25(Dexamethasone drug delivery system )
3133714|NCT01662505|Experimental|Volasertib|Patient to receive escalating dose of volasertib
3133715|NCT01662492|Experimental|Botulinum toxin type A Dose 1|Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.
3133716|NCT01662492|Experimental|Botulinum toxin type A Dose 2|Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.
3133717|NCT01662492|Placebo Comparator|Placebo (Normal Saline)|Placebo (Normal Saline) intramuscular injections into specified muscles.
3133718|NCT01662466|Active Comparator|DHEA+Testosterone|These patients will be administered the testosterone cream along with standard DHEA supplements
3133719|NCT01662466|Placebo Comparator|DHEA+Placebo|These patients will receive the placebo cream along with her DHEA supplements. In other words, no testosterone will be administered.
3133720|NCT01662453||SUDEP Group|The SUDEP group refers to epileptic patients that had a sudden unexplained death; excludes trauma, drowning, status epilepticus, or other known cause, but there is often evidence of an associated seizure.
3133721|NCT01662453||Control Group|We will recruit living patients with epilepsy for the control group. In particular, epileptic patients with Dravet Syndrome of Idic 15.
3133722|NCT01662440|Active Comparator|R/JE - Conv|Subjects received Rabies and Japanese Encephalitis (JE) vaccines following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm.
3133723|NCT01662440|Experimental|R/JE - Acc|Subjects received Rabies and JE vaccines following the accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg; and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm.
3133724|NCT01662440|Active Comparator|R - Conv|Subjects received Rabies vaccine following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and placebo on days 1, 8 and 29 in the left arm.
3133725|NCT01662440|Active Comparator|JE - Conv|Subjects received JE vaccine following the conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg; and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm.
3133726|NCT01662427||Questionniare|
3133727|NCT01662414|Active Comparator|HMS 90®|
3133728|NCT01662414|Placebo Comparator|Placebo (Soy protein)|
3133729|NCT01662401|Experimental|Peripheral Nerve Block|bilateral rectus sheath and ilioinguinal nerve blocks under ultrasound guidance after induction of general anesthesia administered to subject
3133843|NCT01661686|Active Comparator|Insertion of a Fully covered SEMS|
3133730|NCT01662401|Experimental|local anesthetic infiltration|local anesthetic infiltration will be administered after induction of general anesthesia
3133731|NCT01662388|Experimental|automatrix band, Separation ring|The prepared teeth received Automatrix band (similar to the control group, product code# 62422513). The Automatrix was burnished against the adjacent tooth gently. Anatomical wedges were applied in the proximal area and then the separation ring (BiTine® round ring by Palodent systems, Dentsply International, DE, USA product # 659040) placed with the help of retainer forceps.
3133732|NCT01662388|Active Comparator|automatrix band|Teeth received Automatrix band alone (Wide-Regular type, dimensions 7.9 mm height and 0.05mm thickness, product code # 62422513). It was secured on the prepared tooth and burnished against the adjacent tooth gently. Anatomical wedges were placed in the inter-proximal area gingival to the cavity preparation.
3133733|NCT01662375||MIII|
3133734|NCT01662362|Other|Testing Donor Specimens with ESA Chagas|Test blood donor specimens that are ABBOTT PRISM Chagas Repeatedly Reactive with ESA Chagas. Donors will be asked to return for a follow-up blood draw.
3133735|NCT01662349|Experimental|Plasma|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
3133736|NCT01662336||Lopinavir/Ritonavir + KASA|Patients were treated according to the standard of care provided by their respective study sites. Treatments with LPV/r and participation in the KASA program were according to the decision of the treating physician and the participant, and were not affected in any way by their decision to participate in the study.
3133737|NCT01662323|Active Comparator|Training of the GP's, intervention|General practitioners are trained to diagnose and treat heart failure according the recommendations of the NHG-standard.
3133738|NCT01662323|Active Comparator|Controle|General practitioners giving care as usual to their heart failure patients.
3133739|NCT01662310|Experimental|Paliperidone: Run-in or Stabilization phase|Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) once daily for 8 weeks. Dose will be increased from milligram per day (3 mg/day) after 5 days based on Investigator's discretion, up to maximum of 12 mg/day.
3133740|NCT01662310|Experimental|Paliperidone: Double blind (DB) phase|Participants who transitioned from run-in or stabilization phase received 3 to 12 mg fixed dose of paliperidone ER oral tablet once daily during DB phase of the study. Participants who will experience a relapse event during the DB phase or who will remain relapse free for the entire duration of the DB phase and participants, who will be enrolled at the time the study termination will enter in open label extension phase, wherein paliperidone ER oral tablet will be administered once daily as 3 to 12 mg.
3133741|NCT01662310|Active Comparator|Placebo: DB phase|Participants who transitioned from run-in or stabilization phase received matching placebo to paliperidone ER once daily during DB phase of the study. Participants who will experience a relapse event during the DB phase or who will remain relapse free for the entire duration of the DB phase and participants, who will be enrolled at the time the study termination will enter in open label extension phase, wherein paliperidone ER oral tablet will be administered once daily as 3 to 12 mg.
3133742|NCT01662297|Active Comparator|Quetiapine|Veterans remaining on quetiapine for insomnia.
3133743|NCT01662297|Active Comparator|Trazodone|Veterans switching from quetiapine to trazodone for the treatment of insomnia.
3133744|NCT01662284||Triple Negative Breast|124I-NM404 in triple negative breast cancer
3133745|NCT01662284||Prostate|124I-NM404 in prostate cancer
3133746|NCT01662284||Colorectal|124I-NM404 in colorectal cancer
3133747|NCT01662284||Gastric|124I-NM404 in gastric cancer
3133748|NCT01662284||Ovarian|124I-NM404 in ovarian cancer
3133749|NCT01662284||Pancreatic|124I-NM404 in pancreatic cancer
3133750|NCT01662284||Esophageal|124I-NM404 in esophageal cancer
3133751|NCT01662284||Sarcoma|124I-NM404 in soft tissue sarcoma
3133752|NCT01662284||Head & Neck|124I-NM404 in head and neck cancer
3133753|NCT01662271||adolescents with extreme obesity|BMI ≥35kg/m2
3133754|NCT01662271||adolescents with obesity|BMI 30-34.9kg/m2
3133755|NCT01662258|Experimental|Point-of-Care diagnostic laboratory test|Adult patients with community-acquired pneumonia (CAP) who are in the Targeted strategy group will undergo point-of-care (POC) diagnostic laboratory tests.
3133756|NCT01662258|No Intervention|Empiric therapy|Option of no application of POC laboratory tests
3133757|NCT01662232|Active Comparator|Green tea beverage|200 mg EGCG as green tea beverage.
3133758|NCT01662232|Active Comparator|Green tea extract|200 mg EGCG as green tea extract and same volume water as for tea beverage.
3133759|NCT01662232|Active Comparator|Epigallocatechin-3-gallate (EGCG)|200 mg EGCG and same volume water as for tea beverage.
3133760|NCT01662232|Placebo Comparator|Placebo (Water)|Same volume water as for all intervention arms.
3133761|NCT01662219|Experimental|superficial cervical plexus block|superficial cervical plexus block for experimental group
3133762|NCT01662219|No Intervention|No Block|no superficial cervical plexus block for the no intervention group
3133763|NCT01662206|Experimental|Probiotic|Capsules containing Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum
3133764|NCT01662206|Placebo Comparator|Placebo|Capsules containing placebo
3133765|NCT01662193|Experimental|vitamin D3|vitamin D3 supplement 50000 IU vitamin D3 per week
3133766|NCT01662193|Experimental|calcium supplement|calcium supplement 1000 mg calcium carbonate daily
3133767|NCT01662193|Experimental|vitamin D and calcium supplement|vitamin D3 and calcium supplementation 50000 IU vitamin D3 per week and 1000 mg calcium carbonate daily
3133768|NCT01662193|Placebo Comparator|placebo|placebo
3133769|NCT01662180||Subfertile couples|"Subfertile couples presenting at fertility clinics with an indication for IUI in stimulated cycles~All patients will receive a fixed 75 IU recombinant follicle stimulating hormone per day conform normal stimulation protocol starting from cycle day 3, 4 or 5. Once the dominant follicle(s) reach a mean diameter of 16-18 mm, hCG (5000IU or 250 mcg) will be applied and insemination will be scheduled 36-42 hours later. Patients will be followed for the time of one menstrual cycle."
3133770|NCT01662167|Experimental|Multiple dose mtx|mtx
3133844|NCT01661673|Experimental|Arm 1|10 mg EVP-0962 Orally administered once daily for 14 days
3133845|NCT01661673|Experimental|Arm 2|50 mg EVP-0962 Orally administered once daily for 14 days
3133846|NCT01661673|Experimental|Arm 3|100 mg EVP-0962 Orally administered once daily for 14 days
3133771|NCT01662167|Experimental|Single Dose|In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
3133772|NCT01662154|Experimental|Nerve stimulator|Patients in this group will have their nerve blocks assessed with a common nerve stimulator (Stimuplex HNS 12, B.Braun, Germany).
3133773|NCT01662154|Active Comparator|Neurometer|Patients in this group will have their nerve block assessed using the Neurometer.
3133774|NCT01662128|Experimental|Xeloda|Xeloda
3133775|NCT01662115|Active Comparator|Nicotine gum|100 subjects who will actually get the intervention medication
3133776|NCT01662115|Sham Comparator|regular chewing gum|100 subjects who will be part of a control group
3133777|NCT01662115|No Intervention|No gum|100 subjects who will not get neither the intervention nor the placebo gum.
3133778|NCT01662102|Experimental|Zevalin and Rituximab|90Y-Ibritumomab tiuxetan will be administered 8 to 12 weeks after the last chemotherapy infusion. Each patient randomized to this treatment group will receive a therapeutic dose of 14.8 MBq/kg (0.4 mCi/kg of total body weight) of 90Y ibritumomab tiuxetan (maximum 1,184 MBq or 32 mCi). Patients with a pre-treatment platelet count between 100 and 149 x109/L will receive 0.3 mCi/Kg 90Y-ibritumomab tiuxetan.The 90Y ibritumomab tiuxetan regimen is as follows: Day 1 rituximab (250 mg/m^2); Day 7,8, or 9 rituximab (250 mg/m^2) followed by 90Y ibritumomab tiuxetan within 4 hours of the end of the rituximab infusion.
3133779|NCT01662102|Active Comparator|Rituximab|375 mg/m^2 of rituximab, administered by IV infusion every 8 weeks
3133780|NCT01662089|Experimental|Chelate zinc suppliment|15mg Chelate zinc suppliment : additional to standard 5% minoxidil
3133781|NCT01662089|Placebo Comparator|Placebo drug|Placebo drug to compare with 15mg chelated Zn : additional to standard 5% minoxidil
3133782|NCT01662076|Experimental|Sublingual or Oral Liquid Homeopathy|The homeopathic remedy will be administered as 1 lactose/sucrose globule 2.5 mm in diameter to be administered sublingually up to 3 times per day or as 0.2 ml of a 30% ethanol based liquid homeopathic remedy administered orally up to 3 times per day. The homeopathic remedy and/or the homeopathic remedy potency can be changed on a daily basis during the course of treatment. However, only one homeopathic remedy and potency will be administered at a given time.
3133783|NCT01662063|Experimental|SC TCZ QW|Participants who received IV TCZ in the previous trial will be switched to SC TCZ 162 mg QW, and those who received SC TCZ will continue at their same dosage of SC TCZ 162 mg QW. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
3133784|NCT01662063|Experimental|SC TCZ Q2W|Participants who received SC TCZ will continue at their same dosage of SC TCZ 162 mg Q2W. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
3133785|NCT01662050|Experimental|One arm for all patients.|Rituximab, Bendamustine, Cytarabine
3133786|NCT01662037|Experimental|Bosentan group|Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
3133787|NCT01662037|No Intervention|Routinely group|Routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
3133788|NCT01662024|Experimental|Endoscopic gastric restrictive procedure|Restrict gastric size by approximating tissue endolumenally via an incisionless/per-oral approach.
3133789|NCT01662011|Experimental|NAVA group|Patients ventilated with the mode of neurally adjusted ventilatory assist
3133790|NCT01662011|Active Comparator|PSV group|Patients ventilated with the mode of pressure support ventilation.
3133791|NCT01661998||Harms Study Group|
3133792|NCT01661985|Active Comparator|Drug: Azithromycin 1g|Azithromycin 1 g,single dose (per os)
3133793|NCT01661985|Active Comparator|Drug: Doxycycline/lymecycline 9/10days|Tetracycline either as Doxycycline or during June and July lymecycline (due to lower risk of photo-sensitivity) given for treatment in 9(10)days (per os).
3133794|NCT01661985|Active Comparator|Azithromycin 1.5 g|Patients not randomized but receiving the first line treatment when a confirmed Mg infection
3133795|NCT01661972|Experimental|Phase 1: Capecitabine and Aflibercept|A standard 3+3 dose escalation format will be used. Capecitabine will start at 850mg/m2 to be given on days 1-14 and off days 15-21. If tolerated, the dose will then be escalated to 1000mg/m2 for the next cohort, given on the same schedule. The dose of aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.
3133796|NCT01661972|Experimental|Phase 2: Capecitabine and Aflibercept|Once the RPTD of the doublet combination has been identified, an additional 50 subjects with metastatic colorectal cancer will be added to a single, Phase 2 arm
3133797|NCT01661959||Non-Operative|
3133798|NCT01661959||Operative|
3133799|NCT01661946|Active Comparator|Ranibizumab|intravitreal injection of 0.5mg ranibizumab in usual fashion
3133800|NCT01661946|Active Comparator|Bevacizumab|intravitreal injection of 1.25mg bevacizumab in usual fashion
3133801|NCT01661933|Experimental|Necator americanus, gluten challenge|Single arm, vertical.
3133802|NCT01661920|Experimental|INTERVENTION GROUP|Patients with diagnosis of CAP with shorten treatment, defined as 5 days antibiotic treatment.
3133803|NCT01661920|Active Comparator|CONTROL GROUP|Patients with diagnosis of CAP which antibiotic treatment duration will be not modified by their doctors.
3133804|NCT01661907|Experimental|Combined Epi-GA/PCEA|"Patients assigned to this group (experimental group) will receive combined epidural-general anesthesia (combined Epi-GA) and patient controlled epidural analgesia (PCEA).~An epidural catheter will be placed before anesthesia induction. General anesthesia will be induced and maintained in the same manner as in the control group, with the addition of a continuous infusion or intermittent boluses of 0.5%-0.75% ropivacaine given through the epidural catheter for analgesia maintenance. Patient controlled epidural analgesia will be used for postoperative analgesia (0.12% ropivacaine and 0.5 μg/mL sufentanil in 250 mL normal saline, programmed to deliver a 2-mL bolus with a lockout interval of 20 minutes and a background infusion of 4 mL/hr)."
3133847|NCT01661673|Experimental|Arm 4|200 mg EVP-0962 Orally administered once daily for 14 days
3133848|NCT01661673|Placebo Comparator|Arm 5|Placebo orally administered for 14 days
3133849|NCT01661660|Active Comparator|Control subjects|Control subjects were people with memory complaints coming for a consultation and prevention.
3133805|NCT01661907|Active Comparator|GA/PCIA|"Patients assigned to this group (control group) will receive general anesthesia (GA) and patient controlled intravenous analgesia (PCIA).~General anesthesia will be induced with midazolam, sufentanil, propofol and rocuronium. Anesthesia will then be maintained by inhalation of oxygen-nitrous oxide mixture (1:1-2) and sevoflurane, and/or continuous intravenous infusing of propofol. Sufentanil and rocuronium will be given when needed. If necessary, other types of opioids and muscle relaxants are also allowed. Patient controlled intravenous analgesia will be used for postoperative analgesia (50 mg morphine in 100 mL normal saline, programmed to deliver a 2-mL bolus with a 6-10 minutes lockout interval and a 1 mL/hr background infusion)."
3133806|NCT01661894|Active Comparator|Intervention|Subjects will undergo the BrainpalTM intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the BrainpalTM treatment in the first 8 weeks of the trial.
3133807|NCT01661894|No Intervention|Wait-List Control|The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards. They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.
3133808|NCT01661881|Experimental|RB/RC|"Patients received 3 cycles of outpatient RB (rituximab 375 mg/m2 day 1, bendamustine 90 mg/m2 days 1 and 2 of a 4-week cycle), followed by interim CT restaging. Patients with progressive disease (PD) went off study. Those with stable disease (SD) or better went on to receive three cycles of inpatient RC (rituximab 375 mg/m2 day 1, cytarabine 3 g/m2 every 12 h for 4 doses). The cytarabine was dose reduced to:~2 g/m2 for age >60 years old, creatinine 114.9-176.8 lmol/l (for patients ≤60 years old), and pre-existing neurotoxicity;~1.5 g/m2 for age >60 years old AND creatinine 114.9-176.8 lmol/l, or for age >60 years old AND pre-existing neurotoxicity;~1 g/m2 for age > 60 years old AND creatinine 114.9-176.8 lmol/l AND pre-existing neurotoxicity.~Stem cell mobilization and collection, ASCT and post-transplantation supportive care were performed per institutional standard and not as part of this study."
3133809|NCT01661868|Active Comparator|PARP Inhibitor Naive|Patients with no prior PARP inhibitor treatment
3133810|NCT01661868|Active Comparator|Prior PARP Inhibitor|Patients previously treated with a PARP inhibitor other than olaparib
3133811|NCT01661855|Active Comparator|Riluzole|
3133812|NCT01661855|Placebo Comparator|Placebo|
3133813|NCT01661842|Experimental|Conventional plus UC-MSC treatment|"Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.~Participants will then be followed until the week 96 study visit."
3133814|NCT01661842|Experimental|Conventional plus placebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 96 study visit.
3133815|NCT01661829||Biofeedback|Patients will undergo biofeedback therapy between 1st adjuvant chemotherapy and stoma closure(= after 3rd ajduvant chemotherapy)
3133816|NCT01661829||Kegel|Patients will be trained to take excersise for their anal sphincter by Kegel.
3133817|NCT01661816||Within chemotherapy|30 couples, interviewed within chemotherapy (6 to 8 months after diagnosis)
3133818|NCT01661816||within Herceptin|30 couples, within herceptin treatment (the first year after diagnosis)
3133819|NCT01661816||within hormonotherapy|30 couples, within hormonotherapy (between 2 and 7 years after diagnosis)
3133820|NCT01661816||without hormonotherapy|30 couples, did not received hormonotherapy (1 year after diagnosis)
3133821|NCT01661816||end of treatment|30 couples, after end of treatments for patients who did received hormonotherapy (7 years after diagnosis)
3133822|NCT01661803||group-A and group-B|Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15 with 1 mcg/kg preservative free clonidine).
3133823|NCT01661803||group-A and group--B|Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15 with 1 mcg/kg preservative free clonidine).
3133824|NCT01661790|Experimental|Bevacizumab & Cisplatin|Bevacizumab 300mg plus Cisplatin 30mg by intrapleural given every two weeks
3133825|NCT01661790|Active Comparator|Cisplatin|Cisplatin 30mg by intrapleural given every two weeks
3133826|NCT01661777|Other|Nasal steroid and Antihistamine|Patients with ETD will be given nasal steroid and antihistamine for 8 weeks.
3133827|NCT01661777|Active Comparator|Myringotomy tubes|Patients who fail nasal steroid and antihistamine treatment will have myringotomy tubes placed.
3133828|NCT01661777|Active Comparator|Low salt diet and diuretic|Patient's who fail to improve with myringotomy tubes will be treated with low salt det and diuretic
3133829|NCT01661764|Active Comparator|rs174535 (GG), fish oil supplements|Eicosapentanoic acid and docosahexanoic acid
3133830|NCT01661764|Placebo Comparator|rs174535 (GG), placebo|Oleic Acid
3133831|NCT01661764|Active Comparator|rs174535 (GT), fish oil supplements|Eicosapentanoic acid and docosahexanoic acid
3133832|NCT01661764|Placebo Comparator|rs174535 (GT), placebo|Oleic Acid
3133833|NCT01661764|Active Comparator|rs174535 (TT), fish oil supplement|Eicosapentanoic acid and docosahexanoic acid
3133834|NCT01661764|Placebo Comparator|rs174535 (TT), placebo|Oleic Acid
3133835|NCT01661751|Experimental|ACYW135 Meningococcal Vaccine|0.5 ml/ dose, containing 50 μg of each antigen; lot No.: 20040601, manufacturing date: June 9, 2004 and the expiration date: till June 2006
3133836|NCT01661751|Active Comparator|A+C Meningococcal Vaccine|0.5 ml/ dose; each ampoule or dose contains 100 μg (one single human dose) and 50 μg of each antigen; lot No.: 20050805 and the expiration date: Aug. 24, 2007
3133837|NCT01661738|Experimental|Group ACYW135 Meningococcal Polysaccharide Vaccine|0.5 ml/ vial
3133838|NCT01661725|Experimental|Group ACYW135 Meningococcal Polysaccharide Vaccine|0.5ml/ vial
3133839|NCT01661712|Active Comparator|Transcutaneous electrical stimulation|"Transcutaneous electrical stimulation: the patient will undergo a sleep study and continuous transcutaneous electrical stimulation during the night (active treatment)."
3133840|NCT01661712|Sham Comparator|Sham stimulation|"Sham stimulation: the patient will undergo a sleep study with Sham stimulation. An identical setup to the intervention will be used with the software indicating stimulation to keep staff blinded to the intervention (Modes are labelled A and B for real and sham stimulation and observers will not be able to tell the difference on the screen)."
3136132|NCT01645319||Hispanic - Incisional/Other Surgery Treatment Pathway|
3133851|NCT01661660|Experimental|Dementia patient|Subjects at demential stage
3133852|NCT01661647|Experimental|3D knee kinematic assessment|3D knee kinematic assessment under local anesthesia
3133853|NCT01661634|Experimental|Ularitide|Ularitide, lyophilizate for i.v. infusion, 15 ng/kg BW/min, for 48 hours
3133854|NCT01661634|Placebo Comparator|Placebo|Placebo lyophilizate for i.v. infusion
3133855|NCT01661621|Experimental|Group 1|Antimuscarinics (Detrusitol 4 mg QD)
3133856|NCT01661621|Experimental|Group 2|α-blockers (Doxazosin 4 mg QD)
3133857|NCT01661608|Experimental|EOS|Collecting data on the use of the EOS for gastric tissue approximation during primary gastric restrictive procedures
3133858|NCT01661595|Active Comparator|Sildenafil / Placebo|50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 0-4. Placebo for weeks 5-8.
3133859|NCT01661595|Active Comparator|Tadalafil / Placebo|10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 0-4. Placebo for weeks 5-8.
3133860|NCT01661595|Active Comparator|Placebo / Sildenafil|Placebo for weeks 0-4. 50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 5-8.
3133861|NCT01661595|Active Comparator|Placebo / Tadalafil|Placebo for weeks 0-4. 10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 5-8.
3133862|NCT01661582|Placebo Comparator|Filtered Air Exposure|Subjects will be exposed to filtered air for 1 hour during intermittent exercise in a purpose-built exposure facility
3133863|NCT01661582|Experimental|Dilute Diesel Exhaust Exposure|Subjects will be exposed to dilute diesel exhaust (~300 mcg/m3) for 1 hour during intermittent exercise in a purpose-built exposure facility
3133864|NCT01661569|Experimental|Headspace On-the-go app|Participants were given access to a 45-day mindfulness meditation programme via the Headspace smartphone app
3133865|NCT01661569|No Intervention|Waitlist control|Participants will be asked to wait for 8 weeks before starting the intervention
3133866|NCT01661556|Experimental|Miconazole|OTC topical prescription used for fungal treatment that can be useful to the treatment of melasma due to its depigmenting properties.
3133867|NCT01661556|Active Comparator|Hydroquinone|Hydroquinone 4% cream (Topical use) a depigmenting agent used as reference will be used as control. It will be applied twice a day for 9 weeks.
3133868|NCT01661556|Placebo Comparator|Placebo|Moisturizer cream without pharmacological effects will be used as a control.
3133869|NCT01661543|Experimental|Bean consumption to lower cholesterol|This arm will consume 90 grams of beans per day for 5 out of 7 days for 6 weeks.
3133870|NCT01661543|Placebo Comparator|Control (rice) consumed to show results|The control group will consume 90 grams of rice per day for 5 out of 7 days for 6 weeks.
3133871|NCT01661543|Experimental|Peas consumed to lower cholesterol|This arm will consume 90g of peas per day for 5 days out of each week for 6 weeks.
3133872|NCT01661530|Experimental|Vitamin E enhanced diet|Range of three vitamin E enhanced soups (400g/tin) containing 18-20mg vitamin in natural food form. Three portions per week
3133873|NCT01661530|Placebo Comparator|Non-enhanced dietary intervention|Range of three similar looking and tasting soups (400g/tin) with naturally low (<3mg) vitamin E content. Three portions per week
3133874|NCT01661517|Experimental|Lifestyle Counseling|motivational interviewer
3133875|NCT01661504|No Intervention|Referral Card Only|Women participants at control clinics will be given a referral card containing general information on IPV and a list of resources specific to their community
3133876|NCT01661504|Experimental|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions at 3 months post-baseline / initial counseling
3133877|NCT01661491||Cystic Fibrosis|Infants and toddlers with Cystic Fibrosis
3133878|NCT01661491||Non-cystic fibrosis controls|Infants and toddlers without Cystic Fibrosis
3133879|NCT01661478||Emergency Department personnel|survey
3133880|NCT01661478||Department of Psychiatry personnel|survey
3133881|NCT01661452||patients in UAB ER,|
3133882|NCT01661439||Low molecular weight heparin|SC LMWH IN patients with recurrent pregnancy loss
3133883|NCT01661426|Active Comparator|Low-Carbohydrate Diet first, then Low-Fat Diet (IR)|Participants who were more insulin resistant based on the median AUC for insulin concentrations measured from OGTT prior to randomization.
3133884|NCT01661426|Active Comparator|Low-Fat Diet first, then Low-Carbohydrate Diet (IS)|Participants who were more insulin sensitive based on the median AUC for insulin concentrations measured from OGTT prior to randomization.
3133885|NCT01661413||Acute Leukemia|Children diagnosed with acute leukemia, undergoing chemotherapy. Patients with acute leukemia will receive intrathecal methotrexate on day 1 plus intravenous vincristine on day 1 plus oral steroid on days 1-5 plus their regularly scheduled and ongoing daily oral 6-mercaptopurine at the start of a maintenance therapy cycle.
3133886|NCT01661400|No Intervention|Control|No intervention
3133887|NCT01661400|Experimental|Metronomic Cyclophosphamide|Cyclophosphamide will be given PO once daily at 2.5 mg/kg/day for children < 40kg or 100 mg daily for children > 40kg beginning Day + 30 (30 days post transplant) and continue until at least Day +86
3133888|NCT01661400|Experimental|Thalidomide|Thalidomide will be initiated at 3mg/kg PO daily beginning Day + 30 (30 days post transplant) and continue until Day +86
3133889|NCT01661387||Plenadren|Modified release hydrocortisone
3133890|NCT01661387||Other Glucocorticoid Replacement Therapy|
3133891|NCT01661374||Mechanically Ventilated|
3133892|NCT01661374||Chronic obstructive pulmonary disease (COPD).|
3133893|NCT01661361||vancomycin cohort|
3133894|NCT01661348||Prevena System placement|Subjects randomized to this group will receive standard skin preparation and closure followed by application of Prevena Incision Management System (Kinetic Concepts, Inc; San Antonio, TX) negative pressure wound therapy unit (experimental group).
3133895|NCT01661348||Standard of care postoperative care|Subjects randomized to this group will receive a standard surgical skin preparation, closure, and dressing (control group).
3133925|NCT01661088|Experimental|Study Treatment|"Patients will receive FOLFIRINOX x 6 followed by IMRT concurrent with fixed dose rate (FDR)-gemcitabine (1g/m^2) on days 1, 8, 22, 29.~Intensity-modulated radiotherapy (IMRT): The prescribed dose was 50.0Gy in 2.0Gy per fraction.~Patients without metastatic disease will be offered surgical exploration."
3133896|NCT01661335|Experimental|Ondansetron, dexamethasone, aprepitant|Arm A: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
3133897|NCT01661335|Placebo Comparator|Ondansetron, Dexamethasone, placebo|Arm B: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
3133898|NCT01661322|Active Comparator|Intensive antiplatelet therapy|Participants in the intensive antiplatelet group will receive Aspirin+Dipyridamole+Clopidogrel triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
3133899|NCT01661322|No Intervention|Guideline antiplatelet therapy|This may be one or two antiplatelet drugs, as per standard treatment. Clopidogrel or aspirin and dipyridamole.
3133900|NCT01661309|Placebo Comparator|Inactive lozenge|Inactive lozenge containing 2mg sucrose dissolved in the mouth taken after a meal every other day for 16 weeks
3133901|NCT01661309|Experimental|Methylcobalamin|Methylcobalamin 1mg lozenge dissolved in the mouth following a meal taken every other day for 16 weeks.
3133902|NCT01661296|Active Comparator|Sodium stibogluconate|Intralesional SSG was administered in dose of 50 mg cm -2 of lesion once a week for 6 weeks (total six injections)
3133903|NCT01661296|Active Comparator|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia (1% lidocaine) using a current field radio-frequency generator (ThermoMed 1.8, Thermosurgery Inc).
3133904|NCT01661283|Experimental|Arm A|All patients with MPNST will continue everolimus 10 mg daily and bevacizumab 10 mg/kg dose every 14 days
3133905|NCT01661270|Placebo Comparator|Placebo|Placebo for aflibercept intravenous (IV) infusion on Day 1 of each cycle (1 cycle = 2 weeks) in combination with FOLFIRI regimen until disease progression, unacceptable toxicity or participant's refusal. FOLFIRI regimen: Irinotecan 180 mg/m^2 IV infusion and leucovorin 400 mg/m^2 IV infusion, 5-Fluorouracil IV bolus 400 mg/m^2 followed by continuous IV infusion 2400 mg/m^2.
3133906|NCT01661270|Experimental|Aflibercept|Aflibercept 4 mg/kg IV infusion on Day 1 of each cycle (1 cycle = 2 weeks) in combination with FOLFIRI regimen until disease progression, unacceptable toxicity or participant's refusal. FOLFIRI regimen: Irinotecan 180 mg/m^2 IV infusion and leucovorin 400 mg/m^2 IV infusion, 5-Fluorouracil IV bolus 400 mg/m^2 followed by continuous IV infusion 2400 mg/m^2.
3133907|NCT01661257|Experimental|TIM-3|T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) is a novel transmembrane protein that is involved in the regulation of Th1-cell-mediated immunity.
3133908|NCT01661244|Experimental|Part A - Single dose escalation|
3133909|NCT01661244|Experimental|Part B - 14 day repeat dose escalation|
3133910|NCT01661231|Experimental|Investigational Stents|Device: Astron/Pulsar-18 Stents Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease.
3133911|NCT01661218||complications|catheter-related venous thrombosis catheter-related infections
3133912|NCT01661205|Experimental|AtriCure Bipolar System combined with a catheter ablation|Minimally invasive procedure using the AtriCure Bipolar System plus a catheter ablation performed approximately 1-10 days apart
3133913|NCT01661192|Experimental|AAT( Alpha 1 Antitrypsin)|Subjects who maintained peak stimulated C-peptide secretion ≥ 0.2nmol/L will continue treatment with AAT according to the dosage group they were allocated to at the previous study(40mg/kg or 60mg/kg or 80mg/kg), intravenously, once a week for 6 consecutive weeks, at 24-week intervals for a duration of ~54 weeks.
3133914|NCT01661192|No Intervention|Follow up group|Subjects who have not maintained peak stimulated C-peptide secretion ≥ 0.2nmol/L or subjects with peak stimulated C -peptide secretion ≥ 0.2nmol/L who are reluctant to receive additional study drug, will be followed up only with no administration of investigational product
3133915|NCT01661179|Experimental|Vandetanib 300mg|300 mg/day vandetanib
3133916|NCT01661166|Experimental|Double Blinded|
3133917|NCT01661153||Cohort|
3133918|NCT01661140|Experimental|Methotrexate (MTX) Tapering Dosage|At Week 0 participants will start open-label tocilizumab and open-label MTX for 24 weeks. At Week 24, participants achieving a good/moderate European League Against Rheumatism (EULAR) disease response will be randomized to the MTX Tapering group or MTX Maintenance group. In this arm participants will receive a double-blind MTX dose according to the MTX tapering scheme between Week 24 and Week 56. Participants will also continue to receive open-label tocilizumab between Week 24 and Week 56. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.
3133919|NCT01661140|Active Comparator|Methotrexate (MTX) Maintenance Dosage|At Week 0 participants will start open-label tocilizumab and open-label MTX for 24 weeks. At Week 24, participants achieving a good/moderate European League Against Rheumatism (EULAR) disease response will be randomized to the MTX Tapering group or MTX Maintenance group. In this arm participants will continue to be administered a stable dose of MTX in a double-blind fashion between Week 24 and Week 56. Participants will also continue to receive open-label tocilizumab between Week 24 and Week 56. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.
3133920|NCT01661114|Experimental|Gemcitabine, 5-FU and Cisplatin|4 cycles - Gemcitabine, 5-FU and Cisplatin (2 months)-Continue treatment until progression of disease or intolerable toxicity
3133921|NCT01661101|Experimental|Dabigatran|Dabigatran 110 mg capsule taken twice daily
3133922|NCT01661101|Experimental|Omeprazole|Omeprazole 20 mg capsule taken once daily
3133923|NCT01661101|Placebo Comparator|Placebo (dabigatran)|Dabigatran placebo taken twice daily
3133924|NCT01661101|Placebo Comparator|Placebo (omeprazole)|Omeprazole placebo taken once daily
3256572|NCT00793676|Other|C= Control|
3133926|NCT01661075||mTBI|These individuals will have had an mTBI during their respective collegiate athletic season.
3133927|NCT01661075||healthy controls|Recruitment of healthy controls who have not suffered an mTBI for balancing testing.
3133928|NCT01661062|Experimental|Cone Beam CT|All patients will be included in the treatment arm of this study. For the purposes of this study patients will get CT scans every day for the length of their radiation therapy (in order to assess if CT every day provides additional information compared with CT scans performed less frequently). Although the exact amount of radiation patients get will be determined by their doctor, it is expected that they will get approximately 7 weeks, approximately 35 total cone beam CT scans.
3133929|NCT01660971|Experimental|Treatment (gemcitabine, dasatinib, erlotinib)|Patients receive gemcitabine hydrochloride IV over 30-60 minutes on days 1, 8, and 15, and dasatinib PO QD and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3133930|NCT01660958|Experimental|Infants: MNP|• Infants will receive sachets of multiple micronutrient powder (MNP) vs. placebo.
3133931|NCT01660958|Experimental|Infants: Early Learning|• Infant will receive early learning messages delivered in the home by village level workers vs. routine care.
3133932|NCT01660958|No Intervention|Infants: No intervention|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~Infant phase. Routine care - no early learning intervention"
3133933|NCT01660958|Experimental|Infants: MNP/Early Learning|"Infants receive the MNP plus early learning intervention by receiving MNP sachets~Caregivers receive early learning messaged delivered at home biweekly for one year"
3133934|NCT01660958|Experimental|Preschoolers:MNP/High qual preschool|"Preschoolers will receive MNP fortified food in their Anganwadi Centers at the mid-day meal.~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as high quality preschools."
3133935|NCT01660958|No Intervention|Preschoolers:Placebo/High qual preschool|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as high quality preschools."
3133936|NCT01660958|Experimental|Preschoolers:MNP/Low qual preschool|"Preschoolers will receive MNP fortified food in their Anganwadi Centers at the mid-day meal.~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as low quality preschools."
3133937|NCT01660958|No Intervention|Preschoolers:Placebo/Low qual preschool|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as low quality preschools."
3133938|NCT01660945|Placebo Comparator|placebo|placebo
3133939|NCT01660945|Active Comparator|vytorin 10|vytorin 10 mg
3133940|NCT01660945|Active Comparator|vytorin 20|vytorin 20 mg
3133941|NCT01660932|Placebo Comparator|placebo|placebo
3133942|NCT01660932|Active Comparator|omega 1|omega 1 gm
3133943|NCT01660932|Active Comparator|omega 2|omega 2 gm
3133944|NCT01660932|Active Comparator|omega 4|omega 4 gm
3133945|NCT01660919|Placebo Comparator|placebo|placebo
3133946|NCT01660919|Active Comparator|rosuvastatin 5|rosuvastatin 5 mg
3133947|NCT01660919|Active Comparator|rosuvastatin 10|rosuvastatin 10 mg
3133948|NCT01660919|Active Comparator|rosuvastatin 20|rosuvastatin 20 mg
3133949|NCT01660906|Experimental|Dasatinib (100 mg)|
3133950|NCT01660893|Experimental|Kovacaine Mist, 3 sprays unilateral|Tetracaine HCl 3% and oxymetazoline HCl 0.05%
3133951|NCT01660893|Experimental|Tetracaine Only, 3 sprays unilateral|Tetracaine HCl 3%
3133952|NCT01660893|Placebo Comparator|Placebo, 3 sprays unilateral|Placebo
3133953|NCT01660880||aripiprazole|Patient group who is treated with aripiprazole
3133954|NCT01660867|Placebo Comparator|0.9% saline + oral placebo|nebulized epinephrine + 0.9% saline + placebo => epinephrine + 0.9% saline
3133955|NCT01660867|Experimental|3% saline + oral placebo|nebulized epinephrine + 3% saline + placebo => nebulized epinephrine + 3% saline
3133956|NCT01660867|Active Comparator|0.9% saline + oral dexamethasone|nebulized epinephrine + 0.9% saline + dexamethasone => nebulized epinephrine + 0.9% saline
3133957|NCT01660854|Experimental|Heterologous challenge|"Biological: Heterologous challenge with 5 infected mosquito bites (NF135) after previous CPS immunization and challenge.~Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone.~Other Name: atovaquone/proguanil"
3133958|NCT01660854|Active Comparator|Challenge control|"Biological: Plasmodium falciparum mosquito challenge by the bites of 5 Plasmodium falciparum infected mosquitoes (NF135).~Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone.~Other Name: atovaquone/proguanil"
3133959|NCT01660841|Experimental|Arm 1|
3133960|NCT01660828|Active Comparator|Intensive cycling test preceded by RIPC|Intensive cycling test preceded by a RIPC protocol.
3133961|NCT01660828|No Intervention|No intervention/ RIPC|Intensive cycling test not preceded by a RIPC protocol.
3133962|NCT01660815|Experimental|Healthy Volunteers|Cognitively normal, healthy volunteers at least 45 years of age.
3133963|NCT01660802|Experimental|700 μg Dexamethasone|700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
3133964|NCT01660802|Sham Comparator|Sham|Sham administered in the study eye on Day 1.
3133965|NCT01660789|Other|Lifestyle intervention|Lifestyle intervention.
3136133|NCT01645319||Asian - Medication Treatment Pathway|
3133966|NCT01660776||DLBCL (diffuse large B-cell lymphoma)|DLBCL (diffuse large B-cell lymphoma)
3133967|NCT01660776||Hodgkin's lymphoma|Hodgkin's lymphoma
3133968|NCT01660776||metastatic breast cancer|metastatic breast cancer or with lymph node involvement
3133969|NCT01660776||immune thrombocytopenia (ITP)|immune thrombocytopenia (ITP)
3133970|NCT01660776||healthy volunteers|healthy volunteers
3133971|NCT01660776||non-small cell lung cancer|non-small cell lung cancer
3133972|NCT01660763|Experimental|Sufentanil NanoTab PCA System/15 mcg|
3133973|NCT01660763|Placebo Comparator|Placebo Sufentanil NanoTab PCA System|
3133974|NCT01660750|Experimental|Carfilzomib, Cyclophosphamide, Dexamethasone|All eligible subjects will receive Carfilzomib, Cyclophosphamide, and Dexamethasone.
3133975|NCT01660737||PASCALLERG® tablets in patients with hay fever|Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.
3133976|NCT01660724|Experimental|Ultrasound guided arterial puncture|Patients randomised to the this arm has arterial puncture performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
3133977|NCT01660724|Active Comparator|Conventional arterial puncture technique|Patients randomised to the active comparator arm has arterial puncture performed using the conventional technique
3133978|NCT01660711|Experimental|FOLFIRINOX chemotherapy|"5FU 2400 mg/m2 IV over 48 hours Irinotecan 180 mg/m2 IV day 1 Oxaliplatin 85 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1~Cycles administered every 14 days for 4 cycles before and 4 cycles after surgery."
3133979|NCT01660698|Placebo Comparator|Placebo|maltodextrin powder
3133980|NCT01660698|Active Comparator|Probiotic|probiotic blended in maltodextrin
3133981|NCT01660685|Experimental|Tracking + Journaling + Website|In addition to standard care, participants will complete daily tracking and journaling and receive weekly feedback based on their individual entries.
3133982|NCT01660685|Active Comparator|Enhanced Usual Care|Participants receive standard care
3133983|NCT01660672|Other|LEVETIRACETAM|Open label, dose escalation to optimal dose.
3133984|NCT01660659|Experimental|cooking with Biomass Briquettes and Rocket Stove|cooking with Biomass Briquettes and Rocket Stove
3133985|NCT01660659|No Intervention|standard cooking|standard way of cooking
3133986|NCT01660646|Other|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
3133987|NCT01660646|No Intervention|control|
3133988|NCT01660633|Other|High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)|Subjects will receive only High-Dose Melphalan HCL for Injection (Propylene Glycol-free) at 200mg/m2 (100mg/m2/day for two days).
3133989|NCT01660620|Experimental|betaxolol|betaxolol 0.25% 2 per day for 3 weeks
3133990|NCT01660620|Placebo Comparator|placebo|masked labeling also 2 per day administration
3133991|NCT01660607|Experimental|Dose escalation|For the Phase I arm of the study the addition of planned numbers and ratios of Treg compared to Tcon will occur at defined time points after hematopoietic cell infusion. Each cohort will have 3 patients per group. The initial doses and ratios utilized will be 1 x 10^6/kg of T reg cells to 3x10^6/kg of Tcon cells at a 1:3 ratio. In order to progress to the next dose level, there must be no evidence of grade 3 or 4 acute GVHD.
3133992|NCT01660594||Stable chest pain|All patients presenting with stable chest pain and referred by their general practitioners to the chest pain clinic in the hospital who had CT calcium scoring performed besides standard assessment.
3133993|NCT01660581|Experimental|CD133+|intramyocardial injection (electromechanical mapping based) of autological CD133+ cells, isolated from bone marrow
3133994|NCT01660581|Placebo Comparator|Placebo|intramyocardial injection (electromechanical mapping based) of placebo - 0,9% NaCl plus 0,5% solution of patients' serum
3133995|NCT01660568||relapsed or refractory NK/T cell lymphoma with gemcitabine|
3133996|NCT01660555||Patiënts scheduled for colonoscopy|Ill prepared colon during index colonoscopy or sigmoidoscopy: Boston scale <3
3133997|NCT01660542|Experimental|doxorubicin/cyclophosphamide|Neoadjuvant Chemotherapy with Docetaxel(Monotaxel®) after Doxorubicin plus Cyclophosphamide
3133998|NCT01660516||Tea|Black tea ingestion
3133999|NCT01660503|Placebo Comparator|No SCF|Twice daily consumption of snack foods containing no SCF.
3134000|NCT01660503|Experimental|10 grams SCF|Twice daily consumption of snack foods, each containing 5 grams SCF
3134001|NCT01660503|Experimental|20 grams SCF|Twice daily consumption of snack foods, each containing 10 grams SCF
3134002|NCT01660490||Proximal femur fractures with ORIF|Proximal femur fractures treated with ORIF
3134003|NCT01660477|Experimental|Arm 1: isavuconazole only|Isavuconazole three times per day (TID) on Days 1-2, and once daily (QD) on Days 3 thru 13
3134004|NCT01660477|Experimental|Arm 2 : LPV/RTV only|Lopinavir/ritonavir (LPV/RTV) twice daily (BID) on Days 1-12 and once on Day 13
3134005|NCT01660477|Experimental|Arm 3: isavuconazole and LPV/RTV|Isavuconazole three times per day (TID) on Days 1-2, and once daily (QD) on Days 3 thru 13 in combination with lopinavir/ritonavir twice daily (BID) on Days 1-13
3134006|NCT01660464|Experimental|ADHD-Team|Intervention
3134007|NCT01660451|Experimental|Copanlisib (indolent NHL)|Part A: Participants in this arm will be patients with indolent NHL.
3134008|NCT01660451|Experimental|Copanlisib (aggressive NHL)|Part A: Participants in this arm will be patients with aggressive NHL.
3134009|NCT01660451|Experimental|Copanlisib (indolent B-cell NHL)|Part B: Participants in this arm will be patients with indolent B-cell NHL.
3134010|NCT01660438||Stress urinary incontinence|Stress urinary incontinence
3134011|NCT01660425|No Intervention|treatment as usual with MPH|In the first twelve months of intervention the children receive treatment as usual with MPH and do not get any further intervention. Afterwards, the families get the opportunity to take part in the program which is then conducted for a duration of four months. Measurements are performed at the beginning of the program, after six moths, after 12 months and additionally after 16 months.
3134050|NCT01660204|Active Comparator|Betalactam monotherapy|Preferred empirical treatment for patients in this arm is Beta-lactam monotherapy e.g. co-amoxiclav or ceftriaxone
3134295|NCT01658501|Active Comparator|Active Comparator|Active Comparator (Victoza) daily SC injection
3134012|NCT01660425|Active Comparator|Psychosocial intervention|Parenting Enhancement Training as a form of psychosocial intervention is a guided program. Parents get the opportunity to discuss written information with a therapist in 20 minutes telephone calls. 14 telephone calls are offered. The whole intervention lasts for a period of one year. Booklets are mailed via post within the first 4 months. First 9 telephone calls are also within the first 4 months, usually every two weeks. Telephone calls 10 and 11 are within 5th or 6th month, telephone calls 12 to 14 are within 7th to 12th month with a two monthly time period in between.
3134013|NCT01660412|Active Comparator|pH altered first|The first injection administered will be the pH altered solution. The second injection will be the standard of care solution (opposite order). The remaining injections will be randomly assigned as either standard of care or pH altered.
3134014|NCT01660412|Active Comparator|Standard of Care first|The first injection administered will be the standard of care solution (SOC). The second injection will be the pH altered solution. The remaining injections will be randomly assigned as either standard of care or pH altered.
3134015|NCT01660399|Experimental|Docetaxel/Boanmycin|Docetaxel 75mg/m2, intravenous infusion, day 1; Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
3134016|NCT01660399|Placebo Comparator|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1, 21days a cycle.
3134017|NCT01660386|Experimental|Sitagliptin|the subjects are asked to take one pill of sitagliptin(100mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
3134018|NCT01660386|Experimental|Saxagliptin|the subjects are asked to take one pill of saxagliptin(5mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
3134019|NCT01660386|Experimental|Glimepiride|the subjects are asked to take one pill of glimepiride(2mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
3134020|NCT01660386|Other|Blank control|the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
3134021|NCT01660373|Experimental|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
3134022|NCT01660373|Active Comparator|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
3134023|NCT01660360|Experimental|Tanibirumab|The total dose of Tanibirumab for each patient will depend on dose level assignment and the patient's weight. Dose levels to be potentially tested in Phase I include: 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg, 16 mg/kg, and 20 mg/kg.
3134024|NCT01660347|Experimental|Supportive care (allogeneic PBSCT boost)|Patients undergo allogeneic PBSCT boost from cells selected for CD34+ using the CliniMACS CD34 Reagent System.
3134025|NCT01660334||Voriconazole|Subjects who are treated with voriconazole
3134026|NCT01660321|Experimental|Natroba|Natroba (Spinosad) Topical Suspension, 0.9%
3134027|NCT01660308||Tumor induced osteomalcia|
3134028|NCT01660295|Experimental|Certoparin control|Participants receive Certoparin 3,000 IU during period 1. Participants will receive 8,000 IU during period 2, if qualified as per medical criteria.
3134029|NCT01660295|Experimental|Certoparin Renal|"Participants receive dose escalation upon medical criteria qualification at each period:~Certoparin 3,000 IU once a day during period 1. Certoparin 3,000 IU twice a day during period 2. Certoparin 8,000 IU once a day during period 3. Certoparin 8,000 IU in the morning and 3,000 IU in the evening during period 4 OR Certoparin 8,000 IU twice a day during period 4."
3134030|NCT01660256|Experimental|OPC-12759 ophthalmic solution|OPC-12759 ophthalmic solution
3134031|NCT01660256|Placebo Comparator|Placebo|OPC-12759 ophthalmic solution 0%
3134032|NCT01660256|Active Comparator|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension
3134033|NCT01660243|Active Comparator|MT-9938 2.5μg|
3134034|NCT01660243|Active Comparator|MT-9938 5μg|
3134035|NCT01660243|Active Comparator|MT-9938 10μg|
3134036|NCT01660243|Placebo Comparator|Placebo|
3134037|NCT01660230|Active Comparator|6 µg/kg 3K3A-APC, single-dose|Cohort 1: 6 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 20 mL IV infusion over 15 minutes
3134038|NCT01660230|Active Comparator|30 µg/kg 3K3A-APC, single-dose|Cohort 2: 30 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
3134039|NCT01660230|Active Comparator|90 µg/kg 3K3A-APC, single-dose|Cohort 3: 90 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
3134040|NCT01660230|Active Comparator|180 µg/kg 3K3A-APC, single-dose|Cohort 4: 180 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
3134041|NCT01660230|Active Comparator|360 µg/kg 3K3A-APC, single-dose|Cohort 5: 360 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
3134042|NCT01660230|Active Comparator|TBD µg/kg 3K3A-APC, single-dose|Cohort 6: TBD (not to exceed 720) µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
3134043|NCT01660230|Active Comparator|90 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 7: 90 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
3134044|NCT01660230|Active Comparator|180 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 8: 180 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
3134045|NCT01660230|Active Comparator|360 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 9: 360 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
3134046|NCT01660230|Active Comparator|TBD µg/kg 3K3A-APC, q12h for 5 doses|Cohort 10: TBD (not to exceed 720) µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
3134047|NCT01660230|Placebo Comparator|Matching Placebo, 0.9% NaCl in water|Cohorts 1-10: 0.9% sodium chloride in water and administered as either 20 mL IV infusion over 15 minutes (Cohort 1), or 100 mL IV infusion over 15 minutes (Cohorts 2-10)
3134048|NCT01660217|Experimental|Initial Verbal Instruction Group|"The group who initially received only verbal instruction, and then later (in the crossover portion) received a written Eczema Action Plan (EAP)"
3134049|NCT01660217|Experimental|Written Eczema Action Plan (EAP)|The group given a written EAP after verbal instruction
3257705|NCT00785408|Placebo Comparator|4|
3134051|NCT01660204|Active Comparator|Betalactam combination with macrolide|Preferred empirical treatment for patients in this arm is beta-lactam combination therapy with a macrolide e.g. ceftriaxone and erythromycin
3134052|NCT01660204|Active Comparator|Quinolone monotherapy|Preferred empirical treatment for patients in this arm is quinolone monotherapy e.g. moxifloxacin or levofloxacin
3134053|NCT01660191|Active Comparator|Pitavastatin 4mg|Pitavastatin 4mg tablet by mouth once daily for 12 weeks
3134054|NCT01660191|Active Comparator|Atorvastatin 20mg|Atorvastatin 20mg tablet by mouth once daily for 12 weeks
3134055|NCT01660191|Active Comparator|rosuvastatin 5 mg|rosuvastatin 5 mg tablet by mouth once daily for 12 weeks
3134056|NCT01660165||Observational|Pregnant women
3134057|NCT01660152|Experimental|Group A (vacuum therapy, holding erection for 2 minutes)|Patients receive daily vacuum therapy over 10 minutes while holding erection for 2 minutes after undergoing RALP. Patients complete erection process 5 times. SHIM questionnaire administration will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
3134058|NCT01660152|Experimental|Group B (vacuum therapy, holding erection for 5 minutes)|Patients receive daily vacuum therapy over 10 minutes while holding erection for 5 minutes after undergoing RALP. Patients complete erection process 2 times.Patients complete erection process 5 times. SHIM questionnaire administration will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
3134059|NCT01660139||Dermatology Clinic Patients|Patient attending dermatology clinics
3134060|NCT01660139||Primary Clinic Patients|Patient attending primary care clinics
3134061|NCT01660126|Active Comparator|Levothyroxine|Oral Levothyroxine, starting dose 25 or 50 micrograms increased to a maximum of 150 micrograms once daily.
3134062|NCT01660126|Placebo Comparator|Placebo|Matched placebo
3134063|NCT01660100|Active Comparator|Pulmonary vein antrum isolation (PVAI)|Pulmonary vein antrum isolation (PVAI)
3134064|NCT01660100|Active Comparator|PVAI plus left atrial posterior wall (LAPW) isolation|PVAI plus left atrial posterior wall (LAPW) isolation
3134065|NCT01660074|Experimental|Test food, reference food|Test food group of subject need to comsume 50g available carbohydrate of test food. One test food for one ocassion. Reference food need to comsume same 50g available carbohydrate of reference food, usually white bread or glucose syrup.
3134066|NCT01660061||APS patients|Patients with antiphospholipid syndrome requiring long-term anticoagulant therapy with vitamin-K antagonists
3134067|NCT01660061||Controls|Patients without antiphospholipid antibodies requiring anticoagulant therapy with vitamin-K antagonists
3134068|NCT01660048|Experimental|SILS TEP repair|Half of the patients will undergo laparoscopic total extraperitoneal inguinal hernia repair using a single port (Triport)
3134069|NCT01660048|Active Comparator|Multiports TEP repair|Half of the patients will undergo the conventional multiports total extraperitoneal inguinal hernia repair
3134070|NCT01660022|Experimental|OZ439 100mg|100mg OZ439 single oral dose
3134071|NCT01660022|Experimental|OZ439 100 mg + PQP 160mg|100mg OZ439 single oral dose + 160mg Piperaquine single oral dose
3134072|NCT01660022|Experimental|OZ439 100 mg + PQP 480mg|100mg OZ439 single oral dose + 480mg Piperaquine single oral dose
3134073|NCT01660022|Experimental|OZ439 100 mg + PQP 1440mg|100mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
3134074|NCT01660022|Experimental|OZ439 300mg|300mg OZ439 single oral dose
3134075|NCT01660022|Experimental|OZ439 300 mg + PQP 1440mg|300mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
3134076|NCT01660022|Experimental|OZ439 800mg|800mg OZ439 single oral dose
3134077|NCT01660022|Experimental|OZ439 800 mg + PQP 1440mg|800mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
3134078|NCT01660022|Placebo Comparator|Placebo|Placebo
3134079|NCT01660009|Experimental|Hypoglycemia First|Individuals will undergo a hyperinsulinemic hypoglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.
3134080|NCT01660009|Experimental|Euglycemia First|Individuals will undergo a hyperinsulinemic euglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.
3134081|NCT01659996|Experimental|Menactra Vaccine Group|Participants will receive Meningococcal polysaccharide diphtheria toxoid conjugate (Menactra®) at 9 months of age and Menactra® at 15 to 18 months of age.
3134082|NCT01659996|Experimental|Menactra and Pentacel Vaccine Group|Participants will receive Meningococcal polysaccharide diphtheria toxoid conjugate (Menactra®) at 9 months of age and Menactra® + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed (Pentacel®) concomitantly at 15 to 18 months of age.
3134083|NCT01659996|Active Comparator|Pentacel Vaccine Group|Participants will receive only Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Pentacel®) at 15 to 18 months of age.
3134084|NCT01659983|Experimental|Primary wound closure|A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
3134085|NCT01659983|Active Comparator|Delayed primary wound closure|A wound will be left open with saline-soaked gauze packing after the operative procedure and will be sutured around day 3 to 7 after operation
3134086|NCT01659970||Cohort|
3134087|NCT01659957|Experimental|Group Couples Couseling|Patients randomized to this arm will receive group couples counseling plus 12-step oriented alcoholism counseling.
3134088|NCT01659957|Experimental|One-on-One Couples Couseling|Patients randomized to this arm will receive one-on-one couples counseling plus 12-step oriented alcoholism counseling.
3134089|NCT01659944|Experimental|Metoprolol alone then eliglustat + metoprolol|In Period 1 all participants will receive a single oral dose of metoprolol 50 mg on Day 1. In Period 2, participants will receive repeat oral doses of eliglustat 150 mg twice a day from Day 3 to Day 8 and a single oral dose of metoprolol 50 mg on Day 7.
3134090|NCT01659931|Active Comparator|Montelukast|10 mg Tablet
3134091|NCT01659931|Active Comparator|Singulair|10 mg Tablet
3134092|NCT01659918|Active Comparator|Montelukast|10 mg Tablet
3134093|NCT01659918|Active Comparator|Singulair|10 mg Tablet
3134094|NCT01659905|Active Comparator|Montelukast|5 mg Chewable Tablet
3134095|NCT01659905|Active Comparator|Singulair|5 mg Chewable Tablet
3134098|NCT01659879|Experimental|multimedia information|Health information concerning the child's diagnosis, treatment and recovery time after evaluation by the pediatrician, using a 15 minutes long standardized health information package with multimedia elements from the Norwegian website www.syktbarn.no (English version: www.childhealthguide.com)
3134099|NCT01659879|Active Comparator|verbal information|Verbal health information by a nurse in the acute ward concerning the child's diagnosis, treatment and recovery time, after the evaluation by the pediatrician
3134100|NCT01659866|Other|Cipro-susceptible|Patients with ciprofloxacin-susceptible bacteria on their rectal swab cultures will receive ciprofloxacin, the standard of care, as prophylaxis for their prostate biopsy
3134101|NCT01659866|Active Comparator|Cipro-resistant|"Patients with ciprofloxacin-resistant bacteria on their rectal swab will receive one of the following drugs:~trimethoprim-sulfamethoxazole 1 double strength tablet orally 2 hours before the procedure and again 12 hours later~cefuroxime 500 mg orally 2 hours before the procedure then again 12 hours later~ceftriaxone 500 mg intramuscularly 2 hours before the procedure~gentamicin 2mg/kg intramuscularly 2 hours before the procedure~amikacin 5 mg/kg intramuscularly 2 hours before the procedure~aztreonam 500 mg intramuscularly 2 hours before the procedure~imipenem 500 mg intramuscularly 2 hours before the procedure~ceftriaxone 2000 mg intravenously 1 hour before the procedure~gentamicin 2 mg/kg intravenously 1 hour before the procedure~amikacin 5mg/kg intravenously 1 hour before the procedure~aztreonam 2000 mg intravenously 1 hour before the procedure~imipenem 1000 mg intravenously 1 hour before the procedure"
3134102|NCT01659853|Experimental|Overall Study|"In this crossover study of CD07805/47 gel 0.5%/CD07805/47 Vehicle and azelaic acid gel 15%, 70 subjects were randomly assigned to treatment sequence.~During Period 1 (15 days), 35 subjects received topical CD07805/47 gel 0.5% in the morning and topical CD07805/47 gel vehicle in the evening, and 35 received topical azelaic acid gel twice daily according to FDA approved prescribing information. Subjects crossed over to the other treatment in Period 2 (15 days)."
3134103|NCT01659840|Other|Red laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
3134104|NCT01659840|Other|Infrared laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
3134105|NCT01659827|Sham Comparator|Control|Initial injections of Marcaine and Saline (one each)
3134106|NCT01659827|Experimental|0.5cc AmnioFix Injectable|Initial injections of Marcaine and 0.5cc AmnioFix (one each)
3134107|NCT01659827|Experimental|1.25cc AmnioFix Injectable|Initial injections of Marcaine and 1.25cc AmnioFix (one each)
3134108|NCT01659814||Individuals with Major Depressive Disorder|
3134109|NCT01659814||Healthy Control Individuals|
3134110|NCT01659788|Experimental|Coenzyme Q10 concomitant treatment|"Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment~Dose: 600 mg by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the CoEnzyme Q10 if conceives or when the study is completed.~Other name: Ubiquinone"
3134111|NCT01659788|Placebo Comparator|Placebo|1 capsule by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the placebo when she conceives or when the study is completed.
3134112|NCT01659775|Experimental|Sancuso patch|
3134113|NCT01659775|Active Comparator|Zofran|
3134114|NCT01659762|Experimental|autologous mesenchymal stromal cells|
3134115|NCT01659736|Experimental|TMS Therapy|TMS treatment
3134116|NCT01659736|Sham Comparator|TMS-Sham|This is a sham TMS condition
3134117|NCT01659723|Active Comparator|A - Immediate start|Start of treatment within 6 weeks of inclusion in the study. 100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
3134118|NCT01659723|No Intervention|B - delayed start|Delayed start: Start of treatment not before 6 months of inclusion in the study. No intervention is given during the initial period.
3134119|NCT01659710||Study Babies|Study video at 50-55 weeks gestational age, motor assessments at 24m (+/- 6 months) and again at 4 years (+/- 1 year).
3134120|NCT01659710||Control Babies|Video at 50-55 weeks gestational age, motor assessment at 24 months (+/- 6 months).
3134121|NCT01659697||Intensive Lifestyle counseling|
3134122|NCT01659697||usual lifestyle counseling|
3134123|NCT01659684|Experimental|standard intravenous immunoglobulin|Single arm evaluation of neurological consequences of congenital CMV infection in comparison with historical untreated controls.
3134124|NCT01659671|Active Comparator|Uvulopalatopharyngoplasty|One arm is Uvulopalatopharyngoplasty(intervention group of 32 patients), one arm is expectancy (control group of 33 patients). After six months the controls have delayed surgery and then both groups are followed for two years
3134125|NCT01659671|Active Comparator|Control|After six months the controls have delayed surgery then are followed for 2 year
3134126|NCT01659658|Experimental|IXAZOMIB 4 mg + Dexamethasone 20 mg/day|IXAZOMIB 4 mg, capsules, orally, once on Days 1, 8, and 15; plus dexamethasone 20 mg/day, orally, weekly on Days 1, 8, 15, and 22 of each 28-day cycle; dexamethasone may be increased up to 40 mg/day after 4 weeks, if tolerated. Participants may continue to receive treatment until Progressive Disease (PD) or unacceptable toxicity, whichever comes first.
3134127|NCT01659658|Active Comparator|Physician's Choice|"Participants will receive one of the following treatment options as selected by the physician:~Dexamethasone 20 mg/day: dexamethasone 20 mg/day, orally, on Days 1-4, 9-12 and 17- 20 of each 28-day cycle.~Dexamethasone 20 mg/day + Melphalan 0.22 mg/kg: dexamethasone 20 mg/day, orally, on Days 1-4 of each 28-day cycle; plus melphalan 0.22 mg/kg, orally, on Days 1-4 every 28 days.~Dexamethasone 20 mg/day + Cyclophosphamide 500 mg: dexamethasone 20 mg/day, orally, weekly on Days 1, 8, 15 and 22 of each 28-day cycle; plus cyclophosphamide 500 mg, orally, on Days 1, 8 and 15 every 28 days.~Dexamethasone 20 mg/day + Thalidomide 200 mg/day: dexamethasone 20 mg/day, orally, weekly Days 1, 8, 15 and 22 of each 28-day cycle; plus thalidomide total dose up to 200 mg/day, orally.~Dexamethasone 20 mg/day+ Lenalidomide 15 mg/day: dexamethasone 20 mg/day, orally, weekly on Days 1, 8, 15 and 22 of each 28-day cycle; plus lenalidomide 15 mg/day, orally, for 21 days every 28 days."
3134128|NCT01659645|Experimental|FACBC|
3134129|NCT01659619|Experimental|erythromycin|
3134130|NCT01659619|No Intervention|saline|
3134131|NCT01659606|Experimental|alemtuzumab/fludarabine conditioning|alemtuzumab/fludarabine conditioning; cyclosporins/mycophenolate mofetil GVHD prophylaxis
3134132|NCT01659593|Experimental|procog|cognitive remedial program 13 sessions over a 6-month period
3134133|NCT01659593|Placebo Comparator|DISINT|Interactive discussion program of 13 group sessions in a 6-month period
3134134|NCT01659580|Experimental|T89 high dose|T89 225mg bid
3134135|NCT01659580|Experimental|T89 low dose|T89 150mg bid
3134136|NCT01659580|Experimental|Sanqi+Bingpian|225mg bid
3134137|NCT01659580|Placebo Comparator|Placebo|225mg bid
3134138|NCT01659567||Chronic Hepatitis C|Participants with chronic hepatitis C, treated with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) according to the current standard of care and in line with current summaries of product characteristics/local labelling, will be observed for up to 96 weeks.
3134139|NCT01659554|Experimental|Out-Patient Intraperitoneal Chemotherapy|Intraoperative (hyperthermic) cisplatin followed by 4 courses of intraperitoneal cisplatin and doxorubicin given on days 1 & 8 during a 3 week cycle.
3134140|NCT01659541|Experimental|Procedure & Device|Procedure/Surgery: Implantation of device; Device: Expiratory Muscle Stimulator
3134141|NCT01659502|Experimental|TL-118 alone or with pancreas cancer chemotherapy|
3134142|NCT01659489||women undergoing laproscopy fo rsuspected adnexal torsion|
3134143|NCT01659476|Experimental|Asthma|Individuals diagnosed with asthma.
3134144|NCT01659476|Experimental|Cough Variant Asthma|Individuals diagnosed with cough variant asthma.
3134145|NCT01659476|Experimental|Mch-induced cough w/normal airway sensitivity|Individuals with chronic cough normal PC20 MCh(>16 mg/mL) & who cough during Mch challenge testing.
3134146|NCT01659476|Experimental|Normal|Individuals with no history of asthma or chronic cough
3134147|NCT01659463|Experimental|ICON - low viscosity resin|APPLICATION OF A LOW VISCOSITY RESIN IN EARLY PROXIMAL CARIES LESIONS
3134148|NCT01659463|Active Comparator|INSTRUCTIONS ORAL HYGIENE|INSTRUCTION ORAL HYGIENE AND DIET AND TOOPICAL FLUORIDE APPLICATIONS
3134149|NCT01659450|Experimental|Low energy dense|Diet of the LED group contained 30%fat, 15% protein and 55% carbohydrate. Most of the consumed carbohydrates in the LED diet group were fruits, vegetables and whole grains. In addition, this group received more servings of vegetables groups daily in the form of liquid diets or some menus contain more vegetables
3134150|NCT01659450|Experimental|control|In the group with a control diet, 35% of the energy was provided by fat, 15% by protein and 50% by carbohydrate
3134151|NCT01659437|Active Comparator|SR8|Streptomycin (S: 15 mg/kg per day, intramuscularly) in combination with rifampicin (R: 10 mg/kg per day, orally) for 8 weeks
3134152|NCT01659437|Experimental|CR8|Clarithromycin (C: 15 mg/kg per day, oral extended release formulation) in combination with rifampicin (10 mg/kg per day, orally) for 8 weeks
3134153|NCT01659424|Other|Single Arm|This is a single arm study.
3134154|NCT01659411||Adult CHD Patients|observational
3134155|NCT01659398|Experimental|Enhanced external counterpulsation (EECP)|
3134156|NCT01659398|No Intervention|Subjects not receiving EECP|Control group to measure data from experimental group against.
3134157|NCT01659372|Experimental|Low level laser therapy|this arm recieves low level laser therapy treatment for 12 sessions.
3134158|NCT01659372|Experimental|naproxen|this arm takes naproxen 500 mg twice daily for 3weeks
3134159|NCT01659359|Experimental|virtual reality glasses and Lidocaine|virtual reality glasses and 5 ml Lidocaine 2%
3134160|NCT01659359|Experimental|Lidocaine|5 cc Lidocaine2%
3134161|NCT01659346|Experimental|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3 weeks till eradication
3134162|NCT01659346|Active Comparator|Carvedilol|Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
3134163|NCT01659333||Peritoneal dialysis, hypervolemia|All calculations are automatically performed by the software of the BCM device. Absolute over hydration (OH) is the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative over hydration (Rel. OH) is defined as the OH to ECW ratio. Normohydration is defined when OH is between the 10th and the 90th percentile for healthy, age- and gender-matched individuals from the reference population, i.e., between 10th percentile (−1.1 L) to 90th percentile (+1.1 L), while volumes below and above this range define underhydration and overhydration, respectively.
3134164|NCT01659333||Peritoneal dialysis, normovolemia|All calculations are automatically performed by the software of the BCM device. Absolute over hydration (OH) is the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative over hydration (Rel. OH) is defined as the OH to ECW ratio. Normohydration is defined when OH is between the 10th and the 90th percentile for healthy, age- and gender-matched individuals from the reference population, i.e., between 10th percentile (−1.1 L) to 90th percentile (+1.1 L), while volumes below and above this range define underhydration and overhydration, respectively.
3134165|NCT01659320|Experimental|Minocycline|Open label treatment using minocycline.
3134166|NCT01659307|Active Comparator|Aspirin 75mg|Aspirin 75mg once daily for 7 days. Administered by mouth.
3134167|NCT01659307|Active Comparator|Aspirin 1200mg|Asprin 600mg twice daily for 7 days. Administered by mouth.
3134168|NCT01659307|Placebo Comparator|Lactose powder|Placebo for 7 days. Administered by mouth.
3134169|NCT01659294|Experimental|nurse case management|nurse case management of diabetic variables
3134170|NCT01659294|Active Comparator|standard diabetologist care|standard diabetologist care
3134171|NCT01659281|Active Comparator|1|2-day oral treatment with: Artesunate 6mg/kg at 0 and 24 hours Mefloquine 25 mg/kg total dose split into 2 doses of 15 mg/kg at 0 hours and and 10 mg/kg given 6-24 hours later Primaquine 0.5 mg/kg single dose at 24 hours
3134172|NCT01659281|Active Comparator|2|3 days oral treatment with: Artesunate 4 mg/kg/day for 3 days Mefloquine 8 mg/kg/day for 3 days Primaquine 0.5 mg/kg single dose at 24 hours
3134173|NCT01659268|Experimental|Simulation class|"The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.~The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation."
3134296|NCT01658488|Other|Regular Rice|2 servings per day of non-fortified rice
3134174|NCT01659268|Other|Exhibition-dialogued class|Students will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, each subgroup composed of 4-5 students will go to the and practical activity in skill lab using the low-fidelity mannequin for 35 minutes.
3134175|NCT01659255|Experimental|ONO/GS-4059|
3134176|NCT01659242|Active Comparator|Methotrexate plus sulfasalazine|"ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose."
3134177|NCT01659242|Active Comparator|Leflunomide|"ARM 2:Leflunomide(LEF)~LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.~Methotrexate:Off"
3134178|NCT01659229||PFC CR 150 total knee implant|Study group implant: PFC CR 150 Control group implant: PFC CR standard
3134179|NCT01659229||PFC CR Standard|study group implant: PFC CR 150 control group implant: PFC CR Standard
3134180|NCT01659216||patients improved by EPNS; follow-up|Ninety female UFS patients with ≥50% symptom improvement at the end of EPNS treatment (Jul. 2001 to Jun. 2005) were followed up by a telephone questionnaire for at least 5 years.
3134181|NCT01659203|Experimental|Treatment Arm IMPT|IG-IMPT with SIB to the high risk margin
3134182|NCT01659203|Experimental|Treatment Arm IMRT|IG IMRT with SIB to the high risk margin
3134183|NCT01659190|Experimental|Oiled-limestone liniment|the removal of the collecting bag is made with the Oiled-limestone liniment.
3134184|NCT01659190|No Intervention|without Oiled-limestone liniment|the removal of the collecting bag is made without any special precautions
3134185|NCT01659177|Experimental|LY2140023 fasting|Single oral dose of 80 mg LY2140023 given in fasted state
3134186|NCT01659177|Experimental|LY2140023 + food|Single oral dose of 80 mg LY2140023 given after standardized high-fat breakfast
3134187|NCT01659164|Experimental|Group treatment (uncontrolled)|Psychological treatment in group for adults with ADHD (pilot) during 14 weeks with focus on decreasing disabilities due to the condition.
3134188|NCT01659151|Experimental|Combination Therapy|Combination Chemotherapy and Immunotherapy. The combination of vemurafenib followed by lymphodepletion with chemotherapy, Adoptive Cell Therapy (ACT) with Tumor Infiltrating Lymphocytes (TIL) infusion, and High Dose Interleukin-2 (IL-2).
3134189|NCT01659138|Experimental|SAR339658|SAR339658 at Weeks 0, 2, 4, and 6
3134190|NCT01659138|Placebo Comparator|Placebo|Placebo at Weeks 0, 2, 4, and 6
3134191|NCT01659125|Experimental|OCFighter|OCFighter
3134192|NCT01659112|Experimental|Stabilization Group|A core stabilization plus traditional upper extremity rehabilitation approach was performed.
3134193|NCT01659112|Active Comparator|Control Group|A traditional upper extremity rehabilitation-only approach was performed.
3134194|NCT01659099|Experimental|GA101|GA101 - Chemotherapy (ACVBP or CHOP)
3134195|NCT01659099|Active Comparator|Rituximab|Rituximab - Chemotherapy (ACVBP or CHOP)
3134196|NCT01659086|Experimental|Group A|Subjects will receive the investigational vaccine GSK2654911A formulation 1 and placebo
3134197|NCT01659086|Experimental|Group B|Subjects will receive the investigational vaccine GSK2654911A formulation 2 and placebo
3134198|NCT01659086|Experimental|Group C|Subjects will receive the investigational vaccine GSK2654911A formulation 3 and placebo
3134199|NCT01659086|Experimental|Group D|Subjects will receive the investigational vaccine GSK2654911A formulation 4 and placebo
3134200|NCT01659086|Experimental|Group E|Subjects will receive the investigational vaccine GSK2654909A and placebo
3134201|NCT01659086|Experimental|Group F|Subjects will receive the investigational vaccine GSK2654911A formulation 5
3134202|NCT01659086|Experimental|Group G|Subjects will receive the investigational vaccine GSK2654911A formulation 6
3134203|NCT01659086|Experimental|Group H|Subjects will receive the investigational vaccine GSK2654911A formulation 7
3134204|NCT01659086|Experimental|Group I|Subjects will receive the investigational vaccine GSK2654911A formulation 8
3134205|NCT01659086|Experimental|Group J|Subjects will receive the investigational vaccine GSK2654909A
3134206|NCT01659086|Placebo Comparator|Placebo Group|Subjects will receive Placebo
3134207|NCT01659073|Experimental|Caloric Vestibular Stimulation|Caloric vestibular stimulation performed by a modified stethescope ear attachment attached to an MRI compatible infusion pump.
3134208|NCT01659060|Experimental|Dark chocolate|
3134209|NCT01659060|Placebo Comparator|Placebo chocolate|
3134210|NCT01659047|Experimental|GS-1101|GS-1101 (oral; 150 mg BID)
3134211|NCT01659034|Experimental|Thienopyridine|Thienopyridine treatment for 3 months after implantation of everolimus-eluting Stents
3134212|NCT01659021|Experimental|Idelalisib+ofatumumab|"Randomized Initial Therapy (24 weeks): Idelalisib + ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 1000 mg weekly for 7 weeks, and then 1000 mg every 4 weeks for 4 doses)~Continuing Therapy/Observation: Idelalisib 150 mg tablets twice daily until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation."
3134213|NCT01659021|Active Comparator|Ofatumumab|"Randomized Initial Therapy (24 weeks): Ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 2000 mg weekly for 7 weeks, and then 2000 mg every 4 weeks for 4 doses)~Continuing Therapy/Observation: Observation until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation."
3134214|NCT01659008|Experimental|estradiol|estradiol PO 0.5mg 2 tabs three times a day for 2 days
3134215|NCT01659008|Experimental|Lysteda|Lysteda 650mg PO 2 tabs three times a day for 2 days
3134216|NCT01658995|Active Comparator|Doxycycline|Doxycycline 100 mg oral capsules, twice daily for 10 days
3134217|NCT01658995|Placebo Comparator|Placebo|Placebo capsules, identical to oral Doxycycline 100 mg, twice daily for 10 days.
3134218|NCT01658982||cirrhotic patients|cardiopulmonary exercise testing
3257706|NCT00785408|Placebo Comparator|5|
3134219|NCT01658956|Experimental|Subcutaneous GCSF 5 µg/kg days 8 and 12|Prophylactic administration of GCSF on days 8 and 12 following chemotherapy
3134220|NCT01658956|No Intervention|No intervention|
3134221|NCT01658943|Experimental|Arm I (mFOLFOX regimen)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and fluorouracil IV over 46-48 hours on days 1-2 and 15-16.
3134222|NCT01658943|Experimental|Arm II (Akt inhibitor MK2206 and selumetinib)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22, and selumetinib PO daily on days 1-28.
3134223|NCT01658930|Active Comparator|Radical Hysterectomy|
3134224|NCT01658930|Experimental|Simple Hysterectomy|
3134225|NCT01658917||Primary|Patients >=18 years of age who have premalignant, primary or metastatic solid tumors based upon either radiographic or biochemical testing, or histological/cytological analysis
3134226|NCT01658904|Experimental|Cohort 1- CFZ 20 mg/m^2 (Day 1,2)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:~Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2~Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9~Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70."
3134227|NCT01658904|Experimental|Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:~Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2~Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9~Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70."
3134228|NCT01658904|Experimental|Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:~Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2~Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9~Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70."
3134229|NCT01658891|Experimental|CHF 1535 50/6 µg|
3134230|NCT01658891|Active Comparator|beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|
3134231|NCT01658878|Experimental|Non-infected: Nivolumab|Nivolumab intravenous solution on specific days
3134232|NCT01658878|Experimental|HCV-infected: Nivolumab|Nivolumab intravenous solution on specific days
3134233|NCT01658878|Experimental|HBV-infected: Nivolumab|Nivolumab intravenous solution on specific days
3134234|NCT01658878|Experimental|Nivolumab|Nivolumab intravenous solution on specific days
3134235|NCT01658878|Active Comparator|Sorafenib|Sorafenib tablets on specific days
3134236|NCT01658878|Experimental|Nivolumab plus Ipilimumab Combination|Nivolumab intravenous solution + Ipilimumab intravenous solution on specific days
3134237|NCT01658878|Experimental|Child-Pugh B|Nivolumab intravenous solution on specific days
3134238|NCT01658878|Experimental|Nivolumab plus Cabozantinib Combination|Nivolumab intravenous solution + cabozantinib oral tablets on specific days
3134239|NCT01658878|Experimental|Nivolumab plus Ipilimumab plus Cabozantinib|Nivolumab intravenous solution + Ipilimumab intravenous solution + cabozantinib oral tablets on specific days
3134240|NCT01658865||Transnasal endoscopy|Healthy volunteers and patients with esophageal motor symptom will be enrolled and esophageal motility assessed by transnasal endoscopy according to clinical and manometric diagnosis
3134241|NCT01658852|Active Comparator|Metronidazole|active drug: metronidazole 500mg three time per day for 10 days
3134242|NCT01658852|Placebo Comparator|Placebo|Placebo three times per day for 10days
3134243|NCT01658839|Experimental|Travoprost|Travoprost ophthalmic solution, 0.004% (new formulation), one drop administered topically in the inferior cul-de-sac of the eye each morning at 9 AM (± 60 minutes) for 7 days
3134244|NCT01658826|Experimental|AIC316|100 mg once daily for 28 days
3134245|NCT01658826|Active Comparator|Valacyclovir|500 mg once daily for 28 days
3134246|NCT01658813|Experimental|5-Fluorouracil and Interferon|"5-Fluorouracil~Interferon-alfa-2b"
3134247|NCT01658800|Experimental|VAX161C vaccine|Subjects will be injected into the arm on 2 occasions during the study, once on Day 0 and then again on Day 21 with the vaccine VAX161C
3134248|NCT01658787||Endovascular aortic repair|Patients treated with Gore Endovascular Aortic Products.
3134249|NCT01658774|Active Comparator|Albendazole & Vitamin C|Anthelmintics. A single dose of Albendazole (400mg) at month 0 and single dose of Vitamin C (500 mg) at 3, 6, 9 and 12 months.
3134250|NCT01658774|Experimental|Albendazole|Anthelmintics. A single does of Albendazole (400mg) every three months for 12 months
3134251|NCT01658761|Experimental|Myopic traction maculopathy|The 71 eyes of 64 patients (14 men and 50 women) with myopic traction maculopathy in highly myopic eyes (refractive errors ≤-8.0 diopters and axial length ≥26.0 mm) who underwent vitrectomy were retrospectively reviewed.
3134252|NCT01658748|Active Comparator|Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Patients randomized to this arm will have stimulators turned on approximately 1 week after the 3-4 week post-surgery EEG telemetry session that determines safety parameters for stimulator settings. Subjects will be followed weekly for the next 12 weeks, with adjustments in stimulator settings according to prescribed protocol based on changes in rating scale scores (CAPS, CGI-I, ADIPS, LFIPS, HAMA, MADRS, YMRS).
3134297|NCT01658488|Other|Iron-fortified Rice|2 servings per day of Rice enriched in iron for women with iron-deficient anemia to restore their blood counts more efficiently than the standard rice not enriched with iron.
3134298|NCT01658475||periodontitis|those with periodontitis and those without periodontitis
3134299|NCT01658462|Experimental|Arm A|Docetaxel + Nintedanib
3134300|NCT01658462|Active Comparator|Arm B|Docetaxel + increase of the dose
3134301|NCT01658449|Experimental|group A|
3134253|NCT01658748|Sham Comparator|Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS|Patients randomized to this arm will undergo the same procedures and same visit frequency as those in the week 0 stimulation arm, except that the actual stimulation settings will be kept at 0 V, 0 Hz, and the patient, study psychiatrist who does the ratings, and study neurosurgeon who does neurological clinical assessments will be blind to whether the subject is receiving actual or sham stimulation. Only the study neurophysiologist will know whether the patient is in the active or sham stimulation arm during these 12 weeks. After week 12, subjects in this week will begin to receive active stimulation according to pre-specified protocol.
3134254|NCT01658735|Active Comparator|H-Wave Device|H-Wave Device with Usual Care
3134255|NCT01658735|Active Comparator|TENS|Transcutaneous electrical nerve stimulation (TENS) Device with Usual Care
3134256|NCT01658735|Sham Comparator|Sham Electrotherapy|Sham Device plus Usual Care.
3134257|NCT01658722||Observational|Long term follow-up
3134258|NCT01658709||Ankle Injured|Volunteers with an ankle injury
3134259|NCT01658709||Healthy|Healthy Volunteers
3134260|NCT01658696|Active Comparator|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
3134261|NCT01658696|Placebo Comparator|Rabies vaccine|2 x 2.5IU Verorab
3134262|NCT01658683|Experimental|Exercise Facilitator Intervention|The intervention employs small group counseling teleconferences (5),personal telephone contacts (3) and community Heart Wise Exercise program demonstrations.
3134263|NCT01658683|No Intervention|Usual Care|Usual care for cardiac rehab graduates provided by the University of Ottawa Heart Institute Minto Prevention & Rehabilitation Centre and the Cardiovascular Rehabilitation and Prevention Centre at the University Health Network.
3134264|NCT01658670|Active Comparator|Standard Care (SC) exercise group|Standard care exercise group
3134265|NCT01658670|Experimental|HEART Camp|HEART Camp Exercise Group
3134266|NCT01658657|Experimental|PRA-guided therapy|Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.
3134267|NCT01658657|Active Comparator|Fixed-dose combination treatment-guided therapy|Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.
3134268|NCT01658644|No Intervention|Group A|Patients participating in group A, will not be exposed to any interventions, they will partake in the typical hospital and communication experience.
3134269|NCT01658644|Experimental|Group B (text handout)|Patients assigned to group B will be provided with a paper or electronic version displaying a list of the names and roles of their clinical care staff; each name will NOT be accompanied by the respective photograph of each clinician. This document will be presented to the patient at the earliest possible time after admission to the hospital.
3134270|NCT01658644|Experimental|Group C (text & image handout)|Patients assigned to group C will be provided with a paper or electronic version displaying a list of the names and roles of their clinical care staff; each name will also be accompanied by the respective photograph of each clinician. This document will be presented to the patient at the earliest possible time after admission to the hospital.
3134271|NCT01658631||Anesthesia|Arterial pressure measurement using Nexfin (a noninvasive finger cuff system) during the induction of anesthesia
3134272|NCT01658631||Intensive Care Unit patients|Arterial pressure measurement using Nexfin (a noninvasive finger cuff system) during a passive legs raising test
3134273|NCT01658605|Experimental|GSK1605786|Administered orally for 16 weeks in a 2:1 ratio
3134274|NCT01658605|Placebo Comparator|Placebo|Administered orally for 16 weeks in a 2:1 ratio
3134275|NCT01658592|Experimental|NAC-VC Deep Brain Stimulation|The contractors located in NAc and VC are ON at the same time
3134276|NCT01658592|Sham Comparator|Placebo A|Stimulator setting is OFF
3134277|NCT01658592|Experimental|Placebo B|The contractor located in NAc is on
3134278|NCT01658592|Experimental|Placebo C|The contactor located in VC is on
3134279|NCT01658579|Experimental|HOE901-U300 Morning Then Evening|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 millimole per liter (mmol/L).
3134280|NCT01658579|Experimental|HOE901-U300 Evening Then Morning|HOE901-U300 (new insulin glargine 300 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
3134281|NCT01658579|Active Comparator|Lantus Morning Then Evening|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
3134282|NCT01658579|Active Comparator|Lantus Evening Then Morning|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
3134283|NCT01658553|Experimental|GSK1120212 Qtc study|Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects with Solid Tumors
3134284|NCT01658527|Experimental|Orteronel, 300 mg twice daily|
3134285|NCT01658527|Active Comparator|Bicalutamide 50 mg per day|
3134286|NCT01658514|Experimental|Met DR|One dose of 1000 mg metformin delayed-release
3134287|NCT01658514|Active Comparator|Met XR|One dose of 1000 mg metformin extended-release
3134288|NCT01658514|Placebo Comparator|Placebo|One dose of Placebo
3134289|NCT01658501|Experimental|Diet and Exercise|Diet and exercise only.
3134290|NCT01658501|Experimental|Metformin|Metformin only
3134291|NCT01658501|Experimental|Sulfonylurea|Sulfonylurea only
3134292|NCT01658501|Experimental|Metformin and Sulfonylurea|Metformin and Sulfonylurea combination therapy
3134293|NCT01658501|Experimental|PB1023|PB1023 weekly SC injection
3134294|NCT01658501|Placebo Comparator|Placebo Comparator|Placebo (0.9% Sodium Chloride) weekly SC injection
3134302|NCT01658449|Experimental|group B|
3134303|NCT01658436|Experimental|BEZ235 300 mg/400 mg bid (Stage 1)|Stage 1 consisted of a single arm where patients received BEZ235 300mg or 400mg bid. Initially the study started with a dose of 400mg bid. However, following an amendment after the preliminary safety and tolerability data from the first 3 patients treated at the 400mg dose, the dosage was changed to 300mg bid.
3134304|NCT01658423||Junior high school student|All subjects participated in measurements of body composition, muscle strength and motor fitness
3134305|NCT01658410|Active Comparator|BQ-123|
3134306|NCT01658410|Placebo Comparator|NaCl|
3134307|NCT01658397|Experimental|Fasting|Ten day fast
3134308|NCT01658384||cognitive evolution, observational,MS|multiple sclerosis tysabri treated patients
3134309|NCT01658371||efavirenz|HIV patients on efavirenz
3134310|NCT01658358|Experimental|Phase I part :Systemic Therapy|"Drug: Lapatinib~Drug: Lipo-Dox"
3134311|NCT01658358|Experimental|Phase II part|"Drug: Lapatinib~Drug: Lipo-Dox Patients will receive recommended dose according to phase I study result. at least 8 cycles, then, with continue combination treatment cycles or single lapatinib treatment (start with 1500 mg per day) at investigator's discretion."
3134312|NCT01658332|Experimental|specific procedure|Circulating tumor cells will be search with the Veridex method at inclusion and after the third chimiotherapy
3134313|NCT01658319|Experimental|Treatment (chemotherapy)|Patients receive fludarabine phosphate IV over 30 minutes on days 1-5 and methoxyamine IV over 1 hour on day 1 (day 2 of course 1). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3134314|NCT01658306|Experimental|remote ischemic preconditioning|Receiving remote ischemic preconditioning (RIPC) treatment with pressure set at 200 mmHg.
3134315|NCT01658306|Sham Comparator|placebo remote ischemic preconditioning|Receiving sham RIPC treatment with pressure set at 50 mmHg
3134316|NCT01658293|Experimental|thermal stimulation|The experimental group receiving heat and cold-water stimulation, 30 minutes a session, five sessions a week for six weeks.
3134317|NCT01658293|Active Comparator|control group|The control group receiving the similar intensity of ergometer exercise as the experimental group.
3134318|NCT01658280|Active Comparator|Conventional TBNA + ROSE|"Patients allocated in this group will undergo conventional TBNA, performed in a bronchoscopy suite by the same operator under conscious sedation, using 19-G needle size. Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.~In case of samples obtained from conventional TBNA defined as non diagnostic, the operator will shift to the EBUS procedure.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs"
3134319|NCT01658280|Experimental|EBUS-TBNA + ROSE|Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
3134320|NCT01658267|Experimental|Nutritional Supplement|Instructions and techniques to improve the quality of the diet to meet the child's daily nutritional requirements will be provided.
3134321|NCT01658254|Experimental|Survey by email|One arm of investigators will receive the survey to answer by email, reminding the necessity of posting basic results
3134322|NCT01658254|No Intervention|Non interventional arm|This arm will receive no intervention (no email with the survey)
3134323|NCT01658241|Experimental|Single Arm Main population|
3134324|NCT01658228|Other|Donepezil Treatment Group|For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Donepezil was started at 5 mg and increased to 10 mg daily or maximum tolerated dose while continuing antidepressants.
3134325|NCT01658228|Other|Placebo Treatment Group|For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Placebo dose was increased during the study to match Donepezil dose increases while continuing antidepressants.
3134326|NCT01658228|Other|Citalopram|An open treatment 8 week flexible dosing schedule starting with citalopram 10mg/day for the first week, then increasing to 20 mg/day thereafter to treat the depression. At the week 8 visit, citalopram responders will continue citalopram treatment and will be randomized to add-on donepezil or placebo at the week 16 visit.
3134327|NCT01658228|Other|Venlafaxine|For patients who did not respond to citalopram, open treatment 8 week flexible dosing schedule starting with venlafaxine 37.5mg/day for the first week, then 75mg/day for the second week, then 150mg/day for the third and fourth week, then 225mg/day for the fifth through eighth weeks. At the end of the eighth week, we will assess patients for antidepressant response. At this time-point, venlafaxine responders will be randomized to add-on donepezil or placebo.
3134328|NCT01658215|Other|Sequence 1|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days.~Each patch will be applied for 24 hours."
3134329|NCT01658215|Other|Sequence 2|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days.~Each patch will be applied for 24 hours."
3134330|NCT01658202|Other|Sequence 1|"After a 24h washout period free of any nicotine exposure, subjects will be randomly assigned to one of 2 treatment-sequence groups, separated by a 48h-intervals.~Each patch will be applied for 24h."
3134331|NCT01658202|Other|Sequence 2|"After a 24h washout period free of any nicotine exposure, subjects will be randomly assigned to one of 2 treatment-sequence groups, separated by a 48h-intervals.~Each patch will be applied for 24h."
3134332|NCT01658176|Experimental|PF-04691502 + Exemestane|PF-04691502 in combination with Exemestane
3134333|NCT01658176|Active Comparator|Exemestane|Exemestane alone
3134334|NCT01658150|Experimental|isradipine|open label
3134379|NCT01657877|Placebo Comparator|Placebo Dentifrice|Dentifrice containing no CSP and no fluoride
3134380|NCT01657864||Patients with aseptic meningitis|All patients of the study population with a record/diagnosis of aseptic meningitis during the study period
3134335|NCT01658137|Active Comparator|Typical Western Diet|"The comparator dietary pattern (Typical Western Diet) approximates the inflammatory dietary pattern typically consumed by North Americans. It contains refined grains, processed foods, dairy fat, meats, sugar and high glycemic index foods, and few fruits, nuts, legumes, and vegetables. The fruits and vegetables are highly processed (e.g. juices) and lower in micronutrients than those in the intervention diet. The saturated fat content of this diet does not meet national guidelines for health. The polyunsaturated fat:saturated fat ratio is ~0.5 (low)."
3134336|NCT01658137|Experimental|Prudent Diet|"The experimental dietary pattern (Prudent Diet) is based on intakes of foods hypothesized to have beneficial effects on inflammation and long-term health. This dietary pattern includes micronutrient and macronutrient levels consistent with healthy eating in epidemiological studies and randomized controlled trials. The diet is constructed with low-fat dairy products, fish, chicken, and lean meats to minimize saturated fat and increase protein and calcium. The diet is rich in fruits, vegetables, whole grains, nuts, legumes, and seeds that are good sources of potassium, magnesium, and dietary fiber. This diet provides a 'favorable' macronutrient profile that is low in saturated fat, has a polyunsaturated/saturated fat ratio of ~1.0 (high), and low in high glycemic index carbohydrates."
3134337|NCT01658124|Experimental|Tranexamic acid|(total dose 8 grams)
3134338|NCT01658124|Placebo Comparator|Placebo|(Sodium Chloride 0.9%)
3134339|NCT01658111|Active Comparator|Traditional physiotherapy|Each subject will receive 4 weeks of traditional upper limb rehabilitation treatment (20 sessions, 5 days a week for 4 weeks).
3134340|NCT01658111|Experimental|Robot Group|Each subject will be asked to perform five sessions per week goal-directed, planar reaching tasks, which emphasizes shoulder and elbow movements, moving from the centre target to each of 8 peripheral targets equally spaced on a 0.14 m radius circumference around a centre target using the InMotion2 (IM2) system (20 sessions- 5 days a week for 4 weeks).
3134341|NCT01658098||4-6 weeks after delivery|all patients on their 4th-6th weeks after delivery
3134342|NCT01658085||Study group: HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
3134343|NCT01658085||Control group: ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
3134344|NCT01658072|Experimental|Peri-Articular Injection|
3134345|NCT01658072|Active Comparator|Epidural Patient Controlled Analgesia (Epidural PCA)|
3134346|NCT01658059|Other|Anxiety reduction|
3134347|NCT01658059|Placebo Comparator|Placebo|
3134348|NCT01658046|Experimental|NMES group|10 weeks neuromuscular electrical stimulation plus endurance training and quadriceps strength training.
3134349|NCT01658046|Sham Comparator|Control group|10 weeks sham neuromuscular electrical stimulation plus endurance training and quadriceps strength training.
3134350|NCT01658033|Experimental|Avastin + mFOLFOX6|Avastin plus FOLFOX6 regimen in the management of her-2 negative breast cancer patients.
3134351|NCT01658020|Experimental|DW224|Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days
3134352|NCT01658020|Active Comparator|Avelox|Moxifloxacin 400mg tablet P.O. once daily for 7days
3134353|NCT01658007|Experimental|Sirolimus|Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leuk
3134354|NCT01657994|Experimental|therapy plus fes|robotic gait training plus functional electrical stimulation
3134355|NCT01657981|Experimental|Treatment arm 1|
3134356|NCT01657968||Acute tonsillitis|Patients with acute tonsillitis aged 15 to 40 years meeting at least two of Centors criteria.
3134357|NCT01657968||Healthy control patients|Control patients aged 15 to 40 years.
3134358|NCT01657955|Experimental|Bendamustine Hydrochloride Injection|d1-d2,i.v.gtt, 100mg/m2/d, 28 days per cycle, at most 6 cycles.
3134359|NCT01657955|Active Comparator|Chlorambucil|d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC≥4×109 /L at d12-d14 ); d1-d2, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC＜4×109 /L at d12-d14 );
3134360|NCT01657942|Experimental|ExABlate MR Guided Focus Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
3134361|NCT01657929|Experimental|20 µg H5-VLP + 2.5 µg GLA-AF given ID|
3134362|NCT01657929|Experimental|20 µg H5-VLP + 2.5 µg GLA-AF given IM|
3134363|NCT01657929|Active Comparator|20 µg H5-VLP alone given ID|
3134364|NCT01657929|Active Comparator|20 µg H5-VLP + 1 mg Alhydrogel(R) given IM|
3134365|NCT01657929|Active Comparator|90 µg licensed H5N1 vaccine|
3134366|NCT01657916||5 year sling implants|Patients who underwent implant of the Align Urethral Support System between June 2007 and December 2008
3134367|NCT01657903|Experimental|NaF/KNO3 toothpaste, Low RDA|Participants to brush with 1.5 g of low RDA gel to foam toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% weight by weight (w/w) KNO3.
3134368|NCT01657903|Experimental|NaF/KNO3 toothpaste, Medium RDA|Participants to brush with 1.5 g of medium RDA gel to foam toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% w/w KNO3.
3134369|NCT01657903|Active Comparator|NaF/KNO3 toothpaste|Participants to brush with 1.5 g of NaF/KNO3 toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% w/w KNO3.
3134370|NCT01657903|Placebo Comparator|No fluoride/KNO3 toothpaste|Participants to brush with a fluoride free toothpaste (0 ppmF). All study treatments contain 5% w/w KNO3.
3134371|NCT01657890|Experimental|Arm 1: Isavuconazole in healthy non-elderly male subjects|age 18 to 45 years
3134372|NCT01657890|Experimental|Arm 2: Isavuconazole in healthy non-elderly female subjects|age 18 to 45 years
3134373|NCT01657890|Experimental|Arm 3: Isavuconazole in healthy elderly male subjects|age 65 years and older
3134374|NCT01657890|Experimental|Arm 4: Isavuconazole in healthy elderly female subjects|age 65 years and older
3134375|NCT01657877|Experimental|CSP/SMFP Dentifrice|Dentifrice containing high fluoride content as SMFP and CSP
3134376|NCT01657877|Active Comparator|SMFP Dentifrice Prototype 1|Dentifrice containing high fluoride content as SMFP and no CSP
3134377|NCT01657877|Active Comparator|SMFP Dentifrice Prototype 2|Dentifrice containing low fluoride content as SMFP and no CSP
3134378|NCT01657877|Active Comparator|CSP Dentifrice|Dentifrice containing CSP but no fluoride
3134381|NCT01657864||Patients without aseptic meningitis|All patients of the study population without a record/diagnosis of aseptic meningitis during the study period
3134382|NCT01657851|Experimental|dutasteride/tamsulosin|The present study is planned to establish bioequivalence of Duodart® 0.5mg/0.4mg manufactured by GlaxoSmithKline to concomitant dosing with separate capsules of dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg formulations commercially available in Russia.
3134383|NCT01657851|Active Comparator|dutasteride|Dutasteride (Avodart®) is an approved potent dual type I and II, 5-alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery.
3134384|NCT01657851|Active Comparator|tamsulosin|Tamsulosin (Omnic®) is an alpha-1A-adrenocepter blocking agent approved for the treatment of signs and symptoms of benign prostatic hyperplasia
3134385|NCT01657838|Experimental|Arm 1: isavuconazole only|Single dose of isavuconazole on Day 1
3134386|NCT01657838|Experimental|Arm 2: isavuconazole + ketoconazole|Single dose of isavuconazole on Day 4 and ketoconazole twice daily (BID) for 24 days
3134387|NCT01657825|Experimental|Isavuconazole and warfarin|Isavuconazole three times daily (TID) for 2 days followed by once daily (QD) dosing for 11 days and warfarin single doses on Days 1 and 20
3134388|NCT01657812|Experimental|dexmedetomidine|Drug:dexmedetomidine,dexmedetomidine 1.0μg/kg intravenous injection within 15 minutes before the induction of general anesthesia and followed by Dex 0.4μg/kg/h until 40min before the end of surgery
3134389|NCT01657812|Active Comparator|epidural|Epidural:continuous epidural block (T8-9) 4 mL of 1.6% lidocaine as a test dose and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery
3134390|NCT01657812|Placebo Comparator|control|Drug: normalsaline
3134391|NCT01657799|Experimental|Veliparib 200 mg BID + WBRT|Participants received veliparib 200 mg twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
3134392|NCT01657799|Experimental|Veliparib 50 mg BID + WBRT|Participants received veliparib 50 mg twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
3134393|NCT01657799|Placebo Comparator|Placebo BID + WBRT|Participants received placebo twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
3134394|NCT01657786|Experimental|Ondansetron administration group|
3134395|NCT01657773||colorectal cancer, without nonalcoholic fatty liver disease|Patients were performed colonoscopy examination for colorectal cancer and who had been foud colorectal cancer proven by biopsy.Then the colorectal cancer patients who had not been diagnosed with nonalcoholic fatty liver disease was based on blood tests and abdomen ultrasound examination.
3134396|NCT01657773||colorectal cancer, with nonalcoholic fatty liver disease|Patients were performed colonoscopy examination for colorectal cancer and who had been foud colorectal cancer proven by biopsy.Then the colorectal cancer patients who had been diagnosed with nonalcoholic fatty liver disease was based on blood tests and abdomen ultrasound examination ultrasonography.
3134397|NCT01657760|Placebo Comparator|placebo|Intravenous saline control, in a double-blind, crossover study, with infusion days at least 2 weeks apart.
3134398|NCT01657760|Active Comparator|citalopram infusion|40 mg citalopram in 250 ml saline infused over 1 hour, in a double-blind, crossover study, with infusion days at least 2 weeks apart.
3134399|NCT01657747|No Intervention|Not applicable (imaging study)|
3134400|NCT01657734||HGG2003|"**** patients enrolled in the HGG 2003 HGG-IMMUNO 2003 trial~Patients, older than 3 and younger than 60 years with relapse of high-grade glioma (anaplastic astrocytoma WHO grade III or glioblastoma multiforme WHO grade IV), histologically diagnosed in the first stage of the disease as well as after relapse or relapse of glioma which was grade II in the First phase but grade III or IV upon relapse are treated with dendritic cell therapy (immunotherapy) as single treatment approach (No radiotherapy and/or chemotherapy)."
3134401|NCT01657734||HGG2010|"**** patients enrolled in the HGG 2010 HGG-IMMUNO 2010 trial~prospective double blind placebo controlled randomised clinical trial HGG-2010 for patients with newly diagnosed glioblastoma in which immunotherapy is integrated in the current standard of care (concommitant radiochemotherapy)."
3134402|NCT01657721|No Intervention|Wait-list Control|"Participants randomized to this group will not undergo The Cogmed Working Memory Training Program during the 5 week period, but will receive weekly phone calls from a member of the research team to review progress and advice on general time management, organization, and mnemonic strategies.~After a 5-week period, participants in this arm will have access to the working memory training."
3134403|NCT01657721|Experimental|15 Minute Training|Participants will receive a low intensity version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 15 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
3134404|NCT01657721|Experimental|30 Minute Training|Participants will receive the standard-length version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 30 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
3134405|NCT01657708|Other|Shared Desicion Making Model|
3134406|NCT01657682|Experimental|Cohort A - No prior FLT3 TKI exposure|Will enroll relapsed/refractory AML patients with FLT3 activating mutations who progressed on one or more prior chemotherapy regimens excluding any FLT3 TKI.
3134407|NCT01657682|Experimental|Cohort B - Prior therapy with FLT3 TKI|Will enroll relapsed/refractory AML patients with FLT3 activating mutations whose leukemia has progressed and have history of prior therapy with one or more FLT3 TKIs.
3134408|NCT01657669|Other|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mg) via intravitreal injection once every 8 weeks (2 months).
3134409|NCT01657656|Experimental|Vitamin D group|Vitamin D supplement by Tishcon
3134410|NCT01657656|Placebo Comparator|Control group|Identically appearing capsules
3134684|NCT01656005|Active Comparator|Bisoprolol|Beclometasone/Formoterol Beclometasone Tiotropium
3134411|NCT01657643|Placebo Comparator|Placebo|Every day for 12 weeks, subjects are asked to eat 5 grams of a placebo (strawberry-flavored candy powder)
3134412|NCT01657643|Experimental|Probiotics|Every day for 12 weeks, subjects are asked to eat 5 grams of a strawberry-flavored candy that contains probiotics [daily dose minimum of 1 billion CFU of each Lactobacillus rhamnosus LGG® (LGG®), and Bifidobacterium animalis ssp lactis BB-12® (BB-12®)]
3134413|NCT01657630||Accu-Chek Combo|15 type 1 young patients under 6 years old who begin to use the Accu-Chek Combo System
3134414|NCT01657617|Experimental|Radiation Therapy|Boost Stereotactic Body Radiation Therapy
3134415|NCT01657604|Experimental|Nilotinib+IFN|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with Peginterferon α2b at a starting target dose of 30μg/week.
3134416|NCT01657604|Active Comparator|Nilotinib|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily.
3134417|NCT01657591|Experimental|Dose Escalation|The treatment period will include dosing (taking a certain amount on a regular schedule) with vemurafenib along with the study drug, XL888. Everyone in the study will receive both drugs, but the XL888 will be given at different doses (different amounts). Everyone in this study will be given vemurafenib at the standard dose (the amount of the drug that is given as standard treatment) of 960 milligrams (mg) twice per day, unless the first people in the study have severe side effects when taking the lowest dose of XL888 along with vemurafenib. If that happens, the next people in the study may be given a lower dose of vemurafenib (720 mg twice per day) along with the lowest dose of XL888.
3134418|NCT01657578|Experimental|neonates of less than 32 weeks gestational age|omeprazole
3134419|NCT01657578|Experimental|neonates born between 32 and 35 weeks of GA|omeprazole
3134420|NCT01657578|Experimental|neonates of more than 36 weeks of GA|omeprazole
3134421|NCT01657565||open appendectomy|
3134422|NCT01657565||laparscopic appendectomy|
3134423|NCT01657552|Experimental|Eltrombopag|Subjects will receive single oral dose of eltrombopag 200 mg in Period 1 with moderate-fat, low-calcium meal.
3134424|NCT01657552|Experimental|Boceprevir|Subjects will receive boceprevir 800 mg orally every 8 hours (hrs) for 10 days in Period 2 with moderate-fat meals.
3134425|NCT01657552|Experimental|Telaprevir|Subjects will receive telaprevir 750 mg orally every 8 hours hrs for 10 days in Period 2 with moderate-fat meals.
3134426|NCT01657552|Experimental|Eltrombopag and Broceprevir|Subjects will receive eltrombopag 200 mg as single oral dose and boceprevir 800 mg orally every 8 hrs for a day in Period 3 with moderate-fat meals.
3134427|NCT01657552|Experimental|Eltrombopag and Telaprevir|Subjects will receive eltrombopag 200 mg as single oral dose and telaprevir 750 mg orally every 8 hrs for a day in Period 3 with moderate-fat meals.
3134428|NCT01657539|Experimental|Probiotics|Group of patients using yogurt containing probiotics during the experimental phase of the study.
3134429|NCT01657539|Placebo Comparator|Control Yogurt|Group of patients that will use a placebo yogurt for providing comparison with the experimental group.
3134430|NCT01657526|Experimental|Group A|Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 1 of the study
3134431|NCT01657526|Placebo Comparator|Group B|Subjects in this group will receive placebo in Step 1 of the study
3134432|NCT01657526|Experimental|Group C|Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 2 of the study
3134433|NCT01657526|Placebo Comparator|Group D|Subjects in this group will receive placebo in Step 2 of the study
3134434|NCT01657513|Experimental|tnf-alfa treatment (infliximab, adalimumab, or etanercept)|This arm includes all the patients of the study. They are patients who are start treatment with a tnf-alfa blocking drug
3134435|NCT01657500|Active Comparator|Life 4°C media for cornea storage|Donor cornea is stored in the Life 4°C media prior to implantation.
3134436|NCT01657500|Active Comparator|Optisol GS|Donor cornea is stored in the Optisol GS media prior to implantation.
3134437|NCT01657487|Experimental|Fluticasone/salmeterol high dose|COPD patients treating with high dose of ICS (Fluticasone 1000ug/day) combined with Salmeterol (25ug/day)
3134438|NCT01657487|Active Comparator|Fluticasone/Salmeterol medium dose|COPD patients treating with medium dose of ICS (Fluticasone 500ug/day) combined with Salmeterol (25ug/day)
3134439|NCT01657474|Experimental|Weekly Application of EpiFix|Weekly application of EpiFix plus standard of care
3134440|NCT01657474|Experimental|Biweekly application of EpiFix|Biweekly application of EpiFix plus standard of care
3134441|NCT01657461|Experimental|IV t-PA with Solitaire™ revascularization device|Dual IV tPA therapy and adjunctive treatment with the Solitaire revascularization device
3134442|NCT01657461|Active Comparator|IV t-PA|Infusion of intravenous tissue plasminogen activator (IV t-PA)
3134443|NCT01657448|Experimental|Methenamine, Methylthioninium|
3134444|NCT01657448|Active Comparator|Phenazopyridine|
3134445|NCT01657435|Other|Ceramax COC 28mm Acetabular Cup|The 28 mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper. The Pinnacle acetabular shell is a hemispherical type acetabulum replacement prosthesis, is available in a range of outer diameter (OD) sizes, and is used with a 28mm femoral head. Pinnacle 100 shells will be used in this study. The BIOLOX® delta ceramic femoral head components are manufactured from the same ceramic material as the acetabular bearing insert components. The femoral head is secured to the femoral stem component with an interlocking taper.
3134446|NCT01657422|Experimental|PACE+ Intervention|Intervention Group
3134447|NCT01657422|No Intervention|Sun Protection|Control / Comparison group. Patients assigned to the comparison group will receive intervention strategies over a the course of 2 years including: (1) completion of a 30-minute office-based computer program resulting in on-screen feedback to address excess sun exposure prevention, and (2) 4 phone calls and 4 mailings over a 24-month period conducted by PACE+ staff members.
3134448|NCT01657409|Experimental|BoNT-A (10 injection)|100 U in 10ml, 1.0ml for each injection, totally 10 injections at bladder body
3134449|NCT01657409|Experimental|BoNT-A (20 injections)|100 U in 10ml, 0.5ml for each injection, totally 20 injections at bladder body
3134450|NCT01657409|Experimental|BoNT-A (40 injections)|100 U in 10ml, 0.25ml for each injection, totally 40 injections at bladder body
3136134|NCT01645319||Asian - Laser Surgery Treatment Pathway|
3134451|NCT01657396|Active Comparator|Standard Oral Hygiene|Oral hygiene provided by current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.
3134452|NCT01657396|Active Comparator|SAGE Q-care q2|Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
3134453|NCT01657396|Active Comparator|SAGE Q-care q2 with Chlorhexidine|Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
3134454|NCT01657383||Hepatopancreaticobiliary (HPB) Surgery Patients|Patients undergoing surgical HPB procedures
3134455|NCT01657370|Placebo Comparator|Placebo|MK-1602 placebo-matching tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
3134456|NCT01657370|Experimental|MK-1602 1 mg|MK-1602 1 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
3134457|NCT01657370|Experimental|MK-1602 10 mg|MK-1602 10 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
3134458|NCT01657370|Experimental|MK-1602 25 mg|MK-1602 25 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
3134459|NCT01657370|Experimental|MK-1602 50 mg|MK-1602 50 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
3134460|NCT01657370|Experimental|MK-1602 100 mg|MK-1602 100 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
3134461|NCT01657357||PAO, osteoarhritis, THA|
3134462|NCT01657344||ED Patients|All patients (age 0-18 regardless of race, ethnicity, or gender and of diagnosis or chronic health condition) who are registered in the ED in the calendar year of 2011 and during a 24 month study period between 2012 and 2015.
3134463|NCT01657344||ED Practitioners|All licensed independent practitioners who practice in the ED.
3134464|NCT01657331|Experimental|Brentuximab Vedotin / Bendamustine|Subjects with relapsed or refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma will receive Brentuximab Vedotin in combination with Bendamustine, and prophylactic Neulasta
3134465|NCT01657318||Chronic Wound Group|Treatment with Olivamine containing wound care products
3134466|NCT01657305|Experimental|Oleogel-S10, non-adhesive wound dressing|A split-thickness skin graft (STSG) donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to Oleogel-S10 treatment and non-adhesive wound dressing (intra-individual comparison). Oleogel-S10 was administered (1 cm or 100 mg per cm2 wound area corresponding to thickness of about 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
3134467|NCT01657305|Other|Non-adhesive wound dressing only|A STSG donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
3134468|NCT01657292|Experimental|Oleogel-S10 ointment|Intra-individual comparison. Oleogel-S10 ointment is administered to one randomly assigned wound half.
3134469|NCT01657292|Other|Octenilin® wound gel|Intraindividual comparison: The other wound half receives disinfectant Octenilin® wound gel.
3134470|NCT01657279|Experimental|Randomized clinical scenarios|Clinicians are randomized to a sequence of 5 clinical scenarios
3134471|NCT01657266|Experimental|PRO-155|PRO-155 ophthalmic solution
3134472|NCT01657266|Active Comparator|Nevanac|Nepafenac Ophthalmic Solution 0.1%
3134473|NCT01657253|Experimental|PRO-148|"PRO-148 containing: xanthan gum and sulphate chondroitin, ophthalmic solution~doses: 1 drop in each eye, quarter in day"
3134474|NCT01657253|Active Comparator|Systane®|"Systane containing: polyethylene glycol 400 0.4%, propylene glycol 0.3% and hydroxypropyl guar~doses: 1 drop in each eye, quarter in day"
3134475|NCT01657240|Experimental|PRO-118|pro-118 ophthalmic solution, instill one drop in each eye once a day for 21 days
3134476|NCT01657240|Active Comparator|Olopatadine Hydrochloride|Olopatadine Hydrochloride ophthalmic solution 2%, instill one drop in each eye once a day for 21 days
3134477|NCT01657227|Experimental|Intervention to Patients|Only patients receive intervention
3134478|NCT01657227|Experimental|Intervention to healthcare Professionals|Primary care physicians and nurses practitioners receive the intervention. Their associated patients do not receive direct intervention although indirect intervention through professionals
3134479|NCT01657227|Experimental|Mixed Intervention|Patients and healthcare professionals (primary care physicians and nurses practitioners) associated with these patients receive intervention
3134480|NCT01657227|Other|Control|Patients receive usual care
3134527|NCT01656889|Experimental|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
3257707|NCT00785408|Placebo Comparator|6|
3134481|NCT01657214|Experimental|Dose escalation|SAR125844 will be administered as weekly IV infusion. Four weekly administrations are considered as 1 cycle. The starting dose will be either 1 dose level (DL) below the highest cleared dose level in a European TED11449 ongoing study or DL4 (260 mg/m^2), if the highest cleared dose in TED11449 is >340 mg/m^2.
3134482|NCT01657201|Experimental|Sequence 1|SYP-1018 200mg → Voriconazole 200mg
3134483|NCT01657201|Experimental|Sequence 2|Voriconazole 200mg → SYP-1018 200mg
3134484|NCT01657188||Heart failure, sleep-disordered breathing|Patients with stable heart failure NYHA ≥ II, EF ≤ 45% with or without central sleep apnea (apnea-hypopnea index ≥ 15/h) with or without adaptive servoventilation
3134485|NCT01657175|Experimental|Supportive care|The patients randomized to the supportive care arm get an extended supportive care during the first year after surgery.
3134486|NCT01657175|No Intervention|Control|"The patients randomized to the control group get care as usual"
3134487|NCT01657162|Experimental|Alendronate|Alendronate
3134488|NCT01657149|Experimental|Research Group|receive lymphatic massage and individual physiotherapy
3134489|NCT01657149|Active Comparator|Control group|receive individual physiotherapy only
3134490|NCT01657136|Active Comparator|Ivabradine|Ivabradine will be initiated at a dose of 5 mg twice daily. Dosage should be augmented up to 7.5 mg twice daily in case of symptoms persistence and/or HR > 85 bpm at rest ECG and eventually lowered up to 2.5 mg twice daily in the presence of side effects (phosphenes, diplopia and symptomatic bradycardia).
3134491|NCT01657136|Active Comparator|Beta blocker (Bisoprololo)|Bisoprololo will be initiated at a single dose of 5 mg daily. Dosage should be augmented up to 10 mg single dose daily in case of symptoms persistence and/or HR > 85 bpm at rest ECG and eventually lowered up to 2,5 mg single dose daily in the presence of side effects (symptomatic bradycardia, hypotension).
3134492|NCT01657123|Placebo Comparator|placebo|
3134493|NCT01657123|Experimental|hydrocortisone stress dosage|
3134494|NCT01657110|Other|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
3134495|NCT01657097|Experimental|INCS|Fluticasone propionate 400 microgram daily
3134496|NCT01657097|Placebo Comparator|Placebo|Placebo
3134497|NCT01657084|Experimental|Tonic-clonic seizures|Patients with tonic-clonis seizures are observed in a video/EEG room. In the case of seizures, the treatment mask or dummy mask are administered, according to a randomized cross-over study design.
3134498|NCT01657084|Experimental|Generalized Paroxysms|Patients with generalized epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.
3134499|NCT01657084|Experimental|Group 3|Patients with epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.
3134500|NCT01657071|Experimental|Group A|
3134501|NCT01657071|Active Comparator|Group B|
3134502|NCT01657058|Experimental|Treatment # 1|Soluble viscous fibre blend powder in hydrophobic matrix
3134503|NCT01657058|Experimental|Treatment # 2|Soluble viscous fibre blend in pre hydrated form
3134504|NCT01657058|Placebo Comparator|Control # 1|No soluble viscous fibre blend
3134505|NCT01657058|Experimental|Treatment # 3|Soluble viscous fibre blend premixed with ½ carbohydrate gel
3134506|NCT01657058|Placebo Comparator|Control # 2|No soluble viscous fibre blend, ½ carbohydrate jello
3134507|NCT01657045|Experimental|Cohort 1|Subjects will be randomized to receive injections JVS-100 or placebo.
3134508|NCT01657045|Experimental|Cohort 2|Subjects will be randomized to receive injections JVS-100 or placebo.
3134509|NCT01657045|Experimental|Cohort 3|Subjects will be randomized to receive injections of JVS-100 or placebo.
3134510|NCT01657032|Experimental|Lactobacillus GG and Smectite|"Children received:~LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days and~smectite, dose 3 g, once daily orally until diarrhea stopped"
3134511|NCT01657032|Placebo Comparator|Lactobacillus GG and Placebo|"Children received:~LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days and~placebo (glucose), dose 3 g, once daily orally until diarrhea stopped"
3134512|NCT01657019|Experimental|Lisdexamfetamine dimesylate|
3134513|NCT01656993||ASA activity|Participants (age 2.0 days to 12 months) undergoing cardiac surgery for a shunt and planned treatment with aspirin
3134514|NCT01656980|Experimental|Carmustine Sustained Release Implant|For subjects in this group, they will accept intracranially implanted carmustine intraoperatively.
3134515|NCT01656980|Sham Comparator|Tumor Resection Surgery|For subjects in this control group, they accept no implants while gliomas maximally be resected.
3134516|NCT01656967|Experimental|AMBU Aura-I/aScope 2|First, the AMBU Aura-I LMA will be inserted. Then, the patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
3134517|NCT01656967|Experimental|LMA Fastrach|The LMA Fastrach Single Use Laryngeal Mask Airway will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
3134518|NCT01656954||Anticipated volume/blood administration|Patients who may receive IV fluid boluses or blood products for restoration of vascular volume. Prior to receiving IV fluid boluses or blood products, the patient will undergo a passive leg raise. (PLR)
3134519|NCT01656941||d-Transposition of the Great Arteries|Neonates with d-transposition of the great arteries (dTGA) undergoing the arterial switch operation with cardiopulmonary bypass
3134520|NCT01656941||Single ventricle cardiac disease|Neonates with single ventricle cardiac disease (SVCD) undergoing stage I surgical palliation (Norwood) with cardiopulmonary bypass
3134521|NCT01656928|Other|Waiting-list control|Allocation to waiting-list Control. Receives intervention 6 months later.
3134522|NCT01656928|Active Comparator|Intervention|Allocation to intervention. Directly starts with nutritional intervention.
3134523|NCT01656915||Healthy men|Healthy male subjects with normal weight
3134524|NCT01656915||Compromised men|pre-diabetic overweight, male subjects
3134525|NCT01656902|Experimental|N3D plus|NOVOCART® 3D plus (Autologous Chondrocyte Transplantation System)
3134526|NCT01656902|Active Comparator|Microfracture|Microfracture is the standard care surgery.
3134528|NCT01656889|Placebo Comparator|Vehicle|Vehicle Control (fibrinogen solution & thrombin solution without cells)
3134529|NCT01656876|Experimental|Mirror therapy|mirror box training with or without sham mesh glove stimulation
3134530|NCT01656876|Experimental|Mirror therapy + Mesh glove stimulation|Mirror therapy combined with mesh glove stimulation
3134531|NCT01656876|Active Comparator|Controlled intervention|conventional interventions
3134532|NCT01656863||Parents|Parents reporting to the emergency room with dehydrated children
3134533|NCT01656850|Experimental|Almond diet first, then NCEP Diet|In a 28-wk randomized, cross-over, controlled feeding trial with a 2 week washout between alternative diets, subjects were assigned to receive NCEP or almond diet for 12 weeks after a 2-weeks run-in period
3134534|NCT01656850|Experimental|NCEP diet first, then Almond diet|In a 28-wk randomized, cross-over, controlled feeding trial with a 2 week washout between alternative diets, subjects were assigned to receive NCEP or almond diet for 12 weeks after a 2-weeks run-in period
3134535|NCT01656837|Experimental|MST-BSF|MST-BSF integrates two models with empirical support for their effectiveness, MST-CAN for child maltreatment (Swenson, Schaeffer, Henggeler, Faldowski, & Mayhew, 2012) and RBT for adult substance abuse (Tuten, Jones, Schaeffer, Wong, & Stitzer, 2012) into one comprehensive treatment package. MST-BSF is intended to be comprehensive. The major interventions within the MST-BSF arm include safety planning and implementation, functional analysis of the abuse incident, cognitive behavioral interventions for PTSD symptomatology and low anger management, family communication and problem solving, abuse clarification, and Reinforcement Based Treatment for adult substance abuse. RBT is an incentive-based drug treatment program for adults who abuse opiates, cocaine, or other illicit drugs.
3134536|NCT01656837|Experimental|Comprehensive Community Treatment|Families randomized to the CCT condition receive an array of services consistent with existing DCF practices. Project Safe community providers offer individual, couples, and family therapy for substance abuse/dependence, early intervention groups, treatment for co-occurring disorders, gender-specific trauma/substance abuse groups, and relapse prevention groups. The DCF caseworker also is responsible for coordinating care for the behavioral and mental health needs of the children. Services include individual outpatient treatment, family therapy, intensive in-home treatment, extended day programs, intensive outpatient, partial and inpatient hospitalization, residential programs/temporary housing (safe homes, shelters), emergency mobile psychiatric services, and crisis stabilization.
3134537|NCT01656811|Experimental|levalbuterol 90 mcg|levalbuterol 90 mcg delivered via metered dose inhaler (MDI)
3134538|NCT01656811|Experimental|levalbuterol 180 mcg|levalbuterol 180 mcg delivered via MDI
3134539|NCT01656811|Active Comparator|racemic albuterol 180 mcg|racemic albuterol 180 mcg delivered via MDI
3134540|NCT01656811|Placebo Comparator|Placebo|Placebo delivered via MDI
3134541|NCT01656798|Experimental|fasted condition|
3134542|NCT01656798|Experimental|fec condition|
3134543|NCT01656785|Experimental|Brain 68Ga-BNOTA-PRGD2|We will perform brain 68Ga-BNOTA-PRGD2 PET/CT on stroke patients to determine its value.
3134544|NCT01656772|Active Comparator|Manual Lasso navigation|Use of conventional manual navigation techniques with the Lasso catheter
3134545|NCT01656772|Experimental|Vdrive Lasso navigation|Use of the Vdrive to remotely and robotically control the manipulation of a Lasso catheter
3134546|NCT01656759|No Intervention|Control Group|Control group. Will not receive the fibrin spray.
3134547|NCT01656759|Active Comparator|Treatment Group--Evicel Fibrin Spray|"Patient will receive the fibrin spray after implantation of device but before the wound is closed.~Patients will be randomized to receive spray or not and postop parameters measured."
3134548|NCT01656746|Experimental|Treatment (single incision laparoscopic surgery)|Patients undergo single incision laparoscopic surgery with GelPort® attachment.
3134549|NCT01656733|Experimental|Nicotrol Inhaler|Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.
3134550|NCT01656733|Placebo Comparator|Placebo Inhaler|Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
3134551|NCT01656720|Placebo Comparator|Placebo|Placebo 2g Suppository
3134552|NCT01656720|Active Comparator|NRL001 5mg|5mg NRL001 in a 2g suppository
3134553|NCT01656720|Active Comparator|NRL001 7.5mg|7.5mg NRL001 in a 2g suppository
3134554|NCT01656720|Active Comparator|NRL001 10mg|10mg NRL001 in a 2g suppository
3134555|NCT01656707|Experimental|ACRA|Ten weekly 60-minute sessions of Adolescent Community Reinforcement Approach (ACRA) will be provided as an Adaptive treatment condition.
3134556|NCT01656707|Experimental|Cognitive Behavioral Therapy (CBT)|Ten weekly, 60-minute sessions of augmented individualized Cognitive Behavioral Therapy (CBT)will be provided as an Adaptive Treatment condition
3134557|NCT01656681|Experimental|THIAA|"Stage 1 (the first 12 weeks of the study): all subjects participate in a structured lifestyle change program featuring a high-protein, high-phytonutrient food plan (HP2). Those randomized to THIAA arm additionally receive the THIAA tablet, 3 times a day.~Stage 2 (the subsequent 52-week study): All qualified subjects (i.e. those who have lost at least 7.5% of their body weight in Stage 1) participate in a less restrictive lifestyle change program featuring a Mediterranean-style Low-glycemic-load food plan (MLGL). Those randomized to THIAA arm additionally receive the THIAA tablet, 3 times a day."
3134558|NCT01656681|Active Comparator|Placebo|"Stage 1 (the first 12 weeks of the study): all subjects participate in a structured lifestyle change program featuring a high-protein, high-phytonutrient food plan (HP2). Those randomized to Placebo arm receive the placebo tablet, 3 times a day.~Stage 2 (the subsequent 52-week study): All qualified subjects (i.e. those who have lost at least 7.5% of their body weight in Stage 1) participate in a less restrictive lifestyle change program featuring a Mediterranean-style Low-glycemic-load food plan (MLGL). Those randomized to Placebo arm receive the placebo tablet, 3 times a day."
3134559|NCT01656668|Experimental|BC1036|BC1036 300 mg capsule capsule by mouth, twice daily, for 14 days.
3134560|NCT01656668|Placebo Comparator|Sugar Pill|Sugar placebo capsule by mouth, twice daily, for 14 days.
3134561|NCT01656655||PTSD group|Patients with PTSD
3134562|NCT01656655||Control Group|non PTSD group
3134563|NCT01656642|Experimental|Cohort 1 (C1): Ate+Vem - No Run-in|Participants will receive atezolizumab (Ate) 1200 milligrams (mg) every 3 weeks (q3w) along with vemurafenib (Vem) 720 mg twice daily (BID) for 21 days in each cycle followed by 7 days off treatment (28-day cycle). Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of consent occurs.
3134685|NCT01655992|Experimental|S1 generic|40mg／m2 bid four weeks on two weeks off
3134564|NCT01656642|Experimental|Cohort 2 (C2): Ate+Vem (56 Day Run-in)|Run-in period (56 days): participants will receive vemurafenib 960 mg orally BID from Day 1 to 49 and vemurafenib 720 mg orally BID from Day 50 to 56. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg intravenous (IV) q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.
3134565|NCT01656642|Experimental|Cohort 3 (C3): Ate+Vem (28 Day Run-in)|Run-in period (28 days): participants will receive vemurafenib 960 mg orally BID for 21 days, then vemurafenib 720 mg orally BID for 7 days. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg IV q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.
3134566|NCT01656642|Experimental|Cohort 4 (C4): Ate+Vem+Cob (28 Day Run-in)|Run-in period (28 days): participants will receive vemurafenib 960 mg orally BID for 21 days, then vemurafenib 720 mg orally BID for 7 days in combination with cobimetinib (Cob) 60 mg IV once daily, 21 days on/7 days off schedule (21/7). Combination treatment period: Participants will receive fixed dose of atezolizumab 800 mg IV every 2 weeks (q2w) in combination with vemurafenib 720 mg orally BID and cobimetinib 60 mg orally once daily 21/7 in 28 days cycle.
3134567|NCT01656642|Experimental|ECA: Ate+Vem+Cob (Mandatory Biopsy PD)|Expansion Cohort A (ECA): Approximately 10 participants who experienced disease progression (PD) after receiving prior checkpoint inhibitor therapy will be enrolled and treated with atezolizumab plus (+) vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants enrolled in this cohort. The doses will be decided based on the results of Cohorts 1-4.
3134568|NCT01656642|Experimental|ECB: Ate+Vem+Cob (Mandatory Biopsy)|Expansion Cohort B (ECB): Approximately 20 participants will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants. The doses will be decided based on the results of Cohorts 1-4.
3134569|NCT01656642|Experimental|ECC: Ate+Vem+Cob (No Mandatory Biopsy)|Expansion Cohort C (ECC): Approximately 10 participants who experienced disease progression after receiving prior checkpoint inhibitor therapy will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections will be optional for all participants enrolled in this cohort. The doses will be decided based on the results of Cohorts 1-4.
3134570|NCT01656629|Active Comparator|teriparatide|teriparatide 20 mcg sq for 3 months
3134571|NCT01656629|Active Comparator|Alendronate|70 mg po weekly for 3 months
3134572|NCT01656629|Active Comparator|calcium and vitamin D|calcium 630 mg vitamin D 500 units daily for 3 months
3134573|NCT01656616||EMS cyanide exposure patients|
3134574|NCT01656603|Experimental|unlicensed CBU|The Principal Investigators will be the transplant physicians at participating US transplant centers
3134575|NCT01656590|Other|High Protein and Exercise therapy along-with Nocturnal Enteral|
3134576|NCT01656551|Active Comparator|A: Gemcitabine|Single agent gemcitabine dose 1200 mg/m2 days 1 and 8, every 3 weeks
3134577|NCT01656551|Experimental|B: Gemcitabine + Cisplatin|Gemcitabine dose 1000 mg/m2 days 1 and 8, every 3 weeks
3134578|NCT01656551|Active Comparator|C: Pemetrexed|
3134579|NCT01656551|Experimental|D: Pemetrexed + Cisplatin|
3134580|NCT01656538|Experimental|Paclitaxel plus Reolysin|Paclitaxel given weekly on days 1, 8, 15 every 4 weeks plus reolysin days 1, 2, 8, 9, 15 and 16.
3134581|NCT01656538|Active Comparator|Paclitaxel|Paclitaxel given weekly on days 1, 8 and 15 every 4 weeks.
3134582|NCT01656525|Experimental|1|
3134583|NCT01656525|Experimental|2|
3134584|NCT01656525|Experimental|3|
3134585|NCT01656525|Experimental|4|
3134586|NCT01656512|Active Comparator|Arm ( A)|Arm ( A) : patients will receive calcium & vitamin D
3134587|NCT01656512|Experimental|Arm (B)|we will give calcium and Vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of
3134588|NCT01656499|Active Comparator|Arabinoxylanoligosaccharides (AXOS)|AXOS (2 x 5g WBE/day)
3134589|NCT01656499|Placebo Comparator|Maltodextrine (placebo)|Maltodextrine (2 x 5g/day)
3134590|NCT01656486|Experimental|Stereotactic Radiation|Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery.
3134591|NCT01656473|Experimental|MI and DBT|Individual Motivational Interview session followed by 12-week Dialectical Behaviour Therapy skills group
3134592|NCT01656460|Experimental|Stereotactic radiation Arm 1|"Dose Levels/total Dose~1 16 Gy"
3134593|NCT01656460|Experimental|Stereotactic radiation Arm 2|2 20 Gy
3134594|NCT01656460|Experimental|Stereotactic radiation Arm 3|3 24 Gy
3134595|NCT01656460|Experimental|Stereotactic radiation Arm 4|4 28 Gy
3134596|NCT01656447||Patients with Scleroderma|Patients who have been diagnosed at any point in their life with Scleroderma will compose the cohort.
3134597|NCT01656434|Experimental|NOMAC-E2|Participants received a NOMAC-E2 tablet (2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol), taken orally once daily for 13 cycles. Each cycle was 28 days. For each cycle, participants received NOMAC-E2 tablets on Days 1 to 24 and placebo tablets on Days 25 to 28.
3134598|NCT01656434|Active Comparator|NETA-EE|Participants received a NETA-EE tablet (1 mg norethisterone acetate and 10 μg ethinylestradiol), taken orally once daily for 13 cycles. Each cycle was 28 days. For each cycle, participants received NETA-EE tablets on Days 1 to 24; EE 10 μg tablets on Days 25 and 26; and ferrous fumarate 75 mg tablets on Days 27 and 28.
3134599|NCT01656421||COPD|Patients with Chronic Obstructive Pulmonary Disease, including mild, moderate, severe and very severe airflow obstruction
3134600|NCT01656421||Comparators|Current or ex-smokers free from from Respiratory Disease
3134601|NCT01656408|Experimental|Panel A: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
3134602|NCT01656408|Experimental|Panel B: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
3134603|NCT01656408|Experimental|Panel C: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
3134604|NCT01656408|Experimental|Panel D: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
3134605|NCT01656408|Experimental|Panel E-Elderly|Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days
3134830|NCT01655056|Experimental|high male dose|Japanese and Caucasian males
3134606|NCT01656408|Experimental|Panel F - Elderly|Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days
3134607|NCT01656408|Experimental|Panel G - Healthy - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
3134608|NCT01656408|Experimental|Panel H - Crossover|MK-8150 or matching placebo for 10 consecutive days in 2-period crossover with minimum 3 weeks washout period between the 2 treatment periods
3134609|NCT01656408|Experimental|Panel I - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
3134610|NCT01656408|Experimental|Panel J - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
3134611|NCT01656395|Experimental|MK-1029 10 mg|
3134612|NCT01656395|Experimental|MK-1029 30 mg|
3134613|NCT01656395|Experimental|MK-1029 60 mg|
3134614|NCT01656395|Experimental|MK-1029 150 mg|
3134615|NCT01656395|Active Comparator|Montelukast 10 mg|
3134616|NCT01656395|Placebo Comparator|Placebo|
3134617|NCT01656395|Experimental|MK-1029 1 mg or 3 mg|
3134618|NCT01656395|Experimental|Montelukast 10 mg + MK-1029|
3134619|NCT01656382|Active Comparator|5 mg/kg/d ABLC x 14 days|5 mg/kg/d of Amphotericin B Lipid Complex for 14 days
3134620|NCT01656382|Experimental|10/kg/kg/d x 7 days|10 mg/kg/d of Amphotericin B Lipid Complex for 7 days
3134621|NCT01656369|Active Comparator|Group I delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed. Postoperatively, minimal pain medication was required. Early ambulation was encouraged, and patients' diets were advanced as tolerated.
3134622|NCT01656369|Active Comparator|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
3134623|NCT01656356|Active Comparator|A/17/turkey/Turkey/05/133 (H5N2)|
3134624|NCT01656356|Placebo Comparator|Placebo|
3134625|NCT01656343||Belatacept treated kidney-only transplant recipients|
3134626|NCT01656343||CNI treated kidney-only transplant recipients|
3134627|NCT01656330|Experimental|Rivaroxaban + Profilnine SD|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single bolus dose of Profilnine SD 50 IU/kg.
3134628|NCT01656330|Experimental|Rivaroxaban + Beriplex P/N|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single bolus dose of Beriplex 50 IU/kg.
3134629|NCT01656330|Experimental|Rivaroxaban + Saline|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single 100cc bolus of saline.
3134630|NCT01656317|Active Comparator|Mobilisation of patients after SAH|"Patients which were treated after SAH in 2012 will receive early multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.~Mobilisation will be initiated and completed according to mobilisations guidelines which are developed and adjusted to the patients in early stage after aneurysmal SAH."
3134631|NCT01656317|No Intervention|Patients after SAH from 2011|Patients after SAH from 2011 which did not receive early rehabilitation and mobilisation will be followed up 3-6 annd 12 months after SAH and outcome measures compared with patients from 2011.
3134632|NCT01656304|Experimental|Treatment (monoclonal antibody, antiangiogenesis)|Patients receive bevacizumab IV over 30-90 minutes once every 14 days. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
3134633|NCT01656278|Active Comparator|Conventional biochemical and clinical examinations|Biochemical and clinical examinations
3134634|NCT01656278|Experimental|Conventional biochemical and clinical examinations and MRI.|Biochemical and clinical examinations and MRI.
3134635|NCT01656265|Experimental|ARQ 197|
3134636|NCT01656252|Experimental|Phase I- Cytarabine & Eltrombopag|Cycle 1= Cytarabine twice daily on Days 1, 3 and 5 and Eltrombopag (Open-Label) until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.
3134637|NCT01656252|Experimental|Phase II- Sequence A|Cytarabine twice daily on Days 1, 3 and 5. Eltrombopag(dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo with 2nd cycle. Treatment sequence will be blinded to the patient and all study/sponsor personnel.
3134638|NCT01656252|Experimental|Phase II- Sequence B|Cytarabine twice daily on Days 1, 3 and 5. Placebo with 1st cycle of high-dose consolidation therapy and Eltrombopag(dose and schedule as determined in Phase I) with 2nd cycle. Treatment sequence will be blinded to the patient and all study/sponsor personnel.
3134639|NCT01656239|Experimental|fedovapagon 1 mg|Once daily oral dose of 1 mg fedovapagon for 12 weeks
3134640|NCT01656239|Experimental|fedovapagon 2 mg|Once daily oral dose of 2 mg fedovapagon for 12 weeks
3134641|NCT01656239|Experimental|fedovapagon 4 mg|Once daily oral dose of 4 mg fedovapagon for 12 weeks
3134642|NCT01656239|Placebo Comparator|sugar pill|Once daily oral dose of placebo for 12 weeks
3134643|NCT01656226|Experimental|Eryfotona AK-NMSC® cream|
3134644|NCT01656226|Other|Sunscreen SPF 50+|
3134645|NCT01656213|Experimental|visual-feedback handgrip exercise|Subjects allocated to treatment will be trained in the laptop-based exercise that takes 20 minutes/session. Subjects will be encouraged to perform the exercise 2-3 times per dialysis session
3134682|NCT01656018|Experimental|Arm 5B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 600 mg at Months 2 and 4 in Arm 5B.
3136135|NCT01645319||Asian - Incisional/Other Surgery Treatment Pathway|
3134646|NCT01656213|No Intervention|Control Arm|"60 similar ESRD stroke patients will be randomly assigned to the non-intervention arm. These patients will receive standard advice during dialysis (rest or gentle activity, e.g. reading).~Note that both groups of patients will also receive standard multidisciplinary rehabilitation care following a stroke, including therapy sessions at times other than receiving dialysis"
3134647|NCT01656200|Experimental|Vaccine|Single dose live attenuated Japanese encephalitis vaccine SA14-14-2
3134648|NCT01656187|Active Comparator|Intervention|This arm will be given memantine intervention at the beginning of the trial. Following the washout period, this arm will be switched to placebo.
3134649|NCT01656187|Placebo Comparator|Placebo|This group will start off on placebo at the beginning of the study. Following the washout period, this arm will be switched to the memantine intervention.
3134650|NCT01656174||No Treatment|
3134651|NCT01656161|Experimental|Triptorelin embonate 22.5 mg|Participants received subcutaneous injections of triptorelin embonate 22.5 mg 6-month formulation administered on Day 1 and on Day 169.
3134652|NCT01656148|Experimental|Fampridine-SR|Initially all participants receive Fampridine-SR 10 mg BID in an open label enrichment phase lasting four weeks. Those 40% responding the most by SSST will go onto phase two. 50% of these will receive 10 mg Fampridine-SR BID for four weeks.
3134653|NCT01656148|Placebo Comparator|Placebo|In the intervention phase 50% will receive placebo BID
3134654|NCT01656135|Other|Reference Group|"Basiliximab (Simulect®):~Day 0: 20mg IV ≤2h prior to surgery~Day 4: 20mg IV~Prednisolone:~Day 0: 500mg IV (250mg pre-op, 250mg intra-op)~Day 1: 125mg IV~Day 2 - 14: 20mg/day oral~Week 3 - 4: 15mg/day oral~Week 5 - 8: 10mg/day oral~Week 9 - 12: 5mg/day oral~Week 13 - 14: 2.5mg/day oral~Week 15 - Study End: Cessation~Steroid tapering should not proceed if graft rejection has occurred or if renal dysfunction is observed.~Mycophenolate Mofetil (MMF, or biologic equivalent):~Treatment with MMF should commence one day prior to transplantation (on Day -1) and should continue indefinitely, with a dose reduction after two weeks:~Day -1 - 14: 2g/day oral~Day 15 - Study End 1.5g/day oral (750mg twice daily)~Tacrolimus (or biologic equivalent):~Day -4 - 14: 3-12ng/ml~Week 3 - 12: 3-10ng/ml~Week 13 - 36: 3-8ng/ml~Week 37 - Study End: 3-6ng/ml"
3134655|NCT01656122|Experimental|PK|PK of abacavir and lamivudine
3134656|NCT01656109|Experimental|PI-experience group|Using PI-based HAART for ≥6 months at the screening visit HIV-RNA viral load < 50 copies/ml at the screening visit No history of HIV-RNA ≥ 1,000 copies/ml while using PI-based HAART
3134657|NCT01656109|Experimental|PI-naïve group|Never been exposed to any PI-containing regimen HIV-RNA viral load ≥ 1,000 copies/ml at the screening visit
3134658|NCT01656096|Experimental|Renal sympathetic denervation|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)
3134659|NCT01656096|Sham Comparator|Sham procedure|Sham procedure mimicking the renal sympathetic denervation procedure in the experimental arm
3134660|NCT01656083||SM intervention + varenicline|In intervention group, SM is delivered by a standard designed SM platform system. The interactive SM supports are involved and trained professional staff will provide guidance regularly. The drug usage in two groups are the same.
3134661|NCT01656083||Non-SM intervention group: varenicline|varenicline only
3134662|NCT01656070|Experimental|Vitamin D|"oral cholecalciferol 1000000 UI (vitamin D3).~At 0, 3, 6 and 9 months, the vitamin D group received orally 100000 IU of cholecalciferol suspended in 2 mL of olive oil in sealed plastic syringes labeled with the unique identification numbers."
3134663|NCT01656070|Placebo Comparator|placebo|"placebo~At 0, 3, 6 and 9 months, the placebo group received 2 mL of olive oil, in sealed plastic syringes labeled with the unique identification numbers."
3134664|NCT01656057|Experimental|Acetaminophen+saline|Acetaminophen tablet 1500 mg via nasogastric tube + i.v. saline
3134665|NCT01656057|Experimental|Acetaminophen+CCK|Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
3134666|NCT01656057|Experimental|Metformin+saline|Metformin tablet 1500 mg + Acetaminophen tablet 1500 mg via nasogastric tube + i.v. saline
3134667|NCT01656057|Experimental|Metformin+CCK|Metformin tablet 1500 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
3134668|NCT01656057|Experimental|Colesevelam+saline|Colesevelam tablet 3750 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. saline
3134669|NCT01656057|Experimental|Colesevelam+CCK|Colesevelam tablet 3750 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
3134670|NCT01656044|Active Comparator|Arm I (SSD)|Patients receive SSD over their closed laparotomy incision at the conclusion of their surgery.
3134671|NCT01656044|Experimental|Arm II (NPT)|Patients receive NPT dressing over their closed laparotomy incision at the conclusion of their surgery.
3134672|NCT01656031|Experimental|high-dose cytarabine and clofarabine|high-dose cytarabine (2000 milligram/meter squared/day) administered intravenously over 3 hours followed by clofarabine administered intravenously over 2 hours daily for 5 consecutive days
3134673|NCT01656018|Experimental|Arm 1A|Female participants will receive a single dose of long acting TMC278 1200 mg intramuscularly (IM) at baseline (Day 0) in Arm 1A.
3134674|NCT01656018|Experimental|Arm 1B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline in Arm 1B.
3134675|NCT01656018|Experimental|Arm 2A|Female participants will receive a single dose of long acting TMC278 600 mg IM at baseline in Arm 2A.
3134676|NCT01656018|Experimental|Arm 2B|Male participants will receive a single dose of long acting TMC278 600 mg IM at baseline in Arm 2B.
3134677|NCT01656018|Experimental|Arm 3A|Female participants will receive 3 bi-monthly injections of long acting TMC278 1200 mg IM at baseline, Months 2 and 4 in Arm 3A.
3134678|NCT01656018|Experimental|Arm 3B|Male participants will receive 3 bi-monthly injections of long acting TMC278 1200 mg IM at baseline, Months 2 and 4 in Arm 3B.
3134679|NCT01656018|Experimental|Arm 4A|Female participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 900 mg at Months 2 and 4 in Arm 4A.
3134680|NCT01656018|Experimental|Arm 4B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 900 mg at Months 2 and 4 in Arm 4B.
3134681|NCT01656018|Experimental|Arm 5A|Female participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 600 mg at Months 2 and 4 in Arm 5A.
3134683|NCT01656005|Experimental|Carvedilol|Beclometasone/Formoterol Beclometasone Tiotropium
3134686|NCT01655992|Active Comparator|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
3134687|NCT01655979|Experimental|MEP-1|
3134688|NCT01655979|Experimental|MEP-2|
3134689|NCT01655966|Active Comparator|Standard of care|Group A: comprises 40 treatment-naive chronic hepatitis c patients who will receive the standard of care treatment: peginterferon Alfa 2a 160 ug once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
3134690|NCT01655966|Experimental|Triple therapy|Group B: comprises 40 treatment-naive chronic HCV patients who will receive oral vitamin D 1mcg once daily plus peginterferon alfa-2a (160ug once weekly) and weight-based ribavirin 1000-1200 mg daily (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
3134691|NCT01655953|Experimental|Campaign 1|
3134692|NCT01655953|Experimental|Campaign 2|
3134693|NCT01655940||Cardiac bypass patients|
3134694|NCT01655927|Experimental|Tranexamic Acid|15 mg/Kg Tranexamic Acid IV after anesthesic induction,and continues with a dose of 1mg/kg/h intraoperatory
3134695|NCT01655927|Placebo Comparator|Saline (Placebo)|15 mg/Kg of Saline IV after anesthesic induction,and continues with a dose of 1mg/kg/h intraoperatory
3134696|NCT01655914|Active Comparator|Arm A|"Sequence of Exposure:~Sequence A (N=5) Week 1: S/L 1.1 mg Week 2: S/L 2.2 mg Week 3: IV 0.2 mg Week 4: S/L 2.2 mg with 240 ml water"
3134697|NCT01655914|Active Comparator|Arm B|Sequence B (N=5) Week 1: IV 0.2 mg Week 2: S/L 2.2 mg Week 3: S/L 1.1 mg Week 4: S/L 2.2 mg with high fat diet
3134698|NCT01655901|Experimental|Active video gaming|Playing Kinect
3134699|NCT01655901|Experimental|Passive video gaming|Playing Xbox 360
3134700|NCT01655901|Experimental|Resting|Stay seated on a comfortable chair
3134701|NCT01655888|Experimental|single arm with Tremelimumab|Tremelimumab: 10mg/Kg ev day 1 every 4 weeks for 6 doses in induction phase, then every 12 weeks in maintenance phase until disease progression of severe toxicity
3134702|NCT01655875|Experimental|bone marrow transplant|
3134703|NCT01655862||OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
3134704|NCT01655849|Experimental|Z160|375mg BID
3134705|NCT01655849|Placebo Comparator|placebo|matching placebo control
3134706|NCT01655836|Experimental|Treatment (HDR brachytherapy, SBRT)|Patients undergo HDR brachytherapy on day 0 followed by SBRT on days 15-30
3134707|NCT01655823|Placebo Comparator|Placebo (twice daily)|Placebo for injection (1 ml volume), twice a day for four consecutive days.
3134708|NCT01655823|Experimental|Low dose Tetrodotoxin (twice daily)|Low dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
3134709|NCT01655823|Experimental|Mid-range dose of Tetrodotoxin (twice daily)|Mid-range dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
3134710|NCT01655823|Experimental|Max dose Tetrodotoxin (once daily)|Max dose Tetrodotoxin injectable (1 ml volume), once a day in the morning for four consecutive days and Placebo for injection (1 ml volume), once a day in the afternoon for four consecutive days. Total of 4 treatment days.
3134711|NCT01655823|Experimental|Max dose Tetrodotoxin (twice daily)|Max dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
3134712|NCT01655810|Active Comparator|Vitamin D 4000 IU|
3134713|NCT01655810|Active Comparator|Vitamin D 600 IU|
3134714|NCT01655797|Experimental|CBT|The treatment group received manualized CBT-I using a adapted version of a manual designed for use by primary care personnel. Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
3134715|NCT01655797|No Intervention|Wait-list|A deferred treatment wait-list condition, with no restrictions placed on the usual care.
3134716|NCT01655784|Active Comparator|Eighteen Coils (0.014-0.0155 inch)|Subjects who randomize to this arm will receive larger diameter bare platinum coils for treatment of their cerebral aneurysm. Subjects in this arm could receive a combination of the following protocol approved intracranial coils depending on the phase: Target XL 360 Standard, Target XL 360 Soft, Target XL 360 Helical, GDC-18 360 Standard, GDC-18 3D, GDC-18 2D, GDC-18 Soft, and/or 0.014-0.0155 inch diameter bare platinum intracranial coils.
3134717|NCT01655784|Active Comparator|Standard Coils (0.014 inch)|Subjects who randomize to this arm will receive the standard diameter bare platinum coils for treatment of their cerebral aneurysm. Subjects in this arm could receive a combination of the following protocol approved intracranial coils depending on the phase: Target 360 Standard, Target 360 Soft, Target 360 Ultra, Target 360 NANO, Target 360 Helical Ultra, GDC-10 360 Standard SR, GDC-10 360 Soft SR, GDC-10 UltraSoft, GDC-10 3D, GDC-10 2D, GDC-10 Soft 2D SR, GDC-10 Soft SR, GDC-10 Soft, and/or any additional 0.014 inch or less diameter bare platinum intracranial coils.
3134718|NCT01655771|Experimental|Elderly|TD-1211 Dose 1
3134719|NCT01655771|Experimental|Younger|TD-1211 Dose 2
3134720|NCT01655758|Active Comparator|timolol|60-day treatment phase with 0.5% timolol eyedrops, b.i.d.
3134721|NCT01655758|Active Comparator|'timolol-dorzolamide fixed combination'|60-day treatment phase with the fixed combination of 0.5% timolol-2% dorzolamide, eyedrops, b.i.d.
3134722|NCT01655758|Active Comparator|xalatan|60-day treatment phase with 0.005% latanoprost, eyedrops, QD
3134723|NCT01655758|Active Comparator|travatan|60-day treatment phase with 0.004% travoprost, eyedrops, QD
3134724|NCT01655758|Active Comparator|lumigan|60-day treatment phase with 0.03% bimatoprost, eyedrops, QD
3134725|NCT01655745|Experimental|FDG PET/MR, No Chemotherapy Arm|Patients that are NOT receiving chemotherapy but are only completing surgical intervention.
3134726|NCT01655745|Experimental|FDG PET/MR, Chemotherapy Arm|Patients that are receiving chemotherapy prior to completing surgical intervention. These patients will receive a FDG PET/MR prior to chemotherapy and after completion of chemotherapy (at the time of pre-op, before surgical intervention).
3134727|NCT01655732|Experimental|Atraumatic Restorative Treatment|ART is Atraumatic Restorative Treatment involving removal of soft carious enamel and dentine by hand instruments only and then restore the resulting cavity and adjacent pits and fissures with an adhesive restorative material.
3134831|NCT01655056|Experimental|high female dose|Japanese and Caucasian females
3134832|NCT01655056|Experimental|highest male dose|Japanese and Caucasian males
3134728|NCT01655719|Experimental|Pioglitazone Treatment|"If eligible, subjects can participate in 1 or both parts of this study as follows:~Part 1: In the initial main portion of the study subjects will receive 24 -28 weeks of therapy with pioglitazone at the dosage approved for the control of diabetes. Response will be evaluated per RECIST. Safety measure are outlined in the protocol including weekly weigh ins, calls, labs, exams, etc.~Part 2: A secondary protocol is then available to subjects who complete the main initial study with less than complete response per RECIST. They can undergo a radioiodine scan to see if the treatment with pioglitazone has sensitized their disease to radioiodine. If it has - they can pursue the radioiodine treatment."
3134729|NCT01655706|Active Comparator|escitalopram (10-20mg)|Patients are on escitalopram for 8 weeks. At Week 8, patients will be assessed as 'responders' or 'non-responders'. 'Responders' will continue on escitalopram until study endpoint.
3134730|NCT01655706|Active Comparator|aripiprazole (2-10mg)|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
3134731|NCT01655693|Experimental|Doxorubicin Transdrug (DT) at 20mg/m2|DT will be infused over 6 hours through the intravenous (IV) route at dose of 20 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
3134732|NCT01655693|Experimental|Doxorubicin Transdrug (DT) at 30 mg/m2|DT will be infused over 6 hours through the IV route at dose of 30 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
3134733|NCT01655693|Active Comparator|Best Standard of Care|Patients randomized in the control group will receive treatment according to the investigator's choice, until disease progression or unacceptable toxicity
3134734|NCT01655680|Experimental|ABT-126 Low Dose|ABT-126 Low Dose
3134735|NCT01655680|Experimental|ABT-126 Middle Dose|ABT-126 Middle Dose
3134736|NCT01655680|Experimental|ABT-126 High Dose|ABT-126 High Dose
3134737|NCT01655680|Placebo Comparator|Placebo|Placebo
3134738|NCT01655667||Chronic Obstructive Pulmonary Disease|All patients with a coded diagnosis of COPD entered into their electronic clinical record between 1990 and 2009.
3134739|NCT01655654|No Intervention|Cohort 1|All employees within the acute care hospital that signed the informed consent form and provided their individual data.
3134740|NCT01655654|Active Comparator|Cohort 2|All subjects of cohort 1 who also are considered hypertensive and participated in one or more study interventions, which include behavioral interventions (an increase in physical activity, or dietary changes) or who have a primary care provider visit to discuss hypertension.
3134741|NCT01655641|Experimental|Tranexamic acid arm|"Along with the standard of care (routine surgical care involved in preventing blood loss during surgery) this arm will receive drug Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV for non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"
3134742|NCT01655641|Active Comparator|Standard of care arm|Includes routine surgical care involved in preventing blood loss during and after surgery.
3134743|NCT01655628|Experimental|GC chemotherapy plus CIK cells|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks); however,the other 20 patients will not accept CIK cells treatment. After the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus 8 cycles CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
3134744|NCT01655628|Active Comparator|GC chemotherapy|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. After the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
3134745|NCT01655615|Experimental|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
3134746|NCT01655602|Experimental|upper edge trimming|Surgery: trichophytic closure The 1-millimetre trimming of upper edge of linear incision before wound closure
3134747|NCT01655602|Experimental|lower edge trimming|Surgery: trichophytic closure The 1-millimetre trimming of lower edge of linear incision before wound closure
3134748|NCT01655602|Experimental|Both edge trimming|Surgery: trichophytic closure The 0.5-millimetre trimming of both edge of linear incision before wound closure
3134749|NCT01655576|No Intervention|Routine clamping|After delivery of the newborn, umbilical cord at mothers end, will be left clamped until delivery of the placenta.
3134750|NCT01655576|Experimental|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
3134751|NCT01655563|Active Comparator|Standard Dosing Arm|Patients in the standard arm will receive standard starting dose of tacrolimus that is clinically used i.e. 0.1 mg/kg/dose twice a day.
3134752|NCT01655563|Experimental|Pharmacogenetic Arm|Patients in the pharmacogenetic arm will receive a starting dose that is assigned based on age and CYP3A5 expressor status. Patients that are CYP3A5 expressors will receive the higher end of the dose range compared to non-expressors as described in Table 1. All doses recommended in Table 1 represent clinically acceptable and safe dose ranges used at our institution. This proposed pharmacogenetic dosing algorithm is derived from a validated algorithm published in pediatric renal transplant patients.
3134753|NCT01655550|Other|Standard of Care|Patients will get routine CT scans with Oral and Intravenous contrast prior to their CT scan as is routine, standard practice
3134754|NCT01655550|Experimental|Withold Oral Contrast|Subjects will not drink oral contrast, but instead water (in itself a type of contrast agent) prior to their CT. Intravenous contrast will be administered as is routine
3135297|NCT01651884|Experimental|High-Definition tDCS|
3134755|NCT01655524|Experimental|ASSUAGE Protocol|There is only one arm in this cross-over design trial. Patients who had a standard regadenoson stress test will be invited to enroll in the study. All enrolled subjects will undergo an investigational (ASSUAGE) regadenoson stress test. Imaging scans from the same patients (scan 1 and scan 2) will be compared.
3134756|NCT01655511|Experimental|Period 1|240 mg tafamidis arm
3134757|NCT01655511|Experimental|Period 2|480 mg arm
3134758|NCT01655511|Experimental|Period 3|TBD dose
3134759|NCT01655498|Experimental|Vaginal Bowel Control|A vaginal bowel control system intended to manage fecal incontinence.
3134760|NCT01655485|Experimental|Patient teaching|ipad application for social script book
3134761|NCT01655472|Active Comparator|healthy parents|
3134762|NCT01655472|Active Comparator|schizophrenic parents|
3134763|NCT01655459||Ultrasound exam of upper airway|Following Internal Review Board approval(4-2011-0800) and written informed consent, total 100 patients(ASA I and II children aged 1 month to 6years) undergoing infra-umblicular urologic surgeries were included in the study. Children with upper respiratory tract infection, restricted mouth opening, congenital heart disease and those at risk for aspiration were excluded.
3134764|NCT01655446|Experimental|Robotic Rehabilitation with FES|Robotic rehabilitation combined Functional Electrical Stimulation (FES)
3134765|NCT01655446|Experimental|Mirror Therapy|Mirror Therapy (MT)
3134766|NCT01655446|Active Comparator|Conventional Rehabilitation|Conventional Rehabilitation (CR) mainly focuses on occupational therapy training
3134767|NCT01655446|Experimental|Robotic Rehabilitation|Robotic Rehabilitation (RR)
3134768|NCT01655446|Placebo Comparator|Robotic Rehabilitation with PI|Robotic rehabilitation with Placebo Intervention (RR-PI)
3134769|NCT01655433|Experimental|Therapeutic Hypothermia Treatment|
3134770|NCT01655433|Active Comparator|No Hypothermia Treatment|control group is no hypothermia treatment
3134771|NCT01655420||LASIK|Individuals aged 21 to 84 years planning to undergo refractive surgery using LASIK for myopia, hyperopia, or astigmatism
3134772|NCT01655407|Experimental|Treatment|All patients will receive both Autologous Engineered Skin Substitute (ESS-W) and Split-Thickness Autograft (AG).
3134773|NCT01655407|Active Comparator|Control|All patients will receive both Autologous Engineered Skin Substitute (ESS-W) and Split-Thickness Autograft (AG).
3134774|NCT01655381|Experimental|Tocilizumab|Tocilizumab 8 milligrams per kilogram (mg/kg) administered intravenously once every 4 weeks during a minimum of 104 weeks.
3134775|NCT01655368|Experimental|Interventional: STEM modules|8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module (for schizophrenia or depression)
3134776|NCT01655368|Other|Interventional Control|11 sessions + 1 booster session of psychoeducation for schizophrenia or depression)
3134777|NCT01655355||Revison of the hip joint|
3134778|NCT01655342||formocresol|
3134779|NCT01655329||Standard chest radiographs|The radiologists will be viewing two groups of chest images. The first group are standard chest radiographs.
3134780|NCT01655329||Modified chest radiographs|This group of chest radiographs will be presented with the modified image. The modified image is intended to increase the visibility of tubes, lines and wires on chest radiographs
3134781|NCT01655316|Experimental|Verapamil|40 mg Verapamil Per Oral
3134782|NCT01655303|Experimental|Metoprolol Per Oral|50 mg Metoprolol
3134783|NCT01655303|Experimental|Verapamil|40 mg Verapamil Per Oral
3134784|NCT01655303|Experimental|Propranolol|40 mg Propranolol Per Oral
3134785|NCT01655303|Experimental|Diltiazem|60 mg Diltiazem Per Oral
3134786|NCT01655290|Experimental|Gadobutrol|first session gadobutrol second session gadobenate dimeglumin
3134787|NCT01655290|Experimental|Demeglumin|first session gadobenate dimeglumin second session gadobutrol
3134788|NCT01655277|Experimental|Adductor Canal block first|This arm received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
3134789|NCT01655277|Experimental|Femoral nerve block first|This arm received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
3134790|NCT01655264|Active Comparator|Home-based self training exercises|The control group will receive home-based self-training exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
3134791|NCT01655264|Experimental|Tele-rehabilitation exercises|The experimental group will receive tele-rehabilitation treatment of comparable duration and intensity to those in the home-based self training exercise group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
3134792|NCT01655251|Experimental|Intervention|Video (DVD) discharge instructions
3134793|NCT01655251|No Intervention|Control|
3134794|NCT01655238||95-99% BMI ASC|Patients having a BMI between 95-99% who are seen in the ambulatory surgery centers.
3134795|NCT01655238||95-99% BMI NCH main OR|Patients having a BMI between 95-99% who are seen in the main operating rooms.
3134796|NCT01655238||>99% BMI NCH main OR|Patients having a BMI >99% who are seen in the main operating rooms.
3134797|NCT01655225|Experimental|Part A: LY3023414 Once Daily|LY3023414 administered orally once daily (QD) at escalating doses for two 21 day cycles to participants with advanced/metastatic cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.
3134798|NCT01655225|Experimental|Part A2: LY3023414 Twice Daily|LY3023414 administered orally twice daily (BID) at escalating doses for two 21 day cycles to participants with advanced/metastatic cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.
3134799|NCT01655225|Experimental|Part B1 : LY3023414 + Midazolam|LY3023414 administered orally BID for two 21 day cycles to participants with advanced/metastatic cancer; participants receiving benefit may continue until disease progression or discontinuation. Dose based on Part A. 0.2 milligrams (mg) midazolam administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
3134800|NCT01655225|Experimental|Part B2: LY3023414 + Fulvestrant|LY3023414 administered orally BID for two 28 day cycles to participants with advanced/metastatic breast cancer; participants receiving benefit may continue until disease progression or discontinuation. 500 mg fulvestrant administered IM once every 28 days.
3134801|NCT01655225|Experimental|Part B3: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation.
3134802|NCT01655225|Experimental|Part B4: LY3023414 + pemetrexed/cisplatin|LY3023414 administered orally BID for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation. 500 mg/m2 pemetrexed and 75 mg/m2 administered IV once every 21 days.
3134803|NCT01655225|Experimental|Part B5: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with indolent non-Hodgkin's lymphoma; participants receiving benefit may continue until disease progression or discontinuation.
3134804|NCT01655225|Experimental|Part B6: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with squamous NSCLC; participants receiving benefit may continue until disease progression or discontinuation.
3134805|NCT01655225|Experimental|Part B7: LY3023414 + Abemaciclib + Letrozole|LY3023414 administered orally BID with abemaciclib administered orally BID and letrozole administered orally once a day for two 28 day cycles to participants with breast cancer; participants receiving benefit may continue until disease progression or discontinuation.
3134806|NCT01655212|Experimental|Valganciclovir|Valganciclovir 32 mg/kg per day in two doses (16 mg/kg per dose) during 6 weeks in an oral solution.
3134807|NCT01655212|No Intervention|Control|Infants in the control group receive no antiviral therapy. Counseling and treatment assigned by an audiological center remains unchanged.
3134808|NCT01655199|Experimental|COPD group|Moderate and/or severe COPD patients, corresponding to GOLD stages II and III.
3134809|NCT01655186|Placebo Comparator|Placebo|Oral, once daily
3134810|NCT01655186|Experimental|Bardoxolone Methyl|Oral, once daily
3134811|NCT01655173|Experimental|Cognitive behaviour therapy|36 weekly sessions (1 calendar year) of Cognitive behaviour therapy in a group setting.
3134812|NCT01655173|Active Comparator|Recreational activity intervention|36 sessions (1 calendar year) of a group intervention to enable social interaction and to break social isolation.
3134813|NCT01655160|Experimental|mirror therapy treatment|Three groups will be involved in this part of the whole project:MT with low-intensity group (MT-LI), MT with moderate-intensity group (MT-MI), MT with high-intensity group (MT-HI)
3134814|NCT01655160|Active Comparator|control intervention group|The part of this project will involve 1 treatment groups:control intervention group (CI)
3134815|NCT01655147|Experimental|Abiraterone acetate + Rifampicin|Abiraterone acetate 1,000 mg (4 x 250 mg) on Day 1 of Period 1. Rifampicin 600 mg (2 x 300 mg) on Days 8 to 13, and Abiraterone acetate 1,000 mg (4 x 250 mg) on Day 14 of Period 2.
3134816|NCT01655121|Experimental|Autoimmune hepatitis (Non-cirrhotic)|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
3134817|NCT01655121|Experimental|Autoimmune hepatitis (Cirrhotic)|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
3134818|NCT01655108|Placebo Comparator|Saline|After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp, trichogram and trichoscopy and randomized in the placebo group, thirty women will be subjected to intradermal application (mesotherapy) of saline; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results.
3134819|NCT01655108|Active Comparator|Minoxidil 0.5% /2ml|After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp, trichogram and trichoscopy and randomized in the drug active group, thirty women will be subjected to intradermal application (mesotherapy) of minoxidil 0.5%/2ml; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results.
3134820|NCT01655095|Experimental|PEG and Prucalopride|
3134821|NCT01655095|Experimental|Picosalax and Prucalopride|
3134822|NCT01655082|Experimental|V0116|One patch per day (during 24 hours) for 21 days
3134823|NCT01655082|Active Comparator|Reference|One patch per day (during 24 hours) for 21 days
3134824|NCT01655069|Experimental|Children Treated with Placebo in 905-CL-076|Male and female children aged 5 to less than 12 years old who received placebo in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 247.9 days in children.
3134825|NCT01655069|Experimental|Children Treated with Solifenacin in 905-CL-076|Male and female children aged 5 to less than 12 years old who received solifenacin in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 247.9 days in children.
3134826|NCT01655069|Experimental|Adolescents Treated with Placebo in 905-CL-076|Male and female adolescents aged 12 to less than 18 years old who received placebo in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 240.1 days in adolescents.
3134827|NCT01655069|Experimental|Adolescents Treated with Solifenacin in 905-CL-076|Male and female adolescents aged 12 to less than 18 years old who received solifenacin in Study 905- CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 240.1 days in adolescents.
3134828|NCT01655056|Experimental|low male dose|Japanese and Caucasian males
3134829|NCT01655056|Experimental|medium male dose|Japanese and Caucasian males
3134833|NCT01655043|Experimental|coronary artery disease patients|Patients with suspected coronary artery disease prospectively recruited for myocardial perfusion MRI. All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar, Lantheus) at both stress and rest. Stress to be induced using 5 ml intravenous (IV) regadenoson (Lexiscan, Astellas US LLC), and the effects of regadenoson were reversed with 50 mg IV aminophylline following the completion of stress imaging.
3134834|NCT01655030|Experimental|creatine monohydrate|6g qd for 6 weeks
3134835|NCT01655030|Placebo Comparator|placebo|6g qd for 6 weeks
3134836|NCT01655017|Experimental|biopsy|Obesity with BMI> 40 kg/m² or obesity with BMI between >35 kg/m² with comorbidities (OSA, type 2 diabetes, hypertension etc…)
3134837|NCT01655017|No Intervention|healthy volunteers|biopsy during a surgery
3134838|NCT01655004|Experimental|exemestane standard treatment|Patients will receive exemestane 25mg daily orally after a meal until progression of disease, intolerable toxicities, voluntary withdrawal or termination of the study.
3134839|NCT01654991|Active Comparator|Clinic-Based Testing|Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
3134840|NCT01654991|Experimental|Home-Based Testing|Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
3134841|NCT01654965|Experimental|Treatment (tivantinib, topotecan hydrochloride, pegfilgrastim)|Patients receive tivantinib PO BID on days 1-21, topotecan hydrochloride IV over 30 minutes on days 1-5, and pegfilgrastim SC on day 6. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3134842|NCT01654939|Experimental|rifaximin|All patients will be taking rifaximin 550 mg twice daily
3134843|NCT01654926||Heart Failure patients|
3134844|NCT01654913|Experimental|surgical patients|patients studied just before induction of anesthesia
3134845|NCT01654900||Patients age >75 y who underwent open hear surgeary|The cohort study consist of all patients > 75 y, undergoing open heart surgery between 2008-2011 at Hadassah medical center.
3134846|NCT01654887|Experimental|Lung Ultrasound|LUS first with the option of obtaining CXR second
3134847|NCT01654887|Active Comparator|Chest X-Ray|CXR first followed by LUS second
3134848|NCT01654874|Experimental|Preparation A|20 (±3) mCi 99mTc-MIP-1404 (preparation A)
3134849|NCT01654874|Experimental|Preparation B|20 (±3) mCi 99mTc-MIP-1404 (preparation B)
3134850|NCT01654861|Experimental|HDIVC|Gemcitabine (Gemzar), Intravenous and oral Ascorbic Acid (Vitamin C).
3134851|NCT01654848||orthotopic Liver Transplantation|consecutive inclusion of all recipients
3134852|NCT01654835|Active Comparator|low blood pressure alert|"A Low Blood Pressure condition as specified (SAP <80 mmHg)will trigger an page to be sent to all anesthesia providers in <1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support."
3134853|NCT01654835|Placebo Comparator|no low blood pressure alert|The Low Blood Pressure condition will be monitored by treatment team, but additional alert will not be sent to treatment team.
3134854|NCT01654822|Placebo Comparator|olive oil with 10% d-limonene|Topical spray one-time administration 2 puffs of 100µl
3134855|NCT01654822|Experimental|AV2-DM antiviral spray|Topical spray one-time application 2 puffs of 100µl
3134856|NCT01654809|Experimental|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
3134857|NCT01654809|Active Comparator|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
3134858|NCT01654809|Active Comparator|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
3134859|NCT01654796|Active Comparator|Low Field Magnetic Stimulation|Patients in this arm will receive 2 days of active low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of active low field magnetic stimulation (LFMS) in phase 2. LFMS is a novel, non-contact neuromodulation technique. LFMS is administered through a device while the patient lies on his/her back for 20 minutes.
3134860|NCT01654796|Placebo Comparator|Sham (LFMS)|Patients in this arm will receive 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 2.
3134861|NCT01654796|Other|Crossover Arm|Patients in this group will receive two days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by two days of active low field magnetic stimulation (LFMS) in phase 2.
3134862|NCT01654783||5-ASA|Patient's treated with oral 5-ASA
3134863|NCT01654770|Active Comparator|video capsule endoscopy|Video capsule endoscopy is performed every recruited patient.
3134864|NCT01654770|Active Comparator|double balloon enteroscopy|Double balloon enteroscopy is performed after video capsule endoscopy in every recruited patient. (Tandem study)
3134865|NCT01654731|Experimental|Bezafibrate|400 mg/Day
3134866|NCT01654731|Placebo Comparator|Placebo|1 tablet/ day
3134867|NCT01654718|Experimental|Pantoprazole Sodium Delayed release tablets|Pantoprazole Sodium Delayed release tablets USP 40 mg of OHM Laboratories Inc.,USA
3134868|NCT01654718|Active Comparator|Protonix® Delayed Release 40 mg tablets|Protonix® Delayed Release 40 mg tablets of Wyeth Pharmaceuticals Inc.USA
3134869|NCT01654705|Experimental|Pantoprazole Sodium Delayed release tablets|Pantoprazole Sodium Delayed release tablets USP 40 mg of OHM Laboratories Inc.,USA
3134870|NCT01654705|Active Comparator|Protonix® Delayed Release 40 mg tablets|Protonix® Delayed Release 40 mg tablets of Wyeth Pharmaceuticals Inc.USA
3134871|NCT01654692|Experimental|Single arm of ipilimumab and fotemustine|Ipilimumab in combination with Fotemustine
3134872|NCT01654679|Active Comparator|wIRA irradiation|Patients in Group A received local water-filtered infrared A (wIRA) irradiation once for 20 min preoperatively.
3134873|NCT01654679|Sham Comparator|visible light only|Patients assigned to Group B only received normal visible light application for 20 min prior to surgery.
3134874|NCT01654666|Experimental|RIPC group|"Treatment:Patients in this group received standard medical therapy and remote ischemic preconditioning (RIPC) treatment.~Device:RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min,each patient in the RIPC group do it twice a day for at least two weeks before carotid artery stenting.~Procedure: Carotid Artery Stenting"
3135298|NCT01651884|Experimental|Sponge tDCS|
3134875|NCT01654666|Active Comparator|Control group|Treatment:Patients in this group received standard medical therapy alone. Procedure: Carotid Artery Stenting
3134876|NCT01654666|Sham Comparator|Sham RIPC group|"Treatment:Patients in this group received standard medical therapy and sham remote ischemic preconditioning treatment.~Device:Sham RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min, each patient in RIPC group do it twice a day for at least two weeks before carotid artery stenting.~Procedure: Carotid Artery Stenting"
3134877|NCT01654653|Experimental|HSL(Totilac)|Hypertonic Sodium Lactate
3134878|NCT01654653|Active Comparator|6% HES (Voluven)|6% Hydroxyethyl Starch
3134879|NCT01654640|Experimental|Metformin group|Metformin 500mg 1 tablet p.o. bid
3134880|NCT01654640|Placebo Comparator|Placebo group|1 tablet p.o. bid
3134881|NCT01654627|Experimental|Regenecure AMCA GBR Dental membrane|16 patients will undergo the guided bone regeneration procedure using the Regenecure AMCA Membrane
3134882|NCT01654627|Active Comparator|Collagen membrane|16 patients will undergo the guided bone regeneration procedure using a commercially available collagen membrane
3134883|NCT01654614||Forme Fruste Keratoconus Group (FFKG)|Forme Fruste Keratoconus Group (FFKG) included patients diagnosed with FFK.
3134884|NCT01654614||Control Group (CG)|Control group(CG) was formed by refractive surgery candidates.
3134885|NCT01654601|Experimental|A Group|"1.1st Administration - DWCZP tablet 100mg Mutiple dose~2.2nd Administration - Clozaril tablet 100mg Mutiple dose"
3134886|NCT01654601|Experimental|B Group|"1.1st Administration - Clozaril tablet 100mg Mutiple dose~2.2nd Administration - DWCZP tablet 100mg Mutiple dose"
3134887|NCT01654575|Experimental|Methotrexate|25mg/week orally
3134888|NCT01654575|Active Comparator|Placebo|"Placebo-sugar tablets identical in colour and shape to methotrexate given once a week for 16 weeks."
3134889|NCT01654562|Experimental|CHM|Administration of 40mg simvastatin daily, orally for 5 weeks (4-6 weeks window), followed by 5 week (4-6 week window) washout period.
3134890|NCT01654562|Active Comparator|Age-matched controls|Administration of 40mg simvastatin daily, orally for 5 weeks (4-6 weeks window), followed by 5 week (4-6 week window) washout period.
3134891|NCT01654549|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
3134892|NCT01654549|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
3134893|NCT01654536|Experimental|ciclesonide nasal aerosol|ciclesonide nasal aerosol 74 mcg
3134894|NCT01654536|Active Comparator|ciclesonide nasal spray|ciclesonide nasal spray 200 mcg
3134895|NCT01654523|Other|Treatment arm|Open trial with no randomization
3134896|NCT01654510|Experimental|Cognitive Behavioral Therapy Group|
3134897|NCT01654510|Active Comparator|Vocational Services as Usual Control|Vocational services typically present in a comprehensive vocational service center.
3134898|NCT01654497|Experimental|Dexanabinol|
3134899|NCT01654484|Experimental|Low Dose DE-117|Monotherapy
3134900|NCT01654484|Experimental|Medium Dose DE-117|Monotherapy
3134901|NCT01654484|Experimental|High Dose DE-117|Monotherapy
3134902|NCT01654484|Experimental|Low Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
3134903|NCT01654484|Experimental|Med. Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
3134904|NCT01654484|Experimental|High Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
3134905|NCT01654484|Active Comparator|0.0015% tafluprost|Monotherapy
3134906|NCT01654484|Placebo Comparator|Placebo|Monotherapy
3134907|NCT01654471||Medical treatment|only medical treatment (regardless of the kinds of medicine)
3134908|NCT01654471||Surgical or endovascular treatemnt group|patients underwent surgery or endovascular therapy
3134909|NCT01654458|Experimental|Immediate Treatment Condition|Receives the 12-week GyneGals Support Group within a month of completing the baseline assessment.
3134910|NCT01654458|No Intervention|Waitlist Control Condition|Waitlist control group receives the 12-week GyneGals Support Group only after its involvement in the study has ended, as a courtesy.
3134911|NCT01654445|Experimental|TNK-tPA Tenecteplase|This is an open-label trial, all patients will receive tenecteplase.
3134912|NCT01654432|Placebo Comparator|General anaesthesia and sham nerve block|Breast cancer surgery under general anaesthesia
3134913|NCT01654432|Active Comparator|Paravertebral Blocks (PVB)|Breast cancer surgery under ultrasound-guided paravertebral blocks plus general anesthesia
3134914|NCT01654419|Active Comparator|Class II elastics alone|Use of class II elastics alone to correct class II dental malocclusions
3134915|NCT01654419|Experimental|Class II elastics with Sliding Jig|Class II elastics with Sliding Jig for correction of dental class II malocclusion
3134916|NCT01654406|Active Comparator|Control|Pulsed dye laser (V-beam)
3134917|NCT01654406|Experimental|Experimental group|Fractional CO2 laser(eCO2)and pulsed dye laser (V-beam)
3134918|NCT01654393|Experimental|OAR group|Patients with ankle injuries who are assessed by OAR trained triage nurses applying the OAR.
3134919|NCT01654393|No Intervention|Control for OAR Triage Nurses|Patients with ankle injuries that are seen by OAR triage nurses but not assessed in accordance with the OAR.
3134920|NCT01654380|Experimental|Part A, Cohort A: LY2605541|Healthy participants will receive LY2605541 (22 up to 66 nanomoles [nmol]) intravenously (IV) over 8 hours in 3 of 4 study periods. Each dose is separated by a minimum 6 day washout period.
3134921|NCT01654380|Active Comparator|Part A, Cohort A; Insulin Glargine|Healthy participants will receive insulin glargine (30 milliunits/meter squared/minute [mU/m^2/min]) IV over 8 hours in 1 of 4 study periods, separated by a minimum 6 day washout period.
3134922|NCT01654380|Experimental|Part A, Cohort B; LY2605541|Healthy participants will receive LY2605541 (22 up to 66 nmol) administered IV over 8 hours in 3 of 4 study periods. Dose may be adjusted based on Cohort A results. Each dose is separated by a minimum 6 day washout period.
3134923|NCT01654380|Active Comparator|Part A, Cohort B; Insulin Glargine|Healthy participants will receive insulin glargine (60 mU/m^2/min) IV over 8 hours in 1 of 4 study periods. Dose may be adjusted based on Cohort A results. Each dose is separated by a minimum 6 day washout period.
3134924|NCT01654380|Experimental|Part B; LY2605541|Participants with T1DM will receive LY2605541 administered IV up to 10 hours in 2 of 4 study periods. Dose determined by Part A results. Each dose is separated by a minimum 6 day washout period.
3134925|NCT01654380|Active Comparator|Part B; Insulin Glargine|Participants with T1DM will receive insulin glargine administered IV over 8 hours in 2 of 4 study periods. Dose determined by Part A results. Each dose is separated by a minimum 6 day washout period.
3134926|NCT01654367|Experimental|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors for Adjuvant Therapy
3134927|NCT01654341|No Intervention|Usual Care Group|Subjects undergo usual standard of care
3134928|NCT01654341|Experimental|Intervention Group|Intervention with exercise, dietary and educational programs
3134929|NCT01654328|Experimental|Arm A: sodium chloride tablets|Arm A: sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
3134930|NCT01654328|Active Comparator|B: isotonic saline intravenously|Sodium chloride solution (isotonic saline (NaCl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
3134931|NCT01654315|Experimental|Experimental: Myomo Only Group|Experimental: Myomo Only Group Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.
3134932|NCT01654315|Experimental|Experimental: Myomo + RTP Group|Experimental: Myomo + RTP Group Patients are administered rehabilitative therapy using both the Myomo robotic device and RTP targeting their affected arms on 3 days/week during a 8 week period.
3134933|NCT01654315|Active Comparator|Active Comparator: RTP Group|Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period.
3134934|NCT01654302|Active Comparator|Synera|lidocaine/tetracaine patch with heating component which consists of iron powder, activated carbon, sodium chloride, wood flour, water and filter paper.
3134935|NCT01654302|Placebo Comparator|Inactive Patch|placebo patch identical in appearance and composition (namely, the heating components) to the active patch other than lacking the lidocaine and tetracaine active ingredients.
3134936|NCT01654289|Experimental|Mindfulness Meditation|Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and approximately 45 minutes per day at-home daily practice.
3134937|NCT01654289|Experimental|Exercise|The exercise intervention structure is consistent with many standardized exercise programs. The exercise program will match the meditation program in duration (8 weeks), attention (weekly 2½ hour group sessions), and intensity (daily 45 minute at-home practice).
3134938|NCT01654289|No Intervention|Wait-list control|"Apart from not attending any of the specific meditation or exercise training sessions, those in the control group will be treated in essentially the same manner as experimental participants."
3134939|NCT01654276|Experimental|Febuxostat|Adult patients (age > 21 years) with gout and hyperuricemia (serum uric acid > 7.0 mg/dl in men and >6.0 mg/dl in women) requiring uric acid lowering therapy.
3134940|NCT01654263|Experimental|Group IA: Pneumococcal vaccine-naive, age 55 - 64|Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to 147 subjects vaccine-naive adults
3134941|NCT01654263|Experimental|Group IB: Pneumococcal vaccine-naive, age 65 - 74|Open- label, PCV13 given as 0.5 mL IM injection to 147 subjects vaccine-naive adults
3134942|NCT01654263|Experimental|Group IIA: age 55 - 64, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
3134943|NCT01654263|Experimental|Group IIAA: age 55 - 64, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
3134944|NCT01654263|Experimental|Group IIB: age 65 - 74, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
3134945|NCT01654263|Experimental|Group IIBB: age 65 - 74, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
3134946|NCT01654250|Experimental|Active|NWP09
3134947|NCT01654250|Placebo Comparator|Placebo|Placebo
3134948|NCT01654237|No Intervention|Muskind|three questionnaires to be completed by the subjects
3134949|NCT01654224|Active Comparator|High Dose Inactivated Influenza Vaccine|For HDIV,0.5 ml of high dose inactivated influenza vaccine consisting of a total of 180mcg (60 mcg each strain) of influenza virus hemagglutinin
3134950|NCT01654224|Active Comparator|Standard Dose Inactivated Influenza Vaccine|For SDIV, 0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg of each strain) of influenza virus hemagglutinin
3134951|NCT01654211|Experimental|Part 1: iv danoprevir|
3134952|NCT01654211|Placebo Comparator|Part 1: placebo|
3134953|NCT01654211|Experimental|Part 2 A: iv danoprevir|
3134954|NCT01654211|Active Comparator|Part 2 B: oral danoprevir|
3134955|NCT01654211|Active Comparator|Part 2 C: ritonavir|
3134956|NCT01654211|Experimental|Part 3 D: iv danoprevir|
3134957|NCT01654211|Experimental|Part 3 E: iv danoprevir + cyclosporine|
3134958|NCT01654198||Psoriatic arthritis|
3134959|NCT01654185|Experimental|AI plus Dimethyldiguanide|AI 1 tablet qd plus Dimethyldiguanide 0.5 bid
3134960|NCT01654185|Active Comparator|Aromatase Inhibitor|AI monotherapy
3134961|NCT01654172|Experimental|High Flavanol Cocoa|"Cocoa drink containing ~450mg cocoa flavanols and 10g carbohydrate per serving.~Subject consumes 2 servings per day, for 7 days."
3134962|NCT01654172|Placebo Comparator|Low Flavanol Cocoa|"Cocoa drink containing ~25mg cocoa flavanols and 10g carbohydrate per serving.~Subject consumes 2 servings per day, for 7 days."
3134963|NCT01654159|Placebo Comparator|Monofocal|"Monofocal IOL Implant~Manufacturers of IOLs used as monofocal comparator are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
3257708|NCT00785395|Experimental|A|
3134964|NCT01654159|Experimental|Multifocal|"Multifocal IOL~Manufacturers of multifocal IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
3134965|NCT01654159|Experimental|Toric|"Toric IOL~Manufacturers of toric IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
3134966|NCT01654146|Active Comparator|Arm 1 (Control Arm)|Carboplatin and paclitaxel on day 1 of a 21-day cycle for 6 cycles
3134967|NCT01654146|Experimental|Arm 2 (Research arm)|Carboplatin on day 1 and dose-fractionated weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles
3134968|NCT01654146|Experimental|Arm 3 (Research arm)|Dose-fractionated weekly carboplatin and weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles.
3134969|NCT01654133|Experimental|endovascular repair TAAA|Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using Branched stent grafts
3134970|NCT01654120|Experimental|liraglutide plus insulin|
3134971|NCT01654120|Active Comparator|Insulin titration only|
3134972|NCT01654107|Experimental|Persistence Targeted Smoking Cessation|Persistence Targeted Smoking Cessation - 8 weeks counseling + 12 weeks nicotine lozenge
3134973|NCT01654107|Active Comparator|Clearing The Air|Clearing the Air Smoking Cessation intervention - 8 weeks counseling + 12 weeks nicotine lozenge
3134974|NCT01654094|Experimental|P6 Low Adherent Dressing|All participants will serve as their own control. All participants will receive both the P6 Low Adherent Dressings and the Standard of Care (SOC).
3134975|NCT01654094|Active Comparator|Standard of Care (SOC)|All participants will serve as their own control. All participants will receive both the P6 Low Adherent Dressings and the Standard of Care (SOC).
3134976|NCT01654081|Experimental|Irinotecan|Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
3134977|NCT01654068|Experimental|Radiation Therapy 2-3 Spine metastases|Conformal High Dose Intensity Modulated Radiation Therapy
3134978|NCT01654068|Experimental|Radiation Therapy solitary spine metastasis|Conformal High Dose Intensity Modulated Radiation Therapy
3134979|NCT01654042|No Intervention|Standard interval between PT testing|Prothrombin time (PT) is tested every 4 weeks, according to American College of Chest Physicians (ACCP) Guidelines up to 2008 for stable patients on warfarin.
3134980|NCT01654042|Experimental|Prolonged interval between PT testing|Prothrombin time (PT) is tested every 12 weeks, according to suggestion in American College of Chest Physicians (ACCP) Guidelines of 2012 for stable patients on warfarin.
3134981|NCT01654029|No Intervention|Control group receiving usual care|Usual care consists of speech language therapy for some patients. Most care is focused on swallowing assessments.
3134982|NCT01654029|Experimental|PCCI Intervention|The Patient-Centred Communication Intervention consists of 1) development of a communication care plan; 2)a workshop for staff focused on communication and behavioural management strategies,: and 3) implementing a staff support system.
3134983|NCT01654016|Active Comparator|Detralex|Detralex 500 mg twice daily for three month prior to surgery
3134984|NCT01654016|No Intervention|Not taking Detralex|Not taking Detralex for three months prior to surgery
3134985|NCT01654003|Active Comparator|CONTROL|"In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.~At the discretion of the attending anaesthesiologist with the FMH level, a pulmonary artery catheter, a transoesophageal Doppler flow probe or the PiCCO monitor will be inserted to complement the standard hemodynamic monitoring if deemed necessary."
3134986|NCT01654003|Active Comparator|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
3134987|NCT01653990|Experimental|moxifloxacin, pill|Oral dose of 400mg moxifloxacin
3134988|NCT01653990|Placebo Comparator|moxifloxacin-placebo,pill|A pill of moxifloxacin-placebo
3134989|NCT01653977|Active Comparator|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
3134990|NCT01653977|Active Comparator|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
3134991|NCT01653964|Experimental|Molecular breast imaging|Molecular Breast Imaging at 4 mCi dose and at 8 mCi dose, consecutively.
3134992|NCT01653951|Experimental|Nurse-led care management|Nurse-led care management involves a nurse care manager who performs a comprehensive assessment of the patient then presents those assessment findings to an interdisciplinary team. The team makes care recommendations that are implemented by the care manager in collaboration with the patient's PCP.
3134993|NCT01653951|Experimental|peer-led self managment|Peer-led self management follows the chronic disease self management model where peer counselors lead self management classes for 6 weeks, then conduct monthly support groups
3134994|NCT01653938|No Intervention|control group|
3134995|NCT01653938|Experimental|Video Arm|Use of video decision aid in the experimental arm.
3134996|NCT01653925|Experimental|Dietary intervention first|The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids.
3134997|NCT01653925|Experimental|Drug intervention first|Intake of 5α-Reductase Inhibitor
3134998|NCT01653912|Experimental|GSK2110183, carboplatin and paclitaxel|Subjects will be treated with a maximum of six doses of carboplatin + paclitaxel in combination with continuous daily GSK2110183 followed by single agent GSK2110183 at the single-agent MTD of 125 mg or above oral daily.
3134999|NCT01653899|Experimental|IDN-6556|Drug
3135000|NCT01653886|Experimental|Pilot Group 1|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
3135001|NCT01653886|Experimental|Pilot Group 2|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
3135002|NCT01653886|Experimental|Pilot Group 3|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
3135003|NCT01653886|Experimental|Pilot Group 4|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
3135004|NCT01653860|Experimental|The Brøset anger management model|Group treatment
3135005|NCT01653860|Active Comparator|ordinary group treatment|Group treatment
3135006|NCT01653847|Active Comparator|Group 1: Tacrolimus with MMF.|This group will receive a standard dose Tacrolimus and MMF. This will follow standard of care protocol at Northwestern Memorial Hospital's Comprehensive Transplant Center.
3135007|NCT01653847|Active Comparator|Group 2: Tacrolimus with Everolimus|This group will receive a low dose Tacrolimus with concentration controlled Everolimus
3135008|NCT01653847|No Intervention|Donors|One time blood samples will be collected from kidney donors to recipients in this study
3135009|NCT01653834|Experimental|all pts with lymphocyte harvesting and reinfusion|pts will be treated with standard temozolmide and radiation, prior to treatment will have lymphocytes harvested (collected and stored) and at week 10 pts lymphocytes will be re-infused. Lymphocyctes will be checked weekly for 14weeks until week 20
3135010|NCT01653821|Experimental|Carotid body excision|Patients undergoing unilateral or bilateral removal of carotid body.
3135011|NCT01653808|Experimental|Elisio-210H with HD|hemodialysis patients treated with conventional hemodialysis (HD) modality using Elisio-210H dialyzer
3135012|NCT01653808|Active Comparator|Elisio-210H with on line HDF|hemodialysis patients treated with on line hemodiafiltration (HDF) modality using Elisio-210H dialyzer
3135013|NCT01653795|Active Comparator|LMA Unique|
3135014|NCT01653795|Active Comparator|LMA Supreme|
3135015|NCT01653782|Experimental|kUNDALINI YOGA|"Guided kundalini yoga sessions specific for low back pain for 1 hour, twice a week (120 minutes of instructor-led yoga) for 6 weeks. Cd recording for home practice recommended once per day.A written self care pamphlet The Back book"
3135016|NCT01653782|Active Comparator|Self care advice to stay active|Evidence based advice from caregiver to stay active and exercise
3135017|NCT01653782|Active Comparator|Exercise|"Guided exercise at a gym focusing on strength training. Twice a week during 6 weeks. A written self care pamphlet The Back book"
3135018|NCT01653756|Active Comparator|IPI-145|Capsules
3135019|NCT01653756|Placebo Comparator|Placebo|Capsules
3135020|NCT01653743|Experimental|MSJ-0011|
3135021|NCT01653743|Active Comparator|urinary hCG|
3135022|NCT01653730|Experimental|Eclipse 3 portable oxygen concentrator|Use of the Eclipse 3 portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
3135023|NCT01653730|Experimental|iGo portable oxygen concentrator|Use of the iGo portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
3135024|NCT01653730|Experimental|EverGo portable oxygen concentrator|Use of the iGo portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
3135025|NCT01653730|No Intervention|Control portable oxygen concentrator|6-minute walk test completed using each patient's own oxygen delivery system set at their usual oxygen prescription for exercise
3135026|NCT01653717|Experimental|T-Cell Infusion + Chemotherapy|Peripheral blood mononuclear cells (PBMC) collected via venipuncture or steady state leukapheresis after enrollment. Clinically successful T-cell production defined as amount of T-cells required for dose level for which the patient is enrolled. Fludarabine 25 mg/m2 by vein on Days -5 to Day -3. Cyclophosphamide 250 mg/kg by vein on Days -5 to -3. Beginning dose of genetically modified cells is > 5x10^7/m2 but less than or equal to 5 x10^8/m2 infused on Day 0.
3135027|NCT01653704|Experimental|active management of crises scenario|participants assigned to actively manage a crisis scenario
3135028|NCT01653704|Active Comparator|Observer role in crisis scenario|Observational role in management of crises scenario
3135029|NCT01653691|Active Comparator|Pulse Dye Laser, burn scars|A scar will be located on the study subject's torso or thigh and divided in half. Some subjects will receive laser to both sides of their scar, while others will not receive any intervention to one side and laser to the other side. Each side will be evaluated during outpatient visits. 12 months after treatment is completed, 2 burn experts will rate each side of the scar without knowing its treatment.
3135030|NCT01653691|Sham Comparator|No treatment to half of scar|A scar on the child's torso or thigh will be divided in half. One side will receive laser treatment and the other half will receive laser or sham treatment.
3135031|NCT01653678|Active Comparator|Vitamin D + fish oil|
3135032|NCT01653678|Active Comparator|Vitamin D + fish oil placebo|
3135033|NCT01653678|Active Comparator|Vitamin D placebo + fish oil|
3135034|NCT01653678|Placebo Comparator|Vitamin D placebo + fish oil placebo|
3135035|NCT01653665|Active Comparator|Leukine (Sargramostim, GM-CSF)|Participants in dose finding study will receive either 3 or 6 micrograms per kilo per day as a daily subcutaneous injection for either 4 or 7 days. Within the Randomised controlled trial, participants will receive the dose as chosen following the dose finding study.
3135036|NCT01653665|Placebo Comparator|Placebo (normal saline)|Participants in the randomised controlled trial may be randomised to receive a daily subcutaneous injection of normal saline (placebo) for 4 or 7 days as decided following the results of the dose finding study
3135037|NCT01653652|Placebo Comparator|Placebo|maltodextrin powder to be taken daily
3135038|NCT01653652|Active Comparator|Probiotic|Probiotic blended in maltodextrin powder to be taken daily
3135039|NCT01653639|Experimental|Arm 1|
3135040|NCT01653639|Experimental|Arm 2|
3135041|NCT01653626|Experimental|package|
3135042|NCT01653600|Experimental|LifeStent|same to SMART CONTROL Stent
3135043|NCT01653600|Active Comparator|SMART CONTROL Stent|study design is 2x2 randomization design. First, before randomization, stratification will be performed according to lesion length 15cm criteria at web-based computerized program. Patients will be randomized in a 1:1 manner according to different two (SMART versus LifeStent) stents. And then, patients received aspirin and clopidogrel during one month. After one month from index procedure, clopidogrel will be stopped and changed into cilostazol. Patients were randomized to receive cilostazol 100mg bid either 11 month duration or 5 month duration in separate groups of SMART stent group and LifeStent group. Randomization procedure will be performed using a web-based program
3135044|NCT01653587|Active Comparator|Transradial approach|Transradial approach percutaneous coronary intervention using the TR Band device to obtain hemostasis
3135045|NCT01653587|Active Comparator|Transfemoral approach|Transfemoral approach percutaneous coronary intervention using the AngioSeal vascular closure device STS Plus Platform to obtain hemostasis
3135046|NCT01653574|Experimental|Famitinib Malate|Famitinib 25mg/d
3135047|NCT01653561|Experimental|Apatinib|Apatinib 500mg/d
3135048|NCT01653548|Experimental|HR training + Portable HR|100 subjects who receive Habituation Reminder training and who have access to the HR via a cellular phone.
3135049|NCT01653548|Experimental|HR Training + no portable HR|50 subjects who receive Habituation Reminder training and who do not have access to the HR via a cellular phone.
3135050|NCT01653548|Experimental|No HR training|50 subjects who do not receive HR training.
3135051|NCT01653535|Experimental|Fast Track Eligible|"Participants in the Experimental group received the Fast Track intervention. Intervention included school-based curriculum attended by high-risk children, parents, program staff, and occasionally teachers, home visiting, the the in-class PATHS prevention program."
3135052|NCT01653535|No Intervention|Control Group|Participants in the Control group were not eligible to receive the Fast Track intervention. These children received other services as usual, and served as the randomized comparison group for examining Fast Track program impacts
3135053|NCT01653522|Experimental|Triptan|
3135054|NCT01653522|Experimental|Doxycycline|
3135055|NCT01653522|Experimental|Triptan + Doxycycline|
3135056|NCT01653522|No Intervention|Control|
3135057|NCT01653509|Experimental|Test patch|Patch containing acyclovir applied to cold sore
3135058|NCT01653509|Placebo Comparator|Placebo patch|Patch without acyclovir applied to cold sore
3135059|NCT01653496|Experimental|Enhanced recovery after surgery|Patients who receive ERAS program after gastric cancer surgery
3135060|NCT01653483|Experimental|GSK573719|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
3135061|NCT01653483|Placebo Comparator|GSK573719 matched-placebo|Placebo
3135062|NCT01653470|Experimental|Arm A: Paclitaxel + BMS-906024|Paclitaxel 80 mg/m2 solution and BMS-906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity
3135063|NCT01653470|Experimental|Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024|5FU Bolus 400 mg/m2, 5FU Infusion 2400 mg/m2, Irinotecan 180 mg/m2 solution, Leucovorin 400 mg/m2 solution intravenously once every 2 weeks and BMS- 906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity
3135064|NCT01653470|Experimental|Arm C: Carboplatin/Paclitaxel + BMS-906024|Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once weekly intravenously continuously until disease progression or unacceptable toxicity
3135065|NCT01653470|Experimental|Arm D: Paclitaxel + BMS-906024|Paclitaxel 80 mg/m2 solution once weekly and BMS-906024 4 mg or 6 mg solution once every 2 weeks intravenously continuously until disease progression or unacceptable toxicity
3135066|NCT01653470|Experimental|Arm F: Carboplatin/Paclitaxcel and BMS-906024|Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once every 3 weeks intravenously continuously until disease progression or unacceptable toxicity
3135067|NCT01653457|Placebo Comparator|Placebo|
3135068|NCT01653457|Active Comparator|Memantine|
3135069|NCT01653444|Experimental|GC1119 0.5 mg/kg|0.5 mg/kg biweekly
3135070|NCT01653444|Experimental|GC1119 1.0 mg/kg|1.0 mg/kg biweekly
3135071|NCT01653431|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation combined with cognitive training
3135072|NCT01653431|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation combined with cognitive training
3135073|NCT01653418|Experimental|V-BEAM + Stem Cell Infusion|Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0
3135074|NCT01653405|No Intervention|Control Group|Patients in the top 75% of TTR at baseline
3135075|NCT01653405|Experimental|Intervention Group|Patients in the bottom 25% of TTR at baseline
3135076|NCT01653392||Anthrax Vaccine Adsorbed|Active duty women who received one or more doses of BioThrax while pregnant, with the onset of pregnancy defined as the first day of the last menstrual period, and all live born infants born to women who join the registry.
3135077|NCT01653379|Experimental|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
3135078|NCT01653366|Experimental|Arm A-Pedometer and Goal setting|"Physical Activity Goal Setting~Patients receive physical therapy (PT) consult, educational materials, and telephone calls and are contacted weekly/monthly for physical activity (PA) goal setting with registered nurse (RN). Physical Activity completed is measured with pedometers and recorded on patient log."
3135079|NCT01653366|No Intervention|ARM B|Patients receive standard physical activity recommendations and follow up.
3135080|NCT01653353|Experimental|Entire group|A peer-applied guideline will be applied to the physicians.
3135299|NCT01651871|Experimental|Treatment Group 1|
3135081|NCT01653340|Experimental|High Frequency Spinal Cord Stimulation through Senza™|"During the trial implant of Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine, the 2 leads will be positioned to cover the C2-C3 cervical levels.~Over the following 2 weeks, the investigator will optimize therapy delivery by identifying the stimulation settings providing maximal headache pain relief.~The subject will be asked to attend the clinic at the end of the trial period. Together with his/her physician, the subject will discuss his/her experience over the past 2 weeks (satisfaction with the therapy), and decide whether or not move forward with a Nevro Senza IPG.~The Nevro Senza IPG will be implanted in the buttock or abdomen area as outlined in the Physician's Manual. Fluoroscopy and impedance measurements may be used during the procedure to confirm lead placement and location.~Before hospital discharge, the IPG will be programmed with the optimal settings identified during the trial phase."
3135082|NCT01653327|Active Comparator|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
3135083|NCT01653327|Placebo Comparator|Placebo|The placebo will consist of 4 ml of cherry syrup and 1 ml of normal saline.
3135084|NCT01653314|Experimental|Megavec|
3135085|NCT01653314|Active Comparator|Glivec|
3135086|NCT01653301|Experimental|XELOX-RT|"Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost)."
3135087|NCT01653301|Active Comparator|XELAC-RT|"Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost)."
3135088|NCT01653288|Experimental|Coping Coach|Receive access to Coping Coach online intervention at baseline for use (self-guided, with email reminders) over the next 6 weeks.
3135089|NCT01653288|Experimental|Coping Coach Waitlist Control|Treatment as usual from baseline to 12 week follow-up assessment. Then receive access to Coping Coach intervention after 12 week follow-up for use (self-guided, with email reminders) over the next 6 weeks.
3135090|NCT01653275|Experimental|Mediterranean Diet|Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
3135091|NCT01653262|Experimental|Brivaracetam|"The subjects will be treated with Brivaracetam (BRV) tablets 200 mg/day during 12 weeks: four 25 mg tablets, twice daily.~Based on the Investigator's judgement, at any time, the dose can be decreased to BRV 150 mg/day, 100 mg/day, or 50 mg/day. Flexible dosing, can be up- and down-titrated as needed.~At the end of the Treatment Period, the subject will either enter the N01372 long-term follow-up study or down-titrate during 4 weeks."
3135092|NCT01653249|Experimental|vaccination|an escalating dose study of a vaccine consisting of four HPV-16 E6 peptides in combination with Candin® to determine the clinically optimum dose (COD), immunologically optimal dose (IOD), and maximum tolerated dose (MTD). An additional 30 subjects will be vaccinated at the final dose (apparent COD) for further assessment of clinical response.
3135093|NCT01653236|Experimental|Experimental Arm B|48 weeks of peginterferon alfa-2b and ribavirin Plus Boceprevir 800 mg
3135094|NCT01653236|Active Comparator|Control Arm|48 weeks of peginterferon alfa-2b and ribavirin
3135095|NCT01653223|No Intervention|control|untreated
3135096|NCT01653223|Experimental|short statin|Simvastatin (20 mg) was administered every day for the 5-7 days preoperatively, but not the day of surgery in the statin group. Then simvastatin was re-administered at the second day until 7 days postoperatively.
3135097|NCT01653223|Experimental|long statin|Simvastatin (20 mg) was administered every day for the 5-7 days preoperatively, but not the day of surgery in the statin group. Then simvastatin was re-administered at the second day until 6 months postoperatively.
3135098|NCT01653197|Experimental|Control|"On top of reminder, state: Here's a fun fact to cheer you on your way: and include a curiosity-inducing question and answer (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space? // A: Texas)"
3135099|NCT01653197|Experimental|Curiosity|"On top of reminder, state: Here's a fun fact to cheer you on your way. and include a curiosity-inducing question (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space?) Place the answer under a scratch-off patch (A: Texas)."
3135100|NCT01653197|Experimental|Curiosity linked to Action|"On top of reminder, state: Here's a fun fact to cheer you on your way. Reward yourself by scratching off the answer only after you've made your [colonoscopy/mammogram/etc.] appointment! and include a curiosity-inducing question (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space?) Place the answer under a scratch-off patch (A: Texas)"
3135101|NCT01653184|Experimental|Experimental: AREDS 2 Vitamin formula 1g|"Patients will receive oral supplementation with the commercially available AREDS2 vitamin formula (PreserVision AREDS 2 Eye Vitamin and Mineral Supplement. Bausch + Lomb Incorporated), consisting of vitamins C, E, zinc, lutein, zeaxanthin and 1g of omega-3 fatty acids in the ethyl ester formulation"
3135102|NCT01653184|Experimental|Eye Omega Advantage 2g|Patients will receive a similar vitamin combination in the second arm (Eye Omega Advantage® and Macular Vitamin Benefit. Physician Recommended Nutriceuticals) with 2g of omega-3 fatty acids in the triglyceride formulation (see attached document for supplement details)
3135103|NCT01653171|No Intervention|Control|Standard upper endoscopy withouth premedication
3135104|NCT01653171|Placebo Comparator|Water|100 mL of water, 20 minutes before upper endoscopy
3135105|NCT01653171|Experimental|Simethicone|Simethicone 200 mg, in water for up to 100 mL, to take 20 minutes prior to examination
3135106|NCT01653171|Experimental|N-acetylcysteine 500 mg + Simethicone|N-acetylcysteine 500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
3135107|NCT01653171|Experimental|N-acetylcysteine 1000 mg + Simethicone|N-acetylcysteine 1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
3135108|NCT01653158|Experimental|CP-751,871 combined with docetaxel|
3135109|NCT01653145|Active Comparator|Diet A|Low Fat High Energy Density (1.6 kcal/g)-50% Fat, 35% Carbohydrate, and 15% Protein
3135110|NCT01653145|Active Comparator|Diet B|High Fat Low Energy Density (1.05 kcal/g)-50% Fat, 35% Carbohydrate, and 15% Protein
3135111|NCT01653145|Active Comparator|Diet C|High Carbohydrate Low Energy Density (1.05 kcal/g)-20% Fat, 65% Carbohydrate, 15% Protein
3135112|NCT01653132|Experimental|Incobotulinum Toxin A|Twenty units (0.2 ml) of incobotulinum toxin A injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks
3135113|NCT01653132|Placebo Comparator|Placebo|Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
3135114|NCT01653119|Active Comparator|High loading dose of rosuvastatin|rosuvastatin 20mg/d×1w
3135115|NCT01653119|Active Comparator|Routine rosuvastatin therapy|rosuvastatin 10mg/d×1w
3135116|NCT01653106|Experimental|Arm I (cryotherapy 120 minutes)|Beginning fifteen minutes before melphalan treatment, patients receive 1 ounce of shaved ice in their mouth, allow it to melt and then replenish it immediately for 120 minutes.
3135117|NCT01653106|Active Comparator|Arm II (cryotherapy 360 minutes)|Beginning fifteen minutes before melphalan treatment, patients receive 1 ounce of shaved ice in their mouth, allow it to melt and then replenish it immediately for 360 minutes.
3135118|NCT01653093|Experimental|Diagnostic (3T MRI)|Patients undergo 3T MRI, including DCE-MRI, diffusion-weighted MRI, amide-proton-transfer MRI, and MR spectroscopy scans. Patients may undergo an additional 3T MRI scan at least 24 hours after the initial scan.
3135119|NCT01653080|Experimental|Dynamic contrast-enhanced magnetic resonance imaging|Patients undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
3135120|NCT01653067|Experimental|Rituximab, Temsirolimus, DHAP, intravenous|"This is a multicenter, open label, single arm, phase II study. There will be no placebo usage within this trial. In the part I, dose escalation part, of this trial 6 patients will be included in each dose level. There will be 4 cohorts, administering up to a maximum of 4 cycles 25 mg, 50 mg, 75mg or 100mg Temsirolimus in combination with Rituximab and DHAP.~Treatment regimen part I:~Part I - Cohort A, B, C, D, X Temsirolimus 25 (A), 50 (B), 75 (C),100 (D) or 15 (X) mg, Day 1, 8, Rituximab (375 mg/m² day 2) Dexamethasone 40mg day 3-6 Cisplatine 100 mg/m² day 3 Cytarabine 2x2 g/m² day 4~...repeat day 22, up to a maximum of 4 cycles~In the part II of the trial 40 patients will be included to receive the full target dose, established within the part I of the study."
3135121|NCT01653054|Experimental|IBD patients ON Immunosuppression|
3135122|NCT01653054|Experimental|IBD Patients OFF Immunosuppression|
3135123|NCT01653041|Experimental|Everolimus|Single arm
3135124|NCT01653028|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3135125|NCT01653015|Experimental|Influenza vaccine LAIV|Live attenuated influenza vaccine (LAIV).
3135126|NCT01653015|Active Comparator|Influenza vaccine TIV|Trivalent inactivated vaccine (TIV).
3135127|NCT01653002||Lung cancer with lymph node involvement|
3135128|NCT01652989|Experimental|Weight loss maintenance intervention delivered via DVD|Weight loss maintenance intervention delivered via DVD (without a peer facilitator) to employee participants within the respective worksites randomized to this arm. Using DVD technology, a total of 11 additional sessions (designed for weight loss maintenance) over a 9-month period will be delivered to the participants of this arm using DVD-produced lessons of PILI Maintenance
3135129|NCT01652989|Experimental|Weight loss maintenance intervention Face-to-Face|The PILI Maintenance delivered face-to-face in a group setting by trained peer facilitators to employee participants within the respective worksites randomized to this arm. The trained peer facilitator will deliver a total of 11 additional sessions (designed for weight loss maintenance) over a 9-month period, meeting bi-weekly for the first 2 months and then monthly for the remaining 7 months with a group of 8 to 15 participants.
3135130|NCT01652976|Experimental|Treatment Arm|Dasatinib and mFOLFOX6
3135131|NCT01652963|No Intervention|Control task|The no-intervention control task consists of a presentation of the stimuli used in the training task. Participants will see situations and listen to the simultaneous voice recordings. Unlike in the training task participants will not receive instructions to link situations and emotions. There is no task requirement, just a presentation of the situation stimuli to assure that potential training effects are due to the training programme and not merely to the presentation of scenarios. The duration of the presentation of stimulus materials in the control group will range between fifteen and thirty minutes. The variable duration is necessary so the primary investigator cannot assume a participant's intervention group based on the duration of the intervention task.
3135132|NCT01652963|Experimental|Reed and Clements Training Task|The training task consists of 2 blocks of 6 items with items presented randomly within each block and blocks being counterbalanced between participants. Block 1 presents a situation and prompts participants to identify whether they would feel happy or sad in the given situation. Block 2 presents an emotion (happy or sad) and prompts the participant to identify which of two situations (positive or negative) most likely preceded this emotion. Within each block there will be at least one and maximum three training rounds. The second and third training rounds will only consist of the items to which the participant responded incorrect in the previous round. Each item in rounds 2 and 3 will be followed by feedback.
3135133|NCT01652950|Experimental|Vitality Wellness program Direct Payment|In addition to the base program and supplementary communication, members of the Direct Payment group received a gift voucher, corresponding to their level of engagement. Members received payouts at the end of each month of registration, for 5 different levels of engagement. The payout for the lowest level of engagement corresponded to about 25% of the monthly subscription for the wellness program. The payout for the highest level of engagement was 3 times more than the monthly subscription for the wellness program. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
3257709|NCT00785382|Placebo Comparator|1|
3135134|NCT01652950|Experimental|Vitality Wellness Program Lottery Incentive|Members of the Lottery Incentive group were entered into a cash-prize draw at the end of each month following registration, if they achieved physical activity targets. The chance of winning was set at one in fifty with an expected value identical to the direct payment group. Four lottery payouts corresponding to the member's levels of engagement were made at the end of each month following registration. Enrollment took place over a period of 5 months, and the intervention took place over a period of 12 months following registration.
3135135|NCT01652950|Experimental|Vitality Wellness Program Charity Incentive|Members of the Charity Incentive Group were offered a selection of charities to which earned rewards could be donated. Nominated charities received the payouts at the end of each month of registration, for 5 different levels of engagement of the individual members. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
3135136|NCT01652950|Experimental|Vitality Wellness Program Choice Incentive|Members of the Choice Incentive Group were asked to choose one of the three aforementioned incentive options on enrollment to the study. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
3135137|NCT01652950|Other|Vitality Wellness Program Standard of Care|The Vitality Wellness program is the incentive-based wellness initiative of Discovery Health Medical Aid Scheme, a national private health insurer in South Africa. The standard program includes membership to three national gym chains, which is subsidized to 80% of the normal monthly subscription cost. Members have the opportunity to earn points by attending gyms, which contribute, together with points earned from engagement in other wellness and preventive activities, to tier status (Blue, Bronze, Silver, Gold and Diamond). Tier status allows members to receive increasing discounts on a range of goods and services from commercial partners. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
3135138|NCT01652950|Active Comparator|Vitality Wellness Program Enhanced Communication|"In this group, members were offered the base program and, in addition, were sent bi-weekly communications by alternating email and text messaging which included information on the importance of physical activity, tips on accumulating fitness points on the base program, a status update of points earned and information on benefits and rewards offered on the program. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration."
3135139|NCT01652937|Placebo Comparator|Placebo + Background Therapy|Background therapy including DMARD(s) approved by protocol
3135140|NCT01652937|Experimental|BIIB057 Dose 1 + Background Therapy|Background therapy including DMARD(s) approved by protocol
3135141|NCT01652937|Experimental|BIIB057 Dose 2 + Background Therapy|Background therapy including DMARD(s) approved by protocol
3135142|NCT01652937|Experimental|BIIB057 Dose 3 + Background Therapy|Background therapy including DMARD(s) approved by protocol
3135143|NCT01652924|Experimental|Mechanical ventilation|1: Active Comparator Children 1 month-14 years of age Intervention:Mechanical ventilation with facial mask during anesthetic induction
3135144|NCT01652924|Active Comparator|Manual ventilation|2: Active Comparator Children 1 month-14 years of age Intervention: Manual ventilation with facial mask during anesthetic induction
3135145|NCT01652911|Experimental|Cell Pouch|Participants with Type-1 diabetes will receive the Sernova Cell Pouch™ implanted in the subcutaneous site, two to approximately twelve weeks prior to transplantation of islets into the Cell Pouch™.
3135146|NCT01652898|Active Comparator|Esmolol hydrochloride|Esmolol hydrochloride administered as intravenous bolus injection at low (0,5mg/kg), medium (1mg/kg) and high dose (1,5mg/kg) in 15/30/45 seconds once per subject
3135147|NCT01652898|Active Comparator|ONO LDL50|ONO LDL50 administered as intravenous bolus injection at low (0,1mg/kg), medium (0,2mg/kg) and high dose (0,3mg/kg) in 15/30/45 seconds once per subject
3135148|NCT01652898|Experimental|AOP LDLA202|AOP LDLA202 administered as intravenous bolus injection at low (0,1mg/kg), medium (0,2mg/kg) and high dose (0,3mg/kg) in 15/30/45 seconds once per subject
3135149|NCT01652885|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
3135150|NCT01652872|Active Comparator|Hemoglobin Based Titration Group|Subjects randomized to the hemoglobin based titration group will have their dose of investigational product titrated based on the hemoglobin concentration on the date of the visit, the corresponding hemoglobin rate of rise, and the previously assigned dose.
3135151|NCT01652872|Active Comparator|Fixed Dose Group|Subjects randomized to the fixed dose group will receive the same dose as the one assigned at the time of randomization for the duration of the treatment period with one exception: if the hemoglobin is > 12.0 g/dL, darbepoetin alfa therapy will be withheld until the hemoglobin falls below 10.0 g/dL.
3135152|NCT01652859|Experimental|Liposomal Amphotericin B|Generic drug
3135153|NCT01652859|Active Comparator|AmBisome|RLD
3135154|NCT01652833||Round 1|survey of 150 oncologists
3135155|NCT01652833||Round 2|survey of 150 oncologists approximately 12 months after round 1
3135156|NCT01652833||Round 3|survey of 150 oncologists approximately 24 months after round 1
3135157|NCT01652820|Experimental|Docetaxel +Carboplatin +concomitant chemoradiation|Docetaxel 20 mg/m2/weekly plus carboplatin AUC 2/weekly (first, docetaxel will be administered and after that, carboplatin will be administered) and concomitant chemoradiation (total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)
3135158|NCT01652820|Experimental|C) Docetax+ gemcit +concom. docetax + carbopl. + RDT concom|Docetaxel 40 mg/ m2 days 1, 8, 21 y 28 plus gemcitabine 1200 mg/ m2 days 1, 8, 21 y 28 followed by concomitant treatment Docetaxel 20 mg/m2/week plus carboplatin AUC 2/weekly and concomitant chemoradiation total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)
3135159|NCT01652807|Experimental|Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching.
3135160|NCT01652807|No Intervention|Waitlist (Delayed Yoga)|Participants assigned randomly to the control condition will provided an identical free two-month membership to Bikram Yoga Dallas after the week following their post-intervention session.
3135300|NCT01651871|Experimental|Treatment Group 2|
3135301|NCT01651871|Experimental|Treatment Group 3|
3135161|NCT01652794|Experimental|Treatment (carboplatin, gemcitabine hydrochloride, and SBRT)|Patients also receive carboplatin IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on day 1 and undergo SBRT on days 2-4.
3135162|NCT01652781|Experimental|5-day arm|azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care
3135163|NCT01652781|Active Comparator|7-day arm|azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
3135164|NCT01652768|Active Comparator|Arm A: Usual Care Group|Usual care is defined as standard post-operative care on a surgical unit in University Hospitals Case Medical Center. Discharge planning will be provided by the assigned in-patient social worker. Referrals to the assigned outpatient social worker will be made as appropriate. Patients and caregivers will be seen in the ambulatory medical oncology setting about three to six weeks after surgery, depending on post-operative recovery time. The research assistant will administer the research questionnaires at week one post-surgery and 8-10 weeks post surgery.
3135165|NCT01652768|Experimental|Arm B: PRESENCE Intervention|The unique features of the PRESENCE Project (PP) Intervention are 1) the early palliative care intervention (immediately post-op) provided by the new palliative care brain tumor team (Social worker, advanced practice nurse (APN), medical oncology registered nurse); 2) an educational information session for patients and caregivers; and 3) frequent (every two week and as needed) telephone or clinic visits during the first ten weeks post operatively (Figure 1). In usual care, the patient and caregiver receive little supportive care until they begin cancer treatment. The intervention provides aggressive supportive care from the time of diagnosis.
3135166|NCT01652755||AKI group|patients with AKI after cardiopulmonary bypass surgery
3135167|NCT01652755||non-AKI group|patients without AKI during study period
3135168|NCT01652742|Experimental|BI 135585 XX|one single dose
3135169|NCT01652729|Experimental|Exenatide once weekly suspension|Exenatide once weekly suspension 2mg subcutaneous injection
3135170|NCT01652729|Active Comparator|Sitagliptin 100mg|Overencapsulated Sitagliptin 100mg oral tablet once daily
3135171|NCT01652729|Placebo Comparator|Placebo|Placebo oral capsule once daily
3135172|NCT01652716|Experimental|Exenatide once weekly suspension|Exenatide suspension 2 mg weekly subcutaneous injection
3135173|NCT01652716|Active Comparator|Exenatide twice daily (BID)|Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks
3135174|NCT01652703|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
3135175|NCT01652703|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
3135176|NCT01652703|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3135177|NCT01652703|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3135178|NCT01652703|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3135179|NCT01652703|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3135180|NCT01652690||Denosumab|Patients with postmenopausal osteoporosis (PMO) who received at least 1 injection of denosumab 60 mg subcutaneously in the Czech Republic and Slovakia.
3135181|NCT01652677|Experimental|Low-frequency stimulation|Stimulation mode: 1 Hz, 100% MT, 20 minutes, unaffected hemisphere
3135182|NCT01652677|Experimental|High frequency stimulation|Stimulation mode: 10 Hz, 80% MT, 2 seconds - stimulation, 58 seconds - rest. - 8 session; affected hemisphere
3135183|NCT01652677|Sham Comparator|Sham stimulation|Patients will receive standard treatment (kinesotherapy, physiotherapy) and simulate of transcranial magnetic stimulation. Also patients will not know about simulation (blind group)
3135184|NCT01652677|Experimental|Both hemispheric stimulation|Stimulation mode: low-frequency to unaffected hemisphere than high-frequency to affected.
3135185|NCT01652664|Experimental|Travoprost|Travoprost 0.004% PQ ophthalmic solution, 1 drop administered in each eye in the evening with travoprost vehicle administered once daily in the morning for 3 months
3135186|NCT01652664|Active Comparator|Timolol|Timolol, 0.5% or 0.25% ophthalmic solution, 1 drop administered in each eye twice daily (once in the morning and once in the evening) for 3 months
3135187|NCT01652651|Experimental|Psychological Intervention|
3135188|NCT01652638|Experimental|Group A|"First periody: Test Drug (Heparin Blau Farmacêutica S/A)~Secundy periody: Comparator Drug (Heparin APP Pharmaceuticals)"
3135189|NCT01652638|Experimental|Group B|"First periody: Comparator Drug (Heparin APP Pharmaceuticals)~Secundy periody: Test Drug (heparin Blau Farmacêutica S/A)"
3135190|NCT01652625|Experimental|Yunnan Baiyao toothpaste|The toothpaste containing 6.5 milligrams of Yunnan Baiyao was used twice daily as part of the patient's routine oral hygiene for 5 days.
3135191|NCT01652625|Active Comparator|placebo toothpaste|One gram of placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
3135192|NCT01652612|No Intervention|Control|zero PEEP
3135193|NCT01652612|Experimental|OLV strategy: PEEP|1. apply 8 cm H2O positive end expiratory pressure during one lung ventilation and until the end of surgery
3135194|NCT01652612|Experimental|OLV strategy: PEEP followed by AR|"alveolar recruitment strategy before one lung ventilation~8 cmH2O positive end expiratory pressure during one lung ventilation and until the end of surgery"
3135195|NCT01652599|Experimental|Eltrombopag and dexamethasone|
3135196|NCT01652586|Experimental|dexmedetomidine-remifentanil|intravenous infusion of 0.2-0.7 µg/kg/h of dexmedetomidine after a loading dose of 1 µg/kg over 10 min
3135197|NCT01652586|Active Comparator|midazolam-remifentanil|remifentanil 3.6-7.2 mcg/kg/h midazolam 1-2mg
3135198|NCT01652573|Experimental|Nasal calictonin|Subjects will received nasal calcitonin once daily
3135199|NCT01652573|Placebo Comparator|Saline Nasal spray|Patients will receive saline nasal spray once daily
3135200|NCT01652560||bevacizumab combined neoadjuvant chemotherapy|
3135302|NCT01651871|Active Comparator|Treatment Group 4|
3135303|NCT01651871|Placebo Comparator|Treatment Group 5|
3135304|NCT01651858|Experimental|Nurigra Chewable tablet|
3135201|NCT01652547|Experimental|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs), switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
3135202|NCT01652547|Experimental|Pasireotide long acting release|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
3135203|NCT01652534|Active Comparator|Amantadine|Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day
3135204|NCT01652534|Placebo Comparator|placebo|Sugar Pill
3135205|NCT01652521||candidates for pleural fluid drainage|patients who are candidates for pleural fluid drainage.
3135206|NCT01652508|Placebo Comparator|Control|Participants are given printed self-help leaflet on smoking cessation developed by the Department of Health, Hong Kong.
3135207|NCT01652508|Experimental|Acceptance and Commitment Therapy|All participants are given a self-help leaflet on smoking cessation. Participants are also given an initial session of face-to-face ACT at a primary health service clinic. In addition, two more subsequent ACT sessions are provided by telephone at one week and one month after the initial intervention.
3135208|NCT01652495|Active Comparator|methylprednisolone acetate group|Single intrabursal injection of methylprednisolone acetate
3135209|NCT01652495|Active Comparator|Triamcinolone acetonide group|Single intrabursal injection of Triamcinolone acetonide
3135210|NCT01652482|Active Comparator|FOLFIRI + Cetuximab|
3135211|NCT01652482|Experimental|FOLFIRI + MEHD7945A|
3135212|NCT01652469|Experimental|A: Erlotinib|Erlotinib in standard dose. Until progression (clinical or radiological) or unacceptable toxicity.
3135213|NCT01652469|Experimental|B: Docetaxel|Docetaxel in standard dose. Until progression (clinical or radiological) or unacceptable toxicity.
3135214|NCT01652456|Experimental|Group A|
3135215|NCT01652456|No Intervention|Group B|
3135216|NCT01652430||PTSD cohort|
3135217|NCT01652430||No PTSD cohort|
3135218|NCT01652417|No Intervention|oral prednisone|Oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.
3135219|NCT01652417|Experimental|methylprednisolone bolus|methylprednisolone bolus 15 mg/kg/d for 3 days before oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.
3135220|NCT01652404|Experimental|Procalcitonin-guided treatment|The duration of antibiotics will be determined by the procalcitonin levels.
3135221|NCT01652404|Active Comparator|Conventional treatment|The duration of antibiotics will be determined by the treating physician.
3135222|NCT01652391|Experimental|Anodal transcranial direct current stimulation|Anodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus
3135223|NCT01652391|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
3135224|NCT01652378||Cocaine-Addicted Participants|Group of participants diagnosed with cocaine dependence
3135225|NCT01652378||Control Participants|healthy control volunteers
3135226|NCT01652365|Experimental|RDT Training and Subsidy Offered|Licensed drug shops within villages selected randomly to be in this arm will be invited to training on RDTs and offered access to subsidized RDTs available for purchase at a local wholesale pharmacy in Mbale, Uganda.
3135227|NCT01652365|Experimental|Information/Education Campaign|Community meetings describing RDTs and encouraging community members to be diagnosed prior to taking malaria treatment will be held in villages randomly assigned to this treatment arm.
3135228|NCT01652365|Experimental|RDT Training/Subsidy + Information/Education Campaign|Includes both the training and subsidy component and the information/education campaign component.
3135229|NCT01652365|No Intervention|Control|
3135230|NCT01652352||Individuals with Disability|Power wheelchair-bound individuals with conditions which affect upper and lower body mobility, strength, or dexterity. Such conditions may include but are not limited to spinal cord injury, Multiple Sclerosis, Cerebral Palsy, or other conditions which affect overall mobility.
3135231|NCT01652352||Able-Bodied Individuals|Those who possess no condition or injury resulting in loss of mobility.
3135232|NCT01652339|Active Comparator|Exforge tab. 10/160mg|"amlodipine besylate (10mg as amlodipine)~valsartan 160mg"
3135233|NCT01652339|Experimental|Lodivixx tab. 5/160mg|"S-amlodipine nicotinate (5mg as S-amlodipine)~valsartan 160mg"
3135234|NCT01652326||Benzodiazepine-resistant|those patients with either 1) a requirement of either 200 mg of diazepam (or diazepam equivalents) in 4 hrs; 2) >40mg of diazepam (or diazepam equivalents) in 1 hr; or 3) an individual dose of 40 mg or greater of intravenous diazepam for control of agitation
3135235|NCT01652313|Experimental|Rasagiline|
3135236|NCT01652300|Experimental|test group|For test group intervention was two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
3135237|NCT01652300|Other|control|received no education
3135238|NCT01652287|Active Comparator|BB-12 supplemented yogurt|Probiotic, Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12), supplemented strawberry yogurt, 4 ounces taken orally for 10 days
3135239|NCT01652287|Placebo Comparator|Strawberry flavored yogurt|Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
3135240|NCT01652274||Mother|study objectives to Mother only
3135241|NCT01652274||Father|study objectives to Father only
3135242|NCT01652261|Experimental|experimental arm|"An experimental arm (early FDG-PET/CT-response adapted), where all patients are initially treated with a single cycle of ABVD. Very early FDG-PET/CT-negative patients continue on ABVD therapy to a total of six cycles. Very early FDG-PET/CT-positive patients receive 3 cycles of BEACOPPesc followed by another 3 cycles of BEACOPPesc. Mid-treatment evaluation is performed after 4 cycles. In case of treatment failure (less than partial remission (PR)), the patient goes off protocol treatment.~Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es))."
3135243|NCT01652261|Active Comparator|standard arm|"A standard arm, where patients are treated with four cycles of BEACOPPesc followed by 2 cycles of BEACOPPesc. FDG-PET/CT is performed after one cycle, but with no therapeutic consequences. Mid-treatment evaluation is performed after four cycles. In case of treatment failure (less than PR), the patient goes off protocol treatment.~Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es))."
3135244|NCT01652248|Placebo Comparator|Standard generator replacement|Standard generator replacement
3135245|NCT01652248|Active Comparator|Upgrade to cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
3135246|NCT01652235|Experimental|Endovascular|Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft
3135247|NCT01652222|Experimental|CONEM-BETA + socio-educational training|"Caregivers will receive 4 socioeducational training sessions during an 8 week period. These sessions will focus on the description and process of the Alzheimer's disease (AD), and will also provide to the caregivers resources and strategies to cope with AD. During the last 4 weeks, they will also systematically play with the patient at home with the CONEM-BETA game.~After that period, caregivers will use the game based on their preference and frequence during a period of 6 more weeks."
3135248|NCT01652222|Active Comparator|Socio-educational training only|Caregivers will receive the same 4 socioeducational training sessions as the experimental group, during an 8 week period.
3135249|NCT01652222|No Intervention|Control|Caregivers of this group will behave with his/her patient during the trial as they have been doing so far, but will receive no intervention
3135250|NCT01652209|No Intervention|Control|"After implementing PCI, contemporary drug treatment is conducted.~*Contemporary drug treatment is a general drug treatment (Unfractionated heparin, Low Molecular Weight Heparin, Glycoprotein llb/llla inhibitor, Aspirin, clopidogrel or Ticlopidine, Nitrate, ACE inhibitor or ARB, β-blocker, CCB, Diuretics, Statin, etc.)"
3135251|NCT01652209|Experimental|Single dose of Hearticellgram-AMI|Within 30 days (+ / -7 days) after aspirating bone-marrow, approximately 1×10^6/kg (refer to usage/dosage according to mass) of autologous bone marrow-derived mesenchymal stem cells are adminstered into the infarct coronary artery using balloon tipped catheter. Furthermore, contemporary drug treatment is conducted.
3135252|NCT01652209|Experimental|Two doses of Hearticellgram-AMI|Within 30 days (+ / -7 days) after aspirating bone-marrow, approximately 1×10^6/kg (refer to usage/dosage according to mass) of autologous bone marrow-derived mesenchymal stem cells are adminstered into the infarct coronary artery using balloon tipped catheter. Furthermore, contemporary drug treatment is conducted. After 30 days (+ / -7 days) from the first injection, a two dose of hearticellgram-AMI is administered in the same way. Furthermore, temporary drug treatment is conducted.
3135253|NCT01652196|Experimental|Aflibercept (combination chemotherapy)|Patients receive aflibercept and fluorouracil and then continuously over 46 hours on days 1 and 15.If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted. Correlative Studies are required to be available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.DCE MRI (dynamic contrast-enhanced magnetic resonance imaging)images at weeks 0, and after 8 weeks +/- 1 week of treatment(after Cycle 2). 18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG).FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers,including colorectal cancer (99-102).
3135254|NCT01652183|Placebo Comparator|Group Control (n=32):iv 1.5 ml/kg 0.9% NaCl|
3135255|NCT01652183|Active Comparator|Group Paracetamol(n=32):iv 15mg/kg paracetamol|The patients were randomly divided into two groups: Group P (Paracetamol group, n=32) received intravenous 15mg/kg paracetamol during the surgery and Group C (Control Group, n=32) received intravenous 1.5 ml/kg 0.9% NaCl solution 30 minutes before the of surgery.At the end of the surgery, all patients had an nephrostomy catheter and the insertion site was infiltrated with 20 ml 0.25% bupivacaine infiltration for postoperative analgesia. Each patient received patient-controlled intravenous analgesia by meperidine (10 mg bolus, 20-minute lock-out, no infusion dose and 4 hour limit) for postoperative analgesia. All patients were planned to receive tenoxicam 20 mg intravenously as a rescue analgesic when visual analogue scale (VAS) was >3.
3135256|NCT01652157||Cystic fibrosis (CF) patients in the CF Patient Registry|Patients diagnosed with cystic fibrosis at participating sites who are providing data to the Cystic Fibrosis Patient Registry
3135257|NCT01652144|Experimental|AT7519M|AT7519M: 27 mg/m2 IV injection, 1 hour infusion, 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
3135258|NCT01652131|Other|Tetrastarch (130/0.4)|In obese patients candidates to laparoscopic gastrojejunal bypass an infusion of Tetrastarch (130/0.4)) of 15mL/kg (of corrected weight) will be initiated after protocoled induction of general anesthesia. Blood samples will be taken at time 0 (after induction of anesthesia and before initiating infusion) and then every 5 minutes for half an hour and then every 15 minutes up to 90 minutes. Blood samples will be processed in the Institution's laboratory. Urine will be measured at the end of the intervention. With these data kinetic parameters will be estimated for each patient.
3135259|NCT01652118|Active Comparator|Clarithromycin|Fist group treated with clarithromycin which is include 10 days application.
3135260|NCT01652118|Placebo Comparator|placebo|Second group treated with salin as same as amount of clarithromycine volume
3135261|NCT01652105|Experimental|Diet|New developed diet
3135262|NCT01652105|Active Comparator|Prodimed|Standard VLCD
3135305|NCT01651858|Active Comparator|Viagra|
3135306|NCT01651845||Image Guided Intervention|Standard of care white light visual wound assessment followed by fluorescence image-guided wound assessment
3135307|NCT01651832|No Intervention|usual care|routine care and case management
3135263|NCT01652092|Other|Arm A: Fully Myeloablative regimen|For use in patients with diseases including Wiskott-Aldrich syndrome, MHC Class II deficiency, hypomorphic SCID, etc. Receives Alemtuzumab 0.3 mg/kg intravenously (IV) on days -12 through -10, cyclophosphamide 50 mg/kg IV plus MESNA on days -9 through -6, busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2 and stem cell infusion on day 0.
3135264|NCT01652092|Other|Arm B: Reduced Toxicity Ablative Regimen|For use in patients with diseases including SCID, CGD, CHS and other CID. Receives Alemtuzumab 0.3 mg/kg intravenously (IV) on days -12 through -10, busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6, fludarabine phosphate 40 mg/m^2 IV on days -5 through -2 and stem cell infusion on day 0.
3135265|NCT01652092|Other|Arm C: Reduced Intensity Conditioning|For use in patients with diseases including HLH. Receives Alemtuzumab 0.2 mg/kg intravenously (IV) on days -14 through -10, fludarabine phosphate 30 mg/m^2 IV on days -8 through -4, melphalan 140 mg/m^2 IV on day -3 and stem cell infusion on day 0.
3135266|NCT01652092|Other|Arm D: No Preparative Regimen|For use in patients with complete SCID phenotype with no evidence of maternal engraftment or residual immune function who will be receiving their stem cell transplantation from a genotypically matched donor.
3135267|NCT01652079|Experimental|Treatment Arm|CRLX101
3135268|NCT01652066|Placebo Comparator|Placebo|oral consumption, once per day in the morning, fasting, with a glass of water
3135269|NCT01652066|Experimental|Mixture of probiotics|"at least 10x7 cfu/tablet of a mixture of probiotics~oral consumption, once per day in the morning, fasting, with a glass of water"
3135270|NCT01652053||Disc Nucleus Replacement|Disc Nucleus Replacement (InterCushion DNP)
3135271|NCT01652040|Experimental|RT+Tp|Resistance training using electrical stimulation and ankle weights and Testosterone patches
3135272|NCT01652040|Experimental|Tp|Applying Testosterone patches
3135273|NCT01652027||Previously Untreated Patients with Hemophilia A|
3135274|NCT01652014|Experimental|Arm I|"Double UCB transplantation~Patients receive conditioning comprising fludarabine phosphate IV over 30 minutes on days -6 to -2, cyclophosphamide IV over 1 hour on day -6, and undergo TBI on day -1. Patients also receive GVHD prophylaxis comprising tacrolimus IV continuously or PO beginning on day -3 with taper and mycophenolate mofetil PO BID days 1-30. Patients undergo double allogeneic UCB transplant on day 0."
3135275|NCT01652014|Experimental|Arm II|"Sub-threshold single UCB + irradiated PBMCs transplantation~Patients receive conditioning comprising fludarabine phosphate IV over 30 minutes on days -6 to -2, cyclophosphamide IV over 1 hour on day -6, and undergo TBI on day -1. Patients also receive GVHD prophylaxis comprising tacrolimus IV continuously or PO beginning on day -3 with taper and mycophenolate mofetil PO BID days 1-30. Patients undergo single allogeneic UCB transplant on day 0. Patients also undergo irradiated allogeneic PBMC transplant within 8 hours following the UCB infusion."
3135276|NCT01652001|Experimental|Malic Acid 1%|"Intervention group subjects was the delivery to the patients of a topical sialogogue, containing 1% malic acid, xylitol 10% and fluoride 0.05%(Xeros Dentaid Spray©, Dentaid, Barcelona, Spain).~Spray was transferred by foreign personnel into identical opaque flasks(without any brand name)labeled A."
3135277|NCT01652001|Placebo Comparator|Control|Control group was given a placebo with opaque flask(without any brand name)labeled B and with the same presentation and composition than Experimental group (excepting 1% malic acid).
3135278|NCT01651988|Active Comparator|Ketofol 1:1|1. Anesthesia-sedation KETOFOL 1-1: Two milligrams per kilogram of ketamine plus two milligrams per kilogram of propofol in a solution 1:1 (one milligram of ketamine per one milligram of propofol) was given to those patients randomly asigned to this group, who were scheduled for any short surgical procedures previously defined in the inclusion criteria.
3135279|NCT01651988|Experimental|Ketofol 1:2|2. Anesthesia-sedation KETOFOL 1-2: One milligram per kilogram of ketamine plus two milligrams per kilogram of propofol in a solution 1:2 (one milligram of ketamine per two milligrams of propofol) was given to those patients randomly asigned to this group, who were scheduled for any short surgical procedure previously defined in the inclusion criteria.
3135280|NCT01651975|Other|Thickenup|
3135281|NCT01651962|Experimental|Terbutaline|Terbutaline 0.125mg i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
3135282|NCT01651962|Active Comparator|Fentanyl|Fentanyl 100mcg i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
3135283|NCT01651962|Placebo Comparator|Placebo|0.9% NaCl i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
3135284|NCT01651949|Active Comparator|Females|Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
3135285|NCT01651949|Experimental|Heterosexual Males|Healthy heterosexual males 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
3135286|NCT01651949|Experimental|Men who have Sex with Men|Healthy MSM 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
3135287|NCT01651936|Experimental|Base Study: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. The Base Study lasted up to 24 weeks.
3135288|NCT01651936|Placebo Comparator|Base Study: Placebo|Participants received placebo BID orally with MTX at the stable dose received upon study enrollment. The Base Study lasted up to 24 weeks.
3135289|NCT01651936|Experimental|Safety Extension: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. The Safety Extension was to last up to 76 weeks.
3135290|NCT01651923|Other|Group A|"First periody: Heparin Test Drug (Blau Farmacêutica S/A)~Secundy periody: Heparin Comparator Drug (APP Pharmaceuticals)"
3135291|NCT01651923|Other|Group B|"First periody: Heparin Comparator Drug (APP Pharmaceuticals)~Secundy periody: Heperin Test Drug (Blau Farmacêutica S/A)"
3135292|NCT01651910||Controlled Pain|Participants who have controlled pain; requiring regular painkillers which are maintaining the pain as none - mild with no breakthrough pain episodes.
3135293|NCT01651910||Uncontrolled Pain|Participants who have uncontrolled pain; pain that is moderate to severe whether on painkillers or not
3135294|NCT01651910||Breakthrough pain|Participants who have breakthrough pain; pain that is controlled but the patient has episodes when the pain intermittently 'flares up'.
3135295|NCT01651897||Delirious in the ED|Patients who were delirious in the ED at either the 0-hour or 3-hour delirium assessment.
3135296|NCT01651897||Non-Delirious in the ED|Patients who were non-delirious in the ED at both the 0-hour or 3-hour delirium assessment.
3135309|NCT01651819|Experimental|Urological physical therapy|Urologic physical therapy is going to be apply in 20 patients with HTLV-1 infection and overactive bladder symptoms like urgency, incontinence and nocturia. There will be 20 sessions with one hour duration and a interval of 3 or 4 days between the sections.
3135310|NCT01651806|Active Comparator|Females receiving a uniform dose of TA|Women receiving a single dose of 1 gram of TA--includes all women that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
3135311|NCT01651806|Active Comparator|Weighted dose of TA in female patients|Female patients receiving a weighted dose of TA. Will include all women that will get a weighted dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
3135312|NCT01651806|Active Comparator|Tranexamic acid weighted dose male|Male patients randomized to the weighted dose of TA. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
3135313|NCT01651806|Active Comparator|Uniform single dose TA male patient|Male patients receiving a single dose (1gram) of TA during TKA. Includes all men that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss. Patients will be randomized into one of these two groups.
3135314|NCT01651806|No Intervention|Historical Cohort|"25 patients with no TA use in their surgical history.~A control group was established from a historical cohort of primary TKAs performed by the senior author (BL), none of which received TA. The most relevant Pubmed ID would be 24997651."
3135315|NCT01651793|Active Comparator|Caffeinated cocoa|High flavanol, high theobromine, high caffeine, single dose administration in hot water vehicle
3135316|NCT01651793|Active Comparator|Cocoa|High flavanol, high theobromine, low caffeine, single dose administration in hot water vehicle
3135317|NCT01651793|Active Comparator|Caffeine|Low flavanol, low theobromine, high caffeine, single dose administration in hot water vehicle
3135318|NCT01651793|Placebo Comparator|Placebo|No flavanol, no theobromine, no caffeine, single dose administration in hot water vehicle
3135319|NCT01651780|Experimental|Bivalirudin|Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.
3135320|NCT01651780|Active Comparator|Unfractionated heparin (UFH)|The dose of UFH adhered to the standard institutional practice. An activated clotting time (ACT) target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.
3135321|NCT01651767|Experimental|Panel I|Patients will be randomized to receive JNJ-47910382 at a dose of 30 mg or placebo as monotherapy once daily for 5 days.
3135322|NCT01651767|Experimental|Panel II|Patients will be randomized to receive JNJ-47910382 at a dose of 90 mg or placebo as monotherapy once daily for 5 days.
3135323|NCT01651767|Experimental|Panel III|Patients will be randomized to receive JNJ-47910382 at a dose of 300 mg or placebo as monotherapy once daily for 5 days.
3135324|NCT01651767|Experimental|Panel IV|Patients will be randomized to receive JNJ-47910382 at a dose of 400 or 450 mg once daily or 300 mg twice daily (morning dose only on Day 5) or placebo as monotherapy for 5 days.
3135325|NCT01651754|Other|Seasonal influenza vaccination|
3135326|NCT01651741|Experimental|Seaweed and Duolac7S|Seaweed: Real Seaweed granule, Duolac7S: Real probiotics
3135327|NCT01651741|Placebo Comparator|Seaweed and Duolac7S-P|Seaweed: Real Seaweed granule, Duolac7S-P: Placebo probiotics
3135328|NCT01651728|Experimental|Simvastatin|Tablet 20 mg once daily for 30 days
3135329|NCT01651728|Placebo Comparator|Placebo|Placebo tablet once daily for 30 days
3135330|NCT01651715|Experimental|TAO1, oral homeopathic antibodies|TAO1 is an investigational medicinal product containing homeopathic dilutions (<10-24M) of antibodies purified from the serum of rabbit immunised against a synthetic peptide with an amino acid sequence selected in the human toll-like receptor type 3 sequence (anti-TLR3). It is intended for the treatment of viral Upper Respiratory Tract Infections (URTIs) such as common cold, influenza or influenza-like illnesses.
3135331|NCT01651715|Placebo Comparator|Placebo|Same characteristics as investigational medicinal Product except for homeopathic dilutions of oral antibodies to the TLR3 FYW peptide
3135332|NCT01651702|Active Comparator|Carto|Patients in whom Carto system will be used
3135333|NCT01651702|Active Comparator|Ensite|Patients in whom Ensite system will be used
3135334|NCT01651689||Scalp biopsy|Subjects are on scadule list for hair transplantation in Siriraj hospital. Scalp biopsy with punch biopsy No.4 Scalp biopsy by punch biopsy No.4 at occipital area was done in subjects who have hair transplantaion.
3135335|NCT01651676|Experimental|COPD arm|"VQ11 validation:~Stage II, III or IV COPD patients justifying a LABD will benefit from the studied VQ11 questionnaire"
3135336|NCT01651663|Experimental|Arbidol (Umifenovir)|
3135337|NCT01651663|Placebo Comparator|placebo|
3135338|NCT01651663|Experimental|Arbidol (Umifenovir) prophylaxis|
3135339|NCT01651663|Placebo Comparator|placebo prophylaxis|
3135340|NCT01651650|Other|Inhalation of Placebo Dry Powder|Each patient will perform at least two inhalations using the Chiesi NEXThaler DPI device containing placebo dry powder. There is no comparator and all patients will receive the same study treatment.
3135341|NCT01651637|Experimental|Synthetic Surfactant|Cohort Design
3135342|NCT01651624|Experimental|Computed tomographic colonography (CTC), reduced prep|Subjects invited to undergo CTC with reduced cathartic preparation
3135343|NCT01651624|Experimental|Computed tomographic colonography (CTC), standard prep|Subjects invited to undergo CTC with standard bowel preparation
3135344|NCT01651624|Active Comparator|Faecal occult blood test (FOBT)|Subjects invited to undergo FOBT
3135345|NCT01651624|Experimental|Colonoscopy|Subjects invited to undergo colonoscopy
3135433|NCT01651052|Experimental|Aortic Bioprosthesis, Model 11000|Aortic valve replacement therapy
3135434|NCT01651039|Experimental|Panobinostat, Lenalidomide and Dexamethasone|All patients will receive oral panobinostat, lenalidomide and dexamethasone as per protocol.
3135346|NCT01651611|Experimental|Extensive TTA interaction|Persons interested in quitting smoking will receive multiple in-person visits from a peer Tobacco Treatment Advocate (TTA) who will provide motivational interviewing, basic smoking cessation counseling assistance, navigation to smoking cessation resources, and social support.
3135347|NCT01651611|Active Comparator|Minimal TTA interaction|Persons interested in quitting smoking will receive a single in-person visit from a peer Tobacco Treatment Advocate (TTA) who will provide basic smoking cessation counseling assistance.
3135348|NCT01651598|Experimental|BI 144807|Subjects receive multiple BID doses of BI 144807 solution
3135349|NCT01651598|Placebo Comparator|Placebo|Subjects receive multiple BID doses of Placebo solution
3135350|NCT01651585|Experimental|Valacyclovir arrow|Experimental : Valacyclovir arrow 500mg give Valacyclovir arrow to all participants (open phase)
3135351|NCT01651572|Experimental|Cisatracurium|"Induction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl.~Cisatracurium (Nimbex):~initial dose: 0.2 mg/kg~maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)~At the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg.~Patients will be extubated with a TOF-Ratio of at least 0.90."
3135352|NCT01651572|Experimental|Rocuronium|"Induction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl~Rocuronium (Esmeron):~initial dose: 0.6 mg/kg~maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)~At the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg.~Patients will be extubated with a TOF-Ratio of at least 0.90."
3135353|NCT01651546|Other|Cohort|Patients with dysvoiding function and chronic urinary retention, with an indication to CISC.
3135354|NCT01651533|Experimental|Experimental: Mental Practice Group|
3135355|NCT01651533|Active Comparator|Active Comparator: Active Control Group|
3135356|NCT01651520|Experimental|Relapsing patients < 5 years|Relapsing patients < 5 years
3135357|NCT01651520|Experimental|relapsing patients < 10 years|relapsing patients < 10 years
3135358|NCT01651520|Experimental|primary progressive patients < 10 years|primary progressive patients < 10 years
3135359|NCT01651520|Other|healthy volunteers|healthy volunteers
3135360|NCT01651507||HLP|Patients with pulmonary LCH from eight teaching hospitals evaluated between June 1989 and February 2005 were considered for this study, if they were followed for at least 6 months and evaluated by ≥ 2 lung HRCT and lung function tests at the same time or within a 2 months period
3135361|NCT01651494|Active Comparator|DAS181-F04|DAS181-F04: 20 mg single-dose each day via inhalation for 3 days; 6 subjects
3135362|NCT01651494|Placebo Comparator|Placebo|Placebo: 20 mg single-dose each day via inhalation for 3 days; 3 subjects
3135363|NCT01651481|Experimental|TR|HCP1102(Singulair and Xyzal combination tablet) -> coadministration of Singulair and Xyzal
3135364|NCT01651481|Experimental|RT|coadministration of Singulair and Xyzal -> HCP1102(Singulair and Xyzal combination tablet)
3135365|NCT01651468|Experimental|HEMOFIX|3 grams a day
3135366|NCT01651455||Cohort first decade|Patients born between 01/01/1979 and 12/31/1984
3135367|NCT01651455||Cohort second decade|Patients born between 01/01/1991 and 12/31/1996
3135368|NCT01651442|Active Comparator|Non-drug Sleep Therapy 1|
3135369|NCT01651442|Active Comparator|Sleep Medication 1|
3135370|NCT01651442|Active Comparator|Non-drug Sleep Therapy 2|
3135371|NCT01651442|Active Comparator|Sleep Medication 2|
3135372|NCT01651429|Experimental|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation, 17 of which will be spent in the laboratory.
3135373|NCT01651416|Active Comparator|HMM using short-acting ACT|Home management of malaria using Artemether-lumefantrine combination (a short-acting ACT) for treatment in children with malaria diagnosed using RDTs
3135374|NCT01651416|Experimental|HMM using short-acting ACT plus SMC|Home management of malaria using using Artemether-lumefantrine combination (a short-acting ACT) for treatment in children with malaria diagnosed using RDTs plus seasonal malaria chemoprevention with Amodiaquine plus sulphadoxine-pyrimethamine combination.
3135375|NCT01651416|Experimental|HMM using a long-acting ACT|Home management of malaria using Dihydroartemisinin Piperaquine combination (a long-acting ACT) for treatment in children with malaria diagnosed using RDTs
3135376|NCT01651403|Experimental|Tenofovir DF (Blinded Randomized Treatment)|Participants will receive tenofovir disoproxil fumarate (tenofovir DF; TDF) for 48 weeks.
3135377|NCT01651403|Placebo Comparator|Placebo to match TDF (Blinded Randomized Treatment)|Participants will receive TDF placebo for 48 weeks.
3135378|NCT01651403|Experimental|Tenofovir DF (Open-label Treatment)|Following 48 weeks of blinded randomized treatment, participants will switch to open-label TDF treatment for an additional 144 weeks.
3135379|NCT01651403|Experimental|Tenofovir DF (Open-label Extension Phase)|Following the completion of study at Week 192, participants may have the option to receive open-label TDF until it is commercially available in that country for treatment of chronic HBV in patients of their age and weight.
3135380|NCT01651390|Experimental|Drug coated balloon|Percutaneous coronary intervention with the Pantera Lux drug coated balloon.
3135381|NCT01651390|Active Comparator|Drug eluting stent|Percutaneous coronary intervention with the Orsiro drug eluting stent.
3135382|NCT01651377|Placebo Comparator|Placebo|
3135383|NCT01651377|Active Comparator|Pramipexole|
3135384|NCT01651364|Placebo Comparator|Placebo|
3135385|NCT01651364|Active Comparator|Cabergoline|
3135386|NCT01651351|Experimental|Cohort 1|"Day 1:~GLASSIA at 0.04 mL/kg/min~Placebo at 0.2 mL/kg/min~Day 15:~GLASSIA at 0.2 mL/kg/min~Placebo at 0.04 mL/kg/min"
3135387|NCT01651351|Experimental|Cohort 2|"Day 1:~GLASSIA at 0.2 mL/kg/min~Placebo at 0.04 mL/kg/min~Day 15:~GLASSIA at 0.04 mL/kg/min~Placebo at 0.2 mL/kg/min"
3135388|NCT01651338|Experimental|accupuncture,|The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
3135389|NCT01651325|Experimental|Isavuconazole and dextromethorphan|Dextromethorphan on Day 1and Day 10, Isavuconazole three times per day (TID) on Days 6 and 7, and once daily (QD) on Days 8 thru 12.
3135390|NCT01651312|Experimental|14C-labeled YM178|Single oral administration of 14C-labeled YM178
3135391|NCT01651286|Experimental|nasal mask|when the patient is apneic after the injection of anesthetics in the operating room, a nasal mask will be applied with positive pressure ventilation for 1 min. Then the nasal mask will be replaced with a full face mask for 1 min. Subsequently, the face mask will be replaced with the nasal mask.
3135392|NCT01651286|Active Comparator|full face mask|when the patient is apneic after the injection of anesthetics in the operating room, a full face mask will be applied with positive pressure ventilation for 1 min. Then the full face mask will be replaced with a nasal mask for 1 min. Subsequently, the nasal mask will be replaced with the full face mask.
3135393|NCT01651273|Experimental|Arm 1: BMS-852927 (0.25 mg)|
3135394|NCT01651273|Experimental|Arm 2: BMS-852927 (1.0 mg)|
3135395|NCT01651273|Experimental|Arm 3: BMS-852927 (2.5 mg)|
3135396|NCT01651273|Placebo Comparator|Arm 4: Placebo|
3135397|NCT01651260|Other|Endotracheal (ET) tube securement device|Single arm study evaluated an experimental ET tube securement device with a bite block.
3135398|NCT01651247||Group A|Subjects received 3 doses of the combination DTaP-HepB-IPV vaccine or separately administered DTaP, HepB, and IPV vaccines at 2, 4, and 6 months of age, in a previous study (217744/085).
3135399|NCT01651247||Group B|Subjects received a single dose of the combination DTaP-IPV vaccine or separately administered DTaP and IPV vaccines at 4-6 years of age, in a previous study (213503/048).
3135400|NCT01651234|Experimental|Active|
3135401|NCT01651234|Placebo Comparator|Placebo|
3135402|NCT01651221|Experimental|Olfactory|Habituation of olfactory response
3135403|NCT01651221|Experimental|gustatory|Habituation of gustatory response.
3135404|NCT01651221|Experimental|olfactory and gustatory|Habituation of olfactory and gustatory response
3135405|NCT01651208|Experimental|Motivational interviewing (MINT)|The MINT intervention will consist of 4 to 7 telephone encounters between a nurse trained in Motivational interviewing and a minority subject who recently received a coronary stent. All subjects in the MINT arm will be contacted every 3 months to complete 4 encounters. MINT is a well-known, scientifically tested behavioral counseling strategy developed as an amalgamation of principles drawn from several theoretical paradigms, the most important of which are Self-Determination Theory, Patient-Centeredness, Self-Efficacy theory, and the Stages of Change model.
3135406|NCT01651208|Active Comparator|Mailed DVD|A DVD that re-enforces an adequate behavior regarding adherence to anti-platelet will be compared to a MINT intervention. The DVD will also address many questions and concerns patients have after stent placement. The intervention is based on role theory and the effects of vicarious learning via electronic media with respect to Cardiovascular behaviors.
3135407|NCT01651195|Active Comparator|Probiotic tablet|Lactobacillus rhamnosus 8-9 x 10 -9 2 x 2 3 weeks
3135408|NCT01651195|Placebo Comparator|Placebo tablet|Chrystalline celluloce 2 x 2, 3 weeks
3135409|NCT01651182|Placebo Comparator|Standard Care|No tranexamic acid
3135410|NCT01651182|Experimental|Dose 1|1 g bolus + 1 g infusion from induction over 8 hours
3135411|NCT01651182|Experimental|Dose 2|1 g bolus + 10 mg/kg/hr from induction until end of surgery
3135412|NCT01651169|Experimental|methylphenidate tablets (10mg), ADHD|Fifteen patients of ADHD
3135413|NCT01651169|Experimental|methylphenidate tablets, Methamphetamine abusers and ADHD|Fifteen patients of ADHD with Methamphetamine abuse for at least 2 years plus
3135414|NCT01651156|Placebo Comparator|placebo|Frequency: once per day Duration: 7days
3135415|NCT01651156|Experimental|Tolvaptan|Tolvaptan tablet Frequency: once per day Duration: 7days
3135416|NCT01651143|Experimental|SAR100842|"Core part: SAR100842 300 mg, oral administration twice daily, for 8 weeks~Extension part: SAR100842 300 mg, oral administration twice daily, for 16 additional weeks"
3135417|NCT01651143|Placebo Comparator|Placebo|"Core part: Placebo (for SAR100842), oral administration twice daily, for 8 weeks~Extension part: SAR100842 300 mg, oral administration twice daily, for 16 additional weeks"
3135418|NCT01651130|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg, once following delivery of the fetal head.
3135419|NCT01651130|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg, once following delivery of the fetal head.
3135420|NCT01651130|Active Comparator|Carbetocin 15mcg|Carbetocin 15mcg, once following delivery of the fetal head.
3135421|NCT01651130|Active Comparator|Carbetocin 10mcg|Carbetocin 10mcg, following delivery of the fetal head.
3135422|NCT01651130|Active Comparator|Carbetocin 5mcg|Carbetocin 5mcg, following delivery of the fetal head.
3135423|NCT01651130|Active Comparator|Carbetocin 2mcg|Carbetocin 2mcg, following delivery of the fetal head.
3135424|NCT01651117|No Intervention|Usual Care|Enrolled in two different time frames. No interventions will be provided to this arm. They will complete planned surveys, and blood draws (baseline, 6 months, and 12 months).
3135425|NCT01651117|Experimental|Peer Mentoring|Participants in this arm will be mentored for 6 months by a veteran who was once in poor control but is now in good control. They will then be further randomized to either becoming a mentor for 6 months or having no other additional active intervention. All participants in this arm will be evaluated in person at baseline, 6 months, 12 months, and 18 months.
3135426|NCT01651117|Experimental|Peer Mentoring FFM (from former mentee)|Participants in this arm will be mentored by the former mentee for 6 months and will be followed in person for an additional 6 months after the completion of the active intervention.
3135427|NCT01651104|Experimental|Adjuvanted Trivalent Influenza Virus Vaccine|
3135428|NCT01651091|Experimental|Meditation Awareness Training|
3135429|NCT01651091|Active Comparator|Treatment as Usual|
3135430|NCT01651078||Main cohort|Patients with radiographic evidence of lesion regrowth following prior treatment with stereotactic radiosurgery (regardless of the process being suspected recurrent or progressive brain metastasis versus radiation necrosis) and who already scheduled for NeuroBlate procedure.
3135431|NCT01651065|Experimental|Microclinics Group A|Subjects will be receiving a 10/9-month Microclinic Diabetes Education Program (Team Up 4 Health) and 6 months of follow up. In the intervention these subjects will engage in the Microclinic Program support groups. The intervention program consists of 25 event sessions. Sessions are offered weekly the first month, and biweekly thereafter.
3135432|NCT01651065|Placebo Comparator|Group C Controls|Individuals will receive screening by clinical staff. Control group subjects will receive clinic screenings only; they will not participate in program activities.
3135437|NCT01651000|Active Comparator|CTAP101 30 μg capsules|1 CTAP101 30 μg capsule daily at bedtime for 12 weeks, with a possible increase to 2 CTAP101 30 μg capsules daily at bedtime for study duration, if needed (26 weeks total). Subjects not requiring a dose increase after 12 weeks would receive 1 CTAP101 30 μg capsule and one sugar pill (to CTAP101 30 μg capsule) for weeks 13-26.
3135438|NCT01651000|Placebo Comparator|Sugar pill to CTAP101 30 μg capsule|1 sugar pill to CTAP101 30 μg capsule daily at bedtime for 12 weeks, with an increase to 2 sugar pills to CTAP101 30 μg capsules daily at bedtime for weeks 13-26.
3135439|NCT01650987||Col 1|Patient with uterus adenocarcinoma, treated by surgery, then surveillance without complementary treatment
3135440|NCT01650987||Col 2|Patient with uterus adenocarcinoma, treated by surgery then adjuvant radiotherapy
3135441|NCT01650987||Col 3|patient with uterus adenocarcinoma, treated by surgery then curietherapy of vaginal dome
3135442|NCT01650987||Endometrial 4|patient with cervix carcinoma stage IA2 to IIB, treated by surgery only
3135443|NCT01650987||endometrial 5|patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy
3135444|NCT01650987||endometrial 6|patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy and radiotherapy
3135445|NCT01650974|No Intervention|conventional oxygen therapy|conventional nasal prong with FiO2 ~0.4
3135446|NCT01650974|Experimental|HFNOT|high flow nasal oxygen therapy with starting FiO2 0.4 and Flow 40 L/min
3135447|NCT01650974|Sham Comparator|sham-HFNOT|same device with FiO2 ~0.4, NO high flow
3135448|NCT01650961|Experimental|Palonosetron|Intravenous administration of palonosetron 0.075 mg before the induction of general anesthesia
3135449|NCT01650961|Placebo Comparator|Control|Intravenous administration of normal saline before the induction of general anesthesia
3135450|NCT01650948||AMD subjects with GA and/or RPED|All subjects will have AMD and GA and/or RPED.
3135451|NCT01650948||AMD subjects with CNV alone|All subjects will have the CNV form of AMD only.
3135452|NCT01650935|Active Comparator|Oxalate restricted|After a run-in period of 3 weeks patients are allocated into 2 groups. The Oxalate restricted group is prescribed an oxalate restricted diet. They are instructed to avoid oxalate-rich foods such as spinach, rhubarb, beets, chocolate, cereals, nuts, tea, wheat bran, and strawberries and to drink water in amounts of roughly 2 L during cold weather and 3 L during warm/hot weather.
3135453|NCT01650935|Active Comparator|DASH diet|The second group is asked to follow a calorie-controlled DASH diet plan. DASH is an eating pattern recommended by the 2005 Department of Health and Human Services Dietary Guidelines for Americans as a model of healthy eating for the majority of individuals in the population. This group eats a diet which includes higher fruit, vegetables, and low-fat dairy products and lower in saturated fat, total fat, and cholesterol, containing more whole grains and fewer refined grains, sweets, and red meat.
3135454|NCT01650896|No Intervention|General Medicine|
3135455|NCT01650896|Active Comparator|Geriatric Medicine|Daily medical review, adjust medications, treat infection, occupational therapy
3135456|NCT01650883|Experimental|Cholecaliferol 50,000 IU PO Q10 days x 40 days|Patients in this arm receive Cholecalciferol (vitamin D3) via PO route every 10 days for 40 days for a total of 200,000 IU of Vitamin D3. They also receive daily 1200 mg of Calcium Carbonate via PO route daily for 40 days.
3135457|NCT01650883|Experimental|Cholecalciferol 5,000 IU PO daily x 40 days|Patients in this arm receive 5,000 IU of Cholecalciferol (Vitamin D3) via PO route daily for 40 days for a total of 200,000 IU. These patients also receive 1200 mg of daily Calcium Carbonate via PO route for 40 days.
3135458|NCT01650870|Active Comparator|Evening Only (full-dose)|The dosing regimen of Crystalline lactulose will be four 45-gram doses (one dose every 60 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
3135459|NCT01650870|Experimental|Split-dose|The dosing regimen of Crystalline lactulose will be three 45-gram doses (one dose every 60 minutes for 3 straight hours) taken the evening before the colonoscopy procedure followed by one 45-gram dose the morning before the colonoscopy procedure.
3135460|NCT01650844|Experimental|School-based Telemedicine Enhanced Asthma Mangement Group|We will use a web-based system to assess asthma severity or control and will send a symptom report to the child's primary care physician (PCP). Children randomized to the SB-TEAM group, will receive a telemedicine visit in the school health office at the start of the school year to provide an initial asthma assessment. The telemedicine provider will deliver brief asthma education and referrals to community resources, and will send a guideline-based preventive medication prescription electronically to a local pharmacy. The pharmacy will deliver the medications to home and school, and the school nurse will administer the medication as directly observed therapy throughout the school year. Follow-up telemedicine assessments will occur twice during the study period. These follow-up visits will focus on assessment of control, assessment of ongoing triggers or co-morbid conditions, and brief asthma education.
3135461|NCT01650844|Active Comparator|Enhanced Usual Care Group|Children randomized to the enhanced usual care group will receive a symptom assessment using national care guidelines, a recommendation for appropriate preventive medications, and asthma education materials. We will use the web-based system to send a symptom report to the child's PCP with guideline-based recommendations for preventive care. We will provide systematic feedback to the family and providers at the same intervals as in the SB-TEAM group's telemedicine visits, by prompting providers to use care guidelines, and caregivers to schedule recommended follow-up visits with the PCP.
3135462|NCT01650831|Active Comparator|Clinical Suspicion of Hpylori|All subjects arriving at clinic with suspicion of having Helicobacter infection due to symptoms such as reflux, ulcer, gastric cancer and other clinical gastric conditions
3135463|NCT01650818|Experimental|Aerobic exercise training|
3135464|NCT01650818|Active Comparator|Standard physical therapy|
3135465|NCT01650805|Experimental|ponatinib|
3135466|NCT01650805|Active Comparator|imatinib|
3135467|NCT01650792|Active Comparator|Aspirin|Aspirin 300mg per day for 7 days in patients with HITS on transcranial Doppler monitorization
3135468|NCT01650792|No Intervention|Best medical treatment|Best medical treatment including drugs for heart failure and hypertension will be given to both groups.
3135469|NCT01650779|Experimental|Agalsidase beta|
3135470|NCT01650753|Experimental|Probiotic Powder|Probiotic: Bifidobacterium longum subsp longum AH1206
3135471|NCT01650753|Placebo Comparator|Placebo Powder|Equivalent amount (same volume) of maltodextrin
3257710|NCT00785382|Experimental|2|
3135472|NCT01650740|Experimental|Open-label duloxetine|12 week treatment with duloxetine
3135473|NCT01650740|Experimental|Open-label Placebo|4 weeks of open label placebo with option to continue or switch to duloxetine for remaining 8 weeks.
3135474|NCT01650740|Experimental|Supportive clinical management|4 weeks of supportive clinical management visits with option to continue or switch to duloxetine for remaining 8 weeks.
3135475|NCT01650727|Experimental|Dinaciclib + Rituximab|"Rituximab will be administered in Cycles 1 and 3-13.~Dinaciclib will be administered in Cycles 2-13."
3135476|NCT01650714|Experimental|Full thickness gastric biopsy|Full thickness gastric biopsy
3135477|NCT01650701|Experimental|Lenalidomide + Rituximab|"Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles~Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles."
3135478|NCT01650701|Active Comparator|Control|• ONE of the following: Rituximab - CHOP, Rituximab - CVP, Rituximab - Bendamustine. 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
3135479|NCT01650688||Epiblepharon|subjects demonstrating prominent corneal touch by cilia and/or related subjective symptoms
3135480|NCT01650675|Placebo Comparator|Control|Participants randomized into the control condition complete assessment and a time-matched interactive session on infant nutrition.
3135481|NCT01650675|Experimental|Indirect intervention|Participants in this condition review a short series of parenting strengths that benefit infants, and are invited to consider their current status in each area. This list includes factors associated with drug use (e.g., safety, emotional health) as well as substance use itself.
3135482|NCT01650662|Experimental|Cyclosporine A|"The investigational active treatment is CsA, an immunosuppressant indicated for the prevention of acute rejection after organ transplant, including cardiac transplantation.~The preparation used in the trial will be Sandimmun IV, containing CsA 50 mg/ml, Cremophor® EL and 94% ethyl alcohol in a 5 ml vial.~Patients will received Cyclosporine A on the top of recommended standard care for acute myocardial infarction."
3135483|NCT01650662|Experimental|Control group|The control group received on the top of recommended standard care for acute myocardial infarction.
3135484|NCT01650649|Active Comparator|Lofexidine Titration in Methadone Maintained Subjects|Methadone maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID (4 tablets QID) or to the highest level tolerated. Following this initial titration attempt, all subjects will have their methadone dose reduced by 50% and lofexidine titration efforts will resume.
3135485|NCT01650649|Placebo Comparator|Placebo titration in methadone maintained subjects|Methadone maintained subjects will be titrated on placebo tablets in ascending doses of 1 tablet starting with 2 tablets (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc) to mimic titration for subjects randomized to lofexidine.
3135486|NCT01650636|Experimental|Cognitive Behavioral Stress Management|
3135487|NCT01650636|Active Comparator|Health Information|
3135488|NCT01650623|Experimental|Gait training executive functions tasks|The experimental group will perform a gait training associated with the tasks that require the main executive functions (dual-task condition).
3135489|NCT01650623|Active Comparator|Gait training alone|The control group will perform a gait training alone, without associated tasks (single-task condition).
3135490|NCT01650610|Experimental|Gait training executive functions tasks|This group will perform a gait training associated with the tasks that require the main executive functions.
3135491|NCT01650597|Experimental|Part 1 - Panel 1|The participants will receive 3 or 4 ascending doses (2.5, 10, 30, 100, 250, 500 mg) of JNJ-42165279 and placebo during the study.
3135492|NCT01650597|Experimental|Part 1 - Panel 2|The participants will receive 3 or 4 ascending doses (2.5, 10, 30, 100, 250, 500 mg) of JNJ-42165279 and placebo during the study.
3135493|NCT01650597|Experimental|Part 2 (parallel)- additional cohort|The participants will receive repeated daily dosing of 100 mg JNJ-42165279 or placebo for 6 consecutive days.
3135494|NCT01650584|Experimental|ISTA Tears|Sterile ophthalmic solution
3135495|NCT01650584|Active Comparator|Systane|Sterile ophthalmic solution
3135496|NCT01650558|Active Comparator|Standard of Care Prophylaxis (TS)|Standard of care prophylaxis with daily trimethoprim sulfamethoxazole (TS).
3135497|NCT01650558|Experimental|Chloroquine (CQ) prophylaxis|Discontinuation of standard of care TS prophylaxis and starting weekly chloroquine prophylaxis
3135498|NCT01650558|No Intervention|Discontinuation of standard of care|Control arm - Discontinuation of standard of care trimethoprim sulfamethoxazole.
3135499|NCT01650545|Experimental|Liposomal Aerosol Cyclosporine|Arm 1) Aerosol liposomal cyclosporine Open label randomized trial using experimental inhalational therapy with liposomal aerosol cyclosporine in addition to standard immune suppression (tacrolimus , mycophenolate mofetil and prednisone) for 6 month duration at inhalational doses (5mg and 10 mg bid), to be defined by transplant type respectively (single, double lung transplant )
3135500|NCT01650545|Active Comparator|Conventional oral immune suppression|"Arm 2) Standard immune suppression consisting of typical oral immune suppression for lung transplant recipients typically tacrolimus, mycophenolate mofetil and prednisone.~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone rapamycin described in the subsequent section as well."
3135501|NCT01650532|Experimental|Yoga Condition|Participants will be instructed to learn yoga postures as well as yoga based breathing and meditative practices by certified yoga instructors. Primary Hatha yoga postures will be performed using props like yoga mats, blocks, belts and blankets. Classes will be held 3 times a week for 8 weeks.
3135502|NCT01650532|Active Comparator|Stretching Condition|Exercises focusing on stretching and strengthening for all muscle groups will be performed at one-hour long sessions held 3 times a week for 8 weeks. Classes are led by trained exercise specialists.
3135503|NCT01650519|Active Comparator|IV ibuprofen|Intravenous ibuprofen (800 mg) administered intravenously over 10 minutes at study hour 0 and again at study hour 4 (Ibuprofen arm) and a corresponding volume of normal saline (ketorolac arm) will be administered intravenously over no less than 15 seconds at the end of the arthroscopic procedure
3135719|NCT01648829|Active Comparator|Atorvastatin|os, 20 mg, once per day, for 30 days
3257817|NCT00784589|Experimental|Rituximab|
3135504|NCT01650519|Active Comparator|IV ketorolac|A corresponding volume of normal saline (Ibuprofen arm) administered intravenously over 10 minutes at study hour 0 and again at study hour 4 and 30 mg ketorolac for patients < 65 years of age (15 mg ketorolac for patients > 65 years of age) (ketorolac arm) will be administered intravenously over no less than 15 seconds at the end of the arthroscopic procedure
3135505|NCT01650506|Experimental|Erlotinib + Metformin|This is a single arm phase 1 study. All patients will receive erlotinib and metformin.
3135506|NCT01650493||Group A|Clinpro 5000
3135507|NCT01650493||Group B|MI Paste Plus
3135508|NCT01650493||Group C|Toms of Maine
3135509|NCT01650480|Experimental|Intervention group|
3135510|NCT01650480|No Intervention|Control group|
3135511|NCT01650467||Healthy controls|60 healthy controls with no hematological pathologies
3135512|NCT01650467||Imatinib optimal response|30 CML patients who are optimal responders to imatinib treatment
3135513|NCT01650467||Imatinib primary resistance|30 CML patients who have primary resistance to imatinib treatment
3135514|NCT01650454|Experimental|Patients from Memento cohort.|"Patients with mild cognitive impairment included in MEMENTO cohort.~These patients will have a 2 night polysomnography, a battery of neuropsychological tests, a virtual reality test, and a subjective evaluation of sleep and somnolence at inclusion (Month 0) and Month 12."
3135515|NCT01650454|Experimental|Patients with memory disorders|Patients with mild cognitive impairment not included in MEMENTO cohort. For these patients a virtual reality test, and a subjective evaluation of sleep and somnolence will be performed at Inclusion (Month 0)
3135516|NCT01650454|Active Comparator|Healthy volunteers|Healthy volunteers matched in age, sex and educational level with patients. For these volunteers a virtual reality test, and a subjective evaluation of sleep and somnolence will be performed at Inclusion (Month 0)
3135517|NCT01650454|Active Comparator|control group|this group is composed with Healthy volunteers these volunteers will have a 2 night polysomnography, a battery of neuropsychological tests, a virtual reality test, and a subjective evaluation of sleep and somnolence at inclusion (Month 0) and Month 12.
3135518|NCT01650441|Experimental|beclomethasone dipropionate + formoterol fumarate|All patients will be treated with the active product. No placebo arm will be used. The active product is a fixed combination containing extra-fine beclometasone dipropionate and formoterol fumarate in a new dry powder inhaler device, NEXThaler® (Chiesi Farmaceutici, Parma, Italy).
3135519|NCT01650428|Experimental|FOLFOX & Bevacizumab|"Bevacizumab - 5 mg/kg IV over 30-90 minutes (cycles 1-5 only), Oxaliplatin - 85 mg/m2 IV over 2 hours, Folinic acid - 350 mg IV over 2 hours, 5-Fluorouracil - 3200 mg/m2 IV continuous infusion over 48 hour.~Treatment given every 2 weeks for 12 weeks (for 6 cycles)"
3135520|NCT01650428|Experimental|FOLFOXIRI & Bevacizumab|"Bevacizumab - 5 mg/kg IV over 30-90 minutes (cycles 1-5 only), Irinotecan - 165 mg/m2 IV over 1 hour, Oxaliplatin - 85 mg/m2 IV over 2 hours, Folinic acid - 350 mg IV over 2 hours, 5-Fluorouracil - 3200 mg/m2 IV continuous infusion over 48 hour.~Treatment given every 2 weeks for 12 weeks (for 6 cycles)"
3135521|NCT01650415|Experimental|Erythropoietin and Rehabilitation|recombinant human erythropoietin injection and active rehabilitation
3135522|NCT01650415|Placebo Comparator|Placebo and Rehabilitation|Placebo erythropoietin and rehabilitation
3135523|NCT01650402|Active Comparator|Intensive|Multiple antihypertensive therapies to achieve 24H SBP less than or equal to 130 mm Hg
3135524|NCT01650402|Active Comparator|Standard|Single or multiple antihypertensive therapy to achieve 24H SBP less than or equal to 145 mm Hg
3135525|NCT01650389|Experimental|MVA85A|1 x 10(superscript'8') pfu MVA85A vaccine intradermal within 96 hours of birth
3135526|NCT01650389|Active Comparator|Candin|Equal volume intradermal administration within 96 hours of birth
3135527|NCT01650376|Experimental|Olaparib plus carboplatin and paclitaxel|
3135528|NCT01650363|Active Comparator|Acupuncture, homeopathy, osteopathy and reflexology|patients will receive combinations of acupuncture, homeopathy, osteopathy and reflexology
3135529|NCT01650363|Placebo Comparator|homeopathic placebo medication|
3135530|NCT01650350|Experimental|Low Dose Naltrexone|LDN, 5 mg/day-(1 cycle = 28 days).
3135531|NCT01650337|Experimental|Smartphone Application|Patients will be given access to a smartphone application for weight loss and instructed on how to use it.
3135532|NCT01650337|No Intervention|Usual primary care|
3135533|NCT01650324|Experimental|DBPR108|
3135534|NCT01650324|Placebo Comparator|matching placebo|
3135535|NCT01650311||Healthy controls|Healthy control group will include participants consenting prior to colorectal cancer screening.
3135536|NCT01650311||CD patient groups|The patient groups will include patients with clinical diagnosis of CD.
3135537|NCT01650311||UC patient group|The patient groups will include patients with clinical diagnosis of UC.
3135538|NCT01650298|No Intervention|Anticoagulation taken as prescribed by doctor|
3135539|NCT01650298|Other|Anticoagulation to be stopped/started per device information|Other: The physician will manage the patient's anticoagulation medication by weekly remote monitoring device transmissions
3135540|NCT01650285|Experimental|Cabazitaxel and radiation|Radiation therapy (RT) will be delivered to 64.8 Gy, using IMRT treatment Cabazitaxel will be administered IV every 21 days for 3 doses at the assigned dose level.
3135541|NCT01650272|Experimental|5%Minoxidil solution|"This arm AGA patient receive 5%Minoxidil solution ( Propylene glycol solvent ) to use for 6 month.~Record efficacy and safety as described."
3135542|NCT01650272|Experimental|5%Minoxidil milky lotion|This arm AGA patient receive 5%Minoxidil milky lotion to use for 6 month. Record efficacy and safety as described.
3135543|NCT01650259||Oral antidiabetic drug (OAD)|
3135544|NCT01650259||Trazenta|
3135545|NCT01650246|Experimental|lesinurad 400 mg|
3135546|NCT01650233|Experimental|Mindfulness-based stress reduction|The mindfulness-based stress reduction (MBSR) program was previously adapted for urban youth and here further adapted to 12 weekly 50-minute classes for use in school.
3135547|NCT01650233|Placebo Comparator|Healthy Topics|An age-appropriate health education curriculum was used as a non-specific group comparison for the MBSR program to control for the effects of: positive adult instruction, interactive peer group instruction, learning new material, group size and location, time, and attention.
3135548|NCT01650220||Veterans with a history of PTSD|
3135549|NCT01650220||Veterans without a history of PTSD|
3135550|NCT01650207|Experimental|EA group|To acupuncture the Juanyu (Li15) & Jugu (Li16) with sensation of de-qi, and then give 50 Hz electrical stimulation for 20 minutes.
3135551|NCT01650207|Experimental|TENS group|The electrical patches were placed on the Juanyu (Li15) & Jugu (Li16) or Juanyu (Li15), Quchi (Li11), Shousanli (Li10) & Hegu (Li4), connected to a TENS apparatus and then give 50 Hz electrical stimulation for 20 minutes.
3135552|NCT01650207|Sham Comparator|sham-acupuncutre|The Park's Sham Device were placed on the Juanyu (Li15) & Jugu (Li16).
3135553|NCT01650194|Experimental|Enzalutamide combined with abiraterone acetate plus prednisone|Enzalutamide daily, abiraterone acetate daily, prednisone twice daily
3135554|NCT01650181|Active Comparator|Metformin|Patients treated with diet, exercise and metformin
3135555|NCT01650181|Active Comparator|Suplement|Patients treated with diet, exercise and metformin plus Siliphos (140mg) + Selenium (15mcg) -Methionine 3mg + Alpha Lipoic Acid (200mg).
3135556|NCT01650168||NOMAC-E2|New users of NOMAC-E2
3135557|NCT01650168||LNG-COCs|New users of levonorgestrel-containing COCs
3135558|NCT01650155|Experimental|BI 1005273 i.v.|single dose i.v. infusion
3135559|NCT01650155|Placebo Comparator|BI 1005273 i.v. Placebo|single dose i.v. infusion (Placebo)
3135560|NCT01650155|Experimental|BI 1005273 s.c.|single dose s.c. injection
3135561|NCT01650155|Placebo Comparator|BI 1005273 s.c. Placebo|single dose s.c. injection (Placebo)
3135562|NCT01650142||NF1GeneModif Cohort|Adult patients with neurofibromatosis 1
3135563|NCT01650129|Experimental|BIAsp|
3135564|NCT01650129|Experimental|BHI|
3135565|NCT01650090|Experimental|ILC|Inhaled Lipid Cisplatin (ILC) will be administered every two weeks via nebulization and inhalation.
3135566|NCT01650051|Placebo Comparator|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|
3135567|NCT01650051|Experimental|Phenazopyridine Hydrochloride Tables, USP 200 mg|
3135568|NCT01650038|Active Comparator|faecal transplantation; donor faeces|2 times treatment with faecal transplantation: faeces from a healthy donor processed for duodenal tube infusion. after bowel lavage with macrogol.
3135569|NCT01650038|Placebo Comparator|faecal transplantation; placebo|2 times treatment with (own) faecal transplantation: faeces from the patient processed for duodenal tube infusion. after bowel lavage with macrogol.
3135570|NCT01650025|Placebo Comparator|VSL#3 placebo|The placebo comparator is administered in the same form and dose as the active ingredient. The patient will take 2 sachets a day for 4 months.
3135571|NCT01650025|Active Comparator|VSL#3 active probiotic|VSL#3 is a probiotic preparation containing 8 different strains of lactic acid bacteria and bifidobacteria. Each sachet contains 450 billion bacteria and the patient will be requested to take 2 sachets a day for 4 months
3135572|NCT01650012|Experimental|Eplerenone|Target of 50 mg/day
3135573|NCT01650012|Placebo Comparator|Placebo|Matching placebo
3135574|NCT01649999|Experimental|ASP015K lowest dose|Oral
3135575|NCT01649999|Experimental|ASP015K low dose|Oral
3135576|NCT01649999|Experimental|ASP015K medium dose|Oral
3135577|NCT01649999|Experimental|ASP015K high dose|Oral
3135578|NCT01649999|Placebo Comparator|Placebo|Oral
3135579|NCT01649986|Active Comparator|Non-pharmacologic intervention|Patients assigned by their own general practitioner to have non-pharmacologic intervention and prevention strategies will be given details on lifestyle approaches and dietary strategies
3135580|NCT01649986|Active Comparator|Nutraceuticals|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
3135581|NCT01649960|Other|Rapamycin|Oral rapamycin was given during the nonrandomized phase of the study. The doses that were used of rapamycin were 0.5mg, 1mg, or 2mg.
3135582|NCT01649947|Experimental|Cohort 2: Bevacizumab ineligible patients|Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Hydroxychloroquine 200 mg PO BID
3135583|NCT01649947|Experimental|Cohort 1: Bevacizumab eligible patients|Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Bevacizumab 15 mg/kg IV over 90 min for Hydroxychloroquine 200 mg PO BID
3135584|NCT01649934|No Intervention|Scheduling as Usual|Participants will be subject to the current appointment scheduling procedures.
3135585|NCT01649934|Experimental|Contact Clinic|This group will be required to contact the clinic themselves to make appointments.
3135586|NCT01649934|Experimental|Implementation Intentions|This group will create Implementation Intentions to contact the clinic to make their appointments and to attend those appointments.
3135587|NCT01649921|Active Comparator|Interferon-gamma|
3135588|NCT01649921|Placebo Comparator|Saline 0.9%|
3135589|NCT01649908||sectional cross clamping|
3135590|NCT01649908||simultaniously cross clamping|
3135591|NCT01649908||EVAR|
3135592|NCT01649895|Experimental|D-Cycloserine|D-Cycloserine, 5 pills (50mg), once per week in 5 weeks.
3135593|NCT01649895|Placebo Comparator|Placebo|Placebo: 5 pills for 5 weeks, once per week.
3135594|NCT01649882|Experimental|US ETT (ultrasound endotracheal tube)|Subjects will have a brief (< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
3135595|NCT01649869|Active Comparator|Active|27 Children between 1 month and 3 years of age (up to 4th birthday) with sensoneural hearing loss and documented CMV infection will receive valganciclovir HCl 16.0 mg/kg orally twice a day for 6 weeks
3135596|NCT01649869|Placebo Comparator|Placebo|27 Children between 1 month and 3 years of age (up to 4th birthday) with sensoneural hearing loss and documented CMV infection will receive placebo orally twice a day for 6 weeks
3135597|NCT01649856|Experimental|A: Rituximab SC|
3135598|NCT01649856|Active Comparator|B: Rituximab IV|
3135599|NCT01649843|Experimental|EA|Patients were eligible for enrollment in the study if they had an Eckardt symptom score ≥ 4. The diagnosis of achalasia was made on the basis of the absence of peristalsis and on impaired relaxation of the LES on established methods (barium swallow, manometry, esophagogastroduodenoscopy (EGD)).
3135720|NCT01648829|Active Comparator|Pitavastatin|os, 4 mg, once per day, for 30 days
3136136|NCT01645319||Black - Medication Treatment Pathway|
3135600|NCT01649830|Experimental|Radiotherapy plus adjuvant temozolomide|Radiation therapy will start within 8 weeks after neurosurgical procedures. The residue gliomas will receive a total dose of 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks. Four weeks after radiotherapy, patients will then receive 6 cycle of temozolomide dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
3135601|NCT01649830|Active Comparator|Radiotherapy|Radiation therapy will start within 8 weeks after neurosurgical procedures. The residue gliomas will receive a total dose of 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
3135602|NCT01649817||Cohort|
3135603|NCT01649804|Experimental|RoActemra/Actemra single arm|
3135604|NCT01649791|Experimental|Treatment (lenalidomide as chemoprevention)|Patients receive lenalidomide PO once daily for 4 weeks. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3135605|NCT01649778||Pazopanib|Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
3135606|NCT01649765|Experimental|Arm 1|belimumab 10mg/kg IV monthly
3135607|NCT01649765|Placebo Comparator|Arm 2|Normal Saline IV monthly
3135608|NCT01649752|Experimental|Differentiated stem cell therapy group|After ovum pick-up, MSC differentiated to endometrium is deposited in the uterine cavity.Embryo transfer will be done at day 5 at the blastocyst stage.
3135609|NCT01649752|Experimental|undifferentiated stem cell therapy group|Immediately postmenstrual undifferentiated MSC is deposited in the uterine cavity. Ovum pick-up will be done as usual.Embryo transfer will be done at day 5 at the blastocyst stage.
3135610|NCT01649752|No Intervention|Control group|ovum pick-up as usual and embryo transfer at day 5 at the blastocyst stage.
3135611|NCT01649739|Experimental|Levitra|
3135612|NCT01649726|Other|Standard strategy|Apnea test according to recommendations
3135613|NCT01649726|Experimental|CPAP strategy|Apnea test with CPAP connection
3135614|NCT01649713|Experimental|Fluval AB vaccination|In this uncontrolled, open, multi-centre immunogenicity and tolerability study subjects will be enrolled into one vaccination group and will be vaccinated by a single injection of Fluval AB suspension for injection.
3135615|NCT01649700|Experimental|Mesenchymal stem cells treatment|All subjects will receive autologous adipose-derived mesenchymal stem cells
3135616|NCT01649687|Experimental|Mesenchymal stem cells(MSC) treatment|All subjects will receive allogeneic adult adipose-derived mesenchymal stem cells
3135617|NCT01649674|Active Comparator|PEG|polyethylene glycol solution 2 liters
3135618|NCT01649674|Active Comparator|NapP|Sodium picosulphate and magnesium citrate solution 300 ml
3135619|NCT01649661||premenopausal women|Only women already scheduled for a breast MRI will be included in the study, no additional MRIs will be scheduled for study purposes.
3135620|NCT01649661||postmenopausal women|Only women already scheduled for a breast MRI will be included in the study, no additional MRIs will be scheduled for study purposes.
3135621|NCT01649648|Experimental|Intervention|Autologous cord blood cells arm
3135622|NCT01649635|Experimental|Cabazitaxel|25 mg/m2, administered as a 1-hour intravenous infusion, on Day 1 of each cycle, every 21 days Prednisone: 10 mg daily throughout the treatment with cabazitaxel Ciprofloxacin: at a dose of 500 mg for 8 days twice daily (total dose 1.0 g) Granulocyte-Colony Stimulating Factors: maximum dose of 600ug for 7 days or until Absolute Neutrophils Count reaches level ≥ 10.000/mm3
3135623|NCT01649622|Experimental|Bendamustine|"Patients receive Bendamustine at dose of 75 mg/m2 by vein over 30 minutes twice daily for four days (Days 1-4). Bendamustine dose based on actual body weight.~Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses."
3135624|NCT01649609|Active Comparator|Reduction of standard immunosuppression|Low dose Tacrolimus with low dose Mycophenolate acid
3135625|NCT01649609|Active Comparator|mTOR Arm|Low dose Sirolimus with low dose Mycophenolate acid (mTOR Substitution)
3135626|NCT01649596|Active Comparator|Warming Gown|Comparison of two types of warming processes prior to, during, and after the surgery procedure.
3135627|NCT01649596|Other|Standard of Care Warming|Standard of care warming with hospital-issued blankets.
3135628|NCT01649583|Experimental|Jaw Dynasplint System|
3135629|NCT01649583|No Intervention|Control Arm|
3135630|NCT01649570|Experimental|Insulin aspart|
3135631|NCT01649557|Experimental|Open-label OPDC-34712|
3135632|NCT01649544|Experimental|EPICOR|"Cardiac ablation system EPICOR (CE n°0344).~ablation device EpicorTM UltraCinchTM LP (Class III device)~Positioning system and calibration EpicorTM LP (LP PASTM; device Class IIa)~Cable connection EpicorTM LP (unsterile)~Ablation Control System EpicorTM LP (Class IIb)"
3135633|NCT01649544|Active Comparator|Amiodarone|"Cordarone :~400 mg/d during the 2 first months 200 mg/d from 3th to 18th month"
3135634|NCT01649531|Active Comparator|Test group|1 Implant, to be placed in the position with greater vertical bone height with a mesial or distal cantilever.
3135635|NCT01649531|Active Comparator|Control group|2 Implants
3135636|NCT01649505|Experimental|Arm I (fibrin sealant)|Patients undergo sharp dissection technique with fibrin sealant closure.
3135637|NCT01649505|Active Comparator|Arm II (standard electrocoagulation)|Patients undergo standard electrocoagulation dissection technique.
3135638|NCT01649492|No Intervention|diclofenac without pineapple juice|single dose of diclofenac 25 mg without pre-exposure to pineapple juice
3135639|NCT01649492|Active Comparator|diclofenac with pineapple juice|single dose of diclofenac 25 mg with pre-exposure to pineapple juice
3135640|NCT01649479|Other|Suspected Obstetrical APS; confirmed APS|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork later confirms that these patients have APS.~All patients included in this study will have the following interventions:~antiphospholipid antibody tests~thrombophilia bloodwork~psychiatric evaluation"
3135721|NCT01648816||postpartum depression|caucasian mothers with postpartum depression
3135722|NCT01648816||control|caucasian mothers without depression
3135723|NCT01648790|Experimental|5 mg Prasugrel (ODT1)|5 mg Prasugrel as orally disintegrating tablet without Magnasweet® (ODT1) formulation administered once in the fasted state.
3135641|NCT01649479|Other|Sus. Obst. APS, confirmed thrombophilia|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork later confirms that these patients are thrombophilic.~All patients included in this study will have the following interventions:~antiphospholipid antibody tests~thrombophilia bloodwork~psychiatric evaluation"
3135642|NCT01649479|Other|Suspected Obstectrical APS; unconfirmed|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork cannot confirm APS, nor thrombophilia.~All patients included in this study will have the following interventions:~antiphospholipid antibody tests~thrombophilia bloodwork~psychiatric evaluation"
3135643|NCT01649466|Experimental|Vildagliptin|Patients randomized to the vildagliptin group will receive 50mg vildagliptin once daily add-on to their current glimepiride monotherapy for 24 weeks. No dose titrations are permitted during the study.
3135644|NCT01649466|Active Comparator|Protaphane|Patients randomized to the Protaphane group will receive a individualized dose of Protaphane once daily as bedtime dose. The Protaphane dose will be titrated within the first 4 weeks to reach fasting plasma glucose values below 100 mg/dl.
3135645|NCT01649453||Cancer of uncertain primary|
3135646|NCT01649440||Normal control|Healthy volunteers
3135647|NCT01649440||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
3135648|NCT01649440||sepsis|sepsis is defined as SIRS plus confirmed infection.
3135649|NCT01649440||severe sepsis|"sepsis associated with organ dysfunction, hypoperfusion, or hypotension.~sepsis with arterial hypotension, despite adequate fluid resuscitation."
3135650|NCT01649440||death|sepsis patients within 48 hours before death.
3135651|NCT01649427|Experimental|PHASE I|In a first phase of the study, pharmacokinetic parameters will be evaluated with a total of 60 evaluable patients (30 patients per treatment group).One Group on Prograf, the other on Tacrolimus Hexal
3135652|NCT01649427|Experimental|Prograf|After initial Phase 1 Phase two follows until month 12. Group 1 up to 163 pts. on Prograf
3135653|NCT01649427|Experimental|Tacroliums Hexal|After initial Phase 1 Phase two follows until month 12. Group 2 up to 163 pts. on Tacrolimus Hexal
3135654|NCT01649427|Experimental|Immunosupressive Drug|
3135655|NCT01649401|Active Comparator|Standard nubulizer|"Nebulizer sessions for the patients in this arm will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
3135656|NCT01649401|Experimental|Experimental nebulizer|"Nebulizer sessions for the patients in this arm will be administerd using the PARI LC Sprint Sp nebulizer.~Manufacturer: PARI GmbH Germany"
3135657|NCT01649388|Experimental|Living Kidney Allograft|Recipients with the need for a living kidney allograft are treated with an enriched hematopoetic stem cell infusion from living donor bone marrow several months after the renal transplant
3135658|NCT01649375|Experimental|Secukinumab 75 mg|Secukinumab 75 mg once weekly at BSL, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks. Patients may be escalated to 150 mg as judged appropriate by investigator.
3135659|NCT01649375|Experimental|Secukinumab 150 mg|Secukinumab 150 mg once weekly at BSL, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks
3135660|NCT01649375|Placebo Comparator|Placebo|Placebo once weekly at BSL, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks
3135661|NCT01649362|No Intervention|Control group|"No prefeeding oral stimulation~Infants in the control group received neither oral stimulation nor a pacifier before or during gavage feeding."
3135662|NCT01649362|Experimental|Oral stimulation, interventional group|"Infants in the interventional group received pre-feeding oral stimulation. The intervention started on infants born within 32 gestational weeks when the patients were stable and tube-fed, receiving more than 100 ml/kg/day of milk. On infants born after 32 weeks, the intervention started immediately after clinical stability was achieved.~The pre-feeding oral stimulation program consisted of a 15-minute stimulation program delivered by one of the eight trained nurses or one trained member from the medical staff in accordance with the stimulation program proposed by Fucile, Gisel and Lau.~The stimulation program was administered 15 to 30 minutes prior to tube feeding, once daily for at least 10 days. The program was stopped when the infants attained more than three oral feedings per day. The program was interrupted if the infants were medically unstable and/or had episodes of desaturation, apnoea and/or bradycardia during the intervention"
3135663|NCT01649336|Experimental|MEK162 + paclitaxel|
3135664|NCT01649310|Experimental|WVB Training|
3135665|NCT01649297|Experimental|empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
3135666|NCT01649297|Experimental|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
3135667|NCT01649297|Experimental|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
3135668|NCT01649297|Experimental|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
3135669|NCT01649297|Placebo Comparator|Placebo|Patients receive placebo matching Empagliflozin
3135670|NCT01649271|Experimental|Phase Ia, group 1|afatinib escalating dose with 3-weekly trastuzumab
3135671|NCT01649271|Experimental|Phase Ia, group 2|afatinib at MTD dose with weekly trastuzumab
3135672|NCT01649271|Experimental|Phase Ib|afatinib at MTD level with 3-weekly trastuzumab
3135673|NCT01649258|Experimental|Supportive care (antiemetics)|Patients receive granisetron transdermal system patch 24-48 hrs before the initiation of chemotherapy. Patients wear the granisetron transdermal system patch for 7 days. Patients receive fosaprepitant dimeglumine IV over 15 minutes on day 1 of chemotherapy. Treatment repeats every 2 or 3 weeks for up to 4 courses in the absence of unacceptable toxicity.
3135674|NCT01649245|Experimental|Reiferon retard plus ribavirin|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is >75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses
3135724|NCT01648790|Experimental|5 mg Prasugrel (ODT2)|5 mg Prasugrel as orally disintegrating tablet containing Magnasweet® (ODT2) formulation administered once in the fasted state.
3136137|NCT01645319||Black - Laser Surgery Treatment Pathway|
3135675|NCT01649232|Experimental|active tDCS|The patients with ADHD received electro-stimulation at 20 sessions with 2 mAmp 1 session per day alternative days. The investigators used an ERP analysis derived of 20 channel EEG recordings during resting state and visual CPT to define the tDCS site and polarity at refractory ADHD patients to conventional treatments. Time courses, topography and amplitude of ERPs, correlated with clinical scores, were compared with the controls average (data base)to guide the selection of personal tDCS parameters. The following relation shown how many patients were submitted to intervention in each electrode, according to their polarity: Anodal tDCS: T5, T6, etc. Cathodal tDCS: T5, T6, etc.
3135676|NCT01649232|No Intervention|controls|Healthy people that not receive tDCS
3135677|NCT01649219|Experimental|Exercise intervention|3-month supervised exercise intervention 3 times per week; 60min per time.
3135678|NCT01649219|No Intervention|No intervention|Standard couselling at baseline
3135679|NCT01649206|Experimental|Group A: RTA|Percutaneous Radiofrequency Thermal Ablation (RTA).
3135680|NCT01649206|No Intervention|Group B: untreated|No treatment, only follow-up
3135681|NCT01649193||Chronic Respiratory Disease|Any patient with a chronic respiratory disease referred for pulmonary rehabilitation
3135682|NCT01649180|Experimental|Axitinib|Axitinib will be given orally and will continue until progression of disease.
3135683|NCT01649167||Overweight/obesity|Pregnant women with overweight/obesity
3135684|NCT01649167||gestational diabetes|Pregnant women with gestational diabetes
3135685|NCT01649167||normal weight|Pregnant women with normal weight
3135686|NCT01649154|Active Comparator|Ligasure Small-JAW|
3135687|NCT01649154|Active Comparator|Harmonic Focus|
3135688|NCT01649154|Active Comparator|Clamp-and-Tie technique|
3135689|NCT01649141|Experimental|Treatment Group|Trauma-Focused Cognitive Behavioral Therapy
3135690|NCT01649115|No Intervention|Usual Care|The Usual Care arm, will not be receiving the interactive nutrition education. They will be meeting with the Registered Dietitian twice in person after the participants are randomized in each arm, and once on the phone. The first meeting, they will be receiving pamphlets and handouts, which are typically given as part of usual care. The second meeting is a post-test assessment and Newest Vital Sign Assessment Tool. The second meeting and the follow-up phone call are both the same for usual care and the Healthy Lifestyles Passport arm.
3135691|NCT01649115|Experimental|Healthy Lifestyles Passport|The Healthy Lifestyles Passport arm will be receiving the intervention. They will be meeting with the Registered Dietitian twice in person after the participants are randomized into each arm, and once on the phone. The first meeting, they will be receiving the Healthy Lifestyles Passport, including the interactive nutrition education. The second meeting is a post-test assessment and Newest Vital Sign Assessment Tool.
3135692|NCT01649102|Experimental|Palindroom catheter|Insertion of Palindroom catheter
3135693|NCT01649102|Experimental|Hemoglide Bard Catheter|Insertion of Hemoglide Bard Catheter
3135694|NCT01649089|Experimental|Treatment (cone biopsy/lymphadenectomy or hysterectomy)|Patients undergo cone biopsy and pelvic lymphadenectomy or simple hysterectomy and pelvic lymphadenectomy.
3135695|NCT01649063||the shape and frequency of uterine contractions in delivery|Uterine contractions were recorded by using fetal monitoring system (Model FC1400) at the beginning of the active phase (cervical dilatation 3-4 cm) for 30 min in two groups.
3135696|NCT01649063||the shape and frequency of uterine contractions in cesarean|Uterine contractions were recorded by using fetal monitoring system (Model FC1400) at the beginning of the active phase (cervical dilatation 3-4 cm) for 30 min in two groups.
3135697|NCT01649050|Experimental|BGG492|BGG492 tablets administered orally
3135698|NCT01649050|Placebo Comparator|Placebo|Matching placebo administered orally
3135699|NCT01649037|Experimental|nor adrenaline and terlipressin|
3135700|NCT01649037|Active Comparator|step up terlipressin|
3135701|NCT01649024|Experimental|single arm of Tremelimumab|Tremelimumab is administered at 15 mg/kg on day 1 every 12 weeks for 4 doses
3135702|NCT01649011||Scores of the ODI and RMQ for low back pain|
3135703|NCT01648998|Experimental|Fludrocortisone|Fludrocortisone 500 mg in capsule
3135704|NCT01648998|Placebo Comparator|Placebo|Placebo capsule, single dose, main ingredient lactose
3135705|NCT01648985||Acute stroke and TIA patients|
3135706|NCT01648972|Experimental|Gastrografin|
3135707|NCT01648972|Placebo Comparator|Placebo|
3135708|NCT01648946|Active Comparator|Liberal Transfusion Strategy|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
3135709|NCT01648946|Active Comparator|Restrictive Transfusion Strategy|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
3135710|NCT01648933|Experimental|Sarcoidosis|"Rubidium PET:~Myocardial Perfusion Imaging"
3135711|NCT01648920||FeNO|Participants with suspected but undiagnosed asthma will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit. Following that they will have a Methacholine Challenge (MCC) test performed according to the ATS guidelines and the Allergy and Asthma Specialists Procedure for conducting MCC tests
3135712|NCT01648907||SPONDYLARTHRITIS COHORT|
3135713|NCT01648894|Experimental|11 weeks|The cancer surgery is practice 11 weeks after neoadjuvant radio-chemotherapy
3135714|NCT01648894|Other|7 weeks|The cancer surgery is practice 7 weeks after neoadjuvant radio-chemotherapy
3135715|NCT01648868|Experimental|Excitatory effects of rTMS|Study excitatory effects of rTMS applied to the STS in patients with autism
3135716|NCT01648868|Active Comparator|Inhibitory effects of rTMS|Study inhibitory effects of rTMS applied to the STS in healthy controls
3135717|NCT01648855||Preterm babies|Intra uterine growth restricted preterm babies born before 30 weeks of gestational age from mother with preeclampsia
3135718|NCT01648842||Pregnant women|
3258383|NCT00780429||2|MMF+tacrolimus
3135725|NCT01648790|Experimental|5 mg Prasugrel (ODT2)-Suspension|5 mg Prasugrel as ODT2 formulation dispersed in water administered once, in the fasted state.
3135726|NCT01648790|Experimental|5 mg Prasugrel (ODT2)-Fed|5 mg Prasugrel as ODT2 formulation administered once, following a standardized breakfast.
3135727|NCT01648790|Experimental|2 mg Prasugrel (ODT2)|2 mg Prasugrel as ODT2 formulation administered once in the fasted state.
3135728|NCT01648777|Experimental|L bupivacaine|Drug (L bupivacaine) and device (catheter) 750 patients undergoing cardiac surgery with sternotomy are treated with L-bupivacain in the multiperforated catheter of analgesia
3135729|NCT01648777|Placebo Comparator|placebo|Isotonic Nacl 9°/00 solution 750 patients undergoing cardiac surgery with sternotomy are treated with isotonic NaCl solution (placebo) in the multiperforated catheter of analgesia
3135730|NCT01648764|Experimental|LY2334737 - Arm A|LY2334737 administered orally at escalating doses (40 mg - 200 mg) every other day for 21 days followed by 7 days without study drug (28 day treatment cycle). Participants may receive additional treatment cycles until discontinuation criterion is met.
3135731|NCT01648764|Experimental|LY2334737 - Arm B|LY2334737 administered orally at escalating doses (40 mg - 200 mg) every day for 7 days followed by 7 days without study drug (28 day treatment cycle). Participants may receive additional treatment cycles until discontinuation criterion is met.
3135732|NCT01648751|Experimental|Vaginal estrogen|Patients in the experimental group will receive vaginal estrogen cream
3135733|NCT01648751|Placebo Comparator|Placebo cream|Patients in the comparison group will receive placebo vaginal cream
3135734|NCT01648738|Experimental|Spa therapy, exercise and educational therapy|Spa therapy, exercise and educational therapy
3135735|NCT01648738|Active Comparator|Usual care and counselling (Back book)|Usual care and counselling (Back book)
3135736|NCT01648725|Experimental|Hypnosis|standard care plus hypnosis followed by closed-loop administration of propofol for anesthesia induction
3135737|NCT01648725|Active Comparator|Control|standard care without hypnosis followed by closed-loop administration of propofol for anesthesia induction
3135738|NCT01648712|Other|Balance Circuit, Carmeda Circuit|"Prospective, randomized double-blind, double center, phase IV clinical trial comparing heparin (Carmeda TM) and non-heparin (BalanceTM Bio-Passive surface) extracorporeal pediatric circuit for congenital heart disease repair .~74 infants/children will be divided in two groups, 37 patients will be assigned to the Balance group and 37 patients to the Carmeda group."
3135739|NCT01648712|Active Comparator|Bypass Circuit|"Prospective, randomized double-blind, double center, phase IV clinical trial comparing heparin (Carmeda TM) and non-heparin (BalanceTM Bio-Passive surface) extracorporeal pediatric circuit for congenital heart disease repair .~74 infants/children will be divided in two groups, 37 patients will be assigned to the Balance group and 37 patients to the Carmeda group."
3135740|NCT01648699|Experimental|Osmotic Release Oral System (OROS) Hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
3135741|NCT01648686|Active Comparator|Women treated by bisphosphonate|Postmenopausal osteoporotic women treated by alendronate 70 mg weekly per os
3135742|NCT01648686|Sham Comparator|Women didn't treat by bisphosphonate|Postmenopausal osteoporotic women untreated by bisphosphonates
3135743|NCT01648660|Active Comparator|D2x - D1x|"Cross Over from double dosage to single dosage:~daily supplementation with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FAabout two years after one year with 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA"
3135744|NCT01648660|Active Comparator|D1x - D2x|"Cross Over from double dosage to single dosage:~daily supplementation with 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA about two years after one year with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA"
3135745|NCT01648660|Active Comparator|D1x - D1x|single dosage: daily supplementation about two years after one year with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA (dosage remains existing)
3135746|NCT01648634|Experimental|Nebivolol|
3135747|NCT01648634|Placebo Comparator|Placebo|
3135748|NCT01648621|Experimental|Case Management|In addition to usual care, the intervention group will receive case management that includes: 40 minute standardized education session, an individualized action plan, an individualized care plan for management of COPD and comorbidities, standardized reinforcement/motivational interviewing and action plan teach-back sessions and assessment of symptoms, progress and problems, and problem solving by phone weekly for 12 weeks, then monthly for 9 months (21 sessions), tele-home monitoring, coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and CCAC facilitated by the case manager, priority access to ambulatory clinics.
3135749|NCT01648621|Active Comparator|Usual care|Usual care for these patients comprises: Dictated patient summary, referral to an 8 week in-hospital rehabilitation and self-management education program, referral to a smoking cessation program (as applicable), individualized action plan developed with treating respirologist at the discretion of the attending respirologist, Referral to web based educational materials and resources.
3135750|NCT01648608|Experimental|Exemestane|Exemestane for neoadjuvant chemotherapy
3135751|NCT01648595|Experimental|Fentanyl|In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour. In control group was not intervention.
3135752|NCT01648595|No Intervention|Without Fentanyl|The control group did not receive Fentanyl.
3135753|NCT01648582|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.
3135754|NCT01648582|Experimental|0.75 mg Dulaglutide|0.75 mg Dulaglutide administered as one SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.
3135755|NCT01648582|Active Comparator|Insulin Glargine|Insulin glargine administered based on fasting blood glucose concentrations per the dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea for up to 52 weeks.
3135793|NCT01648192|Experimental|7.5 mg|Losmapimod for single dose
3135756|NCT01648556|Other|patients with a thrombopenia isolated|Patients of 60 years old and more presenting a thrombopenia isolated with a rate of platelet < 100 G/l Blood tests and bone marrow biopsy repeated
3135757|NCT01648543|Active Comparator|block method: angle|The entry angle of angular method which is one method of lumbar sympathetic ganglion block is 30 degree of anterior-posterior view of C-arm.
3135758|NCT01648543|Active Comparator|block method: distance|The entry point of modified Reid method which is popular method of lumbar sympathetic ganglion block is 7~7.5cm from midline of spinous process of lumbar spine.
3135759|NCT01648530||Participants with Migraines|Participants who returned completed internet survey with positive screening for migraines. No intervention was administered in this study.
3135760|NCT01648517|Experimental|Arm A|Genomic-driven dual agent chemotherapy Chemotherapy will consist of the assigned two drugs according to ERCC1 and RRM1 mRNA expression level A1: docetaxel + vinorelbine (DV) A2: gemcitabine + vinorelbine (GV) A3: docetaxel + carboplatin (DC) A4: gemcitabine + carboplatin (GC)
3135761|NCT01648517|Active Comparator|Arm B|standard of care All control arm patients received standard platinum-based doublet chemotherapy with docetaxel plus carboplatin
3135762|NCT01648504|Experimental|Intervention with eGuide to colonoscopy|The investigators will prospectively enroll and follow patients who receive the eGuide to Colonoscopy and determine benefit and satisfaction with the intervention as part of a pilot study.
3135763|NCT01648491|Experimental|Stem Cell treatment|Muscle Biopsy and Injection of autologous stem cells
3135764|NCT01648478|Experimental|Single Arm|
3135765|NCT01648465|Experimental|Everolimus|
3135766|NCT01648452|Experimental|NT-501 CNTF-releasing implant|Ocular implantation of a NT-501 CNTF-releasing capsule (20 ng/day) in one eye (the study eye) at baseline
3135767|NCT01648348|Experimental|Arm I (bevacizumab and TRC105)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 8 and 11 of course 1 and days 1 and 8 of all subsequent courses. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3135768|NCT01648348|Active Comparator|Arm II (bevacizumab)|Patients receive bevacizumab as in arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3135769|NCT01648335|Active Comparator|immobilization of the shoulder in internal rotation|
3135770|NCT01648335|Experimental|Immobilization of the shoulder in external rotation|
3135771|NCT01648322|Experimental|80 µg/kg/dose of F-627|This dose of F-627 given only to subjects that are to have TC chemotherapy.
3135772|NCT01648322|Experimental|240 µg/kg/dose of F-627|This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
3135773|NCT01648322|Experimental|320 µg/kg/dose of F-627|This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
3135774|NCT01648322|Active Comparator|Neulasta® (pegfilgrastim)|Given to subjects receiving TC or TAC chemotherapy.
3135775|NCT01648309||TAVI|patients with significant aortic stenosis that are candidates for transvascular aortic valve implantation
3135776|NCT01648296|Experimental|Dosimetry Group|A total of 12 subjects will receive a single intravenous injection of[18F]FluorbetaOx followed by PET-CT imaging. Four normal healthy volunteer subjects and 8 subjects with or without Type 2 Diabetes Mellitus with Chronic Dilated Cardiomyopathy.
3135777|NCT01648296|Experimental|Kinetic Dynamic Group|A total of 38 subjects will receive a single intravenous injection of [18F]FluorbetaOx, [11C]Palmitate, and [15O]Water followed by PET-CT imaging. Ten normal healthy volunteer subjects and 28 subjects with or without Type 2 Diabetes Mellitus of which 18 subjects will have Chronic Dilated Cardiomyopathy and 10 obese subjects with a Body Mass Index of ≥ 30kg/m2.
3135778|NCT01648283|Experimental|Methadone arm|"Intravenous racemic methadone HCl, 6.0 mg bolus~Oral deuterated racemic methadone HCl, 11 mg capsule (IND#58,511)"
3135779|NCT01648270|Experimental|Study Arm|"Subjects will be studied on four occasions. Sessions and drugs are:~Intravenous buprenorphine~Sublingual buprenorphine~Cyclosporine, then intravenous buprenorphine~Sublingual buprenorphine: continue oral cyclosporine for 5 days"
3135780|NCT01648257|Experimental|GSK1265744 Na Salt Tablets|Subjects will receive single dose of GSK1265744 sodium salt (30 mg) tablet on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 milliliter (mL) of water.
3135781|NCT01648257|Experimental|GSK1265744 Free Acid Nanomilled Capsules|Subjects will receive single dose of GSK1265744 free acid nanomilled (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water.
3135782|NCT01648257|Experimental|GSK1265744 Free Acid Micronized Capsules|Subjects will receive single dose of GSK1265744 free acid micronized (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water.
3135783|NCT01648244|Experimental|Computer-Assisted Decision Support|These providers will use the CADS program to treat their enrolled patients.
3135784|NCT01648231|Other|Treatment Period 1|1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
3135785|NCT01648231|Other|Treatment Period 2|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
3135786|NCT01648231|Other|Treatment Period 3|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
3135787|NCT01648218|Active Comparator|Neutral protamine hagedorn (NPH) insulin|"Drug: Neutral protamine hagedorn (NPH) insulin~Other Names:~Humulin N, Novolin N~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 12 hours; for duration subjects are concurrently administered once-daily glucocorticoid."
3135788|NCT01648218|Experimental|Regular or Aspart insulin|"Drug: Regular human insulin or Insulin Aspart~Other Names:~Humulin R, Novolin R, Novolog, NovoRapid~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before meals; Duration: 2 hours (Aspart) or 6 hours (Regular); for duration subjects are concurrently administered once-daily glucocorticoid."
3135789|NCT01648218|Experimental|Insulin glargine|"Drug: Insulin glargine~Other Names:~Lantus~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 24 hours; for duration subjects are concurrently administered once-daily glucocorticoid."
3135790|NCT01648205|Active Comparator|Ranolazine|Ranolazine 1000 mg bid
3135791|NCT01648205|Placebo Comparator|Placebo|Matching Placebo
3135792|NCT01648192|Experimental|2.5 mg|Losmapimod for single dose
3258384|NCT00780429||3|MMF+sirolimus
3135796|NCT01648192|Experimental|7.5 mg BID|Losmapimod for repeat dose (14 days)
3135797|NCT01648192|Placebo Comparator|Placebo BID|Placebo
3135798|NCT01648179|Experimental|GSK1322322 IV formulation|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via IV formulation
3135799|NCT01648179|Experimental|GSK1322322 Wet milled Tablet (Fasted)|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Wet milled Tablet (Fasted)
3135800|NCT01648179|Experimental|GSK1322322 Oral mesylate salt solution|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Oral mesylate salt solution
3135801|NCT01648179|Experimental|GSK1322322 Wet milled Tablet (Fed)|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Wet milled Tablet (Fed)
3135802|NCT01648166||lung cancer cases|subjects with lung cancer who are greater than 17 years of age and live in Appalachian Kentucky
3135803|NCT01648166||control subjects|subjects without lung cancer, greater than 17 who reside in Appalachian Kentucky
3135804|NCT01648153|Active Comparator|GSK1070806 0.25mg/kg|TwoIV administrations of 0.25mg/kg GSK1070806 4weeks apart
3135805|NCT01648153|Active Comparator|GSK1070806 5mg/kg|Two IV administrations of 5mg/kg of GSK1070806 4 weeks apart
3135806|NCT01648153|Placebo Comparator|Placebo (Saline)|Two IV administrations of saline 4 weeks apart
3135807|NCT01648140|Experimental|T40|Hepatitis C virus (HCV) genotype 1 GSK2336805 40 mg, pegylated interferon alpha-2a, and ribavirin arm
3135808|NCT01648140|Experimental|T60|Hepatitis C virus (HCV) genotype 1 GSK2336805 60 mg, pegylated interferon alpha-2a, and ribavirin arm
3135809|NCT01648140|Active Comparator|PRT|Hepatitis C virus (HCV) genotype 1 Telaprevir, pegylated interferon alpha-2a, and ribavirin arm
3135810|NCT01648140|Experimental|G4|Hepatitis C virus (HCV) genotype 4 GSK2336805 60 mg, pegylated interferon alpha-2a, and ribavirin arm
3135811|NCT01648127|Experimental|Ceftaroline|Ceftaroline intravenous 600 mg single dose
3135812|NCT01648114|No Intervention|Control|Usual outpatient antenatal care consists of routine checking of the maternal and foetal health by either clinic midwives or obstetricians along with health education to promote a healthy pregnancy.
3135813|NCT01648114|Experimental|Antenatal Breastfeeding Intervention|Antenatal intervention group will receive usual care plus a 20 to 30-minute one-to-one educational intervention about breastfeeding.
3135814|NCT01648101|Experimental|Retigabine 900mg|900mg total daily dose
3135815|NCT01648101|Experimental|Retigabine 600mg|600mg total daily dose
3135816|NCT01648101|Placebo Comparator|Placebo|Placebo
3135817|NCT01648088||Pre-op THA and TKA patients|Patients who are scheduled for total joint arthroplasty
3135818|NCT01648075|Experimental|Experimental: Probiotic enriched milk|150 ml of skimmed milk enriched with probiotic (Lactobacillus rhamnosus LRH08) once a day
3135819|NCT01648075|Placebo Comparator|Skimmed Milk|150 ml of skimmed milk once a day
3135820|NCT01648062|Active Comparator|Arousal reduction using guided imagery|Sleep Self-Regulation Using Mental Imagery: Participants in the arousal reduction condition were instructed to imagine wearing a backpack loaded with their worries, then putting the heavy backpack down, and then experiencing the relief and freedom from tension.
3135821|NCT01648062|Active Comparator|Mental simulation of sleep behavior|Sleep Self-Regulation Using Mental Imagery: Participants in this condition received instructions to visualize a specific behavioral plan designed to meet the goal of obtaining quality sleep each night through the practice of certain behaviors. To form the behavioral plan, participants visualised changing into comfortable clothes and taking time to relax prior to going to bed, the time they planned to go to sleep, where they planned to sleep, and the bedtime routine they follow to help them to get to sleep. At bedtime, they were instructed to mentally run through a checklist of these behaviors and then do any behaviors that they had not yet completed.
3135822|NCT01648062|Active Comparator|Combination|Sleep Self-Regulation Using Mental Imagery: Participants in this condition were asked to practice a combination of the guided imagery (for relaxation) and mental simulation imagery for sleep-related behaviour
3135823|NCT01648062|Sham Comparator|Control|Sleep Self-Regulation Using Mental Imagery: Participants in this condition were asked to imagine a typical post work activity
3135824|NCT01648049|Experimental|CBT|Cognitive behavior therapy for both insomnia and depression featuring stimulus control and cognitive therapy.
3135825|NCT01648049|Active Comparator|Treatment as Usual|No additional treatment besides regular care.
3135826|NCT01648036|Experimental|Unfractionated Heparin|
3135827|NCT01648036|Active Comparator|Dalteparin|Standard of care
3135828|NCT01648023|Experimental|Randomization to LC OR ONCOZENE Bead with Gem-Cis or Gem-Carbo|Transarterial Chemoembolization (LC or ONCOZENE Bead) with Gem-Cis or Gem-Carbo
3135829|NCT01648023|Active Comparator|Randomization to Gem-Cis or Gem-Carbo|Gem-Cis or Gem-Carbo alone
3135830|NCT01648010|Experimental|TC-3 gel|TC-3 gel group undergo intravesical instillation of the investigatory device
3135831|NCT01648010|Experimental|MMC- gel|MMC gel group undergo intravesical instillation of the reverse thermal gelation device mixed with MMC
3135832|NCT01647997|Experimental|study 1a|whole body lactate production after bacterial endotoxin challenge
3135833|NCT01647997|No Intervention|study 1b|basal whole body lactate production
3135834|NCT01647997|Experimental|study 2a|muscle lactate concentration after bacterial endotoxin challenge
3135835|NCT01647997|No Intervention|study 2b|basal muscle lactate concentrations
3135836|NCT01647984|Placebo Comparator|Placebo|Inert Placebo - Vitamin B complex + diet
3135837|NCT01647984|Active Comparator|Ritmonutra|Omega-3 polyunsaturated fatty acids, Hawthorn, Astaxanthin, Vitamin E, Vitamin B complex + diet
3135838|NCT01647971|Experimental|ublituximab|"Phase I:~4 cohorts with IV ublituximab starting with 450 mg followed by 600 mg, 900 mg or 1200 mg in each cohort (3 - 6 patients per cohort). Infusions will be on days 1, 8, 15 and 22 of cycle 1 followed by a planned maintenance with a single infusion monthly starting cycle 3. Patients with CLL or SLL will have infusions on Days 1, 8 and 15 of cycle 1 & 2 followed by a planned maintenance with a single infusion monthly starting cycle 3. Expansion of patient enrollment in select cohorts will apply."
3135839|NCT01647958|Experimental|Treatment Arm|Transoral incisionless esophago-gastric fundoplication using the EsophyX system with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) and following TIF2.0 protocol.
3135840|NCT01647958|No Intervention|Control|Patients who are dependent upon daily PPIs will continue on single dose twice daily or increase to single dose twice daily for the first six months of the clinical trial.
3135841|NCT01647945|Placebo Comparator|Placebo|
3135842|NCT01647945|Experimental|FK506 level < 2|
3135843|NCT01647945|Experimental|FK506 level 2-3|
3135844|NCT01647945|Experimental|FK506 level 3-5|
3135845|NCT01647932|Active Comparator|Loop plus thiazide-type diuretic|Loop diuretic plus hydrochlorothiazide
3135846|NCT01647932|Placebo Comparator|Loop diuretic plus placebo|Loop diuretic plus placebo
3135847|NCT01647919|Experimental|cogniVida™ 100 mg/day|
3135848|NCT01647919|Placebo Comparator|Placebo|
3135849|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 0.375mg/kg, single-dose|
3135850|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 0.75mg/kg, single-dose|
3135851|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 1.5mg/kg, single-dose|
3135852|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 0.75mg/kg, and dose escalation|
3135853|NCT01647880|Experimental|Fingolimod (Gilenya®)|0,5 mg once a day in the morning, oral
3135854|NCT01647880|Active Comparator|Interferon beta-1b (Extavia®)|every second day, s.c.
3135855|NCT01647867|Experimental|Met analysis|Met analysis on tissue and blood Western Blot Immunohistochemistry ELISA test
3135856|NCT01647854|Experimental|Device: Teleconsultation|"If patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with an audio-connection to the EMS team who receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. Also 12-lead-ECGs can be transmitted to the tele-EMS physician. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, ECG diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The safety and efficacy of the introduction and operation of this system should be evaluated."
3135857|NCT01647841||Pregnant women and infants|HIV+ and HIV- pregnant women, HIV-exposed and HIV-unexposed infants, ARV-exposed and ARV-unexposed infants
3135858|NCT01647828|Experimental|OMP-59R5 plus Gemcitabine and Nab-Paclitaxel|OMP-59R5 plus Gemcitabine and Nab-Paclitaxel
3135859|NCT01647828|Experimental|Gemcitabine and Nab-Paclitaxel plus Placebo|Gemcitabine and Nab-Paclitaxel plus Placebo
3135860|NCT01647815|Experimental|50 healthy volunteers|The study population consists of healthy volunteers aged 18 to 50 years and without previous surgery, trauma, or thrombosis of the axilla or the shoulder girdle.
3135861|NCT01647802|Experimental|Turner-Vertic'Easy-Tina|Standing will be attempted with the three devices in the following order: (1) Turner; (2) Vertic'Easy; (3) Tina.
3135862|NCT01647802|Experimental|Turner-Tina-Vertic'Easy|Standing will be attempted with the three devices in the following order: (1) Turner; (2) Tina; (3) Vertic'Easy.
3135863|NCT01647802|Experimental|Vertic'Easy-Turner-Tina|Standing will be attempted with the three devices in the following order: (1) Vertic'Easy; (2) Turner; (3) Tina.
3135864|NCT01647802|Experimental|Vertic'Easy-Tina-Turner|Standing will be attempted with the three devices in the following order: (1) Vertic'Easy; (2) Tina; (3) Turner.
3135865|NCT01647802|Experimental|Tina-Turner-Vertic'Easy|Standing will be attempted with the three devices in the following order: (1) Tina; (2) Turner; (3) Vertic'Easy.
3135866|NCT01647802|Experimental|Tina-Vertic'Easy-Turner|Standing will be attempted with the three devices in the following order: (1) Tina; (2) Vertic'Easy; (3) Turner.
3135867|NCT01647789|Experimental|CFG920|
3135868|NCT01647776||Individuals without colon polyps|
3135869|NCT01647776||Individuals with colon polyps|
3135870|NCT01647763|Experimental|HAL/RAR|hemorrhoidal artery ligation with rectoanal repair
3135871|NCT01647763|Active Comparator|Stapled hemorrhoidopexy|"procedure for prolapse and hemorrhoids (PPH)~Resection using a circular stapler"
3135872|NCT01647750|Other|Lower dose of levothyroxine|Participants may be randomised to receive a lower dose of levothyroxine (lower than their usual dose) to achieve a target TSH level of 4.1 - 8.0 mU/L
3135873|NCT01647750|Other|Standard dose of levothyroxine|Patients may be randomised to receive their usual dose of levothyroxine (target TSH level 0.4 - 4.0 mU/L)
3135874|NCT01647737|Active Comparator|MighTeaFlow|4-6 times daily lozenge containing green tea, jaborandi extracts, and 500 mg xylitol for 8 weeks
3135875|NCT01647737|Active Comparator|Xylitol|4-6 times daily lozenge containing jaborandi extract, and 500 mg xylitol for 8 weeks
3135876|NCT01647724||control 1|standard recall letter to perform HPV test at the clinic
3135877|NCT01647724||Intervention 1|direct mailing of the self sampling device at home
3135878|NCT01647724||intervention 2|invitation to retire the self sampling device in local pharmacy
3135879|NCT01647711|Experimental|Afatinib|Establish the Maximal Tolerated Dose of a pulsatile, high-dose regimen of afatinib in patients with advanced solid tumors followed by treatment at that dose or a lower dose in patients with stage IV non-small cell lung cancer harboring EGFR T790M mutations who have progressed on therapy with a reversible tyrosine kinase inhibitor
3135880|NCT01647698|Experimental|Early training group|The early training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. They will continue training on the adaptive working memory training task for 5 weeks, after which they will continue for 5 weeks using a non-adaptive working memory task (active control task).
3135881|NCT01647698|Experimental|Late training group|The late training group will consist of 10 randomly assigned participants who will engage in a non-adaptive working memory training task (i.e. an active control task) immediately after baseline assessment for 5 weeks. After the initial 5 weeks of the active control task they will then switch to the adaptive working memory task (the intervention) for 5 weeks. This is a randomized controlled cross-over design.
3135882|NCT01647698|Placebo Comparator|No training group|The no training group will engage in no training over the course of the pilot study, but will still participate in baseline, 5 week, 10 . This will allow us to determine if changes in the outcome and assessment variables are due to the working memory training or progression in the disease itself.
3136138|NCT01645319||Black - Incisional/Other Surgery Treatment Pathway|
3135883|NCT01647685|Active Comparator|Nanocort|Two weekly IV infusions of 144 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
3135884|NCT01647685|Active Comparator|Methylprednisolone|Methylprednisolone sodium succinate 125 mg infusion.
3135885|NCT01647685|Placebo Comparator|Saline|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
3135886|NCT01647672|Experimental|Abraxane|Abraxane for neoadjuvant chemotherapy
3135887|NCT01647659|Experimental|GSK1120212 tablet|GSK1120212 tablet
3135888|NCT01647659|Experimental|GSK1120212 powder for oral solution|GSK1120212 powder for oral solution
3135889|NCT01647646|Active Comparator|Symbicort|"We will evaluate the efficacy fot Symbicort use. The usage was 2 doses bid for one year period.~Intervention drug: Seretide fixed doses therapy"
3135890|NCT01647646|Experimental|Seretide|In non-well asthma controlled patients, experimental study with Seretide regular doses (125 2 doses bid for one year) and higher doses (250 2 doses bid) for one year
3135891|NCT01647633|Experimental|Calcium Glycerophosphate Nasal Wash|Nasal spray wash twice daily and up to four additional times per day as needed for nasal allergy symptoms
3135892|NCT01647620|Active Comparator|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily
3135893|NCT01647620|Placebo Comparator|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
3135894|NCT01647607|Experimental|Young Women's Intervention (YWI)|This arm involves administration of an educational intervention that focuses on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.
3135895|NCT01647607|Active Comparator|Physical Activity Intervention (PAI)|This arm involves administration of an educational intervention that focuses on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
3135896|NCT01647594|Active Comparator|Young Women's Intervention (YWI)|
3135897|NCT01647594|Active Comparator|Physical Activity Intervention (PAI)|
3135898|NCT01647581|Experimental|Clip|A clip is been placed at the polypectomy site.
3135899|NCT01647581|Placebo Comparator|No Clip|A hemoclip is not placed at the site of the polypectomy.
3135900|NCT01647568||Control|Patients who are not on any anti-platelet/anti-coagulant therapy and present to our lab for a elective colonoscopy.
3135901|NCT01647568||Thienopyridine Users|Patients on Clopidogrel or prasugrel when they present for an elective colonoscopy.
3135902|NCT01647555||patient with epidermoid cancer|receiving Cetuximab and radiotherapy
3135903|NCT01647542|Experimental|TAK-875 25 mg|TAK-875 25 mg tablets, orally, once daily for up to 24 weeks.
3135904|NCT01647542|Experimental|TAK-875 50 mg|TAK-875 50 mg tablets, orally, once daily for up to 24 weeks.
3135905|NCT01647542|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily for up to 24 weeks.
3135906|NCT01647529|Experimental|Ganciclovir|Treatment with topical ganciclovir ointment
3135907|NCT01647516|Experimental|RPC1063 Low Dose|oral, low dose, daily for 32 weeks
3135908|NCT01647516|Experimental|RPC1063 High Dose|oral, high dose, daily for 32 weeks
3135909|NCT01647516|Placebo Comparator|Placebo|oral, one capsule, daily for 32 weeks
3135910|NCT01647503||Tumor group|Parathyroid adenoma, hyperplasia and carcinoma
3135911|NCT01647503||Normal|Normal parathyroid samples
3135912|NCT01647490|Active Comparator|Right Ventricular Apex (RVA)|In the RVA group the right ventricular pacing lead will be implanted in the apex region of the right ventricle
3135913|NCT01647490|Experimental|Right Ventricular Septum (RVS)|In the RVS group the right ventricular pacing lead will be implanted in the septal region (mid septum) of the right ventricle
3135914|NCT01647477|Active Comparator|questionnaires|4 questionnaires to answer at baseline 45 minutes approx.
3135915|NCT01647477|Experimental|interview|semi directive interview 105 patients
3135916|NCT01647464||Contrast administration|Patients undergoing contrast-enhanced echo.
3135917|NCT01647451|Experimental|Active|
3135918|NCT01647451|Placebo Comparator|Placebo|
3135919|NCT01647438|Other|Print Health Education|Participants receive print health education materials
3135920|NCT01647438|Experimental|Lifestyle Intervention|Six weekly health education classes and phone counseling.
3135921|NCT01647425||head and neck or lung cancer|patient with a first head and neck cancer or first lung cancer
3135922|NCT01647412|Active Comparator|Growth Hormone, Exclusion Diet, and Nutraceutical therapy|The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered recombinant human growth hormone (rhGH) for the first 26 weeks. After 26 weeks this group will continue on the exclusion diet nutraceutical therapy for the remaining 26 weeks of the study.
3135923|NCT01647412|Placebo Comparator|rhGH placebo, Exclusion diet, and nutraceutical therapy|The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered placebo injections for the first 26 weeks. After 26 weeks this group will continue on the exclusion diet and nutraceutical therapy for the remaining 26 weeks of the study.
3135924|NCT01647399||Phenotypic Clusters|500 urban youth
3135925|NCT01647386||MBT Revision Component|
3135926|NCT01647360||Women with Heavy Menstrual Bleeding (HMB)|
3135927|NCT01647347|Experimental|test treatment|"Test treatment:~1 min mouthwash with 10% PVP-iodine~1 min subgingival rinsing with 10% PVP-iodine~1 min ultrasonic debridement with 10% PVP-iodine as cooling liquid~blood sampling from the V.mediana cupidi"
3135928|NCT01647347|Placebo Comparator|Control group|"Control:~1 min mouthwash with water~1 min subgingival rinsing with water~1 min ultrasonic debridement with water as cooling liquid~blood sampling from the V.mediana cupidi"
3135929|NCT01647334|Experimental|Shrinking Target Adaptive Radiotherapy|Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer
3135930|NCT01647321|Active Comparator|Active cycling|Individuals will receive functional electrical stimulation while on the stationary bike and instructed to actively pedal.
3135931|NCT01647321|Sham Comparator|Passive cycling|Individuals will receive active functional electrical stimulation (FES) while on the stationary bike and instructed to relax their legs, allowing the FES to move their legs on the stationary bike.
3135934|NCT01647282|Experimental|Sc/RP with minocycline micropheres|Sc/RP is the subgingival mechanical removal of calculus and diseased cementum from the tooth root. Local application of minocycline microspheres will be done after scaling and root planing (Sc/RP) has been completed
3135935|NCT01647282|Active Comparator|Sc/RP alone|Sc/RP is the subgingival mechanical removal of calculus and diseased cementum from the tooth root
3135936|NCT01647269|Experimental|DBS Off first|
3135937|NCT01647269|Experimental|DBS On First|
3135938|NCT01647256|Experimental|Nikkomycin Z fed - fasting|"Period 1:~Day 1: Nikkomycin Z 500 mg with high fat breakfast~Period 2:~Day 1: Nikkomycin Z 500 mg under fasted conditions"
3135939|NCT01647256|Experimental|Nikkomycin Z fasting - fed|"Period 1:~Day 1: Nikkomycin Z 500 mg under fasted conditions~Period 2:~Day 1: Nikkomycin Z 500 mg with high fat breakfast"
3135940|NCT01647243|Experimental|Preoperative strength training|Progressive strength training on group basis four weeks before the operation and progressive strength training on group basis four weeks after the operation
3135941|NCT01647243|No Intervention|Living as usual|The patients are living as usual the last 4 weeks before operation
3135942|NCT01647217|Experimental|Terpinen-4-ol Treatment Arm|8 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (3 / 5 patients) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
3135943|NCT01647217|Placebo Comparator|Placepo Pads Contol Arm|9 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (5 / 4 patients) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
3135944|NCT01647204|No Intervention|usual mealtime care|patients admitted to the control ward receiving no intervention but usual mealtime help from ward staff
3135945|NCT01647204|Experimental|mealtime assistance|Additional lunchtime help from trained volunteer mealtime assistants to supplement help from the ward staff
3135946|NCT01647191|Experimental|intervention group|The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
3135947|NCT01647191|Active Comparator|control group|The investigators will adopt previous treatment in the clinics to intervent the patients without any type of target intervention for this group.
3135948|NCT01647178|Active Comparator|Manual closure|Patients are closed with a manual, straight wire, conventional closure technique
3135949|NCT01647178|Active Comparator|TORQ closure|Patients are undergo a TORQ assisted sternal closure
3135950|NCT01646866||Siblings of Children with Autism Spectrum Disorders|This group is comprised of 6-12 month old siblings of a child with an expert clinical diagnosis of autism spectrum disorders.
3135951|NCT01646853|Experimental|Concurrent radiochemotherapy|
3135952|NCT01646840|Experimental|PF-04958242 capsule|
3135953|NCT01646840|Active Comparator|PF-04958242 oral solution|
3135954|NCT01646827|Experimental|Deltoid|Deltoid injection site
3135955|NCT01646827|Experimental|Gluteal|Gluteal injection site
3135956|NCT01646814|Experimental|PL2200|Investigational product, PL2200
3135957|NCT01646814|Active Comparator|Aspirin tablets|Active comparator, 325 mg aspirin tablets
3135958|NCT01646801|Experimental|Experimental|NMB's Paclitaxel Drug ejecting balloon catheter
3135959|NCT01646788|Experimental|Experimental|NMB's PTA Balloon catheter with Paclitaxel drug
3135960|NCT01646775|Experimental|Epidural bupivacaine|
3135961|NCT01646775|Active Comparator|Epidural bupivacaine and fentanyl|
3135962|NCT01646762|Experimental|Treatment (chemotherapy)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3135963|NCT01646749|Experimental|Protein intake of 5 energy percent (En%)|
3135964|NCT01646749|Experimental|Protein intake of 15 En%|
3135965|NCT01646749|Experimental|Protein intake of 30 En%|
3135966|NCT01646736|Placebo Comparator|GC+CYC|Patients were treated with Glucocorticosteroid and Cyclophosphamide.
3135967|NCT01646736|Experimental|GC+T2|Patients were treated with Glucocorticosteroid and oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).
3135968|NCT01646723|Experimental|VALID Intervention|Volunteers Adding Life in Dementia (VALID) Program
3135969|NCT01646710|Experimental|Food Based Recommendations|Developing and pretesting tool for FBRs for infants 9 to 11 months old
3135970|NCT01646697|Experimental|Diagnostic (cytopathologic evaluation)|Patients undergo cytopathologic sample collection during pancreatic resection during which slides are gently pressed against the cut edge of the pancreas, the surgical bed, and along the superior mesenteric artery, and finally against the tumor itself.
3135971|NCT01646684|Experimental|SOM230|
3135972|NCT01646671|Experimental|LCZ696 200 mg|All participants were started on LCZ696 200 mg once daily on day 1. Participants who achieved mean sitting diastolic blood pressure (msDBP) of < 100 mmHg and mean sitting systolic blood pressure (msSBP) of < 160 mmHg at week 2 or a msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4 and for the duration of the study continued at 200 mg LCZ696 once daily.
3135973|NCT01646671|Experimental|LCZ696 400 mg|All participants were started on LCZ696 200 mg once daily on day 1. For participants who did not achieve mean sitting diastolic blood pressure (msDBP) of < 100 mmHg and mean sitting systolic blood pressure (msSBP) of < 160 mmHg at week 2 or a msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4, and did not have any signs of safety concerns, the LCZ696 dose was increased to 400 mg once daily.
3135974|NCT01646671|Experimental|LCZ696 400 mg plus other hypertension (HTN) medications|All participants were started on LCZ696 200 mg once daily on day 1. For participants who received LCZ696 400 mg and did not achieve msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4 and had no signs of safety concerns, another class of antihypertensive drugs (other than Angiotensin II receptor blockers or Angiotensin Converting Enzyme Inhibitor (ACEi) could be added, or the dose of concomitant antihypertensive drugs could be increased as per the package insert. Participants who received LCZ696 400 mg once daily did not change their dose for the remainder of the study.
3258590|NCT00778947|Active Comparator|2|
3135975|NCT01646645|Experimental|Group I|This is a single-arm non-randomized single institution phase 2 trial, designed to evaluate the therapeutic activity of CMVpp65-CTLs generated from seropositive HSCT donors when adoptively transferred into transplant recipients with persistent CMV infection or viremia. Patients eligible for this trial will be consenting recipients of related or unrelated HSCT who have an active CMV infection or persistent CMV viremia for ≥ 2 weeks despite treatment with anti-viral agents or who cannot be maintained on anti-viral therapy due to treatment related toxicity.
3135976|NCT01646632|Experimental|Physical exercise intervention|Progressive resistance training, balance training, functional training
3135977|NCT01646632|Placebo Comparator|Lifestyle counseling|Recreational sessions
3135978|NCT01646619|Active Comparator|Hypothermia + Magnesium Sulphate|
3135979|NCT01646619|Placebo Comparator|Hypothermia+ Placebo|
3135980|NCT01646606|Active Comparator|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Vital signs will be measured at a frequency determined by the responsible physician (as is current practice). The reading will be displayed on the bedside monitor in the participants' room.
3135981|NCT01646606|Experimental|Intermittent oxygen monitoring|
3135982|NCT01646580|Experimental|ciclopirox|
3135983|NCT01646567|Experimental|SHP-141C & Placebo & Calcipotriol & Betamethasone Valerate|A 100 mg dose of SHP-141C cream at three concentrations (0.5%, 1.0% and 2.0%), a matched placebo cream and two reference treatments: Calcipotriol 0.005% cream and Betamethasone Valerate 0.02% cream, applied topically to a selected plaque on each subject, six times per week over 28 days for a total of 24 doses.
3135984|NCT01646554|Active Comparator|Arm A: modified FOLFOX6 and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
3135985|NCT01646554|Experimental|Arm B: modified FOLFOX6 + Aflibercept and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Aflibercept 4 mg/kg intravenous infusion 1-h~Hour 1: Oxaliplatin 85 mg/m2 2-h infusion~Hour 1: Folinic Acid 400 mg/m2 (DL form) or 200 mg/m2 (L form) 2-h infusion~Hour 3: 5-FU bolus 400 mg/m2 IV bolus over 2-4 minutes~Hour 3: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~Day 1 of a 14 day cycle~Aflibercept should be given in all cycles, except cycle 6 of pre-operative treatment."
3135986|NCT01646541||Asymptomatic|No dyspnea with exertion greater than 6 months after mitral valve surgery [New York Heart Association (NYHA) Functional Class I]
3135987|NCT01646541||Symptomatic|Dyspnea with exertion greater than 6 months after mitral valve surgery [New York Heart Association (NYHA) Functional Class II, III, or IV]
3135988|NCT01646528||Consecutive patients for CLE examination|
3135989|NCT01646515|Placebo Comparator|placebo arm|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
3135990|NCT01646515|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
3135991|NCT01646502|Experimental|Esp-supplemented standard wound care|500 pmol Esp protein will be added to the standard wound care protocol.
3135992|NCT01646502|Active Comparator|Standard wound care|"The standard treatment protocol established at the Vancouver Wound Healing Clinic is based on the Best Clinical Practice Guidelines for Venous Leg Ulcers from the Canadian Association of Wound Care."
3135993|NCT01646489|Experimental|Miravirsen sodium|
3135994|NCT01646489|Active Comparator|Telaprevir|
3135995|NCT01646476|Active Comparator|Covered stent (Bona stent, pyloric/duodenal covered)|WAVE covered self-expandable metallic stent (BONASTENT, Standard Sci Tech, Ltd., Seoul, Korea)
3135996|NCT01646476|Active Comparator|Uncovered stent (Bona stent, pyloric/duodenal)|uncovered self-expandable metallic stent (BONASTENT, Standard Sci Tech, Ltd., Seoul, Korea)
3135997|NCT01646463|Experimental|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills is the standard CenteringPregnancy prenatal healthcare intervention combined with mindfulness meditation and mindful movement/yoga applied to pregnancy, childbirth, and parenting.
3135998|NCT01646463|Active Comparator|CenteringPregnancy|CenteringPregnancy is group-based prenatal healthcare delivered according to the guidelines of the American College of Obstetrics and Gynecology. It includes assessment, support, and health education delivered in a healthcare empowerment framework.
3135999|NCT01646450|Experimental|Icotinib|Icotinib: 125mg, oral administration, three times per day.
3136000|NCT01646437|Experimental|Polycap vs. matching placebo|Polycap is a once daily capsule containing thiazide (25mg), atenolol (100mg), ramipril (10mg) and simvastatin (40mg) vs. matching placebo
3136001|NCT01646437|Experimental|Aspirin vs. matching placebo|Once daily 75mg tablet of Aspirin vs. matching placebo
3136002|NCT01646437|Experimental|Vitamin D vs. matching placebo|Monthly oral dosage of 60,000IU vs. matching placebo
3136003|NCT01646411||assorted acute infection|300 patients diagnosed with assorted acute infection.
3136004|NCT01646398|Experimental|>= 65-year age group-13vPnC|
3136005|NCT01646398|Active Comparator|>= 65-year age group-23vPS|
3136006|NCT01646385||etanercept|adult rheumatoid arthritis patients initiating therapy with etanercept as their first biologic therapy
3136007|NCT01646385||nbDMARD|biologic-naive adult rheumatoid arthritis patients with DAS28 >4.2 treated with non-biologic anti-rheumatic drugs(s).
3136008|NCT01646372|Active Comparator|Control Group|This group gets a simulation based ACLS refresher as treatment, but no access to cognitive aids for any of the tests.
3136009|NCT01646372|Active Comparator|2nd Control Group|This group receives a standard Simulation based ACLS refresher as the intervention, like the control group. No mention is made of Cognitive Aids in the teaching, but they are available during the post-test and retention post-test.
3136010|NCT01646372|Experimental|Cognitive Aid Group|This group receives Cognitive Aid based teaching as the intervention. They also have access to cognitive aids for post-test and retention post-test
3136011|NCT01646359|Experimental|corrected flow time|
3136126|NCT01645332|Experimental|Treatment II|100 mg DLBS3233 once daily for 12 weeks + lifestyle modification
3136012|NCT01646346|Experimental|4D Conformal Image-Guided Partial Breast RT|This is a single arm trial designed to look at the results in women treated with partial breast irradiation twice daily for 5 days.
3136013|NCT01646333|Active Comparator|Supportive Therapy|The supportive therapy offers patients and support persons the opportunity to discuss and reflect upon both Parkinson's Disease and non-Parkinson's Disease related problems.
3136014|NCT01646333|Experimental|Memory and Problem-Solving Intervention|The memory and problem solving training consists of a day calendar manual and note taking system and problem solving techniques. The neurocognitive memory intervention was adapted from a 6-week manualized day calendar and note taking system previously evaluated in an amnestic MCI sample and a brain tumor sample. The problem solving intervention was adapted from an originally 12-week intervention, which was later adapted into a 6-week brain tumor sample.
3136015|NCT01646320|Experimental|Arm1: Dapagliflozin (10 mg) + Saxagliptin + Metformin IR|
3136016|NCT01646320|Experimental|Arm 2: Placebo + Saxagliptin + Metformin IR|
3136017|NCT01646307|Placebo Comparator|standard care group|patients receive atorvastatin 20 mg/d
3136018|NCT01646307|Active Comparator|intensive rosuvastatin|administrated with rosuvastatin 20mg 12h prior PCI, then 10mg 2h prior PCI; followed by 10 mg/d for 30 days after PCI
3136019|NCT01646307|Active Comparator|intensive atorvastatin|patients will be administrated with atorvastatin 80mg 12h prior PCI, then 40mg 2h prior PCI, followed by 40 mg/d for 30 days after PCI;
3136020|NCT01646294|Experimental|OCAS-F|YM178 OCAS tablet (OCAS-Fast) taken orally under fasted and fed condition
3136021|NCT01646294|Experimental|OCAS-S|YM178 OCAS tablet (OCAS-Slow) taken orally under fasted and fed condition
3136022|NCT01646294|Experimental|OCAS-M|YM178 OCAS tablet (OCAS-Medium) taken orally under fasted and fed condition
3136023|NCT01646281|Active Comparator|Flecainide|Patients randomized to flecainide will receive a 10-minute infusion of 2 mg/kg (maximal 150 mg) flecainide. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
3136024|NCT01646281|Active Comparator|Vernakalant|Patients randomized to vernakalant will receive a 10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
3136025|NCT01646268|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
3136026|NCT01646268|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
3136027|NCT01646255|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
3136028|NCT01646255|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
3136029|NCT01646242|Experimental|Cold snare polypectomy|
3136030|NCT01646242|Experimental|Double biopsy polypectomy|
3136031|NCT01646229|Active Comparator|Polymyxin-B hemoperfusion|In the HEMOPERFUSION group, a veno-venous dialysis catheter type GamCath 12 F, 3 lumen will be inserted instead of a regular double or triple-lumen central venous catheter, and connected to the Toraymyxin® (PMX-20-R) device for endotoxin adsorption by hemoperfusion with the DECAPSMART pump. The length of the hemoperfusion will be a minimum of 120 min and started just before the beginning of the surgical intervention in the OR and stopped at the end of surgery.
3136032|NCT01646229|Active Comparator|Control|"In the CONTROL group, the administration of fluids (250 to 500ml crystalloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP between > 8 and 12 < mmHg, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mMol/L, normalisation of the BE.~At the discretion of the attending anaesthesiologist with the FMH level, a PiCCO monitoring, a transoesophageal echography, or a pulmonary artery catheter, will be inserted to complement the standard hemodynamic monitoring if deemed necessary."
3136033|NCT01646216|Experimental|Split-belt treadmill training|Split-belt treadmill exercise
3136034|NCT01646203|Experimental|IMC-TR1|"Part A - Dose Escalation:~Cohort 1A: 1.25 mg/kg, intravenously (IV), every 2 weeks of the 6-week treatment cycle~Cohorts 1B-9: Dose Escalation from 12.5 mg to 1600 mg (flat dose), intravenously (IV), every 2 weeks of the 6-week treatment cycles~Cohorts 10-12: Dose escalation from 800 mg to 1600 mg (flat dose), intravenously (IV), weekly during the 6-week treatment cycles~Part B - Disease Specific Cohort Expansion:~Patients will be enrolled into each of three tumor-specific cohort expansions. Patients will be treated with recommended Phase 2 dose."
3136035|NCT01646190|Active Comparator|Standard care|Preoperative: Fasting state after midnight, no intake of oral carbohydrate load Preanesthetic medication No preoperative utilization of inspirex Intraoperative: Effective perioperative analgesia Routine nasogastric tube and abdominal drainage at surgeon discretion Postoperative: Removal of the nasogastric tube after return of bowel function removal of abdominal drainage at surgeon discretion or if volume <50cc Oral liquids and stepwise oral nutrition (water to others liquids to progressive normal or low-fiber nutrition Switch to oral medication after oral nutrition tolerance Urinary catheter removal when the mobilization is satisfactory Mobilization: non standardized and encouraged stepwise mobilization Discharge criteria discussed at surgeon discretion
3136036|NCT01646190|Experimental|FT perioperative care|Preoperative carbohydrate load No preanesthetic medication General anesthesia and intravenous analgesia Transoesophageal US-Doppler for individualized i.v fluids therapy POD 0: No Nasogastric tube postoperatively Oral liquids 0.3-0.5L 6h after extubation First mobilization 6h after surgery (2h) Stimulation of inspirex utilization (6-8t/d) POD 1: Free oral liquids; progressive normal or low-fiber diet Switch to oral medication Urinary catheter removal Mobilization: >4 h out of bed (walking, chair) inspirex utilization POD 2: Free oral liquids; normal or low-fiber diet Mobilization: >6 h out of bed (walking, chair), inspirex utilization POD 3: Complete mobilization as preoperatively First evaluation of discharge criteria in the afternoon
3136037|NCT01646177|Placebo Comparator|Placebo|Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, arm is assigned to Dosing Regimen 2.
3136038|NCT01646177|Active Comparator|50 mg etanercept|Administered by SC injections twice weekly starting at Week 0 up to Week 12. At Week 12, arm is assigned to Dosing Regimen 2.
3136127|NCT01645319||White, non-hispanic - Medication Treatment Pathway|
3136039|NCT01646177|Experimental|80 mg ixekizumab Dosing Regimen 2|Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 264.
3136040|NCT01646177|Experimental|80 mg ixekizumab Dosing Regimen 1|Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, arm is assigned to Dosing Regimen 2.
3136041|NCT01646164||Dill seed|used dill seed infusion (1 tablespoon whole dill seed seeped in a half or whole cup boiling water for 3-4 min)
3136042|NCT01646164||No used Dill seed|those who had not used any herbal drugs were placed at the control group
3136043|NCT01646151||Bimatoprost|Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
3136044|NCT01646138|Experimental|Challenge Virus|The Ca/04/2009/H1N1 Vero Grown Challenge Virus was administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
3136045|NCT01646125|Experimental|AUY922 arm|"Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the investigational drug arm.~AUY922 was to be administered weekly."
3136046|NCT01646125|Active Comparator|chemotherapy arm|"Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the control arm drug arm.~Pemetrexed or docetaxel was to be was to be given once every three weeks."
3136047|NCT01646099|Experimental|Sun Protection Education|Distribution of the internet-based sun protection educational program.
3136048|NCT01646099|No Intervention|Control|Distribution of general skin care information.
3136049|NCT01646086|Experimental|weekly weight tracking|12 month behavioral weight loss intervention
3136050|NCT01646086|Active Comparator|daily weight tracking|12 month behavioral weight loss intervention
3136051|NCT01646086|Active Comparator|no weight tracking|12 month behavioral weight loss intervention
3136052|NCT01646073|Experimental|Adalimumab|Adalimumab 40 mg every other week (eow)
3136053|NCT01646073|Placebo Comparator|Placebo|placebo
3136054|NCT01646060|Experimental|Blood Draw|
3136055|NCT01646047|Experimental|supplement - no retinopathy|subjects receiving active supplement and with no retinopathy based on clinical examination
3136056|NCT01646047|Placebo Comparator|placebo - no retinopathy|patients receiving placebo and who have no diabetic retinopathy based on clinical examination
3136057|NCT01646047|Experimental|supplement - retinopathy|patients receiving the active supplement and who have mild to moderate non-proliferative diabetic retinopathy based on clinical examination
3136058|NCT01646047|Placebo Comparator|placebo - retinopathy|patients receiving placebo and who have mild to moderate non-proliferative diabetic retinopathy based on clinical examination
3136059|NCT01646034|Experimental|intensified alkylating chemotherapy|a course chemotherapy with high dose cyclophosphamide, G-CSF and peripheral blood progenitor cell (PBPC) harvest followed by tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
3136060|NCT01646034|Active Comparator|three cycles of chemotherapy|"three cycles of chemotherapy depending on previously received agents~chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclophosphamide previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine"
3136061|NCT01646021|Experimental|Ibrutinib|
3136062|NCT01646021|Experimental|Temsirolimus|
3136063|NCT01646008||respiratory|
3136064|NCT01645995|Experimental|Reformulated products|Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
3136065|NCT01645995|Experimental|Conventional products|Subjects were asked to supplement their habitual diet with conventional sugar products for 8 weeks. Subjects were provided with conventional beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
3136066|NCT01645969||Cohort|
3136067|NCT01645956||Single group|
3136068|NCT01645943|No Intervention|Conservative|Coronary angiogram only if recurrent ischemia or peristent heart failure or inducible ischemia in predischarge stress test if perfomed
3136069|NCT01645943|Active Comparator|Invasive|Routine coronary angiogram
3136070|NCT01645930|Experimental|IXAZOMIB|IXAZOMIB+Lenalidomide+Dexamethasone
3136071|NCT01645917|Experimental|Ablation|Ablation with Arctic Front Advance Cardiac CryoAblation system
3136072|NCT01645904||Group 1|Patients participate in audiotaped focus group regarding web-based program, and fill out demographics questionnaire.
3136073|NCT01645904||Group 2|Patients come to Behavioral Research and Treatment Center (BRTC) at MD Anderson to use initial version of My Family Garden website. Completion of Website Analysis and MeasureMent Inventory (WAMMI), and demographics questionnaires.
3136074|NCT01645904||Group 3|Patients use final version of My Family Garden website, and are interviewed which will be audiotaped. Completion of Website Analysis and MeasureMent Inventory (WAMMI), questionnaire and demographics questionnaire.
3136075|NCT01645891|Active Comparator|CDO with standard MWT|CDO (continuously supply pure oxygen) with standard Moist Wound Therapy
3136076|NCT01645891|Sham Comparator|Moist Wound Therapy|Moist Wound Therapy. De-activated Sham device placed to wound in order to blind patient and study staff.
3136077|NCT01645878|Experimental|Hands on|breast feeding instructed by direct help of instructor
3136078|NCT01645878|Experimental|hands off|
3136079|NCT01645878|Other|Control|Routin breast feeding education
3136080|NCT01645865||Control|
3136081|NCT01645865||Intervention|
3136082|NCT01645852|No Intervention|Control|No specified diet for one week prior to hepatic resection.
3136083|NCT01645852|Active Comparator|Low calorie diet|Low calorie diet (five units of Optifast 800 {Nestle Nutrition, Vevey, Switzerland} plus an unlimited volume of calorie free fluids per day) for one week prior to hepatic resection.
3136128|NCT01645319||White, non-Hispanic - Laser Surgery Treatment Pathway|
3136129|NCT01645319||White, non-Hispanic - Incisional/Other Treatment Pathway|
3136084|NCT01645839|Experimental|Systemic treatment with Depocyte|Intrathecal injection of Liposomal Cytarabine (Depocyte®) every 14 ± 2 days for a total of 5 cycles and then every 28 ± 4 days until progression.
3136085|NCT01645839|No Intervention|Systemic treatment without Depocyte|No intrathecal injection.
3136086|NCT01645826|Experimental|Diltiazem|The study agent will be Diltiazem and will start at 60 mg po BID then titrated up every two weeks until at a maximum dose of 180mg po BID.
3136087|NCT01645826|Placebo Comparator|Sugar Pill|The placebo group of patients will be treated with Drug A (sugar pill) PO bid and titrated up every two weeks for next titration dose (actually will be an unchanged concentration).
3136088|NCT01645800|Experimental|Lysozyme hydrochloride|
3136089|NCT01645800|Placebo Comparator|Placebo|
3136090|NCT01645787|Active Comparator|4-aminopyridine (Ampyra)|10 mg tab/ 1 tab twice daily
3136091|NCT01645787|Placebo Comparator|Sugar pill|Placebo 1 tab /twice daily
3136092|NCT01645774|Experimental|10s injections duration|10s injections duration
3136093|NCT01645774|Experimental|10s injection duration , waiting 10s|10s injection duration and waiting 10s before withdrawing the needle
3136094|NCT01645774|Experimental|15s injection duration,waiting 5s|15s injection duration and waiting 5s before withdrawing the needle
3136095|NCT01645774|Experimental|5s injection duration , waiting 15s|5s injection duration and waiting 15s before withdrawing the needle
3136096|NCT01645761|Experimental|PPI-based triple therapy with endonase|7-day standard proton pump inhibitor-based triple therapy (the standard dosage of PPI, 1,000 mg of amoxicillin and 500 mg of clindamycin twice daily for one week) plus 20,000 units of endonase twice daily for one week.
3136097|NCT01645761|No Intervention|PPI-based triple therapy|7-day standard proton pump inhibitor-based triple therapy (the standard dosage of PPI, 1,000 mg of amoxicillin and 500 mg of clindamycin twice daily for one week)
3136098|NCT01645748|Experimental|S-1, induction chemotherapy|Cisplatin and 5-FU is the standard treatment for patients with head and neck cancer. Recently,docetaxel was used into CF, and it showed the prolongation of survival. Oral 5-FU showed similar or enhanced response rate, safety than intravenous 5-FU. S-1 showed promising preliminary result in combination with cisplatin in head and neck cancer. In patients with gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid, 60mg/m2 (D1) and 60mg/m2 (D1), respectively. And weekly docetaxel can reduce adverse events compared to 3 week regimen. The aim of this study was to evaluate the efficacy and safety of weekly docetaxel, cisplatin and S-1 combination chemotherapy
3136099|NCT01645735|Experimental|Ceftaroline|Ceftaroline fosamil 600 mg Intravenous (IV) administration over 60 minutes, every 8 hours (q8h); dosing to be adjusted for renal function; treatment duration 5 to 14 days
3136100|NCT01645735|Active Comparator|Ceftriaxone plus vancomycin|Ceftriaxone 2 g IV over 30 minutes once per day (q24h) plus vancomycin 15 mg/kg IV every 12 hours (q12h) initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
3136101|NCT01645722|Other|Procedure/Surgery: Enriched Fat grafting|Enriched Fat grafting
3136102|NCT01645709|Experimental|Verapamil|Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.
3136103|NCT01645709|Placebo Comparator|Placebo|Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.
3136104|NCT01645696|Experimental|BD Continuous Glucose Monitor (CGM) with outer layer|A subcutaneous glucose binding protein sensing device to continuously monitor glucose in diabetics.
3136105|NCT01645696|Experimental|BD CGM without outer layer|A continuous glucose binding protein sensing device used to monitor glucose in Diabetics
3136106|NCT01645696|Active Comparator|Medtronic iPro 2 Professional CGM|Commercial glucose oxidase continuous glucose monitor
3136107|NCT01645566|Experimental|intervention|"instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)"
3136108|NCT01645566|No Intervention|Control|No instructions
3136109|NCT01645475|Experimental|Desmopressin lyophilisate (Melt)|Patients receiving Desmopressin lyophilisate (Melt).
3136110|NCT01645449|Experimental|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
3136111|NCT01645449|Active Comparator|Lipitor 80 mg Tablets|Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
3136112|NCT01645436|Experimental|treatment (exercise)|combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
3136113|NCT01645436|No Intervention|control (usual care)|Usual hospital care with no exercise
3136114|NCT01645423|Experimental|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
3136115|NCT01645423|Active Comparator|Lipitor 80 mg Tablets|Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
3136116|NCT01645410|Experimental|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
3136117|NCT01645410|Active Comparator|Lipitor® 40 mg Tablets|Lipitor® 40 mg Tablets of Pfizer Ireland Pharmaceuticals
3136118|NCT01645397||Asthma, elevated exhaled NO|Children with asthma with elevated exhaled NO at initial evaluation (>25ppb)
3136119|NCT01645384|Experimental|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
3136120|NCT01645384|Active Comparator|Lipitor® 40 mg Tablets|Lipitor® 40 mg Tablets of Pfizer Ireland Pharmaceuticals
3136121|NCT01645371||Subjects with opioid induced constipation|
3136122|NCT01645358|Experimental|Helmet to deliver NIV|
3136123|NCT01645358|Active Comparator|Total Face to deliver NIV|
3136124|NCT01645345|Other|RF Pixel handpiece treatment|There is only one arm, and that is a treatment arm. For patients with wrinkles and acne scars, they are being treated with the RF Pixel handpiece to decrease the appearance of these cosmetic deficiencies. The improvement is documented in before and after photographs.
3136125|NCT01645332|Placebo Comparator|Treatment I (control)|Placebo of DLBS3233 once daily for 12 weeks + lifestyle modification
3260736|NCT00763724||3|SSRI
3136139|NCT01645306|Placebo Comparator|Phosphate buffered saline (PBS), 1% sucrose, 4% mannitol|
3136140|NCT01645306|Active Comparator|40 mg Revacept|in phosphate buffered saline (PBS), 1% sucrose, 4% mannitol
3136141|NCT01645306|Active Comparator|120 mg Revacept|in phosphate buffered saline (PBS), 1% sucrose, 4% mannitol
3136142|NCT01645293|Experimental|Genetically modified T cells #1138|
3136143|NCT01645280|Placebo Comparator|Group 1|
3136144|NCT01645280|Experimental|Group 2|
3136145|NCT01645280|Experimental|Group 3|
3136146|NCT01645280|Experimental|Group 4|
3136147|NCT01645280|Experimental|Group 5|
3136148|NCT01645267|Experimental|Osteotomy|Using hydroxyapatite bone graft material
3136149|NCT01645254|Experimental|Argemone mexicana|"Argemone mexicana is traditional medicinal plant known as having an antimalarial activity.~The aerial part of this plant is used. The decoction of the powder of the plant will be used."
3136150|NCT01645241|Experimental|Lutheal phase ovarian stimulation|Early luteal phase Controlled ovarian hyperstimulation: we will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix to induce luteolysis and FSHr (dose according to BMI and AFC )IU/day for controlled ovarian hyperstimulation until achieving criteria for hCG , to induce final oocyte maturation. Mature oocytes will be vitrified. After warming, oocytes will be inseminated by ICSI with the recipients partners semen sample . Recipient endometrium will be primed with estrogen and progesterone , and embryo transfer will be performed on the 3rd day 3 of embryo cleavage.
3136151|NCT01645228||significant coronary artery stenosis|anyone coronary segment > 50% diameter stenosis
3136152|NCT01645215|Experimental|Fruquintinib capsule|cohort 1: fruquintinb continuous oral dosing (1mg once a day) cohort 2: fruquintinb continuous oral dosing (2mg once a day) cohort 3: fruquintinb continuous oral dosing (4mg once a day) cohort 4: fruquintinb continuous oral dosing (6mg once a day) cohort 5: fruquintinb continuous oral dosing (5mg once a day) cohort 6: fruquintinb oral dosing, 3 weeks on/1 week off (5mg once a day) cohort 7: fruquintinb oral dosing, 3 weeks on/1 week off (6mg once a day)
3136153|NCT01645202|Active Comparator|TAVI with Edwards Sapien XT valve|
3136154|NCT01645202|Active Comparator|TAVI with Medtronic CoreValve|
3136155|NCT01645189|Experimental|Test drug|Idursulfase-beta
3136156|NCT01645176|Experimental|Hydroxychloroquine/Atorvastatin open label|
3136157|NCT01645163|Experimental|Mobile phone counselling|
3136158|NCT01645150|Experimental|Strength training group|12 weeks of progressive strength training
3136159|NCT01645150|No Intervention|Control group|No intervention
3136160|NCT01645137|Experimental|OMT|patients under usual medical care plus osteopathic treatment
3136161|NCT01645137|Other|control|patients under usual medical care
3136162|NCT01645124|Active Comparator|Cytoreduction for HCT < 45%|Patients will be treated with phlebotomy and/or HU more intensively, with the goal to reach and maintain the target of hematocrit(HCT)below 45%. Phlebotomy should be performed initially by removing 250-500 ml of every other day or twice a week until the target HCT is obtained. Hydroxyurea (HU)should be administered initially at a dose of 0.5-1.0 g daily. Blood counts at regular intervals (monthly) will establish the frequency of future phlebotomies with the goal to maintain the target HCT. Supplemental iron therapy should not be given. Low-dose aspirin is the standard antithrombotic therapy in PV and will be administered to all patients with no contraindications to aspirin.
3136163|NCT01645124|Experimental|Cytoreduction for HCT between 45 and 50%|Patients will be treated with phlebotomy and/or HU less intensively, with the goal to reach and maintain the target of hematocrit(HCT)between 45% and 50%. Phlebotomy should be performed initially by removing 250-500 ml of every other day or twice a week until the target HCT is obtained. Hydroxyurea (HU)should be administered initially at a dose of 0.5-1.0 g daily. Blood counts at regular intervals (monthly) will establish the frequency of future phlebotomies with the goal to maintain the target HCT. Supplemental iron therapy should not be given. Low-dose aspirin is the standard antithrombotic therapy in PV and will be administered to all patients with no contraindications to aspirin.
3136164|NCT01645111|Active Comparator|Clevidipine|
3136165|NCT01645098|Experimental|Dexmedetomidine 1 mcg/kg|Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.
3136166|NCT01645098|Experimental|Dexmedetomidine 0.5 mcg/kg|Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.
3136167|NCT01645085|Experimental|Treatment A|100mg MCC-based 13% drug-loaded tablets
3136168|NCT01645085|Experimental|Treatment B|100mg mannitol-based 38% drug-loaded tablets
3136169|NCT01645085|Experimental|Treatment C|150mg MCC-based 13% drug-loaded tablets
3136170|NCT01645085|Experimental|Treatment D|150mg mannitol-based 38% drug-loaded tablets
3136171|NCT01645072|Experimental|Low glycemic index diet|The patients will be started on low glycemic index diet.
3136172|NCT01645072|Other|Control group|Standard care. The control group will receive their usual diet without any alteration. No changes will be made to the patients' antiepileptic medication during the 4-week baseline or the 3-month study periods in both the intervention and control groups, unless medically indicated; e.g. drug side effects, or status epilepticus; in which case appropriate changes will be made to their medications and same will be documented.
3136173|NCT01645046|Active Comparator|Coenzyme A 200mg|Coenzyme A 200mg per day.
3136174|NCT01645046|Placebo Comparator|Placebo|Capsule without coenzyme A.
3136175|NCT01645046|Active Comparator|Coenzyme A 400mg|Coenzyme A 400mg per day.
3136176|NCT01645033|Experimental|TAU plus computerized CBT|Standard treatment (TAU) plus a short session using a computer program containing computerized CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
3136177|NCT01645033|Active Comparator|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~Teaching about the treatment program~Teaching important ideas about sexual behaviors risks~Increasing knowledge about specific sexually transmitted diseases~Discussions of ways to reduce or minimize spread of diseases related to drug use [for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)]"
3136493|NCT01642862|Active Comparator|Tablet formulation of Simvastatin|
3136178|NCT01644994|Experimental|intracavitary cisplatin-fibrin|single dose local intracavitary cisplatin-fibrin application after pleurectomy/decortication
3136179|NCT01644981||VLBW infants|
3136180|NCT01644968|Experimental|KLH + anti-OX40|Day 1: KLH + anti-OX40; Day 3: anti-OX40; Day 4: anti-OX40; Day 29: Tetanus vaccine
3136181|NCT01644968|Experimental|Tetanus vaccine + anti-OX40|Day 1: Tetanus vaccine + anti-OX40; Day 3: anti-OX40; Day 5: anti-OX40; Day 29: KLH
3136182|NCT01644955|Experimental|Treatment (carboplatin)|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room and then receive carboplatin administered intracerebrally by convection enhanced delivery.
3136183|NCT01644942|Other|Insulin sensitive patients|
3136184|NCT01644942|Other|Insulin resistant patients|
3136185|NCT01644929|Experimental|1 tDCS-Sham|tDC stimulation for 3 weeks, then cross-over to sham stimulation
3136186|NCT01644929|Experimental|2 Sham-tDCS|Sham stimulation for 3 weeks, then cross over to tDCS stimulation
3136187|NCT01644929|Sham Comparator|3 Sham-Sham|Treatment for 6 weeks daily with sham stimulation
3136188|NCT01644916|Other|Usual control|Usual control will be provided with usual standard management of COPD and psychiatric comorbidities.
3136189|NCT01644916|Other|Integrated care|Integrated care will be provided with integrated care management.
3136190|NCT01644890|Experimental|NK105|
3136191|NCT01644890|Active Comparator|Paclitaxel|
3136192|NCT01644877|Experimental|DAS181|DAS181-F02, 4.5 mg qd x 10 days
3136193|NCT01644877|Placebo Comparator|Lactose Placebo|placebo, 4.5 mg qd x 10 days
3136194|NCT01644864|Placebo Comparator|Placebo|saline injection
3136195|NCT01644864|Experimental|Experimental|0.375% ROPIVACAINE
3136196|NCT01644851|Experimental|Executive function training|Executive function training
3136197|NCT01644851|Placebo Comparator|Word game training|Computer-based training in tasks related to verbal processing.
3136198|NCT01644838|Experimental|Promethazine|25 mg of promethazine
3136199|NCT01644838|Experimental|Hyoscine|20 mg of hyoscine
3136200|NCT01644825|Experimental|paclitaxel and pazopanib|
3136201|NCT01644825|Active Comparator|paclitaxel|
3136202|NCT01644812|Active Comparator|Aerobic exercise|The exercise intervention is a 12-week program involving 150 minutes of moderate intensity exercise (65-69% of participant's age-predicted [220-age] maximum heart rate) each week. Participants will complete one 50-minute supervised treadmill exercise session in the laboratory and 100 minutes of exercise on their own. These exercises may include walking, jogging, biking, or other forms of aerobic exercise. The at-home exercise regimen will be individualized for each participant.
3136203|NCT01644812|Sham Comparator|stretching|The exercise intervention is a 12-week program involving 150 minutes of stretching each week (one 50-minute stretching session in the laboratory and 100 minutes of stretching at home). Participants in the stretching condition will work with a facilitator to create a stretching regimen for 100 minutes of home stretching throughout the week. The facilitator will provide a list of potential stretches with descriptions on how to perform them.
3136204|NCT01644799|Experimental|lenalidomide and idelalisib|"Lenalidomide:~Lenalidomide will be administered orally on days 1-21 followed by 7 days of rest, every 28 days. A treatment cycle will be considered 28 days in length. In the absence of intolerable toxicity or disease progression, lenalidomide will be given for a total of 12 cycles.~Idelalisib:~Dosing is fixed in all cohorts receiving idelalisib at 150 mg orally (twice daily) for 12 cycles, with the exception of dose modifications for toxicity."
3136205|NCT01644773|Experimental|Chemotherapy|Research participants with high grade glioma or diffuse intrinsic pontine glioma will receive crizotinib and dasatinib.
3136206|NCT01644760|Experimental|Study population|Healthy subjects with spontaneous ventilation, 18 to 50 years of age.
3136207|NCT01644747|Active Comparator|active tDCS|a group named G1 and treated by medication with SSRIs (Selective Serotonin Reuptake Inhibitors) or SNRIs (Serotonine-Norepinephrine Reuptake Inhibitors) for 48 unipolar patients or with Lithium for 12 bipolar patients stabilized for at least 4 months and 10 sessions of active anodal tDCS at 2 sessions per day (1 morning and 1 afternoon with a gap of 3h) for 5 days with an electric current 2 mA.
3136208|NCT01644747|Sham Comparator|sham tDCS|a group named G2 and treated by medication with SSRIs or SNRIs for 48 unipolar patients or with Lithium for 12 bipolar patients stabilized for at least 4 months and sham tDCS.
3136209|NCT01644721|Experimental|Early measles vaccine|An additional measles vaccine at 4 months of age, at least 28 days after the third dose of pentavalent vaccine
3136210|NCT01644721|No Intervention|Control|Follows the normal vaccination schedule
3136211|NCT01644708||Overweight, obese adult patients|Patients following a self empowerment group will be included in the study
3136212|NCT01644695||Candidate for BARS procedure.|The subjects selected for this trial were over 18 years of age with an appropriate complex, incisional hernia. These patients were consented and treated with the BARS(bony anchoring reinforcement system)procedure.
3136213|NCT01644682|Experimental|Arm-1|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive IWFPL intervention.
3136214|NCT01644682|Experimental|Arm-2|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive IDWL intervention.
3136215|NCT01644682|Experimental|Arm-3|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive ITN intervention.
3136216|NCT01644682|No Intervention|Control|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will not receive any intervention, Control group
3136217|NCT01644669|Experimental|Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy
3136218|NCT01644656|Experimental|acoustic radiation force impulse (ARFI)|Imaging of liver and spleen using modified ultrasound
3136219|NCT01644643|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
3136220|NCT01644643|Active Comparator|Best Available Therapy|IV treatment
3136221|NCT01644630|Active Comparator|Cemented single crowns|Cemented single crown: zirconia abutment (Straumann Cares abutment) with an all-ceramic lithium disilicate crown
3136222|NCT01644630|Active Comparator|Screw-retained single crown|Screw-retained single crown: zirconia abutment (Straumann Cares abutment), directly veneered with veneering ceramic
3136223|NCT01644617|Placebo Comparator|Placebo|Placebo rapidly dissolving tablet administered sublingually once daily (q.d.), at approximately the same time each day, for 24 weeks
3136224|NCT01644617|Experimental|MK-8237 6 Developmental Units (DU)|MK-8237 6 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks
3136225|NCT01644617|Experimental|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks
3136226|NCT01644604|Experimental|Renal denervation|Subjects are treated with the renal denervation procedure after randomization and are maintained on baseline anti-hypertensive medications.
3136227|NCT01644604|No Intervention|Control Group|Subjects are maintained on baseline anti-hypertensive medications
3136228|NCT01644591|Experimental|Stereotactic Radiosurgery (SRS)|Dose based on largest diameter of the lesion as measured on the volumetric MRI, modified from RTOG 90-05 (7). Lesions targeted with 20-24 Gy for 2 cm, 16-18 Gy for >2 to 2.5 cm, and 12-16 Gy for >2.5-3.5 cm. SRS performed on day 1. 8 cognitive function tests given at baseline and at 1, 4, 6, 9, and 12 months after Day 1 of radiation treatment. 3 questionnaires regarding quality of life and symptoms given at baseline and at 1, 4, 6, 9, and 12 months after Day 1 of radiation treatment. It should take about 40 minutes to complete the questionnaires.
3136229|NCT01644578|Other|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
3136230|NCT01644565|Experimental|Group A-1|Recombinant fimbrial adhesin dscCfaE: 1 ug of dscCfaE ID on study days 0, 21 and 42
3136231|NCT01644565|Experimental|Group A-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5: 2.6 ug of Chimera ID on study days 0, 21 and 42
3136232|NCT01644565|Experimental|Group A-3|Modified E. coli heat labile enterotoxin LTR192G: 100 ng of LTR192G ID on study days 0, 21 and 42
3136233|NCT01644565|Experimental|Group B-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 1 ug of dscCfaE + 100 ng of LTR192G ID on study days 0, 21 and 42
3136234|NCT01644565|Experimental|Group B-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 and Modified E. coli heat labile enterotoxin LTR192G: 2.6 ug of Chimera + 100 ng of LTR192G ID on study days 0, 21 and 42
3136235|NCT01644565|Experimental|Group C-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 5 ug of dscCfaE + 100 ng of LTR192G ID on study days 0, 21 and 42
3136236|NCT01644565|Experimental|Group C-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 and Modified E. coli heat labile enterotoxin LTR192G: 12.9 ug of Chimera + 100 ng of LTR192G ID on study days 0, 21 and 42
3136237|NCT01644565|Experimental|Group D-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 25 ug dscCfaE + 100 ng LTR192G ID on study days 0, 21 and 42
3136238|NCT01644565|Experimental|Group D-2|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: TBD ug dscCfaE + 50 ng LTR192G TCI on study days 0, 21 and 42
3136239|NCT01644552||eye examinations|
3136240|NCT01644539|Other|Control|"Subjects participated in a 35 min fmri scan. Intervention: intra-gastric infusion of 500 ml non caloric load consisting of water and thickening agent (guar gum), over 5 min.~While scanning:~-5 - 0 min : baseline scan 0 - 5 min: intra-gastric infusion (naso-gastric tube) of 500 ml non caloric load consisting of water and thickening agent (guar gum) in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
3136241|NCT01644539|Other|Oral ingestion|"Subjects participated in a 35 min fmri scan. Intervention: Oral ingestion (through a tube, while drinking and swallowing on command) of 500 ml caloric load consisting of Nutricia Chocolate Milk, over 5 min.~Time frame while scanning:~-5 - 0 min : baseline fmri scan 0 - 5 min: oral ingestion (through a tube, while drinking and swallowing on command) of 500 ml caloric load consisting of Nutricia Chocolate Milk in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
3136242|NCT01644539|Other|Intra Gastric|"Subjects participated in a 35 min fmri scan. Intervention: intra-gastric infusion (naso-gastric tube) of 500 ml caloric load consisting of Nutricia Cholate Milk, over 5 min.~While scanning:~-5 - 0 min : baseline scan 0 - 5 min: intra-gastric infusion (naso-gastric tube) of 500 ml caloric load consisting of Nutricia Cholate Milk in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
3136243|NCT01644526|Experimental|Hemoaccess Valve System|Valve system for use with AV graft
3136244|NCT01644513||Positive Responders|Have received at least one injection with no evidence of residual subretinal or intra-retinal fluid present on Spectral Domain Optical Coherence Tomography (SDOCT) one month (+/- 1 week) following most recent injection.
3136245|NCT01644513||Suboptimal Responders|Have received three or more injections in last six months with residual subretinal or intra-retinal fluid present on SDOCT one month (+/- 1 week) following most recent injection; Have not demonstrated complete resolution of fluid following any of the injections in the last 6 months Show leakage on Fluorescein Angiography (FA) or Indocyanine Green (ICG) imaging at some time during last 12 months
3136246|NCT01644500|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
3136247|NCT01644500|Experimental|0.75 mg Dulaglutide|0.75 mg dulaglutide administered as one SC injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
3136248|NCT01644500|Active Comparator|Glimepiride|1 to 3 mg per day (mg/day) glimepiride administered orally as one to three capsules per day plus one SC injection of placebo once-weekly for blinding purposes for up to 26 weeks.
3136249|NCT01644487|Experimental|Primary stenting|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
3136250|NCT01644487|Active Comparator|Balloon only|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
3136251|NCT01644474|Active Comparator|Ezetimibe 10 mg|Oral ezetimibe 10 mg capsule daily and subcutaneous (SC) placebo injection for alirocumab every 2 weeks (Q2W) for 24 weeks.
3136252|NCT01644474|Experimental|Alirocumab 75/Up to 150 mg Q2W|SC injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe daily for 24 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
3136253|NCT01644461|Other|Study Group|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
3136254|NCT01644448|Other|Study arm A|Subjects will receive one dose of 5 ml of Autologous Human Platelet Lysate with simultaneous micro-needling on day 2
3136255|NCT01644448|Other|Control Arm B|Topical Applications of the standard therapy as directed by the investigator
3136256|NCT01644435|Other|Study arm A|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
3136257|NCT01644435|Other|Study arm B|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring.
3136258|NCT01644422|Other|Study arm A|Subjects will receive hair follicles transplants that are dipped in HPL before transplant
3136259|NCT01644422|Other|Study arm B|Subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection one week after transplant
3136260|NCT01644422|Other|Control arm C|Subject will receive Standard hair follicle transplant
3136261|NCT01644396|Other|Adalimumab|Participants received an initial adalimumab 80 mg subcutaneous dose, followed by adalimumab 40 mg subcutaneous every other week starting one week after the initial dose for up to 24 weeks.
3136262|NCT01644383|Experimental|Treatment arm (logotherapy)|Participants in Arm I will attend the logotherapy group sessions by the trained psychologist for 4 visits (see Table II, III). The number of participants in group sessions will be 20 participants per group.
3136263|NCT01644383|No Intervention|Control arm (general health education)|Participants in Arm II will attend the routine health education by the nurse. The number of participants in group session will be 20 participants per group.
3136264|NCT01644370|Other|HIV positive with aeroallergen|positive for aeroallergen at baseline
3136265|NCT01644370|Other|HIV positive without aeroallergen|negative for aeroallergen at baseline
3136266|NCT01644370|No Intervention|control|HIV negative children (n=10)
3136267|NCT01644357|No Intervention|Dispensing only|Non clinical pharmacists will dispense drugs to patients and usual care will be offered.
3136268|NCT01644357|Experimental|Pharmaceutical care|Patients on experimental group will receive counseling and education on the asthma condition, medication and lifestyle issues. In all visits, the inhaler technique will be reviewed, adherence to treatment and drug related problems were checked. If necessary the patient will be referred to the respiratory specialist to change the medication or to prescribe dose adjustment. Pharmacists document their initial and monthly follow up encounters using a specified form.
3136269|NCT01644344|Active Comparator|X-ray|Control group: patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks. Each time radiographs are completed, the surgeon or resident will document if a change in fixation position is noted and if a change in patient management will be entertained (addition, modification or maintenance of cast or splint use, modification of or decision not to advance activity level, need for further surgery to adjust fixation or fracture reduction). The patients' time spent in clinic will be recorded upon arrival and upon completion of the patient-physician interaction.
3136270|NCT01644344|Active Comparator|No X-ray|
3136271|NCT01644331|Experimental|Tolvaptan|Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral Tolvaptan (given at 0, 24 and 48 hours)
3136272|NCT01644331|Placebo Comparator|Placebo|Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral placebo (given at 0, 24 and 48 hours)
3136273|NCT01644318||authoimmıne thyroiditis and habitual abortus|
3136274|NCT01644318||authoimmune thyroiditis|
3136275|NCT01644318||healthy controls|
3136276|NCT01644305||Polycystic Ovary Syndrome|
3136277|NCT01644305||Idiopathic hirsutism|
3136278|NCT01644305||Control|
3136279|NCT01644292|Experimental|EPIC Wheels Training Intervention|EPIC Wheels skills training program
3136280|NCT01644279||Young|Young (age 20-35 years old)
3136281|NCT01644279||Old high-functioning|Old high-functioning (age 70-99 years old)
3136282|NCT01644279||Old low-functioning|Old low-functioning (age 70-99 years old)
3136283|NCT01644253|Experimental|Cohort 1 - Previously Untreated CLL|20 mg/kg TRU-016 + Rituximab
3136284|NCT01644253|Experimental|Cohort 2 - Relapsed CLL|20 mg/kg TRU-016 + Rituximab
3136285|NCT01644253|Experimental|Cohort 3 - Previously Untreated CLL|10 mg/kg TRU-016 + Rituximab
3136286|NCT01644253|Experimental|Cohort 4 - Previously Untreated CLL|20 mg/kg TRU-016 20 + Obinutuzumab
3136287|NCT01644253|Experimental|Cohort 5 - Relapse CLL|20 mg/kg TRU-016 + idelalisib + rituximab
3136288|NCT01644253|Experimental|Cohort 6 - With CLL on ibrutinib with no complete response|20 mg/kg TRU-016 + ibrutinib
3136289|NCT01644253|Experimental|Cohort 7 - With CLL on ibrutinib with stable disease|20 mg/kg TRU-016 + ibrutinib
3136290|NCT01644253|Experimental|Cohort 8 - With relapsed or refractory PTCL|20 mg/kg TRU-016 + 90 mg/m2 bendamustine
3136291|NCT01644240|Experimental|TD-8954 Dose 1|
3136292|NCT01644240|Placebo Comparator|Placebo|
3136293|NCT01644240|Experimental|TD-8954 Dose 2|
3136294|NCT01644214|No Intervention|Pessary Check at 3 months|Patients seen at 3 month intervals for pessary check-ups is the most common interval check in our clinic so this arm is considered the control group.
3136295|NCT01644214|Experimental|6 month Pessary Check|Those that will be seen at 6 month follow-up visits for pessary maintenance will be considered the experimental group of the study.
3136296|NCT01644201|Active Comparator|High viscosity non-starch polysaccharide, PolyGlycopleX®-PGX®|
3136297|NCT01644201|Placebo Comparator|Placebo (Rice Flour)|
3136298|NCT01644188|Experimental|Alirocumab 75 /up to 150 mg Q2W|Alirocumab 75 mg every 2 weeks (Q2W) and oral placebo capsule for ezetimibe daily added to stable Lipid Modifying Therapy (LMT) for 104 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C level ≥70 mg/dL (1.81 mmol/L) at Week 8.
3136743|NCT01641185|Experimental|protons|irradiation 20 x 3,3 GyE protons
3136299|NCT01644188|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10 mg capsule daily and subcutaneous placebo for alirocumab Q2W added to stable LMT for 104 weeks.
3136300|NCT01644175|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 52 weeks.
3136301|NCT01644175|Experimental|Alirocumab|Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
3136302|NCT01644162|Other|iVAPS ventilation|3 months of ventilator use in iVAPS mode with data monitoring
3136303|NCT01644149|Experimental|Stratis Jet Injector|Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using the Stratis Jet Injector
3136304|NCT01644149|Active Comparator|Needle and Syringe|Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using Needle and Syringe
3136305|NCT01644136|Experimental|Supportive care (microsphere-mediated lymphocele prevention)|Patients undergo standard robotic assisted laparoscopic prostatectomy with pelvic lymph node dissection. After lymph node dissection, patients undergo microsphere-mediated lymphocele prevention to the lymph node basin on one side of the pelvis.
3136306|NCT01644123||Nursing home residents|
3136307|NCT01644110|Experimental|ruxolitinib/pomalidomide|ruxolitinib treatment will be started at 10 mg twice daily, whereas the dose of pomalidomide will be 0.5 mg once daily.
3136308|NCT01644097|Experimental|Arm I (probiotic mix)|Patients receive a mixture of Lactobacillus plantarum strain 299v, Bifidobacterium lactis probiotic supplement, and Lactobacillus acidophilus probiotic PO BID for 9 weeks. Treatment continues in the absence of unacceptable toxicity.
3136309|NCT01644097|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID 9 weeks. Treatment continues in the absence of unacceptable toxicity.
3136310|NCT01644084|Experimental|HA (priming)-HES (up to 15 ml/kg after CPB)|
3136311|NCT01644084|Active Comparator|HES (priming)-HES (up to 15 ml/kg after CPB)|
3136312|NCT01644084|Active Comparator|HA (priming)-nonHES (only crystalloids after CPB)|
3136313|NCT01644071|Experimental|arm 1|application of three treatments and three masurements within 3 weeks
3136314|NCT01644058|Experimental|Immediate loading|Immediate loading of 2 endo-osseous mandibular implants
3136315|NCT01644045|Experimental|Device: Teleconsultation|"In cases of acute obstructive, respiratory emergencies if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician who has an audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures (taken with a smartphone), 12-lead-ECGs and video streaming from the inside of the ambulance can also be carried out, if indicated. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
3136316|NCT01644032|Experimental|Device_ Teleconsultation|"Six ambulances from five different Emergency Medical Service (EMS) districts are equipped with a portable telemedicine system. In cases of emergencies, where intravenous analgesia is necessary, if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with an audio-connection to the EMS team who receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team and can delegate the application of morphine and other analgesics. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene.~The safety, efficacy and the quality of analgesia should be compared with regular EMS."
3136317|NCT01644032|No Intervention|Historical Control Period|After completion of the study arm, matched pairs from a historical phase (without the ability of teleconsultation) were searched. Local cases were always matched with comparable controls from the same location.
3136318|NCT01644019|Experimental|Device: Teleconsultation|"In cases of suspected acute stroke (including intracranial hemorrhage), if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician who has an audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures (taken with a smartphone), 12-lead-ECGs and video streaming from the inside of the ambulance can also be carried out, if indicated. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, neurological diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
3136319|NCT01644006|Experimental|Device: Teleconsultation|"In cases of suspected acute coronary syndrome (including STEMI), if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. Also 12-lead-ECGs can be transmitted to the tele-EMS physician. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, ECG diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene.~The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
3136320|NCT01644006|No Intervention|Historical Matched Pairs|Historical matched pairs were searched from local protocols. During this phase no teleconsultation system was existent.
3136321|NCT01643993|Experimental|hCG at Time of Embryo Transfer|Patients will have hCG and media (for a total of 20 microliters) inserted during a mock embryo transfer immediately prior to actual embryo transfer.
3136322|NCT01643993|Other|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
3136323|NCT01643980|Experimental|Vaginal micronized progesterone|200 mg vaginal route per day
3136324|NCT01643980|Active Comparator|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
3136325|NCT01643967|Experimental|Ozone therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
3136326|NCT01643967|Active Comparator|sunflower oil|"The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.~Other Names:~Sunflower oil"
3136327|NCT01643954|No Intervention|Arm A|Patients with prostate cancer who have undergone robotic radical prostatectomy at The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University Medical Center.
3136328|NCT01643954|Other|Arm B|Patients with prostate cancer that will undergo robotic radical prostatectomy at The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University Medical Center .
3136329|NCT01643941|Experimental|1|SA4Ag vaccine low dose
3136330|NCT01643941|Experimental|2|SA4Ag vaccine mid dose
3136331|NCT01643941|Experimental|3|SA4Ag vaccine high dose
3136332|NCT01643941|Experimental|4|SA3Ag vaccine
3136333|NCT01643941|Placebo Comparator|5|Placebo
3136334|NCT01643928|Experimental|Rituximab-Pfizer|
3136335|NCT01643928|Active Comparator|Rituximab-EU+Rituximab-Pfizer|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses.
3136336|NCT01643928|Active Comparator|Rituximab-US+Rituximab-Pfizer|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses.
3136337|NCT01643915|Active Comparator|Control group|Patients with conventional treatment. No distraction method during the treatment visits.
3136338|NCT01643915|Experimental|Experimental group 1|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
3136339|NCT01643915|Experimental|Experimental group 2|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
3136340|NCT01643902|Experimental|IV tPA|Treatment will be initiated within 4.5 hours of awakening, for patients who meet inclusion criteria
3136341|NCT01643889|Experimental|Sequence group ADBC|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
3136342|NCT01643889|Experimental|Sequence group BACD|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
3136343|NCT01643889|Experimental|Sequence group CBDA|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
3136344|NCT01643889|Experimental|Sequence group DCAB|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
3136345|NCT01643876|Experimental|Palatal brushing|Palatal brushing after each meal for 3 months.
3136346|NCT01643863||Cohort|
3136347|NCT01643850|Experimental|MCS110|Participants will receive a single dose of 10mg/kg on day 1 administered by regular infusion.
3136348|NCT01643850|Placebo Comparator|Placebo|"In the single dose Part A of the study patients were to receive 1 dose of placebo administered i.v. on Day 1.~In the multiple dose Part B, patients receive placebo infusion administered i.v. at Day 1 followed by up to 6 doses of MCS110 (10 mg/kg)."
3136349|NCT01643837|No Intervention|Standard|Standard treatment follow-up: 1. monthly history 2. monthly clinical breast examination.
3136350|NCT01643837|Sham Comparator|Light Touch (LT)|"Standard treatment follow-up: 1. monthly history 2. monthly clinical breast examination.~Light touch protocol."
3136351|NCT01643837|Experimental|Osteopathic Manipulative Treatment (OMT)|"Standard treatment follow-up: 1. monthly history 2. monthly clinical breast examination.~OMT Protocol."
3136352|NCT01643824|Experimental|Proton Beam Therapy|"Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 <40%, and/or RLV30 <30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30<50% and RLV30<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30<60%, and/or RLV30<50%~Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
3136353|NCT01643811||Gastrectomy|Patients who underwent gastrectomy for early gastric cancer
3136354|NCT01643811||Endoscopic submucosal dissection|Patients who underwent endoscopic submucosal dissection for early gastric cancer
3136355|NCT01643798|Placebo Comparator|Saline|Participants received intravenous saline immediately prior to sham and real rTMS of the left dorsolateral prefrontal cortex. The parameters of the stimulation paradigm are as follows: 10 Hz, 5 seconds on, 10 seconds off, 20 minutes, 4000 pulses).
3136356|NCT01643798|Active Comparator|Naloxone|Participants received intravenous naloxone (0.1mg/kg) immediately prior to sham and real rTMS of the left dorsolateral prefrontal cortex. The parameters of the stimulation paradigm are as follows: 10 Hz, 5 seconds on, 10 seconds off, 20 minutes, 4000 pulses).
3136357|NCT01643785|Experimental|with Endonase|Second-line quadruple therapy [PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg) Bid, tetracycline 500 mg QID, metronidazole 500mg Tid, tripotassium dicitrate bismuthate 300mg QID] plus 20,000 units of pronase (endonase), BID for 7 days
3136358|NCT01643785|No Intervention|without Endonase|Second-line quadruple therapy [PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg) Bid, tetracycline 500 mg QID, metronidazole 500mg Tid, tripotassium dicitrate bismuthate 300mg QID] for 7 days
3136359|NCT01643772|Experimental|OxyNorm® Capsules|
3136360|NCT01643759|Experimental|buprenorphine transdermal system|buprenorphine transdermal system
3136361|NCT01643746|Active Comparator|Supera stent|The Supera stent is a novel interwoven nitinol stent design with high flexibility and radial strength. The radial force of the Supera stent is 4 times higher than comparable nitinol stent.
3136362|NCT01643746|Active Comparator|LifeStent|LifeStent is likely the best reference nitinol stent for comparison because a low restenosis rate has been reported at 1 year with low target revascularization.
3136363|NCT01643733|Experimental|Transonics Arm|Intervention will be guided by flow through the fistula as guided by Transonics flow measurements
3136364|NCT01643733|No Intervention|Control arm|Patient will undergo normal fistula intervention guided only by angiographic assessment
3136365|NCT01643720||Autism Spectrum Disorders|Children with Autism Disorders and their parents
3136366|NCT01643720||Typically Developing|Typically Developing children and their parents
3136367|NCT01643707||Phase I|Control
3136368|NCT01643707||Phase II|Treatment
3136369|NCT01643694|Experimental|Electronic intervention|Completion of 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks
3136370|NCT01643694|No Intervention|control group|Completion of baseline and 3 mo survey
3136371|NCT01643681|Experimental|AdMSC|Autologous Adipose Tissue derived Mesenchymal Stem Cells
3136372|NCT01643668|Experimental|BuClo RIC + SCT|Busulfan and Clofarabine (BuClo) reduced intensity conditioning (RIC) followed by allogeneic stem cell Transplantation (SCT)
3136373|NCT01643655|Experimental|Autologous Adipose Tissue Derived MSCs|
3136374|NCT01643642|Experimental|Cognitive behavioral treatment/farmacotherapy intervention|Brief intervention; intake, cognitive behavioral treatment/farmacotherapy (SSRI) and ROM
3136375|NCT01643642|Other|Treatment As Usual|Control group, TAU
3136376|NCT01643629|Other|Study arm A|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
3136377|NCT01643629|Other|Control Arm B|Control arm B will include subjects receiving Standard therapy
3136378|NCT01643616|Active Comparator|group US|"Ultrasound guided block :~20ml Prilocaine 1% and 10ml Ropivacaine 0.75% (30ml Prilocaine 1% in outpatients)"
3136379|NCT01643616|Active Comparator|group NS|"Nerve stimulation technique:~20ml Prilocaine 1% and 10ml Ropivacaine 0.75% (30ml Prilocaine 1% in outpatients)"
3136380|NCT01643603|Experimental|Dasatinib|This is a phase 1 dose escalation study, using a standard 3+3 design. Dasatinib is administered orally once daily in the outpatient setting. Patients who are day 100-180 post transplant will be eligible. The treatment will be started as close to day 100 as possible. The range of days is provided to ensure that patients have recovered from toxicities associated with ASCT and are not deemed ineligible if they were recovering from any toxicity associated with ASCT at day 100.The starting dose of dasatinib is 20 mg daily. The increment of dose escalation is 20 mg per dose level. Thus, there will be 5 dose levels (20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively) with 3 patients in each cohort. Patients will continue on dasatinib for 6 months.
3136381|NCT01643590|Placebo Comparator|Placebo|
3136382|NCT01643590|Experimental|15 mg dose of JVS-100|15 mg dose of JVS-100
3136383|NCT01643590|Experimental|30 mg dose of JVS-100|30 mg dose of JVS-100
3136384|NCT01643577|Active Comparator|Acupuncture protocol for gastroparesis|Patients randomized to this arm will receive an acupuncture protocol that with points designed to treat gastroparesis
3136385|NCT01643577|Placebo Comparator|Acupuncture for musculoskeletal pain|Patients randomized to this arm will receive acupuncture therapy consisting of points designed to treat musculoskeletal pain.
3136386|NCT01643564||Group 1|Heart Transplant Recipients with Unexplained Graft Dysfunction
3136387|NCT01643564||Group 2|Normal Control
3136388|NCT01643564||Group 3|Class III-IV Heart Failure
3136389|NCT01643564||Group 4|Heart Transplant Recipients with Normal Graft Function
3136390|NCT01643551||LVAD Group|18 years and older Planning to undergo VAD implantation
3136391|NCT01643551||Cardiac Surgery Group|18 years or older Planning to undergo valve or coronary bypass surgery
3136392|NCT01643538|Active Comparator|Control Arm|"Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects in the Control Group will only receive pedometers and weekly feedback on their performance through the same mechanisms and with the same frequency as participants in the other three study arms. There will be no financial incentives or charity donations in this group."
3136393|NCT01643538|Experimental|Personal Financial Incentives Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will receive $20. Financial incentive is terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
3136394|NCT01643538|Experimental|Social Goals Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week participants will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity. Charity donation is terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
3136395|NCT01643538|Experimental|Combined Financial Incentives & Social Goals Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will receive money and/or be notified that a donation of the selected amount has been sent to the charity, depending on their selected preference. Incentives are terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
3136396|NCT01643525|Other|Nautilus NeuroWave Recording Arm|Nautilus NeuroWaveTM System
3136397|NCT01643499|Experimental|Treatment (mFOLFIRINOX)|Patients receive oxaliplatin IV over 2 hours on, irinotecan hydrochloride IV over 1.5 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3136398|NCT01643486|Experimental|iTouch phosphate counting program|All patients will have an iTouch that will help them to calculate the required number of phosphate binders to be taken with each meal
3260737|NCT00763724||4|TCA
3136399|NCT01643486|Active Comparator|Usual Care|Participants in the active comparator group will document their meals in the iTouch but continue to take their phosphate binders as prescribed by their MD/dietician
3136400|NCT01643473|No Intervention|Usual Care|Standard care as provided by primary care physician.
3136401|NCT01643473|Experimental|Adherence Intervention|9 adherence counseling sessions with a health coach
3136402|NCT01643460|Experimental|98% Ethanol with Paclitaxel injection|
3136403|NCT01643447|Active Comparator|Diammonium glycyrrhizinate|Conventional drugs protect liver
3136404|NCT01643447|Experimental|Ulinastatin|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
3136405|NCT01643434|Active Comparator|Spironolactone|
3136406|NCT01643434|Active Comparator|Clonidine|
3136407|NCT01643421|Experimental|Deep inspiration and expiratory positive airway pressure|The protocol of deep inspiration combined to expiratory positive airway pressure will be applied in asthmatic subjects.
3136408|NCT01643421|No Intervention|Control|
3136409|NCT01643408|No Intervention|Treatment|Route of administration
3136410|NCT01643395|Experimental|vertebroplasty|
3136411|NCT01643395|Other|conservative therapy (brace)|
3136412|NCT01643382|Experimental|Tight glucose control|Patients randomized to the tight glucose control arm will be placed on an insulin infusion, or continuous low dose insulin drip.
3136413|NCT01643382|Active Comparator|Standard glucose control|Patients randomized to the standard glucose control group will be given subcutaneous doses of insulin every few hours based on their blood sugar.
3136414|NCT01643369|Experimental|Compassion Meditation Group|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
3136415|NCT01643369|Active Comparator|Health Education and Wellness Group|Eight week training in health and wellness, using a curriculum developed specifically for this study.
3136416|NCT01643369|Experimental|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
3136417|NCT01643356|Active Comparator|Fiber Cereal|Women assigned to this arm will receive the group based behavioral intervention plus the recommendation to consume provided high fiber cereal to manage hunger.
3136418|NCT01643356|No Intervention|Control Group|Women assigned to this arm of the study will receive routine clinical care and no additional interventions.
3136419|NCT01643356|Active Comparator|Resistant Starch|Women assigned to this arm will receive the group based behavioral intervention plus the recommendation to consume provided resistant starch to control hunger
3136420|NCT01643343||Typically Developing|Typically developing toddler volunteers between the ages of 8 months and 3 years
3136421|NCT01643343||Autism|Children between the ages of 8 months and 6 years with a diagnosis of an autism spectrum disorder
3136422|NCT01643330|Experimental|AAV1/SERCA2a (MYDICAR)|Intracoronary infusion
3136423|NCT01643330|Placebo Comparator|Placebo|Intracoronary infusion
3136424|NCT01643304||Group 1|
3136425|NCT01643291|Experimental|Ultrasound|
3136426|NCT01643278|Experimental|Treatment (dasatinib and ipilimumab)|Patients receive dasatinib PO QD for 7 days. Patients then receive dasatinib PO QD and ipilimumab IV once on weeks 1, 4, 7 and 10. Beginning on week 24, patients then receive dasatinib PO QD and ipilimumab IV once every 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3136427|NCT01643265|Active Comparator|Whey Milk Protein|
3136428|NCT01643265|Experimental|Bovine Albumin Concentrate|
3136429|NCT01643252|Placebo Comparator|Placebo and UVA light exposure|
3136430|NCT01643252|Active Comparator|Riboflavin drops and UVA light exposure|
3136431|NCT01643239|Experimental|Hospital-based mCIT with individualized intervention|Hospital-based modified constraint-induced therapy(mCIT)
3136432|NCT01643239|Experimental|Hospital-based mCIT with group therapy|Hospital-based modified constraint-induced therapy(mCIT)
3136433|NCT01643239|Other|Hospital-based TR|Hospital-based traditional rehabilitation (TR)
3136434|NCT01643226|Experimental|riboflavin solution and KXL System|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by UVA irradiation for 4 minutes
3136435|NCT01643226|Placebo Comparator|placebo solution and KXL System|Subjects will receive 0.0% riboflavin ophthalmic solution (Placebo) followed by UVA Irradiation for 4 minutes
3136436|NCT01643213|Experimental|BSC approved SCS Trial Therapy w/ OMG|Precision Plus SCS Trial Therapy w/ OMG. Spinal cord stimulation (SCS) trial therapy activated using FDA-approved BSC SCS trial systems with the Observational Mechanical Gateway(OMG) to connect to non-BSC lead(s)
3136437|NCT01643213|Active Comparator|Non Boston Scientific SCS Trial Therapy|Non Boston Scientific SCS Trial Therapy. Spinal cord stimulation (SCS) trial therapy activated using FDA-approved non BSC SCS system that the subject was implanted with, and received SCS therapy from, prior to study enrollment
3136438|NCT01643200|Experimental|Zotarolimus-Eluting Peripheral Stent|Zotarolimus-Eluting Peripheral Stent System
3136439|NCT01643187|Experimental|Fortified beverage|A group of children with some degree of malnourishment considered by a Z-score < -1 for weight for height, height for age or weight for age.
3136440|NCT01643187|Active Comparator|Group receiving lactose-free milk|A group of children with some degree of malnourishment considered by a Z-score < -1 for weight for height, height for age or weight for age.
3136441|NCT01643174||Surgical treatment|
3136442|NCT01643161|Experimental|TAU+GSH|Treatment As Usual plus Guided Self Help.
3136443|NCT01643161|Active Comparator|TAU|Treatment AS Usual.
3136444|NCT01643148||breast cancer patients (cases)|36 subjects
3136445|NCT01643148||controls|36 subjects
3136446|NCT01643135|Active Comparator|tranexamic acid|Tranexamic acid (15 mg/kg in 0.9% NaCl and the total volume is 100 ml) will given before induction and the second dose(15 mg/kg in 0.9% NaCl and the total volume is 100 ml) will be given at 3 hours after the first dose.
3136447|NCT01643135|Placebo Comparator|0.9% NaCl|0.9% NaCl 100 ml will be given as a placebo before induction and 3 hours after the first dose
3136448|NCT01643122||Group 1|
3136449|NCT01643122||Group 2|
3136494|NCT01642849|Experimental|high protein diet|12 subjects will be place on a high protein diet
3136495|NCT01642849|Experimental|high carbohydrate diet|12 subjects will be put on a high carbohydrate diet for 6 months
3136450|NCT01643109|Experimental|CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
3136451|NCT01643109|No Intervention|Comparison|Standard therapy.
3136452|NCT01643096|Other|sumac|Thermic effect of food of Sumac and comparison between hot and cold temperament people
3136453|NCT01643096|Other|Zataria multiflora Boiss|Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
3136454|NCT01643083|Active Comparator|Rifaximin|
3136455|NCT01643083|Placebo Comparator|Placebo|
3136456|NCT01643070|Active Comparator|XELOX RT|Concurrent XELOX-RT
3136457|NCT01643070|Active Comparator|Induction XELOX|Induction XELOX followed by XELOX-RT
3136458|NCT01643057||Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
3136459|NCT01643044|Experimental|Alcohol intervention|Participants in this condition review tailored videos and normed feedback regarding their alcohol use and possible consequences of drinking. Next participants view a goal setting section describing possible ways to quit drinking alcohol and the participant is able to indicate a change goal (if any) and is helped through a specific change plan, should they set a change goal.
3136460|NCT01643044|Placebo Comparator|Control|Participants randomized into the control condition complete assessment and a time-matched interactive session on infant nutrition.
3136461|NCT01643031|Experimental|Ticagrelor|Patients randomized to the ticagrelor group will receive ticagrelor at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient will be invited to a special research clinic in the hospital and his treatment will be switched back to clopidogrel (to complete 1 year of treatment).
3136462|NCT01643031|Active Comparator|Continued Clopidogrel|Patients randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
3136463|NCT01643018|Experimental|laparoscopic surgery|-Laparoscopic surgery group describes the patients treated with laparoscopic surgery
3136464|NCT01643018|Active Comparator|Open Surgery|-open surgery group describes the patients treated with traditional open surgery
3136465|NCT01643005|Active Comparator|Active Control Group|For the active control group we will use Nurturing Parenting Groups currently being run by the community collaborator.
3136466|NCT01643005|Experimental|Relationship Strengthening HIV Prevent.|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
3136467|NCT01642992||Coronary bifurcation lesion|
3136468|NCT01642979|Experimental|Levamisole+cyclosporin A+Glucocorticoids|Levamisole+cyclosporin A+Glucocorticoids
3136469|NCT01642979|Active Comparator|cyclosporin A+Glucocorticoids|cyclosporin A+Glucocorticoids
3136470|NCT01642979|Active Comparator|Glucocorticoids|Glucocorticoids
3136471|NCT01642966|Active Comparator|Prasugrel|Prasugrel 10mg/day for 15 days
3136472|NCT01642966|Experimental|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
3136473|NCT01642953|Experimental|Early recovery|"Patients who enroll in this arm are supplied a liquid diet one day before surgery without bowel preparation.~After gastric cancer surgery, they start sips of water on postoperative first day, and they are discharged once they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination."
3136474|NCT01642940|Active Comparator|Prasugrel|
3136475|NCT01642940|Experimental|Ticagrelor|
3136476|NCT01642927||Intra-Aortic Balloon Pump (IABP) Group|Advanced Heart Failure and/or pre-LVAD surgical patient with IABP
3136477|NCT01642927||IABP/LVAD Group|Post-LVAD surgical patients with IABP
3136478|NCT01642927||Post-LVAD Group|LVAD patients 3 months or greater post-implantation undergoing echocardiography
3136479|NCT01642927||LVAD Event Group|LVAD patients who have developed LVAD thrombosis or GI hemorrhage related to LVAD
3136480|NCT01642927||Arrhythmia group|LVAD patient with an irregular heartbeat.
3136481|NCT01642927||Valvular disease group|LVAD patient with valvular heart disease
3136482|NCT01642927||Normal control group|Healthy participant without any known heart disease (Control group).
3136483|NCT01642914|Experimental|Linaclotide 290 micrograms|Linaclotide 290 micrograms
3136484|NCT01642914|Experimental|Linaclotide 145 Micrograms|Linaclotide 145 micrograms
3136485|NCT01642914|Placebo Comparator|Placebo|Matching placebo
3136486|NCT01642901|Experimental|Zoledronic Acid 5 mg IV infusion|Single infusion of 5 mg intravenous zoledronic acid given within 21 days of acute traumatic spinal cord injury.
3136487|NCT01642901|Placebo Comparator|normal saline 0.9%|Infusion of normal saline of equivalent volume to reconstituted zoledronic acid, given only once and run over 2 hours, to occur within 21 days of acute traumatic spinal cord injury.
3136488|NCT01642888|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
3136489|NCT01642888|Active Comparator|2 T.U. Tuberculin PPD RT 23 SSI|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
3136490|NCT01642875|Experimental|EN|early enteral nutrition with standard enteral formulas administered through a nasojejunal tube
3136491|NCT01642875|Active Comparator|PerOs|early oral nutrition with hospital diets and oral formulas
3136492|NCT01642862|Experimental|Liquid formulation of Simvastatin|
3136496|NCT01642836|Experimental|multi-component, multi-level, multi-setting (MMM)|"a theory-based community team sports program designed specifically for overweight and obese children,~a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and~a primary care provider behavioral counseling intervention linked to the community and home interventions."
3136497|NCT01642836|Active Comparator|Health and Nutrition Education|"Enhanced standard care/health and nutrition education intervention:~notification of primary care providers about metabolic measures and blood pressure~state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights"
3136498|NCT01642823||retinablastoma tumor tissue|
3136499|NCT01642810|Active Comparator|Treatment-as-usual|Participants continue their pre-study treatment plan, based on their physician/other professional recommendations
3136500|NCT01642810|Experimental|Online ABBT treatment + TAU|Participants to complete a 6-unit online Acceptance-based behavioural treatment including training in pacing, mindfulness, acceptance, cognitive defusion, willingness, and exercise while also maintaining their pre-study treatment.
3136501|NCT01642797|Experimental|CLE-TB|Confocal laser endomicroscopy with Targeted Biopsy
3136502|NCT01642797|Experimental|WLE-SB|Standard White-light endoscopy with Standard Biopsy
3136503|NCT01642784||Culprit lesion IRA revascularization|Culprit lesion IRA revascularization
3136504|NCT01642784||Complete IRA revascularization|Complete IRA revascularization
3136505|NCT01642771|Active Comparator|5-Fu/epirubicin/CTX following Docetaxel|Docetaxel for the first 3 cycles of chemotherapy followed by 3 cycles of FEC (Fluorouracil, epirubicin and cyclophosphamide) chemotherapy
3136506|NCT01642771|Experimental|Docetaxel/capecitabine followed by XEC|Docetaxel/ capecitabine (TX) for the first 3 cycles of chemotherapy followed by 3 cycles of capecitabine/epirubicin/cyclophosphamide (XEC) chemotherapy
3136507|NCT01642758|Experimental|Sodium 2,2 dimethylbutyrate|A single dose (20 mg/kg/day) of study drug will be taken once per day by mouth.
3136508|NCT01642745|Experimental|Methacholine (Provocholine) with deep inhalation|
3136509|NCT01642745|Experimental|Mannitol (Aridol)|
3136510|NCT01642745|Active Comparator|Methacholine (Provocholine) tidal breathing|
3136511|NCT01642732|Experimental|Everolimus with combined hormonal and radiation therapy|"Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.~Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).~Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.~Lupron injections will begin on study day 10 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.~Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study."
3136512|NCT01642719|Placebo Comparator|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline
3136513|NCT01642719|Experimental|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks. For example, if they spend 9 hr TIB during baseline, they will reduce their TIB to 8 hr.
3136514|NCT01642706||RA patients|Patients affected by Rheumatoid arthritis.
3136515|NCT01642706||Control|Subjects affected by mechanical pathologies.
3136516|NCT01642693|Experimental|Teeth with intrusive movement and low power laser|Histological changes and root resorption were assesed in Teeth with intrusive movement after a low power laser application
3136517|NCT01642693|Experimental|Teeth with intrusive movements with no laser|Histological changes and root resorption in Teeth with intrusive movements with no laser
3136518|NCT01642680|Experimental|Physical activity during chemotherapy|This group will start with a physical activity program 3 months before the end of their chemotherapeutic regimen. After chemotherapy they will continue the PA program for another 3 months.
3136519|NCT01642680|Active Comparator|Physical activity after chemotherapy|This group will start with a physical activity program after the end of their chemotherapeutic regimen. The physical activity program wil take 6 months to complete.
3136520|NCT01642667|Placebo Comparator|primary PCI|
3136521|NCT01642667|Active Comparator|prouk-PCI|
3136522|NCT01642654|Active Comparator|Control|
3136523|NCT01642654|Experimental|Treatment|
3136524|NCT01642641|Active Comparator|Non-surgical subgingival debridement|
3136525|NCT01642641|Active Comparator|Simplified Papilla Preservation Flap|
3136526|NCT01642641|Active Comparator|Resective Flap with Osseous Recontouring|
3136527|NCT01642628|Experimental|Body Image/Mirror Education|Participants in the mirror arm will receive a mirror and mirror viewing education from oncology nurse navigators.
3136528|NCT01642628|No Intervention|Standard Care|Patients allocated to the control group will receive the usual pre and post-op standard care that does not include the use or discussion of mirrors.
3136529|NCT01642615|Experimental|Healing Phase: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg delayed-release capsules, orally, once daily for up to 8 weeks.
3136530|NCT01642615|Experimental|Maintenance Phase: Dexlansoprazole 30 mg|Participants who are healed at Week 8 will be randomized to receive 30 mg dexlansoprazole delayed-release capsules, orally, once daily for up to 16 weeks.
3136531|NCT01642615|Experimental|Maintenance Phase: Placebo|Participants who are healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 16 weeks.
3136532|NCT01642602|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg delayed-release capsules orally once daily for up to 4 weeks.
3136533|NCT01642589|Experimental|Menactra® Group|Participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)
3136601|NCT01642134|Sham Comparator|acenocumarol|
3264010|NCT00740155|Experimental|Group 1|
3136534|NCT01642589|Active Comparator|Tdap - Adacel® Group|Participants will receive Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap - Adacel®)
3136535|NCT01642576|Experimental|diet modification|counselling on caloric restriction and healthy eating
3136536|NCT01642576|Experimental|weight management program|dietician and sports trainer, physician counselling on weight loss
3136537|NCT01642563|Experimental|Pathogen reduced platelets|Transfusion
3136538|NCT01642563|Active Comparator|Standard platelets|Transfusion
3136539|NCT01642550|Active Comparator|RM-131|Active study drug - RM-131
3136540|NCT01642550|Placebo Comparator|Placebo|Placebo comparator
3136541|NCT01642537|Other|Rhythmia Mapping System & Catheter|This is a single arm diagnostic feasibility study with the Rhythmia Mapping System and the Rhythmia Mapping Catheter
3136542|NCT01642524|Experimental|hypertonic saline mixed Dextran|hypertonic saline mixed Dextran
3136543|NCT01642524|Placebo Comparator|Placebo controlled|Saline solution
3136544|NCT01642511|Active Comparator|Control Group|conventional technique: 99mTc-labeled Sulfur Colloid was injected into the tumor quadrant 3-24 hours before surgery, lymphoscintigraphy was performed 30min before surgery. Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery. Axillary sentinel lymph node biopsy and Internal mammary sentinel lymph node biopsy was performed during surgery. Axillary lymph node dissection was performed if ASLN was positive.
3136545|NCT01642511|Experimental|Study Group|modified technique: 99mTc-labeled Sulfur Colloid was injected into 2 quadrants of the breast 3-24 hours before surgery, lymphoscintigraphy was performed 30min before surgery. Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery. Axillary sentinel lymph node biopsy and Internal mammary sentinel lymph node biopsy was performed during surgery. Axillary lymph node dissection was performed if ASLN was positive.
3136546|NCT01642498|Experimental|Group A|ROX Coupler + continuing standard antihypertensive medications
3136547|NCT01642498|No Intervention|Group B|Continuing standard antihypertensive medications
3136548|NCT01642485|Active Comparator|Moxifloxacin 400 mg fasted|Moxifloxacin 400 mg fasted was administered on Day 3. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo. Additionally, Caucasian vs Japanese subjects were analysed.
3136549|NCT01642485|Experimental|Moxifloxacin 400 mg fed|"Moxifloxacin 400 mg fed was administered on Day 3 after Continental breakfast. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo.~Additionally, Caucasian vs Japanese subjects were analysed."
3136550|NCT01642472|Experimental|Ulipristal Acetate (PGL4001) 10mg|Ulipristal Acetate (PGL4001)10mg daily administration
3136551|NCT01642459|Experimental|Same direction cannulation|The inserted direction of arterial needle is same as the direction of blood flow.
3136552|NCT01642459|Active Comparator|Opposite direction cannulation|The inserted direction of arterial needle is opposite to the direction of blood flow.
3136553|NCT01642446|Experimental|surgery|Precise hepatectomy
3136554|NCT01642446|Active Comparator|combined intervention|transcatheter hepatic arterial chemoembolization and/or ablation
3136555|NCT01642433|Placebo Comparator|Sugar pills|
3136556|NCT01642433|Active Comparator|Prazosin pills|
3136557|NCT01642420||Mild cognitive impairment|Patients diagnosed with mild cognitive impairment
3136558|NCT01642420||Alzheimers disease|Patients diagnosed with mild Alzheimers disease
3136559|NCT01642420||Healthy control persons|Age matched healthy persons
3136560|NCT01642407|Experimental|Sildenafil|
3136561|NCT01642394|No Intervention|Standardized care|The control group will receive usual care for secondary prevention of type 2 diabetes according to usual care in Osakidetza's primary care.
3136562|NCT01642394|Experimental|Self-management education programme|Attendees will receive the Diabetes Self-Management Programme in spanish version (Manejo personal de la diabetes).
3136563|NCT01642381|Active Comparator|Psychotherapy|
3136564|NCT01642381|No Intervention|"Self-Change Control (SCC)"|SCC participants will be told that they should attempt to reduce their drinking over the course of 8 weeks. (If unsuccessful, they will be offered Full Motivational Interviewing therapy sessions.)
3136565|NCT01642368|Placebo Comparator|Regular Diet|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
3136566|NCT01642368|Active Comparator|Medium Omega-3 Group|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
3136567|NCT01642368|Active Comparator|High Omega-3 Group|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
3136568|NCT01642355|No Intervention|Usual Care|Usual care includes physician assistant and/or nurse based medical and lifestyle recommendations in consultation with cardiac catheterization attending or patient's clinical cardiologist to potentially improve the patient's medical and lifestyle regimen. Relevant educational material is routinely distributed to patients.
3136569|NCT01642355|Active Comparator|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
3136570|NCT01642355|Active Comparator|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
3136571|NCT01642342|Experimental|Weekly Treatment (sEphB4-HSA)|Patients receive recombinant albumin fusion protein sEphB4-HSA IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3136572|NCT01642342|Experimental|Every 2 Weeks Treatment (sEphB4-HSA)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3136573|NCT01642342|Experimental|Every 3 Weeks Treatment (sEphB4-HSA)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3136574|NCT01642316|Experimental|washback|students received 8 specific related formative test for that lesson plus a pre-test and post-test, Michigan English language proficiency test
3136575|NCT01642316|Other|control|students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
3136576|NCT01642303|Experimental|vodcasting|students who listen to downloaded vodcasting
3136577|NCT01642303|No Intervention|control|listen to the student book listening file
3136578|NCT01642277|Experimental|Women using Solifenacin for OAB treatment|Solifenacin treated women: Women with OAB who are prescribed solifenacin
3136579|NCT01642277|No Intervention|Control: Women without OAB|Women without OAB who are not prescribed solifenacin.
3136580|NCT01642264|No Intervention|Control (Delayed Training) Condition|Participants in this condition were assessed at 1 week, 1 month and 3 months post-enrollment, and were provided access to the WeBREATHe training website upon completion of their 3-month assessment.
3136581|NCT01642264|Experimental|Intervention (Training) Condition|In this condition, participants used the WeBREATHe training program website for 1 week, and completed assessments at 1 week, 1 month, and 3 months post-training.
3136582|NCT01642251|Experimental|Arm A (veliparib, etoposide, and cisplatin)|Patients receive veliparib PO BID on days 1-7, etoposide IV over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3136583|NCT01642251|Active Comparator|Arm B (placebo, cisplatin, and etoposide)|Patients receive placebo PO BID on days 1-7, etoposide IV over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3136584|NCT01642238|Experimental|Ticagrelor + ASA + Bivalirudin|Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
3136585|NCT01642238|Active Comparator|Clopidogrel + ASA + Bivalirudin|Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
3136586|NCT01642212|Experimental|Oral Budesonide Suspension|Taken once or twice daily for up to 40 weeks
3136587|NCT01642212|Placebo Comparator|Matching Placebo|Taken once or twice daily for 20 weeks
3136588|NCT01642199|Active Comparator|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|
3136589|NCT01642199|Active Comparator|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|
3136590|NCT01642199|Active Comparator|Reduced Intensity Behavioral Weight Loss|
3136591|NCT01642186|Experimental|Arm A everolimus|"Everolimus will be administered at the following doses:~Patients with a BSA ≤ 1.5 m2 will receive everolimus 5 mg PO QD.~Patients with a BSA > than or = to 1.5 m2 will receive everolimus 7.5 mg PO QD. If the patient is randomized to everolimus alone (1) or leuprolide and letrozole (2) and the cancer continues to grow, they may have the option to receive all three drugs together."
3136592|NCT01642186|Experimental|Arm B letrozole plus leuprolide|"Day 1 of Cycle 1: Leuprolide 7.5 mg IM will be administered by a nurse in clinic.~Letrozole will be dispensed and will be taken at home. Patients will be instructed to take letrozole at the same time each day, consistently with food or without food, and swallowed whole with a glass of water. If the patient is randomized to everolimus alone (1) or leuprolide and letrozole (2) and the cancer continues to grow, they may have the option to receive all three drugs together."
3136593|NCT01642186|Experimental|Arm C combination everolimus, letrozole and leuprolide|"Patients with a BSA ≤ 1.5 m2 will receive everolimus 5 mg PO QD.~Patients with a BSA > than or = to 1.5 m2 will receive everolimus 7.5 mg PO QD. Leuprolide 7.5 mg IM will be given every 4 weeks (+/- 7 days). Everolimus and letrozole will be administered continuously using the same dose, schedule and administration. Everolimus, letrozole and leuprolide should be administered concurrently at all times."
3136594|NCT01642173|Other|OCT at baseline|"Subjects enrolled in the NIH funded and IRB approved (08-008161) protocol Lp-PLA2 and Coronary Atherosclerosis in Humans with a positive diagnosis of coronary artery endothelial dysfunction will be studied using Optical Coherence Tomography during the angiogram at baseline."
3136595|NCT01642173|Other|OCT following 6 month Lp-PLa2 inhibition|"Subjects who are enrolled in IRB 10-000044 Lp-PLA2 and Coronary Atherosclerosis in Humans Aim III a study in which the investigators are examining the impact of long-term inhibition of Lp-PLA2, with a specific novel inhibitor or placebo, on Lp-PLA2 activity and improvement in coronary endothelial function will be studied using Optical Coherence Tomography during the 6 month return angiogram."
3136596|NCT01642160|Active Comparator|Standard of care|Participants randomized to this arm will have the usual follow up care without any additional information.
3136597|NCT01642160|Active Comparator|Additional Education|This arm will receive a weekly text message or e-mail asking participants to sign on to the web page that we will provide. Once they sign on, they will see additional educational materials and questions regarding their CPAP use. Based on their response, they will be directed to suggestion or sites to help improve their compliance with their CPAP.
3136598|NCT01642147|Experimental|Patients undergoing craniotomy|"Patients undergoing craniotomy who are scheduled for selective supratentorial tumor removal surgery will be randomly chosen and recruited.~Transcranial Doppler (TCD) measures,jugular venous bulb catheterization, radial artery catheterization, and tumor removal surgery under general anesthesia will be performed."
3136599|NCT01642147|Active Comparator|Patients undergoing abdominal surgery|Randomly chosen patients undergoing selective abdominal surgery. Transcranial Doppler (TCD) measures,radial artery catheterization, and major abdominal surgery under general anesthesia will be performed.
3136600|NCT01642134|Active Comparator|Duoplavin|Both active substances in DuoPlavin: clopidogrel and acetylsalicylic acid, are inhibitors of platelet aggregation. Clopidogrel stops the platelets aggregating by blocking ADP. Acetylsalicylic acid the platelets aggregating by blocking the prostaglandin cyclo oxygenase.
3136602|NCT01642121||Observational|Samples and controls are sorted and re-sorted for CD34, CD38, and CD55 subsets by single-cell PCR analysis, flow cytometry, and reverse-transcriptase PCR. Sorted cell subsets are then transplanted into NSG mice. Beginning 6 weeks after transplantation, peripheral blood samples are collected and analyzed for human lymphoid- and myeloid-lineage cells by FACS.
3136603|NCT01642108|Other|Sitagliptin|
3136604|NCT01642095||Basic science (FAK expression)|Archived tumor tissue samples are analyzed for FAK expression by IHC. IHC staining is compared in normal renal tissue, Wilms tumor (routine and anaplastic), malignant rhabdoid tumor of the kidney, clear cell sarcoma of the kidney, and mesoblastic nephroma.
3136605|NCT01642082|Experimental|Treatment (dalantercept)|Patients receive dalantercept SC on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3136606|NCT01642069||Observational|Cryopreserved specimens are analyzed for NUP98 fusion to NSD1, JARID1A, and TOP1, myeloid/lymphoid or MLL-rearrangements, and other gene expression profiling by RT-PCR and karyotyping or FISH. Results are then compared with each patient's outcome data.
3136607|NCT01642030|Other|Methadone Maintenance|
3136608|NCT01642030|Other|Buprenorphine Maintenance|
3136609|NCT01642017|Experimental|Pazopanib|Pazopanib : 3 dose levels are defined : 400, 600 and 800 mg per day.
3136610|NCT01642004|Experimental|Arm A: Nivolumab|Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
3136611|NCT01642004|Experimental|Arm B: Docetaxel|Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
3136612|NCT01641991|Experimental|Arm B: 0.50mL BioThrax®|BioThrax® 0.50mL subcutaneously on Days 0, 28 and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
3136613|NCT01641991|Experimental|Arm C: 0.50mL BioThrax®|BioThrax® 0.50mL subcutaneously on Days 0, 14, 28 and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
3136614|NCT01641991|Experimental|Arm D: 0.25mL BioThrax®|BioThrax® 0.25mL subcutaneously on Days 0,14, and 28,and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
3136615|NCT01641991|Experimental|Arm A: 0.50mL BioThrax®|BioThrax® 0.50 ml subcutaneously on Days 0, 14, and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
3136616|NCT01641978||ICU patients|neurological level in critical patients
3136617|NCT01641965|Active Comparator|early non invasive ventilation|Patients assigned to this arm will start non invasive ventilation with home pressure ventilator model Vivo 40 (BREAS Medical AB)immediately after randomization (when their FVC reaches the threshold of the 75% of the predicted value)
3136618|NCT01641965|Active Comparator|standard|patients in this arm will start non invasive ventilation with home pressure ventilator model Vivo 40 (BREAS Medical AB) when they fulfil at least one of the following criteria: (i) FVC < 50% predicted, (ii) orthopnea, and/or (iii) PaCO2 > 45 mmHg.
3136619|NCT01641952||Rituximab|Participants who had an inadequate response or intolerance to one anti- tumor necrosis factor (anti-TNF) agent received rituximab (Mabthera) at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
3136620|NCT01641939|Active Comparator|Standard taxane therapy|Docetaxel will be administered at 75 milligram per meter square (mg/m^2) intravenous (IV) on Day 1 of a 21-day cycle, or paclitaxel will administered at 80 mg/m^2 IV weekly (Days 1, 8, and 15 of a 21 day cycle) according to investigator choice until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
3136621|NCT01641939|Experimental|trastuzumab emtansine 2.4 mg|Trastuzumab emtansine will be administered on Day 1, 8, and 15 of a 21-day cycle at 2.4 mg/kg IV infusion until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
3136622|NCT01641939|Experimental|trastuzumab emtansine 3.6 mg|Trastuzumab emtansine will be administered on Day 1 of a 21-day cycle at 3.6 mg/kg IV infusion until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
3136623|NCT01641926|Experimental|HBeAg(+) PEG-Intron|HBeAg-positive participants receive 1.5 mcg/kg/wk PEG-Intron subcutaneously (SC) once weekly for 48 weeks.
3136624|NCT01641926|Active Comparator|HBeAg(+) PEGASYS|HBeAg-positive participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
3136625|NCT01641926|Experimental|HBeAg(-) PEG-Intron|HBeAg-negative participants receive 1.5 mcg/kg/wk PEG-Intron SC once weekly for 48 weeks.
3136626|NCT01641926|Active Comparator|HBeAG(-) PEGASYS|HBeAg-negative participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
3136627|NCT01641913|Experimental|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
3136628|NCT01641900|Experimental|Schizophrenia|"Outpatients with a Structural Clinical Interview confirmed DSM-IV diagnosis of schizophrenia.~All participants receive two interventions: 3 mg eszopiclone and Placebo Intervention conditions are separated by 1 week."
3136629|NCT01641900|Experimental|Healthy Controls|Adult participants screened to exclude a personal history of mental illness, family history of schizophrenia spectrum disorder, and psychoactive medication use. All participants receive two interventions: 3 mg eszopiclone and Placebo Intervention conditions are separated by 1 week.
3136630|NCT01641887||GERD patients|Patients who have GERD will be recruited for this study.
3136631|NCT01641874|Experimental|Specific directional exercise|During the assessment a specific exercise will be identified for this group. The exercise will consist of a repeated specific end range movement of the knee
3136632|NCT01641874|Active Comparator|Evidence based exercise|Quadriceps strengthening and advice on aerobic exercises will be given
3136633|NCT01641874|No Intervention|No intervention|Patient waits on the surgeons waiting list for next appointment or for planned knee surgery
3136740|NCT01641211|Experimental|Video intervention|Group that will watch the Meducation inhaler device technique videos.
3136634|NCT01641861|Experimental|Control arm|control arm is dental caries removal using the conventional method. Dental caries will be removed using rotary instrument following the usual procedures employed by the dentist.
3136635|NCT01641861|Experimental|Intervention arm|Intervention arm is dental caries removal using Papacarie®. The dentist will apply Papacarie® to dental cavity in order to soften the carious dentine. Dental caries will be removed using hand instrument.
3136636|NCT01641848|Experimental|Arthritic and injured ankles|InBone TAA
3136637|NCT01641835||Normals|No eye disease.
3136638|NCT01641822|Active Comparator|AZLI|Participants will be randomized to receive 3 cycles of treatment, each cycle consisting alternating regimens: AZLI for 28 days followed by TIS for 28 days.
3136639|NCT01641822|Placebo Comparator|Placebo|Participants will be randomized to receive 3 cycles of treatment, each cycle consisting alternating regimens: placebo to match AZLI for 28 days followed by TIS for 28 days.
3136640|NCT01641809|Experimental|Arm 1 GSK1265744 10 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 10 mg + matching placebo + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 10 mg + matching placebo + Rilpivirine 25 mg once daily from Week 24 to Week 96.
3136641|NCT01641809|Experimental|Arm 2 GSK1265744 30 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 30 mg + matching placebo + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 30 mg + matching placebo + Rilpivirine 25 mg once daily from Week 24 to Week 96.
3136642|NCT01641809|Experimental|Arm 3 GSK1265744 60 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 60 mg + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 60 mg + Rilpivirine 25 mg once daily from Week 24 to Week 96.
3136643|NCT01641809|Active Comparator|Arm 4 Efavirenz 600 mg|In the Induction Phase and Maintenance Phase subjects will receive oral tablets of Efavirenz 600 mg + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine).
3136644|NCT01641783|Experimental|nanoparticle Albumin-bound paclitaxel|evaluate one dose level of nab-paclitaxel:125mg/m2
3136645|NCT01641770|Experimental|Dietary Counseling + ONS|
3136646|NCT01641770|Active Comparator|Dietary Counseling|
3136647|NCT01641757|Experimental|periodontal treatment group|non surgical periodontal therapy will be given to study subjects which will be selected by randomization from total study sample. at the end of study, serum albumin levels of both study and control groups will be compared.
3136648|NCT01641744|Experimental|Group Attachment Based Intervention (GABI)|
3136649|NCT01641744|Active Comparator|Systematic Training for Effective Parenting (STEP)|
3136650|NCT01641731|Active Comparator|Cow's milk|
3136651|NCT01641731|No Intervention|Control group|
3136652|NCT01641718|Experimental|Single sided glue|Mesh is fixed with Tisseel for single sided inguinal hernias.
3136653|NCT01641718|Active Comparator|Single sided stapled|Mesh is fixed with staples for single sided inguinal hernias.
3136654|NCT01641718|Other|Bilateral glue right|"For bilateral inguinal hernias mesh on the right side is fixed with Tisseel, on the left with staples.~Experimental treatment and active comparator in the same patient."
3136655|NCT01641718|Other|Bilateral glue left|"For bilateral inguinal hernias mesh on the left side is fixed with Tisseel, on the right with staples.~Experimental treatment and active comparator in the same patient."
3136656|NCT01641705||Control Group|Group of nonsmokers individuals without respiratory disease.
3136657|NCT01641705||RA patients 1|RA patients nonsmokers with up to five years of disease.
3136658|NCT01641705||RA group 2|RA patients nonsmokers with six to ten years of disease.
3136659|NCT01641705||RA group 3|RA patients nonsmokers with eleven to fifteen years of disease.
3136660|NCT01641705||RA group 4|RA patients nonsmokers with sixteen or more years of disease
3136661|NCT01641692|Experimental|GSK573719 15.6 mcg|GSK573719 (Umeclinidium bromide) 15.6 mcg once-daily
3136662|NCT01641692|Experimental|GSK573719 31.25 mcg|GSK573719 (Umeclinidium bromide) 31.25 mcg once-daily
3136663|NCT01641692|Experimental|GSK573719 62.5 mcg|GSK573719 (Umeclinidium bromide) 62.5 mcg once-daily
3136664|NCT01641692|Experimental|GSK573719 125 mcg|GSK573719 (Umeclinidium bromide) 125 mcg once-daily
3136665|NCT01641692|Experimental|GSK573719 250 mcg|GSK573719 (Umeclinidium bromide) 250 mcg once-daily
3136666|NCT01641692|Experimental|GSK573719 15.6 mcg twice-daily|GSK573719 (Umeclinidium bromide) 15.6 mcg twice-daily
3136667|NCT01641692|Experimental|GSK573719 31.25 mcg twice daily|Gsk573719 (Umeclinidium bromide) 31.25 mcg twice-daily
3136668|NCT01641692|Placebo Comparator|Matched Placebo|Matched Placebo arm
3136669|NCT01641679||Suspected recurrent DTC|100 patients with biochemically suspected recurrent DTC
3136670|NCT01641666|Experimental|Peg2b + Ribavirin + Boceprevir|Peginterferon alpha-2b (Peg2b) plus ribavirin (RBV) starting on Day 1 and boceprevir starting on Week 5
3136671|NCT01641653|Placebo Comparator|placebo|half of the patients will receive placebo (normal saline 2cc/) prior to entering the OR
3136672|NCT01641653|Active Comparator|Midazolam|half of the patients will receive Midazolam 1-2.5mg prior to entering the OR
3136673|NCT01641640|Experimental|Sofosbuvir+PEG+RBV|
3136674|NCT01641627|Experimental|vibration|proprioceptive stimulation of the lower limb using vibration and plantar pressure boots
3136675|NCT01641614|Experimental|Beating heart surgery|Group A (Beating heart) surgery was performed under normal temperature (36⁰ C) ,once CPB was established, the patient was placed in Trendelenburg position and a retrograde perfusion catheter was inserted into the coronary sinus and ligated by a simple suture line. Aorta cross clamping was immediately established and blood was oxygenated and delivered continuously through a catheter Mitral valve was exposed using the left atrial retractor. Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture De Vegas' technique.
3136741|NCT01641211|Other|Control|This group will watch a nutrition video.
3136744|NCT01641185|Experimental|carbon ions|irradiation 20 x 3,3 GyE carbon ions
3264011|NCT00740155|Experimental|Group 2|
3136676|NCT01641614|Active Comparator|heart surgery Group B|Group B (arrested heart) surgery was performed under moderate hypothermia (32⁰C) as technique requirement (3). After cardiac arrest, during the period of cross clamping, the aortic root was perfused through the cardioplegias's cannula with oxygenated blood at a rate between 200 mL/min to 300 mL/min for 2 minutes with 15 minutes intervals.Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture De Vegas' technique.
3136677|NCT01641601|No Intervention|Usual Management|Patients in the usual management arm will have no pre-hospital cervical ripening and will undergo labor induction according to standard labor induction protocols on an inpatient basis.
3136678|NCT01641601|Experimental|Outpatient transcervical Foley balloon|Patients in the experimental group will have a 30 cc transcervical Foley balloon placed in the outpatient setting approximately 12-18 hours prior to their labor induction. Once admitted, they will undergo inpatient labor induction as per usual protocols.
3136679|NCT01641575|Experimental|CO-1.01 and Cisplatin|
3136680|NCT01641562||TAXANES|patients with early breast cancer, scheduled to receive taxanes, with doses according to the stage of the disease
3136681|NCT01641549|Experimental|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
3136682|NCT01641549|Active Comparator|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent
3136683|NCT01641536|Experimental|1mg of HB-110|The subjects in this group will be administered 1 mg of HB-110 according to the protocol.
3136684|NCT01641536|Experimental|2mg of HB-110|The subjects in this group will be administered 2 mg of HB-110 according to the protocol.
3136685|NCT01641536|Experimental|4mg of HB-110|The subjects in this group will be administered 4 mg of HB-110 according to the protocol.
3136686|NCT01641523||Hydroxyapatite Cranioplasty|patient underwent to cranioplasty reconstruction with customized hydroxyapatite prosthesis
3136687|NCT01641523||polymethylmethacrylate|patient underwent to cranioplasty reconstruction with polymethylmethacrylate prosthesis
3136688|NCT01641523||autologous bone|patients underwent to cranioplasty reconstruction by autologous bone repositioning
3136689|NCT01641510|Experimental|Prasugrel|Loading and maintenance dose of prasugrel
3136690|NCT01641510|Active Comparator|Clopidogrel|Loading and maintenance dose of clopidogrel
3136691|NCT01641497|Active Comparator|3D conformational radiotherapy|25 * 1.8 Gy in 5 weeks (=45 Gy). 3D conformational radiation
3136692|NCT01641497|Experimental|Intensity-Modulated Radiation Therapy|25 * 1.8 Gy in 5 weeks (=45 Gy). IMRT
3136693|NCT01641484|Experimental|local control 19.8Gy|local control at 19.8 Gy, at Day 14
3136694|NCT01641471|Experimental|Active TENS|Active TENS (EMPI Select TENS) in combination with a femoral nerve catheter. Patients will begin using the TENS unit immediately following surgery and continuing throughout the 6 weeks postoperatively.
3136695|NCT01641471|Placebo Comparator|Placebo TENS|Placebo TENS (Placebo EMPI Select TENS) in combination with a femoral nerve catheter. Patients will begin using a sham TENS unit (appears identical to Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation) immediately following surgery and continuing throughout the 6 weeks postoperatively.
3136696|NCT01641458|Experimental|fluoropyrimidine-based chemotherapy|DPYD-genotype and TDM-driven dosing of 5FU/Capecitabine
3136697|NCT01641445|Active Comparator|Topiramate|Topiramate (200 mg) taken orally twice daily
3136698|NCT01641445|Placebo Comparator|Sugar pill|"Placebo (sugar pill) taken twice daily"
3136699|NCT01641432|Experimental|TAPAT|Computerized Tonic and Phasic Attention training consisting of visual, auditory, and spatial stimuli that requires sustained attention (24 minutes). Training is followed by a computerized cognitive exercise (12 minutes).
3136700|NCT01641432|Active Comparator|Active Comparator|Computerized conventional board-games that lack the therapeutic effect of the TAPAT exercises. Active control has stimulus parameters similar to the TAPAT exercises (eg. stimuli is presented on the computer, participant responses are collected, session time and improvement is measured).
3136701|NCT01641419|Placebo Comparator|Placebo|Ropivacaine 0.5% plus 2ml of normal saline used for nerve block
3136702|NCT01641419|Active Comparator|Dexamethasone 4 mg|Ropivacaine 0.5% plus 2ml of dexamethasone 4 mg used for nerve block
3136703|NCT01641419|Active Comparator|Dexamethasone 8 mg|Ropivacaine 0.5% plus 2ml of dexamethasone 8 mg used for nerve block
3136704|NCT01641406|Experimental|ER- (Triple Neg. and ER- PR+ Her 2 -)|Experimental chemotherapy using neoadjuvant approach
3136705|NCT01641406|Experimental|Her 2 +|Experimental chemotherapy using neoadjuvant approach
3136706|NCT01641406|Experimental|ER + (ER+ PR+ Her 2- / ER+ PR- Her 2 -)|Experimental chemotherapy using neoadjuvant approach
3136707|NCT01641393|Experimental|EUR-1008 then Kreon|"EUR-1008 during Treatment Period 1 (29 days ±2 days) and~Kreon during Treatment Period 2 (29 days ±2 days)."
3136708|NCT01641393|Experimental|Kreon then EUR-1008|"Kreon during Treatment Period 1 (29 days ±2 days) and~EUR-1008 during Treatment Period 2 (29 days ±2 days)."
3136709|NCT01641380|No Intervention|Control|Adolescents in the Control Arm received standard of care. They continue to receive the DepoProvera injections through scheduled appointment, but would not receive a call from the nurse case manager regarding DepoProvera appointments until they have missed their scheduled DepoProvera appointment.
3136710|NCT01641380|Experimental|Text Messaging Intervention|Adolescents in the intervention arm receive text message reminders for appointments and positive sexual health messages regarding use of DepoProvera in between scheduled appointments. They are encouraged to seek care for assistance with obtaining condoms and/or if they are having problems with the medication.
3136711|NCT01641367|Experimental|Cohort A|"Under Protocol version 1.0:~No resistance to NRTIs, PIs, or NNRTI~• Continue current second-line regimen; NRTIs could be modified~Changed under LOA#2 to:~No LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure~• Continue second-line regimen which may include LPV/RTV; NRTIs could be modified~Changed under LOA#3 to:~No LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure~• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued."
3136742|NCT01641198|Experimental|Mandibular implants|Each of 58 subjects received 3 types of screw parallel wall endosseous mandibular implants at 5 different sites for a total of 290 implants.
3264012|NCT00740155|Experimental|Group 3|
3136712|NCT01641367|Experimental|Sub-cohort B1|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening~• Best available NRTIs, RAL, & DRV/RTV~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)~• Best available NRTIs, RAL, & DRV/RTV"
3136713|NCT01641367|Experimental|Sub-cohort B2|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening~• ETR, RAL, and DRV/RTV~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)~• ETR, RAL, and DRV/RTV"
3136714|NCT01641367|Experimental|Sub-cohort B3|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening~• RAL, DRV/RTV, and FTC/TDF or TDF+3TC~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)~• RAL, DRV/RTV, and FTC/TDF or TDF+3TC"
3136715|NCT01641367|Experimental|Cohort C|"Under Protocol version 1.0:~Resistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV)~• Best available NRTIs, RAL, and DRV/RTV~Changed under LOA#2:~Resistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure~• Best available NRTIs, RAL, and DRV/RTV"
3136716|NCT01641367|Experimental|Cohort D|"Under Protocol version 1.0:~Multiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:~• Best available regimen, including study-provided and any locally available drugs~Changed under LOA#2:~Not eligible for Cohort A, B, or C:~• Best available regimen, including study-provided and any locally available drugs~Updated under protocol v2.0:~• Best available ART regimen, including study-provided and any locally available non-experimental drugs"
3136717|NCT01641341|Placebo Comparator|Placebo capsule|Placebo capsule (sugar pill with no active medication)
3136718|NCT01641341|Active Comparator|Active treatment|"Active treatment will consist of the following interventions:~Bowel Dysbiosis - probiotics Bifidobacterium infantis,~Maldigestion/Malabsorption - Pancrelipase~Parasitic infection/presence - Nitazoxanide"
3136719|NCT01641328|Active Comparator|Waitlist Control / Home-based training|This group will serve as a waitlist control group while the active group is performing training. Following assessment at the end of the active group period, this group will begin home-based training and will be assessed at the end of that 10 week period.
3136720|NCT01641328|Experimental|Cognitive Activation Group|This group will attend the 3/week group intervention meetings over 10 weeks.
3136721|NCT01641315|Experimental|Rabies vaccine, IM day 0,3,7,28 with RIG|Healthy volunteers received rabies vaccination intramuscularly on day 0,3,7 and 28 with equine rabies immunoglobulin 40 IU/Kg on day 0.
3136722|NCT01641315|Experimental|Rabies vaccine, IM day 0,3,7,14 with RIG|Healthy volunteers received rabies vaccination intramuscularly on day 0,3,7 and 14 with equine rabies immunoglobulin 40 IU/Kg on day 0.
3136723|NCT01641315|Active Comparator|Rabies vaccine, IM Day 0,3,7,14,28 with RIG|Rabies exposed victims receive rabies vaccination intramuscularly on Day 0,3,7,14,28 with equine rabies immunoglobulin 40 IU/Kg on day 0
3136724|NCT01641302||Patients undergoing robot-assisted laparoscopic prostatectomy|Patients undergoing robot-assisted laparoscopic prostatectomy under general anesthesia
3136725|NCT01641289|Experimental|Paracetamol|">50kg: Paracetamol 1gm PO/NG q6hourly for 72 hours and febrile for 24 hours (maximum total dose 4g/24 hours) plus intravenous Artesunate~<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72 hours and febrile for 24 hours (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate"
3136726|NCT01641289|Active Comparator|No Paracetamol|"No paracetamol + Intravenous Artesunate~If temperature > 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
3136727|NCT01641276|Experimental|hepatitis|hepatitis B carriers patients
3136728|NCT01641276|Experimental|hepatocellular carcinoma patients|hepatites B carriers patients with associated hepatocellular carcinoma
3136729|NCT01641263|Experimental|Cognitive Behavioral Therapy|For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
3136730|NCT01641263|Active Comparator|Sleep Seminar|Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
3136731|NCT01641250|Experimental|Part A: RO5429083|
3136732|NCT01641250|Experimental|Part B: RO5429083 + cytarabine|
3136733|NCT01641237|Experimental|Low ppm fluoride dentifrice|Low ppm fluoride as sodium fluoride in a silica base dentifrice
3136734|NCT01641237|Experimental|Medium ppm fluoride dentifrice|Medium ppm fluoride as sodium fluoride in a silica base dentifrice
3136735|NCT01641237|Experimental|High ppm fluoride dentifrice|High ppm fluoride as sodium fluoride in a silica base dentifrice
3136736|NCT01641237|Placebo Comparator|No fluoride dentifrice|no added fluoride in a silica base dentifrice
3136737|NCT01641224|Active Comparator|TCM (Traditional Chinese medicine)|Formula for pain and diarrhea, Atractylodes (~10-15g), Paeonia Lactiflora (~15-30g), Tangerine Peel (~10g), Ledebouriella Root (~10g), Radix codonopsitis (~10-15g), Radix curcumae (~10g), Fingered citron (~10g), Tuckahoe (~15g), etc.
3136738|NCT01641224|Active Comparator|Pinaverium|
3136739|NCT01641224|Placebo Comparator|Placebo|Placebo is blindly given to patients
3136745|NCT01641172|Active Comparator|Patients|Patients with disseminated testicular cancer
3136746|NCT01641172|Placebo Comparator|Healthy volunteers|Healthy men, age 18-50 years old
3136747|NCT01641159|Active Comparator|Buspirone plus TAU|Buspirone titrated to 60 mg/day for the 15-week active study
3136748|NCT01641159|Placebo Comparator|Placebo plus TAU|Placebo taken daily for the 15-week active study
3136749|NCT01641146|Experimental|Enhanced Sexual Health Intervention for Men|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
3136750|NCT01641146|Active Comparator|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
3136751|NCT01641133|Active Comparator|Group A|Subjects will receive Synflorix™ at Month 0, Month 2 and Month 10.
3136752|NCT01641133|Experimental|Group B|Subjects will receive Prevenar 13™ at Month 0 and Synflorix™ at Month 2 and Month 10.
3136753|NCT01641133|Experimental|Group C|Subjects will receive Prevenar 13 ™ at Month 0 and Month 2 and Synflorix™ at Month10.
3136754|NCT01641120|Experimental|30 gauge|Subjects used a 30 gauge needle for intramuscular injection of Avonex.
3136755|NCT01641120|Experimental|25 gauge|Subjects used a 25 gauge needle for intramuscular injection of Avonex.
3136756|NCT01641107|Experimental|Ponatinib|
3136757|NCT01641081|Experimental|Experimental 1|Formoterol Fumarate in the Pressair Pressair Dry Powder Inhaler (DPI), Low Dose
3136758|NCT01641081|Experimental|Experimental 2|Formoterol fumarate in the Pressair Dry Powder Inhaler (DPI), High Dose
3136759|NCT01641081|Active Comparator|Active Comparator 1|Foradil Aerolizer, Low Dose
3136760|NCT01641081|Active Comparator|Active Comparator 2|Foradil Aerolizer, High Dose
3136761|NCT01641081|Placebo Comparator|Placebo|Dose matched placebo
3136762|NCT01641068|Experimental|Arm I (memory and thinking skills workshop)|Patients participate in a memory and thinking skills workshop once weekly for 7 weeks. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3).
3136763|NCT01641068|Active Comparator|Arm II (Education Workshop)|Patients participate in 7 weekly 1-hour group workshops focusing on increasing knowledge and education on the brain and cognition. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3). Patients are then given the option to participate in the memory and thinking skills workshop.
3136764|NCT01641055|Experimental|Salmon protein hydrolysate|
3136765|NCT01641055|Experimental|Herring protein hydrolysate|
3136766|NCT01641055|Sham Comparator|Cod protein|
3136767|NCT01641055|Placebo Comparator|Milk protein|
3136768|NCT01641042|Experimental|Healthy Group|The subjects in the Healthy group will be age-matched to the subjects in the At-risk group. Subjects will receive 2 doses of the investigational vaccine.
3136769|NCT01641042|Experimental|At-risk Group|This group includes subjects with medical conditions placing them at an increased risk for meningococcal disease. Subjects will receive 2 doses of the investigational vaccine.
3136770|NCT01641029||pyelonephritis|Patients > 18 years of age with flank pain and/or costovertebral angle tenderness, documented temperature in the emergency department of ≥38°C/100.4°F by any method of measurement, and clinically suspected acute pyelonephritis. Patients will be identified by their emergency department treating physicians.
3136771|NCT01641016|Active Comparator|Continuous Therapy|Continue with current antiretroviral therapy regime as per standard care
3136772|NCT01641016|Experimental|Short Cycle Therapy|Take current antiretroviral therapy 5 days a week (2 days off) as instructed by clinician
3136773|NCT01641003||Fresh tumor specimen|Fresh tumor specimen taken immediately after surgery of patients diagnosed with pancreatic cancer, GBM and Breast cancer. These specimens will be taken immediately to the lab isolate and grow CSC using the described methods. No specific intervention done regarding the patients- the samples taken will be processed in the lab.
3136774|NCT01640990|Experimental|Cohort 1|slow IV infusion over 6 hours consisting of saline for 30 minutes (run in period), 8 mcg/h GW328267X for 1.5 hours (total dose of 12mcg), and 10 mcg/h GW328267X for 4 hours (total dose of 40 mcg)
3136775|NCT01640990|Experimental|Cohort 2|Dose to be determined after analysis of Cohort 1
3136776|NCT01640977||Open PLIF|The PLIF procedure achieves access to the degenerated disc from the back of the spine, and is performed through a single midline posterior incision that is typically expanded bilaterally past the facet joints to expose bony landmarks for pedicle screw fixation, which are traditionally placed in a trajectory from lateral to medial, requiring a more lateral starting point.
3136777|NCT01640977||MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach, avoiding the far lateral exposure typical of the traditional PLIF.
3136778|NCT01640964|Experimental|Part A: Terlipressin acetate|Patients received terlipressin acetate 2 mg intravenous (IV) bolus injection.
3136822|NCT01640626|No Intervention|Control|Schoolchildren in school B will serve as a control group. No intervention (Health education package) will be given after complete deworming at baseline.
3264013|NCT00740155|Experimental|Group 4|
3136779|NCT01640964|Experimental|Part A: Serelaxin (RLX030)|Randomized patients received an intravenous serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min.; duration of infusion depends on time required for completion of magnetic resonance angiography (MRA) data acquisition
3136780|NCT01640964|Experimental|Part B Serelaxin (RLX030)|The patients enrolled in this part of the study received an intravenous (iv) serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min; duration of infusion depends on time required for completion of Portal pressure gradient (PPG) data acquisition.
3136781|NCT01640951|Experimental|AIN457 150 mg - Fixed Interval (FI)|1 s.c. Secukinumab 150 mg Pre-filled seringue (PFS) injection + 1 s.c. Placebo (PBO) Secukinumab PFS injection every 4 weeks
3136782|NCT01640951|Experimental|AIN457 150 mg - Start of relapse (SoR)|"Start of relapse: 1 s.c. Secukinumab 150 mg PFS injection + 1 s.c. PBO Secukinumab PFS injection every 4 weeks~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks"
3136783|NCT01640951|Experimental|AIN457 300 mg - Fixed Interval (FI)|2 s.c. Secukinumab 150 mg PFS injections every 4 weeks
3136784|NCT01640951|Experimental|AIN457 300 mg - Start of Relapse (SoR)|"Start of relapse: 2 s.c. Secukinumab 150 mg PFS injection every 4 weeks~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks"
3136785|NCT01640951|Experimental|AIN457 300 mg - Open Label (OL)|Open Label - Secukinumab 300mg every 4 weeks
3136786|NCT01640925|Active Comparator|Chlorhexidine gluconate bathing|Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.
3136787|NCT01640925|Placebo Comparator|Standard bathing|Upon study enrollment, patients will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
3136788|NCT01640912|Experimental|RXI-109|
3136789|NCT01640912|Placebo Comparator|Placebo|
3136790|NCT01640899|Other|Single-arm study|This is a single-arm study. Just one group (i.e. the patients)
3136791|NCT01640886||Standard of Care|"Comparison of S. aureus to the reference methods for S. aureus (tube coagulase and Staphaurex.)~Comparison to the reference method (30 ug cefoxitin disc diffusion)."
3136792|NCT01640886||KeyPath Test Group|All specimens collected that meet the inclusion criteria will be tested using the KeyPath BTA Test.
3136793|NCT01640873|Experimental|MK-8655|
3136794|NCT01640873|Placebo Comparator|Placebo|
3136795|NCT01640847|Experimental|Arm RT: HIFU plus ThermoDox|Index lesion has been treated with EBRT and is currently painful, but these subjects have already received their maximum cumulative EBRT dose.
3136796|NCT01640847|Experimental|Arm NRT: HIFU plus ThermoDox|Subjects have no yet received any radiation to the index lesion.
3136797|NCT01640834|Experimental|100 mg LY2409021|Single dose of 100 mg LY2409021 administered orally.
3136798|NCT01640834|Experimental|300 mg LY2409021|Single dose of 300 mg LY2409021 administered orally.
3136799|NCT01640834|Placebo Comparator|Placebo|Single dose placebo administered orally.
3136800|NCT01640821|Experimental|Intervention group (CdM?)|This group will be composed of women that are seeking help for weight-related problems that have been referred to the CdM? program.
3136801|NCT01640821|No Intervention|Control group|This group will be composed of women that are seeking help for weight-related problems but that are actually on the waiting list for participating to the CdM? program.
3136802|NCT01640808|Experimental|NIK-333(peretinoin)|
3136803|NCT01640808|Placebo Comparator|Placebo|
3136804|NCT01640782|Experimental|Sequential regimen|Sequential treatment with CPT-11 plus Fluorouracil (FU), folinic acid (LV) and Docetaxel (TXT) plus Cisplatin (CDDP)
3136805|NCT01640782|Active Comparator|De Gramont regimen|Fluorouracil (5-FU), folinic acid (LV)
3136806|NCT01640769|Active Comparator|Image guided delivery of pacing leads|Patients will be blindly randomized to image guided delivery of pacing leads during cardiac resynchronization therapy device implantation (study arm) versus standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
3136807|NCT01640769|Placebo Comparator|Standard delivery of pacing leads|Patients will be blindly randomized to standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
3136808|NCT01640756|Experimental|AqueSys Microfistula Implant|
3136809|NCT01640743|Experimental|Evertwist 1|Tacrolimus (10-14 ng/ml) + Methylprednisolone (16 mg).
3136810|NCT01640743|Experimental|Evertwist 2|Tacrolimus (4-6 ng/ml) + Everolimus (8-10 ng/ml) + Methylprednisolone (8 mg).
3136811|NCT01640730|Experimental|Kanglaite injection|
3136812|NCT01640691|Experimental|Study vaccine (AdimFlu-W)|0.5 mL/dose, a total of 2 doses, 21 days apart
3136813|NCT01640678|Experimental|ReCell epidermal cell suspension grafting|CO2 laser abrasion + ReCell epidermal cell suspension + UV-therapy
3136814|NCT01640678|Active Comparator|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
3136815|NCT01640678|No Intervention|No treatment + UV-therapy|
3136816|NCT01640665|Experimental|Sorafenib and Capecitabine|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses. Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days
3136817|NCT01640652|Experimental|Low dose vaccine arm|To investigate safety, tolerability and immunogenicity of 25 µg of the serogroup B meningococcal protein vaccine MenPF-1 in healthy adults aged 18 to 50 years of age when given three doses of vaccine with 8 weeks interval.
3136818|NCT01640652|Experimental|High dose vaccine arm|To investigate safety, tolerability and immunogenicity of 50 µg of the serogroup B meningococcal protein vaccine MenPF-1 in healthy adults aged 18 to 50 years of age when given three doses of vaccine with 8 weeks interval.
3136819|NCT01640639|Active Comparator|Thalidomide|Thalidomide
3136820|NCT01640639|Placebo Comparator|Placebo|Placebo
3136821|NCT01640626|Active Comparator|Health Education|Deworming will be conducted in both schools. A health education package will be introduced to schoolchildren in the intervention school (School A) only. Both schools will be followed up for 6 months.
3137022|NCT01639053||Gel Participants|
3136823|NCT01640600||Children exposed to SSRIs in utero|This group are comprised of children whose mothers used antidepressants during pregnancy and who were therefore exposed to antidepressants in utero.
3136824|NCT01640600||Children exposed to nicotine in utero|This group is comprised of children whose mothers smoked cigarettes during pregnancy and who were therefore exposed to nicotine in utero.
3136825|NCT01640600||Children exposed to neither nicotine nor SSRIs|This group is comprised of children who were exposed to neither nicotine nor SSRIs in utero.
3136826|NCT01640587|Experimental|DP|2.4 mg/kg dihydroartemisinin AND 20 mg/kg piperaquine once daily on Days 0, 1 and 2
3136827|NCT01640587|Active Comparator|MAS3|4mg/kg artesunate AND 8 mg/kg mefloquine once daily on Days 0, 1 and 2
3136828|NCT01640574|Experimental|DHA-P 7 days|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
3136829|NCT01640574|Experimental|DHA-P 14 days|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
3136830|NCT01640574|Active Comparator|Chloroquine 7 days|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
3136831|NCT01640574|Active Comparator|Chloroquine 14 days|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
3136832|NCT01640561|Experimental|MISC|The Mediational Interventions for Sensitizing Caregivers (MISC) model developed by Professor Pnina Klein (consultant) has been used to enhance the development of children throughout the developing world, with the support of such international aid agencies as WHO, UNICEF, NORAD, and Redd Barna (Norway).
3136833|NCT01640561|Active Comparator|Enhanced Treatment as Usual|
3136834|NCT01640548||Cohort|
3136835|NCT01640535|Experimental|Test arm|Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg
3136836|NCT01640535|Active Comparator|Comparator arm I|Matching placebo of Montelukast sodium 10mg + Levocetirizine dihydrochloride 5 mg
3136837|NCT01640535|Active Comparator|Comparator arm II|Montelukast sodium 10mg + matching placebo of Levocetirizine dihydrochloride 5mg
3136838|NCT01640522|Experimental|Collaborative Care Intervention|Care coordinator facilitates the assessment and treatment of cancer-related symptoms
3136839|NCT01640522|Active Comparator|Enhanced Usual Care|Upon evaluation of symptoms the patient will be referred for further assessment or treatment if indicated
3136840|NCT01640509|Experimental|synchrotron radiation|treated by synchrotron radiation
3136841|NCT01640496|Active Comparator|Vitamin D|Subjects will take 1 pill per day for 8 weeks.
3136842|NCT01640496|Placebo Comparator|Placebo|Subjects will be asked to take 1 pill per day for 8 weeks.
3136843|NCT01640483|Active Comparator|supportive|
3136844|NCT01640483|Active Comparator|interpretative|
3136845|NCT01640483|Active Comparator|mixed supportive/interpretative|
3136846|NCT01640470|Experimental|Assistive technology|The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will include recommendations for assistive technology, possibly entailing financial assistance to repair or to acquire new AT, and training. New equipment will likely include devices such as bathroom grab bars, raised toilet seats, walkers, and bath chairs.
3136847|NCT01640470|Active Comparator|Customary care|Participants in this arm will receive customary care.
3136848|NCT01640457|Experimental|NDplus|NOVOCART® Disc plus (Autologous Disc Chondrocyte Transplantation System)
3136849|NCT01640457|Placebo Comparator|NDbasic|NOVOCART® Disc basic (media with no active cell component)
3136850|NCT01640457|No Intervention|Sequestrectomy only (SC)|Sequestrectomy (standard of care)
3136851|NCT01640444|Experimental|A|FOLFIRI+bevacizumab
3136852|NCT01640444|Experimental|B|FOLFIRI + cetuximab
3136853|NCT01640431|Experimental|Lumbar stabilization exercises|In the Segmental Stabilization group exercises the focus is on the transversus abdominis and lumbar multifidus muscles.
3136854|NCT01640431|Experimental|TENS group|In this group, patients are treated with TENS in the lumbar region for an hour.
3136855|NCT01640418|Experimental|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
3136856|NCT01640418|No Intervention|Standard Care|Standard Care
3136857|NCT01640405|Active Comparator|Control|modified FOLFOX6 + bevacizumab
3136858|NCT01640405|Experimental|Experimental|FOLFOXIRI+bevacizumab
3136859|NCT01640392|Experimental|HIV prevention groups|Participants randomly assigned to the MyLife Intervention arm receive three 1.5-hour HIV behavioral risk-reduction group sessions over a 1-3 week period.
3136860|NCT01640392|No Intervention|Wait-list control|Participants randomly assigned to the Wait-list Control arm receive the MyLife MyStyle group sessions once they have completed a 6-month follow-up assessment.
3136861|NCT01640379|Experimental|TECH-N|Participants receive the Technology Enhanced Community Health Nursing Visit (CHN) within 5 days during which Sister to Sister and clinical assessment performed and text-messaging support
3136862|NCT01640379|No Intervention|Control|Participants receive enhanced standard of care
3136863|NCT01640366|Experimental|PICO negative pressure|
3136864|NCT01640366|No Intervention|Standard of care dressing arm|
3136865|NCT01640340|Experimental|Arm I (palonosetron hydrochloride)|Patients receive palonosetron hydrochloride IV 30 minutes prior to chemotherapy on day 1, aprepitant PO (by mouth) 60 minutes prior to chemotherapy on days 1-3, and dexamethasone PO 30 minutes prior to chemotherapy on days 1-4.
3136866|NCT01640340|Experimental|Arm II (ondansetron)|Patients receive ondansetron PO 30 minutes prior to chemotherapy on day 1 and aprepitant and dexamethasone as in Arm I.
3136867|NCT01640327|Experimental|TIVf|
3136868|NCT01640314|Experimental|Cell derived subunit trivalent nonadjuvanted vaccine|
3136869|NCT01640301|Experimental|Arm I (high-risk for relapse after HCT)|Patients with no evidence of leukemia or MDS post-HCT receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 14 and aldesleukin SC BID on days 14-28.
3136870|NCT01640301|Experimental|Arm II (relapsed after HCT)|Patients with evidence of AML (minimal residual disease or overt relapse) post-HCT receive cyclophosphamide IV and fludarabine phosphate IV daily on days -4 to -2. Patients also receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 21 and aldesleukin SC BID on days 14-28.
3136871|NCT01640288|Other|Normal Subjects|Subjects with Normal Lung Function by Pulmonary Function Tests (e.g. Spirometry) with or without smoking as a risk factor (non-smokers, ex-smokers, current smokers)
3136872|NCT01640288|Other|Subjects with COPD|Subjects diagnosed with COPD by GOLD criteria.
3136873|NCT01640275|Active Comparator|Propofol based intravenous anesthesia|patients will receive propofol based intravenous anesthesia
3136874|NCT01640275|Experimental|Isoflurane Based Inhaled Anesthesia|patients will receive isoflurane based inhaled anesthesia
3136875|NCT01640262||localized prostate cancer|Danish men with localized prostate cancer
3136876|NCT01640249|Placebo Comparator|Placebo|Placebo capsules will match LY3006072
3136877|NCT01640249|Experimental|LY3006072|LY3006072 capsules starting at 1 milligram (mg) and escalating based on emerging data. Doses will be given orally once per period using capsule strengths of 0.5 mg, 5 mg, and 30 mg.
3136878|NCT01640223|Experimental|D-3 sensor|patients will be equiped with 2 Dexcom sensors 3 days before hospitalization
3136879|NCT01640223|Experimental|D-1 sensor|patients will be equiped with 2 Dexcom sensors one day before hospitalization
3136880|NCT01640197|Placebo Comparator|Placebo|Methyl Cellulose administered in identical capsules as the active.
3136881|NCT01640197|Active Comparator|500mg resveratrol|Transmax from biotivia. 500mg resveratrol (98% purity) with 10mg piperine per capsule. 1 capsule taken daily.
3136882|NCT01640184|Active Comparator|Active vitamin D|Patients in oral medicine group will be treated by active vitamin D and other general treatments according to the suggestions in Kidney Developement Improvement Global Outcomes (KDIGO) guidelines.
3136883|NCT01640184|Experimental|Ultrasonic ablation|Patients in Ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequency ablation.
3136884|NCT01640184|Active Comparator|Parathyroidectomy|Patients in parathyroidectomy group will be treated by parathyroid surgery.
3136885|NCT01640171|Other|Top Anesthesia 1 Eye SC Lidocaine 1 Eye|"One eye:~Proparacaine Hydrochloride 0.5% Drop Tetravisc 0.5% Gel Acuvail Intra-vitreal Anti-VEGF Drug~Fellow Eye:~Proparacaine Hydrochloride 0.5% Drop Tetravisc 0.5% Gel Xylocaine 2% Injectable Anesthetic Acuvail Intra-vitreal Anti-VEGF Drug"
3136886|NCT01640158|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training, up to 65 hours
3136887|NCT01640158|Active Comparator|Active Comparator|Commercially available computerized training, up to 65 hours
3136888|NCT01640145|Placebo Comparator|Carbohydrate|
3136889|NCT01640145|Active Comparator|Protein continous boluses|
3136890|NCT01640145|Active Comparator|Protein 2 boluses|
3136891|NCT01640119|Placebo Comparator|no intervention|
3136892|NCT01640119|Experimental|Bicarbonate|
3136893|NCT01640106|Experimental|Omega-3|Treatment arm, using the omega-3 product (fish oil/paste)
3136894|NCT01640106|Placebo Comparator|Control|
3136895|NCT01640093|Experimental|Treatment B|Abiraterone acetate (500 mg), 2 coated, reformulated tablets.
3136896|NCT01640093|Experimental|Treatment C|Abiraterone acetate (250 mg), 4 coated, reformulated tablets.
3136897|NCT01640093|Experimental|Treatment D|Abiraterone acetate (500 mg), 2 coated, reformulated tablets, showing slower in vitro dissolution.
3136898|NCT01640093|Active Comparator|Treatment A|Abiraterone acetate (250 mg), 4 uncoated, current commercial tablets.
3136899|NCT01640080|Experimental|Esketamine (Group 1)|
3136900|NCT01640080|Experimental|Esketamine (Group 2)|
3136901|NCT01640080|Placebo Comparator|Placebo|
3136902|NCT01640067|Experimental|Human Neural Stem Cells Suspension|50,000 cells/µl. Patients received either unilateral or bilateral hNSCs microinjections (3 microinjections on each side) into the lumbar spinal cord. Each microinjection consisted of 15 µl of the above 50,000cells/µl suspension, yielding a total of 750,000 cells per injection site.
3136903|NCT01640054|Experimental|Dosing regimen|Open label Oral treatment 100mg once daily
3136904|NCT01640041|Experimental|Implanted|All participants.
3136905|NCT01640015|Experimental|low frequency diet|Participants will be assigned to a low frequency diet (fixed energy intake)
3136906|NCT01640015|Experimental|High frequency diet|Participants will be assigned to a high frequency diet (fixed energy intake)
3136907|NCT01640002|Active Comparator|Propantheline|
3136908|NCT01640002|Placebo Comparator|Placebo|
3136909|NCT01639911|Experimental|Treated Patients with Solid Tumor|Patients will receive alisertib orally twice a day for the first 7 days of a 21 day cycle. Patients will also receive pazopanib orally once a day continuously. Treatment continues until disease progression, unacceptable toxicity or patient refusal. The study consists of two components which are the dose finding component and optimally tolerated dose extension with pharmacokinetics component.
3136910|NCT01639898|Experimental|"Group 1 (2-cycles trial)"|"The 2-cycles trial will be available to patients who can be treated by radiation or intensive treatment (75 % of cases occurring in front line); they will then undergo 2 cycles of the lenalidomide-dexamethasone combination before radiation or intensive treatment (Group 1)."
3136911|NCT01639898|Experimental|"Group 2 ( 9 cylces Trial)"|"The 9-cycles trial will be available to all other front-line patients (25 % of front-line patients) or patients in relapse or resistant, they will undergo 9 cycles of the lenalidomide-dexamethasone combination followed by maintenance therapy with lenalidomide alone for one year (Group 2)."
3136912|NCT01639885|No Intervention|Group 1|Patients will receive standard care (gemcitabine)
3136913|NCT01639885|Experimental|Group 2|Patients will receive standard care (gemcitabine) combined with interferon-alpha 2b (Peg-Intron)
3136914|NCT01639885|Experimental|Group 3|Patients will receive standard care (gemcitabine) combined with interferon-alpha 2b (Peg-Intron) and p53 SLP vaccin
3136915|NCT01639872|Experimental|Clozapine|
3136916|NCT01639872|Active Comparator|Risperidone|
3136917|NCT01639859|Experimental|Elastography|
3136918|NCT01639846|Experimental|RX-10045 active arm|RX-10045 Ophthalmic Solution, 0.09%
3136919|NCT01639846|Placebo Comparator|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution
3136920|NCT01639833|Experimental|Veriset Hemostatic Patch|Topical Hemostat
3136921|NCT01639833|Active Comparator|TachoSil®|Topical Hemostat
3136922|NCT01639820|Experimental|Strategy A|Only identification of sentinel nodes (without pelvic lymph-node dissection)
3136923|NCT01639820|Other|Strategy B|Identification of sentinel nodes + full pelvic lymph-node dissection
3136924|NCT01639807|Active Comparator|latanoprost 2-8˚ C|latanoprost(0.005%)stored at 2-8˚ C
3136925|NCT01639807|Experimental|SLT|Selective laser Trabeculoplasty
3136926|NCT01639794||Male patients with non-neurogenic LUTS taking VESITRIM|Male patients diagnosed with non-neurogenic Lower Urinary Tract Symptoms (LUTS) with bothersome storage disorder defined as urgency, and/or frequency and/or Urgency Urinary Incontinence (UUI)
3136927|NCT01639781|Active Comparator|flavanol rich intervention|flavanol rich drink
3136928|NCT01639781|Placebo Comparator|flavanol free intervention|flavanol free drink
3136929|NCT01639768|Placebo Comparator|SUBLIVAC FIX Birch 0 AUN/ml|
3136930|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 3,333 AUN/ml|
3136931|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 10,000 AUN/ml|
3136932|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 20,000 AUN/ml|Evaluation of the SUBLIVAC FIX Birch 20,000 AUN/ml by an independent safety committee
3136933|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 40,000 AUN/ml|Start of SUBLIVAC FIX Birch 40,000 AUN/ml arm depends on safety in the SUBLIVAC FIX Birch 20,000 AUN/ml arm evaluated by an independent safety committee
3136934|NCT01639755|Experimental|All Participants|Al participants who had new texture shaped breast implants surgically implanted.
3136935|NCT01639742|Experimental|All Participants|All participants who had new texture round breast implants surgically implanted.
3136936|NCT01639729|Experimental|Sequence 1 - Treatment A, B, C, D|15 mcg: Sufentanil IV, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Buccal, Sufentanil NanoTab Oral
3136937|NCT01639729|Experimental|Sequence 2 - Treatment A, B, D, C|15 mcg: IV, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Oral,Sufentanil NanoTab Buccal
3136938|NCT01639729|Experimental|Sequence 3 - Treatment A, C, B, D|15 mcg: Sufentanil IV, Sufentanil NanoTab Buccal, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Oral
3136939|NCT01639729|Experimental|Sequence 4 - Treatment A, C, D, B|15 mcg: Sufentanil IV, Sufentanil NanoTab Buccal, Sufentanil NanoTab Oral, Sufentanil NanoTab Sublingual
3136940|NCT01639729|Experimental|Sequence 5 - Treatment A, D, B, C|15 mcg: Sufentanil IV, Sufentanil NanoTab Oral, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Buccal
3136941|NCT01639729|Experimental|Sequence 6 - Treatment A, D, C, B|15 mcg: Sufentanil IV, Sufentanil NanoTab Oral, Sufentanil NanoTab Buccal, Sufentanil NanoTab Sublingual
3136942|NCT01639716||Lymphoma group|
3136943|NCT01639716||healthy group|
3136944|NCT01639716||IL-10 high|
3136945|NCT01639716||IL-10 low|
3136946|NCT01639716||IL-4 high|
3136947|NCT01639716||IL-4 low|
3136948|NCT01639716||lymphopenia|
3136949|NCT01639703|Experimental|CT perfusion|arm with CT perfusion
3136950|NCT01639690|Experimental|Autologous CD34+ cells transduced with TNS9.3.55|An open label study using a non-myeloablative conditioning regimen of busulfan and 1 or several infusions of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the human ß-globin gene.
3136951|NCT01639677|Experimental|Laparoscopic gastric bypass|
3136952|NCT01639677|Active Comparator|Laparoscopic VBG|Laparoscopic vertical banded gastroplasty
3136953|NCT01639664|Experimental|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization.
3136954|NCT01639664|No Intervention|Control group|standard practice
3136955|NCT01639651|Active Comparator|Control Group|
3136956|NCT01639651|Experimental|Mobilization Group|
3136957|NCT01639638|Placebo Comparator|Placebo|
3136958|NCT01639638|Experimental|CIGB-300 - 5 mg|
3136959|NCT01639638|Experimental|CIGB-300 - 15 mg|
3136960|NCT01639625|Experimental|CIGB300|
3136961|NCT01639612|Experimental|ALD-451|Autologous bone marrow derived ALD-451 cells administered intravenously following surgery, radiation therapy and temozolomide
3136962|NCT01639599|Placebo Comparator|dexamethasone|dexamethasone 5mg iv during anesthesia induction
3136963|NCT01639599|Active Comparator|dexamethasone, haloperiol 1mg|dexamethasone 5mg iv during anesthesia induction & haloperidol 1mg iv 30 min before end of anesthesia
3136964|NCT01639599|Active Comparator|dexamethasone + haloperidol 2mg|dexamethasone 5mg iv during anesthesia induction & haloperidol 2mg iv 30 min before end of anesthesia
3136965|NCT01639586|Active Comparator|D|Impact of the day care on health profit of patient
3136966|NCT01639586|Active Comparator|C|No access to a respite structure
3136967|NCT01639586|Active Comparator|B|Respite platform
3136968|NCT01639560|Active Comparator|Varenicline|1 mg of varenicline twice per day for 12 weeks.
3136969|NCT01639560|Placebo Comparator|placebo|1 placebo tablet twice a day for 12 weeks
3136970|NCT01639547|Experimental|PEGASYS® plus ROBATROL® for 36 weeks|
3136971|NCT01639547|Active Comparator|PEGASYS® plus ROBATROL® for 48 weeks|
3136972|NCT01639534||Biomarkers, Carotid Stenting, Blood sample|Subjects requiring Carotid Stenting Procedure at Virginia Commonwealth University/Medical College of Virginia Health Systems
3136973|NCT01639521|Experimental|Arm A (gemcitabine hydrochloride, cisplatin)|Patients receive cisplatin IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3136974|NCT01639521|Experimental|Arm B (MVAC)|Patients receive methotrexate IV on day 1 and vinblastine IV, doxorubicin hydrochloride IV, and cisplatin IV on day 2. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3136975|NCT01639508|Experimental|Cabozantinib|This will be a single-institution, open label, two-stage, single agent trial of cabozantinib in patients with advanced NSCLCs.atients in GROUP A will have tumors with a RET fusion. Patients in GROUP B will have tumors with an NTRK fusion, or MET or AXL overexpression, amplication, or mutatation. Patients in GROUP C will have tumors with a ROS1 fusion.
3136976|NCT01639495|Experimental|THERMOCOOL® SMARTTOUCH™ Catheter|
3136977|NCT01639482||Citalopram|
3136978|NCT01639482||Placebo|
3136979|NCT01639469|Experimental|Structured exercise|Structured exercise instruction by smartphone
3136980|NCT01639469|Active Comparator|lifestyle exercise|Lifestyle exercise program taught via smartphone
3136981|NCT01639456|Experimental|Patients Using CD3-/CD19- NK cell product|Patients receive the apheresis product (collected day -1: enriched for NK cells using the CliniMACS® CD3 and CD19 Reagent System in combination with the large-scale tubing set (Miltenyi Biotec) to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19- natural killer cells). Patients will also receive Cyclophosphamide, Fludarabine and Aldesleukin.
3136982|NCT01639456|Experimental|Patients Using CD3-/CD56+ purified NK cell product|Patients receive the apheresis product (collected day -1): purified for NK cells using the CliniMACS® CD3 Reagent System (Miltenyi Biotec) in combination with the large-scale tubing set to deplete CD3+ cells and then use the CliniMACS® CD56 Reagent System to enrich CD56+ NK cells (CD3-CD56+ natural killer cells). Patients will also receive Cyclophosphamide, Fludarabine and Aldesleukin.
3136983|NCT01639443|Experimental|Fast-tracked|"'Predictive no-show overbooking' intervention. Patients who volunteer to enroll in fast-track line, which gives them an opportunity to overbook their appointment for endoscopy earlier in a predictive no-show slots."
3136984|NCT01639443|No Intervention|Control|Patients who are scheduled routinely
3136985|NCT01639430||Geriatric patients ED|Consecutive patients >= 75 years in the emergency department.
3136986|NCT01639404|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood Administration and Active Rehabilitation
3136987|NCT01639391|Experimental|patients|
3136988|NCT01639378|Experimental|Renal Denervation|Subjects are treated with renal denervation after randomisation and maintained on heart failure medications
3136989|NCT01639378|No Intervention|Control group|Subject will have a sham procedure and not receive renal denervation. They will continue with the heart failure medications
3136990|NCT01639352|Experimental|SOM230|60mg of SOM230 via injection intramuscularly every 28 days
3136991|NCT01639339|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
3136992|NCT01639339|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
3136993|NCT01639326|Experimental|Irinotecan high doses|Patients will receive irinotecan dose of 300 mg / m² in patients UGT1A1 * 1 / * 1 and 260 mg / m² in patients UGT1A1 * 1 / * 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
3136994|NCT01639326|Active Comparator|Irinotecan standard doses|Patients will receive irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours
3136995|NCT01639300|Experimental|GNbAC1|
3136996|NCT01639300|Placebo Comparator|GNbAC1 placebo|
3136997|NCT01639287||Painless|"Painless synovitis group(called cold synovitis)"
3136998|NCT01639287||Painful|Painful synovitis group
3136999|NCT01639274|Other|COPD|
3137000|NCT01639248|Experimental|ENMD-2076 Treatment|ENMD-2076
3137001|NCT01639222|Experimental|Calcium 500 mg and Vitamin D3 800 IU|"Period 1: Low calcium meals for up to 3 days.~Period 2: Calcium 500 mg and Vitamin D3 800 IU chewable tablets, orally, once daily for up to 3 days with low calcium meals."
3137002|NCT01639209|Experimental|Vitrectomy|
3137003|NCT01639209|Experimental|Pneumatic retinopexy|
3137004|NCT01639196|Experimental|Self-compassion writing|
3137005|NCT01639196|Active Comparator|Self-efficacy writing|
3137006|NCT01639183|Experimental|Rotating-oscillating Power Toothbrush|Nursing home residents will be randomly assigned to receive power toothbrushing twice daily by their caregivers using a rotating-oscillating power toothbrush.
3137007|NCT01639183|Active Comparator|Standard Care|This arm comprises the control group where nursing home residents will receive standard daily oral care as usual.
3137008|NCT01639170|Experimental|subjects undergoing abdominal surgery|"Subjects who undergone abdominal intervention and reported major symptoms and signs suggestive of gastrointestinal perforation (abdominal pain, leukocytosis, fever) within the third postoperative day.~Exclusion criteria: inability to consent to the study, age ≤18 yr, certain or probable pregnancy, inability to remain in upright position for more than 10 minutes."
3137009|NCT01639157|Experimental|Buspirone|Subjects will be maintained on 30 mg buspirone daily.
3137010|NCT01639157|Placebo Comparator|Placebo|Subjects will be maintained on placebo (i.e., 0 mg buspirone daily).
3137011|NCT01639144|Active Comparator|Receiving PRP and PPP.|Administration of PRP and PPP to surgical site.
3137012|NCT01639144|No Intervention|Control|Group not receiving autogenous PRP and PPP.
3137013|NCT01639131|Experimental|ARM I|Patients will receive intravenous gemcitabine 800mg/m2 on days 1 and 8 and docetaxel 70mg/m2 on day 8 of each 21 day cycle. Patients will receive filgrastim (G-CSF) on days 9 through 15 or pegfilgrastim 6mg on day 9 or 10 of each cycle.
3137014|NCT01639105|Experimental|treated half of the scar|
3137015|NCT01639105|No Intervention|untreated half of the scar|
3137016|NCT01639092|Experimental|Tenofovir monotherapy|Tenofovir 300 mg/day orally
3137017|NCT01639092|Active Comparator|Tenofovir plus Entecavir combination|Tenofovir 300 mg/day orally and Entecavir 1 mg/day orally
3137018|NCT01639079|No Intervention|Usual Care for Smoking|Usual care for smoking cessation with access to the web site after 6 months
3137019|NCT01639079|Experimental|Internet Smoking Cessation Web Site|"Internet Stop Smoking site (TC5) offers a menu of several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are:~English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx"
3137020|NCT01639066|Experimental|Tenofovir plus Entecavir combination|Tenofovir 300 mg/day orally and Entecavir 1 mg/day orally
3137021|NCT01639066|Active Comparator|Tenofovir monotherapy|Tenofovir 300 mg/day orally
3137024|NCT01639040|Experimental|Placebo QW|Placebo (for Dupilumab) once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent topical corticosteroid (TCS) for up to 28 days
3137025|NCT01639040|Experimental|Dupilumab 300 mg QW|Dupilumab 300 mg once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent TCS for up to 28 days
3137026|NCT01639027|Active Comparator|Drotaverine|Women who will receive 40 mg Drotaverine hydrochloride (Do-Spa) IV injection.
3137027|NCT01639027|Placebo Comparator|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V.
3137028|NCT01639014|Experimental|F2695|
3137029|NCT01639014|Placebo Comparator|placebo|
3137030|NCT01639001|Experimental|Crizotinib|Crizotinib
3137031|NCT01639001|Active Comparator|Chemotherapy|Chemotherapy [Option at Investigator's Choice]
3137032|NCT01638988|Experimental|Metformin|
3137033|NCT01638988|Active Comparator|Clomiphene Citrate|
3137034|NCT01638975|Experimental|Computerized response inhibition training|Participants in this condition receive 8 computerized training sessions over a 4 week period.
3137035|NCT01638975|No Intervention|Waitlist Control|Participants assigned to this condition wait without an intervention until the second assessment (4 weeks after the baseline assessment).
3137036|NCT01638962|Experimental|NEMEX|NEuroMuscular EXercise
3137037|NCT01638962|Active Comparator|PHARMA|PHARMAcological pain relief
3137038|NCT01638949|Experimental|Young controls|
3137039|NCT01638949|Experimental|Middle age controls|
3137040|NCT01638949|Experimental|Elderly controls|
3137041|NCT01638949|Experimental|Asymptomatic subjects|Asymptomatic subjects from families carrying a genetic mutation with an autosomal dominant transmission
3137042|NCT01638949|Experimental|Subjectif Cognitive Impariment patients|
3137043|NCT01638949|Experimental|Mild Cognitive Impairment patients|
3137044|NCT01638949|Experimental|Alzheimer Disease patients|
3137045|NCT01638949|Experimental|Non degenerative amnsesic syndrome|
3137046|NCT01638936|Experimental|BT062|
3137047|NCT01638923|Experimental|Arm 1|
3137048|NCT01638923|Placebo Comparator|Arm 2|
3137049|NCT01638910|Experimental|EV/DNG (Qlaira, BAY86-5027)|
3137050|NCT01638884|Experimental|Young Healthy Subjects|
3137051|NCT01638884|Experimental|Middle age Healthy Subjects|
3137052|NCT01638884|Experimental|Elderly Healthy Subjects|
3137053|NCT01638884|Experimental|Mild Cognitive Impairment patients|
3137054|NCT01638884|Experimental|Alzheimer Disease patients|
3137055|NCT01638871|Experimental|Intervention Group|Study arm will complete the 8-week Internet-based pain coping skills program.
3137056|NCT01638871|No Intervention|Control Group|This study arm will only provide demographic and pain-related information.
3137057|NCT01638858|Experimental|Lucentis (Ranibizumab)|
3137058|NCT01638845|Active Comparator|continuous perineural catheter|
3137059|NCT01638845|No Intervention|Control|
3137060|NCT01638819|Experimental|Autologous Cord Blood Stem Cells|
3137061|NCT01638819|Placebo Comparator|Placebo|Saline
3137062|NCT01638806|Experimental|Group I: PPCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
3137063|NCT01638806|No Intervention|Conventional: Group II|Patients are treated as today: Admission to local hospital, Low-molecular-weight heparin (LMWH), Aspirin, ADP-blocker and within 72 hours transfer for angiography/angioplasty. Patients with a Grace score > 140 will be transferred for angiography/angioplasty within 24 hours. Patients with refractory angina, severe heart failure, life-threatening ventricular arrhythmias or haemodynamic instability will be transferred acutely for angiography/angioplasty according to the european guidelines.
3137064|NCT01638793|Experimental|Capnography|Capnographic respiration monitoring
3137065|NCT01638793|Active Comparator|Pulse-Oxymetry|pulse-oxymetric respiration monitoring
3137066|NCT01638780|Placebo Comparator|placebo|A placebo will be given for 30 days, twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
3137067|NCT01638780|Active Comparator|resveratrol|resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
3137068|NCT01638767|Experimental|NuvaRing|Patients in the NuvaRing group will be inserting the vaginal ring for a period specified by the administrative nurse, ranging from 14 to 35 days.
3137069|NCT01638767|Active Comparator|Marvelon|Patients on Marvelon will be taking the medication for a period ranging from 14 to 21 days. This period will be determined by the administrative nurse.
3137070|NCT01638728||Endotracheal tube|
3137071|NCT01638715|Experimental|Infliximab|Infliximab (Remicade®) will be administered i.v.at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.
3137072|NCT01638715|Experimental|Abatacept|Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: <60 kg Body weight (BW): 500 mg; >60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c.application at a dose of 125mg weekly.
3137073|NCT01638715|Experimental|Tocilizumab|Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.
3137074|NCT01638715|Experimental|Rituximab|Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26. Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©).
3137075|NCT01638702|Active Comparator|Right sided PICC placement|Insertion of PICC on the right arm
3137076|NCT01638702|Placebo Comparator|Left sided arm placement|Insertion of PICC on the left arm
3137077|NCT01638676|Experimental|Vemurafenib and Metformin|
3137078|NCT01638663|Active Comparator|Tolvaptan|Oral administration of 15 mg Tolvaptan on each examination day.
3137079|NCT01638663|Placebo Comparator|Placebo|Oral administration of 15 mg Unikalk tablet on each examination day.
3137080|NCT01638650|Experimental|Single Arm|
3137081|NCT01638637||Specimen Collection|
3137082|NCT01638624|Active Comparator|Propofol|Propofol infusion group: Under spinal anesthesia, a continuous intravenous infusion (2mg/kg/h) of propofol will be use during the operation
3137083|NCT01638624|Placebo Comparator|Control group|Placebo group: Under spinal anesthesia, a continuous intravenous infusion of volume-equivalent placebo will use during the operation
3137084|NCT01638611|Active Comparator|HIP2B|Six subjects per dosing cohort will receive HIP2B
3137085|NCT01638611|Placebo Comparator|Placebo|Two subjects per dosing cohort will receive placebo.
3137086|NCT01638598|Experimental|BI 1021958 dose group 1|subject to receive a tablet containing dose group 1 BI 1021958 single dose
3137087|NCT01638598|Experimental|BI 1021958 dose group 2|subject to receive a tablet containing dose group 2 BI 1021958 single dose
3137088|NCT01638598|Experimental|BI 1021958 dose group 3|subject to receive a tablet containing dose group 3 BI 1021958 single dose
3137089|NCT01638598|Experimental|BI 1021958 dose group 4|subject to receive a tablet containing dose group 4 BI 1021958 single dose
3137090|NCT01638598|Experimental|BI 1021958 dose group 5|subject to receive a tablet containing dose group 5 BI 1021958 single dose
3137091|NCT01638585|No Intervention|standard therapy|patients receiving standard therapy for diabetic foot syndrome with critical limb ischemia, i. e. structured therapy of lesions with antibiosis, pressure relief and therapy of risk factors according to the relevant guidelines.
3137092|NCT01638585|Active Comparator|urokinase|patients receiving urokinase short infusions in addition to standard therapy
3137093|NCT01638572||neuroblastoma patients|
3137094|NCT01638559|Experimental|Immunosuppression withdrawal|Gradual withdrawal of immunosuppressive treatment withdrawal as per protocol.
3137095|NCT01638546|Experimental|Arm I (veliparib and temozolomide)|Patients receive veliparib PO BID on days 1-7 and temozolomide PO on days 1-5.
3137096|NCT01638546|Active Comparator|Arm II (placebo and temozolomide)|Patients receive placebo PO BID on days 1-7 and temozolomide as in Arm I.
3137097|NCT01638533|Experimental|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3137098|NCT01638520|Experimental|Pascolizumab|The dose of study medication will be calculated using the patient's body weight and the appropriate dosing regimen based on the cohort of enrollment. The medication will be administered by slow intravenous infusion over 1 hour under close medical supervision.
3137099|NCT01638520|Placebo Comparator|Placebo|For patients randomized to placebo, Sterile 0.9% w/v Sodium Chloride will be used for Injection, using the same volume that would have been prepared if the patient had been randomized to receive pascolizumab.
3137100|NCT01638507|Other|Resolute Integrity|Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System (Resolute Integrity Stent)
3137101|NCT01638494|Experimental|Colecalcium testing|administration of Colecalcium
3137102|NCT01638481||Group #1 - Burns affecting less than 10% BSA|
3137103|NCT01638481||Group #2 - Burns affecting 10%-30% TBSA|
3137104|NCT01638481||Group #3 - Burns affecting 31%-50% TBSA|
3137105|NCT01638481||Group #4 - Burns affecting 51%-70% TBSA|
3137106|NCT01638481||Group #5 - Burns affecting >70% TBSA|
3137107|NCT01638468|Experimental|AngioJet Ultra PE Thrombectomy System|Patients are treated with the AngioJet Ultra PE Thrombectomy System
3137108|NCT01638455|Experimental|Test Group|All subjects will be enrolled in the test group and will receive the noninvasive device
3137109|NCT01638442|Experimental|Treatment A|Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
3137110|NCT01638442|Experimental|Treatment B|Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.
3137111|NCT01638416|Active Comparator|Standard of care|Blood Transfusion Standard of care- oldest blood.
3137112|NCT01638416|Other|Arm B|Blood Transfusion Freshest blood.
3137113|NCT01638403|Experimental|BF2.649|BF2.649 (pitolisant) is a novel, highly potent, selective, orally active histamine H3 receptor antagonist/inverse agonist (Ki of 0.3 nM) at the human receptor.
3137114|NCT01638403|Active Comparator|Vigil|"Therapeutic indications Narcolepsy with and without cataplexy. Moderate to severe obstructive sleep apnoea syndrome with excessive daytime sleepiness despite adequate CPAP therapy.~Moderate to severe chronic shift work sleep disorder with excessive sleepiness in patients who work rotating night shifts, if other sleep hygiene measures did not lead to a satisfactory improvement."
3137115|NCT01638403|Placebo Comparator|Placebo|
3137116|NCT01638390|Other|Treatment of Myopia|The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
3137117|NCT01638377|Experimental|Naltrexone|Drug: Naltrexone 50 mg/day for 24 weeks.All participants will receive medical intervention in the form of medical management (MM) which will be delovered by a trained health care professional.
3137118|NCT01638377|Placebo Comparator|Control|Drug: Control Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
3137119|NCT01638364|Active Comparator|alcoholic beverage|95% USP alcohol given at a dose of 1.5 g/l of body water mixed with orange juice and tonic water.
3137120|NCT01638364|Placebo Comparator|non-alcoholic beverage|Orange juice and tonic water.
3137121|NCT01638351|Active Comparator|Usual care|Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
3137122|NCT01638351|Experimental|Resistance exercise|Progressive resistance training, 3 times a week for 12 weeks
3137177|NCT01638052|Experimental|0.25% Bupivacaine + Clonidine|These are not two separate drugs, but a mixture of Bupivacaine and Clonidine.
3137178|NCT01638039|Active Comparator|Diarrheal disease|
3137179|NCT01638039|Active Comparator|Control|Samples of stool, blood, urine saliva
3137180|NCT01638026|Experimental|Gnrh agonist , hcg|Gnrh agonist for final oocyte maturation, hcg for luteal support
3137123|NCT01638338|Experimental|Web site|"A specific web site for randomization and risky alcohol consumption counseling will be beta tested and created. Risky drinkers allocated to this arm will receive web assisted brief motivational interview.~They will first be assessed towards risky alcohol consumption and Quality of life (AUDIT and EQ5D). Personal health status will also be assessed with a Likert scale. Brief Intervention will be administered following a consistent number of web pages reporting brief motivational interview Web assisted brief motivational interview on risky drinking"
3137124|NCT01638338|Experimental|Face to Face|Risky drinking brief motivational interview provided by the GP.
3137125|NCT01638325|Active Comparator|Insulin Lispro|15 international units (IU) insulin lispro administered once subcutaneously (SC) during 1 of 3 dosing periods. There is a minimum 7 day washout between dosing periods.
3137126|NCT01638325|Experimental|BC106 Insulin Lispro|15 up to 30 IU BC106 insulin lispro administered once SC during 2 of 3 dosing periods. There is a minimum 7 day washout between dosing periods.
3137127|NCT01638312||HIV infection patient and health people|The study does not have intervention
3137128|NCT01638299|Experimental|Hypo-Hyper Minimizer (HHM) System|
3137129|NCT01638286||Eperisone|
3137130|NCT01638286||Aceclofenac|
3137131|NCT01638286||Eperisone hydrochloride, Aceclofenac|
3137132|NCT01638273|Experimental|GLA5PR GLARS tablet 150mg(mealed)|Pregabalin 150mg
3137133|NCT01638273|Active Comparator|Lyrica Capsule 75mg(mealed)|Pregabalin 75mg
3137134|NCT01638260|Placebo Comparator|Liraglutide|Subjects will inject liraglutide once daily for 26 weeks
3137135|NCT01638260|Active Comparator|Liraglutide and NEAT|Subjects will inject liraglutide once daily and combine this treatment with activating lifestyle, by increasing NEAT.
3137136|NCT01638247|Active Comparator|Tamoxifen|Tamoxifen alone (daily).
3137137|NCT01638247|Experimental|Tamoxifen and GnRH analogue|Tamoxifen (daily) + GnRH analogue (at randomisation and after three months).
3137138|NCT01638247|Experimental|Exemestane and GnRH analogue|Exemestane (daily) + GnRH analogue (at randomisation and after three months).
3137139|NCT01638234|Placebo Comparator|Starch pill|
3137140|NCT01638234|Experimental|Melatonin|
3137141|NCT01638221||heavy weight mesh|Surgipro mesh is a heavier weighted mesh with less flexibility after surgery
3137142|NCT01638221||light weight mesh|UltraPro mesh is a lighter weighted mesh with theoretically less stiffness and more flexibility compared to heavier weighted meshes
3137143|NCT01638208|Experimental|VSL#3|Patients with IBS-D as per ROME III
3137144|NCT01638208|No Intervention|Healthy Controls|Healthy controls
3137145|NCT01638195|Experimental|Externally Focused Ultrasound|
3137146|NCT01638182|Active Comparator|vitamin K1 capsules|27 participants received for three months 1 vitamin K1-capsule per day containing 52 µg of K1
3137147|NCT01638182|Active Comparator|Vitamin K2-capsules|27 participants received for three months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
3137148|NCT01638182|Placebo Comparator|Placebo capsules|27 participants received for 3 months 1 placebo capsule per day
3137149|NCT01638169||20 children with DMD|
3137150|NCT01638143|Active Comparator|Gnosis P-1000 capsules|MK-7 capsules containing 75 µg of MK-7 (source: Gnosis, Italy).
3137151|NCT01638143|Active Comparator|Gnosis M1500 capsules|MK-7 capsules containing 75 µg of MK-7 (source Gnosis, Italy).
3137152|NCT01638143|Active Comparator|MenaQ7 M-1500 capsules|MK-7 capsules containing 75 µg of MK-7 (source: Nattopharma, Norway)
3137153|NCT01638117|Placebo Comparator|PAC14028-Vehicle|PAC-14028 Cream Vehicle
3137154|NCT01638117|Experimental|PAC14028-0.1|PAC-14028 Cream 0.1%
3137155|NCT01638117|Experimental|PAC14028-0.3|PAC-14028 Cream 0.3%
3137156|NCT01638117|Experimental|PAC14028-1.0|PAC-14028 Cream 1%
3137157|NCT01638117|Placebo Comparator|Placebo|Saline
3137158|NCT01638117|Active Comparator|Positive control|Sodium Lauryl Sulfate, 0.5%
3137159|NCT01638104|Experimental|ANX-042: 0.001 mcg/kg/min (with low sodium diet)|0.001 dose unit equal to 1 millionth of a gram of an ANX-042 preparation / 1 kilogram of body mass administered / unit of time equal to 1 minute(mcg/kg/min), w/ diet restricted to 2.5 grams (gm) per day sodium (Na+) and 2.1 liters (L) fluid total daily intake
3137160|NCT01638104|Experimental|ANX-042: 0.001 mcg/kg/min|0.001 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
3137161|NCT01638104|Experimental|ANX-042: 0.003 mcg/kg/min (low sodium diet)|0.003 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
3137162|NCT01638104|Experimental|ANX-042: 0.003 mcg/kg/min|0.003 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
3137163|NCT01638104|Experimental|ANX-042: 0.0065 mcg/kg/min (low sodium diet)|0.0065 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
3137164|NCT01638104|Experimental|ANX-042: 0.01 mcg/kg/min (low sodium diet)|0.01 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
3137165|NCT01638104|Experimental|ANX-042: 0.01 mcg/kg/min|0.01 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
3137166|NCT01638104|Experimental|ANX-042: 0.03 mcg/kg/min|0.03 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
3137167|NCT01638104|Experimental|ANX-042: 0.1 mcg/kg/min|0.1 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
3137168|NCT01638104|Experimental|ANX-042: 0.3 mcg/kg/min|0.3 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
3137169|NCT01638104|Placebo Comparator|Placebo (low sodium diet)|Placebo and diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
3137170|NCT01638104|Placebo Comparator|Placebo|Placebo and diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
3137171|NCT01638091|Experimental|All participating endoscopists|All endoscopists will undergo ex vivo training and will participate in in vivo practice-based learning.
3137172|NCT01638078|Active Comparator|Thalidomide|Thalidomide
3137173|NCT01638078|Placebo Comparator|Placebo|Placebo
3137174|NCT01638065||Standard|Standard IV Access without device
3137175|NCT01638065||VeinViewer|IV access with VeinViewer device
3137176|NCT01638052|No Intervention|0.25% Bupivacaine|This is our standard of care concentration
3137181|NCT01638013|Experimental|ASP015K group|oral
3137182|NCT01638000|Experimental|Mirabegron 50 mg|Participants who received mirabegron 50 mg once daily for 12 weeks.
3137183|NCT01638000|Active Comparator|Solifenacin 5 mg|Participants who received solifenacin 5 mg once daily for 12 weeks.
3137184|NCT01637987|Active Comparator|Unassisted vein visualization|
3137185|NCT01637987|Active Comparator|Wee Sight Transilluminator|
3137186|NCT01637987|Active Comparator|Near Infra-red light (VeinViewer)|
3137187|NCT01637974|Experimental|with INTERCOAT|injection of intercoat into the euterine cavity at the end of hysteroscopy
3137188|NCT01637974|No Intervention|without INTERCOAT|without INTERCOAT
3137189|NCT01637961|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3137190|NCT01637948|Active Comparator|Listerine|essential oil mouthrinse
3137191|NCT01637948|No Intervention|Negative control|without intervention
3137192|NCT01637948|Experimental|Chinese medicine mouthrinse|5% Fructus Mume extract and 2% sodium bicarbonate
3137193|NCT01637935||Pioglitazone exposed group|Defined as those patients having filled at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone group may also have exposure to other diabetic medications
3137194|NCT01637935||Pioglitazone unexposed group|Defined as patients who did not fill at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone unexposed group may have been exposed to other diabetic medications. This group also included diabetic patients without any diabetic medications.
3137195|NCT01637922|Active Comparator|Methadone group|patients on stable methadone therapy (at least 30 days) up to a maximum of 180mg per day
3137196|NCT01637922|Active Comparator|Buprenorphine|patients on stable buprenorphine/naloxone therapy (at least 30 days) up to a maximum dose of 24mg/6mg per day.
3137197|NCT01637909|Active Comparator|general management|
3137198|NCT01637909|Experimental|The treatment group1|Korean DASH diet with sodium reduction intervention
3137199|NCT01637909|Experimental|The treatment group2|Korean DASH diet with sodium reduction intervention and excersize intervention
3137200|NCT01637896|Experimental|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
3137201|NCT01637896|Active Comparator|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
3137202|NCT01637883|No Intervention|nothing|nothing will be dripped on the cuff of the endotracheal tube in the control group
3137203|NCT01637883|Experimental|benzydamine HCl|benzydamine HCl will be dripped on the cuff of the endotracheal tube 5 minutes before induction of general anesthesia
3137204|NCT01637870|Experimental|Negative pressure pump|Will have the Prevena negative pressure wound system placed at the time of surgery.
3137205|NCT01637857|Sham Comparator|lifestyle counseling|Group of patients treated with sham oligoantigenic diet
3137206|NCT01637857|Experimental|oligoantigenic diet|Treatment with oligoantigenic diat
3137207|NCT01637844|Experimental|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation start to orally take telbivudine (600 mg/day) until 4 weeks after delivery. Newborn infants receive standard immunoprophylaxis.
3137208|NCT01637844|No Intervention|Control|Infants of HBsAg- and HBeAg-positive women who are not treated with telbivudine and any other antiviral agents serve as controls. The infants are administered standard immunoprophylaxis against mother-to-infant transmission of HBV, 100-200 IU hepatitis B immunoglobulin (HBIG) within 12 hours after birth and three doses hepatitis B vaccine at 0, 1 and 6-month schedule.
3137209|NCT01637831|Experimental|Patients with OSA and IPF|Participants with Obstructive Sleep Apnea (OSA)and Idiopathic Pulmonary Fibrosis (IPF).This arm will complete pre-treatment questionnaires assessing sleep and quality of life, undergo six months of Continuous Positive Airway Pressure (CPAP) to treat OSA, and complete post-treatment the same questionnaires 1, 3 and 6 months later.
3137210|NCT01637818|Other|Lichtenstein's Operation|
3137211|NCT01637818|Other|Mesh Plug Repair|
3137212|NCT01637805|Experimental|AAV-DC-CTL|
3137213|NCT01637792|Experimental|Three 2-liter exchanges group|A group of randomly assigned patients undergoing three 2-liter exchanges daily CAPD.
3137214|NCT01637792|Active Comparator|Four 2-liter exchanges group|A group of randomly assigned patients undergoing four 2-liter exchanges daily CAPD.
3137215|NCT01637779|Experimental|fact sheet review|mothers will review a fact sheet containing information about pain management during immunization then complete a knowledge test afterward
3137216|NCT01637779|Placebo Comparator|control unrelated material|mothers will review material unrelated to pain management during immunization then complete a knowledge test
3137217|NCT01637779|Experimental|pre-test, review of fact sheet|mothers do a pre-test, then read a fact sheet about how to manage immunization pain, then repeat the test
3137218|NCT01637779|Placebo Comparator|pre-test, control unrelated information|mothers do a pre-test, then read unrelated material, then repeat the test
3137219|NCT01637766|Experimental|Selective intra-arterial chemotherapy|Subjects recruited to this study will receive intra-arterial injections of chemotherapy (melphalan) in the branches of the arteries feeding the metastatic spinal tumor. Subjects will receive general anesthesia or conscious sedation. A catheter will be guided using X-ray from the femoral artery at the top of the leg to the arteries of the spine. A dye will be injected through the catheter to show the arteries in greater detail. The chemotherapy is then injected into the tumor. We will inject the maximum systemic dose adjusted to white blood count and platelet count. Subjects will undergo three cycles of chemotherapy three to six weeks apart.
3137220|NCT01637753|Experimental|Carmustine Sustained Release Implant|
3137221|NCT01637753|Sham Comparator|Surgical control group|
3137222|NCT01637740||eyes with pseudoexfoliation syndrome|cataract myopic eyes with pseudoexfoliation syndrome
3137223|NCT01637740||eyes without pseudoexfoliation syndrome|cataract myopic eyes without pseudoexfoliation syndrome
3137224|NCT01637727||GDM1|The study group will include women who gave birth in Shaare Zedek Medical Center between the years 2000 and 2010. Women with a GDM history will be identified based on the gestational diabetes clinic files. Women without a history of GDM who will be the control group will be identified from the Shaare Zedek Medical Center birth registration records.
3137360|NCT01636739||Rota Group|Subjects will receive Rotarix® as per routine practice
3137225|NCT01637727||GDM|The study group will include women who gave birth in Shaare Zedek Medical Center between the years 2000 and 2010. Women with a GDM history will be identified based on the gestational diabetes clinic files. Women without a history of GDM who will be the control group will be identified from the Shaare Zedek Medical Center birth registration records.
3137226|NCT01637714|Experimental|Multi-strain probiotics|
3137227|NCT01637714|Placebo Comparator|Placebo powder|
3137228|NCT01637701|Active Comparator|PkEP|Patients in this group undergo PkEP using the Gyrus plasmakinetic tissue management system (Gyrus Medical Ltd,Bucks,UK).
3137229|NCT01637701|Active Comparator|B-TURP|Patients in this group undergo B-TURP using the Gyrus plasmakinetic tissue management system (Gyrus Medical Ltd,Bucks,UK).
3137230|NCT01637688||amino acid formula|Newly innovated amino acid formula Commercial amino acid formula
3137231|NCT01637675|Active Comparator|20 mg sildenafil citrate tablets by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
3137232|NCT01637675|Experimental|sodium tanshinone IIA sulfonate, sildenafil citrate tablets|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection also permitted if necessary) 250ml ivdrip once a day for 8 weeks,20mg sildenafil citrate tablets by mouth three times a day for the same duration
3137233|NCT01637662|Experimental|Healthy subjects|
3137234|NCT01637649||Stroke patients with dysphagia|Stroke patients with confirmed evidence of aspiration and severe dysphagia tha would require modified diet or nasogastric tube feeding
3137235|NCT01637649||Stroke patients without dysphagia|Stroke patients but with no gross evidence of dysphagia or with mild dysphagia with a Penetration aspiration scale of less than 4
3137236|NCT01637649||healthy volunteer group|healthy volunteers with no prior history of dysphagia or stroke and who are not included in the exclusion criteria
3137237|NCT01637636|Experimental|Rifampin|
3137238|NCT01637636|Experimental|Ketoconazole|
3137239|NCT01637623|Active Comparator|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.
3137240|NCT01637623|Active Comparator|Allopurinol|Allopurinol 300 mg daily for 6 weeks
3137241|NCT01637623|Placebo Comparator|Placebo|Placebo capsule daily for 6 weeks
3137242|NCT01637610||PPROM|All women presenting to assessment at the labour and delivery unit at RUH with suspected PPROM between 16+0 and 36+6 weeks gestation.
3137243|NCT01637584|Experimental|Prazosin|Active medication arm. Prazosin is an FDA approved medication, originally designed as an anti-hypertension medication. Side effects of the medication in some include sleepiness and once asleep, sustained sleep.
3137244|NCT01637584|Placebo Comparator|Placebo|A placebo is a sugar pill, which will be used to compare with the results of the active medication
3137245|NCT01637571|Active Comparator|Dexilant|60mg of Dexilant QD for 12 weeks
3137246|NCT01637571|Placebo Comparator|Placebo|60mg of Dexilant placebo QD for 12 weeks
3137247|NCT01637558|No Intervention|Main TB cohort|Children with tuberculosis 0-12 years of age
3137248|NCT01637558|Experimental|Lopinavir/Ritonavir - Cases|children 3-20 kg with tuberculosis and indication for LPV/r-based ART
3137249|NCT01637558|Experimental|Lopinavir/Ritonavir - Controls|Children 3-20 kg on LPV/r-based ART; no TB
3137250|NCT01637558|Experimental|Nevirapine arm|children with TB and indication for nevi rapine-based ART
3137251|NCT01637545|Active Comparator|Preop. ramosetron 0.3mg i.v.|G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery
3137252|NCT01637545|Active Comparator|Postop. ramosetron 0.3mg i.v.|G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room
3137253|NCT01637545|Active Comparator|No Ramosetron|G3 - No medication but regular antiemetics injection if the patient wants
3137254|NCT01637532|Other|Group 1|Carboplatin/Caelyx
3137255|NCT01637532|Experimental|Group 2|Carboplatin/Caelyx or doxorubicin plus Tocilizumab
3137256|NCT01637532|Experimental|Group 3|Carboplatin/Caelyx or doxorubicin plus Tocilizumab plus Peg-Intron
3137257|NCT01637519||Ureteral stone|Ten (10) patients with a unilateral, mid- or distal, ureteral (tube connecting kidney and bladder in the urinary system) stone will be enrolled and brought to completion in this study.
3137258|NCT01637506||Study group|"Age > 19~Radiological evidence indicating presence of a current renal or ureteric stone"
3137259|NCT01637506||Control group|"Age > 19.~No history of kidney stone disease"
3137260|NCT01637493|Experimental|Pegfilgrastim, 30mcg/kg|
3137261|NCT01637493|Experimental|Pegfilgrastim, 60mcg/kg|
3137262|NCT01637493|Experimental|Pegfilgrastim, 100mcg/kg|
3137263|NCT01637493|Experimental|Pegfilgrastim, 200mcg/kg|
3137264|NCT01637480|Experimental|Patellofemoral Pain Syndrome|Participants with Patellofemoral Pain Syndrome
3137265|NCT01637480|Active Comparator|Healthy control|Age- and gender-matched participants without Patellofemoral Pain Syndrome
3137266|NCT01637467|Experimental|EMS intervention|The experimental group will received EMS at a therapeutic level.
3137267|NCT01637467|Sham Comparator|Sham|The sham group will receive EMS at a sub-therapeutic level.
3137268|NCT01637454|Active Comparator|Terlipressin and Type-2 HRS|Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour.
3137269|NCT01637454|Active Comparator|Noradrenaline and Type-2 HRS|Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
3137270|NCT01637441|Experimental|laparoscopic sacropexy|under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
3137317|NCT01637077|Experimental|Arm I (pain therapy)|Patients receive pregabalin PO BID, beginning on the first night of chemotherapy, for 12 weeks and then QD for 1 week.
3137271|NCT01637441|Experimental|vaginal mesh|after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
3137272|NCT01637402|Experimental|Abiraterone Acetate in combination with prednisone|
3137273|NCT01637389|No Intervention|Control Arm|All communities (independent units/clusters) start in the control and have no intervention. All control communities cross-over to the intervention in a randomized sequence over the course of 12-15 month study.
3137274|NCT01637389|Experimental|Basic Safe Water Program|The Basic program represents a variation in the implementation of the overall intervention: a community level safe-water program that is initiated with promotional meetings and followed by the offer to install Mesita Azul disinfection systems at the household level. Communities (independent units/cluster) cross-over from the control group to the intervention group in a randomized stepped-wedge fashion -- within each crossover group of 4 clusters, 2 are randomized to the Basic program.
3137275|NCT01637389|Experimental|Enhanced Safe Water Program|The Enhanced program represents a variation in the implementation of the overall intervention: a community level safe-water program that is initiated with promotional meetings and followed by the offer to install Mesita Azul disinfection systems at the household level. Communities (independent units/cluster) cross-over from the control group to the intervention group in a randomized stepped-wedge fashion -- within each crossover group of 4 clusters, 2 are randomized to the Enhanced program.
3137276|NCT01637363|No Intervention|Regular treatment|This group is offered regular treatment from the job center i.e. exercise, mindfulness
3137277|NCT01637363|Experimental|Psychoeducation|6 x 2 hours of psychoeducation
3137278|NCT01637350||Subtotal gastrectomy , BillrothⅠ|
3137279|NCT01637350||Subtotal gastrectomy , BillrothⅡ|
3137280|NCT01637350||total gastrectomy, jejunal interposition|
3137281|NCT01637350||total gastrectomy , Roux-en-Y|
3137282|NCT01637337|Active Comparator|laparoscopic pyelolithotomy|
3137283|NCT01637337|Sham Comparator|percutaneous nephrolithotomy|
3137284|NCT01637311|Experimental|Failed HM|Patients were eligible for enrollment in the study if they were age greater than 18 years and had recurrence/persistence of symptoms after primary HM with an Eckardt symptom score ≥ 4.
3137285|NCT01637285|Experimental|PF-04856883 Treatment Arm 1|
3137286|NCT01637285|Experimental|PF-04856883 Treatment Arm 2|
3137287|NCT01637285|Experimental|PF-04856883 Treatment Arm 3|
3137288|NCT01637285|Experimental|PF-04856883 Treatment Arm 4|
3137289|NCT01637272|Experimental|SOM230|Subjects with dumping syndrome treated with pasireotide
3137290|NCT01637259|Active Comparator|NRTI + PI|arm 1
3137291|NCT01637259|Active Comparator|PI + maraviroc|arm 2
3137292|NCT01637259|Active Comparator|NRTI + maraviroc|arm 3
3137293|NCT01637246||POAG or OHT|Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy
3137294|NCT01637233||NRTI + PI|This is the randomisation of the main study, Arm 1
3137295|NCT01637233||maraviroc + PI|this is the randomisation of the main study, Arm 2
3137296|NCT01637233||maraviroc + NRTI|this is the randomisation of the main study, Arm 3
3137297|NCT01637220||case, control|Blood volume collected specifically for this study
3137298|NCT01637207|Experimental|palpation|
3137299|NCT01637207|Experimental|ultrasound|
3137300|NCT01637194|Experimental|Treatment (enzyme inhibitor, monoclonal antibody therapy)|Patients receive everolimus PO QD on days -14 and then 1-28. Patients also receive cetuximab IV over 60-120 minutes on days -7 and then once weekly beginning on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3137301|NCT01637181|Active Comparator|EVLA 940 nm|
3137302|NCT01637181|Active Comparator|EVLA 1470 nm|
3137303|NCT01637168|Experimental|Test Group|Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin - 1 tablet, 2 times a day (12/12 hours).
3137304|NCT01637168|Active Comparator|Comparator Group|Ginkgo Biloba (Tebonin ®) - 1 tablet, 2 times a day (12/12 hours).
3137305|NCT01637155|Experimental|Cholecalciferol|
3137306|NCT01637142|Experimental|LY2140023 + [14C]-LY2140023|Single oral dose of 80 mg LY2140023 followed by a single 2-hour IV infusion of approximately 100 micrograms (µg) LY2140023 containing approximately 100 nCi [14C]-LY2140023.
3137307|NCT01637142|Experimental|LY2140023 + [14C]-LY404039|Single oral dose of 80 mg LY2140023 followed by a single 2-hour IV infusion of approximately 100 µg LY404039 containing approximately 100 nCi [14C]-LY404039
3137308|NCT01637129|Active Comparator|Magnetic Stimulation|Active Magnetic Stimulation with repetitive transcranial magnetic stimulation
3137309|NCT01637129|Placebo Comparator|No Intervention|Sham Magnetic Stimulation
3137310|NCT01637116||autoimmune chronic spontaneous urticaria|Patients with chronic spontaneous urticaria with a positive ASST, who also test positive in a cell activating assay (BHRA OR CD 63 activation of healthy donor basophils) and who exhibit anti-FcεRI and/or anti-IgE autoantibodies (=autoimmune chronic spontaneous urticaria).
3137311|NCT01637116||autoreactive, non-autoimmune chronic spontaneous urticaria|Patients with chronic spontaneous urticaria with a positive ASST, who test negative in cell activation assay or who do not exhibit anti-FcεRI or anti-IgE autoantibodies (=autoreactive, non-autoimmune chronic spontaneous urticaria)
3137312|NCT01637116||non-autoreactive chronic spontaneous urticaria|Patients with chronic spontaneous urticaria and a negative ASST (= non-autoreactive chronic spontaneous urticaria)
3137313|NCT01637103|Experimental|Cognitive therapy of depression|
3137314|NCT01637103|Experimental|Bright light therapy|
3137315|NCT01637103|No Intervention|Waiting list|
3137316|NCT01637090|Experimental|all patients on study|"This will be a prospective, phase II non-randomized, open label study of single agent everolimus for the treatment of CTCL recurrent or refractory to at least one previous treatment other than topical medication. The purpose will be evaluation of safety and anti-tumor response as evaluated by serial skin examinations and assessment of tumor burden in tissue and blood.~This study will be conducted in 2 stages. During stage 1 we will enroll a maximum of 11 subjects to evaluate response rate and will only continue to stage 2, if we observe two or more responses. During stage 2, we will expand the study to an overall N of 28 patients."
3137318|NCT01637077|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID, beginning on the first night of chemotherapy, for 12 weeks and then QD for 1 week.
3137319|NCT01637051|Other|Zimmer NexGen®, Trabecular Metal Technology (TMT) Monoblock|The tibial component has a monoblock design
3137320|NCT01637051|Other|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|The tibial component has a modular design
3137321|NCT01637038|No Intervention|Control Group|no intervention
3137322|NCT01637038|Experimental|RIPC group|Those undergoing remote ischemic postconditioning
3137323|NCT01637025|Experimental|Traumastem - oxidized cellulose strip|
3137324|NCT01637025|Active Comparator|Surgicel® Original - oxidized regenerated cellulose strip|
3137325|NCT01637012|Experimental|ALEX stent arm|implantation of ALEX stent during index procedure
3137326|NCT01636999|Experimental|Butorphanol|The main study arm will be examining how well a 50% Nitrous Oxide/50% Oxygen gas mixture is in reducing labor pains in term labor patients with less than 5 cm cervical dilation, compared to 2mg of Butorphanol (a common synthetic opiod used for labor pains in this setting).
3137327|NCT01636986|Experimental|DT1|Delefilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 4 weeks
3137328|NCT01636986|Active Comparator|1DAVM|Etafilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 4 weeks
3137329|NCT01636973|Experimental|Vaporizing humidifier|Vaporizing humidifier applying during one-lung ventilation
3137330|NCT01636960|Experimental|Participants receiving PegIFN alfa-2b|Participants receive PegIFN alfa-2b 6 µg/kg subcutaneously (SC) on Day 1 of each week for 8 weeks (Induction) and then 3 µg/kg SC once weekly for up to 252 weeks (Maintenance).
3137331|NCT01636947|Experimental|Aprepitant Regimen|Participants receive one aprepitant 125 mg capsule by mouth (PO) once daily (QD) on Day 1 and one aprepitant 80 mg capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg intravenously (IV) QD and dexamethasone 12 mg PO on Day 1 and placebo for ondansetron 8 mg PO twice daily (BID) on Days 2 and 3.
3137332|NCT01636947|Active Comparator|Control Regimen|Participants receive one placebo capsule PO QD on Day 1 and one placebo capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg IV QD and dexamethasone 20 mg PO on Day 1 and ondansetron 8 mg PO BID on Days 2 and 3.
3137333|NCT01636934|Experimental|Minocycline|Two-arm, placebo-controlled pilot study to obtain preliminary estimates of treatment effects of minocycline in patients with non small cell lung cancer (NSCLC) being consented for concurrent chemoradiation (CXRT). Minocycline 100 mg capsules taken by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy. Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
3137334|NCT01636934|Placebo Comparator|Placebo|Two-arm, placebo-controlled pilot study to obtain preliminary estimates of treatment effects of minocycline in patients with non small cell lung cancer (NSCLC) being consented for concurrent chemoradiation (CXRT). Placebo capsules taken by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy. Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
3137335|NCT01636921|Experimental|Sorafenib + Radiation Therapy|Sorafenib 200 mg twice orally daily + 45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
3137336|NCT01636908|Experimental|Kinase inhibitor|Patients are cohort-wise treated with a registered (tyrosine) kinase inhibitor
3137337|NCT01636895|Experimental|SP-IPTp efficacy|Efficacy of suphladoxine/pyrimethamine as IPTp
3137338|NCT01636882|Experimental|CVA21|Dose of CAVATAK up to 3 x 10⁸ TCID50 for an additional 9 treatments at 3-week intervals
3137339|NCT01636869|Experimental|bupicavaine|
3137340|NCT01636856|Active Comparator|1|Oropharyngeal exercises and oropharyngeal functions
3137341|NCT01636856|Sham Comparator|2|Nasal dilator, respiratory exercise, nasal lavage
3137342|NCT01636843|Experimental|60 mg|
3137343|NCT01636843|Experimental|120 mg|
3137344|NCT01636843|Experimental|240 mg|
3137345|NCT01636843|Experimental|Placebo|
3137346|NCT01636830|Active Comparator|Toothbrush type - medium|This is a crossover study, where the person used either a soft brush (control) and the medium brush (test).
3137347|NCT01636830|Active Comparator|Toothbrush type - soft|This is a crossover study, where the person used either a soft brush (control)and the medium brush(test).
3137348|NCT01636817|Experimental|60 mg|
3137349|NCT01636817|Experimental|120 mg|
3137350|NCT01636817|Experimental|240 mg|
3137351|NCT01636817|Placebo Comparator|Placebo|
3137352|NCT01636804||Quicksite and Quickflex|Patients who have received the leads affected by the medical product advisory
3137353|NCT01636791|Active Comparator|Cognitive Behavior Therapy|As the trial will include several different common mental disorders, the cognitive behavior therapy used in the study will be based on the protocols with best empirical support. Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
3137354|NCT01636791|Experimental|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
3137355|NCT01636791|Experimental|CBT and Return to work|Participants randomized to this arm will receive a combination of cognitive behavior therapy and the return to work treatment. This arm is included in the study as the clinically most relevant therapy, would the return to work treatment be effective in reducing sick leave, is a treatment were patients are provided support to return to work but also is clinically effective in reducing psychiatric symptoms.
3137356|NCT01636778|Experimental|SB-497115-GR|investigational product for thrombocytopenia
3137357|NCT01636765||All participants|Patients with facial erythema associated with rosacea. There was no intervention in this study.
3137358|NCT01636752|Experimental|Deprexis|Online self-help with and without e-mail-support
3137361|NCT01636726||Patients with AMI|All patients of the study population with a record/diagnosis of AMI during the study period
3137362|NCT01636726||Patients without AMI|All patients of the study population without a record/diagnosis of AMI during the study period
3137363|NCT01636713|Experimental|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
3137364|NCT01636713|Experimental|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
3137365|NCT01636713|Placebo Comparator|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
3137366|NCT01636700|Active Comparator|tramadol infiltration|infiltration of tramadol 2mg/kg
3137367|NCT01636700|Placebo Comparator|Saline solution|Infiltration of saline
3137368|NCT01636687|Experimental|Placebo|Subjects who were at placebo at Week 52 cannot continue in the extension treatment period
3137369|NCT01636687|Experimental|Secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period
3137370|NCT01636687|Experimental|Secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period
3137371|NCT01636661|Experimental|Transcranial Direct Current Stimulation|Receiving active tDCS
3137372|NCT01636661|Sham Comparator|Sham tDCS|tDCS equipment set to placebo setting.
3137373|NCT01636635|Active Comparator|Young (18-45 years)|Obese young women (18-45y) undergoing calorie restriction.
3137374|NCT01636635|Experimental|Older (>60 years)|Obese older women (>60y) undergoing calorie restriction.
3137375|NCT01636622|Experimental|Vemurafenib + Carboplatin + Paclitaxel|"All 3 study drugs will start on day 1 of cycle 1. Cycle defined as 3 weeks. On day 1, paclitaxel and carboplatin will be administered first, and the vemurafenib administration will start in the evening that day.~Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.~Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.~Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle."
3137376|NCT01636609|Experimental|Cytarabine + Tosedostat|"Phase I Arm A: Starting dose of Cytarabine 7.5 mg subcutaneous (SQ) twice daily (BID) for 10 days every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 10 mg SQ BID for 10 days.~Phase II (Randomized) Starting dose of Cytarabine: Maximum tolerated dose from Phase I.~Phase I and II Tosedostat: 120 mg by mouth daily. After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade >/= 3 toxicity. Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis."
3137377|NCT01636609|Experimental|5-Azacytidine + Tosedostat|"Phase I Arm B: Starting dose of 5-azacytidine 50 mg/m2 by vein (IV) or subcutaneously (SQ) daily for 7 days, on days 1-7 every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 75 mg/m2 IV (or SQ) daily for 7 days, on days 1-7.~Phase II (Randomized) Starting dose of 5-azacytidine: Maximum tolerated dose from Phase I.~Phase I and II Tosedostat: 120 mg by mouth daily. After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade >/= 3 toxicity. Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis."
3137378|NCT01636583|Experimental|LSF water without meal|Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
3137379|NCT01636583|Active Comparator|LSF water and inhibitory meal|Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
3137380|NCT01636583|Active Comparator|Fortified inhibitory meal with water|Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
3137381|NCT01636570|Active Comparator|Vitamin D3 (cholecalciferol)|10,000 International Units of vitamin D3 will be given daily for 6 months in vitamin D deficient heart failure patients.
3137382|NCT01636570|Placebo Comparator|Sugar Pill|Patients will be given an placebo that is identical in appearance to the active comparator. It will be given as 2 gelcaps per day.
3137383|NCT01636557|Experimental|Sirukumab and 5-probe cocktail|The 5-probe cocktail will consist of oral doses of midazolam, warfarin/vitamin K, omeprazole, and caffeine.
3137384|NCT01636544|Experimental|contralateral healthy tissue biopsy|
3137385|NCT01636531|Experimental|HCLF|
3137386|NCT01636531|Active Comparator|LyoF|
3137387|NCT01636518||Atrial Fibrillation|Patients with Atrial Fibrillation that undergo standard of care procedure at the University of Kansas Hospital
3137388|NCT01636505|Active Comparator|short protocol|gnrh agonist versus gnrh antagonist
3137389|NCT01636505|Active Comparator|long protocol|
3137390|NCT01636492|Experimental|Bitopertin|
3137391|NCT01636492|Placebo Comparator|Placebo|
3137392|NCT01636479|Experimental|SAR405838|SAR405838 in escalating doses
3137393|NCT01636466|Experimental|Everolimus conversion|Subjects who have previously undergone a kidney transplant and are in late stage renal allograft failure will be randomized to take everolimus 0.75 mg twice daily after discontinuing current calcineurin inhibitor. Subjects will be weaned off of all other immunosuppression medicines when dialysis starts.
3137394|NCT01636466|No Intervention|Control|Subjects who have previously undergone a kidney transplant and are in late stage renal allograft failure will be randomized to continue on current immunosuppressive regimen. Subjects will be weaned off of all immunosuppression medicines when dialysis starts.
3137395|NCT01636453|Experimental|Liberty Stent arm|Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
3137396|NCT01636440|Other|Reliability|The same testing procedure is repeated after a delay of 7 days to test the reliability of the measure
3137397|NCT01636414|Active Comparator|Hemovac drain|
3137398|NCT01636414|Active Comparator|Re-infusion drain|
3137399|NCT01636414|Active Comparator|Tranexamic drain|
3137400|NCT01636401|Active Comparator|aclidinium bromide|
3137401|NCT01636401|Placebo Comparator|Placebo|
3137494|NCT01635738|Experimental|LF GM-090 group|Arm: LF GM-090 group One capsule with 2x10^9 (cfu) LF GM-090, once daily, PO
3137402|NCT01636388|Experimental|Allogeneic Stem Cell Transplantation|Reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP specific cytotoxic T-lymphocyte (CTL) infusions in EBV positive patients with poor risk Hodgkin Lymphoma.
3137403|NCT01636375||Direct Anterior Approach|
3137404|NCT01636375||Posterior Approach|
3137405|NCT01636362|Experimental|Mepitel Ag|Mepitel Ag is an antimicrobial, meshed, non-adherent wound contact layer allowing passage of exudate and providing fixation and protection of tissues.
3137406|NCT01636349|Experimental|Recreational soccer training|12 men participate in recreational soccer training for 6 months
3137407|NCT01636349|No Intervention|Control group|10 subjects serve as a control group with no change in lifestyle in the study period
3137408|NCT01636336|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
3137409|NCT01636336|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
3137410|NCT01636323|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
3137411|NCT01636323|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
3137412|NCT01636310|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
3137413|NCT01636310|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
3137414|NCT01636297|Experimental|Forced exercise|
3137415|NCT01636297|Experimental|Voluntary Exercise|
3137416|NCT01636297|Experimental|No Exercise|
3137417|NCT01636284|Experimental|JX-594 recombinant vaccina GM-CSF|JX-594 recombinant vaccina GM-CSF
3137418|NCT01636271||Group 1: subjects from LPL100601|randomized subjects in study LPL100601
3137419|NCT01636271||Group 2: subjects from SB480848/033|randomized subjects in study SB480848/033
3137420|NCT01636258|No Intervention|Arm A: Control group|These participants will continue to receive their usual care from their primary medical care team.
3137421|NCT01636258|Experimental|Arm B|Arm includes diet instruction, exercise, stress management, and culinary education
3137422|NCT01636245|Experimental|Lot 1|inactivated vaccine (Lot 1) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
3137423|NCT01636245|Experimental|Lot 2|inactivated vaccine (Lot 2) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
3137424|NCT01636245|Experimental|Lot 3|inactivated vaccine (Lot 3) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
3137425|NCT01636245|Placebo Comparator|Placebo|Placebo in 350 infants aged 6 months to 5 years old on day 0,28
3137426|NCT01636232||ICU sepsis group|The ICU sepsis group consisting of 105 critically-ill cases diagnosed with sepsis upon admission and sampled within the first 24h of their ICU stay.
3137427|NCT01636232||ICU control group|the ICU control group including 51 critically-ill cases in whom sepsis was clinically excluded and from whom samples were taken upon admission.
3137428|NCT01636232||healthy control group|the healthy control group composed of 50 healthy control outpatients. For the healthy control outpatients, possibilities of acute or past chronic diseases were excluded. Moreover, we made sure that the healthy control subjects had not been hospitalized or taken vitamin-based substitutive drugs in the last 12 months, and proved normal in physical checkups and lab examinations.
3137429|NCT01636206|Placebo Comparator|Placebo|Placebo
3137430|NCT01636206|Experimental|Lifitegrast|Active
3137431|NCT01636193||Rota Group|Subjects will receive Rotarix® as per routine practice.
3137432|NCT01636180|Experimental|Clopidogrel - Repeated Loading Dose|repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
3137433|NCT01636180|Active Comparator|Clopidogrel - standard of care|no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
3137434|NCT01636154|No Intervention|The basic treatment|Comply to the Chinese guidelines of acute ischemic stroke in 2010
3137435|NCT01636154|Other|Clearing heat|Treat with KDZ injection on the basis of the basic treatment
3137436|NCT01636154|Other|Promoting blood circulation|Treat with Xueshuantong injection on the basis of the basic treatment
3137437|NCT01636154|Experimental|Clearing heat & Promoting blood circulation|Treat with both KDZ injection and Xueshuantong injection on the basis of the basic treatment
3137438|NCT01636141|Placebo Comparator|Placebo gel|Each study group consists of 6 subjects randomized in a 5:1 ratio to receive OLT1177 Gel or placebo gel in both Part A and B of the study. Eighteen subjects will be enrolled in Part A and 18 in Part B. A total of 30 subjects will receive OLT1177 Gel and 6 subjects will receive placebo gel.
3137439|NCT01636141|Active Comparator|OLT1177 Gel|Each study group consists of 6 subjects randomized in a 5:1 ratio to receive OLT1177 Gel or placebo gel in both Part A and B of the study. Eighteen subjects will be enrolled in Part A and 18 in Part B. A total of 30 subjects will receive OLT1177 Gel and 6 subjects will receive placebo gel.
3137440|NCT01636128|Experimental|Sulindac first (Treatment Sequence B)|Sulindac alone, washout, DFMO alone, then combination of sulindac and DFMO
3137441|NCT01636128|Experimental|DFMO first (Treatment Sequence A)|DFMO alone, followed by washout, sulindac alone, then combination of DFMO and sulindac
3137442|NCT01636102|Experimental|Arm 1|
3137443|NCT01636089|Experimental|bicarbonates|sodium bicarbonates 1,4%
3137444|NCT01636089|Active Comparator|saline|sodium chloride 0,9%
3137445|NCT01636076|Experimental|QMF149|QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device
3137446|NCT01636076|Active Comparator|Salmeterol xinafoate/fluticasone propionate|Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®
3137447|NCT01636063|Experimental|Mifepristone|Subjects will receive 200 mg of capsulized mifepristone orally for the purpose of cervical preparation before surgical abortion
3137448|NCT01636063|Active Comparator|Misoprostol|Subjects will receive 400 mcg of buccal misoprostol for the purposes of cervical preparation.
3137449|NCT01636050|Experimental|Training group|
3137450|NCT01636050|Experimental|Control group|
3137451|NCT01636037|Experimental|L-Dopa (Sinemet)|Augmentation of current antipsychotic treatment with oral L-Dopa (levodopa/carbidopa) up to 900mg daily for 8 weeks
3265303|NCT00730938|Active Comparator|1|
3137452|NCT01636024|Experimental|1|Subjects will participate in 1 of up to 9 groups in Part A (single ascending dose part) or 1 of 4 groups in Part B (multiple ascending dose part). Ratio of subjects receiving AZD7594 versus placebo is 6:2 in part A and 6:3 in Part B.
3137453|NCT01636024|Placebo Comparator|2|Subjects will participate in 1 of up to 9 groups in Part A or 1 of 4 groups in Part B. Ratio of subjects receiving AZD7594 versus placebo is 6:2 in part A and 6:3 in Part B.
3137454|NCT01636011|Experimental|OMM Treatment|In this group the subjects are given 5 different OMM treatments addressing the thoracic cage.
3137455|NCT01636011|Sham Comparator|Light Touch sham|In this group the physician uses the dorsum of his hand to the same areas and for the same time that the OMM treatment arm receives.
3137456|NCT01635998|Experimental|Intervention arm|These subjects will undergo routine catheter ablation of atrial fibrillation PLUS renal sympathetic denervation with the Boston Scientific Vessix Renal Denervation System.
3137457|NCT01635998|No Intervention|Control arm|These subjects will undergo routine catheter ablation of atrial fibrillation only.
3137458|NCT01635985|Experimental|1|AZD5423 iv
3137459|NCT01635985|Experimental|2|AZD5423 inhalation, Spira
3137460|NCT01635985|Experimental|3|AZD5423 inhalation I-neb
3137461|NCT01635985|Experimental|4|AZD5423 oral
3137462|NCT01635985|Experimental|5|AZD5423 inhalation Turbuhaler
3137463|NCT01635985|Experimental|6|AZD5423, New Dry Powder Inhaler
3137464|NCT01635972|Experimental|Isavuconazole and bupropion|Bupropion hydrochloride on Days 1 and 15, Isavuconazole three times per day (TID) on Days 8 and 9, and once daily (QD) on Days 10 thru 20.
3137465|NCT01635959||Patients with Gastrointestinal Trackt Symptoms|
3137466|NCT01635946|Experimental|Isavuconazole and atorvastatin|Atorvastatin on Days 1 and 12, Isavuconazole three times per day (TID) on Days 8 and 9, and once daily (QD) on Days 10 thru 15
3137467|NCT01635933|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn in daily wear modality for 4 weeks. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
3137468|NCT01635933|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color worn in daily wear modality for 4 weeks, with a replacement pair dispensed at 14 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
3137469|NCT01635920|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn bilaterally for a minimum of 5 days per week, 8 hours per day, in daily wear modality for 4 weeks.
3137470|NCT01635920|Active Comparator|AIR OPTIX® AQUA|Lotrafilcon B contact lens worn bilaterally for a minimum of 5 days per week, 8 hours per day, in daily wear modality for 4 weeks.
3137471|NCT01635894|Experimental|nurse specialist|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment and training and were followed-up for their final assessment at 3 months."
3137472|NCT01635894|Experimental|practice nurse|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment and training and were followed-up for their final assessment at 3 months."
3137473|NCT01635894|No Intervention|Control|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment (but no training given) and were followed-up for their final assessment at 3 months."
3137474|NCT01635881|Experimental|Emerge|Single arm with investigational Emerge™ 1.20 mm PTCA Dilatation Catheter
3137475|NCT01635868||umbilical hernia repair|patients having umbilical or epigastric hernia repair from 2008-2010 in Zealand
3137476|NCT01635855|Experimental|Belotero|Belotero® Hyaluronic acid dermal filler
3137477|NCT01635829|Experimental|Panel 1|Part 1 of Panel 1: Participants will receive telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750-mg dose in the morning on Day 10. Part 2 of Panel 1: Participants will receive phenytoin 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750-mg dose in the morning on Day 17.
3137478|NCT01635829|Experimental|Panel 2|"Part 1 of Panel 2: Participants will receive telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750-mg dose in the morning on Day 10. Part 2 of Panel 2: Participants will receive carbamazepine 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750-mg dose in the morning on Day 17.~brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm."
3137479|NCT01635816|Active Comparator|JE Vaccine existing facilities|will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
3137480|NCT01635816|Active Comparator|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
3137481|NCT01635816|Active Comparator|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
3137482|NCT01635816|Active Comparator|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
3137483|NCT01635803|Active Comparator|Ranibizumab|Monthly injections with ranibizumab during 6 months
3137484|NCT01635803|Active Comparator|Bevacizumab|Monthly injections with bevacizumab during 6 months
3137485|NCT01635790|Active Comparator|Ranibizumab|0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months
3137486|NCT01635790|Active Comparator|Bevacizumab|1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months
3137487|NCT01635777|Experimental|12 weeks|miltefosine 12 weeks
3137488|NCT01635777|Experimental|8 weeks|miltefosine 8 weeks
3137489|NCT01635764|Experimental|Adalimumab Every Week|Adalimumab 40 mg every week.
3137490|NCT01635751|Experimental|GLA5PR GLARS tablet 150mg(fasted)|
3137491|NCT01635751|Experimental|GLA5PR GLARS tablet 150mg(after high fat meal)|
3137492|NCT01635751|Active Comparator|Lyrica Capsule 75mg(fasted)|
3137493|NCT01635738|Experimental|LP GMNL-133 group|Arm: LP GMNL-133 group One capsule with 2x10^9 (cfu) LP GMNL-133, once daily, PO
3137495|NCT01635738|Experimental|LP GMNL-133+LF GM-090 group|One capsule with 2x10^9 (cfu) LP GMNL-133+ 2x10^9 (cfu)LF GM-090, once daily, PO
3137496|NCT01635738|Placebo Comparator|Placebo|
3137497|NCT01635712|Experimental|SNX-5422|Open label administration of SNX-5422 capsules every other day (QOD) for 21 days on a 28 day cycle. Dose escalation will be based on safety outcomes defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level
3137498|NCT01635686|Experimental|DWP422|
3137499|NCT01635686|Active Comparator|ENBREL|
3137500|NCT01635673|No Intervention|Control Group|A group that continues with their normal daily activities for the duration of the study
3137501|NCT01635673|Experimental|Exercise Group|This group exercises 3 times each week
3137502|NCT01635660|Active Comparator|C-MAC System|
3137503|NCT01635660|Active Comparator|AP Advance|
3137504|NCT01635660|Active Comparator|King Vision|
3137505|NCT01635647|Active Comparator|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
3137506|NCT01635647|Placebo Comparator|Rabies vaccine|2 x 2.5IU Verorab
3137507|NCT01635634|Sham Comparator|Sham Cupping|Dry Cupping Therapy 5 serial treatments twice weekly 4-8 cups at the upper and lower back
3137508|NCT01635634|Experimental|Cupping Therapy|Dry Cupping 5 serial treatments twice weekly 4-8 cups at the upper and lower back
3137509|NCT01635634|No Intervention|Wait list|Wait list control no specific intervention for 3 weeks study period
3137510|NCT01635621|Experimental|OKZ 120 mg|
3137511|NCT01635621|Experimental|OKZ 240 mg|
3137512|NCT01635621|Experimental|OKZ 120 mg with 480 mg loading dose at Week 0|
3137513|NCT01635621|Placebo Comparator|Placebo|
3137514|NCT01635608|Active Comparator|non-caloric water|500 mg paracetamol, 50 mg talinolol and 500 mg amoxicillin dissolved in 240 ml non-caloric water immediately before administration after overnight fasting
3137515|NCT01635608|Active Comparator|caloric water|500 mg paracetamol, 50 mg talinolol and 500 mg amoxicillin dissolved in 240 ml caloric water immediately before oral administration after overnight fasting
3137516|NCT01635595||Patients with BIM|Patients affected by adenocarcinoma of the distal esophagus and cardia with preoperative diagnosis of BIM underwent subtotal esophagectomy and gastric pull up.
3137517|NCT01635595||Patients without BIM|Patients affected by adenocarcinoma of the distal esophagus and cardia without preoperative diagnosis of BIM underwent subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy.
3137518|NCT01635582|Active Comparator|Control group|Conventional hand exercise program
3137519|NCT01635582|Experimental|Experimental group|Computer gaming hand exercise regimen'
3137520|NCT01635569|Active Comparator|OCD-affected subjects (Group 1)|OCD-affected subjects will participate in 12 sessions of group therapy (as per GF-CBT protocol).
3137521|NCT01635569|Active Comparator|OCD-affected subjects (Group 2)|Waitlist affected-controls awaiting a treatment spot.
3137522|NCT01635543||Crohn's Disease with peri-anal fistulas|Identifying Crohn's Disease patients with peri-anal fistulas and suffering from sexual dysfunction.
3137523|NCT01635530|Active Comparator|Ceftriaxone|Treatment of intravenous ceftriaxone (2 g/day), three weeks
3137524|NCT01635530|Experimental|Doxycycline|Treatment with oral doxycycline (200mg / day), four weeks
3137525|NCT01635517||Tolvaptan|Tolvaptan administration
3137526|NCT01635504|Experimental|botulinum toxin A|
3137527|NCT01635465||Observation group:vinorelbine plus capecitabine|
3137528|NCT01635465||Control group:docetaxel plus capecitabine|
3137529|NCT01635452||Patients treated with Esmya|
3137530|NCT01635439|Active Comparator|Propess|Propess insert is a preparation of PGE2 packaged in a hydrogel polymer matrix and designed for slow intravaginal release of 10 mg dinoprostone at a rate of 0.3 mg/h.
3137531|NCT01635439|Active Comparator|Prostin E2|PROSTIN E2 Vaginal Suppository, an oxytocic, contains dinoprostone as the naturally occurring prostaglandin E2 (PGE2)3 mg/suppository.
3137532|NCT01635426|Active Comparator|Aspirin|
3137533|NCT01635426|Active Comparator|Clopidogrel|
3137534|NCT01635413|Experimental|Arm I (strength training)|Patients attend strength training classes for 1 hour 2 days per week.
3137535|NCT01635413|Experimental|Arm II (tai chi)|Patients attend tai chi classes for 1 hour 2 days per week.
3137536|NCT01635413|Active Comparator|Arm III (control)|Patients attend supervised stretching and relaxation classes for 1 hour 2 days per week.
3137537|NCT01635400|Other|UGT1A1 wild type (6/6)|
3137538|NCT01635400|Other|UGT1A1 heterozygous genotype (6/7)|
3137539|NCT01635400|Other|UGT1A1 homozygous genotype(7/7)|
3137540|NCT01635387|Experimental|Aliskiren|
3137541|NCT01635387|Placebo Comparator|Placebo|
3137542|NCT01635374|Experimental|Per-Oral Endoscopic Esophagomyotomy|Patients will have a standard pre-operative work-up that may include upper endoscopy (EGD), endoscopic ultrasound (EUS), upper GI X-rays, high-resolution manometry, pH, FLIP and impedance measurement studies. Once a diagnosis of esophageal motility disorder is confirmed, patients will be offered POEM or standard treatment. Patients undergoing POEM will review and sign the study consent prior to their procedure. Patients will return and be evaluated two weeks following their procedure. At this visit, any post-operative complications will be noted in the patient's medical record. Also, at this visit and at the preoperative visit, patients will complete a standardized Quality of Life assessment. Perceived pain levels and type and frequency of pain medications will be recorded in the patient's medical record. Patients will then return at 6 weeks post-op to complete a second set of questionnaires and have a high resolution manometry performed to assess residual LES pressure.
3137543|NCT01635361|Experimental|NMS|Patients in this arm will receive the full NMS service
3137544|NCT01635361|No Intervention|Current Practice|Patients in this arm will receive the normal advice with their new medicine as dictated by current professional practice
3137545|NCT01635348|Experimental|motor skill gait exercise arm|motor skill gait exercise intervention: stepping and walking patterns, and speed interval treadmill-assisted walking to enhance timing and coordination in walking
3137546|NCT01635348|Active Comparator|aerobic gait exercise arm|aerobic gait exercise intervention: treadmill-assisted and overground walking exercise to enhance walking practice and improve endurance in walking
3265663|NCT00728455|Experimental|C|
3137547|NCT01635335|Experimental|HIV-specific|7-hour multiple family workshop focused on providing information and skills related to HIV prevention. Specific focus on parent-adolescent communication and parental monitoring.
3137548|NCT01635335|Active Comparator|General Health Promotion|7-hour multiple family workshop focused on providing information related to various adolescent health risk behaviors, including smoking, alcohol, violence, nutrition, and exercise.
3137549|NCT01635322||Lumbar or thoraco-lumbar Adult Deformity|Lumbar or thoraco-lumbar Adult Deformity
3137550|NCT01635309||Non-cardiac surgical patients|>= 45 years old, undergoing non-cardiac surgery requiring regional or general anaesthetic and an overnight stay with cardiac risk factors
3137551|NCT01635296|Experimental|A: Previously untreated|
3137552|NCT01635296|Experimental|B: Relapse/Refractory|
3137553|NCT01635283|Experimental|Treatment (tumor lysate-pulsed autologous dendritic cells)|Patients receive autologous glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 0, 14, and 28.
3137554|NCT01635270|Experimental|midP arm|Patients treated with midP radiotherapy strategy.
3137555|NCT01635270|Active Comparator|ITV arm|Patient treated with radiotherapy ITV strategy
3137556|NCT01635257||suspected pulmonary embolism patients|patients with clinical suspicion of PE and with a simplified Well's score>4 (PE likely) or with a D-dimer value ≥500ng/ml presenting to the emergency departments of Careggi University Hospital (Firenze), of San Luigi Gonzaga University Hospital (Torino) of Ospedale Pierantoni-Morgagni (Forlì)
3137557|NCT01635244|Active Comparator|Freestyle|Aortic valve replacement will be performed with a Freestyle stentless aortic bioprosthesis (Medtronic Cardiovascular; Minneapolis, MN).
3137558|NCT01635244|Active Comparator|Magna Ease|Aortic valve replacement will be performed with a Magna Ease aortic bioprosthesis (Edwards Lifesciences; Irvine, CA).
3137559|NCT01635244|Active Comparator|Trifecta|Aortic valve replacement will be performed with a Trifecta aortic bioprosthesis (St. Jude Medical; St. Paul, MN).
3137560|NCT01635231|Active Comparator|thiazide, diuretic|1.25 mg thiazide twice daily for 5 days
3137561|NCT01635231|Active Comparator|amiloride, diuretic|5 mg of amiloride twice daily
3137562|NCT01635231|Placebo Comparator|calcium|placebo twice daily for 5 days
3137563|NCT01635218|Experimental|Individualized homeopathic treatment|Selection of the individualized homeopathic remedy based on Hahnemann´s methodology after the case history of each patient.
3137564|NCT01635218|Experimental|Fluoxetine|Selective serotonin reuptake inhibitor.
3137565|NCT01635218|Placebo Comparator|Placebo|Fluoxetine placebo plus individualized homeopathic placebo
3137566|NCT01635205|Experimental|paraspinous block|Paraspinous anesthetic block in the thoracolumbar region, in sensitized segments
3137567|NCT01635205|Sham Comparator|control|Subcutaneous puncture with no anesthetic effect
3137568|NCT01635192|Active Comparator|VSL#3|
3137569|NCT01635192|Placebo Comparator|Inactive treatment|
3137570|NCT01635179|Experimental|Cricoid pressure|A cricoid pressure of 30 N is done to occlude esophagus under a rapid sequence induction.
3137571|NCT01635166|Other|Delta Motion|A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement
3137572|NCT01635153|Active Comparator|Protein calorie supplement plus micronutrient|
3137573|NCT01635153|Placebo Comparator|Micronutrient alone|
3137574|NCT01635140|Experimental|Hypofractionated arm|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed
3137575|NCT01635140|Other|Conventional arm|The same planning and treatment procedures will be performed with the established conventional regimen: 54 Gy in 30 fractions giving 1.8 Gy per fraction.
3137576|NCT01635127|Experimental|Canakinumab|Monoclonal antibody inhibiting interleukin 1 beta
3137577|NCT01635127|Placebo Comparator|Placebo|Constituent, inactive
3137578|NCT01635114|Active Comparator|resVida (resveratrol)|
3137579|NCT01635114|Placebo Comparator|Placebo|
3137580|NCT01635101|Experimental|IV Acetaminophen|IV acetaminophen
3137581|NCT01635101|Placebo Comparator|Normal Saline|Placebo saline
3137582|NCT01635088|Other|Mometasone furoate 220 vs. Mometasone furoate 440|
3137583|NCT01635088|Active Comparator|Mometasone 220 mcg vs. 440 mcg|Inhaled steroid
3137584|NCT01635075|Experimental|Exercise|1-mile treadmill walk
3137585|NCT01635075|Placebo Comparator|Passive|20 min inactivity
3137586|NCT01635062|Experimental|calcitriol|Subjects will receive calcitriol (titrated up to 0.75 mcg daily) for 3 weeks.
3137587|NCT01635062|Placebo Comparator|placebo|Subjects will receive placebo for 3 weeks.
3137588|NCT01635049||Women undergoing IVF treatment and CCS|•Women undergoing fresh IVF treatment and undergoing CCS, as recommended based on medical need by the clinical site reproductive endocrinologist.
3137589|NCT01635036||Women undergoing IVF treatment|Women undergoing IVF treatment
3137590|NCT01635023|Experimental|AZD6244 white capsule|75mg AZD6244 white (current Phase II) capsule
3137591|NCT01635023|Experimental|AZD6244 blue capsule|75mg AZD6244 blue (planned Phase III) capsule
3137592|NCT01635023|Experimental|AZD6244 solution|35mg AZD6244 oral solution
3137593|NCT01635010|No Intervention|Control|
3137594|NCT01635010|Experimental|Obstructive sleep apnea|
3137595|NCT01634971|No Intervention|External Drainage of pancreatic duct|External Drainage of pancreatic duct was used in PD.
3137596|NCT01634971|Experimental|Internal Drainage of Pancreatic Duct|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
3137597|NCT01634958|Experimental|10.000 DPP/ml suspension for s.c. inj.|
3137598|NCT01634958|Experimental|5.000 DPP/ml suspension for s.c. inj.|
3137599|NCT01634958|Experimental|1.000 DPP/ml suspension for s.c. inj.|
3137600|NCT01634958|Experimental|100 DPP/ml suspension for s.c. inj.|
3137601|NCT01634945|Placebo Comparator|Placebo|Placebo
3137602|NCT01634945|Experimental|FeFum porridge + IPT of malaria|
3137603|NCT01634945|Experimental|IPT of malaria|
3137604|NCT01634945|Experimental|FeFum porridge|
3137605|NCT01634945|Experimental|FePP porridge|
3137606|NCT01634932|Experimental|regular-iron millet|
3137607|NCT01634932|Experimental|iron-biofortified millet|
3137608|NCT01634932|Experimental|Post-harvest iron-fortified millet|
3137609|NCT01634919||Chronic hepatitis C|Chronic hepatitis C
3137610|NCT01634906|Experimental|Discontinuation of statin therapy|
3137611|NCT01634893|Experimental|Sorafenib plus Hydroxychloroquine|"Dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2."
3137612|NCT01634880|Experimental|Postoperative Radiotherapy and Panitumumab|
3137613|NCT01634867||Intraosseous (IO) drug delivery|patients in whom intraosseous (IO) vascular access has been established for rapid sequence intubation drug delivery.
3137614|NCT01634867||Peripheral intravenous (IV) drug delivery|patients in whom peripheral intravenous (IV) vascular access has been established for rapid sequence intubation drug delivery.
3137615|NCT01634854|Active Comparator|Vaginal Misoprostol|Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
3137616|NCT01634854|Active Comparator|Intravenous Oxytocin|"2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.~Route of administration: intravenous"
3137617|NCT01634841|Active Comparator|Walnut group|This group will have their habitual diet supplemented with 30 to 45g (1 to 1.5 oz) of walnuts daily.
3137618|NCT01634841|Active Comparator|Control group|This group will eat their habitual diet and refrain from eating walnuts.
3137619|NCT01634828||Minimal blood loss patients|
3137620|NCT01634828||Moderate to heavy blood loss patients|
3137621|NCT01634815|Experimental|lactate group|
3137622|NCT01634802|No Intervention|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
3137623|NCT01634802|Experimental|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
3137624|NCT01634789|Experimental|Test Treatment 1: bazedoxifene|Test Treatment 1
3137625|NCT01634789|Experimental|Test Treatment 2: bazedoxifene|Test Treatment 2
3137626|NCT01634789|Experimental|Test Treatment 3: bazedoxifene|Test Treatment 3
3137627|NCT01634789|Experimental|Reference Treatment: bazedoxifene/conjugated estrogens|Reference Treatment
3137628|NCT01634776|Placebo Comparator|Corn oil|1288 mg/day corn oil
3137629|NCT01634776|Experimental|Flaxseed oil|1200 mg/day flaxseed oil
3137630|NCT01634763|Experimental|Dose-escalation|Open-label dose escalation study of LDK378, administered orally in Japanese patients with tumors characterized by genetic alterations in anaplastic lymphoma kinase (ALK)
3137631|NCT01634763|Experimental|Dose-expansion|Open-label study of LDK378, administered orally in Japanese patients with tumors characterized by genetic alterations in ALK to see further safety, anti-tumor activity, and PK data in patients who has progressed since prior therapy with alectinib
3137632|NCT01634750|Experimental|ManNac|
3137633|NCT01634750|Placebo Comparator|Placebo|
3137634|NCT01634737||Patients with shellfish allergy|Patients with symptoms of allergy to shellfish (OAS-Oral allergy syndrome and/or systemic symptoms) and circulating IgE positive for the extract of shrimp (> 0.10 kU/L)
3137635|NCT01634737||Patients with respiratory allergy|Patients with respiratory allergy and IgE positive to dust mites, asymptomatic for shrimp or other shellfish and circulating IgE positive for shrimp
3137636|NCT01634724|Experimental|GnRH agonist withdrawal|All the patients received a midluteal long GnRH agonist (GnRH-a) and a gonadotropins (recombinant FSH) stimulation protocol. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (0.05mg/d) was withheld in the study group.
3137637|NCT01634724|No Intervention|control group|All the patients received a midluteal long GnRH agonist (GnRH-a) and a gonadotropins (recombinant FSH) stimulation protocol. In the control group, GnRHa (triptorelin, 0.05mg/d,)was used to the day of ovulation trigger.
3137638|NCT01634711|Experimental|The L-C Ligament|Soft Tissue Regeneration's L-C Ligament is an interventional device intended for ACL reconstruction surgery within 13 weeks of acute rupture of the ACL and no previous treatment. The L-C Ligament temporarily replaces the human anterior cruciate ligament (ACL) and provides a bioresorbable scaffold within and around which the native ACL will regenerate over time.
3137639|NCT01634698|Experimental|RDR test (1500 UI vitamin A)|81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 1500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).
3137640|NCT01634698|Experimental|RDR test (2500 IU vitamin A)|81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 2500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).
3137641|NCT01634685|Experimental|Bavituximab, Capecitabine, Radiation|one arm
3137642|NCT01634672||hemodialysis patients|
3137643|NCT01634672||Peritoneal dialysis patients|
3137644|NCT01634659|Other|Delefilcon A, then narafilcon B|Delefilcon A contact lenses (DAILIES TOTAL1®) worn first, followed by narafilcon B contact lenses (1-DAY ACUVUE® TruEye®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
3137645|NCT01634659|Other|Narafilcon B, then delefilcon A|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®) worn first, followed by delefilcon A contact lenses (DAILIES TOTAL1®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
3137696|NCT01634295|Experimental|CKD-828 2.5/40, 2.5/80, 5/80mg|
3137697|NCT01634295|Active Comparator|S-Amlodipine 2.5, 5mg|
3137646|NCT01634646|Placebo Comparator|Overweight, elevated total cholesterol|All individuates enrolled in this study are at least 15 lbs over their ideal weight as described on a BMI chart. Each individual must also have a total cholesterol of at least 200 mg/dl, or higher.
3137647|NCT01634620||FeNO|Participants with chronic obstructive pulmonary disease (COPD) will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit.
3137648|NCT01634607||HIV uninfected|HIV negative patients
3137649|NCT01634607||HIV-infected, HAART naïve, high CD4 count|HIV positive patients with high CD4 and not on HIV treatment
3137650|NCT01634607||HIV-infected with planned to start HAART group|HIV positive patients who will start HIV treatment
3137651|NCT01634594|Experimental|sevoflurane-remifentanil (group R)|Continuous infusion of remifentanil at 0.05 ~ 2 mcg/kg/min with sevoflurane concentration of 1 MAC
3137652|NCT01634594|Active Comparator|sevoflurane-nicardipine (group N)|Continuous infusion of nicardipine at 1 ~ 7 mcg/kg/min with sevoflurane concentration of 1 MAC
3137653|NCT01634594|Active Comparator|sevoflurane-dexmedetomidine (group D)|Continuous infusion of dexmedetomidine at 0.2 ~ 1.0 mcg/kg/hr with sevoflurane concentration of 1 MAC
3137654|NCT01634568|Experimental|Single Ascending Dose|Single Ascending Doses of V81444 compared to placebo
3137655|NCT01634568|Experimental|Multiple Ascending Doses|Multiple ascending doses of V81444 compared to placebo
3137656|NCT01634555|Experimental|ramucirumab (IMC-1121B) and FOLFIRI|Treatment is sequential, Ramucirumab (IMC-1121B) will be administered before FOLFIRI ((Irinotecan + Folinic acid + 5-Fluorouracil). FOLFIRI will be administered each cycle and Ramucirumab (IMC-1121B) will be administered beginning from Cycle 2 (2-week cycle).
3137657|NCT01634542||Cohort|
3137658|NCT01634529|Experimental|Single Ascending Dose|Single ascending doses of V158866 compared to Placebo
3137659|NCT01634529|Experimental|Multiple ascending doses|Multiple ascending doses of V158866 compared to Placebo
3137660|NCT01634516|Experimental|Dietary support|Face to face intervention plus subsequent telephone support
3137661|NCT01634516|Placebo Comparator|No dietary support|No face to face intervention plus subsequent telephone support
3137662|NCT01634503|Experimental|1mg of GX-188E by electroporation|
3137663|NCT01634503|Experimental|2mg of GX-188E by electroporation|
3137664|NCT01634503|Experimental|4mg of GX-188E by electroporation|
3137665|NCT01634490||infants receiving extensively hydrolysed casein formula|infants receiving extensively hydrolysed casein formula as substitutive formula
3137666|NCT01634490||extensively hydrolysed casein formula with Lactobacillus GG|infants receiving extensively hydrolysed casein with LGG as substitutive formula
3137667|NCT01634490||infants receiving rice hydrolyzed formula|infants receiving rice hydrolyzed formula as substitutive formula
3137668|NCT01634490||infants receiving soy-based formula|infants receiving soy-based formula as substitutive formula
3137669|NCT01634490||infants receiving amino-acid based formula|infants receiving amino-acid based formula as substitutive formula
3137670|NCT01634477||HIV-infected patients group|HIV positive
3137671|NCT01634477||HIV-uninfected patients group|HIV negative
3137672|NCT01634464||Control group|women with 18.5 > BMI < 25
3137673|NCT01634464||Pregnant women with overweight|BMI≥25 before the pregnancy
3137674|NCT01634464||Pregnant women with obesity|BMI≥30 before the pregnancy
3137675|NCT01634464||Pregnant women with gestational diabetes|Gestational diabetes
3137676|NCT01634451|Active Comparator|Education Package|2 ICUs; one large and one small. Randomised to receive bespoke education package for the 9 month intervention period
3137677|NCT01634451|Active Comparator|Education and Feedback|2 ICUs; one large and one small. Randomised to receive a bespoke education package and real-time,site specific, outcome process feedback they will disseminate to their staff for the 9 month intervention period.
3137678|NCT01634451|Active Comparator|Education and Sedation Monitoring|2 ICUs; one large and one small. Randomised to receive a bespoke education package and a new novel sedation (responsiveness) monitor for the 9 month intervention period.
3137679|NCT01634451|Active Comparator|Education, Feedback, Sedation Monitoring|2 ICUs; one large and one small. Randomised to receive a bespoke education package, real-time,site specific, outcome process feedback they will disseminate to their staff and a new novel sedation (responsiveness) monitor for the 9 month intervention period.
3137680|NCT01634438|Experimental|low dose heparin|30 units per kilogram of unfractionated heparin
3137681|NCT01634438|Active Comparator|High dose heparin|70 units per kilogram of unfractionated heparin (UFH) intravenously
3137682|NCT01634425|No Intervention|Group 1 - no pre-hospital biomarkers|Standard of Care
3137683|NCT01634425|Experimental|Group 2 - pre-hospital biomarkers|Troponin and BNP measured on a POC meter in the ambulance on the way to the hospital.
3137684|NCT01634412|Experimental|SL TNX-102 at pH 3.5|2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5
3137685|NCT01634412|Experimental|SL TNX-102 at pH 7.1|2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1
3137686|NCT01634412|Active Comparator|Cyclobenzaprine tablets|5 mg cyclobenzaprine tablet once
3137687|NCT01634412|Active Comparator|Cyclobenzaprine IV|2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4
3137688|NCT01634360|Experimental|Perampanel (1-4 mg)|Subjects entered this open-label extension study from the double-blind core study (E2007-E044-204), and dosed placebo or perampanel. Subjects started this open-label extension study on perampanel 1 mg once daily for two weeks, followed by 2 mg once daily for two weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
3137689|NCT01634347|Experimental|Propranolol and memory reactivation|
3137690|NCT01634347|Placebo Comparator|Placebo and memory reactivation|
3137691|NCT01634334|Experimental|Real-time Intervention|
3137692|NCT01634334|Active Comparator|Usual Education|Participants will receive usual education about secondhand and thirdhand smoke.
3137693|NCT01634321|Experimental|Luphere|
3137694|NCT01634308|Experimental|Novosis(bongros/BMP-2)|
3137695|NCT01634308|Active Comparator|Bio-oss|
3137699|NCT01634269|Experimental|MDT-2111 TAVI 23 mm|
3137700|NCT01634256|Experimental|Fermented turmeric|
3137701|NCT01634256|Placebo Comparator|Placebo|
3137702|NCT01634243|Experimental|SPM 962|SPM 962 transdermal patch
3137703|NCT01634230|Experimental|OCR-002|10 g infused over 24 hours/day
3137704|NCT01634217|Experimental|Cohort 1|Administered 3 x 10^6 iTregs/kg infusion
3137705|NCT01634217|Experimental|Cohort 2|Administered 3 x 10^7 iTregs/kg infusion
3137706|NCT01634217|Experimental|Cohort 3|Administered 3 x 10^8 iTregs/kg infusion
3137707|NCT01634217|Experimental|Cohort 4|Administered 10 x 10^8 iTregs/kg infusion
3137708|NCT01634217|Experimental|Cohort 5 Extension|Administered 10 x 10^8 iTregs/kg or best available dose using sirolimus/MMF as graft-versus-host disease (GVHD) prophylaxis. Immunosuppression will consist of a combination of sirolimus and mycophenolate mofetil (MMF). Sirolimus will be administered starting at day -3 with 8mg-12mg oral loading dose followed by single dose 4 mg/day. MMF will be administered starting on day -3 at a dose of 3 gram/day divided in 2 or 3 doses. Intravenous (IV) route between days -3 and +5, then may change to PO between days +6 and +30. Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
3137709|NCT01634204|Experimental|KiloCoach|Study subjects use the KiloCoach program on at least 4 days per week within the first half of the 6 months intervention period. In the second half, program usage is ad libitum.
3137710|NCT01634204|No Intervention|Control|Study subjects try to reduce body weight on their own, without participating in an organized weight loss program, over a period of 6 months.
3137711|NCT01634191|Experimental|Apremilast (A: 30mg dose of apremilast in Elderly subjects)|A: One oral 30 mg dose of apremilast in Elderly subjects
3137712|NCT01634191|Experimental|Apremilast (B: 30mg dose of apremilast in younger subjects)|One oral 30 mg dose of apremilast in younger subjects
3137713|NCT01634178|Experimental|30 mg apremilast while fasting|30 mg apremilast while fasting
3137714|NCT01634178|Experimental|30 mg apremilast after a high-fat meal|30 mg apremilast after a high-fat meal
3137715|NCT01634165|Experimental|0.3 U/kg LY2963016|Single 0.3 units/kilogram (U/kg) subcutaneous dose of LY2963016
3137716|NCT01634165|Experimental|0.3 U/kg Lantus|Single 0.3 U/kg subcutaneous dose of Lantus
3137717|NCT01634165|Experimental|0.6 U/kg LY2963016|Single 0.6 U/kg subcutaneous dose of LY2963016
3137718|NCT01634165|Experimental|0.6 U/kg Lantus|Single 0.6 U/kg subcutaneous dose of Lantus
3137719|NCT01634152|Placebo Comparator|Placebo QD|
3137720|NCT01634152|Experimental|Tiotropium low dose QD|
3137721|NCT01634152|Experimental|Tiotropium medium dose QD|
3137722|NCT01634139|Experimental|Tiotropium high dose QD|
3137723|NCT01634139|Experimental|Tiotropium low dose QD|
3137724|NCT01634139|Experimental|Placebo QD|
3137725|NCT01634126|Active Comparator|1 FIT kit|
3137726|NCT01634126|Active Comparator|2 FIT kit|
3137727|NCT01634113|Experimental|tiotropium low dose|Once daily, delivered with Respimat® inhaler
3137728|NCT01634113|Experimental|tiotropium high dose|Once daily, delivered with Respimat® inhaler
3137729|NCT01634113|Placebo Comparator|placebo|Once daily, delivered with Respimat® inhaler
3137730|NCT01634100|Experimental|A (Reference)|Empagliflozin (BI 10773), Film-coated tablet, single dose
3137731|NCT01634100|Experimental|B (Test 1)|Empagliflozin (BI 10773), Film-coated tablet, single dose, and Rifampicin,Film-coated tablet single dose
3137732|NCT01634100|Experimental|C (Test 2)|Empagliflozin (BI 10773), Film-coated tablet, single dose, and Probenecid Tablet twice daily
3137733|NCT01634087|Experimental|100 mg QD INCB039110|
3137734|NCT01634087|Experimental|100 mg QD Placebo|
3137735|NCT01634087|Experimental|200 mg QD INCB039110|
3137736|NCT01634087|Experimental|200 mg QD Placebo|
3137737|NCT01634087|Experimental|200 mg BID INCB039110|
3137738|NCT01634087|Experimental|200 mg BID Placebo|
3137739|NCT01634087|Experimental|600 mg once a day INCB039110|
3137740|NCT01634087|Experimental|600 mg once a day Placebo|
3137741|NCT01634074||OSA patients|Patients with Obstructive Sleep Apnea (OSA), or suspected OSA
3137742|NCT01634061|Experimental|Dose escalation: BEZ235 + Zytiga®|BEZ235 oral twice daily: 200 mg, 300 mg, and 400 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
3137743|NCT01634061|Experimental|Dose escalation: BKM120 + Zytiga®|BKM120 oral once daily: 60 mg, 80 mg and 100 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
3137744|NCT01634061|Experimental|Dose expansion: BEZ235 + Zytiga®|"BEZ235 oral twice daily: 200 mg, 300 mg, and 400 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate~Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label"
3137745|NCT01634061|Experimental|Dose Expansion: BKM120 + Zytiga®|BKM120 oral once daily: 60 mg, 80 mg and 100 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
3137746|NCT01634048|Experimental|High protein low calorie meal replacements|Meal replacements with added protein powder(1.34g pro/kg).
3137747|NCT01634048|Sham Comparator|Normal protein, low calorie meal replacement group|The control group will have standard meal replacements (0.8g protein/kg body weight).
3137748|NCT01634035||diabetic hemodialysis|all patient diabetic and on hemodialysis were involved if they are on hemodialysis for more than 3 months
3137749|NCT01634022|Experimental|Acupuncture|Adults with depression who are not currently taking an antidepressant medication.
3137750|NCT01634009|Active Comparator|Standard RUTF (control)|Children will receive standard RUTF in this arm and will be considered as control arm
3137751|NCT01634009|No Intervention|Standard RUTF|Will act as control
3137752|NCT01633996|Experimental|Acupuncture|All participants received open acupuncture augmentation treatment per the uniform acupuncture treatment protocol that we developed according to Traditional Chinese Medicine (TCM) principles for treating depression (see Intervention Description).
3265664|NCT00728455|Experimental|D|
3137753|NCT01633983|Experimental|Methotrexate|Chronic CSC will be given an immediate MTX treatment
3137754|NCT01633983|Experimental|Delayed treatment|Acute CSC will be followed for 3 months for a spontaneous resolution before the treatment is offered
3137755|NCT01633970|Experimental|A: Atezolizumab + Bevacizumab|Participants will receive atezolizumab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion (or a selected dose level not to exceed the single agent MTD or MAD determined in Study PCD4989g) with bevacizumab 15 mg/kg every 3 weeks (q3w). After establishment of MTD or MAD, participants will receive bevacizumab 15 mg/kg IV infusion on Day 1 of Cycle 1 followed by atezolizumab 1200 mg IV infusion q3w after Days 5-7 and then atezolizumab 1200 mg q3w and bevacizumab 15 mg/kg q3w on Day 1 of all subsequent cycles until disease progression or unacceptable toxicity.
3137756|NCT01633970|Experimental|B: Atezolizumab + Bevacizumab + FOLFOX|Participants will receive FOLFOX IV infusion (oxaliplatin [85 milligrams per square meter {mg/m^2}], leucovorin [400 mg/m^2], 5-FU [400 mg/m^2]) on Day 1 of Cycle 1 and then atezolizumab 800 mg IV infusion every 2 weeks (q2w), bevacizumab 10 mg/kg IV infusion q3w and FOLFOX q2w on Day 1 of all subsequent cycles as per institutional guidelines until disease progression or unacceptable toxicity.
3137757|NCT01633970|Experimental|C: Atezolizumab + Carboplatin + Paclitaxel|Participants will receive atezolizumab 1200 mg IV infusion q3w in combination with paclitaxel 200 mg/m^2 IV infusion q3w and then carboplatin IV q3w (on Day 1 of every 3-week cycle) to achieve an initial target area under the curve (AUC) of 6 milligrams per milliliter*minute (mg/mL*min) until disease progression or unacceptable toxicity.
3137758|NCT01633970|Experimental|D: Atezolizumab + Carboplatin + Pemetrexed|Participants will receive atezolizumab 1200 mg IV infusion q3w in combination with premetrexed 500 mg/m^2 IV infusion q3w and then carboplatin IV q3w (on Day 1 of every 3-week cycle) to achieve an initial target AUC of 6 mg/mL*min until disease progression or unacceptable toxicity.
3137759|NCT01633970|Experimental|E: Atezolizumab + Carboplatin + Nab-paclitaxel|Participants will receive atezolizumab 1200 mg IV infusion q3w (on Day 1 of every 3-week cycle) in combination with nab-paclitaxel 100 mg/m^2 IV infusion once weekly (qw) (on Days 1, 8 and 15 of every 3-week cycle) and then carboplatin IV infusion q3w (on Day 1 of every 3-week cycle) to achieve an initial target AUC of 6 mg/mL*min until disease progression or unacceptable toxicity.
3137760|NCT01633970|Experimental|F: Atezolizumab + Nab-paclitaxel|Participants will receive atezolizumab 800 mg IV infusion q2w (Days 1 and 15) in combination with nab-paclitaxel 125 mg/m^2 IV infusion qw (on Days 1, 8 and 15 of every 3-week cycle) until disease progression or unacceptable toxicity.
3137761|NCT01633957|Experimental|Genotype-based Warfarin Initiation|
3137762|NCT01633957|Active Comparator|clinical factor-based warfarin initiation|
3137763|NCT01633944|Placebo Comparator|Placebo|Twice Daily Dosing
3137764|NCT01633944|Experimental|Buprenorphine HCl Buccal Film|Twice Daily Dosing
3137765|NCT01633918|Experimental|Internet-supported FeetEnergy approach|Schools which integrate Internet-supported approach with two home works in three health education lessons on physical activity
3137766|NCT01633918|Active Comparator|Usual health education|Schools which follow their usual practices in carrying out health education classes on physical activity
3137767|NCT01633905||alcohol-dependent patients|22 recently detoxified participants diagnosed as alcohol-dependant on the basis of DSM-IV criteria who will performed an emotion-detection task on unimodal (visual or auditory) or crossmodal (visuo-auditory) stimulations presented centrally or peripherally
3137768|NCT01633905||control group|22 healthy controls without any psychiatric or neurological diagnosis who will performed an emotion-detection task on unimodal (visual or auditory) or crossmodal (visuo-auditory) stimulations presented centrally or peripherally
3137769|NCT01633892|Experimental|Fat Grafting|
3137770|NCT01633879|Experimental|parent education|audio-CD parent EDC supporting positive parenting practices
3137771|NCT01633879|Experimental|parent and school intervention|health and success parent and school intervention
3137772|NCT01633879|No Intervention|print materials|brochures to parents
3137773|NCT01633866||Advances in Radio Frequency for MRI|advances in radio frequency (RF) coil magnetic resonance imaging (MRI)
3137774|NCT01633853|Experimental|Vitamin D2 Treatment|Patients will be treated by vitamin D2. Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
3137775|NCT01633853|Active Comparator|1,25(OH)2 Vitamin D3|Patients will be treated by 1,25(OH)2 Vitamin D3. Oral 1,25(OH)2 Vitamin D3(Rocaltrol) by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
3137776|NCT01633840|Active Comparator|Elemental E028 with added food allergens|
3137777|NCT01633840|Placebo Comparator|Elemental E028|
3137778|NCT01633827|Placebo Comparator|Placebo|Subjects will receive both a sugar pill and room air during their overnight sleep studies
3137779|NCT01633827|Active Comparator|Treatment|Subjects will receive both Lunesta (eszopiclone) and medical grade oxygen during their overnight sleep studies
3137780|NCT01633814|Experimental|Transdermal estradiol|Transdermal estradiol, delivery rate 100 µg day-1
3137781|NCT01633814|Placebo Comparator|Placebo|placebo patch.
3137782|NCT01633801|Other|High flows|
3137783|NCT01633801|Other|oxygen therapy|
3137784|NCT01633788|Experimental|AGN-195263 0.1%|1 drop of AGN-195263 0.1% instilled in each eye twice daily.
3137785|NCT01633788|Experimental|AGN-195263 0.03%|1 drop of AGN-195263 0.03% instilled in each eye twice daily.
3137786|NCT01633788|Experimental|AGN-195263 0.01%|1 drop of AGN-195263 0.01% instilled in each eye twice daily.
3137787|NCT01633788|Placebo Comparator|AGN-195263 Vehicle|1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
3137788|NCT01633775||Ahmed glaucoma implant|
3137789|NCT01633775||Trabeculectomy with mitomycin C (MMC)|
3137790|NCT01633762|Experimental|meropenem, gentamicin, vancomycin|
3137791|NCT01633749|Experimental|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
3137792|NCT01633736|Experimental|home progressive resistance exercise|
3137793|NCT01633723|Experimental|DA-6886|
3137794|NCT01633723|Placebo Comparator|DA-6886 placebo|
3137795|NCT01633697|Experimental|Education-Breathing|Subjects will receive education about COPD with special attention to breathing techniques
3137796|NCT01633697|Sham Comparator|Education-Control|Subjects will receive education alone about COPD.
3137797|NCT01633684||Diabetes|patients with Type 1 Diabetes Mellitus
3137798|NCT01633684||Control|Age and sex matched control subjects
3137799|NCT01633671||Suspected APE|Post-surgical patients with clinically suspected acute pulmonary embolism
3137800|NCT01633658|Active Comparator|Vitamin D Cholecalciferol|A single dose of 2500 micrograms cholecalciferol
3137801|NCT01633658|Experimental|25(OH)D|A single dose of 625 micrograms 25(OH)D
3137802|NCT01633645|Experimental|Velcade/GEM/CDDP|Bortezomib / Gemcitabine / Cisplatin
3137803|NCT01633632|Active Comparator|Cognitive behavioral therapy|This group will receive a standardized, 8-session cognitive behavioral therapy course that is offered to the public at our practice.
3137804|NCT01633632|Experimental|Cognitive behavioral therapy + yoga|This group will receive the standardized, 8-session cognitive behavioral therapy course + 8 sessions of Hatha yoga.
3137805|NCT01633632|Experimental|Hatha yoga|This group will receive 8 sessions of Hatha yoga and printed materials to assist with their quit attempt
3137806|NCT01633606||Acute patients|Patients admitted to the surgical and general ICU (including burn unit), to the coronary care unit, to the emergency department high care zone, to the medical ICU, to the medical medium care unit
3137807|NCT01633593|Experimental|donepezil|Donepezil 5mg/day during 2 weeks
3137808|NCT01633593|Placebo Comparator|placebo|placebo comparator to donepezil (double blind)
3137809|NCT01633580|Placebo Comparator|Day 2 group|Patients undergo a standard treatment with a classical start of corifollitropin alfa in a GnRH antagonist protocol.
3137810|NCT01633580|Active Comparator|Day 4 group|Patients undergo an ovarian stimulation, but start on day 4 with corifollitropin alfa
3137811|NCT01633567|Experimental|Culturally Targeted Cessation Program|The culturally targeted program will include the same cognitive and behavioral approaches and smoking education content that is used in the standard program. As such, we will maintain the integrity of the core program. However, cultural targeting of that program has been informed by local LGBT focus group input and testing, the available literature on LGBT smoking rates and behaviors, feedback from a panel of LGBT health experts, and data collected as part of a previous study.
3137812|NCT01633567|Active Comparator|Non-Targeted Cessation Program|Non-culturally targeted program with cognitive and behavioral approaches and smoking education content.
3137813|NCT01633554||Chronic Hepatitis B Group|Patients with chronic hepatitis B
3137814|NCT01633554||Cirrhosis|Patients with liver cirrhosis
3137815|NCT01633554||Control Group|Control Group: Healthy Volunteers
3137816|NCT01633541|Experimental|platinum/docetaxal + AT-101|"platinum/docetaxel + AT-101 The platinum will either be cisplatin or carboplatin as deemed best by the medical oncologist.~(Both Arms) Day #1: Patients will undergo induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).~(AT-101 Arm) Days #1-3: Patients will receive AT-101 40 mg orally twice daily On Day 23 (+/- 3 days), there will be a direct laryngoscopy (DL) with tumor biopsy and blood draw, repeat CT scan of the neck with perfusion within a week biopsy."
3137817|NCT01633541|Active Comparator|Active Comparator arm|"(Both Arms) Day #1: Patients will undergo induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).~Day #23 (+/- 3 days): Patients will undergo a direct laryngoscopy (DL) with biopsy. Patients will also undergo a repeat CT scan of the neck with perfusion within a week (+/-) of their perspective biopsies."
3137818|NCT01633528|Experimental|Asprin|With the onset of endometrial preparation and estrogen treatment, the study group will receive 100 mg of oral aspirin.
3137819|NCT01633528|Placebo Comparator|placebo|With the onset of endometrial preparation and estrogen treatment, the control group will receive placebo
3137820|NCT01633515|Other|Intralesional cryotherapy|10 BCC (skin lesions) in the lower extremity of elderlies with risk factors for surgical complications.
3137821|NCT01633502|Placebo Comparator|Conventional circulatory support|Patients randomized to conventional circulatory support.
3137822|NCT01633502|Active Comparator|Impella|Patients randomized to Impella CP
3137823|NCT01633489||LAL Deficiency patients|Patients are those with a diagnosis of LAL Deficiency (living and deceased), irrespective of treatment status or treatment choice.
3137824|NCT01633476|Active Comparator|Valaciclovir|Active treatment with valaciclovir
3137825|NCT01633476|No Intervention|No additional treatment|No additional treatment
3137826|NCT01633450|Experimental|Zinc biofortified rice|
3137827|NCT01633450|Active Comparator|Rice extrinsically fortified with zinc|
3137828|NCT01633437|Placebo Comparator|Sugar pill|
3137829|NCT01633437|Experimental|CX157|CX157 is a reversible monoamine oxidase inhibitor (RIMA) in Phase II development for the treatment of depression.
3137830|NCT01633411||Cohort A|Subjects in Cohort A will receive 6 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
3137831|NCT01633411||Cohort B|Subjects in Cohort B will receive 8 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
3137832|NCT01633411||Cohort C|Subjects in Cohort C will receive 10 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
3137833|NCT01633385||Subject-Group|Patients suffering from doctors diagnosed bronchiolitis obliterans
3137834|NCT01633385||Control Group|age- and sex matched to subject-group
3137835|NCT01633372|Experimental|itacitinib (INCB039110) 100 mg|itacitinib (INCB039110) 100 mg twice a day
3137836|NCT01633372|Experimental|itacitinib (INCB039110) 200 mg|itacitinib (INCB039110) 200 mg twice a day
3137837|NCT01633372|Experimental|itacitinib (INCB039110) 300 mg|itacitinib (INCB039110) 300 mg once a day
3137838|NCT01633372|Experimental|itacitinib (INCB039110) 400 mg|itacitinib (INCB039110) 400 mg once a day
3137839|NCT01633372|Experimental|itacitinib (INCB039110) 600 mg|itacitinib (INCB039110) 600 mg once a day
3137880|NCT01633021||Diabetes|Self/Family member affected by type-2 diabetes (plus self-referred family-members)
3137881|NCT01633021||Sickle Cell (Trait/Disease/Related)|Self/Family member affected by Sickle Cell Trait or Sickle Cell Disease (plus self-referredfamily-members)
3137882|NCT01633021||Heritable Cancer Screen-Positive|Person who has screened-positive for heritable cancers on genetic tests (plus referred family members)
3265665|NCT00728455|Experimental|E|
3137840|NCT01633359|Experimental|Intensive statin|"Fifty CAD subjects will receive intensive Atorvastatin administration and 50 CAD patients receiving the routine Atorvastatin administration as controls.~All subjects will receive the follow-up for 1 year, and peripheral blood VSELs, SDF-1/CXCR4 are tested, and the MACE (major adverse cardiovascular events) are recorded including angina, repeat myocardial infarction, repeat revascularization, major organ dysfunction, and death.~the Intensive Atorvastatin protocol indicates that 80mg Atorvastatin will be administrated before CAG, and then are followed with 20mg Atorvastatin during the entire study period."
3137841|NCT01633359|Experimental|Routine statin|"Fifty CAD subjects will receive intensive Atorvastatin administration and 50 CAD patients receiving the routine Atorvastatin administration as controls.~All subjects will receive the follow-up for 1 year, and peripheral blood VSELs, SDF-1/CXCR4 are tested, and the MACE (major adverse cardiovascular events) are recorded including angina, repeat myocardial infarction, repeat revascularization, major organ dysfunction, and death.~the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period."
3137842|NCT01633346||Tocilizumab treated patients|Rheumatoid arthritis patients
3137843|NCT01633333|Experimental|Water exchange|Colonoscopy with water exchange as the sole modality to reach the cecum. Carbon dioxide can be used in case of intubation failure with the test method.
3137844|NCT01633333|Active Comparator|Carbon dioxide insufflation|Carbon dioxide insufflation will be used in standard fashion to reach the cecum.
3137845|NCT01633307|Experimental|Experimental|Intervention (Teaching program)
3137846|NCT01633307|No Intervention|Control group|No teaching program
3137847|NCT01633294|Active Comparator|Antibiotic group|women submitted to antibiotic prophylaxis
3137848|NCT01633294|No Intervention|Control group|
3137849|NCT01633281|Experimental|acupuncture treatment|
3137850|NCT01633216|Active Comparator|Bivalent OPV 2 week interval|Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
3137851|NCT01633216|Active Comparator|Bivalent OPV 4 week interval|Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
3137852|NCT01633216|Active Comparator|Monovalent OPV 2week interval|Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
3137853|NCT01633216|Active Comparator|Monovalent OPV 4 week interval|Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
3137854|NCT01633216|Active Comparator|Trivalent OPV 4 week interval|Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
3137855|NCT01633203||locally advanced gastric cancer|Patients with resectable, locally advanced cT3-4 and/or N+ gastric carcinoma treated with 3 perioperative epirubicin cisplatin capecitabine polychemotherapy
3137856|NCT01633190||Rotavirus|- Children (0-16 years of age)admitted to hospital (through to December 31, 2019)
3137857|NCT01633177|Active Comparator|Vitamin D and Omega-3|
3137858|NCT01633177|Active Comparator|Vitamin D and Omega-3 placebo|
3137859|NCT01633177|Active Comparator|Vitamin D placebo and Omega-3|
3137860|NCT01633177|Placebo Comparator|Vitamin D placebo and Omega-3 placebo|
3137861|NCT01633164|Experimental|SCI Reinvention Protocol Participants|This group will receive 6 instructor-led 2 hour long didactic presentations regarding 8 key principles of self-efficacy and experiential exercises, including goal setting and problem solving with extensive group discussion. At the end of each session, tasks are assigned to participants to be completed outside the group during the week between sessions. Experiences from these activities and practice implementing the intervention principles will be shared and discussed each week, providing additional opportunities for problem solving and positive feedback.
3137862|NCT01633164|Other|Waitlist Group|This group will include individuals randomized to receive no treatment for the 30 weeks during which the interventional group will receive the active treatment and have their progress tracked.
3137863|NCT01633151||20 volunteers|
3137864|NCT01633138|Active Comparator|CRT-S|Cognitive Remediation Therapy - Standard
3137865|NCT01633138|Experimental|CRT-CM|Cognitive Remediation Therapy plus Contingency Management
3137866|NCT01633125|Experimental|Group music therapy|Participants in the experimental group will take part in biweekly group music therapy for 10 weeks (20 sessions). Each group will be formed by 6 to 8 people, and each session will last for 90 minutes.The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The active techniques will include musical improvisation as a medium to work with participants according to therapeutic goals and participants' needs.
3137867|NCT01633125|No Intervention|No music therapy|Participants assigned to the control group will not receive any specific treatment in this study. The usual care that is normally available at the prison will continue to be available for all participants during the study.Due to ethical considerations, the control group will receive group music therapy or psychotherapy by academically qualified therapists for 5 weeks after the study is finished.
3137868|NCT01633112|Experimental|fingolimod 0.5 mg orally once daily|
3137869|NCT01633112|Experimental|fingolimod 0.25mg orally once daily|
3137870|NCT01633112|Active Comparator|copaxone 20 mg s.c. once daily|
3137871|NCT01633099|Other|Decitabine, CR rate,OS,EFS,RFS|Therapeutic effect and safety of 10 days of decitabine. Acute myeloid leukemia,no acute promyelocytic leukemia.
3137872|NCT01633086|Active Comparator|nitric oxide gel|"st gel: sodium nitrites~nd gel: maleic/ascorbic acids"
3137873|NCT01633086|Placebo Comparator|Placebo gel|"st gel: phosphate-buffered saline~nd gel: maleic/ascorbic acids"
3137874|NCT01633073|Active Comparator|LMA Supreme|
3137875|NCT01633073|Active Comparator|i-gel|
3137876|NCT01633060|Experimental|BKM120 and fulvestrant|BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol test.
3137877|NCT01633060|Active Comparator|Placebo and fulvestrant|BKM120 matching placebo daily and fulvestrant given until progression or as described in the protocol.
3137878|NCT01633047|Experimental|Electrical stimulation|The subjects on this group will be submitted to a conventional rehabilitation (ROM increase, strength recovery, functional training) associated with electrostimulation.
3137879|NCT01633047|Active Comparator|Physical therapy exercises|The subjects on this group will be submitted to a conventional rehabilitation (ROM increase, strength recovery, functional training).
3137883|NCT01633008|Experimental|1|Attend three 2-hour sessions held over two consecutive days
3137884|NCT01632995|Experimental|Emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
3137885|NCT01632982|Other|standard treatment|the standard drug counseling offered to patients in methadone maintenance treatment at the study site
3137886|NCT01632982|Experimental|Mobile Therapeutic System (MTS)|The Mobile Therapeutic System (MTS) is a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
3137887|NCT01632982|Active Comparator|mobile control|a mobile phone-based application that directs participants to the NIDA website's home page
3137888|NCT01632969||families or next-of-kin of deceased patients|The families of deceased patients treated at MSKCC for non-cutaneous squamous cell carcinomas of the upper aerodigestive tract for whom contact information is available will be recruited by mail and by phone.
3137889|NCT01632956||in-person support group|This is a 1 year pilot study of the feasibility of participation in both in-person and virtual information-based, culturally tailored support groups for Chinese breast cancer patients.
3137890|NCT01632956||virtual support group|This is a 1 year pilot study of the feasibility of participation in both in-person and virtual information-based, culturally tailored support groups for Chinese breast cancer patients.
3137891|NCT01632943|Experimental|Symplicity renal denervation system|
3137892|NCT01632930|Experimental|Results of urinary PCA3 test will be available|In this arm, physicians will have knowledge of urinary PCA3 test results. How they subsequently manage patients with prostate cancer suspicion is likely to be influenced by urinary PCA3 test results
3137893|NCT01632930|Active Comparator|Results of urinary PCA3 test will not be available|In this arm, physicians will not have knowledge of urinary PCA3 test results. How they subsequently manage patients with prostate cancer suspicion will therefore not be influenced by urinary PCA3 test results
3137894|NCT01632917|Experimental|ATX-101 - EU|Open Label study in which subjects will receive ATX-101 (one of the two formulations) in one dosing session in the submental area
3137895|NCT01632917|Experimental|ATX-101 - US|Open Label study in which subjects will receive ATX-101 (one of the two formulations) in one dosing session in the submental area
3137896|NCT01632904|Experimental|ruxolitinib and hydroxyurea (HU)-placebo|
3137897|NCT01632904|Active Comparator|HU and ruxolitinib-placebo|
3137898|NCT01632891|Experimental|Arm A: lopinavir/ritonavir (LPV/r)-based ART|Participants will receive LPV/r-based antiretroviral therapy (ART) for 15 days followed by an nNRTI-based ART and TMP/SMX prophylaxis to take from day 16 through day 30.
3137899|NCT01632891|Experimental|Arm B: non-nucleoside reverse transcriptase (nNRTI)-based ART|Participants will receive nNRTI-based ART for 15 days followed by an nNRTI-based ART and TMP/SMX prophylaxis to take from day 16 through day 30.
3137900|NCT01632878||Post Myocardial Infarction|One single cohort of Index post Myocardial Infarction patients
3137901|NCT01632865|Experimental|recanalization and stenting|
3137902|NCT01632852|Experimental|CSL362|See Intervention Description
3137903|NCT01632839||Vaginal surgery +prothesis +sexuality|The 50 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse with placement of a prothesis; these patients are sexually active.
3137904|NCT01632839||Vaginal surgery +prothesis -sexuality|The 25 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse with placement of a prothesis; these patients are NOT sexually active.
3137905|NCT01632839||Vaginal surgery -prothesis + sexuality|The 50 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse WITHOUT placement of a prothesis; these patients are sexually active.
3137906|NCT01632839||Vaginal surgery -prothesis -sexuality|The 25 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse WITHOUT placement of a prothesis; these patients are NOT sexually active.
3137907|NCT01632839||Abdominal surgery +sexuality|The 50 patients included in this group will have undergone abdominal surgery for pelvic organ prolapse; these patients are sexually active.
3137908|NCT01632839||Abdominal surgery -sexuality|The 25 patients included in this group will have undergone abdominal surgery for pelvic organ prolapse; these patients are NOT sexually active.
3137909|NCT01632839||Urinary incontinence surgery + sexuality|The 50 patients included in this group will have surgery for urinary incontinence; these patients are sexually active.
3137910|NCT01632839||Urinary incontinence surgery - sexuality|The 25 patients included in this group will have surgery for urinary incontinence; these patients are NOT sexually active.
3137911|NCT01632813||CHD group|Seven-year-old children with CHD who were four years old when they participated in Paediatric ICU follow-up study (i.e. first follow-up time point) (Neurocognitive development of children four years after critical illness and treatment with tight glucose control, Clinical Trials # NCT00214916). The children of the CHD-group underwent cardiac surgery as infants (=<1year).
3137912|NCT01632813||Control group|Seven-year-old healthy control children who were four years old when they participated in Paediatric ICU follow-up study (i.e. first follow-up time point) (Neurocognitive development of children four years after critical illness and treatment with tight glucose control, Clinical Trials # NCT00214916). These children have never undergone cardiac surgery.
3137913|NCT01632800|Experimental|Single arm study|Each subjects will undergo escalating exposure to magnetic field
3137914|NCT01632761|Active Comparator|Vitamin D + fish oil|Dietary Supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Other Name: cholecalciferol Drug: omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
3137915|NCT01632761|Active Comparator|Vitamin D + fish oil placebo|Dietary Supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Other Name: cholecalciferol Dietary Supplement: Fish oil placebo Fish oil placebo
3137916|NCT01632761|Active Comparator|Vitamin D placebo + fish oil|"Drug: omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).~Dietary Supplement: Vitamin D3 placebo Vitamin D placebo"
3137970|NCT01632410||Control|Control: Healthy subjects resemble in age and sex
3137917|NCT01632761|Active Comparator|Vitamin D placebo + fish oil placebo|Dietary Supplement:Vitamin D3 placebo Vitamin D placebo Dietary Supplement: Fish oil placebo Fish oil placebo
3137918|NCT01632748|Experimental|Modified Neurotech Vital Device|Checking to observe stimulation delivered using this device
3137919|NCT01632748|Active Comparator|Neurotech Vital Device|Checking to see if stimulation observed using this device
3137920|NCT01632735|Experimental|Mobile Continuing Care|Behavioral: 12-week Structured Texting intervention focused on recovery monitoring, feedback for self-management, social support and education
3137921|NCT01632735|No Intervention|Standard Continuing Care as Usual|Continuing care as usual to 12-step facilitation (Anonymous group)
3137922|NCT01632722|Active Comparator|ArmA|
3137923|NCT01632722|Active Comparator|ArmB|
3137924|NCT01632709|Active Comparator|Sympathetic nerve block of bupivacaine|Sympathetic nerve block of bupivacaine
3137925|NCT01632709|Placebo Comparator|Dry needling at the sympathetic ganglion|Placebo/ Dry needling at the sympathetic ganglion
3137926|NCT01632709|Active Comparator|Neuroma injection of bupivacaine|Neuroma injection of bupivacaine
3137927|NCT01632709|Placebo Comparator|dry needling at the neuroma|Placebo/ dry needling at the neuroma
3137928|NCT01632696|Experimental|I-124 PGN650 for PET/CT|
3137929|NCT01632683|Active Comparator|C-MAC|Providers will utilize the C-MAC video laryngoscope equipped with a D-blade to facilitate intubation
3137930|NCT01632683|Active Comparator|Glidescope|Providers will utilize the Glidescope video laryngoscope equipped with the #4 blade to facilitate intubation
3137931|NCT01632670|Experimental|Music therapy|The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
3137932|NCT01632670|No Intervention|No music therapy|
3137933|NCT01632657|Other|Elective craniotomy and clipping of intracranial aneurysm|
3137934|NCT01632657|Other|Elective craniotomy and microvascular decompression|
3137935|NCT01632644||Physicians|Physicians performing skin biopsies
3137936|NCT01632644||Patients|Patients who have had skin biopsies
3137937|NCT01632631||PROcedure rehearsal|PROcedure rehearsal performed before real EVAR procedure No intervention
3137938|NCT01632631||No PROcedure rehearsal|no PROcedure rehearsal performed before real EVAR procedure No intervention
3137939|NCT01632618|Experimental|Trunk Muscle Training+NMES|Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals
3137940|NCT01632618|Active Comparator|Passive control intervention|Passive physical therapy interventions, including moist heat, ultrasound, massage and flexibility exercises
3137941|NCT01632605|Experimental|Sirolimus|Daily single oral dose of 1-3mg sirolimus with an initial loading dose of 6mg.
3137942|NCT01632592|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone analogue, 2mg subcutaneously every day for 12 months.
3137943|NCT01632592|Placebo Comparator|Placebo|
3137944|NCT01632579|Placebo Comparator|Placebo|Single dose of placebo administered orally on up to one occasion separated by at least a 3 week wash out period.
3137945|NCT01632579|Experimental|LY3023703|Up to 6 single escalating doses of LY3023703 [0.1 milligram (mg) up to 60 mg] administered orally on up to two occasions per participant separated by at least a 3 week wash out period.
3137946|NCT01632579|Active Comparator|400 mg Celecoxib|Positive control. Single 400 mg dose of celecoxib administered orally, open label, on one occasion separated by at least a 3 week washout period.
3137947|NCT01632566|Placebo Comparator|Placebo|Daily oral administration of placebo for 28 days. Dose will match corresponding LY3031207 dosage.
3137948|NCT01632566|Experimental|LY3031207|Daily oral administration of 25 milligrams up to 450 milligrams of LY3031207 for 28 days.
3137949|NCT01632566|Active Comparator|Celecoxib|Daily oral administration of 400 milligrams celecoxib for 28 days. Positive control for LY3031207.
3137950|NCT01632566|Other|LY3031207 + Simvastatin|Daily oral administration of 75 milligram or 225 milligram of LY3031207 for 28 days. Single oral 10 milligram dose of simvastatin administered open label before and after 28-day dosing of LY3031207.
3137951|NCT01632553||Cases|women who have experienced DVA
3137952|NCT01632553||Controls|women who have not experienced DVA
3137953|NCT01632540||Perennial Allergic Rhinitis patients|
3137954|NCT01632527|Experimental|HuCNS-SC|HuCNS-SC cells
3137955|NCT01632514|Active Comparator|Vitamin D deficiency treatment|subjects with 25OHD < 20 ng/mL that will receive 100,000U of cholecalciferol weekly for 4 weeks before surgery
3137956|NCT01632514|No Intervention|Vitamin D deficiency observation|subjects with 25OHD < 20 ng/mL that will not receive cholecalciferol before surgery
3137957|NCT01632514|No Intervention|Vitamin D sufficiency|controls with 25OHD >= 20 ng/mL that will not receive cholecalciferol before surgery
3137958|NCT01632488||Irritable bowel syndrome|Patients admitted to outpatient department with symptoms meeting Rome III criteria of irritable bowel syndrome.
3137959|NCT01632488||Inflammation|Patients with long standing history or short onset of inflammatory bowel disease.
3137960|NCT01632488||Normal controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
3137961|NCT01632475||Pneumostem®|Low Dose Group (3 subjects): 1.0 x 10^7 cells/kg, High Dose Group (6 subjects): 2.0 x 10^7 cells/kg
3137962|NCT01632462|Active Comparator|VSL#3 arm|15 patients with a diagnosis of Crohn's disease will be exposed to VSL#3 for 8 weeks
3137963|NCT01632462|Placebo Comparator|placebo group|15 patients affected by Crohn's disease will be exposed to a placebo for 8 weeks
3137964|NCT01632449|Experimental|1|Test product
3137965|NCT01632449|Experimental|2|Reference product
3137966|NCT01632436|Experimental|Stage 1 -Moderate Hepatic Impairment|Pixantrone
3137967|NCT01632436|Experimental|Stage 2 - Severe Hepatic Impairment|Pixantrone
3137968|NCT01632423||POAG or OHT|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
3137969|NCT01632410||Study group 1|"Post hemispheral ischemic stroke cognitively intact. Exclusion: Subjects with severe visual or hearing impairments, stroke location brain steam.~The group will be divided in to 4 goups acording to stroke specific location as demonstrated in MRI."
3137971|NCT01632410||Study -3|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
3137972|NCT01632410||Stydy -2|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
3137973|NCT01632410||Stydy- 4|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
3137974|NCT01632397|Experimental|CBT-based counseling|Cognitive behavioral based intervention to promote PrEP adherence.
3137975|NCT01632397|Active Comparator|Health education and supportive counseling|Time matched supportive counseling
3137976|NCT01632371|Experimental|Paclitaxel Eluting Balloon + Scoring Balloon|Dilatation of the lesion with an Paclitaxel Eluting Balloon before the utilization of a Scoring Balloon
3137977|NCT01632371|Active Comparator|Paclitaxel Eluting Balloon|Paclitaxel Eluting Balloon
3137978|NCT01632358|Experimental|TAP311 capsules|Patients will receive TAP311 capsule orally once daily for 14 days.
3137979|NCT01632358|Placebo Comparator|Placebo of TAP311 capsules|Matching placebo to TAP311 capsule, once daily for 14 days
3137980|NCT01632345|Experimental|Doravirine 25 mg|Doravirine 25 mg + TRUVADA® Participants in this arm will receive doravirine 25 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
3137981|NCT01632345|Experimental|Doravirine 50 mg|Doravirine 50 mg + TRUVADA® Participants in this arm will receive doravirine 50 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
3137982|NCT01632345|Experimental|Doravirine 100 mg|Doravirine 100 mg + TRUVADA® Participants in this arm will receive doravirine 100 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
3137983|NCT01632345|Experimental|Doravirine 200 mg|Doravirine 200 mg + TRUVADA® Participants in this arm will receive doravirine 200 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
3137984|NCT01632345|Active Comparator|Efavirenz|Efavirenz + TRUVADA® Participants in this arm will receive efavirenz in Part I and in Part II. These participants also receive placebo that matches doravirine.
3137985|NCT01632332|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID every 28 days for up to 6 courses in the absence of disease recurrence or unacceptable toxicity.
3137986|NCT01632319|Experimental|MI + CBT|Motivational Interviewing (MI) and cognitive behavioral therapy (CBT). In this course of therapy students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms.
3137987|NCT01632319|Active Comparator|CBT|Cognitive behavior therapy (CBT)
3137988|NCT01632306|Experimental|LY2090314 + Gemcitabine|LY2090314 given intravenously (IV) on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 milligram/square meter (mg/m^2) gemcitabine given IV on days 1, 8 and 15. Cohort closed to new enrollment per protocol addendum.
3137989|NCT01632306|Experimental|LY2090314 + FOLFOX|LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), and 15 in 28 day cycle in combination with FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin) given IV, on days 1 and 15 in 28 day cycle.
3137990|NCT01632306|Experimental|LY2090314 + Gemcitabine + Nab-paclitaxel|LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 mg/m^2 gemcitabine + 125 mg/m^2 nab-paclitaxel given IV on days 1, 8 and 15 in 28-day cycle. New cohort opened per protocol amendment.
3137991|NCT01632293|Experimental|exercise|Individuals with multiple sclerosis and age and gender matched healthy controls will participate in a supervised exercise program for 12 weeks.
3137992|NCT01632280|Active Comparator|Active tDCS|In this arm, participants will receive active tDCS (2mA, 20 min per session). The anode electrode will be placed over the right inferior frontal gyrus, defined as F8 (10-20 EEG system), with the cathode electrode placed over the contralateral supraorbital area, above the left eyebrow. During each session they will also perform a computerized task designed to engage the inhibitory control circuit when confronted with food stimuli.
3137993|NCT01632280|Sham Comparator|Sham tDCS|Participants will receive sham tDCS sessions with the same duration and electrode montage as in the real tDCS arm. In this case, current will be applied for 30 s only according to standard procedures, and participants will perform a control task where they will observe and provide responses for the same food and non-food pictures as in the active group task, but without requirement of inhibitory control for performance.
3137994|NCT01632267||Depression and anxiety|Subjects with a primary diagnosis of depression or anxiety disorder.
3137995|NCT01632254||Patients with ≥70% carotid artery stenosis|
3137996|NCT01632241|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kilogram (kg) IV every 28 days for an additional 6 months.
3137997|NCT01632241|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
3137998|NCT01632228|Experimental|Onartuzumab + Bevacizumab|All participants will receive onartuzumab intravenous (IV) infusion followed by bevacizumab IV infusion every 3 weeks.
3137999|NCT01632228|Active Comparator|Placebo + Bevacizumab|All participants will receive placebo matched with onartuzumab followed by bevacizumab IV infusion every 3 weeks.
3138000|NCT01632215|Experimental|preoperative gabapentine,|Gabapentine
3138001|NCT01632215|Placebo Comparator|sugar pill|Placebo group
3138049|NCT01631877|Placebo Comparator|Placebo|Injection placebo will be given for 5 days along with placebo tablets.
3138878|NCT01625832|Experimental|1|CSO first
3138002|NCT01632202|Active Comparator|Seprafilm Slurry|The investigators hypothesize that by placing a slurry of Seprafilm in the intrauterine cavity and creating a temporary physical barrier between the walls of the uterus, that we will be able to prevent iatrogenic intrauterine adhesions. Given that approximately 24 to 48 hours after placement, the membrane becomes a hydrated gel that is slowly resorbed within one week, we anticipate that the patient will have minimal to no discomfort; since no physical device is being left in the endometrial cavity, the uterus will not be contracting more than it does in its normal postoperative state.
3138003|NCT01632202|Placebo Comparator|Placebo|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
3138004|NCT01632189|Experimental|Varenicline|Varenicline will be used at the same dosage regimen as used for smoking cessation, i.e. 0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily. The total duration of Varenicline treatment will be three months.
3138005|NCT01632176|No Intervention|Standard of care|Patients in the control group will not receive any intervention, but will receive standard care for dating abuse issues.
3138006|NCT01632176|Experimental|Intervention|Patients in the intervention group will participate in brief, motivational interview and one booster session to prevent adolescent dating abuse.
3138007|NCT01632163|Experimental|Lixisenatide|24-week treatment with lixisenatide once daily on top of basal insulin with or without metformin (at least 1.0g/day)
3138008|NCT01632163|Placebo Comparator|Placebo|24-week treatment with placebo once daily on top of basal insulin with or without metformin (at least 1.0g/day)
3138009|NCT01632150|Experimental|Elotuzumab + Thalidomide + Dexamethasone + Cyclophosphamide|
3138010|NCT01632137|Placebo Comparator|Placebo (vehicle)|
3138011|NCT01632137|Experimental|Rebamipide 2% ophthalmic suspension|
3138012|NCT01632098||extremely obese|BMI ≥35kg/m2
3138013|NCT01632098||obese|BMI 30-34.9kg/m2
3138014|NCT01632085|Other|Group SU (Single use or Laryngobloc ®) ®)|In order to avoid an order effect, the patient acting as his own control, will randomly undergo a laryngoscopy with each laryngoscopes, the intubation being performed during the second laryngoscopy, here with the Laryngobloc ®.
3138015|NCT01632085|Other|Group R (Reusable handle)|In order to avoid an order effect, the patient acting as his own control, will randomly undergo a laryngoscopy with each laryngoscopes, the intubation being performed during the second laryngoscopy, here with the Disposable Metal Blade.
3138016|NCT01632072|Experimental|Nutritional counseling|Dietary supplement
3138017|NCT01632072|No Intervention|No nutritional counceling|
3138018|NCT01632059||septical patients|inclusion criteria are severe sepsis and septical shock and must be > 18 y/o
3138019|NCT01632046|Active Comparator|BicaVera, dialysis|Two Parallel arms. If patient randomised to the BicaVera arm he will be dialysed with bicarbonate based PD fluid (BicaVera) for 10 months. Dialysis prescription is determined according to clinical needs, dialysate glucose concentrations are 1.5, 2.3 and 4.25 %.
3138020|NCT01632046|Active Comparator|Balance, dialysis|If patient is randomised to the Balance arm, he will be dialysed with lactate based PD fluid (Balance) for 10 months. Dialysis prescription is determined according to clinical needs, dialysate glucose concentrations are 1.5, 2.3 and 4.25 %.
3138021|NCT01632033||Investigation for lower limb arteries|Patients referred for investigation of assumed peripheral artery disease (PAD)
3138022|NCT01632020|Placebo Comparator|Placebo|Placebo 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
3138023|NCT01632020|Active Comparator|Metformin|Metformin 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
3138024|NCT01632007|Experimental|SYR-472 100 mg|
3138025|NCT01632007|Active Comparator|Alogliptin 25 mg|
3138026|NCT01632007|Placebo Comparator|Placebo|
3138027|NCT01631994|Experimental|Oral Dissolving metoclopramide|Patient's in this arm will receive the oral dissolving metoclopramide along with the capsule during capsule endoscopy.
3138028|NCT01631994|No Intervention|control group|This is the control group that will only ingest the capsule during video capsule endoscopy.
3138029|NCT01631981|Experimental|PGL2001|PGL2001 + NETA followed by NETA-only follow-up period
3138030|NCT01631981|Placebo Comparator|Placebo|Placebo + NETA followed by NETA-only follow-up period
3138031|NCT01631968|Experimental|Cement with erytromycin and colistin|In this group the knee arthroplasty was fixed with cement with erythromycin and colistin.
3138032|NCT01631968|Placebo Comparator|Cement without antibiotic|In this group the knee arthroplasty was fixed with standard cement, without any antibiotics.
3138033|NCT01631955||Cystitis|female with cystitis symptoms
3138034|NCT01631942|Experimental|Low dose (healthy subjects)|
3138035|NCT01631942|Experimental|Medium dose (subjects with haemophilia)|
3138036|NCT01631942|Experimental|High dose (subjects with haemophilia)|
3138037|NCT01631929|Active Comparator|One bag|IV infusion of fluids, electrolytes and dextrose using one bag
3138038|NCT01631929|Experimental|Two bags|Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
3138039|NCT01631916|Experimental|Corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
3138040|NCT01631916|No Intervention|Control|No intervention
3138041|NCT01631903|Experimental|Arm 2 (3mg)|
3138042|NCT01631903|Experimental|Arm 3 (6 mg)|
3138043|NCT01631903|Experimental|Arm 4 (12 mg)|
3138044|NCT01631903|Experimental|Arm 5 (24 mg)|
3138045|NCT01631903|Experimental|PK arm (12 mg)|PK arm requires one additional 24 hour PK assessment at V3 and daily visits between visits 2 and 3 for drug trough sample collection
3138046|NCT01631890|Active Comparator|standard endotherapy|
3138047|NCT01631890|Experimental|Endoscopic Ultrasound assisted endoscopic glue injection|
3138048|NCT01631877|Experimental|enoxaparin with acenocoumarol|Patients will receive enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg with titration of dose to maintain a target INR of 2-3.intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR.After achieving the target INR this is to be repeated every 4th weekly. The Doppler Ultra Sonography screening will be done every 3monthly to assess the recanalization of portal vein thrombus but the medications will be continue for one year irrespective of recanalization.
3138050|NCT01631864|Experimental|LCZ696|LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks
3138051|NCT01631864|Active Comparator|amlodipine|amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks
3138052|NCT01631838|Experimental|Tocotrienol-rich fraction 400mg|
3138053|NCT01631838|Experimental|Placebo|
3138054|NCT01631825|Experimental|SPM 962|SPM 962 transdermal patch
3138055|NCT01631812|Experimental|SPM 962|
3138056|NCT01631799|Active Comparator|Femoral Block|One group received a femoral block for analgesia after surgery. Ropivacain was administered continuously for three days.
3138057|NCT01631799|Active Comparator|Epidural Analgesia|One group received an epidural analgesia after surgery for three days.
3138058|NCT01631786||Preserved ovaries|Ovaries or ovarian segments that have been fixed in 10% Formalin
3138059|NCT01631786||Fresh/non-preserved ovaries|Ovaries that have been surgically removed and placed in sterile saline
3138060|NCT01631773||subjects w/ Nasal polyps & AERD disease|subjects with nasal polyps and Aspirin-exacerbated respiratory disease (AERD) disease
3138061|NCT01631773||subjects w/ nasal polyps without AERD|subjects with nasal polyps but without Aspirin-exacerbated respiratory disease (AERD)
3138062|NCT01631760||MicroRNA ages 5-12 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
3138063|NCT01631760||MicroRNA ages 13-55 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
3138064|NCT01631760||MicroRNA ages 56-85 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
3138065|NCT01631747|Active Comparator|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
3138066|NCT01631747|Experimental|Lifestyle Intervention Group|Women in the Intervention group will participate in a lifestyle program based on Moms'adopting a healthier diet and becoming more active for 24 months. Implementation is at approximately 15 weeks.Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet & activity and use of pedometer
3138067|NCT01631721||Cohort 1|Cohort of adolescents recruited in 2012-2013 of study
3138068|NCT01631721||Cohort 2|Cohort of adolescents recruited in year 2013-2014 of study
3138069|NCT01631721||Cohort 3|Cohort of adolescents recruited in year 2014-15 of study
3138070|NCT01631708|Active Comparator|Erythrocytapheresis|"Erythrocytapheresis is a procedure whereby whole blood is drawn from an individual and all elements except erythrocytes are returned to the donor. An automated filtration process removes the erythrocytes.~Those in arm 1 will have third weekly erythrocytapheresis until their SF is returned to the normal range."
3138071|NCT01631708|Sham Comparator|Plasmapheresis|"In plasmapheresis, the plasma is removed by the automated filtration process whilst other blood elements including erythrocytes are returned to the subject.~Those in arm 2 will have plasmapheresis with the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm."
3138072|NCT01631682|Active Comparator|Propranolol|a single dose of 40mg propranolol may be given to begin visit 2, followed by 90min wait and subsequently CS reactivation
3138073|NCT01631682|Active Comparator|Reactivation with time delay|For those not receiving propranolol on visit 2, one experimental CS will be reactivated, followed by a 10 minute break and subsequently extinction
3138074|NCT01631682|Experimental|Mifepristone|a single dose of 1800mg (200mg tablets) mifepristone may be given to begin visit 2, followed by 90min wait and subsequently CS reactivation
3138075|NCT01631682|Experimental|Intranasal oxytocin|A single 32IU dose of Syntocinon (intranasal oxytocin) is given to begin visit 2, followed by a 10 minute wait and subsequent CS reactivation.
3138076|NCT01631669|Experimental|Celebrex|Receive Celebrex
3138077|NCT01631669|No Intervention|Control|no placebo administered
3138078|NCT01631656|Experimental|Azelaic Acid plus Laser|Azelaic acid 15% twice daily on half the face for 6 weeks, plus laser treatment with Nd:Yag laser once at 2 weeks.
3138079|NCT01631656|Active Comparator|Laser only|laser treatment on all face once at 2 weeks with no azelaic acid on one side of the face
3138080|NCT01631630|Experimental|Pioglitazone|Subjects received pioglitazone, 15mg/day for 3 days; 30mg day for 3 days; 45mg/day thereafter, for a minimum total of 13 days
3138081|NCT01631630|Placebo Comparator|Placebo|Subjects received placebo on a similar dosing schedule, for a minimum total of 13 days
3138082|NCT01631617|Active Comparator|Cohort 1|A set of 16 healthy volunteers will be randomized to receive open-label antibiotics in order to characterize differences in the microbial shifts observed in subjects taking oral cephalexin versus TMP/SMZ versus low dose doxycycline versus standard dose doxycycline
3138083|NCT01631617|Placebo Comparator|Cohort 2|Healthy volunteers randomized to one of four possible treatment combinations of study baths and study drugs
3138084|NCT01631617|Active Comparator|Cohort 3|Subjects with atopic dermatitis will be randomized to one of two possible treatment combinations of study bath and study drugs
3138085|NCT01631591||eosinophilic esophagitis|PATIENTS WITH A CURRENT DIAGNOSIS OF eosinophilic esophagitis.
3138086|NCT01631591||GERD|PATIENTS WITH A DIAGNOSIS WITH GERD.
3138087|NCT01631578|Experimental|Injection of mitochondrial concentrate|A small volume of mitochondrial concentrate will be injected together with the spermatozoon during ICSI.
3138088|NCT01631578|Active Comparator|Control|ICSI will be performed conventionally.
3138089|NCT01631565|No Intervention|Standard care|Usual care given to the patients. Treatment, follow-up.
3138135|NCT01631331|Experimental|Treatment (vismodegib and Mohs surgery)|Patients receive vismodegib PO daily for 3-6 months based on the size of basal cell carcinoma and then undergo Mohs surgery.
3138600|NCT01627899|Other|VerioIQ|Subjects replaced own Blood Glucose Monitoring system with VerioIQ.
3138090|NCT01631565|Experimental|Early Palliative Care|"Intervention: Early allocation to palliative care. Intervention: Nutritional counseling. Intervention: patient and care-taker psychoeducation, depression and anxiety evaluation.~Standard of care: Oncological treatment according to stage of disease (IIIb/IV).~Treatment: Chemotherapy (platins, taxans, TKIs) Baseline: BMI, and anthropometric characteristics (weight, height). Follow-up: During 6 chemotherapy circles with: Quality of Life (EORTC qlq-c30), HADS, ESAS and ZARIT."
3138091|NCT01631552|Experimental|IMMU-132|IMMU-132 (hRS7-SN38) is an Antibody Drug Conjugate where the antibody, hRS7 is attached to SN38. SN38 is the active metabolite of irinotecan (CPT-11).
3138092|NCT01631539|Other|Chemoembolization|chemoembolization with DC Bead™ loaded with Irinotecan
3138093|NCT01631526|Experimental|Vitamin D|vitamin D 20,000 IU per day for 2 weeks followed by 10,000 IU per day for a further 7 days
3138094|NCT01631513|Experimental|Nucynta ER|Nucynta ER will be 100 to 250 mg every 12 hours
3138095|NCT01631500|Other|Conventional treatment|Patients receive usual treatments provided at primary care settings, e.g. antidepressants, sessions with a curator or psychotherapist and physiotherapy.
3138096|NCT01631500|Experimental|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
3138097|NCT01631500|Active Comparator|Terapeutic acupuncture|Therapeutic acupuncture alone, eight individual sessions, once a week. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
3138098|NCT01631487|Experimental|Japanese Group 1: JNJ-39439335/placebo (Part 1)|
3138099|NCT01631487|Experimental|Japanese Group 2: JNJ-39439335/placebo (Part 1)|
3138100|NCT01631487|Experimental|Japanese Group 3: JNJ-39439335/placebo (Part 1)|
3138101|NCT01631487|Experimental|Caucasian Group 1: JNJ-39439335/placebo (Part 1)|
3138102|NCT01631487|Experimental|Caucasian Group 2: JNJ-39439335/placebo (Part 1)|
3138103|NCT01631487|Experimental|Caucasian Group 3: JNJ-39439335/placebo (Part 1)|
3138104|NCT01631487|Experimental|Japanese Group 1: JNJ-39439335/placebo (Part 2)|
3138105|NCT01631487|Experimental|Japanese Group 2: JNJ-39439335/placebo (Part 2)|
3138106|NCT01631487|Experimental|Japanese Group 3: JNJ-39439335/placebo (Part 2)|
3138107|NCT01631474|Experimental|Low-dose active, BID|low dose of CB-03-01, applied twice a day
3138108|NCT01631474|Experimental|Medium-dose active, BID|medium dose of CB-03-01, applied twice a day
3138109|NCT01631474|Experimental|High-dose active, QD|high dose of CB-03-01, applied once a day
3138110|NCT01631474|Experimental|High-dose active, BID|high dose of CB-03-01, applied twice a day
3138111|NCT01631474|Placebo Comparator|Vehicle, QD or BID|vehicle cream, applied once or twice a day
3138112|NCT01631461||1. Deep pain group|1. Deep pain group; Pain in the breast
3138113|NCT01631461||2. Superficial pain group|Pain on the nipple and/or aereola
3138114|NCT01631461||3. Control group|No pain or other breastfeeding problems
3138115|NCT01631448|No Intervention|Control|Patients fron this group do not receive the fibrin sealant
3138116|NCT01631448|Active Comparator|Fibrin group|Patients from this group will receive the fibrin sealant
3138117|NCT01631435|Other|bowel prep regimen|Each study subject will undergo a bowel preparation followed by a PillCam procedure.
3138118|NCT01631422|Experimental|Single Arm|
3138119|NCT01631409||Cohort 0|"Cohort 0 is allocated for the following two patient groups:~The patients with suspicion of angina although in whom the thorough investigation has not revealed CHD and the pain syndrome has been received the extracardiac interpretation (e.g. vertebral osteochondrosis, left side humeroscapular periarthritis, herpes zoster, intercostal neuralgia Tietze syndrome etc.)~The patients with subclinical manifestation of coronary atherosclerosis without angina (Class 0 angina, here and further is according to the Canadian Cardiovascular Society Angina Classification). This subgroup of the patients is recommended the proper diet, life style modification, lipid targeting medications in some cases, and no antianginal treatment."
3138120|NCT01631409||Cohort I|Represents patients with Class 1 angina, who receive OMT.
3138121|NCT01631409||Cohort II|"Comprises the patients with Class 2-4 angina, they are on MAAMT. The cohort is further divided in two groups:~The patients for whom MAAMT is effective.~The patients for whom MAAMT is not effective or not sufficiently effective, although those patients have not received any invasive, surgical or CSWT interventions yet.~They are those patients who then form cohorts III-VI."
3138122|NCT01631409||Cohort III|Consists of patients already received PCA. They also continue various MAAMT.
3138123|NCT01631409||Cohort IV|Includes the patients after CABG. They also are on various MAAMT.
3138124|NCT01631409||Cohort V|Incorporates the patients who have already underwent CSWT. They also receive individualized MAAMT.
3138125|NCT01631409||Cohort VI|"The cohort is composed of the patients who for various reasons have not been exposed to any intervention except MAAMT and continue to be on it.~The algorithm of the cohort formation is graphically demonstrated in the Diagram The logic tree of the cohort formation (see the link at the bottom of the protocol)."
3138126|NCT01631396||Patients recieving Sugammadex|Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.
3138127|NCT01631396||Patients recieving Neostigmine|Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body.
3138128|NCT01631383|Placebo Comparator|Placebo|
3138129|NCT01631383|Active Comparator|l-THP|
3138130|NCT01631370|Experimental|Renal denervation|The patients will be examined prior to renal denervation and 6 months after. Thus the patients are their own controls.
3138131|NCT01631357|Experimental|Arm 1|Arm 1: We design chemotherapy combination with CIK cell immunotherapy as a experimential arm.
3138132|NCT01631357|Active Comparator|Arm 2|Arm 2: We design chemotherapy alone as a control arm
3138133|NCT01631344|No Intervention|Physical Therapy|Conventional Physical Therapy
3138134|NCT01631344|Experimental|Daily physical activity consultation, Using Stage of change|
3267821|NCT00712452|Other|3|Hodgkin disease
3138136|NCT01631318|Experimental|Diagnostic (3D contrast-enhanced ultrasound imaging)|Patients undergo 3D dynamic contrast-enhanced ultrasound imaging before initiation of chemotherapy and at 2 weeks.
3138137|NCT01631305|Experimental|Levothyroxine|3 mcg/kg/day
3138138|NCT01631305|Placebo Comparator|Control|Calcium magnesia.
3138139|NCT01631292|Placebo Comparator|600 IU D3|
3138140|NCT01631292|Active Comparator|2000 IU D3|
3138141|NCT01631292|Active Comparator|4000 IU D3|
3138142|NCT01631279|Experimental|PR610|
3138143|NCT01631266|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
3138144|NCT01631266|Active Comparator|2 T.U. Tuberculin PPD RT 23 SSI|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
3138145|NCT01631253|Active Comparator|single-port access laparoscopic ovarian cyst enucleation|Procedure: Operative laparoscopic ovarian cyst enucleation was performed only through an umbilical single port. ( 2 cm longitudinal incision was made within the umbilicus and an wound retractor (Alexis Wound Retractor XS) was inserted into the wound opening. A surgical glove with three 5mm trocars inserted into three fingers was draped around the rim of the wound retractor.)
3138146|NCT01631253|Active Comparator|two-port laparoscopic access ovarian cyst enucleation|Procedure: Operative access laparoscopic ovarian cyst enucleation was performed using an umbilical single port ( 2 cm longitudinal incision was made within the umbilicus and an wound retractor (Alexis Wound Retractor XS) was inserted into the wound opening. A surgical glove with two 5mm trocars inserted into two fingers was draped around the rim of the wound retractor.) and one 5-mm trocar in the lower abdomen.
3138147|NCT01631253|Active Comparator|four-port access laparoscopic ovarian cyst enucleation|Procedure: : Operative laparoscopic ovarian cyst enucleation was performed through insertion of a 12-mm subumbilical trocar and three 5-mm trocars in the lower abdomen.
3138148|NCT01631240||Adults 18-39 years|Healthy adults aged 18-39 years
3138149|NCT01631227|Experimental|Eprosartan|Eprosartan + Placebo Eprosartan Mesylate
3138150|NCT01631227|Active Comparator|Eprosartan Mesylate|Eprosartan Mesylate + Placebo Eprosartan
3138151|NCT01631214|Experimental|Romosozumab|Romosozumab sub-cutaneous injections and placebo alendronate (oral) for 12 months, followed by open-label alendronate (oral) for at least another 12 months (until end of study)
3138152|NCT01631214|Active Comparator|Alendronate|Oral alendronate plus placebo AMG 785 sub-cutaneous injections for 12 months, followed by open-label alendronate (oral) for at least another 12 months (until end of study)
3138153|NCT01631201|Experimental|Rifalazil 25 milligram|
3138154|NCT01631201|Active Comparator|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
3138155|NCT01631188|Experimental|Aortic Valve Replacement|During surgery your doctor will utilize a new technique using surgical equipment that have already been FDA Approved for other indication. The combination of the equipment and technique will be experimental and will be closely evaluated during and after each case.
3138156|NCT01631175|Experimental|(PO-Bado, FBK-R10, PHQ) Active Comparator|
3138157|NCT01631162|No Intervention|lung disease|
3138158|NCT01631149|Experimental|Deep surgical block|Continuous rocuronium infusion will be used to induce a deep surgical block with post tetanic twitch count of max 2. Rocuronium loading dose = 1.0 mg/kg, followed by 0.6-1.0 mg/kg per hour.
3138159|NCT01631149|Active Comparator|Moderate/normal surgical block|A normal block will be induced by an atracurium bolus dose followed by a mivacurium infusion to induce a train of four count of 1-2.
3138160|NCT01631136|Active Comparator|Continuous maintenance Therapy|Induction chemotherapy by cisplatin + pemetrexed and maintenance therapy by pemetrexed
3138161|NCT01631136|Experimental|Maintenance according to the response of induction|"Induction chemotherapy by cisplatin + gemcitabine followed by :~continuous maintenance therapy by gemcitabine if response disease~switch maintenance therapy by pemetrexed if stable disease"
3138162|NCT01631123|Experimental|Diet interventions|Sequential dietary intervention
3138163|NCT01631110|Experimental|Elderly subjects aged over 60 years|
3138164|NCT01631110|Experimental|Adults from 18 to 60 years old inclusive|
3138165|NCT01631084|Experimental|JADE|Patients randomized to the JADE group will be followed according to protocol-driven diabetes care based on their individual risk levels, using a web-based disease management program. In addition to their annual comprehensive assessments at baseline, year 1 and year 2, all subsequent follow-up visits will be documented and entered into the JADE portal, which will then issue reports to both patients and doctor to promote sharing of information and informed decisions.
3138166|NCT01631084|Active Comparator|DIAMOND|Patients will receive a comprehensive assessment at baseline, year 1 and year 2. In the interim between these time points patients will be managed according to 'usual care' procedures.
3138167|NCT01631071|Experimental|Elderly subjects aged over 60 years|
3138168|NCT01631071|Experimental|Adults from 18 to 60 years old inclusive|
3138169|NCT01631058|Experimental|Everolimus|"Number of patients: 45 Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.~Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.~Corticosteroids: as clinical practice."
3138170|NCT01631045||15 min|Subjects post-meal brain MRI will be 15 minutes after breakfast.
3138171|NCT01631045||30 min|Subjects post-meal brain MRI will be 30 minutes after breakfast.
3138172|NCT01631045||60|Subjects post-meal brain MRI will be 60 minutes after breakfast.
3138173|NCT01631045||120|Subjects post-meal brain MRI will be 120 minutes after breakfast.
3138174|NCT01631045||180|Subjects post-meal brain MRI will be 180 minutes after breakfast.
3138175|NCT01631045||240|Subjects post-meal brain MRI will be 240 minutes after breakfast.
3138176|NCT01631045||300|Subjects post-meal brain MRI will be 300 minutes after breakfast.
3138177|NCT01631032|Placebo Comparator|Control|control group receive placebo capsule with same look, smell and flavor compared with experiment group. The scheme for medication is 3 times a day, 3gm each time, total 9gm per day.
3138435|NCT01629173|Experimental|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) as an insole
3138178|NCT01631032|Experimental|Chinese herbal products (CHP)|CHP group receive Qi-tonifying Chinese herbal products capsule, 3 times a day, 3gm each time, total 9gm per day
3138179|NCT01631019|Active Comparator|with mobile phone assistance|In the mobile phone group, patients were asked to continue their exercise program at home at a fixed walking speed. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
3138180|NCT01631019|Placebo Comparator|with free walk|Patients in the control group were educated the same exercise protocol, but were only verbally asked to freely take the walking exercise training at home. The adherence to the walking exercise at home was reported by the patients themselves at every return visits. All the patients received ISWT, spirometry and blood sample for inflammatory biomarkers at baseline, 1, 2, 3 and 6 months.
3138181|NCT01631006|Sham Comparator|Low CPAP pressure|Patients are submmited to a CPAP with low pressure for 20 minutes
3138182|NCT01631006|Active Comparator|High CPAP pressure|Patients are submmited to a high pressure of CPAP for 20 minutes
3138183|NCT01630993|Experimental|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
3138184|NCT01630993|No Intervention|Immediate Cord Clamping|At birth, the infant will be held at the level of the placenta and umbilical cord will be clamped within 10 seconds (routine practice).
3138185|NCT01630967|Experimental|Degarelix|Degarelix 240mg subcutaneously loading dose, then 80mg sc every month until disease progression.
3138186|NCT01630954|Active Comparator|Single evacuation of mole,|
3138187|NCT01630954|Active Comparator|Double evacuation of mole|
3138188|NCT01630941|Active Comparator|Denosumab|1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after surgery followed by another injection 6 months later
3138189|NCT01630941|Placebo Comparator|saline|1 ml subcutaneous injection 0.9% saline give in the posterior part of the upper arm after surgery followed by another injection 6 months later
3138190|NCT01630928|Experimental|Renal sympathetic denervation|Patients with treatment resistant hypertension
3138191|NCT01630889|Experimental|FG-4592|FG-4592 Investigational Drug
3138192|NCT01630876|Sham Comparator|Vitrectomy only group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only.
3138193|NCT01630876|Experimental|Combined therapy group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection.
3138194|NCT01630863|Experimental|50% group|power of PDT is applied to the patients at 50% of the full energy based on TAP study.
3138195|NCT01630863|Experimental|40% group|Decreasing power of PDT is applied to the patients at 40% of the full energy based on TAP study.
3138196|NCT01630863|Experimental|30% group|Decreasing power of PDT is applied to the patients at 30% of the full energy based on TAP study.
3138197|NCT01630850|Experimental|Allogenic islet cells (human, U. Chicago)|
3138198|NCT01630837|Other|12h|Frequency of oral hygiene was 12 to 12 hours.
3138199|NCT01630837|Other|24h|Frequency of oral hygiene was 24 to 24 hours.
3138200|NCT01630837|Other|48h|Frequency of oral hygiene was 48 to 48 hours.
3138201|NCT01630837|Other|72h|Frequency of oral hygiene was 72 to 72 hours.
3138202|NCT01630824|Other|Education|Kidney transplant recipients, who undergo the structured education program
3138203|NCT01630824|No Intervention|Control|Kidney transplant recipients without structured education programm
3138204|NCT01630811|Experimental|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg/quinidine sulfate 10 mg), oral, once daily
3138205|NCT01630811|Placebo Comparator|Placebo|Oral, once daily
3138206|NCT01630798|Experimental|Application of peptide|
3138207|NCT01630785||IONM patients|all patients where surgery requires IONM
3138208|NCT01630759|Experimental|Telemonitoring|The telemonitoring group will receive usual care but be asked to download their blood sugar readings and take a blood pressure and weight measurement each week. This will be reviewed by their diabetes health care team to assess the possibility of replacing alternate anti-natal/diabetes clinics with telemonitoring review in a future study. Acceptability to staff and patients will be assessed through a questionnaire (patients only) and qualitative interviews.
3138209|NCT01630759|Active Comparator|Control group|Control group will consist of usual care and review at clinic.
3138210|NCT01630746|Experimental|TAK-438 20 mg/day|
3138211|NCT01630746|Experimental|TAK-438 40 mg/day|
3138212|NCT01630733|Experimental|Custirsen + Docetaxel|Custirsen: Three loading doses of custirsen 640mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
3138213|NCT01630733|Active Comparator|Docetaxel|Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle Continue treatment until disease progression, unacceptable toxicity, withdrawal of consent or protocol specified parameters to stop treatment.
3138214|NCT01630720|Active Comparator|vitamin C|vitamin C 500 mg twice daily
3138215|NCT01630720|Active Comparator|vitamin D|vitamin D 5000 IU daily
3138216|NCT01630694|Active Comparator|Difficult intubation patients|patients who were difficult to intubate during previous anesthetics provided by the staff anesthesiologists.
3138217|NCT01630694|Placebo Comparator|Control|The control group will consist of patients with the easy laryngoscopy and intubation, recruited prospectively.
3138218|NCT01630681|Experimental|Internet-based stepped care|Internet-based stepped care comprises interactive support (Step 1) and Cognitive Behavioral Therapy (CBT; Step 2). Step 1 starts directly after randomization and extends over a 24 months period. Step 2 extends to a period of ten weeks.
3138219|NCT01630681|No Intervention|Standard care|
3138220|NCT01630668|Experimental|One-a-Day L. reuteri NCIMB 30242 supplement capsule|
3138221|NCT01630668|Placebo Comparator|One-a-Day placebo capsule|
3138222|NCT01630629||African-American Lactating Women|Healthy African-American women who are exclusively breast-feeding.
3138223|NCT01630629||Caucasian Lactating Women|Healthy Caucasian women who are exclusively breast-feeding.
3267822|NCT00712439|Experimental|1|
3138224|NCT01630616|Experimental|Adolescents Odanacatib 10 mg|Study drug (single oral dose of odanacatib 10 mg) was administered following at least an 8-hour fast to adolescents.
3138225|NCT01630616|Experimental|Adolescents Odanacatib 50 mg|Study drug (single oral dose of odanacatib 50 mg) was administered following at least an 8-hour fast to adolescents.
3138226|NCT01630616|Placebo Comparator|Adolescents Placebo|Study drug (single oral dose of placebo) was administered following at least an 8-hour fast to adolescents.
3138227|NCT01630616|Experimental|Young Adults Odanacatib 50 mg|Study drug (single oral dose of odanacatib 50 mg) was administered following at least an 8-hour fast to young adults.
3138228|NCT01630616|Placebo Comparator|Young Adults Placebo|Study drug (single oral dose of placebo) was administered following at least an 8-hour fast to young adults.
3138229|NCT01630603||mother infants pairs|
3138230|NCT01630590|Experimental|Cabozantinib + Androgen Ablation Therapy|Patients receive Cabozantinib at starting dose of 60 mg by mouth every day. Study cycles 3 weeks in duration. Patients stay on treatment as long as they are benefitting. Patients receive androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration. Study doctor will decide what hormone therapy patient will receive.
3138231|NCT01630577|Experimental|responder to fluid challenge|fluid challenge
3138232|NCT01630564|Experimental|Ex vivo Expanded T Cell Infusion|Three patients enrolled at Starting Dose 1: 1 * 10e6 T cells/kg infused through central venous catheter (CVC). If no toxicities occur, next three patients enrolled at Dose 2, etc. If any patient develops stage IV graft versus host disease (GVHD), next patient treated at next lower dose. If patient is prescribed a higher dose but the lab is unable to produce this amount of cells, patient will be treated at a lower dose. This will continue for up to 3 dose levels, until the highest tolerable dose of cord blood is found.
3138233|NCT01630551|Active Comparator|Fishoil nutritional supplement|90 day supply of daily oral administration of a fish oil nutritional supplement (TheraTears Nutrition; Advanced Vision Research, Woburn, MA)
3138234|NCT01630551|Placebo Comparator|Olive oil capsules|90 day supply of a daily dose of placebo olive oil capsules
3138235|NCT01630538|Experimental|Cyclophosphamide|Cyclophosphamide 1.5 mg/kg orally daily for 180 days (26 weeks) adjusted for renal function.
3138236|NCT01630525||Prodromal AD participants|
3138237|NCT01630525||Typical AD participants|
3138238|NCT01630525||Control participants|
3138239|NCT01630512|Experimental|MBCT|
3138240|NCT01630512|Experimental|CBT|
3138241|NCT01630512|No Intervention|Waitlist|
3138242|NCT01630499|Experimental|Tailored Lifestyle Intervention (TLI)|Participants randomized to the TLI condition will receive a 3-month weight management program tailored to the specific needs of women in remission from breast cancer.
3138243|NCT01630499|Active Comparator|Commercial Weight Loss Program (CLWP)|Participants randomized to the CWLP condition will receive a 3-month commercial weight loss program (i.e., Weight Watchers) at no cost.
3138244|NCT01630486||glomerulonephritis|adult CKD patients, whose underlying etiology is glomerulonephritis, either clinically diagnosed or pathologically proven
3138245|NCT01630486||hypertensive nephropathy|adult CKD patients, whose underlying etiology is hypertensive nephropathy
3138246|NCT01630486||polycystic kidney disease|adult CKD patients, whose underlying etiology is autosomal dominant polycystic kidney disease
3138247|NCT01630486||diabetic nephropathy|adult CKD patients, whose underlying etiology is diabetic nephropathy
3138248|NCT01630473|Experimental|Corticotomy-assisted orthodontics|This group of patients will receive corticotomy surgical procedure at day 0. Orthodontic activation will start immediately after surgery.
3138249|NCT01630473|Active Comparator|Conventional orthodontics|This group of patients will receive conventional orthodontics starting at day 0.
3138250|NCT01630434|Experimental|OCS Lung (Treatment Group)|The OCS Lung, which is a portable, integrated platform designed to maintain adult donor lungs in a normothermic state through continuous normothermic perfusion and ventilation, will be used to preserve and transport donor lungs.
3138251|NCT01630434|Active Comparator|Cold flush and storage (Control Group)|Donor lungs will be preserved using cold flush and storage (control group)
3138252|NCT01630421||affected, unaffected|Individuals with diagnosed ACC
3138253|NCT01630408|Experimental|Paricalcitol|Paricalcitol oral capsules (1 mcg per day for 48 weeks)
3138254|NCT01630395|No Intervention|conventional|Two-lung ventilation: tidal volume = 10 ml/kg, no PEEP. One-lung ventilation: tidal volume = 10 ml/kg, no PEEP
3138255|NCT01630395|Active Comparator|Protective|Two-lung ventilation: tidal volume 8 ml/kg, PEEP of 5 cmH2O. One-lung ventilation: tidal volume 6 ml/kg, PEEP of 5 cmH2O.
3138256|NCT01630395|Active Comparator|Recruitment|Two-lung ventilation: tidal volume 8 ml/kg, PEEP of 5 cmH2O. One-lung ventilation: tidal volume 6 ml/kg, PEEP of 5 cmH2O. Recruitment maneuver will be applied during one-lung ventilation.
3138257|NCT01630369|Experimental|Human Insulin|Dosage of human insulin (Insuman Basal/Comb/Rapid) will be individually adjusted in accordance with the Summary of Product Characteristics (SmPC). Patients will follow the titration algorithm recommended by the physician.
3138258|NCT01630356|Experimental|Intervention group|
3138259|NCT01630356|Active Comparator|Control group|
3138260|NCT01630343|Experimental|Regular oral Panadol and Tramadol|Geriatric (age >65) Patient having traumatic hip fracture will have three weeks of regular prescription of oral Panadol(500mg) and tramadol (50mg) three times a day. Operation will be done within 3 days usually followed by rehabilitation period.
3138261|NCT01630343|Experimental|Panadol and tramadol oral in prn basis|Control group is that patient having geriatric hip fracture will have oral analgesics ( Panadol 500mg Q4H and tramadol 50mg Q4H ) in prn basis.
3138262|NCT01630330|Active Comparator|Contact Force Known|Ablation with contact force data known
3138263|NCT01630330|Experimental|Contact Force Not Known|Contact Force data unavailable during ablation
3138264|NCT01630317|Experimental|Peripheral acces|
3138265|NCT01630317|Placebo Comparator|Central access|
3138357|NCT01629667|Experimental|Tralokinumab 400 milligram (mg)|Participants will receive Tralokinumab 400 mg intravenous (IV) infusion Q4W for 68 Weeks.
3138358|NCT01629667|Experimental|Tralokinumab 800 mg|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
3138879|NCT01625832|Experimental|2|CSO second
3138266|NCT01630304|Experimental|WelTel SMS service|"In addition to standard care, weekly text messages will be delivered to participants randomized to this arm for a one year period. Participants will be requested to respond to the outgoing message Mambo? within 48 hours; they may respond that they are doing well (sawa) or that they have a problem (shida). A clinician will call to follow-up with all participants who respond indicating a problem or who do not respond within 48 hours."
3138267|NCT01630304|No Intervention|Standard care|This arm will receive standard clinical care.
3138268|NCT01630291|Experimental|Electrical stimulation|
3138269|NCT01630278|No Intervention|Small ductus|
3138270|NCT01630278|Experimental|Large ductus ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
3138271|NCT01630278|Placebo Comparator|Large ductus placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
3138272|NCT01630265|Active Comparator|Written Discharge Instructions|Group of caregivers who read written discharge instructions that are the standard discharge instructions given in our pediatric ED
3138273|NCT01630265|Experimental|Video Discharge Instructions|Group of caregivers who watched the 3-minute video covering the information in the standard written discharge instructions
3138274|NCT01630252|Active Comparator|Part A2 - Active Treatment arm|PGL5001 for 8 weeks + one DMPA injection
3138275|NCT01630252|Placebo Comparator|Part A2 - Placebo Treatment arm|PGL5001 matching placebo for 8 weeks + one DMPA injection
3138276|NCT01630252|Active Comparator|Part B - Active treatment arm|PGL5001 for 20 weeks + two DMPA injections
3138277|NCT01630252|Placebo Comparator|Part B - Placebo Treatment arm|PGL5001 matching placebo for 20 weeks + two DMPA 150mg injections
3138278|NCT01630252|Experimental|Part A1 - Active Treatment arm|PGL5001 for 8 weeks + one unique DMPA 150 mg injection
3138279|NCT01630239|Experimental|Visualise Thermal Therapy System|
3138280|NCT01630226|Experimental|Neoadjuvant Cisplatin Chemotherapy|
3138281|NCT01630213|Active Comparator|Vitamin D3 + fish oil/placebo|Vitamin D3 2000 IU/day and fish oil (840 omega 3-fatty acids; Omacor)(or fish oil placebo)/day
3138282|NCT01630213|Placebo Comparator|Vitamin D3 placebo + fish oil/placebo|Vitamin D3 placebo + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo
3138283|NCT01630200|Active Comparator|Roflumilast|Active arm including patients who receive the study drug (500µg Roflumilast once daily)
3138284|NCT01630200|Placebo Comparator|Placebo|Control arm including patients who receive the placebo tablet (once daily)
3138285|NCT01630187|Active Comparator|Carbetocin 100 mcg|
3138286|NCT01630187|Experimental|Carbetocin 50 mcg|
3138287|NCT01630161|Active Comparator|Usual Care|Participants randomized to the Usual Care condition will receive standard care following recruitment.
3138288|NCT01630161|Active Comparator|Relapse-Prevention Intervention|Participants randomized to the Smoking Relapse Prevention for Cancer Patients (SRP-CaP) intervention will receive standard care plus our self-help smoking-relapse prevention materials.
3138289|NCT01630148|Active Comparator|Bemiparin|group one will be women who are risky for venous thromboembolic diseases after benign gynaecological surgeries, each will receive Bemiparin
3138290|NCT01630148|No Intervention|control group|women will undergo benign gynaecological surgeries and are risky for venous thrombosis, they will not receive any intervention. The patients will be followed up to 30 days after surgery.
3138291|NCT01630135|Experimental|GW685698X|GW685698X 55mcg/day
3138292|NCT01630135|Placebo Comparator|Placebo|Placebo
3138293|NCT01630122||patients newly diagnosed non small cell lung cancer|patients with presumed newly diagnosed non small cell lung cancer, where radiographic studies and clinical description favor a probable diagnosis of non small cell lung cancer
3138294|NCT01630109|Active Comparator|Metoclopramide 5 mg|Pro-motility agent
3138295|NCT01630109|Active Comparator|Metoclopramide 10 mg|Pro-motility agent
3138296|NCT01630109|Placebo Comparator|Placebo control|Placebo to be used as the control group
3138297|NCT01630096|Active Comparator|Nu-Lytely|Bowel prep solution.
3138298|NCT01630096|No Intervention|Control|Standard of care.
3138299|NCT01630083|Active Comparator|EOX|Participants will receive EOX.
3138300|NCT01630083|Experimental|EOX + zolbetuzimab 800/600 mg/m2|Participants will receive EOX and zolbetuximab (800 mg/m^2 loading dose in cycle 1 followed by 600 mg/m^2 every 3 weeks).
3138301|NCT01630083|Experimental|EOX + zolbetuximab 1000 mg/m2|Participants will receive EOX and zolbetuzimab (1000 mg/m^2 every 3 weeks).
3138302|NCT01630070|Experimental|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
3138303|NCT01630057|Experimental|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
3138304|NCT01630057|Active Comparator|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
3138305|NCT01630044|Experimental|TNM device, active treatment|This is an active-only assessment of the experimental neuromodulation device
3138306|NCT01630031||Control group|Use of the THERMOCOOL SF or EZ STEER THERMOCOOL Catheter, Biosense Webster, Inc.
3138307|NCT01630031||CF group|Use of THERMOCOOL SMARTTOUCH Catheter, Biosense Webster, Inc.
3138308|NCT01630018|Active Comparator|Topotecan|Topotecan
3138309|NCT01630018|Active Comparator|Camtobell|Belotecan
3138310|NCT01630005|Experimental|Talk therapy|A cohort of 25 patients
3138311|NCT01629992|Experimental|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
3138312|NCT01629992|No Intervention|Control|The control group received no preoperative counseling either oral or written.
3138359|NCT01629667|Placebo Comparator|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
3138360|NCT01629654|Experimental|Lifestyle counseling|Testing of the teory- and evidence based health promotion program. Patients will participate in a 13 weeks program.
3138436|NCT01629147|Experimental|Biogaia|5 drops containing Lactobacillus reuteri Protectis
3138313|NCT01629979|Experimental|A: Grafting of autologous epidermal harvested cells and UVB|"Grafting with epidermal cells: A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.~Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments."
3138314|NCT01629979|Active Comparator|UVB treatment|UVB treatment twice a week during 3months
3138315|NCT01629966|Placebo Comparator|Placebo|Dose-matched placebo one per day, oral administration
3138316|NCT01629966|Experimental|Vilazadone 20mg|Vilazodone 20mg once per day, oral administration.
3138317|NCT01629966|Experimental|Vilazodone 40mg|Vilazodone 40mg once per day, oral administration
3138318|NCT01629953|Active Comparator|Group Based Vocational Rehabilitation|Group vocational intervention
3138319|NCT01629953|Experimental|Supported Employment Condition|Group vocational intervention + supported employment
3138320|NCT01629940||Male HED-Affected Individuals|Male subjects affected by HED
3138321|NCT01629940||Male controls|Male subjects not affected by HED
3138322|NCT01629927||HED-affected males|Male subjects affected by HED
3138323|NCT01629927||Male controls|Male subjects not affected by HED
3138324|NCT01629888|Experimental|1 = Tested product|
3138325|NCT01629888|Placebo Comparator|2 = Control product|
3138326|NCT01629875|Experimental|DWP450|
3138327|NCT01629875|Active Comparator|Botox|
3138328|NCT01629862|Active Comparator|Active CPAP|Therapeutic continuous positive airway pressure (CPAP).
3138329|NCT01629862|Placebo Comparator|Sham CPAP|Sham (non-therapeutic) continuous positive airway pressure.
3138330|NCT01629849|Experimental|BI 1021958 qd|Multiple rising dose
3138331|NCT01629849|Placebo Comparator|Placebo to BI 1021958 qd|Matching placebo as tablets
3138332|NCT01629849|Experimental|BI 1021958 bid|Multiple rising dose
3138333|NCT01629849|Placebo Comparator|Placebo to BI 1021958 bid|Matching palcebo as tablet
3138334|NCT01629823|Sham Comparator|CPAP less than 1 cm H₂O|
3138335|NCT01629823|Experimental|CPAP 10cm H₂O|
3138336|NCT01629823|Experimental|CPAP 5cm H₂O|
3138337|NCT01629797|Other|Acne Vulgaris|Patients with Acne vulgaris will receive educational teaching on Acne
3138338|NCT01629784|Other|CLE and sun counseling|
3138339|NCT01629771||Lymphatic Filariasis|
3138340|NCT01629771||Patients without Lymphatic Filariasis|
3138341|NCT01629758|Experimental|Part 1-Arm A: BMS-982470 (weekly x 4) + BMS-936558|Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
3138342|NCT01629758|Experimental|Part 1-Arm B: BMS-982470 (3 times/week) + BMS-936558|Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: 3 times/week during weeks 1 and 3, Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
3138343|NCT01629758|Experimental|Part 2-Arm A: BMS-982470 (weekly x 4) + BMS-936558|Cohort Expansion BMS-982470 (dose selected in Part 1) Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
3138344|NCT01629732|Experimental|Arm 1: Daclasasvir + BMS-986094 (100 mg) + Placebo|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 1 to Arm 1a and 1b (additional 12 weeks treatment)"
3138345|NCT01629732|Experimental|Arm 2: Daclasasvir + BMS-986094 (200 mg)|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 2 to Arm 2a and 2b (additional 12 weeks treatment)"
3138346|NCT01629732|Experimental|Arm 3: Daclasasvir + BMS-986094 (100 mg) + Placebo + Ribavirin|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 3 to Arm 3a and 3b (additional 12 weeks treatment)"
3138347|NCT01629732|Experimental|Arm 4: Daclasasvir + BMS-986094 (200 mg) + Ribavirin|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 4 to Arm 4a and 4b (additional 12 weeks treatment)"
3138348|NCT01629732|Experimental|Arm 5: Daclasasvir + BMS-986094 (200 mg)|Genotype 1 PI-failure subjects
3138349|NCT01629732|Experimental|Arm 6: Daclasasvir + BMS-986094 (200 mg)|Genotype 4 naive subjects
3138350|NCT01629732|Experimental|Arm 7: Daclasasvir + BMS-986094 (200 mg)|Genotype 2/3 NR/relapse Subjects
3138351|NCT01629706|Experimental|PV+ClearCare / PV+Renu (Phase 1)|Balafilcon A contact lens pre-soaked overnight in ClearCare cleaning and disinfecting system worn in 1 eye for two hours and four hours at a time, separate days, with Balafilcon A contact lens pre-soaked overnight in renu multi-purpose solution worn in the fellow eye
3138352|NCT01629706|Experimental|Habitual (Phase 2)|Phase 2: Habitual contact lenses worn bilaterally on a daily wear basis for 4 weeks with habitual lens care
3138353|NCT01629693|Experimental|Air Optix|Lotrafilcon B contact lenses worn bilaterally (in both eyes) for at least 4 hours a day, 5 days a week, for 4 weeks, on a daily wear basis (removed nightly for cleaning and disinfection).
3138354|NCT01629693|Active Comparator|Biofinity|Comfilcon A contact lenses worn bilaterally (in both eyes) for at least 4 hours a day, 5 days a week, for 4 weeks, on a daily wear basis (removed nightly for cleaning and disinfection).
3138355|NCT01629680|Experimental|Healthy subjects I|
3138356|NCT01629680|Placebo Comparator|Healthy subjects II|
3138437|NCT01629147|Placebo Comparator|Placebo|- 5 drops identical in appearance and taste
3138361|NCT01629641||Normals|Texas Woman's University students from the School of Physical Therapy - Houston campus will be recruited to participate in this study. The participant will be excluded if they have pain in the shoulder on the day of testing, less than 90 degrees of active or passive shoulder abduction, less than 90 degrees of active or passive elbow flexion, have had any previous surgeries or procedures to either shoulder or identify by self-report any reason that they should not perform active external rotation at the shoulder.
3138362|NCT01629628|Experimental|Adalimumab|
3138363|NCT01629628|Active Comparator|6-mercaptopurine|
3138364|NCT01629615|Experimental|BKM120|
3138365|NCT01629602|Experimental|vascularized nerve graft|The investigators combined the nerve branch with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
3138366|NCT01629589|Experimental|Adacel® Vaccine Group|Participants randomized to receive a single dose of Adacel® vaccine
3138367|NCT01629589|Active Comparator|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine
3138368|NCT01629576|No Intervention|control group|
3138369|NCT01629576|Experimental|low reward|economic incentive
3138370|NCT01629576|Experimental|high reward|economic incentive
3138371|NCT01629563|Experimental|Ulipristal acetate (PGL4001) 5mg|
3138372|NCT01629563|Experimental|Ulipristal acetate (PGL4001) 10mg|
3138373|NCT01629550|Active Comparator|PVI paint|5% alcoholic povidone iodine paint
3138374|NCT01629550|Active Comparator|PVI scrub and paint|detersion with 4% povidone iodine scrub followed by 5% alcoholic povidone iodine paint
3138375|NCT01629550|Active Comparator|Chlorhexidine paint|2% alcoholic chlorhexidine paint
3138376|NCT01629550|Active Comparator|chlorhexidine scrub and paint|Detersion with 4% chlorhexidine scrub followed 2% alcoholic chlorhexidine paint
3138377|NCT01629537|Other|Placebo|Subjects 1 month post in the placebo group who demonstrate either the same level of PTSD severity at enrollment or worsening of the condition (i.e., CAPS score greater than or equal to 40) will be offered SGB treatment and crossed over to active treatment. Patients who cross over from placebo to active SGB treatment will be followed one week, one month and three months after cross over.
3138378|NCT01629537|Experimental|Stellate Ganglion Block (SGB)|Subjects assigned to SGB arm will undergo SGB procedure and be followed one week, one month and three months after procedure or until CAPS score is below 40.
3138379|NCT01629524||Colorectal cancer patients|Colorectal cancer patients undergoing elective colorectal resection
3138380|NCT01629511|Experimental|Busulfan + Clofarabine + Gemcitabine + Transplant|"Clofarabine administered at dose of 30 mg/m2 by vein infused over 1 hour on Days -6 through -3. Busulfan test dose of 32 mg/m2 based on actual body weight given by vein over 60 minutes. Busulfan administered at dose calculated to achieve a systemic exposure dose of 4000 µMol-min in normal saline over 3 hours by vein every 24 hours on Days -6 to -3, starting immediately after the completion of Clofarabine. Gemcitabine dosing begin at 275 mg/m2/dose by vein preceded by a loading dose of 75 mg/m2 administered as a bolus: 75 mg/m2 + (10mg/m2/ min × 10 min) = 175 mg/m2 .~Patients receiving a graft from a matched unrelated donor receive Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.~Allogeneic hematopoietic cell transplantation on Day 0."
3138381|NCT01629498|Experimental|IMPT + SIB + Chemotherapy|"Phase I Starting IMPT Dose: 60 Gy (RBE) in 30 fractions. Phase I Starting SIB Dose: (72 - 84) Gy (RBE).~Fractions given once a day, 5 times a week for six weeks.~All patients receive standard concurrent chemotherapy as prescribed by their treating medical oncologist.~Symptom questionnaire completion before chemoradiation beings, each week during chemoradiation, each week until 16 weeks after chemoradiation is complete, every other week from Week 16 until 12 weeks after chemoradiation is complete, and at follow-up visits.~Dose level 1 of 66-72 Gy(RBE) in 30 fractions used as the planned dose in the Phase II portion of the trial."
3138382|NCT01629498|Experimental|IMRT + SIB + Chemotherapy|"Phase I Starting IMRT Dose: 60 Gy (RBE) in 30 fractions. Phase I Starting SIB Dose: (72 - 84) Gy (RBE).~Fractions given once a day, 5 times a week for six weeks.~Symptom questionnaire completion before chemoradiation beings, each week during chemoradiation, each week until 16 weeks after chemoradiation is complete, every other week from Week 16 until 12 weeks after chemoradiation is complete, and at follow-up visits.~All patients receive standard concurrent chemotherapy as prescribed by their treating medical oncologist.~Dose level 1 of 66-72 Gy(RBE) in 30 fractions used as the planned dose in the Phase II portion of the trial."
3138383|NCT01629485|Experimental|Whole Task|Trainees will undergo whole task mastery training in the TEP simulator after completing the video curriculum portion.
3138384|NCT01629485|Experimental|Part Task|Trainees will undergo a random part task mastery training in the TEP simulator after completing the video portion of the curriculum.
3138385|NCT01629472|Experimental|VSLA + gender dialogue groups: treatment|
3138386|NCT01629472|Active Comparator|VSLA only: control|
3138387|NCT01629459|Experimental|Resistance exercise training|Participants will undergo resistance exercise training 3x/wk for 12 weeks at a physical therapy or cardiac rehabilitation facility near the participant's home.
3138388|NCT01629446|Experimental|Lofexidine HCl with 14C tracer|
3138389|NCT01629433||botulinum A toxin|18 patients with neurogenic DO and 7 with idiopathic DO All the patients had overactive bladder (OAB) symptoms and DO refractory to conventional anticholinergics.
3138390|NCT01629420|Experimental|Drug:KLH-2109 lower dose|
3138391|NCT01629420|Experimental|Drug:KLH-2109 higher dose|
3138392|NCT01629407||Glaucoma|Patients with glaucoma
3138393|NCT01629394|Active Comparator|Group A: Sugammadex CBW-open|Group A patients will undergo open surgery and will receive sugammadex 2mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)] when T2 arises in adductor pollicis.
3138394|NCT01629394|Active Comparator|Group B: Sugammadex IBW-open|Group B patients will undergo open surgery and will receive sugammadex 2mg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
3138395|NCT01629394|Active Comparator|Group C: Neostigmine CBW-open|Group C patients will undergo open surgery and will receive neostigmine 50μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]when T2 arises in adductor pollicis.
3138396|NCT01629394|Active Comparator|Group D: Neostigmine-IBW|Group D patients will undergo open surgery and will receive neostigmine 50μg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
3267823|NCT00712439|Placebo Comparator|2|
3138397|NCT01629394|Active Comparator|Group E: Sugammadex CBW-Lap|Group E patients will undergo laparoscopic surgery and will receive sugammadex 2mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)] when T2 arises in adductor pollicis.
3138398|NCT01629394|Active Comparator|Group F: Sugammadex IBW-Lap|Group F patients will undergo laparoscopic surgery and will receive sugammadex 2mg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
3138399|NCT01629394|Active Comparator|Group G: Neostigmine CBW-Lap|Group C patients will undergo laparoscopic surgery and will receive neostigmine 50μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]when T2 arises in adductor pollicis.
3138400|NCT01629394|Active Comparator|Group H: Neostigmine IBW-Lap|Group D patients will undergo open surgery and will receive neostigmine 50μg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
3138401|NCT01629381|Experimental|Rivaroxaban|Oral Rivaroxaban 10 mg od for 7 days
3138402|NCT01629381|Placebo Comparator|Placebo|oral placebo od for 7 days
3138403|NCT01629368|Experimental|Dosing Period 1|
3138404|NCT01629368|Experimental|Dosing Period 2|
3138405|NCT01629355||Schizophrenia|Five patients with diagnosed schizophrenia will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern. Twelve patients with schizophrenia will then be studied blindly to evaluate the predictive value of the test.
3138406|NCT01629355||ADHD|Five patients with diagnosed ADHD will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern.
3138407|NCT01629355||Bipolar disorder|Five patients with diagnosed Bipolar disorder will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern. Twelve patients with Bipolar disorder will then be studied blindly to evaluate the predictive value of the test.
3138408|NCT01629355||Healthy controls|Fifteen healthy controls will be used to define normal pattern of ABR/SD-BERA potentials. Another twelve normal controls will be studied blindly to evaluate the predictive value of the test.
3138409|NCT01629342||Transient Ischemic Attack Patients|Patients discharged after a Transient Ischemic Attack
3138410|NCT01629329|Active Comparator|Aspirin, Acetaminophen, Caffeine pills|Patients receiving AAC(acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet)will receive 2 pills with active compound and placebo syringe with 2 ml of saline.
3138411|NCT01629329|Active Comparator|Prochlorperazine 10mg|Patients will receive active compound of Prochlorperazine 10mg via IV syringe and 2 unmarked placebo pills
3138412|NCT01629316|Experimental|Text reminders, counseling, link coordinator|Text reminders, counseling, link coordination
3138413|NCT01629316|Active Comparator|Standard of care - control arm|
3138414|NCT01629303|Experimental|Arm on-off|"After the definitive implantation, stimulators are placed in position OFF during 8 weeks.~Then all the stimulators are switched OFF for 15 days. Finally stimulators are switched ON for the second arm during 8 weeks"
3138415|NCT01629303|Experimental|Arm off-on|"After the definitive implantation, stimulators are placed in position ON during 8 weeks.~Then all the stimulators are switched OFF for 15 days. Finally stimulators are maintained in position OFF during 8 weeks"
3138416|NCT01629290|Active Comparator|Enamel Pro|Varnish containing 5%NaF
3138417|NCT01629290|Active Comparator|Duraphat|Varnish containing 5%NaF
3138418|NCT01629290|Active Comparator|Vanish|Varnish containing 5%NaF
3138419|NCT01629290|Placebo Comparator|Placebo|Bland varnish containing no NaF
3138420|NCT01629277|Active Comparator|Control|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
3138421|NCT01629277|Experimental|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
3138422|NCT01629251|Active Comparator|Closed-loop with standard meal insulin bolus|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard meal insulin dosing will be performed at each meal, following individual standard clinical practice.
3138423|NCT01629251|Experimental|Closed-loop with reduced meal insulin bolus|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. The standard meal insulin dose will be reduced by 20 to 50%.
3138424|NCT01629238||group 1|group 1 = consumers of marketed drinkable low fat fermented milk enriched with plant sterol
3138425|NCT01629238||group 2|group 2 = non-consumers of marketed drinkable low fat fermented milk enriched with plant sterol
3138426|NCT01629225|No Intervention|candesartan|All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.
3138427|NCT01629212|Experimental|Tiropramide HCl|
3138428|NCT01629212|Active Comparator|Octylonium bromide|
3138429|NCT01629199|Experimental|rhEGF(recombinant human Epidermal Growth Factor)|BID
3138430|NCT01629199|Placebo Comparator|placebo|BID
3138431|NCT01629186|Experimental|outcome|"Cardiopulmonary parameters were measured and recorded at baseline, just before and at every minute during NC-AC, and at the end of the FB session. In infants who already had an arterial line, arterial blood gas (ABG) analyses were taken for study. Data was represented as mean ± SD. The results obtained from the baseline and different stages. The values were considered statistically significant only when p < 0.05.~Technique failure was defined as: any vital signs of hypoxia did not return to accepted levels(HR>100 beat/min, SpO2>90%, mean BP>50 mmHg)within 2 minutes of the experimental CPR technique. Then traditional CPR procedures involving bag-mask ventilation, endotracheal intubation, Ambu bag ventilation or even chest compressions were substituted."
3138432|NCT01629173|Experimental|Dynamic impression insole|We sequentially padded P-cell, Ethylene Vinyl Acetate, and Multiform on the 9-mm thick plastazote under daily walking compression to make dynamic impression insole.
3138433|NCT01629173|Experimental|Custom molded insole|The custom molded insole was made by sequentially padded Multiform, P-cell, EVA, and cork on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
3138434|NCT01629173|Experimental|9-mm uncompressed Plastazote insole|We used 9-mm flat Plastazote as an insole
3138438|NCT01629134||Volbella|Subjects treated with JUVÉDERM VOLBELLA™ according to the physician's experience and Directions for Use
3138439|NCT01629121|Experimental|education intervention|The intervention delivered education about the benefits of bicycle helmet use and safety and was designed to be sensitive to the age and educational level of the study participant.
3138440|NCT01629121|No Intervention|control|Printed materials were given to the control group, along with a helmet for each participant.
3138441|NCT01629069|Active Comparator|Participant in MBRT|6 sessions of Mindfulness Based Resilience Training
3138442|NCT01629056|Active Comparator|Contact ECI active|Contact ECI active
3138443|NCT01629056|Placebo Comparator|Contact information deactivated|RF ablation without contact data
3138444|NCT01629030||Coronary Artery Bypass Graft Group|Those underwent coronary artery bypass graft surgery with median sternotomy in Samsung Medical Center during the period of January 2008 and December 2011.
3138445|NCT01629004|Other|Non-responders|"Non-responders to an initial mailed CRC screening invitation from their family physician.~FOBT kit. Mailed invitation."
3138446|NCT01629004|Other|Recall patients|"Those who responded to the initial mailed CRC screening invitation and are now due for repeat screening (i.e., recall patients).~FOBT kit. Mailed invitation."
3138447|NCT01628991|Experimental|behavioural intervention|Recieving interventional behavioural program
3138448|NCT01628991|Experimental|vaginal cone|intravaginal device insertion(vaginal cone)
3138449|NCT01628978||Auscultation group|The depth of endotracheal tube placement is determined by auscultation.
3138450|NCT01628978||Ultrasonography group|The depth of placement of endotracheal tube placement is determined by ultrasonographic finding of pleural sliding sign.
3138451|NCT01628965|Experimental|SPM 962|SPM 962 transdermal patch
3138452|NCT01628952|Experimental|TAP|
3138453|NCT01628952|Active Comparator|curare|Patients will be randomized into two parallel groups. One group will receive curare, another benefit of a bilateral TAP block
3138454|NCT01628939||current low back pain|subjects with current low back pain (i.e. more than 30 days of low back pain in the last three months)
3138455|NCT01628939||controls|subjects with less than 30 days of low back pain in the last three months
3138456|NCT01628926|Experimental|SPM 962|SPM 962 transdermal patch
3138457|NCT01628926|Active Comparator|Ropinirole|Ropinirole tablet
3138458|NCT01628926|Placebo Comparator|Placebo|SPM962 placebo patch and Ropinirole placebo tab
3138459|NCT01628913|Experimental|BEZ235|Patients received BEZ235 400 mg bid p.o. (by mouth, twice daily)
3138460|NCT01628913|Active Comparator|Everolimus|Patients received Everolimus 10 mg qd p.o. (by mouth, daily)
3138461|NCT01628900|Active Comparator|ambulatory|Patient will be treated for 7 days at home, then 3 follow-up visit at hospital.
3138462|NCT01628900|Active Comparator|hospitalisation|7 days for mono-antibiotherapy at hospital.
3138463|NCT01628887|Experimental|Supportive Care (BBCEI)|Participants undergo 2 tailored BBCEI sessions within 1 month. At the beginning of the first session the research nurse will present the participants with a list of common physical and social concerns. The participant will then be asked to identify 3 topics that she wants to discuss. The research nurse will discuss with the participant any relevant supportive care resources and make the appropriate referrals. At the second session the focus of the BBCEI will be on psychological and spiritual well-being.
3138464|NCT01628874|Experimental|Lidocaine Injection|0.5 mL (5mg) of 1% lidocaine injection given with the J-Tip
3138465|NCT01628874|Active Comparator|lidocaine 2.5% and prilocaine 2.5% (EMLA) Cream|Patients in this arm will receive 1g EMLA cream if they are in the younger age group and 10g EMLA cream if they are in the older age group. This will be placed for a minimum of 30 minutes.
3138466|NCT01628861|Active Comparator|education only|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet with the same message is also provided.
3138467|NCT01628861|Experimental|prompt + education|"A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet with the same message is also provided. Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
3138468|NCT01628848|Experimental|SPM 962|SPM 962 transdermal patch
3138469|NCT01628848|Placebo Comparator|Placebo|Placebo transdermal patch
3138470|NCT01628835|Experimental|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided.
3138471|NCT01628835|Active Comparator|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
3138472|NCT01628822|Experimental|Active relaxation|
3138473|NCT01628822|Placebo Comparator|Placebo relaxation|
3138474|NCT01628809|Active Comparator|Rest and Relaxation|three-day relaxation retreat without mindfulness components
3138475|NCT01628809|Experimental|Mindfulness-Based Meditation|three-day mindfulness-based meditation retreat
3138476|NCT01628783|Placebo Comparator|Placebo|Microgranular cellulose in gelatine capsules.
3138477|NCT01628783|Experimental|Escitalopram 10 mg|Escitalopram in gelatine capsule
3138478|NCT01628770|Experimental|parenteral iron|dose will be calculated according to Ganzoni's formula, and will be administered by intravenous infusion
3138479|NCT01628770|Active Comparator|oral iron|oral iron in form of ferrous sulphate 200 mg twice daily
3138480|NCT01628757||neoadjuvant chemotherapy|
3138481|NCT01628744||Patients with mycobacterial infection|
3138482|NCT01628731|Active Comparator|furosemide|furosemide, 0.2 mg/kg/h up to 0.8 mg/kg/h for 72 hours
3138483|NCT01628731|Active Comparator|ethacryinic acid|ethacrynic acid, 0.2 mg/kg/h up to 0.8 mg/kg/h for 72 hours
3138962|NCT01625273|No Intervention|IF (Infant formula)|
3138484|NCT01628718|Active Comparator|CPT-C|Cognitive Processing Therapy, cognitive version only (CPT-C) delivered in 12 60-minute one-on-one treatment sessions.
3138485|NCT01628718|Experimental|Adaptive Disclosure (AD)|Adaptive Disclosure delivered in eight 90-minute one-on-one treatment sessions.
3138486|NCT01628705|Sham Comparator|Nutritional intervention|The subjects were undergoing nutritional intervention.
3138487|NCT01628705|Experimental|Nutritional intervention with green tea|The subjects were undergoing nutritional intervention complemented with green tea.
3138488|NCT01628692|Experimental|Cohort 1: (Genotype 1b) Daclatasvir + Simeprevir|Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal for 12 weeks
3138489|NCT01628692|Experimental|Cohort 2: (Genotype 1b) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day) for 12 weeks.
3138490|NCT01628692|Experimental|Cohort 3: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day) for 12 weeks.
3138491|NCT01628692|Experimental|Cohort 4: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day.
3138492|NCT01628679|Experimental|physical therapy treatment|
3138493|NCT01628666|Experimental|Conventional|Preoperative Antibiotics: Cefazolin preoperative, vancomycin in penicillin allergic patients.
3138494|NCT01628666|Experimental|Incremental|Preoperative antibiotics (Cefazolin and Vancomycin) Bacitracin pocket wash and 2 days of oral Cefalexin post operative.
3138495|NCT01628653|Experimental|U-SMART|U-SMART (Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training)
3138496|NCT01628640|Experimental|Arm A (viral therapy in single tumor location)|Patients with hepatocellular carcinoma or advanced solid tumor with liver lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in a single tumor location on day 1.
3138497|NCT01628640|Experimental|Arm B (viral therapy in multiple locations)|Patients with advanced solid tumor with subcutaneous/cutaneous lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in up to 5 cutaneous, subcutaneous, or soft tissue tumor lesions on day 1.
3138498|NCT01628627|Experimental|FREMS|Frequency Modulated Neural Stimulation (FREMS)
3138499|NCT01628627|Sham Comparator|Control|
3138500|NCT01628614||POAG or OHT|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
3138501|NCT01628601||POAG or OHT|Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
3138502|NCT01628588||POAG or OHT|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
3138503|NCT01628575||PAO|patients undergoing orthodontic treatment with the addition of pretreatment periodontal surgery for bone decortication.
3138504|NCT01628562|Active Comparator|GroupE/Esmolol infusion|Heart rate control, Beta blocker
3138505|NCT01628562|Experimental|GroupR/Remifentanil infusion|Heart rate control, opioid
3138506|NCT01628549|Experimental|50 mg P005672|1 50 mg capsule P005672 and 1 matching placebo capsule, 1 capsule from each bottle taken orally each day
3138507|NCT01628549|Experimental|100 mg P005672|Two 50 mg capsules, 1 capsule from each bottle taken orally each day
3138508|NCT01628549|Experimental|200 mg P005672|Two 100 mg capsules, 1 capsule from each bottle taken orally each day
3138509|NCT01628549|Placebo Comparator|Placebo|2 placebo capsules matching WC3035, 1 capsule from each bottle taken orally each day
3138510|NCT01628536|Experimental|Black cohosh|
3138511|NCT01628523||All ED patients requiring mechanical ventilation|
3138512|NCT01628510|Active Comparator|Traditional NICU Positioning|Methods of positioning in the NICU have been used for several decades. These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper® The continued use of these methods of positioning is the control group in the current study.
3138513|NCT01628510|Experimental|Dandle Roo/Dandle Wrap|The new Dandle Roo and Dandle Wrap were developed by NICU professionals to support the neurodevelopment of the preterm infant, and this device is produced by Dandle Lion Medical. The Dandle Roo/Wrap provides all around contact, containment, and proprioceptive input, (which more closely mimics the uterine environment) and can decrease excitability and promote self-regulation, while also allowing for movement with recoil back to flexion.
3138514|NCT01628497||Positive filariasis test|Those testing positive for filariasis
3138515|NCT01628497||Filariasis negative|
3138516|NCT01628484|Other|Skin Preparation Testing|The methodology of this study is an intra-individual comparison. Each study participant is treated with three skin preparation techniques (pricking, tape stripping, microneedle array)on both volar forearms.
3138517|NCT01628471|Experimental|Decitabine + genistein single arm|decitabine injectable, by infusion, 5 ascending doses (60 to 500 mg/m2) genisteine capsules, 3 x 50 mg capsules twice a day
3138518|NCT01628458|Experimental|radiofrequency ablation|
3138519|NCT01628445|Active Comparator|liraglutide|liraglutide 1.8 mg injected once daily
3138520|NCT01628445|Placebo Comparator|Placebo injection|
3138521|NCT01628432|Experimental|conservative hysterectomy I|bilateral salpingectomy during hysterectomy with conservation of the ovaries
3138522|NCT01628432|Active Comparator|conservative hysterectomy II|standard conservative hysterectomy with conservation of both ovaries and tubes
3138570|NCT01628068|No Intervention|Oral anticoagulation|Oral anticoagulation
3268071|NCT00710840|Experimental|1|
3138523|NCT01628419|Experimental|Health intervention program|Health promotion intervention program will be implemented at each workplace and will include: exercise program, nutritional counseling for the kitchen service, lectures on different topics (physical activity, nutrition, sleeping behaviour etc.).
3138524|NCT01628406||Patients treated at the neurosurgery department|Patients treated at the neurosurgery department
3138525|NCT01628393|Experimental|RPC1063 Low Dose|
3138526|NCT01628393|Placebo Comparator|placebo|
3138527|NCT01628393|Experimental|RPC1063 High Dose|
3138528|NCT01628380|Active Comparator|CRS + HIPEC|Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with CDDP+Paclitaxel
3138529|NCT01628380|Active Comparator|CRS alone|Cytoreductive Surgery alone
3138530|NCT01628367|Experimental|Membrane|Test (membrane): Extraction and immediate implant placement will be performed. The gaps between the implant and socket walls will be filled with a bone graft material. Sites in the test group will receive a high-density PTFE (d-PTFE) membrane over the socket.
3138531|NCT01628367|Active Comparator|Collagen plug|Control (collagen plug): Extraction and immediate implant placement will be performed. The gaps between the implant and socket walls will be filled with a bone graft material. Sites in the control group will receive a collagen wound dressing over the socket.
3138532|NCT01628341||Patients with diabetes (type 1 and 2)|
3138533|NCT01628328||Stenting|patient who received colonic stenting for obstructive colorectal cancer
3138534|NCT01628328||Control|patients who had only colonoscopy without obstruction and without stenting
3138535|NCT01628315||Mulitple Sclerosis|Patients with relapsing-remitting MS who had a MRI as part of their participation in the ASA study.
3138536|NCT01628302|No Intervention|Normal salt diet|The group had normal salt diet (250mmol)for three weeks. Subjects had normal salt diet in their daily routine life for the following 2 weeks.According to crossover nature of the study, the group had low salt diet (50mmol) at the last 3 weeks of the study.
3138537|NCT01628302|Experimental|Low salt diet|The group had low salt diet (50mmol)for three weeks. Subjects had normal salt diet in their daily routine life for the following 2 weeks.According to crossover nature of the study, the group had normal salt diet at the last 3 weeks of the study.
3138538|NCT01628289|Other|free screening group|Subjects in this group receive free diabetic retinopathy screening.
3138539|NCT01628289|Other|Pay screening group|Subjects in this group receive diabetic retinopathy screening with charging a co-payment.
3138540|NCT01628276|Experimental|Rehab first|
3138541|NCT01628276|Experimental|Rehab Second|
3138542|NCT01628276|No Intervention|Non Rehab|
3138543|NCT01628263|Experimental|Follow up Clinic|Participants will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse.
3138544|NCT01628263|No Intervention|Control|Participants will not receive an offer of a follow up clinic
3138545|NCT01628250|Active Comparator|laparoscopic complete mesocolic excision|Randomized group of patients receiving laparoscopic colectomy with the concept of complete mesocolic excision
3138546|NCT01628250|Active Comparator|D3 laparoscopic colectomy|Randomized group of patients receiving laparoscopic colectomy with D3-resection
3138547|NCT01628237|Active Comparator|Monocolumn spinal cord stimulation|Specify 5-6-5 Lead (only one column)
3138548|NCT01628237|Experimental|Multicolumn spinal cord stimulation|Specify 5-6-5 Lead
3138549|NCT01628224||CCATT Team|Measurements will be taken on groups of 3 people each. There will be a total of 16 such teams, with total membership of 48 individuals
3138550|NCT01628211|Experimental|Second look laparoscopy|Second look laparoscopy to evaluate for and treat peritoneal carcinosis
3138551|NCT01628211|No Intervention|standard follow up|
3138552|NCT01628198|Experimental|Renal denervation group|Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter
3138553|NCT01628185||Pain Observations|Adult ICU patients who are not comatose with Richmond Agitation-Sedation Scale (RASS) score of -3 to 4 and unable to self-report pain. Patients will be excluded for neurological deficits (acute or chronic) that prevent observation of the muscle tonus or movement
3138554|NCT01628172|Experimental|Biosense Webster Celcius Thermacool catheter|These subjects will undergo catheter-based sympathetic renal denervation. Ablation arm
3138555|NCT01628172|No Intervention|renal angiogram only|Control Group: Control arm will not receive intervention but will be followed for 1 year.
3138556|NCT01628159|Experimental|Lutonix Drug Coated Balloon|Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
3138557|NCT01628146|Experimental|SUPRACOR LASIK treatment|SUPRACOR LASIK treatment
3138558|NCT01628133||blood transfusion group|
3138559|NCT01628120|Experimental|Epoetin Hospira|Epoetin Hospira will be administered by SC bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.
3138560|NCT01628107|Experimental|Epoetin Hospira|Epoetin Hospira will be administered by IV bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.
3138561|NCT01628094|Experimental|A: GT1a 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
3138562|NCT01628094|Experimental|B: GT1a 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
3138563|NCT01628094|Experimental|C: GT1a 2DAA|including RO5466731, RO5190591, ritonavir and ribavirin [Copegus]
3138564|NCT01628094|Experimental|D: GT1b 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
3138565|NCT01628094|Experimental|E: GT1b 2DAA|including RO54664731, RO5190591, ritonavir and ribavirin [Copegus]
3138566|NCT01628094|Experimental|Part II|
3138567|NCT01628081|Experimental|Alga Dunaliella bardawil|After screen phase of maximum two weeks the subjects will be randomized to one of two treatments groups (1:1): Dunaliella or placebo.
3138568|NCT01628081|Placebo Comparator|Placebo|"Dosage Regimen and Treatment Groups~Daily oral administration of:~Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
3138569|NCT01628068|Active Comparator|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
3268072|NCT00710840|Active Comparator|2|
3138571|NCT01628055|Experimental|Privigen|The IVIG preparation to be used is 10% liquid (Privigen). IVIG will be applied at a dose of 1.0g/kg, which is approximately 1/2 of the optimal dose used for other immuno/inflammatory indications. The infusion will start at 0.5 ml/kg/hr for the first 30 minutes, to watch for the signs of hypersensitivity to immunoglobulins, and then increased to 2.5 ml/kg/hr, two times slower than the recommended rate indicated in the product package insert (5 ml/kg/hr). Such a low, single dose has not been associated with hyperviscosity and together with a slow infusion will safeguard against occurrence of adverse events related to IVIG infusions. They will receive a total of 1g/kg and depending on patient's weight, it will take between 3.5 to 4+ hours to infuse that amount.
3138572|NCT01628055|Placebo Comparator|Normal Saline|The placebo is the normal saline. Since saline solution will be infused at the volume equivalent to that in which the intended dose of immunoglobulin molecules will be delivered, the placebo (comparator) arm will also serve as a control for the volume of fluid infused to the treatment arm participants.
3138573|NCT01628042|Experimental|Participants With Severe Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
3138574|NCT01628042|Experimental|Participants With Moderate Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
3138575|NCT01628042|Experimental|Participants With Mild Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
3138576|NCT01628042|Experimental|Healthy Matched Control Participants|Participants receive a single oral dose of vibegron 100 mg on Day 1.
3138577|NCT01628029|Experimental|Litebook + Melatonin + Methylphenidate + CBT|Light therapy over 30 minutes for 14 days. Melatonin 20 mg orally at bedtime and Methylphenidate 5 mg orally twice daily for 15 days. Counseling sessions on Days 8 and 15. Well-being questionnaires completed Days 1, 3, 8, 15, and 29, with Study Diaries completed daily.
3138578|NCT01628029|Experimental|Placebo Litebook + Placebo drugs + CBT|Placebo light over 30 minutes for 14 days. One placebo capsule orally twice during day, and one at bedtime for 15 days. Counseling session on Days 8 and 15. Well-being questionnaires completed Days 1, 3, 8, 15, and 29, with Study Diaries completed daily.
3138579|NCT01628029|Experimental|Placebo Litebook + Melatonin + Methylphenidate + CBT|Placebo light over 30 minutes for 14 days. Melatonin 20 mg orally at bed time, and Methylphenidate 5 mg by mouth twice daily for 15 days. Counseling session on Days 8 and 15. Well-being questionnaires completed Days 1, 3, 8, 15, and 29, with Study Diaries completed daily.
3138580|NCT01628029|Experimental|Litebook + Placebo + Methylphenidate + CBT|Light therapy over 30 minutes for 14 days. Methylphenidate 5 mg by mouth twice daily and one placebo capsule at bedtime for 15 days. Counseling session on Days 8 and 15. Well-being questionnaires completed Days 1, 3, 8, 15, and 29, with Study Diaries completed daily.
3138581|NCT01628029|Experimental|Litebook + Melatonin + Placebo + CBT|Light therapy over 30 minutes for 14 days. Melatonin 20 mg orally at bed time, and one placebo capsule orally twice daily for 15 days. Counseling session on Days 8 and 15. Well-being questionnaires completed Days 1, 3, 8, 15, and 29, with Study Diaries completed daily.
3138582|NCT01628029|Experimental|Litebook + Placebo Drugs + CBT|Light therapy over 30 minutes for 14 days. One placebo capsule orally twice daily, and one at bedtime for 15 days. Counseling session on Days 8 and 15. Well-being questionnaires completed Days 1, 3, 8, 15, and 29, with Study Diaries completed daily.
3138583|NCT01628029|Experimental|Placebo Litebook + Placebo + Methylphenidate + CBT|Placebo light over 30 minutes for 14 days. One placebo capsule at bedtime, and Methylphenidate 5 mg orally twice daily for 15 days. Counseling session on Days 8 and 15. Well-being questionnaires completed Days 1, 3, 8, 15, and 29, with Study Diaries completed daily.
3138584|NCT01628029|Experimental|Placebo Litebook + Melatonin + Placebo + CBT|Placebo light over 30 minutes for 14 days. Melatonin 20 mg orally at bed time, and one placebo capsule orally twice daily for 15 days. Counseling session on Days 8 and 15. Well-being questionnaires completed Days 1, 3, 8, 15, and 29, with Study Diaries completed daily.
3138585|NCT01628016|Experimental|Attentional bias modification training|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. ABMT is a modified dot probe task, in which a probe always appears in the location of neutral stimulus after the two stimuli (i.e. one is the depressive cue and the other is neutral) were simultaneously presented. In the ABMT,the probability that a probe appears in the location of neutral is 90%, and correspondingly,in the location of depressive stimuli is 10%. Each session consists of 218 trials, and the time to complete a training session is approximately 10 minutes.
3138586|NCT01628016|Placebo Comparator|Placebo training|Participants complete 8 sessions of placebo training(PT) during a two-week period. Placebo training is a classic dot probe task, in which a probe appears after either of the locations that the two stimuli (i.e. one is the depressive cue and the other is neutral) were presented, with the same frequencies. In the PT condition, each session also consists of 218 trials, and the time to complete a PT session is approximately 10 minutes as well.
3138587|NCT01628016|No Intervention|blank control|Participants only complete assessment at each point time.
3138588|NCT01628003|Active Comparator|healthy persons|
3138589|NCT01628003|Experimental|patients after moderate-severe TBI|
3138590|NCT01627977|Experimental|Dye of Lutein/Zeaxanthin/Brilliant Blue|during the surgery will be evaluated if the dye is suitable for dyeing the internal limiting membrane as well as the epiretinal membrane
3138591|NCT01627964||normal heart function|normal heart function
3138592|NCT01627964||abnormal heart function|abnormal heart function
3138593|NCT01627951|Active Comparator|NF54|Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
3138594|NCT01627951|Experimental|NF135|Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
3138595|NCT01627951|Experimental|NF166|Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
3138596|NCT01627938|Experimental|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1
3138597|NCT01627938|Placebo Comparator|Placebo plus Mitoxantrone (MX)|Placebo + MX (12 mg/m2)
3138598|NCT01627925|Experimental|Face mask and nasal mask without PEEP|Face mask ventilation and nasal mask ventilation without PEEP
3138599|NCT01627925|Experimental|Nasal mask and face mask with PEEP|Nasal mask ventilation and face mask ventilation with PEEP
3138963|NCT01625273|Experimental|IF with L. paracasei strain F19|
3138601|NCT01627886|Experimental|Ibandronate sodium tablets 150 mg|Ibandronate sodium tablets 150 mg of Dr. Reddy's Laboratories Limited
3138602|NCT01627886|Active Comparator|Boniva|Boniva Tablets 150 mg of Roche Laboratories Inc, USA
3138603|NCT01627873|Experimental|Remifentanyl|In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
3138604|NCT01627873|Active Comparator|Fentanyl|In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
3138605|NCT01627860|Active Comparator|Topiramate add-on therapy|
3138606|NCT01627860|Experimental|Topiramate monotherapy|
3138607|NCT01627847|Experimental|Ropinirole|Ropinirole Hydrochloride ER tablets 2 mg of Dr. Reddy's Laboratories Limited
3138608|NCT01627847|Active Comparator|Requip|Requip XL Tablets 2 mg of Glaxosmithkline, USA
3138609|NCT01627834|Experimental|Ropinirole|Ropinirole Hydrochloride ER tablets 2 mg of Dr. Reddy's Laboratories Limited
3138610|NCT01627834|Active Comparator|Requip|Requip XL Tablets 2 mg of Glaxosmithkline, USA
3138611|NCT01627821|Active Comparator|Jarvik 2000 Treatment|Jarvik 2000 VAS, Post-Auricular Cable
3138612|NCT01627821|Active Comparator|HeartMate II Control|HeartMate II VAS Control
3138613|NCT01627795|Experimental|Oshadi D and Oshadi R|anti cancer agents
3138614|NCT01627782|Placebo Comparator|Placebo 3 times/week|
3138615|NCT01627782|Experimental|Ketamine 3 times/week|
3138616|NCT01627782|Experimental|Ketamine 2 times/week|
3138617|NCT01627782|Placebo Comparator|Placebo 2 times/week|
3138618|NCT01627769||second degree blisters patients|blister fluids of second degree burns
3138619|NCT01627769||cryotherapy blisters|blister fluids of cryosurgery wounds
3138620|NCT01627756|Experimental|Ventilation Group|Volume controlled ventilation was done during the whole surgery.
3138621|NCT01627756|No Intervention|Non-ventilation Group|In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
3138622|NCT01627743||COPD patients grade C and D|
3138623|NCT01627730|Experimental|3th year medical students|
3138624|NCT01627730|Experimental|nurses in critical care units|
3138625|NCT01627717|Experimental|Maraviroc Boceprevir|
3138626|NCT01627704|Other|Fluoroestradiol (18F)|
3138627|NCT01627691|Experimental|Lotus Valve System|Patients enrolled will receive the Lotus Valve.
3138628|NCT01627678|Experimental|Arm 1= Arm A: Vacc-C5 /GM-CSF.|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
3138629|NCT01627678|Experimental|Arm 2=Arm B: Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
3138630|NCT01627665|Active Comparator|D->R->C+R|sequence of treatment: Dabigatran after rivaroxaban after chlarythromycin in association with rivaroxaban
3138631|NCT01627665|Active Comparator|D->R->C+D|sequence of treatment: Dabigatran after rivaroxaban after chlarythromycin in association with Dabigatran
3138632|NCT01627665|Active Comparator|R->D->C+D|sequence of treatment: rivaroxaban after Dabigatran after chlarythromycin in association with Dabigatran
3138633|NCT01627665|Active Comparator|R->D->C+R|sequence of treatment: rivaroxaban after Dabigatran after chlarythromycin in association with rivaroxaban
3138634|NCT01627652|Experimental|altitude|subjects will be studies at sea level and at high altitude
3138635|NCT01627639|Active Comparator|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
3138636|NCT01627639|Placebo Comparator|Placebo|Placebo
3138637|NCT01627626|Experimental|0.1% pilocarpine mouthwash|0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline
3138638|NCT01627626|Placebo Comparator|0.9% saline mouthwash|0.9% saline as a mouthwash
3138639|NCT01627613|Experimental|AP301|Treatment group
3138640|NCT01627613|Placebo Comparator|saline solution|Placebo group
3138641|NCT01627600||Atahualpa residents aged ≥ 40 years|All Atahualpa residentes aged 40 ≥ years will be screened by field questionnaires. Then, those with suspected stroke or ischemic heart disease will be evaluated by neurologists and cardiologists. Cardiovascular health metrics will be evaluated in those negative for stroke or ischemic heart disease.
3138642|NCT01627587|Experimental|Ketoconazole-Part A|Healthy Female volunteers of child bearing potential will receive Treatment A, B and C
3138643|NCT01627587|Experimental|Food-Part B|Healthy Female Volunteers of child bearing potential will receive Treament D and E
3138644|NCT01627574|Experimental|Motivational Intervention|There are two, 45-60 minute sessions of tailored Motivational Interviewing (MI). The first session occurs at the enrollment of the study, the second at 3 month follow-up.
3138645|NCT01627574|Active Comparator|Didactic Educational Intervention|There are two, 45-60 minute sessions of didactic educational intervention related to promoting awareness for sexual health involving contraception and STI prevention. The first session occurs at the enrollment of the study, the second at 3 month follow-up.
3138646|NCT01627561|Experimental|Cervarix Group|Subjects aged 4-6 years receiving 2 doses of Cervarix vaccine at Day 0 and Month 6
3138647|NCT01627561|Experimental|Priorix + Infanrix Group|Subjects aged 4-6 years receiving 1 dose of Priorix vaccine at Day 0 and 1 dose of Infanrix vaccine at Month 6
3138648|NCT01627561|Experimental|HPV_2D CO group|Subjects aged 4-6 years receiving 2 doses of Cervarix vaccine, the first dose co-administered with Priorix vaccine (at Day 0) and the second one co-administered with Infanrix vaccine (at Month 6)
3138649|NCT01627561|Active Comparator|HPV_3D group|Subjects aged 15-25 years receiving 3 doses of Cervarix vaccine at Day 0, Month 1 and Month 6
3138650|NCT01627548|Active Comparator|Waitlisted Intervention|Couple will be consented, assessed and randomized to a waitlist of 4 months. The couple will be reassessed at 8 weeks and prior to initiating intervention.
3138651|NCT01627548|Active Comparator|Immediate Intervention|Eligible couples who are randomized to immediate intervention will begin sessions with a trained interventionist within weeks of consent and initial assessments
3138652|NCT01627535|Experimental|Optical Imaging|Patients undergo i2DOS
3138653|NCT01627522|Active Comparator|Finastide low dose|2 weeks of daily 5mg finastride before operation
3138654|NCT01627522|Active Comparator|Finastide high dose|4 weeks of daily 5mg finastride before operation
3138655|NCT01627522|No Intervention|Control|Control
3138656|NCT01627483|Experimental|Medication review|Assessment of risks of falls and fractures, medication review
3138657|NCT01627483|No Intervention|Controll|
3138658|NCT01627470||Cohort|Emergency Patients with applied arterial blood pressure measurement
3138659|NCT01627457|Experimental|GEx Training|CAD Patients in cardiac rehabilitation phase II (inpatient) and phase III (at home)in order to analyze data for quality of heart rate measurement and data acquisition by device as well as for practicability and technical problems at home.
3138660|NCT01627444|Experimental|ear acupuncture|
3138661|NCT01627444|Placebo Comparator|Placebo acupuncture|No needle insertion, only stickers on acupuncture points.
3138662|NCT01627431|Other|Antiplatelet therapy|Patients underwent peripheral revascularization procedures undergoing a double antiplatelet therapy
3138663|NCT01627418|Experimental|Voucher|"Receive the intervention (Energy Voucher) the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy."
3138664|NCT01627418|Other|Control|"Receive the intervention the second winter enrolled in the study (thus No intervention : control arm). The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy."
3138665|NCT01627392|Experimental|Smoking abstinence|
3138666|NCT01627379|Active Comparator|Arm A: Cisplatin, 5-Fluorouracil|Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.
3138667|NCT01627379|Experimental|Arm B: Cisplatin, 5-Fluorouracil and Panitumumab|Chemotherapy plus Panitumumab will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.
3138668|NCT01627366|Experimental|Survivorship Care Plan|Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
3138669|NCT01627366|No Intervention|Usual care|Receipt of usual medical care.
3138670|NCT01627353|Active Comparator|Standard of Care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
3138671|NCT01627353|Experimental|Pre-emptive wound infiltration|The Wound Infiltration Group will receive 100 mL 0.25% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.
3138672|NCT01627340|Experimental|Diabetes Group|Subjects diagnosed with type 2 diabetes within the five year period before study start who received 3 doses of Engerix™-B vaccine (HBV) at 0, 1 and 6 months. The vaccine was administered intramuscularly (IM) into the deltoid region of the non-dominant arm.
3138673|NCT01627340|Active Comparator|Control Group|Subjects with no diagnosis or documented history of diabetes who received 3 doses of Engerix™-B (HBV) vaccine at 0, 1 and 6 months. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3138674|NCT01627327|Experimental|fluticasone furoate/vilanterol|inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)
3138675|NCT01627327|Active Comparator|tiotropium bromide|anticholinergic
3138676|NCT01627314|Experimental|ProHema-CB|
3138677|NCT01627314|Active Comparator|Control Arm|
3138678|NCT01627301|Experimental|Device-Guided Breathing at low breathing rate|Device-guided breathing at low breathing rate daily for 15 minutes up to 8 weeks
3138679|NCT01627301|Active Comparator|Device guided breathing at normal rate|Device-guided breathing at a normal breathing rate daily for 15 minutes for up to 8 weeks
3138680|NCT01627288|Experimental|Boost Radiation: Dose Level 1|2.4 Gy X 25 fractions = 60 Gy
3138681|NCT01627288|Experimental|Boost Radiation: Dose level 2|2.6 Gy X 25 fractions = 65 Gy
3138682|NCT01627288|Experimental|Boost Radiation: Dose level 3|2.8 Gy x 25 fractions = 70 Gy
3138683|NCT01627288|Experimental|Experimental: Boost Radiation Dose Level 0|"If the 2 dose limiting toxicities are documented at dose level 1, therapy will be de-escalated to Dose level 0 defined below.~Dose level 0: 2.2 Gy X 25 fractions = 55 Gy"
3138684|NCT01627275|Experimental|DLI from HLA-identical donor|Naive T Cell Depleted Donor Lymphocyte Infusion from HLA matched family member donor or 8/8 HLA matched unrelated donor.
3138685|NCT01627262|Placebo Comparator|Placebo|
3138686|NCT01627262|Experimental|Mesalamine|
3138687|NCT01627249|Active Comparator|Ranibizumab|
3138688|NCT01627249|Experimental|Aflibercept|
3138689|NCT01627249|Experimental|Bevacizumab|
3138690|NCT01627236|Experimental|glucocorticoid treatment group|
3138691|NCT01627236|No Intervention|conventional treatment|
3138692|NCT01627223|Experimental|Lamivudine 100 mg p.o. q.d.|"To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.~Cohort 1: Lamivudine 100 mg p.o. q.d.~Cohort 2: Entecavir 0.5 mg p.o. q.d.~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
3138735|NCT01626898|Experimental|HOLA en Grupos|The Spanish language HOLA en Grupos intervention consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants.
3268073|NCT00710827|Experimental|Arm 1|
3138693|NCT01627223|Experimental|Entecavir 0.5 mg p.o. q.d|"To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.~Cohort 1: Lamivudine 100 mg p.o. q.d.~Cohort 2: Entecavir 0.5 mg p.o. q.d.~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
3138694|NCT01627197|Active Comparator|Intraaterial chemotherapy|"This is an open-label, prospective, multicenter, randomized, controlled phase 3 two-arm study.Patients with locally advanced TCC of the bladder are randomized to 1 of 2 treatment arms~Arm 1 (treatment):'Surgery of percutaneous catheter system for arterial chemotherapy is done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique.Gemcitabine 800 mg/m2 intra-arterial,cisplatin 25 mg/m2 intra-arterial once a week for 3 weeks followed by 1-week rest period. Maximum of 3 cycles. Treatment begins between 1-5 weeks after radical operation (within 40 days is recommended)."
3138695|NCT01627197|No Intervention|Watchful waiting|Arm 2 (control): No immediate post-surgery treatment. Patients undergo observation followed by cisplatin and gemcitabine as in arm I at local relapse, or receive intravenously chemotherapy with cisplatin and gemcitabine at multiple metastases
3138696|NCT01627184||Athletes with diabetes mellitus|Athletes who are insulin-requiring and insulin-dependent diabetics undergoing high levels of activity over extended period of time
3138697|NCT01627171|Active Comparator|PEG Lyte|PEGlyte to be reconstituted with 4L of water and taken in the evening before the colonoscopy.
3138698|NCT01627171|Experimental|Pico Salax Split|Two sachets of Pico-Salax with 1 taken the night before colonoscopy and the second taken the morning of colonoscopy.
3138699|NCT01627171|Experimental|Pico Salax Night Before|2 sachets of Pico Salax mixed with water taken about 4 hours apart the night before colonoscopy
3138700|NCT01627158|Experimental|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
3138701|NCT01627158|Active Comparator|Symbicort Turbuhaler|Symbicort Turbuhaler
3138702|NCT01627158|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
3138703|NCT01627158|Active Comparator|Charcoal and Symbicort Turbuhaler|
3138704|NCT01627145|Experimental|antimuscariniz drug|
3138705|NCT01627132|Experimental|dasatinib|
3138706|NCT01627119||Gastric cancer patients|Gastric cancer patients who receive curative surgery at National Taiwan University Hospital
3138707|NCT01627106|Experimental|Vernakalant|
3138708|NCT01627106|Active Comparator|Amiodarone|
3138709|NCT01627093||Proton Therapy Chart Review|Retrospective and prospective chart analysis performed on all patients documented to have head and neck cancer treated with Proton Therapy at UT MD Anderson Cancer Center from January 1, 2008 through December 31, 2017.
3138710|NCT01627080||Cardiac Biomarkers|Patients with histologically proven esophageal cancer to be treated with radiation therapy with concurrent chemotherapy to a final dose of >/=40 Gy included in this study at UT MD Anderson Cancer Center in Houston, Texas.
3138711|NCT01627067|Experimental|Everolimus + Exemestane + Metformin|Patients take one 25 mg tablet of exemestane once daily, everolimus 10 mg orally per day and metformin 500 mg orally per day for three days. If there are no dose limiting toxicities, dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily. Drugs will be taken immediately after a meal at the same time each day.
3138712|NCT01627054|Experimental|AT7519M|
3138713|NCT01627041|Experimental|Arm I (daunorubicin hydrochloride, cytarabine)|Patients receive induction chemotherapy comprising daunorubicin hydrochloride IV daily on days 1-3 and cytarabine IV continuously on days 1-7 in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR after the first induction-chemotherapy course receive a second identical induction course.
3138714|NCT01627041|Experimental|Arm II (decitabine, daunorubicin hydrochloride, cytarabine)|Patients receive decitabine IV over 1 hour on days -5 to -1. Patients then receive induction chemotherapy as in arm I in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR after the first induction-chemotherapy course receive a second identical induction course.
3138715|NCT01627015|Experimental|Modified infant follow-on formula|Infants are fed a modified infant follow-on formula (modified carbohydrate composition) for 4 weeks, according to protocol
3138716|NCT01627015|Active Comparator|Standard infant follow-on formula|Infants are fed a commercial follow-on formula for 4 weeks, according to protocol
3138717|NCT01627002|Experimental|PA401|PA401 is a potent inhibitor of neutrophil activation and transmigration under development as a novel parenteral anti-inflammatory therapy for respiratory indications such as chronic obstructive pulmonary disease (COPD) and Cystic Fibrosis (CF). PA401 is a genetically engineered and recombinantly expressed mutant of the bioactive form of human interleukin-8.
3138718|NCT01627002|Placebo Comparator|Placebo|Placebo
3138719|NCT01626989|Active Comparator|BiPAP auto SV Advanced|BiPAP auto SV Advanced
3138720|NCT01626989|Experimental|BiPAP auto SV 4|Auto Servo Ventilation Device
3138721|NCT01626976|Experimental|Cohort 1|
3138722|NCT01626976|Experimental|Cohort 2|
3138723|NCT01626976|Experimental|Cohort 3|
3138724|NCT01626976|Experimental|Cohort 4|
3138725|NCT01626976|Experimental|Cohort 5|
3138726|NCT01626963|Experimental|SPA|Single-port access surgery
3138727|NCT01626963|Active Comparator|CL|Conventional Laparoscopic access
3138728|NCT01626950||Cases - Stage III-IV breast cancer|The women in this group have been diagnosed with stage III-IV incident cancer.
3138729|NCT01626950||Controls: Stage I-II breast cancer|The women in this group have been diagnosed with stage I-II incident cancer.
3138730|NCT01626937|Experimental|Non invasive ventilation with conventional treatment|
3138731|NCT01626937|Active Comparator|conventional medical treatment|
3138732|NCT01626924|Experimental|2-Iminobiotin|
3138733|NCT01626911|Experimental|CRAI|CRAI of LMWH in the celiac trunk
3138734|NCT01626911|Other|Conservative treatment|Conservative treatment without CRAI, control group
3138794|NCT01626573|Experimental|INCB039110 600 mg once a day|INCB039110 600 mg once a day
3138736|NCT01626898|Active Comparator|General health intervention|The Spanish language comparison condition consists of four 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
3138737|NCT01626885|Experimental|MP-214|
3138738|NCT01626872|Experimental|MP-214 low dose|
3138739|NCT01626872|Experimental|MP-214 middle dose|
3138740|NCT01626872|Experimental|MP-214 high dose|
3138741|NCT01626872|Active Comparator|Risperidone|
3138742|NCT01626859|Experimental|MP-214 low dose|
3138743|NCT01626859|Experimental|MP-214 middle dose|
3138744|NCT01626859|Experimental|MP-214 high dose|
3138745|NCT01626846||NF1 teenagers|
3138746|NCT01626833|Active Comparator|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE* : Norditropine® simplexx®
3138747|NCT01626833|Placebo Comparator|Placebo|Placebo
3138748|NCT01626820|Experimental|Fluviral Adults Group|Subjects 18-60 years of age received 1 dose of Fluviral® vaccine, administered intramuscularly in the deltoid of the non-dominant arm, at Day 0.
3138749|NCT01626820|Experimental|Fluviral Elderly Group|Subjects above 60 years of age received 1 dose of Fluviral® vaccine, administered intramuscularly in the deltoid of the non-dominant arm, at Day 0.
3138750|NCT01626807|Experimental|Walking school bus|
3138751|NCT01626807|No Intervention|Usual care|
3138752|NCT01626794|Experimental|VARIVAX™ VEP|
3138753|NCT01626794|Active Comparator|VARIVAX™ 2007 Process|
3138754|NCT01626768||Enrolled patients|
3138755|NCT01626755|Experimental|Nerve block|"Optimized intravenous pain treatment during surgery and for 7 days postoperatively.~Definition: strong opioid patient-controlled analgesia, non-opioids, ketamine intravenously.~Sciatic nerve block: infusion of local anesthetic."
3138756|NCT01626755|Active Comparator|Control|"Optimized intravenous pain treatment during surgery and for 7 days postoperatively.~Definition: strong opioid patient-controlled analgesia, non-opioids, ketamine intravenously.~Sciatic nerve block: saline infusion."
3138757|NCT01626742|Placebo Comparator|Ready to drink flavored beverage|
3138758|NCT01626742|Experimental|Ready to drink flavored beverage w/ AN 777|
3138759|NCT01626729|Experimental|Traffic Light|
3138760|NCT01626729|Experimental|Traffic Light+|
3138761|NCT01626729|Experimental|Facts Up Front|
3138762|NCT01626729|Experimental|Facts Up Front+|
3138763|NCT01626729|Placebo Comparator|No front of package label|
3138764|NCT01626716|Experimental|case management|patients who assigned to the intervention group will take 7 times phone calls from case manager
3138765|NCT01626716|No Intervention|control|usual care
3138766|NCT01626703|Experimental|intervention|remiding call
3138767|NCT01626703|No Intervention|Control|No intervention
3138768|NCT01626690|Experimental|Pre-Warming|
3138769|NCT01626690|Active Comparator|Control|
3138770|NCT01626677|Experimental|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
3138771|NCT01626677|Active Comparator|Microfracture|conventional treatment method
3138772|NCT01626664|Experimental|KW-0761|anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)
3138773|NCT01626664|Active Comparator|investigator's choice|Comparator is investigator's choice of pralatrexate or gemcitabine plus oxaliplatin or DHAP
3138774|NCT01626651|Experimental|Ibrutinib and Ketoconazole|
3138775|NCT01626638|Experimental|Experimental|
3138776|NCT01626625|Experimental|stem cells|stem cells + hydroxy apatite
3138777|NCT01626625|Active Comparator|autograft|
3138778|NCT01626612|Experimental|a strategy based on de-escalation|
3138779|NCT01626612|Active Comparator|a conservative strategy|
3138780|NCT01626599|Other|Assess product useability|All subjects participate in the same arm. This arm completes the primary objective of product usability.
3138781|NCT01626586|Experimental|Group Therapy|"This study includes having an initial assessment completed; participating in a 6 session group therapy intervention over a 7 week time period; and returning at 2 and 4 months after group therapy intervention for booster follow-up sessions. During the group intervention sessions, the parent group and the youth group will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15 to 20 minutes."
3138782|NCT01626586|Active Comparator|Individual Arm|"This study includes having an initial assessment completed; participating in a 6 session individual therapy intervention over a 7 week time period; and returning at 2 months after the individual therapy intervention for the booster follow-up session. During the individual intervention sessions, the youth and the parents will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15 to 20 minutes."
3138783|NCT01626586|Active Comparator|Recently Diagnosed Arm|"This study includes enrolling patients with Type 1 Diabetes, who are recently diagnosed (<1 year) to participate in a 4 session group therapy intervention over a 4 week time period; and returning at 2 months after the last group session for the booster follow-up session. During the group sessions, the youth and the parents will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15-20 minutes."
3138784|NCT01626573|Experimental|INCB039110 400 mg twice a day|INCB039110 400 mg twice a day
3138785|NCT01626573|Placebo Comparator|INCB039110 400 mg placebo twice a day|INCB039110 400 mg placebo twice a day
3138786|NCT01626573|Experimental|INCB039110 100 mg twice a day|This dose group will be studied twice during the study.
3138787|NCT01626573|Placebo Comparator|INCB039110 100 mg placebo twice a day|This dose group will be studied twice during the study.
3138788|NCT01626573|Experimental|INCB039110 100mg once a day|INCB039110 100mg once a day
3138789|NCT01626573|Placebo Comparator|INCB039110 100 mg placebo once a day|INCB039110 100 mg placebo once a day
3138790|NCT01626573|Experimental|INCB039110 200 mg twice a day|INCB039110 200 mg twice a day
3138791|NCT01626573|Placebo Comparator|INCB039110 200 mg placebo twice a day|INCB039110 200 mg placebo twice a day
3138792|NCT01626573|Experimental|INCB039110 300 mg once a day|INCB039110 300 mg once a day
3138793|NCT01626573|Placebo Comparator|INCB039110 300 mg placebo once a day|INCB039110 300 mg placebo once a day
3138795|NCT01626573|Placebo Comparator|INCB039110 600 mg placebo once a day|INCB039110 600 mg placebo once a day
3138796|NCT01626560|Other|Daptomicina|
3138797|NCT01626560|Other|Vancomycin|
3138798|NCT01626534|Active Comparator|clopidogrel group|
3138799|NCT01626534|Experimental|tricagrelor group|
3138800|NCT01626521||COPD Exacerbation|Patients admitted to hospital with COPD exacerbation
3138801|NCT01626508||breast-milk bank|breast milk collected and processed by the breast-milk bank before being used
3138802|NCT01626508||breast milk|breast milk used without any treatment, directly by children
3138803|NCT01626495|Experimental|CART-19 T Cells|The subject's thawed T cells will be modified in one or two different ways that will allow the cells to identify and kill the tumor cells (B cells). The T cells will be infused over 10-15 minutes on days Days 0, and 1. Day 14 is tentative based on response.
3138804|NCT01626482|Placebo Comparator|Sham tape|
3138805|NCT01626482|Experimental|Kinesio Tape|
3138806|NCT01626469|Active Comparator|Arm A|Captopril 25 mg (Admission 1, Day 1, low salt diet) Matched Placebo (Admission 1, Day 2, low salt diet) Captopril 25 mg (Admission 2, Day 1, high salt diet) Matched Placebo (Admission 2, Day 2, high salt diet)
3138807|NCT01626469|Placebo Comparator|Captopril|Matched Placebo (Admission 1, Day 1, low salt diet) Captopril 25 mg (Admission 1, Day 2, low salt diet) Matched Placebo (Admission 2, Day 1, high salt diet) Captopril 25 mg (Admission 2, Day 2, high salt diet)
3138808|NCT01626456|Experimental|ALKS 9072, Low|
3138809|NCT01626456|Experimental|ALKS 9072, High|
3138810|NCT01626443|Active Comparator|Folic acid|
3138811|NCT01626443|Experimental|Inofolic Combi|
3138812|NCT01626430|Experimental|200 mg gd-TRF|
3138813|NCT01626430|Experimental|400 mg gd-TRF|
3138814|NCT01626430|Experimental|Placebo|
3138815|NCT01626417|No Intervention|Patient Population|Chronic post-stroke subjects with varied impairment level, who have completed routine rehabilitative physical therapy.
3138816|NCT01626404||Patients enrolled|All patients enrolled in the study
3138817|NCT01626391|Experimental|TRx0237|
3138818|NCT01626391|Placebo Comparator|Placebo|
3138819|NCT01626378|Experimental|TRx0237 200 mg/day group|
3138820|NCT01626378|Placebo Comparator|Placebo|
3138821|NCT01626365|Active Comparator|non-thermosoftening|Double-lumen tube is put into a bottle of normal saline at room temperature (25°C) before intubation.
3138822|NCT01626365|Experimental|thermosoftening|Double-lumen tube is put into a bottle of warm normal saline (40°C) before intubation.
3138823|NCT01626352|Experimental|Bendamustine/Ofatumumab|All patients in this study will receive ofatumumab and bendamustine as an IV infusion for 6 cycles (a cycle is defined as 21 days in length). Patients will receive as an IV infusion of bendamustine Days 1 and 2 of Cycles 1-6, ofatumumab Days 1 and 8 during Cycle 1 only and on Day 1 of Cycles 2-6.
3138824|NCT01626326||Stop smoking app|Stop smoking iPhone research app provided at no charge via the iTunes store
3138825|NCT01626313|Active Comparator|Immediate intervention|Subjects are randomized to receive immediate intervention of the 8 session FOCUS IFRT
3138826|NCT01626313|Active Comparator|Waitlisted|Subjects are randomized to be waitlisted for 4 months, re-assessed and then receive intervention of the 8 session FOCUS IFRT
3138827|NCT01626287|Experimental|Black tea bag|
3138828|NCT01626287|Active Comparator|ice packs|20 randomly chosen participants will be given frozen ice packs for perineal pain relief
3138829|NCT01626274|Experimental|Device: in-ear sensor|Patients who routinely undergo a polysomnography night (1 night) are monitored via in-ear sensor which will be embedded in the auditory canal. During this night vital signs parameters are monitored, processed and subsequently compared to the polysomnography data.
3138830|NCT01626261||cardiac pacemaker|
3138831|NCT01626248||Group A TX Naive|Patient decided to start disease modifying treatment, either interferon beta-1a, glatiramer acetate or natalizumab. If interested and consented they would be assigned to Group A. Patient would have blood specimens taken up to 5 times over the next 19 months: Day 0; Day 28; Day 84: Day 336 and Day 508.
3138832|NCT01626248||Group B TY 4-12 doses|Patient is currently prescribed and is taking natalizumab, has 4 to 12 doses. If interested patient could be consented and assigned to Group B. Patients will have their blood drawn Day 0; and around the time of the patient's 18th dose.
3138833|NCT01626248||Group C 18 plus TY|Patient currently or close to being at 18 doses or 18 plus doses of natalizumab. If interested patient consented and assigned to Group C. Patient will have their blood drawn once: Day 0.
3138834|NCT01626248||Group D Other DMT 18 plus|Patient is close to or currently at 18 doses or more of interferon beta-1a or glatiramer acetate. If interested patient consented and assigned to Group D. Patient will have their blood drawn once: Day 0.
3138835|NCT01626248||Group E - Non-MS|10 participants without Multiple Sclerosis or other immunological illness. If interested participants consented and assigned to Group E. Participants will have their blood drawn once: Day 0.
3138836|NCT01626235||NSAID only|Subjects have their pain treated post-ED care with NSAID medication alone
3138837|NCT01626235||Opioid only|Subjects have their pain treated post-ED care with opioid medication alone
3138838|NCT01626235||NSAID + Opioid|Subjects have their pain treated post-ED care with NSAID medication and opioid as PRN rescue analgesia
3138839|NCT01626222|Experimental|Everolimus & Exemestane|This study will be performed in 300 postmenopausal women with hormone receptor positive locally advanced or metastatic breast cancer progressing following prior therapy with non-steroidal aromatase inhibitors (NSAI) as defined by: 1. Recurrence while on or after completion of an adjuvant treatment including Letrozole or Anastrozole, or 2. Progression while on or following the completion of Letrozole or Anastrozole treatment for locally advanced or metastatic breast cancer. Except for prior use of mTOR inhibitors, there are no restrictions as to the last anticancer treatment prior to enrollment. Patients must have documented evidence of recurrence or progression on last therapy prior to enrollment. Written informed consent must be obtained prior to any screening procedures. The investigator or designee must ensure that only patients who meet all the following inclusion and none of the exclusion criteria are offered enrollment in the study.
3138840|NCT01626209|Experimental|BKM120 at: 80 and 100mg/day dose levels|
3138841|NCT01626196||Colonoscopy patients|Patients undergoing with bowel cleansing procedures according to the clinics' usual routine
3138842|NCT01626170||Correlative (laboratory biomarker analysis)|Archived tissue samples of matched primary-relapsed and non-matched primary are analyzed for genomic DNA, DNA methylation profiles, RNA sequencing, differences between alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS), gene expression profiles, target-of-rapamycin complex 1 (TORC1) and TORC2 pathway intermediates, and paired box 3 (PAX3)/forkhead box O1 (FOXO1) translocation by microarray, immunohistochemical staining, and fluorescence in situ hybridization (FISH).
3138843|NCT01626144||Breast cancer, exemestane treatment|Breast cancer patients receiving standard of care exemestane
3138844|NCT01626131|Experimental|Exercise treatment|Aerobic and resistance training
3138845|NCT01626131|Experimental|Stretching treatment|
3138846|NCT01626118|Experimental|Indomethacin 40 mg TID|
3138847|NCT01626118|Experimental|Indomethacin 40 mg BID|
3138848|NCT01626118|Placebo Comparator|Placebo|
3138849|NCT01626118|Experimental|Indomethacin 20 mg TID|
3138850|NCT01626092|Experimental|Intent-To-Treat Patients|Patients with high-risk lysosomal and peroxisomal disorders treated with preparative regimen (Campath-1H 0.3 mg/kg intravenous (IV) on days -12 through -8, clofarabine 40 mg/m^2 IV on days -9 through -5, melphalan 140 mg/m^2 IV on day -4 and Total Body Irradiation with Marrow Boosting [ first dose of 200 cGy single dose; 5 doses of 160cGy for marrow boosting - 1000cGy cumulative exposure] by Volumetric-Modulated Arc Therapy [VMAT] on days -3 through -1). Hematopoietic stem cell transplantation will be infused on Day 0. Post-transplant immunosuppression to follow: Mycophenolate mofetil (MMF) begin day -3 and continue to day +30 or 7 days after engraftment, whichever is later; Cyclosporine A (CsA) begin day -3 and then taper at day +100 if related donor, day +180 for unrelated donor.
3138851|NCT01626079|Experimental|MitraClip System|Percutaneous mitral valve repair using MitraClip System
3138852|NCT01626079|No Intervention|Control Group|Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.
3138853|NCT01626066|Experimental|LUM015|Receive single dose of LUM015 through a vein in the arm the day prior to surgery
3138854|NCT01626053|No Intervention|control group|
3138855|NCT01626053|Experimental|lifestyle counseling|These participant received the ASMART interventions.
3138856|NCT01626040||PEG-P prep|Children taking the one day polyethylene glycol powder preparation for outpatient colonoscopy
3138857|NCT01626014|Experimental|Intervention Group|Using the Prototype System website: An interactive educational system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
3138858|NCT01626014|Active Comparator|Control Group|Using the Usual Care Educational Website : a website which will contain information regarding ovarian cancer however it will not be interactive. It will contain pdf documents of the material handed out in clinic (usual care).
3138859|NCT01626001|Experimental|Cohort 1|Cohort of 18 subjects evaluated. Subject will receive 4DCT cine acquisition gated using a respiratory signal from real-time position management (RPM) gating system. Maximum number of allowable images that may be acquired increased from 3000 to 5999 images. Total imaging time for each subject < 60 minutes.
3138860|NCT01626001|Experimental|Cohort 2|Reproducibility of optimal 4DCT acquisition method determined from cohort 1 tested with cohort of 18 study subjects. Three 4DCT images acquired, all with acquisition method determined from cohort 1. Cohort also receives two spiral-mode 4DCT acquisitions.
3138861|NCT01625988|Experimental|LY2951742|LY2951742: 150 milligrams
3138862|NCT01625988|Placebo Comparator|Placebo|Placebo: 0.9% Sodium Chloride
3138863|NCT01625975||Growth modulation with Eight plate|Pediatric patients undergoing growth modulation with the Eight plate system
3138864|NCT01625962||mTBI|"Service members who have sustained impact-induced mTBI or blast-induced mTBI (n = 74 completers)"
3138865|NCT01625962||ECI|Service members who have sustained an extracranial injury (ECI) with no evidence of TBI (n = 32 completers)
3138866|NCT01625949|Active Comparator|Control Arm (Standard Therapy)|Control Arm Receiving The Standard Therapy including successful coronary intervention and stenting
3138867|NCT01625949|Experimental|Intracoronary stem cells|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting
3138868|NCT01625923|Experimental|Olanzapine|An open-label pilot study of 20 consecutive subjects ages 18 - 70 with documented delayed gastric emptying within the past 2 years and history of nausea, vomiting, bloating, anorexia, early satiation, post-prandial fullness, and weight loss for at least 6 months without structural or organic cause will be enrolled.
3138869|NCT01625910|Experimental|behavioral counseling|Receive counseling via motivational interviewing seeking to encourage health eating habits and increased physical activity
3138870|NCT01625910|Placebo Comparator|Instructions in school readiness and performance|Parents receive instructions in school readiness and performance
3138871|NCT01625897|Experimental|MP-214 low dose|
3138872|NCT01625897|Experimental|MP-214 high dose|
3138873|NCT01625897|Active Comparator|Risperidone|
3138874|NCT01625871|Experimental|artemether-lumefantrine|tablets (containing 20mg artemether and 120 mg lumefantrine) for three days
3138875|NCT01625858||Supreme / other pediatric SGA|pediatric patients undergoing general anesthesia being treated with LMA Supreme or another pediatric supraglottic airway device
3138876|NCT01625845|Experimental|Pentoxifylline + Standard Treatment|"Pentoxifylline: Pentoxifylline is phosphodiesterase inhibitor that interferes with proinflammatory cytokine signaling and synthesis. Participants will be instructed to take pentoxifylline 400 mg p.o. t.i.d. for 12 weeks.~Standard Treatment: Beating the Blues (BtB) is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions."
3138877|NCT01625845|Placebo Comparator|Placebo + Standard Treatment|"Placebos: Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.~Standard Treatment: Beating the Blues (BtB) is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions."
3269970|NCT00697853|Experimental|Group D|
3138880|NCT01625819|Experimental|Tai Chi|32 1-hour group sessions of Tai Chi instruction
3138881|NCT01625819|Active Comparator|Resistance Band|32 1-hour bi-weekly group sessions of Resistance Band exercises
3138882|NCT01625819|Placebo Comparator|Health Education|32 1-hour bi-weekly group sessions of health education
3138883|NCT01625819|No Intervention|Care as Usual|Receive usual cardiology care for 4 months between pre- and post-treatment testing
3138884|NCT01625806|Active Comparator|RO4602522|
3138885|NCT01625806|Experimental|RO4602522 + ketoconazole|
3138886|NCT01625793|Active Comparator|HCV Interferon-alpha group|Subjects receiving treatment with interferon (IFN)-alpha for chronic hepatitis C virus infection.
3138887|NCT01625793|Placebo Comparator|HCV Control Group|Subjects delaying the start of treatment with interferon (IFN)-alpha for chronic hepatitis C virus infection by 7 weeks.
3138888|NCT01625780|Experimental|Study group: 3-layer block|Patients in this group will receive the 3-layer ilioinguinal nerve block.
3138889|NCT01625780|Active Comparator|Control: single-shot block|Patients in this group will receive a standard, single-shot ilioinguinal nerve block.
3138890|NCT01625767|Experimental|Approach Avoidance Task experiment|Approach Avoidance Task experiment
3138891|NCT01625754||Cardiac rehabilitation|This study recruits individuals that are currently participating in a cardiac rehabilitation exercise program.
3138892|NCT01625741|Experimental|rituximab|4 monthly administrations of rituximab
3138893|NCT01625728||Experimental group.|Participants are either student teachers or practicing teachers.
3138894|NCT01625728||Control Group.|Participants are no students teachers or practicing teachers.
3138895|NCT01625715|No Intervention|Case control|Routine therapy during peanut desensitization
3138896|NCT01625715|Experimental|ketotifen|rising doses of ketotifen
3138897|NCT01625702|Experimental|cisplatin plus capecitabine|gastric cancer patients treated with capecitabine/cisplatin
3138898|NCT01625702|Experimental|capecitabine plus paclitaxel|gastric cancer patients treated with capecitabine/paclitaxel
3138899|NCT01625689|Experimental|SIIL LAIV|SII LAIV is a live, trivalent seasonal influenza vaccine. The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
3138900|NCT01625689|Placebo Comparator|Placebo|Placebo identical in appearance to experimental vaccine.
3138901|NCT01625676|Experimental|CIAT-Group|Patients received a modified constraint-induced therapy schedule
3138902|NCT01625676|Active Comparator|standard treatment group|patients received a standard aphasia therapy
3138903|NCT01625663||Barth syndrome|Children (8-17 yrs) and adults (18-35 yrs)
3138904|NCT01625663||Controls|Children (8-15 yrs) and adults (18-35 yrs)
3138905|NCT01625650||Rheumatology|Patients who present at enrolling sites across the US are invited to enroll if eligible.
3138906|NCT01625637|Experimental|AAT-avoid cigarette condition|Adolescent smokers are trained to avoid tobacco in a training AAT
3138907|NCT01625637|Placebo Comparator|AAT-no contingency continued assessment|
3138908|NCT01625624|Placebo Comparator|Control Food Product|
3138909|NCT01625624|Experimental|Experimental Food Product|
3138910|NCT01625611|Experimental|Naltrexone|
3138911|NCT01625598||People with diabetes|People with diabetes who are referred to an ophthalmologist for a dilated eye examination
3138912|NCT01625585||Consecutive patients undergoing SBE for OGIB|
3138913|NCT01625572|No Intervention|general anesthesia and epidural catheter (control)|"General anaesthesia~total intravenous anaesthesia with propofol 5-10 mg / kg / h,~remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~use of a bispectral index~monitoring with a target range of 40-60~at the end of the anaesthesia all patients get 0.1 mg / kg morphine intravenously epidural catheter~plant of the epidural catheter under sterile conditions at the intervertebral space of the vertebral body 8-10 of the thoracic spine• local anaesthesia with lidocaine 1%~puncture with a Tuohy 18 G- needle, Lost of resistance technique~after a negative test dose with bupivacaine 0,5% isobar we inject fractional ropivacaine 10 ml 0,2%, after that continuous administration of ropivacaine 0,2% via patient-controlled-analgesia-device with a sweep rate of 6 ml/h, all Patients also receive an intravenous morphine-patient-controlled-analgesia-device"
3138914|NCT01625572|Experimental|general anesthesia and regional anesthesia|"General anesthesia~anesthesia with propofol 5-10 mg / kg / h, remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~Bispektralindex monitoring with a target range of 40-60~at the end of the anesthesia all patients get 0.1 mg / kg morphine intravenously Transversus abdominis plane blockade~ultrasound visible needles, a special pin detection software~under visual control the needle moves into the space between Musculus obliquus internus and M. transversus abdominis~Under sonographic control we inject a local anesthetic depot (30 ml of ropivacaine 0.375%)~puncture is performed under constant protective nerve stimulation with a current of 1 mA, pulse duration 0.1 ms, frequency 2 Hz All Patients receive an i.v. Morphine-patient-controlled-analgesia-device"
3138915|NCT01625572|Experimental|general anaesthesia and intravenous pain therapy|"General anaesthesia~total intravenous anesthesia with propofol 5-10 mg / kg / h, remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~we use a of BIS monitoring with a target range of 40-60~at the end of the aneasthesia all patients get 0.1 mg / kg morphine intravenously intravenous pain therapy with~Morphine-patient-controlled-analgesia-device"
3138916|NCT01625559|Experimental|50,000 cells|Biological: MA09-hRPE Cellular therapy
3138917|NCT01625546|Experimental|High intensity whole-body infrared heating|Subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C using the Whole Body Hyperthermia system.
3138918|NCT01625546|Sham Comparator|Low intensity whole-body infrared heating|Subjects will be induced to levels of heat that causes only a minor increase in body temperature using Whole Body Hyperthermia system.
3138919|NCT01625533||SA group|Patients using SA for the diagnosis of coronary artery disease are assigned to the SA group.
3138920|NCT01625533||DARCA group|Patients using DARCA for the diagnosis of coronary artery disease are assigned to the DARCA group.
3138964|NCT01625260|Experimental|Gemcitabine in combination with ALT-801|
3139038|NCT01624662|Active Comparator|400 fluticasone prioprionate|16 weeks BID
3138921|NCT01625520|Experimental|SOM230 alone or in combination with RAD001|Patients with progressive metastatic or postoperative persistent medullary thyroid cancer will start the study treatment as a mono therapy with SOM230. Patients benefiting from the treatment will continue with the monotherapy (stable disease or better according to RECIST). Patients progressing will be switched to the combination therapy with SOM230 and RAD001.
3138922|NCT01625507|Experimental|PANDA intervention|12 week nutritional intervention, including 6 classroom/community sessions, plus two sample collection visits.
3138923|NCT01625494|Experimental|Irbesartan/Amlodipine 150/5 mg fixed combination|"1 tablet once daily in the morning for 4 weeks Patient will be first treated with irbesartan 150mg or amlodipine 5mg, 1 tablet /day for 4 weeks.~If OBPM is controlled on monotherapy at week 4 (SBP <140 mmHg and DBP<90 mmHg), patient will be withdrawn from the study"
3138924|NCT01625494|Experimental|Irbesartan/Amlodipine 150/10 mg fixed combination|1 tablet once daily in the morning for 4 weeks
3138925|NCT01625494|Experimental|Irbesartan/Amlodipine 300/5 mg fixed combination|1 tablet once daily in the morning for 4 weeks
3138926|NCT01625494|Experimental|Irbesartan/Amlodipine 300/10 mg fixed combination|1 tablet once daily in the morning for 4 weeks. If OBPM is controlled at week 12, patients will continue on the same therapy until the end of the study
3138927|NCT01625481|Experimental|Seal-V|A vascular sealant intended to achieve adjunctive hemostasis by mechanically sealing areas of potential leakage in surgical reconstruction of large blood vessels.
3138928|NCT01625468|No Intervention|Control|Participant receives usual care
3138929|NCT01625468|Experimental|Intervention|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
3138930|NCT01625455|Active Comparator|Aprepitant|Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
3138931|NCT01625455|Placebo Comparator|Placebo|Matching placebo will be given in place of aprepitant
3138932|NCT01625442|Active Comparator|Saffron|Saffron treatment group received saffron tablets daily for 45 days
3138933|NCT01625442|Active Comparator|Barberry|Barberry group received barberry tablets daily for 45 days
3138934|NCT01625442|Placebo Comparator|Placebo|Placebo group received placebo tablets daily for 45 days
3138935|NCT01625429|Experimental|neoadjuvant|
3138936|NCT01625416|Experimental|Stepped Care Management|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
3138937|NCT01625416|No Intervention|Usual Care|Usual care control patients will be given a list of available community resources and encouraged to proceed using all resources available to them.
3138938|NCT01625403|Experimental|rhBNP treated|standard of care with rhBNP
3138939|NCT01625403|Active Comparator|standard of care|standard of care
3138940|NCT01625390|Experimental|Arm 1|
3138941|NCT01625390|Active Comparator|Arm 2|
3138942|NCT01625390|Experimental|Arm 3|
3138943|NCT01625377|Active Comparator|Tacrolimus|From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids. From randomization to month 6 : tacrolimus (C0 6-10 ng/ml) + mycophenolic acid 1440 mg/d ± oral corticosteroids
3138944|NCT01625377|Experimental|Everolimus (RAD001)|"From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids.~From randomization to month 6 : everolimus (recommended starting dose of 2 mg/day, then adjusted to achieve the target 6 ≤ C0 ≤ 10 ng/mL, until W24) + mycophenolic acid 1440 mg/d ± oral corticosteroids. The dose of tacrolimus was reduced by 50% twice: at the introduction of everolimus and at week 8 post-transplantation. Tacrolimus had to be finally discontinued in week 12 post-transplantation (by week 16 at the latest)."
3138945|NCT01625364|Experimental|Open Airways for Schools|OAS is a school-based non-academic asthma health education program for elementary students with asthma and their parents.
3138946|NCT01625364|Experimental|SHARP program|The Staying Health-Asthma Responsible & Prepared (SHARP) program is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregiver.
3138947|NCT01625351|Experimental|Treatment|"Participants to undergo transplantation. They receive alemtuzumab, fludarabine, sirolimus, busulfan, melphalan, and stem cells.~Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy.~Cells for infusion are prepared using the CliniMACS System."
3138948|NCT01625338|Experimental|SOF+RBV 12 Weeks|SOF+RBV for 12 weeks
3138949|NCT01625338|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
3138950|NCT01625338|Experimental|SOF+RBV+Peg-IFN 12 Weeks|SOF+RBV+Peg-IFN for 12 weeks
3138951|NCT01625325||extremely obese|BMI ≥35kg/m2
3138952|NCT01625325||obese|BMI 30-34.9kg/m2
3138953|NCT01625312||CABG group|Three-vessel disease patients undergoing CABG at index hospitalization
3138954|NCT01625312||PCI group|Three-vessel disease patients undergoing PCI at index hospitalization.
3138955|NCT01625312||OMT group|Three-vessel disease patients undergoing no revascularization at index hospitalization
3138956|NCT01625299|Experimental|Gluten and Milk group|Subject on a gluten and dairy free diet will receive supplement of gluten and dry milk daily
3138957|NCT01625299|Placebo Comparator|Rice flour|Subjects will be on a gluten and dairy free diet and receive daily supplement of rice flour (placebo)
3138958|NCT01625286|Experimental|Part A: Intermittent schedule (2/5)|See intervention description below.
3138959|NCT01625286|Experimental|Part A: Intermittent schedule (4/3)|See intervention description below.
3138960|NCT01625286|Active Comparator|Part B: AZD5363 combined with paclitaxel|See intervention description below.
3138961|NCT01625286|Placebo Comparator|Part B: paclitaxel combined with placebo|See intervention description below.
3138965|NCT01625247|Experimental|1 arm|Patients under LC. Allocated to drain placement . Drainage was removed if the drainage amount was less than 20cc.
3138966|NCT01625247|Active Comparator|2 arm|Patients under LC. Allocation to sham drain,
3138967|NCT01625234|Experimental|X-396 (ensartinib)|Dose escalation starting at 25 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops
3138968|NCT01625221|Experimental|Magnetic anal sphincter augmentation|The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
3138969|NCT01625208|Experimental|Combined nerve block|Participants in this group will receive a supraclavicular brachial plexus block plus a median or ulnar nerve block.
3138970|NCT01625208|Active Comparator|Single nerve block|Participants in this group will receive a supraclavicular brachial plexus block only.
3138971|NCT01625195|Placebo Comparator|Omega-3 fatty acid supplement|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 6 x 1 g fish oil capsules/d, two capsules with each of the main daily meals. The placebo will be composed of 100% corn oil as used in other randomized placebo-controlled trials. The daily treatment will provide 1.4 g/d of DHA and 1.8 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain orange flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
3138972|NCT01625195|Active Comparator|Placebo|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 6 x 1 g fish oil capsules/d, two capsules with each of the main daily meals. The placebo will be composed of 100% corn oil as used in other randomized placebo-controlled trials. The daily treatment will provide 1.4 g/d of DHA and 1.8 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain orange flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
3138973|NCT01625182|Experimental|Fingolimod (FTY720)|Participants received Fingolimod 0.5 mg orally once daily.
3138974|NCT01625182|Placebo Comparator|Placebo|Participants received matching placebo to Fingolimod orally once daily.
3138975|NCT01625169|Other|HIV + pregnant women|Etravirine pharmacokinetics in breast milk and plasma. Etravirine 200mg PO BID for 14 days with PK on days 5 and 14
3138976|NCT01625156|Experimental|Treatment (tivantinib, temsirolimus)|Patients receive tivantinib PO BID and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 (days 8, 15, 22, and 29 of course 1). Courses repeat every 28 days (35 days in course 1) in the absence of disease progression or unacceptable toxicity.
3138977|NCT01625143||Observational|Archived bone marrow samples, collected at the time of diagnosis and relapse, are analyzed for gene expression and histone modifications by microarray, chromatin immunoprecipitation (ChIP) sequencing, and quantitative real-time polymerase chain reaction (qRT-PCR).
3138978|NCT01625130|Active Comparator|broccoli sprout homogenate (BSH)|Two hundred grams of BSH is equivalent to approximately 111 grams fresh sprouts (about one 4 oz package). Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water.
3138979|NCT01625130|Placebo Comparator|alfalfa sprout homogenate|Two hundred grams of commercially available alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
3138980|NCT01625117|No Intervention|Control Group|
3138981|NCT01625117|Experimental|A variant of Narrative exposure therapy|
3138982|NCT01625104|Experimental|Group 1: Aggressive Intervention Strategy|"Hospitals were randomized to an aggressive intervention strategy or to business as usual. The hospitals randomized to the aggressive intervention strategy underwent the following:~Grand Rounds conducted by physician and nurse from the Coordinating Center. This included a formal presentation on the evidence supporting rapid time to treatment in STEMI patients and evidence based strategies for reducing treatment delays.~Discussion with staff regarding perceived barriers to treatment and suggestions/ideas for strategies to overcome these barriers~Follow-up monthly phone conferences to continue to discuss strategies and ideas sharing~Written plan from sites detailing plans to change processes of care."
3138983|NCT01625104|Placebo Comparator|Group 2: Control Strategy|"Hospitals randomized to the control group were instructed to conduct business as usual."
3138984|NCT01625091|Active Comparator|naltrexone|The investigators will administer Naltrexone to women with hazardous drinking and assess the study outcomes.
3138985|NCT01625091|Placebo Comparator|placebo pill|The investigators will administer an inert placebo that looks similar to Naltrexone, to women with hazardous drinking and assess the study outcomes.
3138986|NCT01625078|Experimental|Baska mask|
3138987|NCT01625065||pain patients|patients from a specific pain management department, patients with long duration of pain, mostly insufficiently treated pain
3138988|NCT01625065||pre-surgical patients|patients from a surgical outpatient department with current pain
3138989|NCT01625052|Experimental|Baska|
3138990|NCT01625039|Experimental|Intervention|Participated in weekly educational workshops
3138991|NCT01625039|Active Comparator|Control group|Received once off educational session and materials
3138992|NCT01625026|Active Comparator|Morbid Obesity OCA|Obeticholic acid 25 mg/day in three weeks
3138993|NCT01625026|Placebo Comparator|Morbid Obesity Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
3138994|NCT01625026|Active Comparator|Gallstones OCA|Obeticholic acid 25 mg/day in three weeks
3138995|NCT01625026|Placebo Comparator|Gallstones Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
3138996|NCT01625013|Experimental|Synvisc-One|
3138997|NCT01625000|Experimental|MP-214 low dose|
3138998|NCT01625000|Experimental|MP-214 middle dose|
3138999|NCT01625000|Experimental|MP-214 high dose|
3139000|NCT01625000|Active Comparator|Risperidone|
3139001|NCT01625000|Placebo Comparator|Placebo|
3139002|NCT01624987|Experimental|NET for Forensic Offender Rehabilitation|Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)
3139003|NCT01624974|Experimental|MK-1029/placebo|Participants assigned to receive MK-1029 during the first treatment period and placebo during the second treatment period.
3139039|NCT01624662|Placebo Comparator|placebo|16 weeks BID
3139004|NCT01624974|Experimental|placebo/MK-1029|Participants assigned to receive placebo during the first treatment period and MK-1029 during the second treatment period.
3139005|NCT01624961|Experimental|50 PfSPZ IV|PfSPZ Challenge
3139006|NCT01624961|Experimental|200 PfSPZ IV|PfSPZ Challenge
3139007|NCT01624961|Experimental|800 PfSPZ IV|PfSPZ Challenge
3139008|NCT01624961|Experimental|3200 PfSPZ IV|PfSPZ Challenge
3139009|NCT01624961|Experimental|2500 PfSPZ ID|PfSPZ Challenge
3139010|NCT01624948|Experimental|Everolimus+Tacrolimus/Prednisone|This arm (group 1) will undergo mycophenolic acid (MPA) discontinuation with the addition of Zortress (everolimus) to their current regimen of tacrolimus and prednisone; All patients in group 1 will receive Zortress (everolimus) at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
3139011|NCT01624948|Active Comparator|Standard of care: 50% reduction of MPA|This arm (group 2) patients will continue with tacrolimus (target trough level of 6-10 ng/mL), prednisone, and undergo a 50% reduction of the MPA dose, which is the standard immunosuppression treatment for renal transplant recipients with evidence of BKV infection. At months 1, 2, and 3 post-randomization urine and plasma BKV levels will be re-checked. Renal allograft biopsies will be done for cause as clinically indicated.
3139012|NCT01624935|Experimental|psychotherapy|psychotherapy
3139013|NCT01624935|Other|treatment as usual|TAU control
3139014|NCT01624870||CoreValve aortic valve|Implantation of CoreValve aortic valve
3139015|NCT01624857|Placebo Comparator|control group|Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
3139016|NCT01624857|Active Comparator|statin group|Rosuvastatin 20mg/d for at least 5 days before the CABG surgery, then continue to take for a month
3139017|NCT01624844|Experimental|Calculation of dural sac volume|
3139018|NCT01624831||Individuals with Longstanding Psychosis|Individuals with symptoms of psychosis that have been present for 5 or more years
3139019|NCT01624818|Experimental|Group 2, 6-7 years|18 children (6-7 years) with heart disease participating in a rehabilitation programme in Geilomo childrens hospital
3139020|NCT01624818|Experimental|Group 1, 11-12 years|18 children(11-12 years) with heart disease participating in a rehabilitation programme at Geilomo childrens hospital.
3139021|NCT01624805|Experimental|hATG + Cyclosporine + Methylprednisone + GCSF|"hATG (ATGAM) 40 mg/kg/d by vein over 8 hours daily on days 1 - 4. Methylprednisone 1 mg/kg/day by vein daily for 4 days, on days 1 - 4, to be given prior to the hATG infusion each day.~Cyclosporine 5 mg/kg by mouth daily given in 2 divided doses starting on day 1 and given for 6 months (180 days).~G-CSF starting on day 5, administered as:~Pegfilgrastim 6 mg subcutaneously (SQ) one time on day 5 and/or Filgrastim 300-480 mcg SQ starting on day 5 as needed to keep ANC >/= 1.5."
3139022|NCT01624792|Experimental|Healthy older adults|Healthy controls will receive each intervention (olive oil or fish oil with 3.5 g EPA+DHA) one time and for only one day per intervention .
3139023|NCT01624792|Experimental|COPD patients|COPD patients will receive one out of three possible interventions (olive oil or fish oil with 3.5 g EPA+DHA or fish oil and placebo with 2 g EPA+DHA) for 4 (+/- 7 days) weeks.
3139024|NCT01624766|Experimental|Everolimus + Anakinra Dose Escalating Group:|Starting doses: Everolimus 5 mg by mouth daily for a 28 day cycle. Anakinra 100 mg subcutaneously daily for a 28 day cycle.
3139025|NCT01624766|Experimental|Everolimus + Denosumab Dose Escalating Group|Starting doses: Everolimus 10 mg by mouth daily for a 28 day cycle. Denosumab 120 mg subcutaneously on Day 1 of a 28 day cycle.
3139026|NCT01624753|Experimental|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
3139027|NCT01624740|Experimental|Low Rate Followed By High Rate|The Precision Plus spinal cord stimulation screening trial leads were temporarily implanted by the investigator. Subjects received low rate stimulation (2 Hz) for 3-4 days, followed by high rate stimulation (1200 Hz) for 3-4 days.
3139028|NCT01624740|Experimental|High Rate Followed By Low Rate|The Precision Plus spinal cord stimulation screening trial leads were temporarily implanted by the investigator. Subjects received high rate stimulation (1200 Hz) for 3-4 days, followed by low rate stimulation (2 Hz) for 3-4 days.
3139029|NCT01624727|No Intervention|Usual care|Those randomized to usual care will continue to follow the care provided by their cardiologist. They will have all the follow-up phone calls, visits and testing which the intervention group has.
3139030|NCT01624727|Active Comparator|Lovaza (Omega 3 ethyl esters)|
3139031|NCT01624714|Experimental|Alemtuzumab Naive|Alemtuzumab Subjects (30) with prior treatment refractoriness and treatment experience EDSS 3.0-7.0 inclusive, without contraindications to alemtuzumab
3139032|NCT01624714|Experimental|Alemtuzumab Experienced|Subjects with treatment refractory MS and prior alemtuzumab therapy (30)
3139033|NCT01624701|Experimental|Expanded|'Ex vivo expanded cord blood cells
3139034|NCT01624675|Experimental|Risperidone|Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing >= 45 kg was 3.0 mg. For subjects weighing >=45 kg, the maximum daily dose was 3.0 mg.
3139035|NCT01624675|Placebo Comparator|Placebo|Subjects will receive placebo matching with risperidone orally up to 8 weeks.
3139036|NCT01624662|Active Comparator|100 fluticasone proprionate|16 weeks BID
3139037|NCT01624662|Active Comparator|200 fluticasone proprionate|16 weeks BID
3139337|NCT01622530||Amputees|upper limb amputees
3139040|NCT01624649||Patients with ADHD|Patients will receive methylphenidate hydrochloride or atomoxetine. The methylphenidate hydrochloride is available in three forms. 1) Immediate release 2) Extended release 3) Osmotic release oral system
3139041|NCT01624636|Placebo Comparator|Placebo|
3139042|NCT01624636|Experimental|LFG316: 10 mg/kg (2 doses in cohort 1)|
3139043|NCT01624636|Experimental|LFG316: 20 mg/kg (2 doses in cohort 1, 3 doses in cohort 2).|
3139044|NCT01624610|Active Comparator|Diet 1|Patients randomized to this arm will receive both written and face-to-face advice about how the components of Diet 1 can be used to control their IBS symptoms.
3139045|NCT01624610|Active Comparator|Diet 2|Patients randomized to this arm will receive both written and face-to-face advice about how the components of Diet 2 can be used to control their IBS symptoms.
3139046|NCT01624597|No Intervention|Usual Care|Participants will have a passive in-vehicle video device installed in their car to measure driving errors and safety behaviors.
3139047|NCT01624597|Experimental|In-vehicle video feedback|Participants will receive feedback from an in-vehicle video system. A light on the system will blink when a driving event has been recorded. Parents will receive a weekly report card of driving errors.
3139048|NCT01624597|Experimental|In-vehicle video feedback, parent communication|Participants will receive feedback from an in-vehicle video system. A light on the system will blink when a driving event has been recorded. Parents will receive a weekly report card of driving errors. Parents will participate in an intervention that provides input on teaching and communicating about driving skills and safety behaviors.
3139049|NCT01624584|Experimental|Experimental treatment|6 sessions of anxiety treatment
3139050|NCT01624584|Active Comparator|Traditional Treatment|Six sessions of anxiety treatment
3139051|NCT01624571|Experimental|Group 1|300mg/day
3139052|NCT01624571|Experimental|Group 2|600mg/day
3139053|NCT01624571|Experimental|Group 3|900mg/day
3139054|NCT01624571|Placebo Comparator|Placebo|Control Group
3139055|NCT01624558|Experimental|Treatment (filter in circuit)|After baseline use of volatile anesthetic, this group will have carbon filter placed in-line.
3139056|NCT01624558|No Intervention|No Intervention Control|After baseline use of volatile anesthetic, this group will NOT have carbon filter placed in-line.
3139057|NCT01624545|Active Comparator|1|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
3139058|NCT01624545|No Intervention|2|Patients in this study arm will undergo neurological evaluation on day 2 and day 30 without follow-up CT scan.
3139059|NCT01624532|Experimental|rPA vaccine containing alhydrogel 1.0 mL|GC1109 1.0 mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects
3139060|NCT01624532|Placebo Comparator|Normal Saline|Normal Saline 0.5 mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects
3139061|NCT01624532|Experimental|rPA vaccine containing alhydrogel 0.5 mL|GC1109 0.5 mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects
3139062|NCT01624532|Experimental|rPA vaccine containing alhydrogel 0.3 mL|GC1109 0.3 mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects
3139063|NCT01624519|Other|1|
3139064|NCT01624506||Magnetic Sphincter Augmentation|Patients will be treated with magnetic sphincter augmentation via the LINX Reflux Management System
3139065|NCT01624506||Fundoplication - advanced GERD|Patients treated with laparoscopic fundoplication who have one or more of the following: Large hernia (>3cm), Barrett's esophagus, motility disorder, Grade C or D esophagitis by LA Classification
3139066|NCT01624506||Fundoplication - moderate GERD|Patients treated with laparoscopic fundoplication who do NOT have the following: Large hernia (>3cm), Barrett's esophagus, motility disorder, Grade C or D esophagitis by LA Classification
3139067|NCT01624493|Experimental|Phase II Arm A|Phase II Arm A will randomize patients to treatment regimen of carboplatin and gemcitabine without BNC105P
3139068|NCT01624493|Experimental|Phase II Arm B|Phase II Arm B will randomize patients to treatment regimen of carboplatin and gemcitabine and will include BNC105P
3139069|NCT01624480|Experimental|Armodafinil 50 mg|In period 1, patients will receive a single 50-mg dose of armodafinil on day 1. In period 2, patients will receive a single 50-mg dose daily on days 1 through 42.
3139070|NCT01624480|Experimental|Armodafinil 100 mg|In period 1, patients will receive a single 100 mg dose of armodafinil on day 1. In period 2, patients will receive a single 50-mg dose on day 1 then daily 100-mg doses on days 2 through 42.
3139071|NCT01624480|Experimental|Armodafinil 150 mg|In period 1, patients will receive a single 150-mg dose of armodafinil on day 1. In period 2, patients will receive a single 50-mg dose on day 1, 100-mg doses on days 2 and 3, then daily 150-mg doses on days 4 through 42.
3139072|NCT01624467|Experimental|Necitumumab|800 mg necitumumab, administered once per week as an intravenous infusion (IV)
3139073|NCT01624454|Active Comparator|large volume|bowel cleansing with PEG
3139074|NCT01624454|Active Comparator|Osmotic|
3139075|NCT01624441|Experimental|Treatment (dinaciclib and epirubicin hydrochloride)|Patients receive dinaciclib IV over 2 hours on day 1 and epirubicin hydrochloride IV over 30 minutes on day 2. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3139076|NCT01624428|Active Comparator|varenicline|
3139077|NCT01624428|Placebo Comparator|Placebo|
3139078|NCT01624402|Experimental|Ecosystem Focused Therapy (EFT)|Ecosystem Focused Therapy (EFT) follows a structured personalization approach based on the model of adaptive functioning, in which behavior is a function of the person's competence and the demands of the environment.
3139079|NCT01624402|Active Comparator|Education on Stroke and Depression (ESD)|Education on Stroke and Depression (ESD) is home-delivered and imparts education about depression, stroke, and the role of available treatments.
3139080|NCT01624389|Experimental|F18-AV45|
3139081|NCT01624376|Active Comparator|DLX105|DLX105 local injection into the identified fistula(s)
3139082|NCT01624376|Placebo Comparator|Placebo Injection|
3139083|NCT01624363||Patients undergoing EUS|Patients undergoing EUS for non-pancreatic treatment.
3139084|NCT01624337|Experimental|DHA-piperaquine|DHA-piperaquine monthly 2 day treatment course
3139085|NCT01624337|Placebo Comparator|Placebo|Matching placebo control
3269971|NCT00697853|Experimental|Group E|
3139086|NCT01624311|Experimental|Adjunct Hypothermia Arm|Patients that receive adjunct therapeutic hypothermia in addition to standard of care therapy
3139087|NCT01624311|Other|Historic Controls|Patients that were treated with standard of care therapy for the same conditions at the sponsoring institution over the past 10 years.
3139088|NCT01624298|No Intervention|Wait List Control Group|The wait list control group will be asked to wait for approximately 4 1/2 months before being reassessed and then, unless found to be ineffective or harmful, receive the intervention being provided by the counselor.
3139089|NCT01624298|Experimental|Intervention Group|Children randomized into the intervention group will immediately receive the Trauma Focused Cognitive Behavioral Therapy with a trained counselor for 12 weeks.
3139090|NCT01624285|Experimental|Arm I (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID.
3139091|NCT01624285|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID.
3139092|NCT01624272|No Intervention|Control|Usual care
3139093|NCT01624272|Experimental|Threshold Inspiratory Muscle Training|Inspiratory muscle training regime
3139094|NCT01624272|Experimental|Controlled breathing exercises|Yoga Pranayama breathing exercises
3139095|NCT01624259|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 26 weeks~Metformin: at least 1500 mg/day, oral, for 26 weeks"
3139096|NCT01624259|Active Comparator|Liraglutide|"Liraglutide 0.6 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.2 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.8 mg, SC, once daily for 24 weeks~Metformin: at least 1500 mg/day, oral, for 26 weeks"
3139097|NCT01624246|Experimental|Ceftaroline fosamil/Avibactam|
3139098|NCT01624233|Experimental|80 mg ixekizumab|Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, followed by one 80 mg SC injection per Dosing Regimen 1 up to Week 12. Then administered by one 80 mg SC injection per Dosing Regimen 2 from Week 12 up to Week 52, and for up to 192 weeks following disease relapse occurring during a drug-free period beyond 52 weeks.
3139099|NCT01624220|Experimental|Hypofractionated Radiation|"All patients receive CT-guided spinal SBRT using IMRT to maximize conformality of treatment plan to target volume, while sparing normal structures. Dose given to tumor and number of treatments received determined by patient's doctor.~In second stage, characterize tolerance of esophagus to hypofractionated radiation doses through prospective constraint relaxation and toxicity monitoring. Data collected from Group 1 in first stage will give data on dose delivered to esophagus. Second stage of protocol will begin accrual once Group 1 has filled. Dose constraints used for Groups 3 allow higher dose. Dose constraints for Group 4 represent modest increase of esophageal dose maximums."
3139100|NCT01624220|Experimental|ExacTrac Positioning System|Analysis performed of ExacTrac positioning system with and without fiducial guidance. Four dimensional CT datasets for simulation will allow use of data from this portion of protocol to characterize degree to which organ at risk (OAR) motion is relevant at each spinal level. 20 patients accrued in two groups of 10, with 10 patients in each rostral-caudal position in the spine (Group 1: T4-T12, Group 2: L1-L5). Imaging done with fiducial markers for this study will not impact patient management. Patients will treated with standard dose constraints to normal tissues.
3139101|NCT01624207|Experimental|Atorva|generic formulation (Atorva®) of atorvastatin 20mg once daily
3139102|NCT01624207|Active Comparator|Lipitor|branded formulation (Lipitor®) of atorvastatin 20mg once daily
3139103|NCT01624194|Active Comparator|Oxytocin nasal spray|Prior to randomization, all subjects will participate in a 1-week open-label placebo lead-in trial. Each subject will be administered the placebo nasal spray at Stanford University and then their parent will continue administering the nasal spray to the subject for 1 week at home. Each subject will then be randomly assigned either to the active group or to the placebo (stratified by gender) and will be given the appropriate nasal spray bottle and their parents will be responsible for administering 3 puffs per nostril (4 IU/puff) to their child for a total dose of 24 IU oxytocin or placebo twice daily (BID; morning and evening) for 4-weeks. On completion of this 4-week treatment trial subjects will have the option of participating in a second double-blind trial in which they will be assigned to the alternate nasal spray, to that which they received during the first 4-week trial, for an additional 4-week period.
3139104|NCT01624194|Placebo Comparator|Placebo nasal spray|The placebo nasal spray bottles will be prepared by adding all of the ingredients used in the Syntocinon nasal sprays with the exception of the concentrated oxytocin solution.
3139105|NCT01624168|Placebo Comparator|Anxiety Management Education|
3139106|NCT01624168|Experimental|10 week tai chi intervention|10 week course in Evidence Based Tai Chi meeting 2 times per week
3139107|NCT01624168|Experimental|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
3139108|NCT01624155|Experimental|Women taking teratogens|Women taking teratogens
3139109|NCT01624142|Experimental|Dose 1 of subcutaneous Evolocumab (AMG145)|Dose 1 of subcutaneous Evolocumab (AMG145)every month
3139110|NCT01624142|Experimental|Dose 2 of subcutaneous Evolocumab (AMG145)|Dose 2 of subcutaneous Evolocumab (AMG145)every 2 weeks
3139111|NCT01624129||eosinophilic esophagitis|patients with histopathological defined eosinophilic esophagitis
3139112|NCT01624116|Active Comparator|Diet and lifestyle measures alone.|Type 2 diabetic subjects on lifestyle counselling as part of diabetes treatment would continue as such during Ramadan. They would receive acarbose on one day to be followed by CGMS for a 24 hour period
3139113|NCT01624116|Active Comparator|Metformin monotherapy|Type 2 diabetics on biguanide treatment.
3139114|NCT01624116|Active Comparator|Metformin + Sulphonylurea.|Type 2 diabetics on dual oral hypoglycaemics-metformin and glimepiride.
3139115|NCT01624116|Active Comparator|Metformin + Sitagliptin|Type 2 diabetics managed on dual oral hypoglycaemic therapies: metformin and sitagliptin.
3139116|NCT01624103|Experimental|Elderly (32 mL LA volume)|Population over age of 65 undergoing upper limb surgery using US-SCB receiving 32 ml of LA (50:50 mixture of 0.5% levobupivacaine and 2% lidocaine).
3139117|NCT01624103|Experimental|Elderly (20 ml LA volume)|Population over age of 65 undergoing upper limb surgery using US-SCB receiving 20 ml of LA (50:50 mixture of 0.5% levobupivacaine and 2% lidocaine).
3139118|NCT01624090|Experimental|1/mithramycin|Single agent IV mithramcyin
3139213|NCT01623427|Experimental|Vacuum|the group of patients assigned to application of vacuum to the wound dressing
3269972|NCT00697840|Experimental|Group A|
3139119|NCT01624077|Experimental|Regulatory T cells|Naïve CD4+ T cells isolated from peripheral blood mononuclear cells were stimulated with GMP anti-CD3/CD28 coated beads in the presence of IL-2 ,TGF-β.
3139120|NCT01624064|Active Comparator|Enalapril, Proteinuria < 1g/day|
3139121|NCT01624064|Placebo Comparator|Calcium, Proteinuria < 1g/day|
3139122|NCT01624064|Active Comparator|Enalapril, Proteinuria > 1g/day|
3139123|NCT01624064|Placebo Comparator|Calcium, Proteinuria > 1g/day|
3139124|NCT01624051|Active Comparator|Body Surface Area Dosing|Standard dosing arm based on body surface area
3139125|NCT01624051|Experimental|Lean Body Mass Dosing|Experimental dosing arm based on individual lean body mass
3139126|NCT01624038|Active Comparator|Hydroxyurea,blood transfusion|Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.
3139127|NCT01624038|Experimental|Hydroxyurea, Epiao|"Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued. White cell count and platelet count were determined on a monthly basis. Side effects such as nausea, vomiting, diarrhea, rashes, and malaise, experienced during the first 6 h after taking the HU will be considered as clinical toxicity.~Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week."
3139128|NCT01624025|Experimental|HER2 positive|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.(Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks)
3139129|NCT01624025|Active Comparator|HER2 negative|"Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.~(Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks)"
3139130|NCT01624012|Active Comparator|NIV NAVA|Noninvasive ventilation in this group is practiced with NIV NAVA
3139131|NCT01624012|Active Comparator|ncpap|Patients randomized to this arm will receive noninvasive ventilation with continuous nasal CPAP as routinely in neonatal intensive care unit.
3139132|NCT01623986||St. Michael's Hospital Patients|Patients who are referred to the St. Michael's Hospital echocardiography (ECHO) lab.
3139133|NCT01623973|Experimental|With restraint|The group with restraint underwent specific training of paretic upper limb and use of restraint.
3139134|NCT01623973|Active Comparator|no restraint|"The group control without restraint submitted only to the specific training of paretic upper limb"
3139135|NCT01623947|Placebo Comparator|Placebo|
3139136|NCT01623947|Active Comparator|2.8 g Sustamine|
3139137|NCT01623947|Active Comparator|19.6 g Sustamine|
3139138|NCT01623934||Phase 1: Pregnant women|
3139139|NCT01623934||Phase 2: Mother-offspring dyad|
3139140|NCT01623921|Other|control|Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
3139141|NCT01623921|Active Comparator|Celecoxib|Group 2: Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
3139142|NCT01623921|Active Comparator|rosuvastatin|Group 3: Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
3139143|NCT01623921|Active Comparator|Combined therapy|Group 4: Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
3139144|NCT01623908|Experimental|Zoledronate|
3139145|NCT01623869|Experimental|Treatment (trebananib)|Patients receive 30 mg/kg trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3139146|NCT01623856||Observational|DNA samples are analyzed by single nucleotide polymorphism and genotyped by fluorogenic polymerase chain reaction (PCR)-based allelic discrimination (Taqman) assays using the ABI Prism 7900HT reverse transcriptase (RT)-PCR system.
3139147|NCT01623843|Active Comparator|Arthroscopic Lavage|Participants have three hip portals (antero-lateral, mid anterior, distal antero-lateral) with limited capsulotomy allowing for a complete assessment of the central and peripheral compartments. The participant has a diagnostic arthroscopy and lavage of the hip joint with three litres of normal saline. No osteochondroplasty or rim resection is completed in this group. No instruments are used to treat minor cartilage or labral damage. The labrum should only be repaired if mechanically unstable once probed with visible displacement or chondrolabral separation. The labrum will be refixated only if the above criteria for labral instability is met.
3139148|NCT01623843|Experimental|Arthroscopic Osteochondroplasty|After establishing standard portals, an inter-portal capsulotomy will be completed to allow for complete evaluation of the central compartment of the hip. Significant and obvious labral tears and cartilage damage will be addressed. The labrum will be repaired if mechanically unstable once probed with visible displacement or chondrolabral separation. The acetabular rim will be evaluated and any evident Pincer lesion will be resected using an arthroscopic burr under fluoroscopic guidance. Following this resection, the labrum will be refixated only if the criteria for labral instability is met. Following this, a limited capsulotomy will be completed along the head-neck junction of the femoral neck to allow for visualization and treatment of the impingement lesion in the peripheral compartment. For the FIRST-EPIC sub-study, participants will receive the osteochondroplasty intervention as per standard of care.
3139149|NCT01623830|Experimental|Reactivation + VRE|Virtual reality exposure therapy (VRE) for the fear of flying (FOF) preceded by a reminder of the feared stimulus (a virtual reality clip of a virtual airplane taxiing and taking off) presented in the head mounted display 10 minutes prior to all VR exposure therapy sessions
3139150|NCT01623830|Active Comparator|Neutral Cue + VRE|VRE for the FOF preceded by a neutral cue (a virtual reality clip of a virtual living room) presented in the head mounted display 10 minutes prior to all VR exposure therapy sessions.
3139151|NCT01623817|No Intervention|Vancomcyin|This arm is received only maintaind dose of vancomycin (15mg/kg twice a day or 1g twice a day).
3139152|NCT01623817|Experimental|Vancomycin loading|This group is recived loading dose 30mg/kg. Subsequent doses of vancomycin are considered standard of care.
3139153|NCT01623804|Active Comparator|Low intensity, pulsed ultrasound|
3139154|NCT01623804|Sham Comparator|Sham ultrasound|
3139335|NCT01622543|Active Comparator|Folfox plus Bevacizumab and Reolysin|
3139155|NCT01623791||Group 1|Group 1: mild pre-eclamptic group Mild and severe pre-eclampsia were defined American College of Obstetrics and Gynecology criteria (ACOG practice bulletin no. 33: diagnosis and management of preeclampsia and eclampsia. January 2002.)
3139156|NCT01623791||Group 2|Group 2: severe pre-eclamptic group
3139157|NCT01623778||Add on ADV|Patients with inadequate response to interferon at 24 weeks received interferon add on ADV optimized therapy
3139158|NCT01623778||Switch to LDT|Patients with inadequate response to interferon at 24 weeks received switching to LDT therapy
3139159|NCT01623752||Patients with Rheumatoid Arthritis|
3139160|NCT01623752||Patients with Psoriasis Arthritis|
3139161|NCT01623739|Active Comparator|Type 1 implant placement|Implant is placed immediately following tooth extraction in one surgical procedure
3139162|NCT01623739|Active Comparator|Type 2 implant placement|Once the tooth is extracted. The site is left to heal for 4 to 8 weeks before a dental implant is placed during a second surgical procedure.
3139163|NCT01623726|Experimental|tDCS active|Active tDCS as foreseen in research protocol: daily sessions for 10 days with 2mA intensity stimulation during 20 minutes.
3139164|NCT01623726|Placebo Comparator|tDCS sham|Sham tDCS : as foreseen in research protocol: sham stimulation with initial stimulation followed by turning off the device during the same time of intervention as to guarantee blinding
3139165|NCT01623713|Active Comparator|Risperidone|
3139166|NCT01623713|Experimental|iloperidone|
3139167|NCT01623700||dual antiplatelet treatment 12 months after ACS event|
3139168|NCT01623700||dual antiplatelet treatment 6 months after ACS event|
3139169|NCT01623700||dual antiplatelet treatment 3 months after ACS event|
3139170|NCT01623687|Active Comparator|Regenerex|
3139171|NCT01623687|Active Comparator|Lub cup|
3139172|NCT01623687|Active Comparator|SP II|
3139173|NCT01623687|Active Comparator|Corail|
3139174|NCT01623661|Other|hypertonic saline|hypertonic saline 3.0% (7 ml/kg)
3139175|NCT01623648|Experimental|Arm 1 Whey Breakfast|The arm 1 will be assigned to eating Whey protein in the breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 42 g protein namely from whey at breakfast
3139176|NCT01623648|Active Comparator|Arm 2: No Whey Breakfast|The arm 2 will be assigned to intake other proteins (No Whey) in the breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 42 g protein from other sources at breakfast
3139177|NCT01623648|Placebo Comparator|Arm 3: Low Protein Breakfast|The arm 3 will be assigned to intake low protein and high carbohydrate breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 22 g protein from other sources at breakfast
3139178|NCT01623635|Experimental|Case - adnexal|
3139179|NCT01623635|Placebo Comparator|placebo - adnexal|
3139180|NCT01623635|Experimental|case - uterine|
3139181|NCT01623635|Placebo Comparator|placebo - uterine|
3139182|NCT01623622|Experimental|HC-58 low dose|Low dose
3139183|NCT01623622|Experimental|HC-58 high dose|High dose
3139184|NCT01623622|Placebo Comparator|Placebo|
3139185|NCT01623609|Experimental|A|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation under fasted conditions
3139186|NCT01623609|Experimental|B|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation under fed conditions
3139187|NCT01623609|Experimental|C|Naloxegol film-coated IR tablet 25 mg Phase III formulation under fasted conditions
3139188|NCT01623596|Experimental|Fingolimod|
3139189|NCT01623596|Active Comparator|Disease Modifying Therapy|2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)
3139190|NCT01623583|Experimental|Enhanced Needle Phobia Intervention|Patients will receive enhanced needle phobia intervention comprising the standard intervention plus demonstration of Synera
3139191|NCT01623583|Active Comparator|Standard Needle Phobia Intervention|Patients will receive the standard intervention for needle phobia
3139192|NCT01623570|Experimental|Pergoveris: 150IU r-hFSH+ 75IU r-hLH|This is a prospective randomized study using two in-label treatments for the patient disease: Pergoveris and Menopur. Pergoveris arms can be considered as experimental for the aim of the study, anyway it is standard routine practice for HH women.
3139193|NCT01623570|Experimental|Menopur: hMG-HP (150IU)|This is a prospective randomized study using two in-label treatments for the patient disease: Pergoveris and Menopur. Menopur can be considered as experimental for the aim of the study, anyway it is standard routine practice for HH women
3139194|NCT01623557|Active Comparator|Group 1: ChAd63-MVA CS|1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later.
3139195|NCT01623557|Active Comparator|Group 2: ChAd63-MVA ME-TRAP|1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later.
3139196|NCT01623557|Active Comparator|Group 3: Unvaccinated Infectivity Controls|
3139197|NCT01623544||Symbicort|BFC patients new to ICS/LABA combination therapy
3139198|NCT01623544||Advair|FSC patients new to ICS/LABA combination therapy
3139199|NCT01623531|Active Comparator|RiaSTAP|Intravenous fibrinogen(RiaSTAP) will be administered according to FIBTEM based calculation formula
3139200|NCT01623531|Placebo Comparator|Intravenous saline|Intravenous saline (placebo) will be calculated according to FIBTEM based calculation formula
3139201|NCT01623518|Experimental|ChAdOx1-NP+M1|
3139202|NCT01623505|Experimental|Champix|
3139203|NCT01623505|Experimental|Long & Combination patch treatment|
3139204|NCT01623505|Experimental|Standard patch treatment|
3139205|NCT01623492||diagnosis of Eisenmenger Syndrome|subjects with diagnosis of Eisenmenger Syndrome
3139206|NCT01623479||Hypotrichosis of the Eyelashes|Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
3139207|NCT01623466|Experimental|AG890-6.5|Evaluate levonorgestrel delivery in AG890-6.5
3139208|NCT01623466|Experimental|AG890-12.5|Evaluate levonorgestrel delivery in AG890-12.5
3139209|NCT01623453||Low dose group|Group1. Low dose group
3139210|NCT01623453||High dose group|Group2. High dose group
3139211|NCT01623440|Other|Obese|BMI over 30
3139212|NCT01623440|Other|Lean|BMI between 20 and 24.9
3139336|NCT01622543|Active Comparator|Folfox plus Bevacizumab|
3139214|NCT01623427|Active Comparator|Control|The dressing for the umbilical port site will be the same as the experimental group, except for the application of vacuum. The control group will have no vacuum applied to the wound dressing.
3139215|NCT01623414||Healthy schoolchildren|
3139216|NCT01623401|Experimental|TR-701 FA|TR-701 FA 200 mg oral once daily
3139217|NCT01623388||Phase I|
3139218|NCT01623375|Experimental|s.c.|
3139219|NCT01623375|Experimental|i.v.|
3139220|NCT01623362|Experimental|Low-fluoride acidic dentifrice|
3139221|NCT01623362|No Intervention|Conventional dentifrice|1100µgF/g-pH7.0
3139222|NCT01623362|Experimental|neutral pH and low-fluoride dentifrice|550 ppm pH 7
3139223|NCT01623349|Experimental|Arm BKM|BKM120 and Olaparib
3139224|NCT01623349|Experimental|Arm BYL|BYL719 and Olaparib
3139225|NCT01623336|Active Comparator|Pegasys ®|Patients will receive Pegasys ® (peginterferon alfa-2a 40kDa) at a dose of 180 micrograms, subcutaneously, once a week, associated with ribavirin at a dose 1000-1250 mg,daily. For genotype 1 treatment time is 48 to 72 weeks and for genotypes 2 and 3, 24 weeks.
3139226|NCT01623336|Experimental|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48, 180 micrograms a week, SC, for the same period as Pegasys ®.
3139227|NCT01623323|Other|Fluticasone|
3139228|NCT01623310|Experimental|OPN-375 400 μg BID|OPN-375 400 μg BID for 12 months
3139229|NCT01623297||Laparoscopic colon surgery|Patients over age 65 having laparoscopic colon resection for colonic adenocarcinoma
3139230|NCT01623297||Open colon surgery|Patients over age 65 having open colon resection for colonic adenocarcinoma
3139231|NCT01623284|Experimental|PiB and FDG positron emission tomography (PET)|All subjects will receive PiB and FDG PET diagnosis on approximately day 1 or day 2 of study to determine if they have beta-amyloid deposits in their brains.
3139232|NCT01623271|Experimental|CRPS I Pain Subjects|"This is an open label study that involves taking Gralise pills (gastic-retentive gabapentin) for 8 weeks.~Day 1-15: Titration phase- titrate Gralise from 300 mg/day to 1800 mg/day Day 16-42: Maintenance phase- maintain the dose of 1800 mg/day Day 43-56: Taper phase- taper the Gralise from 100 mg/day to 300 mg/day"
3139233|NCT01623258||Standard of Care|Standard histopathological evaluation using conventional paraffin embedding, sectioning and hematoxylin and eosin staining and microscopy without sentinel lymph node ultrastaging
3139234|NCT01623258||Research|SOC with sentinel lymph node analysis
3139235|NCT01623245||Hypertrophic Cardiomyopathy|In the population of Hypertrophic Cardiomyopathy patients, patients suffering from a cardiac amyloidosis
3139236|NCT01623232|Experimental|adjuvant plus 1 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 1 �g of HA antigen
3139237|NCT01623232|Experimental|adjuvant plus 3 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 3 �g of HA antigen
3139238|NCT01623232|Experimental|adjuvant plus 5 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 5 �g of HA antigen
3139239|NCT01623232|Active Comparator|licensed influenza vaccine|licensed, inactivated, standard dose influenza vaccine without adjuvant
3139240|NCT01623219|Experimental|TeleMedicine Prolonged Exposure|Veterans will receive prolonged exposure therapy (PE)delivered via telemedicine instead of in person. For this study 9 weekly 90 minute sessions will be given over a period of up to 3 months. The first 2 sessions of each treatment will involve education, rational and treatment preparation. Sessions 3-9 will consist of recounting the traumatic event out loud and repeatedly. The purpose of this study is to determine if this treatment is effective when given through telehealth.
3139241|NCT01623206|Experimental|Desmopressin|Four dose levels and two dosing schedules with 3 patients in each group.
3139242|NCT01623193|Active Comparator|Control|Patients receive standard 4:1 cardioplegia for myocardial protection during cardiac surgery
3139243|NCT01623193|Experimental|Treatment|Patients receive all-blood cardiolpegia for myocardial protection during surgery
3139244|NCT01623180|Experimental|BioFreedom™ Drug Coated Stent (DCS)|BA9 drug coated stent implantation for improving coronary luminal diameter in patients with de novo lesions in native coronary arteries with a reference vessel diameter between 2.25 mm and 4.0 mm.
3139245|NCT01623180|Active Comparator|Gazelle™ Bare Metal Coronary Stent (BMS)|GAZELLE™ bare metal stent implantation for improving coronary luminal diameter in patients with de novo lesions in native coronary arteries with a reference vessel diameter between 2.25 and 4.0 mm.
3139246|NCT01623167|Experimental|Cohort 1|Receive horse ATG days 1- 4, receive CsA day 1 to month 6, and receive eltrombopag day 14 to month 6
3139247|NCT01623167|Experimental|Cohort 2|Receive horse ATG days 1- 4, receive CsA day 1 to month 6, and receive eltrombopag day 14 to month 3
3139248|NCT01623167|Experimental|Cohort 3|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18months, and receive eltrombopag day 1 to month 6
3139249|NCT01623167|Experimental|Extrension Cohort|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18 months, and receive eltrombopag day 1 to month 6
3139250|NCT01623154|Other|BreathTek UBT|Comparison of Urea hydrolysis rate (UHR) values derived from Delta over Baseline (DOB)values obtained from the POCone and UBiT-IR300
3139251|NCT01623141||Patients with CRPS|18 patients with unilateral CPRS of the upper limb were included to the study
3139252|NCT01623141||Patients with limb pain of other origin|17 patients with unilateral upper limb pain of other origin served as control group
3139253|NCT01623141||Healthy subjects|18 healthy subjects were included to establish reference data for the pressure pain thresholds
3139254|NCT01623128|Experimental|Breastfeeding video|Participants randomized to this arm view the intervention video - Injoy Videos Better Breastfeeding video.
3139255|NCT01623128|Placebo Comparator|Sham video|Participants randomized to this arm view the sham video Injoy Videos Your Healthy Pregnancy: Prenatal Nutrition and Exercise video.
3139256|NCT01623115|Placebo Comparator|Placebo|Placebo for alirocumab every 2 weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
3139257|NCT01623115|Experimental|Alirocumab 75 mg/Up to 150 mg Q2W|Alirocumab 75 mg Q2W on top of stable LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when low-density lipoprotein cholesterol (LDL-C) levels ≥ 70 mg/dL (1.81 mmol/L) at Week 8.
3139258|NCT01623102|Experimental|Arm I: bevacizumab plus chemotherapy|Patients in the experimental arm receive cisplatin and gemcitabine combination with Bevacizumab. GP chemotherapy (gemcitabine 1250mg/m2 IV D1 and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle) plus bevacizumab (7.5 mg/kg IV on D1 of every 21-day cycle).
3139259|NCT01623102|Active Comparator|Arm II: chemotherapy|Patients receive gemcitabine combined with cisplatin chemotherapy((gemcitabine 1250mg/m2 IV D1 and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle) ) every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3139260|NCT01623089||severe asthma|
3139261|NCT01623076||Neuromyelitis Optica Spectrum Disorder|Patients diagnosed with NMOSD based on revised diagnostic criteria. Seronegative, anti-AQP4 seropositive and ant-MOG seropositive patients will be included
3139262|NCT01623076||Transverse Myelitis and Optic Neuritis|Patients who have had one demyelinating event, not diagnosed with multiple sclerosis and whom are considered at risk for NMO or NMOSD.
3139263|NCT01623076||Healthy Controls|patients without a history of CNS inflammation
3139264|NCT01623076||Neuromyelitis Optica|patients diagnosed with NMO
3139265|NCT01623063|Experimental|Infertile|patients from our human reproduction center
3139266|NCT01623063|Active Comparator|Fertile|patients with comproved fertility
3139267|NCT01623050|Experimental|SinuSys Dilation System|Maxillary Sinus Dilation
3139268|NCT01623037|Experimental|Fat Reduction|
3139269|NCT01623024|Experimental|Vitamin D and Lifestyle counseling|
3139270|NCT01623024|Active Comparator|Lifestyle counseling|
3139271|NCT01623011|Experimental|Arthroscopic Sub-acromial Decompression|Arthroscopic sub-acromial decompression surgery.
3139272|NCT01623011|Active Comparator|Shoulder Arthroscopy|Shoulder arthroscopy only.
3139273|NCT01623011|Other|Active Monitoring with Specialist Reassessment|Active monitoring with specialist reassessment - non-operative control.
3139274|NCT01622998|Active Comparator|Standard transdermal NRT group (UC)|10 week standard transdermal nicotine replacement therapy patch protocol
3139275|NCT01622998|Experimental|Titrated transdermal NRT group (EXP)|10 week titrated transdermal nicotine replacement therapy patch dose regimen based on smoking history with the option to increase dose, if withdrawal symptoms are unmanageable.
3139276|NCT01622972|Experimental|Group 1|Healthy volunteers in Group 1: To give sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2
3139277|NCT01622972|Experimental|Group 2|Healthy volunteers in group 2: To give 2x sachet's A and B made up to 2 litres with tap water on day 1.
3139278|NCT01622972|Experimental|Group 3|Patients with functional constipation and irritable bowel syndrome characterized by constipation: To give sachet's A and B made up to 1 litre with tap water once on day 1
3139279|NCT01622959|Active Comparator|acupuncture|"Inclusion criteria:~Traumatic and non traumatic acute pain with visual analog pain scale ( VAPS) > 40 (on a scale 0-100) Age ≥18 years Presigned consentement to participate in the study.~Exclusion criteria:~Temperature > 37.7° C, Anticoagulation medication use or the presence of a mechanical heart valve, Skin infections that would preclude certain acupuncture points being used, Refusal, inability to consent or communication difficulties, Acute major trauma, Any form of analgesia up to 60 minutes prior to study start, An initial pain score ≤ 40 on the pain scale (score range 0-100), Opiate contraindication, Pregnancy, Presentation to the ED > 4 times in the previous 3 months with the same condition."
3139280|NCT01622959|Sham Comparator|morphine|drug:5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes <30%.
3139281|NCT01622946|Active Comparator|Placebo|The patients who receive placebo form the control group. The results can be compared with the results of the patients who did receive TXA
3139282|NCT01622946|Placebo Comparator|Tranexamic acid|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
3139283|NCT01622933|Experimental|Vaccine + IFN|"Subjects will receive the investigational vaccine, intradermally, every other week for a total of 3 vaccines. Approximately 30 days after the last vaccine subjects will receive IFN intravenously 5 days a week for 4 weeks.~Leukapheresis will be required to be performed for each subject to be able to produce the investigational vaccine and for research testing. Leukapheresis and biopsies will be performed before the first vaccine, after the 3rd vaccine, and after the IFN treatment."
3139284|NCT01622933|Experimental|Vaccine only|"Subjects will receive the investigational vaccine, intradermally, every other week for a total of 3 vaccines.~Leukapheresis will be required to be performed for each subject to be able to produce the investigational vaccine and for research testing. Leukapheresis and biopsies will be performed before the first vaccine, after the 3rd vaccine, and again approximately 2 months after the last vaccine."
3139285|NCT01622920|Other|ultrasound enamel thickness measurements|Enamel thickness will be measured with ultrasound
3139286|NCT01622907||Pts Symptomatic Recurrent Persistent AF|Patients with Symptomatic Recurrent Persistent AF or Long standing AF,for > 1-year < 5 years duration
3139287|NCT01622881|Active Comparator|Nefopam|
3139288|NCT01622881|Placebo Comparator|Control|
3139289|NCT01622868|Experimental|Arm A (WBRT or SRS)|Patients undergo WBRT 5 days a week for 3 weeks for a total of 15 treatments, or SRS for 1 treatment.
3139290|NCT01622868|Experimental|Arm B (lapatinib ditosylate, WBRT or SRS)|Patients undergo WBRT or SRS as in Arm A. Patients also receive lapatinib ditosylate PO QD for 6 weeks.
3139291|NCT01622855|Experimental|PPRS video|Prevention of post sexual assault stress
3139292|NCT01622855|No Intervention|Standard care|Receipt of standard services
3139293|NCT01622842||Bioimpedance|8 females and 8 males BMI from 19 to 46 SBP from 119 to 182
3139294|NCT01622829|Experimental|group1|"Usual Physiotherapy, additional: Prescription for Activity with a structured fitness program and individual instructions to become more active in the daily living situation"
3139295|NCT01622829|Experimental|group 2|"usual Physiotherapy , additional: Prescription for Activity without instructions"
3139296|NCT01622829|No Intervention|group 3|control, usual physiotherapy
3139297|NCT01622803|Active Comparator|parallel stent|parallel stent insertion group
3139298|NCT01622803|Active Comparator|Y-stent|Y-stent insertion group
3139299|NCT01622790|Experimental|Arm 1|33 subjects will receive a single dose of each of a tablet formulation of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg in Period 1followed by dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg) in Period 2. Approximately 6 of these subjects will return for a third period where they will receive a single dose of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg after a high fat breakfast. There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
3139300|NCT01622790|Experimental|Arm 2|33 subjects will receive dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg) in Period 1 followed by a single dose of a tablet formulation of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg in Period 2. Approximately 6 of these subjects will return for a third period where they will receive a single dose of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg after a high fat breakfast. There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
3139301|NCT01622777|Experimental|Rosuvastatin|20 mg daily of oral rosuvastatin
3139302|NCT01622777|Placebo Comparator|Placebo|
3139303|NCT01622764|Experimental|Molecular imaging with 89Zr-RO5323441|
3139304|NCT01622725|Experimental|Resorbable mesh|Long-term resorbable mesh implanted to treat primary and secondary ventral hernia.
3139305|NCT01622725|Active Comparator|Non-resorbable mesh|Non-resorbable synthetic mesh implanted to treat primary and secondary ventral hernia.
3139306|NCT01622712|Experimental|Unilateral inguinal hernia|A Nitinol containing large pore polypropylene mesh will be placed in patients with unilateral inguinal hernia.
3139307|NCT01622699|Experimental|Transcutaneous bilirubin measurements|In this intervention group, the initial visual assessment of jaundice wille be followed by measurement by transcutaneous bilirubinometer
3139308|NCT01622699|Active Comparator|Visual assessment of neonatal jaundice|In this control group (standard of care) the visual assessment will be followed by measurement of blood bilirubin as indicated by the physician
3139309|NCT01622686|No Intervention|Traditional prescription drug labels|Routine drug labels provided by the participating pharmacies
3139310|NCT01622686|Experimental|Reformatted medication labels|Prescription drug container labels that follow a new format and also include illustrations
3139311|NCT01622673|Experimental|RAL, TUMS+RAL, MINTOX+RAL, MINTOX Before RAL, MINTOX After RAL|Participants received Raltegravir in treatment period 1, followed by TUMS® + Raltegravir in treatment period 2, followed by MINTOX® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours After Raltegravir in treatment period 5. There was a 2-day washout between treatment periods.
3139312|NCT01622673|Experimental|TUMS+RAL, MINTOX+RAL, RAL, MINTOX Before RAL, MINTOX After RAL|Participants received TUMS® + Raltegravir in treatment period 1, followed by MINTOX® + Raltegravir in treatment period 2, followed by Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
3139313|NCT01622673|Experimental|MINTOX+RAL, RAL, TUMS+RAL, MINTOX Before RAL, MINTOX After RAL|Participants received MINTOX® + Raltegravir in treatment period 1, followed by Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
3139314|NCT01622673|Experimental|RAL, MINTOX+RAL, TUMS+RAL, MINTOX After RAL, MINTOX Before RAL|Participants received Raltegravir in treatment period 1, followed by MINTOX® + Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
3139315|NCT01622673|Experimental|TUMS+RAL, RAL, MINTOX+RAL, MINTOX After RAL, MINTOX Before RAL|Participants received TUMS® + Raltegravir in treatment period 1, followed by Raltegravir in treatment period 2, followed by MINTOX® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
3139316|NCT01622673|Experimental|MINTOX+RAL, TUMS+RAL, RAL, MINTOX After RAL, MINTOX Before RAL|Participants received MINTOX® + Raltegravir in treatment period 1, followed by TUMS® + Raltegravir in treatment period 2, followed by Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
3139317|NCT01622660|Experimental|Gemcitabine and Pazopanib|This is a phase II trial of gemcitabine and pazopanib in previously untreated patients with advanced/metastatic urothelial carcinoma (UC) who are ineligible for cisplatin-based chemotherapy.
3139318|NCT01622647|Active Comparator|NCPAP Group|Group of patients that do receive NCPAP treatment
3139319|NCT01622647|No Intervention|No NCPAP|subjects will not receive NCPAP
3139320|NCT01622634|Active Comparator|Higher Protein Diet (PRO)|
3139321|NCT01622634|Active Comparator|Higher Carbohydrate Diet (CARB)|
3139322|NCT01622634|Active Comparator|PRO & Interval Exercise (PRO+EX)|
3139323|NCT01622634|Active Comparator|CARB & Interval Exercise (CARB+EX)|
3139324|NCT01622621|Active Comparator|Randomized Sublobar Resection|Randomized by computer to receive a sublobar resection.
3139325|NCT01622621|Active Comparator|Randomized SBRT|Randomized by computer to receive Stereotactic Body Radiotherapy (SBRT).
3139326|NCT01622621|Active Comparator|Observation Sublobar Resection|Patient decides with doctor to undergo a sublobar resection.
3139327|NCT01622621|Active Comparator|Observation SBRT|Patient decides with doctor to undergo SBRT.
3139328|NCT01622608|Experimental|Kiosk Users|
3139329|NCT01622608|No Intervention|Non-Kiosk Users|
3139330|NCT01622569|Active Comparator|fluticasone propionate 100 μg Twice a Day|100 μg Twice a Day
3139331|NCT01622569|Placebo Comparator|Matching placebo|100 μg Twice a Day or 200 μg Twice a Day or 400 μg Twice a Day
3139332|NCT01622569|Active Comparator|fluticasone propionate 200 μg Twice a Day|200 μg Twice a Day
3139333|NCT01622569|Active Comparator|fluticasone propionate 400 μg Twice a Day|400 μg Twice a Day
3139334|NCT01622556|Experimental|Reduced Intensity Conditioning with UCB Transplant|
3139338|NCT01622530||Non-amputees|No longer recruiting non-amputees
3139339|NCT01622504|Experimental|Test Product Dose 1|
3139340|NCT01622504|Experimental|Test Product Dose 2|
3139341|NCT01622504|Active Comparator|Comparator Product|
3139342|NCT01622491||Case control|A case-control study with cases (individuals hospitalized with influenza or pneumonia during the second wave of the pandemic) and controls (non-hospitalized individuals) identified using the MH Hospital Separation Abstract Database and the MH Population Registry, respectively. Information on receipt of vaccines will be obtained by record linkage to the MIMS.
3139343|NCT01622478||Clinically node-positive patients before NAC|"Patients with clinically positive lymph node receiving neoadjuvant chemotherapy~Clinically negative-node after NAC~Clinically positive-node after NAC"
3139344|NCT01622465|Experimental|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises.
3139345|NCT01622465|Active Comparator|Conventional exercises|Patients will participate only of the conventional exercises program.
3139346|NCT01622439|Experimental|Single, open labeld.|
3139347|NCT01622426|Active Comparator|New formula IgE mediated testing|Children with IgE-mediated CMA performed oral food challenge with the new formula
3139348|NCT01622426|Active Comparator|New formula non-IgE-mediated testing|Children with non-IgE-mediated CMA performed oral food challenge with the new formula
3139349|NCT01622413|Experimental|Endscopy|
3139350|NCT01622413|Active Comparator|Microsurgery|
3139351|NCT01622400|Experimental|Therapeutic education HTA Vasc|125 subjects who participate in the therapeutic education program
3139352|NCT01622400|No Intervention|Control group|125 subjects who don't participate in the therapeutic education program
3139353|NCT01622387|Experimental|Radial artery|Use of the radial artery as a conduit in CABG surgery
3139354|NCT01622387|Active Comparator|Long saphenous vein|Use of long saphenous vein as a conduit in CABG surgery
3139355|NCT01622374|Active Comparator|Silence|the subjects received 10 minutes of silence through headphone
3139356|NCT01622374|Experimental|Music for the mind|
3139357|NCT01622374|Experimental|Mozart music|
3139358|NCT01622374|Experimental|Iranian traditional music|
3139359|NCT01622361|Active Comparator|Chemotherapy Group|Chemotherapy Adriamycin+Cyclophosphamide>Docetaxel
3139360|NCT01622361|Experimental|Endocrine therapy group|Endocrine therapy(GnRHa with Tamoxifen) group
3139361|NCT01622348|Placebo Comparator|Placebo|Saline for Injection
3139362|NCT01622348|Active Comparator|IMO-3100 at 0.16 mg/kg|IMO-3100 at 0.16 mg/kg SC once weekly based on body weight at screening, not to exceed 20 mg per injection
3139363|NCT01622348|Active Comparator|IMO-3100 at 0.32 mg/kg|IMO-3100 at 0.32 mg/kg SC q wk x 4 wk based on body weight at screening, not to exceed 40 mg per injection
3139364|NCT01622335|Placebo Comparator|General anesthesia with oxygen|General anesthesia and Air
3139365|NCT01622335|Experimental|nitrous oxide and general anesthesia|General anesthesia with Nitrous Oxide
3139366|NCT01622322|Experimental|Nitrous oxide|Subjects will receive General anesthesia with Nitrous Oxide.
3139367|NCT01622322|Placebo Comparator|Oxygen|Subjects will receive General anesthesia with oxygen.
3139368|NCT01622309|Active Comparator|eggplant meal|13 g meal of eggplant/day
3139369|NCT01622309|Placebo Comparator|cassava meal|13 g of placebo/day
3139370|NCT01622296|Active Comparator|Sodium Bicarbonate with Lidocaine|
3139371|NCT01622296|Placebo Comparator|Lidocaine with no buffer|
3139372|NCT01622283|Experimental|Levocetirizine oral solution 5 mg|Levocetirizine oral solution 5 mg
3139373|NCT01622283|Active Comparator|Cetirizine dry syrup 10 mg|Cetirizine dry syrup 10 mg
3139374|NCT01622257|Experimental|Cavitation US|Cavitation ultrasound was done using ultrasonic cavitation machine 2 times per week for 3 months
3139375|NCT01622257|Experimental|Metformin|Metformin oral tablets 500 mg were given three times daily
3139376|NCT01622257|Experimental|Cavitation US + metformin|Combination of both Cavitation US + Metformin
3139377|NCT01622244|Experimental|Intervention arm|Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
3139378|NCT01622244|Active Comparator|Counseling and Resource Education (CARE)|Participants will receive care as usual in the community. In addition, participants in this arm will receive an educational session and resource guide outlining available community-based services
3139379|NCT01622231|Experimental|GW685698X|GW685698X 55mcg/day
3139380|NCT01622218|Experimental|Medical Clown|Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers.
3139381|NCT01622218|No Intervention|Control|Assessment of child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect on the total consumption of analgesics and on the post- surgery inflammatory markers.
3139382|NCT01622205|Experimental|Active|Early supported discharge
3139383|NCT01622205|Other|Control|Ordinary rehabilitation
3139384|NCT01622192|Experimental|Automated probe|
3139385|NCT01622179|Experimental|Indirectly|The epitenon was repaired and sewed indirectly.
3139386|NCT01622179|Placebo Comparator|Directly|The epitenon was unrepaired and sewed directly.
3139387|NCT01622166|Experimental|art therapy|12 sessions of art therapy / 6 weeks
3139388|NCT01622166|No Intervention|TAU|treatment as usual / 6 weeks
3139389|NCT01622153|Placebo Comparator|Formocresol (control)|This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Cotton pellets are saturated with conventional 1:5 dilution of Buckley's formocresol into the canal orifice for 5 minutes for complete hemostasis. IRM (Zinc Oxide Eugenol) cement will then be placed to seal the pulp chamber. A stainless steel crown will be cemented with Ketac Cement that was triturated for 10 seconds to complete the pulpotomy procedure and final restoration.
3139473|NCT01621516||Healthy controls|10 healthy volunteers
3139474|NCT01621516||Solitary small bowel transplant patients|3
3139390|NCT01622153|Active Comparator|Laser|This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Then a GENTLEray 980 Soft Tissue diode laser (Power: 3.0W, Mode: PW, Fiber: 300µm, Ton: 100ms, Toff: 100ms, Timer: cont) will be used to vaporize the residual pulp tissue and complete hemostasis. IRM (Zinc Oxide Eugenol) cement is then placed to seal the pulp chamber. A stainless steel crown cemented with Ketac Cement for the full coverage final restoration completes the pulpotomy procedure.
3139391|NCT01622127||incisional hernias|
3139392|NCT01622114|Experimental|Menstralean group|"Represents a program which is designed to induce weight loss by taking into account the physiology of each menstrual phase in terms of adjusting diet and physical activity to the body's cyclic changes in energy demands.~The diet will be adjusted to match one menstrual cycle in duration (approx. 1 month) and will be separated into three phases corresponding to three menstrual phases: menstruation (days 1-5), the follicular phase (days 6-14), and the luteal phase (days 15-28). All women in this group will start the program at day 1 in their cycle. The diet will be repeated six times for each woman, which equals six months."
3139393|NCT01622114|Active Comparator|Control Group:|"Represents a program where subjects engage in a similar diet and exercise program as the Menstralean Group, specifically based on the educational diet system Eat for Life. Importantly, the subjects in Control group will start the program at a random time in their menstrual cycles.~Eat for Life is a simple tool for controlling the energy content and nutritional composition of your diet. The method is based on a system of counters that ensure strict control of the diet whilst still allowing a great deal of freedom of choice. The subjects in the Control Group will also receive exactly the same attention and undergo the same visits and measurements as the Menstralean Group."
3139394|NCT01622101|Experimental|zantrex|The test compound was administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules).
3139395|NCT01622101|Placebo Comparator|Control|The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or appearance.
3139396|NCT01622088|Experimental|Dexpramipexole|
3139397|NCT01622075|Experimental|SeQuent® Please|Paclitaxel Drug-eluting Coronary Artery Balloon Catheter
3139398|NCT01622075|Active Comparator|Taxus Liberte|Paclitaxel Drug-eluting Coronary Stent and Conveying System
3139399|NCT01622062|Experimental|Group 1|"Patients with WHO Category II exposure receive PEP with PVRV using one-week, 4-site (4-4-4-0-0) ID vaccination regimen, and a single-visit, 4-site booster vaccination with PVRV 5 years later"
3139400|NCT01622062|Experimental|Group 2|"Patients with WHO Category III exposure receive PEP with PVRV using one-week, 4-site (4-4-4-0-0) ID vaccination regimen and pERIG Favirab®, and a single-visit, 4-site booster vaccination with PVRV 5 years later"
3139401|NCT01622062|Active Comparator|Group 3|"Patients with WHO Category III exposure receive PEP with PVRV using the updated 2-site TRC (2-2-2-0-2) ID vaccination regimen and pERIG Favirab®, and a single-visit, 4-site booster vaccination with PVRV 5 years later"
3139402|NCT01622049||TTTS treatment method|This is an observational trial. Patients who meet eligibility criteria and give written informed consent will have SLPCV. All subjects will receive ongoing standard-of-care prenatal care for the duration of their pregnancy from their referring perinatologist or obstetrician.
3139403|NCT01622036||Cancer patients undergoing first medical oncology visit.|
3139404|NCT01622023|Experimental|Study group|intrauterine insemination after 24 hours
3139405|NCT01622023|Active Comparator|Control group|intrauterine insemination after 48 hours
3139406|NCT01622010|Experimental|Standard care with video enhancement|
3139407|NCT01622010|Active Comparator|Standard care|
3139408|NCT01621997|Experimental|operation inspection|
3139409|NCT01621997|Experimental|verbal education|
3139410|NCT01621997|Experimental|usual care|
3139411|NCT01621984|Experimental|Therapeutic Riding/ Hippotherapy|12 week Therapeutic Riding program that focused on gross motor function, gross motor performance, balance, spasticity, posture and quality of life
3139412|NCT01621984|No Intervention|without Therapeutic Riding/ Hippotherapy|
3139413|NCT01621971|Experimental|milrinone inhalation|inhaled milirinone and IV placebo (0.9% normal saline 0.05 ml/kg) are administered in Group IH.
3139414|NCT01621971|Active Comparator|intravenous milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an IV bolus of milrinone (50 μg/kg) are administered in Group IV
3139415|NCT01621958|Experimental|Motor training|
3139416|NCT01621958|Placebo Comparator|Intensity control|
3139417|NCT01621945||Bras A|children, born between the 06/04/2004 and the 17/04/2008, living around Neufchatel en Bray, before the fourth dose of MenBVac
3139418|NCT01621932|Active Comparator|Surgical approach 1|Direct anterior surgical approach with capsulectomy
3139419|NCT01621932|Active Comparator|Surgical approach 2|Direct anterior approach without capsulectomy
3139420|NCT01621906|Experimental|Cohort 1|Cohort 1 will include the first ten patients treated with WBRT concomitantly with sorafenib (on a separate phase I trial). We will perform a pilot study of serial FLT-PET imaging of the brain at baseline (< 4 weeks prior to initiation of WBRT), up to 7-10 days post-WBRT and 10-12 weeks after WBRT in patients with metastatic breast cancer to the brain (N=20) treated with WBRT with or without sorafenib.
3139421|NCT01621906|Experimental|Cohort 2|Cohort 2 will include patients treated with standard WBRT alone. Patients in both these cohorts will also be assessed with standard non-invasive MRI in addition to [18F] FLT PET at baseline (< 4 weeks of WBRT) and 10-12 weeks after completion of WBRT.
3139422|NCT01621893||BML of the Knee|Subject has single bone marrow lesion of tibia, single BML of femur, or adjoining BML's of tibia & femur on which a Subchondroplasty procedure is performed
3139423|NCT01621880|Active Comparator|Bevacizumab|Patients receive bevacizumab IV over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3139475|NCT01621516||Liver/small bowel transplant patients|3
3139424|NCT01621880|Active Comparator|Methylprednisolone|Patients receive intravenous steroid over 5 consecutive days. The dosage was decreased gradually. The regimen repeats every other month for up to 4 courses.
3139425|NCT01621867|Active Comparator|pGM169/GL67A (CFTR Gene/Lipid Vector)|
3139426|NCT01621867|Placebo Comparator|Placebo|
3139427|NCT01621854|Experimental|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, & 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, & 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days
3139428|NCT01621841||Glaucoma subjects|
3139429|NCT01621841||heathly subjects|
3139430|NCT01621828|Other|video|video showing a patient's pathway into the operating room.
3139431|NCT01621828|Other|leaflet|a written leaflet, about the operating room experience and environment.
3139432|NCT01621815|Active Comparator|Anxiety and Depression|Adolescents diagnosed with anxiety and/or depression
3139433|NCT01621815|Active Comparator|ADD|Adolescents diagnosed with ADD (without hyperactive element)
3139434|NCT01621815|Active Comparator|ADHD, Behavioral|Adolescents diagnosed with ADHD (with hyperactivity), with or without behavioral problems
3139435|NCT01621815|Active Comparator|PDD|Adolescents diagnosed with PDD Spectrum Disorders
3139436|NCT01621815|Active Comparator|Control|Adolescents without a psychiatric diagnosis
3139437|NCT01621802|Experimental|Inv _MMR_CO Group|Subjects received one dose of the study vaccine Priorix along with Kinrix and ProQuad vaccines at Visit 1 (Day 0).
3139438|NCT01621802|Active Comparator|Com_MMR_CO Group|Subjects received one dose of the licensed vaccine M-M-R II (also known as M-M-R Vax Pro) Lot 1 or Lot 2 along with Kinrix and ProQuad vaccines at Visit 1 (Day 0).
3139439|NCT01621802|Experimental|Inv_MMR_I Group|Subjects received one dose of Priorix at Visit 1 (Day 0).
3139440|NCT01621802|Active Comparator|Com_MMR_I Group|Subjects received one dose of M-M-R II (also known as M-M-R Vax Pro) vaccine from Lot 1 or Lot 2 at Visit 1 (Day 0).
3139441|NCT01621802|Experimental|Inv _MMR_S Group|Subjects in this safety cohort received one dose of Priorix at Visit 1 (Day 0).
3139442|NCT01621802|Active Comparator|Com_MMR_S Group|Subjects in this safety cohort received one dose of M-M-R II (also known as M-M-R Vax Pro) vaccine from Lot 1 or Lot 2 at Visit 1 (Day 0).
3139443|NCT01621789|Experimental|dye of lutein, zeaxanthin, trypan blue|during the surgery will be evaluated if the dye is suitable for dyeing anterior lens capsule
3139444|NCT01621776|Active Comparator|Humalog|Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
3139445|NCT01621776|Active Comparator|Apidra|Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
3139446|NCT01621776|Active Comparator|Novolog|Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
3139447|NCT01621763|Experimental|Clopidogrel|Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited
3139448|NCT01621763|Active Comparator|Plavix|Clopidogrel Tablet 300 mg
3139449|NCT01621750|Experimental|Clopidogrel|Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited
3139450|NCT01621750|Active Comparator|Plavix|Clopidogrel Tablet 300 mg
3139451|NCT01621737|Experimental|Oxytocin: Low Dose|42 IU BID for the six weeks
3139452|NCT01621737|Experimental|Oxytocin: High Dose|84 IU BID for six weeks
3139453|NCT01621737|Placebo Comparator|Placebo|
3139454|NCT01621724|Experimental|Single arm cohort study|WT1 TCR-transduced T cells
3139455|NCT01621711|No Intervention|Usual Care|Usual CD treatment, including therapy groups and individual counseling sessions, and six 45-min medical education groups. Physician appointments, pharmacotherapy, and SUD medications were be available as needed.
3139456|NCT01621711|Experimental|Linkage patient activation intervention|Usual Care with the exception that the six 45-min Linkage patient activation education groups replaced the six 45-min Usual Care medical education groups, plus a linkage phone call (and/or a facilitated email) with the patient, clinician, and Primary Care physician.
3139457|NCT01621698|Active Comparator|Early paravertebral block|The early group will have Local anaesthetic placed at the start of surgery and have normal saline placed at the close.
3139458|NCT01621698|Active Comparator|Late paravertebral block|The late group will have normal saline placed at the start of surgery and local anaesthetic placed at the close.
3139459|NCT01621685|Experimental|Spirometry, auscultation, questionnaire|>12% fall in FEV1, wheezing on auscultation, symptom questionnaire score >4
3139460|NCT01621672|Experimental|Revlimid|Revlimid dosing will be in the morning at the same time each day
3139461|NCT01621672|No Intervention|No further treatment|No treatment control.
3139462|NCT01621659|Experimental|multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
3139463|NCT01621659|No Intervention|Observational arm|Participants randomized to observational arm will receive usual care.
3139464|NCT01621646|Placebo Comparator|egg white (control)|egg whites, 4 ounces per day for six months
3139465|NCT01621646|Experimental|eggs|eggs, 2 large per day for 6 months
3139466|NCT01621633|Experimental|Group 1: mild hepatic impairment|LCZ696 200 mg, given as a single oral dose
3139467|NCT01621633|Experimental|Group 2: moderate hepatic impairment|LCZ696 200 mg, given as a single oral dose
3139468|NCT01621633|Experimental|Group 3: healthy volunteers|LCZ696 200 mg, given as a single oral dose. Each healthy volunteer will match in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in groups 1 and 2
3139469|NCT01621620|Experimental|yohimbin|
3139470|NCT01621568|Experimental|Arm 1|Single Group Assignment for Thymoma and Thymic Carcimoma
3139471|NCT01621555||PSOASS Patients|Patients undergoing elective arthroscopic shoulder surgery
3139472|NCT01621542|Experimental|WT2725|WT2725; injection
3139476|NCT01621490|Experimental|Part 1-Cohort 1 and 2: Nivolumab|Nivolumab 3 mg/kg solution intravenously Every 2 weeks, Up to 2 years depending on response
3139477|NCT01621490|Experimental|Part 2-Arm A: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
3139478|NCT01621490|Experimental|Part 3-Arm A: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
3139479|NCT01621490|Experimental|Part 3-Arm B: Nivolumab|Nivolumab 3 mg/kg solution intravenously as specified
3139480|NCT01621490|Experimental|Part 4-Arm D: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
3139481|NCT01621490|Experimental|Part 4-Arm E: Nivolumab|Nivolumab 3 mg/kg solution intravenously as specified
3139482|NCT01621477|Experimental|Treatment|"All study participants.~Interventions: clofarabine, cytarabine, busulfan, plerixafor, cyclophosphamide, antithymocyte globulin (rabbit), stem cells, tacrolimus, mycophenolate mofetil"
3139483|NCT01621464|Placebo Comparator|Control|Pacemaker implanted but NO pacing (mode DDI, 30 bpm and sub-threshold)
3139484|NCT01621464|Experimental|CLS group|pacemaker implanted programmed with the contractility sensor activated (mode DDD-CLS)
3139485|NCT01621451|Active Comparator|immediate|Patients who receive pantoprazole plus aspirin and/or clopidogrel within 3~4 days after EMR/ESD
3139486|NCT01621451|Active Comparator|2 weeks|Patients who receive pantoprazole plus aspirin and/or clopidogrel at 2 weeks after EMR/ESD
3139487|NCT01621425||TAC regimen|Female subject diagnosed with breast carcinoma and will receive docetaxel treatment according to standard hospital protocol
3139488|NCT01621425||PRODOC regimen|male subject diagnosed with metastatic castration-resistant prostate carcinoma and will receive docetaxel treatment according to standard hospital protocol
3139489|NCT01621399|Placebo Comparator|Vehicle|Treatment with the vehicle (placebo)
3139490|NCT01621399|Experimental|Product 55394|Treatment with product 55394
3139491|NCT01621386|Experimental|All Participants|Participants (male or female) that are between 18-65 years of age with a clinical diagnosis of asthma will take montelukast for 2 weeks (treatment period 1) and then take prednisone for 2 weeks (treatment period 2)
3139492|NCT01621373|Other|propofol|All patients receive propofol. Dose will be defined based on response of previous patient in the same stratum.
3139493|NCT01621360|Active Comparator|Arthroscopic surgery|Arthroscopic surgery of the hip plus optimized medical management
3139494|NCT01621360|Active Comparator|Conservative management|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
3139495|NCT01621334|Experimental|Motivational Enhancement Therapy|Motivational Enhancement Therapy
3139496|NCT01621334|Other|Educational brochure|Intimate Partner Violence, Substance Abuse, and HIV risky behaviors Education
3139497|NCT01621321|Experimental|Steroid group|
3139498|NCT01621321|Experimental|Voriconazole group|
3139499|NCT01621308||IP insulin|Patients treated with continuous intraperitoneal insulin infusion using a implantable pump
3139500|NCT01621308||SC insulin|Patients treated with subcutaneous insulin, both multiple daily injections and continuous subcutaneous insulin infusion
3139501|NCT01621282|Experimental|Education|Departments passed 6-month interactive educational course
3139502|NCT01621282|No Intervention|No Education|Departments not passed 6-month interactive educational course
3139503|NCT01621269|Experimental|Fingolimod|
3139504|NCT01621256|Experimental|Ancrod|Ancrod
3139505|NCT01621256|Placebo Comparator|Saline solution|Saline solution
3139506|NCT01621243|Placebo Comparator|nab-paclitaxel, gemcitabine, placebo|"Part A: Not applicable.~Part B: nab-paclitaxel, gemcitabine, and placebo. Placebo administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle."
3139507|NCT01621243|Experimental|nab-paclitaxel, gemcitabine, necuparanib|"Part A: Following a single-dose of necuparanib and a 7-day follow-up period, necuparanib was administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle. Dose escalation of necuparanib proceeded by cohort in a 3+3 design.~Part B: A fixed dose of necuparanib will be administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle."
3139508|NCT01621230|Active Comparator|Group II|Group II will receive a continuous infusion of fentanyl 10 mcg/cc at a basal infusion rate of 10 cc/hr with a patient-controlled epidural analgesia (PCEA) demand dose of 5 cc/hr for pain. Group II (like Group I) will receive meperidine 25 mg iv for breakthrough pain as needed.
3139509|NCT01621230|Placebo Comparator|Group I|Group I will receive bupivacaine plus fentanyl via epidural catheter during the second stage (i.e. 10 cm dilation) of labor via continuous epidural infusion of 10 cc/hr basal infusion plus 5 cc/hr demand dose via patient-controlled epidural analgesia (PCEA). Group I will be allowed to receive meperidine 25 mg iv q1 hour for breakthrough pain.
3139510|NCT01621217|Experimental|Cetuximab, Mitomycin C, Fluoruracil|
3139511|NCT01621204|Experimental|Eltrombopag|Eltrombopag is a small molecule, non-peptide thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. TPO receptor agonists are an effective new class of medications that are non-immunogenic agonists of the TPO receptor (c-Mpl) and work by increasing platelet production in ITP patients.
3139512|NCT01621204|Active Comparator|IVIG infusion|Intravenous immunoglobulin (IVIG) is used to rapidly increase platelet counts in ITP patients. IVIG is associated with a transient platelet count response in approximately 80% of patients, which occurs within 2 - 4 days. It is commonly used to improve platelet count numbers prior to surgery for patients with ITP.
3139513|NCT01621191|Experimental|60 mg Duloxetine|Duloxetine 20 milligrams (mg) taken orally once every day for 1 week, followed by 40 mg taken orally once every day for 1 week, and then 60 mg taken orally once every day for 48 weeks
3139514|NCT01621178|Active Comparator|Insulin glargine|Insulin glargine was administered subcutaneously (SC) at bedtime per a modified forced-titration treat-to-target algorithm. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
3270120|NCT00696891|Experimental|Group A|
3139515|NCT01621178|Experimental|0.75 mg Dulaglutide|0.75 milligram (mg) of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
3139516|NCT01621178|Experimental|1.5 mg Dulaglutide|1.5 mg of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
3139517|NCT01621165|Active Comparator|prazosin|Add prazosin to usual medications and monitor manic symptoms and for adverse effects
3139518|NCT01621165|Placebo Comparator|Placebo|
3139519|NCT01621152|Other|Conventional management arm|Patients with AKI receive standard of care in the conventional manner by the primary clinicians
3139520|NCT01621152|Active Comparator|AKI sniffer instigated AKI management|primary clinicians for the AKI patients in this arm receive a verbal alert and reminder of KDIGO guidelines.
3139521|NCT01621139|Experimental|Real acupuncture|Real acupuncture group
3139522|NCT01621139|Sham Comparator|Sham acupuncture|Sham acupuncture group
3139523|NCT01621126|Experimental|Intra-op neuromonitoring|
3139524|NCT01621113|Experimental|Locomotor Training + Dalfampridine|Subjects randomized to this group will undergo 10 weeks of double-blind treatment with extended release dalfampridine tablets (10 mg twice daily) while simultaneously receiving locomotor training therapy (5 sessions per week x 10 weeks = 50 sessions total).
3139525|NCT01621113|Placebo Comparator|Locomotor Training + Placebo|Subjects randomized to this group will undergo identical treatment, but will take placebo tablets while simultaneously receiving locomotor training therapy (5 sessions per week x 10 weeks = 50 sessions total).
3139526|NCT01621100|Experimental|OROS hydromorphone|Once-Daily OROS (Osmotic release oral system [a controlled release oral drug delivery system in the form of a tablet]) hydromorphone
3139527|NCT01621087|Experimental|Safflower oil|
3139528|NCT01621087|No Intervention|Control group (no diet instruction)|
3139529|NCT01621074|Active Comparator|Sodium bicarbonate|
3139530|NCT01621074|Placebo Comparator|Placebo|
3139531|NCT01621061||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension
3139532|NCT01621061||High altitude control|Healthy highlanders
3139533|NCT01621061||Low altitude control|Healthy lowlanders
3139534|NCT01621035||elderly (> 70 y)|
3139535|NCT01621022|Active Comparator|Active bupropion-Active gum|150 mg bupropion twice daily + 4 mg nicotine gum as needed (up to 12 pcs/day)
3139536|NCT01621022|Active Comparator|Active bupropion-Placebo gum|150mg bupropion twice daily + placebo gum as needed (up to 12 pcs/day)
3139537|NCT01621022|Active Comparator|Placebo medication-Placebo gum|Placebo bupropion, twice daily, plus placebo gum as needed (up to 12 pcs/day)
3139538|NCT01621009|Active Comparator|Active bupropion + counseling|Active bupropion SR plus eight 10-minute individual counseling sessions.
3139539|NCT01621009|Active Comparator|Active bupropion , No counseling|Active bupropion, No counseling, only medication checks
3139540|NCT01621009|Placebo Comparator|Placebo medication + counseling|Placebo bupropion plus eight 10-minute individual counseling sessions
3139541|NCT01621009|Placebo Comparator|Placebo medication, No counseling|Placebo bupropion, No counseling, just medication checks
3139542|NCT01620996|Active Comparator|1|Duffus Street Medical Centre
3139543|NCT01620996|Active Comparator|2|Sydney Family Practice
3139544|NCT01620996|No Intervention|no counseling|HRA assessment pre and post but no counselling
3139545|NCT01620983|Experimental|Pain Coping Skills Training|The pain coping skills training will be delivered by physical therapists in eight one-hour sessions by telephone over a 2-month perioperative period. Patients will be taught a variety of skills designed to improve maladaptive pain related thoughts and actions to enhance recovery following arthroplasty.
3139546|NCT01620983|Active Comparator|Arthritis Education|The eight one-hour perioperative arthritis education sessions will be delivered by nurse educators via telephone and will use a presentation and discussion format. Figures and discussion sessions will present information on the nature of arthritis, what to expect following knee arthroplasty, treatment of osteoarthritis, the role of exercise, joint protection and making future treatment decisions.
3139547|NCT01620983|Other|Usual Care|Patients randomly assigned to this arm will undergo usual care following knee arthroplasty.
3139548|NCT01620970|Experimental|PF03446962|Investigational study drug, administered intravenously every 2 weeks until disease progression or unacceptable toxicity.
3139549|NCT01620957||Coma patients|
3139550|NCT01620944|Experimental|Arm1: ATV/RTVHS+3TC|
3139551|NCT01620944|Active Comparator|Arm2: ATV/RTVHS+TDF/FTC|
3139552|NCT01620931|Experimental|RO5469754|
3139553|NCT01620931|Placebo Comparator|Placebo|
3139554|NCT01620918|Experimental|2 types of healing abutment|Patients who are in need of minimal 2 dental implants, who will receive both types of healing abutments.
3139555|NCT01620905|Experimental|Cervical spine manipulation|Subjects received cervical spine manipulation
3139556|NCT01620892||Unicondylar knee replacement|
3139557|NCT01620866|Experimental|EMDR|
3139558|NCT01620866|No Intervention|TAU|Treatment as usual (TAU)
3139559|NCT01620840||Lacosamid-i.v. treatment|
3139560|NCT01620827|Active Comparator|Hospital Landline|Subjects in this arm have all of their follow-up phone calls placed from a hospital landline number.
3139561|NCT01620827|Active Comparator|Private Cell Phone|Subjects in this arm have all of their follow-up phone calls placed from a private cell phone number.
3139562|NCT01620814|Experimental|Dinoprostone and misoprostol|"For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.~After drugs administration, cervical canal will be again evaluated with above mentioned way by bougie before hysteroscopy"
3139611|NCT01620541||Preference, Ankle Arthrodesis|
3139612|NCT01620541||Preference, Ankle Arthroplasty|
3270156|NCT00696657|Experimental|B|
3139563|NCT01620814|Experimental|Misoprostol and control|For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.
3139564|NCT01620814|Experimental|dinoprostone and control|For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.
3139565|NCT01620801|Experimental|Low dose|AAV8-hFIX19
3139566|NCT01620801|Experimental|Middle dose|AAV8-hFIX19
3139567|NCT01620801|Experimental|High dose|AAV8-hFIX19
3139568|NCT01620788|Experimental|Indapamide 1.5mg / Losartan 50mg|
3139569|NCT01620788|Experimental|Indapamide 1.5mg / Losartan 100mg|
3139570|NCT01620788|Active Comparator|Hyzaar® (Losartan 50mg/Hydrochlorothiazide12,5mg)|
3139571|NCT01620788|Active Comparator|Hyzaar® (Losartan 100mg/Hydrochlorothiazide 25mg)|
3139572|NCT01620775|Experimental|Knee osteoarthritis (MRI, surveys, pain testing)|Subjects previously diagnosed with knee osteoarthritis will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
3139573|NCT01620775|Active Comparator|Healthy controls (MRI, surveys,pain testing)|Healthy volunteers will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
3139574|NCT01620775|Experimental|diabetic peripheral neuropathy|Subjects previously diagnosed with diabetic peripheral neuropathy will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
3139575|NCT01620775|Experimental|chronic low back pain|Subjects previously diagnosed with chronic low back pain will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
3139576|NCT01620762|Experimental|Cat-Pad Treatment 1|Cat-PAD Treatment 1
3139577|NCT01620762|Experimental|Cat-PAD Treatment 2|Cat-PAD Treatment regimen 2
3139578|NCT01620762|Placebo Comparator|Placebo|Placebo
3139579|NCT01620749|Experimental|MEL050|
3139580|NCT01620736|Experimental|Raltegravir|Treatment with raltegravir for 8 wks
3139581|NCT01620723|Experimental|New breastfeeding programme|"The breastfeeding programme consists of four core elements:~breastfeeding is a parental task~skin to skin contact during the first three days~frequent breastfeeding at least 8 times a day~good positioning, preferable in a laid back position~Moreover communication was supposed to enhance breastfeeding self-efficacy, using Banduras theory of self-efficacy"
3139582|NCT01620723|Active Comparator|Treatment as usual|Breastfeeding counselling uses the national handbook of breastfeeding as reference
3139583|NCT01620710|Other|prostate bed|"irradiation of the prostatic bed only (no higher risk of lymph node recurrence); helical IMRT of the prostate bed (18 x 3 Gy)~This arm has already finished recruitment"
3139584|NCT01620710|Other|prostate bed & lymph nodes|irradiation of the prostatic bed and the pelvic lymphatic drainage (in patients with higher risk of lymph node recurrence); helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
3139585|NCT01620697||Perirenal fat|
3139586|NCT01620684|Active Comparator|metyrapone|Overnight metyrapone treatment (total dose of 30 mg/kg)
3139587|NCT01620684|Placebo Comparator|sugar pill|Overnight treatment with placebo capsules
3139588|NCT01620671|Active Comparator|Conventional surgery|The patients who will have a conventional surgical treatment will be included.
3139589|NCT01620671|Active Comparator|Fast-track surgery|The patients who will have fast-track surgery will be included.
3139590|NCT01620658|Active Comparator|standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
3139591|NCT01620658|Experimental|0.3mm XPF cap|Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.
3139592|NCT01620658|Experimental|0.5mm XPF cap|Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.
3139593|NCT01620645||COPD, GOLD II severity or above|
3139594|NCT01620632||Altered gastric anatomy|Patients who have an altered gastric who need an ERCP
3139595|NCT01620619|Active Comparator|Arthroscopic Bankart Repair & Rotator Interval Closure|
3139596|NCT01620619|Active Comparator|Arthoscopic Bankart Repair alone|
3139597|NCT01620606|Experimental|SLCBT|Social Learning and Cognitive Behavioral Therapy
3139598|NCT01620606|Experimental|SLCBT-R|Phone-based Social Learning and Cognitive Behavioral Therapy
3139599|NCT01620606|Active Comparator|ES|Education and Support
3139600|NCT01620593|Placebo Comparator|Placebo|Metabolic consequences including development of hyperinsulinemia and insulin resistance using metformin compared to placebo in men on castration therapy.
3139601|NCT01620593|Active Comparator|Metformin|Metabolic consequences including development of hyperinsulinemia and insulin resistance using metformin compared to placebo in men on castration therapy. In the rare case where a patient may not tolerate 500 mg three times a day, he may remain on the study taking only 500 mg twice a day.
3139602|NCT01620580|Active Comparator|Self Management Strategies|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3."
3139603|NCT01620580|Active Comparator|Dietary Information|Control arm
3139604|NCT01620567|Placebo Comparator|chickpeas/potatoes|
3139605|NCT01620567|Active Comparator|avocados|avocados
3139606|NCT01620554|Experimental|BF2.649 5mg|
3139607|NCT01620554|Experimental|BF2.649 10mg|
3139608|NCT01620554|Experimental|BF2.649 20mg|
3139609|NCT01620554|Experimental|BF2.649 40mg|
3139610|NCT01620554|Placebo Comparator|Placebo|
3139613|NCT01620528|Experimental|Elagolix Dose 1|Elagolix Dose 1
3139614|NCT01620528|Experimental|Elagolix Dose 2|Elagolix Dose 2
3139615|NCT01620528|Placebo Comparator|Placebo|Placebo
3139616|NCT01620515|No Intervention|Active Surveillance|Subjects with low risk localized (T1c) prostate cancer who are being followed with active surveillance and not undergoing active treatment for prostate cancer.
3139617|NCT01620515|Experimental|NX-1207 2.5 mg|
3139618|NCT01620515|Experimental|NX-1207 15 mg|
3139619|NCT01620502|Active Comparator|EPA 3.5 g/day|
3139620|NCT01620502|Placebo Comparator|Placebo capsules|oleic oil
3139621|NCT01620502|Experimental|DHA 1.75 g/day|DHA 1.75 g/day
3139622|NCT01620489|Experimental|Lira 1.8 mg|
3139623|NCT01620489|Placebo Comparator|Placebo|
3139624|NCT01620476|Experimental|5 mcg/kg|
3139625|NCT01620476|Experimental|10 mcg/kg|
3139626|NCT01620476|Experimental|15 mcg/kg|
3139627|NCT01620463|Experimental|NNC 90-1170|
3139628|NCT01620463|Placebo Comparator|Placebo|
3139629|NCT01620450|Experimental|NN2000|
3139630|NCT01620450|Active Comparator|NN-X14|
3139631|NCT01620437|Experimental|Formulation A|
3139632|NCT01620437|Experimental|Formulation B|
3139633|NCT01620424|Experimental|Dosing visit 1|
3139634|NCT01620424|Experimental|Dosing visit 2|
3139635|NCT01620411|Experimental|CMM|This arm will receive standard of care treatment for injuries sustained while on active duty. Non-Invasive.
3139636|NCT01620411|Experimental|CMM + SCS|This arm will combine comprehensive medical management with placement of a spinal cord stimulator.
3139637|NCT01620398|Experimental|BALANCE group|BALANCE Program is composed by 3 concepts: a) a diet composed of 50-60% of energy from carbohydrate, 10-15% of energy from protein; 25-35% of energy from fat (<7% saturated fatty acid; <10% polyunsaturated fatty acid; <20% monounsaturated fatty acid, <1% trans fatty acid), <200 mg/day of cholesterol, 20-30 g/day of fiber and <2400 mg/day of sodium; b) Nutrition education program based on ludic strategies and indication of affordable foods; c) An intense follow up by individual and group visits and phone calls.
3139638|NCT01620398|Active Comparator|Control Diet group|generalized advices to follow a low fat, low energy, low sodium and low cholesterol diet are given.
3139639|NCT01620385|Experimental|ciPDA|
3139640|NCT01620372||Treatment cohort (chemo/radiotherapy)|- those who have survived at least 5 years from the date of diagnosis
3139641|NCT01620372||Self-questionnaire cohort|- those with a complete address, who come of age, are still alive and sent back a signed consent agreement
3139642|NCT01620372||Medical Insurance cohort|- those who come of age and authorize the access to the medical facilities of the French Health Insurance Information System
3139643|NCT01620359|Experimental|ExAblate|
3139644|NCT01620346|Active Comparator|ICSI group|This group was provided with conventional intracytoplasmic sperm injection (ICSI). This treatment is routinely used to treat infertility. Sperm selection in the ICSI group is analysed under a magnification of 400x using an inverted microscope.
3139645|NCT01620346|Experimental|Intracytoplasmic morphologically selected sperm injection|Intracytoplasmic morphologically selected sperm injection (IMSI) is an established modified ICSI procedure. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
3139646|NCT01620333|Experimental|Treatment period 1|
3139647|NCT01620333|Experimental|Treatment period 2|
3139648|NCT01620320||Stress echography|Nine to twelve months after their left main angioplasty, patients will go through a stress echo and then the usual control angiography (done routinely in most patient in our center). Patients will act as their own control.
3139649|NCT01620307|Active Comparator|with Rapamune treatment|"All patients were treated with Oseltamivir (Tamiflu, Roche) 50 mg twice a day for 10 days and oral prednisolone 20 mg/day for 14 days. At ICU admission, patients started on empiric antimicrobial therapy with moxifloxacin 500 mg per day until results of microbiological studies were available.~Each patient received best support treatment including mechanical ventilator, fluid resuscitation, gastrointestinal and thromboembolic prophylaxis, and enteral nutrition for most aspects of care. After radomization, patients were received Sirolimus (Rapamune 2mg/day, Pfizer)for a course of 14 days."
3139650|NCT01620307|Placebo Comparator|Without Rapamune treatment.|"All patients were treated with Oseltamivir (Tamiflu, Roche) 50 mg twice a day for 10 days and oral prednisolone 20 mg/day for 14 days. At ICU admission, patients started on empiric antimicrobial therapy with moxifloxacin 500 mg per day until results of microbiological studies were available.~Each patient received best support treatment including mechanical ventilator, fluid resuscitation, gastrointestinal and thromboembolic prophylaxis, and enteral nutrition for most aspects of care. After radomization, patients were not to receive Sirolimus (Rapamune 2mg/day, Pfizer)for a course of 14 days."
3139651|NCT01620294|Experimental|triclosan|Two arms are separated by computer randomization at abdominal wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
3139652|NCT01620294|Experimental|uncoated|Two arms are separated by computer randomization at abdominal wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
3139653|NCT01620281|Experimental|Immediate treatment (IT)|Subjects from this group will receive the device immediately. Subjects will be instructed to treat themselves daily for 3 weeks, in up to three 10-minutes sessions. All subjects will receive a diary to record details of the daily use of the device (time of day, position of legs, and number of daily uses), degree of pain, a weekly ODI questionnaire, and record of any back/pain related events. After 3 weeks the subjects from the IT group will return the device and at 6 weeks they will visit again for the final evaluation.
3139654|NCT01620281|Other|Waiting List Control (WLC)|The WLC group will go through the same evaluations at the same time intervals but will begin treatments 3 weeks later during which they will fill the diary daily but not use the device.
3139655|NCT01620268|No Intervention|Control Group|Patients receive standard of care.
3139656|NCT01620268|Experimental|Treatment Group|Dose adjusted leflunomide plus 600 mg orotic acid.
3139657|NCT01620255|Placebo Comparator|Placebo|
3139658|NCT01620255|Experimental|Drug Dose Level 1|
3139659|NCT01620255|Experimental|Drug Dose Level 2|
3139660|NCT01620255|Experimental|Drug Dose Level 3|
3139661|NCT01620255|Experimental|Drug Dose Level 4|
3139662|NCT01620242|Experimental|Cabazitaxel|All patients are treated with Cabazitaxel.
3139663|NCT01620229|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV on day 1. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
3139664|NCT01620216|Experimental|Group I (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3139665|NCT01620216|Experimental|Group II (nilotinib)|Patients receive nilotinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3139666|NCT01620216|Experimental|Group III (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3139667|NCT01620216|Experimental|Group IV (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3139668|NCT01620216|Experimental|Group V (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3139669|NCT01620203||Control|Matched group of control infants without diagnosis of intracranial hemorrhage
3139670|NCT01620203||Intracranial Hemorrhage|Group of preterm infant with diagnosis of intracranial hemorrhage.
3139671|NCT01620190|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle formula)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3139672|NCT01620177|Experimental|0% THC with 0.065 g/dL BAC|
3139673|NCT01620177|Experimental|2.5-3.5% THC with 0.065 g/dL BAC|
3139674|NCT01620177|Experimental|6.0-7.5% THC and 0.065 g/dL BAC|
3139675|NCT01620177|Experimental|2.5-3.5% THC with 0 g/dL BAC|
3139676|NCT01620177|Experimental|6.0-7.5% THC with 0 g/dL BAC|
3139677|NCT01620177|Experimental|0% THC with 0 g/dL BAC|
3139678|NCT01620164|Other|Parkinsonian patients OFF/ON|9 patients will be evaluated with psychophysical measurements of 3D perception, in OFF then ON conditions
3139679|NCT01620164|Other|healthy subjects|Healthy subjects will be evaluated with psychophysical measurements of 3D perception, without treatment
3139680|NCT01620164|Other|Parkinsonian patients ON/OFF|9 patients will be evaluated with psychophysical measurements of 3D perception, in ON and then OFF conditions
3139681|NCT01620151|No Intervention|No extended neck|Patient will not undergo thyroid surgery with extended neck
3139682|NCT01620151|Experimental|Extended neck|Patients who undergoing thyroid surgeries are positioned with extended neck by using pillow under shoulder in order to facilitate neck exposure and make the surgery easier.
3139683|NCT01620138|Active Comparator|Pasireotide|"For non-cured patients with prolactinomas resistant to cabergoline, MRI will be performed immediately before and six months after the onset of pasireotide treatment. The anti-secretory effect will be evaluated by prolactin dosage every month.~For patients harboring a NFPA, treatment will be started at least 3 months after neurosurgery, when a pituitary MRI clearly shows the presence of a residual tumor without any possible misinterpretation of postsurgical changes. In this case, the drug efficacy will be evaluated clinically by visual field and by MRI six months after pasireotide treatment."
3139684|NCT01620138|Active Comparator|cabergoline|In patients with non-functioning pituitary adenoma, treatment will be started at least 3 months after neurosurgery, when a pituitary MRI clearly shows the presence of a residual tumor without any possible misinterpretation of postsurgical changes. The drug response will be evaluated clinically by visual field and by Magnetic resonance imaging (MRI) before medical treatment and after six months of cabergoline treatment at maximum dose.
3139685|NCT01620125|Other|Lactobacillus reuteri|Dietary supplementation with Lactobacillus reuteri DSM 17938
3139686|NCT01620112|Active Comparator|low clonidine concentration|clonidine concentration 1 ml on 40 ml of lidocaine 1.5% for upper brachial plexus
3139687|NCT01620112|Active Comparator|lidocaine 20 ml 1,5%|lidocaine 20 ml 1,5% without clonidine for axillary brachial plexus block for upper limb surgery
3139688|NCT01620112|Active Comparator|high clonidine concentration|clonidine concentration 150 mcg on 20 ml of lidocaine 1,5% for upper brachial plexus
3139689|NCT01620112|Active Comparator|40 ml lidocaine 1,5%|40 ml of lidocaine 1,5% without clonidine for upper brachial plexus
3139690|NCT01620099|Experimental|Asthmatic nonsmokers|Asthmatic patients aged 18-50 years old, at stage 2-3 according to GINA international guidelines, on inhaled treatment (ICS alone or combination ICS/LABA) other than extrafine formulations, will be enrolled. This group includes patients who never smoked. Following the initial evaluation (cross-sectional - primary outcome) patients will be switched to an extrafine equipotent dose of the same compound (BDP-HFA if the patient was on ICS) or combination (BDP-HFA/F if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
3139691|NCT01620099|Active Comparator|Asthmatic smokers|Asthmatic patients aged 18-50 years old, at stage 2-3 according to GINA international guidelines, on inhaled treatment (ICS alone or combination ICS/LABA) other than extrafine formulations, will be enrolled. This group includes patients who smoked with a smoking habit ranging from 10 to 20 pack/years. Following the initial evaluation (cross-sectional - primary outcome) patients will be switched to an extrafine equipotent dose of the same compound (BDP-HFA if the patient was on ICS) or combination (BDP-HFA/F if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
3139692|NCT01620086|Experimental|Patients|Patients with Schizophrenia who meet entry criteria for the study and first receive active repetitive transcranial magnetic stimulation for four days over a control site located at the vertex and then are randomized to receive repetitive Transcranial Magnetic Stimulation for four days over the temporal cortex at both 1 Hz and 10 Hz.
3139693|NCT01620086|Experimental|Controls|These subjects are normal controls without schizophrenia who receive sham, repetitive transcranial magnetic stimulation at 1 Hz for two days and then receive active, repetitive Transcranial Magnetic stimulation for two days. All stimulation is delivered at the control site located over the vertex.
3139694|NCT01620073|Other|Partner friendly arm|Proportion of males counseled and tested using routine standards of prenatal care
3139695|NCT01620073|Experimental|Home based arm|Proportion of male partners accepting HIV counseling and testing following home visits for couple HIV counseling and testing during pregnancy
3139696|NCT01620060|Experimental|Lurasidone oral tablets|Lurasidone 20, 40, 80, 120 or 160 mg/day
3139697|NCT01620047|Experimental|Femoral Nerve Fentanyl|Fentanyl 3 µg/ml delivered continuously through a femoral nerve sheath catheter for 24 hours post-total knee replacement. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
3139698|NCT01620047|Active Comparator|Femoral Nerve Ropivacaine|Ropivacaine 0.1% continuously delivered through a femoral nerve sheath catheter for 24 hours post-total knee replacement. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
3139699|NCT01620047|Placebo Comparator|Intravenous Fentanyl with placebo|Control group which received 0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
3139700|NCT01620034|Active Comparator|11 Day Arm|
3139701|NCT01620034|Experimental|4 Day Arm|
3139702|NCT01620021||Healthy|Ten healthy volunteers with no history of gait and balance issues will be recruited to participate in the study.The participants must be between 18 and 65 years of age.
3139703|NCT01620008|No Intervention|Immediate Cord Clamping (ICC)|The infant will be placed on the maternal abdomen and the umbilical cord will be clamped immediately after birth (routine care).
3139704|NCT01620008|Experimental|Delayed Cord Clamping (DCC)|At birth, infants will be placed on the maternal abdomen and the cord clamping will be delayed for 5 minutes. If the provider is unable to delay the cord clamping, the cord will be milked 5 times.
3139705|NCT01619982|Active Comparator|Cefazolin 25 mg/kg body weight and vancomycin|"All infants < 1 year of age with congenital heart diseases requiring cardiac surgery with cardiopulmonary bypass or any patient who requires surgery involving the aorta or the aortic valve will receive both Cefazolin and Vancomycin as preoperative prophylaxis against Surgical Site Infections. This has been recommended in recently published guidelines but not evaluated in children.~Intervention: Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride 15 mg/kg body weight"
3139706|NCT01619982|Other|Cefazolin only 30mg/kg body weight|All infants less than one year of age with congenital heart diseases requiring cardiac surgery with cardiopulmonary bypass or all patients who required surgery involving the aorta or the aortic valve received cefazolin 30 mg/kg body weight as preoperative prophylaxis against surgical site infections
3139707|NCT01619969|Experimental|Celgosivir|
3139708|NCT01619969|Placebo Comparator|Placebo|
3139709|NCT01619956|Experimental|OSFE with grafting|OSFE with grafting (autogenous bone chips+xenograft material with a ratio of 1:4)
3139710|NCT01619956|Active Comparator|OSFE without grafting|OSFE without grafting. No grafting materials or autogenous bone chips were used.
3139711|NCT01619943||Patients with minor head injury|MHI is defined as a blunt trauma to the head within 24 hours with a Glasgow Coma Scale (GCS) score of 13 to 15 and at least one of the following: history of loss of consciousness, short-term memory deficit, amnesia for the traumatic event, post-traumatic seizure, vomiting, headache, external evidence of injury above the clavicles, confusion, and neurologic deficit.
3139712|NCT01619930|Experimental|1a|"In phase 1, group 1 undergoes physical activation without added motivation interviewing. Post-treatment (phase 2), group 1 is divided by randomization into group 1a and 1b, where 1a receives relapse prevention and 1b does not. Both 1a and 1b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 1 + 12 from waiting list control group)"
3139713|NCT01619930|Experimental|1b|"In phase 1, group 1 undergoes physical activation without added motivation interviewing. Post-treatment (phase 2), group 1 is divided by randomization into group 1a and 1b, where 1a receives relapse prevention and 1b does not. Both 1a and 1b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 1 + 12 from waiting list control group)"
3139714|NCT01619930|Experimental|2a|"In phase 1, group 2 undergoes physical activation with added motivation interviewing. Post-treatment (phase 2), group 2 is divided by randomization into group 2a and 2b, where 2a receives relapse prevention and 2b does not. Both 2a and 2b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 2 + 12 from waiting list control group)"
3139715|NCT01619930|Experimental|2b|"In phase 1, group 2 undergoes physical activation with added motivation interviewing. Post-treatment (phase 2), group 2 is divided by randomization into group 2a and 2b, where 2a receives relapse prevention and 2b does not. Both 2a and 2b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 2 + 12 from waiting list control group)"
3139716|NCT01619930|Experimental|3a|"In phase 1, group 3 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 3 is divided by randomization into group 3a and 3b, where 3a receives relapse prevention and 3b does not. Both 3a and 3b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 3 + 12 from waiting list control group)"
3139717|NCT01619930|Experimental|3b|"In phase 1, group 3 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 3 is divided by randomization into group 3a and 3b, where 3a receives relapse prevention and 3b does not. Both 3a and 3b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 3 + 12 from waiting list control group)"
3139718|NCT01619930|Experimental|4a|"In phase 1, group 4 undergoes behavioral activation without added motivation interviewing. Post-treatment (phase 2), group 4 is divided by randomization into group 4a and 4b, where 4a receives relapse prevention and 4b does not. Both 4a and 4b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 4 + 12 from waiting list control group)"
3139719|NCT01619930|Experimental|4b|"In phase 1, group 4 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 4 is divided by randomization into group 4a and 4b, where 4a receives relapse prevention and 4b does not. Both 4a and 4b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 4 + 12 from waiting list control group)"
3270157|NCT00696657|Experimental|C|
3139720|NCT01619930|No Intervention|Phase 1 Waiting list control group|Control group during phase 1, in parallel with treatment groups 1-4. Weekly self-report measurements, the results of which are conveyed in the form of individualized feedback. After 12 weeks, the participants of the control group (n = 100) are randomized to one four phase 1 active treatment groups (1-4) and receive treatment accordingly.
3139721|NCT01619917|Active Comparator|Proximal|location of the scar proximal to heart
3139722|NCT01619917|Experimental|Distal|location of scar distal to heart
3139723|NCT01619904|Experimental|Goal-Directed Therapy|
3139724|NCT01619904|Active Comparator|Standard Therapy|
3139725|NCT01619891|Active Comparator|Vitamin D|Vitamin D 100mcg per day
3139726|NCT01619891|Placebo Comparator|Placebo|Standard optimal therapy
3139727|NCT01619878|Experimental|Cohort 1|"One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.~Infants age >28 days."
3139728|NCT01619865|Experimental|68Ga-DOTATOC PET/CT|68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors
3139729|NCT01619852|Active Comparator|Group L|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
3139730|NCT01619852|Placebo Comparator|.9% normal saline placebo|.9% normal saline administered as a bolus then as a maintenance infusion for the length of the surgical case.
3139731|NCT01619839|Experimental|100 mg NKTR-181|100 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days.
3139732|NCT01619839|Experimental|200 mg NKTR-181|200 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days.
3139733|NCT01619839|Experimental|300 mg NKTR-181|300 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days
3139734|NCT01619839|Experimental|400 mg NKTR-181|400 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days
3139735|NCT01619839|Placebo Comparator|Placebo|Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181.
3139736|NCT01619826|Experimental|Treatment Group|Participants randomized to the physical activity-based afterschool intervention
3139737|NCT01619826|Placebo Comparator|Wait List Group|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
3139738|NCT01619813|Active Comparator|Docetaxel, Reolysin and Prednisone|
3139739|NCT01619813|Active Comparator|Docetaxel and Prednisone|
3139740|NCT01619800|Experimental|Blended Sensor Optimization (BSO)|Patients in this arm will undergo pacemaker placement and will have blended sensor optimization. Minute Ventilation will be optimized/activated
3139741|NCT01619800|Sham Comparator|Accelerometer Alone (AA)|Patients in this arm will undergo pacemaker implantation but will not have Minute Ventilation Sensor activated. Only accelerometer will remain active
3139742|NCT01619774|Experimental|GSK2118436 + GSK1120212|GSK1120212 2 mg by mouth once a day, and GSK2118436 150 mg by mouth 2 times every day (1 time in the morning and 1 time in the evening, about 12 hours apart).
3139743|NCT01619761|Experimental|CB NK + Chemotherapy|"Lenalidomide 10 mg by mouth day -8 to -2. Fludarabine 40 mg/m2 intravenous (IV) from day -7 to -4. Melphalan 140 mg/m2 IV on day -4. The NK cell infusion administered intravenously on day -2 over a period of 30 minutes. The NK dose infused will be 5x 10^6/kg. Remaining cells discarded if not needed for laboratory studies. On Day 0, unmanipulated products (smaller cord blood unit and remnant of the larger unit) infused. Tacrolimus 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no GvHD is present. Mycophenolate mofetil 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth Days -3 to Day +100 in the absence of GvHD.~CD20 positive participants admitted to hospital on day -9 to start hydration, receive rituximab 375 mg/m2 by vein on day -8, receive the designated preparative regimen on days -8 through -4. CD20 negative participants will not receive rituximab and admitted on day -8."
3139744|NCT01619748||Untreated OSA patients|Patients with obstructive sleep apnoea who are untreated
3139745|NCT01619748||OSA patients highly compliant with CPAP|OSA patients established on CPAP therapy (high compliance, > 80% nightly use for ≥ 4 h per night)
3139746|NCT01619748||OSA patients poorly compliant with CPAP|OSA patients established on CPAP therapy (poor compliance, 10% < nightly use < 50% or < 4 h per night)
3139747|NCT01619748||Age and BMI-matched controls|Age and BMI-matched controls without OSA
3139748|NCT01619735||Fragments basketed|"Active extraction is whereby the ureteroscope is passed back and forth into the kidney to remove all visible stone fragments."
3139749|NCT01619735||Fragments dusted|"Dusting is whereby the stones are broken into tiny fragments or dust with the intention that achieving such a small stone size will allow the stones to pass spontaneously."
3139750|NCT01619709|Other|lobar hemorrhage group|PET AV-45 in patients with cortical or corticosubcortical hemorrhage (involving predominantly the cortex and underlying white matter)
3139751|NCT01619709|Other|deep hemorrhage group|PET AV-45patients with subcortical hemorrhage (involving predominately the basal ganglia, periventricular white matter, or internal capsule).
3139752|NCT01619696|Experimental|Intervention|
3139753|NCT01619683|Experimental|Androxal|
3139754|NCT01619683|Placebo Comparator|Placebo|
3139755|NCT01619670|No Intervention|no intervention|standard wound care
3139756|NCT01619670|Active Comparator|Apligraf|non adhesive layer with apligraf
3139757|NCT01619657|Experimental|Hypertonic Saline|Inhalation with 6% Hypertonic Saline twice daily over 1 year
3139758|NCT01619657|Active Comparator|Isotonic Saline|Inhalation with 0.9% Isotonic Saline twice daily over 1 year
3139759|NCT01619644|Experimental|Sodium Valproate|Group of 40 patients receiving one year of sodium valproate
3139760|NCT01619644|Placebo Comparator|Placebo|Group of 20 patients receiving one year of placebo
3139761|NCT01619631|Experimental|12-week Tai Chi intervention|
3139762|NCT01619631|Active Comparator|Education control group|After 24 weeks, and upon completion of the study, each participant will be offered twelve weeks of Tai Chi twice weekly.
3139763|NCT01619631|No Intervention|Waitlist control group|The waitlist control will not receive any intervention during the duration of the study. After 24 weeks, and upon completion of the study, each participant will be offered twelve weeks of Tai Chi twice weekly.
3139764|NCT01619605|Experimental|Shrim|
3139765|NCT01619592|Active Comparator|Intervention group|webbased education (telemonitoring)
3139766|NCT01619592|No Intervention|control group|standard care
3139767|NCT01619579|Experimental|Treatment|Subjects with Fibromyalgia undergo twice daily use of the non-invasive device for 4 weeks.
3139768|NCT01619566|No Intervention|Control|Control subjects undergo a skin biopsy.
3139769|NCT01619566|Experimental|Treatment|Subjects in the treatment arm also undergo a skin biopsy, followed by 8 week treatment with Duloxetine.
3139770|NCT01619553||affected|individuals with keloids
3139771|NCT01619553||unaffected|unrelated unaffected controls or unaffected family members
3139772|NCT01619540|Other|acute heart failure|control arm
3139773|NCT01619540|Experimental|COPD exacerbation|COPD exacerbation
3139774|NCT01619527|Experimental|Treatment A|Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fasted condition)
3139775|NCT01619527|Experimental|Treatment B|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fasted condition).
3139776|NCT01619527|Experimental|Treatment C|Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fed condition - standardized breakfast).
3139777|NCT01619527|Experimental|Treatment D|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - standardized breakfast).
3139778|NCT01619527|Experimental|Treatment E|Single-dose co-administration of the fixed dose combination darunavir/cobicistat 800/150-mg (under fasted condition).
3139779|NCT01619527|Experimental|Treatment F|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - high-fat breakfast).
3139780|NCT01619488|Experimental|Gastric Banding|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
3139781|NCT01619475||Prospective|Individuals approved as liver donors and recipients shortly Pre-donation/Pre-transplant at the study sites.
3139782|NCT01619475||Long-Term Follow-up|"Donors and recipients enrolled in the original A2ALL Cohort study.~Donors and LDLT recipients whose donation/transplant occurred during the period of time that began with the end of enrollment into the original Cohort study (Aug. 31, 2009) and ended with the opening of the enrollment in the current core protocol; this is referred to as the Gap Era.~LDLT recipients and donors who were not in the original Cohort study or from the Gap Era will enter the study at time proximate to time of living donation."
3139783|NCT01619475||HCV-Infected Liver Transplant Recipients|Male and female HCV-infected adult liver transplant recipients from those enrolled in the A2ALL-1 Cohort study and from those concurrently transplanted at the new A2ALL-2 centers (University of Toronto, University of Pittsburgh, Lahey Clinic).
3139784|NCT01619462|Other|Synflorix or PCV10|130 children will receive Synflorix at 1-2-3 months
3139785|NCT01619462|Other|Prevenar 13|130 children will receive Prevenar 13 at 1-2-3 months
3139786|NCT01619449|Experimental|Renal replacement therapy|Liver transplant recipients who receive continuous renal replacement therapy intra-operatively.
3139787|NCT01619449|Active Comparator|No CRRT|This arm consists of standard of care without CRRT in the OR for OLT
3139788|NCT01619436|Active Comparator|clonidine|clonidine 2 mg/kg IV
3139789|NCT01619436|Placebo Comparator|ringer lactato 1 ml|Ringer lactato 1 ml IV as Placebo
3139790|NCT01619423|Active Comparator|FOLFOX6 + PledOx 2 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
3139791|NCT01619423|Active Comparator|FOLFOX6 + PledOx 5 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
3139792|NCT01619423|Active Comparator|FOLFOX6 + PledOx 10 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
3139793|NCT01619423|Placebo Comparator|FOLFOX6 + 0,9% NaCl|Placebo= 0.9% NaCl; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
3139794|NCT01619410|Active Comparator|linezolid|
3139795|NCT01619410|Active Comparator|Clindamycin|
3139796|NCT01619397|Other|Condom|Test condom with new Xanthan gum condom coating
3139797|NCT01619384|No Intervention|Treatment as Usual|Usual VA care
3139798|NCT01619384|Experimental|MBSR|participation in an 8-week stress reduction course (mindfulness-based stress reduction)
3139799|NCT01619371||Lactating women|Lactating women willing to use a breast pump.
3139800|NCT01619345|Experimental|Period 1: NN9924 with 50 mL water|
3139801|NCT01619345|Experimental|Period 2: NN9924 with 240 mL water|
3139802|NCT01619332|Experimental|LEZ763|Part I- Healthy volunteers enrolled into 6 single-ascending dose cohorts Part II- Healthy volunteers enrolled into 5 multiple-ascending dose cohorts. Part III- LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
3139803|NCT01619332|Placebo Comparator|Placebo|Part I : Healthy volunteers enrolled in 6 single ascending dose cohorts to receive matching placebo of LEZ763. Part II: Healthy volunteers enrolled in 5 multiple ascending dose cohorts to receive matching placebo of LEZ763. Part III- Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
3139804|NCT01619332|Active Comparator|Sitagliptin|Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
3139805|NCT01619319|Experimental|Cognitive Remediation Therapy|A computerised cognitive remediation intervention called the Brain Fitness program is compared against a placebo intervention consisting of computer games
3139806|NCT01619319|Active Comparator|computer games|computer games
3139807|NCT01619293||Epidural H.|patients with hematoma epidurale
3139808|NCT01619293||Subdural H.|patients with hematoma subdurale
3139809|NCT01619293||Subarachnoidal H.|patients with hematoma subarachnoidale
3139810|NCT01619293||Intracerebral H.|patients with hematoma intracerebrale
3139811|NCT01619293||E. cerebri|patients with edema cerebri
3139812|NCT01619293||Concussion|patients with concussion
3139813|NCT01619280|Experimental|Nebulized sodium nitroprusside|
3139814|NCT01619267||device associated infection|patients with proven device associated infection
3139815|NCT01619267||control group|patients without device associated infection
3139816|NCT01619254|Experimental|Hand hygiene|Hand washing with soap measures will be carried out as an intervention activity
3139817|NCT01619254|Experimental|Hand finger nail hygiene|Hand finger nail clipping activities
3139818|NCT01619254|Experimental|Hand and finger nails hygiene|Both hand washing with soap and hand finger nail clipping activities will be implemented
3139819|NCT01619254|Placebo Comparator|Customary practice|No hand washing with soap and nail clipping activities. House holds and children assigned to the control group will not have the interventions (hand washing with soap and nail clipping activities)
3139820|NCT01619241||advanced non-small cell lung cancer|
3139821|NCT01619228|Experimental|Vitamin B3 (nicotinamide)|The assigned leg will be treated with a solution of Vitamin B3 (nicotinamide) in sterile water once a day for 14 consecutive days in an amount not to exceed 6 milligrams of Vitamin B3 (nicotinamide) per kilogram of body weight per day.
3139822|NCT01619228|No Intervention|untreated|The contralateral site (leg) will not be treated.
3139823|NCT01619215||Bariatric Surgery|As the number of patients dropping out during follow-up, we had difficulty achieving our secondary outcomes, and so the team decided to continue the recruitment until all our outcomes are reached. Main part of the primary outcomes is finalised and published The effects of bariatric surgeries on nonalcoholic fatty liver disease. Aldoheyan T, Hassanain M, Al-Mulhim A, Al-Sabhan A, Al-Amro S, Bamehriz F, Al-Khalidi H. Surg Endosc. 2016 Jul 12
3139824|NCT01619202|Experimental|Risk Anticipation-Perception Training|Complete the Risk Anticipation-Perception Training (RAPT) program
3139825|NCT01619202|No Intervention|No training program|Does not complete the Risk Anticipation-Perception Training (RAPT) program
3139826|NCT01619176|Experimental|Acupuncture|Acupuncture plus conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)
3139827|NCT01619176|Active Comparator|Control|Conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)
3139828|NCT01619163|Experimental|prednisolone|
3139829|NCT01619163|Placebo Comparator|Placebo|
3139830|NCT01619150|Other|Etoricoxib, followed by placebo|4 weeks of treatment with etoricoxib, followed by a wash out period of at least 6 days, followed by another 4 weeks of treatment with placebo.
3139831|NCT01619150|Other|Placebo, followed by etoricoxib|4 weeks of treatment with placebo, followed by a wash out period of at least 6 days, followed by another 4 weeks of treatment with etoricoxib.
3139832|NCT01619137|Active Comparator|Povidone-iodine And normal salin|40 patients with complaint of ununion wound of laparatomy or episiotomy coming to Gynecologist`s office or hospital enrolled to this study randomly recieve Povidone-iodine And normal salin treatment.
3139833|NCT01619137|Active Comparator|water and soap|40 patients coming to Gynecologist`s offices or hospital with complaint of ununion wound of laparatomy or episiotomy in Bandarabbas enrolled to this study and randomly recieve water and soap to irrigation of the wound (it`s not require to be at hospital), washing is for each 6-8 hours per day. and if not difference seen after 4 day, treatment change to Povidone-iodine And normal salin.
3139834|NCT01619111|Active Comparator|standard therapy|standard chemo- or endocrine therapy
3139835|NCT01619111|Experimental|standard therapy + lapatinib|standard chemo- or endocrine therapy + lapatinib
3139836|NCT01619098|Experimental|Patient Navigator|Hospital-based Patient Navigator (a bilingual community health worker) engaged in discharge planning and made outreach phone calls to patients for 30 days after discharge and assisted patints with follow-up appointments, obtaining and taking medications, transportation, financial barriers, and linkages to community resources
3139837|NCT01619098|No Intervention|Usual Care|Home care plan at discharge, outreach phone call from RN at patient's primary care clinic
3139838|NCT01619085|Experimental|BIBF 1120|patient to receive a capsule containing BIBF 1120 twice a day
3139839|NCT01619072|Active Comparator|Misoprostol|800 mcg sublingual misoprostol + referral to higher level care
3139840|NCT01619072|Placebo Comparator|Placebo|Placebo + referral to higher level care
3139841|NCT01619059|Experimental|Arm 1: Saxagliptin+Dapagliflozin+Metformin IR|
3139842|NCT01619059|Experimental|Arm 2: Placebo+Dapagliflozin+Metformin IR|
3139843|NCT01619046|Active Comparator|PK substudy|A cohort of 13-18 subjects will be included in the pharmacokinetic (PK) evaluation of GreenGene™ F and an approved recombinant Factor VIII product (Refacto AF); a minimum of 13 of these subjects will be re-evaluated at study end (50 exposure day).
3139844|NCT01619046|Experimental|Prophylaxis safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over ≥ 50 exposure days.
3139845|NCT01619046|Experimental|On-demand safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during 50 exposure days.
3139846|NCT01619046|Experimental|Surgical substudy|Peri-operative hemostatic control of GreenGene™ F in surgery or invasive procedures will be assessed in at least 10 surgeries, some of them major, in at least five subjects
3139847|NCT01619033|Experimental|impaired renal function subjects|impaired renal function subjects
3139848|NCT01619033|Other|Healthy volunteers|matched with impaired renal function subjects on ethnic group, sex, age (+/- 5 years), and BMI (+/- 20%)
3139849|NCT01619020|Active Comparator|Flaxseed Lignans|Capsules
3139850|NCT01619020|Placebo Comparator|Placebo|Capsules
3139851|NCT01619007||Group 1|
3139852|NCT01619007||Group 2|
3139853|NCT01618994||Expert Surgeons|Gynecologic robotic surgeons, each averaging >75 robotic cases per year
3139854|NCT01618994||Study Surgeons|Gynecologic surgeons who are completely naive to robotics
3139855|NCT01618994||Control Surgeons|Gynecologic surgeons with full robotic privileges but were not averaging more than 2 cases a month and had never used the simulator
3139856|NCT01618981|Experimental|first active|
3139857|NCT01618981|Experimental|first inactive|
3139858|NCT01618968|Experimental|10 mg Methotrexate (MTX)|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
3139859|NCT01618968|Experimental|15 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
3139860|NCT01618968|Experimental|20 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
3139861|NCT01618968|Experimental|25 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
3139862|NCT01618955|Active Comparator|VIBEX MTX|VIBEX MTX dose based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status
3139863|NCT01618942|Experimental|male subjects|grouped by gender and applied pressure pain test
3139864|NCT01618942|Experimental|female subjects|grouped by gender and applied pressure pain test
3139865|NCT01618929|Active Comparator|asthma with food allergy|The study will be performed in 2 groups of patients (Patients with and without food allergy) parallel to each other at the same time and within each group the patients will take montelukast and placebo (one after another in a double-blind design).
3139866|NCT01618929|Active Comparator|asthma without food allergy|The study will be performed in 2 groups of patients (Patients with and without food allergy) parallel to each other at the same time and within each group the patients will take montelukast and placebo (one after another in a double-blind design)
3139867|NCT01618916|Experimental|1.0 mg/kg LY3015014 Every 2 Weeks|1.0 milligrams per kilogram (mg/kg) LY3015014 given subcutaneously (SQ) once every 2 weeks for 29 days.
3139868|NCT01618916|Experimental|1.0 mg/kg LY3015014 Every 4 Weeks|1.0 mg/kg LY3015014 given SQ once every 4 weeks for 29 days.
3139869|NCT01618916|Experimental|3.0 mg/kg LY3015014 Every 2 Weeks|3.0 mg/kg LY3015014 given SQ once every 2 weeks for 29 days.
3139870|NCT01618916|Experimental|3.0 mg/kg LY3015014 Every 4 Weeks|3.0 mg/kg LY3015014 given SQ once every 4 weeks for 29 days.
3139871|NCT01618916|Placebo Comparator|Placebo Every 2 Weeks|Saline injection (to match LY3015014) given SQ once every 2 weeks for 29 days.
3139872|NCT01618916|Placebo Comparator|Placebo Every 4 Weeks|Saline injection (to match LY3015014) given SQ once every 4 weeks for 29 days.
3139873|NCT01618903|Experimental|Levetiracetam iv infusion|Levetiracetam intravenous (iv) 45 min infusion administered as one single dose.
3139874|NCT01618903|Experimental|Levetiracetam oral tablet|Levetiracetam oral tablet administered as one single dose.
3139875|NCT01618890|Experimental|HVPG-propranolol arm|"A baseline hepatic venous pressure gradient measurement (HVPG measurement) is performed in day-care setting. After this procedure propranolol is started at 20 mg BID. with dose escalation as described in the propranolol arm.~A second HVPG measurement is performed at 4 weeks after adequate propranolol therapy. In patients who reach target HVPG reduction (responders), propranolol is continued at the same dose without routine control endoscopy. In patients who do not reach target HVPG reduction (nonresponders), endoscopic band ligation is performed in day-care setting with intervals of 2-4 weeks until complete obliteration of varices. Follow-up endoscopy with 6 months interval is performed to detect and treat recurrent large varices."
3139876|NCT01618890|No Intervention|Propranolol arm|Propranolol start 20 mg BID. orally with dose escalation based on heart frequency (HF) with 3-days interval to the maximum tolerated dose. No routine control endoscopy is required.
3139877|NCT01618877|Experimental|Levetiracetam iv infusion|Levetiracetam intravenous (iv) infusion.
3139878|NCT01618877|Placebo Comparator|Placebo infusion|
3139879|NCT01618864|Other|Luxe|
3139880|NCT01618851|Experimental|IMRT with SBRT Boost|Patients with clinically localized prostate cancer will be treated with three radiosurgical treatments (6.5 Gy per fraction to PTV) followed by IMRT (45 Gy in 25 fractions) over 6-7 weeks.
3139881|NCT01618838|Other|CyberKnife Radiosurgery, Colonoscopy|CyberKnife radiosurgery for prostate cancer; bowel toxicity will be evaluated at 2 years by colonoscopy (lower endoscopy).
3139882|NCT01618825|Active Comparator|LAMICTAL®|Lamictal® (Lamotrigine) Tablets 25 mg of GlaxoSmithkline, USA
3139883|NCT01618825|Experimental|Lamotrigine Tablets 25 mg|Lamotrigine Tablets 25 mg of M/s Ipca Laboratories Limited, India
3139884|NCT01618812||Pes plano valgus|Children with painful flatfeet
3139885|NCT01618799|Active Comparator|LAMICTAL®|Lamictal® (Lamotrigine) Tablets 25 mg of GlaxoSmithkline, USA
3139886|NCT01618799|Experimental|Lamotrigine Tablets 25 mg|Lamotrigine Tablets 25 mg of M/s Ipca Laboratories Limited, India
3139887|NCT01618786|Experimental|Compliant Flooring (CF)|Compliant flooring
3139888|NCT01618786|Placebo Comparator|Control (CON)|Non-compliant flooring
3139889|NCT01618760|Experimental|Risperidone Tablet 1 mg|Risperidone Tablet 1 mg of M/s Ipca Laboratories Limited, India
3139890|NCT01618760|Active Comparator|Risperdal®|Risperdal® (Risperidone) Tablet 1 mg of Janssen Pharmaceutica Products, USA
3139891|NCT01618747||Cohort|
3139892|NCT01618734||Romiplostim and eltrombopag in ITP|ITP patients who received alternatively romiplostim or eltrombopag with at least two months of follow-up for each period.
3139893|NCT01618708|Experimental|Synvisc-One|Single intraarticular (IA) injection of Synvisc-One (48 mg of Hylan G-F 20 polymer) at Day 1. Participants were observed for 26 weeks in follow up period.
3139894|NCT01618708|Placebo Comparator|Placebo|Single IA injection of placebo matched to Synvisc-One at Day 1. Participants were observed for 26 weeks in follow up period.
3139895|NCT01618695|Experimental|Perampanel|
3139896|NCT01618695|Placebo Comparator|Placebo|
3139897|NCT01618682||Hand Transplant Patients|These will be subjects who have undergone a hand transplant.
3139898|NCT01618682||Hand Replant Patients|These will be patients who have undergone a hand replant procedure.
3139899|NCT01618669|Experimental|Regadenoson After Peak Exercise|On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
3139943|NCT01618370|Experimental|Radium-223 dichloride|
3139900|NCT01618669|Active Comparator|Regadenoson Alone|On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus (1 hour after exercise recovery), and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
3139901|NCT01618656|Active Comparator|PF-04457845|2/3 of subjects will be randomized to fatty acid amide hydrolase (FAAH) inhibitor 4mg
3139902|NCT01618656|Placebo Comparator|Placebo (sugar pill)|1/3 of subjects will be randomized to placebo
3139903|NCT01618643||Acetic acid chromoendoscopy|"Patients with known Barrett's metaplasia under surveillance~Patients with Barrett's metaplasia who had undergone endoscopic treatment for neoplasia previously and were under surveillance for metachronous neoplasia~Patients suspected of neoplasia referred for endoscopic mucosal resection or other targeted endoscopic treatment of the lesion"
3139904|NCT01618630|Active Comparator|Amino acids|Amino acid supplementation for six weeks
3139905|NCT01618630|Placebo Comparator|Placebo|Supplementation of placebo (inert components) for six weeks
3139906|NCT01618617|Experimental|Probiotic, high dose|High dose Multistrain probiotic, 100 billion cfu/day
3139907|NCT01618617|Experimental|Probiotic, low dose|Low dose Multistrain probiotic, 15 billion cfu/day
3139908|NCT01618617|Placebo Comparator|Placebo|Placebo
3139909|NCT01618604||Healthy|26 healthy voluntary probands
3139910|NCT01618591|Experimental|Acute Watery Diarrhea|
3139911|NCT01618591|Experimental|Acute Dysentery/Febrile|
3139912|NCT01618578||Patients with CRPS|24 patients with CRPS of the upper limb type 1 were included into the study.
3139913|NCT01618578||Patients with unilateral upper limb pain|21 patients with unilateral upper limb pain served as controls.
3139914|NCT01618578||healthy subjects|24 healthy subjects were age- and sex matched to patients with CRPS.
3139915|NCT01618565|Experimental|Hands-On Training|30 minutes hands-on training of maneuvers to manage shoulder dystocia
3139916|NCT01618565|Active Comparator|Demonstration|30 minutes passive training by watching an expert instructor explain and perform maneuvers to manage shoulder dystocia
3139917|NCT01618552|Experimental|SEE IT training (interviewing skills)|Intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) with patients who have coexisting depression and diabetes
3139918|NCT01618552|Active Comparator|Control (knowledge enhancement)|Brief video clip designed to increase primary care physician awareness of new medication treatments for patients with diabetes
3139919|NCT01618526|Active Comparator|Healthy Carbohydrate Diet|4 weeks of intervention with a diet rich in Arabinoxylans and Resistent Starch
3139920|NCT01618526|Placebo Comparator|Western Style Diet|4 weeks of intervention with a diet with low content of Resistent Starch and Arabinoxylans.
3139921|NCT01618513|Experimental|SA monitored by GH|
3139922|NCT01618513|Experimental|SA monitored by IGF-I|
3139923|NCT01618513|No Intervention|Control|Control, patients who have achieved sufficient disease control by surgery alone.
3139924|NCT01618500||INPH-patients|"Inclusion criteria~Older than 60 years of age Probable INPH according to the NIH guidelines Planned shunt surgery based on a diagnosis of INPH.~Exclusion criteria~Known cause for hydrocephalus (i.e., secondary NPH). Medical condition preventing cognitive testing (e.g. deafness, blindness).~Patients not considered for shunt operation."
3139925|NCT01618487|Active Comparator|Arthroscopic tenotomy|Patients who are in this group will have arthroscopic tenotomy. A scope is used to see the tendon and release it.
3139926|NCT01618487|Active Comparator|Open tenotomy|Patients in this group will undergo open tenotomy. This involves opening the skin to expose the muscle and tendon, and then the tendon is released.
3139927|NCT01618487|Active Comparator|Debridement and repair|The patients in this group will undergo an arthroscopic technique (scope and small incision) to go in and remove any tissue that is diseased/does not belong and repair the tear(s) in the tendon.
3139928|NCT01618474|Experimental|DX|DX: Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
3139929|NCT01618474|Active Comparator|XELOX|XELOX: oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
3139930|NCT01618461|No Intervention|Text instructions|Medication instructions displayed in text format
3139931|NCT01618461|Experimental|Drug indication icons|Icons illustrate the purpose of each medication
3139932|NCT01618461|Experimental|Structured instructions|Graphical format shows what time(s) of day each medication should be taken
3139933|NCT01618461|Experimental|Icons + Structured instructions|Icons illustrate the purpose of each medication, and a graphical format shows what time(s) of day each medication should be taken
3139934|NCT01618448|Experimental|Placebo|Placebo once daily
3139935|NCT01618448|Experimental|Tolvaptan|Tolvaptan 15mg once daily
3139936|NCT01618435|Active Comparator|Fusion, allograft|Allograft used for fusion in the operation site
3139937|NCT01618435|Experimental|Fusion, i-FACTOR|i-FACTOR used for fusion in the operation site
3139938|NCT01618422|Sham Comparator|Directly Observed Therapy (DOTS)|The DOTS strategy (current standard strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
3139939|NCT01618422|Active Comparator|Directly Observed Therapy (DOTS) plus|The DOTS-Plus strategy (the strategy to be tested) includes additional measures including continuous drug resistance surveillance, culture, drug susceptibility testing for TB patients, and tailoring of individual drug regimen through the use of first and second-line drugs.
3139940|NCT01618409|Experimental|PictureRx cards|Illustrated format of medication instructions that includes pictures of pills and icons to show their purpose
3139941|NCT01618409|No Intervention|Control|Usual care
3139942|NCT01618383|Other|Colonic biopsies|Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy
3139944|NCT01618357|Experimental|Intervention|All subjects will receive pre-operative Neo-Adjuvant Chemotherapy (NAC) but only those with an incomplete response to NAC will be treated with the PARPi experimental portion of the trial explained below. Those with a complete response will be treated per standard of care.
3139945|NCT01618331|Active Comparator|Protein supplementation|Patients consume a drink after each exercise session. The drink consist of whey protein, maltodextrin, and flavors mixed in water.
3139946|NCT01618331|Placebo Comparator|Placebo supplement|Patients consume a drink after each exercise session. The drink consist of flavors mixed in water.
3139947|NCT01618331|No Intervention|Control|Patients will be tested before and after a none-intervention period of 12 weeks.
3139948|NCT01618318||General asthma population|People with asthma, aged 18 years and over, non smoker, all severities of disease, regardless of treatment, broad inclusion and few exclusion criteria.
3139949|NCT01618305|Experimental|Arm A|"Participants will receive lamivudine 150 mg/zidovudine 300 mg* twice a day and efavirenz 600 mg each night.~* Participants may receive a locally supplied nucleoside reverse transcriptase inhibitor (NRTI) backbone in place of lamivudine/zidovudine with permission of the protocol team obtained prior to randomization."
3139950|NCT01618305|Experimental|Arm B|"Participants will receive lamivudine 150 mg/zidovudine 300 mg* twice a day and raltegravir 400 mg twice a day.~* Participants may receive a locally supplied nucleoside reverse transcriptase inhibitor (NRTI) backbone in place of lamivudine/zidovudine with permission of the protocol team obtained prior to randomization."
3139951|NCT01618292||Robotic-assisted sacrocolpopexy patients|Patients who underwent robotic-assisted laparoscopic sacrocolpopexy between January 2007 and August 2011.
3139952|NCT01618279||Tryptase|Patients with clinical manifestations have been discovered and documented symptoms of coronary heart
3139953|NCT01618266||Ozurdex® (dexamethasone intravitreal implant)|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
3139954|NCT01618253|Experimental|Radiation therapy with concurrent sorafenib|
3139955|NCT01618240||Long term ventilated subjects|Muscle Strength Measurement, ventilator
3139956|NCT01618227|Experimental|Rehabilitation with static progressive splinting|Static progressive splinting is a well-established adjunct for restoring motion in stiff joints. Such splints apply a static stress relaxation force to the wrist and forearm tissues, which is sequentially increased as motion is achieved.
3139957|NCT01618227|Experimental|Rehabilitation without splinting|
3139958|NCT01618214|Experimental|Subject-driven titration|
3139959|NCT01618214|Active Comparator|Investigator-driven titration|
3139960|NCT01618201||50 subjects with migraine without aura|Inflammation Migraine Headache
3139961|NCT01618201||50 subjects with migraine with aura|Inflammation Migraine Headache
3139962|NCT01618201||50 subjects with tension headache and cluster headache|Inflammation Migraine Headache
3139963|NCT01618201||50 healthy subjects|Inflammation Migraine Headache
3139964|NCT01618188|Experimental|Formulation A|
3139965|NCT01618188|Experimental|Formulation B|
3139966|NCT01618188|Active Comparator|Insulin Aspart|
3139967|NCT01618175|Experimental|Home oxygen therapy|Infants with acute bronchiolitis of low to moderate severity will be discharged home with supplemental oxygen and monitored by phone calls and home visits.
3139968|NCT01618162|Experimental|Insulin degludec/liraglutide|
3139969|NCT01618162|Placebo Comparator|Placebo|
3139970|NCT01618149||severe knee OA who are indicated for total knee arthroplasty|the woman who are indicated for TKR and are post menopausal will be recruited in this study. We will excluded the patients who had immune disease ,previous fracture of femur and end stage of renal disease
3139971|NCT01618136|Experimental|E7449|
3139972|NCT01618136|Active Comparator|E7449 plus TMZ|
3139973|NCT01618136|Active Comparator|E7449 plus carboplatin and paclitaxel|
3139974|NCT01618123||All CPU subjects|All subjects admitted to the CPU with low to moderate probability for CAD and negative troponin, will undergo the following tests upon arrival following clinical evaluation and their consenting to the study: resting ECG, EndoPAT testing and then after stress nuclear imaging or stress echocardiography. Except for EndoPAT testing, all other tests were conducted according to the routine CPU protocol.
3139975|NCT01618110|Active Comparator|Treatment Group|
3139976|NCT01618110|Sham Comparator|Sham group|Sham TMS coil (same noise, minimal magnetic field)
3139977|NCT01618097|Experimental|DVD Decision Aid|Patient assigned to watch DVD decision aid.
3139978|NCT01618097|Experimental|Internet Based Decision Aid|Patient assigned to watch OA specific internet based decision aid.
3139979|NCT01618084|Experimental|Tritanium cup|
3139980|NCT01618084|Active Comparator|Trident HA cup|
3139981|NCT01618071|Active Comparator|Oleic acid|75 g high oleic acid sunflower oil.
3139982|NCT01618071|Active Comparator|Linoleic acid|75 g high linoleic acid sunflower oil.
3139983|NCT01618071|Experimental|Eicosapentaenoic acid and docosahexaenoic acid|5 g EPA and DHA derived from fish oil, made up to a total of 75 g with high oleic sunflower oil.
3139984|NCT01618071|Experimental|Docosahexaenoic acid|5 g DHA derived from algal oil, made up to a total of 75 g with high oleic sunflower oil.
3139985|NCT01618058||ARV-Treated Participants|Those participants who received dapivirine during HIV seroconversion
3139986|NCT01618058||ARV-Naive Participants|Those participants who received placebo during HIV seroconversion
3139987|NCT01618045||Fermented Papaya Preparation (FPP)|This a is single arm study - all participants will receive and take fermented papaya preparation (FPP) for a total of 6 weeks. Participants will take 3 grams of FPP three times per day (a total of 9 grams per day).
3139988|NCT01618032|Experimental|HVLA|High velocity and low amplitude traction manipulation on the ankle joint
3139989|NCT01618032|Experimental|MWM|Mobilization with movement on ankle joint as Mulligan
3139990|NCT01618032|Sham Comparator|placebo|Contact without therapeutic effect
3139991|NCT01618019|Experimental|N-3 PUFA|5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
3139992|NCT01618019|Placebo Comparator|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
3139993|NCT01618006|Active Comparator|Aspirin 81mg daily|Patients will receive 81mg daily during the postoperative period.
3139994|NCT01618006|Active Comparator|Aspirin 325mg daily|Patients will receive 325mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
3139995|NCT01618006|Experimental|Aspirin 81mg four times daily|Patients will receive ASA 81mg four times daily until postoperative day 7 or end of hospitalization
3139996|NCT01617993||Women undergoing IVF treatment|Women undergoing IVF treatment
3139997|NCT01617980|Other|Multimodal hypoxia imaging|Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
3139998|NCT01617967|Experimental|ALN-TTR02|
3139999|NCT01617954||Subjects with MammaPrint Result|
3140000|NCT01617941|Experimental|BGG492|At Baseline 60 patients will be randomized to receive BGG492 for the upcoming 12 weeks (dose: 75 mg BID administered in approx. 12 hours +/- 2 hours intervals).
3140001|NCT01617941|Placebo Comparator|Placebo|At Baseline 30 patients will be randomized to receive Placebo for the upcoming 12 weeks (matching a dose of 75 mg BID BGG492 administered in approx. 12 hours +/- 2 hours intervals).
3140002|NCT01617928|Experimental|veliparib (ABT-888)|
3140003|NCT01617889|Active Comparator|Powdered milk-based formula, standard fat blend|
3140004|NCT01617889|Experimental|Powder milk-based formula, alternate fat blend|
3140005|NCT01617850|Experimental|optimized physical exercise training|Intervention: Supervised physical exercise training x3 weekly for 12 weeks
3140006|NCT01617850|Active Comparator|conventional group|Intervention: Supervised physical exercise training x2 weekly for 8 weeks
3140007|NCT01617837|Active Comparator|P6 acupressure group|"In the end of the operation Sea-Band®, a single-sized elastic acupressure band with a plastic button, was placed unilaterally at the place of P6 (the P6 Neiguan acupoint, located about 3 cm proximal to the distal wrist, between the tendons of the flexor carpi radialis and the palmaris longus)to apply acupressure."
3140008|NCT01617837|Placebo Comparator|Placebo group|In the end of the operation an identical Sea-Band® with no button and thereby no acupressure was placed unilaterally at the place of P6.
3140009|NCT01617824|Experimental|Linagliptin|Linagliptin 5 mg tablets daily for 4 days
3140010|NCT01617824|Placebo Comparator|Placebo|Placebo tablets 1 daily for 4 days
3140011|NCT01617798|Placebo Comparator|Control-- furosemide (lasix) only|"Control arm receives standard of care diuresis with furosemide(lasix)only. The treatment team will decide the dosing of furosemide (lasix).~No actual placebo is administered."
3140012|NCT01617798|Active Comparator|Study Arm|Study arm receives evolving standard of care diuresis with furosemide and metolazone.
3140013|NCT01617785||CABG group|Three-vessel disease patients undergoing CABG at index hospitalization
3140014|NCT01617785||PCI group|Three-vessel disease patients undergoing PCI at index hospitalization
3140015|NCT01617785||OMT group|Three-vessel disease patients undergoing no revascularization at index hospitalization
3140016|NCT01617772|Experimental|Atorvastatin|20mg atorvastatin daily
3140017|NCT01617772|Experimental|Carnitine|1000mg L-carnitine daily
3140018|NCT01617772|Experimental|Atoral|1000mg L-carnitine and 20mg atorvastatin
3140019|NCT01617772|Placebo Comparator|Placebo|Identically looking placebo
3140020|NCT01617746|Experimental|Ambrisentan|5mg od ambrisentan
3140021|NCT01617746|Experimental|Bosentan|62.5mg bosentan
3140022|NCT01617746|Placebo Comparator|Placebo|
3140023|NCT01617733|Experimental|Pasireotide|4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
3140024|NCT01617707|Active Comparator|conventional sedation group|midazolam
3140025|NCT01617707|Experimental|BPS group|midazolam plus propofol
3140026|NCT01617694|Experimental|group R|continuation of remifentanil target controlled infusion (TCI) at effect-site concentration of 2 ng/ml during anesthetic recovery until extubation.
3140027|NCT01617694|Active Comparator|group D|remifentanil TCI discontinuation and dexmedetomidine 0.5 mg/kg intravenous injection before 10 min of the end of surgery
3140028|NCT01617681|Experimental|Valsartan 0.25 mg/kg|Valsartan oral solution 0.25mg/kg once daily + matching placebo of valsartan oral solution 4 mg/kg once daily for 6 weeks (period 1)
3140029|NCT01617681|Experimental|Valsartan 4 mg/kg|Valsartan oral solution 4 mg/kg once daily + matching placebo of valsartan oral solution 0.25 mg/kg once daily for 6 weeks (period 1)
3140030|NCT01617681|Experimental|Valsartan 1 mg/kg|Open-label (Period 2) valsartan will be optionally titrated from 1 mg/kg to 2 mg/kg. Valsartan will continue to be optionally up titrated in 1 mg/kg increments every 4 weeks until maximum dose of 4 mg/kg is achieved. Duration 20 weeks.
3140031|NCT01617668|Experimental|Paclitaxel with LCL161|Patients randomized to the experimental arm received paclitaxel 80 mg/m2 weekly + LECL161 1800 mg once weekly for 12 weeks. Equal numbers of patients with gene expression signature positive and negative disease were included in each treatment arm.
3140032|NCT01617668|Active Comparator|Paclitaxel without LCL161|Patients randomized to the control arm received paclitaxel 80 mg/m2 weekly for 12 weeks. Equal numbers of patients with gene expression signature positive and negative disease were included in each treatment arm.
3140033|NCT01617655|Placebo Comparator|Placebo Q2W|Placebo for alirocumab subcutaneous (SC) injection every two weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
3140034|NCT01617655|Experimental|Alirocumab 150 mg Q2W|Alirocumab 150 mg SC injection Q2W on top of stable LMT for 78 weeks.
3140035|NCT01617642||Control group|Healthy control group, matched for age and gender
3140036|NCT01617642||Acute intermittent porphyria|Patients with acute intermittent porphyria.
3140037|NCT01617629|Experimental|Cvac Treatment Group|Participants received Epithelial Mucin Surface Antigen 1 (MUC1) Dendritic Cell Vaccine (Cvac) treatment.
3140038|NCT01617616||Normal tilt test|Patients with normal tilt table testing (they may have symptoms which precipitated the tilt, but in the end did not qualify as POTS, NMH, ETC.)
3140039|NCT01617616||confirmed POTS diagnosis|after review of tilt table results, this group will be the confirmed postural orthostatic tachycardic syndrome group patient
3140040|NCT01617616||Neurocardiogenic syncope on tilt|This group is comprised of patients with confirmed diagnosis of neurocardiogenic syncope on tilt
3140419|NCT01615159|Active Comparator|Behavior and lifestyle counseling|
3140041|NCT01617616||Neurally-mediated hypotension|Patients with confirmed diagnosis neurally mediated hypotension
3140042|NCT01617603|Experimental|High polyphenol milk chocolate|High polyphenol milk chocolate containing approximately 1 mg/g of epicatechin
3140043|NCT01617603|Active Comparator|Nestle Noir 70 % chocolate|Nestle Noir 70 % chocolate containing approximately 1 mg/g of epicatechin
3140044|NCT01617603|Placebo Comparator|Low polyphenol milk|Low polyphenol milk control (matched to product 1 as closely as possible for milk content, carbohydrate, fat and calories, made from cocoa butter, sugar, milk powder and small amount of cocoa liquor to improve taste, giving approximately 0.05mg/g epicatechin.
3140045|NCT01617590|Experimental|leflunomide|Leflunomide 10-20 mg/d
3140046|NCT01617590|Active Comparator|methotrexate|MTX 7.5-15 mg/week
3140047|NCT01617577|Experimental|G-CSF (filgrastim) first phase|Subjects assigned to this arm receive G-CSF for 5 days during the first phase of the study. At week 7 these subjects cross over to receive placebo injections for five days
3140048|NCT01617577|Placebo Comparator|Placebo first phase|Subjects assigned to this arm receive placebo injections daily for 5 days; after wk 7 they crossover to receive 5 daily injections of injections of G-CSF.
3140049|NCT01617564|Active Comparator|Bupivacain|
3140050|NCT01617564|Sham Comparator|Sodium Chloride|
3140051|NCT01617551|Experimental|Renal denervation|Patient group randomized to renal denervation
3140052|NCT01617551|Sham Comparator|Sham|Patients randomized to sham procedure
3140053|NCT01617538|Experimental|Atorvastatin|30 patients who had MCA infarction within 6 months prior to screening, and has not received any statins treatment before stroke.in this study ,we will give them atorvastatin 40mg treatment for 24 weeks and monitor and evaluate the change of intracranial hemodynamics after treatment.
3140054|NCT01617538|No Intervention|compare|30 patients who had MCA infarction within 6 months prior to screening, and has not received any statins treatment.we will monitor and evaluate the intracranial hemodynamics as a baseline.
3140055|NCT01617525|Experimental|Korean Recommended Diet|A dietary pattern that follows the recommendations by the Korean Rural Development Administration.
3140056|NCT01617525|Active Comparator|US Recommended Diet|Diet based on recipes and menus developed by the USDA Dietary Guidelines for Americans intramural team.
3140057|NCT01617525|Active Comparator|Typical American Diet|Diet based on data from the NHANES surveys, as summarized in the USDA report What We Eat in America.
3140058|NCT01617499||University employees|Participants will include employees of Washington University in St. Louis. Recruitment will be directed to staff employees of the Central Fiscal Unit (CFU) on the Danforth campus.
3140059|NCT01617486|Experimental|BALANCE|
3140060|NCT01617473|Experimental|procedure/surgery|transplant with G-CSF mobilized PBSCs
3140061|NCT01617473|No Intervention|other|no intervention after transplant with mobilized BMPB
3140062|NCT01617460|Experimental|Aripiprazole|administered orally once daily
3140063|NCT01617447|Placebo Comparator|Placebo|administered orally once daily
3140064|NCT01617447|Experimental|Aripiprazole|administered orally once daily
3140065|NCT01617434|Experimental|Liraglutide|
3140066|NCT01617434|Placebo Comparator|Placebo|
3140067|NCT01617421|Experimental|1|Yoga
3140068|NCT01617382||Registry|Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy
3140069|NCT01617369|Experimental|Acute Hypertonic Saline Effect|2.8% NaCl inhaled 30 minutes before Mucociliary Clearance measured.
3140070|NCT01617369|Active Comparator|Sustained Hypertonic Saline Effect|2.8% NaCl inhaled 4 hours before Mucociliary Clearance measured.
3140071|NCT01617356|Active Comparator|Dextrose Injection|
3140072|NCT01617356|Active Comparator|Sterile Water Injection|
3140073|NCT01617343|No Intervention|Usual care|Patients in this control group will receive usual care following stroke including standard physiotherapy and occupational therapy.
3140074|NCT01617343|Experimental|HEP-OKS|
3140075|NCT01617330|Experimental|Diesel exhaust|2 hour exposure to diesel exhaust at 100 microgram per cubic meter during intermittent exercise
3140076|NCT01617330|Experimental|Filtered air exposure|2 hour exposure to filtered air during intermittent exercise
3140077|NCT01617317|Active Comparator|Intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of simple IVIG which contain no H1N1 2009 antibody (manufactured before 2009).
3140078|NCT01617317|Experimental|Hyperimmune intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG fractionated from convalescent plasma (H1N1 2009 antibody titer was 1:320 by hemagglutination inhibition and neutralizing antibody assays)
3140079|NCT01617304|Experimental|low AGE, glucose|Food prepared by boiling/steaming and 20 g of glucose 3 times a day in a water solution
3140080|NCT01617304|Experimental|low AGE, fructose|Food prepared by boiling/steaming and 20 g of fructose 3 times a day in a water solution
3140081|NCT01617304|Experimental|high AGE, fructose|Food prepared by frying/baking and 20 g of fructose 3 times a day in a water solution
3140082|NCT01617304|Experimental|high AGE, glucose|Food prepared by frying/baking and 20 g of glucose 3 times a day in a water solution
3140083|NCT01617291|Experimental|Induced Hypothermia|Induced hypothermia after the return of spontaneous circulation by the application of ice packs to the axilla and groin with cold IV fluids
3140084|NCT01617291|No Intervention|Regular Care|Treatment of the return of spontaneous circulation under standing paramedic protocol without the addition of induced therapeutic hypothermia
3140085|NCT01617278|Experimental|I-Scan 1|I-Scan 1 modality will be used by the endoscopist for the entire procedure
3140086|NCT01617278|Experimental|HD Colon|High definition white light modality will be used by the endoscopist for the entire procedure
3140087|NCT01617278|Experimental|I-scan 2|I-Scan 2 modality will be used by th endoscopist through out the procedure
3140137|NCT01616953|Experimental|Ixmyelocel-T|iliac bone marrow aspirates are expanded ex vivo to enrich for adult multipotent cells (ixmyelocel-T) capable of regenerating bone and blood vessels and reducing inflammation. Following cell expansion, autologous ixmyelocel-T is then packaged and can be used as an autologous graft for treatment of bone defects.
3270158|NCT00696657|Experimental|D|
3140088|NCT01617265|Experimental|Prevention of oversedation group|In this arm sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated intravenous (IV) hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
3140089|NCT01617265|Active Comparator|Conventional sedation group|In this arm, sedation will be administered according to the usual practices in each participating center.
3140090|NCT01617252|Experimental|Optiflow|
3140091|NCT01617252|Experimental|Facial mask|
3140092|NCT01617239|Experimental|Group 1|1 x standard dose (0.5 mL) on Day 1, Day 29, and Day 57
3140093|NCT01617239|Experimental|Group 2|1 x double standard dose (1.0 mL) on Day 1 and 1 x standard dose (0.5 mL) on Day 57.
3140094|NCT01617239|Experimental|Group 3|1 x triple standard dose (1.5 mL) on Day 1
3140095|NCT01617226|Active Comparator|azacitidine|azacitidine (75mg/m2) by SC injection on 7 consecutive days (excluding weekends), starting day 1 of 28-day cycles for up to 6 cycles. This should be delivered in a 5-2-2 schedule
3140096|NCT01617226|Active Comparator|azacitidine and vorinostat|Patients will receive (75mg/m2) azacitidine by SC injection on 7 consecutive days (excluding weekends), starting day 1 of 28-day cycles for up to 6 cycles. Azacitidine should be delivered in a 5-2-2 schedule. Vorinostat (300mg bid) will be taken orally for 7 consecutive days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles. (Day 3 is defined as the 3rd day of azacitidine administration).
3140097|NCT01617213|Experimental|Maintenance Lenalidomide After Melphalan|
3140098|NCT01617200|Experimental|Asenapine 2.5 mg BID|
3140099|NCT01617200|Experimental|Asenapine 5 mg BID|
3140100|NCT01617200|Active Comparator|Olanzapine 15 mg QD|
3140101|NCT01617200|Experimental|Placebo switched to Asenapine 2.5 mg BID|
3140102|NCT01617187|Experimental|Asenapine 2.5 mg BID|
3140103|NCT01617187|Experimental|Asenapine 5 mg BID|
3140104|NCT01617187|Active Comparator|Olanzapine 15 mg QD|
3140105|NCT01617187|Placebo Comparator|Placebo BID|
3140106|NCT01617174||assessments completed by patients|"A single-arm observational study will be conducted at three institutions in the Prostate Cancer Clinical Trials Consortium (PCCTC): Memorial Sloan-Kettering Cancer Center; Johns Hopkins; and Oregon Health & Science University. MSKCC is the coordinating center. The target enrollment is 400 patients, with at least 250 experiencing moderate or worse pain intensity at baseline, defined as a score of ≥4, the preferred regulatory cutoff."
3140107|NCT01617161|Active Comparator|PBT|Proton Beam Therapy
3140108|NCT01617161|Active Comparator|IMRT|Intensity Modulated Radiation Therapy
3140109|NCT01617148|Experimental|Treatment with Aflibercept|Subjects were given 2 mg (0.05 mL) of intravitreal aflibercept injection administered every month for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
3140110|NCT01617135|Experimental|CVT-301 Low Dose|CVT-Low; levodopa inhalation powder (LIP)
3140111|NCT01617135|Experimental|CVT-301 High Dose|CVT-High; levodopa inhalation powder (LIP)
3140112|NCT01617135|Placebo Comparator|Inhaled Placebo|Inhaled placebo powder
3140113|NCT01617135|Active Comparator|Oral Sinemet (carbidopa/levodopa)|Open-label oral carbidopa/levodopa (CD/LD)
3140114|NCT01617122|Experimental|Bacteriophage|Subjects receive bacteriophage vaccinations and blood draws
3140115|NCT01617109|Placebo Comparator|Placebo|
3140116|NCT01617109|Experimental|Ca/Vit D|
3140117|NCT01617096|Experimental|Dapivirine Vaginal Ring|Vaginal ring containing 25mg dapivirine
3140118|NCT01617096|Placebo Comparator|Placebo Ring|Vaginal ring containing no drug substance
3140119|NCT01617083|Active Comparator|Azithromycin|Antibiotic used to treat infections.
3140120|NCT01617083|Placebo Comparator|Placebo|Compound thickening agent with sugar and flavor additives.
3140121|NCT01617070|Experimental|LNAA, washout, Kuvan, and LNAA+Kuvan|One group of 12 subjects, each under 4 conditions (each phase is 4 weeks)
3140122|NCT01617057|Experimental|Skelid|tiludronic acid
3140123|NCT01617057|Placebo Comparator|Control|Placebo
3140124|NCT01617044|Experimental|Treatment|"iron 3 mg/kg/day elemental iron FeSO4 up to 45 mg (dose to be determined by PI)~+ vitamin C-250 mg chewable tab~+ probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)"
3140125|NCT01617044|Placebo Comparator|Control|"iron 3 mg/kg/day elemental iron FeSO4 to 45 mg~+ vitamin C-250 mg chewable tab~+ placebo (identical capsule)"
3140126|NCT01617031||Diabetic patients with coronary artery disease|Type 2 diabetic patients with previous coronary artery disease. All patients are routinely treated with aspirin in secondary prevention of cardiovascular disease. Coronary artery disease is defined as a previous coronary angiography with at least 1 coronary artery stenosis >50%. Type 2 diabetes is defined as patients with diabetes discovered after 30 years old and insulin was not the first treatment except in case of acute coronary syndrome.
3140127|NCT01617018||Exposed group|Biotherapy
3140128|NCT01617018||Non-exposed group|Major conventional systemic therapy (methotrexate or cyclosporine)
3140129|NCT01617005||Tocilizumab in Moderate to Severe Active RA|Moderate to severe active RA participants, receiving tocilizumab treatment according to effective official Summary of Product Characteristics (SPC), will be observed. The choice of therapy will be based exclusively on the medical decision of the treating physician before study enrollment. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
3140130|NCT01616992||Interstitial Cystitis|
3140131|NCT01616992||Myofascial Pelvic Pain|
3140132|NCT01616992||Healthy|
3140133|NCT01616992||First Degree Relative|
3140134|NCT01616979||OPCAB surgery|Fifteen elective OPCAB surgery patients who undergo grafting in the left circumflex artery territory due to three-vessel disease
3140135|NCT01616966|Active Comparator|Sevoflurane|Anesthesia was maintained with sevoflurane during surgery.
3140136|NCT01616966|Active Comparator|Anesthesia with propofol|Anesthesia was maintained with propofol during surgery.
3140259|NCT01616186|Active Comparator|Sunitinib|"Sunitinib is the concurrent control group~Patients will be stratified by current smoking status (smoker: yes or no), for each smoking stratum patients will be randomized in a 2:1 ratio"
3140138|NCT01616953|Active Comparator|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
3140139|NCT01616940|No Intervention|Standard-of-care|Standard-of-care at 3 demonstration sites includes: HIV medical care, medical case management, and referral to substance abuse, mental health, and housing services.
3140140|NCT01616940|Experimental|Enhanced Peer Intervention|Provides emotional, informational, and instrumental peer support, in addition to Standard-of-Care.
3140141|NCT01616927|No Intervention|standard care|Subjects in this arm will receive standard care
3140142|NCT01616927|Experimental|Lanreotide|
3140143|NCT01616914||delirium group|patients with delirium during ICU stay
3140144|NCT01616914||non-delirium group|patients without delirium during ICU stay
3140145|NCT01616901|Experimental|Spontaneous breathing trial|
3140146|NCT01616888|Active Comparator|Treatment arm|SFA angioplasty with In.Pact Admiral drug eluting balloon
3140147|NCT01616875|Experimental|Cabazitaxel + Cisplatin chemotherapy|Cabazitaxel 15mg/m2 Intravenous (IV)followed by Cisplatin 70mg/m2 IV on day 1 of each 21 day cycle for 4 cycles
3140148|NCT01616862||Parents of PA positive CF children|parents of children with cystic fibrosis who are positive for Pseudomonas aeruginosa
3140149|NCT01616862||parents of Pa negative CF children|parents of children with cystic fibrosis who are negative for pseudomonas aeruginosa
3140150|NCT01616849|Experimental|PF+ Nimotuzumab|Patients treated with cisplatin and 5-Fu combined with nimotuzumab
3140151|NCT01616836|Active Comparator|continuous FNB|Bolus femoral nerve block (ropivacaine 0.5% 20 mL), continuous infusion 48 hours (ropivacaine 0.2%, 5 mL/h), placebo local infiltration
3140152|NCT01616836|Active Comparator|single FNB|femoral nerve block (ropivacaine 0.5% 20 mL), placebo femoral nerve block infusion, placebo local infiltration
3140153|NCT01616836|Active Comparator|LIA|placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia
3140154|NCT01616823||HIV Positive Women|HIV positive women in two downtown Toronto, Ontario academic-affiliated hospitals
3140155|NCT01616810||observation|Healthy participants
3140156|NCT01616797|Experimental|Computerized intervention|Participants will be asked to visit a customized website and engage in computerized exercises. Cognitive and emotion training games.
3140157|NCT01616797|Sham Comparator|Control|Participants will be asked to visit a customized website and engage in computerized games.
3140158|NCT01616784|Active Comparator|Multiple daily injections plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
3140159|NCT01616784|Experimental|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
3140160|NCT01616771|Other|glottis view assessment|Glottis view assessment using Macintosh laryngoscope & GVL selected by weight & smaller sized GVL in single patient
3140161|NCT01616758|Experimental|GTx-024 9mg|GTx-024 dosage of three soft gels once daily to equal 9mg
3140162|NCT01616732|Active Comparator|testosterone|against placebo
3140163|NCT01616732|Placebo Comparator|placebo|
3140164|NCT01616719|Other|DTRAX graft|
3140165|NCT01616693|Experimental|Zinc and probiotic|Receives both zinc and probiotic supplements along with rotavirus and oral polio vaccines
3140166|NCT01616693|Active Comparator|Zinc and probiotic placebo supplements|Receives zinc and probiotic placebo supplements along with rotavirus and oral polio vaccines
3140167|NCT01616693|Active Comparator|Zinc placebo and probiotic supplements|Receives zinc placebo and probiotic supplements along with rotavirus and oral polio vaccines
3140168|NCT01616693|Placebo Comparator|Zinc placebo and probiotic placebo|Receives zinc placebo and probiotic placebo along with rotavirus and oral polio vaccines
3140169|NCT01616680|Experimental|Supportive care (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15.
3140170|NCT01616667|Active Comparator|Modified direct lateral approach|The patients included is operated with a total hip arthroplasty using a modified direct lateral approach
3140171|NCT01616667|Active Comparator|Posterior approach|The patients included is operated with a total hip arthroplasty using posterior approach
3140172|NCT01616654|Experimental|CD5789 50 µg/g cream|CD5789 50 µg/g cream applied once daily for subjects randomized in Stratum 1, 2 and 3
3140173|NCT01616654|Experimental|CD5789 100 µg/g cream|CD5789 100 µg/g cream applied once daily for subjects randomized in Stratum 1, 2 and 3
3140174|NCT01616654|Active Comparator|Tazarotene 0.1% gel|Tazarotene 0.1% gel applied once daily for subjects randomized in Stratum 1 and 2
3140175|NCT01616654|Placebo Comparator|Vehicle cream|Vehicle cream applied once daily for subjects randomized in Stratum 1, 2 and 3
3140176|NCT01616654|Experimental|CD5789 25 µg/g cream|CD5789 25 µg/g cream applied once daily for subjects randomized in Stratum 1, 2 and 3
3140177|NCT01616641||rheumatoid arthritis group|75 patients with rheumatoid arthritis
3140178|NCT01616641||control group|75 healthy women
3140179|NCT01616628|No Intervention|Wait listed control|Participants grocery shop without the intervention for extended baseline and have delayed entrance into the intervention period.
3140180|NCT01616628|Experimental|Rewards for purchases & topic education|Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables.
3140181|NCT01616615|Experimental|ASPIRIN|150 mg milligram(s)/ day oral use
3140182|NCT01616615|Placebo Comparator|PLACEBO|
3140183|NCT01616602|Placebo Comparator|Left-sided Position|
3140184|NCT01616602|Experimental|Prone Position|
3140185|NCT01616589||Fragile X full mutation (affected)|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and molecular analysis for fragile X revealed >200 CGG repeats with abnormal methylation pattern; interpretation is full mutation for fragile X syndrome
3140186|NCT01616589||Fragile X premutation (carriers)|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and molecular analysis for fragile X revealed 55-200 CGG repeats with normal methylation pattern; interpretation is premutation carrier of fragile X syndrome
3140458|NCT01614847|Placebo Comparator|Normal saline|
3141198|NCT01609595|Experimental|Treatment|Study drug treatment
3140187|NCT01616589||Fragile X intermediate|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and fragile X molecular analysis revealed 45-54 CGG repeats; interpretation is intermediate, not a carrier of a fragile X expansion mutation
3140188|NCT01616576|Experimental|Control first, then Experimental (Group A)|Initial subject use of Control Sound Processing Strategy for the first week, followed by subject use of Experimental (HiRes™ Optima) Sound Processing Strategy for the HiResolution™ Bionic Ear System for the second week.
3140189|NCT01616576|Experimental|Experimental first, then Control (Group B)|Initial subject use of Experimental (HiRes™ Optima) Sound Processing Strategy for the first week for the HiResolution™ Bionic Ear System, followed by subject use of the Control Sound Processing Strategy for the second week.
3140190|NCT01616563|Experimental|Diet and exercise|A combined diet and exercise program tailored to individuals incorporating behavioural modification support
3140191|NCT01616550||Patients undergoing thoracic surgery|Assessment of postoperative pain management in patients undergoing elective thoracoscopy or thoracotomy in a teaching hospital
3140192|NCT01616524|Experimental|Arm 1: pegIFNλ + Ribavirin + Placebo matching Daclatasvir|
3140193|NCT01616524|Experimental|Arm 2: pegIFNλ + Ribavirin + Daclatasvir|
3140194|NCT01616524|Experimental|Arm 3: pegIFNα-2a + Ribavirin + Placebo matching Daclatasvir|
3140195|NCT01616511||Pathway CH-1 Subjects|
3140196|NCT01616498||Lean|Comparison data from this lean cohort will be compared to the obese older adults are already being collected in an R01-funded study (Improving Muscle for Functional Independence Trial; IRB00009098; NCT01049698)
3140197|NCT01616485|Experimental|Treatment A|TA-1790 + glyceryl trinitrate
3140198|NCT01616485|Active Comparator|Treatment B|sildenafil citrate + glyceryl trinitrate
3140199|NCT01616485|Placebo Comparator|Treatment C|placebo + glyceryl trinitrate
3140200|NCT01616472||Incident diabetes cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with diabetes during follow-up, subsequent to SLE diagnosis.
3140201|NCT01616472||Incident diabetes controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of diabetes during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
3140202|NCT01616472||Incident hypertension cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with hypertension during follow-up, subsequent to SLE diagnosis.
3140203|NCT01616472||Incident hypertension controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of hypertension during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
3140204|NCT01616472||Incident cataract cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with cataract during follow-up, subsequent to SLE diagnosis.
3140205|NCT01616472||Incident cataract controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of cataract during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
3140206|NCT01616472||Incident osteoporosis cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with osteoporosis during follow-up, subsequent to SLE diagnosis.
3140207|NCT01616472||Incident osteoporosis controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of osteoporosis during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
3140208|NCT01616472||Incident avascular necrosis cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with avascular necrosis during follow-up, subsequent to SLE diagnosis
3140209|NCT01616472||Incident avascular necrosis controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of avascular necrosis during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
3140210|NCT01616459|Experimental|11Pn Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of GSK2830929A, or 11Pn, vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of 11Pn vaccine were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of 11Pn vaccine was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
3140211|NCT01616459|Experimental|12Pn Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of GSK2830930A, or 12Pn, vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of 12Pn vaccine were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of 12Pn vaccine was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
3140260|NCT01616173|Active Comparator|Perineural Dexamethasone|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine and perineural dexamethasone 8mg/2mL, and 50mL IV normal saline infusion
3140261|NCT01616173|Active Comparator|Intravenous Dexamethasone|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine with saline and IV dexamethsone 8mg in 50mL infusion
3140494|NCT01614717|Placebo Comparator|Control Group|CRT-P Implant. Patients randomized in the control Group will have the device programmed to back-up pacing AAI
3140212|NCT01616459|Active Comparator|Synflorix Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of Synflorix™ at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of Synflorix™ were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of Synflorix™ was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
3140213|NCT01616459|Active Comparator|Prevnar13 Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of Prevnar13™ vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of Prevnar13™ were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of Prevnar13™ was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate ).
3140214|NCT01616446||remission|Nephrotic patients in remission
3140215|NCT01616446||relapse|Nephrotic patients in recidive
3140216|NCT01616433|Active Comparator|Arthritis Foundation Exercise Program|
3140217|NCT01616433|Experimental|AFEP + 10 Keys to Healthy Aging|"Arthritis Foundation Exercise Program integrated with the 10 Keys to Healthy Aging"
3140218|NCT01616420|No Intervention|Delayed aPS|
3140219|NCT01616420|Experimental|Immediate aPS|
3140220|NCT01616407|Experimental|MDMA, methylphenidate, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but three treatment conditions in the same subject.
3140221|NCT01616394||children with congenital heart disease|
3140222|NCT01616381|Active Comparator|Sildenafil|Sildenafil tablets 40 mg x 3 daily
3140223|NCT01616381|Placebo Comparator|Placebo|Placebo tablet x 3 daily
3140224|NCT01616368|Experimental|MEAL|Participation in an 8-week mindful eating course
3140225|NCT01616342|Active Comparator|Comprehensive Medical Management|Comprehensive Medical Management will include analgesic management in accordance with guidelines and practices at the site.
3140226|NCT01616342|Active Comparator|Spinal Cord Stimulation (SCS)|Subjects assigned to Arm A, CMM + SCS, will be treated with electrical pulses from a surgically implanted Precision Plus® SCS System (Boston Scientific Corporation).
3140227|NCT01616329||Cases and Controls|Cases: alloantibody formers Controls: non-alloantibody formers
3140228|NCT01616316|Experimental|subfascial flap|
3140229|NCT01616316|Experimental|Subplatysmal flap|
3140230|NCT01616303|Active Comparator|Carboplatin & paclitaxel|first-line chemotherapy for ovarian cancer
3140231|NCT01616303|Experimental|Carboplatin & paclitaxel & oregovomab|first-line chemotherapy for ovarian cancer plus oregovomab
3140232|NCT01616277|Placebo Comparator|1|
3140233|NCT01616277|Placebo Comparator|2|
3140234|NCT01616277|Placebo Comparator|3|
3140235|NCT01616277|Placebo Comparator|4|
3140236|NCT01616277|Placebo Comparator|5|Repeat dose of PF-06252616, IV infusion, single dose - 10.0 miligram per kilogram
3140237|NCT01616277|Placebo Comparator|6|
3140238|NCT01616277|Placebo Comparator|7|
3140239|NCT01616251|Experimental|Vegetable protein meal|Vegetable protein meal based on legumes (3.6 MJ, 19E% protein, 28 g dietary fibers)
3140240|NCT01616251|Experimental|Egg protein meal + fibers|Protein meal based on eggs and added pea dietary fibers (3.6 MJ, 19E% protein, 28 g dietary fibers)
3140241|NCT01616251|Experimental|Egg protein meal|Protein meal based on egg without added dietary fibers (3.6 MJ, 19E% protein, 6 g dietary fibers)
3140242|NCT01616251|Experimental|Meat protein meal + fibers|Protein meal based on meat and added pea dietary fibers (3.6 MJ, 19E% protein, 29 g dietary fibers)
3140243|NCT01616238|Experimental|Philadelphia Positive Patients|All patients with Philadelphia positive ALL will be treated in this group and will receive a standard imatinib-containing chemotherapy regimen
3140244|NCT01616238|Experimental|Philadelphia -ve Patients- Intensive|Patients with Philadelphia negative ALL who are fit for intensive treatment will be allocated into this group.
3140245|NCT01616238|Experimental|Philadelphia -ve Patients- Intensive +|Patients with Philadelphia negative disease and who are fit for intensive treatment will be entered into this group
3140246|NCT01616238|Experimental|Philadelphia -ve Patients- Non Intensive|Patients with Philadelphia negative disease who are not fit for intensive chemotherapy will be entered into this group
3140247|NCT01616238|No Intervention|Registration only|Patients with either Philadelphia positive or negative ALL who do not wish to enter the study will be allocated to this group for data collection purposes only.
3140248|NCT01616225|Active Comparator|No Growth Hormone Supplementation|
3140249|NCT01616225|Experimental|Luteal Growth Hormone Start|Growth hormone starting in the luteal phase of the previous menstrual cycle.
3140250|NCT01616225|Experimental|Follicular Growth Hormone Start|Starting growth hormone during the follicular phase of the prior menstrual cycle.
3140251|NCT01616212|Experimental|TX1|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
3140252|NCT01616212|Experimental|TX 2|Motivational Enhancement Therapy for adolescents
3140253|NCT01616212|Experimental|TX3|Drug Education for adolescents, Parenting Wisely for parents
3140254|NCT01616212|Experimental|TX4|Drug Education for adolescents
3140255|NCT01616199|Experimental|Phase 1 Dose Escalation of PX-866 + vemurafenib|PX-866 given with vemurafenib
3140256|NCT01616199|Experimental|Phase 2 Combination PX-866 + vemurafenib|PX-866 given with vemurafenib
3140257|NCT01616199|Active Comparator|Phase 2 Single-agent vemurafenib|vemurafenib given as a single agent
3140258|NCT01616186|Experimental|Everolimus/Sorafenib|Patients will be stratified by current smoking status (smoker: yes or no0, for each smoking stratum patients will be randomized in a 2:1 ratio
3140262|NCT01616173|Placebo Comparator|No Perioperative Steroids|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine with saline and 50mL infusion
3140263|NCT01616160|Experimental|Nasal polyps subjects|24 subjects with nasal polyps. Intervention: Each subject will receive Nasonex (mometasone furoate) 2 spray per nostril twice daily for 4 weeks.
3140264|NCT01616147|Experimental|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
3140265|NCT01616147|Active Comparator|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
3140266|NCT01616134|Active Comparator|Korea Red Ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks.
3140267|NCT01616134|Placebo Comparator|placebo contating constarch|
3140268|NCT01616121|Active Comparator|Conventional Treatment Heart Failure|Conventional Treatment
3140269|NCT01616121|Experimental|Lung Impedance-Guided Therapy|Lung Impedance-Guided Therapy
3140270|NCT01616108|Experimental|Bupivacaine Injection|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
3140271|NCT01616095||Adults with Growth Hormone Deficiency|if multiple hormonal deficiences exist, long term adequate supplementation is provided and tightly monitored.
3140272|NCT01616095||Healthy Controls|matched for BMI, age, and gender
3140273|NCT01616082|Active Comparator|Overweight, no drug|After screening, overweight (BMI 27.0 - 30.0, inclusive) subjects will be started on a low calorie diet (approximately 900-1000 kcal/d) until a target weight loss is achieved.
3140274|NCT01616082|Active Comparator|Obese with no drug|After screening, overweight (obese subjects (BMI ≥30 - ≤40.0) subjects (n=35) will be started on a low calorie diet (approximately 900-1000 kcal/d) until a target weight loss is achieved. Individuals not on track to achieve their target weight by four weeks will receive the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects will be given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.
3140275|NCT01616082|Placebo Comparator|Overweight with Phentermine|After screening, overweight (BMI 27.0 - 30.0, inclusive) subjects will be started on a low calorie diet (approximately 900-1000 kcal/d) until a target weight loss is achieved. Individuals not on track to achieve their target weight by four weeks will receive the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects will be given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.
3140276|NCT01616082|Placebo Comparator|Obese with Phentermine|After screening, obese subjects (BMI ≥30 - ≤40.0) subjects (n=35) will be started on a low calorie diet (approximately 900-1000 kcal/d) until a target weight loss is achieved. Individuals not on track to achieve their target weight by four weeks will receive the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects will be given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.
3140277|NCT01616069|Active Comparator|epinephrine|Assessment of systolic and diastolic heart function during CABAG with CPB with levosimendan using TEE.
3140278|NCT01616069|Active Comparator|levosimendan|Assessment of systolic and diastolic heart function during CABAG with CPB with epinephrine using TEE.
3140279|NCT01616056|Experimental|Bandage Contact Lenses|Patients wear bandage lenses continuously for at least 3 months in the absence of disease progression or unacceptable toxicity.
3140280|NCT01616043|Experimental|Glyaderm + STSG|All included patients in this arm will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. The wounds of the patients will be covered with glycerol preserved allografts for wound bed preparation. At the second operation, 5-7 days after the first operation, the allografts are removed. If the wound bed is not suitable for grafting, additional wound bed preparation with allografts is required until the wound bed is satisfactory. If the wound bed is suitable for grafting, the wounds of the patients are covered with Glyaderm®. After 6-8 days the wounds are finally covered with a thin STSG.
3140281|NCT01616043|Other|STSG alone|All included patients in this arm will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. The wounds of the patients will be covered with glycerol preserved allografts for wound bed preparation. At the second operation, 5-7 days after the first operation, the allografts are removed. If the wound bed is not suitable for grafting, additional wound bed preparation with allografts is required until the wound bed is satisfactory. If the wound bed is suitable for grafting, the wounds are immediately covered with a thin STSG.
3140282|NCT01616030|Experimental|Strength training, fractured limb|"Knee-extension strength training of the fractured limb:~Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery."
3140283|NCT01616004|Experimental|N2O|N20 70% inhalation 5 minutes O2 100 % inhalation for 5 minutes
3140284|NCT01616004|Sham Comparator|Air|
3140285|NCT01615991|Other|radiosynoviorthesis with yttrium-90 or rhenium -186|Patients suffering from arthritis or chronic inflammatory joint disease.
3140286|NCT01615978|Experimental|Fixed dose: 5 mcg/kg|
3140287|NCT01615978|Experimental|Escalated dose: 10 mcg/kg|
3140288|NCT01615965|Experimental|micrometastases|Molecular biologic detection of micrometastases in lymph nodes of patients with localized prostate cancer treated with radical prostatectomy and lymphadenectomy.
3140289|NCT01615952||Sitting Position (head of bed 90 degrees)|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
3140382|NCT01615393|Active Comparator|Ribavirin capsule arm|
3140383|NCT01615393|Experimental|Ribavirin tablet arm|
3140290|NCT01615952||Semi-sitting position (45 degrees)|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
3140291|NCT01615952||Supine position|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
3140292|NCT01615939|Active Comparator|Single Shot Sciatic Nerve Block|Single shot sciatic nerve blocks will be performed by resident trainees supervised by faculty. Bupivacaine 0.625% with epinephrine 1:300,000 will be injected incrementally in 3-ml aliquots to a total volume of 0.4 ml/kg (minimum, 20 ml; maximum, 35 ml).
3140293|NCT01615939|Active Comparator|Continuous Sciatic Nerve Block|Continuous sciatic nerve block catheters will be performed using an insulated needle connected to the negative lead of a constant current nerve stimulator. The catheter will be advanced under ultrasound guidance. A test dose of 1.5% lidocaine with epinephrine will be injected to confirm catheter placement. All subjects will receive a portable pump that will infuse 0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr. The subjects will follow standard protocol discharge instructions in regards to removing the catheter themselves.
3140294|NCT01615913|Experimental|3% terbinafine patch|A 10‐cm2 patch containing 3 mg terbinafine and 2 mg ketoconazole
3140295|NCT01615913|Experimental|6% terbinafine patch|A 10‐cm2 patch containing 6 mg terbinafine and 2 mg ketoconazole
3140296|NCT01615913|Experimental|8% terbinafine patch|A 10‐cm2 patch containing 8 mg terbinafine and 2 mg ketoconazole
3140297|NCT01615900|Other|Teleconsultation|
3140298|NCT01615900|Other|Standard consultation|
3140299|NCT01615887|Experimental|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
3140300|NCT01615887|Placebo Comparator|Sugar pill|Placebo will be administered in the same fashion as the treatment arm
3140301|NCT01615874|Experimental|MF/F MDI 50/10 mcg BID|
3140302|NCT01615874|Experimental|MF/F MDI 100/10 mcg BID|
3140303|NCT01615874|Experimental|MF/F MDI 200/10 mcg BID|
3140304|NCT01615874|Active Comparator|BDP HFA 160 mcg BID|
3140305|NCT01615874|Active Comparator|Montelukast 5 mg QD (4 mg QD for 5-year-olds)|
3140306|NCT01615861|Experimental|IOL implantation|Hydrophilic acrylic lens implantation through a micro-incision phacoemulsification and cataract surgery (MICS)
3140307|NCT01615848|Experimental|mediterranean diet restricted calorie|1500 k/calories 47-51% carbohydrate 14-17% protein 33-36% fat: 7-7.6% saturated fat 22-30% monounsaturated & polyunsaturated fat
3140308|NCT01615848|Experimental|high protein diet, restricted calorie|1500 k/calories 40 % carbohydrate 30% protein 30% fat
3140309|NCT01615822|Experimental|OZ439 100mg single dose|OZ439 100mg single dose oral suspension
3140310|NCT01615822|Experimental|OZ439 100mg plus MQ 250mg single doses|Single dose OZ439 100mg oral suspension in combination with single dose MQ 250mg tablet
3140311|NCT01615822|Experimental|OZ439 400mg single dose|OZ439 400mg single dose oral suspension
3140312|NCT01615822|Experimental|OZ439 400mg plus MQ 750mg single doses|Single dose OZ439 400mg oral suspension in combination with single dose MQ 750mg tablets
3140313|NCT01615822|Placebo Comparator|Placebo|Placebo
3140314|NCT01615809|Experimental|Amphotericin B (ABELCET®)|"Drug: AMPHOTERICIN B Dosage form: Abelcet® 5mg/ml administered by inhalation. Dosage: 10 ml (50 mg) for the first week with a frequency twice a week. Dosage: from the second week onwards 5 ml (25 mg) with a frequency of a minimum separation of 72 hours between doses, until the neutrophil count is greater than or equal to 1500 cells/mm3.~Duration: 4-5 prophylaxis courses defined as each administration period during a neutropenia period, with a 4-6 weeks length considering the duration of neutropenia."
3140315|NCT01615796|Experimental|Cohort A1|GSK2140944 200mg single dose
3140316|NCT01615796|Experimental|Cohort A2|GSK2140944 600mg single dose
3140317|NCT01615796|Experimental|Cohort A3|GSK2140944 1200mg single dose
3140318|NCT01615796|Experimental|Cohort A4|GSK2140944 1800mg single dose
3140319|NCT01615796|Experimental|Cohort A5|GSK2140944 1800mg single dose
3140320|NCT01615796|Experimental|Cohort A6|GSK2140944 dose to be determined, single dose
3140321|NCT01615796|Experimental|Cohort B1|GSK2140944 400 mg repeat dose BID up to 7 days
3140322|NCT01615796|Experimental|Cohort B2|GSK2140944 750 mg repeat dose BID up to 7 days
3140323|NCT01615796|Experimental|Cohort B3|GSK2140944 1000 mg repeat dose BID up to 7 days
3140324|NCT01615796|Experimental|Cohort B4|GSK2140944 to be determined repeat dose BID up to 7 days
3140325|NCT01615796|Experimental|Cohort B5|GSK2140944 to be determined repeat dose TID up to 14 days
3140326|NCT01615796|Experimental|Cohort B6|GSK2140944 to be determined repeat dose TID up to 14 days
3140327|NCT01615783||Medicaid beneficiaries|Medicaid beneficiaries with at least one medical or pharmacy claim during each year in the identification period (2004-2006)
3140328|NCT01615770|No Intervention|Open Label CBT and Pharmacotherapy|All study participants received 8 weeks of cognitive and behavioral cessation and relapse prevention skills training (CBT) and nicotine patch therapy combined with 9 weeks of bupropion SR therapy. Following open-label, this group received general supportive therapy delivered via four telephone calls made to participants over a 12-week period.
3140329|NCT01615770|Experimental|Behavioral: cognitive behavior therapy|All study participants received 8 weeks of cognitive and behavioral cessation and relapse prevention skills training (CBT) and nicotine patch therapy combined with 9 weeks of bupropion SR therapy. Following open-label treatment, half the participants received an additional 12 weeks of CBT that combined clinic-based skills training sessions, voicemail monitoring and telephone counseling
3140330|NCT01615757|Experimental|Arm B, Ara-c - 12 gm/m2|Arm B will receive HIDAC at 12 gm/m2/cycle for 3 cycles , i.e. 2 gm/m2 BD , Day 1,3,5
3140331|NCT01615757|Active Comparator|Arm A. Ara-c 18 gm/m2|Arm A will receive HIDAC at 18 gm/m2/cycle for 3 cycles , i.e. 3 gm/m2 BD , Day 1,3,5
3140332|NCT01615744||Surgical ORIF calcaneal fx|
3140333|NCT01615744||Conservative treatment calcaneal fx|
3140334|NCT01615731|Active Comparator|Two sets of dilators|Two sets of osmotic dilators inserted 1 and 2 days pre-op
3140335|NCT01615731|Experimental|Mifepristone plus one set of dilators|One set of dilators plus mifepristone
3140418|NCT01615159|No Intervention|Self directed control|
3140336|NCT01615718|Experimental|Active Electrical Stim/Active Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
3140337|NCT01615718|Sham Comparator|Sham Electrical Stim/Sham Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with sham transcranial ultrasound for 20 minutes.
3140338|NCT01615718|Active Comparator|Active Electrical Stim/Sham Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with sham (placebo) transcranial ultrasound for 20 minutes.
3140339|NCT01615718|Active Comparator|Sham Electrical Stim/Active Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
3140340|NCT01615705||Blood Draw|"SOX Subjects:~The cohort consists of original subjects from the SOX Trial who consented to participate in the sub study."
3140341|NCT01615692||36-mth follow up visit|The cohort will consist of original subjects of the SOX Trial who consent to participate in the extension to follow up sub study.
3140342|NCT01615666||Healthy volunteers|Healthy volunteers who will undergo functional MRI (fMRI) to obtain fMRI index
3140343|NCT01615666||Alzheimer's disease|Individuals with Alzheimer's disease who will undergo functional MRI (fMRI) to obtain fMRI index
3140344|NCT01615666||Non-Alzheimer's dementia|Individuals with Non-Alzheimer's dementia who will undergo functional MRI (fMRI) to obtain fMRI index
3140345|NCT01615666||Amnestic mild cognitive impairment|Individuals with Amnestic mild cognitive impairment who will undergo functional MRI (fMRI) to obtain fMRI index
3140346|NCT01615666||Nonamnestic mild cognitive impairment|Individuals with Nonamnestic mild cognitive impairment who will undergo functional MRI (fMRI) to obtain fMRI index
3140347|NCT01615653|Active Comparator|EUS 1|
3140348|NCT01615653|Active Comparator|EUS 2|
3140349|NCT01615640||Osteosarcoma patients|Patients with an histologically proven osteosarcoma will be entered into the study.
3140350|NCT01615627|Experimental|Hypotonic Treprostinil Solution|Hypotonic Treprostinil Solution
3140351|NCT01615627|Active Comparator|Eutonic Treprostinil Solution|Eutonic Treprostinil Solution
3140352|NCT01615614|Experimental|Treatment A|Rilpivirine 25 mg once daily will be administered for 11 days
3140353|NCT01615614|Experimental|Treatment B|Rilpivirine 50 mg once daily will be administered for 11 days and rifabutin 300 mg once daily will be administered for 17 days
3140354|NCT01615614|Experimental|Treatment C|Rilpivirine (in a regimen to be determined based on an interim pharmacokinetic analysis of treatment A and B) will be administered for 11 days and rifabutin 300 mg once daily will be administered for 17 days.
3140355|NCT01615601||darunavir (PREZISTA)|PREZISTA co-administered with 100 mg ritonavir as per Canadian Product Monograph. (Observational Study)
3140356|NCT01615601||etravirine (INTELENCE)|INTELENCE co-administered with other antiretroviral medicinal products as per Canadian Product Monograph (Observational Study)
3140357|NCT01615588|Experimental|honey|Manuka honey
3140358|NCT01615575|Active Comparator|Haemorrhoidal dearterialisation|Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and addiction of rectal mucopexy.
3140359|NCT01615575|Active Comparator|Stapler haemorrhoidopexy|Haemorrhoidopexy was performed with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA.)
3140360|NCT01615562||PCOS adolescents|Post-menarchal females ages 14-17 with and without PCOS (15 each group for a total of 30 subjects).
3140361|NCT01615562||PCOS women|Women ages 18-40 with and without PCOS (15 each group for a total of 30 subjects).
3140362|NCT01615549|Active Comparator|Free training|
3140363|NCT01615549|Experimental|Proficiency-based training|
3140364|NCT01615536|Experimental|Canine fossa trephine group (CFT)|
3140365|NCT01615536|Active Comparator|Non Canine fossa trephine group (NonCFT)|
3140366|NCT01615523||Children/adolescents born preterm|
3140367|NCT01615523||Control children and adolescents|
3140368|NCT01615510|Experimental|Capsaicin (topical)|300 µL of 0.6% capsaicin in 45% ethanol, topically applied on the forearm intervention: tapentadol immediate release or placebo
3140369|NCT01615510|Experimental|Menthol (topical)|1000 µL of 40% menthol in 90% ethanol, topically applied on the forearm intervention: tapentadol immediate release or placebo
3140370|NCT01615497|Active Comparator|Standard Treatment as Usual (TAU)|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on alcohol and substance abuse.
3140371|NCT01615497|Experimental|Web-based CBT4CBT for alcohol plus TAU|A computerized program that teaches skills for stopping drug and alcohol use by increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc. plus standard treatment as usual.
3140372|NCT01615497|Active Comparator|Web-based CBT with minimal clinical contact|A computerized program that teaches skills for stopping drug and alcohol use by increasing coping skills such as how to understand patterns of drug and alcohol use, coping with cravings, etc. plus 10 minute check in with clinician.
3140373|NCT01615484|Experimental|Ex-vivo lung perfusion (EVLP) with STEEN Solution™|The perfusion of the lungs will be performed using STEEN Solution™. The lungs will be physiologically assessed during ex vivo perfusion with STEEN Solution™ perfusate.
3140374|NCT01615484|No Intervention|Lung transplant from conventional brain-dead organ donor|No experimental procedures will be carried out.
3140375|NCT01615471|Active Comparator|Large Group|In person group sessions in large group format (up to 125 others)
3140376|NCT01615471|Active Comparator|Small group|Small group in person sessions (up to 25 other participants)
3140377|NCT01615458|Active Comparator|Usual Care|Patients will receive their usual care from providers at the clinic.
3140378|NCT01615445|Active Comparator|Resveratrol|Group A Participants will received resveratrol 500 mg twice daily for 1 week then 1000 mg twice daily for 3 weeks, according to tolerance. They will discontinue medication for 2 weeks. The will receive placebo for 4 weeks.
3140379|NCT01615445|Placebo Comparator|Placebo|Group B (n=6) Will receive placebo for 4 weeks, they will discontinue medication for two weeks. Then receive resveratrol for 4 weeks
3140380|NCT01615419||Cohort|
3140381|NCT01615406|Experimental|Drug: 99mTc-MIP-1404|20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
3140384|NCT01615380|Active Comparator|CBT+ Contact|In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
3140385|NCT01615380|Experimental|CBT+ Exercise|Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
3140386|NCT01615367|Experimental|NEW Tx|25 people will be randomized to NEW Tx, a weekly individualized psychotherapy. Therapy is 20 weeks long.
3140387|NCT01615367|Active Comparator|Treatment as usual (TAU)|25 people will be randomized to TAU and will meet with their psychiatrist as often as clinically needed over the 20 week study duration.
3140388|NCT01615354|Placebo Comparator|Placebo|
3140389|NCT01615354|Experimental|Treatment|
3140390|NCT01615328|Experimental|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs(TM), which is the PEEK cage filled with b-TCP.
3140391|NCT01615328|Experimental|Bonion|The ACDF surgery will be carried out with Bonion(TM), which is the PEEK cage with HA/DBM.
3140392|NCT01615302|Active Comparator|Mucosa advancement flap|
3140393|NCT01615302|Experimental|Mucosa advancement flap + PRP|Platelet rich plasma added to the mucosa advancement flap
3140394|NCT01615289|Active Comparator|Green tea extract, 250 ml|Single intragastric instillation of 250 ml green tea extract
3140395|NCT01615289|Active Comparator|Green tea extract, 500 ml|Intragastric instillation of 500 ml green tea extract solution
3140396|NCT01615289|Placebo Comparator|Control solution, 250 ml|Intragastric instillation of 250 ml control solution
3140397|NCT01615289|Placebo Comparator|Control solution, 500 ml|Single intragastric instillation of 500 ml control solution
3140398|NCT01615276|Placebo Comparator|Protein ingestion|Protein ingestion directly after the contralateral leg received NMES
3140399|NCT01615276|Experimental|Protein ingestion after NMES|Ingestion of intrinsically labeled protein, directly after one hour of Neuromuscular electrical stimulation (NMES)
3140400|NCT01615263|Active Comparator|Double lumen tube|Lung isolation with a left double lumen tube (BronchoCath, Mallinckrodt Medical, Cornamaddy, Athlone, Westmeath, Ireland.
3140401|NCT01615263|Active Comparator|Bronchial blocker|Lung isolation with a bronchial blocker with the inner channel closed (Fuji Uniblocker 9F, Fuji System Corporation, Tokyo, 113-0033, Japan) inserted via a 8.0 mm simple lumen endotracheal tube.
3140402|NCT01615250|No Intervention|Standard therapy|Treatment with standard therapy. Cardiospec shock-wave therapy
3140403|NCT01615250|Active Comparator|Stem cells|Group of of intramyocardial implantation of peripheral mononuclear cells with CD34+ stem cells in patient with ischemic cardiomyopathy after preparatory course of shock - wave therapy.
3140404|NCT01615237|Active Comparator|CBP + PF|Field sites randomly assigned to Arm 2 will receive as an intervention current best practices and quarterly audits and performance feedback reports (PF) on provider delivery of cessation services using chart audit procedures that we have used successfully in prior work. Depending on what is used at the site, paper or Electronic Dental Record, we will work with the site to create a registry of patients who are tobacco users.
3140405|NCT01615237|Active Comparator|CBP + PF + P4P|Field sites randomly assigned to this implementation condition (Arm 3) will receive current best practices (CBP), quarterly audit and performance feedback reports (PF), and financial incentives (pay for performance, P4P) for every documented (documentation in patient chart of counseling, prescription, or referral to the quit-line) delivery of adherence to clinical practice guidelines.
3140406|NCT01615237|Active Comparator|Current Best Practices (CBP)|All dental field sites will receive current best practices (CBP) for training and technical assistance in promoting adoption of clinical practice guidelines for treating tobacco dependence.
3140407|NCT01615224|No Intervention|single dose|Patients receive the standard treatment with 800mcg of vaginal misoprostol
3140408|NCT01615224|Experimental|repeated doses|patients receive 800mcg of vaginal misoprostol. In addition to this they receive repeated doses of 400mcg oral misoprostol after 3 and 5 hours. Women of more than 9 weeks pregnancy according to last menstrual period will be given a choice of vacuum aspiration or further medical treatment with 2 additional doses of misoprostol given after 7 and 9 hours after the initial vaginal treatment.
3140409|NCT01615211|No Intervention|Standard treatment|patients will receive standard treatment with 200mg Mifepristone and after 36-48 hours 800 mcg of misoprostol vaginally
3140410|NCT01615211|Active Comparator|trilostane|patients will receive Day 1: Mifepristone 200 mg and Trilostane 120mg 1 tablet twice and Day 2 Trilostane 240mg twice. On Day 3 800 mcg misoprostol will be given vaginally.
3140411|NCT01615211|Active Comparator|Letrozole|Patients will receive on Day 1 Mifepristone 200mg and Letrozole 2,5mg 3 tablets and on Day 2 Letrozole 2,5mg 3 tablets. On day 3 800mcg of misoprostol will be given vaginally
3140412|NCT01615198|Experimental|LCZ696|Participants were treated with one LCZ696 100 mg tablet and one placebo of LCZ696 every day (qd) for 4 weeks along with placebo of Olmesartan 10 mg capsule qd. Participants were then up-titrated to LCZ 200 mg tablet and one placebo of LCZ696 qd for 6 weeks along with placebo of Olmesartan 20 mg capsule qd. Participants, who did not achieve their goal BP, were uptitrated to 2 LCZ696 200 mg tablets (LCZ696 400 mg) qd for 4 weeks along with placebo of Olmesartan 40 mg capsule qd.
3140413|NCT01615198|Active Comparator|Olmesartan|Participants were treated with olmesartan 10 mg qd for 4 weeks along with 2 placebo of LCZ696 tablets qd. Participants were then uptitrated to olmesartan 20 mg qd for 6 weeks along with 2 placebo of LCZ696 tablets qd. Participants, who did not achieve their goal BP, were uptitrated to olmesartan 40 mg qd for the remaining 4 weeks and 2 placebo LCZ696 tablets qd.
3140414|NCT01615185|Experimental|sulpiride plus amisulpride|sulpiride 800mg/d + amisulpride 400mg/d
3140415|NCT01615185|Active Comparator|full-dose amisulpride|amisulpride 800mg/d
3140416|NCT01615172|Active Comparator|Aortic cannulation|routine placement of aortic cannula
3140417|NCT01615172|Active Comparator|axilaris cannulation|new type of cannulation
3270159|NCT00696657|Experimental|E|
3140420|NCT01615146|Experimental|Therapeutic Platelet Transfusion Arm|Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions.
3140421|NCT01615146|Active Comparator|Prophylactic Platelet Transfusion Group|Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion (a single dose of random donor platelets (4 unit pool or random donor platelets or one apheresis unit) when the measured platelet count is < 10 x 109/L.
3140422|NCT01615120|Experimental|GTx-758 125mg|one GTx-758 tablet orally administered daily
3140423|NCT01615120|Experimental|GTx-758 250 mg|two GTx-758 tablets orally administered daily
3140424|NCT01615107|Experimental|GROUP 1: Oxytocin infusion alone|GROUP 1: Oxytocin infusion alone
3140425|NCT01615107|Experimental|double balloonand oxytocin|insertion of the double balloon and oxytocin
3140426|NCT01615094||High-risk Stage B Heart Failure Patients|American College of Cardiology/American Heart Association (ACC/AHA) asymptomatic Stage B patients with B-Type natriuretic peptide (BNP) ≥ 65pg/ml
3140427|NCT01615081|Active Comparator|Sucrose solution|75 g sucrose (75 g carbohydrate) desolved in 750 ml water
3140428|NCT01615081|Experimental|Malt extract solution|183 g malt extract (corresponding to 75 g carbohydrate and 103 ml water) desolved in 647 ml water
3140429|NCT01615068||Cohort|
3140430|NCT01615055|Experimental|Fluoxetine tablets|
3140431|NCT01615055|Placebo Comparator|Placebo tablets|
3140432|NCT01615042|Experimental|Dose Escalation/High Dose Lenalidomide|Subjects are given a single dose of the drug while they are observed and tested for a period of time. If they do not exhibit any adverse side effects the dose is escalated, and a new group of subjects is then given a higher dose.
3140433|NCT01615029|Experimental|Daratumumab|Participants will receive daratumumab along with Lenalidomide and dexamethasone.
3140434|NCT01615016|Experimental|MISurf|Minimally Surfactant application via small tube inserted into the trachea under CPAP therapy without formal intubation and without mechanical ventilation
3140435|NCT01615016|Active Comparator|InSurE|Surfactant application via Intubation - Surfactant Application - Extubation sequence
3140436|NCT01615003|Experimental|Xuesaitong soft capsule group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
3140437|NCT01615003|Placebo Comparator|control group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
3140438|NCT01614990|Active Comparator|Macimorelin|
3140439|NCT01614990|Placebo Comparator|Placebo|
3140440|NCT01614977|Experimental|Methylprednisolone|"Clarithromycin 15mg/Kg/day divided into 2 doses for 28 days.~Rifambutin 20mg/Kg/day divided into 2 doses for 28 days.~Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days."
3140441|NCT01614977|No Intervention|Placebo|"Clarithromycin 15mg/Kg/day divided into 2 doses for 28 days.~Rifambutin 20mg/Kg/day divided into 2 doses for 28 days.~placebo pills with an identical outward appearance and volume prescribed according to the same schedule."
3140442|NCT01614964|Experimental|AQ-13|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
3140443|NCT01614964|Active Comparator|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention: Active Comparator: Coartem. Participants randomized to the Coartem arm will be treated with 80 mg artemether and 480 mg lumefantrine at the time of diagnosis and 8 hours later on day 1, the same doses (80 mg artemether and 480 mg lumefantrine) twice on day 2 (24 and 36 hours after diagnosis) and twice more on day 3 (48 and 60 hours after diagnosis) for total oral doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
3140444|NCT01614951|Experimental|Pulmonary perfusion|
3140445|NCT01614951|Experimental|Pulmoplegia|
3140446|NCT01614951|Other|Control group|
3140447|NCT01614938|Active Comparator|cisplatin-radiotherapy (CRT)|The arm receiving docetaxel-cisplatin neoadjuvant chemotherapy followed by concurrent weekly cisplatin and radiotherapy
3140448|NCT01614938|Experimental|cetuximab-radiotherapy (ERT)|The arm receiving docetaxel-cisplatin neoadjuvant chemotherapy followed by concurrent cetuximab and radiotherapy
3140449|NCT01614912|Experimental|SM-13496|
3140450|NCT01614899|Experimental|SM-13496 40mg|
3140451|NCT01614899|Experimental|SM-13496 80mg|
3140452|NCT01614899|Placebo Comparator|Placebo|
3140453|NCT01614886|Experimental|1 step|
3140454|NCT01614886|Active Comparator|3 step|
3140455|NCT01614873|Active Comparator|Pressure Support Ventilator|"Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden).~During pressure support the inspiratory muscles are assisted by a constant inspiratory pressure adjusted by the prescriptor and applied to the airway by either an invasive or a non invasive interface. Then the subject initiate the inspiratory effort and a constant pressure is delivered to the airway in order to assist inspiration. Three levels of pressure will be tested (5 cmH2O, 8 cmH2O and 12 cmH2O)"
3140456|NCT01614873|Experimental|NAVA|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with trigger adjusted on diaphragmatic electromyogram. Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). During NAVA the inspiratory muscles are assisted by a pressure which is proportional to this electrical activity. Then the subject initiate the inspiratory effort and a pressure proportional to the integrated EMG activity is delivered to the airway in order to assist inspiration. The adjustment of the level of NAVA (expressed in cmH2O/microvolt) will be adjusted in order to obtain a peak pressure similar to pressure support (5 cmH2O, 8 cmH2O and 12 cmH2O)
3140457|NCT01614847|Experimental|Hypo-osmolar artificial tear|At random, subjects will receive hypo-osmolar artificial tear or a control (normal saline).
3140459|NCT01614834||chronic urticaria patients|all patients suffering from chronic forms of urticaria (chronic spontaneous urticaria as well as chronic inducible forms such as cold contact urticaria)
3140460|NCT01614821|Experimental|Treatment Arm|PCI-32765; ibrutinib
3140461|NCT01614808||Observational|Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance (NMR) spectroscopy and principal component analysis (PCA). Tumor tissue may also be examined by NMR and PCA.
3140462|NCT01614795|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 1 hour and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.
3140463|NCT01614782|Experimental|0.35 mg MK-5823 - Healthy Participants|
3140464|NCT01614782|Experimental|0.7 mg MK-5823 - Healthy Participants|
3140465|NCT01614782|Experimental|1.4 mg MK-5823 - Healthy Participants|
3140466|NCT01614782|Experimental|2.8 mg MK-5823 - Healthy Participants|
3140467|NCT01614782|Experimental|1.4 mg MK-5823 - Participants with T2DM|
3140468|NCT01614782|Experimental|2.8 mg MK-5823 - Participants with T2DM|
3140469|NCT01614769|Experimental|Placebo → Glimepiride 2 mg → Glimepiride 4 mg|Participants received placebo in the first period, 2 mg glimepiride in the second period and 4 mg glimepiride in the third period, with a 7-day washout between each period.
3140470|NCT01614769|Experimental|Glimepiride 2 mg → Glimepiride 4 mg → Placebo|Participants received 2 mg glimepiride in the first period, 4 mg glimepiride in the second period and placebo in the third period, with a 7-day washout between each period.
3140471|NCT01614769|Experimental|Glimepiride 4 mg → Placebo → Glimepiride 2 mg|Participants received 4 mg glimepiride in the first period, placebo in the second period and 2 mg glimepiride in the third period, with a 7-day washout between each period.
3140472|NCT01614769|Experimental|Placebo → Glimepiride 4 mg → Glimepiride 2 mg|Participants received placebo in the first period, 4 mg glimepiride in the second period and 2 mg glimepiride in the third period, with a 7-day washout between each period.
3140473|NCT01614769|Experimental|Glimepiride 2 mg → Placebo → Glimepiride 4 mg|Participants received 2 mg glimepiride in the first period, placebo in the second period and 4 mg glimepiride in the third period, with a 7-day washout between each period.
3140474|NCT01614769|Experimental|Glimepiride 4 mg → Glimepiride 2 mg → Placebo|Participants received 4 mg glimepiride in the first period, 2 mg glimepiride in the second period and placebo in the third period, with a 7-day washout between each period.
3140475|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.1 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
3140476|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.01 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.01 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
3140477|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.03 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.03 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
3140478|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.06 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.06 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
3140479|NCT01614756|Experimental|Dose Escalation- BMS-981164 (0.1 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
3140480|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.3 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.3 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
3140481|NCT01614756|Experimental|Dose Escalation-BMS-981164 (1 mg/kg SC) or Placebo|"Part 1~Single dose of BMS-981164 1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
3140482|NCT01614756|Experimental|Dose Escalation-BMS-981164 (1 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 1 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
3140483|NCT01614756|Experimental|Dose Escalation-BMS-981164 (3 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 3 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
3140484|NCT01614756|Experimental|Dose Escalation-BMS-981164 (10 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 10.0 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
3140485|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 1)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 3 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 0 mg, once, single dose"
3140486|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 2)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0.1 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
3140487|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 3)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 0.1 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
3140488|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 4)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 3.0 mg/kg and >1.0mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
3140489|NCT01614743|Experimental|IncobotulinumtoxinA|
3140490|NCT01614743|Placebo Comparator|Placebo|
3140491|NCT01614730|Sham Comparator|Modified Neurotech Vital Device|Checking to see no contraction is stimulated during treatment with the Modified Neurotech Device
3140492|NCT01614730|Active Comparator|Neurotech Vital Device|Checking to see a contraction is stimulated during treatment of the Neurotech Vital Device
3140493|NCT01614717|Active Comparator|Treatment Group|CRT-P Implant. Patients randomized in Treatment Group will have the device programmed to optimized DDD pacing
3270160|NCT00696657|Experimental|F|
3140495|NCT01614704||Adjuvant treatment|Patients in this group will be offered the option of ovarien cryopreservation as well as the follow up of the follicule stock during chemotherapy.
3140496|NCT01614704||Neo adjuvant treatment|patients in this group will only have the follow up of the follicule stock.
3140497|NCT01614691|Experimental|SPARC1203 low dose|
3140498|NCT01614691|Experimental|SPARC1203 mid dose|
3140499|NCT01614691|Experimental|SPARC1203 high dose|
3140500|NCT01614691|Placebo Comparator|Placebo|
3140501|NCT01614678|Other|AIR OPTIX® COLORS Auto, then AIR OPTIX® COLORS Semi-auto|Lotrafilcon B contact lens with color, automated, worn first, with Lotrafilcon B contact lens with color, semi-automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
3140502|NCT01614678|Other|AIR OPTIX® COLORS Semi-auto, then AIR OPTIX® COLORS Auto|Lotrafilcon B contact lens with color, semi-automated, worn first, with Lotrafilcon B contact lens with color, automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
3140503|NCT01614665|Active Comparator|Prograf®|oral
3140504|NCT01614665|Experimental|Advagraf®|oral
3140505|NCT01614652|Experimental|Parachute Implant and All Appropriate Medical Therapy (AAMT)|
3140506|NCT01614652|No Intervention|All Appropriate Medical Therapy (AAMT)|
3140507|NCT01614639|Experimental|Traditional Acupuncture|Traditional Acupuncture given at 2 visits.
3140508|NCT01614639|Experimental|Electroacupuncture|Electro-acupuncture given at 2 visits.
3140509|NCT01614613|Experimental|Intended BGM Users|Subjects were assigned to subgroups according to their initial glucose levels. SUBGROUP 1 goal: safely decrease subject glucose levels during the visit. SUBGROUP 2 goal: safely raise subject glucose levels. Also, blood samples were modified to obtain glucose concentrations across the needed glucose ranges while maintaining subject safety. Staff tested the blood samples using the 6 Blood Glucose Monitoring Systems. Bayer G3/Tatsu System;Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips; Freestyle Lite® Meter and Test Strips with ZipwikTM tabs;OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips;One Touch® VerioTM Pro/One Touch® VerioTM Test Strips;Truetrack® Meter/Truetrack® Test Strips
3140510|NCT01614600|Experimental|DAILIES® AquaComfort Plus®|Nelfilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 2 weeks
3140511|NCT01614587||Cases|"Early, unexplained recurrence (within six months of procedure) after Sacrocolpopexy~The recurrence required treatment (surgery or pessary)"
3140512|NCT01614587||Controls|"Sacrocolpopexy during the same period~No recurrence, no reoperation, no retreatment to date (minimum of 12 months from surgery)"
3140513|NCT01614574|Experimental|Investigational|velaglucerase alfa
3140514|NCT01614548||all patients|We selected 9 cities (Zhengzhou, Luoyang, Kaifeng, Anyang, Xinyang, Zhoukou, Shangqiu, Nanyang, Zhumadian) by probability proportional to size sampling from geographical regions in central China. All cases with complete follow-up data of histological-proven prostate cancer treated in 2003 and 2008 at 14 department of urology in the 9 cities were retrospectively collected. Only patients with newly diagnosed prostate cancer were included in the study. Those with a history of prostate cancer who were treated for another disease were excluded from study.
3140515|NCT01614535|Experimental|Female group|Female gender patients undergoing thyroidectomy
3140516|NCT01614535|Active Comparator|Male group|Male gender patients undergoing thyroidectomy
3140517|NCT01614522|Experimental|HER-2 Amplified|
3140518|NCT01614522|Experimental|HER-1 & HER-2 Co-expression|
3140519|NCT01614509|Experimental|Monotherapy group|The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.
3140520|NCT01614509|Experimental|Combined group|The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The Bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
3140521|NCT01614483|Experimental|Yellow cassava + placebo capsule|
3140522|NCT01614483|Placebo Comparator|White cassava + placebo capsule|
3140523|NCT01614483|Active Comparator|White cassava + B-carotene capsule|
3140524|NCT01614470|Experimental|Part 1: Ivacaftor First, Then Placebo|Ivacaftor 150 milligram (mg) tablet orally twice daily for 8 weeks in treatment period 1 followed by placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
3140525|NCT01614470|Experimental|Part 1: Placebo First, Then Ivacaftor|Placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 1 followed by ivacaftor 150 mg tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
3140526|NCT01614470|Experimental|Part 2: Ivacaftor|Ivacaftor 150 mg tablet orally twice daily for 16 weeks.
3140527|NCT01614457|Experimental|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
3140528|NCT01614457|Placebo Comparator|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
3140529|NCT01614444|Active Comparator|Acupressure Treatment|
3140530|NCT01614444|Placebo Comparator|Placebo Acupressure Treatment|
3140531|NCT01614431|Experimental|N acetyl cysteine|NAC will be given to cystinosis patients and we will observe the renal function status and a marker of oxidative stress (TBARS)
3140532|NCT01614418|Experimental|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation using BARRX HALO90 catheter
3140533|NCT01614405|Placebo Comparator|Placebo|6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada. Then there is an option for an 18 month follow-up study.
3140534|NCT01614405|Active Comparator|Truvada and Kaletra|Patients will be take Truvada and Kaletra for 6 months with the option of open label for additional 18 months.
3140535|NCT01614392|Experimental|Lower Extremity Power Training|
3140536|NCT01614392|Experimental|Lower Extremity power training|
3140537|NCT01614379||Healthy control subject|10 healthy control subjects for statistical comparison
3140538|NCT01614379||Type 1 diabetic patient|40 type 1 diabetic patients with diabetic foot ulcers.
3140539|NCT01614366|Active Comparator|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
3140540|NCT01614366|Experimental|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
3140541|NCT01614366|Experimental|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
3140542|NCT01614366|Experimental|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
3140543|NCT01614353||Study Cohort|All participants (N=30) will be asked to identify perceptions and behaviors surrounding the medication-taking process using technology-assisted prompts and recordings. Half (n=15) of the participants will participate in two hermeneutic interviews using an interpretive phenomenological approach to generate an interpretation of the meaning of medication taking.
3140544|NCT01614340|Other|Usual Care|Usual Physical Therapy Plan of Care
3140545|NCT01614340|Other|Usual Care Plus Pain Management Program|Behavioral: Cognitive-Behavioral Pain Self-management Program.
3140546|NCT01614327||Retinal Screening; Diabetes 1 and 2|Patients diagnosed as either having Pre-Diabetes, Diabetes 1 or Diabetes 2
3140547|NCT01614314|Active Comparator|Auto-instructional guide|The subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
3140548|NCT01614314|Experimental|Preceptorship|The subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
3140549|NCT01614301|Experimental|Experimental Arm|Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+ Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory acting therapy, day 1+. Treatment until disease progression or toxicity
3140550|NCT01614301|Other|Controll Arm|Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks. The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.
3140551|NCT01614288|Active Comparator|Knee Arthroscopy + HTO|
3140552|NCT01614288|Active Comparator|HTO Alone|
3140553|NCT01614275|Experimental|Technology-enhanced Parent Training|The investigators will demonstrate that web-based instructional technologies provides an efficient and effective mechanism for training military parents of children with autism, regardless of their geographic location, to implement effective behavior management and teaching strategies with high procedural integrity (90% accuracy).
3140554|NCT01614275|Experimental|Technology-enhanced Tutor Training|The investigators will demonstrate that web-based instructional technologies provides an efficient and effective mechanism for training tutors to implement early intervention services that are commonly used with children diagnosed with autism with high procedural integrity (above 80%).
3140555|NCT01614275|Experimental|Technology-enhanced Early Intensive Behavioral Intervention|The investigators will demonstrate that technology-enhanced service delivery will provide remote access to efficient and effective EIBI services to military families affected by autism.
3140556|NCT01614275|Placebo Comparator|Wait-list No-intervention Control Group|Tutors and families will be assigned to treatment and control groups using the process of minimization, which has been recommended for small clinical trials because it minimizes differences between the groups on relevant covariables while guarding against bias in ways comparable to simple randomization. The control group will not receive intervention services.
3140557|NCT01614262|Experimental|Continuous Glucose Monitoring|The Continuous Glucose Monitoring (CGM) arm will receive care based upon results from there CGM data; treatment decisions are based on algorithm and CGM data
3140558|NCT01614262|Active Comparator|Self Monitoring Blood Glucose|Subjects in the Self Monitoring Blood Glucose group will have treatment decisions based on self monitored blood glucose values and not CGM values, per current standard of care.
3140559|NCT01614249|Placebo Comparator|Soybean oil soft gels|Participants on this arm will receive a dietary supplement of OmegaVia soybean oil soft gels as a placebo for 8 weeks with bi-weekly follow-up visits to monitor side effects and compliance.
3140560|NCT01614249|Experimental|Fish oil omega-3 EPA-rich soft gels|Participants will receive OmegaVia fish oil omega-3 EPA-rich soft gels to take orally for eight (8) weeks with bi-weekly follow-up visits for monitoring of side effects and compliance and data collection.
3140561|NCT01614236|Active Comparator|control|patients will be randomized similarly but will undergo surgery under epidural analgesia
3140562|NCT01614236|Active Comparator|Lyrica|Patients will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
3140563|NCT01614223|Active Comparator|ACP treatment|
3140564|NCT01614223|Active Comparator|Corticosteroid treatment|
3140565|NCT01614210|Experimental|All patients|All patients enrolled in the study.
3140566|NCT01614197|Other|Single Arm|This is a single agent study of Temsirolimus with Etoposide and Cyclophosphamide
3140567|NCT01614184|Experimental|All patients|All patients enrolled in study.
3140568|NCT01614171|Experimental|Growth hormone therapy|Growth hormone treatment for 6 months
3140569|NCT01614158||acute N-AION (< 7 d)|"physical, intellectual and linguistic abilities, in order to understand the test requirements~willingness to comply with the protocol (4 visits)~45 - 80 years, informed consent~acute N-AION (< 7 d)~D-BCVA > 0.1 (2/20)~RAPD ≥ 0.3 logE steps (neutral density filters)"
3140570|NCT01614145||Proven/probable CNS IA|Immunocompromised patients with proven/probable invasive CNS Aspergillosis based on modified criteria by the EORTC/MSG
3140571|NCT01614145||Possible/No CNS IA|Immunocompromised patients with possible/NoIA invasive CNS Aspergillosis based on modified criteria by the EORTC/MSG
3140572|NCT01614132|Experimental|Vincristin, CCNU, cis-platin|"radiotherapy and concomitant chemotherapy (7 cycles of 7 days):~2 mg/m2 vincristin i.v.~55,0 Gy Posterior cranial fossa (M0)~55,0 Gy Posterior cranial fossa / cerebral metastases + 49,6 Gy spinal metastases (M1-M3)~maintenance chemotherapy (8 cycles of 42 days):~once at day 1 at each cycle: 70 mg/m2 cis-platin i.v. 75 mg/m2 CCNU oral 2 mg/m2 vincristin i.v.~once at day 8 and 15 at each cycle: 2 mg/m2 vincristin i.v."
3140573|NCT01614119|Experimental|Sportsmen|One single group of active healthy subjects was investigated
3140692|NCT01613248|Experimental|MK-1602 10 mg|MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
3141993|NCT01604044|Active Comparator|rFSH plus rLH|
3140574|NCT01614106|Experimental|Intervention|The Retention Clinic will incorporate HIV primary care and mental health services with on-site substance abuse treatment and patient navigation. The central components will include: Primary HIV Care; Mental Health Services; Skill-building; and On-Site substance abuse treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
3140575|NCT01614106|No Intervention|Treatment as Usual (TAU)|The treatment as usual (TAU) group condition will represent standard of care at both of the participating clinics. Standard of care at both clinics includes primary HIV care, the provision of mental health services, and the assignment of a clinic case manager. These case managers meet with patients when they first come to clinic and then meet with them as needed and typically offer substance-using patients a referral to substance abuse treatment in the community as needed. Case managers usually do not follow up to determine the uptake of these referrals.
3140576|NCT01614093|Active Comparator|Oxytocin/Placebo|Each participant will receive intranasal oxytocin 24IU or intranasal saline 24IU in random order. All results will be reported by treatment, the sample is too small for order effects.
3140577|NCT01614093|Active Comparator|Placebo/Oxytocin|Each participant will receive intranasal oxytocin 24IU or intranasal saline 24IU in random order. All results will be reported by treatment, the sample is too small for order effects.
3140578|NCT01614080||High sc-tPA/tc-tPA ratio group|A threshold value of the sc-tPA/tc-tPA ratio will be defined as the median value found in the population. The High sc-tPA/tc-tPA ratio group will be defined as the group of patients with a sc-tPA/tc-tPA ratio higher than the median
3140579|NCT01614080||Low sc-tPA/tc-tPA ratio|A threshold value of the sc-tPA/tc-tPA ratio will be defined as the median value found in the population. The Low sc-tPA/tc-tPA ratio group will be defined as the group of patients with a sc-tPA/tc-tPA ratio lower than the median
3140580|NCT01614067|Experimental|Delayed Start|"Study subjects will receive be randomized to receive 7 days of pre-treatment with a GnRH antagonist (Delayed Start) before standard ovarian stimulation with FSH/LH, or standard ovarian stimulation (Conventional Start) with no pre-treatment."
3140581|NCT01614067|Active Comparator|Conventional Start|Ovarian stimulation with standard antagonist protocols (no delay).
3140582|NCT01614054|Experimental|Survey Group|Patients will receive a survey along with their meal tray, provided by Food and Nutrition Services. The survey will consist of questions related to smoking habits, desire for NRT and desire for assistance with smoking cessation. The results of these surveys will be collected by allied health professionals and forwarded to the CTU team. The CTU team will then be encouraged to use that information to engage in a discussion with the patient regarding prescription of NRT. It will then be left to the discretion of the HCP whether or not to prescribe NRT taking into account patient preference, absence of contraindications and clinical benefit. All those participating in the survey will be offered referral to a smoking cessation clinic upon discharge.
3140583|NCT01614054|No Intervention|Standard of Care|In the control arm, surveys will also be given out to all patients along with their meal trays. However, these surveys will include only questions related to smoking habits in order to get a baseline number of smokers. The surveys will then be collected by the allied health and nursing staff and forwarded only to the research team. The HCP taking care of the patients will still provide standard of care treatment with NRT and smoking cessation referral as clinically indicated.
3140584|NCT01614041|Active Comparator|Control Group|Patient randomized to control group is administrated with usual dose of tandospirone treatment, 30 mg/day
3140585|NCT01614041|Experimental|Study Group|Comparative high dose of tandospirone treatment, 60 mg/day
3140586|NCT01614028|Active Comparator|Total Hip Arthroplasty using Fitmore femoral stem|
3140587|NCT01614028|Active Comparator|Total Hip Arthroplasty using M/L Taper Femoral stem|
3140588|NCT01614015|Experimental|Supervision as Usual|Supervision as Usual
3140589|NCT01614015|Experimental|Observation Based Supervision|Behavioral
3140590|NCT01614002||carcinoma, Doce onkovis (Docetaxel)|treatment in mono- or combination therapy with Docetaxel of breast cancer, non-small cell lung cancer, prostata carcinoma, adenocarcinoma of the stomach and advanced squamous cell carcinoma of the head/neck region.
3140591|NCT01613989|Active Comparator|Treatment 1|Reference group, installation of hip prothesis following standard procedure
3140592|NCT01613989|Active Comparator|Treatment 2|:treatment group,installation of hip prosthesis with assistance by computer based on imaging EOS
3140593|NCT01613976|Experimental|Panobinostat and Azacitidine|combination regimen
3140594|NCT01613963||Patients with ocular inflammation|Patients with ocular inflammation
3140595|NCT01613950|Experimental|BYL719 + AUY922|Dose finding study to estimate the maximum tolerated dose(s) (MTD) and/or recommended dose(s) for safety expansion (RDE) followed by an expansion phase to further assess the safety and preliminary activity of the combination. BYL719 tablets will be administered orally on a daily schedule (q.d.). a b.i.d. regimen may be explored. AUY922 will be administered by IV infusion once per week.
3140596|NCT01613937|Experimental|Lifestyle|12 once weekly Lifestyle training program
3140597|NCT01613924|Placebo Comparator|Heat based treatment/no treatment|Split face treatment with handheld acne heat based device and no treatment
3140598|NCT01613924|Active Comparator|Heat based treatment/benzoyl peroxide|Split face treatment with handheld acne heat based device and benzoyl peroxide 4%
3140599|NCT01613911||Epileptics having invasive monitoring|People between 10 and 65 years of age with epilepsy and who are coming in to have invasive electrophysiological monitoring.
3140600|NCT01613898||CTX Group|
3140601|NCT01613885||Twins|Twins that are ages 0 to 80 years, with or without allergy disease.
3140602|NCT01613872|No Intervention|Control|Wait List Control
3140603|NCT01613872|Experimental|Mindfulness Based Stress Reduction|An 8 week standardized protocol of stress reduction using gentle yoga and meditation
3140604|NCT01613846|Experimental|Sorafenib followed by pazopanib|"Sorafenib 400 mg bid orally until progression or intolerable toxicity, followed by pazopanib 800 mg once daily orally until progression or intolerable toxicity.~During first- and second-line, treatment visits are scheduled in weeks 0,2,4,8,12, and every 4 weeks thereafter, with tumor assessments and electrocardiogram after every second cycle (every 8 weeks)."
3140693|NCT01613248|Experimental|MK-1602 25 mg|MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
3141199|NCT01609582|Experimental|TAK-875 50 mg|TAK-875 50 mg tablets, orally, once daily for up to 6 years.
3140605|NCT01613846|Experimental|Pazopanib followed by Sorafenib|"Pazopanib 800 mg once daily orally until progression or intolerable toxicity, followed by Sorafenib 400 mg bid orally until progression or intolerable toxicity:~During first- and second-line, treatment visits are scheduled in weeks, 0,2,4,8,12, and every 4 weeks thereafter, with tumor assessments and electrocardiogram after every second cycle (every 8 weeks)."
3140606|NCT01613833||Primary OA Group|Subjects who are to undergo primary total knee arthroplasty due to primary OA which may include but is not limited to bilateral or peripheral involvement with no significant history of overuse or trauma to the joint.
3140607|NCT01613833||Secondary/Post-traumatic OA Group|Subjects who are to undergo primary total knee arthroplasty due to osteoarthritis of the knee that is secondary to injury or overuse of the joint.
3140608|NCT01613820|Experimental|Ketamine plus placebo|Subjects assigned to this paradigm will receive a 15 minute infusion of normal saline (placebo) followed by IV ketamine at 0.25mg/kg over 45 minutes twice a week for 3 weeks.
3140609|NCT01613820|Experimental|Scopolamine plus placebo|Subjects will receive a 15 minute infusion of IV scopolamine 2ug/kg followed by a 45 minute infusion of normal saline (placebo).
3140610|NCT01613820|Experimental|Ketamine plus scopolamine|Subject will receive an IV scopolamine infusion at a dose of 2ug/kg over 15 minutes, followed by an IV infusion of ketamine at a dose of 0.25mg/kg over 45 minutes.
3140611|NCT01613807|Experimental|Mix 50/50|3 doses of Mix 50/50 at mealtime
3140612|NCT01613807|Active Comparator|Usual insulin regimen|3 injections of Humalog(r) daily with meals; 3 injections of Humulin N (r) daily on rising, mid-afternoon, and at bedtime
3140613|NCT01613794|No Intervention|No intervention|
3140614|NCT01613794|Experimental|Rosuvastatin|
3140615|NCT01613781|Active Comparator|T1/Tc amplitude-guided group|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
3140616|NCT01613781|Active Comparator|TOF count-guided group|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
3140617|NCT01613768|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3140618|NCT01613755|Active Comparator|Metformin therapy with concomitant use of dipyridamole|Metformin 500 mg twice daily for four days in combination with dipyridamole 200 mg twice daily for four days
3140619|NCT01613755|Active Comparator|Metformin therapy|Metformin 500 mg twice daily for four days
3140620|NCT01613729|Active Comparator|Rosuvastation 5 Initiator Arm|These patients will start the study with Rosuvastatin 5 mg and then after 12 weks they will be switched to Rosuvastatin 10 mg.
3140621|NCT01613729|Active Comparator|Rosuvastatin 10 initiator arm|These patients will continue with Rosuvastatin 10 mg and after 12 weeks they will be switched to Rosuvastatin 5 mg
3140622|NCT01613716|Experimental|Ozurdex|Subjects will receive Ozurdex injections and will be monitored for macular edema.
3140623|NCT01613703|Experimental|Experimental|
3140624|NCT01613690|Experimental|Healthy volunteers|control group receiving 100 μg NVA237
3140625|NCT01613690|Experimental|Mild renal impairment|(eGFR 50-80 mL/min/1.73m2) receiving 100 μg NVA237
3140626|NCT01613690|Experimental|Moderate renal impairment|(eGFR 30-49 mL/min/1.73m2) receiving 100 μg NVA237
3140627|NCT01613690|Experimental|Severe renal impairment|(eGFR <30 mL/min1.73m2) receiving 100 μg NVA237
3140628|NCT01613690|Experimental|End-stage subjects requiring dialysis (ESRD)|receiving 100 μg NVA237
3140629|NCT01613677|Experimental|BKM120|
3140630|NCT01613664|Experimental|tisseel|tisseel will be applied during the surgery
3140631|NCT01613664|Placebo Comparator|no tisseel|no tisseel will be applied during the surgery
3140632|NCT01613651|Experimental|Arm I (RALP)|Patients undergo RALP.
3140633|NCT01613651|Experimental|Arm II (RALP and placement of pelvic drain)|Patients undergo RALP and placement of pelvic drain.
3140634|NCT01613638|Other|Congenital malformations|"All livebirths, fetal deaths with gestational age (GA) ≥22 weeks and terminations of pregnancy (at any gestational age) after prenatal diagnosis of malformation.~born from mothers living in Brittany at delivery~with a congenital anomaly according to Eurocat criteria, diagnosed or suspected (and then confirmed) at birth~or with mild congenital heart defects, genital anomalies or hip dislocation diagnosed after birth (and before the age of one)"
3140635|NCT01613638|Other|control|2 controls per case will be included, corresponding to the first 2 births without congenital anomalies, with same sex and same birth place, following the case.
3140636|NCT01613625|Experimental|Elastography|
3140637|NCT01613612|Sham Comparator|control group:core decompression|single core decompression
3140638|NCT01613612|Active Comparator|Treatment group: BMCs+core decompression|Enriched bone marrow cells combined with core decompression
3140639|NCT01613599||Rituximab|Participants with granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) or microscopic polyangiitis (MPA) who received rituximab as per investigator's discretion were followed for a maximum of 4 years.
3140640|NCT01613586|Experimental|Low dose ASP3652 twice daily|
3140641|NCT01613586|Experimental|Medium dose ASP3652 twice daily|
3140642|NCT01613586|Experimental|High dose ASP3652 twice daily|
3140643|NCT01613586|Placebo Comparator|Placebo|
3140644|NCT01613560|Experimental|PEPI：2-4 group-A|
3140645|NCT01613560|Active Comparator|PEPI：2-4 group-B|
3140646|NCT01613560|Active Comparator|PEPI：0-1group|
3140647|NCT01613547|Active Comparator|Routine antibiotic prescription|Routine antibiotic prescription with amoxicillin (80 mg/kg/day for 7 days)
3140648|NCT01613547|Placebo Comparator|No routine antibiotic prescription|
3140649|NCT01613534|Experimental|APC plus oral sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) administration for four weeks.
3140650|NCT01613534|Placebo Comparator|APC plus placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks.
3140694|NCT01613248|Experimental|MK-1602 50 mg|MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
3141406|NCT01608048|No Intervention|control|
3141407|NCT01608048|Experimental|TEAS|
3140651|NCT01613521|Experimental|DCE-MRI and 18F-FMISO PET|Each patient will undergo three DCE-MRI (dynamic contrast-enhanced MRI) studies: a baseline DCE-MRI within two weeks before chemoradiation; a second DCE-MRI after the second week of treatment (within a week); and a third DCE-MRI three months after treatment. As a pilot study in 10 patients, we will perform 18F-FMISO PET/CT on the same day of a baseline DCE-MRI before chemoradiation. Treatment decisions will not be based on DCE-MRI and 18F-FMISO PET/CT studies.
3140652|NCT01613508|Active Comparator|Direct Anterior Approach|An oblique incision is made over the anterior margin of the tensor muscle. The fascia of the tensor muscle is identified and incised. The muscle is swept digitally laterally and a retractor is placed over the superior aspect of the femoral neck. The hip capsule is then incised and retracted.
3140653|NCT01613508|Active Comparator|Mini-Posterior Approach|The surgical approach involved a 7 to 9.5 cm incision along the posterior aspect of the femur starting at the tip of the greater trochanter and proceeding distally. The fascia of the gluteus maximus was split, and blunt dissection revealed the underlying abductor and external rotator musculature. The external rotators an the hip capsule were incised and preserved as one layer, with an attempt being made to preserve the insertion of the quadratus femoris on the femur. The hip was dislocated posteriorly and the femoral neck was cut in accordance with the preoperative plan.
3140654|NCT01613495|Placebo Comparator|Placebo|Normal Saline
3140655|NCT01613495|Active Comparator|Octreotide|They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
3140656|NCT01613482|Active Comparator|Arm A|Without cerebral prophylactic radiation
3140657|NCT01613482|Experimental|Arm B|With cerebral prophylactic radiation
3140658|NCT01613469|Other|5FU/Leucovorin- post distal rectal srgy|Assess complete clinical response rate following neoadjuvant chemoradiation in patients with distal rectal cancer
3140659|NCT01613456|Placebo Comparator|Placebo|Dicalcium phosphate, Maltodextrin and Magnesium stearate.
3140660|NCT01613456|Experimental|Saccharomyces cerevisiae CNCM I-3856|
3140661|NCT01613443||Control|Healthy volunteers without medication
3140662|NCT01613443||Phenprocoumon|Patients receiving Marcumar having target INR 2-3
3140663|NCT01613443||Dabigatran|Patients receiving therapeutic dosis of Pradaxa
3140664|NCT01613443||Rivaroxaban|Patients receiving therapeutic dosis of Xarelto
3140665|NCT01613430|Active Comparator|Printed Educational Material (PEM) only|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
3140666|NCT01613430|Experimental|Coach Training (COACH)|The COACH intervention consists of the Printed Educational Materials (PEM) plus the addition of cancer-related training for participant-designated coaches.
3140667|NCT01613417|Active Comparator|MRI with Gadoteridol|MRI after 0.1 mmol/kg IV ProHance, then with 0.1 mmol/kg Gadovist/Gadavist. MRI performed after both agents with identical sequences.
3140668|NCT01613417|Active Comparator|MRI with Gadobutrol|MRI after 0.1 mmol/kg IV Gadovist/Gadavist, then with 0.1 mmol/kg ProHance. MRI performed after both agents with identical sequences.
3140669|NCT01613404||Patients with nurse case manager|Patients will receive a dedicated nurse case manager (intervention group) in this group.
3140670|NCT01613404||Patients with no nurse case manager|Patients will not receive nurse case manager (control group) in this group.
3140671|NCT01613391||RYGBP|Patients underwent Roux-en-Y Gastric Bypass for morbid obesity.
3140672|NCT01613391||LAGB|Patients underwent Laparoscopic Adjustable Gastric Banding for morbid obesity.
3140673|NCT01613378||Rheumatoid Arthritis Cohort|The cohort included participants with moderate to severe rheumatoid arthritis (RA) in whom the treating physician made the decision to initiate tocilizumab treatment.
3140674|NCT01613365|Experimental|chlorhexidine gluconate|
3140675|NCT01613365|Experimental|placebo|
3140676|NCT01613352|Experimental|Day surgery group|Patients who underwent breast conserving surgery and sentinel node biopsy only and were randomized to ambulatory surgery group.
3140677|NCT01613352|Active Comparator|In-Patient group|Patients who underwent breast conserving surgery and sentinel node biopsy only and were randomized to in-patient group.
3140678|NCT01613339|Experimental|Body awareness therapy|
3140679|NCT01613339|No Intervention|Control|
3140680|NCT01613326|Experimental|NVA237|NVA237 50 μg once a day and placebo to tiotropium once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
3140681|NCT01613326|Active Comparator|Tiotropium|Tiotropium 18 μg once a day and placebo to NVA237 once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
3140682|NCT01613313|Experimental|Dose #1|single injection 0.058 mg Collagenase Clostridium Histolyticum
3140683|NCT01613313|Experimental|Dose #2|single injection 0.15 mg Collagenase Clostridium Histolyticum
3140684|NCT01613313|Experimental|Dose #3|single injection 0.29 mg Collagenase Clostridium Histolyticum
3140685|NCT01613313|Experimental|Dose #4|single injection 0.44 mg Collagenase Clostridium Histolyticum
3140686|NCT01613300|Experimental|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
3140687|NCT01613287|Experimental|Immunoadsorption|Patients are treated with the TheraSorb® Ig flex adsorber used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy (5 treatments) performed over 5 to 8 consecutive days
3140688|NCT01613274|Experimental|Gum chewing|Chewing mint flavored sugarless gum for 10-20 minutes three times a day following colon resection.
3140689|NCT01613274|Placebo Comparator|no gum chewing|no gum chewing
3140690|NCT01613261|Experimental|TAK-733 and alisertib|
3140691|NCT01613248|Experimental|MK-1602 1 mg|MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
3140695|NCT01613248|Experimental|MK-1602 100 mg|MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
3140696|NCT01613248|Placebo Comparator|Placebo|Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
3140697|NCT01613235|No Intervention|No intervention|No induced hypertension (reference group)
3140698|NCT01613235|Active Comparator|Induced hypertension|Patients who are randomised to this arm will have their blood pressure raised with vasopressors and fluids. Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
3140699|NCT01613222|Experimental|Pulse oximetry monitoring|
3140700|NCT01613209|Experimental|Olmesartan/Amlodipin fixed combination|
3140701|NCT01613196|Experimental|Positron Emission Tomography|Positron Emission Tomography
3140702|NCT01613183|Experimental|Chinese Medicine group|Chinese Medicine prescription of one of three prestigious Chinese medicine clinicians
3140703|NCT01613183|Placebo Comparator|placebo group|
3140704|NCT01613170|Experimental|Toviaz and Premarin Vaginal Cream|Toviaz 4 mg PO q day and premarin cream 1 g per vagina 2 times a week.
3140705|NCT01613170|Placebo Comparator|Toviaz , Placebo Premarin Vaginal Cream|Toviaz 4 mg PO q day and placebo cream 1 g per vagina 2 times a week.
3140706|NCT01613144||OsseoScrew|
3140707|NCT01613144||Fenestrated Screw|
3140708|NCT01613131|Active Comparator|Mirena + Estradiol Gel|Subjects will be assigned to use of Estradiol gel for use with Mirena.
3140709|NCT01613131|Placebo Comparator|Mirena + Placebo Gel|Subjects will be assigned to use of placebo gel for use with Mirena.
3140710|NCT01613118|Experimental|RE-021 (Sparsentan) 200 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 200mg.~Patients at </= 50kg will receive half the RE-021 (Sparsentan) dose for the 8 week duration."
3140711|NCT01613118|Experimental|RE-021 (Sparsentan) 400 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 400mg.~Patients at </= 50kg will receive half the RE-021 (Sparsentan) dose for the 8 week duration."
3140712|NCT01613118|Experimental|RE-021 (Sparsentan) 800 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 800mg.~Patients at </= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
3140713|NCT01613118|Active Comparator|Irbesartan 300 mg|"The control will be administered irbesartan as a single oral dose of 150mg for the first week before escalating to 300mg for the remaining 7 weeks.~Patients at </= 50kg will receive 150mg irbesartan for the 8 week duration."
3140714|NCT01613105||Group 1|
3140715|NCT01613092|Experimental|Conventional|Preoperative Antibiotics
3140716|NCT01613092|Active Comparator|Aggressive (Incremental)|Preoperative antibiotics, antibiotic wash and post operative antibiotics
3140717|NCT01613079|Placebo Comparator|Methotrexate|Patients were treated with methotrexate alone.
3140718|NCT01613079|Experimental|T2|Patients were treated with oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).
3140719|NCT01613079|Experimental|MTX+T2|The patients were treated with methotrexate and T2.
3140720|NCT01613066|Experimental|Treatment|Patients with high risk haematological malignancies
3140721|NCT01613040|Experimental|Treatment A|
3140722|NCT01613040|Experimental|Treatment B|
3140723|NCT01613040|Placebo Comparator|Treatment C|
3140724|NCT01613040|Placebo Comparator|Treatment D|
3140725|NCT01613027||Rituximab|Rituximab administered according to prescribing information and normal clinical practice.
3140726|NCT01613014|Placebo Comparator|Sugar Pill|Matched Placebo sugar pill - target dose 2 pills BID
3140727|NCT01613014|Active Comparator|ABT-436|ABT-436 Target dose of 400 mg BID
3140728|NCT01613001||DoD Beneficiaries|"Exclusion: Active Duty Air Force members with the following conditions will be excluded from the study:~Documented preexisting musculoskeletal injury/disease before onset of obesity~Hypothyroidism/Hyperthyroidism~Hyperparathyroidism~Osteopenia/Osteoporosis~Nicotine dependence~Alcohol dependence~Eating disorders (anorexia nervosa, bulimia nervosa)~Cancer requiring chemotherapy or radiation therapy~Status-post gastrectomy~Status-post bilateral oophorectomy~Crohn's Disease~Ulcerative Colitis~Celiac Disease~Cushing's Disease~Prior to or during the study period, more than 6 months of taking proton pump inhibitors, medroxyprogesterone acetate, bisphosphonates, methotrexate, selective serotonin reuptake inhibitors, or inhaled/intranasal corticosteroids~Prior to or during the study period, more than 1 month of taking fluoroquinolones, oral or intramuscular corticosteroids, oral or intramuscular testosterone, or leuprolide"
3140729|NCT01612988|Experimental|Chemotherapy BOMP|Bendamustine, Ofatumumab and Methylprednisolone prephase and a maximum of 6 cycles every 4 weeks
3140730|NCT01612975|Placebo Comparator|Placebo|This study arm will encompass the administration of a placebo (physically identical to Naproxen) orally to participants. Naproxen is a painkiller with intrinsic anti-inflammatory properties, while the placebo has no pharmacological properties associated with it. Participants will also be taking Pantoprazole to negate the gastrointestinal consequences of Naproxen (or the placebo). Participants will not know which arm of the study they belong to. In addition, they will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety.
3140731|NCT01612975|Experimental|Naproxen|Intervention arm involves administering 500mg Naproxen twice a day to participants and 40mg of Pantoprazole once a day in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
3141408|NCT01608048|Experimental|EA:electro-acupuncture|
3140732|NCT01612962||bony debridement or amputation|In this study, the investigators will perform a retrospective chart analysis of patients that underwent a bony debridement or amputation in the operating room at Georgetown University Hospital during 2009-2010 under Drs. Steinberg and Attinger
3140733|NCT01612949||easy to intubate, model derivation|easy to intubate, model derivation. photographing head and neck
3140734|NCT01612949||difficult to intubate, model derivation|difficult to intubate, model derivation.photographing head and neck
3140735|NCT01612949||easy to intubate, model validation|easy to intubate, model validation. photographing head and neck
3140736|NCT01612949||difficult to intubate, model validation|difficult to intubate, model validation. photographing head and neck
3140737|NCT01612936|Experimental|Allergic asthmatic, allergic nonasthmatic|Adults who are allergic asthmatics or allergic non-asthmatics will receive segmental allergen challenge to the lung
3140738|NCT01612923|Experimental|midwife|Gynecological exam and ultrasound performed by midwife, medical abortion service provided by midwife,contraceptive advice provided by midwife. Follow-up visit provided by midwife
3140739|NCT01612923|No Intervention|Physician|Gynecological exam and ultrasound and contraceptive advice provided by physician. Medical abortion service and follow-up visit provided by midwife
3140740|NCT01612910|Experimental|microencapsulated diindolylmethane, lab. biomarker analysis|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
3140741|NCT01612897|Experimental|Computer based reminders to MD|Children in this arm attend a clinic that is randomly assigned to receive physician alerts to screen appropriate children for autism.
3140742|NCT01612897|No Intervention|Usual care arm|Children in this are receive usual care from a clinic randomly chosen to serve as a control.
3140743|NCT01612884|Other|TEG|Clopidogrel non-response defined as MA≥69 Clopidogrel response defined as MA<69
3140744|NCT01612884|Other|Light transmittance aggregometry|Clopidogrel non-response defined as MPA ADP >42.9% Clopidogrel response defined as MPA ADP <42.9%
3140745|NCT01612871|Experimental|hormone therapy treatment|Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day
3140746|NCT01612858|Experimental|Metformin|
3140747|NCT01612858|Experimental|Pioglitazone|
3140748|NCT01612845|Experimental|PRF|the group in which the PRF was administered
3140749|NCT01612845|Active Comparator|Control|repair without PRF
3140750|NCT01612832|Experimental|Lyrica|Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
3140751|NCT01612832|Active Comparator|Control|no liryca treatment
3140752|NCT01612806|Experimental|PriMatrix|PriMatrix Dermal Repair Scaffold
3140753|NCT01612806|Experimental|PriMatrix Ag|PriMatrix Ag Antimicrobial Dermal Repair Scaffold
3140754|NCT01612806|Active Comparator|Standard of Care|Standard of Care Moist Wound Therapy
3140755|NCT01612793||AlphaCore device|AlphaCore device group will consist of subjects enrolled into the study with chronic obstructive pulmonary disease and receive an electrical stimulation to the vagus nerve to help open the subjects airways during the subjects stay in the hospital.
3140756|NCT01612780|Experimental|XprESS Multi-Sinus Dilation Tool|Balloon sinus dilation
3140757|NCT01612767|Experimental|Pro-Kinetic Energy Stent|
3140758|NCT01612754|No Intervention|Reference group - cloaked noise meters|"Reference group or phase 1~Theatre equipped with multiple sound meters disguised as CO2 meter for sound probing in the absence of a research clerk with personnel completely unaware of sound measurements."
3140759|NCT01612754|Sham Comparator|Control Noise AND Stress measurements|"Control Group - Phase 2~No intervention but research clerk is present in theatre to protocoll the operation and test for stress by collecting saliva cortisol and probing electrodermal activity"
3140760|NCT01612754|Experimental|Noise Reduction Intervention Group|"Intervention Group - Phase 3~A panel of noise reduction measures (staff workplace rules, technical devices as optical noise warners, optical telephones) is put into effect. Surgeons are monitored by biometry, psychometry and the outcome."
3140761|NCT01612741||Group 1|
3140762|NCT01612728|Experimental|Women with Arthralgia|Women who develop joint pain on Aromatase Inhibitor therapy will be placed on the clinical algorithm, as specified in the protocol.
3140763|NCT01612728|Other|Women without Arthralgia|Women who do not develop arthralgia will continue to have their joint pain and strength measured, as well as their medication compliance. However, they will not be placed on the clinical algorithm which is meant for alleviation of joint pains.
3140764|NCT01612715||Study Population|Mild asthma, cat-allergic, 18-65 years old, males and females will be recruited for the study.
3140765|NCT01612702|Experimental|Dexamethasone|dexamethasone 10 mg administration 1 hour before surgery
3140766|NCT01612702|No Intervention|Control|No dexamethasone
3140767|NCT01612689|Experimental|Physiologic Data Collection|
3140768|NCT01612676|Experimental|Drug|FE 202158
3140769|NCT01612663|Active Comparator|deep needle non-site specific|
3140770|NCT01612663|Active Comparator|contralateral elbow to the knee pain|
3140771|NCT01612663|Active Comparator|Energy of Living Systems Needling|
3140772|NCT01612663|Placebo Comparator|Sham acupuncture|
3140773|NCT01612650|Active Comparator|breast cancer histologically proven|Patient with breast cancer histologically proven, addressed to Oscar Lambret Center for treatment
3140774|NCT01612650|Active Comparator|surveillance of a treated breast cancer|surveillance of patient already treated for breast cancer must have annual mammography
3140775|NCT01612650|Active Comparator|diagnosis of a detected anomaly|patient addressed for diagnosis of a detected anomaly
3140820|NCT01612273|Experimental|Disgren|Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
3140821|NCT01612273|Experimental|Aspirin|Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
3140822|NCT01612260|Experimental|Shensong Yangxin capsule|Shensong Yangxin capsule 4 granules t.i.d. po for 12weeks
3140823|NCT01612260|Placebo Comparator|placebo Capsule|placebo Capsule 4 granules t.i.d. po for 12weeks
3140956|NCT01611350|Experimental|Novel Sales Offer|This group will receive a free trial and time payments when purchasing an energy efficient cookstove.
3140776|NCT01612637|Experimental|Group 1|Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and they will perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
3140777|NCT01612637|Active Comparator|Group 2|Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
3140778|NCT01612611||a cohort using Shenmai injection|
3140779|NCT01612598|Experimental|Supportive Care (PCI)|"PCI PART I: Patients undergo comprehensive PC assessment based on baseline data and complete goals of care discussion.~PCI PART II: Following the first dose of phase I investigational treatment, patients meet with the IDT, where PC recommendations are made. This is followed by two patient educational sessions that will cover QOL-related domains, including physical, social, emotional, and spiritual well-being. Supportive care referrals are made based on IDT recommendations."
3140780|NCT01612546|Experimental|Treatment (cyclodextrin-based polymer-camptothecin CRLX101)|Patients receive cyclodextrin-based polymer-camptothecin CRLX101 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the completion of 6 courses, patients achieving stable disease or better may receive treatment for an additional 6 months.
3140781|NCT01612520|Active Comparator|telecoaching|
3140782|NCT01612520|No Intervention|control|
3140783|NCT01612507|Experimental|A|600 mg Ceftaroline fosamil 1 h infusion
3140784|NCT01612507|Experimental|B|Placebo 1 h infusion
3140785|NCT01612507|Experimental|C|600 mg Ceftaroline fosamil 2 h infusion
3140786|NCT01612507|Experimental|D|Placebo 2 h infusion
3140787|NCT01612494|Placebo Comparator|Normal Saline|
3140788|NCT01612494|Experimental|Hypertonic Saline|
3140789|NCT01612481|Active Comparator|chest radiography|clinical exam + chest radiography every 3 months during 2 years and every 6 months during 1 year
3140790|NCT01612481|Active Comparator|chest CT|clinical exam + Chest CT every 3 months during 2 years and every 6 months during 1 year
3140791|NCT01612468|Experimental|Liraglutide|
3140792|NCT01612468|Placebo Comparator|Placebo|
3140793|NCT01612455|No Intervention|Standard of Care|Control participants will receive the narcology hospital's standard of care. With regard to linkage to HIV medical care, patients will be given printed information about where to obtain HIV medical care - the outpatient clinic that is involved in the intervention. Control patients will be referred to outpatient narcology care as part of standard of care. If control participants are newly diagnosed with HIV infection at the addiction hospital, they will receive HIV post test counseling consistent with CDC recommendations (this represents an enhancement of the current standard of care in Russia).
3140794|NCT01612455|Experimental|LINC Case Management (Intervention)|LINC Case Management (study Intervention) - see Intervention description
3140795|NCT01612442|Experimental|Integrated education|
3140796|NCT01612442|No Intervention|Control|
3140797|NCT01612442|Experimental|Nutrition education|
3140798|NCT01612429|Experimental|Amino acid supplementation|Up to 500 mL of 5.4% amino acid solution (NephrAmine) by intravenous infusion 3 x weekly for 6 weeks.
3140799|NCT01612416|Sham Comparator|Normal subjects|
3140800|NCT01612416|Active Comparator|Primary open angle glaucoma|
3140801|NCT01612416|Active Comparator|Normal tension glaucoma|
3140802|NCT01612403||Single group|Single group: all participants receive same intervention throughout study (Non-randomised)
3140803|NCT01612390||group 1|receive 400 Mg sublingual misoprostol.
3140804|NCT01612390||group 2|receive 600 Mg sublingual misoprostol.
3140805|NCT01612390||group 3|receive 5IU of intravenous oxytocin.
3140806|NCT01612377|Experimental|prednisolone-dipyridamole|
3140807|NCT01612377|Active Comparator|prednisone 5mg|
3140808|NCT01612377|Active Comparator|prednisone 7.5mg|
3140809|NCT01612364|Experimental|thoracic sympathetic block|Sympathetic block of upper limb via thoracic vertebra T3
3140810|NCT01612364|Active Comparator|control block|Same medication used in experimental group, but in dorsal subcutaneous
3140811|NCT01612351|Experimental|Non-Randomized Single-Arm|All participants will receive induction chemotherapy and transoral surgery. Following surgery, participants will be stratified into a risk category (low, medium, or high). Subjects in the low risk category will receive no further treatment after their transoral surgery. Subjects in the medium risk category will receive ipsilateral radiation concurrent with weekly cisplatin, and subjects in the high risk category will receive cisplatin every three weeks with concurrent bilateral radiation.
3140812|NCT01612338|Experimental|Targeted|Targeted letter and booklet
3140813|NCT01612338|Experimental|Tailored|Tailored letter and booklet, enhanced family communication and support brochure
3140814|NCT01612325|Experimental|Holmium-166 MS radioembolization|Single radioembolization met Holmium-166 polylactic microspheres administered
3140815|NCT01612312|Active Comparator|Thrombectomy|
3140816|NCT01612312|Other|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
3140817|NCT01612299|Active Comparator|Standard Immunosuppression|Tacrolimus + Myfortic®/Cellcept + Corticosteroids
3140818|NCT01612299|Experimental|Zortress®|Tacrolimus + Zortress® + Corticosteroids
3140819|NCT01612286|Experimental|endostatin|chemotherapy concurrently with endostatin
3141001|NCT01610999|Experimental|Cohort A|0.24 mg/kg plerixafor on day 1
3270161|NCT00696657|Placebo Comparator|G1|
3140824|NCT01612234|Experimental|High palmitate or high oleate diet.|This is a solid food diet in which vegetable oils are used to create a dietary fat composition similar to the average American/Western diet in which palmitic and oleic acid are ingested in approximately equal amounts (high palmitate diet) or a composition similar to the Mediterranean Diet (low palmitate, high oleate, using hazelnut oil as the source of fat). There are no interventions other than the diet itself.
3140825|NCT01612234|Experimental|high palmitate or high oleate diet|This is a solid food diet in which vegetable oils are used to create a dietary fat composition similar to the average American/Western diet in which palmitic and oleic acid are ingested in approximately equal amounts (high palmitate diet) or a composition similar to the Mediterranean Diet (low palmitate, high oleate, using hazelnut oil as the source of fat). There are no interventions other than the diet itself.
3140826|NCT01612221|Experimental|Patients receiving N-acetylcysteine|Patients receiving NAC (N-acetylcysteine)
3140827|NCT01612221|Placebo Comparator|Placebo Group|Participants not receiving NAC (N-acetylcysteine)
3140828|NCT01612208||Distal femur fractures|(AO/OTA types 33-A and 33-C)
3140829|NCT01612195|Experimental|Anal fistula plug|
3140830|NCT01612182||ESBL(+) Klebsiella pneumonia|All the patient who's the culture result showed ESBL(+) Klebsiella pneumonia in any site during hospitalization
3140831|NCT01612182||ESBL(-) Klebsiella pneumonia|All the patient who's the culture result showed ESBL(-) Klebsiella pneumonia in any site during hospitalization
3140832|NCT01612169|No Intervention|Treatment as Usual (TAU) Group|"Participants assigned to the TAU group will receive the standard treatment provided at each hospital for linking patients to HIV and substance use care.~During the formal site selection process, a thorough assessment will be conducted of each site's standard practice for linkage to HIV care and substance use treatment. Throughout the course of the trial, hospital sites will be monitored for any potential changes that might occur in standard practice around linkage to HIV care and substance use treatment."
3140833|NCT01612169|Experimental|Patient Navigation (PN) Group|"The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.~After the initial four meetings, patient navigators will meet with PN group participants ideally twice monthly during months 2 and 3 and once monthly during months 4 - 6."
3140834|NCT01612169|Experimental|Patient Navigator Plus Contingency Management (PN+CM) Group|"Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM). Using the principles of contingency management, this combined intervention will incorporate viral load suppression as a target of reinforcement as well as several other behaviors (HIV clinical care, medication adherence, cessation or reduction of substance use) that are hypothesized to be moderators or mediators of the primary outcome.~For participants randomly assigned to the PN+CM study group, patient navigators will: 1) effectively communicate the incentive plan to the participant, 2) track each of the seven target behaviors that may earn participant incentives, 3) verify occurrence of the target behaviors, 4) deliver incentives according to the protocol, and 5) maintain a record of incentives delivered. PNs will use a computer-based tracking program to facilitate this work."
3140835|NCT01612156|Active Comparator|2% lidocaine gel|Subjects in this arm will have all urethral catheters and urethral cotton tipped swabs prepared with 2% lidocaine gel before use in the examination.
3140836|NCT01612156|Active Comparator|water based lubricant|Subjects in this arm will have all urethral catheters and urethral cotton tipped swabs prepared wtih water based lubricant before use in the pelvic floor examination.
3140837|NCT01612143|Active Comparator|A: STV capsule (after high fat meal)|
3140838|NCT01612143|Active Comparator|B: STV capsule (fasted state)|
3140839|NCT01612143|Experimental|C: STV tablet (after high fat meal)|
3140840|NCT01612143|Experimental|D: STV tablet (fasted state)|
3140841|NCT01612130|Experimental|Valeriana officinalis L (100mg)|100 mg of Valeriana officinalis L. (Valerian)
3140842|NCT01612130|Placebo Comparator|Placebo (100 mg)|Placebo 100mg
3140843|NCT01612117||consecutive, PCP patients|All patients requiring percutaneous coronary procedures, such as coronary angiography or intervention
3140844|NCT01612104|Experimental|Psychological First Aid|Psychological material developed for children and adolescents, based on cognitive behavioral theory, used to structure therapeutic conversations and/or for self-help.
3140845|NCT01612091|Experimental|Monitoring Messenger|
3140846|NCT01612091|Active Comparator|Control|Traditional tools (monitors, paper records)
3140847|NCT01612078|Experimental|Droxidopa, antihypotensive drug, tablet|
3140848|NCT01612078|Placebo Comparator|placebo, tablet|
3140849|NCT01612065|Active Comparator|Misoprostol vaginally, 200 ug|200 ug misoprostol in the posterior vaginal fornix
3140850|NCT01612065|Active Comparator|Misoprostol vaginally, 400ug|Misoprostol in the posterior vaginal fornix
3140851|NCT01612052|Active Comparator|Cefazolin plus Daptomycin|
3140852|NCT01612052|Active Comparator|Cefazolin plus Vancomycin|
3140853|NCT01612039|Experimental|ASP3291|
3140854|NCT01612039|Placebo Comparator|Placebo|
3140855|NCT01612026||Ultrasound|
3140856|NCT01612026||Fluoroscopy|
3140857|NCT01612013|Active Comparator|Intravenous NAC plus saline|Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
3140858|NCT01612013|Active Comparator|Sodium bicarbonate plus saline|Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
3141002|NCT01610999|Experimental|Cohort B|0.24 mg/kg plerixafor daily on days 1 & 2
3140859|NCT01612013|Active Comparator|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
3140860|NCT01612013|Placebo Comparator|Saline|Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
3140861|NCT01612000|Experimental|PanBlok 15µg in 2% SE|15µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
3140862|NCT01612000|Experimental|PanBlok 3.8µg in 2% SE|3.8µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
3140863|NCT01612000|Experimental|PanBlok 7.5µg No Adjuvant|7.5µg recombinant hemagglutinin, no adjuvant. 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
3140864|NCT01612000|Experimental|PanBlok 7.5µg in 2% SE|7.5µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
3140865|NCT01611987|Experimental|MSTEP|The MSTEP program is a 6 day tailored exercise program. It includes flexibility, aerobic, peripheral strengthening, core and balance training, power and speed training and push days.
3140866|NCT01611987|Active Comparator|General guideline approach|The general Guideline approach is the general guidelines that are recommended for people with MS by the Canadian Society Exercise Physiology.
3140867|NCT01611974|Experimental|Maribavir 400 mg twice daily|
3140868|NCT01611974|Experimental|Maribavir 800 mg twice daily|
3140869|NCT01611974|Experimental|Maribavir 1200 mg twice daily|
3140870|NCT01611961|Experimental|DT-LM|Docetaxel Lipid Microsphere (DT-LM)
3140871|NCT01611961|Active Comparator|Taxotere|Commerical Product
3140872|NCT01611948|Active Comparator|Active Drug|125mg/d aprepitant for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
3140873|NCT01611948|Placebo Comparator|Placebo pill|Placebo pill daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
3140874|NCT01611935|Active Comparator|Vasopressin|Vasopressin will be given as an initial bolus (4 Units) followed by an infusion titrated between 0 units/min to 0.04 units per min to maintain a mean arterial blood pressure greater than or equal to 65 mmHg
3140875|NCT01611935|Placebo Comparator|Normal Saline|An initial bolus of normal saline will be given (10 cc) and an infusion of 0.1 ml per minute will be started and titrated down in as the mean arterial blood pressure reaches 65 mmHg or more.
3140876|NCT01611922||Symptomatic Lens Wearers|Contact lens wearers reporting a habitual wear time of less than eight hours and a noticeable reduction in comfort over a wearing day
3140877|NCT01611922||Non-Symptomatic Contact Lens Wearers|Contact lens wearers reporting a comfortable wear time of more than 10 hours and minimal reduction in comfort over a wearing day
3140878|NCT01611922||Asymptomatic Non-Contact Lens Wearers|Non-contact lens wearers reporting a minimal reduction in ocular comfort over the course of a day
3140879|NCT01611909|Experimental|2% PMDO|
3140880|NCT01611909|Experimental|5% PMDO|
3140881|NCT01611909|Active Comparator|Mupirocin|
3140882|NCT01611896|Active Comparator|Selenium|
3140883|NCT01611896|Placebo Comparator|Placebo|
3140884|NCT01611883|Experimental|Ezetimibe|10 mg oral dose once daily for 24 weeks
3140885|NCT01611883|Placebo Comparator|Placebo|Placebo to match ezetimibe orally once daily for 24 weeks
3140886|NCT01611870|Experimental|Single arm study|
3140887|NCT01611857|Experimental|Maximum Tolerated Dose|Phase I trial of Tivantinib plus FOLFOX for the treatment of patients with advanced solid tumors followed by a Phase II portion for patients with first-line metastatic GE cancer.
3140888|NCT01611844|Experimental|Medical device : micro-needle BD 1.5 mm 30G|
3140889|NCT01611844|Active Comparator|Manthoux method: lance 26G X 16mm|
3140890|NCT01611831|Experimental|ACT in group|Patients assigned to this arm will receive Acceptation and Commitment Therapy (ACT) in groups of 8-12 patients. Intervention has been protocolized. Therapy will be administered by two experienced therapists (psychologists).
3140891|NCT01611831|Active Comparator|Improved Treatment as usual by General practitioner|Patients assigned to this arm will receive treatment as usual by their General Practitioner in the Primary Care center. To enhance treatment, investigators participating in the trial will receive the Guidelines for fibromyalgia treatment in Primary Care handed by Health Service in Aragón.
3140892|NCT01611818|Other|Low intensity Internet-delivered psychotherapy|Low intensity Internet-delivered psychotherapy + improved treatment as usual by GP.
3140893|NCT01611818|Other|Self-guided Internet-delivered psychotherapy|Self-guided Internet-delivered psychotherapy + improved treatment as usual
3140894|NCT01611818|Other|Improved treatment as usual by GP|
3140895|NCT01611805|Experimental|GSK1605786 250mg|Opaque Swedish orange body and cap.
3140896|NCT01611805|Placebo Comparator|Placebo|Opaque Swedish orange body and cap.
3140897|NCT01611805|Experimental|GSK1605786 500mg|Opaque Swedish orange body and cap.
3140898|NCT01611805|Experimental|GSK1605786 1000mg|Opaque Swedish orange body and cap.
3140899|NCT01611805|Experimental|GSK1605786 500mg in fed|Opaque Swedish orange body and cap.
3140900|NCT01611792|Experimental|Stabilization|
3140901|NCT01611792|Active Comparator|Strengthening and Conditioning|
3140902|NCT01611779|Experimental|Tongue suspension|Tongue-based suspension
3140903|NCT01611766|Experimental|secondary cytoreductive surgery|SCR followed by chemotherapy
3140904|NCT01611766|Active Comparator|Salvage Chemotherapy|platinum-based chemotherapy
3140905|NCT01611753|Active Comparator|liberal group|Patients in the liberal group received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL.
3141159|NCT01609907|Experimental|Sequence 5|
3140906|NCT01611753|Active Comparator|restrictive group|Patients in the liberal group received transfusions immediately, as the objective was to maintain hemoglobin levels above 7.0 g/dL.
3140907|NCT01611740||Preterm infants|Telemonitoring system prototype developed by INSERM U-642
3140908|NCT01611727|Experimental|Cisplatin|
3140909|NCT01611714|Experimental|Audit-feedback|Arm 1: Audit-feedback only
3140910|NCT01611714|Experimental|CDS message|Arm 2: CDS message only
3140911|NCT01611714|Experimental|Both Interventions|Arm 3: Audit-feedback and CDS message
3140912|NCT01611714|No Intervention|Control|Arm 4: Control
3140913|NCT01611701|Active Comparator|Cryoballoon group|
3140914|NCT01611701|Active Comparator|RF group|
3140915|NCT01611688|Experimental|Active|
3140916|NCT01611688|Placebo Comparator|Placebo|
3140917|NCT01611675|Experimental|Treatment Arm|Leflunomide + Vemurafenib
3140918|NCT01611662|Experimental|Treatment (gemcitabine hydrochloride, cisplatin, surgery)|Patients receive gemcitabine hydrochloride IV over 30 minutes on day 1 and cisplatin IV on day 1 or divided over days 1 and 2. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-8 weeks after chemotherapy, patients undergo radical cystectomy.
3140919|NCT01611649|Experimental|Dairy lipids and plant oils|
3140920|NCT01611649|Experimental|Plant oils|
3140921|NCT01611649|Experimental|Dairy lipids and plant oils, DHA+ARA|DHA: docosahexaenoic acid, ARA: arachidonic acid
3140922|NCT01611649|No Intervention|Human milk|
3140923|NCT01611623|Experimental|SNX-5422|Open label administration of SNX-5422 tablets every other day for 21 days on a 28 day cycle. Dose escalation based on safety outcomes
3140924|NCT01611610|Other|Ambulant SMA|
3140925|NCT01611610|Other|Non-ambulant SMA|
3140926|NCT01611584|Experimental|ALA|No arms for the trial. Participants will have proven or presumed lung cancer and will be assessed for participant by a research team member.
3140927|NCT01611571|Active Comparator|Active Risedronate Placebo Teriparatide|Active Risedronate + Placebo Teriparatide for 18 months / Active Risedronate for 6 months
3140928|NCT01611571|Active Comparator|Active Risedronate Active Teriparatide|Active Risedronate + Active Teriparatide for 18 months / Active Risedronate for 6 months
3140929|NCT01611571|Active Comparator|Placebo Risedronate Active Teriparatide|Placebo Risedronate Active Teriparatide for 18 months / Active Risedronate for 6 months
3140930|NCT01611558|Experimental|Arm: Ipilimumab, 10 mg/kg|Participants received 10 mg/kg of ipilimumab administered intravenously once every 3 weeks for 4 doses (Induction Phase). Then, once every 12 weeks (Maintenance Phase), until disease progression or unacceptable toxicity occurs.
3140931|NCT01611545||Clopidogrel|Patients taking or prescribed clopidogrel or under consideration Utilizing pharmacogenomics to determine the most effective treatment
3140932|NCT01611532||Acute pancreatitis|All adult patients (>18y.o.) requiring admission for acute pancreatitis (amylase >3 times the upper limit of normal and typical symptoms of abdominal pain and vomiting)
3140933|NCT01611519||Early (within 48 hours of surgery)|Patients will have their urinary catheter removed within 48 hours of surgery
3140934|NCT01611519||Late (6 hours after epidural removal)|Patients will have their urinary catheter removed 6 hours after their epidural is removed
3140935|NCT01611506|Experimental|Cetuximab, capecitabine, cisplatin based chemoradiation|"Induction chemotherapy:~3 cycles (of 3 weeks) with capecitabine, cisplatin and weekly cetuximab: Cetuximab 400mg/m2 (loading dose)on day 1 and 250mg/m2 weekly thereafter, Cisplatin 80mg/m2 on day 1 every three weeks, Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle.~Followed by:~Radio-chemo-immunotherapy:~Cetuximab 250mg/m2 weekly on day 1, Cisplatin 30mg/m2 weekly on day 1, Radiotherapy (dose escalation levels) 36/39.6/45 Gy(according to dose level) in 5 fractions of 1.8 Gy per week~Surgery:~Will be performed 4-6 weeks after neoadjuvant radiochemotherapy~Postoperative treatment:~3 cycles of Chemo-immunotherapy with cetuximab, cisplatin and capecitabine -as described above- will be administered postoperatively if the patient has recovered adequately from surgery and the treatment is considered as feasible by the investigator."
3140936|NCT01611493|Experimental|Osseotite Prevail Implant|The Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure.
3140937|NCT01611493|Active Comparator|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
3140938|NCT01611467|Experimental|20 mg oral CC-223 with microtracer|A single 20-mg oral dose of CC-223 capsule containing a microtracer of [14C]-CC-223 solution
3140939|NCT01611467|Experimental|20 mg oral CC-223 fasting|A single 20-mg oral dose of CC-223 tablet under fasting conditions
3140940|NCT01611467|Experimental|20 mg oral CC-223 fed|A single 20-mg oral dose of CC-223 tablet under fed conditions
3140941|NCT01611454|Experimental|XPF thyroid collar|Administration of the XPF Thyroid Collar.
3140942|NCT01611454|Active Comparator|Equivalent collar|Administration of the Standard 0.5mm lead-equivalent thyroid collar.
3140943|NCT01611441||Patients with osteoarthritis of the knee|Patients with osteoarthritis of the knee undergoing total knee replacement surgery.
3140944|NCT01611428|Experimental|Ipragliflozin - oral|open label
3140945|NCT01611428|Experimental|Ipragliflozin - i.v.|open label
3140946|NCT01611415|Experimental|ipragliflozin|
3140947|NCT01611415|Experimental|furosemide|
3140948|NCT01611415|Experimental|ipragliflozin & furosemide|
3140949|NCT01611389|Experimental|Long AV delay.|
3140950|NCT01611389|Active Comparator|Short AV delay.|
3140951|NCT01611363|Experimental|Part A|Ipragliflozin (low dose) & Placebo
3140952|NCT01611363|Experimental|Part B|Ipragliflozin (high dose)
3140953|NCT01611350|Experimental|Health Marketing Message|Marketing message focused on health effects of cooking with wood on a three stone fire.
3140954|NCT01611350|Experimental|Savings Marketing Message|Marketing message focused on savings (both time and money) related to using an energy efficient cookstove.
3140955|NCT01611350|Experimental|Savings and Health Marketing Messages Combined|One group will receive both the savings and health marketing messages.
3140957|NCT01611350|Experimental|Early vs. Late Buyers|Of those who accept the Novel Sales Offer, half the buyers will randomly be selected to start their free trial within a few weeks of the sales meeting, while the other half- the late buyers- will start their free trial a within 2 months of the sales meeting.
3140958|NCT01611337|Other|insight evaluation|insight evaluation using the Q8 scale
3140959|NCT01611324|Experimental|Alkalinised anesthetic solution|
3140960|NCT01611324|Active Comparator|Non alkalinised anesthetic solution|
3140961|NCT01611311|Experimental|BI 409306 BS medium dose|Film-coated tablet
3140962|NCT01611311|Experimental|BI 409306 BS high dose|Film-coated tablet
3140963|NCT01611311|Placebo Comparator|Placebo|Film-coated tablet
3140964|NCT01611298|Experimental|Schedule of Tetanus Toxoid Administration|SCT Donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest
3140965|NCT01611285||Robotic Sacrocolpopexy patients|Patients who underwent Robotic Sacrocolpopexy to treat pelvic organ prolapse between 2009 and 2010
3140966|NCT01611285||UPHOLD patients|Patients who underwent the UPHOLD procedure to treat pelvic organ prolapse from 2009-2010.
3140967|NCT01611272||1|Unstable angina, Non ST-segment Elevation Myocardial Infarction or ST-segment elevation myocardial infarction including patients managed medically, and those who are managed with percutaneous coronary intervention or coronary artery by-pass grafting
3140968|NCT01611259|Experimental|Rituximab and Lenalidomide|Single arm: 6 cycles for patients with complete response, 8 cycles for subjects with stable disease or partial remission; cycles duration: 28 days Rituximab (Mabthera®): 375 mg/m² i.v. day 1 Lenalidomide (Revlimid®): 20 mg p.o. daily for 21 days
3140969|NCT01611246||Anesthetization|Anesthetization
3140970|NCT01611233||DePuy ASR THA|Adults having received a Depuy ASR metal on metal hip system which is subject to a voluntary recall.
3140971|NCT01611220|No Intervention|Control|Standard cognitive behavior inpatient treatment
3140972|NCT01611220|Experimental|RePAN|Standard cognitive behavior inpatient treatment plus 8 dissonance relapse prevention groups
3140973|NCT01611207|Experimental|Negative Pressure Wound Therapy|Used therapy systems
3140974|NCT01611207|Active Comparator|Standard Conventional Wound Therapy|Standard conventional wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
3140975|NCT01611194|Experimental|Active group (HBO2)|Hyperbaric oxygen (HBO2) at 1.5 atms. Stratified by site and time from injury (less than one year versus one year or more), in which participants are randomized.
3140976|NCT01611194|Sham Comparator|Sham control|Sham control 1.2 atms. Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
3140977|NCT01611181|Active Comparator|Hemoboost (iron supplementation)|A registered natural product containing specially haemolysed haemoglobin and iron dextran.
3140978|NCT01611181|Active Comparator|Kräuterblut (iron supplementation)|A registered natural product made from a number of herbs with ferrous gluconate as the active substance.
3140979|NCT01611181|Active Comparator|Ferrofumerat (iron supplementation)|Ferrous sulphate
3140980|NCT01611168|No Intervention|Usual Care|
3140981|NCT01611168|Experimental|Intervention Group, treatment algorithms|
3140982|NCT01611155|Experimental|Arm I (management of therapy complications)|Patients receive venlafaxine PO BID beginning on day 1 of and continuing through completion of FOLFOX.
3140983|NCT01611155|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID beginning on day 1 of and continuing through completion of FOLFOX.
3140984|NCT01611142|Experimental|KW-0761|
3140985|NCT01611129|Active Comparator|reading about hearing loss and its management|General self-reading reading about hearing loss and its management This would run for 30 days and the participants have to manage their own time.
3140986|NCT01611129|Experimental|Internet-based counseling|This would involve 4 stages of designated internet sessions and additional tasks which the patients can complete in their own time. This programme should be completed within 30 days.
3140987|NCT01611116|Placebo Comparator|sodium chloride solution 0.9%|
3140988|NCT01611116|Experimental|temsirolimus|
3140989|NCT01611103|Sham Comparator|Sham Stimulation|transcranial direct current stimulation that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS
3140990|NCT01611103|Experimental|Anodal Stimulation|transcranial direct current stimulation using Anodal stimulation over the area of interest
3140991|NCT01611090|Experimental|Ibrutinib + BR|Ibrutinib 420 mg will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with bendamustine and rituximab (BR) for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
3140992|NCT01611090|Placebo Comparator|Placebo + BR|Matching placebo will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with BR for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
3140993|NCT01611077|Other|Single Arm|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days, then olmesartan 40 mg tablets once daily for 42 days, then olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
3140994|NCT01611064|Active Comparator|Oxygen|Volunteer receives oxygen at a rate of 10litres/minute by mask
3140995|NCT01611064|Placebo Comparator|Air|Volunteer receives normal air at a rate of 10litres/minute by mask
3140996|NCT01611051|Experimental|Pegylated rhG-CSF: 100µg/kg|Chemtherapy naive patients receiving chemotherapy and Pegylated rhG-CSF 100µg/kg
3140997|NCT01611051|Experimental|Pegylated rhG-CSF: 6mg|Chemtherapy naive patients receiving chemotherapy and Pegylated rhG-CSF 6mg
3140998|NCT01611051|Active Comparator|rhG-CSF 5ug/kg/day|Chemtherapy naive patients receiving chemotherapy and rhG-CSF 5ug/kg/day
3140999|NCT01611038|Placebo Comparator|Placebo|Placebo given daily
3141000|NCT01611038|Experimental|Methylselenocysteine|Methylselenocysteine given daily
3141160|NCT01609907|Experimental|Sequence 6|
3141003|NCT01610999|No Intervention|Cohort C|"Six control subjects will have research bloods drawn but receive no plerixafor."
3141004|NCT01610986|Experimental|Glucose-fructose|Participants will take glucose-fructose drinks during training sessions
3141005|NCT01610986|Experimental|Water|Participants will take only water during training sessions
3141006|NCT01610973|Experimental|Manual preparation|Manual preparation of the graft
3141007|NCT01610973|Active Comparator|Automatized preparation|Automatized preparation of the graft with microkeratoma
3141008|NCT01610960|Active Comparator|HELMET|The HELMET and HELMET NEXT modes will be tested by each patient.
3141009|NCT01610960|Sham Comparator|Facemask|The facemask will be used by each patient.
3141010|NCT01610947|Active Comparator|Maintain|Continuation of usual treatment with fixed intervals according to standard recommendations
3141011|NCT01610947|Active Comparator|Spacing|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol.
3141012|NCT01610934|Experimental|liraglutide|
3141013|NCT01610934|Active Comparator|glimepiride|
3141014|NCT01610921|Experimental|bronchial provocationtest|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
3141015|NCT01610908|Experimental|Schroth exercises|The experimental group receives the Schroth exercises treatment.Patients in this arm receive 5 individual sessions with a Schroth therapist for introduction to the approach. They they receive a home program consisting of 3-4 exercises to do at home everyday for 30-45 minutes. They come to weekly group therapy sessions to where exercise prescription is adjusted.
3141016|NCT01610908|No Intervention|Standard of care|"The Standard of care is a control group that will continue receiving the standard North American treatment prescribed by a surgeon (observation or brace [if meeting SRS criteria]) for of 6 months. After 6 months, the participants will receive the Schroth exercises intervention for 6 months."
3141017|NCT01610908|Active Comparator|Global Postural Re-education (Montréal)|"The active group (in Montréal only) receives the Global Postural Re-Education exercises treatment.Patients in this arm come to weekly individual 1 hour long therapy sessions where exercise prescription is adjusted. Selection of posture exercises is based on scoliosis type, on muscular chain stiffness associated with posture alterations and on position increasing scoliosis or pain (lying, sitting, standing).~They they receive a 15-min home program consisting of 1 to 2 exercises to do at home everyday."
3141018|NCT01610895|Active Comparator|Split-dose PEG Based Lavage (2L + 2L) + Low-fiber Diet|Patients randomized to this arm will have a split-dose Polyethylene Glycol Based lavage (2L + 2L), have a low-fibre diet 4 days prior to Colonoscopy and the day before Colonoscopy, have a low-fibre breakfast, a low-fibre lunch by 2PM and then drink only clear fluids until after the procedure is completed.
3141019|NCT01610895|Placebo Comparator|Split-dose PEG Based Lavage (2L + 2L) + Clear fluid diet|Patients randomized to this arm will have a split-dose Polyethylene Glycol Based lavage (2L + 2L), have a low-fibre diet 4 days prior to Colonoscopy and the day before Colonoscopy, have a low-fibre breakfast and then drink only clear fluids until after the procedure is completed.
3141020|NCT01610882|Other|Panda first|Panda evaluation of post-operative pain first, followed by manual method of pain assessment.
3141021|NCT01610882|Other|Manual first|Manual evaluation of post-operative pain first followed by Panda pain assessment.
3141022|NCT01610869|Experimental|Cyclophosphamide and BIBF-1120|Patients will receive oral BIBF 1120 (200mg bd) and cyclophosphamide (100mg) on a daily basis until disease progression or unacceptable toxicity.
3141023|NCT01610869|Placebo Comparator|Cyclophosphamide and placebo|Patients will receive oral BIBF 1120 (200mg bd) and placebo capsules on a daily basis until disease progression or unacceptable toxicity.
3141024|NCT01610856|Experimental|PEG - 4 L|4 Litres PEG bowel preparation given the day prior to colonoscopy with a clear fluid diet
3141025|NCT01610856|Active Comparator|Split Dose PEG|4 Litres of Colyte given as two split doses of 2L each either the day before colonoscopy 8 hours apart in the case of an AM colonoscopy or in the case of an afternoon colonoscopy given 5PM the day before and 6:00AM the day of the colonoscopy
3141026|NCT01610830||Group A|have skin involvement +/- an extra renal disease (arthritis, digestive and/or HSP without renal disease. The absence of renal disease is defined by the absence of hypertension (BP <95th percentile for height in children, BP <140/90 mmHg in adults with no known history of hypertension), the absence of hematuria (<5 RBCs per mm3), the absence of proteinuria (proteinuria <0.1 g/24h) and the absence of renal dysfunction (MDRD> 80 ml / min).
3141027|NCT01610830||group B|"HSP with renal impairment, defined by the presence of renal dysfunction (calculated clearance <60 ml/min) and/or proteinuria (daily proteinuria greater than 0.3 g) and/or hematuria (more than 5000 RBC per ml or 5 RBC per mm3). We distinguish:~Group B1 patients with moderate renal disease if renal biopsy was not indicated or no evidence of histologic severity in renal biopsy (histological classification class 1 or 25)~Group B2 patients with severe renal impairment, with signs of histological severity in renal biopsy (class 3, 4 or 5)."
3141028|NCT01610817||Patients with the InPAct intervention|The InPAct intervention will be presented to the last patients recruited by each general practitioner
3141029|NCT01610817||Patients without the InPAct intervention|The InPAct intervention will not be presented to the first patients recruited by each general practitioner
3141030|NCT01610804||CSCR-Patients|Patients suffering from Central Serous Chorioretinopathy
3141031|NCT01610804||Healthy Subjects|Healthy subjects with (assumed) normal choroidal thickness
3141032|NCT01610791|Experimental|Single Arm|
3141033|NCT01610778|Placebo Comparator|Placebo|
3141034|NCT01610778|Experimental|Supplement|
3141035|NCT01610765|Active Comparator|Novel Antiviral Drug|Subjects will be randomized to receive one of 3 oral doses of a Novel Antiviral Drug: 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for up to 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered
3141036|NCT01610765|Placebo Comparator|Placebo|Subjects will be randomized to receive one of 3 oral doses of placebo matched in volume to active drug: 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for up to 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered
3141037|NCT01610752|Experimental|SmartMoms-Clinic|If picked for this group, you will attend study meetings with a weight management counselor. During the second trimester study meetings occur 4 times per month. During the third trimester you will attend study meetings 2 times per month. These meetings will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
3141038|NCT01610752|Experimental|SmartMoms-Phone|If picked for this group, you will have two individual sessions with a weight management counselor. At the first session, you will receive a scale and other technology to help manage your weight during pregnancy. Each week you will receive information from a weight management counselor via a Smartphone (you can use your own Smartphone or one will be provided to you). The information will cover topics to help manage your weight during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to measure your body weight (using a scale we will provide) as well as monitor your food intake and exercise habits with the Smartphone.
3141039|NCT01610752|No Intervention|Physician Directed|If picked for this group, you will receive weight management advice from your physician's office.
3141040|NCT01610739|Other|Median nerve perfusion|Injection of indigocyanine green dye to evaluate perfusion of the median nerve with the SPY scope before and after carpal tunnel release
3141041|NCT01610726|Active Comparator|enhanced recovery|
3141042|NCT01610726|No Intervention|conventional recovery|
3141043|NCT01610713|Experimental|GW-1000-02|Active treatment.
3141044|NCT01610700|Experimental|GW-1000-02|Active treatment
3141045|NCT01610700|Placebo Comparator|Placebo|Control
3141046|NCT01610687|Experimental|GW-1000-02|Active treatment
3141047|NCT01610674|Experimental|Tailored improvement strategy|In 3 hospitals a tailored strategy to improve perioperative diabetes care is performed
3141048|NCT01610674|No Intervention|Usual perioperative diabetes care|Three hospitals that provide usual perioperative diabetes care serve as control hospitals
3141049|NCT01610661|Other|Unrefined-carbohydrate|unrefined carbohydrate diet
3141050|NCT01610661|Other|Refined-carbohydrate|refined carbohydrate diet
3141051|NCT01610661|Other|Simple-carbohydrate|simple carbohydrate diet
3141052|NCT01610648||Patients presenting for a diagnostic sleep study|Patients presenting to the TMC sleep center for sleep study
3141053|NCT01610635|Experimental|Male - 8 weeks|Male donors assigned to an 8 week donation interval frequency
3141054|NCT01610635|Experimental|Male - 10 weeks|Male donors assigned to 10 week donation interval frequency
3141055|NCT01610635|No Intervention|Male - 12 weeks|Male donors assigned to 12 week donation interval frequency
3141056|NCT01610635|Experimental|Female - 12 weeks|Female donors assigned to 12 week donation interval frequency
3141057|NCT01610635|Experimental|Female - 14 weeks|Female donors assigned to 14 week donation interval frequency
3141058|NCT01610635|No Intervention|Female - 16 weeks|Female donors assigned to 16 week donation interval frequency
3141059|NCT01610609|Experimental|Population Health Management Intervention|Participants randomized to this arm will receive the population health management intervention.
3141060|NCT01610609|No Intervention|Usual Care Control Group|Participants randomized to this arm will receive usual care.
3141061|NCT01610596|Experimental|Halobetasol Propionate Lotion 0.05%|Topical lotion, applied twice daily
3141062|NCT01610596|Placebo Comparator|Vehicle Lotion|Topical lotion, applied twice daily
3141063|NCT01610570|Experimental|Phase I Dose Level -1|Dose Escalation Phase 9.0 mcg/kg.dose
3141064|NCT01610570|Experimental|Phase I Dose Level 1|Dose Escalation Phase 13.0 mcg/kg.dose
3141065|NCT01610570|Experimental|Phase I Dose Level 2|Dose Escalation Phase 17.5 mcg/kg.dose
3141066|NCT01610570|Experimental|Phase II - Expansion Phase|Expansion phase 17.5 mcg/kg.dose
3141067|NCT01610557|Experimental|Group 1 - Ranibizumab-Ranibizumab-Bevacizumab Injection Series|"Group 1 eyes were assigned to Ranibizumab-Ranibizumab-Bevacizumab (RRB) treatment sequence and received intravitreal injections of ranibizumab at baseline, Weeks 4, and 8 (period 1), and Weeks 12, 16 and 20 (period 2), then crossed over to receive intravitreal injections of bevacizumab at Weeks 24, 28 and 32 (period 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
3141068|NCT01610557|Experimental|Group 2 - Ranibizumab-Bevacizumab-Bevacizumab Injection Series|"Group 2 eyes were assigned to Ranibizumab-Bevacizumab-Bevacizumab (RBB) treatment sequence and received intravitreal injections of ranibizumab at baseline and Weeks 4 and 8 (period 1), then crossed over to receive intravitreal injections of bevacizumab at Weeks 12, 16, 20, 24, 28 and 32 (periods 2 and 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
3141069|NCT01610557|Experimental|Group 3 - Bevacizumab-Bevacizumab-Ranibizumab Injection Series|"Group 3 eyes were assigned to Bevacizumab-Bevacizumab-Ranibizumab (BBR) treatment sequence and received intravitreal injections of bevacizumab at baseline and Weeks 4, 8, 12, 16 and 20 (periods 1 and 2), then crossed over to receive intravitreal injections of ranibizumab at Weeks 24, 28 and 32 (period 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
3141070|NCT01610557|Experimental|Group 4 - Bevacizumab-Ranibizumab-Ranibizumab Injection Series|"Group 4 eyes were assigned to Bevacizumab-Ranibizumab-Ranibizumab (BRR) treatment sequence and received intravitreal injections of bevacizumab at baseline and Weeks 4 and 8 (period 1), then crossed over to receive intravitreal injections of ranibizumab at Weeks 12, 16, 20, 24, 28 and 32 (periods 2 and 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
3141071|NCT01610518|Experimental|250 mL medium viscosity|250 mL beverage containing 4g low molecular weight oat beta-glucan and 50g glucose
3141072|NCT01610518|Experimental|600 mL low viscosity|600 mL beverage containing 4g low molecular weight oat beta-glucan and 50g glucose
3141073|NCT01610518|Experimental|250 mL high viscosity|250 mL beverage containing 4g high molecular weight oat beta-glucan and 50g glucose
3141074|NCT01610518|Experimental|600 mL medium viscosity|600 mL beverage containing 4g high molecular weight oat beta-glucan and 50g glucose
3141075|NCT01610518|Placebo Comparator|250mL control|250 mL beverage containing 50g glucose
3141076|NCT01610518|Placebo Comparator|600mL control|600mL beverage containing 50g glucose
3141077|NCT01610505|Experimental|KineSpring System|The KineSpring System is implanted through two medial incisions, one on the distal femur and one on the proximal tibia. Femoral and Tibial bases are fixed with screws to the femur and tibia. An absorber connects the two bases and offloads forces normally transmitted to the medial compartment of the knee.
3141078|NCT01610505|Active Comparator|High Tibial Osteotomy|There are two ways to perform a high tibial osteotomy: a closed wedge osteotomy (CWO) or an open wedge osteotomy (OWO). An OWO cuts the bone, increases the angle and fills the gap with bone graft. A CWO removes a wedge of bone to achieve the change of angle. The surgery involves the gaping or wedging of a piece of bone and its removal to change the pressure points of weight-bearing activity, thus redistributing the load to the unaffected compartments of the knee. The cut surfaces of the bone are typically held together with a plate and screw system.
3141079|NCT01610492|Experimental|Cohort 1|10mg/kg belimumab intravenous (IV) administered at weeks 0 and 2, and then every 4 weeks, over a 24-week treatment period, resulting in a total of 8 doses, and will be assessed for the primary endpoint at week 28. Subjects will then enter the long term phase of the study and receive 10mg/kg belimumab every 4 weeks until week 100,or until they have been in complete remission for at least 3 months, resulting in up to 27 doses.
3141080|NCT01610479|Experimental|TAS-114/S-1|TAS-114 plus S-1
3141081|NCT01610466|Experimental|Curriculum training group|Surgical residents in the curriculum training group will complete the entire curriculum. They will participate in a cognitive component, which will consist of self-directed readings and a faculty-led seminar. Participants will also train to proficiency in laparoscopic jejunojejunostomy and gastrojejunostomy using a laparoscopic box trainer with cadaveric porcine bowels. Finally, for the non-technical skills component participants will participate in an introductory lecture on non-technical skills in surgery, as well as a practice crisis scenario with a debriefing session.
3141082|NCT01610466|No Intervention|Conventional training group|Participants in the conventional training group will proceed through surgical residency training in the usual fashion.
3141083|NCT01610453||ultrasound|primiparous women with prolonged labours will be eligible for examination
3141084|NCT01610440|Experimental|Intervention Group|Participants will be given rehabilitation therapy plus human umbilical cord mesenchymal stem cells transplantation with one year follow-up
3141085|NCT01610427|Experimental|HIV-1 Group|Samples for cell-mediated immunity (CMI) in ART-naïve HIV-1-infected subjects aged 18 to 55 years
3141086|NCT01610414|Experimental|GSK1437173A Group|Subjects received 2 doses of the candidate HZ vaccine GSK 1437173A, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
3141087|NCT01610414|Placebo Comparator|Placebo Group|Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
3141088|NCT01610401|Active Comparator|Pretreatment with metformin|Pretreatment with metformin 500 mg three times a day for 3 days.
3141089|NCT01610401|No Intervention|No pretreatment.|no intervention
3141090|NCT01610401|Active Comparator|Pretreatment with Metformin/caffeine|to study whether caffeine (4 mg/kg intravenously over 10 minutes) attenuates the protective effect of metformin (500 mg three times a day for 3 days) on FMD after ischemia/reperfusion
3141091|NCT01610401|Other|No metformin, only pretreatment with caffeine|No pretreatment with metformin, FMD measurement after forearm ischemia/reperfusion and infusion of caffeine (4 mg/kg intravenously over 10 minutes).
3141092|NCT01610388|Experimental|Cohort A1|Single dose 60 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days
3141093|NCT01610388|Experimental|Cohort A2|Single dose 30 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days
3141094|NCT01610388|Experimental|Cohort B|Initial single 1000mg oral GSK1322322/placebo dose, initial single dose 1000mg IV GSK1322322/placebo followed by BID for 4 days
3141095|NCT01610388|Experimental|Cohort C|Initial single 1500mg oral GSK1322322/placebo dose, initial single dose 1500mg IV GSK1322322/placebo followed by BID for 4 days
3141096|NCT01610388|Experimental|Cohort D|Single dose 2000mg IV GSK1322322J/placebo
3141097|NCT01610388|Experimental|Cohort E|Single dose 3000mg IV GSK1322322J/placebo
3141098|NCT01610388|Experimental|Cohort F|1000mg IV GSK1322322J/placebo followed by BID for 4 days
3141099|NCT01610375|Other|Telephone Follow-up|Women previously treated for endometrial cancer will be recruited into one study group and continue to be followed per the current routine clinic follow-up. However, an additional program (telephone follow-up) will be offered in parallel to the current clinic follow-up. Outcomes obtained from the telephone follow-up will be compared with the current clinical assessment.
3141100|NCT01610362|Active Comparator|5-dose IM rabies vaccines, HRIG 20 IU/kg|Rabies exposed victims, 5-dose IM rabies vaccine, HRIG 20 IU/kg
3141101|NCT01610362|Experimental|5-dose IM rabies vaccines, HRIG 40 IU/kg|Healthy volunteers, 5-dose IM rabies vaccine, HRIG 40 IU/kg
3141102|NCT01610336|Experimental|INC280+gefitinib|INC280+gefitinib
3141103|NCT01610323|Experimental|Exercise group|Exercise intervention
3141104|NCT01610323|Other|Control group|Standard care
3141105|NCT01610310|Experimental|peginterferon beta-1a PFS/autoinjector|A single dose of peginterferon beta-1a 125 mcg administered by prefilled syringe (PFS) on Day 1, then by a single dose of peginterferon beta-1a 125 mcg by autoinjector on Day 22.
3141106|NCT01610310|Experimental|peginterferon beta-1a autoinjector / PFS|A single dose of peginterferon beta-1a 125 mcg administered by autoinjector on Day 1, then by a single dose of peginterferon beta-1a 125 mcg by prefilled syringe (PFS) on Day 22.
3141107|NCT01610297|Experimental|ICL670|Oral dose of ICL670 at 10 mg/kg daily
3141195|NCT01609621||Retrograde access|
3141196|NCT01609608|Experimental|vibration|
3141197|NCT01609608|Placebo Comparator|placebo|
3270162|NCT00696657|Placebo Comparator|G2|
3141108|NCT01610284|Experimental|BKM120 and fulvestrant|BKM120 100mg given daily and fulvestrant 500mg given intramuscularly at cycle 1 day 1, cycle 1 day 15 and at day 1 at each cycle thereafter. Treatment will be given until disease progression or as described in the protocol
3141109|NCT01610284|Active Comparator|Placebo and fulvestrant|BKM120 matching placebo given daily and fulvestrant 500mg given intramuscularly at cycle 1 day 1, cycle 1 day 15 and at day 1 at each cycle thereafter. Treatment will be given until disease progression or as described in the protocol
3141110|NCT01610271|Experimental|Air Barrier System|The Air Barrier System will be employed throughout the surgical procedure for this group of patients.
3141111|NCT01610271|No Intervention|Control|The Air Barrier System will not be used during the surgical procedure for this group of patients.
3141112|NCT01610245|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets and one placebo capsule twice daily with food for 5 days
3141113|NCT01610245|Active Comparator|Oseltamivir|Two placebo tablets and one Oseltamivir 75 mg capsule twice daily with food for 5 days
3141114|NCT01610245|Active Comparator|Nitazoxanide and Oseltamivir|Two nitazoxanide 300 mg tablets and one Oseltamivir 75 mg capsule twice daily with food for 5 days
3141115|NCT01610245|Placebo Comparator|Placebo|Two placebo tablets and one placebo capsule with food twice daily for 5 days
3141116|NCT01610232|Experimental|LED Group|Phototherapy associated with treadmill training
3141117|NCT01610232|Active Comparator|Exercise Group|Treadmill training
3141118|NCT01610232|No Intervention|Sedentary Group|Neither physical training nor phototherapy
3141119|NCT01610219|Active Comparator|Lifestyle Modification for Diabetes Prevention|Family based intervention utilizing Traffic Light Diet, self monitoring, parent behavioral skill training and tool kit of items promoting physical activity.
3141120|NCT01610219|Other|Nutrition and Physical Activity|Family based intervention providing education on healthy eating and physical activity but no behavioral skills training, goal setting, self monitoring or physical activity toolkit.
3141121|NCT01610206|Active Comparator|gemcitabine|
3141122|NCT01610206|Experimental|Gemcitabine + pazopanib|
3141123|NCT01610193||Right sided abdominal pain|Patients that present at the Emergency Department with abdominal pain and a clinical suspicion of appendicitis.
3141124|NCT01610180|Other|Eltrombopag Olamine|Eltrombopag Olamine Initial dose 50 mg/day for 14 days. Then adjusted according to platelet count
3141125|NCT01610167|Active Comparator|NUPRO(r) Classic Prophy Paste|
3141126|NCT01610167|Experimental|NUPRO Sensodyne Prophy Paste w/ Novamin(r) w/ fluoride.|
3141127|NCT01610167|Experimental|NUPRO Sensodyne Prophy Paste w/ Novamin|
3141128|NCT01610154|Experimental|Sitagliptin treatment|
3141129|NCT01610141|Experimental|Genotype-guided warfarin dosing|A pharmacogenetic dosing algorithm including clinical factors and genotype information (VKORC1, CYP2C9 and CYP4F2) will be used to determine warfarin doses.
3141130|NCT01610141|Active Comparator|Non-genotype guided warfarin dosing|A fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
3141131|NCT01610128||chronic urticaria patients|all patients suffering from chronic types of urticaria (chronic spontaneous urticaria as well as chronic inducible forms such as cold contact urticaria)
3141132|NCT01610089|Experimental|stable isotope infusion|Infusion of isotopes [15N2-ureido] arginine, [5-13C,4, 4, 5, 5-D4] citrulline, [15N]citrulline, 15N sodium nitrate and [15N][18O3] potassium nitrate,[18O][13C]urea.
3141133|NCT01610076|No Intervention|No Video - Control|"This group does not watch the 10 minute code status video before having the knowledge base video administered."
3141134|NCT01610076|Experimental|Code Status Video|"This group views a 10 minute video about code status prior to knowledge base survey administration"
3141135|NCT01610063|Experimental|Guided|A pharmacogenomic algorithm (GeneSight) guided treatment decisions for antidepressant medication selection and appropriate dosing.
3141136|NCT01610063|No Intervention|Unguided|Treatment as usual
3141137|NCT01610050|Experimental|LFA102|
3141138|NCT01610037|Experimental|QVA149|
3141139|NCT01610037|Active Comparator|Tiotropium|
3141140|NCT01610037|Placebo Comparator|placebo|
3141141|NCT01610024|Active Comparator|Beetroot|
3141142|NCT01610011|Experimental|Glycine administration|Glycine will be administered once orally to all subjects to determine brain and plasma pharmacodynamics.
3141143|NCT01609998|Experimental|Group 1A (12-17yrs):1 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
3141144|NCT01609998|Experimental|Group 1B (6-11yrs):1 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
3141145|NCT01609998|Experimental|Group 2A (12-17yrs):4 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
3141146|NCT01609998|Experimental|Group 2B (6-11yrs):4 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
3141147|NCT01609998|Active Comparator|Group 3A: (12-17yrs): TIV+TIV|Licensed 2012/13 TIV at Day 0 and Week 18±2 wks
3141148|NCT01609998|Active Comparator|Group 3B: (6-11yrs): TIV+TIV|Licensed 2012/13 TIV at Day 0 and Week 18±2 wks
3141149|NCT01609972|Experimental|Test|Subjects randomized to this arm will be trialed and implanted with the Nevro Senza System
3141150|NCT01609972|Active Comparator|Control|Subjects randomized to this arm will be trialed and implanted with a commercially available SCS system.
3141151|NCT01609959|Active Comparator|Azilsartan group|
3141152|NCT01609959|Active Comparator|Valsartan group|
3141153|NCT01609933|Experimental|2-DAA + PegIFN/RBV|2-direct-acting antiviral (2-DAA: ABT-450 [paritaprevir] 200 mg once daily [QD], ritonavir 100 mg QD, ABT-267 [ombitasvir] 25 mg QD) plus pegylated interferon alpha-2a (pegIFN) 180 mcg once weekly and Ribavirin (RBV) weight-based dosing, 1000 to 1200 mg divided twice daily (BID) for 24 weeks (Substudy 1) and followed by pegIFN and RBV alone for an additional 24 weeks (Substudy 2).
3141154|NCT01609920|Experimental|Gadofosveset MRL|
3141155|NCT01609907|Experimental|Sequence 1|
3141156|NCT01609907|Experimental|Sequence 2|
3141157|NCT01609907|Experimental|Sequence 3|
3141158|NCT01609907|Experimental|Sequence 4|
3141161|NCT01609894|Experimental|Individualized fortification of breast milk|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding.~Routine fortifier will be added to breast milk batches.~Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
3141162|NCT01609894|Active Comparator|Routine fortification of breast milk|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding.~Routine fortifier will be added to breast milk batches."
3141163|NCT01609881|Other|Acuvail|Acuvail as preventive for inflammation and possible decrease or prevent diabetic retinopathy. The study has four arms - diabetic ketorolac, diabetic control, normal eyes ketorolac, normal eyes control. patients are randomized to ketorolac or control.
3141164|NCT01609881|Placebo Comparator|Placebo|Placebo using artificial tear drops
3141165|NCT01609868|Active Comparator|control|infants in this arm will receive the current treatment that is standard of care for these infants, powder protein modular to achieve 4 gm/kg/day
3141166|NCT01609868|Experimental|experimental|this group will receive a liquid protein modular that recently became commercially avaliable, to achieve the same protein of 4 grm/kg/day as the powder comparision group
3141167|NCT01609855|Experimental|HBB- Hioscine Butyl Bromide|
3141168|NCT01609855|Placebo Comparator|Placebo arm|
3141169|NCT01609842|Experimental|Phone reminders and pharmacist|An alerted inpatient pharmacist or a designated study team member will bring the clopidogrel medication to the patient who has received a coronary stent. The patient will return home and receive IVR refill reminder calls.
3141170|NCT01609842|Other|Usual Care|The sites will have no interaction with the study personnel. The investigators will use database information to compare with the intervention sites
3141171|NCT01609816|Experimental|Dasatinib|This is a phase 1 dose escalation study, using a standard 3+3 design. Dasatinib is administered orally once daily in the outpatient setting. The starting dose of dasatinib is 20 mg daily. The increment of dose escalation is 20 mg per dose level. Thus, there will be 5 dose levels (20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively) with 3 patients in each cohort. Patients will continue on dasatinib for 6 months
3141172|NCT01609803||Correlative studies|Formalin-fixed paraffin-embedded tissue samples are analyzed for 12q13-q14 frequency and protein overexpression by FISH and IHC.
3141173|NCT01609790|Experimental|Arm I (bevacizumab and trebananib)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3141174|NCT01609790|Active Comparator|Arm II (bevacizumab and placebo)|Patients receive bevacizumab as in Arm I and placebo IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm I.
3141175|NCT01609777|Other|Handover with SBAR|Handover with handover tool.
3141176|NCT01609764|Experimental|Exercise|Follows the fitness program as described in the intervention
3141177|NCT01609764|No Intervention|Control|Will not follow any regular fitness activity during one year
3141178|NCT01609751|Experimental|Yakult 62 ml daily|
3141179|NCT01609738||Sinus node dysfunction|Patients with sinus node dysfunction and structurally normal hearts
3141180|NCT01609738||CRT indication|Patients with an indication for CRT (heart failure with an LVEF <35% and LBBB)
3141181|NCT01609725|Experimental|Comprehensive treatment|Test treatment group
3141182|NCT01609725|Other|Community treatment|Control treatment group
3141183|NCT01609712||Patient with vertebral compression fracture|RF kyphoplasty is standard of care in our hospital for patients with osteoporortic compression fractures. We are intersetd, if it also can improve the lung function.
3141184|NCT01609699|Experimental|Group A - will undergo 3 successive treatments, 1 week apart|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
3141185|NCT01609699|Experimental|Group B - will undergo 3 successive treatments, 2 weeks apart|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
3141186|NCT01609673|No Intervention|Control|"35 patients using Cyclosporin or Tacrolimus (C0=100-200/5-10ng/mL)+ Myfortic® 1440mg/dia + Steroids.~Medications will be administered orally, twice a day"
3141187|NCT01609673|Active Comparator|Intervention|"35 randomized Patients Converted to Certican® (Everolimus C0=6-10 ng/mL) + Myfortic® 1440mg/day + Steroids.~On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
3141188|NCT01609660|No Intervention|Control group|No intervention at all
3141189|NCT01609660|Experimental|Study group|Use of Saccharomyces boulardii, 100mg for at least seven days before surgery
3141190|NCT01609647|Experimental|Prasugrel|Reloading with prasugrel 20mg & followed by administration of 5mg/day for 30 days
3141191|NCT01609647|Active Comparator|Clopidogrel|Reloading with clopidogrel 300mg and followed by administration of clopidogrel 75 mg/day for 30 days
3141192|NCT01609634|Active Comparator|Key Group of interest|Subjects who started test product / control product 1 / control product 2 by 1-month of age
3141193|NCT01609634|Active Comparator|Other-fed Group|Subjects who started test product / control product 1 / control product 2 and continued on breast-feeding
3141194|NCT01609634|Active Comparator|Breast Fed Reference Group|Subjects who are exclusively breast-fed up to 4 months of age and not started on test product / control product 1 / control product 2.
3141200|NCT01609582|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily for up to 6 years.
3141201|NCT01609569||coronary complication|"patients with coronary complication and patients without coronary complications.~pro-calcitonin will be measured in both groups to see if any correlation."
3141202|NCT01609556|Experimental|IMGN853|
3141203|NCT01609543|Experimental|Single Arm|
3141204|NCT01609530|Active Comparator|Liquid Nitrogen Cryotherapy|Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
3141205|NCT01609530|Experimental|Pulsed 1064nm Nd:YAG|Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
3141206|NCT01609517||Obese group|patients with BMI >= 30.0 kg/m2 who received spinal anesthesia with heavy marcaine
3141207|NCT01609517||Non-obese group|patients with BMI < 30.0 kg/m2 who received spinal anesthesia with heavy marcaine
3141208|NCT01609504|Experimental|Transanal Endoscopic Microsurgery|Patients were treated by TEM as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT (ELRR- Endo Luminal Loco Regional Resection)
3141209|NCT01609504|Active Comparator|Total Mesorectal Excision|
3141210|NCT01609491|Active Comparator|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) will be used in the syringes
3141211|NCT01609491|Active Comparator|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
3141212|NCT01609478|Experimental|indacaterol acetate 75 µg|"indacaterol acetate 75 µg od delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
3141213|NCT01609478|Experimental|indacaterol acetate 150 µg|"indacaterol acetate 150 µg od delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
3141214|NCT01609478|Placebo Comparator|placebo|"placebo delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
3141215|NCT01609465||Stable angina|
3141216|NCT01609452|Experimental|Blisibimod|
3141217|NCT01609452|Placebo Comparator|Placebo|
3141218|NCT01609439|Placebo Comparator|Placebo|
3141219|NCT01609439|Experimental|Treatment|Pre-operative Vitamin D 800 units x 4 weeks
3141220|NCT01609426||children with idiopathic nephrotic syndrome|children below 16 years of age with a steroid dependent nephrotic syndrome
3141221|NCT01609413|Experimental|AlgaeCal|Calcium supplements derived from ocean algae. One dose equals 3 capsules containing 180 mg calcium each.
3141222|NCT01609413|Active Comparator|Caltrate 600|Proprietary calcium supplement. One dose contains 600 mg of calcium.
3141223|NCT01609400||Breast enhancement|
3141224|NCT01609387|Experimental|Gastric Banding new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Band patients)
3141225|NCT01609387|Active Comparator|Gastric Banding current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Band patients)
3141226|NCT01609387|Experimental|RYGB new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in RYGB patients
3141227|NCT01609387|Active Comparator|RYGB current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in RYGB patients)
3141228|NCT01609387|Experimental|Gastric sleeve new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Sleeve patients)
3141229|NCT01609387|Active Comparator|Gastric sleeve current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Sleeve patients)
3141230|NCT01609374|Experimental|M6-C Artificial Cervical Disc|
3141231|NCT01609374|Active Comparator|Anterior Cervical Discectomy and Fusion|
3141232|NCT01609361|No Intervention|1: Standard surgery + Standard care|standard surgery and Standard care after surgery
3141233|NCT01609361|Other|2: Laparoscopy + Rehabilitation program|Laparoscopic colorectal surgery with rehabilitation program
3141234|NCT01609348|Active Comparator|Venlafaxine|225 mg daily over 12 weeks
3141235|NCT01609348|Placebo Comparator|Sugar pill|
3141236|NCT01609335|Other|Cognitively Normal Subjects|Study participation will consist of tests of memory and thinking, a MRI, and two PET scans. F-18 FDG and C-11 Pittsburgh compound B (PiB) are two drugs used in PET scans.
3141237|NCT01609322|Active Comparator|Education about falls|In-person education about falls with a health educator.
3141238|NCT01609322|Experimental|Activity, Balance, Learning, and Exposure|Intervention combining medication review, exercise, home safety evaluation, and exposure therapy.
3141239|NCT01609309|Experimental|Laparoscopic gastrectomy|Laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
3141240|NCT01609309|Active Comparator|Open gastrectomy|Open distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
3141241|NCT01609296|Experimental|IN.PACT Admiral DEB|"The subjects in this trial will be treated with the IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon (hereinafter referred as IN.PACT Admiral™ DEB)manufactured by Medtronic. The IN.PACT Admiral™ is a CE (Conformité Europeénne, European Confirmity) marked medical device utilized within its intended use in the IN.PACT Global trial."
3141242|NCT01609283|Experimental|Autologous Mesenchymal Stem Cells|
3141243|NCT01609270|Experimental|CardioRoot|All subjects receive the CardioRoot graft at baseline implant procedure.
3141244|NCT01609257|Experimental|Norovirus Bivalent VLP Vaccine|Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.
3141245|NCT01609257|Placebo Comparator|Placebo|Saline Placebo (0.9% sodium chloride (NaCl) and preservative-free), intramuscular (IM), Days 0 and 28.
3141246|NCT01609244|Active Comparator|Bilevel|Bilevel therapy
3141247|NCT01609244|Active Comparator|Servoventilation|servoventilation therapy
3141248|NCT01609231|Experimental|Arm A: Dalotuzumab + Irinotecan|
3141249|NCT01609231|Active Comparator|Arm B: Cetuximab + Irinotecan|
3141250|NCT01609218|Experimental|80 mg LY2140023|Single oral dose of 80 mg LY2140023 administered alone
3141251|NCT01609218|Experimental|80 mg LY2140023 + 75 g aqueous activated charcoal|Single oral dose of 80 mg LY2140023 followed 1 hour later by single oral dose of 75 g aqueous activated charcoal
3141252|NCT01609205|Experimental|Arm 1|Adalimumab
3141253|NCT01609192|Experimental|hydroxyurea|
3141254|NCT01609179|Experimental|IPI-926|
3141255|NCT01609166|Experimental|Allopurinol 3% cream|Allopurinol 3% cream in one side of the body
3141256|NCT01609166|Placebo Comparator|Placebo cream|Placebo cream in the other side of the body
3141257|NCT01609153|Active Comparator|Olanzapine or Placebo|
3141258|NCT01609153|Active Comparator|Amisulpride or Placebo|
3141259|NCT01609153|Active Comparator|Olanzapine and Amisulpride|
3141260|NCT01609140|Experimental|A|
3141261|NCT01609140|Experimental|B|
3141262|NCT01609140|Experimental|C|
3141263|NCT01609140|Experimental|D|
3141264|NCT01609140|Experimental|E|
3141265|NCT01609140|Placebo Comparator|F|
3141266|NCT01609127|Experimental|Tesetaxel every 3 weeks|Tesetaxel 27 mg/m2 orally on Day 1 in a 21-day cycle
3141267|NCT01609127|Experimental|Tesetaxel weekly|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 in a 28-day cycle
3141268|NCT01609127|Active Comparator|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 in a 21-day cycle
3141269|NCT01609114||control groups|chemotherapy (C/T) is applied in the morning. After 4-6 hrs, RT is delivered (according to the clinical practice).
3141270|NCT01609114||experimental groups|RT is delivered in the morning. After 4-6 hrs, C/T is applied.
3141271|NCT01609101|Other|Coopdech® videolaryngoscope|
3141272|NCT01609101|Other|C-MAC® videolaryngoscope|
3141273|NCT01609101|Other|McGrath® Series 5 videolaryngoscope|
3141274|NCT01609101|Other|Glidescope® Cobalt videolaryngoscope|
3141275|NCT01609101|Other|King Vision® videolaryngoscope|
3141276|NCT01609101|Other|Venner® videolaryngoscope|
3141277|NCT01609101|Other|McGrath MAC® videolaryngoscope|
3141278|NCT01609088|Experimental|Erythritol-containing beverage|
3141279|NCT01609075||Cohort|
3141280|NCT01609062|Experimental|BMN 110 Weekly at 2.0 mg/kg/week|
3141281|NCT01609062|Experimental|BMN 110 Weekly at 4.0 mg/kg/week|
3141282|NCT01609049||Participants with Chronic Hepatitis C|Naive and previously treated participants who received peginterferon alfa-2a in combination with ribavirin as per local labeling requirements.
3141283|NCT01609036||Cohort|
3141284|NCT01609023||Rituximab|Participants with chronic lymphocytic leukemia treated with rituximab in combination with chemotherapy according to SPC and routine clinical practice will be observed for 24 months.
3141285|NCT01609010|Active Comparator|Rituximab Monotherapy|Participants received 375 milligrams per square meter (mg/m2) rituximab intravenously (i.v.) weekly for 4 weeks. Participants achieving minor response (MR), partial response (PR), or completer response (CR) received a second cycle of treatment.
3141286|NCT01609010|Experimental|Rituximab, Interferon|Participants received 375 mg/m2 rituximab i.v. weekly for 4 weeks; and 3 million international units per day (MIU/day) interferon-a2a subcutaneously (s.c.) during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5. Interferon-a2a was not administered on days of rituximab administration. Participants achieving MR, PR, or CR received a second cycle of treatment.
3141287|NCT01608984|Active Comparator|RIPC-CABG|Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery with blood cardioplegia for cardiac arrest (CABG) consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before induction of cardioplegic cardiac arrest and 5 to 10 Minutes after aortic unclamping during reperfusion of the myocardium. Blood samples are taken up to 72 hours postoperatively.
3141288|NCT01608984|Placebo Comparator|Control-CABG|Control group: Coronary artery bypass grafting without RIPC protocol
3141289|NCT01608984|Active Comparator|RIPC-OPCAB|Remote ischemic preconditioning (RIPC) protocol before Off-pump coronary artery bypass surgery (OPCAB) consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before first coronary artery incision and 5 to 10 Minutes after completion of the coronary anastomoses. Blood samples are taken up to 72 hours postoperatively.
3141290|NCT01608984|Placebo Comparator|Control-OPCAB|Control group: Off-pump Coronary artery bypass surgery without RIPC protocol
3141291|NCT01608971||Weight based protamine group|In this group the dose of protamine is calculated by the weight of the patients (400 IU/kg)
3141292|NCT01608971||Heparin level based protamine group|In this group the protamine dose will be calculated 1:1 according to the heparin level measured after termination of cardiopulmonary bypass.
3141293|NCT01608958|Active Comparator|IV infusion|Oxytocin 10 IU will be administered IV infusion according to randomization assignment as soon as possible after delivery of the baby.
3141294|NCT01608958|Active Comparator|IM Injection|Oxytocin 10 IU will be administered IM according to randomization assignment as soon as possible after delivery of the baby.
3141295|NCT01608945||steroid,liver function I/R|
3141296|NCT01608932|No Intervention|Control Group|Treatment as usual
3141409|NCT01608035|Experimental|sciatic catheter|
3141410|NCT01608035|Active Comparator|Stump catheter|
3141297|NCT01608932|Experimental|Telemonitoring for frail patients with chronic diseases|Telemonitoring for frail patients with chronic diseases
3141298|NCT01608919|No Intervention|diagnostic blood tests|We are using 2 standard approved blood tests that may be useful in predicting who may develop a venous thromboembolism after cancer surgery.
3141299|NCT01608906|Experimental|continuous low dose intravenous heparin infusion|titrated to a PTT of 40-45
3141300|NCT01608906|Active Comparator|subcutanous heparin 5000 units 3 times/day|standard of care
3141301|NCT01608893|Active Comparator|Metoprolol|The metoprolol arm patients are stratified by the arrhythmia management strategy Rate or Rhythm control and metoprolol is dose titrated from 25 mg bid to a maximum of 50 mg bid over one month then patients are followed for 6 months.
3141302|NCT01608893|Active Comparator|Carvedilol|The carvedilol arm patients are stratified by the arrhythmia management strategy Rate or Rhythm control and carvedilol is dose titrated from 3.25 mg bid to maximum dose of 25 mg bid over one month then patients are followed for 6 months.
3141303|NCT01608880|Placebo Comparator|Polysporin Control|Patients in control group will receive polysporin ointment application. Polysporin ointment will be made to look like Nitroglycerin ointment.
3141304|NCT01608880|Active Comparator|Nitroglycerin|Patients in treatment group will receive nitroglycerin ointment application
3141305|NCT01608854||24 Hour Antibiotics|Patients were randomized to receive 24 hours of postoperative antibiotics following spine surgery
3141306|NCT01608854||Duration Antibiotics|Patients were randomized to receive antibiotics for the duration of time a spinal drain was in place following spinal surgery
3141307|NCT01608841|No Intervention|Gemcitabine|
3141308|NCT01608841|Experimental|Gemcitabine plus erlotinib|
3141309|NCT01608815|Experimental|Study Group|All participants will receive single dose of typhoid Vi polysaccharide vaccine on Day 0.
3141310|NCT01608802|Active Comparator|Standard care|Standard care will be provided to the control group, i.e. existing HIV outpatient multiprofessional care, ART monitoring and adherence support.
3141311|NCT01608802|Experimental|Palliative care|Palliative care delivered by an existing nurse who has been provided with palliative care training, palliative care patient management planning records, and clinical supervision
3141312|NCT01608789|Experimental|Virtue® Male Sling|
3141313|NCT01608776|Active Comparator|SOC - Standard of Care|Wound cleansing and debridement as needed, moist wound healing dressing, and off-loading
3141314|NCT01608776|Active Comparator|SOC + MIST Therapy|Wound cleansing and debridement as needed, moist wound healing dressing, off-loading, and MIST treatment
3141315|NCT01608763|Experimental|Full personalized feedback|Participant provided with the full CYD personalized feedback summary.
3141316|NCT01608763|Experimental|Only normative feedback|Participant provided with just the normative feedback component of the CYD personalized feedback summary.
3141317|NCT01608763|Experimental|Just other personalized feedback|Participant provided with all the other personalized feedback components of the CYD intervention (i.e., no normative feedback).
3141318|NCT01608763|No Intervention|No intervention control|Participant provided with a list describing the components of the CYD intervention but not provided any personalized feedback.
3141319|NCT01608750|Experimental|pantoprazole|
3141320|NCT01608750|Placebo Comparator|folic acid|
3141321|NCT01608737|Experimental|2. BI 201335 for 24 weeks|BI 201335 once daily low dose for 24 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
3141322|NCT01608737|Experimental|3. BI 201335 for 12 weeks|BI 201335 once daily high dose for 12 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
3141323|NCT01608737|Active Comparator|1. PegIFN/RBV|PegIFN/RBV for 48 weeks in treatment-naive patients
3141324|NCT01608737|Active Comparator|4. PegIFN/RBV|PegIFN/RBV for 48 weeks in prior relapser patients
3141325|NCT01608737|Experimental|5. BI 201335 for 12 weeks|BI 201335 once daily high dose for 12 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in prior relapser patients
3141326|NCT01608724|Experimental|Open label|Saxagliptin, oral 5mg once a day(Q. D.)
3141327|NCT01608711|Experimental|AGS-1C4D4 plus gemcitabine|Subjects will receive a maintenance dose of AGS-1C4D4 every 3 weeks (Q3W) in addition to the gemcitabine administration.
3141328|NCT01608698|Experimental|Belara|The participants who receive OCP in combination of 30 mcg ethinylestradiol/2 mg chlormadinone acetate (Belara®).
3141329|NCT01608698|Experimental|Yasmin|The participants who receive OCP in combination of 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin®).
3141330|NCT01608685||Renal transplant recipients|Inclusion criteria: All renal transplant recipients followed by the Division of Nephrology aged above 18 years, and having accepted study protocol after informed consent
3141331|NCT01608672||All participants|Botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
3141332|NCT01608659||botulinum toxin Type A|Previous treatment with botulinum toxin Type A for treatment of facial lines
3141333|NCT01608646|No Intervention|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
3141334|NCT01608633|Experimental|Spray and stretch|
3141335|NCT01608633|No Intervention|Control|
3141336|NCT01608594|Experimental|Ipilimumab 10 mg/kg + HDI|Ipilimumab 10 mg/kg + standard dose IFN alpha
3141337|NCT01608594|Experimental|Ipilimumab 3mg/kg + HDI|Ipilimumab 3mg/kg + standard dose IFN alpha
3141338|NCT01608581|Experimental|exposure to multi-media campaign|A multimedia campaign highlighting dangers of gasoline and fire was delivered to an intervention region in the state of Queensland
3141339|NCT01608568|Active Comparator|Interrupted suture|interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA)
3141340|NCT01608568|Active Comparator|Quill suture|self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada)
3141341|NCT01608555|Experimental|inhaled tobramycin once-a-day|Adult patients, with cystic fibrosis, requiring inhaled tobramycin prophylaxis. Patient will be treated with a single dose of 300 mg tobramycin od for 28 days.
3141411|NCT01608022|Experimental|PF804|
3141342|NCT01608542|Experimental|Fostamatinib 100mg|Up to two cohorts of Japanese subjects are planned to receive fostamatinib 100mg single and multiple twice daily doses
3141343|NCT01608542|Experimental|Fostamatinib 200mg|Up to two cohorts of Japanese subjects are planned to receive fostamatinib 200mg single and multiple twice daily doses
3141344|NCT01608529|Experimental|Cyclist group|
3141345|NCT01608516|Experimental|68Ga-NODAGA-RGD radiotracer|All patients will undergo a 68Ga-NODAGA-RGD PET/CT, a 18F-FDG PET/CT, a MRI and a US.
3141346|NCT01608503|Experimental|respiration cycle|lung inflation and deflation
3141347|NCT01608490|Experimental|RePneu Lung Volume Reduction Coil System|The RePneu Lung Volume Reduction Coil System is an implantable device, delivered through a fiber-optic bronchoscope. This is a two part system that consists of 1) sterile Nitinol Coils and 2) a sterile, disposable, single-use (single-patient) Delivery System consisting of a Guidewire, Catheter, Cartridge, and Forceps.
3141348|NCT01608490|No Intervention|Control arm is standard medical care|The Control Group will not undergo any bronchoscopies for Coil placement and will not receive prophylactic antibiotics or steroids before and after 'treatment' or chest x-rays in connection with the 'treatment' visits. The frequency of visits to the Study Doctor or designee will be similar to the LVRC Group.
3141349|NCT01608464|Active Comparator|Arm A|Arm A: will receive combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
3141350|NCT01608464|Experimental|Arm B|"Arm B will receive combination of cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.~PET scan will be repeated 3-4 weeks after end of concurrent chemo-radiation therapy Patients in Arm A and B will go for esophagectomy 4-6 weeks after end of concurrent chemo-radiation therapy or chemotherapy"
3141351|NCT01608451|No Intervention|No additional treatment|No Injection Vit D3 or Injection Progesterone prior to chemotherapy cycle
3141352|NCT01608451|Active Comparator|Inj. Proluton|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
3141353|NCT01608451|Active Comparator|Inj. Arachitol|Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
3141354|NCT01608451|Active Comparator|Inj. Proluton and Inj. Arachitol|Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM and Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
3141355|NCT01608438|Experimental|SCI Static|SCI group that practices with a static body-machine map
3141356|NCT01608438|Experimental|SCI Machine Learning|Spinal Cord Injury patients who practice with a body-machine map that is adapted using machine learning
3141357|NCT01608425|No Intervention|Control|Control group. Regular treatment.
3141358|NCT01608425|Experimental|Diabetes ulcer monitoring|Receives a telemedicine intervention: Diabetes ulcer monitoring.
3141359|NCT01608412|Active Comparator|Tacrolimus|"The subjects included in the study will be clinically followed up for at least 12 months. The patients will be selected at 3 months post-transplant according to inclusion and exclusion criteria and randomized in a 1:1 ratio for conversion to everolimus or maintenance of tacrolimus therapy.~Intervention arm: Tacrolimus"
3141360|NCT01608412|Active Comparator|Everolimus|"The subjects included in the study will be clinically followed up for at least 12 months. The patients will be selected at 3 months post-transplant according to inclusion and exclusion criteria and randomized in a 1:1 ratio for conversion to everolimus or maintenance of tacrolimus therapy.~Intervention arm: Everolimus"
3141361|NCT01608399|Experimental|Metacognitive therapy|
3141362|NCT01608399|No Intervention|Waiting list control|
3141363|NCT01608386|Experimental|anterior approach+IVC clamping|Use anterior approach combined with infrahepatic Inferior Vena Cava clamping in right hepatectomy for HCC patients.
3141364|NCT01608386|No Intervention|anterior approach|Only use anterior approach in right hepatectomy for HCC patients.
3141365|NCT01608373|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
3141366|NCT01608373|Active Comparator|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc.
3141367|NCT01608373|Placebo Comparator|Intravenous normal saline group|The patients in Group C (placebo control group) received normal saline intravenous injection
3141368|NCT01608360|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
3141369|NCT01608360|Placebo Comparator|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
3141370|NCT01608347|Experimental|LMWH + Folic acid group|Daily 40 mg of enoxaparin (LMWH) (Clexane, Sanofi Aventis, Paris, France)subconsciously started once positive pregnancy test. Treatment will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tab once/daily until 13 weeks' of gestation.
3141371|NCT01608347|Active Comparator|Folic acid|500 microgram folic acid tab/day started once positive pregnancy test and will be continued until 13 weeks' of gestation.
3141372|NCT01608334|Experimental|group A|Fentanyl
3141373|NCT01608334|Active Comparator|Group B|Sufentanil
3141374|NCT01608321|Experimental|rTMS|Those receiving experimental treatment will receive 20 sessions of rTMS. The treatment will be delivered by trained medical personnel.
3141375|NCT01608321|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 sessions of sham rTMS. The treatment will be delivered by trained medical personnel.
3141412|NCT01608009|Experimental|Pazopanib and paclitaxel|
3141413|NCT01607996|Active Comparator|Patient controlled intravenous analgesia|Fentanyl (10 microg/ml) continuous intravenous infusion at a rate of 10 to 20 microg/h
3141624|NCT01606527|Placebo Comparator|placebo|Avicel placebo capsules three times daily for four days
3141376|NCT01608308|Experimental|IV Acetaminophen|The experimental group will receive a preoperative dose of 1000mg IV acetaminophen over 15 minutes. This will occur at least 15 minutes before the start of surgery. Another 1000mg dose of IV acetaminophen will be administered 4 hours after the first dose. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
3141377|NCT01608308|Placebo Comparator|Control|The control group (Placebo) will receive 100 mL of 0.9% normal saline in place of IV acetaminophen in the same manner as the experimental group; the investigator/physician in question will be blinded to the agent that is being administered. Patients will be discharged with instruction to continue APAP 500 mg PO every 6-8 hours. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
3141378|NCT01608295|Experimental|Vilazodone; Viibryd|After screening and baseline test results are reviewed and eligibility criteria are confirmed, medications will be dispensed if patients continue to meet eligibility criteria and sign the informed consent form. All eligible subjects will be randomized to vilazodone or paroxetine group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups. Doses of the drugs will be adjusted according to individual tolerability and safety.
3141379|NCT01608295|Experimental|Paroxetine; Paxil|After screening and baseline test results are reviewed and eligibility criteria are confirmed, medications will be dispensed if patients continue to meet eligibility criteria and sign the informed consent form. All eligible subjects will be randomized to vilazodone or paroxetine group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups. Doses of the drugs will be adjusted according to individual tolerability and safety.
3141380|NCT01608282|Experimental|OPEN Intervention Group|Intervention group participants will receive an email prompt to access the OPEN website every two weeks for the first three months, with a short message about the ongoing projects at the Arthritis Research Centre of Canada. The OPEN website will remain accessible throughout the study, but no further prompting emails will be sent after Month 3. In addition, they will receive an education pamphlet produced by The Arthritis Society containing information about osteoarthritis, physical activity and other treatments.
3141381|NCT01608282|No Intervention|Control Group|Control group participants will receive, by email, the same Arthritis Society pamphlet as the Intervention group. Participants will also receive, by email, the same short message about the ongoing projects at the Arthritis Research Centre of Canada, every two weeks for the first three months (i.e. the same schedule as the intervention group receiving the prompting email so that the number of contacts is equal in both groups), but without the prompting to use the OPEN website.
3141382|NCT01608269|Other|ABC/3TC (Epzicom), NRTI|
3141383|NCT01608256||mild cognitive impairment|men and women, aged 50 to 70. The inclusion criteria are:diagnosis of MCI (given by a neurologist), valid driver's license and driving experience of at least a year. the exclusion criteria are: people diagnosed with other neurological damage such as: dementia, CVA and head injury, people with sensory or motor impairment.
3141384|NCT01608256||Healthy people|Men and women, ages 50-70. the inclusion criteria are: healthy people with out neurological disease or psychiatric illness, have valid driver's license and driving experience of at least a year.
3141385|NCT01608243|Experimental|SLIT tablets of HDM allergen extracts|
3141386|NCT01608243|Placebo Comparator|Placebo|
3141387|NCT01608217|Active Comparator|Namisol|Namisol is a tablet containing delta-9-tetrahydrocannabinol, the main cannabinoid from Cannabis sativa L. Namisol is added to a standardized treatment with acetaminophen.
3141388|NCT01608217|Placebo Comparator|Placebo|The control product is placebo, consisting of a tablet with similar appearance and taste of the test product. Placebo is added to a standardized treatment with acetaminophen.
3141389|NCT01608191|No Intervention|Ordinary primary care follow up|Ordinary follow up after 24 weeks of LCD diet + reintroduction of food.
3141390|NCT01608191|Active Comparator|CBT follow up|11 weeks intervention programme with CBT conducted via internet.
3141391|NCT01608165|Other|Partial nephrectomy|Patients randomised to this arm will undergo a partial nephrectomy
3141392|NCT01608165|Other|Radiofrequency ablation|Patients randomised to this arm will undergo radiofrequency ablation
3141393|NCT01608165|Other|cryoablation|Patients randomised to this arm will undergo cryoablation
3141394|NCT01608152||Needs Analysis Focus Group|8 hematopoietic stem cell transplantation (HSCT) survivors (between 1-3 years after HSCT hospital discharge) from the greater Houston area.
3141395|NCT01608152||Feasibility Evaluation Group|32 hematopoietic stem cell transplantation (HSCT) recipients who are within 1 year of hospital discharge for HSCT for the feasibility evaluation. These patients will be recruited through the Children's Cancer Hospital (CCH) clinics.
3141396|NCT01608139|Experimental|Curcumin + Sorafenib + Vorinostat|"Participant assigned to a dose level of the study drug combination based on when joined this study. Up to 9 dose levels of the study drug combination will be tested. Three (3) to 6 participants will be enrolled at each dose level of the study drug combination. During first cycle only, Curcumin initiated on Day 1, Vorinostat on Day 3 and Sorafenib on Day 5. Beginning with Cycle 1 Day 5, all agents administered continuously. Cycle of therapy is 28 days.~Starting dose of Curcumin: 4 grams by mouth per day on Day 1. Starting dose of Sorafenib: 200 mg by mouth daily beginning on Day 5. Starting dose of Vorinostat: 100 mg by mouth daily beginning on Day 3."
3141397|NCT01608126|Active Comparator|Combined Cervical Block|
3141398|NCT01608126|Active Comparator|Median Cervical Block US guided|
3141399|NCT01608100|Experimental|ARCHITECT STAT High Sensitive Troponin I Assay testing|All subjects will have their blood tested by the investigational ARCHITECT STAT High SensitiveTroponin I assay.
3141400|NCT01608087|Experimental|BI 695502|Subject to receive one intravenous (i.v.) infusion of BI 695502
3141401|NCT01608087|Active Comparator|bevacizumab A|Subject to receive one i.v. infusion of bevacizumab
3141402|NCT01608087|Active Comparator|bevacizumab B|Subject to receive one i.v. infusion of bevacizumab
3141403|NCT01608074|Experimental|BRCA mutation carriers|"Women with BRCA1 or BRCA 2 mutation or a family history of breast/ovarian cancer.~Radical fimbriectomy. Histopathology SEE-FIM"
3141404|NCT01608061|Experimental|DBS-f on|DBS-f on
3141405|NCT01608061|Sham Comparator|DBS-f off|DBS-f off
3141414|NCT01607996|Experimental|Epidural anesthesia|Carbostesin (0.1%) and Fentanyl (2 microg/ml) at a continuous flow of 6 to 15 ml/hour
3141415|NCT01607983|Experimental|inhaled nitric oxide|
3141416|NCT01607970|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
3141417|NCT01607970|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
3141418|NCT01607957|Experimental|TAS-102|
3141419|NCT01607957|Placebo Comparator|Placebo|
3141420|NCT01607944||Normal Glucose Tolerance|
3141421|NCT01607944||Type 2 Diabetes|
3141422|NCT01607931|No Intervention|Resting Trial|a 1 hour period of rest immediately prior to OGTT or isoglycemic clamp
3141423|NCT01607931|Experimental|Exercise Trial|a 1 hour cycling exercise bout immediately prior to the OGTT or isoglycemic clamp
3141424|NCT01607918|Experimental|Sequential therapy 10 days|Sequential therapy
3141425|NCT01607918|Active Comparator|Triple therapy 14 days|Triple therapy
3141426|NCT01607905|Experimental|Solid Tumors|KPT-330
3141427|NCT01607892|Experimental|selinexor|
3141428|NCT01607879|Experimental|Standard of care ADT + (HMB + AG)|Standard of care androgen deprivation therapy plus the nutritional supplement HMB + arginine + glutamine (AG)
3141429|NCT01607879|Active Comparator|Standard of care ADT|Standard of care androgen deprivation therapy
3141430|NCT01607866|Experimental|Quadrant parotidectomy|Patients in this arm will receive excision of the parotid gland quadrant harboring the tumor
3141431|NCT01607866|Active Comparator|Superficial parotidectomy|Patients in this group will receive superficial parotidectomy
3141432|NCT01607853|Experimental|Daivobet® gel|
3141433|NCT01607840|Experimental|Anodal Stimulation|transcranial direct current stimulation using Anodal stimulation over the area of interest
3141434|NCT01607840|Experimental|Cathodal|transcranial direct current stimulation using cathodal stimulation over the brain area of interest
3141435|NCT01607840|Sham Comparator|Sham Stimulation|transcranial direct current stimulation that is ramped up and ramped down providing the sensation of tDCS without actually delivering tDCS
3141436|NCT01607827|Active Comparator|Polyp removal upon insertion and withdrawal|
3141437|NCT01607827|No Intervention|Polyp removal upon withdrawal only|
3141438|NCT01607814||Cirrhotic Patients|Patients affected by cirrhosis of any etiology and severity
3141439|NCT01607814||Control Group|Subjects age, sex and comorbidities matched
3141440|NCT01607801||non-absorbable suture NAS|having their umbilical hernia repaired with NAS
3141441|NCT01607801||Long-term-absorbable suture (LAS)|patients having their umbilical hernia repair with LAS
3141442|NCT01607801||Absorbable sutures (AS)|patients having their umbilical hernia repair with AS
3141443|NCT01607801||Mesh repair|Patients having umbilical hernia mesh repair
3141444|NCT01607775|Active Comparator|PEEK-cage|Patients will receive a PEEK-cage
3141445|NCT01607775|Experimental|PMMA-cage|
3141446|NCT01607762|Experimental|Cohort A: Aripiprazole|
3141447|NCT01607762|Experimental|Cohort B: Quetiapine|
3141448|NCT01607762|Experimental|Cohort C: Olanzapine|
3141449|NCT01607762|Experimental|Cohort D: Risperidone|
3141450|NCT01607762|Experimental|Cohort E: Paliperidone|
3141451|NCT01607749|Experimental|Educational Program|"Students in the intervention schools learn the educational program Asthma, Sport and Health in three sessions during a period of 6 weeks. The content of the educational program has been published elsewhere."
3141452|NCT01607749|No Intervention|Asthma information for teachers|Information about asthma the Ministry of Education to all schools in the community.
3141453|NCT01607736|No Intervention|Inactive Comparator|
3141454|NCT01607736|Experimental|Virtual Gait Training|
3141455|NCT01607723|Other|NAVA ventilatory mode|
3141456|NCT01607723|Other|PAV+ ventilatory mode|
3141457|NCT01607710||Generalized Anxiety Disorder|The group of participants diagnosed with generalized anxiety disorder.
3141458|NCT01607710||Nonclinical Control Group|The comparison group of participants with no psychiatric diagnoses.
3141459|NCT01607697|Experimental|Mindfulness Training|Group received Mindfulness Training
3141460|NCT01607697|No Intervention|Waitlist Control|Group received Usual Care
3141461|NCT01607684|Other|Diabetes mellitus group|Subjects with Diabetes mellitus and symptoms of diabetic gastroparesis
3141462|NCT01607684|Other|Control group|Healthy volunteers as matched pairs according to gender and age
3141463|NCT01607671|Experimental|Timolol|This group will receive ophthalmic Timolol maleate 0.5%, 1 drop to the effected eye twice daily for 4 weeks.
3141464|NCT01607671|No Intervention|Standard Care|This group will be treated with current standard care. This does not include Timolol or other medications to reduce intraocular pressure.
3141465|NCT01607658|Placebo Comparator|Placebo|Placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
3141466|NCT01607658|Experimental|Experimental 1|Low dose TBS-2 (0.6 mg) testosterone intranasal gel administered prn
3141467|NCT01607658|Experimental|Experimental 2|Medium dose TBS-2 (1.2 mg) testosterone intranasal gel administered prn
3141468|NCT01607658|Experimental|Experimental 3|High dose TBS-2 (1.8 mg) testosterone intranasal gel administered prn
3141469|NCT01607645|Experimental|Arm1: decitabine, idarubicin, cytarabine|Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
3141470|NCT01607645|Experimental|Arm2: decitabine, idarubicin, cytarabine|Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
3141471|NCT01607632|Experimental|loving-kindness meditation|
3141472|NCT01607593||sertraline (Zoloft)|
3141473|NCT01607580|Experimental|low-dose glucocorticoid|drug
3141474|NCT01607580|Other|no intervention after transplant|
3141475|NCT01607554|Experimental|Irinotecan|The starting dose of irinotecan for the study is 180 mg/m2, given intravenously every 14 days. Each 14 day period will constitute one cycle of treatment.
3141582|NCT01606774|Experimental|Low risk patients|Patients who agreed to 4 telemedicine obstetrical visits
3270163|NCT00696657|Placebo Comparator|G3|
3141476|NCT01607541|Experimental|Peer-driven intervention|"The PDI entails structured intervention sessions including a computerized CARE for Prevention tool and HIV pre-test and post-test counseling, the opportunity to educate three peers on core education messages, and navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and six months of navigation)"
3141477|NCT01607541|Active Comparator|Control|The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
3141478|NCT01607528|Active Comparator|Probiotic|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 10E9 cfu/g per day
3141479|NCT01607528|Placebo Comparator|Placebo|A similar looking and tasting powder
3141480|NCT01607515|Other|suspected PH|Patients who undergo right heart catheterization for PH diagnosis undergo impedance cardiography
3141481|NCT01607502||Patients of our outpatient clinic|Patients who have an investigation in our outpatient clinic for pulmonary hypertension like a echocardiography, a right heart catheterization or a cardio pulmonary exercise testing
3141482|NCT01607489|Other|pulmonary vascular disease|Dual-energy computed tomography investigation
3141483|NCT01607476|Experimental|Alzheimer's Disease|"Subjects who have the clinical diagnosis of probable AD ages 50 and older who have a study partner who is the participant's power of attorney (POA) or legally authorized representative (LAR).~Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first."
3141484|NCT01607476|Active Comparator|Cognitive Normal Elderly|Cognitive Normal subjects who are greater than 60 years of age. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
3141485|NCT01607476|Active Comparator|Cognitive Normal Young|Cognitively normal subjects who are between 30-60 years old. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
3141486|NCT01607463|Experimental|active TENS group|Two electrodes were attached to the radial side of dominant forearm. In the active TENS group, TENS was delivered via two electrodes on the venous cannulation site
3141487|NCT01607463|Placebo Comparator|Placebo group|"Two electrodes were attached to the radial side of dominant forearm. In the placebo group the TENS device had no current output although the power on indicator light remained active."
3141488|NCT01607450|Other|Saline|12 hour saline (control) infusion prior to PET study
3141489|NCT01607450|Experimental|GLP-1 Low dose|GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study
3141490|NCT01607450|Experimental|GLP-1 Mid-Range Dose|GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study
3141491|NCT01607450|Experimental|GLP-1 High Dose|GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study
3141492|NCT01607424|Experimental|RECOS: 42 hours CR, 14 week-treatment.|RECOS(Cognitive Remediation for Schizophrenia) exercises were designed by SBT Company and adapted by Vianin et al (2007) for specific use in schizophrenia. It includes computer based and paper and pencil exercises that target 5 main cognitive functions. RECOS modules focus on the relevant cognitive domains, which have been recommended by the MATRICS consensus. Each exercise has 10 difficulty levels. Allocation of the training modules in RECOS was determined according to the standard scores obtained in the comprehensive neuropsychological assessment. Each patient participated in the module corresponding to his/her most altered cognitive area.
3141493|NCT01607424|Active Comparator|CRT: 42 hours CR, 14 week-treatment|CRT (Cognitive Remediation Therapy) exercises are the ones used by Wykes et al (1999). The CRT method consists of 3 modules: flexibility, memory (A and B) and planning (A and B). Each module involves a series of paper and pencil exercises with parallel forms providing with gradual difficulty.
3141494|NCT01607411|Placebo Comparator|Fluoride free toothpaste|toothpaste with no fluoride
3141495|NCT01607411|Experimental|1426ppm Fluoride Toothpaste|Experimental toothpaste containing 1426 ppm Fluoride
3141496|NCT01607411|Experimental|1000 ppm Fluoride Toothpaste|Experimental toothpaste containing 1000 ppm Fluoride
3141497|NCT01607411|Experimental|500 ppm Toothpaste|Experimental toothpaste containing 500 ppm Fluoride
3141498|NCT01607398|Experimental|ADOAIR250|ADOAIR 250mcg inhalations, twice daily, from week0 - 12
3141499|NCT01607398|Placebo Comparator|Placebo|Placebo inhalation, twice daily, from week0 -12
3141500|NCT01607385|Active Comparator|GSK2330672|
3141501|NCT01607385|Placebo Comparator|Placebo|
3141502|NCT01607372|Experimental|GSK2245035 - 40 ng or placebo|Subjects will receive GSK2245035 - 40 nanogram (ng) or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
3141503|NCT01607372|Experimental|GSK2245035 - 80 ng or placebo|Subjects will receive GSK2245035 - 80 ng or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
3141504|NCT01607372|Experimental|GSK2245035 - 120 ng or placebo|Subjects will receive GSK2245035 - 120 ng or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
3141505|NCT01607372|Experimental|GSK2245035 - 160 ng or placebo|Subjects will receive GSK2245035 - 160 ng or placebo once per week, for four treatment weeks. There will be washout period of 7 days between treatment periods.
3141506|NCT01607359||dabigatran group|All patients receiving dabigatran as periprocedural anticoagulation during the study time period
3141507|NCT01607359||warfarin group|A randomly selected group of patients treated with warfarin during the study time period matching the number of dabigatran treated patients in the same time period.
3141508|NCT01607346|Experimental|ezogabine/retigabine|Open-label
3141509|NCT01607333||Completed suicide|Patients who completed suicide
3141888|NCT01604824|Experimental|Cohort 2|Group C: dosing regimen 1; Group D: dosing regimen 2
3141510|NCT01607333||Suicide attempt|Patients who have attempted suicide, or performed preparatory acts toward imminent suicidal behavior, suicidal ideation plus indeterminate or potentially suicidal events
3141511|NCT01607333||Not completed suicide|Patients who have not completed suicide
3141512|NCT01607320|Experimental|Raloxifene|3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7
3141513|NCT01607320|Active Comparator|Clomiphene|3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7
3141514|NCT01607307|Active Comparator|Oral/enteral TJ-100 solution|Oral/enteral TJ-100 solution
3141515|NCT01607307|Placebo Comparator|Oral/enteral placebo solution|Oral/enteral placebo solution
3141516|NCT01607294|Experimental|ETC-1002|ETC-1002 daily Weeks 1-2, 80 mg/day; Weeks 3-4, 120 mg/day
3141517|NCT01607294|Placebo Comparator|Placebo|Placebo daily 4 weeks
3141518|NCT01607281||anesthesiologists, experience|There is one arm. All participating anesthesiologists wıll fulfill the questionary survey and show the imaginary puncture site by USG bilaterally.
3141519|NCT01607268||Pure Autonomic Failure|Pure autonomic failure is a type of primary autonomic failure characterized by peripheral autonomic nervous system impairment.
3141520|NCT01607268||Multiple System Atrophy|Multiple system atrophy is a type of primary autonomic failure characterized by central autonomic nervous system impairment.
3141521|NCT01607255|Experimental|water (exchange) method|Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.
3141522|NCT01607255|Experimental|water (exchange) plus dye method|Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions
3141523|NCT01607255|Active Comparator|air method|The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.
3141524|NCT01607242||patients|patients undergoing total thyroidectomy
3141525|NCT01607229||otherwise healthy with various BMI|
3141526|NCT01607216||Premature Infant|Infants born 23 0/7 weeks gestation to 35 6/7 weeks gestation.
3141527|NCT01607216||Healthy Full Term Infants|Infants born between 37 0/7 weeks gestation to 41 6/7 weeks gestation.
3141528|NCT01607203|Active Comparator|hCG|5000 IU Pregnyl SC
3141529|NCT01607203|Active Comparator|hCG and GnRH agonist|5000 IU Pregnyl SC + 0.2 mg Decapeptyl daily SC
3141530|NCT01607190||Patients with diabetic retinopathy.|
3141531|NCT01607177|Experimental|Text message group|Patients randomised to this group will receive daily text message reminders used to motivate them to exercise in the preoperative period. They will also receive an exercise information sheet to complement the text messages.
3141532|NCT01607177|No Intervention|No text message group|Patients randomised to this group will receive standardised exercise advice but will not receive the text message reminders or the exercise information sheet.
3141533|NCT01607164|Experimental|Online self-help mood management|"Healthy Mood Project Website~Online self-help automated mood management course available in Spanish and English via a website.~Intervention consisted of 8 cognitive-behavioral mood management lessons."
3141534|NCT01607151|Active Comparator|Normothermia|Core temperature 36-37 C
3141535|NCT01607151|Experimental|Hypothermia|Core temperature 32-34 C
3141536|NCT01607138||Total laryngectomy|A group of patients who underwent total laryngectomy with trechea esophageal puncture (TEP)
3141537|NCT01607125|Experimental|Vortioxetine|
3141538|NCT01607125|Placebo Comparator|Placebo|
3141539|NCT01607112|Experimental|Fluarix/Influsplit 18-60 Years Group|Subjects 18-60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
3141540|NCT01607112|Experimental|Fluarix/Influsplit > 60 Years Group|Subjects above 60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
3141541|NCT01607099|Experimental|Pico Prep|Arm in which sodium- picosulfate/magnesium citrate is used for bowel cleansing
3141542|NCT01607099|No Intervention|Standard|The standard drug macrogol is used for bowel cleansing
3141543|NCT01607086|Experimental|Group 1|To receive the sequence of investigational products in the order of AB where A is cherry lamotrigine ODT and B is cherry placebo.
3141544|NCT01607086|Experimental|Group 2|To receive the sequence of investigational products in the order of BA where A is cherry lamotrigine ODT and B is cherry placebo.
3141545|NCT01607073|Other|open label adjunctive add on|open label adjunctive add on of verapamil to existing medications. dosing begins at 1 mg/kg/d and increases weekly to target of 4 mg/kg/d in divided doses (three times/day)
3141546|NCT01607060|Experimental|Lactulone|Patients receiving lactulone
3141547|NCT01607060|Active Comparator|Control|Observational group. Compare to lactulone group.
3141548|NCT01607034|Experimental|Sequence 1 - tablet-fast|150 mg Dexpramipexole (intact tablet) single dose under fasted condition
3141549|NCT01607034|Experimental|Sequence 2 - tablet-fed|150 mg Dexpramipexole (intact tablet) single dose under fed condition
3141550|NCT01607034|Experimental|Sequence 3 - water-fast|150 mg Dexpramipexole single dose dispersed in water under fasted condition
3141551|NCT01607034|Experimental|Sequence 4 - apple-fast|150 mg Dexpramipexole single dose crushed and mixed in applesauce under fasted condition
3141583|NCT01606761|Experimental|Group 1|Patients will receive placebo every 2 weeks from Week 0 through Week 22, followed by a subcutaneous (SC) sirukumab dose regimen every 2 weeks through Week 52.
3141584|NCT01606761|Experimental|Group 2|Patients will receive sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52.
3141552|NCT01607021||Chinese children with HCV RNA positive|"A sample of 200 children with a recent confirmation of anti-HCV-antibody positive and HCV RNA positive. All the children were treated with antiviral therapy, and the course of treatment depend on HCV Viral genotyping(ie, genotype 1,2,3,4 subtypes).~Primary Outcome Measures:~Virologic response [ Time Frame: Weeks 2, 4, 6, 8, 10, and 12 ] Sustained virologic response (SVR, defined as plasma HCV RNA < lower limit of quantification [LLoQ] at 24 weeks after treatment cessation) following antiviral treatment.~Secondary Outcome Measures: Safety and tolerability of therapy. [ Time Frame: Up to 48 weeks ] measured by frequency of laboratory abnormalities , reported adverse events and discontinuations due to adverse events"
3141553|NCT01607008|Other|MRI imaging|Use of MRI imaging in conjunction with standard radiation treatment
3141554|NCT01606995||Group 1|
3141555|NCT01606969|Experimental|Dex group|dexmedetomidine-lidocaine solution,
3141556|NCT01606969|Active Comparator|Control group|epinephrine-lidocaine solution
3141557|NCT01606956|Experimental|resting volume group|
3141558|NCT01606956|Active Comparator|half the maximum volume group|
3141559|NCT01606930|No Intervention|Usual Care Group|"Group will see their physician without receiving the activation instrument."
3141560|NCT01606930|Active Comparator|"Activated Group"|"Group will be given an activation instrument to complete before their appointment and instructed to refer to and use the instrument during their clinical encounter."
3141561|NCT01606917|Experimental|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity.
3141562|NCT01606917|No Intervention|Usual care|Usual care
3141563|NCT01606904|Experimental|Weight loss counseling|Cognitive behavioral therapy - based weight loss program
3141564|NCT01606904|Other|Control|Short term weight loss counseling, control group
3141565|NCT01606891|Experimental|multi-component/setting parent-targeted intervention|experimental
3141566|NCT01606891|No Intervention|Primary Care|Standard primary care
3141567|NCT01606878|Experimental|CLOSED (A: crizotinib+cyclophosphamide+topotecan)|"As of February 16, 2016, this Arm of the study is completed.~Part A: Patients receive crizotinib as an oral solution PO BID on days 1-21, cyclophosphamide IV QD on days 1-5, topotecan hydrochloride IV QD on days 1-5, and filgrastim or pegfilgrastim beginning on day 6 and continuing until blood count recovers. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity."
3141568|NCT01606878|Experimental|CLOSED (B: crizotinib+vincristine/dex/dox)|"As of February 16, 2016, this Arm of the study is completed.~Part B: Patients receive crizotinib as an oral solution PO BID as in part A. Patients also receive vincristine sulfate IV on day 1, dexrazoxane hydrochloride IV on day 1, doxorubicin hydrochloride IV over 15 minutes on day 1, and filgrastim or pegfilgrastim beginning on day 2 and continuing until blood count recovers. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity."
3141569|NCT01606878|Experimental|C: crizotinib+cyclophosphamide+topotecan|Part C: Patients receive crizotinib as formulated capsule PO BID on days 1-21, cyclophosphamide IV QD on days 1-5, topotecan hydrochloride IV QD on days 1-5, and filgrastim or pegfilgrastim beginning on day 6 and continuing until blood count recovers. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3141570|NCT01606878|Experimental|D: crizotinib+cyclophosphamide+topotecan|Part D: Patients receive crizotinib as microsphere formulation PO BID on days 1-21, cyclophosphamide IV QD on days 1-5, topotecan hydrochloride IV QD on days 1-5, and filgrastim or pegfilgrastim beginning on day 6 and continuing until blood count recovers. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3141571|NCT01606865||elective and acute non-cardiac surgery|
3141572|NCT01606852|No Intervention|usual sedative practice|"Subjects will have usual care sedation directed by their patient care team with no protocolized restriction on drug doses, selection or duration."
3141573|NCT01606852|Experimental|Patient controlled sedation|Subjects will be given the hand actuator connected to a Lifecare PCA Infusion System in the PCA + continuous mode with the syringe filled with 4 ucg/ml of dexmedetomidine. A loading dose (0.5 mcg/kg) will be given followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Bedside RNs will adjust the basal rate to a maximum of based on the number of bolus requests in the prior two hours. Subjects can also receive bolus supplemental sedative medications (benzodiazepines and/or opioids)if needed in the judgment of the patient-care nurse.
3141574|NCT01606826||Asthmatics|
3141575|NCT01606813|Active Comparator|Brief physician counseling (BPC) + Usual care (UC)|The participant will receive standard care. They will receive BPC from their PCP on weight loss by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss.
3141576|NCT01606813|Experimental|BPC + Internet Weight Control Program (IWCP)|The participant will receive BPC from their PCP by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss. They will receive referral and access to an internet weight control program.
3141577|NCT01606813|Experimental|BPC + IWCP + Follow up email notes from PCP|The participant will receive BPC form their PCP by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss. They will receive referral and access to an internet weight control program. And they will receive brief follow up email notes from PCPs on how their weight loss is going (from data collected from the weight loss website).
3141578|NCT01606800|Experimental|44 Weeks of PEG-IFN alfa-2b + RBV|Participants achieving RVR at 4 weeks of treatment will receive 44 additional weeks of Peg-IFN Alfa-2b + RBV.
3141579|NCT01606800|Experimental|20 Weeks of PEG-IFN alfa-2b + RBV|Participants achieving RVR at 4 weeks of treatment will receive 20 additional weeks of Peg-IFN Alfa-2b + RBV.
3141580|NCT01606787|Experimental|mannitol arm|This study is a prospective randomized double blind placebo controlled trial comparing renal function outcomes in patients undergoing partial nephrectomy for renal tumors. Patients will be randomized in 1:1 fashion to receive mannitol or saline provided intravenously within 30 minutes prior to renal vascular clamping for performing partial nephrectomy.
3141581|NCT01606787|Placebo Comparator|placebo arm|This study is a prospective randomized double blind placebo controlled trial comparing renal function outcomes in patients undergoing partial nephrectomy for renal tumors. Patients will be randomized in 1:1 fashion to receive mannitol or saline provided intravenously within 30 minutes prior to renal vascular clamping for performing partial nephrectomy.
3141585|NCT01606761|Experimental|Group 3|Patients will receive sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC administrations will be made at Weeks 2, 6, and every 4 weeks through Week 52.
3141586|NCT01606748|Experimental|Necitumumab, Gemcitabine and Cisplatin|The study will be conducted in two sequential periods: a 3-week PK run-in participants will be treated sequentially with single doses of cisplatin, gemcitabine, and necitumumab. Cycle 1 will begin immediately following the PK run-in period.
3141587|NCT01606735|Experimental|Dose 1|
3141588|NCT01606735|Experimental|Dose 2|
3141589|NCT01606735|Experimental|Dose 3|
3141590|NCT01606722||Darunavir-ritonavir monotherapy|HIV-infected patients with undetectable viral load for at least for 6 months on stable therapy and no darunavir related mutations in the HIV-protease gene
3141591|NCT01606709|Experimental|GnRH agonist trigger|Induction of oocyte maturation with GnRH agonist
3141592|NCT01606709|Active Comparator|hCG trigger|Induction of oocyte maturation with hCG
3141593|NCT01606696|Experimental|HIIT|Higher intensity interval training.
3141594|NCT01606696|Active Comparator|Standard intensity non-interval training|Standard intensity non-interval training
3141595|NCT01606683|Experimental|GROUP 1|Infant formula supplemented with with functional ingredients (galacto-oligosaccharides, beta-palmitate, fermented milk). Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae.
3141596|NCT01606683|Other|GROUP 2|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
3141597|NCT01606683|Other|CONTROL GROUP|Breast milk
3141598|NCT01606670||Neupro® Treatment|Routine treatment with Neupro® (2, 4, 6, 8, 10, 12, 14, 16 mg/24 h) as per approved label in the EU, which is applicable in the EU member state Germany.
3141599|NCT01606657|Active Comparator|Irrigation|THE PATIENT IS TO HAVE IRRIGATION OF THE ABSCESS WITH NORMAL SALINE AS PART OF THE I&D PROCEDURE
3141600|NCT01606657|Placebo Comparator|No Irrigation|THE PATIENT IS NOT TO HAVE IRRIGATION OF THE ABSCESS AS PART OF THE I&D PROCEDURE
3141601|NCT01606644|Experimental|HBO|30 90-minute hyperbaric oxygen sessions at 2.4 atm.
3141602|NCT01606644|No Intervention|No HBO|No intervention. No hyperbaric oxygen is administered. Otherwise, the patient will follow the examination program.
3141603|NCT01606631||Arm 1 : experimental (case)|Patients included in the study and admitted to the ICU either directly from UAA or after a hospitalization in a specialty, for a severe sepsis or septic shock on their infectious disease community.
3141604|NCT01606631||Arm 2 : control|Patients included in the study with an infectious disease community, admitted to a specialty, and have not progressed to severe sepsis or septic shock before hospital discharge.
3141605|NCT01606618||Spina bifida aperta|
3141606|NCT01606618||Acquired traumatic spinal cord injury|
3141607|NCT01606605||Diffuse large B-cell lymphoma|Patients diagnosed and treated at the Samsung Medical Center
3141608|NCT01606592|Experimental|Randomized Panic Control Treatment|Patients who have been randomized to the randomization condition are assigned to PCT
3141609|NCT01606592|Experimental|Randomized Panic-Focused Psychodynamic Psychotherapy|Patients who have been randomized to the randomization condition are assigned to PFPP
3141610|NCT01606592|Experimental|Self-selected Panic Control Treatment|Patients who have been randomized to the self-selection condition choose PCT
3141611|NCT01606592|Experimental|Self-selected Panic-Focussed Psychodynamic Psychotherapy|Patients who have been randomized to the self-selection condition choose PFPP
3141612|NCT01606592|Experimental|Waiting-list|Patients who have been randomized to the waiting-list are offered sparse contact over telephone for 12 weeks and are then re-randomized to one of the other four arms
3141613|NCT01606579|Experimental|Part I|Single-agent MTD (or maximum dose to be studied) of PRI-724 will be determined in escalating dose cohorts of Acute Group patients. The MTD cohort will be expanded up to 10 patients to further evaluate tolerability.
3141614|NCT01606579|Experimental|Part II|Single-agent MTD (or maximum dose to be studied) of PRI-724 will be determined in escalating dose cohorts of Non-Acute Group patients. Dosing will begin 2 dose levels below the Part I MTD. The MTD cohort will be expanded up to 10 patients to further evaluate tolerability.
3141615|NCT01606579|Experimental|Part III Arm A|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 2 dose levels below the Part I MTD will be administered in combination with low dose ara-C therapy (20 mg SC BID × 10d q 28d) for AML patients ≥ 65 years of age."
3141616|NCT01606579|Experimental|Part III Arm B|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 2 dose levels below the Part I MTD will be administered in combination with dasatinib (140 mg PO daily) to Acute Group patients with CML-AP or BC."
3141617|NCT01606579|Experimental|Part III Arm C|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 1 dose level below the Part II MTD will be administered in combination with dasatinib (100 mg PO daily) to Non-Acute Group patients with CML-CP."
3141618|NCT01606566|Experimental|Amphinex induced PCI of bleomycin|"Drug: Amphinex induced PCI of bleomycin~Intervention:Intravenous administration of Amphinex (day 0) followed by intravenous administration of bleomycin and laser light application (day 4)"
3141619|NCT01606553|Experimental|High-intensity IMT|High intensity short duration respiratory muscle training (IMT) using a dual-vave prototype
3141620|NCT01606553|Active Comparator|Sham High-intensity IMT|High intensity short duration respiratory muscle training (IMT) using a sham dual-vave prototype
3141621|NCT01606540|Experimental|Reposition and immobilism|"The patient are under sedation before reposition. The patient will be injected with 8-10 ml 1% Lidocain.~After reposition the patient is asked to fill in a questionnaire with information of experienced pain based on VAS score. The patient note down the experience of pain each day 14 days after reposition."
3141622|NCT01606540|Active Comparator|Surgery|"The method of surgery is type bridging.~After surgery the patient is asked to fill in a questionnaire with information of experienced pain based on VAS score. The patient note down the experience of pain each day 14 days after operation."
3141623|NCT01606527|Experimental|Ibuprofen|Ibuprofen 600mg taken three times daily for four days.
3141889|NCT01604811|Experimental|Tested product|
3141625|NCT01606514|Experimental|Child, Parenting, & Parent Web-Intervention|Bounce Back Now Child, Parenting, & Parent Psychoeducation & Self-Help Web-Intervention.
3141626|NCT01606514|Experimental|Child & Parenting Web-Intervention|Bounce Back Now Child & Parenting Psychoeducation and Self-Help Web-Intervention.
3141627|NCT01606514|No Intervention|Child & Parent Web-based Assessment|Bounce Back Now Web-Based Symptom Assessment
3141628|NCT01606501||Limb Salvage patients|Patients undergoing limb salvage following severe distal tibia, ankle and/or foot injuries with major soft tissue, bone and/or ankle articular surface loss.
3141629|NCT01606501||Transtibial Amputation patients|Patients undergoing transtibial amputation following severe distal tibia, ankle and/or foot injuries with major soft tissue, bone and/or ankle articular surface loss.
3141630|NCT01606488|Other|Surgical Group|"Subjects scheduled to undergo total knee or total hip replacement at the SFVAMC.~Subjects in this arm of the study will undergo the florbetapir PET scan once prior to their surgery.~Subjects in this arm of the study will undergo serial neurocognitive assessment, heart rate variability measurement, and blood draws for genetic and inflammatory markers."
3141631|NCT01606488|Other|Non-surgical group|"Subjects being seen in at the SFVAMC orthopedic clinic for knee or hip pain but are not anticipating surgical intervention.~Subjects in this arm will not undergo the florbetapir PET scan.~Subjects in this arm of the study will undergo serial neurocognitive assessment, heart rate variability measurement, and blood draws for genetic and inflammatory markers."
3141632|NCT01606462|Experimental|Oxytocin|one application of 24 IU oxytocin per volunteer
3141633|NCT01606462|Placebo Comparator|Placebo|sodium chloride solution, intranasal application, 3 puffs per nostril one application per volunteer
3141634|NCT01606449||Group 1|Group 1 = Patients with type II Hiatal Hernia submitted to surgical therapy
3141635|NCT01606449||Group 2|Group 2 = Patients with type III Hiatal Hernia submitted to surgical therapy
3141636|NCT01606449||Group 3|Group 3 = Patients with type IV Hiatal Hernia submitted to surgical therapy
3141637|NCT01606436|Placebo Comparator|Sugar pill|Placebo matching pomaglumetad methionil administered orally once during 1 of 3 crossover periods, separated by a 2 day washout period.
3141638|NCT01606436|Experimental|400 mg pomaglumetad methionil|400 mg pomaglumetad methionil administered orally once during 1 of 3 crossover periods, separated by a 2 day washout period.
3141639|NCT01606436|Other|400 mg Moxifloxacin|Positive control, unblinded moxifloxacin administered orally once during 1 of 3 crossover periods, separated by a 2 day washout period.
3141640|NCT01606423|Placebo Comparator|Placebo|Administered once, orally
3141641|NCT01606423|Experimental|10 mg LY2409021|10 mg LY2409021 administered once, orally
3141642|NCT01606423|Experimental|22.5 mg LY2409021|22.5 mg LY2409021 administered once, orally
3141643|NCT01606423|Experimental|60 mg LY2409021|60 mg LY2409021 administered once, orally
3141644|NCT01606423|Experimental|200 mg LY2409021|200 mg LY2409021 administered once, orally
3141645|NCT01606423|Experimental|500 mg LY2409021|500 mg LY2409021 administered once, orally
3141646|NCT01606410||young, sedentary|
3141647|NCT01606410||young, active|
3141648|NCT01606410||old, sedentary|
3141649|NCT01606410||old, active|
3141650|NCT01606397|Placebo Comparator|Placebo|Placebo administered orally once daily for 4 weeks
3141651|NCT01606397|Experimental|5 mg LY2409021|5 mg LY2409021 administered orally once daily for 4 weeks
3141652|NCT01606397|Experimental|30 mg LY2409021|30 mg LY2409021 administered orally once daily for 4 weeks
3141653|NCT01606397|Experimental|60 mg LY2409021|60 mg LY2409021 administered orally once daily for 4 weeks
3141654|NCT01606397|Experimental|90 mg LY2409021|90 mg LY2409021 administered orally once daily for 4 weeks
3141655|NCT01606384|Placebo Comparator|Placebo|Twice daily
3141656|NCT01606384|Experimental|SSR149415 - 100mg|Twice daily
3141657|NCT01606384|Experimental|SSR149415 - 250mg|Twice daily
3141658|NCT01606371|Placebo Comparator|Healthy-Placebo|Placebo (capsule) administered once, orally
3141659|NCT01606371|Experimental|Healthy-2.5 mg LY2409021|2.5 mg LY2409021 administered once, orally
3141660|NCT01606371|Experimental|Healthy-10 mg LY2409021|10 mg LY2409021 administered once, orally
3141661|NCT01606371|Experimental|Healthy-30 mg LY2409021|30 mg LY2409021 administered once, orally
3141662|NCT01606371|Experimental|Healthy-100 mg LY2409021|100 mg LY2409021 administered once, orally
3141663|NCT01606371|Experimental|Healthy-250 mg LY2409021|250 mg LY2409021 administered once, orally
3141664|NCT01606371|Experimental|Healthy-500 mg LY2409021|500 mg LY2409021 administered once, orally
3141665|NCT01606371|Placebo Comparator|Diabetic-Placebo|Placebo (capsule) administered once, orally
3141666|NCT01606371|Experimental|Diabetic-75 mg LY2409021|75 mg LY2409021 administered once, orally
3141667|NCT01606371|Experimental|Diabetic-200 mg LY2409021|200 mg LY2409021 administered once, orally
3141668|NCT01606371|Experimental|Diabetic-500 mg LY2409021|500 mg LY2409021 administered once, orally
3141669|NCT01606358||Ovarian Cancer|
3141670|NCT01606345|Experimental|Phase I Dose Escalation|Dose escalation: 200 mg/75 ml effluent, 400 mg/75 ml effluent, 800 mg/75 ml effluent
3141671|NCT01606332|No Intervention|Single in interscalene block|Single indwelling interscalene block with ropivacaine 0.5% 10ml
3141672|NCT01606332|Experimental|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
3141673|NCT01606319|Experimental|acetaminophen|acetaminophen given as needed for pain or fever
3141674|NCT01606319|Experimental|ibuprofen|ibuprofen given as needed for pain or fever
3141675|NCT01606306|Experimental|Crossover sequence 1|daily fluticasone propionate, followed by daily montelukast, followed by as needed fluticasone propionate
3141676|NCT01606306|Experimental|Crossover sequence 2|daily fluticasone propionate, followed by as needed fluticasone propionate, followed by daily montelukast
3141677|NCT01606306|Experimental|Crossover sequence 3|daily montelukast, followed by as needed fluticasone propionate, followed by daily fluticasone propionate
3141678|NCT01606306|Experimental|Crossover sequence 4|daily montelukast, followed by daily fluticasone propionate, followed by as needed fluticasone propionate
3270164|NCT00696657|Placebo Comparator|G4|
3141679|NCT01606306|Experimental|Crossover sequence 5|as needed fluticasone propionate, followed by daily fluticasone propionate, followed by daily montelukast
3141680|NCT01606306|Experimental|Crossover sequence 6|as needed fluticasone propionate, followed by daily montelukast, followed by daily fluticasone propionate
3141681|NCT01606293||Carcinomas of the Cervix Survey|Women with small and large cell carcinomas of the cervix, who are members of the Facebook group found at the uniform resource locator https://www.facebook.com/SmallCellCC through an online link.
3141682|NCT01606267|No Intervention|Routine HEP|This arm includes routine care provided under the health extension program provided to rural Ethiopian villages with limited access to health facilities.
3141683|NCT01606267|Experimental|HEP+ICCM|This arm includes routine care provided under the Health Extension Program plus the HEWs will be assessing and treating childhood pneumonia cases in rural Ethiopian villages with limited access to health facilities.
3141684|NCT01606254|Experimental|Paliperidone palmitate 50 mg|Paliperidone palmitate 50 milligram (mg) intramuscular (into the muscle) injection on Days 1, 8, 36 and 64.
3141685|NCT01606254|Experimental|Paliperidone palmitate 100 mg|Paliperidone palmitate 100 mg intramuscular injection on Days 1, 8, 36 and 64.
3141686|NCT01606254|Experimental|Paliperidone palmitate 150 mg|Paliperidone palmitate 150 mg intramuscular injection on Days 1, 8, 36 and 64.
3141687|NCT01606254|Experimental|Paliperidone palmitate 150/ 50 mg|Paliperidone palmitate 150 mg intramuscular injection on Day 1 and paliperidone palmitate 50 mg intramuscular injection on Days 8, 36 and 64.
3141688|NCT01606241|Experimental|Treatment (cyclophosphamide and vaccine therapy)|Patients receive cyclophosphamide PO BID on days 1-7 and 15-21 of course 1. Within 3-5 days, patients receive multi-epitope folate receptor alpha peptide vaccine ID on day 1. Vaccine treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3141689|NCT01606228|Experimental|Paliperidone ER|
3141690|NCT01606215|Experimental|mesenchymal stem cells|
3141691|NCT01606215|Sham Comparator|Placebo|
3141692|NCT01606202|Experimental|GW-1000-02|Active treatment.
3141693|NCT01606202|Placebo Comparator|Placebo|Placebo control.
3141694|NCT01606189|Experimental|GW-1000-02|Active treatment.
3141695|NCT01606189|Experimental|GW-2000-02|Active treatment.
3141696|NCT01606189|Placebo Comparator|Placebo|Placebo control.
3141697|NCT01606176|Experimental|GW-1000-02|Each 100 μl actuation contains 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose was 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
3141698|NCT01606176|Placebo Comparator|Placebo|Each 100 μl actuation contains the excipients only. The maximum permitted dose was 48 actuations in any 24 hour period
3141699|NCT01606163|Experimental|group 1|"Drug:GC1102~Amount:3ml (30,000IU)"
3141700|NCT01606163|Experimental|group 2|"Drug: GC1102~Amount: 5ml(50,000IU)"
3141701|NCT01606163|Experimental|group 3|"Drug: GC1102~Amount: 8ml (80,000IU)"
3141702|NCT01606163|Placebo Comparator|group 4|drug: JW normal saline
3141703|NCT01606150|Active Comparator|Subcutaneous Lidocaine|0.1 ml/kg of 1% Lidocaine
3141704|NCT01606150|Active Comparator|Topical Lidocaine|LMX-4, 1 gram placed over lumbar puncture needle insertion site 30 minutes prior to the procedure
3141705|NCT01606137|Experimental|GW-1000-02|Active treatment
3141706|NCT01606124|Experimental|Arm I (Green Tea Catechin Extract)|Patients receive Polyphenon E PO BID. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
3141707|NCT01606124|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
3141708|NCT01606111|Placebo Comparator|0.9% NaCl, saline|
3141709|NCT01606111|Experimental|Cerebrolysin|
3141710|NCT01606098|Active Comparator|Systemic treatment|First-line fluoropyrimidine-based chemotherapy with bevacizumab initiated within 4 weeks of randomization, followed by salvage therapy upon progression at the discretion of the local investigator. Surgery of primary tumour will be performed only when indicated by local signs or symptoms.
3141711|NCT01606098|Experimental|Surgery followed by systemic treatment|Surgery within 4 weeks of randomization followed by fluoropyrimidine-based chemotherapy with bevacizumab until progression or unacceptable toxicity, followed by salvage therapy upon progression at the discretion of the local investigator
3141712|NCT01606085|Experimental|HF-DM Self Care|educational counseling intervention about integrated HF-DM self care outcomes
3141713|NCT01606085|No Intervention|Usual Care|Usual Care provided by providers
3141714|NCT01606072|Experimental|Desmopressin|
3141715|NCT01606059|Active Comparator|DW-0919|
3141716|NCT01606059|Experimental|DW-0920|
3141717|NCT01606046|Active Comparator|vapocoolant spray|
3141718|NCT01606046|Active Comparator|topical anesthetic agent|
3141719|NCT01606046|No Intervention|Control|no interventions
3141720|NCT01606033|Other|phase II non randomized study|"phase II non randomized study, Case : 40 patients description of patients feeling by questionnaires :~Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~understanding of the implications of participating in a clinical trial"
3141721|NCT01606033|Other|blind randomized phase II or III study|"blind randomized phase II or III study: control : 40 patients description of patients feeling by questionnaires :~Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~understanding of the implications of participating in a clinical trial"
3141722|NCT01606033|Other|open randomized phase II or III study|"open randomized phase II or III study : 40 patients description of patients feeling by questionnaires : Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~-understanding of the implications of participating in a clinical trial"
3141723|NCT01606033|Other|receiving standard treatment|"receiving standard treatment : 120 patients description of patients feeling by questionnaires :~-understanding of the implications of participating in a clinical trial"
3141890|NCT01604811|Active Comparator|Comparator|
3142072|NCT01603576|Experimental|Suprachoroidal retinal prosthesis|
3141724|NCT01606020|Active Comparator|Sleep deprivation First|"First night D7 :~Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.~Second night D28 :~Overnight, the subjects stay in their homes. No intervention during this night."
3141725|NCT01606020|Active Comparator|sleep deprivation second|"First night D7 :~Overnight, the subjects stay in their homes. No intervention during this night.~Second night D28 :~Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep."
3141726|NCT01606007|Active Comparator|Arm 1: Saxagliptin+Metformin XR+Placebo|
3141727|NCT01606007|Active Comparator|Arm 2: Dapagliflozin+Metformin XR+Placebo|
3141728|NCT01606007|Experimental|Arm 3: Saxagliptin+Dapagliflozin+Metformin XR|
3141729|NCT01605994|Experimental|Panel 1:BMS-933043(2mg)/Placebo+Antacid Buffer Solution|"BMS-933043 2 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3141730|NCT01605994|Experimental|Panel 2:BMS-933043(5mg)/Placebo+Antacid Buffer Solution|"BMS-933043 5 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3141731|NCT01605994|Experimental|Panel 3:BMS-933043(10mg)/Placebo+Antacid Buffer Solution|"BMS-933043 10 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3141732|NCT01605994|Experimental|Panel 4:BMS-933043(25mg)/Placebo+Antacid Buffer Solution|"BMS-933043 25 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3141733|NCT01605994|Experimental|Panel 5:BMS-933043(50mg)/Placebo+Antacid Buffer Solution|"BMS-933043 50 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days~CSF sampling required"
3141734|NCT01605994|Experimental|Panel 6:BMS-933043(100mg)/Placebo+Antacid Buffer Solution|"BMS-933043 100 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3141735|NCT01605994|Experimental|Panel 7:BMS-933043(200mg)/Placebo+Antacid Buffer Solution|"BMS-933043 200 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3141736|NCT01605994|Experimental|Panel 8:BMS-933043(25mg)/Placebo+Antacid Buffer Predose|"MAD Phase: Japanese Subjects. Cerebrospinal fluid (CSF) sampling not required~BMS-933043 25 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3141737|NCT01605994|Experimental|Panel 9:BMS-933043(200mg)/Placebo+Antacid Buffer Predose|"Japanese Subjects. CSF sampling not required.~BMS-933043 200 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3141738|NCT01605994|Experimental|Panel 10:BMS-933043(350mg)/Placebo+Antacid Buffer Predose|"BMS-933043 350 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3141739|NCT01605994|Experimental|CSF Panel:BMS-933043(MTD)/Placebo+Antacid Buffer Predose|"If Panel 5 does not run. CSF Sampling at steady state~BMS-933043 maximum tolerated dose (MTD), solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3141740|NCT01605981|Experimental|Nilotinib oral|Nilotinib oral dose of 400 mg BID (800 mg/day) continuous dosing for up to 24 months. Nilotinib oral dose of 300 mg BID (600 mg/day) continuous dosing in case of intolerance. Nilotinib oral dose of 400 mg QD (400 mg/day) continuous dosing in case of intolerance
3141741|NCT01605968|Experimental|BCT Silver Bandage|
3141742|NCT01605968|Active Comparator|Aquacel® Ag. Dressing|
3141743|NCT01605955||Fingertip Pulse Oximeter|SPO2 measurement range: 70%-99%
3141744|NCT01605955||CO-oximeter|SaO2 measurement range: 70%-99%
3141745|NCT01605942|Experimental|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
3141746|NCT01605942|Placebo Comparator|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
3141747|NCT01605929|Experimental|Retroclavicular Brachial Plexus Block|
3141748|NCT01605916|Experimental|Selumetinib (AZD6244) 25 mg|monotherapy
3141749|NCT01605916|Experimental|Selumetinib (AZD6244) 50 mg|monotherapy
3141750|NCT01605916|Experimental|Selumetinib (AZD6244) 75 mg|monotherapy
3141751|NCT01605916|Experimental|Selumetinib (AZD6244) 75 mg + Doce|Combination
3141752|NCT01605916|Experimental|Selumetinib (AZD6244) 25 mg + Doce|combination
3141753|NCT01605903|Experimental|Treatment with Ibuprofen|Children in the experimental group will receive grape-flavored ibuprofen 100mg/5 mL. Ibuprofen will be dispensed at 10mg/kg (max dose 600 mg) will be dispensed Q6 hours x 9 days.
3141754|NCT01605903|Active Comparator|Treatment with Acetaminophen|Children in the active comparator group will receive grape flavored acetaminophen 160 mg/5 ml. Acetaminophen will be dispensed at 15 mg/kg (max dose 650/mg) Q6 hours x 9 days.
3141755|NCT01605890|Experimental|raltegravir / emtricitabine / tenofovir disoproxil fumarate|
3141756|NCT01605877|Experimental|SN6AD2|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
3141757|NCT01605851|Other|Closure, Foramen Ovale|Patients undergoing device closure of PFO
3141758|NCT01605825|Placebo Comparator|placebo/dalfampridine-ER|"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:~Period 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36"
3141891|NCT01604798||Colorectal Cancer Patients|Patients with histologically confirmed colorectal cancer
3141759|NCT01605825|Placebo Comparator|dalfampridine-ER/placebo|"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:~Period 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36"
3141760|NCT01605812||high myopia|high myopia (axial length>26mm)
3141761|NCT01605812||emmetropia|emmetropia (22<axial length<25mm) as control group.
3141762|NCT01605799|Active Comparator|IOK Treatment|Six to eight week treatment lasting one to 1.5 hours addressing maladaptive cognitions related to killing in war.
3141763|NCT01605799|Placebo Comparator|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
3141764|NCT01605786|Experimental|PEBS Low dose|
3141765|NCT01605786|Experimental|PEBS High dose|
3141766|NCT01605786|Active Comparator|Control|
3141767|NCT01605773|Experimental|repaglinide|
3141768|NCT01605773|Active Comparator|glyburide|
3141769|NCT01605760|No Intervention|non immunotherapy treatment|
3141770|NCT01605760|Active Comparator|sublingual immunotherapy course|
3141771|NCT01605747|Experimental|Culturelle|
3141772|NCT01605747|Placebo Comparator|Placebo|
3141773|NCT01605734|Active Comparator|Group TACE|TACE will be carried out with chemotherapeutic agents and lipiodol; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated if clinically indicated
3141774|NCT01605734|Experimental|Group Combination|All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
3141775|NCT01605721|Experimental|XIENCE PRIMETM everolimus-eluting coronary stent|
3141776|NCT01605708|Experimental|Cohort 1|
3141777|NCT01605695||Normal healthy adults|The concentration of iNOS will be measured in plasma samples obtained at the time of blood donation from normal healthy adult humans
3141778|NCT01605682|Experimental|Berry extract 125|Fresh berry extract containing 125mg of polyphenols
3141779|NCT01605682|Experimental|Berry extract 250|Fresh berry extract containing 250mg of polyphenols
3141780|NCT01605682|Experimental|Berry extract 500|Fresh berry extract containing 500mg of polyphenols
3141781|NCT01605682|Placebo Comparator|Placebo|Berry flavoured juice containing no polyphenols
3141782|NCT01605669||Aortic stenosis patients|Patients with varying degrees of aortic stenosis without significant additional valvular disease will be considered eligible for this study. All participants will recieve a transthoracic echocardiogram and recorded cardiac auscultation.
3141783|NCT01605656||Focus Groups + Interviews + Questionnaires|HIV-positive women recruited from the population of individuals seeking care at Thomas Street Health Center (TSHC) of the Harris County Hospital District (HCHD).
3141784|NCT01605630|Experimental|Family-based cancer literacy intervention|
3141785|NCT01605630|Active Comparator|Control|Standard of care
3141786|NCT01605617|Active Comparator|PTNS + fesoterodine fumarate first, then PTNS + placebo|Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + 4mg of fesoterodine fumarate first for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + placebo.
3141787|NCT01605617|Placebo Comparator|PTNS + placebo first, then PTNS + fesoterodine fumarate|Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + placebo for 12 weeks followed by 4 weeks of washout followed by 12 weeks of PTNS + 4mg of fesoterodine fumarate
3141788|NCT01605604|Experimental|recieves Buddhist mindfullness|
3141789|NCT01605591|Active Comparator|the DLT bending to the right|
3141790|NCT01605591|Active Comparator|the DLT bending to the left|
3141791|NCT01605552|Experimental|Beating the Blues (BtB)|An 8-session, empirically supported, computerized, cognitive-behavioral intervention for depression (www.beatingthebluesus.com)
3141792|NCT01605552|Other|Usual Care|Patients and their primary care providers were informed of the positive depression screen, and follow-up was encouraged.
3141793|NCT01605539|Placebo Comparator|Control|Subjects will receive pills that resemble the Cannabidiol capsule but do not have have its properties.
3141794|NCT01605539|Experimental|Cannabidiol 400|Subjects in Arm Cannabidiol 400 will receive 400 mg of cannabidiol
3141795|NCT01605539|Experimental|Cannabidiol 800|Subjects in Arm Cannabidiol 800 will receive 800mg of cannabidiol
3141796|NCT01605526|Experimental|Single Arm|
3141797|NCT01605513|Experimental|recombinant interferon|PEG-IFN-SA 1.0μg/kg for 12 times, Peginterferon alfa-2a 180 μg for 12 times, PEG-IFN-SA 1.5 μg/kg for 12 times, PEG-IFN-SA 2 μg/kg for 12 times, PEG-IFN-SA 3 μg/kg for 12 times, PEG-IFN-SA 1.5μg/kg + ribavirin 0.45g/bid group for 12 times, Intergen 15μg/48hours for 7 times, ribavirin 0.45g/bid for 10 times
3141798|NCT01605500||Medtronic ICDs|Patients with Generation 2 Medtronic ICDs
3141799|NCT01605487|Other|Rupatadine 20mg - Placebo - Rupatadine 40mg|
3141800|NCT01605487|Other|Rupatadine 20mg - Rupatadine 40mg - Placebo|
3141801|NCT01605487|Other|Placebo - Rupatadine 20mg - Rupatadine 40mg|
3141802|NCT01605487|Other|Rupatadine 40mg - Placebo - Rupatadine 20mg|
3141803|NCT01605487|Other|Placebo - Rupatadine 40mg - Rupatadine 20mg|
3141804|NCT01605487|Other|Rupatadine 40mg - Rupatadine 20mg - Placebo|
3141805|NCT01605474|Active Comparator|Outpatient Cervical Ripening|Patients who are randomized to this arm will be allowed discharged home for 12 hours after fetal status is assessed and noted to be reassuring with the foley bulb in place. They will return sooner if they experience rupture of membranes or enter active labor or if the foley bulb falls out.
3141806|NCT01605474|No Intervention|Inpatient Cervical Ripening|In this arm, the fetus will be assessed and a foley bulb placed but these patients will be kept in the hospital.
3141807|NCT01605461|Experimental|BI 207127 NA|Single oral solution dose of BI 207127 NA combined with [14C]-BI 207127 NA
3141808|NCT01605448|Experimental|MBSR|Mindfulness Based Stress Reduction
3141809|NCT01605448|No Intervention|Control Group|Continue in Usual care; offered the intervention at the end of the study
3141810|NCT01605435|Experimental|Ghrelin|Dose finding with each participant receiving placebo and three doses of ghrelin, separated by 3-7 days
3141892|NCT01604798||Healthy Controls|Healthy volunteers
3270165|NCT00696657|Placebo Comparator|G5|
3141811|NCT01605409|Active Comparator|Standard ACLS|Patients in the standard ACLS group will be resuscitated until ROSC or termination of efforts. If ROSC is achieved they will be transported to the emergency department and treated according to ERC guidelines and GCP.
3141812|NCT01605409|Experimental|ECPB|"ACLS provided for 15 minutes by EMS personnel according to current guidelines of the ERC.~CPR during transportation will be performed by EMS personnel according to ERC guidelines.~At the ED cannulation will be performed percutaneously if feasible. The femoral artery will be cannulated with a 17-19 - Fr and the femoral vein will be cannulated simultaneously with heparin coated 19-25 - Fr catheter or a smart cannula. An antegrade 8 - Fr cannula will be placed to supply perfusion for the cannulated leg if feasible. The procedures will be performed ultrasound-guided and the size of the cannulae will be adapted according to vessel size. Correct placement of the venous cannulae will be verified via ultrasound. Cardiopulmonary bypass will be performed by using the Lifebridge(Sorin®) or the Cardiohelp(Maquet®) ECMO device, according to protocol."
3141813|NCT01605396|Experimental|Ridaforolimus 10 mg PO QD x5 + Dalotuzumab + Exemestane|
3141814|NCT01605396|Active Comparator|Ridaforolimus 30 mg PO QDx5 + Exemestane|
3141815|NCT01605383|Experimental|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stem cells fixed in allogenic bone tissue (under Xcelia-GMP conditions)for osteonecrosis of the femoral head"
3141816|NCT01605383|Sham Comparator|Standard Treatment|Isolated core decompression
3141817|NCT01605370|Experimental|Nebivolol|Subjects randomized to this arm will receive Nebivolol 2.5 mg once daily.
3141818|NCT01605370|Other|Metoprolol succinate|Subjects randomized to this arm will receive metoprolol succinate 50 mg once daily.
3141819|NCT01605357|Active Comparator|Standard Care|Patients will be managed to maintain a goal serum sodium of > 135 mmol/L , a well recognized value in the management of severe traumatic brain injury.
3141820|NCT01605357|Experimental|Induced Hypernatremia|Patients will be treated with induced, sustained hypernatremia for 5 days following injury by using hypertonic saline to target a goal serum sodium of 150-160 mmol/L
3141821|NCT01605344|Experimental|Arm A|ARM A subjects will receive atorvastatin 20 mg orally once daily given for two weeks prior to FOLFIRI. The last dose of atorvastatin will be taken day 1 of FOLFIRI. ARM A will then receive no statin for the next 2 weeks. Patients will receive FOLFIRI infusion on day 1 and day 15. Blood samples will be collected at baseline and periodically through 24 hours on day 1 and 15 of FOLFIRI.
3141822|NCT01605344|Experimental|Arm B|ARM B subjects will receive no atorvastatin prior to day 1 of FOLFIRI. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks prior to day 15 of FOLFIRI. The last dose of atorvastatin will be taken day 15 of FOLFIRI. Patients will receive FOLFIRI infusion on day 1 and day 15. Blood samples will be collected at baseline and periodically through 24 hours on day 1 and 15 of FOLFIRI.
3141823|NCT01605331|Experimental|sustained-release recombinant human GH (SR-rhGH)|12-week subcutaneous administration, 2mg/week
3141824|NCT01605318|Experimental|IMMU-130|All patients receive IMMU-130 administered in 21-day treatment cycles consisting of once or twice weekly for 2 consecutive weeks followed by a 1-week rest period. Treatment can be continued in the absence of unacceptable toxicity for a period of up to 8 cycles until the first documentation of Progressive Disease by CT (physician discretion), but must terminate study treatment upon the second documentation of Progressive Disease.
3141825|NCT01605305|Experimental|FOLFOX6|
3141826|NCT01605292|Active Comparator|Palpation|Manual palpation of radial pulse, as sole guide to needle cannulation.
3141827|NCT01605292|Experimental|Ultrasound|Real-time ultrasound guidance to facilitate needle cannulation of artery.
3141828|NCT01605279|Experimental|Dobutamine|Patients with low SVCF in the first 12 hours of life will be randomised to receive dobutamine or placebo.
3141829|NCT01605279|Placebo Comparator|Placebo|Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo.
3141830|NCT01605266||Nephrotic Syndrome|The cohort includes all children diagnosed with nephrotic syndrome between ages 1-18. Children and their caregiver must be willing to provide informed consent, complete questionnaires, and provide biospecimens of the child. Those with secondary causes of nephrotic syndrome and/or systemic disease are excluded.
3141831|NCT01605253|Active Comparator|Eszopiclone|The total study duration is 16 weeks, with subjects taking 3mg eszopiclone at bedtime for 12 weeks. There is one follow-up visit after the 12 week treatment phase.
3141832|NCT01605253|Placebo Comparator|Placebo|The total study duration is 16 weeks, with subjects taking placebo at bedtime for 12 weeks. There is one follow-up visit after the 12 week treatment phase.
3141833|NCT01605240|Active Comparator|Acetaminophen and Codeine|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
3141834|NCT01605240|Active Comparator|Acetaminophen and Ibuprofen|Following reduction of their fracture, these patients will receive acetaminophen (15mg/ml) and ibuprofen (10mg/ml) at regular dosing intervals.
3141835|NCT01605227|Experimental|cabozantinib|Subjects randomized to the cabozantinib arm will also receive placebo-matched prednisone capsules.
3141836|NCT01605227|Active Comparator|prednisone|Subjects randomized to the prednisone arm will also receive placebo-matched cabozantinib.
3141837|NCT01605214||Bilateral Lung Transplant|All patients undergoing bilateral lung transplant for any indication will be considered for enrollment in the study. The characteristics of measurements of extravascular lung water will be compared following surgery in those who develop primary graft dysfunction compared to those who do not.
3141838|NCT01605201|Experimental|Implantation of cartilage graft|
3141839|NCT01605162|Experimental|E7016 plus TMZ|
3141840|NCT01605149||Case|Patients with Type 1 Diabetes Mellitus
3141841|NCT01605136|Experimental|Afamelanotide|
3141842|NCT01605136|Placebo Comparator|Placebo|
3141843|NCT01605123||Lean children|n=100 (anticipated), n=70 currently Age: 6-25 years BMI-SDS: -1.88 to +1.23 , currently -0.25±0.77; Height-SDS: > - 2 SDS, currently 0.03±1.07;
3141844|NCT01605123||Obese children|n=106 Age: 6-25 years BMI-SDS: >1.23 , currently 2.41±0.52; Height-SDS: > - 2 SDS, currently 0.80±1.18;
3141845|NCT01605123||Obese Exercise Group|Obese children will engage in increased physical activity (one to two lessons per week) at 40-60 and 60-80% of maximal exercise capacity (n=50 each anticipated). Within the frame of the study we will assess the effect of the exercise on cardiovascular outcomes.
3270166|NCT00696657|Placebo Comparator|G6|
3141846|NCT01605123||Classical Lifestyle Intervention|Obese children will receive a classical lifestyle intervention, including dietary, activity and psychosocial counselling (n=50 anticipated). Within the frame of the study we will assess the effect of the exercise on cardiovascular outcomes.
3141847|NCT01605110|Experimental|Hyperbaric oxygen therapy|We propose to study the effects of two HBOT treatments (one before and one after surgery) with patients who have undergone upper eyelid surgery. Reduction in swelling and bruising will be assessed at 3, 10, 21, 30 and 90 days post-surgery to determine if healing is accelerated by HBOT. Patients that volunteer to participate in this study will be exposed to two treatments of 100% oxygen at 2.0 atmospheres absolute (ATA) or air (sham) 1.2 ATA inside mono-place chambers for 90 minutes. By comparing oxygen treatment groups with a matched control group, we can accurately assess the effectiveness of this treatment for patients. By participating in this study, patients will help in establishing the best treatment practices of using HBOT to accelerate healing and reduce cost in surgical recovery.
3141848|NCT01605110|Sham Comparator|Air sham|We propose to study the effects of two HBOT treatments (one before and one after surgery) with patients who have undergone upper eyelid surgery. Reduction in swelling and bruising will be assessed at 3, 10, 21, 30 and 90 days post-surgery to determine if healing is accelerated by HBOT. Patients that volunteer to participate in this study will be exposed to two treatments of 100% oxygen at 2.0 atmospheres absolute (ATA) or air (sham) 1.2 ATA inside mono-place chambers for 90 minutes. By comparing oxygen treatment groups with a matched control group, we can accurately assess the effectiveness of this treatment for patients. By participating in this study, patients will help in establishing the best treatment practices of using HBOT to accelerate healing and reduce cost in surgical recovery.
3141849|NCT01605097|Experimental|HDR interstitial brachytherapy|HDR prostate brachytherapy with dose escalation to 1250 cGy to the MRI-defined dominant intraprostatic lesion
3141850|NCT01605084|Experimental|Arm 1: ATV/RTV 300/100 mg QD + optimized NRTI backbone|
3141851|NCT01605084|Experimental|Arm 2: DRV/RTV 800/100 mg QD + optimized NRTI backbone|
3141852|NCT01605071|Active Comparator|Early Postmenopausal|Postmenopausal women within 6 years of last menses who never used estrogen-based hormone therapy
3141853|NCT01605071|Active Comparator|Late Postmenopausal|Postmenopausal women more than 10 years since last menses who never used estrogen-based hormone therapy
3141854|NCT01605045|Experimental|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique)versus
3141855|NCT01605045|Active Comparator|Standard technique|Coronary anatomy visualized and documented using cinematography alone (standard technique)
3141856|NCT01605032|Experimental|Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)|"CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.~TRANSPLANT: Patients undergo autologous PBSCT on day 0."
3141857|NCT01605019|Experimental|CoSeal Arm|patient randomized to received Coseal during LVAD implantation
3141858|NCT01605019|Placebo Comparator|BioGlue® Surgical Adhesive|BioGlue® Surgical Adhesive or use of no sealant application
3141859|NCT01605006|Other|NeuRx DPS On-Label Treatment|All study participants who meet the study eligibility criteria will undergo the surgical implantation procedure to receive the NeuRx DPS. Participants who are successfully implanted with the electrodes will use the NeuRx DPS system for diaphragm conditioning.
3141860|NCT01604993|Experimental|High nitrate dietary source|556 grams of high nitrate spinach soup that is orally consumed as a single dose for 7 days.
3141861|NCT01604993|Placebo Comparator|No Nitrate dietary source|556g low nitrate asparagus soup; orally consumed as a single does for 7 days.
3141862|NCT01604980|Experimental|Protein Intakes|subjects will recieve differnt levels of protein intakes varying from 0.2 to2.0g/kg/day.
3141863|NCT01604954|Other|Non-obese|Non-obese women (BMI between 18.5 and 25 kg/m2)
3141864|NCT01604954|Other|Obese|Obese women (BMI between 30 and 40 kg/m2)
3141865|NCT01604941|Experimental|SPD602|50 mg/kg/day orally twice daily for 24 weeks
3141866|NCT01604928|Experimental|YM178 Dose 1|low dose
3141867|NCT01604928|Experimental|YM178 Dose 2|high dose
3141868|NCT01604928|Active Comparator|Tolterodine|Oral
3141869|NCT01604928|Placebo Comparator|Placebo|Oral
3141870|NCT01604915|Placebo Comparator|Group R|Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered.
3141871|NCT01604915|Experimental|Group DR|Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
3141872|NCT01604902||Psoriasis vulgaris|Patients with psoriasis vulgaris who are going to be treated with biological drugs independent of this project(according to national guidelines).
3141873|NCT01604889|Experimental|INCB024360 300 mg|300 mg twice daily (BID) in combination with ipilimumab
3141874|NCT01604889|Placebo Comparator|Placebo in combination with ipilimumab|
3141875|NCT01604889|Experimental|INCB024360 25 mg|25 mg BID in combination with ipilimumab
3141876|NCT01604889|Experimental|INCB024360 50 mg|50 mg BID in combination with ipilimumab
3141877|NCT01604889|Experimental|INCB024360 75 mg|75 mg once a day (QD) in combination with ipilimumab
3141878|NCT01604876|Experimental|light condition 1 + day night structure|exposure to 10.000 lux light twice daily (morning + evening) for 30 minutes during 3 months at home.
3141879|NCT01604876|Active Comparator|light condition 2 + day night structure|exposure to 200 lux light twice daily (morning + evening) for 30 minutes during 3 months at home.
3141880|NCT01604863|Experimental|Arm A|HGS1036 + Paclitaxel + Carboplatin
3141881|NCT01604863|Experimental|Arm B|HGS1036 + Cisplatin + Etoposide
3141882|NCT01604863|Experimental|Arm C|HGS1036 + Docetaxel
3141883|NCT01604850|Experimental|SOF+RBV+placebo|Participants were randomized to receive SOF+RBV for 12 weeks followed by placebo to match SOF plus placebo to match RBV for 4 weeks.
3141884|NCT01604850|Experimental|SOF+RBV|Participants were randomized to receive SOF+RBV for 16 weeks.
3141885|NCT01604837||Pelvic malignancy group|those with diagnosis of gynecologic or urologic malignancy
3141886|NCT01604837||Pelvic chronic disease group|those with chronic pelvic pain with constitutional cause e.g. endometriosis
3141887|NCT01604824|Experimental|Cohort 1|Group A: dosing regimen 1; Group B: dosing regimen 2
3270167|NCT00696657|Experimental|H|
3141893|NCT01604785|Experimental|Experimental Treatment Group|Propofol at subanesthetic dose via IV push
3141894|NCT01604785|Active Comparator|Standard Treatment Group|Metaclopramide in combination with ketorolac and diphenhydramine via IV infusion
3141895|NCT01604772|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3141896|NCT01604759|Other|Polarized probe measurement.|All patients belong under this arm as all will be measured by the polarized probe and the data will be compared to the biopsy site's pathology results.
3141897|NCT01604746|No Intervention|Safety assessment|Vaccine safety will be assessed in the period between 6 and 12 months after the 3rd vaccination in precursor Study 880801 based on diaries distributed to all subjects for documentation of SAEs or AESI. Females who became pregnant after the 3rd vaccination in Study 880801 will be followed until end of pregnancy.
3141898|NCT01604733||HYPERCHOLESTEROLEMIC PATIENTS|
3141899|NCT01604707|No Intervention|Control group|Standard care
3141900|NCT01604707|Experimental|Medical Yoga|Group training with medical yoga in primary health care.
3141901|NCT01604694|Experimental|TAP Block with levobupivacaïne|
3141902|NCT01604694|Placebo Comparator|TAP Block with Placebo|
3141903|NCT01604681|Placebo Comparator|placebo group|3 g of powdered gelatin encapsulated in opaque capsules.
3141904|NCT01604681|Experimental|Flaxseed oil group|Oil extracted from linseed by pressing the cold and encapsulated, providing 3g per day containing 1.75 g of alpha linolenic acid.
3141905|NCT01604668||RevF vs RevG vs Pronto-7|Comparison of hemoglobin levels derived by continuous hemoglobin sensor RevF versus continuous hemoglobin sensor RevG versus an intermittent hemoglobin level derived from the Pronto-7 hand-held device versus a hemoglobin derived from a blood sample.
3141906|NCT01604655|Active Comparator|Coronary CT Angiography|Patient admitted with chest pain is randomized to CCTA for assessment.
3141907|NCT01604655|Active Comparator|Stress Test|Patients admitted with chest pain are randomized to a stress test (stress SPECT or Echocardiography) for assessment.
3141908|NCT01604642|Other|cachectic versus no cachectic patients|blood tests, muscular biopsies
3141909|NCT01604629|Experimental|Reduced doses of anti-TNF|Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
3141910|NCT01604629|Active Comparator|Stable doses of anti-TNF|Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis
3141911|NCT01604616||PCFL GROUP|patients in this group had the PFCL for a period of 7-10 days before it was replaced by SF6 gas or silicone oil
3141912|NCT01604616||control group|in thos group no PFCL was left in the eye and either SF6 or silicone oil was the definitive treatment at the time of the retinal detachment surgery repair.
3141913|NCT01604603||Control|
3141914|NCT01604603||Oligomenorrhea|
3141915|NCT01604603||Amenorrhea|
3141916|NCT01604603||premature ovarian failure|
3141917|NCT01604590||glioblastoma patients on bevacizumab|
3141918|NCT01604577|Active Comparator|interactive educational intervention|Physicians will use an interactive educational worksheet during the standard-of-care clinic visit.
3141919|NCT01604577|No Intervention|control group|Physicians will conduct the standard-of-care clinic visit as usual.
3141920|NCT01604564||Colitis Ulcerosa|Colitis Ulcerosa With creation of IPAA
3141921|NCT01604564||Familial Adenomatous Polyposis|Familial Adenomatous Polyposis with creation of IPAA
3141922|NCT01604538||patients with acute pulmonary embolism|
3141923|NCT01604525|Sham Comparator|Control|Participants randomized to this group received access to an untailored general interest/lifestyle website.
3141924|NCT01604525|Experimental|Tailored Health and Lifestyle Web|Participants randomized to this arm received tailored web content about health and wellness, with weekly goal-setting and feedback.
3141925|NCT01604525|Experimental|Tailored Web plus Peer Coaching|Participants randomized to this arm received access to weekly tailored health and wellness web content, plus weekly feedback from a peer health coach (videos uploaded to the web and phone calls).
3141926|NCT01604512|Experimental|Pts with a brain tumor|The study will prospectively enroll patients who have increasing size and/or enhancement of brain lesion(s) after brain radiation therapy for a neoplasm (either primary or metastatic), where it is unclear if a lesion represents radiation injury or progressive tumor.
3141927|NCT01604499|Experimental|Feedback only|"Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters"
3141928|NCT01604499|Experimental|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
3141929|NCT01604499|No Intervention|Control group|
3141930|NCT01604486||MI without ischaemic preconditioning|Myocardial infarction unheralded by any previous cardiovascular disease diagnosis and without symptoms of chest pain in the previous 90 days.
3141931|NCT01604486||MI with longstanding disease|Patients with myocardial infarction who have had diagnosed atherosclerotic disease for longer than 90 days preceding infarct.
3141932|NCT01604486||MI with only chest pain|Patients with chest pain in the 90 days preceding MI, but with no prior atherosclerotic disease diagnoses.
3141933|NCT01604486||MI with disease and chest pain|Myocardial infarction occurring with previously diagnosed atherosclerotic disease of longer than 90 days' duration, but with chest pain in 90 days preceding infarct.
3141934|NCT01604473||Chronic Kidney Disease|Individuals with Chronic Kidney Disease stages IV or V anticipating the need for hemodialysis access through an arterio-venous fistula.
3141935|NCT01604460|Sham Comparator|Resuscitation-no plastic bag|Resuscitation per standard of care without a plastic bag
3141936|NCT01604460|Active Comparator|Resuscitation-torso bag|Use of plastic bag covering the torso and lower extremities for temperature regulation during and after resuscitation for the first hour after birth
3141991|NCT01604057|Placebo Comparator|Placebo Nasal Spray|
3141992|NCT01604044|Active Comparator|HP-hMG|
3270168|NCT00696657|Experimental|I|
3141937|NCT01604447|Active Comparator|Incubator removal-torso bag|Use plastic bag covering the torso and lower extremities for temperature regulation with standard bundling practices when removing infant from incubator
3141938|NCT01604447|Placebo Comparator|Incubator removal-no plastic bag|Standard bundling practices when removing the infant from the incubator. No plastic bag used.
3141939|NCT01604434|Sham Comparator|Incubator-no plastic bag|Placement into an incubator without a plastic bag
3141940|NCT01604434|Active Comparator|Incubator-torso bag|Placement into a plastic bag inside incubator
3141941|NCT01604421|Sham Comparator|Thermoregulation-standard care|Standard thermoregulation without a plastic bag from one hour after birth until discharge or 24 hours after birth, whichever comes first.
3141942|NCT01604421|Active Comparator|Thermoregulation-with plastic bag|Thermoregulation with plastic bag covering torso and lower extremities from one hour after birth until discharge or 24 hours after birth to assist with thermoregulation. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.
3141943|NCT01604408|Experimental|LY2495655|Participants received a 315-milligram (mg) dose of LY2495655, administered subcutaneously (SC), every 4 weeks (Q4W) for 20 weeks.
3141944|NCT01604408|Placebo Comparator|Placebo|Participants received a LY2495655-matching dose of placebo, administered SC, Q4W for 20 weeks.
3141945|NCT01604395||growth hormone|
3141946|NCT01604382|Experimental|treatment|Receives General Anesthesia as described above
3141947|NCT01604382|Placebo Comparator|Placebo|Patients receives neuraxial anesthesia as described above
3141948|NCT01604369|Experimental|Cryoablation|
3141949|NCT01604356|Experimental|Electro-acupuncture|
3141950|NCT01604343|Experimental|Placebo then Sirukumab 50 mg or Sirukumab 100 mg|
3141951|NCT01604343|Experimental|Sirukumab 100 mg|
3141952|NCT01604343|Experimental|Sirukumab 50 mg + Placebo|
3141953|NCT01604330|Experimental|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
3141954|NCT01604330|Placebo Comparator|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
3141955|NCT01604317|Active Comparator|Resuscitation-torso plastic bag|Resuscitation with plastic bag covering torso and lower extremities for first hour to assist with temperature regulation.
3141956|NCT01604317|Active Comparator|Resuscitation-partial-head plastic bag|Resuscitation with plastic bag covering torso, upper and lower extremities, and a portion of the head for first hour after birth to assist with temperature regulation.
3141957|NCT01604304|Active Comparator|Extracorporeal shockwave lithotripsy|stone treatment using electroconductive technology
3141958|NCT01604304|Active Comparator|Flexible ureteroscopy|intra renal retrograde surgery with or without laser and stone extraction
3141959|NCT01604291||Cohort|
3141960|NCT01604278|Active Comparator|NVA237 + indacaterol|
3141961|NCT01604278|Placebo Comparator|Placebo to NVA237 + indacaterol|
3141962|NCT01604265|Placebo Comparator|Placebo|Placebo control.
3141963|NCT01604265|Experimental|Sativex|Active treatment.
3141964|NCT01604252||Cohort|
3141965|NCT01604239|Experimental|Shinbaro|
3141966|NCT01604226||Gynecologic surgery group|Those undergoing gynecologic laparoscopic surgery with TIVA
3141967|NCT01604226||Urologic surgery group|Those undergoing urologic surgery with TIVA
3141968|NCT01604213|Experimental|Vildagliptin+metformin|Oral Vildagliptin+metformin combination
3141969|NCT01604213|Active Comparator|Metformin only|Oral metformin only
3141970|NCT01604200||Dentists|Dentists in practice
3141971|NCT01604187|Active Comparator|Fentanyl|Ten minutes before the procedure fentanyl 100 mikrograms sublingual tablet will be given to the patient.
3141972|NCT01604187|Placebo Comparator|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
3141973|NCT01604174|Experimental|Interactive Virtual Telerehabilitation|Rehabilitation by IVT
3141974|NCT01604174|Active Comparator|Standard rehabilitation care|Standard care rehabilitation after total knee arthroplasty
3141975|NCT01604161||Somatropin|
3141976|NCT01604148||HoLEP group|Holmium Laser Enucleation of Prostate Group
3141977|NCT01604135|Active Comparator|Corneal Collagen Crosslinking|The keratokonic eye which progresses most is included and randomized. Significant progression is defined in the eligibility criteria section. If randomized to the treatment arm the cornea is treated with collagen crosslinking as described below.
3141978|NCT01604135|No Intervention|Control group|The keratokonic eye which progresses most is included and randomized to either the treatment group (CXL) or the control group.
3141979|NCT01604122||Patients|Patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.
3141980|NCT01604122||Caregivers|Caregivers who are taking care of patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.
3141981|NCT01604109|Active Comparator|Tooth Mousse|10% w/v Calcium Phosphopeptide Amorphous Calcium Phosphate paste
3141982|NCT01604109|Placebo Comparator|placebo control paste|the paste without Calcium phosphopeptide - Amorphous Calcium Phosphate
3141983|NCT01604096|Experimental|Intervention areas|Provinces of Modena and Parma (about 1.100.000 inhabitants - campaign targeted to the general population), in Northern Italy (Emilia-Romagna Region)
3141984|NCT01604096|No Intervention|Control|All the other provinces in the Emilia-Romagna Region (where the information campaign has not been implemented)
3141985|NCT01604070||Nextra fusion|group that has the nextra device
3141986|NCT01604070||k wire fixation|control group fixated with k wire
3141987|NCT01604057|Experimental|Low Dose Nasal Spray|
3141988|NCT01604057|Experimental|Mid Dose Nasal Spray|
3141989|NCT01604057|Experimental|High Dose Nasal Spray|
3141990|NCT01604057|Active Comparator|Forteo|20ug subcutaneous injection daily
3272692|NCT00678704|Experimental|Arm 2|
3141994|NCT01604031|Experimental|B-CLL vaccine|Patients will receive doses of vaccine at 2 week intervals for 5 doses and at 4 week intervals for doses 6-16. The injection will be performed subcutaneously in the deltoid region of the upper arm.
3141995|NCT01604018||Placebo|Subjects previously randomized to receive placebo in study CP005 and completed CP005A.
3141996|NCT01604018||Cat-PAD Group 1|Subjects previously randomized to receive Cat-PAD dose 1 in study CP005 and completed CP005A.
3141997|NCT01604018||Cat-Pad Group 2|Subjects previously randomized to receive Cat-PAD dose 2 in study CP005 and completed CP005A.
3141998|NCT01604005|Experimental|PIT Arm|
3141999|NCT01604005|No Intervention|No PIT Arm|
3142000|NCT01603979|Experimental|Dose-escalation AV-203 Monotherapy|dose-escalation of monotherapy AV-203 (an ERBB3 inhibitory antibody) by IV every two weeks
3142001|NCT01603940|Active Comparator|Losartan|This group will receive 100 mg of losartan per day. Amlodipine will be maintained.
3142002|NCT01603940|Active Comparator|Benazepril|This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.
3142003|NCT01603927||Colonoscopy with Narrow band imaging (NBI)|All patients attending for routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
3142004|NCT01603914|Experimental|scheduled wire-guided every six days|scheduled wire-guided every six days and a replacement of the catheter in a different place after 12 days from randomization.
3142005|NCT01603914|Experimental|Scheduled replacement every six days|Scheduled replacement every six days in a different location
3142006|NCT01603914|Experimental|replacement guided by clinical criteria|re change of catheter strategy guided by clinical suspicious of catheter-related bacteremia and replacement of the catheter in a different location.
3142007|NCT01603901|Experimental|Investigated Wounds|
3142008|NCT01603888||healthy newborns, BNP, NT-proBNP|healthy newborns
3142009|NCT01603888||infants, BNP, NT-proBNP|infants
3142010|NCT01603888||children with heart disease, BNP, NT-proBNP|children with heart disease
3142011|NCT01603875|Active Comparator|PrEP and Simulated PEP with PVRV by intramuscular route|
3142012|NCT01603875|Experimental|PrEP and Simulated PEP with new CPRV by intramuscular route|
3142013|NCT01603875|Experimental|PrEP and Simulated PEP with new CPRV by intradermal route|
3142014|NCT01603862|Experimental|ThinkingFit|
3142015|NCT01603849|Experimental|A Prophylactic Cranial Irradiation|Patients will received PCI 25 Gy in 10 fractions WBRT 4 weeks after initial treatment in the absence of disease progression.
3142016|NCT01603849|No Intervention|B Observation Group|Patients in this arm will be observed (not receiving WBRT)
3142017|NCT01603836|Experimental|bone marrow concentrate|In forty cases, the posterolateral fusion was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
3142018|NCT01603784|Experimental|Combined|Aerobic Exercise + Cognitive Training
3142019|NCT01603784|Experimental|Exercise|Aerobic Exercise + Health Education
3142020|NCT01603784|Experimental|Cognitive|Home Exercise + Cognitive Training
3142021|NCT01603784|Experimental|Control|Home Exercise + Health Education
3142022|NCT01603771||Combined|Participants assigned to this group have been randomized to the Combined group of the parent study, Combining Exercise and Cognitive Training to Improve Everyday Function(EXACT)(Unique Protocol ID 201102416). Participants perform a 6-month standardized aerobic training program at a local recreational center, 3 times per week for 1 hour. Participants in this group also perform an 8-week cognitive training program 3 days per week for 1 hour, during months 5 and 6. The cognitive training program is computer-based, and focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. The cognitive training is conducted on concurrent days with aerobic exercise training sessions, also on site at the recreational center.
3142023|NCT01603771||Control|Participants assigned to this group have been randomized to the Control group of the parent study, Combining Exercise and Cognitive Training to Improve Everyday Function(EXACT)(Unique Protocol ID 201102416). Participants perform a 6-month home exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes and record their activity on a calendar. Participants also attend weekly 1-hour Health Education sessions for 8 weeks, during months 5 and 6. These sessions cover topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and home energy conservation.
3142024|NCT01603758|No Intervention|Observational Arm|Cholesterol metabolic parameters will be measured in 100 subjects in an observational study. Results will be related to circulating biomarkers and carotid intima-media thickness.
3142025|NCT01603758|Placebo Comparator|Ezetimibe Interventional Arm|Cholesterol metabolic parameters will be measured before and after ezetimibe or placebo intervention. Changes due to ezetimibe will be determined
3142026|NCT01603732||Moms w HLHS or variant|Mom's fetal diagnosis Hypoplastic Left Heart Syndrome/variant
3142027|NCT01603732||Moms w/ Other congential heart defect)|Moms fetal diagnosis -other congenital heart defects
3142028|NCT01603732||Moms-fetal - echo normal|Moms echo fetal diagnosis is normal.
3142029|NCT01603732||Random Healthy Moms|Mom with healthy pregnancy.
3142030|NCT01603719|No Intervention|Standard Formula|Standard formula with no supplementation
3142031|NCT01603719|Experimental|experimental formula|infant formula with higher beta-palmitate and supplemented GOS
3142032|NCT01603563|Experimental|Stepped Care TF-CBT|Patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
3142073|NCT01603485|Experimental|Lersivirine|
3142074|NCT01603472||Subjects on Parenteral Nutrition|cases are those on Parenteral Nutrition >6 weeks for intestinal failure.
3142033|NCT01603563|Active Comparator|Standard TF-CBT|Patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, & trauma narrative etc.).
3142034|NCT01603550|Experimental|Energy Restriction|
3142035|NCT01603550|Experimental|Sleep Deprivation|
3142036|NCT01603537||PHTLS|The exposure is defined from the dichotomization of the probability in each event/accident that at least one of the caring ambulance crew members was PHTLS certified.
3142037|NCT01603537||No PHTLS|Not exposed to PHTLS
3142038|NCT01603524|Active Comparator|OMSC Group|"The OMSC Group will receive a multi-component intervention which includes:~Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.~Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.~Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).~Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program."
3142039|NCT01603524|Experimental|OMSC + Performance Feedback Group|The OMSC + Provider Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic.
3142040|NCT01603498|Experimental|Dexamethasone 8mg|
3142041|NCT01603498|Experimental|Methylprednisolone|Methylprednisolone 40mg
3142042|NCT01603407|Experimental|Daily prednisone|daily prednisone (0.75 mg/kg/day)
3142043|NCT01603407|Experimental|Intermittent prednisone|intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off)
3142044|NCT01603407|Experimental|Daily deflazacort|daily deflazacort (0.9 mg/kg/day
3142045|NCT01603823||Healthy volunteers|
3142046|NCT01603823||St.p. Pars plana vitrectomy|
3142047|NCT01603810||BCC|Adult of any age or gender with capacity to give informed consent who has a basal cell carinoma requiring surgical excision and involving the periocular skin
3142048|NCT01603797|Experimental|Internet delivered ACT|Internet delivered acceptance and commitment therapy (ACT), 7 weeks treatment
3142049|NCT01603797|Active Comparator|Online discussion forum|Active wait-list condition. Were offered to participate in a moderated online discussion forum. After post-treatment assessment the control group were offered treatment.
3142050|NCT01603745|Active Comparator|NOMAC-valerate estradiol|E/P therapy
3142051|NCT01603745|Active Comparator|Drospirenone/ethinylestradiol|E/P therapy
3142052|NCT01603706|Active Comparator|Echo guided implantation group|Echo guided implantation group Patients undergoing speckle tracking based LV lead implantation.
3142053|NCT01603706|No Intervention|Conventional implantation group|Patients undergoing conventional LV lead implantation
3142054|NCT01603693|Experimental|Bio-Oss|In this arm,GBR will be performed with DBBM (Bio-Oss, Geistlich) in 25 patients.
3142055|NCT01603693|Experimental|Bio-Oss and BondBone|In this arm, GBR will be performed using a combination of DBBM (Bio-Oss, Geistlich) and bi-phasic calcium sulphate (BondBone, Augma) in 25 patients.
3142056|NCT01603680|Other|Circumferential (C)|"Circumferential(C) spread group will be defined as mepivacaine injectate visualized by ultrasonography all around the median and ulnar nerves imaged in short axis."
3142057|NCT01603680|Other|Non circumferential (NC)|Local anesthetic spread will be asymmetrical around the median and ulnar nerves, the mepivacaine will be partially in contact with the nerve
3142058|NCT01603667|Experimental|PG2 Injection 500 mg|PG2 Injection 500 mg
3142059|NCT01603667|Placebo Comparator|Placebo|Placebo
3142060|NCT01603654|Experimental|sodium picosulphate/magnesium citrate|
3142061|NCT01603654|Active Comparator|low-volume PEG -ascorbic acid|
3142062|NCT01603641|Experimental|BOTOX®|Subjects will receive intramuscular injections of BOTOX® (botulinum toxin Type A) into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments. Treatment dosing will be according to investigator judgment not to exceed a maximum of 10 U per kg of body weight (10 U/kg) per treatment.
3142063|NCT01603628|Experimental|BOTOX® 4 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 U per kg of body weight (4 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly physical therapy (PT).
3142064|NCT01603628|Experimental|BOTOX® 8 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 8 U per kg of body weight (8 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
3142065|NCT01603628|Placebo Comparator|Normal Saline (Placebo)|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
3142066|NCT01603615|Experimental|BOTOX®|Subjects will receive intramuscular injections of BOTOX® (botulinum toxin Type A) into the upper limb muscles and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments. Treatment dosing will be according to investigator judgment not to exceed a maximum of 10 U per kg of body weight (10 U/kg) per treatment.
3142067|NCT01603602|Experimental|BOTOX® 3 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 units (U) per kilogram (kg) of body weight (3 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly occupational therapy (OT).
3142068|NCT01603602|Experimental|BOTOX® 6 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 6 U per kg of body weight (6 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly OT.
3142069|NCT01603602|Placebo Comparator|Placebo|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1. Participants received weekly OT.
3142070|NCT01603589|Active Comparator|MECC group|Patients operated for elective coronary artery bypass grafting with the use of minimal extracorporeal circulation.
3142071|NCT01603589|Active Comparator|CECC group|Patients operated for elective coronary artery bypass grafting under conventional extracorporeal circulation
3273107|NCT00675857|Placebo Comparator|A|
3142075|NCT01603472||Subjects not on Parenteral Nutrion|Controls are those who have never been on PN but can be fed via a feeding tube
3142076|NCT01603459|Experimental|IncobotulinumtoxinA (Xeomin) (up to 800 Units)|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection"
3142077|NCT01603446|Experimental|MELAS Patients|Three siblings with MELAS (A3243G) syndrome (1 male; 2 females) aged 17-23 years, followed or previously followed in the Neurometabolic Clinic at the Hospital for Sick Children will be studied.
3142078|NCT01603446|No Intervention|Control Group|Four age- and sex-matched controls and female controls will be matched according to phase in menstrual cycle corresponding with their age-matched MELAS subjects
3142079|NCT01603433|Experimental|Sapheon™ Closure System|Sapheon™ Closure System for the treatment of incompetent saphenous veins.
3142080|NCT01603420|Active Comparator|Radiation + 24mo luteinizing hormone-releasing hormone (LHRH)|Conformal RT 79.2 Gy(RBE) total dose + 24 months LHRH agonist (androgen suppression).
3142081|NCT01603420|Experimental|Radiation + Chemo + 6mo luteinizing hormone-releasing hormone|Conformal RT 79.2 Gy(RBE) total dose + Chemotherapy: Docetaxel 20mg/m2 x every 7 days x 8 weeks followed by 6 months LHRH (androgen suppression).
3142082|NCT01603394|Experimental|Pregabalin (300-600 mg/day; 150 mg/day starting dose)|
3142083|NCT01603381|Experimental|CBT-I|Cognitive Behavioral Therapy for Insomnia
3142084|NCT01603381|No Intervention|Monitor Only (M.O.)|
3142085|NCT01603368|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938, 125 million bacteria/day
3142086|NCT01603368|Placebo Comparator|Placebo|The same oil drops as the active study product but without Lactobacillus reuteri
3142087|NCT01603355|Experimental|Tocilizumab|
3142088|NCT01603342|Experimental|clopidogrel|
3142089|NCT01603342|Placebo Comparator|Placebo|
3142090|NCT01603329|Experimental|Comprehensive incentives + comprehensive communication|Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
3142091|NCT01603329|Experimental|Comp incentives + comp communication + non-white paper|Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication, and their patient reports are printed on non-white bright colored paper.
3142092|NCT01603329|Experimental|Focused incentives + focused com for oral diabetes medication|Physicians are given financial incentives for improving patient medication adherence for oral diabetes medication.
3142093|NCT01603329|Experimental|Foc incentives + foc comm for Diabetes + non-white paper|Physicians given financial incentives for improving patient medication adherence for oral diabetes medication and patient reports are printed on bright non-white paper.
3142094|NCT01603329|Experimental|Focused incentives + focused comm for hypertension meds|Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication.
3142095|NCT01603329|Experimental|Foc incentives + comm for hypertension meds + non-white paper|Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication with patient reports on non-white paper.
3142096|NCT01603329|Experimental|Focused incentives + focused comm for cholesterol meds|Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication.
3142097|NCT01603329|Experimental|Foc incentives +comm for cholesterol meds + non-white paper|Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication and patient reports are printed on non-white paper.
3142098|NCT01603329|Experimental|Comprehensive communiation|Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
3142099|NCT01603329|Experimental|Comprehensive communication + non-white paper|Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication and patient reports are printed on non-white paper.
3142100|NCT01603329|Experimental|Control Arm|Physicians and their patient adherence is tracked, but they receive no intervention.
3142101|NCT01603316|Experimental|Food Voucher Program (Voucher)|In the Food Voucher arm, each participant will receive a debit card specifically created for this program. Each month for the duration of study participation (6 months), the debit card will be credited with $128 and given to the patient. Patients will be instructed to use these cards only for food purchases. They will be counseled on using their vouchers only for healthful foods, in a way that stretches their food dollars. Purchases will be tracked by having patients bring their receipts in for review each month when they come in to pick-up their next monthly voucher. Patients will be provided with a receipt holder to assist in storing receipts for review.
3142102|NCT01603316|Experimental|Home Grocery Delivery (Delivery)|In the Home Grocery Delivery arm, each participant will receive home grocery delivery from PeaPod grocery delivery service or from FreshDirect (depending on the participant‟s zip code), worth $128 per month, for the duration of study participation (6 months). Patients in the Delivery arm will review a list of food categories and a subset of items in each category with a COA.
3142103|NCT01603316|Experimental|Medically-Tailored Hospital-Based Food Pantry (Pantry)|Patients in this arm will have access to the pantry for the duration of their study participation (6 months). Those accessing the medically-tailored food pantry will schedule a food pick-up appointment weekly at the hospital, either during one of their medical appointments or at another preferred, pre-arranged time. They will be given pre-packaged food bags, tailored when possible to their medical needs and cultural preferences.
3142104|NCT01603303|Other|Usual Care + Education Materials|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Water-based vaginal lubricant used during sexual activity.
3273108|NCT00675857|Active Comparator|B|
3142105|NCT01603303|Experimental|Luvena Group|Luvena used vaginally 2 or 3 times a week. Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs. Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
3142106|NCT01603303|Experimental|Hyalo-Gyn Group|Hyalo-Gyn used vaginally 2 - 3 times a week. Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs. Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
3142107|NCT01603290||Hospitalized Leukemia Patients|leukemia patients with chemotherapy during hospitalization
3142108|NCT01603277|Experimental|Anti-GM-CSF Monoclonal Antibody 400mg|
3142109|NCT01603277|Placebo Comparator|Normal Saline|
3142110|NCT01603264|Experimental|A|PF-05280014
3142111|NCT01603264|Active Comparator|B|Trastuzumab-EU
3142112|NCT01603264|Active Comparator|C|Trastuzumab-US
3142113|NCT01603251|Active Comparator|Artemether-Lumefantrine|
3142114|NCT01603251|Experimental|Artemether-Lumefantrine + single dose Ivermectin|
3142115|NCT01603251|Experimental|Artemether-Lumefantrine + repeated dose Ivermectin|
3142116|NCT01603238|Experimental|[14C]-LC15-0444|A single oral dose of [14C]-LC15-0444 50 mg , containing 4.9 MBq [14C] (batch number 110372/C/01).
3142117|NCT01603225||Autism|Individuals with autism will have either Anodal, Cathodal, or Sham Transcranial Direct Current Stimulation (tDCS).
3142118|NCT01603212|Experimental|Vemurafenib + IL-2 + Interferon Alfa-2b|Starting dose of Vemurafenib 720 mg by mouth twice daily. Three dose levels of Vemurafenib evaluated in combination with interferon and IL-2. These doses are 480 mg, 720 mg and 960 mg. IL-2 given by continuous venous infusion at starting IL-2 dose of 7 million IU/m2 daily for 4 days (total of 96 hours, days 2-5) starting day 2. IL-2 dose levels are 5MU/m2/day, 7MU/m2/day and 9MU/m2 day. Doses of interferon remain constant at 5 MU/m2 subcutaneously daily for 5 days starting Day 1.
3142119|NCT01603199|Experimental|Primary biliary cirrhosis (Non-cirrhotic)|
3142120|NCT01603199|Experimental|Primary biliary cirrhosis (Cirrhotic)|
3142121|NCT01603186|Experimental|Quetiapine Fumarate Tablets 25 mg|Quetiapine Fumarate Tablets 25 mg of M/s Ipca Laboratories Limited, India
3142122|NCT01603186|Active Comparator|Seroquel®|Seroquel® (Quetiapine Fumarate) Tablets 25 mg of M/s AstraZeneca Pharmaceuticals LP, USA
3142123|NCT01603173|Experimental|Quetiapine Fumarate Tablets 25 mg|Quetiapine Fumarate Tablets 25 mg of M/s Ipca Laboratories Limited, India
3142124|NCT01603173|Active Comparator|Seroquel®|Seroquel® (Quetiapine Fumarate) Tablets 25 mg of M/s AstraZeneca Pharmaceuticals LP, USA
3142125|NCT01603160||Emergency Department Staff|"Interventions put in place in the Emergency Department will effect most staff who work in the ED, but different sub-groups will be approached for participation in specific aspects of the study:~All ED attending and resident physicians and ED nurses will be invited to complete the SCD Attitudes survey.~Select ED Staff will be invited to be members of the QI team and will be invited to participate in the FMECA.~Members of the QI team will be invited to participate in a focus group."
3142126|NCT01603147|Placebo Comparator|Saline|A total of 10 subjects will receive placebo
3142127|NCT01603147|Experimental|ch-mAb7F9|The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively.
3142128|NCT01603134|Experimental|Allopurinol 300 mg Tablets USP|Allopurinol 300 mg Tablets USP of M/s Ipca Laboratories Limited, India
3142129|NCT01603134|Active Comparator|Zyloprim®|Zyloprim® (Allopurinol) 300 mg Tablets manufactured by Catalytica Pharma Inc., USA for Prometheus Laboratories Inc., USA,
3142130|NCT01603121|Experimental|Lisofylline subcutaneous|Lisofylline 12mg/kg as a continuous subcutaneous infusion over a 10 hours period
3142131|NCT01603121|Experimental|Lisofylline intravenous|Lisofylline 9 mg/kg as a continuous intravenous infusion over a 10 hours period
3142132|NCT01603108|Experimental|Rifaximin Arm|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
3142133|NCT01603108|Placebo Comparator|Placebo Control Arm|Rifaximin placebo will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo will be taken twice daily for 90 days (+/- 10 days) post-LT.
3142134|NCT01603095||Growth measurements|Approximately 350 patients will be enrolled. Patients from birth to < 17 years on the date of consent will be enrolled. Approximately equal numbers of boys and girls will be enrolled.
3142135|NCT01603082|Experimental|Ticagrelor|Ticagrelor - 180 mg loading dose
3142136|NCT01603082|Active Comparator|Clopidogrel|Clopidogrel - 600 mg loading dose
3142137|NCT01603069|Active Comparator|AZD3241, 300 mg|AZD3241 300 mg BID
3142138|NCT01603069|Active Comparator|AZD3241, 600 mg|AZD3241 600 mg BID
3142139|NCT01603069|Placebo Comparator|Placebo|Placebo to AZD3241
3142140|NCT01603056|Experimental|PANGRAMIN SLIT HDM MIX|PANGRAMIN SLIT HDM MIX Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
3142141|NCT01603056|Placebo Comparator|Placebo|Placebo Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
3142142|NCT01603043|Experimental|AL-78898A|1 intravitreal injection per month for up to 12 months
3142143|NCT01603043|Sham Comparator|Sham Injection|1 mock injection per month for 12 months
3142144|NCT01603030|Experimental|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
3142145|NCT01603030|Active Comparator|moxifloxacin 0,5% + Prednisolone 1%|1 drop of each bottle, BID, 15 days
3142181|NCT01602705|Active Comparator|Usual care + feedback of practice performance|
3142146|NCT01603017|Placebo Comparator|Placebo - no therapy|Patients who were blinded but did not receive therapy
3142147|NCT01603017|Experimental|MRI therapy|Patients receiving MRI therapy but blinded to it
3142148|NCT01603004||everolimus, sunitinib or traditional chemotherapy|A total of 30 patients with well differentiated pancreatic NETs who have known liver metastases and who are planned to initiate therapy with either targeted (everolimus or sunitinib) or traditional cytotoxic chemotherapy will be recruited for this study. We plan to recruit approximately 10 patients for each therapy (everolimus, sunitinib, cytotoxic chemotherapy). Evidence of metastatic disease will be determined at the discretion of the oncologist based on available imaging, surgical and pathologic evidence.
3142149|NCT01602965|Experimental|counseling monthly phone calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviours that need to be changed, problem-solving as to how to make the changes and physical activity levels.
3142150|NCT01602965|Active Comparator|self help informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies.
3142151|NCT01602952|Experimental|Radotinib|"Phase 1 : 200mg/kg or 1200mg/m^2~Phase 2 : 400mg Bid"
3142152|NCT01602939|Experimental|2CDA+IFN|
3142153|NCT01602926|Experimental|conventional surgery arm|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws.
3142154|NCT01602926|Experimental|minimally invasive technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal
3142155|NCT01602913||Patients with diagnosis of Type II Diabetes|Patients indicating T2DM after the index date (ICD-9-CM 250.x), or 1 diagnostic code and 1 prescription of oral anti-diabetic medications or insulin (or Byetta and Victoza) after the index date
3142156|NCT01602913||Patients without diagnosis of Type II Diabetes|Patients not indicating T2DM
3142157|NCT01602900|Experimental|GSK356278|Investigational drug
3142158|NCT01602887|Active Comparator|Reference|This is the reference formulation
3142159|NCT01602887|Experimental|NF1|This is a test formulation
3142160|NCT01602887|Experimental|NF2|This is a test formulation
3142161|NCT01602887|Experimental|SOL|This is a test formulation
3142162|NCT01602874|Experimental|A. Tigecycline|
3142163|NCT01602874|Active Comparator|B. Ceftriaxone regimen|
3142164|NCT01602861|Experimental|Spironolactone|
3142165|NCT01602861|Placebo Comparator|Placebo|
3142166|NCT01602848|Experimental|Intervention enrollee|HIgh risk fee for service Medicaid recipients identified as eligible by the New York State Dept of Health and enrolled in the intensive care management and coordination intervention
3142167|NCT01602848|No Intervention|Eligible, not enrolled|Medicaid fee-for-service patients who are identified as eligible for the intervention but are not enrolled. These patients receive usual services provided by Medicaid.
3142168|NCT01602822|Other|Atazanavir, Ritonavir, Truvada|Open Label
3142169|NCT01602796|Experimental|School-based intervention|
3142170|NCT01602796|No Intervention|Control|
3142171|NCT01602783|Experimental|11C Acetate Imaging|11C acetate imaging
3142172|NCT01602770||Group 1|Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
3142173|NCT01602757|Experimental|Synera|"Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3."
3142174|NCT01602744|No Intervention|Controll|The medications in this arm will not be screened.
3142175|NCT01602744|Active Comparator|Intervention screening medication group|STOPP/START screening tools are used for medication intervention
3142176|NCT01602731|Experimental|Automated Medication Dispensing Device|Subjects with <88% medication adherence, determined by 30-day pillcount, and with cognitive impairment (determined by Saint Louis University Mental Status score) proceeded to AMDD portion of study.
3142177|NCT01602718|No Intervention|Physical Function/Activity|"cross-sectional comparison study of physical function/activity, frailty and inflammation measures in prevalent home Dx and prevalent in-center hemodialysis patients.~Subjects: Forty-five prevalent home dialysis patients will be recruited and tested once for all outcome measures. Forty-five prevalent in-center hemodialysis patients will be identified from prevalent patients in the University of Utah in-center dialysis system who are matched for gender, age, comorbidities and time on dialysis as the home dialysis patients who have been tested. Consenting patients will be tested for all outcome measures once and compared to the home dialysis group."
3142178|NCT01602718|No Intervention|Incident Patients|"Study 2: is a longitudinal cohort study of incident patients starting either home dialysis or in-center hemodialysis.~Consenting patients will be tested upon initiation of dialysis therapy and every 6 months for 18 months to track physical functioning /activity, frailty and inflammation over time."
3142179|NCT01602718|Other|Independent Home Exercise|pilot study of independent home exercise training in home dialysis (PD only) patients. Consenting patients will be tested at baseline, then randomized into exercise training or usual care (no prescribed change in activity levels) and retested after 3 months.
3142180|NCT01602705|Placebo Comparator|Usual care|
3142182|NCT01602705|Active Comparator|Usual care + feedback + health psychology intervention|
3142183|NCT01602692|Active Comparator|Tumescent solution with dilute epinephrine|Subjects in this arm of the study will be randomized to receive tumescent solution containing dilute epinephrine (1:1,000,000) during their breast reduction.
3142184|NCT01602692|Active Comparator|Tumescent solution with dilute lidocaine and epinephrine|Subjects in this arm of the study will receive tumescent solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000).
3142185|NCT01602679|Experimental|oral micronized progesterone suspension|oral micronized progesterone (100 mg p.o.) suspension
3142186|NCT01602679|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
3142187|NCT01602666|Experimental|Treatment (combination chemotherapy, radiation therapy)|See Detailed Description
3142188|NCT01602653|Active Comparator|1|the first group of patients received an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.
3142189|NCT01602653|Active Comparator|2|The second grouop of patients received 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
3142190|NCT01602640|Experimental|Morphine|
3142191|NCT01602640|Active Comparator|Fentanyl and Midazolam|Control
3142192|NCT01602627|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive Hsp90 inhibitor AUY922 IV over 1 hour on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3142193|NCT01602614||Group 1|≤ 27 weeks 6 days gestational age at birth and ≤ 30 days chronologic age at study enrollment
3142194|NCT01602614||Group 2|≤ 27 weeks 6 days gestational age at birth and > 30 days chronologic age at study enrollment
3142195|NCT01602614||Group 3|≥ 28 weeks 0 days gestational age at birth and ≤ 30 days chronologic age at study enrollment
3142196|NCT01602614||Group 4|≥ 28 weeks 0 days gestational age at birth and > 30 days chronologic age at study enrollment
3142197|NCT01602601||Cohort 1|Patients will have a single blood draw for the analysis of antibodies induced by idursulfase. Samples will be used to further evaluate whether the antibodies induced by idursulfase bind to GSK2788723 molecules in vitro and if these antibodies neutralize the bioactivity of GSK2788723 in vitro.
3142198|NCT01602588|Experimental|Arm B|Patients randomised to Arm B will receive Short Course Radiotherapy plus Hydroxychloroquine 200mg bd from 14 days post surgery until clinical or radiological progression.
3142199|NCT01602588|Active Comparator|Arm A: SCRT alone|Patients randomised to Arm A will receive standard treatment of Short Course Radiotherapy
3142200|NCT01602575|Experimental|mindfulness treatment|Mindfulness based stress reduction is the intervention in this single arm trial
3142201|NCT01602562|Experimental|VACV (256U87; valaciclovir hydrochloride)|Adult patients (16-65 years): A VACV tablet (containing 500mg of valaciclovir) is orally given twice daily. Pediatric patients (1-16 years): VACV granules are orally given at a dose of 25 mg/kg b.w. twice daily. The maximum dose per treatment is limited to 500 mg. Pediatric patients weighing 40 kg or over may be orally given a VACV tablet (containing 500 mg of valaciclovir) twice daily.
3142202|NCT01602549|Experimental|Cohort|1:2 ratio, placebo, 50 mg administered orally once daily for 7-9 days
3142203|NCT01602536|Experimental|Twitter|Experimental participants are assigned a 20-person twitter quit-smoking group to interact with, are instructed to use Twitter-enabled interactive peer messaging,and are sent daily messages to encourage interaction. The baseline intervention 'smoking cessation aides' is also provided.
3142204|NCT01602536|Active Comparator|Control|Control participants are not assigned to a twitter group. The baseline intervention 'smoking cessation aides' is also provided.
3142205|NCT01602523|Active Comparator|budesonide/formoterol|budesonide/formoterol 160/4.5 mcg (Symbicort)
3142206|NCT01602523|Placebo Comparator|Placebo|Symbicort placebo
3142207|NCT01602510|Experimental|Lamotrigine CD|lamotrigine chewable dispersible tablets 25mg, 50mg, 100mg
3142208|NCT01602510|Placebo Comparator|Placebo|Placebo
3142209|NCT01602497|Active Comparator|rTMS intervention group|The rTMS intervention group undergo ten session of real TMS therapy.
3142210|NCT01602497|Placebo Comparator|Sham group|Patients will undergo ten session of sham rTMS.
3142211|NCT01602484|Experimental|Splint Pack|Group of post-op patients who have splint applied from prepared Plaster-of-Paris splint pack
3142212|NCT01602484|Active Comparator|Bulk Supplies|Group of post-op patients who have splint applied from bulk supplies
3142213|NCT01602471|Experimental|[F-18]RDG-K5|[F-18]RDG-K5 was administred and PET scan performed
3142214|NCT01602458|Other|Silicone Only Therapy (SOT)|Mepiform™ silicone will be utilized by SOT group.
3142215|NCT01602458|Other|Silicone Pressure Garment Therapy (SPGT)|Mepiform™ silicone and custom compression garments fabricated by Barton Carey™ will be utilized by SPGT group.
3142216|NCT01602445||Cancer patients|All cancer patients with a diagnosed acute symptomatic VTE episode.
3142217|NCT01602432||High Risk Group|"Defined as patients whose primary malignancy is located in the brain, bladder, lung, testicle, stomach, pancreas and lymphatic system and whose risk score before the beginning of anticancer treatment is ≥ 2 according to the Risk Stratification Method proposed by Khorana et al. (2008).~Based on this method, the model includes 5 predictive variables as follows:~Site of cancer: classified as very high-risk (+2 points) or high-risk (+1 point).~Platelet count: (>350 x 109/L) (+1 point)~Hemoglobin level (<100 g/L) and/or use of erythropoiesis stimulating agents (+1 point)~Leukocyte count (> 11 x 109/L)(+1 point).~body mass index (≥ 35 Kg/m2) (+1 point)."
3142218|NCT01602432||Low high Risk Group|"Defined as patients whose primary malignancy is located in the brain, bladder, lung, testicle, stomach, pancreas and lymphatic system and whose risk score before the beginning of anticancer treatment is < 2 according to the Risk Stratification Method proposed by Khorana et al. (2008).~In order to confirm the patient low risk status, we will draw a blood sample to determine serum levels of D- dimer and soluble P selectin in patients of this low risk group according to Ay et al. (2010). If levels of D-dimer are ≥ 1.44 µg/mL and/or soluble P selectin ≥ 53.1 ng/mL, we will add one point for each one of the increased biochemical marker and the total score recalculated."
3142219|NCT01602419||Patients using wilate as standard of care treatment|This patient population is being treated with wilate as standard of care treatment
3142220|NCT01602406|Experimental|LJM716 in combination with trastuzumab|
3142221|NCT01602393|Experimental|CHF 5074 1x|oral tablet, multidose
3142222|NCT01602393|Experimental|CHF 5074 2x|oral tablet, multidose
3142223|NCT01602393|Experimental|CHF 5074 3x|oral tablet, multidose
3142224|NCT01602380|Experimental|faslodex+placebo|Blinded: Fulvestrant 500mg intramuscular injection (2x250mg) plus dummy Anastrozole tablets
3142225|NCT01602380|Active Comparator|arimidex +placebo|Blinded: Anastrozole 1mg tablets plus dummy Fulvestrant intramuscular injection (2x0mg)
3142226|NCT01602367|Experimental|Arm 1: BMS-823778 (2mg)|
3142227|NCT01602367|Experimental|Arm2: BMS-823778 (6mg)|
3142228|NCT01602367|Experimental|Arm 3: BMS-823778 (15mg)|
3142229|NCT01602367|Experimental|Arm4: Placebo|
3142230|NCT01602354||Gram-negative Septic shock|Patients affected by Gram-negative septic shock
3142231|NCT01602341|Experimental|AN2728 Topical Ointment, 2% QD vs 0.5% QD|"AN2728 Topical Ointment, 2% applied once daily for 29 days to a target lesion, and AN2728 Topical Ointment, 0.5% applied once daily for 29 days to a target lesion~Treatments will be randomly assigned to target lesions A and B."
3142232|NCT01602341|Experimental|AN2728 Topical Ointment, 2% BID vs 0.5% BID|"AN2728 Topical Ointment, 2% applied twice daily for 29 days to a target lesion, and AN2728 Topical Ointment, 0.5% applied twice daily for 29 days to a target lesion.~Treatments will be randomly assigned to target lesions A and B."
3142233|NCT01602328|Active Comparator|AC607|Treatment with AC607
3142234|NCT01602328|Placebo Comparator|Placebo|Treatment with Placebo
3142235|NCT01602315|Experimental|Phase Ib: A-BYL719 FC whole tab+cetux|Oral film-coated tablets without swallowing dysfunction.
3142236|NCT01602315|Experimental|Phase II: 2-Cetuximab|Cetuximab in patients naive to cetuximab (phase ll)
3142237|NCT01602315|Experimental|Phase Ib: B-BYL719 FC drink sus+cetux|Crushed film-coated (FC) tablets as an oral suspension with swallowing dysfunction.
3142238|NCT01602315|Experimental|Phase II: 3-BYL719 + Cetuximab|BYL719 + cetuximab in patients resistant to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
3142239|NCT01602315|Experimental|Phase II: 1-BYL719 + Cetuximab|BYL719 + Cetuximab in Patients naive to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
3142240|NCT01602315|Experimental|Phase Ib: C-BYL719 DT+cetux|Dispersible tablet with swallowing dysfunction administered via a gastrostomy tube (G-tube)
3142241|NCT01602315|Experimental|Phase II: Cross over|patients received BYL719 at RP2D in combination with cetuximab.
3142242|NCT01602302|Experimental|single arm ( bDMARD withdrawal )|single arm (bDMARD withdrawal)
3142243|NCT01602289|Experimental|LY2875358|Part A. LY2875358 will be administered intravenously (IV) at escalating doses (700 mg up to 2000 mg) on Day 1 and Day 15 of a 28-day cycle, until any discontinuation criterion is met.
3142244|NCT01602289|Experimental|LY2875358+Erlotinib|Part B1. Erlotinib will be administered orally at 150 mg dose level each day. LY2875358 will be administered intravenously (IV) at recommended dose level in Part A on Day 1 and Day 15 of a 28-day cycle. (Part B1 was added per protocol amendment in January, 2013.)
3142245|NCT01602289|Experimental|LY2875358+Gefitinib|Part B2. Gefitinib will be administered orally at 250 mg dose level each day. LY2875358 will be administered intravenously (IV) at recommended dose level in Part A on Day 1 and Day 15 of a 28-day cycle. (Part B2 was added per protocol amendment in January, 2013.)
3142246|NCT01602276|Experimental|Active Stimulation|Transcranial direct current stimulation using Anodal or Cathodal stimulation over the area of interest
3142247|NCT01602276|Sham Comparator|Sham Stimulation|Transcranial direct current stimulation (tDCS) that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS.
3142248|NCT01602263||Controls|Healthy Controls with no known cognitive impairment will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
3142249|NCT01602263||Individuals with schizophrenia|Individuals with schizophrenia and first-degree relatives will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
3142250|NCT01602263||Individuals with aphasia|Individuals with aphasia will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
3142251|NCT01602263||Individuals with high-functioning autism|Individuals with high-functioning autism will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
3142252|NCT01602250|Placebo Comparator|levobupivacaine placebo|levobupivacaine placebo
3142253|NCT01602250|Experimental|levobupivacaine Intralipid®|levobupivacaine Intralipid®
3142254|NCT01602250|Experimental|ropivacaine Intralipid®|ropivacaine Intralipid®
3142255|NCT01602250|Placebo Comparator|ropivacaine placebo|ropivacaine placebo
3142256|NCT01602237||Bakery workers|
3142257|NCT01602224|Experimental|100 mg Tabalumab+Dexamethasone (Dex)+Bortezomib (BTZ)|"Tabalumab 100 milligram (mg) administered once intravenously (IV) over 30 minutes on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.~Bortezomib 1.3 milligram per square meter (mg/m^2) administered once subcutaneously (SQ) on Days 1, 4, 8 and 11 every 21 days for a minimum 8 cycles.~All treatment may continue past 8 cycles."
3142258|NCT01602224|Experimental|300 mg Tabalumab+Dexamethasone+Bortezomib|"Tabalumab 300 mg administered once IV over 30 minutes on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for a minimum 8 cycles.~Bortezomib 1.3 mg/m^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.~All treatment may continue past 8 cycles."
3142259|NCT01602224|Placebo Comparator|Placebo Comparator: Placebo + Dexamethasone + Bortezomib|"Placebo administered once IV on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for a minimum 8 cycles.~Bortezomib 1.3 mg/m^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.~All treatment may continue past 8 cycles."
3142336|NCT01601743|Active Comparator|Walking|Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
3142337|NCT01601730|Placebo Comparator|Placebo|
3142338|NCT01601730|Active Comparator|Modafinil 200 mg + Escitalopram 20 mg|
3142339|NCT01601730|Active Comparator|Modafinil 200 mg|
3142340|NCT01601730|Active Comparator|Escitalopram 20 mg|
3142341|NCT01601717|Placebo Comparator|Sugar pill|
3142260|NCT01602211|Experimental|Arm I (INSPIRE internet full program access)|Participants receive full access to the INSPIRE internet site comprising an individually tailored program with a greeting home page with links to each target area, a 'My Health Action Plan' health care guideline for transplant survivors, self-care tips and tool pages for each complication and major issues for HCT survivors, a section for each complication (mood, energy, heart health, strengthening bones, second cancers), resource pages, opportunities to send secure messages with questions or comments on any topic, opportunities to request additional assistance or information, mobile texting options, and social media links (Twitter/Facebook/Pinterest) maintained and monitored by the Social Media Specialist.
3142261|NCT01602211|Experimental|Arm II (delayed program access control)|Participants receive annotated website links to existing transplant and cancer survivor sites, followed by delayed access to the INSPIRE internet program after 1 year.
3142262|NCT01602198|Active Comparator|Exelon transdermal patch|Exelon [rivastigmine] transdermal patch
3142263|NCT01602198|Placebo Comparator|Placebo transdermal patch|Placebo transdermal patch
3142264|NCT01602185|Experimental|memantine|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
3142265|NCT01602185|Experimental|dextromethorphan|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
3142266|NCT01602185|Placebo Comparator|placebo|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
3142267|NCT01602172|Experimental|Arm 1|Brief Intervention Condition--3 part motivational discussion in and out of hospital
3142268|NCT01602172|Active Comparator|Arm 2|Traditional Attention Control Condition
3142269|NCT01602172|Active Comparator|Arm 3|Attention Control, Limited Assessment
3142270|NCT01602159|Active Comparator|Open Bypass Surgery|Open Bypass Surgery
3142271|NCT01602159|Active Comparator|Angioplasty and Stenting|
3142272|NCT01602146||ultramarathon runner|People who do the Mont Blanc ultramarathon (31/08/12 to 02/09/12)
3142273|NCT01602133|Experimental|one intervention arm|
3142274|NCT01602120|Experimental|Lampalizumab Monthly: Study CFD4870g|Participants will receive lampalizumab 10 milligrams (mg) ITV injection monthly starting at Day 1 for up to 42 (18 + 24) months. The study treatment period has been extended by another 24 months and again by additional 30 months for a total treatment period of 96 months.
3142275|NCT01602120|Experimental|Lampalizumab Every Other Month: Study CFD4870g|Participants will receive lampalizumab 10 mg ITV injection every other month starting at Day 1 for up to 18 months. The treatment duration has been extended by 24 months and participants have been crossed over to monthly treatment arm to receive monthly lampalizumab treatment for the remainder of study treatment period. The study treatment period has been extended by another 24 months and again by additional 30 months for a total treatment period of 96 months.
3142276|NCT01602120|Experimental|Lampalizumab Monthly: Study GX29455|Participants will receive lampalizumab 10 mg ITV injection monthly starting at Day 1 for up to 54 ITV injections.
3142277|NCT01602107|No Intervention|Control|Participants in the control group will not receive therapist-supervised intervention. An exercise sheet briefly describing pelvic floor muscle exercises will be provided, as would be the standard practice from most physicians.
3142278|NCT01602107|Experimental|Pelvic Floor Therapy|Participants in the experimental group undergo and assessment and treatment by a registered physiotherapist. Treatments will include two sessions of biofeedback training, therapist-assisted strengthening exercises, and will a prescribed home exercise program to strengthen their pelvic floor muscles.
3142279|NCT01602094||Adequate antimeales antibody levels|ELISA test OD > 0.1
3142280|NCT01602094||Inadequate measles antibody levels|ELISA test OD < 0.1
3142281|NCT01602081||LIFT+Biodesign|
3142282|NCT01602068|Experimental|Dexamethasone Phosphate Ophthalmic|Dexamethasone Phosphate Ophthalmic: (40 mg/mL) solution delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)
3142283|NCT01602068|Placebo Comparator|100 mM Sodium Citrate Buffer|Placebo (100 mM sodium citrate buffer solution) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)
3142284|NCT01602055|Experimental|Azivol|
3142285|NCT01602055|Active Comparator|Zithromax|
3142286|NCT01602029|Active Comparator|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
3142287|NCT01602029|Active Comparator|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
3142288|NCT01602029|Placebo Comparator|Placebo|Placebo added to TAU
3142289|NCT01602029|Active Comparator|Odansetron Plus Simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
3142290|NCT01602016|No Intervention|Phase I|Baseline Visit Phase 1: The screening portion of the CELF will be administered to the child to screen for language impairment. If a child is determined to be pre-verbal they will automatically qualify,If there is no language impairment, the subject will not be eligible. If language impairment is confirmed, the participant will immediately go on to the baseline visit of Phase 2.
3142291|NCT01602016|Other|Phase II: 12 week Folinic Acid or Placebo intervention|The child will be consented for Phase 2 (the RCT) and undergo a blood draw (up to 20mL) for metabolic and autoantibody testing. the child will undergo language and behavioral assessment while the parent will be interviewed for the Vineland and other questionnaires (ASQ, RBS-R, SRS, and ABC). Demographic information including; age, race, gender, and ethnicity will be collected. The research pharmacist will randomize the participant to either Intervention A or B (only the research pharmacist will know which intervention has the folinic acid). The research pharmacist will distribute the drug or placebo to the parent and instruct the parent of the proper administration of the intervention. This will be considered the 12 week randomly controlled clinical trial that is investigating the safety and efficacy of folinic acis interventions in ASD and will last for approximately 12 weeks. At the end of 12 weeks, the same assessments that were conducted at baseline will be readministered
3142342|NCT01601717|Active Comparator|RTI-336|
3142343|NCT01601704|Experimental|NB32|
3142344|NCT01601704|Placebo Comparator|PBO|
3142345|NCT01601691|Experimental|Spacer|Subjects with spacer injection
3143230|NCT01595477|Experimental|Mind-Body Skills Groups|
3142292|NCT01602016|Experimental|Phase III: Open Label Extension of Folinic Acid|If consent for Phase 3 is signed by parents with children who qualify for Phase 3, the research pharmacist will provide a 12 week supply of folinic acid to the parent. This arm will be offered to all clients that completed phase 2 of the trial. After consenting and 12 weeks of folinic acid dosing, the client will come back and complete the same protocol and be tested on the same measures used in phase II of the study. This will be a rolling stopping point so that new therapies can be started, if the parent/caregiver is so inclined
3142293|NCT01602003|Experimental|LC15-0444 25 mg bid|LC15-0444 25 mg bid(twice daily)added on Metformin therapy
3142294|NCT01602003|Experimental|LC15-0444 50 mg qd|LC15-0444 50 mg qd(once daily) added on Metformin therapy
3142295|NCT01602003|Active Comparator|Sitagliptin 100mg qd|Sitagliptin 100 mg qd (once daily) added on the Metformin therapy
3142296|NCT01601990|Placebo Comparator|Placebo|
3142297|NCT01601990|Experimental|LC15-0444|
3142298|NCT01601977|Experimental|Intervention|AVAPS-AE
3142299|NCT01601977|Active Comparator|Usual care|Non-invasive ventilation
3142300|NCT01601964||Follow-up or medical treatment.|medical treatment
3142301|NCT01601964||Surgical treatment|Surgical treatment
3142302|NCT01601951||Hip Osteoarthritis|
3142303|NCT01601951||Knee Osteoarthritis|
3142304|NCT01601938|Experimental|Selenium|500 mcg of selenium (10mL) daily for 7 days
3142305|NCT01601938|Placebo Comparator|Placebo|Placebo 10 mL (delivered from biosyn) for 7 days
3142306|NCT01601925|Experimental|neck extended group|We measured the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck.
3142307|NCT01601912||Atomoxetine NRI|We will modulate endogenous adrenergic pain inhibitory mechanisms by using a selective norepinephrine reuptake inhibitor (NRI).
3142308|NCT01601912||Citalopram SSRI|We will modulate serotonergic pain inhibitory mechanisms by using a selective serotonin reuptake inhibitor (SSRI)
3142309|NCT01601899|Active Comparator|ARM A|Stavudine (d4T) 30 mg po BD if wt < 60kg, or 40 mg po BD if wt > 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
3142310|NCT01601899|Active Comparator|ARM B|Stavudine (d4T) 20 mg po BD if wt < 60kg, or 30 mg po BD if wt > 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
3142311|NCT01601899|Active Comparator|ARM C|TDF 300 mg po QD PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
3142312|NCT01601886||Before SUPPORT|01/03-06/05
3142313|NCT01601886||During SUPPORT recruitment|07/05-02/09
3142314|NCT01601886||After SUPPORT|03/09-06/10
3142315|NCT01601873|Experimental|PROPATEN|patients with heparin-bonded graft implantation
3142316|NCT01601873|Active Comparator|Standard Graft|patients undergoing ePTFE hemodialysis graft implantation
3142317|NCT01601860|No Intervention|Control|Control Group (CG) Pregnant women who will not use any physical therapy resource, are subject only to routine procedures of maternity care Pregnant women who will not use any physical therapy resource, are subject only to routine procedures of maternity care
3142318|NCT01601860|Experimental|Protocol|Intervention Group (IG) Pregnant women who will use the following features sequentially: walking (with cervical dilation between 4 and 5 cm), alternating stance associated with ENT (cervical dilatation from 6 to 7 cm), shower (with dilation> 7 cm);
3142319|NCT01601847|Active Comparator|Sustained|Infants will remain on 400 IU/day of cholecalciferol until 6 months of age adjusted for prematurity, regardless of dietary intake
3142320|NCT01601847|Placebo Comparator|Diet-Limited|Infants will receive placebo once their dietary intake of vitamin D has exceeded 200 IU/day
3142321|NCT01601834|Experimental|Cohort 1: Experimental intervention: PF-06273340 or placebo|Subjects in Cohort 1 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated.
3142322|NCT01601834|Experimental|Cohort 2: Experimental intervention: PF-06273340 or placebo|Subjects in Cohort 2 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated.
3142323|NCT01601821|Active Comparator|Arm A (CsA+Rapamune+CS)|
3142324|NCT01601821|Experimental|Arm B (CsA+MMF+CS)|
3142325|NCT01601808|Placebo Comparator|Gemcitabine and Placebo|Standard therapeutic arm. Placebo orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles.
3142326|NCT01601808|Experimental|Gemcitabine and vandetanib|Experimental arm. Vandetanib orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles.
3142327|NCT01601795|Active Comparator|Sevoflurane|During cardiopulmonary bypass, sevoflurane will be administered through a vaporizer integrated into heart-lung-machine.
3142328|NCT01601795|Active Comparator|Isoflurane|During cardiopulmonary bypass, isoflurane will be administered through a vaporizer integrated into heart-lung-machine.
3142329|NCT01601782|Experimental|Volume Imaging scan|New type of ultrasound scan using General Electric US scanner, Model is a GE Logiq E9.
3142330|NCT01601769|Active Comparator|Colposcopy|a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.
3142331|NCT01601769|Experimental|Vitom|The VITOM system, consisting of the VITOM scope, xenon light source, HD camera system, AIDA HD documentation system, 1 monitor, and a mechanical support arm (all Karl Storz, Tuttlingen, Germany) is used for video exocolposcopy.
3142332|NCT01601756|Experimental|navigated revision total knee arthroplasty|revision total knee arthroplasty with the aid of a navigation system
3142333|NCT01601756|Active Comparator|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
3142334|NCT01601743|Active Comparator|Sitting|Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
3142335|NCT01601743|Active Comparator|Running|Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
3142873|NCT01597895|Experimental|Maraviroc + Boceprevir|
3142346|NCT01601678|Active Comparator|Peroral Endoscopic Myotomy POEM|Patients with Achalasia, designated to receive a myotomy of the lower esophageal sphincter, who have been randomised into the POEM therapy group
3142347|NCT01601678|Active Comparator|Laparoscopic Heller Myotomy LHM|Patients with Achalasia, designated to receive a myotomy of the lower esophageal sphincter, who have been randomised into the LHM therapy group.
3142348|NCT01601665||Toric High Cylinder Power IOL|Toric high cylinder power intraocular lens implanted during cataract surgery in the first operative eye, with the second operative eye implanted within 30 days of the first implantation.
3142349|NCT01601665||Monofocal IOL|Monofocal intraocular lens implanted during cataract surgery in the first operative eye, with the second operative eye implanted within 30 days of the first implantation.
3142350|NCT01601652|Experimental|Omeagven|
3142351|NCT01601639|Active Comparator|Argon Plasma Coagulation|Patients with GAVE and/or chronic anemia, active GI bleeding, blood transfusion requirements
3142352|NCT01601639|Active Comparator|Endoscopic Band Ligation|Patients with GAVE and/or chronic anemia, active GI bleeding, blood transfusion requirements
3142353|NCT01601626|Experimental|A: Standard-dose LPV/r w/RBT|"ART: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, rifabutin 300 mg, weight-based dosing for ethambutol and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
3142354|NCT01601626|Active Comparator|B: Double-dose LPV/r w/RIF|"ART: lopinavir 800 mg/ritonavir 200 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, weight-based dosing for rifampin, ethambutol, and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
3142355|NCT01601626|Experimental|C: Standard-Dose LPV/r w/RBT + RAL|"ART: lopinavir 400 mg/ritonavir 100 mg twice daily + raltegravir 400 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, rifabutin 300 mg, weight-based dosing for ethambutol and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
3142356|NCT01601613|Experimental|rFVIIa|
3142357|NCT01601613|Placebo Comparator|placebo|
3142358|NCT01601600|Placebo Comparator|Placebo|
3142359|NCT01601600|Experimental|BYM338|BYM338 active drug
3142360|NCT01601587|No Intervention|Treatment as usual|Patients will receive treatment as usual
3142361|NCT01601587|Other|Introduction Seminar|Psychoeducational group
3142362|NCT01601574|Experimental|Modified Weight Watchers program|
3142363|NCT01601574|Active Comparator|Standard Diabetes Counseling group|
3142364|NCT01601561|Experimental|High-dose insulin|
3142365|NCT01601561|No Intervention|Control|
3142366|NCT01601548|Experimental|Intervention Arm|Subjects are randomized to the Mindfulness Based Cancer Recovery (MBSR) intervention. Participants are presented with mindfulness medication techniques and share their experiences related to these meditation practices. There is a home practice component with an expectation of regular home meditation practice of 45 minutes per day. A full day silent retreat will occur in the second half of the course, providing an opportunity for class participants to gain experience with mindfulness techniques.
3142367|NCT01601548|No Intervention|Control Arm|No intervention is administered. Health-related quality of life questionnaires will be completed.
3142368|NCT01601535|Experimental|Treatment|"Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.~Irinotecan will be administered intravenously during each course on study day 1 through day 5.~Temozolomide will be administered orally during each course on study day 1 through day 5."
3142369|NCT01601522|Experimental|Desentization dose|500 mg Peanut Protein
3142370|NCT01601522|Placebo Comparator|Placebo|Oat flour
3142371|NCT01601509|Active Comparator|nasal spray with tramazoline and dexamethazone|
3142372|NCT01601509|Placebo Comparator|Placebo|
3142373|NCT01601496|Experimental|FUSION™ Vascular Graft|All subjects receive FUSION™ Vascular Graft at baseline implant procedure
3142374|NCT01601483|Experimental|MC-1101 1% Ophthalmic Solution|
3142375|NCT01601483|Placebo Comparator|Vehicle control|
3142376|NCT01601470|Experimental|Period 1:Sildenafil;Period 2:LCZ696;Period 3:LCZ696+Sildenafil|During Treatment Period 1, on study Day 1, participants received a single dose of sildenafil followed by wash out on Day 2. In Period 2 (study Days 3-7), participants received LCZ696 once daily. In Period 3, on study Day 8, participants received LCZ696 , co-administered at the same time with a single dose of sildenafil.
3142377|NCT01601457|Experimental|Activated recombinant human factor VII|
3142378|NCT01601457|Placebo Comparator|Placebo|
3142379|NCT01601431|Experimental|Cap Assisted Colonoscopy|Cap Assisted Colonoscopy uses a Cap which is a transparent hood which is attached to the distal end of the colonscope and allows depressing the colon folds in order to visualize hidden polyps behind the folds.
3142380|NCT01601431|Active Comparator|Conventional colonoscopy|A conventional colonoscopy does not use a Cap in order to perform the procedure
3142381|NCT01601392|Experimental|Anodal tDCS|
3142382|NCT01601392|Active Comparator|Cathodal tDCS|
3142383|NCT01601392|Sham Comparator|Sham|
3142384|NCT01601366|Experimental|LNG-IUS (Mirena)|"Group I the LNG-IUS group where they will have a LNG IUS (mirena) inserted for them"
3142385|NCT01601366|Active Comparator|Combined oral contraceptives|"Group II COCs group where they will receive low dose combined oral contraceptive pills for 6 months"
3142386|NCT01601353|Experimental|Treatment|Injection of adipose derived cells into penis
3142387|NCT01601353|No Intervention|Control|No intervention through 9 months
3142388|NCT01601340|Active Comparator|HQK-1001|
3142389|NCT01601340|Placebo Comparator|Placebo|
3142390|NCT01601327|Other|hypogonadism, treatment|77 patients with idiopathic hypogonadotropic hypogonadism were treated with testosterone gel, testosterone enanthate or human chorionic gonadotropin
3142391|NCT01601327|No Intervention|Control group|42 healthy controls
3142392|NCT01601314|Experimental|magnesium sulphate|The patients who are going to receive Magnesium Sulphate
3142393|NCT01601314|Placebo Comparator|Control|Patients who are going to receive Sodium Chloride 0.9%
3142394|NCT01601301|Experimental|PRECICE System|
3142395|NCT01601262|Experimental|Open label|
3142396|NCT01601249|Experimental|Polscope based embryo grading|Embryos for transfer will be selected based on highest polscope scores, unless are not grade 1-2 by conventional morphology
3142397|NCT01601249|Active Comparator|Morphology based embryo grading|Conventional embryo grading and decision making
3142398|NCT01601236|Experimental|Acthar 8 U (0.1 mL) daily|Repository Corticotropin Injection
3142399|NCT01601236|Placebo Comparator|Placebo (0.1 mL) daily|Placebo
3142400|NCT01601236|Experimental|Acthar 16 U (0.2 mL) daily|Repository Corticotropin Injection
3142401|NCT01601236|Placebo Comparator|Placebo (0.2 mL) daily|Placebo
3142402|NCT01601236|Experimental|Acthar 32 U (0.4 mL) daily|Repository Corticotropin Injection
3142403|NCT01601236|Placebo Comparator|Placebo (0.4 mL) daily|Placebo
3142404|NCT01601223||Surgical mechanically-ventilated|Surgical patients undergoing invasive mechanical ventilation for general anesthesia
3142405|NCT01601210|Placebo Comparator|Placebo|
3142406|NCT01601210|Active Comparator|2 grams of creatine|
3142407|NCT01601210|Active Comparator|4 grams of creatine|
3142408|NCT01601210|Active Comparator|10 grams of creatine|
3142409|NCT01601197|Experimental|Tactile stimulation|Ipsilateral limb will be rubbed immediately before, during and after immunization injection(s)
3142410|NCT01601197|No Intervention|No tactile stimulation|There will be no tactile stimulation of ipsilateral limb before, during and after immunization injection(s)
3142411|NCT01601184|Experimental|combination of vismodegib with temozolomide|"In the first step of the study (Phase I), 9 adult patients with relapsing or refractory medulloblastoma will be randomized (randomization ratio 2:1) to receive~- Arm A: the combination of vismodegib (150 mg/day continuously) with temozolomide (150 mg/m2 during Cycle 1 [day 1 to day 5/ 28 day-cycle] and 200 mg/m2 during subsequent cycles) (6 patients)"
3142412|NCT01601184|Active Comparator|temozolomide alone|In the first step of the study (Phase I), 9 adult patients with relapsing or refractory medulloblastoma will be randomized (randomization ratio 2:1) to receive Arm B: temozolomide alone (150 mg/m2 day1 to day 5/ 28 day-cycle during Cycle 1 and 200 mg/m2 day 1 to day 5/ 28 day-cycle during subsequent cycles) (3 patients).
3142413|NCT01601184|Other|vismodegib alone|Considering the rarity of the disease, the few therapeutic options available and the promising results reported with vismodegib in adult medulloblastoma : the Sponsor will consider (on case by case basis) the enrolment of patients previously treated by temozolomide in a 3rd independent and parallel study arm
3142414|NCT01601171||Patients|Patients with reproductive disorders will be recruited for: specimen collection (DNA/serum/plasma), completion of medical questionnairre, smell testing, and review of medical records.
3142415|NCT01601171||Family members|Family members of patients with reproductive disorders will be recruited for: specimen collection (DNA/serum/plasma), completion of medical questionnairre, and smell testing.
3142416|NCT01601158|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation
3142417|NCT01601145|Experimental|lozenges with Lactobacillus brevis CD2|Randomized group using lozenges for 6 weeks.
3142418|NCT01601145|Placebo Comparator|lozenges|Randomized group using lozenges for 6 weeks.
3142419|NCT01601132|Experimental|theophylline|300mg (80mg/15ml elixir) theophylline
3142420|NCT01601132|Experimental|Colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
3142421|NCT01601119||Rebif cohort|Subject will receive Rebif as the treatment medication as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.
3142422|NCT01601119||Other DMT cohort|Subjects will receive DMT other than Rebif as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.
3142423|NCT01601106|Active Comparator|Liposomal prednisolone|
3142424|NCT01601106|Placebo Comparator|Placebo control|
3142425|NCT01601093|Experimental|High dose|Ceftazidime 3g
3142426|NCT01601093|Experimental|Low dose|Ceftazidime 2g
3142427|NCT01601093|Active Comparator|CFP/SUB|Cefoperazone and sulbactam sodium for injection(2:1)
3142428|NCT01601067|Experimental|Arm 1: Integrated Prolonged Exposure Therapy|Integrated Prolonged exposure Psychotherapy (I-PE; PE integrated with elements of Integrated Cognitive Behavioral Therapy for alcohol use disorder)
3142429|NCT01601067|Active Comparator|Arm 2: Seeking Safety|Seeking Safety
3142430|NCT01601054|Active Comparator|Anterior lumbar interbody fusion|Anterior lumbar interbody fusion using a tantalum cage. Cage will be inserted through a left sided retroperitoneal approach.
3142431|NCT01601054|Active Comparator|Posterior instrumentation alone|Posterior pedicle screw instrumentation
3142432|NCT01601041||urinary tract infection|urinary tract infection in male patients with neurogenic bladder dysfunction due to spinal cord injury managed by intermittent catheterization
3142433|NCT01601041||control group|less than three urinary tract infections / year
3142434|NCT01601028|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 300 mg once daily p.o.
3142435|NCT01601028|Placebo Comparator|Placebo|Placebo
3142436|NCT01601015|Experimental|Manual therapy|Manual therapy of Suboccipital soft tissue Inhibition treatment aims to release the suboccipital muscle spasm that maintains the occiput-atlas-axis joint dysfunction.
3142437|NCT01601015|Experimental|Occiput-atlas-axis joint manipulation|Is bilaterally administered. The aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction
3142438|NCT01601015|Experimental|Combined treatment|The group receiving combined treatment received the two previous techniques exactly with the same sequence.
3142439|NCT01601015|Placebo Comparator|Control group|Control group not receive treatment and stayed in this position for 10 minutes
3142440|NCT01601002|Experimental|Mirtazapine|Mirtazapine in dosage of 7.5 mg to 45 mg/day
3142874|NCT01597895|Experimental|Maraviroc + Telaprevir|
3142441|NCT01600989||Patients with severe sepsis / septic shock|30 Adult patients (age > 18years), with severe sepsis or septic shock as defined by the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference guidelines at the time of admission to ICU.
3142442|NCT01600989||Healthy volunteers|Healthy volunteers
3142443|NCT01600976|Experimental|Group 1|10 patients with moderate hepatic impairment (CPB [Child-Pugh score 7 to 9])
3142444|NCT01600976|Experimental|Group 2|10 healthy control patients with normal hepatic function. Each healthy control patient is matched to a patient in Group 1 with respect to sex, age (± 5 years) and body mass index (BMI) (± 15%)
3142445|NCT01600976|Experimental|Group 3|up to 4 patients with severe hepatic impairment (CPC [limited to Child Pugh score 10 to 12])
3142446|NCT01600963|Experimental|Arm A|
3142447|NCT01600963|Placebo Comparator|Arm B|
3142448|NCT01600950|Experimental|LY2963016|A single 0.3 units per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously followed by a minimum washout period of 7 days.
3142449|NCT01600950|Active Comparator|Lantus|A single 0.3 U/kg dose of Lantus will be administered subcutaneously followed by a minimum washout period of 7 days.
3142450|NCT01600937|No Intervention|Control|Standard care including physician recommendations for daily PA
3142451|NCT01600937|Experimental|Exercise|Theoretical & practical exercise counseling including 2 sessions/ per wk for 1 month of supervised exercise training
3142452|NCT01600898||Asymptomatic BMPR2 mutation carriers|Asymptomatic BMPR2 mutation carriers
3142453|NCT01600885|Active Comparator|Guanfacine then Placebo|During the first study session, the participant will receive guanfacine before undergoing a ketamine-infusion fMRI. During the second study session, at least two weeks later, the participant will receive a placebo before undergoing a ketamine-infusion fMRI.
3142454|NCT01600885|Active Comparator|Placebo then Guanfacine|During the first study session, the participant will receive a placebo before undergoing a ketamine-infusion fMRI. During the second study session, at least two weeks later, the participant will receive guanfacine before undergoing a ketamine-infusion fMRI.
3142455|NCT01600872||Gruop 1|
3142456|NCT01600872||Group 2|
3142457|NCT01600859|Experimental|E2609|
3142458|NCT01600859|Placebo Comparator|Placebo for E2609|
3142459|NCT01600833||Obese women|BMI>25
3142460|NCT01600833||Non obese women|BMI<25
3142461|NCT01600820|Experimental|1 = Tested product 1|
3142462|NCT01600820|Experimental|2 = tested product 2|
3142463|NCT01600820|Placebo Comparator|3 = Control product|
3142464|NCT01600807|Experimental|Gemcitabine, Erlotinib, OSI-906|Experimental treatment arm
3142465|NCT01600807|Active Comparator|Gemcitabine, Erlotinib|Standard treatment arm
3142466|NCT01600794||male/female, immunity or others factor infertility, IVF|
3142467|NCT01600781|Active Comparator|NutriniDrink/Fortini group|this group will receive 2 bottles of NutriniDrink/Fortini MF unflavoured daily (200 ml each) and standard dietary counselling for a period of 6 weeks.
3142468|NCT01600781|No Intervention|control group|this control group will only receive standard dietary counselling
3142469|NCT01600768|Active Comparator|intermittent infusion|
3142470|NCT01600768|Experimental|extended infusion|
3142471|NCT01600755|Experimental|AMDC|
3142472|NCT01600742|Active Comparator|WBRT, placebo|
3142473|NCT01600742|Experimental|WBRT and concurrent vorinostat|
3142474|NCT01600729||All Participants|Participants with facial lines. There was no intervention in this study.
3142475|NCT01600716|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for a second onabotulinumtoxinA 100 U injection.
3142476|NCT01600716|Other|Placebo (Normal Saline)|Placebo (normal saline) is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for an onabotulinumtoxinA injection.
3142477|NCT01600703|Experimental|Sitagliptin|sitagliptin, 100mg, oral, single dose
3142478|NCT01600703|Placebo Comparator|Placebo|Placebo, oral, single dose
3142479|NCT01600690|No Intervention|Continue statin regimen|Patients randomized to this arm will continue their usual statin regimen and dose, without any intervention.
3142480|NCT01600690|Experimental|Statin withdrawal|Patients randomized to this arm will stop statin treatment for 5 days.
3142481|NCT01600677|Experimental|Computerized medication delivery unit|Those hospitalized patients that meet all inclusion and exclusion criteria will be provided with an EMMA MDU for use in their homes for the 90-day period immediately following discharge.
3142482|NCT01600677|Active Comparator|Usual care|Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
3142483|NCT01600664|Experimental|interactive computer game|"Participants will be using the interactive computer game- My Diabetic Friend, installed on Intel-powered convertible classmate PC."
3142484|NCT01600664|Active Comparator|Convertible PC|Participants will be using the convertible classmate PC without the interactive computer game
3142485|NCT01600651|Sham Comparator|Recruitment maneuver (RM) sham group|when recruitment maneuver sequence precedes a sham evaluation period
3142486|NCT01600651|Sham Comparator|Sham Recruitment (RM) maneuver group|a group in which patients receive a sham sequence before the RM sequence
3142487|NCT01600638|No Intervention|Fat Reduction|
3142488|NCT01600625|Experimental|Minocycline treatment group|
3142489|NCT01600612|Active Comparator|Oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
3142490|NCT01600612|Active Comparator|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
3142491|NCT01600612|Active Comparator|misopristol|600 ug of misopristol sublingually will be given intravenously to patients with atonic postpartum hemorrhage
3142492|NCT01600599|Active Comparator|IV & topical TA|patients in this group will receive both intravenous & topical tranexamic acid
3142493|NCT01600599|Placebo Comparator|IV tranexamic acid & Topical Saline|
3142494|NCT01600586|Experimental|Pacifier-Activated-Lullaby system (PAL)|Pacifier-Activated-Lullaby system (PAL) group.
3274155|NCT00668135|Experimental|Arm 1|
3142495|NCT01600586|No Intervention|No PAL group|No PAL. Standard of care procedures.
3142496|NCT01600573|Experimental|pazopanib plus weekly topotecan|pazopanib in combination with weekly topotecan
3142497|NCT01600560||Social media|
3142498|NCT01600547||fall clinic population|women, aged + 65 years
3142499|NCT01600547||control fallers|randomly selected community aged matched female controls with a fall episode
3142500|NCT01600547||control non fallers|randomly selected community aged matched female controls, with out fall episodes
3142501|NCT01600534|Experimental|Lifestyle counseling|Participants obtain access to an internet-based educational intervention.
3142502|NCT01600534|Other|Usual Care Lifestyle counseling|Self directed educational intervention
3142503|NCT01600521|Active Comparator|Paeoniflorin + Polypeptides (PAE + CCPI)|Paeoniflorin (PAE), the extract from peony (Paeonia lactiflora), is an active ingredient with anti-inflammation properties. Polypeptides (3,000 - 10,000 dalton) in Cervus & Cucumis polypeptide injection (CCPI), the extract from Sika deer (Cervus nippon Temmick) bones and muskmelon (Cucumis melo L) seeds, are the active ingredients with bone healing, pain relieving, and anti-inflammation properties. PAE was administrated orally 600 mg twice a day for at least 12 months. CCPI was administered intravenously 8~12 mL daily with 250 mL 5% dextrose injection solution or 0.9% NaCl IV solution for 2 weeks, discontinued 1 week, and restarted for another 2 weeks.
3142504|NCT01600521|Active Comparator|Methotrexate (MTX) + Leflunomide (LEF)|DMARDs (methotrexate: MTX, leflunomide: LEF) were taken orally for at least 12 months. MTX dose: 7.5 mg ~ 10mg / week, LEF dose: 10 mg ~ 20mg daily.
3142505|NCT01600521|Active Comparator|MTX + LEF + CCPI|The DMARDs and CCPI were administrated as in the above two groups.
3142506|NCT01600508|Active Comparator|Traditional stoma care|Being discharged from a hospital with a stoma is a challenge to the patient's quality of life in many aspects. Optimal stoma function and care is essential to keep quality of life best possible. Videoconference can be a useful tool to help patients cope with stoma problems without travelling long distances to a surgical outpatient clinic.
3142507|NCT01600508|Experimental|Videoconference Stoma Consultations|Videoconference Stoma Consultations
3142508|NCT01600495|Experimental|Experimental TENS|TENS Intervention Group(GIE) used for 30 minutes, during uterine contractions between 4-5 cm
3142509|NCT01600495|No Intervention|control Group|Formed by mothers who will not use EAC to receive the routine procedures of motherhood, but will be monitored and evaluated at the same time in the intervention group.
3142510|NCT01600482|Experimental|CELT ACD device|The CELT ACD device is a vascular closure device.
3142511|NCT01600482|No Intervention|Manual Compression|Manual Compression
3142512|NCT01600469|Experimental|DAOI-B|
3142513|NCT01600469|Placebo Comparator|Placebo|
3142514|NCT01600456|Active Comparator|Choice: Prolonged exposure (PE)|"Participants randomized to choice who choose prolonged exposure (PE)."
3142515|NCT01600456|Active Comparator|Choice: PE plus sertraline|"Participants randomized to choice who choose PE plus sertraline."
3142516|NCT01600456|Active Comparator|No choice: Prolonged exposure (PE)|"Participants randomized to no choice who are then randomized to PE."
3142517|NCT01600456|Active Comparator|No Choice: PE plus sertraline|"Participants randomized to no choice who are then randomized to PE plus sertraline."
3142518|NCT01600443|Experimental|LoFric - SC - SCCM|Study period 1: LoFric Study period 2: SpeediCath Study period 3: SpeediCath Compact Male In each study period three catheterizations are made, separated by at least 2 hours.
3142519|NCT01600443|Experimental|LoFric - SCCM - SC|Study period 1: LoFric Study period 2: SpeediCath Compact Male Study period 3: SpeediCath In each study period three catheterizations are made, separated by at least 2 hours.
3142520|NCT01600443|Experimental|SC - SCCM - LoFric|Study period 1: SpeediCath Study period 2: SpeediCath Compact Male Study period 3: LoFric In each study period three catheterizations are made, separated by at least 2 hours.
3142521|NCT01600443|Experimental|SC - LoFric - SCCM|Study period 1: SpeediCath Study period 2: LoFric Study period 3: SpeediCath Compact Male In each study period three catheterizations are made, separated by at least 2 hours.
3142522|NCT01600443|Experimental|SCCM - LoFric - SC|Study period 1: SpeediCath Compact Male Study period 2: LoFric Study period 3: SpeediCath In each study period three catheterizations are made, separated by at least 2 hours.
3142523|NCT01600443|Experimental|SCCM - SC - LoFric|Study period 1: SpeediCath Compact Male Study period 2: SpeediCath Study period 3: LoFric In each study period three catheterizations are made, separated by at least 2 hours.
3142524|NCT01600430|Active Comparator|Oral Vitamin D--200 IU/day|Cholecalciferol 200 IU given orally once per day
3142525|NCT01600430|Placebo Comparator|Placebo|Identical-appearing treatment that does not contain the test drug given orally four times per day.
3142526|NCT01600430|Active Comparator|Oral Vitamin D--800 IU/day|Cholecalciferol 800 IU given orally once per day
3142527|NCT01600417||clinical suspicion of lumbar instability|
3142528|NCT01600404||antimuscarinic treatment|antimuscarinic treatment
3142529|NCT01600404||no antimuscarinic treatment (control)|
3142530|NCT01600391|Active Comparator|Usual Care|A task specific-based intervention that does not include use of visual cues to influence quality or adaptability of gait.
3142531|NCT01600391|Experimental|Overground visual cue training|Overground visual cue training will involve stepping to targets which are positioned to improve gait symmetry and speed. Training will include turning practice and the avoidance of obstacles for adaptability during straight walking.
3142532|NCT01600391|Experimental|Treadmill visual cue training|Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). Walking training will involve stepping to targets which are positioned to improve gait symmetry and speed. Training will include turning practice and the avoidance of obstacles for adaptability during straight walking.
3142533|NCT01600365|Active Comparator|Ganciclovir|Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
3142534|NCT01600365|Placebo Comparator|Ophthalmic gel (placebo)|ophthalmic gel (placebo)in the study eye
3142535|NCT01600339|Experimental|CABAZITAXEL|cabazitaxel at a starting dose of 25 mg/m
3142536|NCT01600326|Active Comparator|Tenotomy Group|Subject enrolled in this arm will receive treatment for tendinitis and pain evaluation of pain pre and post treatment.
3143231|NCT01595477|No Intervention|Control Group|
3142537|NCT01600326|Active Comparator|Plasma Injection Group|Treatment is Ultrasound guided platelet rich plasma injection.
3142538|NCT01600313|Experimental|treatment, control|
3142539|NCT01600300|Placebo Comparator|Sham|Treatment with inactivate Tesmac device
3142540|NCT01600300|Active Comparator|Tesmac|Treatment with active Tesmac device
3142541|NCT01600287|Experimental|IAADS group|dosage of propofol adjusted automatically by IAADS
3142542|NCT01600287|Active Comparator|Manual group|dosage of propofol adjusted manually
3142543|NCT01600261||eye exam|
3142544|NCT01600248|Other|Treatment arm|This is an open-label pilot study with no control group. Participants pre-treatment scores are compared to their post-treatment scores.
3142545|NCT01600235|Experimental|Phenylephrine|Phenylephrine induced-hypertension arm
3142546|NCT01600235|No Intervention|Conventional treatment|Control arm
3142547|NCT01600222|Experimental|LEO 90100|
3142548|NCT01600209||Average risk patients|Subjects will be men and women, 50-84 years of age, inclusive, each with a screening colonoscopy resulting in normal findings.
3142549|NCT01600196|Experimental|Resection arm|Liver resection Plus Thrombectomy
3142550|NCT01600196|No Intervention|Best support care arm|Best supportive care
3142551|NCT01600183|Active Comparator|casting|subjects with MTA will be treated with cast for 20 weeks. casting is replaced during every study visit.
3142552|NCT01600183|Experimental|UNFO-s|subjects with MTA will be treated with the UNFO-s device for 12 weeks - will be worn day and night during first 6 weeks and only at night during next 6 weeks
3142553|NCT01600170|Active Comparator|Atorvastatin|
3142554|NCT01600170|Placebo Comparator|Placebo|
3142555|NCT01600157|Experimental|Laparoscopic Nephrectomy|
3142556|NCT01600144||data collection|
3142557|NCT01600131|Experimental|Caregiver education and support|problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.cidrr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
3142558|NCT01600131|Other|Standard Care|Caregivers receiving standard of care
3142559|NCT01600118|Active Comparator|ESWT|Extracorporeal shockwave therapy
3142560|NCT01600118|Placebo Comparator|ESWT Placebo|No extracorporeal shockwave therapy
3142561|NCT01600105|Experimental|Perfusion MRI|chronic liver disease who underwent/will undergo liver biopsy or will undergo liver transplant or liver resection as part of standard care during the previous 6 months.
3142562|NCT01600092|Experimental|RotaTeq™ Experimental Formulation|Three 2.0 mL oral doses of RotaTeq™ experimental formulation. Vaccination 1 will be administered between 6 and 12 weeks of age and the third vaccination will be administered before 32 weeks of age. Each vaccination will be separated from the next by ≥ 4 weeks (28 days)
3142563|NCT01600092|Active Comparator|RotaTeq™ Existing Formulation|Three 2.0 mL oral doses of RotaTeq™ existing formulation. Vaccination 1 will be administered between 6 and 12 weeks of age and the third vaccination will be administered before 32 weeks of age. Each vaccination will be separated from the next by ≥ 4 weeks (28 days).
3142564|NCT01600079||Vaccinated Cohort|Participants vaccinated with at least one dose of ZOSTAVAX™
3142565|NCT01600079||Unvaccinated Comparison Cohort|Participants who are not yet vaccinated with any zoster vaccine
3142566|NCT01600053|Experimental|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles
3142567|NCT01600040|Other|Proton Radiation Therapy|This is a single arm study; all participants will receive proton radiation therapy.
3142568|NCT01600027|Placebo Comparator|Group B|received 1 ml/kg bupivacaine 0.25%.
3142569|NCT01600027|Active Comparator|group BD|received 1 ml/kg bupivacaine 0.25% with dexmedetomidine 2 μg/kg
3142570|NCT01600014|Active Comparator|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days on the face or scalp
3142571|NCT01600014|Placebo Comparator|Vehicle gel|Topical field treatment once daily for 3 consecutive days on the face or scalp
3142572|NCT01600001|Experimental|Drug:KWA-0711 dose 1|
3142573|NCT01600001|Experimental|Drug:KWA-0711 dose 2|
3142574|NCT01600001|Experimental|Drug:KWA-0711 dose 3|
3142575|NCT01600001|Experimental|Drug:KWA-0711 dose 4|
3142576|NCT01600001|Placebo Comparator|Drug: Placebo|
3142577|NCT01599988|Active Comparator|Milk protein isolate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
3142578|NCT01599988|Active Comparator|Caseinate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate.
3142579|NCT01599975|Active Comparator|Group A: 2 tabs of 18 mg Concerta daily|20 subjects to receive active study drug in a blinded fashion x 2 weeks, then washout x 2 weeks, then cross over to receive matched placebo x 2 weeks.
3142580|NCT01599975|Placebo Comparator|Group B: Matched placebo, 2 tabs daily|Group B to receive matched placebo x 2 weeks, then washout x 2 weeks, then cross over to receive active drug in a blinded fashion x 2 weeks.
3142581|NCT01599962|Experimental|Cinacalcet|
3142582|NCT01599962|Placebo Comparator|Sugar pill|
3142583|NCT01599949|Experimental|Ibrutinib|
3142584|NCT01599936|Experimental|Anascorp|Three vials of Anascorp® will be administered in a total volume of 50 mL, intravenous over not less than 10 minutes or as permitted by IV access
3142585|NCT01599923|Experimental|Alacramyn|
3142586|NCT01599897|Experimental|2 µg ID93 + 2 µg GLA-SE|Low dose and antigen and low dose of adjuvant.
3142587|NCT01599897|Experimental|10 µg ID93 + 2 µg GLA-SE|High dose of antigen and low dose of adjuvant.
3142588|NCT01599897|Experimental|2 µg ID93 + 5 µg GLA-SE|Low dose of antigen and high dose of adjuvant.
3142589|NCT01599897|Experimental|10 µg ID93 + 5 µg GLA-SE|High dose of antigen and high dose of adjuvant.
3142590|NCT01599897|Active Comparator|2 µg ID93 alone|Low dose of antigen alone.
3142591|NCT01599897|Active Comparator|10 µg ID93 alone|High dose of antigen alone.
3142592|NCT01599884|Active Comparator|N-acetylcysteine|N-acetylcysteine, 1800 mg twice daily
3142593|NCT01599884|Placebo Comparator|Sugar pill|Identical to active drug
3142594|NCT01599871|Experimental|Intervention|Inhaled corticosteroids and long-acting beta agonist + theophylline (Slophylline capsules 100 mg/Theo-dur Retard 100 mg b.i.d.)
3142595|NCT01599871|Placebo Comparator|Control|inhaled corticosteroids and long-acting beta agonist + Placebo
3142596|NCT01599845||Nanoparticle exposed|
3142597|NCT01599832|Experimental|Treatment (pazopanib hydrochloride, DCE-MRI)|Patients receive pazopanib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo dynamic contrast-enhanced MRI at baseline, day 8, and prior to courses 3, 5, and 7.
3142598|NCT01599819|Experimental|Cohort 1|Low dose of ADVATE followed by low dose of BAX 855
3142599|NCT01599819|Experimental|Cohort 2|High dose of ADVATE followed by high dose of BAX 855
3142600|NCT01599806|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
3142601|NCT01599806|Active Comparator|Doripenem|IV treatment
3142602|NCT01599793|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive cabozantinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
3142603|NCT01599780||Full-Term Children|≥37 weeks gestation; 18 months old at the start of the study
3142604|NCT01599780||Preterm Children|<33 weeks gestation; 18 months old at the start of the study
3142605|NCT01599767|Experimental|Active tDCS|Subjects will undergo 20 minutes active tDCS.
3142606|NCT01599767|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham stimulation.
3142607|NCT01599754|Experimental|Axitinib|
3142608|NCT01599754|Placebo Comparator|Placebo|
3142609|NCT01599741|Experimental|ClarityIQ|Low-dose DSA (83% reducation compared to normal dose) with novel X-ray imaging technology.
3142610|NCT01599741|Active Comparator|AlluraXper|Normal dose DSA with conventional X-ray imaging technology.
3142611|NCT01599728|Other|Patients with heart failure|Assessing the response to infusion of intra-arterial Urocortin 2, 3 and Substance P in patients with heart failure
3142612|NCT01599728|Other|Healthy controls|Assessing response to intra-arterial infusions of Urocortin 2, 3 and Substance P in age and sex-matched healthy volunteers as controls.
3142613|NCT01599715|Other|Instructional DVD Intervention|Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once
3142614|NCT01599715|Other|Bladder Health Class Intervention|Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
3142615|NCT01599702|Experimental|Group A Monofer|Depending on the body weight, subjects in Treatment Group A will receive a total dose of 1,500 mg or 2,000 mg IV iron isomaltoside 1000 where 1,500 mg is administered as a single infusion and 2,000 mg is divided into 2 administrations: 1 administration of 1,500 mg at baseline and 1 administration of 500 mg 1 week later. All doses will be diluted in 100 ml normal saline (0.9 % sodium chloride) and administered by infusion over approximately 15 minutes.
3142616|NCT01599702|Experimental|Group B Monofer|Depending on the body weight, Subjects in Treatment Group B will receive a total dose of 2,500 mg or 3,000 mg IV iron isomaltoside 1000 divided into 2 administrations; 1 administration of 1,500 mg and 8 weeks later a second administration of 1,000 mg or 1,500 mg.. All doses will be diluted in 100 ml normal saline (0.9 % sodium chloride) and administered by infusion over approximately 15 minutes.
3142617|NCT01599689|Experimental|Mirrors Intervention|Patients allocated to Mirrors will receive a structured, protocol-driven bedside mirrors intervention as part of their postsurgical ICU care. This intervention will commence as soon as all anaesthetic agents have been switched off and the patient is awake following surgery unless considered clinically inappropriate.
3142618|NCT01599689|No Intervention|Standard Care|Patients allocated to Standard Care will receive the usual postsurgical ICU care that does not include the use of mirrors.
3142619|NCT01599676|Sham Comparator|Not essential amino acid|"Non essential amino acid:~The subjects will have a regimen of high-intensity progressive resistance training of the knee extensors 3 days per week for 12 weeks. The subjects will receive 1 unit of an equivalent quantity of nonessential amino acids (alanine, aspartate, glycine, serine, histidine and proline in equimolar quantity) isonitrogenous to 10 g of citrulline, once in the morning for 12 weeks."
3142620|NCT01599676|Experimental|Citrulline|The subjects will have a regimen of high-intensity progressive resistance training of the knee extensors 3 days per week for 12 weeks. The subjects will receive citrulline 10 g/day orally in the morning for 12 weeks.
3142621|NCT01599663|Experimental|Intervention units|"A time period before the clinicians will be educated, trained and guided in the pain management algorithm, pre-test data will be collected in four ICU units.~The clinicians in three of the ICU units will be educated, trained and guided in the pain management algorithm. The algorithm will then be used to assess and treat pain in all consecutive ICU patients. Post-test data will be collected a time period after the intervention is implemented."
3142622|NCT01599663|No Intervention|Control unit|The clinicians in the fourth ICU (control unit) will not be educated, trained and guided in the pain management algorithm. They will continue to assess and treat pain in all consecutive ICU patients as before. The unit, which will be used as a comparison unit, will collect the same post-test data at the same time as data in intervention ICUs were collected.
3142623|NCT01599650|Experimental|1-ranibizumab monotherapy|Ranibizumab 0.5 mg
3142624|NCT01599650|Experimental|2-ranibizumab with laser|Ranibizumab 0.5 mg + laser
3142625|NCT01599650|Active Comparator|3-laser monotherapy|Laser monotherapy with Ranibizumab 0.5 mg from Month 6
3142626|NCT01599637|Experimental|IGE025|Patients will receive omalizumab administered subcutaneously every 4 weeks at the study center.
3142627|NCT01599637|Placebo Comparator|Placebo to IGE025|Placebo administered subcutaneously every 4 weeks at the study center.
3142628|NCT01599624|Experimental|iPad-based SRTS|
3142629|NCT01599624|Experimental|iPad-based PMR program|
3142630|NCT01599611||Exposed group|Children age 5-10 years old who had a total serum bilirubin > 450 umol/L in the neonatal period
3143232|NCT01595464|Experimental|Mind-Body Skills Groups|
3142631|NCT01599611||Non-exposed group|Matched 1:1 to the exposed group on gender, age, gestational age and municipality of residence
3142632|NCT01599598|Active Comparator|Progressive Muscle Relaxation|A stress intervention where subjects will learn to regulate stress based on the tensing and releasing of the major muscle groups in the body, accompanied with relaxed breathing techniques.
3142633|NCT01599598|Active Comparator|Coherence Advantage|A stress intervention where subjects will learn to regulate stress by focusing on breathing and mindfulness techniques while recognizing physiological coherence by way of a portable biofeedback device.
3142634|NCT01599585|Experimental|In Home|Participants in this condition will receive 8 sessions of BA treatment over the course of approximately 8 weeks (one session per week). The sessions will be conducted in their homes using an Army approved secure web-based video conferencing system. BA has been successfully delivered in this time frame, and it has been delivered via in-home video conferencing technology.
3142635|NCT01599585|Active Comparator|In-Person|Participants in this condition will receive 8 sessions of BA treatment over the course of approximately 8 weeks (one session per week with allowance for rescheduled sessions). The sessions will be conducted in a clinic setting at The National Center for Telehealth & Technology.
3142636|NCT01599572|Experimental|30mg/day zinc supplementation|30mg/day of zinc supplement provided for 3 months to zinc deficient elderly
3142637|NCT01599559|Experimental|observation|Follow up visits are scheduled from randomization. Patients will be seen at 3-months intervals for 24 months, then every 6 months until 5 years from randomization.
3142638|NCT01599559|Active Comparator|mediastinal irradiation|Radiotherapy will be delivered in this phase III protocol, as alternative to observation, as consolidation treatment in patients achieving a CR status (PET/CT scan negative) at the end of R-chemotherapy, with a total dose of 30 Gy.
3142639|NCT01599546||Full Term children|born >36 weeks, currently age 6 +/- 6 months
3142640|NCT01599546||Preterm children|born <35 weeks, age 6 +/- 6 months at the beginning of the study.
3142641|NCT01599533|Other|abdominal aortic aneurysms|
3142642|NCT01599520|Experimental|Spanish-Language Self-Administered Training + Usual Care|Participants randomized to this arm will receive Spanish-Language Self-Administered Training + Usual Care.
3142643|NCT01599520|Active Comparator|Usual Care Only|"Patients will be given the Spanish-language version of Chemotherapy and You: Support for People with Cancer (La quimioterapia y usted: Apoyo para las personas con cancer) published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health."
3142644|NCT01599507|Experimental|FG-4592|Active Drug
3142645|NCT01599507|Placebo Comparator|Placebo|
3142646|NCT01599494|Experimental|Single-Dose MK-8962 + recFSH|
3142647|NCT01599494|Active Comparator|Reference Group recFSH only|
3142648|NCT01599481|Experimental|Intervention|Standard Care (IAPT Therapy) + Individual Career Management (ICM)
3142649|NCT01599481|Active Comparator|Control|Standard Care (IAPT Therapy)
3142650|NCT01599468|Experimental|tranexamic acid, post partum hemorrhage|
3142651|NCT01599468|Placebo Comparator|placebo|
3142652|NCT01599455||Inpatient|Youths admitted for inpatient rehabilitation training
3142653|NCT01599455||Outpatient|Youths visiting outpatient clinics
3142654|NCT01599455||Urodynamic study|Youths who undergo scheduled urodynamic study
3142655|NCT01599416|Active Comparator|U-relax Group|Day 1-5: take two capsuals of oral U-relax everyday before sleep Day 6-360: take one capsual of oral U-relax everyday before sleep
3142656|NCT01599416|Placebo Comparator|Placebo Group|Day 1-5: take two capsuals of oral placebo everyday before sleep Day 6-360: take one capsual of oral placebo everyday before sleep
3142657|NCT01599403|Active Comparator|Paravertebral Block|Patients will receive 1 or 2 paravertebral catheters for ongoing infusion of local anesthestic
3142658|NCT01599403|No Intervention|Patient Controlled Anesthesia|Standard usual care
3142659|NCT01599403|Experimental|Epidural Block|"Intervention:~Patients will have epidural catheters placed for the infusion of local anesthetic solution to control pain (if qualified for this approach and randomized here)"
3142660|NCT01599403|Active Comparator|Intercostal Nerve Block|Patients will receive intercostal catheters for the infusion of local anesthetic solution to control pain(if qualified for this arm and randomized here)
3142661|NCT01599390||Influenza Group|
3142662|NCT01599377|Experimental|Cohort 1|
3142663|NCT01599377|Experimental|Cohort 2|
3142664|NCT01599364|Experimental|Switch|Switch to Atazanavir 300 mg with ritonavir 100 mg plus lamivudine 300 mg
3142665|NCT01599364|No Intervention|continue|Continue Atazanavir 300 mg with ritonavir 100 mg with the same NRTI backbone
3142666|NCT01599351|Active Comparator|Prone|Patients were in prone position along the ERCP procedure.
3142667|NCT01599351|Active Comparator|Left lateral decubitus|Patients were in left lateral decubitus along the ERCP procedure.
3142668|NCT01599338|Experimental|Liraglutide|Single Arm study. T2DM patients are studied before and after 3 months of Liraglutide treatment (1.2 mg/day).
3142669|NCT01599325|Experimental|Azacitidine|Azacitidine 75 mg/m^2/day subcutaneously (SC) for 7 days every 28 days until disease progression (DP), adverse events (AE), withdrawal of consent from further treatment, withdrawal of consent, death, lost to follow-up, or protocol violation.
3142670|NCT01599312|Other|Classic Macintosh laryngoscope|Classic Macintosh laryngoscope (Karl Storz, Tuttlingen, Germany)
3142671|NCT01599312|Other|McGrath®|McGrath® (Aircraft Medical Ltd, Edinburgh, UK)
3142672|NCT01599312|Other|C-MAC®|C-MAC® (Karl Storz, Tuttlingen, Germany)
3142673|NCT01599312|Other|GlideScope® Cobalt|GlideScope® Cobalt (Verathon Medical, Bothell, WA, USA)
3142674|NCT01599299||Ultrasound, internal jugular vein|All patients who will need a central venous access (into the right jugular vein) preoperative are included.
3143233|NCT01595464|No Intervention|Control Group|
3142675|NCT01599286|Experimental|Active Comparator|Parallel Trial Comparing NCG + Standard of Care Treatment
3142676|NCT01599286|Active Comparator|Placebo Comparator|Placebo and Standard of Care Therapy
3142677|NCT01599273|Experimental|Triam inj|
3142678|NCT01599273|No Intervention|observation group|
3142679|NCT01599260|Experimental|Resistance Exercise|Subjects will participate in a 16 week long resistance exercise program which will consist of 2 30-minute individually supervised sessions per week.
3142680|NCT01599247||Suicidal ideation/behavior|
3142681|NCT01599234|Experimental|Sativex|Active treatment
3142682|NCT01599234|Placebo Comparator|Placebo|Control
3142683|NCT01599221||Subjects with EBA2|Subjects who have undergone surgery with EBA2 medical device for lateral proximal femoral fractures
3142684|NCT01599208|Experimental|Single-pulse online stimulation|Online single-pulse online stimulation at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
3142685|NCT01599208|Experimental|Repetitive online stim., 400ms, 10Hz|Repetitive online stimulation for 400ms at 10Hz at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
3142686|NCT01599208|Experimental|Repetitive online stim., 400ms, 20Hz|Repetitive online stimulation for 400ms at 20Hz at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
3142687|NCT01599208|Experimental|Repetitive offline stimulation at 10Hz|Repetitive offline stimulation at 10Hz for 4 min before study or for 8 min before test (in accordance with the phase length), comprising 2-second stimulation trains and 20-second breaks. Stimulation will be given at 120% of motor threshold to either the right or the left MTL in comparison to sham condition.
3142688|NCT01599208|Experimental|Repetitive offline stimulation at 20Hz|Repetitive offline stimulation at 20Hz for 4 min before study or for 8 min before test (in accordance with the phase length), comprising 2-second stimulation trains and 20-second breaks. Stimulation will be given at 120% of motor threshold to either the right or the left MTL in comparison to sham condition.
3142689|NCT01599208|Experimental|Repetitive offline stimulation with iTBS|Repetitive offline stimulation with Intermittent Theta Burst Stimulation (iTBS) comprising 3 pulses at 50Hz, repeated at 5Hz for 2-second stimulation trains with 8-second breaks for 192 seconds. Stimulation will be given at 90% of motor threshold to either the right or the left MTL in comparison to sham condition.
3142690|NCT01599195||adults|adults audiodoc use to evaluate for carotid or femoral bruit
3142691|NCT01599182||High-Risk Prostate Cancer|
3142692|NCT01599182||Intermediate-Risk Prostate Cancer|
3142693|NCT01599169|Experimental|B-Back® verum|
3142694|NCT01599169|Placebo Comparator|B-Back® placebo|
3142695|NCT01599156|Experimental|Reflexology|reflexology treatment, x2-3/week for 12 weeks
3142696|NCT01599143|Experimental|Mindfulness-based Stress Reduction group|All eligible participants attend a 3-hour weekly session, for 8 consecutive weeks, to learn meditation and simple Hatha Yoga techniques, and incorporate them into their daily lives.
3142697|NCT01599130|Active Comparator|entecavir|patients continue to use entecavir
3142698|NCT01599130|Experimental|peg-interferon|patients switch to sequential peg-interferon α-2a
3142699|NCT01599117|Placebo Comparator|Placebo arm|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
3142700|NCT01599117|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
3142701|NCT01599104|Experimental|LCZ696 200 mg|LCZ696 200 mg tablet and placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) tablet once daily for 8 weeks
3142702|NCT01599104|Experimental|LCZ696 400 mg|LCZ696 200 mg tablet and a placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) once daily for one week; then up-titrated to LCZ696 400 mg and placebo to Olmesartan (1 capsule) once daily for the remaining 7 weeks
3142703|NCT01599104|Active Comparator|Olmesartan 20 mg|Olmesartan 20 mg capsule and placebo to LCZ696 (2 tablets) once daily for 8 weeks
3142704|NCT01599091||Fibroblast's donors|Patients undergoing tooth extraction will be asked permission to use the anyway extracted teeth and gingiva in order to harvest fibroblasts for further basic research.
3142705|NCT01599078|Placebo Comparator|Placebo|
3142706|NCT01599078|Active Comparator|Paclitaxel|
3142707|NCT01599065||Magnet|group treated by disabling ICD during procedure
3142708|NCT01599065||Off-On|Group having ICD turned off during the procedure
3142709|NCT01599052||Brain Tumour Patients|Newly diagnosed brain tumour patients aged between 5 and 13 years
3142710|NCT01599052||Cystic Fibrosis patients|Patients diagnosed with Cystic Fibrosis aged between 5 and 13 years
3142711|NCT01599052||Healthy control group|Healthy children aged between 5 and 13 years
3142712|NCT01599039||breast cancer patients with SN|1. Breast cancer patients with sentinel node biopsy (n=25)
3142713|NCT01599039||breast cancer patients with AD|2. Breast cancer patients with axillary dissection (n=25)
3142714|NCT01599039||colo-rectal patients|3. Colo-rectal patients as control group (n=25)
3142715|NCT01599013|Other|Vinflunine plus Gemcitabine|
3142716|NCT01599013|Other|Vinflunine plus Carboplatin|
3142717|NCT01599000|Active Comparator|Efficacy arm|Supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
3142718|NCT01599000|Experimental|Effectiveness arm|Un-supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
3142719|NCT01598987|Experimental|Everolimus based regimen|"Conversion at Baseline from an immunosuppressive regimen which contains either cyclosporine (CsA) or tacrolimus (TAC) with or without mycophenolic acid (MPA), with or without corticosteroids in a regimen which contains everolimus combined reduced dose of either cyclosporine (CsA) or tacrolimus (TAC).~The dosing schedule was twice daily, 12 hours apart."
3142720|NCT01598974|Experimental|Traditional Acupuncture|Participants will receive acupuncture over 6 30-minute sessions.
3142721|NCT01598974|Experimental|Laser Acupuncture|Participants will receive laser acupuncture over 6 30-minute sessions.
3142722|NCT01598974|No Intervention|Wait-List|Subjects will be put on a 6 week wait-list and receive vouchers for acupuncture at a local clinic.
3142723|NCT01598961|Active Comparator|TOF count-guided group|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
3142724|NCT01598961|Active Comparator|T1/Tc amplitude group|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
3142725|NCT01598961|Experimental|No neuromuscular blockade group|to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
3142726|NCT01598948|Experimental|Mipomersen|Patients randomized to this arm will receive mipomersen 200 mg weekly
3142727|NCT01598948|No Intervention|Control|patients randomized to this arm will receive no additional drug
3142728|NCT01598935|Placebo Comparator|Control|placebo
3142729|NCT01598935|Active Comparator|High protein intake|Nutrition - High protein
3142730|NCT01598935|Active Comparator|Low protein intake|Nutrition - Low protein
3142731|NCT01598935|Active Comparator|Medium protein intake|Nutrition - Medium protein
3142732|NCT01598922|Experimental|Internet Cognitive Behavioral Therapy|Participants with major depressive disorder receive an 8-week long internet-based cognitive behavioral therapy program.
3142733|NCT01598922|No Intervention|Monitored Attention Control|Participants with major depressive disorder receive no treatment but are monitored closely for 8 weeks. Participants in this arm are offered the treatment at the end of the study.
3142734|NCT01598922|No Intervention|Control|Participants in this arm are healthy, non-psychiatric individuals who receive no treatment.
3142735|NCT01598909|Active Comparator|Arnica ointment|
3142736|NCT01598909|Placebo Comparator|Placebo ointment|
3142737|NCT01598909|No Intervention|Control|
3142738|NCT01598896|Experimental|Dronabinol + Clonidine|Dronabinol titrated to 5 mg three times daily, Clonidine 0.1 mg twice daily
3142739|NCT01598896|Placebo Comparator|Placebo|Placebo
3142740|NCT01598883|Other|ACT after initial heparin bolus less than 450|If a patients activated clotting time (ACT) is less than 450 after the bolus dose of heparin (350U/kg) they will be randomized to one of two interventions.
3142741|NCT01598883|Active Comparator|ACT after first intervention less than 450|
3142742|NCT01598870||Patients with cirrhosis and ascites|Patients requiring diagnostic and/or therapeutic paracentesis.
3142743|NCT01598857|Experimental|Blisibimod|
3142744|NCT01598857|Placebo Comparator|Placebo|
3142745|NCT01598844||High risk patients with aortic stenosis|
3142746|NCT01598844||High risk patients with AI|
3142747|NCT01598831|Active Comparator|ART-123|
3142748|NCT01598831|Placebo Comparator|Placebo|
3142749|NCT01598818||Visual acuity|Comparison of best visual acuity and refraction using the First Sight Refractive System with autorefraction in subjects with refractive error.
3142750|NCT01598805|Experimental|roll out of eAlerts|Roll out of eAlerts providing evidence-based guidelines on prophylaxis against venous thromboembolism. An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
3142751|NCT01598766|Experimental|Diagnostic Coil|This coil is a lightweight, flexible coil which can be used for many pediatric MRI exams
3142752|NCT01598753|Active Comparator|Tramadol|
3142753|NCT01598753|Placebo Comparator|Placebo|
3142754|NCT01598753|Active Comparator|Cognitive Behavior Therapy for FM|
3142755|NCT01598753|Sham Comparator|Health Education|
3142756|NCT01598740|Experimental|CLP with spironolactone|
3142757|NCT01598740|Experimental|CLP without spironolactone|
3142758|NCT01598727|Experimental|Fluobeam(TM) Imaging System (Fluoptics)|Single arm observational pilot study
3142759|NCT01598714|Other|Darco shoe|Darco walking shoe provided
3142760|NCT01598714|Other|Podalux Shoe|Podalus shoe
3142761|NCT01598714|Other|Standard dressing shoe|Standard dressing shoe
3142762|NCT01598701|Experimental|Intravenous Acetaminophen|Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
3142763|NCT01598701|Placebo Comparator|Placebo|Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
3142764|NCT01598688|Active Comparator|Blood collection immediately after interrupting the drug|Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.
3142765|NCT01598688|Experimental|Blood collection five minutes after interrupting the drug|Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.
3142766|NCT01598675|Active Comparator|Control|Symmetric Gait. Dual-belted treadmill belts moving at the same belt speeds during training
3142767|NCT01598675|Experimental|Gait Asymmetry|Error Augmentation. Belts of a dual-belted treadmill may move at different belt speeds to amplify spatiotemporal gait asymmetry during training
3142768|NCT01598675|Experimental|Gait Symmetry|Error Minimization. Belts of a dual-belted treadmill may move at different belt speeds to encourage spatiotemporal gait symmetry during training
3142769|NCT01598662|Active Comparator|1: IUD insertion 6 Weeks after delivery|"Device:Levonorgestrel-releasing intrauterine device marketed as Mirena.~Subjects randomized to interval placement will have their IUD placed in the office at six weeks postpartum or later. They must return for one visit within a month for a string check."
3142770|NCT01598662|Experimental|2: Immediate Post-placental insertion|"Device: Levonorgestrel-releasing intrauterine device marketed as Mirena~Subjects randomized to immediate post-placental placement within 10 minutes of delivery will have an IUD placed manually under sterile technique and with ultrasound guidance. An ultrasound will be performed within two days postpartum to verify proper placement and again at approximately six weeks postpartum."
3142771|NCT01598649|Experimental|Lupin protein|Lupin protein isolate (cultivar: Lupinus angustifolius Boregine; incorporated in study products) and placebo capsules with mannitol
3142772|NCT01598649|Active Comparator|Milk protein|Milk Protein Isolate (75% sodium caseinate (EM7; DMV international) and 25% whey protein (Megglosat HP; Meggle), incorporated in study products) and Placebo capsules
3142773|NCT01598649|Active Comparator|Milk protein and arginine|Milk Protein Isoalte (75% sodium caseinate (EM7; DMV international) and 25% whey protein (Megglosat HP; Meggle), incorporated in study products) and 1,6 g Arginin in four caspules per day
3142774|NCT01598636|Experimental|Lateral Tibial Tunnel technique|
3142775|NCT01598623|Experimental|Oxytocin+ Non Specific Counselling|
3142776|NCT01598623|Experimental|Oxytocin + Social Skills training|
3142777|NCT01598623|Placebo Comparator|Placebo + Non Specific Counselling|
3142778|NCT01598623|Experimental|Placebo + Social Skills Training|
3142779|NCT01598610|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.
3142780|NCT01598597||Cohort|
3142781|NCT01598584|Placebo Comparator|placebo plus gemcitabine|we design placebo plus gemcitabine as control arm
3142782|NCT01598584|Experimental|Mirtazapine plus gemcitabine|We design Mirtazapine plus gemcitabine as experimental arm
3142783|NCT01598571|Experimental|Fostamatinib 50 mg tablet|
3142784|NCT01598571|Experimental|Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose|
3142785|NCT01598558|Experimental|64Cu-DOTA|Subjects will be injected with less than 14 mCi of 64Cu-DOTA-Rituximab. This is a slow infusion, done over 20 minutes.
3142786|NCT01598545|Experimental|Hydromorphone|Laboring patients having a cesarean section will receive ED50 of hydromorphone one time intrathecally
3142787|NCT01598532|Experimental|Transcranial LED Treatment|All study subjects received treatment during 6-Week period (3x per week) for a total of 18 Transcranial LED Treatments using the MedX Health Phototherapy (light). Each session was 30 minutes in duration.
3142788|NCT01598519|Experimental|study group|1500 students are randomized to receive a universal suicide intervention apart from usual school psychology classes. Furthermore, high risk of suicidal students screened in study group will receive an indicated suicide intervention in addition to usual school psychology classes.
3142789|NCT01598519|No Intervention|control group|1500 students are randomized to receive usual school psychology classes. High risk of suicidal students screened in control group will receive usual psychology classes.
3142790|NCT01598506|Experimental|Hydromorphone|Laboring patients receive ED50 of hydromorphone one time intrathecally
3142791|NCT01598493|Active Comparator|Control|Flamazine is applied on the wound in the control group instead and then covered with sterile gauze
3142792|NCT01598493|Experimental|BCT Antimicrobial Dressing|The wound in the experimental group is first cleansed with normal saline and then applied with BCT Antimicrobial Dressing and covered by sterile gauze, and dressings will be changed every 3 days.
3142793|NCT01598480|Active Comparator|Control|Flamazine is applied on the wound in the control group instead and then covered with sterile gauze.
3142794|NCT01598480|Experimental|BCT Antimicrobial Dressing|The wound in the experimental group is first cleansed with normal saline and then applied with BCT Antimicrobial Dressing and covered by sterile gauze, and dressings will be changed every 3 days.
3142795|NCT01598467|Other|Women with pelvic organ prolapse|Women with pelvic organ prolapse (simplified POP-Q > stage 1)
3142796|NCT01598454|Experimental|Racotumomab|
3142797|NCT01598441|Experimental|iloprost|Iloprost nebuliser solution 500 ng/kg inhaled
3142798|NCT01598441|Placebo Comparator|distilled water|aerosolized distilled water 1-2 ml
3142799|NCT01598428|Other|cataract|
3142800|NCT01598415|Experimental|SAR113945|TDU11685 selected dose
3142801|NCT01598415|Placebo Comparator|Placebo|
3142802|NCT01598402|No Intervention|No prophylactic treatment|When a lower airway infection is suspected cultures will be taken and a chest radiography will be made; after that the standard care will be given (in most patients admission to hospital and start of intravenous antibiotics).
3142803|NCT01598402|Experimental|prophylactic treatment|Administration of prophylactic amoxicillin/clavulanic acid suspension, 625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT. If a lower airway infection is suspected cultures will be taken and a chest radiography will be made; after that the standard care will be given (in most patients admission to hospital and start of intravenous antibiotics)
3142804|NCT01598389|Experimental|Low energy-dense preload|
3142805|NCT01598389|Experimental|High energy-dense preload|
3142806|NCT01598389|Experimental|No preload|
3142807|NCT01598376|Active Comparator|5/0 gauge vicryl suture|Patients randomly assigned to 5/0 gauge test everting suture
3142808|NCT01598376|Active Comparator|7/0 gauge vicryl suture|Patients randomly assigned to 7/0 gauge test everting suture
3142809|NCT01598363|Experimental|Digoxin 0.5mg, Bardoxolone Methyl 20mg and 60mg|
3142810|NCT01598363|Experimental|Rosuvastatin 20mg, Bardoxolone Methyl 20mg and 60mg|
3142811|NCT01598350|Experimental|Orthotic|Orthotic Use
3142812|NCT01598337|Active Comparator|Aspirin alone|
3142813|NCT01598337|Experimental|Tirofoban|Patient assigned to this arm will receive tirofiban infusion starting approximately six hours post bypass surgery once hemomstasis established and no evidence of bleeding
3142814|NCT01598337|Experimental|Clopidogrel|Patients receive oral clopidogrel 75 mg 6-8 hours before coronary bypass surgery and continue daily mentenance dose as per instruction by investigators
3142815|NCT01598337|Experimental|Prasugrel|Patients started on prasugrel 6 hours post surgery 10 mg then continue on daily 10mg as per instruction by investigators
3142816|NCT01598324||escitalopram responders no augmentation|Participants who show a clinical response following 8 weeks on an SSRI will have a final magnetic resonance scan at the end of 8 weeks and will complete the study at that time.
3142817|NCT01598324||Ziprasidone augmentation|Participants who do not respond to escitalopram and are randomized to ziprasidone augmentation will have a final magnetic resonance scan following 8 weeks on ziprasidone.
3142818|NCT01598324||Placebo augmentation|Participants who do not respond to escitalopram and are randomized to placebo augmentation will have a final magnetic resonance scan following 8 weeks on placebo.
3142819|NCT01598311|Experimental|CB-183,315|Participants took CB-183,315 250 mg twice daily (b.i.d.) and placebo capsules b.i.d. by mouth for 10 days.
3143344|NCT01594619|Experimental|A|Single dose naloxegol 25mg
3142820|NCT01598311|Active Comparator|Vancomycin|Participants took vancomycin 125 mg four times daily (q.i.d.) by mouth for 10 days.
3142821|NCT01598298|Experimental|Arm I|Patients receive duloxetine hydrochloride orally (PO) once daily (QD) on days 1-7, twice daily (BID) on days 8-84, and then QD on days 85-91.
3142822|NCT01598298|Placebo Comparator|Arm II|Patients receive placebo PO QD on days 1-7, BID on days 8-84, and then QD on days 85-91.
3142823|NCT01598272|Experimental|Vitality product AM + Vitality product PM|"Dietary Supplement:~Proprietary blend of ginseng, cordyceps, and pomegranate + proprietary blend of broccoli seed, red orange, and grape seed taken twice a day for 8 weeks."
3142824|NCT01598272|Placebo Comparator|Placebo|Dietary Supplement: Placebo Placebo taken twice a day for 8 weeks
3142825|NCT01598259|Experimental|melatonin|Subjects will receive melatonin
3142826|NCT01598259|Placebo Comparator|placebo|
3142827|NCT01598246||Extubation Success|Patients who do not require re-intubation, upto 72 hours after a planned extubation in the pediatric intensive care unit.
3142828|NCT01598246||Extubation failure|Patients who required re-intubation within 72 hours after a planned extubation in pediatric intensive care unit. To be further classified as early <12 hour and late 12-72 hour, extubation failures.
3142829|NCT01598233|Experimental|Intragastric balloon|Patients submitted to six-month intragastric balloon
3142830|NCT01598220|Experimental|Computer-assisted cognitive remediation therapy|
3142831|NCT01598220|Placebo Comparator|attentional task|
3142832|NCT01598207|Experimental|Marinol|
3142833|NCT01598207|Placebo Comparator|Placebo|
3142834|NCT01598194|Experimental|Novel 22-gauge Core Biopsy Needle Standard Biopsy Needle|The 22-gauge core biopsy needle with reverse bevel design (EchoTip® Procore™) will be compared prospectively to the standard straight hollow-core 22-gauge or 25-gauge FNA needle already used in our clinical practice for the diagnosis of solid pancreatic lesions.
3142835|NCT01598181|Experimental|active tDCS|
3142836|NCT01598181|Sham Comparator|sham tDCS|tDCS fades out after 20 sec. administered double blind by coded program.
3142837|NCT01598168|Experimental|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
3142838|NCT01598155|Experimental|Supragingival biofilm control|
3142839|NCT01598155|Experimental|Supra- and subgingival biofilm control|
3142840|NCT01598142|Other|experienced assistant group|experienced endoscopist with an experienced assistant.
3142841|NCT01598142|Other|new trained assistant group|same experienced endoscopist with a new trained assistant
3142842|NCT01598129|Experimental|CGTG-102|CGTG-102 dose escalation
3142843|NCT01598116||Hemangioma|Identify biomarkers in children with hemangiomas.
3142844|NCT01598116||Without Hemangioma|Age-matched controlled group without hemangioma.
3142845|NCT01598103|Placebo Comparator|Placebo to SAF312|
3142846|NCT01598103|Experimental|SAF312|
3142847|NCT01598090|Experimental|Part A: Peginterferon Lambda-1a + RBV + TVR|
3142848|NCT01598090|Experimental|Part B (Arm 1): Peginterferon Lambda-1a + RBV + TVR|
3142849|NCT01598090|Experimental|Part B (Arm 2): Peginterferon Lambda-2a + RBV + TVR|
3142850|NCT01598077|Experimental|Dose escalation and dose expansion|
3142851|NCT01598064|Experimental|GK#10|GK#10 1 pk tid for 8 weeks
3142852|NCT01598064|Placebo Comparator|Placebo|Placebo 1 pack tid for 8 weeks
3142853|NCT01598051||Group 1|Patients treated with Xarelto under practical manner for SPAF.
3142854|NCT01598038|No Intervention|Afinitor|"The recommended dose of Afinitor is 10 mg everolimus once daily, at fixed hour.Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.~In case of frail patients, treatment could be initiated at a lower daily-dose (5mg/d for example) and then increase if tolerance is acceptable."
3142855|NCT01598025|Experimental|REGIMEN 1|"REGIMEN 1: Patients undergo hyperfractionated TBI TID for a total of 11-12 doses on days -10 to -7 and receive thiotepa IV over 4 hours QD on days -6 and -5, fludarabine phosphate IV over 30 minutes QD on days -6 to -2, and anti-thymocyte globulin IV on days -4 to -2.~TRANSPLANTATION: Patients undergo CD34-selected allogeneic PBSCT on day 0."
3142856|NCT01598025|Experimental|Regimen 2|"To be given to patients non-malignant, life-threatening diseases and patients with hematologic malignancies, with extensive prior therapy and comorbidities who are unable to receive TBI, consists of Melphalan 70mg/m2 IV x 2 days, thiotepa 5mg/kg IV x 2 days (or 10mg/kg x 1 day), and fludarabine 25 mg/m2 IV x 5 days.~TRANSPLANTATION: Patients undergo CD34-selected allogeneic PBSCT on day 0."
3142857|NCT01598012|Experimental|Ayurved Siriraj Prasaplai|
3142858|NCT01598012|Placebo Comparator|placebo|
3142859|NCT01597999|Other|No treatment|Accuracy of magnetic resonance imaging (MRI) in predicting aggressiveness of early breast cancer according to molecular subtypes identified by ER PR and HER-2 status ( Additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features )
3142860|NCT01597986|Experimental|Isavuconazole and oral contraceptive|Arm description(as needed): Subjects receive single dose of oral contraceptive consisting of ethinyl estradiol and norethindrone on Days 1 and 13 and oral doses of isavuconazole every 8 hours on Days 9 and 10 followed by a once a day dose in the mornings on Days 11 through 16.
3142861|NCT01597973|Active Comparator|colistin and meropenem|
3142862|NCT01597973|Active Comparator|colistin and placebo|
3142863|NCT01597960|Active Comparator|Yoga 12 week programme|Usual care (standard cardiac rehabilitation programme) plus yoga intervention.
3142864|NCT01597960|No Intervention|Usual care|Usual care (standard cardiac rehabilitation programme) only.
3142865|NCT01597947|Experimental|Arm A|
3142866|NCT01597947|Placebo Comparator|Arm B|
3142867|NCT01597934|Active Comparator|Group A:|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
3142868|NCT01597934|Experimental|Group B|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
3142869|NCT01597921||Breast cancer patient receiving RT|Total dose:2Gy/Fx
3142870|NCT01597908|Experimental|Dabrafenib plus Trametinib|BRAF inhibitor plus MEK inhibitor
3142871|NCT01597908|Active Comparator|Vemurafenib|BRAF inhibitor
3142872|NCT01597895|Active Comparator|Maraviroc|
3142875|NCT01597882||Case managed patients|Patients aged 65 years and over receiving community case management.
3142876|NCT01597856|Experimental|SBIRT|"The SBIRT-VA manual codifies basic substance abuse screening, treatment, Motivational Interviewing and referral procedures. It is designed for providers with minimal substance abuse expertise and is easy for experienced substance abuse providers to deliver.~Study sessions include identifying the Veterans' values through a card sort, the change ruler, on which the Veteran rates his/her willingness to change current behavior, listing the pros and cons of changing."
3142877|NCT01597856|No Intervention|No additional treatment|Veterans assigned to the control condition will not receive any study-related therapy. A Veteran who completes a Compensation examination ordinarily has no further treatment, referral, or debriefing as part of the Compensation examination.
3142878|NCT01597843|Experimental|First educational intervention group|Group that receives intervention first. The intervention is a series of training sessions, in person and on line, to educate post superusers who will in turn educate post members on the utility and mechanics of use of MHV.
3142879|NCT01597843|Experimental|Second intervention group|This arm receives a series of training sessions over study months 6-9. The training sessions are in person and on line and are directed at post superusers who will in turn educate post members on the utility and mechanics of use of MHV. They complete survey rounds 1 and 2 before the training and survey round 3 after the training.
3142880|NCT01597843|No Intervention|Education after data collection complete|This group received a similar intervention, but after all quantitative data collection complete.
3142881|NCT01597830|Experimental|active shoe|
3142882|NCT01597830|Sham Comparator|Control|
3142883|NCT01597817|Active Comparator|chitosan coated textile|Chitosan coated cotton long sleeved t-shirts and pants.
3142884|NCT01597817|Placebo Comparator|chitosan free cotton textile|Chitosan free cotton long sleeved t-shirts and pants.
3142885|NCT01597804|Experimental|"Supportive care (Bathing Bundle)"|"Patients undergo preoperative preparation with the Bathing Bundle comprising CHG 4% skin prep solution and disposable wash cloths to bathe or shower with the night before and morning of surgery."
3142886|NCT01597791|Placebo Comparator|Foley catheter|Control group will have a Foley catheter placed after the CSE is performed as is the usual practice at this institution.
3142887|NCT01597791|Experimental|No Foley Catheter|Spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
3142888|NCT01597778|Experimental|Haploidentical Bone Marrow Transplant|Participants will receive haploidentical bone marrow transplant using a reduced intensity conditioning regimen.
3142889|NCT01597778|Experimental|Double Umbilical Cord Blood Transplant|Participants will receive a double umbilical cord blood transplant using a reduced intensity conditioning regimen.
3142890|NCT01597765|Experimental|Curcuminoids|The administrate curcuminoids is intervention for 30 patients
3142891|NCT01597765|Experimental|Vitamin E|The vitamin E is intervention for 30 patients
3142892|NCT01597752|Experimental|1|"Blomia tropicalis allergen extract (four concentrations: 5, 0.5, 0.05, 0.005 mg/ml)~Positive control~Negative control"
3142893|NCT01597739|Experimental|JNJ-40346527|
3142894|NCT01597739|Placebo Comparator|Placebo|
3142895|NCT01597726|Active Comparator|Misoprostol|
3142896|NCT01597726|Experimental|Laminaria|
3142897|NCT01597713|Experimental|Part 1, level 1-7 escalating doses|
3142898|NCT01597713|Experimental|Part 2, cross-over|
3142899|NCT01597700|Experimental|Acotral® ezetimibe 10mg|Subjects will be fasted overnight and receive one tablet by mouth in accordance with a randomisation list and venous blood samples will be taken at specified intervals over the ensuing 3 day.
3142900|NCT01597700|Active Comparator|Zetia® ezetimibe 10mg|Subjects will be fasted overnight and receive one tablet by mouth in accordance with a randomisation list and venous blood samples will be taken at specified intervals over the ensuing 3 days.
3142901|NCT01597687|Other|Group A|Adolescents aged 13-18 years and adults aged >18 years with prolonged cough of 2 weeks or more.
3142902|NCT01597661||Malformed and population-based sample of non-malformed infants|Infants with any of a wide range of malformations are identified at tertiary care and birth hospitals in four study centers (Boston, Philadelphia, Toronto, San Diego) using approaches that include reviewing lists of discharge diagnoses available in medical records; contacting newborn nursery and/or labor and delivery rooms; reviewing admission/discharge lists; and reviewing clinic and surgical logs. A population-based random sample of non-malformed newborns in Massachusetts is also included. Information gathered on each subject includes name, address, telephone number, diagnostic information, and date of birth.
3142903|NCT01597648|Experimental|Sequence 1|Treatment A: 1 tablet of GSK2838510 (maraviroc 300 mg, lamivudine 150 mg, and zidovudine 300 mg as a combined formulation) after an overnight fast Washout Treatment B: 1 tablet of maraviroc 300 mg + 1 tablet of Combivir taken concurrently after an overnight fast.
3142904|NCT01597648|Experimental|Sequence 2|"Treatment B: 1 tablet of maraviroc 300 mg + 1 tablet of Combivir taken concurrently after an overnight fast.~Washout Treatment A: 1 tablet of GSK2838510 (maraviroc 300 mg, lamivudine 150 mg, and zidovudine 300 mg as a combined formulation) after an overnight fast"
3142905|NCT01597635|Experimental|Part A|4 increasing doses of GSK2586881 given over 2 days
3142906|NCT01597635|Experimental|Part B|Repeat Medium-High dose of GSK2586881 (or placebo) over 3 days
3142907|NCT01597622|Experimental|Open-label Belimumab|Belimumab 10 mg/kg administered intravenously every 4 weeks. All study subjects will receive standard SLE therapies during the study. Subjects will continue to receive belimumab treatment until such time belimumab becomes commercially available in a subject's country of participation, or the subject elects to participate in another belimumab continuation study for SLE, or until either the subject's physician withdraws the subject from the study, or upon the decision by the sponsor to discontinue further development of belimumab for SLE.
3142908|NCT01597609|Experimental|Cohort A|- 600 Kcal deficit, Sibutramine placebo
3142909|NCT01597609|Experimental|Cohort B|- 600 Kcal deficit, Sibutramine 10 mg once daily
3142910|NCT01597609|Experimental|Cohort C|- 600 Kcal deficit, Moderate exercise (The energy expenditure will be equivalent to 30 minutes of brisk walking/5 times week i.e. ~1,000 Kcal/week) /sibutramine placebo
3142911|NCT01597596|Experimental|Alglucosidase Alfa 4000 L material (Non-US participants)|Alglucosidase alfa 4000 L material for 52 weeks.
3276089|NCT00654459||B|
3142912|NCT01597596|Active Comparator|Alglucosidase Alfa 160 L material (US participants)|Alglucosidase alfa 160 L material for 52 weeks.
3142913|NCT01597583|Experimental|Use of MobileMedMinder|
3142914|NCT01597583|No Intervention|Usual care|
3142915|NCT01597570|Experimental|FASTSEAL® Bioabsorbable VCD|Fastseal® Bioabsorbable Vascular Access Closure System
3142916|NCT01597570|Active Comparator|Perclose® ProGlide SMC System|Perclose® ProGlide Suture-Mediated Closure System
3142917|NCT01597557|Active Comparator|Magnesium Sulfate|Patients in this arm are give magnesium sulfate 2 grams intravenous drip before the cardioversion procedure
3142918|NCT01597557|Placebo Comparator|Placebo|Patients in this arm receive normal saline drip intravenously before the cardioversion procedure
3142919|NCT01597544|No Intervention|CISC instruction post-operatively|For those patients that are randomized to CISC instruction before surgery, instruction will begin on post-operative day one. One of the nurses from the hospital gynecology unit will teach and supervise the patients until they feel comfortable with the technique or until catheterization is no longer required (e.g. when the patient passes her voiding trial on two separate occasions). This is the protocol currently in use at our institution.
3142920|NCT01597544|Active Comparator|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
3142921|NCT01597531|Active Comparator|Liraglutide only|
3142922|NCT01597531|Active Comparator|Orlistat only|
3142923|NCT01597531|Active Comparator|Liraglutide + Orlistat|
3142924|NCT01597518|Placebo Comparator|Placebo|
3142925|NCT01597518|Experimental|Riluzole|
3142926|NCT01597505|Experimental|Surotomycin|250 mg Surotomycin over- encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg; and Placebo over encapsulated tablet administered orally, twice daily for 10 days
3142927|NCT01597505|Active Comparator|Vancomycin|125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
3142928|NCT01597492|Experimental|Belimumab plus Early Vaccination|Belimumab plus Early Vaccination
3142929|NCT01597492|Experimental|Belimumab plus Late Vaccination|Belimumab plus Late Vaccination
3142930|NCT01597479|No Intervention|No dPNBs group|Patients in this group didn't receive any intervention in the postoperative period.
3142931|NCT01597479|Experimental|dPNBs group|"Patients in this group received ultrasound guided dPNBs on radial and median nerves (target nerves of TRA) in the postoperative period, before discharge.~The procedural objective of dPNBs was to place local anesthetic around the target nerves to achieve a long lasting, sensitive and selective block in the surgical area. dPNBs were performed with 5 ml/nerve of levobupivacaine 0,125%.~Ultrasound guidance allowed us to verify the correct distribution of LA around the target nerves target and optimize needle position if it was necessary, always avoiding the intraneural injection."
3142932|NCT01597466|Experimental|Epidrum|Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
3142933|NCT01597466|Active Comparator|Loss of resistance technique|
3142934|NCT01597453|Other|Lifestyle counseling|
3142935|NCT01597440|Experimental|N-Carbamylglutamate|Active NCG & Standard of Care
3142936|NCT01597440|Placebo Comparator|Placebo|Standard of Care therapy
3142937|NCT01597427|Sham Comparator|Clonidine|Administration of 2 μg/kg of intravenous clonidine.
3142938|NCT01597427|Placebo Comparator|Placebo|Injection of placebo solution.
3142939|NCT01597414|Active Comparator|Pertuzumab + trastuzumab (PH)|Pertuzumab + trastuzumab. After progression,patients will be given the option of receiving T-DM1
3142940|NCT01597414|Experimental|PH + metronomic chemotherapy (PHM)|Pertuzumab + trastuzumab + metronomic chemotherapy. After progression,patients will be given the option of receiving T-DM1
3142941|NCT01597401|Experimental|Aes-103 300 mg to 1000 mg (Group A)|Group A will consist of six subjects receiving a single dose of either a low dose of Aes-103 (300 mg) or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second, higher dose of Aes-103 (1,000 mg), and subjects initially randomized to placebo will receive a second dose of placebo without food.
3142942|NCT01597401|Experimental|Aes-103 2000 mg to 4000 mg (Group B)|Group B will consist of six subjects receiving an initial dose of either Aes 103 (2,000 mg) or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second, higher dose of Aes-103 (4,000 mg), and subjects initially randomized to placebo will receive a second dose of placebo without food.
3142943|NCT01597401|Experimental|Top Dose Expansion (Group C)|Once the top dose (i.e., highest tolerated) of Aes-103 has been determined, the size of this group will be expanded with an additional six subjects (Group C) for a total of 12 at that dose, distributed so that six subjects receiving hydroxyurea (HU) and six subjects not receiving HU (for the past 6 months) will receive study drug (five receiving Aes-103 and one receiving placebo in each of the HU and non-HU treated cohorts). This total of 12 subjects includes the initial six subjects who received the highest dose in the study plus six Group C subjects. These subjects will receive a single dose of the top dose of Aes-103 or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second dose of the top dose of Aes-103 and subjects initially randomized to placebo will receive a second dose of placebo; all subjects will be administered a pre-dose, high fat, high protein meal.
3142944|NCT01597388|Experimental|AZD2014 with Fulvestrant|AZD2014 with Fulvestrant
3142980|NCT01597154|Experimental|Lifestyle counselling|Exercise, nutrition and self-efficacy based lifestyle training in a peer mentoring setting
3142981|NCT01597154|No Intervention|Control|Youth randomized to the control group will receive standard care for the first 16 weeks followed by 16 weeks of intervention
3142945|NCT01597375|Experimental|Placebo then Prasugrel|"Subjects with AERD first received placebo oral tablet for 4 weeks prior to their aspirin challenge/desensitization. After aspirin challenge/desensitization subjects were discharged to home to washout the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to the alternate treatment for 4 weeks of Prasugrel oral tablets [ (5 mg (for patients <60kg) or 10mg (> 60kg) daily, following a 60mg loading dose)] and returned for the second aspirin challenge.~Because no period effect was observed, data obtained from all subjects while on placebo from either visit 2 or 3 were combined."
3142946|NCT01597375|Experimental|Prasugrel then Placebo|"Subjects with AERD first received prasugrel oral tablets [ (5 mg (for patients <60kg) or 10mg (> 60kg) daily, following a 60mg loading dose)] prior to their aspirin challenge/desensitization. After aspirin challenge/desensitization subjects were discharged to home to washout the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to the alternate treatment for 4 weeks of Placebo oral tablet.~Because no period effect was observed, data obtained from all subjects while on Prasugrel from either visit 2 or 3 were combined."
3142947|NCT01597362|Other|Veress needle technique|
3142948|NCT01597362|Other|Direct trocar technique|
3142949|NCT01597362|Other|Open technique|
3142950|NCT01597349|Experimental|FP01 High dose|
3142951|NCT01597349|Experimental|FP01 Low dose|
3142952|NCT01597349|Placebo Comparator|Placebo|
3142953|NCT01597336|Active Comparator|Saline only flush of abscess|Saline alone used to flush abscess
3142954|NCT01597336|Experimental|Saline plus tPA flush of abscess|Saline plus tPA used for abscess flush
3142955|NCT01597323||Treatment Group|Healthy Male of Female between ages 35 and 60 with presence of mild to moderate facial photodamage (sun damage) and presence of mild to moderate facial wrinkling
3142956|NCT01597310|Experimental|Warfarin|25 mg Warfarin, Treatment Period 1 & Treatment Period 2
3142957|NCT01597310|Experimental|Dexpramipexole|150 mg BID Treatment Period 2
3142958|NCT01597297|Experimental|Fampridine-PR|Prolonged-Release Fampridine (Fampridine-PR) 10 mg twice daily (every 12 hours) for up to 24 weeks.
3142959|NCT01597297|Placebo Comparator|Placebo|Matched placebo twice daily (every 12 hours) for up to 24 weeks.
3142960|NCT01597258||Crizotinib (Xalkori)|
3142961|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 1|Administered by two 80 mg subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
3142962|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 2|Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
3142963|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 3|Dosing Regimen 3 is not used until Week 12. At Week 12, ixekizumab responders re-randomized to this arm will receive Dosing Regimen 3.
3142964|NCT01597245|Active Comparator|50 mg etanercept|Administered by one 50 mg SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, etanercept responders are assigned to placebo, and nonresponders to Dosing Regimen 2.
3142965|NCT01597245|Placebo Comparator|Placebo for ixekizumab|Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. At Week 12, placebo responders are assigned to placebo, and nonresponders to Dosing Regimen 2. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12 was used to blind etanercept injections for Dosing Regimen 1, Dosing Regimen 2, and Placebo Comparator groups.
3142966|NCT01597232|Experimental|Transfusion trigger based on WCPTS|Determination of whether a patient need red blood cells transfusion or which hemoglobin level should be maintained is based on WCPTS.
3142967|NCT01597232|Active Comparator|Hemoglobin level 10g/dL|The patient's hemoglobin level is maintained more than 10g/dL perioperatively.
3142968|NCT01597232|Active Comparator|Transfusion trigger based on experience|Determination of whether a patient need red blood cell transfusion or which hemoglobin level should be maintained is base on the physician's experience.
3142969|NCT01597219|Experimental|Reduced intensity haploidentical transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 & +4
3142970|NCT01597219|Experimental|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 & -2 Stem cell transplant day 0
3142971|NCT01597206|Experimental|Removable partial denture Group|Patients with a reduced posterior dental arch will be randomized into one of 2 Groups Group A will receive a removable partial denture prosthesis
3142972|NCT01597206|Active Comparator|Reduced Posterior Dental Arch Group|Patients with a reduced posterior dental arch and not receiving any Intervention will be compared to the removable partial denture group
3142973|NCT01597193|Experimental|enzalutamide (80-mg with increase to 160 mg)|enzalutamide be provided as two or four 40-mg capsules by mouth daily
3142974|NCT01597193|Experimental|enzalutamide and anastrozole|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with anastrozole (1 mg) administered as one 1-mg tablet by mouth once daily.
3142975|NCT01597193|Experimental|enzalutamide and exemestane 25 mg|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as one 25-mg tablet daily
3142976|NCT01597193|Experimental|enzalutamide and exemestane 50 mg|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as two 25-mg tablets daily
3142977|NCT01597193|Experimental|enzalutamide and fulvestrant|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with fulvestrant (500 mg) administered as two 250-mg intramuscular injections every 28 days
3142978|NCT01597167|Experimental|Magnesium sulfate crossover|IV infusion of magnesium sulfate followed by 5-day washout period and crossover to 5% dextrose (placebo)
3142979|NCT01597167|Placebo Comparator|Placebo crossover|IV infusion of 5% dextrose with 5 day washout and crossover to magnesium sulfate
3143345|NCT01594619|Active Comparator|B|Diltiazem 240mg once daily day 4-6
3142982|NCT01597141|Experimental|Family-aided Assertive Community Treatment|The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
3142983|NCT01597141|Active Comparator|Enhanced standard treatment|In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention.
3142984|NCT01597128|Active Comparator|Flex HD|Mesh Type
3142985|NCT01597128|Active Comparator|Strattice|Use of a second mesh type
3142986|NCT01597115|Active Comparator|Duplex|Patients in this group will be examed by duplex ultrasonography at 2 and 4 weeks after surgery
3142987|NCT01597115|No Intervention|physical exam|According to the K/DOQI guideline, patients will be examed by vascular access surgeon at 2 and 4 weeks after surgery
3142988|NCT01597102||Liver transplantation|Patients with liver failure and liver transplantation
3142989|NCT01597076|Experimental|60-240 mL/day|60 -240 mL/day dose group
3142990|NCT01597063||low risk pregnancies|
3142991|NCT01597050|Active Comparator|Drug: R932333|R333 6% (60 mg/g), bid
3142992|NCT01597050|Placebo Comparator|Placebo|Placebo, bid
3142993|NCT01597037|Active Comparator|High complexity, high feedback|Scripts are one grade level higher than the typical script that would be provided for the severity of aphasia; there is an opportunity for the participant to listen to his/her production and assess performance.
3142994|NCT01597037|Active Comparator|High complexity, low feedback|Scripts are one grade level higher than the typical script that would be provided for the severity of aphasia; there is no opportunity for the participant to listen to his/her production and assess performance.
3142995|NCT01597037|Active Comparator|Low complexity, high feedback|Scripts are one grade level lower than the typical script that would be provided for the severity of aphasia; there is an opportunity for the participant to listen to his/her production and assess performance.
3142996|NCT01597037|Active Comparator|Low complexity, low feedback|Scripts are one grade level lower than the typical script that would be provided for the severity of aphasia; there is no opportunity for the participant to listen to his/her production and assess performance.
3142997|NCT01597024|Experimental|Phase 1: Breakfast Study|
3142998|NCT01597024|Experimental|Phase 2: fMRI Study|
3142999|NCT01597011||Fibrin sealant group|Patients who have undergone laparoscopic inguinal hernia repair with fibrin sealant for mesh fixation
3143000|NCT01597011||Tissue-penetrating fixation group|Patients who have undergone laparoscopic inguinal hernia repair with the use of tacks, staples or sutures for mesh fixation
3143001|NCT01596998|Active Comparator|Levobupivacaine without epinephrine|
3143002|NCT01596998|Experimental|Levobupivacaine with epinephrine|
3143003|NCT01596985|Experimental|Ablation using the PlasmaJet system|"Origin of cyst invagination is identified after lysis of adhesions between ovary and adjacent broad ligament, leading to characteristic chocolate fluid evacuation. Surgeon then attempts to turn cyst completely inside out via original invagination site of diameter averaging 1 to 2cm. Ablation of cyst's inner surface is performed using the PlasmaJet system in coagulation mode set at 40, at distance averaging 5mm from tip of handpiece, and with exposure time limited to 1 to 2s on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and corresponding peritoneal implants on adjacent broad ligament. When cyst reversion is not feasible, surgeon progressively exposes cyst interior to guide plasma beam at an angle perpendicular to the inner surface."
3143004|NCT01596985|Active Comparator|Cystectomy|"Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C)."
3143005|NCT01596972|Experimental|Serum quantitative urine pregnancy test|uterine evacuation follow-up consisting of an at-home, self-administered SQ-UPT and standardized pregnancy symptom questionnaire in 1 week
3143006|NCT01596972|No Intervention|serum hCG|follow-up consisting of a 1 week return visit and serum hCG plus standardized pregnancy symptom questionnaire
3143007|NCT01596959|Active Comparator|ECI CONTACT-ACTIVE|Irrigated Radiofrequency ablation performed using the ECI contact data
3143008|NCT01596959|Placebo Comparator|ECI CONTACT-INACTIVE|irrigated RF ablation performed to the right atrium without the use of ECI contact data
3143009|NCT01596946|Active Comparator|Contact tracing mode test at clinic|Conventional mode of contact tracing where the partners were asked by either the index patient or demanded by the counsellor to attend a clinic for C. trachomatis testing. The date of testing for chlamydia of the study subject i e a sexual partner to a chlamydia infected index patient was noted. Those partners being C trachomatis positive were referred to the STD-clinic for contact tracing and following the same study arm a the index patient.
3143010|NCT01596946|Experimental|Self-sampling at home|The intervention: Self-sampling of sexual partners to infected index patient for chlamydia by urine test or vaginal sampling at home. They sent the kit tube to a microbiological laboratorium for analysis. The test kit was sent by post by the counsellor at the STD-clinic or distributed via the index patient. The partner in this arm was informed about the test result from the STD-clinic and those tested C trachomatis positive were given an appointment for treating and contact tracing as soon as possible. Their partners were not randomised but following the same mode. The days from the counselling conversation with the index patient to the date of testing was measured and compared with partners tested following arm 1 mode.
3143011|NCT01596933|Experimental|omega-3 fatty acid supplementation|omega-3 fatty acid supplementation (echium oil)
3143012|NCT01596933|Placebo Comparator|standard nutritional support|sunflower oil supplementation
3143013|NCT01596920|Active Comparator|Grafix®|
3143014|NCT01596920|Placebo Comparator|Control (non-adherent dressing)|
3143120|NCT01596179|Experimental|Interactive navigational support|Patients on the intervention arm are provided with a netbook computer and internet access with ongoing interaction with a nurse and a social worker navigators for a one year period.
3143015|NCT01596907|Active Comparator|Ephedrine and caffiene|"Drug treatment:~ephedrine sulfate 25-mg with caffeine 200-mg per capsule to be given three times per day 4 hours apart for 6 months after gastric bypass surgery. Weight loss rate, resting energy expenditure, fat free mass will be measured during the treatment."
3143016|NCT01596907|Placebo Comparator|placebo|one placebo capsule will be taken three times per day 4 hours apart, identical to the instructions for the active drug for approximately 6 months following gastric bypass surgery. Weight loss rate, resting energy expenditure and fat free mass will be measured during the treatment.
3143017|NCT01596894|Experimental|Azithromycin + Metronidazole|Oral Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the last 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
3143018|NCT01596894|Active Comparator|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
3143019|NCT01596881||Multiple Sclerosis Patients|Physician-confirmed diagnosis of multiple sclerosis. Any subtype is acceptable. For example, relapsing-remitting, secondary progressive, primary progressive
3143020|NCT01596881||Healthy Normal Subjects|Volunteers with healthy eyes.
3143021|NCT01596868|Active Comparator|Gemcitabine and Cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT..
3143022|NCT01596868|Active Comparator|docetaxel and cisplatin|Drug: Docetaxel and cisplatin TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
3143023|NCT01596855|Experimental|FG-4592|Active Drug
3143024|NCT01596855|Active Comparator|Epoetin alfa|Standard of care
3143025|NCT01596842|Active Comparator|Omega-3 fatty acid|
3143026|NCT01596842|Placebo Comparator|Olive oil|
3143027|NCT01596829|Active Comparator|Probiotic|Probiotic consumption during and after course of antibiotic
3143028|NCT01596829|Placebo Comparator|Placebo|Placebo consumed during and after course of antibiotic
3143029|NCT01596816|Experimental|Boost by CyberKnife|
3143030|NCT01596816|Experimental|Boost by linear accelerator|
3143031|NCT01596803|Active Comparator|vitamins minerals|VitE 400/d, vitC 500mg/d, Se 200µg/d (selenomethionine), Zn 25 mg/d gluconate Venous blood samples( analysis oxidative stress inflammatory markers) Needle biopsy of the vastus lateralis muscle (analysis oxidative stress inflammatory markers)
3143032|NCT01596803|Placebo Comparator|Placebo|Supplementation 17 weeks placebo venous blood samples (analysis of oxidative stress inflammatory markers) needle biopsy of the vastus lateralis muscle
3143033|NCT01596790|Other|CTC assay|Detection & characterization of viable CTC in the peripheral blood.
3143034|NCT01596777|Placebo Comparator|Treatment A|Administration of LOP placebo (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX placebo (0 h). To asses the oro-cecal and whole-gut transit time under placebo condition.
3143035|NCT01596777|Placebo Comparator|Treatment B|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX placebo (0 h). To asses the oro-cecal and whole-gut transit time under loperamide-induced obstipation condition.
3143036|NCT01596777|Active Comparator|Treatment C|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX 12 mg sc. (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after subcutaneous administration.
3143037|NCT01596777|Active Comparator|Treatment D|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX IR (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after oral administration of immediate release capsule.
3143038|NCT01596777|Active Comparator|Treatment E|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX ER (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after oral administration of extended release capsule.
3143039|NCT01596764|Placebo Comparator|Treatment A|Administration of LOP Placebo (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), Placebo (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To assess WGT, OCT and CTT under placebo condition.
3143040|NCT01596764|Placebo Comparator|Treatment B|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), Placebo (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To assess WGT, OCT and CTT under loperamide-induced obstipation condition.
3143041|NCT01596764|Active Comparator|Treatment C|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), NLX-ER (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To describe the effects of repeated-dose naloxone in preventing loperamide-induced delay of WGT, OCT and CTT and measure pharmacokinetics of naloxone.
3143042|NCT01596764|Active Comparator|Treatment D|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), MNTX-ER (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To describe the effects of repeated-dose methylnaltrexone in preventing loperamide-induced delay of WGT, OCT and CTT and measure pharmacokinetics of methylnaltrexone.
3143043|NCT01596751|Experimental|Eribulin in combination with PLX3397|"Phase Ib:~21 day treatment cycle: PLX3397 100-200 mg gelcaps, po daily & Eribulin 1.4 mg/m2 IV day 1 and 8~Cohort 1: 600 mg/day~Cohort 2: 800 mg/day~Cohort 3: 1000 mg/day~Phase II:~Lead in period of 5-7 d with PLX3397 at MTD po qd (day -7/5 to day 0)~21 day cycles; Day 1:~Add eribulin 1.4 mg/m2 IV day 1 and 8~Continue PLX3397 at MTD po qd"
3143044|NCT01596738|Experimental|Tranexamic Acid group|"Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction~Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization"
3143121|NCT01596179|Active Comparator|control arm|Patients on the control arm are provided with a netbook computer, internet access and general website information but no interactive navigational support for a one year period.
3143045|NCT01596738|Placebo Comparator|Placebo group|"Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction~Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization"
3143046|NCT01596725|Experimental|Group A|
3143047|NCT01596725|Experimental|Group B|
3143048|NCT01596725|Experimental|Group C|
3143049|NCT01596725|Experimental|Group D|
3143050|NCT01596725|Experimental|Group E|
3143051|NCT01596725|Experimental|Group F|
3143052|NCT01596712|Experimental|QGE031 Dose 1|QGE031 Dose 1: subcutaneous injection, single dose
3143053|NCT01596712|Experimental|QGE031 Dose 2|QGE031 Dose 2: subcutaneous injection, single dose
3143054|NCT01596712|Experimental|QGE031 Dose 3|QGE031 Dose 3: subcutaneous injection, single dose
3143055|NCT01596712|Placebo Comparator|Placebo|Placebo to QGE031 : subcutaneous injection, single dose
3143056|NCT01596699|Experimental|Patients with Myeloid Malignancies|
3143057|NCT01596699|Experimental|Patients with Non-Malignancies|
3143058|NCT01596686|Active Comparator|sodium picosulphate and magnesium citrate (Picoprep)|
3143059|NCT01596686|Active Comparator|polyethylene glycol (Fortrans)|
3143060|NCT01596673|Experimental|BCAD Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet)."
3143061|NCT01596673|Experimental|CDBA Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet (matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet."
3143062|NCT01596673|Experimental|DACB Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet."
3143063|NCT01596673|Experimental|ABDC Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet."
3143064|NCT01596660|Experimental|Bupivacaina|20 cc of bupivacaine 0.5% in 20 cc de saline solution and it is infiltrated 20 cc each side.
3143065|NCT01596660|Placebo Comparator|saline solution|20 cc of saline solution 0.9% to infiltrate each side.
3143066|NCT01596647|Experimental|TKI258 (dovitinib)|dovitinib, 5 days on / 2 days off dose schedule
3143067|NCT01596634|Experimental|Supportive care (bovine lactoferrin)|Patients receive bovine lactoferrin PO (rinse or tablet) TID for 1 month. Treatment continues in the absence of unacceptable toxicity.
3143068|NCT01596621|Experimental|Bendamustine hydrochloride|This is a single-arm study, in which all subjects enrolled are administered the study drug.
3143069|NCT01596608|Experimental|Magnetic Seizure Therapy|
3143070|NCT01596595||Medically Indicated for ICD or CRT-D|Medically Indicated for ICD or CRT-D implantation per guidelines
3143071|NCT01596582|No Intervention|Standard Care|Subjects randomized to the control arm will review the web-based decision aid (http://www.colorectalcancerscreening4u.com) just prior to a scheduled visit with their provider.
3143072|NCT01596582|Experimental|Risk Assessment|Subjects randomized to the experimental arm will complete the ACNI risk assessment tool after reviewing the web-based decision aid (http://www.colorectalcancerscreening4u.com) just prior to a scheduled office visit with their provider.
3143073|NCT01596569|Active Comparator|Active TMS and Cognitive Intervention|"Active TMS and Cognitive Intervention:~Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory)."
3143074|NCT01596569|Sham Comparator|Sham TMS and Cognitive Intervention:|"Sham TMS and Cognitive Intervention:~Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory)."
3143075|NCT01596556|Experimental|smokers|This arm consists of smokers.
3143076|NCT01596556|Active Comparator|non-smokers|non-smoking participants in the study
3143077|NCT01596543|Experimental|sleep deprivation|The research contains only one arm. The subjects will be tested with no sleep deprivation (which will be used as a control measurement) and with partial and complete sleep deprivation.
3143078|NCT01596530|Active Comparator|AZD8931|AZD8931
3143079|NCT01596530|Placebo Comparator|Placebo|Placebo
3143122|NCT01596166|Experimental|Metoclopramide, Ketorolac|"10 mL/kg IV 0.9% sodium chloride~Metoclopramide 0.2 mg/kg (max 10 mg) IV~Ketorolac 0.5 mg/kg (max 30 mg) IV"
3143080|NCT01596517|Experimental|Korean CHC|Two CHC patient groups. One is CHC patients who are treated with combination of peginterferon alfa-2a and ribavirin in a prospective, multicenter, industry-sponsored, open-label, uncontrolled, community-based clinical trial (Pegasys Expanded Access Program) conducted at 6 tertiary referral centers in Korea between 2003 and 2004. Another is a cohort of hepatitis C patients who were treated in a single tertiary referral hospital (Asan Medical Center, Seoul, Korea) between 2004 and 2008.
3143081|NCT01596504|Experimental|Lixisenatide 20 μg|Subcutaneous injection of lixisenatide10 μg once daily (QD) for 2 weeks followed by 20 μg QD for 6 weeks under fasted conditions, on top of insulin glargine with or without metformin.
3143082|NCT01596504|Active Comparator|Liraglutide 1.2 mg|Subcutaneous injection of liraglutide 0.6 mg QD for 1 week followed by 1.2 mg QD for 7 weeks under fasted conditions, on top of insulin glargine with or without metformin.
3143083|NCT01596504|Active Comparator|Liraglutide 1.8 mg|Subcutaneous injection of liraglutide 0.6 mg QD for 1 week followed by 1.2 mg QD for another 1 week and 1.8 mg QD for next 6 weeks under fasted conditions, on top of insulin glargine with or without metformin.
3143084|NCT01596491||patients with peripheral nerve injury|10 patients with neuropathic pain, because of peripheral nerve injury will obtain a baseline-QST and after capsaicin-application a QST 2, 4, 6, 8 and every 2 weeks until re-occurrence of pain and/or recovery of the capsaicin-induced sensory deficits
3143085|NCT01596491||patients with postherpetic neuralgia|10 patients with neuropathic pain, because of postherpetic neuralgia will obtain a baseline-QST and after capsaicin-application a QST 2, 4, 6, 8 and every 2 weeks until re-occurrence of pain and/or recovery of the capsaicin-induced sensory deficits
3143086|NCT01596478|Active Comparator|Treatment As Usual|The standard treatment usually provided at the clinic.
3143087|NCT01596478|Active Comparator|Cognitive Motivational Behavior Therapy|An approach that addresses motivation to change gambling and behavioral patterns related to gambling.
3143088|NCT01596478|Active Comparator|12-week wait list|Participant will start treatment 12 weeks from day of consent.
3143089|NCT01596465|Active Comparator|Control|Control arm
3143090|NCT01596465|Active Comparator|Intervention|Intervention arm
3143091|NCT01596426|Experimental|Sancuso Arm|patch
3143092|NCT01596426|Active Comparator|IV granisetron|IV
3143093|NCT01596413|Experimental|Sancuso Arm|patch
3143094|NCT01596413|Active Comparator|IV Granisetron|IV
3143095|NCT01596400|Experimental|Sancuso Arm|
3143096|NCT01596400|Active Comparator|IV Granisetron Arm|IV
3143097|NCT01596387|Experimental|Propofol|20 obese patients(IMC>35 kg m-2) scheduled for laparoscopic bariatric surgery.
3143098|NCT01596348||RA patients|Patients with Rheumatoid Arthritis
3143099|NCT01596335|Experimental|TA-650|
3143100|NCT01596335|Active Comparator|VGIH|
3143101|NCT01596322||UARTO|
3143102|NCT01596309|Placebo Comparator|control group, placebo|This period will consist on a structured personalised hypocaloric diet containing ready prepared meals without extract added
3143103|NCT01596309|Experimental|Intervention group, cocoa extract|This period will consist on a structured personalised hypocaloric diet containing ready prepared meals with cocoa extract added. Final cocoa extract daily intake will be of 1.4 g.
3143104|NCT01596296|Active Comparator|Transcervical foley catheter|
3143105|NCT01596296|Active Comparator|Dinoprostone|
3143106|NCT01596283|Active Comparator|Standard fluid management|Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
3143107|NCT01596283|Active Comparator|Goal directed fluid therapy|Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
3143108|NCT01596270|Experimental|Once daily dosing|escalating doses, once daily dosing every day, no eating for 2 hours prior and 1 hour after dose
3143109|NCT01596270|Experimental|Twice daily dosing|escalating doses, twice daily dosing every day, no eating for 2 hours prior and 1 hour after dose
3143110|NCT01596257|Active Comparator|bulk SCT|Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on day 0. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months
3143111|NCT01596257|Experimental|fractionated SCT|Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on days 0, 2, 4, and 6. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months
3143112|NCT01596244|Experimental|Microclinics training|Diabetic, pre-diabetic, or those with family members who are diabetic/pre-diabetic who participated in a 4 month long intervention with a focus on disease management, health behavior change, and social network supports in order to improve chronic disease risk factors.
3143113|NCT01596231|Placebo Comparator|Placebo|This is a study designed to test whether a single administration of kudzu extract (2 mg) or placebo will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session when given as a pretreatment 2 ½ hours before the drinking session.
3143114|NCT01596231|Active Comparator|Kudzu|Kudzu 2mg
3143115|NCT01596218|Experimental|Treatment Arm|Treatment Arm for all participants - Brentuximab vedotin
3143116|NCT01596205|Experimental|Robot intervention|Participants were given baseline assessments and randomly assigned into 3 groups; 24 with robot assisted cognitive training group (Robot intervention group), 24 with experienced behavioral therapist group (Conventional intervention group), and 37 without cognitive training (Control group).It was explained that there was a waiting list, therefore, participants in control group had an opportunity to participate in cognitive training program after a delay of 12 weeks for the intervention.
3143117|NCT01596205|Active Comparator|Conventional intervention|conventional cognitive training group - pen and pencil with experienced behavioral therapists
3143118|NCT01596205|No Intervention|Control group|
3143119|NCT01596192||Patients with acute GVHD|Patients after allogeneic hematopoietic cell transplantation who have developed acute GVHD
3143171|NCT01595854|Experimental|Reference 2 (part 3)|low dose dabigatran
3143123|NCT01596166|Placebo Comparator|Metoclopramide, Placebo|"10 mL/kg IV 0.9% sodium chloride~Metoclopramide 0.2 mg/kg (max 10 mg) IV~Placebo (normal saline)"
3143124|NCT01596153|Placebo Comparator|Placebo|BID
3143125|NCT01596153|Active Comparator|Go Live Rx Probiotic|BID
3143126|NCT01596140|Experimental|Vemurafenib + Oral Everolimus|Vemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Oral Everolimus starting dose 5 mg daily.
3143127|NCT01596140|Experimental|Vemurafenib + Intravenous Temsirolimus|Vemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Intravenous Temsirolimus starting dose 15 mg daily on Days 1, 8, 15, and 22 of each cycle.
3143128|NCT01596127|Experimental|Intrathecal Rituximab|"Phase I Starting Dose: Rituximab administered via lumbar puncture at dose of 10 - 25 mg twice weekly according to the dose escalation.~Phase II Rituximab Starting Dose: Maximum tolerated dose from Phase I."
3143129|NCT01596114|No Intervention|Stop treatment|TKI treatment will be stopped in CML patients with very deep molecular responses for at least one year and at least 3 years TKI treatment
3143130|NCT01596101||acute burns|
3143131|NCT01596101||rehab patients|
3143132|NCT01596088|Experimental|Drug: Dexrazoxane|"Dexrazoxane should be given once daily for 3 consecutive days. The dose is:~Day 1: 1000 mg/m2, Day 2: 1000 mg/m2, Day 3: 500 mg/m2 (body surface area)"
3143133|NCT01596075|Experimental|Oral Cannabidiol|Patients undergoing allogeneic SCT will receive standard GVHD prophylaxis consisting of a calcineurin inhibitor and methotrexate or mycophenolate mofetil. Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade>2). Cannabidiol will be given up to 90 days.
3143134|NCT01596062|Active Comparator|Simulect 40mg + Neoral + Myfortic + steroids|A cumulative dose of 40 mg of Simulect® (20mg at Day 0 (D0) and 20mg at Day 4 (D4)+ Neoral® + Myfortic® + corticosteroids
3143135|NCT01596062|Experimental|Simulect 80mg + Neoral + Myfortic + steroids|A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Neoral® + Myfortic® + corticosteroids
3143136|NCT01596062|Experimental|Simulect 80mg + Certican + Myfortic + steroids|A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Certican® + Myfortic® + corticosteroids
3143137|NCT01596049||Self-fixating Mesh|patients attributed to that arm, undergoing surgery of open inguinal unilateral hernia repair, using Self-fixating Mesh which is acceptable in the literature.
3143138|NCT01596036|Experimental|Early Appointment|Patients will receive an early appointment (within 10 days) from the time of their anticipated hospital discharge
3143139|NCT01596036|Placebo Comparator|Standard Referral|Patients will receive an appointment to cardiac rehabilitation at 5 weeks from the date of their anticipated hospital discharge. A routine referral to cardiac rehabilitation will also occur in parallel. Consequently, it is possible that some patients will attend cardiac rehabilitation earlier than their assigned 5 week appointment.
3143140|NCT01596023|Experimental|NIOV Ventilator|Breathe NIOV Ventilator under various volume augmentation settings
3143141|NCT01596010|Experimental|New formulation|
3143142|NCT01596010|Active Comparator|Old formulation|
3143143|NCT01595997|Placebo Comparator|Placebo|
3143144|NCT01595997|Experimental|DLX105|
3143145|NCT01595984|Active Comparator|Cyclosporin + Mycophenolate mofetil|
3143146|NCT01595984|Experimental|Everolimus + mycophenolate mofetil|
3143147|NCT01595971|Experimental|continuing education|RESPIRANET is a multifaceted intervention directed at professionals of the Family Health Teams in the inner cities.Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
3143148|NCT01595971|Placebo Comparator|Usual Care|usual care
3143149|NCT01595958|Experimental|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
3143150|NCT01595958|Active Comparator|Control|usual care of cardiac arrest
3143151|NCT01595945|Other|Gastric bypass|Subjects with planned gastric bypass surgery are followed-up in regard of resting metabolic rate.
3143152|NCT01595945|Other|Caloric restriction|Caloric restriction calculated by an online weight management program (based on subject's starting weight, start BMI, age, target weight and time span). Subjects are followed-up in regard to resting metabolic rate.
3143153|NCT01595932|Placebo Comparator|placebo|
3143154|NCT01595932|Experimental|α-galactosidase|
3143155|NCT01595919|Experimental|1% Milk|
3143156|NCT01595919|Experimental|Regular Cola|
3143157|NCT01595919|Experimental|Diet cola|
3143158|NCT01595919|Experimental|Orange juice|
3143159|NCT01595919|Placebo Comparator|Water|
3143160|NCT01595906|Experimental|The experiment subjects|"The subjects will undergo:~6 acclimatization days carried out by a standard protocol including a daily 2 hour effort performed in a climatic chamber, during which the subjects walk on a treadmill at 5km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% RH). Core (rectal) and skin temperatures and heart rate will be monitored continuously.~Three consecutive days including 3 scenarios:~Without a helmet b.With a helmet c.With a ventilated helmet During the experiment days the subjects will be exposed to the following protocol : A 5 minute sitting, performing cognitive tests on a computer for 15 min, 120 min walking on a treadmill at 5km/h on a 2% incline, at the end of the effort the same cognitive tests will be repeated for extra 15 min, 155 min in total."
3143161|NCT01595893|Experimental|Vitamin D3|
3143162|NCT01595893|Placebo Comparator|Placebo|
3143163|NCT01595880|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg
3143164|NCT01595880|Experimental|C|Combination of gemigliptin50mg/metformin HCl extended release 500mg
3143165|NCT01595867|Placebo Comparator|Treatment A|Placebo
3143166|NCT01595867|Experimental|Treatment B|EMBEDA 30 mg crushed
3143167|NCT01595867|Active Comparator|Treatment C|Morphine Sulfate Controlled Release 30 mg crushed
3143168|NCT01595854|Experimental|Test 2 (part 3)|low dose dabigatran + high dose ticagrelor
3143169|NCT01595854|Active Comparator|Test 1 (part 1 + 2)|high dose ticagrelor
3143170|NCT01595854|Experimental|Reference 1 (part 1 + 2)|medium dose dabigatran
3277815|NCT00642512|Placebo Comparator|4|
3143172|NCT01595841|Experimental|Sirolimus|Participants will take sirolimus for 3 days prior to procedure and 30 days post procedure.
3143173|NCT01595841|No Intervention|Not taking Sirolimus|Participants will not change the standard of care.
3143174|NCT01595828|Experimental|Pitavastatin 4mg daily|4 mg tablets of pitavastatin by oral route for a period of 6 months
3143175|NCT01595815|Active Comparator|Conventional ICSI|The couple showed complete fertilization failure after ICSI.
3143176|NCT01595815|Active Comparator|Convention ICSI|The couple showed a low fertilization rates after ICSI.
3143177|NCT01595802|Experimental|Subjects without Vasospasm|Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. Intervention with Nautilus NeuroWave recording to obtain baseline status.
3143178|NCT01595802|Experimental|Subjects with Vasospasm|"Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. If confirmed by TCD, the degree of vasospasm will also be evaluated and classified as mild, moderate and severe Vasospasm.~Intervention with Nautilus NeuroWave recording to obtain recordings with mild, moderate and severe Vasospasm."
3143179|NCT01595789|Placebo Comparator|Placebo + metformin|
3143180|NCT01595789|Active Comparator|Liraglutide + metformin|
3143181|NCT01595776|Experimental|single arm: autologous EPCs|
3143182|NCT01595763||Deep Vein Thromobosis signs or symptoms|
3143183|NCT01595750|Placebo Comparator|Placebo|
3143184|NCT01595750|Active Comparator|Roflumilast|Roflumilast 500 mcg
3143185|NCT01595737|Experimental|Levosimendan|
3143186|NCT01595737|Placebo Comparator|Placebo|
3143187|NCT01595724||Group 1|
3143188|NCT01595711||Thoracotomized patients|
3143189|NCT01595698|Sham Comparator|Control|
3143190|NCT01595698|Experimental|Physical Exercise|
3143191|NCT01595685|Experimental|Telbivudine|Telbivudine 600 mg Daily Oral
3143192|NCT01595685|Active Comparator|Entecavir|Entecavir 0.5 mg Daily Oral
3143193|NCT01595672|Active Comparator|EHVCVVH group|Patients receive conventional treatments recommended by guidelines with adjunctive early high-volume continuous veno-venous hemofiltration (EHVCVVH).
3143194|NCT01595672|Active Comparator|Control group|Patients receive conventional treatments recommended by guidelines only.
3143195|NCT01595659|Placebo Comparator|no alcohol and passenger|Blood alcohol concentration (BAC) = 0.00% and risk accepting or averse passenger
3143196|NCT01595659|Experimental|low alcohol dose and passenger|BAC = 0.02% and risk accepting or averse passenger
3143197|NCT01595659|Experimental|moderate alcohol dose and passenger|BAC = 0.05% and risk accepting or averse passenger
3143198|NCT01595646|Placebo Comparator|Saline|Saline placebo taken twice per day via intranasal route.
3143199|NCT01595646|Experimental|Insulin Detemir|20IU of Insulin Detemir taken twice per day (40IU total per day) via intranasal route
3143200|NCT01595646|Experimental|Insulin|20IU Insulin, administered twice per day (40IU total per day) via intranasal route
3143201|NCT01595633|Active Comparator|Adefovir, nucleoside analogues|Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg) + Adefovir 10mg
3143202|NCT01595633|Experimental|Tenofovir, nucleoside analogues|Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg) + Tenofovir 300mg
3143203|NCT01595620|Active Comparator|THC 0.01 mg/kg|
3143204|NCT01595620|Placebo Comparator|Placebo|
3143205|NCT01595620|Active Comparator|THC 0.03 mg/kg|
3143206|NCT01595607|Active Comparator|Typical American Diet|Participants will receive a typical American diet for 6 weeks.
3143207|NCT01595607|Experimental|Avocado Diet|Participants will receive a modified typical American diet in which avocado is substituted for foods that contain moderate and high amounts of saturated fat to allow the inclusion of avocado.
3143208|NCT01595594|Active Comparator|Systemic Doxycycline|
3143209|NCT01595594|Experimental|aPDT+ Placebo|
3143210|NCT01595581|Experimental|Testosterone, standard-of-care rehabilitation|
3143211|NCT01595581|Placebo Comparator|Standard-of-care rehabilitation, Saline|
3143212|NCT01595568|Experimental|Learning to cope with your impulsivity|Cognitive-behavioural intervention targeting impulsive personality
3143213|NCT01595568|Experimental|Learning to cope with your sensation seeking|Cognitive behavioural intervention designed to help sensation seeking youth manage their need for stimulation and excitement.
3143214|NCT01595568|Experimental|Learning to cope with your anxiety sensitivity|Cognitive behavioural intervention teaching anxiety sensitive youth to manager their sensitivity to threat and anxiety.
3143215|NCT01595568|Experimental|Learning to manage your negative thinking|Cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
3143216|NCT01595555|No Intervention|Wait-list control|Group with no intervention. Only complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
3143217|NCT01595555|Experimental|Stress Free Now|Participate in the 8 week online stress management program Stress Free Now. Complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
3143218|NCT01595555|Experimental|Stress Free Now + Social Media|Participate in the 8-week Stress Free Now program and a discussion board that provides peer and moderator support. Complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
3143219|NCT01595542|Experimental|Intervention|Parents served by experimental school sites received intervention packets including modified vaccine consent form
3143220|NCT01595542|No Intervention|Control|Did not receive intervention materials
3143221|NCT01595529|Experimental|Active treatment|5 days of active therapy to match the physician-initiated therapy, Trimethoprim sulfamethoxazole, Cefixime or Cefdinir or Cephalexin (subjects originally receiving Cefdinir will receive Cefixime)
3143222|NCT01595529|Placebo Comparator|Placebo treatment|5 days of placebo treatment to match physician-initiated therapy
3143223|NCT01595516|Active Comparator|Nebivolol|
3143224|NCT01595516|Active Comparator|Metoprolol|
3143225|NCT01595516|Placebo Comparator|Placebo|
3143226|NCT01595503|Experimental|fMRI-based targeting|
3143227|NCT01595503|Active Comparator|landmark-based targeting|
3143228|NCT01595490|Experimental|Mind-Body Skills Groups|
3143229|NCT01595490|No Intervention|Control Group|
3143234|NCT01595451|Active Comparator|Traditional Acupuncture|Acupuncture will be delivered to 12 points traditionally used to treat chronic low back pain.
3143235|NCT01595451|Placebo Comparator|Non-traditional Acupuncture|You will receive non-traditional acupuncture at 12 points for chronic low back pain.
3143236|NCT01595438|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
3143237|NCT01595438|Active Comparator|Doripenem|IV treatment
3143238|NCT01595425|Experimental|D961H Sachet 20 mg|2 way crossover
3143239|NCT01595425|Experimental|D961HHPMC Capsule 20 mg|2 way crossover
3143240|NCT01595412|Active Comparator|Cohort 2|Cohort 2 (two) will consist of 120 patients with an external rectal prolapse (Oxford Grade V)treated by Laparoscopic Resection Rectopexy (LRR). These patients will be included in the US centers involved in this study and treated by LRR.
3143241|NCT01595412|Active Comparator|Cohort 1|Cohort one will consist of 120 patients with an external rectal prolapse (Oxford Grade V) which will be treated with Laparoscopic Ventral Rectopexy. As this is the standard treatment in the European centers involved in this study these patients will be selected in the participating centers in the Netherlands, Belgium and England.
3143242|NCT01595399|Active Comparator|Atropine, fentanyl and succinylcholine|20 mcg/kg atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.
3143243|NCT01595399|Placebo Comparator|placebo, fentanyl and succinylcholine|an equivalent volume of normal saline to atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.
3143244|NCT01595386|Placebo Comparator|Normal Saline|The subjects will receive a bolus after successful completion of bypass and the post-pump adrenal corticotrophin hormone (ACTH) stim test equal to a 50mg/m2 dose of Hydrocortisone. This will be followed by a continuous infusion comparable to the rates a Hydrocortisone drip would run at. This infusion will be tapered down over the next 120 hours.
3143245|NCT01595386|Experimental|Hydrocortisone|Subjects enrolled in this arm of the study will receive a 50mg/m2 bolus of Hydrocortisone after successful completion of CPB and the post-pump ACTH stim test has been performed. This will be followed by a continuous infusion of Hydrocortisone that will be tapered over the next 120 hours.
3143246|NCT01595373|Active Comparator|Ghrelin|Ghrelin
3143247|NCT01595373|Placebo Comparator|Placebo|Ringer acetate is used for placebo.
3143248|NCT01595360|Placebo Comparator|Placebo|Placebo
3143249|NCT01595360|Experimental|TT-173|TT-173
3143250|NCT01595347|Active Comparator|Hyper-oxigenated fatty acid|Hyper-oxigenated fatty acid,Equisetum arvense, Hypericum perforatum
3143251|NCT01595347|Experimental|Olive oil's Cream|Cream with 60% extra virgin olive oil.
3143252|NCT01595334|Active Comparator|Study subjects desiring pregnancy|"Study subjects to be treated with rFSH, rLH throughout controlled ovarian hyperstimulation (COH) in appropriate dosages,considering age, body mass index (BMI), ovarian reserve, etc. and GnRH antagonist, cetrorelix in 0.25 mg/d when needed till the desired follicular maturity and the minimum required number of follicles are achieved.~INTRVENTIONS - Monitoring at regular intervals by transvaginal ultrasound and hormonal studies.Once pregnancy established by beta-human chorionic gonadotropin (hCG) and ultrasound will be supported by intervention of adequate luteal support by estrogen (E) + progesterone (P) for 12 weeks of gestation."
3143253|NCT01595334|Other|Control subjects desiring pregnancy|"Control subjects selected in randomized way,desiring pregnancy will be treated with gonadotrophins, rFSH and rLH in appropriate dosages considering age, BMI, ovarian reserve, etc. after standard downregulation with GnRH agonist, Leuprolide acetate, 1 mg/d under established `Long Luteal Suppression Protocol` from the previous cycle.~INTERVENTIONS - Monitoring of response to treatment by hormonal study and sonography evaluation at regular intervals during COH till adequate number of mature follicles of minimum 18 mm mean diameter is achieved, to be followed by hCG trigger and ovum pick-up (OPU) and embryo transfer (ET). Chemical pregnancy by beta-hCG would be confirmed 14 days post-ET. Clinical pregnancy would be confirmed by sonography 6 weeks after ET (visibility of yolk sac and fetal heart-beat). Pregnancy support by E+P for 12 weeks would be provided."
3143254|NCT01595321|Experimental|SBRT and FOLFIRINOX|The first 6 patients will receive SBRT and FOLFIRINOX only.
3143255|NCT01595321|Experimental|Cyclophosphamide, Vaccine, SBRT, and FOLFIRINOX|The last 12 patients will receive cyclophosphamide, Vaccine, SBRT, and FOLFIRINOX.
3143256|NCT01595308|Experimental|Pomegranate juice|Pomegranate juice
3143257|NCT01595295||Hypomethylating Agents|Patients treated with hypomethylating agents
3143258|NCT01595282|Experimental|Ketorolac|Intramuscular injection of ketorolac 60 mg in 2cc -plus- placebo tablet (calcium carbonate 600 mg tablet). For subjects who are 50 kg or less, intramuscular injection of ketorolac 30 mg in 1cc -plus- placebo tablet (calcium carbonate 600 mg tablet)
3143259|NCT01595282|Active Comparator|Ibuprofen|Ibuprofen 800 mg tablet -plus- intramuscular injection of 2cc saline placebo. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet -plus- intramuscular injection of 2cc saline placebo
3143260|NCT01595269|Placebo Comparator|Education mode 1 (control)|Education mode 1 (control) is comprised of participants educated using CHR's current traditional face-to-face delivery method, with printed materials and written log journals. These participants will be trained to use the University's web portal if they elect to access internet-based diabetes information. This allows for the tracking of the type and amounts of diabetes information accessed by participants.
3143261|NCT01595269|Active Comparator|Education mode 2 (static interface)|Education mode 2 (static interface) participants will be educated using digitized forms of the traditional materials provided by CHR as well as an electronic log journal (e-journal) where participants will record their diabetes-related outcomes and behavioural information. Education mode 2 will be assessed and approved by CHR.
3143262|NCT01595269|Active Comparator|Education mode 3 (dynamic interface)|Education mode 3 (dynamic interface) participants will be educated using the digitized traditional materials from education mode 2 as well as an enhanced dynamic e-journal (visualization of blood glucose and alerts). In addition, this mode will provide informative disease-related internet sites and diabetes news and articles vetted by the medical team. Participants and health professionals will then be able to electronically discuss the content and quality of this information (discussion board). New sites and articles will be added on an ongoing basis. Participants will also have access to a chat room that will encourage information sharing with other education mode 3 participants and health professionals at CHR. Education mode 3 will be assessed and approved by CHR.
3143263|NCT01595256|Experimental|walking group|
3143264|NCT01595256|No Intervention|usual care|
3143265|NCT01595243|No Intervention|control|patient with liver cancer in non-surgical treatment after discharge receive usual care
3143266|NCT01595243|Experimental|patient in experiment|patient in the experimental group will receive seven instances of telephone follow-up or face to face education
3143267|NCT01595230|Experimental|Inertervention group_Clips to avoid internal herniation|LRYGB with closure of the defects with simple hernia stapler clips. Aim of this study is to evaluate the benefits and disadvantages of closing the mesenteric defects during gastric bypass in order to avoid internal herniation.
3143268|NCT01595230|No Intervention|Control group|conventional LRYGB without closure of the mesenteric defects
3143269|NCT01595217|Experimental|MRCP and DWI using 3T MRI|MRCP and DWI using Magnetic resonance imaging（GE Signa,3.0 T )
3143270|NCT01595217|Experimental|MRCP only using 3T MRI|MRCP only using Magnetic resonance imaging（GE Signa,3.0 T )
3143271|NCT01595204|Experimental|Diagnostic Laparoscopy|Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.
3143272|NCT01595191|Active Comparator|Music by Mozart|"The sequence by which Bach, Mozart, or no music were administered (over 3 consecutive days) was determined by randomization using random numbers. Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel). The music was played using a music player at a volume of 65-70 dB with attached speakers which were placed at a distance of 30 cm from the infant's ears. According to the American Academy of Pediatrics recommendations (5): the volume did not exceed 75dB and the background noise near the infant's ears was maintained below 45 dB. Music (Mozart or Bach) was initiated 10 minutes prior to the beginning of the metabolic measurements and continued for 30 minutes while energy expenditure (EE) was recorded. In the same manner EE was recorded for each infant with no music therapy."
3143273|NCT01595191|Active Comparator|Bach Music|"The sequence by which Bach, Mozart, or no music were administered (over 3 consecutive days) was determined by randomization using random numbers. Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel). The music was played using a music player at a volume of 65-70 dB with attached speakers which were placed at a distance of 30 cm from the infant's ears. According to the American Academy of Pediatrics recommendations (5): the volume did not exceed 75dB and the background noise near the infant's ears was maintained below 45 dB. Music (Mozart or Bach) was initiated 10 minutes prior to the beginning of the metabolic measurements and continued for 30 minutes while energy expenditure (EE) was recorded. In the same manner EE was recorded for each infant with no music therapy."
3143274|NCT01595165|Placebo Comparator|Control|Control group receiving saline instead of ropivacaine
3143275|NCT01595165|Experimental|TAP|TAP group receiving ropivacaine total of 150 mg at TAP under US
3143276|NCT01595152|Active Comparator|solifenacin succinate (10 mg OD)|
3143277|NCT01595152|Active Comparator|fesoterodine (8mg OD)|
3143278|NCT01595139||NF-1 without evidence of glioma|
3143279|NCT01595139||NF-1 with evidence of glioma|
3143280|NCT01595126||Patients with Central Nervous System Tumors|
3143281|NCT01595087|Experimental|Osteodex, infusion|Osteodex
3143282|NCT01595074||Ancillary-Correlative (laboratory biomarkre analysis)|Archived RNA and DNA samples are analyzed for gene expression, mutations, and variations by RT-qPCR, MassARRAY, molecular inversion probe assay, and microarray assays. Results are then compared with patients' clinical outcomes.
3143283|NCT01595061|Experimental|Treatment (IMRT, gemcitabine, cisplatin, surgery)|Patients undergo IMRT 5 days a week for 6 weeks. Patients also receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 60 minutes weekly for 6 weeks in the absence of disease progression or unacceptable toxicity. Within 6-8 weeks after completion of chemoradiation patients undergo local core biopsy to confirm response or surgical excision of gross residual disease in the vulva and/or inguinal-femoral lymph nodes.
3143284|NCT01595035|Experimental|counselling|Patients who receive the Pain booklet and support by telephone
3143285|NCT01595035|No Intervention|Control|Standard care
3143286|NCT01595022|Placebo Comparator|Flexi ring FR01|
3143287|NCT01595022|Placebo Comparator|Flexi ring FR20|
3143288|NCT01595022|Placebo Comparator|Ultra low dose LCS|
3143289|NCT01595009|Experimental|RAD001|
3143290|NCT01594996||Seroquel XR group|
3143291|NCT01594983|Experimental|LCQ908 1|LCQ908 (Diacylglycerol acyltransferase inhibitor)once daily for 12 weeks
3143292|NCT01594983|Experimental|LCQ908 2|LCQ908 once daily for 12 weeks
3143293|NCT01594983|Experimental|LCQ908 3|LCQ908 once daily for 12 weeks
3143294|NCT01594983|Active Comparator|Fenofibrate|Intervention Type: Drug Intervention Name: Fenofibrate
3143295|NCT01594983|Active Comparator|Fish Oil|Fish oil once daily for 12 weeks
3143296|NCT01594983|Placebo Comparator|Arm Label: Placebo|Intervention Type: other Intervention Name: other
3143297|NCT01594970|Experimental|Bimatoprost 0.01% (Naive Monotherapy)|1 drop in the affected eye(s), administered in the evening in previously treatment naive subjects for 12 weeks.
3143298|NCT01594970|Experimental|Bimatoprost 0.01% (Switched Monotherapy)|1 drop in the affected eye(s), administered in the evening in subjects who were previously on another monotherapy treatment for 12 weeks.
3143299|NCT01594970|Experimental|Bimatoprost 0.01% (with Adjunctive Therapy)|1 drop in the affected eye(s), administered in the evening in subjects who are also receiving adjunctive therapy for 12 weeks.
3143300|NCT01594957|Experimental|LCQ908 (mild hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with mild hepatic impairment and will receive a single dose of LCQ908.
3143301|NCT01594957|Experimental|LCQ908 (moderate hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with moderate hepatic impairment and will receive a single dose of LCQ908.
3143302|NCT01594957|Experimental|LCQ908 (severe hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with severe hepatic impairment and will receive a single dose of LCQ908.
3143303|NCT01594931|Experimental|pyronaridine/artesunate (6:2 mg/kg)|pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg
3143304|NCT01594931|Experimental|pyronaridine/artesunate (9:3 mg/kg)|pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg
3277816|NCT00642499|Experimental|1|
3143305|NCT01594931|Experimental|pyronaridine/artesunate (12:4 mg/kg)|pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg
3143306|NCT01594918|Experimental|Cabazitaxel, Mitoxantrone, Prednisone|
3143307|NCT01594905|Experimental|Entecavir 1.0mg + Tenofovir 300mg|All subjects will orally take investigational drugs once daily for 48 weeks.
3143308|NCT01594892|Experimental|A: Long life expectancy|Patients with long life expectancy based on the modified Mizumoto Score (0-4 points) will be treated with 10 fractions of 4.85Gy in involved parts of the vertebra and 3Gy in not-involved parts using a simultaneous integrated boost
3143309|NCT01594892|Experimental|B: intermediate life expectancy|Patients with intermediate life expectancy based on the modified Mizumoto Score (5-9 points) will be treated with 5 fractions of 7Gy in involved parts of the vertebra and 4Gy in not-involved parts using a simultaneous integrated boost
3143310|NCT01594879|Experimental|Endometrial cancer, LNG-IUS with MPA|
3143311|NCT01594866|Placebo Comparator|Escitalopram, 20mg, placebo|escitalopram 20mg + placebo (same taste, appearance, texture of escitalopram 10mg)
3143312|NCT01594866|Experimental|Escitalopram 20mg, escitalopram 10mg|Escitalopram 20mg + Escitalopram 10mg
3143313|NCT01594853|Experimental|exercise|Female carriers as well as healthy age and gender matched individuals will participate in an exercise paradigm.
3143314|NCT01594840|Experimental|Changing chat|Diapers will have tips on them
3143315|NCT01594840|Active Comparator|Control|Normal diapers
3143316|NCT01594827|Experimental|Inhaled Vancomycin and Oral Antibiotics|In the experimental arm CF participants are randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.
3143317|NCT01594827|Active Comparator|Inhaled Placebo (Sterile Water) and Oral Antibiotics|In the active comparator arm CF participants are randomized to 28 days of inhaled sterile placebo (saline) and are treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.
3143318|NCT01594814||RFA of AVNRT of AVRT|
3143319|NCT01594801|No Intervention|Control|Subject continue their routine therapy
3143320|NCT01594801|Experimental|Test|Subjects using the InsuPad device
3143321|NCT01594775|Active Comparator|nasal spray|
3143322|NCT01594775|Placebo Comparator|Placebo|
3143323|NCT01594762|Placebo Comparator|Topical placebo control|Drug: Topical placebo cream
3143324|NCT01594762|Experimental|Topical pexiganan cream 0.8%|Drug: Topical pexiganan cream 0.8%
3143325|NCT01594749|Experimental|Fosaprepitant Regimen|On Day 1, participants received fosaprepitant, 150 mg intravenous (IV) infusion, ~30 minutes prior to chemotherapy PLUS dexamethasone 12 mg, orally (PO) ~30 minutes prior to chemotherapy PLUS ondansetron 16 mg total dose: 8 mg PO ~30-60 minutes prior to chemotherapy, followed by 8 mg PO, 8 hours after first dose PLUS dexamethasone placebo, PO ~30 minutes prior to chemotherapy. On Days 2 and 3, participants received ondansetron placebo, PO every 12 hours. Rescue Therapy: For established cases of nausea or vomiting, medications may have been prescribed from these permitted choices: 5-HT3 antagonists (granisetron, dolasetron, tropisetron or ondansetron); phenothiazines (e.g. prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine); butyrophenones (e.g. haloperidol or droperidol); benzamides (e.g. metoclopramide or alizapride); benzodiazepines; corticosteroids; domperidone.
3143326|NCT01594749|Active Comparator|Control Regimen|On Day 1, participants received fosaprepitant placebo, 150 mL IV infusion, ~30 minutes prior to chemotherapy PLUS dexamethasone 20 mg, PO ~30 minutes prior to chemotherapy PLUS ondansetron 16 mg total dose: 8 mg PO ~30-60 minutes prior to chemotherapy; followed by 8 mg PO, 8 hours after the first dose. On Days 2-3, participants received ondansetron 8 mg, PO every 12 hours. Rescue Therapy: For established cases of nausea or vomiting, medications may have been prescribed from these permitted choices: 5-HT3 antagonists (granisetron, dolasetron, tropisetron or ondansetron); phenothiazines (e.g. prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine); butyrophenones (e.g. haloperidol or droperidol); benzamides (e.g. metoclopramide or alizapride); benzodiazepines; corticosteroids; domperidone.
3143327|NCT01594736|Active Comparator|ORSIRO|
3143328|NCT01594736|Active Comparator|XIENCE PRIME DES|
3143329|NCT01594723|Experimental|120 mg LY2784544|120 milligram (mg) administered orally once daily for 6 cycles (168 days)
3143330|NCT01594710||Apparently Health People|
3143331|NCT01594697|Experimental|metformin|
3143332|NCT01594684|Active Comparator|drug eluting balloon|treatment with drug eltuing balloon
3143333|NCT01594684|Placebo Comparator|uncoated balloon|treatment with uncoated balloon
3143334|NCT01594684|Active Comparator|double drug eluting balloon|if treatment fails 30 days or later
3143335|NCT01594671|Experimental|Tranexamic acid|"Intravenous Tranexamic Acid Two dosage Tranexamic acid during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule Other Name: Amchafibrin"
3143336|NCT01594671|Active Comparator|Habitual haemostasia|The surgical habitual haemostasia.
3143337|NCT01594671|Experimental|Topical Tranexamic acid|Topical Tranexamic acid one dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
3143338|NCT01594658||Foam sclerotherapy|This arm corresponds to ultrasound-guided foam sclerotherapy of superficial venous reflux plus conservative management
3143339|NCT01594658||Conservative|This arm only has medical standard handling (healings performed by the nurse group)
3143340|NCT01594645|Experimental|Spermatozoa election using a polscope|AR+ spermatozoa are selected for ICSI using a polscope
3143341|NCT01594645|Active Comparator|Control|Spermatozoa for ICSI are selected based on morphology and motion under conventional light microscopy
3143342|NCT01594632|Experimental|Jadelle|Contraception using Jadelle implant
3143343|NCT01594632|Active Comparator|Sino-implant (II)|levonorgestrel containing subdermal contraceptive implant [Zarin, Femplant, Trust or Simplant]
3277817|NCT00642499|Placebo Comparator|2|
3143346|NCT01594619|Active Comparator|C|Diltiazem 240mg once daily day 7 and 8. Single dose naloxegol 25mg day 7
3143347|NCT01594606|Experimental|Animal-assisted|This group receives the dog training program in which they will be teaching a dog basic obedience skills.
3143348|NCT01594606|Active Comparator|Dog Walking|This group will walk a different dog each week but will not engage in dog training.
3143349|NCT01594593|Experimental|Acceptance and Commitment Therapy|Group-based behavioral workshop to address cancer-related distress
3143350|NCT01594593|No Intervention|treatment as usual|
3143351|NCT01594580|Experimental|Antimicrobial impregnated scrubs|Those randomized to this arm of the study will wear scrubs impregnated with an antimicrobial.
3143352|NCT01594580|Placebo Comparator|Non-impregnated scrubs|Those randomized to this arm of the study will wear scrubs not impregnated with an antimicrobial.
3143353|NCT01594554||HCV Patients|A sample of 600 Han ethnic Chinese male or female who are ≥ 18 years old enrolled and completed in the study of AI452-009 (i.e., CCgenos cross sectional phase, ClinicalTrials.gov Identifier: NCT01293279).
3143354|NCT01594541||Patients Treated with CerefolinNAC®|
3143355|NCT01594541||Patients Not Treated with CerefolinNAC®|
3143356|NCT01594528|No Intervention|diagnosis|diagnosis according to the DSM-IV-TR : major depression and schizophrenia, or control.
3143357|NCT01594515|Experimental|BI 1015550 low dose A|Powder for oral solution
3143358|NCT01594515|Experimental|BI 1015550 low dose B|Powder for oral solution
3143359|NCT01594515|Experimental|BI 1015550 low dose C|Powder for oral solution
3143360|NCT01594515|Experimental|BI 1015550 low dose D|Powder for oral solution
3143361|NCT01594515|Experimental|BI 1015550 medium dose A|Powder for oral solution
3143362|NCT01594515|Experimental|BI 1015550 medium dose B|Powder for oral solution
3143363|NCT01594515|Experimental|BI 1015550 medium dose C|Powder for oral solution
3143364|NCT01594515|Experimental|BI 1015550 high dose A|Powder for oral solution
3143365|NCT01594515|Experimental|BI 1015550 high dose B|Powder for oral solution
3143366|NCT01594515|Placebo Comparator|Placebo|Solution for oral administration
3143367|NCT01594502||Dutasteride Year 2 PCa|Subject assigned to dutasteride, prostate cancer found on Year 2 biopsy.
3143368|NCT01594502||Placebo Year 2 no PCa, Year 4 PCa|Subject assigned to placebo, no prostate cancer found on Year 2 biopsy, but prostate cancer found on Year 4 biopsy.
3143369|NCT01594502||Dutasteride Year 2 no PCa, Year 4 PCa|Subject assigned to dutasteride, no prostate cancer found on Year 2 biopsy, but prostate cancer found on Year 4 biopsy.
3143370|NCT01594502||Placebo, Year 2 and 4 no PCa|Subject assigned to placebo, no prostate cancer found on Year 2 or Year 4 biopsy.
3143371|NCT01594502||Dutasteride, Year 2 and 4 no PCa|Subject assigned to dutasteride, no prostate cancer found on Year 2 or Year 4 biopsy.
3143372|NCT01594502||Placebo, Year 2 PCa|Subject assigned to placebo, prostate cancer found on Year 2 biopsy.
3143373|NCT01594489|Experimental|Aminophylline|Additional Aminophylline therapy to hydration (sodium bicarbonate) and N-acetilcysteine
3143374|NCT01594489|Active Comparator|Control group|Control group treated with hydration (sodium bicarbonate) and N-acetilcysteine
3143375|NCT01594476|Experimental|Levonorgestrel IUS insertion at 3 weeks|IUD placement at 3 weeks after delivery.
3143376|NCT01594476|Experimental|Levonorgestrel IUS insertion at 6 weeks|IUD placement at 6 weeks after delivery.
3143377|NCT01594463|Experimental|late ultrasound examination|late examination between 34+1 weeks to 35+6 weeks.
3143378|NCT01594463|Experimental|early ultrasound examination|early examination between 30+1 weeks to 31+6 weeks
3143379|NCT01594450|Experimental|biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
3143380|NCT01594450|Active Comparator|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization.
3143381|NCT01594437|Experimental|TCN-202|
3143382|NCT01594437|Placebo Comparator|Placebo|
3143383|NCT01594424|Experimental|IVIG + Tocilizumab|
3143384|NCT01594411||All subjects|Subjects are enrolled at multiple participating primary care practices. The main inclusion criterion for enrollment is the occurrence of chest pain (or anginal equivalent) in a patient without known significant coronary artery disease (CAD) or a history of prior myocardial infarction.
3143385|NCT01594398|Experimental|entinostat C1D1 fed|Entinostat: Beginning C1D1 fed; C1D15 fasted. Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd. Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
3143386|NCT01594398|Experimental|entinostat C1D1 fasted|Entinostat: Beginning C1D1 fasted; C1D15 fed. Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd. Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
3143387|NCT01594385|Other|Seprafilm|The treatment group will receive Seprafilm while the control group will not receive Seprafilm. Allocation of patients will be in 1:1 ratio.
3143388|NCT01594385|No Intervention|No Seprafilm|This group will be treated according to the current standard of care. No seprafilm will be applied in this subset of patients.
3143389|NCT01594372|Active Comparator|Laparoscopic Repair|Laparoscopic supracervical hysterectomy with sacropexy
3143390|NCT01594372|Active Comparator|Vaginal Repair|Vaginal hysterectomy with uterosacral colposuspension
3143391|NCT01594359|Active Comparator|High iron bean|High-iron bean
3143392|NCT01594359|Placebo Comparator|Low iron bean|Low-iron bean
3143393|NCT01594346|Placebo Comparator|Sugar Pill|
3143394|NCT01594346|Active Comparator|Alpha-Tocopherol|
3143395|NCT01594333|Experimental|Methotrexate|
3143396|NCT01594333|Placebo Comparator|Placebo|
3143397|NCT01594320|Experimental|Group A|
3143398|NCT01594320|Experimental|Group B|
3143399|NCT01594320|Experimental|Group C|
3143400|NCT01594320|Experimental|Group D|
3143401|NCT01594320|Experimental|Group E|
3143402|NCT01594320|Experimental|Group F|
3143403|NCT01594307||blood pressure monitor|Cuff circumference:13.5cm-22cm
3143404|NCT01594307||stethoscopy|Cuff circumference: 13.5cm-22cm
3143405|NCT01594294|Experimental|AOSEPT Plus|AOSEPT® Plus contact lens solution used with etafilcon A contact lenses or lotrafilcon B contact lenses for 3 months (Investigational Phase)
3143406|NCT01594294|Active Comparator|ReNu MultiPlus|ReNu MultiPlus® contact lens solution used with etafilcon A contact lenses or lotrafilcon B contact lenses for 3 months (Investigational Phase)
3143407|NCT01594294|Other|Complete MPS Easy Rub|COMPLETE® MPS Easy Rub® Formula contact lens solution used with etafilcon A contact lenses (14 days) or lotrafilcon B contact lenses (30 days), Screening Phase
3143408|NCT01594281|Experimental|Ranibizumab|
3143409|NCT01594281|Active Comparator|Laser photocoagulation|
3143410|NCT01594281|Experimental|Ranibizumab & laser photocoagulation|
3143411|NCT01594268|Other|Kidney transplantation patient|Kidney transplantation patient; single arm
3143412|NCT01594255|Experimental|AEB071 300 mg|
3143413|NCT01594255|Experimental|AEB071 900 mg|
3143414|NCT01594255|Placebo Comparator|Placebo to AEB071|
3143415|NCT01594255|Active Comparator|Moxifloxacin|
3143416|NCT01594229|Experimental|Arm 1|Non-Hodgkin's Lymphoma (NHL)
3143417|NCT01594216|Experimental|First Stage|Ruxolitinib at 25 mg orally, twice daily and Exemestane, 25 mg orally once daily
3143418|NCT01594216|Experimental|Second Stage|Ruxolitinib at 15 mg orally, twice daily and Exemestane, 25 mg orally once daily
3143419|NCT01594203||Advanced Soft Tissue Sarcoma|patients with advanced Soft Tissue Sarcoma
3143420|NCT01594190|Active Comparator|Low Dose Training|15 minutes/day on a weight-bearing treadmill
3143421|NCT01594190|Active Comparator|High Dose Training|2x 30 minutes/day on a weight-bearing treadmill
3143422|NCT01594177|Experimental|Treatment arm|Afatinib-Trastuzumab (6 weeks) followed by Afatinib*-Paclitaxel-Trastuzumab (12 weeks) followed by Epirubicin-Cyclophosphamide-Trastuzumab (12 weeks). *only 11 weeks.
3143423|NCT01594138||Suicidal Subjects|Suicidal Subjects
3143424|NCT01594138||Non-Suicidal Control Subjects|Non-Suicidal Control Subjects
3143425|NCT01594125|Experimental|Group I|patients with mild liver dysfunction according to their AST/ALT values and Child-Pugh score
3143426|NCT01594125|Experimental|Group II|patients with moderate liver dysfunction according to their AST/ALT values and Child-Pugh score
3143427|NCT01594112||Patient with at least one ID|Patient with ICD who received at least one inappropriate diagnosis (with or without therapy) during the 15 months follow-up.
3143428|NCT01594099|Active Comparator|Radiotherapy alone|
3143429|NCT01594099|Experimental|Radiotherapy plus cisplatin|
3143430|NCT01594099|Experimental|Radiotherapy plus liposome paclitaxel|
3143431|NCT01594086|Experimental|green tea powder|Natural green tea powder
3143432|NCT01594060|Active Comparator|sliding scale|
3143433|NCT01594060|Active Comparator|basal bolus|
3143434|NCT01594047|No Intervention|zero/morphine|Patient received a standard balance anaesthesia and morphine for post operative pain.
3143435|NCT01594047|Experimental|ketamine/morphine|patients received a balance anaesthesia supplemented by low dose of ketamine and Morphine by PCA device for postoperative pain
3143436|NCT01594047|Experimental|zero/metadone|patients received a standard balance anaesthesia and methadone by PCA device for postoperative pain
3143437|NCT01594047|Experimental|ketamine/methadone|Patients received a balance anaesthesia supplemented with low dose of ketamine and Methadone by PCA device for postoperative pain
3143438|NCT01594034||no treatment|
3143439|NCT01594021|Experimental|High pre-emptive volume loading|
3143440|NCT01594021|Active Comparator|Low pre-emptive volume loading|
3143441|NCT01593995|Experimental|EGF ointment|
3143442|NCT01593982|Placebo Comparator|Sham rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of Sham (placebo) rTMS delivered to the left dorsolateral prefrontal cortex.
3143443|NCT01593982|Active Comparator|Active rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of Active rTMS delivered to the left dorsolateral prefrontal cortex.
3143444|NCT01593969|Active Comparator|Standard RUTF|Standard RUTF given according to National Guidelines
3143445|NCT01593969|Experimental|RUTF/Flax Oil|RUTF/Flax Oil is reformulated RUTF to increase n3 content
3143446|NCT01593969|Experimental|RUTF/Flax Oil plus additional Fish Oil|RUTF/Flax Oil plus additional Fish Oil is RUTF reformulated to increase n3. Fish oil to provide long chain n3
3143447|NCT01593956|Other|Concussed athletes|
3143448|NCT01593956|Other|Healthy controls|
3143449|NCT01593943|No Intervention|Control Condition|
3143450|NCT01593943|Experimental|CHARM Intervention|CHARM will be conducted via three 30-minute counseling sessions delivered in a rural setting, with the first session being required and the subsequent sessions being optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
3143451|NCT01593930|Experimental|1 Articaine(Infiltration)|Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
3143452|NCT01593930|Experimental|2 Articaine(Infiltration)|Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine
3143453|NCT01593930|Experimental|Lidocaine(IANB)+1Articaine(Infiltration)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
3143454|NCT01593930|Experimental|Lidocaine(IANB)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine
3143455|NCT01593917||Subjects previously implanted with a Trifecta valve|Subjects enrolled in this clinical study received the Trifecta valve during the investigational study that was conducted to obtain FDA approval
3143456|NCT01593878|Experimental|TV|Test taken with TV on
3143457|NCT01593878|No Intervention|Control|test taken in quiet
3143458|NCT01593865||BIMA Grafting Group|Group consists of patients who received bilateral internal mammary artery grafting for treatment of severe coronary disease since June 2012.
3278897|NCT00634712|Placebo Comparator|2|
3143459|NCT01593865||Control Group|This Group consists of historical control patients who received conventional coronary artery bypass grafting (left mammary artery graft only plus great saphenous vein grafts) in the 2010-2012 period, and who are propensity-matched to the BIMA Group patients.
3143460|NCT01593852|Active Comparator|Regular X-ray dose settings|For patients in this group x-ray images are acquired with regular dose settings of the x-ray system and regular image processing
3143461|NCT01593852|Experimental|Reduced X-ray dose settings|For patients in this group x-ray images are acquired with reduced dose settings of the x-ray system and advanced image processing
3143462|NCT01593826|Active Comparator|Charcoal and Symbicort Turbuhaler|
3143463|NCT01593826|Active Comparator|Symbicort Turbuhaler|
3143464|NCT01593826|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
3143465|NCT01593826|Experimental|Budesonide/formoterol Easyhaler|
3143466|NCT01593800|Experimental|open label probiotics|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
3143467|NCT01593787|Experimental|LCZ696 100 mg|All participants were started on LCZ696 100 mg once daily on day 1.
3143468|NCT01593787|Experimental|LCZ696 200 mg|All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP <80 mmHg and msSBP <130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.
3143469|NCT01593787|Experimental|LCZ696 400 mg|All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP <80 mmHg and msSBP <130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.
3143470|NCT01593774|Experimental|Melatonin|Tablet melatonin 3 mg/day at 9 pm as intervention group for eight week
3143471|NCT01593774|Placebo Comparator|Placebo|Placebo (with the same shape and taste as melatonin) at 9 pm as control group
3143472|NCT01593761|Experimental|Single Arm for CG400549|All the patients will be administered with CG400549.
3143473|NCT01593748|Experimental|Group 1|Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal.
3143474|NCT01593748|Active Comparator|Group 2|Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1).
3143475|NCT01593735|Experimental|Panel A: GT1, low dose|Participants with genotype 1 (GT1) Hepatitis C Virus (HCV) will receive low dose MK-2748 daily for 7 days.
3143476|NCT01593735|Experimental|Panel B: GT1, lower dose|Participants with GT1 HCV will receive lower dose MK-2748 daily for 7 days.
3143477|NCT01593735|Experimental|Panel C: GT1, dose based on Panels A+B|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose) and B (lower dose).
3143478|NCT01593735|Experimental|Panel G: GT1, dose based on Panels A+B+C|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose), B (lower dose), and C.
3143479|NCT01593735|Experimental|Panel H: GT1, dose based on Panels A+B+C+G|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose), B (lower dose), C, and G.
3143480|NCT01593735|Experimental|Panel D: GT3, low dose (Omitted)|Participants with genotype 3 (GT3) HCV were to receive low dose MK-2748 daily for 7 days. Panel D was omitted from the study design and participants were not enrolled in this panel.
3143481|NCT01593735|Experimental|Panel E: GT3, high dose|Participants with genotype 3 (GT3) HCV will receive high dose MK-2748 daily for 7 days.
3143482|NCT01593735|Experimental|Panel F: GT3, dose based on Panel E|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panel E (high dose).
3143483|NCT01593735|Experimental|Panel I: GT3, dose based on Panels E+F|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels E (high dose) and F.
3143484|NCT01593735|Experimental|Panel J: GT3, dose based on Panels E+F+I|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels E (high dose), F, and I.
3143485|NCT01593722|Active Comparator|diethylcarbamazine|diethylcarbamazine 8 mg/kg single oral dose
3143486|NCT01593722|Active Comparator|ivermectin|ivermectin 200 mcg/kg single oral dose
3143487|NCT01593696|Experimental|1|Lymphodepleting regimen of Fludarabine and Cyclophosphamide.
3143488|NCT01593696|Experimental|2|Intensive standard of care chemotherapy, in lieu of the lymphodepleting chemotherapy regimen, to decrease tumor burden in preparation for the administration of the CAR T cells.
3143489|NCT01593683|Experimental|Psychological education program|Patients receive the psychological education program upon study enrollment.
3143490|NCT01593683|No Intervention|Waitlist|Participants are assigned to a 16-week wait-list period upon enrollment. Participants are invited to receive the psychological education program following the waitlist period.
3143491|NCT01593670|Experimental|Patients With High Risk MDS|Patients who received treatment for high risk myelodysplastic syndromes (MDS). Treatment Received: Decitabine 10 mg/m^2/day intravenous (IV) over 1 hour days 1-5; Vorinostat 200 mg by mouth (PO) twice a day days 6-15; Il-2 activated donor natural killer cells (NK) infusion IV over 15 to 60 minutes day 17; Interleukin-2 6 million units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17. Repeat treatment course 6 to 8 weeks after cycle 1 start date.
3143597|NCT01592955|Experimental|EYEOP1 device|cyclocoagulation HIFU
3143645|NCT01592526|Experimental|Untrained, healthy volunteers B|(Endotoxin + Nicotine) before (Endotoxin)
3143492|NCT01593657|Experimental|Mindful Movement and Breathing program|Mindful Movement and Breathing program implemented in a hospital room or clinic room three times by a yoga instructor: prior to surgery, one day and two days after surgery.
3143493|NCT01593644|Experimental|adenosine + dypiridamole|
3143494|NCT01593631|Active Comparator|2 billion lyoph. yoghurt bacteria|
3143495|NCT01593631|Active Comparator|3300 FCC acid lactase|
3143496|NCT01593631|Active Comparator|9000 FCC acid lactase|
3143497|NCT01593631|Active Comparator|Combination of Substances of arm 1 and 2|
3143498|NCT01593631|Placebo Comparator|Placebo|
3143499|NCT01593618|Experimental|Web-Based Intervention|UMFollowUp - web-based internet resource for information about their diagnostic histories, recommendations for follow-up care, and tips to enhance their treatment, psychosocial and physical well-being.
3143500|NCT01593618|Active Comparator|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
3143501|NCT01593605|Active Comparator|Dietary Supplement/insulin sensitivity|The first study supplement contains resveratrol that may improve insulin sensitivity and Leucine.Resveratrol 50mg with leucine 1.11 g. - one tablet taken twice a day by mouth
3143502|NCT01593605|Placebo Comparator|Sugar Pill|Neutral treatment Placebo - one tablet taken twice a day by mouth
3143503|NCT01593605|Active Comparator|Dietary Supplement 2|2nd study supplement contains resveratrol and HMB which may stimulate protein building.
3143504|NCT01593592|Experimental|Lactobacillus reuteri group|The active group that will receive the standard triple therapy and Lactobacillus reuteri
3143505|NCT01593592|Placebo Comparator|Control group|The control group that will receive the standard triple therapy and placebo
3143506|NCT01593579||Patients with Melanoma|Patients with Melanoma that are enrolled in a clinical trial at the Vanderbilt Ingram Cancer Center (VICC) including an arm with an oral Akt inhibitor
3143507|NCT01593566|Active Comparator|0.25% bupivacaine|femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine
3143508|NCT01593566|Active Comparator|0.5% bupivacaine|femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine
3143509|NCT01593553|Experimental|ECG screening|Twice daily screening using intermittent ECG recorder (Zenicor) for two weeks
3143510|NCT01593553|No Intervention|Control group|Standard of care
3143511|NCT01593540|Experimental|metal-free interdental brushes.|
3143512|NCT01593540|Active Comparator|metal-core interdental brushes|
3143513|NCT01593527|Experimental|Arm 1|Canakinumab 150 mg s.c.
3143514|NCT01593527|Experimental|Arm 2|Triamcinelone acetonide 40 mg i.m.
3143515|NCT01593514|Active Comparator|Group 1 Conjugate-conjugate|Group I will receive 2 doses of the MenACWY-CRM conjugate vaccine (Novartis Vaccines) given 1 month apart. All vaccine doses are 0.5ml and will be administered intramuscularly into the deltoid.
3143516|NCT01593514|Experimental|Group 2 Polysaccharide-conjugate|"Group II will receive one full dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.~0.5 mL of MenACWY-PS vaccine will be administered subcutaneously and 0.5 mL of the MenACWY-CRM vaccine will be administered intramuscularly into the deltoid."
3143517|NCT01593514|Experimental|Group 3 Polysaccharide (subcutaneously)-conjugate|Group III will receive a full dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine subcutaneously, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.
3143518|NCT01593514|Experimental|Group 4: 1/5th dose Polysaccharide:conjugate|"Group IV will receive one fifth dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.~0.1 mL of MenACWY-PS vaccine will be administered IM and 0.5 mL of the MenACWY-CRM vaccine will be administered intramuscularly into the deltoid."
3143519|NCT01593501|Active Comparator|High dose vitamin D|50,000 IU vitamin D3 every 15 days, with a loading dose of 50,000 IU per day for the first 15 days of an approximate 365-day treatment.
3143520|NCT01593501|Active Comparator|Low dose vitamin D|800 IU vitamin D3 every day of an approximate 365-day treatment.
3143521|NCT01593501|Placebo Comparator|Placebo|A pill that looks like the low/high dose vitamin D pills, but contains no vitamin D. Given to preserve the double-blind nature of the study.
3143522|NCT01593488|Experimental|Intrathecal liposomal cytarabine|
3143523|NCT01593475|Experimental|Induction chemotherapy followed by CCRT|"In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during RT and CRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy.~Radiotherapy~- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively."
3143524|NCT01593462|Experimental|Pediatric Small Bowel Crohn's Disease|MRE (magnetic resonance enterography) performed 4 weeks after SBCD treatment begins, or ends or treatment changes, or at 6 months whichever comes first. One research MRE will be performed and one MRE may or may not be performed as part of your routine care.
3143525|NCT01593449|Active Comparator|American Heart Association|Participants will receive handouts on increasing physical activity derived from the American Heart Association materials on increasing physical activity.
3143526|NCT01593449|Experimental|Dog Walking|The 6-month dog walking intervention involves 5 components to address the individual, interpersonal and community levels of the socio-ecological model: newsletters, pedometers, social networking website, neighborhood dog walks, and invitations to community events.
3143527|NCT01593436|Active Comparator|mindfulness training|mindfulness training for patients with insomnia
3143528|NCT01593436|No Intervention|polysomnography and actigraphy|The intention is to assess the sleep architecture of meditators and non meditators women without menopausal insomnia by polysomnographic , actigraphy, and questionnaires to assess sleep quality and emotional state
3143529|NCT01593423|Experimental|Homestead Food Production plus small pond aquaculture|
3143530|NCT01593423|Active Comparator|plant-based Homestead Food Production|
3143531|NCT01593423|Sham Comparator|Control|
3143598|NCT01592942|Experimental|glue fixation|Optilene™ mesh 60 g/m2 (B. Braun), fixation Histoacryl™ cyanoacrylate glue (price 14+37 euros)
3143532|NCT01593410|Experimental|Lenalidomide and dexamethasone|Cycle 1: 25 mg oral lenalidomide once daily on Days 1-21 every 28 Days and 40 mg oral dexamethasone on Days 8, 15, and 22. Cycle 2 and beyond: 25 oral lenalidomide once daily on Days 1-21 every 28 days and 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22.
3143533|NCT01593397|Experimental|Propofol and Fentanyl administration|Propofol and Fentanyl will be administered to all subjects. All subjects will have blood drawn to determine pharmacokinetic variables. Processed EEG will be used to determine pharmacodynamics. Plasma samples will be used to ascertain adiponectin levels and for DNA sampling for analysis of adiponectin single nucleotide polymorphisms.
3143534|NCT01593371|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
3143535|NCT01593371|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
3143536|NCT01593345|Experimental|Mentor|
3143537|NCT01593345|Active Comparator|Guidebook|
3143538|NCT01593332|Active Comparator|Rituximab|
3143539|NCT01593332|Active Comparator|Methotrexate|
3143540|NCT01593319|Active Comparator|ropivacaine|
3143541|NCT01593319|Placebo Comparator|Natrium chloride|
3143542|NCT01593306|Experimental|cisplatin and paclitaxel with concurrent radiotherapy|weekly cisplatin at 30mg/m2 and paclitaxel at 50mg/m2 are given with concurrent radiotherapy at 2Gy per fraction at 5 fractions per week for 5 weeks followed by either low dose rate (LDR) Intracavitary (I/C) Brachytherapy or supplement Chemoradiotherapy (CRT); if not fit for I/C Brachytherapy
3143543|NCT01593306|Active Comparator|cisplatin with concurrent radiotherapy|weekly cisplatin @ 40mg/m2 is given along with concurrent radiotherapy at 2Gy per fraction with 5 fractions per week for 5 weeks followed by LDR I/C brachytherapy or supplement CRT; if not fit for I/C Brachytherapy
3143544|NCT01593293|Active Comparator|PemCarbo|Pemetrexed/Carboplatin arm
3143545|NCT01593293|Active Comparator|Pem only|Pemetrexed arm
3143546|NCT01593280|Active Comparator|TAP catheter|Indwelling TAP catheter placed at the end of c-section. It will be dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen OnQ C-block pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The catheters will run at 7cc/hr/side for 50 hrs.
3143547|NCT01593280|Active Comparator|intrathecal morphine|0.3 mg of intrathecal morphine
3143548|NCT01593267|Active Comparator|Endovascular|Subjects randomized to endovascular coil embolization will be treated by one of two neurosurgeons expert in such treatment. All endovascular coil embolization treatments will be accomplished using accepted techniques.
3143549|NCT01593267|Active Comparator|Surgical|Subjects randomized to surgical clip occlusion repair will receive treatment from one of two neurosurgeons expert in clip occlusion surgery for ruptured aneurysms.
3143550|NCT01593254|Active Comparator|Arm 1: Imatinib (≥400 mg)|Imatinib ≥400 mg tablets by mouth once daily (QD) or twice daily (BID) up to 60 months
3143551|NCT01593254|Active Comparator|Arm 2: Dasatinib (100 mg)|Dasatinib 100 mg tablet by mouth QD up to 60 months
3143552|NCT01593241|Experimental|Carboplatin|
3143553|NCT01593228|Experimental|1|"Patients receiving iniparib alone or in combination with other anti-cancer agents as defined by the parental study. Interventions:~Drug: Iniparib monotherapy~Drug: Iniparib + gemcitabine + carboplatin~Drug: Iniparib + topotecan~Drug: Iniparib + irinotecan~Drug: Iniparib + paclitaxel~Drug: Iniparib + liposomal doxorubicin + carboplatin"
3143554|NCT01593215|Active Comparator|Placebo first then yohimbine|placebo first, then yohimbine
3143555|NCT01593215|Active Comparator|Yohimbine first then placebo|Yohimbine first then placebo
3143556|NCT01593202|Experimental|Dialectical behavior therapy|Dialectical Behavior Therapy, delivered for 19 weeks, consisted of 1 weekly session of individual therapy (60 minutes), 1 weekly session of multifamily skills training (120 minutes), and family therapy sessions and Telephone coaching with individual therapists outside therapy sessions as needed.
3143557|NCT01593202|Active Comparator|Enhanced usual care|Enhanced usual care was 19 weeks of standard care (enhanced for the purpose of the study by requiring that EUC therapists agree to provide on average no less than 1 weekly treatment session per patient throughout the trial) delivered by therapists (4 psychiatrists, 16 clinical psychologists, 6 clinical social workers, 2 clinical pedagogues, 1 specialist nurse, and 1 psychology graduate student) not trained in or practicing DBT.
3143558|NCT01593189|Experimental|KITS Program|The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
3143559|NCT01593189|No Intervention|Services as usual|Families continued to receive any services that they had been receiving in the community.
3143560|NCT01593176||Distal Femur Fracture, LISS Plate|Patients presenting with a distal femur fracture requiring surgical fixation with a Less Invasive Stabilization System (LISS) plate will have placement of RSA beads for analysis.
3143561|NCT01593163|Experimental|EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
3143562|NCT01593163|Other|ST (standard treatment)|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
3143563|NCT01593150|Experimental|Conventional|Conventional treatment Pradaxa prior to DC cardioversion
3143564|NCT01593150|Experimental|TEE|Transesophageal echo prior to DC cardioversion (early DC)
3143565|NCT01593150|Active Comparator|Early versus Late DC cardioversion|Comparing early versus late DC cardioversion. Patients randomized to either early or late DC cardioversion, follow-up time after intervention 12 month.
3143566|NCT01593137|Experimental|Liraglutide + metformin|
3143567|NCT01593137|Active Comparator|glimepiride + metformin|
3143568|NCT01593124|Active Comparator|Imiquimod, 2 doses, vaginally|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
3143599|NCT01592942|Active Comparator|self-gripping|ProGrip™ mesh 60 g/m2 (Covidien, USA) (price 113 euros)
3279564|NCT00629382|Other|2|
3143569|NCT01593124|Placebo Comparator|Placebo|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
3143570|NCT01593124|Active Comparator|Nonoxynol-9|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
3143571|NCT01593111|Experimental|Environmental Intervention|If randomized to this part of the study the patient will receive an individualized homebased program. In addition to general handouts provided to at Visit 3, subjects in this arm will also receive home-based education by Intervention Counselors about how indoor allergens can affect asthma and the importance of strategies for removing allergens. The goal of the intervention is to provide the patient with the knowledge and skills necessary to remove allergens from their home, and to assist them with those clean up measures. Some of the measures implemented will be specifically based on data we have previously collected from them in the clinic and from their previous home visit, while others will be general to reduce all allergen level.
3143572|NCT01593111|No Intervention|Control Group|If assigned to this group the patient will receive general health/safety related counseling. At the counselor visit following randomization, the patient will receive handouts related to general health and safety issues. They will also have visits by the Home Evaluators for assessment of the home and collection of dust samples identical to those in the treatment group (week 28 and week 44).
3143573|NCT01593098||Exposed siblings|Siblings (age >40 and <70) of individuals diagnosed with advanced neoplasm on screening colonoscopy. Advanced neoplasm is defined as adenomas≥10mm size, >25% villous features, severe dysplasia or carcinoma-in-situ
3143574|NCT01593098||unexposed siblings|Siblings (age >40 and <70) of individuals diagnosed with no polyp on screening colonoscopy who is age and sex matched to case.
3143575|NCT01593085||patients in palliative cares|patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)
3143576|NCT01593072|Active Comparator|AVI-7537|AVI-7537
3143577|NCT01593072|Other|Placebo|Normal Saline Solution (NSS)
3143578|NCT01593059||Orsiro DES|
3143579|NCT01593046|Experimental|Run-in Period|Oral GSK1265744 30mg once daily for 14 days
3143580|NCT01593046|Experimental|Cohort 1|GSK1265744 LAP injection given subcutaneously once a month for 4 months
3143581|NCT01593046|Experimental|Cohort 2|GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.
3143582|NCT01593046|Experimental|Cohort 3|GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.
3143583|NCT01593046|Experimental|Cohort 4|GSK1265744 LAP injection given intramuscularly once every 12 weeks.
3143584|NCT01593033|Experimental|Fish oil and Micronutrient Supplementation|
3143585|NCT01593033|Experimental|Micronutrient Supplementation|
3143586|NCT01593033|Placebo Comparator|Placebo|
3143587|NCT01593020|Experimental|Paclitaxel + FEC or FAC Group|"ARM 1: Participants receive Paclitaxel 80 mg/m2 by vein over 1 hour weekly for 12 doses of a 21 day cycle.~Participants on both arms receive FEC or FAC for 4 cycles (21 day cycle) at the preference of the treating physicians."
3143588|NCT01593020|Experimental|Eribulin + FEC or FAC Group|"ARM 2: Participants receive Eribulin 1.4 mg/m2 by vein over 2-5 minutes on days 1 and 8 every 3 weeks for 4 cycles (21 day cycle).~Participants on both arms receive FEC or FAC for 4 cycles (21 day cycle) at the preference of the treating physicians."
3143589|NCT01593007|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training
3143590|NCT01593007|Placebo Comparator|Control group|Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
3143591|NCT01592994|No Intervention|control|control participants received basic messages on the utility of condoms in protecting from HIV and other STIs, and they were informed about local HIV/STI counseling and testing services.
3143592|NCT01592994|Experimental|RHANI Wives Intervention|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT) and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
3143593|NCT01592981|Experimental|bortezomib, cyclophosphamide, rituximab|"Bortezomib:1.6 mg/m2 s.c; days 1, 8, 15 of each cycle. Cyclophosphamide:250 mg/m2 oral; days 1, 8, 15 of each cycle. Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only.~Cycle repeated every 28 days. After 3 cycles of treatment, patients are reassessed and those with evidence of progression stop trial treatment. All other patients continue with further 3 cycles (to a total of 6) unless a clear clinical contradiction to further treatment exist."
3143594|NCT01592981|Active Comparator|fludarabine, cyclophosphamide, rituximab|"Fludarabine:40 mg/sq m, oral, days 1,2 and 3 of each cycle. Cyclophosphamide:250 mg/sq m; oral, days 1, 2 and 3 of each cycle. Rituximab: 375 mg/sq m i.v. infusion days 1, 8, 15 and 22 of cycles 2 and 5 only.~Cycle repeated every 28 days.After 3 cycles of treatment, patients are reassessed and those with evidence of progression stop trial treatment. All other patients continue with further 3 cycles (to a total of 6) unless a clear clinical contradiction to further treatment exist."
3143595|NCT01592968|Experimental|Stereotactic Radiosurgery (SRS)|Dose based on largest diameter lesion as measured on volumetric MRI, modified as follows: 20-24 Gy for lesions 2 cm or less in size, 16-18 Gy for lesions >2-2.5 cm in size, and 12-16 Gy for lesions >2.5-3.5 cm in size. SRS performed on day 1.
3143596|NCT01592968|Experimental|Whole Brain Radiation Therapy (WBRT)|Fractionated radiation delivered to whole brain daily to deliver a dose of 30 Gy in 10 fractions.
3143600|NCT01592942|Active Comparator|suture fixation|Ultrapro™ mesh 28 g/m2 (Ethicon, USA) (price 45 euros) fixated by non-absorbable sutures
3143601|NCT01592916||Fibromyalgia|Women with fibromyalgia, aged 20-50 years
3143602|NCT01592916||Healthy controls|Women without severe disease, aged 20-50 years
3143603|NCT01592903||Patients with symptomatic uterine fibroids.|Samples of human leiomyomas are obtained from patients undergoing laparoscopic myomectomy for symptomatic uterine fibroids. These leiomyomas are isolated and cultured for stem cells.
3143604|NCT01592890|Experimental|[14C]-labeled RO4917523|
3143605|NCT01592864|Experimental|Arm 1|Dentifrice containing stannous fluoride
3143606|NCT01592864|Active Comparator|Arm 2|Marketed dentifrice containing Sodium Monofluorophosphate
3143607|NCT01592851|Experimental|Arm 1|Dentifrice containing stannous fluoride
3143608|NCT01592851|Active Comparator|Arm 2|Marketed dentifrice containing Sodium Monofluorophosphate
3143609|NCT01592838||Hospitalized Group|Data collection for changes in hospital pattern pre- versus post-rotavirus vaccination, in children ≤15 years old hospitalised for any reason between June 2004 and May 2010.
3143610|NCT01592812|Experimental|electrical stimulation|Evaluation of the effect of calf stimulation on flow and tissue oxygenation
3143611|NCT01592799|Other|Influenza Group|Children <15 years of age hospitalized for or presenting to an ER for acute ARI and/or isolated fever during the influenza season.
3143612|NCT01592786|Experimental|Memantine Hydrochloride (HCl)|Once daily oral administration of open-label memantine for up to 48 weeks: 6-week dose-titration period followed by up to 42-week maintenance period.
3143613|NCT01592773|Experimental|Memantine|"To maintain the blind of the preceding study, patients who participated in MEM-MD-68 (NCT01592747) began this study with 6 weeks of double blind dosing during which all patients were either titrated to or remained on their maximum target dosages. This was followed by up-to 42 weeks of open-label dosing.~Patients who took open-label memantine in study MEM-MD-67 (NCT01999894) or MEM-MD-91(NCT01592786), received up to 48 weeks of open-label memantine at their maximum tolerated weight based target dosage."
3143614|NCT01592760|Experimental|air-Q SP|air-Q Self-Pressurizing Intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mercury Medical, Clearwater, FL, USA)
3143615|NCT01592760|Active Comparator|air-Q|air-Q Intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mercury Medical, Clearwater, FL, USA)
3143616|NCT01592760|Active Comparator|i-gel|i-gel, sizes 3, 4, and 5 (Intersurgical Inc., Liverpool, NY, USA)
3143617|NCT01592747|Experimental|Memantine 1|Patients randomized to the full dose arm will continue taking memantine at the same tolerability and weight based dose achieved in lead-in Study MEM-MD-91
3143618|NCT01592747|Experimental|Memantine 2|Patients randomized to the reduced dose arm will take memantine at the tolerability and weight based dose that they received in lead in Study MEM-MD-91 reduced by at least 50%.
3143619|NCT01592747|Placebo Comparator|Placebo|Patients randomized to the placebo.
3143620|NCT01592734|Experimental|PEG-only|Polyethylene glycol 4000 only (PEG-only).
3143621|NCT01592734|Active Comparator|PEG-EL|Polyethylene glycol 3350 with electrolytes (PEG-EL).
3143622|NCT01592721|Experimental|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
3143623|NCT01592708|Active Comparator|Antiemetic anesthesia protocol|Scopolamine 1.5 milligram(mg) patch Propofol infusion remifentanil infusion 250mg erythromycin po for 2 doses Solumedrol 0.625mg IV droperidol 4mg IV Ondansetron Ketorolac 30mg IV ibuprofen 600mg po q6h Fentanyl Hydrocodone/Tylenol po
3143624|NCT01592695|Experimental|Tailored Intervention Group|Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues associated with cigarette smoking.
3143625|NCT01592695|Active Comparator|Enhanced Standard of Care Group|Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quit line along with pharmacotherapy to assist with smoking cessation.
3143626|NCT01592682|No Intervention|Usual care|Household pairs that are assessment only and receive usual care of local in-language smoking cessation resource referral including quitline.
3143627|NCT01592682|Experimental|Smokefree counseling|Household pairs assigned to smokefree counseling intervention, consisting of group education sessions, tobacco exposure lab report, individual follow-up phone calls.
3143628|NCT01592669|Experimental|passive leg group|bilateral PLR was achieved by raising the patient's legs to a 45 angle.
3143629|NCT01592669|No Intervention|control|supine baseline position
3143630|NCT01592656|Active Comparator|Non-invasive ventilation (NIV)|30 patients will receive NIV during 6 months = group 1
3143631|NCT01592656|Placebo Comparator|Control group|10 patients will act as control group, they will not be treated with NIV = group 2
3143632|NCT01592630|Experimental|Ropivacaine|Subjects with TAP catheters attached to the On-Q pump with 0.2% ropivacaine
3143633|NCT01592630|Placebo Comparator|Saline|Subjects with TAP catheters attached to the On-Q pump with saline
3143634|NCT01592617|Experimental|S-488410|
3143635|NCT01592604|Experimental|Treatment A|Patients receive supportive compressive bandage for 4 weeks
3143636|NCT01592604|Experimental|Treatment B|Below knee walking plaster cast for 4 weeks
3143637|NCT01592578|Active Comparator|Ligation and Cyanoacrylate Group|
3143638|NCT01592578|Experimental|Ligation plus Sclerotherapy and Cyanoacrylate Group|
3143639|NCT01592552||Neurological Condition|Collect blood and other biospecimens like saliva, urine and CSF for research purposes.
3143640|NCT01592552||Control|Collect blood and other biospecimens like saliva, urine and CSF for research purposes.
3143641|NCT01592539||Case|Patients with Type 1 Diabetes Mellitus
3143642|NCT01592539||Control|Age and sex matched healthy controls.
3143643|NCT01592526|Experimental|Untrained, healthy volunteers A|(Endotoxin) before (Endotoxin + Nicotine)
3143644|NCT01592526|Experimental|Well-trained healthy volunteers A|(Endotoxin) before (Endotoxin + Nicotine)
3143646|NCT01592526|Experimental|Well-trained healthy volunteers B|(Endotoxin + Nicotine) before (Endotoxin)
3143647|NCT01592513|No Intervention|Control|
3143648|NCT01592513|Experimental|BIS monitor|"Patients in this group will be monitored by BIS (placement of an electrode over the forehead before sedation).~Patients in this group will receive propofol (boluses of 10-20 mg) to reach a BIS target value of 80-90."
3143649|NCT01592500|Experimental|MOD-4023 low dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
3143650|NCT01592500|Experimental|MOD-4023 middle dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
3143651|NCT01592500|Experimental|MOD-4023 high dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
3143652|NCT01592500|Active Comparator|Genotropin|Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)
3143653|NCT01592487||Lean BMI|BMI in the 25th - 75th percentile
3143654|NCT01592487||Overweight BMI|BMI in the 85th - 95th percentile
3143655|NCT01592448||Usual Care|"Participants will be shown standard (defined as currently commercially available) over-the-counter and prescription medicine bottles and asked questions regarding safety and use. Participants will also be shown additional standard over-the-counter bottles and asked whether these comparison bottles could safely be taken in addition to the primary products shown."
3143656|NCT01592448||Written Orientation|"Participants will be exposed to over-the-counter and prescription bottles enhanced with an icon pertaining to active ingredient and asked questions regarding safety and use. Participants will be exposed to a flier describing the safe use of acetaminophen and orienting the participant towards the icon that is used to indicate the presence of acetaminophen in a product. This flier will be passively hanging within sight of the participant in the room, but no verbal explanation of the flier will be given to the participant. (This is designed to represent a passive education campaign such as posters in drug stores that may be used should these icons be adopted by manufacturers.)"
3143657|NCT01592448||Written + Verbal Orientation|"Participants will be exposed to over-the-counter and prescription bottles enhanced with an icon pertaining to active ingredient and asked questions regarding safety and use. Participants will be exposed to a flier describing the safe use of acetaminophen and orienting the participant towards the icon that is used to indicate the presence of acetaminophen in a product. Research personnel will also verbally go through the flier with the participant and answer any questions in a standardized fashion. (This is designed to represent an active education campaign such as pharmacist counseling that may be used should these icons be adopted by manufacturers.)"
3143658|NCT01592435||Pred. & Invest.-All Study Participants|"Cedera AccuStitch Software is standard of care software currently used at sites.~Carestream DR LLI software is investigational software used for reconstruction."
3143659|NCT01592422|Experimental|Immunotherapy|Subjects receive autologous cytokine-induced killer cell infusion every month
3143660|NCT01592422|Active Comparator|Best Supportive Care|Best Supportive Care
3143661|NCT01592409|Active Comparator|Active cannabis|In this condition, participants will receive a cigarette containing 12.5% active THC.
3143662|NCT01592409|Placebo Comparator|Placebo|In this condition, participants will receive a cannabis cigarette where the active THC has been removed (contains 0% THC).
3143663|NCT01592396|Experimental|Tralokinumab 300 mg|Participants aged 12 to 14 years and 15 to 17 years will receive a single dose of tralokinumab (CAT-354) 300 milligram (mg), subcutaneously on Day 1.
3143664|NCT01592383|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3143665|NCT01592370|Experimental|Nivolumab monotherapy (Dose Escalation)|"Nivolumab solution intravenously as specified~Non-randomized~Enrollment is closed for this cohort"
3143666|NCT01592370|Experimental|Nivolumab + Ipilimumab|"Nivolumab and Ipilimumab solution intravenously as specified~Non-randomized~Enrollment is closed for this cohort"
3143667|NCT01592370|Experimental|Nivolumab + Lirilumab|"Non-randomized~Nivolumab: 3 mg/kg given every 2 weeks Lirilumab: 3 mg/kg given every 4 weeks~Enrollment is closed for this cohort"
3143668|NCT01592370|Experimental|Nivo + Dara + Pom + Dexa vs. Nivo + Dara|"Randomized~Nivolumab:~Cycle 1: 240 mg Day 15 Cycle 2-6: 240 mg Days 1, 15 Cycle 7 & beyond: 480 mg Day 1~Daratumumab:~Cycle 1-2: 16 mg/kg Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg Days 1, 15 Cycle 7 & beyond: 16 mg/kg Day 1~Pomalidomide:~4 mg po (by mouth) daily on Days 1 - 21 of each 28-day cycle~Dexamethasone:~Weeks without daratumumab dosing:~40 mg po daily (Days 1, 8, 15, 22) of each 28-day cycle for participants ≤ 75 years old~20 mg po daily (Days 1, 8, 15, 22) of each 28-day cycle for participants > 75 years old~Weeks with daratumumab dosing:~20 mg iv before the daratumumab infusion and 20 mg po after the daratumumab infusion in participants ≤ 75 years old~16 mg iv before the daratumumab infusion and 4 mg po after the daratumumab infusion in participants > 75 years old~Enrollment is closed for this cohort"
3143669|NCT01592370|Experimental|Daratumumab vs. Nivolumab + Daratumumab|"Randomized~Nivolumab:~Cycle 1: 240 mg Day 15 Cycle 2 & beyond: 480 mg Day 1~Daratumumab:~Cycle 1-2: 16 mg/kg Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg Days 1, 15 Cycle 7 & beyond: 16 mg/kg Day 1"
3143670|NCT01592357|Experimental|Tai Chi|
3143671|NCT01592357|Sham Comparator|Sham Exercise|
3143672|NCT01592344|Experimental|StimRouter - active stimulation|StimRouter- active electrical stimulation is applied transdermally to a targeted peripheral nerve. This is accomplished via a fully implanted StimRouter lead that receives energy from a rechargeable programmed external pulse transmitter (EPT) with attached gel electrodes. The EPT receives radio frequency (RF) commands from a Patient Programmer. A StimRouter Clinician Programmer is used to program the StimRouter EPT and Patient Programmer. Up to eight stimulation programs may be saved on a Patient Programmer for on-demand selection by the study patient.
3143673|NCT01592344|Sham Comparator|StimRouter - Control|StimRouter- Electrical stimulation is withheld from the targeted peripheral nerve after fully implanting the StimRouter lead. The rechargeable programmed external pulse transmitter (EPT) with attached gel electrodes is placed for transdermal stimulation but no stimulation is delivered. The EPT which normally receives radio frequency (RF) commands from a Patient Programmer is not activated. A StimRouter Clinician Programmer is used to program the StimRouter EPT and Patient Programmer such that no stimulation occurs in the Control Arm of the study.
3143674|NCT01592331|Placebo Comparator|Placebo|
3143675|NCT01592331|Experimental|RO5508887|
3143676|NCT01592318|Active Comparator|DNV + r reference|
3279947|NCT00626795|Active Comparator|3|
3143677|NCT01592318|Experimental|DNV/r fixed dose combination|
3143678|NCT01592305|Experimental|S1 P1 TDF + DNV/r|
3143679|NCT01592305|Experimental|S1/S2 P2 DNV/r + ATZ|
3143680|NCT01592305|Experimental|S2 P1 ATZ/r|
3143681|NCT01592292||Rituximab|Participants who have inadequate response or were intolerant to the first anti-tumor necrosis factor (anti-TNF) agent in rheumatoid arthritis (RA), receiving rituximab as per physician's discretion for RA treatment were observed for 12 months.
3143682|NCT01592292||Other anti-TNF agent|Participants who have inadequate response or were intolerant to the first anti-TNF agent in RA, receiving other anti-TNF agent, including adalimumab, etanercept and infliximab, as per physician's discretion for RA treatment were observed for 12 months.
3143683|NCT01592279|Experimental|liraglutide|
3143684|NCT01592279|Active Comparator|Insulin injections|
3143685|NCT01592266||AML|patients with AML prior and after treatment
3143686|NCT01592240|Experimental|Q28d Dosing Arm|A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q28d dose group will receive subcutaneous administration of PF-04950615 or Placebo once a month.
3143687|NCT01592240|Experimental|Q14d Dosing Arm|A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q14d dose group will receive subcutaneous administration of PF-04950615 or Placebo every 2 weeks.
3143688|NCT01592227|Active Comparator|Marketed paracetamol|Marketed paracetamol
3143689|NCT01592227|Experimental|Experimental paracetamol formulation|Experimental formulations
3143690|NCT01592214|Experimental|Part 1 #2-XF-73 in 2% Klucel® gel, concentration 2.0 mg/g|4 subjects: 2.0 mg/g concentrations of a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares twice in a single day in a volume of 0.3 mL/naris/dose and total daily dose of 2.4 mg.
3143691|NCT01592214|Placebo Comparator|Part 2 #4-Placebo in 4% Klucel® gel, concentration 0 mg/g|12 subjects: a placebo in 4% Klucel® gel intranasally to both nares in a volume of 0.3 mL/naris/dose,3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5.
3143692|NCT01592214|Active Comparator|Part 2 # 3-XF-73 in 4% Klucel® gel, concentration 0.5 mg/g:|12 subjects: a modified 4% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in, 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
3143693|NCT01592214|Experimental|Part 2 #2- XF-73 in 2% Klucel® gel, concentration 2.0 mg/g|12 subjects; a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 2.0 mg/g and volume of 0.3 mL/naris/dose,3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 3.6 mg on Day 1 and 2.4 mg on Days 2 to 5.
3143694|NCT01592214|Experimental|Part 2 #1- XF-73 in 2 % Klucel® gel, concentration 0.5 mg/g|12 subjects: a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose, 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
3143695|NCT01592214|Experimental|Part 1 #1-XF-73 in 2% Klucel® gel, concentration 0.5 mg/g:|4 subjects: 0.5 mg/g concentration of a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares twice in a single day in a volume of 0.3 mL/naris/dose and total daily dose of 0.6 mg.
3143696|NCT01592201|Experimental|Paliperidone ER|Immediate initiation of Paliperidone ER for a total of 12 weeks
3143697|NCT01592201|Experimental|Antipsychotics and paliperidone ER|Delayed initiation included previous atypical antipsychotics for 8 weeks and then be initiated on paliperidone ER at Day 56 for 4 weeks. The atypical antipsychotics includes aripiprazole, olanzapine and risperidone. These antipsychotics belongs to the class of second generation bipolar atypical antipsychotics.
3143698|NCT01592188|Active Comparator|MT|Mindfulness training. Participants will be provided with once per week training in mindfulness meditation.
3143699|NCT01592188|Experimental|CBCT|Cognitively-based compassion training. Participants in this arm will be provided with once weekly training on the cognitively-based compassion training program.
3143700|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 0|propofol 1% (Astra-Zeneca)plus remifentanil 0 ng/ml
3143701|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 2|propofol 1% (Astra-Zeneca)plus remifentanil 2 ng/ml
3143702|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 4|propofol 1% (Astra-Zeneca)plus remifentanil 4 ng/ml
3143703|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 0|propofol 1% (Fresenius) plus remifentanil 0 ng/ml
3143704|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 2|propofol 1% (Fresenius) plus remifentanil 2 ng/ml
3143705|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 4|propofol 1% (Fresenius) plus remifentanil 4 ng/ml
3143706|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 0|propofol 1% (B-Braun) plus remifentanil 0 ng/ml
3143707|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 2|propofol 1% (B-Braun) plus remifentanil 2 ng/ml
3143708|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 4|propofol 1% (B-Braun) plus remifentanil 4 ng/ml
3143709|NCT01592149||Group 1|
3143710|NCT01592123||The participants with septal deviation|
3143711|NCT01592110|Experimental|Cohort 1|25 mg of risperidone-SABER administered as a SC injection of 0.25 mL (100 mg/mL concentration) in the abdominal region
3143712|NCT01592110|Experimental|Cohort 2|50 mg of ZX003 (risperidone-SABER-DosePro) administered as 0.5 mL (100 mg/mL concentration) via the DosePro Needle-free Delivery System in the abdominal region
3143713|NCT01592110|Experimental|Cohort 3|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL (100 mg/mL concentration) in the abdominal region
3143714|NCT01592110|Experimental|Cohort 4|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL (100 mg/mL concentration) in the abdominal region
3143715|NCT01592084||lipid lowering therapy|those with lipid lowering therapy those without lipid lowering therapy
3143716|NCT01592071|Experimental|Replace reactive w/ non-reactive foods|Test results, individual dietary plan: 'Replace reactive foods with non-reactive foods'
3143717|NCT01592045|Experimental|Sequence 1|UTC ch14.18 for two courses and NCI ch14.18 for three courses
3143718|NCT01592045|Experimental|Sequence 2|NCI ch14.18 for two courses and UTC ch14.18 for three courses
3143719|NCT01592032|Experimental|Vancomycin antimicrobial-lock|Vancomycin antimicrobial-lock solution. Dosage: 2 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
3143720|NCT01592032|Experimental|Teicoplanin antimicrobial-lock|Teicoplanin antimicrobial-lock solution. Dosage: 10 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
3143721|NCT01592032|Experimental|Linezolid antimicrobial-lock|Linezolid antimicrobial-lock solution. Dosage: 1.8 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
3143722|NCT01592032|Experimental|Daptomycin antimicrobial-lock|Daptomycin antimicrobial-lock solution. Dosage: 5 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
3143723|NCT01592032|Experimental|Tigecycline antimicrobial-lock|Tigecycline antimicrobial-lock solution. Dosage: 4.5 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
3143724|NCT01592019|Experimental|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
3143725|NCT01592019|Experimental|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
3143726|NCT01592019|Experimental|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
3143727|NCT01592019|Experimental|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
3143728|NCT01592006|Experimental|HCV, LT, Pegasys, ribavirin, telaprevir|Patients are being asked to be part of this arm because they are orthotopic liver transplant recipients (OLT) and have the Hepatitis C Virus (HCV). They will be given the study drugs Pegasys, ribavirin and telaprevir
3143729|NCT01591993|Experimental|Test subject|To each subject, the investigators will randomly apply 10% lactic acid on one nasolabial fold, once.
3143730|NCT01591993|Placebo Comparator|Placebo|To each subject, the investigators will apply placebo (0.9% saline solution) on the contralateral nasolabial fold to the lactic acid, simultaneously.
3143731|NCT01591980|Experimental|Pregabalin 100 mg|
3143732|NCT01591980|Experimental|pregabalin 150 mg|
3143733|NCT01591980|Sham Comparator|Placebo|
3143734|NCT01591967|No Intervention|Control|Control -- no intervention
3143735|NCT01591967|No Intervention|Placebo w/ sham|"Sham intervention with the adjusting tool turned off"
3143736|NCT01591967|Experimental|Activator treatment|Treatment with Activator
3143737|NCT01591954|Experimental|Video Augmentation|Qualitative assessment of the value of video-based navigation system
3143738|NCT01591941|Active Comparator|CON group|Control Group underwent a standard soccer warm-up
3143739|NCT01591941|Experimental|Core-PAC|Experimental took part in the Core position and control movement strategy (Core-PAC) warm-up
3143740|NCT01591928||Infants with heterotaxy syndrome|
3143741|NCT01591915|Experimental|MBSR self care program including weekly sessions|Participants will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 minutes sessions, 6 days/week. Participants will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 hours.
3143742|NCT01591915|Experimental|MBSR self care program|Participants will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 minutes sessions, 6 days/week.
3143743|NCT01591915|No Intervention|Standard care|
3143744|NCT01591902|Experimental|EGRIFTA Treatment Grop|Sterile, lyophilized, nonpyrogenic powder containing tesamorelin acetate with mannitol as excipient
3143745|NCT01591902|Placebo Comparator|Placebo|Placebo-controlled
3143746|NCT01591889|Active Comparator|tindamax|500 mg tablet
3143747|NCT01591889|Active Comparator|tinidazole|500 mg tablet
3143748|NCT01591876|Sham Comparator|Progressive muscle relaxation|As well as usual care participants in the control arm will receive instruction in progressive muscle relaxation.
3143749|NCT01591876|Active Comparator|Aerobic exercise|Intervention -moderate intensity aerobic exercise.
3143750|NCT01591863|Experimental|fidaxomicin|
3143751|NCT01591850|Experimental|1 Ketoconazole DDI|
3143752|NCT01591850|Experimental|2 Rifampicin DDI|
3143753|NCT01591850|Experimental|3 ATZ/r DDI|
3143754|NCT01591837|Experimental|Adults|Healthy volunteers aged 18 to 59 years received a single 0.5 mL dose of CSL Influenza Vaccine by intramuscular or subcutaneous injection.
3143755|NCT01591837|Experimental|Older Adults|Healthy volunteers aged 60 years or older received a single 0.5 mL dose of CSL Influenza Vaccine by intramuscular or subcutaneous injection.
3143756|NCT01591824|Experimental|POLD TREATMENT|Patients who applies the treatment of resonant oscillation according to the Pold Concept
3143757|NCT01591824|Active Comparator|CONVENCIONAL: column exercise group|Patients who applied the conventional treatment of hospital
3143758|NCT01591811|Experimental|Arm 1 Daily Boost of Radiation Therapy|Arm 1 of treatment, you will be receiving 15 daily radiation fractions of 2.7 Gy (measure of radiation dose) daily for three weeks to the entire breast with a daily concomitant boost of 0.5 Gy
3143759|NCT01591811|Experimental|Arm 2 Weekly Boost of Radiation Therapy|Arm 2 Weekly Boost will receive 15 daily radiation fractions of 2.7 Gy for three weeks to the entire breast with a weekly boost of 2.0 GY.
3143760|NCT01591798|Experimental|Robotic surgery|Proctectomy using robot
3143761|NCT01591798|Active Comparator|Laparoscopic surgery|Conventional laparoscopic rectal resection
3143762|NCT01591785|Active Comparator|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
3143763|NCT01591785|Placebo Comparator|Placebo ointment|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
3143764|NCT01591772||diagnosed with ovarian that recieved chemo|
3143765|NCT01591772||healthy controls|
3143766|NCT01591759|Experimental|Citicoline|8-week treatment of 2,000mg/day of citicoline
3143767|NCT01591759|Placebo Comparator|Placebo|
3143768|NCT01591746|Experimental|Group A|Botulinum Toxin A
3143769|NCT01591746|Placebo Comparator|Group B|Placebo
3143770|NCT01591733|Experimental|Treatment Arm|All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
3143771|NCT01591720|Experimental|Tailored Internet-delivered CBT|The intervention is delivered within a primary care clinic.
3143772|NCT01591707|Experimental|ISC+PRT Intervention|For the duration of at least one school year children will receive 45-90 minutes of intervention in the classroom in an attempt to increase social and communication skills.
3143773|NCT01591707|No Intervention|Instruction As Usual|For the duration of at least one year children will receive the typical classroom instruction
3143774|NCT01591694||FamilyLive|Families with a history of intergenerational trauma (maltreatment, violence exposure, domestic violence, substance abuse, etc.)
3143775|NCT01591694||Yoga Based Psychotherapy|Children with a history of maltreatment and/or violence exposure
3143776|NCT01591694||Biofeedback|Children with a history of maltreatment and violence exposure and their caregivers
3143777|NCT01591694||TST-SA|Trauma Systems Therapy for Adolescent Substance Abuse
3143778|NCT01591681|Active Comparator|Pump suspension algorithm|The study laptop will be running actively during the night and suspending the patient's pump if the algorithm predicts hypoglycemia based on the patient's continuous glucose sensor trend.
3143779|NCT01591681|No Intervention|Standard of Care|The control algorithm will run passively and not recommend control the patient's pump.
3143780|NCT01591668|Experimental|0.3mg GS-9620|
3143781|NCT01591668|Experimental|1mg GS-9620|
3143782|NCT01591668|Experimental|2mg GS-9620|
3143783|NCT01591668|Experimental|4mg GS-9620|
3143784|NCT01591668|Experimental|0.3mg GS-9620 QW x 2 doses|
3143785|NCT01591668|Experimental|1mg GS-9620 QW x 2 doses|
3143786|NCT01591668|Experimental|2mg GS-9620 QW x 2 doses|
3143787|NCT01591668|Experimental|4mg GS-9620 QW x 2 doses|
3143788|NCT01591655|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%,
3143789|NCT01591655|Placebo Comparator|Vehicle|The vehicle of the mapracorat ophthalmic suspension
3143790|NCT01591629|Placebo Comparator|Placebo and Placebo|
3143791|NCT01591629|Experimental|Active Naloxone and Placebo|
3143792|NCT01591629|Placebo Comparator|Placebo and Active Delta-9-THC|
3143793|NCT01591629|Experimental|Active Naloxone and Active Delta-9-THC|
3143794|NCT01591616|Other|Oraqix for tooth extraction|
3143795|NCT01591603|Experimental|Group 1|
3143796|NCT01591603|Experimental|Group 2|
3143797|NCT01591590|Experimental|All Patients|This is an Interventional, Non Therapeutic arm
3143798|NCT01591577|Experimental|Lapatinib/Temozolomide/radiation|Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
3143799|NCT01591564|Other|therapy|All participants will receive the intervention.
3143800|NCT01591551|Other|Natalizumab (Tysabri) naive|Patients who are newly prescribed Natalizumab (TYSABRI®), but have not received their first infusion, will be invited to participate.
3143801|NCT01591538||lifestyle condition|
3143802|NCT01591525||Uncontrolled Diabetic|Individuals who were previously diagnosed with Type II Diabetes, but have a HgA1C greater than 7.0%
3143803|NCT01591525||Newly diagnosed Type II Diabetic|Individuals who have never been diagnosed with Type II Diabetes, but have an HgA1c greater than 7.0%
3143804|NCT01591525||Newly diagnosised pre-diabetics|Individuals who have never been diagnosed with Type II Diabetes, but have a HgA1C of 6.0%-6.9%
3143805|NCT01591525||Controlled|Diabetic or non-diabetic individuals with RPCG of less than 130 mg/dl.
3143806|NCT01591499|Experimental|BIOFINITY® MF - AIR OPTIX® AQUA MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
3143807|NCT01591499|Active Comparator|BIOFINITY® MF - PUREVISION® MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
3143808|NCT01591486||Hp-negative cohort|"Hp-negative cohort~The second cohort consists of ASA users with ulcer bleeding but no current or past Hp infection, as evidenced by:~negative rapid urease test~negative histology for Hp infection on both initial and follow-up endoscopy~negative serology test~absence of intestinal metaplasia and atrophy on 4 random biopsies of the antrum and corpus~After ulcer healing, the Hp-negative cohort will receive enteric-coated ASA (<160 mg daily) without regular co-prescription of anti-ulcer drugs."
3143888|NCT01591018|Experimental|cardiac surgery with sonolysis|cardiac surgery (CABG or heart valve surgery) with sonolysis (continual transcranial Doppler monitoring)
3280390|NCT00623675|Experimental|A|
3143809|NCT01591486||Hp-eradicated cohort|Hp-eradicated cohort This cohort consists of ASA users with ulcer bleeding and Hp infection who have healed ulcers and successful eradication of Hp on follow-up endoscopy. They will receive plain ASA (<160 mg daily) without co-prescription of anti-ulcer drugs.
3143810|NCT01591486||Average-risk cohort|Average-risk cohort The third cohort consists of ASA-naive patients without a history of ulcer who attend the general outpatient clinic. They require long-term ASA for established cardiothrombotic diseases. They receive plain ASA (<160 mg daily) without co-prescription of anti-ulcer drugs. Hp status will not be determined in this cohort because Hp testing is not justified in average-risk asymptomatic patients.
3143811|NCT01591473|Experimental|FluMist + Ampligen, Group 1|Nasal administration; dose group 1; FluMist + Poly I:Poly C12U 50 ug; 3 doses separated by 28 days
3143812|NCT01591473|Experimental|FluMist + Ampligen, Group 2|Nasal administration; dose group 2; FluMist + Poly I:Poly C12U 200 ug; 3 doses separated by 28 days
3143813|NCT01591473|Experimental|FluMist + Ampligen, Group 3|Nasal administration; dose group 3; FluMist + Poly I:Poly C12U 500 ug; 3 doses separated by 28 days
3143814|NCT01591473|Experimental|FluMist + Ampligen, Group 4|Nasal administration; dose group 4; FluMist + Poly I:Poly C12U 50 ug; 3 doses separated by 28 days
3143815|NCT01591473|Experimental|FluMist + Ampligen, Group 5|Nasal administration; dose group 5; FluMist + Poly I:Poly C12U 1250 ug; 3 doses separated by 28 days
3143816|NCT01591473|Experimental|FluMist + Placebo, Group 6|Nasal administration; dose group 6; FluMist + placebo; 3 doses separated by 28 days
3143817|NCT01591460|Experimental|Dual Combination Therapy|
3143818|NCT01591460|Experimental|Triple Combination Therapy|
3143819|NCT01591447|Experimental|Solithromycin (CEM-101)|A single oral dose of 1200 mg solithromycin
3143820|NCT01591447|Experimental|Solithromycin 1000 mg|A single oral dose of 1000 mg solithromycin
3143821|NCT01591434|Active Comparator|AQUACEL®|A sterile non-woven sheet of sodium carboxymethylcellulose (NaCMC).
3143822|NCT01591434|Active Comparator|AQUACEL® Extra™|A sandwiched construction of two layers of optimally textiled non-woven fabric, stitch-bonded together using Lyocel (Tencel™ regenerated cellulose) yarns.
3143823|NCT01591421|Experimental|BKM120 and Panitumumab|BKM120 will be given either daily starting day 1 cycle 1or 5 out of 7 days every week, depending on when patient is enrolled on the study, in combination with panitumumab given intravenously every two weeks starting day 1 cycle 1.
3143824|NCT01591408|Experimental|EEG biofeedback|Subjects will receive EEG biofeedback according to their own brain rhythms
3143825|NCT01591408|Sham Comparator|sham EEG biofeedback|Subjects will receive feedback according to someone else's brain rhythms collected during a different session.
3143826|NCT01591395|Active Comparator|Multiport TEP|Adult inguinal hernia patients who randomized to receive multiport endoscopic TEP repair
3143827|NCT01591395|Active Comparator|LESS TEP|Adult inguinal hernia patients who randomized to receive laparoendoscopic single-site TEP repair
3143828|NCT01591382|Active Comparator|Ketamine|Participants received postoperative hydromorphone patient-controlled analgesia (PCA) and continuous ketamine (0.2 mg/kg/hour). Ketamine is being compared to the use of placebo, in addition to intravenous opioids, for postop pain control in opioid dependent patients who undergo major surgery.
3143829|NCT01591382|Placebo Comparator|Placebo|Participants received postoperative hydromorphone PCA and continuous ketamine-matching placebo (infusion of saline).
3143830|NCT01591356|Experimental|siRNA-EphA2-DOPC|siRNA-EphA2-DOPC administered by vein twice weekly on Days 1 and 4 of each week for 3 weeks. One cycle equals 3 weeks of treatment (21 day schedule). Treatment will normally be administered on an outpatient basis; however, inpatient administration may be relevant in some situations. siRNA-EphA2-DOPC administered over 30 (+/- 5 minutes). Starting dose level of siRNA-EphA2-DOPC 450 ug/m2 by vein twice weekly.
3143831|NCT01591343|Experimental|Depigoid® (500 DPP/ml)|Patients will receive either Depigoid® Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml), depending on their sensitization to one or both mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae).
3143832|NCT01591330|Experimental|80 mg LY2140023 - Reference Form|Administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
3143833|NCT01591330|Experimental|80 mg LY2140023 - Test - Medium Form|Medium particle size. Administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
3143834|NCT01591330|Experimental|80 mg LY2140023 - Test - High Form|High particle size. Administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
3143835|NCT01591330|Experimental|80 mg LY2140023 - Test - Low Form|Low particle size. Administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
3143836|NCT01591317|Experimental|Prasugrel - 60 mg/10 mg|Prasugrel 60 mg loading dose given once orally, followed by 10 mg once a day orally for 10 days
3143837|NCT01591317|Experimental|Prasugrel - 30 mg/7.5 mg|Prasugrel 30 mg loading dose given once orally, followed by 7.5 mg once a day orally for 10 days
3143838|NCT01591317|Experimental|Prasugrel - 30 mg/5 mg|Prasugrel 30 mg loading dose given once orally followed by 5 mg once a day orally for 10 days
3143839|NCT01591304|Active Comparator|Group A|Ulthera System Treatment provided using 1.5mm and 1.0mm transducers at 0.25J and 0.20J energy settings, respectively.
3143840|NCT01591304|Active Comparator|Group B|Ulthera System Treatment provided using 1.5mm and 1.0mm transducers, at 0.18J and 0.15J energy settings, respectively.
3143841|NCT01591291|Experimental|Ondansetron|
3143842|NCT01591291|Placebo Comparator|Placebo|
3143843|NCT01591278|Experimental|Pulp dressing agent|
3143844|NCT01591278|Active Comparator|Pulp dressing|MTA
3143845|NCT01591265|Active Comparator|Compensatory Extraction|Patients allocated to this group, both the upper FPM and lower FPM teeth will be extracted.
3143846|NCT01591265|Active Comparator|No Compensatory Extraction|Patients allocated to this group, only the lower FPM tooth will be extracted.
3143889|NCT01591018|Placebo Comparator|cardiac surgery without sonolysis|cardiac surgery (CABG or heart valve surgery) without sonolysis (continual transcranial Doppler monitoring)
3143890|NCT01591005|Experimental|CEA with sonolysis|endarterectomy with sonolysis (continual transcranial Doppler monitoring)
3143847|NCT01591239|Experimental|Home-Based Intervention|Parents will receive a 1-session training on how to deliver a 3-session intervention across a 3-week period. The intervention program begins with a 3 and a half hour training session delivered by the staff Trainer to the participating parent. At the conclusion of training, the parent will be given the intervention manual and supplemental materials. The trainer will phone the parent shortly before session 1, in between each intervention session, and after the third intervention (four phone calls total) to review the objectives and tasks associated with that week's intervention session and to help prepare for the coming session. At the final phone call between the parent and trainer (after the third week), the trainer will deliver to the parent the follow-up resources.
3143848|NCT01591239|Active Comparator|Educational Group|Parents will receive a 2-hour, education-only psychoeducational curriculum (no parent-led intervention with their teen will occur.
3143849|NCT01591226|Active Comparator|Caffeine|6mg per kg bodyweight ingested 60min before test
3143850|NCT01591226|Placebo Comparator|Placebo|Sodium chloride and mannitol as placebo are ingested by the athlete
3143851|NCT01591226|Active Comparator|Sodium Citrate|sodium citrate diluted in 7dl water, ingestion 120 to 90min prior test
3143852|NCT01591226|Active Comparator|Caffeine and Sodium Citrate|sodium citrate 120-90min prior test capsules:60min prior test
3143853|NCT01591213||Healthy Volunteers|Fourth grade students enrolled in Memphis-area schools.
3143854|NCT01591200|No Intervention|Control|This arm will receive standard protocol of care alone
3143855|NCT01591200|Experimental|Stem cells high dose|This arm will receive high dose of Allogeneic Mesenchymal Stem Cells
3143856|NCT01591200|Experimental|Stem cells intermediate dose|This arm will receive intermediate dose of Allogeneic Mesenchymal Stem Cells
3143857|NCT01591200|Experimental|Stem cells low dose|This arm will receive low dose of Allogeneic Mesenchymal Stem Cells
3143858|NCT01591187||Cancer|Participants with a diagnosis of cancer.
3143859|NCT01591187||Sickle Cell Disease|"Participants with a diagnosis of sickle cell disease.~Interventions: Text messaging, Questionnaire, Interviews"
3143860|NCT01591174||Functional Dyspepsia with PDS|Study participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and Clinics in the Abdominal Pain Clinic (APC)or in the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and have Postprandial Distress Syndrome (PDS).
3143861|NCT01591174||Functional Dyspepsia without PDS|Study participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and clinics (CMH) Abdominal Pain Clinic (APC)or the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and do not have Postprandial Distress Syndrome (PDS).
3143862|NCT01591174||Control Group|Healthy participants 8-17 years of age recruited from internal advertising within Children's Mercy Hospital and Clinics.
3143863|NCT01591161|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%,
3143864|NCT01591161|Placebo Comparator|Vehicle|The vehicle of the mapracorat ophthalmic suspension
3143865|NCT01591148|Experimental|Morbidly obese subjects|Morbidly obese subjects (body mass index greater than 40) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
3143866|NCT01591148|Active Comparator|Control subjects (body mass index 20-25)|Normal weight subjects (body mass index 20-25) will be given propofol during induction of general anesthesia. Plasma samples will be collected over time to ascertain propofol plasma concentration.
3143867|NCT01591135|Active Comparator|Cisplatin|Chemoradiotherapy with cisplatin and 5-fluorouracil for 2 cycles followed by adjuvant chemotherapy for 2 cycles.
3143868|NCT01591135|Experimental|Paclitaxel|Patients randomized in Arm B will receive chemoradiation with weekly paclitaxel and 5-fluorouracil for 5 weeks followed by adjuvant chemotherapy with paclitaxel and 5-fluorouracil for 2 cycles.
3143869|NCT01591122|Experimental|Abiraterone acetate and prednisone|
3143870|NCT01591122|Active Comparator|Placebo and prednisone|
3143871|NCT01591109||Bevacizumab including chemotherapy|Patients treated with bevacizumab including chemotherapy for metastatic liver tumor derived from colorectal cancer before metastasectomy.
3143872|NCT01591109||no adjuvant chemotherapy|Patients with no adjuvant chemotherapy including bevacizumab
3143873|NCT01591096|Experimental|Tissue plasminogen activator|All patients will receive study drug.
3143874|NCT01591083|Active Comparator|Double oral dose|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days.
3143875|NCT01591083|Active Comparator|Regular oral dose|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole once daily for 25 days.
3143876|NCT01591083|Active Comparator|Control group|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole once daily for 25 days.
3143877|NCT01591070|No Intervention|vehicle twice weekly|
3143878|NCT01591070|Experimental|tacrolimus once weekly|
3143879|NCT01591070|Experimental|tacrolimus twice weekly|
3143880|NCT01591057|Experimental|2 Portions|
3143881|NCT01591057|Experimental|5 portions|
3143882|NCT01591057|Experimental|8 portions|
3143883|NCT01591044|Active Comparator|R940343 2mg, 2 puffs bid|R343 2mg, 2 puffs bid
3143884|NCT01591044|Placebo Comparator|Placebo|
3143885|NCT01591044|Active Comparator|R940343 1mg, 1 puff bid|R343 1mg, 1 puff bid
3143886|NCT01591031|Active Comparator|sevoflurane|anesthesia induction with propofol, remifentanil and sevoflurane
3143887|NCT01591031|Active Comparator|rocuronium|anesthesia induction with propofol, remifentanil and rocuronium
3143891|NCT01591005|Placebo Comparator|CEA without sonolysis|endarterectomy without sonolysis
3143892|NCT01591005|Experimental|carotid stenting with sonolysis|carotid stenting with sonolysis (continual transcranial Doppler monitoring)
3143893|NCT01591005|Placebo Comparator|carotid stenting without sonolysis|carotid stenting without sonolysis
3143894|NCT01590992|Experimental|Exposure-based Psychotherapy for Somatic Symptoms|First: 1-2 months waiting period; followed by: exposure-based psychotherapy
3143895|NCT01590992|Active Comparator|Relaxation Therapy|First: 1-2 months waiting period; followed by: relaxation therapy
3143896|NCT01590979|Active Comparator|Ranolazine|The antianginal properties of the drug are due to inhibition of the late inward sodium current, demonstrated in animal experiments and human studies that it can prevent atrial and ventricular arrhythmias.
3143897|NCT01590979|Placebo Comparator|Placebo|Company generated placebo, will be similar in size and color to Ranolazine; and administered two times a day (12 hour intervals)
3143898|NCT01590966|Experimental|Patients with an active inflammatory joint disease|In total there will be 20 patients included: 5 patients with active rheumatoid arthritis, 5 patients with active early axial spondyloarthritis, 5 patients with active early peripheral spondyloarthritis and 5 patients with active ankylosing spondylitis.
3143899|NCT01590940||Parietex mesh|Enrolled patients who met criteria for inclusion would have undergone open inguinal hernia repair using the Parietex plug and patch hernia system
3143900|NCT01590927||20 healthy women|
3143901|NCT01590914|Experimental|Roux-En Y Gastric Bypass|40 subjects who plan to undergo Roux-En-Y Gastric Bypass bariatric surgery. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition Pre-Surgery and 3 months post Surgery.
3143902|NCT01590914|Experimental|Gastric Banding|40 Subjects who plan to undergo Gastric Banding bariatric Surgery. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition Pre-Surgery and 3 months post Surgery.
3143903|NCT01590914|Experimental|Formula Diet Weight-Loss|40 subjects will undertake a 12-week liquid formula weight loss plan. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition pre-weight loss and 3 months after a 12-week weight loss plan.
3143904|NCT01590914|Experimental|No Treatment|40 subjects who do not undergo any treatment for weight loss. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition at baseline and after 3 months.
3143905|NCT01590901|Other|probucol in healthy male subjects|multiple oral doses of probucol in single group of healthy male subjects
3143906|NCT01590888|Experimental|PBT2 250mg|
3143907|NCT01590888|Experimental|PBT2 100mg|
3143908|NCT01590888|Placebo Comparator|Sugar pill|
3143909|NCT01590875|Experimental|Adenosine arm|25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose.
3143910|NCT01590875|No Intervention|Observation arm|25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation. This will serve as the control arm.
3143911|NCT01590862||Deep Brain Stimulation Effects on Reward Motivation|We will assess changes in Reward Motivation behavior with Deep Brain Stimulation on and off.
3143912|NCT01590862||Patients with MDD or OCD|Patients with MDD or OCD who do not have a deep brain stimulator.
3143913|NCT01590849|No Intervention|No hormonal contraception|
3143914|NCT01590849|Active Comparator|Hormonal Contraceptive|healthy women, users of COC containing 20 mcg EE and 3 mg DRSP (Yaz®), 24 days of active pills, 4 days of pill-free interval (n=40).
3143915|NCT01590836|Experimental|IDeg-->IDegAsp|
3143916|NCT01590823|Other|Dabigatran etexilate 110 mg|Single dose of Dabigatran etexilate 110 mg po
3143917|NCT01590810|Experimental|Panel A-Healthy|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel A will be 2.0 mg to 90 mg.
3143918|NCT01590810|Experimental|Panel B-Healthy|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel B will be 5.0 mg to 160 mg.
3143919|NCT01590810|Experimental|Panel C-Mild/Moderate Hypertension|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel C will be 160 mg to 1200 mg.
3143920|NCT01590810|Experimental|Panel D-Healthy|Within each panel, 8 subjects will be randomly assigned to MK-8150 and 2 subjects will be randomly assigned to placebo throughout the 5 periods according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel D will be 50 mg to 500 mg.
3143921|NCT01590797|Experimental|Sitagliptin|Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.
3143922|NCT01590797|Placebo Comparator|Placebo|Participants treated with placebo matching sitagliptin, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.
3143923|NCT01590771|Experimental|Sitagliptin|Sitagliptin 100 mg once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during run-in period.
3143924|NCT01590771|Placebo Comparator|Placebo|Matching placebo once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.
3143925|NCT01590758|Placebo Comparator|Topical placebo control|
3143926|NCT01590758|Experimental|Topical pexiganan cream 0.8%|
3143927|NCT01590745|Placebo Comparator|Sham Ultrasound regimen|A switch in the transducer circuit allows mock ionisation as a result no ultrasound emitted.
3143928|NCT01590745|Active Comparator|Real Ultrasound therapy|Pulsed mode ultrasound therapy
3283019|NCT00604149||2|cases of MI
3143929|NCT01590732|Experimental|Romidepsin + ICE|"Starting dose of Romidepsin: 8 mg/m2 by vein on Days 1 and 4 of a 14 Day cycle.~Ifosfamide plus Mesna: 5 gm/m2 for both given by vein over 24 hours on Day 1 of a 14 Day cycle.~Mesna: 2 gm/m2 given by vein given over 12 hours on Day 1 of a 14 Day cycle. Starts after completion of Ifosfamide plus Mesna administration.~Carboplatin: mg to equal target area under curve (AUC) by Calvert equation of 5 mg/ml/min with a maximum of 750 mg, given by vein over 1 hour on Day 1 of a 14 Day cycle.~Etoposide: 100 mg/m2 given by vein over 2 hours on Days 1 - 3 of a 14 Day cycle."
3143930|NCT01590719|Experimental|Onartuzumab (MetMAb) with mFOLFOX6|Onartuzumab (MetMAb) in combination with mFOLFOX6 (modified 5-fluorouracil, folinic acid [leucovorin], and oxaliplatin)
3143931|NCT01590719|Placebo Comparator|Placebo with mFOLFOX6|Placebo in combination with mFOLFOX6 (modified 5-fluorouracil, folinic acid [leucovorin], and oxaliplatin)
3143932|NCT01590693|Experimental|Group 2|Children treated with four weeks of below knee walking casts and botulinum toxin A injections
3143933|NCT01590693|Active Comparator|Group 1|Children treated with four weeks of below knee walking casts.
3143934|NCT01590667|Active Comparator|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
3143935|NCT01590667|Placebo Comparator|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
3143936|NCT01590654|Experimental|0.3mg GS-9620|
3143937|NCT01590654|Experimental|1mg GS-9620|
3143938|NCT01590654|Experimental|2mg GS-9620|
3143939|NCT01590654|Experimental|4mg GS-9620|
3143940|NCT01590654|Experimental|0.3mg GS-9620 QW x 2 doses|
3143941|NCT01590654|Experimental|1mg GS-9620 QW x 2 doses|
3143942|NCT01590654|Experimental|2mg GS-9620 QW x 2 doses|
3143943|NCT01590654|Experimental|4mg GS-9620 QW x 2 doses|
3143944|NCT01590641|Experimental|0.3mg GS-9620|
3143945|NCT01590641|Experimental|1mg GS-9620|
3143946|NCT01590641|Experimental|2mg GS-9620|
3143947|NCT01590641|Experimental|4mg GS-9620|
3143948|NCT01590641|Experimental|0.3mg GS-9620 QW x 2 doses|
3143949|NCT01590641|Experimental|1mg GS-9620 QW x 2 doses|
3143950|NCT01590641|Experimental|2mg GS-9620 QW x 2 doses|
3143951|NCT01590641|Experimental|4mg GS-9620 QW x 2 doses|
3143952|NCT01590628|Experimental|NiCord|
3143953|NCT01590615||Participants with chronic HBV infection|Participants with decompensated liver disease due to chronic HBV infection, who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy, will be included in the study.
3143954|NCT01590602||JHD cases|All ages included, but must have an HD age of onset 25 or below
3143955|NCT01590589||REGISTRY participants|"Individuals~with manifest HD~unaffected but known to carry the HD mutation~unaffected but at risk of carrying the HD mutation~from HD families known not to carry the HD mutation~from outside HD families acting as control research participants (e.g., spouses)"
3143956|NCT01590576||lower urinary tract symptoms and pelvic organ prolapse|
3143957|NCT01590563|Experimental|SCu300A IUB|Insertion of a spherical IUD (intrauterine device) with one year follow-up
3143958|NCT01590550||Single arm|Single arm for all patient receiving inpatient HD
3143959|NCT01590537||Group 1|
3143960|NCT01590537||Group 2|
3143961|NCT01590524|Experimental|CAM group|Subjects receiving the interventions and standard psychological care
3143962|NCT01590524|No Intervention|No-CAM group|Parents receiving only standard psychological care
3143963|NCT01590511||The study population|Patients in the emergency room or intensive care in acute circulatory failure without ventilatory support.
3143964|NCT01590498||Salvage radiotherapy|local radiation to the prostate and metastasis following biochemical or clinical recurrence
3143965|NCT01590498||observation|did not receive salvage following biochemical or clinical recurrence
3143966|NCT01590485|Placebo Comparator|Starch capsule|starch with dose of 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
3143967|NCT01590485|Active Comparator|Saffron capsule|saffron with dose of 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
3143968|NCT01590472||Mesothelioma|Individuals who have been diagnosed with mesothelioma
3143969|NCT01590459|Placebo Comparator|Placebo Arm|
3143970|NCT01590459|Experimental|VX-509 100 mg qd Arm|
3143971|NCT01590459|Experimental|VX-509 150 mg qd Arm|
3143972|NCT01590459|Experimental|VX-509 100 mg bid Arm|
3143973|NCT01590459|Experimental|VX-509 200 mg qd Arm|
3143974|NCT01590446|Placebo Comparator|Placebo|
3143975|NCT01590446|Active Comparator|BMN 111|
3143976|NCT01590433|Experimental|Exenatide|Subjects will be randomly assigned to the exenatide study treatment group or to the placebo study treatment group. Subjects will have a 33 percent chance of being assigned to the placebo study treatment group and a 66 percent chance of being assigned to exenatide study treatment. Subjects will not be able to choose the study group to which they will be assigned. All study participants will receive individualized dietary counseling. Subjects may or may not be assigned to follow a reduced-calorie diet in addition to study treatment. Subjects will not know whether they are receiving exenatide or placebo, but the study team will know which they are receiving.
3143977|NCT01590433|Placebo Comparator|Placebo|Subjects will be randomly assigned to the exenatide study treatment group or to the placebo study treatment group. Subjects will have a 33 percent chance of being assigned to the placebo study treatment group and a 66 percent chance of being assigned to exenatide study treatment. Subjects will not be able to choose the study group to which they will be assigned. All study participants will receive individualized dietary counseling. Subjects may or may not be assigned to follow a reduced-calorie diet in addition to study treatment. Subjects will not know whether they are receiving exenatide or placebo, but the study team will know which they are receiving.
3143978|NCT01590420|Experimental|CPAP treatment|1000 patients with 3-years CPAP treatment after a PSG titration
3143979|NCT01590407|Experimental|ALS-002200|
3143980|NCT01590407|Placebo Comparator|Placebo|
3143981|NCT01590394|Experimental|Pancreatic Cancer Patients|A large plastic biliary stent was placed in the bile duct.
3143982|NCT01590381||personnel in medical training - COURSE 1|
3143983|NCT01590381||personnel in medical training - COURSE 2|
3143984|NCT01590381||personnel in medical training - COURSE 3|
3143985|NCT01590381||personnel in medical training - COURSE 4|
3143986|NCT01590381||personnel in medical training - COURSE 5|
3143987|NCT01590381||personnel in medical training - COURSE 6|
3143988|NCT01590381||personnel in medical training - COURSE 7|
3143989|NCT01590381||personnel in medical training - COURSE 8|
3143990|NCT01590381||personnel in medical training - COURSE 9|
3143991|NCT01590381||personnel in medical training - COURSE 10|
3143992|NCT01590368|Other|Marketed electrode|The currently marketed electrodes using the current CE marked adhesive
3143993|NCT01590368|Active Comparator|Modified hydrogel|"Electrodes with the new modified adhesive - the test electrodes"
3143994|NCT01590355|Active Comparator|Radiotherapy plus or minus Chemotherapy|Radiotherapy plus or minus chemotherapy with surgical treatment for salvage of persistent disease
3143995|NCT01590355|Experimental|Transoral Robotic Surgery + Neck Dissection|Transoral robotic excision will be carried out using the da Vinci surgical robot. The spatula cautery will be used to remove the tumours with 1 cm margins. At the time of surgery circumferential margins will be taken and sent for frozen section analysis. The resection will proceed until negative margins are obtained if feasible.
3143996|NCT01590342|Active Comparator|Diclofenac|
3143997|NCT01590342|Placebo Comparator|Placebo|
3143998|NCT01590329|Experimental|Micrografting|
3143999|NCT01590316|Experimental|Cerebral NIRS oximetry + treatment guideline based on reading|
3144000|NCT01590316|No Intervention|Blinded cerebral NIRS oximetry|
3144001|NCT01590303|Experimental|Vitamin C|Intravenous Vitamin C will be administered (1 gram) every 8 hours for 28 days or discharge from intensive care unit
3144002|NCT01590303|Placebo Comparator|placebo|placebo vehicle administered in same fashion as active treatment
3144003|NCT01590290|Active Comparator|pay for performance|
3144004|NCT01590290|No Intervention|no pay for performance|
3144005|NCT01590277|Experimental|ethanol and iomazenil|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.~Potential Randomizations:~placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil"
3144006|NCT01590277|Experimental|placebo ethanol|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.~Potential Randomizations:~placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil"
3144007|NCT01590277|Experimental|active iomazenil|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.~Potential Randomizations:~placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil"
3144008|NCT01590277|Experimental|placebo iomazenil|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.~Potential Randomizations:~placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil"
3144009|NCT01590264|Other|Bimodal rTMS|"Open-label and single-arm rTMS bimodal treatment with placement of magnet over Dorsolateral Prefrontal Cortex (DLPFC) and Temporoparietal Junction (TPJ) for 2 weeks of treatment (10 days)~Stimulation Settings:~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000"
3144010|NCT01590251|Experimental|Yoga|Gentle yoga for chronic pain and opioid dependence
3144011|NCT01590251|Active Comparator|Educational Counseling|Educational counseling is a didactic, lecture-discussion format to supplement the information and advice provided in opioid agonist maintenance treatment.
3144012|NCT01590238|Experimental|Treatment with PRFM|Subjects treated monthly 3 times with intradermal injections of PRFM into bald/balding scalp. Post-treatment hair density index measured and compared to hair density index measured prior to treatment for each subject.
3144013|NCT01590225|Experimental|Part A: boceprevir + peginterferon alpha-2b + ribavirin|
3144014|NCT01590225|Experimental|Part B: boceprevir + peginterferon alpha-2b + ribavirin|
3144015|NCT01590212|No Intervention|Care as usual|Participants received care in line with local guidelines
3144016|NCT01590212|Active Comparator|Mellow Bumps + care as usual|MB is a six week group-based antenatal programme designed to support families with additional health and social care needs. MB is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation.
3144017|NCT01590212|Active Comparator|Chill-out in Pregnancy + care as usual|CHiP is a relaxation programme that includes all the mother-centred components of Mellow Bumps but none of the baby or mother-baby relationship components. It runs for six weeks at two hours per week. It aims to decrease maternal stress levels.
3144018|NCT01590199|Experimental|RAD001 + SOM230|
3144019|NCT01590173|Experimental|Prednisolone and Heparin during COH for IVF|
3144020|NCT01590173|Active Comparator|COH for IVF|
3144021|NCT01590160|Experimental|Cisplatin/Pemetrexed|Cisplatin 75mg/m2, Day 1 every 21 days Pemetrexed 500mg/m2, Day 1 every 21 days
3144022|NCT01590160|Experimental|Carboplatin/Pemetrexed|Carboplatin AUC5, Day 1 every 21 days Pemetrexed 500mg/m2, Day 1 every 21 days
3144023|NCT01590147|Experimental|Arm 1 (YST)|Patients participate in three 15-minute YST sessions, comprising awareness meditation practice, movement practice, and breathing practice and relaxation. Patients also receive a CD recording of a 15-minute YST session and are instructed to practice the YST at home 4 times weekly.
3144068|NCT01589809|Experimental|Nicotinamide|Comparison is made within-subjects to different doses and no treatment
3144069|NCT01589796|Active Comparator|classic TAP|classic US-guided TAP block in a space between iliac crest and the costal margin in the region of the anterior axillary line
3144024|NCT01590147|Active Comparator|Arm 2 (CE)|Patients participate in three 15-minute CE sessions, comprising empathic attention with an interventionist who allows patients to direct the flow of conversation and provides supportive comments according to standardized procedures. Patients also receive CDs with recorded information related to coping with colorectal cancer similar in length to the suggested practice time in Arm I.
3144025|NCT01590134|No Intervention|Control|"Following randomisation,to no active intervention, blood and urine samples will be collected at 6 stated intervals over a 48 hour period~Total number of participants in arm = 6"
3144026|NCT01590134|Active Comparator|Iron control|"Following randomisation, on each of two consecutive mornings, the participant will receive a single dose of ferrous sulphate 200mg. Blood and urine samples will be collected pre first dose, and at 5 further stated intervals over a 48 hour period.~Total number of participants in arm = 6"
3144027|NCT01590134|Experimental|Dietary supplement|"Following randomisation, on each of two consecutive mornings, the participant will receive the experimental dietary iron supplement. Blood and urine samples will be collected pre first dose, and at 5 further stated intervals over a 48 hour period.~Toal participants in arm = 6"
3144028|NCT01590121||Pateints with hereditary haemorrhagic telangiectasia|
3144029|NCT01590108|Experimental|Apelin|Subject will perform cardiopulmonary exercise testing and receive (Pyr1)apelin-13 intravenously.
3144030|NCT01590108|Placebo Comparator|Control|Subject will take cardiopulmonary exercise testing with receive placebo
3144031|NCT01590095|Active Comparator|Water quality|90 clusters, approx. 720 newborns
3144032|NCT01590095|Active Comparator|Sanitation|90 clusters, approx. 720 newborns
3144033|NCT01590095|Active Comparator|Hand washing|90 clusters, approx. 720 newborns
3144034|NCT01590095|Active Comparator|Combined WASH|90 clusters, approx. 720 newborns
3144035|NCT01590095|Active Comparator|Nutrition|90 clusters, approx. 720 newborns
3144036|NCT01590095|Active Comparator|Nutrition + Combined WASH|90 clusters, approx. 720 newborns
3144037|NCT01590095|No Intervention|Non-intervention|180 clusters, approx. 1,440 newborns
3144038|NCT01590082|Experimental|Doxycycline + Ipilimumab + Temozolomide|Doxycycline to start on day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts) twice a day until morning of Day 1 of Cycle 1. After the Day 1 of Cycle 1, participants receive first dose of Ipilimumab, and evening of same day, Temozolomide received by mouth once a day for 4 days. Doxycycline administration will continue twice daily for rest of cycle without interruption; Cycle 1 is 4 weeks of treatment. Starting Cycle 2, Doxycycline with temozolomide and ipilimumab administration start on Day 1. Each cycle is 3 weeks. 4 cycles of therapy given over a 3 month period to complete induction phase. After induction therapy, participants continue on Doxycycline.
3144039|NCT01590069|Experimental|Aerosol IL-2|Aerosol IL-2 starting 1 mg in 3 mL volume of nebulized solution daily for 21 days of a 28 day cycle. Symptom Assessment (self report), oximetry, and pulmonary function assessed prior to each nebulized dose of IL-2 using remote spirometry and pulse oximetry.
3144040|NCT01590056||PD patients|PD patients that are treated or are candidates for treatment with STN DBS
3144041|NCT01590043||Control|Healthy 3-18 years old participants
3144042|NCT01590043||Inflammatory bowel disease|3-18 years old patients identified with inflammatory bowel disease
3144043|NCT01590043||Abdominal pain|3-18 years old patients suffering from abdominal pain not related to Inflammatory bowel disease
3144044|NCT01590030|Experimental|Laparoscopic mesial incision|
3144045|NCT01590030|Active Comparator|Laparoscopic antimesial incision|
3144046|NCT01590017|Experimental|Cistplatin and Radiation Therapy|Cisplatin 40 mg/m2 (max = 70 mg) IV over 30-60 minutes given weekly on days 1, 8, 15, 22, 29 and 36 for a total of 6 weekly cycles. Radiation therapy over 8 weeks: External pelvic radiation therapy (41.4-45.0 Gy/1.8 Gy per fraction/23-25 fractions/five weeks), intracavitary brachytherapy (low dose: 35-43.6 Gy/1-2 implants; high dose: 18-28 Gy/2-4 implants), with parametrial boost to involved parametria (5.40 - 9.00 Gy/1.8 Gy/3-5 fractions/3-5 days).
3144047|NCT01589991|Placebo Comparator|Non-fluoride toothpaste|
3144048|NCT01589991|Experimental|Toothpaste 550 µg F/g (NaF/SiO2)|
3144049|NCT01589991|Experimental|Toothpaste 1100 µg F/g (NaF/SiO2)|
3144050|NCT01589991|Experimental|Toothpaste 1450 µg F/g (MFP/CaCO3)|
3144051|NCT01589978|Experimental|PROMUS Element|Subjects who receive the PROMUS Element everolimus-eluting coronary stent
3144052|NCT01589965|Experimental|Treatment group: T5|Small Lottery reward
3144053|NCT01589965|No Intervention|Control group|
3144054|NCT01589965|Experimental|Treatment group T1|High Lottery reward
3144055|NCT01589952|Experimental|Pegylated Interferon, Entecavir|'Pegylated Interferon, Entecavir' arm will consist of 20 chronic hepatitis B patients who will receive Pegylated Interferon 90 micro gms subcutaneously once weekly in combination with entecavir 0.5 mg orally once daily for 24 weeks
3144056|NCT01589926|Experimental|Bi-level Positive Airway Pressure|BLPAP initiated for at least 16 hours per day for a minimum of 48hrs.
3144057|NCT01589926|Sham Comparator|Sham CPAP|Physiologic CPAP initiated for at least 16 hours per day for a minimum of 48hrs.
3144058|NCT01589913|Experimental|Treatment as usual plus remote care|"The same treatment as described under treatment as usual plus participation in the intervention ICD-Forum."
3144059|NCT01589913|No Intervention|Treatment as usual|Standard information provided by hospitals on ICD-technology as well as consequences of ICD-implantation plus medical aftercare including cardiology appointments at 1, 3, and 6 months, and one year after ICD-implantation.
3144060|NCT01589874||acute ill patients|
3144061|NCT01589861|Experimental|BKM120+Lapatinib|"BKM120 40, 60 or 80 mg/day per os for 28 days cycle~+ Lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle"
3144062|NCT01589848||von Willebrand women|Referred women who may have von Willebrand Disease
3144063|NCT01589835|Experimental|Lifestyle counseling|Green prescription with facilitator support
3144064|NCT01589835|Other|Usual care|
3144065|NCT01589822|Experimental|EVICEL Fibrin Sealant: Randomized|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen.
3144066|NCT01589822|No Intervention|Standard of Care|Standard surgical technique for GI anastomosis.
3144067|NCT01589822|Experimental|Experimental: EVICEL Fibrin Sealant: Non-Randomized|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen
3144070|NCT01589796|Active Comparator|Medial TAP|US-guided TAP block in a space between iliac crest and the costal margin within 1 inch lateral to transversus abdominis muscle origination
3144071|NCT01589783||Pregnant or newly post partum women|
3144072|NCT01589783||family practice physicians and obstetricians|
3144073|NCT01589770||rheumatoid arthritis patients|People who have rheumatoid arthritis
3144074|NCT01589770||controls|people who do not have RA or other inflammatory disease
3144075|NCT01589757|Placebo Comparator|Standard Care|Standard care dietary advice to emphasize high fiber foods with a moderate to high GI
3144076|NCT01589757|Experimental|Low GI Diet|Low GI dietary advice in addition to standard care
3144077|NCT01589744|Experimental|Suction cup Hemostatic Intra-Uterin|The suction haemostatic cup will be positioned into the uterus, and the aim is to stop haemorrhage
3144078|NCT01589731||Allergic group|The first group (group A) included 45 patients (17 males; mean age: 46.2 years, SD: 12.2 years) with convincing clinical histories of reproducible adverse reactions to bovine milk. All subjects presented βs-IgE that were detectable by SDS-PAGE immunoblotting.
3144079|NCT01589731||Non Allergic group|The second group (group B) was used as a control for the immunoblotting analysis performed in the first group and included 20 individuals selected based on an evident tolerance to cow's milk, an absence of βs-IgE by ImmunoCAP assay and SPT non-reactivity to β-Lg or TgPolβ-Lg (6 males; mean age: 21.9 years, SD: 17.6 years).
3144080|NCT01589731||Atopic group|The third group (group C) included 49 subjects with atopic respiratory and/or dermatological diseases (19 males; mean age: 28.7 years, SD: 20.6 years) regardless of βs-IgE status. This group was used to compare the ex vivo cell-mediated immunoreactivity between β-Lg and TgPolβ-Lg by comparing the mean ex vivo antigenic challenge results determined using the leukocyte adherence inhibition test (LAIT).
3144081|NCT01589718|Experimental|0.3mg Pegaptanib Sodium, Macugen|will receive Macugen intravitreal injection prior to surgery
3144082|NCT01589718|Sham Comparator|Sham injection|will receive a sham injection
3144083|NCT01589705||polycystic kidney ,no hypertension|The study evaluated the association of serum uric acid levels with endothelial dysfunction in early ADPKD patients with normal renal function
3144084|NCT01589692|Experimental|Internal Fixation|Open Reduction and Internal Fixation: Internal fixation with a volar locking plating system
3144085|NCT01589692|Experimental|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
3144086|NCT01589692|Experimental|Pinning|Percutaneous pinning with any number of Kirschner wires
3144087|NCT01589692|Active Comparator|No Surgery|Closed Reduction and casting: Closed reduction and immobilization with a cast and/or splint
3144088|NCT01589679|Other|control/ standard of care|ALL SUBJECTS WILL RECEIVE SHOE INSERTS AND HOME STRETCHING REGIME. Control subjects will be treated with the Standard of Care during the first 12 weeks, but after the 12 weeks patients will be fit with MTP, which delivers a low-load, prolonged-duration stretch after completion of this study.
3144089|NCT01589679|Experimental|Dynasplint|ALL SUBJECTS WILL RECEIVE SHOE INSERTS AND HOME STRETCHING REGIME. Experimental subjects will be immediated treated with the Metatarsal Dynasplint, which delivers a low-load, prolonged-duration stretch for 60 minutes, three times per day.
3144090|NCT01589666|Experimental|Spray-dried S/D-treated plasma|"Resusix (Spray-Dried Solvent/Detergent-Treated Plasma) uses source plasma from U.S.-licensed facilities as the starting material. Source plasma donors are selected from the AB blood type, which is considered a universal product."
3144091|NCT01589653|Experimental|Subject-driven titration|
3144092|NCT01589653|Experimental|Investigator-driven titration|
3144093|NCT01589640||Blink Tears|Blink Tears is an over the counter artificial tear
3144094|NCT01589640||Blink Gel Tears|Blink Gel Tears is an over the counter artifical tear product
3144095|NCT01589640||Systane Balance|Systane Balance is an over the counter artificial Tear product
3144096|NCT01589627|Experimental|experimental|Patients will be treated with the Standard of Care physical therapy, NSAIDs as well as a Wrist Extension Dynasplint
3144097|NCT01589627|No Intervention|Control|Patients will receive standard of care physical therapy and NSAIDS
3144098|NCT01589614|Experimental|PH-797804 6 mg|Subjects will receive a single 6 mg dose in the fed state
3144099|NCT01589614|Experimental|PH-797804 6 mg + erythromycin 800 mg|Subjects will receive multiple 800 mg doses of erythromycin and a single 6 mg dose of PH-797804 in the fed state
3144100|NCT01589601|No Intervention|Usual heart failure care|Patients will be managed by a cardiologist-directed team with expertise in the diagnosis and treatment of heart failure. Until discharge, inpatient care will focus on symptom relief and initiation of evidence-based therapies. Additional goals of care will include treatment of co-morbidities and patient education designed to assist with self-management techniques. However, after discharge, which is where the study actually takes place, patients will only receive outpatient follow-up with a heart failure cardiologist or nurse practitioner who will focus on medication titration to evidence-based dosing, titration of diuretic therapy, assessment of compliance with medical and dietary regimens, and serial monitoring of end-organ function.
3144101|NCT01589601|Active Comparator|Usual care + palliative care|Patients will receive an interdisciplinary, multicomponent palliative care intervention combined with state of the art heart failure management designed to assess and manage the multiple domains of quality of life at the end of life for patients with advanced heart failure, including physical symptoms, psychosocial concerns, and spiritual concerns, and to facilitate advance care planning.
3144102|NCT01589588|Experimental|Mask 1|
3144103|NCT01589588|Experimental|Mask 2|
3144104|NCT01589588|Experimental|Mask 3|
3144105|NCT01589588|Placebo Comparator|Mask 3, placebo|
3144106|NCT01589575||Spouses|This group of relatives includes the spouses of ICU patients (over 16 years of age and intubated and under ventilation for at least 48 hours) meeting stated inclusion criteria.
3144107|NCT01589575||Other relatives|This group of relatives includes the non-spouse relatives of ICU patients (over 16 years of age and intubated and under ventilation for at least 48 hours) meeting stated inclusion criteria.
3144108|NCT01589562|Active Comparator|Megace 800mg/20ml|Fed condition
3144109|NCT01589562|Experimental|DW-ES(B) 625mg/5ml|Fed condition
3144110|NCT01589549|Experimental|Mesenchymal stromal cell therapy|Mesenchymal stromal cell therapy in addition to corticosteroid therapy
3144111|NCT01589549|Active Comparator|Corticosteroid therapy|
3144112|NCT01589536|Experimental|Interventiongroup|A Stationary psychocardiological interval-rehabilitation.
3144113|NCT01589536|No Intervention|controlgroup|The Patients in the control group receive a personal recommendation concerning psychotherapy outpatient counseling and therapy services at home and take therapeutic help.
3144114|NCT01589523|Experimental|GlycoCholic Acid, Study Drug|A Phase III, open label, single arm, non-randomized, non-comparative, treatment study of Glycocholic Acid in the treatment of defects of bile acid metabolism.
3144115|NCT01589510||Lumigan® 0.01%|Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) as prescribed by physician per standard practice for up to 14 weeks.
3144116|NCT01589497|Active Comparator|RHZE-RHZE|Participants were administered rifampin-isoniazid-pyrazinamide-ethambutol (RHZE) from Day 1 to Day 14.
3144117|NCT01589497|Active Comparator|RHZE-RZE|Participants were administered RHZE from Day 1 to Day 2, then rifampin-pyrazinamide-ethambutol (RZE) from Day 3 to Day 14.
3144118|NCT01589497|Active Comparator|RHZE-RMZE|Participants were administered RHZE Day 1 to Day 2 and rifampin-moxifloxacin-pyrazinamide-ethambutol (RMZE) from Day 3 to Day 14.
3144119|NCT01589497|Active Comparator|RZE-RZE|Participants were administered only RZE from Day 1 through Day 14.
3144120|NCT01589484|Experimental|Shockwave lithotripsy (SWL)|All patients will be submitted to a noncontrast computed tomography before to shockwave lithotripsy (SWL). Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
3144121|NCT01589471|Experimental|Botox-A|Intra-rectal (or intra-colic) injection of 100 U of Botox-A
3144122|NCT01589458|Placebo Comparator|Non-fluoride toothpaste|
3144123|NCT01589458|Experimental|NaF/SiO2 toothpaste|
3144124|NCT01589458|Experimental|MFP/CaCO3 toothpaste|
3144125|NCT01589445|Experimental|Pioglitazone (001 group)|The patients received pioglitazone hydrochloride tablet 30 mg (001 drug)once daily for first three months
3144126|NCT01589445|Experimental|Metformin (002 group)|The patients received metformin hydrochloride tablet 850 mg (002 drug)once daily for next three months.
3144127|NCT01589432|Experimental|ABT-639|
3144128|NCT01589432|Placebo Comparator|Placebo|
3144129|NCT01589432|Active Comparator|Lidocaine|
3144130|NCT01589419|Experimental|veliparib and capecitabine and radiation|Veliparib on days 1-7, capecitabine and radiation on days 1-5
3144131|NCT01589406||group A group B|A:Patients for surgical intervention B:Patients for radiotherapy
3144132|NCT01589393|Active Comparator|Early initiation of thromboprophylaxis|Early initiation of thromboprophylaxis with Enoxaparin between 36-48 hours post injury to day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting day 6 post injury.
3144133|NCT01589393|Placebo Comparator|Late initiation of thromboprophylaxis|Initiation of placebo 36-48 hours post traumatic injury until day 5, then standard of care (DVT prophylaxis with Enoxaparin) starting on Day 6.
3144134|NCT01589380|Placebo Comparator|Placebo Arm|Placebo: Capsule that is containing lactate hydrate, identically appearing with fimasartan will be administered to patient in placebo group, once daily. Same placebo drug which was used in phase 3 clinical trial of fimasartan will be provided by Boryoung Phamaceutical company. Dose titration will be done with same criteria of fimasartan group. 30mg form and 60 mg form of placebo will be identical in its morphology.
3144135|NCT01589380|Active Comparator|Fimasartan|"Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP < 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan."
3144136|NCT01589367|Experimental|Arm1_ Metformin|Letrozole with concurrent metformin
3144137|NCT01589367|Placebo Comparator|Arm 2_ Letrole alone|Letrozole with placebo
3144138|NCT01589354|Experimental|Interscalene brachial plexus block|
3144139|NCT01589354|Experimental|Intra-articular injection|
3144140|NCT01589341||Correlative studies|Archived DNA samples are analyzed (laboratory biomarker analysis) for segmental chromosome aberrations by MLPA, a PCR-based technique. The following genomic regions are being studied: 1p, 1q, 3p, 4p, 7q, 9p, 11q, and 17q, as are the copy numbers of MYCN, NAG, DDX1, and ALK genes.
3144141|NCT01589328|Experimental|Early Palliative care|"The interventions consisted of the following:~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education"
3144142|NCT01589328|No Intervention|Contol: usual oncologic care|Patients randomly assigned to usual oncologic care were not scheduled to meet with the palliative care service unless a meeting was requested by the patient, the family, or the oncologist; those who were referred to the service did not cross over to the early palliative care group or follow the specified palliative care protocol.
3144143|NCT01589315|Experimental|FEAST|Active right unilateral focal ECT
3144144|NCT01589302|Experimental|Treatment (ibrutinib)|Patients will be treated with PCI-32765 capsules administered orally once daily at a dose of 420 mg for 28 day cycles. Weekly monitoring during the first month will occur followed by monthly evaluations for 2 additional months. Monitoring for patients at this point would be every 3 months with monthly CBC(complete blood count)and phone follow-up with a co-investigator on the study. A standard questionnaire will be used in this monthly phone assessment. Patients will continue to receive the study drug indefinitely as long as they are deriving clinical benefit (Complete Response or Partial Response or Stable Disease) and not experiencing any unacceptable toxicity. Subjects with disease progression will be removed from the study. Correlative laboratory samples, quality of life assessment, and immunologic data would be collected over time of therapy.
3144208|NCT01588808|Active Comparator|Immobilization without protein (young)|Immobilization without twice-daily protein supplementation - in the young
3144303|NCT01588132|Experimental|Single dose group 6|Anfibatide injection at the concentration of 3.0μg/60kg in healthy volunteers
3144145|NCT01589289|Experimental|Phase 3 RDTs|The different interventions will be assessed for estimation of sensitivity, specificity and predictive values in the patients' cohort, for the respective target conditions. [To be noted that, in addition, also the predictive values of validated RDTs when used alone and in various combinations will be estimated].
3144146|NCT01589276||Emergency hernia repairs|
3144147|NCT01589276||Elective hernia repairs|
3144148|NCT01589263|Active Comparator|ARM 1: onaBoNT-A + placebo|onaBoNT-A 200 U prostate injection and placebo oral capsule daily
3144149|NCT01589263|Active Comparator|ARM 2: Saline + Tamsulosin|Placebo prostate injection (saline) and tamsulosin 0.4 mg capsule daily.
3144150|NCT01589237|Experimental|LCQ908|Patients initiated at 10 mg/day. After at least 8 weeks of treatment with a dose, optional up-titration to the next possible dose will be allowed. One down titration allowed from the highest dose attained.
3144151|NCT01589224||Healthy people|
3144152|NCT01589211|Active Comparator|Brief advice|A brief advice to stop smoking of about 10 min accompanied with self-help material
3144153|NCT01589211|Experimental|Compact cessation course|Cessation intervention of 2 x 120 min in a group setting
3144154|NCT01589211|Active Comparator|Standard cessation course|Cessation course in a group setting over 6 dates
3144155|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 1|1 mg/kg KBSA301
3144156|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 2|3 mg/kg KBSA301
3144157|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 3|10 mg/kg KBSA301
3144158|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 4|20 mg/kg KBSA301
3144159|NCT01589185|Experimental|Placebo|KBSA301-placebo
3144160|NCT01589172||Pediatric Brain Trauma Patients|
3144161|NCT01589159|Experimental|Experimental|
3144162|NCT01589146|No Intervention|short heparin|
3144163|NCT01589146|Experimental|extended heparin|
3144164|NCT01589120|No Intervention|control group|Verbal description of goals of care reflecting usual care
3144165|NCT01589120|Experimental|Video Arm|Video intervention group
3144166|NCT01589107|No Intervention|control group|usual care
3144167|NCT01589107|Experimental|Video Arm|
3144168|NCT01589094|Experimental|Gemcitabine and Cisplatin (DD GC)|This is a Multicenter Phase II study of dose-dense (DD) gemcitabine and cisplatin (GC) neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC) who are candidates for radical cystectomy.
3144169|NCT01589081|Active Comparator|Female Smokers (Luteal Phase)|
3144170|NCT01589081|Active Comparator|Female Smokers (Follicular Phase)|
3144171|NCT01589068|Active Comparator|Male Smokers|
3144172|NCT01589068|Active Comparator|Female Smokers (Follicular Phase)|
3144173|NCT01589068|Active Comparator|Female Smokers (Luteal Phase)|
3144174|NCT01589055|Active Comparator|Male Smokers|
3144175|NCT01589055|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
3144176|NCT01589055|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
3144177|NCT01589042||Above the Knee|Patients treated with the Chocolate balloon for a lesion located above the knee
3144178|NCT01589042||Below the Knee|Patients treated with the Chocolate balloon for a lesion located below the knee
3144179|NCT01589029|Other|CANAKINUMAB (ILARIS®)|
3144180|NCT01589016||PUL (pregnancy of unknown location),|
3144181|NCT01589016||EP ( ectopic pregnancies P)|
3144182|NCT01589016||IUP-singleton intrauterine pregnancies|
3144183|NCT01589003|Active Comparator|Low GI group|Low Glycaemic index growing up milk
3144184|NCT01589003|Other|High GI group|Hi Glycaemic index growing up milk
3144185|NCT01588990|Experimental|Metastatic Colorectal Cancer Participants|Participants will undergo Phase A followed by Phase B. Participants will receive bevacizumab in combination with XELOX regimen (every 3 weeks) or mFOLFOX regimen (every 2 weeks) until first disease progression or the occurrence of an unmanageable toxicity or withdrawal from the study, in Phase A. Upon documented first disease progression, participants will continue receiving bevacizumab in combination with FOLFIRI (every 2 weeks) until second disease progression, unmanageable toxicity, or withdrawal from study, in Phase B.
3144186|NCT01588977||All-Inside TightRope technique|
3144187|NCT01588977||ACL reconstruction with TLS system|
3144188|NCT01588977||Hamstring Tendon Graft Reconstruction of the ACL|
3144189|NCT01588964|Experimental|HIPEC|Surgery plus HIPEC
3144190|NCT01588951|Experimental|No Leukemia Stem Cells - Consolidation|Without LSC, standard cytarabine consolidation
3144191|NCT01588951|Experimental|Leukemia Stem Cells - Consolidation|LSC present, randomized to cytarabine consolidation
3144192|NCT01588951|Experimental|Leukemia Stem Cells - Transplant|LSC present, randomized to allogeneic transplant
3144193|NCT01588925|Experimental|Control group|Cochlear Implantation
3144194|NCT01588925|Active Comparator|Dexamethasone|Cochlear implantation using topical dexamethasone
3144195|NCT01588925|Active Comparator|Dexamethasone+Hyaluronic acid|Cochlear implantation using topical dexamethasone associated with hyaluronic acid
3144196|NCT01588912|Experimental|Telbivudine-Tenofovir roadmap|
3144197|NCT01588912|Active Comparator|Entecavir|
3144198|NCT01588899|Experimental|MR-HIFU Treatment|Patients in this arm will receive MR-HIFU uterine fibroid treatment
3144199|NCT01588886||with PPI|CKD with PPI use, follow up at least 5 years began PPI use
3144200|NCT01588886||with or without Pneumonia outcome|Patients were eligible for inclusion if they received any PPIs treatment between January 1, 1998 and December 31, 2002 and had been diagnosed with pneumonia between January 1, 1998 and December 31, 2008 in an inpatient setting.
3144201|NCT01588873|Active Comparator|Oral contraceptive pill|
3144202|NCT01588873|Active Comparator|Contraceptive ring|
3144203|NCT01588847|Experimental|Regional anesthesia|
3144204|NCT01588847|Active Comparator|General anesthesia|
3144205|NCT01588821|Experimental|Treatment Arm|Cabozantinib
3144206|NCT01588808|Active Comparator|Immobilization with protein (elderly)|Immobilization with twice-daily protein supplementation - in the elderly
3144207|NCT01588808|Placebo Comparator|Immobilization without protein (elderly)|Immobilization without twice-daily protein supplementation - in the elderly
3144209|NCT01588795|Experimental|Denervation + TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
3144210|NCT01588795|Active Comparator|TMNS|Patients are maintained on standardized anti-proteinuric medications
3144211|NCT01588782|Experimental|Abiraterone acetate|All individuals will receive study treatment in the same sequence. Period 1 (Days 1 to 4) consists of a single oral dose of 1000 mg abiraterone acetate tablets on Day 1 only. Period 2 (Days 11 to 17) consists of a daily oral dose of 400 mg ketoconazole tablets on Days 11 to 16 and administration of a single dose of 1000 mg abiraterone acetate on Day 14.
3144212|NCT01588769|Experimental|One arm|3 doses of ALECSAT cell based immunotherapy planned for all enrolled patients
3144213|NCT01588756|Experimental|AcSDKP-NH2 inuline|AcSDKP-NH2 inuline, Once intravenous administration of 100 µg or less
3144214|NCT01588756|Experimental|AcSDKP-NH2 Cr-EDTA|AcSDKP-NH2 Cr-EDTA, Once intravenous administration of 100 µg or less
3144215|NCT01588730|Experimental|Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours).
3144216|NCT01588730|Active Comparator|Static Splint|The control group will be treated with a static splint for a minimum of 6 4 hours each night while sleeping with the end goal of 6-8 hours.
3144217|NCT01588717|Experimental|glycopyrrolate|glycopyrrolate 2 to 6 mg/day
3144218|NCT01588704|Experimental|Neoadjuvant Bevacizumab|Four cycles of neoadjuvant chemotherapy with pemetrexed, carboplatin and bevacizumab.
3144219|NCT01588691|Active Comparator|Low frequency|Programming parameters with the Eon Mini will be set at a low frequency. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
3144220|NCT01588691|Active Comparator|High frequency|Programming parameters with the Eon Mini will be set at a low frequency. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
3144221|NCT01588691|Placebo Comparator|No stimulation|Programming parameters will be set to the lowest possible level and minimal power will be generated. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
3144222|NCT01588678|Experimental|DS-3078a|"Part 1 - Dose escalation of DS-3078a to determine the maximum tolerated dose (MTD) will be guided by the modified continuous reassessment method (mCRM) using a Bayesian logistic regression model (BLRM) following escalation with overdose control (EWOC) principle.~Before starting mCRM, initial dose escalation will proceed following an accelerated titration in which single subjects will be enrolled into sequential dose levels with a dose increment of up to 100% from the previous dose.~Upon completion of Part 1 with established MTD and tentative recommended phase 2 dose (RP2D), the Dose Expansion (Part 2) will begin with the intention of further assessing the safety and tolerability of DS-3078a, confirming the RP2D, determining the Pharmacodynamic response in tumor samples, and evaluating preliminary efficacy of DS-3078a in subjects."
3144223|NCT01588665||Pregnant women and pregnant adolescents|
3144224|NCT01588639||Group 1|
3144225|NCT01588626|Experimental|AZD6140|single administration of 90 mg dose of AZD6140
3144226|NCT01588600|Active Comparator|Control|Breakfast without fiber
3144227|NCT01588600|Experimental|Low-dose|Low-dose of fiber in breakfast
3144228|NCT01588600|Experimental|High-dose|high dose of fiber added to breakfast
3144229|NCT01588587||DPP-IV inhibitors|
3144230|NCT01588574|Active Comparator|BOTOX (registered trade mark)|
3144231|NCT01588574|Experimental|MT10109|
3144232|NCT01588561|Active Comparator|Intravenous Nicotine (1.5 mg/70 kg)|Participants are given a siingle infusion of nicotine (1.5 mg/70 kg), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans
3144233|NCT01588561|Placebo Comparator|Saline - placebo|Participants are given physiological saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans
3144234|NCT01588548|Active Comparator|AZD1208|
3144235|NCT01588535|Active Comparator|benzocaine solution|ear drops
3144236|NCT01588535|Placebo Comparator|Placebo|ear drops
3144237|NCT01588522|Experimental|dose-escalation of compound 31543|compound 31543 Calcitriol, Topical application, 0.25 mL to be applied to each of the four quadrants of the scalp twice daily, morning and night with 10-14 hours between applications
3144238|NCT01588509|Experimental|Romosozumab 140 mg|Participants received romosozumab 140 mg administered subcutaneously once a month for 3 months.
3144239|NCT01588509|Experimental|Romosozumab 210 mg|Participants received romosozumab 210 mg administered subcutaneously once a month for 3 months.
3144240|NCT01588496|Experimental|Part A: Evolocumab|Participants received open-label evolocumab 420 mg subcutaneously once a month for 12 weeks.
3144241|NCT01588496|Experimental|Part B: Evolocumab|Participants received double-blind evolocumab 420 mg subcutaneously once a month for 12 weeks.
3144242|NCT01588496|Placebo Comparator|Part B: Placebo|Participants received double-blind placebo subcutaneously once a month for 12 weeks.
3144243|NCT01588483||giant cell arteritis|patients with biopsy and/or scintigraphy proven GCA
3144244|NCT01588470|Experimental|Pioglitazone|Only subjects with T2DM or non-diabetic subjects with coronary heart disease will receive Pioglitazone
3144245|NCT01588457|Active Comparator|Lithium|This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, lithium [LI] at baseline. Lithium is one of these two mood stabilizers. The person may or may not stay solely on lithium throughout the study.
3144246|NCT01588457|Active Comparator|Divalproex|This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, divalproex (DV)at baseline. Divalproex is one of these two mood stabilizers. The person may or may not stay solely on divalproex throughout the study.
3144247|NCT01588457|Active Comparator|Lithium plus Quetiapine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + quetiapine [QT].
3144248|NCT01588457|Active Comparator|Lithium plus Lamotrigine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + lamotrigine (LM).
3283735|NCT00598078|Experimental|1|
3144249|NCT01588457|Active Comparator|Divalproex plus Quetiapine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + quetiapine [QT].
3144250|NCT01588457|Active Comparator|Divalproex plus Lamotrigine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + lamotrigine (LM).
3144251|NCT01588444|Experimental|cancellous FDBA (LifeNet)|grafting with cancellous mineralized freeze-dried bone allograft (LifeNet Health)
3144252|NCT01588444|Experimental|cortical FDBA (LifeNet)|CORTICAL FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)
3144253|NCT01588431|Experimental|(TPE-A) Followed by Concurrent RT(XPE-A), surgery|Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery
3144254|NCT01588418|Experimental|Exenatide first, then Placebo|Exenatide 5mcg was injected subcutaneously 30 min before Oral Glucose Tolerance Test (OGTT)-PET study. The same subject was studied again a few weeks later with the same protocol with Placebo injection.
3144255|NCT01588418|Experimental|Placebo first, then Exenatide|Placebo was injected subcutaneously 30 min before OGTT-PET study. The same subject was studied again a few weeks later with the same protocol with injection of Exenatide 5mcg .
3144256|NCT01588405|Experimental|UT-15C SR|
3144257|NCT01588392|Experimental|Short bouts of structured activity|
3144258|NCT01588392|Active Comparator|Unstructured physical activity|
3144259|NCT01588379|Experimental|Girls and mothers dance together|African-American girls AND their mom's will participate in the Afro-centric dance program together and also receive weekly newsletter that focuses on health related issues.
3144260|NCT01588379|Experimental|Girls, alone|African-American girls will participate in the Afro-centric dance program alone. Girls and mom's will receive weekly newsletter that focuses on health related issues
3144261|NCT01588379|Active Comparator|No dancing|African-American girls and their mom's will only receive weekly newsletter that focuses on health related issues.
3144262|NCT01588366|Placebo Comparator|Placebo|Part A and B - Up to 4 capsules of placebo administered orally once a day for 28 days.
3144263|NCT01588366|Experimental|15 mg LY2409021|Part B - 1 capsule of 15 mg LY2409021 orally once a day for 28 days. (Arm added in September, 2012, per protocol amendment.)
3144264|NCT01588366|Experimental|60 mg LY2409021|Part A - 4 capsules of 15 mg LY2409021 administered orally once a day for 28 days.
3144265|NCT01588353|Experimental|AK160 0.58 mg|
3144266|NCT01588340|Active Comparator|MRI|The patient will have a rapid noncontrast MRI (magnetic resonance imaging) that will take approximately 15 minutes to complete.
3144267|NCT01588340|Active Comparator|Ultrasound exam|A noncontrast ultrasound examination
3144268|NCT01588327||Experimental|Patient taking FDA approved dose of dabigatran
3144269|NCT01588327||Control group|Person not taking any form of anticoagulation.
3144270|NCT01588314|Active Comparator|gabapentin|
3144271|NCT01588314|Placebo Comparator|placebo|
3144272|NCT01588301|Experimental|Group 1 : Further invitation by mail|Further invitation to attend for cervical cytology
3144273|NCT01588301|Experimental|Group 2 : Kit for Self-collected vaginal sample|Kit for Self-collected vaginal sample sent at home and then test for Human Papillomavirus (HPV)
3144274|NCT01588301|No Intervention|Group 3: Control|
3144275|NCT01588288|Experimental|Galectin 3 dosage|Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy
3144276|NCT01588275|Active Comparator|MRA therapy|During 12 months patients will be treated with a bibloc MRA (SomnoDent® MAS, SomnoMed Australia/Europe AG). The MRA will be customized by certified dentists or dental-specialists experienced in the field of dental sleep medicine.
3144277|NCT01588275|Active Comparator|CPAP therapy|"During 12 months patients will be treated with Continuous positive airway pressure (CPAP).Treatment with CPAP prevents upper airway collapse by pneumatically splinting the upper airway during sleep."
3144278|NCT01588262|Other|Stressmanagement counselling|
3144279|NCT01588262|No Intervention|Control|
3144280|NCT01588249|Experimental|Novel formulation of pasteurized maple cough syrup|
3144281|NCT01588249|Placebo Comparator|Placebo|
3144282|NCT01588236|Experimental|KYG0395 (high dose group)|
3144283|NCT01588236|Experimental|KYG0395 (lower dose group)|
3144284|NCT01588236|Placebo Comparator|placebo|
3144285|NCT01588223|Experimental|Lipids|
3144286|NCT01588210|Experimental|Glass Ionomer Cement group|a high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany)
3144287|NCT01588210|Experimental|Resin Based Fluoride Group|white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein)
3144288|NCT01588210|Placebo Comparator|Resin Based sealant|white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany)
3144289|NCT01588197|Experimental|PreFrontal Cortex|
3144290|NCT01588197|Experimental|Anterior Cingulate|
3144291|NCT01588184|Experimental|Bevacizumab|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
3144292|NCT01588171|Active Comparator|Bemiparin|A new second generation Low Molecular Weight Heparin
3144293|NCT01588171|Active Comparator|Enoxaparin|A well known Low Molecular Weight Heparin
3144294|NCT01588171|No Intervention|control group|Risky group patients for VTE, but they will not receive any thromboprophylactic drug.
3144295|NCT01588158|Active Comparator|Vicodin 5/325 mg|Half of the patients will be randomized to Vicodin
3144296|NCT01588158|Active Comparator|Acetaminophen 325 mg|Half of the patients will be randomized to Acetaminophen
3144297|NCT01588145|Experimental|HM61713|
3144298|NCT01588132|Experimental|Single dose gourp 1|Anfibatide injection at the concentration of 0.33μg/60kg in healthy volunteers
3144299|NCT01588132|Experimental|Single dose group 2|Anfibatide injection at the concentration of 0.66μg/60kg in healthy volunteers
3144300|NCT01588132|Experimental|Single dose groups 3|Anfibatide injection at the concentration of1.0μg/60kg in healthy volunteers
3144301|NCT01588132|Experimental|Single dose group 4|Anfibatide injection at the concentration of 1.5μg/60kg in healthy volunteers
3144302|NCT01588132|Experimental|Single dose group 5|Anfibatide injection at the concentration of 2.0μg/60kg in healthy volunteers
3144304|NCT01588132|Experimental|Single dose group 7|Anfibatide injection at the concentration of 4.0μg/60kg in healthy volunteers
3144305|NCT01588132|Experimental|Single dose group 8|Anfibatide injection at the concentration of 5.0μg/60kg in healthy volunteers
3144306|NCT01588132|Experimental|Multiple dose group 9|Give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours
3144307|NCT01588132|Experimental|Multiple dose group 10|Give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.
3144308|NCT01588132|Experimental|Multiple dose group 11|Give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours
3144309|NCT01588119||Dabigatran|in atrial fibrillation
3144310|NCT01588119||Rivaroxaban|in atrial fibrillation and VTE
3144311|NCT01588119||Apixaban|in atrial fibrillation and VTE
3144312|NCT01588119||Edoxaban|in atrial fibrillation
3144313|NCT01588106||Test group|patients using CONTOUR Next USB
3144314|NCT01588106||Control group|patients using standard CONTOUR
3144315|NCT01588093|Placebo Comparator|Saline|
3144316|NCT01588093|Active Comparator|Increlex|
3144317|NCT01588080|Placebo Comparator|SiPAP|
3144318|NCT01588080|Experimental|Neurally Adjusted Ventilatory Assist|
3144319|NCT01588067||Medical|Patients treated for PAD medically or with exercise therapy
3144320|NCT01588067||Endovascular|Patients with PAD treated with endovascular therapy
3144321|NCT01588067||Surgery|Patients with PAD treated with surgery
3144322|NCT01588054||adults, cervical deformity, surgical treatment|Adults 18years or older at time of enrollment, cervical deformity to include kyphosis (C2-7 greater than 10 degrees) or scoliosis (coronal cobb greater than 10 degrees), plans for surgical treatment of cervical deformity
3144323|NCT01588041||Vitreoretinal Interface Disease Group|A minimum of 50 subjects with vitreoretinal interface disease will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
3144324|NCT01588041||Macular Hole Group|A minimum of 50 subjects with macular hole with be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
3144325|NCT01588041||Retinal Detachment Group|A minimum of 50 subjects with retinal detachment will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
3144326|NCT01588041||Diabetic Retinopathy Group|A minimum of 50 subjects with diabetic retinopathy will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
3144327|NCT01588041||Rare Related Macular Disease Group|Up to 70 subjects with rare related macular diseases will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
3144328|NCT01588041||Generation 2 MIOCT Transition Group|80 of the subjects recruited in years 1 through 5 (40 normal, 40 diseased) will be imaged with both the generation 1 MIOCT and the generation 2 MIOCT systems prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
3144329|NCT01588041||Endothelial Keratoplasty Group|150 subjects undergoing Descemet Stripping Endothelial Keratoplasty (DSEK) will be imaged with MIOCT at the conclusion of the surgical procedure and may be imaged during follow-up visits.
3144330|NCT01588041||Anterior Lamellar Keratoplasty Group|150 subjects undergoing Deep Anterior Lamellar Keratoplasty (DALK) will be imaged with MIOCT at the conclusion of the surgical procedure and may be imaged during follow-up visits.
3144331|NCT01588015|Experimental|Arm I (vaccine therapy)|Patients receive Tet-CMV + PF03512675 SC on days 28 and 56 post-HCT.
3144332|NCT01588015|Active Comparator|Arm II (control)|Patients undergo immune monitoring only.
3144333|NCT01588002|Active Comparator|A danoprevir+ritonavir|
3144334|NCT01588002|Active Comparator|B efavirenz|
3144335|NCT01588002|Experimental|C combination|
3144336|NCT01587989|Active Comparator|A Methotrexate|
3144337|NCT01587989|Experimental|B Methotrexate Placebo|
3144338|NCT01587963|Active Comparator|Ascorbic Acid|Ascorbic Acid
3144339|NCT01587963|Placebo Comparator|Ringers Lactate or Normal Saline|Ringers Lactate or Normal Saline
3144340|NCT01587950|Placebo Comparator|Sterile water|Participants to receive 250 microlitres (μL) of sterile water.
3144341|NCT01587950|Experimental|Potassium nitrate 5% solution|Participants to receive 250 μL of potassium nitrate 5% solution.
3144342|NCT01587950|Experimental|Potassium nitrate 2.5% solution|Participants to receive 250 μL of potassium nitrate 2.5% solution.
3144343|NCT01587937|Experimental|Antibiotic stewardship intervention|Audit-and-feedback intervention to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antimicrobial
3144344|NCT01587937|No Intervention|Control|The pre-intervention period will serve as the control period on each medical and surgical service. The cross-over is uni-directional from control to intervention; all services receive the intervention by the end of the study. This is a stepped wedge design. The order of roll-out is randomized.
3144345|NCT01587924|Experimental|0.5 mg GSK1278863|once daily
3144346|NCT01587924|Experimental|2 mg GSK1278863|once daily
3144347|NCT01587924|Experimental|5 mg GSK1278863|once daily
3144348|NCT01587924|Active Comparator|rhEPO|as required
3144349|NCT01587911|Active Comparator|Whey protein|Complete whey protein.
3144350|NCT01587911|Active Comparator|Whey-CMP|Complete whey protein missing the CMP (aka GMP) portion of the peptide.
3144351|NCT01587911|Placebo Comparator|Control|Placebo preload control, matched for energy.
3144352|NCT01587911|Active Comparator|CMP (casinomacropeptide)|Small peptide cleaved from complete whey protein.
3144353|NCT01587911|Active Comparator|MPI|Complete milk protein.
3144354|NCT01587911|Active Comparator|CPI (casein)|Preload containing casein.
3144355|NCT01587898|Experimental|0.5mg GSK1278863|Once daily
3144356|NCT01587898|Experimental|2mg GSK1278863|Once daily
3144357|NCT01587898|Experimental|5mg GSK1278863|Once daily
3144358|NCT01587898|Experimental|Placebo|Once daily
3283736|NCT00598078|Experimental|2|
3144359|NCT01587885|Experimental|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Participants will receive omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg once a day for 4 days.
3144360|NCT01587885|Active Comparator|Omeprazole 20 mg|Participants will receive omeprazole 20 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days.
3144361|NCT01587872|Experimental|DBC|Double balloon colonoscopy will be attempted in cases where conventional colonoscopy failed due to technical difficulties such as looping or redundant colonic segments.
3144362|NCT01587859||Cohort|Patients submitted to laparoscopic surgery for Type II-IV hiatus hernia
3144363|NCT01587846|Experimental|Probiotic/abdominal pain|Children with functional abdominal pain that will receive probiotic.
3144364|NCT01587846|Experimental|Placebo/abdominal pain|Children with functional abdominal pain that will receive placebo.
3144365|NCT01587846|Experimental|Probiotic/constipation|Children with chronic constipation tha will receive probiotic plus lactulose
3144366|NCT01587846|Experimental|Placebo/chronic constipation|Children with chronic constipation that will receive placebo plus lactulose
3144367|NCT01587833||Patients with a diagnosis of hip or femur fracture|All patients of the study population with a record/diagnosis of a first fracture of the hip or femur during the study period regardless of whether they have a history of past fractures. When the patient has a history of hip or hip/femur fracture, a minimum of 12 months should have elapsed between the two episodes for a current fracture to be considered a new event.
3144368|NCT01587833||Patients without a diagnosis of hip or femur fracture|All patients of the study population without a record/diagnosis of a fracture of the hip or femur during the study period
3144369|NCT01587820|Experimental|Intra-arterial cisplatin and radiation|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
3144370|NCT01587820|Active Comparator|Intravenous cisplatin and radiation|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
3144371|NCT01587807|Experimental|Cohort 1|single inhaled dose of GSK1995057 (dose 1) or placebo
3144372|NCT01587807|Experimental|Cohort 2|single inhaled dose of GSK1995057 (dose 2) or placebo
3144373|NCT01587807|Experimental|Cohort 3|single inhaled dose of GSK1995057 (dose 3) or placebo
3144374|NCT01587807|Experimental|Cohort 4|single inhaled dose of GSK1995057 (dose 4) or placebo
3144375|NCT01587807|Experimental|Cohort 5|single inhaled dose GSK1995057 (dose 4) with bronchoalveolar lavage (BAL)sampling procedure conducted approximately 30 minutes post GSK1995057 dose
3144376|NCT01587807|Experimental|Cohort 6|high dose of GSK1995057 or placebo followed by an inhaled LPS challenge and BAL sampling procedure.
3144377|NCT01587794||retinal detachment group|Patients who were diagnosed with unilateral rhegmatogenous retinal detachment involving only the superior or inferior half of the retina and who underwent successful scleral buckling procedure or vitrectomy by a single surgeon between January 1, 2008 and April 1, 2010 were included in the study sample.
3144378|NCT01587768||Patients with a definite case of acute liver injury|"The information recorded in the patients' medical record met all the criteria to be classified as idiopathic acute liver injury and the patient presents with at least with one of the following conditions (A+B or A+C):~A - A diagnosis of liver injury (codes listed in tables 1a, 1b, 1c) with a referral to a specialist or hospital.~Together with B - An increase of more than two times the upper limit of the normal range in alanine aminotransferase (ALT) or C - A combined increase in aspartate aminotransferase (AST), alkaline phosphatase (AP) and total bilirubin provided one of them is twice the upper limit of the respective normal range."
3144379|NCT01587768||Patients with a probable case of acute liver injury|The information recorded in the patients' medical file was compatible with idiopathic acute liver injury, but not fulfilling all conditions and criteria to be defined as definite case. For example, patients identified with a READ or ICPC code for acute liver injury with a hospitalization or visit to a specialist but without complete laboratory criteria or patients identified with a READ or ICPC code for acute liver injury without a referral to a hospital/specialist, and with or without complete laboratory data.
3144380|NCT01587768||Non-cases|Any potential or probable case that was excluded in one of the previous steps and those with insufficient data to determine their case status. Patients presenting normal liver function tests (LFTs), alcohol related problems, gallbladder disease, pancreatic disease, or other liver diseases with clear aetiology such as viral, alcoholic or autoimmune, or presence of other well defined pathology known to cause acute liver injury will be considered non-cases.
3144381|NCT01587755|Other|Topical Treatment Optimizing Program|Optimized care
3144382|NCT01587755|Other|non-Topical Treatment Optimizing Program|Standard care
3144383|NCT01587742||Patients with a diagnosis of any cancer type|All patients of the study population with a diagnosis of any cancer type based on Read codes and ICD-10 codes
3144384|NCT01587742||Patients with a diagnosis of breast cancer|All patients of the study population with a diagnosis of breast cancer based on Read codes and ICD-10 codes
3144385|NCT01587742||Patients with a diagnosis of prostate cancer|All patients of the study population with a diagnosis of prostate cancer based on Read codes and ICD-10 codes
3144386|NCT01587742||Patients with a diagnosis of colon cancer|All patients of the study population with a diagnosis of colon cancer based on Read codes and ICD-10 codes
3144387|NCT01587742||Patients without a diagnosis of any cancer type|All patients of the study population without a diagnosis of any cancer type
3144388|NCT01587729||Patients with a diagnosis of hip or femur fracture|All patients of the study population with a record/diagnosis of a first fracture of the hip or femur during the study period regardless of whether they have a history of past fractures. When the patient has a history of hip or hip/femur fracture, a minimum of 12 months should have elapsed between the two episodes for a current fracture to be considered a new event.
3144389|NCT01587729||Patients without a diagnosis of hip or femur fracture|All patients of the study population without a record/diagnosis of a fracture of the hip or femur during the study period
3144438|NCT01587378|Placebo Comparator|placebo|
3283737|NCT00598078|Placebo Comparator|3|
3144390|NCT01587716|Experimental|1. Inhaled GSK2339345/Placebo Single Dose (Cohort 1)|administered three ascending doses of GSK2339345 or placebo as a solution via an aqueous droplet inhaler over four treatment periods, with at least 5 days washout between doses
3144391|NCT01587716|Experimental|2. Inhaled GSK2339345/Placebo Repeat Dose (Cohort 2)|administered a dose of GSK2339345 or placebo, four times a day on two consecutive days. Each subject will receive either GSK2339345 or matching placebo as a solution administered via an aqueous droplet inhaler
3144392|NCT01587703|Experimental|Single and Repeat Dose finding cohort|All subjects will follow a 3+3 dose escalation design for GSK525762 and the dose will be escalated based on all available data, including PK data and the safety profile of prior cohorts, as well as the recommended dose from the Neuenschwander- Continuous Reassessment Method (N-CRM) design.
3144393|NCT01587703|Experimental|Expansion Cohort|Up to 150 additional subjects with NMC and other solid tumors may be enrolled in expansion cohorts. The recommended Phase 2 (Part 2) dose (RP2D) of GSK525762 will be determined based on the MTD or biologically active dose (example: clinical response), the safety profile and available pharmacodynamic data generated from all subjects in Parts 1
3144394|NCT01587703|Experimental|Besylate Sub study|Tablet and amorphous tablet in one of the two sequences (ABCD or BACD). Where Treatment A: RP2D/MTD as amorphous free-base tablet + low dose stable isotope in solution, fasted Treatment B: RP2D/MTD as besylate tablet + low dose stable isotope in solution, fasted. Treatment C: half to one-third of RP2D/MTD as besylate tablet + low dose stable isotope in solution, fasted. Treatment D: RP2D/MTD as besylate tablet, fed
3144395|NCT01587690||Healthy subjects|Self-explanatory
3144396|NCT01587690||Untreated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are not on any disease-modifying treatment approved for MS
3144397|NCT01587690||Treated Patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who were prescribed Interferon-beta-1a prior to enrollment
3144398|NCT01587677||Confirmed tuberculosis|
3144399|NCT01587677||Confirmed non-tuberculous mycobacterial infection|
3144400|NCT01587677||Confirmed bronchial carcinoma|
3144401|NCT01587677||Suspected tuberculosis but confirmed alternative diagnosis|
3144402|NCT01587664|Experimental|NewBreez ILP|Implantation of a NewBreez ILP
3144403|NCT01587651|Experimental|Prasugrel Maintenance Dose|Prasugrel 10 mg QD MD
3144404|NCT01587651|Active Comparator|Ticagrelor Maintenance Dose|Ticagrelor 90 mg twice-daily (BID) MD
3144405|NCT01587651|Experimental|Prasugrel Loading Dose|Prasugrel 60mg Loading Dose (LD), followed by prasugrel 10mg once-daily (QD) Maintenance Dose (MD)
3144406|NCT01587638||Hypertensive users of Beta blocker|Patients aged ≥18 years and at least 1 diagnosis of hypertension (ICD-9-CM: 401.xx-405.xx) during this time frame in a US Managed care population
3144407|NCT01587625|Experimental|High dose of oxytocin infusion|Oxytocin: High dose infusion
3144408|NCT01587625|Active Comparator|Low dose of oxytocin infusion|Oxytocin: Low dose infusion
3144409|NCT01587599|Active Comparator|Pharmaceutical care|
3144410|NCT01587599|Placebo Comparator|Standard care|
3144411|NCT01587586|Active Comparator|Pegasys|Pegasys(subcutaneous injection)+Ribavirin, multiple doses(48)
3144412|NCT01587586|Experimental|P1101, 48 doses|P1101(subcutaneous injection)with Ribavirin, multiple doses
3144413|NCT01587586|Experimental|P1101, 24 doses|P1101(subcutaneous injection)+Ribavirin, multiple doses
3144414|NCT01587586|Experimental|P1101, 12 doses|P1101(subcutaneous injection)+Ribavirin, multiple doses
3144415|NCT01587573||oral lesions|oral lesions suspicious for squamous cell carcinoma with saliva collection prior to clinically driven oral biopsy
3144416|NCT01587560|Active Comparator|Pyrocarbon|Patients receiving a shoulder surface replacement implant made of pyrocarbon (the PyroTITAN Humeral resurfacing Arthroplasty)
3144417|NCT01587560|Active Comparator|CoCr|Patients receiving a shoulder surface replacement implant made of Cobalt-Chrome(CoCR) (the TITAN Humeral Resurfacing Arthroplasty)
3144418|NCT01587547||IVF and ICSI patients|Subjects undergoing IVF or ICSI treatment with a maximum of 2 embryos transferred
3144419|NCT01587534|Experimental|pancreatic enzyme replacement therapy|The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
3144420|NCT01587534|No Intervention|Placebo|The placebo will match the active drug in appearance, taste, and weight and contained pharmacologically inactive substances.
3144421|NCT01587508|Active Comparator|meloxicam - Movatec®|
3144422|NCT01587508|Active Comparator|cyclobenzaprine - Miosan®,|
3144423|NCT01587508|Experimental|meloxicam/cyclobenzaprine hydrochloride|
3144424|NCT01587495|Experimental|Ertapenem|Women diagnosed with postpartum endometritis
3144425|NCT01587482||drug eluting balloon|"In this observationnal study, the intervention of interest is the use of drug eluting balloon in stent restenosis.~Only the treated patients were included in this cohort."
3144426|NCT01587469||HIV-infected and -uninfected individuals|HIV-infected and -uninfected individuals with suspected TB infection
3144427|NCT01587443||Hemodialysis|
3144428|NCT01587443||Peritoneal dialysis|
3144429|NCT01587430|Active Comparator|high dose ARA-C|High dose ARA-C will be applied after two 7+3 induction courses during the first and the second consolidation courses: ARA-C 1 g/m2 bid 1-3 days with idarubicin (8mg/m2 3-5 days)and mitoxantrone (10 mg/m2 3-5 days)
3144430|NCT01587430|Active Comparator|standard dose ARA-C|Standard dose ARA-C will be applied after two 7+3 induction courses the first and the second consolidation courses : ARA-C 100 g/m2 bid 1-7 days with idarubicin (8mg/m2 1-3 days)and mitoxantrone (10 mg/m2 1-3 days)
3144431|NCT01587417|Experimental|BI 187004 CL|1 single dose per subject as oral solution
3144432|NCT01587417|Placebo Comparator|Placebo to BI 187004 CL|1 single dose per subject as oral solution
3144433|NCT01587404|Experimental|Constant Catheter Contact Force|No alteration of catheter contact force during recording period
3144434|NCT01587404|Experimental|Variable catheter contact force|change in contact force from low to high after 30seconds of recording.
3144435|NCT01587391|Experimental|BI 163538 XX|1 single dose per subject as oral solution
3144436|NCT01587391|Placebo Comparator|Placebo to BI 163538 XX|1 single dose per subject as oral solution
3144437|NCT01587378|Experimental|metformin|
3144439|NCT01587365|Experimental|Panel 1: BMS-962476 SC (0.01 mg/Kg) or Placebo|BMS-962476 0.01 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
3144440|NCT01587365|Experimental|Panel 2: BMS-962476 SC (0.03 mg/Kg) or Placebo|BMS-962476 0.03 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
3144441|NCT01587365|Experimental|Panel 3: BMS-962476 SC (0.1 mg/Kg) or Placebo|BMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
3144442|NCT01587365|Experimental|Panel 4: BMS-962476 SC (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
3144443|NCT01587365|Experimental|Panel 5: BMS-962476 IV (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day
3144444|NCT01587365|Experimental|Panel 6: BMS-962476 IV (1.0 mg/Kg) or Placebo|BMS-962476 1.0 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day
3144445|NCT01587365|Experimental|Panel 7: Statin + BMS-962476 SC (0.1 mg/Kg) or Placebo|BMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
3144446|NCT01587365|Experimental|Panel 8: Statin + BMS-962476 SC (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
3144447|NCT01587352|Experimental|Treatment (vorinostat)|Patients receive vorinostat PO BID for 3 days weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3144448|NCT01587339||Drug-resistant (or refractory) partial epilepsy of all types|Drug-resistant (or refractory) partial epilepsy of all types
3144449|NCT01587326|Experimental|Escitalopram|Escitalopram 10 mg/d to 20 mg/d
3144450|NCT01587313|Experimental|Group 1|ISDN/HYD 2 SR caps crossover to 1 IR cap at 8 am
3144451|NCT01587313|Experimental|Group 2|ISDN/HYD 2 SR caps crossover to 1 IR cap at 5 pm
3144452|NCT01587313|Experimental|Group 3|ISDN/HYD 2 SR caps crossover to 1 IR cap at 8 pm
3144453|NCT01587313|Active Comparator|Group 4|ISDN/HYD 1 IR cap and two SR caps at 8 am crossover to Day 8: BiDil Tablet tid
3144454|NCT01587287||Corneal power measurement|All recruited volunteers in present study, that underwent corneal power measurement with 8 different instruments
3144455|NCT01587274|Active Comparator|Opioid|Naproxen + opioid
3144456|NCT01587274|Active Comparator|Skeletal muscle relaxant|Naproxen + skeletal muscle relaxant
3144457|NCT01587274|Active Comparator|Naproxen alone|Naproxen + placebo
3144458|NCT01587261|Placebo Comparator|Placebo|Victims of severe thermal injury receiving placebo Lactated Ringers solution for the first 24 hours
3144459|NCT01587261|Experimental|Vitamin C|Victims of severe thermal injury receiving high-dose vitamin C 66 mg/kg/hr for the first 24 hours
3144460|NCT01587248|Active Comparator|Electrocautery|Raising of the flaps with electrocautery
3144461|NCT01587248|Experimental|Harmonic|Dissection with harmonic scalpel in modified radical mastectomy
3144462|NCT01587235|Experimental|Vytorin|
3144463|NCT01587235|Active Comparator|Other Statin|
3144464|NCT01587222|Experimental|Albumin, Midodrine, Octreotide|
3144465|NCT01587209||Divers with decompression sickness|The sole group under study is SCUBA divers who have sustained decompression sickness
3144466|NCT01587196|Experimental|Naltrexone Intervention|Eligible participants receive up to three monthly injections of 380 mg of naltrexone contained in dissolvable polymer microspheres and administered by deep intramuscular injection and slowly released over a period of approximately 4 weeks.
3144467|NCT01587183|Other|Educational materials control|Enhanced usual care
3144468|NCT01587183|Active Comparator|Group running style B|Basic running instruction using group based training.
3144469|NCT01587183|Experimental|Group running style A|Form focused running instruction using group based training.
3144470|NCT01587170||Uninjured control subjects|Uninjured, control subjects who are not taking any of the contraindicated drugs.
3144471|NCT01587170||Spinal-cord injured subjects|Patients who have suffered a spinal cord injury (>1year ago).
3144472|NCT01587157|Experimental|capnography|
3144473|NCT01587144|Placebo Comparator|TMZ + Radiation + Placebo|Subjects will be randomly assigned to Lucanthone or Placebo arm in ratio of 1:1. The treatment period will be in two phases: an initial six weeks of concomitant therapy with TMZ and radiation, followed by a maintenance phase of six cycles of TMZ given on Days 1 to 5 of a 28-day cycle (+/- 3 days). Lucanthone/placebo will be given as an adjunct to TMZ in both phases.
3144474|NCT01587144|Active Comparator|Lucanthone + TMZ + Radiation|Subjects will be randomly assigned to Lucanthone or Placebo arm in ratio of 1:1. The treatment period will be in two phases: an initial six weeks of concomitant therapy with TMZ and radiation, followed by a maintenance phase of six cycles of TMZ given on Days 1 to 5 of a 28-day cycle (+/- 3 days). Lucanthone/placebo will be given as an adjunct to TMZ in both phases.
3144475|NCT01587131|Experimental|Group 1- DNA prime DNA boost|0.9 mg of FVH1 vaccine delivered ID followed by electroporation on Day 0, Week 15 and Week 27
3144476|NCT01587131|Experimental|Group 2 - DNA prime Seasonal Vaccine boost|0.9 mg FVH1 vaccine delivered ID followed by electroporation on Day 0 and Trivalent Seasonal Influenza Vaccine delivered IM on Week 15
3144477|NCT01587131|Placebo Comparator|Group 3 - sWFI prime Seasonal Vaccine boost|100 microliters of sterile water for injection delivered ID followed by electroporation on Day 0 and Trivalent Seasonal Influenza Vaccine delivered IM on Week 15
3144478|NCT01587118|Experimental|antidepressant plus asenapine|adjunctive asenapine
3144479|NCT01587105|No Intervention|Control|Usual Care Group
3144480|NCT01587105|Experimental|Comprehensive Care Management Service|Care Coordination through the Comprehensive Care Management Service at Seattle Children's Hospital
3144481|NCT01587092|Placebo Comparator|Usual Working Condition Group|Participants assigned to the usual working condition control group will continue to work in their usual environment and accustomed manner. The control group participants will have access to the Workstations at the completion of study.
3144534|NCT01586767|Active Comparator|Proton beam therapy|Subjects treated at Massachusetts General Hospital with proton beam therapy
3144535|NCT01586767|Active Comparator|IMRT|Intensity-modulated radiation therapy at institutions other than Massachusetts General Hospital
3144536|NCT01586754||With Metabolic Syndrome|
3144482|NCT01587092|Active Comparator|WorkStation Intervention Group|Participants will be asked to walk for up to 1.5 hours per day on the treadmill. This will be split into two 45 minute sessions per day. Behavioral support will focus on adherence to frequency (attending scheduled sessions). Participants self-select speed of walking and time (they have up to 45 minutes allotted, but may choose less as they like).
3144483|NCT01587079|Experimental|PT003 (Dose 1)|PT003 MDI Dose 1
3144484|NCT01587079|Experimental|PT003 (Dose 2)|PT003 MDI Dose 2
3144485|NCT01587079|Experimental|PT003 (Dose 3)|PT003 MDI Dose 3
3144486|NCT01587079|Experimental|PT003 (Dose 4)|PT003 MDI Dose 4
3144487|NCT01587079|Experimental|PT003 (Dose 5)|PT003 MDI Dose 5
3144488|NCT01587079|Experimental|PT001|PT001 MDI
3144489|NCT01587079|Experimental|PT005|PT005 MDI
3144490|NCT01587079|Active Comparator|Spiriva® Handihaler®|Tiotropium Bromide
3144491|NCT01587066|Active Comparator|Quetiapine fumarate|
3144492|NCT01587066|Active Comparator|Divalproex sodium|
3144493|NCT01587053||AVK|patient with AVK treatment
3144494|NCT01587040|Experimental|SAR245409|"SAR245409 as a single agent or in a combination (the following drugs may be used in combination with SAR245409:~letrozole~temozolomide~rituximab~bendamustine and rituximab)"
3144495|NCT01587040|Experimental|SAR245408|"SAR245408 as a single agent or in a combination (the following drugs may be used in combination:~paclitaxel and carboplatin~letrozole~trastuzumab~paclitaxel and trastuzumab)"
3144496|NCT01587027|Active Comparator|Sequence A|Aminophylline, Methazolamide, Aminophylline and Methazolamide
3144497|NCT01587027|Active Comparator|Sequence B|Methazolamide, Aminophylline, Aminophylline and Mathazolamide
3144498|NCT01587001|Active Comparator|Oral N-acetyl-cysteine|oral NAC 900mg three times daily for 8 weeks
3144499|NCT01587001|Placebo Comparator|Matching Placebo|oral placebo three times daily for 8 weeks
3144500|NCT01586988|Experimental|IMAGE Intervention|mothers are provided the IMAGE Parenting and Self-Care intervention
3144501|NCT01586988|No Intervention|Control|Standard care.
3144502|NCT01586975|Active Comparator|Clopidogrel 75 mg|Clopidogrel 75 mg daily
3144503|NCT01586975|Active Comparator|Aspirin 81 mg|open-label Aspirin 81 mg daily
3144504|NCT01586975|Active Comparator|Aspirin > 300mg|open-label Aspirin over 300 mg daily
3144505|NCT01586962|Experimental|Upper Respiratory Infections|
3144506|NCT01586949|Experimental|Treatment|Intervention: Daily Challenge
3144507|NCT01586949|No Intervention|Control|Weekly Well-being, an email-based health information delivery service.
3144508|NCT01586936||eptacog alpha users|
3144509|NCT01586923|Active Comparator|Short-storage RBC|RBC transfusion using packed RBCs stored for 10 days or less.
3144510|NCT01586923|Active Comparator|Prolonged-storage RBC|RBC transfusion using packed RBCs stored for 25 days or more.
3144511|NCT01586910|Experimental|Medtronic CoreValve® System TAVI|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
3144512|NCT01586910|Active Comparator|SAVR|Surgical Aortic Valve Replacement (SAVR) (Not applicable for Single Arm)
3144513|NCT01586897|Experimental|Use of Medication Metronome|Providers allocated to intervention will automatically see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
3144514|NCT01586897|Active Comparator|Usual Care|PCPs allocated to the control arm will continue with usual care practices for laboratory monitoring.
3144515|NCT01586884|Experimental|Intervention|"Ten patients undergoing LV lead placement for either initial CRT device implant or revision of an existing system at Lancaster General Hospital who meet the inclusion and exclusion criteria will be screened and approached for enrollment in this safety and feasibility study. Study participants may have ischemic or non-ischemic cardiomyopathy; results for ischemic and non-ischemic patients will be analyzed separately. Any device system from any manufacturer may be used; the choice of device and leads will be at the implanting physician's discretion.~Post implant procedures will be the same as those for any CRT implant. Outpatient follow-up other than the 1-month follow-up will be per the implanting physician's usual practice."
3144516|NCT01586858||RAVE subjects|
3144517|NCT01586845|Experimental|Voclosporin|Voclosporin
3144518|NCT01586845|Active Comparator|Tacrolimus|Tacrolimus
3144519|NCT01586832||ED Nurses|"Nurses in the emergency department (ED) providing patient care using supplies found in the stocking towers"
3144520|NCT01586819|Active Comparator|Botulinum Toxin|The botulinum toxin will be injected into the wrinkles. The injections will take about 10 minutes to complete. Five follow-up visits will be scheduled at 1-7 days, 7-10 days, 2.5-3 weeks, and 12-14 weeks.
3144521|NCT01586819|Active Comparator|Chemical Peel Only|"After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water.~Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly."
3144522|NCT01586806|Placebo Comparator|Control|
3144523|NCT01586806|Active Comparator|Dexamethasone 1 mg|
3144524|NCT01586806|Active Comparator|Dexamethasone 4 mg|
3144525|NCT01586793|Experimental|High Frequency rTMS|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
3144526|NCT01586793|Experimental|Low Frequency rTMS|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
3144527|NCT01586780|Experimental|Reference meal|
3144528|NCT01586780|Experimental|Whey protein|
3144529|NCT01586780|Experimental|Whey + 5 amino acids|
3144530|NCT01586780|Experimental|Whey + 6 amino acids|
3144531|NCT01586780|Experimental|Soy protein drink|
3144532|NCT01586780|Experimental|Soy + 5 amino acids|
3144533|NCT01586780|Experimental|Soy + 6 amino acids|
3144537|NCT01586754||Without Metabolic Syndrome|
3144538|NCT01586741|Active Comparator|Polypropylene mesh|Reconstruction of the abdominal wall diastasis with insertion of a polypropylene mesh on 30 patients.
3144539|NCT01586741|Active Comparator|quill suture|Reconstruction of the abdominal wall diastasis with double row absorbable suture ( Quill Self-retaining system) on 30 patients.
3144540|NCT01586741|No Intervention|conservative treatment|Regular abdominal exercises workout for three months for 30 patients.
3144541|NCT01586728|Other|Air - oxygen|One period in room air and one period with nocturnal oxygen therapy, separated by a wash out period of 2 to 6 weeks.
3144542|NCT01586728|Other|Oxygen - Air|One period with nocturnal oxygen therapy and one period in room air, separated by a wash out period of 2 to 6 weeks.
3144543|NCT01586715|Experimental|Autologous Stem Cells|
3144544|NCT01586702|No Intervention|Regular care|Consisting of structured information given at hospital discharge regarding stroke etiology and recommended secondary prevention plus regular outpatient care by general practitioners or family doctors.
3144545|NCT01586702|Active Comparator|Support program|In addition to regular care: Up to 8 appointments in outpatient clinics. Results of risk factor measurements and assessed adherence to medical recommendations are shared with the patients. In case that a patients fails to meet target values, preventive measures will be modified directly or via recommendation to GPs / family doctors. Patients are also offered assistance in finding appropriate physical activities or smoking cessation programs.
3144546|NCT01586689|Experimental|Safe Haven|participants assigned to the Safe haven condition and agree to move into the A Safe Haven residential treatment facility
3144547|NCT01586689|Experimental|Usual aftercare|participants assigned to the control condition, and may or may not seek treatment on their own
3144548|NCT01586689|Experimental|Oxford House|participants who were assigned to the Oxford House condition and agree to move into an Oxford House
3144549|NCT01586676|Experimental|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP)
3144550|NCT01586676|Active Comparator|Supervision-as-usual|Supervision-as-usual consists of the typical clinical supervision services provided to clinicians by their supervisors in their community programs.
3144551|NCT01586663|Experimental|Experimental Group|Splint group
3144552|NCT01586663|Active Comparator|Control Group|Drug treatment
3144553|NCT01586650|Experimental|Aerobic training|The patients in this arm perform a 50-minute-walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
3144554|NCT01586650|Placebo Comparator|Stretching exercises|The control group perform global stretching exercises for approximately 20 minutes 3 times a week for 12 weeks.
3144555|NCT01586637|Experimental|Art Therapy|This group performed dance classes and regarding the art therapy they have art classes where they learn how to use the drawing to express feelings. The classes were twice a week.
3144556|NCT01586637|Experimental|Walking|The group walked twice a week during one hour.
3144557|NCT01586611|Active Comparator|Gemcitabine|Cycles to be 4 weeks in length Gemcitabine 1000 mg/m2 IV weekly for 3 weeks then one week off
3144558|NCT01586611|Experimental|FOLFOX|Cycles to be 2 weeks in length Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1
3144559|NCT01586598|No Intervention|control group|No intervention will be given to this control group. Spontaneous recovery of mandibular nerve will be assessed for sensory function.
3144560|NCT01586598|Experimental|sensory retraining group|Sensory retraining protocol will be applied this group. Any facilitation of sensory function in mandibular nerve will be assessed.
3144561|NCT01586585||post cardiac surgery patients|
3144562|NCT01586572|Experimental|mOPV1- Arm A|Arm A will be administered a second dose of mOPV1 seven days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at day 79.
3144563|NCT01586572|Experimental|mOPV1- Arm B|Arm B will be administered a second dose of mOPV1 fourteen days after after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 86 days.
3144564|NCT01586572|Experimental|mOPV1-Arm C|Arm C will receive the second dose of mOPV1 thirty days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 102 days.
3144565|NCT01586572|Experimental|Arm D- bOPV1,3|Arm D will be administered a second dose of bOPV1,3 thirty days after the 42 day bOPV1,3 index dose.Second dose of tOPV2 will be given at day 102.
3144566|NCT01586559||Control group|Nulliparous women
3144567|NCT01586559||Diastasis|Patients after rectus sheath plication due to diastasis
3144568|NCT01586546|Experimental|Face-to-Face MBM Skills Group|
3144569|NCT01586546|Experimental|Online MBM Skills Group|
3144570|NCT01586546|No Intervention|Waitlist Control I|This group will be given the option to participate in a face-to-face MBM skills group intervention after conclusion of study.
3144571|NCT01586546|No Intervention|Waitlisted Control II|This group will be given the option to participate in an Online MBM skills group intervention after conclusion of study.
3144572|NCT01586533|Experimental|Zoenasa-1:4|
3144573|NCT01586533|Active Comparator|Mesalamine Enema|
3144574|NCT01586520||Disease positive|Imaging or biopsy evidence of disease
3144575|NCT01586520||Disease negative|No evidence of disease
3144576|NCT01586507|Experimental|Group 1|
3144577|NCT01586507|Experimental|Group 2|
3144578|NCT01586494|Experimental|Group 1|
3144579|NCT01586494|Experimental|Group 2|
3144580|NCT01586481|Active Comparator|barouk|
3144581|NCT01586481|Experimental|sanidiab|
3144582|NCT01586468|Placebo Comparator|NaCl Solution|
3144583|NCT01586468|Experimental|WF10 0.5 ml/kg BW|
3144584|NCT01586455|Experimental|Group A|related cord blood with ≥3/6 HLA match to the patient and related HPDSC
3144585|NCT01586455|Experimental|Group B|unrelated cord blood with ≥ 4/6 HLA match to the patient and unrelated HPDSC
3144586|NCT01586455|Experimental|Group C|unrelated cord blood with ≥4/6 HLA match to the patient but related to HPDSC
3144587|NCT01586455|Experimental|Group D|double unrelated cord blood units with ≥4/6 HLA match to patient and each other and unrelated HPDSC
3144588|NCT01586442|Active Comparator|Spironolactone|spironolactone 12.5mg once daily titrated to 25mg once daily
3283949|NCT00596401||2|No eradication group
3144589|NCT01586442|Experimental|Eplerenone|Eplerenone 25mg once daily titrated to 50mg once daily
3144590|NCT01586429||Epidural|
3144591|NCT01586429||Femoral catheter|
3144592|NCT01586416|Experimental|Behavioral Intervention|Brief behavioral intervention on 2-3 sessions of tailored cognitive-behavioral therapy to support chemotherapy adherence and well-being of patients completing chemotherapy for colon cancer.
3144593|NCT01586403|Experimental|Dose 1|Subjects in cohort 1 will receive 2.5 x 106 TIL 1383I TCR transduced T cells per kg body weight
3144594|NCT01586403|Experimental|Dose 2|cohort 2 will receive 7.5 x 106 TIL 1383I TCR transduced T cells per kg body weight.
3144595|NCT01586403|Experimental|Dose 3|Subjects in cohort 3 will receive 2.5 x 107 TIL 1383I TCR transduced T cells per kg body weight.
3144596|NCT01586403|Experimental|Dose 4|Subjects will then receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 4 will receive 7.5 x 107 TIL 1383I TCR transduced T cells per kg body weight.
3144597|NCT01586390|Experimental|MOK|Adjustable and removable brace made out of Softcast material
3144598|NCT01586390|Active Comparator|WRAP|Softcast ankle cast
3144599|NCT01586377||CRPS Type 1|Patients with CRPS 1 affecting a single upper limb
3144600|NCT01586377||Healthy volunteers|Volunteers without the diagnosis of CRPS Type 1
3144601|NCT01586364|Experimental|Ospemifene 60 mg Oral Tablet|Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.
3144602|NCT01586351||Patch and ACP Treatment|Patents who get an patch augmentation and ACP injection following an arthroscopic repair of the rotator cuff.
3144603|NCT01586338|Experimental|Synvisc|Three intra-articular (IA) injections of Synvisc (2.25 ml glass syringe containing 16 mg hylan G-F 20) at intervals of one week. The total duration of observation was 26 weeks.
3144604|NCT01586325|Experimental|Panel 1|Study participants will receive double-blind treatment with JNJ-47910382 30 mg or matching placebo. Participants in each of Panel will be treated sequentially (ie, participants in Panel 1 will be treated before participants in Panel 2, participants in Panel 2 will be treated before participants in Panel 3).
3144605|NCT01586325|Experimental|Panel 2|Study participants will receive double-blind treatment with JNJ-47910382 90 mg or matching placebo. Participants in each of Panel will be treated sequentially.
3144606|NCT01586325|Experimental|Panel 3|Study participants will receive double-blind treatment with JNJ-47910382 200 mg (maxiumum dose) or matching placebo. Participants in each of Panel will be treated sequentially.
3144607|NCT01586312|Experimental|Allogenic mesenchymal stromal cells injection|Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.
3144608|NCT01586312|Active Comparator|Hyaluronic acid (Durolane)|Intraarticular injection of hyaluronic acid (60 mg)
3144609|NCT01586299|Experimental|ibuprofen|
3144610|NCT01586299|Active Comparator|acetaminophen|
3144611|NCT01586286|Placebo Comparator|Ointment Base|Patients in this arm will serve as the control and will undergo pelvic floor physical therapy and receive placebo (lanolin and mineral oil base).
3144612|NCT01586286|Active Comparator|Nifedipine Ointment|Patients in this arm will undergo pelvic floor physical therapy, but will receive compounded vaginal nifedipine.
3144613|NCT01586273|Experimental|MR-HIFU treatment|Subjects undergo a MR-HIFU treatment for pain palliation of bone metastases on their most painful metastasis.
3144614|NCT01586260|Experimental|DFMO|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
3144615|NCT01586247|Experimental|Synbiotic|8g/day gluco-oligosaccharide + 109 CFU/day B. lactis BI07
3144616|NCT01586247|Experimental|Placebo|8g/day maltodextrin
3144617|NCT01586247|Experimental|Prebiotic|8g/day galacto-oligosaccharides (GOS)
3144618|NCT01586247|Experimental|Probiotic|109 CFU/day B. lactis BI07
3144619|NCT01586234|Experimental|DSAEK with graft shaping and smoothing|
3144620|NCT01586234|Active Comparator|Standard DSAEK|
3144621|NCT01586221|Other|Music & Physical Therapy|Subjects will received Music and Physical Therapy in a group setting.
3144622|NCT01586208|Active Comparator|40mg/kg intial valproate bolus|Patient receives a 40mg/kg valproate bolus with a maintenance of 1mg/kg/h, after benzodiazepine + phenytoin administration
3144623|NCT01586208|Active Comparator|20mg/Kg intial bolus valproate|Patient receives a 20mg/kg valproate bolus with a maintenance of 1mg/kg/h, after benzodiazepine + phenytoin administration
3144624|NCT01586195|Experimental|Vemurafenib|Participants with untreated or previously treated locally advanced, unresectable, Stage IIIc or metastatic melanoma who have an activating exon 15 BRAF mutation other than V600E received vemurafenib 960 milligram (mg) orally twice daily (BID) until disease progression.
3144625|NCT01586182|Experimental|Stereotactic Boost|Escalating doses of stereotactic body radiation therapy (SBRT)
3144626|NCT01586156|Active Comparator|Open Label Carvedilol|Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight to the CRU (Clinical Research Unit) for the first-dose challenge of carvedilol. Subjects will take the medication for one week and at the end of one week, eligible subjects will be randomized to one of two groups (blinded). Group 1 will receive 3.125mg twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme. They will be given 3.125mg tablets to take twice daily for one week, followed by 6.25 mg twice daily for one week, followed by 12.5mg twice daily for one week with the option to increase to the max dose of 25mg twice daily for the remainder of the study.
3144627|NCT01586156|Placebo Comparator|Placebo Arm|Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight for the first-dose challenge of carvedilol. After one week run in phase, subjects will be placed on placebo. Subjects and Investigators will be blinded to the group assignment for the duration of the study.
3144671|NCT01585831|Experimental|Testosterone gel 1%|Testosterone gel 1% applied to skin once per day for 1 year. Starting dose 1.25mL per day, titrated in 1.25mL increments for 1st 6 months of study after each study visit up to maximum of 5.0mL per day. Titration based on testosterone levels with target level in mid-range of normal for Tanner stage.
3283950|NCT00596401||3|No Hp group
3144628|NCT01586143|Experimental|transbuccal paracetamol 125 mg|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
3144629|NCT01586143|Placebo Comparator|placebo|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
3144630|NCT01586130|Other|isokinetic exercises in eccentric mode|
3144631|NCT01586130|Other|isokinetic exercises in concentric mode|
3144632|NCT01586117|Experimental|Amifostine|intrarectal Amifostine assign to the Amifostine arm
3144633|NCT01586104|Experimental|Treatment (IMRT)|Patients undergo cardiac-sparing whole lung IMRT.
3144634|NCT01586091|Active Comparator|levocetirizine|
3144635|NCT01586091|Active Comparator|fexofenadine|
3144636|NCT01586065|Experimental|CGM|
3144637|NCT01586065|Other|Control|Fingerstick BGs only, no CGM
3144638|NCT01586052|Experimental|Erythropoietin and Rehabilitation|recombinant human erythropoietin injection and active rehabilitation
3144639|NCT01586039|Active Comparator|Compact Fluorescent Light|
3144640|NCT01586039|Experimental|Blue-depleted LED light|
3144641|NCT01586026||Group A|Maintenance flushes at days 1-28
3144642|NCT01586026||Group B|Maintenance flushes at days 29-56
3144643|NCT01586026||Group C|Maintenance flushes at days 57+
3144644|NCT01586013|Experimental|propofol infusion|Healthy adults scheduled for elective surgery will receive a computer controlled infusion until obtain the loss of counsiousness (BIS <50). After stoping the infusion we observe the emergency of anesthesia and the correspondant BIS curve. Using the complete loss and recovery curve of BIS we can describe the course of the effect of the drug. Venous sample will be taken during the study to evaluate the pharmacokinetic performance of the model.
3144645|NCT01586000|Experimental|10 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
3144646|NCT01586000|Experimental|20 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
3144647|NCT01586000|Experimental|40 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
3144648|NCT01585987|Experimental|Arm A: Ipilimumab|Ipilimumab 10 mg/kg solution intravenously, 90 minute infusion, once every 3 weeks for 4 doses, then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)
3144649|NCT01585987|Other|Arm B: Best Supportive care (BSC)|BSC may include the continuation of the Fluoropyrimidine that was used during the lead-in chemotherapy, but no other systemic anti cancer therapy
3144650|NCT01585974||Group 1|
3144651|NCT01585961||Catheter Ablation|These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and have provided written informed consent to participate in the study, including consent to undergo catheter ablation with the study device.
3144652|NCT01585948||Diabetes Mellitus|All patients undergoing coronary angiography who are diabetics.
3144653|NCT01585948||No diabetes mellitus|All patients undergoing coronary angiography that are non-diabetics.
3144654|NCT01585948||Coronary angiography patients|Diabetics and non-diabetics with or without known CV disease who are admitted in the Department of Cardiology in the University Hospital of Ioannina and the Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. The study will include subjects who 1) have suspected CAD and undergo a scheduled diagnostic angiogram for clinical reasons, and 2) are hospitalized because of an acute coronary syndrome and thus undergo diagnostic angiography (with or without previous history of CAD).
3144655|NCT01585935|Experimental|Smoflipid|SMOFLIPID will be used for parenteral lipid supply
3144656|NCT01585935|Active Comparator|Intralipid|INTRALIPID will be used for parenteral lipid supply
3144657|NCT01585922|Experimental|NPPV|Use the NPPV to treat moderate ARDS
3144658|NCT01585922|Active Comparator|IMV|Use invasive mechanical ventilation in treating the patients allocated to this group.
3144659|NCT01585909|Other|Septic Shock|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients with septic shock
3144660|NCT01585909|Other|SIRS|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients with SIRS
3144661|NCT01585909|Other|healthy/controls|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients without SIRS/septic shock
3144662|NCT01585896|Experimental|Self-help group|The facilitated self-help group, which represents an empirically supported intervention for hoarding (Frost et al., 2011).
3144663|NCT01585883|Experimental|Self-management Intervention|Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session.
3144664|NCT01585883|Active Comparator|Standard of care|Patients in this condition will receive usual care as decided by their oncology clinic team or physician.
3144665|NCT01585870|Experimental|Sorafenib + Eribulin|
3144666|NCT01585857|Experimental|Group 1|2 x 10E6 ASC intra-articular injection (5 ml)
3144667|NCT01585857|Experimental|Group 2|10 x 10E6 ASC intra-articular injection (5 ml)
3144668|NCT01585857|Experimental|Group 3|50 x 10E6 ASC intra-articular injection (5 ml)
3144669|NCT01585844||Women with sleep apnea|
3144670|NCT01585844||Women without sleep apnea|
3144672|NCT01585831|Placebo Comparator|Placebo gel|Placebo gel applied to skin once per day for 1 year. Starting dose 1.25mL per day. Dose randomly adjusted in 1.25mL increments for 1st 6 months of study after each study visit up to maximum of 5.0mL per day.
3290670|NCT00541567|Placebo Comparator|1|
3144673|NCT01585818|Active Comparator|standard dietary intervention (SDI) arm|The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre
3144674|NCT01585818|Experimental|LGI intervention arm|The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI. Participants will be provided with a list of low GI carbohydrates to consume during the intervention period and in addition, they will be provided with a supply of the staples for the same period
3144675|NCT01585805|Experimental|Arm A (veliparib, gemcitabine hydrochloride, cisplatin)|Patients receive veliparib PO BID on days 1-12 or 1-21. Patients also receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 30 minutes on days 3 and 10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3144676|NCT01585805|Active Comparator|Arm B (gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV and cisplatin IV as patients in arm A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3144677|NCT01585805|Experimental|Arm C (veliparib)|Patients receive veliparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3144678|NCT01585792|Experimental|TAK-875 25 mg|
3144679|NCT01585792|Experimental|TAK-875 50 mg|
3144680|NCT01585792|Active Comparator|Glimepiride|
3144681|NCT01585792|Placebo Comparator|Placebo|
3144682|NCT01585779||Contour 3D® Implant|The subject population includes patients indicated for a TV repair procedure concomitant to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® ring most appropriate to reconstruct the diseased valve. Patients with primary TV regurgitation will not be included in this study. Implantation with the Contour 3D® ring will occur in conjunction with another concomitant surgical repair procedure
3144683|NCT01585779||Tri-Ad® Implant|The subject population includes patients indicated for a TV repair procedure concomitant to left-sided heart surgery, and for whom the surgeon considers the implantation of a Tri-Ad® ring most appropriate to reconstruct the diseased valve. Patients with primary TV regurgitation will not be included in this study. Implantation with the Tri-Ad® ring will occur in conjunction with another concomitant surgical repair procedure
3144684|NCT01585766|Experimental|MEDI-551 Dosage 1|Dosage Level 1 x 2 MEDI-551 IV
3144685|NCT01585766|Experimental|MEDI-551 Dosage 2|Dosage Level 2 x 2 MEDI-551 IV
3144686|NCT01585766|Experimental|MEDI-551 Dosage 3|Dosage Level 3 x 1 MEDI-551 SC
3144687|NCT01585766|Experimental|MEDI-551 Dosage 4|Dosage Level 4 x 1 MEDI-551 SC
3144688|NCT01585766|Experimental|MEDI-551 Dosage 5|Dosage Level 5 x 2 MEDI-551 IV
3144689|NCT01585766|Placebo Comparator|Placebo IV|Placebo IV x 2
3144690|NCT01585766|Placebo Comparator|Placebo SC|Placebo SC x 1
3144691|NCT01585753||Arm 1|NRTI and PI
3144692|NCT01585753||Arm 2|Maraviroc + PI
3144693|NCT01585753||Arm 3|maraviroc + NRTI
3144694|NCT01585740|Active Comparator|Normal Saline|250 patients in this arm assigned to receive normal saline as the study fluid
3144695|NCT01585740|Active Comparator|Ringer's Lactate|250 patients in this arm assigned to receive Ringer's Lactate as the study fluid
3144696|NCT01585727|Experimental|TME with neuromonitoring|Total mesorectal excision with intraoperative neuromonitoring of pelvic autonomic nerves.
3144697|NCT01585727|Active Comparator|TME without neuromontoring|Total mesorectal excision without intraoperative neuromonitoring of pelvic autonomic nerves.
3144698|NCT01585688|Experimental|hLL1-DOX|
3144699|NCT01585675||Diagnosis/treatment of lung cancer|Specimen Banking
3144700|NCT01585662|Experimental|Naso-pancreatic tube|The patients enrolled in this group will be treated with modified naso-pancreatic tube drainage method.
3144701|NCT01585662|Experimental|Stents|The patients enrolled this group will be treated by placing the stents (at least 2 stents) between gastric and pancreatic pseudocyst.
3144702|NCT01585649|Experimental|XM22, 100 μg/kg BW|
3144703|NCT01585636|Experimental|5 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
3144704|NCT01585636|Experimental|10 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
3144705|NCT01585636|Experimental|20 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
3144706|NCT01585636|Experimental|50 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
3144707|NCT01585636|Experimental|100 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
3144708|NCT01585636|Experimental|200 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
3144709|NCT01585636|Experimental|300 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
3144710|NCT01585636|Experimental|Food effect group|6 Subjects received single, 300 mg SQ109 after high-fat, high-calorie meal.
3144711|NCT01585623|Experimental|Segment 1|two single doses of omeprazol/metoprolol/midazolam on day-1 and day 15 without food, SAR302503 500 mg once daily without food for 15 days
3144712|NCT01585623|Experimental|Segment 2|SAR302503 500 mg once daily without food in 28-day per cycle
3144713|NCT01585610|Experimental|DVD Program|
3144714|NCT01585610|Active Comparator|Standard Care Printed Materials|
3144715|NCT01585597|Experimental|Mild Hypothermia|Reduction of body temperature to 34 degrees centigrade. This will be accomplished using the Zoll Coolguard .
3144716|NCT01585584|Experimental|Boceprevir|
3144717|NCT01585571||Control|50 individuals of typical development with no known neuromuscular issues.
3144718|NCT01585571||Adults with CP|50 Individuals with a pediatric diagnosis of spastic, hemiplegic, diplegic or quadriplegic cerebral palsy.
3144719|NCT01585558|Experimental|Treatment Group 1|
3144720|NCT01585558|Experimental|Treatment Group 2|
3144721|NCT01585558|Placebo Comparator|Treatment Group 3|
3144722|NCT01585545||patients with NSCLC|
3144723|NCT01585532||TB suspects with alternative final diagnosis|
3144724|NCT01585532||Confirmed tuberculosis patients|
3144725|NCT01585519|No Intervention|(Group 1) Low Apple Diet|
3144726|NCT01585519|Experimental|(Group 2) 2 High Apples|
3144727|NCT01585519|Experimental|(Group 3) 2 Low Apples|
3144728|NCT01585519|Experimental|(Group 4) 2 x 4.4g apple granules|
3144729|NCT01585519|Experimental|(Group 5) 2 x Apple Extract Capsules|
3144730|NCT01585506||Questionnaire responders|
3144731|NCT01585493|Active Comparator|Treatment as usual|Treatment as usual
3144732|NCT01585493|Active Comparator|Care coordinator|
3144733|NCT01585493|Experimental|CHANGE|
3144734|NCT01585480|Experimental|weight gain prevention intervention|
3144735|NCT01585480|No Intervention|No treatment comparison group|
3144736|NCT01585441|Experimental|Finasteride 5 mg|Participants randomly assigned to the finasteride 5 mg arm were instructed to take one capsule daily for three months.
3144737|NCT01585441|Placebo Comparator|Placebo|Participants randomly assigned to the placebo arm will instructed to take one capsule daily for three months.
3144738|NCT01585428|Experimental|Cervical|Patients will receive a non-myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of Young tumor infiltrating lymphocytes (TIL) plus high dose IV aldesleukin.
3144739|NCT01585428|Experimental|NonCervical|Patients will receive a non-myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of Young tumor infiltrating lymphocytes (TIL) plus high dose IV aldesleukin
3144740|NCT01585415|Experimental|Single Arm|Two weeks prior to the start of the preparative regimen, patients will begin taking vemurafenib. Patients will then receive lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine, followed by young TIL and high dose aldesleukin
3144741|NCT01585402|Experimental|Etidronate|20 mg/kg oral 14 days on / 10 weeks off study drug
3144742|NCT01585350|Experimental|Cohort 1|"Vaccines will be administered subcutaneously, intradermally or transdermally in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on days 1, 8, 15, 36, 57, and 78."
3144743|NCT01585350|Experimental|Cohort 2|"Vaccines will be administered subcutaneously, intradermally or transdermally in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on days 1, 8, 15, 36, 57, and 78."
3144744|NCT01585337||patients with lumbar fusion|
3144745|NCT01585324|Experimental|Single Arm|
3144746|NCT01585311||Subarachnoid Hemorrhage patients|SAH patients with hourly eMR values of Heart Rate
3144747|NCT01585298|Experimental|Fingolimod|
3144748|NCT01585285|Experimental|LIMA to SVG Bridge|Patients will receive composite coronary artery bypass grafting (CABG) with left internal mammary artery (LIMA) and saphenous vein graft (SVG) Bridge for the anterolateral targets
3144749|NCT01585285|Active Comparator|Conventional CABG|Patients will receive conventional coronary artery bypass grafting (CABG) with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
3144750|NCT01585272|Experimental|Rivastigmine|Eligible patients, who are under rivastigmine capsule 3 mg b.i.d. treatment for 4 weeks before Visit 2, will be recruited, followed by treatment switch from oral capsule to transdermal patch for 48 weeks maintenance treatment.
3144751|NCT01585259|Active Comparator|Anfibatide|Bolus injection will be finished in 5 minutes immediately when the guidewire passes through the first stenosed vessel; bolus injection of different doses+0.002IU/kg/h intravenous infusion for 48h
3144752|NCT01585259|Placebo Comparator|Placebo|Bolus injection will be finished in 5 minutes immediately when the guidewire passes through the first stenosed vessel; bolus injection of different doses+0.002IU/kg/h intravenous infusion for 48h
3144753|NCT01585246|Other|Phase 1: The dose finding phase (DFP)|Patients received Saw Palmetto Soft Gel capsules in 320mg or 640mg or 960mg to determine the maximum therapeutic dose
3144754|NCT01585246|Active Comparator|Phase 2: RCT phase- Saw Palmetto|Patients received the predetermine the maximum therapeutic dose of Saw Palmetto Soft Gel capsules in phase 1, which is 960mg.
3144755|NCT01585246|Placebo Comparator|Phase 2: RCT phase- Placebo|Patients received Soybean Oil Soft Gel as the placebo treatment
3144756|NCT01585233|Experimental|Cohort 1|ASKP1240 lowest dose
3144757|NCT01585233|Experimental|Cohort 2|ASKP1240 low dose
3144758|NCT01585233|Experimental|Cohort 3|ASKP1240 high dose
3144759|NCT01585233|Experimental|Cohort 4|ASKP1240 highest dose
3144760|NCT01585233|Placebo Comparator|Placebo|
3144761|NCT01585220|Experimental|Neuramis|
3144762|NCT01585220|Active Comparator|Restylane®|
3144763|NCT01585207|Experimental|Vigabatrin|3 tablets, bid for 8 weeks
3144764|NCT01585194|Experimental|Nivolumab + Ipilimumab|"Induction Phase:~Nivolumab 1 mg/kg plus Ipilimumab 3 mg/kg (+/- 7 days) for total of four doses (week 1, 4, 7, 10), continues through week 12.~Maintenance Phase:~For participants with no disease progression or unmanageable toxicity by week 12, Nivolumab monotherapy 480 mg every 4 weeks until disease progression or unmanageable toxicity."
3144765|NCT01585181|Placebo Comparator|Placebo|
3144766|NCT01585181|Experimental|PXVX0200|
3144767|NCT01585168|Experimental|Family history positive, Memantine first, then placebo|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
3144768|NCT01585168|Placebo Comparator|Family history positive, placebo first, then Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
3144769|NCT01585168|Experimental|Family history negative, Memantine first, then placebo|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
3144815|NCT01584843|Active Comparator|GSK1358820 5.0 U (20-50 PD)|Receive 5.0 U of GSK1358820 on Week 0
3144816|NCT01584830|Experimental|Arm 1|
3144770|NCT01585168|Placebo Comparator|Family history negative, placebo first, then Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
3144771|NCT01585155|Experimental|TA-650|
3144772|NCT01585142|Experimental|BabyNes system formula|
3144773|NCT01585129|Experimental|Postpartum Antibiotics|Patients will receive one additional dose of postpartum antibiotics (Clinda, Gentamicin)
3144774|NCT01585129|Placebo Comparator|No postpartum antibiotics|No further postpartum antibiotics
3144775|NCT01585103|Experimental|Cytosponge/ brushing|
3144776|NCT01585090|Experimental|passive ankle dorsi ﬂexion|doing strengthening exercises of PFM in standing position with passive ankle dorsi ﬂexion (on wooden surface with 15 degree angle)
3144777|NCT01585090|Experimental|active ankle plantar ﬂexion with arm up|doing strengthening exercises of PFM in standing position with active ankle plantar ﬂexion with arm up (standing on toe)(n=20) and horizontal standing position
3144778|NCT01585090|No Intervention|horizontal standing position|doing strengthening exercises of PFM in standing position with horizontal standing position
3144779|NCT01585077|Experimental|Naive volunteers|Volunteers without previous exposure to malaria, and negative antibody titers (<1:20) against native protein of P. vivax.
3144780|NCT01585077|Experimental|Pre-immune volunteers|Volunteers with previous exposure to malaria, and positive antibody titers against native protein of P. vivax
3144781|NCT01585064||DAS28-IOMS|Physicians randomized to the DAS28-IOMS will treat patients according to a protocol aimed at achieving a DAS28 score under 2.4.
3144782|NCT01585064||0SJ-IOMS|Physicians randomized to the 0SJ-IOMS will treat patients according to a protocol aimed at attaining a count of zero swollen joint (28 joints evaluated).
3144783|NCT01585064||Routine Care (RC)|Physicians randomized to the RC group will treat study patients as per routine care and according to their own judgment.
3144784|NCT01585051|Active Comparator|vitamin D|Intervention: Intramuscular injection of 300 000 U of 25(OH)vitamin D
3144785|NCT01585051|Placebo Comparator|placebo|administration of 0.9 % NaCl as a placebo
3144786|NCT01585038|Active Comparator|Efavirenz|Efavirenz 600mg given nightly without food for 30 days
3144787|NCT01585038|Active Comparator|Rilpivirine|Rilpivirine 25mg given daily with meals for 30 days
3144788|NCT01585025|Experimental|Obeticholic acid|Obeticholic acid 25mg once daily for 15 days.
3144789|NCT01585012|Experimental|Cervical cap|Collection condom with cervical cap inserted
3144790|NCT01584999|Active Comparator|Fresh not-leukocyte-reduced RBCs|
3144791|NCT01584999|Active Comparator|Fresh RBCs leukocyte-reduced|
3144792|NCT01584999|Active Comparator|RBCs with storage longer than 15 days|
3144793|NCT01584986|Active Comparator|ACP treated|Autologous angiogenic cell precursors (ACPs) were injected into the ischemic gastrocnemius muscle in addition to the conventional treatment.
3144794|NCT01584986|No Intervention|Control|Control patients were treated with the conventional therapy.
3144795|NCT01584973||cruciate ligament group|
3144796|NCT01584973||control group|
3144797|NCT01584960|Experimental|Prostate cancer, endurance training|Prostate cancer patients doing 2 years of home-based endurance training Cross over design with a control group with no intervention
3144798|NCT01584947|Placebo Comparator|Placebo lozenge|The patients will be randomized to start two weeks treatment with either a bupivacaine lozenge or a placebo lozenge (taken three times a day). The two weeks treatment is followed by a week without treatment. Afterwards they start another two weeks treatment with the opposite type of lozenge from the first treatment period.
3144799|NCT01584947|Active Comparator|Bupivacaine lozenge|The patient will be randomized to start two weeks treatment with either a bupivacaine lozenge or a placebo lozenge (taken three times a day). The two weeks treatment is followed by a week without treatment. Afterwards the patient starts another two weeks treatment with the opposite type of lozenge from the first treatment period.
3144800|NCT01584934|Experimental|Sodium oxybate|Patient group receives sodium oxybate as treatment.
3144801|NCT01584934|Placebo Comparator|Placebo|Patient group receives placebo as treatment.
3144802|NCT01584921|Placebo Comparator|Placebo|1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
3144803|NCT01584921|Active Comparator|Low dose Erythropoietin|
3144804|NCT01584921|Active Comparator|High dose Eryhropoietin|
3144805|NCT01584895|Experimental|Rehab|Patients randomized into early cardiac rehabilitation
3144806|NCT01584895|No Intervention|Control|No cardiac rehabilitation until after 6 week post assessment.
3144807|NCT01584882|No Intervention|Control (Usual care)|Return patients seen within the data collection window in HealthPartners Dental Clinics (new patient exams were excluded) who were documented as using tobacco, specifically cigarettes, at their last dental encounter. Randomization was at the clinic level.
3144808|NCT01584882|Experimental|Tobacco Cessation Tool (CATI Tool)|Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a 'CATI'[Computer Assisted Tobacco Intervention] tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
3144809|NCT01584869|Experimental|capsule endoscopy|
3144810|NCT01584843|No Intervention|Non-treatment (10-20 PD)|Receive no treatment on Week 0
3144811|NCT01584843|Active Comparator|GSK1358820 1.25 U (10-20 PD)|Receive 1.25 U of GSK1358820 on Week 0
3144812|NCT01584843|Active Comparator|GSK1358820 2.5 U (10-20 PD)|Receive 2.5 U of GSK1358820 on Week 0
3144813|NCT01584843|No Intervention|Non-treatment (20-50 PD)|Receive no treatment on Week 0
3144814|NCT01584843|Active Comparator|GSK1358820 2.5 U (20-50 PD)|Receive 2.5 U of GSK1358820 on Week 0
3290671|NCT00541567|Experimental|2|
3144817|NCT01584830|Placebo Comparator|Arm 2|
3144818|NCT01584817|No Intervention|normal education|patients in this arm was educated about bowel preparation on the day of reservation by nurse for 15 minutes and meanwhile a booklet was also sent to them.
3144819|NCT01584817|Other|telephone education|A repeated instruction by telephone on the day before colonoscopy was conducted
3144820|NCT01584804|Active Comparator|Monotherapy|Monotherapy with Su-Huang antitussive capsule
3144821|NCT01584804|Placebo Comparator|Sugar pill|Monotherapy with placebo
3144822|NCT01584791|Experimental|clopidogrel napadisilate + aspirin|
3144823|NCT01584791|Active Comparator|clopidogrel bisulfate + aspirin|
3144824|NCT01584778||Behçet patients|
3144825|NCT01584778||Healthy controls|
3144826|NCT01584778||Allergic rhinitis (diseased) controls|
3144827|NCT01584765||Rechallenge|positive, negative, indeterminate and intermediate rechallenge subtypes
3144828|NCT01584765||Severe positive rechallenge|Subtype of positive rechallenge is defined as: ALT≥5 xULN or AP ≥2 xULN and bilirubin ≥2 xULN with one of the following: INR ≥1.5, Ascites, or Encephalopathy where time from liver chemistry elevation to INR≥1.5,ascites, or encephalopathy is less than 26 weeks in the absence of underlying cirrhosis; other organ failure considered due to DILI; liver-related hospitalization
3144829|NCT01584752||Fistula patients|Gore-BioA Fistula Plug
3144830|NCT01584739|Experimental|AZD8683|
3144831|NCT01584739|Placebo Comparator|Placebo to AZD8683|
3144832|NCT01584726|Other|magnesium sulfate arm|magnesium sulfate with standard therapy
3144833|NCT01584726|No Intervention|placebo arm|placebo with standard therapy
3144834|NCT01584713|Experimental|Adipose derived Stem Cells|
3144835|NCT01584700|Other|Renal Artery Denervation|Ontervention
3144836|NCT01584687|Experimental|Omalizumab|All patients will receive omalizumab.
3144837|NCT01584674|Experimental|KLOX Biophotonic System|KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
3144838|NCT01584674|No Intervention|Control (untreated hemiface)|No treatment will be administered on the control hemiface
3144839|NCT01584661||Compliance with nutritional care|"The Inclusion criteria comprise patients who were treated nutritionally with food enrichment supplements during their hospitalization in Bait Balev and were discharged to their homes with dietary recommendations. Participants who are willing to participate will sign an informed consent form. For patients with cognitive impairment or dementia, as reported in their medical records, their formal primary caregiver or proxy will sign the informed consent form."
3144840|NCT01584648|Experimental|Combination|trametinib and dabrafenib combination
3144841|NCT01584648|Active Comparator|Dabrafenib monotherapy|trametinib placebo and dabrafenib
3144842|NCT01584635|Experimental|Peroral Endoscopic Myotomy (POEM)|Peroral Endoscopic Myotomy- a less invasive treatment for patients with Achalasia
3144843|NCT01584609|Experimental|Penumbra System with Separator 3D|
3144844|NCT01584609|Active Comparator|Penumbra System alone|
3144845|NCT01584596|Experimental|Adapted Diet and Physical Activity|Adapted diet and physical activity guidelines sessions
3144846|NCT01584596|Active Comparator|Adapted Diet|Adapted dietary guidelines sessions
3144847|NCT01584583||blood pressure monitor|Cuff circumference:22cm-36cm
3144848|NCT01584583||stethoscopy|Cuff circumference: 22cm-36cm
3144849|NCT01584570|Active Comparator|Control|fentanyl 1 mcg/kg before induction
3144850|NCT01584570|Experimental|D 0.5 group|Dexmedetomidine 0.5 ug/kg + Propofol + Sevoflurane+ Vecuronium
3144851|NCT01584570|Experimental|D 1.0 group|Dexmedetomidine 1.0 ug/kg + Propofol + Sevoflurane+ Vecuronium
3144852|NCT01584557|Active Comparator|Tolvaptan, Samsca|Tolvaptan, Samsca, uncoated tablet, 30 mg, once per day, up to 7 days.
3144853|NCT01584557|Placebo Comparator|sugar pill|placebo, sugar pill
3144854|NCT01584544|Experimental|1000mg|capecitabine 1000mg/m2/d d1-14, d22-25 combined with concurrent radiotherapy will be given to enrolled patients.
3144855|NCT01584544|Experimental|1200mg|capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
3144856|NCT01584544|Experimental|1350mg|capecitabine 1300mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
3144857|NCT01584544|Experimental|1500mg|capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
3144858|NCT01584544|Experimental|1650mg|capecitabine 1650mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
3144859|NCT01584531|Experimental|21-Day Regimen|560 mg oral rigosertib in the morning and 280 mg rigosertib in the afternoon on days 1 to 21 of 21-day cycle
3144860|NCT01584518|Active Comparator|CHF peptide|Diuresis based on CHF-P
3144861|NCT01584518|Active Comparator|Non CHF peptide|Diuresis based on clinical judgement without data for CHF-P
3144862|NCT01584505|Experimental|CHF5993 HFA pMDI dose 1, BID|CHF5993 HFA pMDI dose 1, BID
3144863|NCT01584505|Experimental|CHF5993 HFA pMDI dose 2, BID|CHF5993 HFA pMDI dose 2, BID
3144864|NCT01584505|Active Comparator|CHF1535 HFA pMDI + Placebo|CHF1535 HFA pMDI BID plus placebo BID
3144865|NCT01584492|Experimental|Treatment A|CHF 1535 50/6 administered via a pMDI with spacer, 1 inhalation (dose: BDP 50 µg/FF 6 µg) + placebo HFA pMDI with spacer, 5 inhalations in the morning at the clinic
3144866|NCT01584492|Experimental|Treatment B:|CHF 1535 50/6 administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg/FF 12 µg) + placebo HFA pMDI with spacer, 4 inhalations in the morning at the clinic
3144867|NCT01584492|Experimental|Treatment C|CHF 1535 50/6 (dose: BDP 200 µg/FF 24 µg) administered via a pMDI with spacer, 4 inhalations (dose: BDP 200 µg/FF 24 µg) in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic
3144868|NCT01584492|Active Comparator|Treatment D|formoterol 6 µg HFA administered via a pMDI with spacer, 2 inhalations (dose: FF 12 µg) + extrafine BDP 50 µg, administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg), in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic
3144869|NCT01584492|Placebo Comparator|Treatment E|placebo pMDI with spacer, 6 inhalations in the morning at the clinic
3290672|NCT00541567|Experimental|3|
3144870|NCT01584479||Low Risk Experimental Group|"1 visit - Low Risk~~1200 subjects~- Low Risk Experimental Group = 1 visit intervention, no history of periodontitis, non-smoker, non-diabetic, IL-1 genotype (-)"
3144871|NCT01584479||Low risk Control Group|"2 visits - Low Risk~~1200 subjects~- Low risk Control Group = 2 visit intervention, no history of periodontitis, non-smoker, non-diabetic, IL-1 genotype (-)"
3144872|NCT01584479||High Risk Experimental Group|"1 visit - High Risk~~800 subjects High Risk Experimental Group = 1 visit intervention, one or more of the following risk factors: history of periodontitis, smoker or diabetic, IL-1 genotype (+)"
3144873|NCT01584479||High Risk Control Group|"2 visits - High Risk~~800 subjects High Risk Control Group = 2 visit intervention, one or more of the following risk factors: history of periodontitis, smoker or diabetic, IL-1 genotype (+)"
3144874|NCT01584466|Experimental|Paliperidone|
3144875|NCT01584453|Experimental|Sodium Nitrite|
3144876|NCT01584453|Placebo Comparator|Placebo|
3144877|NCT01584440|Placebo Comparator|Placebo|
3144878|NCT01584440|Experimental|AVP-923|
3144879|NCT01584427|Active Comparator|Healthy Carbohydrate Diet|4 weeks of intervention with a diet rich in Arabinoxylans and Resistent Starch.
3144880|NCT01584427|Placebo Comparator|Western Style Diet|4 weeks of intervention with a diet with low content of Resistent Starch and Arabinoxylans
3144881|NCT01584414||normal samples|
3144882|NCT01584414||premalignant/carcinoma samples|
3144883|NCT01584388|Experimental|Rituximab|
3144884|NCT01584375|Other|Flat midline head position|
3144885|NCT01584375|Other|Right flat lateral head position|
3144886|NCT01584362|Experimental|oxfendazole 0.3|administration of a single oral 0.3mg/kg dose of oxfendazole
3144887|NCT01584362|Placebo Comparator|placebo comparator|administration of a single oral dose of placebo
3144888|NCT01584362|Experimental|oxfendazole 1.0|administration of a single oral 1.0 mg/kg dose of oxfendazole
3144889|NCT01584362|Experimental|oxfendazole 3.0|administration of a single oral 3 mg/kg dose of oxfendazole
3144890|NCT01584362|Experimental|oxfendazole 10|administration of a single oral 10 mg/kg dose of oxfendazole
3144891|NCT01584362|Experimental|oxfendazole 20|administration of a single oral 20 mg/kg dose of oxfendazole
3144892|NCT01584362|Experimental|oxfendazole 30|administration of a single oral 30 mg/kg dose of oxfendazole
3144893|NCT01584336|Experimental|LATG group|It means the patients who will be enrolled in our study.
3144894|NCT01584323|Active Comparator|Pomegranate pills|treatment with pomgranate pills to women suffering preterm premature rupture of membranes
3144895|NCT01584323|Placebo Comparator|placebo pills|treatment with placebo to women with preterm premature rupture of membranes
3144896|NCT01584310|Active Comparator|STAMP using|100 boys and girls aged 1 to 6, attending Clalit Health Care Services Pediatric Centers, will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
3144897|NCT01584310|Placebo Comparator|No STAMP using|150 files shall be reviewed in the beginning of the research and after 6 months in order to estimate the change in medical staff's attention to nutritional status, by way of noting relevant diagnoses, reference to nutritional status- related tests and recording of anthropometric measurements.
3144898|NCT01584297|Experimental|Ketoconazole|Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
3144899|NCT01584271|Active Comparator|2 Dex-Otic ear drops|Dex-Otic(R) ear drops are used for pain relief and treating ears of AOE patients. It contains: Dexamethasone Sodium Phosphate 1 mg; Neomycin sulfate 5 mg; Polymyxin B sulfate 10,000 units. It
3144900|NCT01584271|Experimental|3 Ear Comfort(TM) ear drops|Natural Ear comfort(TM) ear drops contains Chamomile extract and Thyme oil in anhydrous glycerin for pain relief and ear healing.
3144901|NCT01584271|Active Comparator|1 Otidin(R) ear drops|Otidin(R): Ear drops containing Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin for pain relief in AOE patients.
3144902|NCT01584258|Active Comparator|Laparoscopic Prostatectomy vs prostate SBRT|Patients for whom surgery is considered will be randomised to laparoscopic prostatectomy or prostate SBRT delivered with 36.25 Gy in 5 fractions.
3144903|NCT01584258|Active Comparator|Conventionally Fractionated RT vs Prostate SBRT|Patients for whom surgery is not considered or who refuse surgery will be randomised to either conventionally fractionated radiotherapy delivered to a dose of 78 Gy in 2 Gy fractions or SBRT delivered with 36.25 Gy in 5 fractions.
3144904|NCT01584232|Experimental|LY2189265 + OAM|"LY2189265: 0.75 milligrams (mg), administered subcutaneously (SC), once weekly for 26 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin)."
3144905|NCT01584232|Active Comparator|Insulin glargine + OAM|"Insulin glargine: dose based on targeting fasting blood glucose ≤110 milligrams per deciliter (mg/dL), administered subcutaneously (SC), once daily for 26 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin)."
3144906|NCT01584219||Women after cesarean section|Women after cesarean section
3144907|NCT01584219||pregnancy pathologies|pregnancy pathologies
3144908|NCT01584219||first/second trimester pregnancy|
3144909|NCT01584219||Women after vaginal delivery|Women after vaginal delivery
3144910|NCT01584206|Experimental|Ezetimibe|Compare on and off ezetimibe
3144911|NCT01584193|Experimental|US-guided subclavian vein puncture|
3144912|NCT01584193|Active Comparator|Cephalic vein dissection|
3144913|NCT01584180|Active Comparator|Cold infusions|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
3144914|NCT01584180|Active Comparator|EMCOOLS Brain.Pad|Passive external neck cooling with 1 EMCOOLS Brain.Pad (Emergency Medical Cooling Systems AG, Wien, Austria)
3144915|NCT01584167|Active Comparator|Cold infusions|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
3144916|NCT01584167|Active Comparator|EMCOOLS Flex.Pads|Passive surface cooling with 10 EMCOOLS Flex.Pads (Emergency Medical Cooling Systems AG, Wien, Austria)
3144917|NCT01584154|Experimental|cryoablation|
3144918|NCT01584154|Active Comparator|radiofrequency ablation|radiofrequency ablation with a 4mm-tip catheter
3144919|NCT01584128||Oxidized regenerated cellulose|Patients undergoing laparoscopic hysterectomy who have oxidized regenerated cellulose placed at the vaginal cuff at the time of their surgery.
3144920|NCT01584115|Experimental|NY-ESO-1|NY-ESO-1 combined with MPLA vaccine
3144921|NCT01584102|Experimental|Group 1|
3144922|NCT01584102|Active Comparator|Group 2|
3144923|NCT01584076|Experimental|Donepezil|
3144924|NCT01584063|No Intervention|Control|These women received general information about pregnancy and the postpartum period and tips for stress management. This information was delivered during 3 group meetings during pregnancy and 1 group meeting postpartum by trained staff from a local community mental health agency.
3144925|NCT01584063|Experimental|MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
3144926|NCT01584050|Active Comparator|L-MTHF|
3144927|NCT01584050|Active Comparator|folic acid|
3144928|NCT01584050|Placebo Comparator|placebo (methyl cellulose)|
3144929|NCT01584037||Observational|This is a prospective, observational, exposure-registration and follow-up study of pregnant women exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral and their live born offspring through the first year of life. The intent of the Adenovirus Vaccine Pregnancy Registry, Protocol DR-501-401, is to collect observational data on pregnancy outcomes, including birth defects, in women who were exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral.
3144930|NCT01584024|Active Comparator|Resin infiltration|Resin infiltration of early caries lesion in addition to preventative measures (oral hygiene, diet counseling, fluoride varnish)
3144931|NCT01584024|Sham Comparator|Control|Sham treatment of early caries lesion in addition to preventative measures (oral hygiene, diet counseling, fluoride varnish)
3144932|NCT01584011||Middle ear disease|
3144933|NCT01583998|Active Comparator|e-MBC|Patients will receive e-MBC
3144934|NCT01583998|No Intervention|Treatment as Usual Control|Patients receive standard treatment
3144935|NCT01583985|Active Comparator|Opioid-intensive|Opioid-intensive prescribing strategy
3144936|NCT01583985|Active Comparator|Opioid-avoidant|Opioid-avoidant prescribing strategy
3144937|NCT01583972|Experimental|Vitamin A|50,000 IU vitamin A in edible oil
3144938|NCT01583972|Placebo Comparator|Placebo|edible oil used as diluent for vitamin A
3144939|NCT01583959|Active Comparator|Folic acid 30 mg per week|Patients will be administered 5 mg folic acid for 6 days a week, no tablet on the day they take methotrexate (5 mg x 6 days = 30 mg per week)
3144940|NCT01583959|Active Comparator|Folic acid 10 mg|Patients will be given folic acid 5 mg for two days per week and placebo tablets for four days a week, no tablet on the day they take methotrexate (Folic acid 5mg x 2 days = 10mg per week)
3144941|NCT01583946||Male low past-oriented SWB|
3144942|NCT01583946||Male high past-oriented SWB|
3144943|NCT01583946||Female low past-oriented SWB|
3144944|NCT01583946||Female high past-oriented SWB|
3144945|NCT01583946||Black Female high past-oriented SWB|
3144946|NCT01583946||Black Female low past-oriented SWB|
3144947|NCT01583946||Black male low past-oriented SWB|
3144948|NCT01583946||Black male high past-oriented SWB|
3144949|NCT01583933|Experimental|Essix retainer|
3144950|NCT01583933|Active Comparator|Hawley retainer|"Hawley retainer is a device composed of an acrylic base with built-in hooks and a labial arch wire 0.022 x0.036 and attached to the teeth. Its metal component consists of two adams hooks positioned from the first permanent molar right to left, a labial bow that progresses from lingual superface to distal of canine to integrate with the acrylic base."
3144951|NCT01583920|Experimental|Focal salvage HDR prostate brachytherapy|
3144952|NCT01583907||different dietotherapy strategies|
3144953|NCT01583894||Chronic pain patients|
3144954|NCT01583881|Experimental|Renal denervation|Renal denervation
3144955|NCT01583881|No Intervention|control|No intervention
3144956|NCT01583855|Active Comparator|Manual ablation|Patients will have their ablation performed manually.
3144957|NCT01583855|Active Comparator|Ablation using remote catheter system|Ablation for atrial fibrillation using the Amigo remote catheter system
3144958|NCT01583842|Experimental|124I-MIBG no-carrier added|Patients are 3 years of age and older with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG.
3144959|NCT01583842|Experimental|124I-MIBG carrier added|Patients are 3 years of age and older with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG.
3144960|NCT01583829|Experimental|Neurofeedback|
3144961|NCT01583829|Experimental|Cognitive Training|
3144962|NCT01583829|Active Comparator|Waitlist Control|
3144963|NCT01583816|Experimental|Resiquimod Gel 0.03% or placebo|Resiquimod gel 0.03% or placebo, once daily, 3x per week for 4 weeks, break of 8 weeks, repeated once
3144964|NCT01583816|Experimental|Resiquimod or placebo|Once daily, 7x within 2 weeks, break of 8 weeks, cycle repeated once
3144965|NCT01583816|Experimental|Resiquimod or vehicle|Once daily, 5x for 1 week, break of 8 weeks, cycle repeated once
3144966|NCT01583816|Experimental|Resiquimod gel 0.01%|Once daily, 3x/week until occurrence of biological endpoint or for a maximum of 8 weeks (no repetition of cycle), 8 weeks follow-up
3144967|NCT01583816|Experimental|Resiquimod gel 0.03%|Once daily, 3x/week until occurrence of biological endpoint or for a maximum of 8 weeks (no repetition of cycle), 8 weeks follow-up
3144968|NCT01583803||Males|
3144969|NCT01583803||Females|
3144970|NCT01583790||no group|laparoscopic sleeve gastrectomy
3144971|NCT01583777|Experimental|Belinostat|Open Label
3144972|NCT01583751|Experimental|control|excision and primer repair surgical technique will be perform
3144973|NCT01583738|Experimental|V0251|
3144974|NCT01583738|Placebo Comparator|Placebo|
3144975|NCT01583725|Experimental|Roux-en-Y Gastric Bypass|30 subjects who plan to undergo Roux-en-Y Gastric Bypass bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
3144976|NCT01583725|Experimental|Gastric Banding (Lap-band)|30 subjects who plan to undergo Gastric Banding bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
3144977|NCT01583725|Experimental|Formula Diet Weight Loss|30 subjects who plan to begin a formula diet to lose weight. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before subjects undertake a 12-week weight loss intervention (T1), at the end of the weight loss intervention (T2) and 18 months after they completed the weight loss intervention(T3).
3144978|NCT01583725|Experimental|No Treatment|30 subjects who do not undergo any treatment for weight loss. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed at baseline (T1) and at 3 months (T2) and 18 months (T3) later.
3144979|NCT01583725|Experimental|Sleeve Gastrectomy Surgery|30 subjects who plan to undergo Sleeve Gastrectomy bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
3144980|NCT01583712|Experimental|Endomicroscopy|All patients included in the study will undergo endomicroscopy of the upper GI-tract including the reachable parts of the small bowel.
3144981|NCT01583699|Experimental|Endomicroscopy|All patients included into the study will undergo endomicroscopy of the upper GI-tract.
3144982|NCT01583686|Experimental|1/Phase I|Non-myeloablative but lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus anti-mesothelin CAR transduced PBL plus low dose aldesleukin.
3144983|NCT01583686|Experimental|2/Phase II|Non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine + anti-mesothelin CAR transduced PBL + low-dose aldesleukin
3144984|NCT01583673|Experimental|Amino Acid Formula|Hypoallergenic baby formula
3144985|NCT01583673|Active Comparator|Amino Acid commercial formula|Hypoallergenic commercial amino acid formula
3144986|NCT01583647|Experimental|MK-0524A 1 g/20 mg (Panel A)|Single oral dose of 1 tablet of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg
3144987|NCT01583647|Experimental|MK-0524A 2 g/40 mg (Panel B)|Single oral dose of 2 tablets of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg
3144988|NCT01583634||Healthy volunteers|9 subjects (male and female)
3144989|NCT01583621|No Intervention|Placebo|Placebo group
3144990|NCT01583621|Experimental|Supplementation arm 1|cholecalciferol 18000 U/month for 4 months
3144991|NCT01583621|Experimental|supplementation arm 2|cholecalciferol 60000 U/month for 4 months
3144992|NCT01583621|Experimental|Supplementation arm 3|cholecalciferol 120000 U/month for 4 months
3144993|NCT01583582|Experimental|Refined peptide concentrate, 1200 mg|Refined peptide concentrate, 1 200 mg, once a day
3144994|NCT01583582|Experimental|Refined peptide concentrate, 2 x 600 mg|Refined peptide concentrate, 600 mg, twice a day
3144995|NCT01583582|Placebo Comparator|Refined peptide concentrate, 0 mg|
3144996|NCT01583556||Standard treatment|This study will employ a prospective, non-randomized design. After the questionnaires are filled the patients choose whether or not to schedule a second appointment for evaluation of their fracture: The first group will be scheduled for a second visit (standard treatment) as our daily practice after 1-3 months. They will be contacted after 2-6 months either by phone or email and will complete again some questionnaires (Quick DASH, satisfaction, return to work).
3144997|NCT01583556||Optional follow-up group|The alternative (Optional follow-up group) will be to take a handout describing the recovery and providing instructions for how to contact us should they get off course. The questionnaires will be repeated either by phone or email in 2-6 months.
3144998|NCT01583543|Experimental|Olaparib|400mg PO BID Continuous
3144999|NCT01583530|Active Comparator|Belimumab IV 240 mg|
3145000|NCT01583530|Experimental|Belimumab SC 2 x 120 mg|
3145001|NCT01583530|Experimental|Belimumab SC 1 x 240 mg|
3145002|NCT01583530|Experimental|Belimumab SC 1 x 200 mg|
3145003|NCT01583530|Experimental|Belimumab SC 2 x 120 mg weekly|
3145004|NCT01583530|Experimental|Belimumab SC 1 x 200 mg weekly|
3145005|NCT01583517|Active Comparator|Biliary sphincterotomy|Cutting of the biliary sphincter muscle alone
3145006|NCT01583517|Active Comparator|Dual sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
3145007|NCT01583517|Sham Comparator|Sham|Among patients with normal sphincter of Oddi manometry, patients will undergo no sphincterotomy (sham therapy).
3145008|NCT01583517|Active Comparator|Biliary sphincterotomy - Normal SOM|Among patients with normal SOM, patients may be randomized to empiric biliary sphincterotomy alone.
3145009|NCT01583504|Experimental|High volume saline injection|Patients randomised to this trial arm will receive an ultrasound guided steroid and local anaesthetic injection around the achilles tendon in the same way as the control arm patients. In addition they will receive an injected bolus of normal saline (through the same needle) of between 14-25ml until the new vessels seen on ultrasound scan disappear. They will be then given a programme of stretching and strengthening exercises in the same way as patients on the control arm.
3145010|NCT01583504|Active Comparator|Control Arm|"Patients on this trial arm will receive an ultrasound guided injection of steroid and local anaesthetic between Kager's fat pad and the achilles tendon. They will then be given a programme of stretching and strengthening exercises.~Patients on this trial arm will be offered the high volume saline injection at their 6 week follow up appointment after outcome measures have been taken by the blinded assessor. The whole cohort of patients will then be followed up at 12 and 40 weeks"
3145011|NCT01583491|Active Comparator|prf group.peridontal problem|prf insert into surgical site immediate after surgery
3145012|NCT01583491|Placebo Comparator|control group|
3145013|NCT01583478|Active Comparator|incobotulinumtoxinA 20 units|Three patients will be randomly assigned to receive 20 units total of incobotulinumtoxinA to the glabellar region.
3145014|NCT01583478|Active Comparator|incobotulinumtoxinA 40 units|Three patients will be randomly assigned to receive 40 units total of incobotulinumtoxinA to the glabellar region.
3145015|NCT01583478|Active Comparator|incobotulinumtoxinA 60 units|Three patients will be randomly assigned to receive 60 units total of incobotulinumtoxinA to the glabellar region.
3145016|NCT01583478|Active Comparator|incobotulinumtoxinA 80 units|Three patients will be randomly assigned to receive 80 units total of incobotulinumtoxinA to the glabellar region.
3145017|NCT01583478|Active Comparator|incobotulinumtoxinA 100 units|Three patients will be randomly assigned to receive 100 units total of incobotulinumtoxinA to the glabellar region.
3145018|NCT01583465|Experimental|Aquamantys Malleable Bipolar Sealer|In 100 patients randomly assigned, primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of the Aquamantys Malleable Bipolar Sealer with Light.
3145019|NCT01583465|Active Comparator|Standard Treatment|100 patients randomly assigned will undergo primary total hip arthroplasty via the anterior supine intermuscular approach performed with the assistance of standard electrocautery.
3145020|NCT01583452|Experimental|Chewing Gum Group|Group of patients given chewing gum as part of the treatment for prevention of post-operative ileus right after surgery, besides the standard pharmacologic treatment and post-operative care.
3145021|NCT01583452|No Intervention|No intervention|By observing the clinical evolution of the participants not given chewing gum as a prevention for post-operative ileus, and just given the standard pharmacologic treatment and post-operative care.
3145022|NCT01583426|Experimental|nab-Paclitaxel|nab-Paclitaxel (125 mg/m² weekly, infusion) is applicated for 12 weeks, followed by epirubicin and cyclophosphamide, applicated 4 cycles 3-weekly . In case of HER2-positive tumor patients receive tarstuzumab and pertuzumab 3-weekly during all cycles.
3145023|NCT01583426|Active Comparator|Paclitaxel|Paclitaxel (80 mg/m² weekly, infusion) is applicated for 12 weeks, followed by epirubicin and cyclophosphamide, applicated 4 cycles 3-weekly . In case of HER2-positive tumor patients receive tarstuzumab and pertuzumab 3-weekly during all cycles.
3145024|NCT01583413|Experimental|Opt Out Protocol|
3145025|NCT01583400|Active Comparator|RESPECT-D|The RESPECT-D Model: Collaborative Care depression treatment within primary care including care manager
3145026|NCT01583400|Experimental|RESPECT-D-E|RESPECT-D-E: Collaborative Care depression treatment within primary care including care manager plus on-line coaching, education and symptom, side effect and, medication adherence tracking with the digital health coaching program for depressive symptoms.
3145027|NCT01583387|Other|1= Intervention|
3145028|NCT01583387|Other|2= Control|
3145029|NCT01583374|Experimental|Apremilast 20 mg|Apremilast 20 mg will be taken orally twice a day (BID)
3145030|NCT01583374|Experimental|Apremilast 30 mg|Apremilast 30 mg will be taken orally twice a day (BID)
3145031|NCT01583374|Placebo Comparator|Placebo|Placebo
3145032|NCT01583361|Experimental|Arm A:Neoadjuvant sox|Patients in arm a will receive (N=2-4) cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and (8-N) cycles of adjuvant SOX adjuvant chemotherapy.
3145033|NCT01583361|Active Comparator|Arm B:Adjuvant SOX|Patients in arm B will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant SOX later.
3145034|NCT01583348||Women with gallstones|30 women with symptomatic gallstone disease with an indication for elective cholecystectomy
3145035|NCT01583335|Experimental|Improved lifestyle|
3145036|NCT01583335|No Intervention|Control group|The control group was seen at baseline and follow-up, but not in between.
3145037|NCT01583335|No Intervention|Shadow group|The shadow group was followed in registers exclusively
3145038|NCT01583322|Experimental|vargatef/Nintedanib|
3145039|NCT01583322|Placebo Comparator|placebo|
3145040|NCT01583309|No Intervention|low-flux hemodialysis|
3145041|NCT01583309|Experimental|online pre-dilution hemofiltration|
3145042|NCT01583309|Experimental|online pre-dilution hemodiafiltration|
3145043|NCT01583296|Experimental|CBT and HRVB|Cognitive Behavioral Therapy (CBT) and Heart Rate Variability Biofeedback (HRVB)
3145044|NCT01583296|Active Comparator|Music Relaxation Therapy (MRT)|Music Relaxation Therapy (MRT): music relaxation and breathing at resting respiration rate
3145045|NCT01583283|Experimental|ACY-1215, Lenalidomide and dexamethasone|Open label dosing cohorts will evaluate oral ACY-1215 (doses ranging from 40 - 480 mg days 1-5, 8-12, 15-19) in combination with oral Lenalidomide (doses ranging from 15 - 25 mg days 1-21) and oral dexamethasone (40 mg once weekly).
3145046|NCT01583270|Experimental|Arabinoxylan|Porridge rich in arabinoxylan. 50 g available carbohydrate
3145047|NCT01583270|Experimental|rye kernels|Porridge made from rye kernels. 50 g available carbohydrate
3145048|NCT01583270|Experimental|arabinoxylan and rye kernels|Porridge made of rye kernels and arabinoxylan. 50g available carbohydrate
3145049|NCT01583270|Experimental|semolina|Semoline porridge. 50 g available carbohydrate
3145050|NCT01583257|Experimental|Active Video Gaming|An active gaming exercise workout will be provided with QoL measured at baseline and following the 8 week workout schedule. The workout will use the Microsoft Kinect (TM) system with EA Sports Active 2 program.
3145051|NCT01583244||Patients with active rheumatoid arthritis|Patients aged 6 years and over who have moderate-to-severe active rheumatoid arthritis
3145052|NCT01583231|No Intervention|No Prewash|Level 1: participants will be swabbed, then application of brushless scrub, swabbed again
3145053|NCT01583231|Experimental|Prewash|Level 2: participants will be swabbed, perform a wash with soap and water for 1 minute, dry, apply brushless scrub, swabbed again
3145054|NCT01583218|Experimental|Betrixaban|Daily oral (PO) betrixaban capsules for 35 to 42 days and subcutaneous (SQ) injections of enoxaparin placebo for 10 ± 4 days
3145055|NCT01583218|Active Comparator|Enoxaparin|Daily subcutaneous (SQ) injections of enoxaparin for 10 ± 4 days and oral (PO) betrixaban placebo capsules for 35 to 42 days
3145056|NCT01583205|Experimental|Coping Effectiveness Training|Coping Effectiveness Training -ALS (CET-ALS) is an eight session intervention derived from Coping Effectiveness Training (CET), a manualized intervention based on stress and coping theory. It is designed to strengthen coping skills and alleviate distress for either the patient or care partner following a diagnosis of ALS.
3145512|NCT01580085||Pulmonary embolism|Patients who were diagnosed with pulmonary embolism
3145057|NCT01583192|Active Comparator|chloride-hexidine soluted in alcohol|"patients will have skin preparation with chloride-hexidine soluted in alcohol prior to their forefoot surgery.~Skin swabs will be taken prior to skin preparation, after skin preparation and after skin closure at the end of the operation"
3145058|NCT01583192|Active Comparator|povidine-jodine soluted in alcohol|skin perparation will be done with povidine-jodine soluted in alcohol prior to forefoot surgery.
3145059|NCT01583179|No Intervention|Control group|will get only local anesthetic and epinephrine in block. no additive in block
3145060|NCT01583179|Experimental|buprenorphine|will receive local anesthetic, epinephrine and the additive buprenorphine to nerve block
3145061|NCT01583166|Active Comparator|Marcaine + epinephrine|
3145062|NCT01583166|Placebo Comparator|Saline + epinephrine|
3145063|NCT01583153|Active Comparator|Hospital Inpatient Rehabilitation (HI)|
3145064|NCT01583153|Active Comparator|Hybrid Home Programme (HO)|
3145065|NCT01583140|Experimental|Exercise Intervention|Culturally-modified, individually tailored physical activity print materials
3145066|NCT01583140|Active Comparator|Control|Bilingual health education booklets
3145067|NCT01583127|Experimental|School-Wide (SW)-PBIS intervention|SW-PBIS intervention
3145068|NCT01583127|No Intervention|Control|Practice as usual
3145069|NCT01583114|Experimental|perindopril|
3145070|NCT01583114|Placebo Comparator|placebo|same form, administration, posology, frequency and duration as perindopril
3145071|NCT01583101|Experimental|Receiving Highlighted Prompts|Prompts received by physicians were highlighted.
3145072|NCT01583101|Active Comparator|Receiving Non-highlighted Prompts|Prompts received by physicians were not highlighted.
3145073|NCT01583088|Experimental|phenic nerve stimulation|effective phenic nerve stimulation NeurX™ (Synapse Biomedical)
3145074|NCT01583088|Sham Comparator|sham|sham phenic nerve stimulation
3145075|NCT01583075|Other|Circumferential ablation|
3145076|NCT01583075|Experimental|Single ring ablation|
3145077|NCT01583062|Active Comparator|1|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
3145078|NCT01583062|Placebo Comparator|2|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
3145079|NCT01583036|Experimental|Session 1 digoxin alone, Session 2 retigabine plus digoxin|Session 1: Single administration of digoxin (0.25mg) and PK assessments up to 144hrs post-dose. Session 2: Retigabine up-titration to 1200mg (TDD) with co-administration of digoxin (0.25mg) at 3 doses or retigabine during the up-titration (600mg, 900mg and 1200mg) and PK assessments up to 144hrs post-dose following wach co-administration.
3145080|NCT01583023|Experimental|Wellbutrin + Lithium a/o Epival + Sham rTMS|
3145081|NCT01583023|Experimental|Placebo + Lithium a/o Epival + Active rTMS|
3145082|NCT01583023|Experimental|Wellbutrin + Lithium a/o Epival + Active rTMS|
3145083|NCT01583010|No Intervention|Standard Treatment Group|Patients receiving ultrasound guided regional anaesthesia without using Advanced Needle Visualization Technology(R)
3145084|NCT01583010|Active Comparator|ANV ® Group|Patients receiving ultrasound guided regional anaesthesia with using Advanced Needle Visualization Technology(R)
3145085|NCT01582997|Experimental|Dose Escalation Part|Dose escalation will be conducted to assess safety, tolerability, single and repeat dose PK profile and preliminary efficacy of GSK2118436 . The dose may be escalated to the overseas recommended phase III dose.
3145086|NCT01582984|Active Comparator|iMedConsentTM and customized written handout group|iMedConsentTM and a customized written handout
3145087|NCT01582984|Experimental|iMedConsentTM, handout, and standard video g|iMedConsentTM, handout, and standard AAOS video
3145088|NCT01582984|Experimental|iMedConsentTM, handout, video, and formal education|iMedConsentTM, the handout, the video, and a formal education session
3145089|NCT01582971|Experimental|Intervention|Reflexology: 4 weekly foot reflexology sessions delivered by friend/family member
3145090|NCT01582971|No Intervention|Control|Standard medical care: no reflexology
3145091|NCT01582958|Experimental|Treatment|This arm will receive the usual Pulmonary Rehabilitation Program plus OMT, the intervention.
3145092|NCT01582958|Placebo Comparator|placebo|Receives normal pulmonary rehabilitation care plus positioned to receive OMT but OMT is not provided.
3145093|NCT01582958|No Intervention|Control|This arm receives only pulmonary rehabilitation care.
3145094|NCT01582945|Experimental|Ketamine IV|Patients will receive open label augmentation with IV Ketamine at 0.5mg/kg, twice a week for 3 weeks
3145095|NCT01582932|Experimental|Calcipotriene 0.005% Foam|Foam is a vitamin D3 analog (calcipotriene) foam 0.005%. It is applied twice a day for 8 weeks to psoriasis lesions (except the face).
3145096|NCT01582919|Experimental|Participant from AMI cohort|
3145097|NCT01582919|Active Comparator|Participant from 3Ccohort|
3145098|NCT01582906||Control Group|Participants randomised to the control group would receive usual rehabilitation care via the existing referral pathways.
3145099|NCT01582906||Intervention Group|Participants randomised to the intervention group will be offered two rehabilitation appointments at three month intervals. They will complete the screening tool, the Distress (Concerns) Thermometer before the first appointment; this will be reviewed after three months. Appointments will make use of communication skills recognised to promote motivation via self-efficacy. Self efficacy is a person's belief in their ability to achieve a goal. Their sense of mastery will influence their behaviour, their perception of stress and the effort they put into achieving that goal.
3145100|NCT01582893|Experimental|HCO1100-P14L|HCO1100 is connected in row with low flux dialyzer P14L
3145101|NCT01582893|Active Comparator|P210H|High flux Filter P210H
3145102|NCT01582880|Experimental|Riboflavin Cross-linked donor cornea|the donor cornea used as a carrier for the Boston Keratoprosthesis will undergo crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.
3145142|NCT01582607|Active Comparator|Group B|subarachnoid administration of 2.0 mL (10mg) plain bupivacaine hydrochloride 0.5%
3145143|NCT01582607|Active Comparator|Group R|subarachnoid administration of 2.0 ml (15mg) plain ropivacaine 0.75%
3145103|NCT01582867|Experimental|HD and HDF|During one part of the study (study phase A) patients will undergo hemodialysis (HD) treatments with Hemoscan over 2 weeks (Run-In period), followed by 12 HD sessions with HemoControl during the following 4 to 6 weeks. Separated by a one week wash out period, the same patients will be switched to On-Line Hemodiafiltration (HDF) treatments (study phase B), for a Run-In period of 2 weeks with Hemoscan, followed by 12 On-Line HDF sessions with HemoControl over the last 4 to 6 weeks of the study period.
3145104|NCT01582867|Experimental|HDF and HD|patients will be treated vice versa, starting with On-Line Hemodiafiltration (HDF) followed by hemodialysis (HD) with the same respective Run-In periods and a washout period as patients in Arm hemodialysis (HD) and Hemodiafiltration (HDF) .
3145105|NCT01582854|Active Comparator|Actovegin|Actovegin 2000 mg solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin 200 mg, tablets, orally, 3 times a day for up to 6 months.
3145106|NCT01582854|Placebo Comparator|Placebo|Actovegin placebo-matching solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin placebo-matching, tablets, orally, 3 times a day for up to 6 months.
3145107|NCT01582841|Experimental|MSI testing|All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI following surgery. Those with MSI-H results will receive a genetic counseling informational call.
3145108|NCT01582841|No Intervention|Usual care|These patients will be treated as usual by their oncologist and medical team. These patients receive a follow up letter a year after randomization, alerting them to the availability of clinical Lynch Syndrome screening.
3145109|NCT01582828|Active Comparator|Epicardial (surgical) ablation|Epicardial Pulmonary vein isolation
3145110|NCT01582828|Experimental|Hybrid|Epicardial (surgical) ablation & Endocardial assessment
3145111|NCT01582815|Experimental|JNJ-40411813|
3145112|NCT01582815|Placebo Comparator|Placebo|
3145113|NCT01582802||Pregnant women carrying multiples|
3145114|NCT01582789|Active Comparator|enfilcon A/senofilcon A|enfilcon A daily wear soft contact lens 1st then cross over and subject wears the senofilcon A daily wear soft contact lens 2nd
3145115|NCT01582789|Active Comparator|senofilcon A/enfilcon A|senofilcon A daily wear soft contact lens 1st then cross over and subject wears the enfilcon A daily wear soft contact lens 2nd
3145116|NCT01582776|Experimental|Lenalidomide and GA101|Ga101 and lenalidomide
3145117|NCT01582763||GBS|Guillain-Barré syndrome >1000, follow-up 1-3 years
3145118|NCT01582763||NC|Normal controls (NC)
3145119|NCT01582763||IC|Infectious controls (IC)
3145120|NCT01582763||OND|Other neurological diseases (OND)
3145121|NCT01582750||Local advanced rectal cancer EUS|
3145122|NCT01582737||Group 1|
3145123|NCT01582724|Experimental|Self-care acupressure|1
3145124|NCT01582724|No Intervention|Usual care|2
3145125|NCT01582711|Active Comparator|3HP Directly Observed Therapy (DOT)|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) under Directly Observed Therapy (DOT)
3145126|NCT01582711|Experimental|3HP Self Administered Therapy (SAT)|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) as patient Self Administered Therapy (SAT)
3145127|NCT01582711|Experimental|3HP SAT with SMS Reminders|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) as patient Self Administered Therapy (SAT). In addition, patient receives phone Short Message Service (SMS) reminders weekly.
3145128|NCT01582698|Experimental|Seropersistence evaluation + 2nd booster vaccination|Blood will be drawn to assess the seropersistence of TBE virus antibodies at 82, 94, 106 and 118 months after the first booster vaccination with FSME-IMMUN 0.5ml administered during the first precursor study. Timing of the second booster vaccination will depend on the level of serum TBE antibodies observed during the study. Blood will be drawn 21 - 35 days after vaccination to assess the booster response.
3145129|NCT01582685|Experimental|Exercise Group|The intervention is a structured walking program which will be performed partly in the Pavilion Physical Therapy clinic and partly at home. The participant will be instructed in how hard to exercise, how long to exercise, and how many times in a week to exercise. You will also be instructed in how to exercise safely.
3145130|NCT01582685|No Intervention|No Exercise|These participants will receive standard of care follow up.
3145131|NCT01582672|Experimental|AGS-003 + Standard Treatment|Subjects on this arm will receive standard treatment for Renal Cell Carcinoma. In addition, subjects will receive AGS-003.
3145132|NCT01582672|Active Comparator|Standard Treatment|Subjects on this arm will receive standard treatment for Renal Cell Carcinoma.
3145133|NCT01582659|No Intervention|No ekstra counseling|Standardized information about childhood constipation is given and the child receives PEG 3350. No additional follow up appointments are made.
3145134|NCT01582659|Active Comparator|2 counseling sessions|Standardized information about childhood constipation is given and the child receives PEG 3350. 2 additional follow up appointments by telephone are made.
3145135|NCT01582659|Active Comparator|Web access|Standardized information about childhood constipation is given and the child receives PEG 3350. No additional follow up appointments are made but the family are given access to a website with information about childhood constipation.
3145136|NCT01582646|Other|first period with terbutaline and second period with placebo|The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.
3145137|NCT01582646|Other|first period with placebo and second period with terbutaline.|The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.
3145138|NCT01582633|Experimental|0.1 ml ID dose|Dose of 0.1 ml ID trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
3145139|NCT01582633|Experimental|0.2 ml ID dose|Dose of 0.2 ml ID trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
3145140|NCT01582633|Experimental|0.5 ml IM dose - needle-free|Dose of 0.5 ml IM trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
3145141|NCT01582633|Active Comparator|0.5 ml IM - needle and syringe|Dose of 0.5 ml IM trivalent 2012 influenza vaccine administered by needle and syringe
3145516|NCT01580072|Experimental|Nurse monitoring for patients with COPD|
3145144|NCT01582607|Active Comparator|Group LB|subarachnoid administration of 2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5%
3145145|NCT01582607|Active Comparator|Group RF|subarachnoid administration of 2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl
3145146|NCT01582607|Active Comparator|Group BF|subarachnoid administration of 2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl
3145147|NCT01582607|Active Comparator|Group LBF|subarachnoid administration of 2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl
3145148|NCT01582581|Active Comparator|Telephonic CBT|Computer guided, cognitive behavioral therapy (CBT) delivered by a clinician-administered telephone intervention.
3145149|NCT01582581|Sham Comparator|Wait List Control|Randomized wait list control with measurement of study outcomes at week 0, 3 and 5 after the initiation of waiting.
3145150|NCT01582568||Certolizumab|Subjects will take the study drug certolizumab for 8 weeks. They will undergo a endoscopy before study drug and then again after study is complete. The study doctor will be looking for complete closure of the peri-anal fistula identified at visit 1 after the use of certolizumab based on and endoscopic ultrasound (EUS).
3145151|NCT01582555|Experimental|saline irrigation|a control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation;
3145152|NCT01582555|Experimental|intervention arm (group B),|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
3145153|NCT01582542|Experimental|Desmopressin|
3145154|NCT01582516|Experimental|Delta24-RGD|Intracerebral slow continuous infusion of study drug in increasing dose
3145155|NCT01582503|Experimental|MEMP1972A 150 mg|
3145156|NCT01582503|Experimental|MEMP1972A 300 mg|
3145157|NCT01582503|Experimental|MEMP1972A 450 mg|
3145158|NCT01582503|Placebo Comparator|Placebo|
3145159|NCT01582490|Active Comparator|Infiltration - EXPAREL|Group 2 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be administered via local infiltration into each surgical site per the surgeon's normal practice at the beginning of surgery.
3145160|NCT01582490|Experimental|Instillation - EXPAREL|Group 1 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be instilled into each breast pocket at the beginning of surgery.
3145161|NCT01582477|Experimental|EXPAREL 20 mL (undiluted)|20 mL (266 mg) undiluted EXPAREL with 133 mg infiltrated on each the right and left side of the abdomen.
3145162|NCT01582477|Active Comparator|EXPAREL 40 mL (diluted)|20 mL (266 mg) EXPAREL diluted with an equal volume of preservative-free 0.9% normal saline to a total of 40 mL and infiltrated equally to the right and left side of the abdomen.
3145163|NCT01582464||Older Adults in a Senior Community|Residents of a Continuing Care Retirement Community (CCRC) that is a part of The Be Group (previously known as Southern California Presbyterian Homes), with no exclusion other than being able to communicate in English and provide consent to participate.
3145164|NCT01582451|Experimental|LY2605541|Administered by subcutaneous (SQ) injection once daily at bedtime. Initial dose based on dose of prestudy basal insulin and adjusted based on fasting blood glucose (FBG). LY2605541 will be given alone or in combination with up to 3 pre-study oral antihyperglycemic medications (OAMs) whose use is not excluded in combination with insulin. Treatment may last up to 52 weeks.
3145165|NCT01582451|Active Comparator|Insulin glargine|Administered by SQ injection once daily at bedtime. Initial dose based on dose of prestudy basal insulin and adjusted based on FBG. Insulin glargine will be used alone or in combination with up to 3 pre-study OAMs whose use is not excluded in combination with insulin. Treatment may last up to 52 weeks.
3145166|NCT01582425|Experimental|Isavuconazole and methadone|Single dose of methadone on Days 1 and 20, isavuconazole 3 times a day (TID) on Days 16-17 as a loading dose, isavuconazole once a day (QD) on Days 18-28
3145167|NCT01582412|Experimental|Isavuconazole and digoxin|Isavuconazole three times per day (TID) on Days 15 and 16, and once daily (QD) on Days 17 thru 26. Digoxin single dose on Days 1 and 19.
3145168|NCT01582399|Experimental|Arm A: ASKP1240 intravenous (IV) infusion|
3145169|NCT01582399|Experimental|Arm B: ASKP1240 subcutaneous (SC)|
3145170|NCT01582373|Experimental|Cognitive-behavioral couple therapy|The goals of CBCT are to enable participants to: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of their sexual functioning, reduce their sexual distress and increase their sexual satisfaction; (5) consolidate skills.
3145171|NCT01582360||antiinfectiva: vancomycin|80 patients Completed.
3145172|NCT01582360||antiinfectiva: meropenem|80 patients recruiting
3145173|NCT01582360||antiinfectiva: flukonazol|80 patients
3145174|NCT01582360||antiinfectiva: cefotaxim|80 patients
3145175|NCT01582360||antiinfectiva: benzylpenicilline|80 patients
3145176|NCT01582360||antiinfectiva: tazobactam piperacillin|80 patients recruiting
3145177|NCT01582360||antiinfectiva: cloxacillin|80 patients
3145178|NCT01582360||antiinfectiva: ciprofloxacin|80 patients
3145179|NCT01582347|Experimental|RBP-6300|During the Double-Blind Transfer Period (Days 1-7), participants take RBP-6300 at a level (either 10, 20 or 30 mg/day) equivalent to dosing during the Run-In Period, plus Placebo for Subutex®/Suboxone®. This is followed by a 3-day Transition Period (Days 8-10) in which participants take active Subutex®/Suboxone® equal to the dose taken during the Run-In Period plus placebo matching RBP-6000.
3145213|NCT01582217||ASA + 75 mg clopidogrel daily|Clopidogrel 75 mg group (control): PRU ≤ 230; high bleeding risk or high ischemic risk; patients with active malignancy, age >75; Wt< 60kg with previous CVA or TA are prescribed 75 mg of clopidogrel daily along with aspirin.
3145513|NCT01580085||control group|age and sex matched adults with osa and no thromboembolism
3145180|NCT01582347|Active Comparator|Subutex®/Suboxone®|During the Double-Blind Transfer Period (Days 1-7), participants take Subutex®/Suboxone® at a level (either 8, 16 or 240 mg/day) equivalent to dosing during the Run-In Period, plus Placebo for RBP-6000. This is followed by a 3-day Transition Period (Days 8-10) in which participants take active Subutex®/Suboxone® equal to the dose taken during the Run-In Period plus placebo matching RBP-6000.
3145181|NCT01582321|Experimental|Part 1 Male|16 healthy male volunteers will be recruited. Primary and secondary outcome measures will be made on day 1, 3 and 4. At 24 and 72 hours prior to outcome measures on day 3 a cantharidin-soaked 1cm2 filter paper disc will be applied to participants forearm or back on leg for blister formation. Blister fluids will be harvested on day 3.
3145182|NCT01582321|Experimental|Part 1 Female|16 healthy female volunteers will be recruited. Primary and secondary outcome measures will be made on day 1, 3 and 4. At 24 and 72 hours prior to outcome measures on day 3 a cantharidin-soaked 1cm2 filter paper disc will be applied to participants forearm or back on leg for blister formation. Blister fluids will be harvested on day 3.
3145183|NCT01582321|Experimental|Part 2 Male|12 healthy male volunteers will be recruited. Primary and secondary outcome measures will be made on day 0, 1 and 2. At 8 hours prior to outcome measures on day 1 intra-muscular typhoid vaccine will be administered.
3145184|NCT01582321|Experimental|Part 2 Female|12 healthy female volunteers will be recruited. Primary and secondary outcome measures will be made on day 0, 1 and 2. At 8 hours prior to outcome measures on day 1 intra-muscular typhoid vaccine will be administered.
3145185|NCT01582308|Experimental|Treatment Sequence 1|Sitagliptin 100 mg in Period 1 followed by saxagliptin 5 mg in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg in Period 5
3145186|NCT01582308|Experimental|Treatment Sequence 2|Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by placebo in Period 3 followed by sitagliptin 100 mg in Period 4 followed by vildagliptin 50 mg BID in Period 5
3145187|NCT01582308|Experimental|Treatment Sequence 3|Vildagliptin 50 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by sitagliptin 100 mg in Period 3 followed by saxagliptin 5 mg in Period 4 followed by placebo in Period 5
3145188|NCT01582308|Experimental|Treatment Sequence 4|Vildagliptin 50 mg BID in Period 1 followed by placebo in Period 2 followed by saxagliptin 5 mg in Period 3 followed by vildagliptin 50 mg in Period 4 followed by sitagliptin 100 mg in Period 5
3145189|NCT01582308|Experimental|Treatment Sequence 5|Placebo in Period 1 followed by sitagliptin 100 mg in Period 2 followed by vildagliptin 50 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by saxagliptin 5 mg in Period 5
3145190|NCT01582308|Experimental|Treatment Sequence 6|Sitagliptin 100 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by saxagliptin 5 mg in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg BID in Period 5
3145191|NCT01582308|Experimental|Treatment Sequence 7|Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by vildagliptin 50 mg in Period 3 followed by sitagliptin 100 mg in Period 4 followed by placebo in Period 5
3145192|NCT01582308|Experimental|Treatment Sequence 8|Vildagliptin 50 mg in Period 1 followed by placebo in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by saxagliptin 5 mg in Period 4 followed by sitagliptin 100 mg in Period 5
3145193|NCT01582308|Experimental|Treatment Sequence 9|Vildagliptin 50 mg BID in Period 1 followed by sitagliptin 100 mg in Period 2 followed by placebo in Period 3 followed by vildagliptin 50 mg in Period 4 followed by saxagliptin 5 mg in Period 5
3145194|NCT01582308|Experimental|Treatment Sequence 10|Placebo in Period 1 followed by saxagliptin 5 mg in Period 2 followed by sitagliptin 100 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by vildagliptin 50 mg in Period 5
3145195|NCT01582295|Experimental|Treatment Arm|Cabozantinib ( XL 184)
3145196|NCT01582282|Placebo Comparator|placebo|matched placebo BID
3145197|NCT01582282|Active Comparator|psyllium 3.4g BID|3.4g psyllium BID for a Total of 6.8g daily
3145198|NCT01582282|Active Comparator|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day
3145199|NCT01582269|Experimental|LY2157299 monohydrate plus lomustine|"300 mg/day LY2157299, given orally for 14 days, followed by 14 days of rest, equaling a 28-day cycle.~First lomustine dose will be given as 100 mg/m2 on day 7 cycle 1. Remaining doses are based on the investigator's discretion and will be given orally once every 6 weeks in capsules to equal 100 to 130 mg/m2."
3145200|NCT01582269|Experimental|LY2157299 monohydrate|300 mg/day LY2157299, given orally for 14 days, followed by 14 days of rest, equaling a 28-day cycle (unblinded)
3145201|NCT01582269|Active Comparator|lomustine plus placebo|"First lomustine dose will be given as 100 mg/m2 on day 7 cycle 1. Remaining doses are based on the investigator's discretion and will be given orally once every 6 weeks in capsules to equal 100 to 130 mg/m2.~LY2157299 monohydrate-matched placebo, given orally as tablets for 14 days, followed by 14 days of rest, equaling a 28-day cycle."
3145202|NCT01582256||ASD+CNVs|
3145203|NCT01582256||ASD-CNVs|
3145204|NCT01582256||Unaffected siblings of ASD+CNVs|
3145205|NCT01582256||Unaffected siblings of ASD-CNVs|
3145206|NCT01582256||Neurotypicals for ASD+CNVs comparisons|
3145207|NCT01582256||Neurotypicals for ASD-CNVs comparisons|
3145208|NCT01582243|Experimental|Vildagliptin plus metformin (SPC)|Eligible participants received oral vildagliptin 50 mg plus metformin 500 mg (SPC) twice daily from week 1 to week 24.
3145209|NCT01582230|Experimental|Vildagliptin|Eligible patients will receive vildagliptin 50 mg in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
3145210|NCT01582230|Placebo Comparator|Placebo|Eligible patients will receive matching placebo in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
3145211|NCT01582217||SA + 5mg prasugrel|Prasugrel 5 mg group: Patients with Intermediate or high bleeding risks and PRU ≥ 230 are Prescribed 5mg of prasugrel daily along with aspirin.
3145212|NCT01582217||ASA + 10 mg prasugrel|Prasugrel 10 mg group: Patients with Low bleeding risk and high ischemia risk and PRU ≥ 230 are prescribed 10 mg of prasugrel daily along with aspirin.
3145457|NCT01580475|Experimental|Lifestyle (exercise training)|Training, detraining and retraining
3145214|NCT01582204|Experimental|124IcG250|This is a pilot study of 124I-cG250-PET/CT in 25 evaluable patients with advanced and/or metastatic clear cell renal cell carcinoma (ccRCC) who are scheduled to begin treatment with sunitinib or pazopanib. 124I-cG250-PET/CT will be assessed for its ability to predict response in comparison to standard CT scan of the chest, abdomen, and pelvis.
3145215|NCT01582191|Experimental|Vandetanib + Everolimus|"Starting dose of Vandetanib: 100 mg by mouth daily in a 28 day cycle.~Starting dose of Everolimus: 2.5 mg by mouth daily in a 28 day cycle."
3145216|NCT01582178|Experimental|Warm Water Immersion Colonoscopy|Colonoscopy using purely warm water (37°C) infusion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
3145217|NCT01582178|Active Comparator|Cool Water Immersion Colonoscopy|Colonoscopy using purely room temperature water (20-24°C) infusion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
3145218|NCT01582165|Active Comparator|Angina. IMR. Statin.|
3145219|NCT01582165|Placebo Comparator|Angina. IMR. Placebo.|
3145220|NCT01582152|Experimental|TPI 287 + Bevacizumab|"Part I: Patients assigned to receive 1 of 4 dose levels of TPI 287 based on when joining the study.~Phase I Starting Dose of TPI287 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle. Bevacizumab given at 10 mg/kg by vein on Day 1 every 2 weeks of a 42 Day cycle.~Phase II Starting Dose of TPI287: Maximum Tolerated Dose (MTD) from Phase I."
3145221|NCT01582152|Experimental|Bevacizumab Group|"Phase II: Participants randomized to Arm A (bevacizumab alone at 10 mg/kg every 2 weeks) versus Arm B (bevacizumab at 10 mg/kg every 2 weeks plus TPI 287.~Participant may enroll in Crossover Group to receive TPI 287 and bevacizumab if disease gets worse at any time during treatment with bevacizumab alone."
3145222|NCT01582139|Experimental|Experimental Condition: (Heart-Rate Informed SSM+HMM)|An experimental condition involving an exercise session where the Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) is informed about heart rate
3145223|NCT01582139|No Intervention|Control Condition (SSM+HMM)|A control condition involving an exercise session where the Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) is not informed about heart rate.
3145224|NCT01582126|Experimental|Group balance training early start|
3145225|NCT01582126|Experimental|Group balance training late start|
3145226|NCT01582113|Experimental|High Dose Citicoline|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of 500 mg of citicoline, of which they will be instructed to take 500 mg daily. This will be done in a double-blind, randomized fashion.
3145227|NCT01582113|Experimental|Low Dose Citicoline|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of 250 mg of citicoline, of which they will be instructed to take 250 mg daily. This will be done in a double-blind, randomized fashion.
3145228|NCT01582113|Placebo Comparator|Placebo|At visit 1 and again at visit 2, participants assigned to the placebo group will be given 14-day supplies of placebo to be taken daily throughout the study period. This will be done in a double-blind, randomized fashion.
3145229|NCT01582100|Experimental|GERD subjects with nausea|subjects with GERD and nausea will receive treatment with Reletex
3145230|NCT01582087||acute or chronic hepatic failure|All patients presenting at University of Texas Medical Branch (UTMB) with acute and chronic hepatic failure and who are developing coma
3145231|NCT01582061|Experimental|Pasireotide 600 μg|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined on the mean daily dose considering the following grouping rule: 600 μg bid group includes all patients whose mean daily dose < 1500 μg /day.
3145232|NCT01582061|Experimental|Pasireotide 900 μg|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined on the mean daily dose considering the following grouping rule: 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day
3145233|NCT01582035|Experimental|Panel 1|TMC647055 in combination with TVR for 10 days. Immediately followed by the extension phase: TVR at a dose of 750 mg every 8 hours for 12 weeks in combination with Peg IFN and RBV followed by either 12 or 36 weeks of PegIFN -RBV treatment alone.
3145234|NCT01582035|Experimental|Panel 2|TMC647055 in combination with TVR for 10 or 14 days. Immediately followed by the extension phase: TVR at a dose of 750 mg every 8 hours for 12 weeks in combination with Peg IFN and RBV followed by either 12 or 36 weeks of PegIFN -RBV treatment alone.
3145235|NCT01582022|Experimental|local anesthetic|local anesthetic agent
3145236|NCT01582022|Placebo Comparator|normal saline|comparator
3145237|NCT01582009|Experimental|Arm I: Oral Panobinostat and Oral Everolimus|Patients receive oral panobinostat once daily on days 1, 3, 4, 8, 10, and 12 and oral everolimus once daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3145238|NCT01581996|Experimental|Lanthanum carbonate treatment|One Treatment arm. All patients will receive the following doses of lanthanum carbonate(Fosrenol)for 10-12 days each: 0 mg, 500 mg tid, 1000 mg tid and 1500 mg tid.
3145239|NCT01581983|Experimental|Internet Mindfulness Meditation|
3145240|NCT01581983|Experimental|Individual Mindfulness Meditation|
3145241|NCT01581970|Experimental|Cetuximab/low dose Cyclophosphamide|Safety population as defined by all patients receiving at least one treatment with cyclophosphamide on Day 1.
3145242|NCT01581957|Active Comparator|Specific Enteral formulation|
3145243|NCT01581957|Placebo Comparator|Standard enteral formulation|
3145244|NCT01581944|No Intervention|No Treatment (Control)|Women were randomised to receive no gonadotropin-releasing hormone agonist prior to myomectomy.
3145245|NCT01581944|Experimental|2 Doses Goserelin|Women were randomised to receive 2 doses of 3.6mg of gonadotropin releasing hormone agonist prior to the myomectomy.
3145246|NCT01581944|Experimental|3 Doses Goserelin|Women were randomised to receive 3 doses of the gonadotropin-releasing agonist (3.6mg monthly injections).
3145247|NCT01581931|Experimental|Linagliptin/metformin|fixed dose combination tablet (FDC)
3145248|NCT01581931|Experimental|Linagliptin and metformin|single tablets
3145249|NCT01581905|Active Comparator|LH Group|The LH Group includes individuals undergoing conventional laparoscopic hysterectomy, total or supracervical.
3145517|NCT01580046|Experimental|Iodixanol|
3145250|NCT01581905|Active Comparator|RH Group|The RH Group includes individuals undergoing Robot-Assisted laparoscopic hysterectomy, total or supracervical.
3145251|NCT01581892|Experimental|Bone marrow stem cells|Bone marrow is obtained by posterosuperior iliac crest aspiration under topical anesthesia. Mononuclear cells were isolated by Ficoll density gradient and will be resuspended in heparinized isotonic saline for mixing with osteogenic matrix.
3145252|NCT01581879|Experimental|Ziprasidone HCL Capsules, 20 mg|Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited
3145253|NCT01581879|Experimental|Geodon Capsules, 20 mg|Geodon Capsules, 20 mg of Pfizer Inc
3145254|NCT01581866|Experimental|Ziprasidone HCL Capsules, 20 mg|Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited
3145255|NCT01581866|Experimental|Geodon Capsules, 20 mg|Geodon Capsules, 20 mg of Pfizer Inc
3145256|NCT01581853|Other|Lopinavir/ritonavir 800 mg / 200mg|Kaletra 200/50 mg comprimidos recubiertos con película Lopinavir/ritonavir 800 mg / 200mg will be changed from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
3145257|NCT01581840|Experimental|5Fu-mitomycine-panitumumab + radiotherapy|5 FU = 400 or 600 or 80 or 1000 mg depending of phase I results, days 1 to 4 weeks 1, 5 and 8 mitomicyne = 10 mg/m² day 1 week 1 and days 1, weeks 5 and 8 Panitumumab = 3 or 6 mg/kg (depending of phase I results) days 1, weeks: 1, 3, 5, 8 and 10
3145258|NCT01581827||Study population|People at high risk of heart failure (from SCREEN-HF study)
3145259|NCT01581814|Active Comparator|Metformin|31 subjects were randomized to receive 500 mg Metformin per 3/die
3145260|NCT01581814|Active Comparator|0.03 mg EE plus 3 mg of DRPS|
3145261|NCT01581814|Active Comparator|Metformin plus Yasmin|
3145262|NCT01581801|Other|Gastric Bypass|60 subjects obese subjects with complications or morbidly obese subjects will be assigned randomly to this arm to undergo gastric bypass
3145263|NCT01581801|Other|Sleeve Gastrectomy|60 subjects obese subjects with complications or morbidly obese subjects will be assigned randomly to this arm to undergo sleeve gastrectomy
3145264|NCT01581788|Experimental|Divalproex Sodium ER Tablets, 500 mg|Divalproex Sodium ER Tablets, 500 mg of Dr. Reddy's Laboratories Limited
3145265|NCT01581788|Active Comparator|Depakote ER Tablets, 500 mg|Depakote ER Tablets, 500 mg of Abbott Laboratories
3145266|NCT01581775|Experimental|Divalproex Sodium ER Tablets, 500 mg|Divalproex Sodium ER Tablets, 500 mg of Dr. Reddy's Laboratories Limited
3145267|NCT01581775|Active Comparator|Depakote ER Tablets, 500 mg|Depakote ER Tablets, 500 mg of Abbott Laboratories
3145268|NCT01581762|Sham Comparator|Conventional 22G Needle|Device: EUS-FNA with conventional 22G Needle
3145269|NCT01581762|Active Comparator|22G Procore Needle|Device: EUS-FNA with 22G Procore Needle which has a reverse bevel at the tip of the needle to enhance tissue collection
3145270|NCT01581749|Other|36.25Gy to prostate in 5 fractions|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
3145271|NCT01581736|Experimental|Exercise|Proteomics of muscle after a single bout of exercise compared to baseline with U100 Humulin infusion at rate of 80 milliunits(mU)/m^2 surface area.
3145272|NCT01581723|Active Comparator|Monopolar TUR|Monopolar diathermy is used to perform tranurethral resection of bladder tumor
3145273|NCT01581723|Experimental|Biploar TUR|Bipolar diathermy is used to perform transurethral resection of bladder tumor
3145274|NCT01581710|Active Comparator|montelukast to placebo|14 days
3145275|NCT01581710|No Intervention|Washout|14 days
3145276|NCT01581710|Active Comparator|Placebo to montelukast|14 days
3145277|NCT01581697|Experimental|Oat bran|
3145278|NCT01581684|Experimental|BI 411034 low dose - group 1|Solution for oral administration
3145279|NCT01581684|Experimental|BI 411034 low dose - group 2|Solution for oral administration
3145280|NCT01581684|Experimental|BI 411034 medium dose - group 3|Solution for oral administration
3145281|NCT01581684|Experimental|BI 411034 medium dose - group 4|Solution for oral administration
3145282|NCT01581684|Experimental|BI 411034 medium dose - group 5|Solution for oral administration
3145283|NCT01581684|Experimental|BI 411034 high dose - group 6|Solution for oral administration
3145284|NCT01581684|Experimental|BI 411034 high dose - group 7|Solution for oral administration
3145285|NCT01581684|Experimental|BI 411034 high dose - group 8|Solution for oral administration
3145286|NCT01581684|Placebo Comparator|Placebo|Solution for oral administration
3145287|NCT01581671||Patients having a first time angiogram|Patients who are coming to the Cardiac Cath Lab to have an angiogram for the first time
3145288|NCT01581658|Experimental|BI10773 medium dose group 1|BI10773 medium dose tablet single dose group 1
3145289|NCT01581658|Experimental|BI10773 medium dose group 2|BI10773 medium dose tablet single dose group 2
3145290|NCT01581658|Experimental|BI10773 Medium dose group 3|BI10773 medium dose tablet single dose group 3
3145291|NCT01581658|Experimental|BI10773 Medium dose group 4|BI10773 medium dose tablet single dose group 4
3145292|NCT01581645|Experimental|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
3145293|NCT01581619|Experimental|Partial Breast Irradiation|Partial Breast Irradiation using 40 Gy in 10 fractions over 2 weeks
3145294|NCT01581606||Group 1R and 1T AMD Screening|Group 1 patients will be collected through all referrals to any of the physician investigators with a provisional diagnosis of possible wet AMD. Any request for clinical evaluation of a patient for presumed wet AMD will be randomized into Group 1R (Routine Screening) and Group 1T (Tele-ophthalmology screening).
3145295|NCT01581606||Group 2R and 2T Follow up|Group 2 patients will be collected from the patients previously treated for wet AMD within the practices of the physician investigators. All patients in whom the disease is inactive (not receiving active treatment) and who therefore require monitoring will be randomized into Group 2R (Routine Monitoring) and Group 2T (Teleophthalmology Monitoring).
3145296|NCT01581593|Experimental|Kedrion IVIG 10%|Kedrion IVIG 10% treatment.
3145458|NCT01580462||Children and Adolescent with type 1 diabetes on CSII|
3145297|NCT01581541|Experimental|PU-H71|PU-H71 will be administered intravenous (IV) over one hour, once weekly, 2 weeks out of 3, (i.e., on days 1 and 8) every 21 days
3145298|NCT01581515|Active Comparator|P-E group|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
3145299|NCT01581515|Active Comparator|X-P group|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
3145300|NCT01581502||NVAF, acute ischemic stroke/TIA|Consecutive acute ischemic stroke/TIA patients with nonvalvular atrial fibrillation; most of these patients begin to receive anticoagulant therapy after index stroke/TIA for secondary prevention
3145301|NCT01581489||Early cord clamping (ECC)|Early cord clamping consisted of early (=< 10 s) clamping of the umbilical cord at birth.
3145302|NCT01581489||Delayed cord clamping (DCC)|Delayed cord clamping consisted of delayed (>= 180 s) clamping of the umbilical cord at birth.
3145303|NCT01581476|Active Comparator|Statin|Participants receive active statin and placebo ACE Inhibitor
3145304|NCT01581476|Active Comparator|Angiotensin-converting enzyme inhibitor|Participants receive active ACE Inhibitor and placebo statin
3145305|NCT01581476|Placebo Comparator|Placebo|Participants receive placebo ACE Inhibitor and placebo statin
3145306|NCT01581476|Other|Combination therapy|Participants receive both active ACE Inhibitor and active Statin
3145307|NCT01581463|Active Comparator|Liothyronine, Sodium|Healthy adults.
3145308|NCT01581450|Experimental|Tested drug|Remifentanil at 0.1 µg/kg/min Tested drug (N2O 35%): 35%/15%/50% N2O/N2/O2
3145309|NCT01581450|Active Comparator|Gas Active control|Remifentanil at 0.1 µg/kg/min Gas active control (N2O 50%):50%/50% N2O/O2
3145310|NCT01581437|Other|64 pole basket catheter|all patients participating undergo mapping using the 64 pole basket catheter to assess for Atypical areas of drivers that may cause atrial fibrillation
3145311|NCT01581411|Experimental|IA t-PA|intra-ophthalmic artery injection of tissue plasminogen activator
3145312|NCT01581398|Experimental|A1(Genotype2/3)|Ypeginterferon alfa-2b 180μg/week, in combination with Ribavirin 800mg/day
3145313|NCT01581398|Active Comparator|A2(Genotype 2/3)|Pegasys 180μg/week, in combination with Ribavirin 800mg/day
3145314|NCT01581398|Experimental|B1(Non-genotype 2/3)|Ypeginterferon alfa-2b 180μg/week, in combination with Ribavirin 1000-1200mg/day based on body weight
3145315|NCT01581398|Active Comparator|B2(Non-genotype 2/3)|Pegasys 180μg/week, in combination with Ribavirin 1000-1200mg/day based on body weight.
3145316|NCT01581385||Carotid endarterectomy|Adult patient volunteers, male and female, undergoing clinically indicated carotid endarterectomy surgery.
3145317|NCT01581372|Experimental|Pharmacist care|
3145318|NCT01581372|No Intervention|Usual care|
3145319|NCT01581359|Active Comparator|GnRHa|Triptorelin acetate 3,75 mg subcutaneous injection administered on days 1, 28 and 56 after menstrual cycle.
3145320|NCT01581359|Placebo Comparator|Physiological serum|physiological serum subcutaneous injection with same delivery device and same volume that active comparator ) administered on days 1, 28 and 56 after menstrual cycle.
3145321|NCT01581346|Experimental|exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
3145322|NCT01581333|Experimental|Experimental Arm|Empirical antimicrobial treatment discontinuation
3145323|NCT01581333|Active Comparator|Control Arm|Standard empirical antimicrobial treatment discontinuation
3145324|NCT01581320|Experimental|DP-R206|
3145325|NCT01581320|Active Comparator|Bonviva|
3145326|NCT01581307|Experimental|2nd Line Chemotherapy With Radiotherapy|"Administration of 2nd line chemotherapy will consist of a modified FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin) will take place at least 2 weeks after the completion of first‐line chemotherapy. Generally, second‐line chemotherapy is given every two weeks for 6‐10 cycles.~The goal of treatment with TheraSpheres is to allow a large dose of radiation to be delivered directly to the tumor(s) with less risk of toxic effects from radiation to other parts of the body or to healthy liver tissue."
3145327|NCT01581281|Active Comparator|Amitriptyline|Drug to be administered twice daily.
3145328|NCT01581281|Active Comparator|Topiramate|Drug to be administered twice daily.
3145329|NCT01581281|Placebo Comparator|Placebo|To be administered twice daily.
3145330|NCT01581255||Conventional lung protective ventilation|Critically-ill patients with the acute respiratory distress syndrome randomized to the conventional lung protective ventilation arm of the OSCILLATE trial.
3145331|NCT01581255||High frequency oscillation ventilation|Critically-ill patients with the acute respiratory distress syndrome randomized to the high frequency oscillation ventilation arm of the OSCILLATE trial.
3145332|NCT01581242|Experimental|A|
3145333|NCT01581242|Experimental|B|
3145334|NCT01581242|Experimental|C|
3145335|NCT01581229|Experimental|NPPV|
3145336|NCT01581229|Active Comparator|Control|
3145337|NCT01581216|Experimental|10 minute walk|10-minute walk and exercises for the upper limbs with 1 lb-dumbbells
3145338|NCT01581216|Experimental|20 minute walk|20-minute walk and exercises for the upper limbs with 1 lb-dumbbells
3145339|NCT01581216|Experimental|30 minute walk|30-minute walk and exercises for the upper limbs with 1 lb-dumbbells
3145340|NCT01581203|Experimental|Arm 1: Null or Partial Responder to P/R (ASV + DCV)|"Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 Weeks"
3145341|NCT01581203|Experimental|Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV)|"Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 Weeks"
3145342|NCT01581203|Experimental|Arm 3: Treatment naive (ASV + DCV)|"[Subjects will receive ASV + DCV for 24 weeks] followed by ASV + DCV for 24 weeks in protocol AI444026]~Subjects meeting prespecified rescue criteria in the treatment naive cohort may have therapeutic rescue instituted with QUAD regimen (QUAD= ASV + DCV + P/R)~Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 or 48 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 or 48 Weeks~Pegylated-interferon alfa 2a (PegIFN) 180 mcg/0.5 mL injection subcutaneously (SC), once weekly for 24 or 48 weeks~Ribavirin 1000 mg/1200 mg (total daily dose) tablet by mouth for 24 or 48 weeks"
3145343|NCT01581203|Experimental|Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week|"Subjects meeting prespecified rescue criteria in the null or partial responder cohort or active arm of the treatment naive cohort may have therapeutic rescue instituted with QUAD regimen (QUAD= ASV + DCV + P/R)~Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 or 48 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 or 48 Weeks~Pegylated-interferon alfa 2a (PegIFN) 180 mcg/0.5 mL injection subcutaneously (SC), once weekly for 24 or 48 weeks~Ribavirin 1000 mg / 1200 mg (total daily dose) Tablet by mouth, for 24 or 48 weeks"
3145344|NCT01581190|Experimental|Bananas versus 6% carbohydrate beverage|
3145345|NCT01581177|Experimental|T1|Two inhalations, one of Albuterol DPI 25 mcg/inh and one of Placebo DPI; Total Albuterol dose of 25 mcg
3145346|NCT01581177|Experimental|T2|Two inhalations of Albuterol DPI 25 mcg/inh; Total Albuterol dose of 50 mcg
3145347|NCT01581177|Experimental|T3|Two inhalations, one of Albuterol DPI 90 mcg/inh and one of Placebo DPI; Total Albuterol dose of 90 mcg
3145348|NCT01581177|Experimental|T4|Two inhalations of Albuterol DPI 90 mcg/inh; Total Albuterol dose of 180 mcg
3145349|NCT01581177|Placebo Comparator|P|Two inhalations Placebo DPI; Total Albuterol dose of 0 mcg
3145350|NCT01581177|Active Comparator|R1|One inhalation of Albuterol MDI 90 mcg/inh; Total Albuterol dose of 90 mcg
3145351|NCT01581177|Active Comparator|R2|Two inhalations of Albuterol MDI 90 mcg/inh; Total Albuterol dose of 180 mcg
3145352|NCT01581164||HSCT patients|Patients who have been treated with HSCT
3145353|NCT01581151|Active Comparator|Monthly Ranibizumab|"• Patients will receive a ranibizumab intravitreal injection on day 0. During each other visit, patients will receive a ranibizumab intravitreal injection. The protocol will use the term monthly to represent a 30 day interval between treatments."
3145354|NCT01581151|Experimental|Dexamethasone intravitreal implant|"Patients will receive a dexamethasone intravitreal implant injection at day 0.~During monthly visits 1,2,3, and 5, patients will receive a ranibizumab intravitreal injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥ 250 μm or the best-corrected visual acuity is 20/40 or worse. The injection procedure is described in the next section.~During monthly visit 4, patients will receive a dexamethasone intravitreal implant injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥ 250 μm or the best-corrected visual acuity is 20/40 or worse."
3145355|NCT01581138|Experimental|12 week treatment|
3145356|NCT01581138|Experimental|16 week treatment|
3145357|NCT01581125|Experimental|Sleep:wake 2|Sleep and wake durations for arm 2 for inpatient portion of protocol. .There are a variety of sleep and wake durations during the protocol; some of these are longer and some are shorter and some are the same as in arm 1.
3145358|NCT01581125|Experimental|Sleep:wake 1|Sleep and wake durations for arm 1 of the inpatient portion of the protocol. There are a variety of sleep and wake durations during the protocol; some of these are longer and some are shorter and some are the same as in arm 2.
3145359|NCT01581112|Experimental|Heavy armpit odour|Subjects with heavy armpit odour.
3145360|NCT01581112|Experimental|Heavy foot odour|Subjects with heavy foot odour.
3145361|NCT01581099||Clinical treatment|Diabetic individuals refractory to medical treatment kept under clinical treatment guidelines and lifestyle
3145362|NCT01581099||Surgery|Diabetic individuals refractory to conservative clinical treatment subject to Digestive Adaptations III Surgery.
3145363|NCT01581099||Control|Healthy individuals (normal weight and no cardiovascular risk factors) will be used to evaluate the behavior incretin hormones in healthy individuals, serving as a benchmark to analyze the results obtained in other groups.
3145364|NCT01581073|Experimental|High Hb group|Darbepoetin alfa is given to the patients. Target Hb level is 12.0g/dL and it should be maintained greater than or equal to 11.0g/dL and less than 13.0g/dL. If the patients do not have medical history of myocardial infarction, stroke, pulmonary embolism, unstable angina, or peripheral artery disease, the target Hb level will be greater than or equal to 12.0g/dL and less than 13.0g/dL. Maximum dose of darbepoetin alfa is 240 microgram per 4 weeks.
3145365|NCT01581073|Active Comparator|Low Hb group|Darbepoetin alfa is given to the patients. Target Hb level is 10.0g/dL and it should be maintained greater than or equal to 9.0g/dL and less than 11.0g/dL. If the Hb level exceeds 10.0g/dL in patients, reduce the dose amount or stop giving dose.
3145366|NCT01581060|Experimental|WX-554|
3145367|NCT01581047||Amoxicillin/Clavulanic Acid|Patients in the intensive care unit, with an infection which will be treated with Amoxicillin/Clavulanic Acid.
3145368|NCT01581047||Cefuroxime|Patients in the intensive care unit, with an infection which will be treated with Cefuroxime.
3145369|NCT01581034|Active Comparator|Padma|
3145370|NCT01581034|Placebo Comparator|Placebo|
3145371|NCT01581021|Active Comparator|Thoracic Pedicle Screws|Group treated with pedicle screws in the thoracic spine
3145372|NCT01581021|Active Comparator|Laminar Hooks|Group treated with hooks in the thoracic spine
3145373|NCT01581008|Experimental|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
3145374|NCT01581008|Active Comparator|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
3145375|NCT01580995|Experimental|Valacyclovir|Valacyclovir 500 mg po bid
3145376|NCT01580995|Placebo Comparator|Placebo|Matching placebo twice daily
3145377|NCT01580969|Experimental|All patients|All patients enrolled in study.
3145378|NCT01580956|Other|VARIABLE-PSV ventilatory mode|
3145379|NCT01580956|Other|STANDARD-PSV ventilatory mode|
3145459|NCT01580436|Experimental|Tricuspid Valve Annuloplasty|Patients, undergoing mitral valve surgery with no significant tricuspid valve regurgitation despite tricuspid annular dilation, randomized to concomitant tricuspid valve annuloplasty.
3145514|NCT01580072|No Intervention|Control group|Participants in the control group receive usual care.
3145380|NCT01580943|Active Comparator|Antiplaque Efficacy|"This study was designed as a randomized, two group parallel, double-blind, 3-day non-brushing clinical trial. The sample size (50 participants) was determined using similar studies, making it a convenience sample.~Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds."
3145381|NCT01580943|Active Comparator|Taste and Side Effects|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
3145382|NCT01580930|No Intervention|Control group|Group had outcome measures collected and were instructed to not change activity and sedentary time behavior
3145383|NCT01580930|Experimental|Exercise|Participants performed 5 days per week, 40 min per session of exercise training under direct supervision of personal trainer.
3145384|NCT01580930|Experimental|Sedentary time reduction|participants were give strategies to reduce sedentary time
3145385|NCT01580930|Experimental|exercise plus sedentary time reduction|Participants completed exercise training (5 days per week, 40 min per session) plus were given sedentary time reduction intervention
3145386|NCT01580917||Diabetic Test|Diabetic individuals with a history of previous plantar ulcer and a high risk of developing a foot ulceration
3145387|NCT01580917||Healthy Controls|Non-diabetic, healthy individuals with low risk of developing a neurogenic foot ulcer
3145388|NCT01580904|No Intervention|control group|Patients will not be followed by the pharmacist.
3145389|NCT01580904|Experimental|Intervention group|"Patients will be followed by the pharmacist by Pharmacotherapeutic monitoring and dosing parameters such as glucose and glycated hemoglobin.~Intervention: Pharmaceutical Care"
3145390|NCT01580891|Experimental|Naftifine HCl Cream 1%|Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.)
3145391|NCT01580891|Active Comparator|Naftin® (Naftifine HCl) Cream 1%|Naftin® (Naftifine HCl) Cream 1% (Merz Pharmaceuticals)
3145392|NCT01580891|Placebo Comparator|Placebo topical cream|Placebo topical cream (Taro Pharmaceuticals Inc.)
3145393|NCT01580878|Experimental|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% (Taro Pharmaceuticals, Inc.)
3145394|NCT01580878|Active Comparator|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) (Schering Plough HealthCare Products Inc.)
3145395|NCT01580878|Placebo Comparator|Butenafine Vehicle|Butenafine Cream vehicle (Taro Pharmaceuticals Inc.)
3145396|NCT01580865|Active Comparator|Mycophenolate Mofetil (MMF)|"MMF will be initiated in 45 patients at a dose of 750 mg twice daily (for patients > 50 Kg and eGFR > 60 ml/min), and advanced weekly to a maximum dose of 1,000 mg two times daily to achieve or MPA trough level > 3 mg/dL.~Patients will be received concomitant prednisone at a dose of 1 mg/kg/d (maximum 60 mg/d), with tapering by 5 mg/d every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage will be maintained to the end of 24 weeks"
3145397|NCT01580865|Experimental|Tacrolimus (TAC)|"Tacrolimus will be started in 45 patients at a dosage of 0.05 mg/kg/d divided into 2 daily doses at 12-hour intervals, and the dosage will be titrated to achieve 12-hour trough blood concentrations of 10-20 ng/mL in the first and second month and then 6-8 ng/mL thereafter.~Patients will be received concomitant prednisone at a dose of 1 mg/kg/d (maximum 60 mg/d), with tapering by 5 mg/d every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage will be maintained to the end of 24 weeks."
3145398|NCT01580852|Active Comparator|Dead Sea Water|
3145399|NCT01580852|Sham Comparator|Pool Water|
3145400|NCT01580839|Experimental|intravenous tissue plasminogen activator|
3145401|NCT01580839|Placebo Comparator|Placebo|
3145402|NCT01580826|No Intervention|raw milk|Infants who were assigned to the raw group received fresh or thawed milk from their own mother, cultured weekly with a semi-quantitative analysis. Raw milk was withheld if it contained any Gram-negative organisms, S. aureus or enterococci.
3145403|NCT01580826|Active Comparator|pasteurized milk|Infants who were assigned to pasteurization received own mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
3145404|NCT01580813|Experimental|Acipimox|Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visi
3145405|NCT01580813|Placebo Comparator|Placebo|Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit
3145406|NCT01580800||Breast cancer survivors|Patients who have undergone breast cancer treatment (e.g. surgery, node dissection, chemotherapy and/or radiation therapy), and what affect this has had on their arm health.
3145407|NCT01580787|Experimental|Virtual Reality Training|The virtual reality training was done by experimental group with ten games of Nintendo Wii Fit.
3145408|NCT01580787|Active Comparator|Physical Therapy|The Control Group was trained by conventional Physical Therapy exercises.
3145409|NCT01580774||Post-discharge phone call|All patients in this group will receive a phone call within 72-hours of being discharged from hospital.
3145410|NCT01580774||Usual care (no phone call)|
3145411|NCT01580761|Experimental|Sleep restriction|Sleep restriction
3145412|NCT01580761|No Intervention|Normal sleep|Normal sleep
3145413|NCT01580748|Experimental|Treatment arm|single arm study
3145414|NCT01580735|Experimental|ARQ 197|
3145415|NCT01580722|Other|early|patients underwent < 8 weeks reconstruction after injury
3145416|NCT01580722|Other|delay|patients underwent > 8 weeks reconstruction after injury
3145417|NCT01580709|Active Comparator|Multimodality Approach|Patients in the multimodality arm will undergo a single brushing for routine cytology, a second brush sample for Fluorescence In Situ Hybridization and a cholangioscopy with site-directed biopsies for histology.
3145511|NCT01580098|Experimental|Nurse-monitoring for patients with Diabetes mellitus type 2|Nurses are measuring and entering the vital parameters of the patients.
3145515|NCT01580072|Experimental|Self monitoring for patients with COPD|
3145418|NCT01580709|Active Comparator|Multiple brush samples|In patients randomized to multiple brushing samples, subsequent brushings #2-7 will be labeled separately and consecutively and sent to cytology. The cytopathologist will review each specimen for cellularity using a previously validated scoring system and presence of malignancy (positive, highly suspicious, atypical, normal).
3145419|NCT01580696|Active Comparator|Non-vaccine clinically matched control group|HLA-A2-negative patients and HLA-A2+ patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression.
3145420|NCT01580696|Experimental|E39 peptide (100mg)/GM-CSF vaccine|HLA-A2+ patients receive 100mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of either E39 or E39' (J65) 6 and 12 months after completion of the primary vaccine series.
3145421|NCT01580696|Experimental|E39 peptide (500mg) /GM-CSF vaccine|HLA-A2+ patients receive 500mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of either E39 or E39' (J65) 6 and 12 months after completion of the primary vaccine series.
3145422|NCT01580696|Experimental|E39 peptide (1000mg) /GM-CSF vaccine|HLA-A2+ patients receive 1000mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of either E39 or E39' (J65) 6 and 12 months after completion of the primary vaccine series.
3145423|NCT01580683|Experimental|Ascorbic acid|
3145424|NCT01580683|Placebo Comparator|Placebo|
3145425|NCT01580670|Experimental|TA-650|
3145426|NCT01580657|Experimental|Detailed baseline interview, enhanced HIV intervention|Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
3145427|NCT01580657|Experimental|General baseline interview, enhanced HIV intervention|Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.
3145428|NCT01580657|Experimental|No baseline interview, enhanced HIV intervention|This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.
3145429|NCT01580657|Active Comparator|D. Detailed baseline interview, standard of care intervention|Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.
3145430|NCT01580657|Active Comparator|E. General baseline interview, standard of care intervention|Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.
3145431|NCT01580657|Active Comparator|F. No baseline interview, standard of care intervention|Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
3145432|NCT01580644|Experimental|Period 1: formulation 1 oral solution|
3145433|NCT01580644|Experimental|Period 2: formulation 2 capsule|
3145434|NCT01580644|Experimental|Period 3: Selected formulation + food|
3145435|NCT01580644|Experimental|Period 4: Selected formulation at higher dose|
3145436|NCT01580631||BE with dysplasia.|Patients having Barrett's esophagus with dysplasia.
3145437|NCT01580631||BE without dysplasia.|Patients having Barrett's esophagus without dysplasia.
3145438|NCT01580618|Placebo Comparator|Normal Saline|Loculated pleural effusion infused with normal saline twice a day for three days.
3145439|NCT01580618|Active Comparator|TNKase|Loculated pleural effusion infused with TNK twice a day for three days.
3145440|NCT01580605||Users of somatropin|
3145441|NCT01580592|Experimental|Omalizumab 150mg|
3145442|NCT01580592|Experimental|Omalizumab 300mg|
3145443|NCT01580592|Placebo Comparator|Placebo|
3145444|NCT01580579||locally advanced lung cancer|Patients with locally advanced lung cancer who are candidates to chemoradiation
3145445|NCT01580566||Group 1 - Control|"Non-Q wave MI subjects with normal cardiac and renal function (defined as eGFR >60ml/min) not undergoing a cardiac procedure involving contrast will serve as control for renal injury subjects."
3145446|NCT01580566||Group 2 - stable CAD or non-Q wave MI|Patients undergoing coronary angiography +/- PCI for stable CAD or non-Q wave MI with normal cardiac and renal function (defined as eGFR >60ml/min) will control for the contrast STEMI patients are likely to receive as part of their post-MI management
3145447|NCT01580566||Group 3 - Acute STEMI without chronic kidney disease|Acute STEMI patients (n=40), without chronic kidney disease (defined as eGFR ≥60ml/min).
3145448|NCT01580566||Group 4 - Acute STEMI with kidney disease|Acute STEMI patients (n=40), with evidence of background chronic kidney disease (eGFR <60ml/min).
3145449|NCT01580553|Placebo Comparator|Levocarnitine|
3145450|NCT01580553|Active Comparator|L-carnitine|
3145451|NCT01580540||Group A, subjects with colorectal cancer|Subjects between ages 50 and 84 identified to have CRC. Blood and stool specimens are collected and tested after colonoscopy and prior to surgery or other interventions.
3145452|NCT01580540||Group B, subjects without CRC|Subjects between ages 50 and 84 who provide stool and blood specimens prior to colonoscopy.
3145453|NCT01580527|Active Comparator|total parenteral nutrition|
3145454|NCT01580527|Experimental|Early enteral nutrition|
3145455|NCT01580514|Active Comparator|Exenatide|"Drug: Exenatide~10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
3145456|NCT01580514|Placebo Comparator|Saline|"Drug: Saline~10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
3145460|NCT01580436|No Intervention|Conservative arm|Patients, undergoing mitral valve surgery with no significant tricuspid valve regurgitation despite tricuspid annular dilation, randomized to mitral valve surgery without concomitant tricuspid valve annuloplasty.
3145461|NCT01580423|Experimental|aprepitant|
3145462|NCT01580423|Placebo Comparator|inert powder|
3145463|NCT01580410|Experimental|Arm I (mitomycin C)|Patients undergo surgical cytoreduction and receive mitomycin C by HIPEC.
3145464|NCT01580410|Experimental|Arm II (oxaliplatin)|Patients undergo surgical cytoreduction and receive oxaliplatin by HIPEC.
3145465|NCT01580397|Experimental|INNO-206|
3145466|NCT01580384||Cohort|
3145467|NCT01580371|Experimental|Treatment|CKD-581
3145468|NCT01580358|Active Comparator|Shen-Mai San|Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
3145469|NCT01580358|Placebo Comparator|starch|Starch in the same granule as intervention group for this double-blind trial
3145470|NCT01580345|Active Comparator|Docosa-hexaenoic Acid (DHA)|
3145471|NCT01580345|Placebo Comparator|Placebo|Corn-Soy Oil
3145472|NCT01580319|No Intervention|Control|Participants do not receive a physical exercise plan. Participants receive a simple orientations about lifestyle activities.
3145473|NCT01580319|Experimental|Exercise|Participants receive a physical exercise plan to play at home
3145474|NCT01580306|Experimental|BI 201335 relevant treatment dose (A)|Capsule for oral administration
3145475|NCT01580306|Experimental|BI 201335 relevant treatment dose (B)|Capsule for oral administration
3145476|NCT01580293|Experimental|Arm 1|On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds
3145477|NCT01580293|Experimental|Arm 2|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by 2 infusions per week over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
3145478|NCT01580293|Experimental|Arm 3|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 5 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
3145479|NCT01580293|Experimental|Arm 4|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 7 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
3145480|NCT01580280|Experimental|Thrust manipulation|
3145481|NCT01580280|Active Comparator|Non-thrust mobilization and exercise|
3145482|NCT01580254|Active Comparator|IOPIZE© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is IOPIZE©
3145483|NCT01580254|Active Comparator|GALAXIA© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is GALAXIA©
3145484|NCT01580254|Active Comparator|Latanoprost RATIOPHARM© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is Latanoprost RATIOPHARM©
3145485|NCT01580241||Surgery group|Patients with pancreatic cancer who undergo surgical treatment only
3145486|NCT01580241||Chemotherapy group|Patients with pancreatic cancer who undergo chemotherapy treatment only
3145487|NCT01580241||Neoadjuvant group|Patients with pancreatic cancer who undergo neoadjuvant chemotherapy and surgery
3145488|NCT01580241||Adjuvant group|Patients with pancreatic cancer who undergo surgery followed by chemotherapy
3145489|NCT01580228|Experimental|Dinaciclib|
3145490|NCT01580228|Active Comparator|Ofatumumab|
3145491|NCT01580215||Main cohort|"Patients of both genders of at least 18 years of age~Who understand and voluntarily sign an informed consent form~FEV1 > 15% predicted and < 45% predicted~RV >180% predicted~Diagnosis of emphysema with CT evidence of hyperinflation~Absence of collateral ventilation according to Chartis Assessment System~Treated with Zephyr Endobronchial Valve (EBV)"
3145492|NCT01580202|Active Comparator|Lamivudine|LAM (100 mg/day) will be started within 1 week prior to initiation of the 1st cycle of chemotherapy, and continued until 24 weeks after completion of the last chemotherapy.
3145493|NCT01580202|Experimental|Entecavir|ETV (0.5 mg/day) will be started within 1 week prior to initiation of the 1st cycle of chemotherapy, and continued until 24 weeks after completion of the last chemotherapy.
3145494|NCT01580189|Active Comparator|Milk|Chocolate milk compared to protein supplement
3145495|NCT01580189|Active Comparator|Whey protein|Whey protein compared to milk
3145496|NCT01580189|Placebo Comparator|Sugar|Maltodextrin compared to treatments
3145497|NCT01580176|Experimental|GlucoseMonitor|
3145498|NCT01580163|Experimental|JITAI combined therapy group|The investigator will adopt JITAI combined psychological intervention and social support in Shanghai-related community.
3145499|NCT01580163|Experimental|Methadone combined herapy group|The investigator will adopt JITAI combined psychological intervention and social support in Shanghai-related community.
3145500|NCT01580163|Experimental|JITAI therapy group|The investigator will adopt JITAI combined social support in Shanghai-related community and outside of Shanghai.
3145501|NCT01580150|Experimental|Berry meal|Carbohydrate meals with berries
3145502|NCT01580150|Active Comparator|Reference meal|Carbohydrate meals without berries
3145503|NCT01580137||healthy conscripts|non allergic subjects who have not a history of recurrent rhinosinusitis
3145504|NCT01580137||subjects with recurrent rhinosinusitis|subjects who have experienced recurrent rhinosinusitis episodes (3 during the previous 3 years)
3145505|NCT01580124|Active Comparator|PVI alone|Pulmonary vein isolation alone in persistent atrial fibrillation
3145506|NCT01580124|Active Comparator|PVI + Defragmentation + linear lesions|AF ablation continuation aiming for AF termination
3145507|NCT01580111|Experimental|Short storage|Short storage arm: Will receive blood (Packed red blood cells) of 1 (one) to 10 (ten) days in storage.
3145508|NCT01580111|Active Comparator|Long storage arm|Will be transfused with blood ( packed red cells) of storage age 21- 35 days.
3145509|NCT01580098|No Intervention|Control group|treatment as usual
3145510|NCT01580098|Experimental|Self-monitoring for patients with Diabetes mellitus type 2|Patients are self-monitoring and submitting their vital parameters.
3145518|NCT01580046|Active Comparator|iopromide|
3145519|NCT01580033|Experimental|A+C+hib Conjugate Vaccine|600 infants aged 3-5 months, will be vaccinated on day0, 28, 56
3145520|NCT01580033|Active Comparator|Walvax AC vaccine, Pasteur Hib vaccine|300 infants aged 3-5 months, will be vaccinated on day0, 28, 56
3145521|NCT01580020|Experimental|Ranibizumab (Arm A)|"The PRN injection scheme applied in the core study will also be followed during this extension study:~Patients should be monitored monthly (starting at V1E) for VA and treatment is to be resumed when monitoring indicates loss of VA due to disease activity. Monthly injections should then be administered until stable VA is reached again for 3 consecutive monthly assessments (implying a minimum of 2 injections during stable VA). The interval between 2 doses should not be shorter than 1 month"
3145522|NCT01580020|Sham Comparator|Dexamethasone (Arm B)|A PRN re-treatment scheme will be applied for the Ozurdex arm during this extension study, i.e. patients may receive an implant at V1E or later as needed: Patients should be monitored monthly and if there is a decline from stable VA stability due to macular edema patients will receive another intravitreal implant. (700 µg; long acting release (LAR)) given that in the opinion of the investigator the patient would benefit from the re-treatment. However, a minimum period of 5 months in between implantations is required.
3145523|NCT01580007|Active Comparator|Active Sodium Phenylbutyrate and active cholecalciferol|500 mg sodium phenylbutyrate (4-phenylbutyric acid, sodium salt) in tablet form twice daily and 5000 IU of cholecalciferol once daily will be given orally for 2 months
3145524|NCT01580007|Active Comparator|Placebo Sodium Phenylbutyrate plus active cholecalciferol|Drug: Cholecalciferol Placebo: Sodium Phenylbutyrate
3145525|NCT01580007|Active Comparator|Active Sodium Phenylbutyrate and placebo cholecalciferol|Drug: Sodium Phenylbutyrate Placebo: cholecalciferol
3145526|NCT01580007|Placebo Comparator|Placebo Sodium Phenylbutyrate plus placebo cholecalciferol|Placebo Sodium Phenylbutyrate Placebo cholecalciferol
3145527|NCT01579994|Experimental|Ganetespib (STA-9090) and crizotinib|This protocol is a phase I single arm, open label, single institution study of crizotinib and ganetespib (STA-9090) in patients with ALK+ advanced NSCLC who are crizotinib naïve.
3145528|NCT01579968||eptacog alpha users|
3145529|NCT01579955||eptacog alpha users|
3145530|NCT01579942||Patients with Major Depressive Disorder|Patients who have Major Depressive Disorder and are taking a Selective Serotonin Re-uptake Inhibitor (SSRI) as part of another study at our clinic.
3145531|NCT01579942||Healthy Controls|Patient with no history of significant mental health problems.
3145532|NCT01579929|Experimental|LDE225, Etoposide and Cisplatin|This is a single institution phase I trial of LDE225 combined with etoposide and cisplatin in patients with untreated, newly diagnosed extensive stage small cell lung cancer (ES-SCLC). LDE225 is an oral drug, which will be taken daily by patients. Patient self-reporting via STAR will be used in an evaluation of the extent to which patient-reported toxicity influences dose finding in phase I clinical trials. Specifically, STAR reports will be presented to clinicians in real-time at clinic visits, & clinicians will have an opportunity to either agree or modify the patient self-assessments & use this information in their grading & attribution of toxicities.
3145533|NCT01579916|Experimental|Trivalent Influenza Virus Vaccine|Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
3145534|NCT01579916|Placebo Comparator|Placebo|Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
3145535|NCT01579903|Experimental|Sequence 1|Subjects randomized to receive Treatment A during Period 1, then Treatment B during Period 2.
3145536|NCT01579903|Experimental|Sequence 2|Subjects randomized to receive Treatment B during Period 1, then Treatment B during Period 2.
3145537|NCT01579877|Experimental|Yukmijihwang-tang|Yukmijihwang-tang: Real herbal extract granule
3145538|NCT01579877|Placebo Comparator|Yukmijihwang-tang_Placebo|Yukmijihwang-tang_Placebo: Placebo herbal extract granule
3145539|NCT01579864|Active Comparator|succinylcholine|Succinylcholine 1 mg/kg and a second dose if necessary.
3145540|NCT01579864|Experimental|Rocuronium|rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
3145541|NCT01579851|Active Comparator|Propofol-Remifentanil|Anesthesia is maintained with Propofol and Remifentanil; myorelaxation is obtained with rocuronium
3145542|NCT01579851|Active Comparator|Sevoflurane-Remifentanil|Anesthesia is maintained with Sevoflurane and Remifentanil; myorelaxation is obtained with rocuronium
3145543|NCT01579838|Experimental|Eculizumab|Eculizumab will be administrated according to known protocols.
3145544|NCT01579825|Experimental|Buffer|
3145545|NCT01579825|No Intervention|Control|
3145546|NCT01579812|Experimental|Metformin|
3145547|NCT01579799|Active Comparator|Dose 0.5|
3145548|NCT01579799|Active Comparator|Dose 7.5|
3145549|NCT01579799|Active Comparator|Dose 3|
3145550|NCT01579799|Active Comparator|Dose 1.2|
3145551|NCT01579786|No Intervention|Acetaminophen|A group All patients will be treated only with drugs used for this type during the operation and post operative pain controlled with usual acetaminophen drug administration (maximum 3 g/day)
3145552|NCT01579786|Experimental|Acetaminophen and acupuncture|B group patients. All patients will receive the standard pharmacological treatment for the operation. Acetaminophen (maximum 3g/day) during all seven days after surgery and patients will be treated with acupuncture the first day after surgery and thirty minutes before the surgical procedure
3145553|NCT01579760|Experimental|aflibercept every 2 months|
3145554|NCT01579760|Experimental|aflibercept monthly|
3145555|NCT01579747|Placebo Comparator|Nerve stimulation sciatic nerve block|Time taken to complete a sciatic nerve block via the lateral popliteal approach using nerve stimulation
3145556|NCT01579747|Active Comparator|Ultrasound guided sciatic nerve block|Time taken to complete a sciatic nerve block via the lateral popliteal approach when using an ultrasound
3145557|NCT01579734|Placebo Comparator|Placebo|1 tablet day for 5 years
3145558|NCT01579734|Active Comparator|Tamoxifen|Tamoxifen 5 mg, (1 tablet) day for 5 years
3290673|NCT00541567|Experimental|4|
3145559|NCT01579721|Experimental|SILS-group|20 patients undergoing Single Incision Laparoscopic Surgery
3145560|NCT01579721|No Intervention|CLS-group|20 patients undergoing Conventional Laparoscopic Surgery for rectal cancer
3145561|NCT01579708|Experimental|Program SI! educational intervention|
3145562|NCT01579708|No Intervention|Control|
3145563|NCT01579695||Exposed Group will receive Tesamorelin|
3145564|NCT01579695||Control Group will not receive Tesamorelin|
3145565|NCT01579682|Experimental|Psychotherapy|Family-Based Therapy (12 sessions)
3145566|NCT01579682|Experimental|Family-Based Therapy with Intensive Family-Focused Treatment|The patient will receive 4 sessions of Family-Based therapy, and if the participant does not make adequate weight gain within this time period, will be assigned to Intensive Family-Focused Therapy (IFT).
3145567|NCT01579669|Experimental|Use of Toolkit|All participants will have access to the toolkit
3145568|NCT01579656|Experimental|Salba|25g of ground Salba baked into a bran muffin
3145569|NCT01579656|Experimental|Poppy|25g of ground poppy seeds baked into a bran muffin
3145570|NCT01579656|Experimental|Flaxseed|25g of ground flaxseed baked into a bran muffin
3145571|NCT01579656|Experimental|Sesame|25g of ground sesame seeds baked into a bran muffin
3145572|NCT01579656|Placebo Comparator|Wheat Bran|Bran muffin matched for total available carbohydrates, total dietary fibre and calories
3145573|NCT01579643|Experimental|LALAK|
3145574|NCT01579643|Active Comparator|Penetrating Keratoplasty (KP)|
3145575|NCT01579630|Experimental|Pemetrexed 500mg/m2 iv|
3145576|NCT01579630|Experimental|Pemetrexed 500 mg/m2 i.v. and Gefitinib 250 mg|
3145577|NCT01579617|Experimental|BUtiful|Intervention arm, 'BUtiful. Be yoU! Talented, Informed, Fearless, Uncompromised, Loved', has 8 website sessions focused on pregnancy and STI prevention
3145578|NCT01579617|Other|DIVAS|Attention control arm, 'DIVAS. Diversity, Individuality, Vitality, Activity and Strong', has 8 website sessions focused on general health and nutrition
3145579|NCT01579604|Experimental|Surgical arm|"Nerve reconstruction:~Early nerve transfer (around 6-9 months post cervical spine injury) will be performed in this group of patients."
3145580|NCT01579604|No Intervention|Non-surgical (or observed)|Patients in this group will receive standard of care and be observed for up to two years post injury.
3145581|NCT01579591|Experimental|VSL#3 PROBIOTIC PREPARATION|
3145582|NCT01579591|Placebo Comparator|Placebo|
3145583|NCT01579578|Experimental|1|
3145584|NCT01579578|Placebo Comparator|2|
3145585|NCT01579565|Experimental|OMS302|OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
3145586|NCT01579565|Placebo Comparator|Placebo|Placebo diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
3145587|NCT01579552|Experimental|Intervention Group|The EMPOWER intervention trial is a 12-month study of 360 women from the Childhood Cancer Survivor Study who have previously been treated with chest radiation, are 25 to 49 years of age at the time of enrollment, are 8 years or more since their chest radiation, and have not had a mammogram or other breast imaging study in the preceding two years. Following a baseline questionnaire, participants will be randomized to the attention control group (N=120) or the intervention group (N=240).
3145588|NCT01579552|Active Comparator|attention control group|The EMPOWER intervention trial is a 12-month study of 360 women from the Childhood Cancer Survivor Study who have previously been treated with chest radiation, are 25 to 49 years of age at the time of enrollment, are 8 years or more since their chest radiation, and have not had a mammogram or other breast imaging study in the preceding two years. Following a baseline questionnaire, participants will be randomized to the attention control group (N=120) or the intervention group (N=240).
3145589|NCT01579539|Experimental|Patients|Patients with moderate to severe thyroid-associated ophthalmopathy
3145590|NCT01579526|Experimental|FP01 Dose 1|Drug
3145591|NCT01579526|Experimental|FP01 Dose 2|Drug
3145592|NCT01579526|Experimental|FP01 Dose 3|Drug
3145593|NCT01579526|Active Comparator|Comparator|Drug
3145594|NCT01579513|Active Comparator|Intraoperative Methylprednisone|Neonates with congenital heart disease requiring surgery utilizing cardiopulmonary bypass(CPB) in the first month of life that receive one dose of intravenous methylprednisolone (30 mg/kg) during anesthetic induction.
3145595|NCT01579513|Placebo Comparator|Placebo|Neonates with congenital heart disease requiring surgery utilizing cardiopulmonary bypass (CPB) in the first month of life that receive one dose of placebo (normal saline) during anesthetic induction.
3145596|NCT01579500|Active Comparator|botulinum toxin A|
3145597|NCT01579500|Placebo Comparator|normal saline|
3145598|NCT01579474|Experimental|1. BI 201335 low dose plus PegIFN/RBV|low dose BI 201335 NA once daily for 12 or 24 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
3145599|NCT01579474|Experimental|2. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 12 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
3145600|NCT01579474|Experimental|3. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 24 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-experienced (relapser) patients
3145601|NCT01579474|Experimental|4. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 24 weeks combined with PegIFN/RBV for 48 weeks in treatment-experienced (null responder, partial responder, breakthrough) patients
3145602|NCT01579461|Experimental|mild hepatic impairment|
3145603|NCT01579461|Experimental|moderate hepatic impairment|
3145604|NCT01579461|Experimental|healthy volunteers (matched with mild hepatic)|
3145605|NCT01579461|Experimental|healthy volunteers (matched with moderate hepatic)|
3145606|NCT01579448|Experimental|Vaccine to past vaccinated participants|The first arm includes subjects, who were immunized with two Shanchol™ doses, five years prior. In this study, arm one will receive one Shanchol™ booster dose at baseline and one booster dose on day fourteen.
3145607|NCT01579448|Active Comparator|Vaccine to past placebo recipients|The second arm includes subjects, who received two placebo doses, five years prior. Arm two will receive a primary immunization series consisting of one Shanchol™ dose at baseline and one at day fourteen
3145655|NCT01579162|Experimental|NASH patients with F0-F2 fibrosis|
3145608|NCT01579448|Placebo Comparator|No intervention to past placebo recipients|The third arm includes subjects, who received two placebo doses, five years prior. This third arm will not receive any intervention and will serve to represent a baseline immune response by vaccine naïve individuals exposed to natural exposure.
3145609|NCT01579435|Experimental|Therapeutic tDCS|6 patients with essential tremor
3145610|NCT01579435|Experimental|Physiopathological tDCS|6 patients with essential tremor
3145611|NCT01579422|Experimental|social cognitive training|
3145612|NCT01579409|Other|1-25th percentile of the PNNS score|
3145613|NCT01579409|Other|75-100th percentile of the PNNS score|
3145614|NCT01579396|Experimental|septeX|septeX CVVH for 12h after cardiac surgery
3145615|NCT01579396|Other|standard therapy|standard therapy according to local practice
3145616|NCT01579383|Experimental|Part A, Cohorts A - H|ALD403/Placebo
3145617|NCT01579383|Experimental|Part A, Cohort I|ALD403/Placebo
3145618|NCT01579383|Experimental|Part B|ALD403/Placebo/Sumatriptan
3145619|NCT01579370|Active Comparator|Quaternary ammonium|Rooms will be terminally cleaned using quaternary ammonium-containing compounds, the reference standard for hospital cleaning in US hospitals.
3145620|NCT01579370|Experimental|Bleach|Rooms will be terminally cleaned using bleach-containing products.
3145621|NCT01579370|Experimental|Quaternary ammonium and UV-C light|Rooms will be terminally cleaned with quaternary ammonium-containing solutions followed by irradiation by a UV-C light emitting device.
3145622|NCT01579370|Experimental|Bleach and UV-C light|Rooms will be terminally cleaned with bleach-containing solutions followed by irradiation by a UV-C light emitting device.
3145623|NCT01579357|Other|A|Capecitabine in week 1,2,4,5,7 and 8 Cetuximab in week 3 to 9 Oxaliplatin in week 7
3145624|NCT01579357|Other|B|Capecitabine in weeks 1,2,4,5,7, and 8 Cetuximab in weeks 1,8 and 9 Oxaliplatin in week 7
3145625|NCT01579344|Active Comparator|Thyroid carcinoma, Radioactive iodine therapy|50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma undergoing radioactive iodine therapy
3145626|NCT01579344|No Intervention|Thyroid carcinoma, without radioactive iodine therapy|50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma not undergone radioactive iodine therapy
3145627|NCT01579331|Experimental|Dynamic Contour Tonometry|All recruited volunteers in present study, that underwent diurnal GAT tonometry (3 measures) and 5 DCT measurements.
3145628|NCT01579318|Experimental|Treatment|Participants received up to 4 cycles of treatment (3 daily treatments on Days 1, 5 and 8, in a 12-week cycle) of intratumoral injection(s) of tavo at a concentration of 1.0 mg/mL (maximum volume of 1 mL/day distributed over 2-4 lesions), followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid deoxyribonucleic acid (DNA) into tumor cells.
3145629|NCT01579305|Experimental|Juvéderm® Volbella with Lidocaine|Subjects injected with Juvéderm® Volbella with Lidocaine in their lips
3145630|NCT01579305|Active Comparator|Restylane-L®|Subjects injected with Restylane-L® in their lips
3145631|NCT01579292|Experimental|Physical Activity and Diet Intervention|5-month physical activity and diet intervention which includes 6 in-person sessions, mobile app, and pedometer
3145632|NCT01579292|Active Comparator|Pedometer only|Pedometer only
3145633|NCT01579279|Experimental|ABT-652 6 mg|ABT-652 capsules - twice daily
3145634|NCT01579279|Experimental|ABT-652 12 mg|ABT-652 capsules twice daily
3145635|NCT01579279|Experimental|ABT-652 12 mg - 18 mg|ABT-652 capsules twice daily
3145636|NCT01579279|Placebo Comparator|Placebo|Placebo capsules twice daily
3145637|NCT01579279|Active Comparator|Duloxetine|Duloxetine capsules once daily
3145638|NCT01579240|Experimental|program visits|visits to intervention program
3145639|NCT01579227||1-TOP group 1|TOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
3145640|NCT01579227||TOP group 2|TOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
3145641|NCT01579227||OTOP group-1|OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
3145642|NCT01579227||OTOP group-2|OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
3145643|NCT01579227||TAM Group 1|TAM group 1 will have #2 biopsy collected 21 days after 1st biopsy collected. Tamoxifen cream and placebo cream will be applied where biopsies are collected from 1 week prior to having the biopsy procedure until the second biopsy is collected (21 days later).
3145644|NCT01579227||Normal Skin|Placebo group will apply placebo and TCT cream that will be applied daily to a specified area on the subjects legs (normal skin) for 5 weeks. One leg will be applied with placebo and the other will be applied with TCT cream. Subjects will return weekly for 5 weeks, where non-invasive measurements using Laser Speckle imaging, will be completed at each study visit
3145645|NCT01579214|Active Comparator|Direct Text Message|Participants in the intervention period (September 2012 - November 2013) received daily short message service (SMS) messages for up to seven days with messages reporting an abnormal result
3145646|NCT01579214|No Intervention|Pre-Intervention|Participants enrolled in the pre-intervention period (January - August 2012) served as a control group.
3145647|NCT01579201|Experimental|Carbetocin|
3145648|NCT01579188|Experimental|GV1001|The adjuvant GM-CSF is administered first as an intradermal injection followed in 10-15 minutes by the GV1001 peptide injected into the same site.
3145649|NCT01579188|Placebo Comparator|Placebo|Placebo
3145650|NCT01579175|No Intervention|Standard postoperative care|
3145651|NCT01579175|Experimental|Chewing gum arm|Sugar free (extra, spearment) chewing gum given to the patient to chew during waking hours every four hours for 15 minutes
3145652|NCT01579162|Experimental|Healthy Controls|Healthy controls will be recruited to have approximately equal numbers of men and women. Controls will be of healthy weight as defined by a BMI 18-25 and without liver disease or risk factors for liver disease.
3145653|NCT01579162|Experimental|chronic HCV patients with F0-F2 fibrosis|
3145654|NCT01579162|Experimental|chronic HCV patients with F3-F4 fibrosis|
3291340|NCT00536003|Experimental|1|
3145656|NCT01579162|Experimental|NASH patients with F3-F4 fibrosis|
3145657|NCT01579149|Experimental|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg)
3145658|NCT01579149|Placebo Comparator|Placebo|
3145659|NCT01579136|No Intervention|Control group|This group will not get a home blood pressure monitor.
3145660|NCT01579136|Experimental|Home monitors|This group will be given a home blood pressure monitor to use.
3145661|NCT01579123|Active Comparator|Laser atherectomy|
3145662|NCT01579123|Active Comparator|Angioplasty|
3145663|NCT01579110|Experimental|prednisolone + levamisole|
3145664|NCT01579110|Active Comparator|Prednisone|
3145665|NCT01579097|Active Comparator|compounded ternary parenteral nutrition|compounded ternary Parenteral Nutrition admixture
3145666|NCT01579097|Experimental|Oliclinomel N4 formulation|Oliclinomel N4 is a ready-to-use PN product presented as a triple chamber bag
3145667|NCT01579084|Experimental|AGN-199201 Formulation A and B|AGN-199201 Formulation A applied to one side of the face and Formulation B applied to the other side of the face twice daily.
3145668|NCT01579084|Experimental|AGN-199201 Formulation B and C|AGN-199201 Formulation B applied to one side of the face and Formulation C applied to the other side of the face twice daily.
3145669|NCT01579084|Experimental|AGN-199201 Formulation C and A|AGN-199201 Formulation C applied to one side of the face and Formulation A applied to the other side of the face twice daily.
3145670|NCT01579084|Other|AGN-199201 Formulation A and Vehicle|AGN-199201 Formulation A applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
3145671|NCT01579084|Other|AGN-199201 Formulation B and Vehicle|AGN-199201 Formulation B applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
3145672|NCT01579084|Other|AGN-199201 Formulation C and Vehicle|AGN-199201 Formulation C applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
3145673|NCT01579084|Experimental|AGN-199201 Formulation A|AGN-199201 Formulation A applied to both sides of the face twice daily.
3145674|NCT01579084|Experimental|AGN-199201 Formulation B|AGN-199201 Formulation B applied to both sides of the face twice daily.
3145675|NCT01579084|Experimental|AGN-199201 Formulation C|AGN-199201 Formulation C applied to both sides of the face twice daily.
3145676|NCT01579084|Placebo Comparator|AGN-199201 Vehicle|AGN-199201 Vehicle (Placebo) applied to both sides of the face twice daily.
3145677|NCT01579071|Experimental|CO2 sufflation group|
3145678|NCT01579071|Experimental|Room air sufflation group|
3145679|NCT01579058|Active Comparator|bisoprolol|bisoprolol 5mg qd
3145680|NCT01579058|Placebo Comparator|placebo|placebo
3145681|NCT01579045|Experimental|Sequence 1|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, nelfilcon A, etafilcon A, senofilcon A, Filcon II 3"
3145682|NCT01579045|Experimental|Sequence 2|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, nelfilcon A, etafilcon A, Filcon II 3, senofilcon A"
3145683|NCT01579045|Experimental|Sequence 3|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, etafilcon A, nelfilcon A, senofilcon A, Filcon II 3"
3145684|NCT01579045|Experimental|Sequence 4|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, etafilcon A, nelfilcon A, Filcon II 3, senofilcon A"
3145685|NCT01579045|Experimental|Sequence 5|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, Filcon II 3, etafilcon A, senofilcon A, Filcon II 3"
3145686|NCT01579045|Experimental|Sequence 6|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, Filcon II 3, etafilcon A, Filcon II 3, senofilcon A"
3145687|NCT01579045|Experimental|Sequence 7|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, etafilcon A, Filcon II 3, senofilcon A, Filcon II 3"
3145688|NCT01579045|Experimental|Sequence 8|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, etafilcon A, Filcon II 3, Filcon II 3, senofilcon A"
3145689|NCT01579045|Experimental|Sequence 9|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, Filcon II 3, nelfilcon A, senofilcon A, Filcon II 3"
3145690|NCT01579045|Experimental|Sequence 10|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, Filcon II 3, nelfilcon A, Filcon II 3, senofilcon A"
3145691|NCT01579045|Experimental|Sequence 11|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, nelfilcon A, Filcon II 3, senofilcon A, Filcon II 3"
3145692|NCT01579045|Experimental|Sequence 12|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, nelfilcon A, Filcon II 3, Filcon II 3, senofilcon A"
3145693|NCT01579032||CKD patients|
3145694|NCT01579019|Active Comparator|1000 mg 24 weeks|
3145695|NCT01579019|Active Comparator|1000 mg 26 weeks|
3145696|NCT01579019|Experimental|1500 mg 24 weeks|
3145697|NCT01579019|Experimental|1500 mg 26 weeks|
3145698|NCT01579006||Cohort|
3145699|NCT01578980|Experimental|Outpatient Control-to-Range|Outpatient Control-to-Range: Testing system connectivity
3145700|NCT01578967|Other|ABVD followed by Brentuximab vedotin|Single arm trial
3145701|NCT01578954|Experimental|Drug|Lenalidomide (25, 35, or 50 mg induction/10mg maintenance)
3145702|NCT01578941|Placebo Comparator|Placebo|
3145703|NCT01578941|Active Comparator|Treximet|
3145704|NCT01578928|Experimental|SOM230|subjects with varying degrees of renal impairment along with subjects without renal impairment
3145705|NCT01578915||Cases|Women with 4 or more sexual partners during the past year
3145706|NCT01578915||Controls|Women with only one sexual partner during the past year
3145707|NCT01578902|Experimental|Hypofractionated radiation|35 Gy in 5 fractions of image-guided intensity modulated radiotherapy (IGRT) delivered over 29 days.
3145788|NCT01578408|Active Comparator|Cemented Lubinus SPII stem (control arm)|Surgery with a totally cemented option with a Lubinus SPII stem and a IP cup (Link).
3145708|NCT01578889|Experimental|Group 1: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine administered as 0.5 mL by intramuscular (IM) injection in both the left and right deltoids using the Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
3145709|NCT01578889|Placebo Comparator|Group 1: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.5 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
3145710|NCT01578889|Experimental|Group 2: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 250 mcg IL-12 pDNA adjuvant, and divided into two 0.55 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
3145711|NCT01578889|Placebo Comparator|Group 2: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.55 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
3145712|NCT01578889|Experimental|Group 3: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 1,000 mcg of the IL-12 pDNA adjuvant and divided into two 0.75 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
3145713|NCT01578889|Placebo Comparator|Group 3: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.75 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
3145714|NCT01578889|Experimental|Group 4: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 1500 mcg of the IL-12 pDNA adjuvant divided into two 0.9 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
3145715|NCT01578889|Placebo Comparator|Group 4: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.9 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
3145716|NCT01578876|Experimental|CSWT for 3 month|A group
3145717|NCT01578876|Experimental|CSWT for 1 month|B group
3145718|NCT01578876|No Intervention|Control group|C group
3145719|NCT01578863|Active Comparator|Intervention program|6 months intervention program to lose weight in obese children. Behavioral, emotional, physical, familial and demographic questioners will be fulfilled at the beginning and at the end of the program.
3145720|NCT01578863|No Intervention|Untreated obese children|Behavioral, emotional, physical, familial and demographic questioners will be fulfilled twice in a 6 month program.
3145721|NCT01578863|No Intervention|Normal weight children|Behavioral, emotional, physical, familial and demographic questioners will fulfill twice in the 6 month period.
3145722|NCT01578850|Experimental|Group A|
3145723|NCT01578850|Placebo Comparator|Group B|
3145724|NCT01578837|Experimental|Ginseng|Combined Rg3-enriched Korean Red Ginseng and American Ginseng capsule
3145725|NCT01578837|Placebo Comparator|Wheat Bran|100 % Natural Wheat Bran capsule
3145726|NCT01578824|Active Comparator|Healthy Control|
3145727|NCT01578824|Active Comparator|Vitamin D resistant Rickets|Vitamin D resistant Rickets patients
3145728|NCT01578811|Placebo Comparator|Placebo|
3145729|NCT01578811|Experimental|SK-MS10 160mg t.i.d|
3145730|NCT01578811|Experimental|SK-MS10 320mg t.i.d|
3145731|NCT01578785|Experimental|Glatiramer Acetate|Glatiramer acetate (GA) 20 mg/0.5 ml solution in prefilled syringe for subcutaneous injection once daily.
3145732|NCT01578785|Placebo Comparator|Placebo|Placebo solution in prefilled syringe for subcutaneous injection once daily.
3145733|NCT01578772|Experimental|Telmisartan|Open label
3145734|NCT01578759|Experimental|Salpingectomy group|Participants in this group will have their fallopian tubes removed.
3145735|NCT01578759|No Intervention|No Salpingectomy Group|Participants in this group will not have their fallopian tubes removed.
3145736|NCT01578746|Active Comparator|Direct lateral approach|Patient operated using direct lateral approach.
3145737|NCT01578746|Active Comparator|Anterior approach|Patient operated using anterior approach.
3145738|NCT01578733|Experimental|protein intake|different levels of protein intake
3145739|NCT01578720|Other|IVT injection once every 8 weeks after 3 initial monthly doses|"Intravitreal aflibercept injection 2.0mg dosed every 4 weeks (monthly)for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection every eight weeks (2 months).~Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of greater than or equal to 5 letters from the previous visit."
3145740|NCT01578707|Active Comparator|Ofatumumab (Arm A)|An anti-CD20 monoclonal antibody
3145741|NCT01578707|Experimental|ibrutinib (Arm B)|A Bruton Tyrosine Kinase Inhibitor
3145742|NCT01578694|Other|Patient Group|The patient group has been diagnosed by the surgeon as having femoro-acetabular impingement (FAI) of the hip and will undergo a magnetic resonance imaging (MRI) test, more specifically, T1-rho to examine articular cartilage.
3145743|NCT01578694|Other|Control healthy volunteers|The control group has not been diagnosed with any hip problems, but will undergo a magnetic resonance imaging (MRI) test, more specifically, T1-rho to examine articular cartilage.
3145744|NCT01578681|Active Comparator|Airway clearance, bronchiectasis|"The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist.~Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary."
3145834|NCT01578096|No Intervention|Diabetes education|Group-based diabetes education delivered to participants through community health workers
3291341|NCT00536003|Placebo Comparator|2|
3145745|NCT01578681|Placebo Comparator|bronchiectasis, stretching|"The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist.~Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary."
3145746|NCT01578668|Experimental|Erlotinib, pemetrexed, cisplatin|
3145747|NCT01578668|Experimental|erlotinib|
3145748|NCT01578655|Experimental|Cabazitaxel plus Custirsen|cabazitaxel, prednisone, and custirsen sodium
3145749|NCT01578655|Active Comparator|Cabazitaxel|cabazitaxel and prednisone
3145750|NCT01578642|Other|Single Arm open label|EndoStim LES Stimulation System
3145751|NCT01578629|Active Comparator|Healthy Volunteers|Healthy participants randomized into one of 6 groups that will take 4 capsules, twice a day of vitamin E tocotrienol (TCT) capsules ; Low Dose Aspirin or placebo capsule for 7 months.
3145752|NCT01578629|Active Comparator|Hyperlipidemic|hyperlipidemic patients randomized into one of 6 groups that will take 4 capsules, twice a day of Vitamin E Tocotrienol (TCT) capsules; Low Dose Aspirin or placebo vehicle control capsule for 7 months.
3145753|NCT01578616||3 / non-CAD, ACS with or without TCFA|ACS patients with thin cap fibroatheroma. ACS patients without thin cap fibroatheroma. Age-, gender-, and rate of hypertension or diabetes mellitus-matched patients who have never been diagnosed or treated for CAD are also enrolled as non-CAD patients
3145754|NCT01578616||non-CAD, ACS without TCFA, ACS with TCFA|Acute coronary syndrome (ACS) patients with thin cap fibroatheroma. ACS patients without thin cap fibroatheroma. Age-, gender-, and rate of hypertension or diabetes mellitus-matched patients who have never been diagnosed or treated for CAD are also enrolled as non-CAD patients
3145755|NCT01578603|Experimental|sugar substituted chewing gum A|
3145756|NCT01578603|Experimental|Sugar substituted chewing gum B|
3145757|NCT01578590|Experimental|Subjects will consume lean minced meat|Subjects will perform resistance exercise and consume a piece of meat (135 grams, 35 g of protein)
3145758|NCT01578590|Active Comparator|Subjects will consume a milk beverage|Subjects will perform resistance exercise and consume a milk protein beverage
3145759|NCT01578577|No Intervention|Standard Care|This arm will serve as a control group and will not receive any intervention.
3145760|NCT01578577|Experimental|EHMI|Electronic Health Record-based Health Literacy Medication Therapy Management Intervention (EHMI)arm consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
3145761|NCT01578577|Experimental|Nurse Educator + EHMI|
3145762|NCT01578564|Experimental|SOR-C13|
3145763|NCT01578551|Experimental|Arm A|Paclitaxel, Carboplatin, Bevacizumab, and Metformin. Metformin starting at a dose of 500 mg twice a day, orally with meals. After one week, increase the dose of metformin to 1000 mg as the first dose of the day and 500 mg as the second dose. After another week, increase to 1000 mg of metformin two times a day. Metformin treatment will be initiated one week before beginning chemotherapy, if possible, but chemotherapy will not be delayed for metformin loading.
3145764|NCT01578551|Active Comparator|Arm B|Paclitaxel, Carboplatin, and Bevacizumab
3145765|NCT01578538|Active Comparator|mesh used repair|mesh used hernia repair will be perform
3145766|NCT01578538|Active Comparator|nonmesh|nonmesh hernia repair techniques will be used
3145767|NCT01578525|No Intervention|standard care|Standard care (by German definition), traditional care by physician and nurse on the ward
3145768|NCT01578525|Other|Intensified standard care|Intensified standard care: traditional care by physician and nurse, additional pharmaceutical care by a pharmacist during hospitalization
3145769|NCT01578512|Experimental|Face-to-Face|8 sessions of weekly group behavioral weight loss treatment
3145770|NCT01578512|Experimental|Web-based|Participants receive one group face-to-face session followed by 7 web-based lessons, reporting of key behaviors, and feedback on progress.
3145771|NCT01578512|Active Comparator|Single Session|Single session behavioral weight loss
3145772|NCT01578499|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).
3145773|NCT01578499|Active Comparator|Methotrexate or Bexarotene|Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m^2, tablets, orally, once daily with meals for up to 48 weeks.
3145774|NCT01578486|Experimental|salsalate|open-label trial of salsalate 3g/day
3145775|NCT01578473|Active Comparator|Vitamin D and E|Oral Vitamin D and E alone in men with penile curvature due to PD.
3145776|NCT01578473|Active Comparator|Testosterone Pellets and Vitamin D and E|Testosterone in combination with oral Vitamin D an E supplementation in men with penile curvature due to PD.
3145777|NCT01578460|Active Comparator|Control Group|Participants will self-select which group they wish to participate in at time of consent. The control group will use standard glucose meter testing to monitor their glucose levels.
3145778|NCT01578460|Experimental|Continuous Glucose Monitor (CGM) Group|Participants will self-select which group they wish to participate in at time of consent. The CGM group will utilize the iPro2 CGM to monitor their glucose levels during their 28, 32, and 36 week of gestation.
3145779|NCT01578447|Other|Depo-SubQ Provera 104 in Uniject|
3145780|NCT01578447|Other|Intramuscular DMPA|
3145781|NCT01578434|Active Comparator|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
3145782|NCT01578434|Active Comparator|Vitamin D|Vitamin D: 6 lakh IU single im dose
3145783|NCT01578434|Active Comparator|Vitamin D and Calcium|vitamin D and Calcium: combination of above two
3145784|NCT01578421|Other|FX 100 dialyzer|
3145785|NCT01578421|Other|Polyflux 210 H dialyzer|
3145786|NCT01578421|Other|FXCorDiax 100 dialyzer|
3145787|NCT01578408|Active Comparator|Uncemented HA Coated Corail stem|Surgery with an inversed hybrid arthroplasty with an uncemented hydroxyapatite coated Corail stem and a cemented Marathon cup (DePuy).
3293482|NCT00517803|Experimental|1|
3145789|NCT01578395|Experimental|N-acetylcysteine|This arm consists of 30 patients who will receive 1200mg n-acetylcysteine dissolved in 50ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
3145790|NCT01578395|Experimental|Ascorbic acid|This arm consists of 30 patients who will receive 3000 mg ascorbic acid dissolved in 50 ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
3145791|NCT01578395|Placebo Comparator|Sodium Chloride (NaCl)|This arm consists of 30 patients who will receive 50 ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
3145792|NCT01578382||Hypertensive ischemic leg ulcer|"Twenty consecutive patients with Martorell HYTILU as defined in:~Arch Dermatol 2010;146:961-968"
3145793|NCT01578382||Calciphylaxis|"Ten subjects with calciphylaxis (calcific uremic arteriolopathy) as described in:~Vasa 1998;27:137-143"
3145794|NCT01578382||Venous ulcer (controls)|"Twenty subjects with venous ulcers (CEAP C4-6) as described in:~J Vasc Surg. 2004 Dec;40(6):1248-52"
3145795|NCT01578369|Experimental|Exercise group|Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
3145796|NCT01578369|No Intervention|Control|Usual care
3145797|NCT01578356||Radical Retropubic prostatectomy (RRP)|Men who underwent open radical prostatectomy in the past at our centre.
3145798|NCT01578356||Robot-assisted laparoscopic prostatectomy (RALP)|Men who undergo robot-assisted laparoscopic prostatectomy at our centre.
3145799|NCT01578343|Experimental|Vorinostat-FND|Vorinostat-fludarabine, mitoxantrone, dexamethasone Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)
3145800|NCT01578330|Experimental|Fingolimod, FTY720|Patients received fingolimod 0.5 mg oral capsules daily with or without food.
3145801|NCT01578304|Experimental|Imidafenacin|
3145802|NCT01578304|Active Comparator|Fesoterodine|
3145803|NCT01578291|No Intervention|No intervention|Parents given routine information by the medical staff.
3145804|NCT01578291|Active Comparator|Parental information|Parents are provided with an educational brochure of the study and the expectations of the discomfort.
3145805|NCT01578291|Active Comparator|Play Therapy|Child and the parents will spend time in the office with the child life therapist undergoing play therapy.
3145806|NCT01578278|Experimental|Bepotastine besilate formulation|Nasal Spray
3145807|NCT01578278|Experimental|Fluticasone propionate|Nasal Spray
3145808|NCT01578278|Experimental|Bepotastine besilate-fluticasone propionate|Nasal Spray
3145809|NCT01578278|Placebo Comparator|Placebo Comparator|Nasal Spray
3145810|NCT01578265|Experimental|Ondansetron Tablets USP 8 mg|Ondansetron Tablets USP 8 mg of M/s Ipca Laboratories Limited, India
3145811|NCT01578265|Active Comparator|Zofran®|Zofran® (Ondansetron Hydrochloride) Tablets 8 mg of M/s GlaxoSmithKline
3145812|NCT01578252|Experimental|Ondansetron Tablets USP 8 mg|Ondansetron Tablets USP 8 mg of M/s Ipca Laboratories Limited, India
3145813|NCT01578252|Active Comparator|Zofran®|Zofran® (Ondansetron Hydrochloride) Tablets 8 mg of M/s GlaxoSmithKline
3145814|NCT01578239|Experimental|177Lu-DOTA0-Tyr3-Octreotate|"30 mg Octreotide LAR treatment for symptom control will continue until the end of study, unless the patient progresses or dies;~Treatment will consist of a cumulative dose of 29.6 gigaBecquerel (GBq) (800 mCi) 177Lu-DOTA0-Tyr3-Octreotate;~Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate;~Concomitant amino acids will be given with each administration for kidney protection;~177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity (see Dose Modifying Toxicity (DMT) below); in case patients experience clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections are allowed."
3145815|NCT01578239|Active Comparator|Octreotide LAR|"60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the patient progresses or dies (see Dose Modifying Toxicity (DMT));~In case patients experience clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections are allowed."
3145816|NCT01578226||Decompensated cirrhotic patients|Cirrhotic patients presenting with clinically detectable ascites (Grade 2 o Grade 3)
3145817|NCT01578213|Experimental|Imatinib|
3145818|NCT01578200|Experimental|Lanthanum carbonate|Patients are given Lanthanum Carbonate oral administration after meals three times per day in total daily dose of 750-2250mg.
3145819|NCT01578200|Active Comparator|Calcium Carbonate|Patients are given Calcium carbonate oral administration after meals three times per day in total daily dose of 3.0g.
3145820|NCT01578187|Experimental|Hair2Go device|
3145821|NCT01578174|Placebo Comparator|Control|
3145822|NCT01578174|Active Comparator|Dexmedetomidine|
3145823|NCT01578161|Experimental|Dexmedetomidine0.25|dexmedetomidine 0.25 microg.kg(-1),(Group D0.25) ivs. for 10min.
3145824|NCT01578161|Experimental|Dexmedetomidine0.5|dexmedetomidine 0.5 microg.kg(-1),(group D0.5) ivs. for 10min.
3145825|NCT01578161|Experimental|Dexmedetomidine1.0|dexmedetomidine 1 microg.kg(-1) ivs. for 10min.
3145826|NCT01578161|Placebo Comparator|NormalSaline|Normal saline 10ml ivs. for 10min.
3145827|NCT01578148|Experimental|Noxipoint Therapy|
3145828|NCT01578148|Active Comparator|Physical Therapy|
3145829|NCT01578135||Phase I|
3145830|NCT01578135||Phase II|
3145831|NCT01578122|Experimental|25mmHg ECS|Thigh-length graduated elastic compression stockings applying 25mmhg of targeted pressure at the ankle worn daily for two years
3145832|NCT01578122|Active Comparator|35mmHg ECS|Thigh-length graduated elastic compression stockings applying 35 mmhg of targeted pressure at the ankle worn daily for two years
3145833|NCT01578109|Experimental|Treatment (sorafenib tosylate and transplant)|Patients receive sorafenib tosylate PO BID beginning at least 30 days after completion of induction therapy and/or transplant and no more than 120 days after transplant continuing for up to 2 years after transplant in the absence of disease progression or unacceptable toxicity.
3145835|NCT01578096|Experimental|Diabetes education plus stress management|Group-based diabetes education plus stress management delivered to participants through community health workers
3145836|NCT01578083||Cognitive Impairment|With self-report cognitive impairment.
3145837|NCT01578083||No Cognitive Impairment|Without self-report cognitive impairment.
3145838|NCT01578070|Experimental|ViscoGel® and 0.2μg Act-HIB®|
3145839|NCT01578070|Experimental|0.2μg Act-HIB®|
3145840|NCT01578070|Experimental|ViscoGel® and 2μg Act-HIB®|
3145841|NCT01578070|Experimental|2μg Act-HIB®|
3145842|NCT01578070|Active Comparator|10μg Act-HIB®|
3145843|NCT01578057|Experimental|tasimelteon + placebo ethanol|
3145844|NCT01578057|Experimental|ethanol + placebo tasimelteon|
3145845|NCT01578057|Experimental|tasimelteon + ethanol|
3145846|NCT01578057|Experimental|placebo tasimelteon + placebo ethanol|
3145847|NCT01578044|Experimental|Intervention|"Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.~Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescription.~Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban has not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication."
3145848|NCT01578044|Placebo Comparator|Control|Usual care
3145849|NCT01578031|Active Comparator|Obese Patients with Obstructive Sleep Apnea|Obese adults between the 40 and 65 years of age with a new diagnosis of OSA as evidenced by an apnea/hypopnea index ≥ 15, ≤ 75 episodes per hour, who are naïve to CPAP use will be started on CPAP treatment.
3145850|NCT01578031|Active Comparator|Non-obese Patients with Obstructive Sleep Apnea|Non-obese adults between the 40 and 65 years of age with a new diagnosis of OSA as evidenced by an apnea/hypopnea index ≥ 15, ≤ 75 episodes per hour, who are naïve to CPAP use will be started on CPAP treatment.
3145851|NCT01578031|Other|Obese subjects without OSA|Control.
3145852|NCT01578031|Other|Non-obese subjects without OSA|Control.
3145853|NCT01578018|Other|Lung Cancer|Diagnostic
3145854|NCT01578018|Other|Lung Disease|Diagnostic
3145855|NCT01577992|Experimental|Group 1: MSA disease|determination of objective and subjective pain threshold before and after levodopa intake
3145856|NCT01577992|Experimental|Group 2: Parkinson disease|determination of objective and subjective pain threshold before and after levodopa intake
3145857|NCT01577992|Other|Group 3: healthy volunteers.|one determination of objective and subjective pain threshold without treatment
3145858|NCT01577979|Experimental|Reminder/Recall Strategy|The experimental group will consist of patients randomly selected from participating clinics. Patients from private practices and the safety net provider may be exposed to a reminder/recall strategy involving text messaging. Text messages will be used to notify parents that their child is due for an immunization or well-care visit. Parents will be able to reply with one of three response options. Patients presenting to the randomly selected experimental managed care clinics for the first HPV vaccination dose will be offered the ability to provide the clinic with their preferred contact method. The preferred method of contact will be used for the second and third HPV dose reminder/recalls.
3145859|NCT01577979|No Intervention|Usual Care|The patients in the usual care group will receive the clinic's usual care in terms of immunization and well-care reminder/recall.
3145860|NCT01577966|Experimental|Sulfasalazine|
3145861|NCT01577953|Experimental|SB010|The drug SB010 is administered in phosphate-buffered saline solution, inhaled via a controlled breathing system over a 5 to 10 min.
3145862|NCT01577953|Placebo Comparator|Placebo|The placebo (phosphate-buffered saline) is administered as a solution inhaled via a controlled breathing system over a 5 to 10 min.
3145863|NCT01577940|Experimental|Infusion of local anesthetic|TAP block with 20 ml of ropivacaine 0,5%, catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours.
3145864|NCT01577940|Placebo Comparator|Infusion of saline|TAP block with 20 ml of ropivacaine 0,5%, catheter with infusion of saline 5 ml/h 24 hours.
3145865|NCT01577927|Active Comparator|Usual home care|No assistance or care by PT.
3145866|NCT01577927|Experimental|PT-assisted home rehabilitation|Assisted home care is supported by a PT at least 2 times/month. Few brief educational lessons preceeded the training activity that the patient performs by himself at home.
3145867|NCT01577914|Experimental|Carvedilol Tablets USP 12.5 mg|Carvedilol Tablets USP 12.5 mg of M/s Ipca Laboratories Limited, India
3145868|NCT01577914|Active Comparator|Coreg®|Coreg® (Carvedilol Tablets) 12.5 mg of M/s GlaxoSmithKline
3145869|NCT01577888|Experimental|Lithotripsy Treatment|Shockwave System Treatment -Lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic peripheral arteries.
3145870|NCT01577875|No Intervention|control group|histologic prediction only with the narrow band imaging (without magnification)
3145871|NCT01577875|Other|test group|histologic prediction with narrow band imaging plus magnification
3145872|NCT01577862|Active Comparator|Colistin|Colistin alone, 2 million units every 8 hours intravenously or according to renal function
3145873|NCT01577862|Experimental|Colistin plus Rifampicin|Colistin, 2 million units every 8 hours intravenously or according to renal function, plus Rifampicin, 600 mg every 12 hours intravenously
3145874|NCT01577849|Active Comparator|Vitamin D3|
3145875|NCT01577849|Experimental|DP-R206|
3145876|NCT01577836||Robotic assistance, Nîmes|The patients in this group will undergo robot-assisted radial prostatectomy at the University Hospital of Nîmes.
3145877|NCT01577836||Laparotomy, Marseilles|The patients in this group will undergo radical prostatectomy via traditional laparotomy at the University Hospital Marseillles.
3145878|NCT01577823|No Intervention|No foley catheter|
3145879|NCT01577823|Active Comparator|Foley Catheter|
3145880|NCT01577797|Experimental|CBT-based text messages - Week 1 or 3|One week CBT-based text messages followed by a 1-week washout period (Week 2)
3145881|NCT01577797|Placebo Comparator|Placebo text messages - Week 3 or 1|
3145882|NCT01577784|Experimental|Pazopanib|800 mg / day of pazopanib in monotherapy
3145883|NCT01577771|Active Comparator|Child|1 dose of Prevnar13 at 2 to 4 years of age
3145884|NCT01577771|Experimental|Toddler 1 dose|Single dose of Prevnar13 at 12-15 months of age
3145885|NCT01577771|Active Comparator|Toddler 2 dose|2 doses of Prevnar13 2 months apart beginning at 12-15 months of age
3145886|NCT01577771|Experimental|Infants 2+1|Infants receiving Prevnar13 at 6 weeks, 14 weeks and 9 months. Note: This infant immunization schedule is used in many European countries and in South Africa and has been shown to be immunogenic and effective. However, few head-to-head comparisons of the 2+1 and 3+0 schedules have been conducted.
3145887|NCT01577771|Active Comparator|Infants 3+0|Infants receiving Prevnar13 at 6, 10 and 14 weeks
3145888|NCT01577758|Experimental|MLN0264|MLN0264 starting dose 0.3 mg/kg escalated until Maximum Tolerated Dose (MTD) was determined, 30-minute infusion, on Day 1 of each 21-Day treatment cycle.
3145889|NCT01577745|Experimental|MEDI0639 Cohort 1|Participants received MEDI0639 dose level 1 as a 60-minute intravenous (IV) infusion on Day 1 of each 21-day cycle.
3145890|NCT01577745|Experimental|MEDI0639 Cohort 2|Participants received MEDI0639 dose level 2 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
3145891|NCT01577745|Experimental|MEDI0639 Cohort 3|Participants received MEDI0639 dose level 3 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
3145892|NCT01577745|Experimental|MEDI0639 Cohort 4|Participants received MEDI0639 dose level 4 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
3145893|NCT01577745|Experimental|MEDI0639 Cohort 5|Participants received MEDI0639 dose level 5 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
3145894|NCT01577745|Experimental|MEDI0639 Cohort 6|Participants received MEDI0639 dose level 6 as a 60-minute IV infusion on Day 1 of each 21 day cycle.
3145895|NCT01577732|Experimental|Infanrix-IPV+Hib Group|Subjects aged between, and including 12 and 24 months received a single dose of Infanrix-IPV+Hib™. The vaccine was administered intramuscularly in the anterolateral side of the thigh.
3145896|NCT01577719|Active Comparator|Multimedia Lifestyle Improvement|Multimedia lifestyle intervention
3145897|NCT01577719|Placebo Comparator|Usual Care|usual care
3145898|NCT01577706|Active Comparator|Alprazolam (A)|Alprazolam (Xanax), gel-capsule, 1mg, single-dose, 1-day
3145899|NCT01577706|Active Comparator|Dextroamphetamine (D)|Dextroamphetamine (Dexedrine), gel-capsule, 20mg, single-dose, 1-day
3145900|NCT01577706|Placebo Comparator|Placebo (P)|Placebo gel-capsule, single-dose, 1-day
3145901|NCT01577693|Experimental|0.5 mg novel dose form (test)|0.5 mg novel dose form (test)
3145902|NCT01577693|Other|0.5 mg Soft Gel Capsule|0.5 mg Soft Gel Capsule (reference)
3145903|NCT01577680|Experimental|Moderate Hepatic Impairment|Approximately 9 subjects will complete each of these treatment arms
3145904|NCT01577680|Experimental|Matched Healthy Volunteers|Matched to the moderate hepatic impairment subjects based on gender, ethnicity, body mass index (+/-15%) and age (+/-5 years) Approximately 9 subjects will complete each of these treatment arms
3145905|NCT01577667|No Intervention|Conventional ventilation|Usual ventilation is administered according to the protocols implemented in the unit
3145906|NCT01577667|Experimental|Intellivent|"Intellivent is a ventilatory mode included in ventilator S1, Hamilton Medical. Intervention: the patient is ventilated with the same ventilator than in the conventionnal group; but the ASV-Intellivent ventilation has to be activated via a dedicated key on the ventilator screen.~IntelliVent® activation requires selecting the kind of patient: ARDS, COPD and whether hemodynamic instability exists.~The initial settings are IntelliVent® by default settings (% MV: 110%, PEEP: 5 cm H2O, FiO2: 60% - 100% in case of ARDS).~Therefore modification of these various parameters is automatic. FiO2 and PEP are modified according to SpO2; %MV according to EtCO2."
3145907|NCT01577654|Experimental|Arm A: EC145 alone|EC145 alone
3145908|NCT01577654|Experimental|Arm B: EC145 + Docetaxel|EC145 + Docetaxel
3145909|NCT01577654|Active Comparator|Arm C: Docetaxel alone|Docetaxel alone
3145910|NCT01577628|Other|Group 1: Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
3145911|NCT01577628|No Intervention|Group 2: No intervention control group|Subjects may use a moisturizer if they wish to but no instruction or product is provided
3145912|NCT01577615|Experimental|Patterned Experience Group|Infants in the patterned experience group will receive a patterned feeding experience with all feedings through discharge. They will receive a touch intervention at each gavage feeding. Once oral feedings are initiated, they will be offered an oral feeding at every scheduled feeding. They will be held for feedings. They will be observed twice a week utilizing the computer data acquisition system. Follow up visits will occur at 2,6 amd 24 months corrected age.
3145913|NCT01577615|No Intervention|Usual Care Group|In the usual care group infants usually are not held or contained during gavage feeding. Infants in the usual care group are orally fed at the discretion of the nurses or medical team. Once oral feedings are initiated, infants will be observed twice a week using the computer data acquisition system. Follow up visits will occur at 2,6 and 24 months corrected age.
3145914|NCT01577602|No Intervention|Standard practice|
3145915|NCT01577602|Experimental|Printed list intervention|Providing patients a list of their current medications before they see medical assistant and begin their visit.
3145916|NCT01577602|Experimental|Open ended question intervention|"Medical assistants begin the medication review with a scripted, open ended question (i.e., tell me about your medications)"
3145917|NCT01577602|Experimental|Combined intervention|
3145918|NCT01577589|Experimental|A|600 mg ceftaroline fosamil in 50 ml infusion volume
3145919|NCT01577589|Placebo Comparator|B|Placebo in 50 ml infusion volume
3145920|NCT01577589|Experimental|C|600 ceftaroline fosamil in 250 ml infusion volume
3145921|NCT01577589|Placebo Comparator|D|Placebo in 250 ml infusion volume
3145922|NCT01577589|Experimental|E|600 mg ceftaroline in 100 ml infusion volume
3145923|NCT01577589|Placebo Comparator|F|Placebo in 100 ml infusion volume
3145924|NCT01577576||Upper-body athletes|This group includes swimmers, rowers or kayakers with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.
3145925|NCT01577576||Lower-body athletes|This group includes runners (marathon or trail) and cyclists with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.
3147394|NCT01567306|Placebo Comparator|Placebo - Group 6|
3145926|NCT01577576||Sedentary volunteers|This group of healthy volunteers does not participate in athletic activity for more than two hours per week. They are matched by age and sex with the athletic groups.
3145927|NCT01577550|Experimental|i.v. BI 655066|A subject to receive a single i.v. dose of BI 655066
3145928|NCT01577550|Placebo Comparator|i.v. placebo|A subject to receive a single i.v. dose of placebo
3145929|NCT01577550|Experimental|s.c. BI 655066|A subject to receive a single s.c. dose of BI 655066
3145930|NCT01577550|Placebo Comparator|s.c. placebo|A subject to receive a single s.c. dose of placebo
3145931|NCT01577537|Experimental|VivaGel|
3145932|NCT01577537|Placebo Comparator|HEC Placebo|
3145933|NCT01577524|Active Comparator|Diluted Povidone Iodine Solution|
3145934|NCT01577524|Placebo Comparator|Normal Saline Wash|
3145935|NCT01577511||30 Patients|"Patients with operable, stage III or IV, adenocarcino-type colorectal cancer treated at the Nîmes University Hospital.~Intervention: Samples and follow up"
3145936|NCT01577485|Experimental|Probiotic pastille|Test group
3145937|NCT01577485|Active Comparator|Control pastille|Control group
3145938|NCT01577472|Active Comparator|High Dose Clomiphencitrat|450 IU Merional® plus 100mg Serophene®
3145939|NCT01577472|Active Comparator|Low Dose Clomiphencitrat|150 IU Merional® plus 100mg Serophene®
3145940|NCT01577472|Placebo Comparator|High Dose Placebo|450 IU Merional® plus Placebo
3145941|NCT01577472|Placebo Comparator|Low Dose Placebo|150 IU Merional® plus Placebo
3145942|NCT01577459|Experimental|TR-701 FA with PSE|TR-701 FA 200 mg oral with PSE
3145943|NCT01577459|Placebo Comparator|TR-701 FA Placebo with PSE|TR-701 FA Placebo 200 mg oral with PSE
3145944|NCT01577446|Experimental|CRT|The CRT group undergoes implantation of a CRT defibrillator
3145945|NCT01577446|No Intervention|no-CRT|The no-CRT group receives a dual-chamber defibrillator
3145946|NCT01577433||Control Group|Historical control HeartMate II BTT and DT data
3145947|NCT01577433||Prospective and Retrospectively identified SSI|Prospectively and Retrospectively identified HeartMate II patients where the full length of the velour coated portion of the driveline is tunneled under the skin
3145948|NCT01577420|Experimental|Group A|Reflexology Sessions: One session per week performed by certified reflexologist for four consecutive weeks.
3145949|NCT01577420|Placebo Comparator|Group B|Placebo Sessions: One session per week performed by research aide for four consecutive weeks.
3145950|NCT01577420|No Intervention|Group C|Control; no foot sessions
3145951|NCT01577407|Experimental|Nefopam|
3145952|NCT01577407|Placebo Comparator|placebo|
3145953|NCT01577394|Experimental|Early stage of dementia|oculomotor measurements
3145954|NCT01577381|Experimental|PF-04382923|
3145955|NCT01577381|Placebo Comparator|Placebo|
3145956|NCT01577368|Experimental|Piperacillin continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours
3145957|NCT01577368|Active Comparator|Piperacillin intermittent infusion|Piperacillin-Tazobactam 4gr intermittent infusion 4gr every 8 hours
3145958|NCT01577355|Experimental|[C14]-LY2784544|Single 30 mg oral dose containing 100 micro curies of LY2784544
3145959|NCT01577342|Active Comparator|Moxifloxacin 0.5%|1 drop four times daily for 3 days in affected eye post intravitreal injection
3145960|NCT01577342|No Intervention|No antibiotic use|
3145961|NCT01577329|Experimental|mindfulness meditation class|Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
3145962|NCT01577329|No Intervention|wait list|Subjects assigned to the control group will continue with medical treatment as usual and be allowed to attend the mindfulness meditation class after week eight.
3145963|NCT01577316|Experimental|Pregnant Woman|Pregnant Woman
3145964|NCT01577316|Experimental|Nonpregnant women|2011-2012 Seasonal Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.
3145965|NCT01577303|Experimental|CBM training program variant 1|Attention training towards positive cues using words as stimuli
3145966|NCT01577303|Experimental|CBM training program variant 2|Attention training towards positive cues using words and faces as stimuli
3145967|NCT01577303|Experimental|CBM training program variant 3|Attention training towards negative using words as stimuli
3145968|NCT01577303|Experimental|CBM training program variant 4|Attention training towards negative using words and faces
3145969|NCT01577303|Experimental|Control training variant 1|Control training condition using words as stimuli
3145970|NCT01577303|Experimental|Control training variant 2|Control training condition using words and faces as stimuli
3145971|NCT01577290|Experimental|Mindfulness training|Group receives mindfulness training.
3145972|NCT01577290|Active Comparator|Discussion group|Group has access to a discussion group.
3145973|NCT01577264||Cimzia treatment|
3145974|NCT01577238|Experimental|VivaGel|
3145975|NCT01577238|Placebo Comparator|HEC Placebo|
3145976|NCT01577225|Experimental|OPSITE Post-Op Visible|Subject is randomized to OPSITE Post-Op Visible group or Tape&Gauze group. Dressing should be used right after surgery and changed as needed.
3145977|NCT01577225|Active Comparator|Tape&Gauze|Subject is randomized to OPSITE Post-Op Visible group or Tape&Gauze group. Tape and Gauze should be used right after surgery and changed as per routin practice.
3145978|NCT01577212|Experimental|Individualized dose escalation|Individualized dose escalation on the basis of the dose to the organs at risk.
3145979|NCT01577199|Active Comparator|High dose gonadotropins|High dose gonadotropins protocol compared to Low-dose Clomiphene
3145980|NCT01577199|Experimental|Low-dose Clomiphene|clomid-based, low dose gonadotropin protocol compared to High dose gonadotropins
3145981|NCT01577186|Experimental|Paliperidone Extended Release (ER)|
3145982|NCT01577173|Experimental|A: MEHD7945A|
3145983|NCT01577173|Active Comparator|B: Cetuximab|
3145984|NCT01577160|Experimental|Paliperidone Extended Release (ER)|
3293483|NCT00517803|Placebo Comparator|2|
3145985|NCT01577147|Other|sample collection|Ovulation prediction products provided to aid conception
3145986|NCT01577134|Experimental|Intervention to enhance physical activity|Participants in this arm have high motivation to be regularly physically active. Face-to-face group intervention includes behavior change techniques to enhance physical activity.
3145987|NCT01577134|Active Comparator|Active control intervention|Face-to-face group intervention includes behavior change techniques to enhance volunteering and improve attitudes towards volunteering.
3145988|NCT01577134|Other|Passive control intervention|Waiting-list control group, who receives all information (that the active groups got) via mail after completion of 8.5 months follow-up.
3145989|NCT01577121|Placebo Comparator|placebo|
3145990|NCT01577121|Experimental|indomethacin|50 mg/ 6 hours of indomethacin oral use
3145991|NCT01577108|Experimental|Probiotics, GBS Test|Treated with 2 oral probiotics once daily before sleeping for 14 days
3145992|NCT01577108|Placebo Comparator|Non-probiotics, GBS test|Treated with 2 placebo capsules once daily before sleeping for 14 days
3145993|NCT01577095|Experimental|EA + Rosiglitazone|
3145994|NCT01577095|Placebo Comparator|Rosiglitazone|
3145995|NCT01577082|Experimental|CHF 1535 200/6µg|
3145996|NCT01577082|Active Comparator|BDP 100µg|
3145997|NCT01577056|Active Comparator|Fish oil|
3145998|NCT01577056|Placebo Comparator|Placebo|FH subjects with standard treatment (statin treatment)
3145999|NCT01577043|Active Comparator|Racecadotril|intestinal antisecretory
3146000|NCT01577043|Placebo Comparator|cornstach solution|Cornstarch powder diluted in distilled water
3146001|NCT01577030|Experimental|Dairy|Add 4 daily servings of non-fat dairy to diet for a period of 4 weeks
3146002|NCT01577030|Active Comparator|Fruit|Add 4 daily servings of fruit to diet, remove all dairy from diet for a period of 4 weeks
3146003|NCT01577017|Experimental|Letrozole|Group L will be assigned with Letrozole 5 mg on night on day 5 to day 9 of the cycle
3146004|NCT01577004|Experimental|Omega-3 fatty acid supplement|Data obtained after the intervention was compared to baseline data
3146005|NCT01576991||Oocyte collection|This is an observational study; there are no cohorts or groups
3146006|NCT01576978|Active Comparator|postural orientations|The group of postural orientations receive a pamphlet containing information about the sitting, standing and lying postures to be performed at home for 10 weeks.The marking of the note pain will be before and after 10 weeks.
3146007|NCT01576978|Active Comparator|hatha yoga exercises|The allocates women will participate in the Hatha yoga class for 10 weeks. At first in class, the women will make a note of pain according to VAS. Class Moments: heating ten minutes, forty minutes postures of stretching and strengthening exercises and breathing exercises, ten minutes of relaxation and meditation. Marking note of pain after practice.
3146008|NCT01576965|Experimental|Mechanical Bowel Prep Group|Half of the subjects will be randomized to a group that does mechanical bowel preparation with sodium phosphate enema. Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery. All subjects will be instructed to restrict their diet to clear liquids the day prior to their surgery and to continue this diet after midnight, save a small sip of water for medications in the morning.
3146009|NCT01576965|No Intervention|No Bowel Prep Group|Participants randomly assigned to this group will not have the bowel prep treatment before the surgery. All subjects will be instructed to restrict their diet to clear liquids the day prior to their surgery and to continue this diet after midnight, save a small sip of water for medications in the morning.
3146010|NCT01576952|Experimental|ISV-303|0.075% bromfenac in DuraSite vehicle dosed BID
3146011|NCT01576952|Placebo Comparator|DuraSite Vehicle|DuraSite Vehicle dosed BID
3146012|NCT01576939|Experimental|IMRT Modulation|"All patients will undergo a computed tomography (CT) simulation study +/- a positron emission tomography (PET) scan using ≤ 3mm slices for radiation treatment planning. A standard, non-filling optimized IMRT (Intensity Modulated Radiation Therapy) plan will be generated and patients will be treated with megavoltage radiation over a course of > 6 weeks with a planned tumor dose of > 60 Gy. A medical doctor will perform weekly mucositis evaluation and grading for the measured site once a week during radiation therapy~Modulation of an IMRT plan to reduce the dose to less than 35 Gy delivered to adjacent normal mucosa surrounding the dental filling without compromising normal tissue or tumor doses."
3146013|NCT01576926||surgery|patients with obstructive sleep apnea
3146014|NCT01576913|Active Comparator|Music pacing|Exercise testing with music pacing
3146015|NCT01576913|No Intervention|No music pacing|Exercise testing without music pacing
3146016|NCT01576900||Desmopressin monotherapy|Control group: Desmopressin (Minirin Tablet 0.1-0.4mg/day) + simple instruction
3146017|NCT01576900||Combination group|"Study group: Desmopressin (Minirin Tablet 0.1-0.4mg/day) + SyBeMeP~* Patients will be randomized and assigned to each group at the ratio of 1:1."
3146018|NCT01576887|Placebo Comparator|Placebo|
3146019|NCT01576887|Experimental|Bardoxolone Methyl|
3146020|NCT01576874|Experimental|oxytocin|Participants will be administered 40 IUs of oxytocin nasal spray at one study visit.
3146021|NCT01576874|Placebo Comparator|placebo|Participants will be administered 40 IUs of placebo nasal spray at one study visit.
3146022|NCT01576861|Experimental|GH replacement|Patients will receive 48 months of substitutive somatotropin (growth hormone) therapy at a dose of 0,012 mg/kg every second day, added to their background optimized CHF therapy
3146023|NCT01576861|No Intervention|Control CHF patients under optimized CHF therapy|
3146024|NCT01576848|Experimental|GROUP 1 (OLD-PRO)|test drink contains intrinsically labeled protein alone
3146025|NCT01576848|Experimental|GROUP 2 (OLD-PRO/CARB)|test drink contains intrinsically labeled protein and carbohydrate
3146026|NCT01576848|Experimental|GROUP 3 (YOUNG-PRO)|test drink contains intrinsically labeled protein alone
3146027|NCT01576848|Experimental|GROUP 4 (YOUNG-PRO/CARB)|test drink contains intrinsically labeled protein and carbohydrate
3146135|NCT01576133|Active Comparator|Attention visits|Participants in the attention visit arm received 10 visits of one hour length spaced across 16 weeks. These visits included sedentary activities of their choice based on their goals and interests.
3146028|NCT01576822|Active Comparator|Low Dose|Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna). Participants will be able to schedule visits on any of 7 days per week. Maximum flexibility in hours of operation as well as flexibility in which days are attended will be utilized to increase likelihood of retention. Participants will be able to attend 9 consecutive sessions, should they wish.
3146029|NCT01576822|Active Comparator|High Dose|Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna). Participants will be able to schedule visits on any of 7 days per week. Maximum flexibility in hours of operation as well as flexibility in which days are attended will be utilized to increase likelihood of retention. A participant may attend visits for 15 consecutive days, should they wish.
3146030|NCT01576809|Experimental|Upper Respiratory Tract Infection|
3146031|NCT01576783|Experimental|DHA arm|DHA+AA supplement
3146032|NCT01576783|Placebo Comparator|Placebo|Corn oil supplement
3146033|NCT01576770|Active Comparator|ethyl chloride vapocoolant spray|"Half of the patients will randomly be assigned to receive Gebauer's ethyl choride topical anesthetic vapo-coolant spray immediately prior to placing a 22 gauge intravenous catheter.~Pain in this group will be evaluated at the time of IV placement by an independent observer (unblinded) and the patient on a 0-10 scale. Pain will again be evaluated when propofol is injected at anesthesia induction by a blinded observer and the staff anesthesiologist (also blinded) on a scale of 1-4.~Blinding will occur following IV placement by draping and securing the hand and IV site with Coban self-adherent elastic wrap to cover any skin changes due to the ethyl chloride or the patch."
3146034|NCT01576770|Experimental|Synera Patch|"The other half of the patients will randomly be assigned to receive Synera Patches, to be applied to the dorsum of both hands, at least 30 minutes before placing a 22 gauge intravenous catheter.~Pain in this group will be evaluated at the time of IV placement by an independent observer (unblinded) and the patient on a 0-10 scale. Pain will again be evaluated when propofol is injected at anesthesia induction by a blinded observer and the staff anesthesiologist (also blinded) on a scale of 1-4.~Blinding will occur following IV placement by draping and securing the hand and IV site with Coban self-adherent elastic wrap to cover any skin changes due to the patch or ethyl chloride."
3146035|NCT01576757||Heart failure|Patients with heart failure from any cause will be considered as potential participants given their clinical background meets eligibility criteria.
3146036|NCT01576731|Active Comparator|Tenofovir + emtricitabine + lopinavir/r|Standard postexposure prophylaxis combination
3146037|NCT01576731|Experimental|Tenofovir + Emtricitabine + Raltegravir|new postexposure prophylaxis combination
3146038|NCT01576718|Experimental|Fp MDPI 50 mcg|"Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3146039|NCT01576718|Experimental|Fp MDPI 100 mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3146040|NCT01576718|Experimental|Fp MDPI 200 mcg|"Fluticasone propionate (Fp) 200 mcg per dose twice a day (for a total daily dose of 400 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3146041|NCT01576718|Experimental|Fp MDPI 400 mcg|"Fluticasone propionate (Fp) 400 mcg per dose twice a day (for a total daily dose of 800 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3146042|NCT01576718|Placebo Comparator|Placebo MDPI|"Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3146043|NCT01576718|Active Comparator|Flovent Diskus 250mcg|"Fluticasone propionate (Fp) 250 mcg per dose twice a day (for a total daily dose of 500 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3146044|NCT01576705|Experimental|Thyroxin + folinic acid|
3146045|NCT01576705|Active Comparator|Thyroxin+folinic acid placebo|
3146046|NCT01576705|Active Comparator|Thyroxin placebo+ folinic acid|
3146047|NCT01576705|Placebo Comparator|Thyroxin placebo+ folinic acid placebo|
3146048|NCT01576692|Experimental|Treatment|"Participants receive humanized anti-GD2 antibody, chemotherapy, cytokines, and natural killer cells.~Cells for infusion are prepared using the CliniMACS System."
3146049|NCT01576679|Experimental|tPA|tissue Plasminogen Activator
3146050|NCT01576679|Placebo Comparator|Placebo|Saline
3146051|NCT01576666|Experimental|LDE225 and BKM120 in combination|LDE225 and BKM120 in combination
3146052|NCT01576653|Active Comparator|No IFI|Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do not fulfill EORTC/MSG IFI criteria will serve as negative controls.
3146091|NCT01576432|Experimental|Breastfeeding + skin-to-skin contact|In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; breastfeeding (BF) was started at least 5 minutes before heel lance and maintained during sampling
3146053|NCT01576653|Active Comparator|IFI|Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do fulfill EORTC/MSG criteria of possible/probable/proven IFI will serve as study group.
3146054|NCT01576640|Other|Replapse Prevention Therapy|
3146055|NCT01576627|Experimental|zinc citrate|
3146056|NCT01576627|Active Comparator|zinc gluconate|
3146057|NCT01576627|Active Comparator|zinc oxide|
3146058|NCT01576614||Nurse-Physician Rounding by Phone|"The SICU's practice involves daily morning team rounding at the bedside. The team includes the critical care attending physician (AP), surgical resident physician, and critical care nurse. The AP is physically present in the SICU during these rounds and for the hours between approximately 7am and 7pm. During off-shift hours (7pm-7am), the AP is available by phone as the on-call attending physician. In addition to this on-call availability, the standard of practice in SICU for years has been that the on-call physician proactively places a telephone call to the SICU at least once every evening to perform telephone rounds with the resident physician aeach SICU patient."
3146059|NCT01576614||Nurse-Physican rounding by R T P|"Remote Telepresence Robotics (RTP) is a form of telemedicine that enables a fast and direct face-to-face response by a physician, located remotely, and may sometime utilize a mobile robot.~RTP provides the physician the ability to teleconference with patients and other healthcare providers using two way audio visual technology. The sophistication of these devices varies and can range from simple video conferencing to remote robotic control devices with audio visual conferencing capabilities. The robotic capabilities refer to ability of the physician to remotely direct or drive the device from one location to another.~The technology allows clinical experts to provide the right care at the right time and has become an accepted standard of care when used under appropriate circumstances."
3146060|NCT01576601||Hopkins|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
3146061|NCT01576601||Childrens Hospital of Philadelphia|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
3146062|NCT01576601||Childrens Hospital Boston|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
3146063|NCT01576588|Experimental|R-HDMP|"Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).~Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion."
3146064|NCT01576575|Experimental|Session 2|IV buprenorphine or sublingual burenorphine
3146065|NCT01576575|Experimental|Session 3|Rifampin and IV buprenorphine or sublingual burenorphine
3146066|NCT01576575|Experimental|Session 4|Rifampin and IV buprenorphine or sublingual burenorphine
3146067|NCT01576575|Experimental|Session 5|Grapefruit juice and sublingual buprenorphine
3146068|NCT01576575|Experimental|Session 6|Ketoconazole and IV buprenorphine or sublingual burenorphine
3146069|NCT01576575|Experimental|Session 7|Ketoconazole and IV buprenorphine or sublingual burenorphine
3146070|NCT01576575|Experimental|Session 1|IV buprenorphine or sublingual burenorphine
3146071|NCT01576562||Study Group - Control Group|VAD implantation (study group) or other cardiothoracic surgery (control group)
3146072|NCT01576549|Experimental|LY2127399|LY2127399 given subcutaneously (SC) at 240 milligrams (mg) as a loading dose in the first week followed by 120 mg SC every 4 weeks for up to 52 weeks.
3146073|NCT01576536||Healthy volunteers|Normal healthy volunteers
3146074|NCT01576523|Experimental|Low, then medium, C1-esterase inhibitor dose|
3146075|NCT01576523|Experimental|Medium, then low, C1-esterase inhibitor dose|
3146076|NCT01576523|Experimental|Medium, then high, C1-esterase inhibitor dose|
3146077|NCT01576523|Experimental|Low, then high, C1-esterase inhibitor dose|
3146078|NCT01576523|Experimental|High, then low, C1-esterase inhibitor dose|
3146079|NCT01576523|Experimental|High, then medium, C1-esterase inhibitor dose|
3146080|NCT01576510|Experimental|Prolonged Exposure (PE) treatment.|
3146081|NCT01576510|No Intervention|Trauma exposed healthy controls|Clinical assessments at baseline, 7 and 10 weeks. fMRI assessments at baseline and 10 weeks.
3146082|NCT01576497|Active Comparator|EUS-FNA with suction|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA with suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
3146083|NCT01576497|Active Comparator|EUS-FNA without suction|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
3146084|NCT01576484|Experimental|Open Label|
3146085|NCT01576471|Placebo Comparator|Placebo|
3146086|NCT01576471|Experimental|TSO 7500|
3146087|NCT01576458|Active Comparator|ursodeoxycholic acid|10 pregant women with intrahepatic cholestasis of pregnancy
3146088|NCT01576458|Active Comparator|placebo|10 pregnant women with intrahepatic cholestasis of pregnancy
3146089|NCT01576445|Experimental|Mid-vastus approach|
3146090|NCT01576445|Experimental|medial parapatellar approach|
3146248|NCT01575314|No Intervention|hand sewn|hand sewn refer to patients who were randomized to use hand suturing for dividing lung parenchyma.
3297332|NCT00479336|Experimental|2|
3146092|NCT01576432|Experimental|Sucrose + skin-to-skin contact|In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance.
3146093|NCT01576432|Experimental|Skin-to-skin contact|In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given.
3146094|NCT01576432|Active Comparator|Sucrose|In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother
3146095|NCT01576419|Experimental|PG201 tablet|
3146096|NCT01576419|Active Comparator|Celecoxib capsule|
3146097|NCT01576406|Experimental|A1: normal hepatic function|
3146098|NCT01576406|Experimental|A2: normal hepatic function|
3146099|NCT01576406|Experimental|B: mild hepatic impairment|
3146100|NCT01576406|Experimental|C: moderate hepatic impairment|
3146101|NCT01576406|Experimental|D: severe hepatic impairment|
3146102|NCT01576393|Experimental|Home-Based family therapy|12 home-based family therapy sessions
3146103|NCT01576393|Active Comparator|Office-based family therapy|12 office-based family therapy sessions
3146104|NCT01576393|Placebo Comparator|Women's Health Education|12 womens's health education sessions
3146105|NCT01576380|Experimental|TKI258|TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
3146106|NCT01576367|Experimental|canakinumab|Patients will receive a standard dose at an equivalent of 2 mg/kg s.c. of canakinumab (ACZ885) every 8 weeks. Possible dose and/or dosing regimen adjustments that can be administered include: 4 mg/kg s.c. (every 4 to 8 weeks) 6 mg/kg s.c. (every 4 to 8 weeks) 8 mg/kg s.c. (every 4 to 8 weeks)
3146107|NCT01576354|Active Comparator|Prolonged-release Fampridine|
3146108|NCT01576354|Placebo Comparator|Placebo|
3146109|NCT01576341|Experimental|HX575 epoetin alfa (Sandoz)|Single arm
3146110|NCT01576328|Experimental|Cohort 1|MPC dose 1 or Placebo
3146111|NCT01576328|Experimental|Cohort 2|MPC dose 2 or Placebo
3146112|NCT01576328|Experimental|Cohort 3|MPC dose 3 or Placebo
3146113|NCT01576315|Experimental|itraconazole|"itraconazole 10 mg/mL oral solution~patients > 40 kg body weight : 200 mg morning and evening.~patients < 40 kg body weight : 100 mg morning and evening.~dosage out of meal.~Without a loading dose"
3146114|NCT01576315|Experimental|voriconazole|"voriconazole 40 mg/mL oral suspension :~patients > 40 kg body weight : 200 mg morning and evening.~patients < 40 kg body weight : 100 mg morning and evening.~dosage out of meal.~Without a loading dose"
3146115|NCT01576302|Experimental|Diaphragmatic breathing|Training in diaphragmatic breathing as response incompatible with rumination.
3146116|NCT01576302|Active Comparator|Muscle relaxation|Patients in this arm of study will be taught muscle relaxation as intervention for rumination, instructed in habit-reversal paradigm to use after eating food or if urge to ruminate
3146117|NCT01576289||Patients undergoing uppper endoscopy|Consecutive patients with and without symptoms of reflux disease who routinely undergo upper endoscopy from November 2011 through May 2012.
3146118|NCT01576276|Experimental|Morphine condition|
3146119|NCT01576276|Experimental|Ketorolac condition|
3146120|NCT01576263||Total knee arthroplasty|25 consecutive patients diagnosed for total knee arthroplasty.
3146121|NCT01576263||Total hip arthroplasty|27 patients diagnosed for total hip arthroplasty.
3146122|NCT01576250|Experimental|unilateral lower limb suspension|This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
3146123|NCT01576237||healthy apheresis donors|healthy blood donors for blood cell aphereses
3146124|NCT01576224|Experimental|Immediate mobilization|Patients start exercises immediately after osteosynthesis.
3146125|NCT01576224|Active Comparator|Later mobilization|Patients are allowed exercises after 14 days.
3146126|NCT01576185||Observational (xenograft models)|Human acute myeloid leukemia cells are injected into NSG mice. Mice are then treated with sorafenib or quizartinib via gavage once daily for 28 days. Peripheral blood and tissue samples are collected biweekly or weekly and analyzed for the presence of human CD45+ and CD33+ cells by quantitative flow cytometry.
3146127|NCT01576172|Active Comparator|Arm I (abiraterone acetate and prednisone)|Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3146128|NCT01576172|Experimental|Arm II (abiraterone acetate, prednisone, and veliparib)|Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3146129|NCT01576159|Experimental|High-Impact Loading|Performed high-impact running exercise during intervention period.
3146130|NCT01576159|Experimental|Moderate-Impact Loading|Performed moderate-impact cycling exercise during intervention period.
3146131|NCT01576159|Experimental|Non-Impact Loading|Performed low-impact swimming exercise during intervention period.
3146132|NCT01576159|No Intervention|Control Group|Didn't participate any organized physical exercises
3146133|NCT01576146|Experimental|Etelcalcetide|Participants received a bolus IV injection of etelcalcetide 3 times a week (TIW) at the end of each hemodialysis session for up to 144 weeks in the extension study. The starting dose was the same as the final dose administered in the parent study (20120331); the dose was adjusted per protocol-specified guidelines to achieve or maintain parathyroid hormone values in the 150 to 300 pg/mL range.
3146134|NCT01576133|Experimental|CAPABLE|Experimental group participants received up to 10 sessions; up to 6 with an OT, and up to 4 sessions with an RN, and ≤ $1200 of safety and functional modifications from a licensed handyman. These sessions happened in coordinated fashion over the course of 4 months.
3146249|NCT01575288|Placebo Comparator|Maltose|
3146250|NCT01575288|Experimental|High-dose trehalose|
3146136|NCT01576120|Experimental|bowel prep regimen first boost 6 oz. and second boost 3 oz.|4L of PEG split into two doses:1.on the evening before the exam 2.on the morning of exam day.Upon SB Detection 6 oz. SuPrep administered and 3hrs later 3 oz. SuPrep was administered if needed depends on the capsule progress in the GI
3146137|NCT01576120|Experimental|bowel prep regimen first boost 3 oz. and second boost 6 oz.|4L of PEG split into two doses:1.on the evening before the exam 2.on the morning of exam day.Upon SB Detection 3 oz. SuPrep administered and 3hrs later 6 oz. SuPrep was administered if needed depends on the capsule progress in the GI
3146138|NCT01576107|Experimental|Physical activity|Exercise counseling (behavior change techniques)
3146139|NCT01576107|Experimental|Stress-management|Stress-management training
3146140|NCT01576094|Active Comparator|Milrinone|Milrinone (MR) lactate 1 mg/ml: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission; dose 3, after 2 hours of stability with dose 2, and maintained up to 48 hours. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
3146141|NCT01576094|Active Comparator|Levosimendan|
3146142|NCT01576081|Experimental|Unilateral orthotic intervention|The HEPHAISTOS orthotic was worn unilaterally for 56days by 11 healthy male subjects.
3146143|NCT01576068|Other|High Risk Customers|Pharmacy customers with GOLD COPD Criteria of high-risk subjects.
3146144|NCT01576055|Experimental|TIGRIS Vascular Stent|GORE TIGRIS Vascular Stent
3146145|NCT01576055|Active Comparator|BARD LifeStent|BARD LifeStent
3146146|NCT01576042|Other|Catheter ablation|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults
3146147|NCT01576042|Other|Antiarrhythmic medication|The choice of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
3146148|NCT01576029|Active Comparator|Docetaxel|75 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks
3146149|NCT01576029|Experimental|Cabazitaxel|25 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks
3146150|NCT01576016|Active Comparator|Accent MRI system MRI Scan Group|Patient implanted with an Accent MRI system will receive an MRI scan
3146151|NCT01576016|Placebo Comparator|Accent MRI System MRI Control Group|Patient implanted with an Accent MRI system will not receive an MRI scan
3146152|NCT01576003|Experimental|Glutamine|
3146153|NCT01576003|Placebo Comparator|L-alanine|
3146154|NCT01576003|No Intervention|Healthy Control|
3146155|NCT01575990|Experimental|Making A Decision About CRC Screening|A decision support intervention that is a literacy sensitive paper based tool with educational information targeted to the patient's age and gender.
3146156|NCT01575990|Placebo Comparator|Drivers 65 Plus|The placebo comparator is an attention control with information about driving tips for drivers age 65 and older.
3146157|NCT01575951|Experimental|All patients|All participants enrolled.
3146158|NCT01575938|Experimental|HIV group-based prevention intervention|The HIV prevention intervention is a 6-session group-based and manualized intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
3146159|NCT01575938|Active Comparator|Diet and nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
3146160|NCT01575938|No Intervention|Standard-of-care|This arm will receive HIV and STI testing and counseling only.
3146161|NCT01575925|Experimental|4 mg Oral POM + 40 mg Oral DEX|Oral POM at 4 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle
3146162|NCT01575925|Experimental|2 mg Oral POM + 40 mg Oral DEX|Oral POM at 2 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle
3146163|NCT01575912||schizophrenia SC|subjects with a diagnosis of schizophrenia (SC) according to the DSM-IV-TR, submitted to experimental pain tests
3146164|NCT01575912||major depression MD|subjects with a diagnosis of major depression (MD) according to the DSM-IV-TR, submitted to experimental pain tests
3146165|NCT01575912||controls C|subjects without any diagnosis of psychiatric disorder (C) submitted to experimental pain tests
3146166|NCT01575899|Experimental|Levofloxacin-Amoxicillin/clavulanate|7-day levofloxacin, amoxicillin/clavulanate, rabeprazole for Hp eradication.
3146167|NCT01575899|Active Comparator|Clarithromycin-Amoxicillin|7-day clarithromycin, amoxicillin, rabeprazole for Hp eradication.
3146168|NCT01575886|Experimental|Smoking cessation intervention|This group receives the teachable moment communication process intervention focused on smoking cessation and contributes data at baseline (Time 1) and post intervention (Time 2).
3146169|NCT01575886|No Intervention|Delayed intervention group|This group serves as the comparison group for the evaluation of the smoking cessation intervention at Time 1 and Time 2 data collection to complete the group randomized trial. This group of clinicians then has Time 3 data collection focused on weight management receives a revised intervention focused on teachable moment communication for weight management and has Time 4 data collected to evaluate the teachable moment for weight management training as a pre-post design.
3146170|NCT01575873|Experimental|Denosumab|Participants received 60 mg denosumab by subcutaneous injection on day 1 and at months 6, 12, and 18. Participants also received placebo to risedronate orally once a day for 24 months.
3146171|NCT01575873|Experimental|Risendronate|Participants received 5 mg risedronate orally once a day for 24 months and placebo to densumab by subcutaneous injection on day 1 and at months 6, 12, and 18.
3146172|NCT01575847||Part I|"Part 1 will be a feasibility study conducted in the Emergency Department at UAMS and ACH. This Part will test the research use dipsticks and dipstick testing kit in subjects that are having APAP levels obtained as part of their medical evaluation.~Part 1 20 subjects~Part I~Inclusion Criteria:~Subject is 12-18 years of age. Subject has an APAP level ordered as part of clinical management.~Exclusion Criteria:~Previous recent history of APAP overdose in the previous 30 days."
3146251|NCT01575275|Experimental|Diagnostic (aminolevulinic acid)|Patients receive aminolevulinic acid PO 2-4 hours before surgery.
3297333|NCT00479336|Experimental|3|
3146173|NCT01575847||Part 2|"Part 2~Part 2 will be a non-intervention study in adults presenting to hepatology centers participating in the Acute Liver Failure Study Group (ALFSG). The dipstick will be tested in these subjects and the results will be compared to the HPLC-EC measurement of APAP protein adducts. The results of the dipstick testing will not be used for diagnosis or clinical decision-making.~Part 2 100 subjects~Part 2~Inclusion Criteria:~Subject is 18 years of age or older. Subject is enrolled in the ALFSG registry.~Exclusion Criteria:"
3146174|NCT01575834|Experimental|Romosozumab|Participants received 210 mg romosozumab subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
3146175|NCT01575834|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
3146176|NCT01575821|Experimental|Eucalyptus honey ,|75 children
3146177|NCT01575821|Experimental|Labiatae honey|75 children allocated
3146178|NCT01575821|Experimental|Silan date extract (placebo)|75 children allocated
3146179|NCT01575821|Experimental|Citrus honey|75 children allocated
3146180|NCT01575808|Experimental|GP1101|Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft
3146181|NCT01575808|No Intervention|Retrospective Surgical Bypass Outcomes|Retrospective data collection (Apr 2012 - Apr 2014) of 68 surgical procedures (performed after Jan 2002) at six Japanese centers used to treat femoral-popliteal artery symptomatic PAD for purposes of establishing the invasiveness control data for hospital stay duration, avoidance of general anesthesia and avoidance of intra-operative transfusion. Eligibility criteria for inclusion werer established to be consistent with the experimental arm.
3146182|NCT01575795|Active Comparator|Ticagrelor 180mg loading dose|Ticagrelor 180mg loading dose
3146183|NCT01575795|Experimental|Ticagrelor 360mg loading dose|Ticagrelor 360mg loading dose
3146184|NCT01575782|Experimental|Chloroquine|
3146185|NCT01575769|Experimental|1|
3146186|NCT01575756|Experimental|Octafibrin followed by Haemocomplettan® P or RiaSTAPTM|Participants received Octafibrin 70 mg/kg intravenously once followed by Haemocomplettan® P or RiaSTAPTM 70 mg/kg intravenously once 45 days later.
3146187|NCT01575756|Experimental|Haemocomplettan® P or RiaSTAPTM followed by Octafibrin|Participants received Haemocomplettan® P or RiaSTAPTM 70 mg/kg intravenously once followed by Octafibrin 70 mg/kg intravenously once 45 days later.
3146188|NCT01575743|Experimental|Aerobic Exercise|
3146189|NCT01575743|Other|healthy controls|
3146190|NCT01575730|Active Comparator|Oxaliplatin 37°C, high dose, 30 minutes|
3146191|NCT01575730|Placebo Comparator|Oxaliplatin 41 °C, high dose, 30 minutes|
3146192|NCT01575730|Active Comparator|Oxaliplatin 37°C, low dose, 90 minutes|
3146193|NCT01575717|Experimental|Vitamin D 4000|Subjects taking 4000 IU of vitamin D
3146194|NCT01575717|Experimental|Vitamin D 2000|Subjects taking 2000IU of vitamin D
3146195|NCT01575717|No Intervention|No Intervention|
3146196|NCT01575704|Experimental|Sport|
3146197|NCT01575704|Other|Control|
3146198|NCT01575691|Experimental|VPA + 5-aza + ATRA|Daily for 7 days, Valproic acid (VPA) starting dose 75 mg/m^2 subcutaneously in combination with 5-azacytidine (5-aza) 50 mg/kg orally; and all-trans retinoic acid (ATRA) 45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3.
3146199|NCT01575678|Active Comparator|Melatonin|
3146200|NCT01575678|Placebo Comparator|Lactose|
3146201|NCT01575665|Experimental|Partial Rebreathing Mask|A novel membrane breathing mask which facilitates a partial rebreathing of expired gas (thereby raising systemic CO2), while allowing a diffusion of oxygen from the atmosphere to the user, through the membranes.
3146202|NCT01575652|Active Comparator|ACE-I|Group using ACEIs
3146203|NCT01575652|No Intervention|ACE-I, 2|group not using ace-i
3146204|NCT01575639|Experimental|High dose|Oral Prednisolone will be given at dose of 4 mg/kg/day for 14 days
3146205|NCT01575639|Active Comparator|Usual dose|Oral prednisolone will be given at dose of 2 mg/kg/day for 14 days
3146206|NCT01575626|Active Comparator|first sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 0%, 7%, 4%
3146207|NCT01575626|Active Comparator|second sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 4%, 7%, 0%
3146208|NCT01575626|Active Comparator|third sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 7%, 4%, 0%
3146209|NCT01575626|Active Comparator|Propofol|General anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model).Following tracheal intubation, concentration of propofol will be decreased till 0.
3146210|NCT01575613|Experimental|Hotspot Targeting|Four hotspot-targeted interventions will be superimposed on ongoing control measures: hotspots will be targeted with a combination of IRS, long-lasting insecticide treated nets (LLINs), larviciding and a focal screening and treatment (FSAT)campaign.
3146211|NCT01575613|No Intervention|Control|Standard of care as determined by the Division of Malaria Control of the Kenyan Ministry of Health
3146212|NCT01575600|Active Comparator|10 mL/kg/h lactated Ringer's solution|Group 1, 10 mL/kg/h lactated Ringer's solution
3146213|NCT01575600|Experimental|30 mL/kg/h lactated Ringer's solution|Group 2, 30 mL/kg/h lactated Ringer's solution
3146214|NCT01575587|Experimental|Treatment A|
3146215|NCT01575587|Experimental|Treatment B|
3146216|NCT01575587|Experimental|Treatment C|
3146217|NCT01575587|Experimental|Treatment D|
3146218|NCT01575574|Other|GADOXETIC ACID|Is a non comparative study. a magnetic resonance will be done using gadoxetic acid : 0.025mmol/Kg
3146219|NCT01575561|Experimental|Lurasidone|Lurasidone 20, 40, 60,80 mg flexible dose
3146220|NCT01575548|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
3146221|NCT01575548|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
3146222|NCT01575522|Experimental|Treatment (tivantinib)|Patients receive tivantinib 360 mg PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically during study for c-Met expression, relevant markers (HGF and VEGF), PTEN loss, and PI3K mutation analysis by FISH and IHC. Archived tumor tissue samples are also analyzed.
3146223|NCT01575496|Active Comparator|Active tDCS|Subjects will receive 20 minutes of active tDCS.
3146224|NCT01575496|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham tDCS.
3146225|NCT01575483||Patients with T2DM|Patients with diagnosis of type 2 diabetes mellitus (T2DM) initiating Onglyza® treatment within the approved indications will be enrolled
3146226|NCT01575470|Experimental|bone marrow mononuclear cells|a bone marrow harvest will be performed within 36 hours of injury followed by a single intravenous infusion of autologous bone marrow mononuclear cells (BMMNCs)
3146227|NCT01575457|Experimental|Intervention|The Healthy Futures Program is an interactive, multi-session training program. The intervention participants will participate in College/vocational school, Job, and Career Planning activities with a career coach.
3146228|NCT01575457|Other|Comparison|The Healthy Futures Program is an interactive, multi-session training program. The comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
3146229|NCT01575444||Home Based Vaginal Collection|Somali women who are randomized for Home based Vaginal Collection will be given a kit to perform the vaginal sample collection for HPV analysis, with detailed written instructions.
3146230|NCT01575444||Clinic Based Pap Test Collection|30 Somali women who are randomized for Standard Clinic Pap Group will be given a list of clinics that they can attend for cervical cancer screening using pap test. Follow-up will be done on test completion with the clinic at 3 months after enrollment.
3146231|NCT01575431||Stable angina|Patients who undergo an elective and successful single or multivessel percutaneous coronary intervention can be considered for the study.
3146232|NCT01575418|Experimental|Rectal specific formulation (RF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
3146233|NCT01575418|Active Comparator|Vaginal formulation (VF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
3146234|NCT01575418|Active Comparator|Reduced glycerin vaginal formulation (RGVF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
3146235|NCT01575405|Experimental|Rectal-specific formulation (RF) stage|During this stage, participants will receive seven rectally-administered doses of the rectal-specific formulation (RF), with the first and last dose administered in clinic and five doses in between self-administered by a participant at home. Various specimens will be collected after administration of the last dose, including blood, vaginal and rectal fluids, and endoscopic biopsies. Blood and fluids will be additionally collected at 2hr, 4hr, and 24hr post-last-dose administration.
3146236|NCT01575405|Active Comparator|Vaginal formulation (VF) stage|"During this stage, only one exposure to the vaginal formulation (VF) will be administered (as the seventh dose in the stage), but it will be coupled with six preceding exposures to the Universal HEC Placebo Gel to balance it out against the other three stages in the study.~First and last doses will be administered in clinic, and after the administration of the last dose, various specimens will be collected, including blood, vaginal and rectal fluid, and endoscopic biopsies. Additional blood and fluids will be collected at 2, 4, and 24 hours post seventh dose administration."
3146237|NCT01575405|Active Comparator|Reduced Glycerin Vaginal Formulation (RGVF) stage|During this stage, participants will receive seven rectally-administered doses of the reduced glycerin vaginal formulation (RGVF), with the first and last dose administered in clinic and five doses in between self-administered by a participant at home. Various specimens will be collected after administration of the last dose, including blood, vaginal and rectal fluids, and endoscopic biopsies. Blood and fluids will be additionally collected at 2hr, 4hr, and 24hr post-last-dose administration.
3146238|NCT01575392||Patients coming for creatinine clearance|For this single group study, all patients presenting at the laboratory facility for a 24-hour creatinine clearance and patients in the dialysis population of the Isala Clinics who came for their periodical KT/V control, were informed about the study and asked to participate. Moreover, 20 'healthy' volunteers (including the investigators of this study and staff working at the clinical chemistry department of the Isala clinics) participated in this study.
3146239|NCT01575366|Experimental|Slow tracking training|
3146240|NCT01575366|Experimental|Fast tracking training|
3146241|NCT01575353|Active Comparator|Venturi mask|After extubation, patients will receive oxygen therapy through the standard Venturi mask (control)
3146242|NCT01575353|Active Comparator|Nasal high-flow|After extubation, patients will receive oxygen therapy through the nasal high-flow (intervention)
3146243|NCT01575340|Experimental|fish oil encapsuled|will receive the supplementation of 2 g / day of fish oil encapsulated for 9 weeks
3146244|NCT01575340|No Intervention|without supplementation|not will receive supplementation or encapsulated fish oil or placebo
3146245|NCT01575327|Active Comparator|Fixed oxygen flow delivery|Oxygen flow delivery is adjusted by respiratory therapists. Standard medical treatment.
3146246|NCT01575327|Experimental|FreeO2 system|FreeO2 is a new system that automatically adjusts the oxygen flow delivered to patients in a closed-loop based on the SpO2 signal. This system is intended to maintain SpO2 in a predefined target and to adapt oxygen flow to patient's needs.
3146247|NCT01575314|Experimental|stapling device|stapling device refer to patients who were randomized to use stapler for dividing lung parenchyma.
3148121|NCT01562574|Experimental|Activated recombinant human factor VII|
3146252|NCT01575262|Experimental|Incentive|Participants use their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of physical activity = 1 point; capped at 30 points per day) over the 12-week intervention period. Points are redeemed for rewards (extrinsic motivation) at week 6 and week 12.
3146253|NCT01575262|Active Comparator|No Incentive|Participants used their PAL card to self-monitor their physical activity levels (intrinsic motivation) over the 12-week intervention period but do not collect points or earn rewards.
3146254|NCT01575249||Asymptomatic group|one hundred patients with a negative exercise stress echo for symptoms/ECG/wall motion abnormalities (WMA), negative spirometry test for pulmonary disease, without known CAD or other valvular diseases, in sinus rhythm and with a LVEF>55%
3146255|NCT01575249||Symptomatic group|one hundred patients with symptomatic AS (negative pulmonary tests but positive stress echo or prior CAD or other valvular diseases and a LVEF>55%
3146256|NCT01575236|Experimental|Guardian|Guardian Laryngeal Mask
3146257|NCT01575236|Experimental|Supreme|Supreme Laryngeal Mask Airway
3146258|NCT01575223|Active Comparator|High volume saline irrigation|Patients in this group will receive high volume saline irrigation (NeilMed sinus rinse)
3146259|NCT01575223|Placebo Comparator|Placebo|Patients in this group will receive low volume saline irrigation (Salinex)
3146260|NCT01575197|Active Comparator|Rotavirus Vaccine at age 6 & 10 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 6 & 10 weeks of age.
3146261|NCT01575197|Experimental|Rotavirus vaccine at age 10 & 14 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 10 & 14 weeks of age.
3146262|NCT01575197|Experimental|Rotavirus vaccine at age 6,10,&14 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 6, 10, & 14 weeks of age.
3146263|NCT01575184|Experimental|Shoulder traction|The ultrasonographic measurements with shoulder traction
3146264|NCT01575184|Active Comparator|No traction|The ultrasonographic measurements without shoulder traction
3146265|NCT01575171||"Intervention/Nudge"|"Individuals will be analyzed according to their assigned intervention group, to compare the effectiveness of an opt-out EHR decision support system to enhance the prescription of statins to those patients with an elevated LDL-C and to subsequently titrate the medication dose until LDL-C control is obtained. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines."
3146266|NCT01575158|Experimental|citalopram|citalopram
3146267|NCT01575158|Active Comparator|clomipramnine|clomipramine
3146268|NCT01575158|Placebo Comparator|placebo|placebo
3146269|NCT01575145|Experimental|Quitline facilitation intervention|brief quitline facilitation intervention given
3146270|NCT01575145|Active Comparator|Stop-smoking intervention|brief review of tips to maintain smoking abstinence, using brochure
3146271|NCT01575132||Parkinson's Disease, DBS, 10-14 years|
3146272|NCT01575119|Experimental|In-patient surgery|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
3146273|NCT01575119|Active Comparator|In-patient|Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
3146274|NCT01575119|Experimental|Out-patient surgery|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
3146275|NCT01575119|Active Comparator|Out-patient|Standard of care information, including distributing a patient education brochure, to provide information regarding perioperative smoking
3146276|NCT01575106|Experimental|Arm 1|There is only one cohort in this study. All subjects receive the same intervention, the application of heat pain using TSA or CHEPS.
3146277|NCT01575080|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use Contour TS Blood Glucose Monitoring System.
3146278|NCT01575067||blood pressure monitor|Cuff circumference:22cm-42cm
3146279|NCT01575067||stethoscopy|Cuff circumference: 22cm-42cm
3146280|NCT01575054|Experimental|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
3146281|NCT01575054|Other|Normal Saline (Placebo) Followed by botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
3146282|NCT01575041|Active Comparator|Sodium|For 4 weeks subjects will consume 3 grams of sodium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet
3146283|NCT01575041|Active Comparator|Potassium|For 4 weeks subjects will consume 3 grams of potassium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet.
3146284|NCT01575041|Placebo Comparator|Placebo|For 4 weeks subjects will consume placebo capsules (content: cellulose) on top of a low-sodium low-potassium diet
3146285|NCT01575028|Active Comparator|Local anesthetic infiltration injection|Patients will receive local anesthetic infiltration injected at the surgical site by the surgeon at the end of surgery.
3146286|NCT01575028|Experimental|Transversus abdominis plane (TAP) block|Patients will receive a transversus abdominis plane (TAP) block.
3146287|NCT01575015|Active Comparator|Standard intraoperative support (no CRRT)|
3146288|NCT01575015|Experimental|Intraoperative renal support (CRRT)|
3146289|NCT01575002|Experimental|Active tDCS|Subjects will undergo 20 minutes of active tDCS stimulation.
3146290|NCT01575002|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham tDCS stimulation.
3146291|NCT01574989|Experimental|Active low-frequency rTMS/sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the rTMS will be active, low-frequency, and the tDCS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
3146292|NCT01574989|Experimental|Active high-frequency rTMS/sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the rTMS will be active, high-frequency, and the tDCS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
3146293|NCT01574989|Experimental|Sham rTMS/active anodal tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the tDCS will be active, anodal, and the TMS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
3146294|NCT01574989|Experimental|Sham rTMS/active cathodal tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the tDCS will be active, cathodal, and the TMS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
3146295|NCT01574989|Sham Comparator|Sham rTMS/Sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, and both interventions will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
3146296|NCT01574976|Active Comparator|control, no feeback|subjects without ADHD, probabilistic choices without feedback
3146297|NCT01574976|Active Comparator|control, feedback|subjects without ADHD, probabilistic choices with feedback
3146298|NCT01574976|Experimental|ADHD, no feedback|subjects with ADHD, probabilistic choices without feedback
3146299|NCT01574976|Experimental|adhd, feedback|subjects with ADHD, probabilistic choices with feedback
3146300|NCT01574963||CAD Patients|Patients suffering from CAD requiring coronary artery bypass grafting
3146301|NCT01574963||Control Patients|Patients without CAD
3146302|NCT01574937|Experimental|Treatment Arm|Cabozantinib and abiraterone
3146303|NCT01574924||Medical residents|
3146304|NCT01574911||healthy adults|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D laser scanning
3146305|NCT01574911||Adults Chronic venous insufficiency|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D laser scanning
3146306|NCT01574911||patients primary lymphedema|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D
3146307|NCT01574898|Active Comparator|Niquitin® Fresh Mint 4 mg|
3146308|NCT01574898|Active Comparator|V0118 - B mg|
3146309|NCT01574898|Experimental|V0474 - C mg|
3146310|NCT01574898|Experimental|V0474 - B mg|
3146311|NCT01574898|Experimental|V0474 - A mg|
3146312|NCT01574885|Experimental|Aerosal|This arm include all patients treated with Aerosal®
3146313|NCT01574885|Placebo Comparator|Placebo|This arm include all patients treated with placebo
3146314|NCT01574872|Experimental|Aerosal|This arm include all patients treated with Aerosal®
3146315|NCT01574872|Placebo Comparator|Placebo|This arm include all patients treated with placebo
3146316|NCT01574859||hypopituitarism|group of patients with hypopituitarism
3146317|NCT01574846||Vantas|
3146318|NCT01574833|Active Comparator|PEMF|arm that receive PEMF treatment
3146319|NCT01574833|Sham Comparator|Sham|arm that receive sham treatment
3146320|NCT01574820|Placebo Comparator|placebo|
3146321|NCT01574820|Experimental|rosiglitazone (4 mg)/day|
3146322|NCT01574807|Experimental|Pulpal anesthesia|
3146323|NCT01574794|Experimental|Strengthening Exercises|Recreational older runners recruited from local community
3146324|NCT01574794|Experimental|Stretching Exercises|Recreational older runners recruited from local community
3146325|NCT01574794|No Intervention|Control Group|Recreational older runners recruited from local community
3146326|NCT01574781||Women with abnormal fetus|Women carrying fetus that is identified as chromosomally abnormal by CVS/Amniocentesis
3146327|NCT01574781||Women experiencing miscarriage|Women identified as miscarrying, prior to any D&C or D&E procedure
3146328|NCT01574781||Born children|The children born from women participating in other cohorts of the study.
3146329|NCT01574781||Male relatives|The male partners (and presumed biological father of any fetuses/children) of women participating in other cohorts of the study or the biological father's brother and/or father.
3146330|NCT01574781||Non-pregnant women|Healthy women who are not pregnant
3146331|NCT01574781||Pregnant women|
3146332|NCT01574742|Experimental|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
3146333|NCT01574729|Active Comparator|Surgery plus post-surgery chemotherapy|Surgery plus post-surgery chemotherapy
3146334|NCT01574729|Experimental|Surgery combined with rAd-p53 gene therapy|Surgery combined with the surgery wound surface injection of rAd-p53 plus post-surgery chemotherapy
3146335|NCT01574716|Experimental|MORAb-004, gemcitabine, docetaxel|
3146336|NCT01574716|Active Comparator|Placebo, gemcitabine, docetaxel|
3146337|NCT01574703|Experimental|placebo|
3146338|NCT01574703|Experimental|varenicline|
3146339|NCT01574703|Experimental|bupropion|
3146340|NCT01574703|Experimental|Nicotine Replacement Therapy Patch|
3146341|NCT01574690||Heart failure patients|50 subjects (both male and female) Heart failure patients already receiving RHC as part of their usual care
3146342|NCT01574677||Screening FIT positive|Patients aged 49-80, with a positive screening FIT, who are referred to colonoscopy, and who meet inclusion criteria.
3146343|NCT01574664||Subjects scheduled to undergo lumpectomy|
3146529|NCT01573312|Experimental|Inactivated monovalent influenza A/H5N1 without ASO3 adjuvant|Ten subjects will be vaccinated with 3.75 mcg of H5N1 hemagglutinin alone, given intramuscularly, in two doses 28 days apart.
3146344|NCT01574651|Experimental|QVA149 plus placebo to tiotropium and placebo to formoterol|QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use.
3146345|NCT01574651|Active Comparator|Tiotropium plus Formoterol and placebo to QVA149|Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
3146346|NCT01574638|Experimental|Arm 1B|Participants in Arm 1B will receive RPT based on weight at entry, at a dose of 20 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 10 mg/kg twice daily with low-fat meals.
3146347|NCT01574638|Experimental|Arm 1A|Participants in Arm 1A will receive RPT based on weight at entry, at a dose of 10 mg/kg twice daily with low-fat meals, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 20 mg/kg once daily with a low-fat breakfast.
3146348|NCT01574638|Experimental|Arm 2A|Participants in Arm 2A will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a boiled egg, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 70, at a dose of 15 mg/kg once daily with a low-fat breakfast.
3146349|NCT01574638|Experimental|Arm 2B|Participants in Arm 2B will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 15 mg/kg once daily with a boiled egg.
3146350|NCT01574625||Mosaic prosthetic heart valve|All patients who were enrolled and implanted with a Mosaic bioprosthesis in the Albertinen-Krankenhaus (Hamburg, Germany) during the previous Mosaic PMA study and who agree to participate in this long-term follow-up study by informed consent.
3146351|NCT01574612|Experimental|topical cream acyclovir/hydrocortisone|topical cream acyclovir/hydrocortisone used
3146352|NCT01574599|Experimental|Repetitive Facilitative Exercise|Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
3146353|NCT01574599|No Intervention|Conventional Therapy Program|Typical therapy excluding robotics, RFE
3146354|NCT01574586|Active Comparator|2-link stent Nobori|Bifurcation stenting
3146355|NCT01574586|Active Comparator|3-link stent Xience|Bifurcation stenting
3146356|NCT01574573|Experimental|Obese individuals with weight loss|Self support, group sessions
3146357|NCT01574573|Experimental|Obese individuals without weight loss|self support, group sessions
3146358|NCT01574560|Active Comparator|Control Group - Health Education|This group is provided with information regarding secondhand smoke and creating a healthy home environment.
3146359|NCT01574560|Active Comparator|Treatment Group - Counseling|This group is provided with biomarker feedback on child exposure to secondhand smoke. Active participants receive 5 counseling sessions from a trained research counselor; 3 sessions in the home and 2 by phone. The counseling sessions focus on changing smoking behaviors and/or other behaviors that impact smoking.
3146360|NCT01574547||Cat Scratch Colon|Patients with mucosal tears during colonoscopy
3146361|NCT01574547||Control group|Patients without mucosal tears during the colonoscopy
3146362|NCT01574534|Experimental|Drug eluting balloon|paclitaxel-eluting SeQuent® Please balloon, B.Braun Melsungen AG, Berlin, Germany
3146363|NCT01574534|Active Comparator|Drug eluting stent|paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA or everolimus-eluting Xience® stent Abbott Vascular, Santa Clara, California, USA
3146364|NCT01574521||Only father carrier|fetuses whose fathers were HBV carriers whereas mothers negatively.
3146365|NCT01574521||only mother carrier|fetuses whose mothers were HBV carriers whereas fathers negatively.
3146366|NCT01574521||both parents carriers|fetuses whose both parents were HBV carriers
3146367|NCT01574508|Experimental|Continuous Subcutaneous Insulin Infusion|CSII
3146368|NCT01574508|Active Comparator|Multiple Daily Insulin Injections|MDI
3146369|NCT01574495|Experimental|Error Augmentation-Control|
3146370|NCT01574495|Experimental|Control-Error Augmentation|
3146371|NCT01574482|Experimental|1 = Tested product|
3146372|NCT01574482|Placebo Comparator|2 = Control product|
3146373|NCT01574469|Active Comparator|1 = Tested product|
3146374|NCT01574469|Placebo Comparator|2 = Control product|
3146375|NCT01574456||7 patients diagnosed with dementia of the Alzheimer's type|
3146376|NCT01574456||13 patients with mild cognitive impairment|
3146377|NCT01574456||19 healthy controls|
3146378|NCT01574443||epilepsy resection patients|Patients undergoing resection for refractory epilepsy
3146379|NCT01574430|Active Comparator|50% dose PDT|patients in this group was given 50% verteporfin dose PDT
3146380|NCT01574430|Experimental|30% dose PDT|patients in this group was given 30% verteporfin dose PDT
3146381|NCT01574417|Experimental|Plant stanol-enriched margarine|
3146382|NCT01574417|Placebo Comparator|control margarine|
3146383|NCT01574404|Experimental|Polar Body Biopsy with PGS|Polar Body Biopsy with Pre implantation genetic screening
3146384|NCT01574391|Active Comparator|EPIDRUM|EPIDRUM DEVICE IS USED TO SITE THE EPIDURALS IN THE PATIENTS RANDOMISED TO THIS ARM
3146385|NCT01574391|No Intervention|Control|This arm is the control where normal technique is used
3146386|NCT01574378|Active Comparator|Control arm|Control arm- conventional method of wound closure
3146387|NCT01574378|Experimental|V-Loc group|V-Loc 90 barbed sutures
3146388|NCT01574365|Experimental|RTA402|
3146389|NCT01574365|Experimental|RTA402 Low|
3146390|NCT01574365|Experimental|RTA402 Medium-low|
3146391|NCT01574365|Experimental|RTA402 Medium-high|
3146392|NCT01574352|Experimental|Intervention camp|Children's behavior are controlled each week day for six weeks, and children participate in three hours of physical activity every day
3146393|NCT01574352|Experimental|Small intervention|Children are only informed of healthy behavior
3146394|NCT01574339|Experimental|Treatment Arm|
3146530|NCT01573299|Active Comparator|Early vertical positioning|
3146531|NCT01573299|Active Comparator|Progressively vertical positioning|
3146395|NCT01574326|Placebo Comparator|FDP-Placebo for Sevelamer Carbonate, DTP-Sevelamer Carbonate|Participants received placebo for 2 weeks during the fixed dose period (FDP). Participants received sevelamer carbonate for 26 weeks in dose titration period (DTP).
3146396|NCT01574326|Experimental|FDP-Sevelamer Carbonate, DTP-Sevelamer Carbonate|Participants received sevelamer carbonate for 2 weeks during the FDP of the study. Participants received sevelamer carbonate for an additional 26 weeks in DTP.
3146397|NCT01574313|Experimental|Stellate ganglion block|treated with SGB
3146398|NCT01574313|Active Comparator|Oral medication|treated with oral medications: 0.25mg of erispan@ (fludiazine) , 25mg cephadol@ (diphenidol), and 200mg kentons@ (tocopherol nicotinate).
3146399|NCT01574300||Biospecimens and biofluids|"This is a multi-cohort parallel study in which tumor, plasma and serum samples will be collected prior to the start of any therapeutic intervention for stage IV lung cancer. These biospecimens will be correlated with treatment and clinical data and distributed for peer reviewed research purposes to academic and community centers in the U.S. and Europe.~The biospecimens collected in CASTLE will be analyzed for a panel of biomarkers, currently including:~tumor: epidermal growth factor receptor (EGFR), KRAS (Kirsten RAt Sarcoma) gene and EML4-ALK (echinoderm microtubule-associated protein-like 4 - anaplastic lymphoma kinase) translocations, and EGFR, TS (thymidylate synthase), ERCC1 (excision repair cross-complementing 1) and RRM1 (Ribonucleotide Reductase, M1 Subunit) gene expressions~serum: proteomics predictive for EGFR-TKI (tyrosine kinase inhibotors)response"
3146400|NCT01574287|Experimental|FACBC|
3146401|NCT01574274|Active Comparator|SC-PEG|SC-PEG
3146402|NCT01574274|Active Comparator|Oncaspar|Oncaspar
3146403|NCT01574261|Active Comparator|Inositol|Patients will be randomized to receive Inositol 4 g/die per os for four months of treatment
3146404|NCT01574261|Placebo Comparator|Placebo|Patients will be randomized to receive placebo for four months
3146405|NCT01574248|Experimental|icatibant|30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
3146406|NCT01574248|Placebo Comparator|Placebo|Subcutaneous at time 0 and 6 hours
3146407|NCT01574235||Curative or prophylactic Nivestim® treatment for FN|
3146408|NCT01574222|Experimental|Arm 1|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling
3146409|NCT01574209||Celiac Disease|Patients suffering from coeliac diseases confirmed by small intestinal biopsy
3146410|NCT01574209||IBS patients|Patients suffering from irritable bowel syndrome (IBS) according to Rome III criteria
3146411|NCT01574209||Healthy subjects|Healthy subjects as control group
3146412|NCT01574196||Young adult survivors of childhood cancer|Young adult survivors of childhood cancer diagnosed between 1987 and 1992 in the Rhône-Alpes and Auvergne regions of France.
3146413|NCT01574183|Experimental|Vilazodone|Flexible dose up to 40 mg capsule daily
3146414|NCT01574183|Placebo Comparator|Placebo|Flexible dose up to 40 mg capsule daily
3146415|NCT01574157|Active Comparator|Arm 1|Sodium bicarbonate
3146416|NCT01574157|Placebo Comparator|Arm 2|Placebo
3146417|NCT01574144||AVIVO™ PiiX Patch Monitor System|Heart failure patients monitored continuously for 30 days post-discharge.
3146418|NCT01574131|Placebo Comparator|Sugar pill|pill
3146419|NCT01574131|Active Comparator|Fenofibrate|ppar-alpha agonist
3146420|NCT01574118|Experimental|Brief Enhanaced Exposure Therapy|"The following interventions are included in this arm:~Psycho-education addressing common reactions to trauma~Revisiting the Trauma memories~Processing the trauma memories~In vivo Exposure homework~*Use of a brief pre-exposure trauma memory retrieval trial~Exposure to video clips related to the patient's trauma~Compound extinction - simultaneously exposing patient to trauma video clips while they listen to their trauma script"
3146421|NCT01574118|Active Comparator|Standard Prolonged Exposure Therapy|"The following interventions are included in this arm:~Psycho-education addressing common reactions to trauma~Revisiting of the Trauma memories~Processing the trauma memories~Breathing retraining~In vivo Exposure homework"
3146422|NCT01574118|No Intervention|Delayed Treatment Control|Patients assigned to this arm receive assessment only (Week 0, 3, and 6) prior to receiving standard prolonged exposure therapy using the Foa et al treatment manual.
3146423|NCT01574105||Heparin Resistant|Patient whose slope calculated by a heparin dose response test is 89 sec/iu/ml or less.
3146424|NCT01574105||Heparin Sensitive|Patient whose slope calculated by a heparin dose response test is 90 sec/iu/ml or more.
3146425|NCT01574092|Experimental|Irinotecan plus Cisplatin combination|This is a open-label study with only one treatment experimental arm. The patients will be treated, in a weekly basis, with 30 mg/m2 of cisplatino plus 65 mg/m2 of irinotecán (one cycle), until a total of 16 cycles.
3146426|NCT01574079|Active Comparator|Traditional Physical Therapy|The control group will receive traditional physical therapy interventions directed at neuromuscular rehabilitation.
3146427|NCT01574079|Experimental|Physical Therapy plus Mirror Therapy|The mirror therapy will entail 15 minutes of exercises for the lower extremities focusing on ankle dorsiflexion, knee flexion, and hip flexion.
3146428|NCT01574066|Experimental|Chest CT-scan|Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
3146429|NCT01574040|Experimental|Staff (and visitors) of the University Medical Centre Utrecht|This is a dynamic study population
3146430|NCT01574027|Placebo Comparator|Placebo|Some participants were given a placebo pill to take daily for the length of the study. The placebo patients were used as a control group to compare against those taking the Vitamin D supplement.
3146431|NCT01574027|Experimental|Vitamin D3 (cholecalciferol)|Other participants were administered Vitamin D3 (cholecalciferol) for the six month study duration to determine if it would decrease the number of aberrant crypt foci in the colon as compared to the baseline number.
3146432|NCT01574014|Active Comparator|1: CBGT & Hydrocortisone|
3146433|NCT01574014|Placebo Comparator|2: CBGT & Placebo|
3146434|NCT01574001|Experimental|Antismoking intervention with minimal early follow-up|"an intervention according to the 5A's model with one follow-up visit within one week after discharge from the hospital; follow-up assessment will include two visits: 3 and 12 months after stroke"
3146723|NCT01571986||NIV|All patients with acute respiratory failure treated with non-invasive ventilation who give informed consent about treatment of their clinical data
3297334|NCT00479336|Experimental|4|
3146435|NCT01574001|Active Comparator|Antismoking intervention with no early follow-up|"an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke"
3146436|NCT01574001|Experimental|Antismoking intervention with intensive early follow-up|"an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke"
3146437|NCT01573988|Other|non-obese volunteers|Volunteers with a BMI (Body Mass Index) between 20 and 25 kg/m2.
3146438|NCT01573988|Other|Obese volunteers|Volunteers with a BMI (Body Mass Index) between 30 and 35 kg/m2.
3146439|NCT01573975|Experimental|Seq-Metronidazole|10-day sequential therapy with metronidazole
3146440|NCT01573975|Experimental|Seq-Tetracycline|10-day sequential therapy with tetracycline.
3146441|NCT01573975|Active Comparator|Control|10-day standard triple therapy.
3146442|NCT01573949|Experimental|Metformin|Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
3146443|NCT01573936|Experimental|rehabilitation program|Rehabilitation program from January 2008 through July 2010, which consists of 40-minutes of many therapies for 1-2 days a week
3146444|NCT01573923|Sham Comparator|Conventional therapy|only apply for conventional medical therapy without any cell therapy
3146445|NCT01573923|Active Comparator|mesenchymal stem cells|combination of conventional therapy with umbilical mesenchymal stem cells intravenous injection, (4x107/40ml, once per three months, four times in one year)
3146446|NCT01573910|Experimental|Moxifloxacin|Moxifloxacin ophthalmic solution, 0.5%, 1 drop instilled 3 times per day (TID) in each eye for 7 days with a test-of-cure (TOC) at Day 9
3146447|NCT01573910|Active Comparator|Ofloxacin|Ofloxacin ophthalmic solution, 0.3%, 1 drop instilled 3 times per day (TID) in each eye for 7 days with a test-of-cure (TOC) at Day 9
3146448|NCT01573897||Foot-wound without SAS|patients with diabetic foot wound(or at risk of diabetic foot wound) without sleep apnea syndrome
3146449|NCT01573897||Foot-wound with SAS|patients with diabetic foot wound(or at risk of diabetic foot wound) with sleep apnea syndrome
3146450|NCT01573871|Experimental|Hydrolyzed infant formula|Hydrolyzed infant formula to be fed ad libitum
3146451|NCT01573858|Experimental|Acupuncture treatment 1 plus CC|
3146452|NCT01573858|Active Comparator|Acupuncture treatment 2 plus CC|
3146453|NCT01573858|Active Comparator|Acupuncture treatment 1 plus CC placebo|
3146454|NCT01573858|Active Comparator|Acupucture treatment 2 and CC placebo.|
3146455|NCT01573845|Experimental|Healthy Eating + Eco-Friendly Campaign|
3146456|NCT01573845|Active Comparator|Healthy Eating Campaign|
3146457|NCT01573845|No Intervention|Control/Delayed Intervention|
3146458|NCT01573832|Experimental|Diabetic Foot Ulcer Intervention|
3146459|NCT01573832|No Intervention|Diabetic Foot Ulcer Usual Care|
3146460|NCT01573832|Experimental|Pionidal Sinus Ulcer Intervention|
3146461|NCT01573832|No Intervention|Pionidal Sinus Ulcer Usual Care|
3146462|NCT01573819|Experimental|Cohort 1|A dose of 2mg per day for 10 days
3146463|NCT01573819|Experimental|Cohort 2|A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg
3146464|NCT01573819|Experimental|Cohort 3|a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
3146465|NCT01573806|Active Comparator|Exenatide|Subjects dosed with exenatide in Phase 2
3146466|NCT01573806|Placebo Comparator|Exenatide vehicle|Subjects dosed with exenatide vehicle in Phase 2
3146467|NCT01573793|Active Comparator|Intervention|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
3146468|NCT01573793|Sham Comparator|Control|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
3146469|NCT01573780|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive gemcitabine hydrochloride IV over 30 minutes and smac mimetic TL32711 IV over 30 minutes once weekly for 2 weeks. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3146470|NCT01573767|Active Comparator|Arm 1|Vilanterol 25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
3146471|NCT01573767|Active Comparator|Arm 2|Vilanterol 12.5mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
3146472|NCT01573767|Active Comparator|Arm 3|Vilanterol 6.25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
3146473|NCT01573767|Placebo Comparator|Arm 4|Placebo inhalation powder inhaled once daily in the PM via the new powder inhaler
3146474|NCT01573754|Experimental|Hydroxychloroquine|Low-dose hydroxychloroquine 100 mg by mouth twice weekly
3146475|NCT01573754|Active Comparator|Phlebotomy|Phlebotomy 450 mL biweekly
3146476|NCT01573741|Experimental|ketamine,four hours monitoring hydrochloride injection|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
3146477|NCT01573728|Active Comparator|Low Exercise Arm|Low dose exercise (50 Minutes)
3146478|NCT01573728|Experimental|Public Health Exercise|Public Health dose exercise (150 minutes)
3146479|NCT01573715|Active Comparator|severe ARDS patients|
3146480|NCT01573715|Active Comparator|control group|
3146481|NCT01573715|Experimental|moderate SDRA patients|
3146482|NCT01573702|Other|Single Arm Study|Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib
3146483|NCT01573676||Bariatric surgery patients|Candidates for bariatric surgery.
3146484|NCT01573663|Experimental|Ambroxol and Levodropropizine|
3146485|NCT01573663|Active Comparator|Ambroxol|
3146486|NCT01573663|Active Comparator|Levodropropizine|
3146487|NCT01573650||group 1|Group 1a (standard): Epineural Suture Group 1b (experimental): Epineural suture and Fibrin Wrap
3146488|NCT01573650||group 2|Group 2a (standard): Epineural suture and autologous nerve transplantation from lateral antebrachial cutaneous nerve (LACN) Group 2b (experimental): Epineural suture and Fibrin Conduit
3146724|NCT01571973|No Intervention|control group|outpatients receiving usual care
3148122|NCT01562574|Placebo Comparator|Placebo|
3146489|NCT01573637|Experimental|Raloxifene hydrochloride 60 mg|"Patients fulfilling inclusion criteria and those giving the general informed consent for the study will be randomly allocated to one of the two groups in the trial (placebo or raloxifene) in a 1:1 proportion and in blocks of 4 patients, using the random number tables designed for this purpose.~The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Both drugs will be given orally in capsule form. The medication of each of the treatment groups (lactose as placebo, raloxifene) will be introduced into dark green gelatin capsules to guarantee the blinding."
3146490|NCT01573637|Placebo Comparator|Lactosa (placebo)|"Patients fulfilling inclusion criteria and those giving the general informed consent for the study will be randomly allocated to one of the two groups in the trial (placebo or raloxifene) in a 1:1 proportion and in blocks of 4 patients, using the random number tables designed for this purpose.~The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Both drugs will be given orally in capsule form. The medication of each of the treatment groups (lactose as placebo, raloxifene) will be introduced into dark green gelatin capsules to guarantee the blinding."
3146491|NCT01573624|Active Comparator|Fluticasone Furoate (FF)|100mcg, inhaled
3146492|NCT01573624|Active Comparator|Fluticasone Furoate /Vilanterol (VI)|100/25mcg inhaled
3146493|NCT01573624|Experimental|Fluticasone Furoate/GSK573719|100/15.6-250mcg inhaled
3146494|NCT01573611|Experimental|Grape Powder|
3146495|NCT01573611|Placebo Comparator|Placebo Powder|
3146496|NCT01573598|Placebo Comparator|Placebo|Dose-matched placebo capsules, oral administration
3146497|NCT01573598|Experimental|Vilazodone 20mg|Vilazodone tablets, 20 mg per day, oral administration
3146498|NCT01573598|Experimental|Vilazodone 40mg|Vilazodone tablets, 40 mg per day, oral administration
3146499|NCT01573585|Active Comparator|Usual care|The usual care will consist of strength training, endurance, range of motion, patient education, weight shifting in standing and gait re-training.
3146500|NCT01573585|Experimental|FAST protocol|The Fast muscle activation and stepping training will be the Experimental arm of this trial. This program will be exercises emphasizing speed of movement.
3146501|NCT01573572|Experimental|Intravitreal Injections of Macugen|
3146502|NCT01573559||ClearView/Predicate|
3146503|NCT01573546|Experimental|Aerobic Exercise|
3146504|NCT01573546|Experimental|DASH diet|
3146505|NCT01573546|Experimental|Combined aerobic exercise and DASH diet|
3146506|NCT01573546|Active Comparator|Health education control|
3146507|NCT01573533|Experimental|Rituximab|
3146508|NCT01573520|No Intervention|usual care|
3146509|NCT01573520|Active Comparator|adherence intervention arm|Monitoring drug adherence to guide treatment
3146510|NCT01573507|Experimental|sodium lactate infusion|Continuous i.v. infusion of Sodium Lactate (2'400 mOsmol/L) over 3 hours
3146511|NCT01573494|Experimental|Metastatic melanoma patients|Sampling of blood before and after chemotherapy
3146512|NCT01573481|Active Comparator|Pressure support ventilation|"Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure support ventilation mode. The level of the pressure support is the same as the previous day.~During the day (9 AM to 10 PM), patients are ventilated with pressure support ventilation (the level of pressure support is progressively decreased)."
3146513|NCT01573481|Active Comparator|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate > or equal to 12 breath per min). During the day (9 AM to 10 PM), patients are ventilated with pressure support ventilation (the level of pressure support is progressively decreased).
3146514|NCT01573468|Experimental|Capecitabine-tesetaxel|21-day cycle; tesetaxel 27 mg/m2 orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14
3146515|NCT01573468|Active Comparator|Capecitabine-placebo|21-day cycle; placebo orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14
3146516|NCT01573442|Experimental|Arm I|Patients receive testosterone (0.264mL) topical application daily for six months.
3146517|NCT01573442|Placebo Comparator|Arm II|Patients receive placebo (0.264mL) topical application daily for six months.
3146518|NCT01573416|Placebo Comparator|Control group|
3146519|NCT01573416|Active Comparator|Intervention group|
3146520|NCT01573403|Experimental|Treatment 1|one dose of DLBS2411 @250 mg
3146521|NCT01573403|Experimental|Treatment II|two doses of DLBS2411 @250 mg
3146522|NCT01573403|Placebo Comparator|Treatment III|
3146523|NCT01573390||1|Healthy participants.
3146524|NCT01573377|Experimental|metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
3146525|NCT01573377|Experimental|Ethinylestradiol and Cyproterone Acetate|From the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill.
3146526|NCT01573351|Experimental|QUAD: Asunaprevir+Daclatasvir+Peg-interferon Alfa-2a+Ribavirin|"Asunaprevir: Capsule, Oral, 100 mg, Twice daily, 24 weeks~Daclatasvir: Tablet, Oral, 60 mg, Once daily, 24 weeks~Peg-interferon Alfa-2a: Injection, subcutaneous (SC), 180 mcg/0.5 mL, Once weekly, 24 weeks~Ribavirin: Tablet, Oral, 1000 mg/1200 mg (total daily dose), 24 weeks"
3146527|NCT01573338|Experimental|Arm 1|BAY1000394 will be administered in combination with chemotherapy (etoposide and cisplatin or carboplatin) for up to 6 cycles. BAY1000394 will continue beyond Cycle 6 of chemotherapy. Type of chemotherapy for each patient will be decided by the investigator case by case.
3146528|NCT01573312|Experimental|Inactivated monovalent influenza A/H5N1 with ASO3 adjuvant|Ten subjects will be vaccinated with 3.75 micrograms(mcg) of H5N1 hemagglutinin plus AS03 given intramuscularly in two doses 28 days apart.
3146725|NCT01571973|Experimental|intervention group|outpatients receiving pharmaceutical care or pharmacotherapeutic follow-up by 6 months
3146532|NCT01573286|Experimental|Intestinal Failure in children (>1 year)|Children requiring parenteral nutrition for >30% of calories more than 1 year (365) days post surgery will be eligible for treatment with Glucagon-like peptide 2 (20 ug/kg/day) for 6 weeks
3146533|NCT01573286|Experimental|GLP-2 in Infants (<1 year of age)|Infants under one year of age with congenital anomalies, or intestinal resection, leaving them with anatomic short bowel syndrome (total remaining small intestine less than 40 % of predicted for gestational age) or with intestinal resection or repaired gastroschisis who have demonstrated dependence on parenteral nutrition at 45 days post operation with the requirement for >50% of calories by PN (independent of the length of remnant small intestine) will be eligible for treatment with Glucagon-like peptide 2, at a dose of 5, 10 or 20 ug/kg/day.
3146534|NCT01573273|Active Comparator|Oxytocin|intranasal administration
3146535|NCT01573273|Placebo Comparator|Saline|intranasal administration
3146536|NCT01573260|Experimental|Argentinean Tango|A biweekly class of argentinean tango for a period of 3-months the intervention for this arm
3146537|NCT01573260|Placebo Comparator|A 'wait-list' control group|Intervention: Patient will receive information about exercise in PD. After 12 weeks, these patients will then start the same 12-weeks tango program.
3146538|NCT01573247|Experimental|AKN-028|
3146539|NCT01573234|Experimental|MySkin patch|Hydrogel and polyurethane film
3146540|NCT01573234|Active Comparator|Traditional Dressing|
3146541|NCT01573221||stroke|
3146542|NCT01573208|Experimental|Register|Register
3146543|NCT01573195||All prescribing MDs at UWHC|Observational for accept, reject, or accept with modification of Best Practice Alers
3146544|NCT01573182|Experimental|Donor|VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the intramuscular (IM) route 4 to 6 weeks prior to stem cell harvesting..
3146545|NCT01573169|Experimental|low weight molecular heparin|enoxaparin 0.4 ml subcutaneous per day
3146546|NCT01573169|Placebo Comparator|standard therapy|Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization
3146547|NCT01573156|Experimental|VTP treatment to small renal mass|
3146548|NCT01573143|Placebo Comparator|Sugar pill|Placebo
3146549|NCT01573143|Experimental|Rosuvastatin|Rosuvastatin (20 mg od)
3146550|NCT01573130|Experimental|Initial treatment group|Group receives treatment.
3146551|NCT01573130|No Intervention|Waiting list control group|The waiting list control group receives treatment after 9 weeks, before which they do weekly ratings.
3146552|NCT01573117|Active Comparator|Cold infusions|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
3146553|NCT01573117|Active Comparator|RhinoChill|Nasopharyngeal cooling with the RhinoChill device (BeneChill, USA)
3146554|NCT01573104|Experimental|Biomarker group|Patients undergoing CPB having proteomic assays, blood sampling and biomarker assays performed on D0, D1, D2 and D3
3146555|NCT01573091||Heart failure patients|Patients with a CRT device according to current guidelines
3146556|NCT01573078||Crohn's disease patient|Outpatients who carry a diagnosis of Crohn's disease made by a gastroenterologist.
3146557|NCT01573065|Experimental|Single arm|
3146558|NCT01573052|Active Comparator|Chlordiazepoxide|
3146559|NCT01573052|Experimental|Gabapentin|
3146560|NCT01573013|Active Comparator|NaFeEDTA treatment, biscuit|Group receives 10 mg of Fe in form of NaFeEDTA per day. wheat flour based biscuit
3146561|NCT01573013|Active Comparator|EDTA treatment, biscuit|Group receives Na2EDTA enriched biscuit
3146562|NCT01573013|Active Comparator|FeSO4 treatment, biscuit|Group receives 10 mg of iron as FeSo4 per day for 8 months
3146563|NCT01573013|Placebo Comparator|control treatment, biscuit|group receives a biscuit without additional iron
3146564|NCT01573000|Experimental|Open-label, two-arm, Arm A and Arm B Crossover|Arm A Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 milliCurie (mCi) (35 mg) of I-131 TST infused over 30 minutes (inclusive of a 10-minute flush).• Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by a subject-specific mCi activity (35 mg) of I-131 TST to deliver the desired total body dose (TBD) infused over 30 minutes (inclusive of a 10-minute flush). The desired TBD was 65 cGy for subjects with a baseline platelet count of 100,001-149,999 cells/mm3 and 75 cGy for subjects with a baseline platelet count ≥150,000 cells/mm3. Obese subjects (subjects weighing more than 137% of their calculated lean body weight) were dosed based upon 137% of their calculated lean body mass
3146565|NCT01573000|Experimental|Arm B Crossover|Arm B Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 mg of TST infused over 30 minutes (inclusive of a 10-minute flush).Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 mg of TST infused over 30 minutes (inclusive of a 10-minute flush). Subjects randomized to Arm B were allowed to cross-over and receive TST/ I-131 TST once their disease had progressed.
3146566|NCT01572987|Active Comparator|RFA arm|Under this arm, study patients will undergo radiofrequency ablation.
3146567|NCT01572987|Active Comparator|EMR arm|Under this arm, the individuals will undergo endoscopic mucosal resection.
3146568|NCT01572974||No Barrett's esophagus|Subject without columnar lined esophagus
3146569|NCT01572974||Nondysplastic BE|Subject with columnar lined esophagus and absence of dysplasia
3146570|NCT01572974||Low grade dysplastic BE|subject with columnar lined esophagus and presence of low grade dysplasia
3146571|NCT01572974||High grade dysplastic BE|subject with columnar lined esophagus and presence of high grade dysplasia
3146572|NCT01572961|Active Comparator|Aspirin|Aspirin
3146573|NCT01572961|Placebo Comparator|Placebo|Placebo
3146574|NCT01572948|Placebo Comparator|Placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient.
3146575|NCT01572948|Active Comparator|Daliresp|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
3146953|NCT01570452||cancer patient I-II stage|Patients affected by colonic cancer in I-II stage
3146576|NCT01572922|Other|Iron-overloaded|"Patients with iron overload or excessive body iron burden, a serious condition resulting from increased dietary gastro¬intestinal absorption, multiple erythrocyte transfusions, or both.~Interventions: R2*-UTE, R2*-GRE, and if clinically indicated, liver biopsy."
3146577|NCT01572922|Other|Healthy volunteers|"Healthy volunteers without iron overload.~Interventions: R2*-UTE, R2*-GRE"
3146578|NCT01572909|Active Comparator|Bendavia™|
3146579|NCT01572909|Placebo Comparator|Placebo|
3146580|NCT01572896|Experimental|Taking Charge Experimental Group|
3146581|NCT01572896|Active Comparator|Control Group|
3146582|NCT01572870||No ABPA nor Aspergillus infection|CF patients who had neither ABPA nor Aspergillus infection in the past (the control group)
3146583|NCT01572870||persistent Aspergillus infection, without ABPA|CF patients with persistent Aspergillus infection, without ABPA.
3146584|NCT01572870||Current or past ABPA infection|CF patients with current or past ABPA
3146585|NCT01572857||first phase|"This first phase aims to study the variations in urinary excretion of FLC immunoglobulin during the day and night to determine the appropriate time of day for collection of urine.~20 patients hospitalized."
3146586|NCT01572857||Second phase|"Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row. This value will check the quality of urine collection for 24 hours during the study.~30 patients hospitalized."
3146587|NCT01572844|Experimental|Treatment lesion|Lesion A, target lesion, 2cm x 2cm (+/- 1cm) treated with 1 pass Fractionated Carbon Dioxide (FCO2) Laser followed by application of 4 ml of 5% topical sodium thiosulfate solution (STS), 8 to 10 treatments over 6 months.
3146588|NCT01572844|No Intervention|No Treatment Lesion|Lesion B, similar area of calcinosis on the same patient, which did not receive treatment is evaluated.
3146589|NCT01572831|No Intervention|standard care|Abx will be determined by the managing physician
3146590|NCT01572831|Experimental|experimental arm|Abx determined by normalization of PCT and basic clinical parameters
3146591|NCT01572818|Experimental|Phlebotomy|phlebotomy associated with dietary and lifestyle counseling
3146592|NCT01572818|Active Comparator|Lifestyle counseling|dietary and lifestyle counseling
3146593|NCT01572805|Active Comparator|melatonin 3mg|
3146594|NCT01572805|Active Comparator|melatonin 6mg|
3146595|NCT01572805|Placebo Comparator|placebo|
3146596|NCT01572792|Experimental|1|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose
3146597|NCT01572792|Experimental|2|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose
3146598|NCT01572792|Active Comparator|3|Aclidinium bromide 400 μg
3146599|NCT01572792|Active Comparator|4|Formoterol Fumarate 12 μg
3146600|NCT01572792|Placebo Comparator|5|Placebo
3146601|NCT01572779|Experimental|Intervention|BSM device with bio-feedback
3146602|NCT01572779|Placebo Comparator|Control|The BSM device without feed-back
3146603|NCT01572766|Active Comparator|FRAX Assessment|FRAX Assessment Tool administered by a pharmacist. This group also receives a heel ultrasound and pharmacist counseling.
3146604|NCT01572766|No Intervention|Control group|Control group receives heel ultrasound and pharmacist counseling
3146605|NCT01572753|Experimental|Post-dose fasting 120 mins/50 ml water|
3146606|NCT01572753|Experimental|Post-dose fasting 60 mins/50 ml water|
3146607|NCT01572753|Experimental|Post-dose fasting 30 mins/50 ml water|
3146608|NCT01572753|Experimental|Post-dose fasting 15 mins/50 ml water|
3146609|NCT01572753|Experimental|Post-dose fasting 120 mins/120 ml water|
3146610|NCT01572753|Experimental|Post-dose fasting 60 mins/120 ml water|
3146611|NCT01572753|Experimental|Post-dose fasting 30 mins/120 ml water|
3146612|NCT01572753|Experimental|Post-dose fasting 15 mins/120 ml water|
3146613|NCT01572740|Experimental|Lira+Insulin|
3146614|NCT01572740|Placebo Comparator|Placebo+Insulin|
3146615|NCT01572727|Experimental|BKM120 and paclitaxel|Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel.
3146616|NCT01572727|Active Comparator|Placebo and paclitaxel|Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel.
3146617|NCT01572714|Active Comparator|Social Support Program|The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.
3146618|NCT01572714|Active Comparator|Physical Activity Program|The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.
3146619|NCT01572714|Active Comparator|Physical Activity Plus Fatigue|The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
3146620|NCT01572701|Experimental|20 (±3) mCi of study drug|
3146621|NCT01572688|Experimental|autologous stem cell transplant|
3146622|NCT01572675||Group Arcoxia®|Participants who were either previously treated with Arcoxia® or initiated on study treatment with Arcoxia®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use.
3146623|NCT01572675||Group Celebrex®|Participants who were either previously treated with Celebrex® or initiated on study treatment with Celebrex®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use.
3146726|NCT01571960|Experimental|Group 1: study vaccine|Participants in this arm will receive a 0.3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112, 168, and 224.
3146624|NCT01572662|Experimental|Fludarabine + Busulfan|"Fludarabine administered by vein at dose of 40 mg/m2 in 100 ml of normal saline (NS) on Days -6 through -3.~First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies."
3146625|NCT01572649|Placebo Comparator|Placebo|1 single administration (volume matched to the dose lixisenatide: 50 µL or 100µL) once a day subcutaneously
3146626|NCT01572649|Experimental|Dose 1|1 single administration of 5 µg lixisenatide (50 µL) once a day subcutaneously
3146627|NCT01572649|Experimental|Dose 2|1 single administration of 10 µg lixisenatide (100 µL) once a day subcutaneously
3146628|NCT01572636||Laronidase use in Hurler Syndrome|Laronidase receiving prior and post transplant
3146629|NCT01572623|Active Comparator|Antiplatelet before carotid artery stenting|Clopidogrel 600 mg after carotid artery stenting
3146630|NCT01572623|Active Comparator|Statin therapy before carotid artery stenting|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
3146631|NCT01572610|Experimental|RTA 402|
3146632|NCT01572597|Experimental|Acetylcystein|10-day triple therapy plus N-acetyl-cystein to remove the biofilm.
3146633|NCT01572597|Active Comparator|Metronidazole|10-day triple therapy plus metronidazole (concomitant therapy) as active comparator
3146634|NCT01572558|Active Comparator|Appendectomy|Standard surgical treatment, appendectomy
3146635|NCT01572558|Experimental|Conservative, non-surgical treatment|Non-operative treatment with intravenous and oral antibiotics
3146636|NCT01572545|Experimental|Denosumab|
3146637|NCT01572545|Experimental|Zoledronic Acid|
3146638|NCT01572532|Experimental|Intervention Screening and Treatment|"CHWs will collect urine and vaginal samples for all women enrolled. In the control clusters, every eighth woman enrolled will receive the screening-treatment protocol in order to determine the baseline prevalence of these infections in the control areas for comparison. Vaginal specimens will be collected via sterile self-administered vaginal swabs. The women will be instructed by the CHW to insert a Dacron swab ~4-5 cm into the vagina, allow the swab to stand for 15 seconds, and then rotate 360 degrees prior to withdrawal. The CHW will gently roll out the swab onto a plain glass slide and allow to air dry prior to transport to Sylhet field laboratory.~A midstream urine specimen will be obtained for urine culture. The mother will be instructed to separate the labia and collect 20-30mL of midstream urine into a sterile container which will be immediately refrigerated in a cool specimen box."
3146639|NCT01572532|No Intervention|Control Arm|Standard care will be administered, including antenatal and postnatal care. In the control clusters, every eighth woman enrolled will receive the screening-treatment protocol in order to determine the baseline prevalence of these infections in the control areas for comparison.
3146640|NCT01572519|Experimental|JNJ-40346527|
3146641|NCT01572506|Active Comparator|Group 1|Age 70 and older with unexplained
3146642|NCT01572506|Active Comparator|Group 2|Age 70 and older with iron deficient
3146643|NCT01572506|Active Comparator|Group 3|Age 70 and older without anemia
3146644|NCT01572506|Active Comparator|Group 4|Age 18 - 50 without anemia
3146645|NCT01572493|Experimental|Arm A1 (Dose Escalation, 10-day Dosing)|MTD determination in subjects with metastatic cancers receiving rhIL-15 IV for 10 consecutive days
3146646|NCT01572493|Experimental|Arm A2 (Dose Expansion, 10-day Dosing)|Clinical activity evaluation in subjects with metastatic cancers receiving rhIL-15 IV for 10 consecutive days
3146647|NCT01572493|Experimental|Arm B1 (Dose Escalation, 5-day Dosing)|MTD determination in subjects with metastatic unresectable cancers receiving rhIL-15 IV for 5 consecutive days
3146648|NCT01572493|Experimental|Arm B2 (Dose Expansion, 5-day Dosing)|Clinical activity evaluation in subjects with metastatic cancers receiving rhIL-15 IV for 5 consecutive days
3146649|NCT01572480|Experimental|A|Carfilzomib (IV, Days 1, 2, 8, 9, 15, and 16 of the 28-day cycle); Revlimid (PO, Days 1- 21 of the 28-day cycle; exception: not given on cycle 1 day 1); and, Dexamethasone (PO or IV, Days 1, 2, 8, 9, 15, 16, 22, and 23 of the 28-day cycle; exception: not given on cycle 1 day 1)
3146650|NCT01572480|Experimental|B|Carfilzomib (IV, Days 1, 2, 8, 9, 15, and 16 of the 28-day cycle); Revlimid (PO, Days 1- 21 of the 28-day cycle); and, Dexamethasone (PO or IV, Days 1, 2, 8, 9, 15, 16, 22, and 23 of the 28-day cycle)
3146651|NCT01572454|Experimental|Dexmedetomidine group|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
3146652|NCT01572454|Active Comparator|Remifentanil group|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
3146653|NCT01572441||12-14 year olds|No intervention administered. This is a longitudinal observational study including observation of behaviors and physiological responses.
3146654|NCT01572428|Active Comparator|Narrow-Band Imaging (NBI)|Inspection with Narrow-Band Imaging(NBI) versus inspection with standard white light(usual care)
3146655|NCT01572428|Active Comparator|Standard White Light|Inspection with Standard White Light versus Narrow-Band Imaging(NBI)
3146656|NCT01572402|Experimental|Patients with type 2 diabetes|Study group: 40 individuals with type 2 diabetes treated by diet and/or oral hypogylycemic agents, diabetes duration at least 1 year, both men and women, age 30-65 years, BMI 27-50 kg/m². The subjects will be explained aims, methods and risks of the study and they will sign informed consent
3146657|NCT01572402|Active Comparator|Healthy subjects|Mean and women, age 30-70 years, no diabetes, no metabolic syndrome
3146658|NCT01572389|Experimental|Arm 1: HOPE|The Healthy Outcomes through Patient Empowerment (HOPE) intervention group is the intervention arm which will employ behavioral health coaching telephone sessions. Tele-coaching is a theoretically grounded, structured processes guided by intervention manuals.
3146659|NCT01572389|Active Comparator|Arm 2: EUC|The Enhanced Usual Care (EUC) group will serve as a concurrent control group to compare to the intervention arm of the study. Participants are screened for diabetes self-management behaviors and control and for active depressive and anxiety symptoms. Primary care providers are alerted of the patients' status and given decision support to enhance care for these uncontrolled conditions.
3146728|NCT01571960|Experimental|Group 2: study vaccine|Participants in this arm will receive a 3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112, 168, and 303.
3146660|NCT01572376|Experimental|Bone marrow stem cells|Bone marrow was obtained by posterosuperior iliac crest aspiration under topical anesthesia. Mononuclear cells were isolated by Ficoll density gradient and will be resuspended in heparinized isotonic saline for infusion into the wound.
3146661|NCT01572363|Experimental|Sildenafil|All patients will be given Sildenafil 50 mg with evaluation of pulmonary vascular resistance and systemic ventricular function at rest and during exercise after 30 minutes.
3146662|NCT01572350|Active Comparator|Grid laser|It's a reference standard as the treatment which is currently accepted for NTDDME
3146663|NCT01572350|Experimental|Triamcinolone 4 mg|
3146664|NCT01572350|Experimental|Bevacizumab|
3146665|NCT01572337|Experimental|NIV|Non-invasive ventilation
3146666|NCT01572337|Other|Best available treatment|
3146667|NCT01572324|Experimental|Arterial infusion|
3146668|NCT01572311|Experimental|Exercise Intervention Group|For 26 weeks, attend Canadian Centre for Activity and Aging combined classes (75-minute or 60-minute classes, 2 to 3 days/week) and also complete 45 minutes of dual-task gait training (15 minutes for 3 days/week or 22.5 minutes for 2 days/week)
3146669|NCT01572311|Active Comparator|Exercise Control group|For 26 weeks, attend Canadian Centre for Activity and Aging combined classes (75-minute or 60-minute classes, 2 to 3 days/week) and also complete 45 minutes of gait training (15 minutes for 3 days/week or 22.5 minutes for 2 days/week). Note: no dual-task challenges during gait training
3146670|NCT01572298|Active Comparator|allograft alone|guided bone regeneration with allograft alone (includes tenting screws and overlying allograft membrane material)
3146671|NCT01572298|Experimental|allograft with autograft|guided bone regeneration with allograft and autograft combined (includes tenting screws and overlying allograft membrane material)
3146672|NCT01572285|Sham Comparator|Sham|Sham arm received a simulation of transforaminal injection using a non-penetrating needle
3146673|NCT01572285|Experimental|Transforaminal|Subjects received TF with infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml
3146674|NCT01572272||Open|Open group: Data derived from the Capnostream20p and displayed to the medical team. It will allow the treating physician and the nursing team to review the real time data and make clinical decisions based upon it if felt necessary.
3146675|NCT01572272||Masked|Data derived from the Capnostream20p will be recorded; however the medical staff will be masked from it and hence will not use it.
3146676|NCT01572259|Experimental|interruption of the growth hormone treatment.|
3146677|NCT01572259|Experimental|Patients traited by grouth hormone|
3146678|NCT01572246||Non-cardiac above-the-waist surgery|Subjects with an implanted ICD who present for a non-cardiac above-the-waist surgical procedure involving monopolar electrocautery
3146679|NCT01572246||Cardiac surgery|Subjects with an implanted ICD who present for a cardiac surgical procedure involving monopolar electrocautery
3146680|NCT01572246||Below-the-waist surgery|Subjects with an implanted ICD who present for a below-the-waist surgical procedure involving monopolar electrocautery
3146681|NCT01572233|Experimental|Patient with HCV Infection|Personalized Physical Activity and Psycho-Education (PPAPE) Program will be tested on this group.
3146682|NCT01572233|No Intervention|usual care|waiting list group with usual care
3146683|NCT01572220|Other|stress echocardiography|Comparative effectiveness
3146684|NCT01572220|Other|Myocardial SPECT|CER
3146685|NCT01572207|Experimental|Immediate Exercise|Subjects assigned to the immediate group will be prescribed a home exercise program during the first meeting. During the 12 week training period, the subject will read pamphlets (sent by mail) once to twice a month about developing skills to manage MS symptoms and motivational pamphlets about physical activity. In addition, the subject will have a phone conversation every two to three weeks with research staff to discuss the progress of the exercise program and to complete a short survey about his/her physical activity level.
3146686|NCT01572207|Experimental|Delayed exercise|Subjects assigned to the delayed group will be asked to begin the same home exercise program 12 weeks following the first meeting. During the 12 week training period, the subject will receive pamphlets, have phone conversations with research staff, and complete physical activity surveys as described above.
3146687|NCT01572181|Experimental|Drugs|Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)
3146688|NCT01572168|Experimental|Acupuncture|Eight sessions of weekly acupuncture
3146689|NCT01572155|No Intervention|Sham stimulation|No stimulation of nervus vagus
3146690|NCT01572155|Active Comparator|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
3146691|NCT01572155|Active Comparator|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
3146692|NCT01572142||Parkinson disease group|Subjects with Parkinson disease
3146693|NCT01572129|Experimental|Reload|600 mg of clopidogrel loading dose 6-8 h before coronary angiogram, in addition to the chronic daily dose of 75 mg
3146694|NCT01572129|Placebo Comparator|Placebo|Placebo arm in addition to the chronic daily dose of 75 mg
3146695|NCT01572116|Placebo Comparator|Lidocaine with Epinephrine+ Normal saline|
3146696|NCT01572116|Active Comparator|Lidocaine with Epinephrine + sufentanil|
3146697|NCT01572103|Experimental|Administration of coffee|Administration of 4 cups of coffee/day for 1 month
3146698|NCT01572103|No Intervention|Coffee abstinence|Total coffee and caffeine containing beverages abstinence
3146699|NCT01572090|Active Comparator|Conventional weight loss: CONV-NG|"Obese normoglycemic (NG) patients evidenced by a body fat ≥ 35% in women and ≥ 25% in men and a 2-h oral glucose tolerance test.~Conventional weight loss will be achieved by Lifestyle changes including advice on increasing physical activity and prescription of a hypocaloric diet providing a daily energy deficit of 500-1000 kcal/d as calculated from the determination of the resting energy expenditure through indirect calorimetry (Vmax29, SensorMedics Corporation, Yorba Linda, CA) and multiplication by the physical activity level factor to obtain the individual's total energy expenditure. Regular visits with the dietitian will be scheduled as in the surgical groups."
3146727|NCT01571960|Placebo Comparator|Group 1: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112, 168, and 224.
3146906|NCT01570777|Other|optimized medication regimen|optimized medication regimen
3146700|NCT01572090|Active Comparator|Conventional weight loss: CONV-T2D|"Obese type 2 diabetic (T2D) patients evidenced by a body fat >35% in women and ≥ 25% in men and proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice.~Conventional weight loss will be achieved by Lifestyle changes including advice on increasing physical activity and prescription of a hypocaloric diet providing a daily energy deficit of 500-1000 kcal/d as calculated from the determination of the resting energy expenditure through indirect calorimetry (Vmax29, SensorMedics Corporation, Yorba Linda, CA) and multiplication by the physical activity level factor to obtain the individual's total energy expenditure. Regular visits with the dietitian will be scheduled as in the surgical groups."
3146701|NCT01572090|Active Comparator|Laparoscopic Sleeve gastrectomy: SG-NG|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) normoglycemic (NG) patients (evidenced by a 2-h OGTT) undergoing a sleeve gastrectomy (SG). The Sleeve gastrectomy SG-NG involves the removal of the mayor curvature of the stomach. Via a laparoscopic approach. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
3146702|NCT01572090|Active Comparator|Laparoscopic Sleeve gastrectomy: SG-T2D|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) type 2 diabetic (T2D) patients with proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice undergoing a sleeve gastrectomy (SG). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
3146703|NCT01572090|Active Comparator|Laparoscopic R-Y gastric bypass: RYGB-NG|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) normoglycemic (NG) patients (evidenced by a 2-h OGTT) undergoing laparoscopic Roux-en-Y gastric bypass (RYGB). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
3146704|NCT01572090|Active Comparator|Laparoscopic R-Y gastric bypss: RYGB-T2D|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) type 2 diabetic (T2D) patients with proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice undergoing laparoscopic Roux-en-Y gastric bypass (RYGB). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
3146705|NCT01572077|Experimental|FTHA/GDF PET imaging|"This study plans to enrol 60 subjects with Type I pulmonary arterial hypertension (PAH) and 20 healthy, age and sex individuals to serve as normal controls. These subjects will have no known cardiac or pulmonary disease.~Both groups will undergo FTHA/FDG PET imaging."
3146706|NCT01572051|Experimental|Group 1A (3month plus phone)|This group will attend to two courses with a 3 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
3146707|NCT01572051|Experimental|Group 1B (3month no phone)|This group will attend to two courses with a 3 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
3146708|NCT01572051|Experimental|Group 2A (2month plus phone)|This group will attend to two courses with a 2 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
3146709|NCT01572051|Experimental|Group 2B (2month no phone)|This group will attend to two courses with a 2 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
3146710|NCT01572051|Experimental|Group 3A (1month plus phone)|This group will attend to two courses with a 1 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
3146711|NCT01572051|Experimental|Group 3B (1month no phone)|This group will attend to two courses with a 1 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
3146712|NCT01572051|Experimental|Group 4A (no course plus phone)|This group will NOT attend to any courses This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
3146713|NCT01572051|Experimental|Group 4B (no course no phone)|This group will NOT attend to any courses This group will NOT receive phone calls This group will only receive printed material This group will be reassessed in 6 months
3146714|NCT01572038|Experimental|Pertuzumab + Trastuzumab + Taxane|Participants will receive pertuzumab and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first. Taxane chemotherapy can be either docetaxel, paclitaxel or nab-paclitaxel as per investigator's choice.
3146715|NCT01572025|Experimental|DHEA supplementation|
3146716|NCT01572025|Placebo Comparator|Control|
3146717|NCT01572012|Experimental|Subcutaneous Administration|Ondansetron + Hylenex administered subcutaneously
3146718|NCT01572012|Experimental|Oral Administration|Ondansetron administered orally
3146719|NCT01572012|Experimental|Intramuscular Administration|Ondansetron administered intramuscularly
3146720|NCT01572012|Experimental|Intravenous Administration|Ondansetron administered intravenously
3146721|NCT01571999|Experimental|Severe renally impaired subjects|Approximately 9 subjects will complete each treatment arm
3146722|NCT01571999|Experimental|Matched healthy volunteers|Matched to the severe renal impairment subjects based on gender, ethnicity, body mass index (±15%) and age (±5 years). Approximately 9 subjects will complete each treatment arm
3148123|NCT01562561|Experimental|Rep + NPH|
3146729|NCT01571960|Placebo Comparator|Group 2: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112, 168, and 303.
3146730|NCT01571960|Experimental|Group 3: study vaccine|Participants in this arm will receive a 3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112 and 224.
3146731|NCT01571960|Placebo Comparator|Group 3: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112 and 224.
3146732|NCT01571947|Active Comparator|SFA|
3146733|NCT01571947|Active Comparator|MUFA|
3146734|NCT01571947|Active Comparator|PUFA|
3146735|NCT01571947|Active Comparator|CARB|
3146736|NCT01571934||Mild or moderate hemophilia A|Subjects with mild or moderate hemophilia A (fVIII activity 1-40%) who are scheduled to undergo surgery for which at least 5 consecutive days of fVIII replacement therapy is required.
3146737|NCT01571921|Experimental|Gamma-Delta Tocotrienol|
3146738|NCT01571921|Active Comparator|TRF|
3146739|NCT01571908|Experimental|Magnesium perfusion - Rocuronium|60 mg/kg of magnesium perfusion over 15 minutes before Anaesthesia. After Anaesthesia induction 0.6 mg/kg of Rocuronium intravenously
3146740|NCT01571908|Active Comparator|Placebo perfusion - Succinylcholine|1ml/kg of saline (placebo) over 15 minutes before Anaesthesia. After Anaesthesia induction 1 mg/kg of Succinylcholine intravenously
3146741|NCT01571895|Experimental|DF 2156A 150 mg|150 mg capsule twice a day (every 12 h) for a maximum of 14 days
3146742|NCT01571882|Experimental|1 = Tested product 1|
3146743|NCT01571882|Experimental|2 = tested product 2|
3146744|NCT01571882|Active Comparator|3 = Active control product|
3146745|NCT01571869|Experimental|1 = Tested product|
3146746|NCT01571869|Placebo Comparator|2 = Control product|
3146747|NCT01571856|Active Comparator|zinc sulfate|zinc sulphate solution.
3146748|NCT01571856|Placebo Comparator|cornstarch solution|cornstarch powder diluted in distilled water
3146749|NCT01571843|Experimental|PHPT/ Walking + Forearm exercise|Ten participants with PHPT will be randomized to the intervention of 52 weeks of the forearm exercise program plus walking.
3146750|NCT01571843|Placebo Comparator|PHPT/ Walking alone|Ten participants with PHPT will be randomized to the intervention of 52 weeks of the walking program alone. Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks.
3146751|NCT01571843|Active Comparator|Osteopenia/ Walking + Forearm exercise|Ten healthy, postmenopausal women with osteopenia will be randomized to the intervention of 52 weeks of the forearm exercise program plus walking.
3146752|NCT01571843|Placebo Comparator|Osteopenia/ Walking alone|Ten healthy, postmenopausal women with osteopenia will be randomized to the intervention of 52 weeks of the walking program alone. Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks.
3146753|NCT01571804|Active Comparator|pregabalin 150 mg group|one capsule of pregabalin 150 mg and one placebo capsule
3146754|NCT01571804|Active Comparator|pregabalin 300 mg group|two capsules of pregabalin 150 mg
3146755|NCT01571804|Placebo Comparator|placebo group|to receive two identical placebo capsules
3146756|NCT01571791|Placebo Comparator|group SF|either saline infusion and intravenous fentanyl boluses
3146757|NCT01571791|Active Comparator|group KL|ketorolac-lidocaine infusion and intravenous saline boluses
3146758|NCT01571778|Experimental|Donning Gloves without Hand Hygiene|In this arm, healthcare workers will be assigned to don non-sterile gloves prior to patient contact WITHOUT first performing hand hygiene. Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
3146759|NCT01571778|No Intervention|Hand Hygiene before donning Non-Sterile Gloves|In this arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (This is usual,expected practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
3146760|NCT01571765|Experimental|MNCH programming|protocols and training for data collection, referrals, and management for health district. Training in obstetrics, newborn care and management of sick children for health workers, Increased community health promotion such as training of CHWs, health centre management teams and bednet distribution
3146761|NCT01571765|No Intervention|no added MNCH activities|
3146762|NCT01571713||Study|Pediatric patients with pulmonary hypertension
3146763|NCT01571700||Study|Patients with pulmonary hypertension.
3146764|NCT01571700||Control|ASD patients or patients with normal hearts
3146765|NCT01571687|Active Comparator|antioxidant supplements|800 I.E. Vitamin E, 1000mg Vitamin C, 200000 I.E. Vitamin A, 600mg Acetylcystein.
3146766|NCT01571687|Placebo Comparator|Placebo|identically appearing placebo
3146767|NCT01571674|Experimental|Manipulation + Exercise Group|The treatment received by the manipulation+exercise group will differ from the exercise group for the first week only (two treatment sessions). During the first two sessions, patients in the manipulation+exercise group will receive cervicothoracic spine manipulations and range of motion (ROM) exercises only. Beginning on the third session these patients will receive the same exercise program as the exercise group.
3146768|NCT01571674|Active Comparator|Exercise Group|The exercise group will be treated with a stretching and strengthening program.
3146769|NCT01571661|Experimental|Part A Treatment 1|GSK189075A 20mg
3146770|NCT01571661|Experimental|Part A Treatment 2|GSK189075A 50mg
3146771|NCT01571661|Experimental|Part A Treatment 3|GSK189075A 150mg
3146772|NCT01571661|Experimental|Part A Treatment 4|GSK189075A 500mg
3146773|NCT01571661|Experimental|Part A Treatment 5|GSK189075A 1000mg
3146774|NCT01571661|Placebo Comparator|Placebo|Placebo
3146775|NCT01571661|Experimental|Part B Low dose|low dose chosen from Part A
3146776|NCT01571661|Experimental|Part B High Dose|high dose chosen from Part A
3146777|NCT01571648|Experimental|Oral azacitidine|
3146952|NCT01570452||benign colonic tumor patients|patients affected by benign colonic tumor such as adenoma
3148124|NCT01562561|Active Comparator|NPH|
3146778|NCT01571635|Experimental|Sotatercept dose level 0.1mg/kg|Experimental 0.1 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
3146779|NCT01571635|Experimental|Sotatercept dose level 0.3mg/ kg|Experimental 0.3 mg/kg - Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
3146780|NCT01571635|Experimental|Sotatercept dose level 0.5mg/kg|Experimental 0.5 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
3146781|NCT01571635|Experimental|Sotatercept dose level 0.75mg/kg|Experimental 0.75 mg/kg - Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
3146782|NCT01571635|Experimental|Sotatercept dose level 1.0mg/kg|Experimental 1.0 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
3146783|NCT01571635|Experimental|Sotatercept dose level 1.5mg/kg|Experimental 1.5 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
3146784|NCT01571622|Placebo Comparator|Water before breakfast|Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with 250 ml of water
3146785|NCT01571622|Experimental|Whey before breakfast|Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with Whey Protein Concentrate (WPC 80 %) 45 gr dissolved in 250 ml of water\
3146786|NCT01571609|Experimental|Carriers|
3146787|NCT01571609|Experimental|Non-carriers|
3146788|NCT01571596|Experimental|KRN23|Escalating doses of KRN23 (0.05, 0.10, 0.30, and 0.60 mg/kg) will be administered SC every 28 days (up to 12 doses)
3146789|NCT01571583|Experimental|Telaprevir+Peg-IFN-alfa-2a+Ribavirin|Patients will be treated for 12 weeks with telaprevir in combination with Pegylated interferon alfa-2a (Peg-IFN-alfa-2a) and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone.
3146790|NCT01571570|Experimental|Treatment A|Panel 1: single oral dose of 150 mg TMC435 150 mg capsule, fed
3146791|NCT01571570|Experimental|Treatment B|Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fasted
3146792|NCT01571570|Experimental|Treatment C|Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fed
3146793|NCT01571570|Experimental|Treatment D|Panel 2: single oral dose of 150 mg TMC435 150 mg capsule, fed
3146794|NCT01571570|Experimental|Treatment E|Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fasted
3146795|NCT01571570|Experimental|Treatment F|Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fed
3146796|NCT01571570|Experimental|Treatment G|Panel 3: single oral dose of 150 mg TMC435 150 mg capsule, fed
3146797|NCT01571570|Experimental|Treatment H|Panel 3: single oral dose of 150 mg TMC435 capsule concept K, fed
3146798|NCT01571570|Experimental|Treatment I|Panel 3: single oral dose of 150 mg TMC435 capsule concept L, fed
3146799|NCT01571557||OZURDEX®|OZURDEX® (dexamethasone 700 ug intravitreal implant) administered according to standard of care.
3146800|NCT01571544|Experimental|Thermal suit|Randomly selected half of the patients will use thermal suit prior to anesthesia, during the surgery and post anesthesia care unit.
3146801|NCT01571544|Active Comparator|Conventional clothing|Randomly selected half of the patients will use conventional clothing prior to anesthesia, during the surgery and post anesthesia care unit.
3146802|NCT01571518|Experimental|early injection|injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
3146803|NCT01571518|Sham Comparator|late injection|injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
3146804|NCT01571505|Experimental|IPV vaccination|Randomized IPV vaccination to children at the age of 39 weeks.
3146805|NCT01571505|Placebo Comparator|OPV vaccination|Randomized OPV vaccination to children at the age of 39 weeks.
3146806|NCT01571492|Experimental|L2 Paravertebral peripheral nerve block|L2 paravertebral peripheral nerve block catheter will be placed.
3146807|NCT01571492|Active Comparator|Continuous Lumbar plexus peripheral nerve block|Continuous unilateral lumbar plexus peripheral nerve block catheter will be placed.
3146808|NCT01571479|No Intervention|2-mm mini-instrument (M-LC)|M-LC is three-port laparoscopic cholecystectomy using a 2-mm mini-instrument.
3146809|NCT01571479|No Intervention|conventional instrument(C-LC)|C-LC is conventional three port laparoscopic cholecystectomy
3146810|NCT01571466|Experimental|Vaccine group|Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef) (MVA HIV-B)
3146811|NCT01571466|Placebo Comparator|Placebo|
3146812|NCT01571453|Experimental|Vortioxetine (Lu AA21004)|
3146813|NCT01571453|Active Comparator|Venlafaxine extended release|
3146814|NCT01571440|Placebo Comparator|No Soluble Corn Fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times daily.
3146815|NCT01571440|Active Comparator|12 g Soluble Corn Fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times daily
3146816|NCT01571427|Placebo Comparator|Control group|no daily conversational sessions with interviewers using webcam/internet. Weekly web-based heath form must be submitted using internet/PC. If not, subjects receive prompts from study personnel.
3146817|NCT01571427|Active Comparator|Active soocial engagement group|Active Social Engagement: Engage in 30 minutes conversation daily with interviewers using internet/webcam for 6 weeks
3146818|NCT01571414|Experimental|Arm 1A-EFV and PA-824|Participants will receive PA-824 on Days 1 to 7, no study medication on Days 8 to 21, EFV on Days 22 to 35, and EFV plus PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 7, 34, and 41 to 42.
3146819|NCT01571414|Experimental|Arm 1B-EFV and PA-824|Participants will receive EFV on Days 1 to 14, EFV plus PA-824 on Days 15 to 21, no study medication on Days 22 to 35, and PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 13, 20 to 21, and 42.
3146820|NCT01571414|Experimental|Arm 2A-LPV/r and PA-824|Participants will receive PA-824 on Days 1 to 7, no study medication on Days 8 to 21, LPV/r on Days 22 to 35, and LPV/r plus PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 7, 35, and 42.
3146821|NCT01571414|Experimental|Arm 2B-LPV/r and PA-824|Participants will receive LPV/r on Days 1 to 14, LPV/r plus PA-824 on Days 15 to 21, no study medication on Days 22 to 35, and PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 14, 21, and 42.
3146822|NCT01571414|Experimental|Arm 3-RIF and PA-824|Participants will receive PA-824 on Days 1 to 7, RIF on Days 8 to 14, and RIF plus PA-824 on Days 15 to 21. Inpatient study visits will occur at Days 7 and 21.
3146823|NCT01571401|Experimental|Supervised PA plus Exercise Counselling|Participants will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, this group will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at fitness centre. In order to achieve the physical activity guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed. In addition to the supervised sessions, traditional exercise counselling will be provided to teach proper technique, how to monitor intensity, and to progress PA safely and effectively to achieve the public health physical activity guidelines
3146824|NCT01571401|Experimental|Supervised PA plus behavioural counselling|"In addition to the same supervised PA sessions as the SPA group, participants in this group will receive six individual face-to-face behavioural counselling sessions with a physical activity specialist. These counselling sessions will be combined with the supervised PA sessions, and will be provided directly following the supervised PA session. Counselling strategies will be based on the TPB and will target the unique benefits of PA for kidney cancer survivors, strategies for making PA enjoyable, for overcoming barriers, for including social support from family and friends, time management, self-monitoring, goal setting, and planning."
3146825|NCT01571388|Experimental|Group 1|Healthy Subjects to receive dacomitinib
3146826|NCT01571388|Experimental|Group 2|Subjects with mildly impaired hepatic function to receive dacomitinib
3146827|NCT01571388|Experimental|Group 3|Subjects with moderately impaired hepatic function to receive dacomitinib
3146828|NCT01571375||FinnHEMS10|Patients Treated by Helsinki HEMS.
3146829|NCT01571375||FinnHEMS30|PAtients Treated by Tampere HEMS.
3146830|NCT01571362|Experimental|ALO-02|
3146831|NCT01571362|Placebo Comparator|Placebo|
3146832|NCT01571349||chronic ITP group|ITP patients with elevated level of vWF, ITP patients with preserved MA of thromboelastography
3146833|NCT01571349||acute ITP group|ITP patients with normal level of vWF, ITP patients with decreased MA of thromboelastography
3146834|NCT01571323|Active Comparator|Misoprostol|
3146835|NCT01571323|Active Comparator|Oxytocin|
3146836|NCT01571323|Active Comparator|Oxytocin and Misoprostol|
3146837|NCT01571310|Experimental|Omitted Breakfast|Experimental: The patients in Omitted Breakfast day will omit the breakfast and will continue the fast until noon. Thereafter will eat Lunch at 13;30 and Dinner at 19:00
3146838|NCT01571310|Active Comparator|Breakfast|The patients in Breakfast day will consume breakfast at 8:00 and then lunch at 13;30 and dinner at 19:00
3146839|NCT01571297|Active Comparator|RM-131|
3146840|NCT01571297|Placebo Comparator|Placebo|
3146841|NCT01571284|Experimental|Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)|Aflibercept 4 mg/kg IV infusion over 60 minutes followed by Irinotecan 180 mg/m^2 IV infusion over 90 minutes and Leucovorin 400 mg/m^2 IV infusion over 120 minutes at the same time followed by 5-Fluorouracil (5-FU) 400 mg/m^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until disease progression (DP), unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.
3146842|NCT01571271|Experimental|Electrohydraulic lithotripsy|Electrohydraulic lithotripsy: Lithotripsy will be performed using electrohydraulic method
3146843|NCT01571271|Experimental|Laser Lithotripsy|Laser Lithotripsy: Lithotripsy will be performed using laser method
3146844|NCT01571258|No Intervention|Control|
3146845|NCT01571258|Experimental|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
3146846|NCT01571245||Veterans with PTSD|Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) veterans who are ages 18 to 60 and currently in or about to start treatment for deployment-related Post-Traumatic Stress Disorder (PTSD) at the Central Arkansas Veterans Healthcare System Mental Health Clinics.
3146847|NCT01571232|Active Comparator|Ozurdex|Patients in this group receive Ozurdex at initial visit and at month 4
3146848|NCT01571232|Active Comparator|Avastin|Patients in this group receive Avastin Q1 month for 5 months.
3146849|NCT01571219|Experimental|CT-P13|
3146850|NCT01571206|Active Comparator|CT-P13|infliximab
3146851|NCT01571180||Gastric Bypass|Obese patients who have scheduled a gastric bypass
3146852|NCT01571167|Placebo Comparator|Placebo|
3146853|NCT01571167|Active Comparator|Varenicline 2 mg|
3146854|NCT01571167|Active Comparator|Varenicline 1 mg|
3146855|NCT01571141|Experimental|Monogin|
3146856|NCT01571141|No Intervention|No intervention|
3146857|NCT01571128|Experimental|Male-Specific Intervention Package|Gender-specific interventions targeted specifically for boys offered in an integrated services delivery modality. Cross-Sectional Arm.
3146858|NCT01571128|Experimental|Female-Specific Intervention Package|Gender-specific interventions targeted specifically for girls offered in an integrated services delivery modality. Cross-Sectional Arm.
3146859|NCT01571128|No Intervention|HIV Positive Cohort (Males and Females)|Behavioral data on HIV positive youth. Longitudinal Arm.
3146860|NCT01571128|Experimental|Pre-Exposure Prophylaxis (Females)|PrEP adherence and feasibility. Longitudinal Arm.
3146861|NCT01571128|Experimental|Cash Transfer Cohort (Females)|School attendance, behavioral data, and feasibility. Longitudinal Arm
3146862|NCT01571115|Active Comparator|Insomnia Stretching Exercise|This group will realize stretching exercise
3146863|NCT01571115|No Intervention|Control|This group will not realize any type of intervention.
3146864|NCT01571115|Active Comparator|Insomnia Physical Exercise|This group will realize resistance physical exercise
3146865|NCT01571102|Active Comparator|physiotherapy|Promote mobility, strength and stability and exercises to reduce pain and swelling depending on the phase of tissue repair and evolution of the patient.
3146866|NCT01571102|No Intervention|Rest|
3298008|NCT00472368|Experimental|LBH589|
3146867|NCT01571102|Active Comparator|Home exercises|Promote mobility, strength and stability and exercises to reduce pain and swelling depending on the phase of tissue repair and evolution of the patient.
3146868|NCT01571089|Experimental|DBT-inspired exposure treatment|DBT-inspired exposure treatment.
3146869|NCT01571076|Experimental|Group B - Severe Male Factor|PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)
3146870|NCT01571076|Experimental|Group B - Advanced Age|PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)
3146871|NCT01571076|Active Comparator|Group A - Advanced Age|Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Advanced Age group
3146872|NCT01571076|Active Comparator|Group A - Severe Male Factor|Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Severe Male Factor group.
3146873|NCT01571063|Experimental|Vitamin D3|
3146874|NCT01571063|Placebo Comparator|Placebo|
3146875|NCT01571050|Experimental|Fresh NaF/SiO2 toothpaste|
3146876|NCT01571050|Placebo Comparator|Purified water|
3146877|NCT01571050|Experimental|Aged NaF/SiO2 toothpaste|
3146878|NCT01571050|Experimental|Fresh MFP/CaCO3 toothpaste|
3146879|NCT01571050|Experimental|Aged MFP/CaCO3 toothpaste|
3146880|NCT01571037|Other|inhaled nebulized Milrinone|"Drug: Inhaled, nebulized, Milrinone~1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation."
3146881|NCT01571024|Experimental|BKM120 + mFOLFOX6|BKM120 + mFOLFOX6 in patients with advanced solid tumors including metastatic pancreatic cancer.
3146882|NCT01571011|Experimental|CURB Intervention|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
3146883|NCT01571011|Experimental|CURB Intervention (Wait List)|Same as the CURB Intervention arm, however, individuals assigned to this arm wait 3 months before receiving the intervention.
3146884|NCT01570998|Experimental|Treatment (IORT)|Patients undergo IORT in a single fraction over 15-40 minutes at the time of standard of care lumpectomy.
3146885|NCT01570985|Active Comparator|Steroid injection Without distension|Group 1 consists of patients receiving Triamcinolone acetonide 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and a total of 4 ml solution.
3146886|NCT01570985|Active Comparator|Steroid with distension|Patients in group 2 will receive intraarticular Triamcinolone Acetonide 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
3146887|NCT01570985|No Intervention|Control|Group 3 will serve as control group and patients in this group could receive any other treatment other than corticosteroid injections or per oral corticosteroid medication. The control group will remain without treatment with corticosteroids, in injection or tablet form till 61 days, which is also the last day of the outcome measurements.
3146888|NCT01570972|Other|MFG and GCBT|There is a single arm for this study. All participants will be able to participate in MFG and GCBT
3146889|NCT01570946|Experimental|Lifestyle modification|The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
3146890|NCT01570946|No Intervention|Standard Care|Baseline 30-minute interview delivering personalised diet and exercise advice supplemented with educational material on diabetes.
3146891|NCT01570933|Experimental|NAVAfirst|Starting crossover by NIVnava mode
3146892|NCT01570933|Active Comparator|Cpap first|Start crossover by Cpap on nasal canula
3146893|NCT01570920|Experimental|walking|a cohort of stroke patients trained during 3 month, based on walking
3146894|NCT01570881||Delirium,Nondelirium|those with delirium and those without delirium
3146895|NCT01570868|Experimental|Ponatinib|Ponatinib at a dose of 30 mg orally, once daily. If a dose is missed or vomited, the next dose should not be increased to account for missing a dose. Total duration of therapy 3 to 5 years.
3146896|NCT01570842|Other|Anthropometric Measurements; Tissue Samples|All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity. Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
3146897|NCT01570829|Experimental|Dietressa (1 tablet 6 times daily)|
3146898|NCT01570829|Placebo Comparator|Placebo (1 tablet 6 times daily)|
3146899|NCT01570816|Experimental|Experimental|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures
3146900|NCT01570803|Experimental|Complete SE Stent|study design is 2x2 randomization design. First, before randomization, stratification will be performed according to lesion length 15cm criteria at web-based computerized program. Patients will be randomized in a 1:1 manner according to different two (SMART versus Complete-SE) stents. And then, patients received aspirin and clopidogrel during one month. After one month from index procedure, patients were randomized to receive either clopidogrel group (clopidogrel will not be changed but continue) or cilostazol group (clopidogrel will be changed into cilostazol) in separate groups of SMART group and Complete SE group. Randomization procedure will be performed using a web-based program
3146901|NCT01570803|Active Comparator|SMART CONTROL Stent|same to Complete SE
3146902|NCT01570790|Experimental|Cohort 1|
3146903|NCT01570790|Experimental|Cohort 2|
3146904|NCT01570790|Experimental|Cohort 3|
3146905|NCT01570777|Experimental|Renal denervation|
3146907|NCT01570764|Experimental|Cyclophosphamide|Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
3146908|NCT01570764|Placebo Comparator|Placebo|Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
3146909|NCT01570751|Experimental|IDeg followed by IGlar|
3146910|NCT01570751|Experimental|IGlar followed by IDeg|
3146911|NCT01570725|Experimental|1|Virtual reality exposure to a relaxing virtual environment. The virtual experience will be provided using immersive equipment.
3146912|NCT01570725|Experimental|2|Exposure to relaxing music. The music will be selected between classical music tunes.
3146913|NCT01570712|Experimental|Housing First Program|
3146914|NCT01570712|Active Comparator|traditional French services|
3146915|NCT01570699||2: patients included in METHADOSE study|includes opiate-dependent patients substituted by methadone
3146916|NCT01570699||1: opiate-non dependent patients|Will be included in the COM ON study subjects who have consumed illicit opiates (heroin, methadone, buprenorphine or morphine) more than 10 times in their life, without ever having the DSM-IV criteria for opiate dependence or abuse
3146917|NCT01570686|Experimental|Aliskiren: Fed|Aliskiren 300 mg once daily, taken 30 minutes after start of light breakfast
3146918|NCT01570686|Experimental|Aliskiren: Fasting|Aliskiren 300 mg once daily taken after after an overnight fast
3146919|NCT01570673|Experimental|Group Urotherapy|Children in this arm wil receive group urotherapy in small groups with other children.
3146920|NCT01570673|Active Comparator|Individual urotherapy|Children will receive standard individual urotherapy in regular pediatric urology clinic.
3146921|NCT01570660|No Intervention|control group|parallel group without intervention
3146922|NCT01570647||Healthy controls|
3146923|NCT01570647||Chronic low back pain|
3146924|NCT01570647||restricted hamstrings|
3146925|NCT01570647||systemic scleroderma|
3146926|NCT01570647||joint hyperlaxity|
3146927|NCT01570634|Experimental|Open Label CASAD|Treatment with CASAD for 14 days
3146928|NCT01570608|Active Comparator|monotherapy arm|patients receiving 3 initial Ranibizumab injections, thereafter as needed
3146929|NCT01570608|Active Comparator|combined treatment arm|
3146930|NCT01570595|Experimental|Web-Based Intervention|This group will be asked to participate in the online quit smoking program. At their first visit, they will be given an ID number to log in to the quit smoking program, and they will complete their first log in with the research assistant. The online program is made up of 8 separate online sessions that are supposed to be completed approximately once per week. Each sessions is written to take an average reader 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. At the first visit, participants are asked to provide an email address and/or cell phone number so reminders can be sent, by email or text message, to complete the sessions. If participants are late completing a session, they may receive call from clinic staff as a reminder.
3146931|NCT01570595|Active Comparator|Standard Care|"This group will receive standard care for their smoking, including advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches)."
3146932|NCT01570582|Experimental|drug effect|"Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.~Subjects assigned to Arm II Gemcitabine and Latin Neople every week based on the first day of the outpatient / inpatient treatment receive it. The subjects first received Gemcitabine given over 30 minutes followed by 30 minutes will be administered Neople Latin week.~Gemcitabine and eighth day of the foreign / hospitalization are given over 30 minutes.~Regimen of the progression of the disease, the subject can not continue to deny or toxic dose every 3 weeks until at least 6 cycles should be administered to. Subjects completed six cycles of medication which responds subjects, the researchers believe it is necessary to sustain if the regimen is"
3146933|NCT01570569|Active Comparator|Omeprazole|
3146934|NCT01570569|Active Comparator|Losartan|
3146935|NCT01570569|Active Comparator|Dextromethorphan|
3146936|NCT01570569|Active Comparator|Caffeine|
3146937|NCT01570569|Active Comparator|Midazolam|
3146938|NCT01570556|Active Comparator|Patients with positive culture, treatment group|These asymptomatic patients with positive urinary culture, seven days of antibiotics will be given according to the bacteriogram sensitivity.
3146939|NCT01570556|No Intervention|Patients with positive culture, observation only|These asymptomatic patients with positive urine culture, will be observed only during the study period.
3146940|NCT01570543||orthopedic implants, no treatment|
3146941|NCT01570530|Active Comparator|Atorvastatin|Patients treated with atorvastatin
3146942|NCT01570530|Other|Without Atorvastatin|Patients treated without atorvastatin
3146943|NCT01570517|Experimental|Device implantation|Subjects are implanted with the study device.
3146944|NCT01570504|Experimental|ivermectin multiple doses|A dose of 200 mcg/kg of ivermectin given on days 1,2, 15 and 16
3146945|NCT01570504|Active Comparator|1 dose ivermectin|A single 200 mcg/kg dose of ivermectin
3146946|NCT01570491|Active Comparator|ultrasound-guided spinal anesthesia|Anesthesiologist will use ultrasound-guided technique for spinal anesthesia block placement.
3146947|NCT01570491|Placebo Comparator|standard spinal anesthesia|Anesthesiologist will use standard spinal anesthesia insertion technique for block placement.
3146948|NCT01570478|Experimental|Foster® NEXThaler®|Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
3146949|NCT01570478|Active Comparator|Seretide® Accuhaler®|Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
3146950|NCT01570465||All patients enrolled in the GIMEMA AML1310 study.|"All patients enrolled in the GIMEMA AML1310 study;~Signed written informed consent according to ICH/EU/GCP and national local laws."
3146951|NCT01570452||healthy volunteers|healthy subjects not affected by benign or malignant colonic disease
3146954|NCT01570452||cancer patients III-IV stage|Patients affected by colonic cancer in III-IV stage
3146955|NCT01570426||Bipolar Disorder|Children, 7- 17 years-old, who meet diagnostic criteria for bipolar disorder, Type 1
3146956|NCT01570426||ADHD/ADD|Children, 7-17 years-old, who meet diagnostic criteria for attention deficit/hyperactivity disorder (ADHD) OR attention deficit disorder (without hyperactivity)
3146957|NCT01570426||Generalized Anxiety Disorder (GAD)|Children, 7-17 years-old, who meet diagnostic criteria for Generalized Anxiety Disorder (GAD)
3146958|NCT01570426||Health Controls|Children, ages 7-17 years-old, without a history of psychiatric diagnosis
3146959|NCT01570413|Active Comparator|Pelvic Exam|Subjects receive pelvic exam
3146960|NCT01570413|Experimental|No Pelvic Exam|Subjects do not receive pelvic exam
3146961|NCT01570400|Experimental|CBM training program variant 1 + iCBT|Cognitive bias modification training program variant 1 combined with iCBT
3146962|NCT01570400|Experimental|CBM training program variant 2 + iCBT|Cognitive bias modification training program variant 2 combined with iCBT
3146963|NCT01570387|Experimental|Pom plus dex|Pomalidomide dexamethasone
3146964|NCT01570374|Experimental|iCBT|Receives treatment.
3146965|NCT01570374|No Intervention|Waiting list control group|The waiting list control group initially receives no treatment, but do weekly screenings. After 9 weeks, the control group receives the same treatment as the other study arm.
3146966|NCT01570361|Experimental|Catheter Ablation|Radiofrequency catheter ablation treatment in subjects with Paroxysmal Atrial Fibrillation (PAF)
3146967|NCT01570361|Active Comparator|Drug Treatment|Drug therapy (either rate or rhythm control) using current AF management guidelines
3146968|NCT01570348|Experimental|Treatment (allogeneic BMT)|"CONDITIONING THERAPY: Patients receive fludarabine phosphate IV over 30-60 minutes QD on days -6 to -2 and cyclophosphamide IV over 1-2 hours QD on days -6 and -5. Patients undergo total body irradiation on day -1.~TRANSPLANTATION: Patients undergo donor BMT on day 0.~IMMUNOSUPPRESSIVE THERAPY: Patients receive high-dose cyclophosphamide IV over 1-2 hours QD on days 3-4, tacrolimus IV daily or PO BID on days 5-180 with taper to day 365, and mycophenolate acid enteric coated or mycophenolate mofetil PO TID on days 0-35."
3146969|NCT01570309|Active Comparator|Ergocalciferol|50,000 units of ergocalciferol once a week for 12 weeks
3146970|NCT01570309|Placebo Comparator|Sugar pill|
3146971|NCT01570296|Experimental|Gefitinib and BKM120|"Patients with NSCLC who progress on treatment with single-agent EGFR TKI (e.g., gefitinib or erlotinib), and meet the clinical definition of EGFR TKI resistance (Jackman et al., 2010):~A tumour that harbours an EGFR mutation known to be associated with drug sensitivity~Previous objective clinical benefit from treatment with an EGFR TKI~Patients should have systemic progression of disease (by RECIST) while on continuous treatment with gefitinib or erlotinib. Patients that have previously progressed on EGFR TKI (not in the preceding line of treatment) may also be enrolled and will receive gefitinib and BKM120 sequentially.~Patients with any solid tumour-type and activated PI3 kinase pathway and historically known to over express EGFR may also be recruited.~Once the RP2D is reached, an expansion cohort of 40 patients will be accrued for extended safety experience and to ascertain preliminary activity."
3146972|NCT01570283|Experimental|Multivirus-specific T cells|Multivirus-specific T cells given intravenously
3146973|NCT01570270|Experimental|regular cheese|This study was a 3-week, randomized, single blind, controlled, cross over clinical trial. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks −1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. T
3146974|NCT01570257|No Intervention|control group|These patients receive a shunt with the valve preset and fixed at a Performance level of 1.0, corresponding to an opening/closing pressure of 35-55 mm H2O.
3146975|NCT01570257|Experimental|Intervention group|These patients receive a shunt with the valve preset at a Performance level (PL) of 2.5, corresponding to an opening/closing pressure of 135-155 mm H2O. The PL is allowed to be lowered until clinical improvement occurs.
3146976|NCT01570244|Experimental|Reference|multiple doses of Microgynon
3146977|NCT01570244|Active Comparator|Test|multiple doses of Microgynon + BI 201335
3146978|NCT01570231|Experimental|bilateral limb ischemic preconditioning (BLIPC)|5 minutes bilateral limb ischemic preconditioning treatment with an inflating tourniquets to 200 mmHg
3146979|NCT01570231|No Intervention|Control group|underwent equivalent medical treatments only
3146980|NCT01570218|Experimental|Music therapy|Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days.
3146981|NCT01570218|No Intervention|Control|
3146982|NCT01570205|Experimental|XG-102 10 µg/kg|
3146983|NCT01570205|Experimental|XG-102 40 µg/kg|
3146984|NCT01570205|Experimental|XG-102 80 µg/kg|
3146985|NCT01570205|Placebo Comparator|placebo|
3146986|NCT01570192|Experimental|IV meropenem; parenteral aminoglycoside|"Subjects assigned to this group will receive:~IV meropenem (2 g infused over 3 hrs q 8 hr);~a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)~tobramycin nebulization~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat potential Gram-positive pathogens."
3146987|NCT01570192|Active Comparator|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat Gram-positive pathogens.~**NOTE: Empiric MRSA coverage is allowed in both arms. This therapy is advised for any subjects with known or suspected MRSA entering the study. Once microbiologic results are available, this coverage may be discontinued at the investigator's discretion."
3146988|NCT01570179|Experimental|deep block ideal body weight|
3146989|NCT01570179|Active Comparator|deep block real body weight|
3146990|NCT01570179|Experimental|moderate block ideal body weight|
3146991|NCT01570179|Active Comparator|moderate block real body weight|
3146992|NCT01570166|Experimental|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
3146993|NCT01570166|Experimental|HR group|HR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
3146994|NCT01570153||ADHF patients|
3146995|NCT01570140||Web portal users|T2DM patients in the primary care setting, using the web portal.
3146996|NCT01570127|Experimental|Individualized Acupuncture|The patients in this group received individualized acupuncture prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on the pattern diagnosis, which is an unique diagnosis system of Oriental Medicine.
3146997|NCT01570127|Experimental|Standardized Acupuncture|The patients in this group received standardized acupuncture treatment using the same acupuncture points, applied by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on literature review of RCTs.
3146998|NCT01570127|Sham Comparator|Sham acupuncture|Non-penetrating acupuncture device, Park-sham acupuncture, was applied to the patients. The appearance of the acupuncture is same but the needles do not penetrate the skin.
3146999|NCT01570127|No Intervention|Waiting|No interventions were applied to the patients in this group. Only assessments were made at each visit.
3147000|NCT01570114||covered metallic stent|Endoscopically insertion of fully covered metallic stent on benign colonic strictures
3147001|NCT01570101|Experimental|CE Marked Sapheon Closure System in GSV|"CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting."
3147002|NCT01570088|Active Comparator|Folic acid|
3147003|NCT01570088|Experimental|L-5-MTHF|
3147004|NCT01570088|Placebo Comparator|Placebo|
3147005|NCT01570075|Experimental|RFA group|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
3147006|NCT01570075|Experimental|HR group|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
3147007|NCT01570062|Active Comparator|Indoor Air HEPA Filtration|HEPA filters will be placed in participant's main living area and bedroom. Actual filtration will occur during only one of the two 7-day sampling periods.
3147008|NCT01570062|Placebo Comparator|HEPA Filtration Placebo|For one of two 7-day sampling sessions, HEPA filters placed in participants' homes will be run without an actual filter in the housing unit.
3147009|NCT01570049|Experimental|Bendamustine|Dose of 120 mg/m2/day on Day 1 and Day 2 of each treatment cycle (every 21 days), to a maximum of 8 cycles.
3147010|NCT01570036|Experimental|Herceptin + NeuVax vaccine|Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year; the first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive vaccinations of NeuVax vaccine administered intradermally every 3 weeks for 6 total vaccinations, 30-120 minutes after completion of Herceptin infusion. The NeuVax vaccine series will begin immediately after completion of the third Herceptin infusion, but may be delayed to the fourth or fifth Herceptin infusion with prior approval from the PI. Patients will be blinded regarding assigned arm. After completion of primary vaccine series, patients will receive 4 NeuVax vaccine booster inoculations to be administered every 6 months x 4 for total treatment duration of 30 months.
3147011|NCT01570036|Active Comparator|Herceptin + GM-CSF only|Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year. The first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive inoculations of GM-CSF only (250mcg) administered intradermally every 3 weeks for 6 total inoculations, 30-120 minutes after completion of Herceptin infusion. The GM-CSF only inoculation series will begin immediately after completion of the third Herceptin infusion. Patients will be blinded as to whether they are receiving NeuVax vaccine or GM-CSF only. After completion of six-inoculation primary vaccine series, patients will then receive a total of four GM-CSF only booster inoculations to be administered at 12, 18, 24, and 30 months from the date of the first Herceptin infusion.
3147012|NCT01570023|No Intervention|Standard Clinical Care|Standard swallowing intervention is that which is identified by the SLP as appropriate to treat the patient's dysphagia and is in common clinical practice. Such treatment would consist of dietary or postural compensatory strategies (i.e., chin down posture while swallowing).
3147013|NCT01570023|Experimental|Standard Clinical Care Plus Isometric Lingual Exercise|Standard Clinical Care Plus 8-week Isometric Lingual Exercise Regimen. The isometric tongue exercises will be completed using the Madison Oral Strengthening Therapeutic (MOST) device. Baseline maximum lingual pressure will be obtained at the anterior and posterior sensors independently by gathering two sets of data (3 MOST device trials) at each site (anterior and posterior) that differ by less that 5%. During week one of the regimen, the target value of each repetition will be 60% of the maximum baseline pressure. For the remaining seven weeks of the program, the target value will be increased to 80% of the maximum. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.
3147014|NCT01570010|Experimental|Intervention group|
3147015|NCT01570010|Other|Control group|Counseling on physical activity only
3147016|NCT01569997|Other|Intervention group|Intervention group: nursing homes whose residents benefit from MDTM to identify the cases of dementia and to propose an adequate care project
3147017|NCT01569997|No Intervention|control group|Control group: nursing homes whose residents continue to benefit from usual care
3147018|NCT01569984|Experimental|Avastin, SBRT|2 treatments of avastin followed by 6 treatments of SBRT every other day.
3147019|NCT01569971||Adolescents|Adolescents with SCD (all genotypes) age 12 years old up to 18 years old and currently receiving services through the St. Jude Children's Research Hospital Sickle Cell Disease Transition Program.
3147020|NCT01569971||Caregivers|Caregiver of an adolescent with SCD who has resided with the adolescent for at least two years prior.
3147021|NCT01569971||Young Adults|Young adults with SCD (all genotypes) age equal to 18 years up to and equal to 30 years of age who have transitioned to adult care.
3147022|NCT01569958|Active Comparator|tDCS|
3147023|NCT01569958|Sham Comparator|sham|
3147024|NCT01569945|Active Comparator|Tablets|Clomifen (5 days) followed by Ethinyl Estradiol (5 days)
3147025|NCT01569945|Active Comparator|human menopausal gonadotropins|Daily Injections
3147026|NCT01569932||chemotherapy|Patients will be assessed both before and after they undergo treatment with chemotherapy.
3147027|NCT01569919|Experimental|TroVax®|In this single-arm study, all participants will receive 9 injections of the TroVax® vaccine, plus standard cisplatin and pemetrexed chemotherapy.
3147028|NCT01569906||UVB|Children with moderate to severe atopic eczema who undertook a standard course of narrowband Ultraviolet B (NBUVB) phototherapy
3147029|NCT01569906||Controls|Children with moderate to severe atopic eczema who were offered UVB but were unable to undertake treatment
3147030|NCT01569893|No Intervention|Control group|Usual care: treatment as usual
3147031|NCT01569893|Experimental|Self-monitoring for patients with Dibetes mellitus type 2|Self-monitoring for patients with Dibetes mellitus type 2
3147032|NCT01569867||statin|
3147033|NCT01569854||statin|
3147034|NCT01569841|Experimental|IDeg|
3147035|NCT01569841|Active Comparator|IGlar|
3147036|NCT01569828|Experimental|Renal Impaired Subjects|once daily administration of 400 mg LCZ696 for 5 days
3147037|NCT01569828|Experimental|Healthy Volunteers|once daily administration of 400 mg LCZ696 for 5 days
3147038|NCT01569815|Experimental|LCZ696 400 mg|LCZ696 400 mg once daily for 5 days
3147039|NCT01569802||screening|
3147040|NCT01569789|Active Comparator|Ear Stimulation|Comparing cytokine levels pre and post stimulation of the nerve in the ear
3147041|NCT01569789|Placebo Comparator|Calf Stimulation|Comparing cytokine levels pre and post stimulation of the placebo area on the calf
3147042|NCT01569776|Experimental|New Amino Acid formula|
3147043|NCT01569776|Active Comparator|Control formula|Commercially available Amino Acid infant formula
3147044|NCT01569763|Active Comparator|hysteroscopic rollerball resection/ablation|
3147045|NCT01569763|Experimental|Aurora Endometrial Ablation|
3147046|NCT01569750|Experimental|Ibrutinib|"Part 1 (Dose Escalation): Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) until maximum tolerated dose is achieved.~Part 2: Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP."
3147047|NCT01569737||ella|
3147048|NCT01569724|Experimental|bexarotene|
3147049|NCT01569711||Deep brain stimulation|
3147050|NCT01569698||extrarenal replacement therapy|Intermittent Hemodialysis, Continuous Renal Replacement Therapies, and Peritoneal Dialysis
3147051|NCT01569685|Active Comparator|Venlafaxine|6 months treament vith Venlafaxine (if patient has troubles sleeping in combination with Mianserine) in recommended dose in combination with Cognitive Behavioral Therapy
3147052|NCT01569685|Active Comparator|Sertraline|6 months treament vith Sertraline (if patient has troubles sleeping in combination with Mianserine) in recommended dose in combination with Cognitive Behavioral Therapy
3147053|NCT01569672|Active Comparator|Intervention Clinic|Patient Navigator matched with subjects. Patient Navigators will be matched with subjects at the intervention clinics and will assist patients with questions, issues or concerns with their cancer treatment/diagnosis or abnormal test results and followup test or treatments
3147054|NCT01569672|Placebo Comparator|Control Clinics|Subjects are mailed informational/educational materials.
3147055|NCT01569659|Active Comparator|Standard dose of lurasidone|
3147056|NCT01569659|Experimental|High dose of lurasidone|
3147057|NCT01569633|Placebo Comparator|Placebo|This group of infant will not receive any medication but sugar water or placebo
3147058|NCT01569633|Active Comparator|Metclopramide|This group of infants will receive Metoclopramide at 0.1mg/kg q8 hrs.
3147059|NCT01569633|Active Comparator|Erythromycin|mediaction used to treat feeding disorder
3147060|NCT01569620|Active Comparator|Culturally targeted print materials|Best clinical practices plus culturally print materials
3147061|NCT01569620|Active Comparator|Standard print materials|Best clinical practices plus standard print materials
3147062|NCT01569620|Active Comparator|Best clinical practices alone|Best clinical practices alone: This intervention arm includes best clinical practices (or standard/usual care at MSSM) and no additional print materials.
3147063|NCT01569607|Experimental|Hebbian-type Stimulation|Participants will be randomized to receive motor training with Hebbian-type stimulation.
3147064|NCT01569607|Sham Comparator|Sham Stimulation|Participants will be randomized to receive sham stimulation.
3147065|NCT01569594||Carotid Endarterectomy Subjects|
3147066|NCT01569581|Experimental|100U/0.5ml in 6-11 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
3147067|NCT01569581|Experimental|100U/0.5ml in 12-23 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
3147068|NCT01569581|Experimental|100U/0.5ml in 24-35 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
3147169|NCT01568996|Experimental|Low dose BSE-SFN|BSE-SFN will be orally administered at 50 µmol SFN for 28 days.
3147069|NCT01569581|Experimental|100U/0.5ml in 36-71 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
3147070|NCT01569581|No Intervention|0U/0.5ml in infants (6-11 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1750 infants aged 6-11 months old on day 0, 28
3147071|NCT01569581|No Intervention|0U/0.5ml in infants (12-23 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1750 infants aged 12-23 months old on day 0, 28
3147072|NCT01569581|No Intervention|0U/0.5ml in children (24-35 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1500 children aged 24-35 months old on day 0, 28
3147073|NCT01569581|No Intervention|0U/0.5ml in children (36-71 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1000 children aged 36-71 months old on day 0, 28
3147074|NCT01569568||Subjects with OTCD|"males and females ages 7-60 years with OTCD who are able to undergo MRI and cognitive testing MRI scanning~1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing"
3147075|NCT01569568||Healthy controls|"males and females ages 7-60 years who are healthy controls who are able to undergo MRI and cognitive testing MRI scanning~1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing"
3147076|NCT01569529||No ad exposure|Young adults, who enroll in the cessation program, one month prior to presenting the online advertisements (intervention).
3147077|NCT01569529||Ad exposure|Young Adults, who register for the cessation program, by clicking through the online advertisements (intervention).
3147078|NCT01569516|Experimental|low dose|1mg, tid
3147079|NCT01569516|Experimental|Moderate dose|2mg,tid
3147080|NCT01569516|Experimental|High dose|4mg,tid
3147081|NCT01569516|Placebo Comparator|Placebo|0 mg, tid
3147082|NCT01569503|Experimental|VSN|VNS therapy
3147083|NCT01569490|Experimental|Treatment incentives|Incentives for biochemical verification visits, treatment engagement, and abstinence
3147084|NCT01569490|Active Comparator|Attendance incentive|Incentives for only attending the biochemical verification visits
3147085|NCT01569477|Experimental|Treatment incentives|Incentives for biochemical verification visits, treatment engagement, and abstinence
3147086|NCT01569477|Active Comparator|Attendance incentive|Incentives for only attending the biochemical verification visits
3147087|NCT01569464|Active Comparator|Rotigotine|Rotigotine patches titrated from 1 mg/ 24 hr - 3 mg /24 hr or until effective or maximum dose is reached.
3147088|NCT01569464|Placebo Comparator|Placebo|"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours~7 weeks"
3147089|NCT01569451|Active Comparator|(Placebo and) Glatiramer Acetate|Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily.
3147090|NCT01569451|Experimental|Rituximab and Glatiramer Acetate (R-GA)|Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily. There is no placebo arm.
3147091|NCT01569438|Experimental|Gefapixant|
3147092|NCT01569438|Placebo Comparator|Sugar Pill|
3147093|NCT01569425|Experimental|Lifestyle counseling|Lifestyle counseling, with high calorie breakfast
3147094|NCT01569425|Active Comparator|Life Counseling|Diet with high calorie dinner
3147095|NCT01569412|Experimental|Ertumaxomab|Ertumaxomab administration during two treatment cycles will follow a predefined dose escalation scheme, consisting of 5 ascending doses per cycle with each infusion lasting 3 hours.
3147096|NCT01569399|Active Comparator|active rTMS|High frequency (10HZ) on the left DLPFC
3147097|NCT01569399|Placebo Comparator|sham rTMS|
3147098|NCT01569386|Experimental|low intensity physical activity|Daily low intensity physical activity by the half squat
3147099|NCT01569386|Active Comparator|stretch exercise and usual activity|They do whole body stretch exercise for 20 minute in a day
3147100|NCT01569373||Post allogeneic SCT patients|Patients who have undergone an allogeneic stem cell transplant.
3147101|NCT01569360|Active Comparator|Corset|the patients are assigned the use of a custome made corset during daytime
3147102|NCT01569360|No Intervention|No corset|the patients do not use a corset during daytime
3147103|NCT01569347||1: Cocaine users|Adults, cocaine users
3147104|NCT01569334|Other|HTC with Cardiac allograft vasculopathy|HTC:heart transplanted recipients
3147105|NCT01569334|Other|HTR without Cardiac allograft vasculopathy|
3147106|NCT01569334|Other|untransplanted|
3147107|NCT01569321|Experimental|Breast cancer|
3147108|NCT01569295|Experimental|Idelalisib+bendamustine+rituximab|Participants will receive idelalisib plus bendamustine and rituximab
3147109|NCT01569295|Placebo Comparator|Placebo to match idelalisib+bendamustine+rituximab|Participants will receive placebo to match idelalisib plus bendamustine and rituximab
3147110|NCT01569282|Active Comparator|Double bypass|
3147111|NCT01569282|Active Comparator|Stent Strategy|
3147112|NCT01569269|Experimental|Yoga|See intervention description
3147113|NCT01569269|Experimental|Meditation|See intervention description
3147114|NCT01569269|Experimental|Reiki|see intervention description
3147115|NCT01569269|Active Comparator|Holistic Education|see intervention description
3147116|NCT01569256|Active Comparator|Cabergoline administered group|"The patients in this group will have cabergoline (Dostinex tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days) for prevention of OHSS.~All patients were administered long luteal protocol for ovulation induction."
3147117|NCT01569256|No Intervention|Control arm|"The patients in the control group had no manipulation for prevention of OHSS and age-, BMI-matched with the active comparator group.~All patients were administered long luteal protocol for ovulation induction."
3147118|NCT01569243|Other|Usual care group|Subjects in this group will receive the usual standard of care available at MGH.
3147170|NCT01568996|Experimental|Mid dose BSE-SFN|BSE-SFN will be orally administered at 100 µmol SFN for 28 days.
3147171|NCT01568996|Experimental|High dose BSE-SFN|BSE-SFN will be orally administered at 200 µmol SFN for 28 days.
3299003|NCT00460538|Placebo Comparator|2|
3147119|NCT01569243|Experimental|Text messaging group|Subjects in this group will be enrolled to receive text messages aimed at providing bite-sized coaching based on measured step count to help improve activity levels and providing reminder, educational and motivation messages aimed at helping patients to meet their diabetes self-management goals.
3147120|NCT01569230|Experimental|Individualized acupuncture|The patients in this group received individualized acupuncture prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on the pattern diagnosis, which is an unique diagnosis system of Oriental Medicine.
3147121|NCT01569230|Experimental|Standardized Acupuncture|The patients in this group received standardized acupuncture treatment using the same acupuncture points, applied by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on literature review of RCTs.
3147122|NCT01569230|Sham Comparator|Sham acupuncture|Non-penetrating acupuncture device, Park-sham acupuncture, was applied to the patients. The appearance of the acupuncture is same but the needles do not penetrate the skin.
3147123|NCT01569230|No Intervention|Waiting|No interventions were applied to the patients in this group. Only assessments were made at each visit.
3147124|NCT01569217||respiratory muscle dysfunction patients|Neuromuscular patients
3147125|NCT01569217||diaphragmatic dysfunction|patients who present orthopnea, recruitment of accessory muscles, abdominal paradox, respiratory dysfunction or dyssynchronous movement
3147126|NCT01569204|Active Comparator|BrECAPP|modified BEACOPP by omitting Bleomycin and adding Brentuximab Vedotin
3147127|NCT01569204|Active Comparator|BrECADD|modified BEACOPP by omitting Bleomycin, Procarbazine and Prednisone and adding Brentuximab Vedotin, Dacarbazine and Dexamethasone
3147128|NCT01569191|No Intervention|No Treatment|Exposure to grass pollen only
3147129|NCT01569191|Active Comparator|Artificial Tear Supplement|Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006
3147130|NCT01569191|Active Comparator|Cold compress|Cooled gel eye mask http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
3147131|NCT01569191|Active Comparator|Anti-allergic Medication|ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis
3147132|NCT01569178|No Intervention|standard care|optimal standard care post myocardial infarction
3147133|NCT01569178|Experimental|Intracoronary Reinfusion of Cells|Bone marrow-derived progenitor cells aspiration and Intracoronary reinfusion of the cells
3147134|NCT01569165|Experimental|washing after 30 min|washing with water after 30 min following APF treatment
3147135|NCT01569165|Experimental|washing after 15 min|washing with water after 15 min following APF treatment
3147136|NCT01569165|Experimental|immediately washing with water|immediately washing with water after APF treatment
3147137|NCT01569165|Experimental|cleansing teeth with cotton roll|cleansing teeth with cotton roll immediately following APF treatment
3147138|NCT01569165|No Intervention|no fluoride therapy|control group
3147139|NCT01569152|Experimental|Base Study Phase IIa: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
3147140|NCT01569152|Placebo Comparator|Base Study Phase IIa: Placebo|Participants received placebo dosed BID orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
3147141|NCT01569152|Experimental|Safety Extension Period 3: MK-8457|Participants received MK-8457 100 mg BID orally with MTX at the stable dose received upon study enrollment. Period 3 was to last up to 2 years.
3147142|NCT01569139||GPRD MI|Myocardial infarction, as identified in the GPRD data.
3147143|NCT01569139||MINAP MI|Myocardial infarction, as identified in MINAP data.
3147144|NCT01569139||HES MI|Myocardial infarction, as identified in HES data.
3147145|NCT01569126|Experimental|5 milligrams (mg) LY110140 (SD)|5 mg administered once in the fasted state on Day 1
3147146|NCT01569126|Experimental|20 mg LY110140 (SD)|20 mg administered once in the fasted state on Day 1
3147147|NCT01569126|Experimental|40 mg LY110140 (SD)|40 mg administered once in the fasted state on Day 1
3147148|NCT01569126|Placebo Comparator|Placebo (MD)|Placebo once daily oral dosing for 28 consecutive days
3147149|NCT01569126|Experimental|20 mg LY110140 (MD)|20 mg once daily oral dosing for 28 consecutive days
3147150|NCT01569126|Experimental|40 mg LY110140 (MD)|40 mg once daily oral dosing for 28 consecutive days
3147151|NCT01569113|Experimental|ellaOne + microgynon 30|
3147152|NCT01569113|Placebo Comparator|placebo + microgynon 30|
3147153|NCT01569087|Experimental|Empegfilgrastim 3 mg|Patients will receive a single administration of empegfilgrastim at a dose of 3 mg subcutaneously , 24 h after the chemotherapy
3147154|NCT01569087|Experimental|Empegfilgrastim 6 mg|Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy
3147155|NCT01569087|Active Comparator|Filgrastim|Patients will receive filgrastim subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy
3147156|NCT01569074|Experimental|Dosing A regimen|Oral treatment
3147157|NCT01569074|Experimental|Dosing B regimen|Oral treatment
3147158|NCT01569074|Experimental|Dosing C regimen|Oral treatment
3147159|NCT01569074|Experimental|Dosign D regimen|Oral treatment
3147160|NCT01569074|Placebo Comparator|Dosing E regimen|Oral treatment
3147161|NCT01569061|Active Comparator|Active Laser Group (ALG)|
3147162|NCT01569061|Sham Comparator|Sham Laser Group (SLG)|
3147163|NCT01569048|Active Comparator|remifentanil|
3147164|NCT01569048|Experimental|dexmedetomidine|
3147165|NCT01569035|Active Comparator|warfarin|oral anti coagulant
3147166|NCT01569022|Active Comparator|CPAP First, MAD|"CPAP treatment for sleep apnea~CPAP: CPAP Treatment for 12 weeks MAD: MAD treatment for 12 weeks"
3147167|NCT01569022|Experimental|MAD First, CPAP|"MAD treatment for sleep apnea~MAD: MAD Treatment for 12 weeks CPAP: CPAP treatment for 12 weeks"
3147168|NCT01569009||Observational|Patients are asked to continue with their normal daily activities.
3147172|NCT01568983|Placebo Comparator|Control|"12 weeks intake of 0.5 liter/day placebo juice containing sugar, aromas and salt corresponding to the berry juices in the other groups.~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
3147173|NCT01568983|Active Comparator|Mana-juice|"12 weeks intake of 0.5 liter/day of a commercially available berry juice (Mana blue) rich in polyphenols (grape, cherries, bilberries and aronia).~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
3147174|NCT01568983|Active Comparator|Optijuice|"12 weeks intake of 0.5 liter/day of berry juice rich in polyphenols (grape, cherries, blueberry and aronia) and added extract from press cake of black currant.~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
3147175|NCT01568970|Experimental|Return to work follow-up|Regular contact between the patient and his/her caretaker at the rehabilitation center over a 6 month period, including joint communication between patient, caretaker at the rehabilitation center and stake holders such as social security office, general practitioner and workplace.
3147176|NCT01568970|Active Comparator|Standard follow-up|Standard follow-up of the patient after ended rehabilitation by the return-to-work stakeholders, ie. the general practitioner, social security office and the employer. Limited contact between the caretaker at the rehabilitation center and the patient and stakeholders.
3147177|NCT01568957|Experimental|Dual-task gait training|Gait training with simultaneous performance of cognitive tasks for 75% of training session.
3147178|NCT01568957|Active Comparator|Single-task gait training|Gait training (without simultaneous cognitive task performance)
3147179|NCT01568944|Experimental|Oral Antibiotic and Oral Rinse|Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg
3147180|NCT01568944|Other|Standard Treatment|Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
3147181|NCT01568931|Active Comparator|Urokinase|Patients will be randomized to to receive local bolus of 200,000 units urokinase
3147182|NCT01568931|Active Comparator|Saline|Patients will be randomized to to receive local bolus of intracoronary saline
3147183|NCT01568918|Experimental|Tamsulosin|Participants randomized to this arm will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
3147184|NCT01568918|Placebo Comparator|Placebo|Participants randomized to this arm will receive a daily placebo capsule matching the active study drug from 5 days prior to the operation until hospital discharge.
3147185|NCT01568905|Experimental|Arm 1 Low Level Nicotine Cigarette|(0.4 mg/g)
3147186|NCT01568905|Experimental|Arm 2 Intermediate Nicotine Level Cigarette|(5.7-5.8 mg/g)
3147187|NCT01568905|Experimental|Arm 3 High Level Nicotine Cigarette|(11.4-12.8 mg/g)
3147188|NCT01568892|Experimental|DTG 50 mg BID|Subjects will receive dolutegravir (DTG) 50 milligrams (mg) twice daily (BID) and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the Double-blind (DB) Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.
3147189|NCT01568892|Experimental|Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase|Subjects will receive matching placebo BID and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the DB Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.
3147190|NCT01568879|Experimental|Gout Chronic Disease Management Program|
3147191|NCT01568879|Active Comparator|Usual Care|
3147192|NCT01568866|Experimental|Carfilzomib plus Dexamethasone|Participants received 20 mg/m² carfilzomib administered by intravenous (IV) infusion on Days 1 and 2 of Cycle 1, followed by 56 mg/m² on Days 8, 9, 15, and 16 of Cycle 1 and for each 28-day cycle thereafter. Additionally, participants received 20 mg dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28 day cycle.
3147193|NCT01568866|Active Comparator|Bortezomib plus Dexamethasone|Participants received bortezomib 1.3 mg/m² administered IV or subcutaneously (SC) on Days 1, 4, 8, and 11 of a 21-day cycle plus dexamethasone 20 mg administered on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
3147194|NCT01568840|Experimental|Global Postural Reeducation Group|Global Postural Reeducation
3147195|NCT01568840|Active Comparator|Segmental Exercises Group|Segmental Exercises
3147196|NCT01568827|Experimental|Blackraspberry slurry, washout, water|Blackraspberry slurry daily x 5 days, 2 day washout, 8 oz. water daily x 5 days
3147197|NCT01568827|Experimental|Water, washout, Blackraspberry slurry|8 oz. water daily x 5 days, 2 day washout, Blackraspberry slurry daily x 5 days
3147198|NCT01568814|Placebo Comparator|High volume PEG|Patients who are scheduled colonoscopy ingest high volume PEG(4L) for bowel preparation.
3147199|NCT01568814|Active Comparator|Low volume PEG with low residual meals|Patients who are scheduled colonoscopy ingest low volume PEG(2L) and have a prepackaged low residual meals for bowel preparation.
3147200|NCT01568801|No Intervention|Control Group|Individuals randomized into the control arm will receive usual community care services referred by the social worker from SGH and AH.
3147201|NCT01568801|Experimental|Intervention Group|Individuals in the intervention group will go through an integrated program of community based health and social care based on intake and ongoing evaluation by the SingaPACE team.
3147202|NCT01568788|Experimental|Inactivated Influenza Vaccine|15μg HA/strain/0.5ml/syringe, Hualan Biologicals
3147203|NCT01568788|Active Comparator|Inactivated Influenza Vaccine of Pasteur|15ug HA/strain/0.5ml/syringe, Sanofi Pasteur
3147204|NCT01568788|Active Comparator|Inactivated Influenza Vaccine of GSK|15ug HA/strain/0.5ml/syringe, GSK
3147205|NCT01568775|Experimental|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
3147206|NCT01568762|Experimental|VAK694|VAK694 was administered as a 1 hour intravenous infusion
3147207|NCT01568762|Placebo Comparator|VAK694 Placebo|VAK694 placebo was administered as a one hour intravenous infusion
3147208|NCT01568762|Experimental|QAX576|QAX576 was administered intravenously as a 2 hour infusion
3147209|NCT01568762|Placebo Comparator|QAX576 placebo|QAX576 placebo was administered as a 2 hour intravenous infusion
3147210|NCT01568749|Active Comparator|Standard paracetamol|Marketed formulation
3147211|NCT01568749|Experimental|Formulation 1|Paracetamol formulation 1
3147212|NCT01568749|Experimental|Formulation 2|Paracetamol formulation 2
3147213|NCT01568749|Experimental|Formulation 3|Paracetamol formulation 3
3147214|NCT01568749|Experimental|Formulation 4|Paracetamol formulation 4
3147215|NCT01568723||Radiofrequency ablation|participants with barrett's esophagus with high grade dysplasia who undergo radiofrequency ablation (RFA)
3147216|NCT01568606|Experimental|Body Composition Analysis InBody Scale|
3147217|NCT01568593|Experimental|T2750|
3147218|NCT01568593|Active Comparator|Vismed|
3147219|NCT01568580|Experimental|test drug|GreenGene
3147220|NCT01568567|Active Comparator|Double dose|One stick pack with active ingredients contains 1.0 g contains 75% GOS (galactooligosaccharide), 25% L-Rhamnose, 1x108 live bacteria (CFU) Lactobacillus reuteri and silicon dioxide
3147221|NCT01568567|Active Comparator|Single dose|One stick pack with active ingredients contains 1.0 g contains 75% GOS (galactooligosaccharide), 25% L-Rhamnose, 1x108 live bacteria (CFU) Lactobacillus reuteri and silicon dioxide
3147222|NCT01568567|Placebo Comparator|Placebo|One stick pack with placebo contains 1.0 g maltodextrin and silicon dioxide
3147223|NCT01568554||Group 1|Group 1 will include subjects 15 years of age or older who are a first-degree relative (child, sibling, parent, or grandparent) of an individual with genetically proven acute porphyria (AIP, HCP or VP), and have not had any previous genetic testing for porphyria themselves.
3147224|NCT01568554||Group 2 (Not Yet Enrolling)|Group 2 will consist of subjects 15 years of age or older who have a history of clinical features suggestive of acute porphyria, such as such as abdominal, back or limb pain, recurrent nausea lasting days, reaction to medications, psychiatric history, or sun sensitivity, and an increase in urinary, fecal or serum porphobilinogen (PBG) and/or porphyrins.
3147225|NCT01568554||Group 3|"Subjects in Group 3 will participate in the Follow Up Sub-Study. This group will include individuals who have been seen by one of the Porphyria Consortium physicians/investigators for suspicion of porphyria 10 or more years prior to study initiation, but were not given a diagnosis of porphyria at the time of their initial visit."
3147226|NCT01568541|Active Comparator|Children' toothpaste|Children's toothpastes
3147227|NCT01568541|Active Comparator|Regular toothpastes|Regular toothpastes
3147228|NCT01568528|Experimental|Oxytocin|The intranasal oxytocin intervention will be the administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. Each puff is 0.1ml in volume so the total volume administered will be 0.6 ml intranasally. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
3147229|NCT01568528|Placebo Comparator|Placebo|"Intranasal placebo The PBO/control will consist of the OT vehicle administered as three puffs in each nostril. Each puff is is 0.1ml in volume so the total volume administered will be 0.6 ml intranasally.~Treatment assignment will be by random allocation in blocks of six. Both experimenters and subjects will be blind to the treatment they are receiving."
3147230|NCT01568515|Experimental|Electronic Messages|Intervention group participants received electronic (text and/or email) reminder messages coupled with health educational messages about HPV and HPV vaccine across 7 months
3147231|NCT01568515|No Intervention|Standard of Care|Control group participants received standard of care at the student health center which included a card with their next appointment written on it.
3147232|NCT01568502||DSE|Patients, who underwent Dobutamine Stress Echocardiography (DSE)
3147233|NCT01568502||DSCMR|Patients, who underwent Dobutamine Stress Cardiac Magnetic Resonance (DSCMR)
3147234|NCT01568489|Experimental|HL-009 Liposomal Gel (0.07%)|
3147235|NCT01568489|Experimental|HL-009 Liposomal Gel (0.15%)|
3147236|NCT01568489|Experimental|HL-009 Liposomal Gel (0.30%)|
3147237|NCT01568489|Placebo Comparator|HL-009 Liposomal Gel (Placebo)|
3147238|NCT01568476|Active Comparator|Distal|Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation
3147239|NCT01568476|Active Comparator|Interneural|sciatic nerve blockade at the site of bifurcation
3147240|NCT01568450|Experimental|GL2907 XL 20mg (Oxycodone 20mg, fasted)|
3147241|NCT01568450|Experimental|GL2907 XL 20mg (Oxycodone 20mg, after high fat meal)|
3147242|NCT01568450|Active Comparator|Oxycontin CR 10mg (Oxycodone 10mg, fasted)|
3147243|NCT01568437|Active Comparator|Conventional management|On the ward, patients will be prescribed acetaminophen 1 g every 6 hours. If additional analgesia is required, patients will take oxycodone 5-10 mg up to every 2 hours or iv morphine. Patients with contraindications to oxycodone will be prescribed oral hydromorphone 1-2 mg instead. This is the current standard of care at Toronto Western Hospital.
3147244|NCT01568437|Experimental|TAP Block+Conventional Management|The TAP block will be performed after the induction, before the surgery, by an anesthesiologist with experience of at least 10 successful TAP blocks.Also patients will be prescribed acetaminophen 1 g every 6 hours. If additional analgesia is required, patients will take oxycodone 5-10 mg(oral hydromorphone 1-2 mg) up to every 2 hours or iv morphine.
3147245|NCT01568424|Other|Treatment Group|Patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.
3147246|NCT01568411|Active Comparator|TD-1211|
3147247|NCT01568411|Active Comparator|TD-1211+ itraconazole|
3147248|NCT01568398|Experimental|TAK-438 20 mg QD|
3147249|NCT01568385|Experimental|TAK-438 20 mg QD|
3147250|NCT01568372|Experimental|Nurse telephone follow-up|This group received a telephone follow-up by a nurse following discharge from the hospital and up until the 10th postoperative day, which is considered as the usual period of healing for a tonsillectomy
3147251|NCT01568372|No Intervention|Standard care group|This group received the standard care which consisted of an informative session before discharge and no follow-up once discharged home.
3147252|NCT01568359||Group 1 - Acromegaly, Group 2 - control|Group 1 - Acromegaly patients, Group 2 - Nonfunctioning pituitary adenoma patients (control)
3147253|NCT01568346|Active Comparator|MRI|MRI
3147254|NCT01568346|No Intervention|No MRI|No MRI
3147255|NCT01568333|Experimental|Decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
3147256|NCT01568320|Experimental|Endovascular|Endovascular Treatment (Zenith)
3147257|NCT01568294|Experimental|pomalidomide|Patients will receive pomalidomide orally on Days 1-21 of each 28-day cycle until when/if a discontinuation criterion, e.g., disease progression, development of an unacceptable toxicity, voluntary withdrawal, or pomalidomide is in market for the target indication.
3147258|NCT01568281|Experimental|1|2 way crossover
3147259|NCT01568281|Experimental|2|2 way crossover
3147260|NCT01568281|Experimental|3|2 way crossover
3147261|NCT01568281|Experimental|4|2 way crossover
3147262|NCT01568268|Experimental|Palonsetron|
3147263|NCT01568268|Placebo Comparator|Placebo|
3147264|NCT01568255|Experimental|Vitamin D Treatment|Vitamin D Treatment Group
3147265|NCT01568255|Placebo Comparator|Placebo Group|Placebo at 50,000IU for 8 weeks
3147266|NCT01568242|Experimental|Thermoprobe|Determination of vitreous temperature with a thermoprobe
3147267|NCT01568229|Experimental|AMG 747 - Dose 1|
3147268|NCT01568229|Experimental|AMG 747 - Dose 2|
3147269|NCT01568229|Experimental|AMG 747 - Dose 3|
3147270|NCT01568229|Placebo Comparator|Placebo Comparator|
3147271|NCT01568216|Experimental|AMG 747 - Dose 1|
3147272|NCT01568216|Experimental|AMG 747 - Dose 2|
3147273|NCT01568216|Experimental|AMG 747 - Dose 3|
3147274|NCT01568216|Placebo Comparator|Placebo Comparator|
3147275|NCT01568203|Experimental|AMG 579|
3147276|NCT01568203|Placebo Comparator|Placebo|
3147277|NCT01568190|Experimental|AVANZ|AVANZ Mites
3147278|NCT01568177|Other|abnormal CRT|"40 subjects with microvascular coronary dysfunction (MCD) defined as abnormal CRT.~Visits 1, 2, and 3"
3147279|NCT01568177|Other|Cardiac Syndrome X|20 subjects with symptoms and normal stress tests, no MCD. Visits 1 and 2
3147280|NCT01568177|Other|normal reference controls|40 normal reference controls subjects Visits 1 and 2
3147281|NCT01568164|Experimental|Device Treatment|Treatment with the investigational device.
3147282|NCT01568151|Active Comparator|Intervention Clinics|Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions(Clinic-directed intervention program)including: 1)provider-directed interventions; 2)office-based systems; and 3) waiting room materials. If the subjects have not undergone colorectal cancer screening after 12 months, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
3147283|NCT01568151|No Intervention|Usual Care Clinics|Subjects recruited at the Usual Care Clinics (Control Clinics) will not receive any study intervention. The results of how many subjects undergo colorectal cancer screening at the Usual Care Clinics will be compared to the number that undergo colorectal cancer screening at the Intervention Clinics.
3147284|NCT01568125||Incretin-related drugs|
3147285|NCT01568112|Experimental|BG00012|Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA placebo during the first 4 weeks.
3147286|NCT01568112|Placebo Comparator|Placebo|Participants received BG00012 placebo for 8 weeks and premedication with ASA placebo during the first 4 weeks.
3147287|NCT01568112|Experimental|BG00012 + ASA|Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA during the first 4 weeks.
3147288|NCT01568112|Experimental|BG00012 Slow Titration|Participants received BG00012 for 8 weeks (120 mg once daily [QD] during Week 1, 120 mg BID during Week 2, 240 mg AM/120mg PM during Week 3, and 240 mg BID during Week 4, and 240 mg BID during Weeks 5 to 8) and premedication with ASA placebo during the first 4 weeks.
3147289|NCT01568099|Experimental|A: AFFITOPE® PD01A + Adjuvant|4 injections of 15µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
3147290|NCT01568099|Experimental|B: AFFITOPE® PD01A + Adjuvant|4 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
3147291|NCT01568099|Other|Control|Untreated control group
3147292|NCT01568086||AFFITOPE AD03 with adjuvant|
3147293|NCT01568086||AFFITOPE AD03 without adjuvant|
3147294|NCT01568073|Experimental|BIA 9-1067|OPC, Opicapone
3147295|NCT01568073|Active Comparator|Entacapone|Comtan®; Active comparator
3147296|NCT01568073|Placebo Comparator|Placebo|PLC, Placebo
3147297|NCT01568060||Infanrix-IPV group|Infants and children who received at least one dose of Infanrix-IPV as a part of routine practice at a private clinic or hospital in korea
3147298|NCT01568047|Placebo Comparator|Placebo|"PLC, Placebo~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
3147299|NCT01568047|Experimental|BIA 9-1067 - 5 mg|"5 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
3147300|NCT01568047|Experimental|BIA 9-1067 - 15 mg|"15 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
3147301|NCT01568047|Experimental|BIA 9-1067 - 30 mg|"30 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
3147302|NCT01568034|Experimental|Treatment Sequence A|"Treatment Sequence A Period 1 - 25 mg BIA 9-1067 Period 2 - 50 mg BIA 9-1067 Period 3 - 100 mg BIA 9-1067 Period 4 - Placebo~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
3147303|NCT01568034|Experimental|Treatment Sequence B|"Treatment Sequence B Period 1 - Placebo Period 2 - 25 mg BIA 9-1067 Period 3 - 50 mg BIA 9-1067 Period 4 - 100 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
3147304|NCT01568034|Experimental|Treatment Sequence C|"Treatment Sequence C Period 1 - 100 mg BIA 9-1067 Period 2 - Placebo Period 3 - 25 mg BIA 9-1067 Period 4 - 50 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
3147305|NCT01568034|Experimental|Treatment Sequence D|"Treatment Sequence D Period 1 - 50 mg BIA 9-1067 Period 2 - 100 mg BIA 9-1067 Period 3 - Placebo Period 4 - 25 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
3147306|NCT01568021||OZURDEX®|Single dose of dexamethasone 700 ug intravitreal implant (OZURDEX®) which may be repeated over 1 year as per standard of care in clinical practice. No intervention was administered in this study.
3147307|NCT01568008||All participants|Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) eye drops at a dose and frequency as determined by the physician.
3147308|NCT01567995|Experimental|Clobetasone Butyrate 0.05% Cream|Clobetasone Butyrate 0.05% Cream
3147309|NCT01567995|Other|Vehicle (base cream)|Vehicle (base cream)
3147310|NCT01567982|Experimental|smokers and nonsmokers|both smokers and nonsmokers will receive same tDCS
3147311|NCT01567969|Experimental|IICAPS|Provision of Intensive In-home Child and Adolescent Psychiatric Service, a six to seven month family-focused in-home psychiatric intervention.
3147312|NCT01567969|Active Comparator|Home-based CTC|Provision of Home-based Child Treatment Coordination, a six to seven month child-focused case management service with monthly in-home visits with the child's parent/legal guardian.
3147313|NCT01567956|Experimental|Propionyl-L-Carnitine|Modified release tablets containing 500 mg of propionyl-L-carnitine
3147314|NCT01567956|Placebo Comparator|Placebo|Modified release tablets containing inert substances
3147315|NCT01567943|Experimental|Contingency Management|Contingency Management plus treatment as usual
3147316|NCT01567943|No Intervention|Non-contingent control group|Treatment as usual plus reinforcement for attendance
3147317|NCT01567917||Group A|"Patients who gave a permission to this study and underwent doppler US (Doppler US cohort~- Expected subject no.: 400 patients"
3147318|NCT01567917||Group B|"Patient who gave a permission to this study, but who did not receive doppler US (Although this group of patients did not undergo doppler US, these patients will be included as group B [simple observation cohort without doppler US examination])~- Expected subject no.: 200 patients"
3147319|NCT01567904|Experimental|Age group from 12 to 18 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
3147320|NCT01567904|Experimental|Age group from 6 to 12 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
3147321|NCT01567904|Experimental|Age group from 2 to 6 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
3147322|NCT01567904|Experimental|Age group from 3 months to 2 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
3147323|NCT01567904|Experimental|Age group from birth to 3 (<) months|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
3147324|NCT01567891|Experimental|Cohort 1|This is an open label clinical trial. Patients with the HLA-A201, HLA-A205, and/or HLA-A206 allele and whose tumor expresses the NY-ESO-1 tumor antigen will be eligible to receive NYESO-1c259 T cells.
3147325|NCT01567878||ankylosing spondylitis|It will be held ultrasound exam in enthesis and joints in patients with ankylosing spondylitis and healthy subjects
3147326|NCT01567878||Healthy pelople|It will be held ultrasound exam in enthesis and joints of healthy subjects
3147327|NCT01567865|Experimental|JE live attenuated SA 14-14-2 vaccine|
3147328|NCT01567852|Experimental|Ketamine First|This arm will receive ketamine for induction first, followed by alternating treatments between methohexital and ketamine
3147329|NCT01567852|Experimental|Methohexital First|This arm will receive Methohexital first for induction, followed by alternating treatments between ketamine and methohexital.
3147330|NCT01567839|Experimental|4% Lidocaine|1.8 mL of 4% lidocaine with 1:100,000 epinephrine
3147331|NCT01567839|Experimental|4% Articaine|1.8 mL of 4% articaine with 1:100,000 epinephrine
3147332|NCT01567839|Experimental|4% Prilocaine|1.8 mL of 4% prilocaine with 1:200,000 epinephrine
3147333|NCT01567826|Active Comparator|standard of care lipid therapy|standard-care lipid-lowering therapy: Zocor or Lipitor
3147334|NCT01567826|Experimental|aggressive lipid therapy|aggressive lipid therapy: Crestor
3147335|NCT01567813||Regimen Initiators|Any male health plan member who receives at least one dose of GARDASIL™
3147336|NCT01567813||Regimen Completers|Regimen Initiators who complete the 3-dose vaccination regimen within 12 months
3147337|NCT01567813||Autoimmune cohort|Regimen Initiators who were members of the health plan during the 12-month period prior to their first dose of GARDASIL™
3147338|NCT01567800|Experimental|PET FAZA imaging|PET FAZA imaging of tumor hypoxia in patients with prostate cancer
3147339|NCT01567787|Experimental|Proton Radiation for MPNST|Proton radiation 30 cobalt gray equivalent(CGE)at 6 CGE per fraction
3147340|NCT01567787|Experimental|Proton Radiation for neurofibromas|Proton radiation 25 cobalt gray equivalent(CGE) at 5 CGE per fraction
3147341|NCT01567774|Active Comparator|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
3147342|NCT01567774|Active Comparator|Rosuvastatin|Patients will receive randomly rosuvastatin (10 mg per day) for 30 days
3147343|NCT01567748||Hemodynamics Measured|The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
3147344|NCT01567735|Experimental|TMC435|
3147345|NCT01567709|Experimental|Treatment (alisertib, vorinostat)|Patients receive alisertib PO BID on days 1-7 or days 1-3 and 8-10, and vorinostat PO BID on days 1-14 or days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3147346|NCT01567683|Experimental|Limtop solution (imiquimod), Vehicle solution for topical use|
3147347|NCT01567670|Active Comparator|Naloxone|nasal spray before binging, naloxone dose 2 mg, maximum daily dose 4 mg
3147348|NCT01567670|Placebo Comparator|nasal spray|nasal placebo (h2o) spray before binging, max sprays / day
3147349|NCT01567657|Active Comparator|Pethidin plus midazolam|Initial dose of 25 mg Pethidin iv. plus 1-2 mg Midazolam iv. Additional Bolus of Midazolam (1 mg wise iv.) if needed, until a maximal dose of 7 mg Midazolam iv.
3147350|NCT01567657|Active Comparator|Propofol|Initial dose of Propofol of 50-60 mg iv. for patients 50 years or younger. Initial dose of Propofol of 30-40 mg iv. for patients over 50 years. If needed additional Bolus of 20-30 mg Propofol iv. as usual until sedation is achieved.
3147351|NCT01567644|Experimental|Active Shockwave Therapy|Patients in this group receive shockwave therapy.
3147352|NCT01567631|Experimental|intrahepatic Glisson's approach|
3147353|NCT01567631|Active Comparator|classical hepatectomy|
3147354|NCT01567605|Experimental|Lidocaine lubricant|In this arm, subjects will use lidocaine lubricant in their normal bowel care routine (rather than standard lubricating jelly).
3147355|NCT01567605|Placebo Comparator|Placebo lubricant|In this arm, subjects will use regular lubricant (AMG MedPro lubricating gel) in their normal bowel care routine.
3147356|NCT01567592|Experimental|Active Shockwave Therapy|Treatment group. Patients in this group receive actual shockwave therapy.
3147357|NCT01567566|Active Comparator|Local lumbopelvic stabilizers|
3147358|NCT01567566|Experimental|Local lumbopelvic plus hip stabilizers|
3147359|NCT01567553||Control group|Only unenhanced MR scanning will be performed in a control group of normal, age-matched subjects and after acceptance of the protocol by an independent ethical committee for the implication of a normal population in such an MRI research project.
3147360|NCT01567553||Experimental group|CIS at presentation (clinically isolated syndromes) will be recruited with MRI evidence of at least two asymptomatic brain MRI lesions. The group will compromise 50 CIS patients. These CIS patients will be included within three months after first clinical presentation.
3147361|NCT01567540|Experimental|DPPIV Inhibition|The study includes an initial phase of 3 weeks with administration of sitagliptin (100 mg/d) as monotherapy, followed immediately by 12 weeks of triple therapy (sitagliptin 100 mg/d combined with peg-IFN alfa-2a and ribavirin).
3147362|NCT01567527|Active Comparator|1|Active Comparator: Treatment of Aripiprazole IM Depot
3147363|NCT01567527|Placebo Comparator|2|Placebo Comparator: Treatment of IM Depot Placebo
3147364|NCT01567514|Active Comparator|Glass-ionomer cement lining|Presence of glass-ionomer cement lining in posterior resin composite restorations.
3147365|NCT01567514|No Intervention|No glass-ionomer cement lining|Absence of glass-ionomer cement lining in posterior resin composite restorations
3147366|NCT01567501|Experimental|Levocetirizine Dihydrochloride tablets 5 mg|Levocetirizine dihydrochloride Tablets, 5 mg of M/s Ipca Laboratories Limited, India
3147367|NCT01567501|Active Comparator|Xyzal|XYZAL (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA
3147368|NCT01567488|Experimental|Everolimus + Octreotide LAR treatment|
3147369|NCT01567475|Experimental|Everolimus and rituximab|
3147370|NCT01567462|Active Comparator|Monopolar Electrocautery|The current treatment standard of care for patients who present de novo or with a recurrent bladder tumor is transurethral resection of the bladder tumor (TURBT) using monopolar electrocautery in the form a 90-degree loop electrode and has been used since its introduction in 1952. This intervention, accomplished endoscopically through the urethra, is both diagnostic and potentially therapeutic. An adequately performed TURBT will provide the pathologist with enough tissue to provide tumor grade and stage information.
3147371|NCT01567462|Active Comparator|PK Button Vaporization Electrode|Bipolar energy has been available for many years and has been readily adopted for the surgical treatment of benign prostatic enlargement and may provide advantages and solutions to the technical challenges of monopolar electrocautery. A further refinement on bipolar energy has been the recent introduction of the PlasmaKinetic (PK) Button Vaporization electrode which will be used in the intervention arm of this study. This electrode is already approved by the Food and Drug Administration (FDA) for this indication as well. The semi-spherical design of the electrode creates a plasma arc that glides over the tissue, transmitting energy to the cell layers adjacent to the arc which are then quickly vaporized.
3147372|NCT01567449||the case group|The case group referred to SAH patients with aneurysm rebleeding
3147373|NCT01567449||the control group|the control group referred to SAH patients not with aneurysm rebleeding
3147374|NCT01567423|Experimental|Artesunate and Amodiaquine (ASAQ)|children receiving fixed-dose combination of artesunate and amodiaquine
3147375|NCT01567423|Active Comparator|Arthemeter and Lumefantrine (AL)|children receiving fixed-dose combination of arthemeter and lumefantrine
3147376|NCT01567410|Other|traditional Classroom training|one group of nurses receive traditional classroom training to learn about the braden scale and pressure ulcer classification
3147377|NCT01567410|Other|e-learning|one group of nurses receive e-learning as a training method to learn about the braden scale and classification of pressure ulcer
3147378|NCT01567384|Experimental|Combination therapy with OSI and Pemetrexed|
3147379|NCT01567371|Experimental|LiDCO rapid monitor|
3147380|NCT01567358|Experimental|NI-071|
3147381|NCT01567358|Active Comparator|Remicade|
3147382|NCT01567345|Active Comparator|Intrathecal pump with continuous flow|After placement of the implantable pump, continuous flow is scheduled by physician and the patient can't modify it.
3147383|NCT01567345|Experimental|Intrathecal pump with programmable flow.|After placement of the implantable pump, programmable flow is scheduled by physician and patient can do himself morphine bolus injections for a better control of acute episodes of pain.
3147384|NCT01567332|Experimental|rTMS active|
3147385|NCT01567332|Placebo Comparator|rTMS inactive (sham)|
3147386|NCT01567319|Experimental|Allergic Subjects|
3147387|NCT01567319|Active Comparator|Atopic Subjects|Patients sensitized to other allergenic sources but the allergen extracts under investigation.
3147388|NCT01567319|Active Comparator|No Atopic Subjects|Healthy volunteers.
3147389|NCT01567306|Experimental|Allergovac Depot Group 1 Active|
3147390|NCT01567306|Experimental|Allergovac Depot Group 2 Active|
3147391|NCT01567306|Experimental|Allergovac Depot Group 3 Active|
3147392|NCT01567306|Experimental|Allergovac Depot Group 4 Active|
3147393|NCT01567306|Experimental|Allergovac Depot Group 5 Active|
3147395|NCT01567280||Controlled patients|Asthmatic patients with controlled asthma (according to ACQ score)
3147396|NCT01567280||Partly controlled/Uncontrolled patients|Patients with partly controlled or uncontrolled asthma (according to ACQ score)
3147397|NCT01567267|Experimental|Experimental educational intervention|Experimental educational intervention
3147398|NCT01567267|Active Comparator|Standard educational intervention|Standard educational intervention
3147399|NCT01567254|Experimental|guided imaginary|7 children receiving auditory guided imagery disk
3147400|NCT01567254|Active Comparator|music|6 children receiving music disk
3147401|NCT01567241|Placebo Comparator|Relaxation music|
3147402|NCT01567241|Experimental|Clinical hypnosis|
3147403|NCT01567228|No Intervention|routine counseling (control group)|Children will receive typical counseling for obesity prevention, dental caries prevention, or school problems per routine standards for pediatrician anticipatory guidance
3147404|NCT01567228|Experimental|CHICA GIS|In randomly assigned experimental clinics, physicians will counsel patients to increase physical activity, seek dental care, or seek academic support services such as tutoring; this counseling will be assisted by an experimental intervention which consist of an electronic medical record that prompts specific counseling in conjunction with a geographic information system. The enhanced electronic medical record will map community resources to support physician counseling and lifestyle modification
3147405|NCT01567215|Experimental|Granuloma|
3147406|NCT01567202|Experimental|Arm DC|In this arm, the patients will receive DC vaccination in addition to the standard therapy, including Surgery, Chemotherapy, and Radiotherapy.
3147407|NCT01567202|Placebo Comparator|Arm Placebo|In this arm, the patients will receive blank placebo instead of the DC vaccination in addition to the standard therapy.
3147408|NCT01567189|Experimental|Hospital cardiac rehabilitation|The patients will perform physical training sessions in the hospital
3147409|NCT01567189|Active Comparator|Home cardiac rehabilitation|The patients will perform physical training sessions at home
3147410|NCT01567176|Other|Single Arm|
3147411|NCT01567163|Experimental|ramucirumab (IMC-1121B) and docetaxel|"Cycle 1: docetaxel administered on Day 1 of 3-week cycle~Cycle 2: ramucirumab and docetaxel administered on Day 1 of 3-week cycle~Cycle 3 and beyond: ramucirumab and docetaxel administered on Day 1 of each 3-week cycle~Extension Phase: ramucirumab and docetaxel administered on Day 1 of each 3-week cycle"
3147412|NCT01567150|Active Comparator|novel dressing|Treatment with novel dressing
3147413|NCT01567150|No Intervention|Control|Control is treatment without novel dressing
3147414|NCT01567124|Other|Olanzapine|Participants taking olanzapine at the time of recruitment will continue to take this medication as part of standard care for schizophrenia.
3147415|NCT01567124|Other|Clozapine|Participants taking clozapine at the time of recruitment will continue to take this medication as part of standard care for schizophrenia.
3147416|NCT01567111|Experimental|Subjects with PA|All study subjects have biochemically confirmed PA and undergo adrenal CT, AVS and MTO-PET to diagnose lateralization of aldosterone production.
3147417|NCT01567098|Experimental|SILS appendectomy|Single incision laparoscopic appendectomy
3147418|NCT01567098|Active Comparator|3 Ports appendectomy|performing appendectomy through conventional 3 incisions on the abdomen
3147419|NCT01567085|Experimental|Eculizumab|
3147420|NCT01567072|Experimental|NSAIDs in 7 days|NSAIDs (Ibuprofen) in 7 days
3147421|NCT01567072|Active Comparator|NSAIDs in 3 days|NSAIDs (Ibuprofen) in the first 3 days and placebo in the last 4 days
3147422|NCT01567072|Placebo Comparator|Placebo|Only placebo in 7 days
3147423|NCT01567059|Experimental|Arm I (tosedostat and cytarabine)|Patients receive tosedostat PO QD on days 1-35 and cytarabine IV on days 1-5.
3147424|NCT01567059|Experimental|Arm II (tosedostat and decitabine)|Patients receive tosedostat PO QD on days 1-35 and decitabine IV on days 1-5.
3147425|NCT01567046||Correlative studies|Archived DNA tissue samples are analyzed for frequency of genetic mutations, including SNPs, SNVs, and small deletions and/or insertions, by PCR and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.
3147426|NCT01567033|Experimental|Intervention|Intervention participants received HEALTH, which embedded a lifestyle intervention derived from DPP within the standard PAT curriculum
3147427|NCT01567020||Control|Non-blast-exposed and non-TBI, aged younger than 50
3147428|NCT01567020||Blast|Blast-exposed with or without a TBI diagnosis
3147429|NCT01567020||Non-Blast-Exposed TBI|Non-blast-exposed with TBI diagnosis
3147430|NCT01567020||Older|Non-blast-exposed and non-TBI, aged 50 or older
3147431|NCT01567007|No Intervention|control|session of 15-20 minutes duration. It took place guidelines on physical activity, delivering a manual with general information about physical activity
3147432|NCT01567007|Experimental|Individual counseling|Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise steps. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
3147433|NCT01567007|Experimental|group counseling|The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices.
3147434|NCT01567007|Experimental|aerobic training|The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill
3147435|NCT01566994|Experimental|TTM Tailored|
3147436|NCT01566994|Experimental|Motivational Enhancement Therapy|
3147437|NCT01566994|Experimental|Integrated Treatment|
3147438|NCT01566981|Experimental|Diabetes with ICT support (E-diabetes)|The group of randomly selected patients with DM type II, who will get the software application and web- based support Intervention: Computerised support to the Diabetes type II patients
3147439|NCT01566981|No Intervention|Diabetes without support|The group of randomly selected patients with DM type II, without software application and web-based support.
3147440|NCT01566968||Healthy Volunteers|Adults between ages of 18-75 inclusive who have never smoked and have no history of any respiratory disease for which they are on regular treatment.
3147441|NCT01566968||Asthma|Adults between the ages on 18-75 inclusive who have a physician diagnosis of asthma and have no smoking history or minimal smoking history (less than 10 pack years or in other words less than 20 cigarettes per day for 10 years).
3147442|NCT01566968||COPD|Adults between the ages of 18-75 inclusive who have previously been smokers (at least 20 pack years) and have physician diagnosis and spirometry evidence of COPD.
3147443|NCT01566968||Healthy smokers|Adults between the ages of 18-75 inclusive who are currently smokers (at least 10 pack years history)but have no history of any respiratory disease and no evidence of COPD on spirometry.
3147444|NCT01566968||Chronic cough|Adults between ages of 18-75 inclusive who have history of dry cough for at least 8 weeks and have a normal chest x ray and no smoking history or minimal smoking history (less than 10 pack years).
3147445|NCT01566955|Experimental|transgastric adnexectomy|patients are operated transgastric
3147446|NCT01566942|Active Comparator|FOLFOX|In this group, the patients will receive the adjuvant chemotherapy with mFOLFOX6.
3147447|NCT01566942|Experimental|FOLFIRI|in this arm, patients will receive adjuvant chemotherapy with FOLFIRI regimen for about 8 cycles
3147448|NCT01566929|No Intervention|IVF only|IVFtreatment
3147449|NCT01566929|Active Comparator|Weight reduction treatment and IVF|Dietary Supplement: Low calorie diet treatment and then IVFtreatment
3147450|NCT01566916|Active Comparator|Total Hip Arthroplasty performed via direct anterior approach|
3147451|NCT01566916|Active Comparator|Total Hip Arthroplasty using anterolateral approach|
3147452|NCT01566903||arteriovenous malformations|
3147453|NCT01566903||Arterial stenosis|
3147454|NCT01566903||Post-treatment follow-up|Patient with an arteriovenous malformation for which treatment by embolization or radiosurgery is indicated
3147455|NCT01566890|Experimental|Regadenoson ARM|Adult subjects with sickle cell anemia will receive a regadenoson infusion with contrast-enhanced ultrasound
3147456|NCT01566890|Other|Sickle Cell Controls ARM|Adult subjects with sickle cell anemia will receive contrast-enhanced ultrasound
3147457|NCT01566890|Other|Sickle Cell CEU ARM|Adults subjects with sickle cell anemia will receive contrast-enhanced ultrasound
3147458|NCT01566890|Other|Healthy Control ARM|Healthy African American control subjects without sickle cell anemia will receive contrast-enhanced ultrasound
3147459|NCT01566890|Other|Technique Optimization Controls|Healthy volunteers will undergo contrast-enhanced ultrasound.
3147460|NCT01566877|Active Comparator|AVI-7288|AVI-7288 is a phosphorodiamidate morpholino oligomer with positive charges (PMOplus™) that targets Marburg virus nucleoprotein (NP). AVI-7288 is supplied in 5 mL vials containing 5 mL AVI-7288 at a concentration of 50 mg/mL. The dose levels of AVI-7288 will vary in four cohort's.
3147461|NCT01566877|Placebo Comparator|Placebo|Placebo control consists of approximately 150 mL normal saline solution administered by IV infusion over 30 minutes once a day for 14 days.
3147462|NCT01566864|Experimental|Behavioral: Improve clinic based measurement of blood pressur|
3147463|NCT01566864|Experimental|Behavioral: Provider education system to promote patient-cent|
3147464|NCT01566864|Experimental|Behavioral: Introduce care management system in clinics|
3147465|NCT01566851||Patient|Patients with rheumatoid arthritis
3147466|NCT01566838|Active Comparator|On-q pump|Patients in this arm will receive the standard acute pain management regimen during hospital admission and will be sent home after discharge with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
3147467|NCT01566838|Active Comparator|Standard of care|"Patients in this arm will not receive a pain catheter in addition to the standard of care for pain management. Standard of care will consist of a standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and maintained on a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures. Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV once, neuromuscular reversal agents, and an antiemetic (ondansetron 4mg). Patients will also be given additional narcotics (fentanyl) upon emergence, as needed, to facilitate patient comfort and extubation.~The ASA guidelines for acute pain management in the perioperative period will also be provided. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3."
3147468|NCT01566825|Active Comparator|Amitriptyline|
3147469|NCT01566825|Placebo Comparator|white 8 mm Lichtenstein®|
3147470|NCT01566812|Experimental|Breast feeding optimization|
3147471|NCT01566812|Active Comparator|Usual/routine care|
3147472|NCT01566799|Experimental|Metformin|Patients will be receive 12 weeks of paclitaxel followed by 4 cycles of FAC combined with 500 mg/day of metformin p.o.
3147473|NCT01566786|Experimental|activated recombinant human factor VII|
3147474|NCT01566786|Placebo Comparator|Placebo|
3147475|NCT01566773|Experimental|PT001 MDI (Dose 1)|
3147476|NCT01566773|Experimental|PT001 MDI (Dose 2)|
3147477|NCT01566773|Experimental|PT001 MDI (Dose 3)|
3147478|NCT01566773|Experimental|PT001 MDI (Dose 4)|
3147479|NCT01566773|Experimental|PT001 MDI (Dose 5)|
3147480|NCT01566773|Experimental|PT001 MDI (Dose 6)|
3147481|NCT01566773|Placebo Comparator|PT001 Placebo MDI|
3147482|NCT01566773|Active Comparator|Spiriva® Handihaler® (Tiotropium Bromide)|
3147483|NCT01566760|Experimental|Treatment A, Cohort 1|
3147484|NCT01566760|Experimental|Treatment B, Cohort 2|
3147485|NCT01566760|Experimental|Treatment C, Cohort 1|
3147486|NCT01566760|Experimental|Treatment D, Cohort 2|
3147487|NCT01566760|Active Comparator|Treatment E, Cohort 1 and/or Cohort 2|
3147488|NCT01566747|Experimental|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
3147489|NCT01566734|Experimental|Cefazolin|after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients
3147490|NCT01566734|Experimental|Normal Saline|after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients
3147491|NCT01566734|No Intervention|Control|
3147492|NCT01566721|Experimental|Cohort A: SC Herceptin by Needle/Syringe|Participants will receive SC Herceptin by an assisted administration using a conventional syringe and needle/vial formulation.
3147493|NCT01566721|Experimental|Cohort B: SC Herceptin by SID|Participants will receive SC Herceptin with assisted and/or self-administered use of an SID. The first administration will be performed by a trained healthcare professional. If well tolerated and the participant is willing and judged competent to perform self-administration, subsequent administration of SC Herceptin may be performed by the participant.
3147494|NCT01566708|Experimental|treatment group|
3147495|NCT01566708|Active Comparator|waiting list group|
3147496|NCT01566708|Active Comparator|control group|
3147497|NCT01566695|Experimental|Oral Azacitidine|Arm 1: Oral azacitidine 300mg daily + best supportive care (First 21 days of each 28-day cycle)
3147498|NCT01566695|Placebo Comparator|Placebo|Arm 2: Placebo plus best supportive care (First 21 days of each 28-day cycle)
3147499|NCT01566682||Indeterminate Pulmonary Lesions|Patients with Pulmonary Lesions as seen by CT
3147500|NCT01566669|Placebo Comparator|Normal Saline|Before incision, patients in controlled Group received NS
3147501|NCT01566669|Experimental|parecoxib sodium|Before incision, parecoxib patients received 40mg of parecoxib IV
3147502|NCT01566656|Experimental|TLI and anti-thymocyte globulin|
3147503|NCT01566643|Experimental|Hybrid-10|RA3-RACM7: rabeprazole + amoxicillin x 3 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days.
3147504|NCT01566643|Experimental|Hybrid-12|RA5-RACM7: rabeprazole + amoxicillin x 5 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days
3147505|NCT01566643|Experimental|Hybrid-14|RA7-RACM7: rabeprazole + amoxicillin x 7 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days
3147506|NCT01566630|Experimental|RLX030|"In part 1, within each cohort, two (2) patients per cohort will be treated open label with RLX030 and two (2) patients will be treated double blind with RLX030 as intravenous infusion for 72 hours. There will be 3 cohorts in part 1 with different doses of RLX030.~In part 2, there is no open label treatment on RLX030. In part 2, patients will be randomized in a double-blind fashion to this arm with the optimal dose of RLX030 as intravenous infusion for 72 hours as determined from part 1."
3147507|NCT01566630|Placebo Comparator|Placebo|"In part 1, equal number of subjects will be treated with matching placebo of RLX030 as intravenous infusion for 72 hours in 3 cohorts.~In part 2, patients will be treated with matching placebo of RLX030 as intravenous infusion for 72 hours"
3147508|NCT01566617|Other|Standard Care|(1) group who will receive standard care
3147509|NCT01566617|Other|Standard Care and Pharmaceutical Care|(2) group who will receive standard care and pharmaceutical care
3147510|NCT01566604|Experimental|NVA237|NVA237 50 µg once daily delivered via a single dose dry powder inhaler
3147511|NCT01566604|Placebo Comparator|Placebo|Placebo once daily delivered via a single dose dry powder inhaler
3147512|NCT01566591|Sham Comparator|Sham Treatment|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
3147513|NCT01566591|Active Comparator|Deep TMS Treatment|Deep TMS treatment is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions.
3147514|NCT01566578|Experimental|EGF Cream|
3147515|NCT01566578|Placebo Comparator|Placebo cream|
3147516|NCT01566565|Active Comparator|Theophylline|
3147517|NCT01566565|Active Comparator|Bambuterol|
3147518|NCT01566552|Other|SINGLE DOSE AMBISOME|
3147519|NCT01566539|Experimental|Healthy Volunteers - Intranasal Vasopressin (AVP)|The AVP group of healthy volunteers will self-administer vasopressin solution prior to completing the PD task.
3147520|NCT01566539|Experimental|Healthy Volunteers - Intranasal Oxytocin (OT)|The OT group of healthy volunteers will self-administer oxytocin solution prior to completing the PD task.
3147521|NCT01566539|Placebo Comparator|Healthy Volunteers - Intranasal Placebo|The placebo group of healthy volunteers will self-administer a placebo spray prior to completing the PD task.
3147522|NCT01566539|Experimental|Within Subject Group|Some healthy volunteer participants who received drug in their first session will receive placebo in their second session and vice-versa prior to completing the PD task. For each gender, half will receive AVP in one session and placebo in the other session, and half will receive OT in one session and placebo in the second session. In each group, half of the subjects will receive drug first and half will receive placebo first. Additionally, a group of subjects who receive placebo the first time will receive placebo the second time.
3147523|NCT01566539|Experimental|Faces Task - Vasopressin (AVP)|Healthy volunteers between the ages of 21-30 years will receive Faces Intranasal Vasopressin (AVP) prior to completing the Faces task during fMRI scanning.
3147524|NCT01566539|Placebo Comparator|Faces Task - Placebo|Healthy volunteers between the ages of 21-30 years will receive placebo prior to completing the Faces task during fMRI scanning.
3147525|NCT01566539|Experimental|Empathy Task - Oxytocin (OT)|Healthy volunteers between the ages of 18-30 years will receive placebo at scan 1 and OT at scan 2 prior to completing an empathy task.
3147526|NCT01566539|Placebo Comparator|Empathy Task - Placebo|Healthy volunteers between the ages of 18-30 years will receive placebo at scan 1 and placebo at scan 2 prior to completing an empathy task.
3147527|NCT01566539|Experimental|Anxious and Depressed Subjects - OT|Depressed or anxious men between the ages of 18 and 22 will receive intranasal OT prior to completing the Prisoner's Dilemma game task and MRI scan.
3147528|NCT01566539|Placebo Comparator|Anxious and Depressed Subjects - Placebo|Depressed or anxious men between the ages of 18 and 22 will receive intranasal placebo prior to completing the Prisoner's Dilemma game task and MRI scan.
3147736|NCT01565161|Active Comparator|Control Arm|Mailed educational materials
3147529|NCT01566539|Experimental|Healthy Volunteers - Lorazepam|Healthy normal men between the ages of 18 and 22 will receive lorazepam prior to completing the Prisoner's Dilemma game task and MRI scan.
3147530|NCT01566526||Patients Previously Treated with OZURDEX®|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
3147531|NCT01566513|No Intervention|Treatment as usual|
3147532|NCT01566513|Experimental|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
3147533|NCT01566513|Experimental|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
3147534|NCT01566513|Experimental|Peer Case Manager|If a participant is randomized into this condition, they are offered the chance to work with a Case Manager, who is trained in strengths-based case management.
3147535|NCT01566487|Experimental|Quetiapine fumarate tablets 300 mg|Quetiapine fumarate film-coated tablets 300 mg of Dr. Reddy's Laboratories Limited
3147536|NCT01566487|Active Comparator|Seroquel|Seroquel film-coated tablets 300 mg of Astrazeneca Pharmaceuticals, USA
3147537|NCT01566474|Experimental|Melatonin + omeprazole|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
3147538|NCT01566474|Active Comparator|omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
3147539|NCT01566461|Experimental|Drug-Coated Balloon (DCB)|IN.PACT Admiral: Balloon Angioplasty
3147540|NCT01566461|Active Comparator|Standard PTA|Standard Percutaneous Balloon Angioplasty (PTA) Balloon: Balloon Angioplasty
3147541|NCT01566448|Experimental|Ketamine|Ketamine oral mouthwash 20mg/5ml swish and spit four times daily
3147542|NCT01566435|Experimental|Arm 1-ACF Induction Therapy Followed by Chemoradiation Therapy|"ACF Induction Therapy (Cycle 1 and Cycle 2 - each cycle is every 3 weeks)~nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15~Cisplatin 75 mg/m^2 on Day 1~5-FU 750 mg/m^2 on Days 1-3~If patient has complete or partial response, he/she will receive an additional ACF cycle (cycle 3). If patient has stable disease or progressive disease will not receive the third cycle of ACF.~Definitive Therapy~Cisplatin 100 mg/m^2 IV on Days 1, 22, and 43~Intensity modulated radiation therapy (IMRT) 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to area considered to be at intermediate risk. Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 5600 cGy in 35 fractions.~If patient cannot receive cisplatin then he/she will receive cetuximab 250 mg/m^2 IV week for 8 weeks"
3147543|NCT01566422|Experimental|Vancomycin powder|80 randomized patients will be given vancomycin powder in the surgical sites prior to closure following spinal surgery.
3147544|NCT01566422|No Intervention|Control|80 participants who were not randomized to receive Vancomycin powder will receive no intervention at the conclusion of their surgery.
3147545|NCT01566409|Active Comparator|Active maintenance treatment|
3147546|NCT01566409|Placebo Comparator|Placebo maintenance treatment|
3147547|NCT01566396|Experimental|A3F|A3F, Fractional RF treatment
3147548|NCT01566383|Experimental|Healthy Volunteers|Healthy volunteers who are matched (age, weight, gender) to the general patient population undergoing manometry and pH monitoring for GERD will undergo the same procedures to determine pH levels in people without reflux symptoms as compared to pH levels in those patients who have been diagnosed with reflux.
3147549|NCT01566370|Experimental|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind
3147550|NCT01566370|Placebo Comparator|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group
3147551|NCT01566357|No Intervention|Fluoride-free toothpaste|
3147552|NCT01566357|Active Comparator|Fluoride toothpaste|
3147553|NCT01566357|Active Comparator|Milk|
3147554|NCT01566357|Active Comparator|Fluoridated milk|
3147555|NCT01566357|Active Comparator|CPP-ACP|
3147556|NCT01566357|Active Comparator|Fluoridated CPP-ACP|
3147557|NCT01566357|Active Comparator|Fluoride mouthrinse|
3147558|NCT01566344|Experimental|Routine heart failure therapy plus PVC suppression therapy|
3147559|NCT01566344|No Intervention|Routine heart failure therapy|
3147560|NCT01566331|Experimental|Baby-guardTM|Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet.
3147561|NCT01566331|No Intervention|no intervention|Baby-guardTM system, without inflation
3147562|NCT01566318|Experimental|Problem solving therapy (PST)|6-8 sessions of PST, with booster, delivered over 8 weeks
3147563|NCT01566318|No Intervention|Usual care|Usual agency care, monitored for mental health services
3147564|NCT01566305|Experimental|Buttermilk with added egg yolk|
3147565|NCT01566305|Experimental|Buttermilk without added egg-yolk|
3147566|NCT01566305|Experimental|Skimmed milk with added egg-yolk|
3147567|NCT01566305|Placebo Comparator|Skimmed milk without added egg yolk|
3147568|NCT01566292|Experimental|BOTOX|
3147569|NCT01566279|Other|everolimus|All patients in first part will receive everolimus 10mg q.d.
3147570|NCT01566266|Experimental|Amoxicillin|
3147571|NCT01566266|Placebo Comparator|Placebo capsules|
3147572|NCT01566253|Experimental|PCOA|The PCOA arm receiving oral self administered multimodal analgesic protocol (paracetamol, ketoprofen, morphine) by oral use.
3147573|NCT01566253|Active Comparator|Standard/ IV|The standard/IV arm will be received the analgesic treatment by intravenous use, administered by nursing staff.
3147574|NCT01566240|Active Comparator|Chemoradiation|Radiotherapy (external beam and brachytherapy) plus concurrent Cisplatin weekly for 5 weeks
3148125|NCT01562548|Experimental|Arm 1|Guaifenesin 1 tablet BID
3147575|NCT01566240|Experimental|Induction Chemotherapy + Chemoradiation|6 cycles of weekly Paclitaxel and Carboplatin followed by Chemoradiation as per Active Comparator
3147576|NCT01566227|Experimental|number of implants|number of implants (1,2 or 3) used to retained an overdenture
3147577|NCT01566214|Experimental|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
3147578|NCT01566214|No Intervention|Usual Care|For those randomly assigned to the usual care group, they will receive standard-of-care by their regular primary care provider.
3147579|NCT01566201|Active Comparator|anakinra|
3147580|NCT01566201|Placebo Comparator|placebo|
3147581|NCT01566188|Experimental|omega-3 from vegetal origin|
3147582|NCT01566188|Placebo Comparator|Placebo|
3147583|NCT01566175|Experimental|Neovasc coronary sinus reducer|open label: Neovasc coronary sinus reducer
3147584|NCT01566162|Experimental|Lurasidone|Lurasidone 40 - 80mg flexible dose
3147585|NCT01566149|Active Comparator|MF/F 200/10 mcg MDI BID|Participants receiving MF/F 200/10 mcg MDI twice daily (BID) for 12 weeks
3147586|NCT01566149|Active Comparator|MF/F 400/10 mcg MDI BID|Participants receiving MF/F 400/10 mcg MDI BID for 12 weeks
3147587|NCT01566136|No Intervention|Usual care|Current routine rehab care for persons with a hip fracture and CI lacks a well integrated care system within the local hospital network. The usual approach to care at the two sites differ in one major way: patients presenting with a hip fracture to Site 1 receive surgery locally, while those presenting to Site 2 receive surgery at a different hospital because of the absence of an operating suite at this site. Within 2 to 10 days 95% of patients presenting to either site hospital's emergency room with a hip fracture, receive internal fixation or arthroplasty surgery. Patients, including some with mild and moderate CI, are then transferred to in-patient rehabilitation beds at Site 1 or Site 2. Screening of patients for dementia or delirium is not routinely done.
3147588|NCT01566136|Experimental|Rehabilitation Model of Care|Staff will be introduced to five components of the Patient-Centred Rehabilitation Model of Care (PCRM-CI) in a one-day workshop prior to implementing the PCRM-CI model. They will then be provided with eight additional educational sessions throughout the year. A manual detailing all aspects of training, including specifics on how to present the material, ideas for stimulating discussion, and case vignettes to illustrate training concepts was developed for our pilot study and will be used here. We also produced a short video on care of elderly with CI in rehabilitation which will be utilized in the training session. The model will be tested over a one year period with a sustainability plan in place developed by the local hospital network and the two study sites.
3147589|NCT01566123|Experimental|A|Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma
3147590|NCT01566110|Experimental|Diet Intervention Group|
3147591|NCT01566110|No Intervention|Control Group|Subjects assigned to the control group will continue their usual diet. They will receive dietary teaching at each study visit as part of their diabetes management.
3147592|NCT01566097|Experimental|Intervention group|This study is cluster randomized trial, and the randomization level is physician. Current smokers seen by physician allocated into intervention group were provided with Smoking Cessation Decision Aids along with study questionnaires. The intervention was Smoking Cessation Decision Aids provided to current smokers.
3147593|NCT01566097|No Intervention|Control group|Current smokers seen by physician allocated into control group were provided with only study questionnaires and usual care.
3147594|NCT01566084|Other|Normal sodium|Subjects on a 1200 mg sodium diet are given 2300 mg sodium in the form of slow sodium tablets to bring them back up to a normal salt intake. Subjects then cross-over to the low sodium condition in the second half of the study.
3147595|NCT01566084|Other|Low sodium|Subjects on a 1200 mg salt diet are given placebo pills in order to maintain them on a low salt diet. Subjects then cross-over to the normal sodium condition in the second half of the study.
3147596|NCT01566058|Experimental|With BB Box|"The mothers in this arm of the study will have access to a BB Box video system to maintain contact with their premature baby."
3147597|NCT01566058|Active Comparator|Without BB Box|"The mothers in this arm of the study will not have access to a BB Box video system to maintain contact with their premature baby. (Standard care)"
3147598|NCT01566045|Active Comparator|Core Needle TRUS biopsy (Transrectal ultrasound)|Patient receiving core needle TRUS biopsy (Standard of care biopsy)
3147599|NCT01566045|Experimental|Core Needle MRI/US fusion guided biopsy|Patients receiving Standard of Care core needle TRUS biopsy will then receive the MRI / Ultrasound fusion core needle guided biopsy
3147600|NCT01566019|Experimental|Patients with non curable metastatic cancer|
3147601|NCT01566006|No Intervention|control group|group receiving the conventional treatment for DN
3147602|NCT01566006|Experimental|cellcept group|additional to the conventional treatment patients will receive cellcept
3147603|NCT01566006|Experimental|carnitine group|aside to the conventional treatment patients will receive carnitine
3147604|NCT01566006|Experimental|PDE5 group|aside to the conventional treatment patients will receive PDE5 inhibitor
3147605|NCT01565993|Active Comparator|Hemoclip|In group HEMOCLIP, one or more clips were placed (based on the criteria of the endoscopist in accordance with the size of the pedicle), and the polyp was subsequently resected using a diathermy loop
3147606|NCT01565993|Active Comparator|Conventional Polipectomy|In group CONVENTIONAL POLYPECTOMY, a conventional polypectomy was performed, which was not aided beforehand by any other hemostatic technique
3147607|NCT01565980|Active Comparator|symptom assessment|6 weeks of symptom assessment phone calls.
3147608|NCT01565980|Experimental|Mindfulness intervention|Participants receive 6 weeks of the home-based mindfulness intervention, and weekly symptom assessment phone calls.
3147609|NCT01565967||Autotransfusion|All patients undergoing surgery which requires routine use of an autotransfusion system
3148126|NCT01562548|Experimental|Arm 2|Guaifenesin 2 tablets BID
3147610|NCT01565941|Active Comparator|Tight Glycemic Control 1 (TGC-1)|Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm.
3147611|NCT01565941|Active Comparator|Tight Glycemic Control 2 (TGC-2)|Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm.
3147612|NCT01565928|Experimental|MDV3100|
3147613|NCT01565915|Experimental|Perlane-L|Perlane-L treatment
3147614|NCT01565915|Sham Comparator|Non-Treatment|Non-Treatment Arm
3147615|NCT01565902|Experimental|Mild hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
3147616|NCT01565902|Experimental|Moderate hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
3147617|NCT01565902|Experimental|Severe hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
3147618|NCT01565902|Experimental|Matched healthy subjects|Treatment with a single oral dose of 0.25 mg BAF312
3147619|NCT01565889|Experimental|Part A: SOF+EFV/FTC/TDF (Cohort 1)|Participants with a prestudy regimen of EFV/FTC/TDF will receive SOF+EFV/FTC/TDF FDC for 7 days, followed by EFV/FTC/TDF FDC (or EFV+FTC/TDF) for 7 days, coadministered once daily in the evening under fasting conditions.
3147620|NCT01565889|Experimental|Part A: SOF+EFV+ZDV/3TC (Cohort 2)|Participants with a prestudy regimen of EFV+ZDV/3TC will receive SOF+EFV+ZDV/3TC for 7 days followed by EFV+ZDV/3TC for 7 days. Sofosbuvir and EFV will be administered once daily in the evening under fasting conditions; ZDV/3TC will be administered twice daily, in the morning without regard to food and in the evening on an empty stomach.
3147621|NCT01565889|Experimental|Part A: SOF+RTV+ATV+FTC/TDF (Cohort 3)|Participants with a prestudy regimen of RTV+ATV+FTC/TDF will receive SOF+RTV+ATV+FTC/TDF for 7 days followed by RTV+ATV+FTC/TDF for 7 days coadministered once daily in the morning with food.
3147622|NCT01565889|Experimental|Part A: SOF+RTV+DRV+FTC/TDF (Cohort 4)|Participants with a prestudy regimen of RTV+DRV+FTC/TDF will receive SOF+RTV+DRV+FTC/TDF for 7 days followed by RTV+DRV+FTC/TDF for 7 days coadministered once daily in the morning with food.
3147623|NCT01565889|Experimental|Part A: SOF+RAL+FTC/TDF (Cohort 5)|Participants with a prestudy regimen of RAL+FTC/TDF will receive SOF+RAL+FTC/TDF for 7 days followed by RAL+FTC/TDF for 7 days. Sofosbuvir and FTC/TDF will be administered once daily in the morning with food; RAL will be administered twice daily, in the morning with food and in the evening without regard to food.
3147624|NCT01565889|Experimental|Part B: SOF+PEG+RBV|Participants will receive SOF+PEG+RBV for 12 weeks.
3147625|NCT01565876|Experimental|study|"The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.~Then The participants will undergo heat tolerance test 5 times (in different days).~first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards."
3147626|NCT01565863|Experimental|Progressive Goal Attainment Program|
3147627|NCT01565863|No Intervention|VA employment services|
3147628|NCT01565850|Experimental|D/C/F/TAF|D/C/F/TAF FDC tablet plus DRV placebo plus COBI placebo plus FTC/TDF placebo
3147629|NCT01565850|Active Comparator|DRV+COBI+FTC/TDF|DRV tablet plus COBI tablet plus FTC/TDF 200/300 mg FDC tablet plus D/C/F/TAF placebo
3147630|NCT01565837|Experimental|Ipilimumab + SART|Patients with oligometastatic but unresectable malignant melanoma will receive induction ipilimumab plus concurrent SART followed by maintenance ipilimumab.
3147631|NCT01565824|Experimental|Web-based support|The subjects will get access to a website where they can store blood glucose levels, read specialized information concerning pregnancy and early motherhood, and access a discussion forum for peer support.
3147632|NCT01565824|No Intervention|Usual care|
3147633|NCT01565811||Hepatic pedicle lymph node Involvement|Intervention Type: perihepatic lymphadenectomy(surgical procedure)
3147634|NCT01565798|Experimental|Copper Surfaced Room|Patients sequentially randomized to this arm were admitted to an ICU room with copper surfaced objects.
3147635|NCT01565798|No Intervention|Standard Surfaced Room|Patients sequentially randomized to this arm were admitted to an ICU room with standard surfaced objects
3147636|NCT01565785|Experimental|Discharge Prepartion with The FSM-DPI|25 families on each of 2 units will receive the will receive the Family Self-Management-Discharge Preparation Intervention (FSM-DPI). This scripted theory-based intervention is delivered by the study nurse using a e-mobile device. Eight elements of discharge preparation are addressed, the nurse assesses the family status and documents the additional care provided.
3147637|NCT01565785|No Intervention|control group|25 parents on each unit receiving standard of care in discharge preparation.
3147638|NCT01565772|Experimental|Radiation, Chemotherapy and Surgery|Proton beam radiation, plus chemotherapy with cisplatin and etoposide, followed by surgery.
3147639|NCT01565759|Experimental|Lithium|This will be a short-term longitudinal study of 4 weeks of duration. Twenty (20) healthy male subjects will be recruited and treated with lithium carbonate for 4 weeks. Lithium carbonate (150 mg, 300 mg, 600 mg) will be administered to the recruited subjects. The study will be performed in one centre at Capital District Health Authority - Dalhousie University, Halifax, Nova Scotia, Canada. Lithium serum levels will be tested at day 8, at day 14 and at the end of the treatment. Additional tests may be performed as necessary (as in the case of side effects).
3147640|NCT01565746|Experimental|Radium-223 dichloride [50 kBq/kg]|
3147641|NCT01565746|Experimental|Radium-223 dichloride [100 kBq/kg]|
3147642|NCT01565746|Experimental|Radium-223 dichloride [expansion]|
3147643|NCT01565733||NovoMix® 30 users|
3147644|NCT01565720|Experimental|Group 1|Isavuconazole low dose 3 times per day (TID) for 2 days followed by isavuconazole low dose once a day (QD) for 11 days
3147645|NCT01565720|Experimental|Group 2|Isavuconazole low dose 3 times per day (TID) for 2 days followed by isavuconazole high dose once a day (QD) for 11 days
3147646|NCT01565720|Placebo Comparator|Group 3|Placebo 3 times a day (TID) for 2 days followed by placebo once a day (QD) for 11 days
3147898|NCT01564069||Non-opioid management|Patients managing chronic pain without taking opioids
3147647|NCT01565720|Active Comparator|Group 4|Placebo 3 times a day (TID) for 2 days followed by placebo once a day (QD) for 10 days and then moxifloxacin on Day 13
3147648|NCT01565707|Placebo Comparator|Placebo Children|Children aged 5 to 11 years received matching placebo suspension once a day for 12 weeks.
3147649|NCT01565707|Experimental|Solifenacin Succinate Suspension Children|Children aged 5 to 11 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.
3147650|NCT01565707|Placebo Comparator|Placebo Adolescents|Adolescents aged 12 to 17 years received matching placebo suspension once a day for 12 weeks.
3147651|NCT01565707|Placebo Comparator|Solifenacin Succinate Suspension Adolescents|Adolescents aged 12 to 17 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.
3147652|NCT01565694|Experimental|Solifenacin succinate|"Participants aged 5 years to < 18 years received solifenacin orally once a day, with sequential titrated doses for 12 weeks to identify the optimal dose during the dose-titration period. The initial dose was pediatric equivalent dose (PED) 5 mg.~After completing the dose titration period participants entered the fixed-dose period during which solifenacin was taken orally once a day for 40 weeks or until the end of study visit (Week 52)."
3147653|NCT01565681|Experimental|Arm A: ASKP1240 lowest dose|
3147654|NCT01565681|Experimental|Arm B: ASKP1240 second lowest dose|
3147655|NCT01565681|Experimental|Arm C: ASKP1240 third lowest dose|
3147656|NCT01565681|Experimental|Arm D: ASKP1240 fourth lowest dose|
3147657|NCT01565681|Experimental|Arm E: ASKP1240 fifth lowest dose|
3147658|NCT01565681|Experimental|Arm F: ASKP1240 middle dose|
3147659|NCT01565681|Experimental|Arm G: ASKP1240 sixth highest dose|
3147660|NCT01565681|Experimental|Arm H: ASKP1240 fifth highest dose|
3147661|NCT01565681|Experimental|Arm I: ASKP1240 fourth highest dose|
3147662|NCT01565681|Experimental|Arm J: ASKP1240 third highest dose|
3147663|NCT01565681|Experimental|Arm K: ASKP1240 second highest dose|
3147664|NCT01565681|Experimental|Arm L: ASKP1240 highest dose|
3147665|NCT01565681|Placebo Comparator|Arm M: Placebo|Sodium Chloride solution
3147666|NCT01565668|Experimental|AC220 Dose Level 1|
3147667|NCT01565668|Experimental|AC220 Dose Level 2|
3147668|NCT01565655|Experimental|ASP015K lowest dose|
3147669|NCT01565655|Experimental|ASP015K low dose|
3147670|NCT01565655|Experimental|ASP015K medium dose|
3147671|NCT01565655|Experimental|ASP015K high dose|
3147672|NCT01565655|Placebo Comparator|Placebo|
3147673|NCT01565642|Experimental|Decision support intervention|Decision aid and care plan meeting
3147674|NCT01565642|No Intervention|Control|Attention control information on dementia care
3147675|NCT01565629|No Intervention|Waitlist Condition|Children in this condition will withhold from any type of intervention for a period of 12 weeks.
3147676|NCT01565629|Experimental|Computer Assisted CBT|Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
3147677|NCT01565616|Experimental|Bone Marrow Transplant Recipients|Adults with sickle cell disease undergoing a bone marrow transplant from an HLA-identical sibling donor or an unrelated HLA-matched donor.
3147678|NCT01565590|Active Comparator|Propofol|
3147679|NCT01565590|Experimental|Dexmedetomidine|
3147680|NCT01565577|Experimental|Bras A|
3147681|NCT01565564|Active Comparator|The usual care arm|
3147682|NCT01565564|Active Comparator|The shared care arm|
3147683|NCT01565551||Early-Presenting TBI: Acute Sites|This cohort of patients are studied after acute presentation within 24 hours of TBI to one of the three TRACK-TBI acute Level I Trauma Centers (SFGH, UPMC, UMCB).
3147684|NCT01565551||Late-Presenting TBI: Rehabilitation Center|This cohort of patients are studied after presentation to the TRACK-TBI rehabilitation site (MSMC).
3147685|NCT01565538|Experimental|Erlotinib|Erlotinib at the dose of 150 mg orally once a day continually until progression.
3147686|NCT01565538|Experimental|Pemetrexed|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks until progression.
3147687|NCT01565525|No Intervention|Bright Futures|This represents 'usual care' in the pediatric office. The anticipatory guidance regarding nutrition is based on the Bright Futures Pocket Guide.
3147688|NCT01565525|Experimental|Maternal focused intervention|Childhood obesity prevention was approached in this arm via anticipatory guidance aimed at maternal eating habits.
3147689|NCT01565525|Active Comparator|Ounce of Prevention|This is a program of anticipatory guidance given to mothers of infants ages 2 weeks to one year which focuses on serving size per age and tips for introducing new foods for the infant.
3147690|NCT01565512|Placebo Comparator|saline injection|saline injection
3147691|NCT01565512|Active Comparator|Bupivacaine injection|penile block with bupivacaine
3147692|NCT01565499|Experimental|Nab-Paclitaxel|The patients will be included to receive 3 weekly nab-paclitaxel doses of 150 mg/m2 with one week of rest for 4 cycles.
3147693|NCT01565486|Other|Ultrasonic coagulation device|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
3147694|NCT01565486|Other|Bipolar Energy Sealing System|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
3147695|NCT01565473||Parkinson disease patients|
3147696|NCT01565473||Healthy normal controls|
3147985|NCT01563497|Experimental|PF-05089771 TS formulation fed|Tablets TS formulation- fed
3147697|NCT01565460||pancreatic/biliary strictures|Sample Collection: Patients with pancreatic/biliary stricture undergoing intervention will have samples of brushings and bile taken during the procedure.
3147698|NCT01565447||Children with ALL or LL|Children diagnosed with ALL or LL will be recruited for this study
3147699|NCT01565421|Experimental|12mg/m2/dose|12mg per meter squared per dose
3147700|NCT01565421|Experimental|15mg/m2/dose|15mg per meter squared per dose
3147701|NCT01565421|Placebo Comparator|Placebo|5% dextrose infusion (placebo)
3147702|NCT01565408|Experimental|NNC0114-0006|
3147703|NCT01565408|Placebo Comparator|Placebo|
3147704|NCT01565395|Experimental|Xeomin Injections|Fifteen units (0.15 ml) of incobotulinum toxin A injected into each parotid gland and 20 units (0.2 ml) to each submandibular gland for a total dose of 70 units using anatomical landmarks for ALS Twenty units (0.2ml) injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks for PD/parkinsonism
3147705|NCT01565395|Placebo Comparator|Placebo|0.15 ml sterile 0.9% saline injected into each parotid gland and 0.2 ml to each submandibular gland using anatomical landmarks for ALS 0.2ml injected into each parotid gland and 0.3 ml to each submandibular gland using anatomical landmarks for PD/parkinsonism
3147706|NCT01565343|Experimental|AD Subjects|Two bolus IV injections followed by brain PET scan up to 4 weeks apart
3147707|NCT01565343|Experimental|AD Subjects: Slow vs. Fast Bolus|"Two bolus IV injections followed by a brain PET scan up to 4 weeks apart.~The first injection given as a rapid bolus (< 5 second injection, with immediate flush). The second injection given as a slow bolus (approximately 20 to 30 second injection with a flush delayed by 10 seconds after dose administration)."
3147708|NCT01565343|Experimental|Healthy controls|Healthy male or female subjects; 35-55 years old. Two bolus IV injections followed by brain PET scan up to 4 weeks apart
3147709|NCT01565330|Experimental|111 MBq (3 mCi) AD Group|Subjects with AD who received 111MBq (3 mCi) of florbetapir F 18; MBq=megabecquerel
3147710|NCT01565330|Experimental|111 MBq (3 mCi) Control Group|Healthy controls who received 111MBq (3 mCi) of florbetapir F 18
3147711|NCT01565330|Experimental|370 MBq (10 mCi) AD Group|Subjects with AD who received 370MBq (10 mCi) of florbetapir F 18
3147712|NCT01565330|Experimental|370 MBq (10 mCi) Control Group|Healthy controls who received 370MBq (10 mCi) of florbetapir F 18.
3147713|NCT01565317|Experimental|Intensive Treatment (Why WAIT)|Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
3147714|NCT01565317|No Intervention|Control Group|Matched control group will be recruited from obese patients with diabetes followed at Joslin Clinic. This group will receive the routine standard diabetes care.
3147715|NCT01565304|Experimental|POWER Through Choices|10-session group-based sexual education curriculum
3147716|NCT01565304|No Intervention|Usual services|No intervention
3147717|NCT01565291|Experimental|Subjects With AD|Probable AD, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with mild/moderate dementia (Mini-Mental State Examination (MMSE) from 10 to 24)
3147718|NCT01565291|Experimental|Healthy Elderly Subjects|Cognitively normal with MMSE of 29 or higher; age 50 years or older
3147719|NCT01565278|Experimental|Soybean oil + Fish oil|Intralipid (0.25 g/kg/TPN day) + Omegaven (0.4 g/kg/TPN day) for a period of 6 months.
3147720|NCT01565278|Active Comparator|Soybean oil (Standard treatment)|Standard treatment: Intralipid (0.25 g/kg/TPN day) for a period of 6 months
3147721|NCT01565265|Active Comparator|GnRH agonist long protocol|Pergoveris will be administered daily from cycle day 2 to ovulation induction together with decapeptyl, which will be administered from the midluteal phase of the preceding menstrual cycle up to ovulation induction.
3147722|NCT01565265|Experimental|antagonist protocol|Pergoveris will be administered daily from cycle day 2 to ovulation induction together with Cetrotide, which will be administered from the day six up to ovulation induction.
3147723|NCT01565252|No Intervention|Stage 1|"Dietary regimens:~Stage1 - all participants (N=20) in first stage will receive two regular (high n-6 PUFA) hard-boiled eggs/day at breakfast for a three weeks period for each participant."
3147724|NCT01565252|Experimental|Stage 2|Stage 2 will be conduct after 3 weeks for wash-out with no eggs. All participants(N=20) in second stage will receive two high n-3 PUFA hard-boiled eggs/day at breakfast for a three weeks period for each participant.
3147725|NCT01565239|Experimental|Fiix PT (Fiix-INR) monitoring and dosing of warfarin|The modified prothrombin time, sensitive only to factor II and X activity, will be used to monitor and dose warfarin.
3147726|NCT01565239|Active Comparator|PT (INR) monitoring and dosing of warfarin|The prothrombin time, sensitive to factors II, VII and X activity, will be used to monitor and dose warfarin.
3147727|NCT01565226||Open|open, observational study
3147728|NCT01565213|Active Comparator|CBT cognitive behavioral therapy|group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks
3147729|NCT01565213|Active Comparator|MMI Multimodal group intervention|group multimodal intervention
3147730|NCT01565213|Other|CAU|Care as usual given by the GPs
3147731|NCT01565200|Other|T-DM1|After an imaging phase, the patient will receive T-DM1 iv every 3 weeks until progression or toxicity
3147732|NCT01565187||hand transplant candidates|Participants enrolled will be asked to complete behavioral questionnaires.
3147733|NCT01565174||High activity COMT|Carriers of high activity COMT158Val allele who are expected to show higher THC-induced meso-limbic DA release
3147734|NCT01565174||Low activity COMT|Carriers of low activity COMT 158Met homozygotes are expected to release low amount of dopamine after smoking a cigarette with THC
3147735|NCT01565161|Experimental|Home-Based Health Coaching|Intervention delivered in the home.
3148115|NCT01562639||Nexium|
3147737|NCT01565148|Experimental|Group 1|"Drug: iCo-007 350 mcg~iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4"
3147738|NCT01565148|Experimental|Group 2|"Drug: iCo-007 700 mcg~iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4"
3147739|NCT01565148|Experimental|Group 3|"Drug: iCo-007 350 mcg and Laser~iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation"
3147740|NCT01565148|Experimental|Group 4|"Drug: Ranibizumab and iCo-007 350 mcg~Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later"
3147741|NCT01565135|Experimental|Intervention Practices|Intervention offices will adopt a multimodal vaccine program to increase their patients' vaccine rates.
3147742|NCT01565135|No Intervention|Control Practices|Control offices will offer usual health care related to immunizations throughout the duration of the study.
3147743|NCT01565122||Cohort|
3147744|NCT01565109|Experimental|Single arm study|"Docetaxel - Cisplatine - 5FU 2 cycles of Docetaxel - Cisplatine - 5 FU~Radiation: Radiation of 45 Grays on 5 weeks Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks"
3147745|NCT01565096|Experimental|Vildagliptin plus Metformin|Metformin (1000 mg BID) + Vildagliptin 50 mg twice daily
3147746|NCT01565096|Active Comparator|Glimepirid plus Metformin|Metformin (1000 mg BID) + Glimepiride (individual dosage)
3147747|NCT01565083|Experimental|Pertuzumab + Trastuzumab + Vinorelbine: Separate Infusion|Pertuzumab will be administered as IV infusion on Day 1 of the first treatment cycle (1 cycle = 21 days) as a loading dose of 840 milligrams (mg), followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab will be administered as IV infusion on Day 2 of the first treatment cycle as a loading dose of 8 mg per kilogram (mg/kg), followed by 6 mg/kg on Day 2 of each subsequent cycle. Vinorelbine IV infusion (will be administered after trastuzumab) on Day 2 and Day 9 of the first treatment cycle at a dose of 25 mg per meter-squared (mg/m^2) followed by 30-35 mg/m^2 on Day 2 and Day 9 of each subsequent cycle. Pertuzumab and trastuzumab will be administered sequentially in separate infusion bags, followed by vinorelbine until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end (up to 47 cycles).
3147748|NCT01565083|Experimental|Pertuzumab + Trastuzumab + Vinorelbine: Single Infusion|Pertuzumab will be administered as IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab will be administered as IV infusion on Day 2 of the first treatment cycle as a loading dose of 8 mg/kg, followed by 6 mg/kg on Day 1 of each subsequent cycle. Vinorelbine IV infusion on Day 2 and Day 9 of the first treatment cycle at a dose of 25 mg/m^2 followed by 30-35 mg/m^2 on Day 1 and Day 8 of each subsequent cycle. If administration of all 3 drugs is well tolerated in Cycle 1, then on Day 1 of each subsequent cycle, pertuzumab 420 mg and trastuzumab 6 mg/kg will be administered in a single infusion bag, followed by vinorelbine until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end (up to 47 cycles).
3147749|NCT01565070|Active Comparator|Biofreeze|
3147750|NCT01565070|Placebo Comparator|Placebo|Use of placebo ointment
3147751|NCT01565057|Experimental|sedimenting meal|To assess whether rates of gastric emptying of a specifically formulated emulsion drink are significantly different from a control drink and that this in turn leads to differences in satiation (cessation in the desire to eat) and satiety (desire to limit further food intake) as measured by visual analogue scale (VAS) satiety questionnaire and blood CCK.
3147752|NCT01565044|Experimental|" AUTO  Group"|
3147753|NCT01565044|Sham Comparator|" CONTROL  Group"|
3147754|NCT01565031||controlled asthmatics, down-titration|Adults (age between 18 and 80) with asthma under control (see definitions) during the last 3 months, treated with a combination of ICS and long-acting beta-agonist (LABA).
3147755|NCT01565018|Experimental|Treatment A - Treatment B|"Treatment A: Test; drug product PR 2.2.1~Treatment B: Reference; drug product PR 2.1.4~Sequence of two single applications of Rotigotine transdermal patches (PR 2.2.1 first) for 24 hours separated by a Washout Period of 5 days."
3147756|NCT01565018|Experimental|Treatment B - Treatment A|"Treatment B: Reference; drug product PR 2.1.4~Treatment A: Test; drug product PR 2.2.1~Sequence of two single applications of Rotigotine transdermal patches (PR 2.1.4 first) for 24 hours separated by a Washout Period of 5 days."
3147757|NCT01565005||Microcephaly|Microcephaly Intellectual abilities Cranial MRI
3147758|NCT01565005||FANCONI ANEMIA|
3147759|NCT01564992||Parkinson disease|Identification of genes
3147760|NCT01564979|Experimental|preseptal|
3147761|NCT01564979|Experimental|pretarsal|
3147762|NCT01564966||Living kidney donors|Those who donate kidneys
3147763|NCT01564927|Experimental|Electroacupuncture to right LI4 and LI11|
3147764|NCT01564927|Sham Comparator|Electroacupuncture to knee caps|Electroacupuncture to knee caps
3147765|NCT01564927|Placebo Comparator|Sham electroacupuncture to LI4 & LI11|
3147766|NCT01564914|Experimental|TRC105, Bevacizumab|Single arm study
3147767|NCT01564901||Cohort|
3147768|NCT01564888|Placebo Comparator|Patent hemostasis|Patent hemostasis is the technique for radial artery hemostasis after transradial catheterization, with proactive attempt to maintain radial artery hemostasis and radial artery patency.
3147769|NCT01564888|Active Comparator|Ulnar artery compression|Ulnar artery compression will involve radial artery hemostasis using patent hemostasis technique and compression of ulnar artery to the point of occluding flow, in an attempt to augment radial artery flow.
3147770|NCT01564875|Experimental|Simvast CR|"Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.~Placebo with the same appearance and formulation as that of Zocor Tab, 1 tablet once daily to be administered between 6 and 9 p.m."
3147771|NCT01564875|Active Comparator|Zocor|"Placebo with the same appearance and formulation as that of Simvast CR Tab, 1 tablet once daily to be administered between 6 and 9 a.m.~Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m."
3147772|NCT01564862|Experimental|Vortioxetine (Lu AA21004) QD|Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
3147773|NCT01564862|Active Comparator|Duloxetine QD|Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
3147774|NCT01564862|Placebo Comparator|Placebo QD|Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
3147775|NCT01564849||chronic rhinitis,|
3147776|NCT01564849||chronic sinusitis|
3147777|NCT01564849||nasal polyps|
3147778|NCT01564849||control rhinitis|
3147779|NCT01564849||control sinusitis|
3147780|NCT01564849||control polyps|
3147781|NCT01564836|Experimental|Imatinib treatment discontinuing|
3147782|NCT01564823|Experimental|Metronidazole + Azathioprine.|Metronidazole, oral intake. 250 mg/8h. 3 months. Azathioprine, 2.5 mg/weight kg/day, oral intake. All study.
3147783|NCT01564823|Active Comparator|Metronidazole + Adalimumab|Metronidazole Oral Intake. 250 mg/8h. During 3 months. Adalimumab Subcutaneous 160 mg and 80 mg 2wk. Then 40 mg during 2wk as maintenance.
3147784|NCT01564810|Experimental|Arm A|patients received cetuximab in combination with chemotherapy
3147785|NCT01564810|Active Comparator|Arm B|Patients received chemotherapy (mFOLFOX6 or FOLFIRI) alone. mFOLFOX6 (day 1, oxaliplatin 85 mg/m², folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then 2400 mg/m² over 46 h continuous infusion) FOLFIRI (day 1, irinotecan 180mg/m2, folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then continuous infusion for 46 hours of 2400 mg/m2).
3147786|NCT01564797|Active Comparator|Education Intervention|A series of 5 home-based lay health educator-led education sessions (Home Health Parties (HHP)), to educate a Hispanic population about diabetes, management of diabetes, and diet and exercise
3147787|NCT01564797|No Intervention|Control Arm|A delayed intervention where the intervention was delivered after the hA1c level was measured for the second time (3 months after the baseline measurement)
3147788|NCT01564784|Experimental|Arm A|
3147789|NCT01564784|Active Comparator|Arm B|
3147790|NCT01564771||Group one|Adults ≥18 years of age with chest X-ray confirmed CAP
3147791|NCT01564758||Group 1|Subjects that are diagnosed with gram positive infection
3147792|NCT01564745|No Intervention|Cough Determinants|
3147793|NCT01564732|Active Comparator|Standard-LAGB|Subjects will be blinded and randomly assigned to the Standard Laparoscopic Gastric Banding(SLAGB)arm of the study. These subjects will receive the standard of care or standard laparoscopic gastric banding surgery.Subjects will be followed for a period of approximately 36 months.
3147794|NCT01564732|Experimental|Plicated-LAGB|"Subjects will be blinded and randomly assigned to the Plicated Laparoscopic Gastric Banding(PLAGB)arm of the study. These subjects will receive the plicated laparoscopic gastric banding surgery with involves the placement of plication sutures to anchor the redundant stomach around the newly placed device. Subjects will be followed for a period of approximately 36 months."
3147795|NCT01564719|Experimental|Immediate-intervention arm|This is a holistic health intervention. .The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
3147796|NCT01564719|Experimental|One-year waitlist arm|This holistic health intervention arm for Cohort 2 was the same as Cohort 1's, only the intervention delivery was smoother (e.g., Naturally Slim offered at more start times). Cohort 2 waited for one year before beginning the intervention.
3147797|NCT01564719|Experimental|Two-year waitlist arm|This holistic health intervention arm for Cohort 3 was the same as Cohort 2's, only Cohort 3 waited for two years and received the stress management program meQuilibrium rather than Williams LifeSkills.
3147798|NCT01564706|Experimental|Healthy Volunteers|Healthy male or female subjects, between 18 and 85 years of age.
3147799|NCT01564693||ANOREXIC CANCER PATIENTS|Nine lung cancer patients were diagnosed as anorexic based on the results obtained by the appetite assessment tools we used. These patients were studied by fMRI regarding the hypothalamic activity.
3147800|NCT01564693||NON-ANOREXIC CANCER PATIENTS|Four lung cancer patients were diagnosed as non-anorexic based on the results obtained by the appetite assessment tools we used. These patients were studied by fMRI regarding the hypothalamic activity.
3147801|NCT01564693||CONTROL GROUP|Two healthy volunteers with normal appetite were studied by fMRI regarding the hypothalamic activity.
3147802|NCT01564680|Experimental|Lornoxicam|Lornoxicam 16 mg will be given at skin closure and 8 mg will be given 12 hours postoperatively
3147803|NCT01564680|Placebo Comparator|Control|Patients will receive normal saline at skin closure, at 6, 12, 18 hours postoperatively.
3147804|NCT01564680|Experimental|Paracetamol|1 gm of paracetamol will be given at skin closure, 6, 12, 18 hours postoperatively
3147805|NCT01564667|Experimental|Attention Bias Modification Treatment|Attention bias modification training using a computerized spatial attention task (dot-probe) designed to alter threat-bias attention patterns away from threat.
3147806|NCT01564667|Active Comparator|Attentional Control Training|Attention control training using a computerized spatial attention taks (dot-probe) counter balances training toward and away from threat.
3147807|NCT01564654||iTotal KRS|
3147808|NCT01564641||iDuo G2|iDuo G2 to be implanted in the patient.
3147809|NCT01564628||Healthy|Healthy subjects without previous heart disease
3147810|NCT01564628||Moderate to severe stenosis|Patients with moderate to severe stenosis
3147811|NCT01564628||Previously diagnosed patients|Patients with previous MI and/or CAD diagnosis leading to stenting
3147812|NCT01564615|Experimental|AgION catheter|Patients in this arm received an AgION impregnated catheter (4.0-5.0 F Lifecath PICC ExpertTM, Vygon, Ecouen, France).
3147813|NCT01564615|Active Comparator|Non-impregnated polyurethane catheter|Patients in this arm received a non-impregnated polyurethane umbilical catheter (3.5-5.0 F ArgyleTM, Kendall, Tullamore, Iceland)
3147814|NCT01564602|Experimental|single port laparoscopic surgery|2-channel or multiple channel single port laparoscopic surgery in gynecologic disorders
3147853|NCT01564342|Other|wounds irrigated with sterile normal saline|Patients in this arm had their wounds irrigated with sterile normal saline
3147854|NCT01564342|Other|wound irrigation with tap water|Patients in the arm had their wounds irrigated with tap water
3147815|NCT01564576|No Intervention|Conventional neuromuscular blockade|The dose of rocuronium (medication used for NMB during anesthesia)will be adjusted to maintain a depth of NMB of T1 of 10-20% as assessed by a nerve stimulator. At the end of surgery patients will receive neostigmine 2.5 mg and atropine 1 mg to reverse the effect of rocuronium. Extubation will be performed when train-of-four ratio ≥ 0.9.
3147816|NCT01564576|Experimental|Profound neuromuscular blockade|Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
3147817|NCT01564563|Placebo Comparator|Placebo|
3147818|NCT01564563|Experimental|Low dose|
3147819|NCT01564563|Experimental|High dose|
3147820|NCT01564550||type 2 diabetes|
3147821|NCT01564550||healthy subjects|
3147822|NCT01564537|Experimental|Ixazomib + Lenalidomide + Dexamethasone|Ixazomib 4 mg, capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until progressive disease (PD) or unacceptable toxicity, whichever occurred first up to end of treatment (EOT) projected at 80 months.
3147823|NCT01564537|Placebo Comparator|Placebo + Lenalidomide + Dexamethasone|Ixazomib placebo-matching capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until progressive disease (PD) or unacceptable toxicity, whichever occurred first up to EOT projected at 80 months.
3147824|NCT01564511|Experimental|Gait trainer treatment|Roboti gait training by mean of Gangtrainer I
3147825|NCT01564511|Sham Comparator|Conventional group|Convetional physical gait training
3147826|NCT01564498|Placebo Comparator|White potato|Participants will consume 300-500 g of cooked white potatoes per day
3147827|NCT01564498|Experimental|Purple Potato|Participants will consume 300-500 g of cooked purple potato per day
3147828|NCT01564498|Placebo Comparator|Orange carrots|Participants will consume 200-300 g typical varieties of orange carrots during the intervention
3147829|NCT01564498|Experimental|Purple Carrots|Participants will consume 200-300 g raw purple carrots instead of orange carrots in the control arm
3147830|NCT01564485|Experimental|Cardiac CT|Patients randomized to cardiac CT will obtain a non-invasive assessment of their coronary arteries.
3147831|NCT01564485|Placebo Comparator|Usual Care|Patients randomized to usual care will be assigned to continuing usual medical care with their primary care physician
3147832|NCT01564472||PSG Scoring|Retrospective, de-identified PSG studies will be collected and scored by registered polysomnogrpahy technicians. The manually scored studies will be compared to the automatic scoring performed by the new Sleepware Software G3 Autoscoring Algorithm.
3147833|NCT01564459|Experimental|MK-6096 10 mg→MK-6096 10 mg|Participants receive MK-6096 10 mg during run-in once daily for 1 week and receive MK-6096 10 mg once daily for 2 weeks during double-blind treatment period.
3147834|NCT01564459|Placebo Comparator|MK-6096→Placebo|Participants receive MK-6096 10 mg during run-in once daily for 1 week and receive placebo once daily for 2 weeks during double-blind treatment period.
3147835|NCT01564446|Experimental|secure message regarding post-discharge medication|Participants will be sent a secure message to confirm compliance with post-discharge medication.
3147836|NCT01564433|Experimental|Gait trainer treatment|
3147837|NCT01564433|Active Comparator|Conventional group|
3147838|NCT01564420||Intrathecal morphine|Patients were randomized for general anesthesia, and allocated in the control group and morphine intrathecal group.
3147839|NCT01564420||Control group|
3147840|NCT01564407|Experimental|Safety Cohort|"Stable restrictive scar contractures resulting from abdominal surgical incision, not transversing a joint. The minimum scar length of 7 cm and a maximum scar area size of 80cm². The scar is divided into five injection areas with a minimum of 0.5 cm uninjected areas between the 5 sites.Drug Dosing for Cohort 1:~Empty control no injection~Vehicle only (0.5 ml of HypoThermosol solution)~5 million cells / cm² , single administration at Day 0~5 million cells/ cm² , single administration at week 4~5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4 Subjects in Cohort 1 will undergo elective surgeries, at which time the treated scars will be removed, at week 6-8 post-treatment of the first dosed subject."
3147841|NCT01564407|Active Comparator|2.5M cells/cm2|Participants receive intervention treatment of 2.5 million cells/ cm2, single administration injected into the scar.
3147842|NCT01564407|Active Comparator|5M cells/cm2|Participants receive intervention treatment of 5 million cells /cm2, single administration
3147843|NCT01564407|Active Comparator|2.5M cells/cm2 at 4 weeks|Participants receive intervention treatment of 2.5 million cells/ cm2, repeat dose administration @ 4 weeks
3147844|NCT01564407|Active Comparator|5M cells/cm2 at 4 weeks|Participants receive intervention treatment of 5 million cells / cm2 repeat dose administration @ 4 weeks
3147845|NCT01564394|Experimental|Qigong|Qigong originated in China hundreds of years ago and has been practiced for centuries. It consists of a sequence of slow, flowing physical movements with concentration on the breath and awareness and may promote physical and mental relaxation and energy balance.
3147846|NCT01564394|Sham Comparator|Stretching control|The non-aerobic stretching will serve as an attention control group to control for non-specific factors; dose of attention and to mimic being in a group setting.
3147847|NCT01564381|Experimental|Resveratrol|The capsules will contain 90mg of resveratrol.
3147848|NCT01564381|Experimental|ResA|ResA is a product produced by using patented technology that physically binds resveratrol to arginine, creating a novel conjugate. The capsules will contain 90mg of resveratrol.
3147849|NCT01564381|Placebo Comparator|Placebo|The placebo will be cellulose.
3147850|NCT01564368|Experimental|Diffusion Weighted-MRI|Participants on all arms of the I-SPY II trial will undergo diffusion-weighted magnetic resonance imaging as described in the ACRIN 6698 protocol. The experimental component/intervention is whether DW-MRI can predict therapeutic response in neoadjuvant treatment for breast cancer.
3147851|NCT01564355|Experimental|Systemic Steroid Group|Will receive post-operative oral steroids for 10 days as per usual protocol.
3147852|NCT01564355|Placebo Comparator|Placebo|Will receive placebo pills for 10 days post-operatively
3147855|NCT01564329|Experimental|endostar2|CT Perfusion Imaging(CTPI) at D0, D21 of the first cycle、D6, D14 of the second cycle, measure blood flow ( BF ), blood volume ( BV ), mean transit time ( MTT ), start time ( TTS ), time to peak ( TTP ), Patlak blood volume ( pBV ), vascular permeability etc. before/after tumor tissue treatment.
3147856|NCT01564329|Experimental|endostar1|CT Perfusion Imaging(CTPI) at D0，D6, D14, D21 of the first period, measure blood flow ( BF ), blood volume ( BV ), mean transit time ( MTT ), start time ( TTS ), time to peak ( TTP ), Patlak blood volume ( pBV ), vascular permeability etc. before/after tumor tissue treatment.
3147857|NCT01564316||neurodegeneration patients|•neurodegeneration patients and control group include dementia patients visited the part of neurology
3147858|NCT01564303|No Intervention|2. Acetylcysteine group (NAC+S) , aside with the saline, will|2. Acetylcysteine group (NAC+S) , aside with the saline, patients will be given orally Acetylcysteine at a dose of 600 mg twice daily, on the day before and on the day of administration of the contrast agent.
3147859|NCT01564303|Experimental|CAR+S , aside with the saline, carnitne will be adminstrated|Carnitine group (Car+S), aside with the saline, patients will be administrated with 20 mg/kg carnitine over 10 minutes 2 hours prior to the administration of the contrast agent and 8 hours after CT.
3147860|NCT01564303|Experimental|Phosphodiesterase type 5 inhibitor group (PDE5+S), aside with|4. Phosphodiesterase type 5 inhibitor group (PDE5+S), aside with the saline patients will be given orally 20 mg tablets of PDE5 Tadalafil once daily 2 hours prior to the administration of the contrast agent and in the subsequent day.
3147861|NCT01564303|No Intervention|Control group (S) will be treated without any extra agents|Control group ( S ) , which will be treated without any extra agents, just Saline (0.9 %) will be given I.V. at a rate of 1 ml per kilogram of body weight per hour for 12 hours before and 12 hours after administration of the contrast agent.
3147862|NCT01564290|Placebo Comparator|probiotic|Probiotic product with Sacharomices Boulardii
3147863|NCT01564290|Active Comparator|probiotic yogurt|Yogurt with Lactobacilus Rhamnonsus strain spp
3147864|NCT01564277|Experimental|Arm I (1.5mg rasburicase)|Patients receive 1.5mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.
3147865|NCT01564277|Experimental|Arm II (3 mg rasburicase)|Patients receive 3 mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.
3147866|NCT01564264|Experimental|Sentinel Node Biopsy|Each participant will have both measurements, the new diagnostic test (sentinel node biopsy) and the gold standard (complete lymphadenectomy)
3147867|NCT01564251|Experimental|Stage 1 Arm 1: GDC-0575 Monotherapy|Participants will receive escalating doses of GDC-0575, administered orally, for 3 consecutive days, starting on Days 1, 8, and 15 of each 21-day cycle.
3147868|NCT01564251|Experimental|Stage 1 Arm 2a: GDC-0575 + Gemcitabine (750 or 1000 mg/m^2)|Participants will receive gemcitabine 750 milligrams per meter square (mg/m^2) or 1000 mg/m^2, intravenously, on Days 1 and 8 followed by escalating doses of GDC-0575 orally, on Days 2 and 9 of each 21-day cycle.
3147869|NCT01564251|Experimental|Stage 1 Arm 2b: GDC-0575 plus Gemcitabine (500 mg/m^2)|Participants will receive gemcitabine 500 mg/m^2, intravenously, once weekly for approximately 2 consecutive weeks of any 3-week period and escalating doses of GDC-0575 orally approximately 24-hours after each gemcitabine dose.
3147870|NCT01564251|Experimental|Stage 2: GDC-0575 plus Gemcitabine|Participants will receive GDC-0575 in combination with gemcitabine intravenously (1000 mg/m^2 and/or 500 mg/m^2), at or below the MTDs for the combination treatments that are determined during Stage 1.
3147871|NCT01564238|Experimental|High calcium diets (1300 mg or higher)|
3147872|NCT01564238|Experimental|Low calcium diet (800 mg/d)|
3147873|NCT01564225|Experimental|EDI200|
3147874|NCT01564212|Active Comparator|standard airflow and forced air warming|Subjects will lie on operating room bed with standard airflow and forced air warming.
3147875|NCT01564212|Active Comparator|laminar airflow with surgical drapes|Subjects will lie on operating room bed with laminar airflow device on and surgical drapes surrounding bed.
3147876|NCT01564212|Active Comparator|laminar aiflow with forced air warming|Subjects will lie on operating room bed with laminar airflow on and warming forced air.
3147877|NCT01564212|Active Comparator|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow and surgical drapes surrounding bed.
3147878|NCT01564199|Experimental|Treatment A|Salmeterol/fluticasone propionate with concomitant charcoal
3147879|NCT01564199|Experimental|Treatment B|Salmeterol/fluticasone propionate without concomitant charcoal
3147880|NCT01564186||MulitPoint Pacing|
3147881|NCT01564186||BiV Conventional|
3147882|NCT01564173||VT Ablation|Patients undergoing epicardial mapping and ablation procedure for a ventricular tachycardia
3147883|NCT01564160|Experimental|Arm 1: PCSO-524|PCSO-524
3147884|NCT01564160|Active Comparator|Arm 2: Fish Oil|Fish Oil
3147885|NCT01564147|Other|Immediate Education therapeutic|Access to the course of immediate therapeutic education
3147886|NCT01564147|Other|therapeutic education delayed|Group receiving therapeutic education 6 months later (control group)
3147887|NCT01564134|Experimental|HepB 5ug|receive the vaccine with 5ug HBsAg
3147888|NCT01564134|Experimental|HepB 10ug|receive the vaccine with 10ug HBsAg
3147889|NCT01564134|Experimental|HepB 20ug|receive the vaccine with 20ug HBsAg
3147890|NCT01564134|Experimental|HepB 60ug|receive the vaccine with 60ug HBsAg
3147891|NCT01564108|Experimental|Ranibizumab|Series of intravitreal injections of Ranibizumab
3147892|NCT01564095|Experimental|Tacrolimus + HTK|Ex vivo Tacrolimus Rinse (20 ng/ml solved in 1000 ml HTK) of marginal liver grafts prior to implantation
3147893|NCT01564095|Placebo Comparator|HTK|Ex vivo Rinse (1000 ml HTK) of marginal liver grafts prior to implantation
3147894|NCT01564082|Experimental|ETT first|Patients will have the endotracheal tube (ETT) introduced into the pharynx prior to GlideScope insertion, and then advanced under GlideScope guidance into the trachea.
3147895|NCT01564082|No Intervention|Control Group|Patients will have the GlideScope introduced into the pharynx. The endotracheal tube (ETT) will then be advanced under direct vision into the mouth/pharynx. The ETT will then be advanced into the trachea under GlideScope guidance.
3147896|NCT01564069||IT opioids|Patients with IT pumps receiving IT opioids
3147897|NCT01564069||Systemic opioids|Patients taking oral or transdermal opioids for chronic pain
3147899|NCT01564056|Other|Arm A: ENDOCRINE TREATMENT|HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
3147900|NCT01564056|Experimental|Arm B: CHEMOTHERAPY + ENDOCRINE TREATMENT|"HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).~CHEMOTHERAPY regimen will be chosen amongst the following ones:~TC (docetaxel + cyclophosphamide)~AC (doxorubicin + cyclophosphamide)~MC (liposomal non pegylated doxorubicin [Myocet®]+ cyclophosphamide)"
3147901|NCT01564043|Experimental|website and pedometer|
3147902|NCT01564030|Other|Empty stomach|Patients have fasted for 8 hours.
3147903|NCT01564030|Other|Fluid|Patients have fasted for 8 hours, followed by the consumption of 250mL of apple juice.
3147904|NCT01564030|Other|Solid|Patients have fasted for 8 hours, followed by the consumption of their breakfast.
3147905|NCT01564017|Experimental|Allergovac depot. Group 1|Increasing dosages till the maintenance dose of 0.0625 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
3147906|NCT01564017|Experimental|Allergovac depot. Group 2|Increasing dosages till the maintenance dose of 0.125 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
3147907|NCT01564017|Experimental|Allergovac depot. Group 3|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
3147908|NCT01564017|Experimental|Allergovac depot. Group 4|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
3147909|NCT01564017|Experimental|Allergovac depot. Group 5|Increasing dosages till the maintenance dose of 0.75 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
3147910|NCT01564017|Placebo Comparator|Allergovac depot placebo. Group 6|The same scheme of treatment as the active groups
3147911|NCT01564004|Experimental|Clinical hypnosis|20 minutes tape recorded clinical hypnosis intervention
3147912|NCT01564004|Active Comparator|Neuro-linguistic programming|20 minutes tape recording of nouro-linguistic programming intervention
3147913|NCT01563991|Active Comparator|Standard fluid volume|Subject receives normal fluid volume during peri-operative period
3147914|NCT01563991|Experimental|Reduced Fluid Volume|Subject receives a reduced fluid volume during the peri-operative period
3147915|NCT01563978|Experimental|Dosing Regimen A|Oral treatment
3147916|NCT01563978|Placebo Comparator|Dosing Regimen B|Oral treatment
3147917|NCT01563965|Active Comparator|Conventional preoperative fast|Patients underwent surgery after 8h fast
3147918|NCT01563965|Experimental|Carbohydrate plus protein beverage|The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil).All the patients fasted for solids at least 8 hours from the operation
3147919|NCT01563952|Active Comparator|Non-IVUS guided endeavor-R group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
3147920|NCT01563952|Experimental|IVUS guided endeavor-R group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
3147921|NCT01563952|Active Comparator|Non-IVUS guided Nobori group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
3147922|NCT01563952|Experimental|IVUS guided Nobori group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
3147923|NCT01563939|Active Comparator|Continuous infusion|Remifentanil administered by continuous IV infusion, with stepwise increase in infusion rates and placebo demand bolus of normal saline.
3147924|NCT01563939|Active Comparator|Demand Bolus|Demand bolus of remifentanil with stepwise increase in bolus dose and placebo continuous infusion of normal saline.
3147925|NCT01563926|Experimental|Somatropin|
3147926|NCT01563913|Experimental|Arm 1|Docosahexaenoic Acid (DHA)
3147927|NCT01563913|Placebo Comparator|Arm 2|Placebo
3147928|NCT01563900|Sham Comparator|sham-CPAP group|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp).
3147929|NCT01563900|Active Comparator|Auto-titration CPAP|This group will received an auto-titration CPAP, which will have a pressure range of 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
3147930|NCT01563887|Experimental|DD.com|Participants in this arm will receive the DiabetesDriving.com internet intervention intended to help reduce their risk of being in a future collision.
3147931|NCT01563887|Experimental|DD.com + MI|Participants will receive the DiabetesDriving Internet intervention and two 60 minute Motivational Interview (MI) sessions over the telephone. The MI sessions will take place once before and once following completion of the Internet intervention. This interview will focus on making explicit individual's ambivalence around changing behavior.
3147932|NCT01563848|Active Comparator|Group 1 (RFA CTI+Reveal)|assessing the incidence of atrial fibrillation in patients with atrial flutter
3147933|NCT01563848|Active Comparator|Group 2 (RFA CTI+Cryo PVI+Reveal)|efficacy of cryoablation in patients with atrial flutter
3147934|NCT01563835|Active Comparator|Epidural (PCEA)|bupivacaine, fentanyl
3147935|NCT01563835|Active Comparator|IV PCA|Intravenous fentanyl patient controlled analgesia
3147936|NCT01563822|Experimental|follicular fluid group|Follicular fluid group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is done.
3147937|NCT01563822|No Intervention|control group|Control group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is not done.
3147938|NCT01563809|Active Comparator|Low androgens FSH+LH|Patients with androgens below threshold receiving FSH+LH for ovarian stimulation
3147939|NCT01563809|Active Comparator|High androgens FSH+LH|Patients with androgens above threshold receiving FSH+LH for ovarian stimulation
3147940|NCT01563809|No Intervention|High androgens FSH alone|
3147941|NCT01563809|No Intervention|Low androgens, FSH alone|
3148116|NCT01562626|Experimental|Dose escalation|
3147942|NCT01563796||TCC positive|subjects with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones that are found to have a bladder tumor confirmed by histopathology
3147943|NCT01563796||TCC negative|subjects with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones that are found to NOT have a bladder tumor by histopathology or clinical observation.
3147944|NCT01563783|Active Comparator|Woman Suitable for Myomectomy or GFA|This group will consist of women who desire uterine preservation. Women will be randomized 1:1 to GFA or Myomectomy (laparoscopic or abdominal).
3147945|NCT01563783|Active Comparator|Woman Suitable for UAE or GFA|This group will consist of women who desire uterine preservation. Women will be randomized 1:1 to GFA or uterine artery embolization (UAE).
3147946|NCT01563770|Experimental|Salvia miltiorrhiza extract (Danshen)|p.o. Salvia miltiorrhiza extract, 1.5 g twice daily for four consecutive weeks
3147947|NCT01563770|Placebo Comparator|placebo|p.o. placebo, twice daily
3147948|NCT01563757||Fontan Patients with PLE and PB|Fontan Patients with Protein Losing Enteropathy and Plastic Bronchitis
3147949|NCT01563757||Fontan Patients w/out PLE & PB|Protein Losing Enteropathy and Plastic Bronchitis
3147950|NCT01563757||Glenn Physiology Patients|
3147951|NCT01563757||2 ventricle heart with ASD|2 ventricle heart with Atrial Septal Defect
3147952|NCT01563744|Experimental|EGD-assisted colonoscopy prep|2 liters of polyethylene glycol instilled through the channel of the endoscope during EGD when colonoscopy expected the following day. Patients follow a clear liquid diet, then ingest an addition 1 liter polyethylene glycol 4 hours prior to colonoscopy. Patients are also given a tap water enema 1 hour prior to colonoscopy.
3147953|NCT01563744|Active Comparator|Standard Colonoscopy Prep|Split-dose polyethylene glycol (2 liters pm prior to colonoscopy, 1 liter 4 hours prior to colonoscopy)), clear liquid diet, metoclopramide 10 mg IV 30 minutes prior to procedure, tap water enema 1 hr prior to colonoscopy
3147954|NCT01563731|Other|SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l|Highest SBP target. Higher LDL-C target. Control arm
3147955|NCT01563731|Active Comparator|SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l|Intermediate SBP target. Higher LDL-C target
3147956|NCT01563731|Active Comparator|SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l|Lowest SBP target. Higher LDL-C target
3147957|NCT01563731|Active Comparator|SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l|Highest SBP target. Lower LDL-C target.
3147958|NCT01563731|Active Comparator|SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l|Intermediate SBP target. Lower LDL-C target.
3147959|NCT01563731|Active Comparator|SBP < 125 mmHg and LDL-C < 1.8 mmol/l|Lowest SBP target. Lower LDL-C target.
3147960|NCT01563718|Experimental|PRE-release XR-NTX|Participants randomly assigned to the pre-release condition will receive one injection of XR-NTX 1-2 weeks prior to prison release plus up to five additional injections of XR-NTX in the community after release
3147961|NCT01563718|Active Comparator|POST-release XR-NTX|Participant randomly assigned to the post-release group will be referred to Rhode Island Hospital to receive up to six injections of XR-NTX immediately after release from prison
3147962|NCT01563692||Paediatric health care workers|NHS members of staff who regularly care for children admitted with RSV infections, and who therefore have a higher rate of exposure.
3147963|NCT01563692||Non-paediatric health care workers|This is a comparator group made up of healthy adults who do not work in an occupation or have other risk factors for higher exposure to RSV.
3147964|NCT01563653|Experimental|Patients|Women with stress urinary incontinence schelduled for TVT or TOT procedures. See inclusion/exclusion criteria.
3147965|NCT01563640|Placebo Comparator|normal school uniforms|washing only
3147966|NCT01563640|Experimental|insecticide-treated school uniforms|washing and insecticide treatment
3147967|NCT01563627|Experimental|Antiepileptic Drug resistant|Adult patients suffering from epilepsy drug-resistant and potentially surgical candidates
3147968|NCT01563627|Experimental|Antiepileptic drug Controlled group|epilepsy well controlled by antiepileptic drugs
3147969|NCT01563614|Experimental|Treatment|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
3147970|NCT01563601|Experimental|Obatoclax mesylate, Carboplatin and Etoposide (CEO)|
3147971|NCT01563601|Active Comparator|Carboplatin and Etoposide (CE)|
3147972|NCT01563588|Experimental|dietary and physical training|12 days session of physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
3147973|NCT01563588|No Intervention|control|dietary counseling by a dietetician in the anticancer hospital
3147974|NCT01563575|Experimental|Intervention Group|fast-track implementation process
3147975|NCT01563575|No Intervention|Control Group|Continue usual routine
3147976|NCT01563562|Experimental|Bardoxolone Methyl 20 mg|
3147977|NCT01563536|Experimental|ABT-267 1.5 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV|ABT-267 (1.5 mg once daily) as monotherapy for 2 days, then ABT-267 (1.5 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks
3147978|NCT01563536|Experimental|ABT-267 25 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV|ABT-267 (25 mg once daily) as monotherapy for 2 days, then ABT-267 (25 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks
3147979|NCT01563523|Experimental|Activated recombinant human factor VII|
3147980|NCT01563523|Placebo Comparator|Placebo|
3147981|NCT01563510|Experimental|Laparoscopic operation|Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
3147982|NCT01563510|Active Comparator|Open operation|The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
3147983|NCT01563497|Experimental|PF-05089771 Oral Dispersion fasted|Oral dispersion TS formulation- fasted
3147984|NCT01563497|Experimental|PF-05089771 TS formulation fasted|Tablets TS formulation- fasted
3148127|NCT01562548|Placebo Comparator|Arm 3|Placebo 1 tablet BID
3147986|NCT01563484||low-osmolar contrast media|Patients undergo TACE of low-osmolar contrast media on day 1.
3147987|NCT01563484||iso-osmolar contrast media|Patients undergo TACE of iso-osmolar contrast media on day 1.
3147988|NCT01563471|Experimental|Treatment sequence 1|
3147989|NCT01563471|Experimental|Treatment sequence 2|
3147990|NCT01563471|Experimental|Treatment sequence 3|
3147991|NCT01563471|Placebo Comparator|Treatment sequence 4|
3147992|NCT01563458|Experimental|High dose|
3147993|NCT01563458|Experimental|Low dose|
3147994|NCT01563458|Placebo Comparator|Placebo|
3147995|NCT01563445|Experimental|activated recombinant human factor VII|
3147996|NCT01563445|Placebo Comparator|Placebo|
3147997|NCT01563432|Experimental|febuxostat (TR)|
3147998|NCT01563432|Experimental|febuxostat (RT)|
3147999|NCT01563419|No Intervention|Control|dialing up the selected dose of insulin pens without an indicator magnifying window
3148000|NCT01563419|Experimental|Magnifier|dialing up the selected dose of insulin pens clipped on an indicator magnifying window
3148001|NCT01563406|Experimental|Alcohol with 5 second scrub|70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 5 seconds.
3148002|NCT01563406|Experimental|Alcohol with 15 second scrub|70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 15 seconds.
3148003|NCT01563406|Experimental|Chlorhexidine with 5 second scrub|3.15% chlorhexidine/70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 5 seconds.
3148004|NCT01563406|Experimental|Chlorhexidine with 15 second scrub|3.15% chlorhexidine/70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 15 seconds.
3148005|NCT01563393|Active Comparator|STAMP using|Children between 1 and 17 years of age from internal medicine and surgical departments will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale.
3148006|NCT01563393|Placebo Comparator|No STAMP using|In order to examine the effect of the tool on the medical staff awareness, 364 files of hospitalized children will be tested: 182 files at the beginning of the study and prior to using the tool and 182 after 6 months at the same ages and in the same departments.
3148007|NCT01563380|Experimental|PRP arm|Platelet-rich plasma was applied over the wound including the capsule, medial and lateral recesses.
3148008|NCT01563380|No Intervention|Control Arm|
3148009|NCT01563367|Active Comparator|Iron isomaltoside 1000 (Monofer®)|Iron isomaltoside 1000 (Monofer®) - Intravenous Infusion
3148010|NCT01563367|Placebo Comparator|0,9% sodium saline|Placebo (0.9% sodium saline) - Intravenous infusion
3148011|NCT01563354|Experimental|Pasireotide LAR|60 mg i.m. injected once every 28 days
3148012|NCT01563354|Experimental|Everolimus|10 mg p.o. daily
3148013|NCT01563354|Experimental|Pasireotide LAR + Everolimus|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily
3148014|NCT01563341|Experimental|Deep Brain Stimulation|Parkinson's disease patients who would otherwise be undergoing subthalamic nucleus (STN) deep brain stimulation (DBS) will have dual hemispheric stimulation of the STN and globus pallidus interna (GPi).
3148015|NCT01563328|Experimental|Cohort 1|DTG x 5 days followed by BCV + DTG x 10 days
3148016|NCT01563328|Experimental|Cohort 2|DTG x 5 days followed by TVR + DTG x 10 days
3148017|NCT01563315||Adults with CAP admitted to hospital|All adult patients with CAP admitted to Vestre Viken HF-Buskerud Hospital (VVHF-BH), a 400-bed community general hospital, between January 2008 og January 2011 were evaluated for inclusion in the study.
3148018|NCT01563302|Experimental|Group 1|IONIS-STAT3Rx
3148019|NCT01563289|Placebo Comparator|placebo|
3148020|NCT01563289|Experimental|Ibuprofen|
3148021|NCT01563276||Progressive Supranuclear Palsy|Patients with a diagnosis of probable or possible PSP as defined by the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) diagnostic criteria.
3148022|NCT01563276||Parkinson's Disease|Idiopathic PD according to the UK Parkinson‟s Disease Society Brain Bank Clinical Diagnosis Criteria (UKPDSBBCDC)
3148023|NCT01563276||Healthy Control|
3148024|NCT01563263|Active Comparator|IC43 100 mcg|IC43 100 mcg intramuscular injection, IC43 is a recombinant Pseudomonas aeruginosa fusion protein
3148025|NCT01563263|Placebo Comparator|Placebo|phosphate buffered saline solution containing 0,9 % NaCL
3148026|NCT01563250|No Intervention|Core Laboratory|Patients receiving serial routinely available cardiac biomarker testing in a core laboratory setting using Troponin T. (Roche Centaur)
3148027|NCT01563250|Active Comparator|Point of Care|Patients will receive the Point of Care testing intervention using serial cardiac biomarker testing at the bedside including myoglobin, Troponin I and CK-MB. (Triage Cardiac Panel, Alere)
3148028|NCT01563237|Experimental|MIDI Arrow|Implantation of MIDI Arrow
3148029|NCT01563224|Experimental|single group, crossover, 3 interventions|
3148030|NCT01563211||Patients receiving endocrine treatment for breast cancer|Patients who are treated with tamoxifen, anastrozole or letrozole before or after surgery for breast cancer.
3148031|NCT01563211||Patients receiving chemotherapy for breast cancer|Patients receiving FEC (5-FU, cyclophosphamide, epiribicin) or FEC-D (FEC for 3 cycles, followed by 3 cycles of docetaxel).
3148032|NCT01563198|Experimental|Comfort Talk® Training|The MRI units of three clinical sites form the group. Their personnel will be trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests
3148033|NCT01563185|Experimental|DUEXIS|800 mg ibuprofen/26.6 mg famotidine
3148034|NCT01563172|Experimental|Experimental dentifrice 0.5g, 45 seconds brushing group|Participants brush twice a daily for 45 seconds with experimental dentifrice.
3148035|NCT01563172|Experimental|Experimental dentifrice 1.5g, 45 seconds brushing group|Participants brush twice a daily for 45 seconds with experimental dentifrice.
3148036|NCT01563172|Experimental|Experimental dentifrice 0.5g, 2 minutes brushing group|Participants brush twice a daily for 2 minutes with experimental dentifrice.
3148037|NCT01563172|Experimental|Experimental dentifrice 1.5g, 2 minutes brushing group|Participants brush twice a daily for 2 minutes with experimental dentifrice.
3148128|NCT01562548|Placebo Comparator|Arm 4|Placebo 2 tablets BID
3148038|NCT01563172|Active Comparator|Contol group|Participants brush twice a daily for 2 minutes with controll dentifrice.
3148039|NCT01563159||Group A|All children ≤ 5 years old with a rotavirus detection test (inpatient and ambulatory tests) performed during the period of June the 1st 2010 and May the 31st 2011.
3148040|NCT01563146||Group A|All children ≤ 5 years old with a rotavirus detection test (inpatient and ambulatory tests) performed during the period of June the 1st 2006 and May the 31st 2007.
3148041|NCT01563133|Other|Lymph nodes, pancreatic masses & cysts|
3148042|NCT01563120|Active Comparator|metformin|metformin up to 2550mg per day
3148043|NCT01563120|Active Comparator|glybenclamide|glybenclamide up to 20mg per day.
3148044|NCT01563107|Experimental|High Salt Diet|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels.
3148045|NCT01563107|Experimental|Low Salt Diet|
3148046|NCT01563081|Experimental|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution
3148047|NCT01563068|Experimental|Calcipotriene Foam|Calcipotriene foam 0.005% administered under maximal-use conditions to adolescent patients with plaque psoriasis
3148048|NCT01563055|Experimental|ofatumumab + chlorambucil|ofatumumab dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days; chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
3148049|NCT01563042|Experimental|Cohort 1 GSK2434735|Cohort 1: Single intravenous administration of GSK2434735 and Pharmacokinetic (PK) and Immunogenicity assessments up to 42 days post dose.
3148050|NCT01563042|Experimental|Cohort 2 GSK2434735|Cohort 2: Single subcutaneous administration of GSK2434735 and Pharmacokinetic (PK) and Immunogenicity assessments up to 42 days post dose.
3148051|NCT01563029|Active Comparator|Arm 1|Fluticasone Furoate 100mcg inhalation powder once daily in the evening ICS powder
3148052|NCT01563029|Active Comparator|Arm 2|Fluticasone Furoate 50mcg inhalation powder once daily in the evening ICS powder
3148053|NCT01563029|Active Comparator|Arm 3|Fluticasone Furoate 25mcg inhalation powder once daily in the evening ics powder
3148054|NCT01563029|Active Comparator|Arm 4|Fluticasone Propionate 100mcg inhalation powder twice daily ICS powder
3148055|NCT01563029|Placebo Comparator|Arm 5|Placebo inhalation powder once daily in the evening Placebo powder
3148056|NCT01563016|Experimental|Glucose & Depleting|participants will perform in a depleting task and receive a glucose drink
3148057|NCT01563016|Placebo Comparator|Glucose & non-depleting|participants will perform in a non-depleting task and receive a glucose drink
3148058|NCT01563016|No Intervention|Placebo & depleting|participants will perform in a depleting task and receive a placebo drink
3148059|NCT01563016|No Intervention|Placebo & non depleting|participants will perform in a non depleting task and receive a placebo drink
3148060|NCT01563003|Experimental|Cognitive Behavioral Therapy Condition|This arm is the experimental condition; it consists of 16 weekly CBT sessions. This intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposures to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases
3148061|NCT01563003|Active Comparator|Treatment as Usual|This arm acts as the comparison condition. Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
3148062|NCT01562990|Experimental|R-CMC544 and R-GEMOX|Treatment with R-CMC544 and R-GEMOX
3148063|NCT01562977|Other|no arms|no arms were present for the study, only 2 different cohorts:MCL and LDCGB
3148064|NCT01562964|Experimental|Hypnotherapy|Hypnotherapy will be conducted at the Royal Brompton Hospital by a qualified practician (DF). Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
3148065|NCT01562964|Active Comparator|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min. Patients will be encouraged to talk about their physical symptoms and any emotional issues, and to discuss how these might be coped with in a better way.
3148066|NCT01562951|Placebo Comparator|PLACEBO|Treatment with placebo
3148067|NCT01562951|Active Comparator|ADALIMUMAB|Treatment with Adalimumab
3148068|NCT01562938|Placebo Comparator|Placebo|Placebo
3148069|NCT01562938|Active Comparator|MEDI-557 low-dose|
3148070|NCT01562938|Active Comparator|MEDI-557 high-dose|
3148071|NCT01562925|Active Comparator|Red Wine|Patients assigned to red wine group will receive standard care plus two doses of red wine: the evening before contrast-medium use and the morning of contrast-medium exposure
3148072|NCT01562925|Active Comparator|White wine|
3148073|NCT01562925|Active Comparator|Beer|
3148074|NCT01562925|No Intervention|Control|Patients assigned to control group will receive standard care. Patients receive ordinary still water without alcohol the evening before(7.8 ml per kg bodyweight) and 60-120 minutes before contrast exposure (at least 3.9 ml per kg bodyweight)
3148117|NCT01562613||Hypertensive patients|All eligible hypertensive patients treated with eprosartan
3148118|NCT01562600||Nexium|
3148119|NCT01562587|Experimental|Adults|
3148120|NCT01562587|Experimental|Paediatric|
3148075|NCT01562912|Active Comparator|Control|Radiofrequency Ablation Procedure. Subjects who are undergoing AF ablation with traditional ablation technology at the same centers by the same operators. Control patients will be enrolled in a 1:2 ratio compared to the PVAC cohort. Intervention is the use of Radiofrequency Ablation.
3148076|NCT01562912|Experimental|PVAC Ablation Procedure|Intervention is the use of PVAC technology. The PVAC is deployed in the left atrium over a 0.032-inch guidewire inside the PV and advanced until it is wedged within the antrum proximal to the ostium. Energy is delivered through selected electrode pairs with local potentials as well as adjacent electrode pairs, allowing bipolar current to flow to the target electrode(s) from both sides. Each application lasts for 60 seconds. When the temperature does not rise above 50°C within 15 seconds, the application should be discontinued to improve position. The PVAC may be manipulated within the antrum to ablate in a pattern of overlapping circular lesions.
3148077|NCT01562899|Experimental|Dose escalation|Dose finding group chosen in order to establish a safe and tolerated dose of binimetinib in combination with ganitumab in patients with selected advanced solid tumors.
3148078|NCT01562899|Experimental|KRAS mutated colorectal adenocarcinoma|"Patients with KRAS mutant colorectal cancer.~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
3148079|NCT01562899|Experimental|Metastatic pancreatic adenocarcinoma|"Patients with metastatic pancreatic cancer.~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
3148080|NCT01562899|Experimental|BRAF mutated melanoma|"Patients with mutant BRAF V600 melanoma.~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
3148081|NCT01562886|Experimental|Rilpivirine and Truvada|TDF/FTC (Truvada™) one tablet once plus Rilpivirine 25 mg daily
3148082|NCT01562873|Experimental|Ruxolitinib-Cohort A|Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of >/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).
3148083|NCT01562873|Experimental|Ruxolitinib-Cohort B|Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of >/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).
3148084|NCT01562860|Active Comparator|Carpal Tunnel and Pronator Teres Release|Patients enrolled in this arm of the study will have both surgical procedures performed at the same time
3148085|NCT01562860|Active Comparator|Carpal Tunnel Release only|Patients enrolled in this arm will have only Carpal Tunnel Release performed. In they still have symptoms of median nerve neuropathy, they will be scheduled for an additional procedure to release the pronator Teres in a separate surgery.
3148086|NCT01562847||Nilotinib|
3148087|NCT01562834|Experimental|Somatropin|
3148088|NCT01562834|Placebo Comparator|Placebo|
3148089|NCT01562821|Experimental|Low dose|
3148090|NCT01562821|Experimental|High dose|
3148091|NCT01562821|Placebo Comparator|Placebo|
3148092|NCT01562795|Experimental|group 1|
3148093|NCT01562795|Experimental|group 2|
3148094|NCT01562795|Experimental|group 3|
3148095|NCT01562795|Other|group 4|
3148096|NCT01562782|Experimental|Fructose + Glucose Beverage|The arm is an oral sugar challenge with blood sampling over 4 hours.
3148097|NCT01562769||Standard precautions|"One selected part of the unit keep the usual procedure applied in our institution with contact precautions prescriptions when colonized patient is admitted with SA and/or ESBL bacteria.~Second selected part of the unit applies only standard precautions (even for patients colonized with multiple drug-resistant organisms).~After 8 months precaution procedures will be exchanged between the two sectors (cross over design)."
3148098|NCT01562769||contact precautions|"One selected part of the unit keep the usual procedure applied in our institution with contact precautions prescriptions when colonized patient is admitted with SA and/or ESBL bacteria.~Second selected part of the unit applies only standard precautions (even for patients colonized with multiple drug-resistant organisms).~After 8 months precaution procedures will be exchanged between the two sectors (cross over design)."
3148099|NCT01562756|Experimental|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
3148100|NCT01562743|Experimental|SPM 962|Rotigotine transdermal patch
3148101|NCT01562730||No previous cardiovascular disease|Individuals without any history of cardiovascular disease
3148102|NCT01562730||Previous cardiovascular disease|Individuals with history of cardiovascular disease
3148103|NCT01562717|Experimental|Ibuprofen|
3148104|NCT01562717|Placebo Comparator|Placebo|
3148105|NCT01562704|Experimental|paracetamol|
3148106|NCT01562704|Placebo Comparator|placebo|
3148107|NCT01562691|Experimental|Nasopore only|Packing using nasopore without airway integrated
3148108|NCT01562691|Active Comparator|nasopore with airway integrated|packing using airway integrated nasopore
3148109|NCT01562691|Active Comparator|airway-integrated Vaseline gauze|Nasal packing using airway-integrated Vaseline gauze
3148110|NCT01562678|Experimental|Liraglutide|
3148111|NCT01562678|Placebo Comparator|Placebo|
3148112|NCT01562665||All Population|
3148113|NCT01562665||Sample of patients will be invited to complete Quality of Life|
3148114|NCT01562652|Experimental|Research|
3148129|NCT01562535|Experimental|Pronation group|In this group, participants will receive the pronation procedure. The technique is described below
3148130|NCT01562535|Active Comparator|Supination group|Participants in this group will be performed the supination technique. Description below.
3148131|NCT01562522|Experimental|Intervention group|
3148132|NCT01562522|No Intervention|Control group|
3148133|NCT01562509|Active Comparator|Standard implementation strategy|Standard intervention
3148134|NCT01562509|Experimental|Innovative implementation strategy|Implementation tools
3148135|NCT01562496|Experimental|Exercise|Twente patients will perform Aerobic exercise 3 times a week for at least 30 min
3148136|NCT01562496|No Intervention|Control|Fifteen patients will be listed as a control group and will be instructed to continue their previous level of activity throughout the study
3148137|NCT01562483|Experimental|delta-9-tetrahydrocannabinol (namisol)|
3148138|NCT01562483|Placebo Comparator|Placebo|
3148139|NCT01562470|Experimental|herbal-based cellulite cream|Trial subjects will apply the treatment cream to one thigh and placebo to the other thigh, by random allocation.
3148140|NCT01562457|Experimental|Low dose|
3148141|NCT01562457|Experimental|Medium dose|
3148142|NCT01562457|Experimental|High dose|
3148143|NCT01562444|Other|TBE_R Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to rapid (R) schedule i.e., on days 0, 7 (+3) and 21 (+7) in the parent study (V48P7) and who were administered 1 booster dose of Encepur adults either 12-18 months after R schedule completion or in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination (for those subjects boostered before V48P7E1 study start, the blood draw occurred annually starting from >6 years up to >10 years after booster vaccination).
3148144|NCT01562444|Other|TBE_C Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to conventional (C) schedule i.e., on days 0, 28 (+10) and 300 (+21) in the parent study (V48P7) and were administered 1 booster dose of Encepur adults in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination.
3148145|NCT01562444|Other|TBE_AC Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to accelerated conventional (AC) schedule i.e., on days 0, 14 (+3) and 300 (+21) in the parent study (V48P7) and were administered 1 booster dose of Encepur adults in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination.
3148146|NCT01562431|Other|Control|Participants complete the Signal-checklist BUT counselors do not obtain the results of the checklist
3148147|NCT01562431|Other|Intervention|Participants complete the Signal-checklist AND the counselor will get the results of the questionnaire
3148148|NCT01562418|Experimental|Ergonomic consulting|Ergonomic consulting without biofeedback
3148149|NCT01562418|Experimental|Ergonomic consulting with biofeedback|Ergonomic intervention with biofeedback
3148150|NCT01562418|No Intervention|general instructions|general instructions with no intervention
3148151|NCT01562405|Experimental|ACE-011 (sotatercept)|ACE-011, Lenalidomide or pomalidomide, Dexamethasone
3148152|NCT01562392|Experimental|berries and vegetables|subjects include specific berries and vegetables in the diet
3148153|NCT01562392|Placebo Comparator|control product|Control product with equivalent amounts of carbohydrates but without vegetables and berries.
3148154|NCT01562379|No Intervention|No food|A control in which mothers will receive nutrition education about continued breastfeeding and adequate complementary feeding throughout the period of 6-18 months of age.
3148155|NCT01562379|Active Comparator|Plumpy Doz|In this control arm children will receive prepackaged, lipid-based Plumpy'Doz (Nutriset, Mulaunay, France) for daily consumption as a snack.
3148156|NCT01562379|Experimental|Wheat Soy Blend (WSB++)|Children will receive a WFP-developed Wheat-Soy Blend (WSB++) snack to be consumed daily.
3148157|NCT01562379|Experimental|Chickpea based complementary food supplement|Children will receive a Chickpea based complementary food supplement to be consumed daily.
3148158|NCT01562379|Experimental|Rice based complementary food supplement|Children will receive a locally developed rice based complementary food supplement.
3148159|NCT01562366|Experimental|Group 1|
3148160|NCT01562366|Active Comparator|Group 2|
3148161|NCT01562353||Case|Subject has a diagnosis of current prescription opioid dependence (confirmed by the MINI). Subject had no history of dependence on alcohol or illicit or prescription drugs, including opioids, prior to prescription opioid exposure for the treatment of chronic pain.
3148162|NCT01562353||Control|Subject's prescribing physician has reported absence of significant problematic behavior with respect to prescription opioids or other substances while under the physician's care. Subject has a negative urine drug screen for alcohol, illicit drugs, and nonprescribed controlled substances at screening. Subject has no current or past substance abuse or dependence (confirmed by the MINI and medical history).
3148163|NCT01562340|Active Comparator|Pomegranate fruit extract|
3148164|NCT01562340|Active Comparator|Pomegranate juice|
3148165|NCT01562327||Tocilizumab|Participants with moderate to severe rheumatoid arthritis (RA) received Tocilizumab according to individualized physician-prescribed regimens.
3148166|NCT01562314|Experimental|GWP42003|GWP42003 was administered orally at a dose of 50 mg up to 250 mg, BID, in the fasted state in the morning and evening, for 10 weeks. Following randomization, participants entered a 2-week dose escalation period to achieve their maximum tolerated dose, up to 500 mg, and maintained this dose for the rest of the treatment period. Participants were then followed for 1 week.
3148167|NCT01562314|Placebo Comparator|Placebo|Placebo capsules matching the study drug were administered orally, BID, in the fasted state in the morning and evening, for 10 weeks. Participants were then followed for 1 week.
3148201|NCT01562028|Experimental|Erlotinib plus bevacizumab|Patients will be treated with erlotinib and bevacizumab. Bevacizumab: 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days) Erlotinib: 150 mg p.o., daily
3148202|NCT01562015|Experimental|Ganetespib|Ganetespib IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
3148505|NCT01559909|Experimental|Socket wall height|
3148168|NCT01562301|Experimental|Anvirzel + Carboplatin + Docetaxel|Anvirzel administered sublingually. A total of five dose cohorts evaluated (6, 12, 24, 36, 48 mg/m2/day; SL divided into 3 doses given every 8 hrs) with 3 patients per cohort. Patients receive the assigned dose (2, 4, 8, 12, or 16 mg/m2) of Anvirzel three times a day throughout each cycle for a total of 4 cycles of chemotherapy. Cycles occur every 21 days. Patients start with an AUC of 6 for Carboplatin and 75mg/m2 for docetaxel, and on subsequent cycles, modifications at the discretion of the treating team. Questionnaire completion regarding physical and mental at baseline, 7 days before chemotherapy, day 1 of chemotherapy, day 1 of cycles 2, 3, and 4, and at end of dosing visit.
3148169|NCT01562288||Observational|Previously collected serum and DNA from peripheral blood mononuclear cell samples are analyzed for HER2-specific antibodies and FcγR genotype by ELISA and PCR.
3148170|NCT01562275|Experimental|Dose escalation stage 1 (Arm A): Cobimetinib and Ipatasertib|Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 40 mg) and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
3148171|NCT01562275|Experimental|Dose escalation stage 1 (Arm B): Cobimetinib and Ipatasertib|Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
3148172|NCT01562275|Experimental|Stage 2 (Indication specific dose expansion cohort)|Participants will receive cobimetinib (GDC-0973) capsules on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with phosphatase and tensin homolog (PTEN)-loss triple-negative breast cancer and PTEN-loss endometrial carcinoma.
3148173|NCT01562262||CTR|Control group
3148174|NCT01562262||ASS|Apnea without complaints group
3148175|NCT01562262||ACS|SAOS Group
3148176|NCT01562249|Experimental|Experimental group|Inclusion criteria were: Skeletal Class III orthognathic surgery patients; adults (age above 18 years), agreement to perform orthognathic surgery and to undergo all of the necessary procedures determined by the multidisciplinary team (i.e. orthodontic preparation, clinical orofacial myofunctional and electromyographic assessment, surgery, post surgery orthodontic treatment, post surgery clinical orofacial myofunctional and electromyographic assessment and orofacial myofunctional treatment when necessary). Exclusion criteria were: previous orthognathic surgery; previous head and neck surgery; neurologic and/or systemic diseases; facial trauma; syndromes; cognitive impairment; and communication and hearing deficits.
3148177|NCT01562249|Active Comparator|Instruction Group|Inclusion criteria were: Skeletal Class III orthognathic surgery patients, adults (age above 18 years), agreement to perform orthognathic surgery and to undergo all of the necessary procedures determined by the multidisciplinary team (i.e. orthodontic preparation, clinical orofacial myofunctional and electromyographic assessment, surgery, post surgery orthodontic treatment, post surgery clinical orofacial myofunctional and electromyographic assessment and orofacial myofunctional treatment when necessary). Exclusion criteria were: previous orthognathic surgery; previous head and neck surgery; neurologic and/or systemic diseases; facial trauma; syndromes; cognitive impairment; and communication and hearing deficits.
3148178|NCT01562249|No Intervention|Control group|Inclusion criteria for this group were: adults (age above 18 years); absence of stomatognathic system alterations; absence of alterations in the scapular region; complete permanent dentition (absence/extraction of the third molar was accepted); Skeletal and Angle's Class I facial pattern; and absence of malocclusion. Exclusion criteria were: previous orthodontic treatment; and history of previous oral motor intervention.
3148179|NCT01562223|Experimental|Repeatability Assessment|Gadolinium motexafin gadolinium All participants will undergo two consecutive DCE-MRI and DWI scans per same imaging parameters and subsequent comparison for repeatability.
3148180|NCT01562210|Experimental|Olaparib, radiation +/- Cisplatin|Olaparib and radiotherapy with or without Cisplatin
3148181|NCT01562197|Experimental|Axitinib|axitinib treatment arm
3148182|NCT01562197|Experimental|Axitinib plus Lomustine|Axitinib plus Lomustine
3148183|NCT01562184|Active Comparator|Active tDCS|Active tDCS
3148184|NCT01562184|Sham Comparator|Sham tDCS|Sham tDCS
3148185|NCT01562171|Experimental|Cooked Lentils|The study group will be asked to consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
3148186|NCT01562171|Active Comparator|Potato-Based Foods|The control group will be asked to consume one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
3148187|NCT01562158|Placebo Comparator|Placebo|
3148188|NCT01562158|Experimental|Low dose|
3148189|NCT01562158|Experimental|Medium dose|
3148190|NCT01562158|Experimental|High dose|
3148191|NCT01562145||Patients with rotator cuff tears|Patients with ultrasound verified rotator cuff tears
3148192|NCT01562145||Healthy controls|Age and gender matched controls with ultrasound verified intact rotator cuff
3148193|NCT01562132|Experimental|5FC plus fluconazole|Combination therapy with oral fluconazole and flucytosine
3148194|NCT01562132|Active Comparator|fluconazole alone|Fluconazole monotherapy
3148195|NCT01562106|Experimental|ICG Dye|Fluorescence-guided sentinel lymph node detection
3148196|NCT01562093|Experimental|local nasal steroids|
3148197|NCT01562093|Placebo Comparator|placebo|
3148198|NCT01562080|Experimental|Dietary supplement|red yeast, astaxanthin, berberine, policosanol, coenzyme Q10, folic acid
3148199|NCT01562080|Placebo Comparator|microcrystalline cellulose|
3148200|NCT01562041|Other|Ranolazine|Ranolazine bid (twice a day) for 14 days.
3148203|NCT01562002|Experimental|Bone Marrow mesenchymal stem cell|Allogenic Bone Marrow mesenchymal stem cell in amniotic membrane transplant
3148204|NCT01562002|Active Comparator|Allogenic limbal stem cell Transplant|Stem Cell with Amniotic Membrane Transplant
3148205|NCT01561989|Experimental|Arm I (400 IU cholecalciferol and vaccine therapy)|Patients receive low-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.
3148206|NCT01561989|Experimental|Arm II (4,000 IU cholecalciferol and vaccine therapy)|Patients receive high-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.
3148207|NCT01561976|Active Comparator|Metformin hydrochloride prolonged release|1000mg in fasting state
3148208|NCT01561976|Active Comparator|metformin hydrochloride prolonged release|1000mg In fed state
3148209|NCT01561976|Active Comparator|Metformin hydrochloride sustained release/Glimepiride|1000/2mg In fed state
3148210|NCT01561963|Experimental|Apremilast and Rifampin|"A single oral dose of 30 mg apremilast on Day 1 in Period 1;~A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 in Period 2;~Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 in Period 3."
3148211|NCT01561950|Experimental|Factor VII|
3148212|NCT01561950|Placebo Comparator|Placebo|
3148213|NCT01561937|Experimental|Pre-warfarin treatment (trial part A)|
3148214|NCT01561937|Experimental|Post-warfarin treatment (trial part B)|
3148215|NCT01561924|Experimental|Ex vivo|
3148216|NCT01561898|Experimental|Paliperidone extended-release (JNS007ER)|
3148217|NCT01561885|Active Comparator|Patients on Pathway Care|
3148218|NCT01561885|No Intervention|Patients on Usual Care|
3148219|NCT01561872||intervention group|"Rooms of the patient of the intervention group will be equipped of cameras"
3148220|NCT01561872||reference group|"Patient in the non-equipped group will have usual care"
3148221|NCT01561859|Experimental|Cognitive enhancement therapy|Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups
3148222|NCT01561859|Active Comparator|Enriched Supportive Therapy|"Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis."
3148223|NCT01561846|Active Comparator|regular cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trialy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks −1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
3148224|NCT01561846|Experimental|CLA enriched cheese|
3148225|NCT01561833|Experimental|Sorafenib|Sorafenib, 400 mg PO twice daily
3148226|NCT01561820|Active Comparator|Buddy|Participant will be assigned a buddy that will meet with them at the gym for each of their exercise sessions. This person will serve as a source of support and motivation for them and will also help them remember and stick to the goals set for you. This person will also help them maintain their exercise logs and ensure they are correct. The buddy will not be exercising with them, but will just be there with them while you exercise.
3148227|NCT01561820|Placebo Comparator|Non Buddy|Participants will not be assigned a buddy (and are not allowed to bring someone with them as a buddy). They will be asked to exercise on their own and remember the goals set for them. They will also be responsible for filling out their own exercise logs and ensuring they are correct.
3148228|NCT01561807|Experimental|787 low dose|VX-787 low dose capsule, taken orally for 5 days
3148229|NCT01561807|Experimental|787 high dose|VX-787 high dose capsule, taken orally for 5 days
3148230|NCT01561807|Experimental|Placebo low dose|Matching placebo low dose capsule, taken orally for 5 days
3148231|NCT01561807|Experimental|Placebo high dose|Matching placebo high dose capsule, taken orally for 5 days
3148232|NCT01561794|Experimental|Ciprofloxacin|
3148233|NCT01561781|Experimental|digoxin then digoxin + vandetanib|Digoxin alone followed by digoxin in combination with vandetanib
3148234|NCT01561768|Experimental|Group 1|
3148235|NCT01561768|Experimental|Group 2|
3148236|NCT01561768|Experimental|Group 3|
3148237|NCT01561768|Experimental|Group 4|
3148238|NCT01561768|Experimental|Group 5|
3148239|NCT01561755|Experimental|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
3148240|NCT01561755|Placebo Comparator|Placebo|Saline 2gr/kg over 2 days of saline
3148241|NCT01561742|Experimental|Minocycline|
3148242|NCT01561742|Placebo Comparator|Placebo|
3148243|NCT01561729|Experimental|Study group|This is the only arm of the study. All patients enrolled will have a nasogastric or orogastric tube placed. All will be assessed by both the RightSpot pH Indicator and chest radiograph.
3148244|NCT01561716|Experimental|Crossover sequence 1|Resting/Wii Fit Free Run/Wii Fit 3 bouts/treadmill
3148245|NCT01561716|Experimental|Crossover sequence 2|Resting/Wii Fit Free Run/treadmill/Wii Fit 3 bouts
3148246|NCT01561716|Experimental|Crossover sequence 3|Resting/Wii Fit 3 bouts/Wii Fit Free Run/treadmill
3148247|NCT01561716|Experimental|Crossover sequence 4|Resting/Wii Fit 3 bouts/treadmill/Wii Fit Free Run
3148248|NCT01561716|Experimental|Crossover sequence 5|Resting/treadmill/Wii Fit Free Run/Wii Fit 3 bouts
3148348|NCT01561105|Experimental|IMPACT|
3148249|NCT01561716|Experimental|Crossover sequence 6|Resting/treadmill/Wii Fit 3 bouts/Wii Fit Free Run
3148250|NCT01561703|Experimental|Anitibiotic|Patients will receive postoperative antibiotic after surgery.
3148251|NCT01561703|No Intervention|Control|Patients will NOT receive postoperative antibiotic
3148252|NCT01561690|Experimental|ARRY-502|
3148253|NCT01561690|Placebo Comparator|Placebo|
3148254|NCT01561677|No Intervention|apnea/hypopnea index (AHI<5 : no OSAS)|
3148255|NCT01561677|No Intervention|apnea/hypopnea index (5≥AHI<15 : mild OSAS)|
3148256|NCT01561677|No Intervention|apnea/hypopnea index (15≤AHI<30 :moderate OSAS)|
3148257|NCT01561677|Active Comparator|apnea/hypopnea index ( AHI≥30 : severe OSAS treated).|Treated with CPAP
3148258|NCT01561677|Sham Comparator|apnea/hypopnea index ( AHI≥30:severe OSAS untreated).|Treated with sham CPAP (placebo)
3148259|NCT01561664|Active Comparator|volunteers|not overweight Volunteers responding to the study criteria
3148260|NCT01561664|Experimental|overweight patients insulin sensitive|overweight patients insulin sensitive responding to the study criteria
3148261|NCT01561664|Experimental|overweight insulin resistant|overweight patients insulin resistant responding to the study criteria
3148262|NCT01561651|Experimental|Left Atrial Appendage Occlusion Group|Surgeon will close the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure device during the patient's cardiac surgery procedure.
3148263|NCT01561651|No Intervention|No Left Atrial Appendage Occlusion Group|Surgeon will not close the left atrial appendage during the patient's cardiac surgery procedure. Patient will be treated as per best medical practice for stroke prevention in atrial fibrillation. Treatment will be decided by the patient's primary care physician.
3148264|NCT01561638|Active Comparator|group p|pulse radiofrequency lesioning
3148265|NCT01561638|Placebo Comparator|sham group|Controlled, conventional
3148266|NCT01561638|Active Comparator|group C|Pulse dose radiofrequency
3148267|NCT01561612|Experimental|Intervention|Breastfeeding promotion according to World Health Organization's Baby Friendly Hospital Initiative
3148268|NCT01561612|No Intervention|Control|Usual care
3148269|NCT01561599|Placebo Comparator|Normal saline|Placebo
3148270|NCT01561599|Active Comparator|BB3|Small molecule mimetic of hepatocyte growth factor/scatter factor
3148271|NCT01561586|Active Comparator|A: Weekly cisplatin with RT|Weekly cisplatin 40mg/m2 six cycles concurrent to radiation therapy
3148272|NCT01561586|Experimental|B: Tri-weekly cisplatin with RT|Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy
3148273|NCT01561573|Other|Ultrasound colles fracture|This is a single arm study
3148274|NCT01561560|Other|DAILIES TOTAL1, then TRUEYE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.
3148275|NCT01561560|Other|TRUEYE, then DAILIES TOTAL1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.
3148276|NCT01561547|Experimental|Kangaroo Mother Care|Infant is held in skin-to-skin contact with mother at least 15 minutes prior to painful procedure, remains in that position throughout the procedure and after the procedure at least until heart rate returns to baseline. Infant is given sterile water by mouth. This is for every heel lance and venipuncture, and if possible for tape removal.
3148277|NCT01561547|Active Comparator|Sucrose|Two minutes before the painful procedure and at the moment of the procedure, the infant will be given 24% sucrose by mouth. The volume is determined by body weight and is not important in terms of efficacy, it is the percentage of sweetness that is important.
3148278|NCT01561547|Experimental|Combination Kangaroo Mother Care and Sucrose|Infant is held in skin-to-skin contact with mother at least 15 minutes prior to painful procedure, remains in that position throughout the procedure and after the procedure at least until heart rate returns to baseline. Infant is given sucrose water by mouth. This is for every heel lance and venipuncture, and if possible for tape removal.
3148279|NCT01561521|Experimental|AKF-1 0.025%|
3148280|NCT01561521|Experimental|AKF-1 0.035%|
3148281|NCT01561521|Placebo Comparator|AKF-1 0%|
3148282|NCT01561508|Experimental|GABA|2/3 of participants will be randomized to the GABA treatment group. Dosage will be based on body weight and will be adjusted at each study visit.
3148283|NCT01561508|Placebo Comparator|Placebo|1/3 of participants will receive placebo.
3148284|NCT01561495|Experimental|Phase 1|
3148285|NCT01561495|Experimental|Phase 2|
3148286|NCT01561482|Experimental|Metformin, Simvastatin|"Both metformin and simvastatin will be taken every day. Metformin will be taken as 1 pill in the morning and 1 pill before going to bed. Simvastatin will be taken as 1 pill before going to bed.~They will be taken until metastasis from the prostate cancer appears or until the subjects PSA has doubled from what it was before they started the study."
3148287|NCT01561469||Linezolid observational cohort|
3148288|NCT01561469||Vancomycin observational cohort|
3148289|NCT01561456|Experimental|AXL1717|AXL1717
3148290|NCT01561456|Active Comparator|Docetaxel|Docetaxel
3148291|NCT01561430|Experimental|15 mg LY2886721|LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks.
3148292|NCT01561430|Experimental|35 mg LY2886721|LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks.
3148293|NCT01561430|Experimental|70 mg LY2886721|LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks.
3148294|NCT01561430|Placebo Comparator|Placebo|Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks.
3148295|NCT01561417|Active Comparator|CP-rFVIIa|
3148296|NCT01561417|Experimental|VII25|
3148297|NCT01561404|Experimental|Everolimus|Conversion from calcineurin inhibitor (CNI) to MTOR inhibitor (everolimus)
3148298|NCT01561391|Experimental|Continuous infusion|
3148299|NCT01561391|Experimental|Bolus injection|
3148300|NCT01561391|Experimental|Control|
3148301|NCT01561378|Experimental|Insulin|Aspart Insulin 40 IU intranasal spray, four times a day for 7 days or until hospital discharge, whichever occurs first
3148411|NCT01560598||Reflux esophagitis|those with endoscopically proven reflux esophagitis
3148302|NCT01561378|Placebo Comparator|Placebo|Saline intranasal spray, four times a day for 7 days or until hospital discharge, whichever occurs first
3148303|NCT01561365|Experimental|Emergency|
3148304|NCT01561365|Experimental|Orthopedic residents|
3148305|NCT01561352|Experimental|Factor VII|
3148306|NCT01561326|Experimental|Cognitive-affective barriers counseling delivered by phone|Standard care plus cognitive-affective barriers counseling delivered by phone , i.e., culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence
3148307|NCT01561326|Experimental|cognitive-affective barriers counseling via brochure|Standard care plus cognitive-affective barriers counseling delivered via mail-home print material
3148308|NCT01561326|Active Comparator|standard care|Cognitive-affective barriers (CAB) assessment delivered via phone; receipt of a notification letter from physician regarding abnormal Pap test result, need to undergo colposcopy, appointment date and clinic contact numbers; telephone confirmation and post-card appointment reminder
3148309|NCT01561313|Active Comparator|Current formulation adalimumab|One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
3148310|NCT01561313|Experimental|New formulation of adalimumab|One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe
3148311|NCT01561300|Placebo Comparator|Control|Nutrition intervention study with a control
3148312|NCT01561300|Experimental|Tea extract|Nutrition intervention study with a black tea extract
3148313|NCT01561287|Experimental|Dermal Autograft|
3148314|NCT01561287|Experimental|AlloDerm|
3148315|NCT01561274|Active Comparator|2 ml bupivacaine|2 ml of 0.75% hyperbaric bupivacaine, for a total of 15 mg of bupivacaine.
3148316|NCT01561274|Active Comparator|1.5 ml bupivicaine.|1.5 ml of 0.75% hyperbaric bupivacaine, for a total of 12.5 mg of bupivacaine.
3148317|NCT01561248|No Intervention|SOC-treatment|Patients with EHEC associated bloody diarrhoea (n=12) receiving standard of care treatment, consisting of intravenous fluids (2-3 liters/daily), analgetics, including paracetamol and metamizol and metoclopramid, if required.
3148318|NCT01561248|Experimental|PEG-Solution, daily bowel lavage|Patients with EHEC associated bloody diarrhoea (n=21)receiving SOC-treatment, consisting of i.v. fluids (2-3 liter/day), analgetics ( paracetamol and metamizol) or metoclopramid and orally administered polyethylene glycol-solution daily during the clinical course.
3148319|NCT01561235|Active Comparator|Normal Protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).~Macronutrient content: Protein: 14 E%, Fat: 30 E% and carbohydrate: 56E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
3148320|NCT01561235|Experimental|Medium-high protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).~Macronutrient content: Protein: 25E%, Fat: 30 E% and carbohydrate: 45E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
3148321|NCT01561235|Experimental|High Protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).~Macronutrient content: Protein: 50 E%, Fat: 30 E% and carbohydrate: 20E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
3148322|NCT01561222|Placebo Comparator|placebo|
3148323|NCT01561222|Experimental|Calcitriol|
3148324|NCT01561209|Active Comparator|Amitryptiline|Amitryptiline 5 mg before bedtime
3148325|NCT01561209|Placebo Comparator|Placebo|Placebo pill
3148326|NCT01561196|Active Comparator|Ultrasound guided arterial cannulation|The arterial needle is placed using ultrasound monitoring for guiding the operator.
3148327|NCT01561196|Active Comparator|Conventional cannulation|the arterial needle is placed using the traditional method and lidocaine. The operator decides where to place the needle in the forearm
3148328|NCT01561183|Experimental|Indirect pulp capping (IPC)|Indirect pulp capping
3148329|NCT01561183|Experimental|Direct pulp capping (DPC)|Direct pulp capping
3148330|NCT01561183|Experimental|Miniature pulpotomy (MP)|Miniature pulpotomy
3148331|NCT01561183|Experimental|Full pulpotomy (FP)|Full pulpotomy
3148332|NCT01561170||Chronically venous ulcer|A group of 36 patients
3148333|NCT01561157||Acute Intermittent Porphyria (AIP)|Patients with a documented diagnosis of AIP
3148334|NCT01561157||Hereditary Coproporphyria (HCP)|Patients with a documented diagnosis of HCP
3148335|NCT01561157||Variegate Porphyria (VP)|Patients with a documented diagnosis of VP
3148336|NCT01561157||Congenital Erythropoietic Porphyria (CEP)|Patients with a documented diagnosis of CEP
3148337|NCT01561157||Hepatoerythropoietic Porphyria (HEP)|Patients with a documented diagnosis of HEP
3148338|NCT01561157||Porphyria Cutanea Tarda (PCT)|Patients with a documented diagnosis of PCT
3148339|NCT01561157||Erythropoietic Protoporphyria (EPP)|Patients with a documented diagnosis of EPP
3148340|NCT01561157||X-Linked Protoporphyria (XLP)|Patients with a documented diagnosis of XLP
3148341|NCT01561157||Aminolevulinate-Dehydratase Deficiency Porphyria (ALAD, ADP)|Patients with a documented diagnosis of ALAD, ADP
3148342|NCT01561131|Active Comparator|Whey protein supplement|Whey protein
3148343|NCT01561131|Active Comparator|Whey protein enriched with calcium supplement|Whey protein enriched with calcium
3148344|NCT01561131|Active Comparator|Soy protein supplement|Soy protein
3148345|NCT01561131|Placebo Comparator|Control supplement|Maltodextrin
3148346|NCT01561118|Experimental|Bicycle-Ergometer Training Group|"Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes, with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions).~In the second part of the study intervention will be prolonged for another 12 weeks."
3148347|NCT01561118|Other|Control|"No intervention during hemodialysis during the first 12 weeks of the study.~In the second part of the study a training program, according to that of the intervention group, will be performed with a performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes, with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions)."
3148349|NCT01561105|No Intervention|Care as Usual|Patients received all depression care available to them as part of care as usual in the participating primary care clinics.
3148350|NCT01561092|Active Comparator|Escitalopram|
3148351|NCT01561092|Placebo Comparator|Non active drug|
3148352|NCT01561079|Experimental|Maternal buprenorphine treatment|Buprenorphine maintenance during pregnancy
3148353|NCT01561066|Sham Comparator|conservative therapy|Conservative therapy includes orrection of electrolytic disturbances, suppression of gastric/intestinal secretion with octreotide, nutritional support.
3148354|NCT01561066|Active Comparator|Application of autologous PRFG|The application of the glues through the external opening of the fistula was controlled by the drainage tube, which was based on fistulography to assure total occlusion of the internal hole. To allow the adhesion of the fibrin glues patch, all fistulous tracts were debrided to produce a smooth surface. At the time of procedures, the two components were mixed together to yield a gelatinous substance. After the FG was instilled, any redundant glue was removed from the external openings.
3148355|NCT01561053|Experimental|Treatment group 1|Plasmaexchange with 20% albumin and Immune Globulin (IGIV) high dose
3148356|NCT01561053|Experimental|Treatment group 2|Plasmaexchange with 20% albumin and Immune Globulin (IGIV) low dose
3148357|NCT01561053|Experimental|Treatment group 3|Plasmaexchange with 20% albumin (low dose)
3148358|NCT01561053|No Intervention|Control (sham) group - Simulated procedure|Standard treatment with previously prescribed medications
3148359|NCT01561040|Experimental|Omega 3, Vitamins A, D3 and E|Dry eye patients that have been screened with elevated osmolarity dispensed EZ Tears supplements containing Omega 3, Vitamins A, D3 and E to evaluate the change in dry eye conditions subjectively and objectively.
3148360|NCT01561027|Experimental|CNV1014802|CNV1014802 350mg on prescription (BID) for 21 days
3148361|NCT01561027|Placebo Comparator|Placebo|Placebo 350mg BID for 21 days
3148362|NCT01561014|Experimental|Treatment (chemotherapy, enzyme inhibitor therapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy QD, 5 days a week and receive fluorouracil IV continuously and erlotinib hydrochloride PO QD on days 1-38. Patients also receive oxaliplatin IV over 2 hours on days 1, 15, and 29.~SURGERY: Within 4-8 weeks after completion of chemoradiotherapy, patients with potentially resectable disease (i.e., complete response, partial response, or stable disease) undergo surgery to remove the tumor.~CONSOLIDATION CHEMOTHERAPY: Within 2-4 weeks after surgery, patients with tumors that demonstrate positive immunohistochemistry for EGFR and/or cyclin D1 (in the pretreatment biopsy or in the residual tumor in the esophagectomy specimen) receive consolidation chemotherapy comprising erlotinib hydrochloride PO QD for 12 weeks."
3148363|NCT01560988|Experimental|Active Borage and Echium Seed Oils|Borage and echium oil capsules administered daily for six weeks, then a 6 week washout period, followed by ingestion of placebo (corn oil capsules) daily for 6 weeks.
3148364|NCT01560988|Experimental|Corn oil pills|Corn oil capsules daily for six weeks, then a 6 week washout period, followed by ingestion of Borage and echium oil capsules daily for 6 weeks.
3148365|NCT01560975|Experimental|Sensimed Triggerfish|
3148366|NCT01560962|Other|PI vs no intervention|
3148367|NCT01560962|Other|PI vs hygiene|
3148368|NCT01560962|Other|PI vs azasite|
3148369|NCT01560962|Other|PI vs tobradex|
3148370|NCT01560949|Experimental|Chemotherapy + Radiation|"SYSTEMIC PHASE: Chemotherapy with Oxaliplatin followed by Irinotecan followed by 5-FU. m FOLFIRINOX - oxaliplatin 75 mg/m2 d1 + irinotecan 150 mg/m2 d1 + 5-FUl 2,000 mg/m2 46h continuous infusion, every other week for 6 cycles (12 weeks).~CHEMORADIATION PHASE: This phase will start at least 2 weeks, but no more than 6 weeks after completion of the last cycle of mFOLFIRINOX. Chemoradiation with Gemcitabine: 350 mg/m2 IV over 35 minutes every week for 5 doses beginning day 1 (days 1, 8, 15, 22, 29)~Radiation: External beam radiation therapy will be delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions) to the GTV + 1.5 cm margin.~SURGERY- At least 4-6 weeks after last dose of Gemcitabine, if no local progression or distant metastasis. Patients whose scans show unequivocal local or distant progression are not candidates for surgery."
3148371|NCT01560923|Experimental|Treatment Arm|Oral Indoximod will be self-administered by mouth twice daily (1200 mg) for 6 months starting after the last (3rd) infusion of sipuleucel-T. Indoximod is a sterile tan powder compounded in capsule form of 200 mg.
3148372|NCT01560923|Placebo Comparator|Control (Placebo) Arm|Placebo is identical-looking to Indoximod and provided in the same manner.
3148373|NCT01560897|Experimental|C13|The dose of sodium [1-13C] acetate is calculated according to patient weight (27mg/kg) or (0.33 mmol / kg).
3148374|NCT01560884|Active Comparator|Group B|Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
3148375|NCT01560884|Active Comparator|Group C|Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
3148376|NCT01560884|Active Comparator|Group D|Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
3148377|NCT01560884|Active Comparator|Group A|Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
3148378|NCT01560871|Sham Comparator|Low-intensity IMT Plus Walking|"Inspiratory Muscle Training (IMT) intensity will be set at 15% PImax. The walking program will consist of walking every day at an intensity of hard to somewhat hard on the Rating of Perceived Exertion (RPE) scale. Participants will be instructed to walk at 15 minutes twice a day initially, then progress to 45-50 minutes a day by the end of the six weeks."
3148379|NCT01560871|Experimental|High-intensity IMT Plus Walking|"Inspiratory Muscle Training (IMT) intensity will be set at 60% PImax. The walking program will consist of walking every day at an intensity of hard to somewhat hard on the Rating of Perceived Exertion (RPE) scale. Participants will be instructed to walk 15 minutes twice a day initially, then progress to 45-50 minutes a day by the end of six weeks."
3148380|NCT01560845|Experimental|ABMSCi plus surgery group|Autologous bone marrow stem cells infusion through hepatic artery in open abdominal portal hypertension surgery
3148381|NCT01560845|No Intervention|portal hypertension surgery group|only portal hypertension surgery for this group patients
3148412|NCT01560598||Normal|those with normal GFS finding (without definite mucosal break at Z-line)
3148413|NCT01560585|Experimental|Open label|All participants will receive Isotretinoin for 24 weeks
3148382|NCT01560832||Laboratory (PCR)-confirmed C.difficile infection|patient who has experienced the passage of 3 or more unformed or loose stools [diarrhea] conforming to the shape of a container within a 24-hour period and has a positive laboratory test result confirmed by PCR.
3148383|NCT01560819|Experimental|Study Participants|Participants did not receive any bowel preparation before Gut Microbial Transplantation (GMT). Audio-visual aids were used to help reduce participants' anxiety about GMT.
3148384|NCT01560806|No Intervention|Conventional Healthcare services|People with high blood pressure detected during screening survey or opportunistically during study period will be referred to receive the conventional health care services for hypertension at district hospital or local commune health station
3148385|NCT01560806|Experimental|Commune Hypertension Management|People with high blood pressure were managed in commune-based hypertension management programme
3148386|NCT01560793|Experimental|VAX161B|Dose escalating study where subjects are treated with VAX161B at one of six dose levels. Subjects will be injected with VAX161B twice during the study at Day 0 and Day 21. The dosages are: 1 mcg; 2.5 mcg; 4 mcg; 6 mcg; 8 mcg; and 12 mcg.
3148387|NCT01560780|Experimental|Arm 1: Prasugrel|prasugrel 10 mg by mouth daily
3148388|NCT01560780|Placebo Comparator|Arm 2: Placebo|placebo by mouth once daily
3148389|NCT01560767|Active Comparator|Femoral Nerve Block|levobupivacaine
3148390|NCT01560767|Active Comparator|peri-articular infiltration|The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
3148391|NCT01560754|Experimental|Transdermal nicotine patch|Subjects will apply a combination of 7 or 14 mg nicotine transdermal patches until reaching their highest well tolerated dose of 7 to 28 mg/day.
3148392|NCT01560754|Placebo Comparator|Transdermal placebo patch|Subjects will apply a combination of 7 or 14 mg placebo transdermal patches until reaching their highest well tolerated dose.
3148393|NCT01560741|Active Comparator|Telemedicine Group|Patients will be initiated and adapted on non-invasive home mechanical ventilation in Pulmonology Department of S. João Hospital, in an outpatient setting, according to the prevailing standard of care for Chronic Respiratory Diseases patients in this unit. Patients will be provided with a ventilator outfitted with a wireless transmitter to allow the remote data collection of compliance and efficacy information. While patient sleeps, data is collected. If abnormalities criteria will be detected, remote titration of ventilator settings will be done to optimise therapy. Patient will be monitored again and data analyzed. This procedure will be repeated until we obtained the optimal ventilator parameters for each patient in this group. Nocturnal oximetry under home mechanical non-invasive ventilation will be carried out after one week and one month of treatment. Subjects also receive pre-arranged telephone calls to assist with progress.
3148394|NCT01560741|Other|Usual care|Patients will be initiated and adapted on non-invasive home mechanical ventilation in Pulmonology Department of S. João Hospital, in an outpatient setting, according to the prevailing standard of care for Chronic Respiratory Diseases patients in this unit. Patients will be assessed by a hospital visit scheduled at the end of third month after their initial adaptation. In this hospital visit data provided by the ventilator will be transferred to research team computer so they could evaluate patient compliance and efficacy of ventilation criteria under the parameters used at home present at the time of assessment. If abnormality criteria will be detected, re-titration of ventilator settings will be made. Patients will be encouraged to call their respiratory consultant any time they had a problem or concern.
3148395|NCT01560728|Experimental|Trauma-Focused CBT|Adapted or modified Trauma-Focused Cognitive Behavioral Therapy
3148396|NCT01560728|No Intervention|Wait list|Monitored while waiting for intervention
3148397|NCT01560715|Experimental|Experimental: Test group|Retinitis pigmentosa patients with best-corrected visual acuity (BCVA) worse than 20/200 or visual field less than 20 degrees
3148398|NCT01560702|Active Comparator|Autologous blood|Patients will be injected by autologous blood at the edge of actively bleeding ulcer
3148399|NCT01560702|Other|Epinephrine injection|Patients will be injected by diluted epinephrine at the edge of actively bleeding ulcer
3148400|NCT01560689|Active Comparator|BUDESONIDE/FORMOTEROL|
3148401|NCT01560689|Placebo Comparator|control|
3148402|NCT01560676|Active Comparator|HEALTH[e]TEEN|8 lessons over 6-8 weeks Education on healthy eating and physical activity Behavioral support for self-monitoring and goal setting
3148403|NCT01560676|Active Comparator|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks Education on healthy eating and coping skills training Behavioral support for self-monitoring and goal setting
3148404|NCT01560663||Docetaxel Carboplatino|Doses of AUC 5-6 of carboplatin in combination with 75 mg/m2 of docetaxel are easily combined, being myelosuppression the most important toxicity. This combination has been studied in metastatic breast cancer as well as in the neoadjuvant setting. The combination of taxanes and platinum salts is increasingly used as neoadjuvant chemotherapy for TNBC. The docetaxel-carboplatin (TCb) regimen is an active and tolerable regimen in metastatic and locally advanced breast cancer, and the efficacy and toxicity characterization in the clinical setting are regaining interest in the era where the role of anthracyclines is controversial in the adjuvant setting. The avoidance of potentially serious long-term toxicities in specific breast cancer subtypes is a real challenge in an attempt to individualize therapies.
3148405|NCT01560650|Experimental|high dose (35ml/kg/h)|> = 18 years of age, CRRT indications for acute kidney injury (RIFLE criteria) patients with cardiac surgery, was given filtration at a rate of 35 mL/kg/h.
3148406|NCT01560650|Experimental|low dose (25ml/kg/h)|> = 18 years of age, CRRT indications for acute kidney injury (RIFLE criteria) patients with cardiac surgery, was given filtration at a rate of 25 mL/kg/h.
3148407|NCT01560637|Experimental|UT-15C|Open label access
3148408|NCT01560624|Placebo Comparator|Placebo|Matching placebo (sugar pill)
3148409|NCT01560624|Active Comparator|Active|Active UT-15C Sustained release tablet
3148410|NCT01560611||High-risk cardiac surgery patient|
3299004|NCT00460538|Active Comparator|1|
3148414|NCT01560572|Active Comparator|standard immunosuupression|triple maintenance immunosuppression with tacrolimus OD (maintenance 6-10 ng/ml), mycophenolic acid 2 dd 540mg and prednisolone 7.5 mg
3148415|NCT01560572|Experimental|steroidfree|maintenance immunosuppression with tacrolimus OD (target range 6-10 ng/ml), mycophenolic acid (2 dd 540 mg)
3148416|NCT01560572|Experimental|low dose tacrolimus|triple maintenance immunosuppression with tacrolimus OD (maintenance 6-10 ng/ml), mycophenolic acid 2 dd 540mg and prednisolone 7.5 mg. After 6 months lowering of tacrolimus OD maintenance 3-5 ng/ml
3148417|NCT01560559|Experimental|Single Arm|Peroral endoscopic myotomy
3148418|NCT01560546|Active Comparator|Testim|
3148419|NCT01560546|Placebo Comparator|Placebo|Placebo for 24 weeks
3148420|NCT01560533|Other|Treated by HIPEC|Patients treated by HIPEC for peritoneal cancer
3148421|NCT01560533|Other|Standard chemiotherapy|Patients treated by standard chemiotherapy for peritoneal cancer
3148422|NCT01560520||Accelerometer|
3148423|NCT01560507|Active Comparator|varenicline (Chantix)|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation Nicotine Replacement Therapy (NRT) assessed the day before the scheduled quit day. They will receive varenicline.
3148424|NCT01560507|Active Comparator|nicotine patches|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation NRT (assessed the day before the scheduled quit day). They will continue to using only nicotine patches.
3148425|NCT01560507|Active Comparator|bupropion (Zyban) and nicotine patches|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation NRT (assessed the day before the scheduled quit day). They will receive bupropion with nicotine patches.
3148426|NCT01560494|Experimental|STAC curriculum|
3148427|NCT01560494|No Intervention|Conventional Curriculum|
3148428|NCT01560481|Experimental|Step A: metformin glycinate 620 mg|620mg single dose by mouth
3148429|NCT01560481|Experimental|Step A: metformin glycinate 1240 mg|1240mg single dose by mouth
3148430|NCT01560481|Experimental|Step A: metformin glycinate 2480 mg|2480mg single dose by mouth
3148431|NCT01560481|Active Comparator|Step A: metformin hydrochloride 1000 mg|1000mg single dose by mouth
3148432|NCT01560481|Experimental|Step A: metformin glycinate 1240 mg, food intake|1240mg single dose by mouth after food intake
3148433|NCT01560481|Experimental|Step B: metformin glycinate 620 mg BID|620mg BID for 8 days
3148434|NCT01560481|Active Comparator|Step B: metformin hydrochloride 500 mg BID|500mg tablets BID for 8 days
3148435|NCT01560468|Experimental|ITX 5061|Subjects will receive ITX 5061 for 28 days beginning at the time of liver transplantation for hepatitis C virus. 300mg will be administered on the day of surgery and for one week post transplant, followed by 150mg for an additional 21 days.
3148436|NCT01560455|Active Comparator|single stent|single stent
3148437|NCT01560455|Active Comparator|dual stent|dual stent (culotte)
3148438|NCT01560442||buprenorphine|
3148439|NCT01560442||Methadone Hydrochloride|
3148440|NCT01560429|Experimental|Patient controlled epidural analgesia|An epidural catheter sited preoperatively so analgesics can be administered postoperatively. Patients were titrated on a continuous analgesic epidural infusion until stable pain scores of ≤ 3 were reached while in PACU. Once stable, they were allocated to their preoperatively determined randomization which meant they still received 2/3rd of the anesthetic as a background infusion but also had the option to self-administer the remaining 1/3rd dose as patient controlled epidural analgesia (PCEA). Rescue analgesia was available upon request.
3148441|NCT01560429|Active Comparator|continuous epidural analgesia|An epidural catheter sited preoperatively so analgesics can be administered postoperatively. Patients were titrated on a continuous analgesic epidural infusion rate until stable pain scores of ≤ 3 were reached while in PACU (as described in the PCEA group). Once stable, they were allocated to their preoperatively determined randomization assignment which for the CEA group meant they remained on the continuous background epidural infusion rate previously determined to maintain pain scores ≤ 3 while in PACU. Rescue analgesia was available as needed.
3148442|NCT01560416|Active Comparator|Fulvestrant|Fulvestrant
3148443|NCT01560416|Active Comparator|Fulvestrant+Ganetespib|Fulvestrant and Ganetespib
3148444|NCT01560416|Active Comparator|Cross-Over|Fulvestrant and Ganetespib for participants originally assigned to arm A
3148445|NCT01560403|Experimental|Teduglutide|0.05 mg/kg/day
3148446|NCT01560390|Other|Rémifentanil + Kétamine|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
3148447|NCT01560390|Other|Rémifentanil + Placebo|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
3148448|NCT01560377|Experimental|Subjects Imaged with PINPOINT|Colonic tissue perfusion assessed with PINPOINT for laparoscopic left colectomy in the lower tract.
3148449|NCT01560364||Hemofilter|
3148450|NCT01560351|Experimental|rTMS|Session of repeated low-frequency Transcranial Magnetic Stimulation
3148451|NCT01560351|Sham Comparator|Placebo|Sessions of sham rTMS
3148452|NCT01560338||Pediatric after Cardiac Arrest|Pediatric patients greater than 3 kg. and less than 18 years suffering cardiac arrest who have been given or currently receiving morphine and/or midazolam and receiving hypothermia.
3148453|NCT01560325|Experimental|CKD-516 inj.|CKD-516 Inj, 3.3~13mg/m2/day, D1, 4, 8, 11 every 3 weeks
3148454|NCT01560312|Experimental|Renal denervation|Renal denervation + conventional antihypertensive medical treatment without spironolactone (spironolactone can be taken only if started before randomization)
3148455|NCT01560312|No Intervention|Medical treatment|"Conventional antihypertensive treatment including spironolactone (if not contraindicated).~One year after randomization, renal denervation can be performed according to the physician's decision based on the BP levels and if patient desires the procedure."
3148456|NCT01560299|Active Comparator|group one|This group will be advised to discontinue methimazole 24-48 hour before iodine therapy
3148504|NCT01559922|Experimental|Artefill|Dermal Filler
3148457|NCT01560299|Active Comparator|group two|methimazole stopped 48-72 hour before radioiodine therapy
3148458|NCT01560299|Active Comparator|group three|
3148459|NCT01560286|Active Comparator|Group 1|4-8 week induction of rAvPAL-PEG at 2.5 mg, followed by titration to maintenance dose
3148460|NCT01560286|Active Comparator|Group 2|8 mg single bolus dose of rAvPAL-PEG , followed by minimum 3-week break, then titration to maintenance dose
3148461|NCT01560273||Aspen Spinous Process Fixation Device|The Aspen device provides supplemental posterior fixation for fusion
3148462|NCT01560260|Experimental|Treatment (linsitinib)|Patients receive linsitinib 150mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3148463|NCT01560247||Treatment Group|Subjects in whom a MindFrame Device was employed for restoration of flow and clot removal
3148464|NCT01560234|Experimental|AZD8848|
3148465|NCT01560234|Placebo Comparator|Placebo|
3148466|NCT01560221|Experimental|Therapeutic Workplace|Participants will receive all standard services plus the Therapeutic Workplace intervention, in which access to stipend supported training and/or wage subsidies for community employment is contingent upon drug abstinence as verified by urinalysis.
3148467|NCT01560221|Active Comparator|Standard Services|Participants will receive methadone treatment or buprenorphine treatment, depending upon medical recommendations of their physicians, slot availability, and their own preferences. Participants who remain in treatment for at least 90 days will have the charge of prostitution that is pending against them dropped.
3148468|NCT01560195|Experimental|Pegylated rhG-CSF: 100µg/kg|Staged III or IV NSCLC patients receiving chemotherapy and Pegylated rhG-CSF 100µg/kg
3148469|NCT01560195|Experimental|Pegylated rhG-CSF: 6mg|Staged III or IV NSCLC patients receiving chemotherapy and pegylated rhG-CSF 6mg
3148470|NCT01560195|Placebo Comparator|Placebo|Staged III or IV NSCLC patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF in cycle 2 to 4
3148471|NCT01560169||Gluten challenge|Gluten containing or gluten-free study food in established celiac disease patients
3148472|NCT01560169||Observation|Observation in newly diagnosed celiac disease patients
3148473|NCT01560143|Other|Tigecycline|All subjects receive a single dose of tigecycline
3148474|NCT01560130|Active Comparator|Shape Up Rhode Island + Online Weight Loss + Incentives|
3148475|NCT01560130|Active Comparator|Shape Up Rhode Island + Online weight loss program|
3148476|NCT01560130|Active Comparator|Shape Up Rhode Island + Online weight loss program + groups|
3148477|NCT01560104|Experimental|veliparib and carboplatin and paclitaxel|Veliparib on Days 1-7 and carboplatin and paclitaxel on Day 3 of a 21 day cycle
3148478|NCT01560104|Placebo Comparator|placebo and carboplatin and paclitaxel|Placebo on Days 1-7 and carboplatin and paclitaxel on Day 3 of a 21 day cycle
3148479|NCT01560091|Placebo Comparator|Group A|Patients will receive ESWL and no medication
3148480|NCT01560091|Active Comparator|Group B|Patients will receive Flomax after ESWL
3148481|NCT01560091|Active Comparator|Group C|Patients will receive silodosin after ESWL
3148482|NCT01560065|Other|Normospermic patients|
3148483|NCT01560065|Other|Oligoasthenospermic patients|
3148484|NCT01560065|No Intervention|Control|
3148485|NCT01560052|Active Comparator|oral methylprednisolone|"oral methylprednisolone~Original Cohort:~Methylprednisolone group; start at 0.8mg/kg/day with a maximal 48mg/kg/day x 2months, taper by 8mg/day every month with optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines.~Low Dose Cohort:~Methylprednisolone group; start at 0.4mg /kg/day with a maximal dose of 32mg/day and a minimum dose of 24mg/day, reducing over 6-9months.~All participants will also receive standard guideline based care, without steroid therapy. Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months in the low-dose cohort, after randomisation, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
3148486|NCT01560052|Placebo Comparator|placebo|"Original Cohort:~Matching placebo; Optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines; Low Dose Cohort; Matching placebo: Optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines.~All participants will also receive standard guideline based care, without steroid therapy. Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months in the low-dose cohort, after randomisation, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
3148487|NCT01560039|Active Comparator|Real EEG-NF|10 EEG based neurofeedback sessions modulating the activity of the primary motor cortex
3148488|NCT01560039|Sham Comparator|Sham EEG-NF|10 sessions of Sham EEG_NF of the motor cortex area
3148489|NCT01560039|Active Comparator|Transcrainal Magnetic Stimulation|10 dailt TMS stimulation sessions of M1
3148490|NCT01560026||ovarian preservation|endometrial cancer with ovarian preservation
3148491|NCT01560026||oophorectomy|endometrial cancer without ovarian preservation
3148492|NCT01560013|Experimental|Naltrexone|Treatment with naltrexone for two months together with psycho-social support
3148493|NCT01560000|Other|fiber|
3148494|NCT01559987|Other|Control|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
3148495|NCT01559987|Other|Test|MTB + Floss
3148496|NCT01559987|Experimental|MTB + Waterpik Ultra Water Flosser High|MTB + Waterpik Ultra Water Flosser High
3148497|NCT01559974|Active Comparator|Vitamin D|
3148498|NCT01559974|Placebo Comparator|Placebo|
3148499|NCT01559961|Experimental|TTI-1612|Single intravesical 30-minute treatments with escalating doses of TTI-1612.
3148500|NCT01559948|Experimental|Lumbopelvic stabilization exc + belt|The participants will be instructed in the same lumbopelvic stabilization program. Additionally, during the initial session, those participants randomly assigned to the lumbopelvic stabilization plus belt group will also receive a pelvic compression belt.
3148501|NCT01559948|Active Comparator|Lumbopelvic stabilization exercise|The participants will be instructed in a lumbopelvic stabilization program.
3148502|NCT01559935|Experimental|Car-BiRD Therapy|Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD]
3148503|NCT01559922|Placebo Comparator|Placebo|Normal Saline
3299422|NCT00455169||1|Premature infants
3148506|NCT01559896|Experimental|intervention and placebo|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
3148507|NCT01559883||all eligible patients|there is only 1 Cohort in which all patients participating in this NIS are included
3148508|NCT01559870||patients with elective cardiac surgery|adult patients who had undergone elective cardiac surgery with CPB
3148509|NCT01559857|Active Comparator|Pioglitazone|50% of participants will be allocated to 12 weeks of treatment with 30 mg/day of Pioglitazone.
3148510|NCT01559857|Placebo Comparator|Sugar pill|50% of participants will be randomized to 12 weeks of treatment with placebo pill.
3148511|NCT01559844|Experimental|SOF+RBV|Sofosbuvir plus ribavirin for up to 48 weeks or until time of transplant, whichever occurs first.
3148512|NCT01559831|Other|IXIARO|IXIARO, applied according to licensed dose, intramuscular
3148513|NCT01559818|Experimental|IMM-101|IMM-101 1.0 mg administered intradermally
3148514|NCT01559805|Experimental|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
3148515|NCT01559805|Active Comparator|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
3148516|NCT01559779||Normal glucose tolerance|Morbidly obese subjects with normal glucose tolerance undergoing gastric bypass surgery
3148517|NCT01559766||4-6 years old group|
3148518|NCT01559766||7-9 years old group|
3148519|NCT01559753|Experimental|8 days of antibiotic treatment|Patients will receive a combination antibiotic during 5 days and then 3 days of a single Beta Lactam antibiotic
3148520|NCT01559753|Active Comparator|15 days antibiotic treatment|All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for 10 days according to the group. The beta-lactam antibiotics will be administered in high doses during the first 3 days of treatment. Aminoglycosides will be administered in a single daily dose, with a loading dose the first day of treatment.
3148521|NCT01559740|Experimental|0.25% Bupivacaine|All children will receive a single dose of 1 mcg/kg of Fentanyl intravenously prior to incision. Group TAP 1 receiving a TAP block with 0.25% bupivacaine with 1:200,000 epinephrine at a dose of 1 mL/kg.
3148522|NCT01559740|Experimental|0.125% Bupivacaine|All children will receive a single dose of 1 mcg/kg of Fentanyl intravenously prior to incision. Group TAP 2 will receive a TAP block with a total dose of 1 mL/kg given at a concentration of 0.125% bupivacaine with 1:200,000 epinephrine.
3148523|NCT01559727|No Intervention|Control|The patients with symptomatic heart failure were treated with standard treatment.
3148524|NCT01559727|Experimental|15 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
3148525|NCT01559727|Experimental|30 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day.
3148526|NCT01559727|Experimental|60 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day.
3148527|NCT01559714||Clinical HCM patients|Patients with an echocardiographically proven hypertrophic cardiomyopathy according to the ESC and ACCF/AHA guidelines
3148528|NCT01559714||Pre-clinical HCM patients|Individuals with a HCM associated mutation without the clinical characteristics of hypertrophic cardiomyopathy
3148529|NCT01559701|Experimental|PF-00345439 (oxycodone)|PF-00345439 (oxycodone)
3148530|NCT01559688|Experimental|ART therapy group|Participants in this arm will receive 2-5 sessions of ART therapy, depending on individual progress. Each session will last 60-90 minutes over a 2-week period.
3148531|NCT01559688|Active Comparator|Waitlist|Participants in this group will receive 2 fitness assessment or career counseling sessions. Each session will last 60-90 minutes over a 2-week period. Upon completion of this arm, participants will be offered the choice to start ART therapy.
3148532|NCT01559675|Active Comparator|Hydrocortisone High Dose|Intervention: Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
3148533|NCT01559675|Experimental|Hydrocortisone Low Dose|Intervention: 1/3 Intravenous equivalent dose (IVED) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD) 1, followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
3148534|NCT01559662|Experimental|Sugared Chewing Gum|Patient asked to chew sugared chewing gum postoperative day 1 to 7, 3 times a day, 45 minutes at a time
3148535|NCT01559662|No Intervention|No Gum|No gum given, routine postoperative care provided
3148536|NCT01559649||Group 1|Veterans admitted to MEDVAMC with a suspected ischemic or hemorrhagic stroke will be recruited. Individuals with a history of neurological disease other than stroke, head and neck structural surgery, or history of dysphagia unrelated to the current stroke will be excluded from participation. Individuals who are obtunded, medically unstable, greater than 5 days post-admission will be excluded. Patients with language or cognitive deficits who are judged by the attending neurologist to not have capacity to provide informed consent will be eligible to participate, but they must have an authorized representative available within 24 hours of admission to provide consent. Patients will undergo swallowing screening and videofluoroscopic swallowing study to establish validity of screening items
3148537|NCT01559649||Group 2|Stroke ward nurses. The nurses will administer and interpret the swallowing screening items. Speech pathologists will also make blinded, simultaneous interpretations of the screening items. Nurse and speech pathologist interpretation will be used to establish nursing reliability.
3148538|NCT01559636|Active Comparator|Diarrhea|Infants with diarrhea will have blood and stool sample taken and receive zinc and ORS. They will then receive bivalent oral polio vaccine as the intervention. Four weeks later another blood sample will be drawn to measure seroconversion.
3148630|NCT01559090|Experimental|2|MEDI-546 300 mg IV
3148539|NCT01559636|Active Comparator|Non-diarrhea|Infants without diarrhea will have blood and stool sample taken and receive multivitamins. They will then receive bivalent oral polio vaccine as the intervention. Four weeks later another blood sample will be drawn to measure seroconversion.
3148540|NCT01559610|No Intervention|Control Group|Received preoperative guidance by a member of healthcare team with the aid of checklist
3148541|NCT01559610|Other|Group intervention|preoperative guideline by a nurse
3148542|NCT01559597|Active Comparator|Cold chain|Group vaccinated with tetanus toxoid vaccine kept in cold chain
3148543|NCT01559597|Experimental|CTC|Group vaccinated with tetanus toxoid vaccine kept in controlled temperature chain
3148544|NCT01559584|Experimental|Phototherapeutic|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
3148545|NCT01559584|Active Comparator|Conventional therapy|One monthly injections of intralesional potent corticosteroids
3148546|NCT01559558||cystocele|
3148547|NCT01559545|Active Comparator|Metronidazole|Immediate release metronidazole
3148548|NCT01559545|Experimental|Metronidazole-DRF1|Modified release metronidazole (DRF1)
3148549|NCT01559545|Experimental|Metronidazole-DRF2|Modified release metronidazole (DRF2)
3148550|NCT01559532||ATK patients|Patients from our institution that underwent cemented TKA for degenerative knee disorders.
3148551|NCT01559519|Active Comparator|albumin|cirrhotic patients who underwent tips placement
3148552|NCT01559506|No Intervention|No device|Subject does not receive ABS system
3148553|NCT01559506|Experimental|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
3148554|NCT01559493||FFR; iFR|Interventional Cardiology, Pressure wire, fractional flow reserve, coronary flow measurement
3148555|NCT01559480|Active Comparator|Desogestrel|
3148556|NCT01559480|Placebo Comparator|Placebo|
3148557|NCT01559467|Other|Routine clinical care plus early CMR|
3148558|NCT01559467|No Intervention|Routine clinical care|
3148559|NCT01559467|Other|Routine clinical care plus early CTA|
3148560|NCT01559454|Active Comparator|Methadone|10-60 mg/day divided by 2-4 times a day
3148561|NCT01559454|Experimental|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day
3148562|NCT01559441|Experimental|Beetroot juice|
3148563|NCT01559441|Placebo Comparator|Carbohydrate control drink|
3148564|NCT01559428|Experimental|Plant sterol-enriched margarine|
3148565|NCT01559428|Experimental|Plant stanol-enriched margarine|
3148566|NCT01559428|Placebo Comparator|Control margarine|
3148567|NCT01559415|Experimental|Very Low Calorie Diet|
3148568|NCT01559415|Active Comparator|Low Calorie Diet|1250 kcal diet in which Modifast is given in combination with a normal diet
3148569|NCT01559402|Experimental|Start O2 100% and CPAP 10, end O2 100%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with an inspiratory oxygen fraction(FIO2) of 1.0, supplied by a continuous positive airway pressure of 10 centimeters of water(cmH2O), during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 1.0 is used. The intervention associated with this arm is labeled CPAP and 100% oxygen.
3148570|NCT01559402|Experimental|Start O2 100% and CPAP 10, end O2 31%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with a FIO2 of 1.0, supplied by a continuous positive airway pressure of 10 cmH2O, during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 0.3 is used. The intervention associated with this arm is labeled CPAP and 31% oxygen.
3148571|NCT01559402|Experimental|Start O2 100% and CPAP 0, end O2 100%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with a FIO2 of 1.0, without a continuous positive airway pressure, during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 1.0 is used. The intervention associated with this arm is labeled No CPAP and 100% oxygen.
3148572|NCT01559389|Other|solifenacin succinate|Open Label
3148573|NCT01559376||Endoscopic radial artery harvest|
3148574|NCT01559376||Conventional open radial artery harvest|
3148575|NCT01559363|Experimental|Cohort 1|One 50mg KD019 (tesevatinib) tablet per day for 28 days and up to 24 months
3148576|NCT01559363|Experimental|Cohort 2|Two 50mg KD019 (tesevatinib) tablets per day for 28 days and up to 24 months
3148577|NCT01559363|Experimental|Cohort 3|Three 50mg KD019 (tesevatinib) tablets per day for 28 days and up to 24 months
3148578|NCT01559363|Experimental|Phase 2a Monday, Wednesday, Friday|An alternate KD019 (tesevatinib) dosing schedule of dosing on Monday, Wednesday and Friday of each week for 24 months from their first dose or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the subject, or investigator decision
3148579|NCT01559363|Experimental|Phase 2a Monday and Thursday|An alternate KD019 (tesevatinib) dosing schedule of dosing on Monday and Thursday of each week for 24 months from their first dose or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the subject, or investigator decision
3148580|NCT01559363|Experimental|Phase 2a, 50mg|One 50mg KD019 (tesevatinib) tablet per day for 28 days and up to 24 months
3148581|NCT01559363|Experimental|Phase 2a, 50mg (SILK Cohort)|One 50mg KD019 (tesevatinib) tablet per day for 28 days and up to 24 months
3148582|NCT01559350||RGEA group|A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
3148583|NCT01559350||SVG group|A saphenous vein grafting in the right coronary artery system during OPCAB
3148584|NCT01559337|Other|Nerve repair|the dorsal branch of the proper digital nerve was used as a pedicle nerve for reconstructing PDN defects
3148585|NCT01559324|Experimental|Bifrontal ECT (BF)|Formula-based low dose BF ECT
3148586|NCT01559324|Experimental|Right unilateral ECT (RU)|Formula-based high-dose RU ECT
3148631|NCT01559090|Experimental|3|MEDI-546 1000 mg IV
3148632|NCT01559077|Active Comparator|ALN-TTR02|
3148633|NCT01559077|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3148587|NCT01559311|Active Comparator|CRT-P OFF|"Patients randomized into the Echo-guided Group were implanted with a CRT-P device (St. Jude Medical), which was programmed to DDDR pacing mode (CRT-P OFF) at implant. For each Echo-guided Group patient, presence of RVA pacing induced ventricular dyssynchrony was assessed within 24-hour of implant using the standardized criteria of Doppler echocardiography. The Echocardiography Core Laboratory (Echo Core Lab) then analyzed each image and the treatment allocation of the Echo-guided Group was done within 72-hour post implant based on the Echo Core Lab outcomes:~• Patients with the absence of RVA pacing induced ventricular dyssynchrony were allocated to the DDDR standard therapy with CRT-P remained OFF"
3148588|NCT01559311|Experimental|CRT-P ON|"Patients randomized into the Echo-guided Group were implanted with a CRT-P device (St. Jude Medical), which was programmed to DDDR pacing mode (CRT-P OFF) at implant. For each Echo-guided Group patient, presence of RVA pacing induced ventricular dyssynchrony was assessed within 24-hour of implant using the standardized criteria of Doppler echocardiography. The Echocardiography Core Laboratory (Echo Core Lab) then analyzed each image and the treatment allocation of the Echo-guided Group was done within 72-hour post implant based on the Echo Core Lab outcomes:~• Patients with the presence of RVA pacing induced ventricular dyssynchrony were allocated to the CRT-P standard therapy with CRT-P turned ON"
3148589|NCT01559311|Active Comparator|DDDR|Patients randomized into the Control Group were implanted with a DDDR device (St. Jude Medical) standard therapy.
3148590|NCT01559298|Active Comparator|Aspirin + clopidogrel|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin (80 mg/d) + clopidogrel (75 mg/d) following the TAVI procedure.
3148591|NCT01559298|Active Comparator|Aspirin|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin (80 mg/d)
3148592|NCT01559285|Active Comparator|0.375% ropivacaine|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
3148593|NCT01559285|Active Comparator|0.75% ropivacaine|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
3148594|NCT01559285|Active Comparator|0.2% ropivacaine|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
3148595|NCT01559272|Experimental|Panel A|Panel A consists of 2 treatment groups
3148596|NCT01559272|Experimental|Panel B|Panel B consists of 5 treatment groups
3148597|NCT01559272|Experimental|Panel C|Panel C consists of 1 treatment group
3148598|NCT01559272|Experimental|Panel D|Panel D consists of 4 treatment groups
3148599|NCT01559259|Experimental|Ibuprofen/acetaminophen (lower dose)|
3148600|NCT01559259|Experimental|Ibuprofen/acetaminophen (middle dose)|
3148601|NCT01559259|Experimental|Ibuprofen/acetaminophen (high dose)|
3148602|NCT01559259|Active Comparator|Ibuprofen|
3148603|NCT01559259|Placebo Comparator|Placebo|
3148604|NCT01559246||Cardiac Arrhythmia|Subjects 18 years of age or greater that have indications for traditional cardiac(Holter) monitoring.
3148605|NCT01559233|Experimental|FPlus|
3148606|NCT01559220|Experimental|Open Label|DBS Implant and stimulation
3148607|NCT01559207||Patients with VTE|"Group P is composed of all patients with a history of VTE. Group Px is a subgroup of 15 patients from group P. Members of Px are randomly selected from P."
3148608|NCT01559207||Healthy volunteers|"Group T: 15 healthy volunteers with no history of VTE will be included in this group."
3148609|NCT01559194|Active Comparator|Low Fat Diet + Exercise|Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
3148610|NCT01559194|Active Comparator|Low Carbohydrate Diet + Exercise|Subjects were educated about a low carbohydrate diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
3148611|NCT01559181||Exposure to intrauterine hyperglycemia|The study group includes the offspring of women with type 1 diabetes from the national diabetes birth registry (1993-99, n=900) with information of HbA1c prior to conception and/or 1st trimester HbA1c.
3148612|NCT01559181||Control group|The control group including offspring of women without diabetes who delivered during the same period matched with respect to gender and age of offspring and the family's postcode as an indirect marker of the socioeconomic background.
3148613|NCT01559168|Experimental|Prolapse patients recieving UpHold LITE|Non-pregnant female patients >= 50 years who are not considering future pregnancies, who are diagnosed with uterine or vault prolapse with ICS POP-Q score of stage 2 or greater, who are receiving the UpholdTM LITE mesh kit and who agree to be in the study.
3148614|NCT01559155||Bullous pemphigoid|Patients in this cohort are newly diagnosed (or have not started treatment) with bullous pemphigoid
3148615|NCT01559155||Other bullous-like auto-immune|Patients in this cohort are newly diagnosed (or have not started treatment) with pemphigus (15 patients) or cutaneous lupus (15 patients)
3148616|NCT01559155||Control group|Patients in this cohort are hospitalized at the Nîmes University Hospital, and have no history of autoimmune, inflammatory or neoplastic disease. Patients are matched for age and sex with patients in the bullous pemphigoid cohort.
3148617|NCT01559142|Active Comparator|IFX TG|
3148618|NCT01559142|Active Comparator|IFX alone|
3148619|NCT01559129|Active Comparator|Pomalidomide (1 mg once daily)|
3148620|NCT01559129|Placebo Comparator|Placebo|
3148621|NCT01559116|Experimental|tiotropium+olodaterol FDC low dose|tiotropium+olodaterol FDC low dose; 2 inhalations once daily (a.m. dosing)
3148622|NCT01559116|Experimental|tiotropium+olodaterol FDC high dose|tiotropium+olodaterol FDC high dose; 2 inhalations once daily (a.m. dosing)
3148623|NCT01559116|Active Comparator|tiotropium low dose|tiotropium low dose; 2 inhalations once daily (a.m. dosing)
3148624|NCT01559116|Active Comparator|tiotropium high dose|tiotropium high dose; 2 inhalations once daily (a.m. dosing)
3148625|NCT01559116|Active Comparator|olodaterol|one dose only; 2 inhalations once daily (a.m. dosing)
3148626|NCT01559116|Placebo Comparator|placebo|2 inhalations once daily (a.m. dosing)
3148627|NCT01559103|Experimental|MEDI5117|Intravenous infusion administered over 60 minutes
3148628|NCT01559103|Placebo Comparator|MEDI5117 Placebo|Intravenous infusion administered over 60 minutes
3148629|NCT01559090|Experimental|1|MEDI-546 100 mg IV
3148634|NCT01559064||Age group A|Subjects 30 to 40 years old
3148635|NCT01559064||Age group B|Subjects 40 to 50 years old
3148636|NCT01559064||Age group C|Subjects over 50 years old
3148637|NCT01559051|Experimental|Intravenous Injection and Inhalation infusion of AD-SVF|AD-SVF harvested from Autologous Adipose Tissue will be deliver after processing via IV and Inhalation
3148638|NCT01559038||adalimumab|Responding to treatment with non-biologic DMARDs (disease-modifying antirheumatic drugs) and initiated on treatment with adalimumab as monotherapy or in combination with other medications
3148639|NCT01559038||DMARD (disease-modifying antirheumatic drugs)|Initiated on non-biologic DMARD(disease-modifying antirheumatic drugs) or requiring switching to another non biologic DMARD (disease-modifying antirheumatic drugs) as monotherapy, or in combination with other medications
3148640|NCT01559025|No Intervention|Insulin therapy|Patients will receive the conventional treatment with insulin
3148641|NCT01559025|Active Comparator|Vildagliptin|Patients will receive vildagliptin besides the conventional treatment with insulin
3148642|NCT01559012|Other|clonidine first - placebo second|in this group patients are treated with transdermal clonidine first for 5 days then switch to placebo for 5 days
3148643|NCT01559012|Other|placebo first - clonidine second|in this group patients are treated with placebo first for 5 days then with transdermal clonidine for next 5 days
3148644|NCT01558999|Experimental|High concentration SI-614|
3148645|NCT01558999|Experimental|Low concentration SI-614|
3148646|NCT01558999|Placebo Comparator|Vehicle|
3148647|NCT01558986|Active Comparator|Treatment Arm|Patients to receive intravenous cefazolin 1 gram within 30 minutes prior to skin incision
3148648|NCT01558986|Placebo Comparator|Placebo Arm|Patients to receive sterile water only within 30 minutes prior to skin incision
3148649|NCT01558973||Cocaine dependent|
3148650|NCT01558973||Opioid dependent|
3148651|NCT01558973||Alcohol dependent|
3148652|NCT01558973||Healthy controls|
3148653|NCT01558973||Adolescents|
3148654|NCT01558973||Pathological gamblers|
3148655|NCT01558960|Experimental|IVit Treatment group|Intravitreal injections of Melphalan
3148656|NCT01558947|Experimental|chemotherapy with ECX|chemotherapy with ECX
3148657|NCT01558947|Experimental|chemotherapy with XP|chemotherapy with XP
3148658|NCT01558934|Experimental|Lofexidine Titration in Methadone Maintained Subjects|Methadone maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID or to the highest level tolerated. Following this initial titration attempt, all subjects will have their methadone dose reduced by 50% and lofexidine titration efforts will resume. If the therapeutic dose is not reached under 50% methadone reduction conditions, the methadone dose will be further reduced to 0 mg for 2 days followed by reintroduction of 25% of the starting dose on the 3rd day, and on such 3rd day lofexidine titration will resume again.
3148659|NCT01558921|Experimental|B: 5x5Gy -> CAPOX -> surgery|experimental group (arm B) M1 scheme
3148660|NCT01558921|Active Comparator|A: 5 weeks chemoradiation -> surgery|control group (arm A) standard long course chemoradiotherapy
3148661|NCT01558908|Experimental|Intramuscular injection of ERC|
3148662|NCT01558895|Experimental|Conventional Treatment and Infrared ray heat treatment group|conventional treatment consist of antiviral drugs, lowering aminotransferase and jaundice medicine.
3148663|NCT01558895|Active Comparator|conventional treatment group|conventional treatment consist of antiviral drugs, lowering aminotransferase and jaundice medicine.
3148664|NCT01558882||10 patients|The patients included desire tubal sterilization via the ESSURE technique.
3148665|NCT01558869|Experimental|Arm 1|
3148666|NCT01558856|Active Comparator|Unilateral testing|"Following standard procedures, patients in this group will have unilateral testing for neuromodulation of the sacral nerves.~Intervention: Unilateral electrode placement and testing"
3148667|NCT01558856|Experimental|Bilateral testing|"Patients in this group will have bilateral testing for neuromodulation of the sacral nerves.~Intervention: Bilateral electrode placement and testing"
3148668|NCT01558843||traumatic brain injury|
3148669|NCT01558843||aneurysmal subarachnoid hemorrhage|
3148670|NCT01558843||intracerebral hematoma|
3148671|NCT01558843||brain tumor|
3148672|NCT01558830|Placebo Comparator|sugar pill|one pill twice daily, uptitrated to two pills twice daily to mirror ranolazine prescription strategy
3148673|NCT01558830|Active Comparator|Ranolazine|500 mg twice daily, titrated to 1000 mg twice daily if needed for relief of anginal symptoms
3148674|NCT01558817|Active Comparator|Informational brochure|Patients receive an informational brochure
3148675|NCT01558817|Experimental|Intervention|Patients receive physician-directed informed assent intervention regarding CPR and informational brochure.
3148676|NCT01558804||Rapid Strep Positive|Children will be eligible for this study if they are ages 4 to 16 years and have been diagnosed to have acute pharyngitis caused by GAS (with a positive rapid antigen detection test (RADT) and have not been treated with antibiotics in the last 30 days. Children will be excluded if they are allergic to beta lactam antibiotics. Children will be enrolled at either one of two large pediatric practices in Madison, Wisconsin (20 S. Park St or West Clinic) or at the Pediatric Afterhours Clinic at University Station. They will present with acute symptoms of sore throat and fever. A RADT will be used for diagnosis.
3148677|NCT01558791|No Intervention|Arm 1|"Participants will be screened as usual. These participants will have the TBI screening as usual, without the educational intervention."
3148678|NCT01558791|Experimental|Arm 2|Participants will be given the TBI handout (educational intervention) along with the usual TBI screen.
3148679|NCT01558778|Experimental|Supportive care (whole body vibration)|Patients undergo mechanical stimulation over 20 minutes QD beginning on date of hospital admission and continuing through day 100 post-HCT, except for day 0 (date of transplant).
3148680|NCT01558765|Experimental|Intervention group|Patients receive integrated rehabilitation
3148681|NCT01558765|No Intervention|Control group|Patients receive usual follow-up care without physical exercise
3148682|NCT01558752|Experimental|Titanium Shell with CORAIL stem|Patients in Group 1 will receive a total hip replacement with titanium shell and CORAIL stem.
3148729|NCT01558479||Family Member|Has a family history of Parkinson's disease. Can be affected or unaffected with Parkinson's disease
3148683|NCT01558752|Active Comparator|Modular Titanium Femoral Stem (Tri-Lock)|Patients in Group 2 will receive a total hip replacement with Modular Titanium Femoral Stem (Tri-lock).
3148684|NCT01558739|Experimental|INC424|Patients diagnosed with PMF, PPV MF, or PET-MF were treated with oral INC424 at a dose of 15 - 20 mg (dose based on Baseline platelet count) twice daily.
3148685|NCT01558726|Experimental|Case management|
3148686|NCT01558726|Active Comparator|Usual treatment|Usual treatment of the CAPSad
3148687|NCT01558713|Active Comparator|Group BFS|Group B: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
3148688|NCT01558713|Active Comparator|Group RFS|Group R : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
3148689|NCT01558713|Active Comparator|Group LFS|Group L: LEVO-BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
3148690|NCT01558713|Active Comparator|BupivacaineF|Group BupivacaineF: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY
3148691|NCT01558713|Active Comparator|RopivacaineF|Group RopivacaineF : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY.
3148692|NCT01558713|Active Comparator|LevobupivacaineF|Group LevobupivacaineF: LEVO-BUPIVACAINE 0,5% (2ml) + 10μg FENTANYL(0,2ml) INTRATHECALLY.
3148693|NCT01558700|Experimental|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
3148694|NCT01558700|Placebo Comparator|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
3148695|NCT01558687|Experimental|Group A = Cilengitide Group|Cilengitide + SoC (Temolozomide + Radiotherapy)
3148696|NCT01558687|Active Comparator|Group B = Control Group|SoC (Temolozomide + Radiotherapy)
3148697|NCT01558674|Experimental|MK-7145 8 mg (Part I:Period 1)|Single daily dose of 8 mg MK-7145 for 5 days, capsules, orally administered in a fasted state
3148698|NCT01558674|Active Comparator|Furosemide 40 mg (Part I:Period 2)|Two daily doses of one 40 mg Furosemide tablet for 5 days administered in a fasted state
3148699|NCT01558674|Experimental|MK-7145 16 mg (Part I:Period 3)|Single daily dose of 16 mg MK-7145 for 5 days, capsules, orally administered in a fasted state
3148700|NCT01558674|Active Comparator|Furosemide/Torsemide Run-in (Part II:Period1)|Run-in of stable, clinically optimized maintenance dose regimen of furosemide or torsemide for at least 2 weeks
3148701|NCT01558674|Experimental|MK-7145 10 mg (Part II:Period 2)|Single daily dose of 10 mg MK-7145 for 14 days, capsules, orally administered in a fasted state
3148702|NCT01558674|Experimental|MK-7145 16 mg (Part II:Period 3)|Single daily dose of 16 mg MK-7145 for 14 days, capsules, orally administered in a fasted state
3148703|NCT01558674|Experimental|MK-7145 24 mg (Part II:Period 4)|Single dose of 24 mg MK-7145 for 28 days, capsules, orally administered in a fasted state
3148704|NCT01558661|Experimental|AG-013736 (AXITINIB)|This is a single-arm phase II study evaluating the clinical efficacy of axitinib in the treatment of patients with progressive, recurrent/metastatic adenoid cystic carcinoma (ACC).
3148705|NCT01558648||Pts having Minimally Invasive esophagectomy|This is a prospective non-randomized study comprising two surgical cohorts of esophageal cancer patients. Patients will be assigned to each of the two intervention groups, MIE versus OE, based on a combination of patient referral patterns, patient preference, and surgeon preference/expertise.
3148706|NCT01558648||Pts having open esophagectomy|This is a prospective non-randomized study comprising two surgical cohorts of esophageal cancer patients. Patients will be assigned to each of the two intervention groups, MIE versus OE, based on a combination of patient referral patterns, patient preference, and surgeon preference/expertise.
3148707|NCT01558635|Experimental|Cardioblate CryoFlex Surgical Ablation|Subjects with longstanding persistent AF undergoing Maze III procedure using the Cardioblate CryoFlex Surgical Ablation System concomittant to Mitral valve surgery
3148708|NCT01558622|Placebo Comparator|dexketoprofen trometamol|Dexketoprofen trometamol is a water-soluble salt of the dextrorotatory enantiomer of the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen.
3148709|NCT01558622|Placebo Comparator|tramadol hydrochloride|Tramadol Hydrochloride is a well-known centrally acting opioid pain killer.
3148710|NCT01558622|Placebo Comparator|pethidine hydrochloride|Pethidine is a synthetic opioid analgesic which produces a pattern of effects similar to morphine the standard against which opioid analgesics are compared.
3148711|NCT01558622|Placebo Comparator|dexketoprofen trometamol + tramadol hydrochloride|
3148712|NCT01558622|Placebo Comparator|dexketoprofen trometamol + pethidine hydrochloride|
3148713|NCT01558622|Placebo Comparator|vitamin c|
3148714|NCT01558596|Placebo Comparator|Sham|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
3148715|NCT01558596|Experimental|RIPC|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
3148716|NCT01558583|Other|Rating and Ranking Group|A group of individuals from the United States and Australia who complete a rating and ranking task.
3148717|NCT01558583|Other|Discrete Choice Group|A group of individuals from the United States and Australia who complete a discrete choice experiment task.
3148718|NCT01558583|Other|Balance Sheet Group|Individuals from the United States and Australia who will complete an implicit values clarification task
3148719|NCT01558570||Schizophrenia|
3148720|NCT01558557|Experimental|Gluten Free Diet|
3148721|NCT01558544|Other|Use of high dose chemotherapy|Use of chemotherapy without removal of the disease ovary.
3148722|NCT01558531||DEB|paclitaxel-eluting balloon angioplasty
3148723|NCT01558531||conventional PTA|historical conventional balloon angioplasty control group (patients referred to our institution between 2008 and 2009)
3148724|NCT01558505|Active Comparator|standard PTA|conventional balloon angioplasty
3148725|NCT01558505|Experimental|Drug-eluting balloon angioplasty|paclitaxel-eluting balloon angioplasty
3148726|NCT01558492|Experimental|All subjects|Carboplatin and Paclitaxel
3148727|NCT01558479||Case|Has a diagnosis of Parkinson's disease
3148728|NCT01558479||Control|No diagnosis of Parkinson's disease
3148730|NCT01558466|Placebo Comparator|Group A - Placebo|iNO combined with placebo will be administered
3148731|NCT01558466|Active Comparator|Group B- Sildenafil|iNO combined with Sildenafil
3148732|NCT01558453|Experimental|Eloxatin|Oxaliplatin
3148733|NCT01558440|Active Comparator|Infant Formula|A diet that is being fed to the young infants
3148734|NCT01558440|Experimental|F-100|• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
3148735|NCT01558440|Experimental|Diluted F-100|300 ml of water is added to 1000 ml of F-100
3148736|NCT01558427|Experimental|Active clinical surveillance|Active monitoring of patients with low volume metastases with Prostate Specific Antigen (PSA) and sequential imaging.
3148737|NCT01558427|Experimental|Salvage treatment of metastases|Surgical or radiotherapy treatment of metastases.
3148738|NCT01558414|Experimental|SILS|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
3148739|NCT01558414|Experimental|FSIS|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
3148740|NCT01558414|Active Comparator|Conventional laparoscopy|Cholecystectomy performed by a conventional laparoscopic approach
3148741|NCT01558401|Experimental|Physical activity program Group|The physical activity program consists of 123 sessions over 52 weeks. The initial assessment is followed by 12 weeks of physical activity. After this ten-week period, a second assessment is performed, followed by 3 weeks of rest. This is followed by a further 17 weeks of activities, 4 weeks of activities followed by 4 weeks of rest. Finally, there were 12 more weeks of activities.
3148742|NCT01558388|Experimental|Vaginal lactobacilli|
3148743|NCT01558388|Placebo Comparator|Placebo|
3148744|NCT01558375|Placebo Comparator|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injected daily for 12 weeks.
3148745|NCT01558375|Experimental|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
3148746|NCT01558362|Experimental|123I-CMICE-013|Administration and analysis of alternative MPI radiotracer
3148747|NCT01558349||Hospitalized controls|Patients that have been hospitalized at the Nîmes University Hospital and who do not have dermatological cancer.
3148748|NCT01558349||Metastatic melanoma|This cohort includes patients with metastatic melanoma.
3148749|NCT01558336|Experimental|Praziguantel|tablet single dose
3148750|NCT01558323|Experimental|LCQ908 (mild renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with mild renal impairment and will receive a single 40 mg dose of LCQ908.
3148751|NCT01558323|Experimental|LCQ908 (moderate renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with moderate renal impairment and will receive a single 40 mg dose of LCQ908.
3148752|NCT01558323|Experimental|LCQ908 (severe renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with severe renal impairment and will receive a single 40 mg dose of LCQ908.
3148753|NCT01558310|Active Comparator|Group A|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52.The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
3148754|NCT01558310|Placebo Comparator|Group B|Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
3148755|NCT01558297|Experimental|Motivational Interviewing|
3148756|NCT01558297|Active Comparator|Nutritional Counseling|
3148757|NCT01558297|Active Comparator|Treatment as usual|
3148758|NCT01558271|Experimental|LY2189265|Once-weekly subcutaneous (SC) injection of 0.75 milligrams (mg) of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
3148759|NCT01558271|Placebo Comparator|Placebo/LY2189265|Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
3148760|NCT01558271|Active Comparator|Liraglutide|Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy.
3148761|NCT01558258|Experimental|Mindfullness Meditation-based Intervention|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
3148762|NCT01558258|No Intervention|Wait-list control group|The wait-list control condition will control for naturally occurring changes in stress and other outcomes over the six-week intervention period. After the post-treatment assessments have been completed, those assigned to the wait-list control group will be able to participate in the MAP classes.
3148763|NCT01558245|Experimental|Tissue kallikrein group|Patients in this group will be prescribed with intravenous infusion of TK (0.15 PNAU/d, dissolved in 100ml saline) for 7 days after stenting and then oral administration of pancreatic kallikrein enteric-coated tablet (240U, 3/d) to the end of study. As the foundation treatment, all the enrolled patients will receive aspirin (100 mg/d), clopidogrel (75 mg/d), and atorvastatin (20 mg/d) for the first 6 months and continue with the combination of aspirin and atorvastatin at the previous dosage.
3148764|NCT01558245|No Intervention|Control group|Patients in control group will receive foundation treatment, including aspirin (100 mg/d), clopidogrel (75 mg/d), and atorvastatin (20 mg/d) for the first 6 months and continue with the combination of aspirin and atorvastatin at the previous dosage.
3148765|NCT01558232|Experimental|Tibion Arm|Arm of the study in which enrolled subacute post-stroke subjects undergo lower extremity physical therapy using the Tibion Bionic Leg.
3148766|NCT01558219|Experimental|acitive anticancer drug|single cytostatic agent, cabazitaxel every second week in the treatment of castration resistant metastatic prostate cancer after docetaxel
3148767|NCT01558206||Patients with impression of PTE|Those with signs and symptoms in favor of pulmonary thromboembolism.
3148768|NCT01558193|Placebo Comparator|Placebo|Two placebos consumed
3148769|NCT01558193|Active Comparator|Multi-vitamin/mineral|Subjects took multi-vitamin/mineral and placebo fatty acid capsule
3148770|NCT01558193|Active Comparator|Docosahexaenoic acid|Subjects took docosahexaenoic acid capsule and placebo vitamins/minerals
3148771|NCT01558193|Active Comparator|DHA plus vitamins/minerals|Subjects took both fatty acid and vitamin/mineral supplements
3148772|NCT01558180|Experimental|Telephone Care Management|calls from a registered nurse to educate caregivers about behavioral sleep strategies
3148773|NCT01558180|Placebo Comparator|Usual Care|It's a placebo comparator because individuals in this group will receive an educational handout on behavioral sleep strategies. This handout approximates standard of care.
3148774|NCT01558167|Experimental|Bendamustine, Rituximab,Lenalidomide|Dose modification treatment plan of lenalidomide
3148775|NCT01558154|Experimental|Chinese herb|Chinese herbs special for depression
3148776|NCT01558154|Experimental|acupuncture|
3148777|NCT01558154|Experimental|Psychotherapy|
3148778|NCT01558154|Experimental|physiotherapy|
3148779|NCT01558141|Active Comparator|Follicular flushing|Flushing follicles with embryo culture media prior to aspiration.
3148780|NCT01558128|Other|Amiodarone with cardioversion|If subject converts to normal sinus rhythm following amiodarone no further intervention is taken, if subject remains in atrial fibrillation following amiodarone they are cardioverted.
3148781|NCT01558115|Experimental|Denosumab - Group #1|Receive active drug for year 1 and year 2 of the study
3148782|NCT01558115|Placebo Comparator|Placebo - Group #2|Receive placebo for year 1 and active drug for year 2 of the study
3148783|NCT01558089||etanercept + methotrexate|
3148784|NCT01558076||Subjects with sickle cell anemia|60 subjects with sickle cell anemia will be enrolled on the study.
3148785|NCT01558076||30 healthy controls|30 controls without sickle cell anemia or sickle cell trait will be enrolled on the study.
3148786|NCT01558063|Active Comparator|Ketamine Dose 1|0.1 mg/kg, IV (in the vein)
3148787|NCT01558063|Active Comparator|Ketamine Dose 2|0.2 mg/kg, IV (in the vein)
3148788|NCT01558063|Active Comparator|Ketamine Dose 3|0.3 mg/kg, IV (in the vein)
3148789|NCT01558063|Active Comparator|Ketamine Dose 4|0.4 mg/kg, IV (in the vein)
3148790|NCT01558063|Active Comparator|Ketamine Dose 5|0.5 mg/kg, IV (in the vein)
3148791|NCT01558063|Placebo Comparator|Saline Solution|Saline infused over 40 minutes
3148792|NCT01558050|Experimental|red rice|commercially available red rice nutritionial supplement
3148793|NCT01558050|Placebo Comparator|placebo|placebo capsules
3148794|NCT01558037||Main study|Main study patients are enrolled before or at time of solid organ transplant. Qualifying subjects either have tested positive for Cytomegalovirus or have a donor who has tested positive for Cytomegalovirus.
3148795|NCT01558037||Sub study|Subjects are enrolled to this arm who have begun replicating Cytomegalovirus post transplant. These subjects may or may not have been on the main study arm.
3148796|NCT01558024||C1S patients|"18 Patients with venous insufficiency: C1S patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
3148797|NCT01558024||C3 patients|"18 Patients with venous insufficiency: C3 patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
3148798|NCT01558024||C5 patients|"18 Patients with venous insufficiency: C5 patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
3148799|NCT01558024||Sedentary volunteers|18 healthy volunteers with a sedentary lifestyle (< 2h of physical activity per week)
3148800|NCT01558024||Active volunteers|18 healthy volunteers with an active lifestyle (between 2 and 6 hours of physical activity per week)
3148801|NCT01558024||Athletic volunteers|18 healthy volunteers with an athletic lifestyle (over 6 hours of physical activity per week for at least one year)
3148802|NCT01558011|Experimental|chemotherapy|"Chemotherapy:~Drug: Capecitabine, Oxaliplatin, Docetaxel Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy."
3148803|NCT01557998|No Intervention|Control|IDUs in the control arm will receive the behavioral survey, follow-up interviews, health education and training sessions on how to recruit peers, the rapid HIV test, and the point of care CD4 test but will not be assigned a peer case manager.
3148804|NCT01557998|Experimental|CD4 and Peer Case Management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 <500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention.
3148805|NCT01557985|Experimental|Transversus abdominis plane (TAP) Block|All participants in the study will receive a Transverses abdominis plane (TAP) Block in conjunction with their surgery.
3148806|NCT01557972||1. Morning HP and NT|Subjects based on HBP were divided into MH and MN patients
3148807|NCT01557972||2. Clinic HP and NT|Subjects based on CBP were divided into CH and CN patients
3148808|NCT01557959|Experimental|Treatment (chemo, chemoprotection, antiangiogenesis therapy)|Patients receive docetaxel IV over 1 hour on day 1, cisplatin IV over 1 hour on day 1, and pegfilgrastim subcutaneously on day 2. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of docetaxel, cisplatin, and pegfilgrastim, patients receive oral erlotinib hydrochloride once daily in the absence of disease progression or unacceptable toxicity.
3148809|NCT01557946|Experimental|Major Depression|Participants with major depressive disorder received citalopram 20-40 mg daily for 6 weeks. MRI scans were acquired at baseline and days 3, 7, and 42.
3148810|NCT01557946|No Intervention|Healthy Volunteers|Healthy volunteer participants did not receive citalopram and performed one MRI scan.
3148811|NCT01557933||ECT|All study subjects have consented to receive ECT.
3149147|NCT01555424|Active Comparator|Reference dose|
3149148|NCT01555411||No treatment|
3148812|NCT01557920|Active Comparator|Propofol|The healthy subject will be anesthetized with Propofol. Respiratory measurements will be taken while the subject is anesthetized to calculate the airway closing pressure. After recovery from anesthesia, airway diameter and duty cycle will also be measured. In addition to breathing air mixture, subject will be given carbon dioxide to achieve end tidal CO2 levels of 4 mm and 8 mm above baseline. All respiratory measurements will be repeated at each level above baseline. Assessment of swallow patterns during anesthesia and wakefulness, as well as under differential CO2 levels will be assessed offline after recovery from anesthesia.
3148813|NCT01557920|Active Comparator|Sevoflurane|The healthy subject will be anesthetized with Sevoflurane. Respiratory measurements will be taken while the subject is anesthetized to calculate the airway closing pressure. After recovery from anesthesia, airway diameter and duty cycle will also be measured. In addition to breathing air mixture, subject will be given carbon dioxide to achieve end tidal CO2 levels of 4 mm and 8 mm above baseline. All respiratory measurements will be repeated at each level above baseline. Assessment of swallow patterns during anesthesia and wakefulness, as well as under differential CO2 levels will be assessed offline after recovery from anesthesia.
3148814|NCT01557907|Experimental|Intradermal - BD Research Catheter Set|Intradermal delivery of insulin (basal and bolus delivery) using the BD Research Catheter Set with 34G x 1.5 mm side-ported needle and the Animas Vibe insulin pump over a three day period.
3148815|NCT01557907|Active Comparator|Subcutaneous - Medtronic Quick-Set|Subcutaneous delivery of insulin (basal and bolus delivery) using the Medtronic Quick Set with 6 mm Teflon catheter and the Animas Vibe insulin pump over a three day period.
3148816|NCT01557894|Experimental|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for Social Phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
3148817|NCT01557894|No Intervention|Waitlist control group|Waitlist control group
3148818|NCT01557881|Experimental|Diagnostic (PET/MRI)|After undergoing standard PET/CT, patients undergo PET/MRI.
3148819|NCT01557868|Active Comparator|Synvisc (hylan G-F 20)|
3148820|NCT01557868|Active Comparator|Euflexxa (1% sodium hyaluronate)|
3148821|NCT01557842|Active Comparator|Treatment Group|This group receives radiofrequency catheter ablation and drug treatment.
3148822|NCT01557842|Experimental|Control Group|This group receives only drug treatment.
3148823|NCT01557829|Active Comparator|PEEK interbody cage|Posterior fusion with an interbody spacer (cage) made from polyetheretherketone (PEEK) plastic. The open space in the center of the cage is filled with local bone or bone harvested from the iliac crest.
3148824|NCT01557829|Experimental|Valeo OL ceramic cage|Posterior fusion with the Valeo OL cage, a silicon nitride ceramic interbody spacer. The center area of the cage is filled with autograft local bone or bone harvested from the iliac crest.
3148825|NCT01557816|Active Comparator|Naproxen|
3148826|NCT01557816|Sham Comparator|Placebo|
3148827|NCT01557803||Starting ART|Adult patients starting anti retroviral therapy for the first time
3148828|NCT01557777|Experimental|Navitoclax, ABT-263|
3148829|NCT01557764|Experimental|Treatment (enzyme inhibitor and monoclonal antibody)|Patients receive lapatinib PO QD on days 1-21 and trastuzumab IV over 90 minutes on day 1 of a 21-day cycle. Treatment continues in the absence of disease progression or unacceptable toxicity.
3148830|NCT01557751|Other|Total knee arthroplasty subjects who are genotyped|All patients will have whole blood drawn for genotyping, and participate in the various assessments (psychosocial questionnaires, qualitative sensory testing, etc).
3148831|NCT01557738|Experimental|Acute effects of flavanol consumption|The outcome measurements will be made on all study participants before and 2 hours after consumption of the high flavanol beverage.
3148832|NCT01557738|Placebo Comparator|Low Flavanol Trial; acute effects|Once again, the outcome measurements will be made on all study participants before and 2 hours after consumption of the low flavanol beverage.
3148833|NCT01557738|Experimental|Long-term effects of flavanol consumption|Only those study participants over 60 years of age will continue with this arm of the trial. The same outcome measures will be performed following 4 weeks of daily consumption of a high flavanol beverage.
3148834|NCT01557738|Placebo Comparator|Low Flavanol Trial; long-term effects|Only those study participants over 60 years of age will continue with this arm of the trial. The same outcome measures will be performed following 4 weeks of daily consumption of a low flavanol beverage.
3148835|NCT01557725||THR/TKR patients|Any patients receiving fast-track THR or TKR in departments participating in the Lundbeck Foundation Centre for fast-track THR and TKR
3148836|NCT01557712|Experimental|Ketamine+venlafaxine|one injection of 0.5 mg/kg of kentamine the first day plus venlafaxine (150-375 mg day) during 6 weeks
3148837|NCT01557712|Active Comparator|venlafaxine|venlafaxine (150-375 mg day) during 6 weeks
3148838|NCT01557699|Experimental|PMV via Puffhaler® Device|The dry powder measles vaccine will be administered via a Puffhaler® device. A single dose of 10 mg will be used.
3148839|NCT01557699|Experimental|PMV via SoloventTM device|The dry powder measles vaccine will be administered via a SoloventTM device. A single dose of 10 mg will be used.
3148840|NCT01557699|Active Comparator|Licensed Subcutaneous Measles Vaccine|Licensed measles vaccine will be administered subcutaneously as single dose of 0.5 ml.
3148841|NCT01557673|Active Comparator|NG bolus feeding over 5 min|Tube bolus (TB): feed administered via syringe through NG tube over 5 min.
3148842|NCT01557673|Placebo Comparator|Continuous NG feeding over 4 h|Continuous tube drip feeding (TD): feed pump delivered via the NG tube over 4 h.
3148843|NCT01557660|Experimental|inhaled treprostinil|
3148844|NCT01557647|Experimental|inhaled treprostinil|
3148845|NCT01557647|Placebo Comparator|placebo|
3148846|NCT01557634|Experimental|Closed-loop with diluted insulin|Insulin pump therapy using diluted insulin (20 IU/ml) will be driven by computer-based algorithm from 1700 on Day 1 until 0800 on Day 2
3148847|NCT01557634|Active Comparator|Closed-loop with non-diluted insulin|Insulin pump therapy using standard non-diluted insulin (100 IU/ml) will be driven by computer-based algorithm from 1700 on Day 1 until 0800 on Day 2
3148848|NCT01557621|Experimental|Collaborative Population-Based Recall-Phone/Mail Group|Collaborative Pop-Based R/R: Phone/Mail Group Private providers, local public health departments, and the state immunization registry (CIIS) collaborate to send notices to families whose children appear in need of an immunization.
3148849|NCT01557621|Experimental|Collaborative Population-Based Recall-Mail Only Group|Collaborative Pop-Based R/R: Mail-Only Group Private providers, local public health departments, and the state immunization registry (CIIS) collaborate to send notices to families whose children appear in need of an immunization.
3148850|NCT01557621|Active Comparator|Practice-based Recall|Practice-based Recall
3148851|NCT01557608|Experimental|Photon stimulation|
3148852|NCT01557608|Placebo Comparator|Placebo treatment|
3148853|NCT01557595|Experimental|Adults with ADHD|"Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. Subjects will 19 years or older and have ADHD"
3148854|NCT01557582|Other|Right ventrical volumn comparison|Single arm study comparing Ventripoint Medical System (VMS) right ventricle volume measurement to gold standard cardiac Magnetic Resonance Imaging (cMRI) measurement in patients with Pulmonary Arterial Hypertension.
3148855|NCT01557569|Active Comparator|Atomoxetine|Group receiving atomoxetine
3148856|NCT01557569|Placebo Comparator|Placebo|Group will receive placebo instead of atomoxetine
3148857|NCT01557517|Experimental|Group 1|Patients will rinse oral cavity with 10cc of clobetasol 0.05% for 2 minutes 3 times a day.
3148858|NCT01557517|Placebo Comparator|Group 2|Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
3148859|NCT01557504|Experimental|Sitagliptin/metformin XR followed by placebo|Day 1 (Period 1): participants will receive a single dose of two sitagliptin/metformin XR tablets with a low- to moderate-fat meal (breakfast). Days 2-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
3148860|NCT01557504|Placebo Comparator|Placebo only|Days 1-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
3148861|NCT01557491|Active Comparator|Straight Incision|incision made perpendicular to scalp surface
3148862|NCT01557491|Active Comparator|Bevelled Incision|Incision made at 45 degrees to scalp surface
3148863|NCT01557478|Placebo Comparator|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
3148864|NCT01557478|Active Comparator|Melatonin 20mg|20 mg melatonin gelatin capsule
3148865|NCT01557452|Experimental|Givinostat|
3148866|NCT01557439|Experimental|Levocetirizine Dihydrochloride tablets 5 mg|Levocetirizine dihydrochloride Tablets, 5 mg of M/s Ipca Laboratories Limited, India
3148867|NCT01557439|Active Comparator|Xyzal|XYZAL (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA
3148868|NCT01557426|Other|Ultrasound|Single interventional group - patients agree to an ultrasound of their skin or soft tissue infection and an ultrasound to an uninfected portion of skin.
3148869|NCT01557413|Experimental|Intramedullary nail|Intramedullary nail
3148870|NCT01557413|Experimental|Locked plate|Locked plate
3148871|NCT01557400|Experimental|Ataluren|Ataluren
3148872|NCT01557387||Patients with pseudopolyps.|No treatment involved in this study.
3148873|NCT01557374|Active Comparator|Maintenance Tocilizumab, Abatacept|No modification in biotherapy dose and administration frequency
3148874|NCT01557374|Experimental|Decrease Tocilizumab, Abatacept|Progressive decrease by predetermined pattern. Progressive injection interval increase (by stage)
3148875|NCT01557361|Active Comparator|Standard RRT initiation|RRT is initiated >12 hours after eligibility determination. Once a decision is made to start RRT, a dialysis catheter will be placed and RRT initiated as soon as possible.
3148876|NCT01557361|Experimental|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility.
3148877|NCT01557348||Rituximab|Eligible participants will receive rituximab as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
3148878|NCT01557348||Alternative TNFi|Eligible participants will receive alternative TNFi treatment as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
3148879|NCT01557335|Experimental|Clopidogrel (Plavix®) and PA32540|PA32540 and Clopidogrel (Plavix®) tablet, 10 hours post PA32540
3148880|NCT01557335|Active Comparator|EC aspirin, EC omeprazole, Clopidogrel|
3148881|NCT01557322||Biologic|
3148882|NCT01557322||non-biologic DMARD|
3148883|NCT01557296|Placebo Comparator|Diabetic diet|Control group. Subjects with Insulin Treated Diabetes Mellitus and Gastroparesis. Diet: Food of large particle size during 20 weeks.
3148884|NCT01557296|Active Comparator|Diet food in small particle size|Intervention group: Subjects with Insulin Treated Diabetes and Gastroparesis. Intervention Diet: Food of small particle size during 20 weeks.
3148885|NCT01557283||Plaque psoriasis patients|Plaque psoriasis patients treated with Enbrel after the approval of the new belgian reimbursement criteria
3148886|NCT01557270|Experimental|ropivacaine + dexmedetomidine|This group represents the standard of care drug (ropivacaine) plus the new additive to be studied (dexmedetomidine)
3148887|NCT01557270|Active Comparator|ropivacaine + saline|This group represents the current standard of care in peripheral nerve blockade
3148888|NCT01557257|Experimental|40 mg ALO-02 capsule|Single- and multiple-dose of 40 mg ALO-02 capsule under 50 mg naltrexone block
3148889|NCT01557257|Experimental|80 mg ALO-02 capsule|Single- and multiple-dose of 80 mg ALO-02 capsule under 50 mg naltrexone block
3148890|NCT01557257|Experimental|40 mg OxyContin tablet|Single- and multiple-dose of 40 mg OxyContin tablet under 50 mg naltrexone block
3148891|NCT01557244|Experimental|Fesoterodine PR 4 mg|Fesoterodine PR 4 mg for 12 weeks in active comparator period, followed by 12 weeks in safety extension period
3148892|NCT01557244|Experimental|Fesoterodine PR 8 mg|Fesoterodine 8 mg for first week followed by 11 weeks at 8 mg in active control period, followed by 12 weeks in safety extension period.
3148893|NCT01557244|Active Comparator|Oxybutynin|Oxybutynin
3148894|NCT01557244|Experimental|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg for 12 weeks in efficicay period, followed by 12 weeks in safety extension period.
3149149|NCT01555398|Experimental|Fasting conditions|Investigational product administrated under fasting condition.
3148895|NCT01557244|Experimental|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg for first week followed by 11 weeks at 8 mg in the efficacy period, followed by 12 weeks in safety extension period.
3148896|NCT01557231||No treatment|OA
3148897|NCT01557218|Experimental|Cucumber|
3148898|NCT01557218|Experimental|Pepper|
3148899|NCT01557218|Experimental|Tomato|
3148900|NCT01557218|Experimental|Vegetable variety|
3148901|NCT01557218|Experimental|Apple|
3148902|NCT01557218|Experimental|Peach|
3148903|NCT01557218|Experimental|Pineapple|
3148904|NCT01557218|Experimental|Fruit variety|
3148905|NCT01557192|Active Comparator|Active LFMS treatment|20 minute exposure to the LFMS electromagnetic field treatment
3148906|NCT01557192|Placebo Comparator|Sham LFMS treatment|20 minute exposure to either the sham (inactive) electromagnetic field treatment
3148907|NCT01557179|Experimental|Hyaluronic acid vaginal gel (Hyalofemme)|The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
3148908|NCT01557179|Active Comparator|Estriol cream (Ovestin)|The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
3148909|NCT01557166|Experimental|Liraglutide 3.0 mg|
3148910|NCT01557166|Placebo Comparator|Placebo|
3148911|NCT01557153|Experimental|Amlodipine|
3148912|NCT01557153|Placebo Comparator|Placebo|
3148913|NCT01557140|Placebo Comparator|RASi plus placebo|RAS inhibition was optimized and after patients were randomly assigned to receive placebo
3148914|NCT01557140|Experimental|RASi plus carvedilol|RAS inhibition was optimized and after patients were randomly assigned to receive carvedilol
3148915|NCT01557127||Group 1|
3148916|NCT01557114|Experimental|radiation therapy with Ipilimumab|
3148917|NCT01557101|Other|COLON CAPSULE ENDOSCOPY|
3148918|NCT01557101|Other|OPTICAL COLONOSCOPY|
3148919|NCT01557075|Active Comparator|Atorvastatin group|Atorvastatin 40 mg daily for 12 months after randomization
3148920|NCT01557075|Active Comparator|Pravastatin group|Pravastatin 20mg daily for 12 months after randomization
3148921|NCT01557062|Other|Polysomnography|
3148922|NCT01557062|Other|Temperature measure|
3148923|NCT01557062|Other|Fibromyalgia Impact questionary|
3148924|NCT01557049|Experimental|Postural Reeducation Group|The participants, after obtaining a written informed consent, were randomized for one of the two groups: In the Global Postural Reeducation group (GPR), they were submitted 1 time per week, during 12 weeks, at GPR sessions. The duration of sessions was 60 minutes each, with the same physical Therapist of the study. After the intervention, subjects returned to assessment 3 months after, with the blinded assessor. All the 6 postures from GPR were used during the study. All outcomes measurements, in both groups, were validated for Portuguese language and applicable at baseline, 3 months and 6 months after baseline.
3148925|NCT01557049|No Intervention|Control Group|In the control group, no physical intervention was given during the study. After the study, 6 months after, all participants from control group received the same treatment given in GPR group, according to the Unifesp Ethics Committee orientations. All participants, of both groups, have a doctor from the study, if necessary.
3148926|NCT01557036||Aneurysms treated with Pipleline|Aneurysms treated with Pipleline. All patients independently treated according to the labeled indications for use with the Pipeline Embolization Device
3148927|NCT01557023|Experimental|dienogest 2 mg/ethynilestradiol 30 mcg;|
3148928|NCT01557023|Active Comparator|Yasmin®|
3148929|NCT01557010|Experimental|Treatment A|
3148930|NCT01557010|Experimental|Treatment B|
3148931|NCT01557010|Experimental|Treatment C|
3148932|NCT01557010|Placebo Comparator|Treatment D|
3148933|NCT01556997|Experimental|XOMA 985|fixed-dose combination of perindopril arginine/amlodipine besylate(PERa/AMLb)
3148934|NCT01556997|Active Comparator|Amlodipine Besylate (AMLb)|
3148935|NCT01556997|Active Comparator|Perindopril Erbumine (PERe)|
3148936|NCT01556984||DSA group|
3148937|NCT01556984||control group|
3148938|NCT01556971|Active Comparator|Botox|The study will be divided randomly into two groups of equal number; one arm will receive a Botox injection; the other will receive saline solution injection
3148939|NCT01556971|Placebo Comparator|Saline Solution|A saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
3148940|NCT01556958||Active Wheezing - age 5-12|
3148941|NCT01556958||Active Wheezing - under age 5|
3148942|NCT01556958||No Wheezing|
3148943|NCT01556945|Experimental|Group A : FMP1/AS02 + RTS,S/AS02|FMP1 malaria vaccine given with the GlaxoSmithKline (GSK) adjuvant system, number 2 (AS02) and a second experimental malaria vaccine RTS,S also given with AS02 adjuvant concomitantly as separate sites of injection on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
3148944|NCT01556945|Experimental|Group B : FMP1/AS02 + RTS,S/AS02|FMP1 malaria vaccine given with the adjuvant AS02 and a second experimental malaria vaccine RTS,S also given with AS02 adjuvant at one injection site and saline at the opposite site on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
3148945|NCT01556945|Experimental|Group C: FMP1/AS02 + AS02|FMP1 malaria vaccine given with the adjuvant AS02 and a second experimental malaria vaccine RTS,S also given with adjuvant AS02 adjuvant alone at one injection site and saline at the opposite site on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
3148946|NCT01556945|Experimental|Group D : RTS,S/AS02 + AS02|RTS,S malaria vaccine given with the adjuvant AS02 and an adjuvant AS02 alone concomitantly at separate sites of injection on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
3148947|NCT01556945|Placebo Comparator|Control cohort|Infectivity controls (unvaccinated). Non-randomized infectivity controls were recruited specifically for the malaria challenge phase of the trial.
3148992|NCT01556581|Active Comparator|Early Physical Therapy (PT)|All subjects in this group will get usual care approach in addition to immediately receiving eight sessions of physical therapy based on a pragmatic treatment based classification system for treating low back pain.
3148948|NCT01556932|Experimental|Placebo then ABH|"All subjects randomized to two sequences of treatments: either placebo-ABH or ABH-placebo. All participants will receive both drug A and drug B.~After applying gel, Drug A or B, on wrists for 2 minutes, time 0. From baseline to 60 minutes of treatment two options will occur. At 60 minutes, if patients have at least 1 point reduction in their nausea score, they must wait 4 hours before switching to opposite drug. After administration of drug, the study procedures will be repeated. Or, at 60 minutes, if no change or increase in nausea score has been recorded, alternative treatment will be given. If the second treatment is ineffective at one hour (total time 2 hours) then alternative usual medications will be given. After completion of study treatment, patients are followed up for up to 8 hours."
3148949|NCT01556932|Experimental|ABH then placebo|"All subjects randomized to two sequences of treatments: either placebo-ABH or ABH-placebo. All participants will receive both drug A and drug B.~After applying gel, Drug A or B, on wrists for 2 minutes, time 0. From baseline to 60 minutes of treatment two options will occur. At 60 minutes, if patients have at least 1 point reduction in their nausea score, they must wait 4 hours before switching to opposite drug. After administration of drug, the study procedures will be repeated. Or, at 60 minutes, if no change or increase in nausea score has been recorded, alternative treatment will be given. If the second treatment is ineffective at one hour (total time 2 hours) then alternative usual medications will be given. After completion of study treatment, patients are followed up for up to 8 hours."
3148950|NCT01556919||Mucosal Impedance Probe|
3148951|NCT01556906|Experimental|Lomitapide|This is an open label trial where all patients receive lomitapide (AEGR733/BMS-201038)at escalating doses
3148952|NCT01556893|Other|LASIK Flap Arm|This is a single arm study.
3148953|NCT01556880|Experimental|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
3148954|NCT01556880|No Intervention|Standard usual care|
3148955|NCT01556867|Active Comparator|dry cord care|
3148956|NCT01556867|Active Comparator|antiseptic care|
3148957|NCT01556841|Experimental|TroVax®|TroVax® consists of a highly attenuated VV (Modified Vaccinia Ankara, MVA) containing the human TAA 5T4 under regulatory control of a modified VV promoter, mH5.
3148958|NCT01556841|Placebo Comparator|Placebo|
3148959|NCT01556815|Active Comparator|Group TACE|Patients who undergo TACE
3148960|NCT01556815|Experimental|Group Combination|Patients who are treated with sorafenib combined with TACE
3148961|NCT01556802|Experimental|Minocicline|minocicline 100mg oral twice a day for 5 days
3148962|NCT01556802|Placebo Comparator|Placebo|Pills filled with vegetal fiber with similar presentation of the drug. Given one pill oral twice a day for five days
3148963|NCT01556789|Experimental|ONT-10 Vaccine|ONT-10 investigational agent
3148964|NCT01556776|Experimental|Lenalidomide|lenalidomide maintenance following firstline treatment with FCR, BR, FR, or FC(if Rituximab is contraindicated)
3148965|NCT01556776|Placebo Comparator|Placebo|placebo
3148966|NCT01556763|Placebo Comparator|Placebo|Matching placebo was administered as one capsule per day for 21 days.
3148967|NCT01556763|Experimental|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
3148968|NCT01556763|Experimental|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
3148969|NCT01556737|Experimental|Supplement|
3148970|NCT01556737|Placebo Comparator|Placebo|
3148971|NCT01556724|Active Comparator|0.2% ropivacaine nerve block (standard of care)|0.2% ropivacaine in lumbar plexus nerve catheter infusions for postoperative analgesia
3148972|NCT01556724|Experimental|0.1% ropivacaine infusion in nerve block catheter|0.1% ropivacaine in lumbar plexus nerve catheter infusions
3148973|NCT01556711||Head Injury|Males and females ages 18 to 80 (the entire age range), who are admitted to the ED, who are suspected of a traumatically induced structural brain
3148974|NCT01556711||Control|"A 'normal' control group will be recruited for comparison and will consist of ED patients (ED normal control group) who have sustained an injury but do not exhibit any trauma above the clavicle and no history of MVA requiring an ED visit or TBI within the past one (1) year, and no primary complaint of syncope"
3148975|NCT01556698|Experimental|NVN1000 Topical Gel|
3148976|NCT01556698|Placebo Comparator|Topical Gel Vehicle|
3148977|NCT01556685|Active Comparator|Group 1 Avonex|Approximately 90 subjects treated with IFN beta 1a IM 30μg
3148978|NCT01556685|Active Comparator|Group 2 Jumtab|Approximately 90 subjects treated with IFN beta 1a IM biosimilar
3148979|NCT01556672|Experimental|adalimumab|All patients will receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
3148980|NCT01556659|Active Comparator|Triple antithrombotic therapy|Treatment with aspirin, P2Y12 inhibitors and vitamin K antagonist.
3148981|NCT01556659|No Intervention|Triple anti-thrombotic therapy|Treatment with aspirin, P2Y12 inhibitors and vitamin K antagonist.
3148982|NCT01556646|Experimental|Tolvaptan|Open label study of tolvaptan. First 3 days as an inpatient then outpatient for the remainder of the study
3148983|NCT01556633|Experimental|Volunteers on dialysis|
3148984|NCT01556633|Experimental|Volunteers with reduced creatinine clearance|
3148985|NCT01556607|Active Comparator|Experimental: MDT-637|
3148986|NCT01556607|Placebo Comparator|Placebo|
3148987|NCT01556594|Experimental|Nasal Glucagon 1 mg|Nasal glucagon (NG) administered as single dose of 1 milligram (mg).
3148988|NCT01556594|Experimental|Nasal Glucagon 2 mg|NG administered as single dose of 2 mg.
3148989|NCT01556594|Active Comparator|SC Glucagon|Glucagon solution dose of 1 mg administered as a single subcutaneous (SC) injection.
3148990|NCT01556594|Experimental|Nasal Glucagon 3 mg|NG administered as single dose of 3 mg (composed of one dose of 1 mg NG immediately followed by one dose of 2mg NG).
3148991|NCT01556581|Active Comparator|Usual Care (UC)|The usual care (UC) group will be managed with stepped care approach, receiving a screening exam, advice, education, activity limitation profile and medications if needed, but no early physical therapy.
3149314|NCT01554254|Experimental|300mcg/kg/day for 28 days|
3148993|NCT01556568|Experimental|MEK162|Patients will be treated with MEK162 only and will be uptitrated or down titrated based on safety and tolerability observed.
3148994|NCT01556555||Primary sclerosing cholangitis|Patients with a definite diagnosis of sclerosing cholangitis and a clinical indication for ERCP.
3148995|NCT01556542|Active Comparator|standard PTA|nitinol stent implantation
3148996|NCT01556542|Experimental|DEB|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
3148997|NCT01556529|Experimental|risk profile information|patient gets information on quantitative individual complication risk profile and patient gets standard T2DM DMP care
3148998|NCT01556529|Active Comparator|Control|Control group: patient gets standard T2DM DMP care
3148999|NCT01556516||Women with Pompe Disease|
3149000|NCT01556503||Pigmented Lesion|Patients identified as having a concerning pigmented lesion and the physician believes it is appropriate to biopsy to rule out melanoma.
3149001|NCT01556490|No Intervention|Control group|Standard-of-care sorafenib, with no added therapy
3149002|NCT01556490|Experimental|Treatment group|Standard-of-care sorafenib plus TheraSphere
3149003|NCT01556477|Active Comparator|azacitidine|
3149004|NCT01556477|Experimental|azacitidine + lenalidomide|
3149005|NCT01556464|Experimental|ACPAP|Patients in the intervention group will be introduced to the auto-adjusting CPAP (ACPAP) (ResMed S9) during the day and placed on it at night with a nocturnal oximetry and ACPAP download to assess its effectiveness and pressure requirements. The intervention is the application of the ACPAP. The patients will be discharged on ACPAP pressure determined by the ACPAP download (95th percentile pressure in absence of significant air leak) and will be scheduled for an outpatient repeat diagnostic PSG and, if indicated, a full night titration study.
3149006|NCT01556464|No Intervention|Control|The control group will receive nocturnal oxygen or no therapy while in the hospital and after discharge at the discretion of the attending physician. They will be scheduled for outpatient repeat diagnostic PSG and then, if indicated, a full night titration study.
3149007|NCT01556451|Experimental|Zoster Vaccine Live|Single subcutaneous injection of 0.65 mL in the deltoid region of arm on Day 1
3149008|NCT01556438|Experimental|100 mg LY2127399+BTZ IV+Dex|Cohort 1. 100 mg LY2127399 intravenously (IV) on day 1 of each cycle. Bortezomib (BTZ), 1.3 milligram per square meter (mg/m^2), IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dexamethasone (Dex), 20 mg/day, on day of and day after BTZ.
3149009|NCT01556438|Experimental|300 mg LY2127399+BTZ IV+Dex|Cohort 2. 300 mg LY2127399 IV on day 1 of each cycle. BTZ, 1.3 mg/m^2, IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ.
3149010|NCT01556438|Experimental|300 mg LY2127399+BTZ SC+Dex|Cohort 2-SC. 300 mg LY2127399 IV on day 1 of each cycle. BTZ, 1.3 mg/m^2, subcutaneously (SC) on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ. Cohort 2-SC was added per protocol amendment in February 2013.
3149011|NCT01556425|Experimental|Vivitrol Only|The VIVITROL group will be offered one injection of VIVITROL every 4 weeks. Participants in the VIVITROL group will be required to take their scheduled injections to work and earn wages. If a participant misses a scheduled VIVITROL injection (more than 3 days from the scheduled date of administration), the participant will not be allowed to work until the injection is accepted. Additionally, missing a scheduled injection will result in a base pay reset from $8 per hour to $1 per hour. After the reset, the participant's base pay will increase by $1/hour to the maximum of $8/hour for every day that the participant works at least 5 minutes.
3149012|NCT01556425|Experimental|VIVITROL&Opiate Abstinence Reinforcement|This group will be offered VIVITROL and will be required to take it to attend the workplace and to maintain maximum pay. This group will also receive employment-based opiate abstinence reinforcement. This contingency will require participants to provide opiate-negative urine samples on M,W, and F to maintain their maximum pay. If a participant in this group provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
3149013|NCT01556425|Experimental|Opiate Abstinence Reinforcement Only|This group would receive employment-based opiate abstinence reinforcement, but this group will not receive VIVITROL.
3149014|NCT01556425|Other|Usual Care Control|This group will receive neither abstinence reinforcement nor VIVITROL injections, but they will be invited to attend the workplace and outpatient drug abuse counseling.
3149015|NCT01556412||Chronic hepatopathy suspicious of PSC|"All patients with chronic hepatopathy of unknown origin and a high risk of primary sclerosing cholangitis as the underlying disease for chronic hepatopathy.~This group includes all patients with cholestatic hepatopathy (predominantly elevated gamma-glutamyltransferase and alkalic phosphatase) and positive ANCAs (Anti-neutrophil cytoplasmic antibodies) and/or inflammatory bowel disease in medical history.~Other explanations of cholestatic hepatopathy (like pancreatic tumor or cholelithiasis) must not be apparent in patients eligible for this study.~Furthermore, infection oder extrahepatic cholestasis already proven by laboratory results or percutaneous ultrasound, which make endoscopic retrograde cholangiography necessary, are exclusion criteria in this study."
3149016|NCT01556399||Duodenal adenomas|Patients who consent to participate in this study will have a small sample of their adenoma and normal tissue sent for molecular testing.
3149017|NCT01556386||Pharmacogenetic analysis, ALL|
3149018|NCT01556373||severe sepsis|patients with severe sepsis
3149019|NCT01556373||Controls|Controls matched to patients on age, sex and cardiovascular risk factors
3149020|NCT01556347|Experimental|Elimination of Immunologic Memory|A single arm multi-drug regimen is used to delete immunologic memory in order to reduce or eliminate alloreactive anti-HLA antibodies in highly sensitized heart transplant candidates. The intervention includes a protocol of Thymoglobulin, Rituximab, plasmapheresis and Bortezomib.
3149021|NCT01556334|Experimental|Azithromycin|Azithromycin 1g po
3149022|NCT01556334|Active Comparator|Erythromycin|Erythromycin IV followed by po for a total of 5 days.
3149023|NCT01556321|Experimental|Green tea, normal weight|Subjects with a BMI 18.5-25 kg/m2 will receive green tea capsules, which they have to consume daily for a period of twelve weeks
3149360|NCT01554085|Placebo Comparator|Placebo|
3149024|NCT01556321|Placebo Comparator|Placebo, normal weight|Subjects with a BMI 18.5-25 kg/m2 will receive placebo capsules, which they have to consume daily for a period of twelve weeks
3149025|NCT01556321|Experimental|Green tea, overweight|Subjects with a BMI >30 kg/m2 will receive green tea capsules, which they have to consume daily for a period of twelve weeks
3149026|NCT01556321|Placebo Comparator|Placebo capsules, obese|Subjects with a BMI >30 kg/m2 will receive placebo capsules, which they have to consume daily for a period of twelve weeks
3149027|NCT01556308|Experimental|DM-EBS|
3149028|NCT01556295||Experimental|
3149029|NCT01556295||Control|
3149030|NCT01556282|Experimental|Therasphere|
3149031|NCT01556256|Experimental|Arm I (TMV)|See detailed description.
3149032|NCT01556256|Experimental|Arm II (TMV+P)|See detailed description.
3149033|NCT01556243|Experimental|Breast conservation surgery and radiation therapy|Patients undergo breast conserving surgery. Patients receive adjuvant chemotherapy at the physician's discretion. Patients receiving chemotherapy will start treatment within 12 weeks following surgery. Patients receive radiation therapy within 8 weeks following the last dose of chemotherapy or within 10 weeks following surgery if not receiving chemotherapy. Patients receive endocrine therapy at the physician's discretion. Patient observation will occur every 6 months until 5 years after the end of radiation therapy.
3149034|NCT01556230||Group I|The first group of subjects, Group I, will be followed in Protocol I and are a group of subjects with an apparent clinically nonfunctioning pituitary lesion who will be studied in a prospective study of conservative non-surgical management.
3149035|NCT01556230||Group II|A second group of subjects, Group II, are subjects who are undergoing surgical intervention for CNFA or radiotherapy for CNFA and these subjects will be studied in a prospectively follow up as part of Protocol II.
3149036|NCT01556217|Experimental|JNJ-39393406|
3149037|NCT01556217|Placebo Comparator|Placebo|
3149038|NCT01556204|Experimental|Robotic Surgery|Robotic surgery using the da Vinci Surgical System
3149039|NCT01556204|Active Comparator|Laparoscopy|Laparoscopic assisted resection of endometriosis will be performed using up to five 5mm ports.
3149040|NCT01556191|Experimental|Gefinitib + Fulvestrant (patient with EGFR mutations)|
3149041|NCT01556191|Active Comparator|Erlotinib (wild type patients)|
3149042|NCT01556191|Experimental|Erlotinib + Fulvestrant (wild type patients)|
3149043|NCT01556191|Active Comparator|Gefinib (patient with EGFR mutations)|
3149044|NCT01556178||Children without central nervous system tumors|Children without central nervous system tumors between the ages of 1 year and 21 years who are undergoing a neurosurgical procedure to address hydrocephalus
3149045|NCT01556165|Experimental|rasagiline|
3149046|NCT01556165|Placebo Comparator|placebo|
3149047|NCT01556152|Active Comparator|Treatment Arm 1|
3149048|NCT01556152|Active Comparator|Traetment Arm 2|
3149049|NCT01556152|Placebo Comparator|Treatment Arm 3|
3149050|NCT01556139|Experimental|Spirotiger|Patients belonging to this group perform 20 sessions of usual training (cyclette and calisthenic exercises) and additional 20 sessions of a specific training for respiratory muscles with Spirotiger
3149051|NCT01556139|No Intervention|Control|Control group with a placebo device
3149052|NCT01556113|Active Comparator|omega diet carrying CC/CG genotype|Subjects homozygous for the major allele of the rs73049 SNP or heterozygous (CC and CG)
3149053|NCT01556113|Active Comparator|omega diet carrying GG genotype|Subjects homozygous for the minor allele of the rs73049 SNP (GG)
3149054|NCT01556100|Experimental|18F-DTBZ AV-133|18F-DTBZ AV-133 imaging
3149055|NCT01556087|Experimental|Distress Tolerance|7 sessions aimed at increasing distress tolerance skills
3149056|NCT01556087|Placebo Comparator|Health Education|7 didactic health education sessions
3149057|NCT01556074|Experimental|Yoga treatment|
3149058|NCT01556061|Experimental|D-MAC video laryngoscopy|The Dblade is used to perfom laryngoscopy first but second laryngoscopy and intubation is performed with CMAC blade.
3149059|NCT01556061|Active Comparator|C-MAC video laryngoscopy|The CMAC blade is used to perfom laryngoscopy first but second laryngoscopy and intubation is performed with D-blade
3149060|NCT01556048|Experimental|IMMEDIATE START GROUP|Randomized to participate in Behavioral Activation for pathological grief starting at Week 1 of entry into the study
3149061|NCT01556048|Placebo Comparator|DELAY START GROUP|Randomized to participate in Behavioral Activation for pathological grief starting at Week 12 of entry into the study
3149062|NCT01556035|Experimental|Lenalidomide treatment|
3149063|NCT01556022|Experimental|ADRCs processed by the Celution System|400,000 adipose-derived regenerative cells (ADRCs) per kilogram (kg) of body weight not to exceed 40,000,000 cells.
3149064|NCT01556022|Placebo Comparator|Lactated Ringers and Subject's blood|Sterile Lactated Ringers Solution (3mL) mixed with ≤ 0.10 ml of the study Subject's own freshly drawn blood.
3149065|NCT01556009|Active Comparator|Drug (Vismodegib)|Vismodegib taken orally 150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
3149066|NCT01556009|Active Comparator|Aminolevulinic acid %20 topical solution|Aminolevulinic acid HCL 20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
3149067|NCT01555996|Experimental|Early and intensive OT|
3149068|NCT01555996|Active Comparator|Standard non-pharmacological prevention|
3149069|NCT01555983|Active Comparator|Vaporization of Cannabis 6.7% THC|Inhaling of standardized measured puffs of Vaporized High Dose 6.7% THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
3149070|NCT01555983|Active Comparator|Vaporization of Cannabis 2.9% THC|Inhaling standardized measured puffs of Vaporized Low Dose 2.9% THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
3149071|NCT01555983|Placebo Comparator|Vaporization of Cannabis Placebo THC|Inhaling standardized measured puffs of Placebo THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
3149114|NCT01555684|Experimental|venoplasty proceedures|Half of the participants receive treatment and the other half do not
3149115|NCT01555684|Placebo Comparator|Control - no treatment|
3149145|NCT01555450|No Intervention|Control - Without Patient Navigator|People in this arm receive just the usual care of colorectal cancer screening
3149146|NCT01555424|Active Comparator|High dose|
3149072|NCT01555970|Experimental|NAC|Patients allocated in this group will receive N-acetylcysteine 1200 mg (one 600 mg capsule twice a day) during the first week of the study. On day 8 this will increase to 4 capsules per day (2400 mg NAC; 2 capsules twice a day). Finally, on day 15 (after 1 week at 2400 mg) the dose will be increased to the target dose of 5 capsules per day (3000 mg; 2 capsules in the morning and 3 in the evening), at which dose it will be continued for the remainder of the study.
3149073|NCT01555970|Placebo Comparator|Placebo|Patients allocated in this group will receive one capsule of placebo twice a day during the first week of the study. On day 8 this will increase to 4 capsules per day (2 capsules twice a day). Finally, on day 15 the dose will be increased to the target dose of 5 capsules per day (2 capsules in the morning and 3 in the evening), at which dose it will be continued for the remainder of the study.
3149074|NCT01555957|Experimental|low dose intravenous lipids|
3149075|NCT01555957|Placebo Comparator|high dose of intravenous lipids|
3149076|NCT01555931|Experimental|Immediate|Placement within 48 hours of delivery
3149077|NCT01555931|Active Comparator|Control|Placement 4-8 weeks after delivery
3149078|NCT01555918|Experimental|Isavuconazole single oral dose - Part 1|
3149079|NCT01555918|Experimental|Isavuconazole single intravenous (IV) dose - Part 1|
3149080|NCT01555918|Experimental|Isavuconazole multiple oral doses - Part 2|
3149081|NCT01555918|Experimental|Isavuconazole multiple intravenous (IV) doses -Part 2|
3149082|NCT01555905|Experimental|Exercise|Threshold PEP or IMT device Phillips-Respironics
3149083|NCT01555892|Experimental|LMP, BARF1 & EBNA1 specific CTLs: A|"Group A: Patients in second or subsequent relapse (or first relapse or with active disease if immunosuppressive chemotherapy contraindicated or multiple relapsed patients in remission who are at a high risk of relapse)** or any patient with primary disease or in first or subsequent remission if immunosuppressive chemotherapy is contraindicated.~Each group will have the dose escalation done separately. Two patients will be entered at the starting dose level. Each patient will receive 2 injections, 14 days apart, according to the dosing schedules. If there are no dose limiting toxicities, the escalation will continue at the pre-specified dose levels.~** Patients with relapsed or refractory lymphoma that are eligible for a stem cell transplant will not be treated on this study as an alternative to transplant."
3149084|NCT01555892|Experimental|LMP, BARF1 & EBNA1 specific CTLs : B|"Group B: Patients in remission or with minimal residual disease (MRD) status after autologous or syngeneic SCT.~Each group will have the dose escalation done separately. Two patients will be entered at the starting dose level. Each patient will receive 2 injections, 14 days apart, according to the dosing schedules. If there are no dose limiting toxicities, the escalation will continue at the pre-specified dose levels."
3149085|NCT01555879||All patients|All patients in T3 who have used Abatacept for at least 3 months between 2009-03-17 and 2011-11-30.
3149086|NCT01555866|Experimental|Part 1 Subjects with End Stage Renal Disease (ESRD)|
3149087|NCT01555866|Experimental|Part 1 Healthy Subjects|
3149088|NCT01555866|Experimental|Part 2 Subjects with Mild Renal Impairment|
3149089|NCT01555866|Experimental|Part 2 Subjects with Moderate Renal Impairment|
3149090|NCT01555866|Experimental|Part 2 Subjects with Severe Renal Impairment|
3149091|NCT01555866|Experimental|Part 2 Subjects with no Renal Impairment|
3149092|NCT01555853|Experimental|Phase I-Dose Level 0|Abraxane 100 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
3149093|NCT01555853|Experimental|Phase I-Dose Level 1|Abraxane 125 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
3149094|NCT01555853|Experimental|Phase I-Dose Level 2|Abraxane 150 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
3149095|NCT01555853|Experimental|Phase II|Abraxane (dose to be determined in Phase I) IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
3149096|NCT01555840|Other|patients requiring upper GI endoscopy|patients with upper abdominal complaints requiring upper GI endoscopy
3149097|NCT01555827|Experimental|Alzheimer Disease|
3149098|NCT01555827|Active Comparator|Control|
3149099|NCT01555814|Experimental|Amisulpride|For 4 weeks, all patients will be treated with amisulpride open label.
3149100|NCT01555801|Experimental|Submucosal injection combining with EUS|The enrolled patients will be accepted submucosal injection of saline,then ultrasonography will performed(EUS+SIS group).So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) or endoscopic submucosal dissection(ESD) or esophagectomy.
3149101|NCT01555801|Placebo Comparator|ordinary endosonography(EUS)|The enrolled patients will accept ordinary ultrasonography .So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) , endoscopic submucosal dissection(ESD) or esophagectomy.
3149102|NCT01555788|Experimental|Type 1 diabetic population|The only one arm (type 1 diabetic patients treated by basal-bolus insulin and external pumps) of this study will test an artificial pancreas system that uses the intraperitoneal route to deliver insulin (through DiaPort).
3149103|NCT01555775|Experimental|P-CHO supplement|This group will drink the P-CHO supplement in the first trial and the fruit milk shake in the second.
3149104|NCT01555775|Experimental|Fruit Milk Sake|This group will drink the fruit milk shake in the first trial and the P-CHO supplement in the second.
3149105|NCT01555762||Cohort|
3149106|NCT01555749|Experimental|NNC172-2021 low dose / Placebo|
3149107|NCT01555749|Experimental|NNC172-2021 high dose / Placebo|
3149108|NCT01555736|Active Comparator|preseasonal immunotherapy scheme|
3149109|NCT01555736|Active Comparator|perennial immunotherapy scheme|
3149110|NCT01555710|Experimental|Palifosfamide-tris plus Carboplatin and Etoposide|Drug: palifosfamide-tris in combination with carboplatin and etoposide palifosfamide-tris: 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. carboplatin: AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a max of 6 cycles.
3149111|NCT01555710|Active Comparator|Carboplatin plus Etoposide|Drug: carboplatin in combination with etoposide carboplatin: AUC 5mg/mL/min 1 day every 21 days for a maximum of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
3149112|NCT01555697|Active Comparator|Memantine|
3149113|NCT01555697|Placebo Comparator|Placebo|
3149116|NCT01555671|Active Comparator|meperidine administration group|Infusion bags were prepared and labelled as Bag A (meperidine group), containing 25 mg meperidine (Aldolan; Liba Laboratuarları, Istanbul, Turkey) .Providers and patients were blinded to the contents of the bags until the conclusion of the study. Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.
3149117|NCT01555671|Placebo Comparator|plasebo group|Bag B (placebo group), containing 0.5ml of normal saline solution. Providers and patients were blinded to the contents of the bags until the conclusion of the study.Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.
3149118|NCT01555658|Experimental|Bivalirudin|Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to Bivalirudin
3149119|NCT01555658|Experimental|Unfractioned Heparin|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to Unfractioned Heparin.
3149120|NCT01555645|Experimental|Stress management Individual format|The methods and techniques will be the same as those used in the group intervention. The first session will be used for a detailed assessment of the individual's psychosocial problems, as used in earlier studies. The sessions will last 45 - 60 minutes. The number of sessions will depend on the individual patient's problems and the joint assessment made by the patient and nurse together. The total number of sessions will be at least 4, with a maximum of 8. The contents of the sessions are Session 1: Assessment, Session 2: Analysis of diary (self-registration) and suggestions for problem management, Session 3: Evaluation of problem management skills Session 4: Follow-up and conclusion of the intervention. When necessary Sessions 5 -8 will address specific obstacles and continued practice.
3149121|NCT01555645|Experimental|Stress management Group format|Participants will meet for 2 hours every week for a total of 20 hours. In the intervals between the group meetings patients will be asked to do homework. Homework entails practicing problem-solving techniques, keeping a diary, practicing relaxation or physical activities. Each group meeting has a specific subject, i.e. What is stress and stress behaviors, Stress related symptoms, How to manage anger and negative thoughts, Self-registrations and behavioral changes, Future perspectives, Cancer, stress and relations, Expectations and demands, Body, pleasure and sexuality.
3149122|NCT01555632|Placebo Comparator|Arm I (placebo)|Patients receive placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
3149123|NCT01555632|Experimental|Arm II (atorvastatin calcium)|Patients receive atorvastatin calcium PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
3149124|NCT01555619||CRT-D System|St. Jude Medical (SJM) Promote® Q/Promote® Quadra/Unify Quadra™ CRT-D system.
3149125|NCT01555606||Moderate to severe plaque psoriasis patients|The group includes adult patients (either male or female) diagnosed with plaque psoriasis for at least 6 months prior to screening with PGA value of greater than or equal to 3. The patients in the group needed are currently receiving treatment with conventional systemic agents, topical therapy and/or phototherapy or biologic therapy
3149126|NCT01555593|Experimental|COPD FEV1<70%pred feNO Cardioline Exp'air|COPD subjects with FEV1<70% of predicted value and Forced Expiratory Volume Forced to Forced Vital Capacity ratio (FEV1/FVC) less than 88% (males)or less than 89% (females) of Low Levels of Normality (LLN) entering the respiratory rehabilitation unit will undergo multiflow feNo measure with Cardioline Exp'air by Medi-soft - Sorinnes (B)
3149127|NCT01555580|Experimental|GM-CSF|
3149128|NCT01555567|Experimental|Electrical stimulation|Subjects placed into this group will undergo electrical stimulation following anterior cruciate ligament reconstruction (ACLr). Subjects will be required to report 2 times per week for 6 weeks following ACLr for electrical stimulation therapy. Electrical stimulation therapy post-reconstruction will commence immediately post-ACLr and end at week 6.
3149129|NCT01555567|No Intervention|Standard of Care|This group will undergo standard ACL rehabilitation
3149130|NCT01555567|Experimental|Eccentric Exercise|Subjects placed into this group will undergo eccentric exercise strength training following ACLr. Subjects will be required to report 2 times per week for 6 weeks following ACLr. Eccentric strengthening will begin at week 6 post-ACLr and will end at week 12 post-ACLr.
3149131|NCT01555567|Experimental|Stimulation and Eccentrics|Subjects placed into this group will undergo a combined electrical stimulation and eccentric exercise intervention following ACLr. The electrical stimulation intervention will be delivered immediately following ACLr and will end at 6 weeks post-ACLr. Subjects will receive the electrical stimulation therapy 2 times per week for the first 6 weeks post-ACLr. At six weeks post-ACLr, subjects will begin the eccentric strengthening protocol. Subjects will eccentrically train 2 times per week for 6 weeks. The eccentric strengthening will end at 12 weeks post-ACLr.
3149132|NCT01555554|Experimental|Propranolol Hydrochloride|
3149133|NCT01555554|Placebo Comparator|Placebo Group|
3149134|NCT01555541|Experimental|Single-arm study|
3149135|NCT01555528||Growth Disorders|
3149136|NCT01555515|Experimental|EPODURE Low dose|EPODURE pump secreting hEPO 18-25 IU/kg/day
3149137|NCT01555502||low complications|Patients who had VATS lung resection for NSCLC, and have no or low grade (grade 1 and 2) post operative complications based on the Clavien classification system.
3149138|NCT01555502||High complications|Patients who had VATS lung resection for NSCLC, and have no or high grade (grade 3 and 4) post operative complications based on the Clavien classification system.
3149139|NCT01555489|Experimental|Ascorbic Acid, Gemcitabine & Erlotinib|Ascorbic Acid (50-100g, 3x weekly) Standard Chemotherapy of Gemcitabine and Erlotinib for Pancreatic Cancer
3149140|NCT01555476|Experimental|A-IBU|A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits.
3149141|NCT01555476|Active Comparator|B-IBU|A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
3149142|NCT01555463|Experimental|Azelaic acid foam, 15% (BAY39-6251)|0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.
3149143|NCT01555463|Placebo Comparator|Vehicle foam|0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.
3149144|NCT01555450|Experimental|With Patient Navigator|People in this arm receive the Intervention of a Patient Navigator
3299423|NCT00455169||2|Full term infants
3149150|NCT01555398|Active Comparator|Fed conditions|Investigational product administrated 30min after starting a high-fat breakfast.
3149151|NCT01555385|Active Comparator|Dietary supplement: high-protein breakfast|high-protein juice
3149152|NCT01555385|Active Comparator|Dietary supplement: high-carbohydrate breakfast|high-carbohydrate juice
3149153|NCT01555385|Placebo Comparator|Dietary supplement: low energy breakfast|low-calorie juice
3149154|NCT01555372|Active Comparator|Hook Plate|20 participants will be enrolled in this group.
3149155|NCT01555372|Experimental|Locking Plates|20 paticipants will be enrolled in this group
3149156|NCT01555359||Patients undergoing stem cell collection|
3149157|NCT01555346||High risk pregnant subjects undergoing an invasive procedure|Women with one or more high risk factors for fetal chromosome 21 aneuploidy scheduled to undergo an invasive procedure for fetal karyotype determination.
3149158|NCT01555346||High risk subjects electing not to undergo invasive procedure|Women with one or more high risk factors for fetal chromosome 21 aneuploidy who elect not to undergo an invasive procedure for fetal karyotype determination.
3149159|NCT01555333|Experimental|Arbaclofen|Open Label Study
3149160|NCT01555320|Placebo Comparator|Qishen Yiqi dripping pills dummy|
3149161|NCT01555320|Experimental|Qishen Yiqi Dripping Pills|
3149162|NCT01555307|Experimental|Balance group|Typical plus balance exercises
3149163|NCT01555307|Other|Typical group|Typical exercises
3149164|NCT01555294||community-based cohort|"The present study is a substudy in the Nijmegen Biomedical Study (NBS). The NBS is a prospective population survey aimed at investigating the frequency of genetic variations in the general population. The study population is recruited as a sex- and age-stratified random sample of all inhabitants of Nijmegen 20 to 90 years old (n=10.000). Recruitment has started in october 2001.~In the current study 1517 participants aged 50-70 years were included from 2005 to 2008, from whom baseline characteristics were obtained. All visited our hospital and during the visit venous blood was drawn, height and weight were measured, a questionnaire about medical history, life style habits, and family history was completed and non-invasive measurements of atherosclerosis were performed."
3149165|NCT01555294||Familial Combined Hyperlipidemia|FCH is the most common inherited dyslipidemia in man. Affected individuals are characterized by elevated cholesterol and/or triglyceride levels and an increased risk of CVD. Our data base contains a unique population of 40 well-characterized FCH families, including 687 patients, relatives and spouses. These families were recruited in 1994 and extensively studied, including information on an extensive panel of biochemical and genetic parameters. In total 343 participants were included in the NIMA study; 103 FCH patients and 240 unaffected relatives from whom baseline characteristics were obtained.
3149166|NCT01555281|Experimental|Nelfinavir and Lenalidomide/Dexamethasone|"Phase I: Cycles 1-4 (1 cycle = 28 days) Lenalidomide: 25 mg per day p.o., day 1 to 21 Dexamethasone: 40/20 mg per day p.o., days 1, 8, 15, 22 Nelfinavir: Dose escalation in cohorts of 3 patients~Phase II: Cycles 1-4 (1 cycle = 28 days) Lenalidomide: 25 mg per day p.o., day 1 to 21 Dexamethasone: 40/20 mg per day p.o., days 1, 8, 15, 22 Nelfinavir: Dose established in phase I twice daily p.o., day 1 to 21"
3149167|NCT01555268|Experimental|Arm A (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 22.
3149168|NCT01555268|Experimental|Arm B (trebananib, cytarabine)|Patients receive trebananib as in Arm A. Patients also receive cytarabine SC BID on days 1-14 of course 1 and days 1-7 of subsequent courses.
3149169|NCT01555242|Experimental|Aneustat (OMN54)|
3149170|NCT01555229|Experimental|Intermittent drainage|Intermittent subglottic secretion drainage at -100 mmHg during 8 sec every 15 seconds.
3149171|NCT01555229|Active Comparator|Continuous drainage.|Continuous subglottic secretion drainage at -20 mmHg.
3149172|NCT01555216|Active Comparator|Posterior tibial nerve catheter|5 ml bolus of 0.5% ropivacaine. The catheter will then be connected to a portable pump delivering 3 ml/h of 0.2% ropivacaine with a 2ml bolus every two hours.
3149173|NCT01555216|Active Comparator|Single injection PTNB|Single injection posterior tibial nerve block (PTNB) of 0.5% ropivacaine
3149174|NCT01555203|Experimental|liveWell: A healthy foundation for life|
3149175|NCT01555190|Active Comparator|myo-inositol 1500 gr|6 months treatment with myo-inositol 1500 gr
3149176|NCT01555190|Active Comparator|myo-inositol 2000gr + folic acid 200 mcg|
3149177|NCT01555177||Peri-operative NSTEMI patients|Patients with POMI undergoing cardiac catheterization within 72 hours of first troponin elevation and within 2 weeks of their non-cardiac surgery.
3149178|NCT01555177||Non-surgery related NSTEMI patients|Patients with NSTEMI undergoing cardiac catheterization within 72 hours of symptom onset.
3149179|NCT01555164|Experimental|Ranolazine+metformin|"Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening).~Treatment Period: Participants will receive ranolazine 500 mg + metformin 500 mg + placebo to match metformin twice daily on Days 1 through 7, followed by ranolazine 1000 mg + metformin 500 mg + placebo to match metformin twice daily from Day 8 through Week 24.~Participants are required to maintain their diet and exercise regimen."
3149180|NCT01555164|Placebo Comparator|Placebo+metformin|"Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening).~Treatment Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily through Week 24.~Participants are required to maintain their diet and exercise regimen."
3149181|NCT01555151|Experimental|Mometasone furoate 80 μg|Description: Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 80 ug delivered via the Concept1 device for 4 weeks.
3149182|NCT01555151|Experimental|Mometasone furoate 200 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 200 ug delivered via the Twisthaler® device for 4 weeks.
3149183|NCT01555151|Experimental|Mometasone furoate 320 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 320 ug delivered via the Concept1 device for 4 weeks.
3149654|NCT01551875||subjects who are meeting the inclusion criteria|
3149184|NCT01555151|Experimental|Mometasone furoate 800 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 800 ug delivered via the Twisthaler® device for 4 weeks.
3149185|NCT01555138|Experimental|Indacaterol|Indacaterol 150 mcg once daily (o.d.) delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
3149186|NCT01555138|Active Comparator|Salmeterol/fluticasone propionate|Salmeterol 50 mcg /fluticasone propionate 500 mcg for inhalation delivered via a proprietary multi dose dry powder inhaler (MDDPI) device (Seretide® Accuhaler®) twice daily (b.i.d.)
3149187|NCT01555125|Experimental|secukinumab 150 mg|Drug
3149188|NCT01555125|Experimental|secukinumab 300 mg|Drug
3149189|NCT01555125|Placebo Comparator|placebo|
3149190|NCT01555112|Experimental|Topical AS101|15% AS101 ointment applied twice a day for treatment of external genital warts.
3149191|NCT01555099|Experimental|AZD5423|New study drug
3149192|NCT01555099|Active Comparator|Budesonide|Comparator to which the new study drug will be compared
3149193|NCT01555099|Placebo Comparator|Placebo|No drug to which both other arms will be compared
3149194|NCT01555086|Experimental|Limited pelvic Lymphadenectomy|
3149195|NCT01555086|Experimental|Extended pelvic Lymphadenectomy|
3149196|NCT01555073|Active Comparator|Pregabalin/celecoxib group|pregabalin/celecoxib twice a day for 13 days.
3149197|NCT01555073|Active Comparator|Pregabalin/placebo group|pregabalin/placebo twice a day for 13 days.
3149198|NCT01555073|Active Comparator|Celecoxib/placebo group|celecoxib/placebo twice a day for 13 days.
3149199|NCT01555073|Placebo Comparator|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
3149200|NCT01555060|Experimental|Iron supplements|Subjects who are randomized to receive daily iron supplements after donating blood
3149201|NCT01555060|No Intervention|Control|Subjects who are randomized not to receive daily iron supplements after donating blood
3149202|NCT01555047|Active Comparator|males who were not infected by mycoplasma|100 male patients whose spouse was going to conduct IUI, was not infected by mycoplasma.
3149203|NCT01555047|Experimental|infected by mycoplasma males|100 male patients whose spouse was going to conduct IUI, was infected by mycoplasma.
3149204|NCT01555047|No Intervention|fertile males|50 fertile males were chose as control samples
3149205|NCT01555034|Active Comparator|intervention plus therapy|
3149206|NCT01555034|Active Comparator|intervention no therapy|exercise and nutrition
3149207|NCT01555021|No Intervention|Treatment as Usual|
3149208|NCT01555021|Experimental|Assay Guided Treatment|This group will receive a genotyping test to determine the specific levels of genes in their systems. This test is used to guide clinicians in the recommendation of psychotropic drugs.
3149209|NCT01555008|Experimental|Treatment A|
3149210|NCT01555008|Placebo Comparator|LX4211 Placebo|
3149211|NCT01554995|Experimental|LCB01-0371|active
3149212|NCT01554995|Experimental|Linezolid|comparator
3149213|NCT01554982|Other|Ferric Citrate|Open label extension of those completing study KRX-0304
3149214|NCT01554969|Experimental|capecitabine + ganetespib .|Capecitabine oral medication. Ganetespib IV medication
3149215|NCT01554956|Experimental|Human Plasminogen|Human Plasminogen Eye Drop treatment
3149216|NCT01554943|Active Comparator|CMF|adjuvant standard CMF given from 1988 to 1996
3149217|NCT01554943|Experimental|EC|Adjuvant EC chemotherapy given from 1988 to 1996
3149218|NCT01554943|Experimental|HEC|High dose epirubicin (HEC) given from 1988 to 1996
3149219|NCT01554930|Active Comparator|Western therapy|
3149220|NCT01554930|Experimental|Xiyanping injection plus western therapy|
3149221|NCT01554917|Experimental|Iguratimod|
3149222|NCT01554904|Other|Facial-Flex|The facial flex (FF) exerciser manufactured by Facial Concepts, Inc is an FDA approved Class I medical device for treatment of facial muscle laxity. Facial muscles tend to weaken with age. The combination of deteriorating elastic tissue and facial muscle weakness causes the face to sag. Facial flex consists of two plastic tipped curved lower bars which slide across each other. An external dynamic resistance is provided by elastic bands.
3149223|NCT01554891||Cohort 1|100 OEF/OIF/OND veterans returning to Joint Base Lewis-McChord and Fort Bragg who screen positive for TBI on the Post Deployment Health Assessment (PDHA) TBI screen
3149224|NCT01554891||Cohort 2|100 OEF/OIF/OND veterans seeking care at Northern New England VA Research Consortium (NNEVARC) VA Medical Centers (VAMCs) who screen positive for TBI on VA Level 1 TBI screen
3149225|NCT01554891||Cohort 3|200 participants in WRNMMC and Fort Belvoir Community Hospital Brain Indices Study (100 with mild TBI; 100 without mild TBI).
3149226|NCT01554878||knee surgery|
3149227|NCT01554865|Active Comparator|conventional diet counselling|counselling given by dietician on diet modification and caloric restriction
3149228|NCT01554865|Active Comparator|partial meal replacement diet|calorie-restricted diet using 1-2 meal replacements
3149229|NCT01554852|Active Comparator|Intensive pathway|"The intensive pathway is aimed at younger and fitter patients who will receive the standard dose of chemotherapy. The initial treatments will be followed by high-dose chemotherapy with a stem cell transplant which is generally standard practice.~Participants receive one treatment from each following stage in intensive pathway, depending on what they are randomised to (Protocol v6.0):~Induction treatment:~CRD regimen - cyclophosphamide, lenalidomide, dexamethasone~CTD regimen - cyclophosphamide, thalidomide, dexamethasone~CCRD regimen - carfilzomib, cyclophosphamide, lenalidomide, dexamethasone~Consolidation treatment (depending on response to induction treatment):~VCD regimen - bortezomib, cyclosphosphamide, dexamethasone~No consolidation treatment~High-dose therapy and stem cell transplant~Maintenance treatment:~Lenalidomide maintenance~No maintenance~Lenalidomide plus vorinostat maintenance (Protocol v5.0 only)"
3149280|NCT01554514|Experimental|low dose rituximab|this is a single-arm trial
3149281|NCT01554501||Community sample|
3149282|NCT01554488|Experimental|Arm 1|High dose inhaled fluticasone (1760mcg/day)
3149283|NCT01554488|Active Comparator|Arm 2|Low dose inhaled fluticasone (88mcg/day)
3149284|NCT01554462|Active Comparator|ADHD active|4 month intervention with EPA/DHA in ADHD group
3149741|NCT01551238|Experimental|Protein intake of 30 energy percent|
3149230|NCT01554852|Active Comparator|Non-intensive pathway|"The non-intensive pathway is aimed at participants who are not deemed suitable for the stem cell transplant, and will receive lower doses of some of the drugs.~Interventions in each stage of non-intensive pathway (depending on what the participant has been randomised to) - from Protocol v6.0:~Induction treatment~CRDa regimen - cyclophosphamide, lenalidomide, dexamethasone attenuated~CTDa regimen - cyclophosphamide, thalidomide, dexamethasone attenuated~Consolidation treatment (depending on participant's response to induction treatment):~VCD regimen - bortezomib, cyclosphosphamide, dexamethasone~No consolidation treatment~Maintenance treatment~Lenalidomide maintenance~No maintenance~Lenalidomide plus vorinostat maintenance (*for participants recruited under Protocol v5.0 only*)"
3149231|NCT01554839|Experimental|Treatment Group|Treatment group participates in 1 hour online educational tool in addition to baseline and follow up surveys
3149232|NCT01554839|Placebo Comparator|Non Treatment Group|Non Treatment group participates in baseline and follow up surveys
3149233|NCT01554826|Experimental|Influenza Split Vaccine|7.5μg HA/strain/0.25ml/syringe
3149234|NCT01554826|Active Comparator|Inactivated Influenza Vaccine|7.5μg HA/strain/0.25ml/syringe
3149235|NCT01554813|Experimental|Influenza split vaccine of 15μg HA|15μg HA/strain/0.5ml/vial
3149236|NCT01554813|Experimental|Influenza split vaccine of 15 μg HA|15μg HA/strain/0.5ml/syringe
3149237|NCT01554813|Active Comparator|Influenza split vaccine|15μg HA/strain/0.5ml/syringe
3149238|NCT01554800|Experimental|ACP-501|
3149239|NCT01554787|Experimental|Chinese Herb Astragalus membranaceus|
3149240|NCT01554787|Placebo Comparator|Placebo|
3149241|NCT01554774||GOLD II|Will be included in this group the patients with COPD stage II
3149242|NCT01554774||GOLD III|Will be included in this group the patients with COPD stage III
3149243|NCT01554774||GOLD IV|Will be included in this group the patients with COPD stage VI.
3149244|NCT01554748|Other|Patient cohort|TMC total joint arthroplasty
3149245|NCT01554735|Experimental|lifestyle counselling|exercise and diet counselling for weight loss
3149246|NCT01554722|Experimental|in plane needle placement|
3149247|NCT01554722|Experimental|out of plane needle placement|
3149248|NCT01554709|Experimental|CardioGard Cannula|
3149249|NCT01554709|Active Comparator|Reference Cannula|
3149250|NCT01554696|Experimental|ASP015K lowest dose|ASP015K lowest dose daily in addition to concomitant weekly oral methotrexate
3149251|NCT01554696|Experimental|ASP015K low dose|ASP015K low dose daily in addition to concomitant weekly oral methotrexate
3149252|NCT01554696|Experimental|ASP015K medium dose|ASP015K medium dose daily in addition to concomitant weekly oral methotrexate
3149253|NCT01554696|Experimental|ASP015K high dose|ASP015K high dose daily in addition to concomitant weekly oral methotrexate
3149254|NCT01554696|Placebo Comparator|Placebo|Placebo daily in addition to concomitant weekly oral methotrexate
3149255|NCT01554683|Active Comparator|High Dose Levetiracetam|Low Dose Levetiracetam administration via IV infusion over 20 min
3149256|NCT01554683|Active Comparator|Low Dose Levetiracetam|High Dose Levetiracetam administration via IV infusion over 20 min
3149257|NCT01554683|Placebo Comparator|Placebo administration|Saline administration via IV infusion over 20 min
3149258|NCT01554670|No Intervention|arthroscopic subacromial decompression|A thorough subacromial decompression was performed as described by Neer (which include coracoacromial ligament resection, excision of the anterio-lateral tip of the acromion and thorough debridement of the bursa).
3149259|NCT01554670|Active Comparator|decompression+RF micro-tenotomy|A thorough subacromial decompression was performed as described by Neer (which include coracoacromial ligament resection, excision of the anterio-lateral tip of the acromion and thorough debridement of the bursa).an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
3149260|NCT01554657|Experimental|5 Days|
3149261|NCT01554657|Placebo Comparator|7 days|
3149262|NCT01554644|Active Comparator|Prontosan Solution and Gel|ProntosanTM Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and ProntosanTM Wound Gel (PHMB 0.1%, Betaine 0.1%)
3149263|NCT01554644|Placebo Comparator|Saline Solution and Inert Gel|
3149264|NCT01554631|Experimental|Arm 1|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT 100 mg; Day 1: oral sucrose load plus Glucobay ODT 100 mg taken without water
3149265|NCT01554631|Experimental|Arm 2|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT 100 mg; Day 1: oral sucrose load plus Glucobay ODT 100 mg taken with water
3149266|NCT01554631|Active Comparator|Arm 3|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet 100 mg; Day 1: oral sucrose load plus Glucobay standard tablet 100 mg taken with water
3149267|NCT01554618|Experimental|EQW|Exenatide once weekly
3149268|NCT01554618|Placebo Comparator|Placebo|Placebo once weekly
3149269|NCT01554592|Experimental|Statin withdrawal|Participants will received a placebo for 12 weeks.
3149270|NCT01554592|Active Comparator|Stable statin therapy|Participants need to have been receiving statin therapy for at least 3 months and be on a stable dose.
3149271|NCT01554579|Placebo Comparator|Sugar pill|
3149272|NCT01554579|Experimental|Gefapixant|
3149273|NCT01554566|Experimental|honey, no honey|
3149274|NCT01554553|Experimental|Posterior crural repair|
3149275|NCT01554553|No Intervention|No posteriorcrural repair|
3149276|NCT01554540|Experimental|Cutaneous iontophoresis of Treprostenil|
3149277|NCT01554540|Placebo Comparator|Cutaneous iontophoresis of placebo|
3149278|NCT01554527|Experimental|CPAP treatment|Children randomized to this arm will receive 6 months of CPAP (or BPAP) treatment, beginning at approximately 4 months after AT, in addition to standard of care.
3149279|NCT01554527|Other|No CPAP treatment|Children randomized to this comparison arm will not be treated with CPAP or BPAP, but will be followed for approximately 10 months after AT while receiving standard of care.
3149285|NCT01554462|Placebo Comparator|ADHD Placebo|4 month dietary intervention with placebo in ADHD group
3149286|NCT01554462|Active Comparator|Active Healthy control|4 month dietary intervention with DHA/EPA in healthy control group
3149287|NCT01554462|Placebo Comparator|Healthy placebo|4 month dietary intervention with placebo in healthy control group
3149288|NCT01554449|Experimental|Serious game|In this group, patients will have a session of conventional retraining with a serious game retraining.
3149289|NCT01554449|Active Comparator|control patients|In this group, patients will have the conventional retraining with an other conventional retrainning session. The difference between both groups of patients is the serious game session for one group and conventional session for the other group
3149290|NCT01554449|Placebo Comparator|controls|For the neurologic assessments, patients are compared to healthy patient (without stroke)
3149291|NCT01554436|Experimental|patients in smoking cessation|patients in smoking cessation
3149292|NCT01554423|Active Comparator|Testing and Counseling|One of the four RCT arms will be comprised of couples randomly assigned to testing and counseling on HIV and associated STI co-infections based on revised procedures developed by the CDC. Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences. Randomized trial studies of behavioral interventions have incorporated testing and counseling as a comparison condition and studies in the US and SSA countries have shown that testing and counseling on its own can help to reduce HIV/STI risk behaviors.
3149293|NCT01554423|Experimental|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use. Each module is delivered by the clinician using a two-sided laminated card that includes scripted questions and visual aids. Consistent with brief intervention models, the BMI intervention is delivered during one 45 minute session with advice giving as a primary characteristic. Motivational interviewing is also incorporated within the BMI intervention by using a client-centered method of communication to foster behavior change through five techniques of expressing empathy, developing discrepancy, avoiding argumentation, supporting self-efficacy, and motivational rules.
3149294|NCT01554423|Experimental|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present. The six IFCBT sessions are delivered during a 2-week period with two group couples' sessions and one individual couples' session each week.
3149295|NCT01554423|Experimental|BMI + IFCBT|Participants assigned to this experimental arm will receive Brief Motivational Interviewing combined with Integrated Family and Cognitive Behavioral Therapy.
3149296|NCT01554410|Experimental|IMRT/Cisplatin/Gemcitabine|All patients get IMRT with concurrent cisplatin & gemcitabine, with the dose of gemcitabine varying according to cohort
3149297|NCT01554397|Experimental|Phase II|All patients receive IMRT with concurrent cisplatin 40 mg/m2
3149298|NCT01554397|Active Comparator|Phase III - A|Patients in Phase III, Arm A receive 4-field box RT with concurrent cisplatin 40 mg/m2
3149299|NCT01554397|Experimental|Phase III - B|Patients in Phase III, Arm B receive IMRT with concurrent cisplatin 40 mg/m2
3149300|NCT01554384|Experimental|Xpert MTB/RIF|Patients in this arm will receive 1 sputum Xpert MTB/RIF test (point-of-treatment) and 1 sputum sample for MGIT liquid TB culture (regional lab)
3149301|NCT01554384|Active Comparator|Sputum smear microscopy|Patients in this study arm will receive 2 sputum samples for same-day smear microscopy and 1 of the sputum samples will have a MGIT Liquid culture (regional lab).
3149302|NCT01554371|Experimental|Eribulin Combination w/ Cyclophosphamide|Phase Ib: dose escalation; Phase II: advanced breast cancer patients
3149303|NCT01554358|Other|Lifestyle counseling|The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake <30% of energy consumed, 3) saturated fat intake <10% of energy consumed, 4) carbohydrate intake 55-65% of energy consumed, 5) fiber intake 20-30g per day, and 6) moderate or vigorous exercise for at least 30 min daily, seven days each week.
3149304|NCT01554358|No Intervention|Control|"the subjects in the control group had been educated regarding general principles of healthy lifestyle that benefits T2D and obesity prevention, and also informed about the current evidence showing that the lifestyle intervention is effective in women at high risk for T2D during the run-in period."
3149305|NCT01554332|Active Comparator|Active stimulation|
3149306|NCT01554332|Sham Comparator|Sham stimulation|
3149307|NCT01554319|Experimental|SB010|"The drug will be administered in phosphate-buffered saline solution, inhaled over 5 - 10 min, using a hand-held inhalation device.~Initial single dose on Day 1 (single-dose PK profile); after 48 h washout, twice-daily with a dosing interval of 12 h for 9 consecutive days (Days 3 to 11); last inhalation on Day 12."
3149308|NCT01554319|Placebo Comparator|Placebo|"The placebo (phosphate-buffered saline) is administered as a solution, inhaled over 5 - 10 min, using a hand-held inhalation device.~Initial single dose on Day 1 (single-dose PK profile); after 48 h washout, twice-daily with a dosing interval of 12 h for 9 consecutive days (Days 3 to 11); last inhalation on Day 12."
3149309|NCT01554306||parkinson's disease, nocturnal hypokinesia, rotigotine|
3149310|NCT01554293|Experimental|PBL 1427 capsules|
3149311|NCT01554293|Placebo Comparator|Matching placebo|
3149312|NCT01554280|Experimental|Oesophageal Stents|Patients enrolled will receive a fully coated, removable, self-expanding oesophageal stent.
3149313|NCT01554267|Experimental|Mastectomy Skin Flap SPY Excision|Single arm study where areas of necrosis predicted by Laser-Assisted Indocyanine Green Dye Angiography (SPY system) will be excised intraoperatively during breast reconstruction surgery.
3302589|NCT00420888|Experimental|1|
3149315|NCT01554241|Experimental|vitamin D3 800 IU/day|recommended daily dosage of 800 IU/day D3
3149316|NCT01554241|Experimental|2000 IU/day D3|D3 2000 IU/day
3149317|NCT01554241|Experimental|vitamin D3 4000 IU/day|D3 4000 IU/day
3149318|NCT01554241|Experimental|50,000 IU/week D3|D3 50,000 IU weekly
3149319|NCT01554228||Bariatric Surgery|
3149320|NCT01554215|Experimental|Mom Power Intervention Group|Participants that are randomly assigned to be in the intervention group will be invited to learn about parenting and self-care skills information at a community location, facilitated by two trained and experienced clinicians in a group setting. They will benefit from the en-vivo experience of being supported as a parent and will receive feedback and support about their challenges and strengths in parenting.
3149321|NCT01554215|Active Comparator|Mom Power Attentional Control Group|Participants randomly assigned to this group will receive parenting and self-care skills information through the mail weekly.
3149322|NCT01554202|Experimental|Young controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3149323|NCT01554202|Experimental|Middle age controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3149324|NCT01554202|Experimental|Elderly controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3149325|NCT01554202|Experimental|Autosomal dominant forms of early-onset Alzheimer disease|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3149326|NCT01554202|Experimental|Subjectif Cognitive Impariment patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3149327|NCT01554202|Experimental|Mild Cognitive Impairment patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3149328|NCT01554202|Experimental|Alzheimer Disease patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3149329|NCT01554202|Experimental|Non degenerative amnsesic syndrome|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3149330|NCT01554202|Experimental|Frontotemporal lobe dementia|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3149331|NCT01554189|Experimental|Panel A (GT1 10 mg)|
3149332|NCT01554189|Experimental|Panel B (GT1 50 mg)|
3149333|NCT01554189|Experimental|Panel C (GT1 100 mg)|
3149334|NCT01554189|Experimental|Panel D (GT1 200 mg)|
3149335|NCT01554189|Experimental|Panel E (GT3 10 mg)|
3149336|NCT01554189|Experimental|Panel F (GT3 50 mg)|
3149337|NCT01554189|Experimental|Panel G (GT3 100 mg)|
3149338|NCT01554189|Experimental|Panel H (GT3 200 mg)|
3149339|NCT01554189|Experimental|Panel I (GT1a 10 mg)|
3149340|NCT01554189|Experimental|Panel J (GT1a 50 mg)|
3149341|NCT01554189|Placebo Comparator|Placebo Panel|
3149342|NCT01554176|Experimental|Filorexant 10 mg (Treatment Phase)|Treatment Phase: Participants in this group were administered filorexant 10 mg once daily at bedtime for 6 weeks.
3149343|NCT01554176|Placebo Comparator|Placebo (Treatment Phase)|Treatment Phase: Participants in this group were administered placebo once daily at bedtime for 6 weeks.
3149344|NCT01554176|Experimental|Filorexant 10 mg/Filorexant 10 mg (Run-out Phase)|Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered filorexant 10 mg once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
3149345|NCT01554176|Placebo Comparator|Filorexant 10 mg/Placebo (Run-out Phase)|Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
3149346|NCT01554176|Placebo Comparator|Placebo/Placebo (Run-out Phase)|Run-out Phase: Following completion of the 6-week Treatment Phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received placebo once daily during the Treatment Phase.
3149347|NCT01554163|Experimental|Etoricoxib 30 mg|Etoricoxib, 30 mg tablet, orally, once daily for 12 weeks.
3149348|NCT01554163|Active Comparator|Celecoxib 200 mg|Celecoxib, 200 mg capsule, orally, once daily for 12 weeks.
3149349|NCT01554150|Experimental|Method of Levels Cognitive Therapy (MOL)|Participants in this arm will be able to receive therapy over a 3 month period. They will be able to schedule sessions with a therapist as and when they need them.
3149350|NCT01554150|No Intervention|Contact Service|The Contact Service arm is effectively a waiting list control. Participants assigned this arm will remain on the service's waiting list during the 3 months of the therapy phase. These participants will have access to a 'Contact Service' provided by the study therapist, where they are able to contact him if they want further information about the study or their treatment options.
3149351|NCT01554137|Experimental|With isokinetic strength training|60 minutes isokinetic strength training on concentric mode
3149352|NCT01554137|Placebo Comparator|without isokinetic strength training|passive motion 60 minutes
3149353|NCT01554124|Experimental|Meropenem|"Infants will received Meropenem 40 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age).~Treatment duration = 21 ± 7 days"
3149354|NCT01554111|Active Comparator|Picosalax with rectal enema|This arm will receive one satchet of Picosalx and a rectal enema before the sigmoidoscopy for their bowel preparation regimen.
3149355|NCT01554111|Active Comparator|rectal enema|This group of patients will receive only a rectal enema for bowel preparation before their flexible sigmoidoscopy.
3149356|NCT01554111|Active Comparator|Pico-Salax|patient will take one sachet of pico-salax
3149357|NCT01554098|Active Comparator|Strategy : supine first|"This study will be performed as a cross over study, comparing withdrawal in the supine position versus withdrawal with dynamic position change.~Withdrawal in supine position followed by withdrawal with dynamic position change"
3149358|NCT01554098|Active Comparator|Strategy : dynamic first|This study will be performed as a cross over study, comparing withdrawal in the supine position versus withdrawal with dynamic position change.
3149359|NCT01554085|Experimental|ALS-002158|
3149361|NCT01554072|Placebo Comparator|Placebo|Patients will receive a booklet of exercises, besides containing an explanation of his illness and the importance of exercise in their quality of life, an exercise routine physical to be held three times a week for two consecutive months. Patients will be instructed individually on each exercise, performing with supervisor that there be no doubt about execution, thereby minimizing any possible mistake in practice at home. For each day of the year ended data should be recorded in a daily monitoring. At the end of two months of the PR program semi-home patients will be subject to review so that all tests should be applied again.
3149362|NCT01554072|Active Comparator|exercise|Patients will receive a booklet of exercises, besides containing an explanation of his illness and the importance of exercise in their quality of life, an exercise routine physical to be held three times a week for two consecutive months. For each day of the year ended data should be recorded in a daily monitoring. Is also scheduled a visit to the laboratory biweekly in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused. At the end of two months of the PR program semi-home patients will be subject to review so that all tests should be applied again.
3149363|NCT01554046|Experimental|couples of first-degree family members|
3149364|NCT01554033||Huntington's disease patients|Huntington's disease patients and his(/her) family
3149365|NCT01554033||age-sex matched control|age-sex matched control about huntington patients
3149366|NCT01554020|Active Comparator|Multiherb product|Herbal product
3149367|NCT01554020|Placebo Comparator|Placebo|Maltodextrin control
3149368|NCT01554007||Crohn's disease|Korean patients diagnosed with Crohn's disease
3149369|NCT01553994||HPV vaccinated, non-vaccinated|Individuals born between 1989 and 1996. HPV-vaccinated will be compared to non-vaccinated in regards to condyloma status post vaccination.
3149370|NCT01553981|Active Comparator|Tadalafil|Tablet Tadalafil 20 mg every alternate day
3149371|NCT01553981|Placebo Comparator|Placebo|Tablet Placebo every alternate day
3149372|NCT01553968|Other|Endurance Trained Subjects|
3149373|NCT01553968|Other|Untrained Subjects|
3149374|NCT01553942|Experimental|Afatinib|Afatinib
3149375|NCT01553929|Experimental|Physical and cognitive activity group|
3149376|NCT01553929|Active Comparator|Physical activity group|
3149377|NCT01553929|Placebo Comparator|control group|
3149378|NCT01553916|Experimental|Arm 1: Lithium carbonate + prophylactic cranial irradiation|"Lithium carbonate 300 mg PO BID for 7 days prior to the start of prophylactic cranial irradiation (PCI) and will be continued during PCI.~PCI will be given at 2.5 Gy per fraction, 5 days per week, for 2 weeks to a total dose of 25 Gy, starting on Day 8 after 7 days of lithium."
3149379|NCT01553903|Experimental|Tamoxifen,|Current hormonotherapy treatment in hormone dependent breast cancer
3149380|NCT01553903|Experimental|Exemestane|Current hormonotherapy treatment in hormone dependent breast cancer
3149381|NCT01553903|Experimental|Anastrozole|Current hormonotherapy treatment in hormone dependent breast cancer
3149382|NCT01553903|Experimental|Letrozole|Current hormonotherapy treatment in hormone dependent breast cancer
3149383|NCT01553890|Other|Patients diagnosed with scleroderma|patients diagnosed with scleroderma, clinical and lab support
3149384|NCT01553890|Other|No disease|Blood sample, venous blood, about 10 ml will be drawn from participants
3149385|NCT01553877|Active Comparator|Pushti Packet|
3149386|NCT01553877|Experimental|Rice based Ready to Use Complementary Food Supplements|
3149387|NCT01553877|Active Comparator|Chick-pea based Ready to Use Complementary Food Supplements|
3149388|NCT01553851|Experimental|GSK1120212|GSK1120212 2 mg PO daily for a total of 14 days with the intent of the last pill being the day before surgery.
3149389|NCT01553838|Experimental|Sequentially MRI guided and TRUS guided biopsy|Targeted MRI guided biopsy according to findings in a multiparametric MRI followed by transrectal guided biopsy
3149390|NCT01553825||Pathologically diagnosed carcinoma|
3149391|NCT01553799||US check tube|
3149392|NCT01553799||US check tube, Endobronchial|
3149393|NCT01553786|Experimental|lenalidomide|lenalidomide + CHOP
3149394|NCT01553773|Experimental|Isoflavone|a gel with isoflavones (genistein 4%)
3149395|NCT01553773|Experimental|Estradiol|gel with 17-β estradiol 0.01%
3149396|NCT01553760|Experimental|Tri-MICS|
3149397|NCT01553760|Active Comparator|Conventional Phaco|
3149398|NCT01553747|Experimental|Eluxadoline 75 mg|Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks period.
3149399|NCT01553747|Experimental|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks period.
3149400|NCT01553747|Placebo Comparator|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks period.
3149401|NCT01553721|Experimental|udenafil|"Phase IIa Experimental : Udenafil Dose 1, Dose 2~Phase IIb Experimental : Udenafil"
3149402|NCT01553721|Placebo Comparator|placebo|"Phase IIa Placebo Comparator : Placebo~Phase IIb Placebo Comparator : Placebo"
3149403|NCT01553708|Experimental|Epidermal growth factor with silver sulfadiazine cream|Epidermal growth factor with silver sulfadiazine cream was applied to the experimental wounds completely and then covered with sterile gauze. The wound was cleaned every 24 h and the cream was then applied again after cleaning process.
3149404|NCT01553708|Active Comparator|Silver zinc sulfadiazine cream|Silver sulfadiazine cream was applied to cover the controlled-wound completely and then covered with sterile gauze. The wound was cleaned every 24 h and the cream was then applied again after cleaning process.
3149405|NCT01553695|Active Comparator|general population|
3149406|NCT01553695|Experimental|ADHD Patient|
3149407|NCT01553682|No Intervention|Enhanced Standard-Of-Care|Participants will watch a video about how to prevent STIs and HIV, then do question and answer session. This group will be last 1 hour. It will be led by one African American health educator, and have about 4-8 other young women participants. Participants will be asked to rate the workshop anonymously.
3149455|NCT01553292|Experimental|ECALMIST|Large volume 5ml/kg surfactant administered by vascular catheter while maintaining CPAP or ECALMIST; Early CPAP (continuous positive airway pressure) And Large volume Minimal Invasive Surfactant Therapy
3149456|NCT01553279|Experimental|Group 1: PR5I and MCC-TT|
3303465|NCT00411242|Placebo Comparator|3|
3149408|NCT01553682|Active Comparator|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
3149409|NCT01553682|Experimental|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
3149410|NCT01553669|Experimental|reminiscence therapy|Reminiscence therapy is a method of using the memory to protect mental health and improve the quality of life.
3149411|NCT01553669|No Intervention|Control group|The participants assigned to the waiting-list as the control group will be treated as before. After the intervention period, we will conduct reminiscence therapy on them if they ask for.
3149412|NCT01553656|Experimental|Cabozantinib capsules and tablets|Subjects will be enrolled in cohorts at different dose levels in order to determine the maximum tolerated dose of cabozantinib. Initially, subjects enrolled will receive the capsule formulation; other subjects will receive the tablet formulation.
3149413|NCT01553643|Experimental|Chinese Herb Huang-Chi-Wu-Wu-Tang|
3149414|NCT01553643|Placebo Comparator|Placebo|
3149415|NCT01553630|Active Comparator|RIA bone graft|Surgery: open reduction and internal fixation (ORIF) of high energy metaphyseal fractures with Reamed Irrigator Aspirator (RIA) bone graft at the time of fixation.
3149416|NCT01553630|Active Comparator|Surgery without bone graft|Surgery:open reduction and internal fixation (ORIF) of high energy metaphyseal fractures without Reamed Irrigator Aspirator (RIA) bone graft at the time of fixation.
3149417|NCT01553617|Experimental|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)
3149418|NCT01553617|Active Comparator|Human serum albumin|Human serum albumin (HSA 50g/L)
3149419|NCT01553604|Experimental|Postoperative day 6|Dressing is removed on the sixth postoperative day
3149420|NCT01553604|Experimental|Postoperative day 1|Dressing is removed on the first postoperative day
3149421|NCT01553591|Experimental|JNJ-27018966 75 mg twice daily|
3149422|NCT01553591|Experimental|JNJ-27018966 100 mg twice daily|
3149423|NCT01553591|Placebo Comparator|Matching placebo twice daily|
3149424|NCT01553578|Experimental|Arm A (healing touch therapy)|Patients receive 30 minutes of healing touch therapy consisting of magnetic clearing, pain drains, hands in motion/hands still and mind clearing.
3149425|NCT01553578|Experimental|Arm B (guided imagery)|Patients listen to guided imagery audiotapes for 30 minutes.
3149426|NCT01553578|Active Comparator|Arm C (standard care)|Patients receive standard of care.
3149427|NCT01553565|Active Comparator|Conventional polypectomy|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed with electrocautery. Submucosal injection of some solution before the removal are not performed.
3149428|NCT01553565|Experimental|Cold polypectomy|
3149429|NCT01553552||Infected by Schistosoma haematobium|
3149430|NCT01553552||Not infected by Schistosoma haematobium|
3149431|NCT01553539|Experimental|Treatment (antiangiogenesis therapy)|Patients receive therapeutic angiotensin-(1-7) SC once daily in the absence of disease progression or unacceptable toxicity.
3149432|NCT01553526||Orsiro DES|
3149433|NCT01553513||Group 1 - STEMI|Patients with acute cardiovascular event and typical aberrations in the ECG(STEMI) and positive serum markers
3149434|NCT01553513||Group 2 - NSTEMI|Patients with acute coronary syndrome without typical aberrations in the ECG (NSTEMI) or without positive serum markers
3149435|NCT01553513||Group 3 - symptomatic CAD|Symptomatic patients with stable CAD, who are eligible for ICA
3149436|NCT01553513||Group 4 - STEMI|Patients eligible for ICA 6 months after STEMI and revascularization
3149437|NCT01553500|Experimental|glucomannan|
3149438|NCT01553500|Placebo Comparator|placebo|
3149439|NCT01553487|Experimental|Excercise|The forearm vibration training
3149440|NCT01553487|No Intervention|Control|Patients will be treated by routine fracture treatment methods (fixation and rest).
3149441|NCT01553435|Placebo Comparator|Dextromethorphan, opioid analgisia, efficacy|
3149442|NCT01553435|Placebo Comparator|Placebo,opioid analgesia, efficacy|
3149443|NCT01553422|Active Comparator|before fluid Therapy|
3149444|NCT01553422|Active Comparator|after fluid Therapy|
3149445|NCT01553383|Active Comparator|Dental device|"Provent nasal peep valve vs dental device"
3149446|NCT01553383|Active Comparator|CPAP|"continuous positive airway pressure CPAP vs nasap peep valve Provent"
3149447|NCT01553370|Active Comparator|Alternate Intake-time|
3149448|NCT01553370|Experimental|Immediately post-exercise|
3149449|NCT01553331|Active Comparator|conventional diathermy hook|Laparoscopic cholecystectomy made with diathermy hook starting from Calot´s triangle
3149450|NCT01553331|Active Comparator|ultrasonic dissection|Laparoscopic cholecystectomy made with ultrasonic dissection starting from gallbladder fundus
3149451|NCT01553318|Active Comparator|Active Ketotifen|After meeting the full eligibility requirement, participants will be randomized. Approximately 26 of the 51 participants will assigned to this arm of the study.
3149452|NCT01553318|Placebo Comparator|Placebo for Ketotifen|After meeting the full eligibility requirement, participants will be randomized. Approximately 25 of the 51 participants will assigned to this arm of the study. Subjects in this arm will receive the placebo drug.
3149453|NCT01553305|Experimental|Supervised exercise programme|Six-weeks supervised high-intensity exercise programme with training sessions twice a week followed by 6-weeks unsupervised exercise programme.
3149454|NCT01553305|No Intervention|Unsupervised exercise programme|
3149457|NCT01553279|Experimental|Group 2: PR5I and MCC-CRM|
3149458|NCT01553266||MDET intervention|
3149459|NCT01553266||Control group|Patients who have not received the MDET intervention.
3149460|NCT01553240|Experimental|TMS and fMRI|"functional MRI~single and paired pulse TMS (to identify the difference of motor excitability between patients and healthy controls)"
3149461|NCT01553227|Experimental|ventilator|The overall purpose of this study is to determine the effects of auto-Trilevel ventilation on patients with OSAHS and OHS by comparison with BiPAP ventilation. The following parameters are compared such as apnea hypopnea index, lowest SPO2, arousal index, sleep efficiency, PaCO2, daytime sleepiness and so on.
3149462|NCT01553214|Other|1|There are no arms in this study
3149463|NCT01553214|Other|2|There are no arms in this study
3149464|NCT01553214|Other|3|There are no arms in this study
3149465|NCT01553214|Other|4|There are no arms in this study
3149466|NCT01553188|Experimental|B|Abiraterone and prednisone will be given with MTD of AMG
3149467|NCT01553188|Active Comparator|A|Abiraterone and prednisone only
3149468|NCT01553188|Other|Run in|Dose escalation phase to determine MTD of AMG
3149469|NCT01553149|Experimental|Arm I (low-dose lenalidomide)|Patients receive low-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
3149470|NCT01553149|Experimental|Arm II (high-dose lenalidomide)|Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
3149471|NCT01553136|Placebo Comparator|Sugar pill|
3149472|NCT01553136|Active Comparator|Varenicline|
3149473|NCT01553123|Experimental|Ulipristal with iron|
3149474|NCT01553123|Placebo Comparator|Placebo|Placebo with iron
3149475|NCT01553110||Cold Population|Male and female subjects 12 years of age and older with acute nasal discharge fewer then 7 days. Patients must be symptomatic at screening.
3149476|NCT01553110||Allergic Rhinitis|Male and female subjects of 12 years of age and older with a history suggesting nasal allergic symptoms for at least 1 year. Patients must be symptomatic at screening.
3149477|NCT01553097||women with stage I or II BC with adjuvant chemotherapy|"women with Stage I or II BC who~have undergone surgical treatment (biopsy, lumpectomy or mastectomy) and;~will be receiving adjuvant chemotherapy"
3149478|NCT01553097||women with Stage I or II BC without adjuvant therapy|"Women with stage I or II BC who~Have undergone surgical treatment (biopsy, lumpectomy or mastectomy) \~will not be receiving adjuvant chemotherapy"
3149479|NCT01553097||Healthy control|healthy education-age-matched women without cancer
3149480|NCT01553084|Experimental|Effectiveness of Nicotine patch only|
3149481|NCT01553084|Experimental|Effectiveness of Combination NRT|
3149482|NCT01553084|Experimental|Effectiveness of Varenicline [Chantix]|
3149483|NCT01553071|Experimental|Investigational|Fenretinide (4-HPR) plus Intravenous Safingol
3149484|NCT01553058|Active Comparator|Adalimumab (Humira)|Injection of the active drug Humira.
3149485|NCT01553058|Placebo Comparator|Placebo Injection|Injection of placebo in place of active Humira injection.
3149486|NCT01553058|Active Comparator|NB-UVB phototherapy|NB-UVB Phototherapy 3 times per week, no other intervention.
3149487|NCT01553045||atrial fibrillation, catheter ablation|Patients referred for ablation of atrial fibrillation
3149488|NCT01553032|Active Comparator|Erbitux®|
3149489|NCT01553032|Active Comparator|Fractionated Radiotherapy|
3149490|NCT01553019|Experimental|1- R(0) negative|50.40 cobalt gray equivalent (CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
3149491|NCT01553019|Experimental|2- R(1) micro-positive|54.00 cobalt gray equivalent(CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
3149492|NCT01553019|Experimental|3- R(2) gross positive|59.40 cobalt gray equivalent (CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
3149493|NCT01553006|Active Comparator|cefditoren pivoxil|cefditoren 10 mg/kg/day for 14 days
3149494|NCT01553006|Active Comparator|cefditoren pivoxil high dose|cefditoren 20 MKD were used to compare efficacy of treatment.
3149495|NCT01552993|Experimental|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and sucrose
3149496|NCT01552993|Placebo Comparator|placebo|pacifier and sucrose only
3149497|NCT01552954|Experimental|Intensive education of low salt diet|"For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks. (*Intervention in this trial is the intensity of education)"
3149498|NCT01552954|No Intervention|Conventional diet group|Education for low salt diet will be conducted as in office with brief communication with a patient and a physician.
3149499|NCT01552941|Experimental|Vagal Nerve Stimulation|
3149500|NCT01552928|Experimental|Anagrelide Therapeutic (0.5 mg)|
3149501|NCT01552928|Experimental|Anagrelide Supratherapeutic (2.5 mg)|
3149502|NCT01552928|Active Comparator|Moxifloxacin|
3149503|NCT01552928|Placebo Comparator|Placebo|
3149504|NCT01552915|Experimental|Lisdexamfetamine Dimesylate|
3149505|NCT01552915|Active Comparator|Methylphenidate Hydrochloride|
3149506|NCT01552915|Placebo Comparator|Placebo|
3149507|NCT01552902|Experimental|Lisdexamfetamine dimesylate|
3149508|NCT01552902|Active Comparator|Methylphenidate Hydrochloride|
3149509|NCT01552902|Placebo Comparator|Placebo|
3149510|NCT01552889|No Intervention|Usual Care (UC)|Patients will receive only the care provided by their primary care physicians or other medical professionals outside of the study.
3149511|NCT01552889|Experimental|Collaborative Care (CC)|Patients randomized to the Collaborate Care (CC) arm of this study will receive brief screening, consultative, and referral services. This collaborative approach includes the patient, the patient's PCP, the cardiologist, and the nurse case manager (NCM), using evidence based recommendations for depression treatment and follow-up care.
3149512|NCT01552876|Other|etafilcon A / nelfilcon A / Filcon II 3|etafilcon A worn first then nelfilcon A worn second with Filcon II 3 worn third.
3149513|NCT01552876|Other|nelfilcon A / etafilcon A / Filcon II 3|nelfilcon A worn first then etafilcon A worn second with Filcon II 3 worn third.
3303467|NCT00411229|No Intervention|2|
3149514|NCT01552863|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3149515|NCT01552863|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3149516|NCT01552863|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3149517|NCT01552863|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3149518|NCT01552863|Experimental|Treatment E|Single dose of 5 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3149519|NCT01552863|Experimental|Treatment F|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3149520|NCT01552850|Experimental|Oxycodone Formulation A Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
3149521|NCT01552850|Experimental|Oxycodone Formulation B Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
3149522|NCT01552850|Experimental|Oxycodone Formulation C Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
3149523|NCT01552850|Experimental|Oxycodone Formulation D Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
3149524|NCT01552850|Experimental|Oxycodone Oral Solution|40 mg oxycodone oral solution (5 mg/5 ml) under 50 mg naltrexone block
3149525|NCT01552837|No Intervention|Healthy volunteers|MRI compatible, no present or past DSM-IV diagnosis
3149526|NCT01552837|Active Comparator|patients with Bipolar Disorder|MRI compatible, presence of DSM-IV diagnosis for Bipolar Disorder
3149527|NCT01552824|Experimental|Vesico-amniotic shunt|In this arm, patients will be randomly selected to undergo vesico-amniotic shunting.
3149528|NCT01552824|Experimental|CYSTO|In this arm, all patients will be randomly selected for fetal cystoscopy.
3149529|NCT01552811||Type 1 diabetes|
3149530|NCT01552811||healthy controls|
3149531|NCT01552798|Experimental|Arm 1|
3149532|NCT01552798|Active Comparator|Arm 2|
3149533|NCT01552798|Placebo Comparator|Arm 3|
3149534|NCT01552785||Healthy adults|
3149535|NCT01552772|Experimental|Aripiprazole IM Depot|
3149536|NCT01552759|Experimental|Obese subjects with BED|"Subjects who meet the BMI requirement for obesity (>30 kg/m^2) and the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
3149537|NCT01552759|Experimental|Obese without BED|"Subjects who meet the BMI requirement for obesity (>30 kg/m^2) but who do not meet the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
3149538|NCT01552759|Experimental|Normal-weight without BED|"Subjects with BMI 20-25 kg/m^2 who do not meet the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
3149539|NCT01552733|Experimental|Robotic Therapy|Robotic Therapy using 'Inmotion' device plus standard care. Participants randomised to robotic therapy will receive up to 12 sessions (approximately 1 hour each) performing tasks (including circle drawing, reaching targets and holding/moving against moderate resistance.
3149540|NCT01552733|Placebo Comparator|Standard Care|Rehabilitation therapy according to local guidelines.
3149541|NCT01552707|Experimental|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stem cells fixed in allogenic bone tissue for spinal fusion"
3149542|NCT01552707|Sham Comparator|Standard treatment|Instrumented spinal fusion together with patient's bone iliac crest.
3149543|NCT01552694|Experimental|Sitagliptin|100 mg sitagliptin/day for 2 months
3149544|NCT01552694|Placebo Comparator|Placebo|Matching placebo daily for 2 months
3149545|NCT01552681|Experimental|Baminercept|Subcutaneous injections of 100 mg every week for 24 weeks
3149546|NCT01552681|Placebo Comparator|Placebo|Subcutaneous injections of matched placebo every week for 24 weeks
3149547|NCT01552668|Experimental|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
3149548|NCT01552668|Placebo Comparator|Placebo|
3149549|NCT01552655|Other|Dual-time PET/CT|
3149550|NCT01552642|Active Comparator|Intervention Group|Intervention Group
3149551|NCT01552642|No Intervention|Control Group|Control Group
3149552|NCT01552629|Experimental|Group 1 QGE031|QGE031 will be administered as a subcutaneous dose q2 weeks
3149553|NCT01552629|Placebo Comparator|Group 2 Placebo|A QGE031 matched placebo will be administered as a subcutaneous dose q2 weeks
3149554|NCT01552629|Experimental|Group 3 Cyclosporine A|Cyclosporine A will be administered (as per label) for atopic dermatitis.
3149555|NCT01552616|Experimental|Activation Treatment|
3149556|NCT01552616|No Intervention|Usual Care|This arm will not receive any study-motivated intervention. Subjects will receive usual care, but will participate in outcomes assessments.
3149557|NCT01552603|Experimental|Artificial Pancreas Control|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 28 hours. For the entire study, the adaptive component of Artificial Pancreas Control Software will be used to control the subject's blood glucose.
3149558|NCT01552590|Active Comparator|Tolvaptan, Tablet, QD, 2 weeks|
3149559|NCT01552590|Placebo Comparator|Placebo, Tablet, QD, 2 weeks|
3149560|NCT01552577||TBI Group|Adults (civilian or military) with a history of one or more brain injuries / concussions.
3149561|NCT01552577||Control Group|Healthy adults (civilian or military) with no history of brain injury.
3149562|NCT01552564||STEMI patients|Consecutive patients presenting through the PPCI service
3149563|NCT01552551|Active Comparator|Healthy Steps|Healthy Steps program as currently implemented by the PA Department of Aging
3149564|NCT01552551|Experimental|Healthy Steps with Falls Case Management|Healthy Steps program augmented with research interventionist guidance on seeking physician care and home safety assessment
3149565|NCT01552551|Experimental|Healthy Steps in Motion|Healthy Steps program augmented with Healthy Steps in Motion, a 4-week, twice a week program of group exercise.
3149566|NCT01552538|Experimental|Cyberonics VNS System|Continued stimulation w/Cyberonics VNS
3149567|NCT01552525||acute kidney injury|Patients with acute kidney injury according to the definition of AKIN (Acute Kidney Injury Network)
3149568|NCT01552512|No Intervention|MSPP Integrated Package|Participants in this arm only receive the standard care offered by the Ministry of Health (MSPP)called the Integrated Package. During the trial, they do not receive Nutributter.
3149569|NCT01552512|Experimental|Nutributter 3 Months, Integrated Package|Participants receive a one-month supply for the first 3 months of the 6-month trial in addition to the Integrated Package.
3149570|NCT01552512|Experimental|Nutributter 6 Months, Integrated Package|Participants receive a one-month supply for each month of the 6-month trial in addition to the Integrated Package.
3149571|NCT01552499|Other|Control|
3149572|NCT01552499|Experimental|Treatment|
3149573|NCT01552486|Experimental|Chiropractic Spinal Manipulative Therapy|
3149574|NCT01552486|Other|Usual Care|
3149575|NCT01552473|Active Comparator|Brain Training Program 1|Training Program focusing on providing educational information of cognitive issues related to TBI
3149576|NCT01552473|Experimental|Brain Training Program 2|Program focuses on strategies to address cognitive issues following TBI
3149577|NCT01552447|Other|1 application of EpiFix|1 x dehydrated human amnion/chorion membrane
3149578|NCT01552447|Other|2 applications of EpiFix|2 x dehydrated human amnion/chorion membrane
3149579|NCT01552447|Other|Standard of care|Compression bandaging
3149580|NCT01552434|Experimental|Temsirolimus + Bevacizumab + Cetuximab|"Dose Escalation Group: Starting dose of Temsirolimus 5 mg by vein on Days 1, 8, 15, and 22 of each 28 day cycle. Starting dose of Bevacizumab 2.5 mg/kg by vein on Days 1 and 15 of each 28 day cycle. Starting dose of Cetuximab loading dose 100 mg/m2, and maintenance dose 75 mg/m2 by vein on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose Expansion Group Starting dose: Maximum tolerated dose (MTD) from Dose Escalation Group."
3149581|NCT01552434|Experimental|Temsirolimus + Bevacizumab + Valproic Acid|"Dose Escalation Group: Starting dose of Temsirolimus 5 mg by vein on Days 1, 8, 15, and 22 of each 28 day cycle. Starting dose of Bevacizumab 5 mg/kg by vein on Days 1 and 15 of each 28 day cycle. Starting dose of Valproic Acid 5 mg/kg rounded to nearest 250 mg by mouth on Days 1 - 7 and 15 - 21 of each 28 day cycle.~Dose Expansion Group Starting dose: Maximum tolerated dose (MTD) from Dose Escalation Group."
3149582|NCT01552434|Experimental|Temsirolimus + Bevacizumab|"Dose Escalation Group: Starting dose of Temsirolimus 5 mg by vein on Days 1, 8, 15, and 22 of each 28 day cycle. Starting dose of Bevacizumab 5 mg/kg by vein on Days 1 and 15 of each 28 day cycle.~Dose Expansion Group Starting dose: Maximum tolerated dose (MTD) from Dose Escalation Group."
3149583|NCT01552421|Active Comparator|TV NOTES cholecystectomy|Participants randomized to TV NOTES cholecystectomy
3149584|NCT01552421|No Intervention|Laparoscopic cholecystectomy|Participants randomized to laparoscopic cholecystectomy
3149585|NCT01552408|Active Comparator|0.3 mg Ranibizumab|Cohort 1: Subjects will receive 4 IVT of 0.3 mg ranibizumab every 28 days (+/- 7 days), then will be seen monthly (+/- 7 days) & will receive IVT of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria.
3149586|NCT01552408|Experimental|Targeted PRP with 0.3 mg Ranibizumab|Cohort 2: Subjects will receive 4 it of 0.3 mg ranibizumab every 28 days (+/- 7 days), then will then be seen monthly (+/- 7 days) & receive IVT of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at Day 7 they will receive targeted pan-retinal photocoagulation (PRP) based on ultra wide field angiography. Ultra wide field angiography will be performed every 3 months to indicate areas of peripheral ischemia, which will be selectively be treated with PRP at Month 6, Month 18, and Month 25, preserving areas of more perfused retina.
3149587|NCT01552382||cardiac surgical patients|patients undergoing a cardiac surgical procedure
3149588|NCT01552369|Experimental|Preemptive Therapy|900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction. n=88
3149589|NCT01552369|Active Comparator|Prophylaxis|900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction. n=88
3149590|NCT01552356|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course length can be extended to 56 days at the discretion of the treating physician after 12 courses (1 year) of treatment on study.
3149591|NCT01552343|Experimental|Female - Desmopressin 25 μg|Female participants took 1 tablet of 25 μg every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
3149592|NCT01552343|Placebo Comparator|Female - Placebo|Female participants took 1 tablet of placebo every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
3149593|NCT01552343|Experimental|Male - Desmopressin 75 μg|Male participants took 1 tablet 75 μg every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
3149594|NCT01552343|Placebo Comparator|Male - Placebo|Male participants took 1 tablet of placebo every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
3149595|NCT01552330|Experimental|Group A|Primaquine only followed by Pyronaridine-Artesunate and followed by Primaquine together with Pyronaridine-Artesunate.
3149596|NCT01552330|Active Comparator|Group B|Primaquine only followed by Primaquine together Pyronaridine-Artesunate and followed by Pyronaridine-Artesunate only.
3149597|NCT01552317|Experimental|lifestyle counselling|A package of advice and interventions to help participants reduce their salt intake.
3149598|NCT01552317|No Intervention|Normal care|This group will receive the normal care that they would get anyway.
3149599|NCT01552304|Experimental|Oxygen treatment group|Besides routine care, patients in this group will receive postoperative oxygen therapy with nasal prolong at 3 liters/min during the first 3 nights after surgery.
3304563|NCT00398918|Experimental|Zonisamide|
3149600|NCT01552304|Other|Control group|Patients will be managed by the anesthesiologists and surgeons as per routine practice.
3149601|NCT01552291|Active Comparator|Glutamin|
3149602|NCT01552291|Placebo Comparator|Placebo|
3149603|NCT01552265||single-group MCI patients|
3149604|NCT01552252|Placebo Comparator|0% POs-Ca|
3149605|NCT01552252|Active Comparator|0.5% POs-Ca|
3149606|NCT01552252|Active Comparator|1% POs-Ca|
3149607|NCT01552252|Active Comparator|1.5% POs-Ca|
3149608|NCT01552252|Active Comparator|2% POs-Ca|
3149609|NCT01552239|Experimental|1 Arm|"Stratum A:~R0, primary wound closure~Stratum B:~R0, secondary wound closure~Stratum C:~R1, tertiary wound closure"
3149610|NCT01552226|Active Comparator|Continuous Preperitoneal Analgesia|Continuous Preperitoneal Analgesia for pain management
3149611|NCT01552226|Active Comparator|Continuous Epidural Analgesia|Continuous Epidural Analgesia for pain management
3149612|NCT01552213|Active Comparator|Treatment for glucose intolerance|Regular visit with dietician, exercise, self blood glucose monitoring, Insulin therapy if determined necessary.
3149613|NCT01552213|Active Comparator|Minimum intervention control group|Single visit with dietician or health educator followed by routine care per provider.
3149614|NCT01552200|Experimental|A-Standard Colonoscopy, G-Eye procedure|Standard Colonoscopy,G-Eye procedure
3149615|NCT01552200|Active Comparator|B- G-Eye procedure, Standard Colonoscopy|G-Eye procedure,Standard Colonoscopy
3149616|NCT01552187|Placebo Comparator|Placebo|Placebo
3149617|NCT01552187|Active Comparator|Colchicine|Colchicine
3149618|NCT01552174||Outpatients attending general ophthalmologic consultation|"Outpatients of either sex, aged at least 18 years, seen in general ophthalmological consultation~Patients informed of the objectives of the survey and agreeing to participate.~Patient attending to the ophthalmological consultation for any reasons: regular check-up of chronic disease, acute symptoms, or for surgery preparation or follow up."
3149619|NCT01552161||Patients with negative coronarography.|Subjects who underwent coronary angiography and were classified as having no critical lesions in coronary arteries (a lesion of up to 50% of artery lumen is accepted as non-critical).
3149620|NCT01552161||Patients with positive coronarography|Subjects who underwent coronary angiography and were classified as having critical lesions in coronary arteries (over 50% narrowing of artery lumen).
3149621|NCT01552148|Active Comparator|Group TAP (US guided)|23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
3149622|NCT01552148|Other|Group Control|
3149623|NCT01552135||Healthy|Healthy men above 50 years old
3149624|NCT01552122|Experimental|Odanacatib|
3149625|NCT01552122|Active Comparator|Alendronate|
3149626|NCT01552096|Placebo Comparator|Placebo|The placebo group (n=30) will receive a submucosal infiltration with 3 mL of normal saline (1.5 ml around each tonsil), 3 minutes before surgical incision.
3149627|NCT01552096|Active Comparator|lidocaine|will receive a total of 2 mg.kg-1 of 2% lidocaine HCl (Xylocaine, Astra-Zeneca,) in 3 mL of normal saline (1.5 ml around each tonsil), 5 minutes before surgical incision.
3149628|NCT01552096|Experimental|Tramadol|(n=30) will receive a submucosal infiltration with 2 mg kg-1 tramadol in 3 mL of normal saline (1.5 ml around each tonsil), 3 minutes before surgical incision.
3149629|NCT01552070|Experimental|With recruitment maneuver group|Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds. Blood gases were sampled and blood samples taken for culture before, within 2 minutes, 5 minutes, and 30 minutes after intubation. Haemodynamic and respiratory parameters were continuously recorded throughout the study.
3149630|NCT01552070|Active Comparator|Without recuritment maneuver|After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
3149631|NCT01552057|Experimental|Duloxetine 60 mg|Duloxetine hydrochloride up to 60 milligrams (mg) orally for 15 weeks
3149632|NCT01552057|Placebo Comparator|Placebo|Placebo orally for 15 weeks
3149633|NCT01552044|Experimental|spironolactone|Spironolactone 25mg/day
3149634|NCT01552044|Placebo Comparator|Placebo|placebo tablets
3149635|NCT01552031||Observational group|
3149636|NCT01552018|Active Comparator|Saxagliptin|Saxagliptin 5 mg/day
3149637|NCT01552018|Placebo Comparator|Placebo|Placebo
3149638|NCT01552005||Population of patients treated with Saxagliptin|
3149639|NCT01551992|Active Comparator|Interrupted suture|interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA)
3149640|NCT01551992|Active Comparator|Quill suture|self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada)
3149641|NCT01551979|Active Comparator|Active rTMS|High frequency rTMS stimulation of the vermis(lobule VII) of the cerebellum.
3149642|NCT01551979|Sham Comparator|Sham rTMS|Sham rTMS to the vermis (lobule VII) of the cerebellum.
3149643|NCT01551966|Experimental|video capsule endoscopy|
3149644|NCT01551953|Experimental|tai chi exercise|
3149645|NCT01551953|Experimental|mind-body breathing|
3149646|NCT01551953|Active Comparator|education|
3149647|NCT01551940|Experimental|Botox|Botox injection : 100 UI of botulinum toxin type A (Botox®) diluted in 2.2 ml of NaCl 0.9 %
3149648|NCT01551940|Placebo Comparator|Placebo|Placebo injection : NaCl 0.9 %
3149649|NCT01551914|Experimental|ultrasonic scissors|
3149650|NCT01551914|Active Comparator|conventional techniques of haemostasis|clips, ligatures, and bipolar coagulation
3149651|NCT01551901|Experimental|Luna Interbody System|
3149652|NCT01551888|Experimental|Aclidinium/formoterol 400/12μg FDC|Aclidinium/formoterol 400/12μg fixed-dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
3149653|NCT01551888|Active Comparator|Formoterol|Formoterol 12μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
3149655|NCT01551849||VA-ECMO patients|Patients placed on VA-ECMO support for primary cardiac dysfunction.
3149656|NCT01551836|Other|Paracetamol formulation 1|Higher dose level of marketed paracetamol (compared to the other dosage arm)
3149657|NCT01551836|Other|Paracetamol formulation 2|Lower paracetamol concentrations
3149658|NCT01551823|Experimental|Team 1|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
3149659|NCT01551823|Experimental|Team 2|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
3149660|NCT01551810|Experimental|Influenza Virus Vaccine|Influenza Virus Vaccine（no Preservative ) 0.5ml intramuscular injections
3149661|NCT01551810|Experimental|Influenza Virus Vaccine(Preservative)|Influenza Virus Vaccine（add Preservative ) 0.5ml intramuscular injections
3149662|NCT01551797|Experimental|Test Sustained Release (SR) Paracetamol (2000 mg)|A single 2000 mg oral dose of SR paracetamol formulation (2 x 1000 mg) administered with 150 mL of water.
3149663|NCT01551797|Experimental|Test SR Paracetamol (1500 mg)|A single 1500 mg oral dose of SR paracetamol formulation (2 x 750 mg) administered with 150 mL of water.
3149664|NCT01551797|Active Comparator|Reference Paracetamol (2000 mg)|Two single 1000 mg doses of paracetamol (2 x 500 mg/dose) administered orally 6 hours apart, administered with 150 mL of water.
3149665|NCT01551784||1|
3149666|NCT01551771|Experimental|GW824575|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
3149667|NCT01551771|Placebo Comparator|GW824575 matched-placebo|Placebo
3149668|NCT01551758|Experimental|FF/VI|once daily via a Novel Dry Powder Inhaler
3149669|NCT01551758|Other|Existing Maintenance Therapy|"Existing Maintenance Therapy:~Long acting bronchodilator therapy alone~ICS alone or in combination with a long acting bronchodilator~Triple maintenance therapy"
3149670|NCT01551745|Experimental|Vigil™ Vaccine|Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
3149671|NCT01551732|Active Comparator|Anger Control Therapy|10 session manualized cognitive behavioral anger control therapy
3149672|NCT01551732|Experimental|ACT with RAGE-Control|10 session manualized cognitive behavioral anger control therapy augmented with an interactive biofeedback videogame.
3149673|NCT01551719|No Intervention|Standard Procedure (phase I)|Antibiotic prescription following in vitro sensitivity test according to each surgeon's will.
3149674|NCT01551719|Experimental|Implemented procedure|Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection, according to each surgeon's will.
3149675|NCT01551706|Active Comparator|ENI Patented Whole Grape Extract|ENI Patented Whole Grape Extract (350 mg) per day
3149676|NCT01551706|Placebo Comparator|Exicipient pill|
3149677|NCT01551693|Experimental|STA-9090 Cohort A|Patients enrolled into two possible cohorts based on tumor expression of BRAF: Cohort A - BRAF mutant disease or Cohort B - BRAF wild type. Cohort A patients received STA-9090 200 mg/m2 once weekly (d1, 8, 15 of 28 day cycle). Patients were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal.
3149678|NCT01551693|Experimental|STA-9090 Cohort B|Patients enrolled into two possible cohorts based on tumor expression of BRAF: Cohort A - BRAF mutant disease or Cohort B - BRAF wild type. Cohort B patients received STA-9090 150 mg/m2 twice weekly (d1, 4, 8, 11, 15, 18 of 28 day cycle). Patients were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal.
3149679|NCT01551680|Experimental|Concurrent whole brain radiotherapy and iniparib|
3149680|NCT01551667||Cases / bacteraemia|Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases of the participating hospitals and who have (1) inaugural or recurrent diabetic foot/ankle ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed. This infection must involve S. aureus in a mono-or polymicrobial setting. This group of patients has bacteraemia.
3149681|NCT01551667||Controls|Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases of the participating hospitals and who have (1) inaugural or recurrent diabetic foot/ankle ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed. This infection must involve S. aureus in a mono-or polymicrobial setting. This group of patients does not have bacteraemia.
3149682|NCT01551654|Placebo Comparator|Placebo Acu-TENS|No Electrical output was coming out from the TENS unit
3149683|NCT01551654|Experimental|TENS over acupuncture points|A constant mode of electrical stimulation at 2 pulses per second and pulse width at 200µs for 45 minutes. Intensity was set to just initiate muscle contraction.
3149684|NCT01551641|Experimental|VEGF decressed|patients will receive concurrent chemoradiotherapy only
3149685|NCT01551641|Experimental|thalidomide|patients will be given thalidomide concurrent chemoradiotherapy
3149686|NCT01551641|Experimental|without thalidomide|patients will receive concurrent chemoradiotherapy only
3149687|NCT01551628|Experimental|Recombinant Human Arginase 1 Peg5000|
3149688|NCT01551615|Experimental|Metformin then metformin + vandetanib|Metformin alone followed by metformin in combination with vandetanib
3149689|NCT01551602|Experimental|AK159 SD 1|Single administration of AK159 dose level 1
3149690|NCT01551602|Experimental|AK159 SD 2|Single administration of AK159 dose level 2
3149691|NCT01551602|Experimental|AK159 SD 3|Single administration of AK159 dose level 3
3149692|NCT01551602|Experimental|AK159 SD 4|Single administration of AK159 dose level 4
3149693|NCT01551602|Active Comparator|MN-10-T SD|Single administration of MN-10-T
3149694|NCT01551602|Experimental|AK159 MD 1|Multiple administration of AK159 dose level 1
3149695|NCT01551602|Experimental|AK159 MD 2|Multiple administration of AK159 dose level 2
3149696|NCT01551602|Experimental|AK159 MD 3|Multiple administration of AK159 dose level 3
3149697|NCT01551602|Experimental|AK159 MD 4|Multiple administration of AK159 dose level 4
3149698|NCT01551602|Active Comparator|MN-10-T MD|Multiple administration of MN-10-T
3149699|NCT01551602|Placebo Comparator|Placebo MD|Multiple administration of placebo AK159
3149742|NCT01551225|Active Comparator|Escitalopram|17 or 18 Patients with IBS and panic disorder treated with Escitalopram.
3149700|NCT01551589|Experimental|Involved Field Irradiation(IFI)|Involved Field Irradiation(IFI):The clinical target volume of regional lymph node (CTVn) of IFI included the nodal region(s) in which the involved lymph node(s) was/were located.chemothrapy:docetaxel and cisplatin.
3149701|NCT01551589|Active Comparator|Elective Nodal Irradiation (ENI)|Elective Nodal Irradiation (ENI):The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17 were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.chemothrapy:docetaxel and cisplatin.
3149702|NCT01551550|Experimental|GDD & Amniotic Membrane Graft|After GDD implantation, amniotic membrane graft (AmnioGuard™, Bio-Tissue inc, Miami, FL) is used to cover the GDD tube.
3149703|NCT01551550|Active Comparator|GDD & Pericardial Graft|After GDD implantation, a pericardial graft (Tutoplast®, IOP Inc, Costa Mesa, CA) is used to cover the GDD tube.
3149704|NCT01551537||Cohort Group|Healthy females aged 10 years and above will receive 1, 2 or 3 doses of Cervarix as per the Prescribing Information (PI) in Sri Lanka.
3149705|NCT01551524|Experimental|Intravenous Erwinia|
3149706|NCT01551511|Experimental|delta-9-tetrahydrocannabinol (namisol)|
3149707|NCT01551511|Placebo Comparator|Placebo|
3149708|NCT01551498|Placebo Comparator|Placebo|subject takes one oral placebo lozenge, three times per day
3149709|NCT01551498|Active Comparator|Anatabloc Supplement|subject takes one oral Supplement lozenge, three time per day
3149710|NCT01551485|Experimental|Zolpidem|
3149711|NCT01551485|Placebo Comparator|Placebo|
3149712|NCT01551472||3DKnee™ with e-plus Insert|Subjects who meet the indications for use criteria for the 3DKnee™ System with vitamin E UHMWPE tibial inserts (VE) and who are candidates for a primary knee arthroplasty.
3149713|NCT01551459|Active Comparator|Arm 1: Dacarbazine|Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
3149714|NCT01551459|Experimental|Arm 2: Sunitinib|Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity.
3149715|NCT01551446|Experimental|Bardoxolone Methyl 20mg|
3149716|NCT01551433||Pts scheduled for Ivor Lewis esophagectomy|During the operation, once the gastric conduit has been mobilized and positioned, and once the anastomotic site has been identified by the surgeon, the assigned RSA will provide the Wipox instrument to the fellow (the primary surgeon will be blinded to the result) who will then obtain one measurement from the anastomotic site.
3149717|NCT01551420||Group 1|Subjects with upper limb amputation
3149718|NCT01551394|Experimental|Meropenem|"Infants will received the Meropenem 20 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes.~Treatment duration is 11 ± 3 days."
3149719|NCT01551394|Active Comparator|Standard of care|"The two accepted therapeutic options are:~ampicillin + gentamicin (SOC regimen 1) and~cefotaxime + gentamicin (SOC regimen 2)."
3149720|NCT01551381|Experimental|EV-077|Oral administration
3149721|NCT01551381|Placebo Comparator|Placebo|Oral administration
3149722|NCT01551368|Experimental|Nimodipine|Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hCG will be given immediately and two IUIs will be performed 24 hours apart.
3149723|NCT01551368|Placebo Comparator|Placebo|Same as for nimodipine but an identical placebo will be self-administered.
3149724|NCT01551355|Experimental|Children-Multicomponent intervention|"The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide."
3149725|NCT01551355|No Intervention|children - control group|The control preschool facilities continued with their usual preschool curriculum
3149726|NCT01551342||Cystoscopic surveillance, TURT or Cystectomy|The following subjects will be enrolled: Subjects previously diagnosed with bladder cancer undergoing routine cystoscopic surveillance, TURT or Cystectomy.
3149727|NCT01551329|Experimental|Drug: Ketamine|
3149728|NCT01551316|Experimental|MN-221|If the participants qualify, they will be randomized into one of two arms for 4 days. The arms are either Placebo (no medication) or MN-221 intravenously infused.
3149729|NCT01551316|Experimental|PLACEBO|If the participants qualify, they will be randomized into one of two arms for 4 days. The arms are either Placebo (no medication) or MN-221 intravenously infused.
3149730|NCT01551303|Placebo Comparator|Placebo|Matched nasal spray placebo.
3149731|NCT01551303|Experimental|Oxytocin|Liquid intranasal oxytocin administered in a nasal spray.
3149732|NCT01551290|Placebo Comparator|Group I: Placebo|Participants in Group I receive placebo
3149733|NCT01551290|Experimental|Group II: Infliximab|Participants in Group II receive 5 mg/kg infliximab
3149734|NCT01551277|Placebo Comparator|Control Group|
3149735|NCT01551277|Experimental|BREATH STACKING|
3149736|NCT01551264|Other|4-Year Bracing Arm|This group has been randomized to 4 years of bracing after correction of clubfoot using the Ponseti Method.
3149737|NCT01551264|Other|2-Year Bracing Arm|This group has been randomized to 2 years of bracing after correction of clubfoot using the Ponseti Method.
3149738|NCT01551251||Advanced NSCLC with high TAM|All patients with advanced non-small cell lung cancer who had been treated at the Linkou Branch of Chang Gung Memorial Hospital were included. Tumor specimens with high TAM were included as one cohort group.
3149739|NCT01551251||Advanced NSCLC with low TAM|All patients with advanced non-small cell lung cancer who had been treated at the Linkou Branch of Chang Gung Memorial Hospital were included. Tumor specimens with low TAM were included as one cohort group.
3149740|NCT01551238|Experimental|Protein intake of 5 energy percent|
3149743|NCT01551225|Placebo Comparator|Placebo tablets to Escitalopram|17 or 18 Patients with IBS and panic disorder treated with placebo.
3149744|NCT01551212|Active Comparator|tacrolimus group|standby therapy
3149745|NCT01551212|Experimental|tacrolimus minimization group|Everolimus (RAD001) as add-on
3149746|NCT01551199|Experimental|Multiple Channel Exposure Therapy|MCET-V is a cognitive-behavioral treatment for persons with comorbid PTSD and panic attacks
3149747|NCT01551186|Experimental|Probiotic|Patients randomized to probiotic therapy will receive 1 capsule containing 1010 cells of Lactobacillus rhamnosus GG on a twice-daily basis
3149748|NCT01551186|No Intervention|Standard of Care|Patients in the control arm will receive standard care
3149749|NCT01551173|Experimental|Fluvastatin sodium Extended Release Tablet|Oral Fluvastatin sodium Extended Release Tablet 80mg once daily for 12 weeks
3149750|NCT01551173|Active Comparator|Fluvastatin sodium Immediate Release Capsule|Oral Fluvastatin sodium Immediate Release Capsule 40mg twice daily for 12 weeks
3149751|NCT01551160|Experimental|Medical Emergency Team|A communication and team-working initiative
3149752|NCT01551147|Experimental|Experimental 200 mg dose|
3149753|NCT01551147|Active Comparator|Active Comparator|
3149754|NCT01551147|Placebo Comparator|Placebo Comparator|
3149755|NCT01551134|Active Comparator|Open fundoplication|Fundoplication performed with open surgery
3149756|NCT01551134|Experimental|Lap fundoplication|Primary fundoplication performed by laparoscopic surgery
3149757|NCT01551121||intervention group|"Patient in the intervention group will have camera installed in their room. These cameras can either work in visible or infrared range. They are physically linked to a server that will store and analyze images in real-time. The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy"
3149758|NCT01551121||non-equipped group|"Patient in the non-equipped group will have usual care"
3149759|NCT01551108|Active Comparator|Mobile phone intervention: minimal|Intervention: limited behavioral strategies
3149760|NCT01551108|Experimental|Mobile phone intervention: intensive|Intervention: advanced behavioral strategies
3149761|NCT01551095|Experimental|PEGJ|Patients in this arm will receive self-propelled balloon PEGJ tube.
3149762|NCT01551082||Outpatient chest tubes|All patients, mixed gender, race, and age, who underwent thoracic resection by one surgeon over the past seven years and discharged home with air leak present and chest tube to portable drainage device.
3149763|NCT01551069|Active Comparator|HCQ|HCQ 200~400mg, once daily, oral administration
3149764|NCT01551069|Other|Placebo|HCQ-placebo, once daily, oral administration
3149765|NCT01551056|Experimental|AC-170 0.24%|
3149766|NCT01551056|Placebo Comparator|AC-170 0%|
3149767|NCT01551043|Experimental|Arm 1|
3149768|NCT01551030|Experimental|Buparlisib|This is an open-label phase II study of the pan-class I selective phosphoinositide 3-kinase (PI3K) inhibitor Buparlisib in patients with metastatic urothelial carcinoma which has progressed despite treatment with prior cytotoxic chemotherapy.
3149769|NCT01551017||c-treatment|test group
3149770|NCT01551017||standard cooling|comparison group
3149771|NCT01551004|Experimental|Cohort A|8 subjects (6 active, 2 placebo) receive a single oral dose of 100 mg CRS3123 or placebo
3149772|NCT01551004|Experimental|Cohort B|8 subjects (6 active, 2 placebo) receive a single oral dose of 200 mg CRS3123 or placebo
3149773|NCT01551004|Experimental|Cohort C|8 subjects (6 active, 2 placebo) receive a single oral dose of 400 mg CRS3123 or placebo
3149774|NCT01551004|Experimental|Cohort D|8 subjects (6 active, 2 placebo) receive a single oral dose of 800 mg CRS3123 or placebo
3149775|NCT01551004|Experimental|Cohort E|8 subjects (6 active, 2 placebo) receive a single oral dose of 1200 mg CRS3123 or placebo
3149776|NCT01550978|Experimental|Study Group|Patients intubated with AnapnoGuard EndoTracheal Tube and connected to the AnapnoGuard 100 Control System
3149777|NCT01550978|No Intervention|Control Group|Patients intubated with the Standard of Care EndoTracheal Tube and Connected to a Suction Regulator
3149778|NCT01550965|Experimental|Participants Receiving Adalimumab|Adults with active UC who had failed conventional therapy received Adalimumab 160 mg at Baseline Visit, 80 mg at Week 2 Visit, and 40 mg every other week (EOW) starting at Week 4. Non-responders to adalimumab were to be discontinued from treatment at Week 8. After Week 8, dose escalation to 40 mg weekly was allowed for flare or non-response.
3149779|NCT01550939|No Intervention|Time Comparison between the Lenstar and IOLMaster|
3149780|NCT01550926|Active Comparator|Arm 1|60 mg orlistat
3149781|NCT01550926|Active Comparator|Arm 2|120 mg orlistat (2 X 60 mg capsules)
3149782|NCT01550926|Experimental|Arm 3|orlistat experimental formulation
3149783|NCT01550913|Experimental|Sober Network IPT|Participants are assigned to Sober Network Interpersonal Psychotherapy (IPT)
3149784|NCT01550913|Other|Treatment as Usual|Participants are assigned to have Treatment as Usual
3149785|NCT01550900|Experimental|Metformin ER|Participants receive two tablets of Metformin ER 500 mg once daily for no more than twelve to eighteen months allowing time for at least one follow up colonoscopy. Dose will be reached in a gradual escalation scheme to improve gastrointestinal tolerance. If participants experience side effects during dose escalation regimen, they will be reduced to one tablet of 500 mg daily, and may continue taking 500 mg daily for the duration of the study.
3149786|NCT01550900|Active Comparator|Placebo|Control group given matched Placebo once daily for no more than twelve to eighteen months allowing time for at least one follow up colonoscopy.
3149787|NCT01550887|No Intervention|Impulsivity evaluation|
3149788|NCT01550874|No Intervention|Control Group|Wear the pedometer provided by study everyday with weekly charging and syncing of data.
3149789|NCT01550874|Experimental|Experimental Group|Wear the pedometer provided by the study everyday and also participate in phone-based physical activity behavior-change counselling for 6 months and then check sustainability without further motivational support for another 6 months.
3149790|NCT01550861|Experimental|In vitro Maturation|in vitro maturation of immature oocytes
3149791|NCT01550848|Experimental|Abraxane and Gemcitabine|Abraxane and Gemcitabine
3149792|NCT01550835|Experimental|Distal Embolic Protection Only|Carotid stenting with distal embolic protection only
3149793|NCT01550835|Active Comparator|Distal embolic protection and aspiration thrombectomy|Aspiration thrombectomy following stent deployment and prior to removal of distal embolic protection
3149794|NCT01550822|Active Comparator|HEALS|Intervention group which will receive group clinics addressing smoking cessation, healthy eating, physical activity, and the risk factors of stroke.
3149795|NCT01550822|No Intervention|Usual Care|This group will receive usual care for stroke survivors
3149796|NCT01550809|Active Comparator|tBolus (traditional bolus)|Traditional mealtime insulin bolus based on the individual insulin-to-CHO ratio
3149797|NCT01550809|Experimental|iBolus (CGM-based insulin administration)|This is a CGM-based algorithm for prandial insulin administration. An individual patient's model characterizing a 5-hour postprandial period (0-5h PP) is obtained from a 6-day CGM period. A model with interval parameters accounting for patient's variability is calculated considering 20% uncertainty in insulin sensitivity and 10% in carbohydrates (CHO) estimation. Based on this model, constraints on plasma glucose are posed and a set-inversion problem lead to a set of solutions (the iBolus) that contains a bolus insulin dose, a specific mealtime basal insulin dose and the time for restoration of basal to baseline values.
3149798|NCT01550796|Active Comparator|d-cycloserine|d-cycloserine 250 mg two days per week one hour prior to(cognitive training)
3149799|NCT01550796|Placebo Comparator|Placebo|Placebo pill two days per week 1 hour prior to cognitive training
3149800|NCT01550783|Experimental|Group I (home-based HPV screening)|Participants collect 2 vaginal specimens using polyester swabs that are then placed in a specimen tube. Specimens are then submitted to the Harborview Medical Center clinical pathology lab. Participants with a positive HPV test result will have a Pap test. Participants with an abnormal Pap test will undergo standard of care as in Group II.
3149801|NCT01550783|Experimental|Group II (clinic-based standard of care screening)|Participants undergo standard of care cervical cancer screening and follow-up. That is, participants undergo Pap testing. Participants with an abnormal Pap test undergo HPV testing, colposcopy, cervical biopsy and/or ECC. Participants with cervical biopsies showing precancerous changes are offered to undergo LEEP or are referred to appropriate care.
3149802|NCT01550770|Experimental|proprofol|
3149803|NCT01550757|No Intervention|Arm 1|Normal PACT Clinical Care
3149804|NCT01550757|Experimental|Arm 2|Normal PACT Clinical Care + Embedded Peer Mentor
3149805|NCT01550757|No Intervention|Arm 3|Normal Homeless Oriented PACT Clinical Care
3149806|NCT01550757|Experimental|Arm 4|Normal Homeless Oriented PACT Clinical Care + Embedded Peer Mentor
3149807|NCT01550744|Experimental|Group 1: Approved q12w maintenance regimen|Active ustekinumab study agent q12 weeks with sham/placebo as necessary to maintain blind
3149808|NCT01550744|Experimental|Group 2: Subject-tailored fixed-interval maintenance regimen|Subjects will undergo placebo withdrawal and will receive active study agent up to q24w intervals with sham/placebo injections to maintain the blind.
3149809|NCT01550731|Experimental|Arm 1|The intervention group will review the PREPARE advance care planning website and PREPARE materials plus receive an advance directive. The control group will only receive an advance directive.
3149810|NCT01550731|Active Comparator|Arm 2|The control group will only receive an advance directive.
3149811|NCT01550718|Active Comparator|ESML-Exercise (Physical Activity Program)|ESML-Exercise consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic. Classes are carried out in small groups of five to six participant/care partner dyads (10-12 people total), to ensure everyone in the class gets individual attention and that all exercises are done safely using proper form.
3149812|NCT01550718|Active Comparator|ESML-SOCIAL (Social Activity Program)|"ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session. Seminars are carried out in small groups of five to six participant/care partner dyads (10-12 people total), to ensure everyone in the seminar gets individual attention and that everyone has a chance to bring up any concerns."
3149813|NCT01550718|No Intervention|No Intervention|This arm will receive no intervention during the active treatment period. After the 4 month assessment participants can choose to attend a support group.
3149814|NCT01550705|Experimental|Isoniazid|Subjects will receive isoniazid daily for 2 months. Subjects will be seen every 2 weeks to obtain lab samples and health check.
3149815|NCT01550679||Smokers or ex-smokers|Smokers or ex-smokers 40-65 years of age with a smoking history of at least 20 pack-years with no diagnosis of COPD or asthma
3149816|NCT01550666|Experimental|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
3149817|NCT01550666|No Intervention|Treatment As Usual|Participants of this group will continue to receive medication follow up at the Center for Health Care Services. They will not be required to do anything additional except to complete assessment visits.
3149818|NCT01550653|Experimental|Liraglutide|"See Intervention"
3149819|NCT01550653|Placebo Comparator|Placebo|"See Intervention"
3149820|NCT01550640|Experimental|remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
3149821|NCT01550640|No Intervention|standard|control standard group
3149822|NCT01550627|Active Comparator|extra-fluid|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day).
3149823|NCT01550627|Placebo Comparator|non extra fluid (control group)|The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
3149824|NCT01550614|Experimental|Arm A: Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer and standard of care angina medication
3150339|NCT01546896|No Intervention|healthy controls|
3149825|NCT01550614|No Intervention|Arm B|Standard of care angina medication
3149826|NCT01550601|Other|bariatric surgery 1|Longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery. In this arm, patients have a bariatric surgery with conservation of gastric antrum.
3149827|NCT01550601|Experimental|bariatric surgery 2|Longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery. In this arm, patients have a bariatric surgery with ablation of gastric antrum.
3149828|NCT01550588|Placebo Comparator|Medication|Anticoagulation, Antiplatelet agent
3149829|NCT01550588|Active Comparator|Device closure|Amplatzer PFO occluder device
3149830|NCT01550575||SCS-Eligible Patients|Patients who have previously been implanted with, or are eligible for implantation with a spinal cord stimulation system
3149831|NCT01550562|Placebo Comparator|Sham Stimulation|Sham subthreshold spinal cord stimulation therapy
3149832|NCT01550562|Active Comparator|Treatment 1|subthreshold spinal cord stimulation therapy
3149833|NCT01550562|Experimental|Treatment 2|subthreshold spinal cord stimulation therapy
3149834|NCT01550536|Experimental|Training|Sedentary women who exercised <2 hours per week and who had never engaged in a regular exercise program were enrolled in an exercise training intervention, following baseline measurements. See intervention below.
3149835|NCT01550536|No Intervention|Active|Postmenopausal women who exercised >5 hours per week and had been doing so for at least the past 10 years. These women were asked to maintain their normal activity habits for the duration of the study.
3149836|NCT01550523|Experimental|18-mer oligodeoxynucleotide|
3149837|NCT01550510|Experimental|Ascorbic Acid|Ascorbic Acid (50-100g, 3x weekly)
3149838|NCT01550497|Experimental|Home Exercise Group|Perform home exercises of unsupervised spinal stabilization exercises for 8 weeks
3149839|NCT01550497|Experimental|Weeky Physical Therapy Group|weekly physical therapy of supervised spinal stabilization exercises for 8 weeks
3149840|NCT01550471|Experimental|1 Treatment Sequence-A/O, Q/B, P/P|Period 2-Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD Period 4-QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID Period 6-Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
3149841|NCT01550471|Experimental|2 Treatment Sequence-A/O, P/P, Q/B|Period 2-Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD Period 4-Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID Period 6-QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID
3149842|NCT01550471|Experimental|3 Treatment Sequence-Q/B, A/O, P/P|Period 2-QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID Period 4-Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD Period 6-Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
3149843|NCT01550471|Experimental|4 Treatment Sequence-Q/B, P/P, A/O|Period 2-QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID Period 4-Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID Period 6-Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD
3149844|NCT01550471|Experimental|5 Treatment Sequence-P/P, A/O, Q/B|Period 2-Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID Period 4-Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD Period 6-QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID
3149845|NCT01550471|Experimental|6 Treatment Sequence-P/P, Q/B, A/O|Period 2-Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID Period 4-QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID Period 6-Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD
3149846|NCT01550458|Experimental|Mibefradil|
3149847|NCT01550458|Placebo Comparator|Placebo|
3149848|NCT01550445|No Intervention|steroid withdrawal|The clinical outcome after kidney transplantation, under the immunosuppression of steroid withdrawal starting at 3 months post-transplantation using tacrolimus, mycophenolate mofetil, and basilixumab should be analyzed.
3149849|NCT01550432|Experimental|High-Dose Glutathione|2,260 mg/day
3149850|NCT01550432|Experimental|Low-Dose Glutathione|1,130 mg/day
3149851|NCT01550432|Experimental|High-Dose N-Acetylcysteine|1,200 mg/day
3149852|NCT01550432|Experimental|Low-Dose N-Acetylcysteine|600 mg/day
3149853|NCT01550432|Placebo Comparator|Placebo|Volume of liquid placebo product comparable to glutathione and 1 or 2 placebo pills/day.
3149854|NCT01550419|Experimental|Atorvastatin(50 characters)|
3149855|NCT01550419|Placebo Comparator|Placebo(50 characters)|
3149856|NCT01550406|Active Comparator|Tachocomb|Tachocomb will be applicated on the cut surface of distal pancreatectomy
3149857|NCT01550406|Active Comparator|PGA|PGA will be applicated on the cut surface of distal pancreatectomy
3149858|NCT01550406|No Intervention|Control|No mesh will be applicated on the cut surface of distal pancreatectomy
3149859|NCT01550380|Experimental|All participants|
3149860|NCT01550367|Experimental|Hydroxychloroquine + IL-2|One course of treatment (84 days) will consist of high dose (600,000 IU/kg) bolus IL-2 administered intravenously every 8 hours on days 1-5 and 15-19 (maximum 14 doses/5 days of administration) and hydroxychloroquine (HCQ) orally started two weeks prior to IL-2 infusions and continued while able to take oral medication for up to 3 courses.
3149861|NCT01550354|Active Comparator|Propofol group|Intravenous administration of propofol 2 mg/kg before intubation
3149862|NCT01550354|Active Comparator|Alfentanil group|Intravenous administration of alfentanil 14 μg/kg before intubation
3149863|NCT01550354|Active Comparator|Rocuronium group|Intravenous administration of rocuronium 0.3 mg/kg before intubation
3149864|NCT01550341|Active Comparator|Buprenorphine|
3149865|NCT01550341|Placebo Comparator|Placebo|
3149866|NCT01550315|Active Comparator|High Sodium - POTS & Controls|Subjects will receive a high sodium diet for 4-5 days prior to study day. Procedures include: blood work, urine collection, Pulsitile Arterial Tonometry (PAT), PAT analysis, Calf Blood Flow in Reactive Hyperemia (CBF-RH), & evaluation of forearm-mediated dilation.
3149867|NCT01550315|Other|Low Sodium Diet (POTS & Controls)|"Participants will consume a very low sodium diet (10 mEq/day) for 4-5 days prior to study day.~Procedures include: blood work, urine collection, Pulsitile Arterial Tonometry (PAT), PAT analysis, Calf Blood Flow in Reactive Hyperemia (CBF-RH), & evaluation of forearm-mediated dilation."
3149968|NCT01549587|Experimental|Advanced Oral Hygiene plus counseling|toothpaste, toothbrush, mouth rinse and dental floss plus specialized education
3150526|NCT01545609|No Intervention|No intervention|No intervention
3149868|NCT01550302|No Intervention|Controls|Subjects enrolled in this group will only have a line drawn on the side of their neck for superficial cervical plexus block, but we will not perform the injection. The subjects will not be aware whether they received an intra-operative block or not. In addition, neither the Post-Anesthesia Care Unit nurse nor the providers involved in the post-operative care will be aware of subjects group assignment.
3149869|NCT01550302|Active Comparator|Superficial Cervical Plexus Block|Subjects enrolled in this group will have a line drawn and will receive a superficial cervical plexus block at the end of the surgery just prior to emergence from anesthesia.
3149870|NCT01550289|Experimental|Group 1: CYD dengue vaccine|Subjects will receive a dose of CYD dengue vaccine at 0, 6, and 12 months, respectively.
3149871|NCT01550289|Placebo Comparator|Group 2: Placebo|Subjects will receive a dose of placebo at 0, 6, and 12 months, respectively
3149872|NCT01550276|Experimental|Suboccipital soft tissue inhibition|The SI treatment aims to release the suboccipital muscle spasm that maintains the occiput-atlas-axis joint dysfunction.
3149873|NCT01550276|Experimental|Occiput-atlas-axis global manipulation|The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex
3149874|NCT01550276|Experimental|The combination of both treatments|
3149875|NCT01550276|Placebo Comparator|control group|
3149876|NCT01550250|Experimental|Immediate Night-time Compression|Women randomized to the immediate night-time compression system group will be measured for a custom-made night-time compression system. Women in this group will be instructed to wear their night-time compression system garment for a minimum of 5 nights per week over the 12-week intervention period. A gradual increase in nights worn and wear-time of the garment will occur over the first two weeks. From weeks 3 to 12 of the study, the participants will be asked to wear the garment for 8 hours per night, for a minimum of five nights per week.
3149877|NCT01550250|Active Comparator|Delayed Group: Standard Care|Women randomized to the delayed night-time compression system group will receive standard care for lymphedema maintenance. Each participant will be instructed to wear their day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week. Following the twelve-week delay period, women in this arm of the trial will be fitted for their respective night-time compression system garment and will follow the protocol outlined in the experimental arm of the trial.
3149878|NCT01550237|Experimental|radiotherapy daily reduced|radiotherapy, with daily CT position verification and reduced safety margins
3149879|NCT01550237|Active Comparator|radiotherapy weekly standard|radiotherapy, with weekly orthogonal position verification and standard safety margins
3149880|NCT01550224|Active Comparator|Participant Group 1 (methylated MGMT promoter)|Participants with methylated O6-methylguanine DNA methyltransferase (MGMT) promoter, ie, expected to have no expression of MGMT protein, will be assigned into Group 1, and will receive vorinostat 500 mg orally 3 times daily for 3 days, followed by conventional doses of temozolomide (200 mg/m2 for 7 days).
3149881|NCT01550224|Active Comparator|Participant Group 2 (non-methylated MGMT promoter)|Participants with non-methylated O6-methylguanine DNA methyltransferase (MGMT) promoter, ie, expected to have expression MGMT protein, will be assigned to into Group 2, and will initially receive daily, low doses (protracted dose schedule) of temozolomide (100 mg/m2) for 14 days in an attempt to inactivate MGMT activity. Following the protracted dose schedule, participants will receive vorinostat 500 mg orally 3 times daily for 3 days, followed by conventional doses of temozolomide (200 mg/m2 for 7 days).
3149882|NCT01550211||Students|Healthy students from Bar-Ilan University
3149883|NCT01550211||Schizophrenic patients' relatives|Healthy family members (parents or siblings) of the schizophrenic participants (chronic and naive)
3149884|NCT01550211||Naive schizophrenic patients|Naive patients with a diagnosis of schizophrenia, a history of only one psychotic episode and un-medicated
3149885|NCT01550211||Chronic schizophrenia patients|Chronic patients with a diagnosis of schizophrenia and a history of more than one psychotic episode
3149886|NCT01550198||Newborns|"Critically ill newborns admitted to level III neonatal intensive care unit of a university hospital, who will be monitored using transpulmonary ultrasound dilution (advanced hemodynamic monitoring)"
3149887|NCT01550185|Experimental|Treatment (eltrombopag olamine)|Patients receive eltrombopag olamine PO QD from day 1 up to day 62. Treatment continues for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
3149888|NCT01550172|Experimental|Sleep Behavioral Therapy A and NHMS|Participants in this arm receive behavioral therapy A for insomnia and the night home monitoring system.
3149889|NCT01550172|Active Comparator|Sleep Behavioral Therapy B and NHMS|Participants in this arm receive sleep behavioral therapy B and the night home monitoring system.
3149890|NCT01550146|Experimental|Dexamethasone, 0.1 mg/kg|The patients in the Dexamethasone group get iv 0.1 mg/kg dexamethasone preoperative.
3149891|NCT01550146|Placebo Comparator|Placebo|In the Placebo group the patients get 0.1 ml/kg normal saline.
3149892|NCT01550133|Experimental|Not Learned: Non-nutritive bev to Nutritive bev|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive solid and act as a control for the learned effects.
3149893|NCT01550133|Experimental|Not Learned: Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid and act as a control for the learned effects.
3149894|NCT01550133|Experimental|Not Learned: Nutritive beverage to Non-Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive beverage and act as a control for the learned effects.
3149895|NCT01550133|Experimental|Learned: Non-Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid to determine if cephalic phase response changes with learning.
3150001|NCT01549314||Subjects with CF taking ivacaftor|Subjects with CF ages 6 to 75 years old who will be or have started taking ivacaftor within the previous 6 months
3149896|NCT01550133|Experimental|Learned: Non-Nutritive beverage to Non-Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of non-nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive beverage to determine if cephalic phase response changes with learning.
3149897|NCT01550133|Experimental|Learned: Nutritive solid to Nutritive solid|15 participants will be randomly assigned to eat 250 grams of nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive solid to determine if cephalic phase response changes with learning.
3149898|NCT01550133|Experimental|Learned: Nutritive beverage to Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive beverage to determine if cephalic phase response changes with learning.
3149899|NCT01550133|Experimental|Not Learned: Non-Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid to determine if cephalic phase response changes with learning.
3149900|NCT01550107|Active Comparator|Allopurinol|Allopurinol 600mg tablets
3149901|NCT01550107|Placebo Comparator|Lactose tablets|Placebo Lactose tablets
3149902|NCT01550081|Active Comparator|Rate of perceived exertion|Exercise intensity controlled by Borg
3149903|NCT01550081|Active Comparator|Heart rate monitor|Exercise intensity controlled by heart rate monitors
3149904|NCT01550068||1|Schoolchildren aged 5-15 years from public and private schools in urban and rural area in Southeast Nepal
3149905|NCT01550055|Experimental|Cetuximab plus Irinotecan Synchronously|
3149906|NCT01550055|Active Comparator|Irinotecan and Cetuximab Subsequently|
3149907|NCT01550042||Intensive observation cohort|Patients > 18 years of age diagnosed with a recent episode of cryptogenic stroke with long term rhythm observation using an implantable loop recorder for detecting atrial fibrillation.
3149908|NCT01550029|Experimental|Counseling/Mood Management|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help you develop knowledge and skills that can help you quit. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting."
3149909|NCT01550029|Active Comparator|Counseling/Healthy Lifestyle|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways to establish a healthier lifestyle."
3149910|NCT01550016||Febrile Patients|Observation of patients with possible dengue fever in the early phase of disease
3149911|NCT01550003|Experimental|Certolizumab Pegol|Active treatment with Certolizumab Pegol; dose adjustment is based on weight.
3149912|NCT01549990||Sevoflurane group|donors who went through donor nephrectomy under general anesthesia with sevoflurane
3149913|NCT01549990||desflurane group|donors who went through donor nephrectomy under general anesthesia with desflurane
3149914|NCT01549977|Experimental|Febuxostat 80 mg|Febuxostat 80 mg, tablets, orally, once daily for up to 12 weeks.
3149915|NCT01549977|Placebo Comparator|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 12 weeks.
3149916|NCT01549964|Experimental|Fasiglifam (TAK-875) 25 mg|Fasiglifam 25 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
3149917|NCT01549964|Experimental|Fasiglifam (TAK-875) 50 mg|Fasiglifam 50 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
3149918|NCT01549964|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. TAK-875 placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
3149919|NCT01549964|Placebo Comparator|Placebo|Fasiglifam (TAK-875) placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
3149920|NCT01549951|Experimental|Orteronel+Prednisone|
3149921|NCT01549938|Active Comparator|Treatment|20,000 IU cholecalciferol capsule
3149922|NCT01549938|Placebo Comparator|Placebo|Microcellulose capsule
3149923|NCT01549925|Other|standard surgical resection|standard surgical resection using clamps and surgical ligatures
3149924|NCT01549925|Active Comparator|LIGASURE|Resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
3149925|NCT01549912||Rotator cuff tear|
3149926|NCT01549899|Active Comparator|In-person CBT of Insomnia|CBTi consisted of 6 weekly 60-minute sessions and included identical informational material. The treatments contained the following efficacious and commonly used modules of cognitive behavioral treatments for insomnia: Stimulus Control, Sleep Restriction, Sleep Hygiene, Relaxation Training, Cognitive Restructuring.
3150081|NCT01548651|Experimental|Saxagliptin|Saxagliptin 5 mg orally daily for 6 months
3149927|NCT01549899|Active Comparator|Internet CBT of Insomnia|The I-CBTi protocol was developed by the National Center for Telehealth and Technology with the first author (DJT) serving as the subject matter expert, and administered on the afterdeployment.org website. The information and instructions for I-CBTi were identical to in-person CBTi; however, their mode of delivery in I-CBTi is considerably different due to the constraints of its automated, online format. The lessons were presented as audio recordings accompanied by visual graphics and animations and several lessons, had interactive components such as games, quizzes, and prompts for participants to schedule healthy sleep habits.
3149928|NCT01549899|No Intervention|Minimal Contact|Those assigned to the MC control group will be asked to not work with another therapist or seek additional treatment for insomnia-related difficulties during the 6-week MC period. They will be called every other week to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MC participants will also be given contact information to use in case of worsening of symptoms or increasing distress. At the end of six weeks, they will complete the baseline assessments again, which will serve as the post-treatment assessment for the MC period. They will then be randomly assigned to either the CBTi or ICBTi groups.
3149929|NCT01549886|Experimental|Moxtezafin Gadolinium|Experimental Arm with Moxtezafin Gadolinium and Zevalin Regimen
3149930|NCT01549886|Active Comparator|Zevalin Regimen|Day 1 Rituximab 250 mg/m2 intravenous infusion. Day 8 Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL.)
3149931|NCT01549873|Active Comparator|Total intravenous anesthesia (TIVA)|
3149932|NCT01549873|Active Comparator|Inhaled anesthesia|
3149933|NCT01549860|No Intervention|Standard of Care|30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed. Minimum of one treatment per week and up to 3 times per week per investigator discretion for 4 weeks
3149934|NCT01549860|Experimental|SOC + Mist Therapy|30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed plus non-contract low frequency ultrasound 3 x per week for 4 weeks.
3149935|NCT01549847|Experimental|L-carnitine and piracetam|
3149936|NCT01549847|Placebo Comparator|Placebo|
3149937|NCT01549834|Experimental|ABT-126 Low Dose|low dose
3149938|NCT01549834|Experimental|ABT-126 High Dose|high dose
3149939|NCT01549834|Placebo Comparator|sugar pill|Placebo
3149940|NCT01549808|Experimental|group 2|"Participants:~100 patients will be included in the observation phase of this project, and another 100 in the intervention phase, according to the following criteria: Patients hospitalized in Unit 4141, at Rigshospitalet or ICU at Slagelse, who have been intubated for more than 48 hours, age ≥18, and after positive confirmation from relatives that the patient before the hospitalization was able to read and understand instructions.~The research is divided in 3 phases:~An 8 month observation phase.Current practice relatede to mobilize is measured.~An 2 month implementation phase and third: an 8 month intervention phase. The effect is measured as the difference in the functional level between the observation phase and the intervention phase related to primary and secondary outcome.~The effect of the intervention is described by using following test:~walking distance,ADL function, capability to sit and stand"
3149941|NCT01549782|Active Comparator|Fiber supplement|6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
3149942|NCT01549782|Placebo Comparator|Maltodextrine|6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
3149943|NCT01549769|Experimental|Bardoxolone Methyl 20 mg|
3149944|NCT01549756||Qualitative Research|Experiential/opinion based research
3149945|NCT01549743|Experimental|Celecoxib|
3149946|NCT01549743|Experimental|Rebamipide|
3149947|NCT01549743|Experimental|Celecoxib plus Rebamipide|
3149948|NCT01549730|Experimental|PET FAZA imaging|PET FAZA imaging of tumor hypoxia in patients with cervix cancer
3149949|NCT01549717|Experimental|Elective cardiac surgery patients|Patients undergoing elective cardiac surgery
3149950|NCT01549704|Other|Arm RP|first blockade: ropivacaine 7,5mg/ml 30 ml second blockade: placebo: saline 30 ml
3149951|NCT01549704|Other|Arm PR|first blockade: placebo: saline 30 ml second blockade: ropivacaine 7,5mg/ml 30 ml
3149952|NCT01549691|Experimental|zopiclone|zopiclone given before sleep, the day before surgery (placebo given at awakening the day of surgery)
3149953|NCT01549691|Experimental|alprazolam|given at awakening, the day of surgery (placebo given before sleep, the day before surgery)
3149954|NCT01549691|Placebo Comparator|placebo|Placebo given night before operation and the morning of operation
3149955|NCT01549678|Experimental|Intervention foot orthoses|Ethyl Vinil Acetate EVA insole shaped in the cast of the patient's foot.
3149956|NCT01549678|Placebo Comparator|Placebo insole|EVA flat insole.
3149957|NCT01549652|Experimental|Prevention of Physical Dependence|
3149958|NCT01549652|Experimental|Treatment of Opioid Withdrawal|
3149959|NCT01549639||General Anaesthesia|Patients undergoing general anaesthesia using Marsh model target controlled infusion in effect site mode.
3149960|NCT01549626|Active Comparator|defatted flaxseed flour|30 grams per day of defatted flaxseed flour
3149961|NCT01549626|Active Comparator|golden flaxseed flour|30 grams per day of golden flaxseed flour
3149962|NCT01549626|Active Comparator|whole brown flaxseed flour|30 grams per day of whole brown flaxseed flour
3149963|NCT01549613|Active Comparator|standard treatment with daptomycin|Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol
3149964|NCT01549613|Active Comparator|standard treatment of vancomycin|Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.
3149965|NCT01549600|Experimental|psyllium|5.1 g psyllium husk in at least 8 ounces of water
3149966|NCT01549600|Active Comparator|Microcrsytalline Cellulose|1.18 g Microcrystalline Cellulose in at least 8 ounces of water, taken twice a day
3149967|NCT01549587|Active Comparator|Regular Oral Hygiene|toothpaste, toothbrush and dental floss
3151075|NCT01541891|Active Comparator|Arm B. SYSTANE® Ophthalmic Solution|
3149969|NCT01549574|Experimental|crizotinib/crizotinib+esomeprazole crossover|Each subject in this study will receive two treatments (A and B) separated by at least 14 days of washout period. Treatment A is a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule. Treatment B consists of 40 mg daily esomeprazole dose from Day 1 to Day 5 and a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5.
3149970|NCT01549561|No Intervention|Services As Usual|Foster care services as usual
3149971|NCT01549561|Experimental|Parent and Youth Training|16 Weeks of Parent Training in group context with 5 to 10 relative and non-relative foster caregivers; Youth training with skills coaches
3149972|NCT01549561|Experimental|Parent Training|16 weeks of parent training with 5 to 10 relative and non-relative foster caregivers
3149973|NCT01549535|Active Comparator|Group A (study group)|Subjects in Group A (study group) will undergo a Standard view colonoscopy followed immediately by a PeerScope System™ extended view colonoscopy.
3149974|NCT01549535|Active Comparator|Group B (control group)|Group B (control group) will undergo a PeerScope System™ extended view colonoscopy followed immediately by a Standard view colonoscopy.
3149975|NCT01549509|Experimental|VRC-HIVADV014-00-VP Vaccine|All participants will receive one injection of the study vaccine (VRC-HIVADV014-00-VP) in their upper arm at study entry.
3149976|NCT01549496|Experimental|boceprevir|boceprevir 800 mg tid
3149977|NCT01549483||Asthma|asthmatic subjects
3149978|NCT01549483||Asymptomatic AHR|Asymptomatic subjects with airway hyperresponsiveness
3149979|NCT01549483||Control|Healthy controls, without airway hyperresponsiveness
3149980|NCT01549470|Experimental|Study vaccine|Participants in this arm will receive a total of three doses of study vaccine: the first dose at Day 0, the second dose at Day 28 (plus or minus 7 days), and the third dose at Day 56 (plus or minus 7 days). Each dose will consist of a 1-mL injection (dose strength 4 mg/mL) and will be administered by IM injection in the deltoid muscle.
3149981|NCT01549470|Placebo Comparator|Placebo vaccine|Participants in this arm will receive a total of three doses of a placebo vaccine: the first dose at Day 0, the second dose at Day 28 (plus or minus 7 days), and the third dose at Day 56 (plus or minus 7 days). Each dose will consist of a 1-mL injection and will be administered by IM injection in the deltoid muscle.
3149982|NCT01549457|No Intervention|Non-intervention|Participants will only receive standard of care
3149983|NCT01549457|Experimental|Cell phone intervention arm|Upon consent, participants will be randomly assigned to receive either 1) standard of care (9 months of INH or 4 months of RIF) and weekly SMS text messages via mobile phone or 2) standard of care (9 months of INH or months of RIF) without weekly SMS text messages via mobile phone.
3149984|NCT01549444||Group 1|Babies of mothers that have diabetes and/or hypertension and babies that are small for dates
3149985|NCT01549444||Group 2|Babies born to mothers without diabetes and/or hypertension and babies that are correct size for gestational age
3149986|NCT01549431|Experimental|Combo of Panobinostat and Carfilzomib|A cycle of therapy is 4 weeks (28 days in duration). Carfilzomib (with dexamethasone during cycle 1) will be administered intravenously infusion on days 1, 2 and 8, 9 and 15, 16 of every 28 day cycle. Panobinostat is administered orally three times per week.
3149987|NCT01549418|Active Comparator|Aspirin|Patients with at least one large polyps taking aspirin in dose 75 mg daily for 21 days (7 days before and 14 days after polypectomy)
3149988|NCT01549418|Placebo Comparator|Placebo|Patients with at least one large polyps taking placebo daily for 21 days (7 days before and 14 days after polypectomy)
3149989|NCT01549405|No Intervention|Control group|Control group: Group that without intercostal nerve block
3149990|NCT01549405|Experimental|nerve block|Group that performing intercostal block
3149991|NCT01549392|Active Comparator|DECT/MR Spectroscopy +Avastin|-15 Glioma Patients with progression will undergo DECT and MRS before Avastin (10 mg/kg iv q2 weeks until progression) and 3 months later
3149992|NCT01549392|Active Comparator|DECT/MR Spectroscopy no Avastin|15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1
3149993|NCT01549379|Active Comparator|Surgical patients|This group will consist of 15 patients with locally advanced HNSCC of the oral cavity, larynx or hypopharynx presenting with adenopathy ≥ 1 cm where the recommended treatment is surgical resection of the primary malignancy with bilateral neck dissection. These patients will receive a DCE-CT scan of the head and neck prior to surgery.
3149994|NCT01549379|Active Comparator|Chemoradiation Patients|This group will consist of 15 patients with locally advanced HNSCC with lymph nodes ≥3 cm in which chemoradiotherapy is the primary treatment as per standard of care. This group will be composed of patients with a primary malignancy originating in the nasopharynx, oropharynx, hypopharynx or larynx. Pre-treatment DCE-CT of neck will be obtained. The standard therapy, radiation and chemotherapy, will be administered and the patients will have standard follow up. A post-treatment DCE-CT of neck will be obtained 8-10 weeks after treatment along with standard CT neck.
3149995|NCT01549366|Experimental|Aspen Spinous Process Fixation Device|Subjects randomized to the Aspen study arm will have the Aspen device implanted as supplemental posterior fixation only and according to the manufacturer's recommendations.
3149996|NCT01549366|Active Comparator|Pedicle Screws|Subjects randomized to the pedicle screw group will have polyaxial top loading pedicle screws implanted according to the standard procedures and practices at that institution. The procedure may be performed according to surgeon preference, including a traditional open, minimally invasive or percutaneous approach. Only pedicle screws cleared by FDA for this indication will be used in this study.
3149997|NCT01549353|Experimental|chewing gum|
3149998|NCT01549340||Participants with Allergic Rhinitis (AR)|Patients in a private allergy practice who were diagnosed with AR, with or without asthma, and advised to consider AIT between January 2005 and June 2011 and whose medical records were retrospectively reviewed.
3149999|NCT01549327|Active Comparator|Routine Care|Participants who are randomized to the active comparator arm will receive routine care, which is the care routinely provided to the participant's patient population at the study centre.
3150000|NCT01549327|Experimental|Routine Care plus OIN|OIN (Oncology Interactive Navigator) is the intervention. Participants who are randomized to routine care plus OIN will receive routine care and have unlimited access to the website for the study duration.
3150929|NCT01542944|Experimental|TevaGastrim|treatment with TevaGastrim for allogeneic stem cell collection
3150002|NCT01549314||Subjects with CF not taking ivacaftor|Subjects with CF ages 6 to 75 years old who will not be taking ivacaftor, matched for age, race, and gender with cohort 1
3150003|NCT01549314||Healthy subjects|Healthy subjects with no medical conditions known to affect bone between the ages of 6 to 75 years old, matched for age, race, and gender with cohort 2.
3150004|NCT01549301|Experimental|Group D 10 i.v.|Two periods, crossover, single dose, i.v., 10 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
3150005|NCT01549301|Experimental|Group C 5 i.v.|Two periods, crossover, single dose, i.v., 5 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
3150006|NCT01549301|Experimental|Group B 10 s.c.|Two periods, crossover, single dose, s.c., 10 mcg/kg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
3150007|NCT01549301|Experimental|Group A 5 s.c.|Two periods, crossover, single dose, s.c., 5 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
3150008|NCT01549288|Experimental|modified Atkins diet|
3150009|NCT01549288|Other|control arm|the control arm continues the anti-epileptic drugs without any added dietetic input
3150010|NCT01549262|Active Comparator|Standard Incubator|
3150011|NCT01549262|Experimental|ESD Time-lapse Monitoring system|
3150012|NCT01549249|No Intervention|vitrectomy|
3150013|NCT01549223|Active Comparator|Standard Care Group|"Standard Care Group (reflects current clinical regimen at BWH) will receive a 500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request. The obstetrician and anesthesiologist will be asked to consider this infusion oxytocin. If inadequate uterine tone exists in which the obstetrician desires alternative uterotonic agents, these will be provided on their request (e.g. methylergonovine maleate (methergine) 0.2 mg IM (intramuscular) or carboprost tromethamine (hemabate) 0.25 mg IM. The time of the requests will be recorded.~If uterine tone remains inadequate at 15 min, misoprostol 600 mcg will be given buccally."
3150014|NCT01549223|Active Comparator|Protocol Group|"Protocol Group will receive 3 mL syringes marked study solution-oxytocin which contain 3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).~If inadequate uterine tone is noted at 9 min, the 1 mL syringe marked marked study solution-9 min, containing methylergonovine maleate (methergine) 0.2mg, will be given IM.~If inadequate uterine tone is noted at 12 min, the 1 mL syringe marked marked study solution-12 min, containing carboprost tromethamine (hemabate) 0.25 mg, will be given IM.~If uterine tone remains inadequate at 15 min, misoprostol 600 mcg will be given buccally."
3150015|NCT01549197||ICU staff and relatives|
3150016|NCT01549171||Iloprost|This is the study group with 1 uM Iloprost.
3150017|NCT01549171||Control|This is the control group with vehicle (normal saline) only.
3150018|NCT01549158|Experimental|Torasemide PR 10 mg|
3150019|NCT01549158|Active Comparator|Furosemide-IR 40 mg|
3150020|NCT01549158|Active Comparator|Torasemide-IR 10 mg|
3150021|NCT01549145|Experimental|NIMBUS multifunctional stimulator|A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
3150022|NCT01549119|Experimental|Low dose VAC-3S|
3150023|NCT01549119|Experimental|Medium dose VAC-3S|
3150024|NCT01549119|Experimental|High dose VAC-3S|
3150025|NCT01549119|Placebo Comparator|Placebo|
3150026|NCT01549119|Experimental|Double-dose VAC-3S|
3150027|NCT01549106|Experimental|IPI-145|
3150028|NCT01549106|Placebo Comparator|Placebo|
3150029|NCT01549093|Experimental|Endostar -Continued Pumping into+GC|Endostar that is Continued Pumping into vein Combining With Gemcitabine -Carboplatin
3150030|NCT01549093|Active Comparator|Endostar -injecting into +GC|Endostar that is injecting into vein with Gemcitabine -Carboplatin
3150031|NCT01549093|Active Comparator|GC|Gemcitabine -Carboplatin
3150032|NCT01549080||research|biological research on the effects of yisuishengxuegranule
3150033|NCT01549080||clinical research|clinical research on thalassemia
3150034|NCT01549054|Experimental|10-mg dose of E5501 2G tablet|
3150035|NCT01549054|Experimental|10-mg dose of E5501 cyclodextrin oral solution|
3150036|NCT01549054|Experimental|10-mg dose of E5501-P21% powder|
3150037|NCT01549054|Experimental|10-mg dose of E5501 lipid-based oral|
3150038|NCT01549041|Experimental|asenapine 10 mg daily in the evening|Patients will receive their entire daily dose of asenapine as a single dose in the evening
3150039|NCT01549041|Active Comparator|asenapine 5 mg twice daily|Patients will receive asenapine 5 mg daily in the morning and 5 mg daily in the evening
3150040|NCT01549028|Experimental|Mobile-based PR program.|Home based mobile PR program for 3 months.
3150041|NCT01549002|Experimental|Intranasal Fentanyl|"Patients in this arm will receive intranasal Fentanyl (50 micrograms/mL) as their pre-I&D analgesic. The one time total dose to be used is 2 micrograms / kilogram, to a maximum of 100 micrograms. The medication will be delivered intranasally via an atomizer in 4 equally divided aliquots (2 per nare).~The abscess I&D will be followed according to protocol using topical and local anesthetic."
3150042|NCT01549002|Active Comparator|Intravenous Morphine|"Patients in this arm will receive intravenous morphine as their pre-I&D analgesic. The one time total dose to be used is 0.1 milligrams / kilogram, to a maximum of 8 milligrams. The medication will be delivered via slow IV push.~The abscess I&D will be followed according to protocol using topical and local anesthetic."
3150043|NCT01548989||The study population|Patients suffering from pelvic organ prolapse and/or urinary incontinence and/or fecal incontinence. See inclusion/exclusion criteria.
3150044|NCT01548976||The study population|Patients suffering from pelvic organ prolapse and/or urinary incontinence and/or fecal incontinence. See inclusion/exclusion criteria.
3150082|NCT01548638|Experimental|Galantamine ER|The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease.
3150083|NCT01548625||Healthy middle-aged human volunteers|
3150084|NCT01548612|Experimental|Sodium nitroprusside|
3150045|NCT01548963|Experimental|Perioperative glycemia control|Group of perioperative intensive glycemia control: blood glucose level will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) according to actual glycemia to keep it within normoglycemia limits (4.4 - 6.1 mmol/l) since patient's admission to operating room. Samplings will be taken in 1 to 4 hours intervals in accordance with glycemia stability and MPC algorithm suggestions.
3150046|NCT01548963|Active Comparator|Postoperative glycemia control|Group of standard glycemia control: blood glucose level will be maintained by continuous insulin infusion (see above) within normoglycemia limits (4.4 - 6.1 mmol/l) after patient's admission to ICU after cardiac surgery. During surgery hyperglycemia will not be interfered before it will reach level of 10 mmol/l.
3150047|NCT01548950|Other|Single-arm study|Preoperatively, sildenafil until development of pulmonary congestion (1-4 weeks). On treatment pulmonary congestion (dyspnea and need for increasing diuretics) occurs when there is a substantial decrease in pulmonary vascular resistance, which may be confirmed noninvasively by Doppler-echocardiography. At that moment, patient will be assigned to surgery. If pulmonary congestion is not observed, bosentan will be added on top of sildenafil, and the patient will be kept on treatment for 10-12 months. In this case, a new cardiac catheterization will be performed before surgery. In both cases (short-term and medium-term treatment) patients will be kept on treatment for six months following surgery, and then re-catheterized.
3150048|NCT01548937|Experimental|I-123 ADAM|I-123 ADAM Serotonin transporter imaging
3150049|NCT01548924|Experimental|Priming Phase|The study treatment begins with the period of seven days of priming Phase, which is administered in monoterapi dovitinib
3150050|NCT01548924|Experimental|Treatment Phase|The phase of treatment with two drugs (paclitaxel dovitinib more fixed dose of 80 mg/m2 per week) will begin after a washout period of seven days after the priming phase.
3150051|NCT01548911|Experimental|Treatment (monoclonal antibody therapy)|Patients receive gemtuzumab ozogamicin IV over 2 hours on days 1 and 15. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
3150052|NCT01548885|Experimental|Study Staff Test BGMSs|All testing and lancings were performed by the study staff; subjects did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using five Blood Glucose Monitoring Systems(BGMS): FreeStyle Freedom Lite® BGMS; ACCU-CHEK® Aviva BGMS; TRUEtrack® BGMS; OneTouch® Ultra®2 BGMS; CONTOUR® NEXT EZ BGMS.
3150053|NCT01548872|Active Comparator|crystalloid cardioplegia solution|After aortic cross clamp 30ml/kg will be administered
3150054|NCT01548872|Active Comparator|HTK solution|After aortic cross clamp 50ml/kg will be administered
3150055|NCT01548859|Active Comparator|Midazolam|Used for maintenance anaesthesia (0.2 mg/kg/saat continuous infusion)
3150056|NCT01548859|Active Comparator|Sevoflurane|Used for the maintenance for anaesthesia (% 0.5-8 end tidal concentration)
3150057|NCT01548833|Experimental|Dailies Total 1|Delefilcon A, followed by narafilcon A and filcon II 3 in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
3150058|NCT01548833|Active Comparator|TruEye|Narafilcon A, followed by delefilcon A and filcon II 3 in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
3150059|NCT01548833|Active Comparator|Clariti|Filcon II 3, followed by narafilcon A and delefilcon A in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
3150060|NCT01548820||Chronic HBV Egyptian patients|chronic HBV patients receiving Lamivudine therapy in hepatology clinic in the National Hepatology & Tropical Medicine Research Institute in Egypt.
3150061|NCT01548794|Active Comparator|Bupivacaine(Group B)|spinal anesthesia
3150062|NCT01548794|Experimental|Bupivacaine+Lidocaine (Group BL)|spinal anesthesia
3150063|NCT01548794|Active Comparator|Local Infitration Anesthesia(Group LI)|local infiltration anesthesia
3150064|NCT01548781|Experimental|Viscous Resistance & Abduction Loading|The intervention for the experimental group entails practicing reaching utilizing the robotic device, ACT3D, with the experimental element of horizontal viscosity in combination with abduction loading.
3150065|NCT01548781|Active Comparator|Abduction Loading|The intervention for the active comparison group entails practicing reaching utilizing the robotic device, ACT3D, with only abduction loading.
3150066|NCT01548768|Experimental|Patients - DMARDs + TNF Inhibitors|Patients will receive a TNF inhibitor in addition to their current treatment in an open label protocol for increased disease activity and in the context of standard of care.
3150067|NCT01548768|Active Comparator|Patients - DMARDs only|Patients will receive their current treatment in an open label protocol in the context of standard of care.
3150068|NCT01548768|No Intervention|Healthy Volunteers|Subjects without RA who will function as controls.
3150069|NCT01548742|Experimental|Arm 1: Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR)
3150070|NCT01548742|Active Comparator|Arm 2: Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT)
3150071|NCT01548729|Experimental|Patient with cystic fibrosis|Patients with end-stage cystic fibrosis
3150072|NCT01548703|Experimental|BCI-838 Dosing Arm 1|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
3150073|NCT01548703|Experimental|BCI-838 Dosing Arm 2|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
3150074|NCT01548703|Experimental|BCI-838 Dosing Arm 3|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
3150075|NCT01548690|Experimental|Ornithine Phenylacetate|Ornithine Phenylacetate is administered intravenously, through a peripheral venous catheter. Each infusion should will be administered over a period of 120 hours.
3150076|NCT01548677|No Intervention|observation|18 weeks
3150077|NCT01548677|Experimental|Herceptin (trastuzumab)|18 weeks
3150078|NCT01548664|Experimental|Nintendo Wii FitTM|Fifteen minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
3150079|NCT01548664|Active Comparator|Lower extremity exercise|Fifteen minutes of lower extremity exercises that addressed balance, posture, weight shifting and strengthening were provided bilaterally, following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area
3150080|NCT01548651|Placebo Comparator|Placebo|
3150085|NCT01548612|Placebo Comparator|Placebo|Glucose solution 5%
3150086|NCT01548599|Experimental|Multi-sectoral agricultural intervention|Participants enrolled at one study location will receive the Multi-sectoral agricultural intervention as specified below under the intervention.
3150087|NCT01548599|No Intervention|Control|Participants enrolled at one study location will receive the standard of care. At the end of the study, participants in this arm will be eligible for the finance training and those who pay the loan down payment will be eligible for a small loan to purchase a human powered water pump, hosing, fertilizer, and certified seeds.
3150088|NCT01548586|Active Comparator|Anodal tDCS|
3150089|NCT01548586|Active Comparator|Cathodal tDCS|
3150090|NCT01548586|Placebo Comparator|Placebo type tDCS|
3150091|NCT01548573|Experimental|Tandem autologous stem cell transplant|"Induction: DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant 1: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide) Transplant 2: 8 weeks to 6 months after the first transplant, participants will have the second transplant Maintenance: Year 1- VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
3150092|NCT01548560|Experimental|Dapivirine Vaginal Gel|Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
3150093|NCT01548560|Placebo Comparator|Placebo Gel|Dosage form: vaginal gel Dosage: N/A Frequency: 7 daily doses
3150094|NCT01548560|Experimental|Dapvirine Vaginal Film|Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
3150095|NCT01548560|Placebo Comparator|Vaginal Film|Dosage form: vaginal film Dosage: N/A Frequency: 7 daily doses
3150096|NCT01548547|Experimental|LP mastery learning group|
3150097|NCT01548547|Active Comparator|IV mastery learning group|
3150098|NCT01548534|Placebo Comparator|DHA-free arm|Dietary supplementation with vegetable oil.
3150099|NCT01548534|Experimental|DHA arm|Dietary supplementation with fish oil.
3150100|NCT01548521|Experimental|Oxytocin|
3150101|NCT01548508|Experimental|Functionnal ElectroStimulation (FES)|
3150102|NCT01548508|Sham Comparator|SHAM|
3150103|NCT01548495||Responded to rHuEPO treatment|response to EPO was defined as a rise in untransfused hemoglobin concentration of at least 2 g/dl or a 50% decrease in transfusion requirements over the treatment period
3150104|NCT01548495||IR to rHuEPO treatment|No rise in hemoglobine consentration at normal and high dose rHuEPO treatment
3150105|NCT01548495||Responded to high level rHuEPO|Responded to more than 80,000UI of rHuEPO treatment
3150106|NCT01548495||No rHuEPO treatment|
3150107|NCT01548482|Experimental|Treatment (trebananib, temsirolimus)|Patients receive trebananib IV over 60 minutes and temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3150108|NCT01548469|Active Comparator|Perio Total Care toothpaste|A Group which use Perio Total Care toothpaste during participation.
3150109|NCT01548469|Experimental|Bio Mineral toothpaste|A Group which use Bio Mineral toothpaste during participation.
3150110|NCT01548456||Intramedullary nailing|Subjects with a femur fracture who undergo operative fixation with an intramedullary nail
3150111|NCT01548456||Open Reduction Internal Fixation|Subjects with a femur fracture who undergo open reduction internal fixation with a dynamic compression plate
3150112|NCT01548443|Experimental|Medifoam H|"A group which treated with medifoam H on the wound."
3150113|NCT01548443|Active Comparator|Duoderm THIN|"A group which treated with  Duoderm THIN  on the wound"
3150114|NCT01548430|Experimental|TTP4000 1.0 mg/kg|Administered subcutaneously
3150115|NCT01548430|Experimental|TTP4000 3.0 mg/kg|Administered subcutaneously
3150116|NCT01548430|Placebo Comparator|Placebo|Administered subcutaneously
3150117|NCT01548417|Active Comparator|Korlym (mifepristone)|600 mg daily taken orally for one week
3150118|NCT01548417|Placebo Comparator|Sugar Pill|placebo pill daily taken orally for one week
3150119|NCT01548404|Placebo Comparator|Placebo|Placebo (for Dupilumab) once weekly for 12 weeks by subcutaneous (SC) injection.
3150120|NCT01548404|Experimental|Dupilumab 300 mg|Dupilumab 300 mg once weekly for 12 weeks by SC injection.
3150121|NCT01548391|Experimental|HX-1171 20 mg (20mg 1T)|
3150122|NCT01548391|Experimental|HX-1171 40 mg (20mg 2T)|
3150123|NCT01548391|Experimental|HX-1171 80 mg (20mg 4T)|
3150124|NCT01548391|Experimental|HX-1171 160 mg (20mg 8T)|
3150125|NCT01548391|Experimental|HX-1171 300 mg (200mg 1T, 20mg 5T)|
3150126|NCT01548391|Experimental|HX-1171 600 mg (200mg 3T)|
3150127|NCT01548391|Experimental|HX-1171 1200 mg (500mg 2T, 200mg 1T)|
3150128|NCT01548391|Experimental|HX-1171 1500 mg (500mg 3T)|
3150129|NCT01548391|Experimental|HX-1171 2000 mg (500mg 4T)|
3150130|NCT01548378|Experimental|High Dose|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
3150131|NCT01548378|Experimental|Middle Dose|Patients in this treatment group will receive 6mg NL003 respective in D0、14、28
3150132|NCT01548378|Experimental|Low Dose|Patients in this treatment group will receive 4mg NL003 in D0、14、28
3150133|NCT01548378|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、18
3150134|NCT01548365|No Intervention|Control Group|routine care for the selection, placement and maintenance of venous access devices (VAD).
3150135|NCT01548365|Experimental|Infusion Therapy Nursing Expert|Patients in this group will receive the infusion therapy nursing expert (ITNE) service.
3150136|NCT01548339|Active Comparator|Delayed|Laparoscopic cholecystectomy performed secondarily after an initial conservative treatment
3150137|NCT01548339|Experimental|Early|Laparoscopic cholecystectomy performed directly after the initial diagnosis
3150138|NCT01548326|Active Comparator|Atorvastatin|will receive one 40 mg Atorvastatin tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
3151259|NCT01540604|Experimental|CRD007 10 mg tablet|
3150139|NCT01548326|Placebo Comparator|Placebo|will receive one Placebo tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
3150140|NCT01548313||Pregnant women from Ljubljana region|Women at 3rd trimester of pregnancy living in the Ljubljana region.
3150141|NCT01548313||Pregnant women from Izola region|Women at 3rd trimester of pregnancy living in the Izola region.
3150142|NCT01548313||Pregnant women from Murska Sobota region|Women at 3rd trimester of pregnancy living in the Murska Sobota region.
3150143|NCT01548300||Enrolled participants|Subjects will be recruited from clinics affiliated with the Fuwai Hospital, PUMC. The participants will be nonsmokers with cardiometabolic disease, that are not taking anti-hypertensive, glucose-lowering, or lipid-lowering medications or drugs that alter baseline insulin sensitivity, blood pressure, or endothelial function, daily use of NSAIDS is not allowed.
3150144|NCT01548287|Experimental|AZD5213 doseA|AZD5213 doseA daily
3150145|NCT01548287|Experimental|AZD5213 doseB|AZD 5213 doseB daily
3150146|NCT01548287|Experimental|AZD5213 doseC|AZD5213 doseC daily
3150147|NCT01548287|Placebo Comparator|Placebo|Placebo daily
3150148|NCT01548261||Health people.|
3150149|NCT01548248||Levemir® users|
3150150|NCT01548235||BIAsp 30 users|
3150151|NCT01548209|Experimental|Group D|A single dose dexmedetomidine 0.5 mcg/kg iv. 30 min before end of the surgery
3150152|NCT01548209|Placebo Comparator|Group P|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
3150153|NCT01548196|Other|standard percutaneous nephrostomy|Standard PCN
3150154|NCT01548196|Other|double-J ureteral stent,|double-J ureteral stent,
3150155|NCT01548196|Other|open-ended ureteral catheter|open-ended ureteral catheter
3150156|NCT01548196|No Intervention|no nephrostomy or ureteral stent/catheter.|no nephrostomy or ureteral stent/catheter.
3150157|NCT01548183|Experimental|Lifestyle counseling|Weekly SMS assessing risky sexual encounters and providing feedback including concern, goal-setting and tools to reduce risk
3150158|NCT01548183|No Intervention|Usual care|Usual care includes ED provider counseling as per normal clinical care
3150159|NCT01548170|Active Comparator|Sunitinib 50mg|Sunitinib 50 mg administered as a single dose.
3150160|NCT01548170|Experimental|Sunitinib 37.5mg + Ketoconazol 200mg|"The drugs will be administered as follows:~Sunitinib 37.5mg oral single dose.~Ketoconazole 200 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
3150161|NCT01548170|Experimental|Sunitinib 37.5 mg + Ketoconazol 400 mg|"The drugs will be administered as follows:~Sunitinib 37.5mg oral single dose.~Ketoconazole 400 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
3150162|NCT01548170|Experimental|Sunitinib 25mg + Ketoconazol 200mg|"The drugs will be administered as follows:~Sunitinib 25mg oral single dose.~Ketoconazole 200 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
3150163|NCT01548170|Experimental|Sunitinib 25mg + Ketoconazol 400mg|"The drugs will be administered as follows:~Sunitinib 25mg oral single dose.~Ketoconazole 400 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
3150164|NCT01548157|Experimental|HCP1007|HCP1007
3150165|NCT01548157|Active Comparator|omarco and crestor|Rosuvastatin plus Omega-3
3150166|NCT01548144|Experimental|Crizotinib + Pazopanib - Group A|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
3150167|NCT01548144|Experimental|Crizotinib + Pemetrexed - Group B|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting dose for Pemetrexed: 200 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
3150168|NCT01548144|Experimental|Pazopanib + Pemetrexed - Group C|"Starting dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Expansion group starting dose: MTD from Phase 1.~Starting dose for Pemetrexed: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion group starting dose: MTD from Phase 1."
3150169|NCT01548144|Experimental|Crizotinib + Pazopanib + Pemetrexed - Group D|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Dose Expansion Group: MTD from Phase 1.~Starting dose for Pemetrexed: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
3150170|NCT01548131|Experimental|Psychoeducative group therapy|Psychoeducative group therapy
3150171|NCT01548131|No Intervention|Control|Women screened for fear of childbirth were taken cared by primary health care nurses and if needed referred to specialized care in hospital
3150172|NCT01548118|Experimental|Adult Group 1, HPV vaccine 0.5ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines.
3150173|NCT01548118|Placebo Comparator|Adult Group 1, Placebo 0.5ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate.
3150174|NCT01548118|Experimental|Adult Group 2, HPV vaccine 1.0ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines.
3150175|NCT01548118|Placebo Comparator|Adult Group 2, Placebo 1.0ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate.
3150176|NCT01548118|Experimental|Children Group 1, HPV vaccine 0.5ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines.
3150177|NCT01548118|Placebo Comparator|Children Group 1, Placebo 0.5ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate.
3150178|NCT01548118|Experimental|Children Group 2, HPV vaccine 1.0ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines.
3150179|NCT01548118|Placebo Comparator|Children Group 2, Placebo 1.0ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate.
3150216|NCT01547702|Experimental|Treatment|This group will have access to the Teacher Help for ADHD intervention program during the randomized controlled trial.
3150930|NCT01542931|No Intervention|Surgery and radiotherapy|Surgery and post-operative radiotherapy.
3150180|NCT01548105||Prolapse and Smoker|Patients in this arm have been determined to have more than stage 2 pelvic organ prolapse and have been smoking more than one pack per day Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
3150181|NCT01548105||Prolapse and non smoker|Patients in this arm have been determined to have more than stage 2 pelvic organ prolapse and non smoker for more than 7 years Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
3150182|NCT01548105||No prolapse and smoker|Patients in this arm, have been determined not to have prolapse and smokes more than 1 pack per day Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
3150183|NCT01548105||No prolapse and non smoker|Patients in this arm have been determined not to have prolapse and non smoker for more than 7 years Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
3150184|NCT01548092|Experimental|Autologous SVF|Intralesional application
3150185|NCT01548079|No Intervention|Control|Untreated controls
3150186|NCT01548079|Active Comparator|Ursodeoxycholic acid|Oral ursodeoxycholic acid 20 mg/kg/day in three weeks
3150187|NCT01548066|Experimental|Sodium valproate|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
3150188|NCT01548066|Placebo Comparator|Control|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
3150189|NCT01548040|Experimental|quadriceps NMES using Kneehab XP|All subjects in the treatment group will receive quadriceps Neuro Muscular Electrical Stimulation (NMES) using Kneehab XP on the affected leg, 20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.group will also complete the standard TKA post-surgery rehabilitation program used at the Hawkins Foundation
3150190|NCT01548040|Sham Comparator|quadriceps TENS|The sham device will look identical to the Kneehab XP device. All subjects in the control group will receive quadriceps Transcutaneous Electrical Nerve Stimulation (TENS) at a minimal sensory input using Kneehab XP on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.group will also complete the standard TKA post-surgery rehabilitation program used at the Hawkins Foundation
3150191|NCT01548027|Experimental|No intervention|no injection of local anesthetic agents
3150192|NCT01548027|Experimental|Local infiltration group|patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
3150193|NCT01548027|Experimental|TAP block group|Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months
3150194|NCT01548001|Experimental|Iguratimod monotherapy|
3150195|NCT01548001|Experimental|Iguratimod and MTX combination|
3150196|NCT01548001|Active Comparator|MTX monotherapy|
3150197|NCT01547988|Experimental|Balance Training Intervention|The Balance Training Intervention group received 24 training sessions over three months that included perturbation as well as dual-task exercises.
3150198|NCT01547988|No Intervention|Reference Group|
3150199|NCT01547962|Experimental|Split-mouth design: Treatment|
3150200|NCT01547962|Active Comparator|Split-mouth design: Control|
3150201|NCT01547949|Experimental|tart cherry juice|
3150202|NCT01547949|Placebo Comparator|cherry flavored fruit drink|
3150203|NCT01547923|Experimental|A : pre-therapeutic screening for DPD deficiency|Prior to treatment by fluoropyrimidines,a DPD deficiency is identified by a joint phenotypic-pharmacogenetic approach.
3150204|NCT01547923|Other|B : no pretherapeutic research of DPD deficiency|For patients included in this arm, a blood sample will be taken prior to treatment by fluoropyrimidines but not analysed. If grade 3 or 4 toxicity levels are encountered during treatment, DPD deficiency will be detected.
3150205|NCT01547910|Experimental|Fish oil|Children will receive fish oil capsules according to age as described in the protocol
3150206|NCT01547910|Placebo Comparator|Placebo|Sunflower oil in the same capsules (the same shape and colour) given in the same regime as 'fish oil' capsules
3150207|NCT01547897|Active Comparator|NOX-E36|
3150208|NCT01547897|Placebo Comparator|Placebo|
3150209|NCT01547806|Experimental|Hematopoietic Progenitor Cells (HPC)|Subjects will undergo mobilization and collection of HPC, Apheresis for subsequent use in various clinical protocols.
3150210|NCT01547741|Active Comparator|Arm 1: Anthracycline-based chemotherapy|"4 anthracycline-based chemotherapy regimens (Regimens A, B, C, or D).~Regimen A (TAC): 75 mg/m2 docetaxel (T) + 50 mg/m2 doxorubicin (A) + 500 mg/m2 cyclophosphamide (C) IV every 3 weeks for 6 cycles.~Regimen B (AC then WP): 60 mg/m2 doxorubicin (A) + 600 mg/m2 cyclophosphamide (C) every 3 weeks for 4 cycles followed by weekly paclitaxel (WP) 80 mg/m2 IV every week for 12 doses.~Regimen C (DD AC then WP): 60 mg/m2 doxorubicin + 600 mg/m2 cyclophosphamide every 2 weeks for 4 cycles followed by weekly paclitaxel 80 mg/m2 IV every week for 12 doses.~Regimen D (DD AC then DD P): 60 mg/m2 doxorubicin + 600 mg/m2 cyclophosphamide every 2 weeks for 4 cycles followed by paclitaxel (P) 175 mg/m2 IV every 2 weeks for 4 cycles."
3150211|NCT01547741|Active Comparator|Arm 2: docetaxel + cyclophosphamide|TC: 75 mg/m2 docetaxel and 600 mg/m2 cyclophosphamide IV every 3 weeks for 6 cycles
3150212|NCT01547728|Experimental|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
3150213|NCT01547715|Experimental|MenACWY - 2 - 10 Years old|Subjects between 2 and 10 years of age who received one injection of Meningococcal ACWY conjugate vaccine -CRM vaccine on day 1.
3150214|NCT01547715|Experimental|MenACWY - 11 - 18 Years old|Subjects between 11 and 18 years of age who received one injection of Meningococcal ACWY conjugate vaccine-CRM vaccine on day 1.
3150215|NCT01547715|Experimental|MenACWY - 19 - 75 Years old|Subjects between 11 and 18 years of age who received one injection of Meningococcal ACWY conjugate vaccine-CRM vaccine on day 1.
3150255|NCT01547481||Progressive Supranuclear Palsy Cohort|Individuals diagnosed with Progressive Supranuclear Palsy (PSP).
3150217|NCT01547702|No Intervention|Waitlist Control|This group will not receive the intervention until all data collection is complete for their study cohort.
3150218|NCT01547689|Experimental|Human Umbilical Cord Derived MSC|
3150219|NCT01547676|Experimental|Arm A (unclamped partial nephrectomy)|Patients undergo unclamped partial nephrectomy. Some patients may undergo unclamped partial nephrectomy with controlled hypotension.
3150220|NCT01547676|Active Comparator|Arm B (clamped partial nephrectomy)|Patients undergo clamped partial nephrectomy.
3150221|NCT01547650||SIADH, CSWS, CDI, PP, DIH, HF|CSWS (cerebral salt wasting syndrome), SIADH (syndrome of inappropriate ADH) , CDI (central diabetes insipidus), PP (primary polydipsia), DIH (drug-induced hyponatremia), HF (heart failure with hyponatremia)
3150222|NCT01547637|Experimental|Ultrasound Guided|Ultrasound guided obturator nerve block will be performed after induction of general anesthesia. The anterior and posterior divisions of the obturator nerve will be identified with ultrasound. A stimulating needle will be inserted under direct ultrasound visualization. The anterior division will be blocked first. When adductor twitches are present at less than or equal to 0.5 mA, 10 ml of 2% lidocaine will be injected. Next, the needle will be re-directed under direct ultrasound visualization towards the posterior branch of the obturator nerve. After twitches < 0.5 mA are achieved then 10 mL of 2% lidocaine will be injected when the needle tip is visualized in proximity of the posterior branch.
3150223|NCT01547637|Experimental|Anatomic landmark|Obturator nerve block will be performed after induction of general anesthesia. The adductor magnus tendon approach will be used. A 4 cm insulated stimulating needle will be used to verify location of the obturator nerve by contraction of the thigh adductor group. The needle will be advanced until nerve stimulation is still present at less than or equal to 0.5 mA. When the appropriate nerve stimulation is achieved 10 ml of 2% lidocaine will be injected in divided doses with frequent aspiration. Nerve conduction studies will be repeated once a minute for the first 10 minutes after block completion.
3150224|NCT01547624|Experimental|Neck Specific exercises|3 months of neck specific exercises for 30 patients.
3150225|NCT01547624|No Intervention|Waiting list|Thirty patients on the waiting list for 3 month before they have their intervention
3150226|NCT01547624|No Intervention|Healthy controls|Forty healthy controls. Comparisons between forty included WAD patients and 40 healthy controls matched for age and gender will be investigated at baseline.
3150227|NCT01547611|Active Comparator|Customary treatment|Group A (physiotherapy as usual), customary treatment. The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
3150228|NCT01547611|Experimental|structured behavioural medicine program|Group B (extended physiotherapy treatment), customary treatment (please see above) plus a standardised and structured behavioural medicine program. The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
3150229|NCT01547598|Active Comparator|LUMIGAN® RC|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
3150230|NCT01547598|Active Comparator|DuoTrav®|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
3150231|NCT01547585|Placebo Comparator|Control|- Isocaloric control muffins
3150232|NCT01547585|Experimental|Low Dose Soy|- Isocaloric muffins containing low dose of soy
3150233|NCT01547585|Experimental|High Dose Soy|- Isocaloric muffins containing high dose soy
3150234|NCT01547572|Experimental|Study group|The study group will get a video and leaflet on enhanced recovery.
3150235|NCT01547572|No Intervention|Control group|The control group will receive a leaflet only.
3150236|NCT01547559|No Intervention|part1:blank control|NO maintain drugs with Hp negative patients.
3150237|NCT01547559|Experimental|part1:teprenone 1|maintain treatment with Teprenone for Hp negative patients
3150238|NCT01547559|Experimental|part1:EAC-T|eradication of Hp with triple treatment
3150239|NCT01547559|Experimental|part1：EA-EMC-T|eradication of Hp with sequential therapy
3150240|NCT01547559|Active Comparator|part1：T-T|Teprenone as maintain drugs for Hp positive patients
3150241|NCT01547559|Experimental|part2:GGA group|Geranylgeranylacetone plus diclofenac sodium for patients with rheumatic diseases
3150242|NCT01547559|No Intervention|part2:control group|diclofenac sodium only for patients with rheumatic diseases
3150243|NCT01547546|Experimental|Single Arm|
3150244|NCT01547533||Lactating Women with Chagas disease|Women with Chagas disease who fulfill clinical criteria for treatment with benznidazole, and who are also lactating
3150245|NCT01547520|Experimental|meperidine|25 mg of meperidine is injected intramuscularly before EGD
3150246|NCT01547520|Placebo Comparator|placebo|placebo was given intramuscularly before EGD
3150247|NCT01547507|Active Comparator|KimVent Turbo-Cleaning Closed Suction System Kimberly clark|
3150248|NCT01547507|Active Comparator|Airway Medix Closed Suction System|
3150249|NCT01547494|Placebo Comparator|Dietary Supplement|
3150250|NCT01547494|Experimental|Vegan Diet|
3150251|NCT01547481||Parkinson's Disease Cohort|Individuals Diagnosed with Parkinson's Disease
3150252|NCT01547481||Essential Tremor cohort|Individuals Diagnosed with Essential Tremor
3150253|NCT01547481||Rapid Eye Movement Disorder Cohort|Individuals Diagnosed with Rapid-Eye Movement Behavior Disorder (RBD). Eligible individuals will have been diagnosed with RBD based on a sleep study prior to entering the study. This study does not pay for or support a sleep study.
3150254|NCT01547481||Healthy Control group|Individuals are healthy, without a known neurologic disease.
3150338|NCT01546896|Active Comparator|alprazolam|
3150256|NCT01547481||Parkinsonism - Undifferentiated|Individuals with any form of Parkinsonism, not meeting any of the above cohorts.
3150257|NCT01547468|Active Comparator|Intravenous Opioids|
3150258|NCT01547468|Experimental|Femoral Nerve Catheterization|
3150259|NCT01547455|Experimental|Atorvastatin|participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
3150260|NCT01547455|Placebo Comparator|Control|Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
3150261|NCT01547442|Experimental|Artisan Aphakia Intraocular Lens|Implantation of an Artisan intraocular lens to correct aphakia in children
3150262|NCT01547429|Experimental|Intraocular Lens Implantation for the Treatment for Aphakia|Implantation of an Artisan intraocular lens to correct aphakia in Adults. No other information is needed to describe this section
3150263|NCT01547416|Experimental|combined general/epidural anesthesia|epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. Epidural analgesia was maintained using the patient-controlled analgesia technique.
3150264|NCT01547416|Active Comparator|General anesthesia|Patients allocated to general anesthesia group did not receive epidural anesthesia.
3150265|NCT01547390|Experimental|Aspirin|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first
3150266|NCT01547390|Placebo Comparator|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
3150267|NCT01547377|Experimental|zinc and selenium supplementation|Patients received 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation during 4 months
3150268|NCT01547377|Placebo Comparator|rosuvastatin + placebo|Patients received 10 mg rosuvastatin concomitantly placebo pills similar zinc and selenium supplementation
3150269|NCT01547364|Placebo Comparator|Caudal Saline|
3150270|NCT01547364|Active Comparator|Caudal Dextrose|
3150271|NCT01547351||ARMS Questionnaire Group|Patients with confirmed multiple sclerosis relapse who are willing to participate in the ARMS questionnaire. These patients could not have been treated with any therapies other than oral or intravenous corticosteroids for their previous relapse.
3150272|NCT01547338||Breast reconstruction patient|Unilateral breast reconstruction patients
3150273|NCT01547325|Experimental|NanoDOX Hydrogel|
3150274|NCT01547325|Placebo Comparator|Placebo Hydrogel|
3150275|NCT01547312|Experimental|Main Pt. 2: 800 mg Grazoprevir + Peg-IFN/RBV|800 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.
3150276|NCT01547312|Experimental|Main Pt. 2: 100 mg Grazoprevir + Peg-IFN/RBV|100 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.
3150277|NCT01547312|Experimental|Main Pt.1: 800 mg Grazoprevir|800 mg Grazoprevir.
3150278|NCT01547312|Experimental|Procedural Pilot|Optimization of FNA procedure.
3150279|NCT01547299|Experimental|Enzalutamide alone|Enzalutamide 160 mg, orally, once daily
3150280|NCT01547299|Experimental|Enzalutamide & Leuprolide & Dutasteride|Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily
3150281|NCT01547286|Experimental|Allergic asthmatic|
3150282|NCT01547273|Experimental|bone graft inside socket only|bone graft inside socket only
3150283|NCT01547273|Experimental|bone graft inside and outside socket|bone graft inside and outside socket
3150284|NCT01547273|Experimental|no bone graft|no bone graft
3150285|NCT01547260|Experimental|Lenalidomide|Phase I; Lenalidomide capsules will be taken orally each day on days 1-21 of each 28-day cycle. 3 subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day. Gemcitabine, 1000 mg/m2 in 0.9% sodium chloride will be administered iv over 30 minutes, at days 1, 8, 15 of each 28-day cycle. Phase II: Every other consecutive included subject in phase II part will be treated with either single lenalidomide (days 1-21 of 28) or single gemcitabine (days 1, 8, 15 of 28) during Cycle 1. The first included patient in phase II part will start with single lenalidomide. From treatment cycle number 2 and beyond, all subjects in the phase II part of the study will be treated with lenalidomide in combination with gemcitabine.
3150286|NCT01547260|Experimental|gemcitabine|Gemcitabine, 1000 mg/m2 in 0.9% sodium chloride will be administered iv over 30 minutes, at days 1, 8, 15 of each 28-day cycle in both phase I and II. Phase I:Lenalidomide capsules will be taken orally each day on days 1-21 of each 28-day cycle. 3 subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day. Phase II: Every other consecutive included subject in phase II part will be treated with either single lenalidomide (days 1-21 of 28) or single gemcitabine (days 1, 8, 15 of 28) during Cycle 1. The first included patient in phase II part will start with single lenalidomide. From treatment cycle number 2 and beyond, all subjects in the phase II part of the study will be treated with lenalidomide in combination with gemcitabine.
3150287|NCT01547247|Experimental|cap-assisted water immersion colonoscopy|Cap-fitted colonoscopy using purely water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
3150288|NCT01547247|Active Comparator|water immersion colonoscopy|Standard colonoscopy without attached cap using purely water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
3150289|NCT01547221|Active Comparator|3% boric acid|control
3150290|NCT01547221|Experimental|1% clotrimazole ear drop|3% boric acid is set as control while 1% clotrimazole ear drop is set as intervention.
3150291|NCT01547208|Experimental|Group A|Patients will be randomized to a VT ablation procedure immediately after an appropriate ICD shock
3150292|NCT01547208|Active Comparator|Group B|Patients will wait until an arrhythmic storm to undergo a VT ablation procedure
3150293|NCT01547195|Experimental|Group-swimming|
3150294|NCT01547195|Active Comparator|Control-walk|
3150295|NCT01547182|Active Comparator|Weight Loss|Caloric restriction
3150296|NCT01547182|Experimental|Weight Loss and Aerobic Training|Caloric restriction and walking
3150297|NCT01547182|Experimental|Weight Loss and Resistance Training|Caloric restriction and lifting weights
3150298|NCT01547169|Placebo Comparator|Saline|
3150299|NCT01547169|Experimental|Low Dose Insulin Detemir (10IU bid)|
3150300|NCT01547169|Experimental|High Dose Insulin Detemir (20IU bid)|
3150301|NCT01547156|No Intervention|Control group|Control group received usual care
3150302|NCT01547156|Experimental|Telemonitoring group|Intervention patients were given a remote patient monitoring toolbox that included a mobile telephone, software application, and assessment devices for measuring and remote reporting of hypertension and diabetes -related health parameters at home. The monitored parameters were body weight, steps, blood pressure and blood glucose. Based on their self-monitored data, patients received feedback that was automatically generated, theory-based, health promotion rich information that aimed at strengthening their self-care practices.
3150303|NCT01547143|Experimental|IST and/or alloHCT|Patients who are newly diagnosed as HLH by HLH-2004 criteria, excluding those with HLH owing to malignancy or rheumatic disorder.
3150304|NCT01547130|Active Comparator|BLS and Yoga exercise|Patients will take a bolus intake of 8 oz. (240mL) to 16 oz. (480mL) of lukewarm saline water and perform yoga poses.
3150305|NCT01547130|Active Comparator|PEG (HalfLytely)|Patients followed the preparation method according to the manufacturer's standard instructions.
3150306|NCT01547117|Experimental|High Sodium Level|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels.
3150307|NCT01547117|Experimental|Low Sodium Dietary Level|
3150308|NCT01547104|Active Comparator|Glimepiride-ratiopharm|Glimepiride (1-4mg) as add on therapy
3150309|NCT01547104|Experimental|Trajenta|Linagliptin 5 mg as add on therapy
3150310|NCT01547091|Experimental|UC-MSCs Treatment|Patients in UC-MSCs treatment will be infused umbilical cord-derived mesenchymal stem cells intravenously only.
3150311|NCT01547091|Active Comparator|DMARDS|Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs).
3150312|NCT01547091|Active Comparator|UC-MSC+DMARDS|Patients will be treated in combination with UC-MSC and DMARDS.
3150313|NCT01547078|Active Comparator|Licensed Plasma|
3150314|NCT01547078|Experimental|Lyophilized Plasma|
3150315|NCT01547052|Experimental|DBT for children|Dialectical Behavior Therapy adapted for children
3150316|NCT01547052|Active Comparator|Enhanced Supportive-Educational Therapy|Enhanced Treatment-As-Usual, including supportive-educational model, cognitive-behavioral skills and parent management training
3150317|NCT01547039||Carotid endarterectomy (CEA)|Patients undergoing carotid endarterectomy
3150318|NCT01547026|Active Comparator|Psycho-education|Patients receive a 10 min. psycho-education on positive health effects of sports
3150319|NCT01547013||COHORT 1|"Critical Controls: Twenty five (25) critically injured subjects with NO severe traumatic lower extremity traumatic injuries to provide control data for critically injured physiological status, a state which may induce systemic, vs. regional hypoperfusion. (Critical CONTROLS)"
3150320|NCT01547013||COHORT 2|"Ninety five (95) total (35 Cohort 2A; 35 Cohort 2B; 25 Cohort 2C) subjects with severe leg injuries presenting to a participating level 1 trauma center within 12 hours of their injury, to provide data on the acute post-injury phase. (STUDY COHORT)"
3150321|NCT01547013||COHORT 2A|"Subjects meeting COHORT 2 inclusion criteria, who have UNILATERAL severe leg injuries. Unilateral injuries include patients who meet the inclusion criteria for a severe lower extremity injury for ONE lower extremity, with no more than a simple soft tissue injury (eg, simple laceration) on the contralateral leg."
3150322|NCT01547013||COHORT 2B:|"Subjects meeting COHORT 2 inclusion criteria, who have BILATERAL lower extremity injuries, with at least one being a severe leg injury. Bilateral injury patients include patients with at least one lower extremity injury classified as severe based on Cohort 2 inclusion criteria, with a contralateral injury greater than a simple soft tissue injury, including femur, foot, and crush injuries. Note that it is not necessary for both lower extremity injuries to meet the inclusion criteria to be enrolled in this cohort."
3150323|NCT01547013||COHORT 2C|Subjects meeting COHORT 2 inclusion criteria, clinically diagnosed by the treating provider using that treating provider's standards of diagnosing ACS, and in addition to being diagnosed with ACS, the subject undergoes four-compartment leg fasciotomy. data collection to start BEFORE fasciotomy and continue AFTER fasciotomy.
3150324|NCT01547000|Placebo Comparator|Inactive placebo|
3150325|NCT01547000|Experimental|Extended-release Guanfacine|
3150326|NCT01546987|Active Comparator|ADT + GnRH agonist + dose escalated radiation|Patients receive standard androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 24 months from initiation and oral (PO) antiandrogen (such as flutamide or bicalutamide) beginning 2 months prior and for the duration of radiation therapy (RT).
3150327|NCT01546987|Experimental|ADT + GnRH agonist + dose escalated radiation + TAK-700|Patients receive the same standard ADT with a GnRH agonist and oral antiandrogen. In addition, patients also receive steroid 17alpha-monooxygenase TAK-700 (TAK-700) PO twice daily (BID) for 2 years.
3150328|NCT01546974|Experimental|HME filter|
3150329|NCT01546974|Experimental|Heated humidificator MR 730 Fisher & Paykel|
3150330|NCT01546961|Experimental|Chloroquine|"Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).~Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2."
3150331|NCT01546948|Experimental|Methadone|Patients in the methadone group will be administered 0.3 mg/kg of methadone intraoperatively: two-thirds of the dose (6 cc or 0.2 mg/kg of methadone) on induction of anesthesia as a bolus. The remainder of the dose (3 cc or 0.1 mg/kg of methadone) will be administered at approximately 1.5-2 hours before the end of the procedure.
3150332|NCT01546948|Active Comparator|Hydromorphone|Patients in the hydromorphone group will receive 0.03 mg/kg of hydromorphone; two-thirds the dose (6 cc or 0.02 mg/kg) on induction of anesthesia, and the remainder of the hydromorphone (3 cc or 0.01 mg/kg) will be bolused 1.5-2 hours before surgery concludes.
3150333|NCT01546935|Experimental|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
3150334|NCT01546922|Active Comparator|First low dose HC followed by high dose HC|First low dose of hydrocortisone = 0.2-0.3 mg/kg body weight for 10 weeks followed by a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight
3150335|NCT01546922|Active Comparator|First high dose HC followed by low dose HC|First a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight for 10 weeks followed by a low dose of hydrocortisone = 0.2-0.3 mg/kg body weight
3150336|NCT01546909|Experimental|TETRAVAC-ACELLULAIRE|
3150337|NCT01546896|Experimental|buspirone+alprazolam|
3150340|NCT01546883|Experimental|Dabigatran|Patients with Atrial fibrillation taking Dabigatran etexilate as the anti-coagulant
3150341|NCT01546870||pediatric heart transplant recipients|
3150342|NCT01546857|Placebo Comparator|placebo|Placebo one dose in the evening of surgery and post op day #1.
3150343|NCT01546857|Active Comparator|Gabapentin|Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively
3150344|NCT01546844|Experimental|Care4Life|Text message and online interactive component to help patients with self-management.
3150345|NCT01546844|No Intervention|Standard of Care|Patients enrolled in this arm will receive their normal standard of care from their physician for treatment of type II Diabetes Mellitus.
3150346|NCT01546805|Placebo Comparator|Placebo|
3150347|NCT01546805|Experimental|Zinc Group|
3150348|NCT01546792|No Intervention|Usual care control|Leaflet on exercise and diet
3150349|NCT01546792|Experimental|Lifestyle intervention|Exercise training (mixture of supervised and non-supervised) Dietary advice Behaviour change counselling (physical activity, diet)
3150350|NCT01546779|Experimental|lung function|
3150351|NCT01546766||Subjects with diabetes|(Subjects that have been diagnosed with diabetes).
3150352|NCT01546766||Control volunteers|(Subjects with no history of ocular problems).
3150353|NCT01546766||Subjects with retinal conditions|(Subjects with a history of retinal disorders except diabetes).
3150354|NCT01546753|Active Comparator|Walnut Protein Powder|
3150355|NCT01546753|Placebo Comparator|Oat Powder|
3150356|NCT01546740||Glaucoma patients|all the ,medical records of patients who were diagnosed with primary open angle glaucoma, closed angle , pseudoexfoliative and neovascular glaucoma.
3150357|NCT01546727|Experimental|Family Behavioral Treatment|This intervention will provide nutritional counseling for a health diet, parent training in effective child behavioral management strategies, and stimulus control of the home environment delivered via group based clinic visits and individual home visits on alternate weeks
3150358|NCT01546727|Active Comparator|Motivational Interviewing|This intervention will shared information with parents about their child's weight and use motivational interviewing to elicit changes parents would like to make to their child diet and activity patterns.
3150359|NCT01546727|No Intervention|Standard of Care|Participants in this arm will be followed over time and be assessed on the primary and secondary outcomes at the same time points as the two treatment arms
3150360|NCT01546714||AAWSW/AAWSWM|African American Women Who Have Sex with Women/African American Women Who Have Sex with Women and Men
3150361|NCT01546701|Experimental|Buprenorphine|Renal Colic Patients treated by 2 mg sublingual Buprenorphine.
3150362|NCT01546701|Active Comparator|Morphine|Renal Colic Patients treated by 0.1 mg/kg intravenous morphine.
3150363|NCT01546688|Active Comparator|Zonisamide at targeted daily doses of 100-500 mg/day|
3150364|NCT01546688|Placebo Comparator|Placebo administered to match daily doses of 100-500 mg/day|
3150365|NCT01546675|Active Comparator|Traditional 1, Skeletal Stabilization 2|Subjects using the Traditional Socket and socket hypothesized to increase skeletal stabilization in a case cross-over design. The intervention is the socket designed to increase skeletal stabilization.
3150366|NCT01546675|Experimental|Skeletal Stabilization 1, Traditional 2|Subjects using the socket hypothesized to increase skeletal stabilization and Traditional Socket and in a case cross-over design. The intervention is the socket designed to increase skeletal stabilization.
3150367|NCT01546662|Experimental|E-RH-06 - Low Dose|1 Capsule twice daily
3150368|NCT01546662|Experimental|E-RH-06 - High Dose|2 capsules twice daily
3150369|NCT01546662|Placebo Comparator|Placebo ;|Placebo Comparator
3150370|NCT01546649|Experimental|TAP-144-SR(6M)|TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 96 weeks.
3150371|NCT01546649|Active Comparator|TAP-144-SR(3M)|TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 96 weeks.
3150372|NCT01546636|Placebo Comparator|Hypocapnic group|Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
3150373|NCT01546636|Active Comparator|Normocapnic group|Patients will be ventilated to an ETCO2 of 40-42 mm Hg
3150374|NCT01546623|Experimental|TAP-144-SR(6M)|TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.
3150375|NCT01546623|Active Comparator|TAP-144-SR(3M)|TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.
3150376|NCT01546610|Experimental|intervention foot orthoses|Ethyl vinyl acetate (EVA) insole with medial arch support and bar retrocapital
3150377|NCT01546610|Placebo Comparator|placebo insole|Foot orthose with support retrocapital and support of medial arch insole intervention
3150378|NCT01546597|Experimental|Metformin, Ranolazine|"Single cohort, 4-period study:~Period 1, metformin 500 mg bid on Days 1-5~Period 2, metformin 850 mg bid on Days 6-10~Period 3, metformin 500 mg bid + ranolazine 1000 mg bid on Days 11-15~Period 4, metformin 850 mg bid + ranolazine 1000 mg bid on Days 16-20"
3150379|NCT01546571|Placebo Comparator|POL-103A without API|
3150380|NCT01546571|Experimental|POL-103A|
3150381|NCT01546558|Experimental|Metformin, Ranolazine|"Single cohort, 2-period study:~Period 1, metformin 1000 mg bid on Days 1-5~Period 2, metformin 1000 mg bid + ranolazine 500 mg bid on Days 6-10"
3150382|NCT01546545||Enrollment Group|Healthy participants between the age of 18 and 70 years with fasting blood sugar that is between normal and diabetes.
3150383|NCT01546532|Experimental|RLX030|RLX030 as intravenous infusion for 24 hours.
3150384|NCT01546532|Placebo Comparator|Placebo|Placebo as intravenous infusion for 24 hours.
3150385|NCT01546519|Experimental|1|Control cohort with normal renal and normal hepatic function
3150386|NCT01546519|Experimental|2|Severe renal impairment and normal hepatic function
3150387|NCT01546519|Experimental|3|Mild hepatic impairment and normal renal function
3150388|NCT01546519|Experimental|4|Moderate hepatic impairment and normal renal function
3150389|NCT01546519|Experimental|5|Severe hepatic impairment and normal renal function
3150390|NCT01546506|Experimental|Midodrine|Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
3150391|NCT01546506|No Intervention|No treatment|
3150392|NCT01546493|Experimental|Controls|Asymptomatic control subjects with no deformity. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis.
3150393|NCT01546493|Experimental|Symptomatics|Subjects with bilateral cam deformity and unilateral symptoms. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis.
3150394|NCT01546493|Experimental|Asymptomatic|Asymptomatic subjects with cam deformity. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis.
3150395|NCT01546480||Pain patients|Patients with unexplained chronic abdominal pain 12 months after elective cholecystectomy
3150396|NCT01546480||Operated painfree Patients|Painfree patients 12 months after elective cholecystectomy
3150397|NCT01546480||Nonoperated painfree patients|Painfree patients with no previous abdominal operation
3150398|NCT01546467|Experimental|Cognitive remediation|30 hour computer based cognitive remediation integrated in participants current rehabilitation program (school, work, day program)
3150399|NCT01546467|No Intervention|Wait list control group|Participant continues in treatment/rehabilitation program as usual until 9 month assessment when participant receives the same cognitive remediation program as the experimental group.
3150400|NCT01546454|Experimental|Non-steroidal effects|Natural menstrual cycle versus Estrogen/Progesterone replacement cycle. Interventions include leuprolide acetate to induce hypogonadism and estradiol and progesterone to replace hormone levels.
3150401|NCT01546454|Experimental|Contraceptive effects|Oral contraceptive cycle versus Eligard treatment. Interventions include ethinyl estradiol-levonorgestrel combination and leuprolide acetate.
3150402|NCT01546454|Experimental|Steroid effects|Estrogen/Progesterone replacement cycle versus Eligard treatment. Interventions include leuprolide acetate, estradiol, and progesterone.
3150403|NCT01546441|Experimental|interprofessional assessment|patients receive an interprofessional assessment in a team environment
3150404|NCT01546441|Active Comparator|usual care|Usual care in family practice
3150405|NCT01546428|Experimental|INC280|
3150406|NCT01546415|Experimental|Desferasirox|
3150407|NCT01546402|Experimental|Phacoemulsification with IOL implant|This group (Group B) includes patients who will undergo phacoemulsification with intraocular lens implantation. The dexamethasone implant will not be injected at the beginning of cataract surgery. Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
3150408|NCT01546402|Experimental|Phacoemulsification with Ozurdex|This group (Group A) includes patients who will undergo phacoemulsification with intraocular lens implantation with intraoperative long acting steroid injection (Ozurdex ®). The dexamethasone implant will be injected at the beginning of cataract surgery, 4mm from the limbus using the specially designed injector. Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
3150409|NCT01546389|Experimental|Cohort 3, Group E|Cohort 3 (High Dose, Low Aliquot), Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose); 5 subjects
3150410|NCT01546389|Experimental|Cohort 1, Group A|Cohort 1 (Medium Dose, Medium Aliquot), Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose); 5 subjects.
3150411|NCT01546389|Experimental|Cohort 1, Group B|Cohort 1 (Medium Dose, Medium Aliquot), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose); 5 subjects
3150412|NCT01546389|Experimental|Cohort 3, Group F|Cohort 3 (High Dose, Low Aliquot), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose); 5 subjects
3150413|NCT01546389|Experimental|Cohort 2, Group D|Cohort 2 (Medium Dose, Low Aliquot), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose); 5 subjects
3150414|NCT01546389|Experimental|Cohort 2, Group C|Cohort 2 (Medium Dose, Low Aliquot), Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose); 5 subjects
3150415|NCT01546376||HIV-cancer patients who recived RT|
3150416|NCT01546363||Validation|
3150417|NCT01546363||Testing|
3150418|NCT01546350|No Intervention|Control - regular ART treatment|patients will have up to two embryos replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patients in the control group do not have a pregnancy to term from that fresh cycle, they will be offered free PGD either for the frozen embryos of that cycle or for the next cycle (up to the center and patient). Data from that PGD is not part of the study.
3150419|NCT01546350|Experimental|Test - PGD|patients will have grade A,B or C blastocysts hatched on day 5, biopsied on day 5, analyzed by array CGH, and a single euploid embryo transferred on day 6. Any morulas developing to grade A,B or C blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle.
3150420|NCT01546324||Pregnant women|Women pregnant following the use of Natera's PGS/PGD testing
3150421|NCT01546311||lower limb amputees|
3150422|NCT01546285|Experimental|Blood Pressure Reading|Simultaneous blood pressure readings with DINAMAP PRO1000 and B40 monitor; total of 6 successful readings
3150423|NCT01546272|Experimental|Resorbable staples|Suture using Insorb Resorbable staples
3150424|NCT01546272|Active Comparator|Resorbable wires|Suture using Monocryl resorbable wire
3150425|NCT01546259|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
3150426|NCT01546259|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
3150427|NCT01546246|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
3150428|NCT01546246|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
3150429|NCT01546233||multidisiplinary self care program|Patient with Lung cancer will be participated in group education with multidisiplinary self care program
3150430|NCT01546233||Conventional education|Lung cancer patient will be received standard education
3150982|NCT01542554|Active Comparator|Usual diabetic diet|
3150431|NCT01546220|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
3150432|NCT01546220|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
3150433|NCT01546207|Other|catheter-based ablation|catheter ablation - a medical procedure used to treat some types of arrhythmia
3150434|NCT01546194||Morning consent|Consent process consisting of information only provided on the morning of surgery
3150435|NCT01546194||Phone call and morning consent|Consent process consisting of information provided on the morning of surgery. In addition, a phone call on the day prior to surgery will be provided to subjects explaining that they will be approached about participation in a clinical research project
3150436|NCT01546181||Controls|subjects older than 10 years old, with no know ocular or general disease
3150437|NCT01546181||Age-related macular degeneration|
3150438|NCT01546181||inherited retinal dystrophies|
3150439|NCT01546181||retinal trauma|
3150440|NCT01546181||toxic retinopathies|
3150441|NCT01546181||arterial hypertensive patients|
3150442|NCT01546181||diabetic patients|
3150443|NCT01546181||inflammatory diseases|
3150444|NCT01546168|Experimental|esophageal deviation|esophageal deviation with IDE device during AF ablation
3150445|NCT01546168|No Intervention|temperature monitoring|luminal esophageal temperature monitoring, standard temperature monitoring alone
3150446|NCT01546155|Experimental|healthy controls|
3150447|NCT01546142|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3150448|NCT01546142|Experimental|Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3150449|NCT01546129|Experimental|Dianatal Obstetric Gel|Standard of care according to the established Guidelines of the Department plus use of Dianatal applied with a vaginal applicator in stage I and stage II of labor
3150450|NCT01546129|No Intervention|Control|Standard of care according to the established Guidelines of the Department.
3150451|NCT01546116|Experimental|Adefovir and lamivudine combination|
3150452|NCT01546103|Active Comparator|Vitamin D3 supplementation of 1000 IU|
3150453|NCT01546103|Active Comparator|Vitamin D3 supplementation of 5000 IU|
3150454|NCT01546090|Experimental|alprazolam|Alprazolam is a short-acting anxiolytic of the benzodiazepine class of psychoactive drugs
3150455|NCT01546090|Placebo Comparator|placebo|placebo capsules were filled with starch
3150456|NCT01546077|Active Comparator|Hydrolocalization technique group|Technique of placement of popliteal perineural catheter using the hydrolocalization technique with ultrasound
3150457|NCT01546077|Active Comparator|Stimulating Catheter technique group|A technique for placement of popliteal catheter with the aid of a neurostimulator
3150458|NCT01546064|Active Comparator|Bile duct anastomosis with T-tube|
3150459|NCT01546064|Active Comparator|Bile duct anastomosis without T-tube|
3150460|NCT01546051|Experimental|BCI-838 Food Effect Dosing Arm 1|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
3150461|NCT01546051|Experimental|BCI-838 Fasted Dosing (100 & 300 mg)|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
3150462|NCT01546051|Experimental|BCI-1038, BCI-1206 & BCI-1283|Six subjects will be enrolled, all 6 will receive single doses of BCI-1038, BCI-1206 and BCI-1283.
3150463|NCT01546051|Experimental|BCI-838 Fasted Dosing (900 mg)|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
3150464|NCT01546038|Experimental|Arm A (Phase 1B)|PF-04449913 in combination with low dose ARA-C (LDAC)
3150465|NCT01546038|Experimental|Arm B (Phase 1B)|PF-04449913 in combination with Decitabine
3150466|NCT01546038|Experimental|Arm C (Phase 1B)|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
3150467|NCT01546038|Experimental|P2 Fit (Phase 2 Single Arm)|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
3150468|NCT01546038|Other|P2 Unfit (Phase 2 Randomized)|Patients will be randomized 2:1 (low dose ARA-C in combination with PF-04449913: low dose ARA-C alone).
3150469|NCT01546025|Placebo Comparator|Relaxation training|
3150470|NCT01546025|Active Comparator|Brief Motivational Counseling|
3150471|NCT01546012|Experimental|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
3150472|NCT01546012|Active Comparator|HYLO-COMOD®:|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
3150473|NCT01545999|Active Comparator|PAS 25|In humans, paired associative stimulation (PAS-25) is a transcranial magnetic stimulation (TMS) protocol that has been shown to result in LTP-like plasticity (PAS-LTP) in the motor cortex (M1). PAS-LTP has been shown to be dependent on the NMDAR and to correlate significantly with performance on a motor learning task.
3150474|NCT01545999|Sham Comparator|PAS 100|To control for non-specific effects of PAS protocol, the investigators will use a modified PAS protocol (PAS-100) that does not result in any neurophysiologic effects. Patients with schizophrenia and healthy controls will be assessed first with the N-back task and then randomized
3150475|NCT01545986|Experimental|High Velocity Exercise|The high velocity exercise group performed the concentric contraction phase of resisted exercise in one second or less. This group performed sit to stand exercise, walking, curbs, and stairs as fast as was comfortable without an increased limp. Other exercises were performed at the participant preferred rate.
3150476|NCT01545986|Active Comparator|Low Velocity exercise|The low velocity exercise group performed the concentric contraction phase of resisted exercise in two seconds. This group performed sit to stand exercise, walking, curbs, stairs, and other exercises at the participant preferred rate.
3150477|NCT01545973||Healthy Volunteers|Human subjects without chronic medical conditions, defined as conditions requiring chronic medication use.
3150478|NCT01545960||Healthy Volunteers|
3150479|NCT01545947|Experimental|CC-223/erlotinib concurrent|Cohorts will receive escalating continuous daily doses (15 mg and 30 mg) of CC-223 in capsules concurrently with at least two different daily dose levels of erlotinib tablets (100 mg and 150 mg) in 28-day cycles.
3150480|NCT01545947|Experimental|CC-223/oral azacitidine concurrent|Cohorts will receive escalating continuous daily doses of CC-223 (15 mg and 30 mg) with one or more dose levels of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Day 1 to 21 of each 28-day cycle.
3150481|NCT01545947|Experimental|CC-223/oral azacitidine sequential|Cohorts will receive escalating continuous daily dose levels of CC-223 (15 mg and 30 mg) administered on Days 8 through 28 sequentially with one or more dose levels of of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Days 1 to 7 of each 28-day cycle
3150482|NCT01545934|No Intervention|Standard Care|
3150483|NCT01545934|Experimental|Lifestyle intervention|
3150484|NCT01545921|No Intervention|Arm A|"Patients will complete QoL questionnaires in the following order :~MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month until death"
3150485|NCT01545921|No Intervention|Arm B|"Patients will complete QoL questionnaires in the following order :~QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month until death"
3150486|NCT01545921|No Intervention|Arm C|"Patients will complete QoL questionnaires in the following order :~MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month and spontaneous QoL completion, until death"
3150487|NCT01545921|No Intervention|Arm D|"Patients will complete QoL questionnaires in the following order :~QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month and spontaneous QoL completion, until death."
3150488|NCT01545908|Placebo Comparator|placebo enema|Participants in this arm undergo 6 retention enemas, week 1, week 2, week 3, week 4, week 5, week 6
3150489|NCT01545908|Active Comparator|Fecal transplant from an unrelated donor|Participants in this arm undergo 6 retention enemas,week 1, week 2, week 3, week 4, week 5, week 6,using stool specimen prepared from a healthy, screened donor.
3150490|NCT01545882|Experimental|Degarelix|Degarelix treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
3150491|NCT01545869|Experimental|Fractional carbon dioxide laser|
3150492|NCT01545856||New levodopa users|Individuals with one or more prescriptions of levodopa between 1st July 2004 and 30th June 2010 but no previous levodopa prescriptions prior to study period
3150493|NCT01545843|Active Comparator|No sleep deprivation|Sleep scheduling plus fluoxetine. 8 hours time in bed for two weeks plus fluoxetine for 8 weeks
3150494|NCT01545843|Experimental|Late bedtime sleep deprivation|Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Bedtime delayed by 2 hours.
3150495|NCT01545843|Experimental|Early risetime sleep deprivation|Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Risetime advanced by 2 hours.
3150496|NCT01545830|Active Comparator|Regular Dose|Intervention: 600 IUs of cholecalciferol taken by mouth daily.
3150497|NCT01545830|Experimental|High Dose D|Intervention: 6,000 IUs of cholecalciferol taken by mouth daily.
3150498|NCT01545817|Experimental|Pazopanib followed by everolimus|First line pazopanib, followed by second line everolimus
3150499|NCT01545804|Experimental|Lenalidomide|
3150500|NCT01545791||Insulin detemir users|
3150501|NCT01545778||Tapentadol IR|
3150502|NCT01545778||Oxycodone IR|
3150503|NCT01545765|Experimental|lidocaine 7% and tetracaine 7%|
3150504|NCT01545752|No Intervention|coventional group|Teaching just by book
3150505|NCT01545752|Experimental|non-interactive CD|Teaching book with non-interactive CD
3150506|NCT01545752|Experimental|interactive CD|Teaching book with interactive CD
3150507|NCT01545739||CRT pacemaker implantation|
3150508|NCT01545726|Experimental|QAW039|Eligible patients will receive QAW039 po 450 mg daily dose.
3150509|NCT01545726|Placebo Comparator|Placebo|Placebo to QAW039 (oral capsules) will be administered to match QAW039 schedule.
3150510|NCT01545713||Renal Transplant Recipients|Patients undergoing living-donor kidney transplant at NMH who have a positive XM-One AbSorber® positive test result.
3150511|NCT01545700|Placebo Comparator|Control, saline 0-4 hours|2 cc of saline
3150512|NCT01545700|Active Comparator|Dexamethasone 4 mg, 0-4 hours|Dexamethasone 4 mg administered intraoperatively
3150513|NCT01545700|Active Comparator|Dexamethasone 8 mg, 0-4 hours|Dexamethasone 8 mg administered intraoperatively
3150514|NCT01545700|Placebo Comparator|Placebo Comparator saline 8-24 hours|placebo, 2 cc saline
3150515|NCT01545700|Active Comparator|Dexamethasone 4 mg, 8-24 hours|Dexamethasone 4 mg administered intraoperatively
3150516|NCT01545700|Active Comparator|Dexamethasone 8 mg, 8-24 hours|Dexamethasone 8 mg administered intraoperatively
3150517|NCT01545687|Experimental|Arm I|Patients dissolve in mouth 1 lozenge of Lactobacillus bevis CD2 every 2-3 hours (total of 6 per day) daily during CRT (comprising cisplatin and radiotherapy [RT]) and for 4 weeks after, including weekends.
3150518|NCT01545687|Placebo Comparator|Arm II|Patients dissolve in mouth 1 lozenge of placebo every 2-3 hours (total of 6 per day) daily during CRT and for 4 weeks after, including weekends.
3150519|NCT01545674||Pregnant Women Blood Draw|Pregnant Women with elevated risk of trisomic pregnancy to donate a blood sample through one time blood draw
3150520|NCT01545661|Experimental|Sputum induction|Enrolled patients receive sputum induction (using ultrasonic nebulisation with hypertonic saline)
3150521|NCT01545661|Active Comparator|No sputum induction|Enrolled patients randomised to this study arm will receive an observed expectorated sputum collection attempt. Research nurses train study patients on the method of producing sputum spontaneously.
3150522|NCT01545648|Experimental|denosumab|"Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection"
3150523|NCT01545635|Active Comparator|Coagulation factor concentrates|
3150524|NCT01545635|Active Comparator|Fresh Frozen Plasma|
3150525|NCT01545609|Experimental|Text messaging|Text messaging
3150527|NCT01545596|Experimental|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
3150528|NCT01545596|No Intervention|No Notification|No additional notification given to anesthesia team apart from the information on their monitors.
3150529|NCT01545583|Placebo Comparator|Placebo intravenous|Placebo administered once intravenously
3150530|NCT01545583|Experimental|0.1 milligram (mg) LY3016859 intravenous|0.1 mg LY3016859 administered once intravenously
3150531|NCT01545583|Experimental|1 mg LY3016859 intravenous|1 mg LY3016859 administered once intravenously
3150532|NCT01545583|Experimental|10 mg LY3016859 intravenous|10 mg LY3016859 administered once intravenously
3150533|NCT01545583|Experimental|50 mg LY3016859 intravenous|50 mg LY3016859 administered once intravenously
3150534|NCT01545583|Experimental|250 mg LY3016859 intravenous|250 mg LY3016859 administered once intravenously
3150535|NCT01545583|Experimental|750 mg LY3016859 intravenous|750 mg LY3016859 administered once intravenously
3150536|NCT01545583|Placebo Comparator|Placebo subcutaneous|Placebo administered once subcutaneously
3150537|NCT01545583|Experimental|50 mg LY3016859 subcutaneous|50 mg LY3016859 administered once subcutaneously
3150538|NCT01545570|Active Comparator|GSK2376497|single dose escalation or multiple-dose titration
3150539|NCT01545570|Placebo Comparator|0.9% sodium chloride|placebo injection
3150540|NCT01545557|Experimental|Hyaluronic acid|
3150541|NCT01545531||Iohexol GFR|
3150542|NCT01545518|Experimental|all subjects|IVIG
3150543|NCT01545505|Other|In remission phase of PTSD|Patients having suffered from PTSD in the past and in remission od PTSD and their parents
3150544|NCT01545505|Other|Activ PTSD|patients suffering from PTSD (Post-traumatic Stress Disorder) and their parents
3150545|NCT01545492||Tight|"Children born to women in the CHIPS RCT randomized to Tight blood pressure control [target diastolic BP 85mmHg]"
3150546|NCT01545492||Less Tight|"Children born to women in the CHIPS RCT randomized to Less Tight [target diastolic BP 100mmHg]."
3150547|NCT01545479|Other|Captopril 25mg|To study the renal blood oxygenation, the subjects took captopril (25mg).
3150548|NCT01545466|Experimental|Mindfulness Based Stress Reduction|Participants will complete an 8 week course in Mindfulness Based Stress Reduction (MBSR), meeting once/week for 8 weeks and having a 4-6 hour retreat after the 6th class
3150549|NCT01545466|No Intervention|Wait-List Control Group|These participants will continue in usual care during the trial and will be offered the intervention of MBSR after the trial is over.
3150550|NCT01545453|Experimental|lebrikizumab - highest dose|
3150551|NCT01545453|Experimental|lebrikizumab - lowest dose|
3150552|NCT01545453|Experimental|lebrikizumab - middle dose|
3150553|NCT01545453|Placebo Comparator|placebo|
3150554|NCT01545440|Experimental|lebrikizumab - highest dose|
3150555|NCT01545440|Experimental|lebrikizumab - lowest dose|
3150556|NCT01545440|Experimental|lebrikizumab - middle dose|
3150557|NCT01545440|Placebo Comparator|placebo|
3150558|NCT01545427|Experimental|Gleevec|Gleevec 200 mg bid for 6 months.
3150559|NCT01545427|Placebo Comparator|Placebo|Placebo coated to appear identical to Gleevec.
3150560|NCT01545414|Experimental|ICBT|Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
3150561|NCT01545414|Active Comparator|ICONTROL|Internet-based treatment with a focus on relaxation training
3150562|NCT01545414|No Intervention|SMT|Standard Medical Treatment while being on the waitlist for randomization to any of the active treatments
3150563|NCT01545401|Experimental|EMPOWER-PAR Intervention|"The intervention arm receives the EMPOWER-PAR intervention package consisting of:~Chronic Disease Management (CDM) Training Workshops for the staff in the respective clinics~The Global CV Risks Self-Management Booklet (patient self-management tool) to empower patients to self-manage their CV risk factors~Facilitation and support of the staff in these clinics so that they may implement the interventions"
3150564|NCT01545401|No Intervention|Control|"The control arm continues with usual care.~The EMPOWER-PAR intervention package will be made available after the trial ends."
3150565|NCT01545388|Experimental|Metformin 500 mg q.d.|Participants will receive sitagliptin daily (continuing their pre-study dose), 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening.
3150566|NCT01545388|Experimental|Metformin 250 mg b.i.d.|Participants will receive sitagliptin daily (continuing their pre-study dose), 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening.
3150567|NCT01545388|Placebo Comparator|Placebo|Participants will receive sitagliptin daily (continuing their pre-study dose), 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening.
3150568|NCT01545375|Experimental|dPly-PhtD Group|"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving GSK2189242A (dPly-PhtD) vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age.~PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months.~At the primary epoch, the dPly-PhtD vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the dPly-PhtD vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate.~At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate."
3150616|NCT01545037|Placebo Comparator|Placebo capsules|The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria. Dosage of 2 capsules per day , corresponding to 100 billions bacterias for a period of 12 weeks
3150617|NCT01545024||DPP-IV inhibitor|
3150618|NCT01545011|No Intervention|standard|conventional respiratory rehabilitation
3150619|NCT01545011|Experimental|IMT|Inspiratory muscle training and conventional respiratory rehabilitation
3150659|NCT01544764|No Intervention|Control|This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. Practices in this arm were randomly assigned to receive no AFIX visit.
3150983|NCT01542541|Experimental|Rifaximin|
3150569|NCT01545375|Placebo Comparator|Control Group|"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving Placebo vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age.~PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months.~At the primary epoch, the Placebo vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the Placebo vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate.~At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate."
3150570|NCT01545362||Staged bilateral total knee arthroplasty|Patients that have bilateral total knee arthroplasty staged within one week
3150571|NCT01545349|Experimental|LGG|Lactobacillus rhamnosus GG (LGG) containing 1x10^10 LGG per capsule will be given to subjects with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day on an outpatient basis.
3150572|NCT01545349|Placebo Comparator|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis.
3150573|NCT01545336|Experimental|Anastrozole|1 mg tablet by mouth once daily for 3 months
3150574|NCT01545336|Placebo Comparator|Placebo|Placebo tablet by mouth once daily for 3 months
3150575|NCT01545323|Experimental|One 20cm2/10cm2 autologous skin sheet graft|Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
3150576|NCT01545310|Experimental|Group 1 (healthy), Group 2 (schizophrenia)|
3150577|NCT01545297|Active Comparator|Propofol-Remifentanil|Group I. (propofol/remifentanil): Infusions begin at remifentanil (0.01-0.1 mcg/kg/min) and propofol (25-250 mcg/kg/min) for 15 min, and then titrated to effect.
3150578|NCT01545297|Experimental|Dexmedetomidine|Group II. (dexmedetomidine): The infusion begins at 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
3150579|NCT01545284|Experimental|Acitretin|Patients will receive acitretin once daily for a maximum of 24 weeks. Patients who reach a Physician Global Assessment (PGA) of clear or almost clear at week 12 will end the study. Patients who do not reach a PGA of clear or almost clear at week 12 will continue treatment up to week 24. The starting dose will be 10mg/day and, if well tolerated, it will be increased in the first 4 weeks to a maximum of 30 mg/day.
3150580|NCT01545271|Experimental|72h cooling + 18h xenon inhalation|Babies in poor condition at birth and referred to our neonatal unit for standard therapy of cooling to 33.5 degree C body temperature will be randomised to receive xenon gas at 50% concentration for 18 hours
3150581|NCT01545271|Active Comparator|Standard 72 h whole body cooling therapy|Whole body cooling therapy to rectal temperature of 33.5 degree Centigrade (standard therapy)
3150582|NCT01545258|Experimental|Exercise|Exercise training supervised by trained physiotherapists lasting 60 minutes performed 3 times/week.
3150583|NCT01545258|No Intervention|Control|
3150584|NCT01545245||Treated|Palivizumab treated
3150585|NCT01545245||Untreated|Palivizumab untreated
3150586|NCT01545232|Active Comparator|1:1:1 Blood Transfusion Ratio|
3150587|NCT01545232|Active Comparator|1:1:2 Blood Transfusion Ratio|
3150588|NCT01545219|Experimental|Prebiotic|
3150589|NCT01545219|Experimental|Probiotic|
3150590|NCT01545219|Experimental|Synbiotic|
3150591|NCT01545219|Placebo Comparator|Placebo|
3150592|NCT01545206||acute STEMI, Primpary PCI|
3150593|NCT01545193||Age 18-50|This is a younger study cohort who is anticipated to have a lower incidence of residual neuromuscular blockade
3150594|NCT01545193||Age 70-90|This is a older study cohort who is anticipated to have a higher incidence of residual neuromuscular blockade
3150595|NCT01545180||HTPcap in IC|HTPcap active and passive in a population of stable patients with heart failure (left ventricular ejection fraction impaired or preserved) and / or valvular disease who received a left right heart catheterization as part of their care.
3150596|NCT01545167||African Americans with pancreatitis|pancreatitis
3150597|NCT01545167||African Americans without Pancreatitis controls|people without pancreatitis
3150598|NCT01545154||Prostate Cancer|
3150599|NCT01545141|No Intervention|Surgery only|Surgical resection only, performed as standard of care for the disease
3150600|NCT01545141|Experimental|Chemokin Modulatory Regimen prior to surgery|"Chemokine Modulatory Regimen monday through Friday prior to surgery:~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 5, 10, and 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
3150601|NCT01545089|Experimental|Mattress protector days 1,2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
3150602|NCT01545089|Experimental|Mattress protector days 3,4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
3150603|NCT01545076|Experimental|IgPro20 low dose|
3150604|NCT01545076|Experimental|IgPro20 high dose|
3150605|NCT01545076|Placebo Comparator|Placebo|
3150606|NCT01545050|Experimental|Induction Cohort: Placebo matching with BMS-945429|
3150607|NCT01545050|Experimental|Induction Cohort: BMS-945429 (600 IV/200 SC mg)|
3150608|NCT01545050|Experimental|Induction Cohort: BMS-945429 (300 IV/100 SC mg)|
3150609|NCT01545050|Experimental|Induction Cohort: BMS-945429 (150 IV/100 SC mg)|
3150610|NCT01545050|Experimental|Induction Cohort: BMS-945429 (400 SC/200 SC mg)|
3150611|NCT01545050|Experimental|Maintenance Cohort: Placebo matching with BMS-945429|
3150612|NCT01545050|Experimental|Maintenance Cohort: BMS-945429 (100 SC mg)|
3150613|NCT01545050|Experimental|Maintenance Cohort: BMS-945429 (200 SC mg)|
3150614|NCT01545050|Experimental|Open Label Cohort: BMS-945429 (200 SC mg)|
3150615|NCT01545037|Active Comparator|Probiotic capsules|L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®. Dosage of 2 capsules per day , corresponding to 100 billions bacterias for a period of 12 weeks.
3150924|NCT01542970|Experimental|L. reuteri and placebo|Active Lactobacillus reuteri and placebo for omega-3 fatty acids
3150620|NCT01544998|Experimental|Tadalafil plus Placebo, then Tadalafil plus Nesiritide|First intervention period: oral Tadalafil; after 1 hour, subcutaneous (sc) placebo given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting. There was a one week washout period. Second intervention period: oral Tadalafil; after 1 hour, sc Nesiritide given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting.
3150621|NCT01544998|Experimental|Tadalafil plus Nesiritide, then Tadalafil plus Placebo|First intervention period: oral Tadalafil; after 1 hour, sc Nesiritide given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting. There was a one week washout period. Second intervention period: oral Tadalafil; after 1 hour, sc placebo given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting.
3150622|NCT01544985|Experimental|sucrose po|88% sucrose solution (Syrup B.P.)
3150623|NCT01544985|Placebo Comparator|placebo po|sterile water
3150624|NCT01544972|Active Comparator|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days
3150625|NCT01544972|Active Comparator|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
3150626|NCT01544959|Active Comparator|fentanyl|
3150627|NCT01544959|Experimental|beta-blocker|Instead of narcotics (fentanyl), esmolol and lopressor are being used for hemodynamic control
3150628|NCT01544946|Experimental|sucrose po|
3150629|NCT01544946|Placebo Comparator|placebo po|
3150630|NCT01544933||burst fractures in vertebrae with true ribs|between T1 and T10
3150631|NCT01544933||burst fractures in vertebrae with floating ribs|between T11 and T12
3150632|NCT01544920|Active Comparator|Arm 1: peg-IFN + RBV|Participants received an initial 4 week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, participants with undetectable HCV RNA received open label peg-IFN + RBV for an additional 18 weeks (total of 24 weeks of peg-IFN/RBV therapy) [Arm 1a]. Participants with detectable HCV RNA at Week 4 had BOC added to the peg-IFN + RBV regimen at Week 6 and then followed the Response Guided Therapy (RGT) regimen for BOC + peg-IFN + RBV [Arm 1b].
3150633|NCT01544920|Experimental|Arm 2: BOC + peg-IFN + RBV|Participants received an initial 4-week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, all participants had BOC added to the peg-IFN + RBV regimen at Week 6 regardless of HCV RNA levels. Participants who had undetectable HCV RNA at Week 4 continued on the BOC + peg-IFN + RBV regimen for an additional 20 weeks (total of 24 weeks of BOC + peg-IFN + RBV therapy) [Arm 2a]. Participants with detectable HCV RNA at Week 4 followed the RGT regimen for BOC + peg-IFN + RBV [Arm 2b].
3150634|NCT01544907|Active Comparator|Conventional PTA only|"Treatment Arm 1- Conventional PTA only~The conventional balloon is used and the diameter of the balloon should be the same or oversized by 1mm the diameter of the reference vessel.~An inflation device with a pressure gauge is used to inflate up to manufacturers' stated burst pressure. The duration of balloon inflation will be 2 minutes.~At the end of the first angioplasty, an AVFistulogram/AVGraftogram will be obtained to document results. If there is residual stenosis of >30%, a repeat angioplasty using the same balloon or another appropriately oversized balloon by 1mm will be used for an additional 2 minutes. A final angiogram will be obtained for documentation."
3150635|NCT01544907|Experimental|Drug Eluting Balloon (DEB)|"Treatment arm 2 - Conventional Balloon with DEB~A Conventional balloon is used to pre-dilate the target lesion. The DEB of a similar diameter to the conventional balloon used is then inflated across the stenosis. An inflation device with a pressure gauge is used to inflate up to manufacturers' stated burst pressure. The duration of balloon inflation will be 1 minute. A final angiogram will be obtained for documentation. The drug coated on the DEB is Paclitaxel."
3150636|NCT01544894|Active Comparator|raloxifene|60 mg/d for one year.
3150637|NCT01544894|Active Comparator|strontium ranelate|2 g/d for one year.
3150638|NCT01544881|Experimental|TI Inhalation Powder|Technosphere Insulin Inhalation Powder using the Gen2C inhaler
3150639|NCT01544881|Active Comparator|RAA|Rapid Acting Analog
3150640|NCT01544868|Other|Energy expenditure measurement|Descriptive measurements
3150641|NCT01544855|Experimental|APOE4 carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
3150642|NCT01544842|Active Comparator|Tacrolimus|Tacrolimus ointment 0.1%, three times a day for 6-9 weeks.
3150643|NCT01544842|Active Comparator|Triamcinolone|Triamcinolone paste 0.1%, three times a day for 3-6 weeks.
3150644|NCT01544842|Placebo Comparator|Placebo|Orabase paste, three times a day for 3-6 weeks.
3150645|NCT01544829|Active Comparator|Active Comparator: Single serving of theobromine|
3150646|NCT01544829|Active Comparator|Multiple servings of theobromine|
3150647|NCT01544829|Placebo Comparator|Placebo capsules|
3150648|NCT01544816|Placebo Comparator|Control Food Product|Control food product
3150649|NCT01544816|Experimental|Experimental Food Product 1|Experimental food product 1
3150650|NCT01544816|Experimental|Experimental Food Product 2|Experimental food product 2
3150651|NCT01544803|No Intervention|Control group|
3150652|NCT01544803|Experimental|Web based self-monitoring|
3150653|NCT01544803|Active Comparator|Web based self-help|
3150654|NCT01544790|Experimental|Robot-assisted esophagectomy|Robot-assisted thoraco-laparoscopic esophagectomy with gastric conduit formation.
3150655|NCT01544790|Active Comparator|Open transthoracic esophagectomy|traditional open transthoracic esophagectomy with gastric conduit formation.
3150656|NCT01544777|Experimental|Both Eyes|Model 751 IOL implanted in both eyes.
3150657|NCT01544777|Experimental|Single eye|Model 751 IOL in one eye
3150658|NCT01544777|Active Comparator|Control|Aphakia treatment by negatively aspheric IOL implant, Hoya iSert model 251 or equivalent
3150660|NCT01544764|Experimental|AFIX In-Person Visit|"This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. These practices received an in-person AFIX visit from a North Carolina Immunization Branch employee.~Intervention:~Other: Assessment , Feedback, Incentives, and eXchange Program"
3150661|NCT01544764|Experimental|AFIX Webinar Visit|"This arm includes 31 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. These practices received a webinar during which a North Carolina Immunization Branch employee completed the components of an AFIX visit.~Intervention:~Other: Assessment , Feedback, Incentives, and eXchange Program"
3150662|NCT01544751|Active Comparator|Low dose Metformin|500 mg twice a day for one year
3150663|NCT01544751|Active Comparator|Metformin|1000 mg twice a day for one year
3150664|NCT01544751|Active Comparator|Atorvastatin|20 mg day
3150665|NCT01544738|Experimental|Aponeurotic stimulation group|The stimulation consisted of manipulating, with a hook (the diacutaneous fibrolysis method), the aponeurotic tissues enrobing the heads of the trunk and upper limb muscles.
3150666|NCT01544738|Active Comparator|Placebo stimulation group|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the Aponeurotic stimulation group.
3150667|NCT01544725|Experimental|Ketamine-propofol|
3150668|NCT01544725|Active Comparator|Ketamine alone|
3150669|NCT01544712|Active Comparator|Control|Core decompression
3150670|NCT01544712|Experimental|Bone marrow|core decompression plus autologous concentrated bone marrow
3150671|NCT01544699|Active Comparator|Real stimulation|real tDCS
3150672|NCT01544699|Sham Comparator|Sham|sham tDCS
3150673|NCT01544686|Active Comparator|3M™ Tegaderm CHG IV|Patients receive the 3M Tegaderm CHG IV securement dressing after placement of a central venous catheter.
3150674|NCT01544686|Placebo Comparator|3M™ Tegaderm™ Advanced IV'|Patients receive the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
3150675|NCT01544673|Active Comparator|Arm A|
3150676|NCT01544673|Placebo Comparator|Arm B|
3150677|NCT01544660||Scanning|no treatment
3150678|NCT01544660||scanning|no treatment
3150679|NCT01544647|Active Comparator|Usual spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
3150680|NCT01544647|Active Comparator|Active spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
3150681|NCT01544634|Experimental|Propranolol + Low dose Qvar|
3150682|NCT01544634|Active Comparator|Placebo + high dose Qvar|
3150683|NCT01544621||Successful quitters Sustained smokers|Successful quitters
3150684|NCT01544608||Subjects who are hospitalized due to acute psychotic episode.|All subjects who are hospitalized due to acute psychotic episode. The subjects should be managed according to normal clinical practice until discharge time.
3150685|NCT01544595|Placebo Comparator|PASI 75 Responders|"PASI 75 responders will participate in randomized withdrawal. Subjects who were PASI 75 responders at Week 52 visit of the core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies will be randomized to continue same s.c. doses of secukinumab in PFS or receive placebo every 4 weeks up to Week 152 or until relapse. Randomization in each group will be 2:1. Participants on first full relapse will receive loading dose followed by routine dosing with secukinumab s.c. 150 mg or 300 mg regimen."
3150686|NCT01544595|Experimental|Partial responders|Partial responders are not randomized. Subjects who were partial responders at Week 52 visit in core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies do not participate in the randomized withdrawal. These subjects will continue same treatment s.c. dose in PFS (secukinumab s.c. 150 mg or 300 mg) as they were receiving at the time of completing the maintenance period (Week 52) in the core studies
3150687|NCT01544582||Boceprevir + PR|CHC genotype-1 participants included in study and prescribed boceprevir plus PR as routine clinical management.
3150688|NCT01544582||Telaprevir + PR|CHC genotype-1 participants included in study and prescribed telaprevir plus PR as routine clinical management.
3150689|NCT01544582||PR Alone|CHC genotype-1 participants included in study and prescribed PR alone as routine clinical management.
3150690|NCT01544556||Prineo|An open, prospective, controlled, randomized clinical Study
3150691|NCT01544556||Steristrips|An open, prospective, controlled, randomized clinical Study
3150692|NCT01544543||COPD Exacerbation Cohort|Patients hospitalized for a COPD exacerbation
3150693|NCT01544530|Experimental|Hypothermia (32-33 degree C)|Following randomization, hypothermia will be induced by a combination of cold isotonic fluid and sustained until organ procurement by a central venous catheter
3150694|NCT01544530|No Intervention|Normothermia (36.5 - 37.5 degree C)|Normothermia will be maintained until organ procurement as per current standard of care
3150695|NCT01544517|Experimental|5d-QCT|5-day eradication regimen consisting in the concomitant administration of esomeprazole 40mg bid + amoxicillin 1g bid + levofloxacin 500mg bid + tinidazole 500mg bid
3150696|NCT01544517|Active Comparator|10-day sequential regimen|5 days of esomeprazole 40mg bid + amoxicillin 40mg bid followed by 5 more days of esomeprazole 40mg bid + levofloxacin 500mg bid + tinidazole 500 mg bid
3150697|NCT01544504|Experimental|Norepinephrine|Topical norepinephrine
3150698|NCT01544491|Experimental|Investigational arm|Conversion from MMF to everolimus plus reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
3150699|NCT01544491|Active Comparator|Control arm|MMF continuation (in combination with tacrolimus and standard dose steroids)
3150700|NCT01544478|Experimental|V501|Participants received a 0.5-mL vaccination of V501 by intramuscular injection on Day 1, Month 2, and Month 6
3150701|NCT01544465|Experimental|Structured physical activity|Rehabilitation evaluation followed by physical therapy for approximately 8 weeks
3150702|NCT01544465|Active Comparator|Sleep hygiene education|Sleep hygiene education consists of educational materials on insomnia published by the American Academy of Sleep Medicine.
3150703|NCT01544452|Other|Total preoperative MR evaluation|Total diagnostic evaluation with MRI of the liver, abdomen, colonography and rectum in one session combined with CT thorax
3151342|NCT01539941|Experimental|Medication Integration Protocol|
3150704|NCT01544452|Other|Standard diagnostic evaluation|Standard preoperative diagnostic evaluation for patients with rectal cancer, incl. CT thorax, abdomen and MRI of the rectum and colonoscopy
3150705|NCT01544439|Experimental|Oral stabilization appliance,counselling|The reversible occlusal therapy by stabilizing appliance used by patients in Study Group shall be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. Patients receive oral and written instructions about self-care (counseling), including, in addition to instructions on their condition of TMD and an explanation of the possible factors that contribute to the etiology of the same.
3150706|NCT01544439|Placebo Comparator|Non-occluding splint, counselling|The non-occlusive splint (placebo) will also be made by the same dental technician. They differ by the plates did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. As not lead acrylic on the occlusal surfaces of teeth, adequate retention is given by an arch wire in orthodontic buccal surface of teeth. All patients will submitted a counseling approach / self-care. Patients receive oral and written instructions about self-care, including, in addition to instructions on their condition of TMD and an explanation of the possible factors that contribute to the etiology of the same.
3150707|NCT01544426|Experimental|Office hysteroscopy and endometrial snip|Office hysteroscopy and endometrial snip
3150708|NCT01544426|Active Comparator|Office hyteroscopy|Office hysteroscopy
3150709|NCT01544413|Experimental|Laparoscopic sentinel lymph node biopsy|This is a single armed study. After endoscopic marking using Tc99m HSA and indocyanine green fluid, Laparoscopic sentinel lymph node biopsy was performed and evalute at backtable.
3150710|NCT01544387|Other|Bed Rest|Subjects will have limited activity. Bed Rest
3150711|NCT01544387|Other|Activity|Activity
3150712|NCT01544374|Experimental|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
3150713|NCT01544374|No Intervention|Control- no intervention|Usual Care
3150714|NCT01544361|Placebo Comparator|Placebo|A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.
3150715|NCT01544361|Experimental|MEDI7814, 1 MG/KG|A single dose of MEDI7814, 1 milligram per kilogram (mg/kg) intravenous infusion over at least 60 minutes on Day 1.
3150716|NCT01544361|Experimental|MEDI7814, 3 MG/KG|A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.
3150717|NCT01544361|Experimental|MEDI7814, 10 MG/KG|A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.
3150718|NCT01544361|Experimental|MEDI7814, 20 MG/KG|A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.
3150719|NCT01544348|Placebo Comparator|Placebo|A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
3150720|NCT01544348|Active Comparator|Omalizumab|A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
3150721|NCT01544348|Experimental|MEDI4212 5 mg Subcutaneous|A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
3150722|NCT01544348|Experimental|MEDI4212 15 mg Subcutaneous|A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
3150723|NCT01544348|Experimental|MEDI4212 60 mg Subcutaneous|A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
3150724|NCT01544348|Experimental|MEDI4212 150 mg Subcutaneous|A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
3150725|NCT01544348|Experimental|MEDI4212 300 mg Subcutaneous|A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
3150726|NCT01544348|Experimental|MEDI4212 300 mg Intravenous|A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
3150727|NCT01544335||BIS|Subjects evaluated using Bioimpedance Spectroscopy
3150728|NCT01544309|Experimental|Atorvastatin administration group|
3150729|NCT01544309|Experimental|Rosuvastatin administration group|
3150730|NCT01544296|Experimental|KHK6188, high dose|
3150731|NCT01544296|Experimental|KHK6188, low dose|
3150732|NCT01544296|Placebo Comparator|Placebo|
3150733|NCT01544283|Experimental|Patch|Patch will be applied directly to the lateral tip of the affected shoulder, at the site of maximal tenderness. Subjects will apply a single patch at home approximately every 12 hours (e.g., morning and evening patch applications) for 14 days. Subjects will remove each patch after 4 hours. Subjects will have the option of applying the Synera patch as needed for an additional 2 week period (weeks 2-4) if they feel their shoulder impingement pain is severe enough to warrant treatment. Patches will be applied every 12 hours for up to 4 hours as needed during this period.
3150734|NCT01544283|Active Comparator|Subacromial Injection|A single injection will be administered into the subacromial space utilizing triamcinolone acetonide at the baseline visit.
3150735|NCT01544270|Active Comparator|Study product containing milk proteins|Yoghurt-like milk-based product
3150736|NCT01544270|Active Comparator|Study product containing probiotics|Yoghurt-like milk-based product
3150737|NCT01544270|Placebo Comparator|Control product|Yoghurt-like milk-based product without supplemented nutrients
3150738|NCT01544257|Experimental|OMT|patients under standard medical care plus OMT.
3150739|NCT01544257|No Intervention|Control|patients under standard medical care plus only osteopathic evaluation
3150740|NCT01544244|Experimental|GSC physcial therapy|Patients included in this arm of the study will follow the Global Shoulder Concept physical therapy sequence.
3150741|NCT01544244|Active Comparator|Standard|Patients in this arm of the study will follow the standard physical therapy sequence.
3150742|NCT01544231||Patients|Adult patients with suspected rhabdomyolysis admitted to the participating University Hospital emergency rooms (see inclusion/exclusion criteria).
3150743|NCT01544218||YCMC|Youth ages 9-18 with one of four chronic medical conditions - asthma, diabetes, rheumatic or gastroenterologic conditions
3150744|NCT01544205|Experimental|Emotion network up-regulation|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
3150925|NCT01542970|Experimental|Omega-3 fatty acids and placebo|Placebo for L. reuteri and active for omega-3 fatty acids
3150745|NCT01544205|Active Comparator|Place processing network up-regulation|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to place and house pictures (as identified during a functional localiser scan).
3150746|NCT01544192|Active Comparator|retinal nerve fiber thickness|
3150747|NCT01544192|Active Comparator|Mean Deviation|
3150748|NCT01544192|Active Comparator|Pattern Standard Deviation|
3150749|NCT01544192|Active Comparator|ganglion cell count|
3150750|NCT01544192|Active Comparator|c/d ratios|
3150751|NCT01544179|Experimental|Gefitinib|Gefitinib and cisplatin plus pemetrexed combination chemotherapy
3150752|NCT01544179|Placebo Comparator|Placebo|Placebo and cisplatin plus pemetrexed combination chemotherapy.
3150753|NCT01544166|Experimental|Overall study|
3150754|NCT01544153|Other|WEB only|Control group receiving no additional intervention
3150755|NCT01544153|Experimental|WEB+SN|WEB plus social network intervention.
3150756|NCT01544153|Experimental|WEB+NRT|WEB plus nicotine replacement therapy product.
3150757|NCT01544153|Experimental|WEB+SN+NRT|WEB plus social network intervention and nicotine replacement therapy product.
3150758|NCT01544140|Experimental|midazolam then midazolam + vandetanib|Midazolam alone followed by midazolam in combination with vandetanib
3150759|NCT01544127|Experimental|MI-SI 1|Motivational Interviewing to Address Suicidal Ideation (MI-SI)
3150760|NCT01544127|No Intervention|Arm 2|Treatment as Usual (TAU)
3150761|NCT01544127|Experimental|MI-SI 2|Motivational Interviewing to Address Suicidal Ideation (MI-SI)- Revised
3150762|NCT01544114|Experimental|VIMOVO|"Three VIMOVO strengths will be used in this study: 250 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 250/20), 375 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 375/20), and 500 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 500/20). The VIMOVO strength allocated to each participant will be determined by the participant's weight at baseline and based on investigator's discretion.~The target dose of the naproxen component will be within the range of 10-20 mg/kg/day divided twice daily (BID) with a maximum daily dose of 1000 mg."
3150763|NCT01544101|Experimental|Vegan Diet|
3150764|NCT01544101|Placebo Comparator|Supplement|
3150765|NCT01544088|Experimental|Arm 1|Group Cognitive Behavioral treatment (GCBT)
3150766|NCT01544088|Active Comparator|Arm 2|Present Centered Group Treatment
3150767|NCT01544075|Experimental|PNE+PI|The interventional group who will receive the experimental PNE+PI treatment.
3150768|NCT01544075|Active Comparator|NS|The control group who will receive the neck school treatment.
3150769|NCT01544062|Experimental|IV acetaminophen|Study subjects receiving IV acetaminophen
3150770|NCT01544062|Placebo Comparator|Normal saline|Study subjects receiving placebo
3150771|NCT01544049||Fallopian tube removal|Women who have had one or both fallopian tube(s) removed as method of ovarian cancer prevention.
3150772|NCT01544036|Experimental|Contrast Enhanced Ultrasound|Renal blood flow before and after exposure to iodinated contrast agent (perflutren) also known as Definity will be measured using contrast enhanced ultrasound (CEUS).
3150773|NCT01544023||Breast Reconstruction with TilOOP|
3150774|NCT01544010|No Intervention|assessment only control group|Assessment at baseline, 12, and 24 months
3150775|NCT01544010|Active Comparator|Minimal Stage Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Stage Tailored Feedback Reports based on assessments at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
3150776|NCT01544010|Active Comparator|Moderate TTM Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Moderate TTM-Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of stage of change, decisional balance and temptations at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
3150777|NCT01544010|Active Comparator|Full TTM tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Full TTM-Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of stage of change, decisional balance (pros + cons), temptations and (ten) processes of change at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
3150778|NCT01544010|Active Comparator|Enhanced TTM+Addiction Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Enhanced TTM+Addiction Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of addiction levels (# cigarettes/day) stage of change, decisional balance (pros + cons), temptations and (ten) processes of change at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
3150779|NCT01543997|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP)to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
3150780|NCT01543997|Active Comparator|Supportive Education|Supportive Education program will provide educational lectures on disability, sleep hygiene, and current research on depression and non-directive, supportive discussions about these topics.
3150781|NCT01543984|Experimental|Tailored Physical Activity|"Health guidance (1,5h) and Tailored Physical Activity (3*50 min/week in 10 weeks)"
3150782|NCT01543984|Other|Reference group|Health Counselling (1,5h)
3150783|NCT01543971|Active Comparator|TXA127|(Group A) TXA127 at 300 mcg/kg once a day for 5 days
3150784|NCT01543971|Active Comparator|Neupogen|(Group B) Neupogen 10 mcg/kg once a day for 5 days
3150785|NCT01543971|Active Comparator|TXA127 and Neupogen|(Group C) both TXA127 (300mcg/kg) and Neupogen (10mcg/kg) together once a day for 5 days
3150786|NCT01543958|Experimental|Sevelamer carbonate|Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
3150787|NCT01543945|Experimental|Multimodal antiemetic management group|Multimodal antiemetic group : Low risk :no PONV prophylaxis moderate risk : ondansetron 4 mg iv high risk : dexamethasone 4 mg + ondansetron 4 mg Extremely high risk : dexamethasone 4 mg + ondansetron 4 mg + dimenhydrinate 1 mg
3150788|NCT01543945|Active Comparator|Control group|Control group: Low and moderate risk : no PONV prophylaxis High risk : Ondansetron 4 mg. iv Extremely high risk : Ondansetron 4 mg .iv
3150789|NCT01543932|Experimental|Prasugrel standard dose|Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
3150790|NCT01543932|Experimental|high clopidogrel dose|Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 15 days and 30 days we will control the responsivness of the study drug.
3150791|NCT01543932|Experimental|Ticagrelor standard dose|Patient will be randomized to this intervention will receive in the first time ticagrelor and after 15 days and 30 days we will control the responsivness of the study drug.
3150792|NCT01543919|Experimental|PH-787904 (arm1)|
3150793|NCT01543919|Experimental|PH-787904 (arm2)|
3150794|NCT01543919|Experimental|PH-787904 (arm3)|
3150795|NCT01543919|Experimental|PH-787904 (arm4)|
3150796|NCT01543919|Experimental|PH-787904 (arm5)|
3150797|NCT01543919|Experimental|Placebo|
3150798|NCT01543906|Experimental|QLT091001|oral QLT091001 administered once daily for 7 days
3150799|NCT01543893|Experimental|Video instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
3150800|NCT01543893|Active Comparator|Personal instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
3150801|NCT01543880||Users of somatropin|
3150802|NCT01543867||Users of somatropin|
3150803|NCT01543854|Experimental|RLX030|RLX030 as intravenous infusion for 20 hours
3150804|NCT01543854|Placebo Comparator|Placebo|Matching placebo as intravenous infusion for 20 hours.
3150805|NCT01543841||Advanced Cancer|
3150806|NCT01543841||Healthy Volunteers|
3150807|NCT01543828|Experimental|indacaterol then placebo|In treatment 1: participants received indacaterol 75 µg one dose delivered via single-dose dry-powder inhaler (SDDPI) followed by treatment 2: placebo one dose via SDDPI between day 7 and 10. Albuterol was available for use as rescue medication.
3150808|NCT01543828|Placebo Comparator|placebo then indacaterol|In treatment 1, participants received placebo one dose delivered via SDDPI followed by treatment 2: indacaterol 75 µg one dose delivered via SDDPI between Day 7 and Day 10. Albuterol was available for use as rescue medication.
3150809|NCT01543815|Experimental|WBT-WEB|Well-Being Therapy based on Web Mobile technology
3150810|NCT01543815|Active Comparator|CBT|Cognitive Behavior Therapy
3150811|NCT01543815|No Intervention|CM|Standardized Care Management
3150812|NCT01543802|Experimental|Pazopanib|
3150813|NCT01543789|Experimental|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity
3150814|NCT01543789|Active Comparator|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
3150815|NCT01543776|Active Comparator|Arm I (fasting)|Patients receive abiraterone acetate PO daily first thing in morning after an overnight fast of at least 8 hours.
3150816|NCT01543776|Experimental|Arm II (fed)|Patients receive abiraterone acetate PO daily within 30 minutes of a conventional low-fat breakfast.
3150817|NCT01543763|Experimental|Panobinostat with PC124871|
3150818|NCT01543750|Experimental|Study Medication|4-aminopyridine 10mg twice daily for 8 weeks
3150819|NCT01543750|Experimental|Placebo|placebo twice daily for 8 weeks
3150820|NCT01543737|Active Comparator|Single injection hyaluronic acid|3ml hyaluronic acid (DUROLANE)
3150821|NCT01543737|Active Comparator|Three injection hyaluronic acid|2ml hyaluronic acid (HYALGAN)
3150822|NCT01543724|Experimental|Lithium|
3150823|NCT01543711||Breast cancer survivors|Women treated for breast cancer, without signs of recurrence or metastasis
3150824|NCT01543698|Experimental|dual combination|LGX818 QD and MEK162 BID
3150825|NCT01543698|Experimental|triple combination|LGX818 QD and MEK162 BID and LEE011 QD 3 weeks on, 1 week off.
3150826|NCT01543685|Experimental|Indomethacin 40 mg TID|
3150827|NCT01543685|Experimental|Indomethacin 40 mg BID|
3150828|NCT01543685|Experimental|Indomethacin 20 mg TID|
3150829|NCT01543685|Active Comparator|Celecoxib 200 mg|
3150830|NCT01543685|Placebo Comparator|Placebo|
3150831|NCT01543672|Experimental|SBRT group A|escalate MLD in medically inoperable patients with tumors larger than 5 cm in diameter (primary or solitary metastases)
3150832|NCT01543672|Experimental|SBRT group B|Escalate the MLD in patients with ≥ 2 lung metastases
3150833|NCT01543659|Experimental|89Zr-DFO-huJ591|Registered patients will undergo a baseline FDG PET scan up to 14 days before administration of a single dose of the 89Zr-DFO-huJ591 tracer, this scan is considered for research purposes. The exception to the 14-day timeframe is that patients who have already had an FDG PET scan up to 4 weeks prior to registration are not required to repeat the FDG PET scan on study.
3150834|NCT01543646||Liver Biopsy patients|All patients due to have a liver biopsy for the assessment of parenchymal liver disease.
3150835|NCT01543633|Experimental|Active Study Arm|Subjects recruited into this study will be required to undergo a base MRI scan of the brain. On a separate day propofol will be administered with concurrent EEG while subjects respond to stimuli.
3150836|NCT01543620||Patients with cystic fibrosis treated with aminoglycosides|
3150837|NCT01543620||Patients with cystic fibrosis not treated with aminoglycosides|
3150838|NCT01543607|Experimental|Treatment|Radiofrequency ablation catheter
3150839|NCT01543581|Active Comparator|Vismodegib|Oral vismodegib, 150mg per day for 12 weeks.
3150840|NCT01543581|Placebo Comparator|Inactive placebo|Those to whom the inactive placebo is given.
3150926|NCT01542970|Experimental|L. reuteri and omega-3 fatty acids|Active L. reuteri and active omega-3 fatty acids
3150984|NCT01542541|No Intervention|Control|Randomly-selected matched PET-CT scans performed on same day as intervention group.
3150841|NCT01543568|Other|2.0 mg intravitreal Aflibercept|open label, Subjects seen monthly & given mandatory 2.0 mg aflibercept at baseline, months 1, 2 and 4. Pro re nata (PRN) retreatment at months 3 and 5 was performed upon evidence of disease on spectral domain-optical coherence tomography (SD-OCT)
3150842|NCT01543555|Experimental|Atorvastatin active|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
3150843|NCT01543555|Placebo Comparator|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
3150844|NCT01543542|Other|Radiation Therapy Treatment|Whole Brain XRT 30Gy/10 fractions with Simultaneous Infield Boost of Brain Lesions to 60Gy
3150845|NCT01543529|Active Comparator|RO4917838 + non-alcoholic drink|
3150846|NCT01543529|Experimental|RO4917838 + alcohol|
3150847|NCT01543529|Placebo Comparator|RO4917838 placebo + alcohol|
3150848|NCT01543529|Placebo Comparator|RO4917838 placebo + non-alcoholic drink|
3150849|NCT01543516||Patients with Asthma|"Affected patients~-20 Patients suffering from asthma with an eNO over 30 bbp"
3150850|NCT01543516||Healthy Subjects|"Non-affected patients~-20 matched controls not suffering from asthma"
3150851|NCT01543503||Cohort|
3150852|NCT01543490|Experimental|ISV-305|
3150853|NCT01543490|Placebo Comparator|Vehicle|
3150854|NCT01543477||Single group|
3150855|NCT01543464|Experimental|Vaccine+adjuvants+temozolomide treatment|Experimental arm
3150856|NCT01543451|Experimental|Elsiglutide|
3150857|NCT01543451|Placebo Comparator|Placebo|
3150858|NCT01543438|No Intervention|Control|current standard of care
3150859|NCT01543438|Experimental|Intervention Group|receives video prescription
3150860|NCT01543412|Experimental|FOLFIRI|Folfiri consist of Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1and 2, 5-FU 400 mg/m2 iv bolus on day 1and 2, 5-FU 600 mg/m2 iv by ci for 22 hours on day 1 and 2, repeated every 2 wks The use of antiemetic prophylaxis was decided locally.
3150861|NCT01543399|Experimental|Tibolone use|climacteric women will use Tibolone for 30 days
3150862|NCT01543399|Placebo Comparator|Placebo use|climacteric women will use placebo for 30 days
3150863|NCT01543386|Other|curcumin|The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
3150864|NCT01543373|Experimental|CRE8 arm|
3150865|NCT01543373|Active Comparator|Vision/Multilik8 arm|
3150866|NCT01543360|Active Comparator|Axillary strategy|The first two attempts at central venous catheterization will be performed via the distal approach (axillary vein). The third and fourth attempts at central venous catheterization will be performed by the medial approach (subclavian vein).
3150867|NCT01543360|Active Comparator|Subclavian strategy|The first two attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The third and fourth attempts at central venous catheterization will be performed by the distal approach (axillary vein).
3150868|NCT01543347|Experimental|Temocillin|Treatment group
3150869|NCT01543334||Patients|Patients with a vein or artery catheter and who are being administered antibiotics. The latter can be of the following: Amoxicillin-clavulanic acid, ampicillin, piperacillin-tazobactam, penicillin G, flucloxacillin, dicloxacillin, cloxacillin, cefazolin, ceftazidime, ceftriaxone, cefepime, meropenem, imipenem, doripenem, ertapenem; Vancomycin, teicoplanin. (see inclusion/exclusion criteria).
3150870|NCT01543321|Experimental|Tetrabenazine group|Tetrabenazine is a drug that is administered orally. This is 25 mg tablets, divisible into 2.
3150871|NCT01543321|Placebo Comparator|Plagebo group|Patients will receive a buccal tablet identical to the experimental product
3150872|NCT01543308||coronary heart disease|
3150873|NCT01543308||healthy control group|
3150874|NCT01543295||Known Positive Syphilis Infection|Individuals known to have a clinical diagnosis of Syphilis
3150875|NCT01543295||High Risk for Syphilis Infection|Individuals with previous and confirmed STD infection, MSM, persons with high risk sexual behavior or clinical examination with classic manifestations of syphilis.
3150876|NCT01543295||Pregnant Women (High Risk and Low Risk)|"1st or 3rd trimester from either High Risk (see description above) or Low Risk population.~Low Risk are individuals not known to belong to any of the defined high-risk groups - i.e. healthy patients presenting for routine physicals or other unrelated non-life threatening illnesses, or individuals from a general low risk population such as students, employees of academic or other institutions, etc…"
3150877|NCT01543282|Active Comparator|EUS 22 gauge needle|EUS 22 g needle is the most common needle used in clinical practice. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
3150878|NCT01543282|Experimental|EUS 25 gauge needle|25 gauge needle is usually used less frequently but nowadays is increasingly used and is as well a valid option. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
3150879|NCT01543269|Active Comparator|ZYT1 tablets|ZYT1 tablets: Route of administration: Oral Dosage: 0.5mg, 1mg, 2 mg, 4mg, 8 mg, 16mg, 32mg and 64mg
3150880|NCT01543269|Placebo Comparator|Placebo|Placebo tablets: Route of administration: Oral Dosage: 0.5mg, 1mg, 2 mg, 4mg, 8 mg, 16mg, 32mg and 64mg
3150881|NCT01543256|Active Comparator|Metal stents|The WallFlex Biliary Fully Covered Stent System is being evaluated for treatment of benign biliary strictures secondary to chronic pancreatitis.
3150882|NCT01543256|Active Comparator|Plastic Stents|Plastic stents per Investigator preference are being evaluated for treatment of benign biliary strictures secondary to chronic pancreatitis.
3150927|NCT01542957|Experimental|Cognitive Behavioral + Dilemma Therapy|Combines Group Cognitive Behavioral Therapy with a Individual Dilemma-Focused Intervention
3150928|NCT01542957|Active Comparator|Cognitive Behavioral Therapy|Combined Group and Individual Cognitive Behavioral Therapy
3150883|NCT01543243|Experimental|Group 1|"Group 1: immediate effects: T0, Stochastic resonance whole-body vibration A intervention, immediate T1 (one minute after Stochastic resonance whole-body vibration B intervention), 7 days wash-out period; T2, Stochastic resonance whole-body vibration intervention, immediate T3 (one minute after Stochastic resonance whole-body vibration intervention)~long term effect: T4, Stochastic resonance whole-body vibration A intervention over four weeks, three time a week;T5, 16 days wash-out period; T6, Stochastic resonance whole-body vibration B intervention over four weeks, three times week, T7"
3150884|NCT01543243|Experimental|Group 2|"Group 2: immediate effect: T0, Stochastic resonance whole-body vibration B intervention, immediate T1 (one minute after intervention), 7 days wash-out period; T2, Stochastic resonance whole-body vibration A intervention, immediate T3 (one minute after intervention)~Long term effect: T4, Stochastic resonance whole-body vibration B intervention over four weeks, three time a week;T5, 16 days wash-out period;T6, Stochastic resonance whole-body vibration A intervention over four weeks, three times week, T7"
3150885|NCT01543230|Experimental|CoMplete™ Acetabular Hip System (CoM)|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
3150886|NCT01543217|Active Comparator|Control|Ususal care.
3150887|NCT01543217|Active Comparator|Intervention|Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.
3150888|NCT01543204|Experimental|Etanercept 50 mg|Participants received etanercept 50 mg, twice weekly (BIW), subcutaneously (SC) for 12 weeks followed by 50 mg, once weekly (QW), SC for an additional 12 weeks.
3150889|NCT01543191|Experimental|PUR118|
3150890|NCT01543191|Placebo Comparator|Placebo|
3150891|NCT01543178|Experimental|Rifaximin open-label|"Subjects will receive open-label rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up. Responders will continue into Maintenance Phase 1 (treatment free). Nonresponders will withdraw from the study.~Subjects who meet criteria for recurrence in Maintenance Phase 1 enter the double-blind period and are randomized 1:1 to receive rifaximin 550 mg or placebo."
3150892|NCT01543178|Experimental|Double-blind rifaximin (retreatment)|Subjects in this arm receive rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks [treatment free]) followed by a second retreatment with rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up.
3150893|NCT01543178|Placebo Comparator|Double-blind placebo (retreatment)|Subjects in this arm receive placebo TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks [treatment free]) followed by a second retreatment with placebo TID for 2 weeks with a 4-week treatment-free follow-up.
3150894|NCT01543165|Experimental|Group 1|Sequential intravenous administration of ketorolac and nefopam
3150895|NCT01543165|Active Comparator|Group 2|Sequential intravenous administration of ketorolac and morphine
3150896|NCT01543165|Placebo Comparator|Group 3|Intravenous administration of ketorolac
3150897|NCT01543152|Experimental|Cohort 1 - IV cyclophosphamide 200 mg|
3150898|NCT01543152|Experimental|Cohort 2 - IV cyclophosphamide 0.5 g/m2|
3150899|NCT01543152|Experimental|Cohort 3 - IV cyclophosphamide 1.0 g/m2|
3150900|NCT01543152|Experimental|Cohort 4 - IV cyclophosphamide 2.0 g/m2|
3150901|NCT01543152|Experimental|Cohort 5 - IV cyclophosphamide 1.5 g/m2|
3150902|NCT01543139|Experimental|Valproate+Cytidine-+Creatine-|The subjects with bipolar depression, treated with cytidine- and creatine-containing drug and dietary supplement in addition to valproate
3150903|NCT01543139|Active Comparator|Valproate+Cytidine-|The subjects with bipolar depression, treated with cytidine-containing drug and dietary supplement in addition to valproate
3150904|NCT01543139|Active Comparator|Valproate|The subjects with bipolar depression, treated with valproate
3150905|NCT01543126||pleural effusion|patients with pleural effusion
3150906|NCT01543113|Other|melanoma|melanoma
3150907|NCT01543100|Experimental|monoclonal gamopathy|"Patients with monoclonal gammopathy either MGUS or myeloma at diagnosis or more than 3 months after a first myeloma treatment with chemotherapy and/or antiangiogenic drugs.~Patient's age ≥18 yo,~Patients having signed the specific consent of the study."
3150908|NCT01543087|Other|One group of subjects|
3150909|NCT01543074|Placebo Comparator|BSE placebo & garlic oil placebo|Two BSE placebo capsules and one garlic oil placebo capsule per day for seven days
3150910|NCT01543074|Active Comparator|garlic oil plus BSE placebo|one garlic oil capsule plus 2 BSE placebo capsules per day for seven days
3150911|NCT01543074|Active Comparator|BSE plus garlic oil placebo|two BSE capsules plus one garlic oil placebo capsule per day for seven days
3150912|NCT01543074|Active Comparator|BSE & Garlic Oil|two BSE and one garlic oil capsule per day for seven days
3150913|NCT01543061|Active Comparator|New study eye drop|One month of contact lens wear with use of the Test study eye drops
3150914|NCT01543061|Placebo Comparator|No Eyedrop|One month of contact lens wear with no eye drop use
3150915|NCT01543061|Active Comparator|BLINK Contacts Lubricating eye drop|One month of contact lens wear with use of the Control study eye drops
3150916|NCT01543048||Women with CIN3 treated by conization|
3150917|NCT01543035|Experimental|Etravirine switch|Patients in need of lipid-lowering drug switched from boosted PI or EFV to Etravirine
3150918|NCT01543022|Experimental|Symphony system|
3150919|NCT01543009|No Intervention|Emla + no additional intervention|Children in this arm will receive standard preparation of the venipuncture site (local analgesia with Emla) without warming
3150920|NCT01543009|Experimental|Emla + Local Warming|Children in this arm will receive standard preparation of the venipuncture site (local analgesia with Emla) plus warming with a heating pad at 40°C for 5 minutes
3150921|NCT01542983|Active Comparator|Treatment-as-usual|Treatment as usual for fatigue and insomnia
3150922|NCT01542983|Active Comparator|Behavioral treatment|Brief behavioral treatment for insomnia and bright light Light and BBTI combined treatment for insomnia and fatigue
3150923|NCT01542970|Placebo Comparator|Placebo|Placebo for both L. reuteri and omega-3 fatty acids.
3150931|NCT01542931|Experimental|TPF induction chemotherapy|Induction chemotherapy before surgery: docetaxel, cisplatin, and 5-fluorouracil.
3150932|NCT01542918|Experimental|Study intervention|Lenalidomide Plus Rituximab
3150933|NCT01542905|Experimental|Korean Red Ginseng|
3150934|NCT01542905|Placebo Comparator|Placebo|
3150935|NCT01542892|Experimental|Supplement|
3150936|NCT01542892|Sham Comparator|Placebo|
3150937|NCT01542892|Experimental|Exercise|
3150938|NCT01542879|Experimental|WB-DW-MR scan|simultaneous WB-DW-MR scan and 18F FDG PET scan
3150939|NCT01542866|Experimental|Home Monitoring Test|Health management tool (HMT) for measuring vision impairment
3150940|NCT01542827|Placebo Comparator|Placebo|Topical gel containing a menthol scent, but no active menthol
3150941|NCT01542827|Experimental|Biofreeze|Biofreeze topical gel containing 3.5% menthol
3150942|NCT01542814||Fujifilm 3Dimensional Mammography|Group of subjects being given Fujifilm 3D Mammography Imaging
3150943|NCT01542814||2D FFDM|Group of Subjects receiving FujiFilm or other FDA Approved 2D Mammography Imaging
3150944|NCT01542801|Active Comparator|Norfloxacin|norfloxacin 400 mg once daily administration
3150945|NCT01542801|Experimental|Ciprofloxacin|Ciprofloxacin 750 mg per week
3150946|NCT01542788|Experimental|SOF+RBV|Participants were randomized to receive SOF+RBV for 12 weeks.
3150947|NCT01542788|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match SOF plus placebo to match RBV for 12 weeks.
3150948|NCT01542775|Placebo Comparator|Control|
3150949|NCT01542775|Active Comparator|Exercise|
3150950|NCT01542762|Experimental|LMWH|750 patients with lower leg cast immobilization will be randomized tot receive treatment with a LMWH.
3150951|NCT01542762|No Intervention|No intervention|750 patients with lower leg cast immobilization will be randomized tot receive no treatment with LMWH.
3150952|NCT01542736|Experimental|Reduced radiation with concurrent chemotherapy|Reduced dose craniospinal radiation with concurrent carboplatin and vincristine administration
3150953|NCT01542723|Experimental|LMWH|750 patients with an arthroscopy or the knee will be randomized to receive treatment with a LMWH
3150954|NCT01542723|No Intervention|No intervention|750 patients with an arthroscopy of the knee will be randomized to receive no treatment.
3150955|NCT01542710|Experimental|Glaucoma fixed Combination Medications|
3150956|NCT01542697|Active Comparator|Magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline at the end of surgery before closure
3150957|NCT01542697|Placebo Comparator|normal saline|intraperitoneal nebulisation of 5 ml of normal saline after end of surgery before closure
3150958|NCT01542684|Experimental|Azacytidine + GM-CSF|"Azacytidine administered intravenously (IV) or subcutaneously (SQ) at starting dose of 40 mg/m^2, daily for 4 days.~GM-CSF administered IV or subcutaneously at 250 mcg/m^2 one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.~Each treatment cycle will last at least 4 weeks"
3150959|NCT01542671|Experimental|Intervention|Lifestyle counseling at baseline, six, twelve months; Food and exercise log recording and feedback, motivational phone calls monthly for 12 months, 4 tailored mailings on lifestyle change, and weekly mailings on weight loss, exercise, and healthy eating for first 12 months. Maintenance mailings biweekly for six months and then monthly during the second year.
3150960|NCT01542671|Placebo Comparator|Control|Lifestyle counseling at baseline, six and twelve months similar to intervention group, and infrequent non-tailored pamphlets.
3150961|NCT01542658||uterine myoma|
3150962|NCT01542645|Experimental|Methadone|Long-acting opioid
3150963|NCT01542645|Active Comparator|Fentanyl|Shorter-acting opioid
3150964|NCT01542632|Experimental|Group 1|Takeda's Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and placebo, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.
3150965|NCT01542632|Experimental|Group 2|TDV, 0.5 mL, subcutaneous injection in one arm and TDV 0.5 mL, subcutaneous injection in the other arm on Day 0. Placebo, 0.5 mL, subcutaneous injection on Day 90.
3150966|NCT01542632|Experimental|Group 3|TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.
3150967|NCT01542632|Experimental|Group 4|TDV new formulation, 0.5 mL, subcutaneous injection in one arm and new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.
3150968|NCT01542632|Experimental|Group 5|TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.
3150969|NCT01542632|Experimental|Group 6|1/10 TDV, 0.5 mL, subcutaneous injection on Days 1 and 90.
3150970|NCT01542619|Experimental|rVIIa-FP|
3150971|NCT01542619|Placebo Comparator|Placebo (0.9% normal saline)|
3150972|NCT01542606|Experimental|color status|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
3150973|NCT01542593|Experimental|Ureteral catheterization|"During a planned procedure involving ureteroscopy or ureteral stenting, ureteral catheterization will be performed for the purpose of measuring exact ureteral length.~Measurement results will be compared to measurements performed on CT scan (obtained before surgery)."
3150974|NCT01542580||Vanguard SSK 360 with PS Bearing|Patients enrolled using a Vanguard SSK 360 Posterior-Stabilized (non-constrained) tibial bearing.
3150975|NCT01542580||Vanguard SSK 360 with PSC Bearing|Patients enrolled using a Vanguard SSK 360 Posterior-Stabilized Constrained tibial bearing.
3150976|NCT01542580||Vanguard DA 360|Patients enrolled using a Vanguard DA 360 component.
3150977|NCT01542580||Vanguard 360 TiNbN Femur with PS Bearing|The Vanguard 360 TiNbN is the same system and functions in the same manner as the non-coated device.
3150978|NCT01542580||Vanguard 360 TiNbN Femur with PSC Bearing|The Vanguard 360 TiNbN is the same system and functions in the same manner as the non-coated device.
3150979|NCT01542567|Active Comparator|diclofenac|suppositories to prevent BCG side effects
3150980|NCT01542567|Placebo Comparator|placebo suppositories|
3150981|NCT01542554|Experimental|Low glycaemic index diet|
3150985|NCT01542528|Experimental|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
3150986|NCT01542528|No Intervention|Treatment as Usual (TAU)|Whatever care arrangement the parents have arranged for their child during the same two hour period over the same 15 week period.
3150987|NCT01542515||Osteoarthritis of the carpometacarpal joint of the thumb|The group of patients enrolled in this study all have the diagnosis of carpometacarpal arthritis of the thumb. The patients did not respond favorably to non-operative management including oral anti-inflammatory medications, corticosteroid injections, and thumb splinting. Operative management was therefore recommended using the technique of meniscal allograft arthroplasty.
3150988|NCT01542502|Experimental|Anakinra|Treatment with daily subcutaneous injections of Anakinra 100 mg
3150989|NCT01542502|Placebo Comparator|Placebo|Treatment with daily subcutaneous injection of placebo
3150990|NCT01542489||IDet + IAsp users|
3150991|NCT01542489||IDet + HI users|
3150992|NCT01542476||IDet users|
3150993|NCT01542463||IDet users|
3150994|NCT01542450|Experimental|Treatment period 1|
3150995|NCT01542450|Active Comparator|Treatment period 2|
3150996|NCT01542437|Experimental|BIBW 2992|Patients received a daily oral 40mg dose of afatinib. Treatment was continued until docu-mented disease progression, unacceptable toxicity or withdrawal of consent. The Common Terminology Criteria for Adverse Events (CTCAE) v4.0 was used to evaluate toxicity. In patients with severe toxicity (grade ≥3) afatinib was temporary discontinued until the patient recovery to at least grade 1 toxicity and continued with a dose reduction to 30 mg/day. Dose reduction below 30mg/day was not allowed. Patients experiencing more than one grade ≥3 event, those with grade ≥2 toxicity after dose reduction, and/or those showing no recovery within 14 days discontinued treatment.
3150997|NCT01542424||BIAsp 30 users|
3150998|NCT01542424||IDet users|
3150999|NCT01542411||recurrent pregnancy loss|
3151000|NCT01542411||thrombophilia, aspirin|
3151001|NCT01542411||heparin|
3151002|NCT01542398|Experimental|Family-Focused Psychosocial Intervention|Intervention Group
3151003|NCT01542398|No Intervention|Waiting List Control|
3151004|NCT01542385|Active Comparator|Immediate stenting|the stent selection (bare metal vs drug eluting) and implantation will be performed as recommended by current practice guidelines.
3151005|NCT01542385|Experimental|Delayed stenting|participants randomised to delayed stenting will be treated with GPIIb-IIIa inhibitors for 12-18 hours after reperfusion followed by anticoagulation for until the control angiogram, expected no sooner than 18-24 hours after the index reperfusion.
3151006|NCT01542372|Active Comparator|Medication augmentation|In one arm, the patients will be given a medication augmentation for SSRI/SSRN-resistant PTSD
3151007|NCT01542372|Active Comparator|CBT augmentation|In this arm, patients will receive CBT to treat SSRI/SSRN-resistant PTSD.
3151008|NCT01542359|Experimental|Yoga|"The integrated yoga program was designed to: 1) include the three primary elements of yoga as most commonly practiced in western cultures (physical postures, breath control and meditation); and 2) be appropriate for those without any prior yoga experience and with pre- and Stage I hypertension. The yoga program was designed by Eddie Stern, Founder and Director of Ashtanga Yoga New York (AYNY) in consultation with Drs. Hagins and Rundle, and are in large part congruent with the yoga program we studied previously (see Preliminary Studies). The yoga class includes: instruction on yogic principles regarding moral precepts (yamas and niyamas); active postures requiring mild-moderate physical exertion; conscious control of the breath in synchrony with active postures; and meditation. We expect approximately 10-15 minutes of the integrated yoga program to consist of isolated practice of meditation (occurring independently of the moving postures, typically in seated or lying positions)."
3151009|NCT01542359|Active Comparator|Conventional Exercise|Conventional exercise such as standing toe touch with arm swings, curl ups, push ups, leg lifts, etc. All done at a relatively slow rate which will be non-aerobic and at an average rate across the session of 3 METs
3151010|NCT01542346|Experimental|wound closure with subcutaneous adaption|
3151011|NCT01542320|Experimental|Probiotic|Lactobacillus reuteri DSM 17938
3151012|NCT01542320|Placebo Comparator|Placebo|Solution without the active probiotic Lactobacillus reuteri
3151013|NCT01542307|Experimental|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
3151014|NCT01542307|Placebo Comparator|Room Air|Medical air inhaled for 30 minutes during migraine attack
3151015|NCT01542294|Experimental|treatment|s1+oxaliplatin
3151016|NCT01542281|Experimental|Nutritional supplementation and prehab|The first group (pre-hab) will receive both nutritional supplementation and a prehabilitation program.
3151017|NCT01542281|Active Comparator|Prehab exercise|
3151018|NCT01542268|Active Comparator|pentoxifylline|
3151019|NCT01542268|Placebo Comparator|pentoxifylline placebo|
3151020|NCT01542255|Experimental|Combined Low Dose Treatment|"A cycle of therapy is 3 weeks of continuous dosing with a 1 week rest.~Schema of treatment is:~1 mg/m2 vinblastine three times a week iv 60 mg/m2 cyclophosphamide by mouth 15 mg/m2 dacarbazine three times a week iv"
3151021|NCT01542242|Experimental|Liraglutide|Treatment of Diabetes Mellitus Type 2 with Liraglutide in the setting of Prader Willi Syndrome
3151022|NCT01542229|Experimental|Arm 1: PE + TAU|Prolonged Exposure Therapy +Treatment As Usual
3151023|NCT01542229|Active Comparator|Arm 2: Usual Treament|Treatment As Usual
3151024|NCT01542216|Placebo Comparator|Yoga and Stretching Group|Patients undergo yoga and stretching exercises
3151025|NCT01542216|Active Comparator|Nutrition and Exercise Group|Patients are provided with nutrition, cardiovascular exercise and strength exercise consultations
3151026|NCT01542203||Breast Cancer, Various BMIs|18 female breast cancer patients who are normal weight (body mass index [BMI] < 25 kg/m2, overweight or class I obese(BMI 25-34.9 kg/m2), or class II-III obese (BMI > 35 kg/m2).
3151027|NCT01542190|Active Comparator|ketorolac tromethamine|
3151028|NCT01542190|Placebo Comparator|Dextrano 70 / Hypromellose|
3151029|NCT01542177||Pancreatic cancer|
3151030|NCT01542151|Active Comparator|Morning|Women randomized to a labor induction in the morning between 0600 and 1000.
3151031|NCT01542151|Experimental|Evening|Women randomized to a labor induction begun in the evening between 1700-2100
3151032|NCT01542138|Active Comparator|Niacinamide|4% niacinamide cream that will be randomly applied on axillar hyperpigmentation once-a-day for 9 weeks.
3151033|NCT01542138|Active Comparator|Desonide|Once-a-day application of 0.05% desonide cream on axillar hyperpigmentation
3151034|NCT01542138|Placebo Comparator|Placebo|Humectant placebo cream
3151035|NCT01542125|Experimental|Liposomal Lidocaine group|Patients in this groups received 4% Liposomal Lidocaine that was applied to the area immediately surrounding the pin site(s) and was covered with an opaque Tegaderm dressing
3151036|NCT01542125|Placebo Comparator|Placebo Group|This group received a placebo that was applied to the area immediately surrounding the pin site(s) and was covered with an opaque Tegaderm dressing.
3151037|NCT01542112|Experimental|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
3151038|NCT01542112|Experimental|No treament|Usual routine in the department
3151039|NCT01542099|Active Comparator|Single lumen tube|Single lumen tube intubation during remifentanil infusion
3151040|NCT01542099|Active Comparator|Double lumen tube|Double lumen tube intubation during remifentanil infusion
3151041|NCT01542086|Active Comparator|Myocardial SPECT|
3151042|NCT01542086|Experimental|64-channel coronary CT angiography (CCTA)|
3151043|NCT01542073|Experimental|68Ga-BNOTA-PRGD2 cardiac PET/CT scanning|We will perform 68Ga-BNOTA-PRGD2 cardiac PET/CT scanning on myocardial infarction patients to determine its value.
3151044|NCT01542060||BIAsp 30 users|
3151045|NCT01542047|Experimental|Carboplatin AUC5 + escalating pazopanib|Carboplatin AUC5 IV Day 1 Pazopanib in escalating dosages, 200 mg to 800 mg starting on days 2 or 3 and ending on days 19 or 21
3151046|NCT01542034|Experimental|Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3151047|NCT01542034|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3151048|NCT01542021|Experimental|Untreated patients degarelix injection occur at days 4± 1|Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy
3151049|NCT01542021|Experimental|Untreated patients degarelix injection occur at days and 7± 1.|Treatment will consist of a single 240 mg injection of degarelix 7±1 day before radical prostatectomy
3151050|NCT01542021|Experimental|treated patients with androgen deprivation|Patients already treated with androgen deprivation are assigned to Cohort 3 and maintained on current androgen deprivation therapy until they undergo or have already undergone RP at MSKCC. Will include patients who have already undergone hormonal therapy (of any duration between 1 and 6 months) prior to prostatectomy.
3151051|NCT01542021|Experimental|Untreated patients degarelix injection occur at days 14±1|Treatment will consist of a single 240 mg injection of degarelix 14±1 day before radical prostatectomy
3151052|NCT01542008|Experimental|Customized Adherence Enhancement (CAE)|This arm will receive the CAE intervention.
3151053|NCT01542008|Active Comparator|broad non-individualized education (EDU)|This arm will receive the EDU intervention.
3151054|NCT01541995||virtual and classic autopsy|Patients where contrast medium enhanced post mortem CT and classic autopsy will be performed.
3151055|NCT01541995||virtual autopsy only|Patients where only contrast medium enhanced post mortem CT will be performed.
3151056|NCT01541982||virtual and classic autopsy|"Goldstandard: A group of patients in which virtual and classic autopsy is performed."
3151057|NCT01541982||virtual autopsy only|"Intervention: A group of patients in which for various reasons virtual autopsy only is performed."
3151058|NCT01541969|Experimental|CR Neuromodulation|Adaptive NeuroModulation (ANM) T30 CR® Neurostimulator device. Participants receive the intervention according to the manufacturer/funder training given to the study team.
3151059|NCT01541969|Active Comparator|Tinnitus masking|Participants will receive the same Adaptive NeuroModulation (ANM) T30 CR® Neurostimulator device, but it will NOT be programmed according to the therapeutic algorithm (0-12 weeks).
3151060|NCT01541956|Active Comparator|metformin up titration|metformin 500 mg bid will be up titrated (total daily dose up to 2000 mg)
3151061|NCT01541956|Experimental|vildagliptin add on to metformin|Vildagliptin 50 mg twice daily + Metformin 500mg twice daily
3151062|NCT01541943|Experimental|HL-040XC|Once daily, administered orally, 8 week
3151063|NCT01541943|Active Comparator|Atorvastatin|Once daily, administered orally, 8 week
3151064|NCT01541943|Active Comparator|Losartan|Once daily, administered orally, 8 week
3151065|NCT01541943|Placebo Comparator|Placebo|Once daily, administered orally, 8 week
3151066|NCT01541930|Experimental|GK567|GK567: Metronidazole Gel 0.75% Once or twice daily, for 14 days, up to 30g
3151067|NCT01541917|Experimental|Web-based coping skills training|Involves completion of a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support.
3151068|NCT01541917|Active Comparator|Online disease education|Involves viewing 12 educational websites about Juvenile Idiopathic Arthritis over the course of 12 weeks.
3151069|NCT01541904|Experimental|Arm A. PRO-118/Placebo 0.015%,0.020%|
3151070|NCT01541904|Experimental|Arm B. PRO-118/Placebo 0.015%,0.020%|
3151071|NCT01541904|Experimental|Arm C. PRO-118/Placebo 0.015%,0.020%|
3151072|NCT01541904|Experimental|Arm D. PRO-118/Placebo 0.015%,0.020%|
3151073|NCT01541904|Placebo Comparator|Arm E PRO-118/Placebo 0.015%,0.020%|
3151074|NCT01541891|Experimental|Arm A PRO 148 Ophthalmic Solution|
3151076|NCT01541865|Other|Renal Denvervation|All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.
3151077|NCT01541852|Active Comparator|Losmapimod|7.5mg tablet twice daily
3151078|NCT01541852|Placebo Comparator|Placebo|One tablet twice daily
3151079|NCT01541839|Experimental|Septal Stapler|This group will have closure of their nasal septal flaps via septal stapler.
3151080|NCT01541839|No Intervention|Control (Suture)|This arm will have closure of their nasal septal flaps as routinely performed with suture passed in a quilting fashion.
3151081|NCT01541826|Placebo Comparator|Color-matched rice powder pill|Color-matched rice powder pill
3151082|NCT01541826|Active Comparator|Chokeberry extract capsule|Chokeberry extract capsule
3151083|NCT01541826|Experimental|Chokeberry extract capsule (acute)|Chokeberry extract capsule pharmacokinetics
3151084|NCT01541813||iron overloads except C282Y homozygosity|Patients with an iron overloads except C282Y homozygosity
3151085|NCT01541800||Patients|All children who are in treatment for leukemia, lymphoblastic lymphoma and central nervous system tumors between 3 years and 21 years of age
3151086|NCT01541774|Experimental|Phoenix Atherectomy System|
3151087|NCT01541761|Experimental|Family groups|Intervention group members will participate in family groups focused on early childhood obesity prevention in addition to standard care from pediatricians at the primary care clinic.
3151088|NCT01541761|No Intervention|Standard care|Mothers enrolled into the control group will continue to receive care from their pediatrician in the primary care clinic.
3151089|NCT01541748||Axis|
3151090|NCT01541735|Placebo Comparator|Placebo|Placebo of calcined magnesia, capsules
3151091|NCT01541735|Experimental|Pantoprazole|The pantoprazole will be administered in 40mg capsules
3151092|NCT01541709|Experimental|Imatinib|
3151093|NCT01541696||Group B|subjects in this group will receive Micronutrient Supplements only.
3151094|NCT01541696||Group C|Subjects in this Group will receive Micronutrient Supplements plus Zinc.
3151095|NCT01541683|Experimental|Halls|every patient will drink 4 Liters of PEG solution (FORTRANS®) split into 2 days with sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy with Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure with Halls®).
3151096|NCT01541683|Other|no Halls|Every patient will drink 4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
3151097|NCT01541670|Experimental|Open-label Dose-Escalation Arm|Conducted in an ascending dose manner, subjects will be assigned to single- or multiple-dose administration of the investigational product
3151098|NCT01541657|No Intervention|Control Group|This group will only take part in the data collection sessions. After the first testing session (Pre-Intervention) the participants will be asked to rest comfortably for 5 minutes. After the rest period, they will be reassessed. Upon completion of the second testing, they will be asked to maintain the same lifestyle over the course of 2 weeks. They will then be asked to return to the lab after the 2 week interval to be tested again. Upon completion of the third testing session, they will be contacted after 1 month to complete the self-reported function questionnaires.
3151099|NCT01541657|Experimental|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
3151100|NCT01541657|Experimental|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
3151101|NCT01541657|Experimental|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
3151102|NCT01541644|Experimental|Acupuncture|All participants will receive acupuncture treatments over a total of 10 weeks.
3151103|NCT01541631|Experimental|HIV-1 co-infected with schistosoma mansoni|HIV-1 patients co-infected with Schistosoma mansoni
3151104|NCT01541631|No Intervention|HIV-1 positive individuals with negative S. mansoni|HIV-1 positive individuals with negative Schistosoma mansoni
3151105|NCT01541631|Experimental|Schistosoma mansoni positive but HIV-1 negative|Schistosoma mansoni positive individuals but HIV-1 negative to be compared with HIV-1 co-infected with Schistosoma mansoni individuals
3151106|NCT01541631|No Intervention|HIV-1 and Schistosoma mansoni negative|Individuals with no HIV-1 and S. mansoni infections
3151107|NCT01541618||Tysabri Group|Patients with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin Natalizumab (Tysabri) therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
3151108|NCT01541605|Active Comparator|methylphenidate|
3151109|NCT01541605|Placebo Comparator|placebo|
3151110|NCT01541592|Active Comparator|Saturated fat|Palm oil (rich in the saturated fat palmitate)
3151111|NCT01541592|Active Comparator|Monounsaturated fat|Olive oil (rich in the monounsaturated fat oleate)
3151112|NCT01541592|Active Comparator|Polyunsaturated fat|Safflower oil (rich in the polyunsaturated fat linoleate)
3151113|NCT01541579|Experimental|Treatment Arm|Cx601 is a cell suspension in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given at a dose of 120 million cells (5 million cells / mL) for intralesional injection.
3151114|NCT01541579|Placebo Comparator|Placebo-control group|Placebo (saline solution) will be given also for intralesional injection at the same quantity (volume, 24 mL) and following the same schedule.
3151115|NCT01541566||Home blood pressure telemonitoring|Patients regularly monitoring their blood pressure at home with an electronic validated upper arm device, transmitting blood pressure values at monthly intervals to the doctors office through the Internet.
3151116|NCT01541566||Conventional blood pressure measurement|Blood pressure measured only in the doctor's office during quarterly visits, without regular home blood pressure monitoring.
3151117|NCT01541553|Active Comparator|PEP005 Gel, 0.015%|Cryotherapy followed by PEP005 Gel, 0.015%
3151118|NCT01541553|Placebo Comparator|Vehicle gel|Cryotherapy followed by vehicle gel
3151119|NCT01541540|Experimental|e-Counseling plus Usual Care|
3151120|NCT01541540|Active Comparator|e-Info Control plus Usual Care|
3151121|NCT01541527||severe, moderate and mild HA patients|one Arm: biological collection of 300 severe, moderate and mild HA patients
3151122|NCT01541501||Pachymetry|All recruited volunteers in present study, that underwent pachymetry measurement with four different instruments
3151123|NCT01541488|Experimental|BI 1021958|Single rising dose (SRD) part
3151124|NCT01541488|Experimental|BI 1021958 (Food effect)|Food effect part (FE)
3151125|NCT01541488|Placebo Comparator|Placebo to BI 1021958|Matching placebo as drinking solution and tablets
3151126|NCT01541475|Experimental|Escitalopram + Bupropion|
3151127|NCT01541475|Active Comparator|Escitalopram|
3151128|NCT01541462|Active Comparator|Pressure support|Patients randomized to the pressure support arm will wean using pressure support ventilation. The level of pressure support will be decreased by 2 cm H2O every 6 hours. The maximum decrement in pressure support permitted in one day will be 6 cm H2O.
3151129|NCT01541462|Active Comparator|Spontaneous Breathing|Patients randomized to spontaneous breathing arm will be disconnected from the ventilator and allowed to breathe spontaneously through the tracheostomy. Duration of the trial will be increased sequentially as tolerated.
3151130|NCT01541449||RA patients treated with plaquenil|
3151131|NCT01541449||Patients who do not use plaquenil|
3151132|NCT01541436|Active Comparator|Capsaicin, UV-B, RIPC|
3151133|NCT01541436|Sham Comparator|Capsaicin, UV-B|
3151134|NCT01541397|No Intervention|Non-Kuvan treated|Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.
3151135|NCT01541397|Experimental|Kuvan treated|Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).
3151136|NCT01541384|Experimental|Medication Dosage Reminders|Subject will receive electronic pill bottle that will track adherence. They will also be able to activate available dosage reminders (text message, phone message, email).
3151137|NCT01541384|Experimental|Medicaiton Dosage Reminders + Coordinator Support|Subject will receive electronic pill bottle that will track adherence. They will also be able to activate available dosage reminders (text message, phone message, email). The study coordinator will also check adherence every 2 weeks and alert the transplant team when it drops below 90%. The transplant team will determine the next best course of action.
3151138|NCT01541384|Other|Usual Care with GlowCap|Subject will receive electronic pill bottle that will track adherence but all reminders will be deactivated.
3151139|NCT01541371|Experimental|Paliperidone ER|
3151140|NCT01541358|Experimental|Diagnostic (fluorine F 18 sodium fluoride PET/CT)|Patients undergo fluorine F 18 sodium fluoride PET/CT scan.
3151141|NCT01541345|Active Comparator|Control Group (A)|Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland). These course of action is well documented in the literature and standard procedures.
3151142|NCT01541345|Experimental|Test group (B)|The bone augmentation will be performed using a deproteinized bovine bone mineral (DBBM) block (Bio-Oss Spongiosa Block®, Geistlich Parma AG, Wolhusen, Switzerland) and a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland) similarly to the control group. In addition, DBBM will be loaded with rhBMPH-2 (InductOs®, Pfizer AG, Zurich, Switzerland).
3151143|NCT01541332|Experimental|Pomalidomide + PLD + Dexamethasone|Pomalidomide + Pegylated Liposomal Doxorubicin + Dexamethasone in an open label, dose escalation study
3151144|NCT01541319||Randomized to <= 10day RBCs & transfused|Subjects in the RECESS study who were randomized to receive red blood cell (RBC) units stored no more than 10 days, and who received at least one RBC transfusion between randomization and 96 hours after the cardiac surgery ends
3151145|NCT01541319||Randomized to >= 21day RBCs & transfused|Subjects in the RECESS study who were randomized to receive red blood cell (RBC) units stored at least 21 days, and who received at least one RBC transfusion between randomization and 96 hours after the cardiac surgery ends
3151146|NCT01541319||Randomized but not transfused|Subjects randomized in the RECESS study who did not receive any red blood cell units between randomization and 96 hours after the end of surgery
3151147|NCT01541319||Healthy volunteers|
3151148|NCT01541306||achondroplasia or hypochondroplasia|Children or adults with achondroplasia or hypochondroplasia
3151149|NCT01541293|Experimental|Intrauterine Lidocaine|The experimental arm will receive 100mg lidocaine (5mL of 2% concentration) instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
3151150|NCT01541293|Placebo Comparator|Intrauterine Saline|Placebo arm will receive 5mL of normal saline instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
3151151|NCT01541267|Active Comparator|C - A - B|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
3151152|NCT01541267|Active Comparator|B - A - C|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
3151153|NCT01541267|Active Comparator|A - B - C|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
3151154|NCT01541254|Other|Single Arm|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
3151155|NCT01541241||copper IUD used|"Group I: includes 50 cases using CIUD and complaining of menorrhagia or menometrorrhagia.~Group II: includes 50 cases using CIUD and not complaining of abnormal uterine bleeding."
3151156|NCT01541228|Active Comparator|Group I|Patients with actinic keratosis (AK) on the left and right sides of face/scalp region treated with photodynamic therapy using 20% 5-aminolevulinic acid.
3151157|NCT01541228|Active Comparator|Group II|Patients with actinic keratosis (AK) on the left and right sides of the face/scalp region treated with photodynamic therapy using 20% 5-aminolevulinic acid.
3151158|NCT01541215|Experimental|Lira + Met|
3151159|NCT01541215|Placebo Comparator|Placebo + Met|
3151160|NCT01541202|Placebo Comparator|Placebo|placebo in addition to standard therapy
3151161|NCT01541202|Experimental|rhNRG-1|rhNRG-1 in addition to standard therapy
3151162|NCT01541189|Experimental|valsartan|After 1-week screening period, all of the eligible patients receive valsartan 80mg/day for 2 weeks, then the dosage will be titrated to 160mg/day for further 8 weeks therapy for all of the subjects.
3151163|NCT01541176|Experimental|Absence of corticotherapy post-transplantation|All patients included in this arm will receive the usual treatment strategy (including Advagraf, Cellcept ou Myfortic and Simulect) without corticotherapy post-transplantation.
3151164|NCT01541176|Active Comparator|Corticotherapy post-transplantation|All patients included in this arm will receive the usual treatment strategy (including Advagraf, Cellcept ou Myfortic and Simulect) with corticotherapy post-transplantation : prednisone or prednisolone orally for at least one year post-transplantation.
3151165|NCT01541163||Acute Ischemic Stroke|Patients with acute ischemic stroke admitted within 12 hours after onset.
3151166|NCT01541150|Active Comparator|patient suffering pedophilia|This group is the active comparator because patients suffering pedophilia with neuropsychological questionnaires
3151167|NCT01541150|Placebo Comparator|control group|This group is the placebo comparator
3151168|NCT01541137|Active Comparator|diclofenac + IV-PCA|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, intercostal nerve block with 20 ml of 0.5% bupivacaine, IV-PCA programmed with morphine boluses, from the 2nd postoperative morning the patients were given oral diclofenac 75 mg x 2, IV-PCA-morphine was discontinued after removal of pleural drains, and the patients were given oral oxycodone
3151169|NCT01541137|Active Comparator|parecoxib/ valdecoxib + IV-PCA|oral valdecoxib 40 mg, a 44-hour iv-infusion parecoxib 80 mg/24h, intercostal nerve block with 20 ml of 0.5% bupivacaine, IV-PCA programmed with morphine, From the 2nd postoperative morning valdecoxib 40 mg x 2, IV-PCA-morphine was discontinued after removal of pleural drains, and the patients were given oral oxycodone
3151170|NCT01541137|Active Comparator|patient controlled epidural analgesia|At the induction of anesthesia the PCEA-patients were given IV paracetamol 1g and an epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses, IV paracetamol 1g x 4 for the first 24 hours and thereafter 1g x 3 orally, PCEA was discontinued and paracetamol was replaced with ibuprofen 600 mg x 3 and oral oxycodone
3151171|NCT01541124|Experimental|Morphine, Pain intensity|For cancer pain treatment, World Health Organization recomends tritation of opioids associated with non steroidal antiinflamatory drugs. This study compares the analgesic effect with diferents dosages in 63 patients with cancer pain.
3151172|NCT01541111|Other|Magnesiun, pain relief, sugar pills|Magnesiun 75mg po each 12h pain relief Sugar pills po each 12h
3151173|NCT01541098|Active Comparator|Licensed Plasma|
3151174|NCT01541098|Experimental|Lyophilized Plasma|
3151175|NCT01541085||Darunavir/Ritonavir (DRV/r)|
3151176|NCT01541085||Efavirenz (EFV)|
3151177|NCT01541072|Experimental|Pegfilgrastim|
3151178|NCT01541072|Active Comparator|Filgrastim|
3151179|NCT01541059|Placebo Comparator|Placebo|Patients in this arm will have standard anesthesia with the injection of placebo solution into the vestibular of each tooth to be extracted
3151180|NCT01541059|Experimental|Ropivacaine|Patients in this arm will have general anesthesia with injection of ropivacaine into the vestibular next to each tooth to be extracted.
3151181|NCT01541046|Experimental|Biogaia L. reuteri DSM 17938|Biogaia L. reuteri DSM 17938, probiotic infant drops (5 drops=10^8 cfu),5 drops, once per day for 21 days.
3151182|NCT01541046|Placebo Comparator|Probiotic Placebo|Placebo drops (sunflower oil, medium chain triglyceride oil, silicon chloride), 5 drops, once a day for 21 days.
3151183|NCT01541033||Autism with FAH|Children diagnosed with autism with first degree relatives that have autoimmune disorders.
3151184|NCT01541033||Autism without FAH|Children diagnosed with autism without first degree relatives that have autoimmune disorders.
3151185|NCT01541033||Control|Typically developing children
3151186|NCT01541020||Healthy individuals|
3151187|NCT01541020||Individuals with low back pain|
3151188|NCT01541007|Active Comparator|Standard Cabazitaxel Schedule|Cabazitaxel 25 mg/m2 every three weeks
3151189|NCT01541007|Experimental|Weekly cabazitaxel schedule|cabazitaxel 10 mg/m2 given weekly for 5 consecutive weeks of a six week cycle
3151190|NCT01540994|Experimental|SBRT|Stereotactic Body Radiation Therapy
3151191|NCT01540981|Active Comparator|SOC - Standard of Care|Standard of care consists of pressure relief, creams, wound cleansing and dressings as needed
3151192|NCT01540981|Active Comparator|MIST Therapy with SOC|Standard of Care including pressure relief, wound cleansing, creams, and dressings as needed plus MIST Therapy daily for 5 days and then every other day for up to 7 more days
3151193|NCT01540968|Experimental|Nutrition & physical exercise|
3151194|NCT01540968|No Intervention|Control|
3151195|NCT01540955|Experimental|Group Intervention program|
3151196|NCT01540955|No Intervention|Wait-list control group|The wait-list-control group will also be able to participate in the group intervention, but not until after all the study visits have been completed.
3151197|NCT01540942|Active Comparator|Nutrition treat|perioperative nutrition support until the patients get the normal nutrition or disease remission
3151338|NCT01540019|Experimental|Paullinea cupana|50mg of Paullinia cupana as capsule, twice daily
3151198|NCT01540942|Active Comparator|bowel resection|bowel resection until the patients get the normal nutrition or disease remission after bowel resection
3151199|NCT01540929||Study Group|DoD Smallpox Screening Form 600 (2 part format)
3151200|NCT01540916|Experimental|Hyperventilation|Minute ventilation will be increased of about 30% of baseline value, through an increase in respiratory rate
3151201|NCT01540916|Experimental|Hypoventilation|Minute ventilation will be decreased of about 30% of baseline value, through a decrease in respiratory rate
3151202|NCT01540903|Experimental|Group 1 10,000 PfSPZ|12 volunteers, ID PfSPZ Challenge total dose 10,000 PfSPZ administered by 2 injections of 50µL each.
3151203|NCT01540903|Experimental|Group 2 25,000 PfSPZ|12 volunteers, ID PfSPZ Challenge total dose 25,000 PfSPZ administered in 4 injections of 10µL each.
3151204|NCT01540903|Placebo Comparator|Controls - saline|4 Volunteers, ID saline administered in 2 injections of 50µL each and 2 volunteers, ID saline administered in 4 injections of 10µL each.
3151205|NCT01540890||withdrawal|patients who undergo an opioid withdrawal
3151206|NCT01540890||opioids|patients on opioid medication without withdrawal
3151207|NCT01540890||opioid-free|patients with chronic pain without opioid medication
3151208|NCT01540877|Experimental|Capsaicin application|application of 0.6%
3151209|NCT01540877|Experimental|Local anesthetics application|application of EMLA
3151210|NCT01540877|Experimental|Combined application of 1. capsaicin 2. local anesthetics|application of 1. capsaicin 0.6% and 2. EMLA
3151211|NCT01540877|Experimental|Combined application of 1. local anesthetics and 2. capsaicin|application of 1. EMLA and 2. capsaicin 0.6%
3151212|NCT01540864|Experimental|HPP404 35 mg|
3151213|NCT01540864|Experimental|HPP404 50 mg|
3151214|NCT01540864|Placebo Comparator|Placebo|
3151215|NCT01540851|Active Comparator|Care Navigator Intervention Group|Subjects randomized to the Care Navigator Intervention group will receive up to 10 telephone calls from a care navigator for 5 months post-operatively
3151216|NCT01540851|Active Comparator|Usual Care Group|Subjects in the Usual Care group receive the current standard post-operative TKA care
3151217|NCT01540838|Experimental|Infusion with paracetamol|Cefotaxime is administered as 12 hourly infusions, together with high dose paracetamol (acetaminophen)
3151218|NCT01540838|Active Comparator|Bolus with placebo|Cefotaxime is administered as bolus q.i.d. with a placebo of paracetamol
3151219|NCT01540825|Experimental|BI 113608 high dose 1|Powder for oral solution
3151220|NCT01540825|Experimental|BI 113608 low dose 1|Powder for oral solution
3151221|NCT01540825|Experimental|BI 113608 low dose 2|Powder for oral solution
3151222|NCT01540825|Experimental|BI 113608 low dose 4|Powder for oral solution
3151223|NCT01540825|Experimental|BI 113608 low dose 5|Powder for oral solution
3151224|NCT01540825|Experimental|BI 113608 medium dose 1|Powder for oral solution
3151225|NCT01540825|Experimental|BI 113608 medium dose 2|Powder for oral solution
3151226|NCT01540825|Experimental|BI 113608 medium dose 3|Powder for oral solution
3151227|NCT01540825|Experimental|BI 113608 high dose 2|Powder for oral solution
3151228|NCT01540825|Experimental|BI 113608 high dose 3|Powder for oral solution
3151229|NCT01540825|Placebo Comparator|Placebo|Powder for oral solution
3151230|NCT01540812||V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud|Vincristine in induction:5 mg/m2 i.v. days 1, 8, 15 and 22 in induction phase Daunorubicin in induction 45 mg/m2 i.v. days 1, 8, 15 and 22 Prednisone in induction: 60 mg/m2/ day, i.v. o p.o., days 1 to 14; 30 mg/m2/day, i.v. o p.o., days 15 to 21; 15 mg/m2/day i.v. o p.o., days 21 to 28 Metotrexato 12 mg days 1 and 22 (intrathecal) Cytarabine (ARA-C): 30 mg days 1 and 22 (intrathecal) Hydrocortisone: 20 mg days 1 and 22 (intrathecal) Idarubicin-induction 2 12 mg/m2, i.v., days 1, 3 and 5 Fludarabine in induction-2: Fludarabine 30 mg/m2, i.v., days, 1 to 5
3151231|NCT01540799|Experimental|Treatment|
3151232|NCT01540799|Other|Other|Stimulation not able to be felt
3151233|NCT01540786|Experimental|Part 1: OAB subjects|
3151234|NCT01540786|Experimental|Part 2: Healthy subjects|
3151235|NCT01540786|Experimental|Part 2: OAB subjects|
3151236|NCT01540773|Active Comparator|amino acid supplement|supplements with the proprietary amino acid derivative blend.
3151237|NCT01540773|Placebo Comparator|Placebo|Non-Active
3151238|NCT01540760|Experimental|MCAF5352A|
3151239|NCT01540760|Placebo Comparator|Placebo|
3151240|NCT01540747|Experimental|Inofolic plus|178 patients
3151241|NCT01540747|Active Comparator|Inofolic|180 patients
3151242|NCT01540734|Active Comparator|Marketed paracetamol|marketed formulation
3151243|NCT01540734|Experimental|Experimental paracetamol formulation|Experimental formulation
3151244|NCT01540721|Experimental|Experimental paracetamol formulation|Experimental formulation
3151245|NCT01540721|Active Comparator|Marketed paracetamol|Marketed formulation
3151246|NCT01540708|Experimental|SERETIDE Rotacaps|Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a capsule-based inhaler (Rotahaler). Devices with varying airflow resistance, low, intermediate and high, will be used.
3151247|NCT01540708|Active Comparator|SERETIDE Diskus|Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a multi-dose dry powder inhaler
3151248|NCT01540669|Active Comparator|Polydextrose, low dose|Polydextrose, low dose
3151249|NCT01540669|Active Comparator|Polydextrose, medium dose|Polydextrose, medium dose
3151250|NCT01540669|Active Comparator|Polydextrose, high dose|Polydextrose, high dose
3151251|NCT01540669|Placebo Comparator|Placebo powder|Placebo powder
3151252|NCT01540656|Active Comparator|Group 1|This group will receive immediate TMNS treatment beginning at baseline and ending at the 6 week point of the study.
3151253|NCT01540656|Active Comparator|Group 2|This group will receive delayed TMNS treatment beginning at the 6 week point of the study and ending at 12 weeks.
3151254|NCT01540643||Abdominal aortic aneurysm|
3151255|NCT01540630|Experimental|CNV1014802|
3151256|NCT01540630|Placebo Comparator|Placebo|
3151257|NCT01540617||Persons with low back pain|
3151258|NCT01540617||Healthy persons|
3151339|NCT01539993||1|
3151260|NCT01540591|Placebo Comparator|control|Saline 0.9% IV infusion between day 4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
3151261|NCT01540591|Experimental|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
3151262|NCT01540578||Observational|Archived cell samples are analyzed for replication timing by flow cytometry, microarray, and single-cell fluorescence in situ hybridization (FISH) assays. Replication-timing results among cases and controls are also analyzed.
3151263|NCT01540565|Experimental|Treatment (veliparib)|Patients receive veliparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3151264|NCT01540552||Budesonide Arm|Retrospective Medical Chart Review of low dose CT scans for participants who received Budesonide.
3151265|NCT01540552||Placebo Arm|Retrospective Medical Chart Review of low dose CT scans for participants who received Placebo.
3151266|NCT01540539|Experimental|Dosing cohort 1|
3151267|NCT01540539|Experimental|Dosing cohort 2|
3151268|NCT01540539|Experimental|Dosing cohort 3|
3151269|NCT01540539|Experimental|Dosing cohort 4|
3151270|NCT01540539|Experimental|Dosing cohort 5|
3151271|NCT01540539|Experimental|Dosing cohort 6|
3151272|NCT01540539|Experimental|Dosing cohort 7|
3151273|NCT01540539|Experimental|Dosing cohort 8|
3151274|NCT01540526|Experimental|Safety cohort|6 evaluable patients with RECIST measurable solid malignancies will be enrolled to establish the safety and toxicity of axitinib at 7 mg PO BID days 1-14 in 21 day cycles.
3151275|NCT01540526|Experimental|Pharmacodynamic cohort|PD cohort A: Up to 6 patients with metastatic castrate-resistant prostate cancer (evidence of soft-tissue metastases amendable to FLT-PET/CT imaging), and PD cohort B: Up to 12 patients with other solid malignancies (evidence of radiographic metastases amendable to FLT-PET/CT imaging) will be enrolled with scans obtained at baseline, peak exposure, and peak withdrawal of axitinib, in cycle#1, with repeat imaging in select patients in PD cohorts A and B at a later cycle of therapy.
3151276|NCT01540513|Experimental|I124-NM404 brain metastases or GBM imaging|injection of I-124NM404 for imaging
3151277|NCT01540500|Experimental|Steady State PK Group|
3151278|NCT01540487|Experimental|linagliptin/metformin(high dose)|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (high dose) tablets single dose in randomized order
3151279|NCT01540487|Experimental|linagliptin/metformin(low dose)|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (low dose) tablets single dose in randomized order
3151280|NCT01540474|Experimental|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Single center, non-randomized, open label, dose escalation Phase 1 study with sporozoite challenge. The antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion. This is a first-in-human study of FMP012. 30 subjects, divided into 3 groups, will receive 3 doses of the FMP012/GLA-SE vaccine. Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
3151281|NCT01540474|Experimental|Group 2: 10 ug FMP012 with 5 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
3151282|NCT01540474|Experimental|Group 3: 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
3151283|NCT01540461|Experimental|Arm: Brivanib|
3151284|NCT01540448|Active Comparator|No-3DCT|All patients were subjected to a CT scan with 3D mesenteric angiography but the surgeon was able to view the 3D reconstruction only after surgery.
3151285|NCT01540448|Experimental|3DCT|All patients were subjected to a CT scan with 3D mesenteric angiography and the surgeon was able to view 3D reconstruction before and during laparoscopic colorectal resection.
3151286|NCT01540435|No Intervention|Postoperative Arm (Arm A)|"FOLFOX:~Oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)~Duration of treatment:~Treatment will be administered for 12 cycles (6 months) postoperatively starting 6 weeks after surgery."
3151287|NCT01540435|Experimental|Perioperative Arm (Arm B)|"Therapy will be administered in a biweekly schedule. First preoperative cycle will be administered with 75% of dosage for FOLFOXIRI, if no diarrhea ≥ grade 3 occurs, following cycles should be administered in full dosage.~FOLFOXIRI + bevacizumab:~bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)~Duration of treatment:~Treatment will be administered for 6 cycles (3 months) preoperatively (last cycle without bevacizumab), after 6 weeks followed by liver surgery, after further 6 weeks followed by 6 cycles (3 months) postoperatively."
3151288|NCT01540422||CABG w/saphenous vein grafts harvested using endoscopy|Those who have CABG surgery with saphenous vein grafts harvested using endoscopic techniques
3151289|NCT01540409|Experimental|AVI-4658 (Eteplirsen)|Multiple-Dose Extension Study
3151290|NCT01540396|Active Comparator|75 Gram OGTT|The 2011 ADA criteria will be used to diagnose gestational diabetes in this study arm.
3151291|NCT01540396|Active Comparator|100 gram OGTT|A 2 step approach to the diagnosis of gestational diabetes will be used in this arm. Patients who have a 50 gram, 1 hour glucose challenge test result greater than 135 mg/dL will be diagnosed with gestational diabetes if their 3 hour, 100 gram OGTT results exceed the diagnostic threshold recommended by Carpenter and Coustan.
3151292|NCT01540383|Experimental|Intensive aphasia therapy group|Group starts intensive integrative aphasia therapy within 3 workdays (or as soon as possible) after baseline exam
3151293|NCT01540383|Other|Waiting list control group|Group starts intensive integrative aphasia therapy after a waiting period of at least three weeks
3151294|NCT01540370||Patients with OAG and/or OHT|Patients with OAG and/or OHT
3151340|NCT01539980|Experimental|Sericin scaffold|
3151341|NCT01539954||Youth 9-18 years of age|
3151295|NCT01540357|Active Comparator|Mindfulness-based therapy|Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
3151296|NCT01540357|Active Comparator|Treatment after waiting time|Treatment was performed after completion of the active arm.
3151297|NCT01540344|Experimental|Treatment Arm|"FOLFOX/FOLFIRI + cetuximab (6 cycles)~CRS and HIPEC~FOLFOX/FOLFIRI + cetuximab (6 cycles)"
3151298|NCT01540331|Experimental|PNT treatment|all subjects enrolled in the study, that underwent PNT treatment
3151299|NCT01540318|Experimental|Abdominal Ultrasound|"Patients in the experimental arm will receive a Focused Assessment with Sonography for Trauma (FAST) which includes the use of abdominal ultrasound."
3151300|NCT01540318|No Intervention|No Abdominal Ultrasound|
3151301|NCT01540305|Active Comparator|Transcranial Magnetic Stimulation|Actual transcranial magnetic stimulation of supplementary motor areas bilaterally.
3151302|NCT01540305|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham transcranial magnetic stimulation over the supplementary motor areas.
3151303|NCT01540292|Experimental|MSC|Patients with Crohn's disease (refractory or intolerant to conventional therapies) treated with 2 successive injections of 1.5-2.0 x 10E6 allogenic MSC/kg BW at baseline and 4 weeks later.
3151304|NCT01540279||Cohort one with abdominal wall closure with Monocryl|
3151305|NCT01540279||Cohort two with abdominal wall closure with Monocryl plus|
3151306|NCT01540266|Experimental|first year psychology_structured|First year psychology students who watched the video where the physician gives structured information to the patient
3151307|NCT01540266|Active Comparator|First year psychology_non-structured|First year psychology students who watched the video where the physician gives non-structured information to the patient
3151308|NCT01540266|Experimental|First year medical_structured|First year medical students who watched the video where the physician gives structured information to the patient
3151309|NCT01540266|Active Comparator|First year mediclal_non-structured|First year medical students who watched the video where the physician gives non-structured information to the patient
3151310|NCT01540266|Experimental|Third year medical_structured|Third year medical students who watched the video where the physician gives structured information to the patient
3151311|NCT01540266|Active Comparator|Third year medical_non-structured|Third year medical students who watched the video where the physician gives non-structured information to the patient
3151312|NCT01540253|Experimental|Treatment (enzyme inhibitor and chemotherapy)|Patients receive PI3K inhibitor BKM120 PO QD and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3151313|NCT01540240|Active Comparator|standard dosage zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
3151314|NCT01540240|Active Comparator|low dosage zidovudine|
3151315|NCT01540227||Syphilis Patients|Individuals presenting for treatment of primary, secondary or early latent syphilis at the Ottawa Hospital Immunodeficiency Clinic, the Ottawa Sexual Health Clinic or its satellite GayZone, the Montreal Chest Institute Immunodeficiency Clinic, or the Toronto General Immunodeficiency Clinic will be invited by their attending health care worker to participate in this study. Only patients presenting for and requiring treatment of infectious syphilis will be asked to participate.
3151316|NCT01540214||POP surgery|All women who present with POP at the outpatient clinic of our centre and who will undergo prolapse repair surgery will be asked informed consent for participation in this study
3151317|NCT01540201|Active Comparator|1:2 group|conventional I:E ratio group, inspiratory time : expiratory time = 1:1
3151318|NCT01540201|Experimental|1:1 group|inspiratory time : expiratory time = 1:1
3151319|NCT01540188|No Intervention|Starndard care arm|Participants of the standard care arm are control groups of IDUs and family members. They do not attend intervention sessions.
3151320|NCT01540188|Experimental|Intervention arm|"Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community"
3151321|NCT01540175||Participants|Participants enrolled on the study will have blood samples obtained.
3151322|NCT01540162||Group I|Patients of group I are exposed to the probiotic Mutaflor: 1 ml once a day during first week of life, and three times per week during the second and third week of life.
3151323|NCT01540162||Group II|Patients of group II remain unexposed to the probiotic Mutaflor.
3151324|NCT01540149||ICD implant|
3151325|NCT01540136|Experimental|Nedaplatin|Nedplatin combine with IMRT
3151326|NCT01540136|Active Comparator|Cisplatin|Cisplatin combine with IMRT
3151327|NCT01540123|Placebo Comparator|Control|Sugar matched control containing no phytochemicals
3151328|NCT01540123|Experimental|Berry drink standardised to contain 500mg of polyphenols|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
3151329|NCT01540110|Experimental|Docetaxel + cyclophosphamide|
3151330|NCT01540084|Active Comparator|conventional group|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered. To maintain conscious level of patient at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary.
3151331|NCT01540084|Experimental|cocktail group|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered. To maintain conscious level of patient at moderate or deep level, 1% propofol at the rate of 1 mg/kg/hr was administered. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
3151332|NCT01540071|Experimental|NRX 194204|
3151333|NCT01540058|Experimental|test-guided strategy|"Treatment considered as the standard at the time of patient inclusion based on the primary cancer suspected by the BioTheranostics Cancer Type ID test molecular analysis"
3151334|NCT01540058|Active Comparator|Empiric strategy|Gemcitabine/Cisplatin
3151335|NCT01540045||BASELINE|Outpatients from National Cancer Institute with stage III and IV NSCLC candidates for 1 st line chemotherapy paclitaxel-cisplatin based agreeing to participate in the study
3151336|NCT01540032|No Intervention|Control|
3151337|NCT01540032|Experimental|Diet|
3151343|NCT01539928||lung cancer or high suspicion of lung cancer|After initial work-up (chest x-ray, CT of thorax and upper abdomen, spirometry) found to have surgically resectable lung cancer
3151344|NCT01539915|Experimental|BCT194|
3151345|NCT01539902|Experimental|Human Umbilical Cord derived MSCs|
3151346|NCT01539902|Placebo Comparator|Cyclophosphamide|
3151347|NCT01539889|Experimental|DFH-12 PulmoBind|DFH-12 PulmoBind - 3 doses of; 5mCi for 5 subjects, 10mCifor 5 subjects and 15mCi for 10 subject
3151348|NCT01539876|Other|Fine Needle aspiration will be done X5:|Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
3151349|NCT01539863|Experimental|Treatment at regular intervals|Participants will be scheduled to receive the intervention, maintenance care, i.e. care on a regular basis throughout the study period.Care may consist of manual treatment but also of e.g. advice concerning exercises, ergonomic adaptation and stress management
3151350|NCT01539863|Active Comparator|Treatment as needed|Participants will receivethe intervention, i.e.care only when requested by them, i.e. when experiencing a relapse or deterioration
3151351|NCT01539837|Placebo Comparator|A-Placebo|Drug excipient
3151352|NCT01539837|Active Comparator|B-Dferiprone|20mg/kg/day deferiprone
3151353|NCT01539837|Active Comparator|C-Deferiprone|30mg/kg/day Deferiprone
3151354|NCT01539824|Experimental|IMM-101 plus SBRT|The treatment regimen with IMM-101 (Mycobacterium obuense) will be every 2 weeks for the first three doses with the last of these doses being on the same day as the radiotherapy by CyberKnife treatment on a liver lesion targeted by the Principal Investigator. Following a rest of 4 weeks, patients will again receive IMM-101 every 2 weeks for the next 3 doses followed by a further 4 weeks rest. Thereafter, IMM-101 will be given at 4 week intervals for up to 12 months or until patient withdrawal for any reason
3151355|NCT01539811|Active Comparator|Short course antibiotics|Surgical intervention followed by short course of antibiotics (<2 weeks)
3151356|NCT01539811|Active Comparator|Long course antibiotics|Surgical intervention followed by a long course of antibiotics (>2 weeks)
3151357|NCT01539798|Experimental|Oral Saline|Ingestion of 0.9% saline solution
3151358|NCT01539798|Active Comparator|Intravenous Saline|Intravenous infusion of 0.9% saline solution
3151359|NCT01539785|Active Comparator|Secondary cytoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction.
3151360|NCT01539785|Experimental|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique.
3151361|NCT01539772||Becker|BMD participants over 4 years of age with in-frame deletions in the dystrophin gene.
3151362|NCT01539759|No Intervention|Interval IUD Placement|Women randomized to this arm will be scheduled for their IUD placement 4-8 weeks after their cesarean delivery
3151363|NCT01539759|Experimental|Immediate Postplacental IUD placement|Women randomized to this arm will receive on IUD at time of cesarean delivery, immediately after the delivery of the placenta
3151364|NCT01539746|Experimental|TAVI without predilation|
3151365|NCT01539746|Active Comparator|Standard TAVI procedure|
3151366|NCT01539733|Experimental|Olanzapine|
3151367|NCT01539733|Active Comparator|Haloperidol|
3151368|NCT01539720|Experimental|Levonorgestrel Intrauterine System|Participants randomized to the levonorgestrel IUS will undergo placement at the time of randomization. They will follow-up with a self-administered urine pregnancy test 5-6 weeks following.
3151369|NCT01539720|Active Comparator|Ulipristal acetate|Women in this arm will receive the oral Ulipristal acetate (Ella) regimen, which is currently the most effective method of oral emergency contraception.
3151370|NCT01539707|Experimental|Treatment Arm 1|open label, solifenacin succinate suspension
3151371|NCT01539681||Group 1|
3151372|NCT01539668||Pap sampling|Women who have undergone Pap sampling and HPV and cytology analysis. The samples will be collected in Mobile Units and Non-Mobile Units.
3151373|NCT01539655|Experimental|vandetanib then vandetanib + omeprazole|Vandetanib alone in period 1 followed by vandetanib in combination with omeprazole in period 2
3151374|NCT01539655|Experimental|vandetanib + omeprazole then vandetanib|Vandetanib in combination with omeprazole in period 1 followed by vandetanib alone in period 2
3151375|NCT01539655|Experimental|vandetanib then vandetanib + ranitidine|Vandetanib alone in period 1 followed by vandetanib in combination with ranitidine in period 2
3151376|NCT01539655|Experimental|vandetanib + ranitidine then vandetanib|Vandetanib in combination with ranitidine in period 1 followed by vandetanib alone in period 2
3151377|NCT01539642|Experimental|Sufentanil NanoTab PCA System/15 mcg|
3151378|NCT01539642|Placebo Comparator|Placebo Sufentanil NanoTab PCA System|
3151379|NCT01539629||Pulse Width|One group reflecting two different pulse widths.
3151380|NCT01539616|Experimental|ZYH7 4mg|ZYH7 4mg
3151381|NCT01539616|Experimental|ZYH7 8mg|ZYH7 8mg
3151382|NCT01539616|Experimental|ZYH7 16mg|ZYH7 16mg
3151383|NCT01539616|Active Comparator|Fenofibrate 160mg|Fenofibrate 160mg
3151384|NCT01539603|Experimental|DEB-BMS|Drug eluting balloon + Bare metal stent
3151385|NCT01539603|Active Comparator|Drug eluting stent|conventional PCI with drug eluting stent drug eluting stent (Zotarolimus-eluting stent)
3151386|NCT01539590|Experimental|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
3151387|NCT01539590|Placebo Comparator|Normal Saline|Daily intravenous administration for four (4) days
3151388|NCT01539577||OZURDEX®|OZURDEX® (dexamethasone 700 μg intravitreal implant) administered according to general clinical practice.
3151389|NCT01539564|Experimental|Treatment|Treatment (minocycline HCl microspheres, 1mg) administered at Baseline (following randomization) and Day 90 to qualifying implant sites, plus full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180.
3151390|NCT01539564|No Intervention|Control|Full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180; no treatment
3151391|NCT01539551||1|sepsis and septic shock patients
3151392|NCT01539538|Experimental|Sufentanil NanoTab PCA System/15 mcg|
3151393|NCT01539538|Active Comparator|morphine IV PCA|
3151558|NCT01538342|Other|atopic dermatitis|2 biopsies: 1 lesional and 1 non-lesional
3151394|NCT01539525|Experimental|Motivational Interview|Motivational interview provided by a clinical research nurse or physician.
3151395|NCT01539525|Active Comparator|Motivational Interview-Electronic|Motivational Interview provided by an interactive computer program.
3151396|NCT01539525|Placebo Comparator|Treatment as Usual|No intervention- resource list provided.
3151397|NCT01539512|Active Comparator|Idelalisib + rituximab|Participants will receive idelalisib plus rituximab
3151398|NCT01539512|Placebo Comparator|Placebo + rituximab|Participants will receive placebo to match idelalisib plus rituximab
3151399|NCT01539473|Experimental|TR-701 FA with Tyramine|TR-701 FA 200 oral with Tyramine
3151400|NCT01539473|Placebo Comparator|Placebo-controlled with Tyramine|Placebo-controlled with Tyramine
3151401|NCT01539460|Experimental|minimally invasive surgery|There is only one arm to this study. All patients will receive treatment with the minimally invasive surgery for their axillary bromidrosis
3151402|NCT01539447|Active Comparator|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
3151403|NCT01539447|Placebo Comparator|Placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
3151404|NCT01539434|Experimental|Behavioural intervention|Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.
3151405|NCT01539434|Active Comparator|Usual care group|Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
3151406|NCT01539421|Experimental|Exercise Intervention|Use of Wii computer for enhanced exercise in COPD patients.
3151407|NCT01539408|Active Comparator|Misoprostol|400 mcg of sublingual misoprostol in one dose
3151408|NCT01539408|Active Comparator|Manual vacuum aspiration (MVA)|Standard surgical treatment (MVA)
3151409|NCT01539395||Inactive Disease|Inactive disease; RRMS patients who have been treated with monthly infusions of Tysabri for 12 months and have had stable disease for the last 6 months or more and show stable or improving neurological deficits over 3 months on Tysabri.
3151410|NCT01539395||Active Disease|Active disease; RRMS patients in acute clinical relapse or with active MRI. Blood sample obtained within 30 days of event AND before steroid treatment (or) patients in early disease on or off first line agents with relapse in prior 3 months AND not treated with steroids for at least 2 months.
3151411|NCT01539395||Active Disease - Steroid Therapy|Patient with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin steroid therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
3151412|NCT01539382|Experimental|Cerebral oxygenation intervention|Cerebral oxygenation levels for people in this group will be monitored and maintained above 60%. If levels decrease to below 60%, a protocol is followed to guide possible interventions to increase cerebral oxygenation levels above 60%
3151413|NCT01539382|No Intervention|Cerebral oxygenation control|Cerebral oxygenation levels for people in this group will be masked and thus doctors and care staff will not use the cerebral oxygenation levels to make any interventions. If the cerebral oxygenation levels drop to below 40%, the cerebral oxygenation levels will be unmasked so that doctors can follow the protocol to increase levels to above 60%.
3151414|NCT01539369|Experimental|High fibre diet|
3151415|NCT01539369|Active Comparator|Healthy eating diet|
3151416|NCT01539356||preterm infants|"preterm infants receiving blood transfusion~preterm infants with neonatal sepsis."
3151417|NCT01539343|Experimental|Antimicrobial Lock Solution|Participants receive the HEAL antimicrobial solution for 2 hours once daily for a minimum of 5 consecutive days. Participants also receive the lock therapy once weekly for two additional weeks. Principle ingredients include minocycline, calcium disodium ethylenediaminetetraacetate (CaEDTA) and ethanol.
3151418|NCT01539317|Active Comparator|Topical liquid lidocaine|
3151419|NCT01539317|Placebo Comparator|Topical Saline|
3151420|NCT01539304|Experimental|CITUS Dry Syrup|Pranlukast dry syrup 10%
3151421|NCT01539304|Placebo Comparator|Placebo|Placebo
3151422|NCT01539291|Active Comparator|High-dose Idelalisib|Participants will receive idelalisib 300 mg twice daily (600 mg per day).
3151423|NCT01539291|Active Comparator|Standard-dose Idelalisib|Participants will receive idelalisib 150 mg twice daily (300 mg per day)
3151424|NCT01539278|Active Comparator|Observation, no surgery (control)|Patients have been diagnosed with mild OSA, no intervention is done; enrolled patients may be randomly or nonrandomly placed in this group
3151425|NCT01539278|Experimental|Surgery (adenotonsillectomy)|Patients who have been diagnosed with mild OSA. Patient may be randomly assigned or non-randomly choose to be in this group; all undergo adenotonsillectomy
3151426|NCT01539265|Experimental|silodosin, arm 1|
3151427|NCT01539265|Experimental|silodosin, arm 2|
3151428|NCT01539265|Placebo Comparator|placebo|
3151429|NCT01539252|Active Comparator|Single dialyzer|Single dialyzer
3151430|NCT01539252|Experimental|Double dialyzer|Two dialyzers in parallel
3151431|NCT01539239|Experimental|Hydrus Aqueous Implant (Treatment)|Cataract surgery plus Hydrus Aqueous Implant
3151432|NCT01539239|Active Comparator|Cataract Surgery (Control)|Cataract surgery only
3151433|NCT01539226|Placebo Comparator|Placebo Vaginal Ring|Vaginal Ring containing 0.0 mg Dapivirine
3151434|NCT01539226|Experimental|Dapivirine Vaginal Ring|Vaginal Ring containing 25mg of Dapivirine
3151435|NCT01539213|Experimental|AIN457|secukinumab (AIN457)
3151436|NCT01539200|Placebo Comparator|Control|
3151437|NCT01539200|Active Comparator|Oral Nutritional Supplement (ONS) and JDR|
3151438|NCT01539187|Experimental|VizAblate intervention|VizAblate System with subject serving as her own control
3151466|NCT01538979|Experimental|BM32 high dose|7 subcutaneous injections of 40 micrograms over two grass pollen seasons
3151467|NCT01538979|Placebo Comparator|Placebo|7 subcutaneous injections over a time span of two pollen seasons
3151559|NCT01538342|Other|healthy patients|1 biopsy of healthy skin.
3151439|NCT01539174|Experimental|Treatment (monoclonal antibody, combination chemotherapy)|Patients receive rituximab IV on days 0, 1, 4, 8, and 15 of course 1; days 1, 8, and 15 of course 2; and day 1 of all subsequent courses. Patients also receive CHOP chemotherapy comprising cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3151440|NCT01539161|Experimental|Reveal XT plus SOC|Standard of care treatment plus the Reveal XT Implantable Cardiac Monitor. Treatment will follow the same schedule of the standard of care arm regarding exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. The addition will be device interrogation at every 6 month exam. Participation will last 36 months.
3151441|NCT01539161|Active Comparator|Standard of Care|Standard of care arm as described by exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. Participation will last 36 months.
3151442|NCT01539135|Active Comparator|Hi-Lo endotracheal tube|Hi-Lo endotracheal tube with barrel shaped cuff with 20 cc of methylene blue instilled above the cuff once post intubation for the duration of the surgical procedure
3151443|NCT01539135|Experimental|TaperGuard endotracheal tube|TaperGuard endotracheal tube with taper shaped cuff with 20 cc methylene blue instilled above the cuff once post intubation for the duration of the surgical procedure
3151444|NCT01539122|Active Comparator|TM Glenoid|Zimmer TM glenoid shoulder replacement component will be used for the glenoid component of the total shoulder replacement.
3151445|NCT01539122|Active Comparator|Cemented Glenoid|Cemented glenoid shoulder replacement component
3151446|NCT01539109|Experimental|Rehab and tDCS|Patients in this group will receive Noninvasive brain stimulation: tDCS, during rehabilitation exercises of the weak upper limbs for 2 hours per day, 5 times a week, for 2 weeks. tDCS is Transcranial Direct Current Stimulation. Prior to this 2-week intervention phase, all patients will be monitored over a 2-week control phase.
3151447|NCT01539109|Sham Comparator|Rehab and sham tDCS|Patients in this group will receive Sham tDCS: placebo noninvasive brain stimulation, during rehabilitation exercises of the weak upper limbs for 2 hours per day, 5 times a week, for 2 weeks. tDCS is Transcranial Direct Current Stimulation. Prior to this 2-week intervention phase, all patients will be monitored over a 2-week control phase
3151448|NCT01539096|Sham Comparator|Sham tDCS plus CIMT|Subjects in this group will be trained on Constraint induced movement therapy (CIMT) for the hand while concurrently receiving placebo noninvasive brain stimulation (tDCS). They will be receiving Sham tDCS: placebo noninvasive brain stimulation. They will be provided treatment for 3 days a week for 5 weeks for 1 hr each day at the Cleveland Clinic. They would be asked to use affected hand in daily activities for 5 hrs everyday at home while wearing a mitt on their unaffected hand.
3151449|NCT01539096|Experimental|tDCS plus CIMT|Patients with stroke affecting the hand will receive Constraint-induced movement therapy (CIMT) concurrent with tDCS: noninvasive brain stimulation. TDCS will be applied to areas of the brain responsible for movement of the affected hand. This combination of tDCS and CIMT will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
3151450|NCT01539083|Experimental|Bortezomib + Cyclophosphamide + Dexamethasone [VCD Induction]|Bortezomib (Velcade) 1.3 milligram per square meter (mg/m^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m^2 orally on Days 1, 8, and 15; and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.
3151451|NCT01539083|Experimental|Thalidomide + Prednisolone [TP Consolidation]|Thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.
3151452|NCT01539083|Experimental|Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]|Bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.
3151453|NCT01539070|Experimental|Eating and physical activity counseling|Participants randomized to intervention received a 6 week curriculum focused on obesity awareness and prevention. A trained nutritionist led diet, healthy growth and physical activity workshops, while a health educator led workshops on instilling healthy habits and routines in childhood. The nurse provided child care and developed relevant games and activities for children while parents attended the workshops.
3151454|NCT01539070|No Intervention|Usual care|According to the existing clinical practice guide within IMSS, obese children may be referred to a nutritionist if the physician considers it necessary, given general dietary advice by the attending physician, or, if necessary, sent for laboratory analyses of blood lipids and glucose. We gave the parents the height and weight results from the measurement of their child and recommended they share results with their physician in their next medical consultation.
3151455|NCT01539057|Experimental|Intravenous Fibrinogen|Fibrinogen will be administered until an expected plasmatic value of 2.9 g / L is achieved.
3151456|NCT01539057|Placebo Comparator|Saline Serum|the same dose in volume of saline dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of saline dilution
3151457|NCT01539044|Active Comparator|IB-neostigmine|subject will be given intermittent bolus of rocuronium during the surgery and reversal of neostigmine at the end of surgery at TOF 2
3151458|NCT01539044|Experimental|CI-Sugammadex|subject will be given continuous infusion of rocuronium and reversal of sugammadex at the end of surgery at PTC 1-2
3151459|NCT01539031|Experimental|10 mg group|
3151460|NCT01539031|Active Comparator|23 mg group|
3151461|NCT01539018|Active Comparator|Sorafenib alone.|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
3151462|NCT01539018|Experimental|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily continuously and UFT 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
3151463|NCT01538992|Experimental|renal denervation|in this group percutaneous renal denervation with Standard steerable Mariner Radiofreqency ablation Catheter (5F or 7F)
3151464|NCT01538992|No Intervention|medical thrapy|medical treatment
3151465|NCT01538979|Experimental|BM32 low dose|7 subcutaneous injections of 20 micrograms over two grass pollen seasons
3151468|NCT01538966|Active Comparator|High dose SRL + weekly Pegvisomant|"High dose of SRL monthly~Sandostatin 30mg~Lanreotide 120mg~Weekly Pegviosmant (40-120mg/week)"
3151469|NCT01538966|Active Comparator|Low dose SRL + daily Pegvisomant|"Low dose of SRL monthly~Sandostatin 10mg~Lanreotide 60mg~Daily Pegviosmant (15-60mg/day)"
3151470|NCT01538966|Active Comparator|Low dose SRL + weekly Pegvisomant|"Low dose of SRL monthly~Sandostatin 10mg~Lanreotide 60mg~Weekly Pegviosmant (40-120mg/week)"
3151471|NCT01538953|Experimental|Handwashing|participants received weekly, in-home handwashing promotion and soap as needed
3151472|NCT01538953|Experimental|handwashing and water treatment|
3151473|NCT01538953|Experimental|Water treatment with sodium hypochlorite|
3151474|NCT01538953|Experimental|Water treatment with flocculent-disinfectant|participants received a supply of flocculent-disinfectant product and instruction to use it to treat drinking water
3151475|NCT01538953|No Intervention|Control|
3151476|NCT01538940|Active Comparator|HIV+, CD4<200, ID vaccine|
3151477|NCT01538940|Active Comparator|HIV+, CD4<200, IM vaccine|
3151478|NCT01538940|Active Comparator|HIV+, CD4>=200, ID vaccine|
3151479|NCT01538940|Active Comparator|HIV+, CD4 >=200, IM vaccine|
3151480|NCT01538940|Other|HIV-, ID vaccine|
3151481|NCT01538940|Other|HIV-, IM vaccine|
3151482|NCT01538927|Experimental|Fibrin Sealant|One quadrant surgically elevated will be closed with fibrin sealant
3151483|NCT01538927|Placebo Comparator|Suture|The surgically elevated flap is closed with non resorbable sutures.
3151484|NCT01538914|Experimental|PVB|Postoperative pain is controlled with local analgesics delivered via PVB.
3151485|NCT01538914|Active Comparator|PCA|Postoperatve pain is controlled with intravenous PCA.
3151486|NCT01538901|Experimental|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix 160mg/g cream) will be applied 1 mm thick on the treated area, which has a maximal diameter of 8 cm2, and will be covered with a semipermeable dressing (Suprasorb F, Lohmann & Rauscher, Vienna, Austria)for 3 hours. Afterwards the cream leftovers will be removed by 0.9% NaCl solution. Following the treated area will be irradiated with heat-free visible red light at a peak wavelength of 630 nm with a single dose of 37 J/cm2 (Actilite model: CL128, PhotoCure, Norway). This treatment will be repeated in two weeks.
3151487|NCT01538901|Active Comparator|imiquimod 5% cream|250 mg imiquimod 5% cream (Aldara 5% cream) will be applied over night, for a total of 3 nights in a week, for duration of 4 weeks.
3151488|NCT01538888|Experimental|WHOLE BODY VIBRATION|SEARCH THE CARDIOPULMONARY EFFECTS IN WHOLE BODY VIBRATION IN HEALTH ELDERLY
3151489|NCT01538875|Experimental|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes (Maximum number of doses: 3).
3151490|NCT01538875|Active Comparator|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
3151491|NCT01538862|Experimental|Granulocyte Colony Stimulating Factor (GCSF)|GCSF 10mcg/kg/d subcutaneously (SQ) for 7 days
3151492|NCT01538849|Experimental|YH4808 A mg (Twice daily)|YH4808 A mg (Twice daily, Oral administration)
3151493|NCT01538849|Experimental|YH4808 B mg (Once daily)|YH4808 B mg (Once daily, Oral administration)
3151494|NCT01538849|Experimental|YH4808 B mg (Twice daily)|YH4808 B mg (Twice daily, Oral administration)
3151495|NCT01538849|Experimental|YH4808 C mg (Once daily)|YH4808 C mg (Once daily, Oral administration)
3151496|NCT01538849|Active Comparator|Esomeprazole 40mg (Once daily)|Esomeprazole 40mg (Once daily, Oral administration)
3151497|NCT01538836|No Intervention|Weight maintenance|Weight maintenance with normal protein intake
3151498|NCT01538836|Active Comparator|Weight loss with normal protein intake|
3151499|NCT01538836|Experimental|Weight loss with protein supplementation|
3151500|NCT01538823||Group 1|Enrollment of surgical patients at Barnes Jewish Hospital (BJH) with a presumptive diagnosis of RCC and planned nephrectomy or partial nephrectomy.
3151501|NCT01538823||Group 2|Surgical patients at BJH with non urological cancers
3151502|NCT01538823||Group 3|Surgical patients at BJH with a presumptive diagnosis of RCC and planned nephrectomy or partial nephrectomy
3151503|NCT01538823||Group 4|Surgical patients at BJH with non urological cancers
3151504|NCT01538823||Group 5|Healthy volunteers with no history of cancer or renal disease
3151505|NCT01538823||Group 6|Patients at BJH/Washington University School of Medicine under post procedure surveillance for RCC recurrence and patients under treatment for metastatic disease.
3151506|NCT01538823||Group 7|Patients with a presumptive diagnosis of bladder cancer or prostate cancer
3151507|NCT01538771|Placebo Comparator|Control group|Received same volume of saline
3151508|NCT01538771|Active Comparator|Darbepoetin group|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning & conventional treatment
3151509|NCT01538758|Active Comparator|Us guided needling|"Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.~After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance."
3151510|NCT01538758|Active Comparator|corticosteroid injection|Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
3151511|NCT01538745|Experimental|Ketamine|0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.
3151512|NCT01538745|Active Comparator|Morphine|0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.
3151513|NCT01538719|Placebo Comparator|Placebo|2:1 randomization
3151514|NCT01538719|Active Comparator|Rilonacept|2:1 randomization
3151555|NCT01538342|Other|chronic plaque psoriasis|3 biopsies: 2 lesional and 1 non-lesional
3151556|NCT01538342|Other|pustular psoriasis|3 biopsies: 2 lesional and 1 non-lesional
3151557|NCT01538342|Other|erythrodermic psoriasis|3 biopsies: 2 lesional and 1 non-lesional
3151515|NCT01538706|Experimental|Hospital-based home care|Patients were included if below the age of 18, had been diagnosed with any type of cancer at least one month prior to inclusion, on intravenous anticancer therapy with a curative intent, and the parent was fluent in speaking and reading Danish. Patients living within a radius of 50 kilometres from the hospital were assigned to the home care program. Moreover, patients were assigned to one of three groups according to the geographical distance from the hospital and timing of the inclusion period: (1) home care group if participating in the program, (2) historical standard care group for an eight-month period before the program started regardless of their residence distance from the hospital, and (3) concurrent standard care group if living more than 50 km from the university hospital.
3151516|NCT01538693|Active Comparator|escitalopram oxalate|Exercise testing with escitalopram oxalate dose
3151517|NCT01538693|Active Comparator|cyproheptadine|exercise testing with cyproheptadine dose
3151518|NCT01538693|Placebo Comparator|placebo|exercise testing with placebo dose
3151519|NCT01538667|Experimental|Arm 1|
3151520|NCT01538667|Experimental|Arm 2|
3151521|NCT01538667|Experimental|Arm 3|
3151522|NCT01538667|Experimental|Arm 4|
3151523|NCT01538654||'enteral protein tube feeding in obese|protein sparing modified fast with a defined enteral formula by tube
3151524|NCT01538641|Experimental|1|
3151525|NCT01538628|Experimental|SpaceOAR|Men meeting the study eligibility criteria will be scheduled for fiducial marker placement using a transperineal approach with ultrasound guidance. Following successful fiducial marker placement, subjects will be randomized (2:1) to the treatment group or control group. Subjects randomized to the treatment group will undergo placement of 10 mL of SpaceOAR hydrogel
3151526|NCT01538628|No Intervention|Control|Men meeting the study eligibility criteria will be scheduled for fiducial marker placement using a transperineal approach with ultrasound guidance. Following successful fiducial marker placement, subjects will be randomized (2:1) to the treatment group or control group. Subjects randomized to the control group will not receive injection of the SpaceOAR hydrogel.
3151527|NCT01538615|Experimental|HOME Plus Intervention|described below
3151528|NCT01538615|No Intervention|Control|Control participants receive a monthly newsletter for the 10 months of the study with tips on healthy eating. The topics do not overlap the intervention content.
3151529|NCT01538602||PCOS patients|
3151530|NCT01538602||Healthy volunteers|
3151531|NCT01538589||Insulin aspart users|
3151532|NCT01538576||Insulin aspart users|
3151533|NCT01538550|Experimental|Flexible sigmoidoscopy|70,000 men and women at age 50-74 years are randomised from the population registry to be invited to have a screening examination using flexible sigmoidoscopy once-only
3151534|NCT01538550|Experimental|iFOBT|70,000 men and women at age 50-74 years randomised from the population registry to be invited to have a screening examination biennially using an immunochemical test for fecal occult blood testing (iFOBT).
3151535|NCT01538511|Experimental|BIAsp 70|
3151536|NCT01538511|Experimental|BIAsp 30|
3151537|NCT01538485|Experimental|Cholecalciferol|
3151538|NCT01538472|Experimental|Y Zevalin + BEAM|"Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with BCNU (300 mg/m2, intravenously (IV) day -6) VP-16 (200 mg/m2 IV every 12 hours, days -5 to -2) cytarabine (200 mg/m2 IV every 12 hours, days -5 to -2) and melphalan (140 mg/m2 IV day -1). Autologous stem cell infused on day 0 then Rituximab 1000 mg/m2 on days +1, and +8 post transplantation.~G-CSF 5 mg/kg given daily starting Day 0 till recovery of granulocytes of 4.0 * 109/L."
3151539|NCT01538459|Active Comparator|Bupivacaine|50 randomized participants in group receive 20cc 0.25% bupivacaine injected perineurally for interscalene nerve block.
3151540|NCT01538459|Experimental|Dexamethasone and Bupivacaine|50 randomized participants in group will 8 mg(2cc of 4mg/cc solution) Dexamethasone added to 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection. Injected perineurally for interscalene nerve block pre-operatively.
3151541|NCT01538446|Experimental|1: Monitoring Arm|Monitoring Arm: dose adjustment of prasugrel with down-adjustment of the dose of prasugrel in high responders and up-adjustment of the dose of prasugrel in low responders
3151542|NCT01538446|Active Comparator|2: Conventional Arm|Conventional Arm: fixed dose of prasugrel 5 mg
3151543|NCT01538433||biopsy-proven IgA nephropathy|
3151544|NCT01538420|Experimental|GLPG0492 oral solution|Multiple ascending doses once daily for 7 days (part 1) or 14 days (part 2), starting at 0.5 mg/day
3151545|NCT01538420|Placebo Comparator|Placebo|Placebo oral solution, once daily for 7 days (part 1) or 14 days (part 2).
3151546|NCT01538407|No Intervention|Control group|No intervention group
3151547|NCT01538407|Active Comparator|Strength training group|The knee extension strength training intervention period is 12 weeks with training sessions three times per week.
3151548|NCT01538394|Experimental|Varenicline & nicotine patches|"Combined therapy by using Varenicline plus nicotine patches.The intervention-phase will comprise two fasses:~Pre-NRT: Patients take 1 week VRN impregnation (0.5mg/day during the first 3 days + 0.5mg twice daily for the next for days)~Treatment: starting at day 8 and during the next 11 weeks patients continue taking VRN 1mg twice daily plus placebo transdermal patches of 30cm2/24 hours per 8 weeks and then 20cm2/24 hours per 3 weeks."
3151549|NCT01538394|Placebo Comparator|Varenicline & placebo patches|"Monotherapy by using Varenicline plus placebo patches.The intervention-phase will comprise two fasses:~Pre-NRT: Patients take 1 week VRN impregnation (0.5mg/day during the first 3 days + 0.5mg twice daily for the next for days)~Treatment: starting at day 8 and during the next 11 weeks patients continue taking VRN 1mg twice daily plus nicotine transdermal patches of 30cm2/24 hours per 8 weeks and then 20cm2/24 hours per 3 weeks."
3151550|NCT01538381|Experimental|Afatinib|Afatinib given orally for 2 weeks after randomization till day -1 prior to surgery (day 0) at a dose of 40 mg/day
3151551|NCT01538381|Other|Observation|No treatment only observation
3151552|NCT01538355|Experimental|Prolonged fasting|Patients undergo an initial 7-day fasting episode.
3151553|NCT01538355|Experimental|Ketogenic low glycemic load treatment|Patients receive a ketogenic low glycemic load treatment from the outset of the study.
3151554|NCT01538355|Experimental|Control diet|Patients stay on their regular diet.
3151560|NCT01538329|Experimental|Amantadine|Patients with amantadine
3151561|NCT01538329|Placebo Comparator|Placebo|Patients with amantadine placebo
3151562|NCT01538316|Active Comparator|Quercetin supplement|
3151563|NCT01538316|Active Comparator|Genistein supplement|
3151564|NCT01538316|Placebo Comparator|Placebo|
3151565|NCT01538303||measurement absolute flow and resistance|
3151566|NCT01538277|Experimental|Contact Force arm|the real-time contact force will be known to the operator
3151567|NCT01538277|Active Comparator|Standard|Standard ablation arm
3151568|NCT01538251|Experimental|Propionyl-L-carnitine|modified release tablets 500 mg
3151569|NCT01538251|Placebo Comparator|Placebo|Modified release tablet 500 mg
3151570|NCT01538238|Experimental|pazopanib|pazopanib 800mg qd
3151571|NCT01538225|Experimental|first sativex, second placebo|2 weeks first titration period (as per approved SmPC), a 2-week first treatment period (Sativex), a 2-week washout, a cross-over followed by another 2 weeks titration period (as per SmPC), followed by a second 2-week period treatment (placebo)
3151572|NCT01538225|Experimental|first placebo, second sativex|2 weeks first titration period (as per approved SmPC), a 2-week first treatment period (placebo), a 2-week washout, a cross-over followed by another 2 weeks titration period (as per SmPC), followed by a second 2-week period treatment (Sativex)
3151573|NCT01538199|Experimental|TLT Treatment Group 1|The TLT group will receive 2 near-infrared radiation via Transcranial LED Therapy (TLT) treatments per week for 8 weeks
3151574|NCT01538199|Sham Comparator|TLT Treatment Group 2|The sham group will receive 2 treatments of the sham device per week for 8 weeks
3151575|NCT01538186||PCI without treating the side branch|
3151576|NCT01538186||PCI with treating the side branch|
3151577|NCT01538173|Experimental|HES group|Application of twice a day 250ml HES 6% for three days postoperatively.
3151578|NCT01538173|Active Comparator|NaCl group|Application twice a day 500ml 9% NaCl for three days postoperatively.
3151579|NCT01538147||Cases|Patients with Severe preeclampsia
3151580|NCT01538147||Control|Patients with normal pregnancies at term
3151581|NCT01538134||Cases|Patients with ultrasonographic diagnosis of fetal growth restriction.
3151582|NCT01538134||Control|Patients with normal pregnancies at term.
3151583|NCT01538121||Cases-Early Severe Preeclampsia|Patients with severe preeclampsia before 34 weeks of gestation
3151584|NCT01538121||Controls|Patients with normal pregnancies at term.
3151585|NCT01538108|Experimental|NMB's PTA Balloon catheter with paclitaxel|
3151586|NCT01538108|Active Comparator|Standard Angioplasty Balloon|
3151587|NCT01538095|Experimental|Treatment (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3151588|NCT01538082||Patients without stress|Patients without any of the next items: Zung's questionnaire score over 19 points; SF-12 questionnaire score over 5 points; Stressful vital events score over 150 points.
3151589|NCT01538082||Patients with stress|Patients with stress, including: Zung's questionnaire punctuation over 19 points; SF-12 questionnaire score over 5 points; stressful vital events score over 150 points. All combinations are considered positive in stress.
3151590|NCT01538069|No Intervention|Control group|
3151591|NCT01538069|Experimental|Exercise group|
3151592|NCT01538069|Experimental|CPAP group|
3151593|NCT01538069|Experimental|Exercise and CPAP group|
3151594|NCT01538056|Experimental|Fenestrated procedure|Fenestrated device with fenestrations for bilateral renal ateries and SMA. May include all three fenestrations or only one
3151595|NCT01538043|Active Comparator|local mud packs and thermal-mineral bath|50 patients with primary knee OA will be treated with daily local mud packs and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
3151596|NCT01538043|No Intervention|regular routine ambulatory care|50 patients, the control group, will continue regular routine ambulatory care
3151597|NCT01538030||Amniotic Fluid Volume > 5|Pregnant patients with gestations between 24-34 weeks with premature rupture of membranes that, when the decision was made to interrupt the pregnancy, had amniotic fluid volume index above 5.1
3151598|NCT01538030||Amniotic Fluid Volume < 5|Pregnant patients with gestations between 24-34 weeks with premature rupture of membranes that, when the decision was made to interrupt the pregnancy, had amniotic fluid volume index of 5 or less.
3151599|NCT01538017|Active Comparator|Collagenase injection|Injection of collagenase obtained from Clostridium Histolyticum in contracture string
3151600|NCT01538017|Active Comparator|Percutaneous needle fasciotomy|PNF ad modum Lermusiaux and Debeyre
3151601|NCT01538004||BpTRU readings in private office area|Consenting patients will be randomly allocated using a random number table to BpTRU in an exam room. The first reading will be done with the research assistant present to ensure proper placement and recording and will then be left alone for the subsequent five measurements at one minute intervals. This will be immediately followed by a second set of readings in the alternate location. During both sets of readings the patient will be seated comfortably in a chair with arms and will be instructed not to talk or cross their legs. The same arm will be used for both sets of measurements with the blood pressure cuff at heart level. The average of the last five out of six blood pressure readings for each office location will be recorded. The decibel levels in each location will be recorded during BP readings using a Reed Sound Level Meter C-322. The patient's weight in kg, height in cm, gender and self reported history of hypertension will also be recorded.
3151602|NCT01538004||BpTRU readings in open office area|Consenting patients will be randomly allocated using a random number table to BpTRU in an open office area The first reading will be done with the research assistant present to ensure proper placement and recording and will then be left alone for the subsequent five measurements at one minute intervals. This will be immediately followed by a second set of readings in the alternate location. During both sets of readings the patient will be seated comfortably in a chair with arms and will be instructed not to talk or cross their legs. The same arm will be used for both sets of measurements with the blood pressure cuff at heart level. The average of the last five out of six blood pressure readings for each office location will be recorded. The decibel levels in each location will be recorded during BP readings using a Reed Sound Level Meter C-322. The patient's weight in kg, height in cm, gender and self reported history of hypertension will also be recorded.
3151603|NCT01537991|Experimental|Group 1A|Group 1A is where less than or equal to 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.
3151604|NCT01537991|Experimental|Group 1B|Group 1A is where more than 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.
3151605|NCT01537991|Experimental|Phase II|All patients will receive radiotherapy to a maximum dose of 65Gy in 20 fractions. The dose to the individual patient will be determined by their individual dose constraints for organs at risk.
3151606|NCT01537978|Experimental|Video game play|Changes in upper limb; strength, active range of motion, electromyographic activity as well as heart rate response.
3151607|NCT01537939|Other|Walking|Quasi-experimental design with one-group, post-test only
3151608|NCT01537926|Experimental|N-acetylcysteine (NAC)|N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days
3151609|NCT01537926|Placebo Comparator|Placebo|Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.
3151610|NCT01537900|Experimental|Grazoprevir 100 mg|Participants received GZR 100 mg once daily (q.d.) for 7 days. Liver FNA was performed on Day 7.
3151611|NCT01537887|Placebo Comparator|Placebo|Administered orally once daily for 10 days during 1 of the 3 crossover periods, separated by at least a 14 day washout period.
3151612|NCT01537887|Experimental|1200 mg LY2484595|Administered orally once daily for 10 days during 1 of the 3 crossover periods, separated by at least a 14 day washout period.
3151613|NCT01537887|Active Comparator|400 mg Moxifloxacin|Positive control, unblinded treatment administered orally once during 1 of 3 crossover periods, separated by at least a 14 day washout period.
3151614|NCT01537874|Experimental|Motivational Interview Intervention|Motivational interviewing session (1 hour in home) plus 2 follow-up phone calls
3151615|NCT01537874|Other|Usual Best Practices|Standard care delivered using informational materials
3151616|NCT01537861|Experimental|Arm 1|"Filgrastim 5 ug/kg from Day -3 to Day 10 of a single cycle.~Bortezomib will be given at the patient's current dose on Days 1, 4, 8, and 11 OR Carfilzomib will be given at the patient's current dose on Days 1, 2, 8, 9, 15, and 16 OR IMID will be given at the patient's current dose once daily on Days 1-21. Patients receiving an IMID (thalidomide, lenalidomide, or pomalidomide) as part of a bortezomib or carfilzomb regimen should continue the same scheduled as the current regimen.~Dexamethasone should be continued at the same dose and schedule as the patient's current regimen.~PO cyclophosphamide should be continued at the same dose and schedule as the patient's current regimen."
3151617|NCT01537848||post-operative collection|patients suffering from a post-operative abdominal collection
3151618|NCT01537835|No Intervention|Standard Scrubs|Participants will be randomized to one of three types of uniforms. This arm is the standard scrub arm. The participants will wear new standard scrubs.
3151619|NCT01537835|Experimental|Antimicrobial Scrubs 1|Participants will be randomized to one of three types of uniforms. In this arm, the participants will wear one of two types of antimicrobial uniforms. These are commercially available and registered with the Environmental Protective Agency.
3151620|NCT01537835|Experimental|Antimicrobial Scrubs 2|Participants will be randomized to one of three types of uniforms. In this arm, the participants will wear one of two types of antimicrobial uniforms. These are commercially available and registered with the Environmental Protective Agency.
3151621|NCT01537822|Experimental|hysteroscopic morcellator|Women, randomized into getting a treatment with the hysteroscopic morcellator.
3151622|NCT01537822|Active Comparator|Resectoscope|Women, randomized into getting a treatment with the resectoscope.
3151623|NCT01537809|Active Comparator|D3 600 IU/ daily|Subjects randomized to 600 IU/day of vitamin D3 taken orally for six months.
3151624|NCT01537809|Active Comparator|D3 1000 IU/ daily|Subjects randomized to 1000 IU/day of vitamin D3 taken orally for six months.
3151625|NCT01537809|Active Comparator|D3: 2000 IU/daily|Subjects randomized to 2000 IU/day of vitamin D3 taken orally for six months.
3151626|NCT01537796|Experimental|In-Person weight loss|Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
3151627|NCT01537796|Experimental|FIT weight loss|Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
3151628|NCT01537796|Experimental|FIT-BT weight loss|Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
3151629|NCT01537783|Experimental|Intervention group|In this arm, patients are treated with chlorhexidine scrubs once a day for 5 days and mupirocin nasal ointment inserted to both nostrils twice a day for 5 days. Both treatments are begun 7 days after enrollment, or when the abscess has healed fully if it has not healed by day 7.
3151919|NCT01535820|Experimental|Treatment sequence BA|
3151630|NCT01537783|No Intervention|Standard of Care|In this arm, patients receive routine care of their abscess, which may or may not include either topical or oral antibiotics, at the discretion of the treating clinician.
3151631|NCT01537770|Active Comparator|Vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
3151632|NCT01537770|Sham Comparator|lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
3151633|NCT01537757|Experimental|Part 1, Panel A - Severe Renal Impairment Group|
3151634|NCT01537757|Experimental|Part 1, Panel B - Healthy Control Group to Match Panel A|
3151635|NCT01537757|Experimental|Part 2, Panel C - Moderate Renal Impairment Group|
3151636|NCT01537757|Experimental|Part 2, Panel D - Healthy Control Group to Match Panel C|
3151637|NCT01537757|Experimental|Part 2, Panel E - Mild Renal Impairment Group|
3151638|NCT01537757|Experimental|Part 2, Panel F - Healthy Control Group to Match Panel E|
3151639|NCT01537744|Experimental|oral 5-azacitidine + romidepsin|oral 5-azacitidine in combination with romidepsin
3151640|NCT01537731||hysterectomy|Patient who previously underwent vaginal or laparoscopic hysterectomy
3151641|NCT01537718|Experimental|REPLY 200 implanted patients|REPLY 200 implanted patients
3151642|NCT01537705|Experimental|Neuron012703|Amino acid formulation for the dietary management of symptoms related to periphal neuropathy.
3151643|NCT01537692|Experimental|BDP HFA Nasal Aerosol 80 mcg/d|single dose, intranasal aerosol
3151644|NCT01537692|Experimental|BDP HFA Nasal Aerosol 320 mcg/d|single dose, intranasal aerosol
3151645|NCT01537692|Active Comparator|BDP HFA Inhalation Aerosol 320 mcg/d|single dose, orally inhaled aerosol
3151646|NCT01537679|Other|Meditation Intervention|
3151647|NCT01537679|Other|Relaxation Intervention|
3151648|NCT01537666|Experimental|Aerovanc 16 mg in healthy volunteers|
3151649|NCT01537666|Experimental|AeroVanc 32 mg in healthy volunteers|
3151650|NCT01537666|Experimental|AeroVanc 80 mg in healthy volunteers|
3151651|NCT01537666|Active Comparator|IV vancomycin in healthy volunteers|
3151652|NCT01537666|Experimental|AeroVanc 32 mg in CF patients|
3151653|NCT01537666|Experimental|AeroVanc 80 mg in CF patients|
3151654|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 4|Dose Level 4
3151655|NCT01537653|Placebo Comparator|Placebo|Placebo
3151656|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 1|Dose Level 1
3151657|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 2|Dose Level 2
3151658|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 3|Dose Level 3
3151659|NCT01537640|Experimental|SAR231893 (REGN668) Drug Product (DP) 1|SAR231893 (REGN668) Drug Product 1 in a single subcutaneous injection
3151660|NCT01537640|Experimental|SAR231893 (REGN668) Drug Product (DP) 2|SAR231893 (REGN668) Drug Product 2 in a single subcutaneous injection
3151661|NCT01537627|Active Comparator|Low-intensity training (LT)|
3151662|NCT01537627|Active Comparator|High-intensity training (HT)|
3151663|NCT01537614|Experimental|COLIMYCINE injectable|
3151664|NCT01537614|Experimental|COLIMYCINE inhalation|
3151665|NCT01537601|Other|Antibiotic prophylaxis alone|Children will be on antibioprophylaxis and will not have a circumcision.
3151666|NCT01537601|Experimental|Circumcision and antibiotic prophylaxis|Children will have a circumcision at the time of valve resection and will be on antibioprophylaxis
3151667|NCT01537588|Active Comparator|Standard|ACL reconstruction with autograft harvest of STG from ACL-deficient leg
3151668|NCT01537588|Experimental|Autograft harvest of STG from ACL-deficient leg|Autograft harvest of STG from leg contralateral to ACL-deficient leg
3151669|NCT01537588|No Intervention|Normal matched|
3151670|NCT01537575|Placebo Comparator|saline solution|
3151671|NCT01537575|Experimental|intravenous immunoglobulins|
3151672|NCT01537562|Active Comparator|Delayed IUC insertion|Patients randomised to delayed, routine, insertion had their IUC inserted at 3-4 weeks (day 21-35 after mifepristone treatment
3151673|NCT01537562|Active Comparator|Early IUC insertion|Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment.
3151674|NCT01537549|Experimental|Juvenon|
3151675|NCT01537536|Experimental|EndoTAG-1|Weekly treatment with EndoTAG-1 (22 mg/m2) plus paclitaxel (70 mg/m2) for 12 weeks (ET+P) followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
3151676|NCT01537523|Experimental|community-care program|receive intervention for 12 weeks
3151677|NCT01537523|No Intervention|control|
3151678|NCT01537510|Active Comparator|Usual Care|
3151679|NCT01537510|Experimental|Clinician intervention only|This arm will entail the development and deployment of alerts and access to a SmartSet at the time of a well child visit with a child between the ages of 6-12 years with a BMI ≥ 95th percentile.
3151680|NCT01537510|Experimental|Clinician intervention plus Direct-to-parent communication|Parents of children enrolled in this intervention arm will receive mailings, text messages and a series of 4 calls with a health coach to encourage behavior change in addition to the intervention received by the clinicians.
3151681|NCT01537497|Experimental|100 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
3151682|NCT01537497|Experimental|250 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
3151683|NCT01537497|Experimental|600 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
3151684|NCT01537497|Placebo Comparator|Placebo|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
3151685|NCT01537484|Experimental|Swedish Massage|Swedish massage for one hour, once per week, for eight weeks. At week 10, 50% of patients will be randomized to a maintenance dose (one hour of Swedish massage every two weeks), and 50% will be randomized to Usual Care.
3151686|NCT01537484|Active Comparator|Light Touch Bodywork|Light-touch bodywork for one hour, once per week, for eight weeks. At week 10, 50% of the patients will be randomized to a maintenance dose (one hour of light-touch massage every two weeks, and 50% will be randomized to Usual Care.
3151687|NCT01537484|Other|Usual Care|Those initially randomized to the usual care control will be rolled into the Swedish massage intervention (one hour of Swedish massage, once/week for eight weeks) at week 25. At week 34, 50% of patients will be randomized to a maintenance dose (one hour of Swedish massage every two weeks), while 50% will be randomized back to Usual Care.
3151688|NCT01537471|Other|Placebo|A counterbalanced design will be used with each male subject receiving placebo and each of the anti-histamine low (12.5 mg) and high (25 mg) doses in a counterbalanced order to keep order of administration from being confounded with dose level. On one of three visits, a subject will receive placebo. The subject, study coordinator, co-investigator and outcomes assessor will remain blinded to what they received until data analysis is completed.
3151689|NCT01537471|Experimental|Meclizine|A counterbalanced design will be used with each male subject receiving placebo and each of the anti-histamine low (12.5 mg) and high (25 mg) doses in a counterbalanced order to keep order of administration from being confounded with dose level. By the time they finish, they will have all received placebo, 12.5mg meclizine and 25mg meclizine. The subject, study coordinator, co-investigator and outcomes assessor will remain blinded to what they received until data analysis is completed.
3151690|NCT01537458||Isolated TI repair|Patients that underwent isolated tricuspid valve repair
3151691|NCT01537445||Patients with pancreastransplantation|All patients undergoing pancreas transplantation.
3151692|NCT01537432|Placebo Comparator|placebo|placebo
3151693|NCT01537432|Experimental|secukinumab|secukinumab
3151694|NCT01537419|Active Comparator|Family-Enhanced Non-directive Supportive Therapy|Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
3151695|NCT01537419|Experimental|Attachment-Based Family Therapy|Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.
3151696|NCT01537393|Other|0-7d Preservation Time Group|Subjects in this arm will receive cornea tissue transplant with cornea tissue preserved for 0 to 7 days prior to transplant.
3151697|NCT01537393|Other|8-14d Preservation Time Group|Subjects in this arm will receive cornea tissue transplant with cornea tissue preserved for 8 to 14 days prior to transplant.
3151698|NCT01537380|Experimental|Cefazoline|
3151699|NCT01537367|Experimental|Enhanced contact only|"Patients allocated to the Enhanced contact only arm will receive:~HIV information and education~Specific to importance of coming to care regularly~Generic and tailored components~Approximately 10 minutes in length~Enhanced contact over time~Collect locator information~Follow-up contact after medical visit (face-to-face or phone)~Appointment reminders (telephone, e-mail, text message)~Periodic telephone contact across time (support, update locator info, refer any unmet needs to Case Manager)~Attempt to make immediate contact following a missed visit and re-schedule appointment (use locator contact info)"
3151700|NCT01537367|Experimental|Enhanced contact plus behavioral skills|Enhanced contact plus behavioral skills is the longer experimental intervention arm.
3151701|NCT01537367|Active Comparator|Standard of Care|Patients assigned to control arm will receive the standard services offered to all patients at the clinic.
3151702|NCT01537354|Active Comparator|Survanta®|Survanta® (Beractant, Abbot Laboratories, Columbus, OH) Surfactant will be administered by respiratory therapist not involved in patient's care.
3151703|NCT01537354|Active Comparator|Curosurf®|Curosurf® (Cornerstone Therapeutics, Inc., Cary, NC Surfactant will be administered by respiratory therapist not involved in patient's care.
3151704|NCT01537341|Active Comparator|Traditional Treadmill|Participants will follow the same guidelines as the split belt component but will complete the intervention on a traditional, single belt/speed treadmill.
3151705|NCT01537341|Experimental|Split-belt|Participants will walk on a custom-built split-belt treadmill comprised of two separate belts, each with its own motor, that permitted the speed of each belt (i.e. each leg) to be controlled independently.
3151706|NCT01537328|Experimental|Progressive Treatment|Progressive intervention will involve the early initiation of intensive rehabilitation using progressive exercise and faster progression to functional strengthening exercises.
3151707|NCT01537328|Active Comparator|Traditional treatment|Traditional intervention represents the synthesis of previously published total knee arthroplasty rehabilitation programs.
3151708|NCT01537315|Placebo Comparator|Matching Placebo|Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) will be randomized to either hydroxychloroquine (HCQ) or matching placebo in a 3:1 ratio (approximately 39 to HCQ and 13 to placebo)
3151709|NCT01537315|Experimental|Hydroxychloroquine|Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) will be randomized to either hydroxychloroquine (HCQ) or matching placebo in a 3:1 ratio (approximately 39 to HCQ and 13 to placebo)
3151710|NCT01537302|Experimental|Treatment arm|
3151711|NCT01537289|Experimental|Pigtail catheter|
3151712|NCT01537289|Active Comparator|Traditional chest tube|28-French chest tube
3151713|NCT01537276|Experimental|real-time fluoroscopy|evaluating the tubal patency and pathology under fluoroscopy real-timely
3151714|NCT01537276|No Intervention|respective image|evaluating the tubal patency and pathology by Two supine and two oblique static images.
3151715|NCT01537263||Ultrasound Perfusion Imaging|Patient with subarachnoid hemorrhage.
3151716|NCT01537250|Active Comparator|Nemonoxacin 750 mg|Nemonoxacin 750 mg 2 tablets.
3151717|NCT01537250|Active Comparator|Nemonoxacin 500 mg|Nemonoxacin 500 mg 3 tablets
3151718|NCT01537250|Active Comparator|Levofloxacin 500 mg|Levofloxacin 500 mg
3151719|NCT01537237||intra-procedure 3DATG|Patients who will undergo intra-procedure 3DATG rotational angiography to guide their ablation procedure
3151720|NCT01537237||pre-procedure CT|Patients who will undergo pre-procedure CT scan to guide their ablation procedure
3151721|NCT01537224|Other|neurostimulation|
3151722|NCT01537211|Experimental|Microprocessor knee then Mechanical knee|
3151723|NCT01537211|Experimental|Mechanical Knee then Microprocessor knee|
3151724|NCT01537198||Pediatric Participants at High Risk of RSV|Pediatric participants at high risk of respiratory syncytial virus (RSV) in need of the prevention of serious lower respiratory tract disease caused by RSV were prescribed Synagis prophylaxis in usual practice according to the approved Korean product label. The decision to prescribe or not to prescribe Synagis was taken prior to a participant's enrollment in the study.
3151725|NCT01537185|Experimental|Cohort 1 SPWCV+Alum 100 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
3151726|NCT01537185|Experimental|Cohort 2 SPWCV+Alum 300 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
3151727|NCT01537185|Experimental|Cohort 3 SPWCV+Alum 600 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
3151728|NCT01537185|Placebo Comparator|Normal Saline Injection|"placebo group within each cohort receive 3 injections of normal saline 28 days apart~normal saline injection: 3 cohorts of normal saline injection"
3151729|NCT01537172|Experimental|ONO-4053|E Experimental Intervention Drug: ONO-4053
3151730|NCT01537172|Placebo Comparator|Placebo|
3151731|NCT01537159||Acute Myelogenous Leukemia (AML)|Patients who have been diagnosed with AML
3151732|NCT01537146|Active Comparator|Femoral Block|
3151733|NCT01537146|Active Comparator|Local Infiltration Anagesia|
3151734|NCT01537133|Experimental|Inhaled corticosteroid|Fluticasone (250 mcg/puff, one puff, twice a day)
3151735|NCT01537133|Placebo Comparator|Placebo|Placebo fluticasone (one puff, twice a day)
3151736|NCT01537133|No Intervention|Healthy Control|
3151737|NCT01537133|No Intervention|Atopic Non-asthmatics|
3151738|NCT01537120|Experimental|Placebo → Vildagliptin|Participants received placebo tablets orally, twice a day for 3 weeks, and then over the next 12 weeks received vildagliptin 50 mg tablets orally, twice daily
3151739|NCT01537107|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sirolimus PO QD and vismodegib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3151740|NCT01537094|Active Comparator|Vitamin C low dose|vitamin C 250 mg oral once daily
3151741|NCT01537094|Active Comparator|Vitamin C high dose|vitamin C 1,000 mg oral once daily
3151742|NCT01537094|Placebo Comparator|Placebo|Placebo oral once daily
3151743|NCT01537081|Experimental|Mucinex 2400 mg/day|The study is designed to meet regulatory requirement outside the US. The dosing regimen and assessments timepoints were dictated by IR GGE and do not match approved Mucinex labeling. Participants were instructed to take 2 Mucinex 600 mg tablets and 1 placebo tablet matching the 200 mg IR guaifenesin tablet by mouth, every 12 hours for 7 days. To ensure complete blinding, on Hours 6 and 18, this treatment group took 2 matching Mucinex placebo tablets combined with 1 IR guaifenesin placebo tablet.
3151744|NCT01537081|Active Comparator|Immediate-release Guaifenesin 800 mg/Day|The dosing regimen and assessments timepoints were dictated by immediate-release guaifenesin (IR GGE). Participants were instructed to take 1 immediate-release guaifenesin (IR GGE) 200 mg tablet and 2 matching Mucinex placebo tablets by mouth, every 6 hours for 7 days.
3151745|NCT01537081|Placebo Comparator|Placebo|Double dummy technique was employed requiring a large number of tablets and water to be consumed. Participants were instructed to take 2 matching Mucinex placebo tablets combined with 1 matching IR guaifenesin placebo tablet by mouth, every 6 hours for 7 days.
3151746|NCT01537068|Experimental|Desvenlafaxine|Serotonin-norepinephrine reuptake inhibitors (SNRIs) antidepressant drug
3151747|NCT01537068|Placebo Comparator|Placebo|Placebo treatment
3151748|NCT01537055|Experimental|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy
3151749|NCT01537055|Active Comparator|levofloxacin-based triple therapy|levofloxacin-based triple therapy for 10 days
3151750|NCT01537042|Experimental|Rotigotine|"Rotigotine Transdermal Patch~1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h."
3151751|NCT01537042|Placebo Comparator|Placebo|Transdermal patch matched according to patch size and appearance.
3151752|NCT01537029|Experimental|Doxorubicin and cyclophosphamide|
3151753|NCT01537016|Experimental|Promogran and High EPA|Wound with high EPA will be treated with promogran and covered with a secondary dressing that is standard of care
3151754|NCT01537016|Experimental|Promogran and Low EPA|Wounds with low EPA will be treated with Promogran and covered with a secondary which is standard of care
3151755|NCT01537016|Active Comparator|High EPA and standrad of care|Wounds with high EPA will get standard of care as in line with current practice as they is no other test currently available for EPA
3151756|NCT01537016|Active Comparator|Low EPA and standard of care|Low EPA wounds will be treated with the standard of care for diabetic foot ulcers.
3151757|NCT01537003|Experimental|Promogran and Low EPA|Patients with low EPA will be treated with PROMOGRAN and standard of care for vlu compression
3151758|NCT01537003|Active Comparator|Low EPA and compression|Patients with Low EPA will only get standard of care for VLU which is compression.
3151759|NCT01537003|Active Comparator|High EPA and compression|Patients with high EPA will get standard of care for VLU which is compression.
3151760|NCT01537003|Experimental|Promogran High EPA|patients with HIGH EPA will then be treated with PROMOGRAN and standard of care for VLU compression
3152237|NCT01533532|Experimental|KLH-2109, medium dose|
3151761|NCT01536990||Stroke|Medically stable patients receiving inpatient or outpatient physical therapy care for lower extremity dysfunction secondary to stroke.
3151762|NCT01536977|Experimental|Supportive care (BBT-I)|"Patients complete the BBT-I, comprising the following modules: 1) What to expect in terms of fatigue and insomnia as it occurs with cancer and cancer treatment; 2) A review of the Spielman Model of insomnia; 3) A discussion (based on the Spielman Model) regarding how insomnia and fatigue may co-occur and interact in the context of cancer and cancer treatment; 4) An introduction to the concept and practice of Stimulus Control Therapy; 5) An introduction to Sleep Scheduling Specifically modified for cancer patients; 6) Sleep Compression; and 7) Concomitant Medications and Substance Use."
3151763|NCT01536964|Experimental|Morphine|the effect of morphine on prasugrel absorption will be tested
3151764|NCT01536964|Placebo Comparator|Saline|
3151765|NCT01536951|Placebo Comparator|Placebo|Placebo matching LY3009104 tablets in size and appearance will be administered orally in 1 out of 3 study periods in Part A and Part B.
3151766|NCT01536951|Experimental|LY3009104|"Part A. Single escalating dose of up to 40 milligrams (mg) of LY3009104 administered orally in 2 out of 3 study periods separated by at least a 3 day wash-out period between each dose.~Part B. Single dose of LY3009104 determined in Part A administered orally in 1 out of 3 study periods separated by at least a 3 day wash-out period between each period."
3151767|NCT01536951|Active Comparator|400 mg moxifloxacin|Part B. 400 mg moxifloxacin will be administered orally in 1 out of 3 study periods separated by at least a 3 day wash-out period between each period.
3151768|NCT01536938|Active Comparator|Calcipotriol|"Calcipotriol aerosol foam: calcipotriol 50 mcg/g.~Applied once daily for up to 4 weeks"
3151769|NCT01536938|Active Comparator|Betamethasone|"Betamethasone dipropionate aerosol foam: betamethasone 0.5 mg/g (as dipropionate)~Applied once daily for up to 4 weeks"
3151770|NCT01536938|Experimental|LEO 90100|"LEO 90100 aerosol foam: calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)~Applied once daily for up to 4 weeks"
3151771|NCT01536886|Placebo Comparator|LEO 90100 vehicle|Aerosol foam with no active ingredient
3151772|NCT01536886|Active Comparator|Betamethasone plus calcipotriol|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) ointment
3151773|NCT01536886|Experimental|LEO 90100|LEO 90100 aerosol foam: calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)
3151774|NCT01536886|Placebo Comparator|Ointment vehicle|Ointment with no active ingredients
3151775|NCT01536860|Placebo Comparator|Control Test Drink|control drink
3151776|NCT01536860|Experimental|Experimental Test Drink 1|control drink containing ingredient 1
3151777|NCT01536860|Experimental|Experimental Test Drink 2|Control drink containing ingredient 2
3151778|NCT01536847|Placebo Comparator|Control Test Drink|Control drink
3151779|NCT01536847|Experimental|Experimental Test Drink 1|Control drink containing ingredient 1
3151780|NCT01536847|Experimental|Experimental Test Drink 2|Control drink containing ingredient 2
3151781|NCT01536834|Experimental|Medical Device|The Investigational device is a liquid in a delivery system for the treatment of verrucas
3151782|NCT01536808|Experimental|Type 2 Diabetes Mellitus|
3151783|NCT01536795|Experimental|WR279396 with Tegaderm dressing|24 patients will be randomly allocated to WR279396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing
3151784|NCT01536795|Experimental|WR279 396 with Gauze and Tape Dressing|24 subjects will be randomly allocated to WR279396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only).
3151785|NCT01536782|Active Comparator|Bolus|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
3151786|NCT01536782|Active Comparator|Gravity|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
3151787|NCT01536782|Active Comparator|Pump|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
3151788|NCT01536769||Parkinson patients|Parkinson patients, symptom onset > 50 years of age, non-smoker, no relevant gastrointestinal or ENT diseases
3151789|NCT01536769||Control subjects|No parkinsonism, age and gender matched to PD subjects, non-smoker, no relevant gastrointestinal or ENT diseases
3151790|NCT01536756|Experimental|Exercise Intervention -- Physical Rehabilitation Program|
3151791|NCT01536756|No Intervention|Wait List Control Group|
3151828|NCT01536483|Experimental|Butyrate|"New born with a birth weight <1000g: Seven enemas of butyrate will be performed every 2 days from PND5~New born with a birth weight >1000g: Seven enemas of butyrate will be performed every day from PND5"
3151792|NCT01536743|Experimental|PD0332991|"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."
3151793|NCT01536730|Experimental|Homework Intervention Strategy|
3151794|NCT01536730|No Intervention|Control|
3151795|NCT01536717|Active Comparator|Bupivacaine hydrochloride 0.5%|Bupivacaine hydrochloride is related chemically and pharmacologically to the aminoacyl local anesthetics. Bupivacaine hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
3151796|NCT01536717|Placebo Comparator|Sodium chloride 0,9%|
3151797|NCT01536704|Experimental|Test nicotine lozenge (2 mg)|2 mg test nicotine lozenge to be chewed.
3151798|NCT01536704|Experimental|Test nicotine lozenge (4 mg)|4 mg test nicotine lozenge to be chewed.
3151799|NCT01536704|Active Comparator|Reference nicotine lozenge (2 mg)|2 mg reference nicotine lozenge to be chewed.
3151800|NCT01536704|Active Comparator|Reference nicotine lozenge (4 mg)|4 mg reference nicotine lozenge to be chewed.
3151801|NCT01536691|Experimental|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
3151802|NCT01536691|Active Comparator|ondansetron, aprepitant, dexamethasone|ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
3151803|NCT01536678|Active Comparator|Test formulation of levothyroxine|Single dose of 600 mcg of levothyroxine administered in dosing period 1 or 2..
3151804|NCT01536678|Active Comparator|Reference formulation of levothyroxine|Single dose of 600 mcg of levothyroxine administered in dosing period 1 or 2.
3151805|NCT01536665|Experimental|Low|
3151806|NCT01536665|Experimental|Medium|
3151807|NCT01536665|Experimental|High|
3151808|NCT01536652||BIAsp 30 users|
3151809|NCT01536639||BIAsp 30 users|
3151810|NCT01536626||BIAsp 30 users|
3151811|NCT01536613||BIAsp 30 users|
3151812|NCT01536600||BIAsp 30 users|
3151813|NCT01536587|Other|Single Arm|Inhalation of salmeterol 50 µg twice daily over 4 weeks
3151814|NCT01536574|Experimental|Requip PR|Ropinirole PR tablets of 2.0 mg, 4.0mg and 8.0 mg
3151815|NCT01536561|Experimental|open-label, dose escalation|"Each subject will undergo two phases of study. The first phase, termed tracer Study, involves the injection of low-radioactivity doses (about 5 mCi) of 131-I anti-B1 for the purposes of determining the rate of whole body clearance of radiation so that a whole body radiation can be calculated. The calculated whole-body radiation dose per mCi administered can then be used to determined how many mCi will be required to deliver a specified whole-body radiation dose in the second phase of the study for each patient, termed radio-immunotherapy dose in a tracer-projected whole-body radiation dose will be used for dose escalation with a minimum of three subjects per dose level."
3151816|NCT01536548|Experimental|Skin drawing|
3151817|NCT01536548|Active Comparator|No skin drawing|
3151818|NCT01536535|Experimental|Mesalamine Only|"mesalamine (Pentasa®) comes in 500mg capsules, and doses will need to be rounded to the nearest 500mg increment, with a maximum dose of 76 mg/kg/day. The average dose for the pediatric population will be approximately 70 mg/kg/day. Patients will be allowed to escalate to the final dose over 4 days to minimize sideeffects such as headache.~If a patient does not respond to mesalamine then prednisone will be added to the treatment."
3151819|NCT01536535|Experimental|Corticosteroids/mesalamine|Patients will begin with Corticosteroids, which will be weaned as tolerated and mesalamine added.
3151820|NCT01536522|Active Comparator|Nutritional Approach for Asthma|individuals will be provide a pre measured dose of medium chain triglyceride to consume along with their meals. They will be instructed to add the MCT to their meal 3 times per day
3151821|NCT01536522|Placebo Comparator|Standard American Diet|patients will consume their usual diet with a pre measured dose of canola oil in place of the medium chain triglyceride as a control group. They will be instructed to add the placebo dose to their meal 3 times a day
3151822|NCT01536522|Active Comparator|Alternate Day Diet|"patients will consume a regular Standard American Diet for 4 weeks and then provided a regulated dosed quantity of low caloric value shakes. they will consume this on alternating days"
3151823|NCT01536522|Active Comparator|Whole Lung Allergen Challenge|patients with or without asthma will be given controlled doses of specified allergens
3151824|NCT01536509|Experimental|Telehealth Behavioral Treatment|
3151825|NCT01536509|Active Comparator|Education Only|
3151826|NCT01536496|Active Comparator|Control (INR, PTT, fibrinogen, D-dimer)|Patients randomized to the Control Group will receive blood component therapy guided by conventional coagulation tests per usual clinical practice. The control arm involves the use of conventional coagulation tests (aPTT, INR, fibrinogen level, D-dimer) to diagnose and describe post-injury coagulopathy and to guide blood product replacement. In the Control Group, blood will be drawn for conventional coagulation testing (aPTT, INR, platelet count, fibrinogen level, D-dimer) at Baseline (as defined above), then twice more during the first six hours at the discretion of the treating team, then again at 12 hours and at 24 hours post-injury. The current institutional massive transfusion protocol will be followed. Only the results pertinent to the group to which randomized will be released to the treating team, unless otherwise requested.
3151827|NCT01536496|Active Comparator|Test (r-TEG)|Patients randomized to the r-TEG guided haemostatic resuscitation group (Test Group) will receive blood component therapy per usual clinical practice. The test arm involves the use of rapid-TEG to diagnose and describe post-injury coagulopathy and to guide blood product replacement per institutional algorithm. In the Test Group, blood for r-TEG will be collected on admission, or upon entering the operating room, depending on the acuity of the injury (Baseline), and this will be followed by two additional r-TEG analyses during the first six hours at the discretion of the treating team (attending surgeon, anesthesiologist) and then two further r-TEG analyses at 12 hours and at 24 hours post-injury respectively. The current institutional massive transfusion protocol will be followed. Only the results pertinent to the group to which randomized will be released to the treating team, unless otherwise requested.
3151917|NCT01535833|Other|Robotic sacral colpopexy|To assess subjects with stage 2 pelvic organ prolapse undergoing robotic sacral colpopex
3151829|NCT01536483|No Intervention|Therapeutic Abstention|The protocol will pretend enema: instillation in the diaper the product under consideration, to make the two indistinguishable processes (time, odor, wicking diaper ...)
3151830|NCT01536470|Experimental|Noradrenaline|Continuous infusion of noradrenaline to maintain arterial blood pressure management in high-risk surgical patients
3151831|NCT01536470|Experimental|Ephedrine chorhydrate|Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline)using intravenous bolus of Ephedrine chorhydrate
3151832|NCT01536444|Experimental|Micrografting|
3151833|NCT01536431|Experimental|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
3151834|NCT01536431|Active Comparator|Pro insulin peptide & saline|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
3151835|NCT01536431|Placebo Comparator|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls)
3151836|NCT01536418|Experimental|GSK1605786A, 500 milligrams, once daily|500 milligrams once daily, orally administered for 12 weeks
3151837|NCT01536418|Experimental|GSK1605786A, 500 milligrams twice daily|500 milligrams twice daily, orally administered for 12 weeks
3151838|NCT01536405|Experimental|MMRV (AMP)|Participants received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)
3151839|NCT01536405|Active Comparator|MMRV (2006 process)|Participants received two 0.5 mL subcutaneous injections of MMRV vaccine made with the 2006 manufacturing process
3151840|NCT01536392|Experimental|Granisetron|Group A: 34.3 mg of granisetron formulated in transdermal patch replaced every 7 days. Transdermal patch placed/replaced prior to the intravenous (IV) infusion of cisplatin. At cycle 1, participants receive IV granisetron prior to IV cisplatin and prior to administration of transdermal patch.
3151841|NCT01536392|Experimental|Ondansetron|Group B: 8 mg of ondansetron orally thrice daily starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
3151842|NCT01536379|Experimental|Belimumab 10 mg|Subjects will receive belimumab 10 mg/ Kilogram (kg) infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care.
3151843|NCT01536379|Placebo Comparator|Placebo|Subjects will receive placebo infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care
3151844|NCT01536366|Experimental|Group 1|Period 1: BIA 9-1067 + repaglinide Period 2: Repaglinide
3151845|NCT01536366|Experimental|Group 2|Period 1: Repaglinide Period 2: BIA 9-1067 + repaglinide
3151846|NCT01536353|Experimental|AGSAV301|
3151847|NCT01536353|Active Comparator|Exforge 10/160|
3151848|NCT01536327||Observation|Patients with Metachromatic Leukodystrophy disease or profound suspicion for Metachromatic Leukodystrophy disease
3151849|NCT01536301|Active Comparator|Morphine|The patients in this arm will have post-operative analgesia including morphine (patient controlled analgesia).
3151850|NCT01536301|Experimental|Oxycodone|The patients in this arm will have post operative analgesia including oxycodone (patient controlled analgesia).
3151851|NCT01536288|Active Comparator|Rhodiola crenulata-placebo sequence|Rhodiola crenulata for the first treatment period and placebo for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.
3151852|NCT01536288|Active Comparator|Placebo-Rhodiola crenulata sequence|Placebo for the first treatment period and Rhodiola crenulata for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.
3151853|NCT01536275|No Intervention|Early parenteral nutrition|Parenteral nutrition supplements insufficient enteral nutrition from admission to ICU according to the current standard of care per center
3151854|NCT01536275|Experimental|Late parenteral nutrition|Parenteral nutrition will be withheld during the first 7 days of ICU stay
3151855|NCT01536262|Other|Tiotropium + Olodaterol (high dose)|Tiotropium and Olodaterol FDC solution for inhalation - RESPIMAT
3151856|NCT01536262|Other|Olodaterol|Olodaterol solution for inhalation - RESPIMAT
3151857|NCT01536262|Other|Tiotropium + Olodaterol (low dose)|Tiotropium and Olodaterol FDC solution for inhalation - RESPIMAT
3151858|NCT01536249|Experimental|Dexpramipexole single dose & 12 Doses Cimetidine|300 mg Dexpramipexole Oral Dose (to be taken in conjunction with multiple doses of Cimetidine at 400 mg per dose)
3151859|NCT01536249|Experimental|Dexpramipexole single Dose|300 mg Dexpramipexole Oral Dose
3151860|NCT01536236|Active Comparator|Subthreshold programming|During one of the first 2 weeks of the trial the subject will be randomized to a subthreshold stimulation arm. They will be blinded and receiving therapy, but will it will be delivered at a level (subthreshold) that they will not feel the stimulation.
3151861|NCT01536236|Placebo Comparator|Placebo or Stimulation off arm|During one of the first two weeks of the study, the patient will be randomized to a no stimulation arm. They will be blinded and will not be receiving therapy.
3151862|NCT01536236|Active Comparator|Optimal stimulation programming|During the third week of the trial period, all subjects will receive optimal stimulation.
3151863|NCT01536223|Active Comparator|PF group|the group of participants who undergoing cisplatin and 5-fluorouracil(PF)neoadjuvant chemotherapy
3151864|NCT01536223|Experimental|TPF group|TPF(docetaxel , cisplatin and 5-fluorouracil)neoadjuvant chemotherapy
3151865|NCT01536210|Experimental|YY-162|"YY-162(Ginkgo Extract 30mg + Ginseng Extract 50mg)~1T/Three times a day(Tid) for 8 weeks, PO medication"
3151866|NCT01536210|Placebo Comparator|Placebo|Placebo 1T /Three times a day(Tid) for 8 weeks, PO medication
3151867|NCT01536197||Gastric Bypass|morbidly obese subjects undergoing gastric bypass surgery
3151868|NCT01536197||Gastric banding|morbidly obese subjects undergoing laparoscopic gastric banding surgery
3151869|NCT01536197||Sleeve gastrectomy|morbidly obese subjects undergoing sleeve gastrectomy surgery
3151918|NCT01535820|Experimental|Treatment sequence AB|
3151870|NCT01536184|Experimental|Receives COS Intervention|Circle of Security (COS) Family Intervention (B. Marvin model) is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour. The protocol itself involves a series of activities and repeated videotaped interactions between the child and their caregiver which are reviewed by the therapist who has established themselves with the caregiver as a secure base from which the attachment relationship may be explored.
3151871|NCT01536184|No Intervention|Control Group-Regular FASD Services|Regular FASD Services include general information on Fetal Alcohol Spectrum Disorder (FASD) with general behavioural management strategies and parental supports.
3151872|NCT01536171||Shod versus Barefoot Running|two running conditions, with normal running shoes and barefoot
3151873|NCT01536158|Active Comparator|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
3151874|NCT01536158|Active Comparator|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
3151875|NCT01536145|Experimental|Single agent CP-751,871|dose escalation design
3151876|NCT01536132|Active Comparator|Levosimendan|levosimendan at a dose of 0.2 micrograms/kg/min for 6 hours intravenous infusion
3151877|NCT01536132|Placebo Comparator|Placebo|placebo (same appereance than levosimendan in colour) at a dose of 0.2 micrograms/kg/min for 6 hours intravenous infusion
3151878|NCT01536119|Experimental|Coparenting Breastfeeding Support Intervention|The intervention group will receive a in-hospital discussion, a video, a workbook,a breastfeeding booklet, access to a secure study website, two follow-up emails, and one telephone call.
3151879|NCT01536119|No Intervention|Usual Care Group|The usual care group will receive standard postpartum care in the hospital and in the community
3151880|NCT01536106|Experimental|Treatment|Implantation of bone marrow derived mononuclear cells
3151881|NCT01536106|Placebo Comparator|Placebo Control|Infusion of autologous peripheral blood
3151882|NCT01536093|Experimental|Colostrum|oropharyngeal administration of own mother's colostrum
3151883|NCT01536093|Placebo Comparator|Placebo|oropharyngeal administration of sterile water
3151884|NCT01536080||Reflux esophagitis (RE)|
3151885|NCT01536080||Non-erosive reflux disease (NERD)|
3151886|NCT01536080||Functional heartburn (FH)|
3151887|NCT01536067|Experimental|Treatment (monoclonal antibody therapy)|"INDUCTION PHASE: Patients receive ofatumumab IV on days 1, 8, and 15 and bortezomib SC on days 8 and 15. Beginning on course 2, patients receive ofatumumab IV on days 1 and 15 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Beginning 8 weeks after course 4 of induction phase, patients receive ofatumumab IV on day 1 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
3151888|NCT01536054|Experimental|Treatment (vaccine, sirolimus, GM-CSF)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and GM-CSF SC on days 1-4. Patients also receive sirolimus PO QD on days 1-14 OR 15-28 OR 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive an additional course of ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine only followed by ALVAC(2)-NY-ESO-I (M)/TRICOM vaccine SC 8 weeks after completion of course 4.
3151889|NCT01536041|Experimental|Experimental 200 mg dose|
3151890|NCT01536041|Experimental|Experimental 20 mg dose|
3151891|NCT01536041|Active Comparator|Active Comparator Montelukast|
3151892|NCT01536041|Placebo Comparator|Placebo Comparator|
3151893|NCT01536028|Active Comparator|BIAsp 30|
3151894|NCT01536028|Experimental|BIAsp 50|
3151895|NCT01536028|Experimental|BIAsp 70|
3151896|NCT01536028|Active Comparator|IAsp|
3151897|NCT01536015|Experimental|Rotigotine|Rotigotine patch titrated from 4 mg/24 h - 8 mg/24 h or until effective or maximum dose is reached.
3151898|NCT01536015|Placebo Comparator|Placebo|Placebo patch.
3151899|NCT01536002|Experimental|Pharmacokinetics|Propofol pharmacokinetics
3151900|NCT01535989|Experimental|intravenous|dose escalation
3151901|NCT01535976|Placebo Comparator|Placebo|.9 normal saline infusion
3151902|NCT01535976|Active Comparator|Ketamine|Infusion of ketamine
3151903|NCT01535963||cutaneous surgery|Patients undergoing cutaneous surgery
3151904|NCT01535950|Experimental|LFG316|
3151905|NCT01535950|Sham Comparator|Sham|
3151906|NCT01535937|Experimental|Ketamine|0.5 mg/kg of ketamine IV over 40 minutes
3151907|NCT01535937|Active Comparator|midazolam|0.025 mg/kg IV over 40 minutes
3151908|NCT01535924|Experimental|Treatment (combination chemotherapy)|Patients receive gemcitabine hydrochloride IV over 30 minutes on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1 and 2. Treatment repeats every 21-28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3151909|NCT01535898||Pts having an MRI|This is a technology assessment protocol. The study is designed to assess the utility of the technology using a limited number of participants.
3151910|NCT01535885|Experimental|Multi-Virus CTLs|The treatment plan delivers a single dose of Multi-Virus CTL to all patients enrolled on study.
3151911|NCT01535872|Experimental|DHEA treatment|
3151912|NCT01535872|No Intervention|No treatment|
3151913|NCT01535859|Experimental|Cabergoline|
3151914|NCT01535859|Placebo Comparator|Placebo|
3151915|NCT01535846|Experimental|Conscious food tasting intervention|Instead of focusing on dieting rules to restrict food intake, paying attention to sensory stimulation allow the recognition of internal cues of hunger and satiety which can be helpful to facilitate a more internalized regulation of food intake among restrained eaters. In the experimental group, the conscious food tasting intervention will be conducted by a registered dietitian into small groups of ten to twelve women during six weekly 2-hour workshops. Workshops will be taking place in a well-ventilated room to insure that there are no extraneous odours or noises that may hamper the activities involving senses.
3151916|NCT01535846|No Intervention|Control|
3151920|NCT01535807|Active Comparator|CorMatrix Group|"The treatment Cormatrix group will receive the CorMatrix EMC during surgery for the closure of the pericardium according to the specific recommended surgical technique."
3151921|NCT01535807|No Intervention|Control|"The control No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care."
3151922|NCT01535794||18-26 year old men who have sex with men|
3151923|NCT01535781|Placebo Comparator|Placebo|Patients are given saline instead of tranexamic acid in the placebo group
3151924|NCT01535781|Active Comparator|Tranexamic Acid|Tranexamic acid; 1 gram as a bolus prior to surgery. 3 grams of Tranexamic acid in 1 liter of saline as a 24 hour infusion.
3151925|NCT01535768|Experimental|Intervention Group|Patients randomized to the intervention group will receive aqueous suppressant eyedrops in a stepwise fashion in order to maintain their intraocular pressure between 7-10mmHg.
3151926|NCT01535768|No Intervention|Control Group|"Patients randomized to the control group will receive standard of care treatment. They will not be aqueous suppressed within the first three postoperative months unless the bleb hyperencapsulates.~(If they experience the hyperencapsulation phase, they will continue to receive standard of care treatment, which would then be aqueous suppressant eye drops added in a stepwise fashion)"
3151927|NCT01535755|Active Comparator|protocol group|This group patients are weaned as the protocol which the investigators described.
3151928|NCT01535755|Other|clinicians' order group|This group patients are weaned as the clinicians' order.
3151929|NCT01535742|Experimental|Ambu Aura-i size 1.5|patients will receive either the Ambu Aura-i size 1.5 or air-Q ILA 1.5 based on manufacturer recommendations of body weight
3151930|NCT01535742|Experimental|air-Q size 1.5|patients will receive either the Ambu Aura-i size 1.5 or air-Q ILA 1.5 based on manufacturer recommendations of body weight
3151931|NCT01535742|Experimental|Ambu Aura-i size 2|patients will receive either the Ambu Aura-i size 2 or air-Q ILA 2 based on manufacturer recommendations of body weight
3151932|NCT01535742|Experimental|air-Q size 2|patients will receive either the Ambu Aura-i size 2 or air-Q ILA 2 based on manufacturer recommendations of body weight
3151933|NCT01535729||Cohort|
3151934|NCT01535716|Experimental|ECOM group|50 Patients scheduled for elective coronary surgery with cardiopulmonary bypass
3151935|NCT01535716|Active Comparator|standard management group|50 Patients scheduled for elective coronary surgery with cardiopulmonary bypass
3151936|NCT01535690|Experimental|laser and methilene blue|After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler (Profi III Bios, Dabi Atlante, Ribeirão Preto, São Paulo, Brazil) for 1 hour. Specific tips were used (Perio sub, Dabi Atlante, Ribeirão Preto, São Paulo, Brazi). PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl (Photon Laser III - PL7336, DMC, São Carlos -São Paulo, Brazil) was applied (660 nm, 100 mW, 9 J, 90 seconds per site, 320 J/cm2).
3151937|NCT01535677|Experimental|1|5 mg dapagliflozin and 850 mg Glucophage in fasted state
3151938|NCT01535677|Experimental|2|dapagliflozin/metformin (5 mg/850 mg) immediate release (IR) FDC in fasted
3151939|NCT01535677|Experimental|3|5 mg dapagliflozin and 850 mg Glucophage in fed state
3151940|NCT01535677|Experimental|4|dapagliflozin/metformin (5 mg/850 mg) IR FDC in fed state
3151941|NCT01535664||dalfampridine-ER 10mg|Subjects with MS taking dalfampridine-ER 10mg and considered to be responders
3151942|NCT01535651|Experimental|TOP Program plus Text messaging|Boys and Girls Club members who participate in TOP over 9 months will receive regular text messages in addition to TOP
3151943|NCT01535651|No Intervention|TOP Program alone|Boys and Girls Club participants will participate in TOP for 9 months
3151944|NCT01535638|Active Comparator|BI 207127 NA TFII medium dose|Film-coated tablet for oral administration
3151945|NCT01535638|Active Comparator|BI 207127 NA FF medium dose|Film-coated tablet for oral administration
3151946|NCT01535638|Active Comparator|BI 207127 NA FF modified medium dose|Film-coated tablet for oral administration
3151947|NCT01535625|Other|Momo stent|Patients with PCI
3151948|NCT01535612|Experimental|PaQ™ insulin infusion device|PaQ™ insulin infusion device which delivers rapid acting insulin.
3151949|NCT01535599|Experimental|AL-60371|AL-60371, 0.3% Otic Suspension, 4 drops to the affected ear(s) twice daily for 7 days
3151950|NCT01535599|Placebo Comparator|Vehicle|AL-60371 Vehicle, 4 drops to the affected ear(s) twice daily for 7 days
3151951|NCT01535586|Active Comparator|CPAP|participants will be treated with continuous positive airway pressure (CPAP) for 12 weeks
3151952|NCT01535586|Active Comparator|MAD|Participants will be treated with a mandibular advancing device for 12 weeks
3151953|NCT01535573|Active Comparator|Citalopram low dose|Citalopram 20 mg
3151954|NCT01535573|Active Comparator|Citalopram high dose|Citalopram 40 mg
3151955|NCT01535573|Placebo Comparator|Placebo|Placebo
3151956|NCT01535560|Experimental|AL-60371|AL-60371, 0.3% otic suspension, 4 drops in the affected ear(s) twice daily for 7 days
3151957|NCT01535560|Placebo Comparator|Vehicle|AL-60371 Vehicle, 4 drops in the affected ear(s) twice daily for 7 days
3151958|NCT01535547|Experimental|isavuconazole and tacrolimus|
3151959|NCT01535521|Other|SPT in patients with MAD|
3151960|NCT01535508|Experimental|Liquid Vitamin D|
3151961|NCT01535495|Experimental|Complete laser|Patients who have had complete panretinal photocoagulation laser treatment and active retinal neovascularization
3151962|NCT01535495|Experimental|Laser naive|"Patients who have not had panretinal photocoagulation laser treatment and active retinal neovascularization without so called high-risk characteristics"
3151963|NCT01535482|Experimental|Cognitive Therapy|A cognitive therapy protocol specifically designed to target suicidal ideation in older adults.
3151964|NCT01535482|Active Comparator|Enhanced Usual Care|Enhanced usual care consists of the usual care that individuals receive for suicide prevention, plus assessment and referral services provided by project staff, and weekly phone calls provided by study therapists.
3152238|NCT01533532|Experimental|KLH-2109, high dose|
3151965|NCT01535469|Experimental|CrAg Screening and Fluconazole|Cryptococcal Antigen (CrAg) Screening with preemptive antifungal treatment per World Health Organization (WHO) guidelines. Randomized Stepped Wedge design of phased implementation.
3151966|NCT01535456|Experimental|F-FLT PET scan, 5-azacitidine treatment|F-FLT Pet scan followed by 5-azacitidine treatment followed by FLT-PET scan. Three additional cycles of 5-azacytidine and follow up FLT-PET scan.
3151967|NCT01535443|Experimental|PRO-155 Ophthalmic Solution 0.09 %|
3151968|NCT01535417|Experimental|GCSB|
3151969|NCT01535417|Active Comparator|Celebrex|
3151970|NCT01535404|Active Comparator|Right ventricular apex pacing|
3151971|NCT01535404|Experimental|Left ventricular apex pacing|
3151972|NCT01535365|Active Comparator|Heat|Application of Heat pad to site of muscle sprain.
3151973|NCT01535365|Active Comparator|Cold|Application of ice pack to muscle sprain.
3151974|NCT01535352|Experimental|Internet-facilitated CBT|Participants in the randomized trial will be 300 mothers of 3-5 year old children recruited through Head Start (HS) classrooms and screened for the presence of major or minor depression. Subsequent to the pre-intervention assessment, participants will be randomized, with an allocation ratio of 1:1, to either the Mom-Net (MN) intervention or facilitated usual care (FUC) condition. Participants in the MN condition will receive the Mom-Net intervention. The Mom-Net program is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Participants in both conditions will receive Booster calls during the follow-up period.
3151975|NCT01535352|Active Comparator|Coach-facilitated Treatment as Usual|Participants in the FUC condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
3151976|NCT01535339||Phase I - Normative|Athletes who does not participate in contact sport with no recent concussion
3151977|NCT01535339||Phase IIa - Concussed|Athletes with recent concussion
3151978|NCT01535339||Phase IIa - Control|Athletes with no recent concussion
3151979|NCT01535339||Phase IIb - Athletes|Athletes with no recent concussion
3151980|NCT01535326|Placebo Comparator|air insufflation|Use air insufflation during colonoscopy
3151981|NCT01535326|Active Comparator|water immersion|infuse water during insertion, remove water during withdrawal of colonoscopy
3151982|NCT01535326|Active Comparator|water exchange|infuse and remove water during insertion phase of colonoscopy
3151983|NCT01535313|Active Comparator|Manual (Hospital Systems TRAP Needle)|Bone marrow biopsy with a standard manual system
3151984|NCT01535313|Experimental|Powered|
3151985|NCT01535300||Elective pediatric surgery|
3151986|NCT01535287|Active Comparator|Dexmedetomidine|Single injection of Dexmedetomidine (study medication) compared to receiving Placebo in Myringotomy surgery decreases emergence agitation.
3151987|NCT01535287|Placebo Comparator|Placebo|Single injection of Dexmedetomidine (study medication) compared to receiving Placebo in Myringotomy surgery decreases emergence agitation.
3151988|NCT01535274|Experimental|Desflurane|Patients will receive general anesthesia with desflurane. Both arms have rSO2 measured and undergo identical changes in ventilation strategy.
3151989|NCT01535274|Experimental|Propofol|Patients will receive total intravenous general anesthesia (TIVA) with propofol. Both have rSO2 measured and undergo identical changes in ventilation strategy.
3151990|NCT01535261|Experimental|Ranibizumab arm|Intravitreal injection with standard dose of 0.5 mg/0.05mL PRN
3151991|NCT01535248||All ERCP Patients|All patients that will be approached for this study will be undergoing ERCP as part of their medical care.
3151992|NCT01535235|Active Comparator|ACE Inhibitor|Active group
3151993|NCT01535235|Placebo Comparator|Placebo|Placebo group
3151994|NCT01535222|Experimental|Cohort 1|3 patients: loading dose 0.005 mg/kg; infusion 0.0125 mg/kg/h; pump prime 0.02 mg
3151995|NCT01535222|Experimental|Cohort 2|3 pts: loading dose 0.011 mg/kg; infusion 0.0250 mg/kg/h; pump prime 0.04 mg
3151996|NCT01535222|Experimental|Cohort 3|6 patients: loading dose 0.027 mg/kg; infusion 0.0625 mg/kg/h; pump prime 0.09 mg
3151997|NCT01535222|Experimental|Cohort 4|6 patients: loading dose 0.054 mg/kg; infusion 0.1250 mg/kg/h; pump prime 0.18mg
3151998|NCT01535222|Experimental|Cohort 5|6 patients: loading dose 0.108 mg/kg; infusion 0.2500 mg/kg/h; pump prime 0.35 mg
3151999|NCT01535222|Placebo Comparator|Placebo|8 patients: commercially available NaCl as matching placebo to MDCO-2010 administered as IV infusion
3152000|NCT01535209|Experimental|SBRT to resection cavity|18Gy in 1 fraction for resection cavity <2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity >4cm in maximum diameter
3152001|NCT01535209|Active Comparator|WBRT|30Gy in 10 fractions over 12 days to whole brain
3152002|NCT01535196|Experimental|25-OH-D3 vitamin|180 000 IU 25-OH-D3 vitamin oil per os, per month in the 0, 1, 2, 3, and 6 month at the visit. The patient take the drug under medical control
3152003|NCT01535196|Placebo Comparator|MCT oil|9 ml MCT oil as placebo in the 0,1,2,3,6 month at the visit, under medical contol
3152004|NCT01535183|Experimental|Irinotecan|
3152005|NCT01535170|Experimental|bovine Lactoferrin|"Lactoferrin and placebo will be masked as drug A and B in the factory. Randomization will be stratified by center and patients will be randomized into A or B groups by a random-number table sequence after informed consents are obtained. No patients, research nurses, investigators, or other medical staffs in RCC will be aware of the assignment during the study period.~Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) [16] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori [17]. Drug administration will begin within 24 hours after RCC admission and will last for 6 weeks or until discharge. Medication and nutritional support will be prescribed as the medical routine."
3152239|NCT01533532|Placebo Comparator|placebo|
3152006|NCT01535170|Placebo Comparator|Placebo|Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control.
3152007|NCT01535157|Experimental|Fenretinide/LXS + Ketoconozale|One course is defined as 7 days of Fenretinide/LXS + Ketoconazole followed by 14 days of rest. A course is repeated every 21 days if no evidence of disease progression for six courses.
3152008|NCT01535144|Experimental|degradable metallic device|
3152009|NCT01535144|Active Comparator|non-degradable metallic device|
3152010|NCT01535131|Active Comparator|Furlow palatoplasty|standard procedure
3152011|NCT01535131|Experimental|modified Furlow palatoplasty|standard procedure plus modification
3152012|NCT01535118||Adults and Children with Allergic Rhinoconjunctivitis (ARC)|Adults and children with ARC who complete the survey
3152013|NCT01535105||Obese Adolescents|
3152014|NCT01535092|Experimental|silibinin|Silibinin 20mg/Kg/day (Legalon SIL) by intravenous infusion for 14-21 days before OLT and for 7 days after OLT
3152015|NCT01535092|Placebo Comparator|Placebo|Placebo (NaCl 0.9% - saline) administered daily by intravenous infusion for 14-21 days before OLT and 7 days after OLT
3152016|NCT01535079|Placebo Comparator|Placebo|
3152017|NCT01535079|Experimental|V0498TA01A 15 mg|
3152018|NCT01535079|Experimental|V0498TA01A 25 mg|
3152019|NCT01535079|Experimental|V0498TA01A 35 mg|
3152020|NCT01535079|Other|Strefen|Positive control
3152021|NCT01535066|Experimental|Arm I|Patients receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.
3152022|NCT01535066|Sham Comparator|Arm II|Patients receive sham acupuncture twice weekly for 6 weeks and then once weekly for 6 weeks.
3152023|NCT01535066|No Intervention|Arm III|Patients are assigned to a waiting list for 12 weeks with standard follow-up care.
3152024|NCT01535053|Experimental|Arm I (dactinomcin)|Patients receive dactinomycin IV over 15 minutes on day 1.
3152025|NCT01535053|Active Comparator|Arm II (leucovorin calcium and methotrexate)|Patients receive methotrexate IM on days 1, 3, 5, and 7 and leucovorin calcium PO on days 2, 4, 6, and 8 OR single agent methotrexate IV on days 1-5.
3152026|NCT01535040|Active Comparator|Arm I - Memantine|Participants receive memantine hydrochloride PO BID) on days 1-81 in the absence of unacceptable toxicity.
3152027|NCT01535040|Placebo Comparator|Arm II - Placebo|Participants receive a placebo PO BID on days 1-81 in the absence of unacceptable toxicity.
3152028|NCT01535027|Active Comparator|Teriparatide|18 months of daily 20 ug sc. teriparatide monotherapy (TPTD)
3152029|NCT01535027|Active Comparator|Teriparatide and Raloxifene|9 months teriparatide 20 ug/day sc. monotherapy (TPTD) continued by combination therapy of raloxifene 60 mg/day orally(RAL)and TPTD for another 9 months
3152030|NCT01535027|Active Comparator|Teriparatide and Alendronate|9 months teriparatide monotherapy 20 ug/day sc.(TPTD) continued by combination therapy of alendronate 70 mg/week orally(ALN)and TPTD for another 9 months
3152031|NCT01535014|Experimental|Dietressa (2 tablets 3 times daily)|
3152032|NCT01535014|Experimental|Dietressa (1 tablet 6 times daily)|
3152033|NCT01535014|Placebo Comparator|Placebo (2 tablets 3 times daily)|
3152034|NCT01535014|Placebo Comparator|Placebo (1 tablet 6 times daily)|
3152035|NCT01535001|Active Comparator|MEDIC|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.
3152036|NCT01535001|Active Comparator|Standard treatment|Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
3152037|NCT01534975|Active Comparator|Iodixanol 320|"group 1 will receive iodixanol 320 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
3152038|NCT01534975|Active Comparator|iohexol 350|"group 2 will receive iohexol 350 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
3152039|NCT01534975|Active Comparator|iopamidol 370|"group 3 will receive iopamidol 370 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
3152040|NCT01534975|Active Comparator|iodixanol 270|"group 4 will receive iodixanol 270 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
3152041|NCT01534962|Experimental|Ranolazine low dose|Ranolazine, low dose, oral, BID
3152042|NCT01534962|Experimental|Ranolazine intermediate dose|Ranolazine, intermediate dose, oral, BID
3152043|NCT01534962|Experimental|Ranolazin high dose|Ranolazine, high dose, oral, BID
3152044|NCT01534962|Placebo Comparator|Placebo|Placebo (sugar pill), oral, BID.
3152045|NCT01534949|Experimental|CT-P10|rituximab
3152046|NCT01534936||Schizophrenic outpatients with affective symptoms.|
3152047|NCT01534923||Pts having colorectal cancer screening|The target sample of this study will be approximately 200 primary care physician-patient consultations who discuss CRC screening during the course of a clinical visit. Physician and patient participants will come from primary care practices associated with the New York City Research and Improvement Networking Group (NYC RING).
3152048|NCT01534910|Placebo Comparator|Sugar pill|placebo
3152049|NCT01534910|Active Comparator|Aged Garlic Extract|2400 mg of aged garlic extract
3152050|NCT01534897|Experimental|GSK2118436|Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.
3152051|NCT01534884|Active Comparator|MabThera|rituximab
3152052|NCT01534884|Active Comparator|CT-P10|rituximab
3152053|NCT01534871|Experimental|Exercise|Subjects enrolled in the exercise arm will receive the study intervention.
3152054|NCT01534871|No Intervention|Control|Subjects in the control arm will receive standard of care (e.g. medication and medical supervision) for rheumatoid arthritis. These subjects will not participate in the exercise intervention.
3152055|NCT01534858|Experimental|Partial and full thickness burns with split thickness grafts|
3152056|NCT01534845|No Intervention|only Radiotherapy|fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy
3152057|NCT01534845|Active Comparator|CCRT with Temozolomide|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles).
3152058|NCT01534832|Experimental|Smoke clearance|Smoke clearance device active
3152059|NCT01534819||Primary Group|Initial placement of a commercially available AAA/TAA endograft with the concurrent use of Aptus Heli-FX™ EndoAnchor System (Heli-FX)
3152060|NCT01534819||Revision Group|Revision of a previously placed Aptus AAA/TAA endograft with the concurrent use of Aptus Heli-FX™ EndoAnchor System (Heli-FX)
3152061|NCT01534806|Experimental|ketorolac|
3152062|NCT01534806|Placebo Comparator|Placebo|Placebo IV push
3152063|NCT01534793||HoLEP|Holmium Laser Enucleation of the Prostate
3152064|NCT01534780|Experimental|fixation with Protack|
3152065|NCT01534780|Experimental|fixation with Securestrap|
3152066|NCT01534780|Experimental|fixation with Glubran|surgery
3152067|NCT01534754|Active Comparator|Mesalazine|Active mesalazine 800 mg, 2 tablets/day for 10 days/month plus Lactobacillus casei placebo, 1 sachet/day for 10 days/month.
3152068|NCT01534754|Active Comparator|Lactobacillus casei|Active Lactobacillus casei, 1 sachet/day for 10 days/month plus mesalazine 800 mg placebo, 2 tablets/day for 10 days/month.
3152069|NCT01534754|Active Comparator|Mesalazine plus Lactobacillus casei|Active mesalazine 800 mg, 2 tablets/day plus active Lactobacillus casi, 1 sachet/day for 10 days/month.
3152070|NCT01534754|Placebo Comparator|Placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month.
3152071|NCT01534741|Active Comparator|Dialyser|FX CorDiax 60 dialyzer
3152072|NCT01534741|Active Comparator|FXDialyser|FX 60 dialyzer
3152073|NCT01534715|Experimental|IMGN529|Dose escalation study, dosing done every 3 weeks.
3152074|NCT01534702|Experimental|Treatment|
3152075|NCT01534689|Experimental|Erchonia FX-405™ Laser|The Erchonia FX-405™ Laser is a dual-diode laser emitting 15.5-17.5 milliWatts (mW) of 635 nanometer (nm) red laser light and 23.5-25.5 mW 405 nm blue laser light. The the power reaching the surface of the skin is 1 mW
3152076|NCT01534676|Active Comparator|Transfusion of Fresh blood|The recipient will receive one or two units of fresh blood <14 days old, as per their chronic transfusion schedule - on or off chelation therapy.
3152077|NCT01534676|Experimental|Transfusion of Stored blood|The recipient will receive one or two units of old blood >28 days old, as per their chronic transfusion schedule - on or off chelation therapy.
3152078|NCT01534676|Active Comparator|Transfusion of Cryopreserved Blood|The recipient will receive one or two units of cryopreserved (fresh/old) blood, as per their chronic transfusion schedule - off chelation therapy.
3152079|NCT01534676|Active Comparator|Transfusion of Washed Blood|The recipient will receive one or two units of washed (fresh/old) stored blood >28 days old, as per their chronic transfusion schedule - off chelation therapy.
3152080|NCT01534663|Placebo Comparator|Placebo|The placebo for fish oil will be safflower oil. For glutamine, soy powder will serve as the placebo.
3152081|NCT01534663|Active Comparator|Glutamine/Fishoil|3.285 g of EPA and 3.285 g of DHA and L-alanyl-glutamine (8g/d).
3152082|NCT01534637|Experimental|Treatment (antiemetic, chemotherapy, and radiation therapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy once daily on days 1-5 for 5.5 weeks. Patients also receive gemcitabine hydrochloride IV over 30 minutes once weekly and either fluorouracil IV continuously or capecitabine PO twice daily on days 1-5.~PROPHYLACTIC THERAPY: Beginning 1 hour before chemoradiotherapy, patients receive aprepitant PO on days 1-3. Treatment repeats every 7 days for 5.5 weeks in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION CHEMOTHERAPY: Two to four weeks after completion of chemoradiotherapy and prophylactic therapy, patients without disease progression or a declining performance status receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity."
3152083|NCT01534598|Experimental|Single Arm|FdCyd + THU administered on an intermittent schedule in 21-day cycles per dose escalation table. THU will be administered orally at a fixed dose of 3000 mg 30 minutes prior to FdCyd.
3152084|NCT01534572|Experimental|Probiotics_Lactobacillus|Intervention (2 weeks) with a strain of Lactobacillus
3152085|NCT01534572|Experimental|Probiotics_Bifidobacterium|Intervention (2 weeks) of daily supplementation of a probiotic strain of Bifidobacterium.
3152086|NCT01534559|Experimental|Outpatient Medicine Management Clinic|Consented patients will attend two outpatient clinic appointments to receive help with any (potential) medicine-related problems
3152087|NCT01534559|No Intervention|Control|Patients will receive the normal care provided by the hospital
3152088|NCT01534546|Active Comparator|arm A postoperative Oxaliplatin/capecitabine（XELOX）|"postoperative Oxaliplatin/capecitabine（XELOX） patients in arm A will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant XELOX later.~capecitabine：1000 mg/m2 ，bid, d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)"
3152089|NCT01534546|Experimental|arm B: postoperative Oxaliplatin/S-1（SOX）|"postoperative Oxaliplatin/S-1（SOX） patients in arm B will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant SOX later.~S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)"
3152090|NCT01534546|Experimental|Arm C：postoperative Oxaliplatin /S-1（SOX）|"Postoperative Oxaliplatin /S-1（SOX） patients in arm C will receive 3 cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and 5 cycles of adjuvant SOX followed by 3 cycles of S-1 monotherapy.~Dose of s-1 and oxaliplatin are same to arm B Dose of S-1 monotherapy is same to combination therapy (SOX 3 cycles before surgery, 5 cycles of SOX and 3 cycles of S-1 monotherapy, 6 months after surgery)"
3152091|NCT01534533|Placebo Comparator|Placebo|early atherosclerosis cases, received starch in hard shell gelatine capsules, once a day
3152092|NCT01534533|Experimental|Lutein group|early atherosclerosis cases, received 20mg lutein, once a day
3152093|NCT01534533|Experimental|Combination group|early atherosclerosis cases, received 20mg lutein plus 20mg lycopene, once a day
3152094|NCT01534533|Experimental|Normal lutein control group|20mg lutein for subjects free from atherosclerosis, once a day
3152095|NCT01534520|Experimental|Group 1: Intravaginal 2% lidocaine gel|Intravaginal insertion of 4mL of 2% lidocaine gel
3152096|NCT01534520|Placebo Comparator|Group 2: Intravaginal placebo gel|Intravaginal insertion of 4mL of placebo gel ( K-Y Jelly)
3152097|NCT01534507||Healthy Volunteer 1 (Group 1)|For study 1 : Up to 5 healthy volunteers for the initial pilot study and further 21 healthy volunteers for the main study 1
3152098|NCT01534507||Group 2 for study 2|Patients with diarrhoea due to irritable bowel syndrome
3152099|NCT01534507||Group 3 for study 2|Patients with constipation due to irritable bowel syndrome
3152100|NCT01534507||Group 4 for study 2|Patients with mixed bowel habit due to irritable bowel syndrome
3152101|NCT01534507||Group 5 for study 2: Healthy volunteer 2|Healthy participants to act as control
3152102|NCT01534494|Experimental|psilocybin|
3152103|NCT01534481|Active Comparator|Donor Milk|Donor milk provided by the Human Milk Banking Association of North America
3152104|NCT01534481|Placebo Comparator|Preterm Formula|Preterm formula determined by center practice
3152105|NCT01534468|Experimental|Group 1: Previous H7N7 ca LAIV recipients|Participants in Group 1 will have previously received an H7N7 ca LAIV. In this study, they will receive one intramuscular (IM) injection of the H7N7 vaccine at study entry.
3152106|NCT01534468|Experimental|Group 2: Previous H7N3 ca LAIV recipients|Participants in Group 2 will have previously received an H7N3 ca LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
3152107|NCT01534468|Experimental|Group 3: Previous H2N3 ca LAIV recipients|Participants in Group 3 will have previously received an H2N3 ca LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
3152108|NCT01534468|Experimental|Group 4: Vaccine-naive participants|Participants in Group 4 will have not previously received a LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
3152109|NCT01534455|Experimental|Lapatinib + 1,23 mg Eribulin|
3152110|NCT01534455|Experimental|Lapatinib + 1,76 mg Eribulin|
3152111|NCT01534442|Active Comparator|Atropin|Atropin
3152112|NCT01534442|Placebo Comparator|Placebo|Saline
3152113|NCT01534429||chronic post-herniorraphy pain|patients with severe chronic post-herniorraphy pain
3152114|NCT01534416|Experimental|Bupivacaine|Subjects receive paracervical block with bupivacaine-epinephrine
3152115|NCT01534416|Placebo Comparator|Saline|Subjects receive paracervical injection of normal saline
3152116|NCT01534403|Experimental|Epratuzumab 4x600 mg every 12 weeks Group|
3152117|NCT01534390|Experimental|Use of in-line microfilters|
3152118|NCT01534390|No Intervention|Standard therapy without the use of in-line microfilters|
3152119|NCT01534377|Experimental|Interpersonal Psychotherapy|Adolescents will receive Interpersonal Psychotherapy for the treatment and prevention of depression.
3152120|NCT01534377|Experimental|Enhanced Care|Adolescents will receive the Enhanced care model or care that they would typically receive in community setting to treat and prevent depression.
3152121|NCT01534364|No Intervention|control|Ad libitum alimentation
3152122|NCT01534364|Other|calorie restriction|Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery day 0 corresponds to day of surgery)
3152123|NCT01534351|Experimental|Finasteride|Finasteride 5 mg taken orally once daily and tamsulosin-matching placebo taken orally once daily for 12 months. The tamsulosin-matching placebo will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
3152124|NCT01534351|Active Comparator|Tamsulosin|Tamsulosin 0.2 mg taken orally once daily and finasteride-matching placebo taken orally once daily for 12 months. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
3152125|NCT01534351|Experimental|Finasteride and Tamsulosin|Finasteride 5 mg orally once daily and tamsulosin 0.2 mg orally once daily for 12 months, taken concomitantly. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
3152126|NCT01534338|Experimental|Mindfulness Meditation|The MAPs program is based on experiential training in mindfulness meditation offered at the UCLA Mindful Awareness Research Center (MARC). A certified UCLA instructor will provide didactic training in mindfulness meditation in a group-based setting. Participants will be guided through in-class meditation practices and will be assigned daily meditation homework. Active program components include sitting and walking somatosensory-focused meditation, audio-guided body scan meditation, and loving kindness meditation. Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary. In addition to the MAPs training, sleep hygiene material will also be presented to match the sleep hygiene material in the sleep education condition.
3152127|NCT01534338|Active Comparator|Sleep Education|The sleep education condition is founded on knowledge acquisition. In the sleep seminar condition, a trained health educator will provide didactic presentations on sleep, sleep hygiene, sleep problems, and potential solutions to sleep problems in a group-based setting. Active components of sleep education include increasing knowledge of sleep biology, identifying characteristics of healthy and unhealthy sleep, sleep problems, and self-monitoring of sleep behavior. Participants attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary. The health education condition is comparable to MAPs in terms of time, attention, group support, and participant expectancy of a benefit in sleep parameters.
3152128|NCT01534325|Experimental|Study arm|The Arm who uses the real study device Daily use of SD device
3152129|NCT01534325|Sham Comparator|Control Arm|Daily use of Sham comperator
3152130|NCT01534325|Experimental|Staudy2 arm|Uses the under study device in a different time frames Daily use of SD device in a different time frames than of Study Arm
3152131|NCT01534312|Experimental|CGMP protein|Casein glycomacropeptide 30 gram/day, unchanged prophylactic 5ASA dose
3152132|NCT01534312|Active Comparator|Standard oral 5ASA maximal dose|Increase from prophylactic dose 5ASA (mesalazine) to maximal oral dose, i.e. 4800 grams of mesalazine (Asacol/Mezavant)
3152133|NCT01534299||Renal Denervation Treatment|All patients treated with renal denervation procedure will be enrolled as part of this single arm registry
3152134|NCT01534286|Active Comparator|Theramine|Theramine 2 capsules three times per day in addition to post surgical analgesic medication.
3152135|NCT01534286|Placebo Comparator|Theramine-like Placebo|Theramine-like placebo 2 capsules three times per day in addition to post surgical analgesic medication.
3152136|NCT01534273|Placebo Comparator|Placebo|Single oral dose and/or once daily oral dosing for 14 consecutive days
3152137|NCT01534273|Experimental|35 mg LY2886721|Once daily oral dosing for 14 consecutive days
3152138|NCT01534273|Experimental|70 mg LY2886721|Single oral dose followed by once daily oral dosing for 14 consecutive days
3152139|NCT01534273|Experimental|140 mg LY2886721|Single oral dose
3152140|NCT01534260|Experimental|sorafenib, vorinostat and bortezomib|Escalating cohorts of sorafenib, vorinostat and bortezomib
3152141|NCT01534247|Experimental|CAZAVI|CAZ-AVI (2000 mg ceftazidime/500 mg avibactam)
3152142|NCT01534247|Active Comparator|Metronidazole|Metronidazole (500 mg)
3152143|NCT01534247|Active Comparator|CAZAVI+metronidazole|CAZ-AVI (2000mg ceftazidime/500 mg avibactam) + metronidazole (500 mg)
3152144|NCT01534234|Experimental|SonR group|SonR CRT Optimization
3152145|NCT01534234|Active Comparator|ECHO group|Echocardiographic Optimization
3152146|NCT01534221|Active Comparator|Study group two|Endeavor resolute drug eluting stent
3152147|NCT01534221|Active Comparator|Study group three|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
3152148|NCT01534221|Active Comparator|Study group four|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
3152149|NCT01534221|Active Comparator|Study group five|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
3152150|NCT01534221|Active Comparator|Study group one|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
3152151|NCT01534208|Experimental|Androxal 12.5 mg|Androxal 12.5 mg daily
3152152|NCT01534208|Experimental|Androxal 25 mg|Androxal 25 mg daily
3152153|NCT01534195|Experimental|Prednisolone|Prednisolone Sodium Phosphate Ophthalmic Solution, 1%
3152154|NCT01534195|Placebo Comparator|Placebo|Tears Naturale II Ophthalmic Solution, 1%
3152155|NCT01534182|Experimental|Fingolimod|Participants received 0.5 mg orally once a day.
3152156|NCT01534182|Active Comparator|Standard Disease Modifying Therapy (DMT)|Participants received interferon beta-1a (IFN), 44 mcg subcutaneously 3 times a week or glatiramer acetate (GA), 20 mg subcutaneously once a day.
3152157|NCT01534169|Experimental|Isotonic Na chloride|The treatment strategy is the same with intervention, only the drug (dexamethasone) will be changed to isotonic Na chloride.
3152158|NCT01534143|Experimental|Treatment (chemotherapy, enzyme inhibitor)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.~GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0."
3152159|NCT01534130|Experimental|acupuncture|
3152160|NCT01534130|Sham Comparator|sham acupuncture|
3152161|NCT01534117|Active Comparator|Platelets/DDAVP|Fall on ASA/Plavix that sustained head trauma requiring administration of platelets and/or DDAVP
3152162|NCT01534117|No Intervention|No Platelets|Those that sustain head trauma NOT requiring platelet transfusion. The investigators are evaluating platelet function in those not requiring platelet transfusion
3152163|NCT01534104|Experimental|pts who have primary or secondary brain tumors|The study will prospectively enroll subjects who have primary or secondary brain tumors located near the motor pathway (corticospinal tract) or language pathway (arcuate fasciculus). This is a nonrandomized study in which each subject will receive the standard of care as per the treating neurosurgeon.
3152164|NCT01534091|Active Comparator|Pedometer with supervision|Participants will get pedometers to evaluate their daily PA. The sport center stuff will review the child weekly reports, guide the child, encourage him and supervise that the recommended PA level is achieved.
3152165|NCT01534091|Active Comparator|Pedometer without supervision|Participants will get pedometers to evaluate their daily PA. The sport center stuff won't give any recommendation or supervision for PA level.
3152166|NCT01534091|No Intervention|Control group|Overweight & obese children not participating in an intervention.
3152167|NCT01534078|Experimental|Treatment Arm|Brentuximab Vedotin in combination with Adriamycin, Vinblastine and Dacarbazine
3152168|NCT01534065|Experimental|Barricaid|CE Marked Device
3152169|NCT01534052|Experimental|Enzalutamide|Participants received 160 mg enzalutamide orally once a day. Participants continued on treatment unless the dose was reduced or treatment was interrupted during the study.
3152170|NCT01534039|Active Comparator|Sur-Fit Natura/FormaFlex|Subject will be on Surfit Moldable for 2 weeks then crossover to Formaflex
3152171|NCT01534039|Active Comparator|FormaFlex/Sur-Fit Natura|Subject will be on Formaflex for 2 weeks then crossover to Surfit Moldable
3152172|NCT01534026|Active Comparator|Aspirin|Current dose of aspirin for 12 weeks
3152173|NCT01534026|Experimental|Withdrawal arm|Withdrawal of aspirin for 12 weeks
3152174|NCT01534013|Experimental|Closed-loop insulin delivery|The closed loop device (bio-inspired artificial pancreas device, subcutaneous glucose monitor and insulin pump) will be applied to participants with type 1 diabetes
3152175|NCT01534000|Active Comparator|CT guided group|For Patients with chest pain randomised to this arm, clinical decision will be based on the results of a Cardiac computed tomographic angiography (CCTA)
3152176|NCT01534000|No Intervention|Control group|Patients with chest pain randomised to the control group will be evaluated using the standard functional-based strategy with either a treadmill stress-test or SPECT (single-photon emission computed tomography). A Cardiac CT will will be performed, but will be blinded for initial clinical evaluation.
3152177|NCT01533987|Experimental|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
3152178|NCT01533987|Placebo Comparator|Placebo|The placebo consists of microcrystalline cellulose,dicalcium phosphate, magnesium stearate, and FD & C yellow #6.
3152179|NCT01533974|Experimental|ACT|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
3152180|NCT01533974|Active Comparator|CBT|
3152181|NCT01533961|Experimental|SCYX-7158|In each dose group (8 subjects) , 6 Healthy Volunteers receive SCYX-7158
3152182|NCT01533961|Placebo Comparator|Placebo of SCYX-7158|In each dose group (8 subjects) , 2 Healthy Volunteers receive placebo of SCYX-7158
3152183|NCT01533948|Experimental|Treatment (axitinib)|Patients receive axitinib PO BID. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3152184|NCT01533935|Active Comparator|Olodaterol 5 mcg QD|patient will receive olodaterol 5 mcg once daily
3152185|NCT01533935|Placebo Comparator|Placebo QD|placebo comparator for tiotropium + olodaterol
3152186|NCT01533935|Active Comparator|Tiotropium 5 mcg QD|patient will receive tiotropium 5 mcg once daily
3152187|NCT01533935|Experimental|Tiotropium + olodaterol low dose QD|patient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in fixed dose combination once daily
3152188|NCT01533935|Experimental|Tiotropium + olodaterol high dose|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily
3152189|NCT01533922|Experimental|Tiotropium + olodaterol High dose QD|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in a fixed dose combination once daily
3152190|NCT01533922|Experimental|Tiotropium + olodaterol Low dose QD|patient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in a fixed dose combination once daily
3152191|NCT01533922|Active Comparator|Tiotropium 5 mcg QD|patient will receive tiotropium 5 mcg once daily
3152192|NCT01533922|Active Comparator|Olodaterol 5 mcg QD|patient will receive olodaterol 5 mcg once daily
3152193|NCT01533922|Placebo Comparator|Placebo QD|
3152194|NCT01533909||Cancer patients|As this is not an intervention study there is only one cohort. Patients that will be included and excluded are described in the eligibility section.
3152195|NCT01533896|No Intervention|Control|Parents and children in the control group received routine primary care during the well child visit.
3152196|NCT01533896|Experimental|Grow Nicely|Grow Nicely multimedia program.
3152197|NCT01533870|Experimental|NKTR-118|Single dose NKTR-118 25 mg on Day 1 only
3152198|NCT01533870|Active Comparator|Rifampin|Rifampin 600 mg once daily on Days 4 to 12
3152199|NCT01533870|Active Comparator|Rifampin/ NKTR-118|Rifampin 600 mg plus NKTR-118 25 mg on Day 13
3152200|NCT01533857|Experimental|Black tea|black tea
3152201|NCT01533857|Placebo Comparator|placebo|
3152202|NCT01533844||Neonates|Neonates with CDAD
3152203|NCT01533818|Active Comparator|Amoxicillin|This is an active intervention
3152204|NCT01533818|Placebo Comparator|Sugar Syrup|
3152205|NCT01533805|Experimental|Pilates with stabilization|This group will do pilates exercises with a focus on control of segmental stabilization of the lumbar spine neutral.
3152206|NCT01533805|Active Comparator|Classic Pilates|This group will make Pilates exercises its focus is on mobilization exercises of the lumbar spine.
3152207|NCT01533792|Experimental|Supra/subgingival therapy|The experimental group received supra and subgingival scaling associated with oral hygiene orientation (OHO)
3152208|NCT01533792|Active Comparator|Control group|Control group received only supragingival scaling with OHO too.
3152209|NCT01533766|Experimental|CombiflexOmega|
3152210|NCT01533766|Active Comparator|SmofKabiven|
3152211|NCT01533753|Experimental|Arm A: Gabapentin|Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
3152212|NCT01533753|Experimental|Arm B: Venlafaxine|Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
3152213|NCT01533727|Experimental|Group A|Autologous CIK Transfusion plus Chemotherapy
3152214|NCT01533727|Active Comparator|Group B|chemotherapy alone
3152215|NCT01533714|Experimental|Olokizumab 120 mg|Olokizumab 120 mg : subcutaneous injections at q2w (every two weeks).
3152216|NCT01533688|Active Comparator|Golytely + placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely)+ placebo pill
3152217|NCT01533688|Placebo Comparator|Golytely Split + placebo|split dose(2 L day before procedure and 2 L day of procedure) of 4 liters of Golytely + placebo pill
3152218|NCT01533688|Experimental|Golytely Split + Bisacodyl|split dose (2 L day prior to procedure and 2 L day of procedure) of 4 liters of Golytely + bisacodyl 10 mg
3152219|NCT01533675|Experimental|Hydrogen peroxide|
3152220|NCT01533675|Active Comparator|Saline|
3152221|NCT01533662|Experimental|phenylephrine|patients more than 60 years receiving 100micrograms of phenylephrine infusion (2 groups 60-75 years and more than 75 years)
3152222|NCT01533662|Placebo Comparator|placebo|patients more than 60 years receiving saline infusion (2 groups 60-75 years and more than 75)
3152223|NCT01533649|Experimental|A/R intervention|The A/R intervention will accommodate 10 study subjects who will participate in an epilepsy-specific counseling intervention.
3152224|NCT01533649|Experimental|Relaxation|The relaxation group will accommodate 10 study subjects who will participate in a condition unspecific supportive relaxation intervention.
3152225|NCT01533649|No Intervention|Usual care|10 Potential study subjects who are not interested in participating in either intervention will be asked to provide data as a usual care control group.
3152226|NCT01533636||Healthy Control|This group will be comprised of healthy individuals without evidence of lung disease.
3152227|NCT01533636||Cystic Fibrosis|This group will be comprised of individuals who have been diagnosed with cystic fibrosis.
3152228|NCT01533623|Other|mandibular advancement device treatment|Patients diagnosed with sleep-disordered breathing that receive treatment with a titratable, duobloc mandibular advancement devices
3152229|NCT01533597|Active Comparator|Solifenacin|
3152230|NCT01533597|Experimental|Solifenacin plus Tamsulosin|
3152231|NCT01533571|Active Comparator|Immediate implant + xenogenic graft|Treatment with immediate implant and GBR using xenogenic bone graft material
3152232|NCT01533571|Active Comparator|Immediate implant + allogenic graft|Treatment with immediate implant and GBR using allogenic bone graft material.
3152233|NCT01533558||caspofungin|caspofungin dosing
3152234|NCT01533545|Active Comparator|Plain mepivacaine|
3152235|NCT01533545|Active Comparator|Mepivacaine with epinephrine|
3152236|NCT01533532|Experimental|KLH-2109, low dose|
3152240|NCT01533519|Experimental|NPY/placebo|This arm gets NPY first then placebo (saline). The placebo is 0.9% USP-grade saline without NPY.
3152241|NCT01533519|Experimental|placebo/NPY|This arm gets placebo (saline) first then NPY.
3152242|NCT01533493|Placebo Comparator|Placebo|Subjects randomized to receive memantine-matched placebo in addition to open-label OROS-Methylphenidate
3152243|NCT01533493|Active Comparator|Memantine|Subjects randomized to receive memantine in addition to open-label OROS-Methylphenidate
3152244|NCT01533480|Active Comparator|Zirgan, Adenovirus conjunctivitis,|Zirgan
3152245|NCT01533480|Placebo Comparator|genteal gel|0.3% Hypromellose gel (genteal gel)
3152246|NCT01533467|Other|Perineal device used|Use of the perineal device during delivery
3152247|NCT01533467|No Intervention|No intervention|Controls, delivered as normal
3152248|NCT01533454|No Intervention|Control|Control participants will attend a 4-month structured weight-loss program and attend subsequent follow-ups at 4-month intervals upon completion of the program.
3152249|NCT01533454|Experimental|Incentives|Incentive arm participants will be offered an additional program (in addition to the COMM program) where they can earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
3152250|NCT01533441|Placebo Comparator|placebo low VKA|
3152251|NCT01533441|Placebo Comparator|Placebo high VKA|Microcrystalline cellulose
3152252|NCT01533441|Active Comparator|Vitamin K2 Low VKA|
3152253|NCT01533441|Active Comparator|Vitamin K2 high VKA|
3152254|NCT01533428|Experimental|Capsaicin 8%|Capsaicin 8% patch was applied for 30 minutes to the painful area(s) on Day 1
3152255|NCT01533428|Placebo Comparator|Placebo|Placebo patch was applied for 30 minutes to the painful area(s) on Day 1
3152256|NCT01533415|Active Comparator|Active CES treatment|Out of the total population of 150 participants,75 of them will be assigned to the active treatment group. Because this is a double-blind study it is unknown which members will belong to this group until completion of the study.
3152257|NCT01533415|Sham Comparator|Sham CES treatment|Of the 150 participants in this study, half of them will be assigned to the sham treatment group. Because this is a double-blind study, it is unknown which members will be assigned to this group until the completion of the study.
3152258|NCT01533402|Placebo Comparator|Attention control|Weekly support from therapist without CBT-interventions
3152259|NCT01533402|Experimental|Internet CBT|Internet-delivered cognitive behavioural therapy with therapy support
3152260|NCT01533389|Experimental|Silodosin|8mg QD
3152261|NCT01533389|Placebo Comparator|Placebo|8mg QD
3152262|NCT01533376|Experimental|Timolol|Participants in this group will receive topical timolol
3152263|NCT01533376|Placebo Comparator|Placebo|Participants in this group will receive Preservative free artificial tear gel.
3152264|NCT01533363|Active Comparator|Stapled hemorrhoidopexy|surgical procedure to treat hemorrhoids
3152265|NCT01533363|Active Comparator|Milligan Morgan|surgical procedure to treat hemorrhoids
3152266|NCT01533350||group1|women with a ultrasonographic homogeneous echo endometrium in the late follicle phase
3152267|NCT01533350||group2|"women with a ultrasonographic  triple-line endometrium in the late follicle phase"
3152268|NCT01533324|Experimental|S-1 combined with LV|S-1 combined with LV
3152269|NCT01533298|Experimental|CombiflexOmega peri|
3152270|NCT01533298|Active Comparator|SmofKabiven peripheral|
3152271|NCT01533285|Other|Group 1|Treatment AB: Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment B (typhoid vaccination) administered [Period 2]
3152272|NCT01533285|Other|Group 2|Treatment BA: Treatment B (typhoid vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
3152273|NCT01533285|Other|Group 3|Treatment AC: Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment C (TSST+Placebo vaccination) administered [Period 2]
3152274|NCT01533285|Other|Group 4|Treatment CA: Treatment C (TSST+Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
3152275|NCT01533285|Other|Group 5|Treatment AD:Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment D (TSST+typhoid vaccination) administered [Period 2]
3152276|NCT01533285|Other|Group 6|Treatment DA:Treatment D (TSST+typhoid vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
3152277|NCT01533272|Experimental|Tenofovir, emtricitabine, Maraviroc|New postexposure prophylaxis (it is a combination drug)
3152278|NCT01533272|Active Comparator|Tenofovir, emtricitabine, lopinavir/r|Standard prophylaxis (it is a combination drug)
3152279|NCT01533259|Experimental|Stribild|Participants will switch to Stribild for 48 weeks.
3152280|NCT01533246|Experimental|Treatment (linsitinib)|Patients receive linsitinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo serum and plasma sample collection at baseline, on day 1 of courses 2 and 4, and after completion of study treatment for correlative studies.
3152281|NCT01533233|Experimental|nonintubated anesthesia|Thoracoscopic lobectomy using nonintubated anesthesia
3152282|NCT01533233|Active Comparator|intubated general anesthesia|Thoracoscopic lobectomy using intubated general anesthesia
3152283|NCT01533220|Experimental|Test group|"Naphazoline Hydrocloride (1.0mg) + Pheniramine Maleate (0.2mg) + Panthenol(5.0mg).~02 drops in each nostril every 12 hours for 5 days"
3152284|NCT01533220|Active Comparator|Comparator group|"Naphazoline Hydrocloride (0.5mg)~02 drops in each nostril every 12 hours for 5 days"
3152285|NCT01533207|Experimental|Arm I (chemotherapy)|Patients receive adjuvant gemcitabine hydrochloride IV over 70-90 minutes on days 1 and 8 and docetaxel IV over 30-60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo CT and/or MRI. Patients with no evidence of disease receive doxorubicin hydrochloride IV every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim SC on days 2-8 or pegfilgrastim SC on day 2 or 3.
3152286|NCT01533207|Other|Arm II (no treatment)|Patients undergo clinical observation.
3152287|NCT01533194|Experimental|Treatment (wild-type reovirus)|Patients receive wild-type reovirus IV over 60 minutes on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3152288|NCT01533181|Experimental|Arm I: OS-906 (linsitinib)|OS-906 daily, continuously, every 3 weeks.
3152289|NCT01533181|Active Comparator|Arm II (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes or PO QD on days 1-5. Patients may crossover to Arm I at the time of progressive disease.
3152290|NCT01533155|Active Comparator|NKTR-118/ Quinidine|One 25-mg NKTR-118 tablet will be administered once with 3 Quinidine 200mg tablets in the morning of period 1 or period 2 (part 1)
3152291|NCT01533155|Placebo Comparator|NKTR-118/ Placebo|One 25-mg NKTR-118 tablet will be administered once with 3 Placebo tablets in the morning of period 1 or period 2 (part 1)
3152292|NCT01533155|Active Comparator|NKTR-118/ Quinidine/ Morphine|One 25-mg NKTR-118 tablet will be administered with 3 Quinidine 200mg tablets with Morphine inj 5mg/70kg once in the morning on period 3 or period 4 (Part 2)
3152293|NCT01533155|Placebo Comparator|NKTR-118/ Placebo/ Morphine|One 25-mg NKTR-118 tablet will be administered with 3 placebo tables with Morphine inj 5mg/70kg once in the morning of period 3 or period 4 (part 2)
3152294|NCT01533142||surgical methods|Different methods are used among hospitals in Helse-Vest, and this allows us to compare different clinical and biological effects following bariatric surgery different methods) among a homogeneous population in the western part of Norway (Vestlandet
3152295|NCT01533142||Morbid obesity|
3152296|NCT01533129|Active Comparator|Daily testosterone transdermal gel|
3152297|NCT01533129|Active Comparator|Injectable Testosterone esters|Testosteron 250mg injection per 3-4 weeks for 6 months
3152298|NCT01533116|Experimental|5 mg BIA 9-1067|5 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
3152299|NCT01533116|Experimental|Placebo|Placebo once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28.
3152300|NCT01533116|Experimental|15 mg BIA 9-1067|15 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
3152301|NCT01533116|Experimental|30 mg BIA 9-1067|30 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
3152302|NCT01533090|Active Comparator|polyethylene glycol (PEG)|
3152303|NCT01533090|Experimental|PEG low volume with bisacodyl|
3152304|NCT01533077|Experimental|Group 1|Period 1: BIA 9-1067 50 mg Period 2: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 3: BIA 9-1067 50 mg + Sinemet® 100/25 Period 4: Sinemet® 100/25
3152305|NCT01533077|Experimental|Group 2|Period 1: Sinemet® 100/25 Period 2: BIA 9-1067 50 mg Period 3: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 4: BIA 9-1067 50 mg + Sinemet® 100/25
3152306|NCT01533077|Experimental|Group 3|Period 1: BIA 9-1067 50 mg + Sinemet® 100/25 Period 2: Sinemet® 100/25 Period 3: BIA 9-1067 50 mg Period 4: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg
3152307|NCT01533077|Experimental|Group 4|Period 1: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 2: BIA 9-1067 50 mg + Sinemet® 100/25 Period 3: Sinemet® 100/25 Period 4: BIA 9-1067 50 mg
3152308|NCT01533064||Psychiatric Outpatients|
3152309|NCT01533051||Chronic hepatitis B|
3152310|NCT01533038|Active Comparator|UroLift System|UroLift System procedure
3152311|NCT01533038|Active Comparator|Transurethral Resection of the Prostate|Transurethral Resection of the Prostate surgery
3152312|NCT01533025|Active Comparator|bone-tendon Achilles allograft group|the group which underwent anterior cruciate ligament reconstruction using bone-tendon Achilles allograft
3152313|NCT01533025|Active Comparator|free tendon Achilles allogarft group|the group which underwent anterior cruciate ligament reconstruction using free tendon Achilles allograft
3152314|NCT01533012|Experimental|Pressure difference|Peak inspiratory pressures difference between two lungs
3152315|NCT01532999|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
3152316|NCT01532999|Sham Comparator|Present Centered Group Therapy|Present Centered Group Therapy (PCGT) serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
3152317|NCT01532986|Experimental|Arm 1|A delivery system redesign, with nurse care managers, using standardized assessment tools and care coordination protocols to address unmet needs of Veterans with Parkinson's disease, and collaborating with these Veterans and their families, providers, and community partners to manage Parkinson's disease care.
3152318|NCT01532986|Other|Arm 2|Veterans randomized to the usual care arm will continue to receive care they would have received if they had not enrolled in the study; no care or resources that are made available in general by VA will be withheld from participants in either arm or to any Veterans who wish to use those resources.
3152319|NCT01532973|Experimental|GT1 HCV 10-mg Elbasvir (Panel A)|Participants with GT1 HCV receive 10 -mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
3152320|NCT01532973|Experimental|GTI HCV 50-g Elbasvir (Panel B)|Participants with GT1 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
3152321|NCT01532973|Experimental|GT1 HCV 5-mg Elbavir (Panel C)|Participants with GT1 HCV receive 5-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
3152322|NCT01532973|Experimental|GT1 HCV 200-mg Elbasvir (Panel D)|Participants with GT1 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
3152323|NCT01532973|Experimental|GT3 HCV 10-mg Elbasvir (Panel E)|Participants with GT3 HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
3152324|NCT01532973|Experimental|GT3 HCV 50-mg Elbasvir (Panel F)|Participants with GT3 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
3152375|NCT01532596|No Intervention|Wait-List|
3152325|NCT01532973|Experimental|GT3 HCV 100-mg Elbasvir (Panel G)|Participants with GT3 HCV receive 100-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
3152326|NCT01532973|Experimental|GT3 HCV 200-mg Elbasvir (Panel H)|Participants with GT3 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
3152327|NCT01532973|Experimental|GT1a HCV 10-mg Elbasvir (Panel I)|Participants with GT1a only HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.
3152328|NCT01532973|Experimental|GT1a HCV 50-mg Elbasvir (Panel J)|Participants with GT1a only HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.
3152329|NCT01532960|Experimental|9 Peptides from Her-2/neu, CEA, & CTA, peptide-tet, poly-ICLC|9 class I MHC-restricted synthetic peptides (100 mcg each peptide) derived from breast cancer associated proteins, a class II MHC-restricted tetanus derived peptide (200 mcg), plus polyICLC (1 mg).
3152330|NCT01532947|Experimental|post restoration|
3152331|NCT01532947|No Intervention|no post restoration|no post placement
3152332|NCT01532934|Experimental|brief therapy|motivational enhancement therapy for substance use
3152333|NCT01532934|Placebo Comparator|Standard Care|standard care
3152334|NCT01532921||Subjects with Tricuspid Valve Repair|All patients indicated for a Tricuspid Valve (TV) repair procedure concomitantly to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.
3152335|NCT01532908|Experimental|Part 1: MBL-HCV1 and Telaprevir|
3152336|NCT01532908|Experimental|Part 2: MBL-HCV1 and Sofosbuvir|
3152337|NCT01532895||Hydromorphone HCI OROS|
3152338|NCT01532882|Experimental|Diosmin|
3152339|NCT01532882|Placebo Comparator|Placebo|
3152340|NCT01532869|Placebo Comparator|Placebo|
3152341|NCT01532869|Experimental|Tocilizumab|
3152342|NCT01532856|Active Comparator|Group A induction therapy|Thalidomide + Cyclophosphamide + Dexamethasone
3152343|NCT01532856|Active Comparator|Group B induction therapy|thalidomide + dexamethasone
3152344|NCT01532856|Active Comparator|Group C induction therapy|thalidomide + melphalan + prednisone
3152345|NCT01532843|Active Comparator|PegIFN alfa-2b + nucleos(t)ide analogue|Peginterferon alfa-2b 1.5 μg/kg per week s.c. for 48 weeks in addition to standard nucleos(t)ide analogue treatment
3152346|NCT01532843|No Intervention|Nucleos(t)ide analogue|Continuation of Nucleos(t)ide analogue mono-therapy
3152347|NCT01532830|Experimental|Active|n-VNS active therapy
3152348|NCT01532817|Experimental|alphacore|noninvasive neurostimulation of the vagus nerve
3152349|NCT01532804|Experimental|Arm A|FOLFOX6 + bevacizumab (D1=D15, 12 cycles)
3152350|NCT01532804|Experimental|Arm B|Raltitrexed + Oxaliplatin + Bevacizumab (D1=D21, 8 cycles)
3152351|NCT01532791||mtDNA mutation|m.3243 A>G carriers and their maternal relatives Other mutations in the mitochondrial genome may be included
3152352|NCT01532791||Control|controls (people not maternally related to mutation carriers) Preference is for married in relatives
3152353|NCT01532765|Active Comparator|Epiretinal Membrane Surgery without ILM peel|
3152354|NCT01532765|Active Comparator|Epiretinal Membrane Surgery with ILM peel (ICG assisted)|
3152355|NCT01532765|Active Comparator|Combined CE & IOL and ERM surgery without ILM peel|
3152356|NCT01532765|Active Comparator|Combined CE & IOL and ERM surgery with ILM peel (ICG assisted)|
3152357|NCT01532739|Experimental|Cognitive training|
3152358|NCT01532739|No Intervention|No cognitive training|
3152359|NCT01532726||Eslicarbazepine Acetate (ESL)|ESL and concomitant medication should be managed by the neurologist according to the respective SPC.Summary of Product Characteristics
3152360|NCT01532713|Experimental|non-block side|
3152361|NCT01532700|Experimental|Ofatumumab with GSK2110183|
3152362|NCT01532687|Experimental|Arm I (gemcitabine hydrochloride and pazopanib hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and pazopanib hydrochloride PO on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3152363|NCT01532687|Active Comparator|Arm II (gemcitabine hydrochloride, placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and placebo PO on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may receive single-agent pazopanib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3152364|NCT01532674|Experimental|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy and scaling and root planing
3152365|NCT01532674|Active Comparator|scaling and root planing|Only scaling and root planing
3152366|NCT01532661||observational study|haemorrhagic trauma received rFVIIa
3152367|NCT01532648|Active Comparator|Budesonide|Budesonide MMX 9 mg (one tablet)
3152368|NCT01532648|Placebo Comparator|Placebo|Placebo (tablet indistinguishable from budesonide MMX 9 mg tablet)
3152369|NCT01532635|Experimental|Allogeneic HSCT Using Two Related Donors|"CONDITIONING: Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients undergo CD34+ selected allogeneic HSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning on day 42 and mycophenolate mofetil IV or PO BID on days -1 to 28."
3152370|NCT01532622|Active Comparator|Blueberry Powder|Patients will take 30 grams of blueberry powder daily for up to 30 days.
3152371|NCT01532622|Placebo Comparator|Placebo Powder|Patients will take 30 grams of placebo powder daily for up to 30 days.
3152372|NCT01532609|Experimental|Intervention|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
3152373|NCT01532609|No Intervention|Standard care|No additional training or service is provided for standard care group service providers or clients.
3152374|NCT01532596|Experimental|Mindfulness-Based Stress Reduction|A standardized 8-week mindfulness meditation training program
3152376|NCT01532583||Patients operated on with the TOT|
3152377|NCT01532570|Experimental|TA-650|
3152378|NCT01532544|Experimental|Integrilin and Ilomedin given as continous infusion|
3152379|NCT01532544|Placebo Comparator|Standard treatment daily doses of low molecular weight heparin|Standard treatment daily doses of low molecular weight heparin.
3152380|NCT01532531|Experimental|Collateral Meridian Therapy|"The CMT group patients received, according to the CMT protocol described previously, CMT at the selected points with the CMT Electrotherapy Stimulator (GEMORE Multi-Function Electrotherapy Stimulator; GM390TE, GEMORE Co Ltd, Taiwan) to treat the affected OA knee. The 6-minute treatment (electrotherapy was set at 40 Hz biphasic and 30 mA) comprises reduction and enhancement procedures on the specific points. Each patient received CMT twice per week for three weeks during the study."
3152381|NCT01532531|No Intervention|Control (CT) group|Patients in the CT group received electronic lead-patches applied on the treatment points, which was identical to what the CMT patients received, also for 6 minutes, though no electric stimulation was applied.
3152382|NCT01532518|Experimental|Cohort 3|Nepadutant low dose for 7 days followed by Nepadutant high dose for additional 7 days
3152383|NCT01532518|Experimental|Cohort 2|Nepadutant medium dose for 7 days followed by Nepadutant high dose for additional 7 days
3152384|NCT01532518|Experimental|Cohort 1|Nepadutant low dose for 7 days followed by Nepadutant medium dose for additional 7 days
3152385|NCT01532492||Rotator cuff repair group|Patients undergoing an arthroscopic rotator cuff repair
3152386|NCT01532492||DRC without rupture|Disorders of the rotator cuff without rupture
3152387|NCT01532492||Shoulder instability|Shoulder instability
3152388|NCT01532479||Treatment Group|Subjects with ORN treated with Hyperbaric Oxygen Therapy
3152389|NCT01532479||Postive Control Group|Subjects treated with Hyperbaric Oxygen Therapy that have not had head or neck radiation therapy
3152390|NCT01532479||Negative Control Group|Subjects who have had head and neck radiation that have not had Hyperbaric Oxygen Therapy
3152391|NCT01532466|Experimental|Rocuronium, fentanyl-induced cough, normal saline|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
3152392|NCT01532466|No Intervention|Normal saline|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
3152393|NCT01532453|Active Comparator|Standard Sun Protection Measures|Detailed information on standardised sun protection measures and application of self-provided sunscreen products. The Investigator may decide on an individual reimbursement of patient's expenditure (out of the centre's budget).
3152394|NCT01532453|Experimental|MD-3511356|Patients receive detailed information on standardised sun protection measures. Additionally, they will be provided free of charge with MD-3511356 for application to sun exposed skin areas once daily in the morning for 24 months. MD 3511356 lotion will be applied topically on the sun-exposed skin areas (face, neck, head, forearms and hands) in doses corresponding to the surface extent (see chapter 6.1). The dispensers will be provided with a dosage pump to allow application of reproducible amounts (each pump 0,5 g).
3152395|NCT01532414|Experimental|Androxal 12.5 mg|Androxal (enclomiphene citrate), 12.5 mg oral capsules taken once daily
3152396|NCT01532414|Experimental|Androxal 25 mg|Androxal (enclomiphene citrate), 25 mg oral capsules taken once daily
3152397|NCT01532414|Placebo Comparator|Placebo|Placebo oral capsules taken one time daily
3152398|NCT01532401|Experimental|chlorure de sodium|
3152399|NCT01532401|Placebo Comparator|Methylcellulose|
3152400|NCT01532388|Experimental|eScreen|Web based self-monitoring of problematic alcohol and drug use.
3152401|NCT01532388|No Intervention|Control group|Untreated control group
3152402|NCT01532375|Experimental|Kochujang(32g)|
3152403|NCT01532375|Placebo Comparator|placebo(32g)|
3152404|NCT01532362|Experimental|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
3152405|NCT01532362|Other|No drug intervention|
3152406|NCT01532349|Active Comparator|400 IU vitamin D|Children will be randomly allocated to receive cholecalciferol supplementation 400 IU/day (2,800 IU/weekly), which is the recommended dietary allowance. Study participants will be prescribed any clinically indicated additional cholecalciferol supplementation once the 3-month laboratory measures have been obtained, based on serum 25D levels at the end of the study period.
3152407|NCT01532349|Active Comparator|4000 IU vitamin D|Children will be randomly allocated to receive cholecalciferol supplementation 4000 IU/day (28,000 IU weekly) according to the KDOQI recommended supplementation for children with mild 25D deficiency. Study participants will be prescribed any clinically indicated additional cholecalciferol supplementation once the 3-month laboratory measures have been obtained, based on serum 25D levels at the end of the study period.
3152408|NCT01532336|Experimental|NVC-422 Solution, 0.3%|Dosed for 10 days
3152409|NCT01532336|Placebo Comparator|NVC-422 Vehicle Solution|Dosed for 10 days
3152410|NCT01532323|Experimental|Oral disorder children|Oral disorder children aged 2 to 15 years
3152411|NCT01532323|Active Comparator|Control group|No oral disorder children aged 2 to 15 years
3152412|NCT01532310||Pregnant women taking belimumab|Any women with belimumab exposure within the 4 months prior to and/or during pregnancy
3152413|NCT01532310||Infants|Infants through the first year of life whose mothers were exposed to belimumab during pregnancy
3152414|NCT01532297|Active Comparator|HD treated with standard dialysate|
3152415|NCT01532297|Active Comparator|post-dilution oHDF with standard dialysate|
3152416|NCT01532297|Experimental|pre-dilution oHDF with citrate dialysate|
3152417|NCT01532297|Experimental|HD treated with citrate dialysate|
3152418|NCT01532297|Experimental|post-dilution oHDF with citrate dialysate|
3152419|NCT01532297|Active Comparator|pre-dilution oHDF with standard dialysate|
3152461|NCT01532024|Experimental|Patients with Bronchiectasis|Delivery of NAP (80mcgs) to patients with bronchiectasis
3152420|NCT01532284|Experimental|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
3152421|NCT01532284|No Intervention|No Polar Body Biopsy|
3152422|NCT01532271||Concussed|Patients with recent concussion
3152423|NCT01532271||Matched controls|Athletes with no recent concussion
3152424|NCT01532258|No Intervention|Control Group|No intervention provided. These participants will receive access to the Go! Foods for You program after the research trial has been completed (12 weeks after registration).
3152425|NCT01532258|Active Comparator|GFFY-1 without weekly MA support|Utilization of the 8-week online nutrition program Go! Foods for You without weekly contact from staff at the medical provider's office.
3152426|NCT01532258|Active Comparator|GFFY-2 with weekly MA support|Utilization of the 8-week online nutrition program combined with weekly contact from the staff at the medical provider's office.
3152427|NCT01532245|Active Comparator|two-lung ventilation (TLV)|During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
3152428|NCT01532245|Active Comparator|one lung ventillation (OLV) without PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
3152429|NCT01532245|Active Comparator|one lung ventilation (OLV) with PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2Opositive end-expiratory pressure (PEEP) were alternated
3152430|NCT01532232||placebo|This is a randomized, double-blind, placebo-controlled trial comparing the effectiveness and tolerability of varenicline with placebo for smoking cessation in 30 tobacco dependent breast cancer patients.
3152431|NCT01532232||varenicline|This is a randomized, double-blind, placebo-controlled trial comparing the effectiveness and tolerability of varenicline with placebo for smoking cessation in 30 tobacco dependent breast cancer patients.
3152432|NCT01532219|Experimental|Internet-delivered Psychodynamic Treatment|Participants in the experimental condition will receive 8 text-modules delivered as guided self-help, via the Internet. The intervention lasts for 10 weeks and includes weekly contacts with a therapist via a secure online environment similar to e-mail. The treatment is a short-term psychodynamic treatment psychodynamic treatment.
3152433|NCT01532219|Active Comparator|Internet-delivered structured support|Participants in the active control condition will receive a structured support treatment via the Internet. The intervention lasts for 10 weeks and includes weekly contacts with a therapist via a secure online environment similar to e-mail.
3152434|NCT01532206|Experimental|Remote ischemic preconditioning|Remote ischemic preconditioning performed with Blood pressure cuff insufflation
3152435|NCT01532206|No Intervention|Standard of care|Standard of care
3152436|NCT01532193|Experimental|Hipoxia|The low oxygen tension group
3152437|NCT01532193|No Intervention|Control group|Conventional culture conditions
3152438|NCT01532180|Experimental|THN Therapy|
3152439|NCT01532141|Experimental|Group 1|Period 1: 50 mg BIA 9-1067 alone Period 2: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 3: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg
3152440|NCT01532141|Experimental|Group 2|Period 1: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 2: 50 mg BIA 9-1067 alone Period 3: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg
3152441|NCT01532141|Experimental|Group 3|Period 1: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg Period 2: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 3: 50 mg BIA 9-1067 alone
3152442|NCT01532128|Experimental|Group 1|Period 1: rasagiline 1 mg Period 2: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg Period 3: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg
3152443|NCT01532128|Experimental|Group 2|Period 1: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg Period 2: rasagiline 1 mg Period 3: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg
3152444|NCT01532128|Experimental|Group 3|Period 1: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg Period 2: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg Period 3: rasagiline 1 mg
3152445|NCT01532115|Experimental|BIA 9-1067|
3152446|NCT01532115|Placebo Comparator|Placebo|
3152447|NCT01532115|Active Comparator|moxifloxacin|
3152448|NCT01532102|Experimental|AP611074 5% gel|Twice daily application of 100 mg dose of AP611074 5% gel for 41 days followed by a single morning application on Day 42
3152449|NCT01532102|Placebo Comparator|Placebo gel|Twice daily application of 100 mg dose of placebo gel for 41 days followed by a single morning application on Day 42
3152450|NCT01532089|Active Comparator|Arm A (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21.
3152451|NCT01532089|Experimental|Arm B (erlotinib hydrochloride, bevacizumab)|Patients receive erlotinib hydrochloride as in Arm A and bevacizumab IV over 30-90 minutes on day 1.
3152452|NCT01532076|Experimental|cellularized composite graft augmentation|lipoaspiration by experienced plastic surgeon, isolation of SVF cells using a Cellution/CR800® cell isolation device and single use kits (Cytori Therapeutics Inc., San Diego) during open reduction and internal fixation, augmentation of bone with cell-seeded bone graft substitute;
3152453|NCT01532076|Active Comparator|Control acellular composite graft augmentation|open reduction internal fixation (ORIF) of the fracture, augmentation with acellular bone graft substitute.
3152454|NCT01532063|Other|INTUBATION|Subjects intubed in Intensive Care Unit
3152455|NCT01532050|Other|Mandibular Advancement Device (MAD)|Mandibular Advancement Device (MAD)
3152456|NCT01532037|Experimental|Guided Self Help|Participant receives usual care and 4, 45 minute sessions with a therapist to support them to complete the cognitive behavioural therapy based workbook for fatigue in Multiple Sclerosis.
3152457|NCT01532037|Experimental|Pure Self Help|Participant receives usual care and cognitive behavioural therapy based self help work book for fatigue in multiple sclerosis to complete alone
3152458|NCT01532037|Placebo Comparator|Treatment as Usual|Participants receive usual care from healthcare professionals
3152459|NCT01532024|Experimental|Healthy Volunteers|Delivery of intrapulmonary NAP Dose escalation from 5 mcgs to 80mcgs
3152460|NCT01532024|Experimental|Pulmonary Infiltrate in ICU|Delivery of NAP (80mcgs) to ventilated patients with pulmonary infiltrates
3152603|NCT01531010|Active Comparator|Pressure-limited ventilation|
3152462|NCT01532011|Experimental|Erlotinib + Pralatrexate|"Dose escalation group starting dose: Erlotinib 75 mg by mouth daily for a 28 day cycle. Starting dose of Pralatrexate 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
3152463|NCT01531998|Experimental|Siltuximab + Bortezomib + Lenalidomide|"Induction: Lenalidomide 25 mg orally Days 1-14; Bortezomib 1.3 mg/m2 intravenous Days 1, 4, 8 and 11; Dexamethasone 20 mg orally Days 1, 2, 4, 5, 8, 9, 11, 12. Siltuximab 11 mg/kg intravenous Day 1.~If delayed transplant, induction therapy continued up to 2 cycles beyond achieving a CR/nCR (minimum of 4 cycles of therapy and a maximum of 8 cycles of therapy) and then transition to maintenance regimen described below.~Maintenance therapy: Lenalidomide at last tolerated dose Day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.~Siltuximab 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy. Bortezomib at last tolerated dose Day 1 and Day 8 Dexamethasone at last tolerated dose or 20 mg weekly."
3152464|NCT01531972|Experimental|SEP-228432 (Cohort 1)|Subjects will receive 40 mg of SEP-228432 (titration) orally once per day for 3 days; followed by (steady state) at a dose of 200 mg orally once per day for 5 days.
3152465|NCT01531972|Experimental|SEP-228432 (Cohort 2)|Subjects will receive 40 mg of SEP-228432 (titration) orally once per day for 3 days followed by a dose (TBD) of SEP 228432 ≤ 300mg, orally once per day for 5 days.
3152466|NCT01531972|Experimental|SEP-228432 (Cohort 3)|Subjects will receive 40 mg of SEP-228432 (titration) 40 mg of SEP 228432 orally once per day for 3 days followed by a dose (TBD) of SEP 228432 ≤ 300mg, orally once per day for 5 days.
3152467|NCT01531959|Active Comparator|Midodrine|
3152468|NCT01531959|Placebo Comparator|Placebo|
3152469|NCT01531933|Experimental|DLBS3233|
3152470|NCT01531933|Placebo Comparator|Placebo of DLBS3233|
3152471|NCT01531920|Other|alcohol + placebo|Part A alcohol + placebo
3152472|NCT01531920|Other|alcohol + perampanel|Part A : alcohol + perampanel
3152473|NCT01531920|Other|perampanel + alcohol|Part B: perampanel + alcohol
3152474|NCT01531920|Other|placebo + alcohol|Part B: placebo + alcohol
3152475|NCT01531907||Obese|Premenopausal women, 25 - 40 years with BMI of ≥30kg/m2
3152476|NCT01531907||Lean|Premenopausal women, 25 - 40 years with BMI of 18.5-24.9 kg/m2
3152477|NCT01531894|Experimental|Arm 1|subjects who have completed less than 24 weeks of treatment with GSK2110183 monotherapy
3152478|NCT01531894|Experimental|Arm 2|subjects who have completed greater than 24 weeks of treatment with GSK2110183 monotherapy
3152479|NCT01531894|Experimental|Arm 3|subjects who have participated in a combination study where GSK2110183 is administered with an approved anti-cancer agent, regardless of duration
3152480|NCT01531868|Other|Auditory qualitative|
3152481|NCT01531868|Other|Auditory absolute risk|
3152482|NCT01531868|Other|Auditory relative risk|
3152483|NCT01531868|Other|Visual qualitative|
3152484|NCT01531868|Other|Visual relative risk|
3152485|NCT01531868|Other|Visual absolute risk|
3152486|NCT01531855|Other|Insulin dose|Reducing rapid-acting insulin dose (insulin aspart or lispro) after exercise.
3152487|NCT01531842|Experimental|Topical antibiotic|Patients will be randomized in a 1:1 fashion to receive a drop of topical antibiotic before and after the intravitreal injection in the +ABX arm (in addition to the typical prep with betadine).
3152488|NCT01531842|Other|No Antibiotic Arm|No topical antibiotics in the -ABX arm (only the typical prep with betadine)
3152489|NCT01531829|Experimental|Low dose (50mg/2h) rt-PA plus LMWH|Low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) plus low molecular weight heparin(LMWH)regimen
3152490|NCT01531829|Active Comparator|LMWH|Low molecular weight heparin
3152491|NCT01531816|Experimental|Single Arm: Study Intervention|Cycle ergometry and/or Interactive video-game
3152492|NCT01531803|Active Comparator|Kedbumin 25%|
3152493|NCT01531803|Sham Comparator|Normal Saline|
3152494|NCT01531790|Experimental|Endostar plus pemetrexed/carboplatin|21 days as one cycle, for a total of 4-6 cycles
3152495|NCT01531777|Experimental|Apatinib 500mg|500mg,p.o.,qd
3152496|NCT01531777|Experimental|Apatinib 750mg|750mg,p.o.,qd
3152497|NCT01531751|Experimental|High Cut-off Hemodialysis|
3152498|NCT01531738||Control|Normal weight healthy volunteers
3152499|NCT01531738||Gastric banding|obese patients undergoing gastric banding obesity surgery
3152500|NCT01531738||Gastric bypass|obese patients due to undergo gastric bypass surgery
3152501|NCT01531725|Experimental|BMS implantation|Patients meeting the inclusion criteria and none of the exclusion criteria are treated by implanting the study device (the ProKinetic bare metal stent). Since it is a single arm study design, no patients are enrolled to a control arm.
3152502|NCT01531712|Experimental|QT + QRT|"Chemotherapy (6 cycles x 14 days): Gemcitabine 1000 mg/m2 (day 1) + Oxaliplatin 100 mg/m2 (day 2) + Tarceva 100 mg/day.~Chemoradiotherapy (5,5 weeks): Gemcitabine 40 mg/m2 (2 days/week) + Tarceva 100 mg/day + Radiotherapy (1,8 Gy/day x 28 doses, total dose: 50,4 Gy)."
3152503|NCT01531699|Experimental|ALT005 Ophthalmic Prep Solution|
3152504|NCT01531699|Placebo Comparator|saline control|
3152505|NCT01531699|Experimental|Comparator Product|Betadine ophthalmic prep solution
3152506|NCT01531673|Placebo Comparator|Group 1-6d Combined: Placebo|All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a, 5b, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.
3152507|NCT01531673|Experimental|Group 1: VX-661 10 mg qd|All participants in group 1 who received VX-661 10 milligram (mg) tablet orally once daily (qd) for up to 28 days.
3152508|NCT01531673|Experimental|Group 2a: VX-661 30 mg qd|All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet every 12 hours (q12h) for up to 28 days.
3152509|NCT01531673|Experimental|Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h|All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
3152510|NCT01531673|Experimental|Group 3a: VX-661 100 mg qd|All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.
3152604|NCT01531010|Active Comparator|Volume-targeted ventilation|
3152511|NCT01531673|Experimental|Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h|All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
3152512|NCT01531673|Experimental|Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h|All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
3152513|NCT01531673|Experimental|Group 5a: VX-661 150 mg qd|All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.
3152514|NCT01531673|Experimental|Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h|All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
3152515|NCT01531673|Experimental|Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h|All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.
3152516|NCT01531673|Experimental|Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h|All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
3152517|NCT01531673|Placebo Comparator|Group 7: Placebo|All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.
3152518|NCT01531673|Experimental|Group 7: VX-661 100 mg qd|All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.
3152519|NCT01531660|Experimental|training|step up jogging program
3152520|NCT01531647|Active Comparator|Period 1 Control|
3152521|NCT01531647|Experimental|Period 2 danoprevir/ritonavir|
3152522|NCT01531634|Active Comparator|Dynamic Cognitive Intervention Group|Twelve Meetings of Dynamic Cognitive Intervention.
3152523|NCT01531634|No Intervention|No Additional Intervention|
3152524|NCT01531621||mCRC treatments|All used treatments for metastatic colorectal cancer
3152525|NCT01531595|Experimental|Chemotherapy plus bevazicumab|
3152526|NCT01531582|Experimental|Children with Angelman Syndrome|Children with a molecularly confirmed diagnosis of Angelman Syndrome meeting the protocol requirements will be selected randomly. All participants will receive the study drug, minocycline, over an identical time course. Participants will undergo identical baseline, 8 and 16 week follow up assessments.
3152527|NCT01531569|Experimental|BeneFlax|BeneFlax given as a single oral dose to assess pharmacokinetics
3152528|NCT01531543|Experimental|VAC-laparostomy|Primary use of Vacuum Assisted Closure (VAC) laparostomy after surgical revision because of severe peritonitis
3152529|NCT01531543|No Intervention|Primary abdominal closure|The abdominal wall is primary closed after the surgical revision because of severe peritonitis
3152530|NCT01531530|Experimental|Vaccine-recipients|
3152531|NCT01531530|Placebo Comparator|Placebo|
3152532|NCT01531517|Experimental|Pedyphar|Ointment
3152533|NCT01531517|Active Comparator|Panthenol|Ointment
3152534|NCT01531504|Other|Hysterectomy|candidate for a conventional laparoscopic-assisted
3152535|NCT01531491|Experimental|Hypercapnia group|Respiratory rate will be 10/min and the rebreathing tube will be connected between the y-piece of corrugated tube and the tracheal tube to maintain the partial pressure of the end-tidal carbon dioxide at around 50 mmHg during emergence after propofol anesthesia.
3152536|NCT01531491|Experimental|Hypocapnia group|No rebreathing tube (Nothing) will be connected. Respiratory rate will be 10/min and the tidal volume will be modulated to maintain the partial pressure of the end-tidal carbon dioxide at around 30 mmHg during emergence after propofol anesthesia.
3152537|NCT01531478||Young adult survivors of childhood cancer|Young adult survivors of childhood cancer diagnosed between 1987 and 1992 in the Rhône-Alpes and Auvergne regions of France.
3152538|NCT01531465|Other|HFNC to NCPAP|Infants who are currently on HFNC.
3152539|NCT01531465|Other|NCPAP to HFNC|Infants who are currently on NCPAP.
3152540|NCT01531452|Experimental|treatment|oxaliplatin+s1
3152541|NCT01531439|Active Comparator|Naloxone infusion 0.5 mcg/kg/hr|
3152542|NCT01531439|Experimental|Naloxone 2.5 mcg/kg/hr|Naloxone infusion 2.5 mcg/kg/hr
3152543|NCT01531426||NIRS continuous monitoring|
3152544|NCT01531413|Experimental|Oxygen Insufflation|At the end of the laparoscopic appendectomy we will desufflate the abdomen of CO2 then reinsufflate with oxygen to washout the CO2 leaving an oxygen rich environment
3152545|NCT01531400|Experimental|music|Investigators played self-selected background music in the music group
3152546|NCT01531400|No Intervention|no music (control)|Investigators played no music in the music group
3152547|NCT01531387|No Intervention|Standard Therapy: Observation|Half of the subjects will be randomized to clinical observation only, which includes monthly visits with clinical evaluations, laboratory tests, and TCD endpoint examinations
3152548|NCT01531387|Experimental|Hydroxyurea|Half of the subjects will be randomized to hydroxyurea, taken as capsules (300 mg, 400 mg, or 500 mg), or as a liquid formulation (100 mg/mL). Hydroxyurea will be administered once daily by mouth. Subjects will be monitored monthly with clinical evaluations, laboratory tests, and TCD endpoint examinations.
3152549|NCT01531374|Experimental|Extreme Risk: TAVI Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Iliofemoral Access
3152550|NCT01531374|Experimental|Extreme Risk: TAVI Non-Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Non-Iliofemoral Access
3152551|NCT01531374|Experimental|High Risk: TAVI|High Risk Surgical Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
3152552|NCT01531361|Experimental|Vemurafenib + Sorafenib|"There will be two treatment arms, Vemurafenib and Sorafenib and Vemurafenib and Crizotinib. Patients assigned to treatment arms per physician discretion.~Dose Escalation Group Starting dose of Vemurafenib: 240 mg by mouth twice a day for 28 day cycle.~Dose Escalation Group Starting dose of Sorafenib: 200 mg by mouth twice a day for 28 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose (MTD) from dose escalation group."
3152601|NCT01531023||ESBL producing E. coli bacteria|Group of patients with identified ESBL producing E.coli in a urine sample taken in a primary care setting.
3152602|NCT01531023||Non-ESBL E.coli urinary tract infection|E.coli bacteria found in the setting of a urinary tract infection in a primary care setting where ESBL producing bacteria are not found.
3152553|NCT01531361|Experimental|Vemurafenib + Crizotinib|"There will be two treatment arms, Vemurafenib and Sorafenib and Vemurafenib and Crizotinib. Patients assigned to treatment arms per physician discretion.~Dose Escalation Group Starting Dose of Vemurafenib: 240 mg by mouth twice a day for 28 day cycle.~Dose Escalation Group Starting dose of Crizotinib 250 mg by mouth daily for a 28 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose (MTD) from dose escalation group."
3152554|NCT01531348|Experimental|BM-MSC|Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
3152555|NCT01531335|Active Comparator|Standard care|Patients will receive normal nutritional regime of around 25 kcal per kg.
3152556|NCT01531335|Experimental|Hypocaloric hyperproteic nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg
3152557|NCT01531322|Experimental|Group 1|Adults aged 18 through 55 years (before the fifty sixth birthday)
3152558|NCT01531322|Experimental|Group 2|Children aged 3 through 5 years (before the sixth birthday)
3152559|NCT01531322|Experimental|Group 3|Infants aged approximately 2 months (42 to 98 days)
3152560|NCT01531309|Experimental|AGO178|
3152561|NCT01531283|Experimental|decaylated ghrelin|UAG (4.0 µg/kg/hr)
3152562|NCT01531283|Experimental|acyl ghrelin|AG (1.0 µg/kg/hr)
3152563|NCT01531283|Experimental|combined acyl and desacyl ghrelin|the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr)
3152564|NCT01531283|Placebo Comparator|saline|saline
3152565|NCT01531257||Kidney Transplant Recipients|The intention of our biomarker panel is to be broadly applicable to all patients with a kidney transplant with the assumption that there are common underlying molecular mechanisms of AR and CAN/IFTA that can be detected hopefully at early stages of disease. We therefore want to validate and test our biomarker panel in a broad collection of patient types. We chose not to include patients with dual organ transplants so that we could isolate the molecular signal we are studying.
3152566|NCT01531244|Experimental|Treatment (targeted gene therapy and ILI)|Patients receive melphalan and dactinomycin via ILI. Patients then receive CRAd 3/5-delta via ILI.
3152567|NCT01531231||YOUNGER HEALTHY NO CORONARY ARTERY DISEASE (CAD)|- Whether an association between typical daily experiences and recovery time varies with age; this group will be compared to the older comparison group and to previous data collected from those subjects who participated in the Long QT Syndrome study (LQTS).
3152568|NCT01531231||OLDER HEALTHY SUBJECTS NO CORONARY ARTERY DISEASE (CAD)|- Determine whether daily emotion influences ischemia and repolarization differentially as a function of the severity of CAD and presence of CAD when comparing CAD patients with healthy patients
3152569|NCT01531231||HIGH RISK CORONARY ARTERY DISEASE (CAD)|- Determine whether emotion assessed randomly throughout the day is associated with myocardial ischemia
3152570|NCT01531231||LOW RISK CORONARY ARTERY DISEASE (CAD)|- Determine whether typical daily emotion influences ischemia and repolarization differentially as a function of the severity of CAD and presence of CAD
3152571|NCT01531218|Active Comparator|azithromycin|azithromycin 500mg
3152572|NCT01531218|Placebo Comparator|placebo|placebo 500mg
3152573|NCT01531205|Experimental|Drug and Hormonal Therapy with Salvage Surgery|Androgen Ablation (hormonal therapy before surgery), Cabazitaxel (chemotherapy before surgery), Salvage Surgery (radical prostatectomy), Post-operative Hormonal Therapy, Post-operative Follow-up
3152574|NCT01531192|Experimental|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
3152575|NCT01531192|Active Comparator|Nystatin|50000 unit/3 times a day
3152576|NCT01531179|Experimental|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
3152577|NCT01531179|Placebo Comparator|Control|Placebo for 3 months
3152578|NCT01531166||Chronic hepatitis B|
3152579|NCT01531153|Active Comparator|Sugar Pill|Sugar Pill will be compared with the active medication Galantamine
3152580|NCT01531153|Active Comparator|Galantamine|Comparing the active medication with the placebo medication to see if the self administration cocaine decreases.
3152581|NCT01531140|Active Comparator|Polyethylene glycol|Polyethylene glycol p.o.(Fortrans):60 ml/kg for 2 days
3152582|NCT01531140|Experimental|PEG + Bisacodyl|Polyethylene glycol p.o.(Fortrans): 30 ml/kg for 2 days + Bisacodyl p.o.: 10-15 mg/day
3152583|NCT01531140|Experimental|Sennosides|Sennosides: 1tbl/8kg/day for 2 days (1 tbl=8,6 mg sennosides B)
3152584|NCT01531127||Combined Therapy|ADHD Medication and Learning Strategies Treatment
3152585|NCT01531127||ADHD Medication Treatment|Control group
3152586|NCT01531114|Active Comparator|Prasugrel loading dose|Patients will be randomized to this arm to receive loading dose of prasugrel
3152587|NCT01531114|No Intervention|ticagrelor loading dose|Patients will be randomized to this arm to receive loading dose of ticagrelor
3152588|NCT01531101|Experimental|Individual PDT with TW|Individual Psychodynamic psychotherapy with transference work (TW).
3152589|NCT01531101|Active Comparator|Individual PDT without (TW)|Individual Psychodynamic psychotherapy without focus on transference work (TW).
3152590|NCT01531088|No Intervention|Usual care|Recommendations made by consultant pharmacists as part of their federally-mandated medication regimen review process
3152591|NCT01531088|Experimental|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events
3152592|NCT01531075|Experimental|ENGERIX-B|
3152593|NCT01531075|Experimental|Sci-B-Vac|
3152594|NCT01531062|Experimental|Nigella sativa|Nigella sativa extracts, 300 mg twice daily
3152595|NCT01531062|Placebo Comparator|Placebo|
3152596|NCT01531049|Experimental|Varenicline|A varenicline treatment group (with motivational interview technique combined with varenicline and placebo transdermal patch). Intervention with Nicorette 15mg /16 h patch
3152597|NCT01531049|Experimental|Nicotine cutaneous patch 15mg|Intervention with Varenicline for 12 weeks. Nicotine cutaneous patch 15mg/16h
3152598|NCT01531049|Experimental|Nicotine cutaneous patch 10mg|Intervention with Placebo transdermal patch for 8 weeks. Nicotine cutaneous patch 10mg/16h
3152599|NCT01531049|Placebo Comparator|Placebo cutaneous patch|No active medication.One transdermal patch/16 h.Total duration was 8 weeks.
3152600|NCT01531036|Experimental|shear wave imaging|Single arm study evaluating breast 3D elastography by means of shear wave propagation into breast tissue.
3152605|NCT01530997|Experimental|De-escalated Radiation and Chemotherapy|Patients will receive 54 to 60 Gy of Intensity Modulated Radiotherapy (IMRT) with concurrent weekly intravenous cisplatin (30 mg/m2). Diagnostic imaging (CT and/or MRI) will be obtained 4 to 8 weeks after completion of CRT to assess response. All patients will have surgical resection of any clinically apparent residual primary tumor or biopsy of the primary site if there is no evidence of residual tumor and will undergo a limited neck dissection to encompass at least those nodal level(s) that were positive pre-treatment, 4 to 14 weeks after CRT.
3152606|NCT01530984|Experimental|Ipilimumab alone|Ipilimumab 3 mg/kg (IV) will be given every 28 days for six cycles (induction) followed by administration once every three months for patients who are not progressing (maintenance).
3152607|NCT01530984|Experimental|Ipilimumab with GM-CSF|Ipilimumab 3 mg/kg (IV) will be given every 28 days for six cycles (induction) followed by administration once every three months for patients who are not progressing (maintenance). GM-CSF 250 mcg/m2 SQ will be administered on days 1-14 in Cycles 1-6 and then every 3 months for 14 days beginning on the day of ipilimumab administration during the maintenance therapy phase
3152608|NCT01530971|No Intervention|room air|no supplemental oxygen in intraoperative period
3152609|NCT01530971|Experimental|Oxygen|Supplemental 3LPM oxygen via canula
3152610|NCT01530958|Experimental|ATSM + Health Coach and CKD Registry|
3152611|NCT01530958|Active Comparator|CKD Registry|
3152612|NCT01530958|Active Comparator|ATSM + Health Coach|
3152613|NCT01530958|Placebo Comparator|Usual Care (normal standard of care with no interventions)|
3152614|NCT01530919||Parathyroid surgery|Database of patients who have undergone minimally invasive radioguided parathyroidectomy
3152615|NCT01530906|Experimental|rTMS|"patients included in this arm will receive 10 sessions of transcranial magnetic stimulation (10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC).~Fifty percent of patients will be included in this arm. During the first and last session a food challenge task will be administered before and after rTMS. Salivary cortisol level will be assessed throughout the protocol Intervention: Repetitive transcranial Magnetic Stimulation (rTMS)"
3152616|NCT01530906|Placebo Comparator|rTMS SHAM|Transcranial magnetic stimulation SHAM Intervention: Repetitive transcranial Magnetic Stimulation SHAM Fifty percent of patients will be included in this arm. During the first and last session a food challenge task will be administered before and after rTMS. Salivary cortisol level will be assessed throughout the protocol
3152617|NCT01530893|Experimental|Intervention group A: flavanones|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
3152618|NCT01530893|Experimental|Intervention group B: isoflavones|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
3152619|NCT01530893|Experimental|Intervention group C: Flavan-3-ols|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
3152620|NCT01530893|Experimental|Intervention group D: Anthocyanins|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
3152621|NCT01530880|Experimental|Intravenous Ibuprofen|Patients assigned to the ibuprofen treatment group will receive a 400 mg IV ibuprofen bolus over 30 minutes followed by an infusion of ibuprofen at 85 mg/hr.
3152622|NCT01530880|Other|Standard of Care|Patients assigned to the standard of care group will be given 650 mg of oral acetaminophen and continue to receive 650 mg of oral acetaminophen every 6 hours as needed to maintain temperature < 38.3 C (100.9 F).
3152623|NCT01530854||Septic|
3152624|NCT01530854||Healthy|
3152625|NCT01530841|Experimental|AVAPS|Arm assigned to AVAPS mode for nocturnal ventilation with the same setting than bilevel pressure support but with AVAPS mode activated
3152626|NCT01530841|Active Comparator|Bilevel pressure|Arm treated only with bilevel pressure support for nocturnal ventilation without activation of AVAPS mode
3152627|NCT01530828||Premature infants|Weight less than 1000 grams, age 1 - 16 days.
3152628|NCT01530815|Experimental|Bupivicaine Infusion|We will infuse bupivicaine between the abdominal wall and mesh to try and reduce postoperative pain
3152629|NCT01530802|Experimental|Uterine artery clipped|Both uterine arteries are temporarily clipped by Yasargil clips during laparoscopic myomectomy.
3152630|NCT01530802|No Intervention|Control group|Conventional laparoscopic myomectomy is performed. (No intervention to temporarily occlude uterine arteries is made)
3152631|NCT01530776|Experimental|Healthy Lifestyle Group|Participants randomized to this condition will receive information and strategies to help them eat healthier and be more active during and after pregnancy. They will get this information about eating and activity through handouts, text messages, Facebook updates, and in-person visits and phone calls from a health coach.
3152632|NCT01530776|No Intervention|Usual Care|This condition is meant to represent standard clinical care provided to pregnant and postpartum mothers at Temple University.
3152633|NCT01530763|Experimental|Ceftaroline fosamil|
3152634|NCT01530763|Active Comparator|Ceftriaxone|
3152635|NCT01530750||Post cardiac surgery|
3152636|NCT01530737|Placebo Comparator|Control Group|
3152637|NCT01530737|Experimental|Active Antithrombin Group|
3152638|NCT01530724|Experimental|PA (Exercise )+|
3152639|NCT01530724|Experimental|PA (Exercise ) -|
3152640|NCT01530711|Experimental|terlipressin|
3152641|NCT01530698|Experimental|single step DC treatment|vaccination with autologous dendritic cells treated with mRNA electroporation for single-step antigen loading and TLR activation (TriMix-DC)
3152642|NCT01530698|Active Comparator|two step DC treatment|vaccination with autologous dendritic cells treated with mRNA electroporation for antigen loading and separately for TLR activation
3152643|NCT01530685|Experimental|Glycabiane, gelule|
3152644|NCT01530685|Placebo Comparator|Placebo|
3152645|NCT01530672|Experimental|ANC clients|
3152646|NCT01530659|Experimental|NT-501|Encapsulated cell therapy that delivers ciliary neurotrophic factor to the retina
3152647|NCT01530646|Placebo Comparator|Control|Carbohydrate & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of maltodextrin (no protein) for 14 days. Weight loss.
3152648|NCT01530646|Experimental|Whey|Whey protein & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of WPI for 14 days. Weight loss.
3152649|NCT01530646|Experimental|Soy|Soy protein & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of SPC for 14 days. Weight loss.
3152650|NCT01530620|Experimental|Propiverine hydrochloride ER|45 mg
3152651|NCT01530620|Active Comparator|Propiverine hydrochloride IR|15 mg
3152652|NCT01530607|Active Comparator|cyclophosphamide|Standard cyclophosphamide containing adjuvant or neoadjuvant chemotherapy
3152653|NCT01530607|Experimental|Goserelin (Zoladex)|Goserelin (Zoladex) plus Standard cyclophosphamide containing adjuvant or neoadjuvant chemotherapy
3152654|NCT01530594|Active Comparator|Lenalidomide|Lenalidomide/Low dose Dex (LLD)
3152655|NCT01530594|Experimental|Bortezomib/Lenalidomide|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
3152656|NCT01530581|Experimental|G-BM Transplant|
3152657|NCT01530581|Other|G-PB Transplant|G-PB Transplant
3152658|NCT01530568|Active Comparator|Smear|Routine microbiology based diagnostics for TB
3152659|NCT01530568|Experimental|GeneXpert|Arm that will receive the Xpert test
3152660|NCT01530555|Experimental|Treatment arm|"Rabbit ATG, Thymoglobuline (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months, with later tailing according to individual patient response. Aim to maintain trough whole blood CSA levels between 150 and 250 ng/ml."
3152661|NCT01530542|Experimental|Treatment A|
3152662|NCT01530542|Experimental|Treatment B|
3152663|NCT01530542|Experimental|Treatment C|
3152664|NCT01530542|Experimental|Treatment D|
3152665|NCT01530542|Experimental|Treatment E|
3152666|NCT01530529|Experimental|PF-05180999 Immediate-Release|
3152667|NCT01530529|Experimental|PF-05180999 Modified-Release 1|
3152668|NCT01530529|Experimental|PF-05180999 Modified-Release 2|
3152669|NCT01530529|Experimental|PF-05180999 Modified-Release 1 With Food|
3152670|NCT01530516|Active Comparator|Full brackets plus Forsus springs|Standard of care - Class II springs used after le el and alignment.
3152671|NCT01530516|Experimental|Xbow plus full brackets|Alternative treatment - First use the Xbow appliance and then full brackets after Class II occlusion has been corrected.
3152672|NCT01530503|Experimental|capecitabine|oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food
3152673|NCT01530503|Experimental|capecitabine plus mitomycin|oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion Mitomycin 6 mg/m2 day 1
3152674|NCT01530490|No Intervention|Hemoes|
3152675|NCT01530490|Experimental|Cabergoline|cabergoline
3152676|NCT01530477|Experimental|Skeletal|"Recruitment for each cohort will include approximately equal male/female split (no gender bias). Depending on the weight category, for each cohort, a minimum of 30 adult subjects will be measured on two of three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], and 60 will be measured on all three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)],(total of evaluable 90 subjects).~** Subjects can enroll in both Skeletal and Body Composition cohorts. Analysis will be performed within each cohort.**"
3152677|NCT01530477|Experimental|Body Composition|"Recruitment for each cohort will include approximately equal male/female split (no gender bias). Depending on the weight category, for each cohort, a minimum of 30 adult subjects will be measured on two of the three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], and 60 will be measured on all three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], (total of evaluable 90 subjects).~** Subjects can enroll in both Skeletal and Body Composition cohorts. Analysis will be performed within each cohort.**"
3152678|NCT01530477|Experimental|Skeletal & Body Composition|"Skeletal and Body Composition was not a cohort that was actively recruited to, it is a cohort for reporting purposes. Subjects will be measured on two of three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)]Subjects were able to consent and enroll to both Skeletal and Body Composition cohorts and these subjects will be counted for under this joint cohort."
3152679|NCT01530464|Active Comparator|Aminophylline|
3152680|NCT01530464|Active Comparator|Ambrisentan|
3152681|NCT01530464|Experimental|Aminophylline and ambrisentan|Treatment 3: Aminophylline, 500 mg plus Ambrisentan, 5 mg
3152682|NCT01530451|Experimental|A: Drug/ Placebo|Initial phase on Desmopressin and then cross over to placebo on the second phase
3152683|NCT01530451|Experimental|B: Placebo/ Drug|Initial phase on Placebo and then cross over to Desmopressin on the second phase
3152684|NCT01530438|Other|ALS patients without cognitive disorders|Amyotrophic lateral sclerosis without cognitive disorders
3152685|NCT01530438|Other|ALS patients with cognitive disorders|Amyotrophic lateral sclerosis with cognitive disorders
3152686|NCT01530438|Other|ALS patients + frontal-temporal dementia|Amyotrophic lateral sclerosis plus frontal-temporal dementia
3152687|NCT01530425||Phase 1 assessments|Regency Wheelchairs and APDK 12-inch wide wheelchairs
3152688|NCT01530425||Phase 2 assessments|Hope Haven and APDK 14-16 inch wide wheelchairs
3152689|NCT01530425||Phase 3 assessments|Motivation and Whirlwind wheelchairs
3152690|NCT01530412|No Intervention|Control Group|Patients are randomized to the control group and are assessed pre rehabilitation and post rehabilitation after which they proceed to the intervention group.
3152877|NCT01529346|Placebo Comparator|Placebo|
3152691|NCT01530412|Experimental|Pulmonary Rehabilitation|Patients undergo an active seven week pulmonary rehabilitation programme. Assessments occur pre rehabilitation, post rehabilitation, at three months and at one year.
3152692|NCT01530399|Experimental|MDCO 1|MDCO-2010: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
3152693|NCT01530399|Experimental|MDCO 2|MDCO-2010: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
3152694|NCT01530399|Experimental|MDCO 3|MDCO-2010: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
3152695|NCT01530399|Experimental|MDCO 4|MDCO-2010: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume
3152696|NCT01530399|Placebo Comparator|Saline|Commercially available saline (0.9% NaCl solution)
3152697|NCT01530399|Active Comparator|Tranexamic acid|Tranexamic acid: 12 mg/kg loading dose; 5 mg/kg/h infusion; 0.556 mg/mL CPB priming
3152698|NCT01530386|Experimental|Lacosamide|300 mg/day
3152699|NCT01530373|Experimental|solifenacin|oral solifenacin 5.0 mg daily for 3 weeks
3152700|NCT01530373|Active Comparator|clonidine|oral clonidine 0.1 mg daily for 3 weeks
3152701|NCT01530360|Experimental|cerebral oximetry + treatment guideline|Cerebral oximetry applied as soon as possible after birth and continued until 72 hours of life Clinical staff administer the routine medical management according to local practice as well as respond to out-of-range values with the help of the treatment guideline
3152702|NCT01530347|Experimental|Easy Check versus reference glucometer and blood ketone meter|Collection of paired measurements of capillary blood glucose using reference method (approved glucometer)and blood beta Hydroxybutyrate (approved ketone meter) and data generated by the non invasive study device
3152703|NCT01530334|Experimental|open label single arm with Gefitinib 250MG once daily|Gefitinib 250 mg/day open label until progression disease / toxicity / consent withdrawal
3152704|NCT01530321|Experimental|High dose spinal manipulation|18 visits for spinal manipulation
3152705|NCT01530321|Experimental|Moderate dose spinal manipulation|12 visits for spinal manipulation and 6 visits for light massage
3152706|NCT01530321|Experimental|Low dose spinal manipulation|6 visits for spinal manipulation and 12 visits for light massage
3152707|NCT01530321|Other|High dose massage|18 visits for light massage
3152708|NCT01530308|Active Comparator|Investigational medicinal product|Haloperidol 1 mg twice daily at 12am and 20pm
3152709|NCT01530308|Placebo Comparator|Placebo group|Placebo 1 mg twice daily at 12am and 20pm
3152710|NCT01530295|No Intervention|contol|control group
3152711|NCT01530295|Other|chemotherapy|neoadjuvant chemotherapy
3152712|NCT01530282|Experimental|measurement of respiratory mechanics|Invasive method: two catheters will be inserted to measure reference respiratory mechanics Non_invasive method: airway pressure measured during a 150-200 ms occlusion at the beginning of inspiration.
3152713|NCT01530269|Experimental|PET/CT imaging with C11-Sodium Acetate|
3152714|NCT01530256|Experimental|ALD518|
3152715|NCT01530243|Placebo Comparator|Placebo|
3152716|NCT01530243|Active Comparator|Terazosin|
3152717|NCT01530243|Active Comparator|Tolterodine|
3152718|NCT01530243|Active Comparator|Tolterodine + Terazosin|
3152719|NCT01530230|Other|Oxytocin 5 units|
3152720|NCT01530230|Other|Oxytocin 10 units|
3152721|NCT01530204|Active Comparator|Physical Therapy|8-12 sessions of knee-focused physical therapy and a home-based conditioning program.
3152722|NCT01530204|Active Comparator|Cognitive Behavioral Therapy for Pain|8-12 session pain-focused Cognitive Behavioral Therapy
3152723|NCT01530204|Active Comparator|Enhanced Treatment as Usual|Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
3152724|NCT01530191||Abdominal|- Participants undergoing surgeries with an abdominal approach will be given a Morphine PCA at a dose of 2mg every 10 minutes with a 12mg/hour lockout. They will also be given IV Toradol at 30mg every 6 hours as needed for a maximum of four doses.
3152725|NCT01530191||Vaginal|- Participants undergoing surgeries with a vaginal approach will be given hydrocodone/acetaminophen at a dose of 5/325 (1-2 tablets every four hours as needed), and provided with Ibuprofen 800mg every 8 hours as needed.
3152726|NCT01530178|Active Comparator|Part A|Sitagliptin 25mg
3152727|NCT01530178|Active Comparator|Part B|Sitagliptin 50mg
3152728|NCT01530178|Active Comparator|Part C|Sitagliptin 100mg
3152729|NCT01530178|Placebo Comparator|Part D|Placebo oral tablet
3152730|NCT01530165|Other|Standard|Pre diabetics randomized to control arm will receive standard life style advice which is given to all pre diabetics seeking medical advice.
3152731|NCT01530165|Experimental|life style intervention arm|This arm would be given aggressive life style intervention in comparison to standard (control) arm. The intervention would consist of nutritional and physical activity advice.
3152732|NCT01530139|Placebo Comparator|Level 0|Level 0: Control group - participants will receive non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
3152733|NCT01530139|Experimental|Level 1|Level or Group 1: participants will receive personalised dietary advice based on their dietary intake data alone.
3152734|NCT01530139|Experimental|Level 2|Level or Group 2: participants will receive personalised dietary advice taking their dietary intake and phenotypic data ( obesity-related phenotypes and clinical biomarkers) into account.
3152735|NCT01530139|Experimental|Level 3|Level or Group 3 : participants will receive personalised dietary advice taking their dietary intake, phenotypic (obesity-related markers) and genotypic data into account.
3152736|NCT01530126|Active Comparator|B-TCP +buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed in sodium acetate buffer only.
3152737|NCT01530126|Experimental|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 0.3 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.
3152738|NCT01530126|Experimental|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 1.0 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.
3152739|NCT01530087|Experimental|Treatment|CASTLE Barrier
3152740|NCT01530074|Experimental|Study Group|
3152741|NCT01530061|Experimental|Preschool Children age 4-6 years|Preschool children participate in eating either an egg breakfast or a bagel breakfast.
3152742|NCT01530061|Experimental|Teenagers 14-17 years of age|Teenagers participate in eating either an egg breakfast or a bagel breakfast.
3152743|NCT01530048|Experimental|U200|
3152744|NCT01530048|Active Comparator|U100|
3152745|NCT01530035|Active Comparator|soccer training intervention|
3152746|NCT01530035|Other|strength training intervention|
3152747|NCT01530035|No Intervention|control group|elderly men with no change in daily activities
3152748|NCT01530035|No Intervention|active soccer control group|veteran soccer players with a 40 year history of continues soccer playing
3152749|NCT01530022|Other|LCM 300 mg/CBZ-IR 600 mg|Crossover sequence of experimental treatment and active comparator
3152750|NCT01530022|Other|CBZ-IR 600 mg/LCM 300 mg|Crossover sequence of active comparator and experimental treatment
3152751|NCT01530009|Active Comparator|Amoxicillin|A liquid preparation of amoxicillin will be administered during the study through a nasoduodenal catheter after random patient assignment.
3152752|NCT01530009|Placebo Comparator|Placebo|A liquid placebo will be administered via a nasoduodenal catheter to patients based on random assignment.
3152753|NCT01529996|Experimental|YAG laser|
3152754|NCT01529996|Active Comparator|Pulse Dye Laer|
3152755|NCT01529983|Experimental|Fractional photothermolysis|Fractional photothermolysis (FP) for treatment of photo- damaged skin is an FDA-approved method for treating facial rhytids. Fractionated treatment with 1550-nm laser is a safe, nonsurgical method for improvement of periorbital rhytides, photodamage, and scarring
3152756|NCT01529983|Active Comparator|High-intensity focused ultrasound|High-intensity focused ultrasound (HIFUS) is an FDA-approved method for periorbital treatment and nonablative tissue tightening. Ultrasound waves induce a vibration in the tissue, generating heat and increasing the tissue temperature within a focal area. The tissue changes depend on amount of heat and exposure duration. These findings are similar to the thermally induced changes within the skin after CO2 laser fractional ablative treatments.
3152757|NCT01529970||parkinson's disease, young onset|
3152758|NCT01529970||Normal|
3152759|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 25 mg|Nemonoxacin Malate Sodium Chloride 25 mg
3152760|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 50 mg|Nemonoxacin Malate Sodium Chloride 50 mg
3152761|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 125 mg|Nemonoxacin Malate Sodium Chloride 125 mg
3152762|NCT01529957|Placebo Comparator|placebol|placebol
3152763|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 250 mg|Nemonoxacin Malate Sodium Chloride 250 mg
3152764|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 500 mg|Nemonoxacin Malate Sodium Chloride 500 mg
3152765|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 650 mg|Nemonoxacin Malate Sodium Chloride 650 mg
3152766|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 750 mg|Nemonoxacin Malate Sodium Chloride 750 mg
3152767|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 1000 mg|Nemonoxacin Malate Sodium Chloride 1000 mg
3152768|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 1250 mg|Nemonoxacin Malate Sodium Chloride 1250 mg
3152769|NCT01529944|Experimental|Low dose 33 mcg/kg/day|
3152770|NCT01529944|Experimental|High dose 66 mcg/kg/day|
3152771|NCT01529931|Experimental|Maintenance|This arm receives Hair2Go treatments once a month for 6 months
3152772|NCT01529918|Experimental|web-intervention group|Participants will receive access to the CAN-RISK (Canadian Diabetes Risk Assessment) questionnaire either via personal patient electronic health record or an online version
3152773|NCT01529918|No Intervention|paper-based group|Participants allocated to paper-based will receive the CAN-RISK questionnaire for diabetes risk-assessment via paper-based
3152774|NCT01529892|Experimental|methamphetamine EM|Extensive metabolizer will be give a single oral 5 mg of duterium labeled methamphetamine
3152775|NCT01529892|Experimental|methamphetamine PM|Poor Metabolizers will be give a single oral 5 mg of duterium labeled methamphetamine
3152776|NCT01529879|Experimental|New abutment connection implant|Implant with new abutment connection
3152777|NCT01529879|Active Comparator|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
3152778|NCT01529866|Experimental|New abutment connection implant|Implant with new abutment connection
3152779|NCT01529866|Active Comparator|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
3152780|NCT01529853|Experimental|SAR156597 dose 1|SAR156597 dose 1, subcutaneous injection once every week
3152781|NCT01529853|Experimental|SAR156597 dose 2|SAR156597 dose 2, subcutaneous injection once every week
3152782|NCT01529853|Experimental|SAR156597 dose 3|SAR156597 dose 3, subcutaneous injection once every week
3152783|NCT01529853|Placebo Comparator|Placebo|Placebo (for SAR156597), subcutaneous injection once every week
3152784|NCT01529840|Experimental|Low dose 33 mcg/kg/day|
3152785|NCT01529840|Experimental|High dose 66 mcg/kg/day|
3152786|NCT01529827|Experimental|Treatment (reduced intensity allogeneic PBSCT)|PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan IV over 30 minutes on day -2. Patients undergo low-dose TBI BID on day -1. TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0. GvHD PROPHYLAXIS: Patients receive tacrolimus IV or PO BID on days -1 to 100 with taper over 4-6 months, MMF PO or IV every 6-8 hours on days -1 to 60, and methotrexate IV over 15 to 30 minutes on days 1, 3, and 6.
3152787|NCT01529814|Experimental|New abutment connection implant|Implant with new abutment connection
3152788|NCT01529814|Active Comparator|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
3152789|NCT01529801|Experimental|Roughness group A|Osseotite Certain Tapered Group A
3152790|NCT01529801|Experimental|Roughness Group B|Osseotite Certain Tapered Group B
3152791|NCT01529801|Experimental|Roughness Group C|Osseotite Certain Tapered Group C
3152792|NCT01529788|Active Comparator|Lateral orbital injection of Botox Cosmetic or Dysport|Lateral orbital injection of either Botox Cosmetic, 10 units or Dysport, 30 units as a single dose in a randomized (right or left sides) double blind fashion in 90 consecutive subjects
3152793|NCT01529775|Experimental|Osseotite Certain Tapered Prevail|Osseotite Certain Tapered Prevail design with platform switching feature
3152794|NCT01529775|Active Comparator|Osseotite Certain Tapered|Osseotite Certain Tapered implant with non-platform switching design
3152795|NCT01529762||Osseotite Certain Tapered|Dental implant Osseotite Certain Tapered design
3152796|NCT01529749|Active Comparator|EFV/FTC/TDF|
3152797|NCT01529749|Experimental|EFV/FTC/TDF + Losartan|
3152798|NCT01529749|Experimental|FTC/TDF + MK-0518|
3152799|NCT01529749|Experimental|FTC/TDF+MK-0518+Losartan|
3152800|NCT01529736|Experimental|High torque insertion|High torque insertion
3152801|NCT01529736|Active Comparator|Low torque insertion|Low torque insertion
3152802|NCT01529710|Experimental|Mirazid|Mirazid is an antischistosomal drug available in the local Egyptian market since 2001 (Mirazid®). It originates from Myrrh a medicinal herb that has been used for thousands of years. Myrrh (Arabian or Somali Myrrh) is an oleo-gum resin, obtained from the stem of various species of Commiphora (Burseraceae) growing in northeast Africa and Arabia.
3152803|NCT01529710|Active Comparator|Praziquantel|Tablets
3152804|NCT01529697|Active Comparator|Active Feedback|In this arm patients will receive monthly review and education on inhaler technique and use based on a computer download of their last month of inhaler use
3152805|NCT01529697|Placebo Comparator|Control|In this arm patients will be reviewed monthly, however will not have information from INCA device to tailor inhaler education.
3152806|NCT01529684|Experimental|OSI-906|"Two Parts:~Part A: 14C-labeled OSI-906 Part B: (Optional) OSI-906 (non-labeled)"
3152807|NCT01529671|Experimental|Cohort 1: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetics (PK) of PF-05089771.
3152808|NCT01529671|Experimental|Cohort 2: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.
3152809|NCT01529671|Experimental|Cohort 3: Experimental intervention: PF-05089771 or placebo|Subjects with osteoarthritis of the knee will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.
3152810|NCT01529671|Experimental|Cohort 4: Experimental intervention: PF-05089771 or placebo|Elderly Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.
3152811|NCT01529671|Experimental|Cohort 5: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.
3152812|NCT01529658|No Intervention|No hypothermia|After clamping of the renal vessels, no ice slush will be used.
3152813|NCT01529658|Experimental|Hypothermia|saline ice slush around kidney for 10 minutes.
3152814|NCT01529645|Experimental|Group 1: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: low dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
3152815|NCT01529645|Experimental|Group 2: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: medium dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
3152816|NCT01529645|Experimental|Group 3: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: high dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
3152817|NCT01529645|Experimental|Group 4: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, low dose of D (diphteria) toxoid, fixed dose of T (tetanus) toxoid, followed by one administration of saline solution one month apart.
3152818|NCT01529645|Experimental|Group 5: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3152819|NCT01529645|Experimental|Group 6: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3152820|NCT01529645|Experimental|Group 7: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3152821|NCT01529645|Experimental|Group 8: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3152822|NCT01529645|Experimental|Group 9: TDaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3152823|NCT01529645|Active Comparator|Group 10: Licensed TdaP booster|Subject received one dose of a licensed TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) followed by one administration of saline solution one month apart.
3152824|NCT01529632|Experimental|QVA149|QVA149 plus placebo once daily for 28 days.
3152825|NCT01529632|Active Comparator|QAB149 + NVA237|Indacaterol maleate (QAB149) plus glycopyrronium bromide (NVA237) once daily for 28 days.
3152878|NCT01529320|Experimental|Adventan® (metilprednisolona aceponato 0,1%)|
3152879|NCT01529307|Experimental|TAS266|
3152880|NCT01529294|Experimental|Iloperidone|Eligible subjects receive a single oral dose of 2 mg iloperidone as a tablet
3152881|NCT01529281|Experimental|BCAA|Branched chain amino acid
3152882|NCT01529281|Placebo Comparator|Asparmate|Placebo control containing no protein or carbohydrate
3152826|NCT01529619|Experimental|Rivastigmine 18 mg|During the 16-week titration period patients received daily rivastigmine 4.5mg patch for the first 4 weeks, rivastigmine 9mg patch for the next 4 weeks, rivastigmine 13.5mg patch for the next 4 weeks and then rivastigmine 18mg patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
3152827|NCT01529606|Active Comparator|Standard care|Fifty patients will be recruited into standard treatment group and they will receive composite resin restoration for all decayed teeth and standard preventive treatment (cleaning and fluoride varnish application) at baseline.
3152828|NCT01529606|Experimental|Plasma treatment|Fifty patients will be recruited into plasma treatment group and they will receive plasma treatment after cavity preparation, composite resin restoration, standard preventive treatment followed by plasma treatment for non-carious teeth.
3152829|NCT01529593|Experimental|Temsirolimus + Metformin|Starting dose of Temsirolimus 25 mg by vein weekly. Metformin titrated over 3 weeks at 500 mg by mouth daily. Four weeks of treatment constitute 1 cycle. Cycle one (1) however, will be 6 weeks long to allow for metformin titration.
3152830|NCT01529580|Experimental|1 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 1 week before your child begins active treatment with their interventionist.
3152831|NCT01529580|Experimental|2 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 2 weeks before your child begins active treatment with their interventionist.
3152832|NCT01529580|Experimental|3 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 3 weeks before your child begins active treatment with their interventionist.
3152833|NCT01529567|Active Comparator|CBT without exposure|
3152834|NCT01529567|Experimental|CBT with exposure|
3152835|NCT01529554|Active Comparator|Everolimus|Everolimus p.o. for 5 days (d0=7.5 mg, d1=7.5 mg, d2=7.5 mg, d3=5 mg, d4=5mg)
3152836|NCT01529554|Placebo Comparator|Placebo|Placebo comparator with identical composition of tablets except everolimus
3152837|NCT01529541|Active Comparator|Sitagliptin|Sitagliptin 100mg
3152838|NCT01529541|Experimental|CWP-0403|CWP-0403 100mg
3152839|NCT01529528|Placebo Comparator|Placebo of CWP-0403 100mg|Placebo of CWP-0403 100mg
3152840|NCT01529528|Experimental|CWP-0403 200mg|CWP-0403 200mg
3152841|NCT01529528|Experimental|CWP-0403 100mg|CWP-0403 100mg
3152842|NCT01529515|Experimental|Paliperidone palmitate 3-month (PP3M)|
3152843|NCT01529515|Placebo Comparator|Placebo|
3152844|NCT01529502|Experimental|Fresh blood|
3152845|NCT01529502|Experimental|Old blood|
3152846|NCT01529502|Experimental|Old blood + inhaled Nitric Oxide|
3152847|NCT01529489|Active Comparator|Interval physical training Control group|
3152848|NCT01529489|Experimental|Resisted/Aerobic physical training group|
3152849|NCT01529489|Active Comparator|Aerobic/resisted physical training group|
3152850|NCT01529489|Experimental|Interval physical training group|COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic
3152851|NCT01529476|Experimental|Nemonoxacin 500 mg|
3152852|NCT01529476|Active Comparator|Levofloxacin 500 mg|
3152853|NCT01529463||Disease Management|
3152854|NCT01529450|Active Comparator|Refractory Group|Patients previously treated with non-LDE225 Smo inhibitor who were refractory.
3152855|NCT01529450|Active Comparator|Resistance Developed Group|Patients previously treated with non-LDE225 Smo inhibitor who were initially responsive but became resistant with progressive disease.
3152856|NCT01529437|Active Comparator|Sublingual immunotherapy|Subjects will take sublingual immunotherapy who have dust mite and timothy grass allergies
3152857|NCT01529437|Placebo Comparator|placebo arm|The placebo arm will be double blinded and is an important control in SLIT therapies
3152858|NCT01529424|Experimental|Group 1|Non-extensive PK/non post-prandial
3152859|NCT01529424|Experimental|Group 2a|Extensive PK
3152860|NCT01529424|Experimental|Group 2b|Post-prandial assessment
3152861|NCT01529424|Experimental|Group 3|Stable dose of fibrate
3152862|NCT01529424|Experimental|Group 4|Fredrickson Type 1 dyslipidemia
3152863|NCT01529411|Experimental|Vinflunine|"Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance < 60ml/min)~+ best suportive care, with regards clinical practice."
3152864|NCT01529411|Other|Best suportive care|Best suportive care
3152865|NCT01529398|Active Comparator|sensorimotor training (SMT)|
3152866|NCT01529398|Active Comparator|Resistance training (RT)|
3152867|NCT01529398|Sham Comparator|Control group (CG)|
3152868|NCT01529385|Experimental|Mild Compression Diabetic Sock|Diabetic socks that provide 18-25mm Hg of pressure to the lower extremities.
3152869|NCT01529385|Other|Standard Diabetic Sock|A standard diabetic sock that is designed to limit foot ulcer formation, but does not provide compression to the leg.
3152870|NCT01529372|Experimental|Percutaneous renal denervation|
3152871|NCT01529359|Placebo Comparator|Placebo|Probiotics Excipients
3152872|NCT01529359|Experimental|Lactibiane Tolerance|Probiotics combination
3152873|NCT01529346|Experimental|PF-05089771 1600 mg|
3152874|NCT01529346|Experimental|PF-05089771 450 mg|
3152875|NCT01529346|Experimental|PF-05089771 150 mg|
3152876|NCT01529346|Active Comparator|Ibuprofen 400 mg|
3152883|NCT01529268|Active Comparator|DR cysteamine bitartrate capsule|Active DR cysteamine bitartrate capsule
3152884|NCT01529268|Placebo Comparator|DR cysteamine bitartrate placebo|Placebo DR cysteamine bitartrate capsule
3152885|NCT01529255|Experimental|ROADMAP|
3152886|NCT01529255|Active Comparator|SOC (Standard of Care)|
3152887|NCT01529242|Experimental|Desloratadine + Prednisolone|desloratadine 0,5 mg/ml + prednisolone 4 mg/ml - oral solution
3152888|NCT01529242|Active Comparator|Dexchlorpheniramine + Betamethasone|dexchlorpheniramine maleate 0,4 mg/ml + Betamethasone 0,05 mg/ml - oral solution
3152889|NCT01529229|Experimental|Desloratadine + Prednisolone|Desloratadine(0.5 mg/ml) Associated With Prednisolone (4 mg/ml) Oral Solution once a day - bottle 1 + placebo 2 times a day - bottles 2 and 3.
3152890|NCT01529229|Active Comparator|Dexchlorpheniramine + Betamethasone|Dexchlorpheniramine (0.4 mg/ml) + Betamethasone (0.05 mg/ml) three times a day - bottles 1, 2 and 3.
3152891|NCT01529216|Experimental|Electrical signal ON|Subjects randomized to this group (Group A) will receive electrical stimulation delivered to the fundus for 24 months.
3152892|NCT01529216|Sham Comparator|Sham|"Subjects randomized to this group (Group B) will have their device in turned off mode for the first 12 months (48 weeks) after implant. Then the device will be turned ON and these subjects will receive therapy for the remaining 12 months of the study."
3152893|NCT01529203|Other|Azzalure and Restylane|All subjects will be injected with Azzalure and Restylane
3152894|NCT01529190|Active Comparator|pregabalin 300mg|Group 1 patients will receive a single dose of 300 mg pregabalin, 1 hour before the surgical incision; group 2 patients will receive a placebo dose. Pain intensity will be assessed with the numeric rating scale. The consumption of tramadol in 24 hours after surgery and the time for the first complementation dose will be registered. Blood samples will be collected by 6 hours and 24 hours after surgical incision, for IL-6 dosage, and maintained at -70 celsus degree
3152895|NCT01529190|Placebo Comparator|sugar pill|group 2 will receive a placebo dose, 1 hour before tue surgical icnision
3152896|NCT01529177|Experimental|Metformin / clomid / hCG|"Metformin 1000 mg orally to be given daily for one week then twice daily for 2 weeks then 3 times daily for 6 months.~After 3 months from starting metformin the participant will receive 2 more medications in addition to metformin:~Clomid 50 mg orally per day and 5000 IU human chorionic gonadotrophin (hCG ) IM once per week for three months."
3152897|NCT01529177|Experimental|Clomid / hCG|Clomid 50 mg per day will be administered orally and human chorionic gonadotrophin ( choriomon ) 5000 IU will be administered IM once per week. Both medications will be given for 6 month.
3152898|NCT01529164|Experimental|treatment|
3152899|NCT01529151|Active Comparator|OMT Group|Participants will receive Osteopathic Manipulative Treatment (OMT) with the objective of treating diagnosed somatic dysfunction and this will entail the use of specific indirect and direct techniques, including soft tissue, inhibitory, myofascial release, articulatory and high-velocity / low-amplitude (HVLA) techniques.
3152900|NCT01529151|Active Comparator|VRT Group|Participants will receive Vestibular Rehabilitation Therapy (VRT), which includes balance exercises in sitting and standing positions that include gaze stabilization, kinesthetic and proprioceptive retraining.
3152901|NCT01529151|Active Comparator|OMT - VRT Group|Participants will receive both Osteopathic Manipulative Treatment (OMT) and Vestibular Rehabilitation Therapy (VRT).
3152902|NCT01529151|No Intervention|Control Group|
3152903|NCT01529138|Experimental|Temsirolimus|An ester of the macrocyclic immunosuppressive agent sirolimus.
3152904|NCT01529138|Experimental|Axitinib|An oral, selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3.
3152905|NCT01529125||Kwashiorkor|HIV-positive children aged 6-59 months with kwashiorkor receiving nutritional rehabilitation and who are started on HAART.
3152906|NCT01529125||Marasmus|HIV-positive children aged 6-59 months with marasmus receiving nutritional rehabilitation and who are started on HAART.
3152907|NCT01529125||Control|HIV-positive children aged 6-59 months who are not severely malnourished and who are started on HAART for a non-nutritional reason.
3152908|NCT01529112|Experimental|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in each 28-day treatment cycle plus Best Supportive Care (BSC)
3152909|NCT01529112|Placebo Comparator|Lenvatinib matched placebo|Participants received lenvatinib matched placebo orally, once daily continuously in each 28-day treatment cycle plus BSC
3152910|NCT01529099|Experimental|Sigma HP Partial Knee|Partial knee replacement
3152911|NCT01529086||Group 1|"Subjects on Dutasteride that meet the following criteria:~. A rise in PSA from nadir at any time post-nadir~. PSA change from baselin >0.2 mg/ml at any time post-baseline~. Abnormal DRE at any time post-baseline~. Free-PSA <12% at any time post-baseline~. At least one of the above 4 criteria~Subjects on Dutasteride that do not meet the above criteria"
3152912|NCT01529086||Group 2|"Subjects on placebo treatment that meet the following criteria:~Change from baseline PSA between 0.0 and 0.35 (ie, 0.0 ≤ change from baseline PSA < 0.35) at any time post-baseline. Note that in REDUCE PSA was recorded to the nearest 0.1.~Abnormal DRE at any time post-baseline~Change from baseline PSA ≥ 0.35 at any time post-baseline~Change from baseline PSA ≥ 0.75 at any time post-baseline~PSA ≥ 2.5 at any time post-baseline~PSA ≥ 4.0 at any time post-baseline~Percent Free PSA < 12% at any time post-baseline~At least one of the above 7 criteria.~Subjects on placebo that do not meet the above criteria"
3152913|NCT01529073|Experimental|Nitazoxanide|
3152914|NCT01529060|Active Comparator|Phenylbutyrate|Study Drug
3152915|NCT01529060|Placebo Comparator|Inactive Powder|Placebo powder
3152916|NCT01529047|Experimental|In-person PFI|In-person personalized feedback intervention
3152917|NCT01529047|Experimental|Web-based PFI|Web-based personalized feedback intervention
3152918|NCT01529047|No Intervention|Assessment Only|Complete online survey assessments only.
3152919|NCT01529034|Experimental|USL261|5 mg intranasal midazolam
3152998|NCT01528592|Experimental|On / Off medication|Subjects undergo MRI scanning in the medication off state and 1 hour after receiving medications.
3152999|NCT01528579|Active Comparator|Neck Specific exercises|Neck Specific exercises from a structured frame of exercises
3153000|NCT01528579|Active Comparator|Behavioral approach|Behavioral physiotherapeutic approach in combination with neck specific exercises from a structured well defined frame of exercises and how to treat the patient. 2 times a week for 3 months.
3152920|NCT01529021||humanoid robot distration|The robot NAO, academic edition (Aldebaran Robotics) was used in this study. Some of its features include an on-board fully programmable computer CPU: x86 AMD Geode with 500 MHz, 256 MB SDRAM and 1 GB flash memory, WiFi (802.11g) and Ethernet, two cameras with up to 30 frames per second, two hands with self adaptive gripping abilities, force sensitive sensors on its arms and feet to perceive contact with objects, Light Emission Diodes in its eyes and body, four microphones to identify the source of sounds, and two loud speakers for communication where tone and voice pitch can be modified in real-time. It runs on a native Linux Operating system platform and can be programmed using a proprietary SDK called NaoQi, or in C, C++, Ruby and Urbi, which makes it compatible with other robot simulators such as Microsoft Robotics Developer Studio.
3152921|NCT01529021||control|standard care procedures were used during the vaccination
3152922|NCT01529008|Experimental|Core decompression/PREOB® implantation|
3152923|NCT01529008|Placebo Comparator|Core decompression/placebo implantation|
3152924|NCT01528995|Active Comparator|sacral nerve modulation|Implantation of Interstim II-3058 impulse generator after positive PNE test. Randomized controlled trial.
3152925|NCT01528995|Active Comparator|anal bulking agents|anal injection with Permacol after positive PNE test. Randomized controlled trial.
3152926|NCT01528995|Active Comparator|Anal bulking agents|Anal injection with Permacol after negative PNE test. cohort study.
3152927|NCT01528982|No Intervention|Control|Psychoeducation
3152928|NCT01528982|Active Comparator|Mindfulness|Mindfulness activity and psychoeducation
3152929|NCT01528982|Active Comparator|Cognition|Cognitive training and psychoeducation
3152930|NCT01528969|Experimental|Xylitol|A half of the subjects will be randomly allocated into xylitol group.
3152931|NCT01528969|Active Comparator|Sorbitol|About 40 randomly allocated subjects will chew sorbitol chewing gum (1,5, g/pellet) three times a day
3152932|NCT01528943|Experimental|Prostacyclin|
3152933|NCT01528943|Placebo Comparator|Isotonic saline|
3152934|NCT01528930|Experimental|Amikacin for inhalation|"Drug: Amikacin~Amikacin is provided for inhalation via nebulization.~500 mg of amikacin is administered once daily using the Pari-Boy N/Long Life Nebulizer.~Administration time is approximately 20 minutes.~Amikacin will be administered for 2 years."
3152935|NCT01528904||Hyperthyroid pregnant women|hyperthyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination.
3152936|NCT01528904||Hypothyroid pregnant women|hypothyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination
3152937|NCT01528904||Healthy pregnant women|uncomplicated pregnancies in healthy women, older then 35 years, directed for cordocentesis due to age, because of missed karyotyping in previous period of pregnancy
3152938|NCT01528891|Active Comparator|Dexmedetomidine|Dexmedetomidine
3152939|NCT01528891|Placebo Comparator|placebo|Normal saline
3152940|NCT01528878|Experimental|Good liver function.|Patients with good liver function as defined by no more than Child-Pugh Class A.
3152941|NCT01528878|Experimental|Compromised liver function.|Patients with compromised liver function as defined by patients with Child-Pugh Class B.
3152942|NCT01528865|Experimental|Study Drugs|The medications to be used in this study are Lamivudine (EPIVIR®) and Tenofovir disoproxil fumarate (VIREAD®), medications already used in people with certain other types of viruses [but not HERV-K(HML2)] in their body. Treatment will last 16 weeks. This is an experiment combining these two drugs and has been issue an Investigational New Drug (IND) Exemption by the FDA.
3152943|NCT01528852|Experimental|CHX Cord application|Chlorhexidine cord application for 10 days
3152944|NCT01528852|Active Comparator|Control|Same liquid as intervention without the chlorhexidine used for cord cleaning for 10 days once daily
3152945|NCT01528852|No Intervention|Dry Cord care|Use current recommended keep cord dry
3152946|NCT01528839|Placebo Comparator|Pill|
3152947|NCT01528839|Experimental|L-Thyroxine as addon|
3152948|NCT01528826|Experimental|NVBOX regimen|Vinorelbine plus oxaliplatin
3152949|NCT01528813|Active Comparator|Er:YAG + amorolfine lacquer|30 ungual units affected by onychomycosis due to dermatophytes
3152950|NCT01528813|Placebo Comparator|Amorolfine lacquer|30 ungual units affected by onychomycosis due to dermatophytes
3152951|NCT01528800|Placebo Comparator|Placebo|Chrystalline Lactose
3152952|NCT01528800|Active Comparator|Vitamin K1|Vitamin K1
3152953|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.01%|1 drop to study eye once daily
3152954|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.02%|1 drop to study eye once daily
3152955|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.04%|1 drop to study eye once daily
3152956|NCT01528787|Placebo Comparator|AR-13324 Ophthalmic Solution Vehicle|1 drop to study eye once daily
3152957|NCT01528774||Melanoma|Patients with histologically confirmed melanoma
3152958|NCT01528774||Prostate|Patients with histologically confirmed prostate cancer
3152959|NCT01528774||Solid tumors - other|Patients with histologically confirmed solid tumor cancers other than melanoma and prostate
3152960|NCT01528774||Benign Hematologic Conditions|Patients diagnosed with non-cancerous hematologic conditions
3152961|NCT01528774||Healthy Volunteers|Family members of patients undergoing treatment at Comprehensive Cancer Centers of Nevada, or other healthy volunteers
3152962|NCT01528761|Experimental|Prosocial Behavior Physical Activity|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
3153001|NCT01528579|Active Comparator|Prescribed physical activity|Prescribed physical activity from a physiotherapist without neck specific exercises
3152963|NCT01528761|Active Comparator|Healthy Aging (HA)|Behavioral: Healthy Aging (HA) The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
3152964|NCT01528748||Chronically Depressed, Alcohol Dependent|Participants who have been formally diagnosed with a clinical diagnosis of Chronic Depression and Alcohol Dependence.
3152965|NCT01528735|Experimental|BI 207127 NA, BI 201335 NA(high dose), R|Patients receive BI 207127 NA,BI 201335 NA(high dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks
3152966|NCT01528735|Experimental|BI 207127 NA,BI 201335 NA(low dose),RBV|Patients receive BI 207127 NA,BI 201335 NA(low dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks
3152967|NCT01528722|Sham Comparator|Saline sham injection|Sham wash and injection with normal saline (09%)
3152968|NCT01528722|Active Comparator|Bupivacaine|Bupivacaine injection/wash treatment arm
3152969|NCT01528709|Experimental|High-dose statin therapy|Atorvastatin 80 mg daily
3152970|NCT01528709|Active Comparator|Moderate-dose statin therapy|Atorvastatin 10 mg daily
3152971|NCT01528696|Placebo Comparator|Standard Dressing|Obese patients undergoing cesarean section in this arm will receive a standard island-type dressing
3152972|NCT01528696|Experimental|Silverlon|Obese patients undergoing cesarean section in this arm will receive Silverlon, a silver impregnated dressing
3152973|NCT01528683|Experimental|Carbon Ion Radiotherapy|
3152974|NCT01528670||Skull Base|
3152975|NCT01528670||Lower GI|
3152976|NCT01528670||Prostate|
3152977|NCT01528670||Pelvic Region|
3152978|NCT01528670||Head-and-Neck|
3152979|NCT01528670||Upper GI|
3152980|NCT01528670||Brain|
3152981|NCT01528670||Other|
3152982|NCT01528657|Experimental|Ventricular Pace Suppression (VpS)|The function Ventricular Pace Suppression (VpS) is activated
3152983|NCT01528657|Experimental|Intrinsic Rhythm Support (IRSplus)|The function Intrinsic Rhythm Support (IRSplus) is activated
3152984|NCT01528644|Experimental|Iron in beads|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
3152985|NCT01528644|Experimental|Iron in capsule|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
3152986|NCT01528644|Experimental|Iron in beads in presence of calcium|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
3152987|NCT01528644|Experimental|Iron in capsule in presence of calcium|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
3152988|NCT01528631|Placebo Comparator|Control Product|200 ml water with 50g of sucrose
3152989|NCT01528631|Active Comparator|Product 1|200 ml water with 50g of sucrose and supplemented with 30 mg of D-Fagomine
3152990|NCT01528618|Experimental|gemcitabine and cisplatin|gemcitabine 1,000 mg/m2 over 30 to 60 minutes on days 1, 8, and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
3152991|NCT01528618|Active Comparator|5-Fluorouracil and cisplatin|5-Fluorouracil 4,000 mg/m2 CIV over 96 hours and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
3152992|NCT01528605|Placebo Comparator|Placebo|starch in hard shell gelatine capsules
3152993|NCT01528605|Experimental|Low lutein|low lutein group
3152994|NCT01528605|Experimental|High lutein|high lutein group
3152995|NCT01528605|Experimental|Low lutein zeaxanthin|lutein plus zeaxanthin group
3152996|NCT01528605|Experimental|High zeaxanthin|zeaxanthin group
3152997|NCT01528605|Experimental|high lutein zeaxanthin|Zeaxanthin plus lutein group
3153002|NCT01528566|Experimental|Tai Chi|
3153003|NCT01528566|Placebo Comparator|Attentation control|
3153004|NCT01528553|Active Comparator|Staples|Old implant type
3153005|NCT01528553|Active Comparator|8plate|New implant type
3153006|NCT01528540|Placebo Comparator|Placebo|This group will contain a placebo for antioxidant cocktail and pregabalin
3153007|NCT01528540|Experimental|Antioxidant plus pregabalin|This group will contain antioxidant cocktail and pregabalin
3153008|NCT01528514|Active Comparator|Curcuminoids|
3153009|NCT01528514|Placebo Comparator|Placebo|
3153010|NCT01528501|Experimental|I|
3153011|NCT01528488|Experimental|EVOZAC|EVOZAC should be sprayed to the skin of the total face three times per day.
3153012|NCT01528488|Placebo Comparator|Physiological saline|Physiological saline should be sprayed to the total face three times per day.
3153013|NCT01528475|Active Comparator|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs, initiation of an intravenous infusion of cold saline, and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
3153014|NCT01528475|No Intervention|Usual pre-hospital care|Patients in this arm will receive usual post-resuscitation care by paramedics. Usual post-resuscitation care does not include initiation of cooling in the pre-hospital setting.
3153015|NCT01528462||Expedited Treatment of Sleep Disorders|Please see below.
3153016|NCT01528449|Experimental|retrospective|archived specimens from blood donors whose units have already been released and transfused into recipients will be tested. Attempts will be made to contact and obtain follow up specimens from both the donor and recipient of units initially testing positive for B.microti. the interventions are investigational diagnostic tests for B.microti (PCR and IFA).
3153017|NCT01528449|Experimental|prospective, real time|specimens from current blood donors will be tested and those testing positive for B.microti will not be released and the units will be disgarded, and the donors notified and deferred from future blood donation. the interventions are investigational diagnostic tests for B.microti (PCR and IFA).
3153018|NCT01528436|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation
3153019|NCT01528436|Active Comparator|Placebo Umbilical Cord Blood and Rehabilitation|Placebo Umbilical Cord Blood infusion and Active Rehabilitation
3153020|NCT01528423||Men 16 - 18yrs|
3153021|NCT01528423||Men 30 - 32 yrs|
3153022|NCT01528423||Men 70 yrs +|
3153023|NCT01528423||Women 16 - 18 yrs|
3153024|NCT01528423||Women 30 - 32 yrs|
3153025|NCT01528423||Women 70 yrs +|
3153026|NCT01528410|Experimental|ALFApump removal of ascites|Removal of ascites
3153027|NCT01528410|Active Comparator|Large volume paracentesis for removal of ascites|Removal of ascites
3153028|NCT01528371|Active Comparator|Midazolam|Intravenous administration of midazolam at dose of 0.02mg/kg
3153029|NCT01528371|Placebo Comparator|NSS|Intravenous administration of saline solution at dose of 0.004ml/kg as a placebo drug
3153030|NCT01528358||Early Sepsis Critically Ill Patients|Patients who are admitted to ICU with a diagnosis of early sepsis.
3153031|NCT01528358||Non-septic Critically ill patients|Patients who are critically ill and admitted to ICU without diagnosis of sepsis.
3153032|NCT01528345|Experimental|Fulvestrant + Dovitinib active|Fulvestrant in combination with the study drug Dovitinib.
3153033|NCT01528345|Placebo Comparator|Fulvestrant + Dovitinib placebo|Fulvestrant in combination with a placebo matching Dovitinib.
3153034|NCT01528332|Experimental|Pain Relief Patch|Pain Relief Patch: Light wavelength 453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm², 30 minutes
3153035|NCT01528332|Active Comparator|Control PRP device|Control PRP device: Light wavelength 531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm², light on for 5 seconds, device worn for 30 minutes
3153036|NCT01528319|Experimental|MG-1|Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1
3153037|NCT01528306|Experimental|HP802-247|
3153038|NCT01528306|Placebo Comparator|Placebo (Vehicle)|
3153039|NCT01528293|Active Comparator|ActiVAC System+ Compression therapy|ActiVAC System + Compression therapy group consisting of the application of this device along with compression therapy.
3153040|NCT01528293|Other|Compression therapy only|Standard of Care compression therapy only
3153041|NCT01528280|Experimental|Shiftwork|The comparison will consider nightworkers versus dayworkers.
3153042|NCT01528267|Active Comparator|Autologous blood|Patients will have 50mls of autologous blood injected into each of 3 bronchopulmonary segments during bronchoscopy under conscious sedation.
3153043|NCT01528267|Sham Comparator|Saline|Patients will have 50mls of normal saline injected into each of 3 bronchopulmonary segments during bronchoscopy under conscious sedation.
3153044|NCT01528254|Active Comparator|Metformin + vildagliptin|
3153045|NCT01528254|Experimental|Metformin + Placebo of vildagliptin|
3153046|NCT01528241|Experimental|ABP688|Elderly MDD patients and demography matched healthy volunteer
3153047|NCT01528228|Active Comparator|Structured TENS Therapy|This group will be given an active TENS unit to use.
3153048|NCT01528228|Sham Comparator|Sham TENS Therapy|This group will receive a placebo TENS unit which has been functionally disabled to provide a short initial electrical impulse then cease delivering that impulse.
3153049|NCT01528215|Experimental|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
3153050|NCT01528215|Active Comparator|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
3153051|NCT01528202|No Intervention|Baseline placebo|measures taken before administration of placebo
3153052|NCT01528202|Placebo Comparator|Placebo|Placebo intervention given after 'baseline placebo' arm
3153053|NCT01528202|No Intervention|baseline cherry juice|measures taken before the cherry juice intervention
3153054|NCT01528202|Experimental|cherry juice|trial where cherry juice is taken following the 'baseline cherry juice' arm
3153055|NCT01528189|Placebo Comparator|Standard glucose management|
3153056|NCT01528189|Active Comparator|Hyperinsulinemic normoglycemic clamp|
3153057|NCT01528176|Other|(CKD) stages III—V and non -CKD patients|We recruited patients with wide range of eGFR
3153281|NCT01526395|Active Comparator|Low Dose Propofol|Subjects will be given low dose propofol prior to ECT.
3153058|NCT01528163|Experimental|Cabazitaxel|Cabazitaxel (XRP6258) is a new taxoid, which promotes tubulin assembly in vitro and stabilizes microtubules against cold-induced depolymerization as efficiently as docetaxel
3153059|NCT01528163|Active Comparator|Methotrexate|"Methotrexate is the historical control and has been widely used in SCCHN for palliation.~This medication is an antimetabolite and antifolate drug. It acts by inhibiting the metabolism of folic acid."
3153060|NCT01528150||Accent MRI System|Accent MRI system will be implanted = Accent MRI Pacemaker + Tendril MRI Leads
3153061|NCT01528137|Experimental|Treatment (immunomodulator)|Patients receive talactoferrin PO BID for 12 weeks. Courses repeat every 14 weeks in the absence of disease progression or unacceptable toxicity.
3153062|NCT01528124|Placebo Comparator|Placebo|0.9% sodium chloride given as a single subcutaneous injection
3153063|NCT01528124|Experimental|LY3025876|Single escalating doses of LY3025876 given as subcutaneous injections
3153064|NCT01528111|Experimental|Low dose LX7101|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
3153065|NCT01528111|Experimental|High dose LX7101|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
3153066|NCT01528111|Placebo Comparator|LX7101 Vehicle|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
3153067|NCT01528098||PEG plus bisacodyl|Those who taken PEG 4L + bisacodyl 10mg
3153068|NCT01528098||PEG 4L|Those who taken PEG 4L alone
3153069|NCT01528072|Experimental|Dynesys System|All patients will receive the Dynesys System and all patients will be compared to historical literature control. Dynesys Spinal System will be used for all subjects.
3153070|NCT01528059|Active Comparator|Billroth II|After stomach resection, the remnant stomach is connected to the jejunum.
3153071|NCT01528059|Active Comparator|Roux en Y|After stomach resection, the remnant stomach is connected to the distal jejunum while duodenum and the proximal jejunum is reconnected to jejunum.
3153072|NCT01528046|Experimental|Metformin in Combination with VIT|Participants will receive metformin in combination with vincristine, irinotecan and temozolomide (VIT).
3153073|NCT01528033|Experimental|Vacuum Assisted Closure®|Negative pressure wound therapy
3153074|NCT01528033|Active Comparator|Standard conventional wound therapy|According to institutional clinical standards
3153075|NCT01528020|Experimental|Dialectical Behavior Therapy|
3153076|NCT01528020|Active Comparator|Inidividual and Group Supportive Therapy|
3153077|NCT01528007|Placebo Comparator|Placebo pill.|
3153078|NCT01528007|Active Comparator|50mg Naltrexone when needed|
3153079|NCT01527994|Experimental|Aprepitant 125 mg|Day Number Dose Procedure Day 0 Aprepitant 125mg Admitting Medication Treatment Day 1 Aprepitant 125mg Saline-Saline Day 2 Aprepitant 125mg Morphine-Morphine Day 3 Aprepitant 125mg Saline-Morphine Day 4 Aprepitant 125mg Naloxone-Morphine and Discharge
3153080|NCT01527994|Placebo Comparator|Placebo|Day Number Dose Procedure Day 0 placebo Admitting Medication Treatment Day 1 placebo Saline-Saline Day 2 placebo Morphine-Morphine Day 3 placebo Saline-Morphine Day 4 placebo Naloxone-Morphine and Discharge
3153081|NCT01527981|Experimental|CBT-AD|Participants received weekly one-hour CBT-AD sessions focusing on diabetes self-care and depression for approximately 10 sessions. Participants also had meetings with a registered dietitian and a nurse educator, focusing on nutritional management of diabetes and diabetes self-care education, respectively.
3153082|NCT01527968|Active Comparator|Tranexamic Acid|TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)
3153083|NCT01527968|Active Comparator|Epsilon Aminocaproic Acid|eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
3153084|NCT01527968|Placebo Comparator|Placebo|Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
3153085|NCT01527942|Experimental|Arm 1 - Active Drug|Preoperative administration of 1,000 mg IV Acetaminophen will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
3153086|NCT01527942|Placebo Comparator|Arm 2 - Placebo|Preoperative IV Placebo (0.9 Sodium Chloride 100 ml) will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
3153087|NCT01527929|Experimental|Cohort A|Normal renal function - Cabazitaxel administered once every 3 weeks
3153088|NCT01527929|Experimental|Cohort B|Moderate renal dysfunction - Cabazitaxel administered once every 3 weeks
3153089|NCT01527929|Experimental|Cohort C|Severe renal dysfunction - Cabazitaxel administered once every 3 weeks
3153090|NCT01527916|Placebo Comparator|sugar pill|
3153091|NCT01527916|Active Comparator|donepezil|
3153092|NCT01527916|Experimental|ABT-126 Low Dose|low dose
3153093|NCT01527916|Experimental|ABT-126 Middle Dose|middle dose
3153094|NCT01527916|Experimental|ABT-126 high dose|high dose
3153095|NCT01527903|Active Comparator|Propofol|
3153096|NCT01527903|Active Comparator|Midazolam|
3153097|NCT01527877|Experimental|BKM120|
3153098|NCT01527864|Experimental|pegylated endostatin|
3153099|NCT01527864|Placebo Comparator|Control|
3153100|NCT01527838|Experimental|Single FT1050 treated UCB Unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
3153101|NCT01527825|Active Comparator|Single dose|Trivalent Influenza Vaccine (seasonal)
3153102|NCT01527825|Experimental|Double dose TIV|Trivalent Influenza vaccine (seasonal) Two doses will be administered at enrolment
3153103|NCT01527825|Experimental|Two dose TIV|Trivalent Influenza vaccine (seasonal) Participants will receive two doses of TIV, one month apart
3153104|NCT01527812|Experimental|Above the femoral nerve|In Group I we will inject the local anaesthetic below the fascia iliaca and above the femoral nerve.
3153105|NCT01527812|Experimental|Below the femoral nerve|In Group II we will inject the local anaesthetic below the femoral nerve and above the fascia of the iliopsoas muscle.
3153106|NCT01527812|Experimental|Circumferential|In Group III a circumferential spread will be achieved with multiple injections.
3153107|NCT01527799||Subjects with Sickle Cell Anemia|Subjects with Sickle Cell Anemia, 10-21 years of age
3153108|NCT01527799||Healthy controls|Healthy controls, 10 to 21 years of age
3153109|NCT01527786|Experimental|SNRI treatment|Participants are undergoing pharmacotherapy treatment with Desvenlafaxine (SNRI).
3153110|NCT01527773||COPD cohort|Cohort of patients with proven COPD
3153111|NCT01527747|Placebo Comparator|Placebo|Placebo arm
3153112|NCT01527747|Experimental|Saxagliptin|Active drug arm
3153113|NCT01527734|Placebo Comparator|Placebo|
3153114|NCT01527734|Experimental|Tetrodotoxin, TTX|
3153115|NCT01527721|Experimental|CxL group|Volunteers of this group received CxL treatment.
3153116|NCT01527721|Experimental|tCxL group|Volunteers of this group received CxL combined with t-PRK treatment
3153117|NCT01527708||Keratoconus Group (KCG)|Keratoconus group (KCG) included patients with progressive keratoconus.
3153118|NCT01527708||Collagen-Cross-linking group (CXLG)|Collagen-Cross-linking group (CXLG) included keratoconus patients that had been treated with uneventful corneal collagen cross-linking (CXL) at least on year prior to their enrolment in the study.
3153119|NCT01527708||Normal Group (NG)|Normal group (NG) was formed by refractive surgery candidates who visited EIT's refractive surgery service for their preoperative examination. Eligibility for participation in the NG was confirmed by consecutive topographies, while all NG participants had to present uneventful ophthalmologic history, no indications of corneal pathology in slit-lamp biomicroscopy and Placido disk-based videokeratography.
3153120|NCT01527695|Experimental|AZD3241|AZD3241 tablets 25 mg or 100 mg, titration first 5 days (50 mg bd on Day 1, 100 mg bd on Day 2, 200 mg bd on Day 3, 300 mg bd on Day 4, 400 mg bd on Day 5) Maintenance treatment from Day 6, 600 mg bd until Day 56±3 days
3153121|NCT01527695|Experimental|Placebo|AZD3241 placebo bid for 8 weeks
3153122|NCT01527682|Other|Latanoprost, Dorzolamide|According to IOP assessment, the eye will receive Latanoprost, Dorzolamide or both.
3153123|NCT01527669|Experimental|LipoCol Forte capsules|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
3153124|NCT01527669|Experimental|Lovastatin Tablet|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
3153125|NCT01527656|Experimental|Formulation A|
3153126|NCT01527656|Experimental|Formulation B|
3153127|NCT01527643|Experimental|Formulation A|
3153128|NCT01527643|Experimental|Formulation B|
3153129|NCT01527630|Experimental|Formulation A|
3153130|NCT01527630|Experimental|Formulation B|
3153131|NCT01527617|Active Comparator|Cranberry beverage|
3153132|NCT01527617|Placebo Comparator|Non-cranberry beverage|
3153133|NCT01527604|Active Comparator|Avenanthramide-enriched oat muffin|
3153134|NCT01527604|Placebo Comparator|Refined flour muffin|
3153135|NCT01527565|Experimental|Formulation A|
3153136|NCT01527565|Experimental|Formulation B|
3153137|NCT01527552|Experimental|Formulation A|
3153138|NCT01527552|Experimental|Formulation B|
3153139|NCT01527539|Experimental|BIAsp 30|
3153140|NCT01527513|Experimental|Eslicarbazepine acetate (BIA 2-093)|
3153141|NCT01527513|Placebo Comparator|Placebo|
3153142|NCT01527500|Experimental|LFG316 higher dose|LFG316 10 mg/100 μL
3153143|NCT01527500|Sham Comparator|Sham|Sham injection
3153144|NCT01527500|Experimental|LFG316 lower dose|LFG316 5 mg/ 50 μL
3153145|NCT01527487|Experimental|Eribulin+Cyclophosphamide (ErC)|"Eribulin (Er): 1.4mg/m2 IV (Days 1 and 8) given short (≤1.5 minutes) IV infusion, per institutional standard~Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard"
3153146|NCT01527487|Experimental|Docetaxel+Cyclophosphamide (TC)|"Docetaxel (T): 75 mg/m2 IV (Day 1), given by 1-hour IV infusion~Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard"
3153147|NCT01527461||Lung Cancer Patients|diagnosed lung cancer patients .
3153148|NCT01527461||COPD Patients|COPD patients, not diagnosed with lung cancer.
3153149|NCT01527448|Experimental|Atypical antipsychotic treatment|Quetiapine XR is given to postpartum women diagnosed with bipolar disorder II. Starting dose is 50mg, maximum dose is 300mg/day.
3153150|NCT01527409|Experimental|Experimetal Arm|"Providing tailored health care program, which provides various information related to exercise, diet, and posttraumatic growth.~Tailored health partnership program consists of three strategic areas (exercise, diet, and posttraumatic growth). Those areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.~Patients who participate in the tailored health partnership program will be received tailored manual and workbook for tele-coaching that help them to lead their healthy life.~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life."
3153151|NCT01527409|No Intervention|Control Arm|"Providing usual care. Also, patients will be provided a workshop for health education that is dealt with ten areas (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation).~Twelve month later, patients will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth."
3153152|NCT01527383|Experimental|V212|
3153153|NCT01527383|Placebo Comparator|Placebo|
3153154|NCT01527370|Experimental|Zoster Vaccine Live|
3153155|NCT01527357|Experimental|Fibrocaps (PRO-0601)|Fibrocaps (PRO-0601) powder plus gelatin sponge
3153156|NCT01527357|Active Comparator|Gelatin sponge|Gelatin sponge (e.g., Gelfoam, Spongostan)
3153157|NCT01527331|No Intervention|control group|usual care
3153158|NCT01527331|Experimental|Video decision aid arm|
3153159|NCT01527318|Experimental|Fibrate Treatment|Patients will be treated during 28 weeks with a fibrate to assess the effects of PPAR activation on the NLSDM disease.
3153160|NCT01527305|Experimental|Paliperidone palmitate|
3153349|NCT01526005||Active agent (nicotine patch)|
3153161|NCT01527292|Active Comparator|Control Group|Baseline Assessments and followup assessments are the same for both arms. Control group Intervention: Stereotactic Radiation Therapy only
3153162|NCT01527292|Experimental|Treatment Group|Baseline Assessments and followup assessments are the same for both arms. Treatment group Intervention: Stereotactic Radiation Therapy with Vertebral Augmentation Procedure
3153163|NCT01527279|Placebo Comparator|Placebo|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.
3153164|NCT01527279|Experimental|Antazoline|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.
3153165|NCT01527266|Experimental|carbohydrate mouth rinse fasted|sucrose mouth rinse in the fasted state
3153166|NCT01527266|Experimental|carbohydrate mouth rinse fed|sucrose mouth rinse fed state
3153167|NCT01527266|Placebo Comparator|Placebo mouth rinse fed|placebo (non-caloric sweetened drink) in the fed state
3153168|NCT01527266|Placebo Comparator|Placebo mouth rinse fasted|placebo (non-caloric sweetened drink) in the fasted condition
3153169|NCT01527253|Experimental|Active Diet|Subjects eat a diet designed according to the Nordic Dietary Recommendations containing important amounts of specific legume and cereal ingredients that provide substrates for the intestinal microflora (prebiotics)
3153170|NCT01527253|Experimental|Control diet|Subjects eat a diet designed according to the Nordic Dietary Recommendations but lacks the specific legume and cereal ingredients that provide substrates for the intestinal microflora (prebiotics).
3153171|NCT01527240|Experimental|Ciclosporin A|Injection of 50 mg / ml IV infusion. 5 ml ampoules (250 mg of ciclosporin)
3153172|NCT01527240|Placebo Comparator|Placebo|Injectable Saline Solution.
3153173|NCT01527227||children of mentally ill|This research will include 130 children between the ages of 10-18 who live with at least one parent who struggles with serious mental illness in a comparison to 130 children of the same socio-demographic characteristics raised by parents from a non-clinical population
3153174|NCT01527214|Experimental|CT scan and education|All general practices referring to the Department of Pulmonary Medicine, Aarhus University Hospital.Randomized 1:1. In the intervention group, GPs continue to refer to the lung cancer fast track when indicated. In addition, they are allowed to refer directly to a rapid chest CT scan in cases where they find reasons to examine the patient for lung diseases without having sufficient suspicion of lung cancer to refer the patient to the lung cancer fast track. The GPs will be offered special training related to the diagnosis of lung cancer in general practice before the new referral option is introduced. This will be done by offering training sessions and written material.
3153175|NCT01527214|No Intervention|Control|Cluster eligibility: all practices referring to the Department of Pulmonary Medicine, Aarhus University Hospital. Randomized 1:1. Control arm continues with the usual referral pattern
3153176|NCT01527201|Experimental|Treatment Group|Worn out cartilage will be surgically treated.
3153177|NCT01527201|No Intervention|Control Group|Worn out cartilage will be observed, but will not be treated surgically.
3153178|NCT01527188|Experimental|100IR|
3153179|NCT01527188|Experimental|300IR|
3153180|NCT01527188|Experimental|500IR|
3153181|NCT01527188|Placebo Comparator|Placebo|
3153182|NCT01527175|Active Comparator|supraclavicular|supraclavicular: supraclavicular approach for subclavian venous catheterization
3153183|NCT01527175|Placebo Comparator|infraclavicular|infraclavicular: infraclavicular approach for subclavian venous catheterization
3153184|NCT01527162|Experimental|SAFO worn|Child wears their prescribed SAFO for 14 days
3153185|NCT01527162|No Intervention|SAFO not worn|Child does not wear the prescribed SAFO for 14 days
3153186|NCT01527149|Experimental|Treatment (monoclonal antibody and combination chemotherapy)|"COURSES 1, 3, and 5 (O-HyperCVAD): Patients receive ofatumumab IV on day 1, cyclophosphamide IV over 2 hours every 12 hours for 6 doses on days 3-5, doxorubicin hydrochloride IV continuously over 72 hours on days 6-8, vincristine sulfate IV on days 6 and 13, and dexamethasone IV or PO on days 3-6 and 13-16.~COURSES 2, 4, and 6 (O-HD-MA): Patients receive ofatumumab IV on day 1, methotrexate IV continuously over 24 hours on day 3, and cytarabine IV over 2 hours every 12 hours on days 4-5.~All courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Eligible patients then undergo standard HDC-ASCT."
3153187|NCT01527136|Experimental|Treatment (entolimod)|Patients receive entolimod IM or SC on days 1, 4, 8, and 11. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
3153188|NCT01527123|Experimental|GSK2585823|External Preparation
3153189|NCT01527110|Experimental|Intravenous (IV) zanamivir 600mg twice daily|600mg of IV zanamivir infusion twice daily
3153190|NCT01527097|Experimental|Atorvastatin|
3153191|NCT01527097|Placebo Comparator|Placebo|
3153192|NCT01527084|Other|Group A|undergo surgery between days 10 - 15 after PCD
3153193|NCT01527084|Other|Group B|"continued with PCD beyond 15 days and indications for surgery in them will be,~Persistent sepsis or symptoms~Worsening of clinical condition~Failure to thrive~Complications of SAP or PCD"
3153194|NCT01527058|Experimental|68Ga-BNOTA-PRGD2 PET/CT scanning|Determine if 68Ga-BNOTA-PRGD2 PET/CT is safe and effective method for imaging of lung cancer
3153195|NCT01527045|Experimental|Prevention (donor statin treatment)|See Detailed Description
3153196|NCT01527019|Experimental|Cephalosporin oral suspension|130 research subjects on cephalosporin oral suspension (test) 400 mg once daily
3153197|NCT01527019|Experimental|Cephalosporin capsules|130 research subjects on cephalosporin capsules (test) 400 mg once daily
3153198|NCT01527019|Active Comparator|Norfloxacin|130 research subjects on norfloxacin (test) 400 mg twice daily
3153350|NCT01526005||Placebo patch|
3153199|NCT01527006|Experimental|perampanel|Age Cohort 1 ( greater than or equal to 7 to less than 12 years of age at time of consent/assent) and age Cohort 2 ( greater than or equal to 2 to less than 7 years of age).
3153200|NCT01526980|Experimental|Treatment period 1|
3153201|NCT01526980|Active Comparator|Treatment period 2|
3153202|NCT01526967||New moldable user|Subjects presenting with peristomal lesions with a traditional barrier and for whom a ConvaTec Moldable Technology™ Skin Barrier is used as a replacement.
3153203|NCT01526967||New osomate|Subjects for whom a ConvaTec Moldable Technology™ Skin Barrier is used as the first long-term (within 7 days of ostomy surgery) system following surgery and have intact peristomal skin.
3153204|NCT01526954|Experimental|TissuGlu Surgical Adhesive|Experimental Arm: standard of care plus TissuGlu Surgical Adhesive and no drains
3153205|NCT01526954|No Intervention|Control- Standard of Care|Control Arm: standard of care plus drains and no TissuGlu Surgical Adhesive
3153206|NCT01526941|Experimental|Treatment period 1|
3153207|NCT01526941|Experimental|Treatment period 2|
3153208|NCT01526928|Experimental|Rociletinib|Oral Rociletinib monotherapy
3153209|NCT01526915|Experimental|Bone curettage + PRF|Bone curettage and PRF insertion
3153210|NCT01526915|Other|Bone curettage alone|Bone curettage without PRF insertion
3153211|NCT01526902|Active Comparator|omafilcon A / PC 1-D MF|"omafilcon A (PC 1-D MF) / lotrafilcon B (AIR OPTIX MF)~Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses."
3153212|NCT01526902|Active Comparator|lotrafilcon B / Air Optix MF|"lotrafilcon B (AIR OPTIX MF) / omafilcon A (PC 1-D MF)~Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses."
3153213|NCT01526889|Experimental|LFG316 -Intravitreal Injection|
3153214|NCT01526889|Active Comparator|Conventional Therapy|
3153215|NCT01526876|Experimental|Single Arm drug study|The effect of systemic blood pressure reduction using Clevidipine on intracranial pressure (ICP) and cerebral perfusion pressure (CCP)
3153216|NCT01526863|Placebo Comparator|Placebo|
3153217|NCT01526863|Active Comparator|HA egg|
3153218|NCT01526850|Experimental|allogenic mesenchymal stem cells (MSCs)|patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone.
3153219|NCT01526850|Active Comparator|Control group|patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone.
3153220|NCT01526837|Experimental|bevacizumab (Avastin)|Open-label, dose-escalating study conducted in cohorts of 1-3 patients treated at increasing doses of bevacizumab in the dose range of 1-25mg/Ml. A maximum of 24 subjects will be treated in this study (up to 8 cohorts of 3 subjects).
3153221|NCT01526824|No Intervention|Control arm, clopidogrel without Lovaza|These patients will be receiving standard of care therapy with either standard dose (75mg daily) or high dose (150mg daily) clopidogrel +/- aspirin based on physician discretion.
3153222|NCT01526824|Experimental|Clopidogrel plus Lovaza|This is the study arm of the trial, in which patients will be receiving either a standard dose (75mg daily) or high dose (150mg daily) clopidogrel with or without aspirin as well as therapy with daily Lovaza.
3153223|NCT01526811||AAA patients|Subjects presenting with a non-ruptured infra-renal abdominal aortic aneurysm (AAA) and requiring endovascular treatment with Endurant™ Stent Graft, and who meet the inclusion/exclusion criteria are intended to participate in this non-interventional study
3153224|NCT01526798|Experimental|Therlite hemodialysis|
3153225|NCT01526798|Active Comparator|Control group hfHDF|Control group hfHDF
3153226|NCT01526785|Experimental|Alglucosidase alfa|Alglucosidase alfa (4000 L scale) intravenous (IV) infusion administered for 52 weeks as per physician's routine practice.
3153227|NCT01526772||Patients who have undergone RYGB|Patients who have undergone RYGB and have been referred for an EGD
3153228|NCT01526759|Experimental|pectin|10 gram high gelling-high viscous fiber, added to a drink
3153229|NCT01526759|Placebo Comparator|control|10g gelatin, added to a drink
3153230|NCT01526746|Experimental|End Stage Renal Disease, dialysis|eGFR <15 ml/min/1.73m^2
3153231|NCT01526746|Experimental|Severe renal impairment|eGFR < 29 ml/min/1.73m^2
3153232|NCT01526746|Experimental|Healthy controls|eGFR > 80 mL/min/1.73m^2 Matched to renally impaired subjects by age, gender, BMI, and smoking status
3153233|NCT01526733|Sham Comparator|Insulin (Aspart or Lispro)-Sham|"In Phase I or Phase II of the study, participants received 0.15 units per kilogram (U/kg) insulin (either insulin aspart or insulin lispro) as a continuous subcutaneous insulin infusion (CSII) for 16 days, with sham injections administered prior to outpatient euglycemic clamps on Days 1 and 4 and prior to outpatient meal test procedures on Days 7, 10, 13, and 16.~Each Phase was separated by a washout period of 5 to 21 days."
3153234|NCT01526733|Experimental|Insulin (Aspart or Lispro)-rHuPH20|"In Phase I or Phase II of the study, participants received 0.15 U/kg insulin (either insulin aspart or insulin lispro) as a CSII for 16 days. Prior to outpatient euglycemic clamps on Days 1 and 4 and prior to outpatient meal test procedures on Days 7, 10, 13, and 16, participants received a 1 mL (150 U) injection of recombinant human hyaluronidase (rHuPH20).~Each Phase was separated by a washout period of 5 to 21 days."
3153235|NCT01526720||Group A: Diabetic|Newly diagnosed type 2 diabetic patients (i.e. diagnosis made no more than 6 months before recruitment)
3153236|NCT01526720||Group B: Relatives|Relatives of patients with potentially monogenic newly diagnosed type 2 diabetes
3153237|NCT01526707|Experimental|inhaled steroid|inhaled steroid treatment for 7 days
3153238|NCT01526694|Experimental|treatment with BDT|Bendamustine + Dexamethasone + Thalidomide in patients with multiple myeloma (MM) patients after treatment with lenalidomide and bortezomib or which are ineligible to one of these drugs.
3153239|NCT01526681||Avance Nerve Graft|Processed Human Nerve Tissue Scaffold
3153240|NCT01526681||Historical Control for Standard Treatment|Literature review for outcomes from standard treatments, i.e. Autogenous Nerve Graft.
3153241|NCT01526668|Active Comparator|No contact after discharge|In Arm A: The patient do not have planned contacts with the study nurse or doctor after discharge. All patients are seen by the study nurse six weeks postoperatively.
3153242|NCT01526668|Active Comparator|Single telephone contact|In Arm B: The patient has one planned telephone contact with the study nurse the day after discharge. All patients are seen by the study nurse six weeks postoperatively.
3153243|NCT01526668|Active Comparator|Telephone contacts regularly|In Arm C: The patient has planned telephone contacts with the study nurse the day after discharge and then once weekly until the six weeks follow-up visit postoperatively.
3153244|NCT01526668|Active Comparator|Telephone contact using CBT-inspired strategy|In Arm C: The patient has planned telephone contacts with the study nurse the day after discharge and then once weekly until the six weeks follow-up visit postoperatively. At these telephone contacts the study nurse uses a cognitive behavior therapy (CBT)-inspired strategy in counselling and support.
3153245|NCT01526655|Active Comparator|Abdominal total hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision
3153246|NCT01526655|Active Comparator|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
3153247|NCT01526642|No Intervention|Long Term Oxygen Therapy|
3153248|NCT01526642|Active Comparator|Non Invasive Ventilation|
3153249|NCT01526629||ICD patients with remote follow-up|Patients implanted with a fully automatic ICD and remotely followed-up.
3153250|NCT01526616|Active Comparator|Metformin|850 mg/day twice a day
3153251|NCT01526616|Active Comparator|Metformin plus spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
3153252|NCT01526603|Other|Patients Treated for Neuroblastoma|According to patient weight and renal function, consolidation chemotherapy using various doses of Melphalan, Etoposide, and Carboplatin followed by autologous stem cell infusion and serial post-transplant Granulocyte Colony Stimulating Factor, radiation therapy and Isotretinoin maintenance therapy.
3153253|NCT01526590|Experimental|Definity|Patients enrolled in the study will undergo contrast enhanced endoscopic ultrasound of the pancreas with Definity contrast after they have undergone their standard of care endoscopic ultrasound of the pancreas.
3153254|NCT01526577|Experimental|LC23-1306|experimental drug
3153255|NCT01526577|Placebo Comparator|placebo|LC23-1306 placebo
3153256|NCT01526577|Active Comparator|Ticagrelor|active comparator
3153257|NCT01526564|Active Comparator|ALC|ALC
3153258|NCT01526564|Placebo Comparator|Placebo|
3153259|NCT01526551|Experimental|Intervention Schools|High school students attending Wayne County and Monticello Ind. schools will be given opportunity to receive HPV Vaccine and HPV-related Health Education and Reduction of barriers to being vaccinated.
3153260|NCT01526538|Experimental|50 mg d-cycloserine|active drug condition
3153261|NCT01526538|Placebo Comparator|Sugar pill|Inactive placebo
3153262|NCT01526525|Placebo Comparator|TK|In TK group when the closure of the abdominal walls started, a certified acupuncturist expert put needles, Ener-Qi 0.26Χ25mms, in LI4 point in both hands, the needles were not inserted in the skin but they were put atop the skin and were secured by adhesive tape. For 30min in the E/A stimulator ITO ES-160 the indicator light was on but no electrical current was applied. Thereafter the E/A device deactivated and after the awakening of the patients, it was connected in ST36 and LI4 points for 30min with the same technique. The electrodes were connected to each other in every point, as the right with the left point of LI4 and the right with the left point of ST36. The patients were told that they may or may not feel electrical current because of its very high frequency.
3153263|NCT01526525|Active Comparator|TKE|In TKE group when the closure of the abdominal walls started, a certified acupuncturist expert put needles, Ener-Qi 0.26Χ25mms, in LI4 point at 2cm depth in both hands and E/A was applied for 30min with the E/A stimulator ITO ES-160 in constant pulse program with 300μs duration and 100Hz frequency. After the needles were connected to the E/A stimulator, they were secured by adhesive tape. The response which certified the right needle placement was the adjacent muscular twitch. Thereafter the E/A device was deactivated and after the awakening of the patients, E/A was administered in ST36 and LI4 points for 30min with 4Hz frequency. The electrodes were connected to each other in every point, as the right with the left point of LI4 and the right with the left point of ST36.
3153264|NCT01526512|Experimental|metroCX|metroCX Cyclophosphamide 50mg PO d1-28; Capecitabine 1500mg PO d1-28; every 28days
3153265|NCT01526499|Experimental|TC|Docetaxel plus Cyclophosphamide
3153266|NCT01526499|Active Comparator|T|Docetaxel
3153267|NCT01526486|Experimental|Videoscopic (Minimally invasive)|Patients in this arm will have the procedure done through the three port minimally invasive approach.
3153268|NCT01526486|Active Comparator|Open (traditional approach)|Patients in this arm will have the traditional, open approach in conjunction with a sartorius muscle transposition.
3153269|NCT01526473|Experimental|AVX901|AVX901 at 4 x 108 IU intramuscularly, given every 2 weeks for a total of three doses.
3153270|NCT01526460|Active Comparator|Atorvastatin|Atorvastatin 80 mg
3153271|NCT01526460|Active Comparator|Rosuvastatin|Rosuvastatin 40 mg
3153272|NCT01526460|Placebo Comparator|No statin loading dose|No statin loading dose
3153273|NCT01526447|Experimental|Craniosacral Therapy (CST)|Each participant of the experimental group receives 8 Craniosacral Therapy units once a week of 45 minutes.
3153274|NCT01526447|Sham Comparator|Sham Craniosacral Therapy (SHAM)|Each participant of the sham group receives 8 sham therapy units once a week of 45 minutes.
3153275|NCT01526434||Certolizumab Pegol treatment|Patients with RA who begin therapy with Certolizumab Pegol (CZP) will be consecutively included in accordance with the selection criteria. The choice of medical treatment is made independently by the physician before evaluating the possible participation of the patient in the protocol.
3153276|NCT01526421|Experimental|monetary reinforcer|
3153277|NCT01526421|No Intervention|no reinforcer|
3153278|NCT01526408|Placebo Comparator|Placebo Arm|Treatment with 3 months of placebo
3153279|NCT01526408|Active Comparator|Active Arm|Treatment with 3 months of active drug
3153280|NCT01526395|No Intervention|Unmodified ECT|Data will be collected on patients receiving ECT in its unmodified form prior to the introduction of low dose propofol sedation.
3153351|NCT01525992|Experimental|Community Pharmacy-based Program|
3153282|NCT01526382|Active Comparator|intervention arm|patients allocated to intervention arm receive PiCCO monitoring for hemodynamics and pulmonary conditions
3153283|NCT01526382|Placebo Comparator|control arm|Patients in this arm do not receive PiCCO monitoring device to guide fluid management, but central venous catheter can be inserted at the discretion of treating physician.
3153284|NCT01526369|Active Comparator|Paclitaxel and Trastuzumab|Weekly paclitaxel (80mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8mg/kg loading dose on cycle 1 day 1 and 4mg/kg every 2 weeks) until disease progression, unacceptable toxicity or consent withdrawal.
3153285|NCT01526369|Experimental|Paclitaxel, Trastuzumab and Lapatinib|"Weekly paclitaxel (80 mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8 mg/kg loading dose on cycle 1 day 1 and 4 mg/kg every 2 weeks)~+ lapatinib (1,000 mg daily), until disease progression, unacceptable toxicity or consent withdrawal."
3153286|NCT01526356|Placebo Comparator|Placebo|Cream only
3153287|NCT01526356|Active Comparator|0.1 % Rapamycin|0.1% Rapamycin cream
3153288|NCT01526356|Active Comparator|1% Rapamycin|1% Rapamycin cream
3153289|NCT01526343|Experimental|Reveal XT|
3153290|NCT01526330|Experimental|Group A|
3153291|NCT01526330|Experimental|Group B|
3153292|NCT01526330|Experimental|Group C|
3153293|NCT01526330|Placebo Comparator|Group D|
3153294|NCT01526317|Experimental|1|This arm is consist of 6 subject. Crestor 10mg and Glucodown 750mg for 5 day during period 1. Crestor 10mg alone for 5 day during period 2. Glucodown 750mg alone for 5 day during period 3.
3153295|NCT01526317|Experimental|2|This arm is consist of 6 subject. Glucodown 750mg alone for 5 day during period 1. Crestor 10mg and Glucodown 750mg for 5 day during period 2. Crestor 10mg alone for 5 day during period 3.
3153296|NCT01526317|Experimental|3|This arm is consist of 6 subject. Crestor 10mg alone for 5 day during period 1. Glucodown 750mg alone for 5 day during period 2. Crestor 10mg and Glucodown 750mg for 5 day during period 3.
3153297|NCT01526317|Experimental|4|This arm is consist of 6 subject. Glucodown 750mg alone for 5 day during period 1. Crestor 10mg alone for 5 day during period 2. Crestor 10mg and Glucodown 750mg for 5 day during period 3.
3153298|NCT01526317|Experimental|5|This arm is consist of 6 subject. Crestor 10mg alone for 5 day during period 1. Crestor 10mg and Glucodown 750mg for 5 day during period 2. Glucodown 750mg alone for 5 day during period 3.
3153299|NCT01526317|Experimental|6|This arm is consist of 6 subject. Crestor 10mg and Glucodown 750mg for 5 day during period 1. Glucodown 750mg alone for 5 day during period 2. Crestor 10mg alone for 5 day during period 3.
3153300|NCT01526278|No Intervention|Maxmarvil®|single-arm study
3153301|NCT01526265|Active Comparator|Usual Care|Participants will be offered free smoking cessation programs, and be provided web-based education regarding the health and economic benefits of smoking cessation. Participants will also have the opportunity to submit weekly reports on their smoking habits. They will be informed that they will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
3153302|NCT01526265|Experimental|Individual Rewards|Same as USUAL CARE arm, plus financial incentive as follows: if participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators.
3153303|NCT01526265|Experimental|Fixed Deposits|Same as USUAL CARE arm, plus financial incentive as follows: participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
3153304|NCT01526265|Experimental|Competitive Deposits (Pari-Mutuel)|"Same as USUAL CARE, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
3153305|NCT01526265|Experimental|Collaborative Rewards|"Same as USUAL CARE arm, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking."
3153306|NCT01526239|Experimental|Intervention group|Intervention consisted of a pamphlet about the benefit of CRC-S, given to patients prior to their PCP visit and a reminder note about CRC screening to be given to their physician during the encounter.
3153307|NCT01526239|No Intervention|Control group|Control group will not receive the pamphlet regarding colorectal cancers.
3153308|NCT01526226|Experimental|HFNC|High flow nasal cannula
3153309|NCT01526226|Active Comparator|nCPAP|Nasal CPAP
3153310|NCT01526213|Other|Sequence 1: Water, GFJ, FC-free GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
3153311|NCT01526213|Other|Sequence 2: Water, FC-free GFJ, GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
3153352|NCT01525992|Active Comparator|Usual care|
3154239|NCT01519999|Experimental|Shared Decision Making|
3153312|NCT01526213|Other|Sequence 3: GFJ, FC-free GFJ, Water|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
3153313|NCT01526213|Other|Sequence 4: GFJ, Water, FC-free GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
3153314|NCT01526213|Other|Sequence 5: FC-free GFJ, GFJ, Water|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
3153315|NCT01526213|Other|Sequence 6: FC-free GFJ, Water, GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
3153316|NCT01526200||CEIOUS|One hundred and twenty-seven consecutive patients —77 males and 50 females, mean age of patients was 61 years (median 65 years; range 29-85 years)— underwent liver resection using intraoperative ultrasound and contrast-enhanced intraoperative ultrasound.
3153317|NCT01526187||Sub-Saharan Africa|
3153318|NCT01526187||Asia|
3153319|NCT01526187||Latin America|
3153320|NCT01526174|Experimental|First Arm|Determine safety of intratympanic injection
3153321|NCT01526174|Experimental|Second Arm|Efficacy evaluation of 4 intratympanic injections
3153322|NCT01526161|Experimental|Inhaled Fluticasone propionate and salmeterol|inhaled fluticasone propionate 100 micrograms and salmeterol 50 m
3153323|NCT01526161|Active Comparator|Inhaled Fluticasone propionate and placebo|inhaled fluticasone propionate 100micrograms twice daily + placebo
3153324|NCT01526161|Active Comparator|Inhaled Fluticasone propionate and Montelukast|inhaled fluticasone propionate 100micrograms twice daily + Montelukast
3153325|NCT01526148|Active Comparator|Lithium|
3153326|NCT01526148|Active Comparator|Quetiapine|
3153327|NCT01526135|No Intervention|arm A GEMCITABINE|Arm A : Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
3153328|NCT01526135|Experimental|arm B mFolfirinox|"Arm B : mFolfirinox every 14 days, 12 cycles, 24 weeks.~mFolfirinox : Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
3153329|NCT01526122|Experimental|G0041(75/100mg)|
3153330|NCT01526122|Active Comparator|Clopidogrel & Aspirin|
3153331|NCT01526109|Experimental|strength training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of strength training twice a week consists of six exercises for major muscle groups: leg press, bench press, lat pull down, knee extension, knee flexion and Abdominal (3 sets of 10-12 repetitions at 60-80% of 1 RM with 3 min interval between sets and between workouts).
3153332|NCT01526109|Placebo Comparator|Control group|Participants will undergo a training program set for the three functional groups of ten minutes duration, followed by thirty minutes of functional exercises twice a week (2-3 sets of 30 sec. At intervals of 60 s between stimuli) carry out a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk without intensity
3153333|NCT01526109|Experimental|whole-body vibration training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of exercise stimuli to whole-body vibration twice a week (2-3 sets of 30 sec. with frequency of stimulation at 30 Hz with 60 s intervals between stimuli), the platform will hold a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk.
3153334|NCT01526096|Active Comparator|Standard ASCT (Grp 1)|Standard autologous stem cell transplantation (ASCT)
3153335|NCT01526096|Experimental|Depletion of T-cells after ASCT (Grp 2)|Standard ASCT followed by treatment with basiliximab to remove certain immune cells (called regulatory T-cells or Tregs) from the blood
3153336|NCT01526096|Experimental|Depletion of T-cells before ASCT(Grp 3)|Blood collected for an ASCT will be processed using a special cell sorting machine (CliniMACS device) to remove Treg cells before the stem cells are infused back into the body during stem cell transplant.
3153337|NCT01526083|Other|Single dose of Warfarin on day 3|Single dose of Warfarin on day 3 of a 7 day course of Lacosamide 200 mg BID
3153338|NCT01526083|Other|Single dose of Warfarin|
3153339|NCT01526070||Patients with Exudative Age-Related Macular Degeneration|Patients with eAMD who received intravitreal thearpy
3153340|NCT01526057|Experimental|A - PF-05280586|
3153341|NCT01526057|Active Comparator|B - Rituximab EU|
3153342|NCT01526057|Active Comparator|C- Rituximab-US|
3153343|NCT01526044|Experimental|Freestyle group|Glucose levels are being monitored with the Freestyle Navigator up to 5 days, or until discharge from the ICU
3153344|NCT01526044|Active Comparator|AccuChek group|Glucose levels are being measured by the AccuChek. Patients also get a Freestyle Navigator, which will be blinded. The device will stay on the patient up to 5 days, or until discharge from the ICU.
3153345|NCT01526031|Experimental|BV1|1:10,000 bee venom (BV) acupuncture plus physiotherapy
3153346|NCT01526031|Experimental|BV2|1:30,000 bee venom (BV) acupuncture plus physiotherapy
3153347|NCT01526031|Placebo Comparator|NS|Normal saline injection plus physiotherapy
3153348|NCT01526018||Novel bottle|
3153353|NCT01525979|Experimental|Task-Related UAT|Therapist conducted unilateral arm training Task-related unilateral arm training
3153354|NCT01525979|Experimental|Task-Related BAT|Therapist conducted bilateral arm Training Task-related bilateral arm training
3153355|NCT01525979|Experimental|Task-Related UAT coupling BAT|Therapist conducted task-related unilateral training for 45 minutes, followed by task-related bilateral arm training for another 45 minutes during each training session
3153356|NCT01525979|Experimental|Robot-assisted UAT|Robot-assisted unilateral arm training
3153357|NCT01525979|Experimental|Robot-assisted BAT|Robot-assisted bilateral arm training
3153358|NCT01525966|Experimental|Treatment (carboplatin and nab-paclitaxel)|Patients receive carboplatin IV over 30 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once weekly. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3153359|NCT01525940|Other|Colon capsule and CT-colonography|PillCam Colon Capsule Endoscopy (Given® Diagnostic System) ingestion first and CT-colonography about 10-12 hours post-ingestion
3153360|NCT01525927|Active Comparator|Chemotherapy non-responders|Patients treated with three cycles neoadjuvant chemotherapy who do not exhibit response to chemotherapy are then allocated to recieve standard dose and schedule radiotherapy.
3153361|NCT01525927|Experimental|Chemotherapy responders|Patients who respond to chemotherapy are treated with reduced dose radiotherapy.
3153362|NCT01525914||dutasteride, active surveillance|men with favorable risk prostate cancer on surveillance treated with dutasteride
3153363|NCT01525901|Experimental|Insulin-Like Growth Factor-1 (IGF-1)|Injection
3153364|NCT01525901|Placebo Comparator|Normal saline|Injection
3153365|NCT01525888|No Intervention|control|continue with treatment with angiotensin converting enzyme inhibitor or angiotensin blocker during all study period
3153366|NCT01525888|Experimental|drug stop|temporary stop of angiotensin converting enzyme inhibitor and angiotensin blocker treatment at least 72 hours before coronary angiography and renew of treatment 72 hours after angiography
3153367|NCT01525875|Active Comparator|Magnesium oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
3153368|NCT01525875|Placebo Comparator|Placebo|Part 1: 1000 mg (one 500 mg capsule two times daily) of placebo.
3153369|NCT01525849|Active Comparator|Balloon Sinus Dilation|XprESS Multi-Sinus Dilation Balloon, FinESS Sinus Treatment
3153370|NCT01525849|Active Comparator|Functional Endoscopic Sinus Surgery|Traditional endoscopic sinus surgery (maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy) using cutting, grasping, and microdebrider tools.
3153371|NCT01525836|Experimental|combination treatment group|120 enrolled patients are randomly picked up to take Rituximab in combination with Rh-TPO at the indicated dose.
3153372|NCT01525836|Active Comparator|single treatment group|120 enrolled patients are randomly picked up to take Rituximab at the indicated dose.
3153373|NCT01525823|Experimental|BMS-754807 + Metformin|
3153374|NCT01525810||Subjects treated with Peginterferon Lambda-1a (BMS-914143)|Subjects who participated in a clinical trial in which Peginterferon Lambda-1a (BMS-914143) was administered for the treatment of chronic hepatitis C
3153375|NCT01525797||Control|
3153376|NCT01525797||Rejection|
3153377|NCT01525784||Rt-CGMS|Using Rt-CGMS, approved by ministry of health as part f clinical care
3153378|NCT01525784||Control|Not approved or suggested for RtCGMS. Other acceptabl means of therapy
3153379|NCT01525771|No Intervention|No intervention|Single-center, open-label, prospective, single-arm, phase I-II study
3153380|NCT01525758|Experimental|SI000413 400mg|tablet, SI000413 200mg bid
3153381|NCT01525758|Experimental|SI000413 600mg|tablet, SI000413 200mg tid
3153382|NCT01525758|Experimental|SI000413 800mg|SI000413 200mg, 2T bid
3153383|NCT01525758|Placebo Comparator|placebo|placebo 2T tid for 8 weeks
3153384|NCT01525745|Active Comparator|Radiosurgery/SBRT|Radiosurgery/SBRT
3153385|NCT01525745|Active Comparator|External Beam Radiation Therapy|External Beam Radiation Therapy
3153386|NCT01525732|Other|POEM|Per Oral Endoscopic Myotomy
3153387|NCT01525719|Experimental|RAD001|
3153388|NCT01525706|Experimental|Ethanol and Paclitaxel Injection|All patients will receive at least one treatment with alcohol and paclitaxel.
3153389|NCT01525693||Diagnosed within 6 months|No (test) intervention to be adminisitered
3153390|NCT01525680|Active Comparator|Prolonged Exposure therapy with Hydrocortisone|
3153391|NCT01525680|Placebo Comparator|Prolonged Exposure therapy with placebo|
3153392|NCT01525667|Experimental|150M PLX-PAD|Single course, multiple IM injections
3153393|NCT01525667|Experimental|300M PLX-PAD|Single course, multiple IM injections
3153394|NCT01525667|Placebo Comparator|Placebo|Single course, multiple IM injections
3153395|NCT01525654|Active Comparator|Partners|Patients who are matched with support partners and have a billing diagnosis of RA (714.0) or seronegative inflammatory arthritis who are enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) or the Patient-Centered Outcomes Initiative (PACO)
3153396|NCT01525654|No Intervention|Controls|Controls will be BRASS patients who continue to receive regular care without being matched with a peer support partner.
3153397|NCT01525641||Patient with Parkinson's Disease|
3153398|NCT01525628|Experimental|Group A|Effect of BI 207127 on BI 201335, the effect of BI 201335 and dual oral direct acting antiviral (DAAs) on caffeine, tolbutamide and midazolam
3153399|NCT01525628|Experimental|Group B|Effect of BI 201335 on BI 207127, the effect of BI 207127 and metabolites and dual oral DAAs on caffeine, tolbutamide and midazolam
3153400|NCT01525628|Experimental|Group C|Effect of Dual oral DAAs on tenofovir
3153401|NCT01525628|Experimental|Group D|Effect of BI 201335 and BI 207127 at 600 mg b.i.d. on caffeine, tolbutamide and midazolam
3153402|NCT01525628|Experimental|Group E|Effect of BI 201335 and BI 207127 on raltegravir
3153403|NCT01525615|Experimental|tiotropium+olodaterol low dose|once daily 2 puffs, fixed dose combination (FDC) solution for inhalation Respimat
3153404|NCT01525615|Experimental|tiotropium+olodaterol high dose|once daily 2 puffs, FDC solution for inhalation Respimat
3153405|NCT01525615|Placebo Comparator|placebo|once daily 2 puffs, solution for inhalation Respimat
3153406|NCT01525602|Experimental|Part 1|"Open-label, sequential PLX3397 single-agent dose escalation in combination with paclitaxel in approximately 30 patients with advanced solid tumors. Enrollment completed.~(Closed to recruitment)"
3153407|NCT01525602|Experimental|Part 2|"Extension cohort at the RP2D of single-agent PLX3397 in combination with paclitaxel in approximately 30 patients in advanced solid tumors. Enrollment completed.~(Closed to recruitment)"
3153408|NCT01525602|Experimental|Part 3|"Extension cohort at the RP2D of single-agent PLX3397 in combinator with paclitaxel in approximately 30 patients with advanced, metastatic, or non-resectable, platinum-resistant or -refractory epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.~(Closed to recruitment)"
3153409|NCT01525589|Experimental|PM01183|
3153410|NCT01525576|No Intervention|Control group|No offer of booster program.
3153411|NCT01525576|Experimental|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
3153412|NCT01525563||Subjects with irregular Menstrual cycle|Adult subjects with irregular menstrual cycle and can be treated with Duphaston as per locally approved label can be enrolled.
3153413|NCT01525550|Experimental|sunitinib|
3153414|NCT01525537|Experimental|SPI guided arm|sufentanil was adjusted to SPI level
3153415|NCT01525537|Active Comparator|Standard practise|Sufentanil was given at standard practise
3153416|NCT01525524|Sham Comparator|Sham Stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex with the Transcranial Direct Current Stimulation. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp. The device will deliver a charge of 2mA for 1 minute, after that the device will be automatically turned off for 29 minutes.
3153417|NCT01525524|Active Comparator|Active Stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex with the transcranial Direct Current Stimulation device. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp. The device will deliver a charge of 2mA for 30 minutes.
3153418|NCT01525511|Experimental|Group A|Primaquine only followed by Dihydroartemisinin-piperaquine and followed by Primaquine together with Dihydroartemisinin-piperaquine.
3153419|NCT01525511|Active Comparator|Group B|Primaquine only followed by Primaquine together Dihydroartemisinin-piperaquine and followed by Dihydroartemisinin-piperaquine only.
3153420|NCT01525498||1 day catheter removal|Participants randomized to group 1 will have their catheter removed 1 day after surgery.
3153421|NCT01525498||2 day catheter removal|Participants randomized to group 2 will have their catheter removed 2 days after surgery.
3153422|NCT01525485||Electrical Stimulation|Participants will have a dedicated visit with a pelvic floor physical therapist during which instructions on usage and technique for the Minnova unit will be given. The electrical parameters selected will be: 10 Hertz frequency, 5-second on/10=second off cycle, and a pulse width of 0.4 milliseconds. The bipolar square will be delivered over a range that varies from 0 to 100 milliamps, depending on the maximum current intensity comfortably tolerated by the patient. The participant will perform each treatment session for 20 minutes twice daily for 8 weeks. Participants will be asked to keep a log recording the dates, times, and duration of each treatment session.
3153423|NCT01525485||Interstim device|Participants assigned to the sacral neuromodulation group will undergo InterStim device placement by one of the three Urogynecologists at OUHSC using a staged implant technique according to manufacturer's specifications.
3153424|NCT01525459||Glioma patients|
3153425|NCT01525446|Experimental|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of > 3 cm)
3153426|NCT01525433|No Intervention|Control|
3153427|NCT01525433|Active Comparator|Low Intensity Information (DVD)|A low-intensity information program, consisting of a video approach educating women on the importance of cervical cancer screening;
3153428|NCT01525433|Active Comparator|High Intensity Information (Promotora)|A higher intensity information program consisting of the video plus a 'promotora' or lay-community health educator led-intervention at the participant's home to encourage cervical cancer screening.
3153429|NCT01525420|Experimental|ACT|ACT: This is the experimental arm of the study. This included 5 weekly sessions of ACT therapy via telephone.
3153430|NCT01525420|Active Comparator|CBT|CBT: This is the control arm of the study. This included 5 weekly sessions of CBT therapy via telephone.
3153431|NCT01525407|Experimental|Supportive care (donor statin treatment)|Donors receive atorvastatin calcium PO beginning on day -14 and continuing until the last day of stem cell collection.
3153432|NCT01525394|Experimental|Lenvatinib Capsules|
3153433|NCT01525394|Active Comparator|Moxifloxacin tablets|
3153434|NCT01525394|Placebo Comparator|Placebos|
3153435|NCT01525368||cognitive intervention group|
3153436|NCT01525368||active control group|
3153437|NCT01525355||EUS prior to ERCP|
3153438|NCT01525329|Experimental|Solid Organ Transplant with AKs|Patients who have undergone kidney or liver transplant within 2 years and have at least 4 premalignant skin lesions on the face, ears, scalp, forearms and/or dorsal hands. Patients will serve as their own control, and one side of the body will be randomized to either 5-FU plus PDT, and the other will receive PDT alone.
3153439|NCT01525329|Active Comparator|Actinic Keratoses|Patients with at least 4 actinic keratoses on the face, ears, scalp, forearms and/or dorsal hands. Patients will serve as their own control, and one side of the body will be randomized to either 5-FU plus PDT, and the other will receive PDT alone.
3153440|NCT01525316|Experimental|Bovine Lactoferrin|Lactoferrin is a freeze-dried protein purified directly from fresh bovine milk.
3153441|NCT01525316|Placebo Comparator|Maltodextrin|Maltodextrin is an inert sugar.
3153523|NCT01524770|Experimental|Auto-injector|Dulaglutide: Single dose of 1.5 milligrams (mg) dulaglutide administered subcutaneously (SC) by auto-injector in one of two study periods separated by a minimum 28-day washout period
3153524|NCT01524757|Experimental|pantoprazol|
3153525|NCT01524757|Placebo Comparator|placebo|
3154240|NCT01519999|No Intervention|Comparison (control)|
3153442|NCT01525303|Experimental|Exercise-Start (ES)|The ES group will receive standard behavioral treatment in the Self-Management Training Program for Chronic Headaches. In addition to this material, participants in this group will receive an exercise prescription for 20 minutes of moderate-intensity aerobic activity at the beginning of Week 1. The exercise prescription will increase to 25 minutes in Week 2, and 30 minutes in Week 3. They are asked to maintain 30 minutes per day of exercise through Week 8. Participants choose the type of exercise, and have the option to break it up into 10-minute increments throughout the day.
3153443|NCT01525303|Experimental|Exercise-Middle (EM)|The EM group will receive standard behavioral treatment in the Self-Management Training Program for Chronic Headaches.In addition to this material, participants in this group will receive an exercise prescription for 20 minutes of moderate-intensity aerobic activity at the beginning of Week 5. The exercise prescription will increase to 25 minutes in Week 6, and 30 minutes in Week 7. They are asked to maintain 30 minutes per day of exercise through Week 8. Participants choose the type of exercise, and have the option to break it up into 10-minute increments throughout the day.
3153444|NCT01525290|Experimental|intravenous tissue plasminogen activator|Intervention drug: intravenous tissue plasminogen activator (tPA), alteplase
3153445|NCT01525290|Placebo Comparator|Placebo|Intervention drug: placebo
3153446|NCT01525277||left subclavian vein|CVC implanted in the left subclavian vein
3153447|NCT01525277||right subclavian vein|CVC implanted in the right subclavian vein
3153448|NCT01525264|Experimental|Culturally Relavent Education|Education about improving diet using a DVD with Korean role models and native Korean language.
3153449|NCT01525264|Active Comparator|Healthy Wife Intervention|Intervention group of couples who received education about importance of a Healthy Diet. It was an attention control group
3153450|NCT01525238|Experimental|Dapagliflozin 2.5 mg|
3153451|NCT01525238|Experimental|Dapagliflozin 5 mg|
3153452|NCT01525238|Experimental|Dapagliflozin 10 mg|
3153453|NCT01525225|Experimental|Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC|
3153454|NCT01525212|Experimental|Arm 1: BMS-929075 (≤ 25 mg) OR Placebo matching BMS-929075|
3153455|NCT01525212|Experimental|Arm 2: BMS-929075 (≤ 100 mg) OR Placebo matching BMS-929075|
3153456|NCT01525212|Experimental|Arm 3: BMS-929075 (≤ 400 mg) OR Placebo matching BMS-929075|
3153457|NCT01525212|Experimental|Arm 4: BMS-929075 (≤ 800 mg) OR Placebo matching BMS-929075|
3153458|NCT01525199||Case|
3153459|NCT01525199||Control|
3153460|NCT01525173|Active Comparator|ALPHAGAN® P and LUMIGAN®|1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.1% brimonidine tartrate ophthalmic solution (ALPHAGAN® P) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.
3153461|NCT01525173|Active Comparator|LUMIGAN® Alone|1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.2% hypromellose lubricant eye drops (used for masking purposes) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.
3153462|NCT01525147|Experimental|YHB1411-2: Level 2|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
3153463|NCT01525147|Experimental|YHB1411-2: Level 3|The ratio of Test Drug(YHB1411-2) to Placebo is 13 :2.
3153464|NCT01525147|Experimental|YHB1411-2: Level 4|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
3153465|NCT01525147|Experimental|YHB1411-2: Level 5|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
3153466|NCT01525147|Experimental|YHB1411-2: Level 1|All investigational products are YHB1411-2(This level is pilot study).
3153467|NCT01525121|Experimental|Expiratory Rib Cage Compression|This a crossover study, so all subjects performed both, control and experimental interventions. The patients were kept in supine at 30 degree head-up position. Ventilatory mode was changed to volume-controlled, with a tidal volume of 8mL/kg, inspiratory flow of 60 Lpm and positive end expiratory pressure (PEEP) of 5 cmH2O. A first tracheal suctioning was done, and the mucus was discarded. Then, a series of two minutes of bilateral expiratory rib-cage compressions ensued. Aiming to minimize inter-therapist variability, the maneuver was applied by the same registered and trained physiotherapist. Control intervention followed the same sequence, but instead of the compressive maneuver they were kept on normal ventilation with the parameters described above.
3153468|NCT01525121|No Intervention|Control|This a crossover study, so all subjects performed both, control and experimental interventions. The patients were kept in supine at 30 degree head-up position. Ventilatory mode was changed to volume-controlled, with a tidal volume of 8mL/kg, inspiratory flow of 60 Lpm and positive end expiratory pressure (PEEP) of 5 cmH2O. A first tracheal suctioning was done, and the mucus was discarded. Then, a series of two minutes of bilateral expiratory rib-cage compressions ensued. Aiming to minimize inter-therapist variability, the maneuver was applied by the same registered and trained physiotherapist. Control intervention followed the same sequence, but instead of the compressive maneuver they were kept on normal ventilation with the parameters described above.
3153469|NCT01525108|Experimental|Home-based blood pressure monitoring|
3153470|NCT01525108|Active Comparator|Usual care|
3153471|NCT01525095||Candida Positive Patients|Symptomatic adult patients, confirmed via concordant diagnostic blood culture and species identification and subsequent second blood culture results and species identification that are Candida positive
3153472|NCT01525095||Candida Negative Patients|Hospitalized adult patients, confirmed via concordant diagnostic blood culture with subsequent species identification and subsequent second blood culture with subsequent species identification that are Candida negative
3153473|NCT01525082|Experimental|monoclonal antibody therapy, chemotherapy|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, capecitabine PO BID on days 1-14, and temozolomide PO QD on days 10-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3153474|NCT01525069|Experimental|Arm A (HAI FUDR alone)|"14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
3153689|NCT01523743|Active Comparator|Standard Care|Standard Care: Coated intermittent catheter normally used by subject
3153475|NCT01525069|Experimental|Arm B (HAI FUDR + gemcitabine)|"Consists of Cohort B1, B2, and B3. Enrollment to specific cohorts will depend on the number of DLTs in each cohort. Each cohort has a different dose of FUDR and gemcitabine.~Gemcitabine IV will be given on Days 1, 8, and 15 of each 28 day cycle in Cohort B1~Gemcitabine IV will be given on Days 1 and 15 of each 28 day cycle in Cohort B2 & B3~14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
3153476|NCT01525069|Experimental|Arm C (HAI FUDR + gemcitabine + oxaliplatin)|"Consists of Cohort C1, C2, C3, and C4. Enrollment to specific cohorts will depend on the number of DLTs in each cohort. Each cohort has a different dose of FUDR, gemcitabine, and oxaliplatin.~Gemcitabine IV will be given on Days 1 and 15 of each 28 day cycle.~Oxaliplatin IV will be given on Days 1 and 15 of each 28 days cycle.~14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
3153477|NCT01525056|Other|imaging with ct, mri and pet scans|ct,mri and pet scans pre and post radiation
3153478|NCT01525043|Active Comparator|Naproxen|
3153479|NCT01525043|Experimental|Synera single patch applied for 12 hrs/day|
3153480|NCT01525043|Experimental|Synera sinlgle patch applied for 4hrs twice daily|
3153481|NCT01525017|Experimental|Combig-DC Cancer Vaccine|Two vaccinations of Combig-DC (allogeneic dendritic cells) Cancer Vaccine given before nephrectomy.
3153482|NCT01525004|Active Comparator|Standard dose trivalent inactivated influenza vaccine|
3153483|NCT01525004|Experimental|High-Dose trivalent inactivated influenza vaccine|
3153484|NCT01524991|Experimental|Treatment|Gemcitabine 1000 mg/m2 Days 1 & 8 Cisplatin 70 mg/m2 Day 1 Ipilimumab 10 mg/kg Day 1 (start cycle 3)
3153485|NCT01524978|Experimental|Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib|Participants with NSCLC will be treated with vemurafenib monotherapy.
3153486|NCT01524978|Experimental|Cohort 2: Ovarian Cancer - vemurafenib|Participants with ovarian cancer will be treated with vemurafenib monotherapy.
3153487|NCT01524978|Experimental|Cohort 3a: Colorectal Cancer - vemurafenib|Participants with colorectal cancer will be treated with vemurafenib monotherapy.
3153488|NCT01524978|Experimental|Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab|Participants with colorectal cancer will be treated with vemurafenib and cetuximab combination therapy.
3153489|NCT01524978|Experimental|Cohort 4: Cholangiocarcinoma - vemurafenib|Participants with cholangiocarcinoma will be treated with vemurafenib monotherapy.
3153490|NCT01524978|Experimental|Cohort 6: Multiple Myeloma - vemurafenib|Participants with multiple myeloma will be treated with vemurafenib monotherapy.
3153491|NCT01524978|Experimental|Cohort 7: Other Solid Tumors - vemurafenib|Participants with Erdheim-Chester disease (ECD), Langerhans cell histiocytosis (LCH), anaplastic thyroid cancer, advanced stage astrocytoma, early stage astrocytoma and other BRAF V600-positive tumors will be treated with vemurafenib monotherapy. Subcohorts will be analyzed separately if 7 or more participants are enrolled for each indication.
3153492|NCT01524965|Experimental|Immediate mobilisation|
3153493|NCT01524965|Active Comparator|Standard mobilisation|
3153494|NCT01524952|Experimental|Active|cTEMS
3153495|NCT01524939|Experimental|Investigational product|
3153496|NCT01524926|Experimental|Crizotinib in Anaplastic large cell lymphoma|
3153497|NCT01524926|Experimental|Crizotinib in Inflammatory myofibroblastic tumor|
3153498|NCT01524926|Experimental|Crizotinib in Papillary renal cell carcinoma type 1|
3153499|NCT01524926|Experimental|Crizotinib in Clear cell sarcoma|
3153500|NCT01524926|Experimental|Crizotinib in Alveolar soft part sarcoma|
3153501|NCT01524926|Experimental|Crizotinib in Alveolar rhabdomyosarcoma|
3153502|NCT01524913|Experimental|Hyaluronic acid|
3153503|NCT01524913|Active Comparator|Corticosteroid|
3153504|NCT01524913|Placebo Comparator|Saline|
3153505|NCT01524900||nevirapine extended release|
3153506|NCT01524887|Experimental|IGIV, 10% at high dose (0.4 g/kg)|
3153507|NCT01524887|Experimental|IGIV, 10% at low dose (0.2 g/kg)|
3153508|NCT01524887|Placebo Comparator|Placebo control|
3153509|NCT01524874|Active Comparator|Powder D3 Capsule - 2,000 IU per Cap|Vital Nutrients
3153510|NCT01524874|Active Comparator|Chewable D3 Tablet - 2,000 IU per Tab|Integrative Therapeutics Inc.
3153511|NCT01524874|Active Comparator|Liquid D3 Drop - 2,000 IU per Drop|Biotics Research
3153512|NCT01524861|Placebo Comparator|Placebo|30 subjects receive placebo (placebo group)
3153513|NCT01524861|Experimental|alpha-lipoic acid|30 subjects receive alpha-lipoic acid, 400 mg/day per os bis in die (800 mg/day)(ALA group)
3153514|NCT01524861|Experimental|L-acetil-carnitine|30 subjects receive L-acetyl carnitine, 500 mg per os bis in die (1000 mg/day) (LAC group)
3153515|NCT01524848|Other|Open label|Single arm pazopanib
3153516|NCT01524835||Live lung donors|Live lung donors who participated in donation from 1993 through 2006
3153517|NCT01524809|Experimental|Treatment period 1|
3153518|NCT01524809|Experimental|Treatment period 2|
3153519|NCT01524796||Patients with peripheral neuropathic pain treated with Lyrica|
3153520|NCT01524783|Experimental|Everolimus + BSC|Participants received everolimus 10mg once daily until disease progression, intolerable toxicity, or consent withdrawal plus best supportive care (BSC)
3153521|NCT01524783|Placebo Comparator|Everolimus Placebo + BSC|Participants received matching placebo to everolimus with same dose, plus best supportive care (BSC)
3153522|NCT01524770|Active Comparator|Manual syringe|Dulaglutide: Single dose of 1.5 milligrams (mg) dulaglutide administered subcutaneously (SC) by manual syringe in one of two study periods separated by a 28-day minimum washout period.
3153526|NCT01524744|Active Comparator|Pimecrolimus ointment 0.1 %|This group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
3153527|NCT01524744|Active Comparator|Adcortyle|Control group used adcortyle (triamcinolone acetonide 0.1% in orabase, Bristol-Myers Squibbb, Anagn, Italy)
3153528|NCT01524731|Placebo Comparator|Placebo|Placebo group
3153529|NCT01524731|Active Comparator|4 mg dexamethasone|4 mg dexamethasone group
3153530|NCT01524731|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg group
3153531|NCT01524718|Experimental|Imaging with two X-ray image intensifiers|There is no change in the procedure except for the imaging technique, while in the first group the X- ray image intensifier serves in the two planes, and being moved from one plane to the other, and in the second group the two devices are static in the same position, one in the AP plane and the other as the axial plane.
3153532|NCT01524718|No Intervention|Imaging with one X-ray image intensifier.|The X- ray image intensifier serves in the two planes, and being moved from one plane to the other
3153533|NCT01524705|Experimental|Insulin Glargine, metformin, exenatide|Approximately 60 Type 2 DM participants will be instructed on an AHA/ADA meal plan. Insulin Glargine, metformin and exenatide will used as a combination strategy to control individual HBA1Cs between 6.7 and 7.3% throughout the trial.
3153534|NCT01524705|Active Comparator|glargine, metformin, prandial insulin|Approximately 60 type 2 DM participants will be instructed in AHA/ADA meal plan. Insulin Glargine, metformin and one of 3 prandial insulins will be used as combination strategy to control individual HBA1Cs between 6.7 and 7.3%. Prandial Insulins (aspart, glulisine or lispro)
3153535|NCT01524692|Experimental|Single ARM Dovitinib treatment|Single ARM Dovitinib treatment
3153536|NCT01524679|Experimental|Treatment group|pegylated interferon alfa-2a (Pegasys®) 180 μg once weekly for 48 weeks added to an ongoing nucleos(t)ide based treatment in patients with chronic HBeAg-negative hepatitis B
3153537|NCT01524679|No Intervention|Control group|ongoing nucleos(t)ide based treatment alone
3153538|NCT01524653|Experimental|Rosuvastatin First, Placebo Last|This arm will receive rosuvastatin during the first treatment period followed by placebo in the second treatment period after washout.
3153539|NCT01524653|Experimental|Placebo First, Rosuvastatin Last|This arm will receive placebo during the first treatment period followed by rosuvastatin in the second treatment period after washout.
3153540|NCT01524640|Experimental|Killed oral cholera vaccine|"Killed Bivalent (O1 and O139) Whole cell oral cholera vaccine (Shanchol TM) Vaccine strain Reformulated version~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) of lipopolysaccharide (LPS) V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
3153541|NCT01524640|Placebo Comparator|Placebo|"Non biologic placebo~Ingredients Per 1.5 ml dose~Starch 60mg~Red color[1mg/ml] 10 µl~Yellow color [1mg/ml] 5 µl~Xanthum Gum (1% solution) 300 µl~Water for Injection Upto 1.5 ml~All the above ingredients are of pharmaceutical grade.~Non-biological placebo of above composition has been used in 2010 for Randomized, double-blind, placebo controlled trial to evaluate the safety and immunogenicity of orally administered, killed, bivalent whole-cell , cholera vaccine, Shanchol in Bangladeshi Adults and Children. This study involving 330 subjects was carried out at International Center for Diarrheal Disease Research Bangladesh (ICDDR,B) located in Dhaka, Bangladesh with Dr. Firdausi Qadri as Principal Investigator (NCT01042951). There were no safety concerns associated with this placebo in this study and the report of this study has been submitted to the National Regulators in Bangladesh and the World Health Organization."
3153542|NCT01524627|Placebo Comparator|Control Group|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
3153543|NCT01524627|Active Comparator|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
3153544|NCT01524614|Experimental|Nasal mask with no PEEP|Nasal mask with PEEP 0, then add PEEP 5, and 10
3153545|NCT01524614|Experimental|Nasal mask with PEEP|Nasal mask with PEEP 5, then add PEEP 10
3153546|NCT01524614|Experimental|Face mask with no PEEP|Face mask with PEEP 0 then add PEEP 5, 10
3153547|NCT01524614|Experimental|Face mask with PEEP|Face mask with PEEP 5, then add PEEP 10
3153548|NCT01524601|Experimental|Rosuvastatin|Rosuvastatin treatment for 4 weeks
3153549|NCT01524575|No Intervention|ERCC1 high expression|Patients with ERCC1 high expression tumors will be treated at discretion of investigator
3153550|NCT01524575|Experimental|ERCC1 low expression|Patients with ERCC1 low expression will be treated with gemcitabine and oxaliplatin
3153551|NCT01524510|Experimental|MRA|All OSAS patients will be asked to sleep two nights without MRA and, +/- 1 week later, two nights with MRA
3153552|NCT01524497|Active Comparator|Trazodone|
3153553|NCT01524497|Placebo Comparator|Placebo|
3153554|NCT01524484||Anesthesia staff Interviewees|Staff entering quality data into the electronic anesthesia record are interviewed regarding working conditions and record layout
3153555|NCT01524484||Anesthesia records|Anesthesia records (all types of procedures) are checked for correct reporting of defined events
3153556|NCT01524471|Experimental|POEM|Endoscopic Myotomy
3153557|NCT01524458|Experimental|POEM|To perform myotomy using endoscopy through a long submucosal tunnel
3153558|NCT01524445||bortezomib retreatment|bortezomib retreatment due to relapse Patients who received bortezomib-containing chemotherapy as first-line treatment for MM experienced partial response or better and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
3153559|NCT01524432|Experimental|Drug loaded microcapsules socks|Study medication
3153560|NCT01524432|Placebo Comparator|No drug loaded microcapsules socks|Placebo medication
3153561|NCT01524419||women after vaginal birth|
3153562|NCT01524406|Experimental|HPP593|
3153563|NCT01524406|Placebo Comparator|Placebo|
3153564|NCT01524393||IVF pregnancy|
3153565|NCT01524380|Active Comparator|Ginkgo biloba extract, antioxidant|Active treatment with Ginkgo biloba extract
3153566|NCT01524380|Placebo Comparator|Placebo|Treatment with placebo
3153567|NCT01524367|Placebo Comparator|saline group|We administrate the saline single bolus (0.01ml/kg,intravenously) at time of oral cavity sealing.
3153568|NCT01524367|Experimental|dexmedetomidine group|We administrate the dexmedetomidine single bolus (1ug/kg, intravenously) at time of oral cavity sealing.
3153569|NCT01524354|Active Comparator|Control|Patients received maintenance of anesthesia with continuous infusion of propofol according to recommendations of the manufacturer.
3153570|NCT01524354|Active Comparator|cerebral state index|Patients received continuous infusion of propofol with rate maintaining cerebral state index (CSI) between 40 and 60 points.
3153571|NCT01524341|Experimental|Cohort 1|10 subjects with Plasmodium vivax malaria will receive 30 mg KAE609 once a day for three days
3153572|NCT01524341|Experimental|Cohort 2|10 subjects with Plasmodium falciparum malaria will receive 30 mg KAE609 once a day for three days
3153573|NCT01524315|Experimental|Supplementation|6 ml Vitamin-B1-ratiopharm in 100 ml normal saline, intravenous, preoperative
3153574|NCT01524315|Placebo Comparator|Placebo|100 ml normal saline, intravenous, preoperative
3153575|NCT01524302|Active Comparator|Levofloxacin|Pharmacodynamics
3153576|NCT01524302|Active Comparator|Ceftaroline|Pharmacodynamics
3153577|NCT01524289|Experimental|Anacetrapib|
3153578|NCT01524289|Placebo Comparator|Placebo|
3153579|NCT01524250|Experimental|oral prednisone|1250mg oral prednisone daily for 3 days
3153580|NCT01524250|Active Comparator|IV methylprednisolone|1000mg IV methylprednisolone daily for 3 days
3153581|NCT01524237|Experimental|10 mg LY2140023 + ketamine|Single oral dose of 10 mg LY2140023 followed by intravenous (IV) ketamine during one of the crossover periods
3153582|NCT01524237|Experimental|20 mg LY2979165 + ketamine|Single oral dose of 20 mg LY2979165 followed by IV ketamine during one of the crossover periods
3153583|NCT01524237|Experimental|40 mg LY2140023 + ketamine|Single oral dose of 40 mg LY2140023 followed by IV ketamine during one of the crossover periods
3153584|NCT01524237|Experimental|60 mg LY2979165 + ketamine|Single oral dose of 60 mg LY2979165 followed by IV ketamine during one of the crossover periods
3153585|NCT01524237|Experimental|160 mg LY2140023 + ketamine|Single oral dose of 160 mg of LY2140023 followed by IV ketamine during one of the crossover periods
3153586|NCT01524237|Placebo Comparator|Placebo capsules + ketamine|Single oral dose of placebo capsules followed by IV ketamine during one of the crossover periods
3153587|NCT01524237|Placebo Comparator|Placebo tablets + ketamine|Single oral dose of placebo tablets followed by IV ketamine during one of the crossover periods
3153588|NCT01524224|Experimental|LY2495655|"Administered intravenously (IV) every 2 weeks (14 days) for four (4) 14 day cycles. Participants receiving clinical benefit may continue to receive treatment until one or more of the discontinuation criteria are met.~Starting dose in Part 1 (dose escalation) will be 2 mg. The dose will be subsequently increased to 7 mg, 21 mg, 70 mg, 210 mg, and 700 mg. The dose administered in Part 2 (dose confirmation) will be determined from Part 1."
3153589|NCT01524211|Experimental|Single Treatment Arm|All subjects enrolled will receive endovascular treatment with the investigational Zenith t-Branch Endovascular Graft.
3153590|NCT01524198|Placebo Comparator|Normal Saline|Subjects who are receiving normal saline (NS) in addition to Albuterol 2.5 mg if < 20 kg or 5 mg if >= 20 kg body weight and ipratropium bromide (IB) 250 mcg; 3 nebulizations back to back
3153591|NCT01524198|Active Comparator|Budesonide|Subjects with acute asthma exacerbation who receive Budesonide 500 mcg, in addition to Albuterol 2.5 mg if < 20 kg body weight or 5 mg if >= 20 kg body weight and Ipratropium Bromine (IB) 250 mcg; 3 nebulization doses back to back
3153592|NCT01524185|Experimental|FamilyLive|Multi-therapist group intervention for families with a history of intergenerational neglect and trauma exposure
3153593|NCT01524185|Active Comparator|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
3153594|NCT01524172|Active Comparator|Standard Mental Health Treatment|Trauma-informed evidence supported mental health treatment
3153595|NCT01524172|Experimental|Yoga Based Psychotherapy Group|Yoga Based Psychotherapy will be used as an adjunct mental health interventions
3153596|NCT01524159|Placebo Comparator|placebo group|This group will receive placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
3153597|NCT01524159|Active Comparator|bromelain group|Bromelain Group This group will receive bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
3153598|NCT01524146||Photodynamic therapy|Subjects who will receive photodynamic therapy for palliation of unresectable Cholangiocarcinoma.
3153599|NCT01524133|Active Comparator|Sertraline + enhanced medication management (SERT/EMM)|24 weeks of sertraline + enhanced medication management
3153600|NCT01524133|Active Comparator|Prolonged Exposure + sertraline (PE/SERT)|Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline
3153601|NCT01524133|Active Comparator|Prolonged Exposure + placebo (PE/PLB)|Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo
3153602|NCT01524120||Crohn's disease (CD)|Patients with CD and mucosal healing on endoscopy.
3153603|NCT01524120||Crohn's disease|Patients with CD and mucosal healing on endomicroscopy.
3153604|NCT01524120||Ulcerative colitis (UC)|Patients with UC and mucosal healing on endoscopy.
3153605|NCT01524120||Ulcerative colitis|Patients with UC and mucosal healing on endomicroscopy.
3153606|NCT01524107||Urgent Caesarian Section|
3153607|NCT01524107||Elective Caesarian Section|
3153608|NCT01524094|Experimental|Arm A: CRS plus postop intraperitoneal chemotherapy.|Cytoreductive surgery and postoperative intraperitoneal chemotherapy.
3153609|NCT01524094|Active Comparator|Arm B: Systemic chemotherapy alone|Systemic chemotherapy alone
3153610|NCT01524081|Experimental|APPE - antibiotic prophylaxis|Patients indicated for emergent appendectomy with antibiotic prophylaxis
3153611|NCT01524081|Experimental|GERD - antibiotic prophylaxis|Patients indicated for emergent surgery due to gastroduodenal perforation with antibiotic prophylaxis.
3153688|NCT01523743|Experimental|Compact catheter|Compact intermittent catheter
3153612|NCT01524081|Experimental|ILEUS - antibiotic prophylaxis|Patients indicated for emergent due to small bowel obstruction with antibiotic prophylaxis
3153613|NCT01524081|Placebo Comparator|APPE - placebo|Patients indicated for emergent appendectomy without antibiotic prophylaxis. Placebo (saline) was administrated.
3153614|NCT01524081|Placebo Comparator|GERD - placebo|Patients indicated for emergent surgery due to gastroduodenal perforation without antibiotic prophylaxis. Placebo (saline) was administrated.
3153615|NCT01524081|Placebo Comparator|ILEUS - placebo|Patients indicated for emergent due to small bowel obstruction without antibiotic prophylaxis. Placebo (saline) was administrated.
3153616|NCT01524068|Experimental|Arm A - Standard Steroid Treatment|
3153617|NCT01524068|Experimental|Arm B - Experimental Treatment|
3153618|NCT01524055|Other|Air|Air as insufflation gas during single-balloon enteroscopy.
3153619|NCT01524055|Other|CO2|CO2 as insufflation gas during single-balloon enteroscopy.
3153620|NCT01524042|Experimental|group 2|study group:double pants group
3153621|NCT01524029||Breast Cancer Screening Patients|Group 1 consists of Women referred to Breast Cancer Screening examinations at a participating Austrian Breast Imaging Site
3153622|NCT01524029||Diagnostic Patients|Patients referred to a participating Breast Imaging Center for a clinically or radiologically detected breast lesion
3153623|NCT01524016|Experimental|68Ga-DOTATATE, PET/CT scan|We will perform 68Ga-DOTATATE PET/CT scanning on subjects
3153624|NCT01524003|Experimental|Cryotherapy after VIA triage|Women who test HPV positive will be randomized to the experimental arm or the standard of care arm. In the Experimental arm VIA will be done to determine acceptability for cryotherapy [R/O high-grade CIN too large for cryotherapy (usually 3-4 quadrant disease) or cancer]. All acceptable patients will have an ECC done and then immediate cryotherapy.
3153625|NCT01524003|Active Comparator|Colposcopy and biopsy|Standard of care. Women testing positive for HPV will be randomized to the experimental arm (immediate cryotherapy) or the Standard of care arm, for colposcopy, biopsy, and leep based on the pathology results.
3153626|NCT01523990|Experimental|Panel I (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 50 mg (fasted) to 50 mg (fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
3153627|NCT01523990|Placebo Comparator|Panel I (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 50 mg (fasted) to 50 mg (fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
3153628|NCT01523990|Experimental|Panel II (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 100 mg (fasted) to 100 mg (fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
3153629|NCT01523990|Placebo Comparator|Panel II (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 100 mg (fasted) to 100 mg (fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
3153630|NCT01523990|Experimental|Panel III (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 200 mg (fasted or fed) to 400 mg (fasted or fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
3153631|NCT01523990|Placebo Comparator|Panel III (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 200 mg (fasted or fed) to 400 mg (fasted or fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
3153632|NCT01523990|Experimental|Panel IV (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 600 mg (fasted or fed) to 800 mg (fasted or fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
3153633|NCT01523990|Placebo Comparator|Panel IV (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 600 mg (fasted or fed) to 800 mg (fasted or fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
3153634|NCT01523990|Experimental|Panel V (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 100 mg taken by healthy East and Caucasian volunteers .
3153635|NCT01523990|Placebo Comparator|Panel V (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 100 mg taken by healthy East and Caucasian volunteers .
3153636|NCT01523990|Experimental|Panel VI (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 200 mg taken by healthy East and Caucasian volunteers .
3153637|NCT01523990|Placebo Comparator|Panel VI (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 200 mg taken by healthy East and Caucasian volunteers .
3153638|NCT01523990|Experimental|Panel VII (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 400 mg taken by healthy East and Caucasian volunteers .
3153639|NCT01523990|Placebo Comparator|Panel VII (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 400 mg taken by healthy East and Caucasian volunteers .
3153640|NCT01523990|Experimental|Panel VIII (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 600 mg taken by healthy East and Caucasian volunteers .
3153641|NCT01523990|Placebo Comparator|Panel VIII (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 600 mg taken by healthy East and Caucasian volunteers .
3153642|NCT01523990|Experimental|Panel IX (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 200 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
3153643|NCT01523990|Placebo Comparator|Panel IX (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 200 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
3153644|NCT01523990|Experimental|Panel X (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 400 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
3153645|NCT01523990|Placebo Comparator|Panel X (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 400 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
3154882|NCT01515579|Experimental|Formulation 4|
3153646|NCT01523990|Experimental|Panel XI (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
3153647|NCT01523990|Placebo Comparator|Panel XI (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
3153648|NCT01523990|Experimental|Panel XII (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 2 infected, treatment-naive patients.
3153649|NCT01523990|Experimental|Panel XIII (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 3 infected, treatment-naive patients.
3153650|NCT01523990|Experimental|Panel XIV (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 4 infected, treatment-naive patients.
3153651|NCT01523990|Experimental|Panel XV (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 5 infected, treatment-naive patients.
3153652|NCT01523990|Experimental|Panel XVI (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 6 infected, treatment-naive patients.
3153653|NCT01523964|Other|DMD subject ages 3-7 inclusive|Young DMD Testing with EIM
3153654|NCT01523964|Other|DMD subject ages 8-12 inclusive|Older DMD Testing with EIM
3153655|NCT01523964|Other|Healthy Control ages 3-7 inclusive|Young Healthy Testing with EIM
3153656|NCT01523964|Other|Healthy Control ages 8-12 inclusive|Older Healthy Testing with EIM
3153657|NCT01523951||Healthy volunteers|
3153658|NCT01523938|Experimental|Hypnotherapy|
3153659|NCT01523938|No Intervention|No Hypnotherapy|
3153660|NCT01523925|Experimental|Combined dCIT with FET|Combined distributed constraint induced therapy with functional electrical therapy
3153661|NCT01523925|Experimental|Combined BAT with FET|Combined bilateral arm treatment with functional electrical therapy
3153662|NCT01523925|Active Comparator|Control intervention group|Control intervention
3153663|NCT01523925|Experimental|dCIT|distributed constraint induced therapy
3153664|NCT01523925|Experimental|BAT|bilateral arm treatment
3153665|NCT01523912|Experimental|gastric RFA|Ablation of gastric dysplastic mucosa
3153666|NCT01523899|Experimental|Xpert MRSA/SA SSTI|use of the Xpert MRSA/SSTI diagnostic assay
3153667|NCT01523899|Active Comparator|Standard culture|performance of standard bacterial culture of abscess material
3153668|NCT01523886|Active Comparator|Deep neuromuscular blockade|
3153669|NCT01523886|Placebo Comparator|Moderate neuromuscular blockade|
3153670|NCT01523860|Experimental|1|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration.
3153671|NCT01523847|Experimental|MBVD (Myocet+BVD)|"2 MBVD courses, after early restaging with PET scan (PET-2)~The subsequent treatment will be planned as follows:~-Stage I and IIA patients will go on with 1 more course of MBVD (total of 3 courses) followed by involved field radiotherapy (30 Gy-36 Gy).~-Advanced stage (IIB-IV) patients will go on with 4 more courses of MBVD (total of 6 courses). Radiotherapy limited to bulky or non complete responder areas (30 Gy) is optional."
3153672|NCT01523834|Experimental|Panobinosat|"The treatment is divided in three phases: induction phase (course 1 to 6), consolidation phase (courses 7 to 12), maintenance phase (from course 13 until the end of therapy for any reason). The duration of a treatment course will be 28 days. The first dose of panobinostat in course 1 defines day 1 of the treatment cycle, and each cycle thereafter will begin 28 days later.~Treatment:~Panobinostat should be taken p.o. at the dose of 40 mg/day three-times every week (QW) (e.g., on Monday, Wednesday, and Friday or Tuesday, Thursday, and Saturday), as part of a 4 week (28 days) treatment cycle."
3153673|NCT01523821|Experimental|Treatment (GVHD therapy)|Patients receive alpha-1-proteinase inhibitor human IV on days 1, 3, 5, and 7. Patients who experience no toxicity and in whom GVHD is stable or improved by Day 7 can continue therapy with alpha 1 anti-trypsin on days 9, 11, 13 and 15.
3153674|NCT01523808|Experimental|GRASPA 25|
3153675|NCT01523808|Experimental|GRASPA 50|
3153676|NCT01523808|Experimental|GRASPA 100|
3153677|NCT01523808|Experimental|GRASPA 150|
3153678|NCT01523795|Experimental|Motion-controlled video gaming|Participants played motion-controlled video games that involved at least throwing, hitting, or dancing motions using a Wii or Xbox 360 console for one hour
3153679|NCT01523795|Active Comparator|Traditional video gaming|Participants played traditional (handheld gamepad controller-based) video games using a Playstation 3 console for one hour
3153680|NCT01523795|Active Comparator|Television watching|Participants watched television via Netflix instant streaming for one hour
3153681|NCT01523782|Experimental|GRASPA 50 IU/kg|Each patient will receive GRASPA 50 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase.
3153682|NCT01523782|Experimental|GRASPA 100 IU/kg|Each patient will receive GRASPA 100 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
3153683|NCT01523782|Experimental|GRASPA 150 IU/kg|Each patient will receive GRASPA 150 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
3153684|NCT01523769|No Intervention|Control|Control group, the cord was not milked
3153685|NCT01523769|Experimental|Umbilical Cord Milking|Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery
3153686|NCT01523756|Experimental|test product 1 first|"own product (baseline) - test product 1 - test product 2~test product 1 = New ostomy base plate. Due to company confidentiality the product is just called test product 1"
3153687|NCT01523756|Experimental|test product 2 first|"own product (baseline) - test product 2 - test product 1~test product 2 = New ostomy base plate. Due to company confidentiality the product is just called test product 2"
3153690|NCT01523730|Active Comparator|Repetitive Transcranial Magnetic Stimulation (rTMS)|
3153691|NCT01523730|Placebo Comparator|Sham rTMS|
3153692|NCT01523704|Experimental|HM|Patients assigned to HM Group(HM follow-up ONLY) will have Home Monitoring programmed ON. They will be seen in the office for device interrogations at the 3-month follow-up, and at 27 month follow-up. In the meanwhile the device status will be evaluated using HM only for the 9, 15 and 21 month scheduled follow-up. Patients will visit the hospital for device interrogation on 27 month final follow-up.
3153693|NCT01523704|Active Comparator|Control|Patients assigned to Control Group (HM + Conventional In-office follow-up - Control group) will have HM programmed ON. In addition to HM, these patients will visit the hospital for device interrogation at 3, 9, 15, 21 and 27 month follow-ups.
3153694|NCT01523691|Experimental|repeated sleep restriction and recovery|
3153695|NCT01523691|Experimental|control sleep|
3153696|NCT01523678|Experimental|Filgrastim|
3153697|NCT01523652||Nadroparin/control (phase 1)|patients affected by benign pelvic gynaecologic diseases were enrolled and treated with nadroparin for prophylactic anticoagulation; patients untreated with nadroparin were as control group.
3153698|NCT01523652||Nadroparin (phase 2)|patients were enrolled among women planning gynaecological pelvic surgery and treated for 4 weeks with nadroparin for prophylactic anticoagulation. All these patients underwent laparotomy;
3153699|NCT01523639|Active Comparator|Metformin|FOLFIRI + cetuximab + metformin every 2 weeks for 12 cycles
3153700|NCT01523639|Placebo Comparator|Placebo|FOLFIRI + cetuximab + placebo every 2 weeks for 12 cycles
3153701|NCT01523626|Other|Conventional imaging|The control group will be evaluated with X-rays, ultrasonography and selective CT scanning.
3153702|NCT01523626|Other|Immediate total body CT|The intervention group will receive a 'total body' CT scan from head to pelvis. Conventional radiography and FAST will be completely omitted.
3153703|NCT01523613|Active Comparator|ROCK - Single Restorations|ChemFil Rock glassionomer restoration
3153704|NCT01523613|Active Comparator|Fuji IX GP - Single Restorations|Fuji IX GP Extra glassionomer restoration
3153705|NCT01523613|Active Comparator|Rock AND Fuji - Paired Restorations|"ChemFil Rock glassionomer restoration AND Fuji IX GP Extra glassionomer restoration.~While this is not truly a separate arm for outcome analysis, this arm represents those individuals who had paired restorations, one of each: 1 ChemFil Rock restoration and 1 Fuji IX GP restoration."
3153706|NCT01523600|Experimental|Whole body vibration training|
3153707|NCT01523600|Active Comparator|Wellness group|
3153708|NCT01523587|Experimental|Afatinib|Patients receive afatinib tablets once daily
3153709|NCT01523587|Active Comparator|Erlotinib|Patients receive erlotinib tablets once daily
3153710|NCT01523574|Placebo Comparator|Control Group|Five days before chemotherapy:1 x daily Used until one week after third oxaliplatin infusion: 1 x daily
3153711|NCT01523574|Experimental|Vitamin e|Five days before chemotherapy:1 x daily Used until one week after third oxaliplatin infusion: 1 x daily
3153712|NCT01523561|No Intervention|usual care|The participants in the no intervention group were informed that they should continue living as usual
3153713|NCT01523561|Experimental|dance intervention|"The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged."
3153714|NCT01523548|Experimental|Carbon Monoxide|Inhaled Carbon Monoxide therapy administered over 16 weeks
3153715|NCT01523535|Placebo Comparator|normal sleep|Subjects have 8 hours of sleep opportunity per night
3153716|NCT01523535|Experimental|cycles of sleep restriction|subjects are exposed to bouts of reduced sleep duration. The sleep loss is the intervention (experimental challenge).
3153717|NCT01523522|Active Comparator|myoblast injection|autologous myoblast
3153718|NCT01523522|Placebo Comparator|saline solution injection|saline solution injection in anal sphincter
3153719|NCT01523509|Experimental|Contrast|All subjects will be in one group who will have a control radiograph of teeth before applying the Sodium Iodide contrast agent topically between the teeth (the intervention) when another radiograph will be taken to test for the presence of contrast in a cavity.
3153720|NCT01523496|Active Comparator|HIV + Young Adults|All will be HIV+ and receiving randomized dose of vitamin D control dose (low dose) or supplementation dose (vitamin D medium dose or vitamin D high dose)
3153721|NCT01523496|Active Comparator|HIV - Controls|HIV negative controls will be receiving randomized Vitamin D doses: control vitamin D dose (low dose) or vitamin D supplementation dose (vitamin D medium dose or vitamin D high dose)
3153722|NCT01523483|Experimental|Progesterone|Patients in this arm will receive two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
3153723|NCT01523483|Placebo Comparator|placebo|Patients will receive two placebo capsules placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
3153724|NCT01523470|Active Comparator|stepwise withdrawal of NIV|On the day of decision of withdrawal (day0), the duration of non-invasive ventilator (NIV) will be decreased to 16 hours. On the following day (day1), the duration of NIV will be further decreased to 12 hours. The duration will be further decreased to 8 hours at night on the following day (day 2), and it will be stopped on the day after (day 3). Vital signs and blood gases will be monitored for a total of 5 days after withdrawal is planned (day 0 to day 5).
3153725|NCT01523470|Experimental|immediate withdrawal of NIV|The patient will have immediate withdrawal of non-invasive ventilator (NIV). Vital signs and blood gases will be monitored for 2 more days after NIV is stopped (day 0-2).
3153773|NCT01523106|Active Comparator|Carnitine|Patients will take 4grams of L-carnitine (2 grams twice daily) for 3 months
3153938|NCT01521949|Experimental|Acai Juice|2 ounces of Acai Juice Product by mouth twice daily.
3153726|NCT01523457|Experimental|MPC modified FOLFIRINOX|Patients with metastatic pancreatic cancer (MPC) were treated with modified FOLFIRINOX every 2 weeks as follows: oxaliplatin 85 mg m 2 infused over 120 min, immediately followed by folinic acid 400 mg m 2 infused over 120 min with the addition, after 30 min, of irinotecan 135 mg m 2 infused over 90 min, followed by 5FU 300 mg m 2 IV bolus, followed by 2400 mg m 2 continuous infusion for 46 h (25% reduction in bolus 5FU and irinotecan doses). All patients received pegylated filgrastim with each cycle on day 3 or 4 in the absence of severe leukocytosis. All patients routinely received palonosetron, aprepitant and dexamethasone for emesis prophylaxis.
3153727|NCT01523457|Experimental|LAPC modified FOLFIRINOX|Patients with locally advanced pancreatic cancer (LAPC) were treated with modified FOLFIRINOX every 2 weeks as follows: oxaliplatin 85 mg m 2 infused over 120 min, immediately followed by folinic acid 400 mg m 2 infused over 120 min with the addition, after 30 min, of irinotecan 135 mg m 2 infused over 90 min, followed by 5FU 300 mg m 2 IV bolus, followed by 2400 mg m 2 continuous infusion for 46 h (25% reduction in bolus 5FU and irinotecan doses). All patients received pegylated filgrastim with each cycle on day 3 or 4 in the absence of severe leukocytosis. All patients routinely received palonosetron, aprepitant and dexamethasone for emesis prophylaxis.
3153728|NCT01523444|No Intervention|Treatment as Usual|
3153729|NCT01523444|Active Comparator|computer Screening & Brief Advice|All participants receiving care at the site assigned to the computer-facilitated screening and brief advice (cSBA) condition will receive the cSBA intervention as part of their care at that clinic.
3153730|NCT01523444|Experimental|computer Screening & Brief Advice Plus|All participants receiving care at the site assigned to the cSBA+ condition will receive the cSBA intervention elements plus the delivery of a brief, two-session motivational enhancement therapy (MET) intervention to be delivered a Behavioral Health Counselor (BHC) at the clinic immediately after meeting with the primary care provider as part of care at that clinic.
3153731|NCT01523431|Active Comparator|Standard FOLFIRI for wild/hetero UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 180 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
3153732|NCT01523431|Experimental|Reduced Dose of CPT-11 for homo UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 90 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
3153733|NCT01523431|Active Comparator|Standard FOLFIRI for homo UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 180 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
3153734|NCT01523418||Group 1|
3153735|NCT01523405||1|
3153736|NCT01523392|Experimental|Ticagrelor|
3153737|NCT01523392|Active Comparator|Clopidogrel|
3153738|NCT01523366|Experimental|Ticagrelor|
3153739|NCT01523366|Active Comparator|Clopidogrel|
3153740|NCT01523353|Active Comparator|Exercise Intervention|4 week personalised exercise program on a static bicycle.
3153741|NCT01523353|No Intervention|Control Arm|Patients having standard preoperative preparation and advice.
3153742|NCT01523340||Erlotinib treatment|
3153743|NCT01523327||A|40 pregnant Women with hypertension who have uric acid level more than 6 mg per dL.
3153744|NCT01523327||B|40 pregnant women with hypertension who have uric acid level less than 6 mg per dl.
3153745|NCT01523314|Experimental|dexamethasone - Cyclodextrin|
3153746|NCT01523314|Active Comparator|Avastin/Laser|
3153747|NCT01523301|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
3153748|NCT01523301|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
3153749|NCT01523288||Prader-Willi patients|
3153750|NCT01523288||Control group|Control group for ultrasound scan
3153751|NCT01523275|Experimental|Mitomycin-C|Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial incisions and balloon dilation, as well as topical application of MMC in the radial incisions.
3153752|NCT01523275|Placebo Comparator|Saline|Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial incisions and balloon dilation, as well as topical application of isotonic saline in the radial incisions.
3153753|NCT01523262|Active Comparator|Preconditioning and normal treatment|
3153754|NCT01523262|Placebo Comparator|normal treatment|Standard treatment
3153755|NCT01523249||Scanned and palpated|Healthy, pregnant, term women delivering at BC Women's Hospital and expecting to have neuraxial anesthesia.
3153756|NCT01523236|Experimental|Investigational Test Product|Mometasone furoate anhydrous 50 mcg/actuation Nasal Spray (Teva)
3153757|NCT01523236|Active Comparator|Reference Listed Drug|Nasonex® (mometasone furoate monohydrate) 50 mcg/actuation Nasal Spray (Schering)
3153758|NCT01523236|Placebo Comparator|Placebo|Saline Placebo Nasal Spray
3153759|NCT01523223|Experimental|Treatment (DLI)|Patients undergo CD8+ memory T-cell infusion over 10-20 minutes.
3153760|NCT01523210||upper limb spasticity|patients suffering from upper limb spasticity and are treated with botulinum toxin
3153761|NCT01523197|Other|ventilator|The comparison of the curative effect on OS between BiPAP and auto-trilevel ventilations
3153762|NCT01523184|Placebo Comparator|Placebo Capsule|Placebo Capsules
3153763|NCT01523184|Active Comparator|YKP10811 Drug Product Capsule, 10 mg|
3153764|NCT01523184|Active Comparator|YKP10811 Drug Product Capsule, 20 mg|
3153765|NCT01523184|Active Comparator|YKP10811 Drug Product Capsule, 30 mg|
3153766|NCT01523171|Experimental|SAR302503 400 mg|once daily in consecutive 28-day cycles, flexible dosing regimen (the starting dose is 400mg/day), orally, empty stomach, approximately same time each day
3153767|NCT01523158|Other|Immunotherapy|Open label study of changes to cellular responses following immunotherapy
3153768|NCT01523145|Experimental|Intervention|
3153769|NCT01523145|Experimental|Control gruop|
3153770|NCT01523132||Breast cancer patients|Female breast cancer patients without metastasis and locally advanced disease
3153771|NCT01523119|Active Comparator|Zofran ODT|Zofran ODT (Ondansetron) Orally Disintegrating Tablets 8mg Manufactured By Cardinal Health, Blagrove, Swindon, Wiltshire, UK SN58RU
3153772|NCT01523119|Experimental|Ondansetron Orally Disintegrating Tablets|Ondansetron Orally Disintegrating Tablets 8 mg Manufactured By Ohm Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals, USA)
3153774|NCT01523106|Placebo Comparator|Placebo|Patients will take placebo for 3 months. Placebo is manufactured by the same company as the L-carnitine and will have a similar appearance.
3153775|NCT01523093|Active Comparator|Zofran ODT|Zofran ODT (Ondansetron) orally disintegrating tablets 8mg Manufactured By Cardinal Health, Blagrove, Swindon, Wiltshire, UK SN58RU
3153776|NCT01523093|Experimental|Ondansetron Orally Disintegrating Tablets|Ondansetron 8 mg Orally Disintegrating Tablets Manufactured By OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc, USA)
3153777|NCT01523080|Active Comparator|Tylenol® 650 mg|Tylenol® 650 mg of McNeil Consumer and Specialty Pharmaceuticals, Division of McNeil PPC, INC. Fort Washington, PA 19034 USA.
3153778|NCT01523080|Experimental|Acetaminophen extended release Gel tabs 650 mg|Acetaminophen extended release Gel tabs 650 mg of OHM Laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
3153779|NCT01523067|Active Comparator|Vasomera (PB1046)|
3153780|NCT01523067|Placebo Comparator|0.9% Sodium Chloride|
3153781|NCT01523054|Experimental|Metoprolol- Toprol XL|Metoprolol extended release (CR/XL) tablet 200 mg once daily
3153782|NCT01523054|Active Comparator|Metoprolol- Lopressor|Metoprolol immediate release (IR) tablet
3153783|NCT01523041|Experimental|BIAsp 70 clinical trial formulation|
3153784|NCT01523041|Experimental|BIAsp 70 final formulation|
3153785|NCT01523041|Experimental|BIAsp 50 final formulation|
3153786|NCT01523028|Experimental|Coffee, bread and honey|200 mL coffee + 2 bread rolls + honey
3153787|NCT01523028|Experimental|Coffee, bread and peanut butter|200 mL coffee + 1 bread roll + peanut butter
3153788|NCT01523028|Experimental|200 mL black coffee|
3153789|NCT01523015|Experimental|Combined therapy|The combined modality therapy will be consisted of preoperative chemoradiotherapy (Docetaxel, Oxaliplatin, 5-Fluorouracil, 45Gy) for type I i II cancer or preoperative chemotherapy (Docetaxel, Oxaliplatin, 5-Fluorouracil) for type III cancer and followed by surgery.
3153790|NCT01523015|Active Comparator|Surgery|The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
3153791|NCT01523002|Active Comparator|Arm A: Metoprolol DDI and Pyramax 90-day re-dosing|Subjects will take 1 day of metoprolol followed by a 7 day wash out period; then 2 days of Pyramax followed by 1 day of Pyramax + metoprolol and then a 87 day follow-up period. Subjects will then receive Pyramax once daily for three days followed by a 40 day follow-up period and a study completion evaluation.
3153792|NCT01523002|Active Comparator|Arm B: Pyramax 60-day re-dosing|Subjects will take Pyramax once daily for 3 days, followed by a 57 day follow-up period. Subjects will then take Pyramax once daily for 3 days followed by a 40 day follow-up period.
3153793|NCT01522989|Experimental|PD-0332991, 5-FU and oxaliplatin|PD-0332991 with 5-FU and oxaliplatin
3153794|NCT01522976|Experimental|Arm I (azacitidine and lenalidomide)|Patients receive azacitidine SC or IV on days 1-7 or days 1-5 and 8-9, and lenalidomide PO QD on days 1-21. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
3153795|NCT01522976|Experimental|Arm II (azacitidine)|Patients receive azacitidine as in Arm I. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
3153796|NCT01522976|Experimental|Arm III (azacitidine and vorinostat)|Patients receive azacitidine as in Arm I and vorinostat PO BID on days 3-9. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
3153797|NCT01522963|Experimental|Nicotine Lozenge Immediately Prior to Stress task|Subjects will receive the nicotine lozenge immediately prior to the stress task at one laboratory session and after the stress task at the other laboratory session
3153798|NCT01522963|Experimental|Nicotine lozenge 10 Minutes prior to Stress task|Subjects will receive the nicotine lozenge after the stress task during one laboratory session and immediately prior to the stress task at the other laboratory session
3153799|NCT01522963|Experimental|Nicotine lozenge 20 minutes prior to Stress task|Subjects will receive the nicotine lozenge after the stress task during one laboratory session and 10 minutes prior to the stress task at the other laboratory session
3153800|NCT01522963|Experimental|Nicotine Lozenge 30 minutes prior to stress taks|Subjects will receive the nicotine lozenge 10 minutes prior to the stress task during one laboratory session and after the stress task at the other laboratory session
3153801|NCT01522950|Active Comparator|Nebivolol|5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
3153802|NCT01522950|Active Comparator|Atenolol|25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
3153803|NCT01522950|Placebo Comparator|Placebo|"Continue for 1 month; dose titration to high dose placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur."
3153804|NCT01522937|Experimental|Liver cancer patients|The aim of this study is to determine the safety and effectiveness of individualized Stereotactic Body Radiation Therapy (SBRT) in patients who either (1) have had previous liver treatments, and/or (2) have primary hepatocellular carcinoma (HCC).
3153805|NCT01522924|Experimental|Counseling practice sessions|Dental students will be administered the first questionnaire before receiving a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients, and debriefing session.
3153806|NCT01522924|No Intervention|Lecture only|Students will receive the first questionnaire before the lecture and the second questionnaire after the lecture
3153807|NCT01522911|Other|atrial and brain natriuretic peptide|Impact on atrial an brain natriuretic peptide secretion after percutaneous left atrial appendage closure
3153808|NCT01522898|Active Comparator|Medical Rate Control|Medical Rate Control aimed at ventricular rate target of 90 beats per minute. Specific medical therapy to be determined for each patient by individual clinician.
3153809|NCT01522898|Experimental|AV nodal ablation|AV node ablation performed by percutaneous catheter ablation, with endpoint of complete heart block.
3153810|NCT01522885|Active Comparator|KatGuide|Chest tube insertion is performed by using the KatGuide
3153811|NCT01522885|Active Comparator|Conventional group|Chest tubes are inserted by using conventional method (forceps) for large bore chest tube insertion.
3153812|NCT01522872|Experimental|Monotherapy TH-302 Dose Escalation|
3153813|NCT01522872|Experimental|TH-302 and Dexamethasone Dose Expansion|
3153814|NCT01522872|Experimental|TH-302 Dose Escalation and Dexamethasone with Bortezomib|
3153815|NCT01522872|Experimental|TH-302 Dose Escalation and Dexamethasone with Pomalidomide|
3153816|NCT01522859|No Intervention|standard care|A standardised home based programme of specialist respiratory assessment and monitoring provided by the local Community Respiratory Team (CRT) and General Practitioner (GP) for a period of six months.
3153817|NCT01522859|Experimental|Telehealth monitoring|Daily monitoring of patient's health status using a small telecommunications device.
3153818|NCT01522846||Heparin|
3153819|NCT01522833||Cohort A|EGFR Wild Type patients
3153820|NCT01522833||Cohort B|EGFR mutation patients
3153821|NCT01522820|Experimental|Cohort 1a (vaccine therapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 protein vaccine intranodally on days 1, 29, 57, and 113.
3153822|NCT01522820|Experimental|Cohort 1b (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-14, 29-42, and 57-70.
3153823|NCT01522820|Experimental|Cohort 1c (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 vaccine as in Cohort 1a and sirolimus PO or PEG on days 15-28, 43-56, and 71-84.
3153824|NCT01522820|Experimental|Cohort 1d (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-84.
3153825|NCT01522820|Experimental|Cohort 2 (vaccine therapy with or without immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in the Cohort (1a-1d) that is determined to be safe and produces optimal immunological effects and sirolimus PO on days 1-14 as in Cohort 1b dose.
3153826|NCT01522807|Experimental|100 mg PF-05190457|Three fasted treatments and fed with the short-duration osmotic capsule
3153827|NCT01522807|Experimental|100 mg PF - 05190457|Three fasted treatments and fed with the long-duration osmotic capsule
3153828|NCT01522794|Experimental|NOX-H94|Single dose of NOX-H94
3153829|NCT01522794|Placebo Comparator|Placebo|Single dose of placebo control
3153830|NCT01522768|Experimental|Afatinib and Paclitaxel|This is a multi-institution, open-label, non-randomized, Phase II evaluation of oral afatinib daily and intravenous paclitaxel (weekly, 3 weeks on, 1 week off) in patients with trastuzumab refractory HER2-positive metastatic or recurrent esophagogastric adenocarcinoma. An initial biopsy prior to the start of therapy is required for the correlative studies evaluating the biologic effects of afatinib. It will be obtained for all patients whose tumors are feasible to biopsy. At the site investigator's discretion, a second biopsy will also be obtained. At the discretion of the MSK Principal Investigator, select participants who show response on this study and then progress may be asked to have an optional third biopsy.
3153831|NCT01522755||Patients implanted with the CapsureFix MRI pacing lead|Patients implanted with the CapsureFix MRI pacing lead model 5086
3153832|NCT01522742||Healthy control subjects|Healthy control subjects matched to psoriasis patients on traditional cardiovascular risk factors will be studied at baseline.
3153833|NCT01522742||Psoriasis patients starting etanercept|Patients with moderate to severe psoriasis with or without arthritis who are about to be started on etanercept (enbrel) by their treating clinicians will be studied at baseline and 3 months after etanercept therapy.
3153834|NCT01522729|Experimental|Fentanyl|
3153835|NCT01522729|Experimental|Placebo|
3153836|NCT01522716|Experimental|Mesenchymal stromal cell treatment|
3153837|NCT01522703|Experimental|Broccoli Sprouts|Broccoli Sprout sandwich/wrap will be eaten daily for 3 consecutive days
3153838|NCT01522703|Placebo Comparator|Alfalfa Sprouts|Alfalfa Sprouts will be eaten daily in a sandwich form for 3 consecutive days
3153839|NCT01522677|Experimental|PDT|Participants receive neoadjuvant 5-ALA and PDT.
3153840|NCT01522664|Experimental|Single group|
3153841|NCT01522651|Placebo Comparator|Placebo|Ranolazine placebo plus dronedarone placebo for 12 weeks
3153842|NCT01522651|Experimental|Ranolazine|Ranolazine plus dronedarone placebo for 12 weeks
3153843|NCT01522651|Experimental|Dronedarone low dose 1|Ranolazine placebo plus dronedarone low dose 1 for 12 weeks
3153844|NCT01522651|Experimental|Ranolazine + dronedarone low dose 1|Ranolazine plus dronedarone low dose 1 for 12 weeks
3153845|NCT01522651|Experimental|Ranolazine + dronedarone low dose 2|Ranolazine plus dronedarone low dose 2 for 12 weeks
3153846|NCT01522638||ADOA|This group includes subjects diagnosed with autosomal dominant optic atrophy
3153847|NCT01522638||Healthy subjects|
3153848|NCT01522625|Experimental|TDF|tenofovir disoproxil fumarate (TDF) 300mg
3153849|NCT01522625|Placebo Comparator|Placebo|
3153850|NCT01522612|Experimental|5-fluorouracil/leucovorin plus cetuximab|
3153851|NCT01522612|Active Comparator|5-fluorouracil/leucovorin alone|
3153852|NCT01522599|Active Comparator|ARDS-Net strategy (Control)|
3153853|NCT01522599|Experimental|ECCO2-R with 4 mL/Kg Vt (Treatment)|
3153854|NCT01522586|Experimental|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
3153855|NCT01522586|Placebo Comparator|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
3153856|NCT01522573||EUS guided ERCP procedure group|Subjects who will undergo Endoscopic Ultrasound (EUS) guided Endoscopic retrograde cholangiopancreatography (ERCP) procedures for their pancreatico-biliary conditions.
3153857|NCT01522560|Placebo Comparator|Control Group|Residents will be randomly assigned to a feedback group or to the control group. Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a MSF evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation. Only the group assigned to feedback is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the MSF.
3153897|NCT01522326|Active Comparator|Ibuprofen|150 subjects with acute mountain sickness will be randomly assigned to take ibuprofen.
3153858|NCT01522560|Active Comparator|Feedback group|Residents will be randomly assigned to a feedback group or to the control group. Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a MSF evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation. Only the group assigned to feedback is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the MSF.
3153859|NCT01522547|Experimental|Cohort 1: 0.5 mg pomalidomide|0.5 mg pomalidomide orally daily for 84 days
3153860|NCT01522547|Experimental|Cohort 2: 1.0 mg pomalidomide|1.0 mg pomalidomide orally daily for 84 days
3153861|NCT01522547|Experimental|Cohort 3: 2.0 mg pomalidomide|2.0 mg pomalidomide orally daily for 84 days
3153862|NCT01522547|Experimental|Cohort 4: 3.0 mg pomalidomide|3.0 mg pomalidomide orally daily for 84 days
3153863|NCT01522547|Experimental|Cohort 5: 4.0 mg pomalidomide|4.0 mg pomalidomide orally daily for 84 days
3153864|NCT01522534|Experimental|Blind block with mepivacaine|Blind block with mepivacaine and intravenous morphine
3153865|NCT01522534|Active Comparator|Morphine|Intravenous Morphine and placebo blind block
3153866|NCT01522521|Experimental|1.|
3153867|NCT01522521|Placebo Comparator|2.|
3153868|NCT01522508||propofol/remifentanil|patients receive standardized propofol and changing remifentanil concentrations
3153869|NCT01522508||sevoflurane/remifentanil|patients receive standardized sevoflurane and changing remifentanil concentrations
3153870|NCT01522495|Experimental|SPY Imaging|SPY Imaging Prior to Amputation or Debridements (50 participants)
3153871|NCT01522495|No Intervention|No SPY Imaging|Amputation or Debridements as Standard of Care (50 participants)
3153872|NCT01522495|Experimental|Validation Against Angiogram|"Patients who are scheduled to undergo an angiogram will also receive ICG angiography (SPY). This will occur at specific time points: 1.) before the angiogram/intervention is performed 2.) immediately after the angiogram/intervention is performed 3.) 5-7 days after angiogram/intervention 4.) 21-30 days after angiogram/intervention.~(30 participants)"
3153873|NCT01522495|Experimental|Establishing Normal Values|To establish baseline lower extremity perfusion in non-PVD patients. Patients requiring an angiogram for other vascular processes unrelated to the lower extremity will be recruited into this study. ICG angiography (SPY) of the lower extremity will be performed at the time of the angiogram. (30 Participants)
3153874|NCT01522482|Experimental|High saturated fat meal|
3153875|NCT01522482|Experimental|Saturated fatty acid and fish oils meal|Equivalent to two portions of oily fish
3153876|NCT01522482|Active Comparator|High unsaturated fat meal|Provided a fatty acid profile representative of a typical UK diet
3153877|NCT01522469|Experimental|Crenolanib Besylate|
3153878|NCT01522456|Active Comparator|Epiduo Gel|Adapalene 0.1% and benzoyl peroxide 2.5% gel
3153879|NCT01522456|Active Comparator|Retin-A Micro Microsphere 0.1%|Tretinoin gel, 0.1%
3153880|NCT01522443|Experimental|Cabozantinib|"Subjects randomized to the cabozantinib arm will also receive placebo mitoxantrone injections (color-matched with methylene blue) and placebo prednisone capsules.~There will be a maximum of 10 infusions for mitoxantrone placebo."
3153881|NCT01522443|Active Comparator|Mitoxantrone/prednisone|"Subjects randomized to the mitoxantrone + prednisone arm will also receive placebo cabozantinib tablets.~There will be a maximum of 10 infusions for mitoxantrone."
3153882|NCT01522430|Experimental|Renal angiography followed by renal sympathetic denervation|Catheter based therapy for renal denervation using the Simplicity (TM) catheter (Ardian/Medtronic)
3153883|NCT01522430|Sham Comparator|Renal angiography alone|Renal selective angiography using standardized method: Local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
3153884|NCT01522417|Experimental|Short Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.~Patients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
3153885|NCT01522417|Active Comparator|Eptifibatide (Integrilin)|"Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.~Patients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
3153886|NCT01522417|Experimental|Long Tirofiban (Aggrastat)|"(Enrolment Completed) Tirofiban (Aggrastat) will be dosed as a 25 ug/kg i.v. bolus followed by a 0.15 ug/kg/min i.v. infusion for 12 to 18 hours post PCI.~Patients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50U/kg and repeat dosing per protocol guidelines)."
3153887|NCT01522404|Experimental|Atomoxetine|Active treatment. Subjects in this arm will receive atomoxetine, starting with 10 mg po daily and increasing weekly by increments to a maximum of 100 mg po daily or the maximum tolerated dose
3153888|NCT01522404|Placebo Comparator|Inactive compound|Subjects in this arm will receive a matching placebo that have inactive compound
3153889|NCT01522391|Placebo Comparator|Placebo for DPK-060 ointment|
3153890|NCT01522391|Experimental|DPK-060 1% ointment|
3153891|NCT01522378|Experimental|Biv-ICD|Subjects will be imaged with 123 iodine metaiodobenzylguanidine.
3153892|NCT01522365|Active Comparator|Abutment-supported XiVE CAD/CAM bridge|After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed on an abutment.
3153893|NCT01522365|Active Comparator|Implant-supported XiVE CAD/CAM bridge|After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed directly on an implant.
3153894|NCT01522352|Experimental|pericardial aortic valves|Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
3153895|NCT01522339|Experimental|Safety of a Customized NICU MRI System|Device: GE OPTIMA MR430s with HDX/GE Electronics
3153896|NCT01522326|Experimental|Metoclopramide|150 subjects with acute mountain sickness will be randomly assigned to take metoclopramide.
3153898|NCT01522313||Patients|Data of patients anesthetized in the years 2006 to 2012 (Hospital stay: January 2006 - June 2012) will be analysed in the study.
3153899|NCT01522287|Active Comparator|BT STEPS alone|"Subjects assigned to BT STEPS without coaching will receive computer assisted Cognitive Behavior Therapy. They will receive a welcome and orientation call from the project manager and up to three automated reminder e-mails if there is no activity in the BT Steps website for 5 days. E-mails will describe most recent step the participant used and what to expect in upcoming steps. The focus of reminder messages is on the patient‟s progress through BT STEPS."
3153900|NCT01522287|Active Comparator|BT Steps with non-therapist coaching|Subjects randomized to BT STEPS with coaching will receive computer assisted Cognitive Behavior Therapy plus regularly scheduled weekly coaching, encouragement and support via phone. Calls will focus on user's progress in BT STEPS, troubleshoot problems the participant is having with the program, and set progress goals for the next coaching session. Coaches will be supervised by the CBT therapist, and may consult with the CBT clinician as needed.
3153901|NCT01522287|Active Comparator|BT STEPS with therapist coaching|Subjects randomized to BT STEPS with therapist coaching will receive computer-assisted Cognitive Behavior Therapy plus regularly scheduled weekly coaching and support from a CBT therapist via phone. Calls will focus on user's progress in BT STEPS, troubleshoot problems the participant is having with the program, and set progress goals for the next coaching session.
3153902|NCT01522274|Active Comparator|Moderate intensity exercise|Brisk walk on treadmill for 56 minutes 3x per week.
3153903|NCT01522274|Active Comparator|Health education|Attend health education sessions 3x per week.
3153904|NCT01522261|Active Comparator|Mechanical Bowel Prep|Patients randomized to complete a Mechanical Bowel Prep. (complete bowel cleansing) and fleet enemas prior to surgery.
3153905|NCT01522261|Active Comparator|No Mechanical Bowel Prep.|Patients randomized to complete two fleets enemas only prior to surgery.
3153906|NCT01522248|Active Comparator|Cohort 1|receives vaccine in morning. Blood drawn at 3, 7, 24, and 48 hours and 14 days after vaccination.
3153907|NCT01522248|Active Comparator|Cohort 2|receives vaccine in evening, Blood drawn 16, 40 hours and 14 days after vaccination.
3153908|NCT01522235|Active Comparator|IVIg group|Double blinded IVIg and single blinded IVIg
3153909|NCT01522235|Other|Placebo Group|Double blinded Placebo and single blinded IVIg
3153910|NCT01522222|No Intervention|Control|half of the study subjects will receive standard of care during their open heart surgery.
3153911|NCT01522222|Experimental|Treatment|half of the study subjects will receive the prescribed ventilatory support during open heart surgery.
3153912|NCT01522196|Active Comparator|Varespladib|48 hour continuous infusion delivered intravenously (IV)
3153913|NCT01522196|Placebo Comparator|Placebo|48 hour continuous infusion delivered intravenously (IV)
3153914|NCT01522157|Active Comparator|All test patients|All test patients are given low-fat, low-carbohydrate and mediterranean diet, in randomised order on different days.
3153915|NCT01522144|Experimental|Asthma clinical decision support|decision support compared to no decision support in a cluster-randomized trial by practise
3153916|NCT01522131|Other|Bioresorbable membrane will be used as the control|Bioresorbable membrane alone (control)
3153917|NCT01522131|Experimental|laser with bioresorabable membrane (test)|
3153918|NCT01522118|Experimental|HIFU|(high intensity focused ultrasound)
3153919|NCT01522105|Experimental|1|i.v. daptomycin given 24 hours after first ceftriaxone dose at age appropriate dosage
3153920|NCT01522092|Experimental|escitalopram|escitalipram tablets 5mg, 10 mg and 20 mg, once a day for 12 months
3153921|NCT01522079|Experimental|Air stacking|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position.
3153922|NCT01522066|Experimental|Perineural catheter|Local anesthetic will be delivered through an indwelling perineural catheter
3153923|NCT01522066|Active Comparator|Single-shot block|Local anesthetic will be delivered by the conventional, single-shot method.
3153924|NCT01522053|Experimental|Catheter-over-needle|Patients will receive a catheter placed by a catheter-over-needle method.
3153925|NCT01522053|Active Comparator|Catheter-through-needle|Patients will receive a catheter placed by the traditional catheter-though-needle method.
3153926|NCT01522040|Active Comparator|Magnesium|Half the enrolled subjects will be randomized to receive active drug, a magnesium infusion.
3153927|NCT01522040|Placebo Comparator|Control|Half the subjects will be randomized to receive a drip that does not have active drug (magnesium sulfate).
3153928|NCT01522027|Experimental|Nerve stimulator|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
3153929|NCT01522014|Active Comparator|Ceramic on Ceramic|Subjects received a ceramic on ceramic bearing total hip replacement.
3153930|NCT01522014|Active Comparator|Ceramic-on-Highly Crosslinked Polyethylene|
3153931|NCT01522001|No Intervention|Hospital-based|"First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~Dietary counseling with dietician~Exercise (1 hour, 2 timer pr week for 12 weeks)~Smoking cessation if smoker with educated smoking cessation instructor~Patient education and psychosocial support in 2 to 3 individual consultations with nurse specialized in cardiac rehabilitation~Examination by cardiologist 8-12 weeks after discharge."
3153932|NCT01522001|Active Comparator|Shared care Model|"First visit at cardiac ambulatory approximately 14 days after discharge includes examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~Dietary counseling with dietician~Exercise (1 hour, 2 timer pr week for 12 weeks)~Smoking cessation if smoker with educated smoking cessation instructor~Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse~Examination by the patient´s general practitioner 8-12 weeks after discharge."
3153933|NCT01521988|Active Comparator|Atrial flutter ablation|RF atrial flutter ablation
3153934|NCT01521988|Experimental|Atrial flutter ablation and pulmonary vein isolation|RF Atrial flutter ablation and pulmonary vein isolation using cryoablation
3153935|NCT01521975|Experimental|HBeAg Negative Hepatitis|HBeAg Negative Hepatitis patients.
3153936|NCT01521962|Experimental|SYR-322 (Alogliptin) QD|SYR-322 25 mg, orally.
3153937|NCT01521962|Placebo Comparator|Insulin|injection
3153939|NCT01521936|Experimental|Arm I (25(OH)-D3 levels 20-31.9 ng/mL [insufficient levels])|Patients receive a loading dose of cholecalciferol PO on day 1. Patients then receive lower-dose cholecalciferol PO beginning on day 8.
3153940|NCT01521936|Experimental|Arm II (25(OH)-D3 levels 20-31.9 ng/mL [insufficient levels])|Patients receive a loading dose of cholecalciferol PO on day 1. Patients then receive higher-dose cholecalciferol PO beginning on day 8.
3153941|NCT01521923|Experimental|CZP 200 mg Q2W + Methotrexate|
3153942|NCT01521923|Experimental|CZP 200 mg Q4W + Methotrexate|
3153943|NCT01521923|Placebo Comparator|Placebo + Methotrexate|
3153944|NCT01521910|Experimental|Low protein diet|
3153945|NCT01521910|Active Comparator|Normal protein diet|
3153946|NCT01521897||7-valent vaccine injection|Infants starting to receive Prevenar at the age of more than 2 and less than 7 months
3153947|NCT01521884||RA Patients treated with SC anti-TNF|
3153948|NCT01521871|Experimental|Tissue glue wound closure|Skin wound closure by tissue glue
3153949|NCT01521871|Active Comparator|Conventional suture + dressing|Skin wound closure by conventional suture + dressing
3153950|NCT01521845|Active Comparator|omega 3|receive omega 3 in addition to standard treatment
3153951|NCT01521845|No Intervention|control|This group is without omega 3 : just receives standard treatment
3153952|NCT01521832|Experimental|Dose Group A|
3153953|NCT01521832|Experimental|Dose Group B|
3153954|NCT01521832|Experimental|Dose Group C|
3153955|NCT01521832|Experimental|Dose Group D|
3153956|NCT01521832|Experimental|Dose Group E|
3153957|NCT01521832|Experimental|Dose Group F|
3153958|NCT01521832|Experimental|Dose Group H|
3153959|NCT01521832|Experimental|Dose Group I|
3153960|NCT01521832|Experimental|Dose Group J|
3153961|NCT01521832|Experimental|Dose Group K|
3153962|NCT01521832|Experimental|Dose Group L|
3153963|NCT01521819|Experimental|Iray plus Lucentis|open label arm in which all subjects receive a single 16 gy dose of radiation plus an injection of Lucentis.
3153964|NCT01521806|Experimental|Low dose|15 g of fiber per day will be added to snack foods
3153965|NCT01521806|Experimental|High dose|30 g of fiber per day will be added to snack foods
3153966|NCT01521806|Placebo Comparator|No fiber|Snack foods without fiber will be given
3153967|NCT01521780|Experimental|Imaging|Magnetic resonance imaging (MRI) of HCC tumor.
3153968|NCT01521780|Experimental|Pathology|Pathology samples from surgical resection of HCC tumor and adjacent liver.
3153969|NCT01521780|Experimental|Imaging/Pathology|MRI of HCC tumor, followed by pathology samples from surgical resection of HCC tumor and adjacent liver.
3153970|NCT01521767|Experimental|A|4 mg tolterodine extended release capsules, administered with water and under fasting condition.
3153971|NCT01521767|Experimental|B|4 mg microspheres in powder blend release rate 2 (MPB-RR2), administered without water and under fasting condition.
3153972|NCT01521767|Experimental|C|4 mg microspheres in powder blend release rate 1 (MPB-RR1), administered without water and under fasting condition.
3153973|NCT01521767|Experimental|D|4 mg MPB-RR1, administered without water and under fed condition.
3153974|NCT01521767|Experimental|E|4 mg MPB-RR1, administered with water and under fasting condition.
3153975|NCT01521754||Perspective|Prospective cohort: new patients who are initially implanted with a Medtronic neurostimulation system on or after a site's activation date. The classification is static and will not change in the case of a re-implant.
3153976|NCT01521754||Retrospective|Retrospective cohort: existing patients comprised the sub-group of patients who were implanted with a Medtronic neurostimulation system prior to a site's activation date. This cohort contains a part of retrospective data and a part of prospective data according to the enrolment date. The classification is static and will not change even when an existing patient will be subsequently re-implanted after the site's activation date.
3153977|NCT01521741||Breast Cancer|
3153978|NCT01521728|Active Comparator|Resistance Exercise|Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
3153979|NCT01521728|Active Comparator|Endurance Exercise|Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
3153980|NCT01521728|Active Comparator|Stretching/Range-of-Motion Exercise|"In ALS, stretching and range of motion are routinely recommended for the prevention of frozen shoulder syndrome and contractures resulting from weakness. The problem is compounded in ALS where upper motor neuron dysfunction may result in spasticity and incapacitating contractures with pain. Therefore, maintaining an aggressive program for stretching and range of motion exercise is widely accepted as a standard of care for ALS management."
3153981|NCT01521715|Experimental|Pazopanib|800 mg (2x400mg) pazopanib per day
3153982|NCT01521702|Experimental|Neoadjuvant chemotherapy|After initial staging laparoscopy, Neoadjuvant chemotherapy consists of four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours, modified from the Louvet protocol11).
3153983|NCT01521702|Active Comparator|surgery|surgery
3153984|NCT01521689|Experimental|Rituximab|Consolidation treatment with sub cutaneaous low doses of Rituximab
3153985|NCT01521676|Experimental|breast cancer|blood and tumor sample
3153986|NCT01521663|Experimental|IPX159|IPX159 90 mg daily at week 1 with titration to 180 mg daily at week 2 with possible titration to 270 mg daily at week 3.
3153987|NCT01521663|Placebo Comparator|Sugar Pill|IPX159 90 mg matching placebo daily at week 1 with titration to 180 mg matching placebo daily at week 2.
3153988|NCT01521650|Experimental|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria
3153989|NCT01521650|No Intervention|Control|No intervention. What has been the standard procedure so far
3153990|NCT01521637|Experimental|NMES|The 'NMES' arm will be treated with NMES.
3153991|NCT01521637|Sham Comparator|No NMES|The 'No NMES' arm of the experiment will be sham-treated with NMES. The device will be installed, but not used.
3154091|NCT01520987|Placebo Comparator|Caucasian Placebo|Placebo, PLC
3153992|NCT01521624|Active Comparator|Case|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
3153993|NCT01521624|No Intervention|Control|Subjects provided only advice for lifestyle modification with no drug intervention
3153994|NCT01521611|Experimental|Targeted radiotherapy|Patients receive therapy with an yttrium-90 labelled anti-CD66 following favourable dosimetry with the same antibody radiolabelled with indium-111.
3153995|NCT01521598|Experimental|SKL11197|This arm is the experimental drug (SKL11197) arm. Patients will be randomized to this arm.
3153996|NCT01521598|Placebo Comparator|Placebo|This arm is the placebo comparator arm. Patients will be randomized to this arm.
3153997|NCT01521585|Experimental|SEN0014196 50 mg oral tablet|
3153998|NCT01521585|Experimental|SEN0014196 200 mg oral tablet|
3153999|NCT01521585|Placebo Comparator|Placebo tablet|
3154000|NCT01521572|Experimental|Salbutamol|Short-acting bronchodilator for use in humans released by the Ministry of Health, widely used worldwide for the treatment of chronic obstructive pulmonary disease.
3154001|NCT01521559|Sham Comparator|Macular Laser Photocoagulation Treatment (Control)|Participants will receive macular laser treatment at Baseline and then according to laser re-treatment criteria up to week 24. Participants will receive treatment with Intravitreal Aflibercept Injection (IAI) starting at week 24 if they met rescue criteria. Treatment with IAI once initiated was 3 initial monthly doses followed by Q8 week dosing.
3154002|NCT01521559|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4|Participants will receive 2 milligrams (mg) Intravitreal Aflibercept Injection (IAI) every 4 weeks (2Q4) through week 24 followed by injections every 8 weeks (2Q8) through week 48. Participants in this group may receive laser rescue at week 36.
3154003|NCT01521546|Active Comparator|eplerenone|active study drug
3154004|NCT01521546|Placebo Comparator|sugar pill|placebo
3154005|NCT01521533|Experimental|NOX-A12|
3154006|NCT01521520||Clinical Type 1 Diabetes|This group will be subdivided into individuals with recent onset clinical type 1 diabetes (within 6 months of diagnosis), latent autoimmune diabetes of the adult, and longer standing type 1 diabetes.
3154007|NCT01521520||High Risk Pre-Type 1 Diabetes|High risk pre-type 1 diabetes is defined as first degree family relative with type 1 diabetes and at least one islet autoantibody marker (GAD, IAA, or IA-2).
3154008|NCT01521520||Low Risk Pre-Type 1 Diabetes|Low risk pre-type 1 diabetes is defined as first degree family relative with type 1 diabetes but no islet autoantibody markers (GAD, IAA, or IA-2).
3154009|NCT01521520||Normal Control|Normal control is based on history with no known history or family history of type 1 diabetes.
3154010|NCT01521507|Experimental|LipiFlow System|Treatment with LipiFlow System at randomization in Stage 1 of study
3154011|NCT01521507|Active Comparator|Warm Compress and Lid Hygiene|Control group receiving warm compress therapy and lid hygiene at randomization in Stage 1 of study and crossover LipiFlow System treatment in Stage 2 of study
3154012|NCT01521494|Experimental|PA21 750 mg/day|
3154013|NCT01521494|Experimental|PA21 1500 mg/day|
3154014|NCT01521494|Experimental|PA21 2250 mg/day|
3154015|NCT01521494|Experimental|PA21 3000 mg/day|
3154016|NCT01521494|Placebo Comparator|Placebo|
3154017|NCT01521481|Experimental|Triple inguinal nerve block|Ropivacaine 5 mg/ml
3154018|NCT01521481|Active Comparator|Unilateral subarachnoid anesthesia|Bupivacaine 10 mg/ml
3154019|NCT01521455|Experimental|HCP0910|Fluticasone /salmeterol 250/50 combination capsule
3154020|NCT01521455|Active Comparator|Seretide Diskus|Seretide 250 Diskus
3154021|NCT01521442|Experimental|Arm 1|12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
3154022|NCT01521442|Other|Arm 2|12-week delay before beginning Mindful Yoga Therapy treatment which will consist of 12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
3154023|NCT01521429||MPS I|Mucopolysaccharidosis I (Hurler, Scheie, Hurler-Scheie)
3154024|NCT01521429||MPS II|Mucopolysaccharidosis II (Hunter)
3154025|NCT01521429||MPS VI|Mucopolysaccharidosis VI (Maroteaux-Lamy)
3154026|NCT01521416||Cohort Group|
3154027|NCT01521403|Active Comparator|Metronidazole|Metronidazole 3x500 mg per day for 10 days
3154028|NCT01521403|Placebo Comparator|Placebo|Placebo 3x1 tablet per day for 10 days
3154029|NCT01521390|Other|Treatment Arm|Subjects receive one inhalation from each intervention
3154030|NCT01521377|Placebo Comparator|Placebo|Single inhalation from matching placebo dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin.
3154031|NCT01521377|Active Comparator|Moxifloxacin Positive|Single inhalation from matching placebo dry powder inhaler once daily on days 1-10. Single dose oral tablet moxifloxacin (400mg) on day 10.
3154032|NCT01521377|Experimental|GSK573719 Supra-therapeutic dose|Single inhalation from GSK573719 (500 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral moxifloxacin.
3154033|NCT01521377|Experimental|GSK573719/Vilanterol Therapeutic dose|Single inhalation from GSK573719/Vilanterol (125/25 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin on day 10.
3154034|NCT01521377|Experimental|GSK573719/Vilanterol Supra-therapeutic dose|Single inhalation from GSK573719/Vilanterol (500/100 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin on day 10.
3154035|NCT01521364|Other|0mg, 250mg, and 500mg claritromycin|"Patients receive 300mg linezolid twice a day during entire study. After one week, 250mg claritromycin once daily is added for a duration of two weeks.~After another two weeks, 250mg claritromycin is replaced by 500mg claritromycin once daily for another two weeks.~After this, there is a wash-out period of one week during which no claritromycine is administered."
3154036|NCT01521351||carotid thermal heterogeneity|Patients that have carotid thermal heterogeneity detected by MR
3154037|NCT01521351||no carotid thermal heterogeneity|Patients that DONT have carotid thermal heterogeneity detected by MR
3154038|NCT01521351||carotid artery disease|Patients with detected carotid artery disease by ultrasound
3154039|NCT01521351||no carotid artery disease|Patients with no carotid artery disease detected by ultrasound
3154040|NCT01521325|Experimental|Amatuximab infusion|Subjects will receive one infusion of radiolabeled amatuximab.
3154237|NCT01520012|Experimental|Sequence 4|
3154041|NCT01521312|Experimental|Saxagliptin|Saxagliptin 5 mg (tablet) at BREAKFEAST
3154042|NCT01521312|Placebo Comparator|placebo pill|at BREAKFEAST
3154043|NCT01521286||Group A|Subjects presenting with HZ episode.
3154044|NCT01521273|Experimental|high iron bean with native phytic acid concentration|
3154045|NCT01521273|Experimental|normal iron bean with native phytic acid concentration|
3154046|NCT01521273|Experimental|high iron bean partially dephytinized|
3154047|NCT01521273|Experimental|normal iron bean partially dephytinized|
3154048|NCT01521273|Experimental|high iron bean totally dephytinized|
3154049|NCT01521273|Experimental|normal iron bean totally dephytinized|
3154050|NCT01521260|Placebo Comparator|Placebo group|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
3154051|NCT01521260|Active Comparator|Chlorhexidine group|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
3154052|NCT01521247|No Intervention|Control group|Usual care.
3154053|NCT01521247|Other|Asthma Transition Program|Asthma Transition Program
3154054|NCT01521234|Experimental|Feedback group|For participants assigned to the feedback group, physiotherapists will receive a summary of patients' walking activity for the previous week as a tool to guide goal planning. Physiotherapists will use the information as a 'homework checker' to determine if patients are complying with an assigned walking program. In the case of non-compliance, the physiotherapist will discuss a coping strategy for better integrating walking activity into the patients' day. In the event that the patient is meeting their specific sub-goals for walking activity, the physiotherapist will re-evaluate these sub-goals and suggest more challenging goals.
3154055|NCT01521234|No Intervention|No-feedback group|For participants assigned to the control group, physiotherapists will not receive accelerometer-based feedback of daily walking activity. However, physiotherapists will still discuss the achievement of walking goals with their patients. This is usual care around goal planning.
3154056|NCT01521221|Experimental|Patients|Patients with autonomic failure.
3154057|NCT01521221|Experimental|Healthy subjects|Control group
3154058|NCT01521208|Active Comparator|LUCAS, Continuous chest compressions|Mechanical continuous chest compressions performed by LUCAS device (also during defibrillation)
3154059|NCT01521208|Active Comparator|Manual chest compressions|Manual chest compression is performed, chest compressions halted during defibrillation
3154060|NCT01521195|Experimental|Patients on veno-arterial (VA) ECMO|
3154061|NCT01521182|Active Comparator|1 = Tested product|
3154062|NCT01521182|Placebo Comparator|2 = Control product|
3154063|NCT01521169|Active Comparator|1 = Tested product dose 1|
3154064|NCT01521169|Active Comparator|2 = Tested product dose 2|
3154065|NCT01521169|Sham Comparator|3 = Control product|
3154066|NCT01521156|Active Comparator|1 = Control product|
3154067|NCT01521156|Experimental|2 = Tested product|
3154068|NCT01521143|Experimental|Part A - Cvac|Participants received intradermal injections of Cvac given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks. Each injection had an approximate concentration of 60 × 10^6 viable dendritic cells/mL.
3154069|NCT01521143|Placebo Comparator|Part A - Placebo|Participants received intradermal injections of placebo given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks.
3154070|NCT01521143|Experimental|Part B - Cvac|Participants received intradermal injections of Cvac given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks. Each injection had an approximate concentration of 60 × 10^6 viable dendritic cells/mL.
3154071|NCT01521143|No Intervention|Part B - Observational standard of care|Participants in this group did not receive any treatment during the study.
3154072|NCT01521130|No Intervention|Healthy Control|Healthy Control
3154073|NCT01521130|No Intervention|BECTS, no medication|BECTS, no medication
3154074|NCT01521130|Experimental|Levetiracetam Higher dose|Levetiracetam Higher dose
3154075|NCT01521117|Experimental|Donepezil, washout period, placebo|
3154076|NCT01521117|Experimental|Placebo, washout period, Donepezil|
3154077|NCT01521078|Experimental|Intervention|Provided access to the Check Your Drinking University version (CYDU).
3154078|NCT01521078|No Intervention|Control|No invention control group
3154079|NCT01521065|Experimental|16 Gy IRay|16 Gy IRay + PRN Lucentis®
3154080|NCT01521052|Experimental|elderly depressed patients|Twenty seven (27) patients aged 68 years or above, currently suffering from a major depressive episode, who did not respond to treatment with at least one antidepressant medications in the recommended dosage and duration, or could not tolerate at least two antidepressants.
3154081|NCT01521039||Allogeneic SCT recipients|Patients who are receiving allogeneic stem cell transplantation at the Ohio State University are eligible and will be consented for the study.
3154082|NCT01521026|Experimental|Cognitive Training|Cognitive training group
3154083|NCT01521026|No Intervention|Standard Pharmacotherapy|
3154084|NCT01521013|Active Comparator|Supported self-care|
3154085|NCT01521013|Active Comparator|Unsupported self-care|
3154086|NCT01521000|No Intervention|Observation|Observation arm will continue to be followed with serial L-Dex and water volume displacement methods.
3154087|NCT01521000|Other|Intervention-garment sleeve|If the L-Dex is outside the normal range, or has increased 10 units from baseline, the patient will then be randomized to wear a compression sleeve (20 to 30 mm of Hg) daily for 4 weeks or observation (no sleeve). After 4 weeks, L-Dex measurements and water volume displacement will be reassessed in the treatment group.
3154088|NCT01520987|Experimental|Caucasian 5 mg OPC|OPC, opicapone, BIA 9-1067
3154089|NCT01520987|Experimental|Caucasian 25 mg OPC|OPC, opicapone, BIA 9-1067
3154090|NCT01520987|Experimental|Caucasian 50 mg OPC|OPC, opicapone, BIA 9-1067
3154092|NCT01520987|Experimental|Japanese 5 mg OPC|OPC, opicapone, BIA 9-1067
3154093|NCT01520987|Experimental|Japanese 25 mg OPC|OPC, opicapone, BIA 9-1067
3154094|NCT01520987|Experimental|Japanese 50 mg OPC|OPC, opicapone, BIA 9-1067
3154095|NCT01520987|Placebo Comparator|Japanese Placebo|Placebo, PLC
3154096|NCT01520974|Active Comparator|Probiotic tablet|
3154097|NCT01520974|Placebo Comparator|Placebo tablet|Comparison tablet without the probiotic bacteria
3154098|NCT01520961||Hueter Anterior Approach|
3154099|NCT01520961||posterolateral approach|
3154100|NCT01520948|Experimental|Exercise-based behavioral therapy|Pelvic floor muscle exercise-based behavioral therapy
3154101|NCT01520948|Placebo Comparator|Behavioral control|Mirrored Star Drawing
3154102|NCT01520935||Cohort Group|
3154103|NCT01520922|Experimental|Ofatumumab plus bendamustine|In this single arm, Phase II study, each patient who is willing to participate and is found eligible according to the inclusion and exclusion criteria will enter the treatment phase. Eligible subjects will be allocated to receive the following study treatments depending upon their previous CLL treatment status: Subjects with Untreated CLL: Up to 6 monthly intravenous infusions of Ofatumumab (Cycle 1: 300 mg Day 1 and 1000 mg Day 8; subsequent Cycles: 1000 mg at Day 1 every 28 days) in combination with up to 6 Cycles of intravenous infusions of bendamustine (90 mg/m2, Days 1 and 2; every 28 Days). Subjects with Relapsed CLL: Up to 6 monthly intravenous infusions of Ofatumumab (Cycle 1: 300 mg Day 1 and 1000 mg Day 8; subsequent Cycles: 1000 mg at Day 1 every 28 days) in combination with up to 6 Cycles of intravenous infusions of bendamustine (70 mg/m2, Days 1 and 2; every 28 Days).
3154104|NCT01520909|Experimental|Eltrombopag plus standard of care|Part 1, double-blind treatment group
3154105|NCT01520909|Placebo Comparator|Placebo plus standard of care|Part 1, double-blind treatment group
3154106|NCT01520909|Experimental|Eltrombopag plus standard of care (Part 2 open-label)|Part 2, open-label
3154107|NCT01520896|Experimental|Part 1 - A|Single dose NKTR-118 25 mg on Day 1 only
3154108|NCT01520896|Active Comparator|Part 1 - B|Ketoconazole 400 mg once daily on Days 4 to 8
3154109|NCT01520896|Active Comparator|Part 1- C|Ketoconazole 400 mg plus NKTR-118 25 mg on Day 7
3154110|NCT01520883||DEcisional conflict|
3154111|NCT01520870|Experimental|PF-299804 (Dacomitinib)|Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end. Patients at first recurrence will be enrolled onto 1 of 2 cohorts that will be recruited and analysed independently. Cohort A will include patients who have EGFRvIII mutations. Cohort B will include patients who have EGFR gene amplification but no EGFRvIII mutations.
3154112|NCT01520857|Active Comparator|Spinal anesthesia|Transabdominal Preperitoneal repair of inguinal hernia. spinal anesthesia
3154113|NCT01520857|Active Comparator|General Anesthesia|Transabdominal Preperitoneal repair of inguinal hernia. general anesthesia
3154114|NCT01520844|Other|Cohort study|Blood sampling
3154115|NCT01520831|Experimental|BIAsp 30|
3154116|NCT01520831|Experimental|BIAsp 50|
3154117|NCT01520831|Experimental|BIAsp 70|
3154118|NCT01520831|Active Comparator|Insulin aspart|
3154119|NCT01520818|Experimental|BIAsp 50 or 70|
3154120|NCT01520818|Active Comparator|BHI 30|
3154121|NCT01520805|Experimental|CPI-613|CPI-613 will be intravenously infused over 2 hours, given twice weekly for 3 weeks followed by a week of rest.
3154122|NCT01520792|Experimental|Paracetamol|
3154123|NCT01520779||Patients with recurrence|Hepatocellular carcinoma patients with intra-hepatic or distant recurrence of hepatocellular carcinoma within 1 year after radiofrequency ablation
3154124|NCT01520779||Patients with no recurrence|Hepatocellular carcinoma with no intra-hepatic or distant recurrence of hepatocellular carcinoma within 1 year after radiofrequency ablation
3154125|NCT01520766|Experimental|glass fiber|
3154126|NCT01520766|Experimental|titanium|
3154127|NCT01520753|Experimental|BIAsp 70|
3154128|NCT01520753|Experimental|BIAsp 70 + BIAsp 50|
3154129|NCT01520740|Active Comparator|Collateral Ventilation Positive (CV+)|
3154130|NCT01520740|Active Comparator|Collateral Ventilation Negative (CV-)|
3154131|NCT01520727|Experimental|BIA 9-1067 10 mg|BIA 9-1067 (Opicapone, OPC) - 10 mg
3154132|NCT01520727|Experimental|BIA 9-1067 25 mg|BIA 9-1067 (Opicapone, OPC) - 25 mg
3154133|NCT01520727|Experimental|BIA 9-1067 50 mg|BIA 9-1067 (Opicapone, OPC) - 50 mg
3154134|NCT01520727|Experimental|BIA 9-1067 100 mg|BIA 9-1067 (Opicapone, OPC) - 100 mg
3154135|NCT01520727|Experimental|BIA 9-1067 200 mg|BIA 9-1067 (Opicapone, OPC) - 200 mg
3154136|NCT01520727|Experimental|BIA 9-1067 400 mg|BIA 9-1067 (Opicapone, OPC) - 400 mg
3154137|NCT01520727|Experimental|BIA 9-1067 800 mg|BIA 9-1067 (Opicapone, OPC) - 800 mg
3154138|NCT01520727|Experimental|BIA 9-1067 1200 mg|BIA 9-1067 (Opicapone, OPC) - 1200 mg
3154139|NCT01520727|Placebo Comparator|Placebo|Placebo (PLC): single-dose
3154140|NCT01520714|Experimental|Medtronic passive fixation LV lead|Medtronic 4195 Active Fixation LV lead and Medtronic passive fixation LV lead arms will both have same follow-up testing and schedule
3154141|NCT01520714|Experimental|Medtronic 4195 Active Fixation LV Lead|Medtronic 4195 Active Fixation LV lead and Medtronic passive fixation LV lead arms will both have same follow-up testing and schedule
3154142|NCT01520701|Active Comparator|Ialuset® application|Arm with application to the skin Ialuset ® cervical during radiotherapy
3154143|NCT01520701|Experimental|bandage skin Hydrosorb|Arm bandage skin hydrogel (Hydrotac®) on the skin cervical during radiotherapy
3154144|NCT01520688|Experimental|1 Treatment Sequence, FPQ|Period 2 Flovent Diskus Period 4 Pulmicort Flexhaler Period 6 QVAR
3154145|NCT01520688|Experimental|2 Treatment Sequence, FQP|Period 2 Flovent Diskus Period 4 QVAR Period 6 Pulmicort
3154146|NCT01520688|Experimental|3 Treatment Sequence, PFQ|Period 2 Pulmicort Period 4 Flovent Period 6 QVAR
3154147|NCT01520688|Experimental|4-Treatment Sequence, PQF|Period 2 Pulmicort Period 4 QVAR Period 6 Flovent
3154148|NCT01520688|Experimental|5 Treatment Sequence, QFP|Period 2 QVAR Period 4 Flovent Period 6 Pulmicort
3154149|NCT01520688|Experimental|6 Treatment Sequence, QPF|Period 2 QVAR Period 4 Pulmicort Period 6 Flovent
3154150|NCT01520675|Active Comparator|Surgery|Patients will be randomized to surgery
3154151|NCT01520675|Active Comparator|Endotherapy|Patients will be randomized to endoscopic therapy
3154152|NCT01520662|Experimental|Wellness Portal Intervention|Wellness Portal Intervention: patients have access to the portal in the course of the study.
3154153|NCT01520662|No Intervention|Wellness Portal Control|Control patients don't have access to the Wellness Portal in the course of the study.
3154154|NCT01520649|Experimental|NSI-189 Phosphate|There will be 3 ascending cohorts. The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
3154155|NCT01520649|Placebo Comparator|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
3154156|NCT01520636|Placebo Comparator|group 1: standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day.
3154157|NCT01520636|Experimental|group 2: experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
3154158|NCT01520623|Other|Allografted patients|Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
3154159|NCT01520610||CTT|Patients with cardiopathy of tako TSUBO.
3154160|NCT01520610||SCA|Patients with acute coronary syndrome but without Tako-TSUBO cardiomyopathy.
3154161|NCT01520610||Surgical stress|patients with stressful event (emergency postoperative patients) but without Tako-TSUBO cardiomyopathy.
3154162|NCT01520597||Case|Patient with culture-proven listeriosis
3154163|NCT01520597||Control|Patient above the age of 18 years with medical background and clinical features compatible with one of the 3 forms of systemic listeriosis: febrile pregnant women (temp > 38°C), febrile patient with co-morbidity for septicaemic listeriosis, and any febrile symptom leading to empiric amoxicillin prescription.
3154164|NCT01520584|Active Comparator|vitamale|
3154165|NCT01520584|Placebo Comparator|sham pill|
3154166|NCT01520571|Active Comparator|Non-Computer Assistance TKA|Non-Computer Assistance TKA
3154167|NCT01520571|Experimental|Computer Assistance TKA|Computer Assistance TKA
3154168|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 1|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the lowest of these three doses (dose 1) is 3×10^5 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
3154169|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 2|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the middle dose of these three doses (dose 2) is 1×10^6 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
3154170|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 3|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the highest dose of these three doses (dose 3) is 3×10^6 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
3154171|NCT01520545|Experimental|Gablofen 3 mg/mL (baclofen Injection)|3 mg/mL Gablofen (baclofen Injection)
3154172|NCT01520532|Other|Ablation|
3154173|NCT01520519|Experimental|Rituximab + PCI-32765|Rituximab (375 mg/m2) given intravenously (IV) on Day 1, Day 8, Day 15, and Day 22, then continued once every 4 weeks only on Days 1 during cycles 2 - 6. PCI-32765 started on Day 2 of cycle 1 at a dose of 420 mg (3 * 140-mg capsules) orally daily and will be continued daily.
3154174|NCT01520506|Experimental|Rapid Renal Denervation|
3154175|NCT01520493|Experimental|Exercise|All patients are subject to this Arm.
3154176|NCT01520480||Non-pathological fracture|Non pathological subtrochanteric femur fractures
3154177|NCT01520480||Pathological fracture|Pathological subtrochanteric fractures
3154178|NCT01520467|Experimental|Anastrozole|stratification according to the rare disease. Oral administration of Anastrozole (1mg/day) for 18 months
3154179|NCT01520467|Placebo Comparator|Placebo|stratification according to the rare disease. Oral administration of 1 placebo tablet /day for 18 months
3154180|NCT01520454|Placebo Comparator|Placebo|IV saline with heparin, oral water
3154181|NCT01520454|Experimental|High dose fat solution|Intralipid at high dose, with heparin and PO water
3154182|NCT01520454|Experimental|Low dose fat solution|Low dose IV Intralipid with heparin and PO water
3154183|NCT01520454|Experimental|Oral fat|Oral fat load with IV saline
3154184|NCT01520441|Experimental|BOTOX Injection|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
3154185|NCT01520428|Active Comparator|Motivational Interviewing, CBT and E-mail support|
3154186|NCT01520428|Active Comparator|E-Mail-support|
3154187|NCT01520415|Active Comparator|bupivacaine|
3154188|NCT01520415|Placebo Comparator|saline|
3154189|NCT01520402|Experimental|Warfarin|Healthy subjects age 18-74 with no medical indication for warfarin therapy, who are free of medications and co-morbid medical conditions with the potential to interfere with warfarin metabolism, and who are willing to follow a fixed vitamin K diet (men 120 micrograms/day, women 90 micrograms/day) are included.
3154190|NCT01520389|Experimental|MM-151 Dose Escalation|MM-151 Dose escalation frequency - once weekly, once every two weeks, once every three weeks
3154191|NCT01520389|Experimental|MM-151 Expansion in KRAS wild type colorectal cancer|MM-151 given weekly
3154192|NCT01520389|Experimental|MM-151 + irinotecan|MM-151 given weekly, irinotecan 180 mg/m2 given once every two weeks
3154193|NCT01520376|Active Comparator|Counselling|People receiving a psychiatric evaluation after screening (HADS test > 12 points) and revised at 1 and 6 months
3154194|NCT01520376|No Intervention|Usual care|People after screening (HADS test > 12 points) and send to their primary care physician
3154195|NCT01520363|Active Comparator|Study drug-dextromethorphan (DM)|MECP2 mutation positive subjects randomized to receive DM
3154196|NCT01520363|Placebo Comparator|Placebo group|MECP2 positive subjects randomized to the placebo compound
3154197|NCT01520350|Experimental|Mood stabilizer + Aripiprazole|
3154198|NCT01520350|Placebo Comparator|Mood stabilizer + placebo|
3154199|NCT01520337||patients undergoing outpatient colonoscopy|
3154200|NCT01520324||Patients with UC undergoing colonoscopy|
3154201|NCT01520311|Other|SVG + eSVS Mesh vs Control SVG|Either the Circumflex Coronary Artery or the Right Coronary Artery will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
3154202|NCT01520298|Placebo Comparator|Placebo|For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container.
3154203|NCT01520298|Active Comparator|Acetaminophen treatment|For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer.
3154204|NCT01520285|Active Comparator|Zanidip|tablets
3154205|NCT01520285|Placebo Comparator|Control Drug|Felodipine sustained-release tablet (5mg/tablet)
3154206|NCT01520220|Experimental|Part A: LY2784544 Dosing Regimen A|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days.
3154207|NCT01520220|Experimental|Part A: LY2784544 Dosing Regimen B|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days.
3154208|NCT01520220|Experimental|Part B: LY2784544 Dosing Regimen A|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days.
3154209|NCT01520220|Experimental|Part B: LY2784544 Dosing Regimen B|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days.
3154210|NCT01520207|Placebo Comparator|Placebo group: (0.9% normal saline)|0.9% saline will be administered (IV) during the hemodialysis session at 1.25mL/kg/hour (max 375mLs per session). Administration will be discontinued 30 minutes before the end of the hemodialysis session.
3154211|NCT01520207|Active Comparator|Intervention: intravenous mannitol (20%)|Mannitol will be administered (IV) during the hemodialysis session at a maximum rate of 0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session). Administration will be discontinued 30 minutes before the end of the hemodialysis session.
3154212|NCT01520194||psychosocial burden|122 women attending reproductive health clinics were interwied using HPV Impact Profile (HIP) and a socio-economic characteristics questionnaire.
3154213|NCT01520194||economic burden|Medical records of 102 patients diagnosed with genital warts were reviewed in the six BEMFAM's participating reproductive health clinics
3154214|NCT01520155||Systemic lupus erythematosus with renal affection|30 patients will be investigated suffering from a known systemic lupus erythematosus with renal affection
3154215|NCT01520155||Systemic lupus erythematosus without renal affection|30 patients will be investigated suffering from a known systemic lupus erythematosus without renal affection
3154216|NCT01520155||Non-autoimmune kidney disease|Patients with non-systemic, non-autoimmune kidney disease
3154217|NCT01520142|Experimental|Treatment|
3154218|NCT01520142|Placebo Comparator|Placebo|
3154219|NCT01520129|Other|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
3154220|NCT01520116|Experimental|Stage 1 - Arm 1 - Dose 1|
3154221|NCT01520116|Experimental|Stage 1 - Arm 2 - Dose 2|
3154222|NCT01520116|Experimental|Stage 1 - Arm 3 - Dose 3|
3154223|NCT01520116|Experimental|Stage 1 - Arm 4 - Dose 4|
3154224|NCT01520116|Placebo Comparator|Stage 1 - Arm 5 - Vehicle|
3154225|NCT01520116|Experimental|Stage 2 - Arm 1 - Dose A - to be selected based on Stage 1|
3154226|NCT01520116|Experimental|Stage 2 - Arm 2 - Dose B - to be selected based on Stage 1|
3154227|NCT01520116|Active Comparator|Stage 2 - Arm 3 -Timoptic 0.5% BID|
3154228|NCT01520103|Experimental|Vinorelbin and Everolimus|
3154229|NCT01520103|Other|standard therapy|Vinorelbin
3154230|NCT01520077|Other|Vytorin|"Subjects will receive Vytorin for 24 weeks. At 24 weeks if regrowth greater or equal than 20%, subjects will be randomized 1/1 to either stop or continue vytorin. Subjects will be follow for additional 24 weeks.~Subjects that at 24 weeks don't meet the 20% regrowth will be dropped out of the study."
3154231|NCT01520051|Experimental|Mepolizumab|
3154232|NCT01520051|Placebo Comparator|Saline|
3154233|NCT01520025|Experimental|18F-FDG PET imaging|Positron Emission Tomography nuclear stress scan following either pharmacologic or treadmill stress test with radiopharmaceutical injection at peak stress or within 1 hour following peak stress.
3154234|NCT01520012|Experimental|Sequence 1|
3154235|NCT01520012|Experimental|Sequence 2|
3154236|NCT01520012|Experimental|Sequence 3|
3154241|NCT01519986|Experimental|Low fat Meal|50,000 UI vitamin D3 with low fat meal
3154242|NCT01519986|Experimental|Medium fat meal|50,000 UI vitamin D3 with medium fat meal
3154243|NCT01519986|Experimental|High fat meal|50,000 UI vitamin D3 with high fat meal
3154244|NCT01519973|Other|Evaluation of technology in SPECT|Evaluation of the accuracy of SPECT with new technologies for attenuation correction (AC), scatter correction (SC) and resolution recovery (RR) for assessment of myocardial perfusion using Rb-82 PET as the gold standard.
3154245|NCT01519960|Experimental|A Pegasys|
3154246|NCT01519960|No Intervention|B Untreated Control|
3154247|NCT01519960|Experimental|C Fibrosis non-randomized|
3154248|NCT01519960|Experimental|Switch|
3154249|NCT01519947|Experimental|Dialysis >6000 feet|
3154250|NCT01519947|Active Comparator|Dialysis sea level|
3154251|NCT01519947|Experimental|Pre-dialysis >6000 feet|
3154252|NCT01519947|Active Comparator|Pre-dialysis sea level|
3154253|NCT01519934||Ulthera-treated subjects|All enrolled subjects will have received an Ulthera treatment prior to enrollment.
3154254|NCT01519921|Experimental|PEG-IFN alfa-2a (Treatment naïve)|Eligible treatment naïve participants received peginterferon alfa-2a (PEGASYS) 180 micrograms (mcg) subcutaneously (SC) once weekly for 48 weeks, followed by 24 weeks of treatment-free follow-up.
3154255|NCT01519921|Experimental|PEG-IFN alfa-2a (YMDD mutant)|Eligible tyrosine-methionine-aspartate-aspartate (YMDD) mutant participants received PEGASYS 180 mcg SC once weekly for 48 weeks, followed by 24 weeks of treatment-free follow- up. Participants received lamivudine concomitantly for the initial 12 weeks.
3154256|NCT01519895|No Intervention|Existing care|routine existing care
3154257|NCT01519895|Experimental|Telephone intervention|in addition to provide telephone intervention support
3154258|NCT01519882|Placebo Comparator|Placebo|Placebo Transdermal Patches
3154259|NCT01519882|Experimental|Rotigotine|Rotigotine Transdermal Patches
3154260|NCT01519869|Experimental|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
3154261|NCT01519856||tablet|
3154262|NCT01519843|Active Comparator|Real|Real tDCS
3154263|NCT01519843|Placebo Comparator|sham|Sham tDCS
3154264|NCT01519830|Experimental|Verum|Iron Carboxymaltose (Ferinject)
3154265|NCT01519830|Placebo Comparator|Placebo|0.9% NaCl solution
3154266|NCT01519817|Experimental|Yeast-Brachyury vaccine|Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.
3154267|NCT01519804|Experimental|MetMAb+paclitaxel+platinum|
3154268|NCT01519804|Active Comparator|Placebo+paclitaxel+platinum|
3154269|NCT01519791|Experimental|Certolizumab Pegol + Methotrexate|
3154270|NCT01519791|Placebo Comparator|Placebo + Methotrexate|
3154271|NCT01519778|Experimental|TR-701 FA|
3154272|NCT01519765|Experimental|Buccal misoprostol+placebo vaginal pill|
3154273|NCT01519765|Active Comparator|Vaginal Misoprostol+placebo buccal pill|
3154274|NCT01519752|Experimental|Oxiconazole Nitrate Cream 1%|
3154275|NCT01519752|Active Comparator|Oxiconazole Nitrate Cream 1% (Oxistat®)|
3154276|NCT01519752|Placebo Comparator|Placebo|
3154277|NCT01519739|Experimental|MediGuide Arm|
3154278|NCT01519726|Experimental|Morbidly obese patients|
3154279|NCT01519713|Experimental|Adults Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
3154280|NCT01519713|Experimental|Adolescents Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
3154281|NCT01519713|Experimental|Children Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
3154282|NCT01519700|Experimental|EP2006|Eligible patients will be teated with EP2006
3154283|NCT01519700|Active Comparator|Filgrastim|Eligible patients will be teated with Filgrastim
3154284|NCT01519687|Experimental|Levotofisopam|All patients will receive a single dose of 50 mg on Day 1, 50 mg three times a day (TID) on Days 2 through 6, and a single dose of 50 mg on Day 7. Each dose of study drug will be administered by authorized site personnel throughout the 7-day inpatient treatment period.
3154285|NCT01519674|Active Comparator|BIAsp 30 BID + sitagliptin + metformin|
3154286|NCT01519674|Active Comparator|BIAsp 30 BID + metformin|
3154287|NCT01519674|Active Comparator|BIAsp 30 OD + sitagliptin + metformin|
3154288|NCT01519661|Experimental|Tobramycin Inhalation Powder (TIP)|Eligible patients were assigned to four capsules of TIP at 28mg dosage strength, inhaled b.i.d. in the morning and in the evening via the T-326 inhaler, for 28 days (on treatment), followed by 28 days of no study treatment (off treatment). Each treatment therefore consisted of 112mg tobramycin (4 capsules of 28mg each) with the total daily dose = 224mg tobramycin (112mg b.i.d.). These 56 days represented 1 cycle of therapy.
3154289|NCT01519648||Acute leukemia patients|Patients with de novo or relapsed acute myeloid and lymphoid leukemia
3154290|NCT01519648||Allo- or auto- transplant recipients|
3154291|NCT01519635|Active Comparator|Aliskiren|
3154292|NCT01519635|Active Comparator|Hydrochlorothiazide|
3154293|NCT01519622||Sick elderly in community|
3154294|NCT01519609|Active Comparator|Moviprep|Moviprep bowel preb
3154295|NCT01519609|Active Comparator|Phosphoral|Bowel prep
3154296|NCT01519596|Experimental|Arm I (physical activity)|Patients participate in an orientation session introducing the exercise program and protocol, reviewing fundamental principles, and demonstrating each activity. Patients also receive educational materials to facilitate orientation and adherence. Patients are offered 20-50 minute standard, intermediate, and/or low intensity physical activity sessions 5 days a week for 4 weeks. Patients also receive lifestyle-related counseling for 20-30 minutes once weekly.
3154297|NCT01519596|Active Comparator|Arm II (usual care)|Patients undergo usual care for 4 weeks.
3154298|NCT01519583|Experimental|Basic Pedometry Intervention|Basic pedometry intervention: Participants will have a goal of obtaining 10,000 steps/day (with no direction with regards to walking intensity/speed/cadence)
3154299|NCT01519583|Experimental|Enhanced Pedometry Intervention|Enhanced pedometry Intervention: Participants will have the goal of obtaining 10,000 steps/day and at least 30 minutes in moderate intensity (i.e., at a cadence of at least 100 steps/min);
3154300|NCT01519583|Placebo Comparator|Control Group|Control group: Will maintain their usual activity and return for follow-up measures
3154301|NCT01519570|Experimental|An informational packet regarding shingles and the HZV|
3154302|NCT01519570|No Intervention|Standard medical care from their primary care physician|
3154303|NCT01519557|Experimental|DAR-100A|DAR-0100A is a dopamine D1 full agonist, the active component of the racemic mixture DAR-0100
3154304|NCT01519557|Placebo Comparator|Placebo|Intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
3154305|NCT01519544|Active Comparator|Temazepam|50 subjects are instructed to take 7.5mg temazepam by mouth prior to going to sleep for one night only.
3154306|NCT01519544|Active Comparator|Acetazolamide|50 subjects are instructed to take 125mg of acetazolamide by mouth prior to going to sleep one night only.
3154307|NCT01519531|Experimental|VIA-3196|
3154308|NCT01519531|Placebo Comparator|Placebo|Multiple, ascending dosing groups (cohorts) will be evaluated.
3154309|NCT01519518|Active Comparator|Unfractionated heparin|70 units/kg body weight intravenous
3154310|NCT01519518|Active Comparator|bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
3154311|NCT01519505|Experimental|Lifestyle counseling|"Complete lifestyle counseling including~Individual intervention, OR~Group intervention"
3154312|NCT01519505|No Intervention|Usual health care|Usual health care, including self-administered information by leaflets
3154313|NCT01519492|Experimental|AFN-12520000|100 mg tablet
3154314|NCT01519479|Experimental|Palliative Care Consultation|Participant will get one palliative care consultation while in the hospital. The participants desire for subsequent palliative care visits will be determined and mutually agreed upon at the initial consultation.
3154315|NCT01519479|Active Comparator|Control|Usual care for HF patient which may include a palliative care consult if ordered by treating physician.
3154316|NCT01519466|Other|Intervention|Subjects will use a FreeStyle InsuLinx blood glucose meter during the study
3154317|NCT01519466|Other|Control|Subjects will use a FreeStyle Freedom Lite blood glucose meter during the study.
3154318|NCT01519453|Experimental|Home Based Asthma Education|Families will receive 4 home based and 3 phone based asthma education sessions with a community asthma outreach worker
3154319|NCT01519453|No Intervention|Control|There is no control arm specific intervention
3154320|NCT01519440||blunt|Blunt expansion of the primary incision was derived by placing the index fingers of the operating surgeon into the incision and pulling the fingers apart laterally and cephalad.
3154321|NCT01519440||sharp|Sharp expansion of the primary incision was developed by cutting laterally and cephalad using bandage scissors
3154322|NCT01519427|Experimental|Treatment (selumetinib and Akt inhibitor MK2206)|Patients receive selumetinib PO BID on days 1-21 and Akt inhibitor MK2206 PO once weekly.
3154323|NCT01519414|Experimental|Arm I (tivantinib)|Patients receive tivantinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3154324|NCT01519414|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.
3154325|NCT01519401|Active Comparator|3 mg drospirenone and 20 µg ethinyl-estradiol|
3154326|NCT01519401|Active Comparator|3 mg drospirenone and 30 µg ethinyl-estradiol|
3154327|NCT01519388|Experimental|neuromuscular patients|Neuromuscular non invasively ventilated patients in stable at the time of the study
3154328|NCT01519375||1|Patients with Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis, 18 years or older
3154329|NCT01519349|Experimental|Cohort 1|Low Dose: 2E11 vg/kg of rAAV1.CMV.huFollistatin344 administered via intramuscular injection unilaterally to single quadriceps muscle (n=3, sIBM only)
3154330|NCT01519349|Experimental|Cohort 2|Mid Dose: 3E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)
3154331|NCT01519349|Experimental|Cohort 3|Low Dose: 6E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)
3154332|NCT01519336|Active Comparator|A danoprevir|
3154333|NCT01519336|Placebo Comparator|B darunavir|
3154334|NCT01519336|Experimental|C danoprevir/darunavir|
3154335|NCT01519323|Experimental|Vemurafenib|Participants received vemurafenib into two separate cohorts with different starting doses based on greater than or equal to (>=)45 kilogram (kg) and other weighing less than (<)45 kg. The starting dose for participants (>=45 kg) was 720 milligram (mg) of vemurafenib by mouth twice daily (BID) and the next dose level for participants in this cohort was 960 mg by mouth BID. The starting dose level for participants weighing <45 kg was to be 480 mg of vemurafenib by mouth BID, but no participants were enrolled into this cohort.
3154336|NCT01519310|Active Comparator|Group 1|Group 1 (Antibiotics/probioitic):
3154337|NCT01519310|Active Comparator|Group 2|Group 2 (Antibiotics/no-probiotic):
3154338|NCT01519310|Active Comparator|Group 3|Group 3 (no-Antibiotics/probiotic):
3154339|NCT01519297|Other|Single arm intervention|Irbesartan 150 mg orally for one dose
3154340|NCT01519284|Placebo Comparator|Group 1|Placebo at all the dosing times
3154341|NCT01519284|Experimental|Group 2|"Day 1 to 7:~BIA 9-1067 5 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 5 mg: 7 AM dose Placebo+ levodopa/carbidopa 100/25 mg: 8 AM dose"
3154342|NCT01519284|Experimental|Group 3|"Day 1 to 7:~BIA 9-1067 15 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 15 mg: 7 AM dose Placebo+ levodopa/carbidopa 100/25 mg: 8 AM dose"
3154343|NCT01519284|Experimental|Group 4|"Day 1 to 7:~BIA 9-1067 30 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 30 mg: 7 AM dose Placebo + levodopa/carbidopa 100/25 mg: 8 AM dose"
3154344|NCT01519284|Experimental|Group 5|"Day 1 to 7:~Placebo: 7 AM dose; Entacapone 200 mg: 8 AM; 4 PM; 12 PM dose~Day 8:~Placebo: 7 AM dose Entacapone 200 mg + levodopa/carbidopa 100/25 mg: 8 AM dose"
3154345|NCT01519271|Placebo Comparator|Placebo Patch|
3154346|NCT01519271|Active Comparator|Exelon Patch (rivastigmine transdermal system)|
3154347|NCT01519258|Active Comparator|PSV|Patients will be ventilated with the a conventional mode of ventilation called Pressure Support for 15 minutes. Mechanical ventilator settings will be set by the ICU team without interference from the investigators, in accordance to current standard of care recommendations.
3154348|NCT01519258|Experimental|NAVA|Patients will be ventilated with NAVA for 15 minutes. Back up settings in pressure support mode will be set in case the esophageal catheter is misplaced, and back up settings in pressure control ventilation will be set in case no inspiratory efforts are detected for longer than 15 seconds
3154349|NCT01519245|Experimental|Trial Drug|Solution containing 2 grams tranexamic acid + normal saline
3154350|NCT01519245|Placebo Comparator|Placebo|Normal saline
3154351|NCT01519232||Liver Irradiation|patients already scheduled to undergo liver irradiation
3154352|NCT01519219||Hepatic Irradiation|
3154353|NCT01519206|Experimental|Ultherapy treatment|Ulthera System Treatment
3154354|NCT01519193|Experimental|Narrative Exposure Therapy|
3154355|NCT01519193|No Intervention|No treatment control|
3154356|NCT01519180||Control group|Healthy volunteers
3154357|NCT01519180||Idiopathic gastroparesis|Idiopathic gastroparesis
3154358|NCT01519167|Experimental|Dexmedetomidine|
3154359|NCT01519154|Active Comparator|Propofol|Propofol 10 mg/h as maintenance infusion
3154360|NCT01519154|Experimental|Ketamine-Propofol|Additional Ketamine at induction, Propofol 5 mg/h as maintenance infusion
3154361|NCT01519141||HIV-negative controls|HIV-negative individuals
3154362|NCT01519141||HIV-infected patients|HIV-infected patients who are on a stable antiretroviral drug regimen for at least a year; all plasma HIV RNA levels within the past year must be below conventional levels of detection (< 50 copies RNA/mL).
3154363|NCT01519128|Experimental|Treatment sequence AB|In Treatment A, digoxin 0.5 mg (single oral dose) will be administered on Day 1. In Treatment B, TMC278 at 25 mg, once daily will be administered for 16 days, with digoxin 0.5 mg (single oral dose) administered in the morning on Day 11.
3154364|NCT01519128|Experimental|Treatment sequence BA|In Treatment B, TMC278 at 25 mg, once daily will be administered for 16 days, with digoxin 0.5 mg (single oral dose) administered in the morning on Day 11. In Treatment A, digoxin 0.5 mg (single oral dose) will be administered on Day 1.
3154365|NCT01519115|Active Comparator|Usual care|usual care of one physical therapy visit in hospital after ACF surgery
3154366|NCT01519115|Experimental|Early physical therapy intervention|early physical therapy program instructed and followed at home for 6 weeks
3154367|NCT01519102|Active Comparator|CHO-independent partial insulin bolus with closed-loop|
3154368|NCT01519102|Active Comparator|CHO-dependent full insulin bolus combined with closed-loop|
3154369|NCT01519089|Experimental|CP-690,550 10 mg BID|
3154370|NCT01519089|Experimental|CP690,550 5 mg BID|
3154371|NCT01519063|Experimental|Naltrexone and memantine|Treatment with Naltrexone and memantine
3154372|NCT01519063|Placebo Comparator|Naltrexone and Placebo|Treatment with naltrexone and placebo
3154373|NCT01519037|Active Comparator|calcimimetic agent (cinacalcet)|3 days of a low-sodium diet (50 mmol of Na+ per day, equivalent to 3 grams of salt/day), followed by an investigation day at the hospital during which the subjects will be studied before and after exposure to the cinacalcet or the placebo. The 2 periods will be separated by a therapeutic wash-out lasting 14-28 days. The total length of the study per participant will be 1, max. 2 months
3154374|NCT01519037|Placebo Comparator|Placebo|3 days of a low-sodium diet (50 mmol of Na+ per day, equivalent to 3 grams of salt/day), followed by an investigation day at the hospital during which the subjects will be studied before and after exposure to the cinacalcet or placebo. The 2 periods will be separated by a therapeutic wash-out lasting 14-28 days. The total length of the study per participant will be 1, max. 2 months
3154375|NCT01519024||Women with breast hypertrophy|Fourteen women with breast hypertrophy
3154376|NCT01519024||Women without breast hypertrophy.|Fourteen women without breast hypertrophy for de control group (CG).
3154377|NCT01519011|Experimental|1: A, B, C|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
3154378|NCT01519011|Experimental|2: B, C, A|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
3154379|NCT01519011|Experimental|3: C, A, B|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
3154380|NCT01519011|Experimental|4: B, A, C|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
3154381|NCT01519011|Experimental|5: A, C, B|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
3154382|NCT01519011|Experimental|6: C, B, A|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
3154383|NCT01519011|Experimental|Extension|300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
3154384|NCT01518998|Placebo Comparator|Placebo|Take one double-blind capsule filled with a placebo tablet in the every morning
3154385|NCT01518998|Active Comparator|Fimasartan 60mg|Take one double-blind capsule filled with of Fimasartan 60mg in the every morning
3154386|NCT01518998|Active Comparator|Fimasartan 30mg|Take one double-blind capsule filled with Fimasartan 30mg in the every morning
3154387|NCT01518998|Active Comparator|Amlodipine 5mg|Take one double-blind capsule filled with Amlodipine 5mg in the every morning
3154388|NCT01518998|Active Comparator|Amlodipine 10mg|Take one double-blind capsule filled with Amlodipine 10mg in the every morning
3154389|NCT01518998|Experimental|Fimasartan 60mg/ Amlodipine 5mg|Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 5mg in the every morning
3154390|NCT01518998|Experimental|Fimasartan 60mg/Amlodipine 10mg|Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 10mg in the every morning
3154391|NCT01518998|Experimental|Fimasartan 30mg/Amlodipine 5mg|Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 5mg in the every morning
3154392|NCT01518998|Experimental|Fimasartan 30mg/Amlodipine 10mg|Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 10mg in the every morning
3154393|NCT01518985|Placebo Comparator|Placebo|Intravenous infusion of saline (0.9%) for 4 hours with smoking of one unfiltered cigarette at 30 minutes post-study-drug administration start
3154394|NCT01518985|Experimental|Bendavia|Intravenous infusion of Bendavia (0.25mg/kg/hr) for 4 hours with smoking of one unfiltered cigarette at 30 minutes post-study-drug administration start
3154395|NCT01518972|Experimental|Prazosin|Prazosin medication
3154396|NCT01518972|Placebo Comparator|Placebo|Placebo medication
3154397|NCT01518959|Placebo Comparator|Placebo|no treatment
3154398|NCT01518959|Active Comparator|Cholecalcipherol|Treatment with 180 000 IU cholecalcipherol monthly
3154399|NCT01518946|Active Comparator|Midodrine HCl|
3154400|NCT01518946|Placebo Comparator|Placebo|
3154401|NCT01518933|Experimental|Silibilin (Legalon-SIL)|20 mg/kg Silibinin (Legalon SIL) ,as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
3154402|NCT01518933|Placebo Comparator|Saline|Placebo (saline), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
3154403|NCT01518920|Experimental|PF-04958242|
3154404|NCT01518920|Placebo Comparator|Placebo|
3154405|NCT01518907|Experimental|AA4500 0.0029 mg in 1 mL|
3154406|NCT01518907|Experimental|AA4500 0.0145 mg in 5 mL|
3154407|NCT01518907|Experimental|AA4500 0.0145 mg in 1 mL|
3154408|NCT01518907|Experimental|AA4500 0.0435 mg in 5 mL|
3154409|NCT01518907|Experimental|AA4500 0.0435 mg in 1 mL|
3154410|NCT01518907|Experimental|AA4500 0.116 mg in 5 mL|
3154411|NCT01518907|Experimental|AA4500 0.116 mg in 1 mL|
3154412|NCT01518907|Experimental|AA4500 0.232 mg in 5 mL|
3154413|NCT01518907|Experimental|AA4500 at 0.232 in 1 mL|
3154414|NCT01518907|Experimental|AA4500 0.464 mg in 5 mL|
3154415|NCT01518907|Experimental|AA4500 0.464 mg in 1 mL|
3154416|NCT01518894|Experimental|PF-04958242|
3154417|NCT01518894|Placebo Comparator|Placebo|
3154418|NCT01518881|Experimental|TKM-100201|
3154419|NCT01518881|Placebo Comparator|Placebo|
3154420|NCT01518855|Experimental|Arm 1|Adalat CR 20-40mg od + Diovan 40-80mg od
3154421|NCT01518855|Active Comparator|Arm 2|Norvasc 2.5-5mg od + Diovan 40-80mg od
3154422|NCT01518842|Experimental|test group intravitreal stem cell|"Open-label study of Ischemic Retinopathy patients with best-corrected visual acuity (BCVA) worse than 20/200.~Intervention: Biological: intravitreal injection of autologous bone marrow stem cells"
3154423|NCT01518829||Patients with hepatocellular carcinoma|Patients with hepatocellular carcinoma who will undergo locoregional therapy
3154424|NCT01518829||patients with chronic liver disease|patients with chronic liver disease, as a control group
3154425|NCT01518816||preterm labor cases|Group A: 35 pregnant women diagnosed with preterm labor(Preterm labor pain at least 3 contraction every 20 minutes ,cervical dilatation < 2cm and effacement< 50%) which will deliver within one week maximum after hospitalization.
3154426|NCT01518816||control group|Group B: 35 pregnant women( controls )with uncomplicated pregnancies at a similar gestational ages followed routinely in the antenatal care unit.
3154427|NCT01518803|Active Comparator|Mediterranean-style breakfast|
3154428|NCT01518803|Active Comparator|Western-style breakfast|
3154429|NCT01518790|Experimental|Polyethylene glycol 3350|
3154430|NCT01518777|Other|Half-dose isotope for NuclearStressTest|"Intervention is Nuclear stress test of the heart. Single-arm of this study Half-dose of isotope for Nuclear stress test is group of study subjects who will do Research Nuclear stress test with half-dose of isotope that normally used for routine Nuclear stress test. Isotope is the tracer CZT (cadmium zinc telluride) that used for Nuclear stress test routinely to see the function of arteries of the heart. Patients with suspected Coronary Artery Disease who meet entry criteria undergo a research nuclear stress test using a decreased dose of isotope, using a new camera."
3154431|NCT01518764|Experimental|Red Wine Polyphenols|Red Wine Polyphenols 600mg/day (capsules)
3154432|NCT01518764|Placebo Comparator|placebo|placebo (capsules)
3154433|NCT01518738|Experimental|breath attention training|
3154434|NCT01518738|Active Comparator|working memory attention training|
3154435|NCT01518738|No Intervention|no training|
3154436|NCT01518725|Experimental|Vitamin D Supplementation|The vitamin D supplementation will consist of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day.
3154437|NCT01518725|Placebo Comparator|Gel-like Substance|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
3154438|NCT01518712|Experimental|Treatment Sequence AB|
3154439|NCT01518712|Experimental|Treatment Sequence BA|
3154440|NCT01518699|Other|Part 1 Group 1|Low dose study drug in 6 of 8 subjects Placebo in 2 of 8 subjects
3154441|NCT01518699|Other|Part 1 Group 2|Mid dose study drug in 6 of 8 subjects Placebo in 2 of 8 subjects
3154442|NCT01518699|Other|Part 1 Group 3|High dose study drug in 6 or 8 subjects Placebo in 2 of 8 subjects
3154443|NCT01518699|Other|Part 2 Group A|Study drug plus positive-control placebo
3154444|NCT01518699|Other|Part 2 Group B|Placebo plus positive-control placebo
3154445|NCT01518699|Other|Part 2 Group C|Placebo plus positive control
3154446|NCT01518686|No Intervention|one arm|observational study, no cohort, single group of different ages
3154447|NCT01518673||X-rays|
3154448|NCT01518660|Experimental|Training|
3154449|NCT01518660|No Intervention|Control|
3155042|NCT01514383|Experimental|Surgical Adhesive|cyanoacrylate
3154450|NCT01518647|Experimental|Group Therapy|ACT given as conventional group therapy in groups of 7-8 patients 3,5 hours each session, 9 sessions during 3 month
3154451|NCT01518647|Experimental|Workshop|ACT given as a one-day workshop with 15 patients with a following individual consultation
3154452|NCT01518647|Active Comparator|Standard treatment|Standard treatment is one single advisory consultation given 2 weeks after randomization
3154453|NCT01518634|Experimental|Imipramine treatment|
3154454|NCT01518634|Placebo Comparator|Placebo|
3154455|NCT01518621|Active Comparator|Radiotherapy alone|Total brain irradiation, 3Gy x10
3154456|NCT01518621|Experimental|Radiation plus erlotinib|Total brain irradiation, 3Gy x10 plus erlotinib 150 mg q d from radiation day -1 through last day of irradiation
3154457|NCT01518595|Placebo Comparator|placebo|Patients will receive placebo tablets twice daily for 3 months.
3154458|NCT01518595|Active Comparator|bosentan|pts. will receive bosentan for 3 months
3154459|NCT01518582||Radiculopathy Cervical|Radiculopathy, Cervical
3154460|NCT01518569|Placebo Comparator|placebo|normal saline, same amount, iv
3154461|NCT01518569|Active Comparator|ulinastatin|5000 unit/kg iv
3154462|NCT01518556|Experimental|Idarubicin|Idarubicin dose intensification for remission induction in acute myeloid leukemia
3154463|NCT01518543||ASTUS|Patient candidate for an arthrodesis in the following joints:Ankle,1st MTP, Metatarso - Cuneiform (1st), Navicular - Cuneiform, Talo-Navicular, Calcaneum - Cuboid, and whose surgeon has recommended the implantation of an ASTUS Staple from Newdeal-INTEGRA.
3154464|NCT01518530|Experimental|Passive Mobilization Cervical Spine|Patients with chronic neck pain according to the International Association of the Study of Pain criteria of the following types: facet joint disorder, post-whiplash injury, myofascial pain syndrome.
3154465|NCT01518517|Experimental|GRASPA|"Each patient randomized in GRASPA® group is to receive at least 2 and up to 10 administration of GRASPA® 150 IU/kg, in combination with standard chemotherapy (COOPRALL).~GRASPA® administration takes place as below:~for induction phase: at Day 4 and D18 (F1-F2 induction ) or at D6 if Vanda induction applies (according disease severity)~for consolidation phase: at Day 6 of R2 / R1 blocks, each time block of chemotherapy is given (up to 8 cycles)"
3154466|NCT01518517|Active Comparator|reference L-asparaginase|"For patient randomized in control group, reference L-asparaginase 10,000 IU/m² will be administered every 3 days intravenously, in combination with standard chemotherapy (COOPRALL).~•for induction phase:at Day 4 , D7, D10, D13 (F1 block ) then at Day 18, D21, D24, D27 (of F2 Blocks).~NB: administrations take place at D6, D9, D12 and D15 in case of F1-F2 Induction is replaced by VANDA (according disease severity)~•for consolidation phase: at D6, D9, D12 ofR2/R1 blocks, each time block of chemotherapy is given (up to 8 cycles)."
3154467|NCT01518504|Experimental|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
3154468|NCT01518504|Sham Comparator|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
3154469|NCT01518491|Experimental|NanoDOX Hydrogel plus VAC|NanoDOX™ Hydrogel in conjunction with serial wound debridement and irrigation on open traumatic orthopedic and soft tissue wounds in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.
3154470|NCT01518491|Active Comparator|VAC Alone|Serial wound debridement and irrigation alone in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.
3154471|NCT01518478|Other|20 Non-atopic|Non-atopic, healthy control.
3154472|NCT01518478|Other|20 ADEH- (mild to severe AD)|Atopic Dermatitis without previous or current Eczema Herpeticum.
3154473|NCT01518465|Experimental|Arm I (5000 IU dalteparin)|Patients receive a prophylactic dose of dalteparin SC on days 1-28; lenalidomide PO on days 1-21; and low-dose dexamethasone PO on days 1, 8, 15, and 22.
3154474|NCT01518465|Experimental|Arm II (200 IU/kg dalteparin)|Patients receive a therapeutic dose of dalteparin SC on days 1-21 and lenalidomide PO and low-dose dexamethasone PO as in Arm I.
3154475|NCT01518452|Experimental|working memory training|Cogmed JM working memory training
3154476|NCT01518452|Experimental|delayed working memory training|Cogmed JM working memory training after 8 weeks waiting
3154477|NCT01518439|Experimental|neuromuscular patients|neuromuscular patients with cough inefficiency in a stable respiratory state upon inclusion
3154478|NCT01518426|Experimental|Extraction of P300 ERPs|Extract P300 ERPs with Emotiv EEG headset
3154479|NCT01518413|Experimental|Combination Therapy|Three to 6 patient will be enrolled at each dose level and dose escalations will proceed in the absence of dose-limiting toxicity attributed to therapy, first with dose escalation of sorafenib and then, if tolerated, escalation of irinotecan.
3154480|NCT01518400||Eligible Population|Cancer Survivors of all ages (Must be diagnosed with cancer at 21 years or younger)
3154481|NCT01518387|Experimental|Arm 1|750-2250mg/day, tid, 8 weeks
3154482|NCT01518374|Experimental|Florbetapir-PET Scans|
3154483|NCT01518348|Experimental|Patch Test|
3154484|NCT01518335|Experimental|Platelet Rich Plasma|Patients receive Platelet rich plasma injection + standard of care therapy(bandaging or boot and crutches) + non-NSAID pain medicine
3154485|NCT01518335|Placebo Comparator|Placebo/Standard of Care|Patient receives Placebo Comparator: Placebo/Standard of Care [saline injection + standard of care (bandaging or boot and crutches)] + non-NSAID pain medicine
3154486|NCT01518322||FeNO|All subjects will have their Fractional Exhaled Nitric Oxide (FeNO) measured with the NIOX MINO® device according to instructions for NO measurements.
3154487|NCT01518309|Experimental|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
3154648|NCT01517022|No Intervention|Control arm|Control arm patients will receive pre designed pamphlets and structured conselling for smoking cessation by trained counsellors along with routine DOTS treatment
3154488|NCT01518296|Experimental|Patients referred to urodynamic test|Patients that are referred to urogynecology and the pelvic reconstruction unit undergoes a physical gynecological examination and a urodynamic test, During which the degree of pelvic organs prolapse is evaluated with full and empty bladder.
3154489|NCT01518283|Experimental|Cabazitaxel|Drug: Cabazitaxel 10 mg/m2
3154490|NCT01518270||Healthy Females|Healthy Females
3154491|NCT01518257|Experimental|botulinum toxin Type A|A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
3154492|NCT01518257|Placebo Comparator|Placebo|A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
3154493|NCT01518244|Experimental|AZARGA®|Brinzolamide/timolol maleate fixed combination, 1 drop self-administered in study eye(s) twice a day for 8 weeks
3154494|NCT01518231|Experimental|cell transplantation|The study group will not only be implanted with autologous hematopoietic stem cells, but also receive drug therapy.
3154495|NCT01518231|No Intervention|Convention therapy|The control group just receive drug therapy.
3154496|NCT01518218|Experimental|laying-on-of-hands|Patients of this arm received laying-on-of-hands twice a day (45 minutes each) every weekday for 1year, and received conventional medical treatment if necessary.
3154497|NCT01518218|No Intervention|control group|Patients of this arm did not receive any alternatives other than conventional treatment.
3154498|NCT01518205|Experimental|LDL-apheresis and TT|"The patient of the experimental Arm, in addition to Traditional Therapy (TT), will undergo a cycle of 10 LDL-apheresis session.~Apheretic treatment scheme: 10 apheretic session carried out as follow: first and second apheresis with a 3 days interval (i.e. 2 treatment in one week), then one session per week (every 7 days).~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used."
3154499|NCT01518205|No Intervention|Traditional Treatment|"All patients will receive the traditional treatment for the ulcer healing Standardized medication.~All lesions taken into consideration will be treated in a standardized way, with a different approach according to the presence of a possible infection.~The evolution of lesions might be documented by means of mapping the same by drawing their profiles on an Opsite film.~antibiotics therapy (according to antibiogram). Anti-platelet therapy. Statin therapy."
3154500|NCT01518192|Active Comparator|1Doxycycline|
3154501|NCT01518192|Active Comparator|2 Cefuroxime axetil|
3154502|NCT01518179|Experimental|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
3154503|NCT01518179|Other|Control|Routine follow up and treatment
3154504|NCT01518166|Experimental|Trial period A|
3154505|NCT01518166|Experimental|Trial period B|
3154506|NCT01518153|Experimental|Low Dose Donor T-Cells|Fludarabine 40 mg/m^2 by vein on Day -6 to -3. Melphalan 140 mg/m^2 by vein on Day -2. Alemtuzumab 50 mg by vein on Day -1. Reduced intensity stem cell transplant on Day 0. Planned Donor Lymphocyte Infusion CD3+ cells: 3 * 106 CD3+ cells/kg between Day +56 and +64. Tacrolimus 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35. Methotrexate 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
3154507|NCT01518153|Experimental|High Dose Donor T-Cells|Fludarabine 40 mg/m^2 by vein on Day -6 to -3. Melphalan 140 mg/m^2 by vein on Day -2. Alemtuzumab 50 mg by vein on Day -1. Reduced intensity stem cell transplant on Day 0. High Dose Donor T-Cells Planned Donor Lymphocyte Infusion CD3+ cells: 1 * 107 CD3+ cells/kg between Day +56 and +64. Tacrolimus 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35. Methotrexate 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
3154508|NCT01518140|Experimental|VapoTherm|"Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
3154509|NCT01518140|Experimental|BiPAP|"Participants receive air through bilevel positive airway pressure (BiPAP) for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through VapoTherm for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
3154510|NCT01518140|Experimental|Non-Rebreather Mask|"Participants receive air through Non-Rebreather Mask for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through VapoTherm for up to 30 minutes, followed by 30 minutes using bilevel positive airway pressure (BiPAP)."
3154511|NCT01518127|Experimental|stem cell group|intravitreal injection of autologous bone marrow stem cells
3154512|NCT01518114|Experimental|Exercise Training|"Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.~Exercise prescription will be based upon cardiopulmonary test done at baseline."
3154513|NCT01518114|Active Comparator|Best Medical Care|Advanced HCM patients who are eligible to participate in the study but cannot do so for technical reasons will be invited to participate in the project as a control group.These subjects will continue their regular follow up in the Cardiomyopathy Clinic and their usual voluntary physical activity at home.
3154514|NCT01518101|Experimental|Vildagliptin/Metformin followed by Liraglutide+Metformin|In period I, Patients receiving vildagliptin will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for 12 weeks. In period II, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid for the first week (week 13 - week 14) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid.
3154515|NCT01518101|Experimental|Liraglutide + Metformin followed by Vildagliptin/Metformin|In period I, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid (twice daily) for the first week (week 0 - week 1) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid (week 2 -12). In period II, patients will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for next 12 weeks.
3154516|NCT01518088|Experimental|Low dose dietary fiber|
3154517|NCT01518088|Experimental|High dose dietary fiber|
3154518|NCT01518088|Placebo Comparator|No added fiber|
3154519|NCT01518075|Experimental|Non invasive mechanical ventilation|Evaluation of breathing swallowing interaction under non invasive mechanical ventilation
3154520|NCT01518075|Active Comparator|Spontaneous Breathing|Evaluation of breathing swallowing interaction without non invasive mechanical ventilation
3154521|NCT01518062|Experimental|Low dose|
3154522|NCT01518062|Experimental|Medium dose|
3154523|NCT01518062|Experimental|High dose|
3154524|NCT01518036|Experimental|Low dose|
3154525|NCT01518036|Experimental|High dose|
3154526|NCT01518023||Cancer gastrectomy|Patients previously submitted to partial/total gastrectomy for gastric cancer
3154527|NCT01518023||Colorectal cancer operation|Patients previously submitted to right colectomy or rectosignoidectomy for cancer
3154528|NCT01518023||Bariatric patients|Morbidly obese participants who underwent antiobesity Roux-en-Y gastric bypass
3154529|NCT01518010|Experimental|GamePlay|
3154530|NCT01517997|Experimental|Drug Coated Balloon (DCB) Arm|Patients included in this arm will undergo PTA with the use of a paclitaxel coated balloon.
3154531|NCT01517997|Active Comparator|Drug Eluting Stents (DES) Arm|Patients in this arm will undergo primary infrapopliteal stenting of the target lesion using a drug-eluting stent.
3154532|NCT01517984|Experimental|Tacrolimus (CNI) Withdrawal|"Subjects randomized (2:1) to tacrolimus (CNI) withdrawal.~Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test are randomized (2:1) to tacrolimus (CNI) withdrawal."
3154533|NCT01517984|Active Comparator|Standard Immunosuppressive Therapy|"Subjects randomized to standard immunosuppressive therapy, without subsequent tacrolimus (CNI) withdrawal.~Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Tacrolimus (CNI) withdrawal does not occur."
3154534|NCT01517971||Ancillary-correlative (whole-genome expression)|RNA extracted from archived tumor tissue samples are analyzed for whole-genome expression profiling by Gene Profiling Array cGMP U133 P2 and RT-PCR.
3154535|NCT01517958||Respiratory Distress Group|Neonates 28 weeks GA or greater with respiratory distress
3154536|NCT01517958||Control Group|Neonates 28 weeks GA or greater without respiratory distress.
3154537|NCT01517945||Breast cancer survivors|This is a Center for Translational Science Center (CTSC)-funded intervention development and pilot clinical trial of a psychosocial intervention to address fear of cancer recurrence in breast cancer survivors (BCS). BCS form the largest survivor cohort of any cancer, with approximately 2.5 million living in the United States.
3154538|NCT01517932|Experimental|Group-DEX|Patients in this arm received dexmedetomidine 0.2 microgram per kg i.v. during 10 minutes 1 hour before the end of surgery
3154539|NCT01517932|Placebo Comparator|Group-PLB|Patients in this arm received saline placebo 0.05 ml per kilogram i.v. during 10 minutes 1 hour before the end of surgery
3154540|NCT01517919|Experimental|Intervention: Peer Led Self-Management|Intervention: Peer Led Self-Management (PLSM) involves the DSME program followed by 12 months of peer-led ongoing self-management support
3154541|NCT01517919|No Intervention|Diabetes Self-Management Education|Control: Diabetes Self-Management Education (DSME) involves 12 sessions of self-management training including diabetes education, one-on-one sessions, bi-weekly phone contacts, and preparation for a clinic visit.
3154542|NCT01517906|Experimental|Cognitive behavioral counseling|
3154543|NCT01517906|Active Comparator|Supportive therapy|
3154544|NCT01517893|Experimental|Intervention arm|Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
3154545|NCT01517893|Placebo Comparator|Placebo Arm|
3154546|NCT01517880|Experimental|6,000 mg SA-ER|Subjects will receive this dose for the duration of the study (total study duration of 48 weeks).
3154547|NCT01517880|Placebo Comparator|Placebo|Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (48 weeks total study duration).
3154548|NCT01517880|Experimental|3,000 mg SA-ER|Subjects will receive this dose for the duration of the study (total study duration of 48 weeks).
3154549|NCT01517867|Experimental|Intervention Chicago Parent Program arm|The Chicago Parent Program is a 12-session group-based parenting skills training program
3154550|NCT01517867|Active Comparator|Parent-Child Interaction Therapy|Parent-Child Interaction Therapy is an individually tailored treatment for parents and children with behavior problems
3154551|NCT01517854|Active Comparator|Revatio|
3154552|NCT01517854|Placebo Comparator|Placebo|
3154553|NCT01517841||Chronic kidney disease|Patients with chronic kidney disease (20% or less kidney function remaining. Patients with end stage renal disease who are currently receiving dialysis.
3154554|NCT01517828|Experimental|Ketamine Arm|Phial of Ketamine (50mg/5ml) will be used and the dose administered will be 2 mg/kg.
3154555|NCT01517828|Active Comparator|Midazolam Arm|Phials of midazolam (5mg/5ml)will be used and the dose administered will be 0.2 ml/kg.
3154556|NCT01517815|Experimental|No overweight patient|Patient with weight less than or equal to 120kg
3154557|NCT01517815|Experimental|Overweight patients|Patient with weight more than 120kg
3154558|NCT01517802|Experimental|Abiraterone acetate|Patients will continue the same treatment regimen they were receiving during their participation in the previous abiraterone acetate clinical study.
3154559|NCT01517789|Experimental|Patients|
3154560|NCT01517776|Experimental|Cilengitide and metronomic temozolomide|Cilengitide 1800 mg/m² i.v. twice weekly and Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
3154561|NCT01517763|Placebo Comparator|Conventional CPAP|Fisher & Paykel HC244™
3154562|NCT01517763|Active Comparator|CPAP without Humidification|Fixed pressure ICON™ without ThermoSmart™
3154563|NCT01517763|Experimental|APAP with all technologies|Auto ICON™ with SensAwake™ and ThermoSmart™
3154564|NCT01517750|Experimental|APAP with humidification|ICON Auto CPAP™ with Thermosmart heated tube
3154565|NCT01517750|Active Comparator|APAP without humidification|ICON Auto CPAP™ without Thermosmart heated tube
3154566|NCT01517724|Experimental|Bortezomib consolidation|Bortezomib administered once a week 1.3mg/sq m; maximum of 8 cycles (each cycle is 4 weeks)
3154567|NCT01517711|Experimental|Tramadol ER|
3154568|NCT01517711|Placebo Comparator|Sugar pill|
3154569|NCT01517698|Experimental|RO4917523 0.5 mg|
3154570|NCT01517698|Experimental|RO4917523 1.5 mg|
3154571|NCT01517698|Placebo Comparator|Placebo|
3154572|NCT01517685|Experimental|Flax Oil and then Fish Oil|All people in the study will use the flax seed oil and then the fish oil.
3154573|NCT01517659|No Intervention|Fat Reduction|
3154574|NCT01517646|No Intervention|Fat Reduction|
3154575|NCT01517633|Experimental|A device for identifying between amniotic fluid and urine|
3154576|NCT01517620|Experimental|Total Glucosides Paeony, Capsules|
3154577|NCT01517620|No Intervention|no intervention|
3154578|NCT01517607||Mesalazine|
3154579|NCT01517581||Malignant Disease with no visualized BAT|Children 18 years or younger who 1) had PET/CT scans with evidence of malignant disease but no metabolically active brown adipose tissue (BAT) at diagnosis and 2) were disease free within 1 year of diagnosis.
3154580|NCT01517568|Experimental|Liraglutide|
3154581|NCT01517555|Experimental|Liraglutide|
3154582|NCT01517555|Placebo Comparator|Placebo|
3154583|NCT01517542|Experimental|Nutritional counseling|It was composed by patients who received specific written orientation to follow the DASH diet recommendations. Calories were calculated with the goal of maintaining body weight and divided into 3 main meals and two to three snacks.
3154584|NCT01517542|No Intervention|Usual diet|It was composed by patients who were stimulated to follow the general orientations of the neurologist or keep their food intake habits
3154585|NCT01517529||10 Hepatitis C infected subjects|10 chronically HCV-infected patients who fail the standard peg-IFN and Ribavirin therapy (NR) and are therefore eligible for combined treatment with Protease Inhibitor therapy.
3154586|NCT01517516||Functional Pain Conditions and Inflammatory bowel disease|Cyclical Vomiting Syndrome, Irritable Bowel Syndrome, Inflammatory Bowel disease (Ulcerative colitis and Crohns)and Vulvodynia (vestibulodynia)
3154587|NCT01517516||Inflammatory Bowel Disease|Subjects diagnosed with Crohn's Disease or Ulcerative Colitis.
3154588|NCT01517503|Experimental|Cognitive Therapy (CT)|Cognitive Therapy (CT)
3154589|NCT01517503|Experimental|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT)
3154590|NCT01517490||Type 1 Insulin Pump|Patients with type 1 diabetes starting insulin pump treatment
3154591|NCT01517490||Type 1 conventional therapy|Patients with type 1 diabetes continuing treatment with multiple daily insulin injections.
3154592|NCT01517490||Type 2 Bariatric surgery|Patients with type 2 diabetes who are enrolled in pre-operative weight loss protocol prior to bariatric surgery.
3154593|NCT01517490||Type 2 conventional|Severely obese patients with type 2 diabetes who are to continue with non-surgical treatments of diabetes and obesity and with no planned bariatric surgery.
3154594|NCT01517490||Type 1 insulin pumpe follow-up|Patients with type 1 diabetes previously followed in an observational study with electrophysiological and psychophysical measures of retinal function.
3154595|NCT01517490||Healthy|Healthy volunteers.
3154596|NCT01517477|Experimental|First Arm: One iStent|Device: One iStent
3154597|NCT01517477|Experimental|Second Arm: Two iStents|Device: Two iStent devices
3154598|NCT01517477|Experimental|Third Arm: Three iStents|Device: Three iStent devices
3154599|NCT01517464|Experimental|SGT-94|Dose escalation of experimental therapeutic SGT-94 to assess safety
3154600|NCT01517451|Experimental|Radiation with Androgen Deprivation Therapy (ADT)|This will be a Phase I/II study evaluating the effectiveness and toxicity of a combined regimen of 7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions) with androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT (stereotactic body radiation therapy). This choice of daily dose is based on the prior published experience showing safety and efficacy of hypofractionated regimens.
3154601|NCT01517425||Cases|Subjects previously enrolled in the Scripps Genebank Study
3154602|NCT01517425||Controls|Subjects previously enrolled in the Scripps Healthy Elderly Active Longevity (HEAL) Cohort
3154603|NCT01517412|Experimental|Lixisenatide Main Meal|"Lixisenatide 10 mcg once daily (QD) within 1 hour before main meal of the day for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24."
3154604|NCT01517412|Active Comparator|Lixisenatide Breakfast|"Lixisenatide 10 mcg QD within 1 hour before breakfast for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24."
3154605|NCT01517399|Other|Test drug administration|All drugs except vitamin K will be administered as a single dose once by itself as a reference treatment and once with tivantinib
3154606|NCT01517386||paravertebral anesthesia|patients scheduled for elective unilateral thoracic surgery under paravertebral block and general anesthesia
3154607|NCT01517373|Placebo Comparator|Placebo|Placebo to match PF-04937319 and glimepiride
3154608|NCT01517373|Experimental|PF-04937319 10 mg|
3154609|NCT01517373|Experimental|PF-04937319 50 mg|
3154610|NCT01517373|Experimental|PF-04937319 100 mg|
3154611|NCT01517373|Active Comparator|Glimepiride|
3154649|NCT01517022|Active Comparator|Intervention arm|Cessation arm patients will receive pre designed pamphlets and structured conselling for smoking cessation by trained counsellors along and nicotine replacement therapy(NRT) and routine DOTS treatment
3154650|NCT01516996|Active Comparator|Neoadjuvant and CCRT|
3154651|NCT01516996|Experimental|Neoadjuvant and CCRT and Nimotuzumab|
3154612|NCT01517360|Active Comparator|Placebo+Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. The treatment groups will include individuals who are assigned to placebo. Each training session will last for about 90 minutes (1 hour training and 30 minutes between placebo administration and start of training).
3154613|NCT01517360|Experimental|Oxytocin+Social Cognitive Skill Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. The treatment groups will include individuals who are assigned to oxytocin. Each training session will last 90 minutes (1 hour training and 30 minutes between oxytocin administration and start of training).
3154614|NCT01517347|Experimental|Interleukin-2|Interleukin-2 post-transplantation to prevent relapse of standard risk leukemia
3154615|NCT01517347|No Intervention|controlled group|controlled standard risk leukemia received regular transplantation without IL-2 intervention
3154616|NCT01517334|Experimental|Treatment|Treatment (minocycline HCl microspheres, 1mg) administered at Baseline (following randomization) and Day 90 to qualifying implant sites, plus full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180.
3154617|NCT01517334|No Intervention|Control|Full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180; no treatment
3154618|NCT01517321|Experimental|E|
3154619|NCT01517321|Placebo Comparator|P|
3154620|NCT01517308|Active Comparator|Control Arm 24 weeks|PEG-IFN α2a 180 μg/week+ ribavirin 800 mg/die for 24 weeks
3154621|NCT01517308|Experimental|Active arm (48 weeks)|PEG-IFN α2a 180 μg/week + ribavirin 800 mg/die per 48 weeks
3154622|NCT01517295|Experimental|Group 1|Blood will be drawn at 0, 1, 3, and 5 hours after taking one dose of hydrocodone/APAP. Urine will be taken at hour 0 and 3.
3154623|NCT01517295|Experimental|Group 2|Blood will be drawn at 0, 2, 4, and 6 hours after one dose of hydrocodone/APAP. Urine will be taken at hour 0 and 4.
3154624|NCT01517282|Experimental|MOR103 0.5 mg/kg|6 doses of MOR103 0.5 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
3154625|NCT01517282|Experimental|MOR103 1.0 mg/kg|6 doses of MOR103 1.0 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
3154626|NCT01517282|Experimental|MOR103 2.0 mg/kg|6 doses of MOR103 2.0 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
3154627|NCT01517282|Placebo Comparator|Placebo|6 doses of placebo administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
3154628|NCT01517269|Experimental|Education with simulator|Parent randomized to this group will be taught diabetes management with vignette and simulator
3154629|NCT01517269|Active Comparator|Control arm: standard diabetes education|Parents will receive standard diabetes education with a diabetes educator
3154630|NCT01517256|Experimental|Early Intervention Group|
3154631|NCT01517256|Placebo Comparator|Delayed Intervention Group|Initially wait-listed and served as control group. But later participants underwent the experimental intervention.
3154632|NCT01517243|Experimental|Alternating Sunitinib and Temsirolimus|"A cycle is defined as:~Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest"
3154633|NCT01517230|Active Comparator|intervention|seven clusters where radio media campaign will be broadcast.
3154634|NCT01517230|No Intervention|control|Seven clusters where radio media campaign won't be broadcast.
3154635|NCT01517217|Other|No girdle postoperative|patients undergoing major abdominal surgery will get NO individualized girdle. Functional outcomes as pulmonary function and pain are measured daily. Participants will be followed for the duration of 5 days or the duration of hospital stay, if shorter than 5 days.
3154636|NCT01517217|Other|Girdle postoperative|patients undergoing major abdominal surgery will get an individualized girdle. Functional outcomes as pulmonary function and pain are measured daily. Participants will be followed for the duration of 5 days or the duration of hospital stay, if shorter than 5 days.
3154637|NCT01517204|Experimental|Direct laryngoscope|Direct laryngoscope was used to facilitate the intubation of left-sided double lumen endobronchial tube.
3154638|NCT01517204|Experimental|Trachway(R) intubating stylet|Trachway(R) intubating stylet was used to facilitate left-sided double lumen endobronchial tube intubation.
3154639|NCT01517191||Influenza Positive Case|Influenza cases are hospitalized adults who have tested positive for influenza.
3154640|NCT01517191||Influenza Negative Control|Control Controls are hospitalized adults who have tested negative for influenza.
3154641|NCT01517178|Active Comparator|Standard Care base plate|Standard care are the participants own product and can have several manufacture and brand names
3154642|NCT01517178|Experimental|New ostomy base plate (SS)|SS = New ostomy base plate. Due to company confidentiality the product is called SS and this is not short for any name
3154643|NCT01517165|Experimental|Group 1|
3154644|NCT01517165|Placebo Comparator|Group 2|
3154645|NCT01517139||Healthy Volunteers|100 pairs of children and their mothers recruited from 2 provinces.
3154646|NCT01517074|Experimental|Sirolimus|Participants will receive a15 μL (660 μg) subconjunctival injection of sirolimus in the study eye at baseline if a single quadrant or two adjacent quadrants are involved. If greater than two quadrants are involved (i.e., 3 or 4 quadrant involvement) or two non-adjacent quadrants are involved, two 15 μL (660 μg) injections will be given in two quadrants 180 degrees apart (total dose of 30 μL or 1,320 μg). Participants that still demonstrate active inflammation (incomplete or no response to initial injection) or experience a flare-up (as defined by a ≥1-step increase in scleral inflammation) after the initial injection will be eligible for a re-injection in the study eye at or after Week 4 (not to exceed a dose of 1,320 μg per eye within an eight-week period).
3154647|NCT01517035|Experimental|1|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
3154652|NCT01516983|Experimental|Icotinib+WBRT|"Standard whole brain radiotherapy plus icotinib, which is designed to administered at 5 dose according to 3+3 until disease progression or intolerable toxicity."
3154653|NCT01516970|Experimental|DRV/r with 2 NRTIs|DRV/r 800/100 mg q.d. with 2 NRTIs: darunavir (800 mg) in combination with low-dose ritonavir (100 mg) administered once a day for at least 28 days and a maximum of 30 days along with 2 nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs).
3154654|NCT01516970|Active Comparator|Comparator standard of care HIV PEP|Comparator standard of care HIV PEP (as per German-Austrian Guidelines): Administration of the standard of care HIV PEP (postexposure prophylaxis) consisting of 2 NRTIs plus third partner.
3154655|NCT01516957|Experimental|AMG 827 SC 140 mg|140 mg AMG 827
3154656|NCT01516957|Placebo Comparator|Placebo SC|Placebo
3154657|NCT01516957|Experimental|AMG 827 SC 280 mg|280 mg AMG 827
3154658|NCT01516957|Experimental|AMG 827 SC 210 mg|AMG 827 SC 210 mg
3154659|NCT01516944|Active Comparator|postoperative chemotherapy,SOX|
3154660|NCT01516944|Experimental|Perioperative chemotherapy,SOX|
3154661|NCT01516944|Experimental|Perioperative chemotherapy,XELOX|
3154662|NCT01516931|Experimental|active rTMS and venlafaxine|"rTMS：Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months.~venlafaxine：150-225mg/day"
3154663|NCT01516931|Placebo Comparator|sham rTMS and venlafaxine|Sham stimulation will be given at the same site and frequency, using a Magstim sham-coil system. During rTMS, participants will be instructed to keep their eyes open and relax.
3154664|NCT01516931|Placebo Comparator|venlafaxine alone|responders will be maintained on the same effective dose of venlafaxine for the entire duration of the RCT, unless they relapse and will have to exit the protocol and enter a naturalistic follow-up
3154665|NCT01516918|Experimental|Quadruple Regimen|All subjects will receive active study drugs (quadruple regimen: VX-222, telaprevir,Peg-IFN, and RBV) for a fixed treatment duration of 24 weeks.
3154666|NCT01516905||I124-NM404 brain metastases or GBM imaging|determining appropriate imaging timepoints. Image at 6 hour, 24 hour and 48 hour post injection of I-124NM404
3154667|NCT01516892|Experimental|BOTOX®|Participants received 155 U of onabotulinumtoxinA (BOTOX®) approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
3154668|NCT01516879|Experimental|Evolocumab|Participants received evolocumab 420 mg subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
3154669|NCT01516879|Placebo Comparator|Placebo|Participants received placebo subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
3154670|NCT01516866||Cohort A: Microtubule directed chemotherapy treatment|Subjects receiving antimicrotubule chemotherapy-based treatment will have NaF PET/CT scans at baseline and again after 8 weeks of starting treatment. A subset of subjects will have a second NaF PET/CT scan at baseline 1-8 days after the first baseline scan.
3154671|NCT01516866||Cohort B: AR-directed therapy|Subjects receiving AR-directed therapy will undergo a baseline NaF PET/CT scan at baseline and again after having been on treatment for 6 weeks and again at 12 weeks. A subset of subjects will also undergo a second baseline NaF PET/CT scan 1-8 days after the first baseline scan.
3154672|NCT01516840|Experimental|Arm 1|
3154673|NCT01516840|Experimental|Arm 2|
3154674|NCT01516840|Active Comparator|Arm 3|
3154675|NCT01516840|Active Comparator|Arm 4|
3154676|NCT01516827|Experimental|TF-CBT|"12 Sessions Trauma-focused Cognitive Behavioral Therapy including the child/adolescents and a non-abusive caregiver according to the treatment manual:~Cohen JA, Mannarino AP, and Deblinger E (2006) Treating Trauma and Traumatic Grief in Children and Adolenscents. Guilford, N.Y."
3154677|NCT01516827|No Intervention|Wait-list|Patients in the control condition will be assigned to a wait-list (duration 4 months). During waiting time, clinical services will be provided as needed (excluding TF-CBT).
3154678|NCT01516814|Experimental|Arm 1|
3154679|NCT01516814|Active Comparator|Arm 2|
3154680|NCT01516814|Active Comparator|Arm 3|
3154681|NCT01516801|Experimental|PSA flyer|
3154682|NCT01516801|No Intervention|Control|
3154683|NCT01516788|Experimental|Phototesting|
3154684|NCT01516775|Experimental|1 hour fluid fasting|allowed to drink until 1 hour before scheduled anaesthesia induction
3154685|NCT01516775|Active Comparator|2 hours fluid fasting|allowed to drink until 2 hour before scheduled anaesthesia induction
3154686|NCT01516749|Experimental|Anakinra|All patients in this arm will receive the investigation drug anakinra once daily subcutaneously.
3154687|NCT01516736|Experimental|LA-EP2006|During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.
3154688|NCT01516736|Active Comparator|Neulasta®|During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.
3154689|NCT01516723|Experimental|Hybrid sirolimus-eluting stents|ORSIRO, Biotronik Inc.
3154690|NCT01516723|Active Comparator|Everolimus-eluting stents|XIENCE PRIME, Abbott
3154691|NCT01516710|Active Comparator|Open liver resection|Patients will be operated with open liver resection
3154692|NCT01516710|Active Comparator|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
3154693|NCT01516697|Other|Control|The patients in Group A will serve as controls and will receive standard monitoring in addition to continuous measurement of SV and CO. The physicians will not know the CO and SV and will manage the patients in a standard fashion.
3154694|NCT01516697|Experimental|experimental|The patients in Group B will receive the same monitoring as those in Group A. But the physicians will know instantaneously the CO and SV in real time and will manage the patients accordingly.
3154695|NCT01516684|Experimental|Arm I (EMLA)|Patients receive topical EMLA cream 60 minutes to 4 hours prior to the LP followed by standard sedation with fentanyl citrate and propofol.
3154696|NCT01516684|Active Comparator|Arm II (placebo)|Patients receive topical placebo cream 60 minutes to 4 hours prior to the LP followed by standard sedation with fentanyl citrate and propofol.
3154697|NCT01516658|Experimental|Hydrogel coil group|use Hydrogel Coil as much as be able to use
3154698|NCT01516658|Active Comparator|Bare platinum coil group|use only bare platinum coil
3154699|NCT01516645|Experimental|KHK2898|
3154700|NCT01516632|Experimental|SMS USA|The 6-week smoking cessation intervention
3154701|NCT01516632|No Intervention|Attention matched control|Messages aimed at improving one's sleep and increasing one's fitness, along with general messages about the most well known health dangers of smoking. Messages sent on the same schedule as the intervention group.
3154702|NCT01516619|Experimental|romiplostim|
3154703|NCT01516606|Experimental|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
3154704|NCT01516593|Experimental|intensive short term immuno-chemotherapy|Experimental treatment consists of an induction phase followed by a consolidation or intensified phase according to tumor response.
3154705|NCT01516580|Active Comparator|LMB chemo|"Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m²~in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
3154706|NCT01516580|Experimental|LMB chemo + Rituximab|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
3154707|NCT01516567|Experimental|DA-EPOCH-R|6 courses of Dose Adjusted-EPOCH-Rituximab
3154708|NCT01516554|Experimental|Testosterone undecanoate|
3154709|NCT01516554|Placebo Comparator|Sugar pill|
3154710|NCT01516541|Experimental|Dalcetrapib|Dalcetrapib 600 mg orally daily on a background of contemporary, guidelines-based medical care.
3154711|NCT01516541|Placebo Comparator|Placebo|Placebo orally daily, on a background of contemporary, guidelines-based medical care.
3154712|NCT01516528||All|All subjects enrolled in the study
3154713|NCT01516515|Placebo Comparator|placebo, gel|placebo comparator
3154714|NCT01516515|Active Comparator|SR-T100 with 2.3% of SM, gel|2.3% of SM in Solanum undatum plant extract
3154715|NCT01516502|Active Comparator|laser to acupoint|
3154716|NCT01516502|Sham Comparator|sham laser to acupoint|
3154717|NCT01516502|Active Comparator|laser to trigger point|
3154718|NCT01516502|Sham Comparator|sham laser to trigger point|
3154719|NCT01516489|No Intervention|Stage 1 Control Group|In the FOBT kit, individuals will receive a card that asks them to complete and return their FOBT kit within 30 days.
3154720|NCT01516489|Experimental|$5 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $5 at PVAMC.
3154721|NCT01516489|Experimental|$10 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $10 at PVAMC.
3154722|NCT01516489|Experimental|$20 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $20 at PVAMC.
3154723|NCT01516489|Experimental|$5 Voucher-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $5 at PVAMC.
3154724|NCT01516489|Experimental|$50 Lottery-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will have a 1 in 10 chance of being mailed a voucher that can be exchanged for $50 at PVAMC.
3154725|NCT01516489|Experimental|$500 Raffle-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be entered into a raffle in which 1 randomly chosen patient (out of about 100 patients) will be mailed a check in the amount of $500.
3154726|NCT01516489|No Intervention|Stage 2 Control Group|In the FOBT kit, individuals will receive a card that asks them to complete and return their FOBT kit within 30 days.
3154727|NCT01516476|Experimental|Liraglutide Arm|
3154728|NCT01516476|Placebo Comparator|Placebo Arm|
3154729|NCT01516476|Experimental|RO6807952 Arm 1|
3154730|NCT01516476|Experimental|RO6807952 Arm 2|
3154731|NCT01516463|Active Comparator|Collagenase Santyl|
3154732|NCT01516463|Sham Comparator|Bacitracin|
3154733|NCT01516450|Active Comparator|GSK1550188 200mg for SC|Single SC dose of belimumab 200mg
3154734|NCT01516450|Active Comparator|GSK1550188 200mg for IV|Single IV dose of belimumab 200 mg
3154735|NCT01516437|Experimental|HNS Group|Healthy non-smokers aged between 45-75 years
3154736|NCT01516437|Experimental|HS Group|Healthy smokers aged between 45-75 years
3154737|NCT01516437|Experimental|FeCOPD Group|COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years
3154738|NCT01516437|Experimental|NFeCOPD Group|COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years
3154739|NCT01516424|Active Comparator|Risperidone, Schizophrenia|
3154740|NCT01516424|Experimental|Blonanserin, Schizophrenia|
3154741|NCT01516411|Active Comparator|Cognitive app|Cognitive app promotes behavior change via goal setting, feedback, and problem solving
3154742|NCT01516411|Active Comparator|Social app|Social app promotes behavior change via social relationships and feedback
3154743|NCT01516411|Active Comparator|Affect app|Affect app promotes behavior change via game-like elements including the use of a bird avatar as a visual representation of one's activities and operant conditioning
3154744|NCT01516411|Active Comparator|Nutrition app|Nutrition app promotes behavior change bvia tracking of food consumption
3154745|NCT01516385||spinal cord injury|
3154746|NCT01516385||other neurological conditions|
3154747|NCT01516372|Experimental|Treatment 1|Healthy Volunteers will receive Treatments ABDC
3154748|NCT01516372|Experimental|Treatment 2|Healthy Volunteers will receive Treatments BCAD
3154749|NCT01516372|Experimental|Treatment 3|Healthy Volunteers will receive Treatments CDBA
3154750|NCT01516372|Experimental|Treatment 4|Healthy Volunteers will receive Treatments DACB
3154751|NCT01516359||patients with cardiac surgery|
3154752|NCT01516346|Active Comparator|Isosorbide dinitrate|"Research pharmacy-formulated capsules will be given to the subjects in two bottles. For this interventional arm, one of the bottles will contain the active ingredient Isosorbide Dinitrate and the other will contain placebo capsules.~Dosage of Isosorbide Dinitrate will be 20mg (if Stage 1) OR 40mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
3154753|NCT01516346|Active Comparator|Isosorbide dinitrate + Hydralazine|"Research pharmacy-formulated capsules will be given to the subjects in two bottles. For this interventional arm, one of the bottles will contain the active ingredient Isosorbide Dinitrate and the other will contain the active ingredient Hydralazine.~Dosage of Isosorbide Dinitrate will be 20mg (if Stage 1) OR 40mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks.~Dosage of Hydralazine will be 37.5mg (if Stage 1) OR 75mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily, to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
3154754|NCT01516346|Placebo Comparator|Placebo|"Research pharmacy-formulated capsules will be given to subjects in two bottles. For this interventional arm, both the bottles will contain placebo capsules.~Dosage will be same regardless of up-titration from Stage 1 dosing to Stage 2 dosing. Frequency is three times daily, to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
3154755|NCT01516333|Experimental|Diet 1|High GI; High Carb; High GL
3154756|NCT01516333|Experimental|Diet 2|High GI, Low Carb, Med GL
3154757|NCT01516333|Experimental|Diet 3|Low GI, High Carb, Med GL
3154758|NCT01516333|Experimental|Diet 4|Low GI, Low Carb, Low GL
3154759|NCT01516320|Experimental|Gastric Bypass (GBP) Subjects|Subjects enrolled in the study who are receiving Roux-en-Y Gastric Bypass surgical technique for treatment of their obesity.
3154760|NCT01516320|Active Comparator|Laparoscopic adjustable gastric banding (LAGB) Subjects|Subjects enrolled in the study who are receiving laparoscopic adjustable gastric banding surgical technique for treatment of their obesity.
3154761|NCT01516320|Active Comparator|Vertical Sleeve Gastrectomy (VSG) Subjects|Subjects enrolled in the study who are receiving vertical sleeve gastrectomy surgical technique for treatment of their obesity.
3154762|NCT01516307|Experimental|OPT-822/OPT-821 (30 μg/100 μg) and Cyclophosphamide|Patients will be randomized 2:1 to receive OPT-822/OPT-821(30 μg/100 μg) plus Cyclophosphamide IV (300mg/m2).
3154763|NCT01516307|Placebo Comparator|Phosphate Buffer Saline (PBS) and Cyclophosphamide|Patients will receive Phosphate Buffer Saline (PBS) plus Cyclophosphamide IV (300mg/m2).
3154764|NCT01516294|Experimental|Iray plus Lucentis|open label arm in which all subjects recieve a single 16 gy dose of radiation plus an injection of Lucentis.
3154765|NCT01516281||mTBI|Historical cohort of subjects seen in the emergency rooms of NorthShore University HealthSystem with ICD-9 diagnoses of mild or moderate traumatic brain injury during the years 2006-2011 (7,122 subjects). 100 mTBI+ subjects are randomly selected for clinical assessment and DaTscan.
3154766|NCT01516281||mTBI-|Historical cohort of subjects seen in the emergency rooms of NorthShore University HealthSystem with ICD-9 diagnoses of disorders other than mild or moderate traumatic brain injury during the years 2006-2011 (7,122 subjects). 100 mTBI- subjects are randomly selected for clinical assessment and DaTscan.
3154767|NCT01516268|Active Comparator|Sufentanyl group|IN case group we add 1cc sufentanyl to 20 cc bupivacain in TAP block
3154768|NCT01516268|Placebo Comparator|Control group|In control group we add 1cc salin to 20cc bupivacain in TAP block
3154769|NCT01516255|Experimental|Double-blind / liraglutide|
3154770|NCT01516255|Placebo Comparator|Double-blind / placebo|
3154771|NCT01516255|Active Comparator|Open-label / moxifloxacin|
3154772|NCT01516255|Placebo Comparator|Open-label / placebo|
3154773|NCT01516242||NovoPen® 4|
3154774|NCT01516229||Somatropin|
3154775|NCT01516216|Active Comparator|Standard Dose Vitamin D|Standard Dose Vitamin D with Bevacizumab and FOLFOX. FOLFOX contains: 5-FU (5-fluorouracil), Leucovorin and Oxaliplatin (Eloxatin).
3154776|NCT01516216|Active Comparator|Higher Dose Vitamin D|Higher Dose Vitamin D with Bevacizumab and FOLFOX. FOLFOX contains: 5-FU (5-fluorouracil), Leucovorin and Oxaliplatin (Eloxatin).
3154777|NCT01516203|Experimental|Arm 1|AZD5847 500 mg orally once daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
3154778|NCT01516203|Experimental|Arm 2|AZD5847 500 mg orally twice daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
3154779|NCT01516203|Experimental|Arm 3|AZD5847 1200 mg orally once daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
3154780|NCT01516203|Experimental|Arm 4|AZD5847 800 mg orally twice daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
3154781|NCT01516203|Active Comparator|Arm 5|Rifafour e-275 mg tablets given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
3154782|NCT01516190|Active Comparator|Exercise Group|Supervised exercise sessions and independent exercise
3154783|NCT01516190|Active Comparator|Mind-Body Group|Surgical preparation program
3154784|NCT01516177||Renal Transplant Recipients|Subjects who received a kidney transplant within the past 1 to 5 years
3154785|NCT01516164|Active Comparator|MacIntosh|
3154786|NCT01516164|Active Comparator|McGrath MAC direct|
3154787|NCT01516164|Active Comparator|McGrath MAC indirect|
3154788|NCT01516151|Active Comparator|Group A|0.5g total CaPre™ from baseline to week 4 and 1.0g total CaPre™ from week 4 to week 8
3154789|NCT01516151|Active Comparator|Group B|1.0g total CaPre™ from baseline to week 4 and 2.0g total CaPre™ from week 4 to week
3154790|NCT01516151|Active Comparator|Group C|2.0g total CaPre™ from baseline to week 4 and 4.0g total CaPre™ from week 4 to week 8
3154791|NCT01516151|Other|Group D|Standard of care
3154792|NCT01516151|Active Comparator|Group E|4.0g total CaPre™ from baseline to week 8
3154793|NCT01516138|Active Comparator|GIK|glucose-insulin-potassium (GIK) consists of 20% glucose (200 g/L), 66.7 U/L regular insulin and 80 mmol/L potassium chloride (KCl).
3154794|NCT01516138|Placebo Comparator|Control|6.12 g/L sodium acetate, 5.85 g/L sodium chloride, 0.3 g/L potassium chloride and 0.33 g/L calcium chloride
3154795|NCT01516125||Screening only - no intervention|
3154796|NCT01516099|Experimental|General Practitioners|The general practitioner can refer his patients to a physical activity counselor for an individual coaching. The investigators aim for a brief coaching period of 10 weeks with the objective that the people continue their active lifestyle afterwards.
3154797|NCT01516099|Experimental|Social-cultural organizations|In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor. The investigators aim for a brief coaching period of 10 weeks with the objective that the people continue their active lifestyle afterwards.
3154798|NCT01516086|Experimental|Fluticasone Propionate (FP) - arm 1|FP BID (twice daily)
3154799|NCT01516086|Experimental|Fluticasone propionate (FP) - arm 2|FP BID
3154800|NCT01516086|Experimental|Fluticasone Propionate (FP) - arm 3|FP BID
3154801|NCT01516086|Experimental|FLuticasone Propionate (FP) - Arm 4|FP BID
3154802|NCT01516086|Experimental|Fluticasone Propionate (FP) - Arm 5|FP BID
3154803|NCT01516086|Placebo Comparator|Placebo - Arm 6|Placebo inhalation solution
3154804|NCT01516073|Experimental|Fluticasone Propionate (FP) - arm 1|FP BID (twice daily)
3154805|NCT01516073|Experimental|Fluticasone propionate (FP) - arm 2|FP BID
3154806|NCT01516073|Experimental|Fluticasone Propionate (FP) - arm 3|FP BID
3154807|NCT01516073|Experimental|FLuticasone Propionate (FP) - Arm 4|FP BID
3154808|NCT01516073|Experimental|Fluticasone Propionate (FP) - Arm 5|FP BID
3154809|NCT01516073|Placebo Comparator|Placebo - Arm 6|Placebo inhalation solution 2mL
3154810|NCT01516060|Experimental|Reduced dose Efavirenz arm|Patient's on main study that was randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
3154811|NCT01516060|Active Comparator|Normal Efavirenz dose arm|Patient's on main study randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
3154812|NCT01516047|Experimental|Cohort 1|Patients with severe hepatic impairment.
3154813|NCT01516047|Experimental|Cohort 2|Healthy individuals with normal hepatic function.
3154814|NCT01516034|Experimental|Treatment|Cupola Tattoo Removal Device
3154815|NCT01516021|Experimental|high fat yoghurt intake|500 ml of a high fat yoghurt
3154816|NCT01516021|Experimental|low fat yoghurt intake|
3154817|NCT01516008|Experimental|Tapentadol IR 50 mg|
3154818|NCT01516008|Experimental|Tapentadol IR 75 mg|
3154819|NCT01516008|Placebo Comparator|Placebo|
3154820|NCT01515995|Experimental|Magnesium sulfate group|15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour
3154821|NCT01515995|Active Comparator|Normal Saline group|15 mg albuterol in 22 ml of normal saline solution via nebulizer over one hour
3154822|NCT01515982|Experimental|Aerobic exercise|The training exercise intensity is established at 60% of VO2máx. Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
3154823|NCT01515982|No Intervention|Control group|All participants were asked not to commence any new exercise regimen.
3154824|NCT01515969|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD. Starting on day 15, patients also receive dovitinib lactate PO QD on days 1-5 of each week. Treatment continues in the absence of disease progression or unacceptable toxicity.
3154825|NCT01515956|Experimental|BMN 110 Weekly|
3154826|NCT01515943|Active Comparator|Computer-based therapy (CBT)|The CBT group will be assigned active home-based computer vergence/accommodative therapy (15 minutes/day) plus placebo yoked prism flipper therapy (5 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
3154827|NCT01515943|Active Comparator|Near target push-up (NTP)|The NTP group will be assigned placebo home-based computer vergence/accommodative therapy (5 minutes/day) plus near target push-ups (15 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
3154828|NCT01515943|Placebo Comparator|Placebo|The placebo group will be assigned placebo home-based computer vergence/accommodative therapy (15 minutes/day) plus placebo yoked prism flipper therapy (5 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
3154829|NCT01515930|Active Comparator|Active Caregiver and Active Child|Parent & Child Computer-Delivered Motivational Intervention will be delivered to participants. A brief computer delivered behavior change counseling intervention for parents of children with diabetes to improve monitoring of diabetes care and a brief computer delivered behavior change counseling intervention for children with diabetes to improve completion of daily diabetes care.
3154830|NCT01515930|Experimental|Active Caregiver and Child Education|Parent Computer-Delivered Motivational Intervention will be delivered to the parents only. A brief computer delivered behavior change counseling intervention for parents of children with diabetes to improve monitoring of diabetes care and a brief computer delivered informational session about diabetes related topics for their child with diabetes.
3154831|NCT01515930|Active Comparator|Education Caregiver/Education Child|Participants will receive computer-delivered information. A brief computer delivered information session about diabetes related topics for both the caregiver and the child with diabetes.
3154832|NCT01515917|Experimental|Citicoline and Omega-3|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of citicoline and omega-3 fatty acid, of which they will be instructed to take 1000 mg and 2000 mg daily, respectively. This will be done in a double-blind, randomized fashion.
3154833|NCT01515917|Placebo Comparator|Placebo|At visit 1 and again at visit 2, participants assigned to the placebo group will be given 14-day supplies of placebo to be taken daily throughout the study period. This will be done in a double-blind, randomized fashion.
3154834|NCT01515904||Control|
3154835|NCT01515904||STOMP|
3154836|NCT01515891|Experimental|BIA 9-1067|90 µCi (3.33 MBq) [14C]-labeled of 100 mg BIA 9-1067 (single-dose).
3154837|NCT01515878|Experimental|Dialysis with BVT|Dialysis using the BVT monitor biofeedback called Hemocontrol
3154838|NCT01515878|No Intervention|Conventional dialysis|Conventional dialysis without blood volume tracking or similar therapies
3154839|NCT01515865|Experimental|Midodrine HCl|
3154840|NCT01515865|Placebo Comparator|Placebo|
3154841|NCT01515852|Other|Stress level after general anesthesia|
3154842|NCT01515852|Other|Stress level after local anesthesia|
3154843|NCT01515839|Experimental|Supplement intervention|Dietary Supplement: Multivitamin, Omega 3 Supplement, Brain and Memory Formula
3154844|NCT01515826|Experimental|VIGADEXA Gel|VIGADEXA ophthalmic gel topically administered TID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.
3154845|NCT01515826|Active Comparator|VIGADEXA Solution|VIGADEXA ophthalmic solution topically administered QID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.
3154846|NCT01515813|Experimental|Arm A: Pravastatin sodium alone for 24 weeks|One 40 mg tablet of Pravastatin sodium taken orally once daily for 24 weeks starting at week 0 and ending at week 24.
3154847|NCT01515813|Experimental|Arm B: EFV/FTC/TDF plus Pravastatin sodium at week 13|EFV/FTC/TDF once daily for 24 weeks starting at week 0 and ending at week 24 plus pravastatin sodium (80 mg)once daily for 12 weeks starting at week 13 ending at week 24.
3154848|NCT01515813|Experimental|Arm C: Pravastatin sodium + EFV/FTC/TDF for 24 weeks|Participants will be administered Pravastatin sodium once daily for 24 weeks starting at week 0 and ending at week 24 plus EFV/FTC/TDF once daily for 24 weeks starting week 0 and ending at week 24.
3154849|NCT01515800|Experimental|Text message reminder|Patients undergo a text message education checklist involving confirmation of cellular telephone capability to receive text messages, how to retrieve and read messages, including a confirmation evaluation, at baseline and at any time a patient obtains a new cellular telephone. Patients then receive a text message twice a week at 8 o'clock in the morning (for each time zone) for up to 3 years. Additionally, patients receive standard follow-up care.
3154850|NCT01515800|No Intervention|No text message reminder|Patients receive standard follow-up care.
3154851|NCT01515787|Experimental|Group 1|"Patients will receive FOLFOX chemotherapy once every two weeks for 6 cycles total over a period of 12 weeks. After completing FOLFOX chemotherapy, the patient will have an MRI scan or endorectal ultrasound (ERUS) to examine the tumor. If the tumor has not decreased in size by at least 20%, the patient will receive 5FUCMT (radiation with chemotherapy). If the tumor has decreased in size by 20%, then the patient will proceed directly to surgery.~If all borders of the tumor are normal post surgery, then the patient receives six additional cycles of FOLFOX chemotherapy. If all borders of the tumor are not normal then the patient receives chemoradiation therapy for 5.5 weeks after surgery. After chemoradiation, additional cycles of FOLFOX or similar chemotherapy will be recommended for 4 cycles or 8 weeks. Patient observation with follow up evaluations and event monitoring will occur up to 8 years post randomization."
3154852|NCT01515787|Active Comparator|Group 2|Patients receive 5FUCMT including chemotherapy and radiation therapy for 5.5 weeks. Patients will be given either 5-fluorouracil or capecitabine and radiation therapy. After the chemoradiation therapy is completed, patients will proceed directly to surgery. Post-surgery, patients will receive FOLFOX chemotherapy once every two weeks for 8 cycles total over a period of 16 weeks. Patient observation with follow up evaluations and event monitoring will occur up to 8 years post randomization.
3154853|NCT01515774|Active Comparator|Group 1|Give QD dose first then BID dosing
3154854|NCT01515774|Active Comparator|Group 2|Give BID dosing and then QD dosing
3154855|NCT01515761|Active Comparator|Postero-lateral|Left ventricular lateral wall lead position
3154856|NCT01515761|Active Comparator|Antero-lateral|Left ventricular lateral wall lead position
3154857|NCT01515748|Experimental|neoadjuvant chemotherapy + surgery + adjuvant chemotherapy|Docetaxel 50 mg/m² for day 1 , Oxaliplatin 100 mg/m² for day 1, S-1 80 mg/m²/day from day 1 to day 14 + surgery + S-1 80 mg/m²/day for 1yr
3154858|NCT01515748|Other|surgery + adjuvant chemotherapy|surgery + S-1 80 mg/m²/day for 1yr
3154859|NCT01515735||pseudoexfoliation|The study group composted of the patients with pseudoexfoliation syndrome
3154860|NCT01515722|Experimental|Health education intervention (HEI)|
3154861|NCT01515722|No Intervention|No intervention|
3154862|NCT01515709||Chronic Obstructive Pulmonary Disease|Patients with a diagnosis of COPD
3154863|NCT01515696|Active Comparator|Gastrografin|infants receive 3ml/kg Gastrografin + 6ml/kg sterile water
3154864|NCT01515696|Placebo Comparator|Sterile water|infants receive 9ml/kg sterile water
3154865|NCT01515683|Experimental|An anaesthetic nurse|
3154866|NCT01515683|Active Comparator|Theatre nurse + An anaesthetic nurse|Support from theatre nurse and an anaesthetic nurse
3154867|NCT01515683|Experimental|A nurse from ward + an anaesthesic nurse|Support from a nurse from the ward and an anaesthetic nurse
3154868|NCT01515683|Experimental|Optional relative + an anaesthetic nurse|Support from an optional relative and an anaesthetic nurse
3154869|NCT01515670||Fast-track THA/TKA|Any patient receiving THA/TKA in the participating wards
3154870|NCT01515657|Experimental|PL2200 Aspirin Capsules|Investigational drug arm; crossover design
3154871|NCT01515657|Active Comparator|Immediate-Release Aspirin Tablets|Active comparator; crossover design
3154872|NCT01515657|Active Comparator|Enteric-coated aspirin caplets|Active comparator; crossover design
3154873|NCT01515644|Experimental|Intervention group I|Intervention group I: Powder based Infant formula with Inulin I
3154874|NCT01515644|Experimental|Intervention group II|Intervention group II: Powder based Infant formula with Inulin II
3154875|NCT01515644|Placebo Comparator|Intervention group III|Intervention group III: Powder based Infant formula without Inulin
3154876|NCT01515631||Study|Patients with alagille syndrome
3154877|NCT01515605||Patients after kidney transplantation|Patients after kidney transplantation
3154878|NCT01515592|Experimental|15 mcg/kg|
3154879|NCT01515592|Experimental|20 mcg/kg|
3154880|NCT01515592|Experimental|25 mcg/kg|
3154881|NCT01515579|Experimental|Formulation 3|
3154883|NCT01515566|Experimental|Fentanyl|Fentanyl subcutaneously (SQ) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before walk test, and 6 minute walk test (6MWT) at baseline and 15 minutes after Fentanyl. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.
3154884|NCT01515566|Active Comparator|Placebo|Normal saline 0.9% preservative free SQ 15 minutes before walk test, and 6 minute walk test at baseline and 15 minutes after Placebo. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.
3154885|NCT01515553|Experimental|Formulation 4|
3154886|NCT01515553|Experimental|Final formulation 4|
3154887|NCT01515540|Active Comparator|lidocaine|5% lidoderm patch
3154888|NCT01515540|Placebo Comparator|control|placebo patch
3154889|NCT01515527|Experimental|Cladribine + Cytarabine Alt. with Decitabine|"Induction cycle: Cladribine intravenous (IV) over approximately 1 to 2 hours, daily on days 1-5 combined with Cytarabine subcutaneous (SQ) twice daily on days 1-10. Cytarabine should be administered approximately 3-6 hours following the start of the cladribine infusion.~Consolidation cycle: Cladribine IV over 1 to 2 hours, daily on days 1-3 combined with Cytarabine SQ twice daily on days 1-10. Cytarabine should be administered 3-6 hours following the start of the cladribine infusion.~Alternating with: Decitabine IV over 1 to 2 hours, daily on days 1-5."
3154890|NCT01515501|Other|Endoscopic mucosal resection|At time of rectal section biopsy all subjects will under go the additional intervention of an endoscopic muscosal resection.
3154891|NCT01515488|Experimental|Self-triage kiosk|Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
3154892|NCT01515488|Experimental|Nurse-initiated triage|Nurse-initiated triage for obtaining medical history and presenting problem(s)
3154893|NCT01515475|Active Comparator|Glasses|Glasses are prescribed at enrollment and worn per protocol throughout the duration of the study.
3154894|NCT01515475|Placebo Comparator|Observation|Glasses will not be prescribed unless the patient has confirmation of one or more deterioration criteria as described in the protocol.
3154895|NCT01515462|Experimental|Patients diagnosed with Wiskott Aldrich Syndrome|Participants affected by WAS who don't have a suitable matched donor for allogenic hematopoietic stem cell transplantation will be included
3154896|NCT01515436|Active Comparator|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
3154897|NCT01515436|Active Comparator|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
3154898|NCT01515423|Experimental|Paliperidone palmitate 3-month (PP3M)|A formulation of paliperidone palmitate with a 3-month injection interval
3154899|NCT01515423|Active Comparator|Paliperidone palmitate 1-month (PP1M)|A formulation of paliperidone palmitate with a 1-month injection interval
3154900|NCT01515410|Experimental|DM-1992|DM-1992, a gastric-retentive extended-release tablet containing 72.5mg carbidopa (CD) and 230mg levodopa (LD)
3154901|NCT01515410|Active Comparator|Sinemet IR|An Immediate-release (IR) tablet containing 25mg carbidopa (CD) and 100mg levodopa (LD)
3154902|NCT01515397|Experimental|balanced gelatine solution|isotonic colloidal volume substitute
3154903|NCT01515397|Active Comparator|non-balanced gelatine solution|colloidal volume substitute
3154904|NCT01515384|Experimental|Type 1 Diabetes|
3154905|NCT01515384|Experimental|Type 2 Diabetes|
3154906|NCT01515384|Experimental|Healthy Controls|
3154907|NCT01515371|Experimental|IncobotulinumtoxinA (Xeomin) 2.5 Units [U], 5U and 7.4U|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
3154908|NCT01515371|Placebo Comparator|Placebo Comparator|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
3154909|NCT01515358|Placebo Comparator|Placebo|Single dose of placebo administered orally in 1 out of 3 study periods separated by at least a 7-day wash-out period between each dose.
3154910|NCT01515358|Experimental|LY3000328|Single escalating dose of up to 300 mg/kg of LY3000328 administered orally in 2 out of 3 study periods separated by at least a 7 day wash-out period between each dose.
3154911|NCT01515345|Active Comparator|standard therapy|standard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS)
3154912|NCT01515345|Experimental|individualized therapy|dual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer
3154913|NCT01515319|Experimental|Y242|Single ascending dose study in Part A Multiple ascending dose study in Part B
3154914|NCT01515319|Placebo Comparator|Placebo (0.9% saline)|0.9% saline placebo
3154915|NCT01515306|Experimental|Part A: ramucirumab (IMC-1121B) and paclitaxel|"Cycle 1: paclitaxel administered on Day 1 of 2-week cycle.~Cycle 2: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4-week cycle.~Cycle 3 and beyond: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of each 4-week cycle."
3154916|NCT01515306|Experimental|Part B: ramucirumab (IMC-1121B) and paclitaxel|"Cycle 1: ramucirumab (IMC-1121B) administered as monotherapy on Day 1 of 3-week cycle.~Cycle 2 and beyond: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4-week cycle.~*After Cycle 1 (mandatory pharmacokinetic phase) is completed, participants may continue to receive ramucirumab (IMC-1121B) monotherapy or combination therapy with paclitaxel as described in Part A."
3154917|NCT01515293|Experimental|Single Incision Laparoscopic Appendectomy|
3154918|NCT01515293|Experimental|Conventional appendectomy|Conventional appendectomy
3154919|NCT01515280||Chronic cough|Patients taking part in supplementary study must be randomised to main study which includes a placebo arm and treatment arm
3154920|NCT01515254|No Intervention|No intervention- control group|Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken. The control group subjects will have the opportunity to receive the intervention at the end of the study
3155535|NCT01511172|Experimental|NNC 90-1170 + Met|
3154921|NCT01515254|Experimental|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
3154922|NCT01515241|Other|Open label single arm study of CER-001|Open label single arm study of CER-001
3154923|NCT01515228|Active Comparator|Xience Prime stent|everolimus eluting stent
3154924|NCT01515228|Experimental|Cilotax stent|paclitaxel with cilostazol dual drug eluting stent
3154925|NCT01515215|Active Comparator|High-frequency Left rTMS|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Treatment will be delivered at 120% of the RMT.~Site of Stimulation: left hemisphere of DLPFC.~Frequency: 10 Hz.~Duration: 42 Trains, 5 second duration, 25 second inter-train interval."
3154926|NCT01515215|Active Comparator|Bilateral rTMS|"Intensity: rTMS treatment intensity determined by the RMT. Treatment will be delivered at 120% of the RMT.~Sites of Stimulation: right and left hemispheres of the DLPFC.~Frequency: 1 Hz over the right DLPFC followed by 10 Hz over the left DLPFC.~Duration: right: 1 Train of 600 pulses; left: 30 Trains, 5 second duration, 25 second inter-train interval."
3154927|NCT01515215|Sham Comparator|Sham rTMS|Sham rTMS Treatment is applied as either Bilateral rTMS or HFL-rTMS (randomly assigned), but with the coil angled 90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
3154928|NCT01515202|Experimental|Panel 1: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
3154929|NCT01515202|Experimental|Panel 2: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
3154930|NCT01515202|Experimental|Panel 3: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
3154931|NCT01515202|Experimental|Panel 4: BMS-823778 or Placebo matching BMS-823778|Subjects with T2DM
3154932|NCT01515202|Experimental|Panel 5: BMS-823778 or Placebo matching BMS-823778|Subjects with T2DM
3154933|NCT01515189|Experimental|Arm 1: Ipilimumab (3 mg/kg)|Ipilimumab 3 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity
3154934|NCT01515189|Experimental|Arm 2: Ipilimumab (10 mg/kg)|Ipilimumab 10 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity
3154935|NCT01515176|Experimental|Treatment (ofatumumab, dinaciclib)|Patients receive ofatumumab IV over 4-6 hours on days 1, 8, 15, and 22 of courses 1-2, and on day 1 of courses 4-7. Beginning on course 2, patients also receive dinaciclib IV over 2 hours on days 2, 8, and 15 of course 2, and on days 1, 8, and 15 of courses 3-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
3154936|NCT01515163|Experimental|Exercise|3-month exercise training program
3154937|NCT01515163|No Intervention|Control|Control group
3154938|NCT01515163|Experimental|Healthy control|
3154939|NCT01515150||Out-patients in diverticulitis|All patient with acute uncomplicated diverticulitis how accept participation in the study will be enrolled in the study.
3154940|NCT01515137|Experimental|Arm A erlotinib plus sulindac|erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A),
3154941|NCT01515137|Experimental|Arm B erlotinib|erlotinib (150 mg PO QD) (Arm B)
3154942|NCT01515137|Experimental|Arm C|placebo (for Erlotinib) QD (Arm C).
3154943|NCT01515124|No Intervention|Lymphedema Care Only|
3154944|NCT01515124|Experimental|Exercise only|The Exercise Intervention combines 60-90 minute twice-weekly supervised weight-lifting sessions with 180 minutes of weekly aerobic exercise. Women will be trained by certified fitness professionals in both the weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions. All exercise participants will be provided with 'Power Blocks' which are adjustable dumbbells with which they can increase resistance in 1-2 pound increments from 1-21 pounds. All weight training will be done in their homes except for the first 6 weekly session and monthly check-in sessions.
3154945|NCT01515124|Experimental|Weight loss only|The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem®, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day. Participants will be guided to stay at the same number of calories per day until reaching goal weight, followed by a gradual increase in caloric intake (of approximately 500 calories/d) to maintain their weight throughout the remainder of the intervention. The treatment groups will be led by registered dietitians and will receive ongoing supervision via telephone and email contact.
3154946|NCT01515124|Experimental|Exercise and Weight loss combined|Participants in this group will receive a combination of the supervised twice-weekly weight training sessions and the weight loss program.
3154947|NCT01515111||Internal Medicine Staff|All interns, residents and attendings training (or working) at an Internal Medicine department of a Guatemalan teaching hospital.
3154948|NCT01515098|Experimental|Blueberry Group|
3154949|NCT01515098|Placebo Comparator|Placebo Group|
3154950|NCT01515098|No Intervention|Reference Group|
3154951|NCT01515085||biopsy proven glioma, no prior treatment|
3154952|NCT01515072|No Intervention|No Remote Ischemic Preconditioning|The donors assigned to this group will receive standard of care of management of brain death donors in each organ procurement organization.
3154953|NCT01515072|Experimental|Remote Ischemic Preconditioning|The donors assigned to this group would receive two RIPC interventions. The first one would occur immediately after brain death declaration and consent for organ donation. The second one would occur immediately before commencement of organ recovery. At each occasion RIPC would be induced by 4 cycles of mid-thigh inflation of tourniquet for 5 min followed by deflation for 5 minutes.
3154954|NCT01515059||Bariatric sugery patients|Obese patients who are awaiting either a gastric bypass or sleeve gastrectomy
3155009|NCT01514656|Active Comparator|Recruitment with Volunteers|Volunteer subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
3154955|NCT01515046|Experimental|Gemcitabine with escalating IV ascorbate|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off.~Ascorbate (vitamin C) given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbate / infusion for two infusions. Doses are then escalated in 25 gram increments until therapeutic window is achieved (350 mg/dL or above). Dose is then held at that level for the full cycle."
3154956|NCT01515033|Experimental|Continuous exercise training|The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
3154957|NCT01515033|Experimental|interval exercise training|The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
3154958|NCT01515020|Active Comparator|vancomycin monotherapy|vancomycin monotherapy: standard therapy
3154959|NCT01515020|Experimental|daptomycin monotherapy|daptomycin monotherapy: experimental therapy
3154960|NCT01515007|Experimental|Ciprofloxacin dispersion for inhalation|Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin
3154961|NCT01515007|Placebo Comparator|Placebo|Liquid formulation of empty liposomes
3154962|NCT01514994|Experimental|AngioScore's Valvuloplasty Scoring Balloon|
3154963|NCT01514981|Experimental|AMG 761|
3154964|NCT01514981|Placebo Comparator|Placebo|
3154965|NCT01514968|Experimental|DNV/r+cyclosporine|
3154966|NCT01514968|Active Comparator|cyclosporine|
3154967|NCT01514968|Active Comparator|danoprevir+ritonavir|
3154968|NCT01514942|Other|Insulin resistant patients|
3154969|NCT01514942|Other|Non-insulin resistant patients|
3154970|NCT01514929|Experimental|Supratherapeutic Dose|20mg/kg ACHN-490 Injection
3154971|NCT01514929|Experimental|Possible Therapeutic Dose|15mg/kg ACHN-490 Injection
3154972|NCT01514929|Active Comparator|Moxifloxacin|400mg moxifloxacin
3154973|NCT01514929|Placebo Comparator|Placebo|Placebo
3154974|NCT01514903|Active Comparator|viagra,anti-erectile dysfunction agent|
3154975|NCT01514903|Experimental|HIP0908|
3154976|NCT01514890||Telaprevir|
3154977|NCT01514890||Boceprevir|
3154978|NCT01514877|Experimental|Icotinib plus Whole Brain Radiotherapy|Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have shown efficacy in advanced non-small cell lung cancer (NSCLC) patients with brain metastases (BM). Icotinib is a new first generation EGFR-TKI. We conducted a phase II study to evaluate the efficacy and safety of icotinib in combination with whole brain radiotherapy （WBRT） in Chinese NSCLC patients with BM and investigated the cerebrospinal fluid (CSF)/ plasma concentrations of icotinib.
3154979|NCT01514864|Experimental|Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation)|Participants with nonsmall-cell lung cancer (NSCLC) and an inactivating B-RAF mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred
3154980|NCT01514864|Experimental|Dasatinib, 140 mg (NSCLC With DDR2 Mutation)|Participants with NSCLC and a discoidin domain receptor 2 (DDR2) mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred
3154981|NCT01514851|Experimental|Arm 1|750-2250mg/day, tid (three times a day), 8 weeks
3154982|NCT01514851|Active Comparator|Arm 2|1500-4500mg/day, tid, 8 weeks
3154983|NCT01514838|Experimental|1941 group|
3154984|NCT01514838|Active Comparator|acarbose group|
3154985|NCT01514825|Experimental|YM150 low dose group|
3154986|NCT01514825|Experimental|YM150 middle dose group|
3154987|NCT01514825|Experimental|YM150 high dose group|
3154988|NCT01514825|Placebo Comparator|placebo group|
3154989|NCT01514812|Experimental|YM150-placebo sequence group|YM150+digoxin; Washout; Placebo+digoxin
3154990|NCT01514812|Experimental|placebo-YM150 sequence group|Placebo+digoxin; Washout; YM150+digoxin
3154991|NCT01514799|Active Comparator|standard length bp limb, long alimentary limb|our normal way of doing a gastric bypass
3154992|NCT01514799|Experimental|Long BP limb|
3154993|NCT01514786|No Intervention|Control|Same information is presented in the control website as is found in the intervention website, but no interactive component: preferences and risk assessment.
3154994|NCT01514786|Active Comparator|Intervention with Colorectal Website|Intervention website includes an interactive component including preferences and risk assessment.
3154995|NCT01514773||ICD placement|Those subjects who have an ICD.
3154996|NCT01514773||No ICD placement|Those subjects who have not had an ICD placed.
3154997|NCT01514760|Experimental|Mobile-based Asthma Action Plan|The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts.
3154998|NCT01514747||ELBW infants|
3154999|NCT01514734|Experimental|AZARGA|Brinzolamide/timolol maleate fixed combination, one drop self-administered in study eye(s) twice a day for 8 weeks
3155000|NCT01514721|Experimental|DuoTrav|Travoprost/Timolol Maleate BAK-Free Fixed Combination, 1 drop self-administered in treated eye(s) once a day for 12 weeks
3155001|NCT01514708|Experimental|AdimFlu-S Influenza Vaccine, 0.5mL/dose, receive 1 dose|
3155002|NCT01514695|Experimental|Fentanyl|Fentanyl arm
3155003|NCT01514695|Placebo Comparator|Placebo|Placebo of identical appearance
3155004|NCT01514682|Placebo Comparator|Placebo|Placebo pills to be assigned using a permuted randomization system
3155005|NCT01514682|Experimental|Anti-inflammatory Combination Therapy|Salsalate, statin and omega-3-fatty acid combination therapy
3155006|NCT01514669||No treatment|
3155007|NCT01514656|Active Comparator|Video Self-Instruction (VSI) kit|Individuals will learn CPR using American Heart Association's Video Self-Instruction kit. Main data points being collected at various increments over 12 months are: 1) CPR quality at 6 to 12 months 2) Comfort Level using the skills they learned
3155008|NCT01514656|Experimental|Video-only|Individuals will learn CPR skills using a Video training method. Main data points being collected at various increments over 12 months are: 1) CPR Skills at 6 to 12 months 2) Comfort Level with using CPR
3155010|NCT01514656|Active Comparator|Recruitment with Nurses|Nurse subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
3155011|NCT01514656|Active Comparator|Prompting to practice skills|Individuals will be prompted every two months and encouraged to practice the skills that they learned. Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) CPR Skills at 6 to 12 months.
3155012|NCT01514656|Active Comparator|No prompting to practice skills|Individuals will not be prompted to practice skills. Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) CPR Skills at 6 to 12 months.
3155013|NCT01514643||tibial plateau or plafond fracture|Tibial plateau or plafond fracture based on radiographs and/or CT scan will have synovial fluid aspirated from both the injured and uninjured joints in either the operating room if a procedure is planned for within 24 hours or in the emergency department. While the patient is under anesthesia in the operating room, the investigators will obtain blood samples.
3155014|NCT01514630|Experimental|Creatine monohydrate|14 female depressed methamphetamine users received 5 grams of creatine monohydrate daily for eight weeks.
3155015|NCT01514604||Little or no experience.|All participants will be asked to declare their degree of experience in the technique being studied. Those declaring themselves as 'New to in-plane ultrasound guided needling. Little or no experience in technique' belong to this cohort and will form the study group.
3155016|NCT01514604||Regular practitioner. Teaching|Participants declaring themselves as 'Regularly incorporate in-plane ultrasound guided needling in clinical practice. Teaching technique to others' fall within this cohort and form the 'control' group allowing application of a realistic acceptable failure rate to Cusum analysis of the study group.
3155017|NCT01514604||Some exposure. Infrequent clinical use.|Participants declaring themselves as belonging to this group will not form part of the analysis. They will be welcome to complete training and receive feedback on their performance according to the study protocol.
3155018|NCT01514591||Non-elective Cesarean Delivery|We will only enroll patients undergoing non-elective CS with an 'epidural top-up' for surgical anesthesia. By definition, our study will only apply to laboring women with working labor epidurals (which were provided for labor analgesia).
3155019|NCT01514578|Experimental|TRV130A|
3155020|NCT01514578|Placebo Comparator|Dextrose in Water|
3155021|NCT01514552|Placebo Comparator|Placebo gummy|Each 6 gram placebo gummy contains 79% corn syrup (Karo, ACH Food Companies, Memphis, TN), 20% wheat starch (Confectioners G, Tate and Lyle PLC., Decatur, IL), 1% artificial strawberry flavors (Kool-Aid Kraft Foods, East Hanover, NJ).
3155022|NCT01514552|Active Comparator|Strawberry gummy|Each 6 gram strawberry gummy contains 45% freeze-dried fruit (California Strawberry Commission), 44% corn syrup (Karo, ACH Food Companies, Memphis, TN), 11% wheat starch (Confectioners G, Tate and Lyle PLC., Decatur, IL). With this formulation, daily fruit consumption is equivalent to 1 cup of whole strawberries. All ingredients (wheat starch, freeze-dried fruit, and high fructose corn syrup) will be purchased from a single lot. When a single lot is not available then the multiple manufacturing lots will be mixed into a single lot to be used for production of fruit gummies.
3155023|NCT01514539|Other|Four weeks Postpartum Lactating|women between 18 and 45 who delivered their first child 4 weeks prior and who were currently lactating and planning to lactate for one year postpartum.
3155024|NCT01514539|Other|Control Never Pregnant|women between 18 and 45 who have never been pregnant
3155025|NCT01514526|Experimental|Dovitinib|Dovitinib (TKI-258) f 500 mg / day (5 x 100mg) once daily. The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal.
3155026|NCT01514513|Experimental|Licefreee Spray|
3155027|NCT01514513|Active Comparator|Nix Creme Rinse, 1% Permethrin|
3155028|NCT01514500|Experimental|Single dose (SD)|Single dose administered s.c. (subcutaneously, under the skin). Escalation to the next dose level will be based on safety evaluation
3155029|NCT01514500|Experimental|Multiple dose (MD)|Multiple doses administered s.c. (subcutaneously, under the skin). All subjects will be dosed four times with a dosing frequency of once weekly. Escalation to the next dose level will be based on safety evaluation
3155030|NCT01514487|Experimental|pH 7.7|
3155031|NCT01514487|Experimental|pH 7.9|
3155032|NCT01514487|Experimental|pH 8.15|
3155033|NCT01514461|Experimental|LCQ908 20 mg|"In period II (0-12 weeks) double-blind treatment: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40mg tablet, once daily. No dose titration allowed.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 10 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
3155034|NCT01514461|Experimental|LCQ908 40 mg|"In period II (0-12 weeks) double-blind treatment: one LCQ908 40 mg active tablet + one LCQ908 placebo matching to 20mg tablet, once daily. No dose titration allowed.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
3155035|NCT01514461|Placebo Comparator|Placebo|"In period II (0-12 weeks) double-blind treatment: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet, once daily.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
3155036|NCT01514448|Experimental|Everolimus|Everolimus 10 mg orally once daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawn consent.
3155037|NCT01514435|Experimental|ECT verum group|Patients with treatment refractory depression treated with ECT
3155038|NCT01514422|Experimental|Minocycline|All subjects will be given minocycline over 8 weeks
3155039|NCT01514409|Experimental|5-Hydroxytryptophan|
3155040|NCT01514409|Placebo Comparator|Placebo|
3155041|NCT01514396|Experimental|Surgical Glue|Surgiseal
3155043|NCT01514370|Experimental|Treatment group 1|IFN beta 1 a 44 mcg TIW + curcumin (BCM 95)
3155044|NCT01514370|Placebo Comparator|Treatment group 2|IFN beta-1a 44 mcg TIW + placebo
3155045|NCT01514357|Other|Nesiritide (BNP)|Subjects will receive subcutaneous (SQ) BNP bid for seven consecutive days. The initial starting dose was 5 micrograms/kg.
3155046|NCT01514357|Placebo Comparator|Placebo|Subjects will receive SQ placebo bid for seven consecutive days.
3155047|NCT01514344|Experimental|intralesional rituximab|
3155048|NCT01514331|Active Comparator|PSV+VG|Neonates who require mechanical ventilation and randomised to pressure support + volume guarantee (PSV+VG) mode
3155049|NCT01514331|Active Comparator|SIMV+VG|Neonates who require mechanical ventilation and randomised to synchronised intermittant mandatory ventilation + volume guarantee (SIMV+VG) mode
3155050|NCT01514318||Revelation|Subjects who received the Revelation Hip Stem prior to 2002 and have agreed to come into the office for a single visit.
3155051|NCT01514305||Type 1 Diabetes Mellitus (TIDM)Type 2 Diabetes Mellitus (T2DM)|Adults that have been diagnosed with insulin-requiring diabetes and are on multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy;
3155052|NCT01514292|Experimental|Real Time Continuous Glucose Monitoring System|7 day use of real time continuous glucose monitoring system
3155053|NCT01514279|Experimental|HealthyCHANGE|Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.
3155054|NCT01514279|Experimental|SystemCHANGE|Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines
3155055|NCT01514279|No Intervention|Tools4CHANGE|In contrast to the behavioral arms, youths with their parent(s)/guardian randomized to this group will have one 60-minute face-to-face meeting at initiation of the study with a dietitian who is also trained in recommendations for exercise and sedentary behavior.
3155056|NCT01514266|Experimental|Curcumin+bioprine|The study involves active arm of Curcumin+Bioprine
3155057|NCT01514266|Placebo Comparator|Placebo|
3155058|NCT01514253|Experimental|glucose 25%|1 ml of glucose once
3155059|NCT01514253|Experimental|infant formula|Materna RTF stage 1
3155060|NCT01514253|Placebo Comparator|Water for Injection|1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
3155061|NCT01514240|Experimental|D9421-C|D9421-C 9 mg once daily
3155062|NCT01514240|Active Comparator|Mesalazine|Mesalazine 1 g three times a day
3155063|NCT01514227|Experimental|Short-term DAPT (6 months) group|6 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
3155064|NCT01514227|Experimental|Long-term DAPT (18 months) group|18 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
3155065|NCT01514214|Active Comparator|Winged perimeter stent|Patients who receive the Viaduct stent during ERCP
3155066|NCT01514214|Active Comparator|polyethylene stent arm|Patient who receive the traditional polyethylene stent during ERCP
3155067|NCT01514201|Experimental|Treatment (veliparib, temozolomide, 3D-CRT, IMRT)|"DOSE-ESCALATION: Patients receive veliparib PO BID 5 days a week for 6-7 weeks. Patients also undergo concurrent 3D-CRT or IMRT QD 5 days a week for 6-7 weeks.~MAINTENANCE THERAPY: Beginning 3-4 weeks later, patients receive veliparib PO BID on days 1-5 and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 10 courses in the absence of disease progression or unacceptable toxicity."
3155068|NCT01514188|Active Comparator|Doxorubicin|
3155069|NCT01514188|Experimental|INNO-206|
3155070|NCT01514175|Experimental|ibuprofen versus ketoralac|IV ibuprofen (800 mg intravenous ibuprofen administered intravenously over 10 minutes) will be administered as a single dose prior to surgery at the initiation of anesthesia. A corresponding volume of NS will be administered to the group randomized to ketorolac, at the same time to maintain the study blind.
3155071|NCT01514162|Experimental|Trifecta Valve Group|Subjects implanted with a Trifecta valve.
3155072|NCT01514149|Experimental|Arm 1 - Weekly CJC-1134-PC|
3155073|NCT01514149|Experimental|Arm 2 - Weekly CJC-1134-PC|
3155074|NCT01514149|Experimental|Arm 3 - Weekly CJC-1134-PC|
3155075|NCT01514149|Experimental|Arm 4 - Weekly CJC-1134-PC|
3155076|NCT01514149|Placebo Comparator|Arm 5 - Weekly Placebo|
3155077|NCT01514136|Experimental|One arm|The arm consists of two periods: in period one, products are tested in the order A, B, C, D, and in period two, products are tested in the order A*, B*, C*, D*.
3155078|NCT01514123|Experimental|Arm A - VGX-100 alone|Dose escalation of VGX-100 monotherapy
3155079|NCT01514123|Experimental|Arm B - VGX-100 plus bevacizumab|Dose escalation of VGX-100 in combination with escalating doses of bevacizumab
3155080|NCT01514110|Experimental|RAD001|
3155081|NCT01514097||Fractures reduced|
3155082|NCT01514097||Fractures splinted|
3155083|NCT01514084||PEM group|Patients whose lacerations have been repaired by PEM trained physicians.
3155084|NCT01514084||GP group|Patients whose lacerations have been repaired by general pediatricians.
3155085|NCT01514084||PNP group|Patients whose lacerations have been repaired by PNPs.
3155086|NCT01514084||RN group|Patients whose lacerations have been repaired by suture RNs.
3155087|NCT01514071|Experimental|Pop-up picture|
3155088|NCT01514058|Active Comparator|EUS-FNA First|Patients will undergo EUS-FNA first, followed by ERCP with biliary stenting (using a plastic stent).
3155089|NCT01514058|Active Comparator|ERCP with stent placement first|Patients will undergo ERCP with stent placement first, followed by EUS-FNA.
3155090|NCT01514032|Active Comparator|Extracorporal shockwave lithotripsy|
3155091|NCT01514032|Active Comparator|Retrograde intrarenal surgery|
3155092|NCT01514019|Experimental|Acebutolol|Acebutolol 200 mg capsule (Acetanol®)
3155093|NCT01514019|Placebo Comparator|Placebo|
3155094|NCT01514006||Study Cohort|Patients, aged 65 or above, undergoing elective primary unilateral hip arthroplasty in a fast-track setting.
3155095|NCT01513993|No Intervention|Control group|Treatment as usual
3155096|NCT01513993|Experimental|Telemonitoring for patients with Congestive Heart Failure|
3155097|NCT01513980|No Intervention|Control group|Treatment as usual
3155536|NCT01511172|Experimental|NNC 90-1170 + Met placebo|
3155098|NCT01513980|Experimental|Self monitoring for patients with COPD|Procedure: self-monitoring for patients with severe COPD
3155099|NCT01513980|Experimental|Nurse monitoring for patients with COPD|Procedure: nurse-monitoring for patients with severe COPD
3155100|NCT01513967|Experimental|Part A, SAD Treatment 1|RPh201 single dose (SAD Low Dose )
3155101|NCT01513967|Placebo Comparator|Part A, SAD Placebo 1|Placebo single dose (SAD Low Dose )
3155102|NCT01513967|Experimental|Part A, SAD Treatment 2|RPh201 single dose (SAD Mid Dose )
3155103|NCT01513967|Placebo Comparator|Part A, SAD Placebo 2|Placebo single dose (SAD Mid Dose )
3155104|NCT01513967|Experimental|Part A, SAD Treatment 3|RPh201 single dose (SAD High Dose )
3155105|NCT01513967|Placebo Comparator|Part A, SAD Placebo 3|Placebo single dose (SAD High Dose )
3155106|NCT01513967|Experimental|Part B, MAD Treatment 1|RPh201 multiple dose (MAD Low Dose )
3155107|NCT01513967|Placebo Comparator|Part B, MAD Placebo 1|Placebo multiple dose (MAD Low Dose )
3155108|NCT01513967|Experimental|Part B, MAD Treatment 2|RPh201 multiple dose (MAD Mid Dose )
3155109|NCT01513967|Placebo Comparator|Part B, MAD Placebo 2|Placebo multiple dose (MAD Mid Dose )
3155110|NCT01513967|Experimental|Part B, MAD Treatment 3|RPh201 multiple dose (MAD High Dose )
3155111|NCT01513967|Placebo Comparator|Part B, MAD Placebo 3|Placebo multiple dose (MAD High Dose )
3155112|NCT01513967|Experimental|Part C, AD patient, Treatment|3 month treatment schedule, consisting of bi-weekly administration of the RPh201
3155113|NCT01513967|Experimental|Part C, AD patients Placebo|3-month treatment schedule, consisting of bi-weekly administration of the placebo
3155114|NCT01513954||IVF population|Long Lupron IVF Population
3155115|NCT01513954||IUI patients|Patients undergoing IUI
3155116|NCT01513941|Experimental|Telaprevir plus Pegylated-Interferon-alfa-2a /ribavirin (RBV)|All patients who will receive 12 weeks of treatment with telaprevir 750 mg q8h except for patients on efavirenz will receive 1125 mg every 8 hours (q8h) in combination with Pegylated-Interferon-alfa-2a (Peg-IFN-alfa-2a) 180 μg/week and RBV 800 mg/day. At Week 12, telaprevir dosing will end and the patients will continue on Peg-IFN-alfa-2a and RBV.
3155117|NCT01513915|Active Comparator|A parent only group CBT|"There was a Group cognitive behavioral intervention -based on parent training component of FRIENDS program- for parents of children with anxiety disorders who were allocated to intervention group."
3155118|NCT01513915|No Intervention|Waiting list group|Parents of children with anxiety disorders who met the inclusion criteria and gave written informed consent and were allocated to wait list group.
3155119|NCT01513902|Experimental|Cohort 1|Ages 12 to less than 18
3155120|NCT01513902|Experimental|Cohort 2|Ages 6 to less than 12
3155121|NCT01513902|Experimental|Corhort 3|Ages 2 to less than 6
3155122|NCT01513863|Experimental|Metronidazole Topical Gel 1%|
3155123|NCT01513863|Active Comparator|Metronidazole Topical Gel 1% (Metrogel )|
3155124|NCT01513863|Placebo Comparator|Placebo|
3155125|NCT01513850|Experimental|Hepabulin IV|
3155126|NCT01513824|Active Comparator|stress management, acupressure|bio feedback guided stress management by daily measurement of pressure pain sensitivity followed by acupressure´for 3 months
3155127|NCT01513824|No Intervention|bio feedback guided, stress management|control without treatment
3155128|NCT01513811|Active Comparator|group PEG|This group is set as a control group and received 2 packets of Polyethylene glycol electrolyte solutions on the morning of the examination day as us we usually done.
3155129|NCT01513811|Active Comparator|group PEG+Itp|Patients in group were assigned to itopride half hour before administration of lavage solution in the morning of examination day.
3155130|NCT01513811|Active Comparator|group PEG+4Itp|Patients in this group received itopride three times 24 hours before the examination day and another time 30 min before administration of lavage solution.
3155131|NCT01513798|Experimental|Exercise under observation|Modified paleolithic diet and exercise 3 sessions/week under observation
3155132|NCT01513798|Experimental|General advice on exercise|Modified paleolithic diet and general advice on exercise
3155133|NCT01513785|Active Comparator|group R20A|All the patients were sent to a penicillin skin test before treatment except they were given penicillin before. The group R20A will receive 14 days of Amoxicillin 1g t.i.d and Rabeprazole 20 mg b.i.d. PPI was taken 30 minutes before meals while antibiotic was taken 30 minutes after meals.
3155134|NCT01513785|Active Comparator|group R10A|All the patients were sent to a penicillin skin test before treatment except they were given penicillin before. The group R10A will receive 14 days of Amoxicillin 1g t.i.d and Rabeprazole 10 mg b.i.d. PPI was taken 30 minutes before meals while antibiotic was taken 30 minutes after meals.
3155135|NCT01513772|Placebo Comparator|Control|
3155136|NCT01513772|Active Comparator|Dexmedetomidine|
3155137|NCT01513759|Experimental|EkoSonic Treatment Arm|Patients receive 24 mg of recombinant tissue plasminogen activator delivered through the EkoSonic Endovascular System.
3155138|NCT01513733|Experimental|Tasquinimod single dose|
3155139|NCT01513733|Experimental|tasquinimod 0.25 mg followed by 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
3155140|NCT01513733|Experimental|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
3155141|NCT01513720|Experimental|Lamotrigine Tablets 200 mg|Lamotrigine Tablets 200 mg of Dr. Reddy's Laboratories Limited
3155142|NCT01513720|Active Comparator|Lamictal® 200 mg Tablets|Lamictal® 200 mg Tablets of GlaxoSmithKline Inc
3155143|NCT01513707||Hemodialysis group|Hemodialysis group
3155144|NCT01513707||peritoneal dialysis group|peritoneal dialysis group
3155145|NCT01513694|Experimental|MSC seeded onto a phosphate ceramic|Instrumented posterolateral fusion and autologous mesenchymal stem cells arranged in a phosphate ceramic.
3155146|NCT01513681|Experimental|Lamotrigine Tablets 200 mg|Lamotrigine Tablets 200 mg of Dr. Reddy's Laboratories Limited
3155147|NCT01513681|Active Comparator|Lamictal® 200 mg Tablets|Lamictal® 200 mg Tablets of GlaxoSmithKline Inc
3155148|NCT01513668|Experimental|Acetaminophen extended release Gel tabs|Acetaminophen extended release Gel tabs 650 mg of OHM Laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
3155537|NCT01511172|Placebo Comparator|Met + NNC 90-1170 placebo|
3155149|NCT01513668|Active Comparator|Tylenol® 650 mg|Tylenol® 650 mg of McNeil Consumer and Specialty Pharmaceuticals, Division of McNeil PPC, INC. Fort Washington, PA 19034 USA
3155150|NCT01513655|Experimental|LTNIV group|"LTNIV group is discharged with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.~Furthermore, the patients are discharged with usual care, i.e., the golden standard of COPD treatment as described in GOLD-guidelines.~Outpatient visits are given every three months."
3155151|NCT01513655|No Intervention|Control group|"Patients in the control group are discharged with usual care, i.e., the golden standard of COPD treatment as described in GOLD-guidelines.~Outpatient visits are given every three months."
3155152|NCT01513642|Other|Incentive spirometry|
3155153|NCT01513642|No Intervention|Breath Stacking|
3155154|NCT01513616|Experimental|Pulmonary rehabilitation|A supervised 8-wk outpatient pulmonary rehabilitation program consisting of multi-modality exercise training and COPD self-management education.
3155155|NCT01513616|Sham Comparator|Usual care control|An 8-wk control period consisting of usual medical care which included optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education.
3155156|NCT01513603|Experimental|CLAG-M|
3155157|NCT01513590|Experimental|IDegAsp BID|
3155158|NCT01513590|Active Comparator|BIAsp 30 BID|
3155159|NCT01513577|Experimental|Minimal invasive pedicular screw|
3155160|NCT01513577|Experimental|Standard open insertion|
3155161|NCT01513564|Experimental|Conservative treatment program|"The control group were supervised isometric passive and active exercises by a physiotherapist. On the second day patients were allowed to sit in a chair being instructed to a low intensity exercise training program with regard to back pain and fear of activity. From the third or fourth day stair training, low intensity exercise, daily walks and instruction in home training were allowed.~The intervention group received the same training program but with a faster program plus a higher intensity exercise-training program."
3155162|NCT01513551|Experimental|V114|
3155163|NCT01513551|Active Comparator|Pneumococcal Polysaccharide Vaccine|
3155164|NCT01513551|Active Comparator|Pneumococcal 13-Valent Conjugate Vaccine|
3155165|NCT01513538||TherapyGuide|Patients implanted with a dual chamber pacemaker featuring the TherapyGuide function
3155166|NCT01513525|Experimental|Abdomen|
3155167|NCT01513525|Experimental|Thigh|
3155168|NCT01513525|Experimental|Upper arm|
3155169|NCT01513499|Active Comparator|Oxytocin|Intranasal oxytocin
3155170|NCT01513499|Placebo Comparator|Placebo|Intranasal placebo
3155171|NCT01513486|Experimental|Immobilization with NMES|Immobilization with daily NMES
3155172|NCT01513486|Placebo Comparator|Immobilization without NMES|Immobilization without daily NMES
3155173|NCT01513473|Experimental|Insulin Degludec + Insulin Aspart|
3155174|NCT01513473|Experimental|Insulin Detemir +Insulin Aspart|
3155175|NCT01513460|Experimental|NVA237 + Fluticasone/Salmeterol (Flu/Sal)|NVA237 50 µg once daily (NVA237 + Tiotropium placebo + Flu/Sal). NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI) o.d. plus Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
3155176|NCT01513460|Active Comparator|Tiotropium + Flu/Sal|Tiotropium 18µg once daily (NVA237 placebo + Tiotropium + Flu/Sal). Tiotropium 18 μg o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
3155177|NCT01513460|Placebo Comparator|Flu/Sal|Placebo (NVA237 placebo + Tiotropium placebo + Flu/Sal). Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
3155178|NCT01513447|Active Comparator|Sterile Water Injection|"In the sitting position, study subjects will receive a total of 0.4 mL of study drug via four intracutaneous injections: bilateral injections at the posterior superior iliac spine and bilateral injections at 1 cm medial and 1-2 cm inferior to the first point."
3155179|NCT01513447|Placebo Comparator|Normal Saline Injection|"In the sitting position, study subjects will receive a total of 0.4 mL of study drug via four intracutaneous injections: bilateral injections at the posterior superior iliac spine and bilateral injections at 1 cm medial and 1-2 cm inferior to the first point."
3155180|NCT01513434|Active Comparator|transtibial technique|In anterior cruciate ligament reconstruction, femoral tunnel was made via tibial tunnel.
3155181|NCT01513434|Active Comparator|Transportal technique|In anterior cruciate ligament reconstruction, femoral tunnel was made via anteromedial portal.
3155182|NCT01513421||Active vacuum pressure drainage|
3155183|NCT01513421||Free drainage|
3155184|NCT01513408|Experimental|CD8/Foxp3|patient suffering from non-metastatic breast cancer
3155185|NCT01513395|No Intervention|Immediate|"Participants randomized to the Immediate or control arm (voiding within five minutes of cervical assessment), will undergo any indicated trans-abdominal ultrasound imaging and preparations for vaginal ultrasound (including readying the probe and preparing the exam table for lithotomy position) prior to using the restroom. The participant will be instructed to proceed to the restroom to empty her bladder completely. A synchronized clock will be placed in the restroom, and the patient will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. Vaginal ultrasound and cervical assessment will then be performed immediately upon return to the ultrasound room (within a maximum of 5 minutes from voiding time)."
3155224|NCT01513096|No Intervention|Split-dose PEG|Bowel preparation using split dose PEG without prokinetics
3155186|NCT01513395|Experimental|Interval|"Participants randomized to the Interval or experimental arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time"
3155187|NCT01513382|Experimental|Methylene Blue|The effect of methylene blue dye in detection and total excision of pilonidal sinus will be studied histopathologically.
3155188|NCT01513369|Experimental|ferric carboxymaltose|Dose: according to SmPC; Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
3155189|NCT01513369|Placebo Comparator|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
3155190|NCT01513356|Experimental|CBKM120|BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)during 28 days
3155191|NCT01513343|Experimental|Parent and child classes|Parent and child groups focused on self-regulation of eating
3155192|NCT01513343|No Intervention|Treatment as usual|Treatment as usual
3155193|NCT01513330|Experimental|First Standard Care, then SenSura Mio|Subjects first test Standard Care (Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima) and after cross-over SenSura Mio
3155194|NCT01513330|Experimental|First SenSura Mio, then Standard Care|Subjects first test SenSura Mio and after cross-over Standard Care(Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima)
3155195|NCT01513317|Experimental|Siltuximab|15 mg/kg of siltuximab administered as a 1-hour infusion every 4 weeks + best supportive care (BSC)
3155196|NCT01513317|Experimental|Placebo|Placebo administered as a 1-hour infusion every 4 weeks + BSC
3155197|NCT01513304|Experimental|Chiropractic manual therapy|
3155198|NCT01513291|Experimental|MK-6096|Participants were randomized to receive double-blind MK-6096, two 5 mg tablets (10 mg dose), orally, once daily for 12 weeks in the Treatment Period. Those who completed the Treatment Period were randomized 1:1 to receive double-blind MK-6096 or placebo once daily in the 2-week Run-out Period.
3155199|NCT01513291|Placebo Comparator|Placebo|Participants were randomized to receive double-blind placebo, two tablets, orally, once daily for 12 weeks in the Treatment Period. Those who completed the Treatment Period continued to receive double-blind placebo once daily in the 2-week Run-out Period.
3155200|NCT01513278|Placebo Comparator|Control arm|All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201, the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.
3155201|NCT01513278|Active Comparator|APN201|APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel)
3155202|NCT01513265|Active Comparator|RASP|
3155203|NCT01513265|No Intervention|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care with registration of drug use at admission and discharge without interference of RASP or clinical pharmacist.
3155204|NCT01513252|Experimental|1|Gröber and Buschke test
3155205|NCT01513239|Experimental|MK-6072 + SOC|Single intravenous (IV) infusion of 10 mg/kg MK-6072 + Standard of Care (SOC) for CDI
3155206|NCT01513239|Experimental|MK-3415A + SOC|Single IV infusion of 10 mg/kg MK-3415A + SOC for CDI
3155207|NCT01513239|Placebo Comparator|Placebo + SOC|Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI
3155208|NCT01513226|Experimental|Dim light|Day and nighttime dim light conditions
3155209|NCT01513200|Placebo Comparator|UFH + Placebo|UFH (60U/kg bolus followed by 12U/kg/hr for approx.11 hours) with saline (placebo) administered as infusion for the last 4 hours of UFH
3155210|NCT01513200|Experimental|UFH + Bendavia|UFH (60U/kg bolus followed by 12U/kg/hr for approx.11 hours) with Bendavia (0.25mg/kg/hr) administered as infusion for the last 4 hours of UFH
3155211|NCT01513187|Experimental|Pazopanib + interferon|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
3155212|NCT01513174|Active Comparator|Gefitinib|Gefitinib will be administered once daily, continuously, in 28-day cycles, as a fixed dose of 250 mg/day.
3155213|NCT01513174|Experimental|Gefitinib in combination with olaparib|Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase I study) twice a day, continuously, in 28-day cycles.
3155214|NCT01513161|Active Comparator|TRK-820 5μg|Taking TRK-820 5μg(two 2.5μg capsules) by oral route once daily for 14 days
3155215|NCT01513161|Active Comparator|TRK-820 2.5μg|Taking TRK-820 2.5μg(one 2.5μg capsule & one placebo capsule)by oral route once daily for 14 days
3155216|NCT01513161|Placebo Comparator|Placebo|Taking Placebo(two placebo capsule) by oral route once daily for 14 days
3155217|NCT01513148|Experimental|Superluminous Light Diode Irradiation|Application of super luminous diodes light irradiation over the superficial radial nerve
3155218|NCT01513148|Placebo Comparator|Sham Superluminous Light Diode Irradiation|Sham Superluminous Light Diode Irradiation over the Superficial Radial Nerve for the same time period as the intervention group
3155219|NCT01513135|Experimental|Group A, Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin; administered intradermally 3 times at weeks 0, 4 & 8
3155220|NCT01513135|Placebo Comparator|group B, Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin, administered intradermally 3 times at weeks 0, 4 & 8
3155221|NCT01513122|Active Comparator|Arm 1. Lopinavir / ritonavir + 2-3N(t)RTI|
3155222|NCT01513122|Active Comparator|Arm 2. Lopinavir /ritonavir + raltegravir|
3155223|NCT01513109|Experimental|Treatment arm|Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic combined with Treg depletion
3155225|NCT01513096|Active Comparator|Split dose PEG with prokinetics|Bowel preparation using split-dose PEG with prokinetics
3155226|NCT01513083|Experimental|Mild hepatic dysfunction|
3155227|NCT01513083|Experimental|Moderate hepatic dysfunction|
3155228|NCT01513083|Experimental|Normal hepatic function|
3155229|NCT01513070|Experimental|Quick-Acting Heart Reliever group|Drug: Quick-Acting Heart Reliever and Placebo of isosorbide dinitrate and Aspirin Enteric-coated Tablets
3155230|NCT01513070|Active Comparator|Isosorbide Dinitrate group|Isosorbide Dinitrate and Placebo of Quick-Acting Heart Reliever and Aspirin Enteric-coated Tablets
3155231|NCT01513057|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
3155232|NCT01513057|Active Comparator|Cellcept|Cellcept 250 mg capsules of Roche Laboratories Inc.
3155233|NCT01513044|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
3155234|NCT01513044|Active Comparator|Cellcept|Cellcept 250 mg capsules of Roche Laboratories Inc.
3155235|NCT01513031|Experimental|Phone follow-up|All study participants will be receiving education and monthly telephone follow-up.
3155236|NCT01513018|Active Comparator|high (10 ml/kg) tidal volumes|Evaluate the influence of low (5 ml/kg) and high (10 ml/kg) tidal volumes on arterial oxygenation and Intrapulmonary shunt during one lung ventilation.
3155237|NCT01513018|Active Comparator|low tidal volume (5 ml/kg)|Evaluate the influence of low (5 ml/kg) and high (10 ml/kg) tidal volumes on arterial oxygenation and Intrapulmonary shunt during one lung ventilation.
3155238|NCT01513005|Experimental|Laparoscopic Sleeve Gastrectomy|
3155239|NCT01512992|Experimental|Home telehealth|
3155240|NCT01512992|No Intervention|Usual care|
3155241|NCT01512979|Experimental|linagliptin|patients receive linagliptin tablet once daily
3155242|NCT01512979|Experimental|linagliptin plus metformin|patients receive linagliptin tablet once daily and metformin tablets twice daily
3155243|NCT01512966|Experimental|VTE 2Q4 first, then VTE 2Q8|VEGF Trap-Eye [BAY86-5321; EYLEA (aflibercept) Injection] 2 mg Q4 (VTE 2Q4) administered every 4 weeks from Week 0 to Week 16, followed by every 8 weeks until Week 48 (2Q8)
3155244|NCT01512953|No Intervention|no PPI|Patients, stratified according to the genetic stratum, will be randomized not to take any PPI on top of clopidogrel
3155245|NCT01512953|Experimental|PPI|Patients stratified to the genetic stratum will be randomized to take PPI on top of clopidogrel
3155246|NCT01512927||ESRD with regular hemodialysis|
3155247|NCT01512914|Placebo Comparator|CONTROL group|
3155248|NCT01512914|Experimental|PREOPERATIVE nebulization|
3155249|NCT01512914|Experimental|POSTOPERATIVE nebulization|
3155250|NCT01512914|Active Comparator|INSTILLATION group|
3155251|NCT01512901|Experimental|1|
3155252|NCT01512901|Experimental|2|
3155253|NCT01512901|Sham Comparator|3|
3155254|NCT01512888|Experimental|Treatment|Participants will undergo a bone marrow harvest in the operating room to obtain bone marrow cells. Cells will be isolated and purified utilizing the CliniMacs device. These cells will undergo vector transduction with the lentiviral vector that contains a normal copy of the γc gene gene (CL20-i4-EF1α-hγc-OPT) and then the transduced cells will be reinfused back into the patient. Participants will receive a conditioning regimen of busulfan 3 days prior and 2 days prior to infusion of vector-corrected cells.intervention: CL20-i4-EF1α-hγc-OPT
3155255|NCT01512875||biopsy proven H. pylori|Patient must have lived in the districts of Lima, Peru listed in the protocol.
3155256|NCT01512862|Experimental|Calcitriol|
3155257|NCT01512862|No Intervention|Placebo|
3155258|NCT01512849|Experimental|TA-7284 Low|
3155259|NCT01512849|Experimental|TA-7284 High|
3155260|NCT01512836|Experimental|Case Management|The patients who are randomized to the intervention group will be assigned to case management. The case manager is expected to integrate care from a health maintenance and promotion perspective, where the overall goal is the promote and support the patients self care (see intervention description).
3155261|NCT01512836|No Intervention|Usual Care|Patients randomized to the usual care group will receive conventional health and social services. Patients in this group will not receive support from a case manager.
3155262|NCT01512823|Experimental|Interactive educational intervention|Two education sessions (four-hours and two-hours respectively), emailed notes and reminders
3155263|NCT01512823|Experimental|Didactic educational intervention|Education alone
3155264|NCT01512810|No Intervention|Low-risk for nodal involvement|No lymphadenectomy recommended
3155265|NCT01512810|Experimental|High-risk for nodal involvement|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
3155266|NCT01512797|Active Comparator|Sitagliptin phosphate|100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
3155267|NCT01512797|Placebo Comparator|Placebo|1 Placebo pill / day PO once a day for 4-5 weeks
3155268|NCT01512784|Experimental|HIV-infected adolescents and young adults|female and male HIV-infected subjects aged from 13-27 years old
3155269|NCT01512784|Active Comparator|healthy adolescents and young adults|female and male healthy adolescents and young adults aged 13-27 years
3155270|NCT01512758|Experimental|Alisertib|
3155271|NCT01512745|Experimental|apatinib|
3155272|NCT01512745|Placebo Comparator|placebo|
3155273|NCT01512732||healthy control group|Young (20-49) and Older (50-70) healthy group (n=60)
3155274|NCT01512732||Parkinson's disease patients|(n=30).
3155275|NCT01512732||Major depressive disorder patients|(n=30).
3155276|NCT01512719|Experimental|POEM procedure|Patients with achalasia that undergo POEM
3155277|NCT01512706|Experimental|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
3155278|NCT01512706|Experimental|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
3155279|NCT01512706|Experimental|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
3155280|NCT01512706|Experimental|1280Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
3155281|NCT01512706|Placebo Comparator|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
3155282|NCT01512706|Experimental|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
3155283|NCT01512706|Experimental|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
3155284|NCT01512706|Experimental|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
3155285|NCT01512706|Experimental|1280Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
3155286|NCT01512706|Placebo Comparator|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
3155287|NCT01512706|Experimental|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
3155288|NCT01512706|Experimental|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
3155289|NCT01512706|Experimental|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
3155290|NCT01512706|Experimental|1280Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 children aged 24 months-5 years months old on day 0, 28
3155291|NCT01512706|Placebo Comparator|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
3155292|NCT01512693|Experimental|Moderate Hepatic Insufficiency Group|Single-dose administration of odanacatib 50 mg to participants with moderate hepatic insufficiency.
3155293|NCT01512693|Experimental|Healthy Matched Control Group|Single-dose administration of odanacatib 50 mg to healthy matched control participants.
3155294|NCT01512680|Experimental|Type 1 diabetes patient|Type 1 diabetes patient are included in this study to have an education to Functional Insulin Therapy (intervention)
3155295|NCT01512667|Experimental|Severe Renal Insufficiency Group|Single-dose administration of odanacatib 50 mg to participants with severe renal insufficiency.
3155296|NCT01512667|Experimental|Healthy Matched Control Group|Single-dose administration of odanacatib 50 mg to healthy matched control participants.
3155297|NCT01512654|Other|algorithm DIAdvisor activated|Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
3155298|NCT01512654|Other|algorithm of DIAdvisor disactivated|Glucosepredictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
3155299|NCT01512641|Experimental|Children with Dissociative Disorders|Children will take first the primary stage. If one child is positive, he will pass the secondary stage.
3155300|NCT01512628|Active Comparator|PENTA group|Pentaspan is administered as a colloid.
3155301|NCT01512628|Active Comparator|voluVEN group|Voluven is administered as a colloid.
3155302|NCT01512628|Active Comparator|voluLYTE group|Volulyte is administered as a colloid.
3155303|NCT01512615|Experimental|Intervention group|Complex Cardiac Rehabilitation
3155304|NCT01512615|Experimental|Control group|Usual care
3155305|NCT01512602|Active Comparator|Dialectical Behavior Therapy DBT|16 weeks DBT-treatment
3155306|NCT01512602|Active Comparator|CAMS|Collaborative Assessment and Management of Suicidality, CAMS-informed supportive psychotherapy
3155307|NCT01512589|Experimental|Proton Beam Therapy (PBT)|"Radiation therapy 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments. 1.8 Gy (or at RBE (Relative Biologic Equivalence for PBT)) to be delivered to the periphery of the planning target volume (PTV)."
3155308|NCT01512589|Active Comparator|Intensity Modulated Radiation Therapy (IMRT)|Radiation therapy 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments. 1.8 Gy to be delivered to the periphery of the planning target volume (PTV).
3155309|NCT01512576|Experimental|acupuncture|All patients were treated at the basic points bilaterally situated in the local region (neck), distal region (low back, arms and legs) and ear. In addition, acupuncture treatment was performed according to the rules of traditional Chinese medicine and was semi-standardized. This means that the therapist was allowed to choose from a list of the following acupuncture points: GV14, Huatuojiaji C1-C7, GB20, SI11, GB21, TE15, SI14, BL17, MT10, SI3, BL64, TE5, GB41, Zero point, Jerome point, C0. The combination of acupuncture points were chosen individually, according to the patients' self-reported symptoms. In order to obtain the required information, patients had to fill out a Margolis pain diagram, and the acupuncturist questioned the patient and performed a tongue- and pulse diagnosis.
3155310|NCT01512576|Active Comparator|relaxation|For the relaxation treatment the method of guided imagery is applied. Guided imagery is a system of visualization. During guided imagery relaxation, the patient's state of consciousness is similar to one which occurs in meditative status. Patients are instructed to listen to a CD with relaxation music (Arcade TV-CD Ad Vissesr's Brainsessions, track 3). Patients will sit in an identical position like during the acupuncture treatment (i.e. on a relaxation chair) and listened to the audio CD by headphone.
3155311|NCT01512563|Experimental|Paclitaxel ElutingCovered Metal Stent|
3155312|NCT01512563|Active Comparator|Covered Metal Stent|
3155313|NCT01512550|Active Comparator|instrumented hip guide technique|A mechanical device used to measure and decide how the hip prosthesis (ABG II modular) should be implanted
3155314|NCT01512550|No Intervention|conventional measuring technique|Standard way of implanting the prosthesis (ABG II standard) without special measuring device or computer navigation technique
3155315|NCT01512550|Active Comparator|computer assisted navigation|A method to use computer navigation when positioning and sizing the hip prosthesis (ABG II modular).
3155316|NCT01512537|Active Comparator|UVB|UVB exposed group
3155317|NCT01512537|Active Comparator|Oral vitamin D tablet|Vitamin D supplementation
3155318|NCT01512524|Other|Patients With Traumatic Brain Injury|Study of the association between quality of life and MRI scans and endocrinology analysis (quantification of Growth Hormone) 18 months post-trauma.
3155319|NCT01512511|Experimental|nitrous oxide|use nitrous oxide for pneumoperitoneum creation
3155320|NCT01512511|Placebo Comparator|carbon dioxide|use carbon dioxide for pneumoperitoneum creation
3155321|NCT01512498||Patients who underwent allogeneic HSCT|Patients who underwent allogeneic HSCT before the age of 18, who are 18 years or older at the time of the study and who are alive.
3155322|NCT01512485|Experimental|Clopidogrel|Clopidogrel tablets 75 mg of Dr. Reddy's Laboratories Limited
3155323|NCT01512485|Active Comparator|Plavix|Clopidogrel Tablet 75 mg
3155324|NCT01512472|Active Comparator|10 month degarelix therapy|
3155325|NCT01512472|Active Comparator|4 month degarelix therapy arm|
3155326|NCT01512459|Experimental|Venlafaxine MR Capsules 150|Venlafaxine MR Capsules 150 of Dr.Reddy's Laboratories Limited
3155327|NCT01512459|Active Comparator|Effexor XR 150 mg Capsules|Effexor XR 150 mg Capsules of Wyeth Laboratories Philadelphia, PA, USA
3155328|NCT01512446|Active Comparator|Alendronate|
3155329|NCT01512446|Placebo Comparator|Placebo|
3155330|NCT01512433|Active Comparator|True acupuncture|True acupuncture was a real acupuncture which had been used in conventional Chinese medicine practice
3155331|NCT01512433|Sham Comparator|Sham acupuncture|Sham acupuncture was a procedure which mimicked the real acupuncture procedure.
3155332|NCT01512420||Cohort|
3155333|NCT01512407|Experimental|Hepatectomy plus TACE|Transarterial chemoembolisation will be performed 4 to 6 weeks after hepatectomy
3155334|NCT01512407|No Intervention|Hepatectomy alone|
3155335|NCT01512394|Active Comparator|Standard bowel prep|Standard bowel prep
3155336|NCT01512394|Experimental|No bowel prep|No bowel prep
3155337|NCT01512381|Experimental|CRT|
3155338|NCT01512381|Active Comparator|pacemaker|
3155339|NCT01512368|Experimental|Supervised exercising|A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks to participants.
3155340|NCT01512355|Experimental|dexmedetomidine|
3155341|NCT01512355|Placebo Comparator|placebo|
3155342|NCT01512342|Experimental|Pacing|The pacing self-management program focussed on teaching the patient to estimate their current physical capabilities prior to commencing an activity. In order to appropriately pace activities (daily activities and exercise bouts), CFS patients were learned to estimate their current physical capabilities prior to commencing an activity, keeping in mind the regular fluctuating nature of their symptoms. The activity duration used within the program was less than that reported by the patient so to account for typical overestimations made by the patient. Each activity block was interspersed with breaks, with the length of this break equating to the duration of the activity.
3155343|NCT01512342|Active Comparator|relaxation therapy|Relaxation therapy comprised of education about the role of stress in CFS biology, and the opportunities stress management provides to handle this issue. Patients were then taught how to apply stress management techniques like Jacobson relaxation skills, Schultz relaxation skills, visualization, etc.
3155344|NCT01512329|Experimental|pacing|The pacing self-management program (3 one-on-one sessions weekly for 3 consecutive weeks) focused on teaching the patient to estimate their current physical capabilities prior to commencing an activity. In order to appropriately pace activities (daily activities and exercise bouts), MS patients were learned to estimate their current physical capabilities prior to commencing an activity, keeping in mind the regular fluctuating nature of their symptoms. The activity duration used within the program was less than that reported by the patient so to account for typical overestimations made by the patient. Each activity block was interspersed with breaks, with the length of this break equating to the duration of the activity.
3155345|NCT01512329|Active Comparator|relaxation|Relaxation therapy (3 one-on-one sessions weekly for 3 consecutive weeks) comprised of education about the role of stress in MS biology, and the opportunities stress management provides to handle this issue. Patients were then taught how to apply stress management techniques like Jacobson relaxation skills, Schultz relaxation skills, visualization, etc.
3155346|NCT01512316|Active Comparator|d-Cycloserine Acquisition|d-Cycloserine will be given on day1, before acquisition
3155347|NCT01512316|Active Comparator|d-Cycloserine Extinction|d-Cycloserine will be administered on day2, before extinction
3155348|NCT01512316|Placebo Comparator|Placebo|A placebo pill will be administered on day1 and 2
3155349|NCT01512303|Experimental|Sudarshan Kriya Yoga: SKY|SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment. All are soothing and present-focused. Participants will be encouraged to learn all the breathing exercises, and to utilize the exercises the ones that seems most appropriate for their needs. 8-day intensive group class (2.5 hours/day) followed by 4 weekly sessions (3 hours/session).
3155350|NCT01512303|Experimental|Mindfulness-Based Stress Reduction: MBSR|MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts, allowing the practitioner to calm his or her mind and come back to the present moment. The typical MBSR format will be adapted to match the SKY intervention. This intervention will include an 8-day intensive group class (2.5 hours/day) followed by 4 weekly sessions (3hrs/session).
3155351|NCT01512303|No Intervention|Wait-List Control: WLC|Participants will undergo no intervention. These participants will have the option of receiving one of the two interventions at the conclusion of the study.
3155352|NCT01512303|No Intervention|Non-PTSD control|Baseline measures only will be collected from a group of 50 combat-exposed veterans without PTSD to assess group differences on these measures prior to treatment.
3155353|NCT01512290|Active Comparator|Theta burst treatment|patients randomized to this arm will receive 10 TBS treatments distributed over 5 days
3155354|NCT01512290|Placebo Comparator|sham treatment|
3155355|NCT01512277|Experimental|3 administrations of 100 µg of rSh28GST|Adult volunteers (n=8) receive 100μg of rSh28GST together with aluminium hydroxide (Alum) as adjuvant at D0, D28, and D150.
3155356|NCT01512277|Experimental|2 administrations of 300 µg of rSh28GST|Adult volunteers (n=8) receive 300μg of rSh28GST together with aluminium hydroxide (Alum) as adjuvant at D0 and D28.
3155357|NCT01512277|Placebo Comparator|Placebo|Adult volunteers (n=8) receive aluminium hydroxide (Alum) alone at D0 and D28.
3155358|NCT01512264|Experimental|rTMS|3 weeks of nerTMS
3155359|NCT01512264|Sham Comparator|1 week of Sham Treatment + 2 weeks of nerTMS|1 week of Sham Treatment + 2 weeks of nerTMS
3155360|NCT01512264|Sham Comparator|2 weeks of Sham Treatment +1 week of nerTMS|2 weeks of Sham Treatment +1 week of nerTMS
3155361|NCT01512264|Placebo Comparator|Control Group|3 weeks of Sham Treatment
3155362|NCT01512264|Experimental|CIAT + rTMS|2 weeks of nerTMS enhanced by 1 hour of daily CIAT; both therapies will be administered in open-label fashion.
3155363|NCT01512251|Other|No Previous Treatment|150 mg oral dabrafenib twice a day until disease progression, death, or unacceptable adverse events.
3155364|NCT01512238||Pharmaceutical care|
3155365|NCT01512238||Control|
3155366|NCT01512225|Experimental|Domperidone for days 1 to 28|Domperidone maleate tablets 10 mg orally three times daily from days 1 to 28
3155367|NCT01512225|Placebo Comparator|Placebo for days 1 to 14 and domperidone for day 15-28|Identical placebo tablets 10 mg orally three times daily from days 1 to 14 followed by Domperidone maleate tablets 10 mg orally three times daily from days 15 to 28
3155368|NCT01512212|No Intervention|single group|FNAB will be perform first with standart technique and after with new FNAB apparatus
3155369|NCT01512199|Experimental|U3-1287 with trastuzumab + paclitaxel (Phase 1b)|The Phase 1b portion is an open label, dose de escalation, single arm study designed to assess the safety and tolerability of up to 3 dose levels of U3- 1287 in combination with trastuzumab plus paclitaxel and will determine the recommended Phase 2 dose (RP2D) of U3 1287. The first cohort will receive U3- 1287 18 mg/kg intravenously (IV) in combination with trastuzumab plus paclitaxel once every 3 weeks (q3w).
3155370|NCT01512199|Experimental|U3-1287 with trastuzumab+paclitaxel (Ph 2)|The Phase 2 portion is a randomized, 2 arm, placebo controlled, double blind study designed to evaluate the safety and the efficacy of U3-1287 at the recommended phase 2 in combination with trastuzumab plus paclitaxel (experimental arm) relative to the control arm (trastuzumab plus paclitaxel and placebo).
3155371|NCT01512199|Placebo Comparator|Placebo with trastuzumab+paclitaxel (Ph 2)|The Phase 2 portion is a randomized, 2 arm, placebo controlled, double blind study designed to evaluate the safety and the efficacy of U3-1287 at the recommended phase 2 dose in combination with trastuzumab plus paclitaxel (experimental arm) relative to the control arm (trastuzumab plus paclitaxel and placebo).
3155372|NCT01512173|Experimental|propranolol gel|
3155373|NCT01512173|Placebo Comparator|Placebo|
3155374|NCT01512160|Experimental|PF-04531083 2000 mg|
3155375|NCT01512160|Experimental|PF-04531083 1000 mg|
3155376|NCT01512160|Active Comparator|Ibuprofen 400 mg|
3155377|NCT01512160|Placebo Comparator|Placebo|
3155378|NCT01512147|Other|Isoflurane, Propofol, Dexmedetomidine|Our trial will examine the changes in latency and amplitude of SSEP and changes in amplitude and morphology of MEP while using different anesthetic combinations including isoflurane, proposal and dexmedetomidine. Monitoring teams will document any changes throughout the surgery and communicate with the team about those changes. The design of the study will be a prospective AB design.
3155379|NCT01512134|Experimental|DBS Surgery|All patients enrolled will undergo DBS implantation in the targeted region to assess the safety of the procedure and the efficacy through weight loss.
3155380|NCT01512121||functional MRI testing|"fMRI scanning with SCS on and off at different settings."
3155381|NCT01512108|Experimental|Liraglutide + an OAD therapy|
3155382|NCT01512108|Active Comparator|Two OADs combination therapy|
3155383|NCT01512095|Experimental|Norditropin®|
3155384|NCT01512095|Active Comparator|Nutropin AQ®|
3155385|NCT01512082|Experimental|Active pulsed electromagnetic field|
3155386|NCT01512082|Sham Comparator|Non-active pulsed electromagnetic field|
3155387|NCT01512069|Experimental|Web-based, Stage-matched Exercise and Diet Planning program|The experimental arm is a group that assigned to use web-based, stage-matched exercise and diet planning program.
3155388|NCT01512069|Active Comparator|Non-tailored booklet on exercise and diet|The control group is provided a booklet containing same information on exercise and diet as in the experimental group's web-based program, but the information on a booklet is not tailored to participants' stage of motivational readiness for exercise and diet based on the TTM.
3155389|NCT01512056|Experimental|the immunogenicity profiles of the AdimFlu-S|"Experimental group: to receive either only one dose of influenza vaccine at day 0 or one more booster vaccination 3 weeks later.~Negative control group: dialysis patients who refused to receive influenza vaccination."
3155390|NCT01512056|No Intervention|The safety outcome of the vaccine|Any adverse effect, including systemic or local site, will be recorded during the study period.
3155391|NCT01512043|Experimental|1. Breathing control|Description ...
3155392|NCT01512043|Active Comparator|2. Listening to music|Listening to music without guiding on breathing on the same device as breathing control twice a day for four weeks. Using the device to measure breathing movements.
3155393|NCT01512043|Sham Comparator|3. Silence|Using the device to measure breathing movement twice a day for four weeks. No instruction on breathing control and no music.
3155394|NCT01512017|Active Comparator|Veloderm|
3155395|NCT01512017|Placebo Comparator|Vaseline|
3155396|NCT01512004|Active Comparator|Propiverine Hydrochloride Extended-Release Capsule|30 mg/capsule; oral; once per day
3155397|NCT01512004|Placebo Comparator|Tolterodine Extended-release Tablet|4mg/tablet; oral; once per day
3155398|NCT01511991|Experimental|sevoflurane|10 min exposure to sevoflurane 1.0, 2.0 and 3.0 inspiratory vol% at sevoflurane dosage titration
3155399|NCT01511978|Active Comparator|Continuous 3,4-DAP|Subjects continued taking their usual individualized regimen of 3,4-DAP base, 30 to 100 mg daily divided into at least 3 doses.
3155526|NCT01511198|Experimental|0.045 mg|
3155527|NCT01511198|Experimental|0.225 mg|
3155528|NCT01511198|Experimental|0.45 mg|
3155400|NCT01511978|Placebo Comparator|Taper 3,4-DAP to Placebo|Subjects were tapered over 3 days from their usual individualized regimen of 3,4-DAP base (30 to 100 mg daily divided into at least 3 doses) to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
3155401|NCT01511965|Other|traitement A|Lesion 1= graft and lesion 2 = UltraViolet B
3155402|NCT01511965|Other|traitement B|Lesion 1 = UltraViolet B and lesion 2 = graft
3155403|NCT01511952|Active Comparator|Music intervention- SGA|Infants will be randomly assigned to receive one of three music interventions randomized for the AM or PM
3155404|NCT01511952|Active Comparator|Music Intervention- RDS|Infants will be randomly assigned to receive music-one of 3 randomized interventions in the AM or PM
3155405|NCT01511952|Active Comparator|Music Intervention- Sepsis|Infants randomly assigned to receive one of three interventions-randomized for the AM or PM
3155406|NCT01511939|Other|Pennsaid, warfarin|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of warfarin for at least 2 months
3155407|NCT01511939|Other|Pennsaid, dabigatran|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of dabigatran for at least 2 months
3155408|NCT01511939|Other|Pennsaid, aspirin and/or clopidogrel|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of aspirin and/or clopidogrel for at least 2 months
3155409|NCT01511926||1|Adult patients treated with Vimovo™ for diagnosed osteoarthritis (OA), rheumatoid arthritis (RA) or ankylosing spondylitis
3155410|NCT01511913||Ipilimumab treated cohort of 1000 patients|All patients identified and followed prospectively
3155411|NCT01511913||Non-Ipilimumab treated cohort of 800 patients|600 patients will be identified and followed prospectively, and 200 patients retrospectively identified and followed
3155412|NCT01511900|Experimental|Cohort 1: Dose level 1|Multiple dose orally: CAT-1004 Dose level 1 or placebo
3155413|NCT01511900|Experimental|Cohort 2: Dose level 2|Multiple dose orally: CAT-1004 Dose level 2 or placebo
3155414|NCT01511900|Experimental|Cohort 3: Dose level 3|Multiple dose orally: CAT-1004 Dose level 3 or placebo
3155415|NCT01511900|Experimental|Cohort 4: Dose level 4|Multiple dose orally: CAT-1004 Dose level 4 or placebo
3155416|NCT01511900|Experimental|Cohort 5: Dose level TBD|Multiple dose orally: CAT-1004 Dose level TBD or placebo
3155417|NCT01511887|Experimental|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
3155418|NCT01511887|No Intervention|No treatment|No treatment
3155419|NCT01511874|Experimental|ELIGRAD 22.5mg|a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
3155420|NCT01511848|Active Comparator|arm 1|30 Patients will be treated with combined DFP and deferasirox.
3155421|NCT01511848|Active Comparator|arm 2|Patients will be treated for 6 days with a combination of deferoxamine and DFP
3155422|NCT01511835|Experimental|Myo-inositol powder|
3155423|NCT01511835|Experimental|Myo-inositol soft gel capsules|
3155424|NCT01511835|Placebo Comparator|Folic acid|
3155425|NCT01511822|Active Comparator|Drospirenone + Ethinyl estradiol|
3155426|NCT01511822|Experimental|Drospirenone + Ethinyl estradiol + Myo-inositol|
3155427|NCT01511822|Placebo Comparator|Placebo|
3155428|NCT01511809|Experimental|Atazanavir/ritonavir monotherapy|Patients will simplify therapy to ATV/RTV 300mg/100mg OD as monotherapy
3155429|NCT01511809|No Intervention|Atazanavir/ritonavir triple therapy|Patients will continue the same regimen ATV/RTV 300mg/100mg OD plus 2 NRTIs as backbone
3155430|NCT01511796|Experimental|upper limb rehabilitation for total of 6 months|upper limb rehabiliation
3155431|NCT01511783|Experimental|E2609|E2609 at ascending doses
3155432|NCT01511783|Placebo Comparator|Placebo|
3155433|NCT01511770|Experimental|Fluconazole|Fluconazole Tablets 200 mg of Dr. Reddy's Laboratories limited.
3155434|NCT01511770|Active Comparator|Diflucan|Diflucan 200 mg fluconazole tablets of Pfizer
3155435|NCT01511757|Experimental|Fluconazole|Fluconazole Tablets 200 mg of Dr. Reddy's Laboratories limited.
3155436|NCT01511757|Active Comparator|Diflucan|Diflucan 200 mg fluconazole tablets of Pfizer
3155437|NCT01511744|Experimental|Inactivated influenza split vaccine|Biological: Experimental: influenza split vaccine of 15 μg HA, one dose regime
3155438|NCT01511744|No Intervention|Blank control|
3155439|NCT01511731|Experimental|Famotidine|Famotidine tablets 40 mg of Dr. Reddy's
3155440|NCT01511731|Active Comparator|Pepcid|Pepcid 40 mg Tablets of Merck & Co.,
3155441|NCT01511718|Experimental|Ondansetron Hydrochloride Tablets 8 mg|Ondansetron Hydrochloride Tablets 8 mg of Dr. Reddy's Laboratories Limited
3155442|NCT01511718|Active Comparator|Zofran Tablets 8 mg|Zofran Tablets 8 mg of GlaxoSmithKline
3155443|NCT01511705|Experimental|Ondansetron Hydrochloride Tablets 8 mg|Ondansetron Hydrochloride Tablets 8 mg of Dr. Reddy's Laboratories Limited
3155444|NCT01511705|Active Comparator|Zofran Tablets 8 mg|Zofran Tablets 8 mg of GlaxoSmithKline
3155445|NCT01511692|Experimental|Lira --> placebo|
3155446|NCT01511692|Placebo Comparator|Placebo --> glim|
3155447|NCT01511692|Active Comparator|Glim --> lira|
3155448|NCT01511679||Alcohol-naive adolescents|A general population longitudinal cohort of alcohol-naïve (or h/o minimal recent-onset drinking) adolescents in three specific age-groups: early (12-14 y/o), middle (15-17 y/o), and late (18-21 y/o).
3155449|NCT01511679||Treatment sample|A sample of adolescents who have a >1 year history of heavy drinking but have agreed to stop drinking as part of their treatment plan
3155450|NCT01511679||High risk sample|High-risk adolescents who have a family history of alcohol-use disorder and other risk factors (symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD), Conduct Disorder, or Mood Disorder)
3155529|NCT01511198|Experimental|0.60 mg|
3155530|NCT01511198|Experimental|0.75 mg|
3155451|NCT01511666|Experimental|Hyperinvasive arm|Hyperinvasive arm encompasses immediate institution of a mechanical chest compression device (LUCAS) and pre-hospital intraarrest cooling by Rhino-Chill device. Immediately after institution of these two devices the patients will be directly transferred to cardiac center cathlab under continuous CPR. The use of drugs and further defibrillations are on a discretion of the emergency physician. After admission to cathlab, overall status, ROSC presence and ECLS inclusion/exclusion criteria will be evaluated.
3155452|NCT01511666|Active Comparator|Standard arm|Patients in standard arm will be further managed as per recent ERC guidelines, ie. continued ACLS. The use of drugs and further defibrillations are on a discretion of the emergency physician. If ROSC is attained, patients will be transferred to the same hospital to one of intensive care units, coronary angiography/PCI will be performed only if indicated according to routine practice and mild therapeutic hypothermia will be instituted as soon as possible as per recent guidelines recommendation.
3155453|NCT01511640|Experimental|Pregabalin 1|Dose 1
3155454|NCT01511640|Placebo Comparator|Placebo|Placebo
3155455|NCT01511627|Active Comparator|General Anesthesia|
3155456|NCT01511627|Experimental|General Anesthesia + Spinal Anesthesia|
3155457|NCT01511562|Other|Arm I|Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant.
3155458|NCT01511562|Other|Arm II|Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy.
3155459|NCT01511549|Experimental|Dose 1|SAR113945 low dose
3155460|NCT01511549|Experimental|Dose 2|SAR113945 medium dose
3155461|NCT01511549|Experimental|Dose 3|SAR113945 high dose
3155462|NCT01511549|Placebo Comparator|Placebo|Placebo
3155463|NCT01511536|Experimental|Phase 1: Cabazitaxel 20 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
3155464|NCT01511536|Experimental|Phase 1: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
3155465|NCT01511536|Experimental|Phase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel at maximum tolerated dose (MTD) as determined in phase 1 part (25 mg/m^2) IV infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
3155466|NCT01511523|Active Comparator|RGMA001|Proprietary blend of Vitamin E, Silymarin, and Carnitine.
3155467|NCT01511523|Placebo Comparator|Sugar Pill|No treatment.
3155468|NCT01511510|Experimental|PF-04958242|
3155469|NCT01511510|Placebo Comparator|Placebo|
3155470|NCT01511497|Experimental|PF-04427429|
3155471|NCT01511497|Placebo Comparator|Placebo|Normal saline
3155472|NCT01511484|Experimental|Information-only|"Selected pages from the British National Health Service (NHS) information booklets [5 A Day, Just Eat More (fruit & veg); pages i, ii, 12-15, 20 & 21] and [5 A Day, Just Eat More (fruit & veg): What's it all about?; pages i-ii)] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions"
3155473|NCT01511484|Experimental|Generic-appearance intervention|"Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.~Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.~Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour."
3155474|NCT01511484|Experimental|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
3155475|NCT01511471|Experimental|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
3155476|NCT01511458||Case|Patient with a trisomy 21 pregnancy confirmed by genetic testing.
3155477|NCT01511458||Control|Patients without a trisomy 21 pregnancy confirmed by either genetic testing or a normal newborn phenotype.
3155478|NCT01511445|Active Comparator|ACDF with PEEK interbody cage|Anterior cervical discectomy and fusion (ACDF) with an interbody spacer made from polyetheretherketone (PEEK) plastic. The open space in the center of the cage is to be filled with local autologous bone harvested during the decompression phase of the procedure.
3155479|NCT01511445|Experimental|ACDF with Valeo CSC Ceramic Cage|ACDF with the Valeo CSC cage, a silicon nitride ceramic interbody cage. The center area of the cage is filled with porous silicon nitride. No autologous bone is used; the cage is soaked in patient blood.
3155480|NCT01511432|Experimental|Part A|Part A will be a 4-formulation, 4-sequence, 4-period crossover relative bioavailability study of 3 novel oral telaprevir formulations relative to the 375-mg Incivek tablet in the fed state.
3155481|NCT01511432|Experimental|Part B|Part B will be a 2-formulation, 6-sequence, 3-period cross-over relative bioavailability study of the novel oral telaprevir formulation selected from Part A in the fasted relative to the fed state and relative to the 375-mg Incivek tablet in the fasted state
3155482|NCT01511419|Experimental|live attenuated influenza vaccine|Monovalent H7N3 live monovalent influenza vaccine
3155483|NCT01511419|Placebo Comparator|placebo|manufactured placebo based on allantoic fluid of chicken embryos not inoculated with influenza virus
3155484|NCT01511406|Experimental|cognitive behavioral therapy|Cognitive behavioral therapy up to 26 sessions
3155485|NCT01511393||Questionnaire|None. Non-interventional study.
3155531|NCT01511198|Active Comparator|Met|
3155532|NCT01511185|Experimental|NNC 90-1170|
3155533|NCT01511185|Placebo Comparator|Placebo|
3155486|NCT01511380|Experimental|Risk Reduction Therapy for Adolescents|Youth randomly assigned to RRTA will complete a family focused treatment program that will work with the youth and his or her caregiver to help reduce youth substance use and risky sexual behavior using principals of behavior modification and contingency management.
3155487|NCT01511380|Active Comparator|Usual services|For youth randomly assigned to usual treatment services, the youth will receive the treatment services recommended by the drug court.
3155488|NCT01511367|Active Comparator|Flutiform|
3155489|NCT01511367|Active Comparator|Seretide|
3155490|NCT01511367|Active Comparator|Flixotide|
3155491|NCT01511354||Standard clinical care|Standard nutritional therapy and treatment
3155492|NCT01511341|Experimental|Telenursing|
3155493|NCT01511341|No Intervention|Standard practice|Group receive the standard practice, without telephone nursing intervention.
3155494|NCT01511328|Experimental|HPV testing|Women randomised to this arm get primary HPV testing
3155495|NCT01511328|No Intervention|cytology|women included follow the standard procedure with primary cytology
3155496|NCT01511315|Experimental|Ustekinumab|
3155497|NCT01511302|Experimental|RNS60-BD 0.25|RNS60 in combination with Budesonide 0.25mg/2ml concentration
3155498|NCT01511302|Experimental|RNS60-BD 0.5|RNS60 in combination with Budesonide 0.5mg/2ml concentration
3155499|NCT01511302|Placebo Comparator|NS-BD 0.5|Normal Saline control (NS) in combination with Budesonide 0.5mg/2ml concentration
3155500|NCT01511289|Active Comparator|Imatinib|Imatinib 400mg QD
3155501|NCT01511289|Experimental|Radotinib 600mg|Radotinib 300mg BID
3155502|NCT01511289|Experimental|Radotinib 800mg|Radotinib 400mg BID
3155503|NCT01511276|Experimental|Diet-induced weight loss|The diet-induced weight loss group will follow a calorie restricted diet. They are asked to keep their habitual sedentary lifestyle. The aim of this group is to loose 5-6 kg of body weight in 14 weeks time.
3155504|NCT01511276|Experimental|Mainly exercise induced weight loss|"Participants in the exercise- plus diet-induced weight loss group are enrolled in an exercise programme. Next to the exercise programme, they will follow a calorie restricted diet.~The aim of this group is to loose 5-6 kg of body weight in 14 weeks time."
3155505|NCT01511276|No Intervention|Control, stable weight|The control group is asked to follow a baseline isocaloric diet and to not change their habitual sedentary lifestyle.
3155506|NCT01511263|Active Comparator|Arm A|The patients will be divided into 4 strata according to cardiac dysfunction and to the quality of hematologic response. After stratification the patients will be randomized (1:1) within each stratum to receive Standard Therapy alone (Arm A) or Standard Therapy plus Investigational Drug (Arm B).
3155507|NCT01511263|Experimental|Arm B|The patients will be divided into 4 strata according to cardiac dysfunction and to the quality of hematologic response. After stratification the patients will be randomized (1:1) within each stratum to receive Standard Therapy alone (Arm A) or Standard Therapy plus Investigational Drug (Arm B)
3155508|NCT01511250|Experimental|Part I: TDV 21 to 45 Years (yrs)|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 plaque forming units (PFU), 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
3155509|NCT01511250|Placebo Comparator|Part I: Placebo 21 to 45 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
3155510|NCT01511250|Experimental|Part I: TDV 12 to 20 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
3155511|NCT01511250|Placebo Comparator|Part I: Placebo 12 to 20 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
3155512|NCT01511250|Experimental|Part I: TDV 6 to 11 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
3155513|NCT01511250|Placebo Comparator|Part I: Placebo 6 to 11 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
3155514|NCT01511250|Experimental|Part I: TDV 1.5 to 5 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
3155515|NCT01511250|Placebo Comparator|Part I: Placebo 1.5 to 5 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
3155516|NCT01511250|Experimental|Part II: TDV 1.5 to 11 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
3155517|NCT01511250|Placebo Comparator|Part II: Placebo 1.5 to 11 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
3155518|NCT01511237|Experimental|Perinatal intensification|"Perinatal antiretroviral intensification (study treatment):~Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum~Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks~The standard of care in Thailand is defined as:~Maternal: ZDV 300 mg, 3TC 150mg and LPV/r 400/100 twice a day starting as soon possible after 14 weeks of pregnancy + ZDV 300 mg every 3 hours during labor~Newborn: ZDV 4 mg/kg every 12 hours for 4 weeks (ZDV dosing adjusted for premature infants)."
3155519|NCT01511224||Colistin monotherapy|
3155520|NCT01511224||Colistin based combination therapy|Colistin-Tigecycline, Colistin-Carbapenem, Colistin-Rifampin, Colistin-HD Unasyn
3155521|NCT01511224||Non-colistin containing regime|
3155522|NCT01511224||Glycopeptide with colistin combination|
3155523|NCT01511224||Colistin with loading dose|
3155524|NCT01511211|Experimental|Ropivacaine + Dexamethasone Combination|
3155525|NCT01511211|Active Comparator|Ropivacaine-Only Block|
3155538|NCT01511172|Active Comparator|Met + Glim|
3155539|NCT01511159|Experimental|NNC 90-1170, initial dose|
3155540|NCT01511159|Experimental|NNC 90-1170|
3155541|NCT01511159|Active Comparator|Insulin|
3155542|NCT01511159|Experimental|NNC 90-1170, final dose|
3155543|NCT01511146|Experimental|Mitomycin+Gemcitabine|Intrahepatic treatment, where all standard treatments have been used
3155544|NCT01511133||HRV Group|Subjects received two or three doses of HRV in previous studies.
3155545|NCT01511133||Placebo Group|Subjects received two or three doses of placebo in previous studies.
3155546|NCT01511120|Active Comparator|Tetraspan|
3155547|NCT01511107|Active Comparator|Amoxicillin-Clavulanate, 10 days|amoxicillin-clavulanate, 90/6.4 mg/kg/day, 2 divided doses, 10 days
3155548|NCT01511107|Other|Amoxicillin-Clavulanate, 5 days|amoxicillin-clavulanate, 90/6.4 mg/kg/day, 2 divided doses, 5 days plus placebo, 2 divided doses, 5 days
3155549|NCT01511094|Experimental|Eye Surgery|Goniocurettage was used to treat open angle glaucoma patients
3155550|NCT01511081|Experimental|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
3155551|NCT01511081|Experimental|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
3155552|NCT01511068|Experimental|inhaled recombinant|inhaled recombinant human GM-CSF in individuals with hereditary Pulmonary Alveolar Proteinosis (PAP) due to partial dysfunction of the GM-CSF receptor
3155553|NCT01511055|Experimental|Folate-FITC|
3155554|NCT01511029|Experimental|Dexpramipexole|
3155555|NCT01511029|Placebo Comparator|Dexpramipexole (placebo)|
3155556|NCT01511029|Active Comparator|Moxifloxacin|
3155557|NCT01511016|Experimental|human recombinant leptin (metreleptin)|Each subject received 0.02 mg leptin / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg leptin / kg for two more months.
3155558|NCT01511016|Placebo Comparator|Placebo injection|Each subject received placebo at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by a dose of 0.04 mg / kg for two more months.
3155559|NCT01511003|Experimental|Tacrolimus group|oral
3155560|NCT01510990|Experimental|Gefitinib|"After a baseline 18F FDG-PET, patients are treated with gefitinib 250mg/d as 1st line treatment for 7 days. And follow up 18F-FDG PET image is acquired after 1 week's treatment of gefitinib (with window period +/- 2 days).~If % decrease of peak SUV of main lesion is 20% or more, gefitinib treatment is continued till progression, unacceptable toxicities or patient's refusal. But if % decrease of peak SUV of main lesion less than 20% or peak SUV increase, gefitinib treatment is stopped, and changed to Pemetrexed/Cisplatin chemotherapy."
3155561|NCT01510977|Active Comparator|PEG|2L of polyethylene glycol addition immediately after first colonoscopy failure
3155562|NCT01510977|Experimental|PEG + bisacodyl|One week after initial colonoscopy failure, conventional amount (5L) of polyethylene glycol together with bisacodyl administration
3155563|NCT01510964|Experimental|prompt-sheet|"Patients and companions of intervention group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and the prompt sheet. An introduction explains the importance of asking questions during the consultations. The patient (companion) is invited to select among a written list of about 50 possible questions those, if any, s/he would like to ask today to the oncology."
3155564|NCT01510964|Other|control group|"Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist"
3155565|NCT01510951|Placebo Comparator|PLACEBO|
3155566|NCT01510951|Experimental|AMG 811|
3155567|NCT01510938|Placebo Comparator|Placebo|1 g of rice maltodextrin will be reconstituted in 25-50 ml of tepid water or juice and immediately fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
3155568|NCT01510938|Experimental|Probiotic|"powder of L. acidophilus DDS-1, B. lactis UABLA-12, 50 mg of fructooligosaccharide~1 g of probiotic will be reconstituted in 25-50 ml tepid water or juice and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer."
3155569|NCT01510912|Experimental|Diclofenac Capsules 35 mg bid or tid|
3155570|NCT01510899|Experimental|Healthy Subjects Arm|
3155571|NCT01510899|Experimental|Renal Impaired Subjects Arm|
3155572|NCT01510886||1|
3155573|NCT01510873||Newly Diagnosed pITP|Patients within 3 months from diagnosis.
3155574|NCT01510873||Persistent pITP|Patients between 3 to 12 months from diagnosis; includes patients not reaching spontaneous remission or not maintaining complete response off therapy.
3155575|NCT01510873||Chronic pITP|Patients with ITP lasting for more than 12 months.
3155576|NCT01510860|Active Comparator|Ursodeoxycholic acid (UDCA)250 mg|UDCA 250 mg capsule
3155577|NCT01510860|Experimental|Ursodeoxycholic acid (UDCA)500 mg|UDCA 500 mg tablet
3155578|NCT01510847|Other|Oral Testosterone Therapy|90 day oral testosterone therapy
3155579|NCT01510834|Experimental|All STR2IVE Participants|All participants who met study criteria, consented and were enrolled, were asked to complete online assessments at three timepoints(baseline, 1-month, and 3-months) and complete 2 or more behavioral programs each month. Behavioral programs and assessments were provided online via the Multibehavioral, Computerized Tailored Intervention STR2IVE.
3155580|NCT01510821|Experimental|Maquet Vasoshield Arm|Pressure limiting syringe
3155581|NCT01510821|Active Comparator|Non-regulated Arm|standard non-regulated syringe
3155582|NCT01510808||aggressive Periodontitis|Aggressive Periodontitis during maintenance
3155583|NCT01510808||aggressive periodontitis|aggressive periodontitis patients during maintenance
3155584|NCT01510795|No Intervention|retrospective control|
3155585|NCT01510795|Active Comparator|spironolactone|
3155586|NCT01510782|Experimental|BI 655064 subcutaneous|Escalating single dose as solution for subcutaneous injection
3155587|NCT01510782|Placebo Comparator|Placebo to BI 655064 subcutaneous|Escalation single dose as solution for subcutaneous injection (Placebo)
3155588|NCT01510782|Experimental|BI 655064 intravenous|Escalating single dose as solution for intravenous infusion
3155589|NCT01510782|Placebo Comparator|Placebo to BI 655064 intravenous|Escalating single dose as solution for intravenous infusion (Placebo)
3155590|NCT01510769|Experimental|lesinurad 400 mg + febuxostat 80 mg|
3155591|NCT01510769|Experimental|lesinurad 200 mg + febuxostat 80 mg|
3155592|NCT01510769|Placebo Comparator|placebo + febuxostat 80 mg|
3155593|NCT01510756|Experimental|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days).
3155594|NCT01510743|Active Comparator|Group SC|US guided subclavian vein catheterization
3155595|NCT01510743|Active Comparator|Group IJ|US-guided internal jugular vein catheterization
3155596|NCT01510730|No Intervention|control group|no treatment for Helicobacter pylori infection
3155597|NCT01510730|Active Comparator|treatment group|treatment group receive eradication treatment for helicobacter pylori infection
3155598|NCT01510717|Experimental|Multifocal IOL|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
3155599|NCT01510717|Active Comparator|Monofocal IOL|AcrySof® IQ Monofocal IOL Model SN60WF, bilateral implantation
3155600|NCT01510704|Placebo Comparator|Placebo|
3155601|NCT01510704|Experimental|Low dose APD421|1mg dose level
3155602|NCT01510704|Experimental|Mid Dose APD421|5mg dose level
3155603|NCT01510704|Experimental|High Dose APD421|20mg dose level
3155604|NCT01510691||Epiretinal membrane|
3155605|NCT01510691||diabetic macular edema|
3155606|NCT01510691||vein occlusion|
3155607|NCT01510678|Experimental|Decrease Condition|In the Decrease Snack Foods condition participants will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to < 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
3155608|NCT01510678|Experimental|Increase + Decrease Condition|Families will be encouraged to increase fruits and vegetables and decrease snack foods.
3155609|NCT01510678|Experimental|Increase Condition|A parent and child will be encouraged to increase fruits and vegetables. Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables.
3155610|NCT01510665|Experimental|Magnesium Supplement|Magnesium citrate dietary supplement (300 mg elemental Magnesium daily dose) given week 13 to week 28 (two pills daily)
3155611|NCT01510665|Placebo Comparator|Placebo|Identical appearing pill with inactive ingredients given week 13 to week 28 (two pills daily)
3155612|NCT01510665|Active Comparator|Diet|Nutritionist counseling session and advice on following a magnesium rich diet from week 13 to week 28
3155613|NCT01510652|Active Comparator|Quad Group|Patients in the Quad group will be implanted with St. Jude Medical (SJM) quadripolar Left Ventricular (LV) lead Quartet
3155614|NCT01510652|Active Comparator|BiP Group|Patients in the BiP Group will be implanted with a standard (regulatory approved and commercially available) bipolar left ventricular lead from other companies (non St. Jude Medical leads)
3155615|NCT01510639|Experimental|Cuff repair PRP|Cuff repair Platelet Rich Plasma: The application of autologous thrombocyte concentrate in the cuff repair group
3155616|NCT01510639|No Intervention|Cuff repair Control|No intervention
3155617|NCT01510639|Experimental|NEER PRP|Neer Platelet Rich Plasma: The application of autologous thrombocyte concentrate in the NEER surgery group
3155618|NCT01510639|No Intervention|NEER Control|No intervention
3155619|NCT01510626|Experimental|One|
3155620|NCT01510613|Experimental|Pomalidomide and Dexamethasone|
3155621|NCT01510587|Experimental|4-Health Educational curriculum|Parents participate in 10 face-to-face educational sessions delivered by Extension Agents at individual county locations over a 8-month period (fall to spring).
3155622|NCT01510587|Active Comparator|Healthy Living Information|Participants receive 10 mailed packets of written information derived from USDA's MyPlate website on approximately the same schedule as meetings of the experimental group.
3155623|NCT01510574|Active Comparator|misoprostol|3 tablets of 200mcg misoprostol self-administered following home birth, taken orally immediately after delivery of baby
3155624|NCT01510574|Placebo Comparator|placebo|3 tablets of placebo resembling misoprostol self-administered following home birth, taken orally immediately after delivery of baby
3155625|NCT01510561|Experimental|90Y-hPAM4|90Y-hPAM4 is administered weekly for 3 weeks
3155626|NCT01510561|Experimental|90Y-hPAM4 + gemcitabine|90Y-hPAM4 is administered weekly for 3 weeks, while gemcitabine is administered weekly for 4 weeks.
3155627|NCT01510548|Active Comparator|Adalimumab 20 mg per week|Patient will get at double blind situation adalimumab 20 mg every week (six injections) injections
3155628|NCT01510548|Active Comparator|Adalimumab 40 mg per week|Patient will get at double blind situation adalimumab 40 mg per week injections
3155629|NCT01510548|Placebo Comparator|placebo arm|Patient will get at double blind situation placebo (= NaCl liquid solution, absolutely same color as the active drug) injections one per week during six weeks - same as the adalimumab arms
3155630|NCT01510535|Experimental|Placebo and then LBSA0103|The experimental group receive once weekly for 2 weeks intraarticular injections of Placebo(saline). And then, they receive once intraarticular injections of LBSA0103 into the target knee.
3155631|NCT01510535|Active Comparator|Hyruan Plus|The control group received once weekly for 3 weeks intraarticular injections of Hyruan Plus Inj. into the target knee.
3155632|NCT01510522|Experimental|Glucophage sachets|Patients receive Glucophage sachets, the powder formulation for oral solution in sachets.
3155633|NCT01510522|Active Comparator|Glucophage tablets|Patients received Glucophage tablets.
3155634|NCT01510509|Experimental|Titanium bare metal stent|Titanium bare metal stent (Titan2®, Hexacath, Paris, France)
3155635|NCT01510509|Experimental|Everolimus Drug Eluting Stent|Xience-V®, Abbott Vascular, Santa Clara, California, USA
3155636|NCT01510496||Patients who had inguinal herniorraphy.|
3155637|NCT01510496||Patients who had hysterectomy.|
3155638|NCT01510496||Patients who had thoracotomy.|
3155639|NCT01510483|Experimental|Obesity prevention|Orthodontist promotion of physical activity and healthy diet
3155640|NCT01510483|Active Comparator|Tobacco prevention|Orthodontist promotion of tobacco and second hand smoke avoidance
3155641|NCT01510457|Placebo Comparator|Sugar Pill|BID placebo
3155642|NCT01510457|Experimental|Milnacipran|Uptitration from 10mg to 50mg BID Milnacipran
3155643|NCT01510431|Experimental|PROCHYMAL|Mesenchymal stem cells
3155644|NCT01510418||Person with congenital bleeding disorder|Adult men with congenital hemophilia A or B
3155645|NCT01510418||Spouse/Significant Other|Spouse/significant other of person with congenital bleeding disorder participating in this study.
3155646|NCT01510405||40 Participants|Participants undergoing or who have undergone thoracic surgery for presumed lung cancer with a wedge resection, lobectomy, bilobectomy, segmentectomy and/ or pneumonectomy thoracic surgical operation.
3155647|NCT01510379|Active Comparator|Reletex|Reletex plus scheduled IV ondansetron 4 mg q 6 hours for a total of 4 doses. Breakthrough nausea will be treated using IV promethazine 25 mg q 6 hours prn during the hospital stay and in elixir at the same dose and frequency after discharge.
3155648|NCT01510379|Other|Control|Scheduled IV ondansetron 4 mg q 6 hours for a total of 4 doses. Breakthrough nausea will be treated using IV promethazine 25 mg q 6 hours prn during the hospital stay and in elixir at the same dose and frequency after discharge.
3155649|NCT01510366|Experimental|Cohort 1|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections.
3155650|NCT01510366|Experimental|Cohort 2:|Inactivated Poliomyelitis Vaccine (Salk strains) 3 x 0.5ml intramuscular injections.
3155651|NCT01510353|Experimental|Use of a radiation monitoring device|Use of a radiation monitoring device that provides real-time auditory feedback on radiation exposure during cardiac catheterization
3155652|NCT01510353|No Intervention|No use of radiation monitoring device|No use of a radiation monitoring device that provides real-time auditory feedback on radiation exposure during cardiac catheterization
3155653|NCT01510340|No Intervention|Web sites|Patients assigned to this arm are given a list of Web sites where they can collect information related to their condition at their leisure.
3155654|NCT01510340|Experimental|VIH-TAVIE|Patients assigned to this arm must follow the four interactive computer sessions
3155655|NCT01510327|Experimental|PROMUS Element|Patients who received the PROMUS Element everolimus-eluting stent (EES) implanted using standard percutaneous coronary intervention (PCI) technique. Total loaded dose of everolimus per stent is dependent on stent size and in this study the administered dose ranged from 60.1 µg to 138.6 µg per stent. Note that the total dose of everolimus administered to a patient is based on the number of stents received and the size of the stent(s). The total dose received per patient ranged from 60.1 µg to 197.8 µg.
3155656|NCT01510301|Other|Self-report|
3155657|NCT01510288|Experimental|Ipilimumab and GVAX|
3155658|NCT01510275|Experimental|Intervention|Combined use of RESPIVOL® and RESPILIFT® (with resistive load)
3155659|NCT01510275|Sham Comparator|Control|Combined use of RESPIVOL® and RESPILIFT® (without resistive load)
3155660|NCT01510262|Experimental|Tailored Socio-Contextual Intervention|"Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, & piloting.~Recruit/enroll in the intervention 500 subjects (50% women; African American focus).~After subjects receive STI diagnosis, treatment,& partner notification services, randomly assign subjects to:~A. The STI strengths-based prevention case management, or B. Standard care.~Assess participants' risk behavior, determinants of behavior & quality of life. Investigators will assess the incidence of new STI & test the efficacy of the intervention relative to control.~Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.~Conduct cost effectiveness analyses of intervention compared to the standard."
3155661|NCT01510262|Active Comparator|Standard of Care|Currently, the total time spent in an STI exam w/men is 30 minutes & 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners & number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms & testing/treatment resources. Referral information is provided when needed & more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
3155662|NCT01510236|Experimental|Early self-help program|The early self-help program starts directly after randomization i.e. 4 weeks after diagnosis.
3155663|NCT01510236|Experimental|Later self-help program|The later self-help program starts sixty-two weeks after diagnosis.
3155664|NCT01510223|Experimental|Dietary supplementation macademia oil|emia oil
3155665|NCT01510223|Experimental|Dietary supplementation olive oil|Olive oil
3155666|NCT01510223|Experimental|Dietary Supplementation fish oil|fish oil
3155667|NCT01510184|Active Comparator|Zevalin (ibritumomab tiuxetan)|Day 1: Rituximab 250 mg/m2 intravenous infusion Days 7-9:Rituximab 250 mg/m2 intravenous infusion followed by Y-90-Zevalin 14.8 MBq/kg. In centers where biodistribution imaging is performed Day 1: Rituximab 250 mg/m2 intravenous infusion followed by In-111-Zevalin 185 MBq (5mCi), Days 3-4: Biodistribution imaging Days 7-9: Rituximab 250 mg/m2 intravenous infusion followed by Y-90-Zevalin 14.8 MBq/kg
3155668|NCT01510184|No Intervention|Observation Arm|Patients randomized to the observation (control) arm will not receive any further anti-lymphoma therapy unless they have a relapse of their disease.
3155669|NCT01510171|Active Comparator|Prasugrel loading dose|
3155670|NCT01510171|Active Comparator|Ticagrelor Loading dose|
3155671|NCT01510158|Experimental|lesinurad 200 mg + allopurinol|
3155672|NCT01510158|Experimental|lesinurad 400 mg + allopurinol|
3155673|NCT01510158|Placebo Comparator|Placebo + allopurinol|
3155674|NCT01510145|Experimental|TRAVATAN® BAK-free|Travoprost 0.004% BAK-free, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks.
3155675|NCT01510132|Experimental|Travacom|Travoprost/timolol fixed combination self-administered at the rate of 1 drop per eye, one time a day, at approximately 8 a.m. each day for 8 weeks.
3155676|NCT01510093|Other|Insulin Aspart without glucose supply|Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight without intravenous glucose supply
3155677|NCT01510093|Other|Insulin Aspart with glucose supply|Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight combined with intravenous glucose supply
3155678|NCT01510080|Experimental|Computer-assisted live supervision|"Supervisees assigned to this group will receive 8 sessions of computer-assisted live supervision and 4 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. Computer-assisted live supervision is also known as bug-in-the-eye (BITE) supervision. The supervisor observes the therapy session with the help of a webcam and types messages on his computer. The instructions to the supervisee appear on a second monitor located in the therapy room where the supervisee can view it whenever he wants to."
3155679|NCT01510080|Experimental|Delayed video-based supervision|Supervisees assigned to this group will receive 12 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. During delayed video-based supervision the supervisor and the supervisee spend 50 minutes reviewing selected parts of video recorded therapy sessions and discussing the case.
3155680|NCT01510054||steroid support|Endometrial biopsies from subjects of with or without luteal phase steroid support will be compared for miRNA expression
3155681|NCT01510041|Experimental|Inspiratory muscle training group|
3155682|NCT01510041|Experimental|Respiratory exercise group|
3155683|NCT01510028|Experimental|Cohort 1 (10 mg)|6 patients treated with HGT-1110 10 mg EOW by IT injection
3155684|NCT01510028|Experimental|Cohort 2 (30 mg)|6 patients treated with HGT-1110 30 mg EOW by IT injection
3155685|NCT01510028|Experimental|Cohort 3 (100 mg)|6 patients treated with HGT-1110 100 mg EOW by IT injection
3155686|NCT01510028|Experimental|Cohort 4 (100 mg)|6 patients treated with HGT-1110 100 mg EOW by IT injection
3155687|NCT01510015|Active Comparator|Anti-psychotic medication|Participants are treated with psychological treatment both group and individually as well as medications according to their mental condition.
3155688|NCT01510015|Active Comparator|Counseling|Participants will receive individual and group therapy
3155689|NCT01510002|Active Comparator|TT|Extracapsular total thyroidectomy
3155690|NCT01510002|Experimental|TT+CND|Extracapsular total thyroidectomy puls prophylactic central neck dissection
3155691|NCT01509976|Other|Red|This arm will either start with personal care products that contain triclosan and then and cross over to personal care products that do not contain triclosan or vice-versa. Since the investigators are blinded, it is not clear which arm is which.
3155692|NCT01509976|Other|Blue|This arm will either start with personal care products that contain triclosan and then and cross over to personal care products that do not contain triclosan or vice-versa. Since the investigators are blinded, it is not clear which arm is which.
3155693|NCT01509963||patients candidates for the SN procedure|The study will focus on patients candidates for the SN procedure as recommended by Saint-Paul de VENCE initially in 2005 but modified in 2009.
3155694|NCT01509950|Active Comparator|Staples|Use of staples for skin closure at cesarean section
3155695|NCT01509950|Active Comparator|Prolene non-absorbable sutures|Use of Prolene non-absorbable sutures for skin closure at cesarean section
3155696|NCT01509950|Active Comparator|Absorbable sutures|Use of absorbable sutures for skin closure at cesarean section; monocryl or vicryl.
3155697|NCT01509937|Experimental|BCM Arm|BCM measured every 2 months
3155698|NCT01509937|Sham Comparator|Control arm|patients care according to standard of care
3155699|NCT01509924|Experimental|Physical activity on Prescription (PaP)|Intervention group receives a PaP for 12 month.
3155700|NCT01509924|No Intervention|Control Group|The control group has the same monitoring as the experimental group but receives no PaP.
3155701|NCT01509924|No Intervention|Cognitiv function in patients with TIA|"Before discharged from hospital cognitive function is assessed. At the first visit the patients fill in a self assessment questionnaire for mental fatigue.~If impaired at the previous assessment cognitive function will be assessed at 3, 6 and 12 month."
3155702|NCT01509924|No Intervention|Controlgroup Cognitive function|In order to determine whether hospitalization in itself is associated with transient impaired cognition, a comparison group will be included. The comparison group will consist of patients with angina pectoris consecutively admitted to the Norrtälje Hospital. The patients with angina pectoris will be age and sex matched with the patients with TIA and assessed for cognitive function when their angina symptoms have subsided.
3155703|NCT01509911|Experimental|TL-118 with standard of care Gemcitabine|
3155704|NCT01509911|Active Comparator|Gemcitabine with out TL-118|
3155705|NCT01509898|Experimental|water-Jet|use of water jet for 1 month
3155706|NCT01509885||Complete Spinal Cord Injured Subjects|Patients with no motor scores in their legs and suffering a complete spinal cord injury.
3155707|NCT01509885||Incomplete Spinal Cord Injured Subjects|Patient with some motor preservation below the injury and suffering an incomplete spinal cord injury.
3155708|NCT01509872|Experimental|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behaviour Therapy (Cohen, Mannarino, Deblinger, 2006; Smith and Saunders, 2005) is a child-friendly, manualised psychological intervention for children who experience nightmares, flashbacks, anxiety, anger, social isolation, poor concentration or self-blame after experiencing or witnessing a violent and terrifying life event (e.g. rape, murder, abduction etc). This intervention was culturally modified for use with war-affected children.
3155709|NCT01509872|Active Comparator|A Child Friendly Space|A Child Friendly Space is a psychosocial intervention combining creative (e.g. art), imaginative (e.g. drama), physical (e.g. football), communicative (e.g. group discussions) and manipulative activities (e.g. story telling). It aids children's natural development by providing a safe place for children to learn, express themselves, grow and develop, supported by trained animators and peer educators.
3155710|NCT01509859|Active Comparator|PFNA|"these patients will be treated with synthes PFNA device"
3155711|NCT01509859|Active Comparator|INTERTAN|"these patients will be treated with Smith&Nephew INTERTAN device"
3155712|NCT01509846|Experimental|Cohort 4|Three oral doses of 2.6±0.8 x 10^11 vp/mL (20 participants) or placebo (5 participants).
3155713|NCT01509846|Experimental|Cohort 3|Three oral doses of 2.6±0.8 x 10^10 vp/mL (20 participants) or placebo (5 participants).
3155714|NCT01509846|Experimental|Cohort 2|Three oral doses of 2.6±0.8 x 10^9 vp/mL (20 participants) or placebo (5 participants).
3155715|NCT01509846|Experimental|Cohort 1|One oral dose of 2.6±0.8 x 10^8 vp/mL (5 participants) or placebo (2 participants).
3155716|NCT01509833|Experimental|rFSH|Administration of recombinant FSH for ovarian stimulation.
3155717|NCT01509833|Experimental|hCG(100IU)|Administration of late follicular low dose hCG(100U) for ovarian stimulation.
3155718|NCT01509833|Experimental|hCG(200IU)|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
3155719|NCT01509807|Active Comparator|Group 1|IV morphine sulfate (or Sponsor-approved equivalent), Standard of Care (SOC)
3155720|NCT01509807|Experimental|Group 2|EXPAREL (bupivacaine liposome injectable suspension)
3155721|NCT01509794|Active Comparator|Low Valence|Participants in the low valence condition will participate in photo-based simulations. They will see a photo of the patient and hear affectively flattened audio. The script and clinical information remain the same as the high valence condition.
3155722|NCT01509794|Experimental|High Valence|Participants in the high valence condition will participate in video-based simulations. They will see a rich multimedia presentation of the clinical encounter, with affectively enhanced audio. The script and clinical information remain the same as the low valence condition.
3155723|NCT01509781|Active Comparator|Suction drain|Patients in Arm A undergo simplex mastectomy or modified radical mastectomy. One plastic Redon drain (16 Ch) is placed after simplex mastectomy and two plastic Redon drains (16 Ch each) following modified radical mastectomy.
3155724|NCT01509781|Experimental|Adaptive suture|Following mastectomy, wound cavity is closed with adaptive skin sutures. No suction drain is inserted.
3155725|NCT01509768||No treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIB to identify endpoints that may be used for future ERT trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral and imaging measures
3155726|NCT01509755|Placebo Comparator|Placebo|
3155727|NCT01509755|Experimental|0.045 mg|
3155728|NCT01509755|Experimental|0.225 mg|
3155729|NCT01509755|Experimental|0.45 mg|
3155730|NCT01509755|Experimental|0.60 mg|
3155731|NCT01509755|Experimental|0.75 mg|
3155732|NCT01509755|Active Comparator|Glim|
3155733|NCT01509742|Experimental|NNC 90-1170|
3155734|NCT01509742|Placebo Comparator|Placebo|
3155735|NCT01509729|Placebo Comparator|Sham operation|
3155736|NCT01509729|Active Comparator|Knee arthroscopic surgery|
3155737|NCT01509703|Experimental|High flow therapy|
3155738|NCT01509677|Active Comparator|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
3155739|NCT01509677|Active Comparator|Placebo|tablet, once daily, oral administration in the morning after breakfast
3155740|NCT01509664|Experimental|Discount intervention|Receives 50% discount intervention on selected fruits and vegetables at participating supermarket.
3155741|NCT01509664|No Intervention|Control|Received no discount at the participating supermarket.
3155742|NCT01509651|Experimental|Sugammadex|
3155743|NCT01509638|Active Comparator|Group 1 Standard of Care|IV Morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump
3155744|NCT01509638|Active Comparator|Group 2 EXPAREL|bupivacaine liposome injectable suspension.
3155745|NCT01509612|Active Comparator|Additive homeopathy in cancer patients|Lung cancer patients receiving conventional chemo- and/or radiation therapy receive additive classical homeopathy with homeopathic globules
3155746|NCT01509612|Placebo Comparator|Additive homeopathic placebo globules|Lung cancer patients receiving conventional chemo- and/or radiation therapy receive homeopathic placebo globules
3155747|NCT01509612|No Intervention|No intervention|No intervention
3155748|NCT01509599|Experimental|Cryotherapy|"Cryotherapy is delivered via a cooling gel wrap applied to the affected lower leg using a dosing regimen, starting with daily cooling in month one to PRN in the last 3 months over the 9 month study."
3155749|NCT01509599|Sham Comparator|Usual care|"The sham wrap, filled with cotton, is applied to the affected lower leg using a dosing regimen, starting with daily application in month one to PRN in the last 3 months over the 9 month study."
3155750|NCT01509586|Experimental|PREP (Potentially Reduced Exposure Product) Group|
3155751|NCT01509586|No Intervention|cigarette group|
3155752|NCT01509573|Experimental|FSI-R (Intervention group)|The intervention group will participate in the mental health assessments and FSI-R, and will participate in post-intervention assessments and follow-up assessments.
3155753|NCT01509573|No Intervention|TAU (Treatment as Usual)|The TAU control group will not receive any intervention, but will participate in treatment as usual as provided by Partners In Health. They will complete assessments at all three time points.
3155754|NCT01509560|Experimental|Everolimus|All patients will be given everolimus and the magnitude of the side effects will be measured
3155755|NCT01509547|Experimental|varenicline|Participants >55 kg will take varenicline 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily for 11 weeks. Participants ≤55 kg will take varenicline 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily for 11 weeks.
3155756|NCT01509547|Placebo Comparator|placebo|Participants >55 kg will take placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily for 11 weeks. Participants ≤55 kg will take placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily for 11 weeks.
3155757|NCT01509521|Active Comparator|Ephedrine|
3155758|NCT01509521|Active Comparator|Phenylephrine|
3155759|NCT01509508|Experimental|Immediate ARV treatment initiation|Initiation of ARV treatment regardless of participants's immunological and clinical staging
3155760|NCT01509508|Other|South African recommendation guided ARV initiation|HIV-infected individuals will be assessed clinically and immunologically and when eligible for treatment as per South African guidelines will be offered ART
3155761|NCT01509482|Experimental|insulin resistance|unexplained oligospermia and azoospermia. Blood samples will be taken for hormonal and blood lipids analysis.
3155762|NCT01509482|Active Comparator|Fertile males|Healthy Men with proven fertility. Blood samples will be taken for hormonal and blood lipids analysis
3155763|NCT01509469|Experimental|Low dose casein|Ileal infusion of low dose casein
3155764|NCT01509469|Experimental|High dose casein|Ileal infusion of high dose casein
3155765|NCT01509469|Experimental|Low dose sucrose|Ileal infusion of low dose sucrose
3155766|NCT01509469|Experimental|High dose sucrose|Ileal infusion of high dose sucrose
3155767|NCT01509469|Placebo Comparator|Placebo|Ileal infusion saline
3155768|NCT01509469|Active Comparator|Safflower oil|Ileal infusion safflower oil
3155769|NCT01509456|Active Comparator|Potassium Bicarbonate|
3155770|NCT01509456|No Intervention|Control|
3155771|NCT01509443|Experimental|Interventional|Participants will receive standard asthmatic treatment and breathing/mild physical exercise
3155772|NCT01509443|No Intervention|Control Arm|The control arm will receive standard medical care for asthma
3155773|NCT01509430|Experimental|Early training patient|12 weeks of Progressive Resistance Training followed by 12 weeks of a self chosen level of physical activity
3155774|NCT01509430|Experimental|Late training patients|12 weeks of a self chosen level of physical activity followed by 12 weeks of progressive resistance training
3155775|NCT01509417|Experimental|Ad lib feeding|ad lib feedings following pyloromyotomy
3155776|NCT01509417|Active Comparator|FLAP diet after pyloromyotomy|FLAP diet after pyloromyotomy
3155777|NCT01509404|Active Comparator|Valcyte|valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
3155778|NCT01509404|Active Comparator|Valcyte then Cytogam|valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
3155779|NCT01509391|Experimental|Keyhole-limpet hemocyanine|
3155780|NCT01509365|No Intervention|sensible|Patients who show adequate response to loading dose of clopidogrel and receive standard 1x75 mg clopidogrel for at least 7 days.
3155781|NCT01509365|Active Comparator|simple dose|Patients who show suboptimal response to loading dose of clopidogrel and receive 1x75 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.
3155782|NCT01509365|Experimental|double dose|Patients who show suboptimal response to loading dose of clopidogrel and receive 1x150 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.
3155783|NCT01509352|Active Comparator|with esophageal stitches|fundoplication with crural stitches
3155784|NCT01509352|Experimental|without esophageal stitches|fundoplication without crural stitches.
3155785|NCT01509339|Experimental|Vancomycin for Inhalation|250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
3155786|NCT01509326|Active Comparator|Chiropractic|spinal manipulation, mobilization, massage, advice, exercises
3155787|NCT01509326|Experimental|Chiropractic PLUS pillow|spinal manipulation, mobilization, massage, advice, exercises, pillow
3155788|NCT01509313|Experimental|Uterine polypectomy using morcellator|A new instrument using a mechanical cutting edge has come to market for uterine polypectomy. In patients having a general anaesthesia the mechanical cutting instrument has been shown to be easier to learn, more effective at completely removing polyps and quicker than current techniques. However, the instrument is slightly larger, which could potentially cause more discomfort and prolong the procedure in the outpatient setting.
3155789|NCT01509313|Active Comparator|Electical Resection|At present the most commonly used device for removing the uterine polyps in the outpatient setting is by electrical resection. This will provide comparison for the morcellator device being tested
3155790|NCT01509300|Experimental|HAPLO|
3155791|NCT01509287||Donnai-Barrow Syndrome (DBS)|Individuals affected with Donnai-Barrow Syndrome (DBS)
3155792|NCT01509287||Unaffected|Healthy family members of individuals affected with Donnai-Barrow Syndrome (DBS)
3155793|NCT01509274|Experimental|Plasma|
3155794|NCT01509274|Sham Comparator|Saline|
3155795|NCT01509274|Active Comparator|Physiotherapy + heel cap|
3155796|NCT01509261|Experimental|Ilaprazole|Ilaprazole 20mg
3155797|NCT01509261|Active Comparator|lansoprazole|lansoprazole 30mg
3155798|NCT01509235|Experimental|1. Exercise testing and self drainage session|
3155799|NCT01509235|Active Comparator|2. Chest physiotherapy (CP) session|
3155800|NCT01509222|Other|Personalized nurition counseling|Personalized nutrition counseling based on dietary intake and motivation to change.
3155801|NCT01509222|No Intervention|Control|No intervention, control group.
3155802|NCT01509209|Placebo Comparator|Placebo|placebo
3155803|NCT01509209|Experimental|Cossac L|Pseudoephedrine 120mg + Levocetirizine 2.5mg
3155804|NCT01509196|Experimental|HIP0901|Fenofibric acid
3155805|NCT01509196|Active Comparator|Lipidilsupra|Fenofibrate
3155806|NCT01509183|Active Comparator|Intervention Group|Intervention group (IG) participants received access to and feedback from the Propeller Health System (formerly Asthmapolis System).
3155807|NCT01509183|No Intervention|Control Group|Control group (CG) participants were outfitted with sensors from the Propeller Health System, but did not receive feedback.
3155808|NCT01509157|Experimental|MDRS system|Participants will be using the MDRS system combined with their regular treatment with Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
3155809|NCT01509157|Active Comparator|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
3155810|NCT01509144|Active Comparator|nasal active low dose + IM active|Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
3155811|NCT01509144|Active Comparator|nasal active mid dose + IM active|Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
3155812|NCT01509144|Active Comparator|nasal active full dose + IM active|Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
3155813|NCT01509144|Active Comparator|nasal placebo + IM active|Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
3155814|NCT01509144|Placebo Comparator|nasal placebo + IM placebo|Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
3155815|NCT01509131|Experimental|2L PEG-CS plus bisacodyl|Patients will be asked to take 2L PEG-CS plus bisacodyl (10-20 mg according to patient bowel habit)
3155816|NCT01509131|Active Comparator|2L PEG-ASC|Patients will be asked to take PEG-ASC according to labeling instructions
3155817|NCT01509105||Group1|
3155818|NCT01509092|No Intervention|obervation|patients in this arm received 6-months observation alone after injury
3155819|NCT01509092|Active Comparator|Surgical intervention|patients in this arm received vitrectomy surgery as soon as possible after injury
3155820|NCT01509079|Experimental|Vitamin D3 4000 IU|
3155821|NCT01509079|Active Comparator|Vitamin D3 600 IU|
3155822|NCT01509066|Experimental|Vegan diet|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask participants to keep foods low in fat and low in glycemic index.
3155823|NCT01509066|Active Comparator|Low-calorie|A low-calorie diet contains all food groups. However, participants will be provided with a calorie goal which should promote weight loss.
3155824|NCT01509053|Experimental|Aripiprazole IM depot injection|Patients who had no history of tolerability to oral aripiprazole received 10-15 mg/day (up to 30 mg/day) oral aripiprazole for 1 to 4 weeks to determine tolerability in the Tolerability Assessment Phase prior to receiving treatment with aripiprazole IM Depot. In the Open-label Aripiprazole IM Depot Phase, participants received aripiprazole intramuscular (IM) Depot 400 mg injection (dosage could be adjusted to 300 mg at the investigator's discretion) monthly in the clinic for a total of 6 injections + concomitant oral aripiprazole 10-15 mg/day for the first 14 days. Participants at the investigator's discretion were eligible to continue to receive aripiprazole IM depot (400 or 300 mg) injection monthly in the Open-label Aripiprazole IM Depot Extension phase. Oral aripiprazole was available as rescue medication if necessary.
3155825|NCT01509040|Active Comparator|Control|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
3155826|NCT01509040|Experimental|Low Volume Hemofiltration|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Hemofiltration x 48 hours via 11.5F double lumen venous catheter, blood flow 250 mL/h, ultrafiltration 45 mL/kg/h. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
3155827|NCT01509040|Experimental|High Volume Hemofiltration|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Hemofiltration x 48 hours via 11.5F double lumen venous catheter, blood flow 250 mL/kg/h, ultrafiltration 90 mL/kg/h. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
3155828|NCT01509027|Active Comparator|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
3155829|NCT01509027|Active Comparator|Education by unpersonalised DVD|Information on detrimental consequences of hyperphosphatemia is presented on DVD
3155830|NCT01509027|Placebo Comparator|Standard Care|standard care
3155831|NCT01509014|Experimental|Pharmacy Intervention Arm|All patients receiving statins from pharmacies allocated to the pharmacist intervention arm of the study
3155832|NCT01509014|No Intervention|Usual Care|Pharmacies not allocated to the intervention arm will serve as the control. They received no training on the CPATCH intervention and provide usual care to patients at their pharmacy.
3155833|NCT01509001|Active Comparator|metformin|Participants will randomized into Metformin (750 to 2500 mg/day) or Glimepiride (1 to 8 mg/day) therapy. After 4 months, the patients will crossed-over with no washout period to the alternative treatment for an additional 4-month period on similar dosage schedule
3155834|NCT01509001|Active Comparator|glimepiride|Participants will randomized into Metformin (750 to 2500 mg/day) or Glimepiride (1 to 8 mg/day) therapy. After 4 months, the patients will crossed-over with no washout period to the alternative treatment for an additional 4-month period on similar dosage schedule
3155835|NCT01508988|Experimental|Eye drops 0.3 µg/mL|
3155836|NCT01508988|Experimental|Eye drops 1 µg/mL|
3155837|NCT01508988|Experimental|Eye drops 3 µg/mL|
3155838|NCT01508988|Experimental|Eye drops 10 µg/mL|
3155839|NCT01508988|Experimental|Eye drops 20 µg/mL|
3155840|NCT01508988|Experimental|Eye drops 30 µg/mL|
3155841|NCT01508988|Experimental|Eye drops placebo|
3155842|NCT01508975|Experimental|white rice|White rice
3155843|NCT01508975|Experimental|Brown rice|Brown Rice
3155844|NCT01508975|Experimental|Glucose|Glucose
3155845|NCT01508962||Healthy individuals (controls)|
3155846|NCT01508962||Individuals affected with ALS (sporadic or familial)|
3155847|NCT01508949|Experimental|NNC 90-1170|
3155848|NCT01508949|Placebo Comparator|Placebo|
3155849|NCT01508936|Placebo Comparator|Placebo|Placebo intravenous injection every 4 weeks for a total of 4 doses.
3155850|NCT01508936|Experimental|Reslizumab 3.0 mg/kg|Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses.
3155851|NCT01508923|Experimental|Treatment period 1|
3155852|NCT01508923|Placebo Comparator|Treatment period 2|
3155853|NCT01508910|Experimental|Treatment Arm|Targeted intramyocardial delivery of 1 x 10^5 Auto-CD34+ cells after granulocyte-colony stimulating factor (G-CSF) mobilization and apheresis
3155854|NCT01508910|Placebo Comparator|Active Control Arm|Targeted intramyocardial delivery of placebo after G-CSF mobilization and apheresis
3155855|NCT01508910|Other|Unblinded Standard of Care (SOC) Arm|No study-related procedures will be performed.
3155856|NCT01508897|Experimental|Phase 2 formulation|
3155857|NCT01508897|Experimental|Phase 3 formulation|
3155858|NCT01508884|Active Comparator|IM vaccine and placebo cream|A single dose of intramuscular influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream
3155859|NCT01508884|Active Comparator|ID vaccine and placebo cream|A single dose of intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream
3155860|NCT01508884|Experimental|ID vaccine and imiquimod cream|A single dose intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with imiquimod cream applied to the skin before vaccination
3155861|NCT01508871||Cardiomyopathy|
3155862|NCT01508858|Experimental|Treatment period 1|
3155863|NCT01508858|Placebo Comparator|Treatment period 2|
3155864|NCT01508845|Active Comparator|High MUFA/PUFA, 1600 IU vitamin D3|Subjects will receive 3 meals (1 day) with a high MUFA/PUFA ratio (20g/5g), along with 800 IU of vitamin D3 and 800 IU of deuterated vitamin D3
3155865|NCT01508845|Active Comparator|High MUFA/PUFA, 50,800 IU vitamin D3|Subjects will receive 3 meals (1 day) with a high MUFA/PUFA ratio (20g/5g), along with 50,000 IU of vitamin D3 and 800 IU of deuterated vitamin D3
3155866|NCT01508845|Active Comparator|Low MUFA/PUFA, 50,800 IU vitamin D3|Subjects will receive 3 meals (1 day) with a low MUFA/PUFA ratio (5g/20g), along with 50,000 IU of vitamin D3 and 800 IU of deuterated vitamin D3
3155867|NCT01508845|Active Comparator|Fat free meal, 50,800 IU vitamin D3|Subjects will receive 3 fat-free meals (1 day) and 50,000 IU vitamin D3 and 800 IU of deuterated vitamin D3
3155868|NCT01508832|Active Comparator|Lidocaine|Lidocaine 1% Digital Nerve Block (2 cc)
3155869|NCT01508832|Active Comparator|Bupivacaine|Bupivacaine 0.25% Digital Block (2 cc)
3155870|NCT01508819||1|Guidelines for ICU admission of elderly patients arriving in Emergency Departments with a life threatening conditions
3155871|NCT01508819||2|no intervention
3155872|NCT01508806|Experimental|Normal renal function|
3155873|NCT01508806|Experimental|Mild renal impairment|
3155874|NCT01508806|Experimental|Moderate renal impairment|
3155875|NCT01508806|Experimental|Severe renal impairment|
3155876|NCT01508806|Experimental|End-stage renal disease|
3155877|NCT01508793|No Intervention|Control|
3155878|NCT01508793|Experimental|Optimize Sleep|
3155879|NCT01508780|Experimental|Pulmonary Arterial Hypertension, bosentan|Subjects include patients being diagnosed with pulmonary arterial hypertension and starting treatment with bosentan.
3155880|NCT01508767|Experimental|Study group 1|Early removal of urethral catheter 48 hours post-operatively.
3155881|NCT01508767|Other|Study group 2|Removal of urethral catheter once epidural analgesia has been withdrawn.
3155882|NCT01508754|Active Comparator|CPAP|Treatment with Continuous Positive Airway Pressure
3155883|NCT01508754|No Intervention|Control|Usual anti-hypertensive treatment without CPAP treatment
3155884|NCT01508741|Active Comparator|5-Aminolevulinic Acid (5-ALA)|Active component 50 mg. capsules of 5-Aminolevulinic Acid (5-ALA)
3155885|NCT01508741|Placebo Comparator|Placebo capsule|Non-active component capsules
3155886|NCT01508728|Experimental|Active vibration|
3155887|NCT01508728|Placebo Comparator|Placebo Vibration|
3155888|NCT01508715|Active Comparator|Concentric exercise group|The participants in this group will perform the intervention exercises by actively completing the lifting portion of the resistive shoulder exercises. The physical therapist will then perform the lowering portion of the exercise for the participant.
3155889|NCT01508715|Experimental|Eccentric exercise group|The participants in this group will actively perform the lowering portion of the resistive shoulder exercises in the intervention. The physical therapist will perform the lifting portion of the exercise for the participant.
3155890|NCT01508702|Experimental|lesinurad 400 mg|
3155891|NCT01508702|Placebo Comparator|placebo|
3155892|NCT01508689|Other|Receive cereal bars first|This group will receive Kellogg's Nutri-Grain® cereal bars during the second three weeks of the study.
3155893|NCT01508689|Other|Receive cereal bars second|This group will receive Kellogg's Nutri-Grain® cereal bars during the last three weeks of the study.
3155894|NCT01508676|Active Comparator|Pennsaid Phase I|Pennsaid (20-40 drops; 2-4 times daily) Upon completion of the first phase, subjects in each arm will be crossed over (i.e., from placebo to Pennsaid and vise versa). Pennsaid or placebo lotion will be packed in a container with identical appearance before being dispensed to study subjects.
3155895|NCT01508676|Placebo Comparator|Placebo Phase I|Study subject will topically apply placebo lotion (20-40 drops) 2-4 times daily to the painful area for the next two weeks. The dose titration will be based on the size of painful area (approximately 10 drops for every 4 square inches). Subjects will be asked to fill in a daily pain diary and report any side effects to the research center. A phone number and a beeper number will be provided to subjects.
3155896|NCT01508663|Experimental|PCI+OMT group|PCI (Everolimus Eluting Stent or Zotalolimus Eluting Stent) added to OMT after randomization and follow up for 12 months
3155897|NCT01508663|Active Comparator|OMT alone group|OMT alone after randomization and follow up for 12 months
3155898|NCT01508650|Active Comparator|No intervention|Usual care control group
3155899|NCT01508650|Active Comparator|Active Comparator|Multi domain rehabilitation intervention
3155900|NCT01508637|Experimental|Diesel Exhaust + Terazosin|
3155901|NCT01508637|Experimental|Diesel Exhaust + placebo|
3155902|NCT01508637|Sham Comparator|Filtered Air + terazosin|
3155903|NCT01508637|Sham Comparator|Filtered air + placebo|
3155904|NCT01508624|No Intervention|Control|participants will receive standard usual care
3155905|NCT01508624|Experimental|Interaction|Participants will interact with nurses during their procedure
3155906|NCT01508624|Experimental|Music|Participants will listen to music using head phones during their procedure.
3155907|NCT01508624|Experimental|Touch - stress balls|Participants will be provided with stress balls to use during their procedure
3155908|NCT01508624|Experimental|DVD|Participants will watch a DVD during their procedure and will listen to the accompanying audio through head phones
3155983|NCT01508026|Placebo Comparator|Placebo|Dose Matched placebo
3156142|NCT01507012|Experimental|Berryfruit juice|Berryfruit juice containing 500mg polyphenols
3155909|NCT01508611|Active Comparator|30% silver diammine fluoride|The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied in erupting molars with a disposable microbrush for 3m. Then the surface will be washed for 30s.
3155910|NCT01508611|Active Comparator|cross-toothbrushing|Children will be oriented to proceed cross-toothbrushing in erupting molars
3155911|NCT01508585|Active Comparator|Pre-Op CBT|This group will receive CBT (Telephone Based Cognitive Behavioral Therapy) before bariatric surgery
3155912|NCT01508585|Active Comparator|Post-Op CBT|This group will receive CBT (Telephone Based Cognitive Behavioral Therapy) after bariatric surgery
3155913|NCT01508572|Experimental|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
3155914|NCT01508559||HIV infected|HIV infected MSM 18-50 years old
3155915|NCT01508559||HIV uninfected|HIV uninfected MSM 18-50 years old
3155916|NCT01508546|Experimental|Arm 1: breast surgery with axillary lymphnodes removal|
3155917|NCT01508546|Experimental|Arm 2: breast surgery without axillary lymphnodes removal|
3155918|NCT01508533||Cohort 1|Cohort 1: Infants enrolled at ≤1 week and followed up weekly till one year of age.
3155919|NCT01508533||Cohort 2|Cohort 2: Infants enrolled at 12 months and followed up weekly till they are aged 24 months.
3155920|NCT01508507||Cholera cases group|"Any diarrheal cases or suspected cholera cases from study area, whose stool specimen collected in study health center and examined in reference laboratory, reveals V. cholerae serotype O1/O139 is defined as cholera case"
3155921|NCT01508507||Control group|"A randomly selected age matched individual, who have been living in the study area and did not seek care for diarrheal illness in the study health center since vaccination is defined as control"
3155922|NCT01508494|Active Comparator|Galantamine|16mg galantamine progressively
3155923|NCT01508494|Placebo Comparator|placebo|placebo
3155924|NCT01508481||Diabetes high risk group|
3155925|NCT01508468|Active Comparator|active comparator|"Non Immunosuppressive Symptomatic Treatment (NIST). No specific treatment Converting Enzyme Inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin."
3155926|NCT01508468|Experimental|experimental|NIST and Rituximab: 500 Mg and 100Mg in solution to be diluted for IV infusion (Mabthera®)
3155927|NCT01508455|Experimental|Dexmedetomidine|Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)
3155928|NCT01508429|Active Comparator|misoprostol|800mcg misoprostol (four tablets of 200 mcg administered sublingually)
3155929|NCT01508429|Placebo Comparator|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
3155930|NCT01508416||Patients with Multiple Myeloma|Patients with newly diagnosed Multiple Myeloma required chemotherapy
3155931|NCT01508403||Shuxuetong injection|a cohort using Shuxuetong injection
3155932|NCT01508390|Experimental|Boost|CyberKnife Boost 21 Gy in 7 Gy per day, 3 fractions, Every other day
3155933|NCT01508377|Experimental|Treatment of PTSD with cognitive restructuring|"In this arm the PTSD treatment can be divided into three phases.~First phase: self-confrontation (4 essays)~Second phase: cognitive restructuring (4 essays)~Third phase: parting (2 essays)"
3155934|NCT01508377|Experimental|Treatment of PTSD without cognitive restructuring|"In this arm the PTSD treatment can be divided into only two phases. Compared to the other arm the phase dealing with cognitive restructuring is excluded.~First phase: self-confrontation (4 essays)~Second phase: parting (2 essays)"
3155935|NCT01508364||Group 1|
3155936|NCT01508351||Propofol Induction|All patients receiving propofol induction of anesthesia who are ASA 1-3
3155937|NCT01508338|Placebo Comparator|Placebo|
3155938|NCT01508338|Experimental|HMB|
3155939|NCT01508338|Experimental|ATP and HMB|
3155940|NCT01508338|Experimental|ATP|
3155941|NCT01508325|Experimental|Bisoprolol|
3155942|NCT01508325|Active Comparator|Metoprolol|
3155943|NCT01508312|Experimental|FDG-PET abnormal|Patients will receive 2 cycles of weekly brentuximab vedotin and then undergo evaluation with FDGPET/CT. Patients with normalization of FDG-PET/CT will proceed to ASCT. Patients with persistent abnormalities on FDG-PET/CT will receive 2 cycles of augmented ICE chemotherapy followed by repeat FDG-PET/CT prior to ASCT. Following augmented ICE, patients with negative FDG-PET/CT will proceed to ASCT. Those with persistent abnormalities on FDG-PET/CT will be treated according to their physician's recommendations.
3155944|NCT01508312|Experimental|FDG-PET normalization|Patients will receive 2 cycles of weekly brentuximab vedotin and then undergo evaluation with FDGPET/CT. Patients with normalization of FDG-PET/CT will proceed to ASCT. Patients with persistent abnormalities on FDG-PET/CT will receive 2 cycles of augmented ICE chemotherapy followed by repeat FDG-PET/CT prior to ASCT. Following augmented ICE, patients with negative FDG-PET/CT will proceed to ASCT. Those with persistent abnormalities on FDG-PET/CT will be treated according to their physician's recommendations.
3155945|NCT01508299|Experimental|raw food skin test|skin test with the suspected raw food
3155946|NCT01508273|Experimental|Exercise Intervention Program Group|At baseline study visit, participant shown how to complete the physical exercises performed while on study. Pedometer received to track physical activity. Resistance training bands given to use as part of the home-based exercise program. At the baseline study visit, directions received on how to use the study website. Access given to website that will allow tracking of exercise behavior and help set goals. Access given to an internet-based curriculum that will help teach about goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Participant asked to visit website every week. Participant records activity and the number of steps taken every day on the website. Survey completed monthly about attitudes and beliefs about physical activity.
3155947|NCT01508273|Other|Sedentary Behavior and Dietary Intervention Group|Access given to internet-based curriculum to help teach about goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Participants read information about improving the quality of their diet and cutting back on sedentary behavior. Participants record on the website how much television watched and how many fruits and vegetables eaten every day. Survey completed monthly about attitudes and beliefs about sedentary behavior and dietary intake.
3156141|NCT01507012|Placebo Comparator|Placebo|
3155948|NCT01508273|Experimental|Chair-based Study Group|Patients participate in chair-based exercise study. Participants receive chair-based exercise DVD. Chair-based exercise program participation for a total of 8 weeks. Participants receive self-report assessments about quality of life and asked to participate in physical assessments of their balance and coordination.
3155949|NCT01508260|Experimental|Pilot Phase Aquapheresis|The first portion of this study is an open label pilot experience to evaluate the safety of aquapheresis in leukemia patients with severe fluid overload non-responsive to diuretics. A total of 10 patients will be treated.
3155950|NCT01508260|Experimental|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. About 6 teaspoons of blood will flow through the blood circuit, and the excess fluid will slowly be collected in the collection bag. The exact length of time of aquapheresis treatment is determined by how much fluid needs to be removed and how fast it can be removed. The average treatment is about 24 hours but can extend up to 7 days. About 6 liters or 13 pounds will be removed.
3155951|NCT01508260|Active Comparator|Diuretics|Furosemide by vein over about 15 minutes every 8 hours or by vein as a continuous (non-stop) infusion.
3155952|NCT01508247|Experimental|vaccine against EV71|Inactivated vaccine (Vero Cell) against EV71 of 320U /0.5ml in 5000 children aged 6-35 months on day0, 28
3155953|NCT01508247|Placebo Comparator|placebo|0/0.5ml placebo in 5000 children aged 6-35 months on day0, 28
3155954|NCT01508221|Experimental|Trental + Vitamin E|Trental 400 mg TID and Vitamin E 400IU BID starting the first day after the last radiosurgery treatment
3155955|NCT01508208|Other|Hypertensive disorder of pregnancy|Patients with an hypertensive disorder of pregnancy (28 weeks or more of gestation)will collect a random sample of urine for a spot test (protein/creatinine ratio) and urine for 24 hours. The level of proteinuria will be determined in this sample.
3155956|NCT01508195|Experimental|Treatment Sequence AB|Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 1 followed by Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between treatment periods.
3155957|NCT01508195|Experimental|Treatment Sequence BA|Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 1 followed by Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between treatment periods.
3155958|NCT01508182|Experimental|Treatment Sequence AB|Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 1 followed by Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between Treatment Periods.
3155959|NCT01508182|Experimental|Treatment Sequence BA|Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 1 followed by Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between Treatment Periods.
3155960|NCT01508169|Experimental|Foot orthosis|Forty-seven women in treatment in the outpatient clinic of the Rheumatology Division of State University of Campinas(UNICAMP) who met the inclusion criteria for this study (being female with osteoporosis and aged 60 or above) were assigned, at random, to wear ethyl-vinyl-acetate insoles with medial arch supports and metatarsal pads over a four-week period. Balance, using the Berg Balance Scale (BBS) and the Timed Up and Go (TUG) indexes; pain, using a numeric pain scale (NPS); and disability of the feet, using the Manchester Foot Pain and Disability Index (MFPDI), were assessed at baseline and after four weeks.
3155961|NCT01508169|No Intervention|Control Group|Forty-seven elderly women with osteoporosis (in treatment in the outpatient clinic of the Rheumatology Division of State University of Campinas- UNICAMP) were assigned, at random, to enter the control group with no foot intervention. Balance, using the Berg Balance Scale (BBS) and the Timed Up and Go (TUG) indexes; pain, using a numeric pain scale (NPS); and disability of the feet, using the Manchester Foot Pain and Disability Index (MFPDI), were assessed at baseline and after four weeks.
3155962|NCT01508156|Experimental|Group A: Healthy Participants|Healthy participants take IDX719 (5 mg - 100 mg) or matching placebo by mouth as either 1 single dose or as 7 daily doses.
3155963|NCT01508156|Experimental|Group B: HCV Participants|Treatment-naive participants infected with HCV genotype (GT) 1, GT2, or GT3 take IDX719 (1 mg - 100 mg) or matching placebo as either 1 single dose or as 7 daily doses.
3155964|NCT01508143|Experimental|400 microgram misoprostol|400 micrograms misoprostol each 6 hours for 8 dose
3155965|NCT01508143|Active Comparator|800 micrograms misoprostol|800 micrograms misoprostol each 12 hours for 4 dose
3155966|NCT01508130||Cohort|
3155967|NCT01508117|Experimental|Axitinib + Radiation Therapy|Axitinib 5mg twice daily for 28 days followed by concurrent axitinib plus hypofractionated radiation therapy (45 Gy in 15 fractions) followed by maintenance axitinib 5mg twice daily until progression or unacceptable toxicity
3155968|NCT01508104|Experimental|BEZ235 and Everolimus|
3155969|NCT01508091|Experimental|Calorie restricted|25 % calorie restriction respect measured total energy expenditure, using a Mediterranean diet
3155970|NCT01508078||Asthmatics|Otherwise healthy asthmatic subjects
3155971|NCT01508078||Healthy controls|Healthy individuals without evidence of pulmonary disease.
3155972|NCT01508065||controlled type one diabetes mellitus.|
3155973|NCT01508052|Active Comparator|sequential compression device|Apply sequential compression device during the thyroidectomy
3155974|NCT01508052|Experimental|elastic stockings|Apply elastic stockings during the thyroidectomy
3155975|NCT01508039|Experimental|Treatment with chitin micro-particles|The study will involve 14-healthy subjects confirming to the inclusion criteria randomised to the treatments.
3155976|NCT01508026|Experimental|Nebivolol and Valsartan Fixed Dose Combination 1|Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg
3155977|NCT01508026|Experimental|Nebivolol and Valsartan Fixed Dose Combination 2|Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg
3155978|NCT01508026|Experimental|Nebivolol and Valsartan Fixed Dose Combination 3|Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg
3155979|NCT01508026|Experimental|Nebivolol Low Dose|Nebivolol Monotherapy 5 mg
3155980|NCT01508026|Experimental|Nebivolol High Dose|Nebivolol Monotherapy 20 mg
3155981|NCT01508026|Experimental|Valsartan Low Dose|Valsartan Monotherapy 80 mg
3155982|NCT01508026|Experimental|Valsartan High Dose|Valsartan Monotherapy 160 mg
3155984|NCT01508013|Experimental|Appearance-Focused Website Intervention|This is a Internet-based appearance-focused prevention intervention based on the Behavioral Alternatives Model.
3155985|NCT01508013|Active Comparator|Control Website|Control participants viewed an Internet site designed to provide drug and alcohol education for teens.
3155986|NCT01508000|Active Comparator|Arm A: modified FOLFOX6 and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
3155987|NCT01508000|Experimental|Arm B: modified FOLFOX6 + Bevacizumab and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m2 2-h infusion~Hour 0: Folinic Acid 400 mg/m2 (DL form) or 200 mg/m2 (L form) 2-h infusion~Hour 2 (before 5-FU bolus): Bevacizumab 5 mg/kg IV over 90 minutes infusion*.~Hour 3.5: 5-FU bolus 400 mg/m2 IV bolus over 2-4 minutes~Hour 3.5: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
3155988|NCT01508000|Experimental|Arm C: modified FOLFOX6 + Panitumumab and Surgery|"Experimental: Arm B: modified FOLFOX6 + Bevacizumab and Surgery~6 cycles before and 6 cycles after surgery consisting in:~Hour - 1 (pre chemotherapy): Panitumumab 6 mg/kg IV over 60 minutes (≤ 1000 mg) or 90 minutes (> 1000 mg) +/- 15 min. infusion*.~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
3155989|NCT01507974|No Intervention|control arm|The women in this arm will stop the preventive antibiotic treatment after the delivery
3155990|NCT01507974|Active Comparator|preventive antibiotic treatment|The women in this arm will continue the preventive antibiotic treatment after the delivery to 6 weeks
3155991|NCT01507974|No Intervention|FOLLOW UP ARM|this arm will include women who do not want to participate in the study, and those women will stop the preventive treatment after delivery, and THE INVESTIGATORS will contact those women to collect information regarding their health status post partum
3155992|NCT01507948|Experimental|Immediate Prolonged Exposure Treatment|Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. Participants in this arm will complete a concurrent TMS/fMRI scan before beginning Prolonged Exposure (PE). PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA.
3155993|NCT01507948|No Intervention|Wait list, immediately followed by Prolonged Exposure|Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. NOTE: Participants in this arm receive treatment following a waitlist period of 12 weeks. After waitlist, will have a TMS/fMRI scan and then immediately begin Prolonged Exposure treatment. See above for description of Prolonged Exposure.
3155994|NCT01507935|Active Comparator|Intervention Group I|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with added prebiotic oligosaccharides mixture I
3155995|NCT01507935|Active Comparator|Intervention Group II|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with added prebiotic oligosaccharides mixture II
3155996|NCT01507935|Placebo Comparator|Control Group|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
3155997|NCT01507935|No Intervention|Reference group|Exclusively breast-fed infants
3155998|NCT01507922|Experimental|Fenoverine|Fenoverine 100mg three times a day will be administered for 8 weeks.
3155999|NCT01507922|Active Comparator|Trimebutine|Trimebutine maleate 150mg three times a day will be administered for 8 weeks.
3156000|NCT01507896|Experimental|BAX326 in Surgery|
3156001|NCT01507883||human oocytes/embryos|Sibling oocytes cultured in single or sequential media until day6
3156002|NCT01507870|Active Comparator|prophylactic onlay mesh|
3156003|NCT01507870|No Intervention|continuous running suture|continuous running suture of the linea alba
3156004|NCT01507857|Experimental|400U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 400U /0.5ml in 5000 infants aged 6-35 months old on day0,28
3156005|NCT01507857|Placebo Comparator|0/0.5ml placebo in infants|0/0.5ml placebo in 5000 infants aged 6-35 months old on day0,28
3156006|NCT01507844|Sham Comparator|ventilation|
3156007|NCT01507831|Placebo Comparator|Placebo|Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 78 weeks.
3156008|NCT01507831|Experimental|Alirocumab|Alirocumab 150 mg Q2W added to stable LMT for 78 weeks.
3156009|NCT01507818|Active Comparator|Ivivi Torino II|Active treatment with Non-thermal Pulsed Radio Frequency device
3156010|NCT01507818|Sham Comparator|Inactive Sham|Sham treatment
3156011|NCT01507805|Experimental|EA preconditioning|electroacupuncture five days pre-operation
3156012|NCT01507805|Sham Comparator|Sham EA preconditioning|Patients treated with sham EA preconditioning Intervention
3156013|NCT01507779|Experimental|Influenza vaccine|
3156014|NCT01507779|Placebo Comparator|Placebo|
3156015|NCT01507766|Experimental|Early enteral nutrition|The enteral nutrition was started within 48h after admission
3156016|NCT01507766|Active Comparator|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
3156017|NCT01507753|Placebo Comparator|Placebo Supplement and No PEP|Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
3156018|NCT01507753|Experimental|Omega-3 and PEP|"Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
3156019|NCT01507753|Experimental|Omega-3 and No PEP|Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
3156020|NCT01507753|Experimental|Placebo Supplement and PEP|"Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
3156021|NCT01507740||1|Control group n=20
3156022|NCT01507740||2|investigational group (cancer patients) n=40 patients treated with antiangiogenic agent
3156023|NCT01507727|Experimental|Drug: Tolvaptan|
3156024|NCT01507727|Placebo Comparator|Drug: Placebo|
3156025|NCT01507714|No Intervention|control arm|vaginal wall repair surgery will be done to women in this arm, with no treatment for stress incontinence
3156026|NCT01507714|Active Comparator|TVT-O arm|the women in this arm will have a TVT-O procedure in addition to the vaginal wall repair
3156027|NCT01507701|Experimental|Clonidine|
3156028|NCT01507688|Experimental|Arm 1|Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
3156029|NCT01507688|No Intervention|Arm 2|Usual care
3156030|NCT01507675||Military Veterans|Participants will be recruited from the Denver VA Medical Center (DVAMC), regardless of clinic.
3156031|NCT01507662|Experimental|BMD Result Letter and Brochure|Patients who receive the intervention - BMD result letter with brochure.
3156032|NCT01507662|No Intervention|Control|Those who received usual care
3156033|NCT01507649|No Intervention|Control|
3156034|NCT01507649|Experimental|Telephone-based intervention|
3156035|NCT01507636|Active Comparator|Group 1|Occupational therapy using a special arm function training.
3156036|NCT01507636|Active Comparator|Group 2|Physical therapy using the Theraband for training of force.
3156037|NCT01507623|Experimental|With Capnograpy|Intervention group with the addition of capnography to standard monitoring (non-invasive blood pressure, pulse, pulse oximetry, clinical observation of respiration, electrocardiography (ECG) and respiratory frequency measured by the ECG)
3156038|NCT01507623|No Intervention|No Capnography|Control group without the addition of capnography to standard monitoring (non-invasive blood pressure, pulse, pulse oximetry, clinical observation of respiration, electrocardiography (ECG) and respiratory frequency measured by the ECG)
3156039|NCT01507610|Experimental|Investigational|OPTINOSE SUMATRIPTAN, single dose of 20 mg intranasally (10 mg to each nostril).
3156040|NCT01507610|Active Comparator|IMITREX Nasal Spray|IMITREX® (sumatriptan) Nasal Spray, single dose of 20 mg intranasally (20 mg to one nostril).
3156041|NCT01507610|Active Comparator|IMITREX Oral Tablet|IMITREX® (sumatriptan) Oral Tablet, single dose of 100 mg, administered orally with 240 mL water.
3156042|NCT01507610|Active Comparator|IMITREX Subcutaneous Injection|IMITREX® (sumatriptan) Subcutaneous Injection, single dose of 6 mg injected subcutaneously in the abdomen.
3156043|NCT01507597|Other|Healthy Subjects|
3156044|NCT01507597|Other|T2DM|
3156045|NCT01507597|Other|T1DM|
3156046|NCT01507584|Active Comparator|Prostaglandin Analogue|
3156047|NCT01507584|Active Comparator|Carbonic Anhydrase Inhibitor|
3156048|NCT01507571|Experimental|Dignity Therapy|
3156049|NCT01507558|Experimental|Intervention|Perivascular administration of dexamethasone following endovascular superficial femoral and popliteal artery angioplasty or atherectomy.
3156050|NCT01507545|Active Comparator|MORAb-004|
3156051|NCT01507545|Placebo Comparator|Placebo|
3156052|NCT01507532|Other|Ceftazidime|pharmacokinetic monitoring
3156053|NCT01507519|Experimental|BioMime™|BioMime™ DES
3156054|NCT01507506|Active Comparator|Conventional arm|3-dimensional conformal radiotherapy + Temozolomide
3156055|NCT01507506|Experimental|Experimental arm|simultaneous-integrated boost with intensity-modulated radiotherapy guided by magnetic resonance spectroscopic imaging + Temozolomide
3156056|NCT01507493||mutant alleles|grouped by SCN9A mutant alleles including 3312T, 1719R, 1150W.
3156057|NCT01507493||wild-type alleles|grouped by SCN9A wild-type alleles including 3312G, 1719C, 1150R.
3156058|NCT01507480|Experimental|Bevacizumab|This study is to be carried out sequentially (dose escalation) on 5 groups of 8 patients. Each group is made up of 6 verum and 2 placebos.
3156059|NCT01507467|Active Comparator|Accl. RT|Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
3156060|NCT01507467|Experimental|Accl. RT + Nimorazole|Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week + Nimorazole
3156061|NCT01507454||Local treatment|
3156062|NCT01507428|Active Comparator|Arm I (standard chemoradiotherapy)|Patients undergo radiotherapy QD 5 days a week for 30 fractions. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once weekly for 6 weeks. Patients undergo FDG-PET/CT imaging between fractions 18 and 19.
3156063|NCT01507428|Experimental|Arm II (experimental chemoradiotherapy)|Patients undergo an individualized dose of image-guided radiotherapy QD 5 days a week for 30 fractions and undergo 18 F FDG-PET/CT between fractions 18 and 19. Based on the scan results, patients undergo individualized adaptive radiotherapy for the final 9 fractions. Patients also receive paclitaxel and carboplatin as in Arm I.
3156064|NCT01507415||Exacerbation|Patients with Chronic Obstructive Pulmonary Disease (COPD)
3156065|NCT01507402|Experimental|Cohort 1|Dose regimen 1 (Participants 18 to ≤ 65 yrs old)
3156066|NCT01507402|Experimental|Cohort 2|Dose regimen 2 (Participants 18 to ≤ 65 yrs old)
3156067|NCT01507402|Experimental|Cohort 3|Dose regimen 3 (Participants 18 to ≤ 65 yrs old)
3156068|NCT01507402|Experimental|Cohort 4|Dose regimen 4 (Participants 18 to ≤ 65 yrs old)
3156069|NCT01507402|Experimental|Cohort 5|Dose regimen 5 (Participants 18 to ≤ 65 yrs old)
3156070|NCT01507402|Experimental|Cohort 6|Dose regimen 6 (Participants 18 to ≤ 65 yrs old)
3156071|NCT01507402|Experimental|Cohort 7|Dose regimen 7 (Participants 18 to ≤ 65 yrs old)
3156072|NCT01507402|Experimental|Cohort 8|Dose regimen 3 (Participants > 65 to ≤ 85 yrs old)
3156073|NCT01507402|Experimental|Cohort 9|Dose regimen 9 (Participants 18 to ≤ 65 yrs old)
3156074|NCT01507389|Experimental|Mild|
3156075|NCT01507389|Experimental|Moderate|
3156076|NCT01507389|Experimental|Severe|
3156077|NCT01507389|Experimental|Normal|
3156078|NCT01507376|Experimental|A: recombinant hCG(250 µg Ovitrell)|1- Group A consisted of 60 infertile women who received recombinant hCG(250 µg Ovitrelle)
3156079|NCT01507376|Experimental|B: recombinant hCG(500 µg Ovitrell)|2- Group B consisted of 60 infertile women who received recombinant hCG(500 µg Ovitrelle)
3156080|NCT01507376|Experimental|C: urinary hCG|3- Group C consisted of 60 infertile patients received 10,000 IU urinary hCG
3156081|NCT01507363|Active Comparator|"Gabapentin high"|Tables with Gabapentin (1300 mg/day) for 7 days, starting on the day of surgery
3156082|NCT01507363|Active Comparator|"Gabapentin intermediate"|Tables with Gabapentin for 7 days (900 mg/day), starting on the day of surgery
3156083|NCT01507363|Placebo Comparator|Placebo|Placebo tablets for 7 days, starting on the day of surgery
3156084|NCT01507350||gastric band|Patients having gastric band will have blood and urine tests, and 51 Cr-EDTA clearance to assess renal function. These are taken before and after the surgery at 6 weeks , 6 months and 12 months.
3156085|NCT01507350||sleeve gastrectomy|Patients having sleeve gastrectomy will have blood and urine tests, and 51 Cr-EDTA clearance to assess renal function. These are taken before and after the surgery at 6 weeks , 6 months and 12 months.
3156086|NCT01507350||gastric bypass|Patients having gastric bypass will have blood and urine tests, and 51 Cr-EDTA clearance to assess renal function. These are taken before and after the surgery at 6 weeks , 6 months and 12 months.
3156087|NCT01507337|Experimental|Elderly|
3156088|NCT01507337|Experimental|Young|
3156089|NCT01507311|Experimental|NNC 90-1170|
3156090|NCT01507311|Placebo Comparator|Placebo|
3156091|NCT01507298||Capsule endoscopy|
3156092|NCT01507298||24 hour oesophageal pH study|
3156093|NCT01507285|Experimental|NNC 90-1170|
3156094|NCT01507285|Placebo Comparator|Placebo|
3156095|NCT01507272|Experimental|NNC 90-1170 (liraglutide)|
3156096|NCT01507272|Placebo Comparator|Placebo|
3156097|NCT01507259||100 g containing 70% or 34% cocoa|Healthy controls
3156098|NCT01507246|Active Comparator|IV morphine sulfate|Standard of Care (SOC), dosage variable, administered intravenously via PCA pump postsurgically, as need.
3156099|NCT01507246|Experimental|EXPAREL (bupivacaine liposome injectable suspension)|EXPAREL(R), dosage 266 mg, diluted with 0.9% saline to a total volume of 40 cc.
3156100|NCT01507233|Active Comparator|IV morphine sulfate|morphine sulfate (or Sponsor-approved equivalent)
3156101|NCT01507233|Experimental|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
3156102|NCT01507220|Active Comparator|Morphine sulfate|morphine sulfate (or Sponsor-approved equivalent)
3156103|NCT01507220|Experimental|EXPAREL|EXPAREL (bupivacaine liposome extended-release injectable suspension)
3156104|NCT01507194|Active Comparator|Ondansetron 4 mg|
3156105|NCT01507194|Experimental|Vestipitant 6 mg|
3156106|NCT01507194|Experimental|Vestipitant 12 mg|
3156107|NCT01507194|Experimental|Vestipitant 18 mg|
3156108|NCT01507194|Experimental|Vestipitant 24 mg|
3156109|NCT01507194|Experimental|Vestipitant 36 mg|
3156110|NCT01507181|Experimental|Ketamine|single dose IV ketamine, .5mg/kg
3156111|NCT01507181|Placebo Comparator|Midazolam|single dose IV midazolam, .45mg/kg
3156112|NCT01507168|Placebo Comparator|Placebo|
3156113|NCT01507168|Experimental|RO5137382 (GC33)|
3156114|NCT01507155|Experimental|Patient-Reported Measures|Patients age 18 and older with a diagnosis of Major Depressive Disorder or Generalized Anxiety disorder who received genetic testing using the Genecept Assay and completed patient scales.
3156115|NCT01507155|Experimental|Clinician-Reported Outcomes|Prescribing clinicians responsible for the treatment of patients age 18 and older with a primary diagnosis of Major Depressive Disorder or Generalized Anxiety disorder, and for whom the Genecept Assay has been utilized to perform genetic testing.
3156116|NCT01507142||cART-unresponsive AIDS|HIV-positive, AIDS diagnosis, cART for >18 months, <200 CD4 Tcells/mm3 and Viral Load >5000 copies/ml
3156117|NCT01507142||cART-responsive AIDS|HIV-positive, AIDS diagnosis, cART for >18 months, >350 CD4 Tcells/mm3 and Viral Load<50 copies/ml
3156118|NCT01507142||Acute or early HIV infection|Acute HIV: Acute retroviral syndrome, Negative or positive HIV antibody, Positive HIV p24gag, viral load or NAAT / Early HIV: HIV antibody and viral load positive currently, negative in last 12 months, No clinical or immunological evidence of advanced HIV disease
3156119|NCT01507142||HIV-negative Hepatitis B|Negative HIV antibody and viral load, Positive HBV antibody, Positive or Negative HBV surface antigen, Negative or Positive HBV viral load
3156120|NCT01507116||People with Diabetes|
3156121|NCT01507116||Family Members|
3156122|NCT01507116||Healthcare Professionals|
3156123|NCT01507103|Experimental|Chemoradiotherapy+tecemotide (L-BLP25)+CPA|
3156124|NCT01507103|Experimental|Chemoradiotherapy+tecemotide (L-BLP25)|
3156125|NCT01507103|Active Comparator|Chemoradiotherapy|
3156126|NCT01507090||Normal Children|Otherwise healthy children 2 months to 16 years of age.
3156127|NCT01507077|Placebo Comparator|ZGN-440 sterile diluent|
3156128|NCT01507077|Experimental|ZGN-440|
3156129|NCT01507064|Active Comparator|Group A|Patients who undergo to LA without sorafenib pretreatment
3156130|NCT01507064|Experimental|Group B|Patients who are treated with sorafenib before LA
3156131|NCT01507051|Experimental|Warfarin followed by Rivaroxaban (Xarelto, BAY59-7939)|Days -6 and -5: 10 mg warfarin once daily or lower depending on international normalized ratio (INR); Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 20 mg rivaroxaban once daily; Day 5: 10 mg vitamin K once daily
3156132|NCT01507051|Placebo Comparator|Warfarin followed by Placebo|Days -6 and -5: 10 mg warfarin once daily or lower depending on INR; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 1 tablet matching placebo once daily; Day 5: 10 mg vitamin K once daily
3156133|NCT01507051|Active Comparator|Rivaroxaban (Xarelto, BAY59-7939)|Days 0 to 3: 20 mg rivaroxaban once daily
3156134|NCT01507038|Experimental|Group A|
3156135|NCT01507038|Experimental|Group B|
3156136|NCT01507038|Experimental|Group C|
3156137|NCT01507038|Placebo Comparator|Group D|
3156138|NCT01507025||horizontal flap|patients were scheduled to undergo LASIK and with horizontal flaps(nasal- or temporal-hinge)
3156139|NCT01507025||vertical flap|patients were scheduled to undergo LASIK and with vertical flaps(superior- hinge)
3156140|NCT01507012|Experimental|Powdered berryfruit extract|Powdered berry extract containing 500mg of polyphenols
3156143|NCT01506999||Stable phase of ischemic heart disease|patients with history of angina pectoris, or myocardial infarction
3156144|NCT01506999||acute phase of ischemic heart disease|patients with unstable angina or acute myocardial infarction
3156145|NCT01506999||control group|subjects without ischemic heart disease (IHD)
3156146|NCT01506986|Active Comparator|H. pylori eradication treatment|Active treatment will consist of seven days of lansoprazole 30mg twice daily, clarithromycin 500mg twice daily and metronidazole 400mg twice daily.
3156147|NCT01506986|Placebo Comparator|Placebo H. pylori eradication treatment|Placebos to seven days of lansoprazole 30mg twice daily, clarithromycin 500mg twice daily and metronidazole 400mg twice daily.
3156148|NCT01506960|Experimental|Coronary stenting with OCT, NIRS/IVUS|All subjects will have Near Infrared Spectroscopy/Intravascular Ultrasound Imaging performed.
3156149|NCT01506947|Experimental|Paricalcitol|"Participants received paricalcitol intravenously during hemodialysis until serum intact parathyroid hormone (iPTH) levels were below 150 pg/mL or for up to 6 months. Paricalcitol dose was based on iPTH levels and was titrated to maintain iPTH levels between 150-300 pg/mL.~Participants may have also received routine darbepoetin alfa to treat anemia."
3156150|NCT01506934|Experimental|linifanib|Single Doses
3156151|NCT01506921|Active Comparator|Racemic ketamine|
3156152|NCT01506921|Active Comparator|S-ketamine|All subjects receive both study drugs in a cross- over design. Equipotent doses are used. 0,6 mg/kg racemic ketamine equals 0,3 mg/kg s-ketamine
3156153|NCT01506908|Active Comparator|Nicotine Polacrilex mint mini lozenge|
3156154|NCT01506908|Placebo Comparator|placebo|mint mini lozenge with no active
3156155|NCT01506895|Experimental|darapladib|darapladib dosed at 160 mg once daily
3156156|NCT01506895|Placebo Comparator|placebo|Placebo to match once daily
3156157|NCT01506882|Experimental|Levetiracetam 1000 mg/day to 2000 mg/day group|"Subjects in the LEV 1000 mg/day to 2000 mg/day group receive the initial dose of LEV 1000 mg/day for the 1- week Stabilization Period and enter the Evaluation Period. Unless a seizure occurs during the Evaluation Period, the subjects will continue LEV 1000 mg/day for 26 weeks. If a seizure occurs during the Evaluation Period, the dose will be increased to 2000 mg/day and a restart of stabilization on LEV 2000 mg/day for 1 week is required prior to restarting the 26-weeks Evaluation Period on LEV 2000 mg/day.~The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP."
3156158|NCT01506882|Experimental|Levetiracetam 3000 mg/day group|"Unless a seizure occurs, the subjects in this arm will continue LEV 3000 mg/day for 26 weeks. Subjects in the LEV 3000 mg/day group undergo a 4-week Up-Titration Period prior to the 1-week Stabilization Period.~They receive 1000 mg/day for 2 weeks and 2000 mg/day for 2 weeks during the Up-Titration Period and LEV 3000 mg/day for 1 week during the Stabilization Period.~The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP."
3156159|NCT01506869||Type 2 diabetes|
3156160|NCT01506869||Prediabetes|
3156161|NCT01506869||Normal glucose regulation|
3156162|NCT01506856|Active Comparator|Standard treatment: dd−TCiv therapy|Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IV infusion once every 3 weeks
3156163|NCT01506856|Experimental|Study treatment: dd-TCip therapy|Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IP injection once every 3 weeks
3156164|NCT01506843|Active Comparator|mite allergen drop|Children with allergic rhinitis sensitized with dust mites will receive progressive doses of allergen drops comparing those receiving placebo.
3156165|NCT01506843|Active Comparator|mite plus bacterial extracts|Vaccine constituted with mite and bacterial extracts will be compared to placebo.
3156166|NCT01506843|Placebo Comparator|Placebo|Placebo will be constituted by the same solution used to make dilution of the allergen extracts.
3156167|NCT01506830|Active Comparator|Absolute isolation|Absolute isolation of the operatory field with rubber dam: Moisture control is provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
3156168|NCT01506830|Experimental|Relative isolation|Relative isolation of the operatory field with cotton rolls: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
3156169|NCT01506817||Fibromyalgia|patients with fibromyalgia fulfilling the 1990-ACR research criteria and with pain in the hands as a prominent clinical feature
3156170|NCT01506817||Controls|healthy aged matched pain-free controls
3156171|NCT01506804|Experimental|Training of painful shoulder|Steroid injection X 2 and 10 weeks exercise program of painful shoulder
3156172|NCT01506804|Placebo Comparator|Contralateral training|Steroid injection X 2 and 10 weeks exercise program of asymptomatic shoulder
3156173|NCT01506791|Experimental|Desloratadine and pseudoephedrine ER tablets 5/240 mg|Desloratadine and pseudoephedrine ER tablets 5/240 mg of Dr. Reddy's Laboratories Limited
3156174|NCT01506791|Active Comparator|Clarinex D 24-hour|Clarinex D-24 of Schering Corporation Inc USA
3156175|NCT01506778|Active Comparator|Group 1(With Tenaculum)|This group consisted of the patients whose had been applied tenaculum at cervix during the endometrial sampling procedure
3156176|NCT01506778|No Intervention|Group 2 (Without Tenaculum)|This group consisted of the patients whose had been not applied tenaculum during the endometrial sampling procedure.
3156177|NCT01506765|Active Comparator|patients who receive NAC first|this group will receive 2g/day of NAC (2 caps of 0.5g twice day)for a duration of 8 weeks first, and after this 8 weeks their receive placebo for 8 weeks.
3156178|NCT01506765|Placebo Comparator|patients who receive placebo first|this patients will receive first placebo for a duration of 8 weeks, and after this 8 weeks their receive NAC for 8 weeks
3156179|NCT01506752|Active Comparator|E2020 improved 10 mg without water|
3156180|NCT01506752|Active Comparator|E2020 current 10 mg without water|
3156181|NCT01506752|Active Comparator|E2020 improved 10 mg with water|
3156182|NCT01506752|Active Comparator|E2020 current 10 mg with water|
3156183|NCT01506739|Active Comparator|1|
3156184|NCT01506739|Active Comparator|2|
3156185|NCT01506739|Active Comparator|3|
3156186|NCT01506726|Experimental|Active drug - oral salsalate|Subjects randomized to active drug arm will receive 750mg of salsalate (one pill) twice a day (am and pm) for one month. After one month the dose will be increased to 1500mg (2 pills) twice a day (if the 750mg dose was tolerated) for a further 5 months. Total treatment time is 6 months.
3156187|NCT01506726|Placebo Comparator|Placebo Arm|Subjects randomized to the placebo arm will receive a matching placebo pill (one pill) twice a day (am and pm) for one month. After one month the dose will be increased to 2 matching placebo pills twice a day (if the one pill dose was tolerated) for a further 5 months. Total treatment time is 6 months.
3156188|NCT01506713|Experimental|Clopidogrel|Clopidogrel tablets 75 mg of Dr. Reddy's Laboratories Limited
3156189|NCT01506713|Active Comparator|Plavix|Clopidogrel Tablet 75 mg
3156190|NCT01506687|Experimental|Navigator intervention|
3156191|NCT01506687|Active Comparator|Usual Care Control|Usual care
3156192|NCT01506674||criticall ill patients|
3156193|NCT01506661|Experimental|Rheumatoid Arthritis|10 subjects with mild rheumatoid arthritis aged 50 years and older will be enrolled and will receive a single dose of Zostavax vaccine.
3156194|NCT01506661|Active Comparator|Healthy Subjects|10 healthy subjects aged 50 years or older who have not been previously immunized, will receive a single injection of Zostavax.
3156195|NCT01506635|Placebo Comparator|Control group|included patients who received artificial tear twice a day as control group.
3156196|NCT01506635|Experimental|Timolol group|included the patients with myopic regression who received timolol 0.5% eye drop twice a day
3156197|NCT01506622|Active Comparator|Propofol group|intravenous administration of propofol 1 mg/kg at the end of anesthesia
3156198|NCT01506622|Active Comparator|Fentanyl group|intravenous administration of fentanyl 1 mcg/kg at the end of anesthesia
3156199|NCT01506622|Active Comparator|Control group|intravenous administration of saline at the end of anesthesia
3156200|NCT01506609|Experimental|Veliparib with Temozolomide|Veliparib on Day 1 thru 7 and temozolomide on Day 1 thru 5 of a 28-day cycle.
3156201|NCT01506609|Placebo Comparator|Placebo with Carboplatin and Paclitaxel|Placebo on Day 1 thru 7 and carboplatin/paclitaxel on Day 3 of a 21-day cycle.
3156202|NCT01506609|Experimental|Veliparib with Carboplatin and Paclitaxel|Veliparib on Day 1 thru 7 and carboplatin/paclitaxel on Day 3 of a 21-day cycle.
3156203|NCT01506596|Experimental|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
3156204|NCT01506583||General population|This group of participants is primarily an out-patient population.
3156205|NCT01506583||In-patient population|This group of participants is primarily an in-patient population.
3156206|NCT01506583||Pediatric Group|Participants in this group are children 18 years or younger.
3156207|NCT01506570|Experimental|TetraVax-DV Vaccine - Admixture TV003|Participants will receive one SC injection of the TetraVax-DV Vaccine - Admixture TV003 in their upper arm at Day 0 and Day 180.
3156208|NCT01506570|Experimental|TetraVax-DV Vaccine - Admixture TV005|Participants will receive one SC injection of the TetraVax-DV Vaccine - Admixture TV005 in their upper arm at Day 0 and Day 180.
3156209|NCT01506570|Placebo Comparator|Placebo|Participants will receive one SC injection of placebo in their upper arm at Day 0 and Day 180.
3156210|NCT01506557|Experimental|choecalciferol|
3156211|NCT01506557|Placebo Comparator|placebo|
3156212|NCT01506544|Experimental|Arm 1 Pharmacokinetic study|This will be a single dose study where participants will receive 20mg/kg or the participant's usual dose as a liquid containing hydroxyurea 100mg/mL. For a subset of participants (n= at least 6), a multiple-dose, steady state (i.e. at least 4 consecutive days of dosing) study will be performed.
3156213|NCT01506544|Active Comparator|Arm 2: Relative bioavailability study|This will be a single dose study. Participants will receive each of the two following treatments of HU in a randomized, crossover fashion: Either approximately 20 mg/kg/day (rounded to the nearest 200mg and no greater than 30 mg/kg) or the participant's usual daily dose as: 1) a liquid containing 100 mg/mL of hydroxyurea, or 2) Droxia® 200 mg capsules administered orally.
3156214|NCT01506531|Active Comparator|primary closure of gastroschisis|Attempt primary skin closure of gastroschisis shortly after birth
3156215|NCT01506531|Active Comparator|silo for gastroschisis|Surgical placement of silo over gastroschisis shortly after birth
3156216|NCT01506518||Duchenne muscular dystrophy and age 5-6 years|Boys diagnosed with Duchenne muscular dystrophy and age 5-6 years at enrollment.
3156217|NCT01506518||Duchenne muscular dystrophy and age 7-8 years|Boys diagnosed with Duchenne muscular dystrophy and age 7-8 years at enrollment.
3156218|NCT01506518||Duchenne muscular dystrophy and age 9-10 years|Boys diagnosed with Duchenne muscular dystrophy and age 9-10 years at enrollment.
3156219|NCT01506518||No known neuromuscular disorders and age 5-14 years|Volunteer boys ages 5-14 years with no known neuromuscular disorders to serve as controls.
3156220|NCT01506505|Experimental|Polypill in the morning|Cardiovascular agents in a polypill used from 05.00-11.00 in the morning (acetylsalicylic acid 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg)
3156221|NCT01506505|Experimental|Polypill in the evening|Cardiovascular agents in a polypill used from 18.00-00.00 in the evening (acetylsalicylic acid 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg)
3156222|NCT01506505|Active Comparator|Individual agents of the polypill)|"Cardiovascular agents in as acetylsalicylic acid 75 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg used 05.00-11.00 in the morning.~Simvastatin 40 mg used 18.00-00.00 in the evening."
3156223|NCT01506492|No Intervention|Usual Care|Usual care includes routine screening for depression and other distress in oncology outpatient clinics, communication of screening information to the medical treatment team, and referral as needed.
3156224|NCT01506492|Experimental|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
3156225|NCT01506479|Sham Comparator|Control Group|Wait listed to moderate or vigorous exercise after 6 months of no exercise.
3156226|NCT01506479|Experimental|Vigorous Exercise|Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
3156227|NCT01506479|Experimental|Moderate Exercise|Endurance exercise at 60-65% HR max, 4x/wk for 6 months.
3156228|NCT01506466|Other|additional examinations/measurements|
3156229|NCT01506453|Active Comparator|Gabapentin|Active treatment arm.
3156230|NCT01506453|Placebo Comparator|Placebo|Placebo arm.
3156231|NCT01506440||Supportive Care (cognitive assessment)|Patients complete cognitive assessments, comprising HVLT-R, TMT-A, TMT-B, DSC, Animals, MoCA, and DST. Patients also complete the Beck Depression Inventory. Assessments are administered on day 1 of chemotherapy and at 6-8 weeks and 12-16 weeks after day 1 of chemotherapy.
3156232|NCT01506427|Experimental|[F-18] HX4|
3156233|NCT01506414|Experimental|combination treatment|
3156234|NCT01506401|Active Comparator|Conventional Ventilation|Low tidal volumes, relatively high PEEP.
3156235|NCT01506401|Experimental|High Frequency Oscillation|Open-lung strategy for high frequency oscillation.
3156236|NCT01506388|Experimental|folye catheter plus vaginal IMN|intracervical foley catheter plus vaginal IMN
3156237|NCT01506388|Active Comparator|Misoprostol vaginally|intravaginal misoprostol
3156238|NCT01506375|Experimental|gpASIT|grass pollen peptides alone
3156239|NCT01506375|Experimental|gpASIT/adjuvant|grass pollen peptides + adjuvant
3156240|NCT01506362|Experimental|A synthetic oligonucleotide for treatment of IBD.|BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.
3156241|NCT01506349|Experimental|Crossover Group 1|"Group 1 will consume 4 grams of gluten before neurocognitive testing at Visit 2.~Group 1 will consume placebo before neurocognitive testing at Visit 3."
3156242|NCT01506349|Experimental|Crossover Group 2|"Group 2 will consume placebo before neurocognitive testing at Visit 2.~Group 2 will consume 4 grams of gluten before neurocognitive testing at Visit 3."
3156243|NCT01506336|Experimental|masitinib|masitinib 12 mg/kg/day
3156244|NCT01506336|Active Comparator|sunitinib|sunitinib 50 mg/day
3156245|NCT01506323|Experimental|Mantram Repetition Program (MRP)|"A portable meditation-based Mantram Repetition Program (MRP) will be delivered individually in 8-weekly 1 hour sessions to teach a set of strategies for training attention to manage symptoms. For this study, the program targets symptoms of posttraumatic stress disorder (PTSD) in Veterans who have experienced military-related trauma."
3156246|NCT01506323|Active Comparator|Present Centered Therapy (PCT)|Present Centered Therapy (PCT) is a form of individually-delivered 8-weekly, 1 hour sessions that are problem-oriented to improve current coping. For this study, it served as an attention control arm for the non-specific effects of individual therapist interaction.
3156247|NCT01506310|No Intervention|Diet alone|
3156248|NCT01506310|Experimental|Behavioral therapy|
3156249|NCT01506310|Experimental|Exercise|
3156250|NCT01506310|Experimental|Behavioral therapy and exercise|
3156251|NCT01506284||Anesthetized patients ASA I-II|ASA classification I-II, scheduled for elective surgery requiring general anesthesia.
3156252|NCT01506271|Experimental|MK-7655 250 mg with imipenem/cilastatin|MK-7655 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours
3156253|NCT01506271|Experimental|MK-7655 125 mg with imipenem/cilastatin|MK-7655 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours
3156254|NCT01506271|Placebo Comparator|Placebo to MK-7655 with imipenem/cilastatin|Matching placebo to MK-7655 (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours
3156255|NCT01506258|No Intervention|Patients not infused with stem cells|Historic Controls
3156256|NCT01506258|Experimental|Patients infused with stem cells|
3156257|NCT01506245|No Intervention|Control|
3156258|NCT01506245|Experimental|Family-based behavioral therapy|Family-based behavioural therapy either in group or in individual setting. Parents can choose between the 2 types of therapy.
3156259|NCT01506232||ADHD|Youth diagnosed with ADHD.
3156260|NCT01506232||ASD|Youth diagnosed with an Autism Spectrum Disorder (ASD).
3156261|NCT01506232||BPD|Youth diagnosed with Bipolar Disorder.
3156262|NCT01506232||Healthy Controls|Youth not diagnosed with any psychiatric/psychological disorder.
3156263|NCT01506219|Experimental|Geriatrician-performed CGC|Geriatrician-performed CGC in addition to the usual care at Community Rehabilitation Unit.
3156264|NCT01506219|No Intervention|Usual care|Usual services at Community Rehabilitation Unit.
3156265|NCT01506206||Patients with Deep Brain Stimulators|Patients with deep brain stimulation for either major depressive disorder (MDD) or obsessive compulsive disorder (OCD).
3156266|NCT01506206||Patients with MDD or OCD|Patients with MDD or OCD who do not have a deep brain stimulator.
3156267|NCT01506193|Active Comparator|Group A|Subjects in this arm will receive MMRV vaccine at Visit 1 (Day 0) and MenC vaccine at Visit 2 (Days 35-49).
3156268|NCT01506193|Experimental|Group B|Subjects will receive MMRV vaccine and MenC vaccine at Visit 1 (Day 0).
3156269|NCT01506193|Active Comparator|Group C|Subjects will receive Men C vaccine at Visit 1 (Day 0) and MMRV vaccine at Visit 2 (Day 35-49).
3156270|NCT01506180||Patients admitted to Geriatric Department|The patients receive comprehensive geriatric assessment
3156271|NCT01506180||Patients admitted to general medical departments|This group do not receive comprehensive geriatric assessment
3156272|NCT01506167||Bevacizumab and Capecitabine/Oxaliplatin|Participants who receive bevacizumab in combination with capecitabine/oxaliplatin
3156273|NCT01506167||Bevacizumab and Fluorouracil/Folinic Acid/Oxaliplatin|Participants who receive bevacizumab in combination with fluorouracil/folinic acid/oxaliplatin
3156274|NCT01506167||Bevacizumab and Capecitabine|Participants who receive bevacizumab in combination with capecitabine
3156275|NCT01506167||Bevacizumab and Fluorouracil/Folinic Acid/Irinotecan|Participants who receive bevacizumab in combination with fluorouracil/folinic acid/irinotecan
3156276|NCT01506167||Bevacizumab and Capecitabine/Irinotecan|Participants who receive bevacizumab in combination with capecitabine/irinotecan
3156333|NCT01505829||Biological validation cohort 1|
3156277|NCT01506167||Bevacizumab and Fluorouracil +/- Folinic Acid|Participants who receive bevacizumab in combination with fluorouracil +/- folinic acid
3156278|NCT01506167||Other|Participants who receive bevacizumab in combination with other first-line chemotherapy regimens
3156279|NCT01506154|Placebo Comparator|Placebo|Therapy with placebo
3156280|NCT01506154|Experimental|MRX-7EAT|Therapy with experimental drug
3156281|NCT01506141|Experimental|Idursulfase-IT|Idursulfase-IT administered once monthly at the dose used in study HGT-HIT-045 via intrathecal drug delivery device (IDDD)
3156282|NCT01506128||HPV|Premenopausal women with HSIL in Pap test or high-risk HPV
3156283|NCT01506115|Experimental|HCC with bile duct invasion|Photodynamic therapy with biliary drainage in patients with bile duct invasion of unresectable HCC
3156284|NCT01506089|Experimental|36 degree group|36 degrees Celsius for the incubators is the experimental condition in this study.
3156285|NCT01506089|No Intervention|37 degree group|37 degrees Celsius is the standard incubator temperature for the culture of embryos.
3156286|NCT01506076|Experimental|Levocetirizine DiHCl Tablets, 5 mg|Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
3156287|NCT01506076|Active Comparator|XYZAL|XYZAL Tablets 5 mg of UCB Farchim S.A.
3156288|NCT01506063|Experimental|Levocetirizine DiHCl Tablets, 5 mg|Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
3156289|NCT01506063|Active Comparator|XYZAL|XYZAL Tablets 5 mg of UCB Farchim S.A.
3156290|NCT01506050|Experimental|Desloratadine OD tablets 5 mg|Desloratadine OD tablets 5 mg of Dr. Reddy's Laboratories Limited
3156291|NCT01506050|Active Comparator|Clarinex|Clarinex 5 mg of Schering Corporation Inc USA
3156292|NCT01506037|Experimental|Desloratadine OD tablets 5 mg|Desloratadine OD tablets 5 mg of Dr. Reddy's Laboratories Limited
3156293|NCT01506037|Active Comparator|Clarinex|Clarinex 5 mg of Schering Corporation Inc USA
3156294|NCT01506024|Active Comparator|THA Direct lateral|Total hip arthroplasty (THA) carried out by direct lateral approach (DLA)
3156295|NCT01506024|Experimental|THA Posterior|Total hip arthroplasty (THA) carried out by posterior approach (DLA)
3156296|NCT01506024|Experimental|THA Anterior|Total hip arthroplasty (THA) carried out by anterior approach (DLA)
3156297|NCT01506011|Experimental|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Dr. Reddy's Laboratories Ltd.
3156298|NCT01506011|Active Comparator|Lotrel|Lotrel® Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Novartis Pharmaceuticals
3156299|NCT01505998|Experimental|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Dr. Reddy's Laboratories Ltd.
3156300|NCT01505998|Active Comparator|Lotrel|Lotrel® Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Novartis Pharmaceuticals
3156301|NCT01505985|Experimental|Specialized Oral Nutritional Supplement|
3156302|NCT01505985|Placebo Comparator|Placebo|
3156303|NCT01505972|Experimental|Six and three time schedule|
3156304|NCT01505972|Experimental|Four and two time schedule|
3156305|NCT01505959|Experimental|Conventional|
3156306|NCT01505959|Active Comparator|Telemedicine|
3156307|NCT01505946||LOW RESPONDERS|Documented low anamnestic response after FVIII exposure (FVIII inhibitors titre >0.6 and < 5 BU/ml tested by Bethesda assay, Nijmegen modification). Patients who have never been submitted to ITI and also those patients who have completed ITI with partial success (defined as inhibitors titre >0.6 and < 5 BU/ml and no increase in the INH titer > 5 BU over treatment with FVIII)
3156308|NCT01505946||HIGH RESPONDERS|Patients who documented high response after FVIII exposure (FVIII inhibitors titre > 5 BU/ml tested by Bethesda assay, Nijmegen modification) and who are potential candidates to a first or rescue ITI
3156309|NCT01505933|Active Comparator|dexmedetomidine|
3156310|NCT01505933|Active Comparator|propofol|
3156311|NCT01505920|Experimental|Lidocaine spray|10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
3156312|NCT01505920|Active Comparator|Lidocaine submucosal injection|2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally to the four quadrant of the cervix, 3 minutes before starting cervical excision
3156313|NCT01505907|Experimental|CXB909 15mg|CXB909 15mg
3156314|NCT01505907|Experimental|CXB909 30mg|
3156315|NCT01505907|Experimental|CXB909 60mg|
3156316|NCT01505907|Experimental|CXB909 120mg|Dose
3156317|NCT01505907|Experimental|CXB909 250mg|
3156318|NCT01505894|Experimental|BI 409306 low dose|Film-coated tablet
3156319|NCT01505894|Experimental|BI 409306 medium dose|Film-coated tablet
3156320|NCT01505894|Experimental|BI 409306 high dose|Film-coated tablet
3156321|NCT01505894|Experimental|BI 409306 high dose II|Film-coated tablet
3156322|NCT01505894|Placebo Comparator|Placebo|Film-coated tablet
3156323|NCT01505881|Experimental|Dabigatran etexilate|Patient dose determined by dose allocated in 1160.113 and CrCl levels
3156324|NCT01505881|Active Comparator|warfarin|warfarin doses to maintain INR levels
3156325|NCT01505868|Experimental|Cabazitaxel + Prednisone|Starting Dose: Cabazitaxel 25 mg/m² intravenously on Day 1 of each 3 week cycle, plus Prednisone 5 mg by mouth twice daily.
3156326|NCT01505868|Experimental|Cabazitaxel + Carboplatin + Prednisone|"Phase I Starting Dose: Cabazitaxel 20-25 mg/m² + Carboplatin AUC 3-4 intravenously on Day 1 of each 3 week cycle, plus Prednisone 5 mg by mouth twice a day.~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
3156327|NCT01505855|Experimental|anti-TNF only|Crohn's disease, on an anti-TNF agent [infliximab or adalimumab] only
3156328|NCT01505855|Experimental|Combined immunosuppression|Crohn's disease, on combined immunosuppression (both anti-TNF agent and immunomodulator [azathioprine or 6-MP])
3156329|NCT01505855|Experimental|Immunomodulator only|Crohn's disease, on an immunomodulator only
3156330|NCT01505855|Experimental|Non-immunosuppression|Crohn's disease, not on immunosuppressive medications (5-ASA only: control arm)
3156331|NCT01505842|Experimental|Colonoscopy with chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
3156332|NCT01505842|Active Comparator|Conventional colonoscopy|White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
3156334|NCT01505829||Response assessment cohort 2|
3156335|NCT01505816|No Intervention|Toric|Multifocal Toric IOL implantation
3156336|NCT01505803|Active Comparator|Zinc supplement|
3156337|NCT01505803|Active Comparator|Omega 3 supplement|
3156338|NCT01505803|Active Comparator|Zinc and omega 3 supplements|
3156339|NCT01505803|Placebo Comparator|Placebo supplement|
3156340|NCT01505790|Experimental|CLOPIDOGREL GROUP|
3156341|NCT01505790|Active Comparator|PRASUGREL GROUP|
3156342|NCT01505777|Experimental|Probiotics(Medirac) 10/mosapride 10mg|
3156343|NCT01505777|Experimental|Probiotics(Medirac) 15/mosapride 10mg|
3156344|NCT01505777|Experimental|Probiotics(Medirac) 15/mosapride 15mg|
3156345|NCT01505777|Experimental|Probiotics(Medirac) 30/mosapride 15mg|
3156346|NCT01505777|Placebo Comparator|Probiotics(Medirac) placebo/mosapride placebo|
3156347|NCT01505764|Experimental|Arm 1 (Anamorelin HCl)|Anamorelin HCl
3156348|NCT01505764|Placebo Comparator|Arm 2 (Placebo)|Placebo
3156349|NCT01505751||cervical cancer|
3156350|NCT01505738||bacterial cultures|Bacterial samples are collected preoperatively from urine, nose and possible lower limb ischaemic wounds, perioperatively from inguinal area and wound edges, and twice postoperatively. In addition, in case of a wound infection, bacterial samples are taken for diagnosis as usual.
3156351|NCT01505686|Experimental|study group|All patients in this study have MRI scan prior to hernia repair surgery. If inflammatory changes are present, the scan is repeated 6 months after surgery. If not, the scan is performed only if the patient has pain problems at 6 months.
3156352|NCT01505673|Active Comparator|Liraglutide|
3156353|NCT01505673|Placebo Comparator|Saline injection|
3156354|NCT01505660|No Intervention|Usual Care|Patients not randomized to the intervention will receive usual care which includes a patient reported outcomes assessment every 6 months as part of routine clinical procedures and patient-initiated interactions with case managers.
3156355|NCT01505660|Experimental|Care management|The intervention will include frequent healthcare delivery team notification of PROs including medication adherence and adherence barriers such as depression symptoms along with tailored intervention recommendations and targeted care management using a stepped care approach.
3156356|NCT01505647|Experimental|ZOSTAVAX™ (AMP)|ZOSTAVAX™ manufactured with an alternative process
3156357|NCT01505647|Active Comparator|ZOSTAVAX™|ZOSTAVAX™ manufactured with the current process
3156358|NCT01505634|Experimental|MK-7655 250 mg with imipenem/cilastatin|MK-7655 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours
3156359|NCT01505634|Experimental|MK-7655 125 mg with imipenem/cilastatin|MK-7655 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours
3156360|NCT01505634|Placebo Comparator|Placebo to MK-7655 with imipenem/cilastatin|Matching placebo to MK-7655 (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours
3156361|NCT01505621||Young|Healthy adults 18-30 years old
3156362|NCT01505621||Elderly|Healthy adults greater than 65 years old
3156363|NCT01505608|Active Comparator|Arm A- Temozolomide and Irinotecan|"Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle.~Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.~Patients who show progression on the I+TMZ arm may crossover to the I+TMZ+TPI 287 arm at anytime during cycles 1 to 6. If there is evidence of progression after completion of the I+TMZ arm (after completion of cycle 6) then the patient will have been considered to have completed therapy and is not eligible for the crossover."
3156364|NCT01505608|Experimental|Arm B- Temozolomide/Irinotecan + TPI 287|"Cycle 1 to 6: Irinotecan and Temozolomide in combination with TPI 287~Intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.~Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle.~Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle."
3156365|NCT01505595|Experimental|Proprioceptive training|
3156366|NCT01505595|Sham Comparator|Sham proprioceptive training|
3156367|NCT01505582|Experimental|Inspiratory muscle training|
3156368|NCT01505582|Sham Comparator|Sham inspiratory muscle training|
3156369|NCT01505569|Other|Arm A: Patients with High Risk or Relapsed Solid Tumor|Treatment consists of a mobilization chemotherapy (ifosfamide 1.8 g/m^2/day intravenously [IV], etoposide 100 mg/mg^2 IV, mesna 1.8 g/m^2 divided in every 6 hours dosing, and granulocyte colony stimulating factor 10 mcg/kg subcutaneously or IV until absolute neutrophils > 1,000/mm^2) for 5 days in a 30-100 day pretransplant window, busulfan (1.1 mg/kg IV every 6 hours on days -8 through -6), melphalan (50 mg/mg^2 on days -5 and -4), thiotepa conditioning (250 mg/m^2 IV over 2 hours on days -3 and -2) followed by an autologous peripheral blood stem cell transplant (infusion on Day 0) and, if appropriate, disease specific radiation therapy at day +60.
3156370|NCT01505569|Other|Arm B: Certain CNS Tumors|Treatment consists of a mobilization chemotherapy (ifosfamide 1.8 g/m^2/day intravenously [IV], etoposide 100 mg/mg^2 IV, mesna 1.8 g/m^2 divided in every 6 hours dosing, and granulocyte colony stimulating factor 10 mcg/kg subcutaneously or IV until absolute neutrophils > 1,000/mm^2) for 5 days in a 30-100 day pretransplant window, carboplatin (dose based on GFR and age 17 mg/kg/day IV or 510 mg/m^2/day IV) , thiotepa conditioning (10 mg/kg/day or 300 mg/m^2 IV on days -3 and -2) followed by an autologous peripheral blood stem cell transplant (infusion on Day 0). This will be repeated up to 2 additional 30 day cycles.
3156371|NCT01505569|Other|Arm C: Germ Cell Tumors|"High-Dose Chemotherapy (3 cycles)~Carboplatin AUC=8 & Etoposide 400 mg/m^2 daily, days -4, -3, and -2 every 21 days~Autologous Stem Cell Infusion ≥ 3 x 106 CD34+ cells/kg Day 0 Cycles 1, 2 and 3~TI Chemotherapy & PBSC Collection.~Paclitaxel 200mg/m^2 IV over 3 hours on Day 1 every 14 days for 2 cycles~Ifosfamide 2000 mg/m^2 IV daily on Days 1-3 every 14 days for 2 cycles~Mesna 2000 mg/m^2 on Days 1-3 every 14 days for 2 cycles~G-CSF 10 μg/kg sub q daily on day 3 until adequate CD34+ cell collection or day 15, whichever occurs first~Leukapheresis starting on approx. day 11 and continued daily until reaching the collection goal of ≥ 8 x 106 CD34+ cells/kg) or day 15, whichever occurs first"
3156372|NCT01505569|Other|Arm D: Certain CNS Tumors|"Mobilization Chemotherapy and PBSC Collection (day -100 to day -30)~Pre-Transplant Conditioning Chemotherapy (3 cycles)~Day -8, -7, -6: Carboplatin as calculated from AUC of 7 approx.~Day -5, -4, -3: Thiotepa 10 mg/kg, Etoposide 8.3 mg/kg~Day 0: Autologous Hematopoietic Cell Reinfusion~Day +1: Begin G-CSF(filgrastim) 5 mcg/kg"
3156373|NCT01505569|Other|Arm E: Neuroblastoma|"Mobilization Chemotherapy and PBSC Collection (day -100 to day -30)~Pre-Transplant Conditioning Chemotherapy (day -7 to day -0)~Day -7: anti-seizure prophylaxis with lorazepam or levetiracetam~Day -6 - -3: Busulfan IV q24 hours x 4 doses~Day -1: Melphalan 140 mg/m2 IV~Day 0: Autologous Hematopoietic Cell Reinfusion"
3156374|NCT01505556||Diaphragm paresis|
3156375|NCT01505556||Healthy controls|
3156376|NCT01505543||chronic obstructive pulmonary disease|
3156377|NCT01505543||healthy matched controls|
3156378|NCT01505530|Experimental|300 mg LY2495655 + chemotherapy|300 mg LY2495655 intravenous (IV) in combination with standard of care chemotherapy (investigator's choice)
3156379|NCT01505530|Experimental|100 mg LY2495655 + chemotherapy|100 mg LY2495655 intravenous (IV) in combination with standard of care chemotherapy (investigator's choice)
3156380|NCT01505530|Placebo Comparator|Placebo + chemotherapy|Placebo in combination with standard of care chemotherapy (investigator's choice)
3156381|NCT01505517||individuals with low back pain|
3156382|NCT01505517||healthy controls|
3156383|NCT01505491|Experimental|BI 695501|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
3156384|NCT01505491|Active Comparator|adalimumab - US|Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
3156385|NCT01505491|Active Comparator|adalimumab - EU|Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
3156386|NCT01505478||Patients admitted with infection|All consecutive ED patients during the study period that have been admitted and identified to have a suspected infection at ED disposition using a data collection tool
3156387|NCT01505465|Experimental|Study: Melatonin|
3156388|NCT01505465|Placebo Comparator|Control: Placebo|
3156389|NCT01505439|Experimental|Solifenacin group|Once daily
3156390|NCT01505426|Experimental|ASP1941 group|ASP1941 + metformin
3156391|NCT01505426|Placebo Comparator|placebo group|placebo + metformin
3156392|NCT01505413|Experimental|Tarceva, Gemcitabine, Oxaliplatin|"Erlotinib 100 mg po qd daily AND~Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1~Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2 Every 2 weeks~Each two weeks is a cycle. If at end of 12 cycles response continues, will administer Gemcitabine and erlotinib until progression."
3156393|NCT01505400||Advanced cancer|Advanced breast, non-small cell lung, colorectal, genitourinary, pancreatobiliary gastrointestinal, upper aerodigestive tract, gynecological, melanoma, unknown primary, and rare carcinomas; as well as patients who are phase I trial candidates
3156394|NCT01505387|Placebo Comparator|Placebo|Identical to Litramine 2 tablets 3 times daily (oral consumption, after meal)
3156395|NCT01505387|Experimental|Litramine|Fibre complex of plant origin n tablet form 2 tablets 3 times daily (oral consumption, after meal)
3156396|NCT01505374|Experimental|Study Technique Left Leg, Control Technique Right Leg|
3156397|NCT01505374|Experimental|Study Technique Right Leg, Control Technique Left Leg|
3156398|NCT01505361|Experimental|Probiotic|Pregnant women at 30 week of pregnancy(n=50) receiving Lactobacillus salivarius PS2(9 log per day, until birth)
3156399|NCT01505361|Placebo Comparator|Placebo|Pregnant women at 30 week of pregnancy(n=50) receiving the excipient (once a day, until birth)
3156400|NCT01505348|Experimental|Fasting|Overnight fast
3156401|NCT01505348|No Intervention|Feeding|Normal breakfast
3156402|NCT01505335||Implant osteotomy measurements|Drilled implant locations
3156403|NCT01505322||Thoracic surgery|Lung cancer patients
3156404|NCT01505309|Experimental|Stent Graft|TEVAR procedure using devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
3156405|NCT01505296|Active Comparator|Antiarrhythmic drug|Class I or III antiarrhythmic drug
3156406|NCT01505296|Experimental|Catheter ablation|Pulmonary vein isolation
3156407|NCT01505283|Placebo Comparator|Group Saline|Epidural administration of saline
3156408|NCT01505283|Experimental|Group Sufentanil|Epidural administration of sufentanil
3156409|NCT01505283|Experimental|Group Lidocaine|Epidural administration of lidocaine
3156410|NCT01505270||Autistic Children|
3156411|NCT01505257|Experimental|END-DSD Intervention|
3156412|NCT01505257|No Intervention|Control|
3156413|NCT01505244|Experimental|Physical Activity|Before-school moderate to vigorous physical activity 3 days/week
3156414|NCT01505231|Active Comparator|Norepinephrine group|Blinded norepinephrine
3156415|NCT01505231|Active Comparator|Vasopressin Group|Blinded vasopressin
3156416|NCT01505218|Active Comparator|Propofol sedation by nurse anaesthetist|Nurse anaesthetists managed infusion of propofol 10 mg/ml at doses of 0.2 - 0.8 ml/kg during ERCP. The target of moderate sedation was achieved within 5 minutes from start of the sedation.
3156417|NCT01505218|Active Comparator|Patient-controlled propofol sedation|"Self-administration of propofol via patient-controlled sedation pump (CME...). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.~Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness."
3156418|NCT01505218|No Intervention|Midazolam sedation by the ERCP-team|Midazolam doses for sedation during ERCP. Initial dose of 2-3 mg and after ERCP start, 1-2 mg as additional doses. Maximum total dose 6-8 mg. ERCP performing doctor is responsible for dose ordination.
3156419|NCT01505179|Active Comparator|Ranolazine|Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
3156420|NCT01505179|Placebo Comparator|Placebo|Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
3156546|NCT01504373|Other|NAVA-PSV|Subject will receive 4 hours of NAVA followed by 4 hours of PSV.
3156547|NCT01504373|Other|PSV-NAVA|Subject will receive 4 hours of PSV followed by 4 hours of NAVA.
3156421|NCT01505166|Experimental|Vigil™|Patients will receive 1 x 10^7 cells (Group A) via intradermal injection for a minimum of 4 doses and a maximum of 12 doses (vaccine) starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days.
3156422|NCT01505166|Placebo Comparator|Placebo|Patients will receive placebo (Group B) via intradermal injection for a minimum of 4 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days.
3156423|NCT01505166|Experimental|Vigil™ Vaccine (6 patient run-in)|Six patients will be enrolled into the Part 1 of the study to receive intradermal autologous Vigil™ cancer vaccine (1.0 x 10e7 cells/injection; maximum of 12 vaccinations).
3156424|NCT01505153|Experimental|pbi-shRNA STMN1 LP|pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection.
3156425|NCT01505140|No Intervention|Usual Western style diet|Participants will consume their usual Western style diet avoiding tree nuts
3156426|NCT01505140|Experimental|Whole walnuts|Participants will consume usual Western style diet adding 75 gm whole walnuts per day
3156427|NCT01505127|Experimental|TAK-438 20 mg BID|"TAK-438 20 mg, tablets, orally, twice daily for 1 week~Lansoprazole placebo-matching capsules, orally, twice daily for 1 week~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week"
3156428|NCT01505127|Experimental|Lansoprazole 30 mg BID|"TAK-438 placebo-matching tablets, orally, twice daily for 1 week~Lansoprazole 30 mg, capsules, orally, twice daily for 1 week~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week"
3156429|NCT01505114|Experimental|Arm 1|MVC 300 mg plus FTC placebo and TDF placebo orally once daily
3156430|NCT01505114|Experimental|Arm 2|MVC 300 mg plus FTC 200 mg and TDF placebo orally once daily
3156431|NCT01505114|Experimental|Arm 3|MVC 300 mg plus FTC placebo and TDF 300 mg orally once daily
3156432|NCT01505114|Experimental|Arm 4|MVC placebo plus FTC 200 mg and TDF 300 mg orally once daily
3156433|NCT01505101|Experimental|Mindfulness-Oriented Recovery Enhancement|
3156434|NCT01505101|Active Comparator|Conventional Support Group (SG)|
3156435|NCT01505088|Experimental|Iontophoretic Dexamethasone Phosphate Ophthalmic Solution|Dexamethasone phosphate (40 mg/mL) solution delivered by iontophoresis treatment consisting of 4.0 mA-min at 1.5 mA on Day 0 and Day 7 with accompanying placebo eyedrops (saline solution) for up to 28 days.
3156436|NCT01505088|Active Comparator|Prednisolone Acetate Ophthalmic Suspension (1%)|Placebo (100 mM sodium citrate buffer solution) iontophoresis treatment consisting of 4.0 mA-min at 1.5 mA on Day 0 and Day 7 with accompanying prednisolone acetate ophthalmic suspension (1%) (positive control) eyedrops for up to 28 days.
3156437|NCT01505075|Experimental|Hypofractionated radiation|40 Gy in 5 fractions over 29 to prostate; 30 Gy in 5 fractions over 29 days to seminal vesicles
3156438|NCT01505062|Experimental|SAR421869 (Cohort 1)|Starting dose of UshStat given through subretinal injection
3156439|NCT01505062|Experimental|SAR421869 (Cohort 2)|Escalating dose of UshStat given through subretinal injection
3156440|NCT01505062|Experimental|SAR421869 (Cohort 3)|Escalating dose of UshStat given through subretinal injection
3156441|NCT01505062|Experimental|SAR421869 (Cohort 4)|Maximum tolerated dose (MTD)/eye of UshStat given through subretinal injection
3156442|NCT01505062|Experimental|SAR421869 (Cohort 5)|MTD/eye of UshStat given through subretinal injection
3156443|NCT01505049||Previously received all three doses of HPV vaccine|This group will consist of 78 women ages 18 to 30 who have received their third dose of vaccine three or more years ago. Recruitment of this group was completed in Sept 2012.
3156444|NCT01505049||Previously received two doses of HPV vaccine|This group will consist of 78 women ages 18 to 30 who have received two doses of the HPV vaccine. The second dose must have been received six or more months ago.
3156445|NCT01505049||Unvaccinated Cohort|This group will consist of 45 women who have not received their HPV vaccination. Women ages 18-26 are eligible for this cohort. Recruitment for this group was completed in January 2013.
3156446|NCT01505036|Experimental|SMARTCARE service|U-Health service
3156447|NCT01505036|No Intervention|Usual care|Usual care
3156448|NCT01505023|Active Comparator|Partial meal replacement|
3156449|NCT01505023|Experimental|Partial meal replacement with inulin|
3156450|NCT01505023|Active Comparator|Inulin|
3156451|NCT01505023|No Intervention|No intervention|
3156452|NCT01505010|No Intervention|Control group|Standard antihypertensive drug treatment
3156453|NCT01505010|Experimental|Intervention group|Renal denervation plus standard antihypertensive drug treatment
3156454|NCT01504997|Experimental|Robot assisted distal gastrectomy|patients who received robot assisted distal gastrectomy
3156455|NCT01504984|Experimental|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
3156456|NCT01504984|Active Comparator|Glivec film coated tab 4T(400mg)|100mg/tablet, po, 4 tablets once daily for period I&II D1(crossover)
3156457|NCT01504971||Gastroesophageal reflux disease (GERD)|
3156458|NCT01504958|Active Comparator|Active rTMS with real cognitive training|High frequency rTMS stimulation to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent active cognitive training.
3156459|NCT01504958|Sham Comparator|Sham rTMS with real cognitive training|High frequency sham rTMS to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent active cognitive training.
3156460|NCT01504958|Sham Comparator|Sham rTMS with sham cognitive training|High frequency sham rTMS to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent sham cognitive training.
3156461|NCT01504945|Active Comparator|RBC transfusion|
3156462|NCT01504945|Placebo Comparator|Normal saline infusion|
3156463|NCT01504932|Experimental|Arm I: (LBR chemoprevention)|Patients receive lyophilized black raspberry lozenges PO QID for 6 months.
3156548|NCT01504360|Experimental|sarcoma group|patient suffering form radiation-induced sarcoma
3156549|NCT01504360|Active Comparator|free from sarcoma group|patient without sarcoma 5 years after radiation therapy
3156464|NCT01504932|Other|Arm II: (biomarker control)|Patients do not receive lyophilized black raspberries lozenges. Patients will be asked to complete a baseline survey of family history of cancer and tobacco/alcohol usage, a Head and Neck Cancer Inventory Survey (HNCI), an Insomnia Severity Index (ISI) survey, and a Brief Fatigue Inventory (BFI) survey.
3156465|NCT01504919|Experimental|Health Education (HE)|HE of brief counseling and self-help materials addressing 3 risk behaviors, referrals to available resources, and a home-based exercise kit; 6-week supply of nicotine patches for smoking cessation if needed.
3156466|NCT01504919|Experimental|Motivation and Problem Solving (MAPS)|HE counseling, self-help materials, and resource referrals, and home-based exercise kit; 6-week supply of nicotine patches for smoking cessation if needed. Plus 9 proactive, telephone counseling sessions over the 18 month period.
3156467|NCT01504906|Experimental|A|cyclosporine 600 mg+ a single oral dose of 180 mg ticagrelor
3156468|NCT01504906|Experimental|B|single dose cyclosporine 600 mg
3156469|NCT01504906|Experimental|C|single dose 180 mg ticagrelor
3156470|NCT01504893|Experimental|protective|"Two-lung ventilation (TLV): tidal volume = 8 mL / kg, peak pressure streets ≤ 25 cm H2O, I: E = 1:2; after lung re-expansion to the closure of the chest will set a PEEP of 5 cmH2O~OLV (OLV): 4 mL / kg, peak airway pressure ≤ 35 cmH2O, respiratory rate <30, I:E = 1:2 / 1:3.~During OLV in case of desaturation (before increasing the FiO2) and / or within 1 hour you perform recruitment maneuvers followed by the setting of a PEEP of 5 cmH2O"
3156471|NCT01504893|No Intervention|conventional|"Two-lung ventilation (TLV): tidal volume = 8 mL / kg, peak pressure ≤ 25 cmH2O airway; I: E = 1:2; after lung re-expansion to the closure of the chest will set a PEEP of 5 cmH2O~OLV (OLV): 8 mL / kg, peak airway pressure ≤ 35 cmH2O; I: E = 1:2."
3156472|NCT01504867|Experimental|Aspirin|This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.
3156473|NCT01504867|Placebo Comparator|Placebo|This group received matching lactose powder filled capsules on days 1-7.
3156474|NCT01504854|Experimental|Resveratrol|Subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.
3156475|NCT01504854|Placebo Comparator|Placebo|Subjects will receive a matching placebo to be taken with or without food.
3156476|NCT01504841|Experimental|Cohort I: Treatment experienced, 2 to 6 years of age|Children in this arm will be at least 2 but younger than 6 years of age; they will receive the study drug etravirine (ETR) together with an optimized background regimen (OBR) consisting of one active boosted protease inhibitor (PI) and at least one other active antiretroviral (ARV) drug.
3156477|NCT01504841|Experimental|Cohort II: Treatment experienced, 1 to 2 years of age|Children in this arm will be at least 1 but younger than 2 years of age; they will receive ETR together with an OBR consisting of one active boosted PI and at least one other active ARV drug.
3156478|NCT01504841|Experimental|Cohort III: Treatment experienced, 2 months to 1 year of age|Children in this arm will be at least 2 months but younger than 1 year of age; they will receive ETR together with an OBR consisting of one active boosted PI and at least one other active ARV drug.
3156479|NCT01504828|Experimental|Ramipril|Those who are 40 years and older receive an ACE inhibitor to determine if this reduces age-related changes in left ventricular energetics and function
3156480|NCT01504815|Active Comparator|Cisplatinum + conventional RT|Cisplatinum 100mg/m2 on days 1, 22 and 43, with conventional RT 70 Gy in 7 weeks
3156481|NCT01504815|Experimental|Cisplatinum + adaptive high dose RT|Cisplatinum, 100 mg/m2 on days 1, 22 and 43 with adaptive high dose RT to 84 Gy max on 50% uptake GTV in 7 weeks
3156482|NCT01504802||Growth hormone deficient|Children with short stature, a peak growth hormone response on stimulation testing of less than 7 ng/ml, and no other identifiable cause of short stature
3156483|NCT01504802||Idiopathic short stature|Children with short stature, a peak growth hormone response on stimulation testing of greater than or equal to 7 ng/ml, and no identifiable cause for the short stature
3156484|NCT01504789|Experimental|Cultural Related Material Group|Patients will be randomized to receive either culturally adapted AI materials or non-culturally adapted SI materials. Intervention materials will be mailed to patients every 2 weeks. Based on the results of the fitness tests, a specific exercise program will be presented. The research staff will call about every 2 weeks to check that materials were received and have been sent back whatever materials are due. The phone call should take no more than 15 minutes. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. The questionnaire packet will be mailed with a postage-paid return envelope. It should take about 10 minutes to complete the questionnaires.
3156485|NCT01504789|Experimental|Non-Cultural Related Material Group|Patients will be randomized to receive either culturally adapted AI materials or non-culturally adapted SI materials. Intervention materials will be mailed to patients every 2 weeks. Based on the results of the fitness tests, a specific exercise program will be presented. The research staff will call about every 2 weeks to check that materials were received and have been sent back whatever materials are due. The phone call should take no more than 15 minutes. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. The questionnaire packet will be mailed with a postage-paid return envelope. It should take about 10 minutes to complete the questionnaires.
3156486|NCT01504789|Active Comparator|Waitlist Group|Patients may choose to participate in the exercise program after 16-week assessment. After 4 months of exercise, all the follow-up tests repeated. Exercise recommendation then given, and all of the intervention materials.
3156487|NCT01504776|Experimental|Open Label Drug Therapy|Single arm
3156488|NCT01504763|Experimental|Massage|Chair massage for 15 minutes once a week for 10 weeks.
3156489|NCT01504750|Experimental|lighting room|In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals.
3156490|NCT01504750|No Intervention|control room|Normal lighted patient room
3156491|NCT01504737|Experimental|Supervised Exercise Training|12 weeks of 40 min aerobic bicycle ergometer exercise 3 times per week.
3156492|NCT01504737|Active Comparator|Physical Activity Recommendations|Written and verbal information on minimal level of physical activity recommended.
3156493|NCT01504724|Experimental|IVB group|Patients were treated with IVB injections approximately within 1 week before the first PRP. Then patients had PRP, which was done in three sessions at weeks 0, 1, and 2 according to ETDRS guidelines. The superior, inferior, and nasal and temporal areas were treated sequentially.
3156494|NCT01504724|No Intervention|only PRP group|Patients had PRP, which was done in three sessions at weeks 0, 1, and 2 according to ETDRS guidelines. The superior, inferior, and nasal and temporal areas were treated sequentially.
3156495|NCT01504711|Experimental|Treatment (nausea and vomiting prophylaxis)|Receive fosaprepitant dimeglumine IV 30 mins. prior to FOLFIRINOX chemotherapy.
3156496|NCT01504698|Experimental|Treatment with manipulation|
3156497|NCT01504698|Active Comparator|Treatment without manipulation|
3156498|NCT01504685|Active Comparator|Unbanded laparoscopic gastric bypass|Laparoscopic Roux- en-Y gastric bypass without any band around de gastric reservoir
3156499|NCT01504685|Active Comparator|Banded laparoscopic gastric bypass|Placement of a premeasured band or ring around the gastric reservoir, adjacent to the gastroenterostomy.
3156500|NCT01504672|Experimental|Medication review|
3156501|NCT01504672|No Intervention|Usual care|
3156502|NCT01504659|Active Comparator|Bipolar-Ketalar|Children with a diagnosis of BP-I, BP-II or BP-NOS will receive 4 administrations of intranasal ketalar
3156503|NCT01504659|Placebo Comparator|Bipolar-Placebo|Children with a diagnosis of BP-I, BP-II or BP-NOS will receive 4 administrations of placebo
3156504|NCT01504646|Placebo Comparator|Olive Oil Capsule|Ten subjects will take eight placebo olive oil capsules per day for three weeks.
3156505|NCT01504646|Experimental|Lyprinol|Ten subjects will take eight Lyprinol capsules per day for three weeks.
3156506|NCT01504633|Experimental|DHA+EPA Group|DHA/EPA capsule (100mg DHA + 20mg) and placebo syrup per day
3156507|NCT01504633|Experimental|Fe Group|Placebo capsule and Fe syrup (16mg elemental iron) per day
3156508|NCT01504633|Experimental|DHA/EPA+Fe Group|DHA/EPA capsule (100mg DHA + 20mg) and Fe syrup (16mg elemental iron) per day
3156509|NCT01504633|Experimental|Placebo Group|Placebo capsule and placebo syrup
3156510|NCT01504620|Other|Sugar infusion|Diagnostic assessment of blood glucose by means of different devices
3156511|NCT01504620|Experimental|insulin infusion|infusion of insulin to achieve low glucose levels
3156512|NCT01504607||Congenital cataract surgery with IOL implantation|Congenital cataract surgery was performed with or without anterior vitrectomy, followed by in the bag IOL implantation
3156513|NCT01504594|Experimental|Patients|Children which meet eligibility criteria and after being assessed, are stimulated with G-CSF, undergo bone marrow extraction and then have them applied directly to the coronary arteries through cardiac catheterization.
3156514|NCT01504581|Experimental|HM10660A|
3156515|NCT01504581|Active Comparator|Pegasys|
3156516|NCT01504581|Placebo Comparator|HM10660A Placebo|
3156517|NCT01504568|Other|Prophylactic Antibotics|Amoxicillin/clavulanic acid
3156518|NCT01504568|No Intervention|Non Treatment|Subjects will be followed without the use of antibiotics.
3156519|NCT01504555||Patients under investigation for hypercortisolism|Patients undergoing routine evaluation for hypercortisolism at Haukeland University Hospital, Bergen, Norway, will be asked to participate.
3156520|NCT01504542|Experimental|Low-dose HS-110|2,000,000 cells/0.5mls + erlotinib 150mg orally once daily
3156521|NCT01504542|Experimental|High dose HS110|10,000,000 HS110 cells/0.5ml + erlotinib 150mg orally once daily.
3156522|NCT01504542|Placebo Comparator|Placebo vaccine + erlotinib 150mg orally once daily|Placebo vaccine buffered saline solution + erlotinib 150mg orally once daily
3156523|NCT01504529||Neupro Treatment|Data from patients with advanced PD who have been treated with Rotigotine (Neupro®) for at least the previous 6 months as prescribed by physicians according to usual clinical practice in Spain, will be retrospectively collected.
3156524|NCT01504516|Experimental|Donepezil Hydrochloride10 mg Tablets|Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
3156525|NCT01504516|Active Comparator|Aricept 10 mg Tablets|Aricept 10 mgTablets of Pfizer Inc
3156526|NCT01504503|Experimental|Donepezil Hydrochloride10 mg Tablets|Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
3156527|NCT01504503|Active Comparator|Aricept 10 mg Tablets|Aricept 10 mgTablets of Pfizer Inc
3156528|NCT01504490|Experimental|CS-7017 and Bexarotene|Combination of CS-7017 and Bexarotene
3156529|NCT01504477|Experimental|Combination of Panitumumab and Bortezomib|IV panitumumab and bortezomib
3156530|NCT01504464|Experimental|mesenchymal stem cell|Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection.
3156531|NCT01504464|Experimental|placebo|The patients who are in control group and underwent placebo injection.
3156532|NCT01504451|Active Comparator|Biosense Webster ablation|Biosense Webster irrigated multi-electrode phased radiofrequency AF ablation
3156533|NCT01504451|Active Comparator|Surgical ablation|Minimally invasive thoracoscopic surgical AF ablation
3156534|NCT01504451|Active Comparator|Medtronic ablation|Medtronic multi-electrode phased radiofrequency AF ablation
3156535|NCT01504438|Other|Salto Talaris Total Ankle Replacement|
3156536|NCT01504438|Other|STAR Total Ankle Replacement|
3156537|NCT01504412|Experimental|DS-5565 Low Dose|DS-5565 10mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
3156538|NCT01504412|Experimental|DS-5565 Middle Dose|DS-5565 20mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
3156539|NCT01504412|Experimental|DS-5565 High Dose|DS-5565 30mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
3156540|NCT01504412|Placebo Comparator|Placebo|DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day.
3156541|NCT01504412|Active Comparator|Pregabalin|Pregabalin capsules 300mg/day administered in 2 doses
3156542|NCT01504399||Microscopic:|Microscopic (single nostril, direct endonasal with nasal speculum)transsphenoidal nasal surgery
3156543|NCT01504399||Endoscopic|Fully endoscopic: (bi-nostril, no nasal speculum) transsphenoidal pituitary surgery
3156544|NCT01504386|Experimental|TAP block|TAP block with ropivacaine
3156545|NCT01504386|Placebo Comparator|Placebo TAP block|Sham block with saline
3156550|NCT01504347|Experimental|Primary vaccination in seronegative subjects|
3156551|NCT01504347|Experimental|Booster vaccination in seronegative subjects|
3156552|NCT01504347|Experimental|Primary + booster vacc. (seronegative + seropositive subjects)|
3156553|NCT01504334|Experimental|Pirfenidone(200mg)|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
3156554|NCT01504334|Placebo Comparator|Placebo (without active ingredient)|
3156555|NCT01504321|Active Comparator|Active|
3156556|NCT01504321|Placebo Comparator|Placebo|
3156557|NCT01504308|Experimental|MR-HIFU treatment|Patients receiving MR-HIFU treatment
3156558|NCT01504308|Sham Comparator|Sham Treatment|Patients receiving sham treatment
3156559|NCT01504295|Experimental|Metadoxine|Metadoxine 500mg tablet t.i.d.for 12 weeks
3156560|NCT01504295|Placebo Comparator|Sugar pill|Placebo group
3156561|NCT01504282|Active Comparator|MMC group|One eye of each patient was randomly assigned to receive intraoperative topical 0.02% MMC for 5 seconds.
3156562|NCT01504282|Placebo Comparator|BSS group|One eye of each patient was randomly assigned to receive balanced salt solution (BSS) with the same manner.
3156563|NCT01504256|Experimental|catumaxomab|"this arm was stopped. the antibody previously used as a study drug is not available at this time. patients will be randomized only into the standard arm~[Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10) and 7 days after the last catumaxomab infusion FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1))"
3156564|NCT01504256|Active Comparator|standard therapy|"FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)"
3156565|NCT01504243||Control|normal person under medical examination
3156566|NCT01504243||sepsis|SIRS plus inflammation
3156567|NCT01504230||health older adults|
3156568|NCT01504230||Osteoporosis participants|
3156569|NCT01504204|Experimental|Medication with sample and demonstration|Subjects will receive a sample tube of the Adapalene + benzoyl peroxide samples with demonstration of how to use it at the first visit.
3156570|NCT01504204|Active Comparator|Medication without samples|Subjects will receive the Adapalene + benzoyl peroxide from standard tube without a sample or demonstration of proper use of the medication.
3156571|NCT01504191|Experimental|Internet‐based CBT|Randomized patients with symptoms of anxiety and/or depression after MI will participate in an Internet‐based CBT‐program.
3156572|NCT01504191|No Intervention|Treatment as usual (TAU)|"Control: After randomization patients with symptoms of anxiety and/or depression after MI will participate in the treatment as usual (TAU).~Reference: A reference group without depressive or anxiety symptoms will participate in the treatment as usual (TAU)."
3156573|NCT01504178|Experimental|duloxetine|The first group (12 patients) will receive, after 28 days of duloxetine treatment, one duloxetine dose, an injection of apomorphine and a placebo of L-Dopa.
3156574|NCT01504178|Placebo Comparator|positive control (L-Dopa)|The second group (12 patients) will receive, after 28 days of placebo treatment, one placebo dose of duloxetine, an injection of apomorphine and injection of placebo of L-Dopa.
3156575|NCT01504178|Placebo Comparator|negative control|The third group will receive, after 28 days of placebo treatment, one placebo of duloxetine, an injection of placebo of apomorphine and a dose of L-Dopa.
3156576|NCT01504165|Experimental|Group 1|Healthy volunteers: matched subjects with normal renal function
3156577|NCT01504165|Experimental|Group 2|Mild renal impaired subjects
3156578|NCT01504165|Experimental|Group 3|Moderate renal impaired subjects
3156579|NCT01504165|Experimental|Group 4a|First group of Severe renal impaired subjects
3156580|NCT01504165|Experimental|Group 4b|Second group of severe renal impaired subjects
3156581|NCT01504152||patients who received HSCT at MSKCC between 2005-2010|A self-administered patient questionnaire will be used to collect data that will assess the prevalence of international travel after HSCT and travel related morbidity and exposure risks among HSCT recipients.
3156582|NCT01504139|Experimental|hCG in the late follicular phase + luteal phase|
3156583|NCT01504139|Experimental|hCG in the follicular phase + luteal phase|
3156584|NCT01504139|Experimental|LH in the luteal phase|
3156585|NCT01504139|Active Comparator|vaginal progesterone and estradiol in the luteal phase|
3156586|NCT01504126|Experimental|Propranolol|Propranolol 20 mg orally twice a day for 48-72 hours preoperatively, resumed post-operative tumor reduction continued to chemotherapy completion. Intravenous platinum or taxane chemotherapy (without bevacizumab) for six 3-week cycles.
3156587|NCT01504113||Study 1 goup|Patients who are planned to receive targeted agents
3156588|NCT01504113||Study 2 case group|Patients who have received targeted therapy
3156589|NCT01504113||study 2 control group|Psoriasis patients without target therapy
3156590|NCT01504100||femoral internal rotation|
3156591|NCT01504100||no femoral internal rotation|
3156592|NCT01504087||patinet with deep venous thrombosis|patient with deep venous thrombosis by ultrasonography as case; patient with no deep venous thrombosis by ultrasonography as control
3156593|NCT01504087||patient without deep venous thrombosis|
3156594|NCT01504074||Patients suffering on CME secondary to cataract surgery|
3156595|NCT01504061|Experimental|Mederma Ultra Gel|
3156596|NCT01504061|Active Comparator|Mederma N&I|
3156597|NCT01504048|Experimental|Chromoendoscopy|
3156598|NCT01504035|Experimental|Hemostatic putty plus Lidocaine (Orthostat-L)|
3156599|NCT01504035|Active Comparator|Hemostatic putty (Orthostat)|
3156600|NCT01504022|No Intervention|Control group.|Control group.
3156691|NCT01503307||Prenatal/Postpartum CHD Diagnosis|parent of a baby (prenatal or postpartum)who was recently found to have a heart defect.
3156692|NCT01503281|Experimental|Hospital-based exercise program|Exercise monitored at the hospital
3156601|NCT01504022|Experimental|Telecare, self monitoring, lifestyle counseling|Patients in the intervention group will measure their blood pressure with home blood pressure monitor which is linked to a secured website. Patients will measure as recommended in the European guidelines of hypertension. This includes 2 measurements in the morning and two times in the evening on 7 consecutive days every month. The measurements of the first day will be discarded. These measurements will be forwarded to the web-based system, which will be managed by the nurse practitioner and the research doctor. At least every month patients are contacted about the state of their condition. If needed, antihypertensive medication is added of adjusted by the nurse practitioner or research doctor under the supervision of one consultant physician. Tailored lifestyle advices are given every month.
3156602|NCT01504009|Experimental|Muscle strength|
3156603|NCT01503996||glaucoma|hospitalized glaucoma patients
3156604|NCT01503996||controls|hospitalized patients without glaucoma
3156605|NCT01503983|Experimental|Trastuzumab+Oxaliplatine+capecitabine|Patient takes Trastuzumab (initial dose 8 mg/kg and a maintenance dose 6 mg/kg) anda oxaliplatin (dose 130mg/m2) during the first day os cycle and them Capecitabine (dose 2000 mg/m2)during 14 days in cycle of 21 days.
3156606|NCT01503970|Experimental|Chondrocyte implantation|
3156607|NCT01503957|Placebo Comparator|Saline solution|Nasal spray
3156608|NCT01503957|Experimental|Nasya|Thixotropic nasal spray suspension
3156609|NCT01503944|Other|Dementia with Lewy Bodies|
3156610|NCT01503944|Other|Parkinson's disease|
3156611|NCT01503944|Other|Healthy Elderly Volunteers|
3156612|NCT01503944|Other|Alzheimer's Disease|
3156613|NCT01503931||Alcohol-dependent patients|"men and women, aged 18 to 75~legally effective, written informed consent for participation within the study~right handedness~no other psychiatric disorder according to ICD 10~no psychotropic substances within the last 7 days"
3156614|NCT01503931||Healthy control subjects|"men and women, aged 18 to 75~legally effective, written informed consent for participation within the study~right handedness~no psychiatric disorder according to ICD 10~no psychotropic substances within the last 7 days"
3156615|NCT01503918|Experimental|Valaciclovir/Aciclovir|
3156616|NCT01503918|Experimental|Valganciclovir/Ganciclovir|
3156617|NCT01503918|No Intervention|control|
3156618|NCT01503905|Active Comparator|Docetaxel plus epirubicin|
3156619|NCT01503905|Active Comparator|docetaxel plus epirubicin plus cyclophosphamide|
3156620|NCT01503892|Placebo Comparator|Placebo|The control group will receive placebo pill twice daily for twelve months.
3156621|NCT01503892|Active Comparator|Metanx|Metanx group will receive one pill twice daily for twelve months.
3156622|NCT01503866|Experimental|20 mg bardoxolone methyl|
3156623|NCT01503840|Active Comparator|Sugammadex|
3156624|NCT01503840|Placebo Comparator|Sodium chloride solution|
3156625|NCT01503827|Experimental|WBRT|Patients will receive WBRT after local treatment. A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
3156626|NCT01503827|No Intervention|Observation|No Intervention
3156627|NCT01503814|No Intervention|Control (Usual Care)|Control
3156628|NCT01503814|Experimental|Intervention|"Use of a simplified guideline-based CVD prevention and management scheme by village doctors targeting high risk individuals focusing on a2+2model: 2 therapeutic lifestyle recommendations (smoking cessation and salt consumption reduction) plus prescription of 2 low-cost drugs (aspirin and low-dose diuretics) when applicable"
3156629|NCT01503801|Experimental|inhaled nitric oxide|The preterm infants in the experimental group inhaled nitric oxide
3156630|NCT01503801|Active Comparator|oxygen|The preterm infants enrolled but subjected to routine respiratory support.
3156631|NCT01503788|Active Comparator|periprocedural sedation with midazolam|periprocedural sedation with IV midazolam 5-10 minutes before diagnostic lumbar puncture
3156632|NCT01503788|No Intervention|No intervention|Participants will undergo the diagnostic lumbar puncture as routinely practiced
3156633|NCT01503775||TRUFILL® DCS Orbit Galaxy|
3156634|NCT01503762|Experimental|Mirror Therapy Group|Mirror Therapy Group
3156635|NCT01503762|Sham Comparator|Control Group|Control Group receive classical rehabilitation techniques including splinting, tendon gliding, ...
3156636|NCT01503749|No Intervention|Control|Three patients with liver cirrhosis of this arm will not receive any intervention regarding to peripheral blood mononucleated cells.
3156637|NCT01503749|Active Comparator|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm.
3156638|NCT01503749|Experimental|Infusion of the mobilized monocyte cells|"G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells~. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance."
3156639|NCT01503736|Placebo Comparator|Placebo|
3156640|NCT01503736|Experimental|4g/day|Ferric Citrate for a total daily dose of 4g
3156641|NCT01503736|Experimental|6g/day|Ferric Citrate for a total daily dose of 6g
3156642|NCT01503723||Patients with acute lung injury|Patients who are admitted to ICU with the diagnosis of acute hypoxemic respiratory failure
3156643|NCT01503684||Patients with sepsis|Patients who are admitted to ICU with the diagnosis of sepsis
3156644|NCT01503671|Experimental|Atorvastatin|Atorvastatin 40 mg/day for high inflammation CAPD patient
3156645|NCT01503671|No Intervention|No intervention arm|Placebo arm without intervention
3156646|NCT01503658|Experimental|Clopidogrel+Aspirin|Clopidogrel on Day 1, Aspirin on Day 2 - Day 14, Clopidogrel + Aspirin Day 15, Aspirin on Day 16 - Day 28, Clopidogrel + Aspirin Day 29
3156647|NCT01503632|Experimental|Arm I (intervention program and mercaptopurine)|See detailed description.
3156648|NCT01503632|Active Comparator|Arm II (standard of care and mercaptopurine)|Patients receive the usual standard of care and the mercaptopurine from the MEMS? medication bottle with TrackCap? as patients in arm I. Patients and caregivers also view an interactive multimedia educational program on day 29.
3156693|NCT01503281|Experimental|Home-based exercise program|Participants perform exercise at home
3156649|NCT01503619||Basic science (biomarker analysis)|DNA isolated from archived tumor tissue and blood samples are analyzed for genetic mutations and gene expression profiling using Illumina exome sequencing. Results are compared with transcriptome of tumors (or cell lines) with and without the specific mutation. Cell culture studies overexpressing or inhibiting the genes of interest are also performed in a mouse model to identified potential drivers of small cell lung cancer.
3156650|NCT01503606|Active Comparator|one-week treatment group|Cefazolin 1.0gm IVs q 12 hours plus clarithromycin 500mg po bid after randomization for one week
3156651|NCT01503606|Active Comparator|until-delivery treatment group|Cefazolin 1.0gm IVs q 12 hours plus clarithromycin 500mg po bid after randomization until delivery
3156652|NCT01503593|No Intervention|Alveolar ridge dimensions|Control group - Only extraction teeth
3156653|NCT01503593|Experimental|Alverolar ridge dimension|Extraction of teeth and implant a bone substitute
3156654|NCT01503580|Experimental|antimuscarinic drug|
3156655|NCT01503567||Subjects 6 to 18 years old without inhibitors|
3156656|NCT01503567||Subjects 6 to 18 years old with inhibitors|
3156657|NCT01503567||Subjects above18 years old without inhibitors|
3156658|NCT01503567||Subjects above 18 years old with inhibitors|
3156659|NCT01503554|Experimental|Social Worker + Pharmacist Intervention|Intervention arm offering enhanced services from a social worker and a pharmacist post-discharge
3156660|NCT01503554|Experimental|Usual Care|Patients receiving usual care will have a medication reconciliation performed by a physician or nurse during their hospital stay. No further support or interventions are provided post discharge.
3156661|NCT01503528|Active Comparator|Motor Sparing Nerve Block|Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
3156662|NCT01503528|Experimental|Peri-Articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by peri-articular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
3156663|NCT01503515|Experimental|Arm I (caspofungin acetate)|Patients receive caspofungin acetate IV over 1 hour once daily (QD) beginning within 24 hours of allogeneic HSCT (day -1 or 0) and continuing until day 42 in the absence of invasive fungal infections or disease progression.
3156664|NCT01503515|Active Comparator|Arm II (fluconazole or voriconazole)|Patients receive fluconazole IV over 1-2 hours QD or PO QD; or voriconazole IV over 1-2 hours QD or PO BID beginning within 24 hours of allogeneic HSCT (day -1 or 0) and continuing until day 42 in the absence of invasive fungal infections or disease progression.
3156665|NCT01503502|Experimental|flumatinib 400mg qd|
3156666|NCT01503502|Experimental|flumatinib 600 mg qd|
3156667|NCT01503502|Active Comparator|imatinib|
3156668|NCT01503489||Bipolar depressed patients|Bipolar I or II outpatients, current major depressive episode (HDRS-17 over 20).
3156669|NCT01503476|Experimental|Healthy volunteers|healthy volunteers
3156670|NCT01503476|Experimental|symptomatic patients|symptomatic patients with known or suspected gastro esophageal reflux disease
3156671|NCT01503463|No Intervention|Usual Care|Patients in the control group receive usual care delivered by their primary care physicians and cardiologists. Usual care consists of regular visits to the specialist or primary care clinics every time a medication change is required, or a medical examination is needed.
3156672|NCT01503463|Experimental|Home telemonitoring of patients with CHF|
3156673|NCT01503450|Experimental|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
3156674|NCT01503450|Active Comparator|Zyprexa Zydis 5 mg Tablets|Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK
3156675|NCT01503437|Experimental|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
3156676|NCT01503437|Active Comparator|Zyprexa Zydis 5 mg Tablets|Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK
3156677|NCT01503424|Experimental|Olanzapine Tablets, 5 mg|Olanzapine Tablets, 5 mg of Dr. Reddy's Laboratories Limited
3156678|NCT01503424|Active Comparator|Zyprexa|Zyprexa Tablets, 5 mg of Eli Lilly and company
3156679|NCT01503398|Experimental|Olanzapine Tablets, 5 mg|Olanzapine Tablets, 5 mg of Dr. Reddy's Laboratories Limited
3156680|NCT01503398|Active Comparator|Zyprexa|Zyprexa Tablets, 5 mg of Eli Lilly and company
3156681|NCT01503385|Experimental|Celecoxib|"Combination of and concurrent radiotherapy Cisplatin/etoposide with or without Celecoxib.~Intervention: Drug: Celecoxib"
3156682|NCT01503372|Experimental|Arm A: FLO + Pazopanib|
3156683|NCT01503372|Active Comparator|Arm B: FLO|
3156684|NCT01503359|Experimental|Dietary Supplement: Sarcosine|Sarcosine Group
3156685|NCT01503359|Placebo Comparator|Placebo|Control Group
3156686|NCT01503346|Active Comparator|herbal medicine|"Intervention group~1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~2. each package was given to each patient four times a day (three time after meal and one time before sleep);~3. each patient received the usual medication of the hospice ward at the same time;~4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
3156687|NCT01503333|No Intervention|Control|The control condition will complete data collection activities and receive their usual school offerings.
3156688|NCT01503333|Experimental|Physical activity intervention|Receiving Physical activity intervention which includes individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
3156689|NCT01503320|Experimental|Enteral glutamine|
3156690|NCT01503320|Placebo Comparator|Placebo|
3157630|NCT01496911|Placebo Comparator|Placebo|
3156694|NCT01503281|No Intervention|Control|Control Group participants maintained their usual levels of daily activity, with no additional exercise components.
3156695|NCT01503268|Active Comparator|Percutaneous ablation|
3156696|NCT01503268|Active Comparator|Surgical ablation|
3156697|NCT01503268|Active Comparator|DCCV|Direct current cardioversion
3156698|NCT01503255|Experimental|cognitive behavioral group therapy|
3156699|NCT01503255|Active Comparator|health education group|
3156700|NCT01503242|Experimental|Treatment (monoclonal antibody, chemo, TBI, transplant)|Patients receive 90Y-BC8 Ab IV on day -12 and fludarabine phosphate IV on days -4 to -2. Patients undergo TBI and allogeneic peripheral blood stem cell transplant on day 0. Patients also receive graft-vs-host disease prophylaxis comprising cyclosporine PO BID on days -3 to 56 with taper to day 180 or on days -3 to 100 with taper to 180; and mycophenolate mofetil IV or PO BID on days 0-27, or 0-40 with taper to 96.
3156701|NCT01503229|Experimental|Treatment (abiraterone acetate and prednisone)|Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3156702|NCT01503216|Experimental|cholecalciferol|Human volunteers receiving cholecalciferol (vitamin D3) for 8 weeks
3156703|NCT01503216|Experimental|Ergocalciferol|Ergocalciferol 2000 IU per day for 8 weeks
3156704|NCT01503216|Placebo Comparator|Placebo|Placebo for 8 weeks
3156705|NCT01503203|Experimental|Wii Group|This group will do the same training of the Prime Group. However will do also Physical Virtual Training using Nintendo Wii and Wii Balance Board. The physical virtual training going to applied during thirty minutes.
3156706|NCT01503203|Active Comparator|Prime Group|This group will do strength exercises and core training.
3156707|NCT01503177|Experimental|Treatment (viral therapy)|Patients receive MV-NIS intrapleurally on day 1. Treatment repeats every 28 days for up to 6 courses in absence of disease progression or unacceptable toxicity.
3156708|NCT01503164|Active Comparator|Positive pressure therapy (PAP)|Positive airway pressure(PAP) therapy is the standard of care for patients with obstructive sleep apnea. During sleep, a mask is worn over the nose and connected to the PAP machine.
3156709|NCT01503164|Sham Comparator|Lifestyle counseling|
3156710|NCT01503151|Placebo Comparator|Placebo|repeated trials of a dot-probe task and repeated trials of an interpretation task, both not intended to change threat-related biases patterns.
3156711|NCT01503151|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
3156712|NCT01503151|Experimental|Interpretation Bias Modification (IBM)|Interpretation training intended to facilitating a more benign interpretation bias
3156713|NCT01503151|Experimental|Attention and interpretation biases modification|Attention and interpretation training intended to direct cognitive biases away from threat stimulus.
3156714|NCT01503138|Experimental|Purpose-built intervention|A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
3156715|NCT01503138|No Intervention|Standard community health education program|The community health education programme consists of two group sessions with one on the topic of osteoporosis and one on dietary therapy based on the concepts of Chinese medicine.
3156716|NCT01503112||Patients starting incretin treatments|Patients starting GLP-1 agonists or DPPIV inhibitors as part of their normal clinical care.
3156717|NCT01503099||Active ITB|Patients with active intestinal tuberculosis (ITB)
3156718|NCT01503099||Controls India|Healthy subjects serving as controls
3156719|NCT01503099||CD India|Patients with active Crohn's Disease (CD) in India
3156720|NCT01503099||Active PTB|Patients with active pulmonary tuberculosis (PTB)
3156721|NCT01503099||CD Norway|Patients with active Crohn's Disease (CD) in Norway
3156722|NCT01503099||Controls Norway|Healthy subjects serving as controls in Norway
3156723|NCT01503086|Experimental|Arm I (interactive training program)|Patients undergo a home-based, computerized, interactive training program comprising 3-5 sessions of 15-45 minutes every week for 5-9 weeks. The program contains twelve visually engaging and interesting exercises that target skills involving visual-spatial and verbal WM. The program is adaptive in a way that each difficulty task is automatically adjusted on a trial-by-trail basis to match a patient?s current WM. Each patient has an interventional coach who has online access to patient's training sessions and outcomes (pass or fail). Coaches are able to modify the training sequence or make suggestions to patients and/or parents about how progress can be maximized. Coaches also have telephone meetings with patients and/or families once a week to ensure compliance, track progress, provide feedback, and answer questions that arise during training.
3156724|NCT01503086|Experimental|Arm II (non-adaptive training program)|Patients undergo a home-based, computerized, interactive, non-adaptive training program comprising 3-5 sessions of 15-45 minutes a week for 5-9 weeks. Each patient also has an interventional coach as in arm I. Patients in both arms complete a brief neuropsychological/behavioral assessment comprising the WIS-IV, the CMS, and the CVLT-C at baseline, after completion of study, and at 6 months after completion of study. Additionally, parents complete a parent-report questionnaire to gather information about patient's behaviors, thoughts, emotions, adaptive skills, and social and functional impairment. Parents and children also complete surveys about the program regarding technical feasibility, adherence, ease-of-use, and satisfaction.
3156725|NCT01503073|Active Comparator|Real stimulation|real NIBS
3156726|NCT01503073|Sham Comparator|Sham stimulation|sham NIBS
3156727|NCT01503060|Placebo Comparator|Group 1|"Visit 1-4 (2,4,6,12 month vaccinations): Patients will receive standard care~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
3156728|NCT01503060|Active Comparator|Group 2|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
3156729|NCT01503060|Active Comparator|Group 3|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain and their infant will be given sugar~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
3156775|NCT01502800|Experimental|Part 2 Arm C|"ARQ 761 (beta lapachone) will be given 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
3156730|NCT01503060|Active Comparator|Group 4|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain and their infant will be given sugar water and a topical anesthetic~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
3156731|NCT01503047|Experimental|CLA group|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)
3156732|NCT01503047|Placebo Comparator|Placebo group|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo, P group.
3156733|NCT01503034||Study cohort|This cohort is made up of pregnant women with a breast cancer diagnosed between 2000 and 2014.
3156734|NCT01503034||Compared cohort|This cohort is made up of non-pregnant women with a breast cancer diagnosed between 2000 and 2009.
3156735|NCT01503021|Other|SFP/Placebo|Soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks, then 1 week washout, then standard liquid bicarbonate concentrate without SFP x 2 weeks
3156736|NCT01503021|Other|Placebo/SFP|Standard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks.
3156737|NCT01503008|Experimental|Sustained Behavior Change system support|
3156738|NCT01503008|Active Comparator|Control|
3156739|NCT01502995|Active Comparator|With laser light|Trial of walking tasks using laser light on walker.
3156740|NCT01502995|Active Comparator|Without laser light|Trial of walking task without laser light on walker.
3156741|NCT01502982|Experimental|Chemoimmunotherapy|
3156742|NCT01502969|Placebo Comparator|Placebo|Children receiving placebo (cell culture medium in absence of virus)
3156743|NCT01502969|Active Comparator|Rotavirus vaccine|Rotavin-M1, 10e6.3ffu/dose, 2 doses
3156744|NCT01502956|Active Comparator|InterStim® device|The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/>50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.
3156745|NCT01502956|Active Comparator|Botox® injection|Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.
3156746|NCT01502943|Experimental|Phlegm and blood stasis Syndrome G|
3156747|NCT01502943|Placebo Comparator|Phlegm and blood stasis control G|
3156748|NCT01502943|Experimental|Qi deficiency and blood stasis G|
3156749|NCT01502943|Placebo Comparator|Qi deficiency and blood stasis control G|
3156750|NCT01502930|Experimental|IRT|Imagery Rehearsal Therapy
3156751|NCT01502930|Active Comparator|CONT|Stress reduction and positive imagery
3156752|NCT01502930|No Intervention|REG|Registration only
3156753|NCT01502917|Experimental|Radioactive iodine-labeled monoclonal antibody 8H9|This is a therapeutic Phase I study intended to assess the safety of convection-enhanced delivery (CED) of radioimmunotherapy in the treatment of children with diffuse pontine glioma.
3156754|NCT01502904|Active Comparator|Cypher group|
3156755|NCT01502904|Experimental|Nobori group|
3156756|NCT01502904|Active Comparator|Pravastatin group|
3156757|NCT01502904|Active Comparator|Pitivastatin group|
3156758|NCT01502904|Active Comparator|Non-ARB group|
3156759|NCT01502904|Experimental|ARB group|
3156760|NCT01502891|Active Comparator|Decision aid|DEPRESSION CHOICE decision aid is provided to clinician to share with patient
3156761|NCT01502891|No Intervention|Normal care|
3156762|NCT01502878|Active Comparator|Nut challenge|Double-blind placebo controlled oral challenge 5-50-200-1000 mg peanut or hazelnut protein, or placebo administered with 30 min intervals and 2 hour-follow-up after the last dose.
3156763|NCT01502878|Placebo Comparator|Nut challenge: Placebo|See intervention
3156764|NCT01502878|Experimental|Nut oral desensitization|Patients who have moderate to severe immediate allergic reaction at peanut challenge and who enter the oral desensitization program receive peanut protein daily, from 0,1 mg to 800 mg peanut protein, maintenance dose 800 mg.
3156765|NCT01502852||OEF/OIF Veterans with TBI|
3156766|NCT01502852||Family Members and Friends|Family Members and Friends of OEF/OIF Veterans with TBI
3156767|NCT01502852||Community Mental Health Center Providers|Community Mental Health Center providers working with OEF/OIF Veterans with TBI
3156768|NCT01502839||OEF/OIF Veterans|Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans
3156769|NCT01502826||Group A|less insulin-resistant
3156770|NCT01502826||Group B|severely insulin-resistant
3156771|NCT01502813|Experimental|Citicoline, Creatine, and Omega-3 Arm|
3156772|NCT01502800|Experimental|Part 1 (ARQ 761)|"ARQ 761 (beta lapachone) will be given once a week. The same dose of ARQ761 each week for 4 weeks (1 cycle = 28 days). The total infusion time will be one (1) hour.~Beginning dose level will be 195 mg/m2 and will increase until the maximum tolerated dose is defined. Seven dose levels that may be administered:~1-195 mg/m2 2-390 mg/m2 3-450 mg/m2 4-550 mg/m2 5-660 mg/m2 6-800 mg/m2 7-1000 mg/m2"
3156773|NCT01502800|Experimental|Part 2 Arm A|"The same dose of ARQ761 will be given each week for 8 weeks. The total infusion time will be 2 or 3 hours.~Beginning dose level will be 390 mg/m2."
3156774|NCT01502800|Experimental|Part 2 Arm B|"ARQ 761 (beta lapachone) will be given bi-weekly for 8 weeks. The total infusion time may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
3157009|NCT01501175||patients with suspected SVT|patients with suspected SVT and inhabitants of the Saint Etienne region
3156776|NCT01502787|Active Comparator|Initial treatment with metoprolol|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
3156777|NCT01502787|Active Comparator|Initial treatment with nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
3156778|NCT01502774|Experimental|Cyclosporin|Injection of Cyclosporin A : one single intravenous bolus injection of 2.5 mg/Kg Echocardiography
3156779|NCT01502774|Placebo Comparator|Control|one single intravenous bolus injection of Placebo Echocardiography
3156780|NCT01502761|Experimental|Regional Intra-arterial Magnesium 0.75g|Regional Intra-arterial magnesium only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients
3156781|NCT01502761|Experimental|Regional Intra-arterial magnesium 1.5g|Regional Intra-arterial magnesium Sulfate Only 1.5g (100% TD): 5 patients
3156782|NCT01502761|Experimental|Regional/ Distal (75/25%) Magnesium 1.5g|Regional/ Distal intra-arterial magnesium (75% TD regional- 1.125g / 25% distal-0.375g): 5 patients
3156783|NCT01502761|Experimental|Regional/ Distal (50/50%) Magnesium 1.5g|Regional/ Distal intra-arterial magnesium (50% TD regional- 0.75g/ 50% distal-0.75g): 5 patients
3156784|NCT01502748|Experimental|Endovascular Sampling|Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations in acute stroke patients undergoing endovascular recanalization who received intravenous Magnesium Sulfate as a part of the FAST-MAG study
3156785|NCT01502735|Experimental|DENV-1 PIV (high dose)|
3156786|NCT01502735|Experimental|DENV-1 PIV (low dose)|
3156787|NCT01502722|Experimental|Group 1 - Crossover|This group will drink water in the 1st study.
3156788|NCT01502722|Experimental|Group 2 - Crossover|This group will drink Pineapple Soda in the 1st study
3156789|NCT01502722|Experimental|Group 3 - Crossover|This group will drink Pineapple Diet Soda in the 3rd study
3156790|NCT01502709|Experimental|Caloric Vestibular Neurostimulation|Subjects received caloric vestibular neurostimulation
3156791|NCT01502709|Placebo Comparator|Placebo Arm|Subjects received placebo
3156792|NCT01502696|Experimental|PEG IFN alfa-2b|
3156793|NCT01502696|No Intervention|Observation|
3156794|NCT01502683|Experimental|Off-pump No Clamp|Off-pump coronary artery bypass patients randomized to no clamp for proximal anastomoses.
3156795|NCT01502683|Experimental|Off-pump Partial Occluding Clamp|Off-pump coronary artery bypass patients randomized to partial occluding clamp for proximal anastomoses.
3156796|NCT01502683|Experimental|On-pump Single Cross Clamp|On-pump coronary artery bypass patients randomized to single cross clamp for cardioplegic arrest and proximal anastomoses.
3156797|NCT01502683|Experimental|On-pump Double Clamp|On-pump coronary artery bypass patients randomized to cross-clamp for cardioplegic arrest and partial-occluding clamp for proximal anastomoses. This strategy involves the application of two clamps.
3156798|NCT01502670|Experimental|Lung Nodule|
3156799|NCT01502644|Active Comparator|Low Negative Affect (NA)|Participants with low NA (HADS score ≤5 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
3156800|NCT01502644|Active Comparator|Moderate NA|Participants with moderate NA (HADS score ≥6 to ≤8 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
3156801|NCT01502644|Active Comparator|High NA|Participants with high NA (HADS score ≥9 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
3156802|NCT01502631|Active Comparator|SUN13837|
3156803|NCT01502631|Placebo Comparator|Placebo|
3156804|NCT01502618|Experimental|Focus Group|The focus group participants for this study will be Black Young Men who have Sex with Men (B-YMSM) ages 16-24 years (inclusive) who are diagnosed as HIV-positive and receive medical care at one of the two participating AMTUs or their community partners.
3156805|NCT01502605|Experimental|5-ALA|This arm will receive the investigational agent, 5-ALA.
3156806|NCT01502592|Experimental|Cryoablation alone|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
3156807|NCT01502592|Experimental|Ipilimumab alone|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
3157631|NCT01496885||Nonhemorrhagic Ischemic Stroke|Subjects obtained within 24 to 48 hours of a nonhemorrhagic ischemic stroke
3156808|NCT01502592|Experimental|Ipilimumab & Cryoablation|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
3156809|NCT01502566|Experimental|Educational Intervention|Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries. This intervention will be applied at the Brazilian National Vaccination Day
3156810|NCT01502566|No Intervention|Control group|This group will receive no intervention
3156811|NCT01502553|Experimental|Blood Pressure, Heart Rate, Monitor|"Device Comparison Test DUT: Transtek Blood Pressure Monitor, LS-802 Refrence Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.~Groups/Cohorts: Blood Pressure & Heart Rate Monitor"
3156812|NCT01502527|Experimental|Treatment with Femarelle|An open labeled , twice daily treatment with Femarelle
3156813|NCT01502475||Veteran Attitudes toward CAM|
3156814|NCT01502449|Experimental|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program over 8 weeks that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
3156815|NCT01502449|Active Comparator|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
3156816|NCT01502423|Active Comparator|Current formulation adalimumab|One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
3156817|NCT01502423|Experimental|New formulation of adalimumab|One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe
3156818|NCT01502410|Experimental|Group 1 Relapsed/Refractory Rhabdomyosarcoma|"Patients with relapsed or refractory rhabdomyosarcoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
3156819|NCT01502410|Experimental|Group 2 Relapsed/Refractory Wilms tumor|"Patients with relapsed or refractory Wilms tumor receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
3156820|NCT01502410|Experimental|Group 3 Relapsed/Refractory hepatocellular carcinoma|"Patients with relapsed or refractory hepatocellular carcinoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
3156821|NCT01502410|Experimental|Group 4 Papillary thyroid carcinoma|"Patients with relapsed or refractory papillary thyroid carcinoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
3156822|NCT01502397||HBsAg-negative, anti-HBc-positive|HBsAg-negative, anti-HBc-positive subjects undergoing rituximab-containing chemotherapy
3156823|NCT01502384||healthy relatives|healthy 1st degree relatives of PD patients
3156824|NCT01502371|Experimental|MF MDI 50 mcg BID|Participants receive MF MDI 25 mcg x 2 inhalations (50 mcg total dose) BID PLUS Placebo dry powder inhaler (DPI) x 1 inhalation once daily (QD) in the evening for 12 weeks.
3156825|NCT01502371|Experimental|MF MDI 100 mcg BID|Participants receive MF MDI 50 mcg x 2 inhalations (100 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
3156826|NCT01502371|Experimental|MF MDI 200 mcg BID|Participants receive MF MDI 100 mcg x 2 inhalations (200 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
3156827|NCT01502371|Active Comparator|MF DPI 100 mcg QD|Participants receive Placebo MDI x 2 inhalations BID PLUS MF DPI x 1 inhalation QD in the evening for 12 weeks.
3156828|NCT01502371|Placebo Comparator|Placebo|Participants receive Placebo MDI x 2 inhalations BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
3156829|NCT01502358|Experimental|Tetravalent Dengue Vaccine (TVDV)|low dose (no adjuvant)
3156830|NCT01502358|Experimental|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|low dose (with adjuvant)
3156831|NCT01502358|Experimental|Tetravalent dengue Vaccine (TVDV) with Vaxfectin® (high-dose)|high dose (with adjuvant)
3156832|NCT01502345|Experimental|PUUV DNA Vaccine|This group will receive Puumala Virus DNA Vaccine only
3156833|NCT01502345|Experimental|HTNV + PUUV|This group will receive a 1:1 mixture of HTNV and PUUV DNA Vaccines
3156834|NCT01502345|Experimental|HTNV DNA Vaccine|This group will receive Hantaan Virus DNA Vaccine only
3156835|NCT01502332|Experimental|Intensive Alveolar Recruitment|Recruitment with opening pressures of 45 cmH2O in the airways.
3156836|NCT01502332|Active Comparator|Moderate Alveolar Recruitment|Recruitment with opening pressures of 20 cmH2O in the airways.
3156837|NCT01502319||All subjects|Group/Cohort label is not applicable to this umbrella protocol. The Consortium funds specific research teams who will determine the number of group(s)/cohort(s) relevant to their study.
3156838|NCT01502306|Experimental|Telephone counseling|One-on-one, proactive telephone counseling to quit smoking; The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling begins immediately after intake, if the client is available for a 30-minute session or by appointment at the clients' convenience. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls. The follow-up calls (about 10 minutes) will be scheduled as follows: a reminder call if the quit date is more than one week out for the initial counseling, on the quit date, 4-7 days after the quit date, and 10-14 days after the quit date.
3157632|NCT01496859|Experimental|Baska|
3156839|NCT01502306|Experimental|Phone counseling & nicotine patches|"One-on-one, proactive telephone counseling to quit smoking; The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls.~Nicotine patches (four weeks' worth) are sent directly to clients the day after the screening intake. Dosage is 21 mg if smoking 11 or more per day, 14 mg if smoking 6-10 per day and 7mg if smoking <6 per day."
3156840|NCT01502306|Experimental|Phone counseling, NRT and incentives|"One-on-one, proactive telephone counseling to quit smoking; The counseling addresses behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls.~Nicotine patches (four weeks' worth) are sent directly to clients. Dosage is 21 mg if smoking 11 or more per day, 14 mg if smoking 6-10 per day and 7mg if smoking <6 per day.~Gift cards (to one of 4 major chains) are $20 for the first counseling session and $10 for each additional one (up to five sessions total)."
3156841|NCT01502293|Experimental|Main Study|Plasmid interleukin-12 followed by intratumoral electroporation (pIL-12 EP). Treatment cycles consisting of 3 treatments over 1 week period, repeated at 3-month intervals until disease progression or unacceptable toxicity for up to 1 year.
3156842|NCT01502293|Experimental|Addendum Study|Plasmid interleukin-12 followed by intratumoral electroporation (pIL-12 EP). Treatment cycles occur every 6 weeks and two treatment regimens will be explored: Regimen A [treatment on days 1, 8 and 15] -or- Regimen B [treatment on days 1, 5, and 8] and repeated up to 9 treatment cycles (1 year) until disease progression or unacceptable toxicity.
3156843|NCT01502280|Experimental|5-ALA/Gliolan® /5-Aminolevulinic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 5-ALA/Gliolan®/5-Aminolevulinic acid mixed with sterile water (20mg/kg)
3156844|NCT01502280|Placebo Comparator|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
3156845|NCT01502267|No Intervention|Group 1|This group will not receive IVIG and B cell depleting agents
3156846|NCT01502267|Experimental|Group 2|This group will receive IVIG and B cell depleting agents
3156847|NCT01502254|Experimental|Copy of audio recording|Patients receive a copy of the audio recorded information about the clinical trial directly after the clinical visit. This makes it possible to repeat the information before a decision is made to participate in the clinical trial or not.
3156848|NCT01502254|No Intervention|No copy of audio recording|Patients in the control arm receive no copy of the audio recording.
3156849|NCT01502241|Active Comparator|Radiotherapy|6 weeks standard partial brain treatment.
3156850|NCT01502241|Experimental|Temozolomide|Temozolomide in a one week on/one week off schedule per Wick et al. 2004 and A. Wick et al. 2007
3156851|NCT01502228|Experimental|62Cu-ETS PET assessment|CT scan for attenuation correction; 15O-water administered by intravenous injection and 6-minute dynamic PET imaging; 62Cu-ETS administered by intravenous injection; Dynamic PET acquisition for 6-minutes; Whole-body PET acquisition from 6-20 minutes post-62Cu-ETS injection
3156852|NCT01502215|Active Comparator|Liberal Transfusion Strategy|Liberal Group - transfusion when hemoglobin is lower than 9 g/dL. Intervention: Other: Red blood cell transfusion
3156853|NCT01502215|Active Comparator|Restrictive Transfusion Strategy|Restrictive Group - transfusion when hemoglobin is lower than 7 g/dL Intervention: Other: Red blood cell transfusion
3156854|NCT01502202|Active Comparator|Study arm|Pemetrexed plus Cisplatin plus Gefitinib
3156855|NCT01502202|Placebo Comparator|Placebo arm|Pemetrexed plus Cisplatin plus Placebo
3156856|NCT01502189|Experimental|Representational approach|The Representational approach as described in the detailed description.
3156857|NCT01502176||Atrial fibrillation patients|All patients discharged from hospital with a diagnose of atrial fibrillation
3156858|NCT01502163|No Intervention|Control|"No prewarming~Intraoperative forced air warming (Thermoflect™/Mistral Air™) (after induction of anaesthesia, before surgery starting)~Passive insulation with Thermoflect™ material.~All fluids administrated intraoperative will be warmed."
3156859|NCT01502163|Active Comparator|Group passive prewarming|"Passive prewarming / insulation on nursery ward before transport to the OR (Thermoflect TSCI, Amersfoort, NL)~Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.~All fluids administrated intraoperative will be warmed."
3156860|NCT01502163|Active Comparator|Group Active prewarming|"Active prewarming on nursery ward before transport to the OR (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)~Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.~All fluids administrated intraoperative will be warmed."
3156861|NCT01502150||Pediatric Proton Therapy Patients|Data collection of MDACC patients under the age of 18 treated with proton radiotherapy. Proton dosimetry data collection, corresponding radiation dose distribution and imaging data in order to correlate normal tissue response with dose distribution.
3156862|NCT01502137|Experimental|ESRD patients|
3156863|NCT01502137|Experimental|Healthy subjects|
3156864|NCT01502124|Active Comparator|Lyophilized|
3156865|NCT01502124|Experimental|Liquid|
3156866|NCT01502111||Airway management|Patients receiving advanced airway management in physician manned helicopter emergency medical services over a 12-month period.
3156867|NCT01502098|Active Comparator|Early passive motion|Pendulum exercises starting on the first postoperative day. The patients are instructed to commence passive range-of-motion exercises in the plane of the scapula with the assistance with the contralateral limb. Active motion exercises were not permitted until four weeks after surgery.
3156868|NCT01502098|No Intervention|Immobilization|Immobilization with sling during a month. Pendulum exercises starting on the fourth postoperative week. The patients are instructed to commence passive range-of-motion exercises in the plane of the scapula with the assistance with the contralateral limb. Active motion exercises.
3157010|NCT01501162|Placebo Comparator|alcohol, hepatitis, Placebo|We explored the therapeutic effects of probiotics in patients with alcoholic hepatitis
3156869|NCT01502085|Experimental|Vorinostat, Lenalinomide, Dexamethasone|"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21~* Lenalidomide dose for patients with renal impairment (CrCL<50ml/min) has be dose adjusted according to package insert Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"
3156870|NCT01502072|Experimental|Inhaled Ribavirin|Group 1: Inhaled form of Ribavirin 60 milligrams/milliliter 3 times/day for 3 hours for up to 10 days.
3156871|NCT01502072|Experimental|Oral Ribavirin|Group 2: Ribavirin Capsules 20 mg/kg orally 3 times/day for up to 10 days.
3156872|NCT01502072|No Intervention|No Ribavirin|Group 3: No Ribavirin treatment.
3156873|NCT01502059|Experimental|Pilates Group|This group keep their usual treatment and did a Pilates treatment twice a week (one hour each class) during 90 days.
3156874|NCT01502059|No Intervention|Control Groups|This group keep their usual treatment and can do the Pilates training after the end of the study.
3156875|NCT01502046|Experimental|Sativex|
3156876|NCT01502046|Placebo Comparator|Placebo|
3156877|NCT01502033|Experimental|Transcranial Magnetic Stimulation|Open-label course of 30 daily treatments with repetitive transcranial magnetic stimulation (rTMS) at 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
3156878|NCT01502020|Active Comparator|Zyclara™|
3156879|NCT01502020|Experimental|Generic Imiquimod Cream, 3.75%|
3156880|NCT01502020|Placebo Comparator|Vehicle Cream|
3156881|NCT01502007|Experimental|Accelerometer feedback and lifestyle counseling|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling.
3156882|NCT01502007|Experimental|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The control group will continue to wear the fitbit for the next 24 weeks without any feedback or activity counseling. Following the 26th week of the study, the subjects in the control group will complete the same program given to the experimental group in weeks 2 through 26.
3156883|NCT01501994|Experimental|Walking workstation, counseling, accelerometry feedback|2 week baseline: accelerometer with no feedback 12 experimental: Use of the walking workstation, counseling on increasing activity levels, feedback from the accelerometer 12 week crossover: Feedback from accelerometer, no counseling or walking workstation
3156884|NCT01501994|Other|Control then crossover|2 week baseline: accelerometer with no feedback 12 week control period: accelerometer with no feedback 12 week crossover period: accelerometer with feedback, counseling on increasing activity, and use of a walking workstation
3156885|NCT01501968|Active Comparator|Colistin|Colistimethate sodium 2.5-5mg/kg iv
3156886|NCT01501968|Experimental|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv and ascorbic acid 2 grams iv every 12 hours
3156887|NCT01501955|Active Comparator|Stanmore|25 patients will have the Stanmore prosthesis
3156888|NCT01501955|Experimental|Metaphyseal Hip Prosthesis|25 patients will have the Metaphyseal Hip Prosthesis (MHP) prosthesis
3156889|NCT01501942|Experimental|Active|The active drug product is an oral solution of AIM-102 in phosphate buffered saline at a concentration of 35.0 mg/ml.
3156890|NCT01501942|Placebo Comparator|Inactive product|The matching placebo is an oral solution of phosphate buffered saline
3156891|NCT01501929|Active Comparator|Initial treatment with metoprolol|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he/she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. If necessary, 2 weeks after drug withdrawal, subjects will be started on HCTZ if BP > 140/90 mmHg and will continue HCTZ for a 2-week period, after which the subject will be transitioned to nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
3156892|NCT01501929|Active Comparator|Initial treatment with nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. If necessary, 2 weeks after drug withdrawal, subject will be started on HCTZ if BP > 140/90 mmHg and will continue HCTZ for a 2-week period, after which the subject will be transitioned to metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
3156893|NCT01501916|Experimental|vitamin d|
3156894|NCT01501916|Placebo Comparator|Placebo|
3156895|NCT01501903|Active Comparator|Standard|Biopsy using standard technique of FNA
3156896|NCT01501903|Other|Fanning|Biopsy using fanning technique
3156897|NCT01501890|Active Comparator|Progesterone|Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation
3156898|NCT01501890|Placebo Comparator|Placebo|Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation.
3156899|NCT01501877|Experimental|Distress Tolerance|Acceptance and Commitment Therapy based Distress Tolerance (DT) smoking cessation intervention delivered in 7 2-hour group, 1 50-minute individual, and 2 10-minute phone sessions and 8 weeks of transdermal nicotine patch.
3157822|NCT01495455||Knee osteoarthritis|
3156900|NCT01501877|Active Comparator|Standard Smoking Cessation|Standard smoking cessation intervention delivered in 7 2-hour group, 1 50-minute individual, and 2 10-minute phone sessions and 8 weeks of transdermal nicotine patch.
3156901|NCT01501864|Experimental|School Support Group|School Support Intervention
3156902|NCT01501864|No Intervention|Control|No school support
3156903|NCT01501825|Active Comparator|single channel|Single Channel with a coil placed over the left PFC (10 Hz).
3156904|NCT01501825|Experimental|four channels|"Four channels:~10 Hz over the left PFC.~1 Hz over the right PFC.~10 Hz over the left parietal cortex.~1 Hz over the right parietal cortex."
3156905|NCT01501812||Schizophrenia|Subjects who are suffering from Schizophrenia or Schizoaffective disorder acording to the DSM-IV-R criteria
3156906|NCT01501812||Control|Healthy subjects without any mental ilness in axis I or II.
3156907|NCT01501812||Bipolar|Subjects who are suffering from bipolar I or 2 disorder acording to the DSM-IV-R criteria
3156908|NCT01501812||MDD|Subjects who are suffering from Major Depressive disorder acording to the DSM-IV-R criteria
3156909|NCT01501812||Anxiety|Subjects who are suffering from Panic disorder or from Generalized Anxiety disorder acording to the DSM-IV-R criteria
3156910|NCT01501812||PTSD|Subjects who are suffering from Post Traumatic Stress Disorder acording to the DSM-IV-R criteria
3156911|NCT01501799|Experimental|Adapalene 0.1% and benzoyl peroxide 2.5% topical gel|
3156912|NCT01501799|Active Comparator|EPIDUO™ (adapalene 0.1% and benzoyl peroxide 2.5%) Gel|
3156913|NCT01501799|Placebo Comparator|Vehicle Gel|
3156914|NCT01501786|Sham Comparator|control|propofol and saline are administered
3156915|NCT01501786|Experimental|Ket10|ketamine is co-administered with propofol
3156916|NCT01501786|Experimental|Ket20|ketamine is co-administered with porpofol
3156917|NCT01501773|Experimental|Autologous bone marrow stem cell|
3156918|NCT01501773|No Intervention|Control|
3156919|NCT01501760|Experimental|bevacizumab|Three subconjunctival injections of 0.5 ml of bevacizumab at inclusion, 1 month, 2 month.
3156920|NCT01501760|Placebo Comparator|Placebo|Three subconjunctival injections of 0.5 ml of Nacl at inclusion, 1 month, 2 month.
3156921|NCT01501747|Active Comparator|overt drug|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving such medication.
3156922|NCT01501747|Placebo Comparator|Placebo (Covert drug)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
3156923|NCT01501734|Experimental|all patients with symptomatic CHF|"Single arm prospective study~Study population will include all patients referred to our outpatient clinic for congestive heart failure for a two-year period, who will be screened for sleep apnea and found to have sleep disordering breathing (SDB).~200 patients will visit the outpatient clinic for congestive heart failure.~Approximately 30% will be eligible for this study."
3156924|NCT01501721|Experimental|Exercise|Home-based exercise program
3156925|NCT01501721|Experimental|Nutritional counseling|Nutrition counseling aiming to reduce suggar intake
3156926|NCT01501708|Experimental|Caspofugin based combination therapy|"Caspofugin based combination therapy:~Patients will recieve caspofungin with voriconazole or amphotericin B"
3156927|NCT01501695|Experimental|5LGr, granule and placebo tablet|"Drug:5LGr; Dosage form:Granule;Strength:5 gram/sack;Mimic Tablet:0 mg/tablet. Dosage: 5LGr Granule: 1 sack, t.i.d. for patients less than 12 yrs,whereas 1.5 sacks, t.i.d. for patients 13-18 yrs.~Mimic tablet:For patients 5-12 yrs: 0.5 tablet, b.i.d for first 2 weeks, then 1 tablet, bid for next 6 weeks; for patients 13-18 yrs: tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.~Duration: 8 weeks."
3156928|NCT01501695|Active Comparator|tiapride tabletand mimic 5LGr granule|"Tiapride are 100 mg scored tablets. Mimic 5LGr granule are preparation that contain no active ingredient, and act as placebo.~Dosage: Tiaptride tablet: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.~Mimic 5LGr Granule:Strength:0 gram/sack.Dosage:1 sack for patients less than 12 yrs,while 1.5 sacks for patients 13-18 yrs.Frequency: T.i.d.~Duration: 8 weeks."
3156929|NCT01501695|Placebo Comparator|placebo, granule and tablet|"This arm includes mimic preparation of 5LGr granule and tiapride tablets , which doesn't contain active ingredients.~Dosage form: Mimic Granule:Strength:0 gram/sack Dosage:1 sack, t.i.d for patients less than 12 yrs,while 1.5 sacks, t.i.d for patients 13-18 yrs.~Mimic tablet:Strength:0 mg/tablet.For patients 5-12 yrs: 0.5 tablets b.i.d for first 2 weeks, then 1 tablet,b.i.d for next 6 weeks; for patients 13-18 yrs:1 tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.~Duration: 8 weeks."
3156930|NCT01501682||primary suture|operated with primary suture
3156931|NCT01501682||other mesh|operated with insertion of another mesh
3156932|NCT01501682||ventralex|operated with insertion of ventralex mesh
3156933|NCT01501669|No Intervention|Capecitabine alone arm|X arm
3156934|NCT01501669|Experimental|Irinotecan plus capecitabine arm|
3156935|NCT01501643|Active Comparator|Spirometry|Spirometry
3156936|NCT01501643|Experimental|Non invasive positive pressure ventilation|Non invasive positive pressure ventilation
3156937|NCT01501630||PET/CT and MRI|all patients will benefit from PET/CT and MRI
3156938|NCT01501617|Experimental|HSC- Hair Stimulating Complex|Hair Stimulating Complex will be injected intradermally into the scalp of the test subject at 2 timepoints (Baseline and 6 Weeks after Baseline) using sterile syringes with 30 gauge needles at a volume of 0.1 mL per injection. A total of 8 injections (about 3mm apart) will be administered into one of the the 2 randomized sites (left or right) of the subject's scalp. Six weeks after the Baseline injection, the same treatment site will receive a repeat dose (the same volume and number of injections as used in the baseline) with no crossover.
3156939|NCT01501617|Placebo Comparator|Dulbecco's Modified Eagle Medium, DMEM|Dulbecco's Modified Eagle Medium (DMEM) will be administered the same way as described above into treatment zone of the test subject's scalp not treated with HSC.
3157011|NCT01501162|Active Comparator|hepatitis, alcohol, probiotics|We explored the therapeutic effects of probiotics in patients with alcoholic hepatitis
3156940|NCT01501591|Other|Hydroxyzine|This group will receive a first generation H-1 receptor antagonist, hydroxyzine (25 mg) twice on two days; on one day described by the investigator as hydroxyzine and on the other day described by the investigator as placebo, in a randomized balanced crossover design.
3156941|NCT01501591|Other|Placebo|This group will receive a placebo twice on two days; on one day described by the investigator as hydroxyzine and on the other day described by the investigator as placebo, in a randomized balanced crossover design.
3156942|NCT01501591|Other|Hydroxyzine/placebo|This group will receive hydroxyzine and placebo in a randomized double-blind placebo-controled crossover design.
3156943|NCT01501578||telomerase mutation|Patients with interstitial lung disease and telomerase mutation
3156944|NCT01501578||control|Patients with idiopathic pulmonary fibrosis and without telomerase mutation
3156945|NCT01501565|No Intervention|Control|Standard analgesic therapy: iv Metamizol 2 g q8h
3156946|NCT01501565|Experimental|TAP|"Transverse abdominal plain (TAP) blockade with local anesthetic: Bupivacaine chlorhydrate 0.25% adjusted by weight and type of surgery. Maximum dose: 150 mg of bupivacaine.~Two approaches are done: 1)Posterior TAP: the needle insertion point is cephalad to the iliac crest, behind the midaxillary line. The needle is inserted under ultrasound guidance in plane. Local anesthetics is deposited between the internal oblique and transversus abdominis muscles, 2)Subcostal TAP: the needle is inserted ultrasound guided perpendicularly to abdominal wall, directed parallel to the costal margin but oblique to the sagittal plane. Local anesthestic is deposited between transversus abdominis and the rectus abdominis muscles."
3156947|NCT01501552|No Intervention|Treatment as usual|In the no-intervention treatment as usual group, a package, containing a summary card of the national guideline recommendation, will be delivered to each provider unit without demonstration. In Poland, the summary card will be adapted from the PHEPA guidelines (ref) for the purposes of this trial. The treatment as usual group will be requested to screen and offer person-to-person SBI at the PHCU.
3156948|NCT01501552|Experimental|Training & support (T&S)|The T&S only group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
3156949|NCT01501552|Experimental|Financial incentive|The financial incentive only group will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
3156950|NCT01501552|Experimental|E-SBI|The e-SBI (online screening and brief intervention)only group are expected to refer identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
3156951|NCT01501552|Experimental|T&S and financial incentive|The T&S and financial incentive group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. Also, they will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
3156952|NCT01501552|Experimental|T&S and e-SBI|The T&S and e-SBI group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call was offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) was offered. Also this group is expected to refer identified at-risk patients to an approved e-SBI (online screening and brief intervention) programme, which will either be country specific (where these exist) or based on the WHO e-SBI programme (Poland).
3156953|NCT01501552|Experimental|Financial incentive and e-SBI|The financial incentive and e-SBI (online screening and brief intervention) group will be paid for screening and referral performance instead of actual delivery of e-SBI by themselves as in line with the e-SBI only group, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
3156954|NCT01501552|Experimental|T&S, financial incentive and e-SBI|The T&S, financial incentive and e-SBI (online screening and brief intervention) group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Also, they are expected to offer screening at the PHCU and to refer screen positive patients to e-SBI programmes. Additionally, they will be paid for screening and referral performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
3156955|NCT01501539|No Intervention|Standard postop gastrostomy tube care|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions and the gastrostomy tube will be covered with dermabond, steristrips, and/or tegaderm dressings, according to surgeon preference. Standard postop gastrostomy tube care. Insertion site cleaned with soap and water. No dressing added.
3156956|NCT01501539|Experimental|Standard hydrocolloid dressing|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions will be covered with dermabond, steristrips, and/or tegaderm dressings, according to the surgeons preference. The gastrostomy tube will have a thin layer of hydrocolloid dressing (HD) placed around the gastrostomy tube. The HD will be changed once every other day fo the first 30 days after gastrostomy tube placement. After 30 days, care will revert to standard care.
3157012|NCT01501149|Experimental|DDGP regiment|DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment
3157013|NCT01501149|Experimental|SMILE Regiment|Modified SMILE （methotrexate，hexadecadrol，Ifosfamide，L-AsparaginaseL，Etoposide，Mesna）Regiment
3157014|NCT01501136|Experimental|sequential trial,DDGP, radiotherapy|sequential DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment followed by radiotherapy
3156957|NCT01501539|Experimental|Silver hydrocolloid dressing|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions will be covered with dermabond, steristrips, and/or tegaderm dressings, according to surgeon preference. The gastrostomy tube will have a thin layer of silver hydrocolloid dressing (HD) placed around the gastrostomy tube. The silver HD will be changed once every other day for the first 30 days after gastrostomy tube placement. After 30 days, care will revert to standard care.
3156958|NCT01501513|Experimental|BLI800 approved preparation regimen|BLI800 approved preparation regimen
3156959|NCT01501513|Experimental|BLI800 investigational preparation regimen|BLI800 investigational preparation regimen
3156960|NCT01501513|Active Comparator|PEG-3350 based bowel preparation|PEG-3350 based bowel preparation
3156961|NCT01501500|Active Comparator|botulinum toxin type A. HV angle|intramuscular injection of BTA into target muscle
3156962|NCT01501500|Placebo Comparator|Normal saline, HV angle|intramuscular injection of normal saline into target muscle
3156963|NCT01501487|Active Comparator|HER2 negative patients|"In order to provide some consistency in management and have a treatment policy in place only recommended therapy with several well accepted and presumed equivalent chemotherapy regimens will be used. The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients include:~TAC chemotherapy~TC chemotherapy~Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy"
3156964|NCT01501487|Active Comparator|Her2 positive patients|The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients is TCH chemotherapy.
3156965|NCT01501474||CholangioFlex and Fluorescent in situ Hybridization(FISH)|
3156966|NCT01501448|Active Comparator|OCP|
3156967|NCT01501448|Active Comparator|Oral estradiol valerate|
3156968|NCT01501435|Experimental|CJ-30039|Incrementally Modified Drugs of fenofibric acid
3156969|NCT01501435|Active Comparator|fenofibric acid|Greencross Lipidil Supra 160mg
3156970|NCT01501422|Experimental|Estrogen|Use estrogen patch for 8 weeks
3156971|NCT01501422|Experimental|Placebo|Use placebo patch for 8 weeks
3156972|NCT01501409|Experimental|Group I|
3156973|NCT01501409|Active Comparator|Group II|
3156974|NCT01501409|Active Comparator|Group III|
3156975|NCT01501396|Experimental|Arm A (megestrol alone)|Megestrol acetate 800 mg PO daily x 8 weeks
3156976|NCT01501396|Experimental|Arm B (megestrol plus mirtazapine)|"Megestrol acetate 800 mg PO daily x 8 weeks~Mirtazapine 15 mg PO at bedtime x 1 week followed by 30 mg PO at bedtime x 7 weeks"
3156977|NCT01501383|Active Comparator|VX-765 Dose 1 Part A|
3156978|NCT01501383|Active Comparator|VX-765 Dose 2 Part A|
3156979|NCT01501383|Active Comparator|VX-765 Dose 3 Part A|
3156980|NCT01501383|Active Comparator|VX-765 Dose 4 Part A|
3156981|NCT01501383|Placebo Comparator|Placebo Dose Part A|Placebo
3156982|NCT01501383|Active Comparator|VX-765 Dose Part B|
3156983|NCT01501370|Experimental|ZLd|"Patients, who are receiving Lenalidomide maintenance treatment with or without prednisone, will be randomized to receive:~Cohort 1: ZLd association:~Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days~Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle.~Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days."
3156984|NCT01501370|Active Comparator|Ld|"Patients, who are receiving Lenalidomide maintenance treatment with or without prednisone, will be randomized to receive: Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days~• Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days."
3156985|NCT01501357|Experimental|multilevel filaments toothbrush|Children will brush with anteroposterior toothbrushing and a modified toothbrush (multilevel filaments)
3156986|NCT01501357|Active Comparator|cross toothbrushing|Children will brush with cross toothbrushing.
3156987|NCT01501331||RRT diagnostic tool|Patients implanted with an Energen device or successor.
3156988|NCT01501318|Active Comparator|Personalized feedback plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.Treatment as usual with participants receiving a personalized feedback report about the risks associated with their current substance use behaviors and a brief (5-15 minute) motivational interviewing based education session provided by a trained health coach.
3156989|NCT01501318|Experimental|Personalized feedback report alone|Provision of the personalized feedback report alone.
3156990|NCT01501305|Placebo Comparator|Placebo|Mineral rehydration solution
3156991|NCT01501305|Active Comparator|Carob powder|Carob powder and probiotics
3156992|NCT01501292||Immature oocytes (GV, M-I)|
3156993|NCT01501292||Mature oocytes (M-II)|
3156994|NCT01501279|Experimental|pudendal nerve block|USG guided pudendal nerve block performed under general anesthesia
3156995|NCT01501279|No Intervention|no nerve block|Control group without nerve block
3156996|NCT01501266||Faslodex|
3156997|NCT01501253|Experimental|CKD-828 2.5/40mg|CKD-828 2.5/40mg
3156998|NCT01501253|Experimental|CKD-828 2.5/80mg|CKD-828 2.5/80mg
3156999|NCT01501253|Active Comparator|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg
3157000|NCT01501240||liver cirrhosis, liver transplantation|Patients with known liver cirrhosis and planned to undergo liver transplantation within 1 month will be eligible population in the study
3157001|NCT01501227|Active Comparator|Taper Guard Endotracheal Tube|Patients in the test group will be intubated with the Taper Guard Endotracheal Tube. The incidence of VAP, the length of ventilation, the length of intensive care stay, the length of hospital stay and the mortality rate will be monitored.
3157002|NCT01501227|Sham Comparator|conventional endotracheal tube|Patients in the placebo comparator group will be intubated with the conventional Endotracheal Tube. The incidence of VAP, the length of ventilation, the length of intensive care stay, the length of hospital stay and the mortality rate will be monitored.
3157003|NCT01501214|Active Comparator|Atosiban|
3157004|NCT01501214|Placebo Comparator|Placebo|Normal saline
3157005|NCT01501201|Experimental|Gastric By-Pass|group treated with Gastric By-Pass
3157006|NCT01501201|Active Comparator|optimized medical management|group receiving an optimized medical management
3157007|NCT01501188|Experimental|Kinesio taping|Specific type of muscle and joint taping
3157008|NCT01501188|Placebo Comparator|Kinesio taping placebo|Kinesio taping placebo
3157015|NCT01501136|Experimental|sequential trial,VIPD, radiotherapy|sequential VIPD（cisplatin，Etoposide,Ifosfamide,dexamethasone，Mesna） regiment followed by radiotherapy
3157016|NCT01501136|Experimental|sequential trial, radiotherapy,DDGP|sequential radiotherapy followed by DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment
3157017|NCT01501136|Experimental|sequential trial,radiotherapy, VIPD|sequential radiotherapy followed by VIPD（cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna）regiment chemotherapy
3157018|NCT01501136|Experimental|Radiotherapy|Suitable type intensity-modulated radiation therapy (IMRT) 50GY
3157019|NCT01501123|Experimental|Haloperidol|IM Haloperidol
3157020|NCT01501123|Active Comparator|Midazolam|
3157021|NCT01501110|Active Comparator|n-acetylcysteine|intra-venous infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours.
3157022|NCT01501110|No Intervention|no intervention|No intervention
3157023|NCT01501097|No Intervention|Control group|
3157024|NCT01501097|Experimental|early HV-crrt|
3157025|NCT01501084|Active Comparator|Exenatide|Exenatide injection 10 mcg subcutaneous
3157026|NCT01501084|Placebo Comparator|Saline|.2cc SC injection of sterile normal saline
3157027|NCT01501071|Experimental|esophageal calibration|Esophageal calibration tube was applied to this group of patients during laparoscopic Nissen fundoplication operation
3157028|NCT01501071|No Intervention|Control|Standard Laparoscopic Nissen fundoplication without esophageal calibration
3157029|NCT01501058|Experimental|case group|
3157030|NCT01501058|Other|waitlist control group|For this group, same intervention with the Experimental group will be provided after waiting for 14 weeks.
3157031|NCT01501045|Experimental|healthy subjects|healthy subjects
3157032|NCT01501045|Experimental|pain patients|Migraine and muscle headache patients
3157033|NCT01501032|Experimental|Closed Loop Control- MD-Logic|The MD-Logic artificial pancreas system will be used in conjunction with continuous glucose monitoring and insulin pump delivery to manage the subject's blood glucose.
3157034|NCT01501019|No Intervention|Sjogren and Myositis Control (no control for takayasu's)|
3157035|NCT01501019|Experimental|Sjogren, Myositis and Takayasu's Trained|
3157036|NCT01501006||Patient Roles|Physician communication styles will be evaluated with different patient roles.
3157037|NCT01500993|Active Comparator|5-Fluorouracil (5-FU)|Drug - 5FU based chemoradiotherapy and chemotherapy
3157038|NCT01500993|Experimental|Capecitabine|Drug - Capecitabin-based radiochemotherapy and chemotherapy
3157039|NCT01500980|Experimental|Pilot Phase|Pilot phase will include 6 subjects and will investigate the timing of PQ dosing relative to parasite exposure.
3157040|NCT01500980|Experimental|Chloroquine, ITV, primaquine, malaria challenge|
3157041|NCT01500980|Active Comparator|Sporozoite negative vaccine|
3157042|NCT01500980|Active Comparator|Primaquine placebo|
3157043|NCT01500980|No Intervention|malaria challenge|
3157044|NCT01500967|Active Comparator|Traction|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
3157045|NCT01500967|Experimental|Manipulations|Shi-style manipulations is a cervical manipulation for cervical radiculopathy.This manipulation is a kind of traditional Chinese massage and it can dredge the meridians. Patients are treated every day for 30 minutes. Seven times as one course and totally there are two courses. 3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
3157046|NCT01500954||squamous cell carcinoma|
3157047|NCT01500954||non-lesional skin|
3157048|NCT01500941|Active Comparator|probiotics|
3157049|NCT01500941|Placebo Comparator|maltodextrin|
3157050|NCT01500915|Experimental|ranibizumab|
3157051|NCT01500902|Other|vascular testing|We are assessing vascular testing in patients presenting with acute coronary syndrome to determine if this type of testing will help identify which patients are more likely at risk to have another heart attack.
3157052|NCT01500889|Active Comparator|CLI sphincterotomy|Conventional Lateral internal sphincterotomy LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
3157053|NCT01500889|Active Comparator|GroupII: V-Y advancement flap|The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide. Figures 1, 2, 3 and 4 illustrate the procedure.
3157054|NCT01500889|Active Comparator|TLIS with VY anoplasty|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
3157055|NCT01500876|Experimental|Study Arm|Single Arm
3157056|NCT01500863|Active Comparator|hCG|
3157057|NCT01500863|Experimental|Triptorelin 0.2mg s.c.|
3157058|NCT01500863|Experimental|0.2mg triptorelin plus estradiol/progesterone|
3157059|NCT01500863|Experimental|0.2mg tripoterlin plus single bolus hCG 1500 IU|
3157060|NCT01500863|Experimental|0.2mg tripoterlin plus multiple boluses hCG 500 IU|
3157061|NCT01500863|Experimental|0.2mg tripoterlin plus multiple doses recLH|
3157062|NCT01500850|Active Comparator|NPH insulin + insulin glulisine|Patients will be randomized to be treated with NPH insulin + Insulin Glulisine for 24 weeks.
3157063|NCT01500850|Active Comparator|NPH insulin + human insulin|Patients will be randomized to be treated with NPH insulin + human insulin for 24 weeks.
3157064|NCT01500850|Experimental|Insulin glargine + insulin glulisine|Patients will be randomized to be treated with insulin glargine + insulin glulisine for 24 weeks.
3157823|NCT01495455||No knee pain/osteoarthritis|
3157824|NCT01495442|Active Comparator|modified Handihaler DPI|
3157065|NCT01500850|Experimental|Insulin Glargine + Human insulin|Patients will be randomized to be treated with insulin glargine + human insulin for 24 weeks.
3157066|NCT01500837|Active Comparator|RIFAMPIN|CLINDAMYCIN + RIFAMPIN
3157067|NCT01500837|Active Comparator|LEVOFLOXACIN|CLINDAMYCIN + LEVOFLOXACIN
3157068|NCT01500824|Experimental|Crizotinib|
3157069|NCT01500811|Experimental|chondrocyte|Patients with sever hip osteoarthritis who underwent intra articular cell injection.
3157070|NCT01500798|Placebo Comparator|Placebo|
3157071|NCT01500798|Experimental|Bardoxolone methyl|
3157072|NCT01500785|Active Comparator|levosimendan|
3157073|NCT01500785|Placebo Comparator|placebo|
3157074|NCT01500772|Experimental|Alisporivir|ALV 400 mg twice daily (BID), plus PEG and RBV for 48 weeks
3157075|NCT01500746|Experimental|Lavage arm|This group will serve as the experimental arm. They will undergo twice daily pulse lavage of their wounds for 4 days. In between the lavage treatments, their wounds will be dressed with moist gauze.
3157076|NCT01500746|Active Comparator|Moist dressings|This group will serve as the control group. They will undergo twice daily dressing changes with moist gauze dressings for a total of 4 days (8 dressing changes). Bacterial counts and gene expression analysis will be performed prior to the first dressing change and after the last dressing change.
3157077|NCT01500733|Experimental|Elderly greater than 65|
3157078|NCT01500733|Experimental|17p Deletioin|
3157079|NCT01500720|Experimental|Cabazitaxel|
3157080|NCT01500720|Active Comparator|Topotecan|
3157081|NCT01500707|Experimental|SCH 900800|Participants receiving a single dose of SCH 900800
3157082|NCT01500694|Experimental|Extended-release Guanfacine HCl|
3157083|NCT01500681||Maintenance PLEX|
3157084|NCT01500668|Active Comparator|Treatment|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
3157085|NCT01500668|Placebo Comparator|Control|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
3157086|NCT01500655|Experimental|Catheter|An ultrasound guided block of the LFCN is performed, followed by the placement of a catheter underneath the fascia iliaca.
3157087|NCT01500655|Experimental|Ultrasound guided LFCN block|An ultrasound guided regional nerve block --using ropivacaine 0.2%-- will be performed around the lateral femoral cutaneous nerve (LFCN).
3157088|NCT01500655|No Intervention|Control|This group gets the current standard of care--the donor site is infiltrated with 0.25% bupivacaine.
3157089|NCT01500642|Active Comparator|sublingual immunotherapy|15 patients treated with sublingual immunotherapy (SLIT One, ALK Abello) administered at standard dose (200 STU / dose) from June to August 2001
3157090|NCT01500642|Active Comparator|vestibular immunotherapy|15 patients treated with vestibular immunotherapy (SLIT One, ALK Abello) administered at standard dose (200 STU / dose) from June to August 2001
3157091|NCT01500642|Active Comparator|sublingual doubled immunotherapy|15 patients treated with sublingual immunotherapy (SLIT One, ALK Abello) administered at doubled dose (400 STU / dose) from June to August 2001
3157092|NCT01500629|Experimental|C-1266-7|In a crossover design with subjects randomized to treatment sequence, each subject will receive 200 uL of device Intervention C-1266-7. After a washout period of approximately 14 days, subjects will receive 200 uL of device Intervention C-1266-6 (placebo).
3157093|NCT01500629|Experimental|Placebo|In a crossover design with subjects randomized to treatment sequence, each subject will receive 200 uL of device Intervention C-1266-6 (placebo). After a washout period of approximately 14 days, subjects will receive 200 uL of device Intervention C-1266-7.
3157094|NCT01500616|Experimental|open label telaprevir|Depending on the patient's HAART regimen, 750 or 1125 mg telaprevir every 8 hours for 12 weeks in combination with pegylated interferon alfa and ribavirin for 48 weeks.
3157095|NCT01500603|Experimental|Experimental|Patients will receive AdvanceXP retrourethral male sling implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route
3157096|NCT01500603|Active Comparator|Active comparator|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
3157097|NCT01500590|Experimental|renin-angiotensin system blockers|Those eligible patients will be randomized into 2 groups. One group use renin-angiotensin systems (RAS) blockers to control their blood pressure, the other group will use other types of anti-hypertensive agents other than RAS blockers
3157098|NCT01500590|Active Comparator|non-renin angiotensin system blockers|"These includes norvasc adalat retard natrilix betaloc aldomet~amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg once daily to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg once daily to 500mg twice daily"
3157099|NCT01500577|Experimental|Nimesulide|Nimesulide 100 mg (capsules), 100mg/die every day for 1 year. Oral administration
3157100|NCT01500577|Experimental|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
3157101|NCT01500577|Placebo Comparator|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
3157102|NCT01500564|Sham Comparator|Sham tDCS and motor training: sham comparator|"Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).~Intervention: placebo tDCS Other: Motor Training"
3157103|NCT01500564|Experimental|Anodal tDCS and motor training: experimental|"Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).~Interventions:~Device: anodal tDCS~Other: motor Training during physiotherapy"
3157104|NCT01500551|Experimental|Tofacitinib|All patients will be in tofacitinib treatment group.
3157825|NCT01495442|Placebo Comparator|standard Handihaler DPI|
3157105|NCT01500538|Experimental|Eltrombopag and vorinostat combination therapy|Daily oral intake of 400mg vorinostat if necessary with combination therapy eltrombopag commencing at 50mg per day increasing to a maximum of 200mg per day
3157106|NCT01500525||asthmatic children|children diagnosed by a specialist as asthmatic patients
3157107|NCT01500525||non-asthmatic children|children who are healthy and who do not have respiratory syndrom
3157108|NCT01500512||Observation (observe patients undergoing SLN dissection)|Patients receive standard therapy including sentinel lymph node dissection. Patients are then observed to collect information about treatment and outcomes every 2 months for 2 years.
3157109|NCT01500486||PenMate device|
3157110|NCT01500473|Experimental|Females with CCHS > 16 years old on desogetrel|
3157111|NCT01500434|Experimental|PROMUS Element|Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent
3157112|NCT01500421|Experimental|TH - Endovacular alone|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with an endovascular groin catheter (Copenhagen only).
3157113|NCT01500421|Experimental|TH - Endovascular + nasopharyngeal induction|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with endovascular catheter along with nasopharyngeal induction (Copenhagen only).
3157114|NCT01500421|No Intervention|Standard Treatment|Patients are treated with standard care in the stroke ward.
3157115|NCT01500421|Experimental|TH - Surface Cooling|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with cold saline infusion followed by surface cooling with Arctic Sun Cooling system, Medivance, USA (Malmø only)
3157116|NCT01500408|Other|Commercial INFB followed by Investigational INFB|Process A (currently-approved manufacturing process involving FBS) first, then Process B (new serum-free manufacturing process, without FBS)
3157117|NCT01500408|Other|Investigational INFB followed by Commercial INFB|Process B (new serum-free manufacturing process, without FBS) first, then Process A (currently-approved manufacturing process involving FBS)
3157118|NCT01500395||Stent Graft and open surgery|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al.
3157119|NCT01500382|Experimental|Vibegron 100 mg + tolterodine ER 4 mg → placebo|During Treatment Period 1, participants will receive 7 days of once-daily vibegron 100 mg and tolterodine extended-release (ER) 4 mg. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER.
3157120|NCT01500382|Experimental|Placebo → vibegron 100 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily vibegron 100 mg and placebo to match tolterodine ER.
3157121|NCT01500382|Active Comparator|Placebo → tolterodine ER 4 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily tolterodine 4 mg and placebo to match vibegron.
3157122|NCT01500382|Experimental|Placebo → vibegron 50 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily vibegron 50 mg and placebo to match tolterodine ER.
3157123|NCT01500369|Active Comparator|remote ischemic conditiong|"Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
3157124|NCT01500369|Placebo Comparator|Standard Care|Patients in the control group will have the sphygmomanometer cuff placed on their right upper arm, but the cuff will not be inflated. Similar to patients in the treatment group, patients in the control group will undergo the same 30 minute delay before induction of anesthesia and surgery
3157125|NCT01500356|Experimental|Diet alone|Weight loss intervention that focuses only on reducing energy intake of the diet.
3157126|NCT01500356|Experimental|Diet plus Moderate Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
3157127|NCT01500356|Experimental|Diet Plus High Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
3157128|NCT01500343|Experimental|Saccharomyces boulardii|
3157129|NCT01500343|Placebo Comparator|Placebo|
3157130|NCT01500330|Experimental|cupping massage|12 weeks home use of cupping massage (delivered by the partner or friend) twice a week for 20 minutes
3157131|NCT01500330|Active Comparator|control group|progressive muscle relaxation twice a week for 20 minutes
3157132|NCT01500317|Active Comparator|Tapentadol|75 mg tapentadol tid
3157133|NCT01500317|Active Comparator|Oxycodone|5 mg oxycodone tid
3157134|NCT01500317|Placebo Comparator|Placebo|Placebo tid
3157135|NCT01500304|Experimental|Minimally invasive surgery|Minimally invasive inguinal lymph node dissection is a 10-step technique to provide novel inguinal lymph node staging and treatment.
3157136|NCT01500291||Anesthesiologist|
3157137|NCT01500291||Nurse anesthetist|
3157138|NCT01500278|Active Comparator|Certolizumab Pegol + Methotrexate (CZP + MTX)|
3157139|NCT01500278|Active Comparator|Adalimumab + Methotrexate (ADA + MTX)|
3157140|NCT01500278|Active Comparator|CZP + MTX followed by ADA + MTX|Those subjects who received Certolizumab Pegol (400 mg at Weeks 0, 2, 4 followed by 200 mg every two weeks) + Methotrexate (CZP+ MTX) at Baseline and are Non-Responders at Week 12, switch to Adalimumab (40 mg) + Methotrexate (ADA + MTX) after Week 12.
3157832|NCT01495377|Experimental|Dynamometer|
3157141|NCT01500278|Active Comparator|ADA + MTX followed by CZP + MTX|Those subjects who received Adalimumab (40 mg + Placebo at Weeks 0, 2, 4 followed by 40 mg ADA every two weeks) + Methotrexate (ADA+ MTX) at Baseline and are Non-Responders at Week 12, switch to Certolizumab Pegol (400 mg at Weeks 12, 14, 16 followed by 200 mg every two weeks) + Methotrexate (CZP+ MTX) after Week 12.
3157142|NCT01500265||Patient naive|Patient with hepatitis B virus naive untreated
3157143|NCT01500265||Patient with TDF|Patient with hepatits B treated with Tenofovir
3157144|NCT01500265||Patient with ETV|Patient with hepatitis B virus treated with Entecavir
3157145|NCT01500252|Experimental|Patellar Resurfacing|These subjects received a Profix TKR including an all polyethylene patellar implant.
3157146|NCT01500252|Active Comparator|Patellar Retention|This group received a Profix TKR, but retained their native patella
3157147|NCT01500226|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.
3157148|NCT01500226|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.
3157149|NCT01500213|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
3157150|NCT01500213|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
3157151|NCT01500200|Experimental|ALKS 5461|
3157152|NCT01500200|Placebo Comparator|Placebo|
3157153|NCT01500187|Active Comparator|Group 2|Oral B Minute-Gel, fluoride gel
3157154|NCT01500187|Experimental|Group 1|Vanish varnish, 5% sodium fluoride varnish with tricalcium phosphate
3157155|NCT01500174|Experimental|active UVC device|Three times per week irradiation of wound base and periwound skin
3157156|NCT01500174|Placebo Comparator|Placebo UVC device|Three times per week irradiation of wound base and periwound skin
3157157|NCT01500161|Experimental|Single Arm|The following conditioning regimens will be used, depending on the underlying hematologic malignancies. Conditioning regimens with Busulfan/clofarabine and with fludarabine/melphalan will be used for all patients except those with Non-Hodgkin's lymphoma when the conditioning regimen of BCNU, Etoposide, ARA-C and Melphalan will be used.
3157158|NCT01500148|Experimental|Intevention-PMVr Procedure|
3157159|NCT01500135|Experimental|TachoSil®|TachoSil® absorbable patches, applied topically, once, intraoperatively to stop bleeding. The patches were lightly compressed against the suture line for 3 minutes. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
3157160|NCT01500135|Active Comparator|Surgicel® Original|Surgicel® Original absorbable patches, applied topically, once, intraoperatively to stop bleeding. The patches were lightly compressed against the suture line for 3 minutes. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
3157161|NCT01500109|Experimental|Ofirmev®|Oral inert cherry syrup will be administered preoperatively as placebo for oral acetaminophen. Ofirmev® will be administered in the operating room once intravenous access is established. Patients will receive standardized dose of local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon before surgical incision as well as at the completion of surgery with Bupivacaine 0.25% with Epinephrine. Postoperatively patients will receive Ofirmev® every 6 hours as well as placebo oral cherry elixir every 6 hours and morphine as needed for 24 hours.
3157162|NCT01500109|Active Comparator|Oral acetaminophen|Patients will receive oral acetaminophen cherry elixir preoperatively. After intravenous access is obtained intraoperatively patients will receive placebo for Ofirmev® (saline). Patients will receive standardized dose of local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon prior to surgical incision as wel as at the completion of surgery with Bupivacaine 0.25% with Epinephrine. Postoperatively patient will receive oral acetaminophen every six hours and intravenous placebo (normal saline) for intravenous acetaminophen. Intravenous morphine will be administered as needed for 24 hours.
3157163|NCT01500109|Placebo Comparator|Opioid only|This group will receive placebo oral cherry elixir prior to going to the operating room and placebo Ofirmev® after securing intravenous access in the operating room with redosing every six hours. They will receive local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon prior to incision as well as at the completion of surgery with Bupivicaine 0.25% with Epinephrine. Postoperatively they will receive only Morphine prn for pain control.
3157164|NCT01500096|Active Comparator|American ginseng 1000 mg/day|4-week of American ginseng 1000 mg/day every morning
3157165|NCT01500096|Placebo Comparator|Placebo for American ginseng 1000 mg/day|4-week of placebo for American ginseng 1000 mg/day every morning
3157166|NCT01500096|Active Comparator|American ginseng 3000 mg/day|4-week of American ginseng 3000 mg/day every morning
3157167|NCT01500096|Placebo Comparator|Placebo for American ginseng 3000 mg/day|4-week of placebo for American ginseng 3000 mg/day every morning
3157168|NCT01500083|Experimental|Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with CLL will receive bendamustine at a dose of 100 mg/m2 on Days 1 and 2 in treatment cycles of 28 days for up to six cycles.
3157169|NCT01500083|Experimental|Patients with Indolent Non-Hodgkin's Lymphoma (iNHL)|Patients with iNHL will receive bendamustine at a dose of 120 mg/m2 on Days 1 and 2 in treatment cycles of 21 or 28 days for up to eight cycles.
3157170|NCT01500070|Experimental|Drug-eluting stent|Patients implanted with the PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or the PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
3157171|NCT01500057|Active Comparator|Greenlight XPS Laser|Greenlight XPS Laser of the prostate
3157172|NCT01500057|Active Comparator|BiVAP Saline Vaporization|BiVAP Saline Vaporization of the prostate
3157207|NCT01499862|Experimental|Tibion Arm|Arm of the study in which enrolled post-stroke subjects undergo rehabilitative therapy with the Tibion Bionic Leg.
3157208|NCT01499849|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV) + dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
3157307|NCT01499186|No Intervention|Control group|There will be no participation in a training program. The control group will perform all measurements.
3157173|NCT01500044|Active Comparator|Conventional Rehabilitation Program|The conventional program consists in cervicothoracic mobilizations and stabilization exercises. This program is based on the intervention used in clinical practice, and on programs proposed in two RCTs evaluating individuals with neck and arm pain that do not include any specific mobilization or exercise leading to the opening of the intervertebral foramen. Four mobilisation techniques will be executed at each treatment session. However, the therapists will not be allowed to use techniques that specifically open the intervertebral foramen of the affected segment, two segments above and two segments below.
3157174|NCT01500044|Experimental|Program targeting the opening of foramen|"The same interventions as for the conventional rehabilitation program will be applied, except:~Of the four mobilisation techniques, there will be two mandatory techniques targeting the opening of the intervertebral foramen on the same side and at the same level as the radiculopathy: global contralateral rotation mobilisation and ipsilateral lateral shearing in a flexion position. The therapist, according to the biomechanical evaluation results, will choose the two other mobilisation techniques."
3157175|NCT01500031|Experimental|OffRoad Re-entry catheter|Participants treated with OffRoad Re-entry Catheter System
3157176|NCT01500018|Experimental|Crossover Treatment Sequence 1|Period 1: Placebo, Period 2: Phentermine 45 mg, Period 3: Phentermine 90 mg, Period 4: Ketamine 100 mg, Period 5: TC-5214 2 mg, Period 6: TC-5214 8 mg, Period 7: TC-5214 16 mg
3157177|NCT01500018|Experimental|Crossover Treatment Sequence 2|Period 1: Phentermine 45 mg, Period 2: Ketamine 100 mg , Period 3: Placebo, Period 4: TC-5214 8 mg , Period 5: Phentermine 90 mg, Period 6: TC-5214 16 mg, Period 7: TC-5214 2 mg
3157178|NCT01500018|Experimental|Crossover Treatment Sequence 3|Period 1: Ketamine 100 mg, Period 2: TC-5214 8 mg, Period 3: Phentermine 45 mg, Period 4: TC-5214 16 mg, Period 5: Placebo, Period 6: TC-5214 2 mg, Period 7: Phentermine 90 mg
3157179|NCT01500018|Experimental|Crossover Treatment Sequence 4|Period 1: TC-5214 8 mg, Period 2: TC-5214 16 mg, Period 3: Ketamine 100 mg, Period 4: TC-5214 2 mg, Period 5: Phentermine 45 mg , Period 6: Phentermine 90 mg, Period 7: Placebo
3157180|NCT01500018|Experimental|Crossover Treatment Sequence 5|Period 1: TC-5214 16 mg, Period 2: TC-5214 2 mg, Period 3: TC-5214 8 mg, Period 4: Phentermine 90 mg, Period 5: Ketamine 100 mg, Period 6: Placebo , Period 7: Phentermine 45 mg
3157181|NCT01500018|Experimental|Crossover Treatment Sequence 6|Period 1: TC-5214 2 mg, Period 2: Phentermine 90 mg, Period 3: TC-5214 16 mg, Period 4: Placebo, Period 5: TC-5214 8 mg, Period 6:Phentermine 45 mg , Period 7: Ketamine 100 mg
3157182|NCT01500018|Experimental|Crossover Treatment Sequence 7|Period 1: Phentermine 90 mg, Period 2: Placebo, Period 3: TC-5214 2 mg, Period 4: Phentermine 45 mg, Period 5: TC-5214 16 mg, Period 6: Ketamine 100 mg, Period 7: TC-5214 8 mg
3157183|NCT01500018|Experimental|Crossover Treatment Sequence 8|Period 1: TC-5214 16 mg, Period 2: TC-5214 8 mg, Period 3: TC-5214 2 mg, Period 4: Ketamine 100 mg, Period 5: Phentermine 90 mg, Period 6: Phentermine 45 mg, Period 7: Placebo
3157184|NCT01500018|Experimental|Crossover Treatment Sequence 9|"Period 1: TC-5214 2 mg, Period 2: TC-5214 16 mg, Period 3: Phentermine 90 mg, Period 4: TC-5214 8 mg, Period 5: Placebo, Period 6: Ketamine 100 mg, Period 7:~Phentermine 45 mg"
3157185|NCT01500018|Experimental|Crossover Treatment Sequence 10|Period 1: Phentermine 90 mg, Period 2: TC-5214 2 mg, Period 3: Placebo, Period 4: TC-5214 16 mg Ketamine 100 mg, Period 5: Phentermine 45 mg, Period 6: TC-5214 8 mg, Period 7: TC-5214 2 mg
3157186|NCT01500018|Experimental|Crossover Treatment Sequence 11|Period 1: Placebo, Period 2: Phentermine 90 mg, Period 3:Phentermine 45 mg, Period 4: TC-5214 2 mg, Period 5: Ketamine 100 mg, Period 6: TC-5214 16 mg, Period 7: TC-5214 8 mg
3157187|NCT01500018|Experimental|Crossover Treatment Sequence 12|Period 1: Phentermine 45 mg, Period 2: Placebo, Period 3: Ketamine 100 mg, Period 4:Phentermine 90 mg, Period 5: TC-5214 8 mg, Period 6: TC-5214 2 mg, Period 7: TC-5214 16 mg
3157188|NCT01500018|Experimental|Crossover Treatment Sequence 13|Period 1: Ketamine 100 mg, Period 2: Phentermine 45 mg, Period 3: TC-5214 8 mg, Period 4: Placebo, Period 5: TC-5214 16 mg, Period 6: Phentermine 90 mg, Period 7: TC-5214 2 mg
3157189|NCT01500018|Experimental|Crossover Treatment Sequence 14|Period 1: TC-5214 8 mg, Period 2: Ketamine 100 mg, Period 3: TC-5214 16 mg, Period 4: Phentermine 45 mg, Period 5: TC-5214 2 mg, Period 6: Placebo, Period 7: Phentermine 90 mg
3157190|NCT01500005|Experimental|vitamin D|Baby D3 drops
3157191|NCT01499992|Experimental|aquatic physical therapy|aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focussing on the shoulder.
3157192|NCT01499992|No Intervention|standard care|
3157193|NCT01499979|No Intervention|Vascular inflow occlusion|Patients that will receive intermittent vascular inflow occlusion, the standard method for vascular occlusion at our institution, during liver resection.
3157194|NCT01499979|Experimental|Hypothermic perfusion|Patients will receive in situ hypothermic perfusion of the future remnant liver during liver resection.
3157195|NCT01499966|Experimental|group POP|PLASTER OF PARIS
3157196|NCT01499966|Experimental|TG|TUBIGRIP
3157197|NCT01499953|Experimental|Rivaroxaban|Rivaroxaban for 45 days oral dose: 10 mg OD
3157198|NCT01499953|Active Comparator|Fondaparinux|Fondaparinux for 45 days subcutaneous application: 2,5 mg OD
3157199|NCT01499940|Experimental|Vitamin D3 2000 IU/day|Vitamin D3 2000 IU/day on day of 1st cycle of oxaliplatin; continue as long as patient treated with oxaliplatin and remains on study
3157200|NCT01499927|Active Comparator|electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
3157201|NCT01499927|No Intervention|no electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents without computerized decision support
3157202|NCT01499914|Experimental|Influenza vaccination|Influenza vaccination in patients with cystic fibrosis
3157203|NCT01499901|Experimental|sequential|implantation bilateral sequential
3157204|NCT01499901|Experimental|simultaneous|implantation bilateral simultaneous
3157205|NCT01499888|Experimental|Allogeneic Non-Myeloablative Stem Cell Transplantation|The transplant regimen will consist of alemtuzumab 1mg/kg divided over five days, 300 cGy TBI, followed by sirolimus dosed for a target serum trough level of 10- 15 ng/mL.
3157206|NCT01499875|Other|Phenoxymethylpenicillin|It is a descriptive trial to find out about the pharmacokinetics
3157369|NCT01498770||Amisulpride|
3157370|NCT01498770||Sertindole|
3157209|NCT01499849|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
3157210|NCT01499836|Experimental|general anesthesia and PVB|general anesthetics consisting of propofol, cisatracurium and fentanyl for endotracheal intubation and deaflurane for maintenance will be given. After intubation, paravertebral injections will be performed under ultrasound guidance.
3157211|NCT01499836|Experimental|sedation and PVB|After sedation with midazolam and fentanyl, the patients in sedation and PVB group will receive PVB. paravertebral injections will be performed under ultrasound guidance.Intraoperative sedation will be provided with propofol titrated to moderate sedation.
3157212|NCT01499836|Active Comparator|general anesthesia|general anesthetics consisting of propofol, cisatracurium and fentanyl for endotracheal intubation and deaflurane for maintenance will be given.
3157213|NCT01499823||Patients with high-grade glioma|Patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who receive concurrent chemoradiation (CCRT) with temozolomide
3157214|NCT01499810|Experimental|Renal denervation|All eligible patients undergo bilateral radiofrequency sympathetic renal denervation using endocardial ablation system: after standard renal angiography using femoral access a small size endocardial ablation catheter (5-6 F, 4 mm electrode) is inserted into renal artery and 4-8 point ablations are performed consecutively from distal part to aorta with 3-4 mm step and 90 degrees rotation on the upper, lower, front and back aspects of the artery to get circumferential coverage, then the procedure is repeated on the other side.
3157215|NCT01499797|No Intervention|regular medical care|Identified community dwelling frail elderly people receiving regular medical care in their primary care setting
3157216|NCT01499797|Experimental|The CareWell programme|Identified community dwelling frail elderly people receiving care in line with the CareWell programme
3157217|NCT01499784|Experimental|Pelvic Floor muscle Training|educational class for behavioral modification and group exercise class for pelvic floor muscle training
3157218|NCT01499771|Experimental|1|Atorvastatin Calcium Tablets of OHM Laboratories Inc.
3157219|NCT01499771|Active Comparator|2|LIPITOR® Tablets 80mg of Pfizer Ireland Pharmaceuticals
3157220|NCT01499758|Experimental|1|Atorvastatin Calcium Tablets of OHM Laboratories Inc.
3157221|NCT01499758|Active Comparator|2|LIPITOR® Tablets 80mg of Pfizer Ireland Pharmaceuticals
3157222|NCT01499745|Active Comparator|Exercise Training at Pulmonary Rehabilitation Program|Exercise Training at Pulmonary Rehabilitation Program 2 weekly sessions of 60 min for 12 weeks
3157223|NCT01499745|Placebo Comparator|Standard Treatment for IPF|Continue for normal live with standard treatment
3157224|NCT01499732||Early Rheumatoid Arthritis|Subjects currently experiencing active early rheumatoid arthritis (duration of symptoms < or = 2 years) according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening. Must be drug naive (no prior treatment with traditional disease-modifying antirrheumatic drugs (DMARDs), or biologic response modifying agents)
3157225|NCT01499732||Healthy subjects without rheumatoid arthritis|Healthy subjects without rheumatoid arthritis
3157226|NCT01499732||Established Rheumatoid Arthritis|Subjects currently experiencing active established rheumatoid arthritis (duration fo symptoms > or = 2 years) according to the 2010 ACR/EULAR criteria at screening. Subjects with active established RA currently receiving methotrexate, must have received it for at least 12 weeks, and at a stable dose (> or = 15 mg/week) for at least 6 weeks prior to screening. They must be biologic naive, and must recieve at least 5mg oral folic acid weekly
3157227|NCT01499719||Surgical checklist|Compliance for surgical checklist
3157228|NCT01499706|No Intervention|Standard of Care Control|Participants will receive standard sexual risk reduction services available to them through medical and community-based organizations
3157229|NCT01499706|Experimental|1-session motivational interviewing|Participants will receive a single session of motivational interviewing delivered over the telephone
3157230|NCT01499706|Experimental|4-session motivational interviewing|Participants will receive four weekly sessions of motivational interviewing delivered over the telephone.
3157231|NCT01499693|Experimental|Magnesium Pantoprazole 20mg|
3157232|NCT01499693|Active Comparator|Magnesium Pantoprazole 40mg|
3157233|NCT01499680||NV in XLIF|This group will have the XLIF procedure done using NV.
3157234|NCT01499667|Experimental|8-week washout + Fingolimod (FTY720)|8-week washout (8 weeks no treatment) followed by 24 weeks of treatment with fingolimod 0.5mg once a day
3157235|NCT01499667|Experimental|12-week washout + Fingolimod (FTY720)|12-week washout (8 weeks no treatment and 4 weeks placebo) followed by 20 weeks of treatment with fingolimod 0.5mg once a day
3157236|NCT01499667|Experimental|16-week washout + Fingolimod (FTY720)|16-week washout (8 weeks no treatment and 8 weeks placebo) followed by 16 weeks of treatment with fingolimod 0.5mg once a day
3157237|NCT01499654|Experimental|Half-dose radiotracer administration|For this study, researchers would like to administer half of the radiotracer, obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
3157238|NCT01499641|Active Comparator|Epidural steroid|1.0 mL methylprednisolone acetate 40 mg/mL instilled at the decompressed nerve root
3157239|NCT01499641|Experimental|None epidural steroid|
3157240|NCT01499628|No Intervention|Group 1-Control|No extra training will be given.
3157241|NCT01499628|Active Comparator|Group 2-Control plus supervised reading|The same amount of contact time as Groups 3 and 4 - three 45 minute sessions completed over three weeks.
3157242|NCT01499628|Experimental|Group 3-EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
3157243|NCT01499628|Experimental|Group 4-EVT at the TRL|Eccentric viewing training at the Trained Retinal Locus (TRL), using reading/target cards and microperimeter. Three 45 minute sessions completed over three weeks.
3157244|NCT01499615||children undergoing general anesthesia|The intervention was the application of 4 ekg electrodes so as to non-invasivly measure cardiac output
3157245|NCT01499602|Experimental|LNG-IUS|Release rate of 20µg Levonorgestrel(Mirena, Bayer Schering Pharma Oy, Finland) per day with one year follow up.
3157371|NCT01498770||Zotepine|
3157246|NCT01499602|Active Comparator|Norethisterone Acetate|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
3157247|NCT01499589||RA in block room|Performing regional anesthesia in the block room
3157248|NCT01499589||RA inside OR|Performing regional anesthesia inside the main orthopedic operating room
3157249|NCT01499576|Experimental|Acetic acid spraying|
3157250|NCT01499563|Experimental|ITI-007 Low Dose|
3157251|NCT01499563|Experimental|ITI-007 High Dose|
3157252|NCT01499563|Placebo Comparator|Placebo|
3157253|NCT01499563|Active Comparator|Risperidone|
3157254|NCT01499550|Experimental|TNI application|In this study arm the patient is treated with humidified transnasal high flow (TNI) plus oxygen (result flow: 20 L/min).
3157255|NCT01499550|Active Comparator|Oxygen treatment|Long term oxygen treatment (LOT) is the routine treatment in patients suffering from COPD. In this study arm the patient is treated with his individual oxygen flow rate.
3157256|NCT01499537|Active Comparator|Percutaneous Drainage|Percutaneous Transhepatic Biliary Drainage (PTBD)
3157257|NCT01499537|Experimental|EUS-guided drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
3157258|NCT01499511||ASCOT participants|Participants from the ASCOT study recruited to the participating ASCOT study centres in the United Kingdom.
3157259|NCT01499498|Experimental|Sildenafil and Boceprevir|Healthy volunteers
3157260|NCT01499485|Experimental|Acetazolamide|
3157261|NCT01499485|Placebo Comparator|placebo|
3157262|NCT01499472|Active Comparator|shock wave therapy, shortened wound healing time|
3157263|NCT01499472|Other|normal wound care|standard of care intervention
3157264|NCT01499459|Experimental|autologous mesenchymal stem cell transplantation|
3157265|NCT01499446|Experimental|GW685698X (fluticasone furoate) 100mcg Morning|
3157266|NCT01499446|Experimental|GW685698X (fluticasone furoate) 100mcg Evening|
3157267|NCT01499446|Experimental|GW685698X (fluticasone furoate) 250mcg Evening|
3157268|NCT01499446|Placebo Comparator|Placebo|
3157269|NCT01499433|Experimental|caspofungin|
3157270|NCT01499420|Experimental|CSL112|
3157271|NCT01499420|Placebo Comparator|Placebo|
3157272|NCT01499407|Active Comparator|Standard abciximab bolus|
3157273|NCT01499407|Experimental|ClearWay-infused abciximab|
3157274|NCT01499407|Experimental|Thrombectomy plus ClearWay-infused abciximab|
3157275|NCT01499407|Active Comparator|Thrombectomy plus standard abciximab bolus|
3157276|NCT01499394||Normal|"Donor samples reflective of a normal non-disease state"
3157277|NCT01499394||Disease state or condition|Donor samples reflective of a known disease state or condition
3157278|NCT01499381||Routine prostate biopsy patients|
3157279|NCT01499368|Experimental|Lafutidine|Lafutidine 20mg/day
3157280|NCT01499368|Active Comparator|Famotidine|Famotidine 40mg/day
3157281|NCT01499368|Other|Omeprazole|Omeprazole 20mg/day
3157282|NCT01499355|Placebo Comparator|Placebo|Placebo intravenous (IV) infusion on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48, plus background therapy including oral steroids (prednisone or equivalent) and mycophenolate mofetil (MMF)
3157283|NCT01499355|Experimental|BIIB023 3 mg/kg|BIIB023 3 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
3157284|NCT01499355|Experimental|BIIB023 20 mg/kg|BIIB023 20 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
3157285|NCT01499342||Rutherford category 2 - 5|
3157286|NCT01499329||Patient receiving stent therapy|
3157287|NCT01499316|Experimental|High Flow oxygen|10 minute of 10/L min of inhaled oxygen with reservoir bag.
3157288|NCT01499316|Experimental|Room Air|
3157289|NCT01499303|Experimental|Fostamatinib 200|200mg fostamatinib bid n=60
3157290|NCT01499290|Experimental|CAZ-AVI + Metronidazole|IV treatment
3157291|NCT01499290|Active Comparator|Meropenem|IV treatment
3157292|NCT01499277|Experimental|Ceftaroline fosamil|Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
3157293|NCT01499277|Active Comparator|Vancomycin plus aztreonam|Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function
3157294|NCT01499264|Experimental|MySkin patch|Hydrogel e polyurethane film
3157295|NCT01499264|Active Comparator|Traditional Dressing|
3157296|NCT01499251|Experimental|Macitentan|Macitentan in combination with dose-dense temozolomide
3157297|NCT01499238|Active Comparator|nasal SIMV|rate: 30-50/min, PIP: 16, PEEP: 4-6, fİO2: 40%
3157298|NCT01499238|Active Comparator|nasal CPAP|PEEP: 4-6 mmHg, Fio2: 40%
3157299|NCT01499225|Experimental|YH14642 A-I|
3157300|NCT01499225|Experimental|YH14642 A-II|
3157301|NCT01499225|Experimental|YH14642 A-III|
3157302|NCT01499225|Active Comparator|Active Comparator B|
3157303|NCT01499225|Active Comparator|Active Comparator C|
3157304|NCT01499225|Placebo Comparator|Placebo|
3157305|NCT01499212|Experimental|I:E ratio 1:1|
3157306|NCT01499199|Experimental|Dolutegravir 50mg Once Daily|All subjects will receive 50mg dolutegravir once daily in combination with background antiretroviral therapy consisting of one abacavir/lamivudine fixed dose combination tablet once daily
3157372|NCT01498757||Patients treated with Taxane/5-FU/platinum based chemo.|
3157308|NCT01499186|Experimental|Intervention group|The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators. These subjects will perform all measurements.
3157309|NCT01499173|Experimental|Stroke preparedness intervention|Youth and adults from predominately African American churches in Flint will be enrolled to undergo a faith-based, scientific theory-driven, peer-led behavioral intervention utilizing a pre-post test design.
3157310|NCT01499160|Experimental|HER2-positive or negative|Lapatinib 1,500 mg/day + letrozole 2.5 mg/day until progression followed by everolimus 5 mg/day + letrozole 2.5 mg/day + lapatinib 1,250 mg/day.
3157311|NCT01499147|Active Comparator|Arm 1|All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.
3157312|NCT01499147|Active Comparator|Arm 2|All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.
3157313|NCT01499134|Experimental|nebivolol|nebivolol 1 to 4 capsules daily
3157314|NCT01499134|Active Comparator|metoprolol succinate|metoprolol 1 to 4 capsules daily
3157315|NCT01499121|Other|Sunitinib|Starting dose/schedule of Sunitinib 50 mg/28 days on, 14 days off. The intent is to maximize dose intensity of Sunitinib and minimize time off therapy based on individual tolerability using dose modification criteria.
3157316|NCT01499108|Experimental|Liraglutide|single-group study were participants recieve Liraglutide
3157317|NCT01499095|Experimental|HOE901-U300|
3157318|NCT01499095|Active Comparator|Lantus|
3157319|NCT01499082|Experimental|HOE901-U300|
3157320|NCT01499082|Active Comparator|Lantus|
3157321|NCT01499069|Experimental|Antimuscarinic agents|
3157322|NCT01499056|Experimental|hip osteoarthritis|The patients with hip joint osteoarthritis who underwent cell injection
3157323|NCT01499043|Experimental|PLX3397|Subjects will take daily oral dose of PLX3397 for 28 day cycles. Subjects will continue to take PLX3397 until disease progression or toxicity.
3157324|NCT01499017|Experimental|Cohort A|Each subjects in Cohort A will receive 3 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-4.
3157325|NCT01499017|Experimental|Cohort B|Each subjects in Cohort B will receive 2 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-06291874 will be administered in Period 4 in the fed state.
3157326|NCT01499004|Experimental|Treatment A|tofacitinib (CP-690,550) modified-release formulation A-Fed
3157327|NCT01499004|Experimental|Treatment B|tofacitinib (CP-690,550) modified-release formulation B1-Fed
3157328|NCT01499004|Experimental|Treatment C|tofacitinib (CP-690,550) modified-release formulation A-Fasted
3157329|NCT01499004|Experimental|Treatment D|tofacitinib (CP-690,550) modified-release formulation B1-Fasted
3157330|NCT01499004|Experimental|Treatment E|tofacitinib (CP-690,550) modified-release formulation B2-Fasted
3157331|NCT01499004|Experimental|Treatment F|tofacitinib (CP-690,550) immediate-release formulation-Fasted
3157332|NCT01498991|Experimental|AMES Treatment|The subject will receive 30 treatment sessions, conducted 3-4 times per week on the AMES device. Each session will consist of testing followed by 40 minutes of treatment time (20 minutes per each leg) using the AMES device.
3157333|NCT01498978|Experimental|Treatment (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without progression then receive maintenance ipilimumab IV once every 3 months for 4 additional doses.
3157334|NCT01498952|Experimental|Cohort A|MEDI-573 Dose 1 plus Sorafenib
3157335|NCT01498952|Experimental|Cohort B|MEDI-573 Dose 2 plus Sorafenib
3157336|NCT01498952|Experimental|Cohort C|MEDI-573 Dose 2 plus sorafenib
3157337|NCT01498939|Experimental|IDet 0.2 U/kg|
3157338|NCT01498939|Experimental|IDet 0.4 U/kg|
3157339|NCT01498939|Experimental|IDet 0.8 U/kg|
3157340|NCT01498926|Experimental|Glycerol|
3157341|NCT01498926|Active Comparator|Mannitol|
3157342|NCT01498913||Repaglinide|
3157343|NCT01498900||Repaglinide|
3157344|NCT01498887|Experimental|Fingolimod|Both groups of patients in the study will be treated in parallel with Fingolimod.
3157345|NCT01498874|Placebo Comparator|Placebo|
3157346|NCT01498874|Experimental|low dose gevokizumab|
3157347|NCT01498874|Experimental|high dose gevokizumab|
3157348|NCT01498861|Other|Run-In Period|Ortho-Cyclen for 21 days. Only for subjects who are not already taking Ortho-Cyclen prior to the study
3157349|NCT01498861|Experimental|Sequence AB|Subjects will take Ortho-Cyclen once a day from Day 1-21 of their menstrual cycle. In addition they will take dolutegravir 50 mg twice a day from Days 1-10 and placebo twice a day from Day 12-21
3157350|NCT01498861|Experimental|Sequence BA|Subjects will take Ortho-Cyclen once a day from Day 1-21 of their menstrual cycle. In addition they will take placebo twice a day from Days 1-10 and dolutegravir 50 mg twice a day from Day 12-21
3157351|NCT01498848|Active Comparator|Soybean oil|Families were given soybean oil for cooking during 4 weeks
3157352|NCT01498848|Active Comparator|Sunflower oil|Families were given sunflower oil for cooking during 4 weeks
3157353|NCT01498835|Experimental|Combined Sunitinib and irradiation|Patients with locally advanced or recurrent soft tissue sarcoma will receive Sunitinib and irradiation as neoadjuvant treatment. Restaging and tumor resection will be performed 6 weeks after completion of sunitinib and irradiation.
3157354|NCT01498822|Experimental|Levetiracetam|Levetiracetam twice a day treatment group
3157355|NCT01498822|Active Comparator|Oxcarbazepine|Oxcarbazepine twice a day treatment group
3157356|NCT01498796|Experimental|Ketorolac|
3157357|NCT01498796|Placebo Comparator|Placebo|
3157358|NCT01498783|Experimental|Treatment|"Participants meeting the eligibility requirements.~Intervention: 5-fluorouracil"
3157359|NCT01498770||Asenapine|
3157360|NCT01498770||Aripiprazole|
3157361|NCT01498770||Quetiapine|
3157362|NCT01498770||Risperidone|
3157363|NCT01498770||Olanzapine|
3157364|NCT01498770||Ziprasidone|
3157365|NCT01498770||Iloperidone|
3157366|NCT01498770||Paliperidone|
3157367|NCT01498770||Lurasidone|
3157368|NCT01498770||Clozapine|
3157373|NCT01498744|Experimental|5 days postoperative antibiotic|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
3157374|NCT01498744|Experimental|1 day postoperative antibiotic|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
3157375|NCT01498731|Experimental|Copeptin|"Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home without further interventions.~To secure the patients safety they will be transferred into our co-operating network of resident cardiologists using the software Praxis-connect i.e. these patients will be discharged with an electronically booked appointment to see a cardiologist preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.~Patients who test positive for Copeptin will be treated as by standard practise."
3157376|NCT01498731|No Intervention|Standard|Patients will be managed as by standard practice abiding current guidelines for the management of patients with suspected ACS.The copeptin result will not be available for the treating physician.
3157377|NCT01498718|Experimental|Group 1A (18-50 yrs): DNA vaccine + TIV|HA DNA Vaccine (VRC-FLUDNA061-00-VP) at Day 0 and licensed TIV at Week 36
3157378|NCT01498718|Experimental|Group 2A (51-70 yrs): DNA vaccine + TIV|HA DNA Vaccine (VRC-FLUDNA061-00-VP) at Day 0 and licensed TIV at Week 36
3157379|NCT01498718|Placebo Comparator|Group 1B (18-50 yrs): TIV only|Phosphate buffered saline (PBS) on Day 0 + TIV at Week 36
3157380|NCT01498718|Placebo Comparator|Group 2B (51-70 yrs): TIV only|Phosphate buffered saline (PBS) on Day 0 + TIV at Week 36
3157381|NCT01498705||Hemmorhagic Stroke|"Hospitalization for an admitting diagnosis of hemorrhagic stroke admitted to the neurosurgical intensive care unit~Age greater than 18 years~No evidence of ischemic cerebrovascular injury"
3157382|NCT01498692|Experimental|PROMUS Element|Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent
3157383|NCT01498679|Active Comparator|fluticasone furoate/vilanterol trifenatate|Inhaled corticosteroid (ICS)/Long-acting beta2-agonist (LABA) combination
3157384|NCT01498679|Placebo Comparator|Placebo|placebo comparator
3157385|NCT01498666|Experimental|L. reuteri protectis tablets|one tablet a day for 4 weeks
3157386|NCT01498666|Placebo Comparator|Placebo tablet|one tablet a day for 4 weeks
3157387|NCT01498653|Experimental|FF/VI 200/25mcg once daily|ICS/LABA
3157388|NCT01498653|Active Comparator|Fluticasone propionate 500mcg twice daily|ICS
3157389|NCT01498640|Experimental|XIAFLEX/XIAPEX MP Joint|Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the metacarpophalangeal (MP) joint cord
3157390|NCT01498640|Experimental|XIAFLEX/XIAPEX PIP Joint|Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the proximal interphalangeal (PIP) joint cord
3157391|NCT01498627||Case Group|Subjects in this group are incident cases (i.e. newly diagnosed subjects) reported as having occurred in the previous twelve months before the recruitment consultation.
3157392|NCT01498627||Control Group|Subjects selected from the pool of potential referents reported by physicians in general practice, who meet the same general inclusion and exclusion criteria as the cases.
3157393|NCT01498614|Experimental|Affect school|Affect school is an educational intervention which includes 8 group sessions followed by 10 individual meetings with therapist
3157394|NCT01498614|Active Comparator|Basal body awareness|Basal body awareness is an educational method with 9 group sessions followed by 6 individual meetings
3157395|NCT01498601|Experimental|Oral care treatment group|All subjects in the prospective intervention group will receive the same enhanced oral care protocol
3157396|NCT01498601|No Intervention|Retrospective study group|For comparison purposes, a retrospective chart review of matched in-patient population will reveal pneumonia rates in the same population who did not receive the enhanced oral care protocol.
3157397|NCT01498588|Experimental|Eribulin+Doxorubicin+Cyclophosphamide|"Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide~Eribulin Day 1 and Day 8 of a 21 day cycle x 4 cycles:~Day 1: Eribulin 1.4mg/m² IV~Day 8: Eribulin 1.4mg/m² IV~Dose-dense doxorubicin and cyclophosphamide every 14 days x 4 cycles:~Day 1: Doxorubicin 60mg/m² IV~Day 1: Cyclophosphamide 600mg/m² IV~Day 2: Pegfilgrastim support 6mg sc at least 24 hours after chemotherapy at the discretion of the investigator."
3157398|NCT01498575|Experimental|Teen Driving Plan|Access to web-based driving intervention
3157399|NCT01498575|No Intervention|Usual practice|Use of typical supervised practice driving resources
3157400|NCT01498562|Experimental|Gefitinib plus Nimotuzumab|Combination therapy group: Gefitinib(250mg daily) and Nimotuzumab (200mg weekly)
3157401|NCT01498562|Active Comparator|Gefitinib alone|Mono-therapy group: Gefitinib(250mg daily)
3157402|NCT01498549|Active Comparator|Atomoxetine|Atomoxetine compared to the sugar pill
3157403|NCT01498549|Placebo Comparator|Sugar Pill|Sugar pill compared to atomoxetine
3157404|NCT01498523|Experimental|raw camel milk|
3157405|NCT01498523|Experimental|camel milk powder solution|
3157406|NCT01498523|Active Comparator|raw cow milk|
3157407|NCT01498523|Active Comparator|Glucose solution|
3157408|NCT01498510|No Intervention|treatment-as-usual (TAU)|The standard medical treatment provided to chronic pain patients at the study site pain specialty practice
3157409|NCT01498510|Experimental|TAU plus web-based intervention|An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that teaches chronic pain patients with aberrant behavior self-management skills to reduce pain severity and medication misuse and improve functioning
3157410|NCT01498497||PR-021 Eosinophilic Esophagitis (EoE) Subjects|Subjects who received study drug and completed PR-021 study
3157411|NCT01498484|Experimental|EBV-specific T cells|Patients will each receive a course of three weekly infusions of EBV-specific T cells (EBV-CTLs). Each weekly dose will provide 2 x 10^6 T cells/kg recipient weight (+/- 3 days). After the third dose, patients will be observed for approximately 3 weeks.
3157412|NCT01498458|Experimental|pazopanib plus capecitabine|
3157413|NCT01498445|Experimental|Dasatinib + Decitabine 10 mg/m2|Less Intensive, Schedule A Dasatinib starting dose of 100 mg by mouth daily; Decitabine starting dose 10 mg/m2 by vein over 1 hour daily for 10 days; 28 day cycle.
3157414|NCT01498445|Experimental|Dasatinib + Decitabine 20 mg/m2|More Intensive, Schedule B: Dasatinib starting dose 100 mg by mouth daily; Decitabine starting dose 20 mg/m2 by vein over 1 hour daily for 10 days; 28 day cycle.
3157415|NCT01498432|Experimental|Heliox21|
3157416|NCT01498432|Active Comparator|Air O2|
3157417|NCT01498419|Experimental|Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)|Drug Sensitive Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 100 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
3157418|NCT01498419|Experimental|Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)|Drug Sensitive Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 200 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
3157419|NCT01498419|Active Comparator|Drug Sensitive: Rifafour|Drug Sensitive Participants: Rifafour was administered orally once daily for 8 weeks according to weight: 30 kg to 37 kg: two tablets; 38 kg to 54 kg: three tablets; 55 kg to 70 kg: four tablets; ≥71 kg: five tablets
3157420|NCT01498419|Experimental|Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)|Multi Drug-Resistant Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 200 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
3157421|NCT01498406|Experimental|high dose vitamin D3|4,000 IU of vitamin D3 daily for 8 months
3157422|NCT01498406|Active Comparator|low dose vitamin D3|400 IU of vitamin D3
3157423|NCT01498393|Other|Laser treatment|Laser treatment to Improve the Appearance of Onychomycosis
3157424|NCT01498380|Experimental|Dexmedetomidine Rapid Bolus|All subjects will receive a rapid bolus of dexmedetomidine following induction of anesthesia with propofol and remifentanil and placement of laryngeal mask airway.
3157425|NCT01498367|No Intervention|Usual care|Participants in the control group receive usual care. Usual care consists of regular visits to the specialist when required. In the occasion of the visit, HbA1c and glucose measurements are performed and the current oral or insulin therapy is modified if necessary. Patients also receive basic education in the management of diabetes.
3157426|NCT01498367|Experimental|Telemonitoring of diabetes 2 patients|Patients will have one educational visit to set up the system and explain how it works. Patients will download their measurements from their tele-glucose meter to their mobile phone and the data will be transferred to the regional database. The care team (a nurse specially trained and the allocated physician) will regularly access the patient's home diary, and will provide the appropriate counselling and medication changes as frequently as necessary. In addition to blood glucose measurements, routine questions about symptoms and eventual difficulties related to diabetes as well as diabetic management will be routinely captured and reported.
3157427|NCT01498354|Experimental|2-D high definition TEO (transanal endoscopic operation)|
3157428|NCT01498354|Active Comparator|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM), 3-D vision system using a rectoscope, which allows access to rectal tumors located up to 20 cm from the anal verge
3157429|NCT01498328|Experimental|Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut.|About half of the patients who have never received treatment with bevacizumab will receive rindopepimut/GM-CSF in a blinded fashion in combination with bevacizumab.
3157430|NCT01498328|Experimental|Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control|About half of the patients who have never received treatment with bevacizumab will receive KLH in a blinded fashion in combination with bevacizumab.
3157431|NCT01498328|Experimental|Group 2 and 2C: Refractory to Bevacizumab|Patients with progressive disease while currently on or within two months after discontinuing bevacizumab will be administered rindopepimut/GM-CSF while continuing (or restarting if they had stopped bevacizumab).
3157432|NCT01498315||Women following hysterecomy|
3157433|NCT01498289|Experimental|Arm I|FOLFOX regimen: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3157434|NCT01498289|Experimental|Arm II|Patients receive irinotecan hydrochloride IV over 90 minutes and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3157435|NCT01498276||Members of under-resourced communities|Participant recruited from under-resourced communities in the Washington, DC area.
3157436|NCT01498276||General Population|Members of the general population
3157437|NCT01498263||Alzheimers related dementias (family)|Enrollment open to family members of persons diagnosed with Alzheimers (/related dementia) in specific communities around Memphis, TN
3157438|NCT01498263||Inborn metabolic conditions (family)|Enrollment open to family members of persons diagnosed with inborn errors of metabolism. Participation at NIH or remote (internet/phone); request referral of family members for remote participation.
3157439|NCT01498263||Undiagnosed condition: severe/chronic (family)|Enrollment open to family members referred in from the Undiagnosed Disease Network. Participation at NIH or remote (internet/phone); request referral of family members for remote participation.
3157440|NCT01498263||Healthy Volunteers|Enrollment open to parents of healthy child/ren <18yrs (when child is full-time resident of parent's home). Participation at NIH; request referral of family members for remote participation.
3157441|NCT01498263||Inherited inflammatory conditions (family)|Enrollment open to family members of persons diagnosed with inherited inflammatory conditions. Participation at NIH or remote (internet/phone); request referral of family for remote participation.
3157442|NCT01498250||basal cell carcinoma|
3157443|NCT01498250||non-lesional skin|
3157444|NCT01498237|Experimental|Photoacoustic endoscopy|This is a one-arm, feasibility study to determine how well the experimental procedure photoacoustic endoscopy will evaluate the human endometrial cavity in vivo.
3157445|NCT01498224|Active Comparator|Suture|Suture application
3157446|NCT01498224|Experimental|ReSure Sealant|Sealant application
3157447|NCT01498211|Experimental|Biopsy|
3157448|NCT01498198|Experimental|Expedited Surgery|Participants will have surgery within 3 months
3157539|NCT01497535|Active Comparator|Insulin glargine|
3157449|NCT01498198|Experimental|Non Operative Management|Participants will undergo non operative care for as long as they are improving, and will return to the surgeon when no progression is reached.
3157450|NCT01498185|Experimental|Arm 1: Dapagliflozin (1 mg)|
3157451|NCT01498185|Experimental|Arm 2: Dapagliflozin (2.5 mg)|
3157452|NCT01498185|Experimental|Arm 3: Dapagliflozin (5 mg)|
3157453|NCT01498185|Experimental|Arm 4: Dapagliflozin (10 mg)|
3157454|NCT01498185|Experimental|Arm 5: Placebo matching Dapagliflozin|
3157455|NCT01498172|Experimental|NMIBC at intermediate risk of progression|
3157456|NCT01498172|Experimental|NMIBC at high risk of progression|
3157457|NCT01498172|Experimental|NMIBC at low risk of progression|
3157458|NCT01498159|Experimental|Pharmacist + Health Promoter|Participants in this group will receive support from both a pharmacist and health promoter. Number of sessions will be determined by the study team member and patient.
3157459|NCT01498159|Active Comparator|Pharmacist|Participants will receive support from pharmacist.
3157460|NCT01498133|Experimental|skin-to-skin contact|Newborns in the study group had skin-to-skin contact with their mothers in the NICU, twice a day (morning and evening) for 60 minutes, for seven days (including weekends).
3157461|NCT01498133|No Intervention|control group|The control group (n = 49) received routine care without skin-to-skin contact.
3157462|NCT01498120|Experimental|Rotigotine|"Optimal dose after titration period~0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2)"
3157463|NCT01498094|Active Comparator|Control|Standard low-flow oxygen therapy.
3157464|NCT01498094|Experimental|Intervention|High Flow Nasal Cannula Oxygen Therapy
3157465|NCT01498081|Experimental|Single dose of AZD2115 25 µg|
3157466|NCT01498081|Experimental|Single dose of AZD2115 80 µg|
3157467|NCT01498081|Experimental|Single dose of AZD2115 240 µg|
3157468|NCT01498081|Placebo Comparator|Single doses of placebo|
3157469|NCT01498081|Active Comparator|Single dose of indacaterol 150 µg|
3157470|NCT01498081|Active Comparator|Single dose of indacaterol 150 µg + tiotropium 18 µg|
3157471|NCT01498068|Experimental|Treatment-naïve|Treatment naïve participants will receive telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual ontreatment virologic response in this study.
3157472|NCT01498068|Experimental|Treatment-experienced|Treatment-experienced participants received telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual on-treatment virologic response in this study.
3157473|NCT01498055||CIK therapy group|
3157474|NCT01498055||control group|
3157475|NCT01498042||stroke, thrombolysis, over 80, outcome|To study the outcome of stroke patients over 80 years treated with thrombolysis.
3157476|NCT01498029|Active Comparator|Randomized to Microfracture|This group of patients who have been randomised to receive microfracture procedure will be the control group for this study
3157477|NCT01498029|Experimental|Randomized to CAIS|This group of patients who have been randomised to receive the CAIS procedure will be the experimental group for this study
3157478|NCT01498016|Experimental|Iv-Busulfan|iv busulfan 1.6mg/kg given q12h
3157479|NCT01498003|Placebo Comparator|Control group|normal saline was applied to those randomized to control group, with same use as tirofiban
3157480|NCT01498003|Experimental|Tirofiban group|after angioram, and before guiding catheter engagement: 10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion
3157481|NCT01497990|Experimental|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
3157482|NCT01497977|Experimental|soya phytoestrogens|
3157483|NCT01497977|Experimental|red clover phytoestrogens|
3157484|NCT01497977|No Intervention|No drugs|
3157485|NCT01497964|Experimental|Cabazitaxel|Cabazitaxel, several dosages
3157486|NCT01497951|Experimental|Aminolaevulinic acid|
3157487|NCT01497951|Placebo Comparator|Placebo|
3157488|NCT01497938|Experimental|Low Glucose Suspend feature (LGS)|According to randomization, Low Glucose Suspend (LGS) will be turned ON in the treatment arm of the study
3157489|NCT01497938|Experimental|Control Arm|The Low Glucose Suspend feature will not be available to subjects in the control arm
3157490|NCT01497925|Experimental|ADI-PEG 20|
3157491|NCT01497912|Active Comparator|Atorvastatin|Atorvastatin 80mg once daily
3157492|NCT01497912|Placebo Comparator|Placebo|Matched placebo tablets
3157493|NCT01497899|Experimental|E/C/F/TAF|E/C/F/TAF plus E/C/F/TDF placebo for at least 48 weeks
3157494|NCT01497899|Active Comparator|E/C/F/TDF|E/C/F/TDF plus E/C/F/TAF placebo for at least 48 weeks
3157495|NCT01497899|Experimental|E/C/F/TAF Open-Label|"Following study unblinding, participants from the E/C/F/TAF and E/C/F/TDF arms may have the option to receive E/C/F/TAF during an open-label extension phase.~Also, participants who are actively participating in a Gilead-sponsored study of cobicistat-boosted darunavir plus nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) who have reached the protocol-defined secondary endpoint (Week 48) and remain virologically suppressed are eligible to participate and receive E/C/F/TAF in this open-label extension phase."
3157496|NCT01497886|Active Comparator|Hip Hop Stroke educational program|Hip Hop Stroke is a school-based educational program that incorporates educational hip hop music and two cartoons to communicate stroke knowledge to children.
3157540|NCT01497522|Experimental|Vildagliptin|In addition to their stable dose of metformin monotherapy, patients should take vildagliptin 50 mg twice daily.
3157541|NCT01497522|Placebo Comparator|Placebo|In addition to their stable dose of metformin monotherapy, patients should take vildagliptin matching placebo.
3157542|NCT01497509|Experimental|Patients electing to receive intrapartum epidural analgesia|
3157543|NCT01497509|No Intervention|Patients electing not to receive epidural analgesia|
3157826|NCT01495429|Experimental|PICC line (Peripherally)|placement of a picc line
3157497|NCT01497886|Placebo Comparator|Nutrition Education program|"The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence)."
3157498|NCT01497873|Experimental|Belotecan|Camtobell Injection
3157499|NCT01497873|Active Comparator|Topotecan|Hycamtin Injection
3157500|NCT01497860|Experimental|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
3157501|NCT01497847||travelers to tropical destinations|
3157502|NCT01497834|Experimental|Daclatasvir + Asunaprevir|
3157503|NCT01497821|Experimental|Dose exploration|Pre-specified nominal doses are proposed in the dose exploration at two dosing frequencies: every two weeks and every three weeks. Intermediate doses may also be used if required based on the Continuous Reassessment Method (CRM) design.
3157504|NCT01497821|Experimental|Dose expansion|Dose and dosing frequency selected from Part 1 dose exploration.
3157505|NCT01497808|Experimental|Phase 1|
3157506|NCT01497808|Experimental|Phase 2|
3157507|NCT01497782|Experimental|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
3157508|NCT01497782|No Intervention|No instructor feedback|Control group who did not receive instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
3157509|NCT01497769|Experimental|Group 1|Aerosol inhaled MVA85A and intradermal saline placebo
3157510|NCT01497769|Experimental|Group 2|Intradermal MVA85A and inhaled aerosol saline placebo
3157511|NCT01497756|Experimental|CAPP application|Patients in whom device is used
3157512|NCT01497743|Placebo Comparator|placebo|Subjects will be randomized into either the probiotic or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
3157513|NCT01497743|Active Comparator|Probiotic|Subjects will be randomized into either the probiotic or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
3157514|NCT01497730|Experimental|Total Knee Replacement|"Subjects will receive one of the following total knee implants:~fixed bearing cruciate retaining (FB CR)~fixed bearing posterior stabilized (FB PS)~rotating platform cruciate retaining (RP CR)~rotating platform posterior stabilized (RP PS)"
3157515|NCT01497717|Experimental|Adalimumab, Behcet with arthritis|
3157516|NCT01497704|Experimental|YN968D1|Active therapy arm for safety evaluation
3157517|NCT01497691|Other|Control|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol.
3157518|NCT01497691|Sham Comparator|Sham NIPPV|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine. The pressure settings will be fixed at a positive end-expiratory pressure (PEEP) of 5-8 cm H2O.
3157519|NCT01497691|Active Comparator|BiPAP|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine. Settings will be adjusted based on the age and clinical presentation of the child.
3157520|NCT01497678|Other|Extracellular Matrix|Implantation of Extracellular Matrix
3157521|NCT01497665|Experimental|GRN1005 alone|GRN1005 alone
3157522|NCT01497652|Active Comparator|Treatment Group|Treatment group will receive Rasagiline (Azilect) 1mg daily
3157523|NCT01497652|Placebo Comparator|Placebo Group|will receive placebo daily
3157524|NCT01497639|Active Comparator|Process 1|"Visit 1: Baseline evaluation (maximum 1 week before operation)~Visit 2: Testing of electrodes and subsequent initiation of interleaving stimulation mode (4th postoperative week).~Visit 3 Evaluation and cross-over to double-monopolar stimulation mode (16th postoperative week).~Visit 4 Final evaluation. (28th postoperative week)."
3157525|NCT01497639|Active Comparator|Process 2|"Visit 1: Baseline evaluation (maximum 1 week before operation)~Visit 2: Testing of electrodes and subsequent initiation of double-monopolar stimulation mode (4th postoperative week).~Visit 3 Evaluation and cross-over to interleaving stimulation mode (16th postoperative week).~Visit 4 Final evaluation. (28th postoperative week)."
3157526|NCT01497626|Experimental|Bortezomib plus lapatinib|Combination treatment with lapatinib and bortezomib
3157527|NCT01497613|Active Comparator|PRISM B: Notebook Condition|Telephone check-in calls and a notebook containing similar categories of information as the features on the PRISM C computer system such as a resource guide; games; classroom and information, calendar.
3157528|NCT01497613|Experimental|PRISM C: Computer Condition|A computer-based system designed to support socialization and access to resources; knowledge and prospective memory. The system is placed in the homes of those randomized to the condition for 12 months.
3157529|NCT01497600|Experimental|insulin detemir|
3157530|NCT01497600|Active Comparator|insulin NPH|
3157531|NCT01497587|Experimental|Insulin detemir|
3157532|NCT01497574|Experimental|Insulin detemir|
3157533|NCT01497574|Active Comparator|Insulin glargine|
3157534|NCT01497561|Experimental|insulin detemir|
3157535|NCT01497561|Active Comparator|insulin NPH|
3157536|NCT01497548|Experimental|Methylphenidate add on to Mirtazapine|Methylphenidate add on to the usual treatment (Mirtazapine)
3157537|NCT01497548|Placebo Comparator|Placebo add on to Mirtazapine|Non active compund add on to the usual treatment (Mirtazapine)
3157538|NCT01497535|Experimental|Insulin detemir|
3157544|NCT01497496|Experimental|Immunotherapy|Combination regimen consisting of high dose methylprednisolone combined with ofatumumab, followed by consolidative therapy with lenalidomide in combination with ofatumumab.
3157545|NCT01497483|Active Comparator|Pravastatin alone|Subjects will be dosed with Pravastatin alone (40 mg)
3157546|NCT01497483|Experimental|Pravastatin and Cyclosporine|Subjects will be dosed with pravastatin and cyclosporine.
3157547|NCT01497470|Experimental|Paclitaxel/carboplatin with custirsen|Custirsen added to standard paclitaxel/carboplatin chemotherapy
3157548|NCT01497457|Experimental|MR saline peritoneography|Patients that will undergo MR saline peritoneography
3157549|NCT01497444|Experimental|sorafenib and TH-302|Patients will be administered sorafenib tablets to take twice daily by mouth, every day of each cycle. Patients will also be given TH-302 intravenously (IV) on days 8, 15 and 22 of each cycle. A cycle is 28 days.
3157550|NCT01497431|Experimental|Arm I (Se-methyl-seleno L-cysteine)|Participants receive Se-methyl-seleno L-cysteine on days 1-84.
3157551|NCT01497431|Experimental|Arm II (selenomethionine)|Participants receive selenomethionine PO on days 1-84.
3157552|NCT01497431|Placebo Comparator|Arm III (placebo)|Participants receive placebo PO on days 1-84.
3157553|NCT01497405|Active Comparator|Test, Treat, Retain(TTR) only|Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
3157554|NCT01497405|Experimental|Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)|TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment. Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities. This intervention is an adaptation of the evidence-based Women's CoOp(PI: Dr. Wendee M. Wechsberg).
3157555|NCT01497392|Experimental|Treatment (dovitinib lactate, gemcitabine, and capecitabine)|Patients receive dovitinib lactate PO on days 1-5, 8-12, and 15-19, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and capecitabine PO twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3157556|NCT01497379|Experimental|intra-individual implant ON|intra-individual implant activation
3157557|NCT01497379|Placebo Comparator|intra-individual implant OFF|intra-individual implant deactivation
3157558|NCT01497366|Experimental|Sofosbuvir+RBV|Participants were randomized to receive sofosbuvir+RBV for 12 weeks.
3157559|NCT01497366|Active Comparator|PEG+RBV|Participants were randomized to receive PEG+RBV for 24 weeks.
3157560|NCT01497353|Active Comparator|Position at introitus level|The newborn will be held by the neonatologist at the level of the introitus, the cord will be clamped at 2 minutes after birth. New weigh will be obtained after that.
3157561|NCT01497353|Experimental|Position at Maternal Abdomen|The newborn will be placed on the abdomen and of the mother immediately after the first weigh measurement. The cord will be clamped at 2 minutes after birth .
3157562|NCT01497340|Active Comparator|Position at introitus level|The newborn will be held by the neonatologist at the level of the introitus, the cord will be clamped at 2 minutes after birth with a plastic clamp placed at 1 cm from its cutaneous insertion.
3157563|NCT01497340|Experimental|position at Maternal Abdomen|The newborn will be placed on the abdomen and of the mother immediately after the first weight measurement. The cord will be clamped at 2 minutes after birth .
3157564|NCT01497327|Experimental|PSI-352938 Group A|Mild (Child-Pugh Class A; 5-6) hepatic impairment
3157565|NCT01497327|Experimental|PSI-352938 Group B|Moderate (Child-Pugh Class B; 7-9) hepatic impairment
3157566|NCT01497327|Experimental|PSI-352938 Group C|Severe (Child-Pugh Class C; 10-15) hepatic impairment
3157567|NCT01497327|Experimental|PSI-7977 Group A|Mild (Child-Pugh Class A; 5-6) hepatic impairment
3157568|NCT01497327|Experimental|PSI-7977 Group B|Moderate (Child-Pugh Class B; 7-9) hepatic impairment
3157569|NCT01497327|Experimental|PSI-7977 Group C|Severe (Child-Pugh Class C; 10-15) hepatic impairment
3157570|NCT01497314|Other|Low Lactose Infant Formula|
3157571|NCT01497301|No Intervention|Standard Individual Medical Appointment|
3157572|NCT01497301|Active Comparator|Group Visits|
3157573|NCT01497288|Experimental|Sequence 1 (A-B-C)|"A: single dose of 200 μg INFS (100 μL) (Instanyl®), administered on Day 1~B: single dose of 400 μg INFS (100 μL), administered 4 hours after the first treatment~C: two single doses of 400 μg INFS (100 μL) (10 min apart), administered 24 hours after the first treatment (Day 2)"
3157574|NCT01497288|Experimental|Sequence 2 (A-C-B)|"A: single dose of 200 μg INFS (100 μL) (Instanyl®), administered on Day 1~C: two single doses of 400 μg INFS (100 μL) (10 min apart), administered 4 hours after the first treatment~B: single dose of 400 μg INFS (100 μL), administered 24 hours after the first treatment (Day 2)"
3157575|NCT01497275|Experimental|Zevalin + Velcade|"Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan~Other Names:~Rituxan Velcade Zevalin~Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4 millicurie (mCi)/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi."
3157576|NCT01497262|Experimental|Fingolimod|Open-label fingolimod 0.5 mg, taken orally once daily for 4 months
3157577|NCT01497249|Placebo Comparator|Placebo|Placebo Beverage
3157578|NCT01497249|Active Comparator|A dietary fiber (FCHO)|15g/BID
3157579|NCT01497236|Experimental|Experimental: Ready to Use Terapeutic Food (RUTF)|
3157580|NCT01497236|Experimental|Multi Micronutrient Powder (MNP)|
3157581|NCT01497236|No Intervention|no supplement|
3157582|NCT01497223|Experimental|MGCD290 and Fluconazole|Oral Administration of MGCD290 and Fluconazole
3157583|NCT01497223|No Intervention|Fluconazole|This is an Active Comparator: Oral Administration of Fluconazole with Placebo
3157584|NCT01497210|Experimental|EASH|
3157628|NCT01496911|Experimental|Levocetirizine (5 mg)|
3157629|NCT01496911|Active Comparator|Hydroxyzine (50 mg)|
3157585|NCT01497197|Experimental|Gonal-f®+Luveris®|GONAL f® 300 international units [IU] per day as subcutaneous injection using liquid pen from stimulation Day 1-5 followed by Luveris® 150 IU per day lyophilized powder for subcutaneous injection from stimulation Day 1 until required recombinant human chorionic gonadotropin (r-hCG) level is met. The dose will be adjusted from stimulation Day 6 (increased or decreased) based upon the subject's ovarian response and according to the center's standard practice.
3157586|NCT01497197|Experimental|Gonal-f® Followed by Luveris®|GONAL-f® 300 IU per day as subcutaneous injection using liquid pen from stimulation Day 1-5 followed by Luveris® 150 IU per day lyophilized powder for subcutaneous injection from stimulation Day 6 until required r-hCG level is met. The dose will be adjusted from stimulation Day 6 (increased or decreased) based upon the subject's ovarian response and according to the center's standard practice.
3157587|NCT01497184|Experimental|DLI (Adults)|Arm 1: Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously (IV) between 6 weeks - 12 weeks following date of allogeneic hematopoietic stem-cell transplantation (HSCT) as a planned DLI.
3157588|NCT01497184|Experimental|DLI any time|Arm 2: DLI will be administered at any point after disease recurrence following HSCT.
3157589|NCT01497184|Experimental|DLI Pediatrics|Arm 3: DLI administered intravenously between 6 weeks and 12 weeks following date of HSCT as a planned DLI in pediatric patients, aged 1-17 years-old.
3157590|NCT01497184|Experimental|DLI - Haplo-Identical Family Donor|Arm 4: DLI administered as planned DLI or after recurrence in adult and pediatric patients undergoing transplant with a haplo-identical family donor.
3157591|NCT01497171|Active Comparator|Elevate Mesh|Elevate transvaginal mesh - surgical repair of prolapse
3157592|NCT01497171|Active Comparator|Anterior Colporrhaphy|Anterior colporrhaphy - surgical repair of prolapse
3157593|NCT01497158|Active Comparator|Control Group|Participants who received only self-help brochure regarding environmental tobacco smoking (ETS) exposure in the home.
3157594|NCT01497158|Active Comparator|Active Group|Participants who received self-help brochure regarding environmental tobacco smoking (ETS) exposure in the home and biomarker feedback from the urine of cohabitating adult non-smoker in the home.
3157595|NCT01497132|Experimental|Vitamin D3|
3157596|NCT01497132|Placebo Comparator|Placebo|
3157597|NCT01497119|Experimental|JNJ-39758979, 300 mg|
3157598|NCT01497119|Experimental|JNJ-39758979, 100 mg|
3157599|NCT01497119|Placebo Comparator|Placebo|
3157600|NCT01497106|Experimental|Calorie restriction|Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks.
3157601|NCT01497106|Active Comparator|Control|Participants will continue their normal living for entire time of the study, totaling 16 weeks.
3157602|NCT01497093|Experimental|Pomalidomide/Bortezomib/Dexamethasone|1, 2, 3 or 4 mg of pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1 or 1.3 mg/m2 of bortezomib administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [> 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
3157603|NCT01497080||1|
3157604|NCT01497080||activity level|
3157605|NCT01497080||no treatment|
3157606|NCT01497028||Plicated Gastric Banding|
3157607|NCT01497028||Standard Gastric Banding|
3157608|NCT01497015|Experimental|memory training|memory training 10 1-hour sessions with interventionist to be delivered over 6-8 weeks
3157609|NCT01497015|Experimental|speed of processing training|Speed of processing training 10 1-hour sessions delivered over 6-8 weeks
3157610|NCT01497015|Experimental|waitlist control|Breast cancer survivors will be randomized to 1 of 3 groups: memory training, speed of process training or waitlist control
3157611|NCT01497002|Active Comparator|standard arm|standard treatment arm
3157612|NCT01497002|Experimental|OSHO - intensified consolidation|
3157613|NCT01497002|Experimental|OSHO - allografting as consolidation|allogeneic stem cell transplantation
3157614|NCT01496989|Experimental|Group 1: HIV-MAG followed by Ad35-GRIN/ENV|HIV-MAG (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo = 12/3)
3157615|NCT01496989|Experimental|Group 2: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo=12/3)
3157616|NCT01496989|Experimental|Group 3: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo= 12/3)
3157617|NCT01496989|Experimental|Group 4: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Month 0 followed by Ad35-GRIN/ENV (IM) at Month 4. (Vaccine:Placebo=12/3)
3157618|NCT01496989|Experimental|Group 5: Ad35-GRIN/ENV followed by HIV-MAG+GENEVAX® IL-12|Ad35-GRIN/ENV (IM) at Month 0 followed by HIV-MAG + GENEVAX® IL-12 (IM/EP) at Month 4. (Vaccine:Placebo=12/3)
3157619|NCT01496976|Experimental|Immunotherapy|Combination Regimen Followed by Consolidative Therapy: Ofatumumab/High Dose Methylprednisolone (HDMP) plus Ofatumumab/Lenalidomide
3157620|NCT01496963||group a)|Patients with pulmonary artery pressure (PAP) assessed (by echocardiogram) <36 mmHg or a tricuspid regurgitant jet velocity (TG) <3 m / sec and data on PAP and mean left ventricular ejection fraction (LVEF) > 50%
3157621|NCT01496963||group b)|"Patients with:~PAP estimated (by echocardiography)> 40 mmHg or TG> 3.2 m / sec and LVEF> 50% As indicated by the Guidelines, patients b) with increased PAP (TG> 3.2 m / sec or> 40 mm Hg) will be further studied using RHC and vasoreactivity testing. Angio CAT, 6MWT and BNP."
3157622|NCT01496963||group c)|patients with PAP estimated (by echocardiography) in the range of values > 3 m / sec (TG) and <3.2 m / sec or> 36 mm Hg and <40 mmHg and LVEF> 50%
3157623|NCT01496950|Active Comparator|Active Comparator: Active rTMS|10Hz active rTMS delivered to the left dorsolateral prefrontal cortex
3157624|NCT01496950|Placebo Comparator|Placebo|10Hz placebo rTMS delivered to the vertex
3157625|NCT01496937|Experimental|GLPG0974 oral solution|GLPG0974 oral solution
3157626|NCT01496937|Placebo Comparator|Placebo oral solution|Placebo oral solution
3157627|NCT01496924|Other|speech therapy group|All dysphagic patients will be submitted to speech therapy
3157633|NCT01496846|Active Comparator|IANB Articaine|IANB Articaine: Inferior alveolar nerve block (IANB) anesthesia with articaine local anesthetic.
3157634|NCT01496846|Active Comparator|SUP Articaine|SUP Articaine: Supplemental buccal anesthesia (SUP) with articaine local anesthetic after unsuccessful IANB.
3157635|NCT01496846|Active Comparator|SUP Lidocaine|SUP Lidocaine: Supplemental buccal anesthesia (SUP) with lidocaine local anesthetic after unsuccessful IANB.
3157636|NCT01496833|Experimental|Endovascular|Total endovascular arch reconstruction
3157637|NCT01496820|Experimental|GO2KA1|
3157638|NCT01496820|Placebo Comparator|Placebo|
3157639|NCT01496807|Experimental|Yervoy with Sylatron|Participants are given Yervoy induction every 3 weeks for four doses, for 12 weeks, and all participants simultaneously receive Sylatron induction weekly, followed by Sylatron maintenance alone for up to 144 additional weeks (total 156 weeks = 3 years).
3157640|NCT01496794||Endophthalmitis cultures|
3157641|NCT01496781|Experimental|EndoClot|This arm is designed to observe if the Endoclot treatment can achieve comparable hemostasis efficacy compared with hemoclip.
3157642|NCT01496781|Active Comparator|Hemoclip|This arm is used as a control treatment group to compare with Endoclot treatment.
3157643|NCT01496768|Experimental|Leucine|
3157644|NCT01496768|Placebo Comparator|Alanine|
3157645|NCT01496755|Placebo Comparator|Placebo|
3157646|NCT01496755|Experimental|RG7667|
3157647|NCT01496742|Experimental|Bevacizumab+MetMAb|
3157648|NCT01496742|Active Comparator|Bevacizumab+Placebo|
3157649|NCT01496742|Experimental|Pemetrexed+MetMAb|
3157650|NCT01496742|Active Comparator|Pemetrexed+Placebo|
3157651|NCT01496729|Active Comparator|Transversus abdominis plane (TAP) block with ropivacaine|A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure
3157652|NCT01496729|Sham Comparator|Sham TAP block with normal saline|A sham TAP block with normal saline will be performed at the end of the surgical procedure.
3157653|NCT01496716||Hip Osteoarthritis|
3157654|NCT01496703||renal transplantation with MMF from day 1|
3157655|NCT01496690|Active Comparator|pregabalin|The pregabalin dose is 75 mg daily the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response.
3157656|NCT01496690|Placebo Comparator|Pregabalin Placebo Capsules|
3157657|NCT01496677|Experimental|Elderly subjects (65 or older)|
3157658|NCT01496677|Experimental|Younger adults (18-45 years old)|
3157659|NCT01496664|Experimental|Result of combined CABG and PCI treatment|The registry is to assess results of combined operative and catheter based (hybrid procedure) treatment of patients with significant coronary artery disease using essential clinical and angiographic parameters.
3157660|NCT01496651|Active Comparator|Percutaneous coronary intervention|Coronary Artery Bypass Grafting Versus Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis
3157661|NCT01496651|Active Comparator|Coronary artery bypass graft operation|Coronary Artery Bypass Grafting Versus Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis
3157662|NCT01496638|Experimental|"No side branch treatment group"|Implantation of coronary stent in bifurcation lesion
3157663|NCT01496638|Experimental|"Stenting of main vessel and side branch group"|Implantation of coronary stent in bifurcation lesion
3157664|NCT01496573||Basic science (biomarker analysis)|Archived tumor tissue samples are analyzed for CRKL expression.
3157665|NCT01496547|Experimental|intensive chemo - RIC preparation|The intensive chemotherapy is composed of Fludarabine 35mg/m2 D1-5, high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
3157666|NCT01496534|Active Comparator|Cisplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts.
3157667|NCT01496534|Active Comparator|Carboplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts.
3157668|NCT01496521|Experimental|Aspirin|
3157669|NCT01496521|Experimental|Tea Polyphenols|
3157670|NCT01496521|No Intervention|Control|
3157671|NCT01496508|Experimental|HFOV|A SLE5000 infant ventilator was used as the high-frequency ventilator.HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg.Extubation was considered when the patient's condition was stable for 12-24h, while adequate oxygenation could be maintained with an FIO2 <0.3 and respiratory rate <25/min.
3157672|NCT01496508|Experimental|CV|A Servo-i-Maquet will be used as the conventional mechanical ventilator. CV settings were: exhaled tidal volumes set at 5-6 mL/kg, initial peak inspiratory pressure (PIP) of 15-25 cmH2O; positive expiratory end pressure (PEEP) set to 4-6 cmH2O; inspiratory times of 0.25-0.40s; rates set to <60/min. The weaning process was initiated when the following parameters were achieved: PIP <18 cmH2O, PEEP <4 cmH2O, and FIO2 <0.4. Extubation was considered when the patient's condition was stable for 12-24h, while adequate oxygenation could be maintained with an FIO2 <0.3 and respiratory rate <25/min. All infants extubated onto nasal continuous positive airway pressure (Infant Flow, Electro Medical Equipment) and then weaned to a nasal cannula, and then to room air.
3157673|NCT01496495|Experimental|ARRY-614|
3157674|NCT01496482||Patients without dry eye symptoms|Patients without dry eye symptoms as measured by standard questionnaire.
3157675|NCT01496482||Patients with dry eye symptoms|Patients with dry eye symptoms as measured by standard questionnaire.
3157676|NCT01496469|Experimental|Febuxostat 80 mg QD|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks.
3157677|NCT01496469|Placebo Comparator|Placebo QD|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
3157678|NCT01496456|Placebo Comparator|Preventative measures|Caries management by preventative measures of oral hygiene instruction, diet counseling and fluoride supplementation
3157679|NCT01496456|Active Comparator|Lesion infiltration|Resin infiltration of caries lesion in addition to caries management by preventative measures of oral hygiene instruction, diet counseling and fluoride supplementation
3157680|NCT01496443|Experimental|TAK-875 & Glimepiride QD|TAK-875 50 mg, tablets, orally and glimepiride 2 mg, capsules, orally and glimepiride placebo matching capsules, orally, once daily on dosing days for up to 19 days.
3157681|NCT01496430|Placebo Comparator|Placebo QD|Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.
3157682|NCT01496430|Experimental|Azilsartan Medoxomil 40 mg QD|Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.
3157683|NCT01496430|Experimental|Azilsartan Medoxomil 80 mg QD|Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.
3157684|NCT01496417|Experimental|Belatacept therapy|20 Patients receiving belatacept based immunosuppressive protocol for 12 months post-transplantation.
3157685|NCT01496404|Experimental|Electrocautery|Epidermis and dermis incised with cutting setting of electrocautery.
3157686|NCT01496404|Active Comparator|Scalpel|Control, incision of epidermis and dermis with scalpel.
3157687|NCT01496391||Healthy Participants|eGFR ≥60 ml/min/1.73m^2, healthy prospective kidney donor
3157688|NCT01496391||Moderate Renal Function Impairment|eGFR 30-59 ml/minute/1.73m^2
3157689|NCT01496391||Severe Renal Function Impairment|eGFR <30 mL/minute/1.73m^2
3157690|NCT01496378|Experimental|Problem-Solving Skills Training|In addition to standard medical care, parents in the problem-solving skills training group will receive 8 sessions (1 hour each) of individual problem-solving therapy over 8 weeks. Caregivers will be asked to complete the first training session and at least 3 subsequent sessions in person at their local treatment facility (Seattle Children's Hospital or Oregon Health and Science University). Remaining sessions will be completed via telephone.
3157691|NCT01496378|No Intervention|Standard Care|Parents and children in the Standard Care group will continue with the care that has been prescribed for their child's pain problem by their treating physician, which may include medications, physical therapy, and mental health intervention.
3157692|NCT01496365|Experimental|DS-5565 5mg nighttime|DS-5565 5 mg/day (one 5 mg tablet at bedtime)
3157693|NCT01496365|Experimental|DS-5565 10 mg at bedtime|DS-5565 10 mg/day (one 10 mg tablet at bedtime)
3157694|NCT01496365|Experimental|DS-5565 15 mg at bedtime|DS-5565 15 mg/day (one 5 mg tablet plus one 10 mg tablet at bedtime)
3157695|NCT01496365|Experimental|DS-5565 20 mg total per day|DS-5565 20 mg/day (one 10 mg tablet in the morning and one 10 mg tablet at bedtime)
3157696|NCT01496365|Experimental|DS-5565 30 mg total per day|DS-5565 30 mg/day (one 5 mg tablet plus one 10 mg tablet in the morning and one 5 mg tablet plus one 10 mg tablet at bedtime)
3157697|NCT01496365|Active Comparator|Pregabalin 300 mg total per day|Pregabalin 300 mg/day (two 150 mg capsules, in the morning and at bedtime)
3157698|NCT01496352|Experimental|DFA-02|Progressive cohorts of 10 subjects (8 active, 2 placebo) receiving 10, 20 , 30 or 40 mL of DFA-02 or matching placebo.
3157699|NCT01496352|Placebo Comparator|DFA-02 placebo|
3157700|NCT01496339|Active Comparator|Traditional therapy control|
3157701|NCT01496339|Experimental|Stem cell infusion|
3157702|NCT01496326|Experimental|Ibuprofen|
3157703|NCT01496326|Placebo Comparator|Placebo|
3157704|NCT01496313|Active Comparator|300mg vandetanib|
3157705|NCT01496313|Active Comparator|150mg vandetanib|
3157706|NCT01496300|Sham Comparator|Manual|Manual Implantation of THA
3157707|NCT01496300|Experimental|Navigated|Navigated Implantation of THA
3157708|NCT01496287|Experimental|Tube placement group|
3157709|NCT01496274|Experimental|Prophylaxis|"Routine weekly prophylaxis and episodic treatment for bleeding episodes. An individualized dosing interval may be tested in sub-group subjects during the 2nd part of the trial.~Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention."
3157710|NCT01496274|Experimental|On-demand|Episodic treatment for bleeding episodes during the first 6 months then switch to routine weekly prophylaxis for a further 6 months Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention.
3157711|NCT01496261|Active Comparator|Clopidogrel and Aspirin|
3157712|NCT01496261|Experimental|Coprigerl|
3157713|NCT01496248|Experimental|Korean Red Ginseng|Extract of Korean red ginseng was administrated to subjects through capsule form.
3157714|NCT01496235|Active Comparator|Dark chocolate|Presence of 70% cocoa solids
3157715|NCT01496235|Placebo Comparator|White chocolate|
3157716|NCT01496209|Sham Comparator|Placebo control|
3157717|NCT01496209|Experimental|Group: Cardiosphere Treatment|Biological: Allogeneic Human Cardiospheres (allogeneic CSps or alloCSps), a 3D micro-tissue heart-derived cell therapy product. Subjects will receive 150 million cell-equivalents of alloCSps via endomyocardial injection (10 million per site at 15 peri-infarct sites)
3157718|NCT01496196|Active Comparator|tranexamic acid-500 mg/5 ml 3-4 times a day|tranexamic acid arm: inhalations of tranexamic acid 500 mg/5 ml 3-4 times a day
3157719|NCT01496196|Placebo Comparator|tranexamic|placebo arm
3157720|NCT01496183|Placebo Comparator|Placebo|
3157721|NCT01496183|Experimental|Olanzapine|
3157722|NCT01496170|Experimental|Treatment A: MK-8931 12 mg|Participants receiving 12 mg MK-8931 for 7 days
3157723|NCT01496170|Experimental|Treatment B: MK-8931 40 mg|Participants receiving MK-8931 40 mg for 7 days
3157724|NCT01496170|Placebo Comparator|Treatment C: Placebo matching MK-8931 12 mg or 40 mg|Participants receiving placebo matching MK-8931 12 mg or 40 mg for 7 days
3157725|NCT01496170|Experimental|Treatment D: MK-8931 60 mg|Participant receiving MK-8931 60 mg for 7 days
3157726|NCT01496170|Placebo Comparator|Treatment E: Placebo matching MK-8931 60 mg|Participants receiving placebo matching MK-8931 60 mg for 7 days
3157727|NCT01496157|Experimental|Patients with Primary Prostate Cancer|Patients will be imaged with 18F-DCFBC
3157728|NCT01496144|Experimental|Manual therapy and active exercises|Spinal manipulation /mobilisation
3157729|NCT01496144|Placebo Comparator|Detuned ultrasound and active exercises|
3157730|NCT01496131|Active Comparator|Standard therapy|Radiation therapy in combination with androgen deprivation therapy (ADT).
3157731|NCT01496131|Experimental|Standard therapy plus tecemotide (L-BLP25)|Standard therapy (radiation therapy in combination with ADT) plus tecemotide (L-BLP25).
3157732|NCT01496118|Experimental|Carfilzomib and Panobinostat|
3157733|NCT01496105|Active Comparator|lidocaine spray 10%|
3157734|NCT01496105|Placebo Comparator|Saline|
3157735|NCT01496092|Experimental|Keto Acid supplemented with usual protein diet|
3157736|NCT01496092|No Intervention|usual protein diet|
3157737|NCT01496079||Inactivated influenza vaccine in pregnancy|Healthy pregnant women who elect to receive inactivated influenza vaccine in early pregnancy (< 20 weeks gestation) and their infants
3157738|NCT01496079||No inactivated influenza vaccine during pregnancy|Healthy pregnant women who decline inactivated influenza vaccine in pregnancy and their infants
3157739|NCT01496066|Experimental|LAL|LAL implanted
3157740|NCT01496066|Active Comparator|Monofocal control|Monofocal control IOL implanted
3157741|NCT01496053|Active Comparator|AndoSan|AndoSan given to IBD patients
3157742|NCT01496053|Sham Comparator|Sugar extract|Sugar extract to IBD patients
3157743|NCT01496040|Experimental|rAAV2/4.hRPE65|"3 cohortes of 3 patients each.~All the patients enrolled in the study will receive a single subretinal injection in one eye. The eye, that will be injected, will be the eye with the poorest visual acuity."
3157744|NCT01496027||term newborns|
3157745|NCT01496027||Preterm Newborns (32-37 GA)|
3157746|NCT01496014||severe open fractures of the tibia bone|
3157747|NCT01496001|Experimental|Cohort|
3157748|NCT01495988|Active Comparator|Vemurafenib/Cobimetinib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients. Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle. Patients will be assessed for toxicity every 4 weeks and be restaged for tumor response/progression every 8 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
3157749|NCT01495988|Experimental|Vemurafenib/Cobimetinib + Bevacizumab|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients. Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle. Bevacizumab will be administered at the MTD (determined by phase Ib safety lead-in), intravenously, every 2 weeks. Patients will be assessed for toxicity every 4 weeks and be restaged for tumor response/progression every 8 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
3157750|NCT01495988|Active Comparator|Vemurafenib|Vemurafenib will be given at a dose of 960 mg p.o. BID to all patients. Patients will be assessed for toxicity every 3 or 6 weeks (depending on the specific toxicity) and be restaged for tumor response/progression every 6 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
3157751|NCT01495988|Experimental|Vemurafenib + Bevacizumab|Vemurafenib will be given at a dose of 960 mg p.o. BID to all patients. Patients assigned to the combination arm will also receive bevacizumab 15 mg/kg every IV every 3 weeks. Patients will be assessed for toxicity every 3 or 6 weeks (depending on the specific toxicity) and be restaged for tumor response/progression every 6 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
3157752|NCT01495975|No Intervention|Usual Care|Usual care for diabetes in the 1 month after discharge.
3157753|NCT01495975|Experimental|Diabetes Transitions Tool Kit|Remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), in the 1 month after discharge.
3157754|NCT01495962|Active Comparator|Botulinum Toxin A injection|
3157755|NCT01495962|Placebo Comparator|Placebo (Normal Saline) injection|
3157756|NCT01495949|Active Comparator|etomidate|
3157757|NCT01495949|Active Comparator|thiopentone|
3157758|NCT01495936|Active Comparator|Continuous Positive Airway Pressure|"After 20 minutes ventilation on one lung (during anesthesia) the patient will be randomly assigned to the study arm Continuous Positive Airway Pressure (CPAP). CPAP will be applied for 20 minutes to the non-ventilated lung at a pressure of 5cmH20 using the disposable Mallinckrodt Bronchocath CPAP system."
3157759|NCT01495936|Active Comparator|RM + Positive End Expiratory Pressure|"After 20 minutes of ventilation on one lung (during anesthesia) the patient will be randomly assigned to the study arm RM + Positive End Expiratory pressure which is a Recruitment Maneuver (RM) followed by Positive End Expiratory Pressure (RM-PEEP) which will be applied to the ventilating lung at a pressure of 5cmH2O."
3157760|NCT01495923|Experimental|Epidural steroids|Injection of steroids into the epidural space
3157761|NCT01495923|Active Comparator|Gabapentin|Titration of gabapentin to effect
3157762|NCT01495910|Experimental|Abiraterone acetate|Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
3157763|NCT01495897|Other|Healthy|Healthy volunteers
3157764|NCT01495897|Experimental|Dystonia|patients with Primary Dystonia
3157765|NCT01495897|Experimental|Parkinson|patients with Parkinson's disease
3157766|NCT01495897|Experimental|Essential tremor|patients with essential tremor with or without deep brain stimulation
3157767|NCT01495884|Experimental|Lapatinib (Tyverb™) and (Myocet™)|
3157768|NCT01495871|Active Comparator|Amino acids|Amino acid supplementation for 6 weeks
3157769|NCT01495871|Placebo Comparator|Placebo|Supplementation of placebo (inert components)for 6 weeks
3157770|NCT01495871|Active Comparator|Valine|Valine supplementation for 6 weeks
3157771|NCT01495858|Experimental|Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|
3157772|NCT01495858|Active Comparator|Naproxen Sodium 440 mg (BAYH6689)|
3157773|NCT01495858|Active Comparator|DPH 50 mg|
3157774|NCT01495832|Experimental|Pulse Group|The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
3157775|NCT01495832|Active Comparator|Control Group|The control group will consume comparator foods for 12 weeks.
3157827|NCT01495429|Active Comparator|CICVC (central insertion)|placement of a centrally inserted central venous catheter
3157828|NCT01495403|Experimental|hydroxychloroquine|
3157829|NCT01495377|Active Comparator|Remifentanil|
3157830|NCT01495377|Placebo Comparator|Placebo|
3157776|NCT01495819|Active Comparator|Nicotine|subjects will be randomly assigned to one of the five doses of nicotine (0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg). At the beginning of each experimental session, subjects will first sample the assigned nicotine dose and placebo (saline) condition that are randomly labeled as A or B. which may be nicotine or saline. This procedure will allow subjects to sample the nicotine and saline that will be available during that session. In addition, subjective and physiological responses to the sample nicotine dose and saline will be assessed.
3157777|NCT01495819|Placebo Comparator|Saline|Subjects will have sample A and B, one being nicotine and one being saline. The doses will be blinded from PI, subject and staff. The subject must choose A or B for the next ten choices.
3157778|NCT01495806|Experimental|Glucomannan|5 g 2x 10 day
3157779|NCT01495806|Placebo Comparator|Placebo|
3157780|NCT01495793|Experimental|Rotigotine|In the Titration Period a subject received the first dose of rotigotine then the dose was increased weekly by a dose step over 4 weeks.
3157781|NCT01495780|Experimental|Remote Health Monitoring|Subjects assigned to this arm will conduct daily at-home health monitoring using several electronic devices that will transmit data back to the study team. Everyday, subjects will measure pulse oximetry (SpO2) using a finger clip, answer questions about symptoms and medication use, answer a quality of life questionnaire, perform breathing tests, and record physical activity (using a physical activity monitor that will be mailed to the study team). Wearing the activity monitor is optional and will only occur during months 1, 6, and 12.
3157782|NCT01495767||females, males|females: patients of female sex males: patients of male sex
3157783|NCT01495754|Experimental|coffee3|
3157784|NCT01495754|Experimental|coffee6|
3157785|NCT01495754|Placebo Comparator|water|
3157786|NCT01495741||Asenapine|Participants prescribed asenapine
3157787|NCT01495741||Risperidone Comparator|Participants prescribed risperidone
3157788|NCT01495741||Olanzapine Comparator|Participants prescribed olanzapine
3157789|NCT01495728|Experimental|Thrust Manipulation -Thoracic Spine|Mid and Upper Thoracic Spine
3157790|NCT01495728|Placebo Comparator|Sham Manipulation|Mid and Upper Thoracic Spine
3157791|NCT01495715|Experimental|Idebenone|
3157792|NCT01495715|Placebo Comparator|Placebo|
3157793|NCT01495702|Experimental|Stribild|Participants will switch from their baseline treatment regimen to Stribild for up to 96 weeks, and may continue to receive Stribild in the extension phase.
3157794|NCT01495702|Active Comparator|NNRTI+FTC/TDF|Participants will stay on their baseline treatment regimen antiretroviral regimen consisting of an NNRTI plus FTC/TDF for up to 96 weeks, and may switch to Stribild in the extension phase.
3157795|NCT01495689|Active Comparator|Usual Care|Usual care for smoking cessation will be delivered to the control arm which comprises of strong physician advice, brief counseling from the clinic nurse +/- a prescription for smoking cessation aid if requested and willing
3157796|NCT01495689|Experimental|Ottawa Model with SmartCard|On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
3157797|NCT01495676|Active Comparator|Radiotherapy + cisplatin|
3157798|NCT01495676|Experimental|Radiotherapy + cisplatin + gemcitabine|
3157799|NCT01495663|Other|Single Group|I-131-CLR1404
3157800|NCT01495650|Experimental|Intervention arm|
3157801|NCT01495650|No Intervention|Control arm|Routine practice
3157802|NCT01495637|Experimental|GM-CSF|GM-CSF is given in one of four treatment regimens (three days at a dose of 30, 62, or 125 mcg/m2/day, or extended dosing at 125 mcg/m2 through post-trauma day 6) to critically injured children who demonstrate severe reduction in innate immune function on post-trauma day 1, 2, or 3.
3157803|NCT01495624|Placebo Comparator|Ropivacaine with perineural dexamethasone|30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
3157804|NCT01495624|Active Comparator|Ropivacaine with systemic steroid|30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
3157805|NCT01495598|Experimental|1/Phase 1|Up to six subjects will initially be treated with pomalidomide 5mg daily for 21 days of a 28 day cycle
3157806|NCT01495598|Experimental|2/ Phase 2|15 HIV positive and 10 HIV negative subjects evaluable for response will be treated with Pomalidomide 5mgdaily for 21 days of a 28 day cycle
3157807|NCT01495585|Placebo Comparator|Placebo|Placebo control
3157808|NCT01495585|Experimental|Group 1|lonafarnib 100mg
3157809|NCT01495585|Experimental|Group 2|lonafarnib 200mg
3157810|NCT01495572|Experimental|High Dose (HD) Aldesleukin|Pts receiving high dose aldesleukin: Cyclophosphamide 60 mg/kg intravenous (IV) for days -7 and -6, Fludarabine 25 mg/m^2 IV for days -5 to -1, plus melanoma antigen recognized by T cells (MART)-127-35 reactive CD8+ peripheral blood lymphocytes (PBL) up to 3x10^11 IV over 20-30 minutes on day 0, plus aldesleukin 720,000 IU/kg IV over 15 minutes, every 8 hrs for up to 5 days.
3157811|NCT01495572|Experimental|Peripheral Blood Lymphocytes (PBL)|Cyclophosphamide 60 mg/kg intravenous (IV ) for days -7 and -6, Fludarabine 25 mg/m^2 IV for days -5 to -1, plus MART-127-35 reactive CD8+ PBL up to 3x10^11 IV over 20-30 minutes on day 0
3157812|NCT01495546|Experimental|Early loading|
3157813|NCT01495546|Active Comparator|late loading|
3157814|NCT01495533|Placebo Comparator|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
3157815|NCT01495533|Active Comparator|drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
3157816|NCT01495520|Active Comparator|Ranolazine|Patients will receive ranolazine 750 mg bid for 30 days
3157817|NCT01495520|Placebo Comparator|Placebo|Patients will receive placebo for 30 days
3157818|NCT01495507||Patellofemoral Instability|Patients with diagnosis of patellofemoral instability receiving MPFL-reconstruction as part of the clinical routine
3157819|NCT01495494|Active Comparator|Marketed nasal strip|Marketed nasal strip
3157820|NCT01495494|Experimental|Prototype nasal dilator|Prototype nasal dilator
3157821|NCT01495481|Experimental|Adenosine and Dexmedetomidine|Patients will receive adenosine and then dexmedetomidine for the termination of SVT
3157833|NCT01495364|Experimental|NBS10|active treatment - CD34+ cells
3157834|NCT01495364|Placebo Comparator|placebo|matching placebo
3157835|NCT01495351|Experimental|ABT-888/Bortezomib|Patients will be on a treatment schedule including twice daily oral dosing for 14 days followed by 1 week rest in combination with standard dosing of Bortezomib and Dexamethasone in a 21 days cycle for a total of 14 cycles.
3157836|NCT01495338|Experimental|AC-170 0.17%|
3157837|NCT01495338|Experimental|AC-170 0.24% (Formulation 1)|
3157838|NCT01495338|Experimental|AC-170 0.24% (Formulation 2)|
3157839|NCT01495338|Placebo Comparator|Olopatadine hydrochloride 0.2%/Tears Naturale II|
3157840|NCT01495325|Sham Comparator|Filtered Air Exposure|1 hour exposure to filtered air during intermittent exercise
3157841|NCT01495325|Active Comparator|Woodsmoke Exposure|1 hour exposure to dilute woodsmoke at a concentration of 1000µg/m3 during intermittent exercise
3157842|NCT01495312|Experimental|SLT|
3157843|NCT01495299||cataract patients with glaucoma|
3157844|NCT01495273|Experimental|Nerve stimulator|Experimental group; will undergo transtracheal injection with needle connected to nerve stimulator.
3157845|NCT01495273|Active Comparator|Standard needle/syringe|Control group; will undergo transtracheal injection with standard needle/syringe assembly.
3157846|NCT01495260|Experimental|N-acetylcysteine, lipoic acid and vitamin E|Two Dose titration design
3157847|NCT01495247|Experimental|BEZ235 + paclitaxel (phase lb)|Increasing doses of oral BEZ235 administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment will be organized into cycles of 28 days.
3157848|NCT01495234|Experimental|Cohort 1|Each patient will receive 15mg of rhBMP-2 in rhBMP-2/BCP device and implant unilaterally during a posterolateral spinal fusion procedure. The contralateral side was fused using standard fusion techniques with autograft bone.
3157849|NCT01495234|Experimental|Cohort 2|Each patient will receive 20mg of rhBMP-2 in rhBMP-2/BCP device and implant bilaterally.
3157850|NCT01495221|Other|Intravitreal aflibercept|All eligible patients will receive intravitreal aflibercept injection (2.0mg) every 4 weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every 8 weeks (2 months) through Week 24. Patients can be dosed as frequently as 2 mg every 4 weeks (monthly) upon investigator discretion.
3157851|NCT01495208|Experimental|aflibercept|
3157852|NCT01495195|Experimental|Donepezil, high-dose|Titration of donepezil to 22.5 mg daily
3157853|NCT01495195|Experimental|Selegiline & low-dose donepezil|Low-Dose Donepezil [titrated to 10 mg daily] and transdermal selegiline [6 mg daily]
3157854|NCT01495195|Experimental|Selegiline & high-dose donepezil|High-Dose Donepezil [titrated to 22.5 mg daily] and transdermal selegiline [6 mg daily]
3157855|NCT01495195|Placebo Comparator|Sugar pill|Inert pill for comparison
3157856|NCT01495182|Experimental|Dietary Fiber - Dose 1|Dietary fiber will be added to study foods
3157857|NCT01495182|Experimental|Dietary Fiber - Dose 2|Dietary fiber will be added to study foods
3157858|NCT01495182|Active Comparator|Control|Study foods with no added fiber will be given
3157859|NCT01495169|Experimental|Iloperidone|Part A (dose-escalation and fixed dose): Eligible patients receive iloperidone 2mg/day (1 mg BID) on day 1, then escalated every day for up to 12days utilizing a forced titration regimen to achieve a maximum dose of 12, 16, 20 or 24 mg/day given BID. Part B (optional extension phase): Patients who successfully complete Part A of the study are eligible to continue treatment with iloperidone for an additional 26 weeks
3157860|NCT01495156|Experimental|Lithium/Adjunctive SGA|
3157861|NCT01495156|Placebo Comparator|Placebo/Adjunctive SGA|
3157862|NCT01495143|Active Comparator|Healthy group|Eight healthy volunteers (five males and three females) with a body mass index of 23.8 and without chronic metabolic disease or low back pain. They are all non-smokers and non-medicated.
3157863|NCT01495143|Experimental|Surgery group|"Two MD catheters is placed in the paraspinal muscle at the level of midpoint of incision bilaterally.~A reference catheter is placed in the deltoid muscle."
3157864|NCT01495130|Experimental|Diagnostic (TRUS)|Patients undergo TRUS during RALP.
3157865|NCT01495117|Active Comparator|Povidone Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
3157866|NCT01495117|Active Comparator|Chlorhexidine Gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
3157867|NCT01495104|Experimental|Single Arm|
3157868|NCT01495078|Experimental|Telemonitoring|Patients with follow-up telemonitoring
3157869|NCT01495078|No Intervention|Non - telemonitoring|Patients with usual face follow-up
3157870|NCT01495065|Experimental|Part A|Japanese subjects in cohort 1 and 2 will receive treatments A, B and C. Caucasian subjects in cohort 3 will receive treatment B and C.
3157871|NCT01495065|Experimental|Part B|Subjects in cohort 4 and 5 will receive repeat doses of IV GSK2251052 for 10 days.
3157872|NCT01495052|No Intervention|Usual care group|The usual care group was used as control group and didn't receive any intervention except standard health advice at the beginning and the end of the study.
3157873|NCT01495052|No Intervention|diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention.
3157874|NCT01495052|Experimental|50g-ONOG plus diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention. Participants in the 50g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g ONOG.
3157875|NCT01495052|Experimental|100g-ONOG plus diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention. Participants in the 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 100g ONOG.
3157876|NCT01495039|Active Comparator|Nystatin|surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.Patients were allocated to receive systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
3157877|NCT01495039|Placebo Comparator|Control|surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.
3157878|NCT01495026|Experimental|Fixed dose combination product|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg
3157879|NCT01495026|Experimental|Dutasteride|Commercial formulation of Dutasteride 0.5mg
3157880|NCT01495026|Experimental|Harnal-D Tablets|Commercial formulation of Harna--D Tablets comprising 0.2mg Tamsulosin Hydrochloride
3157881|NCT01495013|Active Comparator|Glimepiride Atorvastatin fixed dose combination|All subjects will start on 1mg glimepiride/10 mg atorvastatin fixed dose combination (FDC) and either treatment can be titrated up based on fasting glucose or LDL levels. The following glimepiride/atorvastations FDCs will be available for use 1mg/10mg, 2mg/10mg, 3mg/10mg, 4mg/10mg, 1mg/20mg, 2mg/20mg, 3mg/20mg, 4mg/20mg.
3157882|NCT01495013|Active Comparator|Glimepiride +Atrovastatin loose combination|All subjects will start on 1mg glimepiride/10 mg atorvastatin loose combination (given as separate tablets) and either treatment can be titrated up based on fasting glucose or LDL levels. Glimepiride single dose tablets are available for 1mg, 2mg, 3mg and 4mg. Atorvastatin single dose tablets are available for 10mg and 20mg.
3157883|NCT01495000|Experimental|Arm 1|denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind treatment
3157884|NCT01495000|Placebo Comparator|Arm 2|placebo subcutaneous injection, single dose at the start of the 6-month double-blind treatment
3157885|NCT01494987|Experimental|Ranolazine+glimepiride|"Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride will receive glimepiride 2 mg once daily, and if tolerated the dose will be increased on Day 8 (+ 2 days) to 4 mg once daily.~Qualifying period: participants will receive placebo to match ranolazine twice daily in addition to glimepiride for 14 days (+ 2 days) and if ≥ 80% compliant and meeting eligibility criteria will continue to the treatment period.~Treatment period: participants will be randomized to receive ranolazine 500 mg twice daily plus glimepiride 4 mg once daily on Days 1 through 7, followed by ranolazine 1000 mg twice daily plus glimepiride 4 mg once daily from Day 8 (or by Day 16 if not well tolerated) through Week 24.~Participants will be required to maintain their diet and exercise regimen."
3157886|NCT01494987|Placebo Comparator|Placebo+glimepiride|"Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride will receive glimepiride 2 mg once daily, and if tolerated the dose will be increased on Day 8 (+ 2 days) to 4 mg once daily.~Qualifying period: participants will receive placebo to match ranolazine twice daily in addition to glimepiride for 14 days (+ 2 days) and if ≥ 80% compliant and meeting eligibility criteria will continue to the treatment period.~Treatment period: participants will be randomized to receive placebo to match ranolazine plus glimepiride 4 mg once daily for 24 weeks.~Participants will be required to maintain their diet and exercise regimen."
3157887|NCT01494974|Active Comparator|FP7 implant|
3157888|NCT01494974|Active Comparator|FP8 implant|
3157889|NCT01494961|Experimental|Couple-oriented post-test HIV counseling|Women received couple-oriented post-test HIV counseling
3157890|NCT01494961|No Intervention|Standard post-test HIV counseling|Women received post-test HIV counseling as per standard site protocol
3157891|NCT01494948|Placebo Comparator|placebo|skin test negative
3157892|NCT01494948|Active Comparator|allergic|Skin test positive
3157893|NCT01494935|Experimental|Normal glycemic diet|COntrol diet with fat and glycemic index similar to typical American diet.
3157894|NCT01494935|Experimental|High-fat, high-glycemic diet|High-fat, high-glycemic diet
3157895|NCT01494922|Experimental|Open Label|
3157896|NCT01494909|Experimental|Ensure plus|Ensure sip feeds during 6 hours. After 2 hours pancreatic intake
3157897|NCT01494883|No Intervention|Treatment as usual|
3157898|NCT01494883|Experimental|Mindfulnes Based Stress Reduction|A weekly training of eight session lasting two and a half hours.
3157899|NCT01494857|Experimental|Adalimumab|Adalimumab 40 mg
3157900|NCT01494844|Other|Device interface comfort assessment|Single group rates one noninvasive respiratory monitoring interface and then another.
3157901|NCT01494831|Experimental|TF-CBT|
3157902|NCT01494831|No Intervention|Waiting List control|
3157903|NCT01494818|Experimental|CLEAR CARE/AOSEPT Plus|Hydrogen peroxide-based contact lens care system used per manufacturer's instructions
3157904|NCT01494818|Active Comparator|ReNu MultiPlus|PHMB-containing contact lens solution used per manufacturer's instructions
3157905|NCT01494805|Experimental|Low Dose rAAV.sFlt-1|
3157906|NCT01494805|Experimental|High Dose rAAV.sFlt-1|
3157907|NCT01494805|Active Comparator|Control - ranibizumab only|
3157908|NCT01494779|Experimental|Somatropin Test|Somatropin of Blausiegel Indústria e Comércio Ltda.
3157909|NCT01494779|Active Comparator|Saizen|Somatropin of Merck Serono
3157910|NCT01494766|Other|Tyrosine|"Dietary Supplement: L-Tyrosine~Other Names:~NOW Brand L-Tyrosine 750 mg Tablets~-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study."
3157911|NCT01494753|Active Comparator|Prostaglandin|One drop.
3157912|NCT01494753|Experimental|T2345|One drop
3157913|NCT01494740|Experimental|split-virion, non-adjuvanted vaccine of 7.5 μg|split-virion, non-adjuvanted H1N1 vaccine of 7.5 μg.
3157914|NCT01494740|Experimental|split-virion, non-adjuvanted vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
3157915|NCT01494740|Placebo Comparator|split-virion, non-adjuvanted vaccine of seasonal influenza|split-virion, non-adjuvanted H1N1 vaccine of seasonal influenza.
3157916|NCT01494727|Experimental|CJ Amlodipine/Valsartan 10/160mg|
3157917|NCT01494727|Active Comparator|Novartis Exforge 10/160mg|
3157918|NCT01494714|Experimental|Closed-patch test|
3157919|NCT01494701|Experimental|Cohort 1 (n=6)|
3157920|NCT01494701|Experimental|Cohort 2 (n=6)|
3157921|NCT01494701|Experimental|Cohort 3 (n=6)|
3157922|NCT01494701|Experimental|Cohort 4 (n=10)|
3157923|NCT01494688|Experimental|Part 1 - Dose Escalation: RO5509554|Participants will receive a single, low dose of 100 milligrams (mg) RO5509554 in 7-day PK run-in period (Cycle 0), followed by dose escalation from Day 1 of Cycle 1. RO5509554 will be escalated as monotherapy in approximately 6 cohorts with dose increments between cohorts of up to 100 percent (%). The doses will be escalated further until MTD/OBD as single agent is reached.
3157961|NCT01494480|Experimental|stem cell transplantation|After stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
3157924|NCT01494688|Experimental|Part 1 - Dose Escalation: RO5509554 + Paclitaxel|RO5509554 will be administered in combination with a fixed dose of weekly (QW) paclitaxel (80 milligrams per square meter [mg/m^2]). The starting dose for RO5509554 in combination with paclitaxel will be 2 dose levels below to that of the highest dose of monotherapy RO5509554. Escalation of RO5509554 in combination with QW paclitaxel will start in a standard 3 + 3 design until MTD/OBD as combination dose is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of paclitaxel and lower dose of RO5509554. If insufficient safety, pharmacokinetic or pharmacodynamic data have been collected at the MTD/OBD, up to an additional 4 participants may be enrolled at that dose level.
3157925|NCT01494688|Experimental|Part 2 - Expansion Cohort: RO5509554|Participants will receive RO5509554 1000 mg Q2W, Q3W or initial biweekly followed by monthly maintenance.
3157926|NCT01494688|Experimental|Part 2 - Expansion Cohort: RO5509554 + Paclitaxel|Participants will receive RO5509554 1000 mg Q2W in combination with a fixed dose of QW paclitaxel (80 mg/m^2).
3157927|NCT01494662|Active Comparator|Cohort 1|"Patients With Progressive Brain Metastases~Intervention: HKI-272 (Neratinib)340 mg orally, once daily."
3157928|NCT01494662|Active Comparator|Cohort 2|"Patients Who Are Candidates For Craniotomy.~Intervention: HKI-272 (Neratinib) 240 mg orally, once daily.~Surgical resection (biopsy).~Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib."
3157929|NCT01494662|Active Comparator|Cohort 3a/3b|"Cohort 3a will be made up of participants with No Prior Lapatinib Treatment. They will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest.~Cohort 3b will be made of of participants with Prior Lapatinib Treatment. Cohort 3b participants will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest."
3157930|NCT01494649|Active Comparator|Toothpaste containing 0.454% stannous fluoride|USA marketed toothpaste [test]
3157931|NCT01494649|Other|Toothpaste containing 0.76% sodium monofluorophosphate|USA marketed toothpaste [negative control]
3157932|NCT01494636|Experimental|GSK2339345 (solution) (part A)|Part A
3157933|NCT01494636|Experimental|GSK2339345/ Placebo/ Lidocaine (nebulised) (part B)|Part B
3157934|NCT01494623|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 90% of the RMT. Stimulation will be delivered at either 20 Hz or 10 Hz, depending on the patients' tolerance to the stimulation, with 50 stimulation trains of 30 stimuli each (i.e., 1500 stimuli) and an intertrain interval of 30 sec. 25 trains will be applied to to the left or right hemisphere followed by the other hemisphere.
3157935|NCT01494623|Sham Comparator|Sham rTMS|Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
3157936|NCT01494610|Experimental|SERETIDE Rotacaps|Fluticasone propionate (250 micrograms [ug])/Salmeterol (50 ug) combination delivered in a capsule-based inhaler
3157937|NCT01494610|Active Comparator|SERETIDE Diskus|Fluticasone propionate (250 ug)/Salmeterol (50 ug) combination delivered in a multi-dose dry powder inhaler
3157938|NCT01494610|Placebo Comparator|Placebo Rotacaps|Placebo delivered in a capsule-based inhaler
3157939|NCT01494610|Placebo Comparator|Placebo Diskus|Placebo delivered in a multi-dose dry powder inhaler
3157940|NCT01494597|Experimental|Isavuconazole and cyclosporine|Isavuconazole three times per day (TID) for two days followed by once a day (QD) for 6 days. Cyclosporine single doses on Days 1 and 15.
3157941|NCT01494584|Experimental|ezogabine/retigabine|ezogabine dose escalation
3157942|NCT01494571||90 pediatric, 7 to 14 year old subjects|
3157943|NCT01494571||30 pediatric, 5 to 6 year old subjects|
3157944|NCT01494571||30 pediatric, 3 to 4 year old subjects|
3157945|NCT01494571||30 pediatric, 1 to 2 year old subjects|
3157946|NCT01494571||30 pediatric, 6 to 12 month old subjects|
3157947|NCT01494571||30 pediatric, 4 to 6 month old subjects|
3157948|NCT01494571||30 pediatric, 2 to 4 month old subjects|
3157949|NCT01494558|Active Comparator|PE concurrent chemotherapy|Radiotherapy concurrently with PE chemotherapy
3157950|NCT01494558|Active Comparator|PC concurrent chemotherapy|Radiotherapy concurrently with PC chemotherapy
3157951|NCT01494545|Experimental|Delefilcon A|Delefilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for two weeks. A new pair was inserted each day.
3157952|NCT01494532|Experimental|ropinirole|active treatment 4, 8, 12, 16, or 24mg/day
3157953|NCT01494532|Placebo Comparator|placebo|placebo comparator 4, 8, 12, 16, or 24mg/day
3157954|NCT01494519|Active Comparator|Treament Arm 1|Definitive fixation with an external ring fixator.
3157955|NCT01494519|Active Comparator|Treatment arm 2|Definitive fixation with a locked IM nail or plate
3157956|NCT01494506|Experimental|MM-398|MM-398 120 mg/m2 Q3W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 120 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 100 mg/ m2 of irinotecan free base.
3157957|NCT01494506|Active Comparator|5 Fluorouracil and Leucovorin IV|5 Fluorouracil and Leucovorin IV
3157958|NCT01494506|Experimental|MM-398, 5-FU and Leucovorin|MM-398 80 mg/m2, 5-FU and Leucovorin Q2W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 80 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 70 mg/ m2 of irinotecan free base.
3157959|NCT01494493|Experimental|rhBMP-2/ACS|
3157960|NCT01494493|Active Comparator|Autogenous Bone|
3157962|NCT01494467|Experimental|CD5024|CD5024 1% Cream
3157963|NCT01494467|Placebo Comparator|CD5024 Vehicle|CD5024 Vehicle Cream
3157964|NCT01494454|Experimental|rhBMP-2/BCP|
3157965|NCT01494454|Active Comparator|Autograft|
3157966|NCT01494441|Experimental|rhBMP-2/BCP|
3157967|NCT01494441|Experimental|rhBMP-2/BCP/TSRH® Spinal System|
3157968|NCT01494441|Active Comparator|Autograft/TSRH® Spinal System|
3157969|NCT01494428|Experimental|rhBMP-2/ACS|
3157970|NCT01494428|Active Comparator|Autogenous Bone|
3157971|NCT01494415|Experimental|chemoradiotherapy|This is a single arm study with patients receiving nab-paclitaxel, carboplatin and thoracic radiotherapy.
3157972|NCT01494402|Experimental|D961S|2 way crossover
3157973|NCT01494402|Experimental|esomeprazole + buffered acetylsalicylic acid|2 way crossover
3157974|NCT01494389||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
3157975|NCT01494389||sepsis|SIRS + infection
3157976|NCT01494389||Normal|not SIRS and have no infection
3157977|NCT01494350|Experimental|WR 279,396 topical cream|120 subjects will be enrolled to this open label study to receive WR 279,396 topical cream
3157978|NCT01494337|Active Comparator|HOLEP|HOLEP In the first arm, holmium laser enucleation of the prostate will be done
3157979|NCT01494337|Active Comparator|PVEP/XPS|PVEP/XPS green light photoselective Vapo-Enucleation of prostate using XPS 180W machine will be used in the second arm
3157980|NCT01494324|Experimental|CT guided percutaneous ablation|The selected patients will undergo CT guided percutaneous ablation. The use of multi-tined electrode is encouraged, unless tumor location requires the use of an internally cooled needle electrode to eliminate injury to an adjacent vital structure or the operator prefers to use an internally cooled electrode for a specific reason.
3157981|NCT01494311|Active Comparator|Placebo patch and lidocaine injection|Fourty-five patients were randomly assigned to receive a placebo patch, looking identically to the Rapydan patch and subsequent subcutaneous injection of 0.5 ml of lidocaine 1%.
3157982|NCT01494311|Experimental|Lidocaine/tetracaine patch|Fourty-five patients were randomly assigned to receive a lidocaine/tetracaine patch, followed by subcutaneous injection 0.5 ml of normal saline solution.
3157983|NCT01494298||T2DM|African-American men with type 2 diabetes who are not taking cholesterol-lowering medications.
3157984|NCT01494298||Control|African-American men without type 2 diabetes who are not taking cholesterol-lowering medications.
3157985|NCT01494285|Experimental|ARK-E021 5% foam|
3157986|NCT01494285|Experimental|ARK-E021 10% foam|
3157987|NCT01494285|Placebo Comparator|Placebo foam|
3157988|NCT01494272||Group CB (Caudal Before-study group)|This group will receive caudal ropivacaine and epinephrine after induction of general anesthesia prior to surgical incision
3157989|NCT01494272||Caudal After (CA)-control group|This group will receive caudal ropivacaine with epinephrine after completion of surgery but before emergence from anesthesia
3157990|NCT01494272||Local Infiltration After (LIA) control group|This group will receive local infiltration of ropivacaine around the surgery site at the conclusion of surgery but before emergence from anesthesia
3157991|NCT01494259|Experimental|Bupivacaine (Treatment) Group|The Symbios GOPump is the Food and Drug Administration-approved delivery device used to infuse the bupivacaine. The pump is attached to catheters placed in the patient's breast reconstruction site. A 10cm long 16-guage needle is provided to aid insertion of the catheter into the patient. The entire catheter will pass through the bore of the introducer needle. A 60cc syringe is used to fill the Symbios GOPump through the fill port. After filling the 60cc syringe with up to 300cc of 0.5% bupivacaine, the syringe is attached to the port and the medication injected into the infusion pump. The steady-flow pressure regulator maintains a constant 6 psi pressure in the outflow chamber ensuring a uniform flow of medication through each catheter inserted into the Symbios GOPump.
3157992|NCT01494259|Placebo Comparator|Saline (Placebo) Group|The Symbios GOPump is the Food and Drug Administration-approved delivery device used to infuse the saline. The pump is attached to catheters placed in the patient's breast reconstruction site. A 10cm long 16-guage needle is provided to aid insertion of the catheter into the patient. The entire catheter will pass through the bore of the introducer needle. A 60cc syringe is used to fill the Symbios GOPump through the fill port. After filling the 60cc syringe with up to 300cc of normal saline, the syringe is attached to the port and the medication injected into the infusion pump. The steady-flow pressure regulator maintains a constant 6 psi pressure in the outflow chamber ensuring a uniform flow of medication through each catheter inserted into the Symbios GOPump.
3157993|NCT01494246|Experimental|electronic mail|
3157994|NCT01494246|No Intervention|brief advise|
3157995|NCT01494233|Experimental|Low dose|500 mg LX1033 two times daily
3157996|NCT01494233|Experimental|Mid dose|500 mg LX1033 three times daily
3157997|NCT01494233|Experimental|High dose|1000 mg LX1033 two times daily
3157998|NCT01494233|Placebo Comparator|Placebo|Matching placebo dosing
3157999|NCT01494220||Living donor liver transplantation|Patients undergoing living donor liver transplantation in the Mansoura University Liver Transplantation Program from 2007 to 2010
3158000|NCT01494207|Experimental|Lifestyle intervention|Participants will receive the intervention (counseling) or usual care (control group)
3158001|NCT01494194|Placebo Comparator|placebo for food challenge|
3158002|NCT01494194|Experimental|ASP Skin prick solution|
3158003|NCT01494194|Experimental|ASP sorbet|
3158004|NCT01494155|Experimental|Hydroxychloroquine|Hydroxychloroquine with chemoradiation
3158005|NCT01494142||ADEH-Staph+|Atopic Dermatitis without a history of Eczema Herpeticum and with S. aureus skin colonization. A minimum of 1100 participants will be enrolled; we will target 500 Non-Hispanic Caucasian, 300 Non-Hispanic African American, and 300 Mexican American Caucasian ADEH-Staph+ participants. Although we will target these three groups, no racial/ethnic groups will be excluded.
3158006|NCT01494142||ADEH-Staph-|Atopic Dermatitis without a history of Eczema Herpeticum and without S. aureus skin colonization. A minimum of 1100 participants will be enrolled; we will target 500 Non-Hispanic Caucasian, 300 Non-Hispanic African American, and 300 Mexican American Caucasian ADEH-Staph- participants. Although we will target these three groups, no racial/ethnic groups will be excluded.
3158154|NCT01493193|Experimental|Pyramid-Training|
3158007|NCT01494142||ADEH+|Atopic Dermatitis with previous or current Eczema Herpeticum.We will try to include a minimum of 150 Non-Hispanic Caucasian ADEH+ participants. ADEH+ participants of other racial/ethnic groups will not be excluded
3158008|NCT01494142||ADEV+|Atopic Dermatitis with previous or current Eczema Vaccinatum. ADEV+ sub-phenotype is very rare so all eligible participants will be enrolled.
3158009|NCT01494142||Non-atopic|Non-atopic healthy participants. A minimum of 250 non-atopic participants will be enrolled. Non-atopic participants will serve as a control group for the genetic, biomarker, Staph characterization, and microbiome studies.
3158010|NCT01494116|Experimental|10 mL syringe size|
3158011|NCT01494116|Experimental|20 mL syringe size|
3158012|NCT01494116|Experimental|30 mL syringe size|
3158013|NCT01494116|Experimental|60 mL syringe size|
3158014|NCT01494103|Experimental|iCaspase9-transduced T cells|"The 5 dose levels are:~1 x 10^4 T cells/kg~1 x 10^5 T cells/kg~5 x 10^5 T cells/kg~1 x 10^6 T cells/kg~5 x 10^6 T cells/kg"
3158015|NCT01494090|Active Comparator|Rosuvastatin|
3158016|NCT01494090|Placebo Comparator|placebo|
3158017|NCT01494077||EUS-FNA of Pancreatic Cyst|Patients who have a pancreatic cyst requiring standard of care EUS-FNA that yields 2.25 ML (or greater) of fluid will be included in the study.
3158018|NCT01494064||Retrospective|Included patients have been no specific nursing practice.
3158019|NCT01494064||Prospective|Standardization of nursing supervision of included patients using a grid of appropriate surveillance for the prevention of complications in the ICU
3158020|NCT01494051|Active Comparator|High carbohydrate diet|Diet composition of 10% long-chain fatty acids, 20% medium-chain triglycerides, 12% protein and 68% carbohydrate is the current standard of care in long-chain fatty acid oxidation disorders.
3158021|NCT01494051|Experimental|High protein diet|Diet composition of 10% long-chain fatty acids, 20% medium chain triglycerides, 25% protein and 45% carbohydrate is the comparison diet. Fat content is the same between treatments; only the carbohydrate to protein ratio varies.
3158022|NCT01494038|Experimental|Arm A (Immediate INH Treatment)|Women in Arm A will receive immediate, or antepartum-initiated, INH treatment. Women will receive INH at study entry through Week 28, then will switch to placebo for INH treatment through Week 40 postpartum.
3158023|NCT01494038|Experimental|Arm B (Deferred INH Treatment)|Women in Arm B will receive deferred, or postpartum-initiated, INH treatment. Women will receive placebo for INH at study entry through Week 12 postpartum, then will switch to INH through Week 40 postpartum.
3158024|NCT01494025|Experimental|Diet and Exercise|
3158025|NCT01494012|Experimental|Treatment (SBRT)|Patients undergo SBRT 5 days a week for approximately 1 week in the absence of disease progression or unacceptable toxicity.
3158026|NCT01493999|Active Comparator|Prasugrel arm|A loading dose of 60 mg prasugrel in patients with HPR after 600 mg clopidogrel.
3158027|NCT01493999|Active Comparator|Clopidogrel reloading|A maximum of three adjusted loading doses of 600 mg clopidogrel until normal platelet reactivity is achieved in patients with HPR after the first 600 mg clopidogrel.
3158028|NCT01493973|Experimental|Epoetin alfa|Patients will be treated with Epoetin alfa 1200 IU/Kg s.c. every 12 weeks
3158029|NCT01493973|Placebo Comparator|Placebo|Placebo 1200 IU/Kg s.c. every 12 weeks
3158030|NCT01493960|Experimental|Cobitolimod|2 doses 4 weeks apart
3158031|NCT01493960|Placebo Comparator|Placebo|2 doses 4 weeks apart
3158032|NCT01493947|Experimental|Ivermectin 1% cream|
3158033|NCT01493947|Active Comparator|Metronidazole 0.75% cream|
3158034|NCT01493934|Active Comparator|Healthy volunteers|First injection in human, on 6 healthy volunteers, sequentially : volunteer number1, then volunteers n°2 to n° 6, before infusion in type 2 diabetic patients.
3158035|NCT01493934|Experimental|type 2 diabetic patients|After completion of the study for the 6 healthy volunteers, infusion in 6 type 2 diabetic patients.
3158036|NCT01493921|Experimental|SR-T100 gel|Patient group receiving medication SR-T100 gel with active ingredient under investigation, enrolled subjects randomly assigned to this group to accurately depict statistical significance of the measured outcome.
3158037|NCT01493921|Active Comparator|Vehicle gel|Patients given placebo with non-SR-T100 ingredients as they are being administered to patients, subjects are under random assignments from patient pool to depict statistically significant outcome measurement.
3158038|NCT01493908|Active Comparator|High price|
3158039|NCT01493908|Active Comparator|Low price|
3158040|NCT01493908|Active Comparator|Low price participants aware paying part|
3158041|NCT01493908|Active Comparator|No price|
3158042|NCT01493908|Active Comparator|Free of charge|
3158043|NCT01493895|Active Comparator|control group,|The control group will be treated with a sham B-cure laser machine, emitting only green indicator light and no 808nm laser.
3158044|NCT01493895|Experimental|study, LLLT-808 B-cure laser machine|The study group will be treated with the LLLT-808 B-cure laser machine, emitting the 808nm laser beam together with a green indicator light.
3158045|NCT01493882|Placebo Comparator|Placebo|
3158046|NCT01493882|Experimental|JNJ-39758979 30 mg/d|
3158047|NCT01493882|Experimental|JNJ-39758979 100 mg/d|
3158048|NCT01493882|Experimental|JNJ-39758979 300 mg/d|
3158049|NCT01493869|Experimental|Group 1|Subjects with normal hepatic function: healthy normal adult subjects
3158050|NCT01493869|Experimental|Group 2|Subjects with mild hepatic impairment: adult subjects with a Child-Pugh grade A (score 5-6).
3158051|NCT01493869|Experimental|Group 3|Moderate hepatic impairment: adult subjects with a Child-Pugh grade B (score 7-9).
3158052|NCT01493869|Experimental|Group 4|Severe hepatic impairment: adult subjects with a Child-Pugh grade C (score 10-15).
3158053|NCT01493856|Active Comparator|Rosuvastatin+Olmesartan|single dose of Rosuvastatin 20mg and olmesartan medoxomil(CS-866) 40mg
3158054|NCT01493856|Experimental|DWJ1276|Single dose of DWJ1276
3158055|NCT01493843|Experimental|Arm A: 340 mg pictilisib + CP|Participants with advanced (Stage IV) or recurrent squamous NSCLC will be administered 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P).
3158150|NCT01493219||Epilepsy|Blood and urine sample collection, pre and post op
3158151|NCT01493219||Glioma|Blood and urine sample collection, pre and post op
3158152|NCT01493206|Experimental|intraoperative radiotherapy|
3158056|NCT01493843|Placebo Comparator|Arm B: Placebo + CP|Participants with advanced (Stage IV) or recurrent squamous NSCLC will be administered placebo corresponding to 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm A during the first 4 cycles with carboplatin + paclitaxel or after chemotherapy has been completed (Cycle >/= 5).
3158057|NCT01493843|Experimental|Arm C: 340 mg pictilisib + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P) plus bevacizumab (B).
3158058|NCT01493843|Placebo Comparator|Arm D: Placebo + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered placebo corresponding to 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm C during the first 4 cycles with carboplatin + paclitaxel + bevacizumab or after chemotherapy has been completed (Cycle >/= 5).
3158059|NCT01493843|Experimental|Arm E: 260 mg pictilisib + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered 260 mg pictilisib plus carboplatin (C) plus paclitaxel (P) plus bevacizumab (B).
3158060|NCT01493843|Placebo Comparator|Arm F: Placebo + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered placebo corresponding to 260 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm E during the first 4 cycles with carboplatin + paclitaxel + bevacizumab or after chemotherapy has been completed (Cycle >/= 5).
3158061|NCT01493817||Basic science (biomarker analysis)|Paraffin-embedded specimens are analyzed for macrophage markers. Results of each sample are then compared with patient's tumor stage, presence of vascular invasion, tumor progression, and survival.
3158062|NCT01493778|Experimental|turoctocog alfa|
3158063|NCT01493765||Benchmarking|All resident study subjects will drill virtual temporal bones within the computer based system. The performance data will be used to validate the rating metrics and computer scoring process.
3158064|NCT01493752|Active Comparator|Nitrate-rich beetroot juice|Six weeks once daily dose of nitrate rich beetroot juice
3158065|NCT01493752|Placebo Comparator|Nitrate deplete beetroot juice|six weeks daily dose beetroot juice (nitrate deplete)
3158066|NCT01493739||lymphadenopathy|
3158067|NCT01493726|Experimental|ALKS 9072, Low dose|
3158068|NCT01493726|Experimental|ALKS 9072, Med dose|
3158069|NCT01493726|Experimental|ALKS 9072, High dose|
3158070|NCT01493726|Placebo Comparator|Placebo|
3158071|NCT01493713|Experimental|Bevacizumab, XELOX|Bevacizumab in combination with XELOX
3158072|NCT01493700|Experimental|control|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
3158073|NCT01493700|Active Comparator|electrically heated circuit|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
3158074|NCT01493687|Experimental|CD5024|CD5024 1% Cream
3158075|NCT01493687|Placebo Comparator|CD5024 Vehicle|CD5024 Vehicle Cream
3158076|NCT01493674|No Intervention|placebo tablets|two identical tablets, but composed of crystalline cellulose, lactose and colouring
3158077|NCT01493674|Experimental|a suplemented group|two 5-mg tablets of folic acid
3158078|NCT01493661||Group 1|Men with Total Sleep Time ≤ 6h that will undergo 25 percent of chronic sleep restriction of their TST
3158079|NCT01493661||Group 2|Men with Total Sleep Time (range 7-8h)that will undergo 25 percent of chronic sleep restriction of their TST
3158080|NCT01493661||Group 3|Men with Total Sleep Time ≥ 9h that will undergo 25 percent of chronic sleep restriction of their TST
3158081|NCT01493648|Experimental|Vitamin D|
3158082|NCT01493648|Placebo Comparator|Placebo|
3158083|NCT01493635|Active Comparator|Standard 3 Step approach.|Standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).
3158084|NCT01493635|Experimental|2 Step approach.|2 Step approach of the WHO analgesic ladder (Step 1 - Step 3).
3158085|NCT01493622|Placebo Comparator|placebo|Subjects will be given with 200mg/day placebo(100mg,bid) and variable dose SGA. All drugs will be administered orally.
3158086|NCT01493622|Active Comparator|minocycline|Subjects will be given with 200mg/day minocycline (100mg,bid)and variable dose SGA.All drugs will be administered orally.
3158087|NCT01493609|No Intervention|Waitlist Control|
3158088|NCT01493609|Experimental|Click-East app|Participants will receive a copy of the game immediately following recruitment and assessment.
3158089|NCT01493596|Other|CPP-115 Dose 1|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
3158090|NCT01493596|Other|CPP-115 Dose 2|2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
3158091|NCT01493596|Other|CPP-115 Dose 3|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
3158092|NCT01493596|Other|CPP-115 Dose 4|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
3158093|NCT01493596|Other|CPP-115 Dose 5|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
3158094|NCT01493596|Other|CPP-115 Dose 6|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
3158095|NCT01493583||severely obese women|
3158153|NCT01493193|Active Comparator|Endurance training with constant work load|
3158096|NCT01493583||Women after Roux-en Y gastric bypass surgery|Women recruited for this group had undergone Roux-en Y gastric bypass surgery at least one year before. In this women measurement of brain activity and gastrointestinal and metabolic response took place between 13 and 106 month after surgery.
3158097|NCT01493583||lean women|
3158098|NCT01493570|Experimental|BI 409306 low dose|Film-coated tablet
3158099|NCT01493570|Experimental|BI 409306 low dose II|Film-coated tablet
3158100|NCT01493570|Experimental|BI 409306 medium dose|Film-coated tablet
3158101|NCT01493570|Experimental|BI 409306 high dose|Film-coated tablet
3158102|NCT01493570|Experimental|Placebo|Film-coated tablet
3158103|NCT01493557|Other|Pradaxa (dabigaran etexilate)|Patients with non valvular atrial fibrillation for whom Pradaxa is indicated in accordance with the current local label, not previously treated with Pradaxa, will be provided 3 months of treatment for the prevention of stroke and systemic embolism. Patients who report gastrointestinal symptoms (GIS) will be randomized to one of two management strategies, and data documenting the intensity and duration of the GIS will be collected.
3158104|NCT01493557|Active Comparator|Pradaxa and pantoprazole|Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal
3158105|NCT01493557|Active Comparator|Pradaxa, 30 minutes after a meal|Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal
3158106|NCT01493531|Experimental|lesinurad 200 mg + allopurinol|
3158107|NCT01493531|Experimental|lesinurad 400 mg + allopurinol|
3158108|NCT01493531|Placebo Comparator|Placebo + allopurinol|
3158109|NCT01493518|Placebo Comparator|PLACEBO|
3158110|NCT01493518|Experimental|AMG 557|
3158111|NCT01493505|Placebo Comparator|Placebo|Placebo Paclitaxel Carboplatin
3158112|NCT01493505|Active Comparator|AMG 386|AMG 386 Paclitaxel Carboplatin
3158113|NCT01493492||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
3158114|NCT01493492||sepsis|"Sepsis~sepsis: SIRS plus infection;~severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
3158115|NCT01493492||non-survivors with sepsis|sepsis patients who died within 28 days
3158116|NCT01493479|Experimental|Fractionated Initial Zevalin|
3158117|NCT01493466||Normal|normal person under physical examination
3158118|NCT01493466||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
3158119|NCT01493466||spesis|sepsis is defined as SIRS plus confirmed infection.
3158120|NCT01493466||severe sepsis|"severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
3158121|NCT01493466||death|sepsis patients within 48 hours before death
3158122|NCT01493453|Experimental|Single Arm - aCD19z cells, interleukin 2, Chemotherapy|
3158123|NCT01493440|Other|Atosiban|
3158124|NCT01493427|Experimental|TRAVATAN® BAK-free|Travoprost 0.004%, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks
3158125|NCT01493414|Experimental|INC424|5 - 25 mg twice a day, per os
3158126|NCT01493401|Experimental|Midurethral sling|Currently available midurethral procedures for stress urinary incontinence can be used.
3158127|NCT01493388||A|
3158128|NCT01493362||1|Participants with Bulimia Nervosa
3158129|NCT01493362||2|Participants who are healthy controls
3158130|NCT01493349||Controls|No diverticular disease or other gastrointestinal and liver diseases
3158131|NCT01493349||Uncomplicated diverticular disease|
3158132|NCT01493349||History of complicated diverticular disease|
3158133|NCT01493349||Current complicated diverticular disease|
3158134|NCT01493336|Experimental|Capecitabine RTD|
3158135|NCT01493336|Active Comparator|Xeloda|
3158136|NCT01493323|Experimental|Control|
3158137|NCT01493323|Experimental|Depressive attempters|
3158138|NCT01493310|Experimental|Arm A (hormone therapy, chemotherapy)|Patients will receive mifepristone and nab-paclitaxel in 28-day treatment cycles. Patients receive mifepristone once a day by mouth on days 0, 1, 7, 8, 14, and 15 and nab-paclitaxel by intravenous infusion (IV) on days 1, 8, and 15. Treatment cycles are repeated every 28 days in the absence of disease progression or unacceptable side effects.
3158139|NCT01493310|Active Comparator|Arm B (chemotherapy)|"Patients will receive nab-paclitaxel and placebo for a 28-day treatment cycle (Cycle 1).~Patients receive placebo once a day by mouth on days 0, 1, 7, 8, 14, and 15 and nab-paclitaxel by intravenous infusion (IV) on days 1, 8, and 15. Patients then cross-over to Arm A after completion of the first treatment cycle."
3158140|NCT01493297|Other|Retinyl palmitate|Labeled iron as FeSO4 (4 mg) added to a test meal with or without retinyl palmitate (1000 RE)
3158141|NCT01493297|Other|Beta-carotene|Labeled iron as FeSO4 (4 mg) added to a test meal with or without beta-carotene (1000 RE)
3158142|NCT01493284|Experimental|Transfemoral Access|Transfemoral Access for transcatheter aortic valve implant
3158143|NCT01493271|Placebo Comparator|Placebo|
3158144|NCT01493271|Experimental|RO5093151|
3158145|NCT01493258|No Intervention|Control Group|The study participants randomized to the Group 2 will serve as a control. At the beginning of the study, they will receive a CERSG brochure printed from the AHRQ site. They will be asked to study it to the best of their ability throughout the day.
3158146|NCT01493258|Experimental|iCOPE Intervention group|iCOPE intervention group will receive a CERSG brochure via the iCOPE system.
3158147|NCT01493245|Experimental|JNS020QD|
3158148|NCT01493232|Experimental|Denture, edentulous patient, treatment|Dentures with different type of occlusion
3158149|NCT01493232|Experimental|Denture, Edentulous patient, treatment|Dentures with different type of occlusion
3158155|NCT01493193|Experimental|High-intensity interval training|
3158156|NCT01493180|Experimental|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension
3158157|NCT01493180|Active Comparator|Sodium hyaluronate ophthalmic solution|Sodium hyaluronate ophthalmic solution
3158158|NCT01493167|Other|limb casting/splinting|Patient age 0-90 years. Patient treatment requires extremity immobilization
3158159|NCT01493154|Experimental|Cohort 1 - DNA Vaccine (Dose 0.5 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 0.5 mg/dose) + Cyclophosphamide (200 mg/m2)
3158160|NCT01493154|Experimental|Cohort 2 - DNA Vaccine (Dose 1.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 1.0 mg/dose) + Cyclophosphamide (200 mg/m2)
3158161|NCT01493154|Experimental|Cohort 3 - DNA Vaccine (Dose 2.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 2.0 mg/dose) + Cyclophosphamide (200 mg/m2)
3158162|NCT01493154|Experimental|Cohort 4 - DNA Vaccine (Dose 4.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 4.0 mg/dose) + Cyclophosphamide (200 mg/m2)
3158163|NCT01493141||MOMHR|Patients who have had metal-on metal hip resurfacing (MOMHR)
3158164|NCT01493141||THA|Patients who have had metal-on-polyethylene or ceramic total hip arthroplasty (THA)
3158165|NCT01493128||stable sinus rhythm|
3158166|NCT01493128||permanent atrial fibrillation|
3158167|NCT01493128||paroxysmal atrial fibrillation|
3158168|NCT01493115|Experimental|Sequence 1|Reference (insulin glargine) - Test1 (insulin glargine - new formulation dose 1) - Test2 (insulin glargine - new formulation dose 2)
3158169|NCT01493115|Experimental|Sequence 2|Test1 (insulin glargine - new formulation dose 1) - Test2 (insulin glargine - new formulation dose 2) - Reference (insulin glargine)
3158170|NCT01493115|Experimental|Sequence 3|Test2 (insulin glargine - new formulation dose 2) - Reference (insulin glargine) - Test1 (insulin glargine - new formulation dose 1)
3158171|NCT01493102|Active Comparator|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
3158172|NCT01493102|Active Comparator|Norepinephrine|Norepinephrine: Norepinephrine will be reduced first (0.1 microgram/kg/hour)
3158173|NCT01493089|Experimental|Zegerid|Treatment of heartburn with Zegerid
3158174|NCT01493089|Active Comparator|Losec|Treatment of heartburn with Losec
3158175|NCT01493076||Baby-S group|The baby-sphincterotome was in patients in whom biliary sphincterotomy was clinically indicated but in whom after standard techniques to gain biliary access had failed (study population).
3158176|NCT01493050|Experimental|Sevelamer Carbonate|1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
3158177|NCT01493050|Active Comparator|calcium carbonate|1200 mg of calcium carbonate TID with meals for 26 weeks
3158178|NCT01493037|Other|PICSO|PICSO treatment for 90 minutes
3158179|NCT01493024|Placebo Comparator|Placebo|Placebo (silicified microcrystalline cellulose) randomized to mimic escalating doses of experimental drug administered three times daily (TID) with meals.
3158180|NCT01493024|Experimental|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated, microporous zirconium silicate, an oral sorbent) administered 3 times daily (tid) with meals.
3158181|NCT01493011|Experimental|chemotherapy & WBH|Standard chemotherapy protocol combined with whole body hyperthermia
3158182|NCT01493011|No Intervention|chemotherapy|standard chemotherapy protocol for advanced NSCLC
3158183|NCT01492998|Experimental|Guggulsterone|One arm of 15 chronically HCV genotype one infected patients
3158184|NCT01492985|Placebo Comparator|Vaccine placebos|Vaccine placebos corresponding to the dilutant of these vaccines
3158185|NCT01492985|Experimental|Vaccine arm|
3158186|NCT01492972|Active Comparator|Radiation Alone|Proton Radiation Total Dose=70 Gy(RBE) OR High Dose Radiation with IMRT Alone=81 Gy OR Intraoperative LDR Brachytherapy and IMRT=45 Gy
3158187|NCT01492972|Experimental|Radiation + Androgen Suppression|Androgen Suppression Therapy x 6 months + Radiation
3158188|NCT01492959||Insulin human|
3158189|NCT01492946||Elective surgical patients|Elective surgical patients in the Charité University Berlin Campus Charité Mitte
3158190|NCT01492920|Experimental|Arm I (acetyl-L-carnitine hydrochloride)|Patients receive ALC PO BID on days 1-21 (during chemotherapy treatment).
3158191|NCT01492920|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID on days 1-21 (during chemotherapy treatment) (maximum of 8 courses).
3158192|NCT01492907|Active Comparator|Healthy Control Participants|age/sex matched normal controls - the subject will swallow a capsule with a dietary relevant dose of MeIQx
3158193|NCT01492907|Active Comparator|Pancreatic Cancer Patients|Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
3158194|NCT01492894|Active Comparator|50% decrease in calcineurin inhibitor|
3158195|NCT01492894|Active Comparator|Rapamune|
3158196|NCT01492881|Experimental|Vorinostat, Bortezomib, Doxil|"Induction therapy will consist of up to 8 cycles of vorinostat, bortezomib, and doxil. One cycle is defined as 21 days.~Maintenance therapy will consist of Vorinostat and bortezomib. One maintenance cycle is 28 days and repeated for up to 1 year."
3158197|NCT01492855|Experimental|Operative treatment|
3158198|NCT01492855|Experimental|Conservative treatment|
3158199|NCT01492842||Youth with behaviorally-acquired HIV who enrolled in ATN 106|Behaviorally-acquired HIV-infected adolescents and young adults, ages 12-24, inclusive, who have enrolled in ATN 106.
3158200|NCT01492816|Experimental|Intervention Group|Community members who become engaged in the coalitions and in the broader mobilization effort. A subset of community members.
3158201|NCT01492803|Placebo Comparator|Placebo|Subjects randomized to the placebo arm.
3158202|NCT01492803|Experimental|Probiotics|The probiotics use in the study contains two strains of Lactobacillus plantarum. Each dose of the active study agent contains contains 1 g maltodextrin plus the probiotic bacteria Lp299v (5 x 109 cfu) and Lp299 (5 x 109 cfu).
3158203|NCT01492790|Experimental|Cholecystectomy first|Patients enrolled in this arm will undergo emergency cholecystectomy first without any common bile duct imaging
3158204|NCT01492790|Active Comparator|Sequential common bile duct imaging/cholecystectomy|Patients enrolled in this arm will undergo common bile duct imaging and, if needed, ERCP first followed by emergency cholecystectomy
3158205|NCT01492764||Active Group|This group will receive brief ablation at localized sources (Focal Impulse and Rotor Modulation, FIRM)
3158206|NCT01492764||Control Group|This group receives traditional ablation for this disorder
3158207|NCT01492751||Spanish Multicentric Clinically Localized Prostate Cancer|A consecutive sample of clinically localized prostate cancer patients treated with radical prostatectomy, external beam radiotherapy and prostate brachytherapy in 10 Spanish hospitals.
3158208|NCT01492738|No Intervention|Control Group|Participants will be asked to make themselves comfortable lying on a massage table for 20 minutes.
3158209|NCT01492738|Active Comparator|Acupuncture group|Acupuncture group will receive one acupuncture treatment for twenty minutes.
3158210|NCT01492725|Experimental|Intra-arterial Clot Retrieval after iv tPA|
3158211|NCT01492725|Active Comparator|Standard care iv tPA|
3158212|NCT01492712|Experimental|Low-high-low blood target concentration|Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
3158213|NCT01492712|Experimental|High-low-high target blood concentration|Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
3158214|NCT01492699|Experimental|PRX-03140|PRX-03140 for the treatment of PTSD
3158215|NCT01492686|Experimental|Arm 1|
3158216|NCT01492686|Placebo Comparator|Arm 2|
3158217|NCT01492673|Experimental|Cyclophosphamide, Topotecan, and Bevacizumab (CTB)|This is a multi-center, open label phase II study evaluating the safety and efficacy of the novel combination of agents consisting of bevacizumab, cyclophosphamide, and topotecan.
3158218|NCT01492660|Experimental|Echogenic needle and catheter|The echogenic needle will be positioned using ultrasonography and neurostimulation with an end point of plantar or dorsiflexion with 0.6mA of current strength. The catheter will be inserted using ultrasonography alone. 20 Ml of 2% mepivacaine will be inserted using the catheter. The distribution of drug will be evaluated using short axis and long axis views. Sensory motor block evaluation every 5 minutes for 30 minutes. Duration of block procedure, number of passes and success will be evaluated
3158219|NCT01492660|Active Comparator|Neurostimulation|The non echogenic needle will be positioned using ultrasonography and neurostimulation with plantar or dorsiflexion as the end point with 0.6mA current.The catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current.
3158220|NCT01492647|Experimental|JNJ 10229570-AAA 1.2%|
3158221|NCT01492647|Experimental|JNJ 10229570-AAA 3.6%|
3158222|NCT01492608|Active Comparator|Magnesium sulphate|Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
3158223|NCT01492608|Placebo Comparator|Natriumchlorid|Placebo and the active drug (Magnesium sulphate) will be administered identically (same loading and maintenance dose for the same period of time).
3158224|NCT01492582|Experimental|Prevention (vaccine therapy)|Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) or nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.
3158225|NCT01492569|Experimental|Arm I (TAPS at the P6 point)|Patients undergo TAPS at the true acupuncture point (P6) 30 minutes prior to first chemotherapy infusion and then four times a day for 20 minutes every 2 hours at 8am, 10am, 12pm, and 2pm. Patients then crossover to Arm II for the second course of chemotherapy.
3158226|NCT01492569|Sham Comparator|Arm II (TAPS at a non-P6 point)|Patients undergo TAPS at a sham non-acupuncture point 30 minutes prior to first chemotherapy infusion and then four times a day for 20 minutes every 2 hours at 8am, 10am, 12pm, and 2pm. Patients then crossover to Arm I for the second course of chemotherapy.
3158227|NCT01492556|Experimental|Etoposide|Etoposide Capsules
3158228|NCT01492543|Experimental|Aiyi®|Tegafur Gimeracil Oteracil Potassium Capsule
3158229|NCT01492530|Experimental|6-session, small group|Men of African American Legacy Empowering Self (MAALES) Intervention, a six-session, theoretically grounded, small-group intervention held over 3 weeks. Includes an additional 2 booster sessions at 6 and 18 weeks following Session 6.
3158230|NCT01492530|Active Comparator|HIV Education & Risk Reduction Session|20-30 minute standard, client-centered HIV education and risk-reduction session administered over the phone or in person. Similar to that received during pre-test counseling for HIV testing.
3158231|NCT01492517|Sham Comparator|Clean air exposure|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed to clean air for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC.
3158232|NCT01492517|Other|Ozone exposure|Exposure to 0.3ppm ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. Ozone exposures will be conducted in a (6 ft x 6 ft x 8 ft) stainless steel chamber with a continuous supply of exposure medium. Ozone will be monitored continuously.
3158262|NCT01492335|Experimental|Treatment As Usual|Physicians in the Treatment As Usual Group do not receive the results of their patients cognitive assessment, they do not receive treatment recommendations, nor are they told of the patients diagnosis (Normal, Mild Cognitive Impairment, Dementia)
3158263|NCT01492322||Sated and withdrawal group|To determine differences in TRODAT binding to the DAT between a smoker when sated and when in withdrawal
3158426|NCT01491035|Experimental|Cohort CC3, 6 children|
3158233|NCT01492517|Other|Diesel exhaust exposure|Exposure to diesel exhaust will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed to diesel exhaust (up to 300 ug/m3). Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. The DE will be generated from a diesel generator used to power a load bank that is located outside the Human Studies Facility, and subsequently introduced into the exposure chamber after different dilutions with clean HEPA and charcoal filtered and humidified air to give a chamber concentration of up to 300 μg/m3.
3158234|NCT01492517|Other|18Ozone|Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O). Exposure to 0.3ppm 18O will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. Ozone exposures will be conducted in a (6 ft x 6 ft x 8 ft) stainless steel chamber with a continuous supply of exposure medium. Ozone will be monitored continuously.
3158235|NCT01492504||Subjects with chronic hepatitis C|Subjects who participated in a clinical trial in which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) was administered for the treatment of chronic hepatitis C
3158236|NCT01492491|No Intervention|standard HFR therapy|standard HFR hemodiafiltration therapy
3158237|NCT01492491|Active Comparator|SUPRA-HFR therapy|SUPRA-HFR hemodiafiltration therapy
3158238|NCT01492465|Active Comparator|AMG 876|
3158239|NCT01492465|Placebo Comparator|Placebo|
3158240|NCT01492452|No Intervention|guidelines|22 parents in the intervention group were randomized and received standardized guidelines for nursing:The guidelines took around an hour and involved pre-operative care such as bathing with detergent solution, pre-anesthetic administration (as prescribed), preoperative fasting (as prescribed), clothing, hygiene care and nail oral. They were also provided information on the endotracheal tube, tubes, catheters, epicardial pacemaker wires and electrodes to be used in the perioperative period and which remain for some period after surgery, as well as possible complications.
3158241|NCT01492439|Experimental|Cognitive Remediation and Supported Education|Participants in this group will receive cognitive remediation training in addition to supported education. Cognitive remediation has two components: computer-based cognitive exercise sessions held on a twice weekly basis for 10 weeks as well as 10 weekly group discussion sessions (approximately 60 minutes in duration).
3158242|NCT01492439|Active Comparator|Supported Education Only|The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness (see http://www.georgebrown.ca/marketing/FTCal/access/C702.aspx for a full description). Participants in this arm will receive all services and supports provided by this program. However, they will not receive the additional cognitive remediation training provided to those randomized to the experimental arm of the study.
3158243|NCT01492426|Experimental|Daclatasvir + Peginterferon alfa-2a + Ribavirin|
3158244|NCT01492426|Experimental|Telaprevir + Peginterferon alfa-2a + Ribavirin|
3158245|NCT01492413|Experimental|Online basic lifestyle counseling (OBLI)|Subjects receive one online informational class.
3158246|NCT01492413|Experimental|Online lifestyle counseling (OLC)|Subjects receive 12 weekly online classes with a focus on behavior modification for weight loss.
3158247|NCT01492413|Experimental|OBLI intervention plus a fortified diet beverage (BEV)|Subjects receive online basic lifestyle information (OBLI) plus a fortified diet beverage.
3158248|NCT01492413|Experimental|OLC plus fortified diet beverage (BEV)|Subjects receive OLC plus diet beverage (BEV).
3158249|NCT01492400|Experimental|dexamethasone Intravitreal Implant|Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.
3158250|NCT01492400|Active Comparator|ranibizumab|Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.
3158251|NCT01492387|No Intervention|Local standard of care|Patients randomized to this arm will be treated for the duration of therapy dictated by the primary care physician.
3158252|NCT01492387|Experimental|Individualized arm|Patients randomized to this arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
3158253|NCT01492374|Experimental|Arm 1: BMS-241027 (0.003 mg/kg)|
3158254|NCT01492374|Experimental|Arm 2: BMS-241027 (0.01 mg/kg)|
3158255|NCT01492374|Experimental|Arm 3: BMS-241027 (0.03 mg/kg)|
3158256|NCT01492374|Experimental|Arm 4: Placebo matching BMS-241027|
3158257|NCT01492361|Experimental|AMR101|
3158258|NCT01492361|Placebo Comparator|Placebo|
3158259|NCT01492348|Experimental|STEPS UP Intervention|STEPS UP is a centrally assisted stepped collaborative telecare management program within primary care. The STEPS UP intervention added to Optimized Usual Care (PCMH-BH; formerly RESPECT-Mil) in 4 ways: (1) care management enhancements; (2) stepped psychosocial treatment options (web, phone, in person); (3) electronic symptom registry for measurement-based treatment planning (symptoms are measured at regular intervals and care is intensified for patients with recurrent or persistent PTSD and/or depressive) and for telecare manager caseload and site performance monitoring; and (4) routine assisted review of patient, telecare manager, and site performance by a central psychiatrist and psychologist.
3158260|NCT01492348|Active Comparator|Optimized Usual Care (OUC)|Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system.
3158261|NCT01492335|Experimental|Cognitive Report|Primary care physicians in the Cognitive Report group receive the results of their patients cognitive testing together with clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations.
3158427|NCT01491035|Experimental|Cohort CC4, 6 children|
3158428|NCT01491035|Experimental|Cohort AC1, 6 adolescents|
3158264|NCT01492309|Active Comparator|Active Transcranial Magnetic Stimulation|38 pregnant women with MDD will be randomized to receive active 1 Hz right-sided dorsolateral prefrontal cortex (DLPFC) TMS.
3158265|NCT01492309|Sham Comparator|Sham Transcranial Magnetic Stimulation|38 pregnant women with MDD will be randomized to receive sham transcranial magnetic stimulation.
3158266|NCT01492296|Active Comparator|conventional fasting|patients were evaluated after fasting for 8 hours
3158267|NCT01492296|Experimental|Short fasting|patients who were evaluated with endoscopy after fasting for two hours
3158268|NCT01492283||NAFLD|Non alcoholic fatty liver disease without type 2 diabetes
3158269|NCT01492283||NAFLD+T2D|Non alcoholic fatty liver disease with type 2 diabetes
3158270|NCT01492283||T2D|Type 2 diabetics without non alcoholic fatty liver disease
3158271|NCT01492283||cirrhosis|Patients with liver cirrhosis
3158272|NCT01492283||Kontrol groups|Healthy control subjects
3158273|NCT01492257|No Intervention|SDM Control|The control arm will consist of usual care, patients will receive existing educational materials.
3158274|NCT01492257|Experimental|SDM Intervention|RCT intervention will include a package of decision and communication aids question-asking, and information recall. The intervention includes digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
3158275|NCT01492244||Patients with knee pain and a known diagnosis|
3158276|NCT01492231||Chart Review|Chart review of patients who had a procedure done at H. H. Chao Comprehensive Digestive Disease Center
3158277|NCT01492218||NovoLet®|
3158278|NCT01492205||Human insulin|
3158279|NCT01492192|Experimental|RCC Patients Antiangiogenic treatment|
3158280|NCT01492179|Active Comparator|Intravenous Lidocaine|Intravenous lidocaine would be administered as an infusion for pain management both intra- and post-operatively.
3158281|NCT01492179|Active Comparator|Intra-abdominal Lidocaine|Lidocaine would be administered intermittently, once each hour intra-abdominally for postoperative pain management.
3158282|NCT01492179|Placebo Comparator|Normal saline|Normal saline would be administered intra-abdominally and intravenously in the same patient. Rescue analgesia in the form of morphine (PCA) would be used for pain management.
3158283|NCT01492166||Novolet®|
3158284|NCT01492153||NovoLet® device|
3158285|NCT01492127|No Intervention|Blood test|Blood test :carcinoma in cirrhotic patients
3158286|NCT01492114|Experimental|Resveratrol first|"Subjects in the group resveratrol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting)."
3158287|NCT01492114|Active Comparator|Placebo first|"Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting)."
3158288|NCT01492101|Experimental|NKTR-102|
3158289|NCT01492101|Active Comparator|Physician's Treatment of Choice|
3158290|NCT01492088|Experimental|Brentuximab vedotin: Phase 1|Brentuximab vedotin 1.4 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there was evidence of disease progression or unacceptable toxicity. Dose was escalated up to 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) depending upon the dose limiting toxicity (DLT).
3158291|NCT01492088|Experimental|Brentuximab vedotin: Phase 2|Brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there is evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.
3158292|NCT01492075|Active Comparator|Continuous infusion|Continuous infusion of LA intraabdominally
3158293|NCT01492075|Experimental|PCRA (Intermittent injection)|Patient controlled LA intraabdominally
3158294|NCT01492062|Experimental|closed-loop control|Multiple Model Predictive Controller
3158295|NCT01492049|Experimental|Patient Decision Aid (PtDA)|Participants view Patient decision aid (PtDA) video.
3158296|NCT01492049|Active Comparator|Control|Participants view a video on Essential Hypertension.
3158297|NCT01492036||Gene Transfer Therapy|Study participants receiving gene therapy product at MD Anderson Cancer Center
3158298|NCT01492023||control|control group: no intervention
3158299|NCT01492023||neuropsychological rehabilitation|intervention group: neuropsychological rehabilitation (13 times 60 minutes, once per week, during 13 weeks) control group: no intervention
3158300|NCT01492010|Experimental|25 g protein|25 g whey protein
3158301|NCT01492010|Experimental|6.25 g protein supplemented with leucine|6.25 g protein supplemented with leucine
3158302|NCT01492010|Experimental|6.25 g whey protein with EAA|6.25 g protein supplemented with a mixture of essential amino acids devoid of leucine
3158303|NCT01491997|Active Comparator|Mind Body Medicine Course 1|The subject of each course is Mind/Body medicine. One course is learning about the mind and the body through experiences. The other is learning about the mind and the body through experiences. Both courses will follow the same format, meeting once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. . You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary ½ day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
3158390|NCT01491308|Active Comparator|Restrictive|Hemoglobin concentrations will be maintained in the range of 7.5 to 9.0 g per deciliter, with a transfusion given when the hemoglobin concentration is below 7.5 g per deciliter.
3158429|NCT01491035|Experimental|Cohort AC2, 6 adolescents|
3158430|NCT01491035|Experimental|Cohort AC3, 6 adolescents|
3158304|NCT01491997|Active Comparator|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
3158305|NCT01491984|Experimental|Laryngoscopy order: 1) MAC, 2) Levitan|Levitan FPS Intubation
3158306|NCT01491984|Experimental|Laryngoscopy order: 1) Levitan, 2) MAC|Macintosh Intubation
3158307|NCT01491971|Experimental|Degarelix - Cohort 1|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
3158308|NCT01491971|Experimental|Degarelix - Cohort 2|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
3158309|NCT01491971|Experimental|Degarelix - Cohort 3|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
3158310|NCT01491958|Experimental|Donor|Related donors will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines. Peripheral blood stem cells will not be manipulated or T-depleted prior to administration.
3158311|NCT01491958|Experimental|Patient|Patients will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first. Standard post transplant care will be administered.
3158312|NCT01491945|Experimental|Ventana Fenestrated Stent Graft System|
3158313|NCT01491932|Experimental|AFQ056|Patients entering the study will be titrated to target dose of AFQ056 twice daily or the highest tolerated dose at weekly intervals.
3158314|NCT01491919|Experimental|Low Dose: Lisinopril|Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day
3158315|NCT01491919|Experimental|Medium Dose: Lisinopril|Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day
3158316|NCT01491919|Experimental|High Dose: Lisinopril|Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.
3158317|NCT01491906|Experimental|Text-Messaging|The group that receives the behavioral counseling and text messaging lifestyle intervention
3158318|NCT01491906|No Intervention|Usual Care|This group will receive usual care
3158319|NCT01491893|Experimental|PVSRIPO|PVSRIPO will be delivered in a single infusion directly into the tumor via catheter placed at the time of biopsy. The current dose level is dose level minus one (5 x 10^7 TCID50 (tissue culture infectious dose)).
3158320|NCT01491880|Experimental|Child Anxiety Program by Telephone|The child anxiety program by telephone is an adaptation of Ron Rapee's Cool Kids Outreach Program (Lyneham and Rapee, 2006) for child anxiety, with appropriate adaptations made to meet the needs of rural Latino families (including a Spanish translation). This is a parent mediated program, where parents are taught how all the skills of cognitive behavior therapy (CBT) and how to apply these skills to these children's anxieties. Children are also expected to participate, however all direct contact that a therapist may have, is with the parent only.
3158321|NCT01491880|Experimental|Child Anxiety Program- Self Help|Families randomized to the Self-Help CBT condition will receive program materials along with instructions for completing weekly assignments. Specifically, they will receive the same materials as families in the telephone-based condition however in the self-help group, parents and children are expected to read the materials for that week and complete the workbook activities without planned therapist involvement. Instead they will be given the option to initiate a telephone call to the therapist, if they have questions or need extra support.
3158322|NCT01491867|Experimental|Travoprost arm|All individuals receive travoprost 0.003% 1/day in both eyes after 6 weeks wash-out for 3 months
3158323|NCT01491854|Other|Monitoring of long-term safety|Long-term safety follow-up after the end of treatment with Omnitrope (single arm)
3158324|NCT01491841|Experimental|Bendamustine + Rituximab + Pixantrone|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, variable dosing depending on the cohort and MTD; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
3158325|NCT01491815|Active Comparator|Active conventional therapy (ACT)|Non-biological DMARD's: Methotrexate plus steroids or Methotrexate plus Sulphasalazine and Hydroxychloroquine and steroids
3158326|NCT01491815|Active Comparator|Biologic agent 1|Cimzia: Certolizumab-pegol plus Methotrexate and steroids
3158327|NCT01491815|Active Comparator|Biologic agent 2|Orencia: Abatacept plus Methotrexate and steroids
3158328|NCT01491815|Active Comparator|Biologic agent 3|RoActemra: Tocilizumab plus Methotrexate and steroids
3158329|NCT01491802|Experimental|LAMA alone, then LAMA/LABA combination|Participants will first receive an inhaled long-acting muscarinic antagonist (LAMA) once daily for 4 weeks. After a 2 week washout period, they will then receive the fixed-dose combination product [LAMA plus long-acting beta2-agonist (LABA)] once daily for 4 weeks.
3158330|NCT01491802|Experimental|LABA/LAMA combination, then LAMA alone|Participants will first receive a long-acting muscarinic antagonist (LAMA) plus long-acting beta2-agonist (LABA) combination product once daily for 4 weeks. After a 2 week washout period, they will then receive the LAMA single product once daily for 4 weeks.
3158331|NCT01491789|Experimental|Virtual Sailing|you will be doing 60 minutes of Virtual Sailing training, 1 time a week for 12 weeks
3158332|NCT01491750|Experimental|GUIDED IMAGERY|
3158333|NCT01491750|Placebo Comparator|AUDIO BOOK|
3158423|NCT01491048|Active Comparator|No physiotherapy after THA|No Physiotherapy care during the period of hospitalization after THA.
3158334|NCT01491737|Experimental|Pertuzumab, Trastuzumab, AI or Induction Chemotherapy|"Participants will receive pertuzumab in combination with trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.~Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion."
3158335|NCT01491737|Active Comparator|Trastuzumab, AI or Induction Chemotherapy|"Participants will receive trastuzumab plus AI until predefined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.~Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion."
3158336|NCT01491724||pCLE images|
3158337|NCT01491711|Active Comparator|Fractionated 5-ALA HCl 20% gel PDT|Twice on day 1
3158338|NCT01491711|Active Comparator|Methylaminolevulinate PDT in 2 sessions|On day 1 and 8
3158339|NCT01491698|Experimental|pts undergoing Roux-en-Y pouch reconstruction (RYP)|This is a pilot randomized controlled trial comparing changes in health-related quality of life (HRQOL) in patients undergoing Roux-en-Y pouch reconstruction (RYP) with patients undergoing conventional Roux-en-Y reconstruction (RYC) following total gastrectomy for adenocarcinoma.
3158340|NCT01491698|Active Comparator|pts undergoing conventional Roux-en-Y reconstruction (RYC)|This is a pilot randomized controlled trial comparing change in health-related quality of life (HRQOL) in patients undergoing Roux-en-Y pouch reconstruction (RYP) with patients undergoing conventional Roux-en-Y reconstruction (RYC) following total gastrectomy for adenocarcinoma.
3158341|NCT01491685||Pregnant|
3158342|NCT01491685||Non- Pregnant|
3158343|NCT01491672|Experimental|RAD001|Participants, received RAD001 10 mg orally once daily.
3158344|NCT01491659|Active Comparator|Amoxicillin/clavulanate/Idoform Plus|
3158345|NCT01491659|Placebo Comparator|Amoxicillin/clavulanate/Placebo|
3158346|NCT01491646||Pulmonary Hypertension|Previous diagnosis of PH by right heart catheterization
3158347|NCT01491646||Healthy Controls|Healthy controls without lung/heart conditions
3158348|NCT01491633|Experimental|Dasatinib|Dasatinib 140 mg by mouth each day
3158349|NCT01491620|Experimental|532 nm KTP laser treatment|
3158350|NCT01491607|Experimental|BioThrax (0.5 mL, on days 0, 14, and 28)|
3158351|NCT01491581|Experimental|micronutrient enriched bar|bar enriched with micronutrients
3158352|NCT01491581|Placebo Comparator|control arm|normal bar
3158353|NCT01491568|Experimental|Investigational|
3158354|NCT01491555||DMD patients|35 boys ages 2 through 30 with DMD
3158355|NCT01491555||Control Group|35 healthy boys ages 2 through 30
3158356|NCT01491542|Experimental|rhBMP-2 / ACS|
3158357|NCT01491542|Active Comparator|Autogenous bone|
3158358|NCT01491529|Experimental|AFQ056 150 mg|Patients randomized to the AFQ056 150 mg arm will receive AFQ056 oral tablets to be titrated until reaching the target dose of 150 mg twice daily.
3158359|NCT01491529|Experimental|AFQ056 200 mg|"Patients randomized to the AFQ056 200 mg arm will receive AFQ056 oral tablets to be titrated until reaching the target dose of 200 mg twice daily.~Patients will be randomized in two groups by amantadine status.~Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.~Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)"
3158360|NCT01491529|Placebo Comparator|Placebo|Patients randomized to the Placebo arm will receive oral AFQ056 Placebo twice daily
3158361|NCT01491516|Experimental|Investigational|
3158362|NCT01491503|Experimental|Montelukast and levocetirizine|
3158363|NCT01491503|Active Comparator|Montelukast|
3158364|NCT01491503|Active Comparator|Levocetirizine|
3158365|NCT01491490|Active Comparator|GWP42003 : GWP42004 (40:1)|
3158366|NCT01491490|Placebo Comparator|Placebo|
3158367|NCT01491477|Experimental|INFUSE™ Bone Graft|
3158368|NCT01491477|Active Comparator|Autogenous bone|
3158369|NCT01491464|Experimental|rhBMP-2/ACS|
3158370|NCT01491464|Active Comparator|Autogenous bone|
3158371|NCT01491451|Experimental|rhBMP-2/ACS|
3158372|NCT01491451|Active Comparator|Autogenous bone|
3158373|NCT01491438|Experimental|PRGF and conventional treatment|PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)
3158374|NCT01491438|Active Comparator|Conventional treatment alone|Conventional treatment (cleaning, debridement of the wound and application of the corresponding dressing and using of antibiotics if necessary) twice a week (days 1 and 4).
3158375|NCT01491425|Experimental|rhBMP-2/ACS|
3158376|NCT01491425|Active Comparator|Autogenous Bone|The control group of patients from another study (Protocol ID: C-9702 Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic DDD).
3158377|NCT01491412||Acute psychotic episode in schizophrenia|Subjects suffering from schizophrenia being discharged from the hospital following hospitalisation due to acute psychotic episode
3158378|NCT01491399|Experimental|INFUSE™ Bone Graft/CORNERSTONE-SR™|
3158379|NCT01491399|Active Comparator|Autogenous bone/CORNERSTONE-SR™|
3158380|NCT01491386|Experimental|rhBMP-2/ACS|
3158381|NCT01491386|Active Comparator|Autogenous Bone|
3158382|NCT01491373|Experimental|rhBMP-2/ACS|
3158383|NCT01491373|Active Comparator|Autograft|
3158384|NCT01491360|Experimental|LaserACE(R) procedure performed|The LaserACE(R) procedure (partial depth scleral micro-excisions with an Er:YAG laser in a specified pattern) will be performed.
3158385|NCT01491347||alcohol dependent|
3158386|NCT01491334||Asymptomatic|Asymptomatic women presenting at various ages without prolapse condition.
3158387|NCT01491334||Symptomatic|Symptomatic women presenting with prolapse conditions with no prior surgeries and women presenting with surgery scheduled with or without prior surgery.
3158388|NCT01491321|Experimental|Bee Venom Acupuncture & Loxoprofen|
3158389|NCT01491321|Placebo Comparator|Sham Bee Venom Acupuncture & Loxoprofen|
3158424|NCT01491035|Experimental|Cohort CC1, 6 children|
3158391|NCT01491308|Active Comparator|Liberal|Hemoglobin concentrations will be maintained in the range of 10.0 to 12.0 g per deciliter, with a transfusion given when the hemoglobin concentration is below 10.0 g per deciliter.
3158392|NCT01491295|Active Comparator|Lamivudine plus adefovir|Continue lamivudine/adefovir add on treatment (standard treatment)
3158393|NCT01491295|Experimental|Tenofovir|Switch from lamivudine/adefovir add on threatment to tenofovir monotherapy
3158394|NCT01491282||No treatment|
3158395|NCT01491269|Experimental|Internet delivered CBT|Internet delivered cognitive behavioral intervention, 8 weeks treatment.
3158396|NCT01491269|No Intervention|Control condition|Active wait-list condition. Were offered to participate in a moderated online discussion forum. After post-treatment assessment the control group were offered treatment.
3158397|NCT01491256|Active Comparator|High dose Atorvastatin|Arm of pre-procedural high dose atorvastatin loading
3158398|NCT01491256|Placebo Comparator|Control|No pre-procedural high dose atorvastatin loading
3158399|NCT01491243|Active Comparator|Intensive treatment group|Patients will receive high concentration sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h after PCI in case of abnormal NGAL findings
3158400|NCT01491243|Active Comparator|Standard treament group|Patients will receive i.v. 1 ml/kg/h saline infusion for 48 h after PCI in case of abnormal NGAL findings
3158401|NCT01491230||25 autologous/25 allogeneic patients|
3158402|NCT01491204|Experimental|paclitaxel +HM30181|
3158403|NCT01491191|Experimental|PEA|Administration of PEA from 8 days before surgical operation until 30 days after surgery.
3158404|NCT01491191|Active Comparator|Sugar pill|Administration of placebo from 8 days before surgical operation until 30 days after surgery.
3158405|NCT01491178||Patients with NVAF|
3158406|NCT01491165|Experimental|stem cell transplantation therapy|umbilical cord mesenchyma stem cell transplantation through interventional procedures do in liver cirrhosis patients.
3158407|NCT01491152|Experimental|WBV Training|
3158408|NCT01491152|No Intervention|Control|No WBV Training. Standard of Care.
3158409|NCT01491139|Experimental|single arm|"All patients will receive induction chemotherapy (cisplatin and 5-FU), followed by cisplatin chemotherapy and radiotherapy in addition to oral olaparib.~Induction chemotherapy (21 day cycle)~Drug: cisplatin 80mg/m2 (day 1)~Drug: 5-FU (fluorouracil) 1000mg/m2/day (day 1-4 continuous infusion)~olaparib plus chemoradiotherapy (8 weeks)~Drug: olaparib~Drug: Cisplatin~Radiation"
3158410|NCT01491126||examinees undergoing bidirectional endoscopy|Study population will include sequential examinees undergoing bidirectional endoscopy, age> 18 years
3158411|NCT01491113|Experimental|Group A: Normal renal function|"Subjects who have normal renal function (CLcr >80 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be taken through to Day 4 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours postdose~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72 hours postdose"
3158412|NCT01491113|Experimental|Group B: Mild renal impairment|"Patients who have mild renal impairment (50<CLcr <80 mL/min/1.73 m^2). Subjects will be orally administered (Levetiracetam) LEV 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 5 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 hours postdose~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96 hours postdose"
3158413|NCT01491113|Experimental|Group C: Moderate renal impairment|"Patients who have moderate renal impairment (30<CLcr < 50 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 6 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120 hours postdose"
3158414|NCT01491113|Experimental|Group D: Severe renal impairment|"Patients who have severe renal impairment (CLcr <30 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 7 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours postdose~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120, 120 - 144 hours postdose"
3158415|NCT01491113|Experimental|Group E: End-stage renal disease|"Group E will receive Levetiracetam (LEV) 500 mg on Day 1, 44 hours (h) before the first hemodialysis. As a supplementary dose LEV 250 mg will be administered 1 h after the end of the first hemodialysis on Day 3.~The 4-h Hemodialysis are scheduled as follows:~Dialysis: 44 h to 48 h after the first dose (Day 3)~Dialysis: 92 h to 96 h after the first dose (Day 5)~Dialysis: 140 h after the first dose (Day 7)~Safety assessments and blood samplings will be conducted until Day 7. Safety follow-up assessments will be performed on Day 10.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 30, 44*, 44.25*, 44.5*, 45*, 46*, 47*, 48*, 49, 49.5, 50, 51, 53, 55, 57, 61, 73, 92, 96, 120, 140 hours post first dosing.~49 h-sample should be taken before the additional dose. The 44 h, 92 h, and 140 h sample should be taken before the start of the hemodialysis.~*Inflow blood, outflow blood, and dialysate fluid will be collected."
3158416|NCT01491100||Group 1|
3158417|NCT01491087|Experimental|PENTAXIM® vaccine group|
3158418|NCT01491074|Placebo Comparator|NaCl 0.9% 100 ml|
3158419|NCT01491074|Experimental|Tocilizumab 280 mg|Intravenous infusion, 280 mg Tocilizumab (14 ml) added to 86 ml of 0.9% NaCl
3158420|NCT01491061|Active Comparator|Ranolazine|Administration of two preprocedural doses of Ranolazine 12 hours apart (1,000 mg the night before PCI and 1,000 mg prior to PCI)
3158421|NCT01491061|Placebo Comparator|Placebo|Placebo
3158422|NCT01491048|Active Comparator|THA Physiotherapy|Physiotherapy care during the period of hospitalization after THA.
3158425|NCT01491035|Experimental|Cohort CC2, 6 children|
3158431|NCT01491035|Experimental|Cohort AC4, 6 adolescents|
3158432|NCT01491022|Experimental|Ampyra|Ampyra 10 mg po BID for 4 weeks followed by placebo 4 weeks
3158433|NCT01491022|Sham Comparator|Placebo|placebo 4 weeks followed by Ampyra 10 mg po BID
3158434|NCT01490996|Active Comparator|Chemotherapy only|Patients receiving up to 12 cycles of therapy. Standard care pathway management.
3158435|NCT01490996|Experimental|Chemotherapy plus curcumin|Patients taking daily oral curcumin for up to 12 cycles of therapy. Standard care pathway management.
3158436|NCT01490983|Experimental|eMedonline access|patients will have access to eMedonline access for 3 months
3158437|NCT01490983|Other|no access to eMedonline|patients will be followed for 3 months with no access to eMedonline
3158438|NCT01490944|Active Comparator|Iron and Folic Acid|
3158439|NCT01490944|Experimental|Iron, Folic acid and cyanocobalamin|
3158440|NCT01490931|Experimental|Ketorolac nasal spray 31.5 mg|Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
3158441|NCT01490918|Placebo Comparator|Acarbose placebo, Metformin, Sitagliptin|The dose of Acarbose should be 50mg b.i.d, 50mg t.i.d and 100mg t.i.d at the 18th week, the 20th week and the 24th week respectively. The Acarbose placebo should be changed into real Acarbose from the 16th week.
3158442|NCT01490918|Active Comparator|Sitagliptin, Metformin, Acarbose|The group's drugs not include placebo. (Metformin, Sitagliptin, Acarbose)
3158443|NCT01490918|Placebo Comparator|Metformin placebo, Sitagliptin, Acarbose|The Metformin placebo should be changed into real Metformin from the 16th week.
3158444|NCT01490905|Active Comparator|Theramine active and ibuprofen placebo|2 capsules Theramine twice daily with one ibuprofen-like placebo once daily.
3158445|NCT01490905|Active Comparator|Theramine and Ibuprofen (Theraprofen)|Two capsules Theramine twice daily with Ibuprofen 400mg once daily.
3158446|NCT01490905|Active Comparator|Theramine placebo and Ibuprofen|Two Theramine-like placebo twice daily and one ibuprofen 400mg.
3158447|NCT01490892|Experimental|3D HI and SHI of UCA|Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
3158448|NCT01490879|Experimental|Nexagon® Low Dose|Twice weekly applications of Nexagon® low dose in addition to off-loading using a Removable Cast Walker
3158449|NCT01490879|Experimental|Nexagon® Medium Dose|Twice weekly applications of Nexagon® medium dose in addition to off-loading using a Removable Cast Walker
3158450|NCT01490879|Experimental|Nexagon® High Dose|Twice weekly applications of Nexagon® high dose in addition to off-loading using a Removable Cast Walker
3158451|NCT01490879|Placebo Comparator|Nexagon® vehicle|Twice weekly applications of Nexagon® vehicle in addition to off-loading using a Removable Cast Walker
3158452|NCT01490866|Experimental|FOLFOX/bevacizumab and Axitinib|"Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC. (FOLFOX is a combination of 5-Fluorouracil, Leucovorin and Oxaliplatin.)~All patients will receive FOLFOX/bevacizumab for four 28-day cycles (a total of 16 weeks). After 4 cycles, maintenance axitinib will be started."
3158453|NCT01490853||CML and interpheron alpha|Adult Ph+CML pts in CCgR after IFN alpha.
3158454|NCT01490840|Experimental|E-training|Fingolimod as baseline immunomodulatory multiple sclerosis treatment was prescribed as per clinical practice. During phase 1, participants randomized to this arm had an introductory group session, hosted by a sports therapist. The individual training schedule was comprised of strength exercises twice a week for 30-45 minutes and endurance training once a week for 20-60 minutes for 6 months. The participants documented each training session thoroughly via the web-based application (duration, type of exercises, number of repetitions and sets, perceived exertion). A standard course of corticosteroids (methylprednisolone) on an inpatient or outpatient basis was allowed for treatment of relapses as clinically warranted. Steroid treatment consisted of 3-5 days and up to 1,000 mg methylprednisolone/day. After 6 months, Phase 2, the same Phase 1 regimen applied.
3158455|NCT01490840|Experimental|Waiting|Fingolimod as baseline immunomodulatory multiple sclerosis treatment is prescribed as per clinical practice. During Phase 1, participants randomized to this arm did not receive e-training exercise. After a 6 months waiting period, phase 2, participants had an introductory group session, hosted by a sports therapist. The individual training schedule was comprised of strength exercises twice a week for 30-45 minutes and endurance training once a week for 20-60 minutes for 6 months. The participants documented each training session thoroughly via the web-based application (duration, type of exercises, number of repetitions and sets, perceived exertion). A standard course of corticosteroids (methylprednisolone) on an inpatient or outpatient basis was allowed for treatment of relapses as clinically warranted. Steroid treatment consisted of 3-5 days and up to 1,000 mg methylprednisolone/day.
3158456|NCT01490827||Argus II Retinal Prosthesis|Patients implanted with an Argus II Retinal Prosthesis
3158457|NCT01490814|Active Comparator|Cryoballoon ablation|
3158458|NCT01490814|Active Comparator|Radiofrequency ablation|
3158459|NCT01490788|Experimental|TNX-102 FAST|2.4 mg gelcap once
3158460|NCT01490788|Experimental|TNX-102 FED|2.4 mg gelcap once
3158461|NCT01490788|Active Comparator|cyclobenzaprine FAST|generic cyclobenzaprine 5 mg tablet once or FLEXERIL 5 mg tablet once
3158462|NCT01490775|Experimental|eMedonline access|patients will be followed for 3 months with access to eMedonline
3158463|NCT01490775|Active Comparator|no access to eMedonline|patients will be followed for 3 months with no access to eMedonline
3158464|NCT01490762|Active Comparator|Regular Human Insulin|Subcutaneous injection
3158465|NCT01490762|Experimental|TI and Regular Human Insulin|All subjects have 4 clamp procedures with 10, 30, 60,80 units of TI and 1 clamp with 15 IU Regular Human Insulin
3158466|NCT01490749|Experimental|XELOX/Radiation/Carboplatin/RAD001|Patients receive XELOX comprising oxaliplatin intravenously (IV) over 120 minutes on day 1 and capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo radiotherapy (RT) 5 days a week for up to 6 weeks. Patients also receive carboplatin IV over 15 minutes to 24 hours once weekly for 5-6 weeks and RAD001 PO every other day (QOD) or once daily (QD) for 5-6 weeks during radiation therapy (RT). Patients with resectable disease undergo surgery.
3158467|NCT01490736|Experimental|LTS/Vehicle|Within subject control study
3158505|NCT01490450|Placebo Comparator|PBO: Placebo matching BMS-945429|
3158468|NCT01490723|Experimental|Yttrium-90 Ibritumomab + Chemo|Day -22 and -14, Rituximab 250 mg/m2 preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively. Day -22, -21 to -16, Imaging, repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Day -14, (90Y) ibritumomab tiuxetan administration. Day -5, -4 and -3, Fludarabine and Bendamustine following Stem Cell Transplant (SCT) and CT. Fludarabine 30 mg/m2 intravenously followed by Bendamustine 130 mg/m2 intravenously. All patients receive Graft Versus Host Disease (GvHD) prophylaxis, infections disease prophylaxis, growth factors, blood and platelet transfusion and other supportive treatment.
3158469|NCT01490697|Experimental|Mifepristone plus d-Cycloserine (DCS)|DCS 100 mg capsule orally followed by mifepristone1800 mg tablet orally 4 hours later and 90 minutes prior to traumatic memory retrieval via the traumatic event script preparation procedure, all on Day 7.
3158470|NCT01490697|Placebo Comparator|Placebo plus Placebo|Placebo-matching DCS 100 mg capsule orally followed by placebo-matching mifepristone1800 mg tablet orally 4 hours later and 90 minutes prior to traumatic memory retrieval via the traumatic event script preparation procedure, all on Day 7.
3158471|NCT01490671|Experimental|Group 1a (tenofovir gel)|Group 1a will include women with a gestational age range of 36 0/7 to 37 6/7 weeks; they will receive 1% tenofovir gel
3158472|NCT01490671|Placebo Comparator|Group 1b (placebo gel)|Group 1b will include women with a gestational age range of 36 0/7 to 37 6/7 weeks; they will receive placebo gel.
3158473|NCT01490671|Experimental|Group 2a (tenofovir gel)|Group 2a will include women with a gestational age range of 28 0/7 to 32 6/7 weeks; they will receive 1% tenofovir gel.
3158474|NCT01490671|Placebo Comparator|Group 2b (placebo gel)|Group 2b will include women with a gestational age range of 28 0/7 to 32 6/7 weeks; they will receive placebo gel.
3158475|NCT01490671|Experimental|Group 3a (tenofovir gel)|Group 3a will include women with a gestational age range of 20 0/7 to 24 6/7 weeks; they will receive 1% tenofovir gel.
3158476|NCT01490671|Placebo Comparator|Group 3b (placebo gel)|Group 3b will include women with a gestational age range of 20 0/7 to 24 6/7 weeks; they will receive placebo gel.
3158477|NCT01490671|Experimental|Group 4a (tenofovir gel)|Group 4a will include women with a gestational age range of 12 0/7 to 16 6/7 weeks; they will receive 1% tenofovir gel.
3158478|NCT01490671|Placebo Comparator|Group 4b (placebo gel)|Group 4b will include women with a gestational age range of 12 0/7 to 16 6/7 weeks; they will receive placebo gel.
3158479|NCT01490658|Experimental|Treatment period 1|
3158480|NCT01490658|Experimental|Treatment period 2|
3158481|NCT01490658|Active Comparator|Treatment period 3|
3158482|NCT01490645||one group (all patients)|
3158483|NCT01490632|Placebo Comparator|Placebo|Part A: Placebo administered orally (PO) once daily (QD) for 12 weeks. Part B: Placebo participants stayed on placebo or re-randomized to baricitinib 8 milligram (mg) or 10 mg PO QD for 12 weeks. Part C: Baricitinib participants re-randomized to 4 mg or placebo PO QD for 16 weeks. Part D: Retreated with Part B efficacious dose.
3158484|NCT01490632|Experimental|Baricitinib 2 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
3158485|NCT01490632|Experimental|Baricitinib 4 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
3158486|NCT01490632|Experimental|Baricitinib 8 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
3158487|NCT01490632|Experimental|Baricitinib 10 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or discontinued from the study for 12 weeks. Part C: Participants re-randomized to 4mg dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
3158488|NCT01490619|Experimental|Healthy Thinking in Teens|Group-based, manualized program, based on cognitive behavioral therapy techniques.
3158489|NCT01490619|Active Comparator|Advanced Diabetes Education|Group-based, manualized program designed to provide diabetes education, focused on adolescent-specific topics.
3158490|NCT01490606|Experimental|knee OA project|12 sessions of PT, 6 INDIVIDUAL AND 6 GROUP TREATMENTS
3158491|NCT01490606|No Intervention|conventional PT|
3158492|NCT01490593||Patients with Eye Injuries|The database is being established to record the number and types of eye injuries occurring in Canada. Thus there is only one cohort group, individuals who have sustained an eye injury.
3158493|NCT01490580|Experimental|Atropine + Propofol|
3158494|NCT01490580|Active Comparator|Atropine + atracurium + sufentanil|
3158495|NCT01490567|Placebo Comparator|placebo|Subjects will be given with a dose of 5mg/day placebo. All drugs will be administered orally.
3158496|NCT01490567|Active Comparator|donepezil|Subjects will be given with a dose of 5 mg/day donepezil. All drugs will be administered orally.
3158497|NCT01490554|Experimental|autologous fibroblast grafts|autologous fibroblast grafts
3158498|NCT01490541||Gastric intestinal metaplasia patient|
3158499|NCT01490515|Active Comparator|Morphology embryo evaluation|To compare non-invasive metabolomic profiling and the traditional method of morphology assessment for embryo selection in terms of implantation and pregnancy rates in a clinical IVF program.
3158500|NCT01490515|Experimental|non-invasive metabolomic profiling|To compare non-invasive metabolomic profiling and the traditional method of morphology assessment for embryo selection in terms of implantation and pregnancy rates in a clinical IVF program.
3158501|NCT01490502|Active Comparator|Low-dose vitamin D3|
3158502|NCT01490502|Active Comparator|High-dose vitamin D3|
3158503|NCT01490489|Other|Pregnent women with blood sample|
3158504|NCT01490476|Experimental|RAD001|Patient with Neurofibromatosis Type 2 and Vestibular Schwannoma treated with RAD001.
3158506|NCT01490450|Experimental|BMS-945429 (25mg)|
3158507|NCT01490450|Experimental|BMS-945429 (100mg)|
3158508|NCT01490450|Experimental|BMS-945429 (200mg)|
3158509|NCT01490437|Experimental|PemCis|Pemetrexed plus Cisplatin
3158510|NCT01490424||sepsis|SIRS plus inflammation
3158511|NCT01490424||Control|normal person under medical examination
3158512|NCT01490411|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV.
3158513|NCT01490411|Experimental|20 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
3158514|NCT01490411|Experimental|80 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
3158515|NCT01490411|Experimental|160 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
3158516|NCT01490411|Experimental|320 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
3158517|NCT01490398|Experimental|Rosuvastatin|Rosuvastatin 10mg qd for 12 months.
3158518|NCT01490385|Active Comparator|LED Phototherapy|LED phototherapy will be delivered transdermally via an extra-oral device and in a split mouth manner (half of the dental arch).
3158519|NCT01490385|No Intervention|Control: conventional orthodontic tooth movement|
3158520|NCT01490372||GDM offspring|Children born from gestational diabetes mellitus pregnancy
3158521|NCT01490372||No-GDM offspring|Children born from a normal pregnancy
3158522|NCT01490359|Experimental|HIV/STD risk-reduction|Men Making a Difference HIV/STD Risk Reduction Intervention was designed to reduce sexual risk behaviors that increase risk of HIV and other sexually transmitted diseases.
3158523|NCT01490359|Active Comparator|Health Promotion Control|Health Promotion Intervention was designed to increase physical activity, healthful diet, and other behaviors to reduce risk of noncommunicable diseases, including diabetes, hypertension, and cancers.
3158524|NCT01490346||ART treated individuals|
3158525|NCT01490333|Experimental|2500 IU Vitamin D3|
3158526|NCT01490333|Active Comparator|400 IU Vitamin D3|
3158527|NCT01490320|Placebo Comparator|Control|Parents in control group experienced a routine primary care visit.
3158528|NCT01490320|Experimental|Handout intervention|"Caregivers assigned to the hand-out group were instructed to read the AAP hand-out Pulling the Plug On TV Violence. This 2 page hand-out emphasizes the negative effect that television has on children's behavior and makes recommendations about limiting media. The RA did not supervise the reading of the handout."
3158529|NCT01490320|Experimental|Multimedia intervention|"Caregivers assigned to the multimedia group were instructed to watch Recommendation 3: Decrease Exposure to Violence from the Play Nicely program, a 5 minute video in English and Spanish that teaches caregivers about the negative impact of violent media and instructs parents about the importance of limiting media. The intervention was presented to the parents on a mobile laptop computer."
3158530|NCT01490307|Experimental|FCU offered|
3158531|NCT01490307|No Intervention|No feedback or services offered|
3158532|NCT01490294|Experimental|Gadobutrol 0.01 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.01 mmol/kg body weight (BW) (0.01mL/kg) for stress magnetic resonance imaging (MRI) via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.01 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
3158533|NCT01490294|Experimental|Gadobutrol 0.025 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.025 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.025 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
3158534|NCT01490294|Experimental|Gadobutrol 0.05 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.05 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.05 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
3158535|NCT01490294|Experimental|Gadobutrol 0.1 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.1 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.1 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
3158536|NCT01490281|Experimental|water-based exercise intervention|
3158537|NCT01490281|Experimental|land-based exercise intervention|
3158538|NCT01490281|No Intervention|Control group|
3158539|NCT01490268|Active Comparator|Sufentanil Group 1|Sufentanil Low Titration
3158540|NCT01490268|Active Comparator|Sufentanil Group 2|Sufentanil High Titration
3158541|NCT01490255|Active Comparator|Ranolazine|Patients will receive ranolazine (750 mg bid) for 15 days
3158542|NCT01490255|Active Comparator|Amlodipine|Patients will receive amlodipine (10 mg once daily) for 15 days
3158543|NCT01490229|Active Comparator|Ezetimibe|Patients assigned to ezetimibe will receive for 1 year ezetimibe (10 mg/day)
3158544|NCT01490229|Active Comparator|Nutraceuticals|Patients assigned to nutraceuticals will receive for 1 year 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg
3158545|NCT01490216|Other|lisdexamfetamine|open label
3158546|NCT01490203||Group 1: HCC resection/RFA|Patients who will undergo resection of at least two hepatic segments for HCC or radiofrequency ablation (RFA) for HCC and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI
3158547|NCT01490203||Group 2: Potential liver donor|Potential liver donors with normal hepatic function and and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI
3158550|NCT01490164||scoliosis|young adults requiring surgical correction
3158551|NCT01490151|Experimental|TTR controller|The intervention will consist of using the TTR controller (Medtronic) for post-prandial glucose control following high and low glycemic meals
3158552|NCT01490125|Experimental|QVA149 + placebo to tiotropium|Participants received QVA149 plus placebo to tiotropium during 1 of 3 treatment periods, once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
3158553|NCT01490125|Active Comparator|Tiotropium + placebo to QVA149|Participants received tiotropium 18 μg plus placebo to QVA149 during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
3158554|NCT01490125|Placebo Comparator|Placebo|Participants received placebo to QVA149 plus placebo to tiotropium during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
3158555|NCT01490112||IAsp|
3158556|NCT01490099|Experimental|Treatment period 1|
3158557|NCT01490099|Active Comparator|Treatment period 2|
3158558|NCT01490086|Experimental|15mg RP5063 daily|
3158559|NCT01490086|Experimental|30mg RP5063 daily|
3158560|NCT01490086|Experimental|50mg RP5063 daily|
3158561|NCT01490086|Placebo Comparator|Placebo|
3158562|NCT01490086|Active Comparator|aripiprazole|aripiprazole 15 mg daily
3158563|NCT01490073|Active Comparator|Active nitroglycerin ointment|
3158564|NCT01490073|Placebo Comparator|Placebo ointment|
3158565|NCT01490060|Experimental|Single Dose Day 1|Arm 1, Single Dose: Fosaprepitant 150 mg intravenous (IV) Day 1 of Cycle 1 or Day 1 of Cycle 2. Participants randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2); or Group 2 (No Fosaprepitant Cycle 1 and Fosaprepitant Cycle 2). Dexamethasone intravenously (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.
3158566|NCT01490060|Experimental|Two Doses Day 1 + Day 4|Arm 2, Two Doses: Fosaprepitant 150 mg IV Day 1 + Day 4 of Cycle 1 or Day 1 + Day 4 of Cycle 2. Participants randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2); or Group 2 (No Fosaprepitant Cycle 1 and Fosaprepitant Cycle 2). Dexamethasone intravenously (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.
3158567|NCT01490047|Experimental|rhTNF-α 25 µg/m² + Caelyx 40 mg/m²|Cohort 2: rhTNF-α 25 µg/m² + Caelyx 40 mg/m²
3158568|NCT01490047|Experimental|rhTNF-α 50 µg/m² + Caelyx 40 mg/m²|Cohort 3: rhTNF-α 50 µg/m² + Caelyx 40 mg/m²
3158569|NCT01490047|Experimental|rhTNF-α 100 µg/m² + Caelyx 40 mg/m²|Cohort 4: rhTNF-α 100 µg/m² + Caelyx 40 mg/m²
3158570|NCT01490047|Experimental|rhTNF-α 150 µg/m² + Caelyx 40 mg/m²|Cohort 5: rhTNF-α 150 µg/m² + Caelyx 40 mg/m²
3158571|NCT01490047|Experimental|rhTNF-α 200 µg/m² + Caelyx 40 mg/m²|Cohort 6: rhTNF-α 200 µg/m² + Caelyx 40 mg/m²
3158572|NCT01490047|Experimental|rhTNF-α 250 µg/m² + Caelyx 40 mg/m²|Cohort 7: rhTNF-α 250 µg/m² + Caelyx 40 mg/m²
3158573|NCT01490047|Experimental|rhTNF-α 25 µg/m² + Caelyx 30 mg/m²|Cohort 1 rhTNF-α 25 µg/m² + Caelyx 30 mg/m²
3158574|NCT01490034|Experimental|Energy dense beverage|Metabolic effects of consuming energy dense beverages before and after regular consumption
3158575|NCT01490034|Experimental|Energy dense solid food form|Metabolic effects of consuming energy dense solid foods before and after regular exposure.
3158576|NCT01490034|Experimental|Eenergy dilute beverages|Metabolic effects of consumption of energy dilute beverages on a regular basis.
3158577|NCT01490034|Experimental|Energy dilute solid food form|Metabolic effects of consuming energy dilute sold foods before and after regular exposure.
3158578|NCT01490021|Experimental|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
3158579|NCT01490021|Placebo Comparator|rTMS/Placebo TBS|rTMS/Placebo TBS
3158580|NCT01490008|Experimental|Veregen|Veregen® (sinecatechins) Ointment, 15%, local application of 250 mg corresponding to 0.5 cm strand of ointment, 3 times daily (total dose of 750 mg/d)
3158581|NCT01490008|Active Comparator|Tea|"Lipton® Green Limone, a green tea beverage; oral intake of 500 mL green tea, 3 times daily (total dose on 1500 mL/d)"
3158582|NCT01489995|Experimental|Reference|Fasted
3158583|NCT01489995|Experimental|Glucose Drink|Fed
3158584|NCT01489995|Experimental|Before High Fat Meal|Fed
3158585|NCT01489995|Experimental|Before Light Meal|Fed
3158586|NCT01489995|Experimental|After Light Meal|Fed
3158587|NCT01489982|Experimental|Light therapy|For patients who have sleep maintenance insomnia light therapy will be administered daily. If patients suffer only from sleep onset insomnia, this light therapy will be given upon awakening in the morning. Light boxes will be provided by Litebook company. In the active therapy group, the intensity of the light will be set at 10,000 lux with a head-to-light distance of 20cm. Patients will be instructed to let the light shine indirectly on their eyes (i.e. they do not look directly at the light). Patients can be reading, eating, watching TV, etc., during the time of light therapy.
3158588|NCT01489982|Experimental|CBT and sleep hygiene training|This will involve education about sleep in general, giving techniques related to sleep and relaxation, tips on stress management, etc.. This will take place at the Lady Davis Institute of the Jewish General Hospital. There will be 6 weekly sessions totalling 90 minutes - most of the time this will be in a group setting, with a maximum of 6 patients per group. Light therapy will also be part of this treatment strategy. There will be separate gropus for English and French-speaking patients
3158621|NCT01489826|Experimental|Dexanabinol 22 mg/kg|Dexanabinol 22 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3158622|NCT01489826|Experimental|Dexanabinol 30 mg/kg|Dexanabinol 30 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3158623|NCT01489826|Experimental|Dexanabinol 36 mg/kg|Dexanabinol 36 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3158589|NCT01489982|Experimental|Insomnia medications|Pharmacologic treatment will be individualized depending on patient characteristics and initial response. It will consist of two potential treatments - Doxepin or Zopiclone. Both of these agents are currently used commonly in the general population and also in PD patients. The agents will be prescribed exactly as any other medical prescription (i.e. patients will fill their own prescriptions at their own pharmacy).The decision for which agent to use will be as follows: a)If patients suffer from sleep onset insomnia (with or without sleep maintenance insomnia), or if doxepin is contraindicated, Zopiclone will be prescribedb) or b)If patients suffer from sleep maintenance insomnia only (or if Zopiclone is contraindicated), Doxepin will be the first choice agent.
3158590|NCT01489982|Placebo Comparator|Placebo intervention of light therapy|The inactive/placebo intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles. This therefore functions as a placebo condition for the active light therapy protocol. Patients be informed that some forms of light therapy will be expected to be less active, but we will not disclose what type of condition is inactive.
3158591|NCT01489969|Active Comparator|20 mg|Neu-P11 dose of 20 mg
3158592|NCT01489969|Active Comparator|50 mg|Neu-P11 dose of 50 mg
3158593|NCT01489969|Placebo Comparator|placebo|matching placebo
3158594|NCT01489956|Experimental|Immucothel alone (Part A)|100 µg Immucothel subcutaneously (SQ) on Day 0 and Day 9.
3158595|NCT01489956|Experimental|Immucothel+Montanide (Part A)|If an immune response was not observed in at least nine out of the first 10 participants after receiving Immucothel alone, 10 additional healthy subjects would be recruited and immunized with Immucothel (SQ) plus Montanide (SQ) on Day 0 and Day 9.
3158596|NCT01489956|Experimental|Immucothel alone or Immucothel+Montanide (Part B)|"Dependent on the results for Part A.~Briefly: Ten new, healthy participants were to be fed 50 mg of native keyhole limpet hemocyanin (KLH), a protein extracted from a mollusk (a sea animal), on Days 0 through 4 and Days 10 through 14, for a total dose of 500 mg. The participants were then immunized using the strategy that produced an immune response in at least nine out of 10 participants in Part A (Immucothel alone or Immucothel plus Montanide) on Days 26 and 35."
3158597|NCT01489943|Experimental|All subjects receiving treatment|During the treatment subjects will receive Midazolam 3 mg on Day 1, Pioglitazone 15 mg on Day 2, Omeprazole 40 mg on Day 3, Rosuvastatin 10 mg on Day 4, GSK1605786 500 mg twice daily (BID) from Day 5 to 10, GSK1605786 500 mg BID + Midazolam 3 mg on Day 11, GSK1605786 500 mg BID + Pioglitazone 15 mg on Day 12, GSK1605786 500 mg BID + Omeprazole 40 mg on Day 12, GSK1605786 500 mg BID + Rosuvastatin 10 mg on Day 14 as single sequence.
3158598|NCT01489930|Experimental|Endurance Exercise|Participants will perform 8-weeks of moderate intensity endurance (cycling) exercise
3158599|NCT01489930|Experimental|Resistance Exercise|Participants will perform 8-weeks of whole-body resistance exercise training.
3158600|NCT01489930|Experimental|Control / Combined Training|Participants will perform 8-weeks of no exercise, followed by an additional 8-weeks of combined endurance plus resistance exercise training.
3158601|NCT01489917|No Intervention|Compression without adjustment|TR band (Terumo medical) applied. The TR band is then deflated gradually till pulsatile bleeding is observed under the transparent plastic inflatable chamber and then 1-2 cc of air is placed back in the TR band chamber to stop bleeding. The band is left in place for 2 hours and not adjusted further unless patient complained of symptoms or bleeding occurred.
3158602|NCT01489917|Experimental|Patent hemostasis & heparin|TR-band is placed and positioned similarly to the other study arm. However, in theses cases, patency is evaluated at the time of application of the TR-band, and monitored every 15 minutes afterwards till the band is removed and hemostasis completed. After TR-band placement, if maintenance of radial artery patency is obtained, no heparin is administered and TR band is left in place for 1-hour. If radial artery patency is not maintained, a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the band is left in place for 2 hours.
3158603|NCT01489904|Experimental|Botulinum Toxin|Botulinum Toxin type-A
3158604|NCT01489904|No Intervention|Control Treatment|No intervention
3158605|NCT01489891|Active Comparator|Lidocaine group|Blinded spraying 50 mg of pharyngeal topical lidocaine 180 seconds before sedated esophagogastroduodenoscopy (EGD)
3158606|NCT01489891|Placebo Comparator|Placebo|Excipients without lidocaine. The flavour taste is the same of active comparator ensuring the masking.
3158607|NCT01489878||β-lactams|amoxicillin-clavulanate or penicillins M
3158608|NCT01489878||macrolides|
3158609|NCT01489878||fluoroquinolones|
3158610|NCT01489878||synergistins|
3158611|NCT01489865|Experimental|ABT-888 and mFOLFOX-6|ABT-888 orally at escalating does in Phase I and then at recommended phase II dose with standard mFOLFOX-6
3158612|NCT01489852|Active Comparator|Estrogen pre-treatment|
3158613|NCT01489852|No Intervention|Control|The control group did not receive any pre-treatment.
3158614|NCT01489839||Periodontal diseased|Subjects with periodontal disease will be enrolled. Subjects with mild disease will have at least 4 teeth with at least 1 site with pocketing of 5 mm or more and concomitant attachment greater than or equal to 2 mm, and radiographic evidence of mesial or distal alveolar bone loss around at least 2 of the affected teeth. Subjects with severe disease will have at least 8 teeth with a site having >5mm pocketing and loss of 3 mm attachment with evidence of alveolar bone loss in 2 teeth.
3158615|NCT01489839||Periodontally healthy|Periodontally healthy subjects have no teeth with pocketing of 4 mm or greater and attachment loss, with the exception of the distal of the second molars where a pocket of 4 mm and concomitant attachment of up to 2 mm will be acceptable. Healthy subjects can have up to 3 sites with gingival recession and no radiographic evidence of alveolar bone loss.
3158616|NCT01489826|Experimental|Dexanabinol 2 mg/kg|Dexanabinol 2 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3158617|NCT01489826|Experimental|Dexanabinol 3 mg/kg|Dexanabinol 3 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3158618|NCT01489826|Experimental|Dexanabinol 6 mg/kg|Dexanabinol 6 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3158619|NCT01489826|Experimental|Dexanabinol 12 mg/kg|Dexanabinol 12 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3158620|NCT01489826|Experimental|Dexanabinol 15 mg/kg|Dexanabinol 15 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3158670|NCT01489488|Experimental|Arm 4|
3158624|NCT01489826|Experimental|Dexanabinol Expansion Phase|Dexanabinol 30 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3158625|NCT01489813|Placebo Comparator|Sugar pill|Patients will be given placebo pills for 10 weeks.
3158626|NCT01489813|Experimental|Genistein supplement|30 mg of genistein supplement by mouth three times daily (PO TID).
3158627|NCT01489800|Experimental|Early Feeding|Introduction of clear liquid diet 24 hours after extubation with advancement to regular diet 24 hours thereafter if there is no significant nausea or vomiting.
3158628|NCT01489800|No Intervention|Control Feeding|Standard of care with introduction of clear liquid diet at time of return of bowel function as determined by flatus. Advancement to full diet 24 later if clear diet well tolerated.
3158629|NCT01489787|Experimental|Phase I : HIFU|
3158630|NCT01489787|Experimental|Phase IIa : HIFU|
3158631|NCT01489787|Experimental|Phase IIb : HIFU|
3158632|NCT01489774|Placebo Comparator|Placebo|
3158633|NCT01489774|Experimental|CJ-12406|CJ-12406 Tablet, daily for 1 day or bid for 10 days
3158634|NCT01489761|Active Comparator|zotarolimus-eluting stent|Resolute Integrity or Resolute Onyx stent
3158635|NCT01489761|Experimental|everolimus-eluting stent|Xience Prime or Xience Xpedition or Xience Alpine stent
3158636|NCT01489735||1|
3158637|NCT01489722|Experimental|AZD1208|Single ascending dose escalation of 3 - 6 patient cohorts until maximum tolerated dose (MTD) is established. Up to 12 patients may be included at any dose not determined to be intolerable. Safety expansion using MTD in up to 44 Acute myelogenous leukemia (AML) patients.
3158638|NCT01489709||Vesicare group|Who receive vesicare
3158639|NCT01489696|Experimental|Treatment Arm 1|tamsulosin singles doses; mirabegron multiple dose
3158640|NCT01489696|Experimental|Treatment Arm 2|mirabegron single doses; tamsulosin multiple dose
3158641|NCT01489683|Experimental|control|3 ml of normal saline was instilled to larynx and trachea
3158642|NCT01489683|Active Comparator|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea before endotracheal intubation
3158643|NCT01489670||Lumigan® 0.01%|Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
3158644|NCT01489644|Experimental|Treatment period 1|
3158645|NCT01489644|Experimental|Treatment period 2|
3158646|NCT01489644|Experimental|Treatment period 3|
3158647|NCT01489644|Active Comparator|Treatment period 4|
3158648|NCT01489631|Active Comparator|epidural analgesia|The first group will be treated with epidural analgesia. Before surgery the epidural catheter will be placed according to local guidelines. After the operation epidural infiltration with bupivacaine and sufentanil will be commenced.
3158649|NCT01489631|Active Comparator|local infiltration|The second group will receive local infiltration with ropivacaine of the knee during surgery.
3158650|NCT01489631|Active Comparator|local infiltration and gabapentin|The third group will receive local infiltration with ropivacaine of the knee during surgery and will additionally be treated with gabapentin.
3158651|NCT01489618|Active Comparator|PPS|Group 1: patients will a single administration of the PPS (one dose at W4). 25 patients will be randomised in this group.
3158652|NCT01489618|Experimental|PnCJ PPS|Group 2: patients will receive a first boost with the PnCj (one dose at W0) and then one administration of the PPS vaccines (one dose at W4). 47 patients will be randomised in this group.
3158653|NCT01489605|Experimental|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
3158654|NCT01489605|Active Comparator|Control: Standard GlideScope|Control: Patients will be intubated using standard practice, a standard GlideScope (Verathon)
3158655|NCT01489592|Experimental|curcumin|oral administration of 6g of curcumin
3158656|NCT01489592|Placebo Comparator|placebo|oral administration of 12 sugar pill
3158657|NCT01489579|Active Comparator|BST counseling group|"The patients in the BST counseling group will receive tobacco cessation counseling by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources (Ready to quit patient handout"
3158658|NCT01489579|Placebo Comparator|Usual care group|Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
3158659|NCT01489566|Active Comparator|Tyroserleutide for injection|the Tyroserleutide for injection at the dosage of 6mg/d
3158660|NCT01489566|Placebo Comparator|the placebo|
3158661|NCT01489540|Active Comparator|new diagnostic strategy|Combination of laser Doppler imaging and clinical assessment of burn depth
3158662|NCT01489540|No Intervention|current diagnostic strategy|Clinical assessment of burn depth
3158663|NCT01489527|Active Comparator|Gardasil Vaccine Administration|Gardasil Vaccine Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.
3158664|NCT01489527|Placebo Comparator|Placebo Administration|Placebo Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.
3158665|NCT01489514||Peanut allergic subjects|
3158666|NCT01489501|Experimental|only one arm available|Caomecs transplantation on eye cornea.
3158667|NCT01489488|Experimental|Arm 1|
3158668|NCT01489488|Experimental|Arm 2|
3158669|NCT01489488|Experimental|Arm 3|
3158672|NCT01489462|Experimental|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
3158673|NCT01489462|Experimental|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
3158674|NCT01489462|Active Comparator|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
3158675|NCT01489449|Placebo Comparator|Stent|Stent Implantation (DES or BMS), no further treatment
3158676|NCT01489449|Active Comparator|DCB|"DEBonly strategy: treatment with drug coated balloon, additional spot-stenting in case of severe dissection"
3158677|NCT01489436|Active Comparator|Single port cholecystectomy|In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary; this device is placed percutaneously without the need for a trocar. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port, adequate hemostasis is ensured, the umbilical trocar removed, and the single operative site will be closed and sterile dressings applied (four Band-Aids).
3158678|NCT01489436|Active Comparator|Four-port laparoscopic cholecystectomy|The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder. Trocar sites will be closed and sterile dressings applied (four Band-Aids).
3158679|NCT01489410|Active Comparator|Drug-Eluting Beads with Doxorubicin|Drug-Eluting Beads (DEB) with Doxorubicin is administered via beads that release it to the liver through a groin puncture site and delivered via catheter through the vessels that feed the liver.
3158680|NCT01489410|Active Comparator|Lipiodol Ethanol Mixture (LEM)|Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered via catheter through the vessels that feed the liver.
3158681|NCT01489397|Experimental|Gastric intestinal metaplasia|
3158682|NCT01489397|Placebo Comparator|Normal|
3158683|NCT01489384||3 months: Discontinue vs continue DMARDS|At 3 months those patients who achieved a change in DAS28 of 1.2 or greater will be randomized to discontinue versus continue DMARDs and will be followed for an additional 15 months
3158684|NCT01489384||6 months: discontinue vs continue DMARDs|(Protocol amendment 4.0)At 6 months, those patients still on Cimzia and DMARD therapy who were not randomized at month 3 AND achieve a change in DAS28> 1.2 will be randomized to discontinue versus continue DMARDs and will be followed for an additional 12 months.
3158685|NCT01489384||6 months: D/C vs Cont'd DMARDs if change in DAS28|(Protocol amendment 4.0)At 6 months, if the change in DAS28 is at least 0.6 and there is a decision to continue Cimzia, then the patients will be randomized to discontinue versus continue DMARDs with Cimzia and will be followed for an additional 12 months.
3158686|NCT01489384||3 or 6 months: stop CIMZIA and treat as per SOC|(Protocol amendment 4.0)If a change in DAS28 of <0.6 occurs at 6 months (at 3 months for protocol amendment 6.1)in patients not randomized at month 3 then the patient will stop Cimzia and treatment will be standard of care. However, patient will still be followed until the end of study.
3158687|NCT01489371|Experimental|Treatment (EGEN-001, pegylated liposomal doxorubicin)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and EGEN-001 IP over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3158688|NCT01489358|Experimental|Group 1|Group 1 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 10 mcg.
3158689|NCT01489358|Experimental|Group 2|Group 2 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 20 mcg.
3158690|NCT01489358|Experimental|Group 3|Group 3 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 40 mcg.
3158691|NCT01489345|Experimental|Arm 1: Experimental|
3158692|NCT01489345|Placebo Comparator|Arm 2: Placebo Comparator|
3158693|NCT01489319|Experimental|Nl Wt PCOS - Nl Abdominal Adiposity|10 normal weight women with PCOS who have normal abdominal adiposity established by DEXA
3158694|NCT01489319|Experimental|Nl Wt PCOS - Increased Abdominal Adiposity|10 normal weight women with PCOS who have increased abdominal adiposity established by DEXA
3158695|NCT01489319|No Intervention|Obese PCOS|10 obese women with PCOS
3158696|NCT01489319|No Intervention|Nl Wt Controls - Nl Abdominal Adiposity|10 normal weight ovulatory women serving as controls who have normal abdominal adiposity established by DEXA
3158697|NCT01489319|No Intervention|Nl Wt Controls - Increased Abdominal Adiposity|10 normal weight ovulatory women serving as controls who have increased abdominal adiposity established by DEXA
3158698|NCT01489319|No Intervention|Obese Controls|10 obese ovulatory women serving as controls
3158699|NCT01489306|Experimental|MDT-637|Active formulation
3158700|NCT01489306|Placebo Comparator|Placebo|Matched Placebo Comparator
3158701|NCT01489293||atopic subjects|Patients with one atopic disease or more (atopic dermatitis,rhinitis, asthma, food allergy)
3158702|NCT01489293||non-atopic subjects|Control group without atopic diseases.
3158703|NCT01489267|No Intervention|Control group|Ten patients in the group only receive nerve functional evaluation and electrophysiology examination before and 1,3,6,12 months after recruit. They will not accept cell therapy.
3158704|NCT01489267|Experimental|Stem cell transplantation|10 patients in the group accept stem cell transplantation.
3158705|NCT01489254|Experimental|GTR|Drug
3158706|NCT01489254|Active Comparator|Copaxone®|Drug
3158707|NCT01489254|Placebo Comparator|Placebo|Drug
3158708|NCT01489241|No Intervention|Usual care|Patients in the control group receive usual care and visit the outpatient department at 4 and at 12 weeks after discharge when pulse rate, oxygen saturation and spirometry is performed. In the case of clinical deterioration during the study, the patients contact as usual their general practitioner. Usual care of COPD patients consists of regular visits to the specialist or primary care clinics every time a medication change is made or a medical examination is needed
3158709|NCT01489241|Experimental|Telemonitoring|
3158710|NCT01489228|Experimental|High Dose E1224|High Dose (HD - 8weeks) Group
3158711|NCT01489228|Experimental|Low Dose E1224|Low Dose (LD - 8 weeks) Group
3158712|NCT01489228|Experimental|Short Dose E1224|Short Dose (SD - 4 weeks) Group
3158713|NCT01489228|Placebo Comparator|Placebo|Placebo (8 weeks) Group
3158714|NCT01489228|Active Comparator|Benznidazol|BZN (Laboratório do Estado de Pernambuco -LAFEPE, tablet 100mg), 5 mg/Kg/day PO divided in two daily doses, for 60 days
3158715|NCT01489215|Experimental|"Clinical group-presence intervention"|"The Presence intervention is based on based on the principles of graduated extinction, which has been defined has been defined as effective and recommended therapy in the treatment of bedtime problems and night wakings by the Standard of Practice Committee of the American Academy of Sleep Medicine."
3158716|NCT01489215|Experimental|"Clinical group-checking intervention"|"The Checking training is based on the principles of graduated extinction, which has been defined has been defined as effective and recommended therapy in the treatment of bedtime problems and night wakings by the Standard of Practice Committee of the American Academy of Sleep Medicine"
3158717|NCT01489215|No Intervention|Control Group|
3158718|NCT01489202|Active Comparator|platinum chromium EES|Patients undergoing PCI with stenting will have implantation of platinum chromium everolimus-eluting stents
3158719|NCT01489202|Active Comparator|cobalt chromium everolimus-eluting stent|Patients undergoing PCI with stenting will have implantation of cobalt chromium everolimus-eluting stents
3158720|NCT01489189|Experimental|Anti-VEGF+Deferred PRP|Anti-VEGF= Anti vascular endothelial growth factor. PRP= Panretinal photocoagulation. Intravitreal anti-VEGF with PRP only if indicated.
3158721|NCT01489189|Active Comparator|Prompt PRP|PRP= Panretinal Photocoagulation. PRP alone.
3158722|NCT01489176|Experimental|Regadenoson; Optison|Use of Regadenoson as the chemical stress agent using Optison as a contrast agent during stress echocardiography.
3158723|NCT01489163|Experimental|Lifestyle Counseling|
3158724|NCT01489163|No Intervention|Control|
3158725|NCT01489137|Experimental|neurosurgery with fixation|
3158726|NCT01489124|Experimental|0.5 g of imipenem by 0.5-hr infusion|0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
3158727|NCT01489124|Experimental|0.5 g of imipenem by 2-hr infusion|0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
3158728|NCT01489124|Experimental|1 g of imipenem by 2-hr infusion|1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
3158729|NCT01489111|Experimental|Surgery|
3158730|NCT01489098||Breast Fed reference group|3 and 5 year olds from the above group
3158731|NCT01489098||Infant formula - protein level 1|3 ad 5 year olds from the above group
3158732|NCT01489098||Infant formula - protein level 2|3 and 5 year olds from the above group
3158733|NCT01489072|Experimental|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of remifentanil 0.25 mcg/kg before emergence of a desflurane-based anesthesia
3158734|NCT01489072|Active Comparator|Remifentanil 0.5 mcg/kg|Administration of a bolus dose of remifentanil 0.5 mcg/kg before emergence of a desflurane-based anesthesia
3158735|NCT01489059|Experimental|Part 1 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab|Dose Escalation
3158736|NCT01489059|Experimental|Part 1 - Arm 2: BMS-982470 (Weekly) + Ipilimumab|Dose Escalation
3158737|NCT01489059|Experimental|Part 2 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab|Cohort Expansion
3158738|NCT01489059|Experimental|Part 2 - Arm 2: BMS-982470 (Weekly) + Ipilimumab|Cohort Expansion
3158739|NCT01489059|Active Comparator|Part 2 - Arm 3: Ipilimumab monotherapy|Cohort Expansion
3158740|NCT01489046|Experimental|Arm 1: BMS-986001 (100 mg) + Placebo + Efavirenz + Lamivudine|
3158741|NCT01489046|Experimental|Arm 2: BMS-986001 (200 mg) + Placebo + Efavirenz + Lamivudine|
3158742|NCT01489046|Experimental|Arm 3: BMS-986001 (400 mg) + Efavirenz + Lamivudine|
3158743|NCT01489046|Experimental|Arm 4: Tenofovir (300 mg) + Efavirenz + Lamivudine|
3158744|NCT01489033|Experimental|Group A active|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
3158745|NCT01489033|Placebo Comparator|Group A placebo|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
3158746|NCT01489033|Experimental|Group B active|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
3158747|NCT01489033|Placebo Comparator|Group B placebo|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
3158748|NCT01489033|Experimental|Group C active|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
3158749|NCT01489033|Placebo Comparator|Group C placebo|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
3158750|NCT01489020|Experimental|Group A active|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
3158797|NCT01488747|Active Comparator|Nordic Omega-3 Softgel|4 softgels
3158751|NCT01489020|Placebo Comparator|Group A placebo|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
3158752|NCT01489020|Experimental|group B active|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
3158753|NCT01489020|Placebo Comparator|Group B placebo|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
3158754|NCT01489020|Experimental|Group C active|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 doses of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
3158755|NCT01489020|Placebo Comparator|Group C placebo|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
3158756|NCT01489007||Vegetarian Children|"Self-described lacto-ovo vegetarians for the past 6 months (Subjects who include a small amount of fish or chicken in the diet (not more than 2 servings total/week of both combined) will be allowed to participate in this study as these are not major iron contributors to the diet. Subjects must not have eaten any red meat however for 6 months.) Control subjects will be non-vegetarians."
3158757|NCT01488994|Experimental|BAX326 < 6 years of age|
3158758|NCT01488994|Experimental|BAX326 6 to <12 years of age|
3158759|NCT01488968|Active Comparator|Standard|Standard Radiation Treatment
3158760|NCT01488968|Experimental|Hypofractionated|Hypofractionated
3158761|NCT01488955|Experimental|Ibuprofen|Ibuprofen 400 mg oral once daily from day 0 for 3 days, placebo granulate oral day 0
3158762|NCT01488955|Experimental|Fosfomycin-Trometamol|Fosfomycin-Trometamol (Monuril) 3 g granulate oral at day 0, placebo to Ibuprofen once a day from day 0 for 3 days
3158763|NCT01488942|Experimental|monetary reinforcer|Subjects randomized to this arm will receive an escalating reinforcer initially for attendance at each clinic visit (until month 6 after starting HAART) and subsequently (until month 12 after starting HAART) will receive an escalating variable reinforcer for each month in which a viral load at or below 100 copies/mL is maintained
3158764|NCT01488942|No Intervention|no reinforcer|All subjects will receive HAART and standard medical care, but subjects in the control arm will not receive monetary reinforcers.
3158765|NCT01488929|Experimental|5 mg TC-5619|One tablet of 5 mg TC-5619 will be administered orally once a day.
3158766|NCT01488929|Experimental|50 mg TC-5619|One tablet of 50 mg TC-5619 will be administered orally once a day.
3158767|NCT01488929|Placebo Comparator|Placebo|One tablet of placebo will be administered orally once a day.
3158768|NCT01488916||Vitamin D deficiency|patients with serum vitamin D levels of the lower tertile
3158769|NCT01488916||Vitamin D inadequacy|patients with serum vitamin D levels of the middle tertile
3158770|NCT01488916||Reference group|patients with serum vitamin D levels of the upper tertile
3158771|NCT01488903||Premenopausal Women|600 health premenopausal Women
3158772|NCT01488903||Postmenopausal women|600 healthy postmenopausal women
3158773|NCT01488890|Experimental|CYD Dengue vaccine Group 1|Participants will receive a dose of CYD dengue vaccine at Day 0, Month 6 and 12, respectively.
3158774|NCT01488890|Experimental|CYD Dengue vaccine Group 2|Participants will receive a dose of CYD dengue vaccine at Day 0, Month 2 and 6, respectively.
3158775|NCT01488890|Experimental|CYD Dengue and Yellow Fever vaccine Group|Participants will receive a dose of Yellow Fever and CYD Dengue vaccine at Day 0, and CYD Dengue vaccine at Month 2 and 6, respectively.
3158776|NCT01488890|Active Comparator|Yellow Fever vaccine Group|Participants will receive a dose of Yellow Fever vaccine at Day 0.
3158777|NCT01488877|Experimental|PF03882845|
3158778|NCT01488877|Active Comparator|Spironolactone|25 mg once daily
3158779|NCT01488877|Placebo Comparator|Placebo|Placebo once daily
3158780|NCT01488864|Experimental|Applied Relaxation (AR)|
3158781|NCT01488864|No Intervention|Untreated Control Group (CG)|The women assigned to CG will be told to act as an untreated control group i.e. not to use hormonal treatment, other alternative medication, natural remedies for hot flashes and even not acupuncture, mind-body therapies or intensive physical activity.
3158782|NCT01488838|Experimental|Arm 1:|Radiation: 60-66 Gy in 2 Gy daily fractions Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
3158783|NCT01488838|Active Comparator|Arm 2:|Radiation: 60-66 Gy in 2 Gy daily fractions
3158784|NCT01488825|No Intervention|Wait-list control group|The wait-list control group received no intervention, or instruction and they were observed with their usual care for 12-weeks intervention period. Upon completion of the study, this group received 12 weeks of yoga intervention.
3158785|NCT01488825|Experimental|Yoga Intervention Group|The yoga sessions developed specifically for study participant consisted of 12 weekly 60-minute designed to benefit in episodic tension type headache.
3158786|NCT01488812||Hip-fracture patients|All the hip-fracture patients admitted to the Orthopaedic Depart of Danderyd Hospital between 1st June 2007- 1st June 2008 who fulfilled the inclusion criteria of the study.
3158787|NCT01488799|Active Comparator|MI-CBT|
3158788|NCT01488799|Active Comparator|CBT alone|
3158789|NCT01488786|Experimental|BrainPort Vision Device|Single Arm
3158790|NCT01488773||ICS + salmeterol|"Patients treated with both inhaled glucocorticosteroid (ICS) and salmeterol (long-acting β2-agonist).~90 patients met the inclusion criteria for this group."
3158791|NCT01488773||ICS + montelukast|"Patients treated with both inhaled glucocorticosteroid (ICS) and montelukast (leukotriene receptor antagonist).~42 patients met the inclusion criteria for this group."
3158792|NCT01488760||Nineteen women with low back pain|
3158793|NCT01488760||Twenty pain-free women|
3158794|NCT01488747|Experimental|Coromega Omega-3 Squeeze|5.03 g
3158795|NCT01488747|Experimental|Coromega Nectar|12.22 g
3158796|NCT01488747|Experimental|Barleans Swirl|17.45 g
3158798|NCT01488734|Experimental|Mushroom with 600 IU vitamin D2|Mushroom with 600 IU of vitamin D2 daily and placebo tablet
3158799|NCT01488734|Experimental|Mushroom with 4000 IU Vitamin D2|Mushroom with 4000 IU of Vitamin D2 daily and placebo tablet
3158800|NCT01488734|Active Comparator|600 IU Vitamin D3 and untreated mushroom|Commercially available tablets with 600 IU/day of Vitamin D3 and untreated mushroom
3158801|NCT01488734|Active Comparator|4000 IU Vitamin D3 and untreated mushroom|Commercially available tablets with 4000 IU/day of Vitamin D3 and untreated mushroom
3158802|NCT01488721||General Newborn Population-Prospective|Specimens prospectively collected in the course of routine newborn screening originating from hospitals, birthing centers, and/or clinics.
3158803|NCT01488721||Newborn Specimens-Confirmed Positive|Banked confirmed positive specimens that were originally collected as part of the newborn screening program, but when found to screen positive for a disease, were followed up clinically to definitively diagnose the subject with the disease (CF, CAH or CH). Follow up results were reported to the sites by the treating clinicians.
3158804|NCT01488708|Experimental|LY 2127399 Q2W|If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
3158805|NCT01488708|Experimental|LY2127399 Q4W|If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
3158806|NCT01488695|Experimental|GlideScope Groove|Patient will be intubated using the GlideScope Groove device.
3158807|NCT01488695|Active Comparator|Control|Control Group: Macintosh Blade
3158808|NCT01488682|Experimental|Harmonic scalpel|Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
3158809|NCT01488682|Active Comparator|conventional hand tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels.
3158810|NCT01488669|Experimental|Robotic neck dissection|Robotic neck dissection was performed via modified face lift or retroauricular approach using the robotic arms, while conventional neck dissection was conducted after transverse skin incision from the mastoid tip to the midline.
3158811|NCT01488669|Active Comparator|Conventional neck dissection|Neck dissection is performed after an external transverse skin incision.
3158812|NCT01488656|Placebo Comparator|Placebo dietary supplements|Visually identical inactive dietary supplement pack
3158813|NCT01488656|Experimental|Active dietary supplements|Combination of antioxidants, minerals, fish oil, proflavanol and vitamin D
3158814|NCT01488643||OBESITY PATIENTS|PATIENTS WITH BMI >35
3158815|NCT01488643||CONTROL TEAM BMI <35|
3158816|NCT01488630|No Intervention|Treatment as Usual|Chart review only.
3158817|NCT01488630|Experimental|STaRS|Patients asked to participate in follow-up study to get information on whether they went to referral recommended by their provider through the STaRS system.
3158818|NCT01488604|Experimental|PNS|2 sprays of experimental nasal spray per nostril 4 times per day for 7 days
3158819|NCT01488604|Sham Comparator|SNS|2 sprays of sham nasal spray per nostril 4 times per day for 7 days
3158820|NCT01488578||Tolterodine tartrate.|Subjects taking Tolterodine tartrate.
3158821|NCT01488565|Experimental|Azacitidine and Eltrombopag|Vidaza (azacitidine) Revolade (eltrombopag)
3158822|NCT01488552|Experimental|Gemcitabine & Abraxane Pancreatic Cancer|Gemcitabine+Nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin and Folfiri
3158823|NCT01488539|Experimental|STAIR/NT|Patients will receive STAIR/NT treatment
3158824|NCT01488539|Other|Treatment as Usual (TAU)|Patients will receive Treatment as Usual (TAU)
3158825|NCT01488526|No Intervention|Control arm: HBIG & vaccine for infants|Provide standard of care to mothers and standard immunoprophylaxis to their infants
3158826|NCT01488526|Experimental|TDF treatment arm|tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum for mothers and standard immunoprophylaxis to their infants
3158827|NCT01488513|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sphingosine kinase-2 inhibitor ABC294640 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3158828|NCT01488500|Experimental|Filtered air exposure|3 hour exposure to filtered air with intermittent exercise
3158829|NCT01488500|Experimental|Wood smoke exposure|3 hour exposure to dilute wood smoke generated from incomplete combustion in a wood burning stove at approximately 300 mcg/m3
3158830|NCT01488500|Experimental|Wood pellet smoke emission|3 hour exposure to dilute wood smoke generated from wood pellets during incomplete combustion during intermittent exercise at approximately 300 mcg/m3
3158831|NCT01488487|Experimental|Everolimus + pasireotide|Oral Everolimus 7.5 mg administered daily for 28 days per cycle, plus pasireotide Long Acting Release (LAR) 60 mg administered by intramuscular injection once per 28 day cycle on day 1.
3158832|NCT01488474||Diabetes Mellitus (DM)|Patients with diagnosed diabetes mellitus type 1 or 2 undergoing surgery of the lower limb and are receiving regional anesthesia with peripheral nerve stimulation
3158833|NCT01488474||Control (C)|Patients with no history of diabetes mellitus Type 1 or 2 undergoing surgery of the lower limb and are receiving regional anesthesia with peripheral nerve stimulation
3158834|NCT01488461||patients ataxic|
3158835|NCT01488448|Experimental|Nebulized Hypertonic Saline|4mL nebulized 3% sodium chloride every 4 hours until discharge
3158836|NCT01488448|Placebo Comparator|Nebulized Normal Saline|4 mL nebulized 0.9% sodium chloride every 4 hours until discharge
3158837|NCT01488435|Placebo Comparator|Cow's Milk|Powdered whole cow's milk
3158838|NCT01488435|Experimental|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
3159255|NCT01485302|Experimental|Cohort 2|Dose 2 IV infusion
3158839|NCT01488422|Active Comparator|Group 1|Both groups will receive stress reduction materials. We expect both groups to achieve similar amounts of stress reduction, but to use different brain regions to do so.
3158840|NCT01488422|Active Comparator|Group 2|Both groups will receive stress reduction materials. We expect both groups to achieve similar amounts of stress reduction, but to use different brain regions to do so.
3158841|NCT01488409|Experimental|Acipimox|Treatment with the study drug Acipimox
3158842|NCT01488409|Placebo Comparator|Placebo|Treatment with Placebo control.
3158843|NCT01488396|Experimental|0.05%cyclosporin eye drop|
3158844|NCT01488383|Experimental|Stevioside capsules 200mg|Capsules of 200mg Stevioside
3158845|NCT01488383|Active Comparator|Sodium Saccharin 250 capsules|Capsules of 250mg Saccharin
3158846|NCT01488370|Active Comparator|Glidescope|A device for endotracheal intubation.
3158847|NCT01488370|Active Comparator|Storz|A device for endotracheal intubation.
3158848|NCT01488370|Active Comparator|Standard Laryngoscope|A device for endotracheal intubation
3158849|NCT01488357||Early stage breast cancer patients receiving mastectomy|
3158850|NCT01488344|Experimental|BIBF 1120|
3158851|NCT01488331||Cohort|
3158852|NCT01488318|Experimental|CETUXIMAB AND DASATINIB|"Cetuximab on a standard weekly schedule (see Section 6.2). Group 1 (subjects more than 2 weeks post last dose of Cetuximab): Loading dose of 400 mg/m2 on cycle 1, day 1 then 250 mg/m2 IV weekly.~Group 2 (subjects last Cetuximab treatment within 2 weeks): Cycle 1 will start at a dose of 250 mg/m2 Dasatinib 150 mg once daily without interruption. On the FIRST cycle (1 cycle is 3 weeks) dasatinib will start 3 days after the cetuximab loading dose (i.e. cycle 1, day 4) to avoid headache as shown on the previous phase I trial.~Treatment will continue until progression."
3158853|NCT01488305|No Intervention|Only government regular program|One arm is control arm, in this arm no additional program is added in government regular program
3158854|NCT01488305|No Intervention|AAMA arm (HFP and IYCF BCC)|Second arm is AAMA project intervention which includes HFP activities, ENA and BCC activities
3158855|NCT01488305|No Intervention|MNP added in AAMA|It is actually a intervention arm
3158856|NCT01488292|Experimental|RECAP social skills and reading program|
3158857|NCT01488292|No Intervention|Control group (services as usual)|Control Group (services as usual)
3158858|NCT01488279|Active Comparator|Dexamethasone 2.5mg and Sitagliptin100mg|Participants received Dexamethasone 2.5 mg plus Sitagliptin 100 mg daily for 8 days
3158859|NCT01488279|Placebo Comparator|Dexamethasone 2.5mg and placebo tablet|Participants received Dexamethasone 2.5 mg plus Sitagliptin-matched placebo tablet daily for 8 days.
3158860|NCT01488266|Experimental|aripiprazole augmentation|
3158861|NCT01488266|Active Comparator|different class of antidepressant|
3158862|NCT01488253|Experimental|acute GVHD prevention by sirolimus based regimen|The investigators will evaluated the primary endpoint and secondary endpoints comparing with historical control, that is used tacrolimus/methotrexate as a GVHD prophylaxis after HLA-matched, related PBSCT.
3158863|NCT01488240|Active Comparator|Proximal|part of scar proximal to heart
3158864|NCT01488240|Active Comparator|Distal|part of scar distal to heart
3158865|NCT01488227|Experimental|Vitamin D|Vitamin D
3158866|NCT01488227|Placebo Comparator|Oil pill|Contains vegetable and soybean oil supplied by Nature Made by Pharmavite LLC located in Northridge, CA and is United States Pharmacopeia (USP) certified.
3158867|NCT01488214|Experimental|Scleroderma patient|Evaluation of Scleroderma patient
3158868|NCT01488214|Placebo Comparator|Healthy subjects|Evaluation of healthy subjects
3158869|NCT01488201|Experimental|KHK4827|
3158870|NCT01488201|Placebo Comparator|Placebo|
3158871|NCT01488188|Active Comparator|Influenza vaccine-Nasal|Nasal administration
3158872|NCT01488188|Active Comparator|Influenza vaccine -Sublingual|Sublingual administration
3158873|NCT01488175|Active Comparator|with tourniquet|
3158874|NCT01488175|Placebo Comparator|without tourniquet|
3158875|NCT01488162||Cohort|
3158876|NCT01488149||Recipients of intrapartum epidural analgesia|
3158877|NCT01488149||Non-recipients of intrapartum epidural analgesia|
3158878|NCT01488136|Experimental|Diazoxide|
3158879|NCT01488136|Placebo Comparator|Placebo|
3158880|NCT01488123|Experimental|Ayurvedic Intervention|
3158881|NCT01488110|Experimental|Migraine medical device|Treatment with an active nasal probe
3158882|NCT01488110|Placebo Comparator|Inactive migraine medical device|Treatment with an inactive nasal probe.
3158883|NCT01488097|Experimental|Open-Label Sebelipase Alfa|Participants were administered sebelipase alfa once weekly (qw) as an intravenous (IV) infusion at the same dose received in Study LAL-CL01 (0.35, 1, or 3 milligrams per kilogram [mg/kg]) for 4 weeks. After the initial 4 qw doses, participants transitioned to dosing every other week (qow) at either 1 mg/kg (participants who initiated treatment at 0.35 or 1 mg/kg qw) or 3 mg/kg (participants who initiated dosing at 3 mg/kg qw). Subsequent modifications to the dose and dosing frequency were permitted for individual participants based on observed safety, tolerability, and clinical response to treatment. Participants could continue to receive treatment with sebelipase alfa for up to 5 years.
3158884|NCT01488084|Experimental|"Pedicled no-touch SVG harvesting"|Saphenous vein harvested with a pedicle of surrounding fat and distension with heparinized blood at arterial pressure. No manual distention.
3158885|NCT01488084|Active Comparator|Conventional open SVG harvesting|Saphenous vein is harvested with an open technique, stripped of adventitia, and manually distended with crystalloid solution.
3158886|NCT01488071|Experimental|Vortioxetine 10 mg or 20 mg|
3158887|NCT01488071|Active Comparator|Agomelatine 25 mg or 50 mg|
3158888|NCT01488058|Other|Group 2|Waitlist control
3158889|NCT01488058|Experimental|Group 1|CBM intervention (OxIGen) plus Internet based Cognitive Behavioural Therapy for depression
3158890|NCT01488045|Active Comparator|Fentanyl and Midazolam|Fentanyl and Midazolam sedation for colonoscopy discomfort
3158891|NCT01488045|Active Comparator|Propofol|Propofol sedation for colonoscopy discomfort
3158892|NCT01488032||high-tension glaucoma|subjects with IOP>22 mmHg without eyedrops and signs of glaucomatous optic nerve damage
3159256|NCT01485302|Experimental|Cohort 3|Dose 3 IV infusion
3158893|NCT01488032||low-tension glaucoma|subjects with IOP<22 mmHg without eyedrops and signs of glaucomatous optic nerve damage
3158894|NCT01488019|Experimental|Perforomist, nebulization, COPD|Active
3158895|NCT01488019|Placebo Comparator|Perforomist-Placebo|Placebo
3158896|NCT01488006||Bigliani/Flatow Shoulder System|Other than the Bigliani/Flatow device, there will be no difference in treatment between those patients undergoing arthroplasty with the Bigliani / Flatow prosthesis and those who previously received other prosthesis. APatients who decide to participate in the study will complete various forms prior to surgery (The Informed Consent, Contact Information Form, Demographics Module, and standard outcomes forms such as American Shoulder and Elbow Surgeon Score form, Constant's Score form, and the Simple Shoulder Test, EuroQOL and SF-36). The patient will also complete forms postoperatively at 3-month, 6-month, 1-year, 2-year, 3-year, 4-year and 5-year intervals (American Shoulder and Elbow Surgeon Score form, Constant's Score form, Simple Shoulder Test, EuroQOL and SF-36).
3158897|NCT01487993|Active Comparator|Metformin|Metformin with lifestyle intervention during 18 months
3158898|NCT01487993|Placebo Comparator|Placebo|Placebo and lifestyle intervention during 18 months
3158899|NCT01487980|Active Comparator|Early cord clamping|Within 30 seconds after birth.
3158900|NCT01487980|Experimental|Delayed cord clamping|Between 2 and 3 minutes after birth
3158901|NCT01487967|Experimental|Intervention|Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
3158902|NCT01487967|No Intervention|Control|Parents will receive education on ADHD and its treatment, and otherwise receive standard care.
3158903|NCT01487954|Experimental|Arm I: alkaline water|Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks. Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
3158904|NCT01487954|Active Comparator|Arm II: distilled water|Patients undergo external beam radiation therapy as in arm I. Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy
3158905|NCT01487928|Experimental|Human Milk Cream Group|For infants randomized to the human milk cream group, the human milk (either mother's own or donor) being provided to the infant will be tested each time a new container is used to prepare feedings. The test will be for the caloric content of the milk using a commercially available device provided for this purpose. If the caloric level falls below 20 kcal/oz for any test, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. The amount added will be calculated to the nearest mL rounding down for 0.1-0.4mL and up for 0.5-0.9 mL to avoid imprecision due to the measuring device used in the nutrition preparation area.
3158906|NCT01487928|No Intervention|Control Group|For infants randomized to the Control group, human milk and human milk derived fortifier will be provided according to the institutional standard of care and there will be no use of the milk analysis (mother's own or donor), which is typical for the vast majority of neonatal intensive care units.
3158907|NCT01487915|Active Comparator|GCb|Gemcitabine plus Carboplatin
3158908|NCT01487915|Experimental|GemOx|Gemcitabine plus Oxaliplatin
3158909|NCT01487902|Experimental|ADT arm|Concomitant androgen deprivation treatment
3158910|NCT01487902|Active Comparator|No ADT arm|No concomitant androgen deprivation treatment arm
3158911|NCT01487889|Experimental|Rapeseed oil|Study group receive commercial vegetable-potato-meat-meals containing rapeseed oil as part of complementary food
3158912|NCT01487889|Experimental|Fatty fish|Study group receive 2 times per week a vegetable-potato-meat-meals as part of complementary food.
3158913|NCT01487889|Active Comparator|Corn oil|Study group receive commercial vegetable-potato-meat-meals containing corn oil as part of complementary food
3158914|NCT01487876|Experimental|LAM+DNA vaccine|lamivudine (LAM) chemotherapy and DNA vaccine
3158915|NCT01487876|Placebo Comparator|LAM+Placebo|"Each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.~lamivudine (LAM) chemotherapy and Placebo"
3158916|NCT01487863|Experimental|Concurrent Arm|Subjects received sipuleucel-T concurrent with abiraterone acetate plus prednisone. Abiraterone acetate plus prednisone treatment started the next day after the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
3158917|NCT01487863|Experimental|Sequential Arm|Subjects received sipuleucel-T therapy followed by abiraterone acetate plus prednisone. Abiraterone acetate plus prednisone started at week 10 from the start of the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
3158918|NCT01487837|Active Comparator|Fibrinogen if FibTEM < 8 mm|Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF < 8 mm
3158919|NCT01487837|Experimental|Fibrinogen if FibTEM < 13 mm|Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF < 13 mm
3158920|NCT01487824||Preterm-born Young Adults|
3158921|NCT01487824||Term-born Young Adults|
3158922|NCT01487811|Experimental|Formulation 1|
3158923|NCT01487811|Active Comparator|Formulation 2|
3158924|NCT01487798|Experimental|Treatment period 1|
3158925|NCT01487798|Active Comparator|Treatment period 2|
3158926|NCT01487785|Experimental|LDE225+gemcitabine|Increasing doses of LDE225 (from 400 mg) once a day + 1000 mg/m2 of gemcitabine on days 1, 8 and 15 of every 28 day cycle.
3158927|NCT01487772||Hip-fracture patients|Hip-fracture patients admitted to Orthopaedic Department of Danderyd Hospital
3158928|NCT01487759|Active Comparator|Prebiotic|
3158929|NCT01487759|Placebo Comparator|Placebo|
3158930|NCT01487746||treatment|Stroke patients
3158931|NCT01487746||Controls|healthy controls
3158932|NCT01487720|Experimental|GEMOX|GEMOX treatment
3158933|NCT01487707|Experimental|Voluntary Health Worker (VHW) Program|
3158934|NCT01487707|Experimental|VHW program plus Safe Birth Kit|
3158935|NCT01487707|Experimental|VHW program plus Folk Media Activities|
3158936|NCT01487694|Experimental|Cimicifuga racemosa|patients receive cimicifuga racemosa rhizome and root extract 40 mg/day (equivalent to triterpene glycosides 12.3 mg)
3158937|NCT01487694|Placebo Comparator|Placebo|Placebo containing no active ingredient which match the drug in bottle, shape, color and smell
3158938|NCT01487681||Invasive cervical cancer|
3158939|NCT01487681||Cervical intraepithelial neoplasia 2/3|
3158940|NCT01487681||Cervical intraepithelial neoplasia 1|
3158941|NCT01487668|No Intervention|Arm 1 - Usual Care|Usual care will include standard mental health and medical care available in the VA clinics but with no active management by the LGCC health specialist.
3158942|NCT01487668|Experimental|Arm 2 - Life Goals Collaborative Care|
3158943|NCT01487655||healthy age matched controls|
3158944|NCT01487655||normal tension glaucoma patients|
3158945|NCT01487655||primary open angle glaucoma patients|
3158946|NCT01487642|Experimental|Telephone counselling|
3158947|NCT01487642|Experimental|Proactive telephone counselling|
3158948|NCT01487642|Experimental|web-based smoking cessation programme|
3158949|NCT01487642|Active Comparator|Self-help material|
3158950|NCT01487629|Experimental|Bevacizumab|Treatment of macular edema with intravitreal Bevacizumab
3158951|NCT01487629|Experimental|Ranibizumab|Treatment of macular edema with intravitreal Ranibizumab
3158952|NCT01487616||Women with previous preterm birth|Women with history of preterm birth (birth of a baby of less than 37 weeks gestational age, where labour was spontaneous) regardless of past pregnancy history.
3158953|NCT01487616||Women with previous miscarriage|Women with history of miscarriage (spontaneous pregnancy loss before 24 weeks of gestation), regardless of past pregnancy history.
3158954|NCT01487616||Women with previous term births|Women with previous term births (37 or more weeks of gestation)
3158955|NCT01487603||confirmed or suspected lung cancer|
3158956|NCT01487590|Active Comparator|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
3158957|NCT01487590|Placebo Comparator|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
3158958|NCT01487577|Experimental|Mycophenolate mofetil|Pharmacokinetics-based targeting of mycophenolate mofetil
3158959|NCT01487564|Experimental|Hydromorphone 16 mg|
3158960|NCT01487551|Experimental|paquinimod|
3158961|NCT01487538|Experimental|intervention group|
3158962|NCT01487538|Active Comparator|Standard Advice Group|
3158963|NCT01487525|Placebo Comparator|PBFR-|double leg press without application of partial blood flow restriction to the upper leg
3158964|NCT01487525|Experimental|PBFR+|double leg press with application of partial blood flow restriction to the upper leg
3158965|NCT01487512|Experimental|Sequence 1: Treatment A-D-B-C|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
3158966|NCT01487512|Experimental|Sequence 2: Treatment B-A-C-D|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
3158967|NCT01487512|Experimental|Sequence 3: Treatment C-B-D-A|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
3158968|NCT01487512|Experimental|Sequence 4: Treatment D-C-A-B|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
3158969|NCT01487499|Experimental|patients with limited stage SCLC|Subjects with limited stage SCLC treated sequentially with cisplatin.
3158970|NCT01487499|No Intervention|Historical Controls|No intervention
3158971|NCT01487486||Normal patients|Women with infertility diagnosis of male factor only or women who are oocyte donors
3158972|NCT01487486||Polycystic Ovary Syndrome, High BMI|Women with Polycystic Ovary Syndrome with a BMI between 30-35
3158973|NCT01487486||Polycystic Ovary Syndrome, Low BMI|Women with Polycustic Ovary Syndrom with a BMI between 20 & 25
3158974|NCT01487473|Active Comparator|Mindfulness-Based Stress Reduction|
3158975|NCT01487473|No Intervention|Waitlist Control|
3158976|NCT01487460|Experimental|TAP311 in Healthy Volunteers|
3158977|NCT01487460|Placebo Comparator|Matching Placebo|Healthy Volunteers and Patients will be treated in Placebo group.
3158978|NCT01487460|Experimental|TAP311 and Simvastatin|
3158979|NCT01487460|Experimental|TAP311 in Patients|
3158980|NCT01487447|Experimental|Intervention|
3158981|NCT01487447|Active Comparator|Control|
3158982|NCT01487434|Experimental|Check & Connect|Check and Connect Structured Mentoring and Case Management
3158983|NCT01487421||SIT|
3158984|NCT01487408||Insulin Aspart|
3158985|NCT01487395|Active Comparator|Donepezil|Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
3158986|NCT01487395|Placebo Comparator|Placebo|The placebo will be presented as tablet comparable to ARICEPT
3158987|NCT01487382||Insulin Aspart|
3158988|NCT01487369||Insulin Aspart|
3158989|NCT01487356||Patients undergoing colonoscopy|Data was collected on all adult patients undergoing outpatient colonoscopy at St. Paul's Hospital from May 2008 to June 2009. Exclusion criteria were prior colon resection and repeat colonoscopy for the purpose of endoscopic therapy for known lesions.
3158990|NCT01487343||breast or gastrointestinal cancer pts taking capecitabine|This is a mixed-methodology pilot study of patients currently taking oral chemotherapy for breast or gastrointestinal cancer. The quantitative portion of the study consists of self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions.
3158991|NCT01487330|Experimental|Subjects receiving TAVI valve|
3158992|NCT01487317|Experimental|Rivastigmine transdermal patch|
3158993|NCT01487317|Placebo Comparator|placebo|
3158994|NCT01487304||Low dose HRT|
3158995|NCT01487291||Psychotic patients|Inpatients and outpatients followed at Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro, Brazil
3158996|NCT01487278|Experimental|Misoprostol|600 mcg oral misoprostol administered during the third stage of labor
3158997|NCT01487278|Experimental|UnijectTM|10 IU oxytocin delivered IM with UnijectTM during he third stage of labor
3158998|NCT01487265|Experimental|BKM120 and Erlotinib|"Cycle 1: BKM120 80 mg PO daily; Erlotinib 100mg PO daily~Cycles 2 and beyond: BKM120 100 mg PO daily; Erlotinib 100mg PO daily"
3158999|NCT01487252|Active Comparator|Healthy Controls|
3159000|NCT01487252|Active Comparator|Delayed Sleep Phase Disorder|
3159001|NCT01487239|Experimental|A|[14C]-GDC-0980 administered as a 10-mg oral dose
3159002|NCT01487213|No Intervention|Controls|Routine follow-up at the clinic 2-3 weeks after the treatment
3159003|NCT01487213|Other|Home self test|Intervention
3159004|NCT01487200|Experimental|FX006 10mg|
3159005|NCT01487200|Experimental|FX006 40mg|
3159006|NCT01487200|Experimental|FX006 60 mg|
3159007|NCT01487200|Active Comparator|commercially available triamcinolone acetonide (40 mg)|
3159008|NCT01487187|Active Comparator|immediate umbilical cord clamping|The control group will receive immediate cord clamping at birth which is the standard of care in our institution
3159009|NCT01487187|Experimental|Milking the umbilical cord at birth|Infants in the cord-milked group will be placed at or below the level of the placenta, and about 20 cm of the umbilical cord (or the length of cord that is accessible if less than 20 cm) will be vigorously milked towards the umbilicus three times before clamping the cord.
3159010|NCT01487174|Experimental|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
3159011|NCT01487174|Active Comparator|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
3159012|NCT01487161|Experimental|FX006 10 mg|Single 3 mL intra-articular (IA) injection Extended-Release Formulation
3159013|NCT01487161|Experimental|FX006 40 mg|Single 3 mL intra-articular (IA) injection Extended-Release Formulation
3159014|NCT01487161|Experimental|FX006 60 mg|Single 3mL intra-articular (IA) injection Extended-Release Formulation
3159015|NCT01487161|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-Release Triamcinolone Acetonide
3159016|NCT01487135|Experimental|EVP-6124|A single low dose of 8-mg EVP-6124 and A single high dose of 80-mg EVP-6124
3159017|NCT01487135|Placebo Comparator|Placebo|Cranberry juice (180 mL)
3159018|NCT01487135|Active Comparator|Moxifloxacin|A single dose of 400-mg Moxifloxacin
3159019|NCT01487122|Experimental|Continuous Microwave|
3159020|NCT01487122|Experimental|Pulsed Microwaves|
3159021|NCT01487122|Sham Comparator|sham microwaves|
3159022|NCT01487109|Placebo Comparator|Placebo|matching placebo tablets
3159023|NCT01487109|Active Comparator|CTP-499|600 mg tablet
3159024|NCT01487096|Placebo Comparator|Placebo|"Placebo (for teriflunomide),~two tablets once daily for 1 week then,~one tablet once daily for 35 weeks."
3159025|NCT01487096|Experimental|Teriflunomide 7 mg|"Teriflunomide 7 mg:~two tablets once daily for 1 week then,~one tablet once daily for 35 weeks."
3159026|NCT01487096|Experimental|Teriflunomide 14 mg|"Teriflunomide 14 mg:~two tablets once daily for 1 week then,~one tablet once daily for 35 weeks."
3159027|NCT01487083|Experimental|Pomaglumetad methionil|Pomaglumetad methionil will be administered orally. Participants entering the study will be flexibly dosed between 20 mg, 40 mg, and 80 mg twice daily.
3159028|NCT01487070|Experimental|Macugen (Pegaptanib Sodium)|Open-label, single-center trial. Subjects will recieve intravitreous injections of Macugen 7-14 days before Vitrectomy.
3159029|NCT01487057||Thyroid cancer, lipids, LT4 withdrawal|
3159030|NCT01487057||Thyroid cancer, Lipids, LT4 substitution|
3159031|NCT01487031|Experimental|Music Therapy|Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room.
3159032|NCT01487031|Active Comparator|No music therapy|Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
3159033|NCT01487018|Experimental|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
3159034|NCT01487018|Active Comparator|Traditional Surgery|To compare with the experimental arm.
3159035|NCT01487005||elderly subjects|Healthy
3159036|NCT01486992|Experimental|Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
3159037|NCT01486979|Experimental|Low dose|
3159038|NCT01486979|Active Comparator|High dose|
3159039|NCT01486966|Experimental|Insulin detemir / IAsp|
3159040|NCT01486966|Active Comparator|insulin NPH|
3159041|NCT01486953|Active Comparator|sevoflurane|Anesthesia with sevoflurane
3159042|NCT01486953|Experimental|Desflurane|Anesthesia with desflurane
3159043|NCT01486940|Experimental|Basal/bolus regimen 1|
3159044|NCT01486940|Active Comparator|Basal/bolus regimen 2|
3159045|NCT01486927|Experimental|Recombinant Factor VIII (rFVIII)|
3159046|NCT01486914|Experimental|NN2000|
3159047|NCT01486914|Active Comparator|IAsp|
3159048|NCT01486901|Experimental|Formulation A|
3159049|NCT01486901|Active Comparator|Formulation B|
3159050|NCT01486888|Experimental|Formulation A|
3159051|NCT01486888|Active Comparator|Formulation B|
3159052|NCT01486875||BIAsp 30|
3159053|NCT01486862|Experimental|BIAsp 30|
3159054|NCT01486849|Experimental|Dose Titration of CK-2017357 (Group 1)|Dose titration of active drug as add-on therapy to riluzole
3159055|NCT01486849|Placebo Comparator|Matching Placebo (Group 2)|Placebo as add-on therapy to riluzole
3159056|NCT01486836||ICD therapy|
3159057|NCT01486823|Experimental|Cohort A|
3159058|NCT01486823|Experimental|Cohort B|
3159098|NCT01486550|Placebo Comparator|Sodium Chloride 9mg/ml|Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
3159099|NCT01486537||theeth undergoing pulpotomy|
3159059|NCT01486810|Experimental|Lisdexamfetamine and medication management|Patients will be titrated to the tolerated dose of Lisdexamfetamine over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks. All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
3159060|NCT01486797|Experimental|NOX-A12|
3159061|NCT01486784|Experimental|Phase 1|
3159062|NCT01486784|Experimental|Phase 2|
3159063|NCT01486771|Experimental|IV Macugen Q6|Will receive 3 intravitreal pegaptanib injections at 6-week intervals, then 3 additional injections at 12-week intervals
3159064|NCT01486771|Experimental|IV Mac Q6 Arm|Will Selective Laser Photocoagulation after 3 intravitreal pegaptanib injections
3159065|NCT01486771|Experimental|Pan Retinal Photocoagulation|Will act as the control group, thus subjects in this group will receive standard PRP (modified ETDRS protocol)
3159066|NCT01486758|Active Comparator|Azithromycin|Oral azithromycin
3159067|NCT01486758|Placebo Comparator|Placebo|Oral Placebo
3159068|NCT01486745||Normal colonoscopy|
3159069|NCT01486745||Colonic polyps|
3159070|NCT01486745||Colorectal cancer patients|
3159071|NCT01486745||Breast & Prostate Cancer patients|
3159072|NCT01486732|Experimental|Umbilical Cord Blood & Rehabilitation|Allogeneic umbilical cord blood infusion and active rehabilitation
3159073|NCT01486732|Active Comparator|Placebo Umbilical Cord Blood & Rehabilitation|Placebo Umbilical Cord Blood infusion and active rehabilitation
3159074|NCT01486706|Experimental|Gabapentin|Two to three months of behavioral therapy prior to start of Gabapentin 100mg/capsule, initially 1 capsule once a day for 1 week then titrate dosage according to symptoms until maximum dose of 1500mg/day Placebo tablet of Solifenacin Succinate will titrate dose same as Solifenacin arm according to symptoms of patient
3159075|NCT01486706|Active Comparator|Solifenacin Succinate|Two to three months of behavioral therapy prior to Solifenacin Succinate 5mg/tablet initially 1 tablet once a day then titrate dosage according to symptoms upto maximum dose of 10mg/day Placebo form of Gabapentin will titrate dosage same as Gabapentin group according to symptoms of patient
3159076|NCT01486706|Placebo Comparator|Placebo|Two to three months of behavioral therapy prior to Placebo form of Gabapentin and Solifenacin and titrate accordingly same as the treatment arms
3159077|NCT01486680|Active Comparator|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|
3159078|NCT01486680|Active Comparator|Laparoscopic Sleeve Gastrectomy|
3159079|NCT01486667|Placebo Comparator|sugar pill|
3159080|NCT01486667|Active Comparator|Levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients. Serum levels of TSH and FT4 will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
3159081|NCT01486654|Active Comparator|Anodal stimulation|
3159082|NCT01486654|Active Comparator|Cathodal stimulation|
3159083|NCT01486654|Placebo Comparator|Sham stimulation|
3159084|NCT01486641|Active Comparator|Anterolateral approach|"Patients with a displaced femoral neck fracture operated through the anterolateral approach to the hip arthroplasty.~Lubinus total hip arthroplasty or varikopf hemiarthroplasty."
3159085|NCT01486641|No Intervention|Posterolateral approach|"Patients with a displaced femoral neck fracture operated through the posterolateral approach to the hip arthroplasty.~Lubinus total hip arthroplasty or varikopf hemiarthroplasty."
3159086|NCT01486628|Placebo Comparator|levodopa and carbidopa|
3159087|NCT01486628|Placebo Comparator|Placebo|Saline solution for subcutaneous administration
3159088|NCT01486615|Placebo Comparator|Melatonin|Premedication with 3 mg melatonin (Meloset) tablet orally 1-2 hour prior to anesthesia
3159089|NCT01486615|Placebo Comparator|melatonin and alprazolam premedication|Premedication with 3 mg melatonin and 0.5 mg alprazolam (Stresnil) tablet orally 1-2 hrs prior to anesthesia
3159090|NCT01486615|Placebo Comparator|alprazolam premedication|Premedication with 0.5 mg alprazolam (Alprax) tablet orally 1-2 hr prior to anesthesia
3159091|NCT01486615|Active Comparator|placebo premedication|Premedication with a similar looking placebo tablet orally 1-2 hr prior to anesthesia
3159092|NCT01486602|Experimental|Concurrent therapy + consolidation therapy|"Concurrent Therapy (1 cycle = 14 days, Cycles 1-3): Patients will receive paclitaxel 45 mg/m^2 by IV over 1 hour weekly followed by carboplatin AUC 2 by IV over 30-60 minutes for 4 weeks (there will be no chemotherapy during Cycle 3). Patients will receive radiotherapy concurrently for up to 5.5 weeks, depending on the cohorts the patient is registered defined per the protocol.~Consolidation Therapy (1 cycle = 21 days, Cycles 4-5): Four weeks following the end of radiotherapy patients will receive paclitaxel 200 mg/m^2 by IV over 3 hours followed by carboplatin AUC 6 by IV over 30-60 minutes on day 1 of each 21 day cycle for a total of 2 cycles (days 1 and 22)."
3159093|NCT01486576|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing hip replacement surgery will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride. Patients will receive minimum 7,5 ml/kg in the first hour of the surgery and 5 ml/kg in the subsequent hours.
3159094|NCT01486576|Placebo Comparator|Sodium Chloride 9 mg/ml|Patients undergoing hip replacement surgery will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride. Patients will receive minimum 7,5 ml/kg in the first hour of the surgery and 5 ml/kg in the subsequent hours.
3159095|NCT01486563|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing radical prostatectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
3159096|NCT01486563|Placebo Comparator|Sodium Chloride 9 mg/ml|Patients undergoing radical prostatectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
3159097|NCT01486550|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
3159100|NCT01486537||teeth undergoing pulpectomy|
3159101|NCT01486524||DrotAA Treatment Group|Patients with severe sepsis at high risk of death (INDICATED patients) who received treatment with drotrecogin alfa (activated (DrotAA) as part of standard care in ICU. The standard dosing regimen for DrotAA is 96 hours of continuous infusion at a dose of 24 ug/kg/hour. DrotAA is also known as recombinant human activated protein C.
3159102|NCT01486524||Control Group (non-DrotAA treated)|Patients with severe sepsis at high risk of death (INDICATED patients) who did not receive DrotAA treatment as part of their standard care in an ICU. The Control group patients will be selected to match the DrotAA-treated patients based on numerous clinical covariates, including propensity score (for DrotAA treatment).
3159103|NCT01486511||Liver resection patients|All patients that underwent elective liver resection for both malignant and benign diseases.
3159104|NCT01486485|Experimental|heparinized saline priming group|Experimental group : heparinized saline priming group
3159105|NCT01486485|Active Comparator|nafamostat infusion group after heparinized saline priming|active comparator : nafamostat infusion group after heparinized saline priming
3159106|NCT01486472||GC patients receiving adjuvant S-1 chemotherapy|
3159107|NCT01486459|Experimental|PCI with lithium|Prophylactic cranial irradiation Lithicarb® tablets 250mg/day for 6 weeks. Initial dosing will be 250mg given once daily, and increased by 250 - 500 mg increments depending on plasma levels.
3159108|NCT01486459|No Intervention|Standard|Prophylactic cranial irradiation alone.
3159109|NCT01486446|Experimental|XPF-002|XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
3159110|NCT01486446|Placebo Comparator|Placebo|XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
3159111|NCT01486433|Experimental|Epanova and Simvastatin|
3159112|NCT01486433|Active Comparator|Simvastatin|
3159113|NCT01486420|Active Comparator|Open surgery|
3159114|NCT01486420|Active Comparator|Corticosteroid Injection|
3159115|NCT01486407||Intravenous (IV) drug delivery|patients on whom intravenous vascular access has been established for the purpose of rapid sequence intubation drug delivery.
3159116|NCT01486407||Intraosseous (IO) drug delivery|Patients on whom intraosseous vascular access has been established for rapid sequence intubation drug delivery.
3159117|NCT01486394|Experimental|Focused sonography|Intervention group: After the primary evaluation by a physician in the emergency department, focused sonography of the patients heart, lungs and deep veins in the legs are performed. Hereafter the further examinations and treatment are done according to hospital guidelines.
3159118|NCT01486394|No Intervention|Usual treatment and diagnostic work-up|Control group: After the primary evaluation by a physician in the emergency department. Hereafter the further examinations and treatment are done according to hospital guidelines.
3159119|NCT01486381|Experimental|BIAsp 30|
3159120|NCT01486368|Experimental|PF-03446962|
3159121|NCT01486355|Experimental|Early measles vaccine|Receives an early measles vaccine in addition to the standard measles vaccine at 9 months of age
3159122|NCT01486355|No Intervention|No early measles vaccine|Receives only the standard measles vaccine at 9 months of age
3159123|NCT01486342||Group 1|Mechanically ventilated patients without acute lung injury and lung injury prediction score < 4
3159124|NCT01486329|Experimental|VXM01|Investigational anti-angiogenic live cancer vaccine
3159125|NCT01486329|Placebo Comparator|Placebo|Placebo control
3159126|NCT01486316|Other|Control arm|Subjects in the Control arm will be observed between implant and month 12. During this time, the standard device diagnostic suite will be used as it would normally, in the office using the programmer, or by data transmission from the patient's home (or another remote location). At month 12 through study close (month 18), study doctors for the all subjects will have access to the risk status.
3159127|NCT01486316|Experimental|Risk Status Guided|Study doctors will have access to the experimental IDENTIFY-HF Risk Status for subjects in the Guided arm between months 6 and 18. At all times during the study, study doctors will also be able to use the standard device diagnostics in the office using the programmer, or by data transmission from the patient's home (or another remote location).
3159128|NCT01486303|Experimental|Facial Cosmetic Acupuncture|28 Patients with grade III to IV wrinkling on the face, according to the Glogau classification system, were treated with Facial Cosmetic Acupuncture.
3159129|NCT01486290|Experimental|Geriatric Diabetes Team Intervention|The subjects in this group underwent evaluation for barriers to self care by a diabetes educator well versed with age specific barriers. After consideration of patient clinical, function, and psychosocial background, a geriatric diabetes team devised strategy to help patients cope with respective barriers. An office based diabetes diabetes educator conveyed the strategy to patient and caregivers viz phone calls. the educator called study participants up wot eleven times over a sex month period.
3159130|NCT01486290|No Intervention|Atention Control Arm|The subjects in the group received similar, in person contact, as the intervention group. an educator, separate from the one involved in the intervention team, called patients in this group for a total of eleven times within the first six months. The Phone calls were focused toward general discussion without any diabetes related advice.
3159131|NCT01486277|Experimental|Quisinostat|Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
3159132|NCT01486264|Active Comparator|Xeomin® Short Flex|short flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
3159133|NCT01486264|Active Comparator|Xeomin® Long Flex|long flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
3159134|NCT01486251|Experimental|experimental|"axitinib will be given BID orally. One cycle is defined as a 14-day period (7 days ON / 7 days OFF). The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.~Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade > 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles."
3159135|NCT01486238|Experimental|IVMac q6 Arm|Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6week intervals beginning on Day 0 and ending at Week 18. Macugen® injection will be administered as described in the package insert.
3159136|NCT01486238|Experimental|IVMac q4 Arm|Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Macugen® injection will be administered as described in the package insert.
3159137|NCT01486225|Other|Innothera's brand Stokings|Innothera's branded grip-top silicone band stokingc
3159138|NCT01486225|Other|Other than Innothera's brand|
3159139|NCT01486212||Healthy volunteers.|Male aged 18-40 years. Non-smokers. No known familiar disposition to vascular/heart diseases. No intake of prescription medicine.
3159140|NCT01486199|Experimental|CF pediatric|In the pediatric arm 10 CF subjects ages 6-14 will perform absorptive clearance scans at baseline and at t=2 years.
3159141|NCT01486199|Experimental|Controls adult|In the adult control arm 10 healthy adult subjects will perform a single absorptive clearance scan.
3159142|NCT01486186|Experimental|traditional chinese medicine|The experimental group will receive three type of TCM, they are Baofei granule, Bufeijianpi granule and Bufeiyishen granule.
3159143|NCT01486186|Placebo Comparator|placebo|placebo chinese medicine in addition to best care according to clinical guidelines for COPD patients
3159144|NCT01486173||Premature infants with a GA < 32 Weeks|
3159145|NCT01486173||New born with a GA > 37Weeks|
3159146|NCT01486160||nursing home residents|participants in this group are nursing home residents
3159147|NCT01486160||Nursing home employees|Participants in this group are health care workers, employees at the nursing home
3159148|NCT01486147|Experimental|Visual|Group provided with nutrition information using visual nutrient profiling tool
3159149|NCT01486147|Other|Table|Group provided nutrition information using table format
3159150|NCT01486134|Experimental|procedure|
3159151|NCT01486121|Other|S.O.S.-V|
3159152|NCT01486121|No Intervention|Standard|
3159153|NCT01486108|Experimental|Tonic|5 hz stimulation at an amplitude that the patient find bearable (+/- 1.5 mA)
3159154|NCT01486108|Experimental|Sham|no stimulation, patient receive a sham stimulation (actually the IPG is not running)
3159155|NCT01486108|Experimental|burst|500 hz burst at 5 hz stimulation
3159156|NCT01486095|Experimental|AXXESS + Biomatrix|After mandatory predilatation, a self-expanding, conically shaped nickel-titanium AXXESS biolimus A9-eluting stent is placed at the level of the carina. The device is available in 3.0 and 3.5 mm calibre and 11 and 14 mm length. Depending on the lesion anatomy, additional Biomatrix™ Drug Eluting Coronary Stent Systems are placed distally if necessary. The procedure is completed with kissing balloon postdilatation using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
3159157|NCT01486095|Active Comparator|Culotte technique: Xience V/Prime|The culotte technique consists of stenting one of both branches of the bifurcation lesion first, and after balloon dilatation of the stent meshes, stenting the uncovered branch through the first stent and leaving the main vessel covered with two overlapped stents. The procedure is terminated by kissing balloon dilatation of both branches using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
3159158|NCT01486082||Empirical OCA|This group will be treated with omeprazole, amoxicillin and clarithromycin without having a previous antibiogram.
3159159|NCT01486082||OCA after antibiogram|This group will be treated with omeprazole, clarithromycin and amoxicillin after an antibiotic susceptibility confirmation.
3159160|NCT01486069||Dentofacial Deformity|Patients with dentofacial deformities candidate to orthognathic surgery
3159161|NCT01486056||healthy patients, may have epilepsy|Subjects at least 12 years old and in general good health for Phase I, and at least 18 years old and in general good health for Phase II. It is desired, but not required, for subjects to have epilepsy and taking at least 1 antiepileptic medication.
3159162|NCT01486043|Experimental|Metformin and insulin therapy|Up to 30-40 patients will be in the prospectively recruited treatment group, which will receive both metformin and insulin therapy for transient hyperglycemia
3159163|NCT01486017|Experimental|Treatment A|ASP015K oral dose low strength
3159164|NCT01486017|Experimental|Treatment B|ASP015K oral dose medium strength
3159165|NCT01486017|Experimental|Treatment C|ASP015K oral dose high strength
3159166|NCT01486004|Experimental|001|35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total) + 150 mg capsule once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle
3159167|NCT01485991|Experimental|TMC435/PR|
3159168|NCT01485991|Active Comparator|TVR/PR|
3159169|NCT01485978|Active Comparator|Ramipril blinded|oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years
3159170|NCT01485978|Placebo Comparator|placebo to ramipril|Oral placebo treatment to ramipril once daily for 3 years or until progress to next disease level. After progression to next disease level, patients will be unblinded, and ramipril treatment will be initiated.
3159171|NCT01485978|Other|open label ramipril|Open label treatment with ramipril as per protocol, if randomization is refused.
3159172|NCT01485965|Experimental|Fasted condition|Subjects in the Fasted group will take study drug after an overnight fast (since at least midnight). Additionally, on PK assessment days, no food will be allowed for at least 4 hours after study drug administration.
3159173|NCT01485965|Experimental|Fed condition|Subjects in the Fed group will take study drug within 30 minutes after starting breakfast; these subjects will otherwise maintain their normal eating schedule.
3159174|NCT01485952|Experimental|SEN0014196 (Low Dose)|10 mg, once daily administration (immediate release capsule)
3159175|NCT01485952|Experimental|SEN0014196 (High dose)|100 mg, once daily administration (immediate release capsule)
3159176|NCT01485952|Placebo Comparator|Placebo|Once daily (immediate release capsule)
3159177|NCT01485939|Placebo Comparator|placebo patch|
3159178|NCT01485939|Active Comparator|lidocaine patch|
3159257|NCT01485302|Experimental|Cohort 4|Dose 4 IV infusion
3159179|NCT01485926|Experimental|Docetaxel, Carboplatin and Trastuzumab|Arm A- 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
3159180|NCT01485926|Experimental|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|Arm B - 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
3159181|NCT01485913|Experimental|Lifestyle counseling|"The group subjected to educations will follow the whole process of peer education described in Part 1 of this Protocol.~The control group will perform these classic individual consultations but will not follow the whole process of peer education.~The classical management in diabetes consultations consists of:~A counselling session~A measure of blood glucose~A measurement of blood pressure~A measure of weight and size~A complete clinical examination~A prescription or a renewal of treatment (diabetes pills, insulin, IEC, statins etc ...)"
3159182|NCT01485913|No Intervention|No Lifestyle counseling|"The group subjected to educations will follow the whole process of peer education described in Part 1 of this Protocol.~The control group will perform these classic individual consultations but will not follow the whole process of peer education.~The classical management in diabetes consultations consists of:~A counselling session~A measure of blood glucose~A measurement of blood pressure~A measure of weight and size~A complete clinical examination~A prescription or a renewal of treatment (diabetes pills, insulin, IEC, statins etc ...)"
3159183|NCT01485900|Experimental|Cohort 1|Dose 1: 20 days 3-step uptitration with doses A, B, and C of SAR407899 vs. placebo
3159184|NCT01485900|Experimental|Cohort 2|Dose 2: 20 days 3-step uptitration with doses B, C and D of SAR407899 vs. placebo
3159185|NCT01485887|Experimental|Venlafaxine ER|
3159186|NCT01485874|Experimental|Doxil + BIBF 1120|
3159187|NCT01485861|Experimental|Phase Ib: Ipatasertib 400 mg + abiraterone|Participants will receive ipatasertib 400 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg twice daily (bid) continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
3159188|NCT01485861|Experimental|Phase Ib: Apitolisib 30 mg + abiraterone|Participants will receive apitolisib 30 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg twice daily (bid) continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
3159189|NCT01485861|Experimental|Phase II: Ipatasertib 400 mg + abiraterone|Participants will receive Ipatasertib 400 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
3159190|NCT01485861|Experimental|Phase II: Ipatasertib 200 mg + abiraterone|Participants will receive Ipatasertib 200 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
3159191|NCT01485861|Placebo Comparator|Phase II: Placebo + abiraterone|Participants will receive placebo (for Ipatasertib) once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
3159192|NCT01485848|Active Comparator|Paclitaxel|A single 1 hour intravenous infusion every week for 6 cycles (each cycle is 4 weeks)
3159193|NCT01485848|Experimental|Paclitaxel + EP-100|Paclitaxel every week plus EP-100 twice weekly by 1 hour intravenous infusion for the first 3 weeks of each 4 week cycle for 6 cycles (each cycle is 4 weeks)
3159194|NCT01485835|Experimental|Ganetespib + Bortezomib + Dexamethasone|"Ganetespib: IV; days 1, 4, 8, 11; every 3 weeks~Cohort 1: 100 mg/m²~Cohort 2: 100 mg/m²~Cohort 3: 120 mg/m²~Cohort 4: 144 mg/m²~Cohort 5: 173 mg/m²~Bortezomib: IV or subcutaneous; days 1, 4, 8, 11; every 3 weeks~Cohort 1: 1.0 mg/m²~Cohort 2, 3, 4, 5: 1.3 mg/m²~Dexamethasone: Oral prior to bortezomib~Cohort 1, 2, 3, 4, 5: 20 + 20 mg~Day of and following bortezomib"
3159195|NCT01485822||TRAVATAN|As prescribed by physician for the treatment of open-angle glaucoma and dosed for at least two years
3159196|NCT01485822||Treatment Naive|No prior exposure (or less than 1 month) to any topical, ocular prostaglandin analogue
3159197|NCT01485809|Experimental|Gefitinib|
3159198|NCT01485796|Experimental|Epoch 1 and Epoch 2|In Study Epoch 1 PIDD patients that are already on intravenous treatment or subcutaneous treatment will be enrolled and treated with IGI, 10% and rHuPH20 subcutaneously, with a short dose/interval ramp-up (Epoch 1) consisting of one 1-week dose and interval and one 2-week dose and interval. The ramp-up (Epoch 1) is followed by Epoch 2 which consists of approximately 6 months (24 weeks) of IGI, 10% and rHuPH20 treatment. For subjects pretreated intravenously (IV), this treatment will occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), depending on the subject´s previous IV dosing schedule. For subjects pretreated subcutaneously (SC), treatment will also occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), at the discretion of the investigator and subject.
3159199|NCT01485770|Experimental|ADX-N05|ADX-N05 to be taken once a day for 2 consecutive weeks during 4 week study treatment period
3159200|NCT01485770|Placebo Comparator|Placebo|Placebo to match ADX-N05 to be taken once a day for 2 consecutive weeks during 4 week study treatment period
3159201|NCT01485757|Experimental|L-arginine|
3159202|NCT01485744|Experimental|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|
3159203|NCT01485731|Experimental|Nelfinavir + Cisplatin + Pelvic Radiation Therapy|Nelfinavir in combination with Cisplatin and Pelvic Radiation Therapy
3159204|NCT01485718|Active Comparator|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day.
3159205|NCT01485718|Placebo Comparator|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
3159206|NCT01485692|Active Comparator|ziprasidone injection|ziprasidone injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of the observation
3159207|NCT01485692|Active Comparator|haloperidol + midazolam, injection|Haloperidol plus midazolam injection, after baseline measures of agitation,allowed to be repeated twice over the 90 minutes period of observation
3159253|NCT01485315|Active Comparator|Restrictive blood transfusion|Blood transfusion at haemoglobin 7.0 g/dl (4.3 mM) or less
3159208|NCT01485692|Active Comparator|haloperidol + promethazine, injection|haloperidol + promethazine injection after baseline measures of agitation, could be repeated after 30 minutes, and once more, if necessary, in the 90 minutes period of observation
3159209|NCT01485692|Active Comparator|olanzapine, injection|olanzapine, 10mg, intramuscular injection after baseline measures of agitation, could be repeated twice if necessary, between the 90 minutes of observation
3159210|NCT01485679|Experimental|positrons emission tomography|
3159211|NCT01485653|Experimental|Mepivacaine, Ultrasound Axillary Block|Group 1) 20mL 1.5% mepivacaine Group 2) 30mL 1.5% mepivacaine
3159212|NCT01485640|Experimental|Lurasidone|Lurasidone flexibly dosed
3159213|NCT01485627|Experimental|Intervention|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
3159214|NCT01485627|No Intervention|Control|Patients will receive usual care
3159215|NCT01485614|Experimental|Sitagliptin|Phase A (20 weeks): Sitagliptin 100 mg oral tablet once daily prior to the morning meal and placebo to metformin oral tablet (500 mg), 2 tablets twice daily prior to morning and evening meals. Phase B (34 weeks): Participants who have not initiated glycemic rescue therapy will continue to receive Phase A treatments.
3159216|NCT01485614|Experimental|Placebo|Phase A (20 weeks): Placebo to sitagliptin oral tablet once a day prior to the morning meal and placebo to metformin oral tablets (500 mg), 2 tablets twice daily prior to morning and evening meals. Phase B (34 weeks): Participants who have not initiated glycemic rescue therapy will receive 1 tablet of placebo to sitagliptin daily prior to the morning meal and 2 tablets of metformin (starting at 500 mg/day and uptitrated by 500 mg every week to a final dose of 1000 mg twice daily).
3159217|NCT01485601|Experimental|MT10109|Clostridium botulinum toxin type A
3159218|NCT01485601|Active Comparator|Botox (registered trade mark)|Clostridium botulinum toxin type A
3159219|NCT01485588|Experimental|hI-con1™|Phase 1- This is a dose escalation study (20µl, 50µl, or 100 µl)given at baseline and then the subject is followed up to week 24.
3159220|NCT01485575||Filter use during vitrectomy|
3159221|NCT01485562|Active Comparator|Misoprostol|women who experience a PPH will be randomized to receive 800 misoprostol (four tablets of 200 mcg administered sublingually)
3159222|NCT01485562|Placebo Comparator|placebo|women who experience a PPH will be randomized to receive 4 placebo tablets administered sublingually
3159223|NCT01485549||MSA Patients|Patients suffering from Multiple system atrophy (MSA)
3159224|NCT01485549||Controls|Patients requiring spinal tap without being affected by a neurodegenerative disorder.
3159225|NCT01485536|Experimental|AUY922|AUY922 starting dose 70 mg/m2 intravenous on Days 1, 8, 15, and 22 of 28 day cycle.
3159226|NCT01485523||Patients|A = Patients with allergic rhinitis sensitized to dust mites
3159227|NCT01485523||Control Subjects|B = control subjects with allergic rhinitis not sensitized to dust mites C = control subjects without allergic rhinitis
3159228|NCT01485510|Experimental|Glasgow Infant and Family Team (GIFT)|A service developed by Charles Zeanah and colleagues in New Orleans, that aims to improve the mental health of maltreated infants.
3159229|NCT01485510|Active Comparator|Family Assessment & Contact Service|A social-work based service that aims to assess maltreated children and make recommendations about their future care.
3159230|NCT01485497|Other|3D endoscopic Fourier Domain OCT|3D endoscopic Fourier Domain OCT
3159231|NCT01485484||Sinus|Optic imaging use near-infrared trans-illumination methods
3159232|NCT01485471||Medical Tool|Diffuse optical spectroscopy imaging ear exam
3159233|NCT01485458|Experimental|Early surgery|
3159234|NCT01485458|Active Comparator|Delayed surgery|
3159235|NCT01485445|Experimental|Fluticasone Furoate (single strip configuration)|400mcg, administered as 2 inhalations of 200mcg
3159236|NCT01485445|Experimental|Fluticasone Furoate (two strip configuration)|400mcg, administered as 2 inhalations of 200mcg. Second strip contains lactose and magnesium stearate
3159237|NCT01485445|Experimental|Fluticasone Furoate/Vilanterol|400/50mcg, administered as 2 inhalations of 200/25mcg
3159238|NCT01485432||P group|Group P: Fluid Management according to measurements with PiCCO®
3159239|NCT01485432||C group|Group C: Conventional fluid management
3159240|NCT01485406|Experimental|Pn Group|Toddlers 12-23 months of age receiving GSK2830930A vaccine.
3159241|NCT01485406|Active Comparator|Control Group|Toddlers 12-23 months of age receiving Synflorix.
3159242|NCT01485393|Experimental|Healthy Control Subjects|This arm will be comprised of 15 healthy male and female controls.
3159243|NCT01485393|Experimental|Insomnia subjects|This arm will be comprised of 15 male and female subjects with a sleep initiating and maintenance disorder.
3159244|NCT01485380|Experimental|Active study arm|Subjects recruited into this study will be required to undergo two magnetic resonance imaging- positron emission tomography (MRI-PET) scans of the brain in addition to high density electroencephalogram (EEG) acquisition. The first scan will be a baseline scan while the second scan will be performed while dexmedetomidine is being infused.
3159245|NCT01485367|Active Comparator|Adapalene gel 0.3%|All odd numbered subjects will receive treatment to the left arm. The untreated arm will serve as an intrapatient control and will be evaluated separately from the treated arm for signs of purpura.
3159246|NCT01485367|Active Comparator|Adapalene gel 0.3 %|All even numbered subjects will receive treatment to the right arm. The untreated arm will serve as an intrapatient control and will be evaluated separately from the treated arm for signs of purpura.
3159247|NCT01485354|Experimental|Armeo Spring training|Subjects will participate in upper extremity rehabilitation using the Armeo Spring system for a period of 6 weeks. The intervention will consist of 18 training sessions (60 minute sessions, 3 times a week).
3159248|NCT01485341|Active Comparator|gluten|gluten is administered blindly versus placebo for 15 days at 10 g/day
3159249|NCT01485341|Placebo Comparator|rice starch|placebo (rice starch) will be administered blindly versus gluten for 15 days at 10 g/day
3159250|NCT01485328|Active Comparator|AMARGOL|per oral solution 40 mL single dose
3159251|NCT01485328|Placebo Comparator|Vehicle without active principles|per oral solution 40 mL single dose
3159252|NCT01485315|Active Comparator|Liberal blood transfusion|Blood transfusion at haemoglobin 9.0 g/dl (5.6 mM) or less
3159254|NCT01485302|Experimental|Cohort 1|Dose 1 IV infusion
3159258|NCT01485302|Experimental|Cohort 5|Dose 1 SC injection
3159259|NCT01485302|Experimental|Cohort 6|Dose 2 SC injection
3159260|NCT01485289||Investigational Stabilimax|
3159261|NCT01485289||Control, Posterolateral Fusion|
3159262|NCT01485237||Severe H1N1 pneumonia in adult patients|Severe adult H1N1 pneumonia patients undergoing antiviral and oxygen therapy, mechanical ventilation and support with pulmonary rescue therapies ( nitric oxide, ECMO, HFO)in Winnipeg
3159263|NCT01485237||Severe pneumonia in adults not H1N1|Patients admitted to the hospital and/or ICU with viral pneumonia, bacterial pneumonia, septic shock, ARDS in Winnipeg
3159264|NCT01485224|Experimental|Thalidomide|"Single arm study:~Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.~Treatment will be continued until one of the following criteria is met:~8 additional weeks of treatment after the achievement of complete response~16 additional weeks of treatment after the achievement of partial response~24 weeks of treatment completed without response~unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks."
3159265|NCT01485211|Experimental|crosslinking with hypoosmolar riboflavin|Riboflavin and UVA-induced corneal cross-linking increases the stability of keratoconic corneas. The current inclusion criteria require a minimum stromal thickness of 400 µm. Hypo-osmolar riboflavin solution increases the stromal thickness before CXL in cases with preoperatively thin corneas.
3159266|NCT01485198|Active Comparator|Control|Patients treated with Acetaminophen
3159267|NCT01485198|Experimental|Experimental|Patients who underwent a BMASC extraction and joint infusion
3159268|NCT01485185|Experimental|Gabapentin lower dose alone|low dose
3159269|NCT01485185|Active Comparator|Gabapentin higher dose alone|higher dose
3159270|NCT01485185|Experimental|Gabapentin in combination with donepezil|Gabapentin lower dose and donepezil
3159271|NCT01485185|Placebo Comparator|Placebo|Placebo
3159272|NCT01485172|Experimental|ropinirole|ropinirole 2, 4, 8, 12, or 24 mg/day
3159273|NCT01485172|Placebo Comparator|placebo|placebo comparator 2, 4, 8, 12, or 24 mg/day
3159274|NCT01485159||All|All subjects enrolled in the study
3159275|NCT01485146|Experimental|Cohort 1|8 Healthy Subjects in Phase I Unit
3159276|NCT01485146|Experimental|Cohort 2|8 Healthy Subjects in Phase I Unit
3159277|NCT01485146|Experimental|Cohort 3|8 Healthy Subjects in Phase I Unit
3159278|NCT01485146|Experimental|Cohort 4|8 Healthy Subjects in Phase I Unit
3159279|NCT01485133||Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
3159280|NCT01485133||Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered via a needle adaptor or the built-in scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
3159281|NCT01485120|Experimental|Subjects requiring blood pressure monitoring|
3159282|NCT01485107|Experimental|Ultherapy™ treatment on the décolleté|All enrolled subjects will receive the study treatment.
3159283|NCT01485094|Placebo Comparator|Matching placebo|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
3159284|NCT01485094|Experimental|GRT6010|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
3159285|NCT01485094|Active Comparator|Pregabalin|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
3159286|NCT01485081|Experimental|Danubio|
3159287|NCT01485068|Experimental|Danubio|
3159288|NCT01485055|Experimental|Infliximab and Basiliximab|"Other Names:~Simulect Remicade Monoclonal antibody~Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.~Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times."
3159289|NCT01485042|Experimental|Dose Escalation|This is a Phase 1 dose escalation with an expanded cohort that will enroll at MTD.
3159290|NCT01485029|Experimental|NP children|Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
3159291|NCT01485016||ambulatory epilepsy subjects|
3159292|NCT01484990|Experimental|1|
3159293|NCT01484977|Experimental|Lacosamide|Lacosamide will be added to levetiracetam while withdrawing the sodium channel blocking antiepileptic drug (AED)
3159294|NCT01484964|Experimental|Treatment A|ASP015K Formulation 1 with moderate-fat meal
3159295|NCT01484964|Experimental|Treatment B|ASP015K Formulation 2 under fasting conditions
3159296|NCT01484964|Experimental|Treatment C|ASP015K Formulation 2 with moderate-fat meal
3159297|NCT01484951|Experimental|AZARGA|Brinzolamide 1% and timolol 0.5% fixed combination eye drops, one drop administered to the study eye(s) twice daily (8:00 am and 8:00 pm) for up to 8 weeks.
3159298|NCT01484938|Experimental|OPTI-FREE|OPTI-FREE PureMoist multi-purpose contact lens solution used for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses, per protocol-specified regimen
3159299|NCT01484925||With Barrett's Esophagus|Patients who have been diagnosed in the past with Barrett's Esophagus
3159300|NCT01484925||Without Barrett's Esophagus|Patients without Barrett's Esophagus will be asked to take part so that comparison can be made with patients' tissue for those with the condition and those without the condition.
3159301|NCT01484912|Experimental|STA-2|"STA-2 250 mg capsule, each containing 100 mg green tea polyphenols.~Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state."
3160214|NCT01478880|Sham Comparator|Sham cTBS|
3159302|NCT01484912|Placebo Comparator|Placebo|"Placebo capsule, containing non-active ingredients.~Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state."
3159303|NCT01484899||PAH|Patients with pulmonary arterial hypertension (PH). PH defined as mean pulmonary artery pressure >25mmHg with a pulmonary capillary occlusion pressure ≤ 15mmHg
3159304|NCT01484899||CTEPH|Patients with chronic thromboembolic pulmonary hypertension. CTEPH defined as mean pulmonary artery pressure >25mmHg with a pulmonary capillary occlusion pressure ≤ 15mmHg.
3159305|NCT01484899||Controll group|Data from 16322 (10336 females) participants of the Swiss health survey (SHS) 2007 will serve as control. The SHS was performed in 2007, a representative sample of 30000 Swiss citizens were asked to participate, 66% answered per telephone to detailed health question.
3159306|NCT01484886|Experimental|Restrictive transfusion strategy|RBC will be transfused if the hemoglobin level falls below 7 for bi-ventricular repairs and under 9.0 for single ventricle palliations.
3159307|NCT01484886|Experimental|Liberal RBC transfusion strategy|RBCs will be transfused for Hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
3159308|NCT01484873|Experimental|Exenatide|All patients received exenatide 10mcg BID x 50 weeks
3159309|NCT01484860|Experimental|AUY922|
3159310|NCT01484847|Experimental|PF-00299804|Patients with locally advanced head and neck squamous cell carcinoma will be treated with a single dose (45mg) of PF-00299804 via G-Tube on an empty stomach
3159311|NCT01484834|Experimental|Exercise and Education|Company A received intervention of exercise in the workplace, posters with tips on health and quality of life computer software. The interventions with physical exercise in the workplace, were performed in the morning shift and had duration of three months with 15 minutes each and were applied three times per week every other day. In order to keep the workers motivated and participating in the exercise in the workplace, the sessions were very varied, using broomstick, latex tubes, exercises in pairs, massage, sitting exercises and relaxation on mats.
3159312|NCT01484834|Active Comparator|Exercise|The intervention with physical exercise in the workplace, were performed in the morning shift and had duration of three months with 15 minutes each and were applied three times per week every other day. In order to keep the workers motivated and participating in the exercise in the workplace, the sessions were very varied, using broomstick, latex tubes, exercises in pairs, massage, sitting exercises and relaxation on mats.
3159313|NCT01484834|Active Comparator|Educational Intervention|This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
3159314|NCT01484834|Placebo Comparator|Control Company|No intervention
3159315|NCT01484821|Active Comparator|Arm A|Volunteers (18 -30 years)
3159316|NCT01484821|Active Comparator|Arm B|Volunteers (70 years or older)
3159317|NCT01484821|Experimental|Arm C|70 years patient or older with curative cares for cancer
3159318|NCT01484795|Experimental|Continuous positive airway pressure|
3159319|NCT01484795|Experimental|BILEVEL|
3159320|NCT01484782|Experimental|Interactive Voice Response (IVR) calls|Weekly automated telephone assessment and behavior change calls focused on blood pressure management. The experimental group will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
3159321|NCT01484782|No Intervention|Usual care|This group received results of blood pressure readings. PCP referrals. Educational materials about hypertension and self-management. At follow-up, patients received home blood pressure monitoring cuffs.
3159322|NCT01484756|Placebo Comparator|calcium carbonate 500 mg|Control group received one daily tablet of calcium carbonate 500 mg for 6 months
3159323|NCT01484756|Experimental|daily multi micronutrient supplement|Experimental group received one daily multi micro-nutrient supplement tablet for 6 months
3159324|NCT01484743||Patients with parastomal hernia repair|Patients registered in the Danish Ventral Hernia database
3159325|NCT01484730||Vascular Occulsion|Multi-Spectral & Laser Speckle Imaging
3159326|NCT01484717|Active Comparator|Standard Care|Telephone counseling plus nicotine patch
3159327|NCT01484717|Experimental|Contingency management for abstinence from cigarettes|Telephone counseling and nicotine patch plus contingency management
3159328|NCT01484704||No treatment|
3159329|NCT01484704||MRI|
3159330|NCT01484691|No Intervention|Healthy non-asthmatic controls|Healthy non-asthmatic controls who will be studied at one point in time and serve as a control group for the baseline bronchoscopy and evaluation of T-cell miRNA expression.
3159331|NCT01484691|Active Comparator|Asthmatics (treatment)|Steroid-naïve asthma (randomized to 8 weeks of treatment with inhaled corticosteroids). Asthmatics not on inhaled corticosteroids, randomized to inhaled budesonide, 1 puff (180mcg) twice a day for 8-10 weeks. These subjects will undergo bronchoscopy and T-cell miRNA measurement at baseline (before corticosteroids) and again after treatment with inhaled corticosteroids.
3159332|NCT01484691|No Intervention|Asthmatics (no treatment)|Steroid-naïve asthma (randomized to 8 weeks of no inhaled corticosteroid treatment). Asthmatics not on inhaled corticosteroids, randomized to no change in treatment for 8-10 weeks. These subjects will undergo bronchoscopy and T-cell miRNA measurement at baseline and again after 8 weeks without treatment with inhaled corticosteroids.
3159333|NCT01484678||Age Matched Controls|Age matched non-affected (non-DMD) boys
3159334|NCT01484678||Boys with DMD|This group will include ambulatory and non-ambulatory boys with Duchenne Muscular Dystrophy ranging form 5-18 years old.
3159335|NCT01484665|Experimental|Participants (Males, age 50-75 yrs)|Eligible men will be identified from the administrative database and electronic medical record at the University of Minnesota (EMR) at least 24 hours prior to the clinic visit. They will be asked to complete the PROCASE Decision-Aid.
3159336|NCT01484652|Experimental|COV795|
3159337|NCT01484652|Placebo Comparator|Placebo|
3159338|NCT01484639|Active Comparator|Restrictive transfusion triggers|"Patients allocated to a restrictive transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively."
3159339|NCT01484639|Active Comparator|Liberal transfusion triggers|"Patients allocated to a liberal transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward."
3159340|NCT01484626|Experimental|Bendamustine|Bendamustine is combined with standard chemotherapy.
3159341|NCT01484613||Quadripolar lead|All participants receive a CRT-D system with quadripolar lead
3159342|NCT01484600|Experimental|Group 1|
3159343|NCT01484600|Experimental|Group 2|
3159344|NCT01484587|Experimental|001|
3159345|NCT01484587|Placebo Comparator|002|
3159346|NCT01484574|Experimental|Low dose|Stempeucel - CLI will be administered at the lowest dose
3159347|NCT01484574|Experimental|Intermediate dose|Stempeucel - CLI will be administered at intermediate dose
3159348|NCT01484574|No Intervention|Control arm|Standard protocol of care alone
3159349|NCT01484561|Active Comparator|Sequence 1|
3159350|NCT01484561|Placebo Comparator|Sequence 2|
3159351|NCT01484548|Experimental|Vaccine: 20 ug LEISH-F3 + 2 ug GLA-SE|Low dose of adjuvant.
3159352|NCT01484548|Experimental|Vaccine: 20 ug LEISH-F3 + 5 ug GLA-SE|Higher dose of adjuvant.
3159353|NCT01484548|Active Comparator|20 ug LEISH-F3 alone|20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
3159354|NCT01484535|Other|Ankle aspiration|ankle aspiration
3159355|NCT01484535|Placebo Comparator|placebo procedure|placebo procedure
3159356|NCT01484522||Group A|Influenza A 2009 Monovalent vaccine
3159357|NCT01484522||Group B|Influenza A 2009 monovalent vaccine
3159358|NCT01484522||Group C|Influenza A 2009 monovalent vaccine
3159359|NCT01484509||Intermittent claudication|
3159360|NCT01484496|Placebo Comparator|Placebo plus standard therapy|Placebo SC plus standard therapy; placebo administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo subjects who opt to participate will receive belimumab 200 mg SC weekly for an additional 6-months.
3159361|NCT01484496|Experimental|Belimumab 200 mg SC plus standard therapy|Belimumab 200 mg SC plus standard therapy; belimumab administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, subjects who opt to participate will continue on the same dose of belimumab for an additional 6-months.
3159362|NCT01484483||Cohort|
3159363|NCT01484470|No Intervention|Unmanipulated arm|Participants that do not meet criteria for StemEx®, will be registered into the unmanipulated UCB arm and receive the standard conditioning regimen.
3159364|NCT01484470|Experimental|Stemx Arm|StemEx is a stem/progenitor cell-based product of ex-vivo expanded allogeneic UCB, which is administered to the subject in combination with the non-manipulated portion of the same cord blood unit (CBU). The CBU must be cryopreserved in two portions of which the larger (or equal) CBU portion contains at least 1.5 x 107 total nucleated cells (TNC)/Kg. This portion remains unmanipulated and is transplanted on Day 0. StemEx is derived from the smaller (or equal) CBU portion, which is expanded ex vivo for 21 days starting pre-transplant in the presence of cytokines TPO, IL-6, Flt-3L and SCF at a concentration of 50ng/ml and 5μM tetraethylenepentamine (TEPA)
3159365|NCT01484457|Experimental|Closed-loop control system|"The objective of this study is to automate glucose control in subjects with type 1 diabetes using a computer control algorithm in a controlled in-clinic research setting.~The controller will be evaluated under two conditions:~restoring euglycemia (80-140 mg/dL) when the controller is initiated during a period when the subject's glucose is above the euglycemic range;~restoring euglycemia (80-140 mg/dL) when the controller is challenged with a small unannounced meal (~25 g CHO)."
3159366|NCT01484444||gastrointestinal cancer|
3159367|NCT01484431|Experimental|tadalafil|The dose of tadalafil will be escalated from low to high for each participant based on body weight for 5 weeks at low dose and 5 weeks at high dose.
3159368|NCT01484418|Experimental|A Exposure long|Exposure in vivo for fear avoidant chronic low back pain patients. This treatment means that the individual is exposed to movements and tasks that have been avoided due to fear of (re)injury. The treatment begins after three educational lessons including the rational and developing a fear hierarchy. Exposure phase includes 10 exposures sessions which are highly individualized. Behavioral experiments can be included to correct catastrophic misinterpretations. The main purpose of this intervention type is to reduce pain related disability via diminishing fear avoidance.
3159369|NCT01484418|Experimental|B Exposure short|See above exposure long. This treatment comprises 5 exposure sessions.
3159370|NCT01484418|Active Comparator|C Cognitive behavioural psychotherapy|Cognitive behavioural psychotherapy for fear avoidant chronic low back patients. The therapy is modularized in three main parts. The educational lesson is followed by the module graded activity which represents the behavioral part of the program. The second module comprises relaxation. And the last part contains cognitive interventions. Cognitive behavioural intervention techniques are employed to support the patient in the process of coping with chronic pain: i.e. reduction of disability and improving functional ability.
3159371|NCT01484405|Other|anterolateral approach|surgical intervention THA anterolateral approach
3159372|NCT01484405|Other|posterior approach|surgical intervention THA posterior approach
3159373|NCT01484379|Experimental|unilateral neck exploration|unilateral neck exploration of elderly with primary hyperparathyroidism
3159374|NCT01484366|Active Comparator|intramedullary nailing and plating|intramedullary nailing of the ulna and plating of the radius in the treatment of both bone forearm fractures
3159375|NCT01484366|Active Comparator|plating|plating of both the radius and ulna in the treatment of both bone forearm fractures
3159376|NCT01484353|Experimental|Intervention group|This is the only arm in the study. They will be compared before and after
3159377|NCT01484340|Experimental|Counseling only|Participants in this arm will receive advice to quit smoking and self-help materials from the study interventionist in a standardized fashion (intensive anti-smoking counseling).
3159378|NCT01484340|Experimental|Nicotine Replacement Therapy +counseling|Participants in this arm will receive the nicotine patch in addition to the intensive anti-smoking counseling. Participants will receive instruction on proper use of the nicotine patch (i.e., placement, use of one patch a day, importance of not smoking while using the patch, and tapering of patches).
3159379|NCT01484327||Carvedilol, LVEF, Heart Failure|Patients with Heart Failure on carvedilol therapy measured for their LVEF value
3159380|NCT01484314|Experimental|Migration Arm|Administration of eltrombopag to support platelets during chemotherapy
3159381|NCT01484288|Experimental|Device group|Barostim Neo system
3159382|NCT01484275|Experimental|Siltuximab|Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
3159383|NCT01484275|Placebo Comparator|Placebo|Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
3159384|NCT01484262||Liraglutide|
3159385|NCT01484262||Any insulin|
3159386|NCT01484223|Experimental|Experimental Group|Intervention group: Structured nursing intervention
3159387|NCT01484223|No Intervention|No intervention|Control group: conventional intervention or non_support
3159388|NCT01484210|Experimental|Elpenhaler Active - Diskus Placebo|Patients on treatment with both devices, Elpenhaler and Diskus, first active substance, second placebo.
3159389|NCT01484197|Experimental|75 µg Indacaterol (LB) + Placebo (PoS)|75 µg indacaterol maleate lactose blend (LB) + placebo to indacterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
3159390|NCT01484197|Experimental|75 µg Indacaterol (PoS) + Placebo (LB)|75 µg indacaterol maleate PulmoSphereTM (PoS) + placebo to indacterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
3159391|NCT01484197|Experimental|37.5 µg Indacaterol (PoS) + Placebo (LB)|37.5 µg indacaterol maleate PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
3159392|NCT01484197|Experimental|Placebo (LB) and Placebo (PoS)|Placebo to indacaterol PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
3159393|NCT01484184|Active Comparator|buspirone or levodopa/carbidopa|Another 2-arm design will be tested composed of 16 subjects receiving drug A or drug B at MTD dose of the combined study drug as identified in the previous 2-arm groups.
3159394|NCT01484184|Placebo Comparator|Placebo|First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of SPINALON, the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively with increasing doses, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.
3159395|NCT01484171|Active Comparator|idarubicin|The patients will receive induction chemotherapy containing standard dose of idarubicin in combination with cytarabine.
3159396|NCT01484171|Experimental|microtransplantation|The patients will receive induction chemotherapy containing high dose of idarubicin in combination with cytarabine and follow by infusioning granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells
3159397|NCT01484158||Myocardial Infarction|Patients with myocardial infarction
3159398|NCT01484145|Active Comparator|6 mA.min, 20 mins|
3159399|NCT01484145|Experimental|6 mA/min, 20 mins, clamping|
3159400|NCT01484145|Experimental|6 mA/min, 20 mins, debridement, clamping|
3159401|NCT01484145|Experimental|15 mA/min, 30 mins, clamping|
3159402|NCT01484145|Experimental|15 mA/min, 50 mins, debridement, clamping|
3159403|NCT01484132|Experimental|Composite|
3159404|NCT01484119|Active Comparator|Investigational Drug|ACT-129968
3159405|NCT01484119|Placebo Comparator|Comparative Drug|matching placebo tablets and capsules
3159406|NCT01484119|Active Comparator|Reference Drug|Cetirizine
3159407|NCT01484106|Experimental|Treatment group|"Patients will be randomized (1:1, stratified by site, in permutation blocks of 4) to the Treatment or Standard Care arms."
3159408|NCT01484106|Active Comparator|Control|Standard of Care
3159409|NCT01484093|Experimental|R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.|This is a phase I/phase II multi-institution trial. The phase I part of the trial will determine the MTD of cytarabine. The phase II part of the trial will examine the efficacy of the proposed regimen by evaluating the 3-year event-free survival (EFS) in patients with untreated mantle cell lymphoma. All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR.
3159410|NCT01484080|Experimental|Arm I: BIBF1120+Paclitaxel|2 weeks run-in of BIBF 1120 alone followed by paclitaxel + BIBF 1120 combination
3159411|NCT01484080|Active Comparator|Arm II: Paclitaxel|Paclitaxel monotherapy treatment will start within 2 weeks after randomization.
3159412|NCT01484067|Experimental|Patch|At onset of signs/symptoms, subjects will apply assigned patch, and return to study center within 24 hours. Patch will be worn continuously, being replaced as needed.
3159413|NCT01484067|No Intervention|No Patch|No treatment will be initiated at onset of signs and symptoms although subject is still required to return to study center with 24 hours of onset of signs/symptoms.
3159414|NCT01484054|Other|EAPVPDE/EADE|etafilcon A with embedded print and PVP lens for dark eyes worn daily during the first period of 7-9 days, then etafilcon A control lens worn daily during the second period of 7-9 days, with 1-3 days of wash-out time between the 2 periods.
3159415|NCT01484054|Other|EADE/EAPVPDE|etafilcon A control lens worn daily during the first period of 7-9 days, then etafilcon A with embedded print and PVP for dark eyes lens worn daily during the second period of 7-9 days, with 1-3 days of wash-out time between the 2 periods.
3159416|NCT01484041|Experimental|Dovitinib plus aromatase inhibitors|Dovitinib with aromatase inhibitor
3159417|NCT01484028|Other|EALE/1DM|etafilcon A with PVP for light eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
3159418|NCT01484028|Other|1DM/EALE|etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for light eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
3159419|NCT01484028|Other|EADE/1DM|etafilcon A with PVP for dark eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
3159555|NCT01483183|Placebo Comparator|Persistent or Paroxysmal AF Part 1: Placebo|
3159420|NCT01484028|Other|1DM/EADE|etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for dark eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
3159421|NCT01484015|Experimental|Arm I (standard infusion)|Patients receive cefepime hydrochloride IV over 30 minutes.
3159422|NCT01484015|Experimental|Arm II (prolonged infusion)|Patients receive cefepime hydrochloride IV over 3 hours. Treatment repeats every 8 hours.
3159423|NCT01484002||Crosslinked polyethylene liners|Polyethylene liners from joint replacements that were crosslinked and heat treated to eliminate free radicals.
3159424|NCT01484002||Conventional polyethylene liners|Polyethylene liners from joint replacements that manufactured from conventional UHMWPE and terminally sterilized by methods that did not involve gamma-irradiation.
3159425|NCT01483989|Experimental|SYSTANE® Gel Drops Lubricant eye gel|SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
3159426|NCT01483976|Active Comparator|Oral medical nutritional supplement without AN777|orally over a three hour period
3159427|NCT01483976|Experimental|Experimental oral medical nutritional supplement with AN777|orally over a three hour period
3159428|NCT01483963|Experimental|AA4500 0.29 mg/1 mL|Up to three injections
3159429|NCT01483963|Experimental|AA4500 0.58 mg/2 mL|Up to three injections
3159430|NCT01483963|Experimental|AA4500 0.58 mg/1 mL|Up to three injections
3159431|NCT01483963|Experimental|AA4500 0.58 mg/0.5 mL|Up to three injections
3159432|NCT01483963|Other|Shoulder exercises|Home shoulder exercises for 64 days
3159433|NCT01483950||Patients with hypercholesterolaemia|
3159434|NCT01483937|Active Comparator|Usual care physical therapy only|Subjects will receive usual care physical therapy intervention provided by vestibular and balance specialists. Usual care physical therapy, in general, includes but is not limited to static and dynamic balance activities with or without head movements on firm floor or compliant surfaces.
3159435|NCT01483937|Experimental|Usual care physical therapy plus SEMD|"Subjects will receive usual care physical therapy intervention provided by vestibular balance specialists while using the Sensory Enrichment Multimodal Device (SEMD). SEMD protocols use visual, vibrotactile, and auditory cueing referenced to subject's Center of Gravity (COG) and/or Sum of Pressure (SOP) data collected from a force platform upon which the subject is placed. Static and dynamic balance activities with or without head movement are preformed while watching a computer screen; paced with an auditory metronome; and cued by touch vibration via coin tactors imbedded in a belt worn around the waist matching the COG/SOP data display."
3159436|NCT01483924|Experimental|10 mg Apo805K1, or placebo|
3159437|NCT01483924|Experimental|30 mg Apo805K1, or placebo|
3159438|NCT01483924|Experimental|60 mg Apo805K1, or placebo|
3159439|NCT01483924|Experimental|100 mg Apo805K1, or placebo|
3159440|NCT01483911|Experimental|ALX-0171|
3159441|NCT01483911|Placebo Comparator|Placebo|
3159442|NCT01483898|Experimental|ixmyelocel-T|
3159443|NCT01483898|Placebo Comparator|Placebo|
3159444|NCT01483885|Experimental|TENS 4Hz|
3159445|NCT01483885|Experimental|Interferential Current 4Hz|
3159446|NCT01483885|Placebo Comparator|TENS|
3159447|NCT01483885|Placebo Comparator|Interferential Current|
3159448|NCT01483885|Experimental|Manual Acupuncture|
3159449|NCT01483885|Experimental|TENS 100 Hz|
3159450|NCT01483885|Experimental|Interferential Current 100Hz|
3159451|NCT01483872|Experimental|NAC/Tigecycline/Heparin combination lock solution|A combination of the above three drugs will form the catheter lock solution that will be instilled into the catheter
3159452|NCT01483872|Placebo Comparator|Standard anticoagulant (heparin or citrate)|Standard anticoagulant (heparin or citrate)
3159453|NCT01483859|Other|right hepatectomy with preoperative LSM|patients undergoing right hepatectomy with preoperative LSM between August 2007 and July 2011
3159454|NCT01483846|Experimental|AV-101|Subjects will be randomized into one of three dose cohorts (360, 1,080, and 1,440 mg) to receive a daily oral dose for 14 consecutive days. Each cohort will have 12 subjects on active drug and 4 subjects on placebo.
3159455|NCT01483846|Placebo Comparator|microcrystalline cellulose|Subjects will be randomized into one of three cohorts (360, 1,080, and 1,440 mg) to receive a daily oral dose for 14 consecutive days. Each cohort will have 12 subjects on active drug and 4 subjects on placebo.
3159456|NCT01483833|Active Comparator|Iferanserin|Iferanserin administration intra-anally twice daily for 14 days
3159457|NCT01483833|Placebo Comparator|Placebo|Placebo administration intra-anally twice daily for 14 days
3159458|NCT01483820|Experimental|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
3159459|NCT01483807|Experimental|Arm 1 - Blocked Practice|Sound Production Treatment - Blocked: Sound Production Treatment was delivered using blocking of treatment stimuli = SPT- Blocked (intervention). Treatment stimuli representing two different sound targets were presented during treatment/practice with all stimuli for each target being grouped together. Treatment sessions were 50-60 minutes long. Treatment was administered three times per week for a total of 20 sessions, spanning approximately 7 weeks.
3159460|NCT01483807|Experimental|Arm 2 - Randomized Practice|Sound Production Treatment - Random: Sound Production Treatment was delivered using randomization of treatment stimuli = SPT- Random (intervention). Treatment stimuli representing two different sound targets were presented during treatment/practice with stimuli for both targets being intermingled in a non predictable order. Treatment sesTreatment was administered three times per week for a total of 20 sessions, spanning approximately 7 weeks.
3159461|NCT01483794||Genital warts treated|Patients that have had treatment on their genital warts
3159462|NCT01483794||Genital warts on treatment|Patients currently being treated for genital warts
3159463|NCT01483781|Experimental|Canagliflozin|
3159464|NCT01483781|Placebo Comparator|Placebo|
3159465|NCT01483768|Experimental|Arm A:|Sleeve gastrectomy for morbid obesity
3159466|NCT01483755|Experimental|Postconditionned|36 postconditionned patients
3159467|NCT01483755|Sham Comparator|Conventional intervention|36 control patients with conventional primary percutaneaous intervention (PCI)
3159596|NCT01482897|Placebo Comparator|physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
3159468|NCT01483742|Experimental|Combination without RO5024048|Ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and ribavirin in treatment-naïve patients
3159469|NCT01483742|Experimental|Combination with RO5024048|RO5024048 added to the combination treatment (ritonavir-boosted danoprevir in combination with Pegasys [peginterferon alfa-2a] and ribavirin) in prior null responder patients
3159470|NCT01483729|Active Comparator|Part 1 A|
3159471|NCT01483729|Experimental|Part 1 B|
3159472|NCT01483729|Experimental|Part 1 C|
3159473|NCT01483729|Active Comparator|Part 2 D|
3159474|NCT01483729|Experimental|Part 2 E|
3159475|NCT01483729|Experimental|Part 2 F|
3159476|NCT01483716|No Intervention|Control|NIV alone
3159477|NCT01483716|Experimental|Intervention|Rehabilitation arm
3159478|NCT01483703||Diagnostic tool|Laser Speckle Imaging of Critical Care Neonates
3159479|NCT01483677|Experimental|Nintendo Wii|Subjects in this arm of the study play a game (Boomblox) on the Nintendo Wii for 30 minutes.
3159480|NCT01483677|Active Comparator|Playstation2|Subjects in this arm of the study play a game (Time Crisis 2) on the Playstation 2 for 30 minutes.
3159481|NCT01483664||initial survivorship planning consultation|The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt/TGH). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site.
3159482|NCT01483664||initial wellness rehabilitation consultation|The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt/TGH). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site.
3159483|NCT01483651|Experimental|Low, Medium and High insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at lowest level with glucagon administration.~Second study is regular insulin infused at medium level with glucagon adminstration.~Third study is regular insulin infused at highest level with glucagon administration."
3159484|NCT01483651|Experimental|Low, High and Medium insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at lowest level with glucagon administration.~Second study is regular insulin infused at highest level with glucagon adminstration.~Third study is regular insulin infused at medium level with glucagon administration."
3159485|NCT01483651|Experimental|Medium, Low and High insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at medium level with glucagon administration.~Second study is regular insulin infused at lowest level with glucagon adminstration.~Third study is regular insulin infused at highest level with glucagon administration."
3159486|NCT01483651|Experimental|Medium, High and Low insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at medium level with glucagon administration.~Second study is regular insulin infused at highest level with glucagon adminstration.~Third study is regular insulin infused at lowest level with glucagon administration."
3159487|NCT01483651|Experimental|High, Low and Medium insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at highest level with glucagon administration.~Second study is regular insulin infused at lowest level with glucagon adminstration.~Third study is regular insulin infused at medium level with glucagon administration."
3159488|NCT01483651|Experimental|High, Medium and Low insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at highest level with glucagon administration.~Second study is regular insulin infused at medium level with glucagon adminstration.~Third study is regular insulin infused at lowest level with glucagon administration."
3159489|NCT01483638|Experimental|Experimental|axitinib
3159490|NCT01483638|Placebo Comparator|control|placebo
3159491|NCT01483625|Experimental|tiotropium 18mcg|active
3159492|NCT01483625|Placebo Comparator|Placebo|placebo
3159493|NCT01483612|Experimental|Lifestyle counseling|
3159494|NCT01483612|No Intervention|control|
3159495|NCT01483599|Experimental|CNTO 1959 (5 mg)|CNTO 1959 5 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
3159496|NCT01483599|Experimental|CNTO 1959 (15 mg)|CNTO 1959 15 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
3159497|NCT01483599|Experimental|CNTO 1959 (50 mg)|CNTO 1959 50 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
3159498|NCT01483599|Experimental|CNTO 1959 (100 mg)|CNTO 1959 100 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
3159499|NCT01483599|Experimental|CNTO 1959 (200 mg)|CNTO 1959 200 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
3159500|NCT01483599|Active Comparator|Adalimumab (approved psoriasis dosing)|Adalimumab 80 mg at week 0 followed by 40 mg at week 1 and every second week through Week 39 (i.e., Weeks 3, 5, 7, etc.)
3159501|NCT01483599|Placebo Comparator|Placebo to CNTO 1959 (100 mg)|Placebo at weeks 0, 4, and 8; then crossover to CNTO 1959 100 mg at Week 16, then every 8 weeks through Week 40
3159502|NCT01483586|Experimental|KLTc high dose|6 KLTc gelcaps taken four times a day
3159503|NCT01483586|Experimental|KLTc low dose|3 KLTc gelcaps taken four times a day
3159504|NCT01483573|Experimental|straight leg raise|stretch the muscle
3159505|NCT01483573|Experimental|neural mobilization|stretch the nerve
3159506|NCT01483560|Experimental|Metformin|Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
3159507|NCT01483560|Placebo Comparator|Placebo|
3159508|NCT01483547||Neurosurgical|
3159509|NCT01483547||Non-neurosurgical|
3159510|NCT01483534|Experimental|Targeted Lung Denervation|Targeted Lung Denervation
3159511|NCT01483521|Experimental|Waitlist families|"Experimental arm consisted of randomized waitlist families who received home visitation where mothers were taught to play with their children in a developmentally appropriate manner and also engaged in a co-construction task.~Control arm families did not get any active intervention. Parents from both arm types completed pre and post questionnaires to measure child's externalizing behaviors and parenting stress.~Parents from experimental group were encouraged to keep a diary of their play record."
3159512|NCT01483508|Active Comparator|Flavanol and procyanidins|
3159513|NCT01483508|Experimental|Flavanols only|
3159514|NCT01483508|Experimental|Procyanidins only|
3159515|NCT01483495||Diagnostic tool|Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
3159516|NCT01483482|Other|Conservative treatment|"The group allocated to conservative treatment is treated with a simple sling. The sling is removed when the patient is pain free.~The first 6 weeks max 1 kg of weight-bearing is allowed and the patient is instructed to restrict movement of the arm to the level of the shoulder."
3159517|NCT01483482|Other|Surgical treatment|"Patients allocated to surgical treatment are operated with a superior locking plate.~The first 6 weeks max 1 kg of weight-bearing is allowed and the patient is instructed to restrict movement of the arm to the level of the shoulder."
3159518|NCT01483469|Active Comparator|Concept Proof|
3159519|NCT01483469|Experimental|Receptor Occupancy|
3159520|NCT01483456|Other|Usual care|
3159521|NCT01483443|Experimental|Oophrectomy group|Patient undergone oophrectomy along with primary tumor
3159522|NCT01483443|No Intervention|without oophrectomy|Patient group without oophrectomy
3159523|NCT01483430|Placebo Comparator|Placebo|
3159524|NCT01483430|Experimental|Ginseol Kg1, high dose|
3159525|NCT01483430|Experimental|Ginseol Kg1, low dose|
3159526|NCT01483417|Experimental|SILS|Laparoscopic hysterectomy including LAVH, LH(a), and TLH using SILS port
3159527|NCT01483417|Active Comparator|Conventional multi-port laparoscopic hysterectomy|3-4 ports laparoscopic hysterectomy including LAVH, LH(a), or TLH
3159528|NCT01483404||Patient with fracture of femural neck|All patient with fracture of the femural neck in the listed period of time
3159529|NCT01483391|Active Comparator|Enhanced Care|Three sessions of family education and three sessions of individual support over 4 months.
3159530|NCT01483391|Experimental|Family-Focused Treatment|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training.
3159531|NCT01483378|Other|Subjects who received the vaccine|Patients in this arm were eligible for the herpes zoster vaccine and chose to receive it.
3159532|NCT01483378|No Intervention|Subjects who declined the vaccine|
3159533|NCT01483352|Experimental|Single Arm|Participants were implanted with Accu-Chek DiaPort with Infusion Set connected to an Accu-Chek Insulin Pump to perform continuous intraperitoneal insulin delivery.
3159534|NCT01483339|Experimental|Metacognitive Therapy|
3159535|NCT01483339|Experimental|Exposure and Response Prevention|
3159536|NCT01483326||Cohort|
3159537|NCT01483300|Experimental|lobaplatin|gemcitabine plus lobaplatin
3159538|NCT01483300|Active Comparator|cisplatin|gemcitabine plus cisplatin
3159539|NCT01483287|Active Comparator|Enzyme|Capsules with alpha-galactosidase (enzyme) (400 GaIU x 3) are ingested at breakfast, lunch and dinner.
3159540|NCT01483287|Placebo Comparator|Placebo|3 capsules with a non-active substance are ingested at breakfast, lunch and dinner
3159541|NCT01483274|Experimental|Safety|Decitabine and donor lymphocyte infused dendritic cell (DC).
3159542|NCT01483274|Active Comparator|Vaccine|Decitabine and Dendritic cell (DC) pulsed with MAGE-A1, MAGE-A3, NY-ESO-1 Peptides
3159543|NCT01483261|Experimental|Trauma-Focused Cognitive Behavioral Therapy|
3159544|NCT01483261|No Intervention|Waiting List Control|
3159545|NCT01483248|Experimental|Intervention|Conventional therapy plus MenSCs treatment
3159546|NCT01483248|Active Comparator|No intervention|"Conventional therapy plus placebo treatment:~Oral or intravenous administration"
3159547|NCT01483235|Experimental|Reduced cardiac rehabilitation (rCRP)|The rCRP is the intervention group, compared to the standard cardiac rehabilitation program group (sCRP). The rCRP will have the core elements of the sCRP, that is, in-hospital exercise sessions, dietary counseling, educational sessions, follow-up with the cardiologist, dietician and exercise specialist. The only difference will be the number of in-hospital exercise sessions (10 sessions for the rCRP v/s 32 sessions for the sCRP). Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
3159548|NCT01483235|Active Comparator|Standard cardiac rehabilitation (sCRP)|The standard cardiac rehabilitation (sCRP) follows the standard cardiac rehabilitation program model of a four-month period. Patients receive an initial intake evaluation by a cardiologist, nurse, exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counseling, medical care, psychological screening and smoking cessation if needed.
3159549|NCT01483222|Experimental|QUIKDRAW Pro|Wearing an inelastic lumbar support for 6 months
3159550|NCT01483222|Experimental|MUELLER 4581|Wearing an elastic lumbar support for 6 months
3159551|NCT01483222|No Intervention|Blank Control|Receiving no intervention
3159552|NCT01483209|Experimental|Botox injection|Use of botulinum toxin A to determine efficacy in treating vasopressor-induced digital ischemia
3159553|NCT01483196|Experimental|Diagnostic (TCD)|Patients undergo TCD examination including bilateral evaluation of standard intracranial arterial segments including the M1 and M2 segments of the MCA, the ACA and PCA, via the transtemporal acoustic windows, the ICA siphon via transorbital approach, and the vertebral and basilar arteries (proximal, mid, and distal) via the suboccipital approach. Patients also undergo MRI. All tests occur between 21 days after completion of surgery and up to 30 days prior to adjuvant chemotherapy and between 20-60 days after completion of adjuvant chemotherapy.
3159554|NCT01483183|Experimental|Persistent or Paroxysmal AF Part 1: OPC-108459|To safely meet each of the following Cmax targets: 1.0-10.0 µg/mL. There will be 9 cohorts in all: 1.0, 1.6, 2.4, 3.6, 5.4, 7.0, 8.0, 9.0, and 10.0.
3160215|NCT01478867||Celiac patients|
3159556|NCT01483183|Experimental|Persistent or Paroxysmal AF Part 2: OPC-108459|Single dose to safely meet target concentration from Part 1, if subject fails to convert to sinus rhythm within 10 minutes, second dose will be administered to achieve 25% increase when compared to first infusion
3159557|NCT01483183|Placebo Comparator|Placebo Part 2|
3159558|NCT01483170|Experimental|Fexinidazole|
3159559|NCT01483170|Placebo Comparator|Placebo fexinidazole|
3159560|NCT01483157|Experimental|low intensity with vascular occlusion|
3159561|NCT01483157|Experimental|high intensity resistance training|
3159562|NCT01483157|No Intervention|no exercise training|
3159563|NCT01483144|Experimental|Eflornithine plus Sulindac|Eflornithine 750 mg and Sulindac 150 mg
3159564|NCT01483144|Active Comparator|Eflornithine plus Placebo|Eflornithine 750 mg and Placebo
3159565|NCT01483144|Active Comparator|Sulindac plus Placebo|Sulindac 150 mg and Placebo
3159566|NCT01483131|Experimental|Low intensity resistance training|
3159567|NCT01483131|Experimental|High intensity resistance training|
3159568|NCT01483131|Experimental|Low intensity resistance training with vascular occlusion|
3159569|NCT01483118|Active Comparator|Cinnamon Extract Arm|PCOS patients receiving abstract of cinnamon
3159570|NCT01483118|Placebo Comparator|Placebo Arm|PCOS patients receiving placebo capsules
3159571|NCT01483105|Experimental|DVD self-hypnosis|This group will receive standard care, and parents/children in this group will receive in the mail a set of questionnaires and the DVD self-hypnosis training program. Parents will be asked to review these materials and practice the training at home with their children for one week leading up to the procedure Parents will also be asked to try to use these techniques with their child during his or her upcoming VCUG procedure.
3159572|NCT01483105|No Intervention|Standard care|Children in this arm will receive standard care and parents/children will be mailed a set of questionnaires to complete before and after your child's upcoming VCUG.
3159573|NCT01483092|Experimental|inulin|
3159574|NCT01483092|Placebo Comparator|maltodextrin|
3159575|NCT01483079||Former preterm infants|A cohort of infants less than or equal to 1250 grams birth weight that received donor human milk products in the NICU will be recruited and followed. Some infants recruited will be from a previously studied population of very low birth weight infants receiving donor human milk products in the NICU at Texas Children's Hospital.
3159576|NCT01483066|Experimental|ShapeMatch Instrumentation|
3159577|NCT01483066|Active Comparator|Usual Instrumentation|
3159578|NCT01483053|Active Comparator|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
3159579|NCT01483053|Active Comparator|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
3159580|NCT01483027|Experimental|Treatment group|Standard of care second-line chemotherapy plus TheraSphere
3159581|NCT01483027|No Intervention|Control group|Standard of care second-line chemotherapy with no added therapy
3159582|NCT01483014|Experimental|imatinib|
3159583|NCT01483001|Experimental|Sensitivity Assay|Patients treated with a treatment chosen by sensitivity assay in vitro
3159584|NCT01482988||Critical care patients antipated to stay more than 72 hours|
3159585|NCT01482975|Experimental|Smoking and Alcohol Prevention|TTM expert system
3159586|NCT01482975|Active Comparator|Diet and Exercise|TTM expert system
3159587|NCT01482962|Experimental|Alisertib|Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).
3159588|NCT01482962|Active Comparator|Pralatrexate, or Romidepsin, or Gemcitabine|Pralatrexate 30 mg/m^2, intravenous (IV) push over 3 to 5 minutes, once weekly, for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles were repeated every 7-weeks provided the participant continued to benefit from and tolerate the therapy (Up to 115 Weeks), or Gemcitabine 1,000 mg/m^2 over 30 minutes, intravenously, on Days 1, 8, and 15 of a 28-day cycle until the absence of disease progression or unacceptable toxicity (Up to 32 Weeks), or Romidepsin 14 mg/m^2, intravenously over a 4-hour period, on Days 1, 8, and 15 of a 28-cycle. Cycles were repeated every 28 days provided the patient continued to benefit from and tolerate the therapy (Up to 30 Weeks).
3159589|NCT01482949|Experimental|AGS-003 in combination with sunitinib|Subjects will undergo Induction (AGS-003 every 3 weeks until 5 doses are administered) followed by Booster (AGS-003 at 3 month intervals). Subjects that will begin sunitinib therapy will be on this arm.
3159590|NCT01482936|Experimental|Oxycodone (OxyNorm®) Injection|The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg
3159591|NCT01482923||Treatment As Usual (TAU)|This study is a pilot intervention trial examining the feasibility of a motivational smoking cessation intervention using respiratory biomarker feedback in low income PLWHA. The plan is to recruit a pilot sample of 50 eligible and consented participants, randomized at a 1:1 ratio into either the Treatment As Usual (TAU) condition or the experimental (Aspiration, Inspiration Respiration, or AIR) intervention condition.
3159592|NCT01482923||Aspiration, Inspiration Respiration, or AIR|This study is a pilot intervention trial examining the feasibility of a motivational smoking cessation intervention using respiratory biomarker feedback in low income PLWHA. The plan is to recruit a pilot sample of 50 eligible and consented participants, randomized at a 1:1 ratio into either the Treatment As Usual (TAU) condition or the experimental (Aspiration, Inspiration Respiration, or AIR) intervention condition.
3159593|NCT01482910|Experimental|Aflibercept injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg intravitreal aflibercept injection (IAI) every 4 weeks for the first 12 weeks, followed by additional 2.0 mg IAI every 8 weeks until week 48. Additionally, sham photodynamic therapy (PDT) treatments was administered as needed.
3159594|NCT01482910|Active Comparator|PDT treatments|Participants received PDT as needed. Additionally, sham IAI injections was administered until week 28. Thereafter, participants received active IAI treatment until week 48.
3159595|NCT01482897|Experimental|corticoïd|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
3160296|NCT01478425|Experimental|Active|Lipidic Microemulsion
3159597|NCT01482897|Sham Comparator|feigning of peridural infiltration|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
3159598|NCT01482897|No Intervention|no intervention|natural evolution of discal sciatica
3159599|NCT01482884|Experimental|1|tralokinumab (CAT-354) sc injection
3159600|NCT01482884|Placebo Comparator|2|placebo sc injection
3159601|NCT01482871|Experimental|Arm 1.5 mg ALG-1001|Group Using 1.5 mg per 100 ul of ALG-1001
3159602|NCT01482871|Experimental|Arm 2.5 mg ALG-1001|Group Using 2.5 mg per 100 ul of ALG-1001
3159603|NCT01482871|Experimental|Arm 5.0 mg ALG-1001|Group Using 5.0 mg per 100 ul of ALG-1001
3159604|NCT01482871|Experimental|Arm 7.5 mg ALG-1001|Group Using 7.5 mg per 100 ul of ALG-1001
3159605|NCT01482858|Experimental|Gastrolith|Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.
3159606|NCT01482858|Placebo Comparator|Placebo|Gelatin capsules, each containing 500 mg [comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose] for oral use as placebo
3159607|NCT01482845|Experimental|Group 1|
3159608|NCT01482845|Experimental|Group 2|
3159609|NCT01482832|Experimental|Experimental|Behavioral: Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. Both groups will attend 5 weekly sessions and have a brief booster session postpartum.
3159610|NCT01482832|Active Comparator|Control|Behavioral: Standard care Participants assigned to receive standard care will focus on prenatal education including issues associated with pregnancy and postpartum. Both groups will attend 5 weekly sessions and have a brief booster session postpartum.
3159611|NCT01482819|Other|Sequence 1|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Lotrafilcon A~Spectacles~Galyfilcon A Plus~Polymacon~Galyfilcon A"
3159612|NCT01482819|Other|Sequence 2|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A Plus~Galyfilcon A~Lotrafilcon A~Polymacon~Spectacles"
3159613|NCT01482819|Other|Sequence 3|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A~Polymacon~Galyfilcon A Plus~Spectacles~Lotrafilcon A"
3159614|NCT01482819|Other|Sequence 4|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Spectacles~Lotrafilcon A~Polymacon~Galyfilcon A Plus~Galyfilcon A"
3159615|NCT01482819|Other|Sequence 5|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Polymacon~Galyfilcon A~Spectacles~Galyfilcon A Plus~Lotrafilcon A"
3159616|NCT01482819|Other|Sequence 6|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A~Galyfilcon A Plus~Polymacon~Lotrafilcon A~Spectacles"
3159617|NCT01482819|Other|Sequence 7|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Polymacon~Spectacles~Galyfilcon A~Lotrafilcon A~Galyfilcon A Plus"
3159618|NCT01482819|Other|Sequence 8|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A Plus~Lotrafilcon A~Galyfilcon A~Spectacles~Polymacon"
3159619|NCT01482819|Other|Sequence 9|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Lotrafilcon A~Galyfilcon A Plus~Spectacles~Galyfilcon A~Polymacon"
3159620|NCT01482819|Other|Sequence 10|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Spectacles~Polymacon~Lotrafilcon A~Galyfilcon A~Galyfilcon A Plus"
3159621|NCT01482806|Experimental|Computerized CBT + Internet Support Group|Guided patient access to Beating the Blues plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants (CCBT+ISG; N=300).
3159622|NCT01482806|Experimental|Computerized CBT Alone|Guided patient access to Beating the Blues, a proven-effective, on-line 8-session CCBT program approved for use in the United Kingdom (CCBT-alone; N=300).
3159623|NCT01482806|No Intervention|Usual Care|"Primary care physicians' usual care for mood and anxiety disorders (UC; N=100)."
3159624|NCT01482793|Active Comparator|AVAMAX|Avamax vertebroplasty kits provided by Care Fusion
3159625|NCT01482793|No Intervention|Simulated injection procedure|Patient will be unaware as to whether the control procedure or vertebroplasty had been performed since full sterile preparation, sedation and simulated injection procedure will be used.
3159626|NCT01482780|Experimental|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion), a special coronary sinus catheter will be introduced after induction of anaesthesia until going on bypass.
3159627|NCT01482780|No Intervention|Control|normal procedure of preparing Bypass grafts. Equivalent time before going on Bypass is determined as control period
3159628|NCT01482767|Experimental|HCV Treatment-Naive (Group A)|Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV). Among non-cirrhotics, the Week 8 HCV RNA was used to determine total duration of therapy. Those who had undetectable HCV RNA at Week 8 completed therapy at Week 28. Those with detectable HCV RNA at Week 8 received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
3159629|NCT01482767|Experimental|HCV Treatment-Experienced (Group B)|Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV), and non-cirrhotics received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
3159630|NCT01482754|Experimental|Rituximab Infusion at 90-minutes|
3159733|NCT01482104|Active Comparator|usual MAL-PDT|2 MAL-PDT treatments 1 week apart
3159734|NCT01482091|Placebo Comparator|Intranasal Saline|
3159735|NCT01482091|Experimental|Intranasal Fentnayl|
3159631|NCT01482741||Pts undergoing chemotherapy for Stage IV colorectal carcinoma|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
3159632|NCT01482741||Parents of pediatric patients stage 1-3 neuroblastoma|within the preceding 6 months. Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
3159633|NCT01482741||Women who have undergone tx for early stage breast cancer|within the preceding 6 months. Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
3159634|NCT01482741||Men undergoing surveillance imaging after tx for testicular ca|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
3159635|NCT01482741||Men & women enrolled in the MSKCC lung ca screening program|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
3159636|NCT01482741||Men and women enrolled in the thoracic survivorship|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
3159637|NCT01482715|Experimental|Oral Rucaparib monotherapy|
3159638|NCT01482702|Experimental|weight loss intervention|Behavioral weight loss intervention
3159639|NCT01482702|Experimental|Weight Loss plus Resistance Training|Behavioral weight loss intervention with the addition of resistance training
3159640|NCT01482702|Active Comparator|Comparator|Group of women who did not receive chemotherapy
3159641|NCT01482689|Experimental|Fish oil capsule|
3159642|NCT01482689|Experimental|Multivitamin tablet|
3159643|NCT01482676||1|controls (normal bladder function)
3159644|NCT01482676||2|acontractile bladder
3159645|NCT01482676||3|overactive bladder
3159646|NCT01482676||4|bladder pain syndrome
3159647|NCT01482663|No Intervention|Chronic hand eczema patients|Written information sheets and a 14-minutes DVD about hand eczema handed out by the dermatologist
3159648|NCT01482663|Experimental|Behavioral: Healthy Skin Clinic|1-2 counselling sessions with a nurse, tailored according to individual risks and resources and user access to a website comprising a self-monitoring log, a patients' forum and the possibility of communication with the intervention team of nurses
3159649|NCT01482650|Experimental|Baska mask|
3159650|NCT01482650|Active Comparator|single use laryngeal mask airway (LMA)|
3159651|NCT01482637||CAS|There are no separate groups. All subjects are being asked to complete the CAS measure.
3159652|NCT01482624|Active Comparator|VISCOSEAL® SYRINGE|
3159653|NCT01482624|Other|Standard arthroscopic meniscal surgery|
3159654|NCT01482611|Experimental|Panel 1: Caucasian|10, 75 and 300 mg JNJ-47910382 or placebo
3159655|NCT01482611|Experimental|Panel 2: Caucasian|30, 150, 600 mg JNJ-47910382 or placebo
3159656|NCT01482611|Experimental|Panel 3: Japanese|Session VIII and X: Doses of JNJ-47910382 or placebo to be determined
3159657|NCT01482611|Experimental|Panel 4: Japanese|Session IX: Dose of JNJ-47910382 or placebo to be determined
3159658|NCT01482598|Active Comparator|Optimal Remote Care|Patient follow up is performed through remote care, remote alerts on CRT-D device data are transmitted daily to the hospital, remote follow up is scheduled every 6 months, hospital in clinic follow up is scheduled at 12 months after implant.
3159659|NCT01482598|No Intervention|Optimal Standard Care|Patient standard in clinic visits are performed every 6 months.
3159660|NCT01482585||early stage lung adenocarcinoma|
3159661|NCT01482572||Gene profiling Success|
3159662|NCT01482559|Placebo Comparator|dextrose 5%|IV Infusion
3159663|NCT01482559|Experimental|Dopamine Hydrochloride|IV Infusion
3159664|NCT01482546||Water Colonoscopy Method|As first described by Dr. Felix W. Leung, the maneuvers can be summarized as warm water infusion in lieu of air insufflation combined with suction removal of all residual colonic air and residual feces by water exchange. The air pump will be turned off before insertion of the colonoscope into the rectum to avoid accidental insufflation of air. Warm water (at 36-37ºC) maintained using a water bath and heat saver envelop will be infused intermittently. The minimum amount of water needed to distend the colon and open the lumen will be used during scope insertion. Cecal intubation will be suggested by appropriate movement of the endoscopic image on the monitor screen when the right lower quadrant is palpated or the appendiceal orifice visualized under water. The cecum will then be distended by air to confirm visualization of the ileocecal valve and appendiceal orifice. No specific limit will be set for the volume of water to be used.
3159665|NCT01482546||Air Colonoscopy Method|The minimal amount of air will be used during insertion to open the lumen. Minimal amounts of water (10 to 50 mL) at room temperature will be used for washing of residual feces. If insertion is hindered by scope looping, attempts at loop reduction will be made. If advancement does not occur within 3 to 5 minutes, an assistant will provide abdominal compression, followed by changing the patient's position to facilitate passage of the colonoscope. Cecal intubation will be suggested by identification of the appendiceal orifice and ileocecal valve or intubation of the terminal ileum.
3159666|NCT01482533||Revision Total Hip Arthroplasty|
3159667|NCT01482533||Revision Total Knee Arthroplasty|
3159668|NCT01482520||Renal cell carcinoma|
3159669|NCT01482520||Hepatocellular carcinoma patients|
3160088|NCT01479686|Experimental|intraoperative MRI|iMRI guided resection in adults with glioma
3159670|NCT01482494||Pompe suspected patients|"Patients who go to an Internal Medicine clinic for examination of a limb-girdle myopathy.~Patients with asymptomatic hyper-CK-emia. Patients with a prior diagnosis of polymyositis. Patients with a myopathy of uncertain origin and respiratory insufficiency. Patients with polymyositis unresponsive to steroid therapy"
3159671|NCT01482468|Active Comparator|continuous infusion|continuous infusion of palonosetron added to prophylactic single injection of palonosetron
3159672|NCT01482468|Placebo Comparator|singel injection|continuous infusion of normal saline added to prophylactic single injection of palonosetron
3159673|NCT01482455|Placebo Comparator|Clamp/Glycerol|"Glycerol infusion (glycerol in 0.9% saline provided by the pharmacy of the Vienna General Hospital, will be applied at a rate of 0.7 mg.kg-1.min-1) in order to match the lipid-induced rise in serum glycerol concentrations in the same experimental setting. 0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1. After two hours, a hyperinsulinemic-euglycemic clamp (Actrapid, Novo Nordisk, Bagsvaerd, Denmark; 40 mU.m-2 body surface area min-1) test will be commenced (120-240 min)."
3159674|NCT01482455|Active Comparator|OGTT/Lipid|On study-day 1, four hours after start of a triglyceride/heparin infusion an oral glucose tolerance test (OGTT, 75g glucose dissolved in 300ml flavoured water) will be performed (240-420 min).
3159675|NCT01482455|Placebo Comparator|OGTT/Glycerol|On study-day 2, four hours after start of a glycerol infusion an oral glucose tolerance test (OGTT, 75g glucose dissolved in 300ml flavoured water) will be performed (240-420 min).
3159676|NCT01482455|Active Comparator|Clamp/Lipid|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1. After two hours, a hyperinsulinemic-euglycemic clamp (Actrapid, Novo Nordisk, Bagsvaerd, Denmark; 40 mU.m-2 body surface area min-1) test will be commenced (120-240 min)."
3159677|NCT01482442|Active Comparator|sorafenib group|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
3159678|NCT01482442|Active Comparator|radioembolization group|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
3159679|NCT01482429|Experimental|Protocol-directed|Discontinuation of ventilation was based in multidisciplinary protocol.
3159680|NCT01482429|No Intervention|Usual care|Discontinuation of ventilation was left entirely to the discretion of the physicians.
3159681|NCT01482416|Experimental|Estrogen use|climacteric women will use conjugated equine estrogens
3159682|NCT01482416|Placebo Comparator|use of Placebo|climacteric women will use placebo
3159683|NCT01482403|Experimental|Treatment Arm A|24 weeks of therapy with mericitabine 1000 mg twice a day (BID), boceprevir 800 mg three times daily (TID), Pegasys 180 microgram/week, and Copegus 1000/1200 mg/day (total treatment duration of 24 weeks), followed by a 24-week treatment-free follow-up period.
3159684|NCT01482403|Experimental|Treatment Arm B|24 weeks of therapy with mericitabine + boceprevir + Pegasys/Copegus followed by 24 weeks of therapy with boceprevir + Pegasys/Copegus (triple) (total treatment duration of 48 weeks), followed by a 24-week treatment-free follow-up period.
3159685|NCT01482403|Active Comparator|Treatment Arm C (Control)|4 weeks of therapy with mericitabine placebo, boceprevir placebo + Pegasys/Copegus, then 20 weeks of therapy with mericitabine placebo + boceprevir + Pegasys/Copegus, then 24 weeks of therapy with boceprevir + Pegasys/Copegus (total treatment duration of 48 weeks), followed by a 24-week treatment-free follow-up period.
3159686|NCT01482390|Experimental|TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (24 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV (total treatment duration of 24 weeks).
3159687|NCT01482390|Experimental|TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (48 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV and then 12 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
3159688|NCT01482390|Experimental|TVR, MCB, Placebo MCB( each for 12Weeks),PEG-IFN/RBV(48 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with placebo matching to MCB and PEG-IFN/RBV, and then 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
3159689|NCT01482390|Active Comparator|TVR(12 Weeks), Placebo MCB (24 Weeks), PEG-IFN/RBV(48 Weeks)|Twelve weeks of therapy with placebo matching to MCB, TVR, PEG-IFN/RBV, will be followed by 12 weeks of therapy with placebo matching to MCB along with PEG-IFN/RBV , following 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
3159690|NCT01482377|Experimental|Part A: RO5479599 Dose Escalation|Participants will receive a dose of 100 milligrams (mg) RO5479599 followed by dose escalation from Day 1 of Cycle 1. RO5479599 dose will be escalated as monotherapy in approximately 6 cohorts with dose increments between cohorts of up to 100 percent (%) until MTD.
3159691|NCT01482377|Experimental|Part B: RO5479599 Dose Escalation + Cetuximab|Participants will receive RO5479599 in combination with cetuximab. Escalation of RO5479599 in combination with cetuximab will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of cetuximab and lower doses of RO5479599.
3159692|NCT01482377|Experimental|Part C: RO5479599 Dose Escalation + Erlotinib|Participants will receive RO5479599 in combination with erlotinib. Escalation of RO5479599 in combination with erlotinib will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of erlotinib and lower doses of RO5479599.
3159693|NCT01482377|Experimental|Imaging (IMG) Substudy|RO5479599 will be administered with zirconium- 89-labeled RO5479599.
3159694|NCT01482364|Experimental|HOTMAN-driven therapeutic approach arm|"Hotman-driven therapeutic approach arm(group IHM) will receive treatment according to the results of the HOTMAN® System."
3159695|NCT01482364|Placebo Comparator|Control arm|Control arm will receive usual antihypertensive care according to the 2007 ESH Guidelines.
3159696|NCT01482351|Experimental|Continuous Positive Airway Pressure|Participants diagnosed with OSA who choose to treat their apnea with Continuous Positive Airway Pressure (CPAP) will be compared with those who do not choose to use CPAP and no-apnea controls at 1 year to assess changes in mild cognitive impairment.
3159697|NCT01482338|Experimental|DSG|The low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
3159698|NCT01482338|Active Comparator|DRSP|The other low-dose oral contraceptive pill which consists of 20 microgram ethinyl estradiol and 3 mg drospirenone were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
3159699|NCT01482325|Experimental|Subjects requiring blood pressure monitoring|Any subject (neonate-adult) requiring hospital or clinic blood pressure monitoring
3159700|NCT01482312|Active Comparator|Lotrafilcon A / Comfilcon A / Glasses|Lotrafilcon A contact lenses worn first, followed by comfilcon A contact lenses, followed by habitual glasses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
3159701|NCT01482312|Active Comparator|comfilcon A / glasses / lotrafilcon A|Comfilcon A contact lenses worn first, followed by glasses, followed by lotrafilcon A contact lenses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
3159702|NCT01482312|Active Comparator|glasses / lotrafilcon A / comfilcon A|Glasses worn first, followed by lotrafilcon A contact lenses, followed by comfilcon A contact lenses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
3159703|NCT01482299|Experimental|RAD001 (everolimus)|
3159704|NCT01482286|Experimental|Metformin|Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
3159705|NCT01482286|Experimental|Dietary Restriction|Subjects randomized to the dietary restriction group (DR) will reduce their energy intake by 25% from their weight maintenance energy intake determined at baseline by doubly labeled water.There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
3159706|NCT01482286|Experimental|Exercise|Subjects randomized to the exercise training group will complete a structured program of aerobic training 3 to 4 times per week and resistance exercises 2 times per week.
3159707|NCT01482286|No Intervention|Control|Subjects randomized to the no treatment control group will be asked to continue, as normal their usual dietary and exercise regimen. Subjects will be asked to not begin diet or exercise regimens through the 24-week study or to begin medical treatment for PCOS.
3159708|NCT01482273|Active Comparator|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
3159709|NCT01482273|Active Comparator|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
3159710|NCT01482260||Primary Cutaneous Malignant Melanoma|
3159711|NCT01482260||Cutaneous Malignant Melanoma Metastases|
3159712|NCT01482260||Benign Melanocytic Nevi|
3159713|NCT01482247|Active Comparator|L-arginine|
3159714|NCT01482247|Placebo Comparator|Placebo Supplement|
3159715|NCT01482234|Experimental|pedometers only|Participants randomized to this arm will receive pedometers only. They will participate in baseline and 3 months data collection.
3159716|NCT01482234|Experimental|pedometers + prompts|Participants randomized to this arm will receive pedometers plus a weekly prompt to set a step goal. They will participate in baseline and 3 months data collection.
3159717|NCT01482234|Experimental|pedometer + prompt + messages|Participants randomized to this arm will receive pedometers, weekly prompts, and 6 motivational text messages a week. They will participate in baseline and 3 months data collection.
3159718|NCT01482234|No Intervention|Control|Participants randomized to this group will participate in data collection only; they will not receive an intervention.
3159719|NCT01482221|Experimental|1|
3159720|NCT01482221|Experimental|2|
3159721|NCT01482221|Placebo Comparator|3|
3159722|NCT01482195|Experimental|Recombinant Adeno-Associated Virus|
3159723|NCT01482169|Active Comparator|Adenoscan|Subjects will have the FFR Measurement with IV Adenoscan®
3159724|NCT01482169|Experimental|Regadenoson|Subjects will have the FFR Measurement with IV Regadenoson
3159725|NCT01482156|Experimental|RAD001 + BEZ235|Patients will receive first dose of RAD001 at 2.5mg/5mg/10 mg weekly or 2.5mg/5mg daily in combination of BEZ235 at 50 mg/100 mg/200 mg/300 mg/400 mg twice a day. In the initial cohort of the dose finding phase, patients will receive a single 2.5 mg dose of RAD001 on Cycle 1 Day 1 and the combination therapy of RAD001 2.5 mg/week and BEZ235 200 mg bid starting on Cycle 1 Day 8. Dose escalation phase: patients will start RAD001 and BEZ235 on Cycle 1 Day 1 with both study drugs being administered at the center. Dose expansion phase: the first 15 patients enrolled at selected sites will take RAD001 as monotherapy from Day 1 to Day 7 (for PK sampling). The combination therapy of RAD001 and BEZ235 will start on Day 8. All remaining patients will receive the combination therapy of RAD001 and BEZ235 starting on Cycle 1 Day 1.
3159726|NCT01482143|Experimental|All Study subjects|
3159727|NCT01482130|Experimental|Training group|All participants in the training group will pursue a 12 weeks of strength training.
3159728|NCT01482130|Other|Controls|The control group will be encouraged to follow a training program according to recommended exercise guidelines
3159729|NCT01482117|Active Comparator|Clopidogrel|single oral administration of 300mg of clopidogrel
3159730|NCT01482117|Active Comparator|Cilostarole|single oral administration of 100mg of cilostazole
3159731|NCT01482117|Active Comparator|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
3159732|NCT01482104|Experimental|MAL-PDT re-treatment|1 treatment of MAL-PDT with re-treatment of non-complete responders
3160171|NCT01479153|Active Comparator|Femoral Catheterization|
3159736|NCT01482078||Receive MgSO4 infusion|Parturients who present to the hospital at less than 34 weeks gestational age with potential pre-term labor, pre-term rupture of membranes or intrauterine growth restriction
3159737|NCT01482078||Do not receive MgSO4 infusion|"We will approach a control group of subjects: i.e. parturients undergoing cesarean section (elective or emergency) with neuraxial anesthesia.~We will seek to ensure that the control group is similar to the study group with respect to the following parameters:~Number of singleton or multiple pregnancy~Parity of parturients~Anesthetic technique (spinal or epidural)~Time of cesarean section (08:00-19:59 or 20:00 to 07:59) Once informed consent is obtained these subjects will be treated identically to the study group in terms of anesthetic management and data collection."
3159738|NCT01482065|Experimental|CPAP|"Patients with moderate to severe apnea will be randomized to CPAP or deferred CPAP. Those in the CPAP group will be sent home with an autoset CPAP device, which they will be instructed to utilize for 4 months. The CPAP device will be set in the auto mode so that it will automatically adjust the pressure at night to eliminate upper airway obstruction during sleep.~Criteria for OSA severity are specifically designed to target patients with nocturnal hypoxemia, which is hypothesized to contribute to NAFLD progression. According to the guidelines of the American Academy of Sleep Medicine, apnea will be defined as cessation of airflow for ≥ 10 sec. and hypopnea will be defined as decreased airflow for ≥ 10 sec. leading to oxyhemoglobin desaturation ≥ 4%. Mild, moderate and severe OSA will be diagnosed by an Apnea-Hypopnea Index (AHI) of 5-14.9, 15-29.9, and ≥ 30 events/hr, respectively."
3159739|NCT01482052|Experimental|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
3159740|NCT01482052|Active Comparator|US Licensed Vaccine|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
3159741|NCT01482039|No Intervention|Standard Ultrasound|Current standard of care - one abdominal view of the cervix to rule out placenta previa
3159742|NCT01482039|Experimental|Sequential Screen|Start with 3 abdominal views of the cervix with measurement. If 3 adequate views cannot be obtained, or if measurement is less than 3cm, then will perform transvaginal scan for measurement.
3159743|NCT01482039|Experimental|Screening Transvaginal Ultrasound|Obtain 3 adequate cervical length measurements using transvaginal ultrasound
3159744|NCT01482026|Experimental|Treated patients|Patients for whom ADHD treatment is introduced at enrolment. Evolution of the ADHD Rating Scale-IV inattention subscore
3159745|NCT01482026|Experimental|Non treated patients|Patients for whom no ADHD treatment is required at enrolment. Evolution of the ADHD Rating Scale-IV inattention subscore
3159746|NCT01482013|Experimental|HPP854|Oral HPP854 once a day for 28 days.
3159747|NCT01482013|Placebo Comparator|Placebo|Oral, placebo once a day for 28 days.
3159748|NCT01482000|Experimental|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
3159749|NCT01482000|Active Comparator|Control|The control group will get the usual care with some additional tests for the study.
3159750|NCT01481987|Experimental|Epiretinal Membrane|The investigators prospectively included 49 eyes of 49 patients with idiopathic ERM for which surgical treatment had been planned.
3159751|NCT01481987|No Intervention|Control|Subjects with normal visual acuity and OCT profile
3159752|NCT01481974|Experimental|Treprostinil|This is a single center, open-label, dose-escalation Phase I/II study of Treprostinil.
3159753|NCT01481961|Experimental|rTMS arm|
3159754|NCT01481948|Experimental|story plus behaviorial procedures|The girls randomized to this arm of the study will view an interactive story about 6 8-10 year old African American girls who seek to find clues to solve a mystery about the town in which they live. The episodes will contain information about healthy nutrition and physical activity, as well as basic information about physical activity and kitchen safety tips, developmentally appropriate recipes, and portion sizes. Girls randomized to this arm of the study will also engage in key behavior change procedures, such as goal setting, problem solving, and self monitoring.
3159755|NCT01481948|Active Comparator|story only|The girls randomized to this arm of the study will view an interactive story about 6 8-10 year old African American girls who seek to find clues to solve a mystery about the town in which they live. The episodes will contain information about healthy nutrition and physical activity, as well as basic information about physical activity and kitchen safety tips, developmentally appropriate recipes, and portion sizes. Girls randomized to this arm of the study will not engage in key behavior change procedures, such as goal setting, problem solving, and self monitoring.
3159756|NCT01481948|No Intervention|Wait list control|This group will participate in data collection only; after the 3rd data collection point, they will be given access to the intervention
3159757|NCT01481935|Experimental|Enhanced Cleaning|Rooms in the Enhanced Cleaning arm will receive cleaning of frequently contaminated surfaces by a study researcher in addition to standard room cleaning by hospital housekeeping staff.
3159758|NCT01481935|Sham Comparator|Sham Enhanced Cleaning|Rooms in the Sham Enhanced Cleaning arm will receive a sham cleaning of frequently contaminated surfaces by a study researcher in addition to standard room cleaning by hospital housekeeping staff.
3159759|NCT01481922|Active Comparator|Whitacre 22 gauge|lumbar puncture performed with a Whitacre 22 gauge (BD)
3159760|NCT01481922|Experimental|Whitacre 24 gauge|lumbar puncture performed with a Whitacre 24 gauge (BD)
3159761|NCT01481909|Placebo Comparator|Sugar Pill|All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
3159802|NCT01481623|Other|Gene identification and phenotyping|Identification of patients (probands), questionnaire and informed consent of patients and their families, biological sampling, DNA and RNA extraction, genetic study for gene identification, re-contact of family members and relatives (with consent) for metabolic study of mutation carriers, and complementary studies of homozygous patients in some cases
3160209|NCT01478932|Experimental|Diaphragmatic Breathing Retraining|
3159762|NCT01481909|Active Comparator|Rupafin|All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
3159763|NCT01481896||Metal-on-Metal Total Hip Arthroplasties|Consecutive series of patients who had metal-on-metal primary total hip arthroplasty performed with DePuy Pinnacle cups, Ultamet metal liners and 36-mm cobalt-chromium alloy femoral heads.
3159764|NCT01481883|Experimental|Raloxifene Hydrochloride 120mg oral per day|120mg raloxifene plus antipsychotic drug
3159765|NCT01481883|Placebo Comparator|Placebo tablet - one per day|Lactose pill plus antipsychotic medication
3159766|NCT01481870|Active Comparator|Sorafenib-sunitinib|Sorafenib is first line treatment followed by sunitinib.
3159767|NCT01481870|Active Comparator|Sunitinib-sorafenib|Sunitinib is first line treatment followed by sorafenib.
3159768|NCT01481857|Experimental|Thoracolumbar proprioception|
3159769|NCT01481857|Experimental|Segmental Stabilization|
3159770|NCT01481844|Experimental|sequential treatment|1.drugs experimental-Sequential -PPI( Lansoprazole 30mg x2/day) + amoxicillin 1gx2/day for 5days, followed by 5 days of PPI(Lansoprazole 30mg x2/day) + ( Clarithromycin500mg x2/day and Tinidazole 500mg x2/day )
3159771|NCT01481844|Active Comparator|quadruple therapy|Quadruple drug regimen (i.e.-14 days of PPI (Lansoprazole 30mg x2/day) + Bismuth Subsalicylate 525mg X4/day + Metronidazole 500mg x3/day + Tetracycline 500mg x4/day )-is standard of care as second line treatment in eradication of H pylori
3159772|NCT01481831|Active Comparator|H PALO day 1|Highly Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1
3159773|NCT01481831|Experimental|H PALO day 1,3,5|Highly Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5
3159774|NCT01481831|Active Comparator|M PALO day 1|Moderately Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1
3159775|NCT01481831|Experimental|M PALO day 1,3,5|Moderately Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5
3159776|NCT01481818|Experimental|radioprotector|
3159777|NCT01481805||Hepatocellular carcinoma patients treated with sorafenib|
3159778|NCT01481779|Experimental|LY2605541 + Insulin Lispro|LY2605541 titrated based on blood glucose readings, administered by subcutaneous (SC) injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.
3159779|NCT01481779|Active Comparator|Glargine + Insulin Lispro|Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.
3159780|NCT01481766|Experimental|Iron plus dietary counseling (Non-anemic iron deficiency)|
3159781|NCT01481766|Placebo Comparator|Placebo plus dietary counseling (Non-anemic iron deficiency)|
3159782|NCT01481766|No Intervention|Iron sufficient|From the screening cohort of it is anticipated that 25 children will have iron deficiency anemia and an equal number of randomly selected children with iron sufficiency (n=25) will be sampled. These children will be compared to the children with non-anemic iron deficiency.
3159783|NCT01481766|Active Comparator|Iron deficiency anemia|From the screening cohort of it is anticipated that 25 children will have iron deficiency anemia and an equal number of randomly selected children with iron sufficiency (n=25) will be sampled. These children will be compared to the children with non-anemic iron deficiency.
3159784|NCT01481753|Active Comparator|Braun arm|patients received Braun enteroenterostomy
3159785|NCT01481753|Active Comparator|Non Braun Arm|Patients do not receive a Braun enteroenterostomy
3159786|NCT01481740|Experimental|Phenylephrine bolus|
3159787|NCT01481740|Experimental|Phenylephrine infusion|
3159788|NCT01481727|Placebo Comparator|cpap sham|non invasive mechanical ventilation type cpap sham manoeuver
3159789|NCT01481727|Active Comparator|high-intensity NIMV|Non-invasive mechanical ventilation, biPAP modality, with high-intensity IPAP (>18cmH2O)
3159790|NCT01481714|Active Comparator|Sodium Picosulphate preparation the day before|"Preparation the day before of the procedure using sodium picosulphate:~A sachet mixed with 250 mL of water at 18:00 pm~A sachet mixed with 250 mL of water at 21:00 pm~A minimum of 4 litres of fluid were recommended throughout the preparation"
3159791|NCT01481714|Experimental|Split-dose sodium picosulphate preparation|"The day before the procedure:~- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am."
3159792|NCT01481701|Experimental|intravenous chemotherapy|treatment of ovarian carcinoma in relapse
3159793|NCT01481688|No Intervention|Control|Routine haemodialysis sessions as per usual
3159794|NCT01481688|Experimental|Intradialytic exercise|One hour of exercise completed during haemodialysis.
3159795|NCT01481688|Active Comparator|Extra time|30 minutes extra dialysis time.
3159796|NCT01481675||BPDLL group|Patients subjected to the Biliopancreatic Diversion Long Limbs surgical operation will undergo an oral glucose tolerance preoperatively and 12 months after the operation
3159797|NCT01481675||LSG group|Patients subjected to laparoscopic sleeve gastrectomy will undergo an oral glucose tolerance test preoperatively and 12 months postoperatively
3159798|NCT01481662||retrospective|cases retrospectively reported the last 20 years
3159799|NCT01481662||Prospective|"Diffusion tensor magnetic resonance imaging of the brain:~new cases prospectively reported"
3159800|NCT01481649||HBsAg-negative, anti-HBc-positive|HBsAg-negative, anti-HBc-positive subjects undergoing hematopoietic stem cell transplantation (HSCT)
3159801|NCT01481636||No treatment, OSA (AHI >15)|Patients with OSA recruited prior to receiving NHS treatment.
3160210|NCT01478906||elderly ,adult|
3159803|NCT01481610|Experimental|Lumiracoxib group|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day) for a period of maximum 10 days, but no shorter than 7 days.
3159804|NCT01481610|Active Comparator|Diclofenac group|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
3159805|NCT01481597|Experimental|deuteporfin 1mg/kg|
3159806|NCT01481597|Active Comparator|deuteporfin 2.5mg/kg|
3159807|NCT01481597|Active Comparator|deuteporfin 5mg/kg|
3159808|NCT01481597|Active Comparator|deuteporfin 7.5mg/kg|
3159809|NCT01481597|Placebo Comparator|placebo|
3159810|NCT01481584|Experimental|Canola protein|Canola protein (Brassica juncea; incorporated in a drink)
3159811|NCT01481584|Active Comparator|Reference protein|Reference Protein (soy protein isolate; incorporated in a drink)
3159812|NCT01481584|No Intervention|Wash out|Wash out (four weeks without any intervention between interventional periods)
3159813|NCT01481584|No Intervention|Run-in|Run-in period (three days before intervention, defined diet)
3159814|NCT01481571|Experimental|Vitrification media and device|Vitrification medium oocyte, warming medium oocyte and Rapid-i
3159815|NCT01481558|Sham Comparator|Sham tDCS|sham-tDCS application every 2 days for 2 weeks (total of 6 applications)
3159816|NCT01481558|Experimental|Transcranial direct current stimulation|tDCS application every 2 days for 2 weeks (total of 6 applications)
3159817|NCT01481545|Experimental|preoperative chemoradiotherapy|Preoperative radiation therapy and combination chemotherapy plus bevacizumab
3159818|NCT01481532|Experimental|Cohort 3|The third cohort will include up to 18 patients with Crotoxin doses of 0.12 to 1.16 mg per m2 in which the dose escalation speed will be faster. Drug is administered over 48 hour intervals using ambulatory infusion pumps; treating on an outpatient basis. Subjects will receive increasing doses over the course of 35 treatment days (15 dose levels).
3159819|NCT01481519|Active Comparator|dexamethasone 0.1%/povidone-iodine 0.4%|Patients were instructed to put one drop into each symptomatic eye four times daily for 7 days.
3159820|NCT01481519|Placebo Comparator|artificial tears|Patients were instructed to put one drop into each symptomatic eye four times daily for 7 days.
3159821|NCT01481506|Experimental|Telemonitoring|
3159822|NCT01481506|No Intervention|Usual care|
3159823|NCT01481493|Experimental|Active Treatment|BT061 monoclonal antibody (subcutaneous)
3159824|NCT01481493|Placebo Comparator|Placebo|subcutaneous injection of placebo
3159825|NCT01481480|Experimental|Latissimus dorsi tendon transfer|A Latissimus dorsi tendon transfer is performed
3159826|NCT01481480|Active Comparator|Arthroscopic repair|An arthroscopic repair is performed
3159827|NCT01481467|Experimental|Intervention|Influenza vaccination implementation strategy applied.
3159828|NCT01481467|No Intervention|Control|Usual care.
3159829|NCT01481454|Experimental|Group 1: QIV Lot 1|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 1.
3159830|NCT01481454|Experimental|Group 2: QIV Lot 2|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 2.
3159831|NCT01481454|Experimental|Group 3: QIV Lot 3|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 3.
3159832|NCT01481454|Active Comparator|Group 4: TIV|Participants will receive the Trivalent Influenza Vaccine (TIV).
3159833|NCT01481441|Other|SonoVue|Ultrasound Contrast Agent
3159834|NCT01481428|Active Comparator|Attention Control|
3159835|NCT01481428|Experimental|Computer-facilitated HIV intervention|
3159836|NCT01481402|Placebo Comparator|Placebo-liothyronine|3 months of placebo followed by 3 months of Liothyronine treatment.
3159837|NCT01481402|Other|Liothyronine-Placebo|3 months of Liothyronine treatment followed by 3 months of Placebo treatment.
3159838|NCT01481389|Active Comparator|Theobromine drink|
3159839|NCT01481389|Active Comparator|Cocoa drink|
3159840|NCT01481389|Placebo Comparator|Placebo drink|
3159841|NCT01481389|Active Comparator|Cocoa and theobromine drink|
3159842|NCT01481363|Active Comparator|Treatment as usual|Half of participants recruited will be randomly assigned to the control group to receive treatment as usual. This is will be based on a single one hour consultation which will include communication advice and information.
3159843|NCT01481363|Experimental|The Talking Sense treatment|Half of carer participants recruited will be randomly assigned to receive the Talking Sense treatment. This will be conducted one to one and individualised over 3 sessions and no more than 4.5 hours during no more than 8 weeks.
3159844|NCT01481350|Experimental|Sildenafil|All patient will be treat with a intravenous administration of the drug from the beginning of the intervention, for a maximum of 72 hours.
3159845|NCT01481337||Polypectomy or mucosal endoscopic resection under aspirin|
3159846|NCT01481324||Functioning Pressure Sensor Group|This group will have a functioning pressure sensor placed on the foot ankle orthosis. The group will be blinded as to whether or not the sensor is functioning.
3159847|NCT01481324||Non-Functioning Pressure Sensor Group|This group will have a non-functioning pressure sensor (a placebo) placed on the foot ankle orthosis. The group will be blinded as to whether or not the sensor is functioning.
3159848|NCT01481324||No Sensor Group|This group will not have a pressure sensor placed on the foot ankle orthosis.
3159849|NCT01481311||Patients before dialysis treatment|
3159850|NCT01481311||Patients after dialysis treatment|
3159851|NCT01481298||LVNC|12 patients with left ventricular non-compaction cardiomyopathy
3159852|NCT01481298||HCM|10 patients with hypertrophic cardiomyopathy
3159853|NCT01481298||DCM|11 patients with dilatative cardiomyopathy
3159854|NCT01481298||controls|24 healthy controls
3159855|NCT01481285||healthy adults|The study will cover 992 healthy adults. 496 men and 496 women in an age range of 18 to 65 years are planned to be recruited.
3159856|NCT01481272|Experimental|O-IVAC|Ofatumumab Etoposide Ifosfamide Mesna Cytarabine Methotrexate Leukovorin Granulocyte-Colony Stimulating Factor
3159857|NCT01481259|Experimental|Immunotherapy|Subjects receive autologous cytokine-induced killer cell infusion every 21 days
3159858|NCT01481259|Active Comparator|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days
3159859|NCT01481246||Normal Aging/Cognitive Decline|Health adults as well as adults with MCI and early stage AD are being recruited in the study
3159860|NCT01481233|Experimental|Single arm|Colchicine 0.5 mg BID x 21 days
3159861|NCT01481220|Experimental|Azacitidine + Eltrombopag|
3159862|NCT01481207||neonates with perinatal asphyxia|neonates with suspected perinatal asphyxia (HIE)
3159863|NCT01481194|Experimental|ACVDL|ACVDL is a combination of doxorubicin, cyclophosphamide, bortezomib, dexamethasone, and lenalidomide
3159864|NCT01481181|Experimental|zinc enriched water|zinc enriched purified water at 2-6mg/l per day
3159865|NCT01481181|No Intervention|purified water only|non zinc enriched, purified drinking water
3159866|NCT01481181|No Intervention|control group|group of households receiving hygiene practice recommendations and water guard (water purifying solution)
3159867|NCT01481168|Active Comparator|"Pacemaker on"|DDD+/-R pacing
3159868|NCT01481168|Placebo Comparator|"Pacemaker off"|ODO pacing
3159869|NCT01481168|Experimental|Implantable Loop Recorder|Implantable loop recorder in adenosine test negative patients
3159870|NCT01481142|Experimental|Adacolumn|
3159871|NCT01481129|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3159872|NCT01481116|Experimental|TAK-875 25 mg QD|
3159873|NCT01481116|Experimental|TAK-875 50 mg QD|
3159874|NCT01481116|Active Comparator|Glimepiride 1-2 mg QD|
3159875|NCT01481103|Active Comparator|Acupuncture group|Participants will keep a headache diary for 4weeks and then attend eight weekly acupuncture sessions. Acupuncture will be done by a licensed acupuncturist and will last approximately 25 minutes. Following the acupuncture sessions, participants will keep a headache diary for an additional 4 weeks
3159876|NCT01481103|No Intervention|Control group|participants will be asked to maintain a daily diary of headache occurrences and OTC medication use for 16 weeks.
3159877|NCT01481090|Active Comparator|Electro-Acupuncture|Group will receive 4 acupuncture treatments over 14 days during hormone treatment
3159878|NCT01481090|No Intervention|Control|Group will not receive acupuncture.
3159879|NCT01481077|Experimental|Treatment A|
3159880|NCT01481077|Experimental|Treatment B|
3159881|NCT01481077|Experimental|Treatment C|
3159882|NCT01481064|Active Comparator|Multifaceted approach|After baseline measurement a multifaceted approach will start for 1 year, including audit and feedback, an educational outreach visit, and patient-mediated interventions.
3159883|NCT01481064|No Intervention|Usual care|After baseline measurement no intervention will occur in these hospitals.
3159884|NCT01481038||Group dialysis patients|Patient on hemodialysis with central venous catheter
3159885|NCT01481038||Group hematology patients|Patients with hemato-oncologic underlying disease (plus/minus hematopoietic stem cell transplantation HSCT) and central venous catheter
3159886|NCT01481025|Experimental|Cimicifuga+Hiperico|80 + 450 mg / tablet
3159887|NCT01481025|Active Comparator|Cimicifuga Herbarium|80 mg / caps
3159888|NCT01481025|Active Comparator|Aplause®|20 mg / tablet
3159889|NCT01481012||Group I: Cardiopulmonary Bypass + Heart Transplantation|CPB for orthotopic heart transplantation (excluding any patients with VADs)
3159890|NCT01481012||Group II: Cardiopulmonary Bypass + Pulsatile LVAD|CPB for implantation of a Thoratec HeartMate I LVAD (for destination therapy or bridge to transplantation).
3159891|NCT01481012||Group III: Cardiopulmonary Bypass + Continuous Flow LVAD|CPB for implantation of an axial flow or centrifugal flow LVAD (for destination therapy or bridge to transplantation) (e.g. HeartMate II, DeBakey VAD or VentraAssist LVAS)
3159892|NCT01481012||Group IV: Cardiopulmonary Bypass + CABG Surgery|CPB for CABG surgery
3159893|NCT01480999||Laparotomy (open surgery)|
3159894|NCT01480999||Laparoscopic surgery|
3159895|NCT01480999||Robotic assisted surgery|
3159896|NCT01480986|Experimental|Treatment arm|This is a single arm trial. The patient will enter phase one and will continue to phase two once the disease progresses in phase one or the phase one has been completed.
3159897|NCT01480973|Experimental|MRI post lung SBRT|Feasibility of MRI to differentiate between benign and malignant changes seen after lung SBRT.
3159898|NCT01480960|Active Comparator|Whole body vibration training|Whole body vibration training in addition to pulmonary rehabilitation
3159899|NCT01480960|No Intervention|No whole body vibration training|Pulmonary rehabilitation without whole body vibration training
3159900|NCT01480947|Experimental|Bio-Three|add-on treatment of the probiotics (Bio-three)
3159901|NCT01480947|No Intervention|control treatment|control treatment (intravenous fluid, oral rice and half strength milk formula)
3159902|NCT01480934||Group:A-cases-Patients with a history of Diabetes Mellitus|(N=75 eyes). The inclusion criteria for group A: Diabetes mellitus was defined as glycosylated haemoglobin (Hb A1c ) levels of 6% or more , use of diabetic medication (oral hypoglycemic agents, insulin injection or diet restriction), or a physician's diagnosis of diabetes.
3159903|NCT01480934||Group - B:controls|Patients with uncomplicated age-related cataract who were otherwise healthy constituted the controls(Group:)B (n=75 eyes).
3159904|NCT01480921|Experimental|home based exercise training|
3159905|NCT01480921|Active Comparator|supervised exercise training|
3159906|NCT01480908|Experimental|VSD, +Right bundle branch block|Patients undergone surgical closure of ventricular septal defect and have a postoperative right bundle branch block, about 20 patients
3159907|NCT01480908|Experimental|VSD, -Right bundle branch block|Patients undergone surgical closure of ventricular septal defect and does not have a postoperative right bundle branch block, about 20 patients
3159908|NCT01480908|Experimental|Control|Healthy control subjects, about 20 patients
3159909|NCT01480895|No Intervention|Post GDM follow-up group.|
3159910|NCT01480895|Experimental|lifestyle intervention group.|The women in this group had participated in lifestyle intervention by diet instructions and physical exercise program.
3159911|NCT01480882|Active Comparator|Conventional Chest PhysioTherapy|Conventional Chest Physiotherapy (CCPT) is delivered by professional physiotherapist for 15 minutes.
3159912|NCT01480882|Experimental|Mechanical percussion|"Mechanical percussion will be delivered by a device called LEGA for 15 minutes"
3159913|NCT01480869|Active Comparator|Conventional vitamin D and calcium supplementation|Conventional vitamin D and calcium supplementation with 2 daily OROCAL VITAMINE D3® (500 mg calcium/200 IU cholecalciferol) tablets.
3159914|NCT01480869|Experimental|vitamin D supplementation tailored to vitamin D deficiency|"Conventional calcium supplementation with 2 daily OROCAL 500® (500 mg calcium) tablets to suck + vitamin D3 supplementation (UVÉDOSE®, cholecalciferol, 100 000 IU drinkable solution, 2 ml vial) whose schedule of administration depends on vitamin deficiency level:~100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25OHD level < 10 ng/mL~100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25OHD level < 20 ng/mL~100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25OHD level < 30 ng/mL"
3159915|NCT01480856|Active Comparator|Cobedding|Newborn twins are settled in a single bed : this is cobedding
3159916|NCT01480856|Placebo Comparator|Single -bedding|Newborn twins are settled in two beds : this is single-bedding
3159917|NCT01480843|Experimental|Glargine|We plan to add long acting insulin glargine with/without oral medications to the regimen in all patients.
3159918|NCT01480830|No Intervention|Standard colonoscopy|
3159919|NCT01480830|Experimental|Magnetic endoscopic imaging colonoscopy|
3159920|NCT01480817|Active Comparator|Sorafenib|Sorafenib 400mg po bid
3159921|NCT01480817|Experimental|TACE for HCC with portal vein invasion|Antineoplastic agents are directly injected into the hepatic artery, allowing high intratumoral concentrations of drugs and thereby reducing systemic side effects. The mixture of chemotherapeutic agents and iodized oil is almost completely retained in neoplastic nodules and can remain in HCC tissue for a long time. Subsequent mechanical embolization of the artery feeding the neoplasm causes ischemic damage to the tumor and prolongs the duration of the effects of chemotherapeutic agents.
3159922|NCT01480804|Experimental|Geriatric diabetes team intervention group|The subjects in this group underwent evaluation for barriers to self care by a diabetes educators well versed with age specific barriers. After consideration of patients clinical, functional, and psychosocial background a geriatric diabetes team devised strategy to help patients cope respective barriers. A care manager then implemented the coping strategies by educating patients and caregivers. She also made home visits to assess any safety issues not know to clinic based geriatric team. She helped the patients and caregivers with all aspects of care coordination. Patients in this group received phone contact from care managers as many times as needed over the six month intervention period.
3159923|NCT01480804|No Intervention|Attention Control Group|The subjects in the group received similar, in person, contact as the intervention group. An educator, separate from the one involved in the intervention team, called patents in this group for a total of eleven time within the first six months. The phone calls were forces toward general discussion without any diabetes related advice.
3159924|NCT01480791|Active Comparator|Hydrochlorothiazide|Treatment of patients with hydrochlorothiazide and effect on small arteries
3159925|NCT01480791|Experimental|Aliskiren|Treatment of patients with aliskiren and effect on small arteries
3159926|NCT01480791|No Intervention|Normotensive non diabetic subjects|A comparator non intervention normotensive non diabetic group of healthy subjects will be used for baseline comparison of primary and secondary endpoints
3159927|NCT01480778|Experimental|LNG+EE2|pill test contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
3159928|NCT01480778|Active Comparator|Nordette|pill comparator contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
3159929|NCT01480765|Placebo Comparator|Control: Placebo + Placebo|Placebo capsules and Placebo infusion
3159930|NCT01480765|Active Comparator|Pregabalin and Placebo infusion|Pregabalin capsules and Placebo infusion
3159931|NCT01480765|Active Comparator|Pregabalin + Ketamine infusion|Pregabalin capsules + Ketamine infusion
3159932|NCT01480752|Active Comparator|Lornoxicam|
3159933|NCT01480752|Placebo Comparator|normal saline|
3159934|NCT01480752|Placebo Comparator|no injection|
3159935|NCT01480739|Experimental|1|AZD5069 100 mg capsules (50 mg BD) for 7 days
3159936|NCT01480739|Experimental|2|Placebo twice daily for 7 days
3159937|NCT01480726||Open vein harvest|Conventional open vein harvest from the lower leg
3159938|NCT01480726||Endoscopic vein harvest|Endoscopic vein harvest from the calf
3159939|NCT01480713|Experimental|Monotherapy with IPs+ Raltegravir 400 mg|Lopinavir/r 400/100 mg every 12 hours + Raltegravir 400 mg every 12 hours or Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
3159940|NCT01480700|Experimental|rich-eggs|subjects consume 2 eggs rich in lutein/zeaxanthin and DHA per day during 4 months
3159941|NCT01480700|Active Comparator|standard eggs|subjects consume 2 standard eggs per day
3159942|NCT01480687|Experimental|Omega-3 fatty acid|
3159943|NCT01480687|Active Comparator|Ciprofibrate|
3159944|NCT01480674||Trastuzumab|Eligible participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic or locally advanced breast cancer, who were treated with trastuzumab as a first-line therapy and were progression-free for at least 3 years after treatment initiation, were included and were followed for one year.
3159945|NCT01480661|Active Comparator|Roflumilast|
3159946|NCT01480661|Placebo Comparator|Placebo|
3159947|NCT01480648|Experimental|BI144807|Subjects receive a single oral dose of BI144807solution
3159948|NCT01480648|Placebo Comparator|Placebo|Subjects receive a single oral dose of placebo solution
3159949|NCT01480635||Incomplete Colonoscopy|
3159950|NCT01480622|Experimental|TDF tablets|Tenofovir disoproxil fumarate tablets
3159951|NCT01480609|Active Comparator|Dose-Dialysis|Subjects will be dosed with study drug followed by a scheduled dialysis session
3159952|NCT01480609|Active Comparator|Dialysis-Dose|Subjects will be dosed following the completion of their scheduled dialysis session
3159953|NCT01480596|Experimental|Belimumab|10mg/kg
3159954|NCT01480596|Placebo Comparator|Placebo|placebo IV infusion
3159955|NCT01480583|Experimental|GRN1005|GRN1005 alone in HER2- MBC patients with brain mets. 18F-FLT may also be administered to this arm (if patient enrolled at NCI)
3159956|NCT01480583|Experimental|GRN1005 with trastuzumab|GRN1005 in combination with trastuzumab in MBC patients with brain mets 18F-FLT may also be administered to this arm (if patient enrolled at NCI)
3159957|NCT01480557|Active Comparator|Liquefaction group|Subjects that were operated for cataract using liquefaction technology
3159958|NCT01480557|Active Comparator|Torsional ip group|Subjects that were operated for cataract using torsional ip technology
3159959|NCT01480544|No Intervention|Mothers at endline|Data collected on new mothers (up to three weeks after childbirth) in 180 clusters with 100 mothers in each cluster at endline.
3159960|NCT01480544|Experimental|Treatment 1|Data collected on new mothers (up to three weeks after childbirth) and on providers with incentives for clinical improvements in quality of maternity care in the providers' patient populations and the catchment areas served by the providers.
3159961|NCT01480544|Experimental|Treatment 2|Data collected on new mothers (up to three weeks after childbirth) and on providers with incentives for improvement in maternal and infant health outcomes in the providers' patient populations and in the catchment areas served by the providers.
3159962|NCT01480544|No Intervention|Control|Data collected on new mothers (up to three weeks after childbirth) and providers with no incentives
3159963|NCT01480505||High myopic eye|Persons with high Myopia suffered from Rhegmatogenous Retinal detachment
3159964|NCT01480492|No Intervention|therapy|
3159965|NCT01480479|Experimental|Rindopepimut/GM-CSF plus Temozolomide|
3159966|NCT01480479|Active Comparator|KLH plus Temozolomide|
3159967|NCT01480466|Experimental|Obesity tools in electronic health record|This arm will consist of a new set of tools within the electronic health record to help primary care clinicians address overweight and obesity with their patients.
3159968|NCT01480466|No Intervention|Standard care|This arm is standard care for overweight/obesity.
3159969|NCT01480453||Trabecular Metal Humeral Stem|Patients requiring primary, total or hemi shoulder arthroplasty who receive the Trabecular Metal Humeral Stem.
3159970|NCT01480440||Trabecular Metal Reverse Shoulder System|Patients requiring primary or revision reverse total shoulder arthroplasty who receive the Trabecular Metal Reverse Shoulder System
3159971|NCT01480414|Experimental|4times injection|the patients with ischemic lower limb ulcer who underwent 4times stem cell injection.
3159972|NCT01480414|Experimental|one injection|Patients with peripheral artery disease underwent cell transplantation just one time.
3159973|NCT01480401|Experimental|low-sodium diet|(1500 mg daily)
3159974|NCT01480401|No Intervention|moderate-sodium diet|sodium (100 mmol or 2300 mg daily; Usual Care)
3159975|NCT01480388|Placebo Comparator|Placebo|
3159976|NCT01480388|Experimental|JNJ-39758979 (10 mg/d)|
3159977|NCT01480388|Experimental|JNJ-39758979 (30 mg/d)|
3159978|NCT01480388|Experimental|JNJ-39758979 (100 mg/d)|
3159979|NCT01480388|Experimental|JNJ-39758979 (300 mg/d)|
3159980|NCT01480375|Experimental|Navigo™ and Smartbx™ system.|all biopsy cores were handled using the Smartbx™ system. part of the procedures were performed with both Navigo™ and Smartbx™ system.
3159981|NCT01480375|No Intervention|standard method|all biopsy cores were handled using standard method - shaking the biopsy needle into formalin vial. no navigation system.
3159982|NCT01480362|Experimental|Negative Pressure Wound Therapy|The therapy involves the controlled application of sub-atmospheric pressure to the local wound environment,using a sealed wound dressing connected to a vacuum pump.
3159983|NCT01480362|Active Comparator|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
3159984|NCT01480336|Placebo Comparator|Amiodarone with Placebo|
3159985|NCT01480336|Active Comparator|Amiodarone with Ranolazine|
3159986|NCT01480323|Experimental|Ipilimumab|Ipilimumab i.v. + Interleukin-2 intratumoral
3159987|NCT01480310|Experimental|A|
3159988|NCT01480310|Experimental|B|
3159989|NCT01480297|Experimental|Salsalate|All subjects will take Salsalate, 3 grams daily (as 3 divided doses of 1 gram with breakfast, lunch and dinner).
3159990|NCT01480284|Experimental|GSK548470 300 mg|GSK548470 300 mg tablet and ETV placebo capsule are administered once daily
3159991|NCT01480284|Active Comparator|ETV 0.5 mg|ETV 0.5 mg capsule and GSK548470 placebo tablet are administered once daily
3159992|NCT01480271|Experimental|Part 1 Cohort 1 GSK2445053|2ng GSK2245053
3159993|NCT01480271|Placebo Comparator|Part 1 Cohort 1 Placebo|Placebo
3159994|NCT01480271|Experimental|Part 1 Cohort 2 GSK2445053|20ng GSK2445053
3159995|NCT01480271|Placebo Comparator|Part 1 Cohort 2 Placebo|Placebo
3159996|NCT01480271|Experimental|Part 1 Cohort 3 GSK2245053|100ng GSK2445053
3159997|NCT01480271|Placebo Comparator|Part 1 Cohort 3 Placebo|Placebo
3159998|NCT01480271|Experimental|Part 1 Cohort 4 GSK2445053|200ng GSK2445053
3159999|NCT01480271|Placebo Comparator|Part 1 Cohort 4 Placebo|Placebo
3160000|NCT01480271|Experimental|Part 1 Cohort 5 GSK245053|400ng GSK2445053
3160001|NCT01480271|Placebo Comparator|Part 1 Cohort 5 Placebo|Placebo
3160002|NCT01480271|Experimental|Part 1 Cohort 6 GSK2445053|1000ng GSK2245053
3160003|NCT01480271|Placebo Comparator|Part 1 Cohort 6 Placebo|Placebo
3160004|NCT01480271|Experimental|Part 1 Cohort 7 GSK2445053|2000ng GSK2445053
3160005|NCT01480271|Placebo Comparator|Part 1 Cohort 7 Placebo|Placebo
3160006|NCT01480271|Experimental|Part 1 Cohort 8 GSK2445053|4000ng GSK2445053
3160007|NCT01480271|Placebo Comparator|Part 1 Cohort 8 Placebo|Placebo
3160008|NCT01480258|Experimental|V419|V419 + Rotavirus vaccine + Prevenar 13
3160009|NCT01480258|Active Comparator|Infanrix hexa|INFANRIX hexa + rotavirus vaccine + Prevenar 13
3160010|NCT01480245|Experimental|Continuous Dosing|GSK2402968 6mg/kg/week
3160011|NCT01480245|Experimental|Intermittent Dosing|GSK2402968 6mg/kg/week
3160012|NCT01480245|No Intervention|Natural History Observation|The objective of this arm will be to explore DMD disease progression in a naturalistic setting once discontinuing active treatment
3160013|NCT01480232|Experimental|EVP-6124 + NicoDerm (Active)|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
3160014|NCT01480232|Active Comparator|Placebo + NicoDerm (Active)|One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
3160015|NCT01480232|Experimental|EVP-6124 + NRT Patch (Placebo)|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
3160016|NCT01480232|Placebo Comparator|Placebo + NRT Patch (Placebo)|One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
3160017|NCT01480219||Any Voriconazole|
3160018|NCT01480219||No Voriconazole|
3160019|NCT01480193|Active Comparator|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
3160020|NCT01480193|Experimental|Integrated Medicine Therapies and SBE|2 Sound Based and Educational Sessions 3 Cognitive Based Therapy Sessions 9 Telephonic Health Coaching Sessions 5 Acupuncture Sessions Group-Based 8 week Mindfulness Based Stress Reduction
3160021|NCT01480180|Experimental|Prophylaxis|
3160022|NCT01480180|Experimental|On-demand|
3160023|NCT01480167|Active Comparator|RF-TVA with STABILIT Vertebral Augmentation System|All RadioFrequency-Targeted Vertebral Augmentation (RF-TVA) arm participants will be treated with the StabiliT Vertebral Augmentation System. This system is a commercially available device in the United States designed to perform percutaneous vertebral augmentation (also known as kyphoplasty).
3160024|NCT01480167|Active Comparator|Non Operative Management|All non-operative management (NOM) arm participants will receive non-operative standard of care management, which can include: analgesics, bed rest, back braces, physiotherapy, rehabilitation programs, and walking aids according to standard practices of participating institutions.
3160025|NCT01480154|Experimental|Treatment (Akt inhibitor MK2206, hydroxychloroquine)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15. Beginning on course 2, patients also receive hydroxychloroquine PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3160026|NCT01480141|Experimental|Single Arm Study|Single arm trial where all patients will be treated with afatinib until the day of surgery and for a minimum of two weeks. Patients will receive treatment with afatinib 40mg orally daily.
3160027|NCT01480128|Active Comparator|Multi-port|Multi-port laparoscopic colon resection
3160028|NCT01480128|Experimental|Single-port|Single-port laparoscopic colon resection group
3160029|NCT01480102|Placebo Comparator|Group B- No Block|Participants randodmized to this arm will have a local anesthetic injection and pressure applied to the paravertebral space. A paravertebral injection will not be conducted.
3160030|NCT01480102|Active Comparator|Group A- Paravertebral block|Participants randodmized to this arm will have a local anesthetic (Bupivicaine 0.5% without epinephrine) injection and will be given a paravetebral block into the T10 paravertebral space..
3160031|NCT01480089|Placebo Comparator|Atomized Intraperitoneal Saline (AIS)|Participants randomized to this arm will be given atomized intraperitoneal saline(AIS).
3160032|NCT01480089|Active Comparator|Intraperitoneal Ropivacaine(AIR)|Participants randomized to this arm will receive atomized intraperitoneal ropivacaine (AIR).
3160033|NCT01480076|Experimental|(BIIB041) Fampridine|All participants take 10 mg fampridine twice daily for the first 4 weeks. If deemed a treatment responder, a participant continues 10 mg fampridine twice daily for 44 weeks. Treatment non-responders can continue without treatment by completing quality of life questionnaires.
3160034|NCT01480063||Fampyra|Fampyra administered as prescribed in routine clinical practice.
3160035|NCT01480050|Experimental|Dose Finding|"Dose Escalation of Mibefradil for 7 days followed by TMZ (150-200mg/m2) every 28 days. At MTD 10 additional pts treated with an addition FLT PET-CT scan.~Mibefradil Temozolomide (TMZ) FLT PET CT '3'-deoxy-3'-[18F]fluorothymidine' Pharmacology Studies"
3160036|NCT01480037||Elderly|Individuals between 60 and 70 years-old
3160037|NCT01480037||Long-lived|Individuals above 85 years-old
3160038|NCT01480037||Young|Individuals between 20 and 30 years-old
3160039|NCT01480011|Experimental|lactobacillus lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
3160040|NCT01479998|Active Comparator|Standard care and nicotine replacement therapy|standard care is 4 counseling sessions and nicotine replacement therapy
3160041|NCT01479998|Experimental|standard care plus NRT plus contingency management|standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
3160042|NCT01479985|Experimental|CDM Tool|participants will be randomized to completing the CDM tool
3160043|NCT01479985|No Intervention|Control|Participants will fill out a computer survey similar to CDM tool without the decisive factors and computer print out
3160044|NCT01479972|Experimental|VPM1002|
3160045|NCT01479972|Active Comparator|BCG|
3160046|NCT01479959|Active Comparator|No PEEP level|protocol conducted while no PEEP is applied
3160047|NCT01479959|Active Comparator|effective PEEP level (PEEPeff)|PEEP level allowing the entire expiratory volume to go through the upper airways during quiet breathing
3160048|NCT01479959|Active Comparator|intermediate PEEP level (PEEP50)|50% of PEEPeff
3160049|NCT01479946|Experimental|Early Electrochemotherapy|Electrochemotherapy is given as early as possible after the discovery of skin metastases
3160050|NCT01479946|No Intervention|Delayed or no Electrochemotherapy|patients are to be treated for their breast cancer according to clinical routine with electrochemotherapy as an option only after 6 months from randomization
3160051|NCT01479933|Experimental|Vitamin D 40|Vitamin D3 40 micrograms (1600 IU) per day
3160052|NCT01479933|Experimental|Vitamin D 80|Vitamin D3 80 micrograms (3200 IU) per day
3160053|NCT01479933|Placebo Comparator|Placebo|
3160054|NCT01479920|Active Comparator|DCEAS|"Dense cranial electroacupuncture stimulation (DCEAS)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
3160055|NCT01479920|Sham Comparator|n-CEA|"Non-invasive cranial electroacupuncture (n-CEA)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
3160056|NCT01479907|Active Comparator|Synbiotics|"A specific multistrain/multifi ber synbiotic composition of prebiotics and probiotics (Synbiotic Forte™, IONIA Pharmaceuticals, Athens, Greece) was administered at the active comparator arm of the study. It contained 10 [11] of each of four lactic acid bacteria (LAB): Pediococcus pentosaceus 5-33:3, Leuconostoc mesenteroides 32-77:1, Lactobacillus paracasei ssp. paracasei 19, and Lactobacillus plantarum 2362, and 2.5 g of each of the four fermentable fibers (prebiotics): b-glucan, inulin, pectin and resistant starch. The synbiotics were delivered in sachets and then mixed with water (12 g in 250 mLof water once daily). Th e treatment started on the day patients tolerated per os liquid intake (2nd-4th POD). The intervention period lasted 15 days."
3160057|NCT01479907|Placebo Comparator|Placebo|The patients belonging to the placebo comparator arm received only the 4 fi bers and no LAB (12 gin 250 mLof water once daily for 15 days). All the subjects were interviewed by a dedicated research fellow (KP) and reactions to the product, and any adverse events occurring in the 15-day period were recorded.
3160058|NCT01479894||Sample Collection|This is an exploratory study utilizing archived tumor specimens and demographic and pathologic characteristics derived from the patient's medical charts. As such, all eligible patients must have a stored tumor specimen which can be accessed for analysis.
3160059|NCT01479881|Experimental|001|a single 100-mg dose of cyclosporine, and after a wash out period of at least 10 days, TMC435 150 mg once daily (q.d.) for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7.
3160060|NCT01479881|Experimental|002|TMC435 150 mg once daily (q.d.) for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7 and after a wash out period of at least 10 days, a single 100-mg dose of cyclosporine.
3160061|NCT01479881|Experimental|003|a single 2-mg dose of tacrolimus on Day 1. After a wash out period of at least 10 days, participants will receive TMC435 150 mg q.d. for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7.
3160062|NCT01479881|Experimental|004|TMC435 150 mg q.d. for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7. After a wash out period of at least 10 days, participants receive a single 2-mg dose of tacrolimus.
3160063|NCT01479868|Experimental|TMC435 + pegylated interferon alpha-2a + ribavirin|Patients will be administered TMC435 150 mg along with pegylated interferon alpha-2a 180 microgram and ribavirin 1000 or 1200 mg for 12 weeks. Pegylated interferon alpha-2a and ribavirin will only be continued until 24 to 48 weeks.
3160064|NCT01479855||Patients|Patients referred to a memory clinic due to memory problems and their healthy spouse
3160065|NCT01479842|Experimental|Treatment (enzyme inhibitor, chemo, monoclonal antibody)|Patients receive BTK inhibitor PCI-32765 PO QD on days 1-28. Patients also receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may continue receiving BTK inhibitor PCI-32765 PO in the absence of disease progression or unacceptable toxicity.
3160066|NCT01479829|Active Comparator|ESC + CBX|Escitalopram 10 mg twice day plus Celecoxib 200 mg twice daily.
3160067|NCT01479829|Placebo Comparator|ESC + PBO.|Escitalopram 10 mg twice day plus placebo administered twice daily.
3160068|NCT01479803|Active Comparator|EchoTip HD ProCore 22 Gauge|first passage in the pancreatic tumor with the EchoTip HD ProCore 22 Gauge then with the EchoTip 22 Gauge
3160069|NCT01479803|Active Comparator|Echo Tip 22 Gauge|First passage through the tumor with the EchoTip 22 Gauge then with Echotip HD ProCore 22 Gauge
3160070|NCT01479790|No Intervention|Visante AS-OCT and Cirrus AS-OCT|The tear meniscus is the thin concave strip of the tear film near the eyelid margins. During the acquisition the participants place their chins on a chin rest and look at a fixation light/target. This whole procedure should not take more than 5 minutes. The patients are allowed to blink freely except for during the acquisition time of less than 5 seconds. The procedure will be repeated for the upper and lower tear meniscus of both eyes.
3160071|NCT01479790|Experimental|Thermography measurement|"In total, four pairs of thermographic sequences on the ocluar surface temperature from volunteers will be taken.~A thermographic sequence will be captured from each eye.~After 20 minutes, a second pair of thermographic sequences will be captured.~An eye mask with a temperature of not more than 40 deg C (will be worn by the volunteer for 5 minutes and a third pair of thermographic sequences will be captured immediately after mask removal.~A fourth pair of thermographic sequences will be captured 1 hour after mask removal."
3160072|NCT01479777|Experimental|FES Stepping|For the next 8 weeks, we will ask you to come to the ICSCI twice (2) time per week during which you will perform FES Stepping.
3160073|NCT01479764|Experimental|Sugammadex|Participants receive sugammadex, 2 or 4 mg/kg, depending on level of neuromuscular recovery
3160074|NCT01479764|Active Comparator|Neostigmine/glycopyrrolate|Participants receive neostigmine/glycopyrrolate per usual practice
3160075|NCT01479751|Experimental|ketamine|Patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
3160076|NCT01479751|Experimental|priming|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
3160077|NCT01479751|No Intervention|Roc 0.9|Patients receive Roc 0.9 mg/kg as an induction dose.
3160078|NCT01479751|No Intervention|Control|Patients receive Roc 0.6 mg/kg without any pretreatments of Mg, ketamine, or priming.
3160079|NCT01479751|Experimental|Mg|Patients receive magnesium sulfate (MgSO4) 50 mg/kg over 10 min before Roc injection.
3160080|NCT01479738|Experimental|Capitate bone grafting|18 patients with PIP joint defects were included in the study. There were 13 male and 5 female patients with a mean age of 31 years (range, 18-47 years). The injury occurred in the right hand in 11 patients and on the left hand in 7. The injured PIP joints were in the index finger (n=7), long finger (n=9), and ring finger (n=2).
3160081|NCT01479725|Experimental|Ulcerative IC|HBOT for ulcerative IC
3160082|NCT01479725|Experimental|Non-Ulcerative IC|HBOT for non-ulcerative IC
3160083|NCT01479712|Active Comparator|Irrigation|This is the arm that will receive irrigation.
3160084|NCT01479712|No Intervention|No Irrigation|This is the arm that will not receive irrigation.
3160085|NCT01479699|Placebo Comparator|Placebo capsule|Four placebo capsules containing safflower oil only
3160086|NCT01479699|Active Comparator|Olive leaf extract capsule|Four olive leaf capsules. Each containing 4mg oleuropein plus safflower oil.
3160087|NCT01479686|Active Comparator|conventional neuronavigation|conventional neuronavigation guided resection in adults with glioma
3160089|NCT01479673|No Intervention|Control group|"Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the liberal  regimen, i.e. according to local practice."
3160090|NCT01479673|Experimental|Indirect Calorimetry|Study group: Indirect Calorimetry (IC) Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry measurement of Resting Energy Expenditure (REE).
3160091|NCT01479660|Placebo Comparator|Control|
3160092|NCT01479660|Experimental|Probiotic|
3160093|NCT01479647|Experimental|PH-797804 1 mg Fasted|Subjects will receive a single 1 mg dose in the fasted state
3160094|NCT01479647|Experimental|PH-797804 1 mg Fed|Subjects will receive a single 1 mg dose following a high-fat meal
3160095|NCT01479647|Experimental|PH-797804 10 mg Fasted|Subjects will receive a single 10 mg dose in the fasted state
3160096|NCT01479647|Experimental|PH-797804 10 mg Fed|Subjects will receive a single 10 mg dose following a high-fat meal
3160097|NCT01479647|Experimental|PH-797804 24 mg Fed|Subjects will receive a single 24 mg dose following a high-fat meal
3160098|NCT01479634|Active Comparator|Arm A|Treatment for HIV in participants with CD4+ cell counts 250-350 cells/uL
3160099|NCT01479634|Active Comparator|Arm B|Treatment for HIV in participants with CD4+ cell counts >350 cells/uL
3160100|NCT01479621|Experimental|Fp MDPI 12.5 mcg|"Fluticasone propionate (Fp) 12.5 mcg per dose twice a day (for a total daily dose of 25 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3160101|NCT01479621|Experimental|Fp MDPI 25 mcg|"Fluticasone propionate (Fp) 25 mcg per dose twice a day (for a total daily dose of 50 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3160102|NCT01479621|Experimental|Fp MDPI 50 mcg|"Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3160103|NCT01479621|Experimental|Fp MDPI 100 mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3160104|NCT01479621|Experimental|Placebo MDPI|Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.
3160105|NCT01479621|Experimental|Flovent Diskus 100mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3160106|NCT01479608|Experimental|A: Transplantation or resection (randomized)|Liver transplantation or liver resection by 1:1 randomization (open label)
3160107|NCT01479608|Experimental|B: Liver transplantation|For non-resectable patients metachronous disease.
3160108|NCT01479608|Experimental|C:Liver transplantation|For non-resectable patients synchronous disease.
3160109|NCT01479595|Experimental|QBX258|Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total.
3160110|NCT01479595|Placebo Comparator|Placebo|Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total.
3160111|NCT01479556|Placebo Comparator|Placebo|Study subjects wil be randomized to the Placebo arm following a stratification procedure based on AIS scale (A-E), neurological level of injury (cervical or thoracic), and presence of at-level neuropathic pain before or after 3 months from the time of spinal cord injury.
3160112|NCT01479556|Active Comparator|Pregabalin|Study subjects wil be randomized to the Pregabalin arm following a stratification procedure based on AIS scale (A-E), neurological level of injury (cervical or thoracic), and presence of at-level neuropathic pain before or after 3 months from the time of spinal cord injury.
3160113|NCT01479543|Experimental|Group A|Volunteers received Probiotic CNCM I-4034.
3160114|NCT01479543|Experimental|Group B|Volunteers receive Probiotic CNCM I-4035.
3160115|NCT01479543|Experimental|Group C|Volunteers are given Probiotic CNCM I-4036.
3160116|NCT01479543|Experimental|Group D|Volunteers receive Probiotics CNCM I-4035 and CNCM I-4036.
3160117|NCT01479543|Placebo Comparator|Group E|Volunteers receive a Placebo.
3160118|NCT01479530|Placebo Comparator|Placebo|
3160119|NCT01479530|Experimental|Azilect®|
3160120|NCT01479517|Experimental|Kovacaine Mist 0.1 mL x 4 sprays|Total dose: 12 mg tetracaine/0.2 mg oxymetazoline
3160121|NCT01479517|Experimental|Kovacaine Mist 0.2 mL x 2 sprays|Total dose: 12 mg tetracaine/0.2 mg oxymetazoline
3160122|NCT01479517|Experimental|Kovacaine Mist, 0.2 mL x 1 spray|Total dose: 6 mg tetracaine/0.1 mg oxymetazoline
3160123|NCT01479504|Experimental|1A(nedaplatin and IMRT)|neoadjuvant chemotherapy using nedaplatin plus docetaxel followed by concurrent chemotherapy using nedaplatin and Intensity-modulated Radiation Therapy(IMRT)
3160124|NCT01479504|Active Comparator|1B(cisplatin and IMRT)|neoadjuvant chemotherapy using cisplatin plus docetaxel followed by concurrent chemotherapy using cisplatin and Intensity-modulated Radiation Therapy(IMRT)
3160211|NCT01478893|Experimental|SEL-068|
3160212|NCT01478893|Placebo Comparator|Saline|
3160125|NCT01479504|Experimental|2A(nedaplatin and CRT)|neoadjuvant chemotherapy using nedaplatin plus docetaxel followed by concurrent chemotherapy using nedaplatin and conventional fractionation radiotherapy(CRT)
3160126|NCT01479504|Active Comparator|2B((cisplatin and CRT))|neoadjuvant chemotherapy using cisplatin plus docetaxel followed by concurrent chemotherapy using cisplatin and conventional fractionation radiotherapy(CRT)
3160127|NCT01479491||Case Group|Children aged < 12 months presenting with IS and covered by the Japan Medical Data Centre Company Limited (JMDC), Tokyo referred to as the JMDC Medical Data Bank (JMDC-MDB).
3160128|NCT01479478|Active Comparator|Probiotic dietary supplement|Probiotic dietary supplement one capsule once per day until delivery.
3160129|NCT01479478|Placebo Comparator|Placebo|Placebo capsule, one daily until delivery.
3160130|NCT01479465|Experimental|Simtuzumab 700 mg and FOLFIRI (open-label)|Open-label, non-randomized: Participants will receive simtuzumab 700 mg followed by FOLFIRI for one cycle and continue with 28-day treatment cycles during their entire participation.
3160131|NCT01479465|Experimental|Simtuzumab 200 mg and FOLFIRI (randomized)|Randomized, double blind, placebo-controlled portion; Participants will receive 28-day treatment cycles of simtuzumab 200 mg followed by FOLFIRI for approximately 20 months.
3160132|NCT01479465|Experimental|Simtuzumab 700 mg and FOLFIRI (randomized)|Randomized, double blind, placebo-controlled portion; Participants will receive 28-day treatment cycles of simtuzumab 700 mg followed by FOLFIRI for approximately 20 months.
3160133|NCT01479465|Experimental|Placebo and FOLFIRI (randomized)|Randomized, double blind, placebo-controlled portion; Participants will receive 28-day treatment cycles of placebo to match simtuzumab followed by FOLFIRI for approximately 20 months.
3160134|NCT01479452|Other|Bariatric surgery|Bariatric surgery
3160135|NCT01479452|Other|Controls|Usual care
3160136|NCT01479439|Experimental|Sickle cell disease|The purpose of this research study is to see if losartan can help reduce or reverse damage done to the kidneys of children and adults with Sickle Cell Anemia (SCA) and Sickle Beta-zero (HbSβ0) Thalassemia.
3160137|NCT01479426|Experimental|EFLA400(960mg)|
3160138|NCT01479426|Placebo Comparator|Placebo(960mg)|
3160139|NCT01479413||Schizophrenia|
3160140|NCT01479400||infants who were exposed to antipsychotics as fetus|
3160141|NCT01479400||infants who were not exposed to antipsychotics as fetus|
3160142|NCT01479387||Group 1|
3160143|NCT01479374|Experimental|AL-4943A|AL-4943A ophthalmic solution, 1 drop to each eye, 3 nonconsecutive days
3160144|NCT01479374|Placebo Comparator|Vehicle|AL-4943A vehicle, 1 drop to each eye, 3 nonconsecutive days
3160145|NCT01479374|Active Comparator|Pataday|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop to each eye, 3 nonconsecutive days
3160146|NCT01479348|Experimental|1/IV THU|[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
3160147|NCT01479348|Experimental|2/Oral THU|[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
3160148|NCT01479309|Experimental|SSG + Intron A|Sodium Stibogluconate (SSG) 400 mg/m^2 intravenous (IV) daily on days 1-5 + Interferon Alfa-2b (Intron A) 3x10^6 units subcutaneously three times weekly
3160149|NCT01479296|Experimental|Group 1: rAd5 Plus Placebo|Participants will receive the VRC rAd5 gag-pol/env A/B/C vaccine injection in their right arm (1×10^10 PU), and placebo vaccine injections in their left arm, right thigh, and left thigh.
3160150|NCT01479296|Experimental|Group 2: Separated Vaccine Components|Participants will receive the rAd5 gag-pol vaccine injection in their right arm (0.5×10^10 PU), the rAd5 env A vaccine injection in their left arm (0.17×10^10 PU), the rAd5 env B vaccine injection in their right thigh (0.17×10^10 PU), and the rAd5 env C vaccine injection in their left thigh (0.17×10^10 PU).
3160151|NCT01479296|Experimental|Group 3: Divided Dose rAd5|Participants will receive the VRC rAd5 gag-pol/env A/B/C vaccine injection divided into fourths, with one fourth of the total dose given in each of 4 sites: right arm, left arm, right thigh, and left thigh (each at 0.25×10^10 PU).
3160152|NCT01479283|Active Comparator|Short-Arm Antibiotic Regimen|"Intervention: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen~*or another cephalosporin with equivalent gram-positive coverage in centers where cefazolin is not routinely used or not approved for use"
3160153|NCT01479283|Experimental|Long-Arm Antibiotic Regimen|"Intervention: 5-Days Prophylactic Cefazolin* Antibiotic Regimen~*or another cephalosporin with equivalent gram-positive coverage in centers where cefazolin is not routinely used or not approved for use"
3160154|NCT01479270|Active Comparator|TAP Block|20mL of 0.25% Ropivacaine with Epinephrine 1:200,000 is injected into bilateral transversus abdominal planes under ultrasound guidance.
3160155|NCT01479270|No Intervention|No Block|Patients randomized to this arm have band aids applied to sites on lateral abdomen without injection.
3160156|NCT01479257||Bilingual Latinos|Bilingual Houston area Latinos surveyed for 7 continuous days with objective and subjective assessments using accelerometer and smart phone.
3160157|NCT01479244|Experimental|NeuVax™|NeuVax™ in WFI solution with Leukine®
3160158|NCT01479244|Active Comparator|Leukine®|Leukine® with WFI
3160159|NCT01479231|Experimental|dexlansoprazole|
3160160|NCT01479218|Other|PDA Occluder|single arm
3160161|NCT01479205||mite allergic patients without SIT|patients suffering from allergic asthma/ rhino-conjunctivitis denying specific immunotherapy
3160162|NCT01479205||mite allergic patients with SIT|patients suffering from allergic asthma/ rhino-conjunctivitis undergoing mite specific immunotherapy
3160163|NCT01479192|Experimental|Fenretinide|100mg: 2cps/day for 5 years followed by
3160164|NCT01479192|Placebo Comparator|Placebo|matched placebo 2 cps/day for 5 years
3160165|NCT01479179|Experimental|AMG 479 + Trastuzumab|AMG 479 18 mg/kg or 12 mg/kg intravenously (IV) 30 minutes after trastuzumab. Trastuzumab loading dose (Week 1) 8 mg/kg IV over 90 minutes; maintenance dose 6 mg/kg IV over 30 minutes every 3 weeks.
3160166|NCT01479166||affected patients with small airway disease (SAD)|20 patients suffering from mild cystic fibrosis and involvement of small airways
3160167|NCT01479166||affected patients without small airway disease (SAD)|20 patients suffering from mild cystic fibrosis without SAD
3160168|NCT01479166||non-affected patients|20 matched controls not suffering from cystic fibrosis
3160169|NCT01479153|Active Comparator|Subclavian catheterization|
3160170|NCT01479153|Active Comparator|Internal Jugular catheterization|
3160213|NCT01478880|Experimental|cTBS|
3160172|NCT01479127|Experimental|Levodopa-carbidopa intestinal gel|"Following a 28-day Run-in Period where participants are switched from prior anti-PD medications to monotherapy with an oral 100 mg levodopa/10 mg carbidopa tablet (optimized every 3rd hour during waking hours), participants receive ABT-SLV187 (levodopa-carbidopa intestinal gel), administered over 16 hours a day with an infusion pump directly into the proximal jejunum by an NJ tube, for 3 weeks.~The individually-adjusted infusion dose (composed of the morning dose, the continuous maintenance dose, and the extra dose) is optimized by the Investigator for each participant during the study based on the participant's symptoms."
3160173|NCT01479114|No Intervention|control group|
3160174|NCT01479114|Experimental|G-CSF group|
3160175|NCT01479114|No Intervention|Non-GCSF group|
3160176|NCT01479101||MammaPrint, BluePrint, neo-adj CT or HT|All patients receive the MammaPrint and BluePrint gene expression profile. Treatment at the discretion of the physician while adhering to NCCN guidelines.
3160177|NCT01479088|Experimental|cinacalcet tab or extemporaneous solution po added to SoC|"Subjects who meet all inclusion/exclusion criteria at baseline will be given cinacalcet 30mg film-coated tablet, for oral use added to phosphate binders and vitamin D analogue.~For subjects receiving a cinacalcet dose <30mg, commercially available cinacalcet 30mg tab will be ground and diluted with a 5% dextrose solution. Then, an aliquot of this solution corresponding to the individually prescribed dose will be administered as indicated.~Initial dosing of cinacalcet will be 0.5-0.75mg/kg or 30 mg po once daily (OD) each evening with food.~During the cinacalcet dose-titration 6-month period for efficacy assessment, the dose will be increased on monthly basis by 0.5 mg/kg or by 30mg OD to achieve the target iPTH value <180 pg/mL, as tolerated by the subject, up to maximum of 180mg OD in absence of signs of hypocalcemia, according to the current summary of product characteristics."
3160178|NCT01479075|Experimental|intranasal insulin in patients|intranasal insulin is applied to diabetic patients under fasting conditions
3160179|NCT01479075|Experimental|intransal insulin in study participants|intranasal insulin is applied to healthy patients under fasting conditions
3160180|NCT01479075|Placebo Comparator|placebo in patients|placebo spray is applied intranasally in type 2 diabetes patients under fasting conditions
3160181|NCT01479075|Experimental|placebo in study participants|placebo spray is applied intranasally in healthy participants under fasting conditions
3160182|NCT01479075|Experimental|taNVS|Transcutanoues auricular vagus nerve stimulation is applied for 14 min in the external ear in healthy participants
3160183|NCT01479075|Placebo Comparator|Sham stimulation|Sham stimulation in the ear lobe is applied for 14 min in healthy participants
3160184|NCT01479062|Experimental|participation in Alive-PD|Alive-PD lifestyle intervention with multi-channel delivery
3160185|NCT01479062|Placebo Comparator|Control|Usual care
3160186|NCT01479049|Experimental|MP group|Hearts are arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L) during cardiac surgery.
3160187|NCT01479049|Active Comparator|HP group|Hearts were arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L) during cardiac operation
3160188|NCT01479036|Active Comparator|docetaxel and epirubicin|DE chemotherapy alone
3160189|NCT01479036|Experimental|docetaxel and epirubicin plus endostatin|chemotherapy plus endostatin
3160190|NCT01479023|Experimental|Cohort 1|"64Cu-DOTA-U3-1287 at a radiotracer dosage of 8-15 mCI and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~Patient will have option to continue to Part 2 (extension phase)."
3160191|NCT01479023|Experimental|Cohort 2|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~9.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
3160192|NCT01479023|Experimental|Cohort 3|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~12.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
3160193|NCT01479023|Experimental|Cohort 3a|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~15.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
3160194|NCT01479023|Experimental|Cohort 4|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~18.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
3160195|NCT01479023|Experimental|Cohort 5|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~TBD (to be determined) mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
3160196|NCT01479023|Experimental|Part 2 (extension phase)|Loading dose of 18.0 mg/kg unlabeled U3-1287 followed by 9.0 mg/kg unlabeled U3-1287 every 3 weeks.
3160197|NCT01479010|Experimental|Anakinra|
3160198|NCT01478997|Experimental|Flexsure Capsules|Investigational Product
3160199|NCT01478997|Placebo Comparator|Carboxy Methyl Cellulose Capsules|Placebo
3160200|NCT01478984|Active Comparator|one staged PCI|the patient randomized to this arms complete the myocardial revascularization in one stage PCI, the investigators treat all lesions.
3160201|NCT01478984|Active Comparator|multistaged PCI|the patients randomized to this arms in the first stage the investigators treat only the culprit lesion and in second stage the investigators treat the other vessels
3160202|NCT01478971|Experimental|peginesatide injection|In the first 6 months participants received standard of care treatment with epoetin (the Standard of Care Period [SCP]), followed by a 1-week erythropoiesis-stimulating agent (ESA)-Free Period, followed by peginesatide injection for 6 months (the Peginesatide Treatment Period [PTP]).
3160203|NCT01478958|Active Comparator|high saturated fat diet|
3160204|NCT01478958|Experimental|high monounsaturated fat diet|
3160205|NCT01478958|Experimental|high n-6 polyunsaturated fat diet|
3160206|NCT01478945|Active Comparator|Dermfix 1000 active 311 nm NB-UVB|"Active hand held NB-UVB unit:~Manual device administering NB-UVB"
3160207|NCT01478945|Active Comparator|Waldmann active 311 nm NB-UVB|"Active hand held NB-UVB unit:~Manual device administering NB-UVB (Waldmann)"
3160208|NCT01478945|Sham Comparator|Dermfix 1000 placebo|Manual placebo hand held NB-UVB unit
3160216|NCT01478854|Experimental|Neural Progeniter Cell Sparing Radiation with Temozolomide|All subjects are treated with neural progenitor cell sparing radiation to 60 Gy in 2 Gy per day, 30 fractions Concurrent and adjuvant temozolomide chemotherapy
3160217|NCT01478841|Experimental|Polyphenols|9 weeks of supplementation with polyphenols(D56) and during the last week supplementation with polyphenols associated with a fructose load during the last 6 days (D63).
3160218|NCT01478841|Placebo Comparator|placebo|9 weeks of supplementation with placebo (D56) and during the last week supplementation with placebo associated with a fructose load during the last 6 days (D63).
3160219|NCT01478828|Experimental|Lovastatin|After informed consent and central pathology review of the core prostate biopsy, eligible patients who decide to undergo prostatectomy at Johns Hopkins will be scheduled to receive po lovastatin following a four times a day schedule, at the starting dose of 20 mg/kg/day. Following an initial period of monitoring for safety at this entry dose level of one month, we will then accrue patients to dose de-escalation (to 1, and 10 mg/kg/day) cohorts.
3160220|NCT01478815|Placebo Comparator|Standard Care|
3160221|NCT01478815|Experimental|Contingency management for abstinence from drugs|
3160222|NCT01478802|Active Comparator|CMV Arm|Patients with moderate-to-severe Acute Respiratory Distress Syndrome treated solely with lung protective, low volume high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description section.
3160223|NCT01478802|Experimental|HFO-RMs Arm|Patients with moderte-to-severe Acute Respiratory Distress Syndrome treated initially with a 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO)-Recruitment Maneuvers (RMs), and then with lung protective CMV interspersed to additional HFO-RMs sessions (if required according to study protocol). The protocolized use of HFO-RMs may extend until day 10 post-randomization, according to pre-specified oxygenation criteria. Full details are provided in the Detailed Description Section.
3160224|NCT01478789|Experimental|Water dispersible Plant Sterol (WD-PS)|WD-PS dairy product (a novel formulation for dispersible free sterols in aqueous media produced)2g/d of free plant sterol
3160225|NCT01478789|Experimental|Esterified plant sterol (PS-Ester)|PS-Ester enriched dairy product (2g/d free plant sterol)
3160226|NCT01478789|Placebo Comparator|placebo|100 g/d yogurt with no added plant sterol
3160227|NCT01478776|Active Comparator|diabetes, omega-3|patient with type 2 diabetes who receive 4gr/day omega-3
3160228|NCT01478776|Placebo Comparator|placebo, diabetes|patient with type 2 diabetes who receive 4 cap of placebo/day
3160229|NCT01478750|Experimental|emulsified fat, orally|At 09:00, subjects will ingest the test load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80
3160230|NCT01478750|Experimental|intragastric administration of fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intragastrically
3160231|NCT01478750|Experimental|intraduodenal administration of fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intraduodenally
3160232|NCT01478750|Experimental|intragastric, non-emulsified fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, non emulsified, intragastrically
3160233|NCT01478737|Sham Comparator|Sham|Vitrectomy only
3160234|NCT01478737|Active Comparator|Intravitreal Ozurdex|Intravitreal Ozurdex after vitrectomy
3160235|NCT01478724|Placebo Comparator|Placebo|Animal proteins
3160236|NCT01478724|Experimental|Milk protein fraction dose 1|
3160237|NCT01478724|Experimental|Milk protein fraction dose 2|
3160238|NCT01478711|Active Comparator|Intervention|A clinical decision support tool for the care and management of premature infants will be embedded into the electronic health record.
3160239|NCT01478711|No Intervention|No Intervention|No intervention, No clinical decision support tool will be used for non-intervention sites.
3160240|NCT01478698|Experimental|Single dose|The first 5 consented participants will be administered t-PA 10mg + DNase 5mg instilled into a dialysate bag and infused for a 4 hour intraperitoneal dwell.
3160241|NCT01478698|Experimental|2 doses|The next 5 consented participants will be administered t-PA 10mg + DNase 5mg instilled twice a day for one day
3160242|NCT01478698|Experimental|4 doses|The next 5 consented participants will be administered tPA 10mg + DNase 5mg twice a day for 2 days.
3160243|NCT01478698|No Intervention|control|Any potential participants that have not consented into the intervention arms will be approached to be consented into a non-intervention observational control group. A maximum of 5 participants will be recruited into this control group.
3160244|NCT01478685|Experimental|Arm A: CC-486 plus Carboplatin|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability. Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
3160245|NCT01478685|Experimental|Arm B: CC-486 plus ABI-007|"CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability~ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m^2"
3160246|NCT01478685|Experimental|Arm C: CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
3160247|NCT01478672|No Intervention|Standard care|
3160248|NCT01478672|Experimental|Health coaching and and Life-long Monitoring|
3160249|NCT01478659|Active Comparator|Control bar and yogurt|
3160250|NCT01478659|Experimental|Fiber bar and yogurt|
3160251|NCT01478646|Experimental|Conventional breathing therapy|first: conventional breathing therapy, second: reflectory breathing therapy
3160252|NCT01478646|Experimental|Reflectory breathing therapy|first: reflectory breathing therapy second: conventional breathing therapy
3160253|NCT01478633|Experimental|Galantamine|
3160254|NCT01478620|Experimental|Canephron® N|
3160255|NCT01478607|Experimental|1. Qutenza 30 minutes + SOC|
3160256|NCT01478607|Experimental|2. Qutenza 60 minutes + SOC|
3160257|NCT01478607|No Intervention|3. SOC|Subjects randomized to this group will receive treatment optimized for them on an individual basis. The investigator will be free to provide whatever pharmacological or other treatment is considered optimal for management of the subject's pain.
3160258|NCT01478594|Experimental|Tivozanib + mFOLFOX6|Participants received 1.5 mg of tivozanib orally once daily beginning on Day 1 of each cycle for 21 days followed by 7 days off treatment. Participants also received modified FOLFOX6 (mFOLFOX6) chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
3160259|NCT01478594|Active Comparator|Bevacizumab + mFOLFOX6|Participants received a dose of 5 mg/kg bevacizumab via intravenous infusion every 2 weeks on Days 1 and 15 of each cycle. Participants also received mFOLFOX6 chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
3160260|NCT01478581|Experimental|Cohort 1|PCI-32765 420 mg per day
3160261|NCT01478581|Experimental|Cohort 2|PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week
3160262|NCT01478581|Experimental|Cohort 3|PCI-32765 840 mg per day
3160263|NCT01478581|Experimental|Cohort 4|PCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week
3160264|NCT01478568|Experimental|mirabegron / desipramine|
3160265|NCT01478555|Experimental|Dose 1 of Bromfenac in DuraSite|
3160266|NCT01478555|Experimental|Dose 2 of Bromfenac in DuraSite|
3160267|NCT01478555|Experimental|Dose 3 of Bromfenac in DuraSite|
3160268|NCT01478555|Active Comparator|DuraSite|
3160269|NCT01478555|Active Comparator|Vehicle|
3160270|NCT01478542|Active Comparator|Favourable Prognosis F-A|Induction therapy with 4 cycles of R-CHOP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm [max. 2mg absolute], Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2 additional cycles of R-CHOP-14 + 2xR plus additional involved-site radiotherapy, if FDG-PET negative only 4xR without radiotherapy.
3160271|NCT01478542|Experimental|Favourable F-B|Induction therapy with 4 cycles of R-CHLIP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, liposomal Vincristine 1,4 mg/sqm (max. 2mg absolute), Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2 additional cycles of R-CHLIP-14 + 2xR plus additional involved-site radiotherapy, if FDG-PET negative only 4xR without radiotherapy.
3160272|NCT01478542|Active Comparator|Less Favourable LF-A|Induction therapy with 6 cycles of R-CHOP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm [max. 2mg absolute], Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2xR plus additional radiotherapy to the initial bulky region, if FDG-PET negative only 2xR without radiotherapy. After 3xR-CHOP-14 an interim restaging will be performed.
3160273|NCT01478542|Experimental|Less Favourable LF-B|Induction therapy with 6 cycles of R-CHLIP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, liposomal Vincristine 1,67 mg/sqm [uncapped], , Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2xR plus additional radiotherapy to the initial bulky region, if FDG-PET negative only 2xR without radiotherapy. After 3xR-CHLIP-14 an interim restaging will be performed.
3160274|NCT01478542|Experimental|Less Favourable LF-C|Induction therapy with 6 cycles of CHOP-14 (Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm [max. 2mg absolute], Predniso[lo]ne 100mg/d d1-5) combined with an optimized Rituximab-schedule (375 mg/sqm, d-4, d-1, d1, d4, d14, d28, d42, d56, d91, d126, d175, d238) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive additional radiotherapy to the initial bulky region, if FDG-PET negative omission of radiotherapy. After 3x CHOP-14 an interim restaging will be performed.
3160275|NCT01478542|Experimental|Less Favourable LF-D|Induction therapy with 6 cycles of CHLIP-14 (Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, 1,67 mg/sqm [uncapped], , Predniso[lo]ne 100mg/d d1-5) combined with an optimised Rituximab-schedule (375 mg/sqm, d-4, d-1, d1, d4, d14, d28, d42, d56, d91, d126, d175, d238) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive additional radiotherapy to the initial bulky region, if FDG-PET negative omission of radiotherapy. After 3x CHLIP-14 an interim restaging will be performed.
3160276|NCT01478529|Experimental|Treatment Arm A|low dose of mirabegron
3160277|NCT01478529|Experimental|Treatment Arm B|high dose of mirabegron
3160278|NCT01478516|Experimental|Plasmin|eyes with macular edema
3160279|NCT01478503|Experimental|Treatment Arm A|mirabegron
3160280|NCT01478503|Placebo Comparator|Treatment Arm B|matching placebo
3160281|NCT01478490|Experimental|Treatment Arm 1A|mirabegron, poor metabolizers
3160282|NCT01478490|Experimental|Treatment Arm 1B|mirabegron, extensive metabolizers
3160283|NCT01478490|Experimental|Treatment Arm 2|mirabegron/metoprolol
3160284|NCT01478477|Experimental|Arm I (omega-3 fatty acid supplement)|Omega 3 Polyunsaturated Fatty Acids(n-3 PUFA)
3160285|NCT01478477|Placebo Comparator|Arm II (placebo)|Typical American Diet oils (TAD)
3160286|NCT01478477|Experimental|Clinical Assessments|Brief Pain Inventory (BPI), Stanford's Health Assessment-Disability Index (HAS), FACT-B and endocrine subscale (FACT-ES)
3160287|NCT01478477|Experimental|Assessment of therapy complications|Adverse events will be monitored by self-reporting of signs and symptoms. Patients will maintain a daily diary of time of supplement intake and any possible ill effects, with instructions to contact the PI or Research Nurse to discuss and manage any possible side effects.
3160288|NCT01478477|Experimental|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained
3160289|NCT01478477|Experimental|Correlative/special studies|Enrolled participants will have peripheral blood samples drawn for plasma and RBC n-3 PUFA levels within 4 weeks of starting AI therapy.
3160290|NCT01478464|No Intervention|Control group|Control group, does not receive any intervention
3160291|NCT01478464|Experimental|Massage group|Massage will be performed on the left or right hamstring muscle (randomized) for ten minutes with a massage roller. The contralateral leg will not be massaged, but serve as a non-massaged control leg to assess possible cross-over effects from the massaged leg
3160292|NCT01478451|Experimental|Massage|massage will be provided for 10 minutes at the left or right trapezius (randomized)
3160293|NCT01478451|Experimental|Exercise|exercise (shoulder shrugs with elastic resistance) will be performed for 10 minutes at the left or right trapezius (randomized)
3160294|NCT01478451|No Intervention|Control|control shoulder (randomized)
3160295|NCT01478438|Experimental|Treat and Excise|All subjects will be treated with Interstitial Laser Therapy (ILT) followed by excision no later than 28 days post ablation.
3160297|NCT01478425|Placebo Comparator|Control|Saline nose-spray device
3160298|NCT01478412||Males with prostate adenocarcinoma|English speaking males with histologically confirmed prostate adenocarcinoma and diagnosis of low risk or intermediate risk prostate cancer.
3160299|NCT01478399|Experimental|Impaired Renal Function|Subjects have impaired renal function matched to subjects with normal renal function by age and weight.
3160300|NCT01478399|Experimental|Normal Renal Function|Subjects have normal renal function matched to subjects with impaired renal function by age and weight.
3160301|NCT01478386|Other|Viscosupplementation injections|Control group will receive a series of three viscosupplementation injections into the affected knee
3160302|NCT01478386|Experimental|Off-loading knee brace|
3160303|NCT01478386|Experimental|Viscosupplementation and knee brace|
3160304|NCT01478373|Experimental|Dovitinib (TKI258)|Patients will receive Dovitinib (TKI258) on an outpatient basis at the dose of 500 mg qd for 5 days followed by 2 days off, every week for cycle of 4 weeks (28d) until disease progression, unacceptable toxicity, or consent withdrawal.
3160305|NCT01478360|Experimental|AIN457|AIN457 10 mg/kg
3160306|NCT01478360|Placebo Comparator|Placebo|Placebo intravenous injection
3160307|NCT01478347|Experimental|rMenB+OMV NZ|Healthy adults (≥18 to ≤65 years), at high risk for meningococcal B disease due to routine occupational exposure to N. Meningitidis cultures (e.g. lab workers), were administered two injections of Recombinant meningococcal B (rMenB) + Outer Membrane Vesicle (OMV NZ) vaccine, 2 months apart, in part I of the study, were enrolled for optional blood draws and safety follow-up in part II of the study.
3160308|NCT01478334|Experimental|Exercise then control|
3160309|NCT01478334|Experimental|Control then exercise|
3160310|NCT01478321|Experimental|Treatment (radiation, chemotherapy, monoclonal antibody)|"CONCURRENT THERAPY: Patients undergo hypofractionated radiation therapy 5 days a week beginning on day 0. Patients also receive temozolomide PO QD and bevacizumab IV over 30-90 minutes once every 2 weeks beginning on days -3 to 0. Treatment continues for 5 weeks in the absence of disease progression or unacceptable toxicity.~ADJUVANT THERAPY: Beginning 2 weeks after completion of radiation therapy, patients receive temozolomide PO QD for 6 weeks and bevacizumab IV over 30-90 minutes once every 2 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity."
3160311|NCT01478295|Experimental|CuidaCare Intervention|Regular care in consultation or home and Structured nursing care (CuidaCare intervention): improved strategies for coping, health education on self-care and dependent care and emotional support. 10 visits are structured, with a periodicity of approximately 2 visits per month and last for 30 to 40 minutes each
3160312|NCT01478295|Active Comparator|Control Group/Usual Care|Usual care in consultation or home, which is to respond to the specific demands of care of the caregiver, using the resources of the nursing discipline.
3160313|NCT01478282|Active Comparator|Rivaroxaban|Healthy donors subjected to 20mg/day for 5 days
3160314|NCT01478282|Active Comparator|Dabigatran|Healthy volunteers subjected to 150 mg/12hours for 5 days
3160315|NCT01478269||Cases of aggressive B-cell lymphoma|Cases of aggressive B-cell lymphoma diagnosed between 2001 to 2007 in Italy
3160316|NCT01478256|Active Comparator|Besifloxocin|Use of topical besifloxocin to treat acute blepharitis
3160317|NCT01478256|Active Comparator|Erythromycin|Topical Erythromycin ointment for treatment of acute blepharitis
3160318|NCT01478230|Experimental|N1/3-I5|5 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits
3160319|NCT01478230|Active Comparator|NX-I10|10 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits.
3160320|NCT01478178|Experimental|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
3160321|NCT01478165|Placebo Comparator|Tiva group (Group T)|
3160322|NCT01478165|Active Comparator|TIVA plus palonosetron group (Group T+P)|
3160323|NCT01478152|Experimental|Ectoin Inhalation Solution|"After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose."
3160324|NCT01478139|Experimental|LIFT|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
3160325|NCT01478139|Experimental|LIFT-plug|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
3160326|NCT01478126|Experimental|Glutamine|Intravenous glutamine infusion perioperatively and 24 hours after surgery
3160327|NCT01478126|Placebo Comparator|Placebo|
3160328|NCT01478113|Active Comparator|WBT + amphetamine/dextroamphetamine|In the active group, participants will receive treatment with Well-being therapy and amphetamine-dextroamphetamine.
3160329|NCT01478113|Placebo Comparator|WBT + placebo|In the placebo group, participants will receive treatment with Well-being therapy and pill placebo.
3160330|NCT01478087|Other|Mysorba(single-arm)|
3160331|NCT01478074|Experimental|FLAG + NK Cells + ALT-801|
3160332|NCT01478061|Active Comparator|anastomoses in blood vessels and grafts|
3160333|NCT01478048|Experimental|Arm A: Elotuzumab + Bortezomib + Dexamethasone|On days of Elotuzumab infusion: Dexamethasone (8mg IV + 8mg Oral) will be administered other days Dexamethasone 20 mg Oral will be administered
3160334|NCT01478048|Active Comparator|Arm B: Bortezomib + Dexamethasone|
3160335|NCT01478035|Experimental|phenytoin prophylaxis|Patients with suspected or proven pneumococcal meningitis are allocated to receive phenytoin prophylaxis or placebo to avoid seizures during the 10 days of antibiotic therapy starting after the antibiotic therapy
3160336|NCT01478035|Placebo Comparator|placebo|placebo vials and pills labeled as phenytoin prophylaxis vials and pills
3160337|NCT01478022|Active Comparator|Isosorbide Dinitrate 20 mg|Isosorbide Dinitrate 10 mg b.i.d
3160338|NCT01478022|Active Comparator|Ibuprofen 200 mg|Ibuprofen 200 mg daily, capsule
3160339|NCT01478022|Experimental|Isosorbide dinitrate and Ibuprofen|Isosorbide dinitrate 20 mg daily and Ibuprofen 200 mg daily
3160340|NCT01478009|Experimental|KRG Extract|
3160341|NCT01478009|Placebo Comparator|Placebo|
3160342|NCT01477996|Active Comparator|Group 1|27-gauge needle
3160343|NCT01477996|Active Comparator|Group 2|30-gauge needle
3160344|NCT01477983|Active Comparator|ATP guide additional ablation - AAD|UNDER-ATP trial: ATP guide additional ablation, EAST-AF trial: AAD for 90 days
3160345|NCT01477983|Active Comparator|Control - AAD|UNDER-ATP trial: Control, EAST-AF trial: AAD for 90 days
3160346|NCT01477983|Active Comparator|ATP guide additinal ablation - Control|UNDER-ATP trial: ATP guide additional ablation, EAST-AF trial: Control
3160347|NCT01477983|Active Comparator|Control - Control|UNDER-ATP trial: Control, EAST-AF trial: Control
3160348|NCT01477957|Experimental|Surgery|bariatric surgery
3160349|NCT01477931|Experimental|Wellbutrin XL|
3160350|NCT01477905|Experimental|Remi50 no prime|For using experimental target control infusion device (TCIs), targeting an effect-site concentration (Ceff) of 4.0 ng/ml, were randomly performed using 50 μg/ml (Remi50) of remifentanil, and without PRIMING,
3160351|NCT01477905|Experimental|Remi20 no prmie|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and without PRIMING
3160352|NCT01477892|Experimental|low dose remifentanil|continuous infusion of remifentanil 0.1mcg/kg/min
3160353|NCT01477892|Active Comparator|high dose remifentanil|continuous infusion of remifentanil 0.25mcg/kg/min
3160354|NCT01477879|Active Comparator|Versabase/20% S. purpurea extract|
3160355|NCT01477879|Placebo Comparator|placebo (versabase gel only)|placebo used will be versabase gel alone
3160356|NCT01477866|Experimental|citogenex|citogenex + conventional therapy
3160357|NCT01477866|Active Comparator|conventional therapy|conventional therapy
3160358|NCT01477853|Experimental|Sitagliptin/Sitagliptin + Atorvastatin|In Phase A, participants received sitagliptin 100 mg plus matching placebo to atorvastatin daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
3160359|NCT01477853|Active Comparator|Atorvastatin/Atorvastatin + Glimepiride|In Phase A, participants received atorvastatin 80 mg plus matching placebo to sitagliptin daily for 16 weeks. Participants continuing to Phase B received atorvastatin 80 mg plus matching placebo to sitagliptin plus glimepiride daily for an additional 38 weeks.
3160360|NCT01477853|Experimental|Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin|In Phase A, participants sitagliptin 100 mg plus atorvastatin 80 mg daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
3160361|NCT01477840|Experimental|Misoprostol|
3160362|NCT01477827||Healthy volunteers|Healthy adolescents aged 12-15 years
3160363|NCT01477814|Active Comparator|physician chart reminder|either a paper or an electronic reminder placed on the subject's medical record to remind the physician to screen for colorectal cancer
3160364|NCT01477814|Active Comparator|chart reminder, educational mat'ls, FIT|physician chart reminder plus mailed educational materials, including the Centers for Disease Control CRC Screen for Life, the ACS DVD on CRC screening, a fecal immunochemical test with postage-paid return mailer, a magnet reminding individuals to get screened, and a CRC screening preference sheet where subjects could indicate their preferred CRC test
3160365|NCT01477814|Active Comparator|CR, ed mat'ls, FIT, phone call|physician chart reminder (CR) plus mailed educational materials, including the Centers for Disease Control CRC Screen for Life, the ACS DVD on CRC screening, a fecal immunochemical test with postage-paid return mailer, a magnet reminding individuals to get screened, and a CRC screening preference sheet where subjects could indicate their preferred CRC test, and a motivational telephone call designed to elicit barriers and preferences and motivate individuals to complete a CRC screening test.
3160366|NCT01477801|Experimental|CHOLECALCIFEROL|
3160367|NCT01477801|Placebo Comparator|PLACEBO|
3160368|NCT01477788||women, sonographic ovarian mass|women that will arrive to the sonographic unit of the gynecological department with the sonographic diagnosis of ovarian mass
3160369|NCT01477775|Active Comparator|Standard of Care|The treating physician will be left free to give the oral P2Y12 receptor blocker, including clopidogrel,prasugrel or ticagrelor, which according to his/her clinical judgement is most appropriate for the individual patient.
3160370|NCT01477775|Experimental|Customized choice of the oral P2Y12 receptor blocker|The choice of the oral P2Y12 receptor blocker will be based on an algorithm which integrates phenotype information, including but not limited to residual on-treatment platelet reactivity assessed via Verifynow P2Y12 assay.
3160371|NCT01477762|Active Comparator|PTSD Negative|Participants who do not have PTSD will receive placebo and dexamethasone in random order for the duration of two consecutive study visits separated by at least one month.
3160372|NCT01477762|Experimental|PTSD Positive|Participants with PTSD will receive placebo and dexamethasone in random order for the duration of two consecutive study visits separated by at least one month.
3160373|NCT01477749|Experimental|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
3160374|NCT01477736|Active Comparator|Botulinum toxin A|
3160375|NCT01477736|Active Comparator|oxybutynin|
3160376|NCT01477723|Experimental|Experimental Oral Nutrition Supplement|Experimental ONS orally Two 8 fl oz servings/day
3160377|NCT01477723|No Intervention|No Product|
3160378|NCT01477710|Active Comparator|Hold Mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
3160379|NCT01477710|Active Comparator|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
3160380|NCT01477710|Active Comparator|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
3160381|NCT01477697|Active Comparator|Omega-3|50 mg/kg per day of omega-3 fatty acids (DHA Omega-3, Martek Biosciences, Columbia, MD)
3160382|NCT01477697|Placebo Comparator|Placebo|50 mg/kg per day of vehicle
3160383|NCT01477671||Study Group|Participants aged between 5 and 10 year-old on day of inclusion.
3160384|NCT01477658||Congenital AV Block|Patients diagnosed with Congenital Complete Atrioventricular Heart Block
3160385|NCT01477658||Postoperative AV Block|Patients diagnosed with postoperative AV block
3160386|NCT01477645||Leaded ammunition|
3160387|NCT01477645||Non-leaded ammunition|
3160388|NCT01477645||Modified non-leaded ammunition|
3160389|NCT01477632|Experimental|A|
3160390|NCT01477632|Experimental|B|
3160391|NCT01477632|Active Comparator|C|
3160392|NCT01477619|Experimental|Smokers|Split into BMI categories
3160393|NCT01477619|Experimental|Non-Smokers|Gender, age, and BMI matched to Smokers
3160394|NCT01477619|Experimental|Elderly|
3160395|NCT01477606|Experimental|Midostaurin|
3160396|NCT01477593|Experimental|Group I|
3160397|NCT01477593|Active Comparator|Group II|
3160398|NCT01477593|Active Comparator|Group III|
3160399|NCT01477580|Experimental|Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|
3160400|NCT01477580|Experimental|Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
3160401|NCT01477580|Experimental|Medium-dose Non-adjuvanted V180|
3160402|NCT01477580|Experimental|Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|
3160403|NCT01477580|Experimental|Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
3160404|NCT01477580|Experimental|Medium-Dose V180 with Alhydrogel™ adjuvant|
3160405|NCT01477580|Experimental|High-dose Non-adjuvanted V180|
3160406|NCT01477580|Experimental|High-dose V180 with low-dose ISCOMATRIX™ adjuvant|
3160407|NCT01477580|Experimental|High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
3160408|NCT01477580|Experimental|Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|
3160409|NCT01477580|Experimental|Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|
3160410|NCT01477580|Experimental|High-dose V180 with high-dose ISCOMATRIX™ adjuvant|
3160411|NCT01477580|Placebo Comparator|Placebo|
3160412|NCT01477567|Experimental|0.3 mg LY3009385|LY3009385: 0.3 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
3160413|NCT01477567|Experimental|1 mg LY3009385|LY3009385: 1 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
3160414|NCT01477567|Experimental|3 mg LY3009385|LY3009385: 3 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
3160415|NCT01477567|Experimental|9 mg LY3009385|LY3009385: 9 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
3160416|NCT01477567|Experimental|22 mg LY3009385|LY3009385: 22 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
3160417|NCT01477567|Experimental|54 mg LY3009385|LY3009385: 54 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
3160418|NCT01477567|Placebo Comparator|Placebo|Placebo: saline, subcutaneous (SC) injection, single dose on Day 1
3160419|NCT01477554|No Intervention|Control|Hospitals randomized to the control arm do not receive any intervention.
3160420|NCT01477554|Experimental|PRONTO training|PRONTO training is delivered to medical teams at hospitals randomized to this arm.
3160421|NCT01477541|Experimental|PM/ON integration arm|Health centers where professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
3160422|NCT01477541|No Intervention|Control|
3160423|NCT01477515||End stage renal disease patient|
3160424|NCT01477515||Matched controls|
3160425|NCT01477502|Active Comparator|individual homeopathic treatment|participants receive homeopathic treatment in addition to standard prevention measures for UTI
3160426|NCT01477502|Other|standard prophylaxis|
3160427|NCT01477489|Experimental|Treatment|
3160428|NCT01477476|Active Comparator|Active Treatment|14 subjects with receive active treatment with Anakinra.
3160429|NCT01477476|Placebo Comparator|Placebo|7 subjects will receive the placebo comparator.
3160430|NCT01477463|Experimental|Arm A: Vitamin D|4,000 IU oral vitamin D3
3160431|NCT01477463|Experimental|Arm B: Placebo + Vitamin D|Placebo + 4000 IU oral Vitamin D3
3160432|NCT01477450|Active Comparator|1 L/min ; 16 mL|Cylinder oxygen delivery (1 L/min) followed by pulse-dose oxygen by concentrator (16 mL)
3160433|NCT01477450|Active Comparator|2 L/min ; 32 mL|Cylinder oxygen delivery (2 L/min) followed by pulse-dose oxygen by concentrator (32 mL)
3160434|NCT01477450|Active Comparator|3 L/min ; 48 mL|Cylinder oxygen delivery (3 L/min) followed by pulse-dose oxygen by concentrator (48 mL)
3160435|NCT01477437|Experimental|Intervention (experimental) Group|
3160436|NCT01477437|No Intervention|Control group|
3160437|NCT01477424|Experimental|PA21 and Warfarin with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Warfarin will be 10 mg/day
3160438|NCT01477424|Experimental|No PA21; Warfarin with food|The maximum dosage of Warfarin will be 10 mg/day
3160439|NCT01477424|Experimental|PA21 with food and Warfarin 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Warfarin will be 10 mg/day
3160440|NCT01477411|Experimental|PA21 and Digoxin with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Digoxin will be 0.5 mg/day
3160441|NCT01477411|Experimental|No PA21; Digoxin with food|The maximum dosage of Digoxin will be 0.5 mg/day
3160442|NCT01477411|Experimental|PA21 with food and Digoxin 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Digoxin will be 0.5 mg/day
3160443|NCT01477398|Active Comparator|inspired CO2|Inspired CO2
3160444|NCT01477398|No Intervention|No intervention: Standard of Care|tidal volume and respiratory rate are not changed during recovery from anesthesia
3160445|NCT01477385|Active Comparator|Resin Infiltration|Resin Infiltration 30% Silver Diammine Fluoride Placebo Dental Flossing
3160446|NCT01477385|Experimental|30% Silver Diammine Fluoride|30% Silver Diammine Fluoride Resin Infiltration Placebo Dental Flossing
3160447|NCT01477385|Active Comparator|Oral Hygiene|Dental Flossing 30% Silver Diammine Fluoride Placebo Resin Infiltration Placebo
3160448|NCT01477372|Experimental|Exercise group|Supervised exercise program
3160449|NCT01477372|No Intervention|Control|Sedentary pregnant woman
3160450|NCT01477359||CS screened as underlying etiology|"Patients with active Clinically Manifest CS~Patients diagnosed with extra-cardiac sarcoidosis and being screened for CS"
3160451|NCT01477346|Other|Nurse intervention|Nurse led package of care based on current recommended best practice.
3160452|NCT01477346|Other|Standard care|Continuing standard general practitioner led care
3160453|NCT01477333|Experimental|UT-15C SR BID|Initiated at 0.125 mg twice daily (BID), titrated as clinically indicated.
3160454|NCT01477320|Active Comparator|Pantoprazole 40mg IV daily and tube feed|
3160455|NCT01477320|Placebo Comparator|Placebo and tube feed.|
3160456|NCT01477307||hypocaloric diet|The included patients are assigned to a hypocaloric standardized diet for 3 weeks.
3160457|NCT01477294|Experimental|Caffeine|Intervention with Caffeine in a random order
3160458|NCT01477294|Placebo Comparator|Placebo|Placebo (malt dextrin) administered in a random order
3160459|NCT01477281|Experimental|Venafon (Diosmin and Hesperidin)|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
3160460|NCT01477281|Active Comparator|Daflon|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
3160461|NCT01477268|Other|zoloft|Both arms of the study will include zoloft. However, the treatment response to zoloft will be compared in two different subgroups.
3160462|NCT01477255||Cancer patient|Patient participants will include children and adolescents between the ages of 8-17 years who have been recently diagnosed with cancer. They will use an iPad as a diary to track their daily experiences. They will use an iPad as a diary to track their daily experiences.
3160463|NCT01477255||Control|For each pediatric patient enrolled, a child without a history of a serious medical illness will be recruited from the larger community who is matched on variables of age, race/ethnicity, gender, and socioeconomic status. They will use an iPad as a diary to track their daily experiences. They will use an iPad as a diary to track their daily experiences.
3160464|NCT01477242|Experimental|Ondansetron|Ondansetron use group
3160465|NCT01477242|Placebo Comparator|Placebo|Placebo group
3160466|NCT01477229||Abdominoperineal resection|Patients with low rectal cancers
3160467|NCT01477229||Anterior resection|Patients where it is possible to perform an anterior resection
3160468|NCT01477229||Preoperative chemo-radiation treatment|Patients with locally advanced rectal cancer
3160469|NCT01477229||Palliative treatment|Patients with systemic disease
3160470|NCT01477216|Experimental|Measuring method|To compare glycemic responses and GI values from capillary and venous blood and to compare glucose solution with white bread as the reference food and to study the effect of the number of reference tests on GI values.
3160471|NCT01477216|Experimental|Mixed meals|To examine the glycaemic and insulinaemic responses of a mashed potato-based meal when a high fat food (rapeseed oil) or a high protein food (chicken breast) or fat, protein and salad together were added to the meal. Furthermore, we studied how the predicted and measured GI values of the mixed meal differed from each other.
3160472|NCT01477216|Experimental|Coffee|To examine the effects of two different coffee portions with glucose and caffeine-containing soft drinks on postprandial glucose and insulin responses. Further objectives were to study how coffee and different accompaniments affect glucose and insulin responses.
3160473|NCT01477216|Experimental|Snacks|To measure GI and II values for Finnish snack foods
3160474|NCT01477216|Experimental|Berries|To study the effects of berries on glycemic and insulinemic responses
3160475|NCT01477216|Experimental|GIs of low-carbs|To measure glycemic and insulinemic responses to low-carbohydrates foods
3160476|NCT01477216|Experimental|Glucose metabolism and BMI|To examine the effects of overweight and glucose tolerance on the glucose, insulin and lipid responses to an HGI meal and an LGI meal. Furthermore, the second aim was to study the effect of BMI and glucose tolerance on the GI measured.
3160477|NCT01477216|Experimental|Insulin measurement|To compare how methodological choices affect measured insulin values
3160478|NCT01477216|Experimental|Alcohol|To investigate the effect of alcohol on postprandial glucose and insulin responses, and to determine glycemic and insulinemic indices values for beer and non-alcoholic beer.
3160479|NCT01477203|Active Comparator|Escitalopram|50 Major Depressive Disorder Patients and 50 Anxiety Disorder Patients will receive Escitalopram as medication
3160480|NCT01477203|No Intervention|Remitted Patients|
3160481|NCT01477203|No Intervention|Healthy Controls|
3160482|NCT01477190|Experimental|Spinal group|Isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged > 75 years.
3160483|NCT01477190|Active Comparator|PCA group|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
3160484|NCT01477177|Experimental|Polar Wand Treatment|Cryotherapy device utilizing carbon dioxide (room temperature gas) for treatment of GI neoplasia
3160485|NCT01477164|Experimental|Aerobic Exercise Training|Participants will perform 12-weeks of high intensity aerobic training.
3160486|NCT01477164|Active Comparator|Combined|The combined group will have 12-weeks of no exercise followed by 12-weeks of combined aerobic and resistance exercise training. Assessments will be made at three time points: baseline, after 12-weeks of no training, and after 12-weeks of combined training.
3160487|NCT01477164|Experimental|Resistance Exercise Training|Participants will perform 12-weeks of resistance exercise training.
3160488|NCT01477151|Active Comparator|sevoflurane|These patients will receive sevoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.
3160489|NCT01477151|Experimental|isoflurane|These patients will receive isoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.
3160490|NCT01477138||DDD(R)|SSS. PM programmed to DDD(R) mode with ventricular pacing on the right ventricular septum.
3160491|NCT01477138||AAI(R)<=>DDD(R)|SSS, PM-mode programmed for minimizing right ventricular pacing on the right interventricular septum
3160492|NCT01477125|Experimental|Flex working memory training|30-40 minutes of working memory training, 5 days a week for 5 weeks
3160493|NCT01477125|Placebo Comparator|Control version of Flex|30-40 minutes of training with a control version of Flex, 5 days a week for 5 weeks.
3160494|NCT01477112|Experimental|Supplemented Diabetics (DB)|Diabetics supplemented with betacarotene for 45 days
3160495|NCT01477112|Experimental|Unsupplemented Diabetics (DS)|Diabetics without betacarotene supplementation
3160496|NCT01477112|Active Comparator|Supplemented Controls (CB)|Controls supplemented with betacarotene for 45 days
3160497|NCT01477112|Active Comparator|Unsupplemented Controls (CS)|Controls without betacarotene supplementation
3160498|NCT01477099|Experimental|Toothbrushing with a manual brush|Toothbrushing with a manual brush
3160499|NCT01477099|No Intervention|No toothbrushing|no toothbrushing
3160500|NCT01477086||Hip fracture|We included patients with traumatic hip fracture, with surgery and who are admitted for rehabilitation
3160501|NCT01477073|Experimental|FSH-GEX|
3160502|NCT01477073|Active Comparator|recombinant FSH|recombinant FSH
3160503|NCT01477073|Active Comparator|urinary FSH|urinary FSH
3160504|NCT01477073|Placebo Comparator|Placebo|
3160505|NCT01477060|Other|ARM A - Lapatinib|hormonal therapy + lapatinib (1250mg/die) until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
3160506|NCT01477060|Other|ARM B - Metformin|Hormonal therapy + metformin until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
3160507|NCT01477060|Other|ARM C - Lapatinib + Metformin|Hormonal therapy + lapatinib + metformin until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
3160508|NCT01477047||Patients receiving primary hip or knee arthoplasty|
3160509|NCT01477034|Experimental|2,000 IU/day vitamin D3 x 6 months|Subjects will take a 2,000 IU daily vitamin D3 supplement for 6 months.
3160510|NCT01477034|Experimental|4,000 IU/day vitamin D3 x 6 months|Subjects will take a 4,000 IU daily vitamin D3 supplement for 6 months.
3160511|NCT01477034|Experimental|2,000 IU/day vitamin D3 x 3 months|Subjects will take a 2,000 IU daily vitamin D3 supplement for 3 months.
3160512|NCT01477034|Experimental|4,000 IU/day vitamin D3 x 3 months|Subjects will take a 4,000 IU daily vitamin D3 supplement for 3 months.
3160513|NCT01477021|Experimental|Treatment (NY-ESO-1 specific CD8+ T cells)|Patients receive cyclophosphamide IV on days -3 and -2. Patients receive NY-ESO-1-specific T cells IV on day 0.
3160514|NCT01477008|Experimental|BiCRI|BiPhasic Cartilage Repair Implant
3160515|NCT01477008|Active Comparator|Marrow Stimulation|Microfracture or Subchondral Drilling
3160516|NCT01476995||Controls|Men and women ages 18-85 lacking any medical diagnosis (as defined in the protocol) of one or more of the following systems/organs: cardiovascular system; gastrointestinal system; kidneys; liver; lungs.
3160517|NCT01476995||Five Diagnosis Group|Men and women ages 18-85 with at least one active medical diagnosis (as defined in the protocol) of one or more of the following systems/organs: cardiovascular system; gastrointestinal system; kidneys; liver; lungs.
3160518|NCT01476982||Emergency Department Patients|Patients presenting to the Emergency Department complaining of chest pain.
3160519|NCT01476969|Experimental|Manual Tourniquet|
3160520|NCT01476956||Rheumatoid Arthritis|
3160521|NCT01476943||Patient treated with Belatacept at the time of transplantation|Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with Belatacept at the time of transplantation
3160522|NCT01476943||Patient treated with CNI at the time of transplantation|Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with a Calcineurin inhibitor (CNI) based regimen at the time of transplantation
3160523|NCT01476930|Experimental|cupping serkangabin|migraine cases treated by cupping and serkangabin syrup
3160524|NCT01476930|Active Comparator|conventional|migraine cases treated by conventional drug treatment protocols
3160525|NCT01476917|Experimental|Treatment|Subjects that completed the ATLAST Study
3160526|NCT01476904|Experimental|Arm T|Arm T is the experimental treatment arm consisting of 2 x 125 mcg/inhalations of epinephrine inhalation, QID, with 4-6 hr intervals
3160527|NCT01476904|Placebo Comparator|Arm P|Arm P is a placebo comparator consisting of 2× 0 mcg of placebo inhalations, QID, with 4-6 hr intervals
3160528|NCT01476904|Active Comparator|Arm A|Arm A is an active comparator, Primatene Mist, consisting of 2× 220 mcg/inhalation, QID, with 4-6 hr intervals
3160529|NCT01476891|Active Comparator|Wait-List|Wait-list Control Group. The control group will receive the next available online MBSR program.
3160530|NCT01476891|Active Comparator|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
3160531|NCT01476878|Experimental|Open Arm|Each study patient will receive high dose, single treatment radiation using a plastic mask instead of a head frame that pins into a patient's skull.
3160532|NCT01476865||Healthy|normal, healthy people
3160533|NCT01476865||RA|rheumatoid arthritis patients
3160534|NCT01476839|Experimental|Treatment (radiolabeled monoclonal antibody, chemotherapy)|"DOSIMETRY STUDY: Patients receive basiliximab IV and indium In 111 basiliximab IV on day -21. Patients undergo indium In 111 imaging scans daily. Patients with appropriate biodistribution continue on to treatment.~TREATMENT: Patients receive basiliximab IV and yttrium Y 90 basiliximab IV on day -14. Patients also receive BEAM chemotherapy comprising carmustine IV over 2 hours on days -7 and -6, etoposide IV BID over 4 hours and cytarabine IV over 2 hours BID on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic progenitor cell infusion on day 0."
3160535|NCT01476813|Experimental|Glyco 25|BDP/FF (400/24 daily)+ Glyco 25µg daily
3160536|NCT01476813|Experimental|Glyco 50|BDP/FF (400/24 daily)+ Glyco 50 µg daily
3160537|NCT01476813|Experimental|Glyco 100|BDP/FF (400/24 daily)+ Glyco 100µg daily
3160538|NCT01476813|Active Comparator|BDP/FF 400/24|BDP/FF 400/24
3160539|NCT01476800|Experimental|YM178 OCAS alone|
3160540|NCT01476800|Active Comparator|Ketoconazole alone|
3160541|NCT01476800|Experimental|YM178 OCAS and ketoconazole|
3160640|NCT01476137|Experimental|Part 2A: GSK2110183 MTD|Maximum tolerated dose (MTD) as determined in ongoing single agent trial PKB115340
3160542|NCT01476787|Experimental|Lenalidomide + Rituximab|"Lenalidomide dose 20-mg on days 2-22 every 28 days for 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for up to 18 cycles.~Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles."
3160543|NCT01476787|Active Comparator|Control|• ONE of the following: Rituximab-CHOP, Rituximab-CVP, Rituximab-Bendamustine. 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
3160544|NCT01476774|Active Comparator|Buprenorphine Transdermal System|
3160545|NCT01476774|Active Comparator|Tramadol CR|
3160546|NCT01476761|Active Comparator|MicroCutter Stapling Device|Patients undergoing surgical treatment with the MicroCutter Stapling Device
3160547|NCT01476748|Active Comparator|Ethicon Xcel Trocars|Ethicon Xcel trocars will be used in this arm with Laprostop device
3160548|NCT01476748|Active Comparator|Covidien Veraport Trocars|Covidien Veraport Trocars will be used in this arm with the Laprostop device
3160549|NCT01476748|Active Comparator|Storz Reusable Trocars|Storz Reusable Trocars will be used in this arm with the Laprostop device
3160550|NCT01476735|Active Comparator|split-dose polyethylene glycol solution|first dose (1,5 l) of polyethylene glycol solution taken at 6-7.00 in the evening before colonoscopy, second dose (1,5 l) taken at 5.30-6.00 in the morning of a day of colonoscopy; additional bisacodyl taken at 12.00 at the day before colonoscopy
3160551|NCT01476735|Active Comparator|Individual preparation for colonoscopy|
3160552|NCT01476722|Experimental|OPTI-FREE PureMoist|OPTI-FREE PureMoist multipurpose disinfecting solution used with study contact lenses on a daily wear basis for 30 days
3160553|NCT01476696|Experimental|Part A: Prasugrel Single Dose|Prasugrel 0.03 milligrams per kilogram (mg/kg) to 0.60 mg/kg dosage to be titrated up or down based on desired platelet inhibition, administered orally [oral-disintegrating tablet (ODT)], single dose given up to 3 occasions, at different strengths, with up to 18 days between doses.
3160554|NCT01476696|Experimental|Part B: Prasugrel Once-Daily Dose|Daily prasugrel dose (mg/kg) that is expected to achieve mean platelet activation inhibition of 30% administered orally, once daily for 10-18 days and then followed by prasugrel dose (mg/kg) that is expected to achieve mean platelet activation inhibition of 50% administered orally, once daily for 10-18 days, for a total of 20-36 days.
3160555|NCT01476683|Experimental|FCT|A single 2 x100 mg dose of an experimental Racecadotril Film-coated tablet (FCT) administered orally with 240 ml of water, with a 7- day washout between visits.
3160556|NCT01476683|Experimental|RPB|A single 2 x100 mg dose of an experimental Racecadotril Powder Blend administered orally with 240 ml of water, with a 7- day washout between visits.
3160557|NCT01476683|Active Comparator|TFT|A single 2 x 100 mg dose of a marketed Tiorfast® capsule administered orally with 240 ml of water, with a 7-day washout between visits.
3160558|NCT01476683|Active Comparator|TFR|A single 175 mg dose of a marketed Tiorfanor® 175 mg FCT administered orally with 240 ml of water, with a 7-day washout between visits.
3160559|NCT01476670||Posterior fossa tumor|Patients with posterior fossa tumor scheduled for elective surgery will be enrolled in the study.
3160560|NCT01476657|Experimental|IPI-145|IPI-145 is administered orally as a capsule formulation. The IPI-145 drug product is supplied as 1 mg, 5 mg, 25 mg, and 100 mg formulated capsules. IPI-145 will be administered orally daily during each 28-day cycle. Patients will be evaluated for DLTs in the dose escalation portion of the study during Cycle 1 (28 days), after which treatment may continue for additional cycles.
3160561|NCT01476631|Experimental|Arm A: 30 minutes walking|First Step program with 30 minutes of walking and 10,000 steps per day for 3 months.
3160562|NCT01476631|Experimental|Arm B: 60 minutes walking|First Step program with 60 minutes of walking and 13,000 steps per day for 3 months.
3160563|NCT01476618||Denver VA OIF/OEF and mental health providers|Denver VA OIF/OEF and mental health providers
3160564|NCT01476605|Active Comparator|PrT-DMS|1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.
3160565|NCT01476605|Experimental|PrT-D|PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine
3160566|NCT01476605|No Intervention|Waitlist|
3160567|NCT01476605|Active Comparator|Platelet rich plasma|
3160568|NCT01476592|Experimental|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
3160569|NCT01476579|Other|Non-invasive CT coronary angiography|This study is evaluating diagnostic accuracy of non-invasive CT coronary angiography with invasive coronary angiography.
3160570|NCT01476566|Experimental|Educational intervention|A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented.
3160571|NCT01476566|No Intervention|Control group|
3160572|NCT01476553|Experimental|Intervention arm|Extensive Intraperitoneal Lavage (EIPL)
3160573|NCT01476514|Experimental|1|"In the setting of comparing patients with a genetic mutation and healthy volunteers blinding of the PI would demand a substantial increase in co-workers (i.e. recruitment, selection of age-and sex matched volunteers), reason why no blinding was chosen.~Affected patients will be compared to age and sex matched volunteers, recruited after completion of testing 23 hyperekplexia patients."
3160574|NCT01476501|Experimental|2,000 IU/day vitamin D|2,000 IU/day vitamin D for 6 months (n=60).
3160575|NCT01476501|Experimental|40,000 IU/month vitamin D|40,000 IU/month for 6 months (n=60).
3160576|NCT01476488|No Intervention|Advagraf|single group, conversion of prograf to advagraf
3160577|NCT01476475|Experimental|Insulin glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC injected once daily (QD) for 24 weeks. Dose individually adjusted.
3160578|NCT01476475|Active Comparator|Insulin glargine|Insulin glargine QD for 24 weeks. Dose individually adjusted.
3160579|NCT01476462||ALL diagnosed 1980-2007|Cases of childhood acute lymphoblastic leukemia (ALL) diagnosed between 1980 and 2007 and included in the clinical trials of the participating ALL study groups
3160641|NCT01476124|Experimental|Regimen A|Morphine placebo + GEn 600 mg
3160642|NCT01476124|Experimental|Regimen B|Morphine Extended release (60 mg) + GEn placebo
3160580|NCT01476449|Active Comparator|Monthly Ranibizumab|Patients randomized to the Monthly Ranibizumab arm of the study will be administered intravitreal injections each month for their diabetic macular edema for the duration of the study.
3160581|NCT01476449|Experimental|Treat and Extend Ranibizumab|"Patients randomized to this arm of the study will receive intravitreal injections of ranibizumab until their maculae are anatomically dry, at which point the evaluation and injection interval will be extended."
3160582|NCT01476436|Experimental|Low carbohydrate dietary advice|Advice of a diet low in carbohydrate
3160583|NCT01476436|Active Comparator|Lifestyle counseling to continue usual diet|Subjects shall continue to eat their usual daily diet with no low carbohydrate intervention
3160584|NCT01476423||A|
3160585|NCT01476410|Experimental|Treatment (antibody-drug conjugate and combination chemo)|"LEAD-IN: Patients receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~AVD CHEMOTHERAPY: Patients then receive doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients achieving CR receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
3160586|NCT01476397|Active Comparator|control infant formula|partially hydrolyzed whey infant formula
3160587|NCT01476397|Experimental|test infant formula|partially hydrolyzed whey infant formula with probiotic
3160588|NCT01476384|Experimental|Glucose drink|75 gram glucose, dissolved in 250 ml water
3160589|NCT01476384|Placebo Comparator|Placebo|250 ml water
3160590|NCT01476371|Experimental|Mindfulness-based group treatment|8 group mindfulness sessions (1 per week), complemented by home mindfulness exercises
3160591|NCT01476371|No Intervention|Treatment as usual|Treatment as usual (including individual CBT and medication)
3160592|NCT01476358|Active Comparator|Vitamin A|Capsule containing oil vehicle with Vitamin A (retinyl palmitate). Capsules are prepared by the manufacturer (Strides Arcolab Limited, India) and assigned blinded codes by World Health Organization officials.
3160593|NCT01476358|Placebo Comparator|Placebo|Capsule containing oil vehicle withOUT Vitamin A (retinyl palmitate). Capsules are prepared by the manufacturer (Strides Arcolab Limited, India) and assigned blinded codes by World Health Organization officials.
3160594|NCT01476345|Experimental|LY2963016|A single 0.5 units/kilogram (U/kg) dose of LY2963016 administered subcutaneously followed by minimum washout interval of 7 days.
3160595|NCT01476345|Experimental|Lantus|A single 0.5 U/kg dose of Lantus administered subcutaneously followed by minimum washout interval of 7 days.
3160596|NCT01476332|Experimental|Group 1: Cis-UCA 0.5% eye drops|
3160597|NCT01476332|Experimental|Group 2: Cis-UCA 2.5% eye drops|
3160598|NCT01476332|Placebo Comparator|Group 3: Placebo for cis-UCA, eye drops|
3160599|NCT01476319|No Intervention|control|
3160600|NCT01476319|Experimental|video|
3160601|NCT01476306|Placebo Comparator|In-patient care|
3160602|NCT01476306|Experimental|Telemedicine care|
3160603|NCT01476280|Sham Comparator|Palonosetron|
3160604|NCT01476280|Sham Comparator|Ramosetron|
3160605|NCT01476267|Experimental|Single Arm|
3160606|NCT01476254||Cholecystectomy|Women scheduled for laparoscopic cholecystectomy
3160607|NCT01476254||Hysterectomy|Women scheduled for laparoscopic hysterectomy
3160608|NCT01476241||EarNoseThroatGroup|a cohort of patients that had undergone PEG tube placement from October 2008 until October 2010 at the Department of Otorhinolaryngology - Head and Neck Surgery
3160609|NCT01476241||SurgeryGroup|a historic cohort group of patients with the PEG tube placed in the Department of Surgery from September 2005 until September 2009
3160610|NCT01476228|Experimental|study group|EEG recording
3160611|NCT01476215|Experimental|Fast dissolution suspension|
3160612|NCT01476215|Experimental|Medium dissolution suspension|
3160613|NCT01476215|Experimental|Slow dissolution suspension|
3160614|NCT01476215|Active Comparator|Marketed suspension|
3160615|NCT01476202|Experimental|Nicotine mouth strip|single dose
3160616|NCT01476202|Active Comparator|nicotine lozenge|single dose
3160617|NCT01476202|Active Comparator|nicotine gum|single dose
3160618|NCT01476189|Experimental|Experimental paracetamol formulation|test formulation
3160619|NCT01476189|Active Comparator|Marketed paracetamol|Marketed paracetamol
3160620|NCT01476189|Active Comparator|Higher dose marketed paracetamol|higher dose marketed paracetamol
3160621|NCT01476176|Experimental|Experimental paracetamol formulation|experimental formulation
3160622|NCT01476176|Active Comparator|paracetamol marketed formulation|Paracetamol marketed formulation
3160623|NCT01476150||Dongcheng|
3160624|NCT01476150||Haidian|
3160625|NCT01476150||Xicheng|
3160626|NCT01476150||Chaoyang|
3160627|NCT01476150||Chongwen|
3160628|NCT01476150||Tongzhou|
3160629|NCT01476150||Fengtai|
3160630|NCT01476150||Xuanwu|
3160631|NCT01476137|Experimental|Part 2A and 2B: GSK1120212 + GSK2110183 Dose Combination 1|One of two dose combination levels (GSK1120212+GSK2110183) based on data from Part 1 of the trial
3160632|NCT01476137|Experimental|Part 2A and 2B: GSK1120212 + GSK2110183 Dose Combination 2|One of two dose combination levels (GSK1120212+GSK2110183) based on data from Part 1 of the trial
3160633|NCT01476137|Experimental|Part 1: Cohort 1|GSK1120212 1.5mg + GSK2110183 50mg
3160634|NCT01476137|Experimental|Part 1: Cohort 2|GSK1120212 1.5mg + GSK2110183 100mg
3160635|NCT01476137|Experimental|Part 1: Cohort 3a|GSK1120212 2mg + GSK2110183 100mg
3160636|NCT01476137|Experimental|Part 1: Cohort 3b|GSK1120212 1.5mg + GSK2110183 125mg
3160637|NCT01476137|Experimental|Part 1: Cohort 4a|GSK1120212 2mg + GSK2110183 125mg
3160638|NCT01476137|Experimental|Part 2A: GSK1120212 2mg|Maximum tolerated dose of GSK1120212 as determined in prior single-agent trials
3160639|NCT01476137|Experimental|Part 2A; GSK2110183 125mg|GSK2110183 125mg
3160643|NCT01476124|Experimental|Regimen C|Morphine Extended release (60mg) + GEn 600 mg
3160644|NCT01476111||Group 1|Patients with primary invasive breast cancer
3160645|NCT01476098|Placebo Comparator|Arm 1|incremental doses capsaicin
3160646|NCT01476098|Active Comparator|Arm 2|incremenrtal doses casaicin
3160647|NCT01476085|No Intervention|no treatment|no treatment
3160648|NCT01476072|No Intervention|no treatment|MRI scans only
3160649|NCT01476059|Other|telephone follow-up|Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
3160650|NCT01476059|Other|No telephone follow-up|Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
3160651|NCT01476046|Experimental|GSK1995057|Single intravenous dose
3160652|NCT01476046|Placebo Comparator|Placebo|Single intravenous dose
3160653|NCT01476033|Active Comparator|fruit, berry and vegetable concentrate|20 ladies receive an encapsulated, powdered fruit, berry and vegetable concentrate for 8 weeks
3160654|NCT01476033|Placebo Comparator|20 women with placebo|placebo for 8 weeks
3160655|NCT01476020||no clopidogrel 6 months after DES|Patients with a single treatment antiplatelet therapy (aspirin) 6 months after drug-eluting stent implantation (Xience V Abbott company), including a 12-, 24- and 36-month follow-up analysis.
3160656|NCT01476020||2 antiplatelet therapy 2 years after DES|patients with dual antiplatelet therapy with clopidogrel and aspirin 24 months after drug-eluting stent implantation, including a 12-, 24- and 36-month follow-up analysis.
3160657|NCT01476007|Experimental|oral Cobalamin (vitamin B12)|oral Cobalamin (vitamin B12)
3160658|NCT01476007|Experimental|intramuscular Cobalamin (vitamin B12)|intramuscular Cobalamin (vitamin B12)
3160659|NCT01475994|Experimental|Challenge with grass pollen|
3160660|NCT01475994|Placebo Comparator|Challenge with clean air|
3160661|NCT01475981|Experimental|Dose 1 JTK-853 (fasted condition)|
3160662|NCT01475981|Experimental|Dose 2 JTK-853 (fasted condition)|
3160663|NCT01475981|Experimental|Dose 3 JTK-853 (fasted condition)|
3160664|NCT01475981|Experimental|Dose 2 JTK-853 (fed condition)|
3160665|NCT01475981|Experimental|Dose 3 JTK-853 (fed condition)|
3160666|NCT01475981|Experimental|Dose 4 JTK-853 (fed condition)|
3160667|NCT01475981|Experimental|Dose 5 JTK-853 (fed condition)|
3160668|NCT01475981|Experimental|Dose 6 JTK-853 (fed condition)|
3160669|NCT01475981|Experimental|Dose 7 JTK-853 (fed condition)|
3160670|NCT01475981|Experimental|Dose 5 JTK-853 (high-fat fed condition)|
3160671|NCT01475981|Placebo Comparator|Placebo|
3160672|NCT01475968|Active Comparator|Ultrafine Air Pollution Particulate Matter|<2.5 microns concentrated from outside ambient air
3160673|NCT01475968|Sham Comparator|Filtered Air|Filtered Air
3160674|NCT01475955|Experimental|Broad Area ALA 1-hour incubation|Broad Area ALA 1-hour incubation
3160675|NCT01475955|Experimental|Broad Area ALA 2-hour incubation|Broad Area ALA 2-hour incubation
3160676|NCT01475955|Experimental|Broad Area ALA 3-hour incubation|Broad Area ALA 3-hour incubation
3160677|NCT01475955|Experimental|Spot ALA 2-hour incubation|Spot ALA 2-hour incubation
3160678|NCT01475955|Placebo Comparator|Vehicle PDT|VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.
3160679|NCT01475942|Active Comparator|Probiotic|Lactobacillus
3160680|NCT01475942|Placebo Comparator|Placebo|Sucrose
3160681|NCT01475929|Active Comparator|Probiotic low|Lower dose of probiotic supplement
3160682|NCT01475929|Placebo Comparator|Placebo|
3160683|NCT01475929|Active Comparator|Probiotic high|Higher dose of probiotic supplement
3160684|NCT01475903||sleeve gastrectomy|
3160685|NCT01475890|Active Comparator|7000IU/day|29 subjects will be randomized to receive 7000IU/day of vitamin D3.
3160686|NCT01475890|Placebo Comparator|Placebo|29 subjects will be randomized to receive placebo.
3160687|NCT01475877||Nepafenac|
3160688|NCT01475864||Incomplete biliary stone extraction.|
3160689|NCT01475851|Experimental|GSK548470 300 mg|GSK548470 300 mg tablet is administered orally once daily
3160690|NCT01475838|Experimental|Stribild|Participants will switch from their baseline treatment regimen to Stribild for up to 96 weeks, and may continue to receive Stribild in the extension phase.
3160691|NCT01475838|Active Comparator|PI+RTV+FTC/TDF|Participants will stay on their baseline treatment regimen antiretroviral regimen consisting of a PI boosted with RTV plus FTC/TDF for up to 96 weeks, and may switch to Stribild in the extension phase.
3160692|NCT01475825|Experimental|Blinded mipomersen 200 mg once weekly|Mipomersen sodium 200 mg (1 mL), subcutaneous injections administered once every other week for the first 8 weeks followed by once every week for 52 weeks.
3160693|NCT01475825|Placebo Comparator|Placebo once weekly|Placebo subcutaneous injection (1 mL) administered once every other week for the first 8 weeks followed by once a week for 52 weeks.
3160694|NCT01475825|Experimental|Blinded mipomersen 70 mg thrice weekly|Mipomersen sodium 70 mg (0.5 mL), subcutaneous injections administered three times a week every other week for the first 8 weeks followed by three times a week every week for 52 weeks.
3160695|NCT01475825|Placebo Comparator|Placebo thrice weekly|Placebo subcutaneous injection (0.5 mL) three times a week every other week for the first 8 weeks followed by three times every week for 52 weeks.
3160696|NCT01475825|Experimental|Open-label mipomersen 200 mg once weekly|Mipomersen sodium 200 mg (1 mL), subcutaneous injections administered once every week for 26 weeks following completion of blinded treatment period
3160697|NCT01475825|Experimental|Open-label mipomersen 70 mg thrice weekly|Mipomersen sodium 70 mg (0.5 mL), subcutaneous injections administered three times a week for 26 weeks following completion of blinded treatment period.
3160698|NCT01475812||COPD hyperinflation|
3160699|NCT01475799|Experimental|Percutaneous Aortic Valve 18F System|Evaluation of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the Treatment of Patients with Severe Aortic Stenosis.
3160928|NCT01474265|Placebo Comparator|varenicline placebo|
3160929|NCT01474265|Active Comparator|varenicline|
3160700|NCT01475786|Active Comparator|Low Dose 16mg VM202 and Placebo|intramuscular injections in each calf for a total of 16mg VM202: Day 0 - 32 injections / calf 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf) and 16 injections of normal saline 0.5mL / calf Day 14 - 32 injections / calf and 16 injections of normal saline 0.5mL / calf 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)
3160701|NCT01475786|Active Comparator|High Dose 32mg VM202|Day 0 - 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) Day 14 - 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) For a total of 32mg VM202
3160702|NCT01475786|Placebo Comparator|Control - Placebo (normal saline)|32 injections / calf of 0.5 mL normal saline at Day 0 and Day 14
3160703|NCT01475773||Adults (starting from age 17)|adults seeking orthodontic treatment at the university of Leuven
3160704|NCT01475760|Active Comparator|K2CG chewing gum (20 mg chitosan)|
3160705|NCT01475760|Active Comparator|K2CG chewing gum (60 mg chitosan)|
3160706|NCT01475760|No Intervention|Standard of Care|
3160707|NCT01475747||Observational - SPRINT trial subjects|Subjects in the Systolic Pressure Intervention Trial (SPRINT) observed to examine factors that affect atherosclerosis in chronic kidney disease
3160708|NCT01475734|Active Comparator|albiglutide|single dose of albiglutide
3160709|NCT01475734|Placebo Comparator|placebo|single dose of placebo
3160710|NCT01475721|Experimental|ADVAIR 100/50mcg|experimental drug
3160711|NCT01475721|Experimental|ADVAIR 250/50mcg|experimental drug
3160712|NCT01475721|Experimental|ADVAIR 500/50mcg|experimental drug
3160713|NCT01475721|Active Comparator|FLOVENT 100mcg|active comparator
3160714|NCT01475721|Active Comparator|FLOVENT 250mcg|active comparator
3160715|NCT01475721|Active Comparator|FLOVENT 500mcg|active comparator
3160716|NCT01475708||no symptoms|patients with erythema migrans and no additional newly onset symptoms treated with doxycycline
3160717|NCT01475708||mild symptoms|patients with erythema migrans and mild unspecific newly onset symptoms treated with doxycycline
3160718|NCT01475708||severe symptoms-lumbar puncture|"patients with erythema migrans and newly onset intense neurologic symptoms with lumbar puncture performed, treated with doxycycline"
3160719|NCT01475695|Experimental|Single cohort|14C GSK2251052
3160720|NCT01475682||1|"167 subjects recruited from our previous OSA and metabolic syndrome (OSAMS) cohort from October 2002 to June 2007 will be invited to be reassessed at this time point."
3160721|NCT01475669|Experimental|Fibrinogen Concentrate (Human)|
3160722|NCT01475669|Placebo Comparator|Placebo|
3160723|NCT01475656||Levetiracetam as first line|Babies who receive levetiracetam as a first line drug for seizures
3160724|NCT01475656||Phenobarbital as first line|Babies who receive phenobarbital as a first line drug for seizures and levetiracetam as a second line drug
3160725|NCT01475643|Experimental|Loteprednol etabonate|Loteprednol etabonate 0.5%
3160726|NCT01475643|Active Comparator|Prednisolones acetate|Prednisolone acetate 1.0%
3160727|NCT01475630|Other|control|information, avoiding parafunctions
3160728|NCT01475630|Experimental|physical therapy|mobilisation, exercises ,..
3160729|NCT01475617|Experimental|Novel Multivitamin/Mineral Supplement|These subjects will be given a novel multivitamin/mineral supplement post RYGB bariatric surgery for 6 months duration.
3160730|NCT01475617|Active Comparator|Standard of care supplement|These subjects will be given the standard recommended regimen at Johns Hopkins Bayview Medical Center post RYGB bariatric surgery for 6 months duration.
3160731|NCT01475604|Active Comparator|Targeted pulsed electromagnetic field|
3160732|NCT01475604|Sham Comparator|Sham|
3160733|NCT01475591|No Intervention|Multimodal rehabilitation|The arm intervention is just multimodal rehabilitation.
3160734|NCT01475578|Experimental|STA-1|"STA-1 capsule (Cistanche tubulosa), 2 capsules/time, 3 times/day, orally~Dummy Ergoloid Mesylates tablet (Placebo), 2 tablets/time, 3 times/day, orally"
3160735|NCT01475578|Active Comparator|Ergoloid Mesylates|"Ergoloid Mesylates tablet, 2 tablets/time, 3 times/day, orally before meal~Dummy STA-1 capsule (Placebo), 2 capsules/time, 3 times/day, orally"
3160736|NCT01475565||African-American women|Observational study--no intervention
3160737|NCT01475565||Caucasian women|Observational study--no intervention
3160738|NCT01475552|Experimental|abciximab|
3160739|NCT01475552|Active Comparator|control|
3160740|NCT01475539|Experimental|Group A (Sequential 1): IPV-OPV-OPV|Participants will receive 1 dose of Sanofi Pasteur's injectable Inactivated Poliovirus Vaccine (IPV) followed by 2 doses of a commercially available Oral Poliovirus Vaccine (OPV)
3160741|NCT01475539|Experimental|Group B (Sequential 2): IPV-IPV-OPV|Participants will receive 2 doses of Sanofi Pasteur's injectable Inactivated Poliovirus Vaccine (IPV) followed by 1 dose of a commercially available Oral Poliovirus Vaccine (OPV)
3160742|NCT01475539|Experimental|Group C (Reference): OPV-OPV-OPV|Participants will receive 3 doses of a commercially available Oral Poliovirus Vaccine (OPV)
3160743|NCT01475526|Experimental|Intervention|El Valor de Nuestra Salud Store Intervention
3160744|NCT01475526|No Intervention|Control|No intervention. Business as usual
3160745|NCT01475513|Active Comparator|African-American women|African-American women
3160746|NCT01475513|Active Comparator|Caucasian women|Caucasian women
3160747|NCT01475500||Screening|These high-risk subjects will undergo screening for lung cancer. All subjects will undergo all listed interventions
3160748|NCT01475487|Active Comparator|Cricothyrotomy using Digital Palpation|Group-1 will perform Cricothyrotomy using conventional digital palpation technique
3160749|NCT01475487|Experimental|Ultrasound guided cricothyrotomy group|Group-2 Ultrasound guided cricothyrotomy
3160750|NCT01475461|Placebo Comparator|Placebo|
3160751|NCT01475461|Experimental|PF-04937319 - Dose 1|
3160752|NCT01475461|Experimental|PF-04937319 - Dose 2|
3160753|NCT01475461|Experimental|PF-04937319 - Dose 3|
3160754|NCT01475461|Experimental|PF-04937319 - Dose 4|
3160755|NCT01475461|Active Comparator|Sitagliptin|
3160756|NCT01475448|Experimental|Sedentary older adults - running|Sedentary older adults (60 years old or more) recruited from local community
3160930|NCT01474265|Active Comparator|Nicorette TX|
3160757|NCT01475448|Active Comparator|Sedentary older adults - walking|Sedentary older adults (60 years old or more) recruited from local community
3160758|NCT01475435|Active Comparator|chronic periodontitis|Saliva and GCF samples will be evaluated before and after treatment from patients treated of chronic periodontitis.
3160759|NCT01475435|Placebo Comparator|periodontally healthy individuals|Saliva and GCF samples will be evaluated from periodontally healthy individuals at baseline.
3160760|NCT01475435|Active Comparator|chronic periodontitis with diabetes type 2|Saliva and GCF samples will be evaluated before and after treatment from patients with diabetes type 2 treated of chronic periodontitis
3160761|NCT01475435|Placebo Comparator|periodontally healthy individuals with diabetes type 2|Saliva and GCF samples will be evaluated from periodontally healthy individuals with diabetes type 2 at baseline
3160762|NCT01475422|Experimental|Conversation Maps Diabetes Education|
3160763|NCT01475422|Active Comparator|Usual Care|
3160764|NCT01475409|Experimental|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, tuberculin skin test (TST) and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset.
3160765|NCT01475396|Experimental|Aerobic Exercise|
3160766|NCT01475396|Experimental|Anaerobic Exercise|
3160767|NCT01475396|No Intervention|Unchanged condition|
3160768|NCT01475383|Active Comparator|PF-03654746|Subjects are randomized to either active drug or placebo in Period 1; in Period 2 the sequence is reversed.
3160769|NCT01475383|Placebo Comparator|Placebo|Subjects are randomized to either active drug or placebo in Period 1; in Period 2 the sequence is reversed.
3160770|NCT01475370|Experimental|OCV-501|
3160771|NCT01475357|Other|Arm 1: NPO pre-operative|1) Current care - NPO (nothing by mouth) postnatal intestinal function of neonates with complex CHD who receive enteral trophic breastmilk (10cc/kg/day) feeds (intervention) vs NPO (nothing by mouth) in the pre-operative period.
3160772|NCT01475357|Active Comparator|Arm 2: Fresh Breast Milk pre-operative|2) Intervention - Trophic mother's own fresh (non-frozen) breastmilk gavage feeds via nasogastric tube every 3 hours at 10 cc/kg/day
3160773|NCT01475344|Active Comparator|Human Fibrinogen Concentrate|"Fibrinogen Concentrate will be administrated over 5 min/vial:~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
3160774|NCT01475344|Placebo Comparator|Placebo|"Placebo administrated over 5 min/vial:~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
3160775|NCT01475331|Active Comparator|Control Group|Cyst will be lavaged for 3-5 minutes with Ethanol (alcohol 80%). Following lavage with Ethanol (alcohol 80%), The cyst will be infused with an admixture of chemotherapy drugs (Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
3160776|NCT01475331|Experimental|Study Group|Cyst will be lavaged for 3-5 minutes with Normal Saline .. Following lavage with Normal Saline, The cyst will be infused with an admixture of chemotherapy drugs (Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
3160777|NCT01475318|Experimental|misoprostol + mifepristone + letrozole|
3160778|NCT01475305|Placebo Comparator|Placebo|Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
3160779|NCT01475305|Experimental|MEDI-557|Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
3160780|NCT01475292|Experimental|RV568 treatment group low dose|
3160781|NCT01475292|Experimental|RV568 treatment group high dose|
3160782|NCT01475292|Placebo Comparator|Placebo treatment group|
3160783|NCT01475266|Experimental|EO9 (Apaziquone)|
3160784|NCT01475266|Placebo Comparator|Placebo|
3160785|NCT01475253|Experimental|Lidocaine Releasing Intravesical System|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
3160786|NCT01475253|Placebo Comparator|LiRIS containing inactive substance only|LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
3160787|NCT01475253|Sham Comparator|Cystoscopy Procedure|No intervention. Cystoscopy procedure is performed on study Day 0 and study Day 14 to mimick active and placebo study arms without insertion of Investigational Product into the bladder.
3160788|NCT01475240||Group 1: Controls|HIV-infected patients on stable > 6 months on TDF/FTC or ABC/3TC plus PI/r based ARV regimen with normal bilirubin
3160789|NCT01475240||Group 2: Cases|HIV-infected patients on stable >6 months on TDF/FTC or ABC/3TC plus PI/r based ARV regimen with HBR (>2.5 X upper limit)
3160790|NCT01475227|Experimental|Arm A- early Solvazinc group|Zinc sulphate 125mg (1 Solvazinc tablet) once daily orally after dissolution in water, day 2 to day 15
3160791|NCT01475227|Experimental|Arm B- late Solvazinc group|Zinc sulphate 125mg (1 Solvazinc tablet) once daily orally after dissolution in water, day 15 to day 28
3160792|NCT01475214|Active Comparator|potassium bicarbonate low dose|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
3160793|NCT01475214|Active Comparator|potassium bicarbonate higher dose|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
3160794|NCT01475214|Placebo Comparator|placebo|microcrystalline cellulose
3160795|NCT01475201|Experimental|Step Count Prescription Arm|The active trial arm intervention consists of usual care plus step count prescription delivered by the treating doctor, over a one-year period.
3160796|NCT01475201|Active Comparator|Usual care arm|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week). Consistent with clinical practice guidelines, our collaborating doctors have indicated that the usual care of the target population requires clinic visits at roughly three-month intervals to ensure vascular risk factor monitoring and management.
3160797|NCT01475188|Placebo Comparator|placebo|20 patients with intermittent allergic rhinitis sensitized to grass pollen allergens
3160798|NCT01475188|Active Comparator|Specific subcutaneous immunotherapy|21 symptomatic patients with intermittent allergic rhinitis sensitized to grass pollen allergens
3160799|NCT01475175|Experimental|Adaptive CRT Pacing|Cardiac resynchronization therapy (CRT) with adaptive pacing.
3160800|NCT01475162|Experimental|Tocilizumab|"Drug: Tocilizumab~Other Names:~Actemra~Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response."
3160801|NCT01475149||aPL positive - group 1|aPL positive with APS, receiving HCQ
3160802|NCT01475149||aPL positive - group 2|aPL positive with APS and SLE, receiving HCQ
3160803|NCT01475149||aPL positive - group 3|aPL positive without APS but with SLE, receiving HCQ
3160804|NCT01475149||aPL positive - group 4|aPL positive without APS or SLE, receiving HCQ
3160805|NCT01475149||aPL negative - group 1|aPL negative with SLE, receiving HCQ
3160806|NCT01475149||aPL negative - group 2|aPL negative with SLE, not receiving HCQ
3160807|NCT01475136|Experimental|LY2140023|A single 80 mg dose administered orally, one time
3160808|NCT01475123|Active Comparator|Nicorandil|Nicorandil was administered orally (15mg/day).
3160809|NCT01475123|No Intervention|Non-nicorandil|Nicorandil was not administered.
3160810|NCT01475110||Study cohort group|"Adult patients with Imatinib resistant (failure + suboptimal) or intolerant chronic myeloid leukaemia in all phases, who started treatment with Nilotinib between January 2005 and December 2012 in Italy.~Adult pts treated with Nilotinib as second line therapy after Dasatinib."
3160811|NCT01475097|Active Comparator|Active Arm|
3160812|NCT01475097|Active Comparator|Comparator Arm|
3160813|NCT01475084|Experimental|Cryobiopsy, forceps biopsy|"Cryoiopsies will be obtained by flexible autoclavable cryoprobe 20416-032 (Erbokryo CA, ERBE, Germany) with 2.4 mm in diameter. The tip of the probe is cooled to -890C with nitrous oxide within seconds after footswitch activation.~Forceps biopsies will be obtained by flexible FB-55CD-1 Olympus forceps."
3160814|NCT01475071|Experimental|Metvix and daylight|
3160815|NCT01475071|Active Comparator|Metvix and lamp|
3160816|NCT01475058|Experimental|Treatment (T cell therapy)|Patients undergo one IV infusion of donor-derived CD8+ central memory-derived CMV/CD19 or EBV/CD19 bi-specific T cells, at least 30 days after HCT.
3160817|NCT01475045||Turbuhaler inhaler use|
3160818|NCT01475045||Discus inhaler use|
3160819|NCT01475045||Elpenhaler inhaler use|
3160820|NCT01475032|Experimental|CHF 1535|CHF 1535 (BDP/FF) for 12 weeks
3160821|NCT01475032|Active Comparator|BDP|BDP for 12 weeks
3160822|NCT01475032|Active Comparator|BDP+FF|free combo BDP+FF for 12 weeks
3160823|NCT01475019|Experimental|PCOS obese Orlistat|Obese PCOS women treated with Orlistat, diet and physical exercise
3160824|NCT01475019|Experimental|Obese Orlistat|Obese women (non PCOS) treated with Orlistat, diet and physical exercise
3160825|NCT01475019|Experimental|PCOS obese diet|Obese PCOS women treated with diet and physical exercise
3160826|NCT01475019|Experimental|PCOS obese Sibutramine|Obese PCOS women treated with Sibutramine, diet and physical exercise
3160827|NCT01475006|Experimental|Part I Dose Exploration|Pre-specified nominal doses are proposed in the dose exploration. Intermediate doses may also be used if required based on the CRM design.
3160828|NCT01475006|Experimental|Part II Dose Expansion|Dose selected from Part 1 dose exploration
3160829|NCT01474993|Placebo Comparator|Placebo|inactive placebo.
3160830|NCT01474993|Experimental|Interventional|sulforaphane-rich Broccoli Sprout Extract.
3160831|NCT01474967|Experimental|Lower metformin dose group|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
3160832|NCT01474967|Active Comparator|Higher metformin dose group|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
3160833|NCT01474941|Experimental|5 mg QD PF-04620110 or Placebo|
3160834|NCT01474941|Experimental|5 mg BID PF-04620110 or Placebo|
3160835|NCT01474941|Experimental|Optional Arm, PF-04620110 or Placebo|
3160836|NCT01474928|Experimental|Group 2: community video group|In each community intervention group two subject viewed the patient role played community video
3160837|NCT01474928|Experimental|Group three: both videos group|In each community intervention group three subject viewed two videos (the patient role played community and physician-led knowledge videos)
3160838|NCT01474928|Active Comparator|Group four: pamphlet group|In each community intervention group four subject read an educational pamphlet only - act as active comparator group
3160839|NCT01474928|Experimental|Group one: knowledge video group|In each community intervention group one subject viewed the physician-led knowledge video
3160840|NCT01474915|Active Comparator|Aprepitant|"Aprepitant is given orally, along with an oral or PO placebo depending on their group assignment for uniformity. Each patient will receive three drugs in their respective triple prophylactic medication plus an IV or oral placebo prior to induction of anesthesia.~Triple therapy 40mg Aprepitant PO + IV placebo, 25mg Promethazine IV and 10mg dexamethasone IV"
3160841|NCT01474915|Active Comparator|Ondansetron|"Ondansetron is given via IV, along with an oral or IV placebo depending on their group assignment for uniformity. Each patient will receive three drugs in their respective triple prophylactic medication (25mg promethazine, 10mg dexamethasone, and either 4mg ondansetron or 40mg aprepitant) plus an IV or oral placebo prior to induction of anesthesia.~Triple therapy~4mg Ondansetron IV + PO placebo, 25mg Promethazine IV and 10mg dexamethasone IV"
3160842|NCT01474902|Experimental|Treatment group|"The initial enoxaparin dose will be: 1.75 mg/kg/dose SC q12h for patients ≤ 2 months old or~1 mg/kg/dose SC q12h for patients > 2 months old~Adjust the dose of enoxaparin according to the following monogram. Depending on the Enoxaparin Anti-factor Xa level achieved, successive actions are indicated, including whether to hold the next scheduled dose, whether any dose change is indicated and when the next anti-factor Xa level should be drawn."
3160843|NCT01474902|No Intervention|No-treatment|
3160844|NCT01474889|Experimental|Hypoglycemia Unaware T1 Diabetes RT-CGM|Type 1 Diabetes with Hypoglycemia Unawareness. Patients wear an RT-CGM for 18 months. We are comparing type 1 diabetic patients who experience severe hypoglycemia unawareness to two other (control) groups: Type 1 diabetic patients without hypoglycemia unawareness and patients who are not diabetic at all. The control groups will only have 3 visits. We plan to study glucose production and symptom generation during insulin-induced hypoglycemia (metabolic testing) by subjecting each group to a pair of metabolic clamps (hypoglycemic and euglycemic) at baseline. This group of Hypoglycemia unaware diabetics will have an additional two sets of clamps at 6 months and 18 months after wearing the RT-CGM to determine if hypoglycemia avoidance can reverse unawareness.
3160845|NCT01474876||Ankylosing Spondylitis|Participants with a diagnosis of ankylosing spondylitis
3160846|NCT01474876||Psoriatic Arthritis|Participants with a diagnosis of psoriatic arthritis
3160847|NCT01474863|Active Comparator|Low Dose Citrulline|Low Dose Citrulline
3160848|NCT01474863|Placebo Comparator|Placebo|Placebo IV infusion
3160849|NCT01474863|Active Comparator|High Dose Citrulline|High Dose Citrulline
3160850|NCT01474850|Active Comparator|open lung|The lung recruitment maneuver (RM) immediately after intubation using pressure controlled ventilation, increase in peak inspiratory pressure up to 30 cm H2O during tidal ventilation, respiratory rate 4/min and positive end expiratory pressure (PEEP) 15 cm H20. PEEP 7 cm H2O until extubation. Inspiratory oxygen concentration (FiO2) 40% during recovery from anesthesia.
3160851|NCT01474850|No Intervention|control|No recruitment maneuver is performed. PEEP 0 cm H2O. Inspiratory oxygen concentration (FiO2) 100 % during recovery from anesthesia.
3160852|NCT01474837|Experimental|Exercise with motivational interviewing|Young people with depression exposed to exercise with motivational interviewing
3160853|NCT01474837|No Intervention|Treatment as usual|Young people with depression receiving treatment as usual
3160854|NCT01474798|Experimental|RA-18C3|
3160855|NCT01474785|Experimental|RYGB|Roux-en-Y gastric bypass surgery (RYGB) subjects to undergo hyperinsulinemic-euglycemic clamp with human ghrelin infusion pre-operatively and post-operatively.
3160856|NCT01474785|Experimental|VSG|Vertical sleeve gastrectomy (VSG) subjects to undergo hyperinsulinemic-euglycemic clamp pre-operatively and post-operatively.
3160857|NCT01474785|Experimental|Low Calorie Diet|Subjects will receive very low calorie diet prescribed for RYGB patients and undergo hyperinsulinemic-euglycemic before and after diet.
3160858|NCT01474772|Experimental|Pregabain|
3160859|NCT01474772|Placebo Comparator|Placebo|
3160860|NCT01474759|Experimental|Portion size instruction|Advice on diet, physical activity, and behavior change. Instruction in food portion size.
3160861|NCT01474759|Experimental|Pre-portioned foods|Advice on diet, physical activity, and behavior change. Provision of pre-portioned foods.
3160862|NCT01474759|Active Comparator|Comparison|Advice on diet, physical activity, and behavior change. Advice on healthy eating for weight loss.
3160863|NCT01474746|Placebo Comparator|Placebo|This arm will undergo identical treatment and assessments as the experimental group, with the exception of the active agent, sertraline. This group will be placed on a placebo.
3160864|NCT01474746|Experimental|Active|This arm will undergo identical treatment and assessments as the placebo group. This group will receive the active agent, sertraline.
3160865|NCT01474733|Experimental|educational intervention|participants undergo a series of educational interventions over 3 years
3160866|NCT01474720|Experimental|SLE patients|Subjects with mild SLE over age 50 years will receive open-label Zostavax vaccine.
3160867|NCT01474720|Active Comparator|Healthy subjects|Healthy subjects aged 50 years and older without any history of autoimmune disease will receive zostavax vaccine. Immune responses to varicella zoster virus and adverse events will be compared to those seen in SLE patients
3160868|NCT01474707|Experimental|Group one|Group1 will view the knowledge-based video only
3160869|NCT01474707|Experimental|Group two|Group two will view the motivational video only
3160870|NCT01474707|Experimental|Group three|Group three will view both knowledge-based and motivational videos
3160871|NCT01474707|Experimental|Group four|Group four will view the printed educational pamphlet and will not view either video
3160872|NCT01474681|Experimental|HSC835|HSC835 infusion
3160873|NCT01474668|Experimental|A|Experimental
3160874|NCT01474642|Active Comparator|Capecitabine/Cisplatin(XP)|Capecitabine AND Cisplatin
3160875|NCT01474642|Active Comparator|Capecitabine/Paditaxel(XG)|Capecitabine + Paditaxel(genexol)
3160876|NCT01474629|Active Comparator|probiotic-based dietary supplement|
3160877|NCT01474629|Placebo Comparator|placebo|
3160878|NCT01474616|Other|Sit-to-Stand Activity|
3160879|NCT01474603||1|overweight or obese diabetic
3160880|NCT01474590|Experimental|Epiduo/Tactuo + doxycycline 200mg|
3160881|NCT01474590|Active Comparator|Isotretinoin + vehicle gel|
3160882|NCT01474577||pts who have had Rb-82 PET myocardial perfusion imaging|Eligible patients will have had Rb-82 PET myocardial perfusion imaging at MSKCC, 2008 - 2011. Patients will complete one questionnaire over the phone.
3160883|NCT01474564||Pts with Pancreatic Adenocarcinoma|This is an observational study to assess the feasibility of 1) isolating and enriching circulating tumorigenic cells from the peripheral blood of eligible pancreatic cancer patients and 2) successful gene expression profiling of these circulating tumorigenic cells.
3160884|NCT01474551|Experimental|vemurafenib|This is a single institution phase II trial in stage III or IV melanoma patients with poor ECOG performance status (3 or 4). Patients must have melanoma with a BRAFV600E or BRAFV600K or mutation with measurable disease not curable by surgery.
3160925|NCT01474291||Tocilizumab|Tocilizumab administered as monotherapy or in combination with other standard of care therapy according to prescribing information and normal clinical practice.
3160926|NCT01474278|Experimental|1|
3160885|NCT01474538|Active Comparator|Insulin Lispro, then Insulin Aspart|Insulin lispro [100 units/milliliter (U/mL)] administered by continuous subcutaneous insulin infusion (CSII) pump for 16 weeks in Treatment Period 1, followed by insulin aspart (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 2.
3160886|NCT01474538|Active Comparator|Insulin Aspart, then Insulin Lispro|Insulin aspart (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 1, followed by insulin lispro (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 2.
3160887|NCT01474525|Experimental|Telemonitoring|
3160888|NCT01474525|Active Comparator|Usual Care|
3160889|NCT01474512|Experimental|80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W)|Administered as two 80-mg subcutaneous (SC) injections at Week 0, then one 80-mg SC injection per Dosing Regimen 1 [every 2 weeks (Q2W)] up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 [every 4 weeks (Q4W)] or Dosing Regimen 3 [every 12 weeks Q12W)].
3160890|NCT01474512|Experimental|80 mg Ixekizumab Dosing Regimen 2 (Q4W)|Administered as two 80-mg SC injections at Week 0, then one 80-mg SC injection per Dosing Regimen 2 (Q4W) up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 (Q4W) or Dosing Regimen 3 (Q12W).
3160891|NCT01474512|Experimental|80 mg Ixekizumab Dosing Regimen 3 (Q12W)|Dosing Regimen 3 (Q12W) is not used until Week 12. At Week 12, participants who were re-randomized to this arm were administered one 80-mg SC injection Q12W.
3160892|NCT01474512|Placebo Comparator|Placebo|Administered as 2 SC injections at Week 0, then 1 SC injection per Dosing Regimen 1 (Q2W) up to and including Week 10. At Week 12, arm is re-randomized to placebo or Dosing Regimen 2 (Q4W).
3160893|NCT01474499|Experimental|Docusate sodium and sorbitol rectal solution|
3160894|NCT01474499|Active Comparator|Glycerine|
3160895|NCT01474486|Experimental|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
3160896|NCT01474473|Experimental|CACIPLIQ20 and Cast Boot|This arm receives treatment by CACIPLIQ20 application every 3 to 4 days and the wounded leg is held with a nonremovable, windowed, fiberglass Cast Boot.
3160897|NCT01474473|Placebo Comparator|Placebo and Cast Boot|This arm receives a placebo (saline solution) every 3 to 4 days and the wounded leg is held with a nonremovable, windowed, fiberglass Cast Boot.
3160898|NCT01474460|Placebo Comparator|Control group|The control group only receiving warfarin therapy (individualized therapy, hence no specific form, dosage, frequency and duration is applicable here - i.e. 5mg daily everyday for 6 months may be applicable to one patient but not all researched patients).
3160899|NCT01474460|Experimental|Phytonadione|Patients receiving 200mcg of phytonadione.
3160900|NCT01474447|Experimental|Grinberg Method|
3160901|NCT01474434|Experimental|Pradigastat (LCQ908) followed by placebo|Pradigastat 80 mg (4 x 20-mg tablets) loading dose daily for three days followed by pradigastat 20 mg (2 x 10-mg tablets) daily for two days followed by a 30-day washout period in between followed by 5-day placebo treatment
3160902|NCT01474434|Experimental|Placebo followed by pradigastat (LCQ908)|Placebo (5-day treatment period) followed by a 30-day washout period followed by pradigastat 80 mg (4 x 20-mg tablets) loading dose daily for three days followed by p20 mg (2 x 10-mg tablets) daily for two days
3160903|NCT01474421|Experimental|AQW051 High Dose|AQW051 high dose daily given orally for 28 days.
3160904|NCT01474421|Experimental|AQW051 Low Dose|AQW051 low dose daily given orally for 28 days.
3160905|NCT01474421|Placebo Comparator|Placebo|Placebo daily given orally for 28 days.
3160906|NCT01474408|Experimental|interval training|4 x 4 minutes exercise at 90 - 95 % of peak heart rate separated with 3 minutes at 70 % of peaks heart rate
3160907|NCT01474408|Active Comparator|moderate exercise|moderate continuous exercise at 70 % of peak heart rate on venous function.
3160908|NCT01474408|Other|control|routine measurements, no exercise
3160909|NCT01474395|Experimental|D-serine 60 mg/kg|double blind dose of d-serine
3160910|NCT01474395|Placebo Comparator|Placebo D-serine|
3160911|NCT01474382|Experimental|OraVerse|OraVerse in doses of either 1/4, 1/2 or 1 cartridge (1.8mL)
3160912|NCT01474382|Sham Comparator|Sham injection|Dentist simulates injection with dental syringe
3160913|NCT01474369|Experimental|TAK-438 10 mg QD|
3160914|NCT01474369|Experimental|TAK-438 20 mg QD|
3160915|NCT01474369|Placebo Comparator|Placebo QD|
3160916|NCT01474356|No Intervention|BT (brachytherapy)|Cervical cancer patients after the treatment with external beam radiotherapy combined with chemotherapy. In this group of patients, interstitial brachytherapy only was performed.
3160917|NCT01474356|Experimental|BTHT (brachytherapy and hyperthermia)|Cervical cancer patients after the treatment with external beam radiotherapy combined with chemotherapy. In this group of patients, interstitial brachytherapy with interstitial hyperthermia was performed.
3160918|NCT01474343|Experimental|SAF-301|
3160919|NCT01474330|Experimental|0.5-mg Pomalidomide or placebo (Cohort A)|A single 0.5-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions
3160920|NCT01474330|Experimental|1-mg Pomalidomide or placebo (Cohort B)|This arm may be initiated pending a safety review of Cohort A. A single 1-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.
3160921|NCT01474330|Experimental|2-mg Pomalidomide or placebo (Cohort C)|This arm may be initiated pending a safety review of Cohort B. A single 2-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.
3160922|NCT01474317|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use the G3 investigational blood glucose monitoring system.
3160923|NCT01474304|Active Comparator|Acetaminophen|Craniotomy patients will receive a 1000 mg dose of intravenous (IV) acetaminophen before incision and a second 1000 mg dose of IV acetaminophen 6 hours later.
3160924|NCT01474304|No Intervention|No acetaminophen|Patients will receive standard of care with no intraoperative doses of acetaminophen.
3160927|NCT01474278|Placebo Comparator|2|
3160931|NCT01474265|Active Comparator|Nicorette TX optional|
3160932|NCT01474265|No Intervention|control group smokers|
3160933|NCT01474252|Experimental|RSI technique|"Intubation with RSI technique. RSI technique includes the administration of inductive and neuromuscular blocking agents to facilitate an intubation.~In this study, we have no restriction of medication use. Physicians can chose any of medication as an individual judgement."
3160934|NCT01474252|No Intervention|Non-RSI|Intubation without RSI technique. No any medication use during intubation period.
3160935|NCT01474239|Experimental|Calibration Arm|
3160936|NCT01474239|Experimental|Investigational Arm|
3160937|NCT01474226|Experimental|Lysine Amino Acid|
3160938|NCT01474213|Active Comparator|dexmedetomidine|a loading dose (1.5mcg/kg) infused over10 min followed by a continuous infusion of 0.7 μg/kg/h
3160939|NCT01474213|Active Comparator|remifentanil|The initial target was 3.0 ng/ml and the TCI was adjusted by 0.5 ng/ml after the target concentration at the effect site had equilibrated with the plasma concentration, until the desired level of sedation was acheived.
3160940|NCT01474200|Experimental|Aquapheresis (AQ) - isolated veno-venous ultrafiltration|Excess fluid from the patient is removed by isolated veno-venous ultrafiltration treatment using the Aquadex Flex Flow System
3160941|NCT01474200|Active Comparator|IV Loop Diuretics (LD)|Excess fluid from the patient is removed by IV (Intravenous) loop diuretic treatment
3160942|NCT01474187|Experimental|Irinotecan|irinotecan dose initial from 50mg/m2/week, increased by 15mg/mg/week
3160943|NCT01474174||Supportive care (vaccine therapy)|Patients receive trivalent influenza vaccine IM on day 0.
3160944|NCT01474161|Placebo Comparator|Matching placebo|
3160945|NCT01474161|Active Comparator|GFT505 20mg - old formulation|Study Part I : dose level = 120mg
3160946|NCT01474161|Experimental|GFT505 60mg - new formulation|Study Part I : dose level = 120mg ; Study Part II : dose level = 180mg, 240mg and 300mg ; Study Part III : dose level = 120mg, 180mg and 240mg ; Study Part IV : dose level = 120mg or 180mg.
3160947|NCT01474148|Experimental|Neuroprosthesis|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.
3160948|NCT01474135|Experimental|0.25% AR-12286/ 0.004% travoprost|Fixed dose combination of 0.25% AR-12286 and 0.004% travoprost
3160949|NCT01474135|Experimental|0.5% AR-12286/ 0.004% travoprost|Fixed dose combination of 0.5% AR-12286/ 0.004% travoprost
3160950|NCT01474135|Active Comparator|0.004%Travoprost|Travatan(R) Z(travoprost ophthalmic solution)
3160951|NCT01474122|Active Comparator|Macitentan 3 mg|Oral macitentan 3 mg, once daily
3160952|NCT01474122|Active Comparator|Macitentan 10 mg|Oral macitentan 10 mg, once daily
3160953|NCT01474122|Placebo Comparator|Placebo|Oral placebo, once daily
3160954|NCT01474109|Active Comparator|macitentan 3mg|macitentan 3mg tablet once daily
3160955|NCT01474109|Active Comparator|macitentan 10mg|macitentan 10mg tablet once daily
3160956|NCT01474109|Placebo Comparator|placebo|matching placebo once daily
3160957|NCT01474096|Experimental|implementation strategy|determining whether the use of implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding CPG in primary care is more effective than the usual practice of mere circulation.
3160958|NCT01474096|No Intervention|Conventional intervention|
3160959|NCT01474083|Experimental|GK1-399, low dose|
3160960|NCT01474083|Experimental|GK1-399, high dose, once per day|
3160961|NCT01474083|Experimental|GK1-399, high dose, twice per day|
3160962|NCT01474083|Placebo Comparator|Placebo|
3160963|NCT01474057|Experimental|DESTRESS-PC|A brief, nurse-assisted, Internet-based online self-management tool for PTSD (DESTRESS-PC), based on empirically valid cognitive-behavioral therapy (CBT) strategies and designed for implementation in a primary care setting. DESTRESS-PC stands for DElivery of Self-TRaining and Education for Stressful Situations for Primary Care.
3160964|NCT01474057|Active Comparator|OUC|Optimized Usual Care (OUC) for PTSD--usual PTSD treatment offered within the primary care setting, optimized by training PC providers in PTSD identification and treatment and providing basic care management including phone check-ins to monitor symptoms and feedback to providers.
3160965|NCT01474044|Placebo Comparator|Placebo|
3160966|NCT01474044|Active Comparator|Gastropyloric Complex Capsules|
3160967|NCT01474031||20 DAA subjects|20 DAA subjects: THA with a Deltamotion articulating surface utilizing the Direct Anterior Approach
3160968|NCT01474031||20 controls|20 healthy controls
3160969|NCT01474018|No Intervention|Metformin + Insulin|5 patients to continue on usual type 2 diabetic treatment consisting of 70/30 insulin, metformin and exercise and nutrition counseling.
3160970|NCT01474018|Experimental|QR-Bromocriptine +metformin+insulin|study drug add-on the usual therapy
3160971|NCT01473992|Active Comparator|Prosthetic knee 1 (Otto Bock C-Leg)|This arm included unilateral transfemoral amputees who were assessed while using their preferred knee at study start(C-Leg). The Otto Bock C-Leg is a microprocessor knee using 2 sensors (1 for kinetics and 1 for kinematics).
3160972|NCT01473992|Active Comparator|Prosthetic knee 2 (Otto Bock Genium)|This arm included unilateral transfemoral amputees who were assessed while using the experimental/study knee, the Genium. The Otto Bock Genium is a microprocessor knee using multiple sensors that hypothetically increase mobility functions (e.g. walking backwards, intuitive stance)
3160973|NCT01473992|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
3160974|NCT01473979|Active Comparator|Arm A) Secondary closure with the vacuum-assisted system (VAC|"after the diagnosis of the poststernotomy wound infection is established the clinical procedure is obtained as follows: firstly the empiric antibiotic therapy with vancomycin is induced. The lab samples including bacteriology test are obtained. Surgical debridement is made until occurrence of tissue bleeding. Finally VAC sponge is implanted wit the negative suction pressure of 75 mmHg.~The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 48/72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done."
3161228|NCT01472302|Experimental|ASV|Adaptive Support Ventilation
3160975|NCT01473979|Active Comparator|Arm B) Surgical procedure by delayed primary closure|In the first step, after the diagnosis of the infection was done, and the empiric antibiotic therapy is induced with vancomycin in the first surgical intervention the sternal wires will be removed, the mediastinum is explored and extensive surgical debridement is performed until occurrence of tissue bleeding.The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed.
3160976|NCT01473966|No Intervention|standard of care|patients receive standard care
3160977|NCT01473966|Experimental|Coffee orally|patients will receive standard of care plus coffee orally
3160978|NCT01473966|Experimental|coffee rectally|patients receive standard of care plus coffee rectally
3160979|NCT01473953|Experimental|Cohort 1a: Lira-depot 2.25 mg|
3160980|NCT01473953|Experimental|Cohort 2a: Lira-depot 6.75 mg|
3160981|NCT01473953|Experimental|Cohort 3a: Lira-depot 15 mg|
3160982|NCT01473953|Experimental|Cohort 4a: Lira-depot 30 mg|
3160983|NCT01473953|Placebo Comparator|Placebo|
3160984|NCT01473940|Experimental|Treatment (monoclonal antibody, chemotherapy)|"INDUCTION: Patients receive ipilimumab IV over 90 minutes in weeks 1, 4, 7, and 10 and gemcitabine hydrochloride IV over 30 minutes in weeks 1-7 and 9-11.~MAINTENANCE: Beginning in week 22, patients receive ipilimumab IV over 90 minutes once every 12 weeks and gemcitabine hydrochloride IV over 30 minutes once weekly for 3 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Treatment modifications may apply according to response."
3160985|NCT01473927||1|Crohn's Disease patients
3160986|NCT01473927||2|Ulcerative colitis patients
3160987|NCT01473914|Experimental|Low dose|"Standard renal vitamin plus low dose zinc and selenium plus vitamin E~1 capsule p.o, daily"
3160988|NCT01473914|Experimental|Medium dose|"Standard renal vitamin plus medium doses of zinc and selenium plus vitamin E~1 capsule p.o, daily"
3160989|NCT01473914|Active Comparator|Standard treatment|"Standard renal vitamin~1 capsule p.o, daily"
3160990|NCT01473901|Experimental|BKM120 + Temozolomide (Concomitant Phase)|Cranial radiation: Days 1 - 5 every 7 days for 42 days60 Gy in 30 fractions; Temozolomide: 75 mg/m2 Daily, orally; BKM120: 0, or 40, or 60, or 80 mg/d Daily, orally or Days 1-5 every 7 days, orally
3160991|NCT01473901|Experimental|BKM120 + temozolomide with/without radiotherapy|"Adjuvant phase cycle 1:~Temozolomide ﻿150 mg/m2 - Days 1 - 5 every 28 days Daily; BKM120 60, or 80, or 100 mg/d;~Adjuvant phase cycle 2+:~Temozolomide 200* mg/m2 - Day 1 ~ 5 every 28 days Daily BKM120 0, or 40, or 60, or 80 or 100 mg/d"
3160992|NCT01473888|Other|T89|
3160993|NCT01473875|Experimental|SBC-102|SBC-102 Weekly IV infusions of SBC-102
3160994|NCT01473836|Experimental|Metronidazole|Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) in combination with ceftriaxone sodium
3160995|NCT01473823|Placebo Comparator|Placebo oil|Canola oil with high oleic acid content flavored with lemon supplied as 5 ml daily.
3160996|NCT01473823|Active Comparator|Omega-3 LCPUFA|"The omega-3 LCPUFA supplementation comprises of 5 ml daily of Möller's Tran flavored with lemon. This dose provides the child with 1200 mg of omega-3 fatty acid of which 600 mg is DHA and 400 mg is EPA."
3160997|NCT01473810|Experimental|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
3160998|NCT01473810|Experimental|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
3160999|NCT01473810|Experimental|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
3161000|NCT01473810|Placebo Comparator|Zero dose|Adjuvant only, i.e. 300 µl Endocine divided into two administrations, one for each nose cavity
3161001|NCT01473797|Experimental|cladribine|
3161002|NCT01473784|Experimental|Transoral robotic surgery (TORS)|Patients will undergo TORS for oral and laryngopharyngeal benign and malignant lesions using the Da Vinci Robotic Surgical System. After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
3161003|NCT01473771|Experimental|Caring Letter Condition (CL)|"In the Caring Letters (CL) group, participants will be emailed letters for two years on a planned schedule. The emailed letters are simple expressions of care and include standard contact information for available health care services."
3161004|NCT01473771|No Intervention|Usual Care (UC)|The participants in the Usual Care (UC) group will not receive the emails.
3161005|NCT01473758|Active Comparator|Roflumilast|added on to standard therapy for acute COPD exacerbations
3161006|NCT01473758|Placebo Comparator|Placebo|added on to standard therapy for acute COPD exacerbations
3161007|NCT01473745|Active Comparator|modified alar base cinch suture|Before closure of the maxillary wound, an alar base cinch suture was performed with 3-O Nylon. The modified alar cinch suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
3161008|NCT01473745|Placebo Comparator|conventional alar base cinch suture|Before closure of the maxillary wound, an alar base cinch suture was performed with 3-O Nylon. The conventional alar base cinch suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
3161009|NCT01473732|Experimental|Everolimus (Zortress)+ Mycophenolic acid(Myfortic)|
3161010|NCT01473732|Active Comparator|Reduced dose Prograf+ Mycophenolic acid(Myfortic)|
3161011|NCT01473719|Active Comparator|motivational intervention|7-session individual motivationally-based intervention
3161012|NCT01473719|Placebo Comparator|health education|7-session individual session focusing on health education
3161013|NCT01473706||Consumers|Adults aged ≥ 65 years; Employed part-time, unemployed, retired, full-time or a homemaker; English speaking
3161014|NCT01473706||Caregivers of Consumers|Family, relative, friend, professional caregiver of an individual age ≥ 65 years; Lives with individual aged ≥ 65 years OR Visits individual aged ≥ 65 years five or more days a week; Makes decisions or has strong influence on the individual aged ≥ 65 years' diet and medical needs; English speaking
3161015|NCT01473693||surgery-only group|This will be a prospective study to investigate chemotherapy related structural brain changes in individuals undergoing anatomic lung resection for non-small cell carcinoma with and without, induction systemic chemotherapy treatment.
3161016|NCT01473693||induction chemotherapy group|This will be a prospective study to investigate chemotherapy related structural brain changes in individuals undergoing anatomic lung resection for non-small cell carcinoma with and without induction systemic chemotherapy treatment.
3161017|NCT01473680||Patients who will receive chemo|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
3161018|NCT01473680||Patients who will not receive chemo|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
3161019|NCT01473680||Healthy Controls|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
3161020|NCT01473667|Active Comparator|Superficial Cervical Plexus Block|
3161021|NCT01473667|Active Comparator|Local Infiltration|
3161022|NCT01473654|Experimental|ADAPT tool|prediabetes counseling using ADAPT tool
3161023|NCT01473654|No Intervention|Control|
3161024|NCT01473641||New users of Nexplanon|
3161025|NCT01473628|Experimental|Rituximab + Radiation|Rituximab 375 mg/m^2 weekly for 4 weeks during radiation then every 3 months for 2 years (maintenance). Radiation therapy total dose of 24 to 30 Gy over 12 to 15 treatments.
3161026|NCT01473628|Experimental|Radiation + Observation|Radiation therapy total dose of 24 to 30 Gy over 12 to 15 treatments.
3161027|NCT01473615|Experimental|Treatment As Usual + Mindfulness Based Cognitive Therapy|Subjects randomized into the intervention group will receive, a manualized 8-week MBCT group skills program with sessions that each last 2 hours, in addition to their treatment as usual (TAU).
3161028|NCT01473615|No Intervention|Treatment As Usual|Patients randomized into the TAU group will continue to receive their care as usual and be put on a waitlist. They will be offered the MBCT treatment after the completion of the study.
3161029|NCT01473602|Placebo Comparator|Placebo|Administered once daily by subcutaneous (SC) injection for 6 months
3161030|NCT01473602|Experimental|Teriparatide|20 microgram (µg) administered once daily by SC injection for 6 months
3161031|NCT01473589|Placebo Comparator|Placebo|Administered once daily by subcutaneous (SC) injection for 6 months
3161032|NCT01473589|Experimental|Teriparatide|20 microgram (µg) administered once daily by SC injection for 6 months
3161033|NCT01473576|Experimental|Nitrate|Sodium nitrate ingestion prior to ingesting intrinsically labeled protein
3161034|NCT01473576|Placebo Comparator|Sodium chloride|Sodium chloride placebo group
3161035|NCT01473563|Experimental|Pemetrexed|500 milligrams per square meter (mg/m^2) pemetrexed administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle. Maintenance therapy administered until disease progression or the participant is discontinued for any other reason. The first dose of maintenance therapy will be administered at the hospital; thereafter, therapy will be administered in the home setting by qualified oncology homecare nurses.
3161036|NCT01473550|Experimental|Early Intervention|At Phase 1 (first 3 months of project), the 200 participants in Group 1 will be provided with a Personal Health Record (PHR) through TELUS Health Space, as well as they will be introduced to smart phone technology to ready them for deployment of the prompts and reminders. Two months later, they will be provided with a smart phone.
3161037|NCT01473550|Experimental|Later Intervention|A delayed implementation plan will be used (but will have no effect on the standard of care for the remaining 200 participants), so the remaining 200 participants in Group 2 will initially act as a control group, but at Phase 2 (six months later - approximately June 2012) the remaining 200 participants will be introduced to the technology in the same order (PHR -> Smart Phone). Group 2 will have the benefit of any enhancements made during Phase 1 of the project.
3161038|NCT01473537|Active Comparator|calcium lactate solution 75 mM|
3161039|NCT01473537|Active Comparator|calcium lactate solution 150 mM|
3161040|NCT01473537|Placebo Comparator|placebo|
3161041|NCT01473524|Experimental|OCA 5-10 mg|"OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.~After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated."
3161042|NCT01473524|Experimental|OCA 10 mg|OCA 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.
3161043|NCT01473524|Placebo Comparator|Placebo|One tablet daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.
3161044|NCT01473511|Experimental|Strongest Families Program + Usual care|50% randomized to receive Strongest Families intervention immediately as well as the usual care services available via the referring agency for the 22 month study period.
3161045|NCT01473511|No Intervention|Usual care|50% randomized will not receive Strongest Families Intervention during the 22 month study phase, but will receive the usual care services available via the referring agency. At the end of the 22 month study period study participants will be offered the Strongest Families Intervention services.
3161046|NCT01473498|Experimental|Test group|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients (A maximum dose of 1.2 mcg / kg / min is not exceeded). Key details, e.g., for drugs include dosage form, dosage, frequency and duration."
3161229|NCT01472302|Active Comparator|PCV|Pressure Controlled Ventilation
3161047|NCT01473498|Active Comparator|Control group|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg."
3161048|NCT01473485|Experimental|ExAblate Transcranial Device|
3161049|NCT01473472|Active Comparator|Truvada|associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)
3161050|NCT01473472|Placebo Comparator|Placebo of Truvada|associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)
3161051|NCT01473459|Active Comparator|IVM Treatment|
3161052|NCT01473459|Active Comparator|Antagonist Protocol|
3161053|NCT01473446|No Intervention|Control|Standard monitoring. Initial optimization of fluid status is performed by pulse, BP and anaesthesiologist assessment with Ringer acetate. Followed by an infusion of 10ml/kg/t Ringer acetate. Urinary output and blood pressure is used as a surrogate parameter: the infusion rate is increased by a fall in blood pressure or urine output <0.5ml/kg/t. Bleeding replaced with HES 1:1, otherwise see table for fluid therapy page 9. Vasoactive agents (noradrenaline / phenylephrine) is given if the anesthesiologist considers this necessary. Postoperative give 1000ml Glucose 5%. HES or Ringer when low blood pressure, eventually noradrenaline as vasoactive agent.
3161054|NCT01473446|Experimental|Goal directed fluid therapy|
3161055|NCT01473433|Other|Control|Patients in which the non-revascularizable area will be left untouched and the revascularizable area will be treated normally.
3161056|NCT01473433|Experimental|adiFLAP|Patients in which the non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure.
3161057|NCT01473420|Experimental|Epoetin Hospira|Epoetin Hospira
3161058|NCT01473420|Active Comparator|Epogen (Amgen)|Epogen (Amgen)
3161059|NCT01473407|Experimental|Epoetin Hospira|Epoetin Hospira
3161060|NCT01473407|Active Comparator|Epogen (Amgen)|Epogen (Amgen)
3161061|NCT01473394|Placebo Comparator|Dose-matched placebo|Participants received dose-matched placebo orally once daily for 9 weeks.
3161062|NCT01473394|Experimental|Vilazodone|Participants received vilazodone orally once daily for 9 weeks, as follows: Week 1, 10 mg once a day; Week 2, 20 mg once a day; Weeks 3 to 8, 40 mg once a day; and Week 9 (down-taper period), 20 mg once a day for 4 days, then 10 mg once a day for 3 days.
3161063|NCT01473381|Placebo Comparator|Placebo|Participants received 2 placebo to vilazodone tablets, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study.
3161064|NCT01473381|Experimental|Vilazodone 20 mg/day|Participants received 1 vilazodone tablet, 1 placebo to vilazodone tablet, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20 mg/day during Weeks 2 to 10, and vilazodone 10 mg/day during Week 11.
3161065|NCT01473381|Experimental|Vilazodone 40 mg/day|Participants received 1 placebo to vilazodone tablet, 1 vilazodone tablet, and 1 placebo to citalopram capsule orally once daily during Weeks 1 and 2 of the study. Participants received 2 vilazodone tablets and 1 placebo to citalopram capsule orally once daily during Weeks 3 -10 of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20/day mg during Week 2, and vilazodone 40 mg/day during Weeks 3 to 10. During Week 11, participants received vilazodone 20 mg/day for 4 days and 10 mg/day for 3 days.
3161066|NCT01473381|Active Comparator|Citalopram 40 mg/day|Participants received 2 placebo vilazodone tablets, and 1 citalopram capsule once daily for the 11 weeks of the study. Participants received citalopram 20 mg/day during Weeks 1 and 2, citalopram 40 mg/day during Weeks 3 to 10, and citalopram 20 mg/day during Week 11.
3161067|NCT01473368|Active Comparator|prebiotic (Saccharomyces boulardii)|500 mg, 2 times daily for 14 days
3161068|NCT01473368|Active Comparator|antibiotic (Amoxicillin Clavulanate)|875/125 mg 2 times daily at least 1 hour before meals for 7 days
3161069|NCT01473368|Active Comparator|combination (prebiotic and antibiotic)|Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).
3161070|NCT01473368|No Intervention|control|
3161071|NCT01473355|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
3161072|NCT01473342|Other|Control & Intervention Phases|The control phase will run for 8 weeks, including survey completion and accelerometer wear during Week 1 and Week 8. The intervention phase will run for the 9 weeks following the control phase; where participants are assigned a smartphone to interact with the Mila Blooms gaming app and integrated social network & receive weekly supportive coaching phone calls from study staff for 8 weeks (Week 9 - Week 16) followed by accelerometer wear & survey completion during the 9th and final week (Week 17).
3161073|NCT01473329|Experimental|Structured Diabetes education|The intervention group received a structured DSME course. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
3161074|NCT01473316|Experimental|A|
3161075|NCT01473303|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 48 hours beginning on day 2 (mFOLFIRINOX) and ganitumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
3161076|NCT01473303|Experimental|Arm II|Patients receive mFOLFIRINOX as in arm I and placebo IV over 30-60 minutes on day 1.
3161077|NCT01473290|Experimental|Arm I|Patients receive live freeze-dried lactic acid bacteria probiotic (VSL#3®) orally (PO) 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
3161078|NCT01473290|Placebo Comparator|Arm II|Patients receive placebo PO 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
3161079|NCT01473277|Active Comparator|BT-A (Dysport 500U)|
3161080|NCT01473277|Active Comparator|Triamcinolone acetonide|
3161081|NCT01473264|Placebo Comparator|Control|
3161082|NCT01473264|Experimental|High dose rhCC10|5 mg/kg study drug (rhCC10)
3161083|NCT01473264|Experimental|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)
3161084|NCT01473251|Active Comparator|Avastin for Diabetic Macular Edema|1.25 mg avastin monthly for 4 months
3161085|NCT01473251|Active Comparator|Avastin for Exudative Macular Degeneration|1.25 mg Avastin monthly for 4 months
3161086|NCT01473251|Active Comparator|Lucentis for Exudative Macular Degeneration|0.5 mg Lucentis monthly for 4 months
3161087|NCT01473238|Active Comparator|Desktop PC|Conventional institutional Desktop Personal Computers will be used to collect data of patients via a password protected encrypted interface.
3161088|NCT01473238|Experimental|Mobile|Novel Mobile Clinical Trial Management System on iPads will be used to collect data of patients via a password protected encrypted interface.
3161089|NCT01473225|Experimental|Calorie label|
3161090|NCT01473225|Active Comparator|No calorie label|
3161091|NCT01473199|Experimental|BioPoly RS Implant|
3161092|NCT01473173|Experimental|CJ-12420 50mg|"Single dose~8 volunteers will be administered CJ-12420 50mg or placebo comparators.(CJ-12420:placebo=6:2)"
3161093|NCT01473173|Experimental|CJ-12420 100mg|"Single dose~8 volunteers will be administered CJ-12420 100mg or placebo comparators.(CJ-12420:placebo=6:2)"
3161094|NCT01473173|Experimental|CJ-12420 200mg|"Single dose~8 volunteers will be administered CJ-12420 200mg or placebo comparators.(CJ-12420:placebo=6:2)"
3161095|NCT01473173|Experimental|CJ-12420 400mg|"Single dose~8 volunteers will be administered CJ-12420 400mg or placebo comparators.(CJ-12420:placebo=6:2)"
3161096|NCT01473173|Experimental|CJ-12420 100mg (repeated dose)|"Repeat doses~100mg is the anticipated dose~8 volunteers will be administered CJ-12420 100mg or placebo comparator.(CJ-12420:placebo=6:2)"
3161097|NCT01473173|Experimental|CJ-12420 200mg (repeated dose)|"Repeat doses~200mg is the anticipated dose~8 volunteers will be administered CJ-12420 200mg or placebo comparator.(CJ-12420:placebo=6:2)"
3161098|NCT01473173|Active Comparator|Esomeprazole 40mg|8 volunteers will be administered Esomeprazole 40mg
3161099|NCT01473160|Experimental|delefilcon A|Delefilcon A randomly assigned to one eye, with narafilcon A assigned to the fellow eye for contralateral wear. Both products will be worn for one day for 16 hours (+/- 1 hour).
3161100|NCT01473160|Active Comparator|narafilcon A|Narafilcon A randomly assigned to one eye, with delefilcon A assigned to the fellow eye for contralateral wear. Both products will be worn for one day for 16 hours (+/- 1 hour).
3161101|NCT01473147|Active Comparator|GLP-1|
3161102|NCT01473147|Placebo Comparator|Normal saline|
3161103|NCT01473121||Group 1|
3161104|NCT01473108|Experimental|Finerenone (20 mg solution)|3-fold crossover of single dose 20 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
3161105|NCT01473108|Experimental|Finerenone (10 mg solution)|3-fold crossover of single dose 10 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
3161106|NCT01473108|Experimental|Finerenone (5 mg solution)|3-fold crossover of single dose 5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
3161107|NCT01473108|Experimental|Finerenone (20 mg as tablets)|3-fold crossover of single dose 20 mg BAY 94-8862 as 2 x 10 mg tablet, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
3161108|NCT01473108|Experimental|Finerenone (2.5 mg solution)|3-fold crossover of single dose 2.5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
3161109|NCT01473082|Active Comparator|PFNA|Proximal Femoral Nail Antirotation (PFNA Synthes)
3161110|NCT01473082|Active Comparator|PFNA Augmentation|Proximal Femoral Nail Antirotation PFNA Augmentation (Synthes) with Traumacem V+ Synthes
3161111|NCT01473069|Experimental|Dose 1 JTK-853, 400 mg ketoconazole|
3161112|NCT01473069|Experimental|Dose 2 JTK-853|
3161113|NCT01473069|Experimental|Dose 3 JTK-853|
3161114|NCT01473069|Experimental|Dose 4 JTK-853|
3161115|NCT01473069|Placebo Comparator|Placebo|
3161116|NCT01473056|Experimental|Dose 1 JTK-853|
3161117|NCT01473056|Experimental|Dose 2 JTK-853|
3161118|NCT01473056|Experimental|Dose 3 JTK-853|
3161119|NCT01473056|Experimental|Dose 4 JTK-853|
3161120|NCT01473056|Placebo Comparator|Placebo|
3161121|NCT01473030||Dutasteride|No PCa at Year 2 or Year 4
3161122|NCT01473030||Placebo|No PCa at Year 2 or Year 4
3161123|NCT01473017|Experimental|CBT-based guided self-help|Providing a guided self-help booklet to patients with anxiety/depression meeting criteria, with two telephone calls by a clinician to provide support with this.
3161124|NCT01473017|No Intervention|No CBT intervention|Control group in comparison to CBT guided self-help group
3161125|NCT01473004|Experimental|Sirspheres, response evaluation|Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
3161126|NCT01472991|Experimental|TC-5619-238 (25mg)|TC-5619-238 25 mg will be provided as hard gelatin capsules
3161127|NCT01472991|Placebo Comparator|Placebo|Placebo will be provided as hard gelatin capsules similar to TC-5619-238
3161128|NCT01472991|Experimental|TC-5619-238 (5 mg)|TC-5619-238 5 mg will be provided as hard gelatin capsules.
3161129|NCT01472978|Active Comparator|Immediate antibiotic treatment|Patients will be treated with an antibiotic as soon as the aspirate obtained at the colonoscopy is found to be positive for C. diff.
3161130|NCT01472978|Sham Comparator|Delayed treatment with an antibiotic|Treatment will be started after a delay after the aspirate obtained at the colonoscopy is found to be C. diff positive.
3161131|NCT01472965|Active Comparator|Treatment|Eligible patients with CLABSI will be enrolled within 96 hours of collection of positive blood culture and randomized to blinded treatment with 70% ethanol catheter lock therapy.
3161132|NCT01472965|Placebo Comparator|Control|Eligible patients with CLABSI will be enrolled within 96 hours of collection of positive blood culture and randomized to blinded treatment with heparin-saline placebo catheter lock therapy.
3161133|NCT01472939|Active Comparator|SSP-002358 (0.1 mg) + Proton Pump Inhibitor (PPI)|
3161134|NCT01472939|Active Comparator|SSP-002358 (0.5 mg) + PPI|
3161135|NCT01472939|Active Comparator|SSP-002358 (2.0 mg) + PPI|
3161136|NCT01472939|Placebo Comparator|Placebo + PPI|
3161137|NCT01472926|Experimental|Tenecteplase 0.25 mg/kg|Intravenous tenecteplase 0.25 mg/kg (single bolus, maximum 25 mg)
3161138|NCT01472926|Active Comparator|Alteplase 0.9 mg/kg|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
3161139|NCT01472913|Active Comparator|Fibrin Sealent|
3161140|NCT01472913|Placebo Comparator|Saline water|
3161141|NCT01472900|Experimental|Er:YAG laser|
3161142|NCT01472900|Active Comparator|BP gel|
3161143|NCT01472887|Experimental|SAR3419|All patients will receive SAR3419 until evidence of disease progression, unacceptable toxicity, or other reasons for therapy discontinuation
3161144|NCT01472874|Experimental|Once a day Trientine|Patients receive once a day trientine
3161145|NCT01472861|Placebo Comparator|No AECC|Routine procedures without AECC
3161146|NCT01472861|Experimental|AECC|Endometrial biopsy and Autologous endometrial coculture
3161147|NCT01472848|Experimental|Cohort 1|
3161148|NCT01472848|Experimental|Cohort 2|
3161149|NCT01472848|Experimental|Cohort 3|
3161150|NCT01472848|Experimental|Cohort 4|
3161151|NCT01472848|Experimental|Cohort 5|
3161152|NCT01472848|Active Comparator|Cohort 6|
3161153|NCT01472835|Experimental|Sedation|Pt will receive sedation with their procedure
3161154|NCT01472835|No Intervention|Control|Patient will not receive sedation during procedure
3161155|NCT01472822|Experimental|Omija extract.|
3161156|NCT01472822|Placebo Comparator|Placebo|
3161157|NCT01472809|Placebo Comparator|Placebo|Placebo tablets
3161158|NCT01472809|Experimental|ZYGK1|"ZYGK1 tablets; 0.125, 0.25, 0.5, 1, 2, ... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved"
3161159|NCT01472796|Active Comparator|Tekturna (Aliskirin) with vit. D supplementation|Tekturna (Aliskiren) 300mg daily and vitamin D supplementation (50,000 IU)every other week.
3161160|NCT01472796|Placebo Comparator|Tekturna (Aliskiren) with placebo|Tekturna (Aliskiren) 300mg per day supplemented with placebo (vitamin D)
3161161|NCT01472783|Experimental|Veliparib|
3161162|NCT01472757|Placebo Comparator|Placebo|
3161163|NCT01472757|Active Comparator|Dose 1|
3161164|NCT01472757|Active Comparator|Dose 2|
3161165|NCT01472757|Active Comparator|Dose 3|
3161166|NCT01472744|Experimental|Dance|Participants will be instructed in various forms of dances such as ballroom, swing, waltz, folk, and English country.
3161167|NCT01472744|Active Comparator|Strengthening, Stability, Stretching|Participants will be instructed in various forms of strength, stretching (flexibility) and stability (balance)exercises.
3161168|NCT01472744|Experimental|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate.
3161169|NCT01472744|Experimental|Walking + Nutritional Supplement|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. These participants will also be provided with a daily nutritionally balanced liquid, milk-based formula.
3161170|NCT01472731|Experimental|GC1008 imaging and treatment|"Part 1: Feasibility of 89Zr-GC1008 PET imaging in patients with suspicion of a malignant glioma to assess if GC1008 penetrates into the brain tumor and to quantify its uptake.~Part 2: 89Zr-GC1008 PET imaging in patients with relapsed malignant glioma and phase II extension study with therapeutic GC1008 in these patients"
3161171|NCT01472718|Active Comparator|standard primary coronary intervention|
3161172|NCT01472718|Experimental|coronary thrombectomy|
3161173|NCT01472705||everolimus-eluting stents (EES)|Second-generation everolimus-eluting stents (EES) have been shown to be superior to the first-generation paclitaxel eluting stents (PES) in terms of safety and efficacy.
3161174|NCT01472705||biolimus-eluting stents (BES)|Third generation biolimus-eluting stents (BES) have been shown to be superior to the PES and non inferior to first-generation sirolimus eluting stents in terms of safety and efficacy.
3161175|NCT01472692|Active Comparator|Febuxostat|
3161176|NCT01472692|Placebo Comparator|Placebo|
3161177|NCT01472666|Experimental|Fat rich in MC-SFA|63 gram milk fat with high content of MC-SFA (C6-C12=8.5 g) incorporated in rolls, muffin and as butter.
3161178|NCT01472666|Experimental|Fat low on MC-SFA|63 gram milkfat with low content of MC-SFA (C6-C12=6.9 g) incorporated in rolls, muffin and as butter
3161179|NCT01472666|Experimental|Casein protein|60 gram casein protein (Miprodan 30) ingested twice daily with 600 ml water.
3161180|NCT01472666|Experimental|Whey protein|60 gram whey protein (Lacprodan DI-9224) ingested twice daily with 600 ml water.
3161181|NCT01472640|Active Comparator|Liraglutid|Liraglutid
3161182|NCT01472640|Placebo Comparator|Placebo|Placebo
3161183|NCT01472627||Bortezomib treatment|Subjects receiving standard of care regimen including Bortezomib
3161184|NCT01472614|Experimental|DLBS3233|
3161185|NCT01472601||FOLFOX_6|Oxaliplatin : 85 mg/m2/day D1 Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, first 6 cycles, then Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, 6 cycles
3161186|NCT01472601||FOLFOX_12|Oxaliplatin : 85 mg/m2/day D1 Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, total of 12 cycles
3161187|NCT01472588|Experimental|Community Health Coach|DPP behavioral lifestyle intervention delivered by Community Health Coach (CHWs)
3161188|NCT01472588|Experimental|Public Health Coach|DPP behavioral lifestyle intervention delivered by health professionals (PHCs)
3161189|NCT01472588|Other|Self Help|Booklet, Aim for a Healthy Weight (DHHS, NIH-NHLBI) provided.
3161190|NCT01472575||Pre- rotavirus vaccination introduction|Children aged 0-less than 6 years of age admitted to hospital in South Australia with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause during the period 01May2005-30Apr2007 (pre vaccine introduction)
3161225|NCT01472328|Sham Comparator|Hyperbaric room air|Effect of 2 hrs hyperbaric room air herapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
3161226|NCT01472315|Active Comparator|medroxyprogesterone acetate|
3161191|NCT01472575||post rotavirus vaccine introduction|Children aged 0-less than 6 years of age admitted to hospital in South Australia with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause during the period 01May2009-30Apr2011 (post vaccine introduction)
3161192|NCT01472562|Experimental|all patients|"Induction Phase (week 1 - 48):~Lenalidomide will be given at 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.~Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.~Maintenance Phase (week 49 - progression of disease):~Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle.~Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52."
3161193|NCT01472549|Active Comparator|Iodine-alcohol|8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)
3161194|NCT01472549|Experimental|Chlorhexidine-alcohol|2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)
3161195|NCT01472536|Experimental|3-day sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms
3161196|NCT01472536|No Intervention|Control|No intervention
3161197|NCT01472523||Controls|
3161198|NCT01472523||Aneuploidy|T13, 18, 21 and other chromosomal abnormalities yet to be determined
3161199|NCT01472510|Active Comparator|Arm 1:The PRN Group|You will receive 6 monthly intravitreal injections of 0.5% Ranibizumab administered about every 28 days. It is possible you may receive additional injections into the study eye for the next six months if certain criteria is met.
3161200|NCT01472510|Active Comparator|arm 2:The Monthly Group:|You will receive 12 monthly intravitreal injections of 0.5% Ranibizumab administered every 28 days.
3161201|NCT01472497|Experimental|glymepiride|
3161202|NCT01472484|Experimental|lpa with high polyphenol|
3161203|NCT01472484|Experimental|lpa with low polyphenol|
3161204|NCT01472484|Experimental|control bean with low polyphenol|
3161205|NCT01472484|Experimental|control bean with high polyphenol|
3161206|NCT01472471||acute asthmatic children|Children hospitalized with a diagnosis of acute asthma exacerbation
3161207|NCT01472471||stable asthmatic children|Children with a history of asthma currently asymptomatic
3161208|NCT01472458|Active Comparator|Active Intervention|This stepped-wedge cluster randomized evaluation will randomly allocate 18 hospitals into 4 groups to receive our active intervention at different sequential time points according to the randomly assigned stepped-wedge schedule. Hospitals will function as control hospitals until it is their turn to receive the active intervention, according to the stepped wedge schedule. Each wedge consists of 4-5 hospitals and will last 5 months.
3161209|NCT01472458|No Intervention|Control Hospitals|This stepped-wedge cluster randomized evaluation will randomly allocate 18 hospitals into 4 groups to receive our active intervention at different sequential time points according to the randomly assigned stepped-wedge schedule. Hospitals will function as control hospitals until it is their turn to receive the active intervention, according to the stepped wedge schedule. Each wedge consists of 4-5 hospitals and will last 5 months.
3161210|NCT01472445|Experimental|Vitamin D3, Supportive care, A|Vitamin D 10,000 IU/day
3161211|NCT01472445|Experimental|Vitamin D3, Supportive Care, B|Vitamin D 400 IU/day
3161212|NCT01472432|Placebo Comparator|Placebo|In the placebo group, the dose of other concomitant hypoglycemic medication was changed to obtain a similar profile of metabolic parameters. All patients had diabetes and at least one full-thickness wound below the ankle for >3 months. All patients were examined weekly for the first 4 weeks (day 28) then every other week until day 120 or ulcer closure by any means. At each visit, tracings of the wound margins were made for computer planimetry to document changes in wound size, and photographs were taken for a visual record. All patients followed the regular treatment at the multidisciplinary diabetes foot clinic, included treatment of infection, debridement, off-loading, and metabolic control according to high international standards and standard good medical practice.
3161213|NCT01472432|Experimental|Vildagliptin|The experimental arm followed the same treatment of placebo group, but received also vildagliptin 50 mg per os b.i.d. for 4 months
3161214|NCT01472406|Experimental|Closed-loop session|The study consists of an evaluation of the Sansum Closed-loop Artificial Pancreas Device, insulin infusion pump, Continuous Glucose Monitor, zone-Model Predictive Control algorithm, and a Safety Health Monitoring System. during a 24-hour closed-loop in a clinic environment (Sansum Diabetes Research Institute, Santa Barbara, CA).
3161215|NCT01472393|Experimental|Creatine supplementation|
3161216|NCT01472393|Placebo Comparator|Placebo|
3161217|NCT01472380|Active Comparator|Efavirenz 600mg alone|efavirenz 600mg by mouth taken on Day 1
3161218|NCT01472380|Active Comparator|Efavirenz co-administered with fenofibric acid|co-administered oral doses of efavirenz 600 mg and fenofibric acid 105 mg taken on Day 31
3161219|NCT01472367|Experimental|Sitagliptin + Metformin FDC|Sitagliptin + Metformin fixed-dose combination (FDC) tablet 50/500, 50/850, or 50/1000 mg plus placebo to metformin twice daily for 20 weeks (base period). Participants on background insulin (prestudy) will continue insulin during the study. Participants may continue base period therapy for an optional extension period of 34 weeks.
3161220|NCT01472367|Placebo Comparator|Placebo to Sitagliptin + Metformin FDC|Placebo to sitagliptin + metformin FDC plus metformin 500, 850, or 1000 mg twice daily for 20 weeks (base period). Participants on background insulin (prestudy) will continue insulin during the study. Participants may continue base period therapy for an optional extension period of 34 weeks.
3161221|NCT01472354|No Intervention|Standard of care referral to specialist|Subjects are referred for education, counseling and evaluation for HCV treatment to a specialty health care provider
3161222|NCT01472354|Experimental|LEAP-C Group Intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with HCV treatment to decrease decisional conflict, increase HCV knowledge, improve communication
3161223|NCT01472341||All Participants|Participants receiving routine care under a diabetologist.
3161224|NCT01472328|Experimental|Hyperbaric oxygen therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
3161227|NCT01472315|Placebo Comparator|Placebo|Placebo pills taken in the same way as the active comparator
3161230|NCT01472289|Experimental|BMMNC treated group|Autologous bone marrow mononuclear cell concentrate (BMMNCs) prepared using the Res-Q 60 technology (a point of care system) to be injected intramuscularly into multiple sites in the ischemic muscle tissue of the affected limb at 0.5 cc/injection for a total of 15-20 cc.
3161231|NCT01472276|No Intervention|Control|
3161232|NCT01472276|Active Comparator|Web-based program|
3161233|NCT01472263|Experimental|Pentoxifylline|
3161234|NCT01472263|Placebo Comparator|Placebo|
3161235|NCT01472250||chemotherapy|Eligible patients will accept generalized chemotherapy according to the investigator's assessment.
3161236|NCT01472237|Active Comparator|Nutritional intervention|It will last 6 months. Will be conducted by a physician nutrition specialist assisted by a technician in diet and nutrition. The first visit will take place during admission. The patient receives dietary advice and a customized diet designed to optimize energy intake and macro/micro-nutrients needs.
3161237|NCT01472237|Placebo Comparator|Care as usual|The patients are referred to their cardiologyst and primary care physicians
3161238|NCT01472211|Experimental|intervention filter|children consuming purified and zinc enriched water delivered by a household-based water filter
3161239|NCT01472211|Placebo Comparator|placebo filter|children consuming purified water delivered by a household-based water filter
3161240|NCT01472211|Active Comparator|disinfection tablets|children will consume water treated with government promoted disinfection tablets (aquatabs)
3161241|NCT01472198|Experimental|Simtuzumab (open-label)|Participants will receive simtuzumab 700 mg plus gemcitabine in cycles of 28 days for up to 3 years.
3161242|NCT01472198|Experimental|Simtuzumab 200 mg (randomized)|Participants will receive simtuzumab 200 mg plus gemcitabine in cycles of 28 days for up to 3 years.
3161243|NCT01472198|Experimental|Simtuzumab 700 mg (randomized)|Participants will receive simtuzumab 700 mg plus gemcitabine in cycles of 28 days for up to 3 years.
3161244|NCT01472198|Placebo Comparator|Placebo (randomized)|Participants will receive placebo to match simtuzumab plus gemcitabine in cycles of 28 days for up to 3 years.
3161245|NCT01472185|Placebo Comparator|Placebo|"Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.~Treatment Period: Placebo to match ranolazine (Days 1-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks.~Participants were required to maintain their diet and exercise regimen."
3161246|NCT01472185|Experimental|Ranolazine|"Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.~Treatment Period: Ranolazine tablets (Days 1-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks.~Participants were required to maintain their diet and exercise regimen."
3161247|NCT01472172|Experimental|Cryobiopsy|Biopsies will be obtained by flexible autoclavable cryoprobe 20416-032 (Erbokryo CA, ERBE, Germany) with 2.4 mm in diameter. The tip of the probe is cooled to -890C with nitrous oxide within seconds after footswitch activation. The biopsy sample will by extracted by gently pulling of the probe.
3161248|NCT01472159|No Intervention|CGM-Usual Care|Routine CGM education
3161249|NCT01472159|Experimental|CGM-Teamwork|"Routine CGM education~CGM Family Teamwork Intervention"
3161250|NCT01472146|Experimental|Zometa neoadjuvant HER2 breast cancer|"Zo-Nantax arm - Neoadjuvant chemotherapy with association of zoledronic acid and standard treatment with anthracycline followed taxane plus trastuzumab in locally advanced breast cancer HER2 positive HR positive/negative.~Drug:Cyclophosphamide Drug:Adriamycin Drug:Docetaxel Drug:Trastuzumab Drug:Zolendronic acid"
3161251|NCT01472133||Young Healthy Volunteers|Healthy volunteers under the age of 40
3161252|NCT01472133||Older healthy volunteers|Healthy volunteers over the age of 70
3161253|NCT01472133||Patients with atrial fibrillation|Patients with permanent AF
3161254|NCT01472133||Patients with a pacemaker|Patients who have an implanted pacemaker that is continually pacing
3161255|NCT01472133||Patients with restricted chest movement|Patients whose chest expansion is less than 2.5cm
3161256|NCT01472120||P and C|"P: NAFLD patients~C: Healthy controls"
3161257|NCT01472094||Patients|All patients 65 years old with Stage I to III breast cancer who are beginning adjuvant or neo-adjuvant chemotherapy.
3161258|NCT01472081|Experimental|Arm S: Nivolumab + Sunitinib|"Nivolumab 0.3, 2.0 (starting dose), 5.0 mg/kg solution intravenously every 21 days until Progressive disease (PD), toxicity or discontinue for other reasons~Sunitinib 50 mg capsule by mouth on Days 1-28 of 42 day cycle until Progressive disease (PD), toxicity or discontinue for other reasons"
3161259|NCT01472081|Experimental|Arm P: Nivolumab + Pazopanib|"Nivolumab 0.3, 2.0 (starting dose), 5.0 mg/kg solution intravenously every 21 days until Progressive disease (PD), toxicity or discontinue for other reasons~Pazopanib 800 mg tablet by mouth daily until Progressive disease (PD), toxicity or discontinue for other reasons"
3161260|NCT01472081|Experimental|Arm I-1: Nivolumab + Ipilimumab|"Nivolumab 3 mg/kg solution intravenously (IV) every 21 days during Induction phase and every 14 days during Maintenance phase until Progressive disease (PD), toxicity or discontinue for other reasons~Ipilimumab 1mg/kg solution intravenously (IV) every 21 days during Induction phase (Ipilimumab will not be administered during Maintenance phase) until Progressive disease (PD), toxicity or discontinue for other reasons"
3161261|NCT01472081|Experimental|Arm I-3: Nivolumab + Ipilimumab|"Nivolumab 1mg/kg solution intravenously (IV) every 21 days during Induction phase and 3mg/kg solution intravenously (IV) every 14 days during Maintenance phase~Ipilimumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase. Ipilimumab will not be administered during Maintenance phase"
3161262|NCT01472081|Experimental|Arm IN-3: Nivolumab+Ipilimumab|"Nivolumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase and 3mg/kg solution intravenously (IV) every 14 days during Maintenance phase~Ipilimumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase. Ipilimumab will not be administered during Maintenance phase"
3161263|NCT01472068|Experimental|Inko RS device|30 minutes of treatment with the Inko RS device, five days each week, for 12 weeks.
3161264|NCT01472055|Experimental|Fludarabine|Analysis of the pharmacokinetics of fludarabine for hematopoietic stem cell transplantation in pediatric patients
3161265|NCT01472042||Sports induced concussion|Exposure to sports induced concussion
3161266|NCT01472042||Routine Athletic Exertion|Exposure to routine athletic exertion (non-concussion control)
3161267|NCT01472042||Other Non-Penetrating Trauma to the Head|Exposure to other non-penetrating trauma to the head that is witnessed or self-reported
3161268|NCT01472029|Experimental|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab|
3161269|NCT01472016|Experimental|Cohort A|ABT-700 will be administered by intravenous infusion at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-700.
3161270|NCT01472016|Experimental|Cohort B|ABT-700 plus docetaxel.
3161271|NCT01472016|Experimental|Cohort C|ABT-700 plus FOLFIRI/cetuximab
3161272|NCT01472016|Experimental|Cohort D|ABT-700 plus erlotinib
3161273|NCT01472003|Experimental|ABT-806 Arm|Subjects with advanced solid tumors
3161274|NCT01472003|Experimental|ABT-806i Arm|Subjects with advanced solid tumors
3161275|NCT01471990|Active Comparator|PACAP38|
3161276|NCT01471990|Active Comparator|VIP|
3161277|NCT01471977|Experimental|education, counselling, default tracer|
3161278|NCT01471964|Experimental|MLN8237 and Erlotinib|"Phase I Erlotinib 100 mg PO daily* + MLN8237 30 mg PO BID (days 1 - 7), escalating to Erlotinib 150mg PO daily + MLN8237 starting at 30mg PO BID days 1-7, escalating to 40mg BID (days 1 - 7) , then 50mg BID (days 1 - 7).~Phase II Erlotinib 150mg PO daily + MLN8237 at MTD from phase I."
3161279|NCT01471951|Experimental|single embryo transfer|
3161280|NCT01471938||Caucasians|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
3161281|NCT01471938||Afro Americans|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
3161282|NCT01471938||East and Southeast Asian|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
3161283|NCT01471938||Hispanics|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
3161284|NCT01471925|Experimental|Esomeprazole (40mg) + Sodium Bicarbonate (721mg)|
3161285|NCT01471925|Active Comparator|Nexium®|
3161286|NCT01471899|Active Comparator|Naproxen|2 tablets every 8 hours for 4 days.
3161287|NCT01471899|Experimental|Ketorolac Tromethamine|10 drops every 8 hours for 4 days
3161288|NCT01471886|Active Comparator|Naproxen|Every 8 hours for 4 days.
3161289|NCT01471886|Experimental|Ketorolac Tromethamine|Every 8 hours for 4 days
3161290|NCT01471873||Keratoconus Group (KG)|Keratoconus group (KG) included patients with progressive keratoconus.
3161291|NCT01471873||Collagen-Cross-linking group (CXLG)|Collagen-Cross-linking group (CXLG) included keratoconus patients that had been treated with uneventful corneal collagen cross-linking (CXL) at least on year prior to their enrolment in the study.
3161292|NCT01471860|Experimental|Device group|Barostim Neo System
3161293|NCT01471860|No Intervention|Medical Management group|Medical Management therapy
3161294|NCT01471847|Experimental|BEZ235 + Trastuzumab (Phase l /Phase ll)|"Phase l: Eligible patients will receive increasing doses of oral BEZ235 administered on a continuous twice daily (BID) schedule + weekly trastuzumab at a fixed dose of 2 mg/kg. Treatment will be organized into cycles of 28 days.~Phase ll: Eligible patients will receive weekly trastuzumab (2 mg/kg) + oral BEZ235 on a continuous twice daily (BID schedule) at the MTD or RP2D.~Treatment will be organized into cycles of 21 days."
3161295|NCT01471847|Active Comparator|Lapatinib + Capecitabine (Phase II)|Eligible patients will receive lapatinib (1250 mg given orally once daily on days 1 through 21) in combination with capecitabine (2000 mg/m2/day administered orally in 2 doses approximately 12 hours apart on days 1 through 14). Treatment will be organized into cycles of 21 days .
3161296|NCT01471834|Experimental|Device group|Barostim Neo System
3161297|NCT01471821|Experimental|simplification|Lopinavir/ritonavir (400/100 BID) plus lamivudine (300 QD)
3161298|NCT01471821|Active Comparator|Continue with current treatment|
3161299|NCT01471808|Active Comparator|CSII|continuous subcutaneous insulin infusion
3161300|NCT01471808|Active Comparator|Metformin & Pioglitazone|CSII combined with metformin and pioglitazone
3161301|NCT01471808|Active Comparator|Sitagliptin|CSII combined with sitagliptin 100mg/d
3161302|NCT01471795||Study Population|150 subjects with end-stage heart failure who have been scheduled to undergo device implantation with a VAD, either as a bridge to cardiac transplantation or for destination therapy.
3161303|NCT01471782|Experimental|Blinatumomab|Blinatumomab was administered as a continuous intravenous (cIV) infusion at a constant daily flow rate over 4 weeks followed by a treatment-free interval of 2 weeks. Doses ranged between 5 and 30 µg/m²/day. Each participant received up to five cycles of treatment.
3161304|NCT01471769|Experimental|pain management video|Experimental
3161305|NCT01471769|Placebo Comparator|falls prevention video|placebo
3161306|NCT01471756|Experimental|iSnare with Gonak solution|
3161307|NCT01471756|Experimental|Snaremaster braided snare with Gonak solution|
3161308|NCT01471756|Experimental|iSnare with saline solution|
3161309|NCT01471756|Experimental|Snaremaster braided snare with saline solution|
3161310|NCT01471743|Experimental|Impact Advance Recovery (R)|3 supplements per day for 5 days pre-operatively
3161311|NCT01471743|Active Comparator|Standard Supplement|3 supplement per day for 5 days pre-operatively
3161312|NCT01471730|Placebo Comparator|Saline solution|
3161313|NCT01471730|Active Comparator|Fibrinogen|
3161314|NCT01471730|Active Comparator|Prothrombin complex|
3161315|NCT01471717|Experimental|C 1:INX-08189 50 mg qd X 5 days|Cohort 1: Subjects will begin administration of INX-08189 50 mg every day (QD) on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
3161316|NCT01471717|Active Comparator|C1: INX-08189 / Victrelis 800 mg TID X 3 days|Cohort 1:INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg three times a day (TID) for 3 additional days
3161317|NCT01471717|Active Comparator|C2: Victrelis 800 mg TID x 3 days|Cohort 2: Subjects will begin administration of Victrelis 800 mg three times a day (TID) on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days
3161318|NCT01471717|Active Comparator|C 2:Victrelis 800 mg TID with INX-08189 50 mg QD|Cohort 2: Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days
3161319|NCT01471717|Placebo Comparator|C1: Placebo with Victrelis 800 mg|Cohort 1: Placebo QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days
3161320|NCT01471717|Placebo Comparator|C 2: Victrelis 800 mg with Placebo|Cohort 2: Victrelis 800 mg TID will be administered concurrently with Placebo QD for 5 additional days
3161321|NCT01471704|Experimental|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
3161322|NCT01471704|Active Comparator|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
3161323|NCT01471704|Active Comparator|INX-08189 50 mg & verapamil HCLER 240 mg|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
3161324|NCT01471691|Experimental|intravitreal ranibizumab 0.5mg|
3161325|NCT01471691|Experimental|intravitreal ranibizumab 1.0mg|
3161326|NCT01471678|Experimental|Fixed dose combination product|Fixed Dose Combination capsule containing dutasteride 0.5mg and tamsulosin 0.2 mg
3161327|NCT01471678|Experimental|Dutasteride (0.5mg)|Commercial formulation of dutasteride
3161328|NCT01471678|Experimental|Harnal-D Tablets and Harnal capsules|Commercial formulations of Harnal-D Tablets and Harnal Capsules both comprising 0.2mg tamsulosin HCl
3161329|NCT01471665|Experimental|GSK2190915 100mg|This is a crossover study so patients will receive 100mg of GSK2190915 once daily for up to 16 days followed by a wash out period of at least 14 days before they cross over onto the placebo arm of the study.
3161330|NCT01471665|Placebo Comparator|Placebo|This is a crossover study so patients will receive placebo once daily for up to 16 days followed by a wash out period of at least 14 days before they cross over onto the GSK2190915 100mg arm of the study.
3161331|NCT01471587||Patients with COPD|
3161332|NCT01471548|Experimental|TKI258|dose escalation
3161333|NCT01471431|Experimental|Spontaneous breathing trial|The spontaneous breathing trial will determine the extubation readiness of the subject.
3161334|NCT01471431|No Intervention|Usual care|Subjects will be extubated using usual care, without the use of the spontaneous breathing trial.
3161335|NCT01471418|Experimental|Disease population|
3161336|NCT01471379|Experimental|Group A (50mg - 100mg)|Group A will begin treatment with Milnacipran 50mg BID (n=20) during Phase I and will be increased to 100mg BID during Phase II
3161337|NCT01471379|Active Comparator|Group B (50mg x12)|Subjects in this arm will be maintained at Milnacipran 50mg BID for the entirety of the 12 weeks of the study.
3161338|NCT01471379|Placebo Comparator|Group C (Placebo - 50mg)|Group C will begin treatment with Placebo BID (n=20) during Phase I and will be given 50mg BID during Phase II
3161339|NCT01471366|Active Comparator|Frozen capsule|Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products
3161340|NCT01471366|Active Comparator|Capsule with food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
3161341|NCT01471366|Active Comparator|Capsule without food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
3161342|NCT01471366|Active Comparator|Capsule with milk|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
3161343|NCT01471353|Experimental|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days. Single arm study.
3161344|NCT01471340|Experimental|Mometasone Furoate/Formoterol MDI BID|MF/F MDI BID (pooled MF/F MDI 200/10 mcg BID and MF/F MDI 400/10 mcg BID treatments)
3161345|NCT01471340|Active Comparator|Mometasone Furoate MDI BID|MF MDI BID (pooled from MF MDI 200 mcg BID and MF MDI 400 mcg BID treatments)
3161346|NCT01471652|Active Comparator|Nutraceuticals|Subjects will receive a combination of 4 nutraceuticals (CoEnzyme Q10, acetyl-L-carnitine, alpha-lipoic acid, docosahexaenoic acid (DHA)) and a multivitamin.
3161347|NCT01471652|Placebo Comparator|Placebo|
3161348|NCT01471639|Experimental|Intranasal ketorolac (Sprix)|FDA approved drug used in single arm study
3161349|NCT01471626|Experimental|telematic attended polysomnography|
3161350|NCT01471613|Experimental|Group C - Cord blood cell|Conventional treatment, cord blood cell transplant and placebo
3161351|NCT01471613|Placebo Comparator|Group A - Control|Conventional treatment and placebo
3161352|NCT01471613|Experimental|Group B - Lithium Carbonate|Conventional treatment and lithium carbonate
3161353|NCT01471613|Experimental|Group D - Combination Therapy|Conventional treatment, cell transplant and 6-weeks course of lithium carbonate
3161354|NCT01471600|No Intervention|No intervention|Group overnight fasting
3161355|NCT01471600|Active Comparator|Group drink|Glucose drink (200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia)
3161356|NCT01471574|Experimental|Daclatsvir + Ribavirin + PEG-Interferon alfa-2a|
3161357|NCT01471535|Experimental|peginterferon alpha 2a|the inactive chronic HBsAg carriers were treated with peginterferon alpha 2a for 72 weeks and followed for 24 weeks.
3161358|NCT01471522|Active Comparator|Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization plus optimal medical therapy.
3161359|NCT01471522|Active Comparator|Conservative Strategy|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with acute coronary syndrome, ischemic heart failure, resuscitated cardiac arrest or refractory symptoms.
3161360|NCT01471509|Placebo Comparator|Control|240 ml water
3161361|NCT01471509|Active Comparator|glucose|50 g glucose
3161362|NCT01471509|Active Comparator|Amino acid|1 mmol amino acid/kg lean body mass
3161363|NCT01471509|Active Comparator|amino acid plus glucose|50 g glucose plus 1 mmol amino acid/kg lean body mass
3161364|NCT01471496|Experimental|prophylactic injection therapy group|In addition to medical therapy which included 2x 30 mg Pantoprazole and intravenous fluids this group of the patients recieved injection therapy.
3161365|NCT01471496|No Intervention|control group|This group of the patients recieved medical therapy only.
3161443|NCT01470846|Active Comparator|PCA|Patient with morphine analgesia
3161848|NCT01467960||Group A|Patients at Stage I, H&Y classification
3161366|NCT01471483||patient will receive a phone call from nurse|The proposed study will be a prospective longitudinal feasibility study of 50 older adults with a recent diagnosis of stage II, III or IV ovarian cancer who will receive standard first line chemotherapy and surgery over approximately a six-month period. Half of the 50 patients receive a weekly telephone call from geriatric nurse practitioner (NP); the remaining 25 patients would receive standard oncology care alone (randomization).
3161367|NCT01471483||patients will not receive a phone call from nurse|The proposed study will be a prospective longitudinal feasibility study of 50 older adults with a recent diagnosis of stage II, III or IV ovarian cancer who will receive standard first line chemotherapy and surgery over approximately a six-month period. Half of the 50 patients receive a weekly telephone call from geriatric nurse practitioner (NP); the remaining 25 patients would receive standard oncology care alone (randomization).
3161368|NCT01471470|Experimental|neoadjuvant|
3161369|NCT01471457|Experimental|Trimo-San group|Pessary wearers are instructed to apply one fingertip (approx 1 tablespoon) of Trimo-San gel inside the vagina or to the pessary (for women removing and cleaning pessary before reinsertion after cleaning) once nightly
3161370|NCT01471457|No Intervention|Control group|Pessary wearers are informed on standard care of pessary, which includes topical estrogen application if they are using. Pessary wearers do not use Trimo-San gel
3161371|NCT01471444|Experimental|Flu + Bu|Fludarabine 40 mg/m2 intravenous (IV) over 1 hour. Busulfan dose calculated to achieve a systemic exposure dose of 6000 µMol-min IV over 3 hours every 24 hours. Both delivered for 4 consecutive days (days -6 to -3). Stem cell transplant Day 0.
3161372|NCT01471444|Experimental|Flu +Clo + Bu|Fludarabine 10 mg/m2 over 1 hour. Clofarabine 40 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, infused over 1 hour. Busulfan dose calculated to achieve a systemic exposure dose of 6000 µMol-min IV over 3 hours every 24 hours, immediately after Clofarabine. All delivered on 4 consecutive days (days -6 through -3). Stem cell transplant Day 0.
3161373|NCT01471392|Experimental|Identigene STD Test Kit Arm|Single-Arm trial where the group will complete the Identigene STD Test Kit at home and these results will be compared with the results from testing in the clinic with the Gen-Probe APTIMA kit. The subject will only be informed of the results from the approved test (Gen-Probe APTIMA) that is done in the clinic.
3161374|NCT01471327|Experimental|SB-240563, 10mg|IV, single dose at Day 1
3161375|NCT01471327|Experimental|Placebo|Saline IV, single dose at Day 1
3161376|NCT01471327|Experimental|SB-240563, 75mg|IV, single dose at Day 1
3161377|NCT01471327|Experimental|SB-240563, 250mg|IV, single dose at Day 1
3161378|NCT01471327|Experimental|SB-240563, 750mg|IV, single dose at Day 1
3161379|NCT01471314||Spontaneous migraine|
3161380|NCT01471288|Active Comparator|Group3|Normal controls
3161381|NCT01471288|Placebo Comparator|Group4|Normal controls
3161382|NCT01471288|Active Comparator|Group 1|Hypothyroid patients taking levothyroxin.
3161383|NCT01471288|Placebo Comparator|Group2|Hypothyroid patients taking levothyroxin
3161384|NCT01471275|Experimental|Jiangtangtiaozhi decoction|
3161385|NCT01471275|Active Comparator|metformin|
3161386|NCT01471262||Elderly|Patients more or equal to 70 years old
3161387|NCT01471262||Young|Patients less than 70 years old
3161388|NCT01471236|Experimental|Agili-c bi-phasic implant|mini-arthrotomy
3161389|NCT01471223||Patients receiving Belatacept in CTS|Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving Belatacept at the time of transplantation
3161390|NCT01471223||Patients receiving CNI in CTS|Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving CNI at the time of transplantation
3161391|NCT01471210|Experimental|Part 1 : Urelumab (BMS-663513) Dose escalation|Urelumab (BMS-663513) solution administered intravenously on specified days
3161392|NCT01471210|Experimental|Part 2 : Urelumab (BMS-663513) Cohort Expansion|Urelumab (BMS-663513) solution administered intravenously on specified days
3161393|NCT01471210|Experimental|Part 3:Urelumab (BMS-663513) Tumor-specific Cohort Expansions|Enrollment of subjects of three specific tumor types [(colorectal cancer (CRC), head and neck squamous cell carcinoma (SCCHN), and B-Cell non-Hodgkin's lymphoma (B-NHL)] who will be treated at the Maximum Tolerated Dose (MTD) (or highest dose tested)
3161394|NCT01471210|Experimental|Part 4:Urelumab (BMS-663513) Cohort Expansion in B-NHL|Arm A and Arm B: Urelumab (BMS-663513) liquid administered intravenously on specified days exploring q3w and q6w dosing regimen
3161395|NCT01471197|Experimental|Arm 1: Ipilimumab|
3161396|NCT01471197|Active Comparator|Arm 2: Pemetrexed|
3161397|NCT01471184|Experimental|Ectoin® Eye Drops/Nasal Spray|Eye Drops/Nasal Spray
3161398|NCT01471184|Placebo Comparator|Placebo Eye Drops/Nasal Spray|
3161399|NCT01471171|Experimental|Aclidinium bromide|3-week treatment periods
3161400|NCT01471171|Experimental|Placebo|3-week treatment periods
3161401|NCT01471158|Active Comparator|Azarga/Cosopt|Following administration of the baseline dose (each intervention instilled in one eye in a contralateral fashion to establish baseline ocular comfort for each medication), Azarga will be instilled one drop in each eye on Day One, after which Cosopt will be administered one drop in each eye on Day Two.
3161402|NCT01471158|Active Comparator|Cosopt/Azarga|Following administration of the baseline dose (each intervention instilled in one eye in a contralateral fashion to establish baseline ocular comfort for each medication), Cosopt will be administered one drop in each eye on Day One, after which Azarga will be administered one drop in each eye on Day Two.
3161403|NCT01471145|Experimental|Depot Naltrexone|
3161404|NCT01471132|Experimental|HIPEC|
3161405|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
3161406|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drops of placebo.
3161407|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
3161408|NCT01471119|Experimental|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
3161409|NCT01471106|Experimental|Group 1: Dasatinib 40 mg|Dasatinib 40 mg by mouth once a day for 3 months (+/- 7 days), At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
3161410|NCT01471106|No Intervention|Group 3: No Dasatinib|No treatment control group. At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
3161411|NCT01471106|Experimental|Group 2: Dasatinib 80 mg|Dasatinib 80 mg by mouth once a day for 3 months (+/- 7 days). At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
3161412|NCT01471093|Experimental|Solution|A single dose of OPC-12759 Ophthalmic solution for two-day treatment
3161413|NCT01471093|Active Comparator|Suspension|A single dose of OPC-12759 Ophthalmic suspension for two-day treatment
3161414|NCT01471080|Experimental|RFA group|using RFA to treat cavernous hemangiomas
3161415|NCT01471080|Active Comparator|hepatectomy group|using laparoscopic hepatectomy to treat cavernous hemangiomas of the liver
3161416|NCT01471067|Experimental|Fludarabine/Clofarabine/Busulfan/Rituximab/TBI|Myeloablative Regimen: Rituxan 375 mg/m^2 (B cell malignancy) by vein (IV) on Day -10; Busulfan AUC 4,000 IV either as an outpatient prior to admission or as an inpatient on Day -9; Clofarabine 30 mg/m^2 IV Day -7 to Day -4; ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3; Fludarabine 10 mg/m^2 IV on Days -7 to -4; Total Body Irradiation (TBI) 2 Gy on Day -3; with Cord Blood infusions on Day 0.
3161417|NCT01471067|Experimental|Fludarabine + Melphalan|Reduced Intensity: Fludarabine 40 mg/m^2 IV on Days -5 to -2; Melphalan 140 mg/m^2 IV on Day -2; ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3; with Cord Blood infusions on Day 0.
3161418|NCT01471054|Experimental|Ozurdex|Patients will be followed at 1 week after Ozurdex insertion (0.7 mg) and then at 1,2, 3,4, 5, and 6 months. Following the 6-month visit, patients will be seen every 2 months. At each visit patients will be checked for side effects of treatment, measurement of BCVA, complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Each eye in the Ozurdex group can have a maximum total of three Ozurdex insertions at minimum of 4-month intervals in the first year after enrolling into the study.
3161419|NCT01471054|Active Comparator|Bevacizumab|Patients will be followed at 1 week after the initial bevacizumab injection and then at 1,2, 3,4, 5, and 6 months after implant. Following the 6-month visit, the patients will be examined every 4-8 weeks depending on the status of their macular edema. At each visit patients will be checked for side effects of treatment, measurement of BCVA, complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Eyes in the Bevacizumab group can have a maximum total of twelve (12) bevacizumab injections at minimum of 4-week intervals in the first year after enrolling into the study.
3161420|NCT01471041|Experimental|Venous Window Needle Guide|Venous Window Needle Guide will be implanted onto deep, un-cannulatable arteriovenous fistula
3161421|NCT01471028|Experimental|ELAD Treatment|This group will receive treatment with ELAD plus standard of care treatment.
3161422|NCT01471028|Other|Standard of care (Control)|This group will receive standard of care treatment as defined in the protocol.
3161423|NCT01471015|Active Comparator|High dose Darbepoetin alfa|10 mcg/kg/dose Darbe x2 doses, with the first dose within 12 hours of delivery and the second dose at 7 days
3161424|NCT01471015|Active Comparator|Low dose Darbepoetin alfa|2 mcg/kg/dose Darbe x2, with the first dose given within 12 hours of delivery and the second dose given at 7 days old.
3161425|NCT01471015|Placebo Comparator|Placebo|Placebo given x2 doses, with the first given within 12 hours of delivery and the second given at 7 days old
3161426|NCT01471002|Experimental|Renal cancer without nephrectomy|patients with renal cancer that cannot be offered a partial nephrectomy
3161427|NCT01470989|Experimental|canakinumab|canakinumab 150 mg s.c.
3161428|NCT01470976|Active Comparator|Goal-directed Therapy (GDT) Protocol|
3161429|NCT01470976|Active Comparator|Standard Protocol|
3161430|NCT01470963|Experimental|Referral template|Implementation of the referral templates at the GP office
3161431|NCT01470963|No Intervention|Control|Normal referral pattern
3161432|NCT01470950|Experimental|MotionMaker Training|Device description: MotionMaker™ is a stationary robotic system for the active mobilization of the lower limbs. With its proprietary 'Closed-Loop' technology, it is a novel and exciting development that offers a truly interactive patient training system Training 3 times a week with MotionMaker device together with conventional treatment
3161433|NCT01470937|Experimental|Acarbose|acarbose 100 mg once daily
3161434|NCT01470937|Placebo Comparator|Placebo|Matched placebo was administered for acarbose 100 mg once daily
3161435|NCT01470911|Experimental|SB010|The drug SB010 is administered in phosphate-buffered saline solution, inhaled via a controlled breathing system over a 5 to 10 min.
3161436|NCT01470911|Placebo Comparator|Placebo|The placebo (phosphate-buffered saline) is administered as a solution inhaled via a controlled breathing system over a 5 to 10 min.
3161437|NCT01470898|Experimental|anesthesia monitoring|Bispectral Index Monitoring (BIS) has been proven to be effective in preventing awareness. Optimizing anesthesia level using BIS monitoring, neither to light nor to deep will probably help to shorten recovery time and reduce drug consumption. A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.
3161438|NCT01470898|Experimental|no bispectral index monitoring|At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
3161439|NCT01470885||glucose value|glucose value
3161440|NCT01470859|Active Comparator|pramipexole|0.375mg-4.5mg/day, flexible dosage according to an optimal improvement of movement dysfunction in PD patients
3161441|NCT01470859|Active Comparator|Levodopa|Sinemet CR CR， Controlled Release
3161442|NCT01470846|Experimental|APD|patient with epidural analgesia
3161444|NCT01470833|No Intervention|Non-weight-bearing|"The group of non-weightbearing is instructed as follows:~Week 1 to 6 No weightbearing. Crutches are obligatory. Week 7 to 8 Full weightbearing is allowed.~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
3161445|NCT01470833|Experimental|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:~Week 1 to 2 Weightbearing is allowed with in pain limit. Crutches are recommended.~Week 3 to 4 Full weightbearing is allowed. Week 5 to 8 Full weightbearing is allowed. Crutches should be avoided."
3161446|NCT01470820|Active Comparator|Distance 20 cm|The infants were randomized by sealed and opaque envelopes to one of four phototherapy regimens. Either with distance from the phototherapy device to the mattress of 20, 29, 38 or 47 cm measured by a wood stick for each infant, corresponding to the distances to the infants of averagely 12, 21, 30 and 39 cm, respectively.
3161447|NCT01470820|Active Comparator|Distance 29 cm|
3161448|NCT01470820|Active Comparator|Distance 38 cm|
3161449|NCT01470820|Active Comparator|Distance 47 cm|
3161450|NCT01470807|Experimental|portable artificial pancreas system with CTR algorithms|This is the only arm of the study and concerns all patients.
3161451|NCT01470794|Experimental|Single Arm|Toca 511 vector/Toca FC prodrug
3161452|NCT01470781|Experimental|Cognitive Remediation|This arm will receive computer-based cognitive remediation treatment 3 times per week for 24 weeks, for a total of 70 hours of treatment
3161453|NCT01470781|Placebo Comparator|Computer Control|Group will receive 70 hours of computer time playing pre-selected computer games administered in a similar format as the Cognitive Remediation condition
3161454|NCT01470768|Other|Arm 1 - AA Formula with DHA and ARA|Marketed AA formula with Docosahexanoic Acid (DHA) and Arachidonic Acid (ARA)
3161455|NCT01470768|Other|Arm 2 - AA Formula with alternative levels of DHA and ARA|
3161456|NCT01470755|Other|salbutamol - dose 1|Metered dose inhaler, 100µg+300µg per puff, administered one day
3161457|NCT01470755|Other|Salbutamol - dose2|Metered dose inhaler, 100µg+500µg per puff, administered one day
3161458|NCT01470755|Other|Salbutamol - dose3|Metered dose inhaler, 200µg+600µg per puff, administered one day
3161459|NCT01470755|Other|salbutamol - dose4|Metered dose inhaler, 200µg+200µg per puff, administered one day
3161460|NCT01470742|Active Comparator|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
3161461|NCT01470742|Experimental|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
3161462|NCT01470729||Spinocerebellar Ataxia type 1 (SCA1)|Spinocerebellar Ataxia type 1 (SCA1)
3161463|NCT01470729||Spinocerebellar Ataxia type 2 (SCA2)|Spinocerebellar Ataxia type 2 (SCA2)
3161464|NCT01470729||Spinocerebellar Ataxia type 3 (SCA3)|Spinocerebellar Ataxia type 3 (SCA3)
3161465|NCT01470729||Spinocerebellar Ataxia type 7 (SCA7)|Spinocerebellar Ataxia type 7 (SCA7)
3161466|NCT01470716|Experimental|Study arm|Neo-adjuvant Erlotinib treatment arm.
3161467|NCT01470703|Experimental|ECMO arm|
3161468|NCT01470703|Active Comparator|conventional arm|
3161469|NCT01470690|Active Comparator|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5 (BOC alone)
3161470|NCT01470690|Active Comparator|omeprazole|Omeprazole 40 mg QD for 5 consecutive days (OME alone)
3161471|NCT01470690|Experimental|boceprevir+omeprazole|Omeprazole 40 mg QD for 5 consecutive days combined with boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5 (BOC+OME)
3161472|NCT01470677|Experimental|application of Tachosil fibrin patches|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group.
3161473|NCT01470677|No Intervention|Control group|In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
3161474|NCT01470664|Experimental|FST-100|
3161475|NCT01470664|Experimental|FST-100 (Component #1)|
3161476|NCT01470664|Placebo Comparator|FST-100 Vehicle|
3161477|NCT01470651|Experimental|Armodafinil|Active medication
3161478|NCT01470651|Placebo Comparator|Sugar pill|Inactive pill, matched to look like active medication
3161479|NCT01470625|Other|LCP Program|The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
3161480|NCT01470612|Experimental|CP-690,550 5 mg BID|5 mg BID
3161481|NCT01470612|Experimental|CP-690,550 10 mg BID|10 mg BID
3161482|NCT01470599|Experimental|5mg BID|
3161483|NCT01470599|Experimental|10mg BID|
3161484|NCT01470586|Other|Surgery for colorectal cancer|Colorectal cancer patients
3161485|NCT01470586|No Intervention|Controls|Controls
3161486|NCT01470573|Experimental|Progenitor Autologous Cells|Progenitor Autologous Cells of Sclerocorneal Limbus Amplified ex Vivo
3161487|NCT01470560|Sham Comparator|Sham Yoga Group Treatment|Sham yoga group (control group) will attend 8 weekly sessions for 1-2 hours and will be lead by a certified yoga instructor. The yoga class will be based on Pantajali's Eight Fold Path which is the basis of Yoga. Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
3161488|NCT01470560|Active Comparator|MBSR Group Treatment|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
3161489|NCT01470534|Experimental|Normal body weight|
3161490|NCT01470534|Experimental|Obese|
3161491|NCT01470534|Placebo Comparator|Normal Body Weight placebo|Participants of mormal body weight given placebo
3161492|NCT01470534|Placebo Comparator|Obese placebo|Participants who are obese given placebo
3161493|NCT01470521|Experimental|Hookworm larvae (Necator americanus)|Participants will receive 25 live hookworm larvae
3161494|NCT01470521|Placebo Comparator|Placebo|Participant will receive pharmacopoeial grade water
3161594|NCT01469806||1 - PFJ|Patients who require primary partial knee arthroplasty of the patello-femoral joint.
3161849|NCT01467960||Group B|Patients at Stage II, H&Y classification
3161495|NCT01470508|Experimental|Family Enhancement|PAS is a 27-week program consisting of 25 sessions, 50 minutes in length, between an individual and a therapist. During six (6) family sessions, a family member will accompany the individual to therapy and will take an active role during the session. In this program, individuals and their family members will learn about ways to communicate about their relationship in the context of experiencing an eating disorder. PAS focuses on family-specific skills such as communication skills and problem solving skills while also incorporating eating disorders psychoeducation.
3161496|NCT01470508|Active Comparator|Cognitive Behavioral Therapy|Individuals meet their therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy.
3161497|NCT01470495|Experimental|RFA+Sorafenib|to treat recurrent HCC both with RFA and Sorafenib
3161498|NCT01470495|Active Comparator|RFA group|To treat recurrent HCC with RFA
3161499|NCT01470482|Other|No Tourniquet|We compare tourniquet or not in knee surgery
3161500|NCT01470482|Active Comparator|Tourniquet|We compare tourniquet or not in knee surgery
3161501|NCT01470469|Active Comparator|SPD503|
3161502|NCT01470469|Placebo Comparator|Placebo|
3161503|NCT01470456|Experimental|SAR3419 + Rituximab|Combined therapy will be administered intravenously for 8 doses in the absence of unacceptable toxicity, disease progression or withdrawal of consent.
3161504|NCT01470443|Active Comparator|GEMOX|"Gemcitabine 1,000 mg/㎡, day 1 and 8, every 3 weeks~Oxaliplatin 100 mg/㎡, day 1, every 3 weeks"
3161505|NCT01470443|Experimental|XELOX|Xeloda, 1000mg/㎡ bid, day 1-15, every 3 weeks Oxaliplatin 130mg/㎡, day 1, every 3 weeks
3161506|NCT01470430||ROP infants treated with intravitreal anti-VEGF agents|
3161507|NCT01470430||ROP infants treated with retinal laser photocoagulation|
3161508|NCT01470417|Active Comparator|Chemotherapy|Individuals with low risk disease will receive nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
3161509|NCT01470417|Active Comparator|Chemotherapy and ChemoRadiotherapy|Individuals with high-risk disease or borderline resectable disease will receive nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
3161510|NCT01470404||adjuvant chemotherapy|Patients enrolled on to the adjuvant XP trial + patients who received adjuvant chemotherapy following curative resection of gastric cancer
3161511|NCT01470391|Experimental|Adductor-Canal-Blockade|
3161512|NCT01470391|Active Comparator|Femoral Nerve Block|
3161513|NCT01470378|Active Comparator|Control Group|This group will not be undergoing to manual lymphatic drainage
3161514|NCT01470378|Active Comparator|Study Group|This group will be undergoing to manual lymphatic drainage
3161515|NCT01470365|Experimental|Treatment (radiation therapy)|Patients undergo 3-dimensional CRT or IMRT QD, 5 days a week for 10-30 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
3161516|NCT01470352|Placebo Comparator|Placebo|
3161517|NCT01470352|Active Comparator|treatment|Duloxetine will be given in a daily dose of 30 mg for 5 weeks
3161518|NCT01470339|Placebo Comparator|placebo|migraine patients to receive placebo treatment
3161519|NCT01470339|Active Comparator|duloxetine|migraine patients to receive duloxetine
3161520|NCT01470326||Bazedoxifene Tablets|Subjects taking Bazedoxifene Tablets
3161521|NCT01470313|Experimental|PD-0360324|
3161522|NCT01470313|Placebo Comparator|Placebo|
3161523|NCT01470300|Experimental|Standard ED|100% energy density
3161524|NCT01470300|Experimental|Reduced ED - F/V|80% energy density by adding fruit and vegetables
3161525|NCT01470300|Experimental|Reduced ED - Fat|80% energy density by decreasing fat
3161526|NCT01470300|Experimental|Reduced ED - Plain water|80% energy density by adding plain water
3161527|NCT01470287|Experimental|Arm 1|
3161528|NCT01470261||ADHD medicated|Children aged 5-17 years with clinical diagnosis of ADHD and not previously treated with methylphenidate who have an agreement with their physician to begin treatment with methylphenidate.
3161529|NCT01470261||ADHD unmedicated controls|Children aged between 5-17 years with clinical diagnosis and not previously treated with methylphenidate who have an agreement with their physician NOT to treat with methylphenidate
3161530|NCT01470261||Non-ADHD controls|Any child, including siblings of a child in either the ADHD-medicated or ADHD-unmedicated control group, who is 5-17 years old. These children must have a low rating (<1.5) on the clinician-rated Swanson Nolan and Pelham IV Rating scale (SNAP IV) and not be medicated with with either dexamfetamine or atomoxetine.
3161531|NCT01470248|Experimental|Arsenic Trioxide Treatment|This is a single arm study. All patients will be treated with the investigational agent, Arsenic Trioxide, according to the dose and schedule indicated in the protocol.
3161532|NCT01470235||Ovarian Cancer|"Women treated for ovarian cancer at the departments of obstetrics and gynecology, Aarhus University Hospital and Rigshospitalet, Copenhagen.~Expected recruitment: 200"
3161533|NCT01470235||Control patients|"Women referred to the departments of obstetrics and gynecology in Aarhus University Hospital and Rigshospitalet, Copenhagen on benign indication.~Expected recruitment: 200."
3161534|NCT01470235||HBOC/HNPCC|"Patients registered in the large Danish Register of HBOC( hereditary breast and ovarian cancer) and HNPCC (hereditary nonpolyposis colorectal cancer).~Expected recruitment: 200."
3161535|NCT01470222|Experimental|Intervention Group|"Monthly, all-worksite activities will be implemented to raise awareness of healthy nutrition for weight control throughout the worksite. The purpose of the all-worksite activities is: a) to create a supportive worksite-wide atmosphere for the individuals enrolling in the weight loss support group, and b) to provide low-level weight loss support for individuals who wish to prevent weight gain.~Individuals with eligible weight (defined as BMI ≥ 25 kg/m2) without medical contradictions to weight loss, who wish to join a support group to lose weight, may enroll in the worksite weight control support group that will meet weekly for the first 10 weeks and then monthly until the end of the 6-month intervention"
3161850|NCT01467960||Group C|Patients at Stage more than III, H&Y classification
3161536|NCT01470222|Experimental|Control Group (delayed intervention)|At the end of the study period, subjects will receive a 2-month structured intervention that will provide all of the resources and materials given to the intervention worksite as well as weight control support groups for employees interested in losing weight.
3161537|NCT01470209|Experimental|Combination of BKM120 and everolimus|
3161538|NCT01470196|Experimental|Treatment Arm|Carfilzomib, dexamethasone, rituximab
3161539|NCT01470183||Lupus Nephritis Patients|"Male or female subjects age 18 and older~Must have confirmed diagnosis of Class III or Class IV lupus nephritis by biopsy~Must have stable disease on medication at time of enrollment"
3161540|NCT01470183||Control Patients|Any patient with an idiopathic glomerular disease who does not have lupus nephritis. This includes patients with minimal change disease, membranous nephropathy, focal segmental glomerulosclerosis, and IgA nephropathy.
3161541|NCT01470170|Experimental|Group1|Alfentanil 2.5μg/kg before propofol
3161542|NCT01470170|Experimental|Group2|Alfentanil 5μg/kg before propofol
3161543|NCT01470170|Experimental|Group 3|Alfentanil 2.5μg/kg two minutes before propofol
3161544|NCT01470170|Experimental|Group 4|Alfentanil 5μg/kg two minutes before propofol
3161545|NCT01470170|Placebo Comparator|Group 5 Control|propofol alone
3161546|NCT01470157|Experimental|Ketamine|Oral Ketamine in addition to oral midazolam
3161547|NCT01470157|Placebo Comparator|Placebo|Normal saline (placebo) in addition to oral midazolam
3161548|NCT01470144|Experimental|Treatment|Single arm, open-label
3161549|NCT01470131|Experimental|masitinib 6 mg/kg/day|masitinib in combination with Bortezomib and Dexamethasone
3161550|NCT01470131|Placebo Comparator|placebo|placebo in combination with Bortezomib and Dexamethasone
3161551|NCT01470118|Active Comparator|LASTACAFT® (alcaftadine 0.25%)|One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
3161552|NCT01470118|Active Comparator|Pataday™ (olopatadine 0.2%)|One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
3161553|NCT01470118|Placebo Comparator|Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)|One drop of placebo instilled in each eye at Day 0 and Day 14.
3161554|NCT01470105||pts bone metastases|This is a prospective, cross sectional, human use study conducted using patients with bone metastases requiring orthopaedic stabilization. Though this is an observational study, blood sampling, the SF-36 questionnaire, and ECOG performance status, and correlative studies will be performed.
3161555|NCT01470092|Active Comparator|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed anti-depressant medication.
3161556|NCT01470092|No Intervention|Placebo|Subjects will take oral placebo tablets packaged daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
3161557|NCT01470053|Experimental|mometasone furoate + azelastin HCl|opaque suspension, four times each naris per day
3161558|NCT01470053|Active Comparator|mometasone furoate|opaque suspension, four times each naris per day
3161559|NCT01470053|Active Comparator|azelastine HCl|lucidus colorless liquid, two times each naris per day
3161560|NCT01470040|Experimental|discontinuation of aspirin therapy|
3161561|NCT01470040|Sham Comparator|continuation of aspirin therapy|patients will continue their pre-injury dose of low-dose aspirin therapy per previous medical indication
3161562|NCT01470027|Active Comparator|N-acetylcysteine 1800mg|N-acetylcysteine 1800mg/day for 30 days
3161563|NCT01470027|Active Comparator|N-acetylcysteine 3600mg|N-acetylcysteine 3600mg daily for 30 days
3161564|NCT01470027|Placebo Comparator|Placebo|Placebo effervescent tablets daily for 30 days
3161565|NCT01470014||IVNC|
3161566|NCT01470014||differential diagnosis to IVNC|
3161567|NCT01470001|Active Comparator|solifenacin|patients in this arm will receive drug
3161568|NCT01470001|Placebo Comparator|placebo|patients is this arm will receive placebo
3161569|NCT01469988|Experimental|Testosterone|
3161570|NCT01469988|Placebo Comparator|Placebo|
3161571|NCT01469975|Experimental|Arm A: Dose level 1|1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y
3161572|NCT01469975|Experimental|Arm B: Dose level 2|1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y
3161573|NCT01469975|Experimental|Arm C: Dose level 3|3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y
3161574|NCT01469962||obese patients|
3161575|NCT01469949||Kinesthetic Imagery group|Subjects receiving Kinesthetic Imagery
3161576|NCT01469949||Visual Imagery Group|Subjects receiving visual imagery
3161577|NCT01469949||Control group|Subjects receiving measurement with intervention
3161578|NCT01469936|Experimental|PERMEAPROTECT|
3161579|NCT01469936|Placebo Comparator|PLACEBO|
3161580|NCT01469923|Active Comparator|AZD2820|AZD2820 multiple injections
3161581|NCT01469923|Placebo Comparator|Placebo for AZD2820|Placebo for AZD2820 multiple injections
3161582|NCT01469910|Experimental|Simotinib|
3161583|NCT01469910|Placebo Comparator|Placebo|
3161584|NCT01469884|Experimental|Certican®|Arm1(conversion):Certican®+mycophenolate+prednisone
3161585|NCT01469884|Active Comparator|Tacrolimus or Cyclosporine|Arm2(maintained):Tacrolimus or Cyclosporine+mycophenolate+prednisone
3161586|NCT01469871|Active Comparator|Hypafix Transparent dressing|The Hypafix Transparent dressing, a stretchable dressing, will be used to treat the patients in this group
3161587|NCT01469871|Active Comparator|Mepore Pro dressing|The Mepore Pro dressing, a self-adhesive perforated dressing, will be used to treat the patients in this group
3161588|NCT01469871|Active Comparator|Mepilex Border dressing|The Mepilex Border dressing, a self-adherent soft silicone dressing, will be used to treat the patients in this group
3161589|NCT01469858|Experimental|study group|fMRI
3161590|NCT01469845|Active Comparator|hypertonic saline and usual care|
3161591|NCT01469845|Active Comparator|usual care (oxygen therapy)|
3161592|NCT01469832|Experimental|Subretinal injection of MA09-hRPE|"Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
3161593|NCT01469819|Experimental|Lubiprostone|Lubiprostone 24 mcg by mouth twice a day (BID) for 2 weeks.
3161595|NCT01469793|Experimental|DMOT4039A Q3W: Dose Escalation|Participants in different cohorts will receive DMOT4039A at various escalating dose levels, starting with 0.2 milligrams per kilogram (mg/kg), as intravenous infusion every 3 weeks (Q3W) to determine the maximum tolerated dose (MTD) of DMOT4039A for until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
3161596|NCT01469793|Experimental|DMOT4039A Q3W: Dose Expansion|Participants will receive DMOT4039A at recommended phase 2 dose (RP2D) for Q3W dosing schedule as intravenous infusion Q3W until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
3161597|NCT01469793|Experimental|DMOT4039A Q1W: Dose Escalation|Participants in different cohorts will receive DMOT4039A at various escalating dose levels, starting with a dose 33% of MTD for Q3W dosing schedule, as intravenous infusion every week (Q1W) to determine the MTD of DMOT4039A for until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
3161598|NCT01469793|Experimental|DMOT4039A Q1W: Dose Expansion|Participants will receive DMOT4039A at RP2D for Q1W dosing schedule as intravenous infusion Q1W until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
3161599|NCT01469767|Experimental|Fluocinonide cream|Subjects will apply fluocinonide cream 0.1% twice daily for 5 days.
3161600|NCT01469754||Lymphoma Survivors|
3161601|NCT01469728|Experimental|Awake VATS|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
3161602|NCT01469728|Active Comparator|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
3161603|NCT01469715|Experimental|GBP-CGM|All participants will wear one active GBP-CGM and one inactive GBP-CGM
3161604|NCT01469689|Experimental|Google Adwords only|In these areas,the investigators will display online adverts using Google Adwords, with links to the investigators' project website, and from there to four other websites for depression.
3161605|NCT01469689|Experimental|Local organisation websites|In these areas, the investigators will try to place adverts on the websites of local organizations, with links to the investigators' project website, and from there to four other websites for depression.
3161606|NCT01469689|Experimental|Google Ads and local websites|In these areas, the investigators will place Google Adwords and also try to place adverts on the websites of local organizations, with links to the investigators' project website, and from there to four other websites for depression.
3161607|NCT01469689|No Intervention|Control|Control areas. No Intervention
3161608|NCT01469676|No Intervention|Control group|In the Control group, a standard arterial line filter was inserted on CPB circuit.
3161609|NCT01469676|Experimental|Filtering Group|In the Filtering group, a leukocyte filter was inserted in the arterial line circuit.
3161610|NCT01469663||Healthy Control|Healthy participants without borderline personality or depression
3161611|NCT01469663||Major Depression, No Borderline Personality Disorder|With major depression and no borderline personality
3161612|NCT01469663||Major Depression + Borderline Personality Disorder|With major depression and borderline personality disorder
3161613|NCT01469663||No Major Depression, Borderline Personality Disorder|With no major depression, but with borderline personality disorder
3161614|NCT01469650|Active Comparator|400 IU/day vitamin D|Subjects will receive 400 IU/day of vitamin D3, as per current unit policy
3161615|NCT01469650|Experimental|800 IU/day vitamin D3|Subjects will receive 800 IU/day vitamin D3
3161616|NCT01469637|Experimental|Sulfamethoxazole + MMX placebo|
3161617|NCT01469637|Experimental|Sulfamethoxazole + MMX Mesalazine/mesalamine|
3161618|NCT01469624|Experimental|Test group|This group receives pentoxifylline
3161619|NCT01469624|No Intervention|Control group|
3161620|NCT01469611|Experimental|JX-594|Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.
3161621|NCT01469598|Experimental|Gemcitabine/Docetaxel|Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
3161622|NCT01469585|Active Comparator|Sub-antimicrobial doxycycline|Women will take sub-antimicrobial doxycyline in addition to the continuous oral contraceptive pill.
3161623|NCT01469585|No Intervention|Continuous Oral Contraceptive Pill|Women will take only the continuous oral contraceptive.
3161624|NCT01469572|Experimental|Sir-sphere radioembolization|Everolimus, Pasireotide and Sir-sphere radioembolization
3161625|NCT01469559|Active Comparator|Novolin Toronto insulin|
3161626|NCT01469559|Placebo Comparator|Normal saline|
3161627|NCT01469546|Experimental|Axitinib (AG-013736)|A prospective, single-institution, single-arm phase II study of Axitinib in patients with unresectable recurrent and metastatic head and neck squamous cell carcinoma who have received no more than two prior lines of systemic therapy for recurrent or metastatic head and neck cancer.
3161628|NCT01469533|Experimental|experimental group|The experimental group receives the real spinal mechanical manipulation.
3161629|NCT01469533|Sham Comparator|control group|The control group receives the sham-manipulation procedure.
3161630|NCT01469520|Active Comparator|Reference|Co-administered liquid mixture of Epivir® (lamivudine) solution, Retrovir® (zidovudine)and Viramune® (nevirapine)
3161631|NCT01469520|Active Comparator|Test product|Fixed dose combination of lamivudine, zidovudine and nevirapine reconstitutable suspension
3161632|NCT01469520|Active Comparator|Test Product|Fixed dose combination combination (Lamivudine, Zidovudine and Nevirapine)tablet
3161633|NCT01469507|Experimental|V0220|
3161634|NCT01469507|Active Comparator|Hyaluronan|
3161635|NCT01469494|Active Comparator|DIEP flap group|The standard of care for the patient population is the DIEP or SIEA flap breast reconstruction. Currently the single operating surgeon in the study will always try to perform a SIEA flap reconstruction. If the anatomy does not allow it he will convert to a DIEP flap. The majority of breast surgeons in North America will generally perform a DIEP flap initially. The proposed study does not alter the standard of care received.
3161851|NCT01467947|Experimental|Berinert|
3161636|NCT01469494|Active Comparator|SIEA flap group|The standard of care for the patient population is the DIEP or SIEA flap breast reconstruction. Currently the single operating surgeon in the study will always try to perform a SIEA flap reconstruction. If the anatomy does not allow it he will convert to a DIEP flap. The majority of breast surgeons in North America will generally perform a DIEP flap initially. The proposed study does not alter the standard of care received.
3161637|NCT01469481|Experimental|1|
3161638|NCT01469468|Experimental|Single arm, fixed sequence dosing|
3161639|NCT01469455|Experimental|DT01|
3161640|NCT01469442|Experimental|external biliary duct stent|'External Biliary duct stent in the bile duct by cystic way'
3161641|NCT01469442|No Intervention|without external biliary duct stent|
3161642|NCT01469429|Placebo Comparator|Arm I (Lozenge placebo)|Patients receive lozenge placebo PO QID.
3161643|NCT01469429|Experimental|Arm II (LBR lozenge)|Patients receive lyophilized black raspberries lozenge PO (8gms/day)
3161644|NCT01469429|Placebo Comparator|Arm III (Saliva Substitute placebo)|Patients receive Saliva Substitute placebo PO QID.
3161645|NCT01469429|Experimental|Arm IV (LBR Saliva Substitute)|Patients receive lyophilized black raspberries Saliva Substitute PO (8gms/day).
3161646|NCT01469416|Active Comparator|Rosuvastatin|
3161647|NCT01469416|Experimental|Rosuvastatin + clopidogrel|
3161648|NCT01469403|No Intervention|control group|Standard procedure for knee arthroplasty
3161649|NCT01469403|Active Comparator|Weight loss program|The intervention program consists of 8 weeks of low-diet, using formula foods, and dietary counseling before surgery. When using formula foods the patients can achieve a quicker weight reduction and a greater reduction in fat mass than using conventional dietetic hypo caloric diet.
3161650|NCT01469377|Placebo Comparator|Placebo|Participants received placebo orally once a day for 8 weeks. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
3161651|NCT01469377|Experimental|Cariprazine 1-2 mg|Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2 and 1.0 mg on Days 3-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 1.0 or 1.5 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 1.0, 1.5, or 2.0 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
3161652|NCT01469377|Experimental|Cariprazine 2-4.5 mg|Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2, 1.0 mg on Day 3, 1.5 mg on Day 4, and 2.0 mg on Days 5-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 2.0 or 3.0 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 2.0, 3.0, or 4.5 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
3161653|NCT01469364|Experimental|Aztreonam Lysine for Inhalation (AZLI)|Patients to received Aztreonam Lysine(AZLI)
3161654|NCT01469351|Active Comparator|Drug|the GLP-1 receptor analog liraglutide is the active drug. The dose is 1.8mg daily
3161655|NCT01469351|Placebo Comparator|placebo|non active intervention
3161656|NCT01469338|Experimental|Supportive care (management of therapy complications)|Patients receive cabazitaxel IV over 1 hour on day 1, prednisone PO QD, and octreotide pamoate IM on day 1. Patients also receive octreotide acetate SC TID on days 1-14 of course 1 only. Treatment with cabazitaxel repeats every 21 days and treatment with prednisone and octreotide pamoate repeats every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
3161657|NCT01469325|Active Comparator|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil.
3161658|NCT01469325|Sham Comparator|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
3161659|NCT01469312|Placebo Comparator|Control|The control arm consists of the traditional pasta.
3161660|NCT01469312|Active Comparator|Modified pasta|Dreamfields, Miracle Noodles
3161661|NCT01469286|Active Comparator|TEA|Needleless electroacupuncture at ST36 and PC6
3161662|NCT01469286|Placebo Comparator|Sham-TEA|Needleless acupuncture at sham-points
3161663|NCT01469273|No Intervention|Control group|Only observation; observation period: 1 year.
3161664|NCT01469273|Experimental|Early Treatment group (E)|1 x 1 ml of EcN suspension/day on 10 consecutive days, application in the morning before feeding/nursing, first application 48h after birth, latest. Observation period: 1 year.
3161665|NCT01469273|Experimental|Late Treatment Group (L)|1 x 1 ml of EcN suspension/day on 10 consecutive days, application in the morning after feeding/nursing, starting on the first day of the 7th month of life. Observation period: 1 year.
3161666|NCT01469260|No Intervention|Routine care|ACOG Exercise in Pregnancy pamphlet
3161667|NCT01469260|Experimental|Pedometer|ACOG Exercise in Pregnancy pamphlet, pedometer use, ultimate goal of 10,000 steps per day
3161668|NCT01469247|Experimental|Radiation Therapy|Starting dose of 24 Gray (Gy) in 2 Gy fractions.
3161669|NCT01469234|Experimental|loratadine|Participants will receive one dose of loratadine following randomization at 120 minutes of exposure during visit 4.
3161670|NCT01469234|Experimental|fexofenadine|Participants will receive one dose of fexofenadine following randomization at 120 minutes of exposure during visit 4.
3161671|NCT01469234|Placebo Comparator|placebo|Participants will receive one dose of placebo following randomization at 120 minutes of exposure during visit 4.
3161672|NCT01469221|Experimental|Apaziquone|Apaziquone (4 mg in 40 mL)
3161673|NCT01469221|Placebo Comparator|Placebo|Matching placebo (40 mL)
3161936|NCT01467375|Experimental|A|
3161674|NCT01469195||Group A - No lead protection|Patients who are admitted for an elective percutaneous coronary intervention procedure ( or stable acute coronary syndrome patients) will be ask to participate in the study and sign an informed consent (see inclusions and exclusions).The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual. In group A - no lead protection will be used.
3161675|NCT01469195||Group B plus lead protection|Patients who are admitted for an elective percutaneous coronary intervention procedure ( or stable acute coronary syndrome patients) will be ask to participate in the study and sign an informed consent (see inclusions and exclusions).The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual. In group B - lead protection will be used from the umbilicus and down.
3161676|NCT01469182|Experimental|SCH 39641 12 Amb a 1-U|12 Units short ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) extract in an AIT, sublingual, once daily.
3161677|NCT01469182|Placebo Comparator|Placebo|Matching placebo tablet, sublingual, once daily.
3161678|NCT01469169|Experimental|Arm 1|
3161679|NCT01469156|Experimental|Ranibizumab 2.0 mg|Intraocular injection of 2.0 mg/0.05 cc ranibizumab.
3161680|NCT01469156|Active Comparator|Ranibizumab 0.5 mg|Intraocular injection of 0.5 mg/0.05 cc ranibizumab.
3161681|NCT01469143|Experimental|NN1218|
3161682|NCT01469143|Active Comparator|insulin aspart|
3161683|NCT01469130|Experimental|MEK162|"MEK162 will be administered orally once on Day 1 of Cycle 1 and continuously on a BID schedule, starting on Day 2 of Cycle 1 and on Day 1 of subsequent cycles. Each cycle will be 28 days in duration. Dose will be escalated and starting dose is 30 mg. Any doses that are missed should be skipped and should not be replaced or made up during the evening dosing or on a subsequent day, whichever applies.~The prescribed BID doses should be taken 12 ± 2 hrs apart."
3161684|NCT01469117||Pediatric developmental disabilities|Children aged 1-13 years old with development disabilities, requiring enteral tube feeding for at least 14 days
3161685|NCT01469104|Placebo Comparator|3 day fast|After receiving a standard diet on day 1, subject will fast on days 2, 3, and 4. Water and calorie-fee beverages will be allowed during this 72 hour period.
3161686|NCT01469104|Active Comparator|CHO-free diet|After receiving a standard diet on day 1, a carbohydrate-free diet will be provided on days 2, 3, and 4.
3161687|NCT01469091|Active Comparator|Smoking intervention, Nicotine replacement therapy.|
3161688|NCT01469091|No Intervention|Controlgroup|
3161689|NCT01469078|Active Comparator|100 mg Monofer®|
3161690|NCT01469078|Active Comparator|200 mg Monofer®|
3161691|NCT01469078|Active Comparator|500 mg Monofer®|
3161692|NCT01469065|Experimental|PF-04991532|PF-04991532 experimental study medication
3161693|NCT01469065|Placebo Comparator|Placebo|PF-04991532 Matching Placebo
3161694|NCT01469052|Experimental|Cohort 1|
3161695|NCT01469052|Experimental|Cohort 2|
3161696|NCT01469052|Experimental|Cohort 3|
3161697|NCT01469052|Experimental|Cohort 4|
3161698|NCT01469052|Experimental|Cohort 5|
3161699|NCT01469052|Experimental|Cohort 6|
3161700|NCT01469039|Experimental|ALKS 9072|
3161701|NCT01469039|Placebo Comparator|Placebo|
3161702|NCT01469026|Active Comparator|Early PET/CT|
3161703|NCT01469026|Active Comparator|Conventional diagnostics including CT|
3161704|NCT01469013|Placebo Comparator|Placebo|2 placebo capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg LY3009104 or 8-mg LY3009104 arms. Participants rerandomized to 8-mg LY3009104 arm at Week12 will switch to 4-mg LY3009104 once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
3161705|NCT01469013|Experimental|1-mg LY3009104|1 x 1-mg LY3009104 capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg LY3009104 or 8-mg LY3009104 arms. Participants rerandomized to 8-mg LY3009104 arm at Week 12 will switch to 4-mg LY3009104 once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
3161706|NCT01469013|Experimental|2-mg LY3009104|2 x 1-mg LY3001904 capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg LY3009104 or 8-mg LY3009104 arms. Participants rerandomized to 8-mg LY3009104 arm at Week 12 will switch to 4-mg LY3009104 once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
3161707|NCT01469013|Experimental|4-mg LY3009104|1 x 4-mg LY3009104 capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form.
3161708|NCT01469013|Experimental|8-mg LY3009104|2 x 4-mg LY3009104 capsules administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form. Participants taking 8-mg LY3009104 tablet form will switch to 4-mg LY3009104 once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
3161709|NCT01469000|Experimental|250 mg Gefitinib/500 mg Pemetrexed|250 milligrams (mg) Gefitinib taken orally once daily (QD) and 500 milligrams per square meter (mg/m²) Pemetrexed taken intravenously (IV) once every 3 weeks concurrently with Gefitinib taken orally QD.
3161710|NCT01469000|Active Comparator|250 mg Gefitinib|250 milligrams (mg) Gefitinib taken orally QD
3161711|NCT01468987|Active Comparator|Insulin Glargine + Insulin Lispro|"Participant-specific dose of Insulin Glargine will be administered subcutaneously (SC) once daily at bedtime for 26 weeks.~Participant-specific dose of Insulin Lispro will be administered SC for preprandial (pre-meal) and supplemental doses for 26 weeks."
3161712|NCT01468987|Experimental|LY2605541 + Insulin Lispro|"Participant-specific dose of LY2605541 will be administered SC once daily at bedtime for 26 weeks.~Participant-specific dose of Insulin Lispro will be administered SC for preprandial and supplemental doses for 26 weeks."
3161801|NCT01468207|Experimental|Adalimumab Every Week (EW)|Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
3161713|NCT01468974|Other|ESPRIT BVS|Subjects receiving the ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries.
3161714|NCT01468961|Experimental|Internet-based CBT|
3161715|NCT01468922|Experimental|A|Combination pazopanib plus ARQ197 at doses established during escalation phase
3161716|NCT01468909|Placebo Comparator|Arm I (paclitaxel and placebo)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and placebo PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3161717|NCT01468909|Experimental|Arm II (paclitaxel and pazopanib hydrochloride)|Patients receive paclitaxel as in arm I and pazopanib hydrochloride PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3161718|NCT01468896|Experimental|Treatment (cetuximab and recombinant interleukin-12)|Patients receive cetuximab IV over 1-2 hours on day 1 and recombinant interleukin-12 SC on days 2 and 5 beginning in course 2. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving clinical response or stable disease may continue with therapy until disease progression.
3161719|NCT01468883|Experimental|X|Excisional biopsy plus radiation
3161720|NCT01468883|Active Comparator|M|Modified radical mastectomy
3161721|NCT01468818|Experimental|Immunotherapy for Metastatic Melanoma|Patients will receive non-myeloablative lymphodepleting preparative regimen cons
3161722|NCT01468779|Placebo Comparator|Sugar pill|The patients submitted to periampullary cancer surgery will receive sugar pills in the preoperative and postoperative period.
3161723|NCT01468779|Active Comparator|Probiotics|The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
3161724|NCT01468766|Active Comparator|Resistance training|
3161725|NCT01468766|Active Comparator|Relaxation training|
3161726|NCT01468753|Experimental|Vaginal Insemination|Women will perform vaginal insemination during the fertile period of the menstrual cycle with the collected semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
3161727|NCT01468727|Experimental|xylitol wipe|
3161728|NCT01468727|Placebo Comparator|placebo wipe|
3161729|NCT01468688|Experimental|STI571 (imatinib mesylate) and BKM120|The study will comprise of 2 parts. A dose escalation and a dose expansion part. Patients will receive increasing doses of BKM120 (40, 60, 80, 100 mg) in combination with 400mg imatinib daily until maximum tolerated dose (MTD) and rapid phase 2 dose (RP2D) is determined. 35 patients will enter the expansion phase with 18 patients having a pharmacokinetic (PK) run-in period of 8 days receiving imatinib monotherapy or BKM120 monotherapy.
3161730|NCT01468688|Experimental|STI571+BKM120|BKM120 Monotherapy 8 day run-in followed by STI571 and BKM120 combination therapy
3161731|NCT01468688|Experimental|STI571 monotherapy run-in|STI571 Monotherapy 8 day run-in followed by STI571 and BKM120 combination therapy
3161732|NCT01468675|Experimental|Intervention|The intervention is completion of a validated, web-based risk assessment used to assess personalized risk and generate a risk report
3161733|NCT01468675|No Intervention|Control|Usual Care
3161734|NCT01468662||STEMI|
3161735|NCT01468649|Experimental|Breast Cancer SLN Mapping|Fifty participants consented who will be undergoing standard of care for breast cancer SLN mapping with Tc-99m will be enrolled in this study.
3161736|NCT01468636|Active Comparator|Oral Zinc|
3161737|NCT01468636|Placebo Comparator|Placebo|
3161738|NCT01468623|Experimental|OnDose®|Patients will receive FOLFOX6 with or without bevacizumab (Avastin). Patients' 5-FU dose will be optimized by measuring the Area Under the Curve (AUC) of 5-FU by the commercially available OnDose® assay and their dose for subsequent cycles adjusted following a pre-established dose adjustment algorithm.
3161739|NCT01468623|Active Comparator|Body Surface Area (BSA)|Patients will receive FOLFOX6 with or without bevacizumab (Avastin). Patients will receive 5-FU based on traditional BSA calculation and their dose adjusted based on standard clinical practice. OnDose® AUC measurements will be performed for this arm but will not be used for dose adjustment.
3161740|NCT01468610|Active Comparator|Workers with MDD|
3161741|NCT01468597||One group|Emergency surgery
3161742|NCT01468584|Experimental|MP-424|
3161743|NCT01468571|Experimental|Spironolactone|Drug: Spironolactone Drug: Placebo
3161744|NCT01468571|Experimental|Placebo|Drug: Placebo Drug: Spironolactone
3161745|NCT01468558|Other|All subjects|Subjects received MAP0004 on Day 1 of Visit 2, Ketoconazole on Days 3 through 6 of Visit 2, and MAP0004 again on Day 6 of Visit 2. Subjects then returned for Visit 3, 7-11 days from the end of Visit 2. At Visit 3 subjects received 1.0 mg IV DHE (Intravenous Dihydroergotamine Mesylate).
3161746|NCT01468545||Group 1|
3161747|NCT01468545||Group 2|
3161748|NCT01468532|Experimental|Treatment (chemotherapy, receptor agonist)|Patients receive pasireotide IM on day 1, docetaxel IV over 1 hour, and prednisone PO BID continuously. Courses with docetaxel repeat every 21 days and courses with pasireotide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3161749|NCT01468519|Experimental|CSII|continuous subcutaneous insulin infusion
3161750|NCT01468519|Active Comparator|MDI|multiple daily insulin injections
3161751|NCT01468506||Fistula patients|Consecutive patients with autogenous, brachio-cephalic, brachio-basilic or brachio-brachial arterio-venous fistula creation for hemodialysis
3161752|NCT01468493||steroid-sensitive FSGS|
3161753|NCT01468493||steroid-dependent and resistant FSGS|
3161754|NCT01468493||Healthy volunteers|
3161755|NCT01468480|Experimental|Pro Root MTA- standard method|application of MTA in second group and 24 hour interval before restoration
3161756|NCT01468480|Experimental|Pro Root MTA- single visit|Intervention/Control application of MTA in third group and 15 minute interval before restoration
3161757|NCT01468480|Experimental|MultiCal / LimeLite|application of Multical in forth group
3161758|NCT01468480|Active Comparator|Dycal|application of Dycal in first group as a pulp dressing agent
3161759|NCT01468467|Experimental|AC220|
3161760|NCT01468454|Experimental|(18F-DOPA) PET/CT imaging|Obtain safety and efficacy data on the use of 18-labeled L-fluorodeoxyphenylalanine (18F-DOPA) PET imaging in children with HI for the clinical indication of localizing a focal lesion
3161761|NCT01468441|Experimental|GnRH agonist|Administration of GnRH agonist in alternate days, recombinant FSH and hCG microdose for ovarian stimulation.
3161762|NCT01468441|Active Comparator|GnRH antagonist|Daily administration of GnRH antagonist, recombinant FSH and hCG microdose for ovarian stimulation.
3161763|NCT01468402||Magnetic Resonanse Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroid, and their location in the myometrium was classified. Perfusion and the characterization of the T2 signal were also evaluated.
3161764|NCT01468389|Active Comparator|Taxanes or Platinum in combination with Capecitabine|The patients will received chemotherapy combining capecitabine with platinum or taxanes until progression.
3161765|NCT01468389|Experimental|chemotherapy followed by capecitabine alone|The patients who has received 4 cycle chemotherapy combining capecitabine with platinum or taxanes and the result was SD or CR or PR,will be given capecitabine alone until progression.
3161766|NCT01468376|Experimental|GLU-01|
3161767|NCT01468376|Experimental|GLU-02|
3161768|NCT01468376|Experimental|GLU-03|
3161769|NCT01468376|Experimental|GLU-04|
3161770|NCT01468376|Experimental|GLU-05|
3161771|NCT01468376|Experimental|GLU-06|
3161772|NCT01468363|Active Comparator|Group 1|"Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight as needed before a dialysis session.~If OH is positive value, we will try to reach dry weight by ultrafiltration without regard to the level of blood pressure.~If OH is negative value , we will not change dry weight."
3161773|NCT01468363|No Intervention|Group 2|BCM results obtained at the beginning and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
3161774|NCT01468350|Placebo Comparator|(PART A) AB: dalfampridine-ER 10mg then placebo|Each subject randomized to the AB arm will receive a single witnessed dose of (A) dalfampridine-ER 10 mg, and a single witnessed dose of (B) placebo, two days apart
3161775|NCT01468350|Placebo Comparator|(PART A) BA: placebo then dalfampridine-ER 10mg|Each subject randomized to the BA arm will receive a single witnessed dose of (B) placebo, and a single witnessed dose of (A) dalfampridine-ER 10 mg, two days apart
3161776|NCT01468350|Placebo Comparator|(PART B) AB: dalfampridine-ER 10mg then placebo|Each subject randomized to the AB arm will receive multiple doses of (A) dalfampridine-ER 10mg and multiple doses of (B) placebo
3161777|NCT01468350|Placebo Comparator|(PART B) BA: Placebo then dalfampridine-ER 10mg|Each subject randomized to the BA arm will receive multiple doses of (B) placebo, and multiple doses of (A) dalfampridine-ER 10mg
3161778|NCT01468337|Experimental|Interferon gamma-1b|"Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. A single dropperette contains 1 mL of topical interferon gamma-1b (Actimmune®) at a concentration of 200 µg/mL, which is equivalent to 28 drops. Each drop provides a dose of 7 µg of investigational product.~All participants will receive interferon gamma-1b for two weeks. Doses of interferon gamma-1b eye drops will be escalated among participants during this initial 2-week period; however, additional doses will be dispensed to participants if needed at Week 4 or after the initial 8-week study period. Participants eligible for additional doses after 8 weeks will be administered the maximum dose of 4 drops 4 times daily for a total daily dose of 112 μg."
3161779|NCT01468311|Experimental|Yttrium-90-labeled Daclizumab + Chemotherapy|Yttrium-90-labeled Daclizumab + BCNU, etoposide, cytarabine and melphalan (BEAM) + Auto stem cell transplant (ASCT)
3161780|NCT01468298|Active Comparator|Isostretching|
3161781|NCT01468298|Active Comparator|Global Posture Reeducation|
3161782|NCT01468285|Experimental|Treatment arm 1: betahistine dihydrochloride|
3161783|NCT01468285|Placebo Comparator|Treatment arm 2: placebo|
3161784|NCT01468272|Active Comparator|reference treatment|Free combination of Beclomethasone dipropionate DPI and Formoterol fumarate DPI
3161785|NCT01468272|Experimental|CHF 1535 NEXT DPI|CHF 1535 50/6 NEXT DPI
3161786|NCT01468259|Experimental|Normal renal function|16 subjects with normal renal function (eGFR greater than 90 mL/min/1.73m²)
3161787|NCT01468259|Experimental|Mild RD|Eight (8) with mild (60 less than eGFR less than 89 mL/min/1.73m²)
3161788|NCT01468259|Experimental|Moderate RD|Eight with moderate (30 less than eGFR less than 59 mL/min/1.73m²),
3161789|NCT01468259|Experimental|Severe RD|Eight with severe (15 less than eGFR less than 29 mL/min/1.73m²)
3161790|NCT01468259|Experimental|End Stage Renal Disease|Eight with ESRD (eGFR < 15 mL/min/1.73m² and requiring hemodialysis)
3161791|NCT01468246||Young Women|Young women with newly diagnosed breast cancer
3161792|NCT01468233|Placebo Comparator|Placebo|Placebo for 12 weeks.
3161793|NCT01468233|Experimental|Adalimumab Every Week (EW)|Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
3161794|NCT01468233|Placebo Comparator|Placebo/Placebo|Participants randomized to receive placebo in Period 1 received placebo every week from Week 12 to Week 35 in Period 2 (up to 24 weeks).
3161795|NCT01468233|Experimental|Adalimumab Every Week (EW)/Placebo|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
3161796|NCT01468233|Experimental|Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
3161797|NCT01468233|Experimental|Adalimumab Every Week (EW)/Adalimumab Every Week (EW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
3161798|NCT01468220|Placebo Comparator|normoxic training|6 weeks of endurance training under normoxia
3161799|NCT01468220|Active Comparator|hypoxic training|6 weeks of endurance training under hypoxia
3161800|NCT01468207|Placebo Comparator|Placebo|Placebo for 12 weeks.
3161937|NCT01467362|Experimental|V0034CR01B|
3161802|NCT01468207|Experimental|Placebo/Adalimumab Every Week (EW)|Participants randomized to receive placebo in Period 1 received adalimumab 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to Week 35 in Period 2 (up to 24 weeks).
3161803|NCT01468207|Experimental|Adalimumab Every Week (EW)/Placebo|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
3161804|NCT01468207|Experimental|Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive adalimumab 40 mg eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
3161805|NCT01468207|Experimental|Adalimumab Every Week (EW)/Adalimumab Every Week (EW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
3161806|NCT01468194|Experimental|Breathing procedure 1|"Walking with breathing procedure 1."
3161807|NCT01468194|Experimental|Breathing procedure 2|"Walking with breathing procedure 2."
3161808|NCT01468194|No Intervention|Control group|Walking without any reglementation of breathing
3161809|NCT01468181|Experimental|LY2189265 + Sulfonylureas (SU)|"LY2189265: 0.75 milligrams (mg) administered subcutaneously (SC), once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of SU monotherapy throughout the study."
3161810|NCT01468181|Experimental|LY2189265 + Biguanides (BG)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of BG monotherapy throughout the study."
3161811|NCT01468181|Experimental|LY2189265 + alpha-glucosidase inhibitor (a-GI)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of a-GI monotherapy throughout the study."
3161812|NCT01468181|Experimental|LY2189265 + Thiazolidinedione (TZD)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of TZD monotherapy throughout the study."
3161813|NCT01468181|Experimental|LY2189265 + Glinides|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of glinides monotherapy throughout the study."
3161814|NCT01468168|Experimental|DE-101 Ophthalmic Suspension High Dose|
3161815|NCT01468168|Experimental|DE-101 Ophthalmic Suspension Low Dose|
3161816|NCT01468168|Placebo Comparator|DE-101 Ophthalmic Suspension Vehicle|
3161817|NCT01468155|Active Comparator|Dabigatran|Dabigatran will be compared to historical data using other OAC methods for Pulmonary Vein Ablation
3161818|NCT01468129|Active Comparator|Cell Saver|
3161819|NCT01468129|No Intervention|Non Cell Saver|
3161820|NCT01468116||RYGB patients with type 2 diabetes|Morbidly obese patients with type 2 diabetes undergoing gastric bypass surgery
3161821|NCT01468116||RYGB patients without type 2 diabetes|Morbidly obese patients with normal glucose tolerance undergoing gastric bypass surgery
3161822|NCT01468116||Cholecystectomy patients without type 2 diabetes|Patients with normal glucose tolerance undergoing laparoscopically cholecystectomy
3161823|NCT01468103|Experimental|PACS|primary angle closure suspects
3161824|NCT01468103|Experimental|PAC|primary angle closure
3161825|NCT01468090||Disease course|562 patients diagnosed with Crohn's disease (209), ulcerative colitis (326) or indeterminant colitis (27) in the period of 1st of January 2003 to 31st of December 2004 in Copenhagen City and County (an area covering 23% of the Danish population).
3161826|NCT01468077|Experimental|Tocilizumab, Normal Administration|Tocilizumab 8 mg/kg infusion of 60 minutes duration every 4 weeks for 6 infusions (up to 24 weeks)
3161827|NCT01468077|Experimental|Tocilizumab, Fast Administration|Tocilizumab 8 mg/kg infusion of 31 minutes duration every 4 weeks for 6 infusions (up to 24 weeks). The first infusion was 1 hour. If an infusion reaction occurred during any treatment, 1 hour infusions were used for all subsequent infusions
3161828|NCT01468064|Experimental|BMSCs group|
3161829|NCT01468064|Experimental|EPCs group|
3161830|NCT01468064|Placebo Comparator|Control group|
3161831|NCT01468051|Experimental|40 μg (2 ml) four doses of Euvax B vaccine|40 μg (2 ml) four doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
3161832|NCT01468051|Experimental|20 μg (1 ml) three doses of Euvax B vaccine|20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
3161833|NCT01468038|Active Comparator|Active trazodone and placebo|trazodone 50mg with Sentra PM-like placebo
3161834|NCT01468038|Active Comparator|placebo and active Sentra PM|Trazodone-like placebo and Sentra PM
3161835|NCT01468038|Active Comparator|Sentra PM and trazodone|Active Sentra PM and active trazodone
3161836|NCT01468038|Placebo Comparator|placebo trazodone and placebo Sentra PM|trazadone-like placebo and Sentra PM-like placebo
3161837|NCT01468025|Active Comparator|Theramine and naproxen|Patients in this group were randomly given active Theramine and active naproxen.
3161838|NCT01468025|Active Comparator|Theramine and placebo|Patients in this group were randomly given active Theramine with placebo representing naproxen.
3161839|NCT01468025|Active Comparator|Naproxen and placebo|Patients in this group were randomly given active naproxen and placebo to represent Theramine.
3161840|NCT01468012|Experimental|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily dosing of levodopa carbidopa and entacapone (LCE)
3161841|NCT01468012|Placebo Comparator|Placebo|placebo
3161842|NCT01467999|Experimental|Guanfacine|Guanfacine, 4mg given once daily
3161843|NCT01467986|Active Comparator|Irinotecan, Temozolomide|Patients randomized to the control arm receive irinotecan (I) and temozolomide (T) alone.
3161844|NCT01467986|Experimental|Rapamycin, Dasatinib, Temozolomide, Irinotecan|Patients with rNB receive on the study arm the experimental combination of rapamycin (R)- mTOR Inhibitor, dasatinib (D)- protein kinase inhibitor irinotecan (I)- cytostatic topoisomerase-I-inhibitor and temozolomide (T)- Antineoplastic agent
3161845|NCT01467960||Group I|Healthy Subjects aged 20-40
3161846|NCT01467960||Group II|Healthy Subjects aged 40-65
3161847|NCT01467960||Group III|Healthy Subjects aged more than 65
3161852|NCT01467934||Trivalent inactivated influenza vaccine|Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1
3161853|NCT01467934||TIV and PCV13 together|Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1; 13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1
3161854|NCT01467934||13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1
3161855|NCT01467921|Active Comparator|LV5FU2|leucovorin 200 mg/m2 and 5-fluorouracil 400 mg/m2 intravenously on day 1, followed by a 46-h protracted infusion of 5-fluorouracil 2,400 mg/m2
3161856|NCT01467921|Experimental|FOLFOX|leucovorin 200 mg/m2 and 5-fluorouracil 400 mg/m2 intravenously on day 1, followed by a 46-h protracted infusion of 5-fluorouracil 2,400 mg/m2 oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
3161857|NCT01467908|Experimental|Vegetative state|Patients with the diagnosis of the vegetative state
3161858|NCT01467882|Experimental|Triptorelin|Triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169
3161859|NCT01467856||chronic tetraplegia|
3161860|NCT01467843|Active Comparator|Cognitive Behavioral Therapy|Participants randomized to the CBT intervention will attend eight weekly 2 hour sessions.
3161861|NCT01467843|Active Comparator|Mindfulness-Based Stress Reduction|Participants randomized to the MBSR arm will attend eight weekly 2 hour MBSR sessions.
3161862|NCT01467843|No Intervention|Usual Care|Participants randomized to Usual Care will continue to receive care for their low back pain as prescribed by his/her Primary Care Physician.
3161863|NCT01467830|Experimental|absorbable sutures|patients attributed to that arm, undergoing surgery of Open Inguinal Hernia Repair With Mesh Fixation using absorbable sutures.
3161864|NCT01467830|Other|non absorbable sutures|patients attributed to that arm, undergoing surgery of Open Inguinal Hernia Repair With Mesh Fixation using non absorbable sutures,this is the method being considered the standard of care thus far.
3161865|NCT01467817|Experimental|Lifestyle Intervention|This arm will test the combination of 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
3161866|NCT01467817|Placebo Comparator|Exercise Control|This arm will test the benefits of exercise alone while controlling for investigator contact.
3161867|NCT01467804|Experimental|Chinese medicine|There are 90 patients with mild to moderate depress in JWXY group, who take the JWXY capsule, and placebo of Sertraline, for 2 months
3161868|NCT01467804|Active Comparator|westen medicine|There are 90 patients with mild to moderate depress in westen medicine group, who take Sertraline, and placebo of the JWXY capsule, for 2 months
3161869|NCT01467791||Patients|All patients with sarcoidosis associated pulmonary hypertension
3161870|NCT01467778|Active Comparator|ELAPR001|Tropoelastin 0.1ml SC implant
3161871|NCT01467778|Active Comparator|ELAPR002|Tropoelastin 0.1ml SC implant
3161872|NCT01467778|Active Comparator|ELAPR003|Tropoelastin 0.1ml SC implant
3161873|NCT01467778|Placebo Comparator|Saline|Normal Saline 0.9%
3161874|NCT01467765|Active Comparator|Elemental diet|
3161875|NCT01467765|Placebo Comparator|Liquid nutrient|
3161876|NCT01467752|Experimental|MCP joint|reconstruction of metacarpophalangeal (MCP) joint
3161877|NCT01467739|Active Comparator|Ambu ® aScope®|
3161878|NCT01467739|Active Comparator|a conventional reusable fiberscope.|
3161879|NCT01467726|Experimental|Dose regimen 1|Varied doses
3161880|NCT01467726|Experimental|Dose regimen 2|Varied doses
3161881|NCT01467726|Experimental|Placebo|Matching placebo
3161882|NCT01467713|Placebo Comparator|Placebo|Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.
3161883|NCT01467713|Experimental|Ramelteon SL 0.1 mg|Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
3161884|NCT01467713|Experimental|Ramelteon SL 0.4 mg|Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
3161885|NCT01467713|Experimental|Ramelteon SL 0.8 mg|Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
3161886|NCT01467700|Experimental|Ramelteon SL 0.1 mg|Ramelteon SL 0.1 mg, tablets, sublingual (SL) [dissolved under the tongue], once daily (QD), every night at bedtime for up to 8 weeks.
3161887|NCT01467700|Experimental|Ramelteon SL 0.4 mg|Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
3161888|NCT01467700|Experimental|Ramelteon SL 0.8 mg|Ramelteon SL 0.8 mg tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
3161889|NCT01467700|Placebo Comparator|Placebo|Ramelteon SL placebo-matching, tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
3161890|NCT01467687|Active Comparator|1|300 mg capsule of Verelan PM or 300 mg verapamil controlled release capsule given orally with food as a single dose with blood collected at 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, 30, 36, 48, 60 and 72 hours.
3161891|NCT01467687|Active Comparator|2|300 mg capsule of Verelan PM or 300 mg verapamil controlled release capsule given orally with food as a single dose with blood collected at 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, 30, 36, 48, 60 and 72 hours.
3161892|NCT01467674||Healthy|
3161893|NCT01467674||Chronic Periodontitis|
3161894|NCT01467674||Better Controlled T2DM|
3161895|NCT01467674||Poor Controlled T2DM|
3161896|NCT01467661|Experimental|SPD422 (anagrelide hydrochloride)|
3161897|NCT01467648|Experimental|0.5 g by 4 hour infusion|"Blood samples (approximately 2 ml) in group  0.5 g of doripenem with 4 h infusion every 8 h regimen will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem."
3161898|NCT01467648|Experimental|0.5 g by 1 hour infusion|"Blood samples (approximately 2 ml) in group  0.5 g of doripenem with 1 h infusion every 8 h regimen will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem."
3161899|NCT01467635|Active Comparator|EBUS-TBNA|Sampling using endobronchial ultrasound guided transbronchial needle aspiration
3161900|NCT01467635|Experimental|EBUS-TBNB|Sampling using endobronchial ultrasound guided transbronchial forceps biopsy needle.
3161901|NCT01467622||Study population|Patients undergoing elective pulmonary wedge resection, anatomic segmentectomy, or lobectomy.
3161902|NCT01467596|Experimental|Elderly population|MEAV50, MEAV95 Onset and duration of sensory and motor blockade
3161903|NCT01467596|Active Comparator|Middle aged population|MEAV50, MEAV95 Onset and duration of sensory and motor blockade
3161904|NCT01467583|Experimental|Renal failure on intermittent dialysis|These are patients with renal failure, on intermittent hemodialysis (IHD), receiving fondaparinux 2.5 mg subcutaneously every 48 hours
3161905|NCT01467583|Experimental|Renal failure-renal replacement therapy|These are patients with renal failure, either acute or chronic, on continuous renal replacement therapy (CRRT) receiving fondaparinux 2.5 mg subcutaneously every 48 hours
3161906|NCT01467583|Experimental|Renal failure, not on dialysis|These are patients with acute kidney injury not yet on dialysis, receiving fondaparinux 2.5 mg subcutaneously every 48 hours
3161907|NCT01467570|Experimental|Hipp ORS Apple 200|oral rehydration solution Hipp ORS 200 Apple
3161908|NCT01467570|Active Comparator|ESPGHAN ORS|ESPGHAN oral rehydration solution
3161909|NCT01467557||1-Day ACUVUE TruEye contact lens users|1-Day ACUVUE TruEye contact lens users
3161910|NCT01467557||1-Day ACUVUE MOIST contact lens users|1-Day ACUVUE MOIST contact lens users
3161911|NCT01467544|No Intervention|wait list control group|After completing time three data collection, wait-listed participants will be provided with the complete tai chi intervention (8 weeks).
3161912|NCT01467544|Experimental|Tai Chi intervention group|This participant group completes the 8-week tai chi group intervention.
3161913|NCT01467531|Experimental|Cohort 1|Period 1 Treatment A = Dolutegravir 50mg q24h x 5 days; Period 2 Treatment B = Rilpivirine 25mg q24h x 11; Period 3 Dolutegravir 50mg q24h + Rilpivirine q24h x 5 days
3161914|NCT01467531|Experimental|Cohort 2|Period 1 Treatment A = GSK1265744 30mg q24h x 12 days; Period 2 Treatment B = Rilpivirine 25mg q24h x 12; Period 3 GSK1265744 30mg q24h + Rilpivirine q24h x 12 days
3161915|NCT01467518|Other|Period 1|Subjects will be on individualize stable dose of methdaone for 8 days.
3161916|NCT01467518|Other|Period 2|Subjects will be on individualize stable dose of methadone and open label doses of 50mg Dolutegravir (DTG) every 12 hours for 5 days.
3161917|NCT01467505|Experimental|T/PR + Immunosuppressant Regimen (Tacrolimus)|Participants who were receiving tacrolimus (TAC) based immunosuppressant regimen at baseline, received telaprevir (T) 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
3161918|NCT01467505|Experimental|T/PR + Immunosuppressant Regimen (Cyclosporine)|Participants who were receiving cyclosporine (CsA) based immunosuppressant regimen at baseline, received telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
3161919|NCT01467492|Experimental|Black|Telaprevir 750 milligram (mg) tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 microgram per week (mcg/week) subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 milligram per day (mg/day) (for participants weighing <75 kilograms [kg]) or 1200 mg/day (for participants weighing >=75 kg) for 24 or 48 weeks.
3161920|NCT01467492|Experimental|Non-Black|Telaprevir 750 mg tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day (for participants weighing <75 kg) or 1200 mg/day (for participants weighing >=75 kg) for 24 or 48 weeks.
3161921|NCT01467479|Experimental|T/PR + HAART Regimen (ATV/r-Based)|Participants who were receiving atazanavir/ritonavir (ATV/r) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
3161922|NCT01467479|Experimental|T/PR + HAART Regimen (EFV-Based)|Participants who were receiving efavirenz (EFV) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet three times a day for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
3161923|NCT01467479|Experimental|T/PR + HAART Regimen (RAL-Based)|Participants who were receiving raltegravir (RAL) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
3161924|NCT01467466|Active Comparator|Arm 1|IV isotonic saline and oral placebo drug capsule
3161925|NCT01467466|Active Comparator|Arm 2|IV isotonic saline and oral N-acetylcysteine drug capsule
3161926|NCT01467466|Active Comparator|Arm 3|IV isotonic bicarbonate and oral placebo drug capsule
3161927|NCT01467466|Active Comparator|Arm 4|IV isotonic bicarbonate and oral N-acetylcysteine drug capsule
3161928|NCT01467440||PGA|Patients under glaucoma treatment with prostaglandines
3161929|NCT01467440||NON-PGA|Patient not recieving prostaglandines to treat their glaucoma
3161930|NCT01467427|Experimental|NNC-0156-000-0009|
3161931|NCT01467414|Experimental|NN1250|
3161932|NCT01467401|Experimental|A|
3161933|NCT01467401|Active Comparator|B|
3161934|NCT01467388||phacic|Study patients who still have their own ocular lens
3161935|NCT01467388||pseudophacic|Study patients who have an intraocular lens after cataract surgery
3161938|NCT01467362|Placebo Comparator|Vehicle cream|
3161939|NCT01467349||Raltegravir group|"This study will include subjects who received raltegravir and were previously exposed to NRTIs, NNRTIs, PIs, regardless of the stage of HIV disease at the start of the treatment.~A control group will be used for the evaluation of the primary and secondary objectives in comparison to patients treated with raltegravir (study patients). The control group will be constituted by subjects who never received raltegravir, matched (in a ratio 1:3) with the study subjects by gender, age (± 3 years), CD4+ cells counts (± 50 cells) and HCV co-infection status yes/no). For control patients, the last antiretroviral regimen prescribed will be considered."
3161940|NCT01467336|Other|Passive group|Rehabilitation program is immediate. Active range of motion rehabilitation is started at the sixth week.
3161941|NCT01467336|Other|Immobilization group|No passive Rehabilitation program is started. An active protocol is started after the sixth week
3161942|NCT01467336|Other|Delayed group|Rehabilitation program is delayed to the third week. Active range of motion rehabilitation is started at the sixth week.
3161943|NCT01467323|Experimental|A|
3161944|NCT01467323|Active Comparator|B|
3161945|NCT01467310|Experimental|GSK1120212|
3161946|NCT01467297|Experimental|ceftidoren|ceftidoren 200 mg bid for 5 days
3161947|NCT01467297|Active Comparator|levofloxacin|levofloxacin 500 mg once daily for 7 days
3161948|NCT01467284|Experimental|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
3161949|NCT01467284|Active Comparator|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
3161950|NCT01467258|Experimental|Amantadine|Single dose
3161951|NCT01467245|Experimental|Hypercapnia during thoracoscopy|keyhole surgery through the chest for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
3161952|NCT01467245|Experimental|Open surgery|open surgery for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
3161953|NCT01467232|Experimental|Autologous CD133+ Stem Cells|Autologous CD133+ stem cells
3161954|NCT01467232|Placebo Comparator|Saline solution containing autologous plasma|Saline solution containing autologous plasma without CD133+ (indistinguishable from the autologous CD133+ stem cells)
3161955|NCT01467219|Experimental|PET Probe|"Patients will receive an IV injection of approximately 5 MBq/kg body weight of 18F-FDG (Fludeoxyglucose) (up to 550 MBq). Following injection, patients will undergo CT and PET scans. Intraoperatively, a hand held gamma counter will be used to identify hot lymph nodes."
3161956|NCT01467206|Experimental|Long term follow up program|
3161957|NCT01467206|Active Comparator|Standard care|
3161958|NCT01467193||1|Endurance trained athletes: minimal >50 mlO2/KG body weight
3161959|NCT01467193||2|Sedentary healthy control subjects: age, BMI, Gender and waist matched (to the growth hormone deficient patients)
3161960|NCT01467193||3|GHD patients without a GH substitution therapy in the last 6 months
3161961|NCT01467180|Experimental|HCO CVVHD|treatment of rhabdomyolysis pts with septeX dialyzer
3161962|NCT01467180|Active Comparator|HF CVVH|treatment of rhabdomyolysis pts with standard high flux dialyzer
3161963|NCT01467167||Baseline|Baseline group in which patients are anesthetized without the use of Smart Pilot View, according to common practice.
3161964|NCT01467167||Smart Pilot View Group|Study group in which patients are anesthetized with the use of Smart Pilot View.
3161965|NCT01467154||Control group|
3161966|NCT01467154||NAC group|
3161967|NCT01467141|Experimental|IAsp|
3161968|NCT01467141|Active Comparator|HI|
3161969|NCT01467128|Active Comparator|Structured expert pharmacist review|
3161970|NCT01467128|No Intervention|Normal pharmaceutical care in hospital|
3161971|NCT01467115|Experimental|Treatment|Treatment with induction chemotherapy followed by radiation and cetuximab.
3161972|NCT01467102||Patients|> 18 years of age
3161973|NCT01467089||schizophrenia|"Inclusion Criteria: Inpatients and outpatients aged 18-75 years old who have been taking antipsychotics for longer than 6 months in their life time, and that have been compliant for the past week. Patients will be referred by their treating doctors if they have some evidence of movement disorder based on the physician's clinical judgment. We will also include 25% of the sample without any evidence of movement disorder.~Exclusion Criteria: Patients who have medical conditions which make it difficult to perform a physical examination. Patients who are clinically too ill to consent and/or unable to cooperate with the examination procedures."
3161974|NCT01467076|Active Comparator|Inhaled PGE1 (150 ng/kg/min)|150 ng/kg/min Inhaled PGE1
3161975|NCT01467076|Placebo Comparator|Aerosolized Normal Saline|Eligible infants will be randomly assigned to either IPGE1 [150ng/kg/min], IPGE1 [300ng/kg/min] or control group. Infants in the control group will receive the same volume of aerosolized saline and oxygen from the respirator.
3161976|NCT01467076|Active Comparator|Inhaled PGE1 (300 ng/kg/min)|300 ng/kg/min of Inhaled PGE1
3161977|NCT01467063|Active Comparator|Glutamine|
3161978|NCT01467063|Placebo Comparator|Placebo|
3161979|NCT01467050|Active Comparator|Application of STOPP/START criteria|
3161980|NCT01467050|No Intervention|Control|
3161981|NCT01467037||Rotavirus-negative|Patients with a negative result for rotavirus via enzyme immunoassay (EIA). No intervention done.
3161982|NCT01467037||Rotavirus-positive|Patients with a positive result for rotavirus via enzyme immunoassay (EIA). Rotavirus-positives were confirmed via real-time reverse-transcriptase polymerase chain reactions (RT-PCR). RT-PCR results were used in the event of discordant EIA results. Rotavirus genotyping was performed. No intervention done.
3161983|NCT01467024||EIA Negative|Blood donor specimens that tested non-reactive by previously licensed HTLV screening assay.
3161984|NCT01467024||EIA Repeat Reactive|Blood donor specimens that tested repeat reactive by previously licensed HTLV screening assay, but are unconfirmed.
3162029|NCT01466725|Experimental|Cohort 1|25 mg daily for 4 weeks (8 active/2 control)
3162849|NCT01461408|Experimental|Beauty Salon #8b|Females ages 9-18
3161985|NCT01467024||Known Positive|Blood donor specimens that tested repeat reactive with a licensed HTLV screening assay and have been confirmed through additional, unlicensed supplemental testing.
3161986|NCT01467011||Cases|de novo liver transplant recipients receiving Enteric-coated Mycophenolate Sodium
3161987|NCT01466998|Experimental|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
3161988|NCT01466998|Active Comparator|Music Therapy|Participant will use an identical appearing device, programmed to play quiet, relaxing non-rhythmic music while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
3161989|NCT01466985|Experimental|Panel A doravirine|
3161990|NCT01466985|Experimental|Panel B doravirine|Panel B will initiate upon satisfactory review of safety and tolerability from Panel A, and all safety, tolerability and pharmacokinetic data from the study MK-1439-001.
3161991|NCT01466985|Experimental|Panel C doravirine|Panel C is optional. If conducted, the dose will be confirmed after review of data from prior panels.
3161992|NCT01466985|Experimental|Panel A, B, C Placebo|Participants on each Panel will be randomized to receive placebo.
3161993|NCT01466972|Experimental|Pazopanib in combination with a NSAI|Non-randomized, open label
3161994|NCT01466959|Active Comparator|AD- acetic acid dialysate|AD is a standard bicarbonate based dialysate with a small amount of acetic acid which is the standard of care for dialysis.
3161995|NCT01466959|Experimental|CD - citrasate dialysate|Dialysis with a citric acid based dialyasate.
3161996|NCT01466946||semi-structured interviews|A qualitative study of MSKCC lung cancer patients of Hispanic/Latino descent by collecting retrospective patient narratives to understand the processes that led them to seek medical help when they did, their experiences in seeking and receiving medical guidance, as well as their decisions regarding lung cancer treatment. In addition, we will explore how these patients' representations of lung cancer with its associated risk factors and symptoms affected their treatment decisions.
3161997|NCT01466933|Experimental|Community-based|Community trained peer educator delivers parenting sessions to mothers in the village on a monthly basis
3161998|NCT01466933|Active Comparator|Government-based|Government community health workers, trained, deliver the intervention to mothers in the village
3161999|NCT01466933|No Intervention|Control|Mothers receive the standard care which is a visit from the health worker
3162000|NCT01466907|Active Comparator|Intervention group|Control of secondary prevention at three months and one year after stroke and referral to physician if medical interventions are needed. Assessment of functional status and self-reports on health outcome. Supportive counselling provided.
3162001|NCT01466907|Other|Control group|Standard care with no outlined follow-up until one year after stroke. Control of secondary prevention after one year after stroke and referral to physician if medical interventions are needed. Follow-up one year after stroke according to the same protocol as the intervention group.
3162002|NCT01466894|Experimental|IMM 124-E high dose|IMM 124-E 3600 mg per day
3162003|NCT01466894|Experimental|IMM 124-E low dose|IMM 124-E 1800 mg per day
3162004|NCT01466894|Placebo Comparator|Placebo|Placebo tablets
3162005|NCT01466881|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.
3162006|NCT01466868|Experimental|MK2206|Treatment is started the day after registration (day 1)until progression according to Cheson international response criteria or documented toxicity.
3162007|NCT01466855|Experimental|Treatment of Retinoblastoma|Study of Intra-Ophthalmic Artery Topotecan infusion for the Treatment of Retinoblastoma.
3162008|NCT01466842|Other|Catheter ablation|
3162009|NCT01466842|No Intervention|Antiarrhythmic drugs|Three months before starting antiarrhythmic drugs, a subcutaneous loop recorder will be implanted.
3162010|NCT01466829|Placebo Comparator|Control|Control patients treated with placebo.
3162011|NCT01466829|Active Comparator|Intervention|Daily injection with Parathyroid hormone
3162012|NCT01466816|Experimental|Saturated fatty acid test meal|
3162013|NCT01466816|Experimental|Monounsaturated fatty acid meal|
3162014|NCT01466816|Experimental|Polyunsaturated fatty acid meal|
3162015|NCT01466803|Active Comparator|Vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
3162016|NCT01466803|Placebo Comparator|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
3162017|NCT01466790|Experimental|Arm 1|30 patients will receive TMC435 (150 mg once a day) plus PSI-7977(GS7977) (400 mg once a day) with ribavirin (1000-1200 mg/day) for 24 weeks and followed by a 24-week follow-up phase.
3162018|NCT01466790|Experimental|Arm 2|15 patients wiil receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) for 24 weeks of and followed by a 24-week follow-up phase.
3162019|NCT01466790|Experimental|Arm 3|30 patients will receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) with ribavirin (1000-1200 mg/day) for 12 weeks and followed by a 36-week follow-up phase.
3162020|NCT01466790|Experimental|Arm 4|15 patients will receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) for 12 weeks and followed by a 36-week follow-up phase.
3162021|NCT01466777|Active Comparator|traditional laparoscopic surgery type|
3162022|NCT01466777|Experimental|Robotic assisted operation type|
3162023|NCT01466764|Active Comparator|Anakinra|Two subcutaneous injections of anakinra (IL-1ra) were given, the first one hour prior to surgery and the second 24 hours after surgery.
3162024|NCT01466764|Placebo Comparator|Saline injection|Two subcutaneous injections of normal saline (same volume as the anakinra group injection) were given, the first one hour prior to surgery and the second 24 hours after surgery.
3162025|NCT01466751|Active Comparator|Engaging computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
3162026|NCT01466751|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
3162027|NCT01466738|Experimental|HRV-16 (100 TCID50)|
3162028|NCT01466738|Experimental|HRV-16 (1000 TCID50)|
3162030|NCT01466725|Experimental|Cohort 2|50 mg once daily for 4 weeks (8 active/2 control)
3162031|NCT01466725|Experimental|Cohort 3|100 mg daily for 6 weeks (8 active/2 control)
3162032|NCT01466725|Experimental|Cohort 4|100 mg twice daily for 6 weeks (8 active/2 control)
3162033|NCT01466712|Experimental|Tiotropium+formoterol/beclomethasone|run-in of 4 weeks with thiotropium cross-over after first treatment period of 4 weeks
3162034|NCT01466712|Sham Comparator|tiotropium+placebo|cross-over cfr arm1
3162035|NCT01466686|Experimental|Temozolomide with Low Dose Fractionated Radiation Therapy|"All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.~All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If > 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below. Otherwise, following a 1 month waiting period after the first cycle of adjuvant LDFRT plus temozolomide for the first cohort of patients, the phase 2 study will open for full accrual. Patients will receive radiation with the first six 28-day cycles of temozolomide."
3162036|NCT01466673|Experimental|Ethinyl estradiol/Norgestimate (EE/NGM)|
3162037|NCT01466673|Active Comparator|Ethinyl estradiol/Desogestrel (EE/DSG)|
3162038|NCT01466660|Experimental|afatinib|afatinib once daily.
3162039|NCT01466660|Active Comparator|gefitinib|gefitinib once daily
3162040|NCT01466647|Other|AXL1717 in combination with Gemcitabine HCL and Carboplatin|AXL1717 in combination with Gemcitabine HCL and Carboplatin
3162041|NCT01466634||permanent polymer DES|
3162042|NCT01466634||bioabsorbable polymer DES|
3162043|NCT01466621||Previously RV Paced|Patients who were RV paced prior to receiving a cardiac resynchronization therapy device.
3162044|NCT01466621||Non-Previously RV Paced|Patients who received a CRT device without being previously RV paced.
3162045|NCT01466608|Experimental|Rosuvastatin|Rosuvastatin 20 mg will be administered once a day for 8 weeks (open-label, one-arm, single-sequence design)
3162046|NCT01466595|Experimental|Arm A: Treatment with rifaximin|Participants were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
3162047|NCT01466595|No Intervention|Arm B: No study treatment|No study treatment for 4 weeks
3162048|NCT01466582||HIV-negative controls|A group of HIV-negative controls, aged 45 years and above, that is recruited at the STD-clinic of the Public Health Service Amsterdam or at the existing Amsterdam Cohort Studies.
3162049|NCT01466582||HIV-positive patients|A group of HIV-1-infected patients, aged 45 years and above, that is recruited at the HIV outpatient clinic of the Academic Medical Center.
3162050|NCT01466569|Experimental|AbGn-7 phase 1a cohort 1|
3162051|NCT01466569|Experimental|AbGn-7 phase 1a cohort 2|
3162052|NCT01466569|Experimental|AbGn-7 phase 1a cohort 3|
3162053|NCT01466569|Experimental|AbGn-7 phase 1b cohort 1|
3162054|NCT01466569|Experimental|AbGn-7 phase 1b cohort 2|
3162055|NCT01466556||Obese children|
3162056|NCT01466543|Active Comparator|Zydena (Udenafil)|Zydena (Udenafil) 100 mg, once
3162057|NCT01466543|Placebo Comparator|Placebo|placebo medication
3162058|NCT01466530|Placebo Comparator|Placebo|sublingual two moistened white coated placebo tablets
3162059|NCT01466530|Active Comparator|Misoprostol|sublingual misoprostol (400 µg)
3162060|NCT01466517|Active Comparator|Reference Drug|
3162061|NCT01466517|Active Comparator|Test Drug|
3162062|NCT01466491|Placebo Comparator|4-site injection|The superior technique of Phase 1 will be compared to a 4-site technique (both techniques will have no wait prior to dilation unless wait was superior in Phase 1).
3162063|NCT01466491|Active Comparator|2-site Injection|The superior technique of Phase 1 will be compared to a 2-site technique (2 mL injected at the tenaculum site, 18 mL equally distributed between 4 and 8 o'clock) in a randomized fashion (both techniques will have no wait prior to dilation unless wait was superior in Phase 1).
3162064|NCT01466491|Placebo Comparator|4-Site PCB followed by 3-minute wait|Women will be randomized to receive a 4-site PCB followed by a 3-minute wait (PCB 20/4/3) prior to dilation
3162065|NCT01466491|Active Comparator|4-site PCB followed by no wait|Women will be randomized to receive a 4-site PCB followed by no wait (PCB 20/4/0).
3162066|NCT01466478|Experimental|LEO 29102 plus calcipotriol|
3162067|NCT01466465|Experimental|Vigantol|
3162068|NCT01466465|Placebo Comparator|neutral oil (vigantol carrier)|
3162069|NCT01466452|Active Comparator|Aspirin 100|
3162070|NCT01466452|Active Comparator|Aspirin 200|
3162071|NCT01466452|Active Comparator|Aspirin 100 x 2|
3162072|NCT01466439|Other|high frequency rTMS|
3162073|NCT01466439|Other|low frequency rTMS|
3162074|NCT01466426||DVT confirmed|
3162075|NCT01466426||DVT ruled out|
3162076|NCT01466426||PE confirmed|
3162077|NCT01466426||PE ruled out|
3162078|NCT01466413|Experimental|Restylane|"Patients with an even subject identification number (SIN) (02, 04, 06, 08, 10, 12, 14, 16) will have ELAPR to the right arm and the control to the left, where patients with an odd subject identification number (01, 03, 05, 07, 09, 11, 13, 15) will have the ELAPR to the left arm and the control to the right.~Patients will receive either device ELAPR002c or ELAPR002e. This will alternate to minimise bias between the right and left arms.~The first group of eight patients (01 - 08) will have their biopsy performed at day 169. The second group of eight patients (09 - 16) will have their biopsy at day 85."
3162079|NCT01466400||infants two to six months of age|
3162080|NCT01466387|Active Comparator|TF+YF|Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.
3162081|NCT01466387|Active Comparator|TF + YF + MenACWY-CRM197|Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.
3162082|NCT01466387|Active Comparator|JE + Rabies|Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies vaccine.
3162129|NCT01466088|Experimental|AZD3480|
3162844|NCT01461408|Experimental|Beauty Salon #6a|Mothers of 9-18 year old females
3162083|NCT01466387|Active Comparator|JE + Rab + MenACWY-CRM197|Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.
3162084|NCT01466387|Active Comparator|Rabies|Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine.
3162085|NCT01466387|Active Comparator|MenACWY-CRM197 (Combined)|Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.
3162086|NCT01466374|Experimental|Cohort 1: Induction|Placebo
3162087|NCT01466374|Experimental|Cohort 2: Induction|Anti-IP-10 Antibody
3162088|NCT01466374|Experimental|Cohort 3: Induction|Anti-IP-10 Antibody
3162089|NCT01466374|Experimental|Cohort 1: Maintenance|Placebo
3162090|NCT01466374|Experimental|Cohort 2: Maintenance|Anti-IP-10 Antibody
3162091|NCT01466374|Experimental|Cohort 3: Maintenance|Anti-IP-10 Antibody
3162092|NCT01466374|Experimental|Cohort 1: Open Label|Anti-IP-10 Antibody
3162093|NCT01466361|Active Comparator|Lower dose Nicotine|lower dose nicotine lozenge
3162094|NCT01466361|Active Comparator|Higher dose Nicotine|higher dose Nicotine lozenge
3162095|NCT01466361|Placebo Comparator|Placebo|Placebo
3162096|NCT01466348|Experimental|Paracetamol and Caffeine|Paracetamol and caffeine
3162097|NCT01466348|Active Comparator|Paracetamol|Paracetamol
3162098|NCT01466335|Experimental|Ronacaleret 100mg once daily|1 x 100mg oral tablet
3162099|NCT01466335|Experimental|Ronacaleret 100mg twice daily|1 x 100mg oral tablet twice daily
3162100|NCT01466335|Experimental|Ronacaleret 200mg once daily|2 x 100mg oral tablet
3162101|NCT01466335|Experimental|Ronacaleret 200mg twice daily|2 x 100mg tablets twice daily
3162102|NCT01466335|Experimental|Ronacaleret 400mg once daily|4 x 100mg tablets
3162103|NCT01466335|Placebo Comparator|Placebo|Matching number of identical placebo tablets
3162104|NCT01466322|Experimental|Oral formulations of GSK2018682|Three oral formulations of GSK2018682. A: CD2 Capsule; B: CD3 non-micronised Tablet; C: CD3 micronised Tablet; D: CD3 non-micronised Tablet in fed state
3162105|NCT01466309|Experimental|treatment|patients treated with Somnoguard
3162106|NCT01466296|Experimental|Re-Step|"Mechatronic shoe with a sole made to change slopes in the swing phase of walking.~This unpredictable change will introduce a situation of necessary adaptation to keep balance"
3162107|NCT01466296|Experimental|Dummy shoes|The shoes are in the same shape and weight of the Re-Step without the perturbations.
3162108|NCT01466296|Active Comparator|treadmill|A treadmill with safety adaptation and all the usual characteristics of speed and slopes of fitness treadmills.
3162109|NCT01466270|Experimental|Arm I|Patients receive donepezil hydrochloride PO QD.
3162110|NCT01466270|Placebo Comparator|Arm II|Patients receive placebo PO QD.
3162111|NCT01466231|Experimental|everolimus 10 mg po daily|everolimus 10 mg po daily
3162112|NCT01466218||WTC Volunteers and Workers|Any current participant of the World Trade Center Health Program-Clinical Center of Excellence, formerly known as World Trade Center Medical Monitoring and Treatment Program
3162113|NCT01466205|Experimental|DAR 0-100A|The examination of SPD subjects, who are more likely than schizophrenia patients to show significant cognitive improvement after the use of single doses of dopamine agonists, such as DAR-0100A provides an excellent opportunity to demonstrate the effectiveness of D1 agonists on cognition in the schizophrenia spectrum.
3162114|NCT01466205|Placebo Comparator|Placebo|Some subjects receive placebo, instead of the study drug, in a double-blind randomized fashion. This allows for performance comparison between SPD subjects on DAR-0100A and those on placebo. The hypothesis is that SPD subjects on DAR-100A will show improvement on primary measures greater than SPD subjects randomized to placebo between baseline and post-drug.
3162115|NCT01466192|Experimental|MP-424|
3162116|NCT01466179|Experimental|Blinatumomab|Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.
3162117|NCT01466166||KRYSTEXXA|All participants with exposure to pegloticase
3162118|NCT01466153|Active Comparator|Rituximab + Bendamustine|Rituximab was administered by IV infusion as 375 mg/m^2 on Day 2 of Cycle 1 and then 500 mg/m^2 on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of rituximab in each cycle.
3162119|NCT01466153|Experimental|MEDI-551 2 mg/kg + Bendamustine|MEDI-551 2 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.
3162120|NCT01466153|Experimental|MEDI-551 4 mg/kg + Bendamustine|MEDI-551 4 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.
3162121|NCT01466140|No Intervention|Control group|Patients in the control group were asked to participate in a patient satisfaction study. They were asked to fill in a questionnaire with respect to patient satisfaction.
3162122|NCT01466140|Experimental|Use of request card|Patients in the intervention group were told that the practice was participating in a patient satisfaction study, and they were given an envelope with information about the 'doorknob phenomenon' and a request card. The envelope for the control group only consisted of information about a patient satisfaction study, without any information on the 'doorknob phenomenon', and without a request card. Both groups received the same letter with patient information about the study.
3162123|NCT01466127|Placebo Comparator|Placebo|Matched nasal spray placebo.
3162124|NCT01466127|Experimental|Oxytocin|Liquid intranasal oxytocin administered in a nasal spray.
3162125|NCT01466114|Experimental|Group A: Estriol|Standard MS Treatment + Estriol
3162126|NCT01466114|Placebo Comparator|Group B: Placebo|Standard MS Treatment + Placebo
3162127|NCT01466101|Active Comparator|Pregabalin administration|Administration of pregabalin
3162128|NCT01466101|Placebo Comparator|Placebo|Administration of placebo
3162130|NCT01466088|Active Comparator|Donepezil|Donepezil will be administered at 5 mg daily for 4 weeks and escalated to 10 mg daily for the remainder of the study.
3162131|NCT01466075|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use the Apollo Evolution Investigational BG Monitoring System.
3162132|NCT01466062|Experimental|Palivizumab|15 mg/kg at 30-day intervals; at least 4 intramuscular injections up to a maximum of 7 intramuscular injections as appropriate for prophylaxis of severe respiratory syncytial virus (RSV) during the RSV season.
3162133|NCT01466036|Experimental|Metastatic or Unresectable PNET|35 patients with pancreatic neuroendocrine tumors receiving cabozantinib
3162134|NCT01466036|Experimental|Metastatic or Unresectable Carcinoid|35 patients with advanced or metastatic carcinoid tumor receiving cabozantinib
3162135|NCT01466010||osteoid osteoma|patients with osteoid osteoma at any location
3162136|NCT01465997|Experimental|Lacosamide|50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
3162137|NCT01465997|Active Comparator|Carbamazepine-Controlled Release (CBZ-CR)|200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum of 3.5 Years)
3162138|NCT01465984|Experimental|IV Paracetamol|
3162139|NCT01465984|Active Comparator|IV Morphine Sulfate|
3162140|NCT01465971||not acclimatized|no stay in an altitude above 2500 m within the last 3 Months
3162141|NCT01465971||acclimatized|stay above 2500 m with the last 14 days
3162142|NCT01465958|Active Comparator|Intravenous GAMUNEX-C|
3162143|NCT01465958|Experimental|Subcutaneous GAMUNEX-C|
3162144|NCT01465945|Other|Rectal Defect Sutured|The subject will have his/her defect sutured after the rectal tumors have been removed.
3162145|NCT01465945|Other|Rectal Defect Unsutured|The defect will be left open and let naturally close after the rectal tumor has been removed by TEM.
3162146|NCT01465932|Active Comparator|No proprioception|Nursing professionals to diagnose disorders of the rotator cuff previously randomly allocated in this group did stretching exercises of the muscles of the cervical spine and chest, strengthening the muscles of the rotator cuff and stabilizers of the scapula, in addition to cryotherapy reduction of pain.
3162147|NCT01465932|Experimental|Proprioceptive exercises|Nursing professionals to diagnose disorders of the rotator cuff previously randomly allocated in this group did stretching exercises of the muscles of the cervical spine and chest, strengthening the muscles of the rotator cuff and stabilizers of the scapula, proprioception exercises to improve motor control, besides cryotherapy for reduction of pain.
3162148|NCT01465919|Experimental|mirtazapine|mirtazapine
3162149|NCT01465919|Other|Supportive psychotherapy|Supportive psychotherapy will be given by a specialized psychiatrist.
3162150|NCT01465906|Experimental|tulobuterol combined with tiotropium bromide|
3162151|NCT01465906|Active Comparator|Tiotropium bromide|
3162152|NCT01465893|Active Comparator|vitamin D|vitamin d 50000/w
3162153|NCT01465893|Sham Comparator|control|follow up
3162154|NCT01465880|No Intervention|Part B. Healthy Caucasian adult non-smokers|Non-smokers
3162155|NCT01465880|Experimental|Part A.Healthy Caucasian adult smokers|No product will be investigated in this study. Smokers will smoke their own conventional cigarettes only.
3162156|NCT01465867|Experimental|Selenium|
3162157|NCT01465867|Placebo Comparator|Sugar Pill Placebo|
3162158|NCT01465867|Experimental|Selenium + L-Thyroxine (LT4)|
3162159|NCT01465867|Experimental|Sugar Pill Placebo + L-Thyroxine (LT4)|
3162160|NCT01465854||LCINS|Never smokers with newly diagnosed lung cancer
3162161|NCT01465841|Experimental|Embolization with the PC 400 coils|
3162162|NCT01465828|Active Comparator|high clopidogrel dose|Patients will be randomized to this arm to receive before high clopidogrel dose and after crossover they will receive standard dose of prasugrel
3162163|NCT01465828|No Intervention|prasugrel standard dose|Patients will be randomized to this arm to receive before standard dose of prasugrel and after crossover they will receive high clopidogrel dose.
3162164|NCT01465815|Experimental|Treatment (adjuvant enzyme inhibitor and radiation therapy)|"Optional non-therapeutic (biomarker) portion: Patients are randomized to 1 of 3 treatment arms.~Arm A: Patients receive erlotinib hydrochloride PO QD and linsitinib PO BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
3162165|NCT01465815|Experimental|Erlotinib and Placebo (Sugar Pill)|"Arm B: Patients receive erlotinib hydrochloride PO QD and placebo PO QD or BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
3162166|NCT01465815|Experimental|OSI-906 and Placebo (Sugar Pill)|"Arm C: Patients receive linsitinib PO BID and placebo PO QD or BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
3162167|NCT01465802|Experimental|Cohort I|Arm A: Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Doxycycline placebo orally BID for 4 weeks Arm B: Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Doxycycline 100 mg orally BID for 4 weeks
3162399|NCT01464385|Experimental|Nutritional Beverage #3|Nutritional Beverage with an amino acid Oral 237 ml
3162845|NCT01461408|Experimental|Beauty Salon #6b|Females ages 18-26
3162168|NCT01465802|Experimental|Cohort II|Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
3162169|NCT01465802|Experimental|Cohort III|Cohort III is an interrupted dosing schedule of dacomitinib in the first cycle only
3162170|NCT01465776|Experimental|Treatment (chemoprevention)|
3162171|NCT01465763|Experimental|tofacitinib 10 mg BID|
3162172|NCT01465763|Placebo Comparator|Placebo|
3162173|NCT01465750||Ovarian Cancer|
3162174|NCT01465737||Patients with uterine cancer|All patients diagnosed with uterine cancer in Taiwan between 1979-2008
3162175|NCT01465724|Experimental|Renal denervation|
3162176|NCT01465711||Control|Admission to the Intensive Care Unit (ICU) after abdominal surgery without suspicion / evidence of peritonitis.
3162177|NCT01465711||Peritonitis|Admission to the Intensive Care Unit (ICU) after abdominal surgery with suspicion / evidence of peritonitis
3162178|NCT01465698|Experimental|Exercise|
3162179|NCT01465698|Experimental|Counseling|
3162180|NCT01465698|Experimental|Exercise and counseling|
3162181|NCT01465698|Other|Control group|Participants in the control group only participate in study measurements.
3162182|NCT01465685|Experimental|MDMA, methylphenidate, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
3162183|NCT01465672||neurosurgical patients|Patients undergoing transphenoidal pituitary adenoma resection and patients with transcranial surgery of tumors close to the pituitary gland and hypothalamus.
3162184|NCT01465659|Experimental|Temozolomide 100 mg/m2 and Pazopanib 400 mg|Temozolomide 100 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
3162185|NCT01465659|Experimental|Temozolomide 75 mg/m2 and Pazopanib 400 mg|Temozolomide 75 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
3162186|NCT01465659|Experimental|Temozolomide 75mg/m2 and Pazopanib 200 mg|Temozolomide 75mg/m2 on days 1-7 and 15-21 , Pazopanib 200 mg on days 1-28
3162187|NCT01465659|Experimental|Temozolomide 150 mg/m2 and Pazopanib 400 mg|Temozolomide 150 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
3162188|NCT01465659|Experimental|Temozolomide 150 mg/m2 and Pazopanib 800 mg|Temozolomide 150 mg/m2 on days 1-7 and 15-21 , Pazopanib 800 mg on days 1-28
3162189|NCT01465646|Active Comparator|with idodine|
3162190|NCT01465646|Experimental|without iodine|
3162191|NCT01465633|Active Comparator|with iodine|
3162192|NCT01465633|Experimental|without iodine|
3162193|NCT01465620|Experimental|Coaching|active hygienic-dietetic coaching
3162194|NCT01465620|Active Comparator|control|reference hygienic-dietetic recommendations
3162195|NCT01465607|Experimental|Theory-based counseling (Mujer Segura)|Will consist of 40 FSWs at each of 12 clinics, randomized into this condition from a pool of 80 eligible participants.
3162196|NCT01465607|Active Comparator|CENSIDA counseling program (didactic)|Will consist of 40 FSWs at each of 12 clinics, randomized into this condition from a pool of 80 eligible participants.
3162197|NCT01465594|Active Comparator|transurethral catheter after EERPE/ RALP|Recording of QoL measured by visual analogue ( pain )scale,EORTC QlQ -C 30 and QLQ - PR 25 questionnaires, incontinence rate, complication rate regarding insufficiency and strictures of vesicourethral anastomoses and urinary tract infection; demand of re-catheterization due to urinary retention and demand of antispasmodics
3162198|NCT01465594|Active Comparator|suprapubic catheter after EERPE /RALP|Recording of QoL measured by visual analogue ( pain )scale,EORTC QlQ -C 30 and QLQ - PR 25 questionnaires, incontinence rate, complication rate regarding insufficiency and strictures of vesicourethral anastomoses and urinary tract infection; demand of re-catheterization due to urinary retention and demand of antispasmodics
3162199|NCT01465581||Neurogenic incontinence|The target population of this study is children with primary or secondary daytime urinary incontinence, who have failed to improve adequately despite compliance with at least 6 months of standard medical therapy. These children will have abnormal urodynamics, a normal bladder ultrasound and an MR imaging showing that the conus of the spinal cord is at a normal position and that there is no other significant dysraphic lesion present.
3162200|NCT01465568|Active Comparator|Denosumab|denosumab
3162201|NCT01465568|Active Comparator|bisphosphonates|continuation of bisphosphonates
3162202|NCT01465555|Experimental|Clinical Alert|Counselors in this condition will work with the modified RecoveryTrack tested in the pilot study which has been altered to provide automated Clinical Alerts at either the intake, Month 1, or Month 2 CRM interview for High Risk patients. In addition, High Risk patients will be flagged in the counselor's caseload for discussion with clinical supervisors. Counselors in this condition will receive the Clinical Alert + Cognitive Behavioral Intervention (CBI) training, as well as monthly feedback from the Principal Investigator on their delivery of the CBI Months 1-3, with a booster session at Month 6.
3162203|NCT01465555|No Intervention|Treatment As Usual|Counselors in this condition will work with the original RecoveryTrack which has not been altered to provide automated Clinical Alerts for High Risk patients. Supervisors will receive no automated help in identifying these clients in the counselors' caseloads. The Clinical Alert feature will not be discussed in the training these counselors receive. Rather, the counselors will receive an attention-control training, a one-day training on assessment and treatment planning, with monthly tips and reminders for six months.
3162204|NCT01465542||Oral NAC|Patients receiving oral NAC treatment after an acute acetaminophen ingestion.
3162205|NCT01465542||IV NAC|Patients receiving IV NAC after an acute Acetaminophen ingestion.
3162206|NCT01465529|Experimental|Active|
3162207|NCT01465529|Placebo Comparator|Placebo|
3162208|NCT01465516||Hispanic, HCV genotype 1|Historical group will be a continuous group of Hispanic patients with genotype 1 who were naive to treatment and completed or initiated 48 weeks of pegylated interferon and ribavirin. Patients, who discontinued the treatment due to side effects, adherence issues, or treatment failure, will be included and analyzed based on intention to treat analysis. All patients will be stratified according to their SVR, relapse and no response rate. RVR, EVR, and ETR will be also collated and compared to the study group.
3162209|NCT01465503|Placebo Comparator|Unfractionated Heparin|Patients randomized to the Control group will receive unfractionated heparin (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
3162210|NCT01465503|Active Comparator|Bivalirudin|Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR <30 ml/min/1.73 m2.
3162211|NCT01465490|Experimental|Monitoring and Feedback Intervention|
3162212|NCT01465490|No Intervention|Treatment as usual|
3162213|NCT01465477|Experimental|Fibromyalgia arm|Patients fulfilling ACR 1990 Criteria for classification of Fibromyalgia, receiving the vaccination.
3162214|NCT01465477|Experimental|Heathy controls|Healthy controls receiving Influenza vaccination
3162215|NCT01465464|Experimental|Orantinib|
3162216|NCT01465464|Placebo Comparator|Placebo|
3162217|NCT01465451|Active Comparator|ARM A- surgery alone|all cases will receive standard surgical procedures of curative resection for colorectal cancer, without intra-operative chemotherapy.
3162218|NCT01465451|Experimental|ARM B surgery plus chemotherapy|all cases will receive standard surgical procedures described as arm A. In addition, all cases will receive 5-FU chemotherapy during operation.
3162219|NCT01465438|Experimental|Adalimumab|Responders at week 24 continue treatment with adalimumab. Non-responders at week 24 stops treatment with adalimumab.
3162220|NCT01465425||E3/E4 Case Group|The Case Group will target consenting 141 participants from the cases with indeterminate but potentially significant findings (E3/E4s) other than pulmonary nodules.
3162221|NCT01465425||Pulmonary Nodules Case Group|The Pulmonary Nodules Case Group will comprise 119 cases with E3/E4 ECFs characterized as pulmonary nodules.
3162222|NCT01465425||E1 Control Group|The E1 Control Group will be drawn from the 866 E1 ECF cases from ACRIN 6664 to create a cohort of 260 E1 ECF cases. The Control Group for comparison with the Case Group and the Pulmonary Nodules Case Group will be selected at the Biostatistics and Data Management Center (BDMC). The BDMC will match E1 141 controls to the 141 case-group participants with indeterminate but potentially significant findings (E3/E4s). The BDMC will also match 119 E1 controls to the 119 E3/E4 pulmonary nodules cases. Controls will be matched by site, age caliper (5 years), and sex where possible.
3162223|NCT01465412|Experimental|Mild Hepatic Impaired (HI) Part 1|Participants with mild chronic liver disease enrolled in Part 1 received one 5-mg preladenant tablet, orally, on Day 1.
3162224|NCT01465412|Active Comparator|Healthy to Match Mild HI Part 1|Healthy volunteers with normal hepatic function matched to participants with mild chronic liver disease by race, age, BMI, and gender, enrolled in Part 1 received one 5-mg preladenant tablet, orally, on Day 1.
3162225|NCT01465412|Experimental|Moderate HI Part 2|Participants with moderate chronic liver disease enrolled in Part 2 received one 5-mg preladenant tablet, orally, on Day 1.
3162226|NCT01465412|Active Comparator|Healthy to Match Moderate HI Part 2|Healthy volunteers with normal hepatic function matched to participants with moderate chronic liver disease by race, age, BMI, and gender, enrolled in Part 2 received one 5-mg preladenant tablet, orally, on Day 1.
3162227|NCT01465399|Experimental|PRGF-Endoret|
3162228|NCT01465399|Active Comparator|Conventional treatment|
3162229|NCT01465386|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive bortezomib SC on days 1, 8, 15 and 22. Treatment repeats every 35 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3162230|NCT01465373|Active Comparator|Progesterone in Oil|"Donor egg recipients will begin progesterone 50 mg IM injection starting the day after donor egg fertilization, and continue daily until pregnancy results can be determined.~If pregnant, donor egg recipient will continue progesterone 50 mg IM injections daily until approximately 9 weeks of pregnancy."
3162231|NCT01465373|Active Comparator|Endometrin|"Donor egg recipients will begin Endometrin 100 mg per vagina three times daily starting the day after donor egg fertilization and continue until pregnancy result can be determined.~If pregnant, donor egg recipients will continue Endometrin 100 mg TID until approximately 9 weeks of pregnancy."
3162232|NCT01465360||Study patients|Patients newly referred to a Reference Memory Center with a complaint of memory impairment for AD diagnostic workup.
3162233|NCT01465347|Experimental|TSC 0.25 mg/kg for 9 or 18 doses|This was an open-label, sequential-cohort, dose-escalation study in two phases. Phase 1 was a safety run-in evaluating Trans Sodium Crocetinate (TSC) in 3 subjects who received 3 doses per week for 3 weeks (9 doses in total). Phase 2 engaged 56 subjects who received 3 doses per week for 6 weeks (18 doses in total). TSC was consistently dosed at 0.25mg/kg in both phases.
3162234|NCT01465334|Active Comparator|Previously Treated|Subjects with 17p deletion CLL who have received prior treatment
3162235|NCT01465334|Active Comparator|Treatment Naive|Subjects with 17p deletion CLL with no prior treatment
3162236|NCT01465308|Experimental|receiving Honey|The patients will receive honey mouthwash rinses
3162237|NCT01465308|Active Comparator|Saline mouthwash|The patients in this group will receive saline rinses
3162238|NCT01465295|Experimental|HemiBridge|Patients meeting eligibility criteria will be treated with the HemiBridge System.
3162239|NCT01465282|Experimental|0.05% (w/w) CT327 ointment|0.05% (w/w) CT327 ointment applied BID for up to 8 weeks.
3162240|NCT01465282|Experimental|0.1% (w/w) CT327 ointment|0.1% (w/w) CT327 ointment applied BID for up to 8 weeks.
3162241|NCT01465282|Experimental|0.5% (w/w) CT327 ointment|0.5% (w/w) CT327 ointment applied BID for up to 8 weeks.
3162242|NCT01465282|Placebo Comparator|Placebo ointment|Placebo ointment
3162243|NCT01465269|Experimental|GIST Intervention|
3162244|NCT01465269|Active Comparator|Alternative Intervention|
3162245|NCT01465256|No Intervention|Aspirin holding group|Aspirin holding group (group 1): the patients enrolled into group 1 can stop taking aspirin during colon polypectomy. The patients are usually taking aspirin for primary prevention of vascular disease and have no risk of thromboembolism despite of they stop taking aspirin temporary
3162400|NCT01464385|Placebo Comparator|Nutritional Beverage #1|Nutritional Beverage Oral 237 ml
3162850|NCT01461382|Experimental|Phase I|Entered Study May 2008.
3162246|NCT01465256|Experimental|Aspirin continuing group|Aspirin continuing group (group 2): the patients enrolled into group 2 should take aspirin during colon polypectomy because these patients are usually take thienopyridines and aspirin, and if they would stop taking aspirin during colon polypectomy, they have a thromboembolism risk.
3162247|NCT01465243|Experimental|Icotinib|This is a single arm study.
3162248|NCT01465230|Experimental|lenalidomide|Maintenance treatment with lenalidomide following induction treatment with bendamustine and rituximab.
3162249|NCT01465217|Experimental|text message medication reminders|
3162250|NCT01465217|No Intervention|control|
3162251|NCT01465204|No Intervention|Control|
3162252|NCT01465204|Experimental|Handwashing Intervention|scaling up handwashing with soap
3162253|NCT01465204|Experimental|Sanitation Intervention|total sanitation and sanitation marketing
3162254|NCT01465204|Experimental|Combined|combined scaling up handwashing with soap and total sanitation and sanitation marketing interventions
3162255|NCT01465191|Experimental|50 micrograms spinal morphine|100 subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section
3162256|NCT01465191|Experimental|100 mcg|100 subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section
3162257|NCT01465191|Experimental|150 mcg|100 subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section
3162258|NCT01465178|Active Comparator|2000 IU vitamin D3|Cholecalciferol 2,000 IU capsules
3162259|NCT01465178|Placebo Comparator|Placebo|Non-matching placebo, gelatin filled capsules
3162260|NCT01465165||Depressed, unmedicated|Participants with MDD who are not treated with any antidepressant medication
3162261|NCT01465165||Depressed, on antidepressant|Participants with MDD, currently depressed but on a stable dose of an SSRI antidepressant
3162262|NCT01465165||Healthy control|Healthy participant with no MDD or other psychiatric condition, matched by age and gender to MDD participants
3162263|NCT01465152|Experimental|Met|
3162264|NCT01465152|Active Comparator|Rep|
3162265|NCT01465152|Active Comparator|Met+Rep|
3162266|NCT01465139|Experimental|CDX-301|CDX-301 (rhuFlt3L), administered to healthy patients.
3162267|NCT01465113|Experimental|Indefinite, LGD or no dysplasia arm|Barrett's esophagus patients who have no dysplasia or low grade dysplasia
3162268|NCT01465113|Experimental|high grade dysplasia|Barrett's esophagus with high grade dysplasia
3162269|NCT01465113|Experimental|Indefinite, LGD or no dysplasia arm:Vitamin D/Metformin Subarm|Barrett's esophagus patients who have no dysplasia or low grade dysplasia
3162270|NCT01465100|Experimental|Hepatocyte Transplantation|See Below.
3162271|NCT01465087|Experimental|Diagnosis|Diagnosis, breath and confounding factor
3162272|NCT01465074|Active Comparator|Nicotine gum (4 mg)|Nicotine gum will be given once on one of the two test days in a randomized, double-blinded fashion. Gum will be chewed for 30 min before the plasticity induction occurs.
3162273|NCT01465074|Placebo Comparator|Regular Mint Gum|Regular, taste-, texture- and color matched with the Nicotine Gum will be ingested once on one of the two testing days, 30 min before plasticity induction.
3162274|NCT01465061||Online support user|
3162275|NCT01465048|Experimental|Plasmodium falciparum sporozoites 2sites|2,500 sporozoites intradermally
3162276|NCT01465048|Experimental|Plasmodium falciparum sporozoites 1 site|2,500 sporozoites intramuscularly
3162277|NCT01465048|Experimental|Plasmodium falciparum sporozoites 1site|25,000 sporozoites intramuscularly
3162278|NCT01465035|Experimental|TIV and MVA-NP+M1|"Co-administration group~1 dose of seasonal influenza vaccine (TIV) and 1 dose of 1.5 x108pfu MVA-NP+M1"
3162279|NCT01465035|Placebo Comparator|Saline placebo and seasonal influenza vaccine TIV|"Control group~1 dose of seasonal influenza vaccine (TIV) and 1 dose of a saline placebo"
3162280|NCT01465022|Active Comparator|Study Arm A|Study Arm A is one of two interventions (Combined estrogen-progestin pill)
3162281|NCT01465022|Active Comparator|Study Arm B|Study Arm B is one of two interventions (Progestin-only pill)
3162282|NCT01465009|Experimental|Arm 1|
3162283|NCT01465009|Active Comparator|Arm 2|
3162284|NCT01465009|Placebo Comparator|Arm 3|
3162285|NCT01464996|Experimental|Adhesive OptiBond XTR|Adhesive OptiBond XTR will include composite restorations placed using the dental adhesive OptiBond XTR.
3162286|NCT01464996|Active Comparator|Adhesive OptiBond FL|Adhesive OptiBond FL will include composite restorations placed using the dental adhesive OptiBond FL.
3162287|NCT01464983|Active Comparator|Arm 1|
3162288|NCT01464983|Experimental|Arm 2|
3162289|NCT01464983|Active Comparator|Arm 3|
3162290|NCT01464983|Active Comparator|Arm 4|
3162291|NCT01464983|Placebo Comparator|Arm 5|
3162292|NCT01464970|Active Comparator|SIE Vessels Both Clamped|
3162293|NCT01464970|Active Comparator|SIE Vessels both Unclamped|
3162294|NCT01464970|Active Comparator|SIE Artery Unclamped; Vein Clamped|
3162295|NCT01464970|Active Comparator|SIE Artery Clamped, SIE Vein Unclamped|Superficial Inferior Epigastric Artery Clamped; Vein Unclamped
3162296|NCT01464957|Experimental|Newsletter intervention|Semi-tailored newsletter intervention for parents and children
3162297|NCT01464957|No Intervention|Usual care|No newsletter intervention
3162298|NCT01464944|Experimental|Arm 2|
3162299|NCT01464944|Active Comparator|Arm 3|
3162300|NCT01464944|Active Comparator|Arm 4|
3162301|NCT01464944|Placebo Comparator|Arm 5|
3162302|NCT01464944|Experimental|Arm 1|
3162303|NCT01464931|Experimental|Denosumab|Participants received two 120 mg doses of denosumab administered subcutaneously on Day 1 and Day 29.
3162304|NCT01464918|Experimental|ESD using the MASTER device|Endoscopic submucosal dissection of gastric/colon cancer using the device, MASTER
3162305|NCT01464905|Experimental|NU100|
3162306|NCT01464905|Placebo Comparator|Placebo|
3162307|NCT01464905|Active Comparator|recombinant human interferon beta- 1b|
3162308|NCT01464892|Experimental|Imagery Rescripting|
3162309|NCT01464892|Active Comparator|STAIR plus Imagery Rescripting|
3162310|NCT01464892|No Intervention|Wait-list control|Participants from this arm are randomized to the two active conditions after 8 weeks of waiting.
3162311|NCT01464879|Experimental|Testosterone 2.50 mL (hand)|Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by hand, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm every day for seven days.
3162312|NCT01464879|Experimental|Testosterone 1.25 mL (applicator)|Subjects in this arm self-applied one stroke (1.25 mL) of testosterone gel by applicator to the shoulder/upper arm every day for seven days.
3162313|NCT01464879|Experimental|Testosterone 2.50 mL (applicator)|Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm every day for seven days.
3162314|NCT01464879|Experimental|Testosterone 3.75 mL (applicator)|Subjects in this arm self-applied three strokes (3.75 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm and a third stroke to the first shoulder/upper arm, every day for seven days.
3162315|NCT01464866|Active Comparator|Hospital Feed|Standard hospital food
3162316|NCT01464866|Experimental|Hospital Feed plus nutritional supplement|Standard hospital food plus nutritional supplement
3162317|NCT01464853|Experimental|Specialized Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
3162318|NCT01464853|Active Comparator|Standard Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
3162319|NCT01464840||15 minutes|500 mg of intravenous azithromycin will be administered 15 minutes prior to incision.
3162320|NCT01464840||30 minutes|500 mg of intravenous azithromycin will be administered 30 minutes prior to incision.
3162321|NCT01464840||60 minutes|500 mg of intravenous azithromycin will be administered 60 minutes prior to incision.
3162322|NCT01464827|Experimental|Group A|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 8 weeks.
3162323|NCT01464827|Experimental|Group B|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
3162324|NCT01464827|Experimental|Group C|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
3162325|NCT01464827|Experimental|Group D|Treatment-naïve participants received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
3162326|NCT01464827|Experimental|Group E|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.
3162327|NCT01464827|Experimental|Group F|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
3162328|NCT01464827|Experimental|Group G|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
3162329|NCT01464827|Experimental|Group H|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
3162330|NCT01464827|Experimental|Group I|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
3162331|NCT01464827|Experimental|Group J|Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
3162332|NCT01464827|Experimental|Group K|Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
3162333|NCT01464827|Experimental|Group L|Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
3162334|NCT01464827|Experimental|Group M|Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
3162335|NCT01464827|Experimental|Group N|Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
3162336|NCT01464814|Experimental|Probiotic|Lactobacillus casei in fish oil capsule
3162337|NCT01464814|Placebo Comparator|Placebo|Fish oil capsule
3162338|NCT01464801|Experimental|Resveratrol|Subjects are given resveratrol 500 mg 3 times daily for 6 months.
3162339|NCT01464801|Placebo Comparator|Placebo|Subjects are given Placebo tablets 3 times daily for 6 months.
3162340|NCT01464788|Experimental|Low dose Argatroban + rt-PA (alteplase)|"100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours~and~rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"
3162341|NCT01464788|Experimental|High dose Argatroban + rt-PA (alteplase)|"100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours~and~rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"
3162342|NCT01464788|Active Comparator|rt-PA (alteplase)|rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
3162343|NCT01464775|Experimental|NBI|Women will be randomized to white light/NBI versus white light/white light laparoscopy
3162344|NCT01464775|Active Comparator|White light|Women will be randomized to white light/NBI versus white light/white light laparoscopy
3162401|NCT01464372|Experimental|Investigational Device|Treatment using electrical field stimulation of peripheral nerves
3162402|NCT01464372|Sham Comparator|Sham Device|Control group using sham device to mimic sound and sensation of investigational device
3162446|NCT01464034|Experimental|Carfilzomib, Pomalidomide, Dexamethasone|All eligible subjects will receive the study intervention of Carfilzomib, Pomalidomide, and Dexamethasone.
3162345|NCT01464749|Experimental|Task-oriented circuit class training|"Functional Circuit include 6 different work-stations in which patients exercise for 5 minutes in each one : 3 minutes exercises and 2 minutes rest. Total training takes about 30 minutes (2 laps/session over 60 minutes).~Walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary.~It is a progressive circuit and subjects, while exercising, receives feedback (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One task oriented session may include up to 3 patients and lasts 120 minutes. At the end of the 2 weeks an exercises brochure will be given to patients so that they can independently train for 3 month. Independent home training takes about 90 minutes."
3162346|NCT01464749|Active Comparator|Usual Care|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement (usual care). At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) or do physical rehabilitation in rehabilitative gyms not directly addressed to gait, mobility or balance training such as stretching exercises, active and passive mobilization and Bobath neurorehabilitation or similar.
3162347|NCT01464736|Experimental|Physical Training Group|This group performed aerobic physical training in treadmill.
3162348|NCT01464736|Experimental|NIV Trained|"This group performed aerobic physical training associated with ventilation in the bilevel modality (BiPAP®), using a nasal mask as an interface.~On evaluation day, the levels of inspiratory positive airway pressure (IPAP) (between 10 and 15cmH2O) and expiratory positive airway pressure (EPAP) (between 4 and 6cmH2O) were defined, varying according to the comfort level of each patient."
3162349|NCT01464723|Experimental|Lucentis|Consented, enrolled subjects will receive multiple open-label intravitreally administered 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
3162350|NCT01464697|Experimental|oral micronized progesterone|Oral micronized progesterone is Prometrium 300 mg at bedtime daily
3162351|NCT01464697|Placebo Comparator|Placebo Comparator|Placebo
3162352|NCT01464671|Active Comparator|Bivalirudin|Anticoagulation during percutaneous coronary intervention
3162353|NCT01464671|Active Comparator|Unfractionated Heparin|Anticoagulation during percutaneous coronary intervention
3162354|NCT01464658|Other|panniculectomy|surgical intervention
3162355|NCT01464645||Primary|Post Market Study
3162356|NCT01464632||Primary|Post Market Study
3162357|NCT01464619|Experimental|Delayed Intervention|Those assigned to the delayed intervention arm will receive enhanced mental health referrals, monthly follow-up phone calls, and will be assigned to the parenting intervention 3-4 months after enrollment.
3162358|NCT01464619|Experimental|Intervention|Caregivers assigned to the intervention arm will be assigned to the Incredible Years parenting intervention immediately after enrollment. They will also receive enhanced mental health referrals and monthly follow-up phone calls.
3162359|NCT01464606|Experimental|Type I PPB therapy|PPB Type I therapy: All patients will be treated with surgery. Chemotherapy after surgery is per the treating physician(s) discretion. If chemotherapy is used the Registry will suggest that it be combination chemotherapy with Vincristine, Dactinomycin, Cyclophosphamide (VAC).
3162360|NCT01464606|Experimental|Types II and III PPB therapy|"Combination chemotherapy with Ifosfamide, Vincristine, Dactinomycin and Doxorubicin (IVADo). Second look and possible 3rd look surgery may be required. Radiation therapy is recommended only for residual disease after maximum surgery."
3162361|NCT01464593|Experimental|Thermodox|Thermodox 50 mg/m2 intravenous infusion over 30 minutes starting 15 minutes before thermal ablation.
3162362|NCT01464567|Active Comparator|"T Tube Spontaneous Breathing Trial"|"Spontaneous Breathing Trial wuth T Tube for 30 minutes."
3162363|NCT01464567|Experimental|Pressure Support Ventilation|Spontaneous Breathing Trial wuth Ventilation on Pressure-Support mode set at 10cmH2O for 30 minutes
3162364|NCT01464554|Active Comparator|Usual Care|Teens will receive six sessions of an alcohol and drug education group
3162365|NCT01464554|Experimental|Project Free Talk|Teens will receive six sessions of and evidenced based motivational interviewing alcohol and drug program
3162366|NCT01464541|Experimental|orbital fractures size|patients who undergo surgical repair of orbital fracture with measuring the fracture size intraoperatively and had available orbital Ct scan preoperatively.
3162367|NCT01464528|Active Comparator|Hyaluronan|Use of hyaluronic acid gel
3162368|NCT01464528|No Intervention|control|
3162369|NCT01464515|Active Comparator|Real TMS|this group will receive high frequency deep TMS treatment of 10HZ
3162370|NCT01464515|Sham Comparator|SHAM TMS|this group will receive SHAM treatment of deep TMS
3162371|NCT01464502|Active Comparator|Standard CRT Implant|
3162372|NCT01464502|Active Comparator|Pressure-wire guided CRT Implant|
3162373|NCT01464489|Experimental|Control group|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.And receive normal saline for control group
3162374|NCT01464489|Active Comparator|Atropine group|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1. And receive atropine (atropine sulfate) 10 μg.kg-1 for atropine group.
3162375|NCT01464476|Experimental|Azimilide|Azimilide 75 mg film coated tablets
3162376|NCT01464476|Placebo Comparator|Placebo|
3162377|NCT01464463|Experimental|CBT-active|Patients with Major Depression (N = 50) get a common CBT treatment in combination with physical exercise.
3162378|NCT01464463|Active Comparator|CBT-euthymic|"Patients with Major Depression (N = 50) get the same common CBT treatment as the CBT-active-group, but instead of physical exercise they receive an enjoyment training, which is based on exercises from the Kleine Schule des Genießens (Koppenhöfer, 2004)"
3162379|NCT01464463|Active Comparator|CBASP|Patients with Major Depression (N=50) get a cognitive therapy according to the Cognitive Behavioral Analysis System of Psychotherapy (CBASP).
3162380|NCT01464463|No Intervention|Waiting List|Patients randomized to the waiting list receive psychological treatment after waiting for 4 month.
3162444|NCT01464060|Experimental|"Concomitant therapy"|Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
3162445|NCT01464047||Patients with CML or Ph+ ALL|
3162846|NCT01461408|Experimental|Beauty Salon #7a|Mothers of 9-18 year old females
3162381|NCT01464450|Active Comparator|Sequence 1: Treatment A - B - C|Participants will receive a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment A,) followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment B) and followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment C.)
3162382|NCT01464450|Active Comparator|Sequence 2: Treatment A - C - B|Participants will receive a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment A,) followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment C) and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment B.)
3162383|NCT01464450|Active Comparator|Sequence 3: Treatment B - C - A|Participants will receive a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment B,) followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment C) and followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment A.)
3162384|NCT01464450|Active Comparator|Sequence 4: Treatment B - A - C|Participants will receive a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment B,) followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment A) and followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment C.)
3162385|NCT01464450|Active Comparator|Sequence 5: Treatment C - A - B|Participants will receive a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment C,) followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment A) and followed by and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment B.)
3162386|NCT01464450|Active Comparator|Sequence 6: Treatment C - B - A|Participants will receive a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment C,) followed by and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment B) and followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment A.)
3162387|NCT01464437|Active Comparator|AMG 151 - Arm 1|AMG 151 - Arm 1
3162388|NCT01464437|Active Comparator|AMG 151 - Arm 2|AMG 151 - Arm 2
3162389|NCT01464437|Active Comparator|AMG 151 - Arm 3|AMG 151 - Arm 3
3162390|NCT01464437|Active Comparator|AMG 151 - Arm 4|AMG 151 - Arm 4
3162391|NCT01464437|Active Comparator|AMG 151 - Arm 5|AMG 151 - Arm 5
3162392|NCT01464437|Active Comparator|AMG 151 - Arm 6|AMG 151 - Arm 6
3162393|NCT01464437|Placebo Comparator|Placebo Arm|AMG 151 Placebo Arm
3162394|NCT01464424|Other|TRAVATAN, then LUMIGAN|Travoprost 0.004% ophthalmic solution (TRAVATAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by bimatoprost 0.01% ophthalmic solution (LUMIGAN), same dose, same duration, as randomized, for a total duration of 12 weeks
3162395|NCT01464424|Other|LUMIGAN, then TRAVATAN|Bimatoprost 0.01% ophthalmic solution (LUMIGAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by travoprost 0.004% ophthalmic solution (TRAVATAN), same dose, same duration, as randomized, for a total duration of 12 weeks
3162396|NCT01464398|Active Comparator|Stress reduction|Mindfulness-based stress reduction
3162397|NCT01464398|Active Comparator|Stress reduction with Health education|General stress management and health education
3162398|NCT01464385|Experimental|Nutritional Beverage #2|Nutritional Beverage with an amino acid Oral 237 ml
3162847|NCT01461408|Experimental|Beauty Salon #7b|Females ages 18-26
3162403|NCT01464359|Experimental|Patients with Acute Myelogenous Leukemia|Patients with chemotherapy refractory Acute Myelogenous Leukemia (AML) after a double T-cell depleted (TCD) umbilical cord blood (UCB) transplantation where the smaller unit is activated overnight in interleukin-2 (IL-2). IL-2 will be given three times weekly for 6 doses beginning on days+3 and days +60 to expand UCB-derived natural killer (NK) cells in vivo.
3162404|NCT01464346|Experimental|Enlite sensor, Abdomen/Abdomen|Subjects wearing 2 Enlite sensors in Abdomen
3162405|NCT01464346|Experimental|Enlite sensor, Abdomen/Buttock|Subjects wearing 2 Enlite sensors in Abdomen/Buttock
3162406|NCT01464346|Experimental|Enlite sensor, Buttock/Buttock|Subjects wearing 2 Enlite sensors in Buttock/Buttock
3162407|NCT01464333||Humira|those with an exposure
3162408|NCT01464320|Experimental|ABT-614|
3162409|NCT01464320|Placebo Comparator|Placebo Comparator|
3162410|NCT01464307|Experimental|IncobotulinumtoxinA (Xeomin) 400 Units|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
3162411|NCT01464307|Placebo Comparator|Placebo Comparator Arm|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
3162412|NCT01464294||nano-composite|crowns and onlays
3162413|NCT01464294||ceramic|crowns & onlays
3162414|NCT01464281|Experimental|48-week standard treatment|48-week standard treatment by Peginterferon alfa 2a 180µg/week
3162415|NCT01464281|Active Comparator|96-week prolonged treatment|96-week prolonged treatment by Peginterferon alfa 2a 180µg/week
3162416|NCT01464268|Active Comparator|Riboflavin drops every minute|Administration of riboflavin every 2 minutes for the duration of UV exposure.
3162417|NCT01464268|Active Comparator|Riboflavin drops every 2 minutes|Administration of riboflavin every 1 minute for the duration of UV exposure.
3162418|NCT01464255|Experimental|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
3162419|NCT01464255|Active Comparator|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
3162420|NCT01464242|Experimental|Glucantime® + pentoxifylline|Glucantime® 20mg/kg/day intramuscular injection (IM) daily for 20 days + pentoxifylline 400mg orally 3 times a day for 20 days.
3162421|NCT01464242|Placebo Comparator|Glucantime® + placebo|Glucantime® 20mg/kg/day IM each day for 20 days + placebo 400mg orally 3 times a day for 20 days.
3162422|NCT01464229|Experimental|Iloperidone addition to SSRI antidepressant|
3162423|NCT01464229|Placebo Comparator|Placebo addition to standard SSRI antidepressant|
3162424|NCT01464203|Experimental|CT coronary angiography|Patients in this arm will undergo CT coronary angiography to assess the patency of coronary arteries and their clinical management will be decided by the results of CT coronary angiography.
3162425|NCT01464203|Active Comparator|Control Arm|"Patients in this arm will receive the standard of care (SoC). They will undergo either coronary angiography, myocardial perfusion scan or stress echocardiography as decided by the physician in charge, depending on the local availability of individual investigations and the patient's clinical scenario."
3162426|NCT01464190|Experimental|PA21|
3162427|NCT01464190|Active Comparator|Sevelamer carbonate|
3162428|NCT01464177|Active Comparator|Stereotactic hypofractionated RT 5x5Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~Planning tumor volume (PTV) equals GTV plus 3mm margin.~the dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~RT to begin in a maximum of 2 weeks after randomization."
3162429|NCT01464177|Experimental|Stereotactic hypofractionated RT 5x7Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~Planning tumor volume (PTV) equals GTV plus 3mm margin.~the dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~RT to begin in a maximum of 2 weeks after randomization."
3162430|NCT01464164|Experimental|Sotatercept|Sotatercept to be given as a subcutaneous injection once a month for 4 consecutive months, using a dose escalation scale among 3 cohorts. *Protocol Amendment: Two additional cohorts will be given Sotatercept 0.75mg/kg and 1 mg/kg as a subcutaneous injection once every 3 weeks.
3162431|NCT01464164|Experimental|Sotatercept with prednisone boost|Protocol Amendment: Two additional cohorts will be given Sotatercept 0.75mg/kg and 1 mg/kg as a subcutaneous injection once every 3 weeks along with a prednisone boost of 1 mg/kg daily for 3 weeks (max of 60 mg).
3162432|NCT01464151||Patients with inflammatory bowel disease|patients with a diagnosis of ulcerative colitis, Crohn's colitis or indeterminate colitis between 18 and 70 years of age. Patients should have an indication for surveillance according to the current guidelines, which means a disease duration of at least 8 years and involvement of at least 30% of the colon.
3162433|NCT01464138|Experimental|Fosmidomycin-Clindamycin|Single arm study. Co-administration of Fosmidomycin and Clindamycin.
3162434|NCT01464125|Experimental|Fos-Azi|Open label single arm concurrent administration of fosmidomycin and azithromycin.
3162435|NCT01464112|Experimental|001|
3162436|NCT01464099|Active Comparator|Insulin aspart 100U/mL|
3162437|NCT01464099|Experimental|Insulin aspart 200U/mL|
3162438|NCT01464086|No Intervention|Standard arm|standard follow-up
3162439|NCT01464086|Experimental|Intensive follow-up|Standard follow-up plus whole body MRI at inclusion, one and two years
3162440|NCT01464073|Active Comparator|arm 3 : Good Medical Practices|physical exercise at home monitored by telephone (achieving a minimum of 30 minutes per day)
3162441|NCT01464073|Active Comparator|arm 2 : 60% VO2peak|physical exercise at the intensity of 60% of VO2 peak. 4 times a week. duration will be adjusted for arm 1 and arm 2 have the same total energy expenditure by session.
3162442|NCT01464073|Experimental|arm 1 : LIPOXmax|physical exercise at the LIPOXmax intensity during 60 minutes. 4 times a week
3162443|NCT01464060|Active Comparator|"Hybrid therapy"|Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
3162447|NCT01464021||Adalimumab|Chinese adult participants with a diagnosis of rheumatoid arthritis (RA) (any disease duration) who meet the requirements per the local label for treatment with adalimumab. Participants must be naïve to adalimumab at the Baseline visit.
3162448|NCT01464008||chronic hepatitis C|
3162449|NCT01463995||severe neurological diseases|Patients with severe neurological diseases treated on the neurological intensive care unit
3162450|NCT01463982|Experimental|Oratecan and Capecitabine|"Oratecan(HM30181AK + Irinotecan HCl) and Capecitabine~Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1~Day5~HM30181AK Tablet - Fixed dose 15 mg, Day1~Day5~Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1~Day14"
3162451|NCT01463969||PCOS patients|
3162452|NCT01463969||Control group|
3162453|NCT01463956|Experimental|Boceprevir, Pegylated interferon and Ribavirin|"Lead-in phase (4 week): Pegylated interferon + Ribavirin~Triple therapy regimen for 44 weeks :Boceprevir + Pegylated interferon + Ribavirin~Pegylated interferon + Ribavirin therapy until transplantation (less or equal to 24 weeks)"
3162454|NCT01463943|Experimental|Saccharomyces boulardii capsules (200 mg).|
3162455|NCT01463943|Active Comparator|Floratil®|
3162456|NCT01463943|Experimental|Saccharomyces boulardii powder (200 mg).|
3162457|NCT01463930|Experimental|Audiovisual videodisc and medical verbal information|
3162458|NCT01463930|Active Comparator|Medical verbal information|
3162459|NCT01463917|Active Comparator|Hypertonic|Use of Hypertonic solution during left marginal branch CABG surgery.
3162460|NCT01463917|Placebo Comparator|Isotonic|Use of Isotonic solution during left marginal branch CABG surgery.
3162461|NCT01463904||Morbid obese, diabetics|Patients with morbid obesity or severe metabolic disease
3162462|NCT01463891||Eribulin Mesylate|
3162463|NCT01463878|Experimental|Glycerna|Diabetic specific formula. The volume /rate of glycerna will be determined by the dietician according to standard formula.
3162464|NCT01463878|Active Comparator|Control - Jevity|The control arm of the study. Patients to receive Jevity. The volume /rate of Jevity will be determined by the dietician according to standard formula.
3162465|NCT01463865|Placebo Comparator|Placebo|Sodium chloride
3162466|NCT01463865|Active Comparator|ropivacaine|Naropin
3162467|NCT01463852|Experimental|Vincrisitne 2mg|Single Arm study: Vincristine 2mg administered IV by infusion over 5 minutes.
3162468|NCT01463839||Children 3 to 6|Fifty children (3 to 6 years of age) from a private school in the city of Sao Paulo
3162469|NCT01463826||Children with bruxism|14 children with bruxism
3162470|NCT01463826||children without bruxism|19 children without bruxism
3162471|NCT01463813|Placebo Comparator|Placebo|Placebo, no Vitamin D3
3162472|NCT01463813|Experimental|Vitamin D3 80|Vitamin D3 80 micrograms (3200 IU) per day
3162473|NCT01463813|Experimental|Vitamin D3 40|Vitamin D3 40 micrograms (1600 IU) per day
3162474|NCT01463800|Active Comparator|Structured Exercise training|12 weeks ambulatory low level exercise training
3162475|NCT01463800|No Intervention|Control group|No structured exercise training
3162476|NCT01463787|Experimental|inguinal group|
3162477|NCT01463787|Active Comparator|sub-inguinal group|
3162478|NCT01463774|Experimental|Treatment Sequence AB|The study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
3162479|NCT01463774|Experimental|Treatment Sequence BA|The study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
3162480|NCT01463761||high-level athletes|High-level athlete, enrolled in a Ministry-recognized Pôle
3162481|NCT01463748|Experimental|Placebo|starch
3162482|NCT01463748|Experimental|Graptopetalum paraguayense E. Walther|Graptopetalum paraguayense E. Walther
3162483|NCT01463722|Other|Amniotic fluid Lamellar Body Counting|
3162484|NCT01463709|Experimental|nanopulse|Administer nano pulse to lesion for varying time intervals.
3162485|NCT01463696|Experimental|MK-8242 60 mg BID|In Cycle 1, participants received MK-8242 60 mg administered orally (PO) twice a day (BID) on Days 1-6 and PO once daily (QD) in the morning on Day 7 of the 21-day cycle to accommodate pharmacokinetic (PK) sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 60 mg PO BID on Days 1-7 of each 21-day cycle.
3162486|NCT01463696|Experimental|MK-8242 120 mg BID|In Cycle 1, participants received MK-8242 120 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 120 mg PO BID on Days 1-7 of each 21-day cycle.
3162487|NCT01463696|Experimental|MK-8242 170 mg BID|In Cycle 1, participants received MK-8242 170 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 170 mg PO BID on Days 1-7 of each 21-day cycle.
3162488|NCT01463696|Experimental|MK-8242 250 mg BID|In Cycle 1, participants received MK-8242 250 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 250 mg PO BID on Days 1-7 of each 21-day cycle.
3162489|NCT01463696|Experimental|MK-8242 300 mg BID|In Cycle 1, participants received MK-8242 300 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 300 mg PO BID on Days 1-7 of each 21-day cycle.
3162490|NCT01463696|Experimental|MK-8242 350 mg BID|In Cycle 1, participants received MK-8242 350 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 350 mg PO BID on Days 1-7 of each 21-day cycle.
3162491|NCT01463696|Experimental|MK-8242 400 mg BID|In Cycle 1, participants received MK-8242 400 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 400 mg PO BID on Days 1-7 of each 21-day cycle.
3162492|NCT01463696|Experimental|MK-8242 500 mg BID|In Cycle 1, participants received MK-8242 500 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 500 mg PO BID on Days 1-7 of each 21-day cycle.
3162493|NCT01463683|Experimental|V232-2XP SC|2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6
3162494|NCT01463683|Active Comparator|V232-1XP SC|1XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6
3162495|NCT01463683|Experimental|V232-2XP IM|2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6
3162496|NCT01463670|Experimental|lenalidomide|The proposed study is designed as a Phase II, multi-center trial of lenalidomide intensification in patients with asymptomatic POD while on low dose lenalidomide maintenance after HDM/ASCT or on continuous/maintenance therapy after initial treatment.
3162497|NCT01463657|Experimental|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
3162498|NCT01463657|Active Comparator|Juvéderm® Ultra Plus|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
3162499|NCT01463644|Active Comparator|mepolizumab|
3162500|NCT01463644|Placebo Comparator|placebo|
3162501|NCT01463631|Experimental|LY3007113|Study has a dose escalation phase (Part A) and dose confirmation phase (Part B). Participants in the dose escalation phase will receive 1 of 6 doses of LY3007113 administered orally every 12 hours for at least one cycle. Participants in the dose confirmation phase will receive the maximum tolerated dose from the dose escalation phase administered orally every 12 hours for at least 1 cycle. Three days prior to the start of the first cycle, participants will receive 1 dose at their assigned level to allow for the collection of single dose pharmacokinetics. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
3162502|NCT01463605|Other|radiotherapy|It is just a single group assignment
3162503|NCT01463592|Experimental|Group II a|TRIPPLE THERAPY
3162504|NCT01463592|Active Comparator|Group II b|DUAL THERAPY
3162505|NCT01463592|Experimental|Group I|ORAL RENESSANS
3162506|NCT01463579|Experimental|Exercise programme|
3162507|NCT01463579|Other|Standard Care|
3162508|NCT01463566||1 - Gender Natural Knee|Patients suffering from severe knee pain and disability.
3162509|NCT01463553|No Intervention|wedge resection|
3162510|NCT01463553|Experimental|Wedge resection and pleurodosis|
3162511|NCT01463540|Active Comparator|Push/pull endoscopic gastrostomy|
3162512|NCT01463540|Experimental|Gastrostomy after gastropexy|
3162513|NCT01463527|Experimental|Open Capnography|
3162514|NCT01463527|Placebo Comparator|Capnography Blind|
3162515|NCT01463514|Experimental|AIR|"Randomization sequences according to modified catheter protocol.~1. AIR 2. Target Oxygen(88-90%) 3. 100% Oxygen 4. Nitric Oxygen"
3162516|NCT01463514|Experimental|NO|"Randomization sequences according to modified catheter protocol.~1.Nitric Oxygen 2. AIR 3. Target Oxygen(88-90%) 4. 100% Oxygen"
3162517|NCT01463514|Experimental|Oxygen|"Randomization sequences according to modified catheter protocol.~1. 100% Oxygen 2. NO 3. AIR 4. Target Oxygen (88-90%)"
3162518|NCT01463514|Experimental|Target Oxygen|"Randomization sequences according to modified catheter protocol.~1. Target Oxygen (88-90%) 2. 100% Oxygen 3. NO 4. AIR"
3162519|NCT01463501|Experimental|Neoadjuvant Treatment|Preoperative chemotherapy/radiotherapy
3162520|NCT01463501|Experimental|Adjuvant Treatment|Postoperative chemotherapy/radiotherapy
3162521|NCT01463488|Experimental|SAR113945 - Dose 1|
3162522|NCT01463488|Experimental|SAR113945 - Dose 2|
3162523|NCT01463488|Experimental|SAR113945 - Dose 3|
3162524|NCT01463488|Placebo Comparator|Placebo|
3162525|NCT01463475|Other|Bone Marrow Aspirate|A qualified enrolled donor will have an aspirate bone marrow draw.
3162526|NCT01463462||Electronic Catheter Stethoscope|
3162527|NCT01463449||Obese|Obese subjects half with type 2-diabetes. Before and after gastric bypass. Expected reduction in weight 25 %. We expect a reduction in low grade inflammation in adipose tissue after weight loss.
3162528|NCT01463436|Experimental|soy isoflavone 100 mg|the experimental group receiving tablet contain soy isoflavone 100 mg and calcium carbonate 500 mg
3162529|NCT01463436|Placebo Comparator|calcium carbonate 500 mg|The control group receiving a tablet contains calcium carbonate 500 mg for 6 months and 12 months
3162530|NCT01463423|Experimental|SABR|
3162531|NCT01463397|Experimental|SAR292833 dose level 1|Dose level 1 twice daily immediately after breakfast/dinner
3162532|NCT01463397|Experimental|SAR292833 dose level 2|Dose level 2 twice daily immediately after breakfast/dinner
3162533|NCT01463397|Placebo Comparator|Placebo|Placebo (for SAR292833) twice daily immediately after breakfast/dinner
3162534|NCT01463384|Active Comparator|Minocycline|Subjects will be administered 50mg minocycline twice daily.
3162535|NCT01463371|No Intervention|Control|without azithromycin
3162536|NCT01463371|Active Comparator|azithromycin|treatment with azithromycin during three months
3162537|NCT01463358|Other|DDI30|Control group based only on backup pacing with lower rate 30 ppm
3162538|NCT01463358|Active Comparator|DDD60|Treatment arm based on full pacing support (60 Lower Rate)
3162539|NCT01463345|Experimental|Conservative Transfusion Arm|Subjects in the conservative transfusion arm will receive transfusion only when their hemoglobin levels reach 7.5 g/dl.
3162540|NCT01463345|Active Comparator|Liberal Transfusion Arm|Subjects in the liberal transfusion arm will receive transfusion only when their hemoglobin levels reach 9.0 g/dl.
3162541|NCT01463332|Placebo Comparator|Group NS|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
3162542|NCT01463332|Active Comparator|Group D25|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
3162543|NCT01463332|Active Comparator|Group D50|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D50 were injected intravenously with 0.50mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
3162544|NCT01463319|Experimental|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
3162545|NCT01463319|Experimental|air insufflation|air insufflation during insertion phase of colonoscopy
3162546|NCT01463306|Experimental|Open|Pregabalin open label flexible dose
3162547|NCT01463293|Experimental|High-dose probiotic|Capsule containing 10 billion cfu B. lactis HN019
3162548|NCT01463293|Experimental|Low dose probiotic|Capsule containing 1 billion cfu B. lactis HN019
3162549|NCT01463293|Placebo Comparator|Placebo|Placebo capsule
3162550|NCT01463280|Experimental|tumescent lidocaine infiltration|Assess Platelet function with respect to dosage of tumescent lidocaine There is only one arm.
3162551|NCT01463267|Active Comparator|Device 2 passive|Device 2 will NOT remind patients to take medications
3162552|NCT01463267|Active Comparator|Device 2 active|Device 2 will remind patients to take medications
3162553|NCT01463267|Active Comparator|Device 1 active|Device 1 will remind patients to take their medications
3162554|NCT01463267|Placebo Comparator|Device 1 Passive|Device 1 will NOT remind patients to take medications.
3162555|NCT01463254||Surveillance|- a surveillance cohort of 300 women who will report back to the clinic during 12 months after enrolment only if they have complications, medical problems, pregnancy, or want to remove the implant
3162556|NCT01463254||Prospective|a prospective cohort consisting of 300 women who will be followed-up 3 and 12 months after enrollment
3162557|NCT01463241|Other|BASIC treatment|As an open trial, all participants in this study will receive the BASIC treatment.
3162558|NCT01463228|Experimental|Treatment Sequence AB|
3162559|NCT01463228|Experimental|Treatment Sequence BA|
3162560|NCT01463215|Experimental|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
3162561|NCT01463202|Active Comparator|DMPA postpartum|Depot medroxyprogesterone acetate postpartum
3162562|NCT01463202|Active Comparator|DMPA at 4-6 weeks after delivery|Depot medroxyprogesterone acetate at 4-6 weeks after delivery
3162563|NCT01463189|Experimental|painACTION: Arthritis|
3162564|NCT01463189|No Intervention|treatment as usual|
3162565|NCT01463176|No Intervention|Standard Care|Children in the Standard Care Control group will receive standard care and will be videotaped by the music therapist but will not receive music therapy during their immunization
3162566|NCT01463176|Experimental|Music Therapy|Children in this group will receive live music therapy during their immunization.
3162567|NCT01463163|Active Comparator|Prasugrel|Prasugrel 60mg LD followed by 10mg MD starting post 24 hours
3162568|NCT01463163|Experimental|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting post 12±6 hours
3162569|NCT01463150|Active Comparator|Clopidogrel|Clopidogrel 150mg per day for 15 days
3162570|NCT01463150|Experimental|Prasugrel|Prasugrel 5mg for 15 days
3162571|NCT01463137|Sham Comparator|Control training with words|Computerized, internet-based control training program. Participant is exposed to a pair of words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive word and the more negative word with equal frequency.
3162572|NCT01463137|Sham Comparator|Control training with words + pictures|Computerized, internet-based control training program. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
3162573|NCT01463137|Active Comparator|Positive bias training with words|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session, of one third is the neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word.
3162574|NCT01463137|Active Comparator|Positive bias training with words + pictures|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word or face.
3162575|NCT01463137|Active Comparator|Negative bias training with words|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 3. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word.
3162848|NCT01461408|Experimental|Beauty Salon #8a|Mothers of 9-18 year old females
3162576|NCT01463137|Active Comparator|Negative bias training with words + pictures|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
3162577|NCT01463124|Experimental|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
3162578|NCT01463124|Active Comparator|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
3162579|NCT01463111|Other|Mood stabilizer|Participants diagnosed with Bipolar Disorder will receive standard of care open-label treatment with a mood stabilizer for six weeks.
3162580|NCT01463098|Experimental|E2006 1.0 mg|
3162581|NCT01463098|Experimental|E2006 2.5 mg|
3162582|NCT01463098|Experimental|E2006 5.0 mg|
3162583|NCT01463098|Experimental|E2006 10.0 mg|
3162584|NCT01463098|Experimental|E2006 25.0 mg|
3162585|NCT01463098|Experimental|E2006 50.0 mg|
3162586|NCT01463098|Experimental|E2006 100 mg|
3162587|NCT01463098|Experimental|E2006 200 mg|
3162588|NCT01463098|Experimental|zolpidem 10 mg|
3162589|NCT01463098|Experimental|zolpidem matched placebo|zolpidem - matched placebo (Part B Only)
3162590|NCT01463098|Experimental|E2006 - matched placebo|(Part A and Part B)
3162591|NCT01463085|Placebo Comparator|Control foods|3 servings per day of control foods
3162592|NCT01463085|Experimental|Low-fat dairy|3 servings per day of low-fat dairy products
3162593|NCT01463072|Experimental|Treatment (chemotherapy)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3162594|NCT01463059|Placebo Comparator|Placebo every 2 weeks|Injections administered at week 0, 2, 4, 6, 8 and 10
3162595|NCT01463059|Experimental|Olokizumab 60 mg every 2 weeks|Olokizumab 60 mg injections administered at week 0, 2, 4, 6, 8 and 10
3162596|NCT01463059|Experimental|Olokizumab 60 mg every 4 weeks|Olokizumab 60 mg injection administered at week 0, 4, and 8 and Placebo injection administered at week 2, 6, and 10
3162597|NCT01463059|Experimental|Olokizumab 120 mg every 2 weeks|Olokizumab 120 mg injections administered at week 0, 2, 4, 6, 8 and 10
3162598|NCT01463059|Experimental|Olokizumab 120 mg every 4 weeks|Olokizumab 120 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10
3162599|NCT01463059|Experimental|Olokizumab 240 mg very 4 weeks|Olokizumab 240 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10
3162600|NCT01463046|Experimental|Panobinostat|
3162601|NCT01463033|Active Comparator|Levetiracetam|66 subjects with acute head injury with a high risk for developing post-traumatic epilepsy will receive levetiracetam 55 mg/kg/day in a b.i.d. schedule. Treatment will commence within 8 hours of the acute head injury and will last for 30 days. In addition, subjects will receive phenytoin for 1 week following head injury as standard clinical care.
3162602|NCT01463033|No Intervention|No Intervention Control|60 subjects with acute head injury with a high risk for developing post-traumatic epilepsy enrolled 8-24 hours after injury will not receive levetiracetam. Subjects will receive phenytoin for 1 week following head injury as standard clinical care.
3162603|NCT01463020|Experimental|Smartphone delivered BA|
3162604|NCT01463020|Active Comparator|Smartphone delivered mindfulness|
3162605|NCT01463007|Experimental|Radiation|AccuBoost APBI- 34.0 Gy in 10fx
3162606|NCT01463007|Experimental|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
3162607|NCT01462994|No Intervention|Single arm|
3162608|NCT01462968|Active Comparator|Activated clotting time (ACT) group|heparinization measured as activated clotting time during surgery
3162609|NCT01462968|Experimental|Hepcon group|heparinization measured as heparin concentration in the blood during surgery
3162610|NCT01462942|Experimental|Aclidinium/Formoterol 400/6 μg|24 week, double blind treatment period
3162611|NCT01462942|Experimental|Aclidinium/Formoterol 400/12 μg|24 week, double blind treatment period
3162612|NCT01462942|Experimental|Aclidinium monotherapy 400 μg|24 week, double blind treatment period
3162613|NCT01462942|Active Comparator|Formoterol monotherapy 12 μg|24 week, double blind treatment period
3162614|NCT01462942|Placebo Comparator|Placebo|24 week, double blind treatment period
3162615|NCT01462929|Experimental|Aclidinium bromide|Aclidinium bromide 400 µg administered twice per day during 6 weeks of treatment
3162616|NCT01462929|Active Comparator|Tiotropium|Tiotropium bromide 18 µg administered once per day during 6 weeks of treatment
3162617|NCT01462929|Placebo Comparator|Placebo|Placebo comparator administered during 6 weeks of treatment
3162618|NCT01462916||honey, no honey|
3162619|NCT01462903|Experimental|Drug, T cell immunoterhapy|
3162620|NCT01462890|Other|Control Arm|Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 16 cycles.
3162621|NCT01462890|Experimental|Research Arm|Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 38 cycles.
3162622|NCT01462877|Other|Fenofibrate arm|
3162623|NCT01462864|Active Comparator|Intervention|Lifestyle education intervention
3162624|NCT01462864|No Intervention|Control|The control group will receive an information leaflet which is generally distributed in our speciality clinic to patients with diagnosis of PCOS. The leaflet includes general information on PCOS, treatment options and advice on increasing physical activity.
3162625|NCT01462851|Experimental|Dose Escalation|Ascending doses in healthy volunteers
3162626|NCT01462851|Experimental|Part 2: CSF PKPD|Pharmacokinetic and pharmacodynamic cerebrospinal fluid assessment
3162627|NCT01462838|Experimental|Immunization|P16_37-63 peptide plus Montanide ISA-51 VG
3162628|NCT01462825|Experimental|tomato ketchup meal|
3162629|NCT01462825|Placebo Comparator|Placebo meal|
3162630|NCT01462812|Active Comparator|Sumatriptan|
3162631|NCT01462812|Placebo Comparator|Matching placebo|
3162632|NCT01462799|Experimental|PBL- patient education|Patients will be randomised to PBL in patient education (experiment group)
3162633|NCT01462799|Experimental|Mailed patient information|Patients will be randomised to controlgroup receiving mailed patient information during the year
3162634|NCT01462786|Experimental|ATX-101 in abdomen area|Crossover study in which subjects will receive 2 mg/cm2 ATX-101 in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session
3162635|NCT01462786|Experimental|ATX-101 in submental area|Crossover study in which subjects will receive 2 mg/cm2 ATX-101 in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session
3162636|NCT01462773|Experimental|Treatment (enzyme inhibitor, interferon therapy)|Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15, and 22 and recombinant interferon alfa-2b SC on days 1, 3, and 5 (days 1 and 3 only in week 4 course 1) of weeks 1-4. Treatment repeats every 5 weeks for 5 courses in the absence of disease progression or unacceptable toxicity.
3162637|NCT01462760|Other|First assessment: inclinometer|First assessment: inclinometer Second assessment: actigraph and inclinometer
3162638|NCT01462760|Other|first: Inclinometer and actigraph|first: Inclinometer and actigraph second: inclinometer
3162639|NCT01462747|Experimental|KULIST|Medical Device, Activated carbon
3162640|NCT01462734||human vitreous, human blood serum, PCR|Vitreous and bloodserum samples from macula hole patients without previous ocular or systemic disease
3162641|NCT01462721|Other|SVG + eSVS Mesh vs Control SVG|Either the Circumflex Coronary Artery (Cx) or the Right Coronary Artery (RCA) will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
3162642|NCT01462708|Experimental|Assess [18F]MK-9470 and PET imaging|To Assess [18F]MK-9470 and PET imaging
3162643|NCT01462695|Experimental|Treatment (sunitinib)|Patients receive sunitinib malate orally (PO) once daily (QD) on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
3162644|NCT01462669|Other|Treatment Period 1|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
3162645|NCT01462669|Other|Treatment Period 2|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
3162646|NCT01462669|Other|Treatment Period 3|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
3162647|NCT01462669|Other|Treatment Period 4|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
3162648|NCT01462656||Patients with urinary retention|Patients with urinary retention
3162649|NCT01462643|Experimental|variant1|topical ointment, once daily application
3162650|NCT01462643|Experimental|variant 2|topical ointment, once daily application
3162651|NCT01462643|Experimental|variant 3|topical ointment, once daily application
3162652|NCT01462643|Experimental|variant4|topical ointment, once daily application
3162653|NCT01462643|Experimental|variant 5|topical ointment, once daily application
3162654|NCT01462643|Placebo Comparator|variant 6|topical ointment, once daily application
3162655|NCT01462643|Active Comparator|control positive|topical ointment,once daily application
3162656|NCT01462630|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive pazopanib hydrochloride PO QD. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3162657|NCT01462617|Experimental|Pi3K|Experimental
3162658|NCT01462617|Placebo Comparator|Placebo|Placebo Comparator
3162659|NCT01462604||HER2 overexpressing metastatic or advanced breast cancer pts|
3162660|NCT01462591|Experimental|L-citrulline|L-citrulline (100mg/kg of body weight per day for 2 weeks)
3162661|NCT01462591|Placebo Comparator|Maltodextrin|6g/day of placebo (maltodextrin)
3162662|NCT01462578|Experimental|Azacytidine|Azacytidine injection: 75 mg/m²/d, subcutaneous
3162663|NCT01462565|Experimental|All subjects|Subjects enter the study already taking current marketed FLOLAN (epoprostenol sodium) and continue for 4 weeks (run-in). At baseline, they will be swopped to the new thermo stable formulation of epoprostenol sodium for 4 weeks (or longer if they continue in the extension phase of the study).
3162664|NCT01462552||Metastatic breast cancer pre-label group|Patients with metastatic breast cancer who initiated lapatanib between January 1, 2007 and December 31, 2007. Follow-up time for this group will continue until June 30, 2008 to allow these patients to have at least six months of follow-up time prior to the label change.
3162665|NCT01462552||Metastatic breast cancer post-label group|Patients with metastatic breast cancer who initiated lapatanib between July 9, 2008 and December 31, 2009. Follow-up time for this group will continue until June 30, 2010 to allow these patients to have at least six month of follow-up.
3162666|NCT01462539||OSAS group|
3162667|NCT01462539||Non-OSAS group|
3162668|NCT01462526||Control|Participants who do not have glaucoma in either eye
3162669|NCT01462526||Glaucoma|Participants who have glaucoma in one or both eyes
3162670|NCT01462513|Experimental|L-BLP25|L-BLP25 treatment
3162671|NCT01462513|Placebo Comparator|Placebo|Placebo
3162672|NCT01462500|Experimental|Miltefosine|Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days
3162715|NCT01462201|Experimental|Group 2 - Non Invasive Ultrasound|Group 2 3 visits - Treatment with Contour I VER 3.1 system 3 visits - Measurements of abdominal circumference 4 visits - Follow Up visits The intervention is non invasive ultrasound.
3162673|NCT01462487||Pregnancy outcomes analysis group|Pregnant women evaluated for the following pregnancy outcomes: elective termination, spontaneous abortion (defined as spontaneous fetal loss at < 20 weeks' gestation), fetal death (defined as death of a fetus at > 20 weeks' gestation), premature birth (defined as a birth occurring at < 37 weeks' gestation), and live birth at term
3162674|NCT01462487||Congenital anomalies analysis group|Infants evaluated for congenital anomalies
3162675|NCT01462487||Treatment-emergent diagnoses analysis group|Pregnant women evaluated for treatment-emergent diagnoses
3162676|NCT01462474|Experimental|Drug: Famitinib|
3162677|NCT01462448||Phantom Limb Pain|Subjects will have lower or upper extremity amputation(s) that have resulted in the presence of phantom limb pain.
3162678|NCT01462448||No Phantom Limb Pain|Subjects in the group will have a lower or upper extremity amputation(s) without the presence of phantom limb sensation.
3162679|NCT01462435|Experimental|Diclofenac Test (lower dose)|
3162680|NCT01462435|Experimental|Diclofenac Test (upper dose)|
3162681|NCT01462435|Active Comparator|Celecoxib|
3162682|NCT01462435|Placebo Comparator|Placebo|
3162683|NCT01462422|Other|Primary prevention|
3162684|NCT01462422|Other|Secondary Prevention|
3162685|NCT01462409|Experimental|heated humidification|
3162686|NCT01462409|Experimental|No Humidification|
3162687|NCT01462409|Experimental|Controlled heated Humidification with heated tube|
3162688|NCT01462396|Experimental|Single Arm|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
3162689|NCT01462370|Experimental|Etoricoxib+placebo ibuprofen then placebo etorcoxib+ibuprofen|Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.
3162690|NCT01462370|Experimental|Ibuprofen+placebo etoricoxib then etoricoxib+placebo ibuprofen|Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.
3162691|NCT01462357|Experimental|Cervarix 2 dose Group|Subjects who received 2 doses of CervarixTM vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
3162692|NCT01462357|Experimental|Gardasil 2 dose Group|Subjects who received 2 doses of Gardasil® vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
3162693|NCT01462357|Experimental|Gardasil 3 dose Group|Subjects who received 3 doses of Gardasil® vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
3162694|NCT01462344|Experimental|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
3162695|NCT01462344|Experimental|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
3162696|NCT01462344|Active Comparator|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
3162697|NCT01462344|Active Comparator|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
3162698|NCT01462331|Other|VitaSugar/VitaFiber-IMO dose-1|A group of 20 subjects (10 male and 10 females) will take IMO dose-1 (12g/dose) powder; three times a day dissolved in a glass of water
3162699|NCT01462331|Other|VitaSugar/VitaFiber-IMO dose-2|A group of 20 subjects (10 male and 10 females) will take IMO dose-2 (18g/dose) powder; three times a day dissolved in a glass of water
3162700|NCT01462331|Placebo Comparator|Placebo|A group of 20 subjects (10 male and 10 females) will take Placebo (12g/dose) powder; three times a day dissolved in a glass of water
3162701|NCT01462318|Experimental|DAC HYP|"DAC HYP 150 mg by a subcutaneous (SC) injection using the pre-filled syringe (PFS) every 4 weeks for 24 weeks followed by a 20-week washout period. After completion of the washout period, participants may resume monthly DAC HYP 150 mg using the PFS for up to 3 additional years.~Participants in the TP-DI sub-study will receive probe-drug cocktail administration at Weeks 43 and 53. The probe-drug cocktail consists of oral midazolam 5 mg, caffeine 200 mg, S-warfarin 10 mg, vitamin K 10 mg, omeprazole 40 mg, and dextromethorphan 30 mg. The oral vitamin K is used to counteract warfarin's anticoagula nt effect prophylactically."
3162702|NCT01462305|Experimental|goLITE|light therapy using 467nm LED source, within 30 minutes of waking in the morning every day for 6 weeks
3162703|NCT01462305|Active Comparator|Control|light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks
3162704|NCT01462292|Experimental|GSK2402968 3 mg/kg/week|3 mg/kg/week of investigational product
3162705|NCT01462292|Experimental|GSK2402968 6 mg/kg/week|6 mg/kg/week of investigational Product
3162706|NCT01462292|Experimental|Placebo to match GSK2402968 3 mg/kg/week|Placebo
3162707|NCT01462292|Experimental|Placebo to match GSK2402968 6 mg/kg/week|Placebo
3162708|NCT01462279|Experimental|Thiamine|Open label - 200mg IV
3162709|NCT01462266|Experimental|Sitagliptin|Sitagliptin 100 mg once daily
3162710|NCT01462266|Placebo Comparator|Placebo|Placebo to sitagliptin once daily
3162711|NCT01462240||1 - LPS Flex Pororus Femoral Components|Patients suffering from severe knee pain and disability.
3162712|NCT01462227|Experimental|Naltrexone (higher dose)|Naltrexone 100mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the high dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
3162713|NCT01462227|Experimental|Naltrexone (lower dose)|Naltrexone 50mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the low dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
3162714|NCT01462201|Experimental|Group 1 - Non Invasive Ultrasound|Group 1 3 visits - Measurement of abdominal circumferences 3 visits - Treatment with Ultrashape Contour I VER 3.1 4 visits - Follow up visits The intervention is non invasive ultrasound.
3162716|NCT01462188|Active Comparator|Immediate stenting|Patients being randomized to the immediate stenting arm will be managed according to the guidelines. Irrespective of TIMI flow at presentation, investigators will be requested to thrombus aspirate immediately after successful wiring of the culprit vessel followed by direct stenting. In cases where insertion of thrombus removal catheter and/or direct stenting is not successful, balloon angioplasty will be allowed.
3162717|NCT01462188|Experimental|Delayed stenting|"Patients being randomized to the delayed/staged stenting arm will be managed with the aim to obtain stable TIMI 3 flow with no considerations given at the percentage of residual stenosis at the culprit lesion.~In patients presenting with TIMI 3 flow, investigators will be left free to wire the vessel and proceed to thrombus aspiration to decrease thrombus burden in the culprit lesion or to leave the vessel untreated at the time of index PCI. Patients presenting with suboptimal TIMI flow (i.e. less than 3), investigators are required to wire the vessel and thrombus aspirate. If stable (persisting for at least 5 minutes) TIMI 3 flow is obtained, investigators are requested to stop the procedure. The goal is to achieve s table TIMI 3 flow with no considerations given to the percentage of residual stenosis. Stenting in this arm will be allowed only on a bail-out strategy."
3162718|NCT01462175|Experimental|Schedule A: RO5503781 QW|Participants will receive multiple ascending doses of RO5503781 orally once weekly (QW) x 3 followed by 13 days of rest in a 28 days cycle.
3162719|NCT01462175|Experimental|Schedule B: RO5503781 QD|Participants will receive multiple ascending doses of RO5503781 orally QD x 5 followed by 13 days of rest in a 28 days cycle.
3162720|NCT01462162||Rheumatoid Arthritis Participants|Participants with moderate to severe rheumatoid arthritis (RA) who have been considered and proposed by the rheumatologist to start treatment with Tocilizumab (RoActemra) according to the indications of the summary of product characteristics of the product and the standard clinical practice of each participating center will be followed-up for 6 months.
3162721|NCT01462149|Experimental|Chemotherapy|Neoadjuvant chemotherapy with docetaxel plus carboplatin
3162722|NCT01462136|Experimental|ACHN-490 Injection|
3162723|NCT01462123||small polyps patients|Patients with one small polyps at colonoscopy
3162724|NCT01462097|Experimental|Aerobic exercise|12 months of treadmill walking and strength training exercise. Exercise is gradually progressed in walking speed and time on the treadmill based on the individual's tolerance, abilities, and safety. For months 1-6 exercise will take place 3 times per week at the research center. For months 6-12 exercise will take place 2 times per week at the center and 1 time per week at home.
3162725|NCT01462097|Active Comparator|Health Education|12 months of Health education sessions which will cover topics important to older adults (safe travel, age-appropriate preventative screenings, resources for reliable health information, and topics relevant to chronic kidney disease). For months 1-6 classes will take place 1 time per week. For months 6-12 classes will take place 1 time per month.
3162726|NCT01462084|Experimental|Adaptive Servo-Ventilation (ASV) then BiLevel PAP|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual. ASV adjusts to the breathing events the individual is experiencing and provides enough PAP to resolve the breathing event. This is a crossover study, so all patients enter both treatment groups.
3162727|NCT01462084|Experimental|Bi-Level PAP then Adaptive Servo-Ventilation (ASV)|Bi-level pressure delivers two pressures, IPAP and EPAP. Both pressures are fixed and do not adjust based on the individuals breathing events. This is a crossover study, so all patients enter both treatment groups.
3162728|NCT01462071||Chronic kidney disease|
3162729|NCT01462058|Active Comparator|Vitamin D3|one tablet of vitamin D3 (70µg) per day for 12 weeks.
3162730|NCT01462058|Placebo Comparator|placebo|one tablet of sugar pill per day for 12 weeks.
3162731|NCT01462045|Experimental|Exercise Group|Participants who are screened positive for PTSD and participate in the series of 16 standardized, semiweekly 60-minute mindfulness-based exercise sessions. The intervention consists of stretching and balancing movements combined with breathing and a focus on mindfulness.Over the course of 8 weeks, the intensity of the exercise increases, but the sequence of the movements is the same.
3162732|NCT01462045|No Intervention|Control Group|Participants who are screened positive for PTSD but do not participate in the mindfulness-based exercise.
3162733|NCT01462045|No Intervention|Base Group|Healthy volunteers who are not screened positive for PTSD and do not participate in the mindfulness-based exercise.
3162734|NCT01462032|Experimental|Cognitive enhancing games|Children will be introduced to specific games believed to enhance cognitive functioning. Parent will be encouraged to play these games with their children.
3162735|NCT01462032|Active Comparator|Parent support and education|Parents will participate in groups designed to provide information about ADHD and support for working with their child.
3162736|NCT01462019|No Intervention|Control|
3162737|NCT01462019|Experimental|Photobiomodulation|
3162738|NCT01462006|Experimental|Sirolimus|
3162739|NCT01462006|Placebo Comparator|Placebo|
3162740|NCT01461993|Active Comparator|Group 1|rLP2086 + Gardasil
3162741|NCT01461993|Placebo Comparator|Group 2|rLP2086 and saline
3162742|NCT01461993|Active Comparator|Group 3|Saline + Gardasil
3162743|NCT01461980|Active Comparator|MCV4 + Tdap+ rLP2086|Group 1 - MCV4 + Tdap + rLP2086
3162744|NCT01461980|Active Comparator|MCV4 + Tdap + saline|Group 2, MCV4 + Tdap+ saline
3162745|NCT01461980|Placebo Comparator|Saline + saline + rLP2086|Group 3- rLP2086 + saline
3162746|NCT01461967|Experimental|Part 1a|
3162747|NCT01461967|Placebo Comparator|Part 1b|
3162748|NCT01461967|Experimental|Part 2|
3162749|NCT01461954|Experimental|FST-100|
3162750|NCT01461954|Placebo Comparator|FST-100 Vehicle|
3162751|NCT01461941|Experimental|Drug: 0.2% E6005 ointment|
3162752|NCT01461941|Placebo Comparator|Drug: 0.0% E6005 ointment (vehicle)|
3162753|NCT01461928|Other|Maintenance II Period Observation Only|Participants will receive standard chemotherapy regimen in combination with 375 mg/m^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); no treatment in Maintenance II period until disease progression or end of study, whichever occurs first.
3162842|NCT01461408|Experimental|Beauty Salon #5a|Mothers of 9-18 year old females
3162843|NCT01461408|Experimental|Beauty Salon #5b|Females ages 9-26
3162754|NCT01461928|Experimental|Maintenance II Period Rituximab|Participants will receive standard chemotherapy regimen in combination with 375 mg/m^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); 1400 mg rituximab SC every 8 weeks until disease progression or end of study, whichever occurs first (Maintenance II period).
3162755|NCT01461915|Experimental|Run-in|10 Subjects to be enrolled in the study to receive : gemcitabine + nab-paclitaxel + ODSH
3162756|NCT01461915|Experimental|Arm A|25 patients to be enrolled to receive gemcitabine + nab-paclitaxel + ODSH
3162757|NCT01461915|Active Comparator|Arm B|25 patients will be enrolled in the study to receive gemcitabine + nab-paclitaxel
3162758|NCT01461902||Pediatric Traumatic Brain Injury|Children from 5 days to 15 years of age who have been admitted to the hospital with a traumatic brain injury.
3162759|NCT01461889|Experimental|High INR|Transfuse plasma to High INR target. Plasma will be transfused to reach a target INR=2.5 for 48 hours while patient is actively bleeding.
3162760|NCT01461889|Active Comparator|Low INR|Transfuse plasma to Low INR target. Plasma will be transfused to reach a target INR=1.8 for 48 hours while patient is actively bleeding.
3162761|NCT01461876||HIV-infected cohort|
3162762|NCT01461876||HIV-uninfected control group|
3162763|NCT01461863|Active Comparator|protein calorie supplement|250 gm daily of specially designed porridge plus standard multivitamin
3162764|NCT01461863|Placebo Comparator|Multivitamin|Standard multivitamin control
3162765|NCT01461850|Active Comparator|Primary debulking surgery|All patients with suspicion of advanced ovarian carcinoma (FIGO stage IIIC) will undergo to a diagnostic laparoscopy in order to obtain a laparoscopic score (PIV) based on seven parameters: omental cake, peritoneal and diaphragmatic extensive carcinosis, mesenteric retraction, bowel and stomach infiltration, spleen and/or liver superficial metastasis, as previously published (Fagotti et al, American Journal of Obstetrics and Gynecology, 2008) Patients with PIV ≥ 8 and ≤ 12 randomized in this group will be submitted to an attempt of primary debulking surgery in order to obtain RT < 1 cm, followed by adjuvant chemotherapy.
3162766|NCT01461850|Experimental|Interval debulking surgery|All patients with suspicion of advanced ovarian carcinoma (FIGO stage IIIC) will undergo to a diagnostic laparoscopy in order to obtain a laparoscopic score (PIV) based on seven parameters: omental cake, peritoneal and diaphragmatic extensive carcinosis, mesenteric retraction, bowel and stomach infiltration, spleen and/or liver superficial metastasis, as previously published (Fagotti et al, American Journal of Obstetrics and Gynecology, 2008) Patients with PIV ≥ 8 and ≤ 12 randomized in this group will be submitted only to diagnostic laparoscopy followed by neoadjuvant chemotherapy and subsequent Interval Debulking Surgery, followed by further cycles of chemotherapy.
3162767|NCT01461837|Experimental|Haplo Stem Cell Transplantation|CD34 selected T-cell depleted allogeneic SCT
3162768|NCT01461824|Active Comparator|150 mg DMPA|Depot medroxyprogesterone acetate (DMPA) 150 mg every 12 weeks IM
3162769|NCT01461824|Experimental|104mg DMPA|Depot medroxyprogesterone acetate (DMPA) 104 mg every 12 weeks IM
3162770|NCT01461824|Experimental|75mg DMPA|Depot medroxyprogesterone acetate (DMPA) 75 mg every 12 weeks IM
3162771|NCT01461811|Experimental|DAILIES® AquaComfort Plus® Toric|Nelfilcon A toric contact lenses (with comfort additives) worn in both eyes on a daily wear, daily disposable basis for three months
3162772|NCT01461811|Active Comparator|Focus® DAILIES® Toric|Nelfilcon A toric contact lenses worn in both eyes on a daily wear, daily disposable basis for three months
3162773|NCT01461798|Experimental|Benecol|In 2009, the dairy Cooperative Colanta Launches Benecol ® yogurt, a product with optimal daily dose of plant stanol, each portion of 100 g containing 3.4 g of Benecol ®, corresponding to 2 g of plant stanol esters . Skim yogurt with Benecol ® is a product made from pasteurized skim milk, sweetened with sucralose homogenized and fermented by the action of specific lactic culture to obtain the optimal characteristics of texture and acidity. With the addition of fruit pulp and supplemented with plant stanol esters (Benecol ®) to help reduce the risk of cardiovascular disease (31). According to Weiss et al, drinkable yogurt with Benecol ® reduces total cholesterol by 5.8% and 9.8% in LDL cholesterol (32).
3162774|NCT01461798|Placebo Comparator|yogurt|Yogurt without plant stanols
3162775|NCT01461785|Experimental|GROUP A: PRP +|Group A (16 subjects) will receive lipofilling enriched with 3 ml of autologous PRP ( Platelet rich plasma) with lipofilling
3162776|NCT01461785|Placebo Comparator|GROUP B: PRP -|Group B ( 16 subjects) will receive lipofilling without addition PRP. 27 ml blood will be drawn from the patient, but will be discarded, and not turned into PRP.
3162777|NCT01461772|Experimental|CCRT weekly carboplatin|Concurrent chemoradiation therapy with weekly carboplatin
3162778|NCT01461772|Active Comparator|CCRT weekly cisplatin|Concurrent chemoradiation therapy with weekly cisplatin
3162779|NCT01461759|Experimental|Chemotherapy|Docetaxel 70mg/m2BSA + Cisplatin 60mg/m2BSA, q 3 weeks, 8cycles
3162780|NCT01461746|Experimental|Chemotherpay and radiation therapy|Docetaxel plus cisplatin followed by radiation therapy
3162781|NCT01461733|Experimental|amiodarone|standard dose amiodarone
3162782|NCT01461733|Placebo Comparator|placebo|
3162783|NCT01461720|Other|Standard medical care|This is the control arm, which is given the best evidence-based standard treatment for the management of acute stroke
3162784|NCT01461720|Experimental|BM-MSCs|Autologous bone marrow-derived mesenchymal stem cells(BM-MSCs)
3162785|NCT01461707|Experimental|Mobile app plus activity monitor group|Participants in the group will receive the mobile phone-based physical activity program and an activity monitor
3162786|NCT01461707|Active Comparator|Activity monitor group|Participants in the group will receive an activity monitor
3162787|NCT01461694|Active Comparator|IPL|Half face treated with IPL
3162788|NCT01461694|Active Comparator|Alexandrite Laser|Half face treated with Alexandrite Laser
3162789|NCT01461681|Experimental|Symptom Management Service for heart failure|Subjects randomized to the SMS-HF group will receive a comprehensive PC consultation by the interdisciplinary PC team at each site consisting of a nurse practitioner, physician, social worker and chaplain with 6 months of follow up. All members of the PC team are experienced PC clinicians. The SMS-HF intervention is based on National Quality Forum preferred practices and the National Consensus Project guidelines for quality PC. The SMS-HF will include assessment and management of symptoms, particularly focused on depression, pain and dyspnea, and a discussion of goals of care.
3162790|NCT01461681|No Intervention|Usual cardiology care|The usual cardiology care group will receive usual care provided by the HF clinic. We will assess symptoms and QoL at enrollment and symptoms, QoL, satisfaction, advance care planning documentation, and resource utilization at follow up 6 months later.
3162791|NCT01461668|Experimental|Retapamulin|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of retapamulin with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (retapamulin) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).
3162792|NCT01461668|Placebo Comparator|Placebo|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of a placebo with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (placebo) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).
3162793|NCT01461655|Placebo Comparator|Topical retinoid - Placebo|
3162794|NCT01461655|Active Comparator|Topical retinoid-NSAID|
3162795|NCT01461642|Experimental|Asthma - ICT support.|
3162796|NCT01461642|No Intervention|Asthma, comparator - no ICT support|
3162797|NCT01461629||heart failure|left systolic heart failure (EF </= 40%)
3162798|NCT01461616|Experimental|NPH insulin injection|NPH insulin will be injected in random order in one of three seperated visit days.
3162799|NCT01461616|Experimental|detemir insulin injection|insulin detemir will be injected in random order in one of three seperated visit days.
3162800|NCT01461616|Experimental|glargine insulin injection|insulin glargine will be injected in random order in one of three seperated visit days.
3162801|NCT01461603|Active Comparator|Amino acids|Amino acids compared to saline
3162802|NCT01461603|Active Comparator|3hydroxybutyrat (3OHB)|Ketone body, 3OHB compared to saline
3162803|NCT01461590|Active Comparator|20ml/kg of whole blood transfusion|Standard care recommended by WHO
3162804|NCT01461590|Experimental|30ml/kg of whole blood|Higher volume than currently recommended
3162805|NCT01461577|Experimental|insulin glargine|Insulin glargine will be administered once a day, in the morning, at initial dose of 4 units/day. Titration of insulin dose will be performed referred with the median fasting plasma glucose value for the last 3 consecutive days according to the titration algorithm
3162806|NCT01461564|Experimental|Carbon dioxide|Patients insufflated with carbon dioxide during screening colonoscopy
3162807|NCT01461564|Active Comparator|Air|Patients insufflated with air during screening colonoscopy
3162808|NCT01461551|Experimental|Sevoflurane|
3162809|NCT01461551|Experimental|Propofol|
3162810|NCT01461551|Experimental|Combine of sevoflurane and propofol|
3162811|NCT01461538|Experimental|Brentuximab vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
3162812|NCT01461538|Experimental|Brentuximab vedotin 2.4 mg/kg|Brentuximab vedotin 2.4 mg/kg every 3 weeks by IV infusion
3162813|NCT01461538|Experimental|Brentuximab vedotin 1.2 mg/kg|Brentuximab vedotin 1.2 mg/kg weekly, 3 out of 4 weeks, by IV infusion
3162814|NCT01461525|Experimental|Sphincter preservation surgery|Temporary ileostomy with anal sphincter preservation
3162815|NCT01461525|Experimental|Abdominoperineal Resection|Permanent colostomy with total anal sphincter sacrifice
3162816|NCT01461512|Placebo Comparator|Placebo|
3162817|NCT01461512|Experimental|Heme arginate treatment|
3162818|NCT01461499|Active Comparator|Direct renin inhibitor|
3162819|NCT01461499|Active Comparator|Angiotensin receptor blockers|
3162820|NCT01461486|Active Comparator|Continuous Positive Airway Pressure|Intervention group
3162821|NCT01461486|Active Comparator|Oral Appliance (BRD)|Intervention group
3162822|NCT01461486|No Intervention|Hygiene sleep care|Control group
3162823|NCT01461473|Active Comparator|Positive Airway Pressure|Participants randomized to standard clinical Positive Airway Pressure (PAP) treatment for Obstructive Sleep Apnea (OSA).
3162824|NCT01461473|Active Comparator|Oral Appliance|Subjects randomized to standard Oral Appliance (OA) treatment for Obstructive Sleep Apnea (OSA).
3162825|NCT01461460|Active Comparator|Moxifloxacin 400 mg|
3162826|NCT01461460|Experimental|TR-701 FA 1200 mg|
3162827|NCT01461460|Experimental|TR-701 FA 200 mg plus Placebo|
3162828|NCT01461460|Placebo Comparator|Placebo|
3162829|NCT01461447|Experimental|MVA|Volunteers who were primed with 3 HIVIS DNA and further boosted with 2 MVA vaccine will receive a third MVA there shall not be an comparator for this study.
3162830|NCT01461434|Experimental|loop recorder|patients will be implanted with a subcutaneous loop recorder and have regular follow-ups
3162831|NCT01461434|No Intervention|regular follow-up|patients will receive regular follow-ups with standard ECG
3162832|NCT01461421|Active Comparator|Standard Behavioral Treatment|Nutrition education, behavioral weight loss techniques, and standard cognitive strategies for dealing with stress and emotions. Six months weekly, 3 months bi-weekly, 3 months monthly.
3162833|NCT01461421|Experimental|Acceptance Based Behavioral Intervention|Nutrition education, behavioral weight loss techniques, and acceptance based strategies for dealing with stress and emotions. Six months weekly, 3 months bi-weekly, 3 months monthly.
3162834|NCT01461408|Experimental|Beauty Salon #1b|Females ages 18-26
3162835|NCT01461408|Experimental|Beauty Salon #1a|Mothers of 9-18 year old females
3162836|NCT01461408|Experimental|Beauty Salon #2b|Females ages 18-26
3162837|NCT01461408|Experimental|Beauty Salon #3a|Mothers of 9-18 year old females
3162838|NCT01461408|Experimental|Beauty Salon #3b|Females ages 18-26
3162839|NCT01461408|Experimental|Beauty Salon #4a|Mothers of 9-18 year old females
3162840|NCT01461408|Experimental|Beauty Salon #4b|Females ages 18-26
3162841|NCT01461408|Experimental|Beauty Salon #2a|Mothers of 9-18 year old females
3162851|NCT01461382|Experimental|Phase II|Phase II entered 6 months after Phase I. Phase II was a no intervention control for 6 months, then followed an identical intervention protocol to Phase I.
3162852|NCT01461369|Experimental|Diclofenac Capsules 35 mg bid|
3162853|NCT01461369|Experimental|Diclofenac Capsules 35 mg tid|
3162854|NCT01461369|Placebo Comparator|Placebo Capsule|
3162855|NCT01461356|Experimental|Minimally Invasive Surgical approach|Minimally invasive surgical approach for total knee replacement.
3162856|NCT01461356|Active Comparator|Medial Parapatellar surgical approach|Standard medial parapateller surgical approach for total knee replacement.
3162857|NCT01461343|Experimental|pulmonary hypertension|Patients with Group I pulmonary arterial hypertension and exercise-induced pulmonary hypertension to undergo CT imaging, functional PET imaging
3162858|NCT01461343|Active Comparator|healthy controls|healthy adults to serve as controls and to undergo the same study procedures: CT imaging, functional PET imaging
3162859|NCT01461330|Experimental|DASH diet|DASH DIET + EXERCISE
3162860|NCT01461330|Active Comparator|ADA DIET|DIET ACCORDING AMERICAN DIABETES ASSOCIATION DIETARY RECOMMENDATIONS FOR DIABETES
3162861|NCT01461317|Experimental|Etrolizumab|Etrolizumab 100 milligrams (mg) subcutaneous (SC) administration every 4 weeks during the treatment period of up to 240 weeks.
3162862|NCT01461291|Experimental|iStent inject|Implantation of two GTS400 stents using G2-M-IS iStent inject
3162863|NCT01461291|Active Comparator|Cataract surgery|Cataract surgery alone
3162864|NCT01461278|Experimental|Cataract surgery plus iStent supra|
3162865|NCT01461278|Active Comparator|Cataract surgery|
3162866|NCT01461265|Other|Cryoablation|All subjects will have cryoablation on one or two painful metastatic bone tumors.
3162867|NCT01461252|Other|Cryoablation combined with radiation|All subjects will have cryoablation combined with radiation on one or two painful metastatic bone tumors.
3162868|NCT01461239|Active Comparator|cast post and core|
3162869|NCT01461239|Experimental|fiber post - self-adhesive cement|
3162870|NCT01461239|Experimental|fiber post - conventional cement|
3162871|NCT01461226|Experimental|Exercise training|
3162872|NCT01461226|Other|Usual Care|
3162873|NCT01461213|Experimental|Dose 1|Dose 1 = single subretinal injection of vector suspension containing approximately 10e10 rAAV2.REP1 genome particles. Six patients have now received Dose 1.
3162874|NCT01461213|Experimental|Dose 2|Dose 2 = single subretinal injection of vector suspension containing approximately 10e11 rAAV2.REP1 genome particles. Three patients thus far have received Dose 2.
3162875|NCT01461200||Non allergics|
3162876|NCT01461200||allergics|
3162877|NCT01461187|Experimental|exercise in pregnancy|37 pregnant women who performed supervised aerobic physical exercises twice a week
3162878|NCT01461187|No Intervention|Control group|29 pregnant women who had not performed any kind of physical activity during pregnancy
3162879|NCT01461174|Experimental|Modafinil|200 mg tablet, single dose
3162880|NCT01461174|Experimental|Donepezil|5 mg tablet one per day, 15 days
3162881|NCT01461174|Experimental|Memantine|10 mg tablet one per day, 15 days
3162882|NCT01461161|Experimental|20 mg bardoxolone methyl|
3162883|NCT01461161|Experimental|60 mg bardoxolone methyl|
3162884|NCT01461161|Experimental|80 mg bardoxolone methyl|
3162885|NCT01461148|Experimental|FSP peptides|Vaccination with three FSP peptides
3162886|NCT01461109|Experimental|Assess [18F] CFPyPB and PET imaging|To assess [18F]CFPyPB and PET imaging
3162887|NCT01461096|Experimental|Quadrivalent HPV Vaccine|Participants were prescribed the quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
3162888|NCT01461096|Placebo Comparator|Placebo Vaccine|Participants were prescribed the placebo vaccine at baseline and Weeks 8 and 24.
3162889|NCT01461083|Experimental|Assess [18F]MPPF and PET imaging|To assess [18F]MPPF and PET imaging
3162890|NCT01461057|Experimental|Pertuzumab 840/420 mg|Participants received pertuzumab as an intravenous (IV) infusion at a loading dose of 840 milligrams (mg) for cycle 1 and a dose of 420 mg every three weeks (Q3W) for cycles 2-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 milligram per meter squared (mg/m^2) was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 milligram per kilogram (mg/kg) Q3W for subsequent cycles.
3162891|NCT01461057|Experimental|Pertuzumab 840/840 mg|Participants received 840 mg as an IV infusion Q3W for cycles 1-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 mg/m^2 was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg Q3W for subsequent cycles.
3162892|NCT01461044||Cohort|
3162893|NCT01461018|Experimental|IgPro20|
3162894|NCT01461005|Experimental|Dynamic Stabilization System|Dynamic Stabilization System (DSS) System
3162895|NCT01460992||Pacemaker therapy|Patients with an EVIA/ ENTOVIS pacemaker device. See inclusion and exclusion criteria.
3162896|NCT01460979|Experimental|Temsirolimus|
3162897|NCT01460966|Active Comparator|Filtrap™+ Thrombus aspiration catheter|
3162898|NCT01460966|Active Comparator|Thrombus aspiration catheter|
3162899|NCT01460953|Experimental|training intervention|Students participating in didactic training
3162900|NCT01460940|Experimental|Lenalidomide and Panobinostat|In the phase I trial, three patients will be enrolled at each dose level, starting at dose level 1 using a standard 3 + 3 dose escalation phase I design.
3162901|NCT01460927|Other|TriActive+ RF|Healthy male or female subjects 30-60 years of age, having at least two facial sub-areas (left peri-orbital, right peri-orbital or peri-oral) with visible lines/wrinkles and elastosis, which correlate to a score of 2-6 on the Fitzpatrick Classification of Wrinkling and Degree of Elastosis.
3162902|NCT01460888|Experimental|OLA-0 (de-escalation dose)|25mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
3162903|NCT01460888|Experimental|OLA-1|50mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
3162904|NCT01460888|Experimental|OLA-2|100mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
3162905|NCT01460888|Experimental|OLA-3|200mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
3162906|NCT01460888|Active Comparator|RT alone|
3162907|NCT01460875|Experimental|Treatment (interferon therapy)|Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
3162908|NCT01460862||Omalizumab Cohort|
3162909|NCT01460836||Tobramycin Solution|
3162910|NCT01460836||Aztreonam lysine|
3162911|NCT01460823|Experimental|Use of image guided surgery|
3162912|NCT01460810|Experimental|1000CsK Silicon Oil Tamponade|In 20 patients, a standard three-port vitrectomy will be performed. Following a standard air-fluid exchange, the eye will be filled with Silikon-1000 silicone oil in standard fashion. At a subsequent surgery, a standard two-port pars plana vitrectomy will be performed to remove the silicone oil and replace it with saline. The removed silicone oil will be tested onsite for traces of radiation.
3162913|NCT01460797|Other|High Glycemic Index|Hypocaloric diet with predominating high glycemic index foods
3162914|NCT01460797|Other|Low Glycemic Index|Hypocaloric diet with predominant low glycemic index foods
3162915|NCT01460797|Other|Low Glycemic Index plus Metformin|Hypocaloric diet with predominant low glycemic index foods plus Metformin (1g/d)
3162916|NCT01460784||N=60|Cross-sectional study of obese young adults who underwent PET/CT after cold exposure to identify active brown fat. No intervention. Enrolled 44 participants.
3162917|NCT01460784||N=600|Cross-sectional study of patients undergoing clinical PET/CT to identify active brown fat. No intervention. Enrolled 405 participants.
3162918|NCT01460784||N=220|Longitudinal observational study of obese adolescents to determine changes in adiposity and adipokines during puberty. No intervention. Enrolled 125 participants.
3162919|NCT01460771|Experimental|Treatment|Active Transcranial Direct Current Stimulation (TDCS) at 1mA or highest tolerated current
3162920|NCT01460771|Sham Comparator|sham|inactive Transcranial Direct current stimulation (TDCS) at 0mA
3162921|NCT01460758|Experimental|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
3162922|NCT01460758|Experimental|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
3162923|NCT01460758|Sham Comparator|Placebo Stimulation|Sham Stimulation (Conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz,2000 Stimuli each session, 110% motor threshold
3162924|NCT01460732|Other|All patients|All eligible patients in the study consist a single group and the same intervention is assigned to all of them.
3162925|NCT01460719|Experimental|V212 Arm|0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen.
3162926|NCT01460706|Experimental|68Ga-DOTATOC|
3162927|NCT01460693|Active Comparator|Arm A - Imatinib|Imatinib 400mg daily
3162928|NCT01460693|Experimental|Arm B - Dasatinib|Dasatinib 100mg daily
3162929|NCT01460680||Fibromyalgia patients|Patients diagnosed as suffering from Fibromyalgia according to the ACR 1990 criteria
3162930|NCT01460680||SLE patients|Patients diagnosed as suffering from Systemic Lupus Erythematosus by the ACR criteria
3162931|NCT01460680||Healthy controls|Healthy controls
3162932|NCT01460667|Active Comparator|IV acetaminophen|
3162933|NCT01460667|Placebo Comparator|IV 0.9% normal saline|
3162934|NCT01460654|Placebo Comparator|Testosterone and Placebo Alendronate|
3162935|NCT01460654|Placebo Comparator|Alendronate and Placebo Testosterone|
3162936|NCT01460654|Experimental|Testosterone and Alendronate|
3162937|NCT01460641||CT perfusion|
3162938|NCT01460628|Experimental|Armodafinil|Armodafinil is the drug being tested.
3162939|NCT01460602|Experimental|Part 1: establish MTD|Part 1 consists of dosing to determine maximum tolerated dose (MTD) and dose limiting toxicity (DLT).
3162940|NCT01460602|Experimental|Part 2: The MTD from Part 1|During the Phase 2 part of the study, approximately 24 additional subjects will be enrolled in order to obtain a total of 30 response-evaluable subjects treated at the maximum tolerated dose.
3162941|NCT01460589|Experimental|early commencement|Individuals who initiate the adjuvant chemotherapy from 10 to 14 days after surgery
3162942|NCT01460589|Active Comparator|conventional commencement|Individuals who initiate the adjuvant chemotherapy after 14 days after surgery
3162943|NCT01460563|Experimental|Mg_orfil|patients preloaded with sodium valproate receives MgSO4 during the craniotomy.
3162944|NCT01460563|Placebo Comparator|control_orfil|patients preloaded with sodium valproate receives 0.9% saline as placebo.
3162945|NCT01460563|Placebo Comparator|control_no orfil|patients not preloaded with sodium valproate receives 0.9% saline as placebo.
3162946|NCT01460550|Experimental|gastrointestinal reconstruction|
3162947|NCT01460537|Experimental|Treatment A: Gemcitabine-Copanlisib|The treatment consists of repetitive cycles, each over 28 days. Treatment continues until disease progression or dose limiting toxicity. If gemcitabine is discontinued for toxicity, Copanlisib may be continued at the discretion of the Investigator if a clinical benefit (response or stable disease for 3 months) is noted. - Hour 0 to 0.5: Gemcitabine (1000 mg/m2 as 30-minute IV infusion) on Days 1, 8 and 15 every 28 days - Hour 1.5 to 2.5: BAY80-6946 (starting dose = 0.6 mg/kg as 60-minute IV infusion, starting 1 hour post completion of gemcitabine infusion) on Days 1, 8 and 15 every 28 days
3162977|NCT01460303|Active Comparator|Transurethral catheter w/leg bag|"Patients who fail postop bladder challenge and are randomized to indwelling catheter with leg bag arm will be instructed in the use and care of this catheter, discharged home with it in place and given an appointment between 5-10 days postop for a bladder challenge."
3162978|NCT01460290|Experimental|Asenapine|12-weeks of open-label asenapine treatment
3162979|NCT01460277|Experimental|Hydrokinesiotherapy|A 6-week water-based exercise program that focused on balance and weight bearing exercises (3 days a week for 1 hour a session)
3162981|NCT01460264||exposed|current daily smokers 100 cigarettes or more during lifetime
3162982|NCT01460264||unexposed|current non-smokers
3162948|NCT01460537|Experimental|Treatment B: Cisplatin-Gemcitabine-Copanlisib|Treatment consists of repetitive 21 day cycles for a maximum of 8 cycles. Treatment continues until disease progression, DLT or completion of 8 cycles. After 8 cycles, gemcitabine and Copanlisib, without cisplatin, may continue at the discretion of the Investigator until disease progression or DLT if a clinical benefit is noted (response or stable disease for 3 months). Treatment is administered on Days 1 and 8 every 21 days as follows: - Hour 0 to 1: Cisplatin IV infusion over 60 min (One liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 mmol of magnesium sulfate) - Hour 1 to 1.5: IV infusion of 500 ml of 0.9% NaCl over 30 min - Hour 1.5 to 2: Gemcitabine (1000 mg/m2 as 30 min IV infusion) - Hour 3 to 4: Copanlisib IV infusion at the MTD determined in Treatment A over 60 min. [If Treatment A MTD is not tolerable, further subject enrollment will begin at one Copanlisib Dose Level lower with the cisplatin-gemcitabine doses remaining constant.]
3162949|NCT01460511|Placebo Comparator|P - Placebo-HFA|Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
3162950|NCT01460511|Experimental|T - E004 (Epinephrine Inhalation Aerosol) HFA-MDI|E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID
3162951|NCT01460498|Experimental|Dose Escalation Group (AZA)|Azacitidine (AZA) starting dose 50 mg/m2 a day for 3 days subcutaneous or intravenous of 28 day cycle. TKI at dose received during last 6 months.
3162952|NCT01460498|Experimental|Expansion Group (AZA MTD)|Dose Escalation Group plus additional 36 participants for Azacitidine 75 mg/m2 (or Phase I MTD) either subcutaneous or intravenous every day for 3 days of 28 day cycle. TKI at dose received during last 6 months.
3162953|NCT01460472|Experimental|Racotumomab plus Best Support Treatment|Patients will receive Racotumomab and Best Support Treatment, which includes any further onco-specific therapy for progressive disease.
3162954|NCT01460472|Active Comparator|Best Support Treatment|Patients will receive best support treatment for advanced NSCLC including onco-specific therapies when disease progresses.
3162955|NCT01460459|Experimental|high frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) one day weekly in group A.
3162956|NCT01460459|Experimental|middle frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) one day per two weeks in group B.
3162957|NCT01460459|Experimental|low frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) Group C: one day monthly
3162958|NCT01460446|Experimental|Aviva Expert blood glucose meter|Participants used the Accu-Chek® Aviva Expert blood glucose meter with an integrated bolus advisor to determine the dose of insulin for each injection in their 24 week multiple daily injection therapy.
3162959|NCT01460446|Active Comparator|Aviva Nano blood glucose meter|Participants used the Accu-Chek® Aviva Nano blood glucose meter and manual bolus calculation to determine the dose of insulin for each injection in their 24 week multiple daily injection therapy.
3162960|NCT01460420|Experimental|Bortezomib + Lenalidomide|After conditioning treatment and graft versus host disease prophylaxis with Bz 1.3 mg/m2 on days +1, +4 and +7 plus sirolimus/rapamycin at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL, a maintenance therapy with Bz 1.3 mg/m2 on days 1, 8 and 15 in cycles of 56 days up to 6 cycles post-transplant and on day +180 Len will be started at a dose of 5 mg and will be maintained until relapse.
3162961|NCT01460407|Experimental|LY2216684 + Clarithromycin|Participants will receive a single 18 mg oral dose of LY2216684 on Days 1 and 10. Clarithromycin (500 mg) will be administered twice a day (BID) on Days 6 through 13.
3162962|NCT01460394||Healthy adolescents and young adults|
3162963|NCT01460381|Experimental|LY2216684 + Quinidine|In Period 1 (Day -1 up to Day 6), a single 18 mg oral dose of LY2216684 will be administered on Day 1 for CYP2C19 poor metabolizers (PM). In Period 2 (Day 7 up to Day 16), a 300 mg oral dose of quinidine sulfate controlled release (CR) will be administered once daily (QD) on Days 8 through 15 and a single 18 mg oral dose of LY2216684 will be administered on Day 11.
3162964|NCT01460381|Experimental|LY2216684|In Period 1, a single 18 mg oral dose of LY2216684 will be administered on Day 1 for CYP2C19 extensive metabolizers (EM) participants. EM participants do not participate in Period 2.
3162965|NCT01460368|Experimental|Part A: LY2409021|Participants will receive 2 standard meals; one alone without LY2409021, and one along with a single dose of LY2409021 300 mg administered orally. Participants enrolled in Part A will not be allowed to participate in Part B.
3162966|NCT01460368|Placebo Comparator|Part B: Placebo|Administered orally as a single dose on Day 1 of the relevant treatment period. Each subsequent treatment period will begin approximately 15 days after dosing.
3162967|NCT01460368|Active Comparator|Part B: Moxifloxacin|Moxifloxacin 400 mg administered orally as a single dose on Day 1 of the relevant treatment period. Each subsequent treatment period will begin approximately 4-15 days after dosing.
3162968|NCT01460368|Experimental|Part B: LY2409021|LY2409021 300 mg administered orally as a single dose on Day 1 of the relevant treatment period. Each subsequent treatment period will begin approximately 15 days after dosing.
3162969|NCT01460355|Active Comparator|Botulinum toxin plus surgery|Intraoperative injection of 5U (0.1 ml) of Botulinum Toxin will be given to the recessed muscle during surgery
3162970|NCT01460355|Placebo Comparator|Saline solution plus surgery|Saline solution (0,1 ml)will be given to the recessed muscle during surgery procedure
3162971|NCT01460342|Placebo Comparator|Placebo|Following the 4-week placebo lead-in period, this arm will consist of a 12-week placebo treatment period involving 2 x 2.5-milligram (mg) tadalafil placebo tablets taken orally once daily.
3162972|NCT01460342|Experimental|Tadalafil|Following the 4-week placebo lead-in period, this arm will consist of a 12-week treatment period involving 2 x 2.5-mg tadalafil tablets taken orally once daily.
3162973|NCT01460329||USCOM Cardiac index|
3162974|NCT01460316||Conotruncal cardiac defects patients|
3162975|NCT01460316||Mothers of patients|
3162976|NCT01460303|Experimental|OPTION-vf patient controlled catheter|"Patients who fail postop bladder challenge and are randomized to OPTION-vf arm will be instructed in the use and care of this catheter, discharged home with it in place and given an appointment between 5-10 days postop for a bladder challenge."
3162980|NCT01460277|Active Comparator|Conventional exercise intervention|A 6-week land-based exercise program that focused on balance and weight bearing exercises (3 days a week for 1 hour a session)
3162983|NCT01460251|Experimental|Drug:Diapep277|1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
3162984|NCT01460238||No treatment|No intervention. Each patient will have blood drawn at a standard of care venipuncture.
3162985|NCT01460225|Experimental|Treatment|24 micrograms of lubiprostone twice daily for one week.
3162986|NCT01460212|Experimental|Cognitive-Behavior Therapy group|treatment with Cognitive-Behavior Therapy
3162987|NCT01460212|Active Comparator|SSRI antidepressants|treatment by SSRI antidepressant
3162988|NCT01460199|Placebo Comparator|Placebo|Matching Placebo
3162989|NCT01460199|Experimental|CTP-499|
3162990|NCT01460186|Experimental|Blood samples|
3162991|NCT01460173|Other|Normal subjects|
3162992|NCT01460173|Other|OSA Patients|
3162993|NCT01460160|Experimental|Arm 1: Dasatinib|
3162994|NCT01460147|Other|DXA scan + MRI|
3162995|NCT01460134|Experimental|Hematologic Malignancies (Dose Escalation)|B-Cell Enrollment COMPLETED T-Cell Enrollment COMPLETED
3162996|NCT01460134|Experimental|Solid tumors (Dose Escalation; COMPLETED)|
3162997|NCT01460134|Experimental|Solid Tumors (Expansion Phase; COMPLETED)|Several expansion cohorts of up to 15 patients each are planned, including melanoma and renal cell carcinoma.
3162998|NCT01460134|Experimental|Hematologic Malignancies (COMPLETED)|Several expansion cohorts of up to 15 patients each are planned, including Hodgkin lymphoma.
3162999|NCT01460121|Experimental|SpotOn's corrective elements|
3163000|NCT01460121|Placebo Comparator|Placebo corrective elements|
3163001|NCT01460108|Experimental|AeriSeal System Treatment|Candidates for the trial include patients with advanced non-bullous upper lobe predominant emphysema who have a DLco between 20 and 60% predicted and target sites in at least 1 upper lobe. Eligible and consented patients will undergo evaluation with the Chartis System, and only patients found to have significant collateral ventilation will be enrolled.
3163002|NCT01460095|Experimental|HbA1c measurement and education|3-monthly Hba1c determination with immediate feedback and targeted education delivered to all participants
3163003|NCT01460082||Exacerbation|The study sample will consist of patients admitted to the hospital because of an acute exacerbation of COPD
3163004|NCT01460069|Active Comparator|Victoza treatment|
3163005|NCT01460069|Placebo Comparator|Placebo|The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
3163006|NCT01460056||Peritoneal dialysis|
3163007|NCT01460043|Placebo Comparator|placebo|
3163008|NCT01460043|Experimental|Homeopathy|Individualized symptom based therapy
3163009|NCT01460030|Experimental|KRN1493|
3163010|NCT01460017|Active Comparator|DS arm|Deep sclerectomy surgery will be conduct in this arm
3163011|NCT01460017|Active Comparator|Trab arm|combined Trabeculectomy and Trabeculotomy surgery will be conducted in this arm
3163012|NCT01460004|No Intervention|patella knee strap|infra patella knee strap- cotton, applied in straight leg
3163013|NCT01459991|Experimental|Mediterranean|Participants in this arm will follow a Mediterranean style diet, rich in olive oil and fruits and vegetables, and also consume 1 ounce of walnuts daily.
3163014|NCT01459991|Active Comparator|MyPyramid|
3163015|NCT01459978||Early CUSUM result group|"Phase 1: 3 months testing and observation period. During this phase, rates of each quality indicator selected will be collected to adjust the acceptable and unacceptable rate set by practitioners of each maternity.~Phase 2: results of the CUmulative SUM (CUSUM) will be provided for a period of 12 months (Early CUSUM result group), Phase 3: maternity will continue to receive the results of the CUmulative SUM (CUSUM) for a period of 12 months,"
3163016|NCT01459978||CUSUM result Delayed group|Phase 1: 3 months testing and observation period. During this phase, rates of each quality indicator selected will be collected to adjust the acceptable and unacceptable rate set by practitioners of each maternity Phase 2: the results of CUmulative SUM (CUSUM) will not be shared. Phase 3: group receive CUmulative SUM (CUSUM) result (CUSUM result Delayed group) during the same period 12 months
3163017|NCT01459965|Active Comparator|10 French Stent|10 French biliary plastic stent
3163018|NCT01459965|Active Comparator|11.5 French stent|11.5 French biliary plastic stent
3163019|NCT01459952|Experimental|Rose hip Liquid|20 ml Rose hip Liquid BID
3163020|NCT01459952|Placebo Comparator|Placebo|20 ml placebo liquid BID
3163021|NCT01459939|Placebo Comparator|Placebo|Daily treatment with placebo
3163022|NCT01459939|Active Comparator|Rose-hip powder|Daily treatment with Rose-hip powder
3163023|NCT01459926|Experimental|Dose 1|
3163024|NCT01459926|Experimental|Dose 2|
3163025|NCT01459926|Experimental|Dose 3|
3163026|NCT01459926|Experimental|Placebo|
3163027|NCT01459913|Experimental|Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)|Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met rapid viral response (RVR, undetectable Hepatitis C Virus [HCV] Ribonucleic Acid [RNA] at Week 4) criteria, were randomized in this group, as planned, and did not receive any further treatment.
3163028|NCT01459913|Experimental|Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.
3163103|NCT01459432||Follow-on blood sample from previous study|
3163104|NCT01459419|Experimental|anti-CD3 monoclonal antibody|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up to 9 subjects will be treated at each dosage level
3163029|NCT01459913|Experimental|Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.
3163030|NCT01459913|Experimental|Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.
3163031|NCT01459900|Active Comparator|Renal artery ablation|By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to active treatment, renal artery ablation will be carried out straight away.
3163032|NCT01459900|Sham Comparator|Sham|By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to sham procedure, no renal artery ablation are performed.
3163033|NCT01459887|Experimental|combination group|
3163034|NCT01459887|Experimental|sequential group|
3163035|NCT01459874||Cardiac Implantable Device recipients|
3163036|NCT01459861|Experimental|Canal Block and Capsular Injection|Adductor canal block with a continuous catheter and ultrasound guided posterior capsular injection with local anesthetic solution.
3163037|NCT01459861|Active Comparator|Femoral with Tibial Nerve Block|Continuous femoral nerve block with catheter and selective tibial nerve block in the popliteal fossa.
3163038|NCT01459848|Active Comparator|block play|30 minutes of block play with parent
3163039|NCT01459848|Experimental|baby dvd|watch baby dvd with parent
3163040|NCT01459835|Experimental|media diet|advice tips and tools to reduce exposure to violent programming
3163041|NCT01459835|Active Comparator|Nutrition intervention|diet advice
3163042|NCT01459822||Survival Group|
3163043|NCT01459822||Death Group|
3163044|NCT01459809|Experimental|ARM 1: glimepiride alone|24-week treatment period: After randomization, starting dose will be of 2 mg /day or 1 mg/day of glimepiride if Fasting Plasma Glucose (FPG) at baseline < 180 mg/dL (10 mmol/L) taken once in the morning before breakfast. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 4 mg, and adjusted throughout the 24-week treatment period according to fasting Self Monitored Plasma Glucose (SMPG) values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
3163045|NCT01459809|Experimental|ARM 2: metformin alone|24-week treatment period: After randomization, starting dose will be of 500 mg of metformin twice a day during or after meals. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 2000 mg, and adjusted throughout the 24-week treatment period according to fasting SMPG values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
3163046|NCT01459809|Experimental|ARM3: Glimepiride/metformin free combination|24-week treatment period: After randomization, starting dose will be of 2 mg /day or 1 mg/day of glimepiride if FPG at baseline < 180 mg/dL (10 mmol/L) taken once in the morning and 500 mg of metformin twice a day taken during or after meals. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 4 mg of glimepiride and 2000 mg of metformin, and adjusted throughout the 24-week treatment period according to fasting SMPG values in the objective to obtain values ≤.
3163047|NCT01459796|Experimental|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 51.
3163048|NCT01459796|Experimental|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 51.
3163049|NCT01459783|Active Comparator|Dementia care management in person|The dementia care management protocol will be delivered via face-to-face interactions in participants' homes or in mutually convenient locations between a trained care manager and the care recipient/informal family caregiver dyad, supplemented by telephone.
3163050|NCT01459783|Active Comparator|Dementia care management telephone only|The dementia care management protocol will be delivered via telephonic meetings only. Assessment, education, counseling, and social support procedures as well as referral and follow-ups will follow the same procedural content as stipulated for the face-to-face intervention, however, contact will not be planned in person.
3163051|NCT01459770|Active Comparator|control|"usual care for hospital discharge:~CKD group~ESRD group"
3163052|NCT01459770|Active Comparator|intervention|"pharmacist administered medication information transfer intervention~CKD group~ESRD group"
3163053|NCT01459757||Data generated from the past sunitinib A6181036 GIST study|
3163054|NCT01459744|Experimental|Communication training for cardiologists|The intervention consists of an educational workshop for heart failure physicians, a reminder system, and a system providing aggregated feedback on their conversations with patients about ICD deactivation.
3163055|NCT01459744|Placebo Comparator|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
3163056|NCT01459731||Age 18-29|
3163057|NCT01459731||Age 30-39|
3163058|NCT01459731||Age 40-49|
3163059|NCT01459731||Age 50-59|
3163060|NCT01459731||Age 60-69|
3163061|NCT01459731||Age 70+|
3163062|NCT01459718|Experimental|Deferasirox|Monotherapy of deferasirox
3163063|NCT01459718|Active Comparator|Deferasirox + Deferioxamine (DFO)|Combination Therapy: Deferasirox-DFO
3163105|NCT01459419|Placebo Comparator|Sodium chloride|Up to 9 subjects will receive placebo. Subjects will receive the drug in a similar manner as as the treatment group
3163439|NCT01457248|Experimental|endotracheal tube with taper-shaped cuff|
3163064|NCT01459705|Active Comparator|Prolonged Exposure Therapy (PE)|The PE protocol is based on manualized procedures, which are derived from the theory that effective treatment for PTSD requires that the underlying pathological fear structure be activated and paired with new information that is incompatible with the fear structure. PE involves imaginal exposure and in vivo exposure as the two primary strategies to elicit repeated confrontation of feared but objectively safe thoughts, feelings, situations and events.
3163065|NCT01459705|Experimental|Virtual Reality Exposure Therapy (VRET)|The VRET protocol follows the same procedures as the PE protocol with the primary exception being that all instances of imaginal exposure will be augmented by immersion into Virtual Iraq environments, thus creating a situation known as immersive exposure.
3163066|NCT01459705|Placebo Comparator|Waitlist|The waitlist (WL) participants will be asked to refrain from psychotherapy during the 5 weeks of study participation.
3163067|NCT01459692|No Intervention|Control group - No Music Exposure|Subjects that were assigned to the control group of the study were not exposed to music.
3163068|NCT01459692|Experimental|Music Exposure|The treatment subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
3163069|NCT01459679|Active Comparator|VibeX Treatment Group A|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 8 minutes
3163070|NCT01459679|Active Comparator|VibeX Treatment Group B|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 4 minutes
3163071|NCT01459679|Active Comparator|VibeX Treatment Group C|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 2 minutes and 40 seconds
3163072|NCT01459666|Experimental|Dysport (abobotulinumtoxinA)|Each patient will be able to receive up to 120 units of Dysport/placebo at the initial visit to treat the entire forehead area (the frontalis, procerus, and corrugator muscles) to insure cosmetic symmetry. Injections will be placed a minimum of 1.5cm above the orbital rim at the mid papillary line to minimize the risk of lid ptosis. The actual amount to be injected will be at the discretion of the Mohs surgeon based on his or her opinion of what amount is needed for sufficient wound paralysis and cosmetic symmetry.
3163073|NCT01459666|Placebo Comparator|Placebo|
3163074|NCT01459653||Only 1 group|Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.
3163075|NCT01459640|Active Comparator|Hyaluronic acid|
3163076|NCT01459640|Experimental|Bone marrow mesenchymal stem cells|Autologous bone marrow-derived mesenchymal stem cells
3163077|NCT01459627|Active Comparator|6 months DAPT|Dual antiplatelet therapy consisting of aspirin (ASA) and prasugrel or ticagrelor will be discontinued after randomisation.
3163078|NCT01459627|Active Comparator|12 months DAPT|Dual antiplatelet therapy consisting of aspirin (ASA) and prasugrel or ticagrelor will be continued till 12 months after enrollment in the study
3163079|NCT01459614|Experimental|GTX-C|"Each cycle is 21 days (2 weeks Tx + 1 week off). Xeloda given days 1-14, Gemcitabine, Taxotere, and Cisplatin given days 4 and 11.~For expansion cohort, each cycle is 28 days (2 weeks of Tx + 2 weeks off)"
3163080|NCT01459588|Experimental|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
3163081|NCT01459588|Experimental|Carboxymethylcellulose Based Eye Drop Formulation B|Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
3163082|NCT01459588|Active Comparator|Carboxymethylcellulose Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
3163083|NCT01459588|Active Comparator|Carboxymethylcellulose Based Lubricant Eye Drops|Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
3163084|NCT01459562|Experimental|NI-0501|
3163085|NCT01459562|Placebo Comparator|Placebo|
3163086|NCT01459549|No Intervention|Control Group|Just clear the stone without choledochojejunostomy
3163087|NCT01459549|Experimental|Experimental Group|Clear the stone combined with Roux-en-y choledochojejunostomy
3163088|NCT01459536||Rotator Cuff Tear-surgical|
3163089|NCT01459536||Health Older Adult Control|
3163090|NCT01459536||Rotator cuff tear - non surgical|
3163091|NCT01459523|Active Comparator|Imaging technique|In one substudy, subjects will be randomly assigned to either short axis or long axis target ultrasound imaging for perineural catheter insertion. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
3163092|NCT01459523|Active Comparator|Catheter location|In another substudy, subjects will be randomly assigned to receive their perineural catheters either proximally or distally along the same target nerve or plexus.
3163093|NCT01459510|Experimental|multi media intervention|Play Nicely Program
3163094|NCT01459510|No Intervention|Routine primary care|Routine primary care
3163095|NCT01459497|Active Comparator|Radiation Therapy|Arm A:Image-Guided Radiation Therapy (IGRT), 60 Gy in 15 fractions in 3 weeks
3163096|NCT01459497|Active Comparator|Conventional Radiation|Arm B: Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
3163097|NCT01459484|Experimental|Mifamurtide arm|Chemotherapy for patients who over express ABCB1/P-glycoprotein (methotrexate, cisplatinum, doxorubicine, ifosfamide + mifamurtide)
3163098|NCT01459484|Other|3 drugs arm|High grade osteosarcoma treatment for patients who do not over express ABCB1/P-glycoprotein
3163099|NCT01459471|Experimental|bleeding, leak, operative time|
3163100|NCT01459458|Experimental|Clinics trained in brief intervention|Female clients ages 16-29 seeking care in 11 reproductive health clinics in Western Pennsylvania where clinic providers are trained to implement the brief partner violence/reproductive coercion intervention.
3163101|NCT01459458|No Intervention|Control sites providing standard of care|Female clients ages 16-29 seeking care in 14 reproductive health clinics in Western Pennsylvania where clinic providers are providing standard domestic violence screening per usual standard of care.
3163102|NCT01459445|Other|Metformin+Drospirenone / EE 30µg|
3163106|NCT01459406|Experimental|Glucose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g glucose
3163107|NCT01459406|Experimental|Fructose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructose
3163108|NCT01459406|Experimental|Fructan drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructan
3163109|NCT01459406|Experimental|Fructose and glucose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructose and 40 g glucose
3163110|NCT01459393|Experimental|5-ALA Photodynamic Therapy|Topical application of a 2mm of thickness layer of 20% 5-aminolevulinic acid (5-ALA) associated with 20% dimethyl sulfoxide (DMSO) and 3% ethylene diamine acid (EDTA) emulsion, over the actinic keratosis lesion and over a 0,5 cm margin around it. After a 4 hours interval under light protection with plastic film and aluminum foil, the light protection and the emulsion is removed. Then the lesion is lightened with a red (630 nm) incoherent LED lamp AKTILITE CL 128 (PhotoCure ASA, Oslo, Norway) with a total light dose of 37J/cm2.After that dressings are done and kept for 24H, and removed at patient home.
3163111|NCT01459393|Active Comparator|Cryotherapy with liquid nitrogen|Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
3163112|NCT01459380|Experimental|Regimen I (intermittent veliparib)|Patients receive veliparib PO BID on days 1-7, and pegylated liposomal doxorubicin hydrochloride IV over 1 hour and carboplatin IV over 30 minutes on day 1.
3163113|NCT01459380|Experimental|Regimen II (continuous veliparib)|Patients receive veliparib PO BID on days 1-28, and pegylated liposomal doxorubicin hydrochloride and carboplatin as in Regimen I.
3163114|NCT01459367|Experimental|TAK-438 10 mg QD|
3163115|NCT01459367|Experimental|TAK-438 20 mg QD|
3163116|NCT01459367|Active Comparator|Lansoprazole 15 mg QD|
3163117|NCT01459354||post, bimanual laryngoscopy, POGO score|one control, one study group
3163118|NCT01459328|Active Comparator|Arm A: Conventional Long Course Chemo-Radiation|Conventional long course chemo-radiation
3163119|NCT01459328|Experimental|Arm B: Short Course Radiation Followed by Chemotherapy|Experimental short course radiation followed by chemotherapy.
3163120|NCT01459315|Experimental|GSK1349572|
3163121|NCT01459302||Familial and Sporadic ALS|Individuals with ALS and families with a history of two or more people in the family who have had ALS or other forms of motor neuron disease.
3163122|NCT01459289|Active Comparator|leaflet|
3163123|NCT01459289|Active Comparator|counseling|
3163124|NCT01459276|Experimental|FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μg HA of seasonal A/H1N1, A/H3N2 and B influenza antigens
3163125|NCT01459276|Active Comparator|FLUVALAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μg HA of seasonal A/H1N1, A/H3N2 and B influenza antigens
3163126|NCT01459263||GSV insufficiency|Patients with insufficiency of the greater saphenous vein (GSV) will be included.
3163127|NCT01459250|Experimental|AGO178C|
3163128|NCT01459211|Other|Lenalidomide & Dexamethasone|Lenalidomide, 5mg daily, increased to 10mg after 1st cycle. Dexamethasone, 20mg days 1-4 each cycle
3163129|NCT01459198|Experimental|Adults: Vaccine (Group 1)|Adult participants will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
3163130|NCT01459198|Experimental|Seropositive Children: Vaccine (Group 2)|Seropositive children will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
3163131|NCT01459198|Placebo Comparator|Seropositive Children: Placebo Vaccine (Group 2)|Seropositive children will receive one dose of the placebo vaccine intranasally.
3163132|NCT01459198|Experimental|Seronegative Infants and Children: Vaccine (Group 3)|Seronegative infants and children will receive one dose of the 10^5 RSV MEDI ΔM2-2 vaccine intranasally.
3163133|NCT01459198|Placebo Comparator|Seronegative Infants and Children: Placebo Vaccine (Group 3)|Seronegative infants and children will receive one dose of the placebo vaccine intranasally.
3163134|NCT01459198|Experimental|Seronegative Infants and Children: Vaccine (Group 4)|Seronegative infants and children will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
3163135|NCT01459198|Placebo Comparator|Seronegative Infants and Children: Placebo Vaccine (Group 4)|Seronegative infants and children will receive one dose of the placebo vaccine intranasally.
3163136|NCT01459185|Experimental|S-1|Single arm of the patients who received complete resection of pathological stage IB, II, or IIIA Non-small cell lung cancer
3163137|NCT01459172|Experimental|Limonene intervention|
3163138|NCT01459146|Experimental|AL plus ABZ; Arm 1|Artemether-Lumefantrine combination 20mg/120mg 12 hourly for 3 days oral, plus albendazole 400mg stat oral
3163139|NCT01459146|Active Comparator|AL plus PZQ plus ABZ; Arm 2|artemether-lumefantrine combination 120mg/20mg 12 hourly for 3 days; plus praziquantel 40mg/kg stat; plus albendazole 400mg stat oral
3163140|NCT01459146|Active Comparator|ABZ plus PZQ; Arm 3|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
3163141|NCT01459133|Experimental|Technosphere® Insulin Inhalation System|Single Site, Single Subject use of Technosphere® Insulin Inhalation System
3163142|NCT01459120|Experimental|Door-to-Door|Health care workers propose the integrated service package including VCT at the peoples' homes.
3163143|NCT01459120|Active Comparator|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (pitso)."
3163144|NCT01459120|No Intervention|control|Within each cluster (catchment area of a health center), five villages are randomly chosen as comparators on cluster level. These villages get no particular intervention (VCT-campaign). However, routine services continue to be provided. These villages serve as a control for the third primary outcome that assesses the overall numbers newly enrolled into chronic HIV/AIDS care at facility-level.
3163145|NCT01459107|Experimental|Treatment (Transplantation)|Hand/arm transplantation in combination with a novel donor bone marrow cell-based therapy followed by single-drug immunosuppression with potential weaning.
3163146|NCT01459094|Experimental|Treatment Sequence AB|
3163147|NCT01459094|Experimental|Treatment Sequence BA|
3163148|NCT01459081|Experimental|Zanamivir|
3163149|NCT01459081|Placebo Comparator|Placebo|
3163253|NCT01458431|Experimental|Levobupivacaine|Continuous levobupivacaine subfascial infusion
3163150|NCT01459068|No Intervention|Waitlist-Control|Eligible study subjects were assigned to the waitlist-control arm on a rolling admissions basis. The waitlist-controls waited for a period equivalent to the duration of the intervention and then were re-interviewed.
3163151|NCT01459068|Experimental|Common Elements Treatment Approach|Eligible study subjects randomized into the CETA intervention were offered ten weeks of counseling sessions, consisting of nine elements designed to treat symptoms of common mental health disorders including depression, PTS, and anxiety and to provide skills to deal with life stressors.
3163152|NCT01459042||primary aldosteronism|
3163153|NCT01459042||essential hypertension|
3163154|NCT01459029|Active Comparator|D-serine|D-serine up to 6000 mg/day subject to tolerability
3163155|NCT01459029|Placebo Comparator|Control|Treatment with inert capsules (placebo)
3163156|NCT01459016|Experimental|Imaging Biomarkers|
3163157|NCT01459003|Experimental|experimental|
3163158|NCT01459003|No Intervention|control|
3163159|NCT01458990|Experimental|PPI inititation|Adding 40mg omeprazole QD for 14 days
3163160|NCT01458990|Active Comparator|PPI withdrawal|The intervention here is systematically withdrawing chronic PPI for 14 days
3163161|NCT01458977|Experimental|TDF/FTC (3 months) + Placebo (6 months)|TDF/FTC (3 months) + Placebo (6 months)
3163162|NCT01458977|Placebo Comparator|Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months)|Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months)
3163163|NCT01458964|Active Comparator|Quetiapine|Quetiapine will be administered orally, QHS at a dosage of 100 mg for 1 week increasing to a target dosage of 200 mg for 11 weeks.
3163164|NCT01458964|Placebo Comparator|Sugar pill|Sugar pill will be administered orally, QHS at a dosage of 100 mg for 1 week increasing to a target dosage of 200 mg for 11 weeks.
3163165|NCT01458951|Experimental|tofacitinib 10 mg BID|
3163166|NCT01458951|Placebo Comparator|Placebo BID|
3163167|NCT01458938||Healthy volunteers|
3163168|NCT01458938||surgery for spinal radiculopathy|
3163169|NCT01458938||surgery for axial spine pain|
3163170|NCT01458938||myelography for spinal pain|
3163171|NCT01458925|Other|P1 capsule and screening Cscopy|"Male and female patients older than 40 and younger than 75 years old who volunteer for the experiment and qualify with the inclusion / Exclusion criteria.~The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study"
3163172|NCT01458912|Experimental|BI 54903 HD q.d.|Patients receive 2 puffs BI 54903 HD q.d. via Respimat inhaler (p.m.) combined with 2 puffs placebo (a.m.)
3163173|NCT01458912|Placebo Comparator|Placebo|Patients receive 2 puffs Placebo b.i.d. via Respimat inhaler
3163174|NCT01458912|Experimental|BI 54903 MD b.i.d.|Patients receive 2 puffs BI 54903 MD b.i.d.via Respimat inhaler
3163175|NCT01458899|Experimental|A - first fed then fasted treatment|TC-5214
3163176|NCT01458899|Experimental|B - first fasted then fed treatment|TC-5214
3163177|NCT01458886|Experimental|BI 54903 LD b.i.d.|Patients receive 2 puffs b.i.d. via Respimat inhaler
3163178|NCT01458886|Experimental|BI 54903 MD q.d.|Patients receive 2 puffs q.d. via Respimat inhaler (p.m.) combined with 2 puffs placebo (a.m.)
3163179|NCT01458886|Placebo Comparator|Placebo|Patients receive 2 puffs b.i.d. via Respimat inhaler
3163180|NCT01458873|Experimental|sodium bicarbonate 4.2%|"sodium bicarbonate 4.2% 50 ml"
3163181|NCT01458873|Experimental|sodium bicarbonate 2.1%|"sodium bicarbonate 2.1% 1 50 ml"
3163182|NCT01458873|Placebo Comparator|normal saline|"50 ml normal saline"
3163183|NCT01458860||GROUP A|patients had a CT
3163184|NCT01458860||GROUP B|patients with severe carotid artery stenosis
3163185|NCT01458847|Experimental|Cohort I: 2% cis-UCA solution (50 ml)|
3163186|NCT01458847|Experimental|Cohort II: 4% cis-UCA solution (50 ml)|
3163187|NCT01458847|Experimental|Cohort III: 6% cis-UCA solution (50 ml)|
3163188|NCT01458834|Experimental|Active attention training condition|
3163189|NCT01458834|Placebo Comparator|Control condition|
3163190|NCT01458821|Experimental|Brain Fitness Program - Tinnitus|Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
3163191|NCT01458821|No Intervention|No treatment|Subject will make no changes in their usual daily routine. No intervention. Will repeat all study procedures at end of 8 weeks.
3163192|NCT01458808|Experimental|Group A|Composed by 21 patients treated with reduction of 2 grams of sodium reduction in their habitual diet.
3163193|NCT01458808|Experimental|Group B|Composed by 20 patients treated by reduction of dialysate concentration from 138 to 135 mEq/L
3163194|NCT01458808|No Intervention|Group C|Composed by 18 patients followed without changes in dialysate sodium concentration or diet sodium amount.
3163195|NCT01458782|Active Comparator|ACI-C|Autologous chondrocyte implantation using collagen membrane (ChondroGide) Please see reference 1 and 2 for details regarding ACI. In this study we are using the collagen membrane instead of periosteum- the other details are exactly the same as in our previous RCT.
3163196|NCT01458782|Active Comparator|AMIC|"Autologous matrix induced chondrogenesis. Microfracture of the defect and covering using the collagen membrane (ChondroGide).~Please see reference 3 for details regarding AMIC"
3163197|NCT01458769|Active Comparator|Part A1|"Part A1 will evaluate two single ascending doses of the single agent C-10276 (an ATV isotopolog), and a dose of Reyataz.~C-10276 200 mg -> C-10276 400 mg -> Reyataz 400 mg~C-10276 200 mg -> Reyataz 400 mg -> C-10276 400 mg"
3163198|NCT01458769|Active Comparator|Part A2|"Part A2 will evaluate the single agent C-10276, co-administration of CTP-518 and C-10276, and a dose of Reyataz.~C-10276 300 mg -> Co-dose Ratio 1 CTP-518 (100 mg) with C-10276 (300 mg)-> C-10276 400 mg~C-10276 300 mg -> C-10276 400 mg -> Co-dose Ratio 1 CTP-518 (100 mg) with C-10276 (300 mg)"
3163199|NCT01458769|Active Comparator|Part B Group 1|"Group B1 will evaluate single doses of an ATV isotopolog, C-10297.~C-10297 200 mg"
3163200|NCT01458769|Active Comparator|Part B Group 2|"Group B2 will evaluate single doses of an ATV isotopolog, C-10299.~C-10299 200 mg"
3163201|NCT01458769|Active Comparator|Part B Group 3|"Group B3 will evaluate two single ascending doses of isotopologs C-10297 and 400 mg dose of Reyataz in a 3-way crossover design.~C-10297 400 mg -> Reyataz 400 mg -> C-10297 600 mg"
3163202|NCT01458769|Active Comparator|Part B Group 4|"Group B4 will evaluate two single ascending doses of isotopolog C-10299 and a 400 mg dose of Reyataz in a 3-way crossover design.~C-10299 400 mg -> Reyataz 400 mg -> C-10299 600 mg"
3163203|NCT01458769|Active Comparator|Part B Group 5|"Group B5 will evaluate a single dose of C-10276 and a 400 and 600 mg dose of Reyataz in a 3-way crossover design.~C-10276 600 mg -> Reyataz 400 mg -> Reyataz 600 mg"
3163204|NCT01458756||liver transplant patients|Population of adult patients awaiting liver transplant, status on the waiting list in the transplant center of University Hospital of Lille.
3163205|NCT01458743|Experimental|Ceftaroline q12h|Ceftaroline 600mg q12h
3163206|NCT01458743|Experimental|Ceftaroline q8h|ceftaroline 600mg q8h
3163207|NCT01458717|Experimental|Neoadjuvant|Neoadjuvant - operation - maintenance chemotherapy
3163208|NCT01458717|Active Comparator|Upfront surgery|Operation - adjuvant chemoradiation - maintenance chemotherapy
3163209|NCT01458704||fresh frozen tumor tissue|patients providing fresh frozen tumor tissue
3163210|NCT01458691|Active Comparator|Steroid group|Triamcinolone injection group
3163211|NCT01458691|Experimental|PRP group|Allogeneic PRP injection group
3163212|NCT01458678|Active Comparator|Oesophageal Doppler (OD)|Goal directed volume therapy is most often guided by stroke volume measurements by OD.
3163213|NCT01458678|Active Comparator|Pleth Variability Index (PVI)|The Pleth variability index (PVI) is an automated function in pulse oximetry that continuously calculates the dynamic variation between the pulse oximetry pulse variation and its baseline for every breathing circuit. Dynamic indicators are advantageous in predicting a responder to a volume bolus, thus facilitating goal directed volume therapy.
3163214|NCT01458665|Experimental|PRP group|
3163215|NCT01458665|Placebo Comparator|Conventional group|
3163216|NCT01458652|Experimental|Lifestyle counseling|"Drug:Kremezin~Other Names:AST-120~Kremezin is an oral adsorbent, 9g/day in treatment arm"
3163217|NCT01458639|Experimental|Technegas|Technegas V SPECT imaging with Technetium-99m (Tc-99m) labeled carbon particles; approximately 1.1 milliCuries of Technegas, compared with the results of Xenon-133 ventilation scan
3163218|NCT01458639|Active Comparator|Xenon-133|Xenon-133 ventilation Planar imaging compared with the results of the Technegas scan.
3163219|NCT01458626|Active Comparator|Add-on therapy|mirtazapine 30mg QD and paroxetine 20mg QD
3163220|NCT01458626|Active Comparator|mirtazapine monotherapy|mirtazapine 30mg QD
3163221|NCT01458626|Active Comparator|paroxetine monotherapy|paroxetine 20mg QD
3163222|NCT01458613||Observation|Patients with Maroteaux-Lamy disease
3163223|NCT01458600|Active Comparator|diclofenac|12 months treatment with diclofenac 50 mg 1x2 in addition to regular treatment for thyrotoxicosis.
3163224|NCT01458600|Other|without diclofenac|12 months treatment without diclofenac in addition to regular treatment for thyrotoxicosis.
3163225|NCT01458587|Experimental|ALA|
3163226|NCT01458587|Placebo Comparator|Vehicle|
3163227|NCT01458574|Placebo Comparator|Placebo Comparator|
3163228|NCT01458574|Experimental|CP-690,550 5 mg Arm|
3163229|NCT01458574|Experimental|CP-690,550 10 mg Arm|
3163230|NCT01458561|Experimental|BioFoam Surgical Matrix|Control of bleeding using BioFoam Surgical Matrix as a surgical adjunct
3163231|NCT01458561|Active Comparator|Gelfoam Plus|Control of bleeding using Gelfoam Plus as a surgical adjunct
3163232|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 1 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided twice daily (BID) in treatment-naïve participants with HCV genotype 1 infection.
3163233|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 2 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided BID in treatment-naïve participants with HCV genotype 2 infection.
3163234|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 3 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided BID in treatment-naïve participants with HCV genotype 3 infection.
3163235|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 1 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 1 infection.
3163236|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 2 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 2 infection.
3163237|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 3 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 3 infection.
3163238|NCT01458522|Active Comparator|fPHT 20mg|fPHT treatment arm, a bolus of 20 mg PE/kg will be administered at a rate of no greater than 75 mg PE/minute. If a further bolus is required, 5 mg PE/kg will be administered. The daily maintenance dose for fPHT will be 5 mg PE/kg divided into 2 doses.
3163239|NCT01458522|Experimental|LCM 400mg|LCM treatment arm, a bolus of 400 mg will be administered over 30 minutes. If a further bolus is required, 200 mg will be administered. Regardless of whether the subject received a rebolus, he or she will begin receiving a maintenance dose 12 hours after the initial dose. The daily maintenance dose will be the same as the total bolus (400 mg or 600 mg) divided into 2 doses.
3163240|NCT01458509||IVRS ( interactive voice response system) EASP|Telephone Group with Nurse Intervention
3163241|NCT01458509||Web EASP|Web Group with Nurse Intervention
3163242|NCT01458509||IVRS ( interactive voice response system) No EASP|Telephone Group without nurse intervention
3163243|NCT01458509||Web No EASP|Web Group without nurse intervention
3163244|NCT01458496|Experimental|Health Coaching|
3163245|NCT01458496|No Intervention|Usual Care -Control|Patients assigned to the control (usual care) group will be advised to seek standard lifestyle counselling from their primary care physician.
3163246|NCT01458483|Experimental|Baroreceptor Stimulation|
3163247|NCT01458470|Active Comparator|Memantine|NMDA Receptor Antagonist
3163248|NCT01458470|Placebo Comparator|Sugar pill|
3163249|NCT01458457|Active Comparator|Usual care|
3163250|NCT01458457|Active Comparator|Usual Care + Complementary Medicine|
3163251|NCT01458444|Active Comparator|BIPAP|Non invasive ventilation (VNI) by BIPAP® vision
3163252|NCT01458444|Experimental|OPTIFLOW|OPTIFLOW system
3163254|NCT01458431|Placebo Comparator|NaCl|Continuous NaCl subfascial infusion
3163255|NCT01458418|Experimental|Montelukast 10 mg/day|Subjects will receive two 5mg tablets of Montelukast/day.
3163256|NCT01458418|Experimental|Montelukast 5mg/day|Subjects will receive one 5mg tablet of montelukast and 1 placebo tablet per day.
3163257|NCT01458418|Placebo Comparator|placebo|Subjects will receive two placebo tablets per day.
3163258|NCT01458405|Placebo Comparator|Placebo|
3163259|NCT01458405|Active Comparator|CAP-1002 Allogeneic Cardiosphere-Derived Cells|
3163260|NCT01458392|Experimental|Dalantercept|dalantercept
3163261|NCT01458366|Experimental|Bendamustine, Ofatumumab, Carboplatin, and Etoposide (BOCE)|Combination of Bendamustine, Ofatumumab, Carboplatin, and Etoposide
3163262|NCT01458353|Experimental|Handsewn ileocolonic anastomosis|Swabs obtained from patients undergoing handsewn ileocolonic anastomosis
3163263|NCT01458353|Experimental|Stapled ileocolonic anastomosis|Swabs obtained for culture in those patients undergoing stapled ileocolonic anastomosis
3163264|NCT01458340|Experimental|TD-9855 Dose 1|
3163265|NCT01458340|Experimental|Placebo|
3163266|NCT01458340|Experimental|TD-9855 Dose 2|
3163267|NCT01458327|Experimental|3,4-methylenedoxymethamphetamine (MDMA) and psychotherapy|125 and 62.5 mg MDMA
3163268|NCT01458314|Active Comparator|Rehabilitation without NIV|A usual rehabilitative training will be performed in patients using nocturnal NIV, without adoption of daily NIV
3163269|NCT01458314|Experimental|Daily NIV during rehabilitation|Daily NIV will be adopted during the rehabilitation program in patients already using nocturnal NIV
3163270|NCT01458301|Placebo Comparator|Placebo|
3163271|NCT01458301|Experimental|TAK-385 10 mg QD|
3163272|NCT01458301|Experimental|TAK-385 20 mg QD|
3163273|NCT01458301|Experimental|TAK-385 40 mg QD|
3163274|NCT01458301|Other|Leuplin|
3163275|NCT01458288|Experimental|TG-0054 (3.14 mg/kg)|TG-0054 (3.14 mg/kg)
3163276|NCT01458275|Active Comparator|ciclesonide nasal aerosol 37mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
3163277|NCT01458275|Active Comparator|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
3163278|NCT01458275|Placebo Comparator|Placebo|
3163279|NCT01458249|Experimental|eribulin mesylate 1.4 mg/m^2|
3163280|NCT01458236|Experimental|BPS-314d-MR|Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration.
3163281|NCT01458236|Experimental|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group.
3163282|NCT01458223|Active Comparator|Control|24 hours post-operative antibiotics
3163283|NCT01458223|Experimental|experimental|72 hours of post-operative antibiotics
3163284|NCT01458210|Experimental|Ortho-Cyclen (OC) Alone (Period 1); OC+Dulaglutide (Period 2)|"Ortho-Cyclen (OC) (0.25 milligram [mg] norelgestromin [NGMN] + 0.035 mg ethinyl estradiol [EE] [active tablets] for 21 days + non-active tablets for 7 days): A 28-day course of OC consists of 0.25 mg NGMN and 0.035 mg EE (active tablets), administered orally, once per day for 21 days, then non-active tablets, administered orally, once per day for 7 days. Participants received the first 28-day course (Lead-in) followed by 2 subsequent 28-day courses (Periods 1 and 2, respectively). Following the Lead-in period, the Period 1 sample was taken during the first 28-day course and the Period 2 sample was taken during the second 28-day course.~Dulaglutide: A single, 1.5-mg subcutaneous injection on Day 19 of Period 2."
3163285|NCT01458197|Experimental|Tarafenacin 0.2 mg|Group 1
3163286|NCT01458197|Experimental|Tarafenacin 0.4 mg|Group 2
3163287|NCT01458197|Placebo Comparator|Placebo|Group 3
3163288|NCT01458184|Experimental|PhoneCare system|This arm is evaluating whether utilizing the PhoneCare system aids participants with their complex health care needs.
3163289|NCT01458184|No Intervention|Control Group: without PhoneCare System|Subjects in this arm will receive the usual care. Usual care is defined as receiving regular care from their physicians and no additional care or intervention from the study.
3163290|NCT01458171|Experimental|IgPro20|
3163291|NCT01458158||Diabetic nephropathy|Diabetic nephropathy in patients with type 2 diabetes
3163292|NCT01458158||chronic glomerulonephritis|chronic glomerulonephritis in patients without diabetes mellitus
3163293|NCT01458158||controls|participants without diabetic nephropathy and chronic glomerulonephritis
3163294|NCT01458145|Experimental|Home visits|
3163295|NCT01458145|No Intervention|routine primary care at community health center|
3163296|NCT01458132|Experimental|Subjects who experienced seizure|Subjects who were previously randomized in the Phase 2b studies SGN113399 or SGN113404 and experienced seizure
3163297|NCT01458132|Experimental|Subjects who did not experience seizure|Subjects who were previously randomized in the Phase 2b studies SGN113399 or SGN113404 and did not experience seizure
3163298|NCT01458119|Experimental|migalastat HCl 150 mg|Migalastat HCl s provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken taken on the days between migalastat HCl.
3163299|NCT01458106|Experimental|All participants|"PK subgroup: After a Washout Period of ≥72 hours, at the Baseline Visit (28±7 days prior to Day 1), participants receive a single IV injection of prestudy FVIII over 5 (±2) minutes at a dose of 50 IU/kg, rounded up to the nearest 250 IU increment, for a PK assessment. Following a second Washout Period of ≥72 hours, participants receive a single IV injection of rFVIIIFc over 5 (±2) minutes at a dose of 50 IU/kg for PK assessment. The first prophylactic dose of rFVIIIFc is administered at a starting dose of 25 IU/kg IV injection on Day 1 and 50 IU/kg on Day 4. Dose increases to a maximum of 80 IU/kg, and frequency of administration to a minimum interval of once every 2 days, are allowed as indicated.~Non-PK subgroup: On Day 1, a first prophylactic dose of rFVIIIFc of 25 IU/kg IV injection is given, followed by a dose of 50 IU/kg on Day 4. Dose increases to a maximum of 80 IU/kg, and frequency of administration to a minimum interval of once every 2 days, are allowed as indicated."
3163300|NCT01458093||Colonoscopy patients|Consecutive colonoscopy outpatients referred to one of 29 endoscopy units in Italy
3163301|NCT01458080||Patients w/secondary thrombocytopenia related to hepatitis C|Patients w/secondary thrombocytopenia related to hepatitis C
3163302|NCT01458067|Experimental|Part 1|GSK2636771 single dose and then daily dosing after approximately 1 week
3163303|NCT01458067|Experimental|Part 2|GSK2636771 single dose and then daily dosing starting on Day 4
3163304|NCT01458067|Experimental|Part 3|GSK2636771 daily dosing
3163305|NCT01458054|Experimental|Treatment A|GSK2336805 60mg x 1 dose (fasted) [Reference Treatment]
3163306|NCT01458054|Experimental|Treatment B|Omeprazole 40 mg q24h x 4 days (fed)
3163307|NCT01458054|Experimental|Treatment C|GSK2336805 60 mg x 1 dose and Omeprazole 40 mg on Day 1 (fasted) [Test Treatment]
3163308|NCT01458054|Experimental|Treatment D|GSK2336805 30mg x 1 dose (fasted) [Reference Treatment]
3163309|NCT01458054|Experimental|Treatment E|Ritonavir 100mg q12h x 4 days (fed)
3163310|NCT01458054|Experimental|Treatment F|GSK2336805 30 mg x 1 dose (fasted) and ritonavir 100mg q12h on Day 1 (fasted) [Test Treatment]
3163311|NCT01458054|Experimental|Treatment G|Ritonavir 100mg q12h x 1 day
3163312|NCT01458041||Group 1|
3163313|NCT01458028|Experimental|Arm 1|
3163314|NCT01458028|Placebo Comparator|Arm 2|
3163315|NCT01458015|Active Comparator|oxycodone|
3163316|NCT01458015|Active Comparator|tapentadol|
3163317|NCT01458002|No Intervention|Control|Assessment only
3163318|NCT01458002|Other|Tailored Internet Communications|TTM expert system only
3163319|NCT01458002|Experimental|Tailored Internet Communication with Relational Agent|TTM expert system plus relational agent
3163320|NCT01457989||retigabine/ezogabine|retigabine/ezogabine; dose range up to 1200 mg/day
3163321|NCT01457976||Members of the US public, non-probability sample|
3163322|NCT01457976||Members of the German public, non-probability sample|
3163323|NCT01457976||Members of the US public, probability sample|
3163324|NCT01457963||pulmonary embolism, deep venous thrombosis|
3163325|NCT01457950|Experimental|Arm 1|denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind phase
3163326|NCT01457950|Placebo Comparator|Arm 2|placebo subcutaneous injection, single dose at the start of the 6-month double-blind phase
3163327|NCT01457950|Experimental|Arm 3|open-label phase follows the double-blind phase, denosumab 60mg subcutaneous injection, single dose at the start of the 6-month open-label phase
3163328|NCT01457937|Active Comparator|PEG IFN/Ribavirin|Standard of care for HCV-positive CAH
3163329|NCT01457937|Experimental|PEG IFN/Ribavirin/Boceprevir|Combination to be tested for possible higher efficacy
3163330|NCT01457924|Experimental|Cohort 1|Placebo and one dose of Ofatumumab 3mg over 24 weeks
3163331|NCT01457924|Experimental|Cohort 2|Two doses of Ofatumumab 3mg over 24 weeks
3163332|NCT01457924|Experimental|Cohort 3.1|Two doses of Ofatumumab 30mg over 24 weeks
3163333|NCT01457924|Experimental|Cohort 3.2|Conditioning dose of Ofatumumab 3mg at randomization, two doses of Ofatumumab 30mg over 24 weeks
3163334|NCT01457924|Experimental|Cohort 4.1|Two doses of Ofatumumab 60mg over 24 weeks
3163335|NCT01457924|Experimental|Cohort 4.2|Conditioning dose of Ofatumumab 3mg at randomization, two doses of Ofatumumab 60mg over 24 weeks
3163336|NCT01457924|Experimental|Cohort 5.1|Six doses of Ofatumumab 60mg over 24 weeks
3163337|NCT01457924|Experimental|Cohort 5.2|Conditioning dose of Ofatumumab 3mg at randomization, six doses of Ofatumumab 60mg over 24 weeks
3163338|NCT01457911|Experimental|AMARYL M (Glimepiride and Metformin hydrochloride combination)|AMARYL M at a dosage regimen from 1 tablet to 6 tablets, once during a meal or twice during a meal
3163339|NCT01457911|Active Comparator|AMARYL (Glimepiride)|AMARYL at a dosage regimen from 1 mg to 6 mg, once during a meal or twice during a meal
3163340|NCT01457898|Experimental|VPAP II®|VPAP II® Group
3163341|NCT01457885|Experimental|CloBu4 regimen|After pre-conditioning with CloBu4 (Clofarabine/Busulfan x 4), subjects will receive a peripheral blood stem cell transplant
3163342|NCT01457872|Experimental|Strength-based case management|Case management plus referral (vs referral-only)
3163343|NCT01457872|Active Comparator|Referral only|Referral only (no case management intervention)
3163344|NCT01457859|Active Comparator|Conventional sutures|
3163345|NCT01457859|Experimental|Antiseptic sutures|
3163346|NCT01457846|Experimental|AZD4547|AZD4547 taken orally in tablet formation, 80mg b.d., in a 2 week on, 1 week off schedule
3163347|NCT01457846|Active Comparator|Paclitaxel|Paclitaxel - 80mg/m² as a 1 hour infusion given weekly on days 1, 8 and 15 of a 28 day cycle (up to the maximum number of cycles per local practice)
3163348|NCT01457833|Active Comparator|Endobronchial valves (EBV)|Complete occlusion of one emphysematous destroyed lobe by implantation of endobronchial valves
3163349|NCT01457833|Active Comparator|Intrabronchial valves (IBV)|Complete occlusion of one emphysematous destroyed lobe by implantation of intrabronchial valves
3163350|NCT01457820|Experimental|Allopurinol High dose|
3163351|NCT01457820|Experimental|Allopurinol Low dose|
3163352|NCT01457820|Placebo Comparator|Placebo|
3163353|NCT01457807|Experimental|1|AZD3241 300mg extended release formulation 1
3163354|NCT01457807|Experimental|2|AZD3241 300mg extended release formulation 2
3163355|NCT01457807|Placebo Comparator|3|Placebo
3163356|NCT01457794|Other|NewNordicDiet first|Intervention with NND for 3 mo then no intervention for 3 mo
3163357|NCT01457794|Other|NewNordicDiet last|No intervention for 3 mo and then intervention with NND for 3 mo
3163358|NCT01457781|Active Comparator|0.025 mg inhaled nitric oxide|Inhaled nitric oxide (iNO) 0.025 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L [2440 ppm] NO mini-cylinder; change q 24 hours)
3163359|NCT01457781|Active Comparator|0.075 mg inhaled nitric oxide|Inhaled nitric oxide (iNO) 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (6.0 mg/L [4880 ppm] NO mini-cylinder; change q 24 hours)
3163360|NCT01457781|Placebo Comparator|placebo|Placebo 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks* (99.999% Nitrogen [N2] mini-cylinder; change q 24 hours)
3163361|NCT01457742|Active Comparator|Pulsed Radio Frequency (PRF)|
3163362|NCT01457742|Sham Comparator|Sham|Use of Sham device for 15 minutes simulated treatment twice per day
3163363|NCT01457729|No Intervention|No Motivation|Patients are asked to complete a telemonitored Ergometer training for 4 Weeks, at least 30 minutes per day, no more intervention is done.
3163364|NCT01457729|Other|Motivation|Patients are asked to complete a telemonitored Ergometer training for 4 Weeks, at least 30 minutes every day. If training time declines to less than 20 minutes per day for one week, a motivation phone call will take place once a week.
3163365|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler A|
3163366|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler B|
3163367|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler C|
3163368|NCT01457716|Active Comparator|Budesonide/Formoterol Turbohaler Forte|
3163369|NCT01457703|Active Comparator|BMI ≥30 kg/m2|"Group 2:~BMI ≥30 kg/m2~History of regular menstrual cycles every 25-40 days~Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2."
3163370|NCT01457703|Experimental|BMI 18-25 kg/m2|"BMI 18-25 kg/m2~History of regular menstrual cycles every 25-35 days~Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2."
3163371|NCT01457690|Experimental|Tocofersolan: Vitamin E water-soluble|2 months off the conventional treatment before the study. Administration of a daily dose of vitamin E for 4 months
3163372|NCT01457690|Active Comparator|Tocopherol alpha: Vitamin E conventional fat-soluble form|2 months off the conventional treatment before the study. Administration of a daily dose of vitamin E for 4 months
3163373|NCT01457690|Active Comparator|volunteers|
3163374|NCT01457677|Placebo Comparator|Placebo|
3163375|NCT01457677|Experimental|RO4995819 15 mg|
3163376|NCT01457677|Experimental|RO4995819 30 mg|
3163377|NCT01457677|Experimental|RO4995819 5 mg|
3163378|NCT01457664|Placebo Comparator|Placebo|
3163379|NCT01457664|Experimental|RO4995819|
3163380|NCT01457651|Active Comparator|Recruitment 40x40|The group where recruitment is performed by increase in airway pressure up to 40 cm H2O for 40 seconds
3163381|NCT01457651|Active Comparator|Recruitment PEAK40|Increase in peak airway pressure up to 40 cm H2O during tidal ventilation
3163382|NCT01457651|Active Comparator|Recruitment 15x300|Recruitment by increase in airway PEEP up to 15 cm H2O for 300 sec
3163383|NCT01457651|Active Comparator|No recruitment|No recruitment is performed: standard respiratory support.
3163384|NCT01457638|Sham Comparator|No inferior turbinate surgery|During rhinoseptoplasty there is no intervention on inferior turbinates
3163385|NCT01457638|Experimental|Inferior Turbinate surgery|During rhinoseptoplasty, inferior turbinate submucosal cauterization is performed.
3163386|NCT01457625||liver fat contents|
3163387|NCT01457612|Placebo Comparator|Placebo1|Placebo Beverage 1 without fiber
3163388|NCT01457612|Active Comparator|Strawberry|Strawberry Beverage 20g/BID
3163389|NCT01457612|Placebo Comparator|Placebo2|Placebo Beverage 2 with Fiber
3163390|NCT01457599||Marking Liver|
3163391|NCT01457586|Active Comparator|Transfusion|Patient who received blood transfusion in the perioperative period
3163392|NCT01457586|No Intervention|No Transfusion|Patients who did not receive blood transfusion in the perioperative period
3163393|NCT01457573|Experimental|One (single arm)|All men will receive morning dosing with Tamsulosin (Flomax) 0.4 mg (1 tab) and Solifenacin (Vesicare) 5 mg (1 tab) orally at the same time.
3163394|NCT01457560|Experimental|Group A|
3163395|NCT01457547|Experimental|DTPa 1 Group|
3163396|NCT01457547|Active Comparator|DTPa 2 Group|
3163397|NCT01457534||liver transplantation|
3163398|NCT01457521|Active Comparator|Therapeutic|Ibuprofen
3163399|NCT01457521|Active Comparator|Prophylactic|Ibuprofen
3163400|NCT01457508|Experimental|Group A|Subjects will receive one single injection of DTPa-HBV-IPV vaccine mixed with Hib vaccine.
3163401|NCT01457508|Active Comparator|Group B|Subjects will receive two separate injections of DTPa-HBV-IPV and Hib vaccine.
3163402|NCT01457495|Experimental|DTPa 1 Group|
3163403|NCT01457495|Active Comparator|DTPa 2 Group|
3163404|NCT01457482|Experimental|Art therapy group|Treatment in this arm consists of five Art Therapy sessions and therapeutic conversations.
3163405|NCT01457482|Active Comparator|Therapeutic conversation group|Treatment by therapeutic conversations only
3163406|NCT01457469|Active Comparator|Arm I (usual care plus) (closed to accrual as of 3/6/2012)|"Patients receive a personalized letter from their physician with advice to quit smoking and a copy of the National Cancer Institute's Cleaning the Air smoking cessation booklet."
3163407|NCT01457469|Experimental|Arm II (enhanced quitline)|Patients receive a personalized letter and a smoking cessation booklet. Patients also receive an 8-week supply of nicotine replacement patches and undergo a counseling session over 30-45 minutes with a trained nurse or midlevel provider that focuses on the benefits of quitting smoking for cancer patients and addresses cancer-specific concerns about smoking cessation. Patients also undergo a quitline-based smoking cessation intervention comprising 5 individual 25- to 30-minute telephone counseling sessions and unlimited inbound phone-based access to Quit Coaches over 8-11 weeks, mailed written materials, and an interactive online program.
3163408|NCT01457456||Observation|Patients with Morquio disease
3163409|NCT01457443||Observation|Patients with Pompe disease
3163410|NCT01457430|Experimental|Icatibant|Open-label study
3163411|NCT01457417|Experimental|75 milligram (mg) DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
3163436|NCT01457261|Experimental|Particle size 2|Monodisperse particle delivered with radiolabel
3163437|NCT01457261|Experimental|Nebulised salbutamol|Polydisperse particle via a nebuliser
3163438|NCT01457261|Experimental|Salbutamol MDI|Unlabelled salbutamol via a metered dose inhaler
3163412|NCT01457417|Experimental|150 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
3163413|NCT01457417|Experimental|300 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
3163414|NCT01457417|Experimental|600 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
3163415|NCT01457417|Experimental|300 mg DKN-01 Part B|Dose Confirmation: Once the MTD had been established or the highest planned dose level completed, 300 mg of DKN-01 was administered as IV on days 1 and 15 of every 28 day cycle.
3163416|NCT01457404|Experimental|Integrated Cognitive Behavioral Therapy|Integrated Cognitive Behavioral Therapy (ICBT) is a non-exposure based, manual-guided individual or group therapy. ICBT consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Mindful relaxation: A behavioral anxiety reduction skill including centering and breathing techniques; and 3) Cognitive restructuring/flexible thinking: A cognitive approach and functional analysis of the link among emotions, cognitives and situations.
3163417|NCT01457404|Active Comparator|Treatment-as-usual|Treatment-as-usual (TAU) is the typical outpatient treatment that patients would receive ordinarily at the PVAMC Substance Abuse Treatment Program (SATP) or PTSD Clinic.
3163418|NCT01457391|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a non-exposure based manual-guided individual therapy. CBT for PTSD consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Breathing retraining: A behavioral anxiety reduction skill; and 3) Cognitive restructuring: A cognitive approach and functional analysis of the link among emotions, cognitions and situations.
3163419|NCT01457391|Active Comparator|Individual Addiction Counseling|Individual Addiction Counseling (IAC) was adapted from the Individual Drug Counseling (IDC) manual used in the NIDA Cocaine Collaborative Study. IAC is a manual-guided treatment that focuses on substance use and history of use, consequences of use and denial, developing strategies for relapse prevention, and facilitation of connection with peer recovery support groups, specifically twelve step groups. The current adaptation of IAC modified the IDC manual by broadening the focus to include drugs other than cocaine, as well as alcohol.
3163420|NCT01457391|Active Comparator|Treatment-as-usual|Treatment-as-usual (TAU) is the typical intensive outpatient (IOP) treatment that the patient would receive ordinarily at the identified addiction treatment program. Each TAU service operates using the American Society of Addiction Medicine criteria for Level II Intensive Outpatient services: 9-12 hours per week; group and individual sessions focused on motivation to address substance use, education about the consequences of substance use on major life areas, education about the disease concept and brain changes associated with addiction, exposure to information about social and family relationships and recovery, and relapse prevention skills.
3163421|NCT01457378||Healthy volunteers|100 healthy volunteers
3163422|NCT01457378||IBS Subjects|100 IBS Subjects
3163423|NCT01457365||subjects|it is a cross-sectional research and there is only one group.
3163424|NCT01457352|Experimental|SPARC0921|
3163425|NCT01457352|Placebo Comparator|Placebo0921|
3163426|NCT01457339|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
3163427|NCT01457339|Placebo Comparator|Placebo|
3163428|NCT01457326||Immersion Therapy- Study|1. Patients who participate in the immersion therapy post-operative protocol and begin progressive weight bearing at 4 weeks (study)
3163429|NCT01457326||Control Group|2. Patients who undergo the traditional 10-week non-weight bearing post-operative care protocol (control)
3163430|NCT01457313||BTKA|patients undergoing bilateral staged total knee arthroplasty
3163431|NCT01457300||District Rehabilitation Centre (Model 1)|Patients admitted to Primary Health Care Rehabilitation, either Post-Acute from the Same District General Hospital or Directly from their Homes. They were recruited continuously at Entrance to the Rehabilitation Centre.
3163432|NCT01457300||Standard PHC Rehabilitation (Model 2)|Patients admitted to Standard Primary Health Care (PHC) Rehabilitation, either Post-Acute from the Same District General Hospital or Directly from their Homes. They were recruited Continuously at Entrance to the Short Term Rehabilitation Beds in Nursing Homes or at the Beginning of Rehabilitation in their Own Homes.
3163433|NCT01457274|Experimental|"light sedation"|"In this study the depth of sedation will be guided by the Bispectral Index monitor (BIS monitor). A BIS value of 70-80 will be targeted in the light sedation arm."
3163434|NCT01457274|Active Comparator|"deep sedation"|"In this study the deep sedation arm will have a BIS value of less than 60 targeted."
3163435|NCT01457261|Experimental|Partical size 1|Monodisperse particle delivered with radiolabel
3163440|NCT01457248|Active Comparator|Endotracheal tube with cylindrical-shaped cuff|
3163441|NCT01457235|Active Comparator|Active Group|This group receives cognitive remediation in groups (each group consisting of 6-8 subjects)
3163442|NCT01457235|No Intervention|Waiting List|Patients randomized to the waiting list group continues standard treatment and will be offered a course of cognitive remediation upon completion of participation provided that they still meet the inclusion criteria.
3163443|NCT01457222|Active Comparator|Mindfulness|Mindfulness intervention 10 minutes daily
3163444|NCT01457222|Active Comparator|Music relaxation|Music intervention 10 minutes daily
3163445|NCT01457222|No Intervention|Business as usual|No intervention - control group.
3163446|NCT01457196|Other|Sequencing Arm|
3163447|NCT01457183|Experimental|Lavage group|Healthy subjects with intact skin will be lavaged within the device in 3 locations on their bodies.
3163448|NCT01457170|Experimental|Apelin/Saline|Apelin infusion then crossover to Saline infusion
3163449|NCT01457170|Experimental|Saline/Apelin|Saline infusion then crossover to Apelin infusion
3163450|NCT01457144|Experimental|RiBVD|Rituximab Bendamustine Velcade® Dexamethasone 6 cycles every 28 days
3163451|NCT01457118|Experimental|NKTR-102|
3163452|NCT01457105|Experimental|ComVi biliary stent|
3163453|NCT01457092|Experimental|FC Nitinol SEMS|FC Nitinol SEMS
3163454|NCT01457066|Experimental|Intervention|This group will receive the peer navigator intervention.
3163455|NCT01457066|No Intervention|Control|This group will receive usual care.
3163456|NCT01457053|Active Comparator|Ultrafiltration|Patients with acute decompensated heart failure will be randomized to either ultrafiltration or diuretics (loop diuretics: furosemide, bumetanide, and/or torsemide). Patients in this arm are randomized to ultrafiltration.
3163457|NCT01457053|Active Comparator|Diuretic Therapy|Patients with acute decompensated heart failure will be randomized to either ultrafiltration or diuretic therapy ((loop diuretics: furosemide, bumetanide, and/or torsemide). The myocardial blood flow of patients treated with ultrafiltration will be actively compared to diuretic therapy with either furosemide, bumetanide, and/or torsemide.
3163458|NCT01457040|Experimental|Complete Remission (CR)|CR Cohort: high-risk ALL in CR and standard-risk ALL in the status of ≥CR2
3163459|NCT01457040|Experimental|Non-Remission (NR)|NR Cohort: ALL in non-remission
3163460|NCT01457027|Experimental|All subjects|
3163461|NCT01457014|Active Comparator|servo ventilation auto mode|Inspiratory and expiratory pressures automatically determined by the servo ventilation device.
3163462|NCT01457014|Active Comparator|Continuous positive airway pressure|Airway pressure delivered at a constant pressure level.
3163463|NCT01457014|Active Comparator|servo ventilation manual|Inspiratory and expiratory pressures automatically determined by the servo ventilation device with mandatory minimal inspiratory minus expiratory pressure difference.
3163464|NCT01457001|Experimental|25-OH-D vitamin|
3163465|NCT01457001|No Intervention|control|
3163466|NCT01456975|Experimental|Valsalva|Reimplantation procedure using Valsalva prosthesis
3163467|NCT01456962||Raltegravir group|HIV-1-infected women on a regimen of tenofovir (TDF) and emtricitabine (FTC) with raltegravir (RAL)
3163468|NCT01456962||Atazanavir group|HIV-1-infected women on a regimen of tenofovir (TDF) and emtricitabine (FTC) with ritonavir (RIT)-boosted atazanavir (ATZ)
3163469|NCT01456949|Other|Single Arm|Cryoablation
3163470|NCT01456936|Placebo Comparator|placebo|Subjects randomized to placebo will receive placebo treatments for all three study drugs. Blinded placebo will be provided for varenicline, bupropion hydrochloride and transdermal nicotine patch (NRT). In addition, subjects will receive blinded placebo treatments for the study drugs they are not randomized to receive.
3163471|NCT01456936|Active Comparator|varenicline|
3163472|NCT01456936|Active Comparator|bupropion|
3163473|NCT01456936|Active Comparator|Nicotine Replacement Therapy Patch|
3163474|NCT01456923|Active Comparator|Control (chemotherapy and surgery)|Patients treated with chemotherapy + surgery
3163475|NCT01456923|Active Comparator|Study|Patients treated only with chemotherapy
3163476|NCT01456910|Experimental|Working group|G1 intervention group of 20 participants aged 14-36 years old and mild to severe intellectual disability of both gender.
3163477|NCT01456910|Active Comparator|Daily Living|G2 control group continue usual routine
3163478|NCT01456897|Experimental|OPC-34712|
3163479|NCT01456884|Experimental|Live - Vibroacoustic|Treatment order A: live guitar and vocal music therapy on day one, vibroacoustic music therapy on day two.
3163480|NCT01456884|Experimental|Vibroacoustic - Live|Treatment order B: vibroacoustic music therapy live guitar on day one, and vocal music therapy on day two.
3163481|NCT01456871||Healthy adult females|Females, aged 20 to 30 with no history of upper extremity injury or disorder in the non-dominant arm, no history of neurologic or bleeding disorder, and no evidence of Linburg-Comstock syndrome.
3163482|NCT01456858|Placebo Comparator|Child UPS Largo Camp|Children 4months-36months enrolled who resided in Largo refugee camp under Untreated plastic sheeting (interior wall and ceiling lining)
3163483|NCT01456858|Experimental|Child ITPS Largo Camp|Children 4months-36months enrolled who resided in Largo refugee camp under Insecticide treated plastic sheeting (interior wall and ceiling lining)
3163484|NCT01456858|Placebo Comparator|Child UPS Tobanda Camp|Children 4months-36months enrolled who resided in Tobanda refugee camp under Untreated plastic sheeting (ceiling and interior roof lining)
3163485|NCT01456858|Experimental|Child ITPS Tobanda Camp|Children 4months-36months enrolled who resided in Tobanda refugee camp under Insecticide treated plastic sheeting (ceiling and interior roof lining)
3163486|NCT01456845||2|"Cases - those patients who develop DIH while on regular treatment with anti-TB drugs.~Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs."
3163487|NCT01456832||Renal Transplant Patients with Post-operative Hypoatremia|All renal transplant recipients at the Mayo Clinic of Florida from 1/1/2010 through 8/19/2011 who received a kidney from either a living or cadaveric donor.
3163488|NCT01456819|Experimental|Mononuclear and mesenchymal stem cells|Autologous bone marrow-derived mononuclear cells and mesenchymal stem cells
3163489|NCT01456819|Active Comparator|Mononuclear cells only|Autologous bone marrow-derived mononuclear cells
3163490|NCT01456806|No Intervention|Patients and provider non educated|In this arm neither the patients nor the providers have attended the groupal education courses
3163491|NCT01456806|Active Comparator|Provider educated|Provider attend the interactive group education, while patients do not.
3163492|NCT01456806|Active Comparator|Patients Educated|Patients attend the interactive group education, while providers do not.
3163493|NCT01456806|Active Comparator|Providers/Patients Educated|Provider and Patients both attend the interactive group education.
3163494|NCT01456793|Experimental|Teen Options to Prevent Pregnancy|
3163495|NCT01456793|No Intervention|Usual care services|
3163496|NCT01456780|Active Comparator|Zylet|Subject randomized to this arm will be treated with Zylet (Loteprednol/tobramycin), twice a day, for 4 weeks. Zylet is a combination of loteprednol and tobramycin. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation. Tobramycin is an antibiotic.
3163497|NCT01456780|Active Comparator|Lotemax|Subject randomized to this arm will be treated with Lotemax, twice a day, for 4 weeks. Lotemax is also known as loteprednol. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation.
3163498|NCT01456780|Placebo Comparator|B+L Advanced Eye Relief Lubricant Drop|Subject randomized to this arm will be treated with B+L Advanced Eye Relief Lubricant Eye Drops (Artificial Tears), twice a day, for 4 weeks.
3163499|NCT01456767|Active Comparator|Lactobacillus plantarum WCFS1|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum WCFS1).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
3163500|NCT01456767|Active Comparator|Lactobacillus plantarum CIP104448|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum CIP104448).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
3163501|NCT01456767|Active Comparator|Lactobacillus plantarum CIP104450|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum CIP104450).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
3163502|NCT01456767|Placebo Comparator|Placebo|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of a placebo).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
3163503|NCT01456754|Experimental|High feeding frequency (14x)|
3163504|NCT01456754|Experimental|low feeding frequency (3x)|
3163505|NCT01456741|Experimental|1-EBNA with ROSE|
3163506|NCT01456741|Experimental|1-EBNA without ROSE|
3163507|NCT01456728|Experimental|Progastria|One chewable tablet of the study product is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day together with omeprazole 2x20mg. The study product and omeprazole will be taken daily for 28 consecutive days.
3163508|NCT01456728|Placebo Comparator|Placebo|The placebo will have identical appearance and taste with the study product only lacking the bacteria. All subjects from this group will receive 2 x 20 mg omeprazole per day and Placebo 1 chewable tablet per day for 28 days.
3163509|NCT01456715|Active Comparator|Gardasil, Immunogenicity, Booster dose.|
3163510|NCT01456715|Experimental|Cervarix, Immunogenicity, Booster dose.|
3163511|NCT01456702|No Intervention|control arm|volume therapy via standard operating procedure
3163512|NCT01456702|Experimental|intervention arm|goal-directed volume therapy due to svv in dependence of preoperative risk stratefication
3163513|NCT01456689|Experimental|LGH447|Eligible patients will be treated with oral LGH447 until disease progression or occurrence of unacceptable toxicity.
3163514|NCT01456689|Experimental|LGH447 and midazolam|Eligible patients will receive midazolam on two separate days, the first dose will be administered prior to the start of LGH447 and the second will be co-administered with LGH447. After that, the patients will continue to be treated with oral LGH447 until disease progression or occurrence of unacceptable toxicity.
3163515|NCT01456676|Experimental|Nilotinib + LDE225|The planned dose of nilotinib 400 mg b.i.d (twice a day) was selected for the combination as this is the dose approved for the treatment of the patient population that will be included in the present study. The starting dose for LDE225 chosen for the current study is 400 mg once daily(q.d.). The maximum dose of LDE225 that will be tested in combination with nilotinib is 800 mg once dail.y
3163516|NCT01456663|Experimental|AFQ056|
3163517|NCT01456650|Experimental|Glyburide|Patients in which the fasting glucose persisted above the treatment goal (fasting glucose <126 mg/dl) after a 4 week diet period will receive glyburide. The dose of the medication will be adjusted based on the results of fasting glucose values. At each visit patients will return the leftover tablets; counts of the tablets will be the method for measuring the adherence to treatment. The medical study participants who decided to doses of glibenclamide will not know the allele of ABCA1 gene under study.
3163518|NCT01456637|Experimental|CBT for insomnia with feedback|In this arm participants received internet based self-help CBT for insomnia with e-mail feedback form a therapist.
3163519|NCT01456637|Experimental|CBT for insomnia without feedback|In this arm participants receive internet based self-help CBT for insomnia without feedback from a therapist.
3163520|NCT01456624|Active Comparator|Megace / Fasting condition|800mg
3163521|NCT01456624|Experimental|DW-ES(B) / Fasting condition|625mg
3163522|NCT01456624|Active Comparator|Megace / Fed condition|800mg
3163523|NCT01456624|Experimental|DW-ES(B) / Fed condition|625mg
3163524|NCT01456611|Experimental|Diclofenac Sodium Gel|Diclofenac sodium Topical Gel 1%
3163525|NCT01456611|Active Comparator|Voltaren (R) Gel|Voltaren (R) Gel 1%
3163526|NCT01456611|Placebo Comparator|Placebo|Placebo Topical Gel
3163527|NCT01456598|Experimental|Laparoscopic gastrectomy|Laparoscopic subtotal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer.
3163528|NCT01456598|Active Comparator|Open gastrectomy|Open subtotal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer.
3163529|NCT01456572|Active Comparator|satiation_obese weight|Obese subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.
3163530|NCT01456572|Active Comparator|gastric emptying_obese weight|Obese subjects will receive a standardized meal, consisting of two scrambled eggs (cooked with 10 g butter), placed on two slices of whole wheat bread and 200 mL of milk (in total: 468 kcal). The test meal will be labeled with 100 mg of 13C-octanoic acid for determination of gastric emptying.
3163531|NCT01456572|Placebo Comparator|gastric emptying_normal weight|Normal weight subjects will receive a standardized meal, consisting of two scrambled eggs (cooked with 10 g butter), placed on two slices of whole wheat bread and 200 mL of milk (in total: 468 kcal). The test meal will be labeled with 100 mg of 13C-octanoic acid for determination of gastric emptying.
3163532|NCT01456572|Placebo Comparator|satiation_normal weight|Normal weight subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.
3163533|NCT01456572|Active Comparator|hormone profiles_obese weight|Obese subjects will receive 500 mL of a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate). At regular time intervals fasting and post-prandial blood samples will be collected.
3163534|NCT01456572|Placebo Comparator|hormone profiles_normal weight|Normal weight subjects will receive 500 mL of a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate). At regular time intervals fasting and post-prandial blood samples will be collected.
3163535|NCT01456546|Active Comparator|Period A: proguanil|Proguanil pharmacokinetics
3163536|NCT01456546|Active Comparator|Period B: clopidogrel|Clopidogrel pharmacokinetics
3163537|NCT01456533||hospitalized patients|hospitalized patients with hyponatremia
3163538|NCT01456520|Experimental|A: single dose Vycavert (Test)|
3163539|NCT01456520|Active Comparator|B: single dose Norco (Reference)|
3163540|NCT01456507|Experimental|A|1×40 mg ALO-02 capsule administered with 240 mL of water under fasting conditions.
3163541|NCT01456507|Experimental|B|1×40 mg ALO-02 capsule administered with 240 mL of water under fed conditions (standard high fat breakfast).
3163542|NCT01456507|Experimental|C|1×40 mg ALO-02 with the ALO-02 pellets sprinkled approximately on one table spoon of applesauce, and administered with 240 mL of water under fasting conditions.
3163543|NCT01456494|Experimental|Teach-to-Goal|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
3163544|NCT01456494|Experimental|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
3163545|NCT01456481|Active Comparator|midodrine hydrochloride pills|
3163546|NCT01456481|Placebo Comparator|oral placebo or sugar pill|
3163547|NCT01456468|Experimental|UDCA + ATRA|This is a single-arm study. All subjects will take UDCA and ATRA.
3163548|NCT01456429|Experimental|Thoracic endosonography|Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
3163549|NCT01456416||Glatiramer Acetate|GA administered SQ daily in MS patients who met all Inclusion-Exclusion Criteria and were approved by their Health Care Plans for GA treatment.
3163550|NCT01456403||Carotid endarterectomy patients|Patients scheduled for clinically indicated carotid endarterectomy
3163551|NCT01456390|Other|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
3163552|NCT01456377|Active Comparator|corticosteroids, analgesics oral pill|Oral Corticosteroids and oral analgesics
3163553|NCT01456377|Placebo Comparator|placebo|oral placebo and oral analgesics
3163554|NCT01456364|Active Comparator|Ticagrelor|A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily
3163555|NCT01456364|Active Comparator|Prasugrel|A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients < 75 years or a 5 mg maintenance dose per day for patients >= 75 years
3163556|NCT01456351|Experimental|Bendamustine plus Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
3163557|NCT01456351|Active Comparator|Fludarabine plus Rituximab|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
3163558|NCT01456338|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a non-exposure based, manual-guided individual therapy. CBT for PTSD consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Breathing retraining: A behavioral anxiety reduction skill; and 3) Cognitive restructuring: A cognitive approach and functional analysis of the link among emotions, cognitions and situations.
3163559|NCT01456338|Active Comparator|Individual Addiction Counseling|Individual Addiction Counseling (IAC) was adapted from the Individual Drug Counseling (IDC) manual used in the NIDA Cocaine Collaborative Study. IAC is a manual-guided treatment that focuses on substance use and history of use, consequences of use and denial, developing strategies for relapse prevention, and facilitation of connection with peer recovery support groups, specifically twelve step groups. The current adaptation of IAC modified the IDC manual by broadening the focus to include drugs other than cocaine, as well as alcohol.
3164007|NCT01453426|Experimental|Chinese Subjects - Dose 2 BG00012|
3163560|NCT01456325|Experimental|Onartuzumab+Erlotinib|Participants will receive onartuzumab 15 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally once daily (QD) from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
3163561|NCT01456325|Placebo Comparator|Placebo+Erlotinib|Participants will receive onartuzumab matching placebo on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally QD from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
3163562|NCT01456312|Sham Comparator|HBsAg quantification>20,000 IU/ml|stop peginterferon alfa 2a if patients reach HBsAg quantification>20,000 Iu/ml at 12w
3163563|NCT01456312|Sham Comparator|HBsAg<=1500IU/ml|extend peginterferon alfa 2a until 48weeks
3163564|NCT01456312|Sham Comparator|HBsAg >1500 <=20,000 IU/ML|add Entecavir for 12w with peginterferon alfa 2a then, extend peginterferon alfa 2a until 48w
3163565|NCT01456299|Placebo Comparator|Control|The control group, which received an infusion of normal saline.
3163566|NCT01456299|Active Comparator|Remifentanil 1|"Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml."
3163567|NCT01456299|Active Comparator|Remifentanil 2|"Remifentanil 2: The R2 group, which received a target effect-site remifentanil concentration of 2 ng/ml."
3163568|NCT01456286|Experimental|Sapropterin|5 mg/kg daily first week; 10 mg/kg daily second week of treatment
3163569|NCT01456286|Placebo Comparator|placebo|
3163570|NCT01456273|Placebo Comparator|A2- Medical consultation + placebo|Traditional medical interview + placebo
3163571|NCT01456273|Active Comparator|B1 - Therapeutic Encounter / Omeprazol|
3163572|NCT01456273|Placebo Comparator|B2 - Therapeutic Encounter / Placebo|
3163573|NCT01456273|Active Comparator|A1- Medical consultation + omeprazole|Traditional medical interview + omeprazole
3163574|NCT01456260|Experimental|TAK-438 10 mg QD|
3163575|NCT01456260|Experimental|TAK-438 20 mg QD|
3163576|NCT01456260|Active Comparator|Lansoprazole 15 mg QD|
3163577|NCT01456247|Experimental|TAK-438 10 mg QD|
3163578|NCT01456247|Experimental|TAK-438 20 mg QD|
3163579|NCT01456247|Active Comparator|AG-1749 15 mg QD|
3163580|NCT01456234|Active Comparator|Patients with Oseltamivir Prescription|Patients arriving at the pharmacy with a prescription for Oseltamivir
3163581|NCT01456234|Experimental|Patients with signs, symptoms of flu|Patients arriving at the pharmacy with signs, symptoms of flu that the pharmacist diagnoses as having flu and being suitable for pharmacist prescribing of Oseltamivir according to an algorithm.
3163582|NCT01456221|Experimental|omega 3 and an hypocaloric diet|Participants will receive a supplement containing omega 3: DHA and EPA fatty acids together with an hypocaloric diet.
3163583|NCT01456221|Placebo Comparator|Placebo|Participants will receive a supplement containing sunflower oil with an hypocaloric diet.
3163584|NCT01456195|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, orally, once daily for up to 24 weeks.
3163585|NCT01456195|Experimental|Fasiglifam 25 mg|Fasiglifam 25 mg, tablets, orally, once daily for up to 24 weeks.
3163586|NCT01456195|Experimental|Fasiglifam 50 mg|Fasiglifam 50 mg, tablets, orally, once daily for up to 24 weeks.
3163587|NCT01456182|Other|Dose arm 1|
3163588|NCT01456182|Other|Dose arm 2|
3163589|NCT01456182|Other|Dose arm 3|
3163590|NCT01456182|Other|Dose arm 4|
3163591|NCT01456182|Other|Dose arm 5|
3163592|NCT01456169|Active Comparator|Azilsartan medoxomil 40 mg|Azilsartan medoxomil 40 mg and placebo to chlorthalidone combination tablets, orally, once daily for up to 8 weeks.
3163593|NCT01456169|Experimental|Azilsartan medoxomil + chlorthalidone 40/12.5 mg|Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.
3163594|NCT01456169|Experimental|Azilsartan medoxomil + chlorthalidone 40/25 mg|Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.
3163595|NCT01456156|Experimental|hepatectomy plus radiotherapy|
3163596|NCT01456143|Experimental|HRME with proflavine|High Resolution Microendoscopy (HRME) imaging device that operates as a fluorescence microscope with a fiber optic imaging probe. The probe is placed against the mucosa to obtain images relayed to a tablet computer. 0.01% Proflavine hemisulfate used as a fluorescent contrast agent applied topically to mucosa. HRME is used to capture images of suspicious areas sprayed with proflavine hemisulfate.
3163597|NCT01456130|Experimental|Alogliptin|Alogliptin 25 mg (or 12.5 mg for participants with moderate renal dysfunction) tablets, orally once daily and a rapid-acting insulin secretagogue as prescribed by the Investigator for up to 52 weeks.
3163598|NCT01456117|Experimental|Pioglitazone (Dose 1) QD|
3163599|NCT01456117|Experimental|Pioglitazone (Dose 2) QD|
3163600|NCT01456117|Experimental|Pioglitazone (Dose 3) QD|
3163601|NCT01456117|Placebo Comparator|Placebo QD|
3163602|NCT01456104|Experimental|vaccine|This is a single-arm phase I trial in patients with AJCC stage IIB, IIC, III, and IV (MIa) melanoma in which autologous human Langerhans-type dendritic cells (CD34+hematopoietic progenitor cell (HPC)-derived Langerhans cells, or LCs) will be electroporated with mRNA encoding full-length murine tyrosinase-related peptide 2 (TRP2). LCs will also be loaded with control antigens (HLA-A*0201-restricted flu matrix peptide).
3163603|NCT01456091|Experimental|AIM 4 Teen Moms|
3163604|NCT01456091|No Intervention|Control|
3163605|NCT01456078|Experimental|177Lu-DOTA-TATE|
3163606|NCT01456065|Other|Vaccine weekly administration|
3163607|NCT01456065|Other|Vaccine biweekly administration|
3163608|NCT01456052|Experimental|Low Dose LX1606|
3163609|NCT01456052|Experimental|High Dose LX1606|
3163610|NCT01456052|Placebo Comparator|Placebo|
3163611|NCT01456039|Experimental|Romidepsin|Patients will receive romidepsin intravenously for 4 hours on Days 1, 8, and 15 of each 28-day cycle until when/if a discontinuation criterion, e.g., disease progression, severe adverse events, or consent withdrawal.
3163653|NCT01455714||A, B, C|Group A- 40 patients without symptoms of heart failure Group B- 40 patients with exertional dyspnoea Group C - 40 patients with overt heart failure
3163811|NCT01454726|Other|control group|receiving the Western medical treatment alone.
3163612|NCT01456026|Experimental|Glycated beta-lactoglobulins|In this randomized, double blind,cross-over study, half of the subjects will receive on one day a beverage with a high AGE content and will be switched after a wash-out of min. 7 days to receive a low-AGE beverage (comparator). The other half will receive the beverages in inverse sequence.
3163613|NCT01456026|Active Comparator|Non-glycated beta-lactoglobulins|In this randomized, double blind,cross-over study, half of the subjects will receive on one day a beverage with a high AGE content and will be switched after a wash-out of min. 7 days to receive a low-AGE beverage (comparator). The other half will receive the beverages in inverse sequence.
3163614|NCT01456013|Active Comparator|Standard Therapy|Standard of care for patients at risk of CIN
3163615|NCT01456013|Experimental|RenalGuard Therapy|Induced Diuresis with Matched Replacement
3163616|NCT01456000|Experimental|EAS-AC (HeartLight)|Treatment with the EAS-AC.
3163617|NCT01456000|Active Comparator|Control Arm Ablation|Treatment with standard ablation.
3163618|NCT01455974|Experimental|Dialysate sodium set at 136 mmol/L|
3163619|NCT01455948|Active Comparator|Balloon Sinuplasty™ System|
3163620|NCT01455948|Active Comparator|Functional Endoscopic Sinus Surgery|
3163621|NCT01455935|Active Comparator|Medical Therapy|"Current standard of care per the latest stroke guidelines~Permissive Hypertension up to 220~Antipletelets therapy:~ASA 81 mg PO daily or~Plavix 75 mg PO daily or~Aggrenox 225mg PO twice daily~Anti-inflammatory therapy:~Lipitor 80 mg PO daily or~Crestor 20 mg PO daily"
3163622|NCT01455935|Experimental|Intravenous Thrombolysis|"Full dose Intravenous thrombolysis~0.9 mg/kg~Maximum dose is 90 mg~10% of the dose will be given over one minute~90% of the dose will be infused over 1 hour~Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications~Neuro checks every 5 minutes during the infusion~Neuro checks every hour after the infusion for 24 hours"
3163623|NCT01455935|Experimental|Intra-Arterial Therapy|"-Choice of therapy per experienced Endovascular surgeon and includes:~Intra arterial Activase (Maximum dose of 22 mg)~MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)~PENUMBRA device (no standard time frame for how long the procedure takes)"
3163624|NCT01455922|Experimental|ITCA 650 60 mcg/day|
3163625|NCT01455922|Active Comparator|glimepiride|
3163626|NCT01455909|Experimental|ITCA 650 60 mcg/day|
3163627|NCT01455909|Active Comparator|sitagliptin|sitagliptin 100 mg/day
3163628|NCT01455896|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
3163629|NCT01455896|Other|ITCA placebo|
3163630|NCT01455883|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
3163631|NCT01455883|Active Comparator|glimepiride|glimepiride up-titrated to 8 mg/day over first 13 weeks
3163632|NCT01455870|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
3163633|NCT01455870|Active Comparator|sitagliptin|sitagliptin 100 mg/day
3163634|NCT01455857|Experimental|ITCA 650 40 mcg/day|
3163635|NCT01455857|Experimental|ITCA 650 60 mcg/day|
3163636|NCT01455857|Placebo Comparator|ITCA placebo|
3163637|NCT01455844|Experimental|CaPre 1.0g|
3163638|NCT01455844|Experimental|CaPre 2.0g|
3163639|NCT01455844|Placebo Comparator|Placebo|
3163640|NCT01455831|Experimental|Extended peri-operative thromboprophylaxis|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
3163641|NCT01455831|Active Comparator|Standard thromboprophylaxis|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
3163642|NCT01455805|Active Comparator|Minuteman Fusion Implant|Minuteman™ interspinous interlaminar fusion Implant (interspinous interlaminar fusion device) which gained CE Mark approval in May 2011
3163643|NCT01455805|Other|Surgical decompression|Surgical decompression refers to the following operations Laminectomy, Foraminotomy, Discectomy or any other surgical procedure that the clinician feels is relevant for the decompression of lumbar spinal stenosis.
3163644|NCT01455792|Experimental|MRI and soft image fusion biopsy|Preoperative MRI and soft image ultrasound guided biopsy.
3163645|NCT01455792|Active Comparator|Gold standard biopsy|Gold standard TRUS biopsy
3163646|NCT01455779|Other|Lyrette|"The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.~The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment."
3163647|NCT01455753||Employees|A total of 1,801 employees of a health benefits administrator that held a free workplace influenza vaccination clinic.
3163648|NCT01455740|Experimental|Provider Visit Incentive (PVI)|"Participants were told that they would receive $30 after attending each scheduled provider visit (a CCT).~A block randomization scheme, stratified on whether or not the majority of the participant's three previous viral load measurements were suppressed, assigned 21 individuals to the PVI arm."
3163649|NCT01455740|Experimental|Incentive Choice (IC)|"Participants were given a choice between the CCT described in the PVI arm and a commitment contract, which made the $30 payment conditional on the patient attending the provider visit AND meeting an ART adherence threshold.~A block randomization scheme, stratified on whether or not the majority of the participant's three previous viral load measurements were suppressed, assigned 19 individuals to the IC arm."
3163650|NCT01455740|No Intervention|Passive Control (PC)|The study also included 70 individuals in a PC arm, who did not receive financial incentives. Individuals in the PC arm were not enrolled in the randomized trial but met basic study eligibility criteria during the same time period.
3163651|NCT01455727|Experimental|Pharmaceutical care|The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.
3163652|NCT01455727|Active Comparator|Usual care|Patients received usual care directed by their physician.
3163812|NCT01454713||Veritas|Breast reconstruction with Veritas
3163654|NCT01455701|Experimental|Tocilizumab|Participants will receive tocilizumab intravenous (IV) infusion at a dose of 12 milligrams per kilogram (mg/kg) every two weeks (Q2W) during main evaluation period of 12 weeks (a total of 6 infusions including one at baseline visit). Participants will have the option to be treated in an optional extension period after completion of main evaluation period. In optional extension period, participants will receive tocilizumab 12 mg/kg IV infusion Q2W from Week 12 until the participant reaches 2 years of age or has been treated for one year from baseline, whichever is longer.
3163655|NCT01455688|Experimental|Early antiviral therapy|
3163656|NCT01455688|Active Comparator|Conventional therapy|
3163657|NCT01455675|Experimental|IgY, gargling solution|Avian polyclonal anti-pseudomonas antibodies (IgY), 70 ml gargling solution contains 50 mg IgY with an activity against PA, once daily
3163658|NCT01455675|Placebo Comparator|Placebo, gargling solution|70 ml gargling solution without antibodies, once daily
3163659|NCT01455662||all patients after cardiac arrest|
3163660|NCT01455649|Experimental|Everolimus|
3163661|NCT01455649|Active Comparator|calcineurin inhibitor|
3163662|NCT01455636|Experimental|Hand hygiene with Hand Sanitizer (HS)|"To obtain 480 low birth weight infants the entire area of Kaliganj and Norsinghdi will be divided into 48 clusters based on the list of pregnant women identified through a household survey.~24 clusters will be randomized to receive Hand Sanitizer plus nutrition and hygiene education and the remaining 24 will receive only nutrition and hygiene education."
3163663|NCT01455636|Experimental|Hand hygiene with no Hand Sanitizer|"To obtain 480 low birth weight infants the entire area of Kaliganj and Norsinghdi will be divided into 48 clusters based on the list of pregnant women identified through a household survey.~24 clusters will be randomized to receive Hand Sanitizer plus nutrition and hygiene education and the remaining 24 will receive only nutrition and hygiene education."
3163664|NCT01455636|Experimental|Micronutrient Powder|"From 6 months of age, children in randomized clusters will be assigned to receive one sachet of Improved Micronutrient Powder, I-MNP per day for six months with or without hand sanitizer.~Throughout the entire intervention period, mothers/caregivers of the children in all groups will receive simple, standardized, and age and culturally appropriate nutrition and health education that aims to improve feeding and health-seeking behavior and caring practices."
3163665|NCT01455636|Placebo Comparator|Control|"From 6 months of age, children in randomized clusters will be assigned to receive no hand sanitizer or no micronutrient powder~Throughout the entire intervention period, mothers/caregivers of the children in all groups will receive simple, standardized, and age and culturally appropriate nutrition and health education that aims to improve feeding and health-seeking behavior and caring practices."
3163666|NCT01455623||Health Care Provider|A person working within the field of CMT.
3163667|NCT01455623||Patient with CMT|Any person of any age self-identifying as having CMT and belonging to the Inherited Neuropathies Consortium Contact Registry hosted by the Rare Disease Clinical Research Network.
3163668|NCT01455597|Experimental|Estradiol Vaginal Gel|WC3011 Estradiol Vaginal Gel, administered 3X weekly for 40 weeks
3163669|NCT01455584|Experimental|HM781-36B|HM781-36B
3163670|NCT01455571|Experimental|HM781-36B|Dose : 0.5mg, 1mg, 2mg, 4mg, 8mg, 12mg, 16mg, 20mg,...
3163671|NCT01455558|Experimental|Cilostazol|
3163672|NCT01455532|Experimental|Iniparib, single agent|Iniparib will be initially administered intravenously once weekly (days 1, 8, and 15) for 3 weeks, in a 21-day cycle. Then, iniparib will be administered twice weekly (days 1, 4, 8, 11, 15, and 18) in a 21-day cycle. Cycle1 (day 1 thru day 21) will be defined as the dose limiting toxicities (DLT) observation period. Starting dose is 15 mg/kg once weekly.
3163673|NCT01455532|Experimental|Iniparib/Gemcitibine/Carboplatin|Gemcitabine/carboplatin (GC) : Gemcitabine will be administered at 1,000 mg/m² as a 30min IV infusion and carboplatin area under the curve (AUC) 2 as a 60min IV infusion. Patients will receive gemcitabine/carboplatin infusions once weekly (days 1 and 8). Iniparib will be administered for two weeks, followed by a 1week of rest in a 21-day cycle (weekly schedule: days 1 and 8; twice weekly schedule: days: 1, 4, 8 and 11).
3163674|NCT01455532|Experimental|Iniparib/Paclitaxel|Paclitaxel (P): Paclitaxel will be administered at the dose of 80 mg/m2 as a 60-minute intravenous infusion administered on days 1, 8, and 15 followed by a 1week of rest. Iniparib will be administered for three weeks, followed by 1week of rest in a 28-day cycle (weekly schedule: days 1, 8 and 15; twice weekly schedule: days 1, 4, 8, 11, 15 and 18).
3163675|NCT01455532|Experimental|Iniparib/Pegylated liposomal doxorubicin/Carboplatin|Pegylated liposomal doxorubicin (Doxil)/Carboplatin (PLD) : Doxil will be administered at 30 mg/m² as a 30min IV infusion and carboplatin AUC 4 as a 60min IV infusion on day 1 every four weeks. Iniparib will be administered for two weeks in a 28-day cycle (weekly schedule: days 1, and 8; twice weekly schedule: days 1, 4, 8, and 11).
3163676|NCT01455519|Placebo Comparator|Sugar pill|Subjects may receive a pill with no medicine.
3163677|NCT01455519|Active Comparator|Hydromorphone ER|Subjects received study drug: Hydromorphone ER
3163678|NCT01455506|Experimental|Decitabine with fludarabine and busulfan|decitabine with fludarabine and busulfan in the setting of allogeneic stem cell transplantation
3163679|NCT01455493|Experimental|A|
3163680|NCT01455480|Experimental|RPh201|
3163681|NCT01455467|Active Comparator|One iStent|Implantation of one iStent in conjunction with cataract surgery
3163682|NCT01455467|Active Comparator|Two iStent|Implantation of two iStent devices in conjunction with cataract surgery
3163683|NCT01455454||coronary artery disease|patients undergoing coronary artery bypass grafting using cardiopulmonary bypass
3163684|NCT01455441|Active Comparator|Training and liraglutide|Treatment with both training and liraglutide for 16 weeks
3163685|NCT01455441|Placebo Comparator|Training and placebo|Treatment wiht both training and placebo for 16 weeks
3163686|NCT01455428|Experimental|Lyrica (pregabalin)|
3163687|NCT01455428|Placebo Comparator|Placebo|
3163688|NCT01455415|Experimental|1: Pregabalin|
3163689|NCT01455415|Placebo Comparator|2: Placebo|
3163690|NCT01455389|Experimental|DOTAP + Erlotinib|DOTAP:Chol-fus1 0.045 mg/kg by vein over 25-35 minutes on day 1 of each 21 day cycle; and Erlotinib 100 mg by mouth daily for each 21 day cycle.
3163691|NCT01455376|No Intervention|Hyperosmolar sodium chloride|Patients in this group received intravenous infusion of hyperosmolar Sodium Chloride 3% at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
3163692|NCT01455376|Experimental|Hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
3163693|NCT01455350|Active Comparator|Lidocaine|10 week treatment of daily application of topical lidocaine
3163694|NCT01455350|Experimental|Multimodal physiotherapy|10 weeks of weekly multimodal physiotherapy treatments
3163695|NCT01455337|Active Comparator|prednisolone|
3163696|NCT01455337|Experimental|pentoxifylline|
3163697|NCT01455324||Lower Limb Amputees|Those with lower limb amputations
3163698|NCT01455311||Cystic Pancreatic Tumor Specimens|Specimen collection via EUS Guided Fine Needle Aspiration EchoBrush Sampling
3163699|NCT01455298|Other|Transient elastography and fibrotest|
3163700|NCT01455272|Experimental|high-risk leukemia|
3163701|NCT01455259|Experimental|AdCD40L|Treatments once a week with 2.5x10e11 VP AdCD40L, maximum 4 treatments (total dose 1x10e12 VP). If no effect in less than 2 out of 6 melanoma patients, the following 9 melanoma patients and 6 patients with other solid tumors will receive preconditioning therapy 1-2 days prior to first and last treatment with 300mg/m2 cyclophosphamid. The next 9 melanoma patients will receive one local radiotherapy.
3163702|NCT01455246|Experimental|Daptomycin + Meropenem|30 patients with cirrhosis and nosocomial SBP
3163703|NCT01455246|Active Comparator|Ceftazidime|30 patients with cirrhosis and nosocomial SBP
3163704|NCT01455233|Active Comparator|besivance|ocular antibiotic
3163705|NCT01455233|Active Comparator|vigamox|ocular antibiotic
3163706|NCT01455207|Other|alcoholic patients|
3163707|NCT01455207|Other|korsakoff patients|
3163708|NCT01455207|Other|healthy controls|
3163709|NCT01455194|Active Comparator|CIC 160|Two puffs of 40 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 160 mcg)
3163710|NCT01455194|Active Comparator|CIC 320|Two puffs of 80 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 320 mcg)
3163711|NCT01455194|Active Comparator|CIC 640|Two puffs of 160 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 640 mcg)
3163712|NCT01455181|Experimental|NPSP558|
3163713|NCT01455168||No treatment|Capsular tension ring is not used in the group.
3163714|NCT01455168||CTR simply implanted|Capsular tension ring is simply implanted in the group.
3163715|NCT01455168||CTR with the eyelets closed|Capsular tension ring is implanted and closed by tying both eyelets in the group.
3163716|NCT01455155|Experimental|Creative therapy|Conventional physical therapy program (5 times/week) plus creative therapy (Art and Music) 2 times/week for 4 weeks
3163717|NCT01455155|Active Comparator|Control|Conventional physical therapy (5 times/week) for 4 weeks
3163718|NCT01455142|Experimental|Formulation 1|
3163719|NCT01455142|Experimental|Formulation 2|
3163720|NCT01455129|Active Comparator|tiotropium group|18 mcg tiotropium, once daily, inhaled by HandiHaler
3163721|NCT01455129|Placebo Comparator|placebo group|matching placebo, once daily, inhaled by HandiHaler
3163722|NCT01455116|Experimental|Mild induced hypothermia|Induced hypothermia to 32-34 degrees Celsius (90 - 93 degrees Fahrenheit)
3163723|NCT01455116|No Intervention|Fever Respect|Standard of care septic shock therapy according to Surviving Sepsis Campaign guidelines
3163724|NCT01455103|Experimental|Arm 1: BMS-936559 (1mg/kg)|
3163725|NCT01455103|Experimental|Arm 2: BMS-936559 (3mg/kg)|
3163726|NCT01455103|Experimental|Arm 3: BMS-936559 (10mg/kg)|
3163727|NCT01455090|Experimental|Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)|"BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 60 mg tablet by mouth once daily for 24 Weeks~BMS 791325 75 mg table by mouth twice daily for 24 Weeks"
3163728|NCT01455090|Experimental|Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)|"BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 60 mg tablet by mouth once daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
3163729|NCT01455090|Experimental|Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)|"* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 60 mg tablet by mouth once daily for 24 Weeks~BMS 791325 150 mg table by mouth twice daily for 24 Weeks"
3163730|NCT01455090|Experimental|Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)|"* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 60 mg tablet by mouth once daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
3163731|NCT01455090|Experimental|Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
3163732|NCT01455090|Experimental|Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
3163733|NCT01455090|Experimental|Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 4 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
3163734|NCT01455090|Experimental|Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 4 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
3163735|NCT01455090|Experimental|Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
3163736|NCT01455090|Experimental|Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
3163861|NCT01454349|Experimental|PRX302|
3163737|NCT01455090|Experimental|Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks~BMS 791325 75 mg table by mouth twice daily for 24 Weeks"
3163738|NCT01455090|Experimental|Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks~BMS 791325 150 mg table by mouth twice daily for 24 Weeks"
3163739|NCT01455090|Experimental|Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV|"* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablets orally twice daily 12 weeks~BMS-790052 30 mg tablets orally twice daily 12 weeks~BMS-791325 75 mg tablets orally twice daily 12 weeks~Ribavirin (RBV) tablets orally weight based dosing daily 12 weeks [if subject is < 75 kg: 1000 mg per day orally (2 x 200 mg tablets in AM and 3 x 200 mg tablets in PM), or if ≥ 75 kg: 1200 mg per day orally (3 x 200 mg tablets in AM and 3 x 200 mg tablets in PM]"
3163740|NCT01455077||Obese patients|BMI > 35
3163741|NCT01455064||Type 1 or 2 diabetes, MDI or pump|
3163742|NCT01455051|Experimental|Ofatumumab|We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
3163743|NCT01455038||Control group|Healthy controls had no history of psychiatric disorder and had no psychiatric symptom when interviewed by a board-certified psychiatrist.
3163744|NCT01455038||Bipolar group|individual patient as being in subsyndromal depressive phase when the patient had a Montgomery-Åsberg depression rating scale score of 10 or less and Clinical Global Impression severity of 3 or less for last one month.
3163745|NCT01455025|Experimental|Plerixafor granulocyte-colony stimulating factor|4 steps of plerixafor doses from 240 to 480 microgram/kg per day concomitant with GCSF and chemotherapy 3 to 6 evaluable patients will be enrolled at each dose level in a modified 3 + 3 design.
3163746|NCT01455012|Experimental|Rotigotine|Rotigotine, optimal dose (minimum dose 1 mg/24 h, maximum dose 3 mg/24 h)
3163747|NCT01455012|Placebo Comparator|Placebo|Placebo
3163748|NCT01454999|Experimental|CTI|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change.
3163749|NCT01454999|Experimental|CTI + text|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change. Tailored feedback messages based on stage of change will also be sent by cell phone.
3163750|NCT01454986|Active Comparator|Cohort 1|0.06 mg/kg ALXN1007
3163751|NCT01454986|Active Comparator|Cohort 2|0.1 mg/kg ALXN1007
3163752|NCT01454986|Active Comparator|Cohort 3|0.3 mg/kg ALXN1007
3163753|NCT01454986|Active Comparator|Cohort 4|1.0 mg/kg ALXN1007
3163754|NCT01454986|Active Comparator|Cohort 5|3.0 mg/kg ALXN1007
3163755|NCT01454986|Active Comparator|Cohort 6|6.0 mg/kg ALXN1007
3163756|NCT01454986|Active Comparator|Cohort 7|10.0 mg/kg ALXN1007
3163757|NCT01454973||Healthy obese individuals|
3163758|NCT01454960|Experimental|SA, AJ, PC|"Participants are given all 3 interventions:~Suggested Alternatives, Accountable Justification, and Peer Comparison."
3163759|NCT01454960|Experimental|SA, AJ|Participants receive the Suggested Alternatives and Accountable Justification interventions, but not the Peer Comparison intervention.
3163760|NCT01454960|Experimental|SA, PC|Participants receive the Suggested Alternatives and Peer Comparison interventions, but not the Accountable Justification intervention.
3163761|NCT01454960|Experimental|AJ, PC|Participants receive the Accountable Justification and Peer Comparison interventions, but not the Suggested Alternatives intervention.
3163762|NCT01454960|Experimental|Peer Comparison|Participants receive the Peer Comparison intervention, but do not receive the Suggested Alternatives or Accountable Justification interventions.
3163763|NCT01454960|Experimental|Suggested Alternatives|Participants receive the Suggested Alternatives intervention, but not the Accountable Justification or Peer Comparison interventions.
3163764|NCT01454960|Experimental|Accountable Justification|Participants receive the Accountable Justification intervention, but do not receive the Suggested Alternatives or Peer Comparison interventions.
3163765|NCT01454960|No Intervention|Control|Participants do not receive any of the 3 interventions.
3163766|NCT01454947|Experimental|SA, AJ, PC|Participants are given all 3 interventions.
3163767|NCT01454947|Experimental|SA, AJ|Participants receive the Suggested Alternatives and Accountable Justification interventions, but not the Peer Comparison intervention.
3163768|NCT01454947|Experimental|SA, PC|Participants receive the Suggested Alternative and Peer Comparison interventions, but not the Accountable Justification intervention.
3163769|NCT01454947|Experimental|AJ, PC|Participants receive the Accountable Justification and Peer Comparison interventions, but not the Suggested Alternative intervention.
3163770|NCT01454947|Experimental|Peer Comparison (PC)|Participants receive the Peer Comparison intervention, but do not receive the Suggested Alternatives or Accountable Justification interventions.
3163771|NCT01454947|Experimental|Suggested Alternatives (SA)|Participants receive the Suggested Alternatives intervention, but not the Accountable Justification or Peer Comparison interventions.
3163772|NCT01454947|Experimental|Accountable Justification (AJ)|Participants receive the Accountable Justification intervention, but do not receive the Suggested Alternatives or Peer Comparison interventions.
3163773|NCT01454947|No Intervention|Education Control|Participants do not receive any of the 3 interventions.
3163774|NCT01454934|Experimental|Arm A|
3163775|NCT01454934|Active Comparator|Arm B|
3163776|NCT01454921|Experimental|Intervention I|"Intervention group participants will be enrolled for the duration of one intervention program, which will last approximately 6 months. Each intervention program will consist of two individual and six group intervention sessions with each session lasting approximately 2-3 hours.~Intervention participants will also complete two ACASI assessments (baseline and post-intervention) lasting approximately 1.5-2 hours each."
3163862|NCT01454349|Placebo Comparator|Inactive substance|
3163777|NCT01454921|Experimental|Intervention II|"Intervention group participants will be enrolled for the duration of one intervention program, which will last approximately 6 months. Each intervention program will consist of two individual and six group intervention sessions with each session lasting approximately 2-3 hours.~Intervention participants will also complete two ACASI assessments (baseline and post-intervention) lasting approximately 1.5-2 hours each."
3163778|NCT01454908|Other|Partial Knee Arthroplasty|Oxford Mobile Bearing Unicompartmental Knee Arthroplasties
3163779|NCT01454895|Experimental|Interactive Web-based Info (IWI) & HPDs|Subjects will receive interactive Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing, as well as a mailed sample of various types of hearing protection devices.
3163780|NCT01454895|Experimental|Interactive Web-based Information (IWI)|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
3163781|NCT01454895|Experimental|Static Web information (SWI) & HPDs|Subjects will receive static Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing, as well as a mailed sample of various types of hearing protection devices.
3163782|NCT01454895|Active Comparator|Static Web information only|Subjects will receive interactive Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing.
3163783|NCT01454895|Experimental|Hearing protection Devices only|Subjects will receive a mailed sample of various types of hearing protection devices.
3163784|NCT01454895|Other|Interactive Web-based information only|used for cases enrolling after achievement of study enrollment goal
3163785|NCT01454882||Behavioral effects of clothing and temperature|In this first study, we will determine how variations in clothing and ambient temperature influence the accuracy of EE determined from measurements of total heat production. 65 individuals will be studied. This will be a randomized cross-over trial with two within subject factors: 1) ambient temperature and 2) amount of clothing. There will be two temperature conditions; warm temperature [WT, 75°F (24°C)] and cool temperature [CT, 60°F (16°C)]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
3163786|NCT01454882||Behavioral effects of age, sex, and adiposity|THe aim of this study is to Determine how age, sex, and adiposity influence the accuracy of EE determined from measurements of total heat production . This will be a randomized study with two within subject conditions(high and low physical activity levels). A heterogenous sample of adult men and women in stable health will be studied. We will study subjects across a wide range of weight (up to 300 lbs) and age range (≥ 18 yrs).
3163787|NCT01454882||Effects of free living energy expenditure|The primary aim of this study is to compare the accuracy of measuring free-living energy expenditure in humans measured using portable direct calorimetry. This will be a comparison study; TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied. We will study subjects across a wide range of weight (up to 300 lbs) and age (>18 yrs).
3163788|NCT01454869|Active Comparator|Standard care|nac + salotamul
3163789|NCT01454869|Experimental|heparin group|heparin group
3163790|NCT01454856||Surgical cancer patients|No modification of the treatment
3163791|NCT01454856||Non-surgical cancer patients|No modification of the treatment
3163792|NCT01454856||Surgical non-cancer patients|No modification of the treatment
3163793|NCT01454856||Non-surgical non-cancer patients|No modification of the treatment
3163794|NCT01454843|Active Comparator|Wavefront-guided LASIK - Allegretto|Wavefront-guided LASIK using the Allegretto excimer laser.
3163795|NCT01454843|Active Comparator|Wavefront-guided LASIK - AMO|Wavefront-guided LASIK using AMO CustomVue excimer laser.
3163796|NCT01454830|Experimental|Tailored|Tailored, or individualized, intervention addressing patient education, skills training, and cognitive perceptions
3163797|NCT01454830|Active Comparator|Usual care|The comparison group, usual care, includes the standard of care delivered to all newly-diagnosed OSA persons proceeding to CPAP treatment
3163798|NCT01454817|Other|Patients with ICDs|
3163799|NCT01454817|Other|Caregivers of Patients with ICDs|
3163800|NCT01454804|Experimental|Arm A: Pazopanib + Lapatinib|Oral Pazopanib 200 mg every other day starting on day 1 and oral Lapatinib 500 mg daily starting day 1, both for 28 days.
3163801|NCT01454804|Experimental|Arm B: Pazopanib + Trastuzumab|Oral Pazopanib 200 mg daily for 28 day cycle and Trastuzumab (Herceptin®) 4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1, with a maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.
3163802|NCT01454791|Experimental|Diclofenac Sodium Topical Gel first then Placebo|1:1 randomization to either of two treatment phases of 2 weeks duration (active-placebo or placebo-active).
3163803|NCT01454791|Placebo Comparator|Placebo first then Diclofenac Sodium Topical Gel|1:1 randomization to either of two treatment phases of 2 weeks duration (active-placebo or placebo-active).
3163804|NCT01454778|Experimental|Paclitaxel|
3163805|NCT01454765||Sperm sample from healthy volunteers|
3163806|NCT01454752|Active Comparator|Intermittent parasite clearance|Children sleeping under a long-lasting insecticidal net (LLIN) receive an additional intermittent preventive treatment for clearance of asymptomatic malaria infection given once a year at the end of the malaria transmission season
3163807|NCT01454752|Placebo Comparator|Control|Children sleeping under a long-lasting insecticidal net (LLIN) receive placebo
3163808|NCT01454739|Experimental|On-Demand|The individual dose of rFVIIIFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor VIII (FVIII) levels.
3163809|NCT01454739|Experimental|Prophylaxis|Tailored prophylaxis, Weekly prophylaxis or Personalized prophylaxis available.
3163810|NCT01454726|Experimental|experimental group|receiving both Diaoshi Jifa therapy and the Western medical treatment.
3163813|NCT01454700|Experimental|CSII plus CGM|Patients who has never been treated with insulin pump are randomized to 12 months with insulin pump therapy plus continuous glucose monitoring.
3163814|NCT01454700|Active Comparator|Multiple daily insulin injections|randomized to 12 months standard/usual insulin regimen (multiple daily injections). (stays on insulin pen).
3163815|NCT01454661|Active Comparator|placebo mother - LGG infant|Placebo is administered to the lactating mother whilst the infant receives the probiotic LGG.
3163816|NCT01454661|Placebo Comparator|placebo mother - placebo infant|Placebo is administered to both the lactating mother and her infant.
3163817|NCT01454661|Active Comparator|LGG mother - placebo infant|The probiotic LGG is administered to the lactating mother whilst the infant receives placebo.
3163818|NCT01454661|Active Comparator|LGG+Bb-12 mother - Placebo infant|A combination of the probiotics LGG and Bb-12 is administered to the lactating mother, the infant receives placebo.
3163819|NCT01454661|Active Comparator|Pacebo mother - LGG+Bb-12 infant|Placebo is administered to the lactating mother, the infant receives a combination of the probiotics LGG and Bb-12
3163820|NCT01454648||Physician-staffed|Patients treated by physician-staffed emergency medical service (EMS) unit
3163821|NCT01454648||Paramedic-staffed|Patients treated by paramedic-staffed emergency medical service (EMS) unit
3163822|NCT01454635|Other|Sertraline, Treatment response|dosage, frequency and duration
3163823|NCT01454622|Experimental|Treatment Sequence AB|
3163824|NCT01454622|Experimental|Treatment Sequence BA|
3163825|NCT01454609|Placebo Comparator|Saline|0.9% normal saline
3163826|NCT01454609|Experimental|Bupivacaine|0.25% bupivacaine
3163827|NCT01454609|Experimental|Bupivacaine with clonidine|0.25% bupivacaine with 1 microgram/kg of clonidine
3163828|NCT01454596|Experimental|1/Phase I Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Anti-EGFRvIII CAR transduced PBL + aldesleukin
3163829|NCT01454596|Experimental|2/Phase II Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Anti-EGFRvIII CAR transduced PBL + aldesleukin
3163830|NCT01454583||Aliskiren|Patients getting Aliskiren at baseline
3163831|NCT01454583||ACE-I/ARB|Patients getting ACE-I (angiotensin-converting enzyme inhibitors) or ARB (angiotensin-receptor blockers) at baseline, but not Aliskiren
3163832|NCT01454583||No RAS-inhibition|Patients getting no drugs at baseline that inhibit the renin-angiotensin-aldosterone-system (RAAS)
3163833|NCT01454557|Experimental|Acquired Brain Injury|auditory stimuli for ABI group
3163834|NCT01454557|Experimental|Controls|Auditory stimuli for control group
3163835|NCT01454544|Experimental|ALK house dust mite tablet 6 DU|
3163836|NCT01454544|Experimental|ALK house dust mite tablet 12 DU|
3163837|NCT01454544|Placebo Comparator|Placebo|
3163838|NCT01454531|Experimental|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
3163839|NCT01454518|Experimental|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
3163840|NCT01454518|Placebo Comparator|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
3163841|NCT01454505|Experimental|Stage B/AL-53817|Stage B: AL-53817 nasal spray solution, 1 spray to each nostril twice a day for 4 days. On Day 5, 1 spray to each nostril 60 minutes before entering the EEC.
3163842|NCT01454505|Placebo Comparator|Stage B/Vehicle|Stage B: Vehicle nasal spray, 1 spray to each nostril twice a day for 4 days. On Day 5, 1 spray to each nostril 60 minutes before entering the EEC.
3163843|NCT01454492||Allergy rhinitis|Allergy rhinitis patients group
3163844|NCT01454492||Non- Allergy rhinitis|Non- Allergy rhinitis patients group
3163845|NCT01454479|Experimental|Lapatinib (Tykerb) Plus Ixabepilone|
3163846|NCT01454453|Experimental|Patients - dose titration|Amisulpride 50-200mg, 4-12 weeks, with brain imaging
3163847|NCT01454440|Experimental|Eptifibatide|Intravenous eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure).
3163848|NCT01454440|Placebo Comparator|Placebo|
3163849|NCT01454427||healthy volunteers|
3163850|NCT01454414|Experimental|Permethrin Impregnated Uniforms|Uniforms (including pants, shorts, shirts, socks, and hats) treated with long-lasting permethrin.
3163851|NCT01454414|No Intervention|Placebo|Uniforms sent to Insect Shield, washed and refolded (no permethrin applied).
3163852|NCT01454401|Other|Weekly LeucoPatch treatment|Weekly treatment of diabetic foot ulcers with LeucoPatch
3163853|NCT01454388|Active Comparator|PEG plus breakfast|patients are allowed to have a low residue breakfast the day prior to colonoscopy
3163854|NCT01454388|No Intervention|PEG without breakfast|
3163855|NCT01454388|Active Comparator|picosalax plus breakfast|patients are allowed to have a low residue breakfast the day prior to colonoscopy
3163856|NCT01454388|No Intervention|picosalax without breakfast|
3163857|NCT01454375|No Intervention|Control Arm|No change in current practice
3163858|NCT01454375|Experimental|Referral fo QuitNow Services|Behavioural - referral to QuitNow Services, smoking cessation counseling telephone line supported by the Ministry of Healthy Living and Sport
3163859|NCT01454362|Experimental|Electronic cigarette|We analysed 15 brands of the most popular E-Cs in the UK, EU and US for nicotine levels in the mist. Vapours were generated from cartridges of various nicotine content using a standard single-port linear smoking machine with a puff volume of 70 ml, 1 puff every 7 sec., and a puff duration of 1.8 sec (based on averaged puffing conditions from 10 E-C users found during preliminary studies). Nicotine was absorbed in two sequential washing bottles with methanol and internal standards and analysed with gas chromatography. One brand was selected for this study as it consistently delivers about 1mg of nicotine with 20 puffs.
3163860|NCT01454362|Active Comparator|Nicotine Inhalator|The inhalator consists of a nicotine cartridge which is placed into a plastic mouthpiece. One cartridge contains 10mg of nicotine of which 4mg of nicotine can be extracted. Nicotine is delivered mainly through the oral cavity, throat, and upper respiratory tract with a minor fraction reaching the lungs. A single cartridge can be used for one 20-minute period of continuous puffing or periodic use of up to 400 puffs per cartridge.
3163863|NCT01454336|Experimental|Cirrhotic Patients|3 cirrhotic patients who underwent a combination of cell therapy and chemotherapy
3163864|NCT01454323|Experimental|Intervention|Dose of bone marrow mononuclear cells: 5-7 x 108 total cells
3163865|NCT01454310|Experimental|Acellular skin substitute|
3163866|NCT01454310|Active Comparator|Autologous skin graft|
3163867|NCT01454297||Newly diagnosed Multiple Myeloma|This is a prospective observational study in patients with symptomatic multiple myeloma who have not yet initiated therapy for their disease.
3163868|NCT01454284|Experimental|LY2605541 + Insulin Lispro|LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC) once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered SC at meal times for 52 weeks.
3163869|NCT01454284|Active Comparator|Glargine + Insulin Lispro|Glargine dose titrated based on blood glucose readings, administered SC once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered SC at meal times for 52 weeks.
3163870|NCT01454271|Experimental|Total Hip Arthroplasty CERAFIT® grafted|
3163871|NCT01454245|Experimental|001|"JNJ-39439335 Part 1:Type=1 unit=mg number=25 form=capsule route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.~or Part 1:Type=2 unit=mg number=12.5 form=capsule route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods.,JNJ-39439335 Part 2:Type=2 unit=mg number=12.5 form=capsule route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods."
3163872|NCT01454232|Other|gastric surgery|obese patients addressed for gastric surgery
3163873|NCT01454232|Active Comparator|lean healthy subjects evaluated once|lean healthy subjects evaluated once
3163874|NCT01454206|No Intervention|Treatment as Usual|
3163875|NCT01454206|Experimental|iSBIRT|Participants will receive the internet-facilitated screening, brief intervention and referral to treatment (iSBIRT intervention)
3163876|NCT01454180|Active Comparator|Arm A|Control treatment arm will be treated with any of the schemes used in the study according to the discretion of the physician responsible
3163877|NCT01454180|Experimental|Arm B|treatment guided by the therapeutic targets
3163878|NCT01454154|Active Comparator|Glyburide|RP-1127 (Glyburide for Injection)
3163879|NCT01454154|Placebo Comparator|Placebo|Placebo
3163880|NCT01454141|Experimental|Peripheral Vision Task|During this task participants viewed a circular array of 15 discs and were asked to move their attention, but not their eyes, clockwise around the array while auditory tones were presented. Following the presentation of a distinct target tone, the discs changed color and participants reported the color of the disc by pressing a designated button on the keyboard. This task was developed to be a non-active control condition, targeting visual and occipital areas of the brain, and therefore allows us to discriminate between the effects of completing a computer-based task from interventions that specifically target the PFC.
3163881|NCT01454141|Experimental|Cognitive Control Training|Cognitive Control Training (CCT) A modified version of the Paced Auditory Serial Addition Task (PASAT) and the Attention Control Intervention were used to train participants' attentional control in accordance with procedures used by Siegle and colleagues.
3163882|NCT01454128|Active Comparator|Non-EPB|with exercise
3163883|NCT01454128|Experimental|EPB with exercise|with exercise
3163884|NCT01454115|Experimental|Panel 1: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
3163885|NCT01454115|Experimental|Panel 2: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
3163886|NCT01454115|Experimental|Panel 3: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
3163887|NCT01454115|Experimental|Panel 4: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
3163888|NCT01454115|Experimental|Panel 5: BMS-708163 or Placebo|"Healthy male subjects (age: 18 to 45 years).~In Period 2: Subjects will receive BMS-708163 or placebo as a capsule formulation.~In Period 3: Subjects will receive BMS-708163 or placebo as a capsule formulation within 5 minutes of consuming a standard high-fat breakfast on Day 1"
3163889|NCT01454115|Experimental|Panel 6: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
3163890|NCT01454115|Experimental|Panel 7: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
3163891|NCT01454115|Experimental|Panel 8: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
3163892|NCT01454115|Experimental|Panel 9: BMS-708163 or Placebo|Healthy, elderly male subjects (age: 60 years and greater)
3163893|NCT01454115|Experimental|Panel 10: BMS-708163 or Placebo|Healthy, elderly female subjects (age: 60 years and greater)
3163894|NCT01454115|Experimental|Panel 11: BMS-708163 or Placebo|Healthy male subjects (age: between 46 to 59 years)
3163895|NCT01454115|Experimental|Panel 12: BMS-708163 or Placebo|Healthy male and/or female subjects or subjects with MCI (age: between 60-74 years)
3163896|NCT01454115|Experimental|Panel 13: BMS-708163 or Placebo|Healthy male and/or female subjects or with AD or MCI (age: 75 years or greater)
3163897|NCT01454115|Experimental|Panel 15: BMS-708163 or Placebo|Healthy young male subjects
3163898|NCT01454102|Experimental|Arm A: Nivolumab + Gemcitabine + Cisplatin|"Nivolumab solution intravenously every 3 weeks until progressive disease (PD) or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Gemcitabine solution intravenously on Day 1 and Day 8 of every cycle for 4 cycles~Cisplatin solution intravenously on Day 1 of each cycle for 4 cycles"
3163899|NCT01454102|Experimental|Nivolumab + Pemetrexed + Cisplatin|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Pemetrexed solution intravenously on Day 1 of every cycle for 4 cycles~Cisplatin solution intravenously on Day 1 of each cycle for 4 cycles"
3163900|NCT01454102|Experimental|Arm C: Nivolumab + Paclitaxel + Carboplatin|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Paclitaxel solution intravenously on Day 1 of every cycle for 4 cycles~Carboplatin area under curve (AUC) 6 solution intravenously on Day 1 of every cycle for 4 cycles"
3163962|NCT01453790|Active Comparator|General Depression Education|Mothers receive general depression education (verbal and written) which are drawn from previous research. They also receive attention control telephone calls at 2 days.
3164005|NCT01453439|Active Comparator|Supportive Psychotherapy|Group receiving Supportive Psychotherapy
3163901|NCT01454102|Experimental|Arm D: Nivolumab + Bevacizumab maintenance|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Bevacizumab administered prior to intravenous infusion on Cycle 1 Day 1 followed by intravenous infusion every 3 weeks on Cycle 2 onwards and until PD or discontinuation due to toxicity"
3163902|NCT01454102|Experimental|Arm E: Nivolumab + Erlotinib|"Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Erlotinib tablet by mouth daily until PD or discontinuation due to toxicity"
3163903|NCT01454102|Experimental|Arm F: Nivolumab|Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered over 60 minutes
3163904|NCT01454102|Experimental|Arm G: Nivolumab + Ipilimumab|"In Squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered until PD or discontinuation due to toxicity"
3163905|NCT01454102|Experimental|Arm H: Nivolumab + Ipilimumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
3163906|NCT01454102|Experimental|Arm I: Nivolumab + Ipilimumab|"In squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
3163907|NCT01454102|Experimental|Arm J: Nivolumab + Ipilimumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
3163908|NCT01454102|Experimental|Arm K: Nivolumab|"In squamous histology subjects (NSCLC)~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered as switch maintenance therapy. A cycle is 2 weeks"
3163909|NCT01454102|Experimental|Arm L: Nivolumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered over 60 minutes as switch maintenance therapy. A cycle is 2 weeks"
3163910|NCT01454102|Experimental|Arm M: Nivolumab|"NSCLC subjects with untreated, asymptomatic brain metastases and have no evidence of cerebral edema~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered for up to an hour as monotherapy. A cycle is 2 weeks"
3163911|NCT01454102|Experimental|Arm N: Nivolumab + Ipilimumab|"In subjects with any histology (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
3163912|NCT01454102|Experimental|Arm O: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
3163913|NCT01454102|Experimental|Arm P: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
3163914|NCT01454102|Experimental|Arm Q: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
3163915|NCT01454102|Experimental|Arm R: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
3163916|NCT01454102|Experimental|Arm S: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
3163917|NCT01454089|Experimental|OGX-427 600 mg|Standard chemotherapy (gemcitabine and cisplatin) in combination with OGX-427 (600 mg)
3163918|NCT01454089|Experimental|OGX-427 1000 mg|Standard chemotherapy (gemcitabine and cisplatin) in combination with OGX-427 (1000 mg)
3163919|NCT01454089|Active Comparator|Placebo|Standard chemotherapy (gemcitabine and cisplatin) in combination with placebo
3163920|NCT01454076|Experimental|Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg|Ixazomib 2.5 milligram (mg), capsule B, orally, once on Day 1 and 15 along with ketoconazole 400 mg, tablets, orally, once daily from Day 12 to 25 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
3163921|NCT01454076|Experimental|Arm 2: Ixazomib 4 mg Capsule A or B|Ixazomib 4 mg, capsule A, orally, once on Day 1 followed by ixazomib 4 mg, capsule B once on Day 15 of Cycle 1 (28-day treatment cycle) or ixazomib 4 mg, capsule B, orally, once on Day 1 followed by ixazomib 4 mg, capsule A once on Day 15 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
3163922|NCT01454076|Experimental|Arm 3: Ixazomib 4 mg Fasted or Fed|Ixazomib 4 mg, capsule B, orally, under fasted state, once on Day 1 followed by ixazomib 4 mg, capsule B, orally, under fed state, once on Day 15 of Cycle 1 (28-day treatment cycle) or ixazomib 4 mg, capsule B, orally, under fed state, once on Day 1 followed by ixazomib 4 mg, capsule B, orally, under fasted state, once on Day 15 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
3163963|NCT01453764|Experimental|Adipose SVF IV Infusion|IV Infusion of Autologous Adipose Derived Stromal Vascular Fraction Intervention: Intravenous Infusion
3163964|NCT01453751|Experimental|Intravenous Injection of AD-SVF|Intravenous administration of AD-SVF.
3164006|NCT01453426|Experimental|Chinese Subjects - Dose 1 BG00012|
3163923|NCT01454076|Experimental|Arm 4: Ixazomib 4 mg + Rifampin 600 mg|Ixazomib, 4 mg, capsule B, orally, once on Day 8 along with rifampin 600 mg, capsule, orally, once daily from Day 1 to 14 of Cycle 1 (21-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
3163924|NCT01454076|Experimental|Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg|Ixazomib, 2.5 mg, capsule B, orally, once on Day 6 along with clarithromycin, 500 mg, tablet, orally, twice daily from Day 1 to 16 of Cycle 1 (21-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
3163925|NCT01454063|Experimental|OMS302|OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
3163926|NCT01454063|Placebo Comparator|Placebo|Placebo diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
3163927|NCT01454037||Prostate cryoablation|Subjects receiving cryotherapy for prostate cancer
3163928|NCT01454037||Radical prostatectomy|Subjects receiving radical prostatectomy
3163929|NCT01454037||Radiation|Subjects receiving radiation for prostate cancer
3163930|NCT01454024||Total study population|
3163931|NCT01454011|Active Comparator|Testosterone 250mg injection,|
3163932|NCT01454011|Active Comparator|Testosterone transdermal application|
3163933|NCT01453998|Experimental|GSK217744 Group 1|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation A vaccine in the primary study and a booster dose of either GSK217744 formulation A vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa™ vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13®. The Infanrix hexa™/GSK217744 and Prevenar 13® vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
3163934|NCT01453998|Experimental|GSK217744 Group 2|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation B vaccine in the primary study and a booster dose of either GSK217744 formulation B vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa™ vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13®. The Infanrix hexa™/GSK217744 and Prevenar 13® vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
3163935|NCT01453998|Active Comparator|Infanrix hexa Group|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the Infanrix hexa™ vaccine in the primary study and a booster dose of Infanrix hexa™ in this study, co-administered with a booster dose of Prevenar 13®. The Infanrix hexa™ and Prevenar 13® vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
3163936|NCT01453985|Experimental|Full-Thickness-Gastroplication|
3163937|NCT01453972|Experimental|Long distanse moderate training|40 minutes moderate treadmill running
3163938|NCT01453972|Experimental|Long interval training|4x4min interval treadmill running
3163939|NCT01453972|Experimental|Short interval training|10x1min interval treadmill running
3163940|NCT01453959|Other|Diet cycles|The patient will be analysed for salt sensitivity by two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days). After 4 weeks without any intervention, the patient will received fludrocortisone in a dose of 0.4 mg/day for 7 days.
3163941|NCT01453959|Other|Fludrocortisone|The patient will received fludrocortisone in a dose of 0.4 mg/day for 7 days. After 4 weeks without any intervention, the patient will be analysed for salt sensitivity by two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days).
3163942|NCT01453946|Other|Entocort|Study Medication
3163943|NCT01453933|Active Comparator|Raltegravir|At baseline, lopinavir-ritonavir will be switched to raltegravir (cross-over after 8 weeks).
3163944|NCT01453933|No Intervention|Lopinavir/ritonavir|Subjects will continue lopinavir/ritonavir (cross-over after 8 weeks)
3163945|NCT01453920|Active Comparator|Treat-and-extend|Ranibizumab injection every 3 months, with follow-up assessments at each visit (every 3 months)
3163946|NCT01453920|Experimental|Treat-and-observe'|No injection, follow-up assessments every month
3163947|NCT01453907|Experimental|ETI-204|ETI-204, Anthim
3163948|NCT01453907|Sham Comparator|placebo|
3163949|NCT01453894|Experimental|Reminder and Outreach Intervention|Participants randomized to this arm will receive the Reminder and Outreach intervention.
3163950|NCT01453894|No Intervention|Usual Care Control Group|Patients assigned to this arm will receive usual care.
3163951|NCT01453881|Experimental|Spacer|Beclomethasone/Formoterol 100/6mcg/puff pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
3163952|NCT01453881|Active Comparator|Comparator|Beclomethasone/Formoterol pMDI 100/6mcg/puff pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
3163953|NCT01453868|Active Comparator|Active non impact aerobics|This group will be performing a 12 week non impact aerobics program twice a week.
3163954|NCT01453868|Active Comparator|Control group: Passive lecture series|The control group will also be measured for balance and then attend a 12 week lecture series with no exercise. They will then also be remeasured post lectures series
3163955|NCT01453855|Experimental|Travoprost 0.003%|Travoprost ophthalmic solution, 0.003%, one drop instilled in each eye, once daily, for three months
3163956|NCT01453855|Active Comparator|TRAVATAN|Travoprost ophthalmic solution, 0.004%, one drop instilled in each eye, once daily, for three months
3163957|NCT01453842|Experimental|Diet oil|
3163958|NCT01453842|Active Comparator|Olive oil|
3163959|NCT01453842|Placebo Comparator|Carrot|
3163960|NCT01453803|Experimental|Intravenous Injection and Intanasal infusion of AD-SVF|AD-SVF
3163961|NCT01453790|Experimental|Parent-Specific Depression Education-Motivation|Mothers receive depression education (verbal and written) with messages targeted to parent status which are drawn from previous research. They also receive motivational messages at 2 days via telephone.
3164004|NCT01453439|Experimental|Cognitive Behavioral Therapy|Group receiving Cognitive-Behavioral Therapy
3163965|NCT01453738|Experimental|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2-4ml Plasmalyte A followed by 2 ml of Hyaluronan
3163966|NCT01453738|Placebo Comparator|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte
3163967|NCT01453725|Experimental|Golimumab→Golimumab|In Part 1, participants receive golimumab 50 mg, administered subcutaneously (SC) every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 48 weeks treatment with golimumab.)
3163968|NCT01453725|Placebo Comparator|Placebo→Golimumab|In Part 1, participants receive placebo, administered SC every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 32 weeks treatment with golimumab.)
3163969|NCT01453712|No Intervention|Control group|Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
3163970|NCT01453712|Experimental|Intervention group|Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
3163971|NCT01453686|Experimental|Hydrocortisone 1%|
3163972|NCT01453686|Experimental|Clobetasol Propionate 0.05%|
3163973|NCT01453660||Cisplatin-Based Chemotherapy Group|GCT patients who are planned to start cisplatin-based chemotherapy will be identified within the genitourinary oncology service clinics and offered inclusion in the trial.
3163974|NCT01453660||Surgery-Only Group|GCT patients who have been treated with surgery and who do not require chemotherapy or radiation will be used as a comparison group to confirm that there is not a significant change in endothelial function among GCT patients treated with surgery alone.
3163975|NCT01453647|Experimental|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
3163976|NCT01453647|No Intervention|control|Participants in the control group will be instructed to maintain their FM treatment regimens as reported at baseline.
3163977|NCT01453634|Experimental|Lunacalcipol 180|180 µg (n=4)Lunacalcipol Injection
3163978|NCT01453634|Experimental|Lunacalcipol 270|270 µg (n=8)Lunacalcipol Injection
3163979|NCT01453621|Experimental|Clinical decision support (post-intervention phase)|Clinicians will receive computerized clinical decision support regarding the risk of clinically important traumatic brain injury (TBI) based on the prediction rules
3163980|NCT01453621|No Intervention|Standard care (pre-intervention phase)|Prior to implementation of the computerized clinical decision support, we will collect data to determine the baseline rate of CT use for children with minor blunt head trauma at very low risk of clinically-important traumatic brain injuries.
3163981|NCT01453608|Experimental|Ferinject (ferric carboxymaltose)|
3163982|NCT01453608|Placebo Comparator|Placebo (saline)|
3163983|NCT01453595|Experimental|BEZ235|"This is a single-institution, open label, single-arm Phase 1b/2 trial of BEZ235 in patients with advanced RCC. The study will be conducted in two phases:~Phase 1b: dose-escalation will be performed to determine the maximally tolerated dose (MTD) of twice daily BEZ235 to use in Phase 2 (RP2 dose).~Phase 2: subjects with clear cell who have experienced disease progression on prior first or second-line mTOR targeted therapy will be treated on the MTD of twice daily BEZ235."
3163984|NCT01453582|Experimental|Propolis|Total Flavonoids of Propolis dropping pill
3163985|NCT01453582|Placebo Comparator|Placebo|Simulant of total Flavonoids of Propolis dropping pill
3163986|NCT01453569|Experimental|sodium oligo-mannurarate 900mg|
3163987|NCT01453569|Experimental|sodium oligo-mannurarate 600mg|
3163988|NCT01453569|Placebo Comparator|Placebo|
3163989|NCT01453556|Experimental|Intracorpopreal anastomosis|Intracorporeal mechanical anastomosis
3163990|NCT01453556|Active Comparator|Extracorporeal anastomosis|Extracorporeal mechanical anastomosis
3163991|NCT01453543|Experimental|Deep transverse friction massage|Massage technique will be used.
3163992|NCT01453530|Active Comparator|Sugammadex|A single dose of sugammadex 2 mg/kg iv. Dose calculation will be based on the patient's actual body weight. No dose adjustments are allowed
3163993|NCT01453530|Active Comparator|Neostigmine/glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv. Dose calculation will be based on the patient's actual body weight. No dose adjustments are allowed.
3163994|NCT01453530|Placebo Comparator|No reversal agent|No treatment
3163995|NCT01453504|Active Comparator|Ever-DHAP|Combination of Everolimus and DHAP
3163996|NCT01453504|Placebo Comparator|Placebo-DHAP|
3163997|NCT01453491|Experimental|50mg SRT2104|Single oral administration of 50mg SRT2104 study drug will be supplied as 25 mg and 250 mg capsules and will be taken orally once daily for 56 days. SRT2104 is to be taken at approximately the same time every morning, in the fasted state. Water is permitted ad libitum. Subjects are allowed to consume liquids but should refrain from eating solid food for approximately 1 hour after dosing.
3163998|NCT01453491|Experimental|500mg SRT2104|Single oral administration of 500mg SRT2104 will be taken orally once daily for 56 days. SRT2104 is to be taken at approximately the same time every morning, in the fasted state. Water is permitted ad libitum. Subjects are allowed to consume liquids but should refrain from eating solid food for approximately 1 hour after dosing.
3163999|NCT01453478|Experimental|GSK1325756 Immediate Release 50 mg|Administered to volunteers in the fasted and fed states
3164000|NCT01453478|Experimental|GSK1325756 Bioenhanced Formulation 1 50 mg|Administered to volunteers in the fasted and/or fed states
3164001|NCT01453478|Experimental|GSK1325756 Bioenhanced Formulation 2 50 mg|Administered to volunteers in the fasted and/or fed states
3164002|NCT01453465||Ancillary-Correlative (gene expression profile, miRNA profile)|Archived tumor tissue samples are analyzed for gene expression profile and microRNA profile.
3164003|NCT01453452|Experimental|Exercise and Lifestyle counseling|Patients will receive behavioral dietary intervention & counseling intervention by phone, exercise intervention at Curves(R) facility, and take a quality-of-life assessment online.
3164008|NCT01453426|Experimental|Japanese Subjects - Dose 1 BG00012|
3164009|NCT01453426|Experimental|Japanese Subjects - Dose 2 BG00012|
3164010|NCT01453426|Experimental|Caucasian Subjects - Dose 1 BG00012|
3164011|NCT01453426|Experimental|Caucasian Subjects - Dose 2 BG00012|
3164012|NCT01453413|Other|People with type 2 diabetes|People with type 2 diabetes who were in attendance at a diabetes conference were asked for their perceived Blood Glucose (BG) value. Then, after staff measured BG on a Blood Glucose meter, subjects were informed of their BG value.
3164013|NCT01453400|Experimental|Arm 1|
3164014|NCT01453400|Active Comparator|Arm 2|
3164015|NCT01453400|Placebo Comparator|Arm 3|
3164016|NCT01453387|Experimental|Part 1 - MSC2015103B (Schedule 1)|
3164017|NCT01453387|Experimental|Part 1 - MSC2015103B (Schedule 2)|
3164018|NCT01453374|Experimental|VIVITROL|380 mg IM injection
3164019|NCT01453361|Experimental|Vigil™ Vaccine|Autologous Vigil™ vaccine will be supplied by Gradalis, Inc. Patients will receive 1 x 10e7 cells via intradermal injection one day each month for a minimum maximum of 12 doses as long as subject is clinically stable.
3164020|NCT01453348|Active Comparator|Group 1|This group will receive Inactivated hepatitis A and recombinant hepatitis B or 'Combined inactivated hepatitis A & recombinant hepatitis B vaccine' alone on the different visits.
3164021|NCT01453348|Active Comparator|Group 2|This group will receive Inactivated hepatitis A vaccine and recombinant hepatitis B Vaccine or 'Combined inactivated hepatitis A & recombinant hepatitis B vaccine' concomitantly with MenACWY-CRM.
3164022|NCT01453348|Active Comparator|Group 3|This group will receive only MenACWY-CRM.
3164023|NCT01453309|Active Comparator|Cell Saver|Patients will have the use of a cell-saver during surgery
3164024|NCT01453309|Placebo Comparator|No Cell saver|Patient will not have cell saver available during surgery.
3164025|NCT01453296|Active Comparator|COHORT 1 (RANDOMISATION AB or BA)|"8-11 years old; Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence.~Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home).~Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods."
3164026|NCT01453296|Active Comparator|COHORT 2 (RANDOMISATION AB or BA)|"5-7 years old. Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence.~Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home).~Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods."
3164027|NCT01453270|Experimental|NICOM and PLR|A systematic approach to resuscitation started in the ED and using a step-wise approach to optimize cardiac preload, afterload, and contractility, thus optimizing oxygen delivery to the tissues will be applied to the intervention group using the Non-Invasive Cardiac Output Monitor (NICOM) and passive leg-raising (PLR) maneuver.
3164028|NCT01453270|Active Comparator|Usual care|
3164029|NCT01453257|Experimental|Chemotherapy treatment|Tailored chemotherapy by Therapeutic Targets
3164030|NCT01453244||SVR group|A patients who achieved SVR (sustained virologic response)
3164031|NCT01453244||non-SVR group|A patients who not achieved SVR (sustained virologic response)
3164032|NCT01453231|No Intervention|Control|No surgery
3164033|NCT01453231|Experimental|thighplasty|
3164034|NCT01453218|No Intervention|Basiliximab|Historical comparable cohort treated with Basiliximab 20mg iv administered at 0 and 4th day post-transplant
3164035|NCT01453218|Active Comparator|ATeGe-Fresenius|
3164036|NCT01453205|Active Comparator|Rituximab+ ICE/DHAP|Participants will receive Rituximab in combination with ifosfamide + carboplatin + etoposide (ICE) or dexamethasone + cisplatin + cytarabine (DHAP) for 3 cycles (21-day cycles) and will followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). Rituximab (375 mg/m^2) will be administered intravenous (IV) on 2 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of rituximab, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of rituximab, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
3164037|NCT01453205|Experimental|MEDI-551 2 mg/kg + ICE/DHAP|Participants will receive MEDI-551 (2 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (2 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
3164038|NCT01453205|Experimental|MEDI-551 4 mg/kg + ICE/DHAP|Participants will receive MEDI-551 (4 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (4 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
3164234|NCT01451957|Experimental|Exercise|90 min exercise on Day 1
3164039|NCT01453192|Experimental|Raltegravir|Raltegravir associated to an antiretroviral regimen without ritonavir boosted antiprotease
3164040|NCT01453179|Experimental|Aldara 5% Cream|
3164041|NCT01453179|Active Comparator|Solaraze 3% Gel|
3164042|NCT01453166|Experimental|Group 1|Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
3164043|NCT01453166|Experimental|Group 2|Group B received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions
3164044|NCT01453166|Experimental|Group 3|Group C received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
3164045|NCT01453153|Active Comparator|Gemcitabine|Gemcitabine + Placebo
3164046|NCT01453153|Experimental|PEGPH20|PEGPH20+Gemcitabine
3164047|NCT01453140|Experimental|Cyclophosphamide and Sirolimus|Patients will be treated in sequential cohorts of 5. In cohort A, the first 5 enrolled patients will be receive cyclophosphamide and sirolimus only
3164048|NCT01453140|Experimental|Low dose IL-2 with Cytoxan + Sirolimus|
3164049|NCT01453140|Experimental|Low dose IL-2, Vidaza, Cytoxan & Sirolimus|
3164050|NCT01453127|Experimental|Alzheimer's Disease|Alzheimer's Disease
3164051|NCT01453127|Experimental|Dementia with Lewy Bodies|Dementia with Lewy Bodies
3164052|NCT01453127|Experimental|Frontotemporal Dementia|Frontotemporal Dementia
3164053|NCT01453127|Experimental|Parkinson's Disease|Parkinson's Disease
3164054|NCT01453127|Experimental|Corticobasal Degeneration|Corticobasal Degeneration
3164055|NCT01453127|Experimental|Essential Tremor|Essential Tremor
3164056|NCT01453127|Experimental|Mild Cognitive Impairment|Mild Cognitive Impairment
3164057|NCT01453127|Experimental|REM sleep behavior disorder|REM sleep behavior disorder
3164058|NCT01453114|Experimental|Psychotherapy|Cognitive Behavioral Therapy
3164059|NCT01453101|Other|Fludarabine, Melphalan, Bortezomib|
3164060|NCT01453088|Active Comparator|Treatment A|"Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.~Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.~Dosing will be based on body surface area calculated using actual body weight~Stem cell infusion:~Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.~Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least)."
3164061|NCT01453088|Experimental|Treatment Arm B|"Bortezomib:~Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1."
3164062|NCT01453075|Experimental|Arm 1: valacyclovir|Assigned patients will take 1.5 mg po valacyclovir twice daily
3164063|NCT01453075|Placebo Comparator|Arm 2: placebo|Assigned patients will receiving matching placebo twice daily
3164064|NCT01453062||Patients with a diagnosis of CLL|Patients with a diagnosis of CLL
3164065|NCT01453049|Experimental|fix dose of rosiglitazone/glimepiride|4mg/1mg, 4mg/2mg, 4mg/4mg
3164066|NCT01453049|Active Comparator|glimepiride|1mg, 2mg, 4mg
3164067|NCT01453036|Active Comparator|Conventional AOC group|The investigators do not perform mutation test in the conventional group apply amoxicillin 1 g, bid , rabeprazole 20 mg bid, clarithromycin 500 mg bid during 1weeks
3164068|NCT01453036|Active Comparator|Mutation test group|Mutation test group is composed of two groups, clarithromycin group and metronidazole group Clarithromycin subgroup ; no point mutation at 23S rRNA apply clarithromycin 500 mg bid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week Metronidazole subgroup ; point mutation at 23S rRNA apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week
3164069|NCT01453036|Active Comparator|Conventional AOM group|The investigators do not perform mutation test in the conventional group apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week
3164070|NCT01453023|Active Comparator|Fluticasone Furoate|One of two study treatments subjects will receive. Given to allow comparison of FF exposure in combination versus as mono therapy.
3164071|NCT01453023|Experimental|Fluticasone Furoate/Vilanterol|One of two study treatments subjects will receive. FF/VI combined is being tested and compared to fluticasone furoate.
3164072|NCT01453010|Experimental|8 individual case reviews|SaeboFlex Self-directed training
3164073|NCT01452997|Active Comparator|Ibuprofen Gel|Ibuprofen 5% gel
3164074|NCT01452997|Placebo Comparator|Ibuprofen placebo|K-Y jelly
3164075|NCT01452997|Active Comparator|Eumovate|0.05% w/w clobetasone butyrate
3164076|NCT01452997|Placebo Comparator|Cream Placebo|Aqueous Cream B.P.
3164077|NCT01452984||Single Retrospective Interviews|Each retrospective interview will be conducted by the Principal Investigator and/or Project Manager to collect denmographic information and experiential narratives from the patient, using open-ended questions and structured probes based on individual responses. Retrospective interviews will be recorded and scheduled at the patients' convenience either in the clinic, at the home, or at a place that is convenient to them.
3164078|NCT01452984||Prospective Observations|Prospective Observations of clinic visits will be combined with informal interview to document conversations with their treating physicians about concerns emerging from appearance, function, and other factors that may impinge on clinical decision making and experience including quality of life. The Project Manager will be present for the clinical visit during which the Mohs surgery takes place and record field observations as well as informal interview notes in a notebook.
3164079|NCT01452958|Experimental|TNF-α|Beromun, Boehringer-Ingelheim, Germany
3164080|NCT01452958|Experimental|Endotoxin|
3164081|NCT01452932|Experimental|Physiotherapy|Group of participants who recive physiotherapy treatment using Kabat technique for the upper limbs resistance training during 12 weeks
3164082|NCT01452932|Other|Yoga|Group of participants who recive Yoga sessions during 12 weeks
3164083|NCT01452919|Experimental|LY2140023/LY2140023|"Open label phase: 40 milligram (mg) LY2140023 administered orally; given twice daily for up to 4 weeks. At the discretion of the investigator, dose may be adjusted one time to 80 mg. 80 mg dose may be adjusted back to 40 mg one time. Current dose level at randomization will remain constant through the double blind phase.~Double blind phase: 40 mg or 80 mg LY2140023 administered orally; given twice daily for up to 3 weeks."
3164084|NCT01452919|Placebo Comparator|LY2140023/Placebo|"Open label phase: 40 mg LY2140023 administered orally; given twice daily for up to 4 weeks. At the discretion of the investigator, dose may be adjusted one time to 80 mg. 80 mg dose may be adjusted back to 40 mg one time.~Double blind phase: placebo administered orally; given twice daily for up to 3 weeks."
3164085|NCT01452906|Experimental|PA21 and Omeprazole with food|
3164086|NCT01452906|Experimental|No PA21; Omeprazole with food|
3164087|NCT01452906|Experimental|PA21 with food, Omeprazole 2 hrs later|
3164088|NCT01452893||Type I diabetes|Adult patients with diabetes mellitus type I but normal adrenal function
3164089|NCT01452893||Addison's disease|Adult patients with Addison's disease
3164090|NCT01452893||Type I diabetes and Addison's disease|Patients suffering from both, diabetes mellitus type I and Addison's disease
3164091|NCT01452893||healthy controls|healthy controls with normal adrenal function and normal glucose regulation
3164092|NCT01452867|Active Comparator|Bag-Mask-Ventilation|Bag-Valve Mask-Ventilation in 50 patients in general anesthesia
3164093|NCT01452867|Active Comparator|Laryngeal Mask Ventilation|Laryngeal Mask Ventilation in 50 patients in general anesthesia
3164094|NCT01452867|Active Comparator|Laryngeal Tube Ventilation|Laryngeal Tube Ventilation in 50 patients in general anesthesia
3164095|NCT01452854||Cancer|The study cohort will include adult women of childbearing potential with a diagnosis of low grade glioma (WHO grade II) who are being treated with low doses of Temozolomide (Temodar).
3164096|NCT01452841|Experimental|Grapefruit Consumption|
3164097|NCT01452841|Active Comparator|Control|
3164098|NCT01452828|Experimental|Renal Impairment Nondialyzed|
3164099|NCT01452828|Experimental|Renal Impairment Dialyzed|
3164100|NCT01452828|Experimental|Matched Control|
3164101|NCT01452815|Placebo Comparator|1|Drug: placebo
3164102|NCT01452815|Experimental|2|10mg TZP-102
3164103|NCT01452815|Experimental|3|20mg TZP-102
3164104|NCT01452802||HM II (HeartMate II LVAD)|Subjects who elect to, and receive HM II LVAD therapy at baseline
3164105|NCT01452802||OMM (Optimal Medical Management)|Subjects who elect to remain on optimal medical management
3164106|NCT01452789|Experimental|sublingual buprenorphine|
3164107|NCT01452789|Active Comparator|oral morphine|
3164108|NCT01452776|Experimental|TAK-438 10 mg QD|
3164109|NCT01452776|Experimental|TAK-438 20 mg QD|
3164110|NCT01452763|Experimental|TAK-438 10 mg QD|
3164111|NCT01452763|Experimental|TAK-438 20 mg QD|
3164112|NCT01452763|Active Comparator|Lansoprazole 15 mg QD|
3164113|NCT01452750|Experimental|TAK-438 10 mg QD|
3164114|NCT01452750|Experimental|TAK-438 20 mg QD|
3164115|NCT01452750|Active Comparator|Lansoprazole 15 mg QD|
3164116|NCT01452737|Experimental|2L Golytely/15mg bisacodyl|Subjects will be asked to take 2L Golytely + 15mg bisacodyl for bowel prep the day before colonoscopy.
3164117|NCT01452737|Active Comparator|Standard bowel prep|Subject will receive standard bowel prep (4L Golytely) prior to colonoscopy.
3164118|NCT01452724|Experimental|TAK-438 20 mg QD|
3164119|NCT01452724|Active Comparator|Lansoprazole 30 mg QD|
3164120|NCT01452711|Experimental|TAK-438 20 mg QD|
3164121|NCT01452711|Active Comparator|Lansoprazole 30 mg QD|
3164122|NCT01452698|Experimental|TAK-438 20 mg QD|
3164123|NCT01452698|Active Comparator|AG-1749 30 mg QD|
3164124|NCT01452685|Placebo Comparator|Placebo|
3164125|NCT01452685|Experimental|TAK-385 10 mg QD|
3164126|NCT01452685|Experimental|TAK-385 20 mg QD|
3164127|NCT01452685|Experimental|TAK-385 40 mg QD|
3164128|NCT01452685|Other|Leuplin|
3164129|NCT01452672|Active Comparator|RT to chest wall and S/C|Irradiation of the chest-wall and supraclavicular fossa
3164130|NCT01452672|Experimental|RT to chest wall|Irradiation of the chest-wall alone
3164131|NCT01452659|Experimental|TAK-385 10 mg QD|
3164132|NCT01452659|Experimental|TAK-385 20 mg QD|
3164133|NCT01452659|Experimental|TAK-385 40 mg QD|
3164134|NCT01452659|Placebo Comparator|Placebo|
3164135|NCT01452646|Experimental|MRD-directed therapy|
3164136|NCT01452633|Placebo Comparator|Preincision Placebo|This group of patients will receive saline injection at study port site before incision
3164137|NCT01452633|Active Comparator|Preincision Marcaine|This group will receive marcaine injection at the study port site prior to incision
3164138|NCT01452633|Placebo Comparator|Postincision Placebo|This group of patients will receive preincisional marcaine and then saline injection at study port site prior to closure
3164139|NCT01452633|Active Comparator|Postincision marcaine|This group will receive preincisional marcaine and then marcaine injection at study port site prior to closure
3164140|NCT01452620||EVAR cohort|All consecutive patients undergoing endovascular AAA repair (EVAR) in our community setting were followed for outcomes.
3164141|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x1|Lowest Dose Evaluated, 200mg Ebselen Total, Delivered as a Single Dose
3164142|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x2|2x Lowest Dose Evaluated, 400mg Ebselen Total, Delivered as a Single Dose
3164143|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x4|4x Lowest Dose Evaluated, 800mg Ebselen Total, Delivered as a Single Dose
3164144|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x8|8x Lowest Dose Evaluated, 1600mg Ebselen Total, Delivered as a Single Dose
3164145|NCT01452607|Placebo Comparator|SPI-1000 Capsule 0 mg Ebselen Placebo|Matching Placebo Capsule, 0mg Ebselen Total, Delivered as a Single Dose
3164146|NCT01452594||Diphenylcyclopropenone|topical gel administration to skin
3164147|NCT01452581|Active Comparator|RBC transfusion|"Administration of up to 2 RBC units on the first postoperative day.~(1 unit at a time followed by evaluation of the primary outcome measure)"
3164148|NCT01452581|Placebo Comparator|Restrictive: Colloid infusion|Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
3164149|NCT01452568|Experimental|Aspirin|Aspirin 150mg daily, starting day 1 after surgery, for three months.
3164150|NCT01452568|Active Comparator|Warfarin|Warfarin daily dosage to International normalized ratio(INR) value between 2,0 to 3,0.
3164151|NCT01452555|Active Comparator|In Person Counseling|Participants will receive an in person HIV and HIV testing counseling session
3164152|NCT01452555|Experimental|Video Presentation|Participants will watch an HIV and HIV testing video
3164153|NCT01452542|Experimental|Sequence 1|Participants will receive a single oral dose of the following two study treatments under fasting conditions, in accordance with a randomly allocated treatment sequence: three 50-mg Phase 3 capsules of eliglustat (Reference Treatment [R]) or one 150-mg common blend capsule of eliglustat (Test Treatment [T]) according to the following treatment sequence: TRTR, with a 7-day washout between dosing in each period.
3164154|NCT01452542|Experimental|Sequence 2|Participants will receive a single oral dose of the following two study treatments under fasting conditions, in accordance with a randomly allocated treatment sequence: three 50-mg Phase 3 capsules of eliglustat (Reference Treatment [R]) or one 150-mg common blend capsule of eliglustat (Test Treatment [T]) according to the following treatment sequence: RTRT, with a 7-day washout between dosing in each period.
3164155|NCT01452529|Experimental|Hydrocodone bitartrate|Hydrocodone bitartrate (HYD) once daily (q24h) tablets
3164156|NCT01452529|Placebo Comparator|Placebo|Placebo to match hydrocodone bitartrate once daily tablets
3164157|NCT01452516|Other|nanOss Bioactive Bone void filler|Lumbar fusion using interbody cages with autograft in conjunction with instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
3164158|NCT01452503|Active Comparator|PATH Women's Condom|PATH Women's Condom
3164159|NCT01452503|Active Comparator|FC2 female condom|Female Health Company's FC2 female condom
3164160|NCT01452503|Active Comparator|Reddy 6 female condom (V-Amour)|Reddy 6 female condom (Commercially known as the V-Amour female condom)
3164161|NCT01452490|Experimental|Diode Laser Treatment|
3164162|NCT01452477|Active Comparator|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
3164163|NCT01452477|Placebo Comparator|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
3164164|NCT01452464||MenACYW-CRM vaccinated adolescents|All adolescent recipients of MenACYW-CRM vaccines during the study period. Among these, adolescents who have additionally experienced an event of interest within the 1-year observation period following vaccination will be included in the self-controlled case series.
3164165|NCT01452451|Placebo Comparator|Placebo|Placebo
3164166|NCT01452451|Active Comparator|HM11260C|HM11260C
3164167|NCT01452438||MenACYW-CRM vaccinated children|All children between the age of 2 to 10 years old who have received of MenACYW-CRM vaccine during the study period.
3164168|NCT01452425|Experimental|Tourniquet|Inflation of a tourniquet
3164169|NCT01452412|Experimental|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
3164170|NCT01452412|Placebo Comparator|Placebo|placebo dosage/frequency equivalent to sodium bicarbonate
3164171|NCT01452399|Experimental|Shave Margins|
3164172|NCT01452399|Active Comparator|No shave margins|
3164173|NCT01452386||Experimental Group|
3164174|NCT01452386||Control Group|
3164175|NCT01452373|Placebo Comparator|Control (placebo)|
3164176|NCT01452373|Experimental|DHEA + Acolbifene|
3164177|NCT01452360||Collection of CKD patient group|
3164178|NCT01452360||Collection of CKD high-risk group|
3164179|NCT01452360||Collection of healthy control group|
3164180|NCT01452347|Experimental|Dabigatran etexilate|Patient dose dependent on screening CrCl levels and TT
3164181|NCT01452347|Active Comparator|warfarin|warfarin doses to maintain INR levels
3164182|NCT01452334|Experimental|Arm 1: BMS-936559|
3164183|NCT01452321|Placebo Comparator|Sham rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of sham (placebo) rTMS delivered to the left dorsolateral prefrontal cortex.
3164184|NCT01452321|Active Comparator|Active rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of active rTMS delivered to the left dorsolateral prefrontal cortex.
3164185|NCT01452308|Experimental|Cohort 1|Participants will receive simtuzumab at a dose of 10 mg/kg by intravenous (IV) infusion every other week for a total of 3 infusions.
3164186|NCT01452308|Experimental|Cohort 2|Participants will receive simtuzumab IV every other week for a total of 3 infusions. The dose will depend on the safety and tolerability of simtuzumab seen in Cohort 1 but will not exceed 20 mg/kg.
3164187|NCT01452295|Experimental|AOCH patients|Patients with acute on chronic hepatitis
3164188|NCT01452295|Experimental|AAH patients|Patients with acute alcoholic hepatitis
3164189|NCT01452282||Ankle Brachial Index|
3164190|NCT01452269|Experimental|Immediate intervention group|This arm will receive the intervention immediately following baseline data collection.
3164191|NCT01452269|Experimental|Delayed intervention group|This arm will receive the intervention one year following the immediate intervention group.
3164192|NCT01452256|Experimental|Desflurane|Desflurane for pharmacological conditioning
3164193|NCT01452256|Experimental|Propofol|
3164591|NCT01449565|Active Comparator|Naltrexone|
3164194|NCT01452243|Experimental|Calcium and vitamin D|The pharmacological intervention will be the daily administration of chewable tablets containing vitamin D and calcium.
3164195|NCT01452230|Experimental|Supervised physical activity|
3164196|NCT01452230|No Intervention|Usual care|
3164197|NCT01452217|Experimental|Secretin|
3164198|NCT01452204|Experimental|Pulsed Electromagnetical Field|
3164199|NCT01452204|Placebo Comparator|Placebo|
3164200|NCT01452191|Active Comparator|Injury Prevention Briefing and facilitation|Children's Centres will be given an Injury Prevention Briefing which offers guidance on best evidence on reducing fire related injuries in the home, and facilitation by the research team to support implementation of the IPB
3164201|NCT01452191|Active Comparator|Injury Prevention Briefing only|Children's Centres will be given an Injury Prevention Briefing (IPB) , which offers guidance on best evidence on reducing fire related injuries in the home.
3164202|NCT01452191|No Intervention|Usual Care|
3164203|NCT01452152|Experimental|Genotype-directed, clopidogrel|Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.
3164204|NCT01452152|Experimental|Genotype-directed, prasugrel|Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.
3164205|NCT01452152|No Intervention|Standard of Care|Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.
3164206|NCT01452139|Experimental|At-Risk Genetics Arm: Prasugrel|Treatment of STEMI patients carrying at least 1 at-risk genetic variant with prasugrel 10mg daily for 1 month.
3164207|NCT01452139|Active Comparator|At-Risk Genetics Arm: Clopidogrel|Treatment of STEMI patients carrying at least 1 at-risk genetic variant with clopidogrel 150mg daily for 1 week followed by 75mg daily.
3164208|NCT01452139|Active Comparator|Low Risk Genetics Arm: Clopidogrel|Treatment of STEMI patients with no at-risk genetic variants with clopidogrel 75mg daily.
3164209|NCT01452126|Experimental|Ropivacaine|Sequential allocation of ropivacaine concentration depending on the success or failure of surgical anesthesia of the previous patient
3164210|NCT01452113|Other|neuropathy|patients with autonomic neuropathy
3164211|NCT01452113|Other|control|patients without autonomic neuropathy (ewing score <= 0.5)
3164212|NCT01452100|Experimental|prednisone|• Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
3164213|NCT01452100|Placebo Comparator|placebo|Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
3164214|NCT01452087|Other|Exercise Session|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
3164215|NCT01452074|Other|Exercise Training with Weight Loss|"During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, ~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week~After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight"
3164216|NCT01452061||ASD|Participants with autism spectrum disorder.
3164217|NCT01452061||ADHD/DD|Participants with attention deficit/hyperactivity disorder, developmental delay or psychiatric disorder.
3164218|NCT01452061||Siblings|Siblings without a developmental or psychiatric disorder.
3164219|NCT01452061||Control|Unrelated individuals without a developmental or psychiatric disorder.
3164220|NCT01452048||Obese Sedentary Adults, but otherwise healthy|
3164221|NCT01452035|Experimental|Exercise|
3164222|NCT01452035|No Intervention|Sedentary Control|
3164223|NCT01452022|Experimental|Inductigraft|open label non randomised to assess performance of synthetic bone graft using the product, Inductigraft, in posterolateral lumbar fusion
3164224|NCT01452009|Experimental|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|
3164225|NCT01452009|Active Comparator|TRAVATAN®|TRAVATAN® administered one drop once daily
3164226|NCT01451996|Other|Claritin ads|Subject will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
3164227|NCT01451996|Other|Zyrtec ads|Subject will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
3164228|NCT01451983||ASD with PTEN|Individuals with autism spectrum disorder who are also found to have a PTEN mutation.
3164229|NCT01451983||ASD no PTEN macrocephaly|Individuals with autism spectrum disorder who do not have a PTEN mutation with a large head circumference.
3164230|NCT01451983||ASD no PTEN no macrocephaly|Individuals with autism spectrum disorder who do not have a PTEN mutation without a large head circumference.
3164231|NCT01451983||Siblings|Siblings of individuals with autism spectrum disorders.
3164232|NCT01451970|Other|High Monounsaturated Fat Diet|Subjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated.
3164233|NCT01451970|Other|High Saturated Fat Diet|Subjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
3164235|NCT01451957|Experimental|Sedentary Control|Subjects remain sedentary on Day 1 and will either consume a hyper-caloric or a caloric balanced diet
3164236|NCT01451944|Experimental|asthma education and case management|asthma education and case management
3164237|NCT01451931|Experimental|Point-of-care Ultrasound|Patient with suspected urolithiasis will receive ultrasonography performed in the emergency department. Perform ultrasonography in the ED (physician).
3164238|NCT01451931|Experimental|Radiology Ultrasound|Patient with suspected urolithiasis will receive diagnostic ultrasonography in the radiology department. Diagnostic ultrasound completed in the radiology department at time 0.
3164239|NCT01451931|Experimental|Radiology CT|Patient with suspected urolithiasis will receive computed tomography in the radiology department. Computed tomography of abdomen completed in the radiology department at time 0.
3164240|NCT01451918|Active Comparator|Resveratrol|
3164241|NCT01451918|Placebo Comparator|Placebo|
3164242|NCT01451905|Active Comparator|Psoriasis|
3164243|NCT01451905|Placebo Comparator|Placebo|
3164244|NCT01451892|Experimental|Dance therapy|overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
3164245|NCT01451892|Active Comparator|Education|overweight individuals participating in a patient education ambulatory program for obese people
3164246|NCT01451879||Age 0 months to 65 years|Confirmed diagnosis of Pompe Disease, and clinically prescribed immune modulation regimen with agents such as rituximab, sirolimus, methotrexate, IVIg or other immunomodulatory agents such as pharmacological chaperone Miglustat, N-butyldeoxynojirimycin (NB-DNJ), alone or in combination, at the discretion of their primary/specialist caregiver.
3164247|NCT01451866|Active Comparator|classic leg-press training|Classic resistance training on the dynamic leg press. 6 x 8 repetitions at 60% 1 RM
3164248|NCT01451866|Experimental|Complex leg-press training|Complex leg-press training with visual feed-back on a dynamic leg-press.
3164249|NCT01451853|Active Comparator|SPI-1005 Low Dose|200 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
3164250|NCT01451853|Active Comparator|SPI-1005 Middle Dose|400 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
3164251|NCT01451853|Active Comparator|SPI-1005 High Dose|600 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
3164252|NCT01451853|Placebo Comparator|Placebo|0 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
3164253|NCT01451840|Active Comparator|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of intravenous remifentanil before emergence of a desflurane-based anesthesia
3164254|NCT01451840|Experimental|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
3164255|NCT01451827|Experimental|Tolvaptan MR 50 mg|Tolvaptan MR 50 mg capsule and 2 placebo IR tablets ( 8 AM) and 1 placebo IR tablet (4 PM) daily.
3164256|NCT01451827|Experimental|Tolvaptan MR 80 mg|Tolvaptan MR 80 mg capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
3164257|NCT01451827|Experimental|Tolvaptan IR 60/30 mg|Two tolvaptan IR 30-mg tablets and 1 placebo MR capsule (8 AM) and 1 tolvaptan IR 30-mg tablet (4 PM) daily.
3164258|NCT01451827|Placebo Comparator|Placebo|Placebo MR capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
3164259|NCT01451814|Experimental|Positive psychotherapy|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
3164260|NCT01451814|Active Comparator|Standard treatment|6 sessions of individual behavioral smoking cessation counseling with 8 weeks of transdermal nicotine patch. Inlcudes relaxation training to match time in the experimental condition
3164261|NCT01451801|Other|HBsAg|
3164262|NCT01451788|No Intervention|Conventional group|conventional blood saving methods (use of bone wax for cancellous bony bleeding; bipolar diathermy and epidural space packing for epidural venous bleeding)
3164263|NCT01451788|Experimental|Floseal|Gelatin matrix with human derived thrombin (Floseal) used in adolescents undergoing posterior spinal deformity surgery for adolescent idiopathic scoliosis (AIS)
3164264|NCT01451775|Experimental|Treatment A|high dose of empagliflozin after overnight fasting for at least 10 h
3164265|NCT01451775|Experimental|Treatment B|high dose of empagliflozin after a standardised high fat breakfast
3164266|NCT01451775|Experimental|Treatment C|low dose empagliflozin after overnight fasting for at least 10 h
3164267|NCT01451762|Placebo Comparator|Placebo|.9 normal saline IV
3164268|NCT01451762|Active Comparator|25 mg diphenhydramine IV|25 mg diphenhydramine IV administered before surgery
3164269|NCT01451762|Active Comparator|50 mg diphenhydramine IV|50 mg diphenhydramine IV administered before surgery
3164270|NCT01451749|Experimental|Shenwu Capsule|"Shenwu Capsule:1 capsule contains 451 mg of Shenwu extracts. 5 capsules/time, 3 times/day for 6 months.~Placebo: Placebo identical to donepezil tablets,1 placebo tablet/time, 1 time/day for 6 months."
3164271|NCT01451749|Active Comparator|Donepezil|"Donepezil: 1 tablet contains 5 mg of donepezil, 1 tablet/time, 1time/day for 6 months.~Placebo: Placebo identical to shenwu capsules,5 placebo capsules/time,3 times/day for 6 months"
3164272|NCT01451736|Experimental|paliperidone palmitate (Invega Sustenna)|Participants will be provided paliperidone palmitate (Invega Sustenna), administered in injectible long-acting form, plus group skills training and case management
3164273|NCT01451736|Active Comparator|oral risperidone|Participants will be provided oral risperidone, plus group skills training and case management
3164274|NCT01451723|Experimental|Polyphenon E 400mg twice a day|Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.
3164275|NCT01451723|Placebo Comparator|Placebo|Matching placebo capsules.
3164276|NCT01451710|Experimental|Prednisone or Prednisolone|
3164315|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 170 mg BID|Participants received MK-8242 170 mg BID monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 170 mg was administered QD in the morning) in Part 1 Arm A.
3164316|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 210 mg BID|Participants received MK-8242 210 mg BID monotherapy on Days 1-7 of a 21-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 210 mg was administered QD in the morning) in Part 1 Arm A.
3164277|NCT01451697|Experimental|Experimental: Cognitive Remediation|The remediation intervention will consist of a sequence of computerized cognitive exercises designed to improve a variety of aspects of attention, through repeated drill-and-practice (Bell, Bryson, Greig, Corcoran, & Wexler, 2001; Bracy, 1995; Kurtz et al., 2007). Exercises will be started and continued at the highest level of difficulty, in order to best establish improvement over time. Components of the planned intervention produce performance gains on practiced tasks (e.g., Wexler et al., 1997) and generalization of improvement to other tasks (Kurtz et al., 2007). All training on computer exercises will be conducted with coaching from staff trained in these procedures.
3164278|NCT01451697|Placebo Comparator|Control (Placebo)|The placebo control condition will consist of structured relaxation training, which will involve viewing and participating with meditation and stress-reduction DVDs, and listening to and following a CD of Progressive Muscle Relaxation. Participants will benefit from learning stress reduction techniques in this condition, but will not exercise any of the cognitive domains of interest targeted in the treatment group.
3164279|NCT01451658|No Intervention|EVL or GVS treatment|"Endoscopic treatment alone is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.~endoscopic variceal ligation (EVL) or Gastric Variceal Sclerotherapy (GVS)"
3164280|NCT01451658|No Intervention|Endoscopic treatment alone versus combined propranolol|Endoscopic treatment alone versus combined propranolol is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.
3164281|NCT01451645|Other|placebo|daily placebo dosing for 16 weeks with background allopurinol therapy
3164282|NCT01451645|Active Comparator|Colchicine (Colcrys®)|daily 0.6 mg colchicine dosing for 16 weeks with background allopurinol therapy
3164283|NCT01451632|Experimental|Part 1: MM-121 + cetuximab|increasing doses of weekly MM-121 + weekly cetuximab
3164284|NCT01451632|Experimental|Part 2: MM-121 + cetuximab + irinotecan|increasing doses of irinotecan + the Recommended Phase 2 Dose/Maximum Tolerated Dose (RP2D/MTD) of MM121 + cetuximab as determined in Part 1
3164285|NCT01451619|Experimental|Laropiprant|
3164286|NCT01451619|Placebo Comparator|Placebo|
3164287|NCT01451606|Placebo Comparator|Placebo pill|A pill that looks like the active drug, but does not contain any active ingredients.
3164288|NCT01451606|Active Comparator|Duloxetine|The drug, Duloxetine, is marketed under the trade name Cymbalta. It is a serotonergic and noradrenergic reuptake inhibitor (SNRI).
3164289|NCT01451593|Experimental|phenytoin|active arm of trial 1:1 allocation active versus placebo
3164290|NCT01451593|Placebo Comparator|placebo|1:1 allocation active versus placebo
3164291|NCT01451554|Active Comparator|Portion Control Intervention|Individuals will be given a portion control plate and dietary counseling
3164292|NCT01451554|Placebo Comparator|Usual Care|Provided with self-help booklets on diet and exercise.
3164293|NCT01451541|Active Comparator|ciclesonide nasal aerosol 37mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37mcg once daily
3164294|NCT01451541|Active Comparator|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg once daily
3164295|NCT01451541|Placebo Comparator|Placebo|
3164296|NCT01451528|Experimental|Allogeneic Umbilical Cord Blood|Allogeneic Umbilical Cord Blood Transplantation
3164297|NCT01451515|Experimental|Treatment|"Patients will undergo treatment as described in the intervention section. Interventions include:~Remission induction: prednisone, vincristine, daunorubicin, PEG-asparaginase (or Erwinia asparaginase), IT-MHA (Methotrexate, hydrocortisone, and cytarabine), cyclophosphamide, cytarabine, thioguanine~Consolidation: PEG-asparaginase, High-dose methotrexate (HD-MTX), mercaptopurine~Postremission continuation: Dexamethasone, doxorubicin, vincristine, mercaptopurine, PEG-asparaginase, cyclophosphamide, cytarabine~Reintensification: dexamethasone, cytarabine, etoposide, PEG-asparaginase, clofarabine, cyclophosphamide~All patients receive IT-MHA on days 1 and 15. Some patients also receive additional IT-MHA on days 8 and 22."
3164298|NCT01451502|Experimental|Unlicensed Umbilical Cord Blood Infusion|"All patients will be registered in OnCore under this protocol as well as the specific treatment protocol.~Pre-infusion treatment using intravenous hydration, acetaminophen and diphenhydramine hydrochloride~Unlicensed Umbilical Cord Blood Infusion according to institutional guidelines.~Infusion of minimally manipulated unlicensed UCB units:~vital signs Monitoring during and after UCB infusion:~Management of infusion reactions~Post-transplant care and follow-up: will be done according to the disease specific treatment protocol and institutional guidelines."
3164299|NCT01451489|Active Comparator|Cyclophosphamide|CTX
3164300|NCT01451489|Experimental|FK506|0.05-0.1mg/kg/d;adjust the dose according the serum concentration(aim 5-10ng/ml),maximum dose 6mg/day;divided in twice, interval 12 hours.
3164301|NCT01451476||Healthy females aged >=18|Healthy female volunteers of skin type I or II
3164302|NCT01451450|Experimental|QGE031 A|
3164303|NCT01451450|Experimental|QGE031 B|
3164304|NCT01451450|Experimental|QGE031 C|
3164305|NCT01451450|Experimental|QGE031 D|
3164306|NCT01451450|Placebo Comparator|Placebo A|
3164307|NCT01451450|Placebo Comparator|Placebo B|
3164308|NCT01451450|Placebo Comparator|Placebo C|
3164309|NCT01451450|Placebo Comparator|Placebo D|
3164310|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 30 mg QD|Participants received MK-8242 30 mg once daily (QD) monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
3164311|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 60 mg QD|Participants received MK-8242 60 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
3164312|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 120 mg QD|Participants received MK-8242 120 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
3164313|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 250 mg QD|Participants received MK-8242 250 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
3164314|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 120 mg BID|Participants received MK-8242 120 mg twice daily (BID) monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 120 mg was administered QD in the morning) in Part 1 Arm A.
3164461|NCT01450293|No Intervention|Group C|5 to 12 months old infants; no vaccination
3164317|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 250 mg BID|Participants received MK-8242 250 mg BID monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 250 mg was administered QD in the morning) in Part 1 Arm A.
3164318|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 300 mg BID|Participants received MK-8242 300 mg BID monotherapy on Days 1-7 of a 21-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 300 mg was administered QD in the morning) in Part 1 Arm A.
3164319|NCT01451424|Experimental|Proellex 12 mg PK group|Subjects receiving 12 mg Proellex administered vaginally, and completing a PK arm consisting of 1 x 24 hr PK of Proellex, 14 days of daily Proellex trough measurements, and 1 x 24 hr PK of Proellex after 14 days of daily dosing. 12 mg PK subjects will continue with the protocol as written after the first 2 week period and will be treated for a total of 16 weeks.
3164320|NCT01451424|Experimental|Proellex 12 mg per protocol|Subjects receiving 12 mg Proellex daily, vaginally for 12 weeks
3164321|NCT01451424|Experimental|Proellex 6 mg per protocol|Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks
3164322|NCT01451424|Experimental|Proellex 3 mg per protocol|Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.
3164323|NCT01451424|Experimental|24 mg Proellex|24 mg vaginal Proellex daily for 16 weeks
3164324|NCT01451411|Experimental|Conivaptan hydrochloride|
3164325|NCT01451411|Placebo Comparator|Placebo|
3164326|NCT01451398|Experimental|TI inhalation powder|Technosphere® Insulin powder administered via the Gen2 inhaler added to 2 or more stable OADs
3164327|NCT01451398|Placebo Comparator|Technosphere powder|Technosphere powder (with no insulin) administered via the Gen2 inhaler added to 2 or more stable OADs
3164328|NCT01451385|Experimental|COV795|
3164329|NCT01451359|Experimental|endobronchial valve|The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
3164330|NCT01451346|Placebo Comparator|Placebo|Placebo sachets contained 5 grams of Maltodextrin only.
3164331|NCT01451346|Experimental|B Infantis 35624|Each 5gram freeze-dried powder contained ≥1*1010 Colony forming units (CFU) of B. infantis 35624/sachet.
3164332|NCT01451333|Experimental|Reduced dose Efavirenz arm|Patient's on main study that was randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
3164333|NCT01451333|Active Comparator|Normal Efavirenz dose arm|Patient's on main study randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
3164334|NCT01451320|Active Comparator|rapid streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
3164335|NCT01451320|Active Comparator|high dose tpa|5-hour infusion of 90 mg t-PA(Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
3164336|NCT01451320|Active Comparator|slow streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
3164337|NCT01451320|Active Comparator|half-dose slow infusion tpa|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
3164338|NCT01451320|Active Comparator|low dose slow infusion tpa|6-hour infusion of 25 mg t-PA(Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
3164339|NCT01451307||Gastrointestinal malformations|Children who underwent standardized neonatal pediatric surgery due to gastrointestinal malformations
3164340|NCT01451307||No gastrointestinal malformations|Control group of healthy children matched concerning gestational age, weight class and gender
3164341|NCT01451294|Active Comparator|Ephedrine|
3164342|NCT01451294|Active Comparator|Phenylephrine|
3164343|NCT01451268|Experimental|Panobinostat Arm A|
3164344|NCT01451268|Experimental|Panobinostat Arm B|
3164345|NCT01451242||brain injury|
3164346|NCT01451216||ABI 50-70 y|patients suffering from acquired brain injury aged 50-70 years old
3164347|NCT01451216||ABI 25-50y|Patients suffering from acquired brain injury aged 25-50 years oled
3164348|NCT01451203|Placebo Comparator|PBO + MTX|Participants who received placebo subcutaneously every two weeks (Q2W) at Weeks 0, 2, and 4; followed by placebo subcutaneously Q2W from Week 6 to Week 50 and an oral dose of MTX administered from Week 0 onwards
3164349|NCT01451203|Experimental|CZP + MTX|Participants who certolizumab pegol (CZP) subcutaneously at a loading dose of CZP 400 mg every 2 weeks (Q2W) at Weeks 0, 2, and 4; followed by a dose of CZP 200 mg subcutaneously Q2W from Week 6 to Week 50 and an oral dose of MTX administered from Week 0 onwards
3164350|NCT01451190|Experimental|Treated|
3164351|NCT01451177|Experimental|Treated|
3164352|NCT01451164|Experimental|High dose|
3164353|NCT01451164|Experimental|Mid dose|
3164354|NCT01451164|Experimental|Low dose|
3164355|NCT01451164|Placebo Comparator|Placebo|
3164356|NCT01451151|Experimental|Treated|
3164357|NCT01451138|Experimental|Treated|
3164358|NCT01451125|Experimental|Treated|
3164359|NCT01451112|Experimental|Treated|
3164360|NCT01451086|Experimental|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
3164361|NCT01451086|Active Comparator|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
3164362|NCT01451034|Active Comparator|WHYX cancer group|WHYX cancer diagnosed by pathologic report
3164363|NCT01451034|Placebo Comparator|non-WHYX cancer group|all cancer except WHYX cancer diagnosed by pathologic report
3164364|NCT01450995|Active Comparator|Treximet|
3164365|NCT01450995|Active Comparator|Imitrex and Aleve|
3164366|NCT01450982|Experimental|001|JNJ-38518168 / MTX Day 1: MTX: Route=oral use single dose of participant's weekly MTX dose Days 2-15: MTX: Route=oral use single dose of participant's weekly MTX dose and of JNJ-38518168 Type=exact unit=mg number=100 form=capsule route=oral use administered daily.
3164367|NCT01450969||Interventional Radiologists|All operators are Interventional Radiologists and co-investigators. Prior to start of the study, all operators are asked to provide written informed consent to participate in the study.
3164368|NCT01450956|Experimental|Sevoflurane|Patients will receive 2% sevoflurane via oxygenator during CPB
3164369|NCT01450956|No Intervention|Control|Patients will receive only oxygen and air through oxygenator
3164370|NCT01450943|Active Comparator|Standard of care|debridement, irrigation , PRIMARY dressing Adaptic and Iodosorb, SECONDARY dressing gauze and tape
3164371|NCT01450943|Experimental|Dermagraft|debridement, irrigation , PRIMARY dressing Dermagraft and Adaptic, SECONDARY dressing gauze and tape
3164372|NCT01450943|Experimental|Oasis|debridement, irrigation , PRIMARY dressing Oasis and Adaptic, SECONDARY dressing gauze and tape
3164373|NCT01450930|Active Comparator|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
3164374|NCT01450930|Active Comparator|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
3164375|NCT01450917||Group A|Brachial plexus injured patients with phrenic nerve dysfunction
3164376|NCT01450917||Group B|Brachial plexus injured patients without phrenic nerve dysfunction
3164377|NCT01450917||Group C|Non brachial plexus injured patients
3164378|NCT01450904|Experimental|Group A|The length of Quadriceps incision was less than 2 cm.
3164379|NCT01450904|Experimental|Group B|The length of Quadriceps incision was 2 to 4 cm.
3164380|NCT01450904|Experimental|Group C|The length of Quadriceps incision was more than 4 cm.
3164381|NCT01450891||total patient group|all new consecutive patients of the participating memory clinics who are suspected of having a primary neurodegenerative disease, meaning that all patients with subjective as well as objective memory complaints are included
3164382|NCT01450878|Experimental|Graft with EPO|intravenous 1000 000UI beta-epoietin one hour before organe retrieval.
3164383|NCT01450878|No Intervention|graft without EPO|no injection befoe organ retrieval
3164384|NCT01450865|Experimental|Placebo first|Volunteers receive placebo first and after a cross-over period of at least 7 days flupirtine second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention
3164385|NCT01450865|Experimental|Flupirtine first|Volunteers receive flupirtine first and after a cross-over period of at least 7 days placebo second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention
3164386|NCT01450852|Experimental|Strength Training|The strength training group completed 12 weeks of progressive, periodized resistance training 3d/wk.
3164387|NCT01450852|No Intervention|Active Control Group|The active control group was instructed to maintain normal activity and eating habits. They participated in all pre and post intervention measures.
3164388|NCT01450839|Experimental|E2020 5 mg tablet and tape|
3164389|NCT01450839|Placebo Comparator|2|
3164390|NCT01450826|Active Comparator|aprepitant+ondansetron|On day 1, patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide). Additionally, On days 1-5, patients receive a single dose of Ondansetron 30 minutes before the receiving their prescribed dose of 5-day oral temozolomide.
3164391|NCT01450826|Active Comparator|ondansetron|On days 1-5, patients receive a single dose of Ondansetron 30 minutes before the receiving their prescribed dose of 5-day oral temozolomide.
3164392|NCT01450813|Sham Comparator|Group 1|Saline 0.06 ml/kg
3164393|NCT01450813|Active Comparator|Group 2|Rocuronium 0.2 mg/kg
3164394|NCT01450813|Active Comparator|Group 3|Rocuronium 0.4 mg/kg
3164395|NCT01450813|Active Comparator|Group 4|Rocuronium 0.6 mg/kg
3164396|NCT01450800|Active Comparator|Nitrofurantoin|Nitrofurantoin 100mg by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
3164397|NCT01450800|Placebo Comparator|Placebo|Placebo drug 1 tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
3164398|NCT01450787||diabetics|diabetics
3164399|NCT01450787||non diabetics|non diabetics
3164400|NCT01450774|Experimental|CHF 1535 50/6µg|
3164401|NCT01450774|Active Comparator|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|
3164402|NCT01450761|Experimental|Ipilimumab+Etoposide+Cisplatin/Carboplatin|"Ipilimumab: IV solution, Intravenous (IV), 10 mg/kg, Once every 3 weeks for 4 doses, then every 12 weeks, Until progression of disease or unacceptable toxicity, or until the maximum treatment period of 3 years is reached~Etoposide: IV solution, IV, 100 mg/m2, Days 1-3 every 3 weeks, 4 cycles~Cisplatin: IV solution, IV, 75 mg/m2, Once every 3 weeks, 4 doses~Carboplatin: IV Solution, IV, Area Under the Curve (AUC) 5, Once every 3 weeks, 4 doses"
3164403|NCT01450761|Placebo Comparator|Placebo matching Ipilimumab+Etoposide+Cisplatin/Carboplatin|"Placebo matching Ipilimumab: IV solution, IV, 0 mg/kg, Once every 3 weeks for 4 doses, then every 12 weeks, Until progression of disease or unacceptable toxicity, or until the maximum treatment period of 3 years is reached~Etoposide: IV solution, IV, 100 mg/m2, Days 1-3 every 3 weeks, 4 cycles~Cisplatin: IV solution, IV, 75 mg/m2, Once every 3 weeks, 4 doses~Carboplatin: IV Solution, IV, Area Under the Curve (AUC) 5, Once every 3 weeks, 4 doses"
3164404|NCT01450748|Experimental|Sodium alginate|oral suspension, 50 mg/ml
3164405|NCT01450748|Placebo Comparator|Placebo|oral suspension without active ingredient
3164406|NCT01450722|Active Comparator|drug eluting stent|Paclitaxel eluting stent for long superficial femoral artery obstruction
3164407|NCT01450722|Active Comparator|bypass operation|femoropopliteal artery bypass operation by using synthetic PTFE graft
3164408|NCT01450709||Dialysis patients|
3164409|NCT01450696|Active Comparator|Capecitabine + Cisplatin + Herceptin (6 mg/kg)|Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 mg/kg q3w as a standard of care from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m^2 intravenously q3w plus capecitabine 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
3164462|NCT01450293|Experimental|Group D|10 week old babies; AdCh63 ME-TRAP, MVA ME-TRAP
3164592|NCT01449565|Placebo Comparator|Placebo|
3164410|NCT01450696|Experimental|Capecitabine + Cisplatin + Herceptin (10 mg/kg)|Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 10 mg/kg q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m^2 intravenously q3w plus capecitabine 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
3164411|NCT01450683|Experimental|Itraconazole|600 mg/day oral (PO)
3164412|NCT01450670||Dialysis patients|
3164413|NCT01450657||Chronic Kidney Failure 3/4|
3164414|NCT01450644|Other|Fast track|If patients are randomised to fast-track, their information will be passed to the H2H nurse to organise a case conference within one week of discharge.
3164415|NCT01450644|Other|Waiting list|If patients are in the control arm, they will continue to receive Standard Best Practice (SBP) and their data will be held by the researcher until after the second interview (4 weeks). After this time, they will be contacted by the H2H nurse to receive the intervention and will be interviewed and followed up as for the fast track group.
3164416|NCT01450631|Active Comparator|Standard Dressing|Standard-of-care includes coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™) consistent with the national standard for dressing Cesarean section incisions.
3164417|NCT01450631|Experimental|Prevena™ (PIMS)|PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period.
3164418|NCT01450618||Atazanavir|HIV patients on antiretroviral therapy using Atazanavir
3164419|NCT01450618||Darunavir|HIV patients on antiretroviral therapy using Darunavir
3164420|NCT01450618||Fosamprenavir|HIV patients on antiretroviral therapy using Fosamprenavir
3164421|NCT01450618||Lopinavir|HIV patients on antiretroviral therapy using Lopinavir
3164422|NCT01450605||Patients ≥ 13 years of age with HIV-1|Patients ≥ 13 years of age with HIV-1 who are on Reyataz® treatment at the time of enrollment and have never been participated in this study previously or who are initiating Reyataz® treatment for the first time in the real-life conditions in its registered indication(s) as required by KFDA
3164423|NCT01450592||Group 1|
3164424|NCT01450592||Group 2|
3164425|NCT01450579|Placebo Comparator|Placebo|Saline
3164426|NCT01450579|Experimental|Dose -1|ASP7373
3164427|NCT01450579|Experimental|Dose -2|ASP7373
3164428|NCT01450579|Experimental|Dose -3|ASP7373
3164429|NCT01450566|Experimental|Lidocaine|Use of lidocaine
3164430|NCT01450566|Placebo Comparator|No lidocaine|No lidocaine/standard of care
3164431|NCT01450527||Patient fulfilling the criteria of ARDS|
3164432|NCT01450514|Placebo Comparator|Placebo|Sugar pill
3164433|NCT01450514|Experimental|Pipamperone|15 mg once daily
3164434|NCT01450501||Patients with vascular chronic Q-fever|All patients with chronic Q-fever and an aneurysm or vascular reconstruction
3164435|NCT01450488|Experimental|masitinib 3 mg/kg/day|
3164436|NCT01450488|Experimental|masitinib 6 mg/kg/day|
3164437|NCT01450475|Experimental|Remote ischemic postconditioning|At the time of reperfusion, remote ischaemic postconditioning will be induced by inflating a cuff around leg to 100 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
3164438|NCT01450475|No Intervention|control|A blood cuff was around leg without inflation or deflation.
3164439|NCT01450462|Experimental|Vitamin D (cholecalciferol)|
3164440|NCT01450462|Placebo Comparator|Placebo|
3164441|NCT01450449|Experimental|Arm 1 - Short Course Radiotherapy|Short Course
3164442|NCT01450449|Active Comparator|Arm 2 - Standard Course Radiotherapy|Standard Course
3164443|NCT01450436||preterm infants (<35 weeks gestation)|
3164444|NCT01450423|Experimental|Physical activity|
3164445|NCT01450423|No Intervention|Control|
3164446|NCT01450410|Active Comparator|Nicotinic Acid|
3164447|NCT01450410|Placebo Comparator|Placebo|
3164448|NCT01450397|Other|XIAFLEX|XIAFlEX
3164449|NCT01450384|Experimental|Treatment (enzyme inhibitor therapy, antiangiogenesis)|Patients receive pemetrexed disodium IV on day 1 every 2 weeks and sorafenib tosylate PO BID for 4 weeks on days 1-5. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3164450|NCT01450371||Interferential|The individuals are treated acutely with interferential electrical stimulation (IES) during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
3164451|NCT01450371||Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
3164452|NCT01450358|Active Comparator|Pathogen detection by Multiplex PCR|Blood samples for cultures and Multiplex PCR will be collected before start the antibiotic therapy in patients with sepsis. Multiplex PCR will be immediately undertaken and its results will be reported to prompt medical researcher (6-12 hours).The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR.
3164453|NCT01450358|No Intervention|Pathogen detection by blood culture|Blood samples for cultures and Multiplex PCR will be collected before start the antibiotic therapy in patients with sepsis. The results of multiplex PCR will be not informed to the medical researcher, being focused care as a result of blood culture (at least after 72 hours).
3164454|NCT01450345|Experimental|Pregabalin Group|The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
3164455|NCT01450332|Experimental|study|
3164456|NCT01450319|Experimental|Cetuximab|
3164457|NCT01450306|Experimental|D-cycloserine plus exposure therapy|Single session (up to 3 hr) of in vivo exposure therapy plus 50 mg oral d-cycloserine administered 1 hr prior to exposure therapy session
3164458|NCT01450306|Placebo Comparator|Placebo plus exposure therapy|Single session (up to 3 hr) of in vivo exposure therapy plus oral placebo capsule administered 1 hr prior to exposure therapy session
3164459|NCT01450293|Experimental|Group A|5 to 12 months old infants; AdCh63 ME-TRAP, MVA ME-TRAP
3164460|NCT01450293|Experimental|Group B|5 to 12 months old infants; AdCh63 ME-TRAP, MVA ME-TRAP
3164463|NCT01450293|Experimental|Group E|10 week old babies; AdCh63 ME-TRAP, MVA ME-TRAP
3164464|NCT01450293|No Intervention|Group F|10 week old babies; no vaccination
3164465|NCT01450280|Experimental|Group 1A|AdCh63 CS 5x10^9 vp
3164466|NCT01450280|Experimental|Group 1B|ChAd63 CS 5x10^9 vp Day 0; MVA CS 2x10^8 pfu Day 56
3164467|NCT01450280|Experimental|Group 2A|AdCh63 CS 5 x 10^10 vp
3164468|NCT01450280|Experimental|Group 2B|ChAd63 CS 5x10^10 vp Day 0; MVA CS 2x10^8 pfu Day 56
3164469|NCT01450267|Placebo Comparator|Physiological solution|
3164470|NCT01450267|Experimental|Reduced Inhaled Glutathione|
3164471|NCT01450254|Experimental|Experimental|These patients will carry out a therapy program with the study intervention device.
3164472|NCT01450254|Active Comparator|Control|The patients in this group will not carry out a therapy program with the study intervention device.
3164473|NCT01450241|Experimental|Early antibiotic discontinuation|Antibiotic treatment stopped after 72h, regardless of fever.The antibiotics used will be piperacillin tazobactam for high-risk patients and amoxycillin-clavulanate + ciprlofloxacin for low-risk patients (defined by MASCC scoring system). Alternatives in case of penicillin allergy will be ceftazidine and levofloxacin, respectively.
3164474|NCT01450241|Other|Usual practice|Antibiotic treatment continued according to accepted guidelines and current clinical practice. The antibiotics used will be piperacillin tazobactam for high-risk patients and amoxycillin-clavulanate + ciprlofloxacin for low-risk patients (defined by MASCC scoring system). Alternatives in case of penicillin allergy will be ceftazidine and levofloxacin, respectively.
3164475|NCT01450228|Placebo Comparator|Placebo KI1001|
3164476|NCT01450228|Experimental|KI1001|
3164477|NCT01450215|Experimental|Revlimid|
3164478|NCT01450215|No Intervention|Revlimid and dexamethasone|
3164479|NCT01450202|Placebo Comparator|Air insufflation, colonoscopy, esophagogastroduodenoscopy|
3164480|NCT01450202|Active Comparator|CO2 insufflation, colonoscopy, esophagogastroduodenoscopy|
3164481|NCT01450189|Active Comparator|Standard Counseling Arm|The SC arm consists of a single session of standard HIV prevention messages during HIV post-test counseling. The counseling will be comparable to that given to persons with established HIV infection with supplemental information regarding the acute stage of their infection.
3164482|NCT01450189|Active Comparator|Behavioral Intervention Arm only|Behavior- BI: Information-Motivation-Behavioral Skills Model the Information-Motivation-Behavioral Skills (IMB) Model. The 5 sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
3164483|NCT01450189|Active Comparator|Behavioral Intervention plus ARV|The BIA arm consists of the behavioral intervention plus antiretroviral drugs (ARVs) with raltegravir (400 mg twice daily) and fixed dose combination (FDC) emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) (200/300 mg daily) orally for 12 weeks.
3164484|NCT01450176|Active Comparator|Pataday once daily|15 subjects will administer Pataday once daily for 2 weeks. Then these subjects will administer Bepreve twice daily for 2 weeks.
3164485|NCT01450176|Active Comparator|Bepreve twice daily|Bepreve twice daily for 2 weeks, then subjects will use Pataday once daily for 2 weeks
3164486|NCT01450163|Active Comparator|Pregabalin|
3164487|NCT01450163|Placebo Comparator|Placebo|
3164488|NCT01450150|Experimental|Active tDCS|
3164489|NCT01450150|Sham Comparator|Sham tDCS|
3164490|NCT01450137|Experimental|Tocilizumab|Tocilizumab 8mg/kg every 4 weeks until week 52.
3164491|NCT01450137|Placebo Comparator|Placebo|Placebo every 4 weeks until week 52.
3164492|NCT01450124|Experimental|Boswellic acids (BOSWELAN)|Baseline to treatment single arm - 4 months baseline and 8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg of BOSWELAN.
3164493|NCT01450111|Experimental|Lacosamide 50 mg group|Lacosamide 50 mg tablet, once a day per os (po)
3164494|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 50 mg|Placebo matched with lacosamide 50 mg tablet, po
3164495|NCT01450111|Experimental|Lacosamide 100 mg group|Lacosamide 100 mg tablet, po
3164496|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 100 mg|Placebo matched with lacosamide 100 mg tablet, po
3164497|NCT01450111|Experimental|Lacosamide 200 mg group|Lacosamide 200 mg tablet, po
3164498|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 200 mg|Placebo matched with lacosamide 200 mg tablet, po
3164499|NCT01450098|Experimental|Cohort A: fixed sequence of meal conditions|200 mg of LY2484595 administered orally, one time only, as a spray-dried solid dispersion-propyl gallate (SDSD-PG) tablet given with no food. There will be a washout of a minimum of 14 days before crossing over and receiving a 200 mg of LY2484595 administered orally, one time only, as a SDSD-PG tablet given with low fat breakfast. There will be another washout of a minimum of 14 days before crossing over and receiving a 200 mg of LY2484595 administered orally, one time only, as a SDSD-PG tablet given with high fat breakfast.
3164500|NCT01450098|Experimental|Cohort B: Comparison of randomized treatments|100 mg of LY2484595 administered orally as reference formulation (RF) tablet given with a low fat breakfast. There will be a washout of a minimum of 14 days before crossing over and receiving 100 mg of LY2484595 administered orally as a SDSD-PG tablet given with a low fat breakfast. There will be another washout of a minimum of 14 days before crossing over and receiving 300 mg of LY2484595 as a SDSD-PG tablet given with a low fat breakfast.
3164501|NCT01450085|Active Comparator|GeneXpert|Point of care GeneXpert
3164502|NCT01450085|Active Comparator|LED Microscopy|Point of care LED Microscopy
3164503|NCT01450072|Sham Comparator|Control arm|Venography and sham angioplasty
3164504|NCT01450072|Active Comparator|Active arm|therapeutic balloon angioplasty
3164505|NCT01450059||Spontaneous delivery|Approximately 15 HiV exposed Newborns with low HiV transmission risk, born via spontaneous delivery.
3164506|NCT01450059||Cesarean section|Approximately 15 HiV exposed Newborns with low HiV transmission risk, born via cesarean section.
3164586|NCT01449578|Placebo Comparator|Part A, Treatment 3 placebo|Dexpramipexole single dose placebo (SAD Dose 3)
3164587|NCT01449578|Experimental|Part B, Treatment 1|Dexpramipexole multiple dose (MAD Dose 1)
3164593|NCT01449552|Experimental|Group A|No clamp and placebo
3164507|NCT01450046|Experimental|Phase I Dose Escalation|Each investigator will be provided with adequate supplies of Vitamin E δ -Tocotrienol, which will be supplied as 100-mg, 200-mg, and 400-mg capsules. Vitamin E δ-Tocotrienol will be administered orally once. The dose administered to each subject will be fixed and based on cohort assignment. Doses will be administered at the clinical site during each protocol-defined visit.
3164508|NCT01450033|No Intervention|Control group|Standard of care
3164509|NCT01450033|Experimental|Mentoring group|Subjects in this group will participate in the following intervention activities: medical record review; questionnaires including the Hollingshead Socioeconomic Status Survey, modified Medication Adherence Module, Peds QL Transplant Module, Medical Outcomes Study Social Support Scale, and self-efficacy scale; in-person meetings with mentor; e-communication with mentor (i.e. texts, Facebook, phone calls, etc); and collection of pharmacy refill data and clinical data.
3164510|NCT01450020|Experimental|Arm I (PN and ACS material)|Participants receive 4 PN sessions tailored to their needs followed by a 6 month booster session and ACS materials.
3164511|NCT01450020|Active Comparator|Arm II (ACS material)|Participants receive ACS materials only.
3164512|NCT01450007|Experimental|Dexamethasone block|Blockade with 25 ml ropivacaine 0.5% mixed with 8 mg dexamethasone (0.8 ml), and 5 ml intravenous normal saline
3164513|NCT01450007|Active Comparator|Dexamethasone IV|Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and intravenous 8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml
3164514|NCT01450007|Placebo Comparator|Placebo|Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and 5 ml intravenous normal saline
3164515|NCT01449994|Placebo Comparator|Placebo-Activator|Treatment with Placebo Activator IV
3164516|NCT01449994|Active Comparator|Activator|Treatment with Activator IV adjusting instrument
3164517|NCT01449981|Experimental|Integrated Twelve-Step Facilitation|
3164518|NCT01449981|Experimental|Cognitive Behavioral Therapy|
3164519|NCT01449968||home visit of UMG|home visit with evaluation and management of the situation (control over in-home telephone)
3164520|NCT01449968||telephone management|geriatric mobile unit provides a telephone advice only to the general practitioner with guidance and recommendations (call control)
3164521|NCT01449955|Placebo Comparator|Placebo (e.g., sugar pill)|15 mg Placebo will be administered once, in pill form.
3164522|NCT01449955|Active Comparator|Rapamycin|15 mg of Rapamycin will be administered once, in pill form.
3164523|NCT01449942|Experimental|DZ1|DZ1 group receives DZ1 intratumoral injection in combination with radiation therapy.
3164524|NCT01449942|Placebo Comparator|Saline|Placebo group receives saline injection in combination with radiation therapy.
3164525|NCT01449929|Experimental|dolutegravir 50mg once daily (OAD)|in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD
3164526|NCT01449929|Active Comparator|darunavir 800mg OAD in combination with ritonavir 100mg OAD|in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD
3164527|NCT01449916|Experimental|Simplified Severe Sepsis Protocol|This protocol consists of an early aggressive fluid strategy, early blood cultures and antibiotics, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
3164528|NCT01449916|Active Comparator|Usual care|Patients are managed according to admitting doctors' orders
3164529|NCT01449903||Rebilda DC|
3164530|NCT01449903||Clearfil Core DC|
3164531|NCT01449903||Multicore Flow|
3164532|NCT01449890|Experimental|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises they have learned during the initial treatment phase in order to cope with depression, e.g. integrating positive activities in their all day life or monitoring the interdependence of cognition, emotion and behaviour.
3164533|NCT01449890|No Intervention|Treatment as usual|After having terminated inpatient CBT patients receive treatment as usual within routine care.
3164534|NCT01449877|Active Comparator|Trimethoprim-Sulfamethoxazole|1 tablet every other day, morning.
3164535|NCT01449877|Placebo Comparator|Starch tablet|1 starch tablet every other day, morning.
3164536|NCT01449838|Placebo Comparator|Saline|Subjects were administered single dose or twice daily for 2.5 days repeat dose of placebo by the intravenous route.
3164537|NCT01449838|Experimental|Colistimethate sodium|2.5 milligrams (mg)/kilogram (kg) of CMS-NA (as colistin activity or 75,000 International Unit/kg) was administered as single dose or twice daily for 2.5 days repeat dose by the intravenous route.
3164538|NCT01449825||Prescriber compliance group|Adult (18+ years) new users of pazopanib with an indication of RCC evaluated for prescriber compliance
3164539|NCT01449825||Incidence of liver chemistry test (LCT) elevation group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib in monotherapy who have a baseline LCT evaluated for LCT elevations
3164540|NCT01449825||Incidence of drug induced liver injury (DILI) cases group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib with RCC (as defined by ICD-9 codes) longitudinally followed up in order to capture occurrences of LCT elevations consistent with Hy's Law to evaluate for drug-induced liver injury
3164541|NCT01449825||Incidence of cases of ALF group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib with RCC (as defined by ICD-9 codes) longitudinally followed up in order to capture occurrences of ICD-9 codes indicative of possible ALF to evaluate for drug-induced liver injury
3164542|NCT01449812|Experimental|INFANRIX+HIB/POLIORIX 1 GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
3164588|NCT01449578|Placebo Comparator|Part B, Treatment 1 placebo|Dexpramipexole multiple dose placebo (MAD Dose 1)
3164589|NCT01449578|Experimental|Part B, Treatment 2|Dexpramipexole multiple dose (MAD Dose 2)
3164590|NCT01449578|Placebo Comparator|Part B, Treatment 2 placebo|Dexpramipexole multiple dose placebo (MAD Dose 2)
3164543|NCT01449812|Experimental|INFANRIX+HIB/POLIORIX 2 GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 3, 4 and 5 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
3164544|NCT01449812|Active Comparator|CONTROL GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix+Hib™ and of Poliorix™ vaccines at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
3164545|NCT01449799|Experimental|Sequence 1|In period 1, subjects will be administered GSK961081/fluticasone propionate blend via Diskus inhaler followed by the administration of GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers in period 2. In period 3 and period 4, the subjects will receive fluticasone propionate and GSK961081 respectively.
3164546|NCT01449799|Experimental|Sequence 2|In period 1, subjects will be administered GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers followed by administration of GSK961081 in period 2. In period 3 and period 4, the subjects will receive GSK961081/fluticasone propionate blend via Diskus inhaler followed by the administration of fluticasone propionate respectively.
3164547|NCT01449799|Experimental|Sequence 3|In period 1, subjects will be administered GSK961081 followed by administration of fluticasone propionate in period 2. In period 3, subjects will be administered GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers followed by GSK961081/fluticasone propionate blend via Diskus inhaler in period 4.
3164548|NCT01449799|Experimental|Sequence 4|In period 1, subjects will be administered fluticasone propionate followed by the administration of GSK961081/fluticasone propionate blend via Diskus inhaler in period 2. The subjects will receive GSK961081 in period 3 and concurrent administration of GSK961081 and fluticasone propionate in period 4.
3164549|NCT01449786|Experimental|treatment with rMal d 1|these apple and birch pollen allergic patients are treated with daily sublingual application of 25µg recombinant Major apple allergen, Mal d 1 during 4 months
3164550|NCT01449786|Active Comparator|treatment with rBet v 1|These apple and birch pollen allergic patients are treated with daily sublingual application of 25µg recombinant Major birch pollen allergen,Bet v 1 during 4 months
3164551|NCT01449786|Placebo Comparator|treatment with placebo drops|These apple and birch pollen allergic patients are treated daily with placebo applied sublingually during 4 months
3164552|NCT01449773|Experimental|n-3 PUFAs|
3164553|NCT01449773|Placebo Comparator|Corn and soybean oil pill|
3164554|NCT01449760|No Intervention|No treatment|
3164555|NCT01449760|Active Comparator|Physical Therapy|
3164556|NCT01449760|Experimental|Wii Balance group|
3164557|NCT01449747|Active Comparator|study group|sitagliptin hypo-response patients
3164558|NCT01449747|Sham Comparator|control group|sitagliptin response patients
3164559|NCT01449721|No Intervention|Control|Standard medical care by the primary treatment team.
3164560|NCT01449721|Experimental|Interventional arm|Protocolized empiric resuscitation delivering weight-based intravenous fluid resuscitation targeting lactate normalization
3164561|NCT01449708|No Intervention|Balanced Anesthesia|Patients will receive balanced general anesthesia including volatile anesthetics and narcotics. This reflects our current clinical practice.
3164562|NCT01449708|Active Comparator|NoNarc TIVA|Patients will receive narcotic free total intravenous anesthesia with Propofol, dexmedetomidine and ketamine
3164563|NCT01449695|Experimental|Lifestyle counseling|Group consultation and individual nurse consultation
3164564|NCT01449695|Experimental|e health|An individual web based entry
3164565|NCT01449695|No Intervention|usual care|Usual care
3164566|NCT01449682|Active Comparator|Ozurdex PRN|0.7 mg intravitreal DEX implant at Visit 1 then PRN for duration of trial (48 weeks) if evidence of fluid on OCT
3164567|NCT01449682|Active Comparator|Ozurdex Q16 weeks|0.7 mg intravitreal DEX implant at Visit 1 then Q16 weeks
3164568|NCT01449656||LMA proseal|
3164569|NCT01449656||LMA Supreme|
3164570|NCT01449643|Active Comparator|IMT Group|Threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cm H20). When patients inhale through Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
3164571|NCT01449643|Sham Comparator|Sham Group|Non-training protocol
3164572|NCT01449630|Experimental|LY3031207|Single dose of up to 900mg of LY3031207 administered orally in up to three occasions separated by at least a 3 week wash-out period between each dose.
3164573|NCT01449630|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to two occasions separated by at least a 3 week wash-out period between each dose.
3164574|NCT01449630|Active Comparator|Celecoxib|Single 400mg dose of celecoxib administered orally on one occasion.
3164575|NCT01449617||Aspirin plus clopidogrel|Patients undergoing stenting for critical carotid stenosis, either symptomatic (previous events of cerebral ischemia) or asymptomatic, undergoing CAS.
3164576|NCT01449604|Active Comparator|stereotactic radiosurgery|Radio surgery single fraction 12 Gy
3164577|NCT01449604|Active Comparator|stereotactic radiotherapy|Stereotactic radiotherapy hypo fraction 18 Gy in 3 fraction
3164578|NCT01449591|Experimental|BFH772|
3164579|NCT01449591|Placebo Comparator|Vehicle|
3164580|NCT01449591|Active Comparator|Metronidazole|
3164581|NCT01449578|Experimental|Part A, Treatment 1|Dexpramipexole single dose (SAD Dose 1)
3164582|NCT01449578|Placebo Comparator|Part A, Treatment 1 placebo|Dexpramipexole single dose placebo (SAD Dose 1)
3164583|NCT01449578|Experimental|Part A, Treatment 2|Dexpramipexole single dose (SAD Dose 2)
3164584|NCT01449578|Placebo Comparator|Part A, Treatment 2 placebo|Dexpramipexole single dose placebo (SAD Dose 2)
3164585|NCT01449578|Experimental|Part A, Treatment 3|Dexpramipexole single dose (SAD Dose 3)
3164594|NCT01449552|Experimental|Group B|Tranexamic acid
3164595|NCT01449552|Experimental|Group C|Drain clamping
3164596|NCT01449552|Experimental|Group D|Drain clamping and tranexamic acid
3164597|NCT01449526|Experimental|B&L Investigational Contact Lens|The Bausch + Lomb investigational silicone hydrogel contact lens
3164598|NCT01449526|Active Comparator|B&L PureVision Contact Lens|The Bausch + Lomb PureVision silicone hydrogel contact lens
3164599|NCT01449513|Active Comparator|PEP005 Gel 0.05%|active ingredient of PEP005: Ingenol mebutate
3164600|NCT01449513|Placebo Comparator|Placebo Gel|Vehicle of PEP005 Gel
3164601|NCT01449500|Placebo Comparator|Placebo|Placebo
3164602|NCT01449500|Active Comparator|L. reuteri|"L. reuteri will be delivered at a dose of 1x108 CFU of each strain of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day.~Intervention: Dietary Supplement: L. reuteri DSM 17938 and ATCC PTA 6475"
3164603|NCT01449487|Active Comparator|PPC-5650|
3164604|NCT01449487|Placebo Comparator|Placebo|
3164605|NCT01449474|Experimental|Group 1|Patient matched instruments
3164606|NCT01449474|Experimental|Group 2|Jig based instruments
3164607|NCT01449461|Experimental|Brigatinib 30 mg QD/60 mg QD|Brigatinib 30 mg/60 mg, tablets, orally, once daily (QD) in each cycle of 28 days (approximately, up to 44.4 months).
3164608|NCT01449461|Experimental|Brigatinib 90 mg QD|Brigatinib 90 mg, tablets, orally, once daily (QD) in each cycle of 28 days (approximately, up to 44.4 months).
3164609|NCT01449461|Experimental|Brigatinib 120 mg QD/60 mg BID|Brigatinib 120 mg, once daily or 60 mg, twice daily (BID), tablets, orally, in each cycle of 28 days (approximately, up to 44.4 months).
3164610|NCT01449461|Experimental|Brigatinib 90 mg QD-180 mg QD|Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in cycle 2 and onward cycles of 28 days.
3164611|NCT01449461|Experimental|Brigatinib 180 mg QD/90 mg BID|Brigatinib 180 mg, once daily or 90 mg, twice daily (BID), tablets, orally in each cycle of 28 days (approximately, up to 44.4 months).
3164612|NCT01449461|Experimental|Brigatinib 240 mg QD/120 mg BID/300 mg QD|Brigatinib 240 mg, once daily (QD) or 120 mg, twice daily (BID) or 300 mg once daily, tablets, orally, in each cycle of 28 days (approximately, up to 44.4 months).
3164613|NCT01449448|Experimental|NSAID|Test Group: This group was given subacromial injections of Ketorolac.
3164614|NCT01449448|Active Comparator|Steroid|This group was given a subacromial injection triamcinolone.
3164615|NCT01449422|Experimental|URGO 310 3082|
3164616|NCT01449422|Active Comparator|Aquacel|
3164617|NCT01449409|No Intervention|Usual care|
3164618|NCT01449409|Experimental|Real-time asthma care outreach|
3164619|NCT01449396|Sham Comparator|SHAM ACUPUNCTURE|Sham intervention: acupuncture needle without puncture nor stimulation
3164620|NCT01449396|Experimental|REAL ACUPUNCTURE|Experimental: acupuncture in selected points of the protocol designed
3164621|NCT01449396|Other|Control|Bed Rest
3164622|NCT01449383|Active Comparator|low meat high fibre (lmhf)|consumption of less than 30g red meat per day and at least 40g dietary fibre per day
3164623|NCT01449383|Active Comparator|high meat low fibre (hmlf)|consumption of 200g red meat and not more than 20g dietary fibre per day
3164624|NCT01449370|Experimental|Arm A|TAK-117 administered once a day orally
3164625|NCT01449370|Experimental|Arm B|TAK-117 administered orally intermittently, once every other day (Monday, Wednesday, and Friday) each week
3164626|NCT01449370|Experimental|Arm C|TAK-117 administered orally intermittently, once a day for 3 consecutive days (Monday, Tuesday, and Wednesday) each week
3164627|NCT01449357|Experimental|zalutumumab|
3164628|NCT01449344|Experimental|R-HAD + Bortezomib|
3164629|NCT01449344|Active Comparator|R-HAD|
3164630|NCT01449318|No Intervention|Patients undergoing hysterectomy|
3164631|NCT01449305|Experimental|Nanoone Woman Underwear|"Nanoone negative ion of textiles, which is health material specifically designed for human body, in short distance and long time to produce negative ion, the human body really needed, it can neutralize free radical in the human body."
3164632|NCT01449292|Experimental|Treatment plus Optimal Medical Therapy|Patients will be treated with the AeriSeal System and Optimal Medical Therapy
3164633|NCT01449292|Active Comparator|Optimal Medical Therapy|Patients will be treated according to Optimal Medical Therapy
3164634|NCT01449279|Experimental|Ipilimumab Treatment + Radiation Therapy|Ipilimumab (BMS-734016, MDX010, MDX-CTLA4, Yervoy) will be administered as standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments. Palliative radiation therapy to 1 to 2 sites of disease will start within 5 days of the first ipilimumab dose. Subjects will have follow up visits 2 to 4 weeks after the last ipilimumab dose and then every 3 months (±2 weeks) thereafter until progression of disease.
3164635|NCT01449266|Other|Dotarem®-injected patients|Male or female subjects, aged ≥18 years,suffering from end-stage renal failure and requiring hemodialysis treatment 3 times per week, were submitted to a single Dotarem® IV injection at 0.1 mmol/kg before being submitted to 3 hemodialysis sessions to assess the decrease of Dotarem® concentration in the blood.
3164636|NCT01449253|Active Comparator|Monotherapy|Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months
3164637|NCT01449253|Active Comparator|Sequential Therapy|Bosentan will be started at 62.5mg BD for 4 weeks and then increased to 125mg BD. Sildenafil will be started be added after 3 months. Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months. Bosentan and sildenafil will be in combination in the last 3 months. No fixed dose combination will be used.
3164638|NCT01449253|Active Comparator|Combination therapy|Bosentan will be started at 62.5mg BD for 4 weeks and then increased to 125mg BD. Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months. No fixed dose combination will be used.
3164639|NCT01449240||No treatment|Approximately 5 adults (equal to or not less than 18yrs old) and 5 children (equal to or not over 18yrs old)
3164640|NCT01449214|Experimental|Ultrasound|Use of ultrasound to identify interlaminar spaces for needle insertion. Intervention/Procedure: ultrasound-guided technique.
3164641|NCT01449214|Active Comparator|Landmarking|Use of manual palpation to identify anatomic landmarks for needle insertion. Procedure/Intervention: landmark-guided technique.
3164642|NCT01449201|Experimental|PF-00299804|
3164643|NCT01449188|Active Comparator|ondansetron, 8 mg IV over 15 minutes|the lower ondansetron IV dose will be used in one of the four treatment periods
3164644|NCT01449188|Active Comparator|ondansetron, 32 mg IV over 15 minutes|the higher ondansetron IV dose will be used in one of the four treatment periods
3164645|NCT01449188|Placebo Comparator|placebo for ondansetron, IV over 15 minutes|placebo for ondansetron IV dose will be used in one of the four treatment periods
3164646|NCT01449188|Active Comparator|moxifloxacin, 400mg tablet (oral)|moxifloxacin is known to produce mild QT prolongation and will be used in one of the four treatment periods
3164647|NCT01449162|Experimental|masitinib|masitinib 6 mg/kg/day
3164648|NCT01449162|Placebo Comparator|placebo|placebo matching masitinib 6 mg/kg/day
3164649|NCT01449136|Experimental|antibacterial cement|
3164650|NCT01449123|Experimental|Inhaler|Subjects prescribed fixed dose combinations perform Mannitol Challenge Test and Reversibility Test once
3164651|NCT01449110|Placebo Comparator|Placebo in PP|Placebo arm in primary cardiovascular prevention (PP)
3164652|NCT01449110|Placebo Comparator|Placebo in SP|Placebo arm in secondary cardiovascular prevention (SP)
3164653|NCT01449110|Active Comparator|Grape extract in PP|Grape extract obtained without resveratrol in primary cardiovascular prevention
3164654|NCT01449110|Active Comparator|Grape extract in SP|Grape extract without resveratrol in secondary cardiovascular prevention
3164655|NCT01449110|Experimental|Resveratrol-enriched grape extract in PP|Resveratrol-enriched grape extract (Stilvid) in primary cardiovascular prevention
3164656|NCT01449110|Experimental|Resveratrol-enriched grape extract in SP|Resveratrol-enriched grape extract (Stilvid) in secondary cardiovascular prevention
3164657|NCT01449097|Experimental|Adductor-Canal-Blockade|
3164658|NCT01449097|Active Comparator|The femoral nerve block|
3164659|NCT01449097|Placebo Comparator|Placebo|
3164660|NCT01449084|Active Comparator|early removal of pancreatic duct stent|immediate removal of the pancreatic duct stent at the end of the ERCP procedure
3164661|NCT01449084|No Intervention|leaving the stent in place|the pancreatic duct stent is left in place
3164662|NCT01449071|Placebo Comparator|Placebo Group|
3164663|NCT01449071|Experimental|Epratuzumab 600 mg Group|
3164664|NCT01449071|Experimental|Epratuzumab 100 mg Group|
3164665|NCT01449071|Experimental|Epratuzumab 400 mg Group|
3164666|NCT01449071|Experimental|Epratuzumab 1200 mg Group|
3164667|NCT01449058|Experimental|BYL719 + MEK162|BYL719 plus MEK162. Dose escalation with a starting dose for the first cohort of 200mg QD BYL719 and 30mg BID MEK162
3164668|NCT01449045|Placebo Comparator|Community Case Management|Provision of access to prompt diagnosis and treatment for malaria by community volunteers in the village (PECADOM)
3164669|NCT01449045|Experimental|Community Case Management plus IPTc|Monthly Intermittent Preventive Treatment with sulfadoxine pyrimethamine plus amodiaquine, in addition to community case management
3164670|NCT01449032|Active Comparator|MSC|Adipose derived stem cells
3164671|NCT01449032|Placebo Comparator|Saline|
3164672|NCT01449019|Active Comparator|intravenous infusion|
3164673|NCT01449019|Experimental|intraduodenal perfusion|
3164674|NCT01449006|No Intervention|Standard of care HAART regimen|Participants randomised to this arm of the trial will remain on their usual prescribed HAART regimen.
3164675|NCT01449006|Experimental|Maraviroc|Participants randomised to this arm will remain on their usual prescribed HAART regimen, with the addition of Maraviroc. Maraviroc will be prescribed according to the Product Information Sheet, with consideration given to background therapy.
3164676|NCT01448993|Placebo Comparator|Placebo|Taking placebo 3 times per week for four weeks
3164677|NCT01448993|Active Comparator|AZI|
3164678|NCT01448980|Active Comparator|Physical therapy|The control group will receive physical therapy 2 time per week for 6 weeks
3164679|NCT01448980|Experimental|Thai Traditional Massage|The experimental group will receive Thai traditional massage program 2 times per week for 6 weeks.
3164680|NCT01448954|Experimental|ADC3680B oral|
3164681|NCT01448954|Placebo Comparator|Placebo oral|
3164682|NCT01448941|Active Comparator|Primary arthrodesis TMT 1|Arthrodesis TMT 1 when instability is present. Primary arthrodesis TMT 2 and 3 when instability present
3164683|NCT01448941|Experimental|Temporary extraarticular plate fixation|Temporary extraarticular plate fixation of TMT 1 when instability is present. Primary arthrodesis TMT 2 and 3 when instability present
3164684|NCT01448928||Group 1|
3164685|NCT01448915||Persons with HIV and HCV coinfection|Persons with HIV and HCV coinfection who receive medical care for HIV infection at Johns Hopkins Hospital
3164686|NCT01448902|Experimental|OC000459|
3164687|NCT01448902|Placebo Comparator|Placebo|
3164688|NCT01448889|Active Comparator|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
3164689|NCT01448889|Placebo Comparator|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
3164690|NCT01448876||chlamydia care as usual|
3164691|NCT01448863||CONTROL|Fertile women (egg-donors)
3164692|NCT01448863||WITH PCO|Obese women with Polycystic Ovarian Syndrome
3164693|NCT01448863||NO PCO|Obese women without Polycystic Ovarian Syndrome
3164694|NCT01448850|Placebo Comparator|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
3164695|NCT01448850|Experimental|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 milligram (mg) as intravenous (IV) infusion on Day 1 followed by 300 mg injection subcutaneously (SC) every 4 weeks up to Week 53.
3164696|NCT01448837|Active Comparator|Bimatoprost/Timolol drops|The patients will be treated with bimatoprost/timolol fixed combination therapy
3164697|NCT01448837|Active Comparator|Latanoprost drops|The patients will be crossed over to therapy with latanoprost
3164741|NCT01448551|No Intervention|Control|Participation in the MPOWER program without receiving tailored text messages
3164698|NCT01448824|Experimental|Part 1: LY2484595|100 mg tablets administered to 4 cohorts as multiple ascending doses of ≤ 1800 mg LY2484595 given orally for 14 consecutive days
3164699|NCT01448824|Experimental|Part 2: LY2484595|100 mg LY2484595 will be administered orally on 2 separate days as single oral doses (Period 1 Day 1 and Period 2 Day 5)
3164700|NCT01448824|Placebo Comparator|Part 1: Placebo|Administered orally once daily for 14 consecutive days
3164701|NCT01448824|Active Comparator|Part 2: Ketoconazole|400 mg Ketoconazole administered orally once daily for 14 consecutive days in Period 2
3164702|NCT01448811|Experimental|AEP monitoring|
3164703|NCT01448811|Active Comparator|RSS monitoring|
3164704|NCT01448798|Experimental|gelatine-thrombin matrix|Nerves-paring during robotic-assisted laparoscopic prostatectomy is conducted without mono- or bipolar electrocautery and clipping by using a hemostatic gelatine-thrombin matrix.
3164705|NCT01448798|Sham Comparator|Control|Nerve-sparing during robotic-assisted radical prostatectomy is conducted with the use of mono- and bipolar electrocautery and surgical clipping.
3164706|NCT01448785|Active Comparator|abiliti Group|Subjects will receive implanted abiliti System. The device will be activated to deliver therapy at implant. Gastric stimulation performance testing, therapy adjustment and dietary/exercise counseling will be conducted at each visit.
3164707|NCT01448785|Active Comparator|Gastric Band Group|Subjects will receive an implanted laparoscopic adjustable gastric band. The subjects will have their band adjusted following the standard of care. Dietary/exercise counseling will be conducted at each visit.
3164708|NCT01448772|Active Comparator|Marinol|
3164709|NCT01448772|Experimental|oral solution|
3164710|NCT01448746|Experimental|intermittent pneumatic compression|another arm include intermittent pneumatic compression plus low molecular weight heparin
3164711|NCT01448733|Experimental|Acanya Plus Atralin|A single, open-label arm treating acne with Cerave lotion plus Acanya gel in the morning in combination with Cerave lotion plus Atralin gel in the evening.
3164712|NCT01448720|Experimental|Paliperidone palmitate|
3164713|NCT01448707|Experimental|Darunavir monotherapy|Darunavir (DRV) + ritonavir (rtv): 2 tablets DRV 400 mg should be taken together with 1 tablet rtv 100 mg within 30 minutes after a meal. Following the primary efficacy analysis after Week 48, patients who entered the study with a nadir CD4+ count of <200 cells/μL will also receive 2 N[t]RTIs (ie, triple therapy) as soon as possible
3164714|NCT01448707|Active Comparator|Triple therapy containing darunavir|Darunavir (DRV) + ritonavir (rtv) + 2 N[t]RTIs: 2 tablets DRV 400 mg should be taken together with 1 tablet rtv 100 mg within 30 minutes after a meal in combination with 2 N[t]RTIs (an investigator-selected dual combination of either abacavir (ABC), lamivudine (3TC), zidovudine (AZT), tenofovir disoproxil fumarate (TDF) or emtricitabine (FTC)
3164715|NCT01448694||Blood donors|Healthy volunteers who are donating a pint of whole blood
3164716|NCT01448681||SICU patients with ICP|Surgical intensive care unit patients with elevated intracranial pressure
3164717|NCT01448668||Test group with Iscador® Qu|The test group will receive the mistletoe extract Iscador® Qu as supportive treatment in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
3164718|NCT01448668||Control group|The parallel control group will receive no mistletoe but only post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
3164719|NCT01448655||Test group with Iscador® Qu|The test group will receive the mistletoe extract Iscador® Qu as supportive treatment in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
3164720|NCT01448655||Control group|The parallel control group will receive no mistletoe but only post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
3164721|NCT01448642|Active Comparator|Atorvastatin|
3164722|NCT01448642|Placebo Comparator|Placebo|
3164723|NCT01448629|Experimental|River|
3164724|NCT01448629|Active Comparator|Standard Care|Standard Care can have several manufacture and brand names. Standard Care is defined af the participants currently used stoma care product.
3164725|NCT01448616|No Intervention|Run-in Phase|Women will first participate in a run-in phase with twice daily swabbing.
3164726|NCT01448616|Experimental|Study Drug Phase: TDF|Participants will take tenofovir disoproxil fumarate (TDF) tablets and apply a placebo vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
3164727|NCT01448616|Experimental|Study Drug Phase: Vaginal TFV Gel|Participants will take oral placebo tablets and apply a tenofovir 1% (TFV) vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
3164728|NCT01448616|Placebo Comparator|Study Drug Phase: Double Placebo|Participants will take oral placebo tablets and apply a placebo vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
3164729|NCT01448603||Placebo|Subjects previously randomised to placebo in TR002
3164730|NCT01448603||ToleroMune Ragweed Regimen 1|Subjects previously randomised to receive ToleroMune Ragweed regimen 1 in study TR002
3164731|NCT01448603||ToleroMune Ragweed Regimen 2|Subject previously randomised to receive ToleroMune Ragweed regimen 2 in study TR002
3164732|NCT01448603||ToleroMune Ragweed regimen 3|Subject previously randomised to receive ToleroMune Ragweed regimen 3 in study TR002
3164733|NCT01448603||ToleroMune Ragweed regimen 4|Subjects previously randomised to receive ToleroMune Ragweed regimen 4 in study TR002
3164734|NCT01448590||Epidural Resite|After ADP, those patients who receive an epidural resite.
3164735|NCT01448590||Spinal catheter|After ADP, those who receive the epidural catheter into the spinal space
3164736|NCT01448577||Dose 3 x 1011 gc/kg|Subjects received AMT-011 at dose 3 x 1011 gc/kg
3164737|NCT01448577||Dose 1 x 1012 gc/kg|Subjects received AMT-011 at dose 1 x 1012 gc/kg
3164738|NCT01448564|Active Comparator|Laser therapy|Recently has been using the LED, known by its acronym in English LED (Light Emitting Diode), devices that are light-emitting non-coherent and monochromatic, having a longer wavelength (± 10 - 30 nm) compared to lasers. The difference between the fundamental radiation emitted by a laser and an LED is the coherence of the beam.
3164739|NCT01448564|Placebo Comparator|Placebo Laser therapy|
3164740|NCT01448551|Experimental|Text Messaging|
3164743|NCT01448525|Active Comparator|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
3164744|NCT01448525|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
3164745|NCT01448512|Other|Usual Care|Participation in 4 time matched sessions on health education topics
3164746|NCT01448512|Experimental|PartnerPlus intervention|Four group counseling sessions focused on prevention of mother to child transmission (PMTCT) sexual risk reduction & adherence.
3164747|NCT01448499|Experimental|Clozapine|Clozapine monotherapy
3164748|NCT01448499|Experimental|Amisulpride|Amisulpride monotherapy
3164749|NCT01448499|Experimental|Augmentation|Augmentation of clozapine with amisulpride
3164750|NCT01448486|No Intervention|Standard of Care HAART|Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART).
3164751|NCT01448486|Experimental|Raltegravir|Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART) with the addition of Raltegravir 400 mg twice daily (BID).
3164752|NCT01448473|Experimental|4 views radiograph serie|The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.
3164753|NCT01448473|Active Comparator|2-view radiography serie|The 2-film series will include the following views: anterior-posterior and one lateral.
3164754|NCT01448460||Fertility Patients|IVF patients with extra eggs or other subjects who desire egg vitrification for fertility preservation
3164755|NCT01448447|Experimental|Sole method|patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS
3164756|NCT01448447|Experimental|Boost|patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS
3164757|NCT01448434|Experimental|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs
3164758|NCT01448434|Placebo Comparator|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte
3164759|NCT01448421|Experimental|Transcatheter Aortic Valve Replacement (TAVR).|
3164760|NCT01448408||Forme Fruste Keratoconus group (FFKG)|FFK eyes had to present a) no apparent signs of KC in clinical examination b) stage 0 in the Amsler-Krumeich scale, and c) demonstrate a KISA index value between 60-100%
3164761|NCT01448408||Normal Group (CG)|Eligibility for participation in the CG was confirmed by consecutive topographies, while all CG participants had to present uneventful ophthalmologic history, no indications of corneal pathology in slit-lamp biomicroscopy and Placido disk-based videokeratography and KISA index value less than 60%, as well.
3164762|NCT01448395|Experimental|1|
3164763|NCT01448382|Experimental|Healthy volunteers|healthy volunteers
3164764|NCT01448382|Experimental|GI bleeding subjcets|Symptomatic patients referred to undergo standard Gastroscopy (EGD) as part of their standard medical care
3164765|NCT01448369|Active Comparator|EyeGiene|EyeGiene (Eyedetec Medical Inc., US) is a self-contained, convenient warm compress system for the eyes. The system is composed of a reusable eye mask and one time use warmers that are inserted into the eye mask. The warming units are activated by squeezing just prior use and deliver 40°C heat for up to 5 minutes within 30-60 seconds.
3164766|NCT01448369|Active Comparator|Blephasteam|Blephasteam (Spectrum Théa, France) is an eyelid warming device that can be conveniently used at home. The goggles provide standardised heat of about 38 degrees to liquefy lipids and also humidify the chambers with mineral water to ensure optimal moisture levels.
3164767|NCT01448369|Placebo Comparator|Control- Hot Compress|The participants in this group will be using warm compresses with a hot towel.
3164768|NCT01448356|Experimental|temperature and humidity|"The volunteer is exposed to a controlled environment with a chamber setting of:~25°C and 45% humidity;~25°C and 65% humidity;~30°C and 45% humidity;~30°C and 65% humidity"
3164769|NCT01448343|Experimental|FMS|Patients who received blood transfusion using FMS
3164770|NCT01448330|Experimental|HCP0911|clopidogrel/aspirin combination tablet
3164771|NCT01448330|Active Comparator|clopidorel and aspirin|coadministration of clopidogrel and aspirin
3164772|NCT01448317|Experimental|Cohort 1|Alirocumab dose 1 versus placebo
3164773|NCT01448317|Experimental|Cohort 2|Alirocumab dose 2 versus placebo
3164774|NCT01448317|Experimental|Cohort 3|Alirocumab dose 3 versus placebo
3164775|NCT01448317|Experimental|Cohort 4|Alirocumab dose 4 versus placebo
3164776|NCT01448304|Experimental|alirocumab SAR236553 (REGN727) - Dose A|A single subcutaneous injection of Dose A
3164777|NCT01448304|Experimental|alirocumab SAR236553 (REGN727) - Dose B|A single subcutaneous injection of Dose B
3164778|NCT01448291|Experimental|Nuvaring|This is a single-group study in which data points after use of the etonogestrel/ethinyl estradiol vaginal ring will be compared to baseline.
3164779|NCT01448278|Experimental|All-inside technique|
3164780|NCT01448278|Active Comparator|Classical technique|
3164781|NCT01448265|Experimental|Paroxysmal atrial fibrillation.|
3164782|NCT01448252|Active Comparator|TCV|multiple T cell vaccinations against nine myelin peptides at days 1, 30, 90, 180
3164783|NCT01448252|Sham Comparator|Placebo|saline injections subcutaneously at the same 4 time points with active treatment
3164784|NCT01448239|Experimental|alirocumab SAR236553 (REGN727) - Dose A|A single subcutaneous injection of Dose A
3164785|NCT01448239|Experimental|alirocumab SAR236553 (REGN727) - Dose B|A single subcutaneous injection of Dose B
3164786|NCT01448226||proven or probable aspergillosis|
3164787|NCT01448226||possible aspergillosis|
3164788|NCT01448213|Active Comparator|Fluorometholone 0.1% Solution|Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
3164826|NCT01447940|Placebo Comparator|Conventional Care|Patients will have conventional care with 2 standard visits (inclusion and 12 months) + HbA1c measure at 6 months. Patients won't use Meos ePortal
3164789|NCT01448213|Active Comparator|Prednisolone acetate 1% Solution|Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
3164790|NCT01448200|Experimental|Part I: single dose escalation in healthy volunteers|"There will be three sequential single dose cohorts:~Cohort A: PPI-668 dose D1 or placebo~Cohort B: PPI-668 dose D2 or placebo~Cohort C: PPI-668 dose D3 or placebo"
3164791|NCT01448200|Experimental|Part I: multiple dose administration to healthy volunteers|"Upon completion of the single dose escalation phase, an additional cohort will receive repeat doses:~Cohort D: highest well-tolerated dose from Cohorts A-C or placebo once daily for five days"
3164792|NCT01448200|Experimental|Part II: multiple dose escalation in HCV subjects|"Upon completion of Part I, there will be 3, and potentially 4, sequential cohorts of HCV patients:~Cohort E (genotype-1): PPI-668 dose E1 or placebo~Cohort F (genotype-1): PPI-668 dose E2 or placebo~Cohort G (genotype-1): PPI-668 dose E3 or placebo~Cohort H (genotype-1): if necessary for dose-response assessment; dose to be determined~Cohort I (genotype-2 or -3): PPI-668 dose E4 or placebo"
3164793|NCT01448174|Active Comparator|atorvastatin|"The prospective, randomized, double-blind, placebo-controlled study:~will be preceded by one month non-pharmacological treatment of hyperlipidemia (prerandomization phase)~130 hyperlipidemic hemodialysis (HD) patients will be randomly assigned to receive blinded study drug: 65 patients will be allocated to start with atorvastatin and 65 patients - with placebo.~Atorvastatin will be administered and monitored according to the K/DOQI guidelines (2003).~The prospective, observational study:~- 35 hyperlipidemic patients will be followed for 30 weeks on the prescribed non-pharmacological treatment of hyperlipidemia"
3164794|NCT01448174|No Intervention|Lifestyle counseling|"Protocol of the prospective study in obese persons:~after taking the anthropometric measurements and collecting a blood sample, the start of weight lowering therapy with a prescribed diet and planned physical activity~follow-up for 30 weeks (measurement of body weight every week)."
3164795|NCT01448174|No Intervention|The controls (healthy volunteers)|
3164796|NCT01448161||Pediatric and Adult ICU patients|Pediatric and Adult ICU patients
3164797|NCT01448148|Experimental|Cognitive intervention|Use of Memo protocol for 8 weeks
3164798|NCT01448148|Experimental|Psychosocial intervention|"Use of Programme d'intervention psychosociale axé sur le bien-être psychologique for 8 weeks"
3164799|NCT01448148|No Intervention|no contact control group|waiting list
3164800|NCT01448135|Experimental|Vital AF|
3164801|NCT01448135|Active Comparator|Osmolite 1.2|
3164802|NCT01448122|Active Comparator|Avene Compact Honey SPF 50|Study product will be scraped from compact case and weighed. Product will be applied to half the area to be exposed with visible light at a concentration of 2 mg/mL.
3164803|NCT01448122|No Intervention|No intervention|Half of the area to be exposed to visible light will have no study product applied.
3164804|NCT01448109|Active Comparator|Hydrocortisone|
3164805|NCT01448109|Placebo Comparator|Sterile air filled vial|
3164806|NCT01448096|Experimental|primary breast DLBCL|isolated breast involvement with or without nodal disease
3164807|NCT01448083||Neuroendocrine tumor patients|
3164808|NCT01448070|Experimental|NN729 manufacturing process|
3164809|NCT01448070|Active Comparator|Current manufacturing process|
3164810|NCT01448057|Experimental|Combination Product|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
3164811|NCT01448057|Active Comparator|Paracetamol tablets|Paracetamol (500 mg) tablets
3164812|NCT01448044|Experimental|BMS-790052 + PegIFNα-2a + Ribavirin|"BMS-790052 60 mg Tablets, Oral, once daily for 24 weeks~PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 24 or 48 weeks depending on response~Ribavirin 400 mg (2 tablets for participants < 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 24 or 48 weeks depending on response"
3164813|NCT01448044|Placebo Comparator|Placebo matching BMS-790052 + PegIFNα-2a + Ribavirin|"Placebo matching BMS-790052 0 mg Tablets, Oral, once daily for 48 weeks~PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 48 weeks~Ribavirin 400 mg (2 tablets for participants < 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 48 weeks"
3164814|NCT01448031|Experimental|1|Capsule ASA 81mg/esomeprazole 20mg
3164815|NCT01448031|Active Comparator|2|ASA (Acetylsalicylzuur Apotex cardio 80 mg) Tablet 80 mg
3164816|NCT01448018|Active Comparator|ranibizumab|patients in this arm receive 3 monthly injection of ranibizumab
3164817|NCT01448018|Active Comparator|Hemodilution|hemodilution using erythrocytapheresis is performed as early as possible after inclusion, in order to lessen hematocrit level (target hematocrit of 35%)
3164818|NCT01448018|Active Comparator|ranibizumab and hemodilution|patients receive both treatments
3164819|NCT01448005||wearable defibrillator use|subjects will use a wearable defibrillator
3164820|NCT01447992|Experimental|Portable artificial pancreas system with Control-To-Range|
3164821|NCT01447979|Experimental|All patients|this is the only arm of the study, and concerns all patients.
3164822|NCT01447966|No Intervention|Treatment as Usual|Participants randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice.
3164823|NCT01447966|Experimental|Immediate CBT|Therapists will work with families for 12 twice weekly sessions, each lasting up to 60 minutes implementing a developmentally appropriate modulated cognitive behavioral therapy approach. A manualized CBT protocol will be followed.
3164824|NCT01447953|Experimental|Activity targeted pain rehabilitation|A new activity and life-role targeting pain rehabilitation program (ALAR) has been developed to reduce psychosocial barriers to rehabilitation progress, promote re-integration into life-role activities and facilitate return-to-work.
3164825|NCT01447953|Active Comparator|Treatment as usual|Usual treatment consisting of multimodal rehabilitation provided by multi-professional teams in primary health care in the County of Dalarna, Sweden.
3165614|NCT01442246|Experimental|Adjuvant treatment|Leuproreline acetate
3164827|NCT01447940|Experimental|Meos ePortal use|Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
3164828|NCT01447927|Experimental|Arm I|Patients receive extended-release metformin hydrochloride PO QD on week 1, and BID on weeks 2-12 (QAM QPM on week 3) in the absence of unacceptable toxicity or disease progression.
3164829|NCT01447927|Placebo Comparator|Arm II|Patients receive extended-release placebo PO QD on week 1and BID on weeks 2-12 (QAM and QPM on week 3) in the absence of unacceptable toxicity or disease progression.
3164830|NCT01447914|Experimental|ARQ 197 Treatment (Tivantinib)|Oral Tivantinib 360 mg twice daily continuously for each day (days 1-28) of every 4-week treatment cycle (taken as three tablets of 120 mg each). Courses continue every 28 days in the absence of disease progression or unacceptable toxicity.
3164831|NCT01447901||previously treated LPLD Cohort|Subjects in Cohort 1 (previously treated LPLD Cohort) must have received AMT-011 during Studies CT-AMT-011-01 or -02
3164832|NCT01447901||untreated LPLD control Cohort|Subjects in Cohort 2 (untreated LPLD control Cohort)) may have completed study PREPARATION-02 or known patients with genetically confirmed LPLD
3164833|NCT01447901||normal healthy control Cohort|Volunteers in Cohort 3 (normal healthy control Cohort) must not have LPLD
3164834|NCT01447888|Experimental|150% Oral Morphine Equivalent (OME)|Perioperative goal-directed opioid dosing at 150% of patient baseline oral morphine equivalent (OME) for opioid-tolerant patients
3164835|NCT01447888|Active Comparator|Control|Standard perioperative dosing, which does not currently account for patients' baseline opiate use.
3164836|NCT01447862|Active Comparator|Vernakalant|Initially, patients will be given 3mg/kg Vernakalant in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of Vernakalant (2mg/kg), again over 10 minutes. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.
3164837|NCT01447862|Active Comparator|Ibutilide|Patients will be given 1mg of ibutilide in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide, again over 10min. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.
3164838|NCT01447849|Active Comparator|Lubiprostone 24 mcg Twice a day|Both controls and patients with chronic constipation will receive 1 week of therapy with lubiprostone and one week of placebo.
3164839|NCT01447849|Placebo Comparator|Placebo|Both controls and patients with chronic constipation will receive placebo pills twice daily for one week in cross over design
3164840|NCT01447836||Sepsis|Sepsis patients who are admitted to SICU of our clinical center.
3164841|NCT01447836||Control|Postoperative patients who underwent abdominal surgery and then was directly transferred to SICU of our clinical center.
3164842|NCT01447810|Experimental|Treatment|
3164843|NCT01447797|Experimental|HCP0912|Irbesartan/Atorvastatin combination tablet
3164844|NCT01447797|Active Comparator|Irbesartan and Atorvastatin|coadministration of irbesartan and atorvastatin
3164845|NCT01447784|Placebo Comparator|Placebo|
3164846|NCT01447784|Experimental|ToleroMune HDM Dose 1|
3164847|NCT01447784|Experimental|ToleroMune HDM Dose 2|
3164848|NCT01447784|Experimental|ToleroMune HDM Dose 3|
3164849|NCT01447771|Experimental|Lifestyle counseling|Decision control preference intervention
3164850|NCT01447758|Experimental|LEO 29102 2,5 mg/g cream|
3164851|NCT01447758|Placebo Comparator|LEO 29102 Cream Vehicle|
3164852|NCT01447745||Observational, longitudinal study|Adult men and women representative of the population of asymptomatic adult men and women aged from 35-65 years living in the Québec City metropolitan area
3164853|NCT01447732|Experimental|Part 1|Dose escalation in subjects with advanced solid tumors with Part 1 which includes intervention of CEP-37250/KHK2804
3164854|NCT01447732|Experimental|Part 2|Subjects with colorectal or pancreatic cancer Part 2 which includes intervention of CEP-37250/KHK2804
3164855|NCT01447706|Active Comparator|Paclitaxel|Standard dosing paclitaxel: 80 mg/m2 QW intravenously)
3164856|NCT01447706|Experimental|MM-121 (SAR256212) + Paclitaxel|administered intravenously at 40 mg/kg loading dose on Cycle 1, Week 1 followed by 20 mg/kg QW for all subsequent doses
3164857|NCT01447680||Blood samples, low risk population|
3164858|NCT01447680||Blood samples, high risk population|
3164859|NCT01447680||Blood samples, known HIV positive|
3164860|NCT01447667|Experimental|Magnetic resonance elastography|Magnetic resonance elastography before radiofrequency ablation therapy will be performed.
3164861|NCT01447654|Active Comparator|Losartan|
3164862|NCT01447654|Placebo Comparator|Placebo|
3164863|NCT01447641||Cluster headache|Cluster headache sufferers (both chronic and episodic)
3164864|NCT01447628|Active Comparator|Ferinject or CosmoFer|"IV iron formulation used in Europe - Ferinject - given over 15 minutes~IV iron formulation used in China - CosmoFer - over a period of 4 to 6 hours"
3164865|NCT01447628|Placebo Comparator|Saline|
3164866|NCT01447615|Experimental|Bridges|
3164867|NCT01447615|Experimental|Bridges PLUS|
3164868|NCT01447615|Other|Usual Care|
3164869|NCT01447602|Experimental|Interpersonal psychotherapy (IPT-A)|Interpersonal psychotherapy for depressed adolescents which focuses on identifying problematic relationships connected to onset or maintenance of depression and suicidal behavior. The treatment teaches skills such as communication and problem-solving to the adolescent and parents.
3164870|NCT01447589|Experimental|Nelfinavir plus radical radiotherapy|Nelfinavir given in combination with radical RT
3164871|NCT01447576|Experimental|OPC-34712 + ADT|Experimental: OPC-34712, Oral Tablets, 0.25 - 3 mg; Antidepressant drug treatment
3164872|NCT01447563|Experimental|Clopidogrel tablets 75mg|subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
3164873|NCT01447563|Experimental|Clopidogrel|subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
3164874|NCT01447550||Bosentan|Bosentan
3164875|NCT01447537|Active Comparator|Exercise, relaxation|Active comparator: Exercise + relaxation Patients will perform exercise + relaxation for 3 months
3164876|NCT01447537|Other|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
3164877|NCT01447511|Other|CYP2C9*1/*1 Genotype|This genotype is considered the wild type genotype. Individuals with the CYP2C9*1/*1 genotype have two *1 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
3164878|NCT01447511|Other|CYP2C9*1B/*1B Haplotype|Individuals with the CYP2C9*1B/*1B haplotype have two *1B alleles and participated in the following interventions: Control - Warfarin only and Rifampin - Warfarin.
3164879|NCT01447511|Other|CYP2C9*1/*3 Genotype|Individuals with the CYP2C9*1/*3 genotype have one *1 allele and one *3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
3164880|NCT01447511|Other|CYP2C9*2/*3 Genotype|Individuals with the CYP2C9*2/*3 genotype have one *2 and one *3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
3164881|NCT01447511|Other|CYP2C9*3/*3 Genotype|Individuals with the CYP2C9*3/*3 genotype have two *3 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
3164882|NCT01447498|No Intervention|Control group|
3164883|NCT01447498|Active Comparator|Screening and risk assessment|
3164884|NCT01447485|Experimental|Valsartan 20 mg or 40 mg|
3164885|NCT01447472|Experimental|MDMA|One single dose of MDMA (1.5 mg/kg; range 75-100 mg)
3164886|NCT01447459|Experimental|Reinforced Education|"The caregivers of the subjects enrolled in this group will be administered two survey instruments at enrollment (t0), and again via telephone at 2 weeks (t1), 1 months (t2), and 3 months (t3) after enrollment.~This group will also receive reinforced asthma education via telephone at 2 weeks, 1 month, and 3 months after enrollment."
3164887|NCT01447459|No Intervention|No Reinforced Education|"The caregivers of the subjects enrolled in this group will be administered two survey instruments at enrollment (t0), and again via telephone at 2 weeks (t1), 1 month (t2), and 3 months (t3) after enrollment.~This group will not receive reinforcing of the asthma education at 2 weeks, 1 month, and 3 months after enrollment."
3164888|NCT01447446||Dual Therapy: Peg-IFN Alfa-2a + Ribavirin|Participants with chronic hepatitis C (CHC) receiving dual therapy (pegylated interferon alfa-2a [peg-IFN Alfa-2a] along with ribavirin according to standard of care and in line with local labeling) were followed up for the duration of their treatment and for up to 24 weeks after therapy.
3164889|NCT01447446||Dual Therapy: Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving dual therapy (pegylated interferon alfa-2b [peg-IFN Alfa-2b] along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
3164890|NCT01447446||Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
3164891|NCT01447446||Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
3164892|NCT01447446||Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
3164893|NCT01447446||Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
3164894|NCT01447433|Experimental|Calcium+D|Calcium supplements provide 600mg of calcium and 125IU vitamin D per day. A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
3164895|NCT01447433|Placebo Comparator|Control|A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
3164896|NCT01447420|Experimental|Peginterferon Alfa-2a Plus Ribavirin|
3164897|NCT01447407|Active Comparator|NDV-3 vaccine with alum|
3164898|NCT01447407|Active Comparator|NDV-3 vaccine without alum|
3164899|NCT01447407|Placebo Comparator|Placebo|
3164900|NCT01447407|Active Comparator|NDV-3 vaccine ID|
3164901|NCT01447394|Experimental|Arm 1: Pegylated Interferon Lambda + Ribavirin|
3164902|NCT01447394|Active Comparator|Arm 2: Pegylated Interferon Alfa-2a + Ribavirin|
3164903|NCT01447381||mycophenolate mofetil|Moderate to severe atopic dermatitis being treated with systemic mycophenolate mofetil
3164904|NCT01447381||cyclosporine|Moderate to severe atopic dermatitis being treated with systemic cyclosporine
3164905|NCT01447381||azathioprine|Moderate to severe atopic dermatitis being treated with systemic azathioprine
3164906|NCT01447381||methotrexate|Moderate to severe atopic dermatitis being treated with systemic methotrexate
3164907|NCT01447368|Experimental|Cinacalcet treatment|Oral Cinacalcet treatment arm, 25mg daily to be administered and gradually step up as required to control iPTH between 2 - 9 times lab reference range, Maximum dose to be given is 100mg daily
3164908|NCT01447368|Active Comparator|Surgical total parathyroidectomy|Surgical total parathyroidectomy with forearm autografting will be performed for patients randomized to this arm.
3164909|NCT01447355|Experimental|Prevention (cholecalciferol)|Participants receive cholecalciferol PO twice weekly for up to 8-9 weeks.
3164910|NCT01447329|Experimental|Standard treatment plus ear acupuncture|Standard treatment plus ear acupuncture
3164911|NCT01447329|Placebo Comparator|standard|placebo
3164912|NCT01447316||Bariatric surgery|Patients undergoing bariatric surgery for weight loss.
3164913|NCT01447303||Outcomes following viscosupplemantation|Patients with documented knee osteoarthritis receiving viscosupplementation of the knee.
3164914|NCT01447290||Women being evaluated for preeclampsia|
3164915|NCT01447277|Experimental|Femoral and Sciatic Block|
3164916|NCT01447277|Other|Femoral Block Only|
3164917|NCT01447264|Placebo Comparator|Land exercises|The patients of this group will perform the same exercises from water exercises
3164918|NCT01447264|Active Comparator|Water exercises|The patients of this group will perform the same exercises from land exercises
3164919|NCT01447264|No Intervention|Control group|No intervention will be recommended
3164920|NCT01447251|Experimental|A: Newly Diagnosed/CPAP/NO DM/PreDx DRS|patients who have newly-diagnosed obstructive sleep apnea (OSA) requiring continuous positive airway pressure (CPAP) therapy without diabetes and are given the result of the diabetes risk score
3164921|NCT01447251|Experimental|B: Newly Diagnosed/CPAP/NO DM/NO PreDx DRS|patients who have newly-diagnosed OSA requiring CPAP therapy without diabetes and are not given the result of the diabetes risk score
3164922|NCT01447251|Active Comparator|C: Controls|age, sex, and BMI-matched controls without OSA or diabetes
3164923|NCT01447251|Active Comparator|D: Controls on CPAP|age, sex, BMI, and OSA severity matched patients on CPAP therapy for OSA
3164924|NCT01447225|Experimental|MM-121 plus Gemcitabine|escalating doses of MM-121 and gemcitabine on Day 1 and Day 8 of every 3 week cycle
3164925|NCT01447225|Experimental|MM-121 plus Carboplatin|carboplatin at AUC 6 with escalating doses of MM-121 on Day 1 of every 3 week cycle
3164926|NCT01447225|Experimental|MM-121 plus Pemetrexed|pemetrexed at 500 mg/m2 with escalating doses of MM-121 on Day 1 of every 3 week cycle
3164927|NCT01447225|Experimental|MM-121 plus Cabazitaxel|escalating doses of MM-121 and cabazitaxel on Day 1 of every 3 week cycle
3164928|NCT01447212|Experimental|Hydromorphone|Phase I: Injectable Hydromorphone is received for 6 months of the study. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; or 2) switch to oral hydromorphone, for another six months.
3164929|NCT01447212|Active Comparator|Diacetylmorphine|Phase I: Injectable Diacetylmorphine is received for 6 months of the study. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable Diacetylmorphine; or 2) switch to oral Diacetylmorphine, for another six months.
3164930|NCT01447199||Gene Mutation|Group with increased risk for developing colorectal and/or other cancers as the result of an inherited gene mutation, family history of cancer, or an early age of cancer onset.
3164931|NCT01447199||No Cancer History|Group with little/no personal or family history of cancer.
3164932|NCT01447199||Spouses|Spouses of those who may have an increased risk for developing colorectal and/or other cancers as the result of an inherited gene mutation, family history of cancer, or an early age of cancer onset, or little/no personal or family history of cancer.
3164933|NCT01447186||Patient Decision Aid for Spanish Speaking Men|Spanish-Language Slide Set
3164934|NCT01447173|Experimental|2000 IU vitamin D Daily|
3164935|NCT01447173|Placebo Comparator|400 IU Vitamin D pill|
3164936|NCT01447160|Experimental|facet joint infiltration|The experimental group will be submitted to intra-articular infiltration of six facet joints (L3/L4;L4/L5;L5/S1 bilaterally) with triamcinolone hexacetonide
3164937|NCT01447160|Active Comparator|intramuscular injection|The control group which were submitted to triamcinolone acetonide intramuscular injection of six lumbar paravertebral points
3164938|NCT01447147|Placebo Comparator|Placebo (Group A)|
3164939|NCT01447147|Experimental|CCX140-B (Group B)|
3164940|NCT01447147|Experimental|CCX140-B (Group C)|
3164941|NCT01447134||Surgical|Group (a) [Those to undergo surgical excision or biopsy] patients will receive RGD-K5 scan within two weeks of conventional image evaluations. The image result will be confirmed with histopathological results.
3164942|NCT01447134||Chemotherapy concurrent Radiation|Group (b) patients [Those with N2c-3M0 disease to receive chemotherapy followed by concurrent chemoradiotherapy] will receive RGD-K5 scan prior to beginning of the therapy, after induction chemotherapy, within two weeks after concurrent chemoradiotherapy and two months after completion of concurrent chemoradiotherpy; all within two weeks of conventional image evaluations.
3164943|NCT01447134||RGD-K5 scan|Group (c) patients [Those with M1 disease to receive biotherapy or chemotherapy] will receive RGD-K5 scan prior to the beginning of the first line systemic therapy, two weeks after beginning of the first line systemic therapy, within two weeks of first response evaluation for the first line systemic therapy, and within two weeks after end of the first line systemic therapy; each RGD-K5 scan would be performed within two weeks of conventional image studies. The systemic therapy might be biotherapy or chemotherapy.
3164944|NCT01447121|Experimental|Intended Users of the System|Untrained subjects with diabetes use an investigational blood glucose monitoring system (Tatsu/Tradewind Investigational BG Monitoring System) to self-test capillary blood obtained from fingerstick.
3164945|NCT01447108|Experimental|TN patients|Patients suffering from Trigeminal neuralgia
3164946|NCT01447095|Active Comparator|Low dose prostacyclin|
3164947|NCT01447095|Active Comparator|High dose prostacyclin|
3164948|NCT01447095|Placebo Comparator|Placebo|
3164949|NCT01447082||Quetiapine XR group|
3164950|NCT01447082||Non-quetiapine comparison group|
3164951|NCT01447069|Active Comparator|Salbutamol|The patients in the study groups will receive the selective β2 agonist, Salbutamol, in addition to their ongoing optimal heart failure therapy.
3164952|NCT01447069|No Intervention|control|The patients in the control group will continue with their regular optimal medical therapy without any intervention.
3164953|NCT01447056|Experimental|LMP Specific T cells|LMP specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line and the IV flushed with saline. The volume of infusion will depend upon the concentration of the cells when frozen, the dose level, and the size of the patient.
3164954|NCT01447043||Group 1|
3164955|NCT01447017|Experimental|DPK-060 2% ear drops|DPK-060 2% ear drops, 0.3 mL/pipette, 3 times daily for 7 or 10 days (as applicable).
3164956|NCT01447017|Placebo Comparator|Placebo for DPK-060 ear drops|Placebo for DPK-060 ear drops, 0.3 mL/pipette, 3 times daily for 7 or 10 days (as applicable).
3164957|NCT01446991|Experimental|Favorable prostate cancer with pubic arch interference|Men in this arm have chosen brachytherapy for management of localized prostate cancer and do not require androgen ablation for oncologic reasons but have an enlarged prostate causing pubic arch interference and thus require prostate size reduction prior to brachytherapy. They will have 2-3 months of Degarelix with measurement of prostate volume at 8 and 12 weeks.
3165045|NCT01446406|Active Comparator|MONARCA|MONARCA self-monitoring application on a cell phone to monitor affective symptoms every day.
3165615|NCT01442246|No Intervention|Surveillance|Surveillance
3164958|NCT01446991|Experimental|Intermediate risk prostate cancer, 6 months Degarelix|Men in this arm have higher risk prostate cancer (upper tier intermediate risk by National Comprehensive Cancer Network [NCCN] guidelines) and require 6 months of androgen ablation in conjunction with brachytherapy. Prostate size must be > 40 cc at baseline so that prostate size reduction measurements are appropriate. Prostate measurements by transrectal ultrasound with be taken at 12 weeks and 20 weeks.
3164959|NCT01446978|Active Comparator|initial single dose of hep A vaccine|The participants will receive a single dose of hepatitis A vaccine at 0+1+6 months
3164960|NCT01446978|Active Comparator|initial double dose|Participants will receive one dose of hepatitis A vaccine in each M. deltoids and an additional dose at 6 months later
3164961|NCT01446965|Experimental|Wearable defibrillator|subjects will use a wearable defibrillator for three months following myocardial infarction
3164962|NCT01446965|No Intervention|Conventional treatment|
3164963|NCT01446952|Experimental|Dose Escalation|Vitamin E δ-Tocotrienol will be administered orally as a single agent once. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules.
3164964|NCT01446939||Parkinson's disease|Patients with primary Parkinson's disease
3164965|NCT01446939||Essential tremor|Patients with essential tremor
3164966|NCT01446939||Healthy volunteers|Healthy volunteers
3164967|NCT01446926|Experimental|Group 1: Adults High Dose (Formulation 1)|Adults who will receive a single injection of high dose investigational Pneumococcal vaccine
3164968|NCT01446926|Placebo Comparator|Group 2: Adults Placebo|Adult participants who will receive an injection of placebo
3164969|NCT01446926|Experimental|Group 3: Toddlers High Dose (Formulation 1)|Toddlers who will receive a single injection of high dose Pneumococcal vaccine
3164970|NCT01446926|Placebo Comparator|Group 4: Toddlers Placebo|Toddlers who will receive a single injection of placebo
3164971|NCT01446926|Experimental|Group 5: Infants Low Dose (Formulation 2)|Infants who will receive 3 injections of low dose low dose Pneumococcal vaccine
3164972|NCT01446926|Placebo Comparator|Group 6: Infants Placebo|Infants who will receive 3 injections of placebo
3164973|NCT01446926|Experimental|Group 7: Infants Middle Dose (Formulation 3)|Infants who will receive 3 injections of middle dose Pneumococcal vaccine
3164974|NCT01446926|Experimental|Group 8: Infants Middle Dose (Formulation 4)|Infants who will receive 3 injections of middle dose Pneumococcal vaccine
3164975|NCT01446926|Placebo Comparator|Group 9: Infants Placebo|Infants who will receive 3 injections of placebo
3164976|NCT01446926|Experimental|Group 10: Infants High Dose (Formulation 1)|Infants who will receive 3 injections of high dose Pneumococcal vaccine
3164977|NCT01446926|Placebo Comparator|Group 11: Infants Placebo|Infants who will receive 3 injections of placebo
3164978|NCT01446913|Active Comparator|Standard Intervention group|This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.
3164979|NCT01446913|Active Comparator|Enhaced CPAP intervention|This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.
3164980|NCT01446913|No Intervention|Usual Care|This group usual care after TIA/stroke and a sleep study at the end of the study.
3164981|NCT01446900|Experimental|Rituximab cladribine|
3164982|NCT01446887|No Intervention|non-prophylactic anticoagulation|without prophylactic anticoagulation
3164983|NCT01446887|Experimental|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
3164984|NCT01446874|Experimental|Pre-operative brushing (Pilot Portion)|-Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution
3164985|NCT01446874|Experimental|Pre-operative & Post-Operative Brushing (Esophageal Resection)|"Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution~The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group."
3164986|NCT01446874|Experimental|Pre-operative & Post-Operative Brushing (Lung Resection)|"Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution~The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group."
3164987|NCT01446861||Cystic fibrosis patients|Consecutive cystic fibrosis patients attending regular Controls at the CF clinic in Bergen
3164988|NCT01446861||Healthy controls|Age and gender matchet healthy Controls recruited by Board notice and advertising.
3164989|NCT01446848|Experimental|iron supplement|open-label iron supplement intervention group
3164990|NCT01446835|Experimental|nelfilcon A|Nelfilcon A printed contact lens randomly assigned to one eye, with etafilcon A printed contact lens assigned to the fellow eye for contralateral wear. Lenses will be worn for 20 minutes.
3164991|NCT01446835|Active Comparator|etafilcon A|Etafilcon A printed contact lens randomly assigned to one eye, with nelfilcon A printed contact lens assigned to the fellow eye for contralateral wear.
3164992|NCT01446822|Experimental|Bipolar transurethral resection|
3164993|NCT01446822|Active Comparator|Monopolar transurethral resection|
3164994|NCT01446809|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
3164995|NCT01446809|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
3164996|NCT01446796|Placebo Comparator|Native Conduction|Devices will be programmed to continuous atrial pacing at an AAI (atrial inhibited pacing) setting with base rate 90 bpm. Patients will not receive ventricular pacing.
3164997|NCT01446796|Experimental|Continuous RV Pacing|Devices will be programmed to continuous dual chamber pacing at a DDD (dual chamber dual pacing) setting with base rate ≥ 90 bpm (not to exceed 100 bpm) to achieve a majority (>80%) of paced right ventricular beats
3164998|NCT01446783|Active Comparator|mecasermin + Ehlers-Danlos|
3164999|NCT01446783|Placebo Comparator|Saline + Ehlers-Danlos|
3165000|NCT01446783|Active Comparator|Mecasamin + healthy control|
3165001|NCT01446783|Placebo Comparator|Saline + healthy control|
3165173|NCT01445509|Experimental|Group 2|Group 2 will be randomized as to which agent they receive for cycle one. Cycles 2 and beyond are treated using both agents.
3165002|NCT01446757|Experimental|The intervention group|The intervention group will receive Comprehensive Geriatric Assessment and follow up as a complement to the same standard health care services as the control group. The Comprehensive Geriatric Assessment and follow up will be provides through an outpatient facility that tailors care from a holistic perspective and, based on each patient's individual needs in line with the policy program that Sweden's pensioners' organizations have presented in 2010 together with the Swedish Association of Geriatric Medicine. The team includes, among other things. a. geriatricians, nurses, physiotherapists, assistance officer, dietician, pharmacist and co-operation with the dental hygienist.
3165003|NCT01446757|Placebo Comparator|Control group|The control group will receive care in the same way as usual meaning access to primary care, hospital in- and outpatient care and care received by the municipality. The only difference between the two groups are that the control group will not have access to the geriatric care team.
3165004|NCT01446744|Active Comparator|Standard arm|Standard of care, palliative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
3165005|NCT01446744|Experimental|Stereotactic arm|Stereotactic ablative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
3165006|NCT01446731|Experimental|Arm A|DC vaccine (mRNA transfected dendritic cell) + Docetaxel
3165007|NCT01446731|Active Comparator|Arm B|Docetaxel alone
3165008|NCT01446718||Gardasil Vaccine|"This is an extension of follow up for participants who received 3 doses of Gardasil vaccine in the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Vaccine in HIV-Infected Pre-Adolescent Girls and Boys in Kenya study."
3165009|NCT01446705||No Exchange|Patients in this arm will represent Veterans seen at the Indianapolis VA Medical Center (VAMC) for whom information exchange has not been activated.
3165010|NCT01446705||Enrolled in Exchange|"Patients in this arm will represent Veterans seen at the Indianapolis VAMC for whom information exchange has been activated by the patient choosing to opt-in."
3165011|NCT01446692||Patients with suboptimal response|
3165012|NCT01446692||Patients with symptomatic remission|
3165013|NCT01446679||atrovastatin group|Who receive atrovastatin
3165014|NCT01446666||HCC high-risk group|"Patients with liver cirrhosis with the 1-year risk of HCC of 5% or higher~; High Risk Index (>=2.33)~Risk Index = 1.65 (if the prothrombin activity is <=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is <=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus [HCV] or hepatitis B surface antigen [HBsAg] is positive)."
3165015|NCT01446653|Experimental|EARLY|Motivational Interviewing plus feedback counseling with information via video and brochures
3165016|NCT01446653|Active Comparator|Video Information|Providing FASD information via documentary video clips
3165017|NCT01446653|Active Comparator|Informational Brochure|Participants will receive informational brochures on contraception, women and drinking, and cutting down your drinking.
3165018|NCT01446640|Experimental|MSC|Intravenous combined with intrathecal administration of autologous bone marrow derived mesenchymal stem cells to patients with spinal cord injury.
3165019|NCT01446627||metal staples|
3165020|NCT01446627||Insorb vicryl staples|
3165021|NCT01446614|Experimental|MSC|Intravenous autologous bone marrow derived mesenchymal stem cells infusion to patients with Parkinson's disease.
3165022|NCT01446601|Experimental|Treatment|The Treatment Arm is implanted with the HGNS System and therapy is turned on at 1 month post-implant.
3165023|NCT01446601|Other|Control|The Control Arm is implanted with the HGNS System and therapy is turned on at 7 months post-implant.
3165024|NCT01446588|Experimental|Yoga|Yoga group
3165025|NCT01446562|Experimental|Y90 Ibritumomab Tiuxetan|Addition of Y90 Ibritumomab Tiuxetan RIT to CHOP-R treatment for follicular lymphoma-patients also receive maintenance Rituximab every 3 months for 2 years after the Y90 Ibritumomab Tiuxetan
3165026|NCT01446549|Experimental|Deep Brain Stimulation|
3165027|NCT01446549|Experimental|Locomotor Exercise|
3165028|NCT01446536|No Intervention|Control group|This arm which was control group, was randomly selected among patients with acute decompensated heart failure in whom the checklist was not used. This group was managed as per the standard guidelines.
3165029|NCT01446536|Active Comparator|Checklist (intervention) cohort|checklist was used in this group arbitrarily by their treating physician
3165030|NCT01446523|Placebo Comparator|Lactulose|Group L receives lactulose Group NL receives placebo
3165031|NCT01446523|Placebo Comparator|Placebo|Group NL receives placebo
3165032|NCT01446510||Hospitalized Medical Patients|All hospitalized medical adult patients
3165033|NCT01446497|Active Comparator|Timolol|non selective beta blocker, aqueous humor suppressant ophthalmic solution
3165034|NCT01446497|Active Comparator|Combigan (Timolol/Brimonidine) combination drug|Brimonidine: alpha-2 agonist
3165035|NCT01446484|Experimental|T reg therapy|Kidney transplantation, followed by immunotherapy given along with autologous CD4+CD25+CD127lowFoxP3+ T regulatory cells infusions
3165036|NCT01446484|Active Comparator|Immunosuppression|Patients will undergo immunosuppressive therapy followed by living related kidney transplantation
3165037|NCT01446471||Cardiac Arrest|Patients in Cardiac Arrest will be enrolled
3165038|NCT01446458|Experimental|5-Fluorouracil, Oxaliplatin, Irinotecan|5-Fluorouracil, Oxaliplatin, Irinotecan are administered as a modified FOLFIRINOX regimen every 15 days. Subjects receive bi-weekly cycles of therapy on the 1st week, the 3rd week, the 5th week and finally the 7th week for a total of 4 cycles. Assessments include history and physical, laboratory tests on a weekly basis throughout the treatment period prior to and including week 8 assessment for stereotactic body radiotherapy (SBRT).
3165039|NCT01446445|Active Comparator|1.A (Prophylaxis-SPC)|Prophylaxis for CMV infection and Ganciclovir/ Valganciclovir doses according to summaries of product characteristics (SPC).
3165040|NCT01446445|Experimental|1.B (Prophylaxis- PK model)|Prophylaxis for CMV infection and Ganciclovir/Valganciclovir doses according to pharmacokinetic model.
3165041|NCT01446445|Active Comparator|2.A (Treatment-SPC)|Treatment for CMV infection/disease and Ganciclovir/ Valganciclovir doses according to summaries of product characteristics (SPC).
3165042|NCT01446445|Experimental|2.B (Treatment-PK model)|Treatment for CMV infection/disease and Ganciclovir/Valganciclovir doses according to pharmacokinetic model
3165043|NCT01446419|Experimental|Intracept Treatment|
3165044|NCT01446419|Sham Comparator|Sham Treatment|
3165046|NCT01446406|Placebo Comparator|NON-MONARCA|This is the same mobile phone as the MONARCA mobile phone. Yet the MONARCA application has not been installed. The mobile phone can only be used as a normal mobile phone for communication purposes.
3165047|NCT01446380||Pseudoxanthoma elasticum|
3165048|NCT01446354||Cardiac surgery with HCA|Patients undergoing cardiac surgery with the help of hypothermic cardiac arrest for pathologies of the proximal aorta
3165049|NCT01446341|Active Comparator|Immobilization|50 patients will be randomly assigned to have their lateral ankle sprain immobilized in a below knee cast
3165050|NCT01446341|Active Comparator|Functional Rehabilitation|50 patients will be randomly assigned to a functional rehabilitation program for their lateral ankle sprain
3165051|NCT01446328|Active Comparator|Amisulpride|
3165052|NCT01446328|Active Comparator|Aripiprazole|
3165053|NCT01446328|Active Comparator|Olanzapine|
3165054|NCT01446315|Experimental|Asthma APGAR|Use of new asthma care tools. Primary care practices will be provided and educated about the Asthma APGAR tool system to guide asthma care. The practices will adopt this system for all people in their practices with asthma. Outcomes will be assessed only for those who meet enrollment criteria and sign informed consent.
3165055|NCT01446315|Placebo Comparator|Usual care|Usual asthma care as provided by the sites.
3165056|NCT01446302|Active Comparator|Double meal on a HD day|A standardized meal is served 1 h after start of HD and 1 h after end of HD
3165057|NCT01446302|No Intervention|Single meal on a HD day|A standardized meal is served 1 h after start of HD. After the meal participants fast for 9 h (6 h after end of HD).
3165058|NCT01446302|No Intervention|Single meal on a non-HD day|A standardized meal is served 1 h after study start. After the meal participants fast for 9 h.
3165059|NCT01446302|No Intervention|Single meal (healthy controls)|A standardized meal is served 1 h after study start. After the meal participants fast for 9 h.
3165060|NCT01446289|Experimental|Group B Streptococcus Trivalent Vaccine|Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine.
3165061|NCT01446289|Placebo Comparator|Placebo|Pregnant women who received one injection of saline solution.
3165062|NCT01446276|Experimental|Resveratrol|Resveratrol 500mg 3 times daily for six month
3165063|NCT01446276|Placebo Comparator|Placebo|Placebo 1 tablet 3 times daily for six month
3165064|NCT01446276|No Intervention|Control group|Men without non-alcoholic fatty liver disease
3165065|NCT01446263|Active Comparator|Radial access|
3165066|NCT01446263|Active Comparator|Femoral access|
3165067|NCT01446250|Experimental|Alisporivir|At the time of partial clinical hold, participants randomized to original treatment arms A and B (Alisporivir triple therapy arms with Peginterferon alfa-2a and Ribavirin) discontinued alisporivir treatment immediately while continuing their treatments with the other two therapies. These participants were combined into the same arm because they received the same dose of alisporivir 400 mg twice per day (BID) for the same duration. Amendment 1 offered them the opportunity to continue in the study receiving boceprevir triple therapy.
3165068|NCT01446250|Active Comparator|Boceprevir|Participants randomized to boceprevir triple therapy with Peginterferon alfa-2a and Ribavirin (the original treatment arm C).
3165069|NCT01446237|Experimental|Acne system - benzoyl peroxide 2.5%, Salicylic Acid 0.5%|open label - no comparator; only Acne system - benzoyl peroxide 2.5%, Salicylic Acid 0.5%
3165070|NCT01446224||Subjects who experience cardiac ischemia|Subjects who experience cardiac ischemia including myocardial infarction, unstable angina, transient ischemic attack, and cerebrovascular accident
3165071|NCT01446224||Subjects who do not experience cardiac ischemia|Subjects who do not experience cardiac ischemia
3165072|NCT01446224||Subjects who experience Torsades de Pointes|Subjects who experience Torsades de Pointes
3165073|NCT01446224||Subjects who do not experience Torsades de Pointes|Subjects who do not experience Torsades de Pointes
3165074|NCT01446211|Experimental|Test group - gusperimus|Both severity subgroups (severe and non-severe) will be treated with gusperimus + glucocorticoids.
3165075|NCT01446211|Active Comparator|Control group|"The severe subgroup will receive a course (13 - 22 weeks) of cyclophosphamide followed by methotrexate + glucocorticoids. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids.~The non-severe subgroup will receive methotrexate + glucocorticoids(or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function)."
3165076|NCT01446198||AHPV positive and negative subjects|
3165077|NCT01446185|Other|a HR+, N- or pN1(mi), Her2- breast cancer adjuvant population|
3165078|NCT01446172||cognitive, schema focused, guided mastery, exposure|
3165079|NCT01446159|Experimental|MEDI-573 10 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort A of the study will receive intravenous infusion of MEDI-573 10 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
3165080|NCT01446159|Experimental|MEDI-573 30 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort B of the study will receive intravenous infusion of MEDI-573 30 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
3165081|NCT01446159|Experimental|MEDI-573 45 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort C and Phase 2 Arm 1 of the study will receive intravenous infusion of MEDI-573 45 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
3165082|NCT01446159|Experimental|Aromatase Inhibitor|Participants who will be enrolled in Phase 2 Arm 2 of the study will receive oral AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
3165083|NCT01446146|Experimental|IDM intervention|Will receive a 40 minute intervention session with a clinician, learning about PTSD treatment options and choosing a preferred treatment.
3165084|NCT01446146|Placebo Comparator|Treatment as usual plus placebo session|Will work with provider to select a treatment plan and will receive a 40 minute session without IDM intervention.
3165651|NCT01441999|Active Comparator|Rigid Rods|Titanium rods
3165085|NCT01446133|Experimental|Untreated 65 +|"Patients with untreated SLL/CLL with indications for treatment that are age 65 or older.~Rituximab (375 mg/m2) will be given intravenously on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2. Lenalidomide will be started on Day 9 of cycle 1 at the dose of 10 mg/day and will be continued daily. Treatment duration will be 12 cycles and it will be possible to continue beyond 12 cycles if there is a significant benefit such as an ongoing Partial Response or Complete Response."
3165086|NCT01446133|Experimental|Prior Treatment Any Age|"Patients of any age with previously treated CLL/SLL and recurrent disease.~Rituximab (375 mg/m2) will be given intravenously on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2. Lenalidomide will be started on Day 9 of cycle 1 at the dose of 10 mg/day and will be continued daily. Treatment duration will be 12 cycles and it will be possible to continue beyond 12 cycles if there is a significant benefit such as an ongoing Partial Response or Complete Response."
3165087|NCT01446120|Experimental|Insulin loaded Orally Dissolved Films (insulin-ODF)|
3165088|NCT01446120|Active Comparator|Human Insulin Specific RIA Kit <5uCi|
3165089|NCT01446107|Experimental|fissure sealant|single placement of resin fissure sealant on tooth surface
3165090|NCT01446107|Experimental|fluoride varnish|application of a 5% sodium fluoride varnish every 6 months
3165091|NCT01446107|Experimental|SDF solution|application of a 38% silver diamine fluoride solution onto tooth surface every year
3165092|NCT01446107|Placebo Comparator|control|application of water onto tooth surface every year
3165093|NCT01446094|Other|single-arm|Additional images collected during routine cardiac MRI (CMR) with diagnostic imaging agent, regadenoson.
3165094|NCT01446081|Experimental|Exercise|Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP).
3165095|NCT01446081|No Intervention|Control|Participants assigned to this arm will receive usual care.
3165096|NCT01446068|Experimental|Lean Subjects|
3165097|NCT01446068|Experimental|Obese subjects|
3165098|NCT01446055|Experimental|ResQ process group|Autologous BM-MNC is enriched with ResQ process(an automatic cell separator). Then the cell product is transplanted into the ischemia limbs of a patient.
3165099|NCT01446055|Active Comparator|Ficoll-based conventional method|A conventional method based on Ficoll cell separation is used to process bone marrow.
3165100|NCT01446042|Experimental|TBS-1 - b.i.d.|5.5 mg per nostril of 4.5% TBS-1 BID
3165101|NCT01446042|Experimental|TBS-1 - t.i.d.|5.5 mg per nostril of 4.5% TBS-1 TID
3165102|NCT01446029|No Intervention|Usual Care|
3165103|NCT01446029|Active Comparator|Intervention Device|
3165104|NCT01446016|Active Comparator|Taxane|Taxane
3165105|NCT01446016|Active Comparator|Taxane-Like|Taxane-Like (Paclitaxel, Docetaxel, Abraxane, Ixabepilone)
3165106|NCT01446003|Experimental|MK-8457-Placebo Sequence|Participants received MK-8457 100 mg twice daily (BID) for 10 days followed by Placebo for 10 days. Each treatment was separated by a 10-day washout.
3165107|NCT01446003|Experimental|Placebo-MK-8457 Sequence|Participants received Placebo for 10 days followed by MK-8457 100 mg BID for 10 days. Each treatment was separated by a 10-day washout.
3165108|NCT01445964|Experimental|1|SLCO2B1 wild type allele
3165109|NCT01445964|Experimental|2|SLCO2B1 variant allele
3165110|NCT01445951|Experimental|Technosphere® Insulin with MedTone C Inhaler|Subjects will receive TI with the MedToneC inhaler and remain on the basal insulin they were taking prior to study entry
3165111|NCT01445951|Active Comparator|Aspart Group|Subjects will receive insulin aspart and remain on the basal insulin they were taking prior to study entry
3165112|NCT01445951|Experimental|Technosphere ® Insulin-Gen2 Group|Subject will receive Technosphere Insulin with Gen2 Inhaler and remain on the basal insulin they were taking prior to study entry
3165113|NCT01445938|Experimental|Step 1 (SAR97276A od)|1 group of paediatric patients will receive 0.5 mg/kg SAR97276A administration once daily (od) for 3 days
3165114|NCT01445938|Experimental|Step 1 (SAR97276A bid)|1 group of paediatric patients will receive 0.25 mg/kg SAR97276A administration twice daily (bid) for 3 days
3165115|NCT01445938|Active Comparator|Step 1 (ACTs)|1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days
3165116|NCT01445938|Experimental|Step 2 (SAR97276A)|1 or 2 groups of paediatric patients will receive SAR97276A once daily (od) or twice a day (bid) administration for 3 days (the choice of the od or bid regimen will be based on the results obtained in step 1)
3165117|NCT01445938|Active Comparator|Step 2 (ACTs)|1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days
3165118|NCT01445938|Experimental|Step 3 (SAR97276A)|1 group of paediatric patients (2 to 11 years old) will receive: SAR97276A od or bid administration for 3 days (depending on results of step 1)
3165119|NCT01445925|Active Comparator|Pulmonary vein isolation|Patients will undergo pulmonary venous isolation plus pharmacological substrate modification
3165120|NCT01445925|Experimental|Pulmonary vein isolation + Linear Lesions|Patients will undergo pulmonary venous isolation plus both pharmacological and interventional substrate modification
3165121|NCT01445899|Experimental|PF-04523655 (Stratum II)|Stratum II, 6 monthly injections of PF-04523655 only
3165122|NCT01445899|Experimental|PF-04523655 and ranibizumab|Stratum II, 6 monthly injections of PF-0423655 and ranibizumab administered in combination
3165123|NCT01445899|Active Comparator|ranibizumab|Stratum II, 6 monthly IVT injections of ranibizumab only
3165124|NCT01445899|Experimental|PF-04523655 (Stratum I)|Stratum I
3165125|NCT01445886|Experimental|Indigo Naturalis Oil Extract|
3165126|NCT01445886|Active Comparator|Calcipotriol solution|
3165127|NCT01445873||PAH patients receiving Sitaxentan|
3165128|NCT01445860|Experimental|Treatment|
3165129|NCT01445847|Active Comparator|Lidocaine|Lidocaine 1% was prepared in 10 mL syringe= 10 mg/mL, dosage was 1mg/kg, one bolus or 10 mL/kg, with range of 2mg could be added or missed. The maximum dose is 100 mg for patients with weight of more than 100
3165130|NCT01445847|Placebo Comparator|Placebo|Normal saline was prepared in 10 mL syringe, dosage was 1 mL/10 kg.
3165131|NCT01445834||Incontinent women|
3165955|NCT01439958|Experimental|L-CsA|Twice daily inhalation of L-CsA
3165132|NCT01445821|Active Comparator|Cytoxan rATG/HSCT|The control arm will have the same conditioning regimen used in ASSIST study. The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. Peripheral blood stem cells (PBSC) will be infused intravenously on day 0. Filgrastim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
3165133|NCT01445821|Experimental|Cytoxan rATG/Fludarabine/HSCT|The conditioning regimen will be 120 mg/kg of intravenous cyclophosphamide given in 2 equal fractions on days -3 and -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Fludarabine 30 g/m2 will be given IV on days -5, -4, and -3. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. PBSC will be infused intravenously on day 0. Filgrastim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
3165134|NCT01445808|Experimental|Psychodynamic Motivation and Training Program (PMT)|
3165135|NCT01445808|Active Comparator|Advice in Exercise Training|One session of advice in exercise training based on the results of spiroergometry
3165136|NCT01445808|Other|Treatment as usual (TAU)|Usual care by family doctor and cardiologist
3165137|NCT01445795|Experimental|200 mg INX-08189 Fasted|Cohort 1: 200 mg INX-08189 QD fasted for seven days
3165138|NCT01445795|Placebo Comparator|Placebo QD Fasted|Cohort 1: Placebo QD fasted for seven days
3165139|NCT01445795|Experimental|100 mg INX-08189 with Ribavirin|Cohort 2: 100 mg INX-08189 100 mg dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID, the AM dose will be taken 4 hours after INX-08189 so it may be taken with food)
3165140|NCT01445795|Active Comparator|Placebo QD dosed with ribavirin|Cohort 2: Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
3165141|NCT01445795|Experimental|100 mg INX-08189 with a low-fat meal|Cohort 3: 100 mg INX-08189 with a low-fat meal QD x7 days
3165142|NCT01445795|Placebo Comparator|Placebo with low-fat meal|Cohort 3: Placebo administered with a low-fat meal QD for 7 days
3165143|NCT01445795|Experimental|100 mg INX-08189 Fasted|Cohort 4: 100 mg INX-08189 BID fasted x7 days
3165144|NCT01445795|Placebo Comparator|Placebo BID Fasted|Cohort 4: Placebo BID fasted x7 days
3165145|NCT01445782|Experimental|1|AZD2115
3165146|NCT01445782|Placebo Comparator|2|Placebo to AZD2115
3165147|NCT01445769|Experimental|Ruxolitinib|Participants initially received ruxolitinib 10 mg twice a day (bid) for 24 weeks. Dose increases of 5 mg bid were possible at Weeks 12 and 18 up to a maximum dose of 20 mg bid.
3165148|NCT01445756|Active Comparator|Topical Lidocaine|Topical Lidocaine
3165149|NCT01445756|Placebo Comparator|Placebo|Placebo
3165150|NCT01445743|Experimental|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention women will receive a blinded dose of Tdap vaccine (ADACEL)
3165151|NCT01445743|Placebo Comparator|Placebo Comparator: Physiologic Saline solution|Administration of Tdap vaccine or placebo as a single 0.5 mL of Saline (0.9% NaCl) solution
3165152|NCT01445730|Experimental|Hypercaloric fructose diet|1. TG ≤1.7 mmo/l 2. TG > 1.7 mmol/l
3165153|NCT01445730|Active Comparator|Isocaloric fructose diet|3. TG ≤1.7 mmo/l 4. TG > 1.7 mmol/l
3165154|NCT01445704|Experimental|Probiotics|Patients treated with a probiotic (in capsule form) once daily for 12 weeks
3165155|NCT01445704|Placebo Comparator|Placebo|Patients treated with a placebo (in capsule form) identical to that of the probiotic capsule once daily for 12 weeks
3165156|NCT01445691|Experimental|5-ALA (Gliolan)|Fluorescent substance to help visualize and remove as much tumor as possible without harming healthy tissue.
3165157|NCT01445678|Experimental|CXA-201 and Metronidazole as treatment for cIAI|
3165158|NCT01445678|Active Comparator|Meropenem as treatment for cIAI|
3165159|NCT01445652|Experimental|nelfilcon A|Nelfilcon A contact lenses worn in both eyes on a daily disposable basis a minimum of five days per week, eight hours per day, for six months
3165160|NCT01445652|Active Comparator|Spectacles|Spectacles per current prescription worn a minimum of five days per week, eight hours per day, for six months
3165161|NCT01445639|Experimental|Dexmedetomidine group|
3165162|NCT01445639|Placebo Comparator|Placebo group|
3165163|NCT01445626||All participants|Patients who received at least two OZURDEX® (dexamethasone intravitreal implant) injections.
3165164|NCT01445613|Other|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
3165165|NCT01445600||ALTARGO(retapamulin)|The subjects with bacterial skin and skin structure infections (SSSI)
3165166|NCT01445587|Experimental|GSK2110183|The oral dose of GSK2110183 the subjects received will be dependent on when the subject is enrolled to the study. GSK2110183 will be provided in 25mg and 50mg capsules containing the hydrochloride salt form of the API, microcrystalline cellulose, magnesium stearate, and microcrystalline cellulose (optional). They are filled into hard gelatin capsules. The 25mg tablets are opaque, swedish orange, size 2 capsules with no external markings, filled with a white powder. The 50mg tablets are opaque, white, size 1 capsules with no external markings, filled with a white powder.
3165167|NCT01445587|Other|Bortezomib|Bortezomib salvage therapy will be administered as a 3 to 5 second intravenous (IV) push at 1.3 mg/m2 on Days 1, 8, and 15 in each 21-day cycle until one of the Treatment Discontinuation Criteria is met.
3165168|NCT01445561|Experimental|Cohort 1|Interleukin-2 100,000 international units/m2 SQ daily for 5 days
3165169|NCT01445561|Experimental|Cohort 2|Interleukin-2 200,000 international units/m2 SQ daily for 5 days
3165170|NCT01445548|Experimental|Sirolimus|"Participants initially received a 20 μL (440 μg) intravitreal injection sirolimus in the study eye at baseline and every two months thereafter unless contraindicated.~As of September 2012, sirolimus intravitreal injections were no longer administered to participants."
3165171|NCT01445535|Experimental|1|siplizumab will be given with EPOCH (combo chemo) and rituximab every 21 days
3165172|NCT01445509|Experimental|Group 1|Group 1 will receive dasatinib and bevacizumab together at the start of study in a dose escalation fashion
3165174|NCT01445444|Experimental|HRT group|This group receives habit reversal training immediately.
3165175|NCT01445444|Active Comparator|TAU group|This group receives treatment as usual for 8 weeks.
3165176|NCT01445431|Experimental|Virgin Coconut Oil|
3165177|NCT01445431|Active Comparator|Mineral Oil|
3165178|NCT01445418|Experimental|Arm 1|Standard dose escalation
3165179|NCT01445418|Experimental|Arm 2|Expanded cohort
3165180|NCT01445392|Experimental|1|Multi-cycle cohort
3165181|NCT01445392|Experimental|2|Single cycle cohort
3165182|NCT01445379|Experimental|1|Ipilumumab (DSE) given on day 1 of 21 day cycle for 4 cycles, from cycle 5+ ipilumumab will be given ~every 12wks
3165183|NCT01445366|Experimental|Patients with end-stage renal disease|
3165184|NCT01445301|Experimental|GSK2585823(CLDM 1%-BPO 3% gel) once daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime.
3165185|NCT01445301|Experimental|GSK2585823(CLDM 1%-BPO 3% gel) twice daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be twice daily in the morning and evening/bedtime.
3165186|NCT01445301|Active Comparator|CLDM 1% gel twice daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be twice daily in the morning and evening/bedtime.
3165187|NCT01445275||Ancillary-Correlative (Health Services Research)|Outcome data, such as incidence and stage at diagnosis of ovarian, fallopian tube, and peritoneal cancers; number and timing of screening and serum tests performed; number and timing of pelvic ultrasounds performed; surgical procedures performed; cancer-specific and overall survival (if available); and the incidence, type, and grade of significant adverse events, are collected from the Gynecologic Oncology Group (GOG)-0199 records and analyzed. Cost of each medical intervention is also estimated.
3165188|NCT01445262||Subjects prescribed levocetirizine tablets|Subjects prescribed levocetirizine tablets for treatment of allergic rhinitis, urticaria, eczema, dermatitis, skin irritation, prurigo or pruritus cutaneous
3165189|NCT01445249|Active Comparator|Landmark guided ankle block|This group will receive a landmark guided ankle block.
3165190|NCT01445249|Active Comparator|This group will be given a PNS guided ankle block|Peripheral nerve stimulation will be used in this group to guide local anaesthetic infiltration. The technique is termed medial forefoot block.
3165191|NCT01445236|Experimental|Weaning patients|
3165192|NCT01445223|Active Comparator|lopinavir/ritonavir|400/100 mg BID + 2 NRTIs BID
3165193|NCT01445223|Active Comparator|atazanavir/ritonavir|300mg+100mg QD+ 2 NRTI QD
3165194|NCT01445223|Active Comparator|efavirenz|600mg QD + 2NRTI QD
3165195|NCT01445210|Active Comparator|0,2% Ropivacaine|"Patients randomized to the experimental group receive a continuous infusion of 0,2 % Ropivacaine by elastomeric infusion pump at 5 ml/h in the saphenous catheter after major ankle surgery. Infusion for 48 postoperative hours.~All patients receive a preoperative single shot of Ropivacaine around saphenous and sciatic nerve and a postoperative continuous sciatic nerve block."
3165196|NCT01445210|Placebo Comparator|Control|"Patients randomized to the control group receive a continuous infusion of isoton saline by elastomeric infusion pump at 5 ml/h in their catheter after major ankle surgery. Infusion for 48 postoperative hours.~All patients receive a preoperative single shot of Ropivacaine around saphenous and sciatic nerve and a postoperative continuous sciatic nerve block."
3165197|NCT01445197|Experimental|Biostate|
3165198|NCT01445171|Other|Study Valve|Subjects act as own control
3165199|NCT01445080|Experimental|A|Establlish MTD in patients with solid tumors
3165200|NCT01445080|Experimental|B|Expand MTD in patients with leukemia
3165201|NCT01445080|Experimental|C|MTD in patients with AML and FLT3-ITD mutations
3165202|NCT01445067|Active Comparator|Arm 1: BMS-927711 (300 mg)|
3165203|NCT01445067|Active Comparator|Arm 2: BMS-927711 (600 mg)|
3165204|NCT01445054|Experimental|1-Arm 1|Subjects with primary or metastatic cancer other than melanoma, basal cell carcinoma, sarcoma, or lymphoma.
3165205|NCT01445041|Experimental|Single infusion of UCB|(autologous red blood cell and volume reduced cord blood cells)
3165206|NCT01445041|Experimental|Three infusions of UCB|(autologous red blood cell and volume reduced cord blood cells)
3165207|NCT01445028|Experimental|Primary, high-risk retinal detachment|Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
3165208|NCT01445028|Experimental|Recurrent RD associated with PVR|Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
3165209|NCT01445015|Experimental|Stress management program|
3165210|NCT01445015|Active Comparator|peer viewed movies|
3165211|NCT01445002|Experimental|BM32 low dose|3 subcutaneous injections of 10 micrograms in a time span of 8 weeks
3165212|NCT01445002|Experimental|BM32 medium dose|3 subcutaneous injections of 20 micrograms in a time span of 8 weeks
3165213|NCT01445002|Experimental|BM32 high dose|3 subcutaneous injections of BM32 over a time span of 8 weeks
3165214|NCT01445002|Placebo Comparator|Placebo|3 subcutaneous injections over a time span of 8 weeks
3165215|NCT01444989|Experimental|Patients without actinic keratosis|Patients with out the diagnosis of actinic keratosis will receive the experimental questionnaire.
3165216|NCT01444989|Experimental|Patients with Actinic Keratosis|Patients with the diagnosis of actinic keratosis will receive the experimental questionnaire.
3165217|NCT01444976|Active Comparator|topical pharyngeal anesthesia|There were 26 patients who had the procedure under topical pharyngeal anesthesia.
3165218|NCT01444976|Active Comparator|midazolam|There were 25 patients who received midazolam.
3165219|NCT01444976|No Intervention|hypnosis|There were 27 patients receiving hypnosis.
3165220|NCT01444924|Experimental|Bupivicaine|TAP block with bupivicaine/epinephrine placed prior to surgery.
3165221|NCT01444924|Placebo Comparator|Placebo|TAP block with placebo placed prior to surgery
3165222|NCT01444911|Experimental|Vaginal Renewal Program|
3165223|NCT01444911|Active Comparator|Standard of care|This will consist of still vaginal dilator and/or lubricant.
3165283|NCT01444469|Placebo Comparator|Placebo|Placebo
3165421|NCT01443546|Active Comparator|hCG|standard dose of hCG for ovulation trigger
3165224|NCT01444898|Experimental|Exenatide|All subjects enrolled in this study will be given Exenatide for 6 months. Exenatide: The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
3165225|NCT01444885|Experimental|Cilostazol|To investigate the efficacy and safety of Pletaal(Cilostazol) in comparison with placebo for 4 weeks in vasospastic angina patients who have an insufficient response to Amlodipine (Calcium channel blocker).
3165226|NCT01444872|Experimental|TRV120027|TRV120027 administered as an IV infusion
3165227|NCT01444872|Placebo Comparator|Normal Saline|Normal Saline administered as an IV infusion
3165228|NCT01444859|Placebo Comparator|Placebo capsule|40 subjects allocated to daily placebo capsule for 10 weeks
3165229|NCT01444859|Experimental|Trenev Trio®/Healthy Trinity®|80 subjects allocated to Trenev Trio®/Healthy Trinity® for 10 weeks
3165230|NCT01444846|Active Comparator|SPI-1005 Low dose|200mg SPI-1005, capsule, bid, po, x4d
3165231|NCT01444846|Active Comparator|SPI-1005 Middle Dose|400mg SPI-1005, capsule, bid, po, x4d
3165232|NCT01444846|Active Comparator|SPI-1005 High Dose|600mg SPI-1005, capsule, bid, po, x4d
3165233|NCT01444846|Placebo Comparator|Placebo|0mg SPI-1005, capsule, bid, po, x4d
3165234|NCT01444820|Experimental|Hypofractionation|One phase technique (IMRT or 3D-CRT): radiotherapy to the prostate + pelvic lymphnodes
3165235|NCT01444820|Other|Conventional|two-phase technique (IMRT or 3D-CRT): 1) whole pelvis including the prostate and regional lymph nodes; 2) boost to the prostate
3165236|NCT01444807|Experimental|Sorafenib|Active Arm
3165237|NCT01444807|No Intervention|Best Supportive Care|Comparator
3165238|NCT01444781|Experimental|Study Group 1|Participants previously primed with DTaP-IPV-Hep B-PRP~T, will receive one dose of DTaP-IPV-Hep B-PRP~T vaccine + one dose of Prevenar™
3165239|NCT01444781|Active Comparator|Study Group 2|Participants previously primed with DTaP-IPV-Hep B-PRP~T, will receive one dose of Infanrix hexa™ vaccine + one dose of Prevenar™
3165240|NCT01444781|Experimental|Study Group 3|Participants previously primed with Infanrix hexa™ will receive one dose of DTaP-IPV-Hep B-PRP~T + one dose of Prevenar™.
3165241|NCT01444755||1-Neoadjuvant Chemotherapy|This arm will take a neoadjuvant chemotherapy regimen previous gastrectomy operation.
3165242|NCT01444755||2 Surgery|Surgery will be performed in patients of this arm.
3165243|NCT01444742|Experimental|Clofarabine + Cytarabine|"Induction:~Clofarabine 10 mg/m2 1-2 hours by vein daily for 5 days (days 1-5) Cytarabine 20 mg subcutaneously twice daily for 7 days (days 1-7)~Consolidation:~Clofarabine 10 mg/m2 1-2 hours by vein daily for 3 days (days 1-3) Cytarabine 20 mg subcutaneously twice daily for 5 days (days 1-5)"
3165244|NCT01444729||xiapex|Subject treated with Xiapex
3165245|NCT01444729||Surgery|Fasciotomy or fasciectomy
3165246|NCT01444716|Experimental|Ofatumumab|Four weekly intravenous infusions at 300 mg during week 1, then 2,000 mg weeks 2, 3 and 4, then monthly during months 2-12.
3165247|NCT01444703|Placebo Comparator|sugar solution|Gargle 5 minutes before induction of general anesthesia with sugar solution.
3165248|NCT01444703|Active Comparator|licorice|Gargle 5 minutes before induction of general anesthesia with licorice solution.
3165249|NCT01444690|Experimental|Active|Dimiracetam 400 mg capsules
3165250|NCT01444690|Placebo Comparator|Pseudo-placebo|Dimiracetam 25 mg capsules
3165251|NCT01444677|Experimental|MB12066 300mg|single dose
3165252|NCT01444677|Active Comparator|MB12066 400mg|single dose
3165253|NCT01444677|Active Comparator|MB12066 100mg|multiple dose
3165254|NCT01444677|Active Comparator|MB12066 200mg|multiple dose
3165255|NCT01444677|Placebo Comparator|Placebo|Placebo 300mg(single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
3165256|NCT01444664|Experimental|Aneurysm|
3165257|NCT01444651|Active Comparator|Tadalafil|20 mg Tadalafil tablet taken by mouth once a day for 3 months
3165258|NCT01444651|Placebo Comparator|Placebo|Placebo tablet taken by mouth once a day for 3 months
3165259|NCT01444638|Experimental|Ultrasound|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
3165260|NCT01444638|No Intervention|Control|Control group. (Standard practice) Trainees will NOT receive pre-procedure U/S guided examination.
3165261|NCT01444625|Experimental|Dark chocolate|Flavanol-rich chocolate
3165262|NCT01444625|Placebo Comparator|Placebo chocolate|Flavanol-free chocolate
3165263|NCT01444612||Cancer-related surgery patient records|Healthcare claims records from patients aged 18 years or older with at least one primary inpatient discharge diagnosis of cancer and a cancer-related surgery during the hospitalization
3165264|NCT01444599||low FFR group (<0.8)|the patient with FFR values less than 0.8
3165265|NCT01444599||high FFR group (>0.8)|the patient with FFR values greater than 0.8
3165266|NCT01444586||Group 1|
3165267|NCT01444573|Active Comparator|Group 2 (Lenient control <120bpm)|
3165268|NCT01444573|Active Comparator|Group 1 (Strict control <80 bpm)|
3165269|NCT01444560||Cutaneous Melanoma|
3165270|NCT01444560||Cutaneous Melanoma Metastases|
3165271|NCT01444560||Benign Melanocytic Nevi|
3165272|NCT01444547|Experimental|single-arm Paclitaxel-Cisplatin|
3165273|NCT01444534|Experimental|use of the diabetes application|
3165274|NCT01444534|Active Comparator|Control arm without app (usual care)|
3165275|NCT01444521|Experimental|single-arm Irinotecan-Cisplatin|
3165276|NCT01444508|Active Comparator|crystalloid|
3165277|NCT01444508|Placebo Comparator|colloid|
3165278|NCT01444495|Active Comparator|Short time interval|Patients operated on 7-10 days after completing preoperative radiotherapy 5x5Gy.
3165279|NCT01444495|Experimental|Long time interval|Patients operated on 4-5 weeks after completing preoperative radiotherapy 5x5Gy.
3165280|NCT01444482|Experimental|Matrix M adjuvanted influenza vaccine|1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M
3165281|NCT01444482|Active Comparator|Seasonal influenza vaccine|1 human dose of seasonal influenza vaccine
3165282|NCT01444469|Experimental|Azithromycin (Zithromax)|500 mg of azithromycin (2×250mg capsules)
3165284|NCT01444456||Cohort 1: Darbepoetin alfa|Participants receiving systemic chemotherapy for solid tumors who also received darbepoetin alfa (Aranesp®) to treat symptomatic anemia according to routine institutional practice.
3165285|NCT01444456||Cohort 2: Any ESA|Participants receiving systemic chemotherapy for solid tumors who also received darbepoetin alfa (Aranesp®) or another erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia according to routine institutional practice.
3165286|NCT01444443|Experimental|Closed-loop glucose control|Blood glucose controlled by control algorithm.
3165287|NCT01444443|Active Comparator|Open-loop glucose control|Blood glucose controlled by patient
3165288|NCT01444430|Experimental|1|Symbicort
3165289|NCT01444430|Active Comparator|2|budesonide
3165290|NCT01444417|Experimental|Romiplostim|Participants received once weekly subcutaneous romiplostim for 24 weeks at a starting dose of 1 µg/kg; weekly dose increases continued in increments of 1 µg/kg/week to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L.
3165291|NCT01444417|Placebo Comparator|Placebo|Participants received weekly subcutaneous placebo for 24 weeks.
3165292|NCT01444404|Experimental|Dose Expansion|The dose expansion will consist of up to 20 subjects and the dose level of AMG 820 will be dependent upon emerging safety and PK data from the dose escalation part of the study.
3165293|NCT01444404|Experimental|Dose Escalation|The dose escalation part of the study is aimed at evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 820.
3165294|NCT01444391|Experimental|Tympanostomy Tube Placement|
3165295|NCT01444378|Experimental|Absolute Pro® and Pro LL® Peripheral Stent Systems|
3165296|NCT01444365|Experimental|ABT-652 NSAID|ABT-652 capsules -2 ABT-652 capsules twice daily (add-on) NSAID - as prescribed
3165297|NCT01444365|Placebo Comparator|Placebo NSAID|Placebo - 2 placebo capsules twice daily NSAID - as prescribed
3165298|NCT01444352|Experimental|Vaccine Formulation 1 (Low dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 1 (Low dose).
3165299|NCT01444352|Experimental|Vaccine Formulation 2 (Middle dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 2, (Middle dose).
3165300|NCT01444352|Experimental|Vaccine Formulation 3 (High dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 3, (High dose).
3165301|NCT01444352|Placebo Comparator|Placebo Pooled|Participants who receive 2 injections of tris buffered saline
3165302|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 1|Participants will receive an injection of pneumococcal vaccine (Formulation 1, 1 middle dose) on Day 0 and Day 30, respectively.
3165303|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 2|Participants will receive an injection of Pneumococcal vaccine (Formulation 2, 2 low doses) on Day 0 and Day 30, respectively.
3165304|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 3|Participants will receive an injection of pneumococcal vaccine (Formulation 3, 2 middle doses) on Day 0 and Day 30, respectively.
3165305|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 4|Participants will receive an injection of pneumococcal vaccine (Formulation 4, 2 middle doses) on Day 0 and Day 30, respectively.
3165306|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 5|Participants will receive an injection of pneumococcal vaccine (Formulation 5, 2 high doses) on Day 0 and Day 30, respectively.
3165307|NCT01444339|Placebo Comparator|Pooled placebo Group|Participants will receive an injection of a placebo on Day 0 and Day 30, respectively.
3165308|NCT01444326|Experimental|Dairy diet|
3165309|NCT01444326|Placebo Comparator|Control diet|
3165310|NCT01444313|Other|nelfilcon A OD / narafilcon A OS|Soft contact lens without UV protection worn on the right eye (OD) and soft contact lens with UV protection worn on the left eye (OS).
3165311|NCT01444313|Other|narafilcon A OD / nelfilcon A OS|Soft contact lens with UV protection worn on the right eye (OD) and soft contact lens without UV protection worn on the left eye (OS).
3165312|NCT01444300|Experimental|Dalfampridine|
3165313|NCT01444300|Placebo Comparator|Placebo|
3165314|NCT01444287|Placebo Comparator|Spectacles No Lenses|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
3165315|NCT01444287|Experimental|narafilcon B|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
3165316|NCT01444287|Active Comparator|polymacon|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
3165317|NCT01444287|Active Comparator|lotrafilcon A|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
3165318|NCT01444274||Obalon Gastric Balloon|One or two balloons administered to each patient
3165319|NCT01444261|Active Comparator|Intervention|Fer-in-Sol drops and iron-fortified cereal
3165320|NCT01444261|Other|Control|No intervention
3165321|NCT01444248|Experimental|Amaryl MEX|
3165322|NCT01444248|Active Comparator|Amaryl M|
3165323|NCT01444235|Active Comparator|Custodiol|After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.
3165324|NCT01444235|Experimental|Custodiol-N|After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol-N solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.
3165325|NCT01444222||Pulmonary Hypertension|
3165326|NCT01444222||pulmonic valve stenosis|
3165327|NCT01444222||pulmonic valve homograft|
3165328|NCT01444222||pulmonic valve insufficiency|
3165329|NCT01444222||atrial septum defect|
3165330|NCT01444222||Ebstein's anomaly|
3165331|NCT01444222||transvalvular right ventricular lead|
3165332|NCT01444222||control|
3165333|NCT01444209|Experimental|Radiation Therapy|Interstitial Radioactive Iodine Implants
3165334|NCT01444196|Other|Desloratadine dose|"Study group: 5 mg Desloratadine during the whole study~Study group: 5 mg every day for 14 (+-2 days) start with Visit 2, 10 mg every day for 14 (+-2 days) start with Visit 3, 20 mg every day for 14 (+-2 days) start with Visit 4."
3165422|NCT01443546|Active Comparator|Lupron Trigger|Leuprolide acetate 2 mg ovulation trigger
3167157|NCT01431300|Experimental|0.01 mmol/kg|
3165335|NCT01444196|Other|Dose of Desloratadine|"Study group: 5 mg Desloratadine during the whole study~Study group: 5 mg every day for 14 (+-2 days) start with Visit 2, 10 mg every day for 14 (+-2 days) start with Visit 3, 20 mg every day for 14 (+-2 days) start with Visit 4."
3165336|NCT01444183|Active Comparator|Progressive muscle relaxation|Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM
3165337|NCT01444183|Sham Comparator|Sham exercise|Subjects practice a sham exercise consisting of focused attention activities
3165338|NCT01444170|Placebo Comparator|Sugar pill|"Placebo sugar pill was used as a sham control"
3165339|NCT01444170|Experimental|dicreatinol sulfate|
3165340|NCT01444157|Experimental|Palliative homecare nursing group|In addition to the standard homecare nursing the families will receive six home visits from a research nurse with at least 1 year specialised palliative care experience. During the first 2 hour visit a family assessment is obtained containing identification of family roles, resources and coping strategies. The first home visit takes place no later than one week after randomization. The visits continues every third week up to 16 weeks, each visit with a duration of 1,5 hours. At every visit the EORTC-QLQ-C30 patient administered questionnaire is used to identify the nature, frequency and intensity of the patients physical and psychosocial problems.
3165341|NCT01444157|No Intervention|Standard homecare nursing group|Patients continue to receive the standard homecare nursing. They can contact municipality services for visitation to homecare nursing if they feel that additional homecare is needed or if they do not yet receive this service and feel they need homecare nursing.
3165342|NCT01444144||Ankle Fracture|Patients aged 55 years at time of surgery undergoing treatment for ankle fractures.
3165343|NCT01444131|Placebo Comparator|Varenicline and Placebo Patch|Varenicline and Nicotine Patch (placebo)
3165344|NCT01444131|Active Comparator|Varenicline and Nicotine Patch|Varenicline and Nicotine Patch 15mg
3165345|NCT01444118|Experimental|EGF Vaccine|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
3165346|NCT01444118|No Intervention|Best Supportive Care|Patients in this arm will receive best supportive care
3165347|NCT01444105|Active Comparator|iStent|implantation of two iStent devices
3165348|NCT01444105|Active Comparator|SLT|Laser treatment
3165349|NCT01444092|Experimental|Entocort|Study Medication
3165350|NCT01444079||Liver transplant recipients|Recipients who will undergo liver transplantation during study period
3165351|NCT01444066|Placebo Comparator|dilation to 27 French|
3165352|NCT01444066|Experimental|Dilation of the esophagus to 54 French|Esophagus will be dilated with a Savory dilator
3165353|NCT01444053||Wearers of contact lenses without UV Protection|Subjects who have worn a soft contact lens without UV protection for the past five years or more.
3165354|NCT01444053||Wearers of contact lenses with UV Protection|Subjects who have worn a soft contact lens with UV protection for the last 5 years or more.
3165355|NCT01444040|Active Comparator|iStent inject|Implantation of two iStent inject devices
3165356|NCT01444040|Active Comparator|Drug|Travoprost drops
3165357|NCT01444027|No Intervention|Attention Control|"This group receives standard care with the attention of social support/ friendly interactions and serves as an attention control group."
3165358|NCT01444027|Experimental|Intervention Group 1 (Face to Face)|This group receives Problem Solving Therapy in face to face visits.
3165359|NCT01444027|Experimental|Intervention Group 2 (Video)|This group receives Problem Solving Therapy via video.
3165360|NCT01444014|Experimental|YF476|
3165361|NCT01444001|Experimental|Pneumococcal Vaccine Dose 1 (Low dose)|Participants will receive 2 injections of Dose 1 investigational Pneumococcal vaccine (Low dose) on Day 0 and Day 30, respectively.
3165362|NCT01444001|Experimental|Pneumococcal Vaccine Dose 2 (Middle dose)|Participants will receive 2 injections of the investigational Pneumococcal vaccine (Middle dose) on Day 0 and Day 30, respectively.
3165363|NCT01444001|Experimental|Pneumococcal Vaccine Dose 3 (High dose)|Participants will receive 2 injections of the investigational Pneumococcal vaccine (High dose) on Day 0 and Day 30, respectively.
3165364|NCT01443988|Active Comparator|iStent|Implantation of two iStent devices
3165365|NCT01443988|Active Comparator|Drug|Travoprost drops
3165366|NCT01443975||All patients|Measurement with x-pander in acetabulum prior to inserting the artificial hip socket.
3165367|NCT01443962|Experimental|Zero positive end expiratory pressure|Number: 30, apply no PEEP during the pneumoperitoneum during the laparoscopic cholecystectomy PEEP was not applied whole investigation period
3165368|NCT01443962|Active Comparator|positive end expiratory pressure|applying PEEP 10 cmH2O during pneumoperitoneum continuously
3165369|NCT01443923|Active Comparator|1-HCV|Hepatitis C Mono-infected
3165370|NCT01443923|Active Comparator|2 HCV/HIV|Hepatitis C and HIV co-Infected
3165371|NCT01443897|Placebo Comparator|Group 1|Untreated mushrooms plus placebo capsule.
3165372|NCT01443897|Experimental|Group 2|UVB-treated mushrooms (400 IU vitamin D2 per serving) plus placebo capsule.
3165373|NCT01443897|Experimental|Group 3|UVB-treated mushrooms (1,000 IU vitamin D2 per serving) plus placebo capsule.
3165374|NCT01443897|Experimental|Group 4|Untreated mushrooms plus 1,000 IU Vitamin D2 in capsule
3165375|NCT01443884|Experimental|Group 1|After a 1 week baseline, volunteers will consume two packets of grape powder stirred into water for three weeks. Each packet will contain the equivalent of approximately 2 servings of fresh grapes (46 grams of powder). Following a two week washout period, volunteers will cross-over to a placebo powder.
3165376|NCT01443884|Experimental|Group 2|After a 1 week baseline, volunteers will consume two packets of placebo powder stirred into water for three weeks. Following a two week washout period, volunteers will cross-over to grape powder for three weeks.
3165415|NCT01443624|Experimental|critical care patients venofer|Critically ill patients are injected with Venofer (ferric hydroxide sucrose) 100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
3165416|NCT01443611||Infants with first episode of Febrile Convlusions|
3165417|NCT01443572|Experimental|desflurane group|
3165418|NCT01443572|Active Comparator|sevoflurane group|
3165419|NCT01443559|Experimental|Xenogenic cornea|
3165377|NCT01443871|Experimental|Aromatherapy|Experimental procedures were conducted in the morning. Subjects individually entered the closed room where the temperature was kept at 25-26 oC and humidity 50-60%. The subjects were blinded using mask and were seated comfortably with eyes closed during experimental period. The EEG was recorded using silver electrodes. EEG activity was monitored 4 areas (F7, F8, T3 and T4) and ground electrodes. The experiments were divided into 3 parts. The first part, no-odor were recorded EEG activity for 10 minutes as a baseline. The second part, subject was exposure to the odor for 10 minutes as during inhalation. The last part, the odor was dispersed and assessed EEG activity for 10 minutes as after inhalation.
3165378|NCT01443871|Placebo Comparator|Pure water|Experimental procedures were conducted in the morning. Subjects individually entered the closed room where the temperature was kept at 25-26 oC and humidity 50-60%. The subjects were blinded using mask and were seated comfortably with eyes closed during experimental period. The EEG was recorded using silver electrodes. EEG activity was monitored 4 areas (F7, F8, T3 and T4) and ground electrodes. The experiments were divided into 3 parts. The first part, no-odor were recorded EEG activity for 10 minutes as a baseline. The second part, subject was exposure to the water for 10 minutes as during inhalation. The last part, the water was dispersed and assessed EEG activity for 10 minutes as after inhalation.
3165379|NCT01443858|Active Comparator|Placebo + Nicotine Patch|Subjects in this group will take placebo meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Placebo meclizine will be administered in two doses each day.
3165380|NCT01443858|Experimental|25mg Meclizine + Nicotine Patch|Subjects in this group will take 25mg of meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Meclizine will be administered in two doses each day.
3165381|NCT01443858|Experimental|50mg Meclizine + Nicotine Patch|Subjects in this group will take 50mg of meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Meclizine will be administered in two doses each day.
3165382|NCT01443845|Experimental|1|Roflumilast
3165383|NCT01443845|Placebo Comparator|2|Placebo
3165384|NCT01443832||iron absorption|
3165385|NCT01443819|Other|Lumbar Transforaminal Epidural Corticosteroid Injection|
3165386|NCT01443819|Other|Physical Therapy|
3165387|NCT01443819|Other|Cohort observational|
3165388|NCT01443806|Experimental|Oseltamivir, genetic testing|
3165389|NCT01443780|Experimental|sellenium + Q10|Active dietary supplement that is compared against a placebo arm
3165390|NCT01443780|Placebo Comparator|Sugar pills|Placebo arm that is compared against active intervention with a dietary supplement with selenium + Q10
3165391|NCT01443767||Partial liver resection|Adult patients scheduled for elective partial liver resection
3165392|NCT01443754||Hybrid group|Patients with multi-vessel coronary artery disease (CAD) amenable to hybrid revascularization (LIMA-LAD surgical revascularization followed by PCI)
3165393|NCT01443741|Active Comparator|FIT Therapy|Patient with functional insulin therapy
3165394|NCT01443741|Active Comparator|Traditional way|Patient with traditional way
3165395|NCT01443728|Experimental|Vitamin D3 100,000 IU|Oral vitamin D3, 100,000 IU [2.5 mg] given once a month
3165396|NCT01443728|Active Comparator|Vitamin D3 12,000 IU|Standard dose oral vitamin D3 12,000 IU [0.3 mg] given once a month
3165397|NCT01443715|Experimental|Stepped Care IPT-A - Interpersonal Psychotherapy|IPT-A focuses on communication and problem-solving skills.
3165398|NCT01443715|Active Comparator|Treatment as Usual|Treatment as Usual is the standard treatment received in the community
3165399|NCT01443702|Placebo Comparator|Placebo|
3165400|NCT01443702|Active Comparator|Lapis judaicus|
3165401|NCT01443689|Experimental|Group1 :Conventional plus hUCMSCs treatment|Participants will be given conventional therapy plus human cord mesenchymal stem cells transplantation with a 6 months follow-up.
3165402|NCT01443689|Experimental|Group 2: Conventional plus hCBMNCs and hUCMSCs therapy|Participants will be given conventional therapy plus combination of hCBMNCs together with hUCMSCs transplantation with a 6 months follow-up.
3165403|NCT01443689|Active Comparator|Group 3:Conventional therapy|Participants will be given conventional therapy only with a 6 months follow-up.
3165404|NCT01443676|Active Comparator|Radiotherapy|Radiotherapy
3165405|NCT01443676|Experimental|Radiotherapy plus Bevacizumab|Radiotherapy plus Bevacizumab
3165406|NCT01443663|Experimental|Group 1 (Previously Received H5N1 VN 04 ca Vaccine)|Participants will have previously received two doses of 10^7.5 tissue culture infectious dose (TCID)50 of H5N1 A/VN/1203/04 x A/AA/6/60 ca LAIV (H5N1 VN 04 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
3165407|NCT01443663|Experimental|Group 2 (Previously Received H5N1 HK 03 ca Vaccine)|Participants will have previously received two doses of 10^7.5 TCID50 of H5N1 A/HK/213/03 x A/AA/6/60 ca LAIV (H5N1 HK 03 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
3165408|NCT01443663|Experimental|Group 3 (Previously Received H7N3 ca Vaccine)|Participants will have previously received two doses of 10^7.5 TCID50 of H7N3 A/ck/BC/CN-6/04 x A/AA/6/60 ca LAIV (H7N3 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
3165409|NCT01443663|Experimental|Group 4 (Have Not Previously Received LAIV)|Participants will have not previously received an LAIV of any kind. In this study, they will receive one dose of the H5N1 vaccine at baseline.
3165410|NCT01443663|Experimental|Group 5 (Have Not Previously Received LAIV)|Participants will have not previously received an LAIV of any kind. In this study, they will receive two doses of the H5N1 vaccine at baseline and Day 28.
3165411|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation A x 1)|A single subcutaneous injection of Formulation A
3165412|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation B x 1)|A single subcutaneous injection of Formulation B
3165413|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation A x 2)|2 single subcutaneous injections of Formulation A
3165414|NCT01443637||Coronary CT Angiography (CCTA)|Patients included in the CONFIRM Registry are those that have previously undergone clinically-indicated CCTA as part of their standard of care.
3165420|NCT01443559|Active Comparator|human cornea|
3165423|NCT01443546|Experimental|Dual Trigger|Lupron and hCG combined ovulation trigger
3165424|NCT01443533|Experimental|LARC script|Received routine postpartum counseling and LARC script.
3165425|NCT01443533|No Intervention|No LARC script|Received only routine postpartum counseling
3165426|NCT01443520|Placebo Comparator|Placebo|
3165427|NCT01443520|Active Comparator|Duloxetine|
3165428|NCT01443520|Active Comparator|Venlafaxine|
3165429|NCT01443507|Experimental|high intensity long interval|A group training four by four minutes interval at 90-95% of maximal heart rate dispersed by three minutes active pauses at 70% of maximal heart rate.
3165430|NCT01443507|Experimental|long duration at moderate training|a continuous training group exercising at 70% of maximal heart rate for 90 minutes.
3165431|NCT01443494|Experimental|NE group|Adjust NE dose to titrate MAP to usual level regardless of fluid responsiveness when after EGDT.
3165432|NCT01443481|Experimental|TKI258 normal hepatic function|TKI258 Capsule, @ 500 mg p.o. o.d. 5 days on/2 days off
3165433|NCT01443481|Experimental|TKI258 mild hepatic impairment|TKI258 capsule @ 500 or 400 mg p.o. o.d. 5 days on/2 days off
3165434|NCT01443481|Experimental|TKI258 moderate hepatic impairment|TKI258 capsule @ starting dose at 400 mg p.o. o.d. 5 days on/2 days off
3165435|NCT01443481|Experimental|TKI258 severe hepatic impairment|TKI258 capsule Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
3165436|NCT01443468||1|Patients within a family with a known TP53 mutation who are positive for that mutation.
3165437|NCT01443468||2|Patients within a family with a known TP53 mutation who are negative for that mutation.
3165438|NCT01443468||3|Unaffected family members.
3165439|NCT01443468||4|Patients who meet clinical LFS criteria but haven't had TP53 testing.
3165440|NCT01443468||5|Patients within a family with an negative/unknown TP53 mutation.
3165441|NCT01443455|Experimental|VideoDance|
3165442|NCT01443455|Active Comparator|Brisk Walking|
3165443|NCT01443455|Other|Delayed entry control|Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.
3165444|NCT01443442|Experimental|bepotastine besilate|Two weeks treatment with 1.5% bepotastine besilate, twice per day
3165445|NCT01443442|Active Comparator|loteprednol etabonate|Two weeks treatment with 02 % loteprednol etabonate, four times per day
3165446|NCT01443429|Experimental|subjects with normal renal function|
3165447|NCT01443429|Experimental|patients with mild renal impairment|
3165448|NCT01443429|Experimental|patients with moderate renal impairment|
3165449|NCT01443429|Experimental|patients with severe renal impairment|
3165450|NCT01443416|Experimental|13-valent pneumococcal conjugate vaccine|12 month booster dose of Prevenar
3165451|NCT01443416|Experimental|10-valent pneumococcal conjugate vaccine|12 month booster dose of Synflorix
3165452|NCT01443403|Placebo Comparator|Placebo|Participants received placebo orally once daily for 28 days.
3165453|NCT01443403|Experimental|Naldemedine 0.1 mg|Participants received 0.1 mg naldemedine orally once daily for 28 days.
3165454|NCT01443403|Experimental|Naldemedine 0.2 mg|Participants received 0.2 mg naldemedine orally once daily for 28 days.
3165455|NCT01443403|Experimental|Naldemedine 0.4 mg|Participants received 0.4 mg naldemedine orally once daily for 28 days.
3165456|NCT01443364|Experimental|Certolizumab pegol|
3165457|NCT01443351||ITP patients|Patients with refractory ITP eligible for treatment with TPO-ra
3165458|NCT01443338|Active Comparator|Triptergium Wilfordii|a kind of traditional chinese medicine
3165459|NCT01443338|Active Comparator|Acitretin|
3165460|NCT01443325|Experimental|lidocaine patch|
3165461|NCT01443312||Thalassemia Intermedia Patients|Patients with Beta Thalassemia Intermedia treated at the Pediatric Hematology Unit. The characterization of Thalassemia Intermedia was based on age at diagnosis (Older than 2 ys) and / or clinical characteristics that are milder than Thalassemia Major in patients homozygous for beta globin genes.
3165462|NCT01443273||Infants with thrombotic events|All infants (premature and term) diagnosed at the Neonatal Intensive Care Unit with thrombotic events
3165463|NCT01443247|Experimental|platelet support + anti-d|
3165464|NCT01443247|No Intervention|platelet support|
3165465|NCT01443234|Experimental|OxIGen program|Internet based intervention taking place over 4 weeks
3165466|NCT01443234|Placebo Comparator|OxIGen: control version|A control version of the internet-based OxIGen intervention
3165467|NCT01443221|Active Comparator|Free combination|Free combination of Mitiglinide 10mg and Metformin 500mg
3165468|NCT01443221|Experimental|Fixed-dose combination|Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
3165469|NCT01443208|Experimental|50 mg|
3165470|NCT01443208|Experimental|100 mg|
3165471|NCT01443208|Experimental|200 mg|
3165472|NCT01443195|Experimental|Iron suplementation|Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal
3165473|NCT01443182|Experimental|STAIR + MPE|A two-phased treatment with Skills Training in Affective and Interpersonal Regulation (STAIR) in Phase 1 en modified prolonged exposure (MPE) in Phase 2
3165474|NCT01443182|Active Comparator|STAIR + EMDR|a two-phase treatment Phase 1: Skills Training in Affective and Interpersonal Regulation (STAIR) Phase 2: Eye Movement Desensitization and Reprocessing (EMDR)
3165475|NCT01443169|Experimental|Sequence 1|
3165476|NCT01443169|Experimental|Sequence 2|
3165477|NCT01443169|Experimental|Sequence 3|
3165478|NCT01443169|Experimental|Sequence 4|
3165479|NCT01443156||Caregivers|Employees at a local medical facility, including (but not limited to): nurses, laboratory technicians, non-clinical hospital staff
3165480|NCT01443143|Experimental|Commercial diet|Commercially available diet program (i.e., Nutrisystem D) that includes pre-packaged low-glycemic index portion-controlled entrees and snacks that are supplemented with grocery items in accordance with a structured meal plan.
3165481|NCT01443143|No Intervention|Usual Diet|Participants' usual consumption of food and beverages.
3165482|NCT01443130|Experimental|Chloroquine IPT|300 subjects to receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) will be administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.
3165483|NCT01443130|Experimental|Chloroquine Prophylaxis|300 subjects to receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week.
3165484|NCT01443130|Active Comparator|SP IPT|300 subjects to receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.
3165485|NCT01443117|Experimental|Step 1: PPV-23 Vaccine (Arm 1a)|Participants will receive one intramuscular (IM) injection of 0.5 mL of the PPV-23 vaccine at baseline.
3165486|NCT01443117|Experimental|Step 1: PCV-13 Vaccine (Arm 1b)|Participants will receive one IM injection of 0.5 mL of the PCV-13 vaccine at baseline.
3165487|NCT01443117|Placebo Comparator|Step 1: Placebo Vaccine (Arm 1c)|Participants will receive one IM injection of 0.5 mL of the placebo vaccine at baseline.
3165488|NCT01443117|Experimental|Step 2: PPV-23 Vaccine (Arm 2a)|Participants will receive one IM injection of 0.5 mL of the PPV-23 vaccine 6 months after delivery.
3165489|NCT01443117|Experimental|Step 2: PCV-13 Vaccine (Arm 2b)|Participants will receive one IM injection of 0.5 mL of the PCV-13 vaccine 6 months after delivery.
3165490|NCT01443104|Active Comparator|Orsiro Stent|Sirolimus-eluting Stent with a Biodegradable Polymer
3165491|NCT01443104|Active Comparator|Xience Prime Stent|Everolimus-eluting Stent with a Durable Polymer
3165492|NCT01443091|Experimental|Colostrum|
3165493|NCT01443091|Placebo Comparator|Sterile water|
3165494|NCT01443078|Experimental|pemetrexed plus cisplatin, vinorelbine and docetaxel|This is a phase 2 clinical trial for patients with clinical Stage IB-III resectable and operable non-small cell lung cancer, evaluating whether the switch to an alternative, non-platinum neoadjuvant chemotherapy is safe and effective in patients who do not respond to neoadjuvant platinum-based chemotherapy. Those who fail to respond to platinum-based chemotherapy will be switched to the alternative neoadjuvant chemotherapy vinorelbine 45 mg/m2 and docetaxel 45 mg/m2 on day 1 followed by pegylated filgrastim on day 2, repeated every 2 weeks for 4 doses, followed by repeat FDG PET and CT scan.
3165495|NCT01443065|Active Comparator|Arm A : simplified Folfox 4|"Every 2 weeks :~Oxaliplatin : 85 mg/m2 over 120 mn (2h) IV on D1~Folinic acid : 400 mg/m² (racemic form) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 followed by :~5-fluoro-uracil : 400 mg/m² in IV bolus on D1 followed by :~5-fluoro-uracil : 2400 mg/m² in IV infusion over 46 h"
3165496|NCT01443065|Experimental|Arm B : simplified FOLFOX 4 + panitumumab|"Every 2 weeks :~Oxaliplatin : 85 mg/m2 over 120 mn IV on D1~Folinic acid : 400 mg/m² (racemic form) (or 200 mg/m² with L-folinic acid) over 2 h IV on D1 (in Y to oxaliplatin) followed by :~5-fluoro-uracil : 400 mg/m², IV bolus on D1, followed by :~5-fluoro-uracil : 2400 mg/m², IV infusion IV over 46 h~Panitumumab : 6 mg/kg de 60 à 90 mn ± 15 mn IV every 14 days, just before chemotherapy administration (oxaliplatin and folinic acid), on Day 1 of each cycle. If the 1st infusion of panitumumab is well tolerated, the next infusions can be administered over 30 ± 10 mn."
3165497|NCT01443065|Experimental|Arm C : simplified FOLFOX 4 + AMG 102|"Every 2 weeks :~Oxaliplatin : 85 mg/m2 over 120 mn IV on D1~Folinic Acid : 400 mg/m² (racemic) (or 200 mg/m² with L-folinic acid) over 2 h IV on D1 (in Y/concomitant with oxaliplatin) followed by :~5-fluoro-uracil : 400 mg/m² IV bolus on D1 followed by :~5-fluoro-uracil : 2400 mg/m² in IV perfusion over 46 h~AMG 102 : 10 mg/kg over 60 ± 15 mn IV every 14 days, just before chemotherapy administration (oxaliplatin and folinic acid), on Day 1 of each cycle. If the first infusion is well tolerated (without severe infusion-related reactions), the following infusions can be administered over 30 ± 10 mn."
3165498|NCT01443052||post-stroke patients|Stroke patients who had only one cerebrovascular accident, at least one year before inclusion and Able to walk without using assisting devices or ambulatory aids
3165499|NCT01443052||healthy subjects|Aged 65 to 80 years
3165500|NCT01443052||fallers|Reported 2 or more falls within 6 months prior to the beginning of the study and Able to walk without using assisting devices or ambulatory aids
3165501|NCT01443039|Experimental|phenotypical approach|phenotypical approach
3165502|NCT01443026|Experimental|Lycopene|Lycopene 30 mg/day
3165503|NCT01443026|Placebo Comparator|Placebo|Placebo
3165504|NCT01443013||Cohort of Renal Transplant recipients|
3165505|NCT01442987|Experimental|Irbesartan/Atorvastatin A|
3165506|NCT01442987|Active Comparator|Irbesartan|
3165507|NCT01442987|Active Comparator|Atorvastatin A|
3165508|NCT01442987|Placebo Comparator|Placebo|
3165509|NCT01442987|Experimental|Irbesartan/Atorvastatin B|
3165510|NCT01442987|Active Comparator|Atorvastatin B|
3165511|NCT01442974|Experimental|Gemcitabine plus nab-paclitaxel|This is a single arm study.
3165512|NCT01442961|Active Comparator|laparoscopy|Intervention: Procedure: laparoscopy
3165513|NCT01442961|Active Comparator|vaginal|Intervention: Procedure: vaginal
3165514|NCT01442948||Acute coronary syndrome|
3165515|NCT01442948||Stable Angina|
3165516|NCT01442935|Active Comparator|Arm A1 : Folfiri + targeted therapy|"Every 2 weeks :~irinotecan 180 mg/m² D1~Folinic acid 400 mg/m² D1~5FU 400 mg/m² bolus~5FU 2400 mg/m² infusion over 46 h, D1~And targeted therapy in function of Kras:~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
3165517|NCT01442935|Active Comparator|Arm A2 : Folfox 4 + targeted therapy|"Every 2 weeks :~oxaliplatin 85 mg/m² D1~Folinic acid 400 mg/m² D1~5FU 400 mg/m² bolus~5FU 2400 mg/m² infusion over 46 h, D1~And targeted therapy in function of Kras:~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
3165556|NCT01442623|Active Comparator|Conventional Vestibular Rehabilitation|Six week program of conventional vestibular rehabilitation.
3165557|NCT01442623|Experimental|Nintendo Wii Vestibular Rehabilitation|Six week program of vestibular rehabilitation using the Nintendo Wii Fit Plus.
3165558|NCT01442610|Experimental|Rasagiline|Effect of Rasagiline on sleep parameters in PD Patients
3165518|NCT01442935|Experimental|Arm B : Folfirinox + targeted therapy|"Every 2 weeks :~oxaliplatin 85 mg/m² D1~irinotecan 150 mg/m² D1~Folinic acid 400 mg/m² D1~5FU 400 mg/m² bolus~5FU 2400 mg/m² infusion over 46 h, D1. From D7 to D12, prophylactic G-CSF such as Granocyte® will be administered.~And targeted therapy in function of Kras:~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
3165519|NCT01442922||Human Meniscus Allograft (HMA)|Patients with degenerative disk disease at L3-L4, L4-L5, or L5-S1 scheduled to undergo surgery for (HMA) implantation to replace the nucleus pulposus.
3165520|NCT01442909|Active Comparator|D followed by P|Docetaxel 60 mg/m2 intravenous infusion (IV) day 1 every 3 weeks for 4-6 cycles (stable disease up to 4 cycles, partial or complete response up to 6 cycles), followed by pemetrexed 500 mg/m2 IV day 1 every 3 weeks for 4-6 cycles (stable disease up to 4 cycles, partial or complete response up to 6 cycles).
3165521|NCT01442909|Active Comparator|P followed by D|"Pemetrexed treatment followed by docetael (in reverse sequence of Arm D followed by P"
3165522|NCT01442896||Primary Open Angle Glaucoma|
3165523|NCT01442896||Healthy Individuals|
3165524|NCT01442883||treatment resistant hypertensives with CKD 3-5|
3165525|NCT01442870|Experimental|Metformin|Metformin
3165526|NCT01442870|No Intervention|No metformin|No metformin during primary endpoint assessment period (at least 3 weeks). Patients will subsequently be initiated on metformin.
3165527|NCT01442857|Experimental|Block technique|"Active Comparator: Arm 1: catheter injection 40 ml of LA through the catheter~Active Comparator: Arm 2: catheter and transarterial injection 20 + 10 ml transarterial block and 10 ml through the catheter"
3165528|NCT01442844|Active Comparator|Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
3165529|NCT01442844|No Intervention|No intervention|No intervention will be performed. Subject will receive dressings that are standard of care.
3165530|NCT01442831|Experimental|Human ADME|
3165531|NCT01442818|Experimental|Scheduled IV post op|Patient's will receive scheduled nurse administered IV pain medications post operatively.
3165532|NCT01442818|Experimental|PCA post op|Patients will receive PCA for pain control post operatively.
3165533|NCT01442805|Experimental|RV|Cognitive Behavioral Therapy with Virtual Reality Exposures
3165534|NCT01442805|Experimental|IMAGO|Cognitive Behavioral Therapy with Exposure Therapy through Imagination
3165535|NCT01442792|Active Comparator|Arm 1|
3165536|NCT01442792|Experimental|Arm 2|
3165537|NCT01442792|Experimental|Arm 3|
3165538|NCT01442792|Experimental|Arm 4|
3165539|NCT01442766|Experimental|Donepezil|
3165540|NCT01442766|Placebo Comparator|Placebo|
3165541|NCT01442753|Active Comparator|Intervention Group|Families will be randomized to either receive the intervention (family-skills training) immediately. The intervention will be delivered over eight weeks. Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
3165542|NCT01442753|Active Comparator|Control Group|Control group will receive the intervention (family-skills training) in approximately ten months. The intervention will be delivered over eight weeks. Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
3165543|NCT01442740|Experimental|15-degree Reverse Trendelenburg Position|Patients will be placed on the operating table in a position where the lower extremities are leveled lower than the head and neck. The angle of incline will be set at 15 degrees from the horizontal.
3165544|NCT01442740|No Intervention|0-degree Supine Position|Patients will be placed on the operating table in the standard, 0-degree supine position.
3165545|NCT01442727|Placebo Comparator|Placebo|Patients who receive control (placebo)
3165546|NCT01442727|Active Comparator|Selenium|Patients who receive treatment (selenium)
3165547|NCT01442714|Experimental|Azacitidine plus Lenalidomide|Patients will receive a single dose of azacitidine 75 mg/m² SC or IV on days 1 to 7, followed by lenalidomide 50 mg PO daily on days 8 to 28 of a 42-day cycle.
3165548|NCT01442701||No triclosan / Triclosan|Participants are randomized to receive household and personal cleaning products from one of 2 arms: products that either do not contain triclosan or that may contain triclosan. Participants select products from an arm-specific list of commercially available items.
3165549|NCT01442688|Experimental|Amoxicillin + MMX placebo|
3165550|NCT01442688|Experimental|Amoxicillin + MMX mesalazine/mesalamine|
3165551|NCT01442675|Experimental|Meningococcal vaccine Group|Participants must have received Menactra vaccine 4 to 6 years prior to enrollment
3165552|NCT01442662|Experimental|pazopanib, gemcitabine|
3165553|NCT01442649|Experimental|Arm A : bevacizumab + fluoropyrimidine-based chemotherapy|"Every 2 weeks :~- mFOLFOX6 : Oxaliplatin 85 mg/m2 over 120 mn IV on D1, Folinic Acide 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~OR~- FOLFIRI : Irinotecan 180 mg/m2 en 90 mn IV on day D1, Folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~AND~Bevacizumab 5 mg/kg IV every 2 weeks."
3165554|NCT01442649|Experimental|Arm B : cetuximab + fluoropyrimidine-based chemotherapy|"Every 2 weeks :~- mFOLFOX6 : Oxaliplatin 85 mg/m2 over 120 mn IV on D1, Folinic Acide 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~OR~- FOLFIRI : Irinotecan 180 mg/m2 en 90 mn IV on day D1, Folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~AND~Cetuximab : 500 mg/m² IV every 2 weeks"
3165555|NCT01442636|Experimental|Xience Prime stent|Patients with critical limb ischemia due to below the knee arterial lesion between 30 and 100mm in length, treated with the XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
3165559|NCT01442610|Placebo Comparator|Placebo|Effect of placebo on sleep parameters in PD Patients
3165560|NCT01442597|Active Comparator|Individual clinician-provided CBT|Individual treatment provided by a trained Cognitive Behavioral Therapy (CBT)clinician who will cover the same skills provided by the CBT4CBT computer program.
3165561|NCT01442597|Experimental|CBT4CBT|A computerized program that teaches skills for stopping drug use and increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc.
3165562|NCT01442597|Active Comparator|Standard Treatment as Usual (TAU)|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on substance abuse.
3165563|NCT01442584|Experimental|fertility restoration by transplantation|fertility restoration by transplantation of ovarian cortex slivers that were cryopreserved prior to chemotherapy
3165564|NCT01442571|Experimental|Hyaluronic Acid Injection, pain, function|
3165565|NCT01442571|Placebo Comparator|Saline Injection|
3165566|NCT01442558|Active Comparator|SCL|Supraclavicular ultrasound-guided brachial plexus block
3165567|NCT01442558|Active Comparator|ICL|Infraclavicular ultrasound-guided brachial plexus block
3165568|NCT01442558|Active Comparator|AX|Axillary ultrasound-guided brachial plexus block
3165569|NCT01442545|Experimental|001|
3165570|NCT01442532|Experimental|1|
3165571|NCT01442532|Experimental|2|
3165572|NCT01442532|Experimental|3|
3165573|NCT01442532|Placebo Comparator|4|
3165574|NCT01442532|Experimental|5|
3165575|NCT01442519|Active Comparator|Intravesical BCG alone|
3165576|NCT01442519|Experimental|Intravesical sequential BCG and EMDA MMC|
3165577|NCT01442506||Barrett|
3165578|NCT01442493|Experimental|Patient-Centered Methadone Treatment|Patient-Centered Methadone Treatment alters the rules and staff roles in methadone treatment as usual in an attempt to increase treatment retention and improve patient outcomes.
3165579|NCT01442493|Active Comparator|Methadone Treatment as Usual|Methadone treatment provided as usual in the U.S.
3165580|NCT01442480|Experimental|Fish oil|
3165581|NCT01442480|Experimental|Olive oil|
3165582|NCT01442467||Mild to Severe MAC|
3165583|NCT01442467||No to mild MAC|
3165584|NCT01442454||Chronic Pancreatitis|
3165585|NCT01442441||chronic pancreatitis|
3165586|NCT01442428|Experimental|Steroid+Statin|"Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration)"
3165587|NCT01442428|Active Comparator|NSAID+Statin|"Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration)"
3165588|NCT01442428|Active Comparator|Steroid+Placebo|"Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Placebo"
3165589|NCT01442428|Active Comparator|NSAID+Placebo|"Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Placebo"
3165590|NCT01442415|Other|Lifestyle Modification|Weekly 2 hour study sessions for 10 weeks; each session includes one hour of physical activity and one hour of dietary counseling
3165591|NCT01442402||2 APOL1 genotypes|African American transplant recipients with homozygous APOL1 gene variants
3165592|NCT01442402||0 or 1 APOL1 genotypes|African American transplant recipients without homozygous APOL1 gene variants
3165593|NCT01442376|Experimental|Palonosetron 10 mcg/kg|"Palonosetron and placebo to Ondansetron~Intervention:~Drug: Palonosetron"
3165594|NCT01442376|Experimental|Palonosetron 20 mcg/kg|"Palonosetron and placebo to Ondansetron~Intervention:~Drug: Palonosetron"
3165595|NCT01442376|Active Comparator|Ondansetron|"Ondansetron and placebo to Palonosetron~Drug:~Comparator: Ondansetron"
3165596|NCT01442363|Experimental|BLI-1300 (low dose)|Low dose BLI-1300
3165597|NCT01442363|Experimental|BLI-1300 (high dose)|High dose BLI-1300
3165598|NCT01442363|Placebo Comparator|placebo|placebo (vehicle)
3165599|NCT01442337|Experimental|ASP8597 low dose|
3165600|NCT01442337|Experimental|ASP8597 high dose|
3165601|NCT01442337|Experimental|ASP8597 highest dose|
3165602|NCT01442337|Placebo Comparator|Placebo|Placebo comparator used in Part 2 only
3165603|NCT01442324|Experimental|IRE|Patients will be subjected to irreversible electroporation (IRE) as the sole treatment of nodules not considered treatable by resection or thermal ablation.
3165604|NCT01442311|Experimental|enhanced DOT (PEG/RBV-DOT)|Subjects randomized to the PEG/RBV-DOT arm receive weekly provider-administered pegylated interferon alfa-2a injections plus modified directly observed ribavirin therapy. We describe this as modified because ribavirin ingestion is observed at the methadone window three to six days per week based on the participants' methadone pick-up schedule, and only one of two daily doses is observed.
3165605|NCT01442311|Active Comparator|standard DOT (PEG-DOT)|Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
3165606|NCT01442298|Active Comparator|conventional treatment|the Standard method;tourniquet pressure based on systolic blood pressure, plus a safety margin.
3165607|NCT01442298|Experimental|limb occlusion pressure(LOP)|cuff pressure is based on limb occlusion pressure measurement
3165608|NCT01442285|Experimental|personalized, motivational messages|A Healthcare Provider Report will be reviewed by oncologist. If mental health functioning scores are elevated or high range,treatment plan is constructed. Subjects receive personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
3165609|NCT01442285|No Intervention|Control Group|Control subjects will receive a resource packet upon initial diagnosis consisting of brochures and printed material describing local resources and support groups as part of their routine care. At 12 months, subjects will receive the full assessment with reports and referrals.
3165610|NCT01442272|No Intervention|Habitual medication withuot additional|
3165611|NCT01442272|Active Comparator|Habitual medication plus Hidroferol®|
3165612|NCT01442272|Active Comparator|Habitual medication plus Zemplar®|
3165613|NCT01442259|Experimental|All study subjects|
3165616|NCT01442233|Experimental|plasma exchange|6 plasma exchanges during 2 weeks after randomization
3165617|NCT01442233|Sham Comparator|sham exchange|6 sham plasma exchanges during 2 weeks after randomization
3165618|NCT01442207|Active Comparator|Placement of Cervical Cerclage|Cervical Cerclage is to be placed in an inpatient hospital setting within 24 to 72 hours of being assigned to this treatment group
3165619|NCT01442207|Placebo Comparator|Expectant Management|"Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:~Standard management for placenta previa.~Hospital admission for vaginal bleeding/hemorrhage~Antenatal corticosteroids > 24w0d of gestation~Tocolytic therapy per physician's discretion~Magnesium sulfate for neuroprotection~Fetal Heart Rate Monitoring~Avoidance of digital examinations of the cervix~Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, Premature rupture of the membranes (PROM) > 34 wks, worsening maternal or fetal condition )~Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound."
3165620|NCT01442194||Fingolimod|non-interventional
3165621|NCT01442194||parallel cohort|non-interventional
3165622|NCT01442181|Active Comparator|Minimally Invasive Surgery|Thumb sized incisions are made on each sides of the chest wall where instruments are placed in the chest to perform the surgery.
3165623|NCT01442181|Active Comparator|Medical Therapy|Patients are treated with rhythm and rate control medications.
3165624|NCT01442168|Experimental|Sevuparin/DF02|Sevuparin/DF02 plus anti-malarial regimen (Malanil®)
3165625|NCT01442168|Active Comparator|Control|Anti-malarial regimen (Malanil®) alone
3165626|NCT01442155||Capecitabine + Oxaliplatin|Participants with stage lll colon cancer, who were starting adjuvant chemotherapy with capecitabine in combination with oxaliplatin according to standard of care.
3165627|NCT01442142|Experimental|Appetitie Awareness|"Parents and kids assigned to this group with learn about appetite awareness and to appropriately respond to their hunger meter."
3165628|NCT01442142|Experimental|Cue Reactivity and Sensitivity Training|Parents and kids in this group learn about how external cues can lead to overeating and how to better respond to these cues.
3165629|NCT01442142|Experimental|Combined CAAT/CRST|In this 14 week intervention combining Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST), parents and kids learn about both internal hunger cues and external cues that can cause one to overeat. Skills to learn the internal hunger cues and better responses to external cues are taught.
3165630|NCT01442142|No Intervention|Control|Between baseline and the post-intervention data collection point, no intervention is given. Participants are given a take home binder of intervention materials at that second data collection point; they have the option of reviewing the material prior to the final follow-up data collection point.
3165631|NCT01442129|Experimental|MPC Intramyocardial injection|Intramyocardial injections of 25 million Mesenchymal Precursor Cells (MPCs)
3165632|NCT01442129|Sham Comparator|Control Solution|Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
3165633|NCT01442116|Experimental|Hypertensives|
3165634|NCT01442103|Experimental|Device, dressing|Normlgel Ag is an opaque, amorphous hydrogel containing a high water content, water soluble polymer chains and an antimicrobial silver compound.
3165635|NCT01442090|Active Comparator|Everolimus|Participants will receive everolimus (10 mg) orally daily until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
3165636|NCT01442090|Experimental|GDC-0980|Participants will receive GDC-0980 (40 mg) orally daily until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
3165637|NCT01442077|Active Comparator|arm 1|Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments.
3165638|NCT01442077|Active Comparator|arm 2|Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.
3165639|NCT01442077|Active Comparator|arm 3|Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).
3165640|NCT01442077|Active Comparator|arm 4|Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
3165641|NCT01442064|Experimental|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) for 24 months.
3165642|NCT01442051|Experimental|Acute Normovolemic Hemodilution|A pilot study will be performed. Intraoperative data including vital signs, procedures performed, and transfusions of allogenic blood will be collected prospectively. Postoperative outcomes, including transfusions of allogenic blood, perioperative complications, and 30-day mortality will be collected prospectively. These outcomes will be compared to historical controls to assess for the safety and efficacy of ANH in ovarian cancer cytoreductive surgery.
3165643|NCT01442038|Experimental|Ranolazine|
3165644|NCT01442038|Placebo Comparator|Placebo|
3165645|NCT01442025|Placebo Comparator|Cohort 1 =Control Group|the dose of IFX will be increased by 5 mg/kg (maximally 1 time) based on symptom relapse (usual clinical practice) Dose will be kept stable ofr the rest of the trial Dose decreases will not be allowed.
3165646|NCT01442025|Active Comparator|Cohort 2|Dose of IFX will be increased by 2.5 mg/kg (maximally 2 times) if the following criteria are met A dose increase is maintained for the following infusions
3165647|NCT01442025|Active Comparator|Cohort 3|Dose of IFX will be increased by 5 mg/kg (maximally 1 time) if the following criteria are met A dose increase is maintained for the following infusions
3165648|NCT01442012|Active Comparator|Group A|Patients receive cutaneous stimulation and self-stimulation of acupuncture points Pericardium 6, Heart 7 and Stomach 25
3165649|NCT01442012|Sham Comparator|Group B|Patients receive cutaneous stimulation and self-stimulation of acupuncture points Gall Bladder 34, Kidney 6 and Liver 3
3165650|NCT01441999|Active Comparator|Less rigid rods|Titanium rods that have a soft, plastic end
3165652|NCT01441973|Experimental|Elotuzumab, 20 mg/kg|Intravenous solution administered in 28-day cycles. Cycle 1: Days 1 and 8. Cycle 2 and beyond: Day 1 only.
3165653|NCT01441973|Experimental|Elotuzumab, 10 mg/kg|Intravenous solution administered in 28-day cycles. Cycle 1 and 2: Days 1, 8, 15, and 22. Cycle 3 and beyond: Days 1 and 15.
3165654|NCT01441960|Experimental|Succinylcholine first, then Rocuronium|Cross-over randomized controlled, assessor blinded clinical trial.
3165655|NCT01441960|Experimental|Rocuronium first, then succinylcholine|Cross-over randomized controlled, assessor blinded clinical trial.
3165656|NCT01441947|Experimental|Cabozantinib plus fulvestrant|Combination therapy with cabozantinib 60 mg daily plus fulvestrant 500 mg monthly Intramuscularly (IM)
3165657|NCT01441934|Active Comparator|Sildenafil citrate|20 mg t.i.d.
3165658|NCT01441934|Placebo Comparator|Sugar pill|
3165659|NCT01441921|Active Comparator|Control diet|Low-fat normocaloric diet (30% fat, 55% carbohydrates, 15% proteins)
3165660|NCT01441921|Experimental|Pistachio diet|Diet supplemented with 2 ounces of pistachio (35% fat, 50% carbohydrates adn 15% protein)
3165661|NCT01441908|No Intervention|Control Group|Control Group
3165662|NCT01441908|Active Comparator|Statin|Receiving Statin
3165663|NCT01441882|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3165664|NCT01441869|Experimental|A|5-mg Onglyza (saxagliptin) tablet +1000-mg Diabex extended release tablet
3165665|NCT01441869|Experimental|B|5-mg saxagliptin/1000 mg metformin extended release fixed dose combination tablet
3165666|NCT01441869|Experimental|C|5-mg Onglyza (saxagliptin) tablet + 500-mg Diabex extended release tablet
3165667|NCT01441869|Experimental|D|5-mg saxagliptin/500 mg metformin extended release fixed dose combination tablet
3165668|NCT01441856|Active Comparator|Open or Laparocopic Left|Open or Laparoscopic left hemihepatectomy
3165669|NCT01441856|Active Comparator|Open or Laparoscopic Right|Open or Laparoscopic right hemihepatectomy
3165670|NCT01441856|Active Comparator|Prospective registry|Prospective registry of patients that cannot be randomized (both open and laparoscopic left + right hemihepatectomy)
3165671|NCT01441843|Active Comparator|Lorazepam|Lorazepam 4mg/4ml
3165672|NCT01441843|Placebo Comparator|NaCl 0.9%|NaCl 0.9% 4ml
3165673|NCT01441830|Sham Comparator|sham rESWT|
3165674|NCT01441830|Active Comparator|rESWT|
3165675|NCT01441817|Other|Surgery|
3165676|NCT01441804|Experimental|24-Week treatment group|Genotype 1 chronic hepatitis C patients with IL28B CC Polymorphism and rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 20 weeks
3165677|NCT01441804|Active Comparator|48-Week treatment group|Genotype 1 chronic hepatitis C patients with IL28B CC Polymorphism and rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 44 weeks
3165678|NCT01441791|Experimental|Lung protective strategy ventilation|Lung protective strategy ventilation: PEEP at 12 cmH2O, Recruitment maneuvers (after intubation, after any disconnection from the mechanical ventilator, directly before detubation)
3165679|NCT01441791|No Intervention|Conventional Strategy|"PEEP at maximum 2 cmH2O, if possible 0 cmH2O~No recruitment maneuvers Patients are randomized and intra-operatively ventilated with conventional strategy (PEEP at maximum 2 cmH2O without recruitment maneuvers)."
3165680|NCT01441778|Active Comparator|NSS irrigation salt|
3165681|NCT01441778|Experimental|BHS nasal irrigaiton salt|
3165682|NCT01441765|Active Comparator|CT-011|CT-011 3 mg/kg for 4 cycles of 6 weeks
3165683|NCT01441765|Active Comparator|CT-011 with DC/RCC fusion vaccine|CT-011 with DC/RCC fusion vaccine for subjects undergoing nephrectomy, resection of tumor tissue, or aspiration of malignant effusion
3165684|NCT01441752|Experimental|Chemotherapy + TCM group|"The chemotherapy for NSCLC patients is a combination of Vinorelbine, 25mg/m2, d1, 8 and DDP, 75mg/m2, d1 (NP) giving three-weekly for four cycles.~Prescriptions formulated into granules origin from Professor Liu Jiaxiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe . Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number."
3165685|NCT01441752|Placebo Comparator|Chemotherapy + placebo group|The chemotherapy for NSCLC patients is a combination of Vinorelbine, 25mg/m2, d1, 8 and DDP, 75mg/m2, d1 (NP) giving three-weekly for four cycles.we compromise the raw materials for the placebo including 10% of Chinese medicine, food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages.
3165686|NCT01441739||NEC suspected - Final diagnosis NEC|
3165687|NCT01441739||NEC suspected - Final diagnosis no NEC|
3165688|NCT01441739||Controls|
3165689|NCT01441726||Training of staff|
3165690|NCT01441726||No training of staff|
3165691|NCT01441713||Pharmaceutical group|Patients in pharmaceutical castration treatment for advanced prostate cancer
3165692|NCT01441713||Surgical group|Patients having undergone surgical castration treatment for advanced prostate cancer
3165693|NCT01441700|Active Comparator|Prone position|
3165694|NCT01441700|Active Comparator|Supine position|
3165695|NCT01441687|Experimental|Arm I (PMU)|Patients receive digital rectal palpation and then void a spontaneous urine sample for PMU analysis. Patients then undergo a prostate biopsy.
3165696|NCT01441687|Experimental|Arm II (EPS)|Patients receive DRE with prostatic massage for 30-60 seconds and are then milked at the urethra to provide a collection of EPS. Patients then undergo a prostate biopsy.
3165697|NCT01441674|Experimental|Animal Assisted Therapy Visit 1|Standard OT Therapy with Animal Assisted Therapy at Visit 1 and Not at Visit 2
3165698|NCT01441674|Experimental|Animal Assisted Therapy at Visit 2|Standard OT Therapy with Animal Assisted Therapy at Visit 2 and not Visit 1
3165909|NCT01440218||Patients with idiopathic diseases|Study population is limited to individuals with a rare severe illness, and/or their family members.
3165699|NCT01441661||Sunitinib Renal Cell Carcinoma|Patients diagnosed with Renal Cell Carcinoma (RCC) and treated with Sunitinib from 2008 to present will be eligible. This will include current active patients as well as patients who have expired and have medical records available.
3165700|NCT01441648||experimental group|(1) age 20-35 years old (2) myopia less than -6.00D and astigmatism less than -1.50D (3) previous soft contact lens wear discontinued for at least 2 weeks. Exclusion criteria includes: (1) subjects with previous Rigid Gas Permeable (RGP) wear (2) any ocular inflammation or infection, dry eye syndrome, glaucoma, ocular trauma or surgery, and topical medication instillation (3) diabetic mellitus (4) pregnancy (5) any corneal disorders or dystrophies.
3165701|NCT01441635|Placebo Comparator|Placebo Cohort 1|Placebo
3165702|NCT01441635|Experimental|Elagolix Dose 1|
3165703|NCT01441635|Placebo Comparator|Placebo Cohort 2|
3165704|NCT01441635|Experimental|Elagolix Dose 2|
3165705|NCT01441635|Experimental|Elagolix Dose 1 plus estradiol/norethindrone acetate|Elagolix Dose 1 plus estradiol/norethindrone acetate
3165706|NCT01441635|Placebo Comparator|Placebo Cohort 4|Placebo
3165707|NCT01441635|Experimental|Elagolix Dose 3|Elagolix Dose 3
3165708|NCT01441635|Experimental|Elagolix Dose 4|Elagolix Dose 4
3165709|NCT01441635|Experimental|Elagolix Dose 5|
3165710|NCT01441635|Experimental|Elagolix Dose 2 plus estradiol|Elagolix Dose 2 plus estradiol
3165711|NCT01441635|Experimental|Elagolix Dose 2 plus cyclical progesterone|Elagolix Dose 2 plus cyclical progesterone
3165712|NCT01441622|Experimental|AL539|Device AL539
3165713|NCT01441609||the value of anti-HBs =0 mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs be zero.
3165714|NCT01441609||the value of anti-HBs≤5mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs≤5mIU/ml.
3165715|NCT01441609||5mIU≤anti-HBs≤10mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of 5mIU≤anti-HBs≤10mIU
3165716|NCT01441609||anti-HBs≥1000mIU|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs≥1000mIU.
3165717|NCT01441596|Experimental|arm A: Afatinib monotherapy|Afatinib monotherapy: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
3165718|NCT01441596|Experimental|arm B: Afatinib in combination with vino|Afatinib 40 mg per day, continuous treatment, in combination with vinorelbine Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course.
3165719|NCT01441596|Active Comparator|arm C: investigator's choice of treatmen|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
3165720|NCT01441583|Active Comparator|RYTHMIQ Off at Pre-discharge, On at 1-Month|For the RYTHMIQ endpoint only, subjects implanted with a pacemaker will be randomized. Those randomized to RYTHMIQ Off at Pre-Discharge will have RYTHMIQ programmed Off until their 1-month follow up, when they will be crossed over to RYTHMIQ On until their 3-month follow up.
3165721|NCT01441583|Active Comparator|RYTHMIQ On at Pre-Discharge, Off at 1-Month|For the RYTHMIQ endpoint only, subjects implanted with a pacemaker will be randomized. Those randomized to RYTHMIQ On at Pre-Discharge will have RYTHMIQ programmed On until their 1-month follow up, when they will be crossed over to RYTHMIQ Off until their 3-month follow up.
3165722|NCT01441570|Active Comparator|Nebivolol|
3165723|NCT01441570|Active Comparator|Metoprolol Succinate|
3165724|NCT01441544|Experimental|VAREITY|
3165725|NCT01441544|Experimental|NON-VARIETY|
3165726|NCT01441531|Experimental|Gabapentin|Gabapentin 600 mg po given 1 hour before surgery
3165727|NCT01441531|Placebo Comparator|Placebo sugar pill|
3165728|NCT01441518|Experimental|Home care|
3165729|NCT01441518|Active Comparator|Hospital care|
3165730|NCT01441492|Experimental|No Drains|Patients who will not receive intraperitoneal drainage following pancreas resection.
3165731|NCT01441492|Experimental|Drains|Patients who will receive drains, the standard of care treatment, following pancreas resection.
3165732|NCT01441466||Group without isolation|Patients in this arm are nursed together (in the same room) independent of viral agent.
3165733|NCT01441466||group with isolation|Patients in this arm are nursed separately until the test result of the PCR (polymerase chain reaction) for viral agents is known (within 24-48 hrs). RS-positive patients are nursed separately (separate room) from RS-negative patients
3165734|NCT01441453|Other|Preoperative FibroScan|
3165735|NCT01441440|Experimental|venlafaxine ER 75 mg/day (fixed dose)|
3165736|NCT01441440|Experimental|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|
3165737|NCT01441440|Placebo Comparator|Placebo|
3165738|NCT01441427|Experimental|G-CSF|
3165739|NCT01441427|Experimental|EPO|
3165740|NCT01441427|Experimental|G-CSF and EPO|
3165741|NCT01441427|Placebo Comparator|Placebo|
3165742|NCT01441414|Experimental|ARM A|PF-04856884 in combination with AG-013736
3165743|NCT01441414|Active Comparator|ARM B|AG-013736 alone
3165744|NCT01441401||Gabapentin|Peadiatric subjects taking Gabapen Tablets and syrup.
3165745|NCT01441388|Experimental|Dose Escalation|Histological or cytological diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.
3165746|NCT01441388|Experimental|Expansion Population 1|Patients with histologically confirmed metastatic renal cell cancer with no prior systemic therapy directed at the malignant tumor.
3165747|NCT01441388|Experimental|Expansion Population 2|Patients with histologically confirmed metastatic renal cell cancer whose prior systemic therapy directed at the malignant tumor was single agent VEGF inhibitor and who now have acquired resistance to this treatment.
3165828|NCT01440777|No Intervention|Control Group|No intervention provided. These participants will receive the Go! to Sleep program after the research trial has been completed (10 weeks after registration).
3165748|NCT01441388|Experimental|Expansion Population 3|Patients with histologically confirmed glioblastoma whose disease has failed on previous therapy, and which must have included treatment with external beam radiation and temozolomide chemotherapy, and who now have radiographically recurrent or progressive disease.
3165749|NCT01441388|Experimental|Expansion Population 4|Patients with histologically confirmed advanced-stage (unresectable or metastatic) hepatocellular carcinoma who have not received previous systemic therapy directed at the malignant tumor will be eligible to receive crizotinib plus sorafenib, should this combination be tested.
3165750|NCT01441375||Sickle cell patients non-transfused|
3165751|NCT01441375||Sickle cell patients transfused with no ICT|
3165752|NCT01441375||Sickle cell patients transfused with ICT|
3165753|NCT01441362|Active Comparator|90 degrees rotation|Double-lumen tube intubation with 90 degrees rotation
3165754|NCT01441362|Experimental|180 degrees rotation|Double-lumen tube intubation with 180 degrees rotation
3165755|NCT01441349|Active Comparator|Control arm|IP chemotherapy arm
3165756|NCT01441349|Experimental|Treatment arm|IP chemotherapy plus simvastatin arm
3165757|NCT01441336|Experimental|Laparoscopic gastrectomy|"Laparoscopic gastrectomy procedure:~D2 lymphadenectomy & total omentectomy in case of tumor with serosa exposure under laparoscopic exploration"
3165758|NCT01441323|No Intervention|Control (C)|
3165759|NCT01441323|Experimental|Nutrition (N)|
3165760|NCT01441323|Experimental|Strength Training & Nutrition (ST)|
3165761|NCT01441310|Experimental|Laparoscopic sentinel node navigation surgery|Laparoscopic sentinel node navigation surgery
3165762|NCT01441297|Experimental|study arm|BIBF 1120 study arm
3165763|NCT01441284|Active Comparator|Process 1|10 weeks of pramipexole treatment 2 weeks wash-out period (cross-over) 10 weeks placebo treatment
3165764|NCT01441284|Placebo Comparator|Process 2|10 weeks of placebo treatment 2 weeks wash-out period (cross-over) 10 weeks pramipexole treatment
3165765|NCT01441271|Active Comparator|total abdominal colectomy|the standard of care for fulminant clostridium difficile colitis is a total abdominal colectomy
3165766|NCT01441271|Experimental|Ileal diversion and lavage|The tested intervention in this trial will be: intraoperative colonic lavage using a high volume polyethylene glycol/electrolyte solution, that will clear Clostridium difficile infection resulting in eradication of FCDC while preserving the colon.
3165767|NCT01441258|Experimental|Dialectical Behavior Therapy Skills (DBT-S) Groups|Patients in the Dialectical Behavior Therapy Skills (DBT-S) group will receive the newly adapted 18-week group-skills training protocol, one-and-a-half hours in length, with weekly homework assignments to facilitate skill generalization.
3165768|NCT01441258|Placebo Comparator|Wait List-Treatment as Usual|Participants assigned to the wait-list condition will be given the opportunity to participate in a DBT skills group after their 18-week wait period has ended.
3165769|NCT01441245|Experimental|Continuous furosemide infusion|The group that received the continuous infusion of furosemide (cIV), consisted of 30 patients;
3165770|NCT01441245|Experimental|Intermittent furosemide infusion|The group that received the bolus infusion of furosemide (iIV), consisted of 27 patients
3165771|NCT01441232|Experimental|Treatment A|
3165772|NCT01441232|Experimental|Treatment C|
3165773|NCT01441232|Active Comparator|Treatment B|
3165774|NCT01441219|Experimental|Colon 2|using Colon 2 capsule in detecting bleeding events in small bowel
3165775|NCT01441206|Other|rifampin|Cohort 1 will include infants who will be receiving up to 4 doses rifampin per study protocol.
3165776|NCT01441206|No Intervention|rifampin per standard of care|Cohort 2: Receiving rifampin per standard of care
3165777|NCT01441193|Experimental|HIV-1 Tat/delta-V2 Env combined vaccine|Tat 7.5 microg and delta-V2 Env 100 microg associated proteins administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at weeks 24 and 36
3165778|NCT01441193|Active Comparator|HIV-1 delta-V2 Env vaccine|delta-V2 Env 100 microg administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at week 24 and 36
3165779|NCT01441193|Active Comparator|HIV-1 Tat vaccine 7.5 microg|Tat 7.5 microg administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at week 24 and 36
3165780|NCT01441193|Active Comparator|HIV-1 Tat vaccine 30 microg|Tat 30 microg administered i.d. at week 0, 4 and 8
3165781|NCT01441180|Experimental|Phase 1|Participants (N =10) will receive GS-7977 QD in combination with RBV for a total of 24 weeks. The study team will perform an interim evaluation of data and safety at the end of 12 weeks of treatment.
3165782|NCT01441180|Active Comparator|Phase 2 Arm A|(N =25) 24 weeks of GS-7977 QD in combination with weight based RBV (1000 mg for participants weighing <75 kg and 1200 mg for participants weighing ≥75kg)
3165783|NCT01441180|Active Comparator|Phase 2 Arm B|(N = 25): 24 weeks of GS-7977 QD with low dose RBV (600mg).
3165784|NCT01441128|Experimental|Arm 1|The starting doses will be 200 mg by mouth, twice a day of PF 02341066 in tablet form and 30 mg by mouth once a day of PF 0029804 in tablet form. Thedose of each drug in the combination will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
3165785|NCT01441128|Experimental|Arm 2|45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
3165786|NCT01441102|Experimental|Dextromethorphan hydrobromide|
3165787|NCT01441076|Experimental|Anakinra|Treatment with Anakinra 100mg subcutaneous daily with option to escalate dose up to 300mg subcutaneous daily
3165788|NCT01441063|Experimental|1|Tocilizumab 8 mg/kg on Day 1 of a 14 day cycle a maximum of 6 cycles. If indicated, AZT and VGC will be administered concurrently with toclizumab, with day 1 of the cycle being the day toclizumab is administered.
3165789|NCT01441037|Experimental|Danazol|Single arm in which danazol is administered orally at 800 mg daily for 2 years.
3165790|NCT01441024|Experimental|1|DAS181
3165791|NCT01441024|Placebo Comparator|2|Placebo
3165792|NCT01441011|Experimental|Group (GRP) phone counseling|The group phone counseling includes 26 bi-weekly phone sessions from 6 to 18 months and focuses on group problem-solving. Women continue in the same group as in weight loss intervention phase.
3165902|NCT01440257|Experimental|Active study medication (Group B)|CCX140-B
3165793|NCT01441011|Active Comparator|Mail-based Comparison Condition|Participants in this group will receive a newsletter by mail every other week for 12 months starting after the initial 6 month weight loss period. The newsletters will provide problem-solving tips and will review nutrition and physical activity information.
3165794|NCT01440998|Experimental|Treatment (dasatinib, paclitaxel, carboplatin)|Patients receive induction therapy comprising dasatinib PO QD for 14 days. *Beginning 7 days later, patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1, and dasatinib PO QD on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3165795|NCT01440985|Experimental|Nicotine Gum|After being randomized to the gum or tablet, dosage will be based on baseline level of nicotine dependence. Highly dependent smokers will receive nicotine 4 mg gum, while low nicotine-dependent smokers will receive nicotine 2 mg gum to help them quit. Subjects will be advised to use the treatment frequently, according to the product labeling, in order to minimize or avoid symptoms of tobacco withdrawal. Study medication will be used for 12 weeks.
3165796|NCT01440985|Active Comparator|Nicotine Microtab|After being randomized to the gum or tablet, subjects will receive instructions according to their baseline level of nicotine dependence. Highly dependent smokers will be instructed to use a 4 mg dosage of the Microtab (2 x 2 mg tablets), while low nicotine-dependent smokers will be instructed to use a 2 mg dosage of the Microtab to help them quit. Subjects will be advised to use the treatment frequently, according to the product labeling, in order to minimize or avoid symptoms of tobacco withdrawal. Study medication will be used for 12 weeks.
3165797|NCT01440972|Active Comparator|Exercise without PBFR|
3165798|NCT01440972|Experimental|exercise with PBFR|
3165799|NCT01440959|Experimental|TKI258|
3165800|NCT01440946|Experimental|rFIXFc Prophylaxis|"At Baseline and at Day 1, participants receive a single intravenous (IV) injection of prestudy FIX and rFIXFc, respectively, over 10 (±5) minutes at a dose of 50 IU/kg. Immediately after the last PK sampling, the first prophylactic dose of approximately 50 to 60 IU/kg will be administered in clinic as an IV injection.~Dose could be increased or decreased in increments of 10 IU/kg; increases to a maximum of 100 IU/kg and frequency of administration to a maximum of twice weekly, were allowed as indicated."
3165801|NCT01440933|Active Comparator|Magnesiumsulphate|
3165802|NCT01440933|Placebo Comparator|Physiologic saline|
3165803|NCT01440920|Experimental|Cohort 1|0.3 mg
3165804|NCT01440920|Experimental|Cohort 2|1 mg
3165805|NCT01440920|Experimental|Cohort 3|3 mg
3165806|NCT01440907|Experimental|Intervention Group|Those age 65 or older who are discharged from Maimonides Medical Center to home during the study period and enrolled in the Care Coordination Program
3165807|NCT01440907|No Intervention|Control Group|Those age 65 or older who are discharged from Maimonides Medical Center to home
3165808|NCT01440894||Body Analysis|
3165809|NCT01440881|Active Comparator|Nesiritide|infuses at 0.01 MCG (micrograms)/KG (kilograms)/min (minute) for 48 hours
3165810|NCT01440881|Placebo Comparator|Placebo|infuses at 0.01MCG/KG/min for 48 hours
3165811|NCT01440868|Experimental|SLI group|In this group the preterm infants will receive sustained lung inflation (SLI) with mask in the delivery room
3165812|NCT01440868|No Intervention|Control|Preterm infants will be assisted in the delivery room without sustained lung inflation.
3165813|NCT01440855|Active Comparator|CIS Fact Sheet (CIS: Cancer Information Service)|CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
3165814|NCT01440855|Experimental|Facing Forward booklet|NCI's Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
3165815|NCT01440842|Experimental|Closed-loop (Model Predictive Control Algorithm)|
3165816|NCT01440842|Active Comparator|Open loop (Standard treatment)|
3165817|NCT01440829|Experimental|LOLA group|Intervention: LOLA (30g per day) for a week.
3165818|NCT01440829|No Intervention|Control group|Patients will not be treated with LOLA.
3165819|NCT01440816|Experimental|Cohort A: Tavo-EP|Patients in Cohort A received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation, after which they proceeded to definitive treatment (surgery and/or radiation therapy) which started between 2 and 4 weeks after the first injection.
3165820|NCT01440816|Experimental|Cohort B: Tavo-EP|Patients in Cohort B received up to 4 cycles (3 daily treatments on Days 1, 5, and 8, per cycle) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation, with 12 planned weeks between each cycle, lasting up to 12 months.
3165821|NCT01440803|Active Comparator|Teriparatide (Forteo)|Daily injection of Teriparatide for treatment of idiopathic osteoporosis
3165822|NCT01440803|Placebo Comparator|Placebo saline injection|Daily injection of saline placebo for 6 months, followed by 24 months of teriparatide treatment for idiopathic osteoporosis.
3165823|NCT01440790|Placebo Comparator|Glucose bolus alone|50g glucose dissolved in water and consumed within 5 minutes.
3165824|NCT01440790|Experimental|Glucose sipping alone|50g glucose dissolved in water and consumed gradually over 3 hours.
3165825|NCT01440790|Active Comparator|Glucose bolus plus 1g vitamin C|50g glucose dissolved in water and consumed in 5 minutes with 1g vitamin C
3165826|NCT01440790|Experimental|Glucose sipping plus 1g vitamin C|50g glucose dissolved in water and consumed gradually of 3 hours. In addition 1g vitamin C will be taken with the first mouthful of glucose solution.
3165827|NCT01440777|Active Comparator|Go! to Sleep|Participants access and utilize the 6-week online program that provides a set of various psycho-educational materials and behavioral techniques to treat insomnia.
3165903|NCT01440244|Other|Single group assignment|Cervical mediastinoscopy
3165829|NCT01440764|Experimental|F(40), then Saline, then IV.F|"On Test Day 1, participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 4ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes."
3165830|NCT01440764|Experimental|IV.F, then F(40), then Saline|"On Test Day 1, participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 4ml by inhalation for 5-10 minutes."
3165831|NCT01440764|Experimental|Saline, then F(40), then IV.F|"On Test Day 1, participants received Aerosol Saline 4ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 3), participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes."
3165832|NCT01440764|Experimental|F(80), then Saline, then Saline|"On Test Day 1, participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes."
3165833|NCT01440764|Experimental|Saline, then F(80), then Saline|"On Test Day 1, participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes."
3165834|NCT01440764|Experimental|Saline, then Saline, then F(80)|"On Test Day 1, participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes."
3165835|NCT01440751|Experimental|ologen Collagen Matrix|When performing glaucoma surgery, a trabeculectomy, use ologen Collagen Matrix instead of MMC before closing the conjunctiva
3165836|NCT01440751|Active Comparator|Mitomycin-C (MMC)|When performing glaucoma surgery, a trabeculectomy, use MMC as antifibrotic agent before closing the conjunctiva
3165837|NCT01440738|Experimental|health workshops|
3165838|NCT01440725|Experimental|PRP|Administration of 4-8cc of autologous Platelet-rich plasma (PRP)into the muscle wound after the evacuation of the haematoma.
3165839|NCT01440725|Active Comparator|Evacuation of haematoma|Evacuation of the hematoma, and simulation of the administration of PRP
3165840|NCT01440712|Experimental|Gastrografin|Patients located in this group will be treated with the administration of 100 ml of gastrografin by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
3165841|NCT01440712|Placebo Comparator|physiological serum|Patients included in this group will be treated with 100 ml of physiological serum 0,9% by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
3165842|NCT01440699|Experimental|Treatment|For ALLO-ASC 1xE7 cells/ml,3 patients are to be enrolled. If there is no safety issue, 3 more patients will be enrolled to be treated with ALLO-ASC 3xE7 cells/ml.
3165843|NCT01440686|Experimental|HL-032 30mg|A single dose 30mg administered orally
3165844|NCT01440686|Experimental|HL-032 60mg|A single dose 60mg administered orally
3165845|NCT01440686|Experimental|HL-032 120mg|A single dose 120mg administered orally
3165846|NCT01440673|Active Comparator|aprepitant 125mg|NK1 receptor antagonist
3165847|NCT01440673|Active Comparator|Aprepitant 80 mg|
3165848|NCT01440660||Leaking Phenotype|Retinal thickness (RT) increase (increase in RT above normal range as measured by OCT, considering the macular thickness normative data) in the central subfield, the inner ring and/or the outer ring.
3165849|NCT01440660||Ischemic Phenotype|Neovascular disease activity as shown by microaneurysms (MA) turnover (MA formation rate >= 2, i.e. number of new MA per year) computed from CFP using the RetmarkerDR software.
3165850|NCT01440647|Experimental|NIPPV|Extubation to NIPPV (nasal intermittent positive pressure ventilation)
3165851|NCT01440647|Active Comparator|CPAP|After extubation this arm was placed on CPAP (continuous positive airway pressure) and was not offered NIPPV in the first month on life
3165852|NCT01440634|Other|supervised exercise|It consists of six months of supervised, intermittent track walking to near maximal leg pain or discomfort three days per week. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month.
3165853|NCT01440634|No Intervention|Standard of Care|Patients will be observed during the time of the study, no intervention will be applied. Patients are allowed to do their regular activity at home.
3165854|NCT01440621|Active Comparator|Arm M|Will be treated with Tab Modafinil (generic) 100mg Once a Day in the Morning starting from Day 1 of RT till the first follow-up.
3165855|NCT01440621|Placebo Comparator|Arm P|Will be given placebo (Tab Pyridoxine 10mg) which physically resembles Tab Modafinil 100mg.
3165856|NCT01440608|Experimental|Zinc therapy|High-dose zinc, equivalent 20 mg elemental zinc, to be given once per day for 14 days
3165857|NCT01440608|Experimental|Albendazole|Albendazole to be given once on the day of enrollment. Placebo will then be given for 13 days following.
3165858|NCT01440608|Placebo Comparator|Placebo|Placebo will be given for 14 days
3165859|NCT01440595|Experimental|Grazoprevir 200 mg + Peg-IFN + RBV|Grazoprevir 200 mg in combination with Peg-IFN and RBV for 12 weeks.
3165860|NCT01440595|Experimental|Grazoprevir 400 mg + Peg-IFN + RBV|Grazoprevir 400 mg in combination with Peg-IFN and RBV for 12 weeks.
3165861|NCT01440595|Placebo Comparator|Placebo + Peg-IFN + RBV|Placebo to grazoprevir in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.
3165862|NCT01440595|Experimental|Grazoprevir 800 mg + Peg-IFN + RBV|Grazoprevir 800 mg in combination with Peg-IFN and RBV for 12 weeks.
3165904|NCT01440231|Placebo Comparator|Arm 1|
3165905|NCT01440231|Experimental|Arm 2|
3165863|NCT01440582|Experimental|Panobinostat + Bortezomib + Lenalidomide + Dexamethasone|"Induction Starting Doses: Lenalidomide 25 mg orally daily on days 1-14; Bortezomib 1.3 mg/m^2 intravenous (IV) daily on days 1, 4, 8 and 11; Dexamethasone 20 mg orally daily on days 1, 2, 4, 5, 8, 9, 11, 12 and Panobinostat orally 10 mg on days 1, 3, 5, 8, 10 and 12. Induction therapy consists of 21 day cycle in Part A and 28 day cycle in Part B.~Symptom Questionnaire completed on day 1 of each cycle."
3165864|NCT01440569|Experimental|COBI-boosted DRV|Participants will receive DRV+COBI+2 investigator-selected NRTIs for 48 weeks, and may continue their regimen in the open-label rollover phase.
3165865|NCT01440543|Experimental|Water/CO2|water immersion during colonoscope insertion and CO2 insufflation during colonoscope withdrawal
3165866|NCT01440543|Experimental|Water/Air|Water immersion during colonoscope insertion and air insufflation during colonoscope withdrawal
3165867|NCT01440543|Experimental|CO2/CO2|CO2 insufflation during both colonoscope insertion and withdrawal
3165868|NCT01440543|No Intervention|Air/Air|room air insufflation during both colonoscope insertion and withdrawal
3165869|NCT01440530|Experimental|Educational Intervention|
3165870|NCT01440530|Active Comparator|Control Group (usual care)|
3165871|NCT01440517|Experimental|Tc99m-Maraciclatide|
3165872|NCT01440491|Other|physiotherapy orientated|"G1 patients were orientated by the physiotherapist during the performance of physiotherapy exercises, using the booklet~G2 received the booklet to self perform the physiotherapy exercises"
3165873|NCT01440478|Experimental|LY2140023 + ammonium chloride|1 g of ammonium chloride administered orally every 3 hours for 33 hours (totaling 12 doses) in combination with a single 80 mg dose of LY2140023 administered orally 17 hours after first dose of ammonium chloride (acidified urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
3165874|NCT01440478|Experimental|LY2140023 + sodium bicarbonate|4 g of sodium bicarbonate administered orally every 4 hours for 32 hours (totaling 9 doses) in combination with a single 80 mg dose of LY2140023 administered orally 18 hours after first dose of sodium bicarbonate (alkalized urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
3165875|NCT01440478|Experimental|LY2140023|A single 80 mg dose of LY2140023 administered orally (normal urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
3165876|NCT01440452|Experimental|Group A|For 3 weeks, you will need to come to the International Center for Spinal Cord Injury at Kennedy Krieger Institute (ICSCI) one (1) time per week during which you will perform FES cycling for 1 hour each.
3165877|NCT01440452|Experimental|Group B|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform FES cycling for 1 hour each.
3165878|NCT01440452|Experimental|Group C|For 3 weeks, you will need to come to the ICSCI five (5) times per week during which you will perform FES cycling for 1 hour each.
3165879|NCT01440452|Experimental|Group D|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform cycling without FES for 1 hour each.
3165880|NCT01440439|Active Comparator|Insulin detemir|Metabolism during and after submaximal exercise during treatment with insulin detemir
3165881|NCT01440439|Active Comparator|Insulin glargine|Metabolism during and after submaximal exercise during treatment with insulin glargine
3165882|NCT01440426|Active Comparator|Autologous connective tissue graft|Soft tissue harvested from patient palate
3165883|NCT01440426|Experimental|Collagen Matrix Construct|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland
3165884|NCT01440400|No Intervention|Conventional spinal anesthesia|
3165885|NCT01440400|Experimental|Ultrasound guided spinal anesthesia|
3165886|NCT01440387|Experimental|FLULAVAL QUADRIVALENT Adult Group|Subjects 18-60 years of age received 1 dose of FLULAVAL® QUADRIVALENT vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
3165887|NCT01440387|Experimental|FLULAVAL QUADRIVALENT Elderly Group|Subjects above 60 years of age received 1 dose of FLULAVAL® QUADRIVALENT vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
3165888|NCT01440374|Experimental|Part 1, Open Label|100 mg daily (50 mg for subjects of East Asian heritage), intrasubject dose escalations to a maximum dose 300 mg (150 mg for subjects of East Asian heritage) are allowed.
3165889|NCT01440374|Experimental|Part 2, eltrombopag arm|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
3165890|NCT01440374|Experimental|Part 2, placebo arm|100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
3165891|NCT01440374|Experimental|part 3 extension|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
3165892|NCT01440361|Experimental|Belimumab|Reconstituted solution for intravenous infusion
3165893|NCT01440361|Placebo Comparator|Normal saline|Solution for intravenous infusion
3165894|NCT01440348|Experimental|Achilles allograft|
3165895|NCT01440322|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lenses with color worn in both eyes on a daily wear, monthly replacement basis for 3 months
3165896|NCT01440322|Active Comparator|AIR OPTIX® AQUA|Lotrafilcon B contact lenses worn in both eyes on a daily wear, monthly replacement basis for 3 months
3165897|NCT01440309|Experimental|allogenic mesenchymal stem cells (MSCs)|Patients who have primary biliary cirrhosis.
3165898|NCT01440309|Active Comparator|ursodeoxycholic acid (UDCA)|Patients who have primary biliary cirrhosis.
3165899|NCT01440283|Experimental|Treatment|"Patients with high-risk abdominal neuroblastoma who receive any high-risk neuroblastoma treatment regimen will be eligible to enroll prior to surgical resection of the primary tumor. Following implantation of fiducial markers within the tumor bed and autologous hematopoietic rescue, patients will begin the planning process for abdominal irradiation.~Interventions: Intensity Modulated Radiation Therapy (IMRT)"
3165900|NCT01440270|Experimental|Neo-adjuvant Erbitux-based chemotherapy|Neo-adjuvant Erbitux-based chemotherapy before surgery: Erbitux, Docetaxel, Cisplatin.
3165901|NCT01440257|Placebo Comparator|Placebo (Group A)|
3165910|NCT01440205|Experimental|Easy list of healthy habits|"In this condition, participants will be prompted to think about a list of healthy behaviors and check off (privately - they will never send this flyer back or show it to anyone) whether yes they conform to the healthy habit or no they do not. The list of healthy behaviors is a list that most people will find fairly easy, and thus most participants will answer yes to each habit. The final question will be a prompt to get a flu shot. The hope is that when people realize how healthy their habits are, it will seem natural to them to engage in yet another healthy habit and receive a flu shot."
3165911|NCT01440205|Experimental|Challenging list of healthy habits|"In this condition, participants will be prompted to think about a list of healthy behaviors and check off (privately - they will never send this flyer back or show it to anyone) whether yes they conform to the healthy habit or no they do not. The list of healthy behaviors is a list that most people will find fairly difficult, and thus most participants will answer no to each habit. The final question will be a prompt to get a flu shot. The hope is that when people realize how unhealthy their habits are, it will seem wise to engage in one healthy habit that is easy (to make up for other bad behaviors) and receive a flu shot."
3165912|NCT01440205|Experimental|Control|A control condition with no list of healthy behaviors.
3165913|NCT01440192|Experimental|Cohort A: 1 Unit PDA001 (cenplacel-L)|
3165914|NCT01440192|Experimental|Cohort B: 1 Unit PDA001 (cenplacel-L)|1 unit PDA001(cenplacel-L)
3165915|NCT01440179|Experimental|SAR3419|Administered for one to two induction cycles, followed by maintenance cycles up to 6 cycles.
3165916|NCT01440166|Experimental|Cohort 1 / Dose level 1|Single dose orally: CAT-1004 Dose level 1 or placebo
3165917|NCT01440166|Experimental|Cohort 2 / Dose level 2|Single dose orally: CAT-1004 Dose level 2 or placebo
3165918|NCT01440166|Experimental|Cohort 3 /Dose level 3|Single dose orally: CAT-1004 Dose level 3 or placebo
3165919|NCT01440166|Experimental|Cohort 4/ Dose level 4|Single dose orally: CAT-1004 Dose level 4 or placebo
3165920|NCT01440166|Experimental|Cohort 5/ Dose level 5|Single dose orally: CAT-1004 Dose level 5 or placebo
3165921|NCT01440166|Experimental|Cohort 2/ Dose level 2 ( FE)|Single dose orally (Under fed conditions): CAT-1004 Dose level 2 or placebo
3165922|NCT01440166|Experimental|Cohort 3/ Dose level 3 (FE)|Single dose orally (Under fed conditions): CAT-1004 Dose level 3 or placebo
3165923|NCT01440166|Experimental|Cohort 6 / Dose level 6 (FE)|Single dose orally (Under fed conditions) CAT-1004 Dose level 4 or placebo Subjects may be reenrolled from Cohort 4.
3165924|NCT01440166|Experimental|Cohort 7 / Dose level 7 (FE)|Single dose orally (Under fed conditions)CAT-1004 Dose level 5 or placebo Subjects may be reenrolled from Cohort 5.
3165925|NCT01440153|Experimental|Active Intervention|
3165926|NCT01440153|Active Comparator|passive intervention|
3165927|NCT01440140|Experimental|Closed loop (algorithm)|
3165928|NCT01440140|Placebo Comparator|Open loop|
3165929|NCT01440127|Experimental|Metformin|Subjects in this arm are randomized to receive metformin during the period of time between planning the surgery or biopsy and the actual procedure. After approximately 1 week of taking metformin, we will re-check the blood glucose. We will draw blood for cancer stem cells (about 2 teaspoons) and ask about symptoms. Subjects will stop taking metformin 2 days before the procedure.
3165930|NCT01440127|No Intervention|Observation|No metformin will be given prior to the scheduled surgery or biopsy.
3165931|NCT01440114|Active Comparator|fentanyl group|First arm: intervention group. Patient in this group received fentanyl 1 mcg/kg (concentration 10mcg/ml) intravenous route 15 minutes before the end of surgery.
3165932|NCT01440114|Placebo Comparator|controlled group|patient in this group received NSS 0.1 ml/kg 15 minutes before the end of surgery
3165933|NCT01440101|Experimental|Double-blind Natalizumab 300 mg|300 mg IV infusions of natalizumab over 60 minutes every 4 weeks for 20 weeks
3165934|NCT01440101|Placebo Comparator|Double-blind Placebo|IV infusions of placebo over 60 minutes every 4 weeks for 20 weeks
3165935|NCT01440101|Experimental|Open-label Natalizumab|300 mg IV infusions of natalizumab over 60 minutes every 4 weeks for 20 weeks
3165936|NCT01440088|Experimental|TH-302 in Combination with Doxorubicin|
3165937|NCT01440088|Active Comparator|Doxorubicin|
3165938|NCT01440075|Other|Patients KD|Adults with a history of KD disease in childhood
3165939|NCT01440075|Other|Case Control|Control group, healthy volunteers matched for age and sex with the KD group
3165940|NCT01440062|Experimental|Verum (high dose)|verum arm receiving high dose Vitamin D oil
3165941|NCT01440062|Experimental|Verum (low dose)|low dose arm receiving neutral oil and low dose of Vitamin D
3165942|NCT01440049||Eplerenone|
3165943|NCT01440036||Carotid endarterectomy|Patients that have the common indication for the treatment of carotid artery stenosis by surgery - CEA (carotid endarterectomy), symptomatic and asymptomatic patients.
3165944|NCT01440023|Experimental|CBIT + Response Inhibition Training|CBIT is an 8 session treatment protocol held over 10 weeks. In CBIT, core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child. Each core component is briefly described below. HRT/CBIT involves three components, awareness training, competing response training, and social support training (Woods, Twohig, Roloff, & Flessner, 2003). For this condition, CBIT will be combined with adjunctive computerized response inhibition training, which will be delivered over the first 4 weeks of the CBIT treatment.
3165945|NCT01440023|Placebo Comparator|Experimental: CBIT + Placebo Computer Training|In this condition, participants receive the same package of CBIT treatment, which consists of awareness training, competing response training, and social support training (Woods, Twohig, Roloff, & Flessner, 2003). Additionally, the standard CBIT treatment is combined with computer-based placebo cognitive training that is irrelevant to the target cognitive ability (i.e., response inhibition). During the first 4 weeks of the CBIT treatment, participants will receive 8 sessions of placebo cognitive training.
3165946|NCT01440010||IORT with 50 kV x-rays, 20 Gy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
3165947|NCT01439997|Experimental|Desmopressin Melt Therapy in Nocturnal Polyuria Patients|
3165948|NCT01439984|Experimental|PED-1|PED-1 (Clomipramine 15 mg)
3165949|NCT01439984|Placebo Comparator|placebo|
3165950|NCT01439971|Experimental|1|
3165951|NCT01439971|Experimental|2|
3165956|NCT01439945|Experimental|Arm I|Patients receive a low-dose of magnesium oxide orally (PO) daily (QD).
3165957|NCT01439945|Experimental|Arm II|Patients receive a high-dose of magnesium oxide PO QD.
3165958|NCT01439945|Placebo Comparator|Arm III|Patients receive a low-dose of placebo PO QD.
3165959|NCT01439945|Placebo Comparator|Arm IV|Patients receive a high-dose of placebo PO QD.
3165960|NCT01439932|Experimental|ankle mobilization for pain release|"stretching exercise for the plantar fascia and triceps surae muscles three times a day throughout the study period.~During each visit the exercise performance will be checked by the therapist. In addition, participants from both groups will get ultra sound therapy in frequency of 1 MHz, power of 1.5 watts per centimeter-squared, pulses of 50% for 5 minutes.~The study group will receive the same treatment and a number of manual techniques that include antero-posterior (AP) mobilization for talocrural joint in two variations (weight baring and non-weight baring) to improve the range of dorsi flexion, subtalar joint mobilization to improve range of eversion and mid-tarsal mobilization to improve pronation / supination of the forefoot. Each technique will be carried out for 1 to 1.5 minutes for a total of 5 minutes of manual treatment.~All patients will receive information and guidance to practice at home."
3165961|NCT01439919|Experimental|SSR411298 200 mg|SSR411298 200 mg, one tablet once daily for 4 weeks
3165962|NCT01439919|Placebo Comparator|Placebo|Placebo (for SSR411298), one tablet once daily for 4 weeks
3165963|NCT01439906||Adult degenerative scoliosis|Patients aged 40-75 years affected by lumbar or thoraco-lumbar degenerative kyphoscoliosis presenting chronic low back pain from six months at least and/or neurological deficits who underwent a surgical correction of the deformity
3165964|NCT01439893|Active Comparator|rhNRG-1|Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure
3165965|NCT01439893|Placebo Comparator|Placebo|Excipient placebo in addition to basic therapy of chronic heart failure
3165966|NCT01439880|Experimental|Evolocumab (AMG 145) and standard of care|Evolocumab (AMG 145) and standard of care
3165967|NCT01439880|Active Comparator|Standard of care|Standard of care therapy as per local practice
3165968|NCT01439867|Experimental|Cinacalcet|"Prior to the partial clinical hold, the starting dose was 0.25 mg/kg (based on dry weight) and was titrated upwards (maximum allowed daily dose of 4.2 mg/kg) based on plasma intact parathyroid hormone (iPTH), corrected serum calcium levels obtained monthly, and adverse signs and symptoms.~After the partial clinical hold the starting dose was 0.20 mg/kg (based on dry weight) and was titrated upwards (maximum allowed daily dose of 2.5 or 60 mg, whichever was lower) based on plasma iPTH, corrected serum calcium levels obtained monthly, weekly monitoring of ionized calcium levels, and adverse signs and symptoms.~All participants also received standard of care, which may have included vitamin D sterols."
3165969|NCT01439854|Placebo Comparator|Placebo|this arm is control
3165970|NCT01439854|Experimental|Dapagliflozin|Interventional arm
3165971|NCT01439841|Experimental|Probiotics|A multi-strain Probiotic consisting of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk (Biola®, TINE SA, Oslo), 250 mL/day for 8 weeks.
3165972|NCT01439841|Placebo Comparator|Placebo|Fermented and subsequently heat-treated, sterile skimmed milk (TINE SA) as active placebo.
3165973|NCT01439841|No Intervention|Control|No intervention
3165974|NCT01439828|Experimental|Experimental : N-acetylcystein|N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h
3165975|NCT01439828|Placebo Comparator|Placebo Comparator|N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h
3165976|NCT01439815|Placebo Comparator|Placebo Nasal Spray|
3165977|NCT01439815|Active Comparator|Fluticasone Propionate|
3165978|NCT01439789|Active Comparator|rhNRG-1|Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure
3165979|NCT01439789|Placebo Comparator|Plaebo|Excipient placebo in addition to basic therapy of chronic heart failure
3165980|NCT01439776|No Intervention|Peginterferon alfa 2a+Ribavirin|standard of care for HCV : peginterferon alfa 2a and ribavirin
3165981|NCT01439776|Experimental|Vit D+Peginterferon alfa 2a+Ribavirin|VitD+Peginterferon alfa 2a+Ribavirin
3165982|NCT01439750|Experimental|Phase I|The phase I portion of the study is a standard dose-escalation schemed designed to determine the maximum tolerated dose (MTD) of cladribine in the combination of bortezomib, cladribine, and rituximab therapy. The MTD is defined as the dose level in which ≤1 out of 6 patients have dose-limiting toxicity (DLT). Rituximab 375 mg/m2 on day 5,12, 19, 26 for 1st cycle, then day 5 of cladribine for next 5 cycles and then every 2 months maintenance dose. Cladribine 3-5 mg/m2 days 1-5 for 6 cycles. Bortezomib 1.6 mg/m2 sub Q days 12,19,26 for 3 cycle, then every 2 weeks maintenance dose until toxicity or progression.
3165983|NCT01439750|Experimental|Phase II|The phase II portion of the study is a two-arm, single-stage design with no interim analysis. One arm will accrue newly diagnosed patients, and one arm will accrue relapsed patients. In each arm, the progression-free survival rate at 2 years will be used as the primary endpoint for determining whether the treatment is sufficiently active in each arm. No comparisons will be made between the arms. Rituximab 375 mg/m2 on day 5,12,19,26 for 1st cycles, then day 5 montly for next 5 cycles, then every 2 months maintenance dose. Cladribine 3-5 mg/m2 days for 6 cycles (dose determined from phase I). Bortezomib 1.6 mg/m2 weekly on day 12,19,26 for 3 cycles then every 2 weeks as maintenance dose until toxicity or progression.
3165984|NCT01439737||asthma|
3165985|NCT01439724|Placebo Comparator|Placebo|Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
3165986|NCT01439724|Experimental|Low Level Laser Therapy|The investigators used a Low Level Laser Therapy, diode laser (DMC, São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
3166024|NCT01439399|Active Comparator|Ketamine-Lidocaine|Intravenous association of ketamine and lidocaine administered preoperatively (at anesthesia induction) and postoperatively during 48 hours.
3166025|NCT01439399|Placebo Comparator|Saline 0,9%|Control group
3165987|NCT01439711|Experimental|letrozole + MRI + surgery|Patients receive letrozole (2.5 mg) one tablet each day after confirmation that the MRI is acceptable. There is a 3 and 6 month disease evaluation by MRI of both breasts. If the DCIS has grown, the patient will have surgery to remove it and will continue to take letrozole until the day before surgery. It is expected that decisions regarding any adjuvant treatment will be made individually based on best practice guidelines, using informed and shared decision making between the patient and provider.
3165988|NCT01439698||RFA for Pancreatico-biliary disorders|Subjects who will receive radiofrequency ablation for pancreatico-biliary disorders, including malignancies.
3165989|NCT01439685||Biliary Stent plus Photodynamic therapy|Biliary Stent plus Photodynamic therapy
3165990|NCT01439685||Biliary Stent group|Biliary Stent group
3165991|NCT01439672|Experimental|Insulin Sensitivity|Single arm. Each subject will consume a mixed meal beverage along with insulin administration in order to calculate insulin sensitivity.
3165992|NCT01439659|Other|Nutritional Counseling|For 6 months control group receives dietary counseling.
3165993|NCT01439659|Experimental|Daily Supplements|2 capsules (Juice Plus+) twice a day (morning and evening) plus Juice Plus+ Complete drink each evening for 6 months.
3165994|NCT01439646||Non neutropenic, ICU, empiric ,antifungals|
3165995|NCT01439633|Experimental|MGH OFDI marking and imaging|OFDI imaging
3165996|NCT01439620|Experimental|OFDI imaging|Subject will swallow an OFDI capsule and images will be acquires using OFDI imaging system
3165997|NCT01439607|Experimental|Bone marrow and blood sampling|
3165998|NCT01439594|Experimental|MGH OFDI Imaging|OFDI imaging
3165999|NCT01439581|Experimental|Patients on mapping systems|
3166000|NCT01439581|Active Comparator|Patients not on mapping systems|
3166001|NCT01439568|Experimental|LY2510924 + Carboplatin + Etoposide|LY2510924: 20 milligram (mg) administered once daily as a subcutaneous injection on days 1 to 7 of the 21 day cycle; repeat every 21 days for 6 cycles. Carboplatin: 5 milligram/millimeter/per minute (mg/mL/min) area under the curve (AUC) administered intravenously on day 1 of the 21 day cycle; repeat every 21 days for 6 cycles. Etoposide: 100 milligram square meter (mg/m^2) administered intravenously on days 1 to 3 of the 21 day cycle; repeat every 21 days for 6 cycles.
3166002|NCT01439568|Active Comparator|Carboplatin + Etoposide|Carboplatin: 5 mg/mL/min area under the curve administered intravenously on day 1 of the 21 day cycle; repeat every 21 days for 6 cycles. Etoposide: 100 milligram square meter (mg/m^2) administered on days 1 to 3 of the 21 day cycle; repeat every 21 days for 6 cycles.
3166003|NCT01439555|Experimental|Simvastatin + L-Arginine + Tetrahydrobiopterin|Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
3166004|NCT01439542|Experimental|Radiotherapy|
3166005|NCT01439529|Active Comparator|Nominal|CRT device is programmed with the nominal values.
3166006|NCT01439529|Experimental|Narrow QRS|CRT device is programmed by QRS optimization
3166007|NCT01439516|Experimental|Information|Participants randomized to this arm of the study will received the PREPARED educational book and video.
3166008|NCT01439516|Experimental|Information and Financial Assistance|Participants randomized to this arm of the study will receive the PREPARED educational book and video plus financial assistance for family members to cover costs associated with an evaluation for becoming a live kidney donor.
3166009|NCT01439516|No Intervention|Usual Care|Participants randomized to this arm of the study will receive usual care from their physician.
3166010|NCT01439503|No Intervention|Control|Men receiving the control condition will be comprised of standard of care counseling from the clinic plus a variety of free condoms and water-based lubricants. They will also provide a specimen for STD testing, and receive text message questions for 12 weeks. The text messaging system will be used to collect self-reported dependent variables from men on a weekly basis. Texting will also serve as a constant method of contact between the PD and the enrolled men to remind them of follow-up assessments. In addition, the participants will complete the ACASI questionnaire to assess their sexual behavior, as well as demonstrate their condom application ability.
3166011|NCT01439503|Experimental|Treatment|Men receiving the treatment condition will receive text messages each week after their enrollment date and this will continue for 12 weeks to collect self-reported dependent variables. Text messaging will also be used to confirm and remind men about the day of each follow-up assessment. Each participant will also provide a specimen for STD testing, as well complete the ACASI questionnaire to assess sexual behavior and demonstrate their condom application ability. These participants will also be provided with a variety of free condoms and water-based lubricants. In addition, men in the treatment condition will also be enrolled in an education program.
3166012|NCT01439490|Experimental|FES-PET|Patients undergo FES-PET prior to obtaining histology
3166013|NCT01439464|Active Comparator|Control device|
3166014|NCT01439464|Experimental|Investigational device|
3166015|NCT01439451|Experimental|experimental|perturbation training during walking
3166016|NCT01439451|Active Comparator|controls|treadmill walking
3166017|NCT01439438|Active Comparator|Test formulation|Test product: Topiramate 100 mg coated tablets produced by Dr. Reddy's Laboratories Ltd. in Period 1, followed by 28 days washout period during which no medication was administered; followed by reference product: Topamax® 100 mg coated tablets in Period 2
3166018|NCT01439438|Active Comparator|Reference formulation|Topamax® 100 mg coated tablets marketed by Janssen-Cilag farmacêutica Ltda. in Period 1, followed by 28 days washout period during which no medication was administered; followed by test product: Topiramate 100 mg coated tablets produced by Dr. Reddy's Laboratories Ltd. in Period 2
3166019|NCT01439425|Experimental|weight loss|balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
3166020|NCT01439412|Experimental|Acupuncture and standard treatment|Adults (20-55 years) who contact their general practitioners office because of acute nonspecific low back pain (0-14 days).
3166021|NCT01439412|Other|Standard treatment in general practice|Adults (20-55 years) who contact their general practitioners office because of acute nonspecific low back pain (0-14 days).
3166022|NCT01439399|Active Comparator|Lidocaine|Intravenous lidocaine administered preoperatively (anesthesia induction) and postoperatively during 48 hours
3166023|NCT01439399|Active Comparator|Ketamine|Intravenous ketamine administered preoperatively (anesthesia induction) and postoperatively during 48 hours
3166026|NCT01439386|Active Comparator|AF ablation with or without AFL ablation|Pulmonary vein antral isolation (PVAI)with or without cavo-tricuspid isthmus (CTI) ablation
3166027|NCT01439386|Active Comparator|AFL ablation only|Cavo-tricuspid isthmus ablation only
3166028|NCT01439373|Experimental|GSK2336805|Study Part 1
3166029|NCT01439373|Placebo Comparator|Placebo|Study Part 1
3166030|NCT01439373|Experimental|GSK2336805 + pegylated interferon alfa-2a + ribavrin|Study Part 2
3166031|NCT01439373|Active Comparator|Placebo + pegylated interferon alfa-2a + ribavirin|Study Part 2
3166032|NCT01439360|Experimental|D-QIV|Subjects received 1 or 2 doses of candidate influenza Influsplit™ Tetra vaccine (GSK2321138A).
3166033|NCT01439360|Active Comparator|Control|In function of their age and D-QIV-vaccine status, subjects received Prevenar 13® or Havrix® Junior and possibly a varicella vaccine (Varilrix® or Varivax/ProVarivax ®).
3166034|NCT01439347|Active Comparator|Vincristine Sulfate Injection (VSI)|This is a phase 3, international, multicenter, open-label randomized, controlled trial with 2 treatment arms that vary only in the administration of standard VSI vs. Marqibo. Eligible subjects will be randomized to combination chemotherapy containing either VSI or Marqibo
3166035|NCT01439347|Experimental|Marqibo|administration of standard VSI vs. Marqibo
3166036|NCT01439334|Experimental|Online Program Brief|Online Program Brief
3166037|NCT01439334|Experimental|Online Program Extended Length|Online Program Extended Length
3166038|NCT01439334|Active Comparator|Control|Control
3166039|NCT01439321||Patient with Chronic Immune Thrombocytopenic Purpura|Patients with chronic ITP who switch from their previous treatment of corticosteroids, rituximab, or eltrombopag or romiplostim to eltrombopag or romiplostim and have been on the new treatment for at least four weeks
3166040|NCT01439308|Placebo Comparator|Arm 1|3 incremental capsaicin doses
3166041|NCT01439308|Active Comparator|Arm 2|3 incremental capsaicin doses
3166042|NCT01439295||Preterm less than 33 weeks|This cohort will be composed of premature infants born before 33 weeks of gestational age, admitted to the neonatal intensive care unit at Sainte-Justine hospital and receiving parenteral nutrition (PN) during their first week of life.
3166043|NCT01439282|Experimental|Eribulin + Capecitabine|
3166044|NCT01439269|No Intervention|Phase 1: Standard Care|Mothers are given infant care instruction as part of standard care
3166045|NCT01439269|Experimental|Phase 1: Facilitated infant care|Family Nurture Intervention (FNI)
3166046|NCT01439269|Experimental|Phase 2: Effectiveness|All participants who agree to participate will receive Family Nurture Intervention.
3166047|NCT01439256|Experimental|Computer Controlled Telephone Counseling|This arm intervenes with subjects and their treating physicians. The intervention is periodic medical adherence promotion counseling for subjects regarding their prescribed HTN medications through a computer-controlled telephone counseling program that has data on subject's recent BP values and their prescribed HTN medications. The subjects' treating physicians receive at regularly scheduled office visits information about subject's recent BP and medication adherence for each prescribed medication and also get physician information and management recommendations
3166048|NCT01439256|No Intervention|Usual Care|In this arm, patients with hypertension that is not adequately controlled receive usual care from their physicians. Usual care is defined as receiving regular care from the physician and no additional care or intervention from the study.
3166049|NCT01439243|Experimental|Investigational Test Product|Donepezil 10 mg Tablets
3166050|NCT01439243|Active Comparator|Reference Listed Drug|Aricept® 10 mg Tablets
3166051|NCT01439230|Experimental|Investigational Test Product|Donepezil 10 mg Tablets
3166052|NCT01439230|Active Comparator|Reference Listed Drug|Aricept® 10 mg Tablets
3166053|NCT01439204|Active Comparator|Abatacept (BMS-188667) manufactured at Lonza, NH facility|
3166054|NCT01439204|Experimental|Abatacept (BMS-188667) manufactured at Devens, MA facility|
3166055|NCT01439191|Experimental|combination agent group|
3166056|NCT01439191|Experimental|single agent group|In this arm, patients would be treated with Cipterbin® for 12 or 24 weeks
3166057|NCT01439178|Experimental|Intravitreal Avastin Day 2|randomized to either treatment with preoperative IVB 2 days before PPV (Group A) or 7 days before PPV (Group B).
3166058|NCT01439178|Active Comparator|Intravitreal Avastin Day 7|randomized to either treatment with preoperative IVB 2 days before PPV (Group A) or 7 days before PPV (Group B).
3166059|NCT01439165|Experimental|Adacel® Vaccine Group|Participants randomized to receive a repeat dose of Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine (Adacel®)
3166060|NCT01439165|Active Comparator|Td Adsorbed Vaccine Group|Participants randomized to receive Subjects randomized to receive a Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (TENIVAC) vaccine.
3166061|NCT01439152|Experimental|BAY94-9343 (Dose-Escalation)|BAY94-9343 will be administered intravenously in this study. The starting dose for this first-in-man study is 0.15 mg/kg administered as a 1 hour infusion every 21 days. (ENROLLMENT CLOSED).
3166062|NCT01439152|Experimental|BAY94-9343 (Expansion)|"After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose. Overall up to 32 subjects are planned to be enrolled in the expansion cohort:~Ovarian Carcinoma, 20 subjects~Mesothelioma, 6-12 subjects (ENROLLMENT CLOSED)."
3166063|NCT01439152|Experimental|BAY94-9343 (1.8 mg/kg)|This part of study will be randomized and open-label. BAY94-9343 in two parallel dose cohorts of twenty (20) patients with recurrent platinum-resistant or platinum partially-sensitive ovarian cancer and up to four (4) patients with advanced malignant epithelioid peritoneal mesothelioma and eight (8) patients with advanced pleural mesothelioma.
3166064|NCT01439152|Experimental|BAY94-9343 (2.2 mg/kg)|This part of study will be randomized and open-label. BAY94-9343 in two parallel dose cohorts of twenty (20) patients with recurrent platinum-resistant or platinum partially-sensitive ovarian cancer and up to four (4) patients with advanced malignant epithelioid peritoneal mesothelioma and eight (8) patients with advanced pleural mesothelioma..
3166065|NCT01439126|Active Comparator|Subjects on KAPVAY™ (clonidine hydrochloride)|Subjects in the KAPVAY™ arm receive their optimal dose of KAPVAY™ for the 26-week randomized-withdrawal period (Period 3)
3166066|NCT01439126|Placebo Comparator|Subjects on Placebo|Subjects in placebo arm tapered off optimal dose of KAPVAY™ (ie, Period 2 Maintenance Dose) at weekly intervals in decrements of 0.1 mg/day until reaching dose of 0 mg/day; subjects then receive only placebo for the rest of the study
3166067|NCT01439113|No Intervention|Standard of care|In this arm, patients who have difficult IV access will undergo the standard of care. The options include a) repeated attempts by a primary nurse, b) new attempts by a second nurse, c) central line placement by a physician, d) intraosseous line placement by a physician, e) physician use of ultrasound for peripheral IV placement
3166068|NCT01439113|Experimental|Ultrasound-guided IV|In this arm, the emergency nurse will apply the ultrasound machine to locate and cannulate a patient's peripheral veins
3166069|NCT01439100|Active Comparator|OXN PR|Oxycodone/Naloxone Prolonged Release tablets
3166070|NCT01439100|Placebo Comparator|Dummy tablet|Placebo
3166071|NCT01439087|Experimental|OFDI imaging|OFDI imaging
3166072|NCT01439074|Active Comparator|Mepilex Ag|Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
3166073|NCT01439074|Active Comparator|Silver Sulphadiazine Ag cream|SSD Ag cream is white cream, 1% SSD Ag, 40g/tube This cream is indicated for prevent and treat secondary wound infection of small area, mild burn/scald.
3166074|NCT01439048||Term infants|Infants born at greater than 37 weeks gestation
3166075|NCT01439048||Preterm Infants|Infants born at less than 37 weeks gestation
3166076|NCT01439035|Experimental|MGH OFDI imaging|OFDI imaging
3166077|NCT01439022|Experimental|Exercise Programme|6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist.
3166078|NCT01439022|Active Comparator|Hand writing programme|6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
3166079|NCT01439009|Experimental|Tolvaptan|15 mg
3166080|NCT01439009|Placebo Comparator|Placebo|Placebo
3166081|NCT01438996|Experimental|NVGH Vi-CRM/NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study
3166082|NCT01438996|Experimental|Vi-PS/NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study
3166083|NCT01438996|Experimental|NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults
3166084|NCT01438983||breastfeeding infants|
3166085|NCT01438983||bottle feeding infants|
3166086|NCT01438970|Other|ALFApump system implantation|Implantation of ALFApump system
3166087|NCT01438957|Placebo Comparator|Placebo|Dexmedetomidine 0 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0 mcg/kg/hr Maintenance dose
3166088|NCT01438957|Experimental|Dexmedetomidine 0.067 mcg/kg|Dexmedetomidine 0.4 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
3166089|NCT01438957|Experimental|Dexmedetomidine 0.25 mcg/kg|Dexmedetomidine 1.5 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
3166090|NCT01438957|Experimental|Dexmedetomidine 0.5 mcg/kg|Dexmedetomidine 3 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
3166091|NCT01438957|Experimental|Dexmedetomidine 1.0 mcg/kg|Dexmedetomidine 6 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
3166092|NCT01438944|Other|Nicabate 21mg transdermal NRT|21mg Transdermal NRT applied for 24hrs over a 14day period.
3166093|NCT01438931|Placebo Comparator|Placebo group|Loading infusion of Placebo over 10 minutes followed by maintenance infusion of Placebo
3166094|NCT01438931|Active Comparator|DA-9501 0.5 mcg/kg group|Loading infusion of Dexmedetomidine 3.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr
3166095|NCT01438931|Active Comparator|DA-9501 1.0 mcg/kg group|Loading infusion of Dexmedetomidine 6.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr
3166096|NCT01438918|Active Comparator|200 mg|High dose active comparator
3166097|NCT01438918|Active Comparator|50 mg|Low dose active comparator
3166098|NCT01438918|Placebo Comparator|Placebo|Placebo comparator to be used for control purposes
3166099|NCT01438905|No Intervention|Control|Parameters will be identical to the lower intensity (Small amplitude oscillation mobilization; Grade IV) talocrural mobilization. No force, other than light hand contact will be applied by the therapist.
3166100|NCT01438905|Experimental|Lower intensity mobilization|The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
3166101|NCT01438905|Experimental|Higher intensity mobilization|The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
3166102|NCT01438892||tDMARDs Group|traditional DMARDs
3166103|NCT01438892||Biologics group|Biologics used in RA
3166104|NCT01438879||pleocytosis group|40 patients with clinical signs of CNS infection and having CSF pleocytosis.
3166105|NCT01438879||non-pleocytosis group|20 patients not having CNS infection clinically and not having CSF pleocytosis.
3166106|NCT01438866|Experimental|Preventing occlusal caries|Comparing preventing effect of fissure sealants vs. fluoride varnish
3166107|NCT01438853|Experimental|TNX-832|Anti-tissue factor antibody
3166108|NCT01438853|Placebo Comparator|Drug Placebo|Placebo control
3166109|NCT01438840|Active Comparator|Avatrombopag (Core Study)|Avatrombopag will be administered orally as 5 mg, 10 mg, 20 mg, 30 mg, or 40 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag, one daily and allowed to have their dose titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on their response to study drug.
3166150|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 4)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
3166236|NCT01437917|Experimental|Bread with 20% amylose content|Bread with 20% amylose content
3166237|NCT01437917|Experimental|Bread with 10% amylose content|Bread with 10% amylose content
3166110|NCT01438840|Placebo Comparator|Placebo (Core Study)|Placebo will be administered as 5 mg, 10 mg, 20 mg, 30 mg or 40 mg in a flexible dose design for 26 weeks. Placebo will be administered orally at a starting dose of 20 mg, once daily. Afterwards the dose can be titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on the participant's response to the study drug; placebo titration will be used to maintain the blind.
3166111|NCT01438840|Experimental|Avatrombopag (Open-Label Extension)|Participants who meet all eligibility criteria requirements of extension phase and who discontinue the core study because of lack of treatment effect will continue into the extension phase. Avatrombopag will be administered to participants who enter extension phase, with a starting dose of 20 mg avatrombopag, once daily for 76 weeks and undergo dose titration.
3166112|NCT01438827|Active Comparator|Avanz Phleum pratense 15,000 SQ+|
3166113|NCT01438827|Active Comparator|Avanz Phleum pratense 4,000 SQ+|
3166114|NCT01438827|Placebo Comparator|Injection with no active grass component|
3166115|NCT01438814|Experimental|linagliptin + metformin|patients to receive linagliptin +metformin QD
3166116|NCT01438814|Active Comparator|metformin|patients to receive metformin BID
3166117|NCT01438801|Experimental|NutropinAq|
3166118|NCT01438788|Experimental|All patients on a low protein diet|
3166119|NCT01438775|Experimental|Open Label Injection of NX-1207|Intraprostatic injection of 2.5 mg NX-1207
3166120|NCT01438762|Active Comparator|Information and patient education|All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.
3166121|NCT01438762|Active Comparator|Information, education and physiotherapy|"Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking.~In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas."
3166122|NCT01438762|No Intervention|Observational cohort|Those who do not wish to participate in the randomization procedure will be followed through an observational cohort. The observational cohort will be followed at the same time-points and they will be asked which treatment they have received.
3166123|NCT01438749|Active Comparator|A|
3166124|NCT01438749|Placebo Comparator|B|
3166125|NCT01438749|Experimental|C|
3166126|NCT01438736|Experimental|Desogestrel, Etonogestrel|Arm 1: 75 microgr desogestrel POP (cerazette) daily for 3 months followed by etonogestrel implant (Nexplanon, 68 mg etonogestrel) for following 6 months
3166127|NCT01438736|Experimental|Etonogestrel|Arm 2: Women staring straight with Nexplanon implant for 6 months
3166128|NCT01438723|Experimental|metformin|
3166129|NCT01438723|Placebo Comparator|placebo|
3166130|NCT01438710|Experimental|LCP-Tacro|LCP Tacro tables for once daily oral administration
3166131|NCT01438710|Experimental|Prograf|Tacrolimus capsules for twice daily oral administration
3166132|NCT01438697|Experimental|Internet Intervention|Assigned to Sleep Healthy Using the Internet (SHUTi)
3166133|NCT01438697|Active Comparator|Patient Education Website|Assigned to Patient Insomnia Educational Website
3166134|NCT01438684|Active Comparator|RPh201 group|7 patients will receive the treatment
3166135|NCT01438684|Placebo Comparator|non RPh201 group|3 patients will receive placebo
3166136|NCT01438671|Experimental|All participants|Nintendo Wii Fit Balance training followed by traditional balance training
3166137|NCT01438658||All|A cohort of all the patients.
3166138|NCT01438645|Experimental|ScopeGuide-assisted colonoscopy|These patients will undergo colonoscopy with the assistance of the Olympus ScopeGuide system.
3166139|NCT01438645|No Intervention|Conventional colonoscopy|These patients will undergo colonoscopy identical to that in the intervention arm, except with endoscopes lacking the ScopeGuide system.
3166140|NCT01438632|Experimental|jet injector|Jet injectors deliver insulin at a high velocity (typically >100m/s) across the skin in the subcutaneous tissue, without the use of a needle
3166141|NCT01438632|Active Comparator|conventional insulin pen|
3166142|NCT01438619||representitives of Goyang city|"Representative population of Goyang city who were randomly selected by digit dialing (RDD) method~Volunteers who are reside in Goyang city"
3166143|NCT01438606|Experimental|1 x 10^4 PFU VSV-Indiana HIV gag vaccine (Group 1)|Participants will receive 1 x 10^4 PFU of the study vaccine by intramuscular (IM) injection in each deltoid at baseline and Week 8. (1 x 10^4 PFU is the nominal dose; the actual dose is 4.6 x 10^3 PFU given as 2.3 x 10^3 PFU in each deltoid)
3166144|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 1)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
3166145|NCT01438606|Experimental|1 x 10^5 PFU VSV-Indiana HIV gag vaccine (Group 2)|Participants will receive 1 x 10^5 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^5 PFU is the nominal dose; the actual dose is 4.6 x 10^4 PFU given as 2.3 x 10^4 PFU in each deltoid)
3166146|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 2)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
3166147|NCT01438606|Experimental|1 x 10^6 PFU VSV-Indiana HIV gag vaccine (Group 3)|Participants will receive 1 x 10^6 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^6 PFU is the nominal dose; the actual dose is 4.8 x 10^5 PFU given as 2.4 x 10^5 PFU in each deltoid)
3166148|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 3)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
3166149|NCT01438606|Experimental|1 x 10^7 PFU VSV-Indiana HIV gag vaccine (Group 4)|Participants will receive 1 x 10^7 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^7 PFU is the nominal dose; the actual dose is 4.2 x 10^6 PFU given as 2.1 x 10^6 PFU in each deltoid)
3166151|NCT01438606|Experimental|1 x 10^8 PFU VSV-Indiana HIV gag vaccine (Group 5)|Participants will receive 1 x 10^8 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^8 PFU is the nominal dose; the actual dose is 3.4 x 10^7 PFU given as 1.7 x 10^7 PFU in each deltoid)
3166152|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 5)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
3166153|NCT01438593|Experimental|HUCB, Medicine, Rehabilitation|Stroke patients are received intracerebral implantation of human cord blood stem cells (CD34+), Antiplatelet Medication, and Rehabilitation.
3166154|NCT01438580|Experimental|standard intensity warfarin group|Eligible 80 patients(83.14±4.05,33.0%)with chronic NVAF were randomly assigned to this group and the target international normalised ratio(INR) was 2.1-3.0
3166155|NCT01438580|Experimental|low intensity warfarin group|Eligible 81 patients(84.0±4.71,33.5%)with chronic NVAF were randomly assigned to this group and the target international normalised ratio(INR) was 1.5-2.0
3166156|NCT01438580|Active Comparator|aspirin group|Eligible 81 patients(83.4±5.13,33.5%)with chronic NVAF were randomly assigned to this group and 100mg aspirin was administrated every day
3166157|NCT01438567|Experimental|OXN PR tablets|
3166158|NCT01438567|Active Comparator|OxyPR tablets|
3166159|NCT01438554|Experimental|Pazopanib and GSK1120212|Treatment will be administered on an outpatient basis. Both drugs are taken orally. Each cycle lasts 28 days. The doses of each drug will depend on when patient enters study.
3166160|NCT01438541|Experimental|Window|WindowTM is a protective layer that may reduce the shear and friction on the skin and may help to prevent skin breakdown. Window TM provides instant tack adhesion that minimizes the requirement of extra pressure in order to fixate well. The product does not leave residues and the adhesion level does not increase over time.
3166161|NCT01438515|Experimental|Systemic decolonization|7-day course of 4% chlorhexidine gluconate daily washes and 2% mupirocin ointment to the anterior nares twice daily in addition to oral rifampin (600mg daily), and doxycycline (100mg twice daily)
3166162|NCT01438515|Active Comparator|Standard decolonization|7-day course of 2% mupirocin ointment to the anterior nares twice daily and 4% chlorhexidine gluconate washes once per day.
3166163|NCT01438502||HyperHAES|
3166164|NCT01438489|Experimental|Anifrolumab (MEDI-546) 300 mg|Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
3166165|NCT01438489|Experimental|Anifrolumab (MEDI-546) 1000 mg|Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
3166166|NCT01438489|Placebo Comparator|Matching Placebo|Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
3166167|NCT01438476|Experimental|IV Pain Management|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures. Hourly post surgery rating level of pain on a scale of 0-10. Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
3166168|NCT01438476|Experimental|Epidural Pain Management|Thoracic epidurals placed preoperatively in either holding area or in operating room. Hourly post surgery rating level of pain on a scale of 0-10. Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
3166169|NCT01438463|Placebo Comparator|placebo|
3166170|NCT01438463|Experimental|PURETHAL Mites, 6,667 AU/ml|
3166171|NCT01438463|Experimental|PURETHAL Mites, 20,000 AU/ml|
3166172|NCT01438463|Experimental|PURETHAL Mites, 50,000 AU/ml|
3166173|NCT01438463|Experimental|PURETHAL Mites, 100,000 AU/ml|
3166174|NCT01438450|No Intervention|Supportive|Supportive therapy
3166175|NCT01438450|Active Comparator|Oral|Oral thalidomide and capecitabine
3166176|NCT01438437|Active Comparator|Percutaneous acetic acid|
3166177|NCT01438437|Active Comparator|Radiofrequency ablation|
3166178|NCT01438424|Experimental|Entecavir, 1.0 mg, with or without lamivudine|
3166179|NCT01438411|Other|Cholic Acid|Active drug
3166180|NCT01438398|Other|Submucosal Endoscopic Mucosal Flap Technique|Submucosal Endoscopic Mucosal Flap Technique
3166181|NCT01438385||Interventional Endoscopy|Any group that went Interventional Endoscopy procedures.
3166182|NCT01438372|Experimental|Intravenous iron sucrose arm|
3166183|NCT01438372|Active Comparator|Oral ferrous sulfate|
3166184|NCT01438359|Experimental|PA21 and Furosemide with food|
3166185|NCT01438359|Experimental|No PA21; Furosemide with food|
3166186|NCT01438359|Experimental|PA21 with food and Furosemide 2hrs later|
3166187|NCT01438346|Active Comparator|Substance Abuse Education (SED)|The Substance Abuse Education (SED) group will serve as the control intervention in which participants will receive instruction on a variety of topics included in the substance abuse treatment program curriculum. These will include, but are not limited to, information about anger management, smoking cessation, women's issues, and stress management, and approaches to help reduce cravings. Each week the TAU group will meet and a House of Hope (HOH) clinical staff member will discuss the above and related issues and how these may help individuals deal with their substance abuse and related psychological issues.
3166188|NCT01438346|Experimental|Mind-body Bridging (MBB)|Participants in the experimental Mind-Body Bridging (MBB) group, in addition to their usual treatment for substance abuse, will additionally receive instruction on the basics of MBB, and will learn MBB techniques to help deal with their cravings and comorbid psychological conditions. A workbook will be incorporated into the curriculum to provide MBB participants with daily exercises and activities to help facilitate adherence to the MBB program.
3166189|NCT01438333|Experimental|Lactobacillus brevis|
3166190|NCT01438333|Placebo Comparator|Placebo|5 tablets a day for 6 weeks
3166191|NCT01438320|Experimental|Quercetin|Quercetin is a bioflavonoid.
3166192|NCT01438307|Experimental|Schedule A|"Subjects with advanced non-small cell lung cancer who have been previously treated will be given a specific regimen of the novel taxane, Cabazitaxel-XRP6258.~Subjects with asymptomatic brain metastases will be eligible for the study and a subset analysis will take place to help determine what, if any, effect Cabazitaxel-XRP6258 has on brain metastases."
3166235|NCT01437930|Placebo Comparator|placebo|products (sausage, bread rolls, milk beverage, wafers) enriched with 20g sunflower oil/d
3166193|NCT01438307|Experimental|Schedule B|"Subjects with advanced non-small cell lung cancer who have been previously treated will be given a specific regimen of the novel taxane, Cabazitaxel-XRP6258, different from Schedule A.~Subjects with asymptomatic brain metastases will be eligible for the study and a subset analysis will take place to help determine what, if any, effect Cabazitaxel-XRP6258 has on brain metastases."
3166194|NCT01438294|Active Comparator|Aerobic exercise|The aerobic training will be done on the treadmill with heart monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.
3166195|NCT01438294|Experimental|Video game|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( reflex ridge- Adventure).
3166196|NCT01438281|Experimental|SYL1001|
3166197|NCT01438268||Reconstructive breast cancer patients|Patients having unilateral, bilateral immediate or delayed TRAM flaps who are discharged 18 hours postoperatively
3166198|NCT01438255||Alvesco|
3166199|NCT01438242|Experimental|Assay Guided Treatment - Genecept Asay|Subjects donate DNA sample for genetic testing and treatment decisions take genetic results into account. Genetic analysis is performed using the Genecept Assay, a genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
3166200|NCT01438242|Experimental|Clinician's utilizing Assay Guided Treatment in Psychiatry|Prescribing clinicians responsible for the treatment of patients age 18 and older with a primary diagnosis of Major Depressive Disorder or Generalized Anxiety disorder, and for whom the Genecept Assay has been utilized to perform genetic testing.
3166201|NCT01438229|Experimental|renal artery ablation|Catheter-based RF ablation in renal artery
3166202|NCT01438216||VUmc IC|Due to multicentre, 2 groups of patient in 1 cohort
3166203|NCT01438216||UMCN IC|Due to multicentre, 2 groups of patient in 1 cohort
3166204|NCT01438203|Experimental|Thrust manipulation|Clinicians will use thrust manipulation at a targeted level to provide the treatment on selected individuals
3166205|NCT01438203|Active Comparator|Non-thrust manipulation|Clinicians will apply non-thrust manipulation (targeted) as performed in a clinical manner for treatment for included individuals
3166206|NCT01438190|Experimental|Experimental|Metformin plus step-down protocol
3166207|NCT01438190|Active Comparator|Control|Placebo and step-up protocol
3166208|NCT01438177|Experimental|Velcade+Cyclophosphamide+Chloroquine|"VELCADE given by intravenous push at 1.3 mg/m^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.~Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.~Chloroquine given at 500 mg orally daily on days 1-14 and 22-35.~Each cycle is 42 days in length."
3166209|NCT01438164||oncologic patients|initial staging
3166210|NCT01438151|Experimental|Remicade|Subjects will begin with receiving infliximab at 5 mg/kg for the first visits. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
3166211|NCT01438138||Correlative studies|Archived bone marrow mononuclear cells are analyzed by single cell network proteomic profiling assay, the My Profile™ AML Risk of Relapse Assay. Molecular markers analyzed include Flt3-ITD, NPM1, and MRA. Results are then correlated with each patient's clinical data including patient's age, race/ethnic background, gender, treatment received, and outcomes.
3166212|NCT01438125|Active Comparator|MF-4181|Scar halves randomized to treatment with device, opposite side treated per standard of care
3166213|NCT01438125|Active Comparator|Standard surgical wound closure|
3166214|NCT01438112|Experimental|CG0070 oncolytic virus|Interventions: CG0070 oncolytic virus intravesical instillations weekly X6 with each instillation lasting 45 minutes after prior transduction agent of DDM intravesically for 15 minutes
3166215|NCT01438112|Active Comparator|Chemotherapy or Interferon|"Quadruple Choice as interventions~Mitomycin C~Interferon~Valrubicin~Gemcitabine"
3166216|NCT01438099||normal subjects|parturients admitted to the labor ward who request epidural analgesia with BMI < 30
3166217|NCT01438099||obese subjects|parturients admitted to the labor ward who request epidural analgesia with BMI > 30
3166218|NCT01438086|Active Comparator|mecasermin low dose|
3166219|NCT01438086|Active Comparator|mecasermin high dose|
3166220|NCT01438086|Placebo Comparator|saline placebo|
3166221|NCT01438073|Experimental|kisspeptin, GnRH|24-hour continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg), and single bolus of GnRH (gonadotropin-releasing hormone) (2.5-250 ng/kg)
3166222|NCT01438060|Experimental|Aripiprazole (BMS-337039)|Double blind Acute Phase (Week 1 to Week 10), Open label Extension Phase (Week 11 to Week 140)
3166223|NCT01438060|Placebo Comparator|Placebo|Double blind Acute Phase (Week 1 to Week 10)
3166224|NCT01438034|Experimental|kisspeptin|intravenous administration of kisspeptin 112-121 0.24 nmol/kg.
3166225|NCT01438021|Experimental|Treatment (intraventricular chemotherapy)|Patients receive intraventricular methotrexate continuously on days 1-14. Treatment continues in the absence of disease progression or unacceptable toxicity.
3166226|NCT01438008|Experimental|Sucrose 24% po|"24% sucrose solution. The CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum dose of 1 mL of a 24% sucrose solution"
3166227|NCT01438008|Placebo Comparator|Placebo po|"The CHEO pharmacy department will provide a syringe labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (contents almost identical in color, consistency and odor to the sucrose solution) in identical packagings"
3166228|NCT01437995|Active Comparator|Fluticasone/Salmeterol Diskus 250/50 ug|Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
3166229|NCT01437995|Active Comparator|Fluticasone/Salmeterol Diskus 100/50 ug|Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
3166230|NCT01437995|Active Comparator|Fluticasone Diskus alone 250 ug|Fluticasone Diskus alone 250 ug twice daily without Salmeterol
3166231|NCT01437982|Experimental|Loteprednol Etabonate|Ophthalmic Gel 0.5%
3166232|NCT01437982|Experimental|Prednisolone Acetate 1% Oph Susp|Ophthalmic suspension 0.5%
3166233|NCT01437943|Active Comparator|Aliskiren|Aliskiren 150 mg daily for 180 days
3166234|NCT01437943|Placebo Comparator|Placebo|Placebo identical to Aliskiren drug daily for 180 days
3166238|NCT01437917|Experimental|carbohydrates|50g of carbohydrates ingested with 400 ml of water
3166239|NCT01437904|Experimental|Outpatient|Outpatient recovery following Percutaneous nephrolithotomy
3166240|NCT01437904|Sham Comparator|In hospital|Inpatient recovery following Percutaneous nephrolithotomy
3166241|NCT01437878|Experimental|iloprost|single dose inhalation using the power disc-6 with I-neb Adaptive Aerosol Delivery (AAD) system
3166242|NCT01437878|Placebo Comparator|placebo|matching placebo using the power disc-6 with I-neb AAD system
3166243|NCT01437865|Experimental|Gadofosveset enhanced MRI Axilla|
3166244|NCT01437852|Experimental|StrataGraft skin tissue|
3166245|NCT01437839|Experimental|1|Period I: fasting state, Period II: fed state
3166246|NCT01437839|Experimental|2|Period I: fed state, Period II: fasting state
3166247|NCT01437826|Experimental|antioxidants|tablets composed of 200 mcg selenium [as l-selenomethionine], 30 mg zinc, 2 mg vitamin A [retinol], 180 mg vitamin C [ascorbic acid] and 30 mg vitamin E [D-α-tocopherol acetate]
3166248|NCT01437826|Placebo Comparator|Sugar pill|placebo had an identical appearance as intervention
3166249|NCT01437787|Placebo Comparator|Placebo comparator|once daily X 28 days, orally, empty stomach, approximately same time each day
3166250|NCT01437787|Experimental|SAR302503 400 mg|once daily X 28 days, orally, empty stomach, approximately same time each day
3166251|NCT01437787|Experimental|SAR302503 500 mg|once daily X 28 days, orally, empty stomach, approximately same time each day
3166252|NCT01437774|Active Comparator|Concentric Thrombectomy Catheter|Control Arm
3166253|NCT01437774|Experimental|Reverse ReStore mechanical thrombectomy|Reverse ReStore Device mechanical thrombectomy Each arm will use either ReStore or Merci as the primary thrombectomy device
3166254|NCT01437761||2008 Sorbent system|Hemodialysis with the 2008 Sorbent system
3166255|NCT01437748|Experimental|Indacaterol maleate|Indacaterol 300 mcg via Breezehaler Inhaler will be administered by a third independent investigator not involved in the performing of any of the tests decribed, following a randomization list
3166256|NCT01437748|Active Comparator|Tiotropium bromide|Tiotropium 18 mcg, via HandiHaler inhaler will be administered by a third independent investigator not involved in the performing of any of the tests decribed, following a randomization list
3166257|NCT01437735|Experimental|QAW039 po dose 1|
3166258|NCT01437735|Experimental|QAW039 po dose 2|
3166259|NCT01437735|Experimental|QAW039 po dose 3|
3166260|NCT01437735|Experimental|QAW039 po dose 4|
3166261|NCT01437735|Experimental|QAW039 po dose 5|
3166262|NCT01437735|Experimental|QAW039 po dose 6|
3166263|NCT01437735|Experimental|QAW039 po dose 7|
3166264|NCT01437735|Experimental|QAW039 po dose 8|
3166265|NCT01437735|Experimental|QAW039 po dose 9|
3166266|NCT01437735|Experimental|QAW039 po dose 10|
3166267|NCT01437735|Experimental|QAW039 po dose 11|
3166268|NCT01437735|Experimental|QAW039 po dose 12|
3166269|NCT01437735|Experimental|QAW039 po dose 13|
3166270|NCT01437735|Active Comparator|leukotriene receptor antagonist (LRTA).|
3166271|NCT01437735|Placebo Comparator|Placebo|
3166272|NCT01437722|Experimental|1% SPL7013 Gel|
3166273|NCT01437722|Experimental|3% SPL7013 Gel|
3166274|NCT01437722|Placebo Comparator|placebo gel|
3166275|NCT01437709|Experimental|patients receiving Immunotherapy (This arm is closed)|The proposed study is a Simon 2 stage optimal study design investigating the activity of ofatumumab alone or in conjunction with Bendamustine for patients with MCL who are either not candidates for ASCT or aged 65 or older. The study design will allow for an estimation of the single agent response of ofatumumab in patients at low biologic risk for immediate disease progression.
3166276|NCT01437709|Experimental|patients receiving Chemoimmunotherapy|The proposed study is a Simon 2 stage optimal study design investigating the activity of ofatumumab alone or in conjunction with Bendamustine for patients with MCL who are either not candidates for ASCT or aged 65 or older. The combined regimen will assess the response rates of the combined chemo- immunotherapy program in patients with need for cytoreductive therapy, or high risk for disease progression. Patients with a leukemic phase only presentation of mantle cell lymphoma generally have clinically low-risk disease, regardless of mantle cell IPI calculations. Upon reciew with the principal investigator, these patients may be stratified to the immunotherapy only arm if clinically appropriate.
3166277|NCT01437696|Experimental|Vitamin D fortified food 500 IU|One portion of a specific food item will be provided each day. 500 IU Vitamin D added.
3166278|NCT01437696|Experimental|Vitamin D fortified food 1000 IU|One portion of a specific food item will be provided each day. 1000 IU Vitamin D added.
3166279|NCT01437696|Placebo Comparator|Placebo|One portion of a specific food item will be provided each day. No vitamin D added.
3166280|NCT01437683||traumatic brain injury patients|a large group of traumatic brain injury patients
3166281|NCT01437670||dry mouth patients with solifenacin|dry mouth patients with solifenacin 5mg, 10mg
3166282|NCT01437657|Placebo Comparator|Placebo|Matching RO4917523 placebo orally daily, 6 weeks
3166283|NCT01437657|Experimental|RO4917523 0.5 mg|0.5 mg orally daily, 6 weeks
3166284|NCT01437657|Experimental|RO4917523 1.5 mg|1.5 mg orally daily, 6 weeks
3166285|NCT01437644|Active Comparator|Botulinum Toxin TypeA|"A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. A total of 2 ml of isotonic saline will be used to dissolve the contents of the trial vial of Botox. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo arm of the study."
3166319|NCT01437397|Experimental|2|Aclidinium/formoterol Fixed Dose Combination (FDC) 400/6μg
3166320|NCT01437397|Active Comparator|3|Aclidinium monotherapy 400 μg
3166321|NCT01437397|Active Comparator|4|Formoterol monotherapy 12 μg
3166322|NCT01437397|Placebo Comparator|5|Placebo
3166286|NCT01437644|Placebo Comparator|Saline|The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Injections of normal saline will be administered in those children randomised to the placebo arm of the study. The volume of normal saline injected will be equal to the volume of normal saline that would have been used if the child had been randomised to botulinum toxin. The injector will be blinded, as the solution is drawn up by unblinded nurses.
3166287|NCT01437631|Experimental|endoclip|The group of patients who undergo prophylactic clip application after colonoscopic polypectomy of a large pedunculated polyp(>1cm).
3166288|NCT01437631|No Intervention|no endoclip|The group of patients who do not undergo prophylactic clip application after colonoscopic polypectomy of a large pedunculated polyp(>1cm).
3166289|NCT01437618||BRAF mutant mCRC|
3166290|NCT01437605|Active Comparator|A: recMAGE-A3 + AS15|ASCI injections without Poly IC:LC
3166291|NCT01437605|Active Comparator|B: recMAGE-A3 + AS15 + Poly IC:LC|ASCI injections with Poly IC:LC
3166292|NCT01437592|Experimental|IDeg|
3166293|NCT01437579|Active Comparator|Botulinum toxin|Bladder intratrigonal injection of botulinum toxin (100 units) in 10 injection sites during cystoscopy under general anesthesia
3166294|NCT01437579|Sham Comparator|cystoscopy with hydrodistension|cystoscopy with hydrodistension under general anesthesia
3166295|NCT01437566|Placebo Comparator|GDC-0941 Matching Placebo + Fulvestrant (Arm E)|Participants with PIK3CA mutation will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 matching placebo QD orally starting on Day 1 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
3166296|NCT01437566|Experimental|GDC-0941-260 mg + Fulvestrant (Arm D)|Participants with PIK3CA mutation will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 260 mg QD orally starting on Day 1 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
3166297|NCT01437566|Experimental|GDC-0941-340 mg + Fulvestrant (Arm A)|Participants will receive fulvestrant 500 milligrams (mg) as 2 intramuscular (IM) injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 340 mg once daily (QD) orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
3166298|NCT01437566|Placebo Comparator|GDC-0948 or GDC-0980 Matching Placebo + Fulvestrant (Arm C)|Participants will be randomized in 1:1 ratio to receive GDC-0948 matching placebo or GDC-0980 matching placebo with fulvestrant. Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0948 or GDC-0980 matching placebo QD orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
3166299|NCT01437566|Experimental|GDC-0980-30 mg + Fulvestrant (Arm B)|Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0980 30 mg QD orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
3166300|NCT01437553|Other|IVUS|Patients undergoing catheterization due to acute coronary syndrome will have IVUS done with grayscale and iMAP analysis performed.
3166301|NCT01437540|Experimental|1|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg fixed dose combination (FDC), high dose twice per day
3166302|NCT01437540|Active Comparator|2|Inhaled formoterol fumarate 12 μg, twice per day
3166303|NCT01437527|Experimental|Interventional arm|Body image therapy with Anamorphic Micro software
3166304|NCT01437527|Active Comparator|control arm|Body image therapy as usual
3166305|NCT01437514|Experimental|lower risk group with pSRT|the patients that was divided into the lower risk group that the mesorectum involvement less than 5mm, and no lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients accept the preoperative short-course radiotherapy before the surgery
3166306|NCT01437514|No Intervention|lower risk group with operation only|the patients that was divided into the lower risk group that the mesorectum involvement less than 5mm, and no lymph node larger than 8mm,according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.
3166307|NCT01437514|Experimental|higher risk group with pSRT|the patients that was divided into the higher risk group that the mesorectum involvement more than 5mm, or with lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.these patients have the preoperative short-course radiotherapy before the surgery.
3166308|NCT01437514|No Intervention|higher risk group with operation directly|the patients that was divided into the higher risk group that the mesorectum involvement more than 5mm, or with lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.
3166309|NCT01437501|Experimental|Broccoli Sprout Extract Beverage|
3166310|NCT01437501|Placebo Comparator|Placebo beverage|
3166311|NCT01437488|Experimental|Cabazitaxel|Cabazitaxel following platinum-based chemotherapy
3166312|NCT01437475|Experimental|Sci-B-Vac|The study involves only one, open label arm. Rate of immunization will be compared to results obtained using the ENGERIX B vaccine among HIV positive persons in formerly published, historical cohorts.
3166313|NCT01437449|Experimental|cisplatin/docetaxel/cetuximab|Patients will be treated weekly with cisplatin, docetaxel, and cetuximab.
3166314|NCT01437436||obesity|otitis media patient with obesity
3166315|NCT01437436||non obesity|otitis media patient with non obesity
3166316|NCT01437423|Experimental|TETRAXIM™ vaccine|Participants will receive a primary or booster dose of TETRAXIM™
3166317|NCT01437410||EUS-FNA|
3166318|NCT01437397|Experimental|1|Aclidinium/formoterol Fixed Dose Combination (FDC) 400/12μg
3166323|NCT01437384|Experimental|E5501 plus minus verapamil; plus minus cyclosporine|
3166324|NCT01437371|Other|optimized|The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
3166325|NCT01437371|Other|usual care|
3166326|NCT01437358||intensive care unit|
3166327|NCT01437332||Diabetes|
3166328|NCT01437332||Nerve injury|
3166329|NCT01437332||Other|
3166330|NCT01437319|Active Comparator|lotrafilcon A, comfilcon A|All subjects are assigned to lotrafilcon A during a run-in (Phase 1) and then randomized to one of two lenses. This arm is assigned to comfilcon A at phase 2. Subjects classified as a Neophyte wore etafilcon A for 2-weeks before entering the run-in period in Phase I.
3166331|NCT01437319|Active Comparator|lotrafilcon A, balafilcon A|All subjects are assigned to lotrafilcon A during a run-in (Phase 1) and then randomized to one of two lenses. This arm is assigned to balafilcon A at phase 2. Subjects classified as a Neophyte wore etafilcon A for 2-weeks before entering the run-in period in Phase I.
3166332|NCT01437306|Experimental|Lofexidine following overnight fast|A single dose of lofexidine (400 mcg or 2 x 200 mcg tablets) will be given to subjects following a minimum 10 hour overnight fast.
3166333|NCT01437306|Experimental|Lofexidine Following a High Fat Meal|A single dose of lofexidine 400 mcg (or 2 x 200 mcg tablets) will be administered to subjects following a standard high-fat meal.
3166334|NCT01437293|Experimental|Experimental|L-dopa / carbidopa / entacapone (LCE)
3166335|NCT01437280|Experimental|CGTG-102|CGTG-102 is an oncolytic adenovirus
3166336|NCT01437267|Experimental|Vi-CRM, Older infants|Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
3166337|NCT01437267|Active Comparator|PNC13, Older infants|Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
3166338|NCT01437267|Experimental|Vi-CRM, Infants|Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
3166339|NCT01437267|Active Comparator|PNC13, Infants|Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine
3166340|NCT01437267|Experimental|Vi-CRM, Children|Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
3166341|NCT01437267|Active Comparator|Vi-PS, Children|Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine
3166342|NCT01437254|Experimental|Arm Number 1 CPERT|1 CPERT scan, blood and vital sign collection
3166343|NCT01437254|Active Comparator|Arm Number 2 GPERT|1 GPERT Scan
3166344|NCT01437241||etravirine|Antiretroviral regimens based on etravirine plus 2 active nucleos(t)ide reverse-transcriptase inhibitors (NRTIs)
3166345|NCT01437228|Other|povidone iodine|30-second vaginal scrub with povidone- iodine solution.
3166346|NCT01437228|Placebo Comparator|CONTROL|
3166347|NCT01437215|Experimental|Fenestrated Endografting|
3166348|NCT01437202||high risk group|Identified by the predictive model using 2 genotypes and disease stage
3166349|NCT01437202||intermediate risk group|Identified by the predictive model using 2 genotypes and disease stage
3166350|NCT01437202||Low risk group|Identified by the predictive model using 2 genotypes and disease stage
3166351|NCT01437176|Experimental|Stable intertrochanteric fracture|The type of intertrochanteric fracture was below A2.1 (with A2.1) according to the AO/ATO classification.
3166352|NCT01437176|Experimental|Unstable intertrochanteric fracture|The type of intertrochanteric fracture was above A2.1 (without A2.1) according to the AO/ATO classification.
3166353|NCT01437163|Sham Comparator|Red Incandescent light source|
3166354|NCT01437163|Active Comparator|TopHat 655|
3166355|NCT01437150|Experimental|Simple posterior wall fracture|Simple posterior wall fracture means the fracture was only occurred in the posterior wall of acetabular.
3166356|NCT01437150|Experimental|Complex posterior wall fracture|Complex posterior wall fracture means the fracture was not only occurred in the posterior wall of acetabular, but also occurred in other part of acetabular.
3166357|NCT01437137|Active Comparator|LMA group|
3166358|NCT01437137|Experimental|I-gel group|
3166359|NCT01437124||Ceramic on metal THA|Those who have received a ceramic on metal total hip replacement
3166360|NCT01437111|Experimental|Fosamax Plus|Calcium supplement (elemental calcium and/or calcium carbonate) without vitamin D will also be supplied to participants
3166361|NCT01437098|Experimental|MDT-2111 CoreValve TAVI|Transcatheter Aortic Valve Implantation (TAVI) with MDT-2111 CoreValve system. Access sites for the implant include: Iliofemoral, Subclavian and Direct Aortic.
3166362|NCT01437072||Total study population|
3166363|NCT01437059|Active Comparator|ALN-PCS02|
3166364|NCT01437059|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3166365|NCT01437046|Experimental|Doxazosin|Doxazosin 16mg/day
3166366|NCT01437046|Placebo Comparator|Placebo|Placeno
3166367|NCT01437020|Experimental|Dose escalating-IV infusion of SCH708980 and Ambisome|
3166368|NCT01436994|Active Comparator|Block and Replace|Carbimazole is commenced in a dose of 0.75 mg/kg/day. The intention is to completely prevent endogenous thyroxine production. Thyroxine is then added in a replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principal measure of control during the first 6 months will be thyroid hormone levels rather than TSH.
3166369|NCT01436994|Active Comparator|Dose Titration|"Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining the euthyroid state. The principal measure of control during the first 6 months will be thyroid hormone levels rather than TSH.~Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.~Drug: Carbimazole 5mg and 20 mg tablets. Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry Drug: propylthiouracil 50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry."
3166370|NCT01436981||CABG with papaverine|Patients with CABG procedure
3166371|NCT01436968|Experimental|ProstAtak®|ProstAtak® (AdV-tk) + valacyclovir + radiation therapy +/- ADT
3166372|NCT01436968|Placebo Comparator|Control|Placebo + valacyclovir + radiation therapy +/- ADT
3166373|NCT01436955|Experimental|A|
3166374|NCT01436955|Placebo Comparator|B|
3166375|NCT01436942|Experimental|Exercise group|
3166376|NCT01436942|No Intervention|Control group|
3166377|NCT01436929|Experimental|Silymarin|Silymarin: prophylactic administration of silymarin with anti-TB drugs Placebo: prophylactic administration of placebo with anti-TB drugs
3166378|NCT01436929|Placebo Comparator|Placebo|administration of placebo with anti-TB drugs
3166379|NCT01436916|Active Comparator|oral cholecalciferol + lifestyle counselling|will receive Oral cholecalciferol
3166380|NCT01436916|Placebo Comparator|Placebo + lifestyle counselling|will receive placebo
3166381|NCT01436890|Experimental|Low dose|Low dose revamilast
3166382|NCT01436890|Experimental|Medium dose|Medium dose Revamilast
3166383|NCT01436890|Experimental|High dose|High dose Revamilast
3166384|NCT01436890|Placebo Comparator|Placebo|Matching placebo in triple dummy format
3166385|NCT01436877|Experimental|device|Insertion of Temporary Implantable Nitinol Device (TIND)
3166386|NCT01436864|Experimental|0.5 mg KH902|Patients will receive intravitreal injection of KH902 0.5mg/eye once per month for three times in the study eye, and then patients will receive 2 sham injections monthly, respectively, at the end of month 3 (visit 5), and following these injections you will receive intravitreal injection of KH902 once every three months, till month 12 (respectively at month 5, month 8 and month 11)
3166387|NCT01436864|Sham Comparator|Sham-injection|Patients will receive sham injection once per month for three times, and then you will receive intravitreal injection of KH902 0.5mg/eye once per month for three times in the study eye, after three months' treatment they will receive intravitreal injection of KH902 once every three months, till month 12 (respectively at month 8 and month 11.
3166388|NCT01436851|Experimental|Storage mite and placebo nasal challenge|Provocation in the nose with an allergen extract of a storage mite (A. Siro or L. Destructor) and with placebo allergen extract (physiologic salt water)
3166389|NCT01436838||Group 1|
3166390|NCT01436825||Group 1|
3166391|NCT01436812|Placebo Comparator|zero end-expiratory pressure|not applying PEEP during operation just applying TV=IBW*6-8ml IBW = (male; 50+0.91[(Ht-cm)-152.4], female; 45.5 +0.91[(Ht-cm)-152.4], RR 8-12/min,
3166392|NCT01436812|Active Comparator|positive end expiratory pressure|applying PEEP 10cmH2O during operation just applying TV=IBW*6-8ml IBW = (male; 50+0.91[(Ht-cm)-152.4], female; 45.5 +0.91[(Ht-cm)-152.4], RR 8-12/min,
3166393|NCT01436799|Experimental|Desflurane|anaesthesia was induced with thiopental sodium 2 mg kg-1, alfentanil 10 μg kg-1 and rocuronium 0.6 mg kg-1. Anesthetic maintenance by desflurane
3166394|NCT01436799|Active Comparator|propofol|anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1, alfentanil 10 μg kg-1, and rocuronium 0.6 mg kg-1. A commercially available target controlled infusion (TCI) pump (Orchestra®, Fresenius Vial, France) was used and the pharmacokinetic set used to calculate target effect-site concentrations for propofol was Schnider and colleagues' model
3166395|NCT01436786|Experimental|Guided Imagery Intervention|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
3166396|NCT01436786|No Intervention|Control group|continues usual plan of care
3166397|NCT01436773||Recent Acute Coronary Event|Patients admitted to the hospital for recent STEMI or NSTEMI.
3166398|NCT01436773||Stable Coronary Artery Disease|Patients with known Coronary Artery Disease without recent acute coronary event.
3166399|NCT01436773||No Coronary Artery Disease|Patients with no evidence of coronary artery disease, assessed by coronary angiography.
3166400|NCT01436747|Active Comparator|Paricalcitol|
3166401|NCT01436747|Placebo Comparator|Matching placebo|
3166402|NCT01436734|Experimental|GIP|
3166403|NCT01436721|No Intervention|Surgicel® absorbable Haemostat|
3166404|NCT01436695||Epicall group|patients will be connected to Epicall sensor
3166405|NCT01436656|Experimental|LGX818 - Dose escalation|
3166406|NCT01436656|Experimental|LGX818 - Dose Expansion at MTD or RP2D|
3166407|NCT01436643|Experimental|Fluoxetine and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Fluoxetine, supplied in blistered packs containing 20 tablets; starting dose 20 mg; final dose 40 mg
3166408|NCT01436643|Experimental|Venlafaxine and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Venlafaxine, supplied in blistered packs containing 14 capsules; starting dose 75 mg; final dose 150 mg
3166409|NCT01436643|Experimental|Citalopram and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Citalopram, supplied in blistered packs containing 20 tablets; starting dose 20 mg, final dose 40 mg
3166410|NCT01436630||Stroke|"To accomplish the study it was assessed a group of 12 post-stroke patients who were admitted in the Rehabilitation Clinic inside the University. As inclusion criteria it was established to be able to walk alone without supervision and with no aids.~All the patients signed an informed consent before performing the tests. To characterize the sample it were used the Fugl-Meyer scale, Orpington test, Mini Exam of the Mental State and some other data regarding the age, gender, type of the lesion and side of the lesion."
3166411|NCT01436604|Other|LV dysfunction group|Cardiac MRI
3166412|NCT01436604|Other|Control group|Cardiac MRI
3166413|NCT01436578||All Participants|All participants treated with posaconazole oral suspension during the pre-specified surveillance period.
3166414|NCT01436565|Experimental|dose escalation and expansion|SAR245408 taken every day in the morning: no eating 2 hours prior and 1 hour after dose; SAR256212 will be given weekly by IV infusion over 1 hour, right after the SAR245408 oral dose
3166415|NCT01436539|Experimental|Adefovir Dipivoxil and polyene phosphatidylcholine|Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
3166416|NCT01436539|Active Comparator|Adefovire Dipivoxil|Adefovir Dipivoxil 10 mg once daily for 48 weeks
3166550|NCT01435707|Experimental|STE 20 group|subjects who undergo selective transforaminal block with triamcinolone 20 mg
3166417|NCT01436526|Experimental|Rivaroxaban (Xarelto, BAY59-7939) first 2*5 mg, then 1*10 mg|Single oral dose of rivaroxaban administered under fasting conditions 2*5 mg tablet in first intervention period and 1*10 mg tablet in second intervention period (after washout period)
3166418|NCT01436526|Experimental|Rivaroxaban (Xarelto, BAY59-7939) first 1*10 mg, then 2*5 mg|Single oral dose of rivaroxaban administered under fasting conditions 1*10 mg tablet in first intervention period and 2*5 mg tablet in second intervention period (after washout period)
3166419|NCT01436513|Experimental|A|Premarin reference tablet as a single oral dose under fasted conditions
3166420|NCT01436513|Experimental|B|Premarin new tablet as a single oral dose under fasted conditions
3166421|NCT01436513|Experimental|C|Premarin reference tablet as a single oral dose under fed conditions
3166422|NCT01436513|Experimental|D|Premarin new tablet as a single oral dose under fed conditions
3166423|NCT01436500|Experimental|5 mg ifetroban, Type 1|60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
3166424|NCT01436500|Placebo Comparator|Placebo, Type 1|60-minute intravenous infusion of 5% dextrose in sterile water given once daily for 3 days to subjects with Type 1 HRS.
3166425|NCT01436500|Experimental|5 mg ifetroban, Type 2|60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
3166426|NCT01436500|Experimental|15 mg ifetroban, Type 1|60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
3166427|NCT01436500|Experimental|15 mg ifetroban, Type 2|60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
3166428|NCT01436500|Experimental|50 mg ifetroban, Type 1|60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
3166429|NCT01436500|Experimental|50 mg ifetroban, Type 2|60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
3166430|NCT01436500|Experimental|150 mg ifetroban, Type 2|60-minute intravenous infusion of 150 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
3166431|NCT01436500|Placebo Comparator|Placebo, Type 2|60-minute intravenous infusion of 5% dextrose in sterile water given once daily for 3 days to subjects with Type 2 HRS.
3166432|NCT01436487|Experimental|Cohort 1|Low dose MultiStem or Placebo
3166433|NCT01436487|Experimental|Cohort 2|High dose MultiStem or Placebo
3166434|NCT01436487|Experimental|Cohort 3|Highest, safe MultiStem dose (from Cohorts 1 and 2) or Placebo
3166435|NCT01436474|Experimental|Varenicline|We will be comparing Varenicline to placebo in a single-blinded placebo controlled, randomized study
3166436|NCT01436474|Placebo Comparator|Placebo|We will be using a placebo in a randomized, controlled, single-blinded trial to look at varenicline for the indication of facilitating opioid tapering in opioid-dependent patients with chronic pain.
3166437|NCT01436448|Experimental|Probiotics Lactobacillus Rhamnosus|dose of 1010 Colony forming Units (CFU) once daily till delivery will be given orally
3166438|NCT01436448|No Intervention|Placebo|Microcrystalline cellulose/d each, up till deliver
3166439|NCT01436435|Experimental|Jetstream Atherectomy System|Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention including Atherectomy utilizing the Jetstream Atherectomy System with or without adjunctive therapy.
3166440|NCT01436422|Experimental|TetraVax-DV Vaccine - Admixture TV003|Participants will receive the TetraVax-DV Vaccine - Admixture TV003 at Day 0 and Day 180.
3166441|NCT01436422|Experimental|TetraVax-DV Vaccine - Admixture TV005|Participants will receive the TetraVax-DV Vaccine - Admixture TV005 at Day 0 and Day 180.
3166442|NCT01436422|Placebo Comparator|Placebo|Participants will receive the placebo at Day 0 and Day 180.
3166443|NCT01436409|Other|only vaginal touch|
3166444|NCT01436409|Experimental|vaginal touch +echography|
3166445|NCT01436396|Experimental|CYD Dengue Vaccine Group 1|Participants will receive Stamaril® + CYD dengue vaccine dose 1 at age 12 to 13 months; measles, mumps, and rubella vaccine + pneumococcal conjugated vaccine + hepatitis A vaccine at 13 to 14 months; CYD dengue vaccine dose 2 at 18 to 19 months; DTaP IPV/Hib vaccine at 19 to 20 months; and CYD dengue vaccine dose 3 at 24 to 25 months.
3166446|NCT01436396|Experimental|CYD Dengue Vaccine Group 2|Participants will receive Stamaril + placebo at age 12 to 13 months; measles, mumps, and rubella vaccine + pneumococcal conjugate vaccine + hepatitis A vaccine at 13 to 14 months; CYD dengue vaccine dose 1 at 18 to 19 months; DTaP IPV/Hib vaccine at 19 to 20 months; and CYD dengue vaccine dose 2 at 24 to 25 months.
3166447|NCT01436370|Experimental|Group 1 Controls|40 (up to 50) adults, healthy gender and age-matched controls, given a single 15 mcg intramuscular dose of Sanofi Pasteur Fluzone®
3166448|NCT01436370|Experimental|Group 2|40 (up to 50) adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy, given a single 60 mcg intramuscular dose of Sanofi Pasteur Fluzone® High Dose.
3166449|NCT01436370|Experimental|Group 2 Controls|40 (up to 50) adults, healthy gender and age-matched controls, given a single 60 mcg intramuscular dose of Sanofi Pasteur Fluzone® High Dose.
3166450|NCT01436370|Experimental|Group 1|40 (up to 50) adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy, given a single 15 mcg intramuscular dose of Sanofi Pasteur Fluzone®
3166451|NCT01436357|Experimental|Arm A (Stage I and II)|Receive AdCh3NSmut1 at 2.5 x 10^10 total virus particles (vp)/dose at day 0 followed by 1 dose of MVA-NSmut intramuscularly 56 days later at the dosage 1.8 x10^8 plaque forming units (pfu): 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.
3166452|NCT01436357|Placebo Comparator|Arm B (Stage I and II)|Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56: 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.
3166453|NCT01436344||1|"Cases: 30 patients with known paroxysmal atrial fibrillation (pAF) will consecutively be recruited from the cardiology ward and the cardiological ambulatory. They will form the cases group."
3166454|NCT01436344||2|Controls: For every case patient, an age (+/- one year) and gender matched control person (n=30) without known paroxysmal atrial fibrillation will be included and matched to every case patient.
3166455|NCT01436331|Active Comparator|Treatment As Usual (TAU)|
3166456|NCT01436331|Experimental|TAU+CBT for pts+Family Intervention+CM|
3166457|NCT01436318||Respiratory Function|Children will undergo one session of pulmonary function and strength testing
3167253|NCT01430624|No Intervention|Standard care|Treatment as usual
3166458|NCT01436305|Active Comparator|Tac maintenance|"Group 1 Study Therapy Regimen:Induction with alemtuzumab and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF).~Campath® (alemtuzumab); long-term Prograf® (tacrolimus), or equivalent ; CellCept® (mycophenolate mofetil- MMF), or equivalent , and 4 day course of MEDROL® (methylprednisolone)"
3166459|NCT01436305|Experimental|Belatacept maintenance|"Group 2 Study Therapy Regimen: Induction with alemtuzumab and maintenance with Nulojix® (belatacept) and mycophenolate mofetil (MMF).~Campath® (alemtuzumab); Nulojix® (belatacept); CellCept® (mycophenolate mofetil- MMF), or equivalent, and 4 day course of MEDROL®(Methylprednisolone)"
3166460|NCT01436305|Experimental|Basiliximab induction/Short-term Tac|"Short term = 3 months~Group 3 Study Therapy Regimen: Induction with 2 doses of basiliximab and tacrolimus for 84 days and maintenance with Nulojix® (belatacept) and mycophenolate mofetil (MMF).~Simulect® (basiliximab); Nulojix® (belatacept); short-term course of Prograf® (tacrolimus), or equivalent; CellCept® (mycophenolate mofetil- MMF), or equivalent, and 4 day course of MEDROL® (methylprednisolone)"
3166461|NCT01436292|Experimental|Albumin|Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level
3166462|NCT01436279|Experimental|Mifepristone + misoprostol|Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure
3166463|NCT01436279|Active Comparator|Osmotic dilators|Placed 20-24 hours prior to procedure
3166464|NCT01436266|Active Comparator|Misoprostol|400 mcg buccally 2 hours prior to procedure
3166465|NCT01436266|Placebo Comparator|Placebo (Folic acid)|Two 1-mg tablets buccally 2 hours prior to procedure
3166466|NCT01436253||Croatian participants with hyperlipidemia|Participants being treated in a physician's office for hyperlipidemia who have not achieved target lipid levels on their current hypolipemic therapy.
3166467|NCT01436240||Spanish-speaking Latino participants|The investigators will conduct up to two rounds of PRO-CTCAE (patient-reported outcome- Common Terminology Criteria for Adverse Events) version questionnaire administration followed by cognitive interviews in Spanish-speaking Latino patients who are receiving cancer treatment or who have completed treatment for cancer within the past six months at one of the participating sites.
3166468|NCT01436227|Experimental|Pazopanib|800 mg by mouth once daily for up to six, four week cycles.
3166469|NCT01436214|Experimental|APC-100|
3166470|NCT01436201|Experimental|Digoxin + Dulaglutide|"Digoxin: Two 0.5-milligram (mg) doses, oral, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, oral, once daily on Day 2 to Day 17.~Dulaglutide (LY2189265): 1.5 mg, subcutaneous injection, once on Day 8 and once on Day 15."
3166471|NCT01436188|Other|001 (Healthy Elderly Cohort 1)|standard frequent CSF sampling procedure for 36 hours
3166472|NCT01436188|Other|002 (Healthy Elderly Cohort 2)|an alternative frequency of CSF sampling procedure for 36 hours
3166473|NCT01436188|Other|003 (Healthy Elderly Cohort 3)|standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
3166474|NCT01436188|Other|004 (Elderly Volunteers with MCI or AD)|standard CSF sampling procedure for 36 hours
3166475|NCT01436188|Other|005 (Healthy Eldely Cohort 5)|an alternative lower frequency of CSF sampling in comparison to Cohort 1
3166476|NCT01436175|Experimental|SPD489 + Antidepressant|
3166477|NCT01436162|Experimental|Antidepressant + SPD489|
3166478|NCT01436162|Placebo Comparator|Antidepressant + Placebo|
3166479|NCT01436149|Experimental|Antidepressant + SPD489|
3166480|NCT01436149|Placebo Comparator|Antidepressant + Placebo|
3166481|NCT01436136|Active Comparator|Intervention group|Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
3166482|NCT01436136|Active Comparator|Usual care (control) group|Within the context of an open, cohort study, GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.
3166483|NCT01436123|Experimental|Stenting + Micro-infusion|Step 1 - implantation of everolimus-eluting stent with imaging by MSCT, IVUS and OCT; Step 2 - injection of stem cells containing gold nanoparticles with silica-iron oxide shells.
3166484|NCT01436123|Active Comparator|Stenting|Put in everolimus-eluting stent
3166485|NCT01436110|Experimental|Fluticasone furoate 50 mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
3166486|NCT01436110|Active Comparator|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ ACCUHALER
3166487|NCT01436110|Placebo Comparator|Placebo|Inhalation Powder via Novel Dry Powder Inhaler and DISKUS/ ACCUHALER
3166488|NCT01436097|Active Comparator|Usual Care arm|Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
3166489|NCT01436097|Experimental|Information provision intervention|Participants in the Information provision group will receive the same care as those in the Usual Care arm. In addition, the Information provision group participants will receive weekly reminders about the benefits of eating five servings of fruits and vegetables a day and their Way to Health portal will provide graphical depictions of their produce purchase proportions through information from their Price Plus card. This data will be available to them throughout the entire intervention.
3166490|NCT01436097|Experimental|Information provision + flat incentive|Participants assigned to the Information provision + flat group will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the Information provision arm.
3166551|NCT01435707|Experimental|Caudal 20 mg|subjects who undergo caudal epidural block with triamcinolone 20 mg
3166552|NCT01435707|Experimental|STE 40 group|subjects who undergo selective transforaminal block with triamcinolone 40 mg
3166918|NCT01433185|Experimental|Text message (SMS)|Text messages sent to women before and after delivery
3166491|NCT01436097|Experimental|Information provision + tiered incentive|In addition to receiving all features of the Information provision treatment the participants assigned to the Information provision + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption. In this arm, the more participants spend on produce the more money they can earn back.
3166492|NCT01436084|Experimental|SB1518|400 mg orally a day for 28 day cycle.
3166493|NCT01436071|Experimental|Fluticasone furoate 50mcg|Inhalation powder delivered by Novel Dry Powder Inhaler
3166494|NCT01436071|Placebo Comparator|Placebo|Inhalation powder delivered by Novel Dry Powder Inhaler
3166495|NCT01436058|Experimental|stem cell recipient|patients with ankle joint osteoarthritis
3166496|NCT01436045|Experimental|Insulin glulisine|A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
3166497|NCT01436045|Placebo Comparator|Saline|A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
3166498|NCT01436032|Experimental|N1539 15 mg|
3166499|NCT01436032|Experimental|N1539 30 mg|
3166500|NCT01436032|Active Comparator|Ketorolac|IV
3166501|NCT01436032|Placebo Comparator|Placebo|IV
3166502|NCT01436032|Experimental|N1539 7.5mg|
3166503|NCT01436019||anti-TNF treatment|Children or young adolescents with juvenile idiopathic arthritis receiving either infliximab, adalimumab or etanercept.
3166504|NCT01436006||CT scan|patient with cancer
3166505|NCT01435993|Experimental|Active|GSK1223249 slow (60 minutes) intravenous infusion
3166506|NCT01435993|Placebo Comparator|Placebo|Saline slow (60 minutes) intravenous infusion
3166507|NCT01435980|No Intervention|basal treatment|basal treatment
3166508|NCT01435980|Experimental|Gastric Bypass|basal treatment and Gastric Bypass
3166509|NCT01435980|Experimental|Exenatide|basal treatment and Exenatide
3166510|NCT01435967||Cohort A|Children aged <=5 years in Belgium, with opportunity to receive Rotarix, requiring hospitalisation during which rotavirus detection test was performed and with available results.
3166511|NCT01435954||Patients with Benign Prostatic Hyperplasia (BPH)|Insured male patients age 50 or older with BPH but no evidence of acute urinary retention (AUR) or prostate surgery at the index date
3166512|NCT01435941||Respondents who report episodic migraines (EM)|Survey respondents whose headaches meet the diagnostic criteria for migraine and report that they experienced between 1 and 14 headache days in the month prior to the survey administration
3166513|NCT01435928|Experimental|Lurasidone|Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
3166514|NCT01435928|Placebo Comparator|Placebo|Matching placebo once daily in the evening with a meal or 30 minutes after eating
3166515|NCT01435915|Experimental|Subjects receiving ropinirole|Eligible subjects will receive single and multiple oral dose of ropinirole prolonged release tablet in sequence over 14 days without dosing on washout period from Day 2 to Day 7.
3166516|NCT01435902|Active Comparator|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 4 weeks
3166517|NCT01435902|Active Comparator|Fluticasone Propionate|Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 4 weeks
3166518|NCT01435876|Active Comparator|Surgical arm|UNIOCULAR/BINOCULAR RECESSION/RESECTION PROCEDURES
3166519|NCT01435876|Active Comparator|Exercises|ORTHOPTICS/MINUS LENS THERAPY
3166520|NCT01435876|Active Comparator|Postoperative Exercises|POST SURGICAL ORTHOPTICS/MINUS LENS
3166521|NCT01435876|Active Comparator|Surgical|
3166522|NCT01435863|Experimental|SP-02L|
3166523|NCT01435850|Sham Comparator|HIP STEM SL PLUS|study group
3166524|NCT01435850|Active Comparator|HIP STEM SL PLUS MIA|control group
3166525|NCT01435837|Experimental|Caffeine and hydration.|"200 mg of caffeine (over the counter caffeine tablet)~1 liter of water"
3166526|NCT01435837|Placebo Comparator|No caffeine, no hydration.|
3166527|NCT01435824|Experimental|Healthy Controls|
3166528|NCT01435811|Experimental|Norovirus challenge pool (GII.4, CIN-1)|
3166529|NCT01435811|Placebo Comparator|Sterile water|
3166530|NCT01435798|Placebo Comparator|0% MTD Dex|0% MTD Dextromethorphan
3166531|NCT01435798|Experimental|25% MTD Dex|25% MTD Dextromethorphan
3166532|NCT01435798|Experimental|50% MTD Dex|50% MTD Dextromethorphan
3166533|NCT01435798|Experimental|100% MTD Dex|100% MTD Dextromethorphan
3166534|NCT01435772|Experimental|BMN 701 20mg/kg|BMN 701 20mg/kg IV every other week
3166535|NCT01435772|Experimental|BMN 701 10mg/kg|BMN 701 10mg/kg IV every other week
3166536|NCT01435772|Experimental|BMN 701 5mg/kg|BMN 701 5mg/kg IV every other week
3166537|NCT01435759|Experimental|Antidepressant + SPD489 10 mg|
3166538|NCT01435759|Experimental|Antidepressant + SPD489 30 mg|
3166539|NCT01435759|Experimental|Antidepressant + SPD489 50 mg|
3166540|NCT01435759|Experimental|Antidepressant + SPD489 70 mg|
3166541|NCT01435759|Placebo Comparator|Antidepressant + Placebo|
3166542|NCT01435746|Experimental|Liberal Transfusion|Patients in the liberal transfusion group will receive red blood cell transfusions when their hemoglobin concentration drops below 10 g/dl. The aim should be to reach a hemoglobin concentration between 10 and 12 g/dl.
3166543|NCT01435746|Active Comparator|Conservative Transfusion|Patients in the conservative transfusion group will receive red blood cell transfusions when their hemoglobin concentration drops below 8 g/dl. The aim should be to reach a hemoglobin concentration between 8 and 10 g/dl.
3166544|NCT01435733||Parents of children with ASD|Parents with one or more children diagnosed with Autism Spectrum Disorder
3166545|NCT01435720|Experimental|Cohort 1|0.0125 mg/kg
3166546|NCT01435720|Experimental|Cohort 2|0.05 mg/kg
3166547|NCT01435720|Experimental|Cohort 3|0.2 mg/kg
3166548|NCT01435720|Experimental|Cohort 4|0.375 mg/kg
3166549|NCT01435707|Experimental|Caudal 40 group|subjects who undergo caudal epidural block with triamcinolone 40 mg
3166553|NCT01435694|Experimental|Robot-assisted gait training|Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. Training sessions will last for an hour with 30 minutes of real walking time, because subject set-up in the device take approximately 30 minutes.
3166554|NCT01435694|Active Comparator|Conventional Therapy|Training sessions will focus on locomotor function improvements. Subjects will receive 45 minutes of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that they will be trained on walking abilities (like walking at different speeds, rapid changes directions) for 30 minutes with or without assistive aids.
3166555|NCT01435681||DYT-1 Postive|This group includes those participants who enroll having a genetically confirmed primary generalized dystonia diagnosis.
3166556|NCT01435681||Control|This group includes healthy subjects between the ages of 18 and 80.
3166557|NCT01435668|Other|Control|A simple written advice.
3166558|NCT01435668|Experimental|Brief Motivational Intervention (BMI)|Brief Motivational Intervention (BMI)
3166559|NCT01435655|Experimental|open|tafamidis
3166560|NCT01435642||A|
3166561|NCT01435629||Norditropin®|
3166562|NCT01435616|Experimental|LY2605541|LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC), once daily in combination with at least 2 pre-study oral antihyperglycemic medications (OAMs) prescribed by the personal physician, for 52 or 78 weeks
3166563|NCT01435616|Active Comparator|Glargine|Glargine titrated based on blood glucose readings, administered SC, once daily in combination with at least 2 pre-study OAMs prescribed by the personal physician, for 52 or 78 weeks
3166564|NCT01435603|Active Comparator|Standard Lifestyle Advice|Primary care-based identification of pre-diabetes and/or type 2 diabetes with standard clinical education (offered by participant's usual primary care providers) and brief lifestyle advice (delivered by a study Research Assistant).
3166565|NCT01435603|Experimental|Advice Plus Lifestyle Intervention|Primary care-based identification of pre-diabetes and/or type 2 diabetes with standard clinical education (offered by participant's usual primary care providers) and brief lifestyle advice (delivered by a study Research Assistant) Plus access to an intensive group-based lifestyle intervention offered in a community setting.
3166566|NCT01435577|Experimental|Tapentadol intravenous|Tapentadol will be given by intravenous infusion. Tapentadol will be administered every 4 hours. Ibuprofen 600 mg orally may be given as rescue medication for pain not controlled by Tapentadol alone.
3166567|NCT01435577|Placebo Comparator|Matching placebo intravenous|Placebo (0.9% sodium chloride and water for injection). Ibuprofen 600 mg orally may be given as rescue medication for pain.
3166568|NCT01435564|Active Comparator|pedometer|
3166569|NCT01435564|Experimental|Mobile phone physical activity intervention|
3166570|NCT01435538|Experimental|Care pathway teams.|In this experimental arm, the interprofessional teams will develop and implement a care pathways.
3166571|NCT01435538|No Intervention|Usual care teams.|In the no intervention arm, the interprofessional teams will deliver usual care without implementing the intervention.
3166572|NCT01435525||Nexium|
3166573|NCT01435512|Experimental|Group|PTSD-Focused Cognitive Behavioral Therapy for Partner Violence
3166574|NCT01435512|No Intervention|Waitlist|Control group - no intervention
3166575|NCT01435499|Experimental|Cohort A|Cohort A will receive four doses of vaccine, each containing 5E7 melanoma GVAX cells.
3166576|NCT01435499|Experimental|Cohort B|Cohort B will receive four doses of vaccine, each containing 2E8 melanoma GVAX cells.
3166577|NCT01435499|Experimental|Cohort C|Cohort C will receive four doses of vaccine, each containing 2E8 melanoma GVAX cells. One day prior to each vaccination, patients in cohort C will receive a single, low dose of intravenous cyclophosphamide.
3166578|NCT01435486|Active Comparator|caffeine Citrate|
3166579|NCT01435486|Placebo Comparator|Normal saline|
3166580|NCT01435473||Children undergoing heart surgery|The study will follow children undergoing cardiac surgery at The Hospital for Sick Children from pre-consultation, throughout surgery, recovery and post-operative follow-up
3166581|NCT01435460|Experimental|Alrex|Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2%
3166582|NCT01435460|Active Comparator|Patanol|Ophthalmic solution containing olopatadine, 0.1%
3166583|NCT01435447|Experimental|FLu-Bu-Cy|Patients received Fludarabine and iv Busulfan and post-infusion Cyclophosphamide as conditioning
3166584|NCT01435434|Experimental|sepax, ignite, fracture healing|the mesenchymal cells will be separated by sepax separation system and demineralized bone matrix will be done using IGNITE INJECTABLE REPAIR GRAFT
3166585|NCT01435408|Active Comparator|Conventional treatment.|Conventional primary PCI in STEMI.
3166586|NCT01435408|Experimental|IPost|Ischemic postconditioning in STEMI.
3166587|NCT01435408|Experimental|Deferred primary PCI.|Deferred strategy in STEMI.
3166588|NCT01435395|Experimental|Therapy|Therapy with temozolomide, bevacizumab and bortezomib
3166589|NCT01435382|Experimental|Group A|
3166590|NCT01435382|Experimental|Group B|
3166591|NCT01435382|Experimental|Group C|
3166592|NCT01435382|Experimental|Group D|
3166593|NCT01435369|Active Comparator|CT-011 at dose level 1 (1.5 mg/kg).|
3166594|NCT01435369|Active Comparator|CT-011 at dose level 2 (6 mg/kg).|
3166595|NCT01435356|Active Comparator|recMage-A3 + AS15 ASCI|MAGE A3 positive patients treated with recMAGE-A3 + AS15 ASCI
3166596|NCT01435356|Placebo Comparator|Placebo|
3166597|NCT01435330|Experimental|BVS857|
3166598|NCT01435330|Placebo Comparator|Placebo|
3166599|NCT01435317|Experimental|standard|Standard treatment with the ANM T30 CR®-System
3166600|NCT01435304|Experimental|Hemobag®|Hemobag® method of returning residual CPB blood (study group)
3166829|NCT01433731|Experimental|SHAPE (SHP-141) 0.5% BID|SHAPE (SHP-141) topical gelled solution at 0.5% concentration twice weekly
3166601|NCT01435304|No Intervention|cell saver|Standard method of returning the residual pump volume to the patient as washed, centrifuged cells (control group)
3166602|NCT01435291|Experimental|Advagraf|
3166603|NCT01435291|Active Comparator|Prograf|
3166604|NCT01435278|Active Comparator|Glucosanol|2 tablets 3 times a day
3166605|NCT01435265|Active Comparator|Normal Nurse Education|Subjects receive normal nurse education materials provided by their physician.
3166606|NCT01435265|Experimental|Additional Nurse Education-|Subjects will receive additional nurse education beyond the normal education materials provided by their physician
3166607|NCT01435252|Experimental|Arm A|Patients will be treated with chemoradiation in combination with concurrent cetuximab. Two weeks after end of chemoradiation the consolidation phase will start and patients will receive biweekly consolidation cetuximab, maximally 6 infusions over 12 weeks.
3166608|NCT01435252|Experimental|Arm B|Patients will be treated with chemoradiation in combination with concurrent cetuximab.
3166609|NCT01435239|Experimental|resting volume group|
3166610|NCT01435239|Active Comparator|maximum volume group|
3166611|NCT01435226|Active Comparator|Arm 1|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir 30 mg BID + RBV BID
3166612|NCT01435226|Active Comparator|Arm 2|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir 30 mg BID + RBV placebo BID
3166613|NCT01435226|Active Comparator|Arm 3|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir placebo BID + RBV BID
3166614|NCT01435213|Experimental|Atipamezole|
3166615|NCT01435213|Experimental|Atomoxetine|
3166616|NCT01435213|Experimental|Ketamine|
3166617|NCT01435213|Experimental|Insulin-induced hypoglycemia|
3166618|NCT01435213|Experimental|Cold pressor test|
3166619|NCT01435213|Experimental|Placebo|
3166620|NCT01435200|Experimental|Intravenous iron|Iron sucrose 200 mg intravenous infusion in 15 minutes
3166621|NCT01435200|Placebo Comparator|Oral iron|Ferrous fumarate 200 mg oral three times a day
3166622|NCT01435187||Infant Pulmonary Function Testing (iPFT)|A standardized method of performing infant PFTs using the raised volume rapid thoracoabdominal compression (RVRTC) technique will be used. This test will be performed on infants at one year (corrected age). The target sample size of 180 studies will represent the largest number of RVRTC PFTs in the preterm population and will enhance study of the relationship between lung function at 1 year of age and clinical and biologic factors associated with respiratory disease. Although the primary PFT measures will be derived from RVRTC, V'maxFRC, respiratory system compliance (Crs) and resistance (Rrs) will also be measured because these can be easily obtained. Crs and Rrs will be obtained using the single breath occlusion method.
3166623|NCT01435174|Experimental|Ranolazine|End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.
3166624|NCT01435161|Active Comparator|Nifedipine|Patients in arm 1 receive Nifedipine;
3166625|NCT01435161|Active Comparator|Telmisartan|Arm 2 receive telmisartan
3166626|NCT01435148|Experimental|Stimulation of SGC then VACNAC targets|Stimulation of the subgenual cingulate cortex (SGC) target will take place first, followed by stimulation of the ventral anterior capsule nucleus accumbens target (VACNAC) if no clinical response after a minimum of 4 months.
3166627|NCT01435148|Experimental|Stimulation of VACNAC then SGC targets.|Stimulation of the ventral anterior capsule nucleus accumbens target (VACNAC) will take place first, followed by stimulation of the subgenual cingulate cortex target (SGC) if no clinical response after a minimum of 4 months.
3166628|NCT01435135|Experimental|Group I|ALVAC-HIV + AIDSVAX B/E or ALVAC-HIV placebo + AIDSVAX B/E placebo at Weeks 0 and 24
3166629|NCT01435135|Experimental|Group II|AIDSVAX B/E or AIDSVAX B/E placebo at Weeks 0 and 24
3166630|NCT01435135|Experimental|Group III|ALVAC-HIV or ALVAC-HIV placebo at Weeks 0 and 24
3166631|NCT01435122|Experimental|Axitinib Administration|"The investigational drug used in this study is axitinib, and is available as tablets.~You will take the tablet orally with food. Doses should be taken around 12 hours apart continuously, without scheduled breaks. If you vomit anytime after taking a dose do not take another tablet to make up the dose but instead continue taking your next dose as planned.~Any missed dose may be taken late (up to 3 hours before the next scheduled dose); otherwise it should be skipped. If doses are missed or vomited, please keep track of this and report at your next visit."
3166632|NCT01435109|No Intervention|Usual Care|
3166633|NCT01435109|Experimental|Patient Behavioral Intervention|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
3166634|NCT01435109|Experimental|Provider Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
3166635|NCT01435109|Experimental|Patient and Provider Interventions|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
3166636|NCT01435096|Experimental|BN80927|
3166637|NCT01435083|Experimental|nocturnal polyuria patient with desmopressin MELT|
3166638|NCT01435070||Distal radius fracture|Patients aged 18 years and older with a fracture of the distal radius, within 3 cm of the radiocarpal joint
3166639|NCT01435057|Active Comparator|endurance training|"Endurance training:~Supervised, twice a week, each training session consists of a 20 min warm up and cool down period and a minimum of 40min tread mill, rawing device or bicycle training.~During the study period of 24 months, we will perform an open randomized, prospective training intervention study comparing the effects of three times a week either strength or endurance training on reduction of visceral fat area as determined by MRI scans at the level of L4-L5."
3166640|NCT01435057|Active Comparator|strength training|"Strength training:~Supervised, twice a week, each training session consists of a 20 min warm up and cool down period and a minimum of 40min circle training~During the study period of 24 months, we will perform an open randomized, prospective training intervention study comparing the effects of two to three times a week either strength or endurance training on reduction of visceral fat area as determined by MRI scans at the level of L4-L5."
3166641|NCT01435044|Experimental|SOF+RBV 12 Weeks|Participants were randomized to receive sofosbuvir plus RBV plus placebo to match GS-0938 for 12 weeks.
3166642|NCT01435044|Experimental|SOF+RBV 24 Weeks|Participants were randomized to receive sofosbuvir plus RBV plus placebo to match GS-0938 for 24 weeks.
3166643|NCT01435044|Experimental|GS-0938 Alone|Participants were randomized to receive GS-0938 plus placebo to match sofosbuvir for up to 24 weeks.
3166644|NCT01435044|Experimental|GS-0938+SOF|Participants were randomized to receive GS-0938 plus sofosbuvir for up to 24 weeks.
3166645|NCT01435044|Experimental|GS-0938+SOF+RBV|Participants were randomized to receive GS-0938 plus sofosbuvir plus RBV for up to 24 weeks.
3166646|NCT01435044|Experimental|Placebo|Deferred start group: Participants were randomized to receive placebo to match GS-0938 plus placebo to match sofosbuvir for 24 Weeks.
3166647|NCT01435044|Experimental|Retreatment Group - SOF+RBV 24 Weeks|After discontinuing a regimen containing GS-0938, participants received sofosbuvir plus RBV for up to 24 weeks.
3166648|NCT01435031|Other|CTO Treatment|"Subjects receiving at least 1 of the following for the treatment of CTO:~XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent~HT PROGRESS and/or HT PILOT guide wires in recanalization~MINI-TREK Coronary Dilatation Catheter in predilatation"
3166649|NCT01435018|Experimental|Arm 1A: Coformulated EFV/FTC/TDF plus ET|
3166650|NCT01435018|Experimental|Arm 1B: Coformulated EFV/FTC/TDF plus BV|
3166651|NCT01435018|Experimental|Arm 1C: Coformulated EFV/FTC/TDF plus PTX|
3166652|NCT01435005|Active Comparator|High Volume|Participate in one year of high volume (300 minutes per week) aerobic exercise with free provision of a personal trainer, membership to an exercise facility, body composition assessment.
3166653|NCT01435005|Active Comparator|Moderate Volume|Participate in one year of moderate volume (150 minutes per week) aerobic exercise with free provision of a personal trainer, membership to an exercise facility, body composition assessment.
3166654|NCT01434992||H. pylori gastritis|
3166655|NCT01434979||Controls|
3166656|NCT01434979||Cases who have suffered from Exertional Heat Illness / Stroke|
3166657|NCT01434966|Experimental|Lumbopelvic Manipulation|The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.
3166658|NCT01434966|Experimental|TENS- Spine|The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
3166659|NCT01434966|Experimental|TENS- Knee|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
3166660|NCT01434953|Experimental|Labeled|
3166661|NCT01434953|Active Comparator|Unlabeled|
3166662|NCT01434940|Experimental|Alzheimer|Patients suffering of Alzheimer disease
3166663|NCT01434940|Experimental|Depression|Patients suffering from depression
3166664|NCT01434940|Experimental|Healthy|Healthy volunteers
3166665|NCT01434927||Colonoscopy outpatients|All patients referred to our Unit to undergo colonoscopy for any indication
3166666|NCT01434914|Active Comparator|verum|
3166667|NCT01434914|Placebo Comparator|Placebo|
3166668|NCT01434901|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
3166669|NCT01434901|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
3166670|NCT01434901|Experimental|Type 2 Diabetes Mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
3166671|NCT01434888|Active Comparator|Tafluprost 0.0015%|
3166672|NCT01434888|Active Comparator|Timolol 0.5%|
3166673|NCT01434888|Experimental|Fixed-dose combination of tafluprost 0.0015% and timolol 0.5%|
3166674|NCT01434862|Experimental|Closed loop with pramlintide|Pramlintide will be provided to study subjects who will subsequently be admitted for inpatient testing with the closed loop system. The term closed loop refers to insulin adjustment automatically regulated by computer input to the insulin pump based on monitoring (often a combination of patient blood glucose (BG) testing and/or continuous glucose monitoring (CGM)).
3166675|NCT01434862|Experimental|Closed loop without pramlintide|This visit is necessary to assess how well the closed loop system works without the pramlintide (how well it protects from hypoglycemia and hyperglycemia). It will be the exact protocol as for the closed loop with pramlintide but without the medication.
3166676|NCT01434862|Experimental|Open loop with pramlintide|The term open loop refers to insulin infusions regulated in their delivery based on patient self-monitoring and adjustment. The study subject will be in charge of their insulin treatment while also receiving pramlintide.
3166677|NCT01434849|Experimental|Timolol|Application of 1-2 drops of Timolol maleate 0.5% ophthalmic aqueous solution to hemangioma twice daily.
3166678|NCT01434849|Placebo Comparator|Placebo|Application of 1-2 drops of placebo gel twice daily to hemangioma.
3166679|NCT01434836|Active Comparator|active tDCS and working memory training|
3166680|NCT01434836|Placebo Comparator|sham tDCS and working memory training|
3166830|NCT01433731|Experimental|SHAPE (SHP-141) 1.0% BID|SHAPE (SHP-141) topical gelled solution at 1.0% concentration twice weekly
3166681|NCT01434823|Experimental|Intervention - nocturnal coverage|Nocturnal coverage from intensivists will be randomized by week. The weeks that have intensivists in the MICU during the 7pm to 7am shift are the intervention weeks.
3166682|NCT01434823|No Intervention|Control - standard of care|The weeks that are not randomized, the intervention arm will retain the current standard of care in the HUP MICU: attending intensivist availability by phone (home call).
3166683|NCT01434810|Active Comparator|Window tinting film for filtered sunlight phototherapy|Window tinting film
3166684|NCT01434810|Active Comparator|Conventional phototherapy|Infants will be randomized to conventional phototherapy (new arm)
3166685|NCT01434797||Confirmed CVCP infection before removal|Patients with permanent central venous catheter infection confirmed by conventional method
3166686|NCT01434797||Presumed CPVP infection before removal|Patients with probable permanent central venous catheter infection (standard methods for infection detection not conclusive)
3166687|NCT01434797||Uninfected CVCP before removal|Patients with planned permanent central venous catheter removal (no infection)
3166688|NCT01434784||Surgery alone|Patients undergoing any kind surgery for lung cancer, no additional surgery, quality of life assessment with the provisional updated lung cancer module within 3 months after surgery
3166689|NCT01434784||Surgery in combination with any other tx|Patients undergoing any kind surgery for lung cancer, additional therapy is permitted, quality of life assessment with the provisional updated lung cancer module within 3 months after surgery
3166690|NCT01434784||Surgery (late effects)|Patients undergoing any kind surgery for lung cancer, additional therapy is permitted, quality of life assessment with the provisional updated lung cancer moduleat least 3 months after surgery and 3 months after any other active treatment
3166691|NCT01434784||Chemotherapy alone|Patient undergoing any kind of chemotherapy for lung cancer, no additional therapy, quality of life assessment with the provisional updated lung cancer module during or up to 4 weeks after completion of therapy
3166692|NCT01434784||Radiotherapy alone|Patient undergoing radiotherapy for lung cancer, no additional therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
3166693|NCT01434784||Sequential radiochemotherapy|Patient undergoing sequential radiochemotherapy for lung cancer, no surgery, no targeted therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
3166694|NCT01434784||Concurrent radiochemotherapy|Patient undergoing concurrent radiochemotherapy for lung cancer, no surgery, no targeted therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
3166695|NCT01434784||Targeted therapy alone|Patient undergoing targeted therapy for lung cancer, no surgery, no radiochemotherapy , quality of life assessment with the provisional updated lung cancer module during or up to 4 weeks after completion of therapy
3166696|NCT01434784||Targeted therapy in combination|Patient undergoing targeted therapy for lung cancer, additional therapies permitted, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
3166697|NCT01434758||Children|Children age 0-15 years presenting to NHP thought to have TB infection
3166698|NCT01434745|Experimental|Simvastatin|
3166699|NCT01434745|Placebo Comparator|Placebo - Lactose|
3166700|NCT01434732|Experimental|Umbilical Cord Milking|Umbilical Cord Milking involved milking the umbilical cord at birth.
3166701|NCT01434732|Active Comparator|Immediate Cord Clamping|Umbilical cord is clamped soon after birth without any milking of the cord.
3166702|NCT01434719||S.suis cases|This group consists of human cases with S.suis infection (confirmed or probable) admitted to National Hospital for Tropical Diseases in 2010.
3166703|NCT01434719||Sepsis controls|This group consists of hospital controls diagnosed with sepsis (not caused by S.suis) admitted to National Hospital for Tropical Diseases in 2010.
3166704|NCT01434706|Other|Nucleic Acid Amplification Testing|Nucleic Acid Amplification Testing
3166705|NCT01434693|Experimental|TSO 500|
3166706|NCT01434693|Experimental|TSO 2500|
3166707|NCT01434693|Experimental|TSO 7500|
3166708|NCT01434693|Placebo Comparator|Placebo|single dose
3166709|NCT01434680|Experimental|MenC-CRM LIQ (Liquid Formulation)|Subjects received 1 injection of MenC-CRM vaccine,liquid formulation.
3166710|NCT01434680|Experimental|MenC-CRM ROS (Rosia)|Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy
3166711|NCT01434680|Active Comparator|MenC-CRM EMV (Emeryville)|Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA
3166712|NCT01434667|Active Comparator|APOE Genotype Non-Disclosure|
3166713|NCT01434667|Experimental|APOE Genotype Disclosure|
3166714|NCT01434654||Non Neuro-HAART (low CNS penetrance)|Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.
3166715|NCT01434654||Neuro-HAART (high CNS penetrance)|Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.
3166716|NCT01434641|Other|low-dose stress MPI SPECT|Patients will receive a low-dose stress/high-dose rest protocol. Subject results are compared to archived patients undergoing a standard protocol./
3166717|NCT01434628|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
3166718|NCT01434615|Experimental|No-CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
3166719|NCT01434615|Experimental|CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
3166720|NCT01434602|Experimental|1/Phase I (closed)|daily everolimus (days 1- 28) in combination with sorafenib as per the Phase I dosing table
3166721|NCT01434602|Experimental|2/Phase II|combination of sorafenib and everolimus. Sorafenib will be taken daily for 7 days on, then 7 days off. Everolimus will be taken daily.
3166722|NCT01434589|No Intervention|Wait list control|
3166723|NCT01434589|Experimental|STICA Intervention|
3166724|NCT01434576|Experimental|HGS1025 2 mg/kg|
3166725|NCT01434576|Experimental|HGS1025 10 mg/kg|
3166726|NCT01434576|Placebo Comparator|Placebo|
3166727|NCT01434563||HIV positive|Subjects must have documented HIV, be english speaking, with life expectancy greater than 6 months, and must have adequate information available in their medical record to apply HAND predictive algorithm (HIV-associated neurological disease)
3166728|NCT01434563||HIV negative|Must have documented negative HIV test within 12 months of study entry, have no traumatic brain injury or history of chronic neurological illness/psychiatric conditions (such as bipolar or depression),be english speaking and have no history of drug or alcohol abuse.
3166729|NCT01434550|Active Comparator|TBRI Subgroup: TBRI and SBRT|"Six patients will be asked to be part of a subgroup called TBRI (Tissue, Blood, Research Imaging). In this subgroup, we want to study if there is early death of tumor cells from the treatment by looking at the tumor using PET/CT scans and biopsies, and by testing the participant's body's white blood cells taken by a procedure called leukapheresis.~Participants do not have to take part in the TBRI subgroup to get treatment on this study with SBRT.~SBRT:~30 Gy in 5 fractions to pancreatic tumor~50 Gy in 5 daily consecutive fractions unresectable portion and avoiding bowel, stomach, and duodenum"
3166730|NCT01434550|Active Comparator|SBRT Alone|"30 Gy in 5 fractions to pancreatic tumor~50 Gy in 5 daily consecutive fractions unresectable portion and avoiding bowel, stomach, and duodenum"
3166731|NCT01434537||SCAN|Venepuncture performed with support of the AccuVein 300 vein scanner.
3166732|NCT01434537||NO_SCAN|Venepuncture without support of the vein scanner.
3166733|NCT01434524|No Intervention|Control|normal dietary
3166734|NCT01434524|No Intervention|LIVACT|The present study used LIVACT for preoperative supplementation, commencing two weeks prior to surgery, and continuing for at least 6 months postoperatively with careful monitoring of compliance.
3166735|NCT01434511|Experimental|OBI-1|
3166736|NCT01434498|Active Comparator|Arm 1|GS-5885, GS-9451, tegobuvir (GS-9190), and Copegus® for 24 weeks
3166737|NCT01434498|Active Comparator|Arm 2|GS-5885, GS-9451, tegobuvir (GS-9190), and a placebo matching ribavirin for 24 weeks
3166738|NCT01434498|Active Comparator|Arm 3|GS-5885, GS-9451, a placebo matching tegobuvir, and Copegus® for 24 weeks
3166739|NCT01434485||Nexium|
3166740|NCT01434472|Experimental|Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)|Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).
3166741|NCT01434459|Experimental|Gemcitabine with TheraSphere|
3166742|NCT01434420|Experimental|Triple negative breast cancer|Triple negative breast cancer
3166743|NCT01434407|Experimental|Low AGE meal|Test meal prepared by boiling/steaming the food
3166744|NCT01434407|Experimental|High AGE meal|Test meal prepared by frying/grilling the food
3166745|NCT01434394|Experimental|Neo-adjuvant Erbitux-based chemotherapy|Neo-adjuvant Erbitus-based chemotherapy before surgery: Erbitus, Docetaxel, Cisplatin.
3166746|NCT01434394|No Intervention|Surgery and radiotherapy|Surgery and post-operative radiotherapy.
3166747|NCT01434381|Experimental|Pfs25-EPA/Alhydrogel|Dose-escalation of Pfs25-EPA/Alhydrogel. Participants will receive 1 of 3 doses of Pfs25-EPA/Alhydrogel- 8 micro g, 16 micro g, or 47 micro g.
3166748|NCT01434355||Correlative studies|Patients and parents or siblings undergo saliva sample collection. DNA extracted from saliva samples and from patients' archived tumor tissue samples is genotyped and analyzed by methylation arrays, including methylation-specific PCR (pyrosequencing) assays. Genetic variation between pediatric germ cell tumors and parent or sibling is also analyzed. Patients' and family members' health history, demographics, and environmental exposures are collected by questionnaires or telephone interviews. Medical history, such as chronic conditions, prescribed medications and congenital abnormalities, including cryptorchidism, is also collected. Birth characteristics of the child, including birth weight and gestational age, are also captured.
3166749|NCT01434342|Experimental|Arm I - Quitline|"Participants receive a letter from their physician advising them to quit smoking, and undergo a 15-30-minute smoking-cessation counseling session by a trained research staff.~The participants are educated and motivated about the importance of quitting smoking, and cancer-specific quitting issues. They will be called by Quitline in 2-3 days and receive a fact sheet about benefits of SC for cancer patients.~Participants receive 8 weeks of nicotine replacement patches and up to 5 proactive telephone calls over a 12-week period.~Participants also learn behavioral tips and coping skills."
3166750|NCT01434342|No Intervention|Arm II - Usual Care|"Participants receive a letter from their physician advising them to quit smoking, the importance of quitting smoking for cancer patients, and a copy of the National Cancer Institute's Clearing the Air smoking cessation booklet. Participants also receive standard of care from their oncology and other treatment providers which may or may not include nicotine replacement therapy."
3166751|NCT01434316|Experimental|Treatment (veliparib and dinaciclib)|"PART 1A: Patients receive veliparib PO BID on days 1-28 and dinaciclib IV over 2 hours on days 8 and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PART 1B: Patients receive veliparib and dinaciclib as patients in Part 1A. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PART 1C: Patients receive veliparib PO BID on days 1-7 of course 0. Patients then receive veliparib PO BID on days 1-21 and dinaciclib IV over 2 hours on days 1, 4, 8, and 11 or days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3166790|NCT01434017|Active Comparator|Dexamethasone and Ondansetron|Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
3166831|NCT01433718|Experimental|ACL prevention training|
3167809|NCT01426607|Placebo Comparator|placebo|placebo device in upper jaw
3166752|NCT01434303|Experimental|Treatment (entinostat, lapatinib ditosylate and trastuzumab)|Patients receive entinostat PO on days 1 and 15 and lapatinib tosylate PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in the Phase I Trastuzumab Cohort also receive maintenance dose of trastuzumab IV over 30-90 minutes every 3 weeks.
3166753|NCT01434290|Experimental|5 Fractions|36.25 Gy IMRT in 5 fractions over two and a half weeks
3166754|NCT01434290|Experimental|12 Fractions|51.6 Gy IMRT in 12 fractions over two and a half weeks
3166755|NCT01434277|Experimental|Healthy Subjects|Healthy Subjects instill 1-2 drops of the experimental eye drops into each eye four times per day for two weeks.
3166756|NCT01434277|Experimental|Dry-Eye Subjects|Dry-Eye Subjects instill 1-2 drops of the experimental eye drops into each eye four times per day for two weeks.
3166757|NCT01434264|Experimental|Self-selected energy healing|Self-selected healing in the self-selection arm
3166758|NCT01434264|No Intervention|self-selected control|Self-selected control in the self-selection arm
3166759|NCT01434264|Experimental|randomized to energy healing|Randomized to healing in the randomization arm
3166760|NCT01434264|No Intervention|Randomized control|Randomized to control in the randomization arm
3166761|NCT01434251|Active Comparator|Standard care|Infants will be treated according to the treatment policy operative in the Neonatal Intensive Care Unit (NICU) of the Wilhelmina Children's Hospital/University Medical Centre Utrecht (UMCU): anti-hypotensive therapy will be started when the mean blood pressure (in mmHg) is below the gestational age in weeks.
3166762|NCT01434251|Other|Delayed intervention|Anti hypotensive therapy will be started when the mean blood pressure (in mmHg) is < (gestational age in weeks - 5 mmHg) or when there is clinical or biochemical evidence of impaired tissue perfusion.
3166763|NCT01434238|Experimental|Intervention participant|
3166764|NCT01434225|Experimental|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
3166765|NCT01434212||Interferon and ribavirin|All the patients followed the standard treatment protocol.
3166766|NCT01434199|Experimental|UPD guided group|Both the colonoscopist and assistant will be viewing the imager screen during the whole procedure.
3166767|NCT01434199|No Intervention|non-UPD guided group|Conventional colonoscopy would be done without image guidance.
3166768|NCT01434186|Experimental|Arm 1: Saxagliptin +Metformin XR/IR|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight) Metformin XR/IR 1000 mg-2000 mg
3166769|NCT01434186|Placebo Comparator|Arm 2: Placebo +Metformin XR/IR|Placebo matching saxagliptin 0 mg Metformin XR/IR 1000 mg - 2000 mg
3166770|NCT01434173||Group 1|
3166771|NCT01434173||Group 2|
3166772|NCT01434160|Experimental|Arm 1|
3166773|NCT01434147|Experimental|induction chemotherapy + radiochemotherapy|preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine induction chemotherapy: starts within 28 days after bioptical diagnosis. All patients are administered with capecitabine (Xeloda®) 1000 mg/m2 bid during 14 days (d1-d14), oxaliplatin 130 mg/m2 and bevacizumab (Avastin®) 7.5 mg/kg body weight on day 1; repetition days 22 and 43 (3 cycles) Combined radiochemotherapy: starts at the earliest one week after concluded third cycle of induction chemotherapy. Radiotherapy takes place on 5 x 5 days (dose: 1.8 Gy; cumulative dose: 45 Gy). For chemotherapy patients are administered with capecitabine (Xeloda®) 825mg/m² bid, on each radiation day during the first 4 weeks of radiochemotherapy.
3166774|NCT01434134|Experimental|Metoprolol|Tablet, target dose 100 mg once daily
3166775|NCT01434134|Placebo Comparator|Placebo for Metoprolol|Tablet, target dose 100 mg once daily
3166776|NCT01434134|Experimental|Candesartan|Tablet, target dose 32 mg once daily
3166777|NCT01434134|Placebo Comparator|Placebo for Candesartan|Tablet, target dose 32 mg once daily
3166778|NCT01434121|Active Comparator|High Dose Ascorbic Acid|Subject receives a high dose of infused Vitamin C
3166779|NCT01434121|Active Comparator|Low Dose Ascorbic Acid|Subject receives a low dose of infused Vitamin C
3166780|NCT01434121|Placebo Comparator|Placebo|Subject receives an infusion of saline
3166781|NCT01434108|Experimental|Ornithine-phenylacetate|Administration of OP (OCR-002) during 5 days in addition to standard treatment of gastrointestinal bleeding.
3166782|NCT01434108|Placebo Comparator|Saline iv|Administration of control infusion (saline infusion) during 5 days in addition to standard treatment of gastrointestinal bleeding.
3166783|NCT01434095|Active Comparator|half-dose PDT(photodynamic therapy)|The study include single arm; treated group, and no control group was included.
3166784|NCT01434069|Experimental|Combination Therapy: FOLFIRI and SOM 230|"Treatment will be administered on an outpatient basis. FOLFIRI is administered by IV infusion every 2 weeks. The dose should be based on the patient's actual baseline body weight; the dose will be recalculated if there is a weight change of > 10% from baseline.~SOM 230 will be administered as an intramuscular dose determined by the dosing schema, every 28 days."
3166785|NCT01434056||Liver transplantation waiting list|Patients waiting for liver transplantation with chronic end staged liver disease
3166786|NCT01434043||Myocardial ischemia patients|
3166787|NCT01434030|Other|Behavioral Observer|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
3166788|NCT01434017|Active Comparator|Dexamethasone|Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
3166789|NCT01434017|Active Comparator|Dexamethasone and Droperidol|Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
3167916|NCT01425905|Active Comparator|Health Education|
3166791|NCT01434004|Experimental|Lifestyle counseling|"Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations."
3166792|NCT01434004|No Intervention|Control group|Usual care (watchful waiting).
3166793|NCT01433991|Experimental|E7050 plus lenvatinib|"Dose Escalation: Up to 36 patients with unresectable advanced or metastatic solid tumors will be dosed with E7050 in combination with lenvatinib to identify a Maximum Tolerated Dose. Subjects will continue on treatment until disease progression, development of unacceptable toxicity, or withdrawal of consent.~Expansion: A minimum of 6 subjects with either recurrent glioblastoma or unresectable Stage III or Stage IV melanoma will receive E7050 in combination with lenvatinib at the recommended dose from the Dose Escalation phase. Subjects will continue on treatment until disease progression, development of unacceptable toxicity, or withdrawal of consent.~Cohort 1: Up to 100 patients with Recurrent Glioblastoma will be treated. Cohort 2: Up to 84 patients with unresectable Stage III or Stage IV Melanoma"
3166794|NCT01433991|Experimental|E7050|Cohort 2: Up to 84 patients with unresectable Stage III or Stage IV Melanoma
3166795|NCT01433978|Active Comparator|Avatrombopag (Core Study)|Avatrombopag will be administered orally as 5 mg, 10 mg, 20 mg, 30 mg or 40 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag, once daily and allow to have their dose titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on their response to study drug.
3166796|NCT01433978|Active Comparator|Eltrombopag (Core Study)|Eltrombopag will be administered orally as 25 mg, 50 mg, or 75 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 50 mg eltrombopag once daily and allow to have their dose titrated up (maximum dose of 75 mg eltrombopag) or down (minimum dose of 25 mg eltrombopag) depending on their response to study drug.
3166797|NCT01433978|Experimental|Avatrombopag (Open-label Extension)|Participants who meet the eligibility requirements for the Open-label Extension (OLE) Phase or who discontinue the Core Study early because of lack of treatment effect will be eligible to continue into the OLE Phase for up to 104 weeks of open-label avatrombopag therapy. Participants who enter the OLE from the Core Study will receive a starting dose of open-label avatrombopag which will be determined by the last dose of study drug at the End of Treatment (EOT) Visit (Visit 22) of the Core Study. Participants who discontinue the Core Study early because of lack of treatment effect and enter the OLE will receive open-label avatrombopag at a starting dose of 20 mg once daily of open-label avatrombopag.
3166798|NCT01433965|Experimental|Phase I Dose Escalation|Subjects are given a single dose of the drug while they are observed and tested for a period of time. If they do not exhibit any adverse side effects the dose is escalated, and a new group of subjects is then given a higher dose.
3166799|NCT01433952|Placebo Comparator|0 mg Thiamine|
3166800|NCT01433952|Experimental|100 mg Thiamine|
3166801|NCT01433952|Experimental|500 mg Thiamine|
3166802|NCT01433952|Experimental|1500 mg Thiamine|
3166803|NCT01433913|Experimental|Arm I (metformin hydrochloride)|Patients receive extended-release metformin hydrochloride PO QD for 4-12 weeks.
3166804|NCT01433913|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 4-12 weeks.
3166805|NCT01433900|Active Comparator|Tafluprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
3166806|NCT01433900|Active Comparator|Latanoprost|1 drop of latanoprost to eligible eye(s) once daily (at 9 pm)
3166807|NCT01433887|Experimental|Genotype 6|Genotype 6 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks
3166808|NCT01433887|Experimental|Genotype 1|Genotype 1 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks
3166809|NCT01433887|Experimental|Genotype 2/3|Genotype 2/3 chronic hepatitis C patients will be treated with Peginterferon alfa-2a/2b plus ribavirin for 24 weeks
3166810|NCT01433874|Experimental|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
3166811|NCT01433874|Experimental|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc we will leave the fluid in the abdominal cavity.
3166812|NCT01433874|Experimental|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH20. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
3166813|NCT01433874|Placebo Comparator|Control group|Co2 was removed by passive exsufflation through the port site
3166814|NCT01433861|Active Comparator|LAPG|LAPG : laparoscopy-assisted proximal gastrectomy with double tract reconstruction group
3166815|NCT01433861|Active Comparator|LATG|LATG : laparoscopy-assisted total gastrectomy group
3166816|NCT01433848||Child A liver cirrhosis|
3166817|NCT01433848||Child B liver cirrhosis|
3166818|NCT01433848||Child C liver cirrhosis|
3166819|NCT01433835|Placebo Comparator|Placebo|
3166820|NCT01433835|Experimental|MBX-400|
3166821|NCT01433796||Antiretroviral therapy, tuberculosis|Patients eligible for starting ART in health centres in Ethiopia
3166822|NCT01433770|Experimental|Alefacept action on memory T cells|
3166823|NCT01433757|Active Comparator|Ampicillin|Patients who are randomly selected to receive the active drug will receive Ampicillin (2mg daily for adults and 1 mg daily for children).
3166824|NCT01433757|Placebo Comparator|Placebo|Patients who are randomly selected to receive the placebo will be given a sugar pill that resembles the active drug.
3166825|NCT01433744|Experimental|Chronic periodontal disease|C-reactive protein levels assesments and periodontal treatment
3166826|NCT01433744|No Intervention|Periodontally healthy|
3166827|NCT01433731|Placebo Comparator|placebo for SHAPE (SHP-141)|placebo for SHAPE (SHHP-141) topical gelled solution
3166828|NCT01433731|Experimental|SHAPE (SHP-141) 0.1%BID|SHAPE (SHP-141) topical gelled solution at 0.1% concentration twice weekly
3166832|NCT01433705|Other|Rb-82 and N-13 ammonia Pet scans|Rest and vasodilator stress Rb-82 images or N-13 ammonia images will be taken according to standard clinical imaging protocol. Each of these two imaging studies require the injection of Rb-82 or N-13 ammonia by intravenous administration (IV) in the patient's arm.
3166833|NCT01433705|Other|F-18 FDG Imaging and Rb-82|Volunteers not excluded by abnormal rest/stress imaging with Rb-82, will begin F-18 FDG protocol.
3166834|NCT01433705|Other|F-18 FDG Imaging and N-13 ammonia|Volunteers not excluded by abnormal rest/stress imaging with N-13 ammonia, will begin F-18 FDG protocol.
3166835|NCT01433692|Experimental|intervention group|
3166836|NCT01433692|Other|control group|
3166837|NCT01433679|Experimental|Website intervention|Participants randomly assigned to the Website Intervention arm receive access to the motivational rewards website. The website displays the individual's physical activity data and allocates reward points based on the amount and intensity of physical activity. The website also allows reward points to be redeemed for various rewards such as gift cards to retail outlets, donations to charities, small tangible goods, and customization of participants' cartoon-like avatars on the website.
3166838|NCT01433679|No Intervention|Control|Participants in the control group will not have access to the motivational website. No other product or intervention will be introduced to the control group.
3166839|NCT01433666|Experimental|roflumilast 100ug|
3166840|NCT01433666|Experimental|roflumilast 300ug|
3166841|NCT01433666|Experimental|roflumilast1000ug|
3166842|NCT01433666|Placebo Comparator|placebo|
3166843|NCT01433653|Experimental|CG-CBT|
3166844|NCT01433653|No Intervention|wait list control|
3166845|NCT01433640||Contrast-enhanced Mammography|Subjects will undergo 2D imaging with iodine contrast.
3166846|NCT01433640||Contrast-enhanced Breast Tomosynthesis|Subjects will undergo 3D imaging with iodine contrast.
3166847|NCT01433640||Contrast-enhanced MRI|Each subject imaged with iodine contrast will also be imaged with contrast-enhanced MRI using gadolinium.
3166848|NCT01433627|Experimental|trans-radial and short-term Bivalirudin|Patients will be randomized to receive a trans-radial intervention and concomitant bivalirudin infusion. bivalirudin will be stopped at the end of PCI.
3166849|NCT01433627|Experimental|trans-radial and long-term bivalirudin|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
3166850|NCT01433627|Experimental|trans-radial and standard of care pharmacology|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~unfractionated heparin (UFH) which may be followed by the addition of a glycoprotein IIb/IIIa inhibitor"
3166851|NCT01433627|Experimental|trans-femoral and short-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI."
3166852|NCT01433627|Experimental|Trans-femoral and long-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
3166853|NCT01433627|Active Comparator|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
3166854|NCT01433614|Active Comparator|Epirubicin + paclitaxel (Taxol)|Epirubicin 75mg/m2 i.v., paclitaxel 175 mg/m2 i.v. on day 1 every 21 days.
3166855|NCT01433614|Active Comparator|Paclitaxel + epirubicin + capecitabine|Paclitaxel 155 mg/m2 i.v., epirubicin 75 mg/m2 i.v day 1, capecitabine 1650 mg/m2 p.o. on days 1-14 every 21 days.
3166856|NCT01433601|No Intervention|Self Supervised Treatment (SST)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling before initiation of ART and clinical follow up every 3 months. The patient is self responsible to take the drugs and no additional adherence support is provided.
3166857|NCT01433601|Experimental|Enhanced Treatment Support (ETS)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling before initiation of ART and clinical follow up every 3 months. In addition adherence support is provided according to the description under intervention.
3166858|NCT01433588|Active Comparator|Calmer|This therapeutic platform, called the Calmer interacts with the infant to help reduce stress to help promote better outcomes. It is being tested to see if it mimics Kangaroo care, maternal skin to skin, to help promote better health outcomes. Infants would be placed on it prior, during and after bloodwork to see if it elicits a favorable response.
3166859|NCT01433588|Placebo Comparator|Standard Care|Standard of care during bloodwork is receiving a soother and facilitated tucking.
3166860|NCT01433575|Experimental|A|
3166861|NCT01433575|Experimental|B|
3166862|NCT01433562|Experimental|DLBS1425|
3166863|NCT01433562|Placebo Comparator|Placebo|
3166864|NCT01433549|Other|Lotrafilcon B / Senofilcon A|Lotrafilcon B worn first, with senofilcon A worn second, as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).
3166865|NCT01433549|Other|Senofilcon A / Lotrafilcon B|Senofilcon A worn first, with lotrafilcon B worn second, as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).
3166866|NCT01433536||cranial trauma and fracture|Individuals presenting a cranial trauma that are classified at equal to or less than 8 on the Glasgow scale, combined with a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
3166867|NCT01433536||cranial trauma|Individuals presenting a cranial trauma that are classified at equal to or less than 8 on the Glasgow scale
3166868|NCT01433536||spinal trauma with fracture|Individuals presenting a spinal fracture that are classified with an ASIA score of A, B, or C, combined with a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
3166869|NCT01433536||spinal trauma|Individuals presenting a spinal fracture that are classified with an ASIA score of A, B, or C
3166870|NCT01433536||high velocity fracture, inferior limb|Individuals that present a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
3166871|NCT01433536||Control|Healthy individuals
3166872|NCT01433523|Placebo Comparator|Placebo|
3166873|NCT01433523|Experimental|ALK HDM AIT 6 DU|
3166874|NCT01433523|Experimental|ALK HDM AIT 12 DU|
3166875|NCT01433510|Experimental|Grazax Tablets 75000 SQT|Timothy Extract
3166876|NCT01433497|Experimental|masitinib|masitinib 4.5 mg/kg/day
3166877|NCT01433497|Placebo Comparator|placebo|
3166878|NCT01433484|Active Comparator|Maintenance of Weight Loss--Control|The control arm will receive bi-monthly telephone contacts during the one-year maintenance phase.
3166879|NCT01433484|Experimental|Maintenance of Weight Loss--Experimental|The experimental arm will receive monthly telephone contacts for one year during the maintenance phase.
3166880|NCT01433471|Experimental|Trichuris suis ova followed by placebo|Subjects in this arm will receive Trichuris suis ova for 12 weeks, followed by placebo for 12 weeks after crossover
3166881|NCT01433471|Active Comparator|Placebo followed by Trichuris Suis Ova|Subjects in this arm will receive placebo for 12 weeks, followed by Trichuris suis ova for 12 weeks after crossover
3166882|NCT01433458|Experimental|RLX030: Group 1 mild hepatic impairment|Patients with mild hepatic impairment will receive a single IV 24 hour infusion of RLX030
3166883|NCT01433458|Experimental|RLX030: Group 2 moderate hepatic impairment|Patients with moderate hepatic impairment will receive a single IV 24 hour infusion of RLX030
3166884|NCT01433458|Experimental|RLX030: Group 3 severe hepatic impairment|Patients with severe hepatic impairment will receive a single IV 24 hour infusion of RLX030
3166885|NCT01433458|Active Comparator|RLX030: Group 4 - healthy volunteers|Participants will receive a single IV 24 hour infusion of RLX030. This group will consist of 3 sub-groups to match patients of groups 1, 2and 3.
3166886|NCT01433445|Experimental|panobinostat + ruxolitinib|Escalating doses of ruxolitinib from 5 mg BID to 15 mg BID in combination with panobinostat from 10 to 30 mg tiw QOW depending on determination of MTD of each drug
3166887|NCT01433432|Active Comparator|Purinethol|Subjects who previously received 12 weeks of Purinethol (at 1-1.5 mg/kg)in the original study will now receive 80 mg DR-6MP (2 x 40 mg tablets) once dailyh, in the evening, for an additional 12 weeks
3166888|NCT01433432|Experimental|Test Drug|Subjects who previously received test drug (80 mg DR-6MP) for 12 weeks in the original study, will continue to receive 80 mg DR-6MP (2 x 40 mg tablets) once daily, in the evening, for an additional 12 weeks
3166889|NCT01433419|Experimental|TAK-875 25 mg|
3166890|NCT01433419|Experimental|TAK-875 50 mg|
3166891|NCT01433406|Experimental|TAK-875 25 mg|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
3166892|NCT01433406|Experimental|TAK-875 50 mg|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
3166893|NCT01433393|Experimental|TAK-875 25 mg|
3166894|NCT01433393|Experimental|TAK-875 50 mg|
3166895|NCT01433393|Placebo Comparator|Placebo|
3166896|NCT01433380|Experimental|600 mg PF-05175157|Subjects will receive one dose of PF-05175157. The sequence of receiving 600 mg PF-05175157 or placebo will be randomized.
3166897|NCT01433380|Placebo Comparator|Placebo|Subjects will receive one dose of placebo. The sequence of receiving placebo or 600 mg PF-05175157 will be randomized.
3166898|NCT01433367||CerPass® Total Disc Replacement|
3166899|NCT01433354|Experimental|AFQ056 Treatment|All patients will initiate treatment with AFQ056 at a starting dose of 25 mg b.i.d. The dose will be titrated from 25 mg b.i.d to 50 mg b.i.d., 75 mg b.i.d. and 100 mg b.i.d. at weekly intervals. Dose adjustments (up- and down-titrations) will be permitted as needed to manage any tolerability issues and to ensure that patients reach their highest tolerated dose, not to exceed 100 mg b.i.d.
3166900|NCT01433341||Young athletes|
3166901|NCT01433328|Experimental|Lidocaine|
3166902|NCT01433328|Placebo Comparator|Placebo|Remodulin only
3166903|NCT01433315|Experimental|sleep restriction|restricted sleep during the experimental period
3166904|NCT01433315|No Intervention|normal sleep|normal sleep during the experimental period
3166905|NCT01433302||Punch Biopsy|
3166906|NCT01433289|Experimental|Polyphenon E 1600 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Four capsules twice a day.
3166907|NCT01433289|Experimental|Polyphenon E 2400 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Six capsules twice a day.
3166908|NCT01433289|Experimental|Polyphenon E 3200 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Eight capsules twice a day.
3166909|NCT01433276|Experimental|Totilac|
3166910|NCT01433276|Active Comparator|Ringer's lactate|
3166911|NCT01433263|Experimental|30mg/kg BYM338|
3166912|NCT01433263|Placebo Comparator|Placebo / late 30mg/kg BYM338|
3166913|NCT01433250|Experimental|AIN 457 Core|(10mg/kg i.v.). AIN 457 core study /AIN 457 Extension
3166914|NCT01433250|Experimental|AIN457 Placebo Core|(10mg/kg i.v.). AIN 457 placebo core study /AIN 457 Extension
3166915|NCT01433211||No treatment|
3166916|NCT01433198|Active Comparator|Aquatic exercise group|
3166917|NCT01433198|No Intervention|Control group|
3166919|NCT01433185|No Intervention|Usual care (current standard of care)|Current standard of care for women enrolled in PMTCT programs
3166920|NCT01433172|Experimental|Phase I Vaccinations|Participants enrolled in the Phase I trial will receive GM.CD40L.CCL21 vaccinations on 3 occasions, at 2 week intervals. Note for the phase I portion: the use of steroid medication is to be avoided for 4 weeks prior to the initiation of vaccine therapy and during the vaccine treatment period.
3166921|NCT01433172|Active Comparator|Phase II Arm A Vaccinations|Arm A participants will receive GM.CD40L cells vaccinations on 3 occasions, at 2 week intervals. Note on either Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
3166922|NCT01433172|Active Comparator|Phase II Arm B Vaccinations|Arm B participants will receive GM.CD40L.CCL21 vaccinations on 3 occasions, at 2 week intervals. Note on either Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
3166923|NCT01433159|Experimental|HP011-101|
3166924|NCT01433159|Active Comparator|Various|Standard Care at each site other than Xenaderm Ointment or other BCT-containing products
3166925|NCT01433133|Experimental|1|• Genotype 3 chronic HCV with detectable serum HCV RNA
3166926|NCT01433120|Experimental|Probiotic L. casei F19|
3166927|NCT01433120|Experimental|Flax seed fibres|
3166928|NCT01433120|Placebo Comparator|Placebo|
3166929|NCT01433107|Experimental|Terbinafine|Drug
3166930|NCT01433107|Placebo Comparator|Placebo|Drug
3166931|NCT01433094|Experimental|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving
3166932|NCT01433094|Active Comparator|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
3166933|NCT01433081|Active Comparator|Magnesium sulfate infusion|Administration of magnesium suflate
3166934|NCT01433081|Placebo Comparator|Placebo|.9 normal saline infusion
3166935|NCT01433068|Experimental|NBTXR3|
3166936|NCT01433055|Active Comparator|Minocycline|
3166937|NCT01433055|Placebo Comparator|Sugar Pill|
3166938|NCT01433042|Experimental|capsule endoscopy|
3166939|NCT01433029||Conventional Rater (CR)|CR Group receives conventional training from PI about how to rate coronary artery bypass (CAB) videos.
3166940|NCT01433029||Video Rater (VR)|VR Group receives conventional training from PI about how to rate CAB videos, along with a video rater training manual.
3166941|NCT01433029||CAB Recording|CAB recording of performance cardiothoracic surgeon or surgical trainee in 1st, 2nd, or 3rd year of training.
3166942|NCT01433016|Experimental|Octanaote Breath Test|A Octanoate breath test will be performed on this single arm population
3166943|NCT01433003|Active Comparator|Standard-dose plasma exchange|50-75 ml/kg/day
3166944|NCT01433003|Experimental|High-dose Plasma Exchange|125 ml/kg/day up to 10 L/day
3166945|NCT01432990|Experimental|robotic gait training|conventional physical therapy plus robot gait training program for SCI patients.
3166946|NCT01432990|No Intervention|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
3166947|NCT01432977|Active Comparator|comparateur|paracetamol / droperidol
3166948|NCT01432977|Experimental|Eperimental|paracetamol / ondansetron
3166949|NCT01432964||1|Adult patients (>18 years) presenting a unilateral orbital blow-out or blow-in fracture of ≥ 2.0cm2, causing an actual or expected functional or aesthetical deficit.
3166950|NCT01432951|Experimental|Enzastaurin|"Pharmacokinetic Phase: Enzastaurin 500 mg, four 125-mg tablets administered orally once daily for 14 days. Dosing is held for 3 days, and resumes on Day 18. Patients may be allowed to receive enzastaurin for an additional (approximately) 2 to 4 weeks.~Safety Extension: Patients are allowed to continue receiving enzastaurin until disease progression or discontinuation criteria are met, as per the investigator's assessment."
3166951|NCT01432938|Experimental|Warfarin first, then Dulaglutide + Warfarin|A single, 10-milligram (mg) dose of warfarin administered orally on Day 1 (Treatment 1). There was a washout period of at least 24 days between treatment periods. Then a single, 1.5-mg dose of dulaglutide administered subcutaneously on Day 1, followed by a single, 10-mg dose of warfarin administered orally on Day 3 (Treatment 2).
3166952|NCT01432938|Experimental|Dulaglutide + Warfarin first, then Warfarin|A single, 1.5-mg subcutaneous dose of dulaglutide on Day 1, followed by a single, 10-mg oral dose of warfarin on Day 3 (Treatment 2). There was a washout period of at least 24 days between treatment periods. Then a single, 10-mg oral dose of warfarin on Day 1 (Treatment 1).
3166953|NCT01432925|Other|evaluation surgical intervention at week 8|
3166954|NCT01432925|Other|evaluation surgical intervention at week 14|
3166955|NCT01432912|No Intervention|Patients|
3166956|NCT01432886|Experimental|1|
3166957|NCT01432873|Experimental|Experimental|Oral selenium therapy arm
3166958|NCT01432873|Placebo Comparator|Placebo|Oral placebo
3166959|NCT01432860|Active Comparator|In-person Counseling and Education|In the in-person training the Research Assistant demonstrates the use of a mm ruler, a lighted magnifying lens, a set of body maps and a scorecard, 4 pens, ABCDE rule on the skin exam card and discusses the ABCDE rule by pointing to the color examples on the skin exam card. 165 pairs (330 subjects) are randomized to this arm.
3166960|NCT01432860|Active Comparator|Workbook|The workbook, which includes all of the information delivered in the in-person intervention, is 39 pages in length, and has 76 color figures. Each element of the in-person training represents a chapter in the workbook. The introduction explores the partners' understanding of melanoma and their personal risk of developing another melanoma, and attitudes about the benefit of early detection assisted by a partner. The early detection segment uses a skin diagram to illustrate the difference between thin and thick melanoma and presents the treatment based on the depth of the melanoma. 165 pairs (330 subjects) are randomized to this arm.
3167155|NCT01431300|Active Comparator|0.03 mmol/kg|FDA-approved dose for lower extremity arterial imaging
3166961|NCT01432860|No Intervention|Control|Education and counseling as usually delivered in clinical practice. 100 pairs (200 subjects) are randomized to this arm.
3166962|NCT01432860|Active Comparator|Tablet Computer-Based Education|Education will be given by an interactive tablet app. Each pair will view video recordings of certain parts of the in-person presentation as well as select slides from the in-person PowerPoint presentation. Parts of the workbook will be incorporated as well. 70 pairs (140 subjects) are randomized into this arm.
3166963|NCT01432834|Other|LASIK group (LG group)|Volunteers of this group received LASIK treatment.
3166964|NCT01432834|Other|PRK group (PG group)|Volunteers of this group received PRK treatment
3166965|NCT01432821|Experimental|Apomorphine|"After randomization healthy volunteers or patients with idiopathic generalized epilepsy receive:~-sequence A: 1 mg/kg and then 5 mg/kg of apomorphine"
3166966|NCT01432821|Placebo Comparator|Saline|"After randomization healthy volunteers or patients with idiopathic generalized epilepsy receive:~sequence B: 2 injections of saline"
3166967|NCT01432795|Experimental|Test series of 6 types of gliding aids|"Each study subjects tests a series of gliding aids or stocking butlers:~4 gliding aids~2 stocking butlers, one with and without handle~3 medical compression stockings with open tip, compression class 3 (36-46mmHg)~3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)~2 superimposed stockings with closed tip, compression class 1 (18-21 mmHg)"
3166968|NCT01432782|Placebo Comparator|Placebo|Placebo arm: per-endoscopic injection of saline
3166969|NCT01432782|Active Comparator|Botulinum toxin|Botulinum toxin (Botox) 100 u in 4 ml, injected per-endoscopically
3166970|NCT01432769|Active Comparator|individualized diet|patients will receive a diet individualized to their calorie and protein requirements besides to dietary supplementation with a polymeric formula
3166971|NCT01432769|No Intervention|standardized diet|"patients in the standardized diet will receive the dietary management established by the hospital"
3166972|NCT01432756|No Intervention|Wait-list control|Participants in the wait-list control group will not receive the intervention until after the 3-month follow-up assessment.
3166973|NCT01432756|Experimental|Let's Talk Worskite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
3166974|NCT01432743|Experimental|Cartomerge|Use of Cartomerge to guide ablation
3166975|NCT01432743|Active Comparator|NavX Fusion|Use of NavX fusion to guide ablation
3166976|NCT01432730|Experimental|Gefapixant|
3166977|NCT01432730|Placebo Comparator|Placebo|
3166978|NCT01432717|Experimental|ACE-536|Subjects assigned to 1 of 5 possible dosing groups.
3166979|NCT01432717|Placebo Comparator|Placebo|
3166980|NCT01432704|Placebo Comparator|placebo capsules|Identically appearing placebo capsules not containing colecalciferol
3166981|NCT01432704|Active Comparator|colecalciferol capsules|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
3166982|NCT01432691|Other|Surgery|RSA study on hemi
3166983|NCT01432678||asthma patients|controlled asthma partly controlled asthma uncontrolled asthma
3166984|NCT01432665|Experimental|Placebo|30 subjects administered a placebo
3166985|NCT01432665|Experimental|sildenafil + testosterone combination drug 1|30 subjects are given combination drug 1 (sildenafil 25mg and testosterone 0.25mg)
3166986|NCT01432665|Experimental|Sildenafil and testosterone combination drug 2|Sildenafil 50mg and testosterone 0.25mg
3166987|NCT01432665|Experimental|Sildenafil and testosterone combination drug 3|30 subjects are given sildenafil 25mg and testosterone 0.50mg
3166988|NCT01432665|Experimental|Sildenafil and Testosterone Combination drug 4|30 subjects are given sildenafil 50mg and testosterone 0.50mg
3166989|NCT01432665|Experimental|Sildenafil 50mg|30 subjects are given sildenafil 50mg
3166990|NCT01432665|Experimental|Testosterone 0.50mg|30 subjects are given testosterone 0.5mg
3166991|NCT01432652||vascular surgery|Patients undergoing vascular surgery
3166992|NCT01432639|Experimental|Experimental group|Patients undergoing the exercise-based cardiac rehabilitation program (intervention)
3166993|NCT01432639|No Intervention|Control group|Usual medical care
3166994|NCT01432626|Experimental|Stress Induced Cardiomyopathy Patients|Patients presenting with stress induced cardiomyopathy, after meeting the Mayo criteria (normal coronary anatomy, EKG changes/Enzyme abnormalities, wall motion abnormalities consistent with stress induced cardiomyopathy and no evidence of pheochromocytoma) and signing informed consent, will receive an I123-mIBG scan to determine the sympathetic function of the heart during the acute presentation and after functional recovery.
3166995|NCT01432613|Other|MRI-oriented muscle biopsy|Muscle sample will be done following the usual care.
3166996|NCT01432600|Experimental|A: Dose Escalation of Cyclophosphamide|"Phase I: Pomalidomide, high dose dexamethasone and oral cyclophosphamide:~Pomalidomide 4 mg by mouth (PO) days 1-21 of a 28 days cycle.~Dexamethasone 40* mg PO days 1- 4, 15-18 of a 28 days cycle for the first 4 cycles and subsequently 40 mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Dose Escalation of Cyclophosphamide, orallly (PO) days 1, 8, 15 as follows:~Level 1: 300 mg; Level 2: 400 mg; Level 3: 500 mg.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
3166997|NCT01432600|Active Comparator|B: Pomalidomide and Dexamethasone|"Randomized Phase II - Pomalidomide high dose dexamethasone:~Pomalidomide 4 mg PO days 1-21 of a 28 days cycle.~Dexamethasone 40* mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
3167041|NCT01432197|No Intervention|Standard treatment and care|Control group: Standard treatment and care. No occupational therapy intervention.
3166998|NCT01432600|Active Comparator|C: Pomalidomide/Dexamethasone/Cyclophosphamide|"Randomized Phase II - Pomalidomide high dose dexamethasone and oral cyclophosphamide:~Pomalidomide 4 mg PO days 1-21 of a 28 days cycle.~Dexamethasone 40* mg PO days 1- 4, 15-18 of a 28 days cycle for the first 4 cycles and subsequently 40 mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Cyclophosphamide 400 mg PO days 1, 8, 15.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
3166999|NCT01432600|Other|D: Crossover|Crossover from Arm B to Arm D. Participants who experienced progressive disease in arm B were allowed to crossover to arm D at the discretion of the treating physician, in which case oral weekly Cyclophosphamide (400 mg orally on days 1, 8, and 15) was added to their tolerated dose of pomalidomide and dexamethasone.
3167000|NCT01432574|Experimental|Gardasil Vaccine|Vaccine Administration: A total of 3 injections (shots) at 3 separate visits.
3167001|NCT01432561|Experimental|Cysteamine bitartrate|Cysteamine bitartrate, 500mg once a day, three days.
3167002|NCT01432535|Active Comparator|Healthy Participants|Participants with normal renal function defined as having a creatinine clearance test value of ≥80 mL/min/1.73 m^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
3167003|NCT01432535|Experimental|Participants with Moderate Renal Impairment|Participants with moderate renal impairment defined as having a creatinine clearance test value of 30-50 mL/min/1.73 m^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
3167004|NCT01432535|Experimental|Participants with Severe Renal Impairment|Participants with severe renal impairment defined as having a creatinine clearance test value of <30 mL/min/1.73 m^2 or end stage renal disease on hemodialysis. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
3167005|NCT01432522|Experimental|epinephrine IN, epinephrine IM, saline IN|"Intranasal saline~Intramuscular epinephrine~Intranasal epinephrine"
3167006|NCT01432496|Experimental|Ropivacaine 150 mg|Nebulization of Ropivacaine 150 mg in the peritoneal cavity with the Aeroneb Pro system
3167007|NCT01432496|Placebo Comparator|Saline 15 ml|Nebulization of Saline 15 ml in the peritoneal cavity with the Aeroneb Pro system
3167008|NCT01432470|Experimental|Oxytocin, Intravaginal administration|
3167009|NCT01432470|Placebo Comparator|Placebo, Intravaginal administration|
3167010|NCT01432457|Experimental|desvenlafaxine succinate sustained-release 50 mg/day|
3167011|NCT01432457|Experimental|desvenlafaxine succinate sustained-release 100 mg/day|
3167012|NCT01432457|Placebo Comparator|Placebo|
3167013|NCT01432444|Experimental|OPC-14597|Aripiprazole IM depot injection 300 mg or 400 mg.
3167014|NCT01432431|Experimental|Supportive care (spiritual care)|See Detailed Description.
3167015|NCT01432418|Experimental|wheelchair training|
3167016|NCT01432418|No Intervention|Control|Standard of care only
3167017|NCT01432405|Experimental|Pioglitazone and exenatide|Exenatide 10 micrograms injected subcutaneously twice daily plus pioglitazone 45 mg daily orally for 12 months.
3167018|NCT01432405|Experimental|Pioglitazone|Pioglitazone 45 mg daily orally for 12 months
3167019|NCT01432392||1|
3167020|NCT01432379||botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
3167021|NCT01432366||Rheumatoid arthritis patients treated with SC anti-TNF|
3167022|NCT01432353|Experimental|Single Arm|
3167023|NCT01432340||Vaccinated group|Children between 6months- 10years of age who have received the influenza vaccine
3167024|NCT01432340||Unvaccinated group|Eligible children between 6months and 10years who didn't receive the influenza vaccine
3167025|NCT01432327|Placebo Comparator|Control group|This group receives no kind of feedback during the intervention period. The participants wear the SenseWear Armband for 4 weeks and results of the intervention are discussed after the 4 week intervention period.
3167026|NCT01432327|Experimental|Step Group|This group receives feedback about the daily amount of steps by means of a pedometer.
3167027|NCT01432327|Experimental|Display Group|Participants receive real time feedback on their energy expenditure, minutes of physical activity and step count by means of the SenseWear Display
3167028|NCT01432327|Experimental|Coaching Group|Participants receive real-time feedback on their energy expenditure, step count and minutes of physical activity by means of the SenseWear Display and weekly meet with a Personal Coach to discuss their progress
3167029|NCT01432314|Experimental|Treatment group|Child A Hepatocellular carcinoma patients with unilobar portal vein invasion.
3167030|NCT01432275|Experimental|ADC, Then Comparator, Then ADC With Calculator|Subject used the ADC blood glucose meter for 7 days with the insulin calculator not activated, followed by a comparator blood glucose meter for 7 days. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.
3167031|NCT01432275|Experimental|Comparator, Then ADC, Then ADC With Calculator|Subject used a comparator blood glucose meter for 7 days, followed by the ADC blood glucose meter for 7 days, with the insulin calculator not activated. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.
3167032|NCT01432262|Experimental|Group 1|=> 65 years of age
3167033|NCT01432262|Experimental|Group 2|50 to 64 years of age
3167034|NCT01432249||Enbrel|The patients who are prescribed Enbrel for pediatric psoriasis
3167035|NCT01432236|Experimental|Pregabalin|Group 1 as Pregabalin vs. Placebo (cross over study in which period one has this group)
3167036|NCT01432236|Placebo Comparator|Placebo|Group 2 as placebo vs. pregabalin (cross over study in which period two will have this group)
3167037|NCT01432223|Experimental|Nab-paclitaxel|Nab-paclitaxel q3w 260mg/m2
3167038|NCT01432210|Other|Tomato Meal|A tomato meal will be fed with and without avocado.
3167039|NCT01432210|Other|Carrot Meal|A carrot meal will be fed with and without avocado.
3167040|NCT01432197|Experimental|Occupational therapy intervention|"Intervention group: Standard treatment and care added with an ADL intervention program: 1) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.~Control group: Standard treatment and care. No occupational therapy intervention."
3167156|NCT01431300|Experimental|0.02 mmol/kg|
3167042|NCT01432184|Active Comparator|Intervention|an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
3167043|NCT01432184|No Intervention|Control|the cerebral oxymetry screen will be blinded and changes in NIRS values will be unknown to the anesthesiologist. The management of the case will proceed as per normal local practice. The screen will remain blinded in the ICU and the intensivist will not see the values.
3167044|NCT01432171|Experimental|Lacosamide|Lacosamide or placebo will be taken by mouth twice a day, at approximately the same time each day, spaced as close to 12 hours apart as possible. The starting dose of lacosamide or placebo will be 50 mg PO bid. Over 4 weeks, the dose should be increased to a target dose of 200 mg bid. A recommended scheme for dose escalation is to increase by 100 mg/day weekly until 200 mg bid is achieved.
3167045|NCT01432171|Placebo Comparator|Placebo|Lacosamide or placebo will be taken by mouth twice a day, at approximately the same time each day, spaced as close to 12 hours apart as possible. The starting dose of lacosamide or placebo will be 50 mg PO bid. Over 4 weeks, the dose should be increased to a target dose of 200 mg bid. A recommended scheme for dose escalation is to increase by 100 mg/day weekly until 200 mg bid is achieved.
3167046|NCT01432158|Experimental|PCV-13 group|1 dose of Prevenar-13
3167047|NCT01432158|Experimental|PPV-23 group|1 dose of Pneumovax-II
3167048|NCT01432145|Experimental|6MP/MTX|
3167049|NCT01432132||Head & Neck Patients|Patients undergoing surgical treatment for head and neck cancer.
3167050|NCT01432132||Clinicians|Clinical staff who care for head and neck surgical participants during active treatment.
3167051|NCT01432119|Experimental|Arm 1 SIR-Spheres + Cetuximab|"Arm 1: SIR-Spheres with yttrium-90 attached and cetuximab. SIR-Spheres Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
3167052|NCT01432119|Experimental|Arm 2 SIR-Spheres + Cetuximab + Erlotinib.|"Arm 2: SIR-Spheres with yttrium-90 attached, cetuximab, and erlotinib. Physicians will assign patients to Arm 1 or Arm 2 based on their discretion. SIR-Spheres on Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Erlotinib start 100 mg by mouth daily starting with Cycle 2. 28-day Cycles. Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
3167053|NCT01432106|Active Comparator|Aliskiren/Valsartan (Valturna)|Valturna contains two prescription medicines in one tablet that work together to lower blood pressure. It contains aliskerin (Tekturna), a direct rennin inhibitor (DRI), and valsartan (Diovan), an angiotensin II receptor blocker (ARB). Aliskerin reduces the effect of rennin, and the harmful process that narrows blood vessels. It also helps blood vessels relax and widen so blood pressure is lower. Valsartan can help lower blood pressure by blocking a potent chemical, angiotensin II, which leads to blood vessel constriction and narrowing.
3167054|NCT01432106|Active Comparator|Ramipril|Ramipril (Altace) is an angiotensin-converting enzyme inhibitor (ACEI). It is a chemical compound that helps create a protein named angiotensin II. Angiotensin II can raise blood pressure by causing your blood vessels to narrow. Altace helps lower blood pressure by decreasing the amount of ACE the body makes. Ramipril has been proven by the investigators to stabilize decline in kidney function in African American patients with evidence of damage.
3167055|NCT01432093|Active Comparator|Intensive glycemic management|Multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
3167056|NCT01432093|Active Comparator|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
3167057|NCT01432080|No Intervention|Standard of Care|Standard of Care includes fluids, antipyretics, ribavirin for RSV infection, and oseltamivir for influenza infection, and intravenous immune globulin for patients with low IgG levels.
3167058|NCT01432080|Experimental|SAMS|Subjects randomized to the SAMS arm will receive a four-drug combination (Steroids, Azithromycin, Montelukast, and Symbicort).
3167059|NCT01432067|Other|Adaptated physical activity|Physical activity advices adaptated to physical status of patients
3167060|NCT01432067|Other|Standard physical activity|Daily physical activities based on a standard guide
3167061|NCT01432028|Active Comparator|Non-oral hormone therapy|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
3167062|NCT01432028|Active Comparator|oral homone therapy|estradiol 1mg and drospirenone 2 mg/day
3167063|NCT01432015|Active Comparator|Fosaprepitant|Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Oral Placebo given on days 1-3
3167064|NCT01432015|Active Comparator|Aprepitant|Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. 100 cc of IV placebo administered on day 1
3167065|NCT01431989|Active Comparator|Test formulation|Test product: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL in Period 1; followed by 14-days washout period during which no medication was administered; followed by reference product: Amoxil® 500mg/5mL in Period 2.
3167066|NCT01431989|Active Comparator|Reference formulation|Reference product: Amoxil® 500mg/5mL powder for oral suspension in Period 1; followed by 14-days washout period during which no medication was administered; followed by test product: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL in Period 2
3167067|NCT01431976|Experimental|Lamotrigine|No comparison
3167068|NCT01431963|Experimental|Lamotrigine|No comparison.
3167069|NCT01431950|Experimental|FF 100mcg once daily|Inhaled corticosteroid (ICS)
3167070|NCT01431950|Experimental|FF 200mcg once daily|Inhaled corticosteroid
3167071|NCT01431937|Active Comparator|GSK2018682|Active Drug
3167072|NCT01431937|Placebo Comparator|Placebo Control|Placebo
3167073|NCT01431924||Adolescent and adult patients with asthma|Adolescents and Adults age 12-65 with an ICD-9 code for asthma and a prescription for an inhaled corticosteriod or a corticosteriod/salmeterol combination
3167074|NCT01431911||Patients diagnosed with COPD|Patients diagnosed with COPD using ICD codes with a COPD-related exacerbation and receiving maintenance therapy
3167075|NCT01431898|Experimental|Multiple-dose, dose-escalation study of GS-9669|Multiple-dose, dose-escalation study of GS-9669, a nonnucleotide NS5B inhibitor of hepatitis C virus (HCV), in subjects with chronic HCV infection. Dosing is planned in up to 7 unique dosing cohorts. Each cohort will be comprised of 10 genotype 1a (Cohorts 1, 2, 3, 4, and 5) or genotype 1b (Cohort 6 and 7), with eight subjects randomized to receive active drug and two subjects randomized to receive placebo per cohort.
3167076|NCT01431885|Active Comparator|PLAT|Diagnosis of preterm labor will be made by the March of Dimes Preterm Labor Assessment Toolkit Algorithm B, incorporating transvaginal ultrasound measurement of cervical length, and vaginal fetal fibronectin
3167077|NCT01431885|Placebo Comparator|Cervical Change|Diagnosis of preterm labor will be made by cervical change by digital examination
3167078|NCT01431872||Post menopausal breast cancer patients|
3167079|NCT01431859|Placebo Comparator|Subcutaneous injection of placebo|
3167080|NCT01431859|Active Comparator|Birch pollen immunotherapy|
3167081|NCT01431846|No Intervention|Discharge Patient|Eight patients who were being discharged from Denver VA Medical Center for cardiac care to their primary care providers were recruited at the time of discharge and completed an interview two weeks following their discharge. Patients were asked to describe their transition to home and identify barriers and facilitators of this process, their understanding of their medical condition, new medications prescribed, timeliness of follow-up visit with their PCP and knowledge of signs/symptoms in which they should seek medical attention.
3167082|NCT01431846|No Intervention|Providers|Three providers who refer patients to the Denver VA Medical Center for cardiac care were interviewed to identify barriers and facilitators from their perspective of following-up with patients after their hospitalization at Denver VAMC. Additionally, the same information was asked of providers who participated in two focus groups in the Grand Junction VA.
3167083|NCT01431846|Experimental|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
3167084|NCT01431833|Experimental|Moderate hepatic|
3167085|NCT01431833|Experimental|Severe Hepatic|
3167086|NCT01431833|Experimental|Matched control|
3167087|NCT01431820|Experimental|Luliconazole Solution, 10% Regimen 1|
3167088|NCT01431820|Experimental|Luliconazole Solution, 10% Regimen 2|
3167089|NCT01431820|Placebo Comparator|Vehicle Solution Regimen 1|
3167090|NCT01431820|Placebo Comparator|Vehicle Solution Regimen 2|
3167091|NCT01431807|Experimental|SYR-472 group|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
3167092|NCT01431794|Experimental|Phase I, Arm A: gem, nab-paclitxel, and LDE225|Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2on days 1, 8, and 15 every 28 days cycle in combination with oral LDE225 600 mg daily.
3167093|NCT01431794|Active Comparator|Phase II, Arm A: gem, nab-paclitaxel, and LDE 225|"Phase II:~Arm A: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.~Arm B: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days."
3167094|NCT01431794|Active Comparator|Phase II, Arm B: gemcitabine and nab-paclitaxel|"Phase I:~Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2on days 1, 8, and 15 every 28 days cycle in combination with oral LDE225 600 mg daily.~Phase II:~Arm A: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.~Arm B: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days."
3167095|NCT01431781|Experimental|stilamin+common daily treatment|
3167096|NCT01431781|Active Comparator|common daily treatment|
3167097|NCT01431755|Other|Restylane SubQ|
3167098|NCT01431755|Other|Restylane SubQ Lidocaine|
3167099|NCT01431742|Experimental|BEMA Buprenorphine|buprenorphine buccal soluble film
3167100|NCT01431729||mucositis|
3167101|NCT01431716|Experimental|EFI/ACT-385781A|EFI/ACT-385781 administered by continuous intravenous infusion via a central venous catheter using an ambulatory infusion pump
3167102|NCT01431690|Experimental|Warfarin and Epanova|
3167103|NCT01431690|Active Comparator|Lovaza|
3167104|NCT01431651|Experimental|probiotic, lifestyle counseling|
3167105|NCT01431638|Experimental|Canakinumab 150mg|Canakinumab 150mg in prefilled syringe subcutaneously
3167106|NCT01431625|Active Comparator|COPD with emphysema-predominant|The degree of involvement of the lung parenchyma and the airway are assessed by computed tomography. The HRCT is performed using 2-mm collimation, scan time 1.0 s, 120 kVp, and 200 mA. Images at three different levels (a cranial section is obtained 1 cm above the superior margin of the aortic arch, a middle section is taken at 1 cm below the carina, and a caudal section is taken approximately 3 cm above the top of the diaphragm) are selected and LAA% is then automatically calculated. The identification threshold of normal lung density and LAA is set at -960 HU. The cut-off level between high or low LAA% is the mean + 2SD of LAA% of the asymptomatic non-COPD smokers.
3167107|NCT01431625|Active Comparator|COPD with airway-predominant|The degree of involvement of the lung parenchyma and the airway are assessed by computed tomography. The HRCT is performed using 2-mm collimation, scan time 1.0 s, 120 kVp, and 200 mA. Images at three different levels (a cranial section is obtained 1 cm above the superior margin of the aortic arch, a middle section is taken at 1 cm below the carina, and a caudal section is taken approximately 3 cm above the top of the diaphragm) are selected and LAA% is then automatically calculated. The helical scan is performed using 120 kVp, 50 mA, 3-mm collimation, and pith 1.0. The dimensions of the right apical segmental bronchus are measured and WA% is calculated. The cut-off level between high or low WA% is the mean + 2SD of WA% of the asymptomatic non-COPD smokers.
3167108|NCT01431612|Active Comparator|Esmolol|50 µg/kg/min of the ß-1-receptor-blocker esmolol (Qilu Pharmaceutical Co, Shandong, China) wss infused intravenously over 3 hours
3167109|NCT01431612|Active Comparator|Phenylephrine|Intravenous infusion of 0.01 µg/kg/min of phenylephrine (alpha1-adrenergic agonist) over 3 hours.
3167110|NCT01431612|Placebo Comparator|Lactated Ringer´s solution|10 ml/h lactated Ringer's solution without active drug was infused intravenously over 3 hours.
3167111|NCT01431599|Experimental|short-course|
3167112|NCT01431586|Experimental|Single dose JDTic 1 mg, 3 mg, or 10 mg|
3167113|NCT01431573|Experimental|Wake Therapy + light box +/- lithium|"Bipolar patients must take lithium; others do not take lithium~all patients are hospitalized for a week during which they do not sleep on alternating nights~for six weeks, including the week in the hospital all patients sit in front of bright lights at specified times and for specified durations"
3167114|NCT01431560|Active Comparator|metallic implant|fixation of the ankle fracture with metallic implants
3167115|NCT01431560|Active Comparator|biodegradable implant|fixation of the ankle fracture with Freedom plate and screws
3167116|NCT01431547|Experimental|Part 1: Dalotuzumab|
3167117|NCT01431547|Experimental|Parts 2 and 3: Dalotuzumab + ridaforolimus|
3167118|NCT01431534|Experimental|Ridaforolimus|
3167119|NCT01431521|Experimental|MK-4074|Participants will receive oral doses of MK-4074 200 mg (2 x 100-mg capsules) twice daily for 4 weeks.
3167120|NCT01431521|Placebo Comparator|Placebo for MK-4074|Participants will receive oral doses of placebo to match MK-4074 twice daily for 4 weeks.
3167121|NCT01431521|Experimental|Pioglitazone|Participants will receive oral doses of pioglitazone hydrochloride 30 mg (1 x 30-mg tablet) once daily for 4 weeks.
3167122|NCT01431521|Placebo Comparator|Placebo for pioglitazone|Participants will receive oral doses of placebo to match pioglitazone hydrochloride once daily for 4 weeks.
3167123|NCT01431508|Experimental|Losartan 50 mg / HCTZ 12.5 mg|Participants with mild to moderate essential hypertension who will receive Losartan 50 mg / HCTZ 12.5 mg once-a-day for 12 weeks.
3167124|NCT01431495|Active Comparator|plavix|patient treated by the princeps
3167125|NCT01431495|Active Comparator|Pidogrel|patient treated by Pidogrel
3167126|NCT01431469|Placebo Comparator|Cow's Milk|Powdered Whole Cow's Milk
3167127|NCT01431469|Experimental|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
3167128|NCT01431456|Active Comparator|Dabigatran|Dabigatran
3167129|NCT01431456|Active Comparator|Rivaroxaban|Rivaroxaban
3167130|NCT01431456|Active Comparator|Nadroparin|Nadroparin
3167131|NCT01431443|Experimental|Dark chocolate|
3167132|NCT01431443|Placebo Comparator|Placebo chocolate|Placebo intervention
3167133|NCT01431430|Experimental|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
3167134|NCT01431430|Active Comparator|Cholecalciferol 12 000 UI (Control)|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
3167135|NCT01431417||Healthy volunteers|Healthy volunteers, less than 35 years old and presenting with no shoulder condition
3167136|NCT01431417||Patients with rotator cuff condition|Patients with rotator cuff condition, conservative treatment indicated
3167137|NCT01431417||Patients with shoulder instability|Patients with shoulder instability, conservative treatment indicated
3167138|NCT01431417||Patients with proximal humerus fracture|Patients with diaphyseal humerus fracture or subcapital humerus fracture treated surgically or conservatively, at 6 weeks post stabilization. (Surgical and conservative treatment will be considered as the same population from the functional point of view as functional outcome is similar) (Handoll et al. 2003).
3167139|NCT01431417||Patients with frozen shoulder|Patients with frozen shoulder, conservative treatment indicated
3167140|NCT01431404|Active Comparator|Enbrel, prefilled syringe|
3167141|NCT01431404|Experimental|HD203, prefilled syringe|
3167142|NCT01431391|Experimental|Arm 1: Sipuleucel-T followed by ADT|Arm 1: Subjects received one infusion of sipuleucel-T every two weeks for a total of three infusions. Two weeks after the third sipuleucel-T infusion, subjects started ADT with 45 mg leuprolide acetate depot injection (Eligard® 45 mg). An additional leuprolide acetate injection was administered at 6 months after the first injection for a total of 2 injections and 12 months of ADT.
3167143|NCT01431391|Experimental|Arm 2: ADT followed by sipuleucel-T|Arm 2: Subjects started ADT with 45 mg leuprolide acetate depot injection (Eligard® 45 mg) 12 weeks before infusion 1 of sipuleucel-T. An additional leuprolide acetate injection was administered at 6 months after the first injection for a total of 2 injections and 12 months of ADT. Twelve weeks after the initial leuprolide 45 mg depot injection, subjects began one infusion of sipuleucel-T every two weeks for a total of three infusions.
3167144|NCT01431378||CNS|CNS: Known or suspected pathology in the posterior fossa
3167145|NCT01431378||Thorax|Thorax: Patients referred for staging of a known or suspected lung cancer
3167146|NCT01431378||Abdomen 1|Abdomen: Patients with acute flank pain and suspected urolithiasis
3167147|NCT01431378||Abdomen 2|Abdomen: Patients with a known or suspected focal liver lesion
3167148|NCT01431365|Experimental|Moderate Exercise Group|The moderate exercise condition will involve participants walking briskly (equivalent to moderate intensity) on a treadmill for 10 minutes. Moderate intensity exercise will be defined as 40-68% of the resting heart rate reserve. Heart rate (HR) will be monitored in participants using a Polar RS100 Heart Rate monitor to serve as a guide for participants to attain the appropriate intensity.
3167149|NCT01431365|Active Comparator|Passive Sitting Group|The passive sitting condition will involve participants sitting passively for 10 minutes on a chair. Heart rate (HR) will be monitored in participants of the passive sitting group to help maintain group equivalency (with the moderate exercise condition) in regards to distraction effects and researcher contact.
3167150|NCT01431352|Experimental|Letrozole+ Chinese herbal medicine granules|
3167151|NCT01431352|Placebo Comparator|Letrozole+ Chinese herbal medicine granules placebo|
3167152|NCT01431339|Active Comparator|Vancomycin with possible switch to oral linezolid|
3167153|NCT01431339|Experimental|Dalbavancin|
3167154|NCT01431313|Experimental|Inhaled Nitrite|Sodium Nitrite Inhalation Solution (AIR001) 45mg dosage with one subsequent escalation dosage of 90mg based on tolerability.
3167158|NCT01431287|Experimental|tiotropium+olodaterol high dose FDC|Once daily 2 puffs solution for inhalation Respimat
3167159|NCT01431287|Experimental|tiotropium+olodaterol low dose FDC|Once daily 2 puffs solution for inhalation Respimat
3167160|NCT01431287|Active Comparator|olodaterol|Once daily 2 puffs solution for inhalation Respimat
3167161|NCT01431287|Active Comparator|tiotropium low dose|Once daily 2 puffs solution for inhalation Respimat
3167162|NCT01431287|Active Comparator|tiotropium high dose|Once daily 2 puffs solution for inhalation Respimat
3167163|NCT01431274|Experimental|tiotropium+olodaterol low dose FDC|Once daily 2 puffs solution for inhalation Respimat
3167164|NCT01431274|Experimental|tiotropium+olodaterol high dose FDC|Once daily 2 puffs solution for inhalation Respimat
3167165|NCT01431274|Active Comparator|olodaterol|Once daily 2 puffs solution for inhalation Respimat
3167166|NCT01431274|Active Comparator|tiotropium low dose|Once daily 2 puffs solution for inhalation Respimat
3167167|NCT01431274|Active Comparator|tiotropium high dose|Once daily 2 puffs solution for inhalation Respimat
3167168|NCT01431261|Active Comparator|Pain Management + Training|Education in pain management strategies and treatment sessions including instructions in neck exercises and aerobic training
3167169|NCT01431261|Active Comparator|Pain Management|Education in pain management strategies
3167170|NCT01431248||Azithromycin|Azithromycin 1gm PO once
3167171|NCT01431248||Erythromycin 250mg|Erythromycin 250mg IV Q 6hrs x 48 hours followed by 500 mg PO Q 8 hours x 5 days.
3167172|NCT01431235|No Intervention|standard addiction treatment|10 sessions of standard addiction treatment. No ADHD treatment.
3167173|NCT01431235|Experimental|addiction treatment and ADHD treatment|10 sessions cognitive behavioral therapy on addiction treatment combined with 5 sessions on ADHD treatment.
3167174|NCT01431222|Active Comparator|percutaneous treatment|
3167175|NCT01431222|No Intervention|optimal medical treatment|
3167176|NCT01431209|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3167177|NCT01431196|Experimental|DENDRITIC CELL VACCINATION|Px will receive standard neoadjuvant chemotherapy plus active vaccination. we will compare results with an historic cohort of patients treated with the same chemotherapy without the vaccines
3167178|NCT01431183|Active Comparator|mailed reminder notice|Seasonal influenza vaccination reminder sent by postal mail
3167179|NCT01431183|No Intervention|No reminder notice|No seasonal influenza vaccination reminder sent by postal mail
3167180|NCT01431170|Experimental|Besivance Treatment Group|Besivance™ ophthalmic suspension, 0.6%
3167181|NCT01431170|Active Comparator|Polytrim Treatment Group|Polytrim ophthalmic solution
3167182|NCT01431157|Active Comparator|Nasal oxygen|Nocturnal nasal oxygen
3167183|NCT01431157|Placebo Comparator|No nasal oxygen|
3167184|NCT01431144|Active Comparator|Connective tissue autograft|A connective tissue autograft harvested from the palate was grafted onto the facial of a simultaneously placed dental implant and soft tissue thickness was measured at baseline and Time 4.
3167185|NCT01431144|Experimental|connective tissue allograft|An acellular dermal matrix allograft was grafted on the facial surface of a simultaneously placed dental implant and soft tissue thickness was measured at baseline and Time 4.
3167186|NCT01431131|Active Comparator|Intrasocket graft|Positive control
3167187|NCT01431131|Experimental|Intrasocket plus facial overlay graft|Intrasocket cancellous allograft plus a facial overlay bovine xenograft
3167188|NCT01431118|Active Comparator|sports intervention male|male athletes of the german national dragon boat team
3167189|NCT01431118|Active Comparator|sports intervention women|women athletes of the german national dragon boat team
3167190|NCT01431105|Experimental|Atorvasatin|Atorvastatin dose titration to maximum tolerated dose
3167191|NCT01431092|Experimental|Melatonin|
3167192|NCT01431092|Placebo Comparator|Placebo|
3167193|NCT01431079|Experimental|Health belief model based education|This experimental arm will provide an educational intervention designed to modify constructs of health belief model regarding HPV vaccine acceptability.
3167194|NCT01431079|Active Comparator|Knowledge-based education|This comparison arm will provide education based on knowledge regarding HPV vaccine acceptability.
3167195|NCT01431066|Placebo Comparator|Control|Sham device that resembles the Actipatch PRFE device, including the light that illuminates when active, but the transmitting function has been disabled.
3167196|NCT01431066|Experimental|Actipatch|Use of the Actipatch PRFE device that is integrated into a viscoelastic heel pad for the treatment of plantar fasciopathy
3167197|NCT01431053|Experimental|Exemestane + Aspirin|
3167198|NCT01431053|Active Comparator|Exemestane|
3167199|NCT01431040|Active Comparator|Group A|Group A will have no bowel preparation and be permitted a regular diet the day prior to surgery until midnight.
3167200|NCT01431040|Active Comparator|Group B|Participants in this group will consume a clear liquid diet and perform 2 Fleets enemas in the late afternoon the day before surgery and nothing after midnight.
3167201|NCT01431027||Diastolic Function|Patients scheduled for cardiac catheterization.
3167202|NCT01431014|Active Comparator|"Dexamethasonelow-dose"|5mg
3167203|NCT01431014|Experimental|"Dexamethasonehigh-dose"|15mg
3167204|NCT01431001|Experimental|Coil Configuration A|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
3167205|NCT01431001|Experimental|Coil Configuration B|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
3167206|NCT01430988||Head Injured Group|Subjects who are suspected of a traumatically induced structural brain injury and/or clinical manifestations of functional brain injury, as a result of insult to the head from an external force, e.g., the head being struck by an object, the head striking an object, the head being exposed to forces generated from a blast or explosion, and/or the brain undergoing an acceleration/deceleration movement without direct external trauma to the head will be recruited from patients who enter the Emergency Department at hospitals that are participating as clinical sites for this study
3167251|NCT01430624|Experimental|PPRS video|Prevention of post sexual assault stress
3167252|NCT01430624|Active Comparator|PIRI video|Pleasant imagery and relaxation instruction
3167207|NCT01430988||Normal Control Group|A normal control group will be recruited for comparison and will consist of Emergency Department patients who have sustained an injury but do not exhibit any trauma above the clavicle and no history of Road Traffic Accident requiring an ED visit or TBI within the past one (1) year, and no primary complaint of syncope.
3167208|NCT01430988||Head Injured Control Group|A 'head injured' control group will be recruited and will consist of Emergency Department patients who are suspected or who have sustained a head injury but do not report or manifest symptoms, e.g. facial lacerations and/or whiplash.
3167209|NCT01430962||General Anesthesia|Patients will receive Total Intravenous Anesthesia (TIVA) with a combination of Propofol, Ketamine and neuromuscular blockade by anesthesia. Either an LMA or an ETT will be used to secure airway.
3167210|NCT01430962||Moderate Sedation|Patients will receive moderate sedation given by the physician performing EBUS with a combination of Versed and Fentanyl per hospital protocol.
3167211|NCT01430949|Experimental|Over-the-Wire Mesh Ablation System|
3167212|NCT01430923|Experimental|Refrigeration free Latanoprost|Latanoprost refrigeration free formulation as per randomization schedule.
3167213|NCT01430923|Active Comparator|latanoprost 2-8˚ C|latanoprost stored at 2-8˚ C
3167214|NCT01430910|Experimental|1|CAZ104 (2000mg Ceftazidime/500mg Avibactam)
3167215|NCT01430910|Active Comparator|2|500mg Avibactam
3167216|NCT01430910|Active Comparator|3|2000mg Ceftazidime
3167217|NCT01430884||Aspirate Blood|
3167218|NCT01430871||Carcinoid syndrome|Patients: Men and women age 18 years or older with carcinoid syndrome attending the Sheffield neuro-endocrine tumour clinic
3167219|NCT01430871||Healthy Volunteers|Control group: Healthy men and women individually matched to the patients by gender, age, height and BMI
3167220|NCT01430858|Other|Strain Gauge|We wish to determine the relationship between tibial bone strain (recorded from implanted tibial strain gauges) and measured displacements of the limb and pelvis (using video motion analysis) during vibration exercise and a range of habitual locomotor activities. Only healthy volunteers will be recruited to this one arm.
3167221|NCT01430832||Normal Development|The infant's development level will be assessed using a phone interview with parents
3167222|NCT01430832||Abnormal Development|The infant's level of development will be assessed using a phone interview with parents
3167223|NCT01430819|Experimental|Fluzone® Vaccine Group|Participants will receive the Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation
3167224|NCT01430819|Active Comparator|Fluzone® High-Dose Vaccine Group|Participants will receive the Influenza Virus Vaccine, Fluzone® High-Dose 2011-2012 Formulation.
3167225|NCT01430806|Other|Dronedrone Arm|
3167226|NCT01430793|Active Comparator|Vitamin D 600,000 IM|Vitamin D3 600,000 units will be given by intramuscular injection
3167227|NCT01430793|Active Comparator|Vitamin D 600,000 orally|Vitamin D3 600,000 units will be given orally
3167228|NCT01430793|Active Comparator|Vitamin D 200,000 IM|Vitamin D3 600,000 units will be given by intramuscular injection
3167229|NCT01430793|Active Comparator|Vitamin D 200,000 orally|Vitamin D 200,000 units will be given orally
3167230|NCT01430780||control group|placebo
3167231|NCT01430780||nitrate group|Isosorbide Mononitrate orally 20mg twice per day.
3167232|NCT01430767||Depression|Ten subjects with diagnosis of major depressive disorder from the Wake Forest University Student Health Clinic, being treated with FDA-approved standard-of-care medication for depression.
3167233|NCT01430767||ADHD|Ten subjects with a diagnosis of attention-deficit hyperactivity disorder (ADHD) from the Wake Forest University Student Health Clinic, being treated with FDA-approved standard-of-care medication for their ADHD.
3167234|NCT01430754|Experimental|tasimelteon|20 mg tasimelteon capsules
3167235|NCT01430754|Placebo Comparator|Placebo|Placebo capsules
3167236|NCT01430741|Other|Implementation as Usual Case Management|"Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition):MISSION-Vet has been developed to target mental health, substance abuse and related issues faced by homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources.~Implementation as Usual (IU) - standard training on the MISSION model via a 1.5 hour webinar"
3167237|NCT01430741|Other|Implementation as Usual Veterans|"Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition):MISSION-Vet has been developed to target mental health, substance abuse and related issues faced by homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources.~Implementation as Usual (IU) - standard training on the MISSION model via a 1.5 hour webinar. Staff then deliver MISSION to Veterans."
3167238|NCT01430741|Experimental|Getting to Outcomes Case Management|Getting To Outcomes (GTO) is used to strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. In GTO, staff receive ongoing technical assistance using the GTO implementation platform.
3167239|NCT01430741|Experimental|Getting to Outcomes Veterans|Getting To Outcomes (GTO) is used to strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. In GTO, staff receive ongoing technical assistance using the GTO implementation platform, that guides staff while delivering MISSION to Veterans.
3167240|NCT01430728||Very low birthweight infants|
3167241|NCT01430715|Experimental|Outside play|
3167242|NCT01430715|Experimental|Active video game|
3167243|NCT01430702|Experimental|Computerized medication delivery unit|Those hospitalized patients that meet all inclusion and exclusion criteria will be provided with a computerized medication delivery unit for use in their homes for the 30-day period following discharge.
3167244|NCT01430689|Experimental|Inactivated Influenza Vaccine Trivalent Types A and B|Women will be vaccinated with Influenza vaccine: Inactivated Influenza Vaccine Trivalent Types A and B
3167245|NCT01430689|Active Comparator|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate|Women will be vaccinated with IM injection of Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine
3167246|NCT01430676||Danish Ventral Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
3167247|NCT01430663||Hematological patients with proven or probable aspergillosis|
3167248|NCT01430663||Hematological patients with possible aspergillosis|
3167249|NCT01430650|Experimental|Oral strogen|
3167250|NCT01430650|Experimental|Transdermal strogen|
3167254|NCT01430611|Experimental|Sanofi Pasteur Meningococcal A+C Polysaccharide Vaccine|
3167255|NCT01430611|Active Comparator|Lanzhou Institute Meningococcal A+C Polysaccharide Vaccine|
3167256|NCT01430598|Active Comparator|A|Subacromial decompression before repair of a complete rotator cuff tear.
3167257|NCT01430598|Active Comparator|B|Subacromial decompression after repair of a complete rotator cuff repair.
3167258|NCT01430585|Experimental|A|
3167259|NCT01430585|Experimental|B|
3167260|NCT01430585|Active Comparator|C|
3167261|NCT01430572|Experimental|Pazopanib + Everolimus|Pazopanib 200 mg and Everolimus 5.0 mg oral dosing every other day (except for lead in 5 days of Cycle 1 where both drugs administered daily).
3167262|NCT01430559|Other|Meloxicam|
3167263|NCT01430559|Placebo Comparator|Placebo|2 Placebo capsules once a day for 12 weeks
3167264|NCT01430533|Experimental|Verum|Topical application of verum (azelaic acid pre foam formulation) on the skin
3167265|NCT01430533|Placebo Comparator|Vehicle|Topical application of vehicle formulation (same as verum but without active drug substance) on the skin
3167266|NCT01430533|Placebo Comparator|Negative control|Topical application of distilled water (negative control) on the skin
3167267|NCT01430520|Active Comparator|Escitalopram|
3167268|NCT01430520|Placebo Comparator|Placebo|
3167269|NCT01430507|Experimental|Medium Dose|Medium Dose Revamilast
3167270|NCT01430507|Experimental|High Dose|High Dose Revamilast
3167271|NCT01430507|Placebo Comparator|Placebo|Matching Placebo in Triple Dummy Format
3167272|NCT01430507|Experimental|Low dose|Low dose Revamilast
3167273|NCT01430494||No treatment|
3167274|NCT01430481|Active Comparator|Standard Rosehip Powder (A)|6 capsules of standardized hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
3167275|NCT01430481|Experimental|New rosehip formulation (B)|6 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
3167276|NCT01430481|Experimental|New rosehip formulation in half dose (C)|3 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
3167277|NCT01430468|Experimental|Glenoid Positioning System|For the patients randomized to the GPS group, the surgeon will be given the GPS patient specific instrumentation and a model of the glenoid surface showing the exact placement and fit of the GPS alignment instruments.
3167278|NCT01430468|No Intervention|Standard Group|Each surgeon will use their standard methods of pre-operative planning using the pre-operative x-rays and CT scan.
3167279|NCT01430455|Experimental|Tranylcypromine|Active, open-label tranylcypromine treatment
3167280|NCT01430442|Placebo Comparator|Arm 1: Placebo matching BMS-927711|
3167281|NCT01430442|Experimental|Arm 2: BMS-927711 and Placebo matching BMS-927711|
3167282|NCT01430442|Experimental|Arm 3: BMS-927711 and Placebo matching BMS-927711|
3167283|NCT01430442|Experimental|Arm 4: BMS-927711 and Placebo matching BMS-927711|
3167284|NCT01430442|Experimental|Arm 5: BMS-927711 and Placebo matching BMS-927711|
3167285|NCT01430442|Experimental|Arm 6: BMS-927711 and Placebo matching BMS-927711|
3167286|NCT01430442|Experimental|Arm 7: BMS-927711 and Placebo matching BMS-927711|
3167287|NCT01430442|Active Comparator|Arm 8: Sumatriptan and Placebo matching BMS-927711|
3167288|NCT01430429|Experimental|NI-0801|
3167289|NCT01430416|Experimental|AEB071|
3167290|NCT01430403|Experimental|Omalizumab|Participants receive active omalizumab (Xolair®) injections and a placebo Flovent® Diskus® (fluticasone) inhaler. Each participant will receive omalizumab (Xolair®) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) [IU/mL] every 2 or 4 weeks during the 4-5 months treatment period. In addition, all participants receive standardized specialist asthma care.
3167291|NCT01430403|Experimental|Inhaled Corticosteroid Boost Therapy (ICS)|Participants in this group, the Inhaled Corticosteroid (ICS) boost arm, receive active ICS and placebo omalizumab (Xolair®) injections. Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone will be used. In addition, all participants receive standardized specialist asthma care.
3167292|NCT01430403|Placebo Comparator|Placebo|The placebo group receive placebo omalizumab (Xolair®) injections and placebo Flovent® Diskus® (fluticasone) inhaler. In addition, all participants receive standardized specialist asthma care.
3167293|NCT01430390|Experimental|Biological/Genetically Modified T cells|Patients with persistent minimal residual disease (+MRD)/ relapsed/refractory CD19+ malignancy will receive EBV specific cytotoxic T-cells (EBV-CTLs) genetically modified ex vivo to express the CD19-specific 19-28z chimeric artificial receptor.
3167294|NCT01430377|Experimental|SB predilatation|
3167295|NCT01430364|Active Comparator|BIOSS implantation|
3167296|NCT01430351|Experimental|Arm 1: TMZ + MEMTN|Temozolomide 150 m/m2 by mouth 1 time each day on alternate weeks on Days 1-7 and Days 15-21 of every 28 day cycle. Memantine 30 mg by mouth twice a day for a 28 day cycle.
3167297|NCT01430351|Experimental|Arm 2: TMZ + MFLOQ|Temozolomide 150 m/m2 by mouth on alternate weeks days 1-7, 15-21 of a 28 day cycle. Mefloquine 250 mg by mouth 1 time a day on Days 1-3 of the first week, then on Monday, Wednesday, and Friday of every week after that for a 28 day cycle.
3167298|NCT01430351|Experimental|Arm 3: TMZ + MFRMN|Temozolomide 150 m/m2 by mouth on alternate weeks days 1-7, 15-21 of a 28 day cycle. Metformin 1000 mg by mouth twice a day for a 28 day cycle.
3167299|NCT01430351|Experimental|Arm 4: TMZ + MEMTN + MFLOQ|Temozolomide 150 m/m2 by mouth on alternate weeks days 1-7, 15-21 of a 28 day cycle. Memantine 30 mg by mouth twice a day for a 28 day cycle. Mefloquine 250 mg by mouth 1 time a day on Days 1-3 of the first week, then on Monday, Wednesday, and Friday of every week after that for a 28 day cycle.
3167300|NCT01430351|Experimental|Arm 5: TMZ + MEMTN + MFRMN|Temozolomide 150m/m2 by mouth 1 time each day on alternate weeks on Days 1-7 and Days 15-21 of every 28 day cycle. Memantine 30 mg by mouth twice a day for a 28 day cycle. Metformin 1000 mg by mouth twice a day for a 28 day cycle.
3167340|NCT01430104|Experimental|Teriparatide + Aspara-CA + Alfarol|Aspara-CA 600 milligrams (mg) and Alfarol 1.0 microgram (µg) administered orally once daily throughout the study. Teriparatide 20 µg administered subcutaneously once daily for 28 days during the Treatment Period.
3167301|NCT01430351|Experimental|Arm 6: TMZ + MFLOQ + MFRMN|Temozolomide 150 m/m2 by mouth 1 time each day on alternate weeks on Days 1-7 and Days 15-21 of every 28 day cycle. Mefloquine 250 mg by mouth 1 time a day on Days 1-3 of the first week, then on Monday, Wednesday, and Friday of every week after that for a 28 day cycle. Metformin 1000mg by mouth twice a day for a 28 day cycle.
3167302|NCT01430351|Experimental|Arm 7: TMZ + MEMTN + MFRMN + MFLOQ|Temozolomide 150 m/m2 by mouth 1 time each day on alternate weeks on Days 1-7 and Days 15-21 of every 28 day cycle. Memantine 30 mg by mouth twice a day for a 28 day cycle. Metformin 1000 mg by mouth twice a day for a 28 day cycle. Mefloquine 250 mg by mouth 1 time a day on Days 1-3 of the first week, then on Monday, Wednesday, and Friday of every week after that for a 28 day cycle.
3167303|NCT01430338||BAT|brown adipose tissue detected, undetected
3167304|NCT01430325|Sham Comparator|Sea Level Equivalent 1.2 atm abs (air)|"Sham Chamber Session~Sea Level Equivalent 1.2 atm abs (2.6 psig) breathing regular air 20-chamber excursion"
3167305|NCT01430325|Experimental|Sea Level Equivalent 1.5 atm abs (O2)|"Hyperbaric Oxygen (1.5 atm abs)~Sea Level Equivalent 1.5 atm abs (6.2 psig) breathing 100% oxygen 20-minute chamber excursion"
3167306|NCT01430325|Sham Comparator|Altitude Equivalent 1.2 atm abs (air)|"Sham Chamber Session~Altitude Equivalent 1.2 atm abs (5.1 psig) breathing regular air 20-minute chamber excursion"
3167307|NCT01430325|Experimental|Altitude Equivalent 1.5 atm abs (O2)|"Hyperbaric Oxygen (1.5 atm abs)~Altitude Equivalent 1.5 atm abs (9.6 psig) breathing 100% oxygen 20-minute chamber excursion"
3167308|NCT01430312|Experimental|Verum|Topical application of verum (azelaic acid pre-foam formulation) on the skin
3167309|NCT01430312|Placebo Comparator|Vehicle|Topical application of vehicle formulation (same as verum but without active drug substance) on the skin
3167310|NCT01430312|Placebo Comparator|Negative control|Topical application of distilled water (negative control) on the skin
3167311|NCT01430312|Active Comparator|Positive control|Topical application of 0.5% Sodium Lauryl sulfate (positive control) on the skin
3167312|NCT01430299|Other|Demineralized Bone Matrix|a prospective cohort of patients undergoing posterolateral lumbar fusion with Evo3 in the posterolateral space
3167313|NCT01430299|Other|rh-BMP2|A retrospective cohort of patients who were age- and sex- matched to the prospective cohort who underwent posterolateral lumbar fusion with use of rh-BMP2
3167314|NCT01430286|Experimental|Psycho-educational program|This group is trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
3167315|NCT01430286|Active Comparator|Standard treatment|This group will receive treatment as usual : consultation in memory clinic every 6 months during the AD patient's consultation.
3167316|NCT01430273||Planned hip or knee arthroplasty|Patients with planned hip or knee arthroplasty
3167317|NCT01430273||urgent hip or knee arthroplasty|Patients with hip or knee arthroplasty in emergency.
3167318|NCT01430260|Experimental|ciclesonide nasal spray|ciclesonide nasal spray, alone
3167319|NCT01430260|Active Comparator|Levocetirizine|Levocetirizine, alone
3167320|NCT01430260|Active Comparator|Ciclesonide nasal spray & Levocetirizine|Ciclesonide nasal spray & Levocetirizine in combination
3167321|NCT01430247|Other|Amblyopia screening|
3167322|NCT01430234|Other|Panzytrat fixed dose vs. self-dosing|In Phase I (week 1-4) patients will use the fixed amount of lipase as was prescribed by their treating physician. Phase II (week 5-9) patients will start the self-dosage regimen with pancreatic enzymes (without exceeding the maximum amount of 16 capsules per day). They are properly educated by the researcher and dietician how to adjust the amount of pancreatic enzymes to the fat intake in their diet.
3167323|NCT01430221|Experimental|MB-PHP Group|Mindfulness-based Personalized Health Planning (MB-PHP)with health coaching. MB-PHP includes weekly small group meetings for 22-weeks and 10 bi-weekly telephonic health coaching.
3167324|NCT01430221|Active Comparator|SAGE Group|Structure & Guided Education (SAGE) includes small group-education sessions once per week for 22 weeks. Subjects also participate in 10 bi-weekly telephone calls with education partners who use supportive listening techniques..
3167325|NCT01430208|Active Comparator|mini-resectoscope|
3167326|NCT01430208|Active Comparator|tradiorional resectoscope|
3167327|NCT01430208|Active Comparator|bettocchi resectoscope|
3167328|NCT01430195|Experimental|Afamelanotide + NB-UVB: Experimental|Subject in this arm will receive both afamelanotide implants (one implant administered every 28 days, 4 implants in total) and NB-UVB light (administered thrice weekly, 72 treatments in total).
3167329|NCT01430195|Active Comparator|NB-UVB alone: Active Comparator|Subjects in this arm will receive NB-UVB light only (administered thrice weekly, 72 treatments in total).
3167330|NCT01430182|Experimental|Methadone 0.2 mg/kg|0.2 mg/kg methadone by actual body weight, administered over ten minutes, initiated after induction of anesthesia and endotracheal intubation complete.
3167331|NCT01430182|Active Comparator|Morphine 0.2 mg/kg|0.2 mg/kg morphine by actual body weight, administered over ten minutes, initiated after induction of anesthesia and endotracheal intubation complete.
3167332|NCT01430169|Experimental|AA4500|"collagenase clostridium histolyticum (AA4500) contains purified collagenase AA4500 (clostridium histolyticum) consisting of two microbial collagenases in a defined mass ratio, Collagenase AUX-I and Collagenase AUX-II, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria.~2 injections of AA4500 0.58 mg were administered 24 hours apart."
3167333|NCT01430156|Active Comparator|Heme arginate (Normosang)|This arm will receive 2 doses of Heme Arginate (trade name Normosang); 1 dose prior to transplant and another on day 2. This is a product derived from human hemin and has been used for over 20 years in clinical practice with few side-effects.
3167334|NCT01430156|Placebo Comparator|0.9% saline|The saline will be given as an IV infusion in the same manner as the Heme Arginate (active comparator) infusion.
3167335|NCT01430143|Experimental|600 kcal/day|Exercise combusting 600 kcal/day, 7 days/week for 12 weeks.
3167336|NCT01430143|Experimental|300 kcal/day|Exercise combusting 300 kcal/day, 7 days/week for 12 weeks.
3167337|NCT01430143|No Intervention|Sedentary|Continued sedentary living.
3167338|NCT01430130|Experimental|All Study Participants|Half of the revised incision was treated with the embrace device. Half of the revised incision was treated according to the Investigator's standard of care. Participant served as his/her own control.
3167339|NCT01430117|Experimental|1|"Poa pratensis allergen extract at 4 different concentrations.~Positive control.~Negative control."
3167341|NCT01430091|Active Comparator|Prasugrel clinical formulation|A single 5-milligram (mg) prasugrel tablet administered orally by swallowing it whole on 1 occasion.
3167342|NCT01430091|Experimental|Prasugrel (ODT) - on tongue|A single 5-mg prasugrel orally disintegrating tablet (ODT) administered orally by placing it on top of the tongue and keeping it there until it disintegrates.
3167343|NCT01430091|Experimental|Prasugrel (ODT) - apple juice|A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue followed by drinking approximately 180 milliliters (ml) apple juice within 1 minute after the tablet finishes disintegration.
3167344|NCT01430091|Experimental|Prasugrel (ODT) - chewed|A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue, but then chewed and swallowed rather than waiting for it to disintegrate.
3167345|NCT01430091|Experimental|Prasugrel (ODT) - under tongue|A single 5-mg prasugrel ODT administered orally by placing it under (rather than on top of) the tongue and keeping it there until it disintegrates.
3167346|NCT01430078|Experimental|Regimen A|ASP015K oral tablet
3167347|NCT01430078|Experimental|Regimen B|ASP015K solution delivered to distal small bowel via oral capsule
3167348|NCT01430078|Experimental|Regimen C|ASP015K solution delivered to ascending colon via oral capsule
3167349|NCT01430078|Experimental|Regimen D|ASP015K solution delivered to distal transverse colon via oral capsule
3167350|NCT01430065|Experimental|Tacrolimus and ASP015K|
3167351|NCT01430052|Other|Gemcitabine , S-1|Gemcitabine 1000mg/m2 on Day 1 and 8, every 3 weeks. S-1 60-100mg/day on Day 1 to 14, every 3 weeks
3167352|NCT01430052|Experimental|Gemcitabine, S-1, radiotherapy|Gemcitabine 600mg/m2 on Day 1 and 8, every 3 weeks. S-1 60-100mg/day on Day 1 to 14, every 3 weeks with radiotherapy 50.4Gy in 28 fractions
3167353|NCT01430039||Crohn's, ulcerative colitis|Patients with diagnosed with Crohn's disease or ulcerative colitis who agreed to participate in the study and singed informed consent and answered a Crohn's disease activity index questioner for Crohn's disease or the ulcerative colitis activity index questioner for ulcerative colitis.
3167354|NCT01430039||No disease|Healthy subjects with no known inflammatory disease. For basal serum levels of syndecan 1
3167355|NCT01430013|Experimental|Endostar|CHOPT chemotherapy plus Endostar
3167356|NCT01429987|Experimental|plecanatide 0.3 mg|Subjects receive plecanatide 0.3 mg for 12 consecutive weeks
3167357|NCT01429987|Experimental|plecanatide 1.0 mg|Subjects receive plecanatide 1.0 mg for 12 consecutive weeks
3167358|NCT01429987|Experimental|plecanatide 3.0 mg|Subjects receive plecanatide 3.0 mg for 12 consecutive weeks
3167359|NCT01429987|Placebo Comparator|Placebo|Subjects receive placebo for 12 consecutive weeks
3167360|NCT01429974||volunteers|
3167361|NCT01429961|Experimental|SOX|TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1-14
3167362|NCT01429948||Case group|Healthy subjects with silent cerebral infarction
3167363|NCT01429948||Control group 1|Patients with acute cryptogenic embolic stroke
3167364|NCT01429948||Control group 2|Patients with acute stroke with conventional stroke mechanisms
3167365|NCT01429935|Active Comparator|Ginger powder|
3167366|NCT01429935|Active Comparator|Ibuprofen|capsules of Ibuprofen 400 mg
3167367|NCT01429935|Placebo Comparator|placebo|capsules contain starch
3167368|NCT01429896|Experimental|Arm 1|Exercise followed by sleep restriction followed by control challenge
3167369|NCT01429896|Experimental|Arm 2|Sleep restriction followed by exercise followed by control challenge
3167370|NCT01429896|Experimental|Arm 3|control followed by sleep restriction followed by exercise
3167371|NCT01429896|Experimental|Arm 4|control followed by exercise followed by sleep restriction
3167372|NCT01429896|Experimental|Arm 5|Sleep Restriction followed by control followed by exercise
3167373|NCT01429896|Experimental|Arm 6|Exercise followed by control followed by sleep restriction
3167374|NCT01429870|Active Comparator|Steroid active treatment|Triamcinolone acetonide 0.1% in unguentum leniens topically
3167375|NCT01429870|Placebo Comparator|Vehicle|unguentum leniens topically
3167376|NCT01429844|Active Comparator|Tacrolimus|Tacrolimus in combination with mycophenolate mofetil and steroids for denovo immunosuppression after lung transplantation
3167377|NCT01429844|Active Comparator|Cyclosporine|Cyclopsorine in combination with mycophenolate mofetil and steroids for denovo immunosuppression after lung transplantation
3167378|NCT01429831|Experimental|Aripiprazole|
3167379|NCT01429818|Experimental|Glimepiride/metformin|
3167380|NCT01429818|Active Comparator|Metformin|
3167381|NCT01429792|Experimental|Single Arm|
3167382|NCT01429779|Experimental|Movicol|Administration of 1 sachet of Movicol® daily during one week preoperatively (experimental care) and 2 sachets of Movicol® daily postoperatively (standard care).
3167383|NCT01429779|No Intervention|Control|Control group; standard postoperative care (administration of 2 sachets of Movicol® postoperatively daily)
3167384|NCT01429753|Active Comparator|Standard LV lead placement|
3167385|NCT01429753|Experimental|Advanced Imaging Guided LV Lead Placement|
3167386|NCT01429740|Experimental|PF-05180999|
3167387|NCT01429740|Placebo Comparator|Placebo|
3167388|NCT01429727||SCAD Registry|Individuals who have experienced at least one episode of spontaneous coronary artery dissection.
3167389|NCT01429714|Experimental|Intervention: individually tailored ECS|Individually tailored duration of elastic compression therapy, based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months.
3167390|NCT01429714|Active Comparator|Control: ECS 24 months|Elastic compression therapy with a standard duration of 24 months
3167391|NCT01429701|Experimental|Test association cream|polymyxin B sulphate + prednisolone + benzocaine + clioquinol
3167392|NCT01429701|Active Comparator|Comparative association cream|betamethasone + gentamicin + tolnaftato + clioquinol
3167393|NCT01429688|Experimental|DP-R202|Multiple oral administration for 3 days
3167394|NCT01429688|Active Comparator|Anplag|Multiple oral administration for 3days
3167395|NCT01429675|Active Comparator|Bonviva|
3167396|NCT01429675|Experimental|DP-R206|
3167537|NCT01428674|Experimental|10 minutes touch|
3167538|NCT01428661|Experimental|tasimelteon|
3167397|NCT01429662|Sham Comparator|Lifestyle Education (LE)|Lifestyle Education (LE) Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
3167398|NCT01429662|Experimental|Modified Relaxation (MR)|Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.
3167399|NCT01429649|Experimental|ablation|Cryoablation or Radiofrequency ablation for the pGGO
3167400|NCT01429649|No Intervention|Follow up CT scann|The patients will receive follow up with CT scan every 6-9 months.
3167401|NCT01429636|Experimental|Applied Relaxation (AR)|
3167402|NCT01429636|Experimental|Modified Relaxation (MR)|
3167403|NCT01429623|Experimental|ladostigil hemitartrate|10mg ladostigil base
3167404|NCT01429623|Placebo Comparator|Placebo Control|drug product excipients
3167405|NCT01429610|Experimental|Rituximab+mVPDL|Patients who were CD20(+), newly-diagnosed adult ALL and treated with rituximab + mVPDL treatment plan
3167406|NCT01429597||Observation|All Patients with a diagnosis of Fabry disease with N215S
3167407|NCT01429584|Active Comparator|0.25% bupivacaine|interscalene nerve block with 0.25% bupivacaine
3167408|NCT01429584|Active Comparator|0.125% bupivacaine|interscalene nerve block with 0.125% bupivacaine
3167409|NCT01429571||Systemic and local antibiotics|
3167410|NCT01429571||Local antibiotics|
3167411|NCT01429571||No antibiotics|
3167412|NCT01429545|Active Comparator|Group 1 - Atosiban|Patients on single agent atosiban alone
3167413|NCT01429545|Experimental|Group 2|Patients on combination of atosiban and nifedipine
3167414|NCT01429532||Group I|1.8-mm-incision-size phacoemulsification system
3167415|NCT01429532||Group II|2.2-mm-incision-size phacoemulsification system
3167416|NCT01429532||Group III|3.0-mm-incision-size phacoemulsification system
3167417|NCT01429519|Experimental|Treatment|
3167418|NCT01429506|Active Comparator|Sleeve gastrectomy|Will undergo laparoscopic sleeve gastrectomy
3167419|NCT01429506|Active Comparator|Intensive medical management|Will receive VLCD, exenatide, metformin, insulin detemir
3167420|NCT01429493|Active Comparator|Conventional radiotherapy|
3167421|NCT01429493|Experimental|Biological image-guided radiotherapy with conventional dose.|
3167422|NCT01429493|Experimental|Biological image-guided SBRT with dose-escalation.|
3167423|NCT01429480|Active Comparator|TAP Block|
3167424|NCT01429480|Active Comparator|II/IH Block|
3167425|NCT01429480|Active Comparator|Control Group|
3167426|NCT01429467|Other|Continuous Glucose Monitoring (CGM)|10 participants from phase 1 will undergo 6 weeks of CGM with telemedicine support at weeks 1,3 + 5. After this period HIF, Erythropoietin, VEGf and cortisol will again be measured and compared with the subjects glucose variability.
3167427|NCT01429454|Placebo Comparator|Soybean-Corn Blend Capsule|The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them.
3167428|NCT01429454|Experimental|Omega 3 long chain fatty acid|The Omega-3 Fatty Acid compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
3167429|NCT01429441|Experimental|Ocriplasmin|
3167430|NCT01429441|Sham Comparator|Sham injection|
3167431|NCT01429428|Placebo Comparator|Stockings side one|This side of the compression stockings is just the fabric (placebo).
3167432|NCT01429428|Active Comparator|Stocking side two|This side of compression stocking emits far-IR radiation.
3167433|NCT01429415|Experimental|Experimental Group|Magnesium Sulfate Sandoz/PPC 600mg and Salbutamol (GlaxoSmithKline/Pharmascience) 5mg by inhalation via Aeroneb Go nebulizer (Philips) with Idehaler Pocket chamber DTF q 20 minutes, 3 treatments.
3167434|NCT01429415|Placebo Comparator|Control Group|Sodium Chloride USP PPC/Omega (5.5%) placebo and salbutamol GlaxoSmithKline/Pharmascience 5 mg by inhalation via Aeroneb Go nebulizer Philips with Idehaler Pocket chamber DTF q 20 minutes, 3 treatments.
3167435|NCT01429402|Experimental|study group I|For primary lip surgery, immediately after primary lip repair will received botulinum toxin injection (1-2U/kg, at 25U/mL) into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site
3167436|NCT01429402|Experimental|Study Group II|For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room.
3167437|NCT01429402|Placebo Comparator|Control Group I|Similar amount as group I (in C.C.) of normal saline will be injected after primary lip surgery at 3 months of age.
3167438|NCT01429402|Placebo Comparator|Control II|Similar amount (in C.C.) as Study Group II of normal saline will be injected after revision lip surgery (secondary cleft lip repair).
3167439|NCT01429363|Experimental|Targeted disc decompression|
3167440|NCT01429350|Active Comparator|IV rtPA|IV infusion of rtPA at 0.9mg/kg to a maximum of 90mg
3167441|NCT01429350|Experimental|IV rtPA and IA Penumbra System|Dual IV rtPA therapy (0.9mg/kg to a maximum of 90mg) and IA adjunctive treatment with the Penumbra System
3167442|NCT01429337|Experimental|Normal hepatic function group|
3167443|NCT01429337|Experimental|Mild hepatic impairment group|
3167444|NCT01429337|Experimental|Moderate hepatic impairment group|
3167445|NCT01429337|Experimental|Severe hepatic impairment group|
3167446|NCT01429324||Cardiac disease|Aortic arch surgery
3167447|NCT01429311||ADEH+|Subjects classified as Atopic Dermatitis (AD) and history of previous Eczema Herpeticum (EH) as defined by the ADRN Standard Diagnostic Criteria
3167448|NCT01429311||ADEH-|Subjects classified as AD without a history of EH as defined by the ADRN Standard Diagnostic Criteria
3167449|NCT01429311||Non-atopic Controls|"Subjects classified as Non-Atopic controls as defined by the ADRN Standard Diagnostic Criteria"
3167450|NCT01429298|Experimental|Hydromorphone|2 mg of IV dilaudid will be administered over 2-3 minutes as initial dose.
3167451|NCT01429298|Active Comparator|Usual care|The attending physician administers whatever IV opioid he/she deems appropriate in whatever dose he/she chooses for initial dosing
3167452|NCT01429285|Experimental|Hydromorphone|Hydromorphone protocol
3167453|NCT01429285|Active Comparator|Usual care|Usual care
3167454|NCT01429272|Placebo Comparator|Placebo & Placebo|Placebo for minocycline & placebo for aspirin
3167455|NCT01429272|Active Comparator|minocycline & aspirin|Minocycline 100mg PO BID for 6 weeks & Aspirin 81 mg PO BID for 6 weeks
3167456|NCT01429259|Experimental|Meropenem 3 hour prolonged infusion|All 30 participants will receive meropenem as a 3 hour infusion.
3167457|NCT01429246|Active Comparator|Normal Salt|100% Sodium Chloride
3167458|NCT01429246|Experimental|Salt Substitute|65% Sodium Chloride, 25% Potassium Chloride, 10% Magnesium Sulphate)
3167459|NCT01429194|Experimental|ACE procedure|ACE procedure for the treatment of obesity
3167460|NCT01429181|Experimental|Non Racemic Methadone|Non-Racemic Methadone Hydrochloride 5 mg Capsules containing a non-racemic mixture of methadone isomers.
3167461|NCT01429181|Placebo Comparator|Placebo|Matching placebo capsules
3167462|NCT01429168|Experimental|Part 1: All Enrolled Participants|All participants will receive open-label etoricoxib 60 mg orally daily during Part 1.
3167463|NCT01429168|Experimental|Part 2: Etoricoxib|
3167464|NCT01429168|Placebo Comparator|Part 2: Placebo|
3167465|NCT01429155||Liver transplant recipeints|Patients suffering from chronic hepatitis C that required a living donor liver transplant.
3167466|NCT01429155||Liver Donors|Patients who donated part of their liver to a patient suffering from chronic hepatitis C
3167467|NCT01429142|Experimental|AIMS intervention|see http://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-13-274
3167468|NCT01429142|Active Comparator|Treatment as usual|see http://www.tandfonline.com/doi/abs/10.1080/08870446.2014.1001392
3167469|NCT01429129|Experimental|Nicotine Replacement Therapy|
3167470|NCT01429129|No Intervention|Control|
3167471|NCT01429116|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
3167472|NCT01429103||Early Perimenopause|Early perimenopause is defined as the presence of irregular periods (cycle length differs by 7 days from usual).
3167473|NCT01429103||Late Perimenopause|Late perimenopause is defined as at least 2 skipped periods over the past 12 months (cycle double usual length) and one period of amenorrhea (over 60 days without a period), with at least one menstrual cycle over the past 12 months.
3167474|NCT01429090|Experimental|Test|Pharmacokinetics and -dynamics after single dose administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
3167475|NCT01429090|Active Comparator|Reference|Pharmacokinetics and -dynamics after single dose administration 100 ml methantheline solution (100 mg methantheline bromide)
3167476|NCT01429077|Active Comparator|Levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
3167477|NCT01429077|Placebo Comparator|Inactive pill|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
3167478|NCT01429064|Experimental|ODM-201|
3167479|NCT01429051|Experimental|Intranasal Fentanyl Spray (INFS)|All participants were step-wise titrated to an effective dose of 50, 100, 200 or 400 μg INFS in the Titration Phase (I). Participants titrated to 200 or 400 μg INFS in the Titration Phase were randomized to an 8-spray sequence in the Efficacy Phase (II); 6 BTP episodes were treated with 400 μg INFS and 2 BTP episodes with placebo in a random sequence. Participants entered the Tolerability Phase (III) either directly from the Titration Phase (with an effective dose of 50 or 100 μg) or from the Efficacy Phase (400 μg) and continued with this specific dose, unless adjustment was needed, for a total treatment time of 12 weeks.
3167480|NCT01429038|Experimental|MSC Liver Transplantation|Patients undergoing a first liver transplantation. Beside receiving standard liver tranplantation care (antibacterial and viral prophylactic treatments as well as a standard immunosuppressive regime i.e. tacrolimus, mycophenolate mofetil and steroids), patients will be infused with 1,5-3,0 10E6 MSC/kg on postoperative day 3+/-2
3167481|NCT01429038|Experimental|MSC Kidney Transplantation|Patients undergoing a first kidney transplantation. Beside receiving standard kidney tranplantation care (antibacterial and viral prophylactic treatments as well as a standard immunosuppressive regime i.e. tacrolimus, mycophenolate mofetil and steroids associated with ant-IL-2 antibodies), patients will be infused with 1,5-3,0 10E6 MSC/kg on postoperative day 3+/-2.
3167482|NCT01429025|Experimental|rituximab, bendamustine and lenalidomide|Patients receive rituximab IV on day 1, bendamustine IV on days 1-2, and lenalidomide PO on days 1-10. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3167483|NCT01429012|Experimental|Mesenchymal Stem Cells|"2 ml with 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion space of the bone fracture.~MSC will be injected even if the number of available cells is lower than 40 X 10E6.~The injection of MSC in the nonunion space will be performed percutaneously using a 3-mm trephine needle under fluoroscopic control and loco-regional or general anesthesia, as deemed appropriate by the anesthetist."
3167484|NCT01429012|Placebo Comparator|Culture medium without MSC.|Culture medium used to resuspend the Mesenchymal Stem Cells.
3167485|NCT01428999|Experimental|probiotics|1 pack bid use for 3 weeks
3167486|NCT01428999|Placebo Comparator|Placebo|placebo 1pack bid for 3 weeks
3167487|NCT01428986||Maraviroc|Those whose take maraviroc as a part of their HIV treatment
3167488|NCT01428986||No maraviroc|Those who do not take maraviroc
3167489|NCT01428973|Active Comparator|Arm 1|GVHD prophylaxis: Mycophenolate mofetil (MMF) orally from the evening of day 0 through day 28 (sibling recipients) or day 42 (alternative donor recipients) at the dose of 15 mg/kg t.i.d. Tacrolimus (Tac)given orally at the dose of 0.06 mg/kg bid starting on day -3. The dose adapted according to through whole blood values following standard procedures (between 10 and 15 ng/ml the first 28 days and between 5-10 ng/ml thereafter). Full doses given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
3167539|NCT01428661|Placebo Comparator|placebo|
3168255|NCT01423604|Experimental|Capecitabine and ruxolitinib|
3167490|NCT01428973|Experimental|Arm 2|GVHD prophylaxis: Tacrolimus, orally (0.06 mg/kg) bid starting on day -3. The dose adapted between 5-10 ng/ml. Full doses until day 60 (sibling recipients) or day 100 (alternative donor recipients). Doses tapered to be definitely discontinued by day 100 (sibling donors) or 180 (alternative donor recipients) in the absence of GVHD. Sirolimus 6 mg loading dose on day −3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD
3167491|NCT01428960|Experimental|Palm Mid Fraction|
3167492|NCT01428960|Experimental|Shea Butter|
3167493|NCT01428960|Experimental|High Oleic Sunflower Oil|
3167494|NCT01428947||Coronary angiography|Patents scheduled for elective coronary angiography
3167495|NCT01428934||Intermediate risk population|Population aged between 35 to 74 years who have an intermediate cardiovascular risk, defined as coronary risk between 5% -15% at 10 years according to the Framingham adapted risk equation or vascular mortality risk between 3-5% at 10 years according to the SCORE equation [27].
3167496|NCT01428921|Experimental|Extended Education|"Standard education programme as described above,~Plus~Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration~Follow-up phone call would be arranged within 1 week after using CPAP.~Video, slides and booklets would be used as education media."
3167497|NCT01428921|No Intervention|Standard education|- Each subject will receive advice from Sleep Lab staff on the need for CPAP treatment, and the care of CPAP device and mask.
3167498|NCT01428908|Experimental|children group A|600 children aged 2-5 years old, will be vaccinated on day0
3167499|NCT01428908|Experimental|infants group A|600 infants aged 6-23 months old, will be vaccinated on day0, 28
3167500|NCT01428908|Active Comparator|children group B|600 children aged 2-5 years old, will be vaccinated on day0
3167501|NCT01428908|Active Comparator|infants group B|600 infants aged 6-23 months old, will be vaccinated on day0, 28
3167502|NCT01428895|Active Comparator|Surgery Alone|
3167503|NCT01428895|Active Comparator|Surgery + Radiation Therapy|
3167504|NCT01428882|Active Comparator|Midazolam balanced propofol sedation|2 mg midazolam in 2 ml saline midazolam followed by continuous propofol iv infusion
3167505|NCT01428882|Placebo Comparator|Single-agent propofol sedation|2 ml saline followed by continuous propofol iv infusion
3167506|NCT01428869||statin+ASA+dutasteride|
3167507|NCT01428869||statin+ASA|
3167508|NCT01428869||dutasteride+statin|
3167509|NCT01428869||dutasteride+ASA|
3167510|NCT01428843|Active Comparator|Ferrisat|Infusion of Ferrisat (50mg/ml) at inclusion under usual practices
3167511|NCT01428843|Placebo Comparator|Placebo|Infusion of placebo at inclusion visit
3167512|NCT01428830|Experimental|7-day catheterization|
3167513|NCT01428830|Active Comparator|14-day catheterization|
3167514|NCT01428817|Active Comparator|Carbetocin 20mcg|
3167515|NCT01428817|Active Comparator|Carbetocin 40mcg|
3167516|NCT01428817|Active Comparator|Carbetocin 60mcg|
3167517|NCT01428817|Active Comparator|Carbetocin 80mcg|
3167518|NCT01428817|Active Comparator|Carbetocin 100mcg|
3167519|NCT01428804|Active Comparator|active tDCS|a group named G1 and treated by medication with escitalopram (Seroplex®) stabilized for at least 1 month and 10 sessions of tDCS anode active at 2 sessions per day (1 morning and 1 afternoon) for 5 days with an electric current 2 mA
3167520|NCT01428804|Sham Comparator|sham tDCS|a group named G2 and treated by medication with escitalopram (Seroplex®) stabilized for at least 1 month and sham tDCS.
3167521|NCT01428791|Active Comparator|Generations older adult member program|Rush Generations is a membership program for older adults, providing chronic disease prevention and management through educational programming, civic engagement, and individual and family consultations with social work staff.
3167522|NCT01428791|Experimental|BRIGHTEN Heart Virtual Team|BRIGHTEN Heart provides older adults with an interdisciplinary team evaluation of physical and mental health and on-going support for mental health and health behavior change for a minimum of six months. The five core components of the BRIGHTEN intervention consist of: 1) Assessment; 2) Virtual team case review; 3) Patient centered action planning; 4) Plan implementation, and; 5) When indicated, short-term evidence-based geriatric specialty psychotherapy.
3167523|NCT01428752||Family history|30- to 49-year-old asymptomatic subjects with a first relative history of colorectal cancer
3167524|NCT01428726|Placebo Comparator|Placebo|
3167525|NCT01428726|Experimental|NT-KO-003 low dose|
3167526|NCT01428726|Experimental|NT-KO-003 high dose|
3167527|NCT01428713|Active Comparator|Group A-Oral tranexamic acid|Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
3167528|NCT01428713|Active Comparator|Group B-Combined oral contraceptive pills|Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
3167529|NCT01428700||Non-Immune/Non-Viral (NINV)|Patients enrolled in ITN030ST transplanted for liver failure resulting from non-viral, non-immune causes
3167530|NCT01428700||Hepatitis C Virus (HCV) positive|Patients enrolled in ITN030ST transplanted for liver failure resulting from HCV genotype 1 infection
3167531|NCT01428687|Active Comparator|Increase Sleep Gradually|Subjects in this condition are taught to increase their sleep by 30 minutes per night during week 1 of the intervention; 60 minutes during week 2; and 90 minutes during week 3. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
3167532|NCT01428687|Active Comparator|Increase Sleep Immediately|Subjects in this condition are taught to increase their sleep by 90 minutes per night starting in week 1. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
3167533|NCT01428687|Active Comparator|No Intervention: Control Group|This group is told to make no changes in their sleep habits. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
3167534|NCT01428674|Experimental|10 minutes reading|
3167535|NCT01428674|Experimental|20 minutes touch|
3167536|NCT01428674|Experimental|20 minutes reading|
3167540|NCT01428648|Active Comparator|intervention|group of patients receiving ballroom dancing classes
3167541|NCT01428648|No Intervention|control|group of patients who will not receive dancing classes.
3167542|NCT01428635|Experimental|Eltrombopag|Starting dose 50 mg by mouth daily. Dose escalation allowed every 2 weeks to 100 mg, 150 mg, 200 mg and 300 mg according to platelet response (except for patients of East Asian ancestry who receive starting dose of 25 mg daily with dose escalation allowed every two weeks to 50 mg). Treatment cycle defined as daily continuous dosing.
3167543|NCT01428622|Placebo Comparator|Placebo + BI 54903|"patient to receive 2 puffs of respimat A and 2 puffs of respimat B"
3167544|NCT01428622|Experimental|Olodaterol low dose + BI54903|"patient to receive 2 puffs of respimat A and 2 puffs of respimat B"
3167545|NCT01428622|Active Comparator|Olodaterol medium dose + BI54903|patient to receive 2 puffs of each device
3167546|NCT01428622|Experimental|Olodaterol high dose + BI54903|patient to receive 2 puffs of each device
3167547|NCT01428622|Experimental|Olodaterol l dose + BI54903|patient to receive 2 puffs of each device
3167548|NCT01428622|Experimental|Olodaterol m dose + BI54903|patient to receive 2 puffs of each device
3167549|NCT01428622|Experimental|Olodaterol h dose + BI54903|patient to receive 2 puffs of each device
3167550|NCT01428596|Experimental|Arm I|Lower dose HIVAX vaccine
3167551|NCT01428596|Placebo Comparator|Arm II|lower dose, placebo control
3167552|NCT01428596|Experimental|Arm III|Higher dose HIVAX vaccine
3167553|NCT01428583|Experimental|oxycodone HCl and naltrexone HCl extended-release capsules|
3167554|NCT01428570|Experimental|Pentax-AWS|Patients in this group will be intubated using Pentax-AWS
3167555|NCT01428570|Active Comparator|laryngoscopy|Patients in this group will be intubated using Macintosh laryngoscope.
3167556|NCT01428557||Heart Failure patients|Patients admitted with clinical diagnosis of decompensate heart failure, > 18 years old.
3167557|NCT01428544||Patients with VTE treated with fondaparinux|Patients with VTE treated with fondaparinux
3167558|NCT01428531||Patients prescribed fondaparinux|
3167559|NCT01428518||Patients with bipolar disorder|Patients with bipolar disorder prescribed lamotrigine tablets for the first time
3167560|NCT01428505|Other|no treatment|
3167561|NCT01428492|Experimental|Part 1-Dose Escalation|GSK2110183 is administered in combination with bortezomib and dexamethasone until MTD is met.
3167562|NCT01428492|Experimental|Part 2- Pharmacokinetic/Pharmacodynamics Cohort|Once the MTD(s) has been determined, up to 9 subjects of the total enrolled in Part 2 will be entered in the Pharmacokinetic/Pharmacodynamic Cohort. Subjects will be enrolled in this cohort to explore whether exposure to GSK2110183 at dose identified in Part 1 is similar when GSK2110183 is administered alone or in combination with bortezomib and dexamethasone. The same relationship will be explored for bortezomib and dexamethasone when the two drugs are give alone or in combination with GSK2110183.
3167563|NCT01428492|Experimental|Part 2- Safety/Clinical Activity Cohort|"Enrolment into the safety/clinical activity cohort in Part 2 will begin prior to enrollment in the PK/PD cohort. Subjects with relapsed multiple myeloma who are either bortezomib sensitive or naive after failing one line of prior systemic therapy will be enrolled in the Safety/Clinical Activity cohort. Bortezomib sensitive is defined as having a response (PR or better) to the last bortezomib-containing therapy lasting at least 60 days beyond the end of therapy. A minimum of 15 subjects and a total of 40 subjects will be enrolled. This expansion cohort will further characterize the safety and clinical activity profile of GSK2110183 to inform the future development of this combination regimen."
3167564|NCT01428479|Experimental|Treatment Arm A|In Arm A subjects will receive 100 mg of GR121167 in Period 1 and 300 mg of GR121167 in Period 2. In Period 3 subject will receive single doses of placebo on Day 1 and multiple doses of placebo from Day 3 to Day 8
3167565|NCT01428479|Experimental|Treatment Arm B|In Arm B subjects will receive 100 mg of GR121167 in Period 1 and placebo in Period 2. In Period 3 subject will receive 600 mg of GR121167 as single dose on Day 1 and multiple doses of GR121167 from Day 3 to Day8
3167566|NCT01428479|Experimental|Treatment Arm C|In Arm C subjects will receive placebo in Period 1, 300 mg of GR121167 in Period 2. In period 3 subject will receive 600 mg of GR121167 single dose on Day 1 and multiple doses from Day 3 to Day 8
3167567|NCT01428466|Experimental|GSK2585823|external preparation
3167568|NCT01428466|Active Comparator|Benzoic peroxide 3%|external preparation
3167569|NCT01428466|Active Comparator|Benzoic peroxide 5%|external preparation
3167570|NCT01428466|Placebo Comparator|Vehicle|external preparation
3167571|NCT01428453|Experimental|250mg rilapladib|Experimental drug
3167572|NCT01428453|Placebo Comparator|placebo|Placebo comparator
3167573|NCT01428440|Other|no treatment|
3167574|NCT01428427|Experimental|Cohort|Dose escalation to maximum tolerated dose of GSK1120212 and Gemcitabine.
3167575|NCT01428414|Active Comparator|Trastuzumab+ Carboplatin+Paclitaxel|Neoadjuvant treatment regimen:Trastuzumab,Carboplatin,Paclitaxel
3167576|NCT01428414|Active Comparator|Trastuzumab+Epirubicin+Paclitaxel|Neoadjuvant treatment regimen:Trastuzumab,Epirubicin,Paclitaxel
3167577|NCT01428401|Experimental|Arm A|
3167578|NCT01428401|Placebo Comparator|Arm B|
3167579|NCT01428388|Active Comparator|Bevacizumab|
3167580|NCT01428388|Active Comparator|Ranibizumab|
3167581|NCT01428375|Active Comparator|(1) Active (Paracetamol) arm: n=60|(Paracetamol)
3167582|NCT01428375|Placebo Comparator|(2) Placbo (Sterile water) arm: n=60|Sterile water
3167583|NCT01428362|Experimental|Placebo/VI-1121|Subjects received placebo during first treatment period and active treatment with VI-1121 during the second treatment period.
3167584|NCT01428362|Experimental|VI-1121/Placebo|Subjects received active treatment with VI-1121 during the first treatment period and placebo during the second treatment period.
3167585|NCT01428349|Experimental|Attention to Context|
3167586|NCT01428349|Experimental|Affective Cognitive Control|
3167587|NCT01428336|Active Comparator|Patients|Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test
3167588|NCT01428336|Active Comparator|Volunteers|Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test
3167589|NCT01428310|Active Comparator|Anatabloc(TM)|dissolvable bit containing dietary ingredients, binders, fillers, and flavors
3167590|NCT01428310|Active Comparator|CigRx(R)|dissolvable bit containing dietary ingredients, binders, fillers, and flavors
3167591|NCT01428297|Experimental|Cohort A and B, BPR277 and Placebo (vehicle)|
3167592|NCT01428297|Experimental|Part 2 BPR277|
3167593|NCT01428297|Placebo Comparator|Part 2 Placebo (vehicle)|
3167594|NCT01428297|Experimental|Part 3 BPR277 and Placebo (vehicle)|
3167595|NCT01428284|Experimental|001|Canagliflozin/Probenecid
3167596|NCT01428271||Herniorrhapy with caudal block|Children aged 0-72 months who are scheduled to undergo elective inguinal herniorrhapy under general anesthesia with caudal block
3167597|NCT01428258|Experimental|GMP Diet/GMP Medical Foods|The experimental intervention is the GMP diet followed at home for 3-wk. In this randomized crossover study, half of subjects (n=15) were randomized to receive the GMP diet as the first arm, and half of the subjects (n=15) were randomized to receive the GMP diet as the second arm.
3167598|NCT01428258|Active Comparator|AA Diet/AA Medical Foods|The experimental intervention is the AA diet followed at home for 3-wk. In this randomized crossover study, half of subjects (n=15) were randomized to receive the AA diet as the first arm, and half of the subjects (n=15) were randomized to receive the AA diet as the second arm.
3167599|NCT01428245|Experimental|Progesterone, estrace|"oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr to achieve mean plasma concentrations over the range of 2-8 ng/ml for seven days~oral estrace, 0.5-1 mg once a day for seven days"
3167600|NCT01428232|Experimental|BFHI steps 1-9|Hospital retrained in BFHI steps 1-9 Mothers can call hospital to obtain BF support/Mothers given phone # of maternity nurse whom she can call or go see if she has BF problems
3167601|NCT01428232|Experimental|BFHI steps 1-9 +well-child clinic|Hospital retrained in BFHI steps 1-9 Mothers can call hospital to obtain BF support/Mothers given phone # of maternity nurse whom she can call or go see if she has BF problems Provision of BF support during 1) clinic visit to obtain birth certificate or home visit if mother does not come into clinic and 2) well-child clinics Flyers to mother with culturally appropriate messages designed to address some of the most important local barrier to EBF
3167602|NCT01428232|No Intervention|usual care|
3167603|NCT01428219|Experimental|Cabozantinib (XL184)|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
3167604|NCT01428206|Other|Liverpool care pathway|Liverpool care pathway for dying at nursing homes
3167605|NCT01428206|No Intervention|control|Usual care is performed for the control group
3167606|NCT01428193|Experimental|Flutamide, estrace, progesterone|"For flutamide, subjects weighing > 50 kg will receive 250 mg orally twice a day, and subjects weighing < 50 kg will receive 125 mg orally twice a day for approximately 3 weeks.~Subjects will be given oral estrace, 0.5-1 mg once a day for 7 days following the first overnight study admission.~Subjects will be given oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days following the first overnight study admission."
3167607|NCT01428180||Indomethacin|Infants treated with Indomethacin
3167608|NCT01428180||Ibuprofen|Infants treated with Ibuprofen
3167609|NCT01428180||Ligation|Infants undergoing surgical ligation
3167610|NCT01428167||Thyroidectomy|All patients undergoing thyroidectomy for a variety of indications.
3167611|NCT01428154|Experimental|Darbepoetin alfa|
3167612|NCT01428141|Experimental|E7050|
3167613|NCT01428128|Experimental|Arsenic Trioxide|
3167614|NCT01428115||Patients with severe active Crohn's disease|Patients with severe active Crohn's disease for whom adalimumab was prescribed in the usual manner in accordance with the terms of the local marketing authorization.
3167615|NCT01428102||RapidTEG|Samples tested with TEG which are both citrated and non-citrated and are activated using the reagent RapidTEG.
3167616|NCT01428102||Kaolin|Samples tested with TEG which are both citrated and non-citrated and are activated using the reagent Kaolin.
3167617|NCT01428089|Experimental|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml)
3167618|NCT01428089|Placebo Comparator|placebo|placebo at 1100, 1500, and 1900 h.
3167619|NCT01428076|Experimental|High Dose Polidocanol Endovenous Microfoam|
3167620|NCT01428076|Experimental|Medium Dose Polidocanol Endovenous Microfoam|
3167621|NCT01428063|Experimental|Daclatasvir + Asunaprevir + PegIFNα-2a + Ribavirin|Patients received daclatasvir, 60-mg tablet, by mouth once daily + asunaprevir, 100-mg capsule or 200-mg tablet, by mouth twice daily + pegIFNα-2a, 180-μg solution, subcutaneously weekly + ribavirin, weight-based dosing (<75 kg=1000 mg once daily; >=75 kg=1200 mg once daily) for 24 weeks
3167622|NCT01428063|Experimental|Daclatasvir + PegIFNα-2a + Ribavirin|Patients received daclatasvir, (two 30-mg tablets or one 60-mg tablet, by mouth once daily) + pegIFNα-2a, 180-μg solution, subcutaneously weekly + ribavirin, weight-based dosing (<75 kg=1000 mg once daily; >=75 kg=1200 mg once daily) for 24 weeks
3167623|NCT01428063|Experimental|Daclatasvir + Asunaprevir|Patients received daclatasvir, 60-mg tablet, by mouth once daily + asunaprevir, 100-mg capsule, by mouth twice daily for 24 weeks
3167624|NCT01428050|Experimental|3% saline|Patients will received 3% saline in conjunction with lactated ringers solution intra and post operatively for a net reduction in total fluid administration
3167625|NCT01428050|Active Comparator|Lactated Ringers|15cc/kg/hr of lactated ringers solution intraoperatively
3167626|NCT01428037|Experimental|Misoprostol Vagianl Tablet|Misoprostol Vaginal Tablet 25 mcg.
3167627|NCT01428037|Placebo Comparator|Placebo|Tablet without active ingredient
3167628|NCT01428024|Other|Restylane LipVolume and Restylane Lip Refresh|Open label
3167629|NCT01428011||No treatment|African American/Black and Caucasian/White patients with hypertension
3167671|NCT01427686|Active Comparator|Dobutamine|Start Dobutamine. If no success switch to Dopamine.
3167630|NCT01427998|Active Comparator|olive leaf extract|Olive leaf polyphenol concentrate (OLPC) extraction OLPC was prepared from olive leaves as follows (Zaslave et al, 2005) : The leaves were randomly picked from the Barnea cultivar in the Jezreel Valley region of Israel and immediately freeze-dried on dry ice. After the leaves were thoroughly rinsed with sterile distilled water to remove dust, insecticides, and contaminating material, the leaves were ground and successively Soxhlet extracted with hexane for 3 h and 80% aqueous ethanol for 6 h. The alcoholic extract was concentrated under reduced pressure at 25 °C, and reconstituted with 30% ethanol in water.
3167631|NCT01427998|Placebo Comparator|placebo|matched placebo
3167632|NCT01427985|Experimental|Relaxation followed by analgosedation|Give Atropin, then Mivacurium, immediately followed by Fentanyl
3167633|NCT01427985|Active Comparator|Analgosedation followed by Relaxation|Give atropin, then Fentanyl, then Mivacurium
3167634|NCT01427972|Experimental|0.2 mg LY2623091|Daily by mouth for 21 days. Day 1 - 20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
3167635|NCT01427972|Experimental|1.5 mg LY2623091|Daily by mouth for 21 days. Day 1 - 20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
3167636|NCT01427972|Experimental|10 mg LY2623091|Daily by mouth for 21 days. Day 1 - 20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
3167637|NCT01427972|Active Comparator|50 mg Eplerenone|Daily by mouth for 21 days. Day 1 - 20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
3167638|NCT01427946|Experimental|Retaspimycin HCl (IPI-504) and Everolimus|Retaspimycin HCl (IPI-504) and everolimus will be administered on a 21-day cycle. All patients will remain on study until progression of disease or intolerability to study treatments occurs.
3167639|NCT01427933|Experimental|Ramucirumab and Eribulin|"Ramucirumab 10 milligrams/kilogram (mg/kg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle~Eribulin 1.4 milligrams/square meter (mg/m²) administered by IV bolus on Day 1 and Day 8 of each 3-week cycle"
3167640|NCT01427933|Active Comparator|Eribulin Monotherapy|Eribulin 1.4 mg/m² administered by IV bolus on Day 1 and Day 8 of each 3-week cycle
3167641|NCT01427920|Experimental|Subject-driven titration BIAsp 30 (BID) + metformin|The subjects performed the titration of BIAsp 30 dose.
3167642|NCT01427920|Active Comparator|Investigator-driven titration BIAsp 30 (BID) + metformin|The investigator performed the titration of BIAsp 30 dose.
3167643|NCT01427907|Experimental|Phoslyra - Calcium Acetate Oral Solution|The investigational compound is calcium acetate oral solution (COS) or Phoslyra. It is a pale, light greenish-yellow clear liquid with a characteristic black cherry odor and flavor for oral ingestion. Each 5 mL of COS contains 667 mg calcium acetate equal to 169 mg of elemental calcium. Each subject will follow their usual prescription.COS will be taken either prior to or during meals and snacks.
3167644|NCT01427907|Active Comparator|Sevelamer Carbonate|Sevelamer carbonate is an anion exchange resin that binds phosphate in the gastrointestinal tract and is a buffered form of sevelamer hydrochloride developed for the treatment of hyperphosphatemia in End-Stage Renal Disease (ESRD) patients. Each film-coated tablet of sevelamer carbonate (trade name Renvela™) contains 800 mg of sevelamer carbonate on an anhydrous basis. Subjects will receive sevelamer tablets according to their prescription.
3167645|NCT01427894|Experimental|Maternal Singing|Maternal singing during Kangaroo Care of stable preterm infants
3167646|NCT01427894|No Intervention|Kangaroo Care|Kangaroo Care without singing
3167647|NCT01427881|Experimental|Treatment (TBI, PBSCT, and cyclophosphamide GVHD prophylaxis)|"PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126."
3167648|NCT01427868|Experimental|LB80380 maleat salt|
3167649|NCT01427868|Active Comparator|LB80380 free base|
3167650|NCT01427855|Experimental|High Saturated Fat Red Meat Diet|
3167651|NCT01427855|Experimental|High Saturated Fat White Meat Diet|
3167652|NCT01427855|Experimental|High Saturated Fat Non-Meat Diet|
3167653|NCT01427855|Experimental|Low Saturated Fat Red Meat Diet|
3167654|NCT01427855|Experimental|Low Saturated Fat White Meat Diet|
3167655|NCT01427855|Experimental|Low Saturated Fat Non-Meat Diet|
3167656|NCT01427842|Experimental|DEVINE vancomycin regimen|This is the intervention arm and will be the pharmacokinetically derived vancomycin dosing regimen.
3167657|NCT01427829|Experimental|Intervention (CaPRA)|
3167658|NCT01427829|No Intervention|Control (usual care)|
3167659|NCT01427816|Experimental|KCT-0809 ophthalmic solution, low dose|
3167660|NCT01427816|Experimental|KCT-0809 ophthalmic solution, high dose|
3167661|NCT01427816|Placebo Comparator|Placebo|
3167662|NCT01427803|Experimental|Arm 1|
3167663|NCT01427777||HPV Vaccine|People that receive HPV vaccine in V501-030
3167664|NCT01427751|Active Comparator|Ozurdex®|Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
3167665|NCT01427751|Active Comparator|Lucentis®|Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
3167666|NCT01427738|Experimental|Arm A: Topical GV solution|Topical GV 0.00165% solution (5 mL swish and gargle for 1 minute and expectorate [spit] 2 times per day [BID]) for 14 days
3167667|NCT01427738|Active Comparator|Arm B: Nystatin oral suspension|Nystatin oral suspension (5 mL of 100,000 units/mL swish for 1 minute and swallow 4 times per day [QID]) for 14 days
3167668|NCT01427725||LipaCreon|those with an exposure
3167669|NCT01427712||LipaCreon|those with an exposure
3167670|NCT01427699|Experimental|T2-18C3 therapeutic antibody|9 subjects will receive the T2-18C3 therapeutic antibody.
3167672|NCT01427686|Active Comparator|Dopamine|Start Dopamine. If no success switch to Dobutamine.
3167673|NCT01427673|Active Comparator|CPAP Procedure control group|Overlap patients randomly assigned to the CPAP titrated per AASM guidelines.
3167674|NCT01427673|Experimental|Bipap procedure group|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
3167675|NCT01427660|Active Comparator|Traditional CERSG Arm|CHWs will provide and review with patients language-appropriate versions of the AHRQ consumer guides. CHWs will highlight key points on each page, review information on each medication and elicit and address questions. They will use the autonomy enhancing, motivational-interviewing based skills. As with the first arm, CHWs will schedule follow-up clinic appointments for participants who note a specific treatment change they would consider and will call participants two times after the session at three and six weeks to address additional questions and to follow up on any goals the participant set.
3167676|NCT01427660|Experimental|Web-Based Materials Arm|Participants randomized to this arm will be scheduled within 3 weeks of enrollment to have a one-hour face-to-face session with a CHW who will deliver the ipad platform personally tailored diabetes medication decision aid. Participants will receive a printed tailored preference summary at the completion of this visit. If participants note a specific treatment change they would like to discuss with their providers, the CHW will facilitate scheduling a clinic visit within the next month. Finally, CHWs will call participants two times after the session at 3 and 6 weeks to assess if the participant has additional questions and to follow up on any treatment or other goals the participant set during their session.
3167677|NCT01427647|Active Comparator|Control group|Control group: open surgery under general anesthesia
3167678|NCT01427647|Active Comparator|Epidural group|Epidural group: Open surgery under thoracic epidural anesthesia
3167679|NCT01427647|Active Comparator|Laparoscopic group|Laparoscopic group: Laparoscopic surgery under general anesthesia
3167680|NCT01427634|Active Comparator|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
3167681|NCT01427634|Other|Control|Usual Care
3167682|NCT01427621|Experimental|RIPCcom group|
3167683|NCT01427621|No Intervention|Control group|
3167684|NCT01427608|Active Comparator|Olanzapine|Olanzapine 15mg/day plus sertraline 150mg/day. Fluctuations in dosing are allowed up to a maximum of olanzapine 20mg/day, sertraline 200mg/day.
3167685|NCT01427608|Placebo Comparator|Placebo|Placebo will be used to taper the olanzapine over a period of four weeks and then substitute for the olanzapine for the remainder of the 36 week study.
3167686|NCT01427595|Experimental|Metformin, progesterone , estrace|12 weeks Metformin oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days (2X) oral estrace, 0.5-1 mg once a day for seven days (2X)
3167687|NCT01427569|Experimental|IZN-6D4 Gel|patients in this arm will be treated by twice a week bandaging the wound with active IZN-6D4 Gel
3167688|NCT01427569|Placebo Comparator|Placebo Hydrogel|patients in this arm will be treated by twice a week bandaging the wound with a hydrogel used for wound care, but without the active IZN-6D4
3167689|NCT01427556||Breakfast Eaters|Women who self-report eating breakfast regularly.
3167690|NCT01427556||Non-Breakfast Eaters|Women who self-report skipping breakfast regularly.
3167691|NCT01427543|Experimental|MILE group sessions|Participants will attend 6 - 2 hour long, interactive, culturally congruent, group sessions that address knowledge, beliefs, attitudes, and skills related to reducing HIV risk behaviors.
3167692|NCT01427543|No Intervention|Control|These subjects will be provided with access to post-incarcerations services that will be provided by the Center for Health Justice.
3167693|NCT01427517|Experimental|NAC in PD|single intravenous administration of N-acetylcysteine in PD patients
3167694|NCT01427517|Experimental|NAC in GD|single intravenous administration of N-acetylcysteine in GD patients
3167695|NCT01427517|Experimental|NAC in controls|single intravenous administration of N-acetylcysteine in control subjects
3167696|NCT01427504|Experimental|Sequence 1a|Sequence 1,2,3: boceprevir only, then etravirine only, then both boceprevir and etravirine.
3167697|NCT01427504|Experimental|Sequence 1b|Sequence 1,3,2: boceprevir only, then both boceprevir and etravirine, then etravirine only.
3167698|NCT01427504|Experimental|Sequence 2a|Sequence 2,1,3: etravirine only, then boceprevir only, then both boceprevir and etravirine.
3167699|NCT01427504|Experimental|Sequence 2b|Sequence 2,3,1: etravirine only, then both boceprevir and etravirine, then boceprevir only.
3167700|NCT01427504|Experimental|Sequence 3a|Sequence 3,1,2: both boceprevir and etravirine, then boceprevir only, then etravirine only.
3167701|NCT01427504|Experimental|Sequence 3b|Sequence 3,2,1: Both boceprevir and etravirine, then etravirine only, then boceprevir only.
3167702|NCT01427491|Active Comparator|Aquacel® Ag|
3167703|NCT01427491|Active Comparator|Mepilex® Border Ag|
3167704|NCT01427478|Experimental|AFATINIB|Radiotherapy combined with a chemotherapy by Cisplatin IV at the dose of 100mg/m2 every 3 weeks, followed by a maintenance therapy with BIBW 2992 for 1 year at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
3167705|NCT01427478|Placebo Comparator|PLACEBO|Radiotherapy associated with a chemotherapy by Cisplatin IV at the dose of 100mg/m2 every 3 weeks, followed by a maintenance therapy with placebo of BIBW 2992 for 1 year at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
3167706|NCT01427465|Experimental|Consult|Consult
3167707|NCT01427465|Experimental|Newsletter|Newsletter
3167708|NCT01427465|Experimental|Parent Letter|Parent Letter
3167709|NCT01427465|Active Comparator|Control|Control
3167710|NCT01427452||Living Kidney Donor, Transplant Recipient, Healthy Control|Living kidney donors and their transplant recipient will be enrolled. Also, a smaller cohort of healthy controls (potential donors who were medically suitable but not used) will be enrolled.
3167711|NCT01427439||Major Depressive Disorder|
3167712|NCT01427426|Experimental|All Greens|Subjects will consume the All Greens product daily. Product is prepared by mixing with either water, juice or in a smoothie.
3167713|NCT01427426|Sham Comparator|Control formulation|Subjects will consume a product of similar consistency and comparable taste that does not have the same healthy ingredients as the All Greens.
3167714|NCT01427413||Hyper1|Only patients who achieved hyperstimulation pathology after external administration of gonadotrophin during IVF treatment
3167715|NCT01427400|Experimental|Expander Placement, Botulinum Toxin-A|During surgery, administered only once, 5 cc in 5 different locations on chest muscle.
3167716|NCT01427400|Placebo Comparator|Tissue expander Placement WITH Saline|During surgery, administered only once, 5 cc in 5 different locations on chest muscle.
3167717|NCT01427387|Experimental|Part-1 ASP group|ASP0456 receiving group
3167718|NCT01427387|Placebo Comparator|Part-1 Placebo group|Placebo treatment
3167719|NCT01427387|Experimental|Part-2 group|cross-over study group to evaluate food effect on ASP0456 plasma concentration
3167720|NCT01427348|Experimental|with assistant|head extension by an assistant during direct laryngoscopy
3167721|NCT01427348|Active Comparator|without assistant|without the help of an assistant during direct laryngoscopy
3167722|NCT01427335|Placebo Comparator|saline|0.9% saline intravenous infusion
3167723|NCT01427335|Experimental|calcium|Calcium intravenous infusion
3167724|NCT01427322|Experimental|lapatinib + radiation therapy|lapatinib given orally 2-4 hours prior to first fraction of radiation
3167725|NCT01427322|Active Comparator|No therapy prior to radiation|Radiation therapy alone
3167726|NCT01427309|Experimental|High Dose Trivalent Inactivated Influenza Vaccine|Participants will receive an injection of High Dose Trivalent Inactivated Influenza Vaccine
3167727|NCT01427309|Active Comparator|Trivalent Inactivated Influenza Vaccine|Participants will receive an injection of the Trivalent Inactivated Influenza vaccine
3167728|NCT01427296|Active Comparator|OsmoPrep Tablets|
3167729|NCT01427296|Active Comparator|HalfLytely and Bisacodyl Tablet|
3167730|NCT01427283|Experimental|OXN|Oxycodone/Naloxone controlled-release tablets (OXN)
3167731|NCT01427283|Active Comparator|OXY|Oxycodone HCl controlled-release tablets (OXY)
3167732|NCT01427283|Placebo Comparator|Placebo|Placebo tablets to match OXN or OXY
3167733|NCT01427270|Experimental|OXN|Oxycodone/Naloxone controlled-release tablets (OXN)
3167734|NCT01427270|Active Comparator|OXY|Oxycodone HCl controlled-release tablets (OXY)
3167735|NCT01427270|Placebo Comparator|Placebo|Placebo tablets to match OXN or OXY
3167736|NCT01427257|Active Comparator|PB1023 Formulation A|
3167737|NCT01427257|Active Comparator|PB1023 Formulation B|
3167738|NCT01427257|Active Comparator|PB1023 Formulation B (2-8C)|
3167739|NCT01427244|Experimental|Trastuzumab|Open Label
3167740|NCT01427231|Active Comparator|Drink with 50 g glucose|The glucose drink contains 50 g of glucose soluted in 250 ml of water and lemon juice.
3167741|NCT01427231|Active Comparator|Drink with 100 gram of sacharose|The sacharose drink contains 100 g of sacharose soluted in 250 ml of water and lemon juice.
3167742|NCT01427231|Placebo Comparator|Placebo with sweeteners|The placebo contains a mixture of artificial sweeteners in order to have the same sweetness and appearance of the test drinks (the glucose drink and the sacharose drink).
3167743|NCT01427218|Experimental|Medication Therapy Management (MTM)|Medication Therapy Management visits with a pharmacotherapist will occur at a minimum of 6-9 weeks, 20-24 weeks, and 28-32 weeks. Additional interim face to face and telephonic visits may be scheduled based on patient's progress with meeting treatment goals and need for follow-up physical assessment and laboratory analysis.
3167744|NCT01427218|Placebo Comparator|Usual Care|Visits with a pharmacotherapist to create an accurate list of medications for those patients randomized to placebo (who receive usual care by their cardiologist and primary care provider).
3167745|NCT01427205|Experimental|Group A: Cetuximab + OSI-906|Cetuximab loading dose of 400 mg/m2 by vein (IV) then 250 mg/m2 weekly + OSI-906 150 mg orally twice a day. 21-Day Cycle.
3167746|NCT01427205|Experimental|Group B: Cetuximab + Placebo|Cetuximab loading dose of 400 mg/m2 by vein (IV) then 250 mg/m2 weekly + Placebo orally twice a day. 21-Day Cycle.
3167747|NCT01427192|Experimental|acetazolamide|1 week therapy, cross-over design
3167748|NCT01427192|Placebo Comparator|Placebo tablet|One week, cross-over design
3167749|NCT01427192|Experimental|supplemental oxygen during nights|One week, cross-over design
3167750|NCT01427192|Experimental|Non-invasive ventilation|One week, cross-over design
3167751|NCT01427192|Sham Comparator|room air|room air applied via sham-oxygen-concentrator
3167752|NCT01427166|Experimental|Ultrasound imaging|Cords that are present in the participant's axilla and/or arm will be imaged with an ultrasound
3167753|NCT01427153|Active Comparator|Corticosteroid|Corticosteroid injection
3167754|NCT01427153|Active Comparator|Orthopaedic Manual Physical Therapy|OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
3167755|NCT01427140|Active Comparator|Saturated fatty acid group|Addition of saturated fatty acids to the diet inte the form of pastries
3167756|NCT01427140|Active Comparator|Polyunsaturated fatty acid group|Addition of polyunsaturated fatty acids to the diet in the form of pastries
3167757|NCT01427127|Experimental|ramosetron|Patients received intravenous ramosetron 0.3 mg at the end of surgery and 24hr after surgery.
3167758|NCT01427127|Placebo Comparator|Normal saline|Patients received intravenous normal saline at end of surgery and 24hr after surgery.
3167759|NCT01427114|Experimental|R-CVP|6 cycles of R-CVP followed by 2 cycles of rituximab
3167760|NCT01427088|Experimental|repetitive TMS|repetitive TMS is a quantified stimulation method of specifie area of brain, for which CR Technology, TAMAS for repetitive TMS was used.
3167761|NCT01427075|Experimental|lateral pharyngoplasty|lateral pharyngoplasty
3167762|NCT01427062|Experimental|anticipatory and compensatory postural control training|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
3167763|NCT01427062|Active Comparator|strength-focused training|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
3167808|NCT01426607|Experimental|AMO|Adjustable mandibular repositioning appliance
3167764|NCT01427049||renal denervation|Adults with a systolic BP ≥160 mmHg (≥150 mmHg for type 2 diabetics) with a stable drug regimen including 3 or more antihypertensive medications, including a diuretic, or inability to follow a stable drug regimen due to unacceptable side-effects of antihypertensive medication.
3167765|NCT01427036|Experimental|MISS surgery group|hip screw MISS® (Minimally Invasive Screw System) : minimally invasive approach
3167766|NCT01427036|Active Comparator|PHS surgery group|PHS® hip screw design for standard approach
3167767|NCT01427010|Experimental|Reirradiation of recurrent and 2nd primary head/neck cancer.|
3167768|NCT01426997||High inflammation group (CRP>3 mg/L)|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level >3 mg/L
3167769|NCT01426997||Medium inflammation group (CRP=1-3 mg/L)|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level = 1-3 mg/L
3167770|NCT01426997||Low inflammation group (CRP<1 mg/L).|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level <1 mg/L
3167771|NCT01426984|Experimental|BPD adults|adults with Borderline Personality Disorder (BPD)
3167772|NCT01426971|Experimental|Ibuprofen+caffeine|2 capsules
3167773|NCT01426971|Active Comparator|Ibuprofen|2 capsules
3167774|NCT01426958|Active Comparator|treatment A|1 tablet afatinib single dose
3167775|NCT01426958|Experimental|treatment B|2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day
3167776|NCT01426958|Experimental|treatment C|2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day
3167777|NCT01426919||Suspected traumatic brain injury with head CT|
3167778|NCT01426906|Experimental|Study A|
3167779|NCT01426906|Experimental|Study B|
3167780|NCT01426893||1|The inhaler device usage in patients with asthma or COPD
3167781|NCT01426880|Experimental|Carboplatin + background treatment|Carboplatin AUC 2 min/mL weekly, infusion will be used as Add-on to the background therapy (same as comparator arm)
3167782|NCT01426880|Active Comparator|background treatment only|background treatment with NLPD (Myocet), Paclitaxel, Herceptin (Trastuzumab fpr Her2 pos), Tyverb (Lapatinib for Her2 pos), Avastin (Bevacizumab for triple negative) agents are used according to marketed formulation via normal procedures at each site and applied according to recommendations of the manufacturers.
3167783|NCT01426867|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each affected eye 3 times a day for 7 days
3167784|NCT01426867|Active Comparator|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, 1 drop instilled in each affected eye 3 times a day for 7 days
3167785|NCT01426867|Active Comparator|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, 1 drop instilled in each affected eye 3 times a day for 7 days
3167786|NCT01426854|Active Comparator|Nepafenac|Nepafenac Ophthalmic Suspension, 0.1%, 1 drop to the operative eye, 3 times a day, beginning 1 day preoperatively and continuing through the day of surgery and for 14 days postoperatively. An additional dose was administered prior to surgery.
3167787|NCT01426854|Placebo Comparator|Placebo|Nepafenac Vehicle, 1 drop to the operative eye, 3 times a day, beginning 1 day preoperatively and continuing through the day of surgery and for 14 days postoperatively. An additional dose was administered prior to surgery.
3167788|NCT01426828|Other|Arm A|"Arm A will receive the CD3/CD28 activated autologous lymphocytes intravenously and subcutaneous injections of KLH only vaccine."
3167789|NCT01426828|Other|Arm B|Arm B will receive the CD3/CD28 activated autologous lymphocytes intravenously and subcutaneous injections of ID-KLH Vaccine Myeloma Immunoglobulin Idiotype Vaccine (id-KLH vaccine)
3167790|NCT01426815|Placebo Comparator|Placebo|
3167791|NCT01426815|Experimental|Golimumab 50mg (Simponi ®)|
3167792|NCT01426802|Experimental|Vildagliptin 50 bid|
3167793|NCT01426789|Experimental|Secukinumab|10 mg/kg intravenous (I.V.)
3167794|NCT01426789|Placebo Comparator|Placebo|Placebo I.V.
3167795|NCT01426776|Other|heart valve replacement|
3167796|NCT01426763|Experimental|SC CINRYZE with rHuPH20 Dose Level 1|Subcutaneous injection of 1000 Units of CINRYZE with 20,000 Units of rHuPH20 twice weekly for two weeks
3167797|NCT01426763|Experimental|SC CINRYZE with rHuPH20 Dose Level 2|Subcutaneous injection of 2000 Units of CINRYZE with 40,000 Units of rHuPH20 twice weekly for two weeks
3167798|NCT01426750|Experimental|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
3167799|NCT01426698|Active Comparator|Immediate cord clamping|Infants in this arm will have had immediate cord clamping at birth which is routine care at the hospital
3167800|NCT01426698|Experimental|Delayed Cord Clamping|Intervention: Following the delivery of the infant, the obstetrician holds the infant approximately 10-15 inches below the mother's introitus at vaginal delivery or 10 to 15 inches below the level of the placenta at Cesarean section. The research nurse records the time when the infant's buttocks are delivered from the vagina or the uterus and counts out the time elapsed in ten second intervals to the obstetrician while he/she is doing the suctioning and drying maneuvers. At 30 to 45 seconds, the obstetrician milks the umbilical cord once, clamps, and cuts it. If the baby appears jeopardized in any way, the obstetrician can alter the protocol for the safety of the infant.
3167801|NCT01426672|Experimental|Monovision Correctoin|Monovision correction
3167802|NCT01426659|Active Comparator|"Protocol say and do"|reeducation implicit 5 minutes every day at home and 30 minutes of speech therapy every week
3167803|NCT01426659|Active Comparator|"no stimulation say and do"|
3167804|NCT01426646|Experimental|S-1 treatment|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
3167805|NCT01426646|Experimental|S-1 plus cisplatin treatment|"S-1 plus cisplatin every 3 weeks, A total of eight cycles~S-1: 40mg/m2 orally twice daily (days 1-14)~Cisplatin: 60mg/m2 IV on day 1"
3167806|NCT01426633|Experimental|Gemcitabine + Trabectedin|
3167807|NCT01426620|Experimental|Blueberry powder|This is a two-part open-label clinical trial of blueberry powder administered to patients with stage IV NSCLC in combination with docetaxel as a second line treatment. Patients will initially be enrolled in part 1 of the study, which is the feasibility/toxicity evaluation section of the study. Once the part I enrollment is completed, the patients will be enrolled in part 2 of the study.
3167810|NCT01426581|Experimental|Educational Intervention A|Intervention: Teach to Goal
3167811|NCT01426581|Experimental|Educational Intervention B:|Brief Intervention
3167812|NCT01426568|Active Comparator|Course of Multi-Convergent Thearpy|
3167813|NCT01426568|No Intervention|Waiting List for Multi-Convergent Therapy|
3167814|NCT01426555|Active Comparator|FES Rowing|Group 1 - FES-Rowing Exercise for entire study period
3167815|NCT01426555|Experimental|FES Rowing + Zoledronic acid|Group 2 - FES-Rowing Exercise for entire study period plus Zoledronic Acid 5mg administered by i.v. infusion one-time at the end of observation period
3167816|NCT01426542|Experimental|Topiramate|
3167817|NCT01426542|Active Comparator|Control|These infants will undergo surgery, but will not receive topiramate
3167818|NCT01426516|No Intervention|Treatment as usual (TAU)|Subjects will give DNA sample for genetic testing but will not receive genetic results and will therefore receive treatment as usual.
3167819|NCT01426516|Experimental|Genecept Assay|Subjects donate DNA sample for genetic testing and treatment decisions take genetic results into account.
3167820|NCT01426490|Other|Vitamin C|Vitamin C as control group.
3167821|NCT01426490|Experimental|Vitamin B6|
3167822|NCT01426490|Experimental|Folic acid|
3167823|NCT01426490|Experimental|Vitamin B6 plus folic acid|
3167824|NCT01426477||Veritas Collagen Matrix|Observational study of subjects who undergo open ventral hernia repair using Veritas Collagen Matrix in an underlay technique.
3167825|NCT01426451|Experimental|Theatre intervention|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
3167826|NCT01426451|Experimental|Group tutoring intervention|In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes weekly). Individualized student objectives on reading fluency and math will be implemented (one in math and one in reading per student).
3167827|NCT01426451|No Intervention|No intervention|Classes not participating neither in drama workshops nor in group tutoring activities will fill out a questionnaire as a basis for comparison.
3167828|NCT01426438|Experimental|Arm A: Extended-release niacin with aspirin|
3167829|NCT01426438|Experimental|Arm B: Fenofibrate|
3167830|NCT01426425|Experimental|Cryoablation|Subjects diagnosed with atrioventricular nodal reentrant tachycardia and treated by cryoablation with Freezor Xtra.
3167831|NCT01426412|Experimental|LY3015014 IV|A single dose of LY3015014 up to 10.0 mg/kg administered intravenously
3167832|NCT01426412|Experimental|LY3015014 IV Japanese|Single dose of LY3015014 10.0 mg/kg administered intravenously to Japanese participants. Added per protocol amendment effective October, 2012.
3167833|NCT01426412|Placebo Comparator|Placebo IV|Administered intravenously once only
3167834|NCT01426412|Experimental|LY3015014 SC|A single dose of LY3015014 up to 3.0 mg/kg administered subcutaneously
3167835|NCT01426412|Experimental|LY3015014 SC + Statin|A single dose of LY3015014 up to 3 mg/kg administered subcutaneously in addition to participant's dose of statin
3167836|NCT01426412|Placebo Comparator|Placebo SC|Administered subcutaneously once only
3167837|NCT01426399|Experimental|LC15-0444|LC15-0444 50mg qd
3167838|NCT01426399|Experimental|Metformin|Metformin 1000mg bid
3167839|NCT01426399|Experimental|LC15-0444+Metformin|LC15-0444 50mg qd +Metformin 1000mg bid
3167840|NCT01426386|Experimental|5.2 µg|
3167841|NCT01426386|Experimental|6.9 µg|
3167842|NCT01426386|Experimental|8.6 µg|
3167843|NCT01426386|Experimental|10.3 µg|
3167844|NCT01426386|Experimental|12.1 µg|
3167845|NCT01426386|Active Comparator|11 µg FbM (150 IU)|
3167846|NCT01426373|Experimental|Deoxycholic Acid 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3167847|NCT01426360|Experimental|strontium chloride/potassium nitrate dentifrice|
3167848|NCT01426360|Placebo Comparator|control dentifrice|
3167849|NCT01426347|Placebo Comparator|placebo group|"RA Patients with vitamin D deficiency will be randomized to placebo and active intervention arms.~Patients in the placebo arm will receive I placebo pill per week for 16 weeks. After completing this arm, they will cross-over to the active treatment arm."
3167850|NCT01426347|Active Comparator|Ergocalciferol|Patients with vitamin D deficiency will be randomized to either active or placebo group. In the active group, patients will receive ergocalciferol 50,000 IU per week for 16 weeks.
3167851|NCT01426334|Experimental|Treatment (dasatinib and cyclosporine)|Patients receive dasatinib PO QD on days 1-28 and cyclosporine PO BID on days 8-28. Treatment repeats every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
3167852|NCT01426321|Active Comparator|Imaging guided LV lead positioning|
3167853|NCT01426321|No Intervention|Standard LV lead positioning|The LV lead position is decided at the discretion of the treating physician. Cardiac CT images are available for viewing, but no echocardiography data regarding segmental myocardial strain are available.
3167854|NCT01426308||Method Comparison Group|The method comparison group will consist of de-identified, leftover DNA samples from patients referred for post-natal cytogenetic testing.
3167855|NCT01426308||Clinical Specificity Group|The clinical specificity group will consist of de-identified, leftover DNA samples from non-phenotypic patients, or patients not referred for post-natal cytogenetic testing.
3167856|NCT01426295|Experimental|Caphosol|
3167857|NCT01426295|Active Comparator|Référence|•Bicarbonate de sodium à 1.4% Biosedra Versylène® or PAROEX® :
3167858|NCT01426282|No Intervention|control|
3167859|NCT01426282|Experimental|nurse education|
3167860|NCT01426269|Placebo Comparator|Placebo|Subjects will receive placebo during phase 2 (week 12 - week 52)
3167861|NCT01426269|Other|Doxycycline and Metronidazole|Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) and MetroGel® 1% (topical metronidazole) during phase 1 (baseline to week 12)
3167862|NCT01426269|Active Comparator|Doxycycline|Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) during phase 2 (week 12 - week 52)
3167863|NCT01426256|Experimental|Cholecalciferol (Vitamin D3)|Patients will be given 250,000 IU cholecalciferol in one bolus oral dose while they are in the hospital. Three months after the initial bolus dose, patients will take 50,000 IU oral cholecalciferol every other week for 9 months.
3167864|NCT01426256|No Intervention|Placebo|Patients will be given placebo pills in one bolus oral dose while they are in the hospital. Three months after the initial bolus dose, patients will take a placebo pill every other week for 9 months.
3167865|NCT01426243|Active Comparator|Voluntary HIV positive subjects|40 HIV positive adults under HAART for at least one year (and stable on treatment for at least 3 months prior to enrolment), > 350 CD4/mm3 (with half of them a nadir < 200 CD4/mm3) and a viral load < 50 copies/mL for at least 6 months. Patients were HCV negative or non-replicative and treated for at least 2 years with normal ALT and negative HBs antigen.
3167866|NCT01426243|Other|HIV negative subjects|Voluntary HIV negative subjects matched according to age (18-40 years and 40-55 years) and with HIV positive subjects, vaccinated at J0 and followed over one year
3167867|NCT01426230||Open Label|"Cohort by age-~- Patients >70 Yrs old"
3167868|NCT01426230||Open label|"Cohort by age-~- Patients < 70 Yrs old"
3167869|NCT01426191||xinzhijun|1.5-3.0g,iv,bid or tid for 5-12 days
3167870|NCT01426165|Experimental|Magnesium 8 grams over 4 hours|
3167871|NCT01426165|Experimental|Magnesium 8 grams over 8 hours|
3167872|NCT01426152||Low level progesterone group (1)|Progesterone < 1.50 ng/mL on day of ovulation induction
3167873|NCT01426152||Medium level progesterone group (2)|Progesterone 1.51-1.99 ng/mL on the day of ovulation induction
3167874|NCT01426152||High level progesterone group (3)|Progesterone > 1.99 ng/mL on the day of ovulation induction
3167875|NCT01426139|Experimental|Biotronik Orsiro DES|
3167876|NCT01426126|Experimental|Genexol PM|Genexol PM intravenous infusion every 3 weeks
3167877|NCT01426113|Experimental|bimatoprost ophthalmic solution formulation A and vehicle|1 drop bimatoprost vehicle in the affected eye(s) in the morning and 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning and 1 drop bimatoprost vehicle in the affected eye(s) in the evening for 6 additional weeks.
3167878|NCT01426113|Active Comparator|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
3167879|NCT01426100|Experimental|CKD-828 40/2.5mg|
3167880|NCT01426100|Experimental|CKD-828 40/5mg|
3167881|NCT01426100|Active Comparator|Telmisartan 80mg|
3167882|NCT01426087|Experimental|endoscopic and somatostatin treatment|
3167883|NCT01426087|Other|endoscopic therapy|
3167884|NCT01426061|Experimental|Reflexology plus conventional treatment|
3167885|NCT01426061|Experimental|Homeopathy plus conventional treatment|
3167886|NCT01426061|No Intervention|Conventional treatment|
3167887|NCT01426048||Patients operated on with the TVT|
3167888|NCT01426035|Experimental|GROUP 1|
3167889|NCT01426035|Active Comparator|GROUP 2|
3167890|NCT01426022|Placebo Comparator|Alcohol|"3 glasses of sparkling white wine (30g alcohol) with dinner~3 glasses of alcohol free sparkling white wine (<2g alcohol) with dinner"
3167891|NCT01426022|Experimental|Ambiance|"Pleasant ambiance~Unpleasant ambiance"
3167892|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 25 ug|EP-101 via nebulizer (eFlow®)
3167893|NCT01426009|Active Comparator|Tiotropium bromide via (Spiriva® Handihaler®)|Tiotropium bromide via (Spiriva® Handihaler®)
3167894|NCT01426009|Active Comparator|Ipratropium bromide Inhalation Solution|Ipratropium bromide Inhalation Solution via Handihaler® DPI
3167895|NCT01426009|Placebo Comparator|Placebo EP-101|Placebo
3167896|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 50 ug|EP-101 via nebulizer (eFlow®)
3167897|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 100 ug|EP-101 via nebulizer (eFlow®)
3167898|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 200 ug|EP-101 via nebulizer (eFlow®)
3167899|NCT01425996|Experimental|Lipotecan® (TLC388)|"Dosage form: 40mg TLC388 base/vial lyophilized cake Dose: Chemotherapy, i.v. q.w. x 6 doses (dose-escalation)~* The dosage regimen would be escalated gradually until MTD had been found out."
3167900|NCT01425983|Active Comparator|amino acid composition (asn01)|Dietary supplement: specific amino acid composition with micronutrients
3167901|NCT01425983|Placebo Comparator|Sugar powder|Placebo contains no amino acids and no micronutrients and is identical in appearance and solution properties.
3167902|NCT01425970|Experimental|25 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 1
3167903|NCT01425970|Experimental|50 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 2
3167904|NCT01425970|Experimental|100 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 3
3167905|NCT01425970|Placebo Comparator|Placebo + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 4
3167906|NCT01425970|Experimental|100 mg INX-08189 + Ribavirin|PART B Arm 1
3167907|NCT01425970|Experimental|200 mg INX-08189 + Ribavirin|PART B Arm 2
3167908|NCT01425970|Experimental|Daclatasvir + INX-08189 100 mg|PART B Arm 3
3167909|NCT01425970|Experimental|Daclatasvir + INX-08189 200 mg|PART B Arm 4
3167910|NCT01425970|Experimental|Daclatasvir + INX-08189 50 mg + Ribavirin|PART B Arm 5
3167911|NCT01425957|Other|MCI Patient with Lumbar puncture|PartB: Patients affected by amnestic Mild Cognitive Impairment (aMCI).
3167912|NCT01425931||Extracorporeal circulation|all patients were measured by microcirculation device O2C
3167913|NCT01425918|Experimental|Social Enhancement Intervention|"For 5 months children will come in 4 days a week for 2-2.5 hours a session to participate in a classroom in an attempt to increase social communication and understanding.~Parent education sessions once a week for 2 hours each session over the 5-month period."
3167914|NCT01425918|Active Comparator|Parent Education|o Parent education sessions once a week for 2 hours each session over the 5-month period.
3167915|NCT01425905|Experimental|Depression Prevention|
3167917|NCT01425879|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3167918|NCT01425866|Experimental|2 years self management education|Long-term program including initial self-management education program (1 to 7 sessions, based on individual assessment), and follow-up group sessions maintained for 2 years (4-monthly assessment, empowerment, and contextual action planning; facultative additional specific thematic sessions being delivered if needed).
3167919|NCT01425866|Active Comparator|Initial self-management education|Initial self-management group education: 1 to 7 sessions (< 3 months), based on individual assessment.
3167920|NCT01425853|Experimental|Chondroitin/Glucosamine (Droglican)|"Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.~Pharmacotherapeutic group: Other specific antirheumatic agents. Anatomical Therapeutic Chemical Classification System (ATC) code: M01CX."
3167921|NCT01425853|Active Comparator|Celecoxib|Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
3167922|NCT01425840|Experimental|Liposomal lidocaine, topical anesthesia|Efficacy of Liposomal lidocaine in topical anesthesia.
3167923|NCT01425814|Experimental|Arm #2|Single dose, double blind treatment period
3167924|NCT01425814|Experimental|Arm #3|Single dose, double blind treatment period
3167925|NCT01425814|Experimental|Arm #4|Single dose, double blind treatment period
3167926|NCT01425814|Active Comparator|Arm #5|Single dose, double blind treatment period
3167927|NCT01425814|Placebo Comparator|Arm #6|Single dose, double blind treatment period
3167928|NCT01425814|Experimental|Arm #1|Single dose, double blind treatment period
3167929|NCT01425801|Experimental|LAS100977 0.625 μg|Single-dose LAS100977 0.625 μg, during double-blind treatment period
3167930|NCT01425801|Experimental|LAS100977 1.25 μg|Single-dose LAS100977 1.25 μg, during double-blind treatment period
3167931|NCT01425801|Experimental|LAS100977 2.5 μg|Single-dose LAS100977 2.5 μg, during double-blind treatment period
3167932|NCT01425801|Active Comparator|Salbutamol|Single-dose salbutamol 400 μg, during double-blind treatment period
3167933|NCT01425801|Placebo Comparator|Placebo|Placebo to LAS100977, and placebo to salbutamol
3167934|NCT01425801|Experimental|LAS100977 0.313 μg|Single-dose LAS100977 0.313 μg, during double-blind treatment period
3167935|NCT01425788|Active Comparator|Osiris Phleum pratense - Group A|"Group A up-dosing schedule from 1IR (index of Reactivity) /day to 240 IR/day in 11 days and thereafter 300 IR/day in 19 days.~Day 1-6: 1,2,4,6,8,10 IR/day Day 7-11: 30, 60, 120, 180, 240 IR/day Day 12-30: 300 IR/day"
3167936|NCT01425788|Active Comparator|Osiris Phleum pratense - Group B|"Group B Up-dosing schedule:~Day 1-5: 50 IR/day Day 6-10: 150 IR/day Day 11-30: 300 IR/day"
3167937|NCT01425788|Active Comparator|Osiris Phleum pratense - Group C|"Group C up-dosing schedule:~Day 1-10: 50 IR/day Day 11-20: 150 IR/day Day 21-30: 300 IR/day"
3167938|NCT01425775|Active Comparator|Vitamin D|
3167939|NCT01425775|Placebo Comparator|Placebo|
3167940|NCT01425762|Experimental|Choice Group|
3167941|NCT01425762|Active Comparator|No Choice Group|
3167942|NCT01425749|Experimental|Arm A|Intramuscular injections of recMAGE-A3 + AS15 ASCI.
3167943|NCT01425749|Experimental|Arm B|Intradermal/Subcutaneous injections of recMAGE-A3 + AS15 ASCI. Requires an injection site biopsy at Day 8 and Day 50.
3167944|NCT01425736|Placebo Comparator|Chemotherapy|"Chemotherapy~:Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)"
3167945|NCT01425736|Experimental|Nimotuzumab and Chemotherapy|"Nimotuzumab treatment:(200mg/w,18weeks );~Chemotherapy treatment: Docetaxel(75mg/m²,1 time/21d, 6times，);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times),Nimotuzumab treatment:(200mg/w,18weeks )."
3167946|NCT01425723|Experimental|On-Demand|The individual dose of rFIXFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor IX peak (recovery) levels.
3167947|NCT01425723|Experimental|Prophylaxis|Weekly prophylaxis, individualized prophylaxis or personalized prophylaxis available.
3167948|NCT01425710||Pheochromocytoma Group|Intraoperative esophageal doppler sonography during laparoscopic adrenalectomy performed for pheochromocytoma
3167949|NCT01425710||Control group|Intraoperative esophageal doppler sonography during laparoscopic adrenalectomy for non-pheochromocytoma adrenal tumor
3167950|NCT01425697|Active Comparator|2% Chlorhexidine Gluconate cloths|2% Chlorhexidine Gluconate wipes will be used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery
3167951|NCT01425697|Other|Standard of Care Preoperative Preparation|Subject will receive standard of care preoperative preparation for the clinical site.
3167952|NCT01425684||schizophrenia|smokers and nonsmokers
3167953|NCT01425684||control|smokers and nonsmokers
3167954|NCT01425671||Schizophrenic patients, family members|Schizophrenia Spectrum Disorder Patients
3167955|NCT01425671||Controls|Normal controls
3167956|NCT01425658|Active Comparator|clonidine|The clonidine group (groupC) received bupivacaine 10mg combined with 75 microgram clonidine preservative free intrathecally
3167957|NCT01425658|Active Comparator|Fentanyl|The fentanyl group (groupF) received bupivacaine 10mg combined with 25 microgram clonidine preservative free intrathecally
3167958|NCT01425658|Placebo Comparator|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
3167959|NCT01425645|Active Comparator|Lifestyle and behavioural change support|Interventional arm will be offered a 12 month lifestyle program translating DM prevention issues to the family milieu
3167960|NCT01425645|No Intervention|control|Control arm will receive standard diabetes prevention care as outlined in the current Canadian diabetes association Clinical Practice Guidelines.
3167961|NCT01425632|Experimental|TAU-284 Low|
3167962|NCT01425632|Experimental|TAU-284 High|
3167963|NCT01425632|Placebo Comparator|Placebo|
3167964|NCT01425619|Placebo Comparator|Placebo cream, Skin test, Anxiety, Pain|After placing a placebo cream on both arms, pain and anxiety resulting from performing allergy skin test on one of the arms will be evaluated
3168005|NCT01425281|Active Comparator|XIENCE™|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
3167965|NCT01425619|Active Comparator|Anesthetic cream, pain and anxiety, skin test|After placing a placebo cream on one arm and anesthetic cream on the second arm, pain and anxiety resulting from performing allergy skin test on the second arm will be evaluated
3167966|NCT01425619|Active Comparator|Medical clown, placebo cream, skin test|After placing a placebo cream on both arms and after receiving care and treatment from a medical clown, pain and anxiety resulting from performing allergy skin test on one of the arms will be evaluated
3167967|NCT01425619|Active Comparator|Medical clown, Anesthetic cream, Skin test|After placing a placebo cream on one arm and anesthetic cream on the second arm and after receiving care and treatment from a medical clown, pain and anxiety resulting from performing allergy skin test on the second arm will be evaluated
3167968|NCT01425606||blood test|to measure levels of sodium, albumin and acid - base status in venous blood
3167969|NCT01425580|Experimental|liraglutide|The present trial is a two centre, open, assessor-blinded and active-controlled, parallel-group trial, in combination with metformin. The trial will compare the treatment with liraglutide 1.8 mg (s.c) QD + metformin up to 1 g BID, with that of glimepiride 4 mg QD (comparator) + metformin up to 1 g BID, on LV function in subjects with type 2 diabetes.
3167970|NCT01425580|Active Comparator|glimepiride|4 mg p.o. (QD)
3167971|NCT01425567|Experimental|Omegaven Intravenously|Infants in this arm have PNALD with direct bilirubin >4 mg/dL
3167972|NCT01425567|Experimental|Omegaven Intravenously for PNALD High Risk Patients|Infants in this arm are at HIGH Risk of developing PNALD and have direct bilirubin >1mg/dL but less than 4 mg/dL.
3167973|NCT01425554|No Intervention|Diagnostic study|
3167974|NCT01425541|Experimental|estrogen, progesterone|Estrace, 0.5-1 mg once a day Micronized progesterone powder (Spectrum Chemical Manufacturing Corporation, Irving, CA), Three times a day at 0700, 1500, and 2300 hr
3167975|NCT01425528|Experimental|Kuvan Cohort 1|This cohort will be enrolled first. Analysis will be done to determine the optimum dosing of Kuvan to normalize BH4 levels in the Cerebral Spinal Fluid. This cohort will begin at a dose of 20mg/kg/day.
3167976|NCT01425528|Experimental|Kuvan Cohort 2|Participants in cohort 2 will be enrolled after the analysis of cohort 1 data has taken place. Dosing for cohort 2 will be based on results obtained in cohort 1, but will plan on starting at 30 mg/kg/day.
3167977|NCT01425502|Other|All practices|The design is a stepped-wedge cluster randomised trial. All participating practices therefore receive the intervention at a start time which is randomised.
3167978|NCT01425489||Observation|Patients with Krabbe Disease
3167979|NCT01425476|Placebo Comparator|Placebo & cholecalciferol 400 IU|In this arm, the placebo is in place of celecoxib and the current RDA for cholecalciferol is used the control of the cholecalciferol higher dose.
3167980|NCT01425476|Active Comparator|Placebo & cholecalciferol 2,000 IU|
3167981|NCT01425476|Experimental|celecoxib 400 mg & cholecalciferol 2,000 IU|
3167982|NCT01425463|Experimental|Ferrous (II) Glycine Sulphate Complex|Ferrous (II) Glycine Sulphate Complex treatment with 567.7 mg three times a day (t.i.d.) for 12 weeks plus Placebo to Polyferose.
3167983|NCT01425463|Active Comparator|Polyferose|Polyferose treatment with 150 mg twice daily (b.i.d) for 12 weeks plus Placebo to Ferrous (II) Glycine Sulphate Complex.
3167984|NCT01425450|Experimental|HF1020|
3167985|NCT01425450|Placebo Comparator|Placebo|
3167986|NCT01425437||Patients with keloid|All patients will have a clinical diagnosis of keloid and will consent to participate in this study.
3167987|NCT01425424|Experimental|Fasting glucose (blood sugar)|This group is associated with a diagnosis of prediabetes
3167988|NCT01425424|Experimental|Resting Blood pressure|This group is associated with a diagnosis of prehypertension.
3167989|NCT01425424|Experimental|Fasting Glucose & Resting Blood Pressure|coexisting prediabetes and prehypertension
3167990|NCT01425411|Experimental|Valsartan treatment|
3167991|NCT01425398|Experimental|Rosuvastatin|
3167992|NCT01425398|Placebo Comparator|Placebo|
3167993|NCT01425385||Autoregulation monitoring|Patients will be grouped into Meld Score
3167994|NCT01425359|Placebo Comparator|Placebo|"Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period.~Treatment Period: Placebo to match ranolazine (Day 1: 1 tablet in the evening; Days 2-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 8 weeks."
3167995|NCT01425359|Experimental|Ranolazine|"Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period.~Treatment period: Ranolazine tablets (Day 1: 1 × 500 tablet in the evening; Days 2-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 8 weeks."
3167996|NCT01425346||Normal Healthy|Normal, healthy males and females between the ages of 21 and 70 with healthy eyes as determined by a standard ophthalmic examination.
3167997|NCT01425333|Active Comparator|Cystectomy|Patients undergoing cystectomy for ovarian endometrioma
3167998|NCT01425333|Active Comparator|Ablation|Patients undergoing ablation for ovarian endometrioma
3167999|NCT01425320|Experimental|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
3168000|NCT01425320|Experimental|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
3168001|NCT01425320|Active Comparator|dapsone 5% gel (ACZONE®)|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
3168002|NCT01425320|Active Comparator|adapalene 0.3% gel (Differin®)|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
3168003|NCT01425307|No Intervention|Standard Therapy|Standard Therapy of monthly transfusions
3168004|NCT01425307|Experimental|Treatment Arm|Hydroxyurea will be provided as capsules or liquid
3168006|NCT01425281|Experimental|ABSORB BVS™|Experimental: Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
3168007|NCT01425268|Experimental|AeroForm Tissue Expansion|AeroForm Tissue Expansion inflation with carbon dioxide by remote control
3168008|NCT01425268|Active Comparator|Saline Tissue Expansion|Saline Tissue Expansion inflated by needle injections of saline
3168009|NCT01425255||Parents of children with Type 1 diabetes|before and several weeks after initiating using RT-CGM of their children.
3168010|NCT01425242|Experimental|Aliskiren|Half of all subjects with mild to moderate hypertension and a small abdominal aortic aneurysm are treated with aliskiren, combined with hydrochlorothiazide if hypertension cannot be treated sufficiently with aliskiren monotherapy
3168011|NCT01425242|Active Comparator|Amlodipine|Half of all subjects with mild to moderate hypertension and a small abdominal aortic aneurysm are treated with amlodipine, combined with hydrochlorothiazide if hypertension cannot be treated sufficiently with amlodipine monotherapy
3168012|NCT01425229||Bosentan|Haplotypes of CYP2C9 and OATP1B1 characterisation of CYP2C9 (CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910)) and OATP1B1 (SLCO1B1*15 (rs2306283, rs4149056))
3168013|NCT01425216|Experimental|Sorafenib arm|All patients will be treated with sorafenib.
3168014|NCT01425203|Experimental|RGT BOC + PR|Participants received PR for 4 weeks before addition of BOC. Participants then received response guided therapy (RGT) with BOC + PR for up to 32 weeks followed by PBO + PR for up to 20 weeks.
3168015|NCT01425203|Placebo Comparator|PBO + PR (Control)|Participants received PR for 4 weeks before addition of BOC-matched PBO. Participants then received BOC + PR for up to 44 weeks.
3168016|NCT01425203|Experimental|Crossover Arm|Participants randomized to the PBO + PR Control arm who failed the futility rule at treatment week (TW) 12 or 24 were rolled over to the Crossover arm and received BOC + PR.
3168017|NCT01425190|Experimental|Cohort 1: Children 17 to ≥13 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such pudding or applesauce. The first 4 participants were treated with a 11.4 mg/kg dose of boceprevir powder. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
3168018|NCT01425190|Experimental|Cohort 2: Children <13 to ≥7 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such as pudding or applesauce. The first 4 participants were treated with boceprevir at a dose contingent on the PK and safety results in Cohort 1. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
3168019|NCT01425190|Experimental|Cohort 3: Children <7 to ≥3 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such as pudding or applesauce. The first 4 participants were treated with boceprevir at a dose contingent on the PK and safety results in Cohort 2. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
3168020|NCT01425177|Experimental|Normal saline irrigation|
3168021|NCT01425164|Active Comparator|Carvedilol|
3168022|NCT01425164|Experimental|Ivabradine|
3168023|NCT01425151|Active Comparator|i-Gel|
3168024|NCT01425151|Experimental|ProSeal|
3168025|NCT01425138||Psoriasis|Published data on moderate-to-severe plaque psoriasis.
3168026|NCT01425125|Experimental|Tolvaptan in euvolemic hyponatremia|This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
3168027|NCT01425112|Experimental|Topical/Subconjunctival|Depending upon the mode of administration
3168028|NCT01425099|Experimental|Part 1|In Part 1, approximately 12 healthy subjects will receive DTG 50mg q24h for 5 days in Period 1. Subjects will then be administered DTG 50mg q24h in combination with prednisone 60mg for 5 days followed by a 5 day taper (60 mg Days 1-5, 50 mg Day 6, 40 mg Day 7, 30 mg Day 8, 20 mg Day 9 and 10 mg Day 10 - total duration of 10 days) in Period 2. There will be a screening visit 30 days before the first dose and a follow-up visit 7-14 days after the last dose of drug.
3168029|NCT01425099|Experimental|Part 2|If DTG Cτ is reduced by more than 50% in Part 1, Part 2 will be carried out where a second cohort of subjects will receive DTG 50mg q24h DTG for 5 days in Period 1 followed by DTG 50mg q24h in combination with prednisone 20mg for 5 days followed by a 5 day taper (20 mg Days 1-5, 10 mg Days 6 and 7, 5 mg Days 8-10 - total duration of 10 days) in Period 2. There will be a screening visit 30 days before the first dose and a follow-up visit 7-14 days after the last dose of drug.
3168030|NCT01425086||Incubator temperature support|Infant will be cared for in the current ongoing policy-driven temperature support provided by the incubator and handling as per bedside nursing interventions. Infant will be followed clinically until discharge from Lucile Packard Hospital (average 4 weeks).
3168031|NCT01425086||Embrace blanket warming|Infant will be placed and wrapped in the embrace blanket and cared for and monitored for temperature support and monitored by bedside nursing interventions, as needed. Infant will be followed clinically until discharge from Lucile Packard Hospital (average 4 week
3168032|NCT01425073|Experimental|Stop TMP/SMZ|Arm 1 will have patients discontinue trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis; patients will follow up every 3 months with study staff.
3168033|NCT01425073|No Intervention|Standard of care TMP/SMZ prophylaxis|Arm 2 will continue standard of care treatment with trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis.
3168034|NCT01425060|Experimental|Contraceptive management program|
3168035|NCT01425060|Active Comparator|Usual care|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
3168036|NCT01425047||Females ingesting mangosteen juice|
3168037|NCT01425047||Males ingesting mangosteen juice|
3168038|NCT01425034|Active Comparator|Cast group|The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
3168039|NCT01425034|Active Comparator|Motion group|The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
3168040|NCT01425021||Total hip/knee joint revisions|All University of Utah orthopedic patients who have had total or partial joint arthroplasties at the time of revision surgery.
3168041|NCT01425008|Experimental|MLN2480|
3168042|NCT01424982|Experimental|Hyper-CVAD + Ponatinib|Hyper-CVAD Odd courses 1, 3, 5, 7. Cyclophosphamide 300 mg/m^2 by vein (IV) every 12 hours for 6 doses Days 1-3; Vincristine 2 mg IV Day 1 and Day 11; Doxorubicin (Adriamycin) 50 mg/m^2 continuous IV Day 4; Dexamethasone 40 mg IV/orally/day Days 1-4 and days 11-14; Methotrexate 12 mg intrathecally (6mg via Ommaya reservoir) on Day 2; Cytarabine 100 mg intrathecally Day 7; and Ponatinib 45 mg orally daily days 1-14 for Course 1 then 30 mg daily other odd courses. Pegfilgrastim (Neulasta) may replace G-CSF at 6 mg subcutaneously on Day 4.
3168043|NCT01424982|Experimental|Methotrexate + Cytarabine + Ponatinib|Even courses 2,4, 6, and 8. Methotrexate 12 mg intrathecally (6 mg via Ommaya reservoir); Cytarabine 3 g/m^2 IV every 12 hours for 4 doses Days 2 + 3; Ponatinib 30 mg orally/day; Citrovorum (Leucovorin) rescue 50 mg by vein or by mouth followed by 15 mg by vein or by mouth every 6 hours for 8 doses beginning 12 hours post Methotrexate completion. Pegfilgrastim (Neulasta) may replace G-CSF at a dose of 6 mg subcutaneously on Day 5.
3168044|NCT01424982|Experimental|Maintenance Therapy|"Maintenance chemotherapy with vincristine, and prednisone for approximately 24 months.~Vincristine 2 mg by vein on day 1 approximately every 28 days for 24 months. Ponatinib 30 mg by mouth daily as tolerated and 15 mg by mouth daily in patients who have achieved complete molecular response.~Prednisone 200 mg by mouth daily days 1-5 approximately every 28 days with vincristine for 24 months."
3168045|NCT01424969||PRFM Group|Patients were selected prospectively for the study based on a 3-part algorithm used to identify rotator cuff tears at risk for retear. A total algorithm score of 3 or greater was required for enrollment in the study.
3168046|NCT01424969||Control Group|The control group were recruited retrospectively. Patients who have undergone arthroscopic repair of rotator cuff tears with similar size characteristics without PRFM augmentation will be encouraged to participate by letter initially, and then by telephone invitation. The same inclusion and exclusion criteria applied. MRI, pain, and functional scores will be collected in the same manner as the PRFM group at one time point at least one year post operatively.
3168047|NCT01424956||Asymptomatic Women who have Dense Breast Tissue|Women who have no signs or symptoms of breast cancer who have > 50% parenchymal density on mammography.
3168048|NCT01424943|Experimental|Stepping Stones Triple P|10-15 sessions of Level 4 Standard Stepping Stones Triple P delivered in family homes
3168049|NCT01424943|Other|BabyNet Services As usual|BabyNet services as usual based on IFSP
3168050|NCT01424930|Experimental|Abiraterone+prednisone (low-fat meal)|Participants will receive abiraterone acetate at a starting dose of 1,000 milligram (mg) once daily for 7 days post 30-minutes of a standardized low-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
3168051|NCT01424930|Experimental|Abiraterone+prednisone (high-fat meal)|Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
3168052|NCT01424917||Heart Transplant|Heart Transplant subjects
3168053|NCT01424904|Experimental|DGB-01|All subjects will receive DGB-01 during the study. Approximately one-half of the subjects during the first period and the other half during the second period.
3168054|NCT01424891|Placebo Comparator|Placebo|Treatment with placebo over 8 weeks
3168055|NCT01424891|Active Comparator|Simvastatin 80 mg|treatment with 80 mg of simvastatin over 8 weeks
3168056|NCT01424891|Active Comparator|Sim10/Eze10|treatment with 10 mg of simvastatin in combination with 10 mg ezetimibe over 8 weeks
3168057|NCT01424852|Active Comparator|Probiotics in milk formula|B. lactis BB-12 and L. rhamnosus GG delivered in milk formula during the first year of infancy
3168058|NCT01424852|Placebo Comparator|Control milk formula|The children received milk formula with no probiotics
3168059|NCT01424839|Other|Germinoma metastatic|"• Metastatic or incompletely staged germinomas (± teratoma) Do not receive chemotherapy in this protocol~Radiotherapy~Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracranial metastases and spinal deposits (total tumour dose 40 Gy)~Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)"
3168060|NCT01424839|Other|germinoma non-metastatic|"Chemotherapy:~• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide Note: Bifocal germinoma (pineal+suprasellar) are treated as non-metastatic germinoma, if staging shows no additional dissemination~Radiotherapy~Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)~Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles~Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)"
3168061|NCT01424839|Other|Non-germinoma non-metastatic standard risk|"Chemotherapy:~• Standard risk non-germinomatous malignant GCT Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment ) After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions"
3168062|NCT01424839|Other|Non-Germinoma metastatic standard risk|Chemotherapy Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment ) Radiotherapy After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
3168063|NCT01424839|Other|Non-germinoma non-metastatic high risk|Chemotherapy Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support Radiotherapy After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
3168064|NCT01424839|Other|Non-Germinoma metastatic high risk|Chemotherapy Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support Radiotherapy After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
3168065|NCT01424839|No Intervention|Teratoma|collection of information on surgery, applied treatment and outcome
3168164|NCT01424254|Experimental|Push Enterosopy|
3168066|NCT01424813|Placebo Comparator|Placebo MDPI|Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
3168067|NCT01424813|Experimental|Albuterol MDPI|Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.
3168068|NCT01424800|Experimental|change in blood pressure and blood flow|34 patients will form the experimental group, in which changes of blood pressure and blood flow will be induced and monitored.
3168069|NCT01424787||OsvaRen treatment|Dialysis patients on OsvaRen treatment
3168070|NCT01424761|Experimental|Placebo|Placebo:starch
3168071|NCT01424761|Experimental|Coenzyme Q10|
3168072|NCT01424748|Placebo Comparator|Placebo|Placebo juice
3168073|NCT01424748|Experimental|30 mL Tahitian Noni Juice|30 mL Tahitian Noni Juice per day dose
3168074|NCT01424748|Experimental|300 mL Tahitian Noni Juice|300 mL Tahitian Noni Juice per day
3168075|NCT01424748|Experimental|750 mL Tahitian Noni Juice|750 mL Tahitian Noni Juice per day
3168076|NCT01424735|Experimental|Mw.|Administration of immunomodulator Mw.
3168077|NCT01424722|Experimental|ST Monitoring Feature|
3168078|NCT01424709|Experimental|Arm 1|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
3168079|NCT01424709|Active Comparator|Arm 2|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
3168080|NCT01424696||Cystic Fibrosis in 1st 3 months of life|Early Diagnosis: Children diagnosed with CF in first 3 months of life
3168081|NCT01424683||Endoscopic Vein Harvest (EVH)|A short saphenous vein segment is commonly used as a conduit for coronary artery bypass grafting (CABG), and clinicians must decide whether to obtain it by performing a traditional open vein harvest (OVH) or by performing an endoscopic vein harvest (EVH).
3168082|NCT01424683||Open Vein Harvest (OVH)|A short saphenous vein segment is commonly used as a conduit for coronary artery bypass grafting (CABG), and clinicians must decide whether to obtain it by performing a traditional open vein harvest (OVH) or by performing an endoscopic vein harvest (EVH).
3168083|NCT01424670|Placebo Comparator|Placebo tablet|Matching Placebo tablet
3168084|NCT01424670|Experimental|Delamanid|100mg BID for 2 months and 200mg QD for 4 months
3168085|NCT01424657|Experimental|ERCP|ERCP is an endoscopic examination that allows opacification of the biliary tree by direct injection into the common bile duct through its distal opening in the duodenum at the ampulla of Vater
3168086|NCT01424657|Experimental|MRCP|The magnetic resonance cholangiopancreatography (MRCP)allows direct visualization of the biliary tree and pancreatic duct, similar to contrast cholangiography, but without the need for administration of contrast medium
3168087|NCT01424644|Placebo Comparator|Placebo + Tdap + HPV|This group will receive Tdap, HPV and placebo concomitantly for the first vaccination. The second and third doses of HPV vaccine will be administered to all subjects 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.
3168088|NCT01424644|Experimental|MenACWY-CRM + Tdap + HPV|This group will receive Tdap, HPV and MenACWY-CRM concomitantly. The second and third doses of HPV vaccine will be administered to this group 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.
3168089|NCT01424631|Active Comparator|single incision laparoscopic appendectomy|
3168090|NCT01424631|Placebo Comparator|conventional laparoscopic appendectomy|
3168091|NCT01424618|Active Comparator|GnRh agonist|This arm will use a GnRH agonist to suppress pituitary-ovarian function
3168092|NCT01424618|Experimental|GnRH antagonist|A GnRH antagonist will be used to suppress pituitary-ovarian function
3168093|NCT01424605|Experimental|DLT intubation|
3168094|NCT01424592||Study Group|Hospitalized inpatients referred by a general medicine service for evaluation of obstructive sleep apnea.
3168095|NCT01424579|Experimental|Actual Diacutaneous Fibrolysis|The group received tree weeks of a daily protocolized treatment and additionally six sessions (two a week) of actual Diacutaneous Fibrolysis.
3168096|NCT01424579|Placebo Comparator|Placebo Diacutaneous Fybrolisis|This group received tree weeks of a daily protocolized treatment and additionally six sessions (two a week) of placebo Diacutaneous Fibrolysis.
3168097|NCT01424579|Other|No Diacutaneous Fibrolysis|This group received only tree weeks of a daily protocolized treatment.
3168098|NCT01424566|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 2 or 7 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligrams [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%)flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
3168099|NCT01424566|Placebo Comparator|Placebo (GA-0034)|Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorings.
3168100|NCT01424553|Other|Cohort|All patients
3168101|NCT01424540|Experimental|Treatment A|GSK2336805 150mg
3168102|NCT01424540|Placebo Comparator|Treatment B|GSK2336805 Placebo
3168103|NCT01424527||Chronic Obstructive Pulmonary Disease|Males and females 40 years of age or older with a diagnosis of COPD
3168104|NCT01424514|Experimental|SB-705498|
3168105|NCT01424514|Placebo Comparator|Placebo|
3168106|NCT01424501|Experimental|Group A|Subjects from TB-treated cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
3168107|NCT01424501|Placebo Comparator|Group B|Subjects from TB-treated cohort will receive 2 doses of physiological Saline.
3168108|NCT01424501|Experimental|Group C|Subjects from TB-treatment cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
3168109|NCT01424501|Placebo Comparator|Group D|Subjects from TB-treatment cohort will receive 2 doses of physiological Saline.
3168110|NCT01424501|Experimental|Group E|Subjects from TB-naive cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
3168111|NCT01424501|Placebo Comparator|Group F|Subjects from TB-naive cohort will receive 2 doses of physiological Saline.
3168112|NCT01424488|Experimental|sugammadex group|4 mg/kg of sugammadex for reversal of pipecuronium-induced neuromuscular blockade
3168113|NCT01424488|Placebo Comparator|placebo group|3 ml of saline (placebo) for reversal of pipecuronium-induced neuromuscular blockade
3168114|NCT01424475|Other|PKD Patients|PKD Patients with LRRK2 mutation
3168115|NCT01424475|Other|Healthy Controls|Healthy Controls with no LRRK2 mutation
3168116|NCT01424462|Experimental|Firategrast XRA|Low extended release tablet
3168117|NCT01424462|Experimental|Firategrast XRB|Medium extended releast tablet
3168118|NCT01424462|Experimental|Firategrast XRC|High extended release tablet
3168119|NCT01424462|Experimental|Firategrast IR|Immediate Release reference tablet
3168120|NCT01424449|Experimental|no treatment|Aripiprazole is a D2/D3 antagonist registered in the UK for use in the treatment of schizophrenia. It allows the highest clinically acceptable blockade of central D2/D3 receptors and will allow us to examine the amount of displaceable binding in the brain - a proposed reference tissue for [11C]PHNO.
3168121|NCT01424436|Experimental|GSK933776 1mg/kg|single dose
3168122|NCT01424436|Experimental|GSK933776 0.1 or 3mg/kg|single dose
3168123|NCT01424436|Experimental|GSK933776 3 or 6mg/kg|single dose
3168124|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 1|Eligible subjects will receive intravenous infusion of GSK1223249 with a starting dose of 0.02 milligrams per kilograms, followed by 0.2, 2, 10 and 30 milligrams per kilograms, administered by a programmable syringe pump.
3168125|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 1|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
3168126|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 2|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 0.2 milligrams per kilograms administered by a programmable syringe pump.
3168127|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 2|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
3168128|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 3|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 2 milligrams per kilograms administered by a programmable syringe pump.
3168129|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 3|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
3168130|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 4|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 10 milligrams per kilograms administered by a programmable syringe pump.
3168131|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 4|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
3168132|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 5|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 30 milligrams per kilograms administered by a programmable syringe pump.
3168133|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 5|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
3168134|NCT01424397|Experimental|SB-705498|Experimental
3168135|NCT01424397|Active Comparator|Flucticasone Propionate|Active Comparator
3168136|NCT01424397|Placebo Comparator|Placebo|Placebo Comparator
3168137|NCT01424397|Experimental|SB-705498+FP|Experimental
3168138|NCT01424384|Active Comparator|Citalopram|Marketed comparitor
3168139|NCT01424384|Experimental|Investigational Medicinal Product|GSK424887
3168140|NCT01424384|Placebo Comparator|Placebo To Match Treatment|Placebo control
3168141|NCT01424371||Adjuvanted Vaccine Group|
3168142|NCT01424371||Unadjuvanted Vaccine Group|
3168143|NCT01424371||Unvaccinated Elderly|
3168144|NCT01424358|Experimental|Web-based Educational|
3168145|NCT01424345|Active Comparator|control group|Dosages of immunosuppressants will be given according to the results of conventional post-transplant lab
3168146|NCT01424345|Experimental|ImmuKnow Study group|The dosages of immunosuppressants will be adjusted according to the results of ImmuKnow and conventional post-transplant lab
3168147|NCT01424332|Experimental|Treatment arm 1|darexaban, wash-out, ASA, wash-out, darexaban plus ASA
3168148|NCT01424332|Experimental|Treatment arm 2|darexaban, wash-out, darexaban plus ASA, wash-out, ASA
3168149|NCT01424332|Experimental|Treatment arm 3|ASA, wash-out, darexaban, wash-out, darexaban plus ASA
3168150|NCT01424332|Experimental|Treatment arm 4|ASA, wash-out, darexaban plus ASA, wash-out, darexaban
3168151|NCT01424332|Experimental|Treatment arm 5|darexaban plus ASA, wash-out, darexaban, wash-out, ASA
3168152|NCT01424332|Experimental|Treatment arm 6|darexaban plus ASA, wash-out, ASA, wash-out, darexaban
3168153|NCT01424319|Experimental|ABT-627, Low dose|
3168154|NCT01424319|Experimental|ABT-627, High dose|
3168155|NCT01424319|Placebo Comparator|ABT-627, Placebo|
3168156|NCT01424306|Experimental|Fructose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days.
3168157|NCT01424306|Experimental|Glucose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days.
3168158|NCT01424306|Experimental|High-fructose corn syrup-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days.
3168159|NCT01424293|Experimental|Indocyanine Green|1ml of intravenous ICG and imaging transanally using the Spyscope system
3168160|NCT01424280|Experimental|Active drug|
3168161|NCT01424280|Placebo Comparator|Placebo|
3168162|NCT01424267||1|
3168163|NCT01424254|Experimental|Video-Capsule Endoscopy|VCE will be performed in the early morning following 200 mg of simethicone and 250 - 500 mg of erythromycin (as per physician's prescription), ingestion also in the absence of contra-indications
3168165|NCT01424241|Experimental|Sandostatin LAR|This is a 9 month, open label dose escalation study of Sandostatin LAR therapy.
3168166|NCT01424228|Placebo Comparator|Placebo|Placebo 2 mg tablet once daily before breakfast
3168167|NCT01424228|Active Comparator|prucalopride|Prucalopride 2 mg once daily before breakfast
3168168|NCT01424215|Experimental|ICG injection with Spyscope imaging|Indocyanine Green (ICG)
3168169|NCT01424215|No Intervention|Standard Critical View Technique|50 patients will be randomized to the no treatment arm. These patients will not get ICG injection but rather will have the standard technique for laparoscopic cholecystectomy performed including the critical view technique to expose the important structures prior to clipping and division.
3168170|NCT01424202|Experimental|Group B|Patients received (post-extubation) standard medical treatment (SMT), including NIV in case of specific indications plus daily sessions of mechanical in-exsufflation (MI-E).
3168171|NCT01424202|No Intervention|Group A|Patients received (post-extubation) standard medical treatment (SMT), including NIV in case of specific indications.
3168172|NCT01424189|Experimental|ReSTOR Toric IOL|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
3168173|NCT01424189|Active Comparator|ReSTOR IOL|AcrySof® ReSTOR® Multifocal IOL Model SA60D3, bilateral implantation
3168174|NCT01424176|Experimental|Dexpramipexole (dose 1)|Subjects with mild or moderate renal impairment.
3168175|NCT01424176|Experimental|Dexpramipexole (dose 2)|Subjects with severe renal impairment and end stage renal disease (ESRD).
3168176|NCT01424163|Experimental|Treatment 1 (Part A)|Dexpramipexole single dose (reduced dose)
3168177|NCT01424163|Experimental|Treatment 2 (Part A)|Dexpramipexole single dose (Standard dose)
3168178|NCT01424163|Experimental|Treatment 3 (Part A)|Dexpramipexole multiple dosing
3168179|NCT01424163|Experimental|Treatment for Part B|Dexpramipexole multiple dosing
3168180|NCT01424150|Experimental|Liberal|At the commencement of surgery a bolus of Hartmann's balanced salt crystalloid 10 ml/kg followed by 8 ml/kg/h will be administered until the end of surgery. A maintenance infusion will then continue at 1.5 ml/kg/h, for at least 24 hours, but this can be reduced postoperatively if there is evidence of fluid overload and no hypotension, and increased if there is evidence of hypovolaemia or hypotension. Alternative fluid types (crystalloid, dextrose, colloid) and electrolyte supplements will be allowed postoperatively in order to account for local preferences and patient biochemistry, for which we will collect data.
3168181|NCT01424150|Experimental|Restrictive|Will provide less than 2.0 L water and 120 mmol sodium per day. Induction of anaesthesia will limit IV bolus fluid to ≤5 ml/kg; no other IV fluids will be used at the commencement of surgery (unless indicated by goal-directed device [see below]). Hartmann's balanced salt crystalloid 5 ml/kg/h will be administered until the end of surgery, and bolus colloid/blood used intraoperatively to replace blood loss (ml for ml); then an infusion at 1 ml/kg/h until expedited cessation of IV fluid therapy within 24 hours. The rate of postoperative fluid replacement can be reduced if there is evidence of fluid overload and no hypotension, and can be increased if there is hypotension AND evidence of hypovolaemia.
3168182|NCT01424137|Other|Easyhaler type A|
3168183|NCT01424137|Other|Easyhaler type B|
3168184|NCT01424137|Other|Diskus inhaler|
3168185|NCT01424124|Experimental|YHD001 dose level 1|
3168186|NCT01424124|Experimental|YHD001 dose level 2|
3168187|NCT01424124|Active Comparator|Singulair|
3168188|NCT01424124|Placebo Comparator|Placebo|
3168189|NCT01424111||Treatment|Those receiving an open-label, 10-20 mg/day, flexible-dose of escitalopram. The treatment period is 8 weeks long.
3168190|NCT01424111||Healthy Control|Those not receiving treatment.
3168191|NCT01424098|Experimental|Balance Training|The treatment group will complete a specific balance training program in addition to conventional pulmonary rehabilitation.
3168192|NCT01424098|No Intervention|Usual care|The control group will undergo the usual pulmonary rehabilitation program offered at our centre with no additional balance training classes.
3168193|NCT01424085||Those receiving antibiotics|Patients who received one prophylactic dose of antibiotics.
3168194|NCT01424085||Placebo|Patients who did not receive one prophylactic dose of antibiotics (received placebo).
3168195|NCT01424072|No Intervention|Control Group|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
3168196|NCT01424072|Experimental|Auriculotherapy by needles|The investigators used 3 points, Shenmen, Kidney, and Brain Stem with semi-permanent needles of 1.8 mm, 1 time per week for 8 sessions.
3168197|NCT01424072|Experimental|Auriculotherapy by seeds|The investigators used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.
3168198|NCT01424059||fear of labor|Parous women with fear of labor
3168199|NCT01424046|Experimental|basal insulin approach|Participants will be treated primarily with a daily basal insulin injection ( glargine) with later introduction of prandial coverage with a shortacting insulin.
3168200|NCT01424046|Active Comparator|standard therapy|Participants will continue current mixed insulin management and education
3168201|NCT01424033|Experimental|N-Acetylcysteine|This is an open label trial, all patient will be entered into one treatment arm.
3168202|NCT01424020|Experimental|questionnaire|Patients suspected of peripheral artery disease and, as such, referred for a vascular investigations and submitted the WELCH questionnaire
3168203|NCT01424007|Experimental|Lower fat diet|Participants in this group will be individually counseled and receive print materials on a higher-carbohydrate, lower-fat diet.
3168204|NCT01424007|Experimental|Lower carbohydrate diet|Participants in this group will be individually counseled and receive print materials on a lower-carbohydrate, higher-monounsaturated fat diet.
3168205|NCT01424007|Experimental|Walnut-rich diet|Participants in this group will be individually counseled and receive print materials on a lower-carbohydrate, walnut-rich higher-fat diet.
3168206|NCT01423994|Active Comparator|implantable loop recorder|
3168207|NCT01423994|Active Comparator|pacemaker|
3168208|NCT01423981||Patients with keloid disorder.|All participants have a clinical diagnosis of keloid.
3168209|NCT01423968|Experimental|Lipopolysaccharide infusion|Lipopolysaccharide infusion; dosage 4ng/kg body weight
3168210|NCT01423968|Placebo Comparator|saline|0.9% saline infusion
3168211|NCT01423955|Placebo Comparator|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
3168212|NCT01423955|Experimental|Erythropoietin|• Active substance: Erythropoietin zeta with the ATC-code: B03XA01. The drug is a Clear colorless solution for injection. The active substance will be diluted with NaCl 9mg/ml to a to a concentration of 2000 U/ml. A dose of 400U/kg will be prepared and marked before the operation. The drug will be administrated after the anesthesia induction and before the start of surgery.
3168213|NCT01423929|Experimental|10 L O2/min|Oxygen breathing via Oxymask TM
3168214|NCT01423929|Sham Comparator|Room air|Room air breathing via Oxymask TM
3168215|NCT01423916|Active Comparator|Arm 1 (OPC-34712, placebo)|Arm 1 will be administered 4 mg OPC-34712 once daily (QD) for 11 days and OPC-34712 placebo for 1 day.
3168216|NCT01423916|Active Comparator|Arm 2 (OPC-34712, placebo)|Arm 2 will be administered 12 mg OPC-34712 QD for 11 days and OPC-34712 placebo for 1 day.
3168217|NCT01423916|Active Comparator|Arm 3 (moxifloxacin, placebo)|Arm 3 will be administered 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for 1 day and OPC-34712 placebo QD for 11 days.
3168218|NCT01423916|Active Comparator|Arm 4 (moxifloxacin, placebo)|Arm 4 will be administered OPC-34712 placebo QD for 11 days and 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for one day.
3168219|NCT01423903|Experimental|OPDC-51602|Subjects with advanced solid tumors will be treated with OPDC-51602 once daily by mouth
3168220|NCT01423890|Other|Early Stage Breast Cancer|Women and men with node negative, ER positive breast cancer who are receiving (or will receive) endocrine therapy, and who are candidates for chemotherapy.
3168221|NCT01423864|Sham Comparator|conventional ECMO with intravenous steroid|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome unresponsive to conventional extracorporeal membrane oxygenation
3168222|NCT01423864|Experimental|Drug: intrapleural steroid instillation|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome unresponsive to conventional extracorporeal membrane oxygenation
3168223|NCT01423851|Experimental|Intervention: Drug: NS-018|
3168224|NCT01423838|Active Comparator|Solifenacin|Anticholinergic molecule used in the treatment of overactive bladder.
3168225|NCT01423838|Active Comparator|Oxybutynin|Anticholinergic molecule used in the treatment of overactive bladder.
3168226|NCT01423825|Experimental|Sub C gp140/MF59C.1 Vaccine|Participants will receive Sub C gp140 vaccine (100 mcg) admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid at baseline and Month 3.
3168227|NCT01423825|Placebo Comparator|Sodium chloride for injection|Participants will receive placebo injection administered as 0.5 mL IM in either deltoid at baseline and Month 3.
3168228|NCT01423812|Experimental|Once-daily Darunavir and ritonavir|Subjects switched from Darunavir 600mg plus Ritonavir 100mg twice-daily to Darunavir 800mg plus Ritonavir 100mg once-daily
3168229|NCT01423812|Active Comparator|Twice-daily Darunavir and ritonavir|Subjects remain on regimens containing Darunavir 600mg plus Ritonavir 100mg twice-daily
3168230|NCT01423799|Experimental|Nutritional product|Nutritional intervention containing immuno-nutrients
3168231|NCT01423799|Active Comparator|Control Group|Isocaloric and isonitrogenous control without immuno nutrients.
3168232|NCT01423773|Other|Lotrafilcon A test/lotrafilcon A control|Lotrafilcon A test contact lens worn first, with lotrafilcon A control contact lens worn second. Each product worn bilaterally for two days as follows: 20 minutes on Day 1 and 10 hours on Day 2.
3168233|NCT01423773|Other|Lotrafilcon A control/lotrafilcon A test|Lotrafilcon A control contact lens worn first, with lotrafilcon A test contact lens worn second. Each product worn bilaterally for two days as follows: 20 minutes on Day 1 and 10 hours on Day 2.
3168234|NCT01423760|Experimental|Tecemotide (L-BLP25)|
3168235|NCT01423760|Other|Observational|
3168236|NCT01423747|Other|MSD - matched sibling donor|patients with a MSD receive a conditioning of total body irradiation (TBI) (12 Gy, 6 fractions) and VP16 60mg/kg for one day (-3)
3168237|NCT01423747|Other|MD - matched donor|patients with a HLA (Human Leukocyte Antigen) matched unrelated Donor (9/10 oder 10/10) receive total body irradiation (TBI) (12Gy in 6 fractions), VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
3168238|NCT01423747|Other|MMD - mismatched Donor|Patients with a mismatched donor receive stem cells either from cord blood, a haploidentical donor (parent) or from a non-related donor with a match less or equal 8/10
3168239|NCT01423734||MRI|Patients will be consented for a second MRI without additional intravenous contrast, referred to from now on as 'research MRI', to be performed later on the same day as their clinical liver MR examination, on one of two 3.0 Tesla MR 750 GE scanners at the Breast and Imaging Center. The research MRI will consist only of the localizer and diffusion weighted imaging (DWI) sequences, with acquisition parameters identical to our clinical MRI. The reproducibility of DWI is best assessed in separate MR imaging sessions, although the examinations can be performed the same day.
3168240|NCT01423721|Experimental|Bromihexine hydrochloride granules|16 mg granules
3168241|NCT01423721|Experimental|Bromihexine hydrochloride syrup|16 mg syrup
3168242|NCT01423708|No Intervention|Control|Standard immunosuppression protocol with Tacrolimus, maintaining trough levels between 6 and 12 ng/ml in the first month, in association with steroids (20 mg/day with subsequent weaning within 3 months after transplantation).
3168243|NCT01423708|Experimental|Everolimus|Administration of Everolimus in association with Tacrolimus and steroids.
3168244|NCT01423695|Experimental|paclitaxel/trastuzumab|Single experimental arm in a phase II trial
3168245|NCT01423682|Placebo Comparator|Healthy subjects|
3168246|NCT01423682|Active Comparator|Rotator cuff tendinopathy|
3168247|NCT01423669||Community dwelling adult population|
3168248|NCT01423656|Experimental|LEO 29102|
3168249|NCT01423656|Placebo Comparator|LEO 29102 vehicle|
3168250|NCT01423643||Main cohort|Adults infected with both HIV and Hepatitis C
3168251|NCT01423643||Control Group|Adults at risk for liver disease, but not infected with both HIV and Hepatitis C
3168252|NCT01423630|Experimental|Probiotics and fruit fibre|Probiotics and fruit fibre
3168253|NCT01423617|Active Comparator|Zenoctil|
3168254|NCT01423617|Placebo Comparator|Placebo|
3168256|NCT01423604|Placebo Comparator|Capecitabine and placebo|
3168257|NCT01423591|Experimental|infliximab|
3168258|NCT01423591|Placebo Comparator|inactive powder|
3168259|NCT01423578|Active Comparator|Hatha Yoga (HY)|Exercise and Smoking Cessation Counseling
3168260|NCT01423578|Experimental|Cardiovascular Exercise (CE)|Exercise and Smoking Cessation Counseling
3168261|NCT01423578|Other|Smoking Cessation Counseling Only|Control Group - Smoking Cessation Counseling
3168262|NCT01423565|Experimental|Deep Brain Stimulation|
3168263|NCT01423552||Post-heart transplant|All patients undergoing heart transplantation at the Queen Elizabeth Hosptial Birmingham in the last 12 months or in the next year.
3168264|NCT01423539|Active Comparator|A|
3168265|NCT01423539|Experimental|B|
3168266|NCT01423526|Placebo Comparator|Placebo|"Drug: Placebo tablets, oral administration, single administrations~Arms: Placebo"
3168267|NCT01423526|Experimental|DWP10292|"Drug: DWP10292 tablets, oral administration, single administrations~Arms: DWP10292"
3168268|NCT01423513|Experimental|Fibular Taping|With the ankle in a neutral position, two strips of nonrigid hypoallergenic tape will be applied beginning at the distal aspect of the fibula, wrapping around the posterior aspect of the leg, and finishing superior and medial to the starting point. Next,a strip of rigid zinc oxide tape will be applied to the distal aspect of the fibula with tension.
3168269|NCT01423513|Sham Comparator|Sham Taping|Sham taping will be applied in the same manner as the fibular taping, but tension will not applied to the zinc oxide tape
3168270|NCT01423500|Other|MSD - Matched Sibling Donor|patients with a MSD receive a conditioning of TBI (12 Gy, 6 fractions) and VP16 60mg/kg for one day (-3)
3168271|NCT01423500|Other|MD - Matched Donor|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions), VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
3168272|NCT01423500|Other|MMD - Mismatched Donor|Patients with a MMD receive stem cells either from cord blood, a haploidentical donor (parent) or from a non-related donor with a match less or equal 8/10
3168273|NCT01423487|Experimental|efficacy and safety|To investigate the efficacy and safety of Metformin in preventing patients with Risperidone from weight gain and amenorrhea.
3168274|NCT01423487|Placebo Comparator|placebo comparator|To investigate whether plcebo also could preventing patients with Risperidone from weight gain and amenorrhea.
3168275|NCT01423474|Experimental|Short treatment time (11 days)|
3168276|NCT01423474|Experimental|Long treatment time (29 days)|
3168277|NCT01423448|Experimental|Bulletin board|Participants will be given access to the online bulletin board (intervention) for a 6 month period
3168278|NCT01423448|No Intervention|Control|After 6 months participants allocated to the control group will receive access to the intervention
3168279|NCT01423435|Experimental|Japanese|
3168280|NCT01423435|Experimental|Chinese|
3168281|NCT01423435|Experimental|South Korean|
3168282|NCT01423422||Frequency exposed patients|Patients exposed to the magnetic field with the specific frequency
3168283|NCT01423409|Active Comparator|pictorial VAS|VAS with colours and 6 expressive faces
3168284|NCT01423409|Sham Comparator|usual VAS|VAS
3168285|NCT01423396|Other|standard care|Follow up with city doctor with recommendation HAS French guidelines
3168286|NCT01423396|Experimental|optimal care of VRF|Monitoring according to the strict recommendations of the HAS French guidelines
3168287|NCT01423383||Random Populations|The aim of this study is to determine the prevalence and incidence of keloid in large populations.
3168288|NCT01423370|Experimental|Group A|
3168289|NCT01423370|Experimental|Group B|
3168290|NCT01423370|Experimental|Group C|
3168291|NCT01423370|Active Comparator|Group D|
3168292|NCT01423370|Placebo Comparator|Group E|
3168293|NCT01423357|Experimental|Condom distribution and peer education|Youth peer educators distribute condoms and conduct condom demonstration in venues where people meet new sexual partners, i.e. bars, night clubs, sherbeens, guest houses
3168294|NCT01423357|No Intervention|Business as usual|
3168295|NCT01423318|Experimental|A|
3168296|NCT01423318|Placebo Comparator|B|
3168297|NCT01423305|Experimental|Treatment A|Budesonide/formoterol capsule (Orion Pharma) for oral administration.
3168298|NCT01423305|Experimental|Treatment B|Budesonide/formoterol capsule (Orion Pharma) for oral administration.
3168299|NCT01423292|Active Comparator|an odd numbered patients|TAP block with local anesthetics
3168300|NCT01423292|Placebo Comparator|an even numbered patients|TAP block without local anesthetics
3168301|NCT01423266|Experimental|High Protein Group|12-week supervised weight loss program consisting of a HP diet defined as 30% of energy from protein, 40% from carbohydrates and 30% from fat
3168302|NCT01423266|Active Comparator|Standard Protein Group|12-week supervised weight loss program consisting of a SP diet defined as 15% of energy from protein, 55% from carbohydrates and 30% from fat
3168303|NCT01423253|Experimental|Lurasidone 20, 40, 60 mg|Lurasidone 20, 40, or 60 mg/day flexibly dosed
3168304|NCT01423240|Experimental|Lurasidone 20 mg|
3168305|NCT01423240|Experimental|Lurasidone 60 mg|
3168306|NCT01423240|Placebo Comparator|Placebo|
3168307|NCT01423227|Experimental|Home-based pulmonary rehabilitation|Home visit plus 8 weeks of once-weekly telephone calls
3168308|NCT01423227|Active Comparator|Hospital-based pulmonary rehabilitation|Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
3168309|NCT01423214|Experimental|Robotic LAR|Individuals who underwent robot-assisted surgery for primary rectal cancer
3168310|NCT01423214|Active Comparator|Lap LAR|Individuals who underwent laparoscopic surgery for primary rectal cancer
3168311|NCT01423188|Experimental|RVX000222, 200 mg daily|
3168312|NCT01423188|Placebo Comparator|Placebo|
3168313|NCT01423175|Experimental|ClAraC|
3168314|NCT01423175|Active Comparator|FLAMSA|
3168315|NCT01423162|Experimental|Drink with Vit C then drink without Vit C|Fortified oat drink with vitamin C on day 1 followed by fortified oat drink without vitamin C on day 2
3168316|NCT01423162|Experimental|Drink without Vit C then drink with Vit C|Fortified oat drink without vitamin C on day 1 followed by fortified oat drink with vitamin C on day 2
3168317|NCT01423149|Experimental|36 mg/m2 Combretastin A-4 Phosphate|
3168318|NCT01423149|Experimental|45 mg/m2 Combretastatin A-4 Phosphate|
3168319|NCT01423149|Experimental|27 mg/m2 Combretastatin A-4 Phosphate|
3168320|NCT01423136||Routine postop care + Holter Monitoring|With sham remote ECG ST Monitoring
3168321|NCT01423136||Routine postop care + Holter + remote ECG monitoring|
3168322|NCT01423123|Experimental|Neratinib|Paclitaxel (80 mg/m2 IV on days 1, 8, and 15 every 28 days) and trastuzumab (4 mg/kg/ loading dose, then 2 mg/kg) IV weekly beginning on day 1 of paclitaxel, neratinib orally daily beginning on day 1 of paclitaxel until disease progression.
3168323|NCT01423110|Experimental|BYM338|
3168324|NCT01423110|Placebo Comparator|Placebo|
3168325|NCT01423084|Experimental|MenB Lot 1|MenB vaccine Lot 1: 2 doses administered 1 month apart
3168326|NCT01423084|Active Comparator|MenB Lot 2|MenB vaccine Lot 2: 2 doses administered 1 month apart
3168327|NCT01423071||COPD with PH|COPD patients with confirmed diagnosis of PH.
3168328|NCT01423071||COPD without PH|COPD patients without confirmed diagnosis of PH
3168329|NCT01423071||PAH without COPD|PAH patients who do not suffer from COPD
3168330|NCT01423058|Experimental|Momelotinib|
3168331|NCT01423032|Experimental|Bendamustine|
3168332|NCT01423032|Active Comparator|Fludarabine|
3168333|NCT01423019|Active Comparator|Advantra Z|Proprietary ingredient for: stimulating thermogenesis, reducing weight, increasing lean muscle mass to total body mass, improving athletic performance, and suppressing appetite
3168334|NCT01423019|Active Comparator|Advantra Z + Naringin + Hesperiden|
3168335|NCT01423019|Placebo Comparator|Sugar pill|Capsule contains inert ingredient.
3168336|NCT01423006|Experimental|Focal Prostate Radio-Frequency Ablation|Treatment is performed under a spinal or general anesthetic and will include the one to three regions of the prostate containing cancer based on the mapping biopsy.
3168337|NCT01422993|Experimental|Excercise and Questionnaire|12 week exercise program followed by questionnaire.
3168338|NCT01422980|Active Comparator|1 = Test product|Arm 1 - intervention 1 (test product)
3168339|NCT01422980|Placebo Comparator|2 = Control product|Arm 2 - intervention 2 (control product)
3168340|NCT01422967|Active Comparator|Osteoarthritis group|
3168341|NCT01422967|Active Comparator|without osteoarthritis|
3168342|NCT01422954|Active Comparator|Chloroquine immunisation|This group will receive chloroquine prophylaxis, and three times infected mosquito-bites.
3168343|NCT01422954|Experimental|Mefloquine immunisation|This group will receive mefloquine prophylaxis and infected mosquito-bites.
3168344|NCT01422954|Placebo Comparator|Mefloquine control|This group will receive mefloquine prophylaxis, and uninfected mosquito-bites.
3168345|NCT01422941|Experimental|CAVU Attune Device|
3168346|NCT01422928|No Intervention|Standard treatment|"Patients receiving standard radiation therapy for gastrointestinal or urogenital cancers.~All subjects will be asked to give 20 mL of blood and complete the Edmonton Symptom Assessment Form (ESAS) on 3 occasions:~before radiation~at 1st follow up 4-10 weeks after radiation completion~at second follow up 6 months after 1st follow up"
3168347|NCT01422928|Experimental|Acupuncture|"Patients receiving standard radiation therapy for gastrointestinal or urogenital cancers with concurrent acupuncture once a week for 4 weeks.~All subjects will be asked to give 20 mL of blood and complete the Edmonton Symptom Assessment Form (ESAS) on 3 occasions:~before radiation~at 1st follow up 4-10 weeks after radiation completion~at second follow up 6 months after 1st follow up"
3168348|NCT01422915|Experimental|colestipol treatment|2 grams morning and bedtime for 180 days
3168349|NCT01422902|Experimental|Plasticity-based Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 130 hours
3168350|NCT01422902|Active Comparator|Non-plasticity-based Training|Commercially available computerized training, up to 130 hours
3168351|NCT01422889||ION Registry|The ION Registry population was designed to collect real world safety and clinical outcomes data. There were 1120 subjects were enrolled, however 9 subjects did not receive a study stent therefore 1111 subjects were eligible for follow up.
3168352|NCT01422876|Experimental|BI 10773/linagliptin FDC (high dose)|Patients receive BI 10773/linagliptin FDC (high dose) once daily
3168353|NCT01422876|Experimental|BI 10773/linagliptin FDC (low dose)|Patients receive BI 10773/linagliptin FDC (low dose) once daily
3168354|NCT01422876|Active Comparator|BI 10773 (high dose)|Patients receive BI 10773 (high dose) once daily
3168355|NCT01422876|Active Comparator|BI 10773 (low dose)|Patients receive BI 10773 (low dose) once daily
3168356|NCT01422876|Active Comparator|Linagliptin|Patients receive linagliptin once daily
3168357|NCT01422863|Experimental|Lifestyle Intervention|
3168358|NCT01422824||Cohort|
3168359|NCT01422811|Experimental|Intervention|
3168360|NCT01422811|Other|Control|No Intervention
3168361|NCT01422785|Active Comparator|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|
3168362|NCT01422785|Active Comparator|clindamycin / tretinoin gel plus benzoyl peroxide|
3168363|NCT01422772|Experimental|Cohort I|0.5mg/1mL of VM202RY was intramuscularly injected into 4 sites
3168364|NCT01422772|Experimental|Cohort II|1mg/2mL of VM202RY was intramuscularly injected into 8 sites
3168365|NCT01422772|Experimental|Cohort III|2mg/4mL of VM202RY was intramuscularly injected into 8 sites
3168366|NCT01422759|Experimental|spironolactone|12 weeks spironolactone with pre- and post-intervention dexamethasone, and ACTH to perform standardized adrenal stimulation testing; dexamethasone and rhCG to perform standardized ovarian stimulation testing
3168367|NCT01422746|Experimental|metformin|12 weeks metformin, with pre- and post- dexamethasone and ACTH to perform standardized adrenal stimulation testing; dexamethasone and rhCG to perform standardized ovarian stimulation testing
3168368|NCT01422733|Experimental|hydrocortisone, dexamethasone, Cosyntropin (ACTH), rhCG|12 weeks hydrocortisone, dexamethasone, and Cosyntropin (ACTH) to perform standardized adrenal stimulation testing; dexamethasone, and rhCG to perform standardized ovarian stimulation testing
3168369|NCT01422720|Experimental|Eslicarbazepine Acetate tablets (800 mg)|
3168370|NCT01422707|Experimental|hydrocortisone|4 weeks hydrocortisone with pre- and post-intervention Dexamethasone and Cosyntropin to perform standardized adrenal stimulation testing
3168371|NCT01422681|Experimental|DECOPD|patients with severe COPD exacerbation on NIV treated with the minimally invasive extracorporeal carbon dioxide removal device (Decap Smart)
3168372|NCT01422668|Active Comparator|GI of Khalas dates|The Glycemic indices of the Khalas dates were measured for healthy and diabetic subjects.
3168373|NCT01422668|Experimental|GI of the Khalas dates with Coffee|measuring the effect of 100 ml of coffee consumption on the GI of the Khalas dates among healthy and diabetic subjects.
3168374|NCT01422642|Experimental|legacy posterior stabilized high-flexion|NexGen LPS-Flex total knee system
3168375|NCT01422642|Experimental|legacy posterior stabilized standard|standard NexGen LPS prosthesis
3168376|NCT01422629|Experimental|High Intensity Focused Ultrasound (HIFU)|
3168377|NCT01422616|Experimental|Low-dose rtPA (Recruitment completed in August 2015)|low-dose 0.6 mg/kg (maximum of 60 mg) i.v. rtPA
3168378|NCT01422616|Active Comparator|Standard-dose rtPA (Recruitment completed in August 2015)|standard-dose 0.9 mg/kg (maximum of 90 mg) i.v. rtPA
3168379|NCT01422616|Experimental|Early intensive BP lowering|"The trial is an assessment of BP lowering management strategies, using routinely available drugs.~Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents (e.g. Labetalol Hydrochloride, Metoprolol tartrate, Hydralazine Hydrochloride, Glycerol Trinitrate, Phentolamine mesylate, Nicardipine, Urapidil, Esmolol, Clonidine, Enalaprilat, Nitroprusside) will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA."
3168380|NCT01422616|Active Comparator|Control / guideline-based BP management|"The trial is an assessment of BP lowering management strategies, using routinely available drugs.~Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the American Heart Association (AHA). For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved."
3168381|NCT01422603|Experimental|Clofarabine and Full intensity SCT|Cohort One: Patients suitable for full intensity conditioning will receive Clofarabine pre-conditioning followed by a Cyclophosphamide and Total Body Irradiation conditioned allogeneic stem cell transplant (SCT).
3168382|NCT01422603|Experimental|Clofarabine and Reduced intensity SCT|Cohort 2: Patients not suitable for a full intensity TBI-based transplant due to age or co-morbidity will receive Clofarabine pre-conditioning followed by a reduced intensity allogeneic stem cell transplant using Fludarabine, intravenous Busulphan and Campath 1H.
3168383|NCT01422590|Active Comparator|Sitagliptin|
3168384|NCT01422590|Active Comparator|Mitiglinide|
3168385|NCT01422590|Experimental|Sitagliptin + Mitiglinide|
3168386|NCT01422577|Active Comparator|Bright Narrow Band Imaging|Bright Narrow Band Imaging
3168387|NCT01422577|Active Comparator|White Light Endoscopy|White Light Endoscopy
3168388|NCT01422564|Active Comparator|Metal on Metal|Metal on Metal articulation system
3168389|NCT01422564|Active Comparator|HCLPC|THA using Highly Cross Linked Polyethylene cup System
3168390|NCT01422551|Experimental|Cognitive Behavioral Stress Management|10 weekly 2-hour sessions of group-based cognitive behavioral stress management
3168391|NCT01422551|Active Comparator|Psycho-educational Control|a single day group-based psycho-educational seminar
3168392|NCT01422538|Active Comparator|Group A|Subjects will receive Ulthera® System alone.
3168393|NCT01422538|Active Comparator|Group B|Sculptra® only
3168394|NCT01422538|Active Comparator|Group C|Sculptra® treatment followed by Ultherapy™ treatment
3168395|NCT01422525||Trabeculectomy RNFL thickness OCT|
3168396|NCT01422512|Experimental|cell culture derived TIV|single dose of cell culture derived seasonal trivalent influenza vaccine (TIV)
3168397|NCT01422486|Experimental|ezatiostat hydrochloride (Telintra®)|Patients received ezatiostat at a starting dose of 2000 mg total daily dose in divided doses (1000 mg PO b.i.d.) for three weeks (21 days) on therapy followed by a one-week (7 days) off therapy rest period in four-week (28 days) treatment cycles.
3168398|NCT01422473|Experimental|EnSeal Device|EnSeal Trio Tissue Sealing Device
3168399|NCT01422460|Experimental|Platelet Rich Plasma|intra articular injection 2ml of platelet-derived preparation rich in growth factors
3168400|NCT01422447|Experimental|community intervention|Feedback on assessment results: distribute relevant brochures and hold regular lectures on depression, anxiety and alcohol—abuse.
3168401|NCT01422447|Active Comparator|regular intervention control|the subjects in the control group live in the used model
3168402|NCT01422434|Active Comparator|LEO 90105 ointment|LEO 90105 ointment applied once daily for 4 weeks.
3168403|NCT01422434|Active Comparator|Dovonex® ointment|Applied twice daily for 4 weeks.
3168404|NCT01422434|Active Comparator|Rinderon® - DP ointment|Applied once daily for 4 weeks
3168405|NCT01422421|Active Comparator|intensive control|systolic blood pressure less than 120mmHg and LDL cholesterol within 70- 85mg/dl
3168406|NCT01422421|Active Comparator|standard control|systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
3168407|NCT01422408|Experimental|Supportive care (fluocinonide cream)|Patients apply topical fluocinonide cream BID in weeks 1-2 and QD in weeks 3-4.
3168408|NCT01422395|Experimental|freezing|
3168409|NCT01422395|No Intervention|No freezing|
3168410|NCT01422382|Experimental|All Subjects|There was 1 treatment period, with each subject receiving a once-daily dose of pitavastatin 4 mg on Days 1 through 5 and on Days 11 through 15 and a once-daily dose of diltiazem 240 mg on Days 6 through 15
3168411|NCT01422369|Experimental|All Subjects|pitavastatin 4 mg
3168412|NCT01422343||1|
3168413|NCT01422330|Experimental|Etravirine|
3168414|NCT01422317|Experimental|n-3 fatty acids|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each capsule containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters, in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
3168415|NCT01422317|Active Comparator|Corn Oil|Two gelatine capsules twice a day, each containing 1 gram of corn oil. Alpha-Tocopherol (4 mg) was added to each capsule.
3168416|NCT01422304|Experimental|Sugammadex|Prior to randomization, participants will be assigned to planned active reversal or planned spontaneous recovery by the anesthesiologist according to the recovery method the anesthesiologist would have chosen if the participant were not in the study. In this treatment arm, participants assigned to planned active reversal will receive sugammadex and placebo to neostigmine, and participants assigned to planned spontaneous recovery will receive sugammadex. Study drug will be administered after the last dose of rocuronium or vecuronium and after wound closure.
3168417|NCT01422304|Experimental|Usual Care|Prior to randomization, participants will be assigned to planned active reversal or planned spontaneous recovery by the anesthesiologist according to the recovery method the anesthesiologist would have chosen if the participant were not in the study. In this treatment arm, participants assigned to planned active reversal will receive neostigmine and placebo to sugammadex, and participants assigned to planned spontaneous recovery will receive placebo to sugammadex. Study drug will be administered after the last dose of rocuronium or vecuronium and after wound closure.
3168418|NCT01422291|Active Comparator|morphine|
3168419|NCT01422291|Experimental|Paracetamole, dexketoprofen|Paracetamole, dexketoprofen
3168420|NCT01422265||Cohort|
3168421|NCT01422252|Experimental|Persons equipped|Precocious fall detection device
3168422|NCT01422252|No Intervention|Persons non-equipped|No fall detection device
3168423|NCT01422239|Experimental|Tailored behavioral counseling|"The focus of the first three sessions for participants receiving the tailored treatment will be their three most highly endorsed perceived risks of quitting. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's Smoke Free and Living It manual. The last 5 counseling sessions will be based on perceived risks of quitting."
3168424|NCT01422239|Active Comparator|Standard behavioral counseling|"The focus of the first three sessions for participants receiving the standard treatment will be the benefits of quitting smoking. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's Smoke Free and Living It manual. All participants will receive identical counseling sessions during week 4-8 based on material from the Mayo Clinic manual."
3168425|NCT01422226|Experimental|Experimental active comparator|"Drug: Misoprostol~Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion"
3168426|NCT01422226|Placebo Comparator|Placebo comparator|"Other: Placebo~Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion"
3168427|NCT01422213|Placebo Comparator|Placebo|
3168428|NCT01422213|Experimental|Vortioxetine 10 mg|
3168429|NCT01422213|Experimental|Vortioxetine 20 mg|
3168430|NCT01422200|Experimental|Subcutaneous|
3168431|NCT01422200|Active Comparator|Intromuscular|
3168432|NCT01422187|Experimental|Taliglucerase alfa 30 units/kg|Subjects randomized to receive 30 units/kg
3168433|NCT01422187|Experimental|Taliglucerase alfa 60 units/kg|Subjects randomized to 60 units/kg
3168434|NCT01422174||ICD implantation|Patients that receive an ICD implantation (non randomized, by clinical decision) will enter this group
3168435|NCT01422174||Non ICD implantation|Patients that do not receive ICD implantation (non randomized, by clinical decision); they can receive any other treatment (e.g. antiarrhythmic drugs)
3168436|NCT01422161|Experimental|Botulinum Toxin commonly known as BOTOX®|Some subjects will receive BOTOX® injections. Subject will not be informed of what injection they received.
3168437|NCT01422161|Placebo Comparator|Placebo|Some subject will receive a safe Placebo injection. Subjects will not be informed of what injection they have received.
3168438|NCT01422148|Other|Amiodarone|oral amiodarone
3168439|NCT01422148|Experimental|minocycline|intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
3168440|NCT01422135|Experimental|AG200-15|Subjects will be randomly assigned to one of six treatment (site of application) sequences. Each sequence will include three patch application sites: abdomen, buttock, or upper torso excluding breasts.
3168441|NCT01422122|Experimental|Vitamin D|Oral vitamin D3 in syrup form
3168442|NCT01422122|Placebo Comparator|placebo|Placebo syrup identical in colour and taste to that of intervention
3168443|NCT01422109|Experimental|Group A|
3168444|NCT01422109|Active Comparator|Group B|
3168445|NCT01422096|Experimental|leuprolide|leuprolide 11.25 mg IM with adrenal suppression/stimulation testing with dexamethasone/Cortrosyn and ovarian stimulation testing with r-hCG before and 3 weeks after injection
3168446|NCT01422083|No Intervention|Control group|This group of athletes do not perform a 6-week stretching program.
3168447|NCT01422083|Experimental|Home stretching program|These athletes take on a home stretching program (sleeper's stretch).
3168448|NCT01422070||Patients admitted to the Study Units|Consecutive adult patients consecutively admitted to the Study Units during one month (either from 7th November to 4th December 2010, or from 16th January to 12th February 2012)
3168449|NCT01422031||Regular Family Doctor (RFD)|People had a regular primary care doctor who is a family doctor
3168450|NCT01422031||Regular not Family doctor (RnFD)|People had a regular primary care doctor who is not a family doctor
3168451|NCT01422031||Not regular doctor (NRD)|People had no regular primary care doctor
3168452|NCT01422018|Experimental|one arm for Anastin injection|intravitreal Avastin injection
3168453|NCT01422005|Experimental|Experimental group|Simultaneous Bimanual training: Patients who have had either an acute/subacute and a Chronic stroke will get training on the devices.
3168454|NCT01422005|Active Comparator|Control Group|Conventional Occupational Therapy: Patients who have had either an acute/subacute and Chronic Stroke with hemiperisis will get conventional therapy.
3168455|NCT01421992|Placebo Comparator|Arm 1: Methylphenidate versus baseline|
3168456|NCT01421992|Placebo Comparator|Arm 2: Placebo versus baseline|One table placebo per day during 3 week
3168457|NCT01421979|Experimental|exposure under sleep deprivation|Examination of the effects of EDs in combination with alcohol consumption and sleep deprivation.
3168458|NCT01421979|Experimental|Exercise after consumption|Examination of the effects of EDs in combination with alcohol consumption and exercise.
3168459|NCT01421966|Experimental|CureXcell®|
3168460|NCT01421966|Sham Comparator|Sham injection|
3168461|NCT01421953|Experimental|Patients|
3168462|NCT01421940|Placebo Comparator|Control|Individuals who take placebo after total mesorectal excision
3168463|NCT01421940|Experimental|Udenafil|Individuals who take udenafil after total mesorectal excision
3168464|NCT01421927|Experimental|lenalidomide|
3168465|NCT01421914|Other|Bupivacaine 0,5%|Single arm study
3168466|NCT01421901|Experimental|Ertapenem|
3168467|NCT01421901|Active Comparator|appendectomy|Appendectomy is compared to Ertapenem
3168468|NCT01421849|Experimental|Elderly with an unstable mandibular denture.|
3168469|NCT01421836|Active Comparator|ERCP guided stent insertion|
3168470|NCT01421836|Active Comparator|EUS guided stent insertion|
3168471|NCT01421823|Experimental|alpha agonist ointment|
3168472|NCT01421823|Placebo Comparator|Placebo|
3168473|NCT01421810|Experimental|dexamethasone, rhCG (Ovidrel)|rhCG (Ovidrel) administered 25 mcg IV; dexamethasone administered 1 mg PO
3168474|NCT01421797|Experimental|Dexamethasone, Cortrosyn|Dexamethasone given 1 mg PO Cortrosyn given single IV bolus 0f 0.25 mg
3168475|NCT01421784|Other|Cine-MRI|Rapid Cine-MRI
3168476|NCT01421771|Active Comparator|Treatment to an intensive BP goal|Treatment to a pre-dialysis standardized dialysis unit systolic blood pressure of 110-140 mm Hg
3168477|NCT01421771|Placebo Comparator|Treatment to standard BP goal|Treatment to a pre-dialysis Standardized dialysis unit systolic BP of 155-165 mm Hg
3168478|NCT01421758|Experimental|online social network|
3168479|NCT01421758|Active Comparator|web education control|
3168480|NCT01421745|Experimental|Cultural Competence Module|The module will include lecture, case studies, and discussion of cultural competence.
3168481|NCT01421732||Suspected dengue fever|Children aged 1-15 presenting at participating hospitals with symptoms of dengue fever
3168482|NCT01421719|Experimental|botulinum toxin treatment|botulinum toxin treatment Injection of Botox into urinary bladder for neurogenic symptoms.
3168483|NCT01421706|Active Comparator|sibutramine-clopidogrel|sibutramine-clopidogrel
3168484|NCT01421706|Active Comparator|sibutramine-clarithromycin|sibutramine-clarithromycin
3168485|NCT01421693|Active Comparator|Gatifloxacin|Gatifloxacin 10mg/kg/day for 7 days
3168486|NCT01421693|Active Comparator|Ceftriaxone|"≥2-<14 years - 60mg/kg/ once daily for 7 days~14 years and older - 2g once daily for 7 days"
3168487|NCT01421680|Active Comparator|Ensure powder|Oral Nutritional Supplements with carbohydrate, lipid, protein, vitamin and minerals
3168488|NCT01421680|No Intervention|Standard care|Standard care without oral nutritional supplements
3168489|NCT01421667|Experimental|Brentuximab vedotin+rituximab|
3168490|NCT01421667|Experimental|Brentuximab vedotin|
3168491|NCT01421654|Experimental|Fixed Mode + Acclimate|S9 Elite flow generator with Acclimate feature activated.
3168492|NCT01421654|Active Comparator|Fixed Mode only|S9 Elite Flow Generator with Fixed Mode only
3168493|NCT01421641|Active Comparator|Intracervical Lidocaine Injection|Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle.
3168494|NCT01421641|Active Comparator|Topical Lidocaine Gel|Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip (this amount of lidocaine will be measured out prior to procedure)
3168495|NCT01421628|Experimental|exercise|
3168496|NCT01421615|Placebo Comparator|lotion|lotion:the patients in control group receive washing medicine and are followed up to the 4rd～7th days of postpartum.
3168497|NCT01421615|Experimental|lactobacilli capsule|
3168498|NCT01421615|Experimental|lactobacilli capsules|
3168499|NCT01421589|Experimental|Growth Hormone|
3168500|NCT01421576|Active Comparator|High fat meal|
3168501|NCT01421576|Experimental|DP-R202|under fed condition
3168502|NCT01421563|Active Comparator|Anplag|
3168503|NCT01421563|Experimental|DP-R202|
3168504|NCT01421550|Active Comparator|Conservative treatment|Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.
3168505|NCT01421550|Active Comparator|Surgical repair|Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
3168506|NCT01421524|Experimental|CC-122 MM-2|A new MM cohort (MM-2) will be enrolled in order to evaluate tolerability, safety and preliminary efficacy of the CC-122 formulated capsule given on an intermittent schedule (5/7 days per week) in 2 parallel dose escalation cohorts (MM-2a and MM-2b, respectively) (DEX) in Pomalidomide naïve subjects
3168507|NCT01421524|Experimental|CC-122- DLBCL-2|A new DLBCL cohort (DLBCL-2) in order to evaluate intermittent schedules of CC-122 (5 continuous days out of 7 days per week [5/7 days] and/or 21 continuous days out of 28 days per cycle [21/28 days]). Doses to be explored include 4 mg and 5 mg on an intermittent schedule using the 3+3 design described in Part A in order to establish an MTD for the intermittent dosing schedules. Following dose escalation, one or more intermittent dosing schedules may be expanded at or below the new intermittent schedule MTD in at least 20 total subjects per dosing schedule.
3168508|NCT01421524|Experimental|CC-122- GBM-2|A new GBM cohort (GBM-2) in order to evaluate doses of CC-122 above the 3 mg QD MTD determined in all comers in Part A. CC-122 dose will increase in 1 mg increments starting with 4 mg daily on a continuous schedule using the 3+3 design described in Part A in order to establish an MTD specific for GBM subjects. Following dose escalation, the cohort will be expanded at or below the new MTD in up to 20 total subjects.
3168509|NCT01421524|Experimental|Primary Central Nervous System Lymphoma (PCNSL)|During dose expansion of selected intermittent schedules, an additional cohort of up to 10 subjects with PCNSL will also be explored at the same dose and schedule as DLBCL to confirm some safety and preliminary efficacy signal
3168510|NCT01421511|Experimental|TR-701 FA|• TR-701 FA IV followed by TR-701 FA tablets
3168511|NCT01421511|Active Comparator|Linezolid|• Linezolid IV followed by Linezolid Tablets
3168512|NCT01421498|Experimental|5.0% Lifitegrast|Lifitegrast
3168513|NCT01421498|Placebo Comparator|Placebo|
3168514|NCT01421485|Experimental|Integrated treatment Program|
3168515|NCT01421485|Active Comparator|Treatment as Usual|
3168516|NCT01421472|Experimental|MM-121 (SAR256212) + paclitaxel|2 week run-in of MM-121 followed by MM-121 + dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
3168517|NCT01421472|Active Comparator|Paclitaxel only|Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
3168518|NCT01421459|Experimental|LY2963016 + OAMs|LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 oral antihyperglycemic medications (OAMs) [alpha glucosidase inhibitors (AGI), dipeptidyl peptidases intravenous (DPP-IV), meglitinide (MEG), metformin (MET), sulfonylurea (SU), and thiazolidinedione (TZD)] administered per standard of care for 24 weeks
3168519|NCT01421459|Active Comparator|Lantus + OAMs|Lantus titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 OAMs (AGI, DPP-IV, MEG, MET, SU, and TZD) administered per standard of care for 24 weeks
3168520|NCT01421433|Active Comparator|Tandrilax|Reference product Intervention: Drug: Tandrilax (caffeine+carisoprodol+sodium diclofenac+paracetamol)
3168521|NCT01421433|Experimental|Dolamin Flex|Test product Intervention: Drug: Dolamin Flex (Lysine clonixinate and cyclobenzaprine)
3168522|NCT01421420||Alzheimer's Disease|
3168523|NCT01421420||Mild Cognitive Impairment|
3168524|NCT01421420||Other forms of Dementia, not AD|
3168525|NCT01421420||Normal Elderly Individuals|
3168526|NCT01421407|Active Comparator|High Intensity Focused Ultrasound|
3168527|NCT01421407|No Intervention|Control group|
3168528|NCT01421394||single group study|
3168529|NCT01421368|Experimental|DMPA and tenofovir 1% gel|
3168530|NCT01421368|Experimental|Oral contraceptive and tenofovir 1% gel|
3168531|NCT01421355|Experimental|Atazanavir 300 mg BID|Atazanavir 300 mg BID for 4 days.
3168532|NCT01421342|Active Comparator|Switching: Bupropion-SR|Switching: Bupropion-SR
3168533|NCT01421342|Active Comparator|Augmenting: Antidepressant + Bupropion-SR|Augmenting: Antidepressant + Bupropion-SR
3168534|NCT01421342|Active Comparator|Augmenting: Antidepressant + Aripiprazole|Augmenting: Antidepressant + Aripiprazole
3168535|NCT01421303||AS patients who are working and treated with Enbrel|
3168536|NCT01421290|Active Comparator|Conservative treatment|
3168537|NCT01421290|Active Comparator|Surgery|
3168538|NCT01421277||Participants Enrolled in Protocol Version (V)1.1|Participants with physician-diagnosed migraine with or without aura who are treatment-naive to triptans, who received their first prescription for a triptan and took at least one dose within 6 months prior to being included in Protocol V1.1 of this study.
3168539|NCT01421277||Participants Enrolled in Protocol V2|Participants with physician-diagnosed migraine with or without aura who are treatment-naive to triptans, who received their first prescription for a triptan and took at least one dose within 6 months prior to being included in Protocol V2 of this study.
3168540|NCT01421264|Experimental|Gabapentin|
3168541|NCT01421251||Matched cohorts - population based|Two cohorts: vaccinated individuals are matched to unvaccinated individuals on the basis of age, sex, and postal code of residence.
3168542|NCT01421238|Experimental|Resuscitation Default Arm|"After receiving a description of an impending delivery of a 23 week gestational infant, participants in this arm were presented with the following information:~The doctor goes on to say that at this hospital infants born at 23 weeks will receive resuscitation, unless their parents object. If you decline resuscitation please check the box below:~Please check if you decline resuscitation []"
3168543|NCT01421238|Experimental|Comfort Care Default Arm|"After receiving a description of an impending delivery of a 23 week gestational infant, participants in this arm were presented with the following information:~The doctor goes on to say that at this hospital infants born at 23 weeks will receive comfort care, unless their parents object. If you decline comfort care please check the box below:~Please check if you decline comfort care []"
3168544|NCT01421225|Active Comparator|Standard Insulin Pump Therapy first, then Closed Loop|Standard therapy day 1, Closed-Loop therapy day 2.
3168545|NCT01421225|Active Comparator|Closed Loop first, then Standard Insulin Pump Therapy|Closed-loop therapy day 1, standard therapy day 2.
3168546|NCT01421199|Other|Myringotomy|On arm
3168547|NCT01421186|Experimental|Phase 1 dose escalation|"Part A: MOR03087 dose escalation; biweekly treatment~Part B: MOR03087 dose escalation; weekly treatment~Part C: MOR03087 dose escalation (weekly treatment) + dexamethasone~Part D: MOR03087 weekly treatment in combination with pomalidomide + dexamethasone~Part E: MOR03087 weekly treatment in combination with lenalidomide + dexamethasone~For all parts, patients will be treated until disease progression or until a maximum of 2 years after first treatment."
3168548|NCT01421186|Experimental|Phase 2a confirmatory cohorts|"Confirmatory cohorts of MOR03087 monotherapy (plus or minus dexamethasone), in combination with pomalidomide plus dexamethasone, and in combination with lenalidomide plus dexamethasone.~Following completion of Parts A, B, and C (dose escalation of MOR03087 biweekly and weekly schedules), the MTD or recommended dose and dosing regimen will be confirmed in a minimum of 6 subjects.~Following completion of Parts D (dose escalation of MOR03087 in combination with pomalidomide + dexamethasone) and E (dose escalation of MOR03087 in combination with lenalidomide + dexamethasone), the MTD and/or recommended dose in each part will be confirmed in a minimum of 6 subjects.~For all parts, patients will be treated until disease progression or until a maximum of 2 years after first treatment."
3168580|NCT01420926|Experimental|Arm A (decitabine)|"REMISSION INDUCTION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-10. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving CR CRi proceed to continuation therapy. Patients achieving CR or CRi proceed to maintenance therapy.~CONTINUATION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3168758|NCT01419639|Experimental|RAD001|RAD001 taken orally continuously until disease progression or unacceptable toxicity, dosed according to age
3168549|NCT01421173|Experimental|Vorinostat + GemBuMel|Vorinostat 200 mg by mouth on Days -8 to -2. Gemcitabine loading dose of 75 mg/m2 followed by continuous infusion. Remaining dose is 10 mg/m2/min on Day -8 and -3. Busulfan pharmacokinetics (PK) will be performed with the first dose of 105 mg/m2 by vein on Day -8. The doses of days -6 and -5 will be subsequently adjusted to target an area under curve (AUC) of 4,000 microMol.min-1. In the event that PK adjusting were not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5. Melphalan 60 mg/m2 by vein on Days -2 and -3. Stem cells by vein over about 30-60 minutes on Day 0. Rituximab 375 mg/m2 on days +1 and +8 for cluster of differentiation antigen 20 (CD20+) tumors. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented. Palifermin 60 mcg/kg by vein daily for 6 doses starting on Day 0. Dexamethasone 8 mg by vein twice a day from day -8 AM to day -2 PM.
3168550|NCT01421147|Experimental|LY2963016 + Insulin Lispro|LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily at the same timing (daytime or evening/bedtime) as participant's prestudy basal insulin injection schedule in combination with premeal insulin lispro. Insulin lispro titrated based on blood glucose readings, administered subcutaneously, three times a day for 52 weeks.
3168551|NCT01421147|Active Comparator|Lantus + Insulin Lispro|Lantus titrated based on blood glucose readings, administered subcutaneously, once daily at the same timing (daytime or evening/bedtime) as participant's prestudy basal insulin injection schedule in combination with premeal insulin lispro. Insulin lispro titrated based on blood glucose readings, administered subcutaneously, three times a day for 52 weeks.
3168552|NCT01421134|Experimental|Lurasidone|Lurasidone 20, 40 or 60 mg
3168553|NCT01421134|Placebo Comparator|Placebo|Placebo
3168554|NCT01421121|Experimental|100U EV71 vaccine with adjuvant|120 infants received 2 doses of 100U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
3168555|NCT01421121|Experimental|200 U EV71 vaccine with adjuvant|120 infants received 2 doses of 200U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
3168556|NCT01421121|Experimental|400U EV71 vaccine with adjuvant|120 infants received 2 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
3168557|NCT01421121|Experimental|200U EV71 vaccine without adjuvant|60 infants received 2 doses of 200U EV71 vaccine without adjuvant 28 days apart
3168558|NCT01421121|Placebo Comparator|Placebo|120 infants received 2 doses of placebo 28 days apart.
3168559|NCT01421108|Experimental|Loss-framed messages|
3168560|NCT01421108|Experimental|gain-framed messages|"Adolescents will randomly assign to three groups: gain-framed message , loss-framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images (6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing."
3168561|NCT01421095|Experimental|Basal Testing|
3168562|NCT01421082|Experimental|LVRC Treatment|
3168563|NCT01421069|Experimental|1|
3168564|NCT01421056|Experimental|CHF 5074 1x|oral tablet, multidose
3168565|NCT01421056|Experimental|CHF 5074 2x|oral tablet, multidose
3168566|NCT01421056|Experimental|CHF 5074 3x|oral tablet, multidose
3168567|NCT01421043|Experimental|triazolam liquid oral drops|
3168568|NCT01421043|Active Comparator|triazolam tablets|
3168569|NCT01421030|Other|quality of life, clinical outcomes and costs|Quality of life, clinical outcomes and costs after two different treatment options in patients and closest relatives
3168570|NCT01421017|Experimental|IMQ+RT|"This arm has been closed as of 6/4/2014.~Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied to all skin sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.~Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
3168571|NCT01421017|Experimental|CTX/IMQ/RT|"Week -1 (day-7): cyclophosphamide 200mg/m2 IV as single infusion~Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied all sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.~Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
3168572|NCT01421017|Experimental|CTX/RT|"For patients with only non-skin metastatic sites~First cycle (Cycle 1):~Week -1 (day -7): cyclophosphamide 200mg/m2 IV as single infusion~Weeks 1-2: RT given to one site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
3168573|NCT01421004|Experimental|500 mg FMI capsule + 250 mg FMI tablet|BE phase sequence 1= 3 weeks on FMI capsule then 1 week on FMI tablet
3168574|NCT01421004|Experimental|500 mg TKI258 FMI capsule +250 mg FMI tablet|BE phase sequence 2= 3 weeks on FMI tablet then 1 week on FMI capsule
3168575|NCT01420978|Experimental|High volume CSF diversion|The EVD will be set to an initial level of 5 mmHg. The drain will remain in place at a level of ≤ 5 mmHg until at least day 10 after SAH before a weaning trial is attempted.
3168576|NCT01420978|Active Comparator|Conventional CSF diversion|The EVD will be set to a level of 15 mmHg for as long as needed for the treatment of hydrocephalus, and subsequently weaned at the discretion of the treating physician. Lowering the level of the EVD can be considered by the treating physician if sustained intracranial hypertension occurs
3168577|NCT01420965|Active Comparator|Arm A|Sipuleucel-T autologous active cellular immunotherapy only for 3 cycles (cycle = 14 days)
3168578|NCT01420965|Experimental|Arm B|Sipuleucel-T for 3 cycles (cycle = 14 days) + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion
3168579|NCT01420965|Experimental|Arm C|Sipuleucel-T for 3 cycles (cycle = 14 days)+ cyclophosphamide (125 or 250mg/m2) IV [first cycle only] + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion
3168712|NCT01419964|Placebo Comparator|Group 02|Placebo
3168581|NCT01420926|Experimental|Arm B (decitabine and bortezomib)|"REMISSION INDUCTION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 2-11 and 1.3 mg/m^2 bortezomib SC on days 1, 4, 8, and 11. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving CR or CRi proceed to continuation therapy. Patients achieving CR or CRi proceed to maintenance therapy.~CONTINUATION THERAPY: Patients receive 1.3 mg/m^2 bortezomib SC on day 1 and 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive 1.3 mg/m^2 bortezomib SC on day 1 and 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3168582|NCT01420913|Active Comparator|Lyrica capsule(Pregabalin 150mg)|
3168583|NCT01420913|Experimental|YHD1119 A(Pregabalin SR 300mg)|
3168584|NCT01420913|Experimental|YHD1119 B(Pregabalin SR 300mg)|
3168585|NCT01420913|Experimental|YHD1119 C(Pregabalin SR 300mg)|
3168586|NCT01420900|Active Comparator|ABG II / Trident|
3168587|NCT01420900|Active Comparator|CLS / Trilogy|
3168588|NCT01420887|Experimental|Continuous Passive Motion|Subjects randomized to CPM therapy.
3168589|NCT01420887|Active Comparator|Physical Therapy|Subjects randomized to physical therapy.
3168590|NCT01420874|Experimental|FOLFOX6 & EGFRBi armed ATC Infusions|"FOLFOX6: IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, & in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.~EGFRBi armed ATC Infusions: Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion"
3168591|NCT01420861|Experimental|1000 mg GTx-758|subjects will receive daily doses of 1000 mg GTx-758
3168592|NCT01420848|Active Comparator|Auriculotherapy Group|"The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.~Two points were chosen to treat stress and anxiety (Shenmen and Brainstem)."
3168593|NCT01420848|Placebo Comparator|Placebo Group|Auriculotherapy by sham, at the fist and outer ear points. These points aren't indicated for stress and anxiety.
3168594|NCT01420848|No Intervention|Control Group|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
3168595|NCT01420835|Active Comparator|Without Protocol Group|"The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.~Five points will be chosen to treat stress according to the symptoms and Chinese diagnosis."
3168596|NCT01420835|Active Comparator|Auriculotherapy with protocol|Auriculotherapy with stress protocol points. Five points are indicated for stress (Liver yang1, Liver yang2, Shenmen, Brainstem and Kidney).
3168597|NCT01420835|No Intervention|Control Group|Control Group won't receive any treatment and will be evaluated at the same time and the same way of interventions group
3168598|NCT01420822||Subjects prescribed ALLERMIST|Subjects with allergic rhinitis prescribed ALLERMIST during study period
3168599|NCT01420796|Experimental|Swallowing and breathing exercises|This group will perform both swallowing and breathing exercises for five weeks.
3168600|NCT01420796|Experimental|Swallowing exercises|This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will perform sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
3168601|NCT01420796|Experimental|Breathing exercises|Expiratory Muscle Training will be performed with Threshold® (Respironics HealthScan, Inc, Cedar Grove, Nova Iorque, EUA).
3168602|NCT01420783|Experimental|SAR302503 100 mg|once daily X 28 days
3168603|NCT01420783|Experimental|SAR302503 200 mg|once daily X 28 days
3168604|NCT01420783|Experimental|SAR302503 400 mg|once daily X 28 days
3168605|NCT01420783|Experimental|SAR302503 600 mg|once daily X 28 days
3168606|NCT01420770|Experimental|SAR02503 300 mg qd|daily X 28 days
3168607|NCT01420770|Experimental|SAR302503 400 mg qd|daily X 28 days
3168608|NCT01420770|Experimental|SAR302503 500 mg qd|daily X 28 days
3168609|NCT01420757|Active Comparator|open|open incisional hernia repair
3168610|NCT01420757|Active Comparator|laparoscopic|laparoscopic incisional hernia repair
3168611|NCT01420744|Experimental|BT086 infusion|
3168612|NCT01420744|Placebo Comparator|1% Human Albumin infusion|
3168613|NCT01420718|Active Comparator|Mineral Trioxide Aggregate|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
3168614|NCT01420718|Experimental|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
3168615|NCT01420705||Low birth-weight cohort|Children previously enrolled in randomised trial NCT00146302 who are currently living within the Bandim Health Project study area
3168616|NCT01420692|Active Comparator|Gliclazide MR|
3168617|NCT01420692|Active Comparator|Insulin Detemir|Early initiation of insulin detemir in contrast to Gliclazide MR treatment
3168753|NCT01419678|Experimental|'collection of blood samples for PK testing'|collection of PK samples around a dosing of Posaconazole
3168618|NCT01420679|Experimental|Pralatrexate|Patients randomized to the Pralatrexate Arm will receive pralatrexate injection and Vitamins B12 and Folic Acid until a criterion for pralatrexate injection treatment discontinuation is met.
3168619|NCT01420679|No Intervention|Observation|Patients randomized to the Observation Arm will receive Vitamins B12 and Folic Acid and remain under observation until a criterion for observation discontinuation is met.
3168620|NCT01420666|Active Comparator|Maxigesic 325|Maxigesic 325 (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day, orally, with food
3168621|NCT01420666|Active Comparator|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
3168622|NCT01420666|Active Comparator|Ibuprofen|ibuprofen 97.5mg, three tablets four times a day, orally, with food
3168623|NCT01420666|Placebo Comparator|Placebo|Placebo tablets
3168624|NCT01420653|Experimental|Maxigesic 325|Acetaminophen 325mg + ibuprofen 97.5mg per tablet, two tablets every 6 hours, orally
3168625|NCT01420653|Active Comparator|Acetaminophen|Acetaminophen 325mg per tablet (standard dose acetaminophen), two tablets every 6 hours, orally
3168626|NCT01420653|Active Comparator|Ibuprofen|Ibuprofen 97.5mg per tablet (i.e. low dose ibuprofen), two tablets every 6 hours, orally
3168627|NCT01420653|Placebo Comparator|Placebo|Placebo tablets, every 6 hours, orally
3168628|NCT01420640|Active Comparator|Tai Chi|
3168629|NCT01420640|Active Comparator|Aerobic Exercise Training|
3168630|NCT01420627|Experimental|EZN-2279|Patients crossed over to receive EZN-2279 following an Adagen lead-in period
3168631|NCT01420627|Active Comparator|Adagen|Patients start on Adagen and cross over to experimental EZN-2279 treatment
3168632|NCT01420614|Experimental|Radial|group of patients undergoing primary angioplasty by transradial approach
3168633|NCT01420614|Active Comparator|Femoral|group of patients undergoing primary angioplasty by transfemoral approach
3168634|NCT01420601||Temsirolimus|Among the cases registered and treated in the Special Investigation, All-case Survey of temsirolimus, those continuously treated with temsirolimus for more than 24 weeks will be included.
3168635|NCT01420588||gastric cancer|
3168636|NCT01420588||gastritis|
3168637|NCT01420588||gastric ulcer|
3168638|NCT01420588||normal|
3168639|NCT01420575|Experimental|Visual Decision Making Aid|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower overweight patients with schizophrenia/schizoaffective disorder and help them efficiently arrive at a treatment decision that can be successfully implemented.
3168640|NCT01420575|Active Comparator|Usual Care|Usual care reflects the standard of care in psychiatry. Psychiatrists will recommend treatment for overweight patients with schizophrenia on olanzapine who have failed to lose weight despite life style and dietary modifications. They may recommend switching to a comparable antipsychotic with a lower incidence of weight gain.
3168641|NCT01420562||Posaconazole oral suspension|"One group of patients will receive posaconazole oral suspension as prophylactic agent.~Blood sampling: At day of transplantation, day 7 and 14, 9 blood samples will be collected to calculate AUC. Moreover, citrulline will be determined to objectively evaluate the severity of mucositis."
3168642|NCT01420562||Posaconazole oral tablet|"Once the oral tablet is available for adminstration to patients, a second group of patients will receive these tablets as prophylactic agent.~Blood sampling: At day of transplantation, day 7 and 14, 9 blood samples will be collected to calculate AUC. Moreover, citrulline will be determined to objectively evaluate the severity of mucositis."
3168643|NCT01420549|Experimental|Group 01|Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according with titration.
3168644|NCT01420549|Active Comparator|Group 02|Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according with titration.
3168645|NCT01420536|Experimental|Canine Guidance|"Complete dentures adjusted with mutually protected articulation in which the vertical and horizontal overlap of the canine teeth disengage the posterior teeth in the excursive movements of the mandible (The Glossary of Prosthodontic Terms. J. Prosthet. Dent., 94(1): 10-92)"
3168646|NCT01420536|Sham Comparator|Bilateral Balanced Occlusion|Complete dentures as conventionally adjusted: anterior and posterior teeth presented bilateral contact in excentric positions
3168647|NCT01420523|Experimental|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
3168648|NCT01420510|Experimental|Adelmidrol|Efficacy of Adelmidrol vaginal gel in preventing vaginitis in oncologic patients
3168649|NCT01420510|Placebo Comparator|Placebo|Efficacy of Placebo in preventing vaginitis in oncologic patients
3168650|NCT01420497|Active Comparator|methylprednisolone,infiltration|
3168651|NCT01420497|Active Comparator|epidural injection|
3168652|NCT01420484||different blood pressure intervals|
3168653|NCT01420471|Active Comparator|Saline-impregnated spacer|Saline-impregnated spacers are actively being used as the standard of care. It does not contain any active ingredients.
3168654|NCT01420471|Experimental|Triamcinolone-impregnated spacer|This study arm receives the experimental treatment, a Triamcinolone-impregnated spacer.
3168655|NCT01420445|Experimental|YHD001 dose level 1|YHD001 dose level 1
3168656|NCT01420445|Experimental|YHD001 dose level 2|YHD001 dose level 2
3168657|NCT01420445|Active Comparator|Pelargonium sidoides extract|Pelargonium sidoides extract (Syrup)
3168658|NCT01420445|Placebo Comparator|Placebo|Placebo for YHD001 & active comparator(syrup)
3168659|NCT01420432|Experimental|Human umbilical cord-derived MSCs and DMARDs|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated after three months and DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months
3168660|NCT01420432|No Intervention|DMARDs|DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months
3168661|NCT01420419|Experimental|Lanolin|Pea sized amount of lanolin to be applied to nipple and areola after every breast feed (approximately every 2-3 hours), until pain is completely resolved for a maximum of 7 days
3168754|NCT01419665|Experimental|GP2013|Type: Biological/Vaccine
3168755|NCT01419665|Active Comparator|rituximab|Type: Biological/Vaccine
3168756|NCT01419652|Active Comparator|continue hypglycemic meds|
3168662|NCT01420419|Other|Standard postpartum nursing care|Women in standard care control group may receive any other nursing intervention to manage their nipple pain, including (but not limited to): recommending application of expressed breast milk, analgesics (such as acetaminophen or ibuprofen), breast shells, air drying, changing position / latch, cold or warm compresses
3168663|NCT01420406|Placebo Comparator|0 mg retinol|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
3168664|NCT01420406|Experimental|12 mg BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule.
3168665|NCT01420406|Experimental|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
3168666|NCT01420406|Experimental|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
3168667|NCT01420393|Active Comparator|Rhythm Control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal Heart Failure therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug.
3168668|NCT01420393|Active Comparator|Rate Control|Patients in the rate control group will receive optimal Heart Failure therapy and rate control measures to achieve a resting HR < 80 bpm and 6-minute walk HR < 110 bpm.
3168669|NCT01420367|Experimental|Single dose of antibiotics|This group will receive one dose of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) in the pre-operative period and two post-operative IV 'doses' of normal saline 8 and 16 hours after the pre-operative dose, which will act as a placebo and facilitate blinding.
3168670|NCT01420367|Active Comparator|Three doses of antibiotics|This group will receive one pre-operative dose of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) and two post-operative doses of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) 8 and 16 hours after the pre-operative dose.
3168671|NCT01420341|Active Comparator|Co-trimoxazole 12|Receive treatment with co-trimoxazole for 12 weeks.
3168672|NCT01420341|Experimental|Co-trimoxazole 20|Receive treatment with co-trimoxazole for 20 weeks.
3168673|NCT01420328|Placebo Comparator|Placebo Arm|Obese subjects with near normal cholesterol
3168674|NCT01420328|Active Comparator|Vytorin Arm|Obese subjects with near normal cholesterol
3168675|NCT01420302|Experimental|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
3168676|NCT01420302|Active Comparator|Nurse-directed|Nurse-directed blood glucose control (80-110 mg/dL)
3168677|NCT01420289|Experimental|HPIPC|High Pressure Intermittent Pneumatic compression (HPIPC)to be performed for 45 minutes twice daily
3168678|NCT01420289|Active Comparator|Excercise|Walking on a graded treadmill for 45 minutes once daily
3168679|NCT01420263|Active Comparator|Re-feeding gastric residuals|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
3168680|NCT01420263|Active Comparator|Fresh feeding breastmilk/formula only|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be discarded and fresh breast milk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
3168681|NCT01420250|Experimental|Cabazitaxel with Intensity Modulated Radiation Therapy (IMRT)|Weekly Cabazitaxel with concurrent IMRT
3168682|NCT01420237|Other|Restoration ADM X3 Device|Restoration ADM X3 Device in total hip replacement.
3168683|NCT01420224||Healthy volunteers|
3168684|NCT01420224||Chuvash polycythaemia|
3168685|NCT01420211|Experimental|Primovist|
3168686|NCT01420198|Experimental|Lifestyle intervention|Lifestyle intervention: 500 participants from Iraq with obesity and/or prediabetes (impaired fasting glucose) and we expect to recruit 308 participants. Half of them will be randomized to lifestyle intervention i.e. group counseling and physical activity during a period of 1 year. An equal amount of controls will have treatment as usual. Every third month blood tests and a physical exam will be conducted in the intervention group.
3168687|NCT01420198|No Intervention|Controls|Controls have treatment as usual. Every third month blood tests and a physical exam will be conducted in the control group.
3168688|NCT01420172||Post hematopoietic stem cell transplantation|Patients who were seen post hematopoietic stem cell transplantation between 01Jan2000 and 30Jun2011
3168689|NCT01420159|Experimental|Methoxyflurane|
3168690|NCT01420159|Placebo Comparator|Normal Saline|
3168691|NCT01420146|Experimental|Zr89-trastuzumab PET/CT|Zr89-trastuzumab PET/CT single arm
3168692|NCT01420133|Experimental|Normal regimen|without special regimen for corticosteroid therapy
3168693|NCT01420133|Active Comparator|Standard arm|with diet low in salt and sugar
3168694|NCT01420094|Experimental|Arm 1|
3168695|NCT01420094|Active Comparator|Arm 2|
3168696|NCT01420094|Placebo Comparator|Arm 3|
3168697|NCT01420081|Experimental|B|PI3K Basal, IV Compound
3168698|NCT01420081|Experimental|C|PI3K Activated, Oral Compound
3168699|NCT01420081|Experimental|F|Japanese lead in cohort, IV compound
3168700|NCT01420068||All patients|All patients previously treated with study medication in the CSPP100A2365 and CSPP100A2365E1 studies.
3168701|NCT01420055|Experimental|fingolimod|
3168702|NCT01420042|Placebo Comparator|Placebo (lemon flavoured cordial)|NNZ-2566 reconstituted in Lemon flavoured cordial and Water for Injection. 6/8 subjects in each cohort (3 cohorts in total) to receive NNZ-2566 experimental treatment.
3168703|NCT01420042|Experimental|NNZ-2566|
3168704|NCT01420016|Active Comparator|Prioritized Clinical Decision Support|
3168705|NCT01420016|No Intervention|Usual Care|
3168706|NCT01420003|Experimental|Allergen Challenge|
3168707|NCT01419990|Experimental|GLPG0634 capsules|
3168708|NCT01419990|Placebo Comparator|Placebo capsules|
3168709|NCT01419977|Placebo Comparator|Placebo|Normal saline solution
3168710|NCT01419977|Experimental|Dalteparin|5000 unites subcutaneously, Other Name: Fragmin
3168711|NCT01419964|Experimental|Group 01|ACH24
3168713|NCT01419951|Active Comparator|Clinic Only Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
3168714|NCT01419951|Active Comparator|Pediatrician Counseling|A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
3168715|NCT01419951|Experimental|Clinic + Home Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
3168716|NCT01419938|Active Comparator|Light therapy for two weeks|
3168717|NCT01419938|Active Comparator|Light therapy and CBT|Two weeks of light therapy and after that 4 weeks of Cognitive behaviour therapy (CBT)
3168718|NCT01419925|Experimental|Group A|Two Multimeric-001 administrations followed by TIV
3168719|NCT01419925|Experimental|Group B|One administration of Multimeric-001 followed by TIV
3168720|NCT01419925|Experimental|Group C|One administration of adjuvanted M-001 followed by TIV
3168721|NCT01419925|Active Comparator|Group D|One administration of placebo followed by TIV
3168722|NCT01419912|Experimental|soy milk|
3168723|NCT01419912|Experimental|cow's milk|
3168724|NCT01419899|Experimental|Brief Intervention|This arm of the study will receive an assessments survey followed by a brief intervention concerning the relationship between the participants use of drugs and/or sexual risk and rik for HIV and hepatitis C infections. Following the intervention the participants will be offered free rapid testing for HIV and hepatitis C.
3168725|NCT01419899|No Intervention|Standard Care|This arm of the study will receive an assessments survey. Following the assessment the participants will be offered free rapid testing for HIV and hepatitis C.
3168726|NCT01419886||Dysphagia|
3168727|NCT01419860|Experimental|Pixel intensity|Pixel intensity of fluorescence signal describing pixel microcirculation of colon
3168728|NCT01419847|Active Comparator|topical Penlac nail lacquer|3-1 randomization of active to placebo
3168729|NCT01419847|Placebo Comparator|Placebo|
3168730|NCT01419834|Experimental|Humanized 3F8 Monoclonal Antibody (Hu3F8)|This phase I single arm trial assesses the toxicity of escalating doses of hu3F8.
3168731|NCT01419821|Active Comparator|Vit D supplementation|Group 2-Infants with 25(OH)D below 15ng/ml receiving continued vitamin D supplementation of 800IU (4gtt/d) for one year.
3168732|NCT01419821|Placebo Comparator|Placebo group|Group 3- Infants with 25(OH)D below 15ng/ml those receiving the placebo.
3168733|NCT01419821|No Intervention|Normal group|Group 1- infants with 25(OH)D above 15ng/ml (normal levels) will receive no intervention.
3168734|NCT01419808|Active Comparator|Vascularized Bone Graft|Patients randomized to a vascularized bone graft will undergo a 1, 2-ICRSA vascularized bone graft based upon the 1,2 supra-retinacular vessels as described by Zaidemberg . (9. Zaidemberg C, Siebert JW, Angrigiani C. A new vascularized bone graft for scaphoid nonunion. J Hand Surg. 1991; 16A: 474-478.)
3168735|NCT01419808|Active Comparator|Non-Vascularized Bone Graft|Patients randomized to the non-vascularized group will undergo trapezoidal bone grafting from the iliac crest as described by Fernandez . (10. Fernandez DL. A technique for anterior wedge-shaped grafts for scaphoid nonunions with carpal instability. J Hand Surg [Am]. 1984 Sep;9(5):733-7.)
3168736|NCT01419795|Experimental|Arm I (lenalidomide, rituximab)|Patients who have relapsed/progressed within 180 days post-transplant (Cohort 1), beyond day 180 post-transplant (Cohort 2), or within 6 months but were not started within 3 months of relapse, receive lenalidomide PO QD on days 1-28 (patients with CLL/SLL/PLL) or days 1-21 (patients with NHL). Patients in Cohorts 1 and 2 also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and then every two months for courses 3, 5, 7, 9, and 11.
3168737|NCT01419795|Active Comparator|Arm II (lenalidomide)|Patients who have relapsed/progressed at any time point post-transplant and who have contraindications, prior severe hypersensitivity reaction to rituximab infusion, to receive rituximab or have CD20 negative disease (Cohort 3) receive lenalidomide as in Arm I.
3168738|NCT01419782|Experimental|Whole-body vibration|whole body vibration will be applied the right lower limb.
3168739|NCT01419769|Experimental|AXIOS Stent and Delivery System|
3168740|NCT01419756||Single Arm|Imaging comparison study. No intervention.
3168741|NCT01419743||patients with Vit D level of < 20ng/mL: Group 1|randomized to receive 400 IU of vitamin D per day
3168742|NCT01419743||patients with Vit D levels <20ng/mL: Group 2|Randomized to receive 2000IU of Vitamin D per day
3168743|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 3|Randomized to receiving placebo
3168744|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 4|Randomized to receive 400IU of vitamin D per day
3168745|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 5|Randomized to receive 2000IU of vitamin D per day
3168746|NCT01419743||patients with vit D levels > 30ng/mL: Group 6|No treatment
3168747|NCT01419730|Active Comparator|Vitamin D3 50,000 IU|Vitamin D3 50,000 IU: Patients will be assigned to receive a daily multivitamin, calcium supplement and 50,000 IU/week of vitamin D for a period of 24 weeks.
3168748|NCT01419730|Active Comparator|Vitamin D3 50,000 IU and Physical Activity|Vitamin D3 50,000 IU and Physical Activity: Patients will be assigned to receive a daily multivitamin, calcium supplement, 50,000 IU/week of vitamin D, and a progressive walking and resistance band exercise prescription for a period of 24 weeks.
3168749|NCT01419730|No Intervention|Control|Patients will be assigned to receive a daily multivitamin, calcium supplement, vitamin D placebo, and standard care monitoring.
3168750|NCT01419717|Experimental|denosumab|120 milligrams of denosumab injected subcutaneously every 4 weeks
3168751|NCT01419704|Experimental|Hemoglobinopathies diagnosed patients|Recipients diagnosed with Hemoglobinopathies are treated with an enriched hematopoetic stem cell infusion from living donor bone marrow
3168752|NCT01419691|Experimental|Phase 2 Dose|Auranofin 6 mg orally in the morning / 6 mg orally in the evening
3168757|NCT01419652|No Intervention|control - hold drug|
3168759|NCT01419613|Experimental|Motivational Interviewing|
3168760|NCT01419613|Active Comparator|Physical Activity Counseling|
3168761|NCT01419600|Experimental|Group 1 - 4, single ascending dose AZD 8683|Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo.
3168762|NCT01419600|Placebo Comparator|Group 1-4 single ascending dose Placebo|Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo.
3168763|NCT01419587|Experimental|Ketogenic diet|Diet formulated to maintain elevated ketones during therapy
3168764|NCT01419561||Group A|Treatment
3168765|NCT01419561||Group B|Treatment
3168766|NCT01419561||Group C|Observation
3168767|NCT01419483|Experimental|Ketogenic diet|Diet designed to maintain elevated ketone levels during therapy
3168768|NCT01419470|Experimental|YHD1044 I|
3168769|NCT01419470|Experimental|YHD1044 III|
3168770|NCT01419470|Experimental|YHD1044 V|
3168771|NCT01419457|Experimental|Group 1|Normal hepatic function
3168772|NCT01419457|Experimental|Group 2|Mild hepatic impairment
3168773|NCT01419457|Experimental|Group 3|Moderate hepatic impairment
3168774|NCT01419457|Experimental|Group 4|Severe hepatic impairment
3168775|NCT01419444|Active Comparator|Traditional, Onsite Treatment|Onsite treatment using airflow exercises. Patients will receive face-to-face treatment with the research speech pathologist two times per week.
3168776|NCT01419444|Experimental|Telemedicine Treatment|Participants will receive treatment via telemedicine at select AHEC sites around the state of Arkansas. Treatments will occur twice per week with the research speech pathologist.
3168777|NCT01419431||Colon cancer patients|Laparoscopic resection
3168778|NCT01419418||Peripheral Arterial Disease (PAD)|This is a longitudinal observational study. There were no interventions administered.
3168779|NCT01419405|Experimental|Pregabalin/placebo|
3168780|NCT01419405|Active Comparator|placebo/remifentanil|
3168781|NCT01419405|Placebo Comparator|placebo/placebo|
3168782|NCT01419405|Experimental|Pregabalin/Remifentanil|
3168783|NCT01419392|Experimental|Sildenafil citrate|
3168784|NCT01419392|Placebo Comparator|placebo|
3168785|NCT01419379||1|
3168786|NCT01419353|Experimental|Follicular Estrogen, Antagonist, IVF|Follicular Estrogen in Antagonist IVF protocol
3168787|NCT01419353|Active Comparator|long IVF protocol|long IVF protocol
3168788|NCT01419327||Group 1|Drug (incl. Placebo)
3168789|NCT01419314|Experimental|Splinting application|Participants will be asked to wear a pair of LE night splints for the duration of the study (6 weeks) at night/during sleep only.
3168790|NCT01419314|Placebo Comparator|Splint liner application|The liner or protective sheath from the Walkabout™ splint will be applied to the LEs, with the structural frame of the splint removed by the researcher in advance, patients will be blinded to this arm of the study.
3168791|NCT01419288|Active Comparator|No Body weight support|
3168792|NCT01419288|Experimental|Body weight support|
3168793|NCT01419275|Experimental|Moyamoya|Approximately 60 Moyamoya patients will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
3168794|NCT01419275|Experimental|Acute stroke|Approximately 60 acute stroke patients will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
3168795|NCT01419275|Experimental|Healthy participants|Approximately 30 healthy participants will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
3168796|NCT01419275|Experimental|Diagnosis unspecified|Approximately 60 participants with diagnosis unspecified will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
3168797|NCT01419262|Experimental|2000 IU per day vitamin D|
3168798|NCT01419262|Active Comparator|400 IU per day vitamin D|
3168799|NCT01419249|Other|Retrospective cohort|
3168800|NCT01419236|Experimental|Testosterone Solution 2% 60 milligrams (mg)|Testosterone Solution 2% 60 mg applied topically once daily with possible 1-time titration to 30 milligrams per day (mg/day) or 90 mg/day for 16 weeks
3168801|NCT01419236|Placebo Comparator|Placebo|Placebo solution applied topically once daily for 16 weeks
3168802|NCT01419223||Consent to participate (Group 1)|Active military and veterans who consent to participate in an INTRuST PTSD or TBI research trial.
3168803|NCT01419223||Decline to participate (Group 2)|Active military and veterans who decline to participate in an INTRuST PTSD or TBI research trial.
3168804|NCT01419210|Experimental|Complementary and Alternative Medicine (CAM) therapies|This pilot program attends to the need for appropriate patient-centered interventions that integrate CAM with traditional care to maximize both quantity and QOL for women with ovarian cancer.
3168805|NCT01419197|Experimental|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.
3168806|NCT01419197|Active Comparator|Treatment of physician's choice|Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.
3168807|NCT01419184|Experimental|Daptomycin|4 milligrams per kilogram (mg/kg) daptomycin administered intravenously (IV) once a day until end of antibiotic therapy for complicated skin and skin structure infections (cSSSI) or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
3168808|NCT01419184|Active Comparator|Vancomycin|Vancomycin was reconstituted per the manufacturer's instructions and was dosed per investigator's discretion and was administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occured first. Investigators treated participants according to their usual decision-making and discretion
3168809|NCT01419171|Experimental|OMEGA™ Monorail Coronary Stent System|
3168810|NCT01419145|Experimental|Multimodal intervention|
3168811|NCT01419145|Active Comparator|Standard Care|
3168812|NCT01419132|Placebo Comparator|High doses furosemide|administration of furosemide alone
3168813|NCT01419132|Experimental|HSS plus furosemide|administration of hypertonic saline solution plus high doses of furosemide bid
3168814|NCT01419119|Experimental|Group 1|Vitamin D3, 10 000 IU daily. Treatment to patients with Serum-vitamin D levels below 25 nmol/L
3168815|NCT01419119|Experimental|Group 2a|Vitamin D3 2000 IU daily, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 nmol/l will be randomised to
3168816|NCT01419119|Experimental|Group 2b|Vitamin D3 2000 IU weekly, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 mol/l will be randomised to
3168817|NCT01419119|Experimental|Group 3|Vitamin D3, 2000 IU daily i.e. 3 drops orally once daily for 12 weeks, treatment to patients with Serum-vitamin D levels between 50 and 74 nmol/L
3168818|NCT01419106|No Intervention|Control|This arm of the study will NOT receive point of care ultrasound. They will receive all other standard care implemented during their visit to the ED (currently, ultrasound is NOT standard of care). The same blood tests will be done in both groups, as this will offer a means of comparing physiological changes between the two arms.
3168819|NCT01419106|Experimental|Ultrasound|This group WILL receive point of care ultrasound. The protocol they will receive is the ACES protocol (described above).
3168820|NCT01419093|No Intervention|5A Communication|Behavioral: 5 A intervention for physical activity
3168821|NCT01419080||Peripheral Arterial Disease (PAD) patients|Patients with new onset or exacerbation of peripheral artery (PA) symptoms.
3168822|NCT01419067|Other|Craniopharyngioma Patients|"Craniopharyngioma patients will have limited surgery and a 5mm clinical target volume margin in combination with proton therapy. Proton therapy will be indicated for patients with diagnosed craniopharyngioma who are not treated with radical surgery (gross-total resection). Patients who have had radical surgery or limited surgery prior to enrollment on this study and have no evidence of tumor will be observed for 5 years.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine will be given to aid in tumor visualization."
3168823|NCT01419041|Other|Arm A|CLCR: Creatinine clearance
3168824|NCT01419041|Other|Arm B|CLCR: Creatinine clearance
3168825|NCT01419028||Patients with perinatal and/or infantile onset HPP|Patients with a confirmed diagnosis of perinatal or infantile onset hypophosphatasia (HPP)
3168826|NCT01419015|Experimental|TAVI-TF Approach|Transcatheter aortic valve implantation and transfemoral approach. SAPIEN XT NovaFlex delivery system will be used.
3168827|NCT01419002|Experimental|Neoadjuvant RTx|
3168828|NCT01419002|Active Comparator|Surgery|
3168829|NCT01418989|Experimental|1|
3168830|NCT01418989|Experimental|2|
3168831|NCT01418976|Experimental|Intensive Mobility Training (IMT)|Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
3168832|NCT01418963|Experimental|Active|
3168833|NCT01418963|Placebo Comparator|Placebo|
3168834|NCT01418950|Active Comparator|Control group|The control group will receive standard verbal counseling regarding outcome of premature infants
3168835|NCT01418950|Experimental|Study Group|Study Group will receive gestational age specific written information prior to receiving standard verbal counseling about outcome of premature infants.
3168836|NCT01418937|Experimental|HPV Group|
3168837|NCT01418911||diabetes type 2|type 2 diabetes patients 40-70 years of age hebrew speaking members of maccabi healthcare services
3168838|NCT01418898|Experimental|Nutrient Fortified Beverage|
3168839|NCT01418898|Placebo Comparator|Control|
3168840|NCT01418885||SIVD,VaD|vascular disease in patients with SIVD
3168841|NCT01418885||SIVD,VCIND|vascular cognitive impairment no dementia in patients with SIVD
3168842|NCT01418885||normal controls|normal elderly controls
3168843|NCT01418872|Active Comparator|Healthy Breakfast|"The activity will be performed at the school dining hall, scheduling 1 hour for breakfast,within the school hours, with maximum 50 children per turn It involves placing a table mat, a cup, a plate and two slices of bread per child, plus 1-liter bottle of milk for each four children and 1-liter bottle of oil for each twelve. The dining hall will be all set up before the students come in.~Participatory lesson : Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, The role of dairy products at breakfast,The role of fruits at breakfast, Importance of exercise for cardiovascular health, The role of unhealthy habits: sedentary lifestyle.~The students will be invited to take the table mat and the cup, in which is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity.~A pamphlet of the NAOS strategy will also be delivered."
3168844|NCT01418872|Experimental|Didactic concerts|"The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered."
3168845|NCT01418859||radiation therapy only|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive radiation therapy only. radiation therapy regimen: 3D-CRT pelvic radiation, 95%CTV DT 45Gy/25f. Radiation field include tumor bed and regional lymph nodes area. Upper border: branching of abdominal aorta. The radiation fields go down along the iliac vessels (including regions of 7mm out of the iliac vessels) and include the tumor bed region. Lower border: the inferior margin of obturator foramen.
3168888|NCT01418508|Experimental|very low protein diet plus α-keto acid|0.3g of proteins per kilo of body weight per day
3168938|NCT01418183|Experimental|2.5ml 5% levobupivacaine|2.5ml 5% levobupivacaine to both maxillary and mandibular branches of trigeminal nerve on experimental side. (total 10ml)
3168846|NCT01418859||concurrent chemoradiotherapy|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive concurrent chemotherapy and radiation therapy. radiation therapy regimen is the same with radiation therapy only group. Chemotherapy regimen: Topotecan (1.5mg /m2 d1,2, 1mg d3) and Cisplatin (25mg /m2 d1-3). Chemotherapy will be carry out in the 2nd and 6th week of radiation therapy.
3168847|NCT01418859||concurrent and additional chemotherapy|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive concurrent chemotherapy and radiation therapy, and additional chemotherapy after concurrent treatment. radiation therapy regimen is the same with radiation therapy group. Chemotherapy regimen: Topotecan (1.5mg /m2 d1,2, 1mg d3) and Cisplatin (25mg /m2 d1-3). Chemotherapy will be carry out in the 2nd and 6th week of radiation therapy. Additional chemotherapy regimen is the same with concurrent chemotherapy, and will be carry out in the 4th and 8th week after radiation therapy.
3168848|NCT01418846||adult hematology patients|
3168849|NCT01418846||pediatric patients age 5-18years|
3168850|NCT01418846||adult pneumology patients|
3168851|NCT01418820|Experimental|Verum stimulation|repetitive transorbital alternating current stimulation (rtACS)
3168852|NCT01418820|Sham Comparator|Placebo stimulation|compared to verum stimulation the same electrode montage set-up is used during placebo stimulation, except that placebo patients receive a minimal stimulation
3168853|NCT01418807|Experimental|TRANSVAGINAL EXTRACTION|
3168854|NCT01418807|Active Comparator|TRANSUMBILICAL EXTRACTION|
3168855|NCT01418794|Active Comparator|Low dose rapamycin group|Concentration of rapamycin was 1.5%
3168856|NCT01418794|Experimental|High dose rapamycin group|Concentration of rapamycin is 2.5%
3168857|NCT01418781||Gout|Patients with ICD-9 for gout
3168858|NCT01418781||No Gout|Patients withOUT ICD-9 for gout
3168859|NCT01418781||Tophaceous gout|Patients with ICD-9 for tophaceous gout
3168860|NCT01418781||non-tophaceous gout|those with ICD-9 for gout other than the codes specific for tophaceous gout
3168861|NCT01418768|Experimental|Rehabilitation|
3168862|NCT01418755|Experimental|platelet rich plasma injection|Fifty consecutive and strictly selected patients, affected by Grade II or III chondromalacia, underwent one year treatment (9 injections) with autologous PRP in a liquid form with 2,0 to 2,5-fold platelets concentration. Outcome measures included the Lysholm, Tegner, IKDC, and Cincinnati scores. Magnetic resonance imaging was used to evaluate cartilage thickness and degree of degeneration.
3168863|NCT01418742|Active Comparator|Doxycycline 100 mg BID oral use|
3168864|NCT01418742|Placebo Comparator|Placebo 100 mg BID oral use|
3168865|NCT01418729|Active Comparator|Sorafenib plus Pravastatin|The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h.
3168866|NCT01418729|Placebo Comparator|Sorafenib plus Placebo|The treatment received will be sorafenib 400 mg/12 h + placebo/24 h.
3168867|NCT01418716|Experimental|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
3168868|NCT01418716|Active Comparator|Passive diffusion|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
3168869|NCT01418703|Experimental|Closed Loop Control (CLC)|"The CLC used a computer to make recommendations for their insulin treatment. This study arm was designed to demonstrate management of glucose using a modular insulin management system based on continuous glucose monitoring and targeted towards the avoidance of hypoglycemic and prolonged hyperglycemic episodes (i.e. control to range). This system was designed to both:~monitor the meal boluses of the patient and correct it in case of observed/predicted under insulinization (avoidance of prolonged hyperglycemia), based on a coarse and subjective knowledge of the meal amount, a precise understanding of the subject's day to day insulin treatment, continuous glucose monitoring, and past insulin injections;~predict and avoid hypoglycemic events, based on continuous glucose reading and past insulin injection."
3168870|NCT01418703|Placebo Comparator|Open Loop|The subject were in charge of their insulin treatment.
3168871|NCT01418690||Non-invasive near infra-red device (NIRS)|
3168872|NCT01418677|Active Comparator|Cohort 1|
3168873|NCT01418677|Active Comparator|Cohort 2|
3168874|NCT01418677|Active Comparator|Cohort 3|
3168875|NCT01418664|Active Comparator|Study group|Each woman in above group will recieve in addition to routine ferrous sulphate and calcium lactate, 4000IU of vitamin D
3168876|NCT01418664|No Intervention|control group|Women in this group will recieve ferrous sulphate and calcium lactate
3168877|NCT01418651|Experimental|Milnacipran|Drug
3168878|NCT01418638||30 Patients with MDD.|30 Patients aged 18-65, who were diagnosed with MDD according to the DSM-IV criteria.
3168879|NCT01418573|Experimental|Palaeolithic-type meal 1|
3168880|NCT01418573|Experimental|Palaeolithic-type meal 2|
3168881|NCT01418573|Placebo Comparator|The reference meal|
3168882|NCT01418560|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with chronic renal failure.
3168883|NCT01418560|No Intervention|Absolute medicine therapy|Maintenance of anti-renal failure medications only
3168884|NCT01418521|Active Comparator|Ringer-albumin|Patients receiving the standard care of ringer-albumin as volume replacement after cardiac surgery
3168885|NCT01418521|Experimental|Tetraspan|patients receiving a 3rd generation HES solution (tetraspan) for volume replacement after cardiac surgery
3168886|NCT01418508|No Intervention|low protein diet|Behavioral: low protein diet 0.6g of proteins per kilo of body weight per day
3168887|NCT01418508|Experimental|low protein diet plusα-keto acid|0.6g of proteins per kilo of body weight per day
3169220|NCT01416103|Experimental|Intervention group|Intervention group
3168889|NCT01418495||Ancillary-Correlative (pharmacokinetics of ch14.18)|Patients undergo blood sample collection at baseline and during and after course 1, 3, or 5 of treatment for pharmacokinetic analysis. Some patients undergo blood sample collection at baseline and during and after two treatment courses (1 and 3, 1 and 5, or 3 and 5).
3168890|NCT01418482|Experimental|Mepilex Border Ag|Mepilex Border Ag, a silver dressing will be used
3168891|NCT01418469|Experimental|Caseinate protein intake|18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
3168892|NCT01418469|Experimental|Whey protein isolate intake|18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
3168893|NCT01418469|Experimental|Soy protein intake|18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
3168894|NCT01418469|Experimental|soy+BCAA protein intake|18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
3168895|NCT01418456|Experimental|Active Antibiotic Group|Patients in the antibiotic group will remain on antibiotics until their foot ulcer heals or up to 20 weeks
3168896|NCT01418456|No Intervention|Non antibiotic group|
3168897|NCT01418430|Experimental|CHOP-daclizumab|
3168898|NCT01418404|Experimental|Noxious TS in study A|Noxious TS in study A
3168899|NCT01418404|Active Comparator|Innocuous TS|Innocuous TS in study A
3168900|NCT01418404|Experimental|High Frequency of Noxious TS|High Frequency of Noxious TS in study B
3168901|NCT01418404|Active Comparator|Low Frequency of Noxious TS|Low Frequency of Noxious TS in study B
3168902|NCT01418404|Experimental|High Intensity of Noxious TS|High Intensity of Noxious TS in study C
3168903|NCT01418404|Active Comparator|Low Intensity of Noxious TS|Low Intensity of Noxious TS in study C
3168904|NCT01418391|Experimental|morphine consumption|
3168905|NCT01418378|Active Comparator|Sigma CR150|Sigma CR150 femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
3168906|NCT01418378|Active Comparator|Sigma CR|Sigma CR femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
3168907|NCT01418365|Experimental|Metronidazole + MMX placebo|
3168908|NCT01418365|Experimental|Metronidazole + MMX Mesalazine/mesalamine|
3168909|NCT01418352|Placebo Comparator|Matching Placebo|
3168910|NCT01418352|Experimental|Group A: Aripiprazole 52.5 mg|The dose of Aripiprazole 52.5 mg will be achieved after a mandatory titration schedule.
3168911|NCT01418352|Experimental|Group B: Aripiprazole 77.5 mg|The dose of Aripiprazole 77.5 mg will be achieved after a mandatory titration schedule.
3168912|NCT01418352|Experimental|Group C: Aripiprazole 110 mg|The dose of Aripiprazole 110 mg will be achieved after a mandatory titration schedule.
3168913|NCT01418339|Placebo Comparator|Matching Placebo|Once weekly matching placebo
3168914|NCT01418339|Experimental|Aripiprazole|Once-weekly tablets
3168915|NCT01418326||Sevoflurane|Sevoflurane exposure for radical cancer surgery
3168916|NCT01418326||Propofol|Propofol exposure for cancer surgery
3168917|NCT01418313||DCE-MRI|Magnetic resonance imaging (MRI) with and without FDA approved contrast agents: MRI is a non invasive imaging technique used to visualize the internal structure of the body in detail. The MRI machine is an oversized magnet that is always on. It will be used in this study to provide anatomical and functional (MRI with contrast) information about atherosclerotic plaques.
3168918|NCT01418313||PET/CT and PET/MR|Positron emission tomography (PET)/ computer tomography (CT): PET is a nuclear medicine imaging technique, which produces images of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on a biologically active molecule. Nowadays PET imaging is most useful in combination with anatomical imaging, such as CT scanners, thereby PET scanners are now available with integrated high-end multi-detector row CT scanners. Because the two scans can be performed in immediate sequence during the same session and with the patient not changing position between the two scans, areas of abnormality on PET images can be directly correlated with anatomy on the CT images.
3168919|NCT01418313||PET/MR|Positron emission tomography (PET)/MRI: PET is a nuclear medicine imaging technique, which produces images of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on a biologically active molecule. To avoid the additional radiation deriving from the CT scan during PET/CT imaging, nowadays PET imaging can be paired with MR anatomical images.
3168920|NCT01418300|Active Comparator|sequential therapy|first five day amoxicillin+PPI later five day PPI+clarithromycin+metronidazole
3168921|NCT01418300|Active Comparator|conventional triple thearpy|PPI+amoxicillin+clarithromycin
3168922|NCT01418287||Hospitalized|Subjects who are hospitalized due to influenza-like illness
3168923|NCT01418287||Non-hospitalized|Subjects who are not hospitalized
3168924|NCT01418274|Experimental|Single arm|
3168925|NCT01418261|Experimental|Renal Denervation|Subjects are treated with the renal denervation procedure after randomization and maintained baseline anti-hypertensive medications
3168926|NCT01418261|Sham Comparator|Control group|Subjects go through renal angiogram and Subjects maintained baseline anti-hypertensive medications
3168927|NCT01418235|Experimental|Group 1: MVA-C + gp140/MF59|
3168928|NCT01418235|Experimental|Group 2: MVA-C + gp140/MF59|
3168929|NCT01418235|Experimental|Group 3: DNA-C2 + MVA-C|
3168930|NCT01418235|Experimental|Group 4: DNA-C2 + MVA-C + gp140/MF59|
3168931|NCT01418222|Experimental|A|
3168932|NCT01418222|Active Comparator|B|
3168933|NCT01418209|Active Comparator|Low-dose 17-ß-estradiol with progesterone taper|
3168934|NCT01418209|Active Comparator|Venlafaxine XR|
3168935|NCT01418209|Placebo Comparator|Placebo|
3168936|NCT01418183|Experimental|5ml 5% levobupivacaine|5ml 5% levobupivacaine to both maxillary and mandibular branches of trigeminal nerve on experimental side. (total 10ml)
3168937|NCT01418183|Placebo Comparator|5ml normal saline|5ml for maxillary and mandibular branches of trigeminal nerve (total 10ml on controlled side)
3168939|NCT01418170|Experimental|Two rcSMT group|A rcSMT will be performed to the C5-C6 segment. A thrust maneuver will then be given to the C5-C6 segment. A rotational inferior drop thrust maneuver will be performed. Immediately after the first rcSMT the subject will turn over on the chiropractic table to lie in the prone position for a post-rcSMT PPT measurement with the same algometer performed by the research assistant. These will be taken at 5-minute intervals. A second rcSMT will be performed at 30 minutes after the first rcSMT. The invention protocol will be repeated. The subject will turn over to the prone position for repeat PPT measurements at 5-minute intervals post-rcSMT for 30 mins. Once the subject has left the treatment area the clinician will mark on the treatment card whether the rcSMT was performed with or without cavitation for quality control purposes.
3168940|NCT01418170|Sham Comparator|One scSMT + One rcSMT Group|A scSMT will be performed with the contact hand of the clinician resting lightly on the paraspinal area of the neck of the subject. The subject's head will be rotated to 45 degrees and supported by the clinician's forearm, lying on headpiece. A inferior drop thrust will be applied to the drop piece. After the first scSMT maneuver the subject will turn over on the chiropractic table to lie in the prone position for a post-scSMT PPT measurement. PPT measurements will be taken at 5-minute intervals for 30 minutes. A rcSMT will be performed 30 minutes after the first scSMT. The subject will turn over to the prone position for repeat PPT measurements in 5-minute intervals for 30 minutes post-rcSMT. Once the subject has left the treatment area the clinician will mark on the treatment card weather the scSMT was performed adequately without cavitation and whether a cavitation occurred with the rcSMT.
3168941|NCT01418157|Active Comparator|Acetazolamide|
3168942|NCT01418157|Placebo Comparator|Placebo|
3168943|NCT01418144|Experimental|Transversus abdominis plane (TAP) block|Transversus abdominis plane (TAP) block with ropivacaine
3168944|NCT01418144|Placebo Comparator|Block with saline|Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
3168945|NCT01418131|Active Comparator|Rectal tacrolimus|Active medications - Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml 3mls will be applied rectally twice a day
3168946|NCT01418131|Placebo Comparator|Rectal Placebo|Placebo 3ml applied rectally twice a day. Identical to Interventional agent expect for the lack of tacrolimus
3168947|NCT01418118|Experimental|Pressors|Epinephrine, Norepinephrine, Dobutamine, Dopexamine
3168948|NCT01418105|Active Comparator|Videofluroscopic swallow study (VFSS)|To investigate the swallowing ability of patients with neurologic problems
3168949|NCT01418105|Active Comparator|cervical spine isometric excercises|isometric exercises in patients with cervical spine scoliosis
3168950|NCT01418105|Active Comparator|Fiberoptic endoscopic esophageal study (FEES)|To investigate the anatomic structures during swallowing of patients with neurologic problems
3168951|NCT01418092|Placebo Comparator|Placebo|Capsules for oral administration
3168952|NCT01418092|Experimental|ALKS 37|Capsules for oral administration
3168953|NCT01418079|Experimental|PMS-3000|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
3168954|NCT01418066|Placebo Comparator|Placebo|Tea decoction made of Graminis Flores abd Maidis stigmata.
3168955|NCT01418066|Experimental|Ayurvedic herbs|Tea decoction made of Murraya koenigii leaves, Punica granatum and Curcuma
3168956|NCT01418053|Experimental|Hot Cataplasm with Caraway Oil|
3168957|NCT01418053|Active Comparator|Hot Cataplasm with Olive oil|
3168958|NCT01418053|Active Comparator|Cold cataplasm with Olive oil|
3168959|NCT01418040||High risk prostate cancer|Histologically confirmed patients with high risk prostate cancer seen at Calvary Mater Newcastle.
3168960|NCT01418027|Experimental|Intensive exercise|The subjects receive an intensive exercise for 6 months and a subsequent conventional exercise for another 6 months.
3168961|NCT01418027|No Intervention|Lifestyle counseling|Subjects receive a general lifestyle counseling for 12 months
3168962|NCT01418027|Experimental|Regular exercise|Subjects receive conventional exercise for 12 months
3168963|NCT01418014||Infected Cohort|Perinatally HIV-infected adolescents from 7 years of age (7th birthday) up to but not including the 16th birthday at enrollment, engaged in care with ART treatment history available.
3168964|NCT01418014||Uninfected Cohort|HIV-uninfected adolescents from 7 years of age (7th birthday) up to but not including the 16th birthday at enrollment born to HIV-infected mothers.
3168965|NCT01418001|Experimental|Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination|This will be a multicenter single arm phase IB/II trial to evaluate the clinical safety and efficacy of gemcitabine/docetaxel and pazopanib in the neoadjuvant treatment of soft tissue sarcoma.
3168966|NCT01417988|Experimental|Empiric TB treatment|Empiric initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
3168967|NCT01417988|Active Comparator|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
3168968|NCT01417975|Experimental|Moderate Exercise Group|The moderate exercise condition will involve participants waking briskly (equivalent to moderate intensity) on a treadmill for 10 minutes. Moderate intensity exercise is defined as 40-68% of heart rate reserve (HRR). Heart rate (HR) will be monitored using a Polar RS100 Heart Rate monitor to serve as a guide for participants to attain the appropriate intensity.
3168969|NCT01417975|Active Comparator|Passive Sitting Group|The passive sitting condition will involve participants sitting passively in a chair for 10 minutes. Heart rate (HR) will be monitored in participants of the passive sitting group to help maintain group equivalency (with the moderate exercise condition) with regards to distraction effects and researcher contact.
3168970|NCT01417962||Fetuses|Still birth and Termination of pregnancies
3168971|NCT01417962||Children|Includes Newborns, Infants and Children
3168972|NCT01417949|Active Comparator|Immediate arm|Immediate arm: ART should be initiated as soon as possible but no later than 3 days after initiation of OI treatment.
3168973|NCT01417949|Active Comparator|Deferred arm|Deferred arm: ART should be initiated after the completion of OI treatment which is achieved at the earliest at day 21 for PCP and at day 28 for TE. ART should be initiated no later than 6 weeks after initiation of OI treatment.
3168974|NCT01417936|Experimental|Sym004|
3169050|NCT01417338||Pulmonary hypertension group|Patients who were firstly diagnosed as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
3168975|NCT01417923|Experimental|vitamin D|We enrolled 80 patients of the age 18-80 years suffering from chronic musculo-skeletal pain (low back pain, fibromyalgia, chronic widespread pain) at least 6 months. The 40 patients will receive daily doses of 4000 units of vitamin D for 6 weeks
3168976|NCT01417910||Peripheral vascular disease|Subjects who have peripheral vascular disease
3168977|NCT01417897|Experimental|Insulin Glulisine: bolus injections before each main meal|Patients are already on an Insulin Glargine therapy when they start and will them after randomization receive additionally Insulin Glulisine bolus injections before each of the main meals.
3168978|NCT01417897|Active Comparator|Insulin Aspart: bolus injections before each main meal|Patients are already on an Insulin Glargine ± metformin therapy when they start the start and will them after randomization receive additionally Insulin Aspart bolus injections before each of the main meals.
3168979|NCT01417897|Active Comparator|Regular human insulin:bolus injections before each main meal|Patients are already on an Insulin Glargine ± metformin therapy when they start the start and will them after randomization receive additionally regular human insulin bolus injections before each of the main meals.
3168980|NCT01417884||ischemic heart disease|stable coronary artery disease, acute coronary syndromes
3168981|NCT01417884||non-ischemic heart disease|inflammatory heart disease, heart failure (non-ischemic), valvular heart disease
3168982|NCT01417871||case goup|Lifestyle counseling, ABC program
3168983|NCT01417871||control group|usual care
3168984|NCT01417858|Active Comparator|brimonidine 0.2%|
3168985|NCT01417858|Active Comparator|brimonidine 0.1%|
3168986|NCT01417845|Experimental|High Intensity Exercise|High intensity resistance and aerobic training
3168987|NCT01417845|Active Comparator|Moderate Intensity Exercise|Moderate intensity resistance and aerobic training
3168988|NCT01417832|Experimental|Treatment with Infiltrant/Adhesive|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
3168989|NCT01417832|Placebo Comparator|Placebo, placebo treatment|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with a placebo treatment: At baseline one caries lesion was cleaned with a microbrush for 30 seconds and the procedure was repeated after two minutes.
3168990|NCT01417819|Other|SMS reminder|SMS reminders four days and one day before their appointments
3168991|NCT01417793|Experimental|Smoking Cessation Program|
3168992|NCT01417780|Active Comparator|AB103 0.25 mg/kg|
3168993|NCT01417780|Active Comparator|AB103 0.5 mg/kg|
3168994|NCT01417780|Placebo Comparator|NaCl 0.9%|
3168995|NCT01417767|Experimental|CHG regimen|one course of CHG regimen (low-dose cytarabine, homoharringtonine and G-CSF priming)
3168996|NCT01417767|Active Comparator|Decitabine|one course of Decitabine (5-aza-deoxycytidine,Dacogen)
3168997|NCT01417754|Other|Toremifene|
3168998|NCT01417741|No Intervention|Standard Therapy Only|Patients will not receive acupuncture. Standard anti-emetic therapy will be given.
3168999|NCT01417741|Experimental|Acupuncture Plus Standard Therapy|Bilateral P6 acupuncture applied after anesthesia induction and removed at the termination of the surgery. Patients will also receive standard anti-emetic therapy.
3169000|NCT01417715||Crohn´s disease - active|Patients with Crohn´s disease in the active phase.
3169001|NCT01417715||Crohn´s disease - quiescent|Patients with Crohn´s disease in the quiescent phase.
3169002|NCT01417715||Ulcerative colitis - active|Patients with ulcerative colitis in the active stage.
3169003|NCT01417715||Ucerative colitis - quiescent|Patients with ulcerative colitis in the quiescent stage.
3169004|NCT01417702||Crohn´s disease - active|Patients in the active phase of the disease
3169005|NCT01417702||Crohn´s disease - quiescent|Patients in the quiescent phase of the disease
3169006|NCT01417702||Ulcerative colitis - active|Patients in the active phase of the disease
3169007|NCT01417702||Ucerative colitis - quiescent|Patients in the quiescent phase of the disease
3169008|NCT01417689|Active Comparator|Open-eyes|Patients in this arm are encourage to attempt eye drop instillation using the most commonly used technique that involves looking up, pulling inferior lid down and putting the drop in the inferior cul de sac.
3169009|NCT01417689|Experimental|Closed-eyes|Patients in this group are encouraged to attempt eye drop instillation with both eyes closed near the medial canthal region. After feeling contact with the drop on the skin the drop is expected to enter the eye when opening the eye and resuming blinking.
3169010|NCT01417676|Experimental|Radiation|
3169011|NCT01417663|Placebo Comparator|Alagebrium|"In this study there will be four different groups:~One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training"
3169012|NCT01417663|Other|Exercise training|"In this study there will be four different groups:~One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training"
3169013|NCT01417650|Active Comparator|laser|In this group, the 890 nm diode laser (Mustang 2000+,Russia) will be used with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
3169014|NCT01417650|Placebo Comparator|placebo|In this group the low power laser will be applied with minimal dose that is very lower than the threshold necessary for therapeutic effects.
3169015|NCT01417637|Active Comparator|low level laser|"In this group, the 890 nm diode laser (Ga As) Mustang 2000+, Russia) with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the painful muscles.~Laser therapy for both the treatment and placebo groups will be applied on all painful muscles three times a week for four weeks."
3169016|NCT01417637|Placebo Comparator|Placebo|In Group 2 (placebo) the low power laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
3169051|NCT01417312|Active Comparator|Green tea extract|
3169052|NCT01417312|Placebo Comparator|Placebo|
3169053|NCT01417299|Active Comparator|RPh201 group|Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
3169054|NCT01417299|Placebo Comparator|placebo group|Patients will receive 400 microliter s.c., of saline twice a week for 3 months
3169017|NCT01417624|Placebo Comparator|Control Group - Standard|"This will be a randomised controlled unblinded prospective study recruiting patients in sinus rhythm with LBBB (QRS width ≥ 120ms) and a LV ejection fraction of below 35% who meet the current guidelines for CRT implantation. Patients will be randomised to one of two groups (1:1 randomisation)~Conventional LV lead placement - the LV lead will be placed according to standard techniques without knowledge of the patient's CMR findings"
3169018|NCT01417624|Active Comparator|Active CMR guided Arm|"This will be a randomised controlled unblinded prospective study recruiting patients in sinus rhythm with LBBB (QRS width ≥ 120ms) and a LV ejection fraction of below 35% who meet the current guidelines for CRT implantation.Patients will be randomised to one of two groups (1:1 randomisation):~CMR guided LV lead placement - an expert panel will decide pre-operatively the optimal branch of the coronary sinus for LV lead placement based on the presence of myocardial scar tissue and coronary sinus anatomy. The operator will informed as to the optimal vein to target for delivery of the LV lead. Should this be technically unfeasible (e.g. due to pacing considerations or stability of LV lead position), then the most suitable vein will be used at the time of implantation."
3169019|NCT01417611|Experimental|i-scan-CE/SE|Study Group using i-scan SE and CE mode: i-scan-CE/SE group was explored whole colon from the cecum to the rectum with i-scan-CE 2+ and SE 2+ mode. They had a chance to switch from i-scan to WL to perform polyp removal using cold biopsy or polypectomy
3169020|NCT01417611|Experimental|i-scan-CE/SE/TE-c|Study Group using i-scan SE & CE mode as well as TE-c mode: i-scan-CE/SE/TE-c group was explored whole colon from the cecum to the rectum with i-scan CE2+, SE2+, TE-c mode. They had a chance to switch from i-scan to WL to perform polyp removal using cold biopsy or polypectomy
3169021|NCT01417598|Experimental|Gait and balance group training|The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
3169022|NCT01417598|Experimental|Gait and balance trainig + nordic walking|(only for Osteoporosis group)
3169023|NCT01417598|No Intervention|Control group|
3169024|NCT01417572|Experimental|lidocaine|
3169025|NCT01417546|Experimental|A|NHS-IL12 will be administered every 4 weeks at a starting dose level of 2 mcg/kg as a subcutaneous injection.
3169026|NCT01417507||Supportive care (neurocognitive assessment and MRI)|"Patients undergo neurocognitive assessment using the CogState Test battery (the DET, the IDN, the OCLT, and the GMLT) at baseline* and at 12, 24, 36, 42, 48, 54, and 60 months. Patients also complete the EORTC QOL-30, the BCM20, and the EQ-5D questionnaires at baseline*, at 12, 24, 36, 48, and 60 months afterwards, and before undergoing any further treatment. Patients are instructed to complete a seizure and medication diary during study.~Patients undergo MRI scans at baseline*, at 12, 24, 36, 48, and 60 months, and at the time of radiological, clinical, or neurological failure."
3169027|NCT01417494|Experimental|Chemotherapy associated with bevacizumab|Chemotherapy (FOLFIRI, FOLFOX, LV5FU2) associated with bevacizumab
3169028|NCT01417494|Active Comparator|Chemotherapy|Chemotherapy (FOLFIRI, FOLFOX, LV5FU2)
3169029|NCT01417481|Active Comparator|Glycine|Patients will receive a daily oral supplement of 0.5 g/kg glycine dissolved in water.
3169030|NCT01417481|Placebo Comparator|Placebo|Patients will receive a daily supplement of 0.5 g/kg sugar glass dissolved in water.
3169031|NCT01417468|Experimental|CLSI - Known|Participants will be assigned to a specific learning group via the Canfield Learning Style Inventory (CLSI).
3169032|NCT01417468|Active Comparator|CLSI - Unknown|Participants will be assigned to a traditional learning group (Control).
3169033|NCT01417455||Rheumatoid Arthritis|Active Rheumatoid Arthritis patients
3169034|NCT01417455||Ankylosing Spondylitis|Active Ankylosing Spondylitis
3169035|NCT01417455||Controls|Healthy donors age and sex matched to the patients
3169036|NCT01417442|Experimental|BRAF V600E POSITIVITY|This mutation will be analysed using the tumor tissues of the patients operated for thyroid diseases and diagnosed with papillary thyroid carcinoma. And mutation positive patients will be investigated for the aggressive characteristics of the tumor.
3169037|NCT01417429|Active Comparator|Galantamine|galantamine will be given with intravenous nicotine
3169038|NCT01417429|Experimental|Nicotine|Subject will be given IV Nicotine
3169039|NCT01417416||with combat training stress|
3169040|NCT01417416||without combat training stress|
3169041|NCT01417403|Experimental|Treatment (radiosensitization therapy)|Beginning 3 days before the initiation of radiotherapy, patients receive hydroxychloroquine PO QD or BID. Treatment continues until completion of radiotherapy.
3169042|NCT01417390|Experimental|Concurrent chemoradiotherapy|Patients receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy
3169043|NCT01417390|Experimental|Inductive and concurrent|Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
3169044|NCT01417377||Cohort|Mircera
3169045|NCT01417364|Active Comparator|Testosterone weekly injections continuously|Testosterone enanthate 100 mg Intramuscular (IM) weekly injections throughout the study
3169046|NCT01417364|Experimental|Cyclic testosterone administration|Testosterone injections 100 mg. IM weekly for one month alternating with placebo injections weekly for one month throughout the study
3169047|NCT01417364|Placebo Comparator|Placebo injections|Placebo injections weekly throughout the study.
3169048|NCT01417351|Placebo Comparator|400 IU Vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
3169049|NCT01417351|Experimental|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
3169218|NCT01416116|Experimental|Tramadol|Tramadol prior to QUTENZA
3169055|NCT01417286|Experimental|Radiation Therapy|Patients undergo hypofractionated accelerated radiation therapy over 11 weekdays (for 15 elapsed days) within 21-63 days after last surgery or last course of chemotherapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
3169056|NCT01417273|Active Comparator|vitamin A, multiple sclerosis,|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A for 6 months and 10000 IU/day for next 6 months
3169057|NCT01417273|Placebo Comparator|placebo/Multiple Sclerosis|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day
3169058|NCT01417260||Nocebo|Told breastfeeding may worsen pain
3169059|NCT01417260||No treatment|Told nothing
3169060|NCT01417260||Placebo|Told will improve pain
3169061|NCT01417247|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with metabolic syndrome.
3169062|NCT01417247|No Intervention|Absolute medicine therapy|Maintenance of anti-metabolic syndrome medications only
3169063|NCT01417234||SNaP® Wound Care System|
3169064|NCT01417221|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with essential hypertension.
3169065|NCT01417221|No Intervention|Absolute medicine therapy|Maintenance of anti-hypertensive medications only
3169066|NCT01417208||SNaP® Wound Care System|
3169067|NCT01417195|Experimental|Menopur and Bravelle combination|The initial daily dose consisted of 225 IU of gonadotropins, mixed in the same syringe and administered by subcutaneous (SC) injection for 5 days. The initial daily dose, based on the Investigator's judgment, consisted of either 150 IU of Menopur and 75 IU of Bravelle or 150 IU of Bravelle and 75 IU of Menopur. Dosing adjustments were allowed as of day 6. Dose could vary between 150-450 IU daily and was always to include at least 75 IU of Menopur and 75 IU of Bravelle. Treatment could not continue beyond day 20.
3169068|NCT01417195|Active Comparator|Menopur alone|The initial daily dose consisted of 225 IU of Menopur administered by subcutaneous (SC) injection for 5 days. Dosing adjustments were allowed as of day 6. Dose could vary between 150-450 IU daily and treatment could not continue beyond day 20.
3169069|NCT01417182|Experimental|Melanoma|
3169070|NCT01417169|Experimental|Micafungin|
3169071|NCT01417156|Experimental|All patients|
3169072|NCT01417143|Experimental|TKI258 (Dovitinib)|TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
3169073|NCT01417130||Naproxen sodium (220 mg b.i.d)|Original assignment in the ADAPT trial
3169074|NCT01417130||Celecoxib (200 mg b.i.d.)|Original assignment in the ADAPT trial
3169075|NCT01417130||Placebo|Original assignment in the ADAPT trial
3169076|NCT01417117||Spontaneous Intracerebral Hemorrhage|Patients with primary intracerebral hemorrhage within 24 hours of admission diagnosed by non-contrast head computed tomography (CT)
3169077|NCT01417104|Active Comparator|Aliskiren|Aliskiren will be administered for 2 weeks at 150mg/day oral pill, followed by 34 weeks oral therapy with 300mg/day
3169078|NCT01417104|Placebo Comparator|Placebo|Placebo (sugar pill) built to mimic both the 150mg Aliskiren tablet ( administered for the first 2 weeks) and the 300mg Aliskiren tablet ( administered for the rest of treatment period)
3169079|NCT01417091|Experimental|Treatment group|
3169080|NCT01417091|No Intervention|Untreated reference group|
3169081|NCT01417078|Experimental|Diazepam Nasal Spray|
3169082|NCT01417065|Experimental|Temsirolimus|Starting dose 0.02 mg intravenous administered once.
3169083|NCT01417052|Experimental|50 mg LX3305 QD|
3169084|NCT01417052|Experimental|100 mg LX3305 QD|
3169085|NCT01417052|Experimental|150 mg LX3305 QD|
3169086|NCT01417052|Experimental|200 mg LX3305 QD|
3169087|NCT01417052|Experimental|250 mg LX3305 QD|
3169088|NCT01417052|Experimental|300 mg LX3305 QD|
3169089|NCT01417052|Experimental|400 mg LX3305 QD|
3169090|NCT01417052|Experimental|250 mg LX3305 BID|
3169091|NCT01417052|Experimental|500 mg LX3305 QD|
3169092|NCT01417052|Placebo Comparator|Placebo|
3169093|NCT01417026|Active Comparator|Intranasal Oxytocin|"Intranasal oxytocin (Trade name: Syntocinon)~Pharmacological class: The pharmacologic and clinical properties of Syntocinon are identical with the naturally occurring hormone oxytocin, which is released from the posterior pituitary.~Route of administration: Intranasal~Planned exposure: Each participant will receive one dose of intranasal oxytocin (24 IU) per day for 5 days.~One dose of 24 IU equals 6 spray puffs (3 puffs in each nostril).~Oxytocin will be imported from Victoria Pharmacy Zurich- Switzerland."
3169094|NCT01417026|Placebo Comparator|Intranasal Placebo|"Intranasal placebo~The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal~Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril).~Placebo will be imported from Victoria Pharmacy Zurich- Switzerland."
3169095|NCT01417013|Active Comparator|Systane Ultra|Systane Ultra Lubricant Eye Drops
3169096|NCT01417013|Active Comparator|Optive|Optive Lubricant eye drops
3169097|NCT01417000|Experimental|Cy/GVAX + CRS-207|200 mg per square meter (mg/m^2) cyclophosphamide (Cy) administered by intravenous (IV) infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (GVAX, 5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 colony forming units [CFU]) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.
3169098|NCT01417000|Experimental|Cy/GVAX|200 mg/m^2 Cy administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16; GVAX (5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1, 4, 7, 10, 13, 16.
3169099|NCT01416974|Experimental|consolidative therapy with autologous T cells genetically|A phase I trial of consolidation therapy with autologous T cells genetically targeted to the B cell specific antigen CD19 for patients with chronic lymphocytic leukemia following upfront chemotherapy with pentostatin, cyclophosphamide and rituximab.
3169100|NCT01416948|Placebo Comparator|Sugar Pill|
3169101|NCT01416948|Active Comparator|Galantamine|
3169102|NCT01416948|Experimental|Methylphenidate|
3169103|NCT01416935|Active Comparator|No Amiodarone|Patient will be randomized not to receive to Amiodarone post Cox-Maze procedure unless indicated.
3169104|NCT01416935|No Intervention|Amiodarone|Patients randomized to receive Amiodarone post Cox-Maze procedure which is our current standard of care.
3169105|NCT01416922||LSIL|Women 21 years of age or older with an LSIL diagnosis
3169106|NCT01416909|Active Comparator|Dose Intervention - Opioid|Laxative Treatment: Participants Receiving Opioids for the Treatment of Pain. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be based on the dose of the opioid pain medication they are receiving.
3169107|NCT01416909|Active Comparator|Assessment Intervention - Opioid|Laxative Treatment: Participants Receiving Opioids for the Treatment of Pain. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be determined based on their severity of constipation.
3169108|NCT01416909|Other|Control Group - Opioid|Standard of Care: Participants Receiving Opioids for the Treatment of Pain will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
3169109|NCT01416909|Active Comparator|Assessment Intervention - Vinca Alkaloid|Laxative Treatment: Participants Receiving a Specific Type of Chemotherapy (vinca alkaloids). Vinca alkaloids include medication such as Vincristine, Vinblastine, or Vinorelbine. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be based on their level of constipation.
3169110|NCT01416909|Other|Control Group - Vinca Alkaloid|Standard of Care: Participants Receiving a Specific Type of Chemotherapy (vinca alkaloids). Vinca alkaloids include medication such as Vincristine, Vinblastine, or Vinorelbine. Patients will receive standard of care while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
3169111|NCT01416896|Experimental|"New venous needle, the BME needle"|"Hemodialysis using the new venous needle, the BME needle."
3169112|NCT01416896|Active Comparator|"Standard venous needle, the standard needle"|"One hemodialysis using the standard venous needle, the standard needle (device)."
3169113|NCT01416883|Experimental|Active 1|8 subjects will receive ICI176,334-1
3169114|NCT01416870|Experimental|Active 1|34 subjects will receive ICI176,334-1without water
3169115|NCT01416870|Experimental|Active 2|34 subjects will receive ICI176,334-1 with water
3169116|NCT01416870|Experimental|Active 3|34 subjects will receive Casodex 80 mg tablet
3169117|NCT01416857|No Intervention|MOD|Group evaluated using the currently available ED measure of disability (MOD)
3169118|NCT01416857|Experimental|RDDT|Group will be evaluated using ED Rasch Disability Diagnostic Tool (RDDT)
3169119|NCT01416831|Active Comparator|High-dose IL-2|Patients receive standard high-dose IL-2 therapy, with an opportunity to crossover to the experimental arm if there is disease progression noted after two cycles of high-dose IL-2.
3169120|NCT01416831|Experimental|Radiation therapy and high-dose IL-2|Patients 1-20 who are assigned to receive radiation therapy will receive a single dose of radiation before IL-2; patients 21-44 assigned to receive radiation will receive two doses of radiation before receiving high-dose IL-2.
3169121|NCT01416818|Experimental|group 1|
3169122|NCT01416818|Active Comparator|group 2|
3169123|NCT01416818|Placebo Comparator|group 3|
3169124|NCT01416805|Experimental|Computerized Cognitive Behavioral Therapy|
3169125|NCT01416805|Active Comparator|Treatment as Usual|
3169126|NCT01416792|Experimental|Multiple-pass hemofiltration|
3169127|NCT01416779|Experimental|Writing Group|This group will receive the writing intervention.
3169128|NCT01416779|No Intervention|No Intervention|Non Writing Group
3169129|NCT01416766|No Intervention|Control|Control participants will receive usual care during their year of enrollment. At enrollment, prior to randomization, they will be informed that, if randomized to control status, they will be offered a free BP monitor and the opportunity to receive the study intervention after completing the exit interview in 1 year.
3169130|NCT01416766|Experimental|Intervention|Self-monitoring-nurse-primary care provider feedback loop After randomization, intervention participants will receive the intervention (free home BP monitor, assistance setting up to upload BP readings from home/work or clinic computer; feedback loop with nurse-driven protocols to manage uncontrolled hypertension and maintain control once attained).
3169131|NCT01416753|Active Comparator|UCR|regulation of ultrafiltration and conductivity
3169132|NCT01416753|Active Comparator|UTR|regulation of ultrafiltration and temperature
3169133|NCT01416753|No Intervention|conventional dialysis|dry weight reduction without BVM
3169134|NCT01416740|Experimental|Indirect MRA|After patient has signed consent and had blood tests to ensure normal kidney function (BUN and Creatinine) as well as serum and urine pregnancy tests for females to ensure there is no pregnancy, the patient will have an Indirect MRA. The participant will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into participant's arm. The gadopentetate dimeglumine will be injected into the IV and the patient will be asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
3169135|NCT01416727|Experimental|OSkER|"Observed SKills in the Emergency Room - workplace-based supervision."
3169136|NCT01416727|Experimental|EPIC|"Emergency Psychiatry Immersion Course - simulation-based training."
3169137|NCT01416714||Gastric Cancer|
3169138|NCT01416714||Gastrointestinal Stromal Tumors (GIST)|
3169139|NCT01416714||Esophageal Cancer|
3169140|NCT01416714||Pancreas Cancer|
3169141|NCT01416714||Hepatocellular Cancer|
3169142|NCT01416714||Biliary Cancer|
3169143|NCT01416714||Neuroendocrine Cancer|
3169144|NCT01416714||Peritoneal Mesothelioma|
3169145|NCT01416714||Anal Cancer|
3169146|NCT01416714||Colorectal Cancer|
3169147|NCT01416701|Active Comparator|Vitamin D (D3, cholecalciferol)|
3169148|NCT01416701|Placebo Comparator|Placebo (cellulose)|
3169149|NCT01416688||Observation and Questionnaires|Patients will be given questionnaires for the assessment of therapy complications, psychosocial assessment and care, and quality-of-life assessment.
3169150|NCT01416662|Other|gemcitabine|gemcitabine
3169151|NCT01416636|Experimental|Treprostinil sodium high dose|
3169152|NCT01416636|Active Comparator|Treprostinil sodium low dose|
3169153|NCT01416623|Experimental|Henatinib|Henatinib either at 12.5,25,37.5,50,62.5,75,87.5 or 100 mg, p.o. once daily
3169154|NCT01416610||All Participants|Participants with chronic hepatitis C, Genotype 2, 3, 1 or 4, undergoing an opioid maintenance therapy
3169155|NCT01416597||Cross-Protection Studies|
3169156|NCT01416584|No Intervention|Usual Care Control|Participants in this group were offered employment in the Therapeutic Workplace without urinalysis testing or the methadone treatment requirement. They were offered the methadone treatment but were not required to join in order to gain access to the workplace.
3169157|NCT01416584|Experimental|Methadone Contingency Group|Participants in this group were allowed to work and earn wages as long as they enrolled in the methadone treatment and continued to take does of methadone consistently (employment-based reinforcement).
3169158|NCT01416584|Experimental|Methadone & Abstinence Contingency|Participants in this group were able to access work if they enrolled in the methadone treatment and consistently took their medication, but they also received a decrease in base pay if they test positive for opiates or cocaine on the drug screens (employment-based reinforcement).
3169159|NCT01416571|Experimental|Influenza A (H5N1) Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm.
3169160|NCT01416545|Active Comparator|Lifestyle counseling|Children received the same educational material for their parents and, additionaly, were exposed to a weekly educational program directed for cardiovascular prevention.
3169161|NCT01416545|Placebo Comparator|Control group|The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
3169162|NCT01416519|Experimental|Group 1|After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
3169163|NCT01416519|Experimental|Group 2|After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
3169164|NCT01416506||Group 1|
3169165|NCT01416493|Experimental|bIAP treatment|
3169166|NCT01416480|Experimental|Theobromine|Theobromine capsule 300mg
3169167|NCT01416480|Active Comparator|levodropropizine|levodropropizine syrup
3169168|NCT01416454||Elective Cesarean delivery, age <35 yrs|Women undergoing elective cesarean delivery with a spinal anesthetic who are less than 35 y of age (at the time of delivery).
3169169|NCT01416454||Elective Cesarean delivery, age =>35 yrs|Women undergoing elective Cesarean delivery with a spinal anesthetic who are => 35 yrs of age (at the time of delivery).
3169170|NCT01416441|Experimental|Aripiprazole|Once-weekly tablets
3169171|NCT01416428|Experimental|QDx2 Dosing Schedule|"QDx2 is defined as patients receiving Oprozomib Tablets once daily on Days 1, 2, 8, and 9 of the 14-day cycle.~The schedule will be evaluated in Phase 1 for MTD in patients with hematologic malignancies, and will also be evaluated in Phase 2 for ORR in patients with MM and WM."
3169172|NCT01416428|Experimental|QDx5 Dosing Schedule|"QDx5 is defined as patients receiving Oprozomib Tablets once daily on Days 1 to 5 of the 14-day cycle.~The schedule will be evaluated in Phase 1 for MTD in patients with hematologic malignancies, and will also be evaluated in Phase 2 for ORR in patients with MM and WM."
3169173|NCT01416415|Experimental|Educational intervention|The educational intervention arm will contain subjects who will watch a video on proper eye drop instillation technique.
3169174|NCT01416415|Placebo Comparator|Attention placebo|The attention control placebo group will receive an educational intervention that mimics the amount of time and attention received by the treatment group. The video chosen is regarding healthy eating tips.
3169175|NCT01416402|Other|Arhalofenate with febuxostat and colchicine|
3169176|NCT01416389|Experimental|LY2523355 + pegfilgrastim or filgrastim|LY2523355: Five milligrams per meter squared per day (mg/m^2/day) (dosage determined by calculating participant's body surface area) administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Pegfilgrastim or Filgrastim: Dosage is determined by standard of care and is administered intravenously on Day 4 of 21-day Cycle for 2 Cycles. If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.
3169177|NCT01416389|Active Comparator|ixabepilone|Forty milligrams per meter squared per day (mg/m^2/day) (dosage determined by calculating participant's body surface area) administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles. If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.
3169178|NCT01416376|Active Comparator|50mg SRT2379|Single oral administration of 50mg SRT2379
3169179|NCT01416376|Active Comparator|250mg SRT2379|Single oral administration of 250mg SRT2379
3169180|NCT01416376|Active Comparator|1000mg SRT2379|Single oral administration of 1000mg SRT2379
3169181|NCT01416376|Placebo Comparator|Placebo|Single oral administration of placebo
3169182|NCT01416363|Experimental|Treatment Arm ACB: Part 1|Subjects will receive treatment sequence ACB; A : Firategrast immediate release tablet 1200 milligram (mg) once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, B : Firategrast 3 hour release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
3169183|NCT01416363|Experimental|Treatment Arm BAC: Part 1|Subjects will receive treatment sequence BAC; B : Firategrast 3 hour release tablet 1200 mg once only orally, A : Firategrast immediate release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route. There will be a washout period of 5 days between doses.
3169219|NCT01416116|Experimental|Lidocaine|Lidocaine prior to QUTENZA
3169184|NCT01416363|Experimental|Treatment Arm CBA: Part 1|Subjects will receive treatment sequence CBA; C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, B : Firategrast 3 hour release tablet 1200 mg once only orally, A : Firategrast immediate release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
3169185|NCT01416363|Experimental|Treatment Arm BCA: Part 1|Subjects will receive treatment sequence BCA; B : Firategrast 3 hour release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, A : Firategrast immediate release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
3169186|NCT01416363|Experimental|Treatment Arm CAB: Part 1|Subjects will receive treatment sequence CAB; C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, A : Firategrast immediate release tablet 1200 mg once only orally, B : Firategrast 3 hour release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
3169187|NCT01416363|Experimental|Treatment Arm ABC: Part 1|Subjects will receive treatment sequence ABC; A : Firategrast immediate release tablet 1200 mg once only orally, B : Firategrast 3 hour release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route. There will be a washout period of 5 days between doses.
3169188|NCT01416363|Experimental|Treatment Arm D: Part 2|Subject will receive D: Firategrast immediate release tablet 600 mg twice daily for 7 days
3169189|NCT01416363|Experimental|Treatment Arm E: Part 2|Subject will receive E: Firategrast 3 hour release tablet 1200 mg twice daily for 7 days
3169190|NCT01416363|Experimental|Treatment Arm F: Part 2|Subject will receive F: Firategrast simulated gastro-retentive solution 1200 mg twice daily for 7 days
3169191|NCT01416350|Active Comparator|Part A - randomized, open-label parallel group|Part A is a randomized, open-label parallel group study evaluating PK/PD of a single azithromycin dose of 250 or 1000 mg. Data from Part A will be used to assess the dose resulting in induction/inhibition of various ex vivo biomarkers relative to a 250 mg dose of azithromycin (the clinical dose used in treatment of neutrophil-induced inflammatory conditions). This information will guide the range of doses to be studied in a FTIH study of a new chemical entity.
3169192|NCT01416350|Active Comparator|Part B - repeat dose group|Part B is a repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions. This information will provide insight into whether the biomarker effects change over time on repeat dosing and any potential differences observed between single and repeat doses.
3169193|NCT01416337|Experimental|Treatments A & B|Single 2 mg GSK1120212 oral tablet, fasted Single IV dose of 5 ug (no more than 7.4 kBq or 200 nCi) [14C]GSK1120212 Both doses are given together.
3169194|NCT01416324|Experimental|GSK2330672|experimental study drug
3169195|NCT01416324|Placebo Comparator|Placebo|placebo
3169196|NCT01416311||Subjects prescribed REVOLADE|Subjects with chronic idiopathic thrombocytopenic purpura prescribed REVOLADE during study period
3169197|NCT01416285||control group|control group receiving regular education from a nurse
3169198|NCT01416285||Case management group|This is the study group. Extensive education and case management program will be performed in this group.
3169199|NCT01416272|Experimental|KeraSoft IC Soft Contact Lenses|KeraSoft IC Soft Contact Lenses, with CIBA Clear Care solution provided for lens care
3169200|NCT01416259||APF530 Exposure, Granisetron and Moxifloxacin, Placebo|Arm 1:APF530 Exposure Arm 2:Granisetron IV Arm 3:Moxifloxacin Arm 4:Placebo
3169201|NCT01416246|Experimental|Fractionated Stem Cell Infusions|A single arm, open-label, single institution pilot trial is planned. Patients with chemosensitive MM and at least 7 x 10^6 CD34+ stem cells/kg (+/- 0.5 x 10^6 CD34+ stem cells/kg)available for use will be enrolled following initial induction or salvage therapy.
3169202|NCT01416233|Experimental|autologous fat grafting|There is one arm of this study. People with anophthalmic sockets and orbital atrophy are given a single session of autologous fat grafting by a closed cannula technique and are observed to measure, by MRI, the amount of fat retained at one year
3169203|NCT01416220|Experimental|Lithium|Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l).
3169204|NCT01416220|Active Comparator|Paroxetine|Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or Paroxetine.Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7.At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines.
3169205|NCT01416207|Experimental|Avonex|4 weekly injections of Avonex (IM)
3169206|NCT01416194||Bazedoxifene|
3169207|NCT01416194||Primary Comparator|
3169208|NCT01416194||Secondary Comparator|
3169209|NCT01416181|Experimental|natalizumab|In Part 1 participants were randomized to receive 300 mg of natalizumab intravenously (IV) every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
3169210|NCT01416181|Experimental|Placebo|In Part 1 participants were randomized to receive placebo IV every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
3169211|NCT01416168|No Intervention|Control Arm|Usual post-surgical care
3169212|NCT01416168|Experimental|Intervention arm|In addition to usual post-surgical care, the patients will receive a 4 week geriatric nurse practitioner-centered intervention, based on the McCorkle model.
3169213|NCT01416155|Experimental|natalizumab|300 mg intravenous (IV) infusions of natalizumab every 4 weeks until product is approved in Japan or development is discontinued in Japan, whichever comes first.
3169214|NCT01416142|Active Comparator|Spectacles|The subject's habitual spectacles (updated or confirmed as correct within the last 2 years)
3169215|NCT01416142|Experimental|PureVision2 HD contact lenses|Currently marketed Bausch + Lomb PureVision2 HD contact lenses
3169216|NCT01416129|Active Comparator|Active Comparator: Prosthetic socket standard of care|
3169217|NCT01416129|Active Comparator|Active Comparator: Prosthetic brimless socket|
3169221|NCT01416103|Placebo Comparator|Intervention control|Control group
3169222|NCT01416077|No Intervention|standard treatment|Fluid and inotropic drugs are given based on conventional parameters such as blood pressure and heart rate as judged by the individual anesthesiologists judgement.
3169223|NCT01416077|Active Comparator|goal-directed fluid treatment|Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised
3169224|NCT01416064|Other|Molindone|Extension study, all subjects will be given Molindone at different (established) dosage levels based on the patient's weight, response and investigator discretion.
3169225|NCT01416051|Active Comparator|Test|Subjects consumed a vegetable oil emulsion in yogurt at a food intake test and were asked to consume the product twice daily for 12 weeks.
3169226|NCT01416051|Placebo Comparator|Control Group|Subjects were given a placebo of milk fat in yogurt at food intake tests and asked to consume the placebo twice daily for 12 weeks.
3169227|NCT01416038|Experimental|Vaccine|Cohort A: 0.5 mL of DPX-Survivac (injection)
3169228|NCT01416038|Experimental|Vaccine + low dose cyclophosphamide|Cohort B: 0.1 mL DPX-Survivac (injection) with low dose cyclophosphamide (oral)
3169229|NCT01416038|Experimental|Vaccine + low dose cyclophosphamide.|Cohort C: 0.5 mL DPX-Survivac (injection) with low dose cyclophosphamide (oral)
3169230|NCT01416025|Experimental|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
3169231|NCT01416025|No Intervention|Standard dosing|Standard doses of voriconazole will be used
3169232|NCT01416012|Experimental|Group Kinect|Use of the available Kinect games on the Xbox to train balance and gait
3169233|NCT01416012|Active Comparator|Physical Therapy Standard|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
3169234|NCT01416012|Experimental|Group Nintendo|Use of video games available Balance and Gait training in Individualized training sessions.
3169235|NCT01416012|Experimental|Group Xbox Kinect (MK)|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
3169236|NCT01415999||patient|adult survivors of childhood malignancies
3169237|NCT01415999||control|healthy age-matched individuals
3169238|NCT01415986|Experimental|Subjects receiving Temoporfin|
3169239|NCT01415973|Experimental|3 ounces of cooked, 85% lean ground beef|Subjects would consume 3 ounces of cooked, 85% lean ground beef at one setting on one day.
3169240|NCT01415973|Experimental|20 grams of Beef protein isolate|Subjects would consume 20 grams of beef protein isolate dissolved into 200mL water at one setting on one day.
3169241|NCT01415960|Experimental|Leuprolide acetate 22.5 mg depot|Leuprolide acetate 22.5 mg depot administered twice, 3 months apart
3169242|NCT01415934|No Intervention|Continue Statins|Participant will continue on statins as per usual
3169243|NCT01415934|Experimental|Discontinue statins|Participant will stop taking their statin drugs
3169244|NCT01415921|Experimental|Pyridostigmine Bromide|Forced titration protocol 15-60 mg every 8 hours as tolerated
3169245|NCT01415921|Placebo Comparator|Placebo|Matching placebo forced titration 15-60 mg as tolerated
3169246|NCT01415908|Active Comparator|Control Group|
3169247|NCT01415908|Experimental|Investigational Group|
3169248|NCT01415895|Experimental|ATNC05 - a study drug capsule|ATNC05, a capsule containing a weighed piece of generic tablet A and a weighed piece of generic tablet B
3169249|NCT01415895|Placebo Comparator|placebo|subjects will receive placebo capsules for double blind treatment for the duration of the trial
3169250|NCT01415882|Experimental|Arm A (ixazomib citrate and dexamethasone, closed to accrual)|Patients receive ixazomib citrate PO on days 1, 8, and 15. Patients with lack of minor response by the end of the second course or lack of partial response by the end of the fourth course also receive dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3169251|NCT01415882|Experimental|Arm B (ixazomib citrate and dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8 and 15 and dexamethasone PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3169252|NCT01415882|Experimental|Arm C (higher-dose ixazomib citrate and dexamethasone)|Patients receive higher doses of ixazomib citrate PO on days 1, 8, and 15 and dexamethasone PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3169253|NCT01415882|Experimental|Arm D (ixazomib citrate, dexamethasone, and cyclophosphamide)|Patients receive ixazomib citrate PO on days 1, 8, and 15, cyclophosphamide PO and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3169254|NCT01415869||Cross Sectional|Patients with implanted non-pulsatile ventricular assist devices of any type and at any time after implantation
3169255|NCT01415869||Prospective|Patients with usual VAD indications will be invited to participate, when, in the opinion of their treating physician a VAD will be highly likely within one month.
3169256|NCT01415856|Placebo Comparator|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
3169257|NCT01415856|Active Comparator|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
3169258|NCT01415830|Experimental|Anti-scorpion venom serum Birmex|Patients 0 to 15 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex
3169259|NCT01415830|Active Comparator|Anti-scorpion venom serum Alacramyn|Patients 0 to 15 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)
3169260|NCT01415817|No Intervention|Baseline Data collection|
3169261|NCT01415817|Experimental|Randomization and Training Arm|
3169262|NCT01415804|Active Comparator|stentgraft|Stentgraft
3169263|NCT01415804|No Intervention|Medical management|Antihypertensive medication
3169264|NCT01415791|Experimental|Active 1|8 subjects will receive ICI176,334-1
3169265|NCT01415778|Experimental|Active 1|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
3169266|NCT01415778|Experimental|Active 2|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
3169307|NCT01415531|Placebo Comparator|2|Dose-matched placebo
3169267|NCT01415778|Experimental|Active 3|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
3169268|NCT01415778|Experimental|Active 4|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
3169269|NCT01415752|Experimental|Arm A|Patients receive induction therapy comprising rituximab IV on day 1 and bendamustine hydrochloride IV over 60 minutes on days 1-2. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm E.
3169270|NCT01415752|Experimental|Arm B|Patients receive induction therapy comprising bortezomib IV subcutaneously (SC) on days 1, 4, 8, and 11 and rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm F.
3169271|NCT01415752|Experimental|Arm C|Patients receive induction therapy comprising rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm G.
3169272|NCT01415752|Experimental|Arm D|Patients receive bortezomib, rituximab, and bendamustine hydrochloride as patients in arm B. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm H.
3169273|NCT01415752|Experimental|Arm E|Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
3169274|NCT01415752|Experimental|Arm F|Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
3169275|NCT01415752|Experimental|Arm G|Patients receive consolidation therapy comprising lenalidomide orally (PO) daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
3169276|NCT01415752|Experimental|Arm H|Patients receive consolidation therapy comprising lenalidomide PO daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
3169277|NCT01415739||Novel Molecular NSCLC Classification (H & E staining, IHC)|Previously collected tissue samples are analyzed via H&E staining and IHC.
3169278|NCT01415726|Experimental|Cord blood stem cell|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations. Stem Cell Educator will be used for isolation and purification of cord blood stem cells for the treatment.
3169279|NCT01415726|Experimental|Stem Cell Educator|used for the isolation and purification of cord blood stem cells.
3169280|NCT01415713|Experimental|Statin dose titration|"SLOG regimen:~S-1 20-40 mg/m2/b.i.d., day 1-7;Leucovorin 20 mg/m2/b.i.d., day 1-7;Oxaliplatin 85 mg/m2 in 250 mL of D5W,given as 2-hour intra-venous infusion, day 1;Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate infusion,day 1;After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin; Every 14 days, as one cycle.Prophylactic G-CSF or GM-CSF will not be allowed in this study. In case of grade 4 or complication neutropenia, patients may receive G-CSF according to the regulation of National Insurance Bureru treated with appropriate antibiotics. Therapeutic G-CSF may be used at the discretion of attending physicians."
3169281|NCT01415700|Experimental|Stimulator|
3169282|NCT01415700|Active Comparator|Orthosis|
3169283|NCT01415687|Active Comparator|PEG Arm|Patients randomized to this arm of the trial will be following preparation instructions using Polyethylene Glycol-Based Lavage in a split dose format
3169284|NCT01415687|Active Comparator|Pico-Salax + Bisacodyl Arm|Patients randomized to this arm will follow preparation instructions using Pico-Salax preparation plus Biscacodyl in a split dose format
3169285|NCT01415674|Experimental|Arm A: Afatinib 40mg per os daily|Patients randomized to the arm A will take a single oral dose of Afatinib from Day 1, for 14 to 28 days, depending on the date of surgery. The number of dosing days will be chosen so that patients are off treatment for a maximum of 7 days before surgery.
3169286|NCT01415674|No Intervention|Arm B : No pre operative treatment|
3169287|NCT01415661|Experimental|obese patient|
3169288|NCT01415661|Experimental|non obese patient|
3169289|NCT01415648|Experimental|open NIRS|continuous per operative cerebral oximetry monitoring (using INVOS™ cerebral oximeter) associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
3169290|NCT01415648|Sham Comparator|Blinded NIRS|Continuously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre
3169291|NCT01415635|Experimental|Nutritional intervention|"The study will compare standard nutritional care (control group) with tailored nutritional care (the possibility to order small energy and protein-enriched dishes called Delights of Herlev Hospital)(intervention group)."
3169292|NCT01415622|Experimental|PlasmaDerm|Treatment of small to medium-sized Ulcera crurum with the PlasmaDerm VU-2010 device in addition to standard care.
3169293|NCT01415622|Other|standard care|standard care of Ulcera crurum
3169294|NCT01415596|Placebo Comparator|Placebo|
3169295|NCT01415596|Active Comparator|Salbutamol|
3169296|NCT01415583|Placebo Comparator|Saline|Placebo is described in chart
3169297|NCT01415583|Experimental|Dexamethasone|Dexamethasone is described in chart
3169298|NCT01415570||Chronic Hemodialysis Patients|Adult hemodialysis patients
3169299|NCT01415570||Chronic hemodialysis patients|Adult hemodialysis patients
3169300|NCT01415557|Placebo Comparator|Non-Fortified Control Product|Non-fortified control beverage
3169301|NCT01415557|Active Comparator|Micronutrient Fortified Test Product|Micronutrient fortified test beverage
3169302|NCT01415544||Type 2 Diabetes|Those previously diagnosed with type 2 diabetes
3169303|NCT01415544||Type 1 Diabetes|Those previously diagnosed with type 1 diabetes
3169304|NCT01415544||Gestational Diabetes|Those that are currently diagnosed with gestational diabetes
3169305|NCT01415544||Healthy Human Volunteers|Those that have not been diagnosed with any type of diabetes
3169306|NCT01415531|Experimental|1|Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
3169308|NCT01415518|Other|1|budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
3169309|NCT01415518|Other|2|ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
3169310|NCT01415505|Other|1|Nebivolol and Valsartan free tablet combination
3169311|NCT01415492|No Intervention|Usual Care|At recruitment this group only received five pamphlets from the study. Four of these pamphlets were from the American Cancer Society, and one from Quitworks (a smoking cessation program).
3169312|NCT01415492|Active Comparator|HD2|The intervention study information was delivered via print materials or access to a HD2 Web Site. Patients chose modality. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention.
3169313|NCT01415492|Active Comparator|HD2+|The intervention study information was delivered via print materials or access to a HD2 Web Site. Patients chose modality. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention.
3169314|NCT01415479|Experimental|Quantitative|"Subjects view:~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)"
3169315|NCT01415479|Experimental|Default|"Subjects view:~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT)."
3169316|NCT01415479|Experimental|Quantitative + Default|"Subjects view:~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)~Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT)."
3169317|NCT01415479|Active Comparator|Control|Subjects view a computer-based presentation regarding colorectal cancer (CRC) and available screening tests for CRC, primarily a video produced by the American Cancer Society.
3169318|NCT01415466|Experimental|R|multiple dose of Rosuvastatin 20mg
3169319|NCT01415466|Experimental|O|multiple dose of CS-866 40mg
3169320|NCT01415466|Experimental|R+O|multiple dose of the combination of Rosuvastatin 20mg and CS-866 40mg
3169321|NCT01415453|Experimental|Retinitis Pigmentosa|Subject will have retinitis pigmentosa and will be legally blind in one or both eyes
3169322|NCT01415440|Experimental|Psychostimulant|30-70 mg capsule of Lisdexamfetamine once daily for 12 weeks
3169323|NCT01415440|Placebo Comparator|Placebo|30-70 mg capsule of placebo (sugar pill) once daily for 12 weeks
3169324|NCT01415427|Experimental|BMN 110 Weekly|BMN 110 Weekly: In Part 1, patients will receive an intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
3169325|NCT01415427|Experimental|BMN 110 Every Other Week|BMN 110 Every Other Week: In Part 1, patients will receive an intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and will receive infusions of placebo on alternating weeks.
3169326|NCT01415414||Group 1|
3169327|NCT01415401|Experimental|AZARGA|Brinzolamide 1% / timolol 0.5% maleate fixed combination, 1 drop self-administered in study eye(s) twice daily for 8 weeks (8AM and 8PM)
3169328|NCT01415375|Experimental|Prostate Cancer Screening Education|Men in the experimental intervention group received an educational pamphlet on prostate cancer testing as well as tailored telephone education in which the interventionist provided information, answered questions, and conducted a values clarification exercise with the participant.
3169329|NCT01415375|Other|Fruit and Vegetable Intake Education|Men in the attention control group received an educational pamphlet on daily recommended servings of fruits and vegetables as well as tailored telephone education in which the interventionist provided information, answered participant's questions, and discussed any barriers to eating fruits and vegetables.
3169330|NCT01415362|Active Comparator|Active tDCS|The subject will receive sessions of active tDCS remotely triggered by the EEG monitoring system each time seizure activity is detected during the 24-hour period.
3169331|NCT01415362|Sham Comparator|Sham tDCS|The subject will receive sessions of sham tDCS remotely triggered by the EEG monitoring system each time seizure activity is detected during the 24-hour period.
3169332|NCT01415349|Experimental|SSP-002358 alone|
3169333|NCT01415349|Experimental|SSP-002358 + omeprazole|SSP-002358 + omeprazole
3169334|NCT01415336|Active Comparator|AC|doxorubicin 60 mg/m², iv, day 1 Cyclophosphamide 600 mg/m², iv, day 1 every 3 weeks for 4 cycles
3169335|NCT01415336|Experimental|AX|doxorubicin 60 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 4 cycles
3169336|NCT01415323||Acutely admitted psychiatric in-patients|
3169337|NCT01415310||Geriatric psychiatry|Elderly patients with psychiatric disorders in geriatric psychiatry units
3169338|NCT01415297|Experimental|NKP-1339|"NKP-1339 will be administered in single patient cohorts until ≥ Grade 2 toxicity encountered, at which time cohorts converted to a standard 3 + 3 dose escalation scheme.~When MTD is reached, an expanded cohort of up to 25 patients will be enrolled at the MTD."
3169339|NCT01415284|Experimental|Hydroxyethylstarch 130/0.4|
3169340|NCT01415271|Experimental|Internet Intervention|
3169341|NCT01415245|Experimental|Treatment|Device applied to saphenous vein graft
3169572|NCT01413581|Placebo Comparator|Placebo|Placebo
3169342|NCT01415245|No Intervention|Control|Saphenous vein graft without device support
3169343|NCT01415232|Experimental|Ultrasound measurement|Ultrasound using the Sonosite S-Nerve® US system (SonoSite, Bothell,WA) to measure depth to epidural space in morbidly obese parturients.
3169344|NCT01415219|Active Comparator|active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
3169345|NCT01415219|No Intervention|conventional care|community based physiotherapy
3169346|NCT01415206|Experimental|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
3169347|NCT01415206|Other|Usual Care|Participants in the usual care condition will complete the core assessments and the Staging Health Risk Assessment (S-HRA) online at baseline, 3, 6, 12, and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
3169348|NCT01415193|Experimental|Selective Tibial Nerve Block|
3169349|NCT01415193|Active Comparator|Control: Sciatic Nerve Block|
3169350|NCT01415180||Children: previously healthy|Previously healthy children, without chronic disease prior to the sepsis episode, expected to comprise about 50-60% of the total study population.
3169351|NCT01415180||Children: chronic, complex conditions|Children with chronic, complex conditions prior to the sepsis episode, expected to comprise about 40-50% of the study population.
3169352|NCT01415154|Experimental|Scheduled Treatment Arm|3 Week TMS taper, clinical assessments and one NeuroStar TMS session every 4th week of block and TMS reintroduction as needed for clinical deterioration.
3169353|NCT01415154|Experimental|Monthly Observational Follow up Arm|3 Week TMS Taper, clinical assessments and office follow up every 4th week of block and NeuroStar TMS reintroduction as needed for clinical deterioration.
3169354|NCT01415141|Active Comparator|PR|"Treatment with Peginterferon and Ribavirin for up to 48 weeks~Those who achieve eRVR will receive 24 weeks of treatment"
3169355|NCT01415141|Active Comparator|TPR|"Treatment with Telaprevir, Peginterferon and Ribavirin. Patients will receive all 3 drugs for 12 weeks then switch to Peginterferon and Ribavirin for 36 weeks~Those who achieve eRVR will receive 12 weeks of treatment with all 3 drugs and then 12 weeks of treatment with the 2 drugs."
3169356|NCT01415128|Active Comparator|Omeprazole|Omeprazole with single dose of avanafil (200 mg)
3169357|NCT01415128|Active Comparator|Rosiglitazone|Rosiglitazone with single dose of avanafil (200 mg)
3169358|NCT01415128|Active Comparator|Desipramine|Desipramine with single dose of avanafil (200 mg)
3169359|NCT01415115||Type 1 Diabetes|Must have been diagnosed with type 1 diabetes. Subject group will be measured on SCOUT and compared to Type 2 diabetes cohort.
3169360|NCT01415115||Type 2 Diabetes|Must have been diagnosed with Type 2 diabetes. This group will be compared to the Type 1 cohort.
3169361|NCT01415102|Experimental|Cohort 1|Subjects will be assigned to receive either PF-05212372 or placebo in each period
3169362|NCT01415102|Experimental|Cohort 2|Subjects will be assigned to receive either PF-05212372 or placebo in each period
3169363|NCT01415076|Placebo Comparator|Insertion without CO2 insufflation|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
3169364|NCT01415076|Experimental|Insertion with CO2|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
3169365|NCT01415063|Experimental|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
3169366|NCT01415063|Experimental|TACE-RFA|TACE first, then RFA within 2 weeks
3169367|NCT01415050|Active Comparator|Alendronate|
3169368|NCT01415050|Active Comparator|Raloxifane|
3169369|NCT01415037||Annular Array Ultrasound|Subject with possible or with known posterior vitreous detachment. Subjects with diabetic retinopathy will receive annular array ultrasound exam.
3169370|NCT01415011|Experimental|Afatinib (BIBW 2992)|All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
3169371|NCT01414998|Active Comparator|Stress Ball|This is the active comparator for study 1
3169372|NCT01414998|Experimental|De-nicotinised Cigarette|This will be the experimental arm for study 2
3169373|NCT01414998|Experimental|Nicotine-free Electronic Cigarette (1)|This will be the experimental arm for study 1
3169374|NCT01414998|Active Comparator|Nicotine-free Electronic Cigarette (2)|This will be the active comparator for study 2
3169375|NCT01414985|Experimental|Group A|Group A consists of 2 subjects who received 9x10^11 molecules of AAVrh.10CUCLN2, the gene transfer vector carrying the CLN2 gene. This is equal to 900,000,000,000 molecules of the study drug. The drug will be administered only once in the study.
3169376|NCT01414985|Experimental|Group B|Group B will consist of 6 subjects who will receive 2.85x10^11 molecules of AAVrh.10CUCLN2, the gene transfer vector carrying the CLN2 gene. This is equal to 285,000,000,000 molecules of the drug. The drug will be administered only once in the study.
3169377|NCT01414972|Active Comparator|patients with atherosclerosis/ vitamin A|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive 25000 IU/day vitamin A
3169378|NCT01414972|Placebo Comparator|patients with atherosclerosis/ placebo|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive placebo
3169379|NCT01414972|Active Comparator|people without athrosclerosis/ vitamin a|people in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive 2500 Iu/day vitamin A
3169380|NCT01414946|Experimental|Glucose and amino acids|Perioperative nutrition with glucose and amino acids
3169381|NCT01414946|Active Comparator|Amino acids only|Perioperative nutrition with amino acids only
3169382|NCT01414920|Placebo Comparator|Placebo QD|
3169383|NCT01414920|Experimental|TAK-875 25 mg QD|
3169384|NCT01414920|Experimental|TAK-875 50 mg QD|
3169385|NCT01414920|Experimental|Sitagliptin 100 mg QD|
3169386|NCT01414920|Experimental|TAK-875 25 mg QD + Sitagliptin 100 mg QD|
3169387|NCT01414920|Experimental|TAK-875 50 mg QD + Sitagliptin 100 mg QD|
3169388|NCT01414907|Active Comparator|Health Promotion activities|
3169389|NCT01414907|No Intervention|No Intervention|
3169390|NCT01414894|Active Comparator|Normal Fluids & Normal Blood Pressure|Patients are treated with conventional fluid replacement (Normovolemia) and maintenance of blood pressure in a normal range (Conventional Blood Pressure).
3169391|NCT01414894|Active Comparator|Increased Fluids & Normal Blood Pressure|Patients are treated with fluids to achieve higher volume expansion (Hypervolemia) and maintenance of blood pressure in a normal range (Conventional Blood Pressure)
3169392|NCT01414894|Active Comparator|Normal Fluids & Higher Blood Pressure|Patients are treated with conventional fluid replacement (Normovolemia) and maintenance of blood pressure in a higher range (Augmented Blood Pressure).
3169393|NCT01414894|Active Comparator|Increased Fluids & Higher Blood Pressure|Patients are treated with fluids to achieve higher volume expansion (Hypervolemia) and maintenance of blood pressure in a higher range (Augmented Blood Pressure).
3169394|NCT01414881|Experimental|mipomersen|mipomersen 200mg subcutaneously (SC) once weekly
3169395|NCT01414881|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC) once weekly
3169396|NCT01414855|Experimental|obinutuzumab + CHOP|Participants received 1000 mg obinutuzumab intravenously on Day 1 of each 21-day cycle for 8 cycles; during Cycle 1 administration also on Days 8 and 15. Participants also received standard CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisone) for 6 cycles.
3169397|NCT01414842|Active Comparator|Standard|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
3169398|NCT01414842|Experimental|Automated profiled|Automate sodium profiling in endogenous hemodiafiltration
3169399|NCT01414816||Group 1|
3169400|NCT01414803|Experimental|rosuvastatin/fenofibrate combination|rosuvastatin 10 mg/fenofibrate 160 mg per day
3169401|NCT01414803|Active Comparator|rosuvastatin monotherapy|rosuvastatin 10 mg per day
3169402|NCT01414790|Experimental|ADM group|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
3169403|NCT01414790|No Intervention|control group|41 patients (control group) had a total parotidectomy alone
3169404|NCT01414777|Experimental|ondansetron|ondansetron 8 mg IV will be administered prior to placement of the spinal anesthesia
3169405|NCT01414777|Placebo Comparator|Placebo|Ondansetron 8 mg IV or Placebo will be administered prior to placement of the spinal anesthestic
3169406|NCT01414764|Active Comparator|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The red blood cells will be discarded, and the supernatant containing ACP (with additional CaCl to activate the ACP and local anaesthetic) is injected into the tendon bone junction and adjacent area under ultrasound guidance. No adverse consequences are anticipated by using the Arthrex ACP injection.~First injection at approximately 10 days post-operatively~Second Injection at approximately 21 days post-operatively~Other Names:~Platelet rich plasma (PRP)"
3169407|NCT01414764|Placebo Comparator|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~First injection at approximately 10 days post-operatively~Second Injection at approximately 21 days post-operatively"
3169408|NCT01414751|Active Comparator|Absolute risk reduction information|Patients belonging to this arm receive effectiveness information by means of absolute risk reduction when talking with their general practitioner concerning their cholesterol level and possible gain if starting therapy.
3169409|NCT01414751|Active Comparator|Prolongation of life information|Patients belonging to this arm receive effectiveness information by means of prolongation of life/life extension when talking with their general practitioner concerning their cholesterol level and possible gain if starting therapy.
3169410|NCT01414738|Experimental|Radiation|Whole-Brain Radiotherapy
3169411|NCT01414725|Experimental|Core Stability Training|
3169412|NCT01414725|Placebo Comparator|Relaxation|
3169413|NCT01414725|Active Comparator|Standard Physiotherapy Exercises|
3169414|NCT01414712||prostate cancer patients|
3169415|NCT01414699|Active Comparator|One-Course, Variety|Participants will receive a snack in one course with a variety of fruit.
3169416|NCT01414699|Active Comparator|Two-Course, Variety|Participants will receive a snack in two courses with a variety of fruit.
3169417|NCT01414699|Active Comparator|One-course, Non-Variety|Participants will receive a snack in one course with no variety of fruit.
3169418|NCT01414699|Active Comparator|Two-Course, Non-Variety|Participants will receive a snack in two courses with no variety of fruit.
3169419|NCT01414686|Experimental|Immediate Treatment Group|
3169420|NCT01414686|No Intervention|Delayed Treatment Group|
3169421|NCT01414673|Other|spontaneous LH|
3169422|NCT01414673|Experimental|HCG|
3169423|NCT01414660||islet|type 1 diabetic patients undergoing islet transplantation
3169424|NCT01414660||liver|non diabetic patients undergoing a liver transplantation
3169425|NCT01414660||kidney|non diabetic patients undergoing a kidney transplantation
3169426|NCT01414647|Experimental|SRC|Strawberry, raspberry and cloudberry intervention for 8 weeks
3169427|NCT01414647|Experimental|BB|Bilberry intervention for 8 weeks
3169428|NCT01414647|Experimental|C|Control diet with restricted berry consumption
3169429|NCT01414634|Experimental|ETIMS 1x10^3|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^3 cells.
3169515|NCT01414062|Experimental|Arm B|Participants attending Cocinar Para Su Salud Program held over a 12-week period
3169516|NCT01414049|Experimental|On-pump CABG|
3169430|NCT01414634|Experimental|ETIMS 1x10^5|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^5 cells.
3169431|NCT01414634|Experimental|ETIMS 1x10^7|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^7 cells.
3169432|NCT01414634|Experimental|ETIMS 1x10^8|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^8 cells.
3169433|NCT01414634|Experimental|ETIMS 5x10^8|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 5x10^8 cells.
3169434|NCT01414634|Experimental|ETIMS 1x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^9 cells.
3169435|NCT01414634|Experimental|ETIMS 2.5x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 2.5x10^9 cells.
3169436|NCT01414634|Experimental|ETIMS 3x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 3x10^9 cells.
3169437|NCT01414621||CABG patients|atrial tissue samples from CABG patients
3169438|NCT01414608|Experimental|Arm I (cisplatin, radiation therapy, brachytherapy)|Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate, pulsed-dose rate, or low-dose rate intracavitary brachytherapy.
3169439|NCT01414608|Experimental|Arm II (cisplatin, radiation therapy, brachytherapy, chemo)|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as in arm I. Beginning 4 weeks later, patients also receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3169440|NCT01414595||Group 1|CALGB 140202 outlines the standard procedures for sample procurement. Samples to be used for this project have already been obtained and are currently banked at the CALGB Pathology Coordinating Office (PCO) and the Lung Cancer Tissue Bank at Brigham and Women's Hospital.
3169441|NCT01414582|Experimental|Anodal tDCS and Motor Training|Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
3169442|NCT01414582|Sham Comparator|Sham tDCS and Motor Training|Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
3169443|NCT01414569|Active Comparator|8 mg dexamethasone|
3169444|NCT01414569|Placebo Comparator|Placebo, saline|
3169445|NCT01414569|Experimental|40 mg dexamethasone|
3169446|NCT01414556|Experimental|hyperglycemia|
3169447|NCT01414556|Experimental|fasting glycemia|
3169448|NCT01414556|Experimental|hypoglycemia|
3169449|NCT01414543|Other|providing information sheet|providing participants with information regarding the purpose of the research
3169450|NCT01414543|Other|Seeking consent|
3169451|NCT01414543|Other|Interview Participant|
3169452|NCT01414543|Other|Debrief|The Participants will be debriefed after the interview.
3169453|NCT01414530|Experimental|oral contraceptive|
3169454|NCT01414530|Active Comparator|NSAID|
3169455|NCT01414517|Active Comparator|FOS|Prebiotic (FructoOligoSaccharide-FOS.
3169456|NCT01414517|Placebo Comparator|Placebo|Maltodextrin (non-prebiotic carbohydrate).
3169457|NCT01414504|Active Comparator|Neonatal PCV + PPV 9 months|Group 1: Children receiving 7VPCV at 0-1-2 months of age and PPV at 9 months of age
3169458|NCT01414504|Active Comparator|Infant PCV + PPV at 9 months|Group 2: Children receiving 7VPCV at 1-2-3 months of age and PPV at 9 months of age
3169459|NCT01414504|Active Comparator|No PCV + PPV at 9 months|Group 3: Children who only received PPV at 9 months of age
3169460|NCT01414504|Active Comparator|Control|Group 4: Children who have not received any previous pneumococcal vaccine
3169461|NCT01414478|Active Comparator|High Protein Shake|Protein shake that contain 30 grams of protein in 11 fluid ounces.
3169462|NCT01414478|No Intervention|Ice Chips|Patients allowed consumption of ice chips only during labor.
3169463|NCT01414465|No Intervention|low caloric diet|10 health obese women (BMI 30 to 40 kg/m2)
3169464|NCT01414465|Experimental|Orlistat|10 obese women treated with Orlistat 120mg 3 times per day
3169465|NCT01414465|Sham Comparator|lifestyle counseling|Women with BMI < 30 kg/m2, no taking drug in study
3169466|NCT01414452||STEMI patients|Patients with ST elevation myocardial infarction,lasting <12 hour, who were succesfully treated with primary PCI
3169467|NCT01414439||Congestive Heart Failure Patients|40 patients diagnosed with heart failure at levels III and IV, according to the classification of the NYHA will participate in the research. The researchers will randomly allocate the patients to the treatment group or the control group. The subjects in the treatment group will participate in Existential Group Therapy, while the subjects in the control group will not participate in the treatment until after the completion of the study. Psychological data will be collected in the form of a self-reported questionnaire completed by all participants prior to the beginning of the research and again upon completion of the final group session.
3169468|NCT01414426|Experimental|Arm I (chemoprevention)|Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
3169469|NCT01414426|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
3169517|NCT01414049|Experimental|Off-pump CABG|
3169571|NCT01413581|Experimental|rhBSSL|rhBSSL (recombinant human bile-salt-stimulated lipase)
3169470|NCT01414413|Experimental|Home assessment and initiation of ART|"Participants with a positive home-based HIV test result will receive a home visit from a study nurse who will complete the following on the first home visit:~Confirmatory fingerprick HIV testing~TB symptom screening~ART eligibility assessment (Word Health Organization clinical staging, sampling of blood for measurement of CD4 count and treatment education)~At a second home visit (within 5 days), participants who are ART eligible (as defined in National ART guidelines) will be initiated onto ART (using National Treatment Programme ART regimens).~Following home initiation of ART, participants in the intervention arm will receive detailed counselling from the study nurse about the need to attend their first 2-week follow-up appointment at the primary health care clinic that serves their household's residence. They will receive a referral slip detailing the date, time and place of their appointment."
3169471|NCT01414413|Other|Clinic-based ART assessment and initiation|Participants who meet eligibility criteria and reside in a cluster that has been allocated to the control arm of this study will receive supported access to ART care through the primary care system for confirmation of HIV status and entry into HIV following disclosure to the resident community counsellor. HIV care, including ART, will be started from the primary care clinic.
3169472|NCT01414387|Active Comparator|Carotid filter|For this intervention group, patients will receive FDA-approved filter devices for cerebral embolic protection during carotid artery stenting intervention.
3169473|NCT01414387|Active Comparator|Carotid reversal of flow|For this intervention group, patients will receive reversal of flow with the FDA-approved Gore Neuroprotection System for cerebral protection during carotid artery stenting.
3169474|NCT01414374|Active Comparator|Iron|
3169475|NCT01414374|Experimental|Herbal|
3169476|NCT01414361||intermediate lesion|intermediate lesions evaluated by both IVUS and FFR
3169477|NCT01414348|Active Comparator|Conventional rehabilitation|In-home work on problems in daily living.
3169478|NCT01414348|Experimental|Novel rehabilitation approach|
3169479|NCT01414335|Placebo Comparator|placebo|
3169480|NCT01414335|Active Comparator|amino acid composition|
3169481|NCT01414322||Group 1: Patients ages 0 - 3|
3169482|NCT01414322||Group 2: Patients ages 3 - 7|
3169483|NCT01414322||Group 3: Patients ages 7 - 15|
3169484|NCT01414309||Observational patients|Heart Failure patients with moderate to severe central sleep apnea
3169485|NCT01414296|Experimental|Arm 1|
3169486|NCT01414283|Experimental|Arm 1|
3169487|NCT01414257||Methotrexate (MTX)|Patients who receive the MTX Preparation at the dose higher than 8 mg/week for the treatment of Rheumatoid Arthritis.
3169488|NCT01414244|Active Comparator|Glutamine supplementation|Glutamine
3169489|NCT01414244|Placebo Comparator|Placebo|Whey protein powder
3169490|NCT01414231|Active Comparator|Cytarabine low dose|This is the golden standard of AML treatment
3169491|NCT01414231|Active Comparator|Cytarabine intermediate dose|This is the OSHO internal arm
3169492|NCT01414218|Experimental|Humor as Way of Life Seminar|See description of study in previous section for further details.
3169493|NCT01414205|Experimental|Obinutuzumab 1000 mg|Participants received a 1000 mg intravenous (IV) infusion, on days 1 (split dose 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1 and day 1 of cycles 2 - 8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
3169494|NCT01414205|Experimental|Obinutuzumab 2000 mg|Participants received a 2000 mg IV infusion, on days 1 (split dose 100 mg Day 1, 900 mg Day 2 and 1000 mg Day 3), 8 and 15 of cycle 1 and day 1 of cycles 2 -8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
3169495|NCT01414192||Ezetimibe monotherapy without prior treatment|Enrolled participants who had no prior lipid-lowering therapy and were currently receiving Ezetimibe alone (Ezetrol®).
3169496|NCT01414192||Ezetimibe monotherpay with prior treatment|Enrolled participants with prior lipid-lowering therapy and were currently receiving Ezetimibe alone (Ezetrol®).
3169497|NCT01414192||Ezetimibe plus statin|Enrolled participants who were being coadministered ezetimide (Ezetrol®) and another prescription statin.
3169498|NCT01414192||Ezetimibe/simvastatin|Enrolled participants who were receiving ezetimibe and simavastatin fixed dose combination tablet (Inegy®).
3169499|NCT01414166|Experimental|ERN/LRPT group|All participants will begin with a screening period of 1 week, followed by a placebo run-in period of 2 weeks before being randomized to receive ERN/LRPT for 16 weeks.
3169500|NCT01414166|Placebo Comparator|Placebo group|All participants will begin with a screening period of 1 week, followed by a placebo run-in period of 2 weeks before being randomized to receive placebo for 16 weeks.
3169501|NCT01414153|Experimental|Monotherapy|4.0 mg iSONEP followed by sham injection; given monthly intravitreously for 4 months
3169502|NCT01414153|Experimental|0.5 mg iSONEP & Lucentis/Avastin/Eylea|0.5 mg iSONEP and 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea; given monthly intravitreously for 4 months
3169503|NCT01414153|Experimental|4.0 mg iSONEP & Lucentis/Avastin/Eylea|4.0 mg iSONEP followed by 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea; given monthly intravitreously for 4 months
3169504|NCT01414153|Active Comparator|Lucentis or Avastin or Eylea|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea followed by a sham injection; given monthly intravitreously for 4 months
3169505|NCT01414140||Group 1|
3169506|NCT01414114|Experimental|Etelcalcetide|Participants received etelcalcetide three times a week (TIW) administered by intravenous bolus injection at the end of each hemodialysis session for 12 weeks. The starting dose was 5 mg and may have been titrated every 4 weeks based on the preceding serum parathyroid hormone (PTH) and corrected calcium (cCa) levels to a maximum dose of 20 mg per hemodialysis session in order to achieve the targeted PTH range while maintaining serum calcium within an acceptable range.
3169507|NCT01414101|Experimental|Group A|Dose 1 ISIS CRP Rx versus Placebo
3169508|NCT01414101|Experimental|Group B|Dose 2 ISIS CRP Rx versus Placebo
3169509|NCT01414101|Experimental|Group C|Dose 3 ISIS CRP Rx versus Placebo
3169510|NCT01414088|Placebo Comparator|glucose|glucose 5 %
3169511|NCT01414088|Active Comparator|isotonic saline|isotonic saline 0.9 mg/ml
3169512|NCT01414088|Active Comparator|hypertonic saline|hypertonic saline 2.9 mg/ml
3169513|NCT01414075|Experimental|Experimental Drug|
3169514|NCT01414062|Active Comparator|Arm A|Participants receiving written dietary recommendations for breast cancer survivors (control arm)
3169518|NCT01414036|Active Comparator|Enhanced Traditional Care control|This arm will receive a low literacy smoking cessation educational brochure, a list of hospital and community resources for smoking cessation, in addition to usual care.
3169519|NCT01414036|Experimental|Patient Navigation|Patients in this arm will receive a low literacy smoking cessation educational brochure and a list of hospital and community resources for smoking cessation. Patients will also receive navigation from a trained navigator Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
3169520|NCT01414023|Experimental|CCT|Cognitive Control Training - Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
3169521|NCT01414023|Placebo Comparator|PVT|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
3169522|NCT01414010|Active Comparator|Prebiotic|
3169523|NCT01414010|Active Comparator|Probiotic|
3169524|NCT01414010|Active Comparator|Antibiotic|
3169525|NCT01414010|No Intervention|Control|Control group, no intervention given.
3169526|NCT01413997||Chronic Low Back Pain|
3169527|NCT01413997||No Low Back Pain|
3169528|NCT01413984|Experimental|cognitive behavioral group treatment|Helping Women Recover/Beyond Trauma integrated substance abuse and trauma treatment group. (Dr. Covington)
3169529|NCT01413984|No Intervention|comparison group|a comparison group of incarcerated women will receive the pre and post assessments with no interventions.
3169530|NCT01413958|Experimental|Phenylephrine|
3169531|NCT01413958|Placebo Comparator|Placebo|
3169532|NCT01413945||Normal volunteers|Normal volunteers without Irritable bowel syndrome who are undergoing screening colonoscopy.
3169533|NCT01413945||Irritable bowel syndrome|Patients with Irritable bowel syndrome are undergoing colonoscopy as standard of care.
3169534|NCT01413932|Experimental|HT-2157|
3169535|NCT01413932|Placebo Comparator|Placebo|
3169536|NCT01413906|Experimental|Arm 1: BMS-833923 (XL139)|
3169537|NCT01413893|Experimental|linifanib|
3169538|NCT01413867|Experimental|EEA group|Group of patients with III degree hemorrhoids treated by EEA stapler
3169539|NCT01413867|Active Comparator|PPH group|group of patients with III degree hemorrhoids treated by PPH stapler
3169540|NCT01413854|Active Comparator|diclofenac|
3169541|NCT01413854|Placebo Comparator|sugar pill|
3169542|NCT01413841|Active Comparator|Nasal oxygen|3 liter per minute
3169543|NCT01413841|Placebo Comparator|Nasal Air|3 l regular nasal air
3169544|NCT01413828|Experimental|concurrent|trastuzumab was administered concurrently with any anthracycline-containing adjuvant regimen
3169545|NCT01413828|Active Comparator|sequential|trastuzumab was administered sequentially to any anthracycline-containing adjuvant regimen
3169546|NCT01413815|Active Comparator|L-arginine|L-Arginine
3169547|NCT01413815|Placebo Comparator|corn starch|Placebo: Corn Starch
3169548|NCT01413802|Experimental|Thyroid surgery.|Patients who undergo thyroid surgery during which intra operative continuous nerve monitoring will be used.
3169549|NCT01413789|Experimental|Patients and healthy volunteers|Patients with healed full thickness burns and healthy volunteers will be included in the study
3169550|NCT01413776|Experimental|Dietary supplement|Pregnant women in 37 villages.
3169551|NCT01413776|No Intervention|Control group|Pregnant women in 38 villages
3169552|NCT01413763|Active Comparator|Imiquimod cream|
3169553|NCT01413763|Placebo Comparator|Placebo cream|
3169554|NCT01413750|Experimental|Arm I (paclitaxel, carboplatin, vorinostat)|Patients receive paclitaxel IV over 3 hours, and carboplatin IV over 30 minutes on day 0. Patients also receive vorinostat PO once daily on days -2 to 2.
3169555|NCT01413750|Active Comparator|Arm II (paclitaxel, carboplatin, placebo)|Patients receive paclitaxel and carboplatin as in arm I. Patients also receive placebo PO once daily on days -2 to 2.
3169556|NCT01413724||Surgical patients|PAtients who had surgery the previous day and are still hospitalized
3169557|NCT01413711|Experimental|Vigabatrin|
3169558|NCT01413698||Patient with chronic cough|
3169559|NCT01413685|No Intervention|Tacrolimus|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
3169560|NCT01413672||person with ostomy|Community dwelling subject with either colostomy or ileostomy and at least 3 months post-surgery.
3169561|NCT01413659|Experimental|Symbiotic|Symbiotic is a combination of prebiotics and probiotics that is designed to have synergistic or additive effects benefiting the host
3169562|NCT01413646|Experimental|Walnut Supplementation|Eight weeks with walnut supplementation to an ad lib diet
3169563|NCT01413646|Placebo Comparator|2|Eight weeks ad lib diet without walnut supplementation
3169564|NCT01413633|Experimental|cholecystectomy|single incision laparoscopic cholecystectomy
3169565|NCT01413620|Experimental|Vitamin E Treated|
3169566|NCT01413620|No Intervention|Untreated|
3169567|NCT01413607|Experimental|Quill knotless tissue-closure device|During partial nephrectomy participants in this group will receive the Quill Knotless Tissue-Closure device (Angiotech Pharmaceuticals) to close the central defect in their kidney.
3169568|NCT01413607|Active Comparator|2-0 absorbable vicryl suture|Participants in this group will be receiving traditional 2-0 vicryl sutures (Ethicon) during partial nephrectomy.
3169569|NCT01413594|Experimental|HABIT|Hand-Arm Bimanual Intensive Therapy (HABIT)
3169570|NCT01413594|No Intervention|Ongoing usual and customary rehabilitation care|Subjects are tested over 6 months while receiving their ongoing usual and customary care schedule of physical and occupational therapy or following constraint-induced movement therapy received as usual and customary care independent of the study, and then are crossed-over to receive HABIT.
3169573|NCT01413568|Experimental|Donor (Phase I and Phase II)|"On Day 1 (and possibly Day 2) POL6326 IV Infusion with increasing dose levels in Phase I or with random dose assignment (from the 2 selected from Phase I) in phase II~Leukapheresis collection on Day 1 (and possibly Day 2)"
3169574|NCT01413568|Experimental|Recipient|Day 0 - PBSC transplant with stem cells mobilized with IV POL6326
3169575|NCT01413555|Experimental|Blood Culture QI Program|
3169576|NCT01413542|Placebo Comparator|Placebo then sitagliptin (DPP4 inhibition) group 1|The effect of vehicle and enalaprilat on the forearm blood flow and t-PA responses to bradykinin and substance P are studied after administration of placebo or sitagliptin (DPP4 inhibition).
3169577|NCT01413542|Placebo Comparator|Sitagliptin (DPP4 inhibition) then placebo group 1|The effect of vehicle and enalaprilat (ACE inhibition) on the forearm blood flow and t-PA responses to substance P and bradykinin are studied after administration of sitagliptin (DPP4 inhibition) or placebo
3169578|NCT01413542|Placebo Comparator|Placebo then sitagliptin group 2|The effect of vehicle and enalaprilat (ACE inhibition) on the forearm blood flow and t-PA responses to glucagon-like peptide-1 and brain natriuretic pepdie are studied after administration of placebo or sitagliptin (DPP4 inhibition).
3169579|NCT01413542|Placebo Comparator|Sitagliptin (DPP4 inhibition) then comparator group 2|The effect of vehicle and enalaprilat on the forearm blood flow and t-PA responses to glucagon-like peptide and brain natriuretic peptide are studied after administration of placebo or sitagliptin (DPP4 inhibition).
3169580|NCT01413529|Experimental|HEART to HAART|HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
3169581|NCT01413529|Active Comparator|Adherence counseling|Adherence counseling with the addition of a smart phone control
3169582|NCT01413516|Placebo Comparator|Placebo Control|Smoking cessation counseling with placebo comparator
3169583|NCT01413516|Active Comparator|Experimental: Varenicline|Smoking cessation counseling with varenicline
3169584|NCT01413503|Experimental|131I-MIBG|
3169585|NCT01413477|Active Comparator|Calcipotriol ointment|
3169586|NCT01413477|Active Comparator|Betamethasone dipropionate ointment|
3169587|NCT01413477|Active Comparator|Calcipotriol and betamethasone ointment|
3169588|NCT01413477|Placebo Comparator|Vaseline Petroleum Jelly|
3169589|NCT01413412|Experimental|Hernia repair using full-thickness skin graft|25 patients
3169590|NCT01413412|Experimental|Hernia repair using Mesh|25 patients
3169591|NCT01413399|Active Comparator|Intra-Arrest Therapeutic Hypothermia|
3169592|NCT01413399|Active Comparator|Post-Arrest Therapeutic Hypothermia|
3169593|NCT01413386|Experimental|Paclitaxel Eluting Covered Metal Stent|
3169594|NCT01413386|Active Comparator|Covered Metal Stent|
3169595|NCT01413373|No Intervention|three-dimensional cephalometry|3D cephalometry performed on CBCT imaging
3169596|NCT01413360|Experimental|HD Vitamin C|High dose vitamin C
3169597|NCT01413347|Active Comparator|pillow|confirmation of double-lumen tube position with a head on a pillow
3169598|NCT01413347|Experimental|neutral|confirmation of double-lumen tube position in neutral position of a head
3169599|NCT01413321||SHABI|Subacute hemiparetic ABI subjects group
3169600|NCT01413321||CHABI|Chronic hemiparetic ABI subjects group
3169601|NCT01413295|Experimental|Dendritic Cells Vaccine|Dendritic Cells Vaccine after 2 lines of chemotherapy
3169602|NCT01413295|Other|Supportive treatment|Supportive treatment after 2 lines of chemotherapy
3169603|NCT01413282|Active Comparator|Cardiac CT|Triage based on cardiac CT results.
3169604|NCT01413282|No Intervention|Standard Care|Standard diagnostic management according to the European guidelines.
3169605|NCT01413269|Experimental|hypofractionation radiotherapy|irradiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.
3169606|NCT01413269|Active Comparator|conventional fractionation radiotherapy|irradiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.
3169607|NCT01413243|Experimental|Drug: Trichuris suis ova|Experimental: Trichuris suis ova (TSO) 2500 eggs every 2 weeks for 12 months
3169608|NCT01413243|Placebo Comparator|Placebo|Drug: Placebo, fluid every 2 weeks
3169609|NCT01413217||Egg Breakfast|This group will be given a breakfast consisting of eggs. A breakfast consisting of eggs induces greater satiety and reduces Lunch Time intake.
3169610|NCT01413217||Cereal Breakfast|This breakfast will consist of a breakfast that will include cereal. A breakfast cereal or white bread increases lunchtime energy intake.
3169611|NCT01413204|Experimental|TA-7284 Low|
3169612|NCT01413204|Experimental|TA-7284 High|
3169613|NCT01413204|Placebo Comparator|Placebo|
3169614|NCT01413191|Experimental|CixutumumabTreatment|Cixutumumab 10 mg/kg intravenous (IV) over 1 hour on days 1 and 15 for 4 week courses.
3169615|NCT01413178|Experimental|Busulfan + Melphalan|Busulfan test dose (32 mg/m^2) on day -9 then 130 mg/m^2 intravenous (IV) Days -7, -6, -5, and -4 + Melphalan 70 mg/m2 IV on Days -2 and -1. Stem Cell Transplant (SCT) Day 0.
3169616|NCT01413178|Experimental|Melphalan|High-dose Melphalan 200 mg/m2/day IV over 30 minutes on day -2. SCT Day 0.
3169617|NCT01413152|Experimental|0|
3169618|NCT01413139|Other|4F portfolio products from Biotronik|The devices under investigation are the 4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18 and Cruiser-18.
3169619|NCT01413126|Experimental|Peanut butter|42.5 g of Peanuts butter were added to a 75g available carbohydrate-matched breakfast meal
3169620|NCT01413126|Experimental|Whole peanut|42.5 g of whole peanuts were added to a 75g available carbohydrate-matched breakfast meal
3169621|NCT01413126|No Intervention|No peanuts (control)|
3170571|NCT01406158|Experimental|Treatment A|
3169622|NCT01413113|Experimental|Treatment (enzyme inhibitor and radioactive drug therapy)|Patients receive iodine I 131 IM QD 5 days a week in weeks 5-6. Patients also receive pazopanib hydrochloride PO QD beginning in week 1 and continuing for 8 weeks post-radioactive iodine therapy.
3169623|NCT01413100|Experimental|Treatment (HDIT autologous PBSCT)|"STEM CELL MOBILIZATION AND PREPARATION: Patients receive filgrastim SC on mobilization days 1-4 followed by apheresis until a target dose of CD34+ cells >= 2.5 x 10^6/kg are collected. Patients difficult to mobilize with filgrastim alone receive cyclophosphamide IV or *plerixafor SC on mobilization days 1-2 and filgrastim SC on mobilization days 5-7.~HDIT CONDITIONING: Patients receive high-dose cyclophosphamide IV over 1-2 hours on days -5 to -2 and anti-thymocyte globulin IV on days -5, -3, -1, 1, 3, and 5.~TRANSPLANTATION: Patients undergo autologous PBSCT on day 0.~MAINTENANCE THERAPY: Beginning 2-3 months after transplant, patients receive mycophenolate mofetil PO BID for 2 years."
3169624|NCT01413087|Experimental|BC-819 and Gemcitabine|
3169625|NCT01413074|Active Comparator|ESRD patients receiving HD treatment|no investigational drug involved. Only oberseve therapy treatment
3169626|NCT01413074|Experimental|ESRD patients receiving PD treatment|no investigational drug involved. Only oberseve therapy treatment
3169627|NCT01413061|Active Comparator|AlloStem Live Cellular Allograft|AlloStem is the combination of the Mesenchymal Stem Cells (MSC) derived from adipose with demineralized bone.
3169628|NCT01413061|Active Comparator|Control: Autologous Bone Marrow Aspirate|Autologous bone graft is recovered from the patient's own tibia or iliac crest, for transplantation in the subtalar joint.
3169629|NCT01413048|Experimental|AGSCT101|
3169630|NCT01413048|Active Comparator|Carvedilol|
3169631|NCT01413035|Experimental|MSC and the oral hypoglycemic drugs|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former oral hypoglycemic drugs, such as Dimethylbiguanide, Glurenorm and Acarbose, et al. and regulates the dosage for 1 year.
3169632|NCT01413035|Experimental|MSC and insulins|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former insulins and regulates the dosage for 1 year.
3169633|NCT01413035|Experimental|MSC and the combination of drugs and insulins|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former combination of the oral hypoglycemic drugs and insulins and regulates the dosage for 1 year.
3169634|NCT01413022|Active Comparator|Group A (FOLFIRINOX chemotherapy)|"Patients receive FOLFIRINOX chemotherapy comprising of:~oxaliplatin 85 mg/m2 IV on Day 1~irinotecan 180 mg/m2 IV on Day 1~leucovorin 400 mg/m2 IV on Day 1~5FU 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1~Treatment is repeated every 14 days for 6 cycles."
3169635|NCT01413022|Experimental|Group B (FOLFIRINOX and PF-04136309)|"Patients receive FOLFIRINOX chemotherapy comprising of:~oxaliplatin 85 mg/m2 IV on Day 1~irinotecan 180 mg/m2 IV on Day 1~leucovorin 400 mg/m2 IV on Day 1~5FU 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1~PF-04136309 500 mg PO BID on days 1-14~Treatment is repeated every 14 days for 6 cycles."
3169636|NCT01413009||ICU patients|
3169637|NCT01412996|Active Comparator|single ACCESS cholecystectomy|single ACCESS laparoscopic cholecystectomy
3169638|NCT01412996|Active Comparator|traditional|conventional laparoscopic cholecystectomy
3169639|NCT01412983|Experimental|Bausch & Lomb Test Lens|Bausch + Lomb investigational soft contact lens
3169640|NCT01412983|Active Comparator|Ciba Vision soft contact lens|Ciba Vision Air Optix Aqua soft contact lens
3169641|NCT01412970|Other|study group|comparison of ability to predict volume responsiveness and precision of measurement of stroke volume variation assessed by electrical impedance tomography in comparison to clinically established invasive hemodynamic monitoring devices, i.e. arterial pulse contour analysis during volume loading procedures
3169642|NCT01412957|Experimental|Panitumumab + BSC|Participants received panitumumab administered intravenously 6 mg/kg every 14 days plus BSC until disease progression, withdrawal of consent, death, or intolerance of study drug.
3169643|NCT01412957|Other|BSC Alone|Participants received best supportive care until disease progression, withdrawal of consent, or death.
3169644|NCT01412944|Experimental|AIN457 subcutaneous (s.c.)|During the intravenous (I.V.) period, participants received two 150 mg s.c. injections of AIN457 at randomization and week 4, and AIN457 placebo I.V. at randomization, week 2 and week 4. During the maintenance period, participants received 300 mg s.c. of open-label AIN457.
3169645|NCT01412944|Experimental|AIN457 I.V.|During the I.V. period, participants received AIN457 10mg/kg I.V. at randomization, week 2 and week 4, and AIN457 placebo s.c. at randomization and week 4. During the maintenance period, participants received 300 mg s.c. of open-label AIN457.
3169646|NCT01412931||1) Pregnant women with a single intrauterine pregnancy|50 women with uncomplicated pregnancies and no history of preterm birth.
3169647|NCT01412931||2) Pregnant women with a single intrauterine pregnancy|50 multiparous women with history of spontaneous preterm labor or preterm premature rupture of membranes (PPROM).
3169648|NCT01412931||3) Pregnant women with a single intrauterine pregnancy|20 women evaluated on the labor and delivery unit because they are deemed to be at high risk for preterm birth.
3169649|NCT01412918|Experimental|Tinnitus|"Individual with tinnitus. Intervention: inhibitor device demonstration.~The Inhibitor™ Tinnitus Masking Device is a new tinnitus treatment device recently available in the United States for use of temporary relief of tinnitus. The device emits an ultra high frequency sound for 60 seconds via bone conduction when applied to the mastoid. Patients reporting tinnitus will be provided the opportunity to demonstrate the device to observe any changes in their tinnitus. The device may be demonstrated up to 5 times. The investigators will be recording the the degree and duration of change in tinnitus perception following treatment with the Inhibitor™ Tinnitus Masking Device."
3169650|NCT01412918|No Intervention|No tinnitus|Individuals without tinnitus will also be masked with the device.
3169651|NCT01412892|Experimental|Everolimus|RAD001: Everolimus
3169689|NCT01412606|Placebo Comparator|Control|Uterine sounding on day 21-26 of a spontaneous menstrual cycle
3169690|NCT01412593|Experimental|Stem cell transplant|
3169691|NCT01412593|No Intervention|Control|
3169731|NCT01412281|Active Comparator|Group D - Elderly|1 x 0.5 mL i.m. virosomal influenza vaccine (CSL HA Antigen) 2011/2012
3170529|NCT01406418|Placebo Comparator|Cohort 3: Placebo|5% dextrose in water
3169652|NCT01412879|Experimental|Arm I|Course 1 and 3: Patients receive induction therapy comprising rituximab IV on day 1; cyclophosphamide IV over 3 hours every 12 hours on days 2-4; doxorubicin hydrochloride IV over 72 hours on days 5-7; vincristine sulfate IV on days 5 and 12; and dexamethasone IV or orally (PO) once daily (QD) on days 2-5 and 12-15. Patients with responsive disease after course 1 proceed to course 2. Course 2 and 4: Patients receive rituximab IV on day 1; methotrexate IV over 2-22 hours on day 2; cytarabine IV over 2 hours every 12 hours on days 3-4; and leucovorin calcium PO or IV on days 3-6. Patients then undergo stem cell collection after completion of course 2. Patients undergo stem cell collection after completion of course 2.
3169653|NCT01412879|Experimental|Arm II|Course 1-6: Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-4 weeks later, patients with responsive disease receive 2 additional courses of treatment. Beginning within 8 weeks, patients receive rituximab IV and cyclophosphamide IV over 1 hour on day 1. Patients then undergo stem cell collection about 26 days later.
3169654|NCT01412866|Active Comparator|EDSS with CO monitor feedback|
3169655|NCT01412866|Experimental|EDSS without CO monitor feedback|
3169656|NCT01412853|Experimental|MR-spectroscopy|
3169657|NCT01412840|Experimental|Standard care and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
3169658|NCT01412840|Placebo Comparator|Standard care and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
3169659|NCT01412840|No Intervention|Standard care|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac.
3169660|NCT01412827|Other|Comparison of radioisotope dosing|
3169661|NCT01412814|Experimental|Experimental|These patients will carry out the specified intervention of the study with the AposTherapy Biomechanical System in addition to the typical physical therapy regiment prescribed to them by their physician.
3169662|NCT01412814|Active Comparator|Control|The patients within this group will also carry out the typical physical therapy program for total knee replacement as prescribed by their physician. The patients will carry out a similar therapy program to the experimental group, but without the study intervention device (placebo walking shoe).
3169663|NCT01412801|Experimental|HIVneg|HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of Group B streptococcus vaccine.
3169664|NCT01412801|Experimental|HIVposCD4HIGH|HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count >350 cells/µL received one dose of Group B streptococcus vaccine.
3169665|NCT01412801|Experimental|HIVposCD4LOW|HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but > 50 cells/µL received one dose of Group B streptococcus vaccine
3169666|NCT01412788|Experimental|peri-areolar incision|Peri-areolar incision was used to carry out lumpectomy
3169667|NCT01412788|Active Comparator|traditional incision|traditional incision above tumor was used to carry out lumpectomy
3169668|NCT01412775|Experimental|Psychological stress and exhaustion|Twenty four male and female nurses from the cardiac intensive-care unit (CCU) of Meir Hospital, who consent to take part in the offered intervention program, will participate in the study. The participants will be randomly assigned to an experiment group of 12 participants and a control group of 12 participants.
3169669|NCT01412762||patient interviews|We aim to interview 15 patients with confirmed thyroid malignancy both pre- and postoperatively, for a total of 30 interviews. For the expansion of this study, we will accrue 25 patients with biopsy-proven thyroid cancer undergoing thyroidectomy to be educated with the CITSAV application prior to surgery.
3169670|NCT01412749||eHNS Participant Registry|Participants diagnosed with head and neck cancer who are candidates for definitive surgical resection of the primary tumor and who are candidates for eHNS.
3169671|NCT01412736|Experimental|2mg|sterile lyophilized formulation, 2mg
3169672|NCT01412736|Experimental|20mg|sterile lyophilized formulation, 20mg
3169673|NCT01412736|Experimental|100mg|sterile lyophilized formulation, 100mg
3169674|NCT01412736|Placebo Comparator|Placebo|two SC administration on day 1
3169675|NCT01412723|Active Comparator|Ferrous sulphate|Preschool children with depleted levels of iron enrolled in FAN Foundation of Medellin, which will be supplied with ferrous sulfate-fortified milk
3169676|NCT01412723|Experimental|Iron Amino acid chelate|Preschool children with depleted levels of iron enrolled in FAN Foundation of Medellin , which will be supplied with iron amino acid chelate-fortified milk
3169677|NCT01412710|Experimental|4000 IU group|This group will be given 4000 IU of vitamin D3 once daily, orally for 6 months.
3169678|NCT01412710|Experimental|6000 IU group|This group will be given 6000 IU vitamin D3 once daily, orally for 6 months.
3169679|NCT01412697|Experimental|Fruit and Vegetable Intake Behavioral Intervention|measure fruit and vegetable intake in rural youth based on specific behavioral intervention.
3169680|NCT01412697|No Intervention|Control Group|control group received the standard health information
3169681|NCT01412671||Group 1|
3169682|NCT01412658|Experimental|Milk Peptides|
3169683|NCT01412658|Placebo Comparator|Placebo|Participants ingested 6ml - 21ml (based on participants' weight) of clear, sugar-less liquid placebo mixed with 1/2 cup milk twice daily (once immediately after breakfast and once immediately after dinner). The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a glycerol-based placebo matched for color, texture, and taste to the active supplement.
3169684|NCT01412645|Placebo Comparator|Placebo|
3169685|NCT01412645|Experimental|High-dose Resveratrol|
3169686|NCT01412645|Experimental|Low-dose Resveratrol|
3169687|NCT01412632|Experimental|General vs deep sedation|General anesthesia: remifentanil and propofol Deep sedation: remifentanil, propofol and citanest
3169688|NCT01412606|Experimental|Scrathcing|scratching of endometrium on day 21-26 of a spontaneous menstrual cycle
3170530|NCT01406418|Experimental|Cohort 4: CR6261|30 mg/kg CR6261
3169692|NCT01412580||observational followup|This was an observational follow-up to a larger study in which treatment group was given 20 mg of vitamin B1, 20 mg of vitamin B2, 25 mg of vitamin B6, 100 mg of niacin, 50 μg of vitamin B12, 500 mg of vitamin C, 30 mg of vitamin E, and 0.8 mg of folic acid
3169693|NCT01412567|Active Comparator|Vaccine+HBIG|
3169694|NCT01412567|Placebo Comparator|Vaccine+Placebo|
3169695|NCT01412554||Young caucasian men|During 1991-96 healthy young men recruited from the military enlistments in the Oslo/Akershus area were examined at Center of Cardiovascular and Renal Research, Division of Medicine, Oslo University Hospital, Ullevål. A total of 158 young men, mean age of 21, were examined using the hyperinsulinaemic isoglycaemic glucose clamp technique which is the gold standard to assess insulin sensitivity.
3169696|NCT01412541|Experimental|Moxy Drug Coated Balloon|Paclitaxel coated balloon catheter
3169697|NCT01412541|Active Comparator|Standard Uncoated Angioplasty Balloon|PTA Catheter
3169698|NCT01412528|Other|Eight different allergens will be standardized in this study|
3169699|NCT01412515|Experimental|Everolimus|everolimus 10 mg per day
3169700|NCT01412502||Brain death with organ donation|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death includes brain death with multiple organ donation +/- tissues."
3169701|NCT01412502||Limitation/cessation of active treatment|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death includes limitation/cessation of active treatment without brain death."
3169702|NCT01412502||Sudden death|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death was sudden death of a previously healthy patient (no physical or mental limitations; MacCabe score = 0) within 3 days of admission to ICU without LATA nor brain death."
3169703|NCT01412489|Experimental|1|For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
3169704|NCT01412476||case group|Subjects with metabolic syndrome
3169705|NCT01412476||control group|Healthy individuals
3169706|NCT01412463|Experimental|Protégé EverFlex+|Stenting with Protégé EverFlex+
3169707|NCT01412450|Experimental|nitinol stent|Protégé EverFlex stent
3169708|NCT01412437|Experimental|Diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
3169709|NCT01412437|Experimental|sapropterin dihydrochloride|Intervention: 24 participants will be randomized to receive the drug 10 mg/kg per day. Responders and non responders will remain on drug for four months
3169710|NCT01412424|Experimental|Octreotide capsules|Participants received octreotide capsules orally twice a day for up to 13 months. Dosing started at 40 mg per day (20 in the morning + 20 in the evening) and increased to 60 mg per day (40 in the morning + 20 in the evening) or 80 mg per day (40 in the morning + 40 in the evening) if there was inadequate IGF-1 suppression.
3169711|NCT01412411|Active Comparator|Nutrition Education plus Multiple Micronutrient Fortification|In this group along with the nutritional education, multiple micronutrient fortification was given in the form of Sprinkles
3169712|NCT01412411|Active Comparator|OIS plus Nutritional Eductaion|In this group, along with the nutritional education, Oral Iron Supplementation was given.
3169713|NCT01412411|Active Comparator|Nutrition Education Group|This is group was followed for the growth of the child and was given Nutritional Education to children's mothers.
3169714|NCT01412398||Group 1|Drug (incl. Placebo)
3169715|NCT01412385|Experimental|Epoch 1 (intravenous pre-study treatment) + Epoch 2|Study Epoch 1 (13 weeks): treatment with KIOVIG (once every 3 or 4 weeks, dose as during pre-study period) + Study Epoch 2 (same for all subjects, 51 weeks): treatment with IGSC, 20% (every week, dose to be calculated on the basis of weekly equivalents)
3169716|NCT01412385|Experimental|Epoch 1 (subcutaneous pre-study treatment) + Epoch 2|Study Epoch 1 (12 weeks): treatment with SUBCUVIA (once every week or once every two weeks, dose as during pre-study period) + Study Epoch 2 (same for all subjects, 51 weeks): treatment with IGSC, 20% (every week, dose to be calculated on the basis of weekly equivalents)
3169717|NCT01412372|Experimental|Placebo|This arm will include those who are randomized to the placebo
3169718|NCT01412372|Experimental|Mesalamine|This arm is for subjects randomized to the study drug, Mesalamine
3169719|NCT01412359|Experimental|Omegaven®|Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 12 -24 hours every day until patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
3169720|NCT01412346|Active Comparator|Plant-based food and fish with salt restr.|The subjects consume plant based foods (fruits, berries, vegetables, whole grain) and fish in addition to a salt-restricted diet. Intake of salt is normal to high for 8 weeks and low for 8 weeks (subjects receive salt and placebo capsules in a crossover design).
3169721|NCT01412346|Placebo Comparator|Diet with salt restriction|The subjects follow a salt-restricted diet. Intake of salt is normal to high for 8 weeks and low for 8 weeks (subjects receive salt and placebo capsules in a crossover design).
3169722|NCT01412333|Active Comparator|Interferon beta-1a 44 mcg SC|Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
3169723|NCT01412333|Experimental|Ocrelizumab|Ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.
3169724|NCT01412320|Experimental|Flavanol rich cocoa|
3169725|NCT01412320|Experimental|Flavanol poor|
3169726|NCT01412307|Experimental|lenalidomide plus bendamustine|
3169727|NCT01412294|Experimental|Capecitabine, Cisplatin|
3169728|NCT01412281|Experimental|Group A - Young adults|1 x 0.5 mL i.m. virosomal influenza vaccine (AdImmune HA Antigen) 2011/2012
3169729|NCT01412281|Active Comparator|Group B - Young adults|1 x 0.5 mL i.m. virosomal influenza vaccine (CSL HA Antigen) 2011/2012
3169730|NCT01412281|Experimental|Group C - Elderly|1 x 0.5 mL i.m. virosomal influenza vaccine (AdImmune HA Antigen) 2011/2012
3169732|NCT01412242|Experimental|Extensive search for isolated calf DVT|As this is a prospective cohort study, for definition there is only 1 arm
3169733|NCT01412229|Experimental|Treatment|"nab-paclitaxel 100mg/m2~Carboplatin area under curve (AUC)2 (IV)~Cetuximab 400mg/m2 week 1 then 250mg/m2 for six weeks"
3169734|NCT01412216|Experimental|Fish Oil (Omega-3 Fatty Acids)|High-dose, short-duration dietary omega-3 fatty acids supplementation
3169735|NCT01412216|Placebo Comparator|Placebo|Placebo control
3169736|NCT01412203|No Intervention|Usual Practice|School continues with regular programming
3169737|NCT01412203|Experimental|Action Schools! BC|School adopts the AS!BC model
3169738|NCT01412190|Other|Untreated|
3169739|NCT01412190|Active Comparator|Restylane Vital Light|Restylane Vital Light administered at 3 treatment sessions 4 weeks apart
3169740|NCT01412177|Experimental|OTO-104|
3169741|NCT01412177|Placebo Comparator|Placebo|
3169742|NCT01412164|Experimental|Firehawk|Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
3169743|NCT01412151|Other|Creatine monohydrate|single arm long-term open label follow-up
3169744|NCT01412138||ARM 1|ENDOMETRIAL SAMPLE
3169745|NCT01412125||Patient|Voluntary Huntington patients symptomatic or asymptomatic, with a number of nucleotide expansion(CAG) ≥36 and who know their genetic status
3169746|NCT01412125||Healthy subject|Voluntary controls with no family history of huntington's disease
3169747|NCT01412099|Experimental|Feedback report plus peer counseling|
3169748|NCT01412099|Experimental|Feedback report|
3169749|NCT01412086||All Participants|Healthy volunteers. No treatment (intervention) was received.
3169750|NCT01412073|Active Comparator|oxytocin bolus|"5 IU bolus iv over 3 minutes after delivery of the baby Operative blood loss will be estimated in theatre based on the volume in the suction bottle and the weight of swabs used. We will record blood loss up until the time the woman will be discharged from the theatre recovery ward.~Hemoglobin level and haematocrit value will be done as follow:-~After admission of each case in the pre-operative period.~Immediately post- operative.~24 hours post- operative."
3169751|NCT01412073|Active Comparator|oxytocin bolus & oxytocin infusion|5 IU oxytoxin bolus over 3 minutes and 30 IU oxytocin infusion in 500 ml 0.9% saline over 4 hours after delivery of the baby
3169752|NCT01412073|Active Comparator|misoprostol intrauterine|misoprostol 800 micrograms intrauterine, placed manually on the bottom of the uterine cavity after delivery of the placenta and cleaning of the cavity
3169753|NCT01412060|Experimental|Cariprazine - Open-label Phase|Participants received 3, 6, or 9 mg cariprazine orally once a day for 6 weeks; the dose could be modified during this time. The cariprazine dose was fixed at 3, 6, or 9 mg for the last 14 weeks of this 20 week Open-label Phase.
3169754|NCT01412060|Experimental|Placebo - Double-blind Treatment Phase|Participants received placebo orally once a day for 26 to 72 weeks.
3169755|NCT01412060|Experimental|Cariprazine - Double-blind Treatment Phase|Participants received 3, 6, or 9 mg cariprazine orally once a day for 26 to 72 weeks
3169756|NCT01412034|Experimental|CER-001|Open label single arm study of CER-001
3169757|NCT01412021||Humira|those with an exposure
3169758|NCT01412008|No Intervention|botox diffusion|Each subject was given 3 injections in lateral gastrocnemius muscle:2 botox, 1 saline, each injection was 2.5mL. MRI of the lower leg was taken prior to injections and 2 months post for a comparison of diffusion properties.
3169759|NCT01411995|Experimental|2% Lidocaine gel|Women randomized to the Lidocaine arm will receive a total of 3-5cc of 2% gel at the tenaculum site and within the endocervical canal
3169760|NCT01411995|Placebo Comparator|Water based lubricant|Women randomized to the placebo arm will receive a total of 3-5cc of water based lubricant at the tenaculum site and within the the endocervical canal
3169761|NCT01411969||External nasal dilator, decongestion|
3169762|NCT01411956|Experimental|Treatment Group|"This group viewed the intervention video, a 24-minute episode of the sitcom White Coats, deliberately scripted with the five health behavior theory constructs we are testing."
3169763|NCT01411956|Placebo Comparator|Control Group|The control group viewed a 25-minute video on an unrelated subject (depression).
3169764|NCT01411930|Experimental|Olanzapine -> Aripiprazole|Crossover design. Order of agents is randomized. For this arm, the order will be IM olanzapine (1st clamp study) and IM aripiprazole (2nd clamp study).
3169765|NCT01411930|Experimental|Aripiprazole -> Olanzapine|Crossover design. Order of agents is randomized. For this arm, the order will be IM aripiprazole (1st clamp study) and IM olanzapine (2nd clamp study).
3169766|NCT01411917|Experimental|TAP block group|Patients in this group will have a preoperative, ultrasound guided injection of 30ml of 0.375% bupivacaine into the muscle plane between the transversus abdominis muscle and internal oblique muscles.
3169767|NCT01411917|Placebo Comparator|Placebo|Patients in this group will have an ultrasound guided subcutaneous injection of 30 ml of sterile preservative free saline.
3169768|NCT01411904|Experimental|MagProbe (TM)|"Patients whose bone marrow aspirates are exposed to the MagProbe and CD34 nanoparticles.~Leukemia patients~MagProbe (TM)~Diagnosed or suspected leukemia~Non-leukemia patients~MagProbe (TM)~Requiring bone marrow biopsy"
3169769|NCT01411891|No Intervention|Control|Patients assigned to this study group will not have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
3169770|NCT01411891|Experimental|Chlorhexidine impregnated patch.|Patients assigned to this study group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
3169771|NCT01411878|Experimental|Reducing the Risk|Students will be randomly assigned to participate in Reducing the Risk training
3169772|NCT01411878|Experimental|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, & Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov).
3169773|NCT01411865|Experimental|Intervention|
3169774|NCT01411865|Other|Control|
3169808|NCT01411618|Active Comparator|alcohol containing essential oil mouthwash|
3169775|NCT01411852|Experimental|0.9% Sodium Chloride 250 mL bolus|0.9% Sodium Chloride 250 mL bolus - A large bore IV will be placed and a 250cc bag of normal saline (NS) will be hung. If IV placement is difficult, NS can be given through an intraosseous line. Using small bags versus large bags will physically limit the amount of fluid given to patients in the experimental group. The requirement to change the smaller bags of fluid and recheck the pulse or blood pressure will limit the amount of fluid given. The procedure will continue until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first. Hemorrhage control will be defined as ligation of a bleeding vessel, packing of a solid organ, removal of a solid organ, and angiographic embolization of a bleeding vessel.
3169776|NCT01411852|Active Comparator|0.9% Sodium Chloride 2000 mL bolus|0.9% Sodium Chloride 2000 mL bolus - The treatment of the control group will be consistent with traditional Prehospital Trauma Life Support and Advanced Trauma Life Support guidelines which recommend early aggressive fluid resuscitation. An intravenous line (IV) will be placed and a 1000cc bag of normal saline will be hung. If IV placement is difficult, fluid can be given through an intraosseous line. This procedure will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first. Hemorrhage control will be defined as ligation of a bleeding vessel, packing of a solid organ, removal of a solid organ, and angiographic embolization of a bleeding vessel.
3169777|NCT01411839|Experimental|Cognitive-Behavioral Therapy (CBT-AD)|This arm type is a cognitive-behavioral therapy program intervention for issues of medication adherence and depression. The intervention is a therapy program intervention involves 10-weekly or biweekly sessions, with 2 booster session, and focused on psychoeducation, behavioral activation, cognitive restructuring, and problem-solving. A letter was sent to their medical provider indicating that mild symptoms of depression were detected and that they were enrolled in this intervention, but no details were provided regarding their assignment to one of two conditions/arms.
3169778|NCT01411839|No Intervention|Control-Standard Care|Those randomized to the control condition are not involved in the CBT-AD therapy intervention. They receive standard care as usual. A letter was sent to their medical provider indicating that mild symptoms of depression were detected and that they were enrolled in this intervention, but no details were provided regarding their assignment to one of two conditions/arms. The participants in the control arm are followed and matched to a participant in the intervention arm.
3169779|NCT01411826|Active Comparator|Information|
3169780|NCT01411826|Experimental|Information + Narratives + Support group|
3169781|NCT01411813||Alprazolam|Patients receiving Alprazolam.
3169782|NCT01411800|Experimental|Treatment A|500 mg LX1033, capsules administered two times per day orally
3169783|NCT01411800|Experimental|Treatment B|500 mg LX1033, tablets administered two times per day orally
3169784|NCT01411787|No Intervention|Control Group|Patient will continue normal activities. Ki-67 will be measured in the initial core biopsy and then again in the final pathologic specimen which is removed for definitive surgical intervention. Insulin resistance levels will be measured by obtaining insulin-like growth factor binding protein one and C-peptide levels just prior to initiation of neoadjuvant chemotherapy, and then again after the last chemotherapy dose. Body mass index, percent body fat, and improving fitness levels will also be measured.
3169785|NCT01411787|Experimental|Exercise|"Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.~Ki-67 will be measured in the initial core biopsy specimen and then again in the final pathologic specimen which is removed for definitive surgical intervention. Insulin resistance levels will be measured by obtaining insulin-like growth factor binding protein one and C-peptide levels just prior to inititation of neoadjuvant chemotherapy and then again after the last chemotherapy dose in both arms. Body mass index, percent body fat, and improving fitness levels will also be measured."
3169786|NCT01411774|Active Comparator|Cognitive-behavioral therapy plus pill placebo|This study arm involves the subject receiving 10 sessions of cognitive behavioral therapy with pill placebo taken 1 hour before the session.
3169787|NCT01411774|Experimental|Cognitive-behavioral Therapy plus d-cycloserine|This study arm involves the subject receiving 10 sessions of cognitive behavioral therapy with d-cycloserine taken 1 hour before the session.
3169788|NCT01411761|Experimental|Saccharomyces boulardii|study group
3169789|NCT01411761|Placebo Comparator|placebo|serum physiologic
3169790|NCT01411748|Experimental|S. boulardii|The patients in this group will be given 5 million unit/day S. boulardii until discharge.
3169791|NCT01411748|Active Comparator|nystatin|
3169792|NCT01411735|Active Comparator|Enalapril|2.5mg titrated up to 10mg- twice daily
3169793|NCT01411735|Placebo Comparator|placebo|2.5 mg titrate up to 10mg twice daily placebo comparator
3169794|NCT01411722|Other|EADIWEANING|Patients mechanically ventilated for more than 48 hours during the weaning process.
3169795|NCT01411709|Active Comparator|Vitano|
3169796|NCT01411709|No Intervention|Control|No tablets - control group
3169797|NCT01411696||All Participants|Patients who received at least 2 injections of OZURDEX® (dexamethasone intravitreal implant) to treat Macular Edema.
3169798|NCT01411683|Experimental|4 mini dental implants|Retention of an overdenture by means of 4 mini implants.
3169799|NCT01411683|Experimental|2 mini dental implants|Retention of an overdenture by means of 2 mini implants.
3169800|NCT01411683|Active Comparator|2 conventional dental implants|Retention of an overdenture by means of 2 conventional implants associated to ball attachments.
3169801|NCT01411670|Experimental|Human protein C concentrate|
3169802|NCT01411670|Active Comparator|activated protein C|Continuous infusion of Activated Protein C
3169803|NCT01411670|Placebo Comparator|Placebo|Standard treatment
3169804|NCT01411657|Experimental|NT-501 CNTF Implant|Patients will receive single NT-501 CNTF implant in one eye
3169805|NCT01411631|Active Comparator|Grape juice|Participants will drink 100% concord grape juice daily for 12 weeks
3169806|NCT01411631|Placebo Comparator|Placebo drink|Participants will drink the placebo for 12 weeks. The placebo will be equicaloric and matched on appearance, taste, volume and macronutrient composition to the grape juice drink.
3169807|NCT01411618|Experimental|free alcohol essential oil moutwash|
3169809|NCT01411605|Experimental|Exercise training|"12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).~Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol."
3169810|NCT01411592|Active Comparator|Multilink|RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system [A/B primer and Multilink-Automix] with Metal/Zirconia primer)
3169811|NCT01411592|Active Comparator|Panavia 21 TC|RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
3169812|NCT01411579||Clinical Benefit|The patients responding to the chemotherapy, i.e. who show at least a non progressive disease
3169813|NCT01411579||Non responder|The patients non responding to the chemotherapy, i.e. who show a progressive disease
3169814|NCT01411566|Experimental|Treatment|
3169815|NCT01411566|Active Comparator|Control|
3169816|NCT01411553|No Intervention|Reusable ECG leadwires-ICU|Current ECG leadwires will be used
3169817|NCT01411553|Active Comparator|Disposable ECG leadwires-ICU|Disposable ECG-LW
3169818|NCT01411540|Experimental|Whole grain diet|Subjects will eat a whole grain based diet for eight weeks. Pre-and post-diet intervention testing will determine effects on body composition. Whole grain-based are will be compared to the refined grain based diet.
3169819|NCT01411540|Active Comparator|Refined grain diet|Subjects will eat a refined grain diet for 8 weeks matched with the whole grain arm for calorie and macro nutrient intake. Pre-and post-diet testing will determine effects on body composition.
3169820|NCT01411527||Cross- sectional cohort|Schools were randomly selected and 6203 children (50.0 % girls) were invited to participate. 1864 (1097 girls and 767 boys) (age 5.6-20.0 years) were included, resulting in an overall participation-rate of 30%. Blood samples were drawn, and a thorough clinical examination was performed in all participating children
3169821|NCT01411527||Longitudinal cohort|"209 healthy Danish children (108 girls), were examined and blood samples were drawn every 6 months. In july 2011, the mean (range) number of examinations per child was 7 (2-10).~116 (63 boys and 53 girls) continued from the cross sectional study to the longitudinal study. Thus, the total number of participants in The COPENHAGEN Puberty Study was 2020 children."
3169822|NCT01411514|Experimental|Prednisone|
3169823|NCT01411514|Placebo Comparator|Placebo|
3169824|NCT01411501|Experimental|Acupuncture at ST25 and BL25|the points formula of back-shu point combination with front-mu point.
3169825|NCT01411501|Experimental|Acupuncture at LI11 and ST37|the points formula of He-points
3169826|NCT01411501|Experimental|Acupuncture at ST25, BL25, LI11 and ST37|the formula of He-point,back-shu point and front-mu point
3169827|NCT01411501|Active Comparator|medicine|oral use of mosapride citrate
3169828|NCT01411488|Experimental|Fecal Management System- Company 1|80 adult patients to be randomly assigned to receive a fecal management system by Bard Medical
3169829|NCT01411488|Active Comparator|Fecal Management System- Company 2|80 adult patients to be randomly assigned to receive a fecal management system by ConvaTec
3169830|NCT01411475||Bifurcation restenosis|Patients with either a main vessel or a side branch restenosis following succesful percutaneous coronary intervention
3169831|NCT01411462||VIBE-DEB|
3169832|NCT01411449||Group 1|
3169833|NCT01411436||Group 1|
3169834|NCT01411423||Group 1|
3169835|NCT01411410|Experimental|Copanlisib (BAY80-6946)|The treatment of consists of repetitive cycles, each over 4 weeks. It continues until disease progression or limiting toxicity. If paclitaxel is discontinued for toxicity, BAY80-6946 may continue at the discretion of the investigator if a clinical benefit (response or stable disease for 6 months) is noted.
3169836|NCT01411397|Active Comparator|mesh repair|MESH HERNIA REPAIR WHEN REqUIRE INTESTINAL RESECTION
3169837|NCT01411397|Active Comparator|mesh repair without intestinal resection|mesh repair of strangulated hernia without resection
3169838|NCT01411371|Experimental|Catheter Ablation|Catheter ablation of persistent atrial fibrillation to restore normal sinus rhythm.
3169839|NCT01411371|Active Comparator|Medical treatment alone|Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
3169840|NCT01411358|Experimental|AdimFlu-S 2011-2012|
3169841|NCT01411345|Active Comparator|Arm I: SSRT|"Standard Salvage Radiation Treatment (SSRT)~SSRT: 68 Gy in 34 fractions (2.0 Gy) Homogenous Plan.~Expanded Prostate Cancer Index Composite-SF12 (EPIC SF12) quality of life questionnaire;~Memory Anxiety Scale for Prostate Cancer patients (MAX-PC) quality of life questionnaire;~International Prostate Symptom Score (IPSS) quality of life questionnaire;~OPTIONAL: Ultrasound guided biopsy, blood and urine sample collection for correlative studies"
3169842|NCT01411345|Active Comparator|Arm II: MTSRT|"Mapped Tumor Salvage RT (MTSRT):~MTSRT: 68 Gy in 34 fractions plus MT Boost to gross tumor volume (GTV) 76.5 Gy (2.25 Gy/fx) equivalent to 80 Gy in 2.0 Gy fractions.~Expanded Prostate Cancer Index Composite-SF12 (EPIC SF12) quality of life questionnaire;~Memory Anxiety Scale for Prostate Cancer patients (MAX-PC) quality of life questionnaire;~International Prostate Symptom Score (IPSS) quality of life questionnaire;~OPTIONAL: Ultrasound guided biopsy, blood and urine sample collection for correlative studies"
3169843|NCT01411332|Active Comparator|Arm I: SIMRT|Arm I: Standard Fractionated Intensity Modulated Radiotherapy (SIMRT), EPIC SF-12 Questionnaire, MAX-PC Questionnaire, IPSS Questionnaire
3169844|NCT01411332|Active Comparator|Arm II: HTIMRT|Arm II: Hypofractionated Targeted Intensity Modulated Radiotherapy (HTIMRT), EPIC SF-12 Questionnaire, MAX-PC Questionnaire, IPSS Questionnaire
3169845|NCT01411319|Experimental|LEAD Radiation Therapy|"Lattice Extreme Ablative Dose Radiation Therapy~Standard IMRT~EPIC SF-12 Questionnaire~MAX-PC Questionnaire~IPSS Questionnaire"
3169846|NCT01411306||Med/Surg ICU Inpatients, Intubated ≥ 48 hours|
3169847|NCT01411293|Experimental|Low-Fat Dairy|Participants will ingest 2 cups of low-fat milk on 1 occasion prior to measure postprandial changes in vascular function
3170572|NCT01406158|Experimental|Treatment B|
3169848|NCT01411293|Active Comparator|Rice Milk|Participants will ingest 2 cups of rice milk on 1 ocassion prior to measuring postprandial vascular function
3169849|NCT01411280|Placebo Comparator|Laboratory trial|Compare methylphenidate to placebo in an acute laboratory trial
3169850|NCT01411280|Experimental|Home/School trial|Low dose and moderate dose methylphenidate are compared to placebo in a home and school trial
3169851|NCT01411254|Experimental|1|
3169852|NCT01411254|Experimental|2|
3169853|NCT01411254|Sham Comparator|3|
3169854|NCT01411241|Experimental|CYD Dengue Vaccine Group 1|Participants will receive CYD dengue vaccine dose 1 at age 9 to 12 months, Trimovax® + booster with Prevenar® at 10 to 13 months, Pentaxim™ + CYD dengue vaccine dose 2 at 15 to 18 months, placebo at 16 to 19 months, and CYD dengue vaccine dose 3 at 21 to 24 months.
3169855|NCT01411241|Experimental|CYD Dengue Vaccine Group 2|Participants will receive CYD dengue vaccine dose 1 at age 9 to 12 months, Trimovax® + booster with Prevenar® at 10 to 13 months, Pentaxim™ + placebo at 15 to 18 months, CYD dengue vaccine dose 2 at 16 to 19 months, and CYD dengue vaccine dose 3 at 21 to 24 months.
3169856|NCT01411228|Experimental|60 Units/kg|
3169857|NCT01411228|Experimental|30 Units/kg|
3169858|NCT01411215||RA, AS|Rheumatoid arthritis patients Ankylosing spondylitis patients
3169859|NCT01411202|Experimental|Doxycycline|Pleurx insertion with injection of 500mg of doxycycline in 50cc of normal saline.
3169860|NCT01411202|Placebo Comparator|Normal Saline|Pleurx insertion with placebo injection of 50cc of normal saline
3169861|NCT01411189|Other|Menthol|20 mL NPO-11
3169862|NCT01411176|Active Comparator|Menthol|20 ml NPO-11
3169863|NCT01411176|Placebo Comparator|Placebo|20 ml NPO-11(Placebo)
3169864|NCT01411163|Experimental|Creatine|
3169865|NCT01411150|Experimental|Creatine|
3169866|NCT01411137|Experimental|IPX066|Subjects were to receive individualized IPX066 doses orally in an open-label manner using four dosage strengths.
3169867|NCT01411124|Experimental|Gabapentin Enacarbil|600 mg of Gabapentin Enacarbil
3169868|NCT01411124|Active Comparator|diphenhydramine|50 mg
3169869|NCT01411124|Placebo Comparator|placebo|placebo to match
3169870|NCT01411111|Active Comparator|Rosuvastatin foll by GSK2190915 30mg + rosuvastatin|Subjects will be orally administered rosuvastatin 10 mg/day for 7 days in treatment period 1. The subjects will then receive rosuvastatin 10 mg/day in combination with GSK2190915 30 mg/day for 7 days in treatment period 2A.
3169871|NCT01411111|Active Comparator|Rosuvastatin foll by GSK2190915 100mg + rosuvastatin|Subjects will be orally administered rosuvastatin 10 mg/day for 7 days in treatment period 1. The subjects will then receive rosuvastatin 10 mg/day in combination with GSK2190915 100 mg/day for 7 days in treatment period 2B.
3169872|NCT01411098|Experimental|Treatment (radiation therapy and chemotherapy)|Patients undergo 3D-CRT or IMRT 5 days a week for 8 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 28, and 36 and etoposide IV over 60 minutes on days 1-5, and 28-32.
3169873|NCT01411085|Experimental|Risperidone + Desipramine|All participants will be treated with risperidone (or a risperidone-like agent including: risperidone long-acting, paliperdione, and paliperidone palmitate) at the time treatment with desipramine is initiated. The target dose of oral risperidone is 4mg though variations are allowed. The target dose of desipramine is 100mg.
3169874|NCT01411072|Experimental|Gemcitabine|
3169875|NCT01411072|Experimental|5-fluorouracil|
3169876|NCT01411059|Experimental|yoga|32 weeks of yoga training
3169877|NCT01411046||RA treated with prednisolone|Patients with RA treated with prednisolone, minimum 5 mg/day for minimum 6 months. Patients are grouped according to haplotype of 4 SNPs of the glucocorticoid recepror gene. Patients with or without these polymorphisms were invited to a Synacthen® test, but patients with a mixed hetero- and homozygote genotype were not. Adrenal function is evaluated with a Synacthen test.
3169878|NCT01411033||Newly diagnosed diabetes mellitus type 1|
3169879|NCT01411020|Experimental|Grupo 1|Doses of induction: propofol 4 mcg/ml and fentanyl 3 mcg/kg
3169880|NCT01411020|Experimental|Grupo 2|Dose of induction: propofol 4.5 mcg/ml and fentanyl 3 mcg/kg
3169881|NCT01411020|Experimental|Grupo 3|Doses of propofol: propofol 5 mcg/ml and fentanyl 3 mcg/kg
3169882|NCT01411020|Experimental|Grupo 4|Doses of induction: propofol 5.5 mcg/ml and fentanyl 3 mcg/kg
3169883|NCT01411020|Experimental|Grupo 5|Doses of induction: propofol 6 mcg/ml and fentanyl 3 mcg/kg
3169884|NCT01411020|Experimental|Grupo 6|Doses of induction: propofol 4 mcg/ml and fentanyl 5 mcg/kg
3169885|NCT01411020|Experimental|Grupo 7|Doses of induction: propofol 4.5 mcg/ml and fentanyl 5 mcg/kg
3169886|NCT01411020|Experimental|Grupo 8|Doses of induction: propofol 5 mcg/ml and fentanyl 5 mcg/kg
3169887|NCT01411020|Experimental|Grupo 9|Doses of induction: propofol 5.5 mcg/ml and fentanyl 5 mcg/kg
3169888|NCT01411020|Experimental|Grupo 10|Doses of induction: propofol 6 mcg/ml and fentanyl 5 mcg/kg
3169889|NCT01411007||Smokers|Nicotine addicted smokers, smoking an average of at least 10 cigarettes per day.
3169890|NCT01411007||Non-Smokers|
3169891|NCT01410981||Multiple Myeloma subjects with bone marrow aspirate/biopsy|All patients seen at MUSC with a diagnosis of multiple myeloma or possible multiple myeloma who undergo bone marrow aspirate and biopsy will be approached for participation in this study.
3169892|NCT01410968|Experimental|Vaccination|vaccination with investigational Poly-ICLC & peptide-pulsed dendritic cells
3169893|NCT01410955|Experimental|Probiotics|Patients receiving probiotics.
3169894|NCT01410955|Placebo Comparator|Placebo|Patients receiving placebo
3169895|NCT01410942|Placebo Comparator|Placebo + Sham Exercise|Placebo capsules by mouth twice daily. Participants in sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
3169896|NCT01410942|Experimental|Methylphenidate + Sham Exercise|Methylphenidate starting dose 5 mg by mouth twice daily. Participants in sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
3169966|NCT01410409|Active Comparator|MEDIC|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.
3169897|NCT01410942|Placebo Comparator|Exercise + Placebo|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Placebo capsules by mouth twice daily.
3169898|NCT01410942|Placebo Comparator|Cognitive Therapy + Placebo|Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill. Placebo capsules by mouth twice daily.
3169899|NCT01410942|Experimental|Methylphenidate + Exercise|Methylphenidate starting dose 5 mg by mouth twice daily. Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
3169900|NCT01410942|Experimental|Methylphenidate + Cognitive Therapy|Methylphenidate starting dose 5 mg by mouth twice daily. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
3169901|NCT01410942|Placebo Comparator|Exercise + Cognitive Therapy + Placebo|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill. Placebo capsules by mouth twice daily
3169902|NCT01410942|Experimental|Methylphenidate + Exercise + Cognitive Therapy|Methylphenidate starting dose 5 mg by mouth twice daily. Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
3169903|NCT01410903|Experimental|TheraSorb Ig|
3169904|NCT01410890|Experimental|alglucosidase alfa|alglucosidase alfa intravenous (IV) infusion of 20mg/kg body weight
3169905|NCT01410877||Inhaler naive healthy volunteers|
3169906|NCT01410864||DuraSeal Arm|Prospective enrollment of subjects who have received DuraSeal Exact Spinal Sealant System for treatment of an intentional or incidental dural tear during spine surgery.
3169907|NCT01410864||Control Arm|Subjects who have undergone a spinal procedure where techniques other than DuraSeal were administered for the treatment of either an intentional or incidental opening of the dura may be enrolled either prospectively or retrospectively (via medical record screening)
3169908|NCT01410851|Experimental|Pasta, tomato sauce & added chickpeas|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
3169909|NCT01410851|Experimental|Pasta, tomato sauce and added lentils|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
3169910|NCT01410851|Experimental|Pasta, tomato sauce and added navy beans|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
3169911|NCT01410851|Experimental|Pasta, tomato sauce with yellow peas|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
3169912|NCT01410851|Experimental|Pasta and tomato sauce|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
3169913|NCT01410838|Placebo Comparator|Broth- NaCl|Sodium chloride containing broth matched for sodium content to the MSG broth
3169914|NCT01410838|Active Comparator|Broth- MSG|MSG containing broth with the same sodium content as the placebo comparator.
3169915|NCT01410825|Experimental|Gene transfer|Open label single arm study
3169916|NCT01410812|Experimental|Suggested Tying|Receive same treatments as control group, but instead of receiving cash they receive 4 iTunes audio novels for their own iPods. Further, they are prompted to try to listen to those novels only when exercising at the gym in order to increase their attendance.
3169917|NCT01410812|Experimental|Forced Tying|Receives same treatment as the control group. However, in addition to receiving the cash, they also receive 4 iTunes audio novels for a loaned iPod that they will only have access to at the gym. They are told they may only listen to these novels only when at the gym in order to increase their attendance.
3169918|NCT01410812|Experimental|Control|Control group of participants who do not receive any intervention but are weighed at the beginning and end of a 10 week period and receive weekly emails asking them about their exercise. They also receive the equivalent cash value of 4 iTunes audio novels
3169919|NCT01410799|Experimental|Growth Hormone Releasing Hormone (GHRH)|Drug: GHRH
3169920|NCT01410786|Active Comparator|Conventional Oxford instrumentation|Patients who receive an Oxford Partial Knee with Conventional instrumentation.
3169921|NCT01410786|Experimental|Signature Guides Oxford|Patients who receive an Oxford Partial Knee with Signature Custom Guides
3169922|NCT01410773|Experimental|Intended Users of the System|Untrained subjects with diabetes (at least 70% of subjects will be insulin users) use an investigational blood glucose monitoring system (Ninja 2) to self-test capillary blood obtained from fingerstick and palm.
3169923|NCT01410747||tacrolimus group|Oral
3170573|NCT01406158|Experimental|Treatment T|
3169924|NCT01410734|Experimental|ICG|Patient will received IV injection of ICG intra-operatively. Surgeon will view bile ducts under fluorescence imaging mode to see if ICG helps to identify biliary ducts.
3169925|NCT01410721|Experimental|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
3169926|NCT01410721|Active Comparator|Cognitive Rehabilitation Control Arm|Baseline training and follow-up at two months and four months.
3169927|NCT01410695|Experimental|masitinib 3 mg|masitinib 3 mg/kg/day, tablets, orally, twice a day
3169928|NCT01410695|Experimental|masitinib 4.5mg|masitinib 4.5mg/kg/day, tablets, orally, twice a day
3169929|NCT01410695|Active Comparator|methotrexate|methotrexate at the dose of 15 or 20 mg per week
3169930|NCT01410682|Experimental|0.12% Chlorhexidine Digluconate|Oral care included use of an oral gel containing chlorhexidine digluconate 0.12% as an active ingredient (chlorhexidine digluconate 0.12%; methylcellulose gel 2.12%, 25 g; gooseberry syrup, 4 drops; menthol solution 50%,3 drops; and distilled water, to 30 g).The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular,lingual, occlusal, and incisal). After each quadrant was cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto- anterior movements.
3169931|NCT01410682|Placebo Comparator|tothbrushing|This group received the same oral care that experimental group with the use of a similarly formulated gel without the antiseptic agent.The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
3169932|NCT01410669|Experimental|Motivational Interviewing (MI)|
3169933|NCT01410656|No Intervention|Standard PA Recommendation|Received the standard physical activity recommendation.
3169934|NCT01410656|Experimental|Telephone Implementation Intention|Behavioural Telephone Assisted Implementation Intention Intervention
3169935|NCT01410656|Experimental|Self-completed implementation intention|Self-administered implementation intention intervention.
3169936|NCT01410643|Active Comparator|Reduced Carbohydrate|42% carbohydrate macronutrient modification
3169937|NCT01410643|Active Comparator|STandard Carbohydrate|60% carbohydrate macronutrient modification
3169938|NCT01410630|Experimental|FLT-PET/CT and FDG-PET/CT scan|Patients will have FLT-PET/CT and FDG-PET/CT scans performed 18-24 days after the second cycle of R-CHOP.
3169939|NCT01410617|Active Comparator|dialysis|the patients who undergo 3 sessions prophylactic hemodialysis
3169940|NCT01410617|No Intervention|control group|the patients who do not undergo hemodialysis
3169941|NCT01410604|Experimental|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
3169942|NCT01410604|Placebo Comparator|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
3169943|NCT01410591|Active Comparator|10-mm covered stent group|Patients treated with 10-mm covered stent.
3169944|NCT01410591|Active Comparator|8-mm covered stent group|Patients treated with 8-mm covered stent.
3169945|NCT01410578||systemic inflammatory response syndrome|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
3169946|NCT01410578||sepsis|SIRS + infection
3169947|NCT01410578||bacteremia|(1) The blood culture tested positive at least for the same pathogen;(2) The patient had at least one of the following symptoms: fever, shivering, or low blood pressure and showed signs of at least one of the following conditions: the blood culture tested positive at least twice for common skin flora from different sites; the blood culture tested positive only once for the skin flora listed above, the intravascular catheter culture tested positive for the same pathogen and the correct antibiotic treatment had been initiated for the patient; or a positive serology test consistent with other clinical laboratory test results and unrelated to infections at different sites.
3169948|NCT01410565|Active Comparator|Apaziquone|
3169949|NCT01410565|Placebo Comparator|Placebo|Placebo
3169950|NCT01410552|Other|ICD or CRT-D with PARAD+|only 1 arm is the study: all patients implanted with ICD or CRT-D with PARAD+ enabled, no comparator
3169951|NCT01410539|Experimental|Stent Thrombosis|Consecutive patients with stent thrombosis with stent strut assessment by OCT
3169952|NCT01410539|Active Comparator|Controls|Control subjects without stent thrombosis from the RHR OCT database
3169953|NCT01410526||VAC group|Patients with intra-abdominal sepsis treated with Vacuum Assisted Closure (VAC) system plus the dynamic sutures
3169954|NCT01410526||Control group|Patients suffering major abdominal surgery
3169955|NCT01410513|Experimental|SAR245409 + rituximab|Subjects will receive oral SAR245409 twice daily continuously and weekly rituximab intravenously
3169956|NCT01410513|Experimental|SAR245409 + rituximab + bendamustine (iNHL, MCL)|Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine intravenously.
3169957|NCT01410513|Experimental|SAR245409 + rituximab+ bendamustine (CLL)|Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine and rituximab intravenously
3169958|NCT01410487||Obese group|
3169959|NCT01410474|Experimental|2-18 years|
3169960|NCT01410461||Patients with painful bladder syndrome|Patients with diagnosis of PBS Will be offered to take part in the following study.
3169961|NCT01410448|Active Comparator|Immediate Everolimus (IE)|Everolimus was started within 48 hours after graft reperfusion at a starting dose of 0.75 mg twice daily in combination with low-dose cyclosporine and steroids for 3 months.
3169962|NCT01410448|Experimental|Delayed Everolimus|The standard dose of mycophenolate sodium was administered within 48 hours after graft reperfusion in combination with a full dose of cyclosporine and steroids. After28 +/- 4 days of treatment, mycophenolate sodium was discontinued and everolimus was introduced at a starting dose of 0.75 mg twice daily for 3 months.
3169963|NCT01410435|Experimental|Treatment|
3169964|NCT01410422||COPD|COPD
3169965|NCT01410422||Bronchiectasis|Bronchiectasis
3169967|NCT01410409|Active Comparator|MEDIC + TKR|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months after a total knee replacement.
3169968|NCT01410409|Active Comparator|Observational Cohort|If the patient can be included, but doesn't want to participate in the randomization, the patient is offered to enter into a prospective observational cohort with the same endpoints and the same follow-up as in the randomized study. The participant can then, in consultation with his/her physician, choose whether they would like MEDIC-treatment or TKR in combination with MEDIC-treatment.
3169969|NCT01410383|Placebo Comparator|Placebo|
3169970|NCT01410383|Experimental|Eprotirome I|
3169971|NCT01410383|Experimental|Eprotirome II|
3169972|NCT01410370|Experimental|treatment|Radiotherapy plus Endostar
3169973|NCT01410370|Active Comparator|control|Radiotherapy
3169974|NCT01410357|Experimental|Targeted Training in Illness Management (TTIM)|Participants in this arm will receive the TTIM intervention as well as receiving regular treatment for their DM and SMI from their normal medical and mental health care providers.
3169975|NCT01410357|No Intervention|Treatment As Usual (TAU)|Participants in this arm will continue to receive Treatment as Usual from their usual medical and mental health care providers. They will not receive any intervention.
3169976|NCT01410344|Other|Allogeneic Transplant|One regimen from either reduced-intensity conditioning (RIC) (Fludarabine and Busulfan; or Fludarabine and Melphalan) or myeloablative conditioning (MAC) (Busulfan and Fludarabine; or Cyclophosphamide and Total Body Irradiation) will be administered prior to allogeneic hematopoietic cell transplantation (HCT).
3169977|NCT01410331|Experimental|Cohort 1|Subjects will be randomized to receive either 4 mg of JVS-100 or placebo over 8 injections.
3169978|NCT01410331|Experimental|Cohort 2|Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 8 injections.
3169979|NCT01410331|Experimental|Cohort 3|Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 16 injections.
3169980|NCT01410331|Experimental|Cohort 4|Subjects will be randomized to receive either 16 mg of JVS-100 or placebo over 16 injections.
3169981|NCT01410305||HIV+|HIV Positive children or young people between the ages of 8 and 25
3169982|NCT01410305||HIV Negative|HIV Negative matched controls by age and race
3169983|NCT01410292|Experimental|meal D|low fiber and low GI
3169984|NCT01410292|Experimental|meal C|low Fiber and High GI
3169985|NCT01410292|Experimental|meal B|high Fiber and low GI
3169986|NCT01410292|Experimental|meal A|high fiber and high GI meal
3169987|NCT01410266|No Intervention|Standard of care|Standard of care includes a routine clinic visit two weeks after misoprostol administration. At the clinic visit, the woman undergoes a bimanual examination. In the event the woman fails to return for the follow-up visit, clinic procedure is followed for contacting her to determine abortion status and the need for further intervention, if any.
3169988|NCT01410266|Active Comparator|Alternative follow-up|At a clinic visit, before mifepristone administration, the woman completes a semi-quantitative pregnancy test. After mifepristone administration, she is provided with another pregnancy test and a checklist to be self-administered two weeks after she takes misoprostol. On an assigned date, the woman is contacted by phone by the clinic staff and asked to report on the results of both tests. The provider then confirms whether, based on the woman's responses, she should return for a follow-up visit.
3169989|NCT01410253|Experimental|Group 1|
3169990|NCT01410253|Experimental|Group 2|
3169991|NCT01410253|Experimental|Group 3|
3169992|NCT01410253|Placebo Comparator|Group 4|
3169993|NCT01410240|Active Comparator|Standard of Care (SoC)|SoC: conventional hemostatic techniques such as cautery and manual compression
3169994|NCT01410240|Experimental|FLOSEAL + Standard of Care (SoC)|"FLOSEAL: consists of bovine-derived gelatin granules and a human plasma-derived thrombin component.~SoC: conventional hemostatic techniques such as cautery and manual compression"
3169995|NCT01410227|Experimental|PK 80 Arm (minimum of 22 subjects with severe VWD)|PK assessment (80 IU/kg rVWF) + 12-month treatment period
3169996|NCT01410227|Experimental|PK 50 Arm (14 subjects with type 3 VWD)|Two single-blinded PK assessments (50 IU/kg rVWF + rFVIII/placebo) + 12-month treatment period
3169997|NCT01410227|Experimental|PK 50 Only Arm (minimum of 7 subjects with type 3 VWD)|PK assessment (50 IU/kg rVWF) only, no treatment of bleeding episodes
3169998|NCT01410227|Experimental|Treatment Only (up to 7 subjects independent of VWD subtype)|Treatment of bleeding episodes for a total of 12 months
3169999|NCT01410214|Experimental|Erlotinib arm|In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
3170000|NCT01410214|Active Comparator|Chemo arm|In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
3170001|NCT01410201|Experimental|PPV + MP + DEX|Patients will undergo pars plana vitrectomy, membrane peel, and concomitant Ozurdex implant (0.7 mg dose).
3170002|NCT01410201|Active Comparator|PPV + MP|Patients will undergo pars plana vitrectomy with membrane peel, without Ozurdex implant.
3170003|NCT01410188|Experimental|OPA-6566 low dose|Treatment with OPA-6566 low dose
3170004|NCT01410188|Experimental|OPA-6566 medium dose|Treatment with OPA-6566 medium dose
3170005|NCT01410188|Experimental|OPA-6566 high dose|Treatment with OPA-6566 high dose
3170006|NCT01410188|Active Comparator|Latanoprost|Treatment with Latanoprost
3170007|NCT01410188|Placebo Comparator|Placebo|Placebo
3170008|NCT01410188|Experimental|OPA-6566 additional dose|Treatment with OPA-6566 additional dose
3170009|NCT01410175|Experimental|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layer.
3170010|NCT01410175|No Intervention|Electric scalpel|Use of electric scalpel to incise the skin and subcutaneous layer.
3170011|NCT01410162|Active Comparator|Advagraf|
3170012|NCT01410162|Active Comparator|Prograf|
3170013|NCT01410149|Active Comparator|PAV|Proportional Assist Ventilation (PAV+ on PB840 ventilator)
3170014|NCT01410149|Active Comparator|PSV|Pressure Support Ventilation (PSV on PB840 ventilator)
3170015|NCT01410149|Active Comparator|ACV|Assist Control/ Pressure limited Ventilation (on PB840 ventilator)
3170016|NCT01410136|Other|Chondrofix|Subjects with one or two confirmed knee articular cartilage lesion(s) each less than 8cm2, of the femoral condyle or trochlear groove
3170017|NCT01410123|Other|Treatment as Usual (TAU)|
3170018|NCT01410123|Other|Integrated Stepped Care (ISC)|
3170019|NCT01410110|Experimental|Cognitive Training + Work Therapy|"Cognitive Training using auditory and visual Positscience software 5 hours/per week for 13 weeks.~Work Therapy for 15 hours per week at half minimum wage doing entry level duties at medical center job sites, supervised by regular medical center staff."
3170020|NCT01410110|Active Comparator|Work Therapy Only|Same work therapy but for 20 hours per week.
3170021|NCT01410097|Experimental|Lifestyle intervention|Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.
3170022|NCT01410097|Placebo Comparator|Diabetes Support and Education (DSE)|It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
3170023|NCT01410084|Experimental|Vitamin D3|100,000 IU vitamin D3 once monthly
3170024|NCT01410084|Placebo Comparator|Vitamin E|400 IU vitamin E once monthly
3170025|NCT01410071||sphincter of oddi dysfunction|endoscopic therapy vs conservative care
3170026|NCT01410058||Nevirapine|HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder
3170027|NCT01410058||Efavirenz|HIV positive patients on efavirenz containing regimen, taking Moringa oleifera
3170028|NCT01410045|Experimental|Surgery|Ovariectomy
3170029|NCT01410032|Active Comparator|Plate fixation|Reconstruction plate
3170030|NCT01410032|Active Comparator|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
3170031|NCT01410019|Experimental|1|Gene transfer
3170032|NCT01409993|Experimental|sildenafil Aim 1|sildenafil 25 mg p.o. tid
3170033|NCT01409993|Placebo Comparator|placebo Aim 1|matching placebo p.o. tid
3170034|NCT01409993|Experimental|sildenafil Aim 2|sildenafil 25 mg p.o. tid
3170035|NCT01409993|Placebo Comparator|placebo Aim 2|matching placebo p.o. tid
3170036|NCT01409980||Triphalangeal Thumb|A search will be performed using CPT code 26587 (reconstruction of a supernumerary digit) at both Primary Children's Hospital and Shriners to identify all patients who Dr. Wang and Hutchinson operated on with a delta phalanx.
3170037|NCT01409954||Spinal decompression|Spinal decompression with an instrumented posterolateral fusion
3170038|NCT01409928|Experimental|Lap-Band|
3170039|NCT01409915|Experimental|Sagramostim (Leukine)|5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
3170040|NCT01409915|Placebo Comparator|Control Group|Saline -- placebo comparator. Given as a subcutaneous injection.
3170041|NCT01409889|Active Comparator|Diabetes Prevetion Program|Individuals in this group will receive the Diabetes Prevention Program
3170042|NCT01409889|Active Comparator|Healthy Living Program|Individuals in this group will receive the Healthy Living Program
3170043|NCT01409876|Experimental|Brachytherapy|
3170044|NCT01409863|No Intervention|laser and standard diamond fraise dermabrasion|laser and standard diamond fraise dermabrasion
3170045|NCT01409850|Active Comparator|Aqualizer|
3170046|NCT01409850|Active Comparator|Soft splint|elastic splint made of copolyester foil
3170047|NCT01409850|No Intervention|Counselling|
3170048|NCT01409837|Placebo Comparator|Sugar pill|Started with Placebo until the crossover.
3170049|NCT01409837|Experimental|Lisinopril|Started with Lisinopril until the crossover
3170050|NCT01409824|No Intervention|without CDSS|This arm includes 6 health facilities in each partner country, where the clinical decision support system will not be implemented
3170051|NCT01409824|Experimental|with CDSS|This arm includes 6 health facilities in each partner country, where the clinical decision support system will be implemented, parallel to the performance based incentive package
3170052|NCT01409811|Experimental|Treatment (zoledronic acid)|Patients receive zoledronic acid IV over 15 minutes on day 1. Patients then undergo planned definitive surgery (lumpectomy or mastectomy) on day 10-14. Tissue and blood samples from the initial biopsy and definitive surgery are collected to measure changes in biomarkers of tumor growth and metastasis, immunologic function, and the expression of genes important to breast cancer progression and metastasis.
3170053|NCT01409785||LMA Supreme|
3170054|NCT01409785||LMA unique|
3170055|NCT01409772||Intestinal Rehab|
3170056|NCT01409759|Experimental|Perforator based interposion flap|In our concept the flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
3170057|NCT01409759|Other|Full thickness graft|
3170058|NCT01409746||twins|twin pairs
3170059|NCT01409733|Experimental|Stage IV melanoma patients|
3170060|NCT01409720|Experimental|A|patients in arm A carry out daily physical training consisting of three different isometric exercises under the guidance and supervision of a physiotherapist. Training starts day one (first radiotherapy session), 10 daily units of 30 min each are scheduled during radiotherapy. Patients are expected to continue training until 12 weeks post completion of radiotherapy at home.
3170061|NCT01409720|No Intervention|B|Patients in arm B (control group) receive 10 daily sessions of 15 min manual therapy (i.e. massage, etc) starting from day one of radiotherapy.
3170062|NCT01409707|Experimental|Healthy lifestyles sessions|Healthy lifestyles sessions is a structured 9-12 session intervention that provides education about a variety of health-related topics. Each therapy session was 50-60 minutes long. Sessions included the provision of information, discussing participants' understanding of information, and answering questions about the information provided.
3170104|NCT01409447|Experimental|Biphasic osteochondral composite|feasibility study for the new medical device & technique
3170531|NCT01406418|Placebo Comparator|Cohort 4: Placebo|5% dextrose in water
3170063|NCT01409707|Experimental|Trauma-focused exposure therapy|Trauma focused exposure therapy is a well-described cognitive-behavioral therapy that utilizes imaginal and in vivo exposure techniques to reduce the symptoms of posttraumatic stress disorder. In addition to imaginal and iv vivo exposure techniques, in the current study patients were provided psychoeducation about posttraumatic stress disorder, a rationale for trauma focused exposure therapy, and were taught breathing retraining as a method to manage arousal associated with posttraumatic stress disorder. Nine to 12 50-60 minutes sessions were provided.
3170064|NCT01409707|Experimental|Motivational enhancement + trauma-focused exposure therapy|A one session, 90 min. trauma-focused motivational enhancement therapy session was provided prior to starting the trauma-focused exposure therapy. Trauma focused exposure therapy is a well-described cognitive-behavioral therapy that utilizes imaginal and in vivo exposure techniques to reduce the symptoms of posttraumatic stress disorder. In addition to imaginal and iv vivo exposure techniques, in the current study patients were provided psychoeducation about posttraumatic stress disorder, a rationale for trauma focused exposure therapy, and were taught breathing retraining as a method to manage arousal associated with posttraumatic stress disorder. Nine to 12 50-60 minutes sessions were provided.
3170065|NCT01409694|Active Comparator|Intervention|All participants start the treatment with memantine on the first day of the study and immediately start vitamin D supplementation.
3170066|NCT01409694|Placebo Comparator|Placebo|Participants in this arm start the treatment with memantine in the same way as the 'Intervention' group. They also immediately start Vitamin D placebo administered at the same pace.
3170067|NCT01409681||Observational Group|NSCLC subject undergoing bronchoscopy
3170068|NCT01409668|Experimental|L. Amylovorus|
3170069|NCT01409668|Experimental|L. Fermentum|
3170070|NCT01409655|Experimental|cognitive-behavioral therapy intervention|Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
3170071|NCT01409642|Active Comparator|Individual Child CBT|12 sessions of individual child-focused cognitive behavior therapy with a parent component
3170072|NCT01409642|Experimental|Positive Family Interaction Therapy|12 sessions of standard individual child CBT plus six sessions of positive family interaction therapy (PFIT)
3170073|NCT01409629||Activity choices|Observe individuals' activity choices after playing a computer game.
3170074|NCT01409616|Experimental|Treatment arm A|ASA, wash-out (w.o.), ASA + darexaban
3170075|NCT01409616|Experimental|Treatment arm B|ASA + darexaban, w.o., ASA
3170076|NCT01409616|Experimental|Treatment arm C|ASA, w.o., darexaban (double dose) + ASA
3170077|NCT01409616|Experimental|Treatment arm D|darexaban (double dose) + ASA, w.o., ASA
3170078|NCT01409616|Experimental|Treatment arm E|ASA + clopidogrel, w.o., ASA + clopidogrel + darexaban
3170079|NCT01409616|Experimental|Treatment arm F|ASA + clopidogrel + darexaban, w.o., ASA + clopidogrel
3170080|NCT01409616|Experimental|Treatment arm G|ASA + clopidogrel, w.o., darexaban (double dose) + ASA + clopidogrel
3170081|NCT01409616|Experimental|Treatment arm H|darexaban (double dose) + ASA + clopidogrel, w.o., ASA + clopidogrel
3170082|NCT01409603|Experimental|Treatment arm A|darexaban, wash-out, naproxen, wash-out, combination therapy
3170083|NCT01409603|Experimental|Treatment arm B|darexaban, wash-out, combination therapy, wash-out, naproxen
3170084|NCT01409603|Experimental|Treatment arm C|naproxen, wash-out, darexaban, wash-out, combination therapy
3170085|NCT01409603|Experimental|Treatment arm D|naproxen, wash-out, combination therapy, wash-out, darexaban
3170086|NCT01409603|Experimental|Treatment arm E|combination therapy, wash-out, naproxen, wash-out, darexaban
3170087|NCT01409603|Experimental|Treatment arm F|combination therapy, wash-out, darexaban, wash-out, naproxen
3170088|NCT01409590|Other|Exercise and Diet program|All patients recruited in the study, participated in an homogeneous exercise program and diet.
3170089|NCT01409577||FFR|Patients with intermediate coronary stenosis Patients with successful fractional flow measurement Feasible > 9months clinical follow-up
3170090|NCT01409564|Experimental|Cilostazol|Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation.
3170091|NCT01409564|Placebo Comparator|Placebo|Placebo group means dementia patients group receiving donepezil with placebo.
3170092|NCT01409551|Active Comparator|VATS hyperthermic pleural chemoperfusion|The patients undergo a VATS drainage of pleural effusion with adhesiolysis and complete mobilization of the lung, following by a 1 hour hyperthermic (40oC)chemoperfusion by means of a pump machine.
3170093|NCT01409551|Active Comparator|Bedside talc slurry pleurodesis|The patients undergo tube thoracostomy under local anesthesia. When the lung is fully expanded, talc slurry bed-side pleurodesis is performed.
3170094|NCT01409538|Placebo Comparator|Placebo|Asymptomatic control participants receive Natural History and Placebo instructions in a within-subject design. There are no patients, or active agents in this study. It is not a Clinical Trial.
3170095|NCT01409538|Active Comparator|Control condition|"The control condition represents a no-intervention, repeated baseline control, since the active intervention in this study is placebo."
3170096|NCT01409525||cardiac surgery patients|
3170097|NCT01409512||Women with OAB|Patients that will be diagnosed as having OAB syndrome by an urogynecologist based on their clinical symptoms (urinary urgency, with or without urinary urgency incontinence, urinary frequency or nocturia).
3170098|NCT01409499|Experimental|A, surgery|The patients in this group will receive palliative resection of HCC, then take sorafenib as remain therapy.
3170099|NCT01409499|Experimental|B, TACE|Patients in group B will receive transcatheter hepatic arterial chemoembolization, then take sorafenib as remain therapy.
3170100|NCT01409499|Experimental|C, sorafenib|Patients in group C will receive monotherapy of sorafenib.
3170101|NCT01409473|Experimental|Prostate SBRT|Prostate SBRT with concurrent boost to intraprostatic lesion (IPL) will be delivered in 5 fractions using intensity-modulated radiotherapy planning techniques.
3170102|NCT01409460|Experimental|True Obturator Nerve Block|
3170103|NCT01409460|Sham Comparator|Sham Block|
3170105|NCT01409434|Other|Follow-Up Arm|All patients are recruited for inclusion in the Follow-Up Arm, which is the sole arm of the study. The Follow-Up Arm includes a one time study visit in which study interventions are performed. The Follow-Up Arm involves patients from the parent study who were enrolled in the follow-up study. The intervention in the Follow-Up Arm is the Oral Glucose Tolerance Test.
3170106|NCT01409421|Experimental|motivational interviewing|3 phone and 3 in person counseling support sessions with glaucoma educator
3170107|NCT01409421|Active Comparator|reminder calls|behavioral: three phone calls to remind patients to take their eye drops
3170108|NCT01409421|No Intervention|standard care|standard care for glaucoma
3170109|NCT01409408|Active Comparator|Aliskiren|
3170110|NCT01409408|Active Comparator|Amlodipine|
3170111|NCT01409395|Experimental|Metformin|Subjects will be dosed with Metformin alone (850 mg)
3170112|NCT01409395|Experimental|Metformin and Nizatidine|Subjects will be dosed with metformin in conjunction with nizatidine
3170113|NCT01409382|Active Comparator|Lifestyle counseling|Daily brisk walking plus a carbohydrate-restricted diet
3170114|NCT01409382|No Intervention|Standard follow-up|Prenatal care will proceed according to the routine.
3170115|NCT01409369|Experimental|1|
3170116|NCT01409369|Active Comparator|2|
3170117|NCT01409356|Experimental|Diet+Exercise|Program of weight loss through diet+exercise (=intervention)
3170118|NCT01409330|Experimental|hypocaloric diet containing increased fibers and coffee|In the intervention group the patients are allowed to eat only white meat and fish. They also need to increase their daily fiber intake to 50grams and drink 5 cups of coffee a day.
3170119|NCT01409330|Active Comparator|hypocaloric diet containing red meat|control group (n=20): diet according to the ADA/EASD guidelines (50% carbohydrates, 20% proteins, 30% fat). In the control group the patients should eat 150 grams of red meat a day and are not allowed to consume alcohol, coffee and whole grains.
3170120|NCT01409317|Experimental|Deep Transcranial Magnetic Stimulation|
3170121|NCT01409317|Active Comparator|Repetitive Transcranial Magnetic Stimulation|
3170122|NCT01409278|Experimental|Ropivacaine infiltration and infusion.|Ropivicaine infiltration followed by continuous ropivicaine infusion for 48 hours.
3170123|NCT01409278|Experimental|Ropivacaine and Saline|Ropivicaine infiltration followed by normal saline infusion.
3170124|NCT01409278|Placebo Comparator|Saline infiltration and infusion.|Normal saline infiltration followed by saline infusion.
3170125|NCT01409265||No treatment|
3170126|NCT01409252||Hemorrhagic stroke patients|
3170127|NCT01409239|Active Comparator|Subcutaneous Insulin|
3170128|NCT01409239|Experimental|Intravenous insulin|
3170129|NCT01409226|Experimental|MRI|
3170130|NCT01409213||All Enrolled Participants|
3170131|NCT01409200|Experimental|ADT Group|Androgen deprivation therapy (ADT) for 8 weeks (specific drugs/dose/frequency not mandated by protocol) then up to 6 more months of hormone therapy following assignment to study group. Radical prostatectomy and pelvic lymph node dissection approximately 8 months after androgen deprivation therapy (ADT) with or without open label Axitinib.
3170132|NCT01409200|Experimental|ADT + Axitinib|Androgen deprivation therapy (ADT) with Axitinib 5 mg orally twice/day for 30 days. Radical prostatectomy and pelvic lymph node dissection approximately 8 months after androgen deprivation therapy (ADT) with or without open label Axitinib.
3170133|NCT01409187|Experimental|Ipilimumab + Interferon + Interleukin-2|Ipilimumab starting dose 2 mg/kg intravenous (IV) day 1 only; IFN alfa-2b at 5 million U/m2 subcutaneously daily for 5 days starting day 1; IL-2 at 9 million IU/m^2 daily IV continuous infusion for 4 days on days 2-5.
3170134|NCT01409174|Experimental|Ipilimumab + Chemotherapy|Ipilimumab starting 1 mg/kg by vein (IV) Day 1 each cycle; Temozolomide 200 mg/m^2 orally Days 2-5 of Induction; Cisplatin 25 mg/m^2 IV for Days 2-4 of Induction; Interferon alfa-2b 5 million U/m2 subcutaneously on Days 1-5 of each cycle Induction + Consolidation; and Interleukin-2 9 million IU/m^2 IV as a continuous infusion on Days 2-5 of Induction + Consolidation.
3170135|NCT01409161|Experimental|ATRA + ATO|Induction: All-trans retinoic acid (ATRA) 45 mg/m2 daily orally and Arsenic trioxide (ATO) 0.15 mg/kg by vein daily beginning on day 1 with Gemtuzumab ozogamicin (GO) 9 mg/m2 by vein. Methylprednisolone 50 mg by vein daily for 5 days followed by rapid taper starting on day 6 (Induction).
3170136|NCT01409148|Other|I-124 Mu 11-1F4 sterile injection|Single arm study
3170137|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 1|
3170138|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 2|
3170139|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 3|
3170140|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 4|
3170141|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 5|
3170142|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 6|
3170143|NCT01409135|Experimental|ASG-22CE Expansion Cohort 1|Breast Cancer
3170144|NCT01409135|Experimental|ASG-22CE Expansion Cohort 2|Bladder Cancer
3170145|NCT01409135|Experimental|ASG-22CE Expansion Cohort 3|Lung plus other solid tumor cancers
3170146|NCT01409122|Experimental|Part A Multiple Dose|Ascending multiple dose administration (every 8 hours, [Q8H]) of AIR001 or placebo for 16 consecutive doses
3170147|NCT01409122|Experimental|Part B Single Dose with Sildenafil|Single escalating doses of AIR001 or placebo (Q8H, Day 4-6) administered in combination with steady-state sildenafil administration (Q8H, Days 1-6)
3170148|NCT01409122|Experimental|Part C, administration of AIR001 to patients with PAH|Four doses of AIR001 will be administered via nebulization to patients with PAH.
3170149|NCT01409122|Experimental|Part D, device crossover study|PK, safety and tolerability of single doses of AIR001 administered in a randomized order with three different nebulizers.
3170150|NCT01409109||Patient volunteers|This group is comprised of persons with Schizophrenia and Schizoaffective.
3170151|NCT01409109||Healthy volunteers|This group is comprised of individuals who have no current or past psychiatric diagnosis.
3170152|NCT01409096|Active Comparator|Pregnenolone|This arm will be given 50mg Pregnenolone twice per day for 2 weeks, then 150mg Pregnenolone twice per day for 2 weeks, then 250mg Pregnenolone twice per day for 8 weeks.
3170153|NCT01409096|Placebo Comparator|Placebo|The arm will be given placebo that matches the Pregnenolone at the same frequency as the Pregnenolone for 12 weeks.
3170532|NCT01406418|Experimental|Cohort 5: CR6261|50 mg/kg CR6261
3170154|NCT01409083|Experimental|intravenous bicarbonate|Diluted sodium bicarbonate will be injected to s new IV catheter expecting a rise in end-tidal CO2
3170155|NCT01409083|Placebo Comparator|control|equal volume of normal saline will be randomely injected
3170156|NCT01409070||Azacitidine|200 MDS patients taking Azacitidine will be assessed
3170157|NCT01409070||Decitabine|100 MDS patients taking Decitabine will be assessed
3170158|NCT01409057||No heart lung machine|Coronary-artery-disease
3170159|NCT01409057||Heart lung machine|Coronary artery disease
3170160|NCT01409044|Experimental|Music|Research participant listened to music
3170161|NCT01409031|Experimental|Intravenous Sildenafil|
3170162|NCT01409031|Placebo Comparator|Placebo|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
3170163|NCT01409018|Experimental|Itraconazole|
3170164|NCT01409005|Experimental|Gemcitabine plus UFTE|Gemcitabine plus UFTE chemotherapy (Single arm)
3170165|NCT01408992|Experimental|FMHT|All community people will be interviewed with Thai Five Minute Hearing Test questionnaire and will be tested with an audiometry.
3170166|NCT01408979|Experimental|12 hours of magnesium sulfate|Patients in this group will have magnesium sulfate administered for 12 hours after delivery
3170167|NCT01408979|Active Comparator|24 hours of magnesium sulfate|Patients in this group will have magnesium sulfate administered for 24 hours after delivery
3170168|NCT01408966|Experimental|DarkChocolate|11 patients were randomized to receiving dark chocolate 0.55 g/kg of body weight (Lindt Excellence 85% Cocoa, Lindt & Sprüngli España) together with the test meal
3170169|NCT01408966|Placebo Comparator|White chocolate supplementation|11 patients received 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt & Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight.
3170170|NCT01408953|Experimental|bevacizumab for all patients|This is a single arm trial. All patients receive treatment with bevacizumab.
3170171|NCT01408914|No Intervention|RIF 600|
3170172|NCT01408914|Experimental|RIF 900|
3170173|NCT01408914|Experimental|RIF 1200|
3170174|NCT01408901|Experimental|A: GM-CSF + supervised treadmill exercise therapy|
3170175|NCT01408901|Active Comparator|B: GM-CSF + attention control group|
3170176|NCT01408901|Active Comparator|C: placebo + supervised exercise therapy|
3170177|NCT01408901|Placebo Comparator|D: placebo + attention control group|
3170178|NCT01408888|Experimental|LY2189265, Sitagliptin + LY2189265|A single 1.5-milligram (mg) dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2).
3170179|NCT01408888|Experimental|Sitagliptin + LY2189265, LY2189265|100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). There was a washout of at least 21 days before crossing over and receiving a single 1.5 mg dose of LY2189265 administered subcutaneously (Treatment 1).
3170180|NCT01408875|Experimental|Rehabilitation and EMS Group|Patient Heart Failure who follows physical training and sessions of electrical quadricipital myostimulation.
3170181|NCT01408875|No Intervention|Rehabilitation Group only|Patient Heart Failure who follows physical training
3170182|NCT01408862||controls|Healthy volunteers will be asked to donor a 10-80 ml blood through a venous puncture
3170183|NCT01408849|Experimental|Maytenus|Tea of Martens ilicifolia leaves
3170184|NCT01408849|Active Comparator|Omeprazole|Omeprazole as active comparator
3170185|NCT01408836|Experimental|1|Plasma exchange x 7 over 14 days
3170186|NCT01408836|Active Comparator|2|Methyl prednisolone 1g x 3
3170187|NCT01408823||Idiopathic Scoliosis|
3170188|NCT01408823||Non-idiopathic Scoliosis|
3170189|NCT01408810|Experimental|Infliximab|Infliximab 5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter. The treatment should follow infliximab's Summary of Product Characteristics.
3170190|NCT01408797|Experimental|Donor specific transfusion|Subjects with uremia will undergo donor specific transfusion before transplantation
3170191|NCT01408797|Experimental|Clonal deletion|
3170192|NCT01408797|Experimental|Drugs Added When Needed|
3170193|NCT01408758|Other|VCRT|This group will have 2 visits with a study physician in addition to using the VCRT.
3170194|NCT01408758|Other|no VCRT|This group will have 2 visits with study physician only, no VCRT.
3170195|NCT01408745|Experimental|Sternumfix|sternotomy closure with Sternumfix
3170196|NCT01408745|Active Comparator|Steel wire|sternotomy closure with steel wire
3170197|NCT01408732|Experimental|Standard Treatment then Sclerotherapy Intervention|"The standard treatment group will continue their pre-study standard treatment methods to treat epistaxis on the first 6 weeks of the study, followed by intervention with sclerotherapy on the second 6 weeks of the study, plus any additionally needed standard treatments for breakthrough epistaxis. Wash out period 2 weeks"
3170198|NCT01408732|Experimental|Sclerotherapy Intervention then Standard Treatment'|This group will receive, on the first 6 weeks of the study, sclerotherapy with STS to any visible lesions in the nose at the outset, followed by any needed standard treatments for breakthrough epistaxis. On the second 6 weeks of the study this group will continue with standard treatments that they had been receiving for epistaxis prior to the study. Wash out period of two weeks
3170199|NCT01408719|Experimental|5g LMW beta glucan|5 gram low molecular weight barley beta-glucan diet for 35 days
3170200|NCT01408719|Experimental|3g HMW beta glucan|3 gram high molecular weight barley beta-glucan diet for 35 days
3170201|NCT01408719|Experimental|3g LMW beta glucan|3 grams of low molecular weight beta-glucan diet for 35 days
3170202|NCT01408719|Placebo Comparator|Control|control diet containing negligible amount of beta glucan
3170203|NCT01408706|Active Comparator|Miller enema air tip|The Miller enema air tip rectal balloon is inserted into the rectum prior to radiation simulation and also prior to each radiation treatment to immobilize prostate gland and displace rectal tissue during radiation therapy.
3170204|NCT01408706|Active Comparator|Radiadyne Immobilizer|The Radiadyne Immobilizer Treatment Device is inserted into the rectum prior to radiation simulation and also prior to each radiation treatment to immobilize prostate gland and displace rectal tissue during radiation therapy
3170205|NCT01408693|Active Comparator|Anterior minimal invasive approach, AMIS|AMIS in 95 randomized patients.
3170206|NCT01408693|Active Comparator|Trans-gluteal approach, CLAS|CLAS in 95 randomized patients.
3170207|NCT01408680|Active Comparator|Coenzyme Q10 600 mg|
3170208|NCT01408680|Active Comparator|Coenzyme Q10 1200 mg|
3170209|NCT01408680|Placebo Comparator|Placebo|
3170210|NCT01408667|Placebo Comparator|Placebo|
3170211|NCT01408667|Active Comparator|TRC150094|
3170212|NCT01408654|Experimental|Peer Companionship|Behavioral intervention: Receipt of peer companionship provided by trained, supervised volunteer companions.
3170213|NCT01408654|No Intervention|Care-as-Usual|Care-as-Usual in Primary Care
3170214|NCT01408641|Experimental|Topiramate|Topiramate arm will be titrated (dose will increase slowly) over 6 weeks to 400mg or highest tolerated dose.
3170215|NCT01408641|Placebo Comparator|Placebo (Sugar Pill)|Placebo arm will receive matching capsules without topiramate.
3170216|NCT01408628|Experimental|Internet Insulin Education|"Single arm study; intervention represented by subjects' participation in 4 synchronous (live) interactive Internet classes."
3170217|NCT01408615||All Enrolled Participants|Women undergoing COS in combination with a GnRH antagonist for the development of multiple follicles in an ART program.
3170218|NCT01408602|Experimental|MRC375 75 mg|MRC375 (enteric coated Tetracycline) 75 mg 3 times a day
3170219|NCT01408602|Experimental|MRC375 150mg|MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks.
3170220|NCT01408602|Placebo Comparator|Placebo|Placebo
3170221|NCT01408589|Placebo Comparator|Sugar Pill|
3170222|NCT01408589|Experimental|Atomoxetine 40 mg|
3170223|NCT01408589|Experimental|Atomoxetine 60 mg|
3170224|NCT01408589|Experimental|Atomoxetine 80 mg|
3170225|NCT01408576|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles
3170226|NCT01408576|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles
3170227|NCT01408563|Experimental|Fludarabine/Melphalan/TBI|All patients receive same therapy
3170228|NCT01408550|Active Comparator|NPB-01|Active Comparator: 1 Intravenous immunoglobulin
3170229|NCT01408550|Placebo Comparator|Placebo|Placebo Comparator: 2 Physiological saline
3170230|NCT01408537|Experimental|JEVAC|JEVAC 0.5 mL/ dose subcutaneously injected on upper thigh at D0, 1-4wk, and 1 year
3170231|NCT01408524|Active Comparator|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
3170232|NCT01408524|Active Comparator|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
3170233|NCT01408511|Experimental|Arm 1|
3170234|NCT01408498|No Intervention|Placebo Control|Control group who will not receive exogenous testosterone administration. Will act as a comparison group to the testosterone group.
3170235|NCT01408498|Experimental|Testosterone administration group|Experimental group that will receive a single 10 g dose of 1% testosterone topical gel.
3170236|NCT01408485|Experimental|Treatment Arm|Radio-frequency cardiac ablation for treatment of isthmus-dependant atrial flutter using the Therapy™ Cool Flex™ Irrigated Ablation System
3170237|NCT01408472|Experimental|NT-501 CNTF Implant|Patients will receive single NT-501 CNTF implant in one eye.
3170238|NCT01408459|Active Comparator|Tomato product|
3170239|NCT01408459|Placebo Comparator|Control|No Motivation telephone Counseling
3170240|NCT01408446|Active Comparator|Menthol|Interventions Drug: Menthol Arms: Group 1
3170241|NCT01408446|Placebo Comparator|Placebo|Interventions Drug: Placebo Arms: Group 2
3170242|NCT01408433|Other|Single Embryo Transfer|Patients will have a single, chromosomally normal embryo transferred.
3170243|NCT01408433|Other|Double Embryo Transfer|Patients will have two (2) untested embryos transferred.
3170244|NCT01408420|No Intervention|Standard blood pressure|Extracorporeal circulation during the surgery are conducted using standard blood pressure
3170245|NCT01408420|Active Comparator|MAP > 60 mmHg|A blood pressure of MAP > 60 mmHg is used during extracorporeal circulation. The higher MAP is maintained by using continuous intravenous administration of norepinephrine titrated to the appropriate dose for each patient.
3170246|NCT01408407|Active Comparator|Arm A: standard of care|Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatment
3170247|NCT01408407|Experimental|Arm B: standard of care plus Alkagin paste|Patients will apply Alkagin Paste to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. They will also perform standard of care skin treatment.
3170248|NCT01408394|Active Comparator|100 mg immediate release form|This is the formulation currently in use
3170249|NCT01408394|Experimental|90 mg controlled release|This is the low dose of the controlled release form
3170250|NCT01408394|Experimental|180 mg controlled release form|This is the medium controlled release dose
3170251|NCT01408381|No Intervention|Control|No cell therapy
3170252|NCT01408381|Experimental|Low dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 108
3170253|NCT01408381|Experimental|Intermediate dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 5 x 108
3170254|NCT01408381|Experimental|High dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 109
3170255|NCT01408368|Active Comparator|Bilateral subtotal thyroidectomy|
3170256|NCT01408368|Experimental|Total thyroidectomy|
3170257|NCT01408355|Experimental|50 microgram PF-06273588 intravenous|Subjects will receive a single intravenous microdose of PF-06273588 in period one
3170258|NCT01408355|Experimental|50 microgram PF-06273588 oral|Subjects will receive a single oral microdose of PF-06273588 in period two
3170259|NCT01408342|Other|Rituximab, Alemtuzumab|
3170260|NCT01408329|Sham Comparator|Control|Sham altitude changes - The CVAC device consists of a small pod-like chamber attached to a computer system that controls a strong pump that can draw air rapidly out of the chamber to increase the simulated altitude. The sham-treated group (SH) was exposed to regular, slowly-fluctuating pressures that reached a maximum altitude of 607 m for all 30 sessions. Sham sessions mimicked the noises and initial pressure-change sensations created in the active sessions, thus giving naıve subjects the impression that they were experiencing altitude treatment. All subjects were blind to their elevation throughout the intervention.
3170261|NCT01408329|Experimental|Hypoxic intervention|Cyclic Hypobaric Hypoxia (CHH) subjects were given 40 min sessions inside the CVAC device per day (two 20 min sessions sequentially per day), 3 days a week for 10 weeks, for a total of 30 sessions or 20 hours. After familiarization sessions, pre-programmed sessions were administered, progressing from Tier 1 to 5. Subjects rotated through three pre-programmed sessions per Tier and each session varied the pattern and rate of hypoxic fluctuations, so that subjects would experience a constantly changing stimulus at each elevation. Five weeks were allotted to progress from Tier 1 (3048 m) to Tier 4 (5486 m). At Tier 5 (6096 m), there was an additional 5 weeks of exposure.
3170262|NCT01408316|Experimental|Part 1 (Crystalline vs. Amorphous)|Volunteers in part 1 of the study will initially receive either crystalline PX-866 tablets or amorphous PX-866 capsules, then after seven days, the same volunteers will respectively cross-over to receive the alternate amorphous PX-866 capsules or crystalline PX-866 tablets.
3170263|NCT01408316|Experimental|Part 2 (Crystalline Food Effect)|Volunteers in part 2 of the study will receive two single dose treatments of PX-866 crystalline tablets initially administered in either fed or fasted state, then after at least seven days, the same volunteers will respectively cross-over to receive PX-866 tablets in the alternate fed or fasted state.
3170264|NCT01408303|Placebo Comparator|Olive Oil|olive oil: 4 g/day + prescription statin
3170265|NCT01408303|Experimental|Epanova, 2 g|omega-3-carboxylic acids, 2g/day + prescription statin
3170266|NCT01408303|Experimental|Epanova, 4 g|omega-3-carboxylic acids, 4g/day + prescription statin
3170267|NCT01408290|Experimental|FAB-6011|- One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 2A/ and 32 subjects aged over 60 years /Group 2E/).
3170268|NCT01408290|Experimental|FAB-9011|- One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 3A/ and 32 subjects aged over 60 years/Group 3E/).
3170269|NCT01408290|Experimental|FLUVALAB|- One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 4A/ and 32 subjects aged over 60 years/Group 4E/).
3170270|NCT01408290|Experimental|FAB-3511|- One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 1A/ and 32 subjects aged over 60 years /Group 1E/).
3170271|NCT01408277|Active Comparator|Santyl|2mm Santyl applied once daily.
3170272|NCT01408277|Active Comparator|Control|Standard Care
3170273|NCT01408264|Active Comparator|0.035 guidewire|conventional 0.035 guidewire
3170274|NCT01408264|Active Comparator|Olympus Visiglide 0.025 guidewire|Olympus Visiglide 0.025
3170275|NCT01408238|Experimental|1|"Secale cereale allergen extract at 4 different concentrations~Positive control~Negative control"
3170276|NCT01408212|Experimental|Acupuncture therapy|
3170277|NCT01408199|Experimental|Lenalidomide Group|
3170278|NCT01408186|Active Comparator|Rabeprazole|Tablet 20mg daily for 12 months
3170279|NCT01408186|Active Comparator|Famotidine|Tablet 40mg daily for 12 months
3170280|NCT01408173|Experimental|NPC-11|"Loading Dose (Day 1): Caffeine citrate 20 mg/kg body weight will be administered intravenously using a syringe infusion pump over 30 minutes.~Maintenance Dose (Day 2～Day 10): After an interval 24 hours, caffeine citrate 5 mg/kg body weight will be administered intravenously (over 10 minutes) or orally if the patients will be able to receive oral administration once a day. The maintenance dose can be increased to a maximum 10 mg/kg caffeine citrate once a day if apnea persists."
3170281|NCT01408160|Experimental|Treatment (Combotox, cytarabine)|Patients receive high-dose cytarabine IV over 2-3 hours every 12 hours on days 1-3 and deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins IV over 4 hours on days 8, 10, and 12. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3170282|NCT01408147|Active Comparator|Treatment Group|This group will be allowed access to an online weight loss program. The program is designed to help low income women lose weight through lifestyle intervention.
3170283|NCT01408147|No Intervention|Standard WIC care|The control group will received Standard Care as provided through WIC.
3170284|NCT01408121||African-American on clopidogrel|
3170285|NCT01408121||African-American on prasugrel|
3170286|NCT01408121||Caucasian on clopidogrel|
3170287|NCT01408121||Caucasian on prasugrel|
3170288|NCT01408108|Active Comparator|Lightweight mesh repair|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh
3170289|NCT01408108|Active Comparator|Primary crural repair|Laparoscopic primary posterior crural repair
3170290|NCT01408095|Experimental|LY2608204|80 to 400 mg, Doses will be titrated to reach glycemic targets during the first 4 weeks. The starting dose level depends on the participant's HbA1c level measured at Screening. Administered orally, daily for 12 weeks
3170291|NCT01408095|Active Comparator|Glimepiride|1 to 6 mg, Doses will be titrated to reach glycemic targets during the first 4 weeks. Administered orally, daily for 12 weeks
3170292|NCT01408082|Experimental|ISV-502|
3170293|NCT01408082|Active Comparator|AzaSite|
3170294|NCT01408082|Active Comparator|Dexamethasone|
3170295|NCT01408082|Placebo Comparator|Vehicle|
3170296|NCT01408069|Experimental|MIGRANE|1 to 2 tablets ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg
3170297|NCT01408069|Active Comparator|PARCEL|1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
3170298|NCT01408056|Experimental|Timolol 0.5% Gel Forming Solution (GFS)|Half of enrolled subjects will receive topical Timolol
3170299|NCT01408056|Active Comparator|Mupirocin 2% ointment|Half of enrolled subjects will receive Mupirocin
3170300|NCT01408043|Experimental|Treatment (stem cell supermobilization)|Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of >= 8 x 10^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =< 2 x 10^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician.
3170301|NCT01408030|Placebo Comparator|Placebo spray|
3170302|NCT01408030|Active Comparator|Bevacizumab spray|
3170303|NCT01408030|Active Comparator|Estriol spray|
3170304|NCT01408030|Active Comparator|Tranexamic acid spray|
3170305|NCT01408004|Experimental|Alternating regimen|In the experimental arm (Arm A) alternating treatment will consist of 8 weeks of Pazopanib 800 mg qd alternated by 8 weeks of Everolimus 10 mg qd until first progression(PD per RECIST 1.1)followed thereafter by Pazopanib (when PD after 8 weeks of Everolimus)or Everolimus (when PD after 8 weeks of Pazopanib) monotherapy until second progression.
3170306|NCT01408004|Active Comparator|Sequential treatment|The comparative arm (Arm B) will be the standard regimen of Pazopanib (800 mg qd continuously) until progression, followed thereafter by Everolimus (10 mg qd continuously) until progression.
3170307|NCT01407991|Experimental|Length or graph method|The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.
3170308|NCT01407991|Active Comparator|NEM method for NG/OG tube placement|Standard method- measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length. Nose to ear to mid-xiphoid-umbilicus (NEM).
3170309|NCT01407978|Active Comparator|Vaccination with Fluval AB Novo|"Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose."
3170310|NCT01407978|Active Comparator|Vaccination with Fluval AB|"Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose."
3170311|NCT01407978|Experimental|Vaccination with Fluval P|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose."
3170312|NCT01407965|Experimental|Ertapenem|"Free tissue kinetics of ertapenem in fatty tissue and intraperitoneal fluid in mg/L~Free and bound plasma concentration of ertapenem or meropenem in mg/L"
3170313|NCT01407965|Experimental|Meropenem|Free tissue kinetics of meropenem in fatty tissue and intraperitoneal fluid in mg/L up to 24 hours after administration. Free and bound plasma concentration of meropenem in mg/L.
3170314|NCT01407952|Other|HydroCoil Embolic System|Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
3170315|NCT01407952|Other|Control|Aneurysm treatment using bare platinum coil(s)
3170316|NCT01407939||Children, Adults|3- to 15-year old children and their parent (adults
3170317|NCT01407926||Nurse-Led Mental Health Promotion Group|
3170318|NCT01407900|Placebo Comparator|5% Dextrose in Water|Infusion of D5W
3170319|NCT01407900|Active Comparator|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
3170320|NCT01407887|Active Comparator|artesunate, amodiaquine methylene blue|two arms, open randomized controlled study in children with uncomplicated falciparum malaria in Burkina Faso. Intervention: artesunate (AS) - amodiaquine (AQ) - methylene blue (MB) control: artesunate (AS) - amodiaquine (AQ)
3170321|NCT01407887|No Intervention|artesunate amodiaquine|The control group will receive once daily a fixed dose AS-AQ over three days.
3170322|NCT01407874|Experimental|Placebo|Placebo + Allopurinol 200mg
3170323|NCT01407874|Experimental|Ulodesine (BCX4208) 5mg|BCX4208 5mg + Allopurinol 200 mg
3170324|NCT01407874|Experimental|Ulodesine (BCX4208) 10mg|BCX4208 10mg + Allopurinol 200mg
3170325|NCT01407861|Active Comparator|Relaxation training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
3170326|NCT01407861|Active Comparator|Aerobic endurance training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
3170327|NCT01407848|Experimental|Furosemide|1 mg/kg/Ed
3170328|NCT01407848|Active Comparator|Saline 0,9%|1ml/kg/Ed
3170329|NCT01407835|Experimental|1|"Dactylis glomerata allergen extract at 4 different concentrations~Positive control~Negative control"
3170330|NCT01407822|Experimental|Erlotinib arm|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
3170331|NCT01407822|Active Comparator|Chemo arm|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
3170332|NCT01407809|Experimental|Intervention|
3170333|NCT01407796|Experimental|Endotoxin and [18F](+/-)NOS|All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation. They will also be imaged before and after endotoxin instillation with the novel PET tracer F-18 (+/-) NOS
3170334|NCT01407783|Experimental|Problem Solving Tools|The home visitation nurse will teach and utilize the problem solving tools to help low-income depressed mothers. It is a brief treatment with the a non-pathologizing intervention being done in 4-8 sessions.
3170335|NCT01407783|No Intervention|Enhanced Referral|
3170469|NCT01406847|Sham Comparator|Static Touch|Practitioner hands are placed on the lumbar spine with the participant in prone.
3170470|NCT01406847|Active Comparator|Spinal Mobilization|Oscillation of the third lumbar level performed with the participant in prone
3170336|NCT01407744||Correlative studies|Archived tumor tissue samples are analyzed by laboratory biomarker analysis for cellular density, mitotic count, tumor cell invasion, hTERT expression, telomere dysfunction, 1q gain, 9p deletion, and genetic mutations by IHC, Affymetrix MIP arrays, and FISH. Results are then correlated with patient-outcome variables and known risk factors, namely gender, age at diagnosis, tumor location infratentorial vs. supratentorial), tumor grade (differentiated vs anaplastic), and extent of surgery as well as pathologic variables.
3170337|NCT01407705||Control Group|"No diagnosis of cervical degenerative or traumatic disease~30 to 80 years of age~Ability of volunteers to tolerate 1 hr examination"
3170338|NCT01407705||Disease (Non-healthy) Group|"Cervical Spinal Cord:~Clinical and Radiographic evidence of cervical spondylotic myelopathy~18 to 80 years of age~Safe and stable clinical scenario to undergo imaging~Awake, alert patient able to cooperate with physical examination~Give written informed consent prior to any testing under this protocol~Degenerative Disease Group:~Have signs or symptoms consistent with spinal cord injury.~Be diagnosed with cervical spondylosis (degenerative disease).~Traumatic Group:~• A spinal cord injury associated with a traumatic event."
3170339|NCT01407679|Experimental|Alitretinoin|
3170340|NCT01407666|Experimental|Bilateral paravertebral blocks|Bilateral continuous paravertebral blocks for open liver resection
3170341|NCT01407666|No Intervention|epidural block|received thoracic epidural block for open liver resection
3170342|NCT01407653|Experimental|virtual reality|
3170343|NCT01407653|Other|usual care|
3170344|NCT01407640|Experimental|1|Allergy tests
3170345|NCT01407627|Experimental|Fructose First|"Study Day 1 - measurement of renal hemodynamics and blood pressure~Subjects will ingest fructose 200g daily x 14d~Study Day 2 - measurement of renal hemodynamics~Minimum 1 week washout period~Subjects will ingest dextrose 200g daily x 14d~Study Day 3 - measurement of renal hemodynamics and blood pressure"
3170346|NCT01407627|Active Comparator|Dextrose First|"Study Day 1 - measurement of renal hemodynamics and blood pressure~Subjects will ingest dextrose 200g daily x 14d~Study Day 2 - measurement of renal hemodynamics~Minimum 1 week washout period~Subjects will ingest fructose 200g daily x 14d~Study Day 3 - measurement of renal hemodynamics and blood pressure"
3170347|NCT01407614|Active Comparator|external lumbar drainage|Within 96 hours of initial subarachnoid hemorrhage, patients were randomized for external lumbar drainage (ELD)of cerebrospinal fluid during a maximum of 7 days or standard treatment of subarachnoid hemorrhage without ELD
3170348|NCT01407614|No Intervention|No intervention|In this arm the patients received standard treatment following protocol for patients with subarachnoid hemorrhage
3170349|NCT01407601|Experimental|45 µg MK-7|45 µg MK-7 daily over 6 weeks
3170350|NCT01407601|Experimental|135 µg MK-7|135 µg MK-7 daily over 6 weeks
3170351|NCT01407601|Experimental|360 µg MK-7|360 µg MK-7 daily over 6 weeks
3170352|NCT01407588|Experimental|Magnetic navigation|
3170353|NCT01407588|Experimental|Manual navigation|
3170354|NCT01407575|Experimental|Buprenorphine|0.2 to 1.6mg of buprenorphine sublingual over the course of 8 weeks
3170355|NCT01407575|Placebo Comparator|Placebo|matching placebo- sublingual- over the course of 8 weeks
3170356|NCT01407562|Experimental|Pazopanib with paclitaxel and carboplatin|
3170357|NCT01407549|Experimental|Intervention group|The intervention group will participate in the Mindfulness Program consists of one 2-hour session each week for 6 consecutive weeks plus a half day retreat near the end of the intervention.
3170358|NCT01407549|No Intervention|Control group|Participants in the control group will be assigned to a waiting list group. Participants will be told that they will be eligible for the intervention three months after the completion of a preliminary documentation of their symptoms and additional measures. Participants will complete the same battery of measures according to the same time table as participants in the intervention group.
3170359|NCT01407523|Experimental|Levetiracetam|Twice daily intravenous (IV) infusion of Levetiracetam solution equivalent (mg-for-mg) to oral dose of Levetiracetam.
3170360|NCT01407510|Experimental|Arm 1|
3170361|NCT01407497|Active Comparator|IA|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 108 pfu i.m. MVA boosting at weeks 24 and 36
3170362|NCT01407497|Placebo Comparator|IB|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 saline solution i.m at weeks 24 and 36
3170363|NCT01407497|Active Comparator|IIA|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12;108 pfu i.m. MVA boosting at weeks 24 and 36
3170364|NCT01407497|Placebo Comparator|IIB|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
3170365|NCT01407484|Experimental|Treatment|Cortancyl (prednisone) 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
3170366|NCT01407484|Placebo Comparator|Placebo|Placebo
3170367|NCT01407471|Experimental|Clobetasol + Spironolactone|0.05% clobetasol and 5% spironolactone
3170368|NCT01407471|Active Comparator|Clobetasol + Placebo|0.05% clobetasol + inert excipient
3170369|NCT01407471|Active Comparator|Placebo + Spironolactone|Inert excipient + 5% spironolactone
3170370|NCT01407471|Placebo Comparator|Placebo + placebo|Inert excipient
3170371|NCT01407458|Active Comparator|Experimental Group|Children doing additional exercises with upper limbs in physical education class
3170372|NCT01407458|Active Comparator|Control Group|Children doing normal physical education exercises
3170373|NCT01407445|Placebo Comparator|Placebo|1 tablet of placebo/ oral/ 3 times a day for three months
3170374|NCT01407445|Active Comparator|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for three months
3170375|NCT01407432|Experimental|Folic acid|tablets of 5 mg of folic acid
3170376|NCT01407432|Placebo Comparator|Placebo|Tablets of placebo of folic acid
3170377|NCT01407419|Experimental|Treat to Target Intervention Strategy|Subjects at sites randomized to this arm will be expected to return to the clinic for Monthly Assessments until low disease activity (LDA) defined as CDAI of 10 or less has been achieved. Providers are prompted to accelerate therapy (Treatment Acceleration) at each visit that CDAI is >10 (unless not felt to be medically appropriate or refused by the subject.) Accelerations are expected at least every 3 months, until/unless LDA has been achieved.
3170471|NCT01406821|Sham Comparator|Dry needling|Blood will be drawn, and tendon will be penetrated with dry needle. Nothing will be injected into the tendon.
3170378|NCT01407419|No Intervention|Control Group Treated with Usual Care|Subjects in this arm will be expected to complete study visits with their rheumatologist/study doctor at Baseline, Month 3, Month 6, Month 9 and Month 12. Data collection will occur at each of those visits. Subjects and Providers will continue managing disease per usual practices and do not receive protocol prompts relative to visit frequency or acceleration of therapy, regardless of disease activity level (by CDAI)
3170379|NCT01407406|Experimental|Chinese Subjects - low dose BIIB023 IV|
3170380|NCT01407406|Experimental|Chinese Subjects - high dose BIIB023 IV|
3170381|NCT01407406|Experimental|Japanese Subjects - low dose BIIB023 IV|
3170382|NCT01407406|Experimental|Japanese Subjects - high dose BIIB023 IV|
3170383|NCT01407406|Experimental|Causasian Subjects - low dose BIIB023 IV|
3170384|NCT01407406|Experimental|Caucasian Subjects - high dose BIIB023 IV|
3170385|NCT01407393|Experimental|Glucosanol|Glucosanol
3170386|NCT01407393|Placebo Comparator|Placebo|Placebo
3170387|NCT01407367||Phase I and Phase II|"Phase I (First 100 participants):~Medical alert bracelet/necklace, Medical event diary, Medical event ascertainment, Repeated measurement of renal function and other electrolytes, Review for CKD-PSIs~Phase II (Next 250 participants):~Medical event diary, Medical event ascertainment, Repeated measurement of renal function and other electrolytes, Review for CKD-PSIs"
3170388|NCT01407354|Experimental|Lokomat Training|Lokomat robotic assisted treadmill training Lokomat Treadmill Training
3170389|NCT01407354|Active Comparator|Aquatic Therapy|Aquatic exercise therapy
3170390|NCT01407341|Experimental|Supportive care (ChronOS)|Patients undergo placement of beta-tricalcium phosphate bone graft strips posterolaterally during surgery.
3170391|NCT01407315|Experimental|GlucoMenDay - Multiple sampling (A)|
3170392|NCT01407315|Experimental|GlucoMenDay - Meal/Insulin test (B)|
3170393|NCT01407302||LMA group|patients undergoing general anesthesia with LMA insertion
3170394|NCT01407302||E-tube group|patients undergoing general anesthesia with e-tube
3170395|NCT01407289|Experimental|Insulin titration protocol|Patients in care at the Division of Endocrinology will be treated by enhanced version of published best paper based practice insulin titration protocol to control glycaemia in hospitalised patients with type 2 diabetes.
3170396|NCT01407289|No Intervention|Standard care|Patients in care of the Division of Cardiology will be treated using antihyperglycaemic therapy according to standard care.
3170397|NCT01407276|Experimental|Part 1: Mild Renal Impairment (Panel A)|
3170398|NCT01407276|Experimental|Part 1: Control to Match Panel A (Panel B)|
3170399|NCT01407276|Experimental|Part 1: Moderate Renal Impairment (Panel C)|
3170400|NCT01407276|Experimental|Part 1: Control to Match Panel C (Panel D)|
3170401|NCT01407276|Experimental|Part 1: Severe Renal Impairment (Panel E)|
3170402|NCT01407276|Experimental|Part 1: Control to Match Panel E (Panel F)|
3170403|NCT01407276|Experimental|Part 2: End-stage Renal Disease needing hemodialysis (Panel G)|
3170404|NCT01407276|Experimental|Part 2: Control to Match Panel G (Panel H)|
3170405|NCT01407263|Experimental|Lymph node template|In patients randomized to standard, only the nodal packet under the external iliac vein and above the obturator nerve will be dissected. For patients randomized to the modified template, the external iliac, hypogastric and obturator fossa nodal groups will be removed.
3170406|NCT01407263|Experimental|Transverse versus vertical closure of the port site incision|
3170407|NCT01407263|Experimental|One vs. three days of antibiotic prophylaxis|
3170408|NCT01407237||HIV-infected Individuals|
3170409|NCT01407237||non-HIV-infected Individuals|
3170410|NCT01407224|Experimental|Only training|Training on Early Breastfeeding Practices to front line health workers
3170411|NCT01407224|Active Comparator|Training and supervision|Training as well as supervision by field supervisor for six months intervention
3170412|NCT01407224|No Intervention|Control|No intervention such as training or supervision
3170413|NCT01407211|Active Comparator|with Multiple Sclerosis/ vitamin A|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A
3170414|NCT01407211|Placebo Comparator|with Multiple Sclerosis/ placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day
3170415|NCT01407198|Experimental|Nilotinib/XRT|Nilotinib is administered 400mg PO BID for 2 weeks and then administered concurrently with daily radiation therapy until completion of radiation therapy. Participants can then undergo surgery if clinically possible. After either surgery or definitive radiation, participants have the option to continue on nilotinib therapy.
3170416|NCT01407185|Experimental|Resistive Training|Subjects will be working at 30-60% of 1 RM. The therapist selects theraband that will produce muscle fatigue ~ 15 reps. Subjects should report that the exercise was somewhat light to somewhat hard 11 to 14 on RPE scale. Increase or decrease resistance until the desired RPE is obtained. Continues until momentary fatigue is evidenced. Fatigue is defined as the inability to move through the full ROM in a slow controlled fashion. Record the exercise performed, amount of resistance, and # of good quality reps performed before fatigue was reached. A single set will be done for each muscle group.
3170417|NCT01407172||Symptomatic PAD|Patient with symptomatic PAD as defined by the presence of typical or atypical claudication symptoms or critical limb ischemia in conjunction with ABI <0.9.
3170418|NCT01407172||Patients without PAD|Patients without PAD as defined by ABI>0.9 and <1.3.
3170419|NCT01407172||Asymptomatic PAD|Patients with asymptomatic PAD as defined by ABI<0.9 but no symptoms.
3170420|NCT01407159||Thoracic Stentgraft plus E-XL|male and female patients with complicated type B aortic dissection involving the infra-diaphragmatic aorta treated with any thoracic stentgraft extended by the E-XL aortic stent
3170421|NCT01407159||Control group|"historical control group fulfilling the following criteria:~Age +/- 3 years~Sex matched~Same follow-up period"
3170472|NCT01406821|Experimental|Platelet-rich plasma (PRP)|Blood will be drawn, and platelet-rich plasma will be injected into the tendon.
3170473|NCT01406808|Other|standard of care plus genetic information|
3170474|NCT01406808|No Intervention|usual standard of care without genetic information|
3170475|NCT01406795|Experimental|Venous Stent Arm|The study is a single treatment arm study and the venous stent will be placed in all eligible participants.
3170422|NCT01407133|Experimental|Active rTMS|"48 subjects will receive active temporal rTMS, applied with the following combined parameters:~intensity: 100% of resting motor threshold~stimulation frequency: low-frequency continuous stimulation (0.5 or 1 Hz) or high-frequency stimulation trains (4 or 12 Hz)~number of stimulations per session: 300, 900 or 1800 per session~number of sessions per week: spaced out / low density protocol (1 per week) or dense / high density protocol (5 per week)~total number of sessions for the whole intervention: short protocol (5 sessions) or long protocol (20 sessions)."
3170423|NCT01407133|Sham Comparator|Sham rTMS|16 subjects will receive sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session (300 or 900)
3170424|NCT01407120|Experimental|Mother Program|11 session program focused on parenting skills
3170425|NCT01407120|Experimental|Mother Plus Child Program|11 session Mother Program focused on parenting skills plus 11 session Child program focused on child coping skills
3170426|NCT01407120|No Intervention|Literature Control|Families received books on children's post-divorce adjustment
3170427|NCT01407107|Experimental|Nitroglycerin|Dose escalation trial of Nitroglycerin
3170428|NCT01407094|Active Comparator|Sertraline|SSRI monotherapy
3170429|NCT01407094|Placebo Comparator|Placebo|Placebo control
3170430|NCT01407094|Active Comparator|Bupropion|BupropionXL
3170431|NCT01407081|Experimental|Training|telerehabilitation cognitive strategy training
3170432|NCT01407068|Experimental|AA4500|AA4500 collagenase clostridium histolyticum
3170433|NCT01407055|No Intervention|Standard Medical Care|Patients receive standard treatment protocol for Coronary Artery Bypass Graft Surgery
3170434|NCT01407055|Active Comparator|Attention Control Group|In addition to standard medical care patients receive a comparable amount of therapist´s attention (common and unspecific factors = supportive therapy) to the intervention group, without targeting patients' expectations.
3170435|NCT01407055|Experimental|Expectation Manipulation Intervention|In addition to standard medical care patients' expectations prior to surgery are targeted in a brief psycho-educational intervention.
3170436|NCT01407042||mb-UKA|Patients with unicondylar osteoarthritis of the knee
3170437|NCT01407016|Experimental|1.0|
3170438|NCT01407003|Experimental|LIK066 in healthy subjects|
3170439|NCT01407003|Placebo Comparator|Matching placebo in healthy subjects|
3170440|NCT01407003|Experimental|LIK066 in patients with type 2 diabetes mellitus|
3170441|NCT01407003|Placebo Comparator|Matching placebo in patients with type 2 diabetes mellitus|
3170442|NCT01406990||Aspirin 81 mg|Women with CAD taking 81 mg aspirin.
3170443|NCT01406977|Experimental|BPS804 dose escalation|
3170444|NCT01406964|Experimental|Arm A|Arm A performs a CAT test to study tubal factor causes
3170445|NCT01406964|Experimental|Arm B|In Arm B a histerosalpingography is performed.
3170446|NCT01406951||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
3170447|NCT01406951||sepsis|SIRS + infection
3170448|NCT01406951||VAP|(1) after 48-72h endotracheal intubation, X-ray film displays new or progressive infiltrating focus; (2)The patient is in two of the following conditions: a. fever (temperature >38 ℃ or higher than basal temperature; b. peripheral WBC count≥10×10∧9/L，or <4×10∧9/L; c. appearance or increase of purulent respiratory tract secretion. Besides the diagnostic norms above, it is suggested that lower respiratory tract secretions be collected under the bronchoscope and half-quantitative etiological culture be carried out through the medium of BALF samples (diagnostic threshold value:104cfu/mL ).
3170449|NCT01406938|Experimental|AIN457150 mg- Induction period Only(IPO)|secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)
3170450|NCT01406938|Experimental|AIN457 300 mg - IPO|secukinumab- 2 x 150mg injections per dose
3170451|NCT01406938|Experimental|AIN457 150 mg - Fixed Interval (FI)|1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection
3170452|NCT01406938|Experimental|AIN457 300 mg FI|2 s.c. secukinumab 150 mg injections
3170453|NCT01406938|Experimental|AIN457 150 mg- Start of relapse (SoR)|1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection
3170454|NCT01406938|Experimental|AIN457 300 mg- SoR|2 s.c. secukinumab 150 mg injections
3170455|NCT01406925|Placebo Comparator|Control|Placebo control
3170456|NCT01406925|Experimental|Low dose NRL001|0.5% NRL001 cream
3170457|NCT01406925|Experimental|Intermediate dose NRL001|0.75% NRL001 cream
3170458|NCT01406925|Experimental|High dose NRL001|1.0% NRL001 cream
3170459|NCT01406912|Active Comparator|Recreational Activity Arm|recreational activity includes playing cards, ominoes, jenga or a ball game.
3170460|NCT01406912|Experimental|Wii Gaming System Arm|Use of Wii gaming technology (e.g. commercially available games)
3170461|NCT01406899|No Intervention|Treatment as Usual|Standard treatment as usual (TAU) in the VA Connecticut Healthcare System substance abuse clinic consisting of individual and group therapy sessions and regular urine monitoring.
3170462|NCT01406899|Experimental|Computer-based treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
3170463|NCT01406886|Experimental|Energy density|Low or high energy density meal
3170464|NCT01406873|Active Comparator|Mexiletine|20 subjects will be randomized (assigned) to receive Mexiletine. Mexiletine is available on the market for the treatment of cardiac arrhythmias, but it is not currently approved for the treatment of myotonia or myotonic dystrophy.
3170465|NCT01406873|Placebo Comparator|Sugar pill|20 subjects will be randomized (assigned) to receive placebo (sugar pill). This control group is necessary to definitely establish the antimyotonic efficacy and safety of mexiletine.
3170466|NCT01406860|Experimental|Droperidol|
3170467|NCT01406860|Active Comparator|Metoclopramide + Diphenhydramine|
3170468|NCT01406847|Experimental|Spinal Manipulation|High-velocity manual technique applied to the pelvis with the participant in supine
3170476|NCT01406769|Experimental|Diagnostic (bioimpedance to measure lymphedema)|Patients undergo preoperative and postoperative lower-extremity lymphedema assessment comprising serial circumferential measurements, bioimpedance spectroscopy measurements, and clinical evaluation using the Stemmer sign. Patients undergo radical vulvectomy or radical local excision as prescribed by GOG-0244, and unilateral or bilateral inguinal or inguinal-femoral lymphadenectomy.
3170477|NCT01406743||EOS™ Acquisition|
3170478|NCT01406730|Experimental|exercise|16 weeks of running exercise
3170479|NCT01406730|No Intervention|control|
3170480|NCT01406717|Experimental|SPIL1033|
3170481|NCT01406717|Placebo Comparator|Placebo|
3170482|NCT01406704|No Intervention|Control|
3170483|NCT01406704|Experimental|Rosiglitazone|Rosiglitazone (8 mg/day)
3170484|NCT01406704|Experimental|alpha-lipoic acid|alpha-lipoic acid (1800 mg/day)
3170485|NCT01406704|Experimental|Rosiglitazone/alpha-lipoic acid|combination of Rosiglitazone (8 mg/day) and alpha-lipoic acid (1800 mg/day)
3170486|NCT01406691|Experimental|Light|three hours of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during three hours immediately prior to desired waketime
3170487|NCT01406691|Placebo Comparator|Fake light|during three hours immediately prior to desired waketime, subjects will receive no light (light flash device will be disabled)
3170488|NCT01406678|Active Comparator|RIPC|Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before induction of cardioplegic cardiac arrest and 5 and 10 Minutes after aortic unclamping during reperfusion of the myocardium.
3170489|NCT01406678|Placebo Comparator|Control|Control group: Coronary artery bypass surgery without remote ischemic preconditioning protocol
3170490|NCT01406665||increased diabetes risk|the recruited group consists of persons with moderate to high risk for impaired glucose tolerance or diabetes
3170491|NCT01406652|Experimental|One-stage bursectomy|Bursectomy with debridement and primary closure of the wound during one surgical intervention
3170492|NCT01406639|Experimental|Ranibizumab|Patients treated with topical ranibizumab.
3170493|NCT01406626|Experimental|Health Navigation Intervention Arm|"Subjects will receive the following health navigation services:~1) 10 Navigator meetings: Navigators will meet with participants in person to teach linkage/retention skills and knowledge~2a) 2 Navigator accompaniment sessions: the health navigator will accompany participants to HIV care appointment. Before and after the appointment, participants and navigators will review linkage and retention skills/knowledge things that make it hard or easy for him to get regular HIV care~2b) Optional health navigator accompaniment sessions: If the participant requests, the health navigator will provide accompaniment to supportive HIV care appointments (one per month max)~3) 14 Health navigator care calls: During these calls, navigators and participants will talk about any problems that could make it difficult to get regular HIV care."
3170494|NCT01406626|No Intervention|Usual Care|Participants assigned to the control arm will receive the transitional case management (TCM) services that are currently offered at the jail
3170495|NCT01406613||Particpants of previous TRIO study|All participants to this study are being observed as a follow up to a previous study which involved 4 arms. All participants to this follow up study will be subject to identical study procedures.
3170496|NCT01406600|Active Comparator|rhCG 250mcg|For final oocyte maturation triggering in ART, rhCG 250mcg will be administrated.
3170497|NCT01406600|Experimental|rhCG 500mcg|For final oocyte maturation triggering in ART, rhCG 500mcg will be administrated.
3170498|NCT01406587|Experimental|PP4001 50 mg|
3170499|NCT01406587|Experimental|PP4001 100 mg|
3170500|NCT01406587|Experimental|PP4001 200 mg|
3170501|NCT01406587|Placebo Comparator|Placebo|
3170502|NCT01406574|Experimental|OPB-31121 p1|Phase1 step
3170503|NCT01406574|Experimental|OPB-31121 p2|Phase2 step
3170504|NCT01406561|Experimental|OMS103HP-S|OMS103HP-S injected into vehicle irrigation solution for administration during meniscectomy surgery
3170505|NCT01406561|Placebo Comparator|Vehicle Irrigation Solution|Vehicle Irrigation Solution
3170506|NCT01406548|Experimental|BPS804 dosing frequency 1|
3170507|NCT01406548|Placebo Comparator|placebo dosing frequency 1|
3170508|NCT01406548|Experimental|BPS804 dosing frequency 2|
3170509|NCT01406548|Placebo Comparator|placebo dosing frequency 2|
3170510|NCT01406548|Experimental|BPS804 dosing frequency 3|
3170511|NCT01406548|Placebo Comparator|Placebo dosing frequency 3|
3170512|NCT01406522|Placebo Comparator|Oral placebo|Inactive treatment
3170513|NCT01406522|Experimental|Oral tacrine|Oral tacrine
3170514|NCT01406509|Experimental|children aged 2-5 years (1 dose)|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccines of 0.5ml/dose for a person in 20 children aged 2-5 years, on day 0
3170515|NCT01406509|Experimental|children aged 6-23months (2 doses)|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccines of 0.5ml/dose for a person in 20 children aged 6-23 months old, on day 0, 28
3170516|NCT01406496|Experimental|Timing of insulin administration|
3170517|NCT01406483|Other|CABG|
3170518|NCT01406470|Experimental|IVIG-SN™|Immune Globulin Intravenous (Human) 5% Liquid
3170519|NCT01406444|Active Comparator|rhIGF-1 followed by Risedronate|Sequential therapy with rhIGF-1 for 6 months followed by 6 months of risedronate 35mg
3170520|NCT01406444|Active Comparator|Risedronate|Risedronate 35mg for 12 months
3170521|NCT01406444|Placebo Comparator|Placebo|Placebo for 12 months
3170522|NCT01406431|Active Comparator|Pitavastatin + Valsartan|Intervention: Drug: Pitavastatin, Valsartan
3170523|NCT01406431|Experimental|Livalo fixed combination drug|Intervention: Drug: Livalo® fixed combination drug
3170524|NCT01406418|Experimental|Cohort 1: CR6261|2 mg/kg CR6261
3170525|NCT01406418|Placebo Comparator|Cohort 1: Placebo|5% dextrose in water
3170526|NCT01406418|Experimental|Cohort 2: CR6261|5 mg/kg CR6261
3170527|NCT01406418|Placebo Comparator|Cohort 2: Placebo|5% dextrose in water
3170528|NCT01406418|Experimental|Cohort 3: CR6261|15 mg/kg CR6261
3170533|NCT01406418|Placebo Comparator|Cohort 5: Placebo|5% dextrose in water
3170534|NCT01406418|Experimental|Cohort 6: CR6261|30 mg/kg CR6261
3170535|NCT01406418|Placebo Comparator|Cohort 6 Placebo|5% dextrose in water
3170536|NCT01406405||PEEK cages|Patients will have fusion surgery performed using polyetheretherketone (PEEK) cages
3170537|NCT01406405||Allograft spacers|Patients will have fusion surgery performed using allograft spacers
3170538|NCT01406392|Active Comparator|Sublingual Misoprostol 12,5mcg|Sublingual misoprostol or placebo tablete will be administered for each six hours until the maximum dose of 100mcg or eight tablets.
3170539|NCT01406392|Active Comparator|Vaginal Misoprostol 25 mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets. Each pacient will receve at the same time a sublingual placebo tablet and vaginal misoprostol or sublingual misoprostol and vaginal placebo tablet. It will depend of the randomization.
3170540|NCT01406379|Experimental|Prophylactic clip|Prophylactic clip
3170541|NCT01406379|Active Comparator|Detachable snare|Detachable snare
3170542|NCT01406366||Group 1|Group 1: 16 programs / 148 residents
3170543|NCT01406366||Group 2|Group 2: 16 programs / 142 residents
3170544|NCT01406353|Active Comparator|Early Percutaneous Mitral Intervention|early elective percutaneous mitral commissurotomy within 3 months of enrollment
3170545|NCT01406353|No Intervention|Conventional Treatment|All patients in the conventional treatment group regularly visit their attending physicians at 3 monthly interval for maintenance of anticoagulation therapy or every year for annual re-evaluation. Patients who become symptomatic during follow-up are referred for percutaneous mitral commissurotomy or mitral valve surgery.
3170546|NCT01406340|Experimental|Normal subjects and subjects with Stage 3/4 renal function|Subjects will receive 5mg GSK1278863 for 14 days.
3170547|NCT01406340|Experimental|Subjects with Stage 5 renal function|Subjects will receive 5mg GSK1278863 for 15 days.
3170548|NCT01406327||Subjects prescribed ambrisentan|Subjects with pulmonary arterial hypertension (PAH) prescribed ambrisentan during study period
3170549|NCT01406314|Experimental|Intervention|Intravenous infusion for approximately 48 hours followed by subcutaneous injection
3170550|NCT01406301||Patients with a discharge diagnosis of ACS (UA/NSTEMI or STEMI|Patients with a discharge diagnosis of ACS (UA/NSTEMI or STEMI)
3170551|NCT01406288||HUS epidemy in Bordeaux, E. coli of the O104H4 serotype|
3170552|NCT01406275||Pediatrics patients prescribed amoxicillin and clavulanate|Pediatrics patients prescribed amoxicillin and clavulanate for treatment of diseases other than otitis media during study period
3170553|NCT01406262|Active Comparator|Albiglutide + moxifloxacin placebo|Once weekly subcutaneous injection of albiglutide for 6 weeks plus oral tablet of moxifloxacin matching placebo on Days -1 and 40
3170554|NCT01406262|Active Comparator|Albiglutide matching placebo + moxifloxacin|Once weekly subcutaneous injection of albiglutide matching placebo for 6 weeks, given with oral 400mg moxifloxacin tablet on Day -1 and moxifloxacin matching placebo on Day 40, or weekly albiglutide matching placebo for 6 weeks plus oral moxifloxacin matching placebo on Day -1 then oral 400mg moxifloxacin on Day 40
3170555|NCT01406249|Active Comparator|S-1,Cisplatin|
3170556|NCT01406249|Experimental|Capecitabine, Cisplatin|
3170557|NCT01406236|Other|Transradial PCI|
3170558|NCT01406236|Other|Transfemoral PCI|
3170559|NCT01406223|Active Comparator|varenicline|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks. During the time they receive varenicline, smokers in this group will also receive placebo bupropion and placebo patches.
3170560|NCT01406223|Active Comparator|NRT (nicotine patches only)|21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. After the 1st week, smokers in this group will also receive placebo bupropion and placebo varenicline.
3170561|NCT01406223|Active Comparator|varenicline + bupropion|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus bupropion at a dose of 150mg once per day. Subsequently, the dose of varenicline will be 1 mg twice per day and the dose of bupropion will be 150 mg twice per day, and will remain at that dose for the remainder of the 12 weeks. During the time they receive varenicline and bupropion, smokers in this group will also receive placebo patches.
3170562|NCT01406223|Placebo Comparator|Post-quit NRT|Nicotine patches at 21 mg/24 h for 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. After the 1st week, smokers in this group will also receive placebo bupropion and placebo varenicline.
3170563|NCT01406210||Prospective Group|Those patients that will be consented and data collected prospectively
3170564|NCT01406210||Retrospective Group|Those charts that will be utilized to collect retrospective data, waiver of consent will be granted by the IRBs.
3170565|NCT01406197|Experimental|Vaginal progesterone|vaginal 150 mg micronized progesterone cream delivered via a vaginal applicator; dosed daily (Prochieve, Columbia Laboratories)
3170566|NCT01406197|Experimental|Topical progesterone|topical 150 mg micronized progesterone gel applied to abdomen via a novel applicator; dosed daily
3170567|NCT01406197|Experimental|Intramuscular progesterone|injected IM (upper arm or thigh via syringe) 50mg/day micronized progesterone (Watson Pharmaceuticals)
3170568|NCT01406184|Experimental|Durham Connects Eligible Group|From July 1, 2009 - December 31, 2010, all even-birth-date residential births in Durham County, North Carolina were randomly assigned to receive the Durham Connects nurse home visiting program.
3170569|NCT01406184|No Intervention|Control Group|From July 1, 2009 - December 31, 2010, all odd-birth-date residential births in Durham County, North Carolina were randomly assigned to a control group condition. These families were assigned to receive services as usual and served as the randomized comparison group for evaluating Durham Connects program impact.
3170570|NCT01406171|Experimental|Isavuconazole and Midazolam|Isavuconazole three times per day (TID) for 2 days followed by once a day (QD) for 9 days. Midazolam single doses on days 1 and 12
3170574|NCT01406145|Experimental|ASP0777 low dose|ASP0777 low dose for 6 weeks
3170575|NCT01406145|Experimental|ASP0777 low dose, then high dose|ASP0777 low dose for 1 week and ASP0777 high dose for 5 weeks
3170576|NCT01406145|Experimental|ASP0777 high dose|ASP0777 high dose for 6 weeks
3170577|NCT01406145|Placebo Comparator|Placebo|Placebo for 6 weeks
3170578|NCT01406132|Experimental|ASP015K|
3170579|NCT01406119|Experimental|ABT-806 Arm|
3170580|NCT01406106|Experimental|Liquid yoghurt with plant stanol esters|"Dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g).~It also contains: proteins 1.8 g, carbohydrates 9.8 g, fat 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg."
3170581|NCT01406106|Placebo Comparator|Yoghurt without plant stanol esters|Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg.
3170582|NCT01406093||Candidemia patients|Patients with diagnosis of candidemia
3170583|NCT01406080|Active Comparator|Adapalene|Differin® gel 0.3% (adapalene Gel 0,3%)
3170584|NCT01406080|Active Comparator|Tretinoin|Tretinoin 0,05% emollient cream
3170585|NCT01406067|Experimental|Social Skills Training|
3170586|NCT01406067|Active Comparator|Play group|
3170587|NCT01406054|Experimental|neuromuscular training|subjects in this arm will be exposed to a neuromuscular warm-up before practices and games
3170588|NCT01406054|No Intervention|control|
3170589|NCT01406041||Diseases|1. Pituitary adenomas; 2. Craniopharyngioma; 3. Sellar germinoma; 4. Sellar tuberalis meningioma; 5. Hypophystis; 6. Sellar glioma; 7. Rathke's cleft cyst; 8. Hypothalamic hamartoma
3170590|NCT01406028|No Intervention|Standard of Care|Standard of care includes discharge instructions from one of our IVF nurses regarding medications and timing of follow-up, at which point patients are told what day they need to return for their pregnancy test. Patients have access to phone numbers for their IVF nurses and physicians, as well as information about how to contact the social workers if additional support is needed. They also are provided the emergency phone numbers for after-hour calls to the fellow on call. However, during the time between the embryo transfer and the pregnancy test, the current standard of care is that contact between the patient and our team is patient-initiated.
3170591|NCT01406028|Active Comparator|Intervention phone calls|The intervention consisted of two phone calls from an IVF social worker during the time between embryo transfer and pregnancy test. The first phone call occurred between days 2-4 after transfer and the second phone call occurred between days 5 and 9 after embryo transfer. Standard language for introductions to phone calls and for voice mails was established prior to the start of the study.
3170592|NCT01406015|Active Comparator|Spironolactone|
3170593|NCT01406015|Placebo Comparator|Placebo|
3170594|NCT01406002|Experimental|Treatment arm 1|darexaban, wash-out, rifampicin + darexaban
3170595|NCT01405989|Experimental|Treatment arm A|darexaban, wash-out, ketoconazole + darexaban
3170596|NCT01405989|Experimental|Treatment arm B|ketoconazole + darexaban, wash-out, darexaban
3170597|NCT01405976|Active Comparator|1|NIV for severe OSA group
3170598|NCT01405976|Active Comparator|2|CPAP for severe OSA group
3170599|NCT01405976|Active Comparator|3|Life stile modification for severe OSA group
3170600|NCT01405976|Active Comparator|4|NIV for non-severe OSA group
3170601|NCT01405976|Active Comparator|5|Life stile modification for non-severe OSA group
3170602|NCT01405963|Experimental|Active Arm|One dose level of AMG 157 administered as multiple IV doses in subjects with mild atopic asthma.
3170603|NCT01405963|Placebo Comparator|Placebo Arm|Placebo comparator administered as a multiple IV doses in subjects with mild atopic asthma
3170604|NCT01405950|Experimental|Dose Level 1|
3170605|NCT01405950|Experimental|Dose Level 2|
3170606|NCT01405950|Experimental|Dose Level 3|
3170607|NCT01405950|Experimental|Dose Level 4|
3170608|NCT01405937|Experimental|Vaniprevir 12 Week Arm|Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV
3170609|NCT01405937|Experimental|Vaniprevir 24 Week Arm|Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV
3170610|NCT01405924|Experimental|Fosaprepitant 150 mg|Women with breast cancer receiving anthracycline-cyclophosphamide (AC)-like chemotherapy and women with gynecological cancer receiving carboplatin-paclitaxel (CT) chemotherapy receive fosaprepitant 150 mg administered intravenously (IV) on Day 1 of Cycle 2 of chemotherapy
3170611|NCT01405911|Experimental|Sitagliptin 25 mg|Participant will take one tablet of sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks
3170612|NCT01405911|Experimental|Sitagliptin 50 mg|Participant will take one tablet of sitagliptin 50 mg and one tablet of placebo for sitagliptin 25 mg orally once daily for 8 weeks
3170613|NCT01405911|Placebo Comparator|Placebo|Participant will take one tablet of placebo for sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks
3170614|NCT01405898|Experimental|Beetroot Juice|
3170615|NCT01405898|Placebo Comparator|Nitrate-free beetroot juice|
3170616|NCT01405885|Experimental|Arm A - 0.9mg of INO-3605|
3170617|NCT01405885|Experimental|Arm B - 0.9mg of INO-3609|
3170618|NCT01405885|Experimental|Arm C- 0.9mg of INO-3401|
3170619|NCT01405885|Experimental|Arm D- 0.3mg of INO-3609|
3170620|NCT01405885|Experimental|Arm E - 0.45mg each INO-3605 , INO-3609|
3170621|NCT01405885|Experimental|Arm F - 0.3mg each of INO-3401,INO-3605,INO-3609|
3170622|NCT01405885|Experimental|Arm G - 0.9mg of INO-3609|
3170623|NCT01405885|Experimental|Arm H - 0.9mg of INO-3609|
3170624|NCT01405885|Active Comparator|Arm I - Seasonal influenza vaccine|
3170625|NCT01405885|Experimental|Arm J - 1.8mg of INO-3609|
3170626|NCT01405859||TS controls|10
3170627|NCT01405859||Non TS Controls|11
3170628|NCT01405859||TS remission|0
3170629|NCT01405846|Other|Gefitinib|Single arm study
3170630|NCT01405833|Experimental|BG00010 (Neublastin)|Participants may be randomized to escalating doses of BG00010
3170631|NCT01405833|Placebo Comparator|Placebo|Participants may be randomised to a matching placebo
3170632|NCT01405820|Active Comparator|Natalizumab 300 mg Intravenous (IV) Every 4 Weeks|Natalizumab 300 mg IV every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
3170633|NCT01405820|Experimental|Natalizumab 300 mg Subcutaneous (SC) Every 4 Weeks|Natalizumab 300 mg SC every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
3170634|NCT01405820|Experimental|Natalizumab 300 mg IV Every 12 Weeks|Natalizumab 300 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
3170635|NCT01405820|Experimental|Natalizumab 300 mg SC Every 12 Weeks|Natalizumab 300 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
3170636|NCT01405820|Experimental|Natalizumab 150 mg IV Every 12 Weeks|Natalizumab 150 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
3170637|NCT01405820|Experimental|Natalizumab 150 mg SC Every 12 Weeks|Natalizumab 150 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
3170638|NCT01405807|Experimental|Alemtuzumab - high dose (60mg)|Alemtuzumab 30mg will be administered on Day 1 and Day 2 at 0 and 6 months
3170639|NCT01405807|Experimental|Alemtuzumab - low dose (30mg)|Alemtuzumab 15mg will be administered on Day 1 and Day 2 at 0 and 6 months
3170640|NCT01405794|Experimental|32ppm Oral Silver|14 Days Active Silver Solution
3170641|NCT01405794|Placebo Comparator|Sterile Water|No Silver Nanoparticles
3170642|NCT01405768|Active Comparator|Lidocaine Arm|Women in this arm will receive plain lidocaine with epinephrine injected into their cervix prior to the LEEP procedure.
3170643|NCT01405768|Experimental|Buffered Lidocaine|Women in this arm will receive sodium bicarbonate buffered lidocaine mixed with epinephrine injected into their cervix prior to the LEEP procedure.
3170644|NCT01405755|Experimental|National Vaccine Program Plus Radio|Appropriate complementary feeding messages delivered using: (a) nurses during the 1st National Vaccination Week (NVW); and (b) radio.
3170645|NCT01405755|No Intervention|Comparison (no intervention)|No complementary feeding messages delivered.
3170646|NCT01405742|Experimental|Arm A|"The intervention for Arm A is 40 IU/kg recombinant factor VIII (rFVIII) by once-weekly intravenous injection for 26 weeks.~Cross-over will occur at 26 weeks after a 72 hour washout period, after which 40 IU/kg recombinant factor VIII (rFVIII) will be given thrice-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds."
3170647|NCT01405742|Experimental|Arm B|"The intervention for Arm B is 40 IU/kg recombinant factor VIII (rFVIII) by thrice-weekly intravenous injection for 26 weeks.~Cross-over will occur at 26 weeks after a 72 hour washout period, after which 40 IU/kg recombinant factor VIII (rFVIII) will be given once-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds"
3170648|NCT01405716|Active Comparator|Behavioral-Mindfulness|Mindfulness Meditation
3170649|NCT01405716|Placebo Comparator|Behavioral-Health|Health Education Class
3170650|NCT01405703||percuataneous plate fixation|an approach with three small longitudinal incisions
3170651|NCT01405703||open plate fixation|large transverse incision
3170652|NCT01405677|Experimental|Epaxal 0.25 mL|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
3170653|NCT01405677|Active Comparator|Epaxal 0.5 mL|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
3170654|NCT01405677|Active Comparator|Havrix Junior|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
3170655|NCT01405664|No Intervention|Non-Weight Bearing x 6 weeks|
3170656|NCT01405664|Experimental|Immediate Weight-Bearing as Tolerated|
3170657|NCT01405651|Experimental|E|ONO-6950
3170658|NCT01405651|Placebo Comparator|P|Placebo
3170659|NCT01405638|Experimental|Motivational Interviewing|The use of a one-on-one motivational interviewing counseling intervention, 4 visits over 5 months, focusing on changes to behavior related to blood pressure control.
3170660|NCT01405638|Experimental|Patient Navigation|The use of a patient navigation intervention to guide participants through the process of getting screened for colorectal cancer.
3170661|NCT01405638|Experimental|PLUS|This group receives both the motivational interviewing intervention and the patient navigation intervention.
3170662|NCT01405625|Active Comparator|AAAAI Action Plan|Asthma Action Plan from the American Academy of Allergy, Asthma, and Immunology
3170663|NCT01405625|Experimental|Asthma pictogram written action plan|Cartoon/pictogram-based written action plan sheet
3170664|NCT01405612|Experimental|Midazolam|Those subjects to receive Treatment A will receive a single dose of midazolam on Day 1 and will be discharged from the study unit on Day 2, at least 30 hours after midazolam dosing.
3170665|NCT01405612|Experimental|Ulimorelin|Those subjects to receive Treatment B will receive once daily ulimorelin on Days 1 to 5. Midazolam will be administered on Day 5 with the last dose of ulimorelin and subjects will be discharged from the study unit on Day 6, at least 30 hours after midazolam dosing.
3170666|NCT01405599|Experimental|Control|Healthy subjects
3170667|NCT01405599|Experimental|Severe hepatic impairment|CTP class C
3170668|NCT01405599|Experimental|Moderate hepatic impairment|CTP class B
3170669|NCT01405599|Experimental|Mild hepatic impairment|CTP class A
3170670|NCT01405586|Active Comparator|gemcitabine|
3170671|NCT01405586|Experimental|gemcitabine + cisplatin|
3170672|NCT01405573|Active Comparator|A: Best Supportive Care|best supportive care
3170673|NCT01405573|Experimental|B: Sorafenib 400 mg, twice a day + Best Supportive Care|sorafenib + best supportive care
3170674|NCT01405560|Experimental|Vaniprevir 24 Week Arm|Participants receive 24 weeks of vaniprevir (300 mg twice daily) with concomitant peg-IFN and RBV treatment
3170675|NCT01405534||Central venous catheter|All patients who require the placement of a central venous catheter
3170676|NCT01405521|Experimental|M01ZH09 vaccine|
3170677|NCT01405521|Placebo Comparator|Vaccine placebo|
3170678|NCT01405521|Other|Ty21a vaccine|Positive control
3170679|NCT01405508|Experimental|Placebo tablets / Brivaracetam bolus|"Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) bolus for 4.5 days.~Down-Titration:~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive Placebo tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
3170680|NCT01405508|Experimental|Brivaracetam (BRV) tablets / BRV bolus|"Subjects will receive Brivaracetam (BRV) tablets for one week followed by BRV bolus for 4.5 days.~Down-Titration:~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake bid for the fourth week"
3170681|NCT01405508|Experimental|Placebo tablets / Brivaracetam infusion|"Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) intravenous infusion for 4.5 days.~Down-Titration:~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
3170682|NCT01405508|Experimental|Brivaracetam (BRV) tablets / BRV infusion|"Subjects will receive Brivaracetam (BRV) tablets for one week followed by Brivaracetam intravenous infusion for 4.5 days.~Down-Titration:~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
3170683|NCT01405495||PTSD group|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
3170684|NCT01405495||Exposed without PTSD|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
3170685|NCT01405495||Healthy Controls|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
3170686|NCT01405482|Active Comparator|Botulinum Toxin Type A injection|Double-blind, randomized, placebo-controlled trial evaluating changes in pain, paresthesias, and function in subjects with TOS before, at six weeks, and four months following injection of BTX-A into the scalene muscles and pectoralis minor muscle under EMG guidance.
3170687|NCT01405482|Placebo Comparator|Normal Saline|Double-blind, randomized, placebo-controlled trial evaluating changes in pain, paresthesias, and function in subjects with TOS before, at six weeks, and four months following injection of placebo into the scalene muscles under EMG guidance.
3170688|NCT01405469|Experimental|Peroral Endoscopic Myotomy|Patients with achalasia who are designed to either get balloon dilatation or have botulinum toxin injection, or to have surgical intervention (Heller myotomy)for treatment
3170689|NCT01405456|Experimental|Eplerenone and Lifestyle|First 6 months: eplerenone 50mg daily along with lifestyle modification (counseling regarding lifestyle and diet, as well as following healthy activity guidelines) Second 6 months: same (eplerenone open label during second 6 months)
3170690|NCT01405456|Placebo Comparator|Placebo and Lifestyle|First 6 months: placebo pill daily along with lifestyle modification (counseling regarding lifestyle and diet, as well as following healthy activity guidelines) Second 6 months: eplerenone (open label) 50mg daily along with continued lifestyle modification
3170691|NCT01405443||Basic training|Theory lecture esophagogastroduodenoscopy (EGD). One hour simulator training for EGD. 30 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. One hour simulator training for Colonoscopy. 30 minutes supervised training. Supervised endoscopy. Group will be followed up for 2 weeks training time.
3170692|NCT01405443||Intermediate training|Theory lecture EGD. Three hours simulator training for EGD. 60 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. Three hours simulator training for Colonoscopy. 60 minutes supervised training. Supervised endoscopy. Group will be followed up for 4 weeks training time.
3170693|NCT01405443||Extended training|Theory lecture EGD. Five hours simulator training for EGD. 90 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. Five hours simulator training for Colonoscopy. 90 minutes supervised training. Supervised endoscopy. Group will be followed up for 6 weeks training time.
3170694|NCT01405430|Experimental|Bevacizumab + blood samples|
3170695|NCT01405417|Experimental|Peroral endoscopic myotomy|"Patients with achalasia who are designed to either have balloon dilatation or botulinum toxine injection, or to have surgical intervention (Heller myotomy) for therapy.~Peroral endoscopic myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips."
3170696|NCT01405404|No Intervention|No intervention control|Parents complete surveys only
3170697|NCT01405404|Experimental|parent training but no discount|parent enrolled in the parent training intervention but do not receive childcare discounts for attending
3170698|NCT01405404|Experimental|Parent training with discount|parents receive parent training and a childcare discount for attending
3170699|NCT01405391|Experimental|A|Patients will receive PM01183 on Days 1 and 8 q3wk (three weeks = one treatment cycle) as an i.v. infusion, starting at 3.0 mg/day, flat dose (FD), over a minimum total volume of 100 ml dilution (on 5% glucose or 0.9% sodium chloride) via a central catheter or over a minimum total volume of 250 ml via a peripheral line, over one hour (at a fixed rate) and through a pump device.
3170700|NCT01405378|Experimental|Robot Therapy and Real Transcranial Direct Current Stimulation|This group will involve carrying out robot therapy and real transcranial Direct Current Stimulation (tDCS).
3170756|NCT01405014|Experimental|Relationship enhancement group|One group, all involved in the intervention
3170701|NCT01405378|Placebo Comparator|Robot Therapy and sham tDCS|Participants will be randomised to group 2 whereby they will carry out the same robot therapy programme however, receiving sham stimulation.
3170702|NCT01405365|Experimental|Metronidazole|
3170703|NCT01405365|Placebo Comparator|Placebo|
3170704|NCT01405352|Active Comparator|Non obese/ vitamin A|Non obese individuals with body mass index 18.5-24.9 kg/m2 who receive 25000 IU/day vitamin A for 4 months .
3170705|NCT01405352|Placebo Comparator|obese/ placebo|obese individuals with body mass index greator than 30 kg/m2 who receive 1 cap placebo per day for 4 months .
3170706|NCT01405352|Active Comparator|Obese/ vitamin A|obese individuals with body mass index greater than 30 kg/m2 who receive 25000 IU/day vitamin A for 4 months
3170707|NCT01405339|Experimental|Budesonide via MAD|The current standard of care at St. Paul's Sinus Centre is to administer budesonide via the Mucosal Atomization Device (MAD). Its believed that MAD is a better device than the standard nasal lavage (Budesonide diluted in saline and delivered via Nasal Irrigation Bottle)because its fine mist and higher concentration enhances absorption and improves bioavailability.
3170708|NCT01405339|Active Comparator|Budesonide via Sinus Rinse Bottle|Budesonide via Sinus Rinse Bottle is the most commonly used delivery method.
3170709|NCT01405326|Experimental|Adalimumab|Adalimumab treatment for 6 months
3170710|NCT01405326|Placebo Comparator|Pacebo|Corresponding placebo for active treatment group
3170711|NCT01405313|Experimental|Modified ASV|Modified ASV Enhanced ASV algorithm which includes auto-adjusting expiratory pressure.
3170712|NCT01405313|Active Comparator|Conventional ASV|Conventional ASV This is the current (predicate) ASV algorithm.
3170713|NCT01405300|Experimental|Peanut|
3170714|NCT01405300|Placebo Comparator|Control|
3170715|NCT01405287|Experimental|Combo Stent|PTCA with Combo Stent
3170716|NCT01405287|Active Comparator|Everolimus Eluting Stent (EES)|PTCA with DES (Everolimus Eluting Stent: Xience V or Promus)
3170717|NCT01405274|Experimental|Physiotherapy intervention|
3170718|NCT01405274|No Intervention|standard care|
3170719|NCT01405261|Experimental|NNC 0113-0987 (gastro)|
3170720|NCT01405261|Experimental|NNC 0113-987 (coated)|
3170721|NCT01405261|Experimental|NNC 0113-987 (i.v)|
3170722|NCT01405248|Experimental|Butylphthalide|Single center of the placebo control a double-blind randomized control study to evaluate Butylphthalide prevention stents restenosis effect
3170723|NCT01405248|Placebo Comparator|control|Placebo
3170724|NCT01405235|Active Comparator|Arm B: Cisplatin/Topotecane|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
3170725|NCT01405235|Experimental|Arm A: Paclitaxel/Topotecan|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
3170726|NCT01405222||Acute COPD exacerbation|Patients admitted in to hospital with an acute exacerbation of COPD
3170727|NCT01405209||Atrial Fibrillation|Patients who develop atrial fibrillation
3170728|NCT01405209||Non Atrial FIbrillation|Patients without atrial fibrillation
3170729|NCT01405196|Other|10 mg of PF-04236921|
3170730|NCT01405196|Other|50 mg of PF-04236921|
3170731|NCT01405196|Other|200 mg of PF-04236921|
3170732|NCT01405196|Other|Placebo|
3170733|NCT01405183||Renal Cell Carcinoma patients|Newly diagnosed (within 6 months) renal cell carcinoma patients in who a biopsy or surgery will be performed
3170734|NCT01405183||Colorectal cancer patients|Newly diagnosed (6 months) colon cancer patients
3170735|NCT01405170|Experimental|methylprednisolone suspension|
3170736|NCT01405170|Active Comparator|methylprednisolone tablets|
3170737|NCT01405157|Experimental|methylprednisolone suspension|
3170738|NCT01405157|Active Comparator|methylprednisolone tablets|
3170739|NCT01405144|Active Comparator|5% 5-fluoruracil cream|30 patients will use 5% 5-fluoruracil cream, twice a day, during 3 weeks, in one randomized forearm
3170740|NCT01405144|Active Comparator|5% 5-fluoruracil peeling|The same 30 patients will be submitted to 4 applications of 5% 5-fluoruracil superficial peeling in the other forearm
3170741|NCT01405131|Experimental|methylprednisolone suspension|
3170742|NCT01405131|Active Comparator|methylprednisolone tablets|
3170743|NCT01405118|Experimental|Metformin/CP-690,550|
3170744|NCT01405105||Patients with Flares of IBD|Active flare of Crohn's or UC
3170745|NCT01405105||Control Group|Patients with quiescent Crohn's disease or UC
3170746|NCT01405092|Placebo Comparator|Standard volume management|patients on this arm will receive usual care volume management during continuous renal replacement therapy
3170747|NCT01405092|Active Comparator|continuous volume management|use of Critline, Hemametrics USA, in conjunction with continuous renal replacment therapy to determine volume removal
3170748|NCT01405079|Experimental|Gefitinib|Gefitinib 250 mg/day oral daily
3170749|NCT01405079|Active Comparator|Vinorelbine+Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
3170750|NCT01405066|Experimental|Dose Reports and Educational Seminar|
3170751|NCT01405053|Active Comparator|Rufinamide|
3170752|NCT01405053|Active Comparator|Any other approved AED|
3170753|NCT01405040||EV1000 Observational Group|Patient must have an indwelling femoral arterial catheter and central venous catheter considered necessary for routine clinical monitoring; Patient, or legal guardian, will give consent prior to study enrollment and data capture; Patient must be at least 18 years old; Patient height and weight are available prior to study.
3170754|NCT01405027|Other|Group A - HCEE|Group A - CLDF Hepatology Centers of Educational Expertise (HCEE) are hepatologists experienced in educating health professionals about current developments in the management of chronic liver disease and with clinical trial experience using an HCV protease inhibitor. HCEE investigators provided patient education and management skills training during four (4) educational interventions to Community Site investigators.
3170755|NCT01405027|Other|Group B - Community Sites|Group B - community physicians treating HCV but without clinical trial experience with an HCV protease inhibitor received patient education and management skills training from Hepatology Centers of Educational Expertise (HCEEs) during four (4) educational interventions.
3170757|NCT01404988|Experimental|Telephone-Delivered BI|Comprehensive behavioral intervention (BI) - Participants will receive the BI that is based on the transtheoretical model, which targets stage of change, decisional balance and self-efficacy, while also assessing and counseling regarding the barriers and facilitators of HF care, and to improve self-regulatory care such as self-monitoring, self-evaluation, feedback and reinforcement.
3170758|NCT01404988|Experimental|Telephone-Delivered BEI|Behavioral & Environmental Intervention (BEI) - Participants in this arm will receive the BI but will also receive environmental tailoring. Environmental Tailoring consists of Built Environment Tailoring (BET) where the intervention will incorporate aspects from the patients' environment, such as accessibility of health food stores or recreational facilities. Environmental Tailoring also consists of Human Environment Tailoring (HET) which incorporates patients' social support. Caregivers will be enrolled for patients in this arm of the study and they will also receive health education.
3170759|NCT01404988|Placebo Comparator|Telephone-Delivered API|Attention Placebo Intervention (API) - patients will receive non-tailored counseling on general health topics.
3170760|NCT01404975|Experimental|Paravertebral Block|Patients randomized to receive PVB will have a continuous thoracic paravertebral block using local anesthetic after trans-apical aortic valve replacement. The patient will be placed in lateral decubitus position and under aseptic conditions the skin entry points will be 2.5-3cm from the spinal processes of the vertebra at a level of the proposed surgical incision. A 17G Touhy needle will be inserted perpendicular to the skin until the transverse process is contacted. After negative aspiration test an initial bolus of 8ml of plain ropivacaine 0.5% will be administered. This will be followed by a continuous infusion of 0.2% ropivacaine at 10 mL/hr. For break through pain additional doses of ropivacaine will be administered as required.
3170761|NCT01404975|Active Comparator|Standard intravenous opioid analgesia|"Patient Controlled Analgesia (PCA) :~PCA: the patients who are randomized to PCA group will receive standard of care for this modality."
3170762|NCT01404962|Other|Group 1|
3170763|NCT01404949|Experimental|Tretinoin and Arsenic Trioxide|This is a multicenter, phase II trial to study the efficacy of combined tretinoin and ATO in the treatment of newly diagnosed APL in an effort to reduce or eliminate the amount of standard chemotherapy required for long-term remission.
3170764|NCT01404936|Experimental|Interferon-2A + Chemotherapy|Interferon-2A 4 (x106 IU/m^2) subcutaneously Day 1 - 4 + ABVD Chemotherapy on Day 4 (ABVD: Adriamycin 25 mg/m2 intravenous (IV), Bleomycin 10 mg/m^2 IV, Velban 6 mg/m2 IV, and Dacarbazine 375 mg/m2 IV)
3170765|NCT01404923|Experimental|meteospasmyl|
3170766|NCT01404923|Active Comparator|standard of care|
3170767|NCT01404910|Experimental|Apheresis|Apheresis using Liposorber LA-15 System
3170768|NCT01404897|Experimental|Dietary Intervention: Control Diet|
3170769|NCT01404897|Experimental|Dietary Intervention: DASH-based diet|
3170770|NCT01404897|Experimental|Dietary Intervention: Modified DASH diet|
3170771|NCT01404884|Experimental|SUPRACOR|Treatment arm consisting of patients with history of myopia or myopic astigmatism who are also diagnosed with presbyopia.
3170772|NCT01404871|Active Comparator|Randomization to ECIT or CMI|Randomized trial of clomipramine or escitalopram
3170773|NCT01404871|Active Comparator|Open label Duloxetine|Open label trial of duloxetine
3170774|NCT01404858||Patients undergoing IVF|
3170775|NCT01404845|Active Comparator|B: patients with wet AMD in one eye.|group B: patients with wet AMD in one eye. In each group, A and B, half the patients will be randomized in a subgroup to Nutrof Total, and the other half in a subgroup to a food supplement not containing Lutein and Zeaxanthin.
3170776|NCT01404845|Active Comparator|A :patients without retinal pathology|"group A :patients without retinal pathology who underwent cataract surgery 1 month previously.~In each group, A and B, half the patients will be randomized in a subgroup to Nutrof Total, and the other half in a subgroup to a food supplement not containing Lutein and Zeaxanthin."
3170777|NCT01404819|Experimental|Experimental arm|Patients in this arm undergo anesthesia with Xenon.
3170778|NCT01404819|Active Comparator|Standard arm|Patients in this arm undergo standard anesthesia
3170779|NCT01404806|Experimental|GSK1349572|
3170780|NCT01404793||Liver transplant recipient|
3170781|NCT01404780|Experimental|The GlideScope (GVL)|
3170782|NCT01404780|Active Comparator|Macintosh direct laryngoscope (MDL)|
3170783|NCT01404767|Active Comparator|Metoprolol oral dose or Placebo infusion|
3170784|NCT01404767|Experimental|Esmolol infusion or Placebo oral dose|
3170785|NCT01404754|Placebo Comparator|Lactose (Inactive Placebo)|Participant receives inactive placebo during day-long experimental session. Mood, interpersonal closeness, psychological symptoms are measured before, during and after the session, and vital signs (blood pressure, heart rate, body temperature) are measured during the session.
3170786|NCT01404754|Active Comparator|3,4-methylenedioxymethamphetamine|Participant receives 125 mg MDMA possibly followed by 62.5 mg MDMA during a day-long experimental session. Mood, interpersonal closeness, psychological symptoms are measured before, during and after the session, and vital signs (blood pressure, heart rate, body temperature) are measured during the session.
3170787|NCT01404741|Active Comparator|5-azacytidine treatment until progress|5-azacytidine until progress
3170788|NCT01404741|Experimental|allogeneic stem cell transplantation|after 4 cycles 5-azacytidine and if donor available: allogeneic stem cell transplantation after reduced intensity conditioning
3170789|NCT01404728||Pelvic Malignancies|Women with Vaginal Stenosis
3170790|NCT01404715|Experimental|Metformin and Imatinib Co-Adminisdered|Subjects will be dosed with Metformin (1850 mg) in conjunction with imatinib (600mg).
3170791|NCT01404715|Experimental|Metformin Alone|Subjects will be dosed with Metformin alone (1850mg)
3170792|NCT01404702|Experimental|Zoledronic Acid and Interleukin-2|
3170793|NCT01404689|Experimental|Midazolam-Meperidine-Dexmedetomidine|midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and dexmedetomidine 1μg/Kg•hr infusion (30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)
3170794|NCT01404689|Sham Comparator|Midazolam-Meperidine|midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and placebo(saline) infusion(30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)
3170795|NCT01404676|Experimental|Vildagliptin, metformin|groupA:Vildagliptin 50 mg bid + Metformin 500-1000mg bid q day.
3171603|NCT01398839|Experimental|CXL Treatment|
3170796|NCT01404676|Active Comparator|glimepiride, metformin|groupB:Glimepiride 2 mg + Metformin 500-1000 mg bid q day.
3170797|NCT01404663|Experimental|stem cell recipients|The 4-12 years old patients with cerebral palsy who undergone bone marrow derived CD133 transplantation
3170798|NCT01404650|Experimental|AUY922|
3170799|NCT01404637|Experimental|Tamsulosin 0.4mg|
3170800|NCT01404637|Active Comparator|tamsulosin 0.2mg|
3170801|NCT01404611|Active Comparator|DF289|Ear drops
3170802|NCT01404611|Active Comparator|DF277|Ear drops
3170803|NCT01404611|Experimental|DF289 plus DF277|Ear drops
3170804|NCT01404598|Experimental|naproxcinod 750 mg bid|
3170805|NCT01404598|Experimental|naproxcinod 3000 mg od|
3170806|NCT01404598|Active Comparator|naproxen 500 mg bid|
3170807|NCT01404585|Placebo Comparator|Arm 1: Placebo|
3170808|NCT01404585|Experimental|Arm 2: BMS-817399 (200 mg)|
3170809|NCT01404585|Experimental|Arm 3: BMS-817399 (400 mg)|
3170810|NCT01404572|Active Comparator|Atazanavir + 10% aspartame|
3170811|NCT01404572|Active Comparator|Atazanavir + 4.2% aspartame|
3170812|NCT01404572|Active Comparator|Atazanavir + 4.2% aspartame and sucralose|
3170813|NCT01404559|Active Comparator|Prosthetic foot 1 (Ossur Variflex)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 1 (Ossur Variflex).
3170814|NCT01404559|Active Comparator|Prosthetic foot 2 (Ossur Ceterus)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 2 (Ossur Ceterus).
3170815|NCT01404559|Active Comparator|Prosthetic foot 3 (Endolite Elite Blade)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 3 (Endolite Elite Blade).
3170816|NCT01404559|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
3170817|NCT01404546|Experimental|Cost Free Pharmacotherapy|Participants assigned to the CF group received a starter kit (4-week supply) of cost-free quit smoking medication (nicotine replacement therapy, bupropion, or varenicline) and a pre-printed prescription to be filled by the patient at the end of the 4-weeks.
3170818|NCT01404546|Active Comparator|Usual Care Group|Participants assigned to the prescription only usual care group received a prescription for smoking cessation pharmacotherapy to be filled at their own cost at their local community pharmacy.
3170819|NCT01404533|Experimental|Iron supplement without food|
3170820|NCT01404533|Experimental|Iron supplement with food|
3170821|NCT01404533|Experimental|Iron fortificant with food|
3170822|NCT01404520|Experimental|Exercise based multimodal intervention|The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme
3170823|NCT01404520|No Intervention|Control Group|Control group receives usual care
3170824|NCT01404507|Active Comparator|Intracoronary abciximab|Intracoronary injection of bolus abciximab
3170825|NCT01404507|Active Comparator|Aspiration thrombectomy|Aspiration thrombectomy
3170826|NCT01404507|Active Comparator|Both use|Both use of intracoronary injection of bolus abciximab and aspiration thrombectomy
3170827|NCT01404481||Single use group|New catheter for each Clean Intermittent Self Catheterisation (CISC), then discard.
3170828|NCT01404481||Re use of catheters group|"Use same catheter for 1week- Cleaning with sunlight liquid soap, air dry or dry with lint free towel, store in a snap lock bag.~Discard catheter and snap lock bag at end of each week."
3170829|NCT01404468|Active Comparator|pulsed|
3170830|NCT01404468|Sham Comparator|control|
3170831|NCT01404468|Active Comparator|continuous|
3170832|NCT01404455|Other|Normal pulse pressure|pulse pressure <60mmHg
3170833|NCT01404455|Other|Wide pulse pressure|pulse pressure ≥60mmHg
3170834|NCT01404442|Active Comparator|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally .
3170835|NCT01404442|Active Comparator|midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
3170836|NCT01404442|Placebo Comparator|placebo|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
3170837|NCT01404429|Active Comparator|Methotrexate 7.5 mg per week|
3170838|NCT01404429|Experimental|Methotrexate 15 mg per week|
3170839|NCT01404403|Other|Stroke patients|
3170840|NCT01404390|Experimental|Arm 1|
3170841|NCT01404390|Experimental|Arm 2|
3170842|NCT01404377|Active Comparator|ropivacaine|treated group (ropivacaine infiltration)
3170843|NCT01404377|Placebo Comparator|placebo|placebo group : infiltration with saline solution
3170844|NCT01404364|Active Comparator|Intravitreal Triamcinolone|Patients with phthisis bulbi received 0,3ml intravitreal triamcinolone injection
3170845|NCT01404364|Active Comparator|Retrobulbar Chlorpromazine|Patients with refractory glaucoma and blind painful eye were submitted to 2,5mL Chlorpromazine retrobulbar injection
3170846|NCT01404351|Experimental|PEAK PlasmaBlade|
3170847|NCT01404351|Active Comparator|Standard of Care|The Standard of Care arm will consist of the scalpel for the skin incision and traditional electrosurgery for subcutaneous dissection.
3170848|NCT01404338|Active Comparator|Active Arm|1. Active arm/Target Lesion: Halobetasol 0.05% ointment applied under occlusion to be left in place for one week
3170849|NCT01404338|Placebo Comparator|Vehicle Arm|Vehicle arm/Comparator Lesion: Vehicle ointment applied under occlusion to be left in place for one week
3170850|NCT01404325|Experimental|Arm 1|centre specific CNI-based triple drug immunosuppression
3170851|NCT01404325|Experimental|Arm 2|quadruple immunosuppressive regimen consisting of everolimus, CNI, MPA and steroids
3170885|NCT01404065|Experimental|Active tDCS + visual illusion|Subjects will receive active tDCS while watching a visual illusion movie (legs walking on a treadmill). Stimulation will last for 20 minutes.
3170852|NCT01404312|Experimental|RPT plus INH Regimen (Arm A)|Participants will receive RPT (dosage based on their weight), 300 mg of INH, and 25 mg or 50 mg of pyridoxine (vitamin B6) each day during Weeks 1 to 4. During Weeks 5 to 36, participants will not receive any study medications.
3170853|NCT01404312|Active Comparator|INH Regimen (Arm B)|Participants will receive 300 mg of INH and 25 mg or 50 mg of pyridoxine (vitamin B6) each day during Weeks 1 to 36.
3170854|NCT01404299|Experimental|Supplementary Group|
3170855|NCT01404299|No Intervention|Control Group|
3170856|NCT01404286|Experimental|physical exercise|Experimental group: physical exercise Control group: no physical exercise
3170857|NCT01404286|No Intervention|Control group|
3170858|NCT01404273|Experimental|Meditation/Relaxation Response Training|
3170859|NCT01404260|Experimental|Gemcitabine +Carboplatin +Gefitinib|Arm A: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles, Gefitinib 250mg/d every cycle d15-25, and Gefitinib 250mg/d from d15 of last cycle until disease progression
3170860|NCT01404260|Active Comparator|Gemcitabine +Carboplatin|Arm B: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum4 cycles, observation until disease progression
3170861|NCT01404247|Experimental|OCT imaging in neonates|OCT imaging of all neonates, 38-42 weeks, enrolled in this study
3170862|NCT01404234|Experimental|Open-label AZLI|Participants received three 28-day courses of AZLI, each followed by 28 days off-treatment.
3170863|NCT01404208|Active Comparator|D-Cycloserine|
3170864|NCT01404208|Placebo Comparator|Sugar Pill|
3170865|NCT01404195|Experimental|Ensure Plus Advance, Supplement|Participating patients will be dispensed two bottles daily, one at breakfast and one in the evening, seven days a week.
3170866|NCT01404195|No Intervention|Control|without supplementation
3170867|NCT01404182|Experimental|Influenza vaccination|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
3170868|NCT01404169|Experimental|1|
3170869|NCT01404169|Placebo Comparator|2|
3170870|NCT01404156|Active Comparator|Neoadjuvant Chemotherapy|"NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)~1) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days~2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous intravenous infusionIV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2 PO BID (ECX)"
3170871|NCT01404156|Experimental|Neoadjuvant Chemoradiation|"1) -carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29~paclitaxel: 50 mg / m2 IV over 1 hour~carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.~Dose specifications:~Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy.~Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment."
3170872|NCT01404143|Active Comparator|Subscapularis Tenotomy|
3170873|NCT01404143|Experimental|Subscapularis Peel|
3170874|NCT01404130|Experimental|Isotretinoin therapy|0.5-1mg /kg titrated by clinical need and tolerance of each patient according to normal clinical practice
3170875|NCT01404117|Experimental|Laquinimod 0.6|GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 0.6 mg
3170876|NCT01404117|Experimental|Laquinimod 1.2|GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 1.2 mg
3170877|NCT01404117|Experimental|GA or IFN + Placebo|GA 20 mg/1mL or an IFN-B preparation + oral daily placebo
3170878|NCT01404104|Experimental|Temsirolimus (pre-surgery)|
3170879|NCT01404091|Experimental|Cohort 1: 40 milligram (mg) LY2940094|"40 mg LY2940094 was administered orally, one time only (it was originally expected that 100 mg LY2940094 would be administered).~If the receptor occupancy (RO) for a given dose is lower than 50%, (time to maximum concentration [tmax] or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
3170880|NCT01404091|Experimental|Cohort 2: 10 mg LY2940094|"The dose levels for subjects in Cohort 2 will be defined based on the results of the receptor occupancy (RO) data of previous cohort and the ongoing review of safety data. This dose was determined to be 10 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
3170881|NCT01404091|Experimental|Cohort 3: 4 mg LY2940094|"The dose levels for subjects in Cohort 3 will be defined based on the results of the receptor occupancy (RO) data of previous cohort(s) and the ongoing review of safety data. This dose was determined to be 4 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
3170882|NCT01404091|Experimental|Cohort 4: 20 mg LY2940094|"The dose levels for subjects in Cohort 4 will be defined based on the results of the receptor occupancy (RO) data of previous cohort(s) and the ongoing review of safety data. This dose was determined to be 20 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
3170883|NCT01404078|Active Comparator|SD Polycap without potassium|Single dose polycap without pottasium
3170884|NCT01404078|Experimental|DD Polycap plus potassium|Double Dose polycap with potassium
3171050|NCT01402947|Experimental|Ciprofloxacin + MMX placebo|
3170886|NCT01404065|Sham Comparator|Sham tDCS + visual illusion|Subjects will receive sham tDCS stimulation (30 seconds ramp up/ramp down) while watching a visual illusion movie (legs walking on a treadmill)
3170887|NCT01404065|Other|Healthy Subjects|Healthy subjects will receive both interventions (active and sham) in a randomized and counterbalanced order. Each stimulation session will be at least 1 week apart to prevent carry-over effects
3170888|NCT01404052|Experimental|Active tDCS + transcranial ultrasound|Subjects will undergo 20 minutes active tDCS in conjunction with transcranial ultrasound measurements.
3170889|NCT01404052|Sham Comparator|Sham tDCS + transcranial ultrasound|Subjects will receive sham tDCS in conjunction with transcranial ultrasound measurements.
3170890|NCT01404039|Experimental|Motor Learning (ML) sighted|"In this arm, subject will perform motor Learning with visual feedback - ML sighted.~There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session."
3170891|NCT01404039|Experimental|Motor Learning (ML) blind|"In this arm, subject will perform motor Learning without visual feedback - ML blind.~There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session."
3170892|NCT01404039|Placebo Comparator|Motor Learning (ML) control group|In this arm, subject will perform simple hand movements - control group. There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session.
3170893|NCT01404039|Experimental|Somatosensory Learning (SL sighted)|"In this arm, subject will perform sensory Learning with visual feedback - SL sighted.~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
3170894|NCT01404039|Experimental|Somatosensory Learning (SL blind)|"In this arm, subject will perform sensory Learning without visual feedback - SL blind.~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
3170895|NCT01404039|Experimental|Somatosensory Activation (S activation)|"In this arm, subject will receive simple sensory stimulation over their left index finger - Sactivation.~There will be an anticipated total of 10 subjects in this experimental arm.This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
3170896|NCT01404039|Placebo Comparator|Somatosensory Learning (SL) control group|"In this arm,the subjects will not receive any somatosensory input (SL control group).~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
3170897|NCT01404039|Experimental|Observational Task (OT) - real|In this arm, the subjects will perform an observational task - observation of hand movements. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
3170898|NCT01404039|Placebo Comparator|Observational Task (OT) - control group|In this arm, the subjects will perform a controlled observational task - observation of geometric shapes. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
3170899|NCT01404039|Experimental|Mental Imagery (MI) - real|In this arm, the subjects will perform mental imagery - mental imagery of finger movements. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
3170900|NCT01404039|Placebo Comparator|Mental Imagery (MI) - control group|In this arm, the subjects will perform a controlled task - simple mental calculation. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
3170901|NCT01404039|Experimental|transcranial direct current stimulation - tDCS real|tDCS will be applied over the motor cortex for 20minutes at an intensity of 2mA. 15 subjects will be enrolled. The subjects will undergo two interventions, real and sham in a counterbalanced randomized order. There will be at least 3 days between each experimental session.
3170902|NCT01404039|Placebo Comparator|transcranial direct current stimulation - tDCS sham|"tDCS will be applied over the motor cortex for 20minutes at an intensity of 2mA. The stimulation will be stopped after 30seconds.~15 subjects will be enrolled. The subjects will undergo two interventions, real and sham in a counterbalanced randomized order. There will be at least 3 days between each experimental session."
3170903|NCT01404026|Active Comparator|Active tDCS|Subjects will undergo 20 minutes of active tDCS stimulation.
3170904|NCT01404026|Sham Comparator|Sham tDCS|Subjects will undergo sham tDCS stimulation, where the current is only active for 30 seconds.
3170905|NCT01404013|Active Comparator|Montelukast|Monotherapy with Montelukast 10mg, take orally ,every night,for 8 weeks
3170906|NCT01404013|Active Comparator|ICS/LABA and Montelukast|Combination therapy with inhaled corticosteroid/β2 agonist 160/4.5ug,twice a day and Montelukast 10mg，take orally,every night for 8 weeks
3170907|NCT01404013|Active Comparator|ICS/LABA|Monotherapy with corticosteroid/β2 agonist 160/4.5ug,inhaled, twice a day, for 8 weeks
3170908|NCT01404000|Active Comparator|Iodinated Active Charcoal|Iodinated activated charcoal 3 gram daily in the morning for 56 days +- 2 days (=8 weeks)
3170909|NCT01404000|Placebo Comparator|non-iodinated activated charcoal|3g non-iodinated activated charcoal is given daily for 8 weeks
3170910|NCT01403987|Active Comparator|Control Arm|Control group will receive standard teaching by the Residency Program regarding management of ascites and performance of paracentesis.
3170911|NCT01403987|Experimental|Intermediate Education Arm|In addition to the teaching provided by the residency program, the intermediate education group will receive a dedicated lecture by a gastroenterology fellow designed to teach consensus guidelines and their rationale in management of ascites. They will also receive a pocket card noting specific indications for paracentesis, and a brief summary of guidelines.
3170912|NCT01403987|Experimental|"Intensive Education Arm (Pager Arm)"|This group will receive the residency teaching, the specialist lecture, the pocket card, and have access to a pager carried by a gastroenterology fellow for personal assistance in performing paracentesis.
3170913|NCT01403974|Experimental|Monotherapy|BI 836845 dose escalation, infusion, once every week, monotherapy
3170914|NCT01403961||HbA1c > 7|Diabetic patients with HbA1c > 7
3170915|NCT01403961||HbA1c ≤ 7|Diabetic patients with HbA1c ≤ 7
3170916|NCT01403948|Experimental|Patients with relapsed or refractory NHL|Adult patients with relapsed or refractory non-Hodgkin lymphoma of B cell origin after at least two prior treatments
3170917|NCT01403922|Experimental|1|TC-5214
3170918|NCT01403922|Experimental|2|TC-5214 with placebo
3170919|NCT01403922|Experimental|3|TC-5214 with placebo
3170920|NCT01403922|Experimental|4|TC-5214
3170921|NCT01403909|Experimental|With compression|The patients randomized to this group will have intermittent pneumatic venous compression of the lower limbs during surgery.
3170922|NCT01403909|Active Comparator|Without compression|The patients randomized to this group will not have intermittent pneumatic venous compression of the lower limbs during surgery. (Standard care)
3170923|NCT01403896|Active Comparator|Plerixafor Group|
3170924|NCT01403896|Experimental|Plerixafor + G-CSF group|
3170925|NCT01403883|Active Comparator|Standard care|standard care of patient with psychological and enterostomal therapy clinic if necessary
3170926|NCT01403883|Experimental|Optimal care|Optimal care of patient with systematic and repeated psychological and enterostomal therapy follow up
3170927|NCT01403870||Low Back Pain Subjects|Subjects who have low back pain at the time of the study, and wish to receive physical therapy to reduce their low back pain.
3170928|NCT01403857|Experimental|Whole Grain|Whole grain products as defined by the American Association of Cereal Chemists (AACC) given in a market basket that contains eight commonly used grain products over six weeks.
3170929|NCT01403857|Placebo Comparator|Refined Grains|Time control compared to experimental intervention.
3170930|NCT01403844|Other|Skin Carotenoids|Skin carotenoids will be measured under conditions of depletion or repletion
3170931|NCT01403831|Experimental|Text messages|Patients randomized to this arm will receive daily text messages to their mobile phones consisting of educational materials, motivational materials, trivia questions, and challenges to engage in healthy lifestyle choices
3170932|NCT01403831|No Intervention|Control|
3170933|NCT01403818|Experimental|Part 1|"Subjects will receive ASP1941 alone and ASP1941 + Mitiglinide calcium hydrate in different orders."
3170934|NCT01403818|Experimental|Part 2|"Subjects will receive Mitiglinide calcium hydrate alone and ASP1941 + Mitiglinide calcium hydrate in different orders."
3170935|NCT01403805|Experimental|Oral care and vaccines|Oral care and pneumococcal plus influenza vaccines
3170936|NCT01403805|Active Comparator|Vaccine|Influenza vaccine only
3170937|NCT01403792|Experimental|Up to 7mg P2G12|
3170938|NCT01403792|Experimental|Up to 14mg P2G12|
3170939|NCT01403792|Experimental|Up to 28mg P2G12|
3170940|NCT01403792|Placebo Comparator|Placebo (saline solution)|
3170941|NCT01403779|Active Comparator|1-Hypofractionated IMRT|hypofractionated IMRT for right sided breast cancer
3170942|NCT01403779|Active Comparator|2-Normofractioated IMRT|normofractionated IMRT for left sided breast cancer
3170943|NCT01403766||Pediatric post-kidney transplant|Patients having standard of care surviellance biopsies.
3170944|NCT01403753||Non-clinical sample of children|
3170945|NCT01403740||Acquired haemophilia patients|
3170946|NCT01403727||Unassisted Biopsy - CONTROL GROUP|Routine biopsy needle placement and Physician blinded to needle location
3170947|NCT01403727||Assisted Biopsy - STUDY GROUP|The physician will be shown the PercuNav screen and will correct the desired approach path.
3170948|NCT01403714|No Intervention|Medical Management|Patients may be randomized to medical management alone
3170949|NCT01403714|Active Comparator|Renal Artery Stenting|Those patients with recent heart failure exacerbations that cannot be attributed to poor left ventricular function and have a hemodynamically significant renal artery stenosis may be randomized to renal artery stenting
3170950|NCT01403701|Experimental|Physical therapy|Standardized pelvic floor physical therapy
3170951|NCT01403701|No Intervention|routine care|Standard postoperative visits
3170952|NCT01403688||Random Fine Needle Aspiration (RPFNA)|RPFNA
3170953|NCT01403675|Experimental|Ovarian autotransplantation|
3170954|NCT01403662|Experimental|Minocycline|
3170955|NCT01403649|Experimental|Increasing flu vaccination|Collect from billing records in the 10 intervention practice sites to test for an increase in the rate of receipt of ≥1 influenza vaccine during the post-intervention year compared to the pre-intervention year among children 6 months to 18 years during the season. The interventions include: 1. Develop practice-based intervention strategies (like use of reminder-recall of children due for influenza,2. Develop Private/public collaboration to increase flu vaccination between the intervention practices, their county public health department and visiting nursing associations, and 3. Implement both practice-based and private-public collaborative strategies in the intervention practices while monitoring only in the control practices
3170956|NCT01403649|Other|Usual care|Patients in control practices will continue to receive usual care with no change in practice regarding influenza immunization delivery.
3170957|NCT01403636|Experimental|mantle cell|50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
3170958|NCT01403636|Experimental|follicular lymphoma|50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
3170959|NCT01403636|Experimental|CLL/SLL|50 mg twice daily:no eating for 2 hours prior and 1 hour after dose
3170960|NCT01403636|Experimental|Diffuse large B cell lymphoma|50 mg twice daily:no eating for 2 hours prior and 1 hour after dose
3170961|NCT01403623|Active Comparator|Resuscitation with plastic bag|Plastic bag will be used during and after resuscitation to assist with temperature regulation.
3170962|NCT01403623|Sham Comparator|Standard resuscitation- no plastic bag|Infant will be resuscitated per standard of care without being placed in a plastic bag for temperature regulation.
3171051|NCT01402947|Experimental|MMX Mesalazine/mesalamine + Ciprofloxacin|
3171052|NCT01402934|Experimental|fluid infusion|
3170963|NCT01403610|Experimental|TH-302 Preoperatively|Single center, dose-escalation, prospective study with TH-302 single dose at 575 mg/m2 administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 670 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302 (surgical subjects only).
3170964|NCT01403610|Placebo Comparator|Placebo|Single center, dose-escalation, prospective study with placebo administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 670mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302 (surgical subjects only).
3170965|NCT01403610|Experimental|TH-302 Non-Surgical|Subjects not receiving surgery will receive combination therapy of bevacizumab at 10 mg/kg every 2 weeks and TH-302 at 240 - 670 mg/m2 every 2 weeks (4 week cycles) starting from Cycle 1, Day 1 until disease progression.
3170966|NCT01403597|Experimental|Treatment|The defined areas for treatment are the entire face or at least two facial sub areas (e.g., peri-orbital and peri oral) with the combination of two devices where a total of 5 treatments every 4 weeks will be administered
3170967|NCT01403571|Experimental|Salba supplement|30g/1000kal
3170968|NCT01403571|Placebo Comparator|Oat-bran based Control Supplement|36g/1000kcal
3170969|NCT01403558|Experimental|CBT (with MI)|Ten weekly individual sessions before bariatric surgery aiming to improve dysfunctional eating behaviors
3170970|NCT01403558|No Intervention|Control group|Usual care consisting of up to three voluntary sessions with nutritionist and physiotherapist
3170971|NCT01403558|No Intervention|4 years follow-up|4 years follow-up of the intervention group
3170972|NCT01403545|Experimental|Liposomal Curcumin|Single dose, dose escalation
3170973|NCT01403545|Placebo Comparator|5% Glucose|
3170974|NCT01403532|Active Comparator|Traditional|
3170975|NCT01403532|Experimental|Sequential|
3170976|NCT01403532|Experimental|Sequential Plus|
3170977|NCT01403519||Alzheimer's disease patients|Patients blood and CSF samples
3170978|NCT01403519||Control group|Blood and CSF samples
3170979|NCT01403519||FTD patients|Blood ad CSF samples
3170980|NCT01403506|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine: receive N-Acetyl Cysteine in addition to standard treatment
3170981|NCT01403506|No Intervention|standard treatment|This group is without N-Acetyl Cysteine : just receives standard treatment
3170982|NCT01403493|Active Comparator|Multidisciplinary patient education|A multidisciplinary (nurse, gastroenterologist, dietician, physiotherapist, psychologist) group education with six sessions for patients with IBS.
3170983|NCT01403493|Active Comparator|Nurse based patient education|A nurse based patient education with three sessions for patients with IBS.
3170984|NCT01403467|Experimental|NIPPV|
3170985|NCT01403454|No Intervention|usual care|
3170986|NCT01403454|Active Comparator|Health Communication Application|
3170987|NCT01403441|Experimental|Radiosurgical Neuromodulation|Bilateral Radiosurgical Neuromodulation using the Cyberknife
3170988|NCT01403428|Experimental|NPPV plus standard of care|Noninvasive positive pressure ventilation (NPPV) plus standard of care in the management of children admitted to the hospital with status asthmaticus
3170989|NCT01403428|No Intervention|Standard of care|standard of care treatment in the management of children admitted to the hospital with status asthmaticus
3170990|NCT01403415|Experimental|Treatment (temsirolimus, combination chemotherapy)|Patients receive dexamethasone PO or IV on days 1-5 and 15-19; mitoxantrone hydrochloride IV over 30 minutes on days 1-2; temsirolimus IV over 30 minutes on days 1 and 8; vincristine sulfate IV on days 1, 8, 15, and 22; and pegaspargase IV over 1 hour on days 3 and 17. Some patients may also receive methotrexate IT up to 72 hours prior to or on day 1 and on day 8.
3170991|NCT01403402||Congenital Muscle Disease|The congenital muscle diseases include congenital muscular dystrophy, congenital myopathy, congenital myasthenic syndrome and bridge into the limb girdle/late onset spectrum. For data collection and analysis, subtype specific reports will be generated. True incidence of the congenital muscle diseases is unknown.
3170992|NCT01403389|Experimental|Eculizumab|
3170993|NCT01403389|Placebo Comparator|0.9% Sodium Chloride|
3170994|NCT01403376|Experimental|Teriflunomide 7 mg|Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months
3170995|NCT01403376|Experimental|Teriflunomide 14 mg|Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months
3170996|NCT01403376|Active Comparator|IFN-β-1|Influenza vaccine in participants treated with a stable dose of Interferon-β-1 (IFN-β-1) for at least 6 months
3170997|NCT01403363|Experimental|fentanyl patch|
3170998|NCT01403350|No Intervention|Current Practice|Study Phase I: No RDT or other parasite based diagnosis; Study Phase II: RDT used under the standard programme of training and support
3170999|NCT01403350|Active Comparator|Intervention Arm|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
3171000|NCT01403337|Placebo Comparator|Control|Blood pressure cuff inflated in the right or left arm to 40-50 mmHg
3171001|NCT01403337|Active Comparator|Preconditioning|The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP > 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.
3171002|NCT01403324|Other|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
3171003|NCT01403311|Experimental|ALA|5-Aminolevuline Acid (ALA)
3171004|NCT01403298|Active Comparator|Adolescent Only Health Promotion|An individual adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
3171005|NCT01403298|Experimental|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
3171006|NCT01403272|Experimental|DermaTherapy® Linen group|The DermaTherapy® Linen group uses bed sheets and underpads made with DermaTherapy® fabric.
3171007|NCT01403259|Experimental|S-1 plus oxaliplatin|S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks for 6 cycles
3171008|NCT01403233|Experimental|cogniVida™ 50 mg/day|
3171009|NCT01403233|Experimental|cogniVida™ 100 mg/day|
3171010|NCT01403233|Active Comparator|Rebaudioside-A 303.7 mg/day|
3171011|NCT01403220|Active Comparator|Group 1 (hemodiafiltration first)|This group of patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
3171012|NCT01403220|Active Comparator|Group 2 (hemofiltration first)|This group of patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
3171013|NCT01403207||knee osteoarthritis|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
3171014|NCT01403194|Experimental|CPAP/Bi-PAP|Subjects will be treated with either CPAP or Bi-PAP for three months.
3171015|NCT01403181||Chronic hepatitis C|"10 naïve genotype 1 chronic hepatitis C patients treated with PEG plus RBV (control arm)~20 naïve genotype 1 chronic hepatitis C patients treated with a response guided therapy consisting of Boceprevir in combination with PEG plus RBV (experimental arm)"
3171016|NCT01403168|Experimental|osteopathy + conventional analgesic treatments|
3171017|NCT01403168|Placebo Comparator|conventional analgesic treatments|
3171018|NCT01403155|Experimental|All subjects|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine) at Day o and Month 3.
3171019|NCT01403129||Keratoconus-Suspect|A person who has or is suspected of having keratoconus. Will have either or both Artemis-2 exam and OCT exam.
3171020|NCT01403129||Keratoconus-Related|A person who is genetically related to someone with keratoconus. Will have either or both Artemis-2 exam and OCT exam.
3171021|NCT01403129||Age-Matched Normal|"A person who is approximately the same age as subjects who have been enrolled in the study.~Will have either or both Artemis-2 exam and OCT exam."
3171022|NCT01403116|Experimental|Oral testosterone undecanoate (TU)|"Treatment Period 1: 100 mg capsules, BID, with food~Treatment Period 2: One of the following dosages:~100 mg BID~150 mg BID~100 mg BID~100 mg and 150 mg BID~150 mg capsules BID~Safety Follow-up Phase:~Initial dose: ~84 doses Maintenance dose—Titrated dose: ~96 doses Safety follow-up at maintenance dose: ~540 doses"
3171023|NCT01403116|Active Comparator|topical testosterone gel|"Treatment Period 1: 5 g of 1% transdermal T-gel applied QD~Treatment Period 2:~2.5 g of 1% transdermal T-gel applied QD~5 g of 1% transdermal T-gel applied QD~7.5 g of 1% transdermal T-gel applied QD~10 g of 1% transdermal T-gel applied QD~Safety Follow-up Phase:~Initial dose: ~42 doses Maintenance dose—Titrated dose: ~48 doses Safety follow-up at maintenance dose: ~270 doses"
3171024|NCT01403103|Experimental|Treatment (chemoprevention)|Patients receive cholecalciferol orally (PO) 7 days prior to scheduled surgery or endorectal ultrasound. Patients with sigmoid colon cancer or clinical stage I rectal cancer would proceed with surgical resection without preceding chemoradiation and will have a portion of normal colorectal mucosa and tumor tissue obtained for research purposes.
3171025|NCT01403090|Experimental|Angel Catheter|
3171026|NCT01403077|Experimental|Scaffold Treatment|
3171027|NCT01403064|Experimental|Open Label ALD518|
3171028|NCT01403064|Experimental|ALD518 Dose 1|
3171029|NCT01403064|Experimental|ALD518 Dose 2|
3171030|NCT01403064|Placebo Comparator|Placebo|
3171031|NCT01403051|Experimental|Arm A: EFV/FTC/TDF plus vitamin D3 and calcium carbonate|Participants were administered FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), calcium carbonate and vitamin D3 4000 IU.
3171032|NCT01403051|Experimental|Arm B: EFV/FTC/TDF plus vitamin D placebo and calcium placebo|Participants were administered FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), a placebo for calcium carbonate, and a placebo for vitamin D3.
3171033|NCT01403038|Experimental|Elagolix Dose Regimen 1|Elagolix Dose regimen 1 for 84 days
3171034|NCT01403038|Experimental|Elagolix Dose Regimen 2|Elagolix Dose Regimen 2 for 84 days
3171035|NCT01403038|Experimental|Elagolix Dose Regimen 3|Elagolix Dose Regimen 3 for 84 days
3171036|NCT01403038|Experimental|Elagolix Dose Regimen 4|"Elagolix Dose Regimen 4 for 84 days~Additional Dose Regimens may be added and will be administered for 84 days."
3171037|NCT01403038|Experimental|Elagolix Dose Regimen 5|Elagolix Dose Regimen 5 for 84 days
3171038|NCT01403038|Experimental|Elagolix Dose Regimen 6|Elagolix Dose Regimen 6 for 84 days
3171039|NCT01403038|Experimental|Elagolix Dose Regimen 7|Elagolix Dose Regimen 7 for 84 days
3171040|NCT01403025||Liraglutide|
3171041|NCT01402986|Placebo Comparator|Placebo, Q2W - Cohort 1|Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
3171042|NCT01402986|Experimental|Tralokinumab 300 mg, Q2W - Cohort 1|Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
3171043|NCT01402986|Placebo Comparator|Placebo, Q2/4W - Cohort 2|Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.
3171044|NCT01402986|Experimental|Tralokinumab 300 mg, Q2/4W - Cohort 2|Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.
3171045|NCT01402973|Experimental|High-AGE Diet|The high-AGE diet will be approximately four times higher in AGEs than the low-AGE diet.
3171046|NCT01402973|Experimental|Low-AGE Diet|The low-AGE diet will be approximately four times lower in AGEs than the high-AGE diet.
3171047|NCT01402960|Experimental|Active Anodal HD-tDCS|Subject will receive one 20-minute session of active anodal HD-tDCS.
3171048|NCT01402960|Experimental|Active Cathodal HD-tDCS|Subject will receive one 20-minute session of active cathodal HD-tDCS.
3171049|NCT01402960|Sham Comparator|Sham HD-tDCS|Subject will receive one sham session of HD-tDCS
3171053|NCT01402921|Experimental|Elastic Medical Compressive Therapy|"V0322BC verum medical compressive therapy is a progressive compressive sock with:~ankle pressure: 10 mmHg~calf pressure : 23 mmHg"
3171054|NCT01402921|Placebo Comparator|Placebo|"V0322BC placebo medical compressive therapy is a progressive compressive sock with:~ankle pressure: <5 mmHg~calf pressure : <7 mmHg"
3171055|NCT01402908|Experimental|PI-88|Arm 1
3171056|NCT01402908|Placebo Comparator|Placebo|Arm 2
3171057|NCT01402895|Active Comparator|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
3171058|NCT01402895|Active Comparator|Exercise|The physiotherapist will teach the participant how to tighten the transversus abdominus muscle. The participant will be asked to do a series of these exercises.
3171059|NCT01402882|Experimental|Tranexamic acid|
3171060|NCT01402882|Placebo Comparator|Placebo|(Sodium Chloride 0.9%)
3171061|NCT01402869|Experimental|Prilocaine|30 subjects will receive 5mg/kg of 4% prilocaine plain local anesthetic for restorative dental treatment under general anesthesia
3171062|NCT01402869|Experimental|Lidocaine|30 subjects will receive 2.5mg/kg of 2% lidocaine with 1:100,000 epinephrine local anesthetic for restorative dental treatment under general anesthesia
3171063|NCT01402869|No Intervention|No local anesthetic|30 subjects will not receive local anesthetic for dental treatment under general anesthesia-Negative control
3171064|NCT01402856||Southern Lehigh HS, PA School District|This school will not receive the education, yet, will be surveyed, quizzed and observed at the same time.
3171065|NCT01402856||Bethlehem HS, PA Area School District|Freedom & Liberty HS's in Bethlehem, PA will serve as the study's control group.
3171066|NCT01402856||Phillipsburg HS, NJ Area School District|This school will not receive the education, yet, will be surveyed, quizzed and observed at the same time.
3171067|NCT01402843|Experimental|pitavastatin + valsartan|
3171068|NCT01402843|Placebo Comparator|pitavastatin + placebo|
3171069|NCT01402843|Placebo Comparator|valsartan + placebo|
3171070|NCT01402843|Placebo Comparator|placebo|
3171071|NCT01402830||001|Visual analogue scales (EVAs) This scale measures the pain intensity.
3171072|NCT01402817|Experimental|Sutent®/Sunitinib|Upon enrollment, subjects will receive Sutent® orally. Adults (Age >18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.
3171073|NCT01402804||Stable CAD, ASA, NSAID|
3171074|NCT01402804||Stable CAD, ASA|
3171075|NCT01402791||The study population|All patients included according to state inclusion and exclusion criteria.
3171076|NCT01402778||Cather fixation by tunneling and suture|
3171077|NCT01402778||Catheter fixation by adhesive tape|
3171078|NCT01402765|Active Comparator|Group 1 (Summit first)|In Group 1 pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
3171079|NCT01402765|Active Comparator|Group 2 (Nimbus 3 first)|In Group 2 pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
3171080|NCT01402752|Experimental|All patients|All patients included in this study according to stated inclusion and exclusion criteria.
3171081|NCT01402739|Experimental|PoC algorithm guided transfusions|experimental arm
3171082|NCT01402739|Active Comparator|standard of care transfusions|control arm
3171083|NCT01402726|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with heart failure.
3171084|NCT01402726|No Intervention|Absolute medicine therapy|Maintenance of anti-heart failure medications only
3171085|NCT01402713|Experimental|GC1107-T5.0|Dosage: 0.5ml
3171086|NCT01402713|Experimental|GC1107-T7.5|Dosage: 0.5ml
3171087|NCT01402713|Active Comparator|TD_PUR INJ /SK Td vaccine|The name: step 1(phase 2)-SK Td vaccine step 2(phase 3)-TD_PUR INJ Dosage: 0.5ml
3171088|NCT01402700|Experimental|Visi-Pro™ Balloon Expandable Stent System|The objective of the study is to confirm the safety and effectiveness of the Visi-Pro stent in the treatment of stenotic, restenotic or occluded lesions in the common and external iliac artery.
3171089|NCT01402687||Mucositis Positive|Participants who developed severe mucositis
3171090|NCT01402687||Mucositis Negative|Participants who did not develop severe mucositis
3171091|NCT01402674|Active Comparator|LPT|Subjects treated with phentermine for 2 years or more.
3171092|NCT01402674|No Intervention|APT|Patients treated with phentermine for 7 to 14 days.
3171093|NCT01402661||Rheumatoid Arthritis|Pts presenting to enrolling sites across the US are invited to enroll if eligible.
3171094|NCT01402648|Placebo Comparator|Dietary supplement|900 mg Maltodextrins
3171095|NCT01402648|Active Comparator|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside) + 750 mg non starch, insoluble and indigestible fiber (6% in lignin).
3171096|NCT01402635|Experimental|POCT lab|The patient group whose laboratory test perform by POCT chemistry analyzer.
3171097|NCT01402635|Active Comparator|central laboratory group(CLT)|The patients group whose laboratory test perform by central laboratory.
3171098|NCT01402622|Active Comparator|Control group|balanced anaesthesia with antiemetic prophylaxis
3171099|NCT01402622|Active Comparator|TIVA group|TIVA without antiemetic prophylaxis
3171100|NCT01402622|Active Comparator|TIVA-P group|TIVA with antiemetic prophylaxis
3171101|NCT01402609|Placebo Comparator|Control group, usual care|Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
3171147|NCT01402245|Active Comparator|PPV Group|Volunteers immunized with Pnc polysaccharide vaccine
3171148|NCT01402245|Active Comparator|PCV Group|Volunteers immunized with Pnc conjugate vaccine
3171102|NCT01402609|Experimental|electronic discharge communication tool|Patients allocated to the experimental arm will receive a copy of the discharge summary that is generated by the electronic discharge communication tool. The same copy is shared with their healthcare providers using an electronic, web-based, communication platform that allows communication between acute-care and community -care physicians. The electronic discharge communication tool allows physicians to start generating the discharge summary from time of admission to hospital.
3171103|NCT01402596|Active Comparator|Chloral hydrate|Children undergoing CT scanning will receive in this arm 50 mg per kg of rectal chloral hydrate.
3171104|NCT01402596|Active Comparator|Midazolam|Children undergoing CT scanning will receive in this arm 0,4 mg/kg of nasal midazolam.
3171105|NCT01402583||PEG IFN/Ribavirin|Subjects with Hepatitis C undergoing PEG IFN/Ribavirin treatment
3171106|NCT01402570|Experimental|Glutathione supplement|All subjects will be taking a glutathione supplement.Glutathione is a naturally occuring antioxidant and a nonessential amino acid.
3171107|NCT01402557|Active Comparator|Telephone Support Only|These participants receive telephone support only during the weight maintenance phase.
3171108|NCT01402557|Experimental|Telehealth|These participants receive telehealth support (with Internet-enabled digital video recorders) during the weight maintenance phase. These participants also receive telephone support monthly.
3171109|NCT01402544|Other|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg Intravitreal Injection, monthly, open-label, for the duration of 1 year
3171110|NCT01402531|Experimental|Submucosal Bevacizumab|200mg Bevacizumab, submucosal injection
3171111|NCT01402518||Per-oral endoscopic myotomy|
3171112|NCT01402505||Transvaginal NOTES sleeve gastrectomy|Transvaginal NOTES sleeve gastrectomy
3171113|NCT01402492|Experimental|BUP4+XR-NTX|4mg buprenorphine plus naltrexone for 8 weeks of treatment
3171114|NCT01402492|Experimental|BUP16+XR-NTX|16mg buprenorphine plus naltrexone for 8 weeks of treatment
3171115|NCT01402492|Placebo Comparator|PLB+XR-NTX|Placebo plus naltrexone for 8 weeks of treatment
3171116|NCT01402479|Active Comparator|ramipril|open label single arm trial
3171117|NCT01402466|Active Comparator|Standard Referral|Participants randomized to this arm will be referred to local HIV care resources
3171118|NCT01402466|Experimental|Project Bridge|Participants randomized to this arm will be given the Project Bridge intervention
3171119|NCT01402453|No Intervention|Control Subjects|Receive educational materials and a home BP monitor.
3171120|NCT01402453|Experimental|Intervention Subjects|Receive educational materials and a home BP monitor, as well as monetary incentives tied to amount of improvement in BP from baseline and a personalized intervention to internalize motivation for BP control. Monthly monetary incentives will cease after 6 months.
3171121|NCT01402440|Experimental|AEB071|
3171122|NCT01402427|Active Comparator|Verapamil|
3171123|NCT01402427|Placebo Comparator|Placebo|
3171124|NCT01402414|Active Comparator|NB-UVB|NB-UVB irradiations adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session.
3171125|NCT01402414|Active Comparator|Bath-PUVA|Phototherapy with UVA irradiation following bathing in psoralen water
3171126|NCT01402414|Active Comparator|NB-UVB plus salt water baths|Balneophototherapy with NB-UVB and 3% Dead Sea salt water baths
3171127|NCT01402401|Experimental|AUY922 + Trastuzumab|
3171128|NCT01402388|Experimental|Lifestyle intervention group.|
3171129|NCT01402375|Experimental|Hydrocodone (first trial)|Hydrocodone 5mg / Acetaminophen 500mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
3171130|NCT01402375|Active Comparator|Codeine (first trial)|Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
3171131|NCT01402375|Experimental|Oxycodone (for second trial)|Oxycodone 5mg / Acetaminophen 325mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
3171132|NCT01402375|Active Comparator|Codeine (for second trial)|Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
3171133|NCT01402375|Experimental|Oxycodone (third trial)|Oxycodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
3171134|NCT01402375|Active Comparator|Hydrocodone (third trial)|Hydrocodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
3171135|NCT01402362||Ethiopians participating in previous study, year 2000|
3171136|NCT01402336|Experimental|GnRH antagonist, SD #1 starting group|Start GnRH antagonist from stimulation day 1 during ovulation induction cycles
3171137|NCT01402336|Experimental|GnRH antagonist, SD #6 starting group|Start GnRH antagonist from stimulation day 6 during ovulation induction cycles
3171138|NCT01402336|Active Comparator|Conventional GnRH agonist long group|Conventional GnRH agonist long protocol
3171139|NCT01402323|Other|early or late tooth extraction|
3171140|NCT01402310||Women attending antenatal clinic|Women attending antenatal clinic were consecutively enrolled at between 39+6 and 40+1 weeks of gestation.
3171141|NCT01402297|Experimental|COPD patients|Thirteen nonsmoking patients, suffering from GOLD II and GOLD III stage participated in the study (mean age 57 years (range 42-79), 9 men, 4 women). COPD was diagnosed based on GOLD 2009 criteria. All the participants were diagnosed at Department of Clinical Physiology, Medical university of Lodz.
3171142|NCT01402284|Experimental|Carfilzomib, Lenalidomide, Dexamethasone|Patients will receive 8 cycles of induction combination therapy of carfilzomib, lenalidomide, and dexamethasone (CRd). Patients achieving stable disease or better after 8 cycles of CRd will receive lenalidomide extended dosing (phase I) for 12 cycles. After 12 cycles, patients will have the option to continue extended dosing (phase II) for one additional year
3171143|NCT01402271|Experimental|pazopanib in combination with paclitaxel and carboplatin|Phase I: Dose-escalation study of pazopanib in combination with paclitaxel and carboplatin given weekly in a group of patients with platinum-refractory or -resistant ovarian, fallopian tube or peritoneal carcinoma Phase II: Paclitaxel 30 mg/m² and Carboplatin 2.0 AUC weekly for 18 courses PLUS Pazopanib 400 mg daily
3171144|NCT01402271|Active Comparator|Paclitaxel and carboplatin only|Carboplatin AUC 2.7 and paclitaxel 60mg/m² weekly for 18 courses.
3171145|NCT01402258|Experimental|Tailored Internet-delivered CBT|Behavioral: Tailored Internet-delivered CBT
3171146|NCT01402245|No Intervention|Pneumonia group|Patients with Pnc pneumonia
3171149|NCT01402232||coronary angiography|We recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention.
3171150|NCT01402219|Active Comparator|Iopamiro-370|
3171151|NCT01402219|Active Comparator|Visipaque 320|
3171152|NCT01402206|Other|Structured patient visits|Participants in the intervention group visit their general practitioner at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation.
3171153|NCT01402206|Other|Treatment as usual|The control group receives treatment as usual by general practitioner (no intervention).
3171154|NCT01402193|Active Comparator|Study Arm|"Investigational treatment: Arimidex commenced before and continued during radiotherapy.~Interventions:~Drug: Pre-radiotherapy commencement of Arimidex Radiation: Radiotherapy"
3171155|NCT01402193|Active Comparator|Control Arm|"Standard Treatment: Arimidex delayed until 2 weeks after radiotherapy~Interventions:~Radiation: Radiotherapy Drug: Post radiotherapy commencement of Arimidex"
3171156|NCT01402180|Experimental|A|Patients randomized in Arm A will receive chemoradiation and weekly Nimotuzumab for 6 weeks concurrent with radiation
3171157|NCT01402180|Active Comparator|B|Patients randomized in Arm B will receive chemoradiation only
3171158|NCT01402167|Experimental|Kyphoplasty|Patients randomized to this arm will be treated via balloon kyphoplasty.
3171159|NCT01402167|Active Comparator|Vertebroplasty|Patients randomized to this arm will be treated via vertebroplasty.
3171160|NCT01402154||All study patients|All patients included according to stated inclusion and exclusion criteria.
3171161|NCT01402141|Experimental|Chungkookjang|
3171162|NCT01402141|Placebo Comparator|Placebo|
3171163|NCT01402128|Experimental|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
3171164|NCT01402128|Placebo Comparator|Placebo|Placebo for 12 weeks
3171165|NCT01402115|Experimental|Polycan|Polycan 150mg for 12 weeks
3171166|NCT01402115|Placebo Comparator|Placebo|Placebo 15mg for 12 weeks
3171167|NCT01402102|Experimental|Aged garlic powder|
3171168|NCT01402102|Placebo Comparator|Placebo|
3171169|NCT01402076|Experimental|Steady State PK Group|
3171170|NCT01402076|Experimental|No steady state PK|
3171171|NCT01402063|Experimental|radiation plus PPX(CT2103|"Radiation therapy, Monday through Friday, for 6 weeks for a total of 30 treatments~+ intravenous PPX every week x 6 weeks for a total of 6 treatments"
3171172|NCT01402063|Active Comparator|radiation + Temozolomide|"Radiation therapy, Monday through Friday, for 6 weeks for a total of 30 treatments~+ Daily oral temozolomide(TMZ) (7 days) x 6 wks for a total of 42 days"
3171173|NCT01402050|Active Comparator|FOLEY BALLOON|Comparing foley balloon to cervidil for decreased time from the start of the induction process to delivery
3171174|NCT01402050|Active Comparator|CERVIDIL|
3171175|NCT01402037|Other|NDP 12-39 y|In newly diagnosed patients a hyperglycemic clamp tests will be performed within 4 weeks after diagnosis and 6, 12, 18 and 24 months later in 40 patients. The clamp will not be carried out in participants who became Cpeptide negative (defined as AUC C-peptide ≤ 0.03 nmol/L x min.) at a previous visit. HbA1c will be determined at the day of the clamp and glycemic variability during 5 days starting immediately after the clamp procedure. Insulin requirements and severe hypoglycemia (defined as an episode in which a patient required the assistance of another person and which was associated with a blood level of < 50 mg/dL or prompt recovery following intravenous glucose, glucagon or oral carbohydrate) will be recorded
3171176|NCT01402037|Other|NDP 5-12 y|Ten childhood-onset patients (under age 12) will be tested for 5 days with CGM (without clamp) and their glycemic variability compared with that of 10 patients aged 12-17 years at diagnosis.
3171177|NCT01402037|Other|FDR 12-39 y|In first degree relatives of type 1 diabetes patients a hyperglycemic clamp tests will be performed at inclusion and 6, 12, 18 and 24 months later in 40 high-risk first-degree relatives (see previous definition) with a non-diabetic OGTT performed 1 to 2 weeks before the clamp procedure. An OGTT result suggestive of diabetes will be confirmed and the relative will be offered participation in the patient arm of the study. HbA1c will be determined at the day of the OGTT and glycemic variability during the 5 days preceding the OGTT procedure.
3171178|NCT01402037|Other|FDR 5-12 y|"Ten high-risk first-degree relatives (see criteria) aged 5 to 12 years will also be tested for CGM and their results correlated with beta-cell function derived from a mini-clamp procedure (first 10 min. C-peptide release in hyperglycemic clamp) and results (CGM and first clamp phase) from relatives aged 12-17 years."
3171179|NCT01402024|Experimental|Aprepitant|It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy. Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm. The patient on aprepitant arm will receive the study drug (aprepitant)along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
3171180|NCT01402024|Placebo Comparator|Control|It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy. Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm. The patient on the control arm will receive the placebo along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
3171181|NCT01402011|Experimental|25% dextrose in shoulder entheses|25% dextrose and .1% lidocaine injected in the shoulder entheses (ligament and tendon insertions on the periosteum).
3171182|NCT01402011|Active Comparator|.1% lidocaine in shoulder entheses|.1% lidocaine injected in the shoulder entheses (ligament and tendon insertions on the periosteum).
3171183|NCT01402011|Placebo Comparator|.1% lidocaine subcu. above shouldr enth.|.1% lidocaine injected subcutaneously above the shoulder entheses (ligament and tendon insertions on the periosteum).
3171184|NCT01401985|Experimental|TD-1211|TD-1211
3171185|NCT01401959|Experimental|Cohort A: Triple-negative breast cancer|Eribulin 1.4 mg/m^2 intravenously (IV)
3171186|NCT01401959|Experimental|Cohort B: ER/PR+ /HER2- breast cancer|Eribulin 1.4 mg/m^2 intravenously (IV)
3171187|NCT01401959|Experimental|Cohort C: HER2+ breast cancer|"Eribulin 1.4 mg/m^2 intravenously (IV)~Trastuzumab 6mg/kg intravenously (IV)"
3171188|NCT01401946|Active Comparator|soy isoflavones|
3171189|NCT01401946|Placebo Comparator|Placebo|
3171191|NCT01401920||patients undergoing open heart surgery|small infant or children patients undergoing open heart surgery
3171192|NCT01401907|Experimental|Early Palliative Care|Subjects receive standard of care with early palliative care.
3171193|NCT01401907|No Intervention|Standard of Care|Subjects receives standard of care
3171194|NCT01401881||Post STEMI|The study population will consist of adult patients with acute STEMI and primary PCI with clear identification of symptoms onset, willing to participate in the research protocol and not having any of the exclusion criteria. Patient screening will take place after the primary PCI in the cardiac catheterization laboratory or in the coronary care unit. Participation will be offered to all those who meet eligibility criteria.
3171195|NCT01401868|Experimental|single arm|dose escalation
3171196|NCT01401855||In Vivo Probe Prediction|
3171197|NCT01401855||Cytology Results|
3171198|NCT01401842|Experimental|Strengthening Exercise|Lumbar ext. high intensity progressive resistance exercise
3171199|NCT01401842|Active Comparator|Stabilization Exercise|Low intensity core stabilization exercise
3171200|NCT01401829|Experimental|75 weekly minutes walking|12-week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week
3171201|NCT01401829|Experimental|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week
3171202|NCT01401829|Active Comparator|Stretching and Flexibility exercise|Stretching/Flexibility exercise
3171203|NCT01401816|Experimental|Intervention Group|Subjects in this group will receive a prescription for emergency contraception and then text-messages (on Day 1, 3 and 5 after enrollment) to their personal cell phone with a reminder to fill their prescription.
3171204|NCT01401816|No Intervention|Control Group|Subjects in this group will receive a only a prescription for emergency contraception and no reminder text messages.
3171205|NCT01401803|Other|Dysport|Dysport injections into the glabella and orbicularis oculi muscles with dose based on muscle mass.
3171206|NCT01401790|Experimental|Telehomecare|3 month use of a new telehomecare program
3171207|NCT01401790|Active Comparator|Control|3 month regular education program and follow up at the Diabetes Clinic
3171208|NCT01401777||Control, No PercuNav|Patient having procedure without PercuNav Guidance information
3171209|NCT01401777||PercuNav aided procedure|Biopsy procedure aided with use of PercuNav
3171210|NCT01401764|Other|Platform II, PASS, ARG 100|
3171211|NCT01401751|Other|Single Arm|non-randomized, uncontrolled, feasibility study
3171212|NCT01401725|Experimental|Hamilton General Hospital|
3171213|NCT01401725|Active Comparator|Juravinski Hospital|
3171214|NCT01401725|Other|St. Joseph's Hospital|
3171215|NCT01401712|Experimental|Paravertebral catheter (ON-Q® Pain Relief System)|
3171216|NCT01401712|Active Comparator|Thoracic epidural catheter|
3171217|NCT01401699|Experimental|Optical Frequency Domain imaging System|OFDI imaging
3171218|NCT01401660||Group A|Subjects who do not currently have low back pain.
3171219|NCT01401660||Group B|Subjects who have low back pain at the time of the study, and who are currently being treated or have been previously treated for their low back pain and do not wish to receive further treatment for their pain.
3171220|NCT01401660||Group C|Subjects who have low back pain at the time of the study, and wish to receive physical therapy to reduce their low back pain.
3171221|NCT01401647|Active Comparator|Amiodarone|Intravenous (IV) or intraosseous (IO) administration of amiodarone if VF/pulseless VT reoccurs after initial defibrillation.
3171222|NCT01401647|Active Comparator|Lidocaine|IV or IO administration of lidocaine if VF/pulseless VT reoccurs after initial defibrillation.
3171223|NCT01401647|Placebo Comparator|Normal saline|IV or IO administration of normal saline if VF/pulseless VT reoccurs after initial defibrillation.
3171224|NCT01401634|Other|Intravenous Fluids|Intravenous fluids for patients with hyperglycemia is part of the standard protocol in our department
3171225|NCT01401634|Experimental|Oral Fluids|
3171226|NCT01401621|Experimental|Scratch-Off Test Name Condition|The name of the test the recipient needs is hidden behind a scratchoff on the reminder
3171227|NCT01401621|Experimental|Scratch-Off Call to Action Condition|The recipient will be prompted to scratch-off the paper in order to find out how to follow the recommendation that the test be received.
3171228|NCT01401621|Experimental|Control Condition|A control condition with no scratch-off element.
3171229|NCT01401608||Treatment|Ablation of VT/PVCs using a magnetic RF ablation catheter
3171230|NCT01401595|Experimental|Night Eaters|Subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing. For women, a pregnancy test will also be administered no more than 48 hours before SPECT-CT imaging and the beginning of escitalopram oxalate (Lexapro) treatment. Escitalopram oxalate (Lexapro) open-label treatment will last 12 weeks. Dosing will start at 10 mg and increase to 20 mg per day flexibly. Treatment will be discontinued starting at 12 weeks under the supervision of our study physician.
3171231|NCT01401595|No Intervention|Control Subjects|"At the beginning of the study, control subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing.~An ADAM SPECT or SPECT-CT study of SERT binding will be conducted which will compare SERT binding of the 10 control subjects with that of the 30 night eating subjects. The first procedure will be to assess SPECT or SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls."
3171232|NCT01401582|No Intervention|care as usual|care as usual, no intervention, just observation of natural change/ trajectories over time
3171233|NCT01401582|Experimental|Implementation of Dementia Care Manager|"Subjects in this arm will be provided with a specialised Dementia Care Manager to be included in a subsidiary support system"
3171234|NCT01401569|Active Comparator|Control|All subjects (intervention and control groups) participate in a smoking cessation program composed of a pharmacological treatment (including nicotine replacement therapy or varenicline) and counseling.
3171277|NCT01401257|Experimental|PXT3003 High dose|Oral Liquid formulation, 1/10, bid, 12 months
3171235|NCT01401569|Experimental|physical activity program|Experimental group subjects were required to attend 2 supervised exercise sessions and 2 counseling sessions during Week 1 and Week 2. Supervised exercise and counseling sessions are realized successively. For Week 3 to 8, participants were required to attend 1 supervised exercise session and 1 counseling session plus 1 home exercise session.
3171236|NCT01401556|Experimental|Case Manager Intervention|Osteoporosis case-managers will identify older fracture patients in Emergency Departments and Fracture Clinics; arrange bone mineral density (BMD) tests; meet with patients to counsel them and go over their results; and then offer and prescribe bisphosphonate treatment to those with low BMD.
3171237|NCT01401556|Active Comparator|Multifaceted quality improvement intervention|Active-comparator control consisting of telephone-based education for patients and treatment guidelines with reminders for family physicians
3171238|NCT01401543|Active Comparator|5 mg LY2452473 + 5 mg Tadalafil|5 mg LY2452473 oral capsule and 5 mg tadalafil oral tablet, administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.
3171239|NCT01401543|Experimental|LY900010 (particle size #1)|Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a small particle size, administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.
3171240|NCT01401543|Experimental|LY900010 (particle size #2)|Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with an intermediate particle size, administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.
3171241|NCT01401543|Experimental|LY900010 (particle size #3)|Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a larger particle size, administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.
3171242|NCT01401530|Experimental|E7777|
3171243|NCT01401517|Placebo Comparator|Placebo|
3171244|NCT01401517|Experimental|40 mg Sodium Nitrite|40 mg dose, BID
3171245|NCT01401517|Experimental|80 mg Sodium Nitrite|80 mg dose, BID
3171246|NCT01401504|Experimental|ASP3026|
3171247|NCT01401491|Active Comparator|clozapine + fluvoxamine|
3171248|NCT01401491|Placebo Comparator|clozapine + placebo|
3171249|NCT01401478||Stage 5 Chronic Kidney Disease|Planned for Zemplar administration due to secondary hyperparathyroidism
3171250|NCT01401465|Experimental|Ciclesonide Nasal Aerosol|74 mcg ciclesonide nasal aerosol once daily
3171251|NCT01401465|Active Comparator|Mometasone Nasal Spray|200 mcg mometasone aqueous nasal spray once daily
3171252|NCT01401452||Participants with psoriasis and at least one co-morbid disease|Participants with moderate to severe plaque psoriasis with at least one co-morbid disease and/or symptom such as hypertension, psoriatic arthritis confirmed by a rheumatologist or other appropriate specialist, obesity, diabetes, metabolic syndrome or depression
3171253|NCT01401426|Active Comparator|Single incision laparoscopic vertical sleeve gastrectomy|Active Comparator Patients in this group will undergo laparoscopic vertical sleeve gastrectomy through a single periumbilical incision.
3171254|NCT01401426|Active Comparator|Five port laparoscopic vertical sleeve gastrectomy|Patients in this group will undergo conventional laparoscopic vertical sleeve gastrectomy using 5 small incisions.
3171255|NCT01401413|Placebo Comparator|1|placebo control nightly
3171256|NCT01401413|Active Comparator|2|8 mg ramelteon nightly
3171257|NCT01401400||(Peg) interferon|Patients who are treated for at least 12 weeks with (peg-)interferon for chronic hepatitis B
3171258|NCT01401387|Active Comparator|Standard treatment|Treatment with pancreatic enzymes after clinical sings and symptoms of steatorrhea and 10% decrease of weight at time of randomisation.
3171259|NCT01401387|Active Comparator|Preventive treatment|Patients will be prescribed with pancreatic enzymes immediately after diagnosis with pancreatic cancer, regardless of the presence of steatorrhea
3171260|NCT01401374||Vitiligo Patients|patients with vitiligo vulgaris
3171261|NCT01401374||Controls|Individuals without vitiligo vulgaris
3171262|NCT01401361|Experimental|Treatment Arm|Atrial Flutter RF Ablation treatment with the Contact Therapy Cool Path ablation catheter, 1500 T9 V1.43 RF Generator, Model 1611 connection cable, EnSite Velocity Contact™ Kit, and EnSite Velocity Contact software controlled via entitlement.
3171263|NCT01401335|Other|Trauma counseling|
3171264|NCT01401322|Experimental|Lenalidomide 50 mg/day x 28 days|Lenalidomide 50 mg daily for 28 consecutive days every 42 days (+/-7 days). Treatment to continue until evidence of disease progression or development of unexpected toxicities not reversed by dose reductions and/or interruptions.
3171265|NCT01401296|Active Comparator|Wait-list group|Subjects receive access to deprexis after eight weeks
3171266|NCT01401296|Experimental|Deprexis|Web-based intervention deprexis consists of ten online modules (plus one introductory and one summary module) representing different psychotherapeutic strategies with a strong focus on evidence-based cognitive-behavioral techniques (e.g. interpersonal skills). Each module lasts approximately 10-60 minutes (e.g. depending on the user´s reading speed). Modules are sequential and organized as simulated dialogues. Each module refers and builds upon previous one. The program is delivered at no cost to participants.
3171267|NCT01401283|Active Comparator|Study group|intraoperative guidance of hemodynamics by measures of cardiac index and pulse pressure variation, measurement of cardiac output and pulse pressure variation, hemodynamic optimization according to cardiac index and pulse pressure variation
3171268|NCT01401283|No Intervention|Control group|hemodynamic management according to institutional clinical standards
3171269|NCT01401270|No Intervention|Treatment Group A|Standard Care
3171270|NCT01401270|Experimental|Treatment Group B|100% probability of winning a prize with each draw and has 3 prize categories
3171271|NCT01401270|Experimental|Treatment Group C|31% probability of winning and has 3 prize categories
3171272|NCT01401270|Experimental|Treatment Group D|100% probability of winning and has 7 prize categories
3171273|NCT01401270|Experimental|Treatment Group E|31% probability of winning and has 7 prize categories
3171274|NCT01401270|Experimental|Treatment Group F|usual prize contingency management with a 50% probability of winning from 3 prize categories
3171275|NCT01401257|Experimental|PXT3003 Low dose|Oral Liquid formulation, 1/100, bid, 12 months
3171276|NCT01401257|Experimental|PXT3003 Intermediate dose|Oral Liquid formulation, 1/50, bid, 12 months
3171278|NCT01401257|Placebo Comparator|Placebo|Oral Liquid formulation, bid, 12 months
3171279|NCT01401244|Experimental|Norditropin®|
3171280|NCT01401244|Active Comparator|Genotropin®|
3171281|NCT01401231|Experimental|Behavioral Activation|Behavioral activation psychotherapy
3171282|NCT01401231|Placebo Comparator|Usual Care|Continued care as usual
3171283|NCT01401218||thoracic aortic surgery group|patients who underwent thoracic aortic surgery
3171284|NCT01401205||shoulder arthroscopic surgery group|the patients who undergo the elective shoulder arthroscopic surgery of rotator cuff repair
3171285|NCT01401192|Experimental|TS positive cohort & Gem/Cis Tx arm|Among TS expression positive patients, some will be randomized to Gem/cis therapy
3171286|NCT01401192|Active Comparator|TS+ cohort & Pem/Cis arm|Among patients with TS+, randomised to Pem/cis chemotherapy
3171287|NCT01401192|Active Comparator|TS negative cohort & Pem/Cis Tx arm|Among patients with TS-, some will be randomised to Pem/cis Tx arm
3171288|NCT01401192|Experimental|TS negative cohort & Gem/Cis Tx arm|Among patients with TS-, some will be randomised to Gem/Cis Tx arm
3171289|NCT01401179|Active Comparator|cefazolin|
3171290|NCT01401179|Active Comparator|cefazolin plus erythromycin|cefazolin, erythromycin
3171291|NCT01401179|Active Comparator|cefazolin plus clarithromycin|
3171292|NCT01401166|Experimental|Cohort 1: SC (SID) then IV Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via single-use injection device (SID), and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.
3171293|NCT01401166|Experimental|Cohort 1: IV then SC (SID) Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via SID. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.
3171294|NCT01401166|Experimental|Cohort 2: SC (Vial) then IV Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via handheld syringe using the vial formulation, and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.
3171295|NCT01401166|Experimental|Cohort 2: IV then SC (Vial) Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via handheld syringe using the vial formulation. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.
3171296|NCT01401153|Experimental|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water available on both days.
3171297|NCT01401153|Experimental|Skipping lunch/having lunch|No lunch on test day 1 and lunch ad libitum on test day 2. Water available on both days.
3171298|NCT01401140|Active Comparator|St Thomas|
3171299|NCT01401140|Experimental|Custodiol|
3171300|NCT01401127||Type 1 Diabetes|Participants with type 1 Diabetes running their insulin pump at 70% of usual basal rate
3171301|NCT01401127||Participants without diabetes|Participants without diabetes or evidence of impaired glucose regulation
3171302|NCT01401114||Group 1|Drug (incl. Placebo)
3171303|NCT01401101|Experimental|PTSD Care Management (PCM)|PCM has six intervention components: 1) patient education, 2) patient screening and written feedback of screening information to primary care clinicians, 3) clinician education on practice guidelines , 4) structured feedback between primary care and mental health clinicians, 5) continuity of patient care, and 6) a resource guide detailing available community services where the FQHC has established reciprocal referrals. All of the intervention components will be implemented through the CM, except for the clinician education component, which will combine onsite and online continuing medical education (CME)-accredited sessions.
3171304|NCT01401101|Placebo Comparator|Minimally Enhanced Usual Care (MEU)|The MEU condition consists of only the clinician education and patient screening without written feedback.
3171305|NCT01401088|Experimental|Artificial drainage implant|Aurolab Artificial Drainage Implant (AADI) on intraocular pressure reduction will be implanted in patients with refractory glaucoma.
3171306|NCT01401075|Active Comparator|doxifluridine|oral chemotherapy with the 5-FU prodrug doxifluridine
3171307|NCT01401075|Experimental|doxifluridine + mistletoe extract|oral chemotherapy with the 5-FU prodrug doxifluridine + mistletoe extract as subcutaneous injection
3171308|NCT01401062|Experimental|Arm 1 (Fresolimumab 1 mg/kg)|Fresolimumab is administered intravenously (i.v.) at a dose of 1 mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2).
3171309|NCT01401062|Experimental|Arm 2 (Fresolimumab 10 mg/kg)|Fresolimumab is administered intravenously (i.v.) at a dose of 10 mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2).
3171310|NCT01401049|Experimental|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
3171311|NCT01401049|Active Comparator|Propofol/Lidocaine|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol (a lipid based medication); Lusedra (a water based medication); and the drug combination of propofol with lidocaine (a local anesthetic commonly used with propofol injection).
3171312|NCT01401036|Active Comparator|Nobori|subjects receiving Biolimus A9 eluting stent implantation
3171313|NCT01401036|Sham Comparator|Uncoated stents|subjects receiving uncoated stent implantation
3171314|NCT01401023|Experimental|Clostridium difficile Patient|Open non-comparative trial
3171315|NCT01401010|Active Comparator|Doripenem 500 mg|pharmacokinetics/pharmacodynamics
3171316|NCT01401010|Active Comparator|Doripenem 1000 mg|pharmacokinetics/pharmacodynamics
3171317|NCT01400971||Insulin Progressors|
3171318|NCT01400971||Insulin non- progressors|
3171319|NCT01400958|Active Comparator|A: Nuvigil®|Study evaluation times correspond to standard follow-up evaluations for newly diagnosed malignant glioma patients. After 6 weeks of concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ), there is typically a 4 week treatment break prior to the start of the 6 monthly cycles of TMZ. No further placebo or Nuvigil® will be given after the 6 week treatment regimen. Thus, study evaluations will occur at baseline (Week 0), immediately after completion of EBRT, TMZ, and Nuvigil® or placebo (Week 7), at the end of the 4 week washout period (Week 10), after the first 2 cycles of TMZ (Week 18), and after the 6th cycle of TMZ (Week 34).
3171320|NCT01400958|Placebo Comparator|B: Placebo|Study evaluation times correspond to standard follow-up evaluations for newly diagnosed malignant glioma patients. After 6 weeks of concurrent EBRT and TMZ, there is typically a 4 week treatment break prior to the start of the 6 monthly cycles of TMZ. No further placebo or Nuvigil® will be given after the 6 week treatment regimen. Thus, study evaluations will occur at baseline (Week 0), immediately after completion of EBRT, TMZ, and Nuvigil® or placebo (Week 7), at the end of the 4 week washout period (Week 10), after the first 2 cycles of TMZ (Week 18), and after the 6th cycle of TMZ (Week 34).
3171321|NCT01400945|Experimental|S-Pantoprazole|Experimental drug: AGSPT201 Tab. (contain S-Patoprazole) Active comparator: Pantoloc Tab. (contain pantoprazole)
3171322|NCT01400932|Experimental|GI148512 (Benzoyl Peroxide 3% Gel)|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime. Comparison of 2 arms (GI148512 vs vehicle)
3171323|NCT01400932|Placebo Comparator|vehicle gel|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime.
3171324|NCT01400919|Experimental|Protégé™ EverFlex™ and GPS™ Self-Expanding Stent Systems|The objective of the study is to confirm the safety and effectiveness of the Protégé EverFlex and Protégé GPS Self-Expanding Stent Systems in the treatment of stenotic, restenotic or occluded lesions in the common and external iliac artery.
3171325|NCT01400906|Placebo Comparator|3 periods cross-over study|Each subject will receive each intervention BID during a 7 days period. The treatment periods are separated by 14 days washout. The sequence in which the interventions are administered are at random and double blind.
3171326|NCT01400893|Experimental|CRRT + SCD|Patients with a diagnosis of AKI requires CRRT will be randomized
3171327|NCT01400893|No Intervention|CRRT alone|Patients with a diagnosis of AKI requires CRRT will be randomized
3171328|NCT01400880||Pregnant|In Labor
3171329|NCT01400867|Experimental|Ceftaroline fosamil|
3171330|NCT01400867|Active Comparator|Comparators|Vancomycin +/- Aztreonam Cefazolin +/- Aztreonam
3171331|NCT01400854||Effentora®|Single group prospective treatment cohort
3171332|NCT01400841|Experimental|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
3171333|NCT01400828|Experimental|Bilastine|Intervention: Drug: Bilastine
3171334|NCT01400828|Active Comparator|Desloratadine|Intervention: Drug: Desloratadine
3171335|NCT01400828|Placebo Comparator|Placebo|Intervention: Drug: Placebo
3171336|NCT01400815|Experimental|X-22 Smoking Cessation Product|The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.
3171337|NCT01400815|Active Comparator|Active Control Cigarette|"The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette."
3171338|NCT01400802|Experimental|Listro Mix75/25®|Insulin Lispro/ insulin Lispro protamine (Listro Mix75/25®; 100 U/mL), DispoPen 3.0 mL.
3171339|NCT01400802|Active Comparator|Humalog Mix75/25®|Insulin Lispro/ insulin Lispro protamine (Humalog® Mix75/25TM; 100 U/mL), Humalog Mix 75/25® Kwik PenTM 3.0 mL.
3171340|NCT01400789|Experimental|ListroMix 50/50®|Insulin Lispro/ insulin Lispro protamine ( ListroMix 50/50®; 100 U/mL), DispoPen 3.0 mL.
3171341|NCT01400789|Active Comparator|Humalog Mix50/50®|Insulin Lispro/ insulin Lispro protamine (Humalog Mix50/50® ; 100 U/mL), Humalog Mix 50/50® Kwik PenTM 3.0 mL.
3171342|NCT01400776|Experimental|Vaginal Gel Three Times Weekly|Estradiol gel applied vaginally daily for 2 weeks, followed by dosing 3X/week for 10 weeks
3171343|NCT01400776|Placebo Comparator|Vehicle Twice Weekly|Vehicle Vaginal Gel applied daily for 2 weeks, followed by dosing 2X/week for 10 weeks
3171344|NCT01400776|Experimental|Vaginal Gel Twice Weekly|Estradiol gel applied vaginally daily for 2 weeks, followed by dosing 2X/week for 10 weeks
3171345|NCT01400776|Placebo Comparator|Vehicle Three Times Weekly|Vehicle Vaginal Gel applied daily for 2 weeks, followed by dosing 3X/week for 10 weeks
3171346|NCT01400750|Active Comparator|Ciproxin-inhaled Colistin|oral ciprofloxacin (30mg/kg/day) plus inhaled colistimethate sodium (Colistineb® 2x2 mill U daily) for 3 months
3171347|NCT01400750|Active Comparator|Tobramycine for inhalation (TIS)|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
3171348|NCT01400737|Experimental|ibuprofen|The patients in the control group were given 3 doses of an orange starch suspension as placebo that looked like ibuprofen.
3171349|NCT01400724|Experimental|Inofolic NRT|
3171350|NCT01400711|Active Comparator|ERAS patients|Patients planned to undergoing major intrabdominal surgery, following the ERAS perioperative care.
3171351|NCT01400711|Active Comparator|Control patients|Patients planned to undergo major intrabdominal surgery, following the conventional perioperative care.
3171352|NCT01400698|Experimental|Saizen® (Continuous or intermittent treatment)|
3171353|NCT01400698|Experimental|Saizen® (Observed and then continuous or no treatment)|
3171354|NCT01400698|Other|Observation only|
3171394|NCT01400386|Experimental|Soluble coffee 4|
3171651|NCT01398449|Active Comparator|A|After esophagectomy, patients in Arm A will receive adjuvant chemotherapy only
3171355|NCT01400672|Experimental|DIPG Patients Receiving Vaccine|Patients with diffuse intrinsic pontine glioma (DIPG) receiving radiation therapy, Tumor Lysate Vaccine (dose of 4 x 10^6 cells divided into 2 doses then every 4 weeks for up to 1 year) and Imiquimod (5% Aldara cream at a total dose of 12.5 mg) topically at each site prior to and 24 hours after vaccination.
3171356|NCT01400659|Active Comparator|CARB Counting|For CARB counting, insulin dose will be calculated according to the carbohydrate content of the test meal (1 carb unit = 10 g carbohydrate). The insulin-to-carbohydrate ratio will be applied according to the current individual therapy of the patient.
3171357|NCT01400659|Active Comparator|CFP counting|For CFP counting, insulin dose will be calculated according the carbohydrate content (1 carb unit = 10 g carbohydrate) as well as fat/protein content (1 FPU = 100 kcal from fat and protein) of the meal. The insulin-to-carbohydrate ratio will be applied according to the current individual therapy of the patient. The insulin-to-FPU ratio is the same as the insulin to carb ratio.
3171358|NCT01400646|Experimental|Rivaroxaban + Warfarin Concomitant Therapy Phase|Rivaroxaban monotherapy 20 mg/day for 5 days followed by Rivaroxaban 20 mg/day + Warfarin. 10 mg/day for >= 2 to <= 4 days concomitant therapy, then Warfarin monotherapy 0-15 mg/day for 4 days (Treatment Period 1). A 14-day washout period will separate Treatment Periods 1 and 2.
3171359|NCT01400646|Experimental|Warfarin Monotherapy Phase|Warfarin monotherapy 10 mg/day for >=2 to <=4 days, then Warfarin 0-15 mg/day for 4 days (Treatment Period 2). A 14-day washout period will separate Treatment Periods 1 and 2.
3171360|NCT01400633||001|decitabine injection decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
3171361|NCT01400620|Experimental|Active oral rinse|Oral rinse containing botanical extracts
3171362|NCT01400620|Placebo Comparator|Placebo rinse|
3171363|NCT01400607|Active Comparator|Neocartilage Implant|Neocartilage Implant surgically implanted and affixed to subchondral bone using commercial fibrin during mini-open knee arthrotomy.
3171364|NCT01400607|Other|Microfracture|Standard of care cartilage repair technique.
3171365|NCT01400594|Experimental|HTU-520 Patch|Subjects will receive HTU-520 patch in a 1:1 ratio for 48 weeks applied to all toenails.
3171366|NCT01400594|Placebo Comparator|Placebo Patch|Subjects will receive placebo patch in a 1:1 ratio for 48 weeks applied to all toenails.
3171367|NCT01400581|Experimental|Collaborative Care [CC] Intervention|The CC intervention will consist of offering subjects: 1) an in-depth baseline assessment, 2) frequent (weekly first, then monthly) visits with a nurse care manager, 3) alcohol dependence medications prescribed by a Nurse Practitioner. An interdisciplinary CC team will supervise nurse care managers weekly.
3171368|NCT01400581|No Intervention|Usual Care|Observational
3171369|NCT01400568|Experimental|LPS challenge and fluticasone propionate|In case LPS induced airway inflammation is reproducible, the effect of a single high dose of inhaled fluticasone propionate will be assessed after a 4-week wash-out period.
3171370|NCT01400555|Experimental|001|Cohort 1 Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
3171371|NCT01400555|Experimental|002|Cohort 2 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
3171372|NCT01400555|Experimental|003|Cohort 3 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
3171373|NCT01400555|Experimental|004|Cohort 4 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
3171374|NCT01400542||OSAS +|Patient with obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography
3171375|NCT01400542||OSAS -|Patient without obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography
3171376|NCT01400516|Experimental|Teriparatide|The participants who are in treatment arm received teriparatide 20 μg, subcutaneous injection, 1 injection per day, with a biologic for 12 months. A second year of teriparatide was offered to all interested participants. All participants received daily 1000 milligrams (mg) of calcium citrate, 800 IU of vitamin D and a Tumor Necrosis Factor (TNF) antagonist.
3171377|NCT01400516|Other|Control Arm|The participants randomized to the control arm had the same testing as those in the treatment arm and were offered teriparatide, if determined to be effective in healing bone erosions, after the first 12 months. All participants received daily 1000 mg of calcium citrate, 800 IU of vitamin D and a TNF antagonist.
3171378|NCT01400503|Experimental|Siltuximab|Siltuximab 11 mg/kg, intravenous infusion, given as a 1-hour infusion every 3 weeks.
3171379|NCT01400490|Placebo Comparator|Olive Oil 6 grams/day|
3171380|NCT01400490|Active Comparator|DHA 1800 mg/day|
3171381|NCT01400490|Active Comparator|EPA 1800 mg/day|
3171382|NCT01400490|Active Comparator|Fish Oil with EPA 1800 mg/day and DHA 1200 mg/day|
3171383|NCT01400477|Experimental|DMXB-A-SR|Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR), 3-2, 4 dimethoxybenzylidene anabaseine sustained release (GTS-21)
3171384|NCT01400477|Placebo Comparator|Arm #2: Placebo Comparator|Inert capsule to resemble active drug.
3171385|NCT01400451|Experimental|Ipilimumab + Vemurafenib|
3171386|NCT01400438|Experimental|patients group with Herceptin|Patients beginning Herceptin in adjuvant after chemotherapy
3171387|NCT01400438|Active Comparator|Control group|patient not beginning Herceptin after chemotherapy : control group
3171388|NCT01400425|Experimental|Subjects with Progressive Cognitive Decline|Subjects who have previously or are currently being evaluated for progressive cognitive decline. Enrolling physicians must have a confidence of less than 85% in their initial diagnosis of the subject's progressive cognitive decline and that there was at least a 15% chance that the subject's progressive cognitive decline was due to Alzheimer's disease. All subjects who did not complete the study withdrew before receiving a florbetapir F 18 injection and PET scan.
3171389|NCT01400412|Experimental|MVC Arm: DRV/r + MVC + FTC + TDF placebo|Darunavir 800 mg PO QD + Ritonavir 100 mg PO QD + Maraviroc 150 mg PO QD + Emtricitabine 200 mg PO QD + Placebo for Tenofovir disoproxil fumarate PO QD
3171390|NCT01400412|Experimental|TDF Arm: DRV/r + TDF + FTC + MVC placebo|Darunavir 800 mg PO QD + Ritonavir 100 mg PO QD + Emtricitabine 200 mg PO QD + Tenofovir disoproxil fumarate 300 mg PO QD + Placebo for Maraviroc PO QD
3171391|NCT01400386|Experimental|Soluble coffee 1|
3171392|NCT01400386|Experimental|Soluble coffee 2|
3171393|NCT01400386|Experimental|Soluble coffee 3|
3171395|NCT01400373|No Intervention|Control|Patients in the control group standard advanced cardiac life support care. Patients that achieve return of spontaneous circulation will be treated with hypothermia according to current guidelines upon arrival at the intensive care unit.
3171396|NCT01400373|Experimental|Intervention|Intra-arrest trans-nasal cooling with RhinoChill will be initiated during advanced cardiac life support. In patients achieving return of spontaneous circulation, trans-nasal cooling will continue until systemic cooling is started at the intensive care unit.
3171397|NCT01400360|Active Comparator|invasive|After proof of perfusion relevant CVS in interventional therapy should be performed as best possible combination from TBA and intraarterial vasodilators additional to the conventional treatment.
3171398|NCT01400360|No Intervention|conventional|After proof of perfusion relevant CVS only conventional treatment should be performed (no intraarterial therapy).
3171399|NCT01400334||Ischemic Cardiomyopathy|Subjects with ischemic cardiomyopathy [pre-enrollment left ventricular ejection fraction ≤0.35, with coronary artery disease documented by cardiac catheterization, a history of definite myocardial infarction, or reversible ischemia on nuclear imaging] who are considered eligible to receive an implantable cardiac defibrillator for the primary prevention of sudden cardiac death.
3171400|NCT01400321||Distal region|Patients with loss of tooth in the premolar and molar region of the atrophied mandible
3171401|NCT01400321||aesthetic zone|Patients with loss of tooth within the aesthetic zone (canine to canine)
3171402|NCT01400308|Active Comparator|Chlorhexidine + Mupirocin|"Will be treated with the protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07, as shown listed in Table 4. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)."
3171403|NCT01400308|Experimental|Prontoderm|Will be treated with the protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.
3171404|NCT01400295||coronary angiography|The investigators reviewed all consecutive patients who were undergoing coronary angiography
3171405|NCT01400282|Other|Sequence 1|Conventional stimulation (2 weeks)- High frequeny stimulation (2 weeks)- Conventional stimulation (2 weeks)and sham stimulation (2 weeks)
3171406|NCT01400282|Other|Sequence 2|Conventional stimulation (2 weeks)- sham stimulation (2weeks) - Conventional stimulation (2 weeks) - high frequeny stimulation (2 weeks)
3171407|NCT01400269|Experimental|Pacific Autism Center for Education (PACE)|Behavioral: Pacific Autism Center for Education (PACE) developmentally based parent delivered intervention
3171408|NCT01400243|Placebo Comparator|Placebo Patch|Placebo patch for 15-day quit period
3171409|NCT01400243|Active Comparator|Nicotine Patch|7 mg Habitrol nicotine patch-15 day quit period
3171410|NCT01400230||CCTA-IVUS-FFR|Patients suspected ischemic heart disease by the symptom and CCTA and undergone IVUS and FFR in the Cath Lab with CAG enrolled consecutively.
3171411|NCT01400217||IPDI EF HFA-BDP|Patients initiating inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
3171412|NCT01400217||IPDI SP HFA-BDP|Patients initiating inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
3171413|NCT01400217||IPDA SP HFA-BDP|Patients increased inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
3171414|NCT01400217||IPDA EF HFA-BDP|Patients increased inhaled corticosteroid therapy as extra fine particle HFA-BDP MDI at the index date
3171415|NCT01400217||IPDS SP HFA-BDP|Patients increased inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
3171416|NCT01400217||IPDS EF HFA-BDP|Patients increased inhaled corticosteroid therapy as extrafine particle HFA-BDP MDI at the index date
3171417|NCT01400204||MDMA|poly drug users that used MDMA at New Years Eve
3171418|NCT01400204||Other Drugs|poly drug users that used drugs at New Years Eve, but not MDMA
3171419|NCT01400204||Alcohol|poly drug users that used no drugs at New Years Eve, but did consume alcohol
3171420|NCT01400191|Active Comparator|Homozygote wildtype OCT1|
3171421|NCT01400191|Active Comparator|Heterozygote OCT1|
3171422|NCT01400191|Active Comparator|Homozygote OCT1 variant|
3171423|NCT01400165|Active Comparator|Desyrel/Teva-Trazodone|Both drugs will be given at the dose of 150 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication.
3171424|NCT01400165|Active Comparator|Visken/Teva-Pindolol|Both drugs will be given at the dose of 10 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication
3171425|NCT01400165|Active Comparator|Seroquel/Teva-Quetiapine|Both drugs will be given at the dose of 100 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication
3171426|NCT01400152|Active Comparator|Passive warming with additional active warming|
3171427|NCT01400152|No Intervention|Passive warming|
3171428|NCT01400139|Experimental|Hydrocodone bitartrate|Hydrocodone bitartrate (HYD) once daily (q24h) tablets
3171429|NCT01400113|Experimental|Asenapine|This group received 10mg asenapine sl x 1 dose
3171430|NCT01400113|Placebo Comparator|Placebo|This group received placebo sl x 1 dose
3171431|NCT01400100|Experimental|Octreotide|Study patients receive after randomization a single shot of 5 mL 500 µg Octreotide in the gastroduodenal artery at the time of its transection.
3171432|NCT01400100|Placebo Comparator|Control|Control patients receive after randomization a single shot of 5 mL 0,9% NaCL solution in the gastroduodenal artery at the time of its transection.
3171433|NCT01400087|Active Comparator|Cap-attached Colonoscopy|
3171434|NCT01400087|Placebo Comparator|Regular colonoscopy|
3171435|NCT01400074|Active Comparator|Nilotinib|400 mg twice daily
3171436|NCT01400074|Active Comparator|Imatinib|400 mg twice daily
3171437|NCT01400061||normal|body mass index: 19-24
3171438|NCT01400061||overweight|body mass index: 25-29
3171439|NCT01400061||obesity|body mass index: 30-40
3171440|NCT01400061||modbid obes|body mass index: over 40
3171441|NCT01400048|Active Comparator|Aloe vera effervescent tablet (AVH200)|
3171442|NCT01400048|Placebo Comparator|Placebo|
3171527|NCT01399463|Experimental|DEB + BMS|Paclitaxel drug-eluting balloon (DEB) dilatation and bare metal stenting
3171528|NCT01399463|Active Comparator|Stenting with commonly used Drug Eluting Stents (DES)|
3171443|NCT01400035||test group, control group|"Test group: Patients will be given cytidine diphosphate choline 0.4-0.5g, aspirin 75-100mg or Clopidogrel 75mg, intravenous infusion of Cavinton 30mg once a day.~Control group: Patients will be given cytidine diphosphate choline 0.4-0.5g, aspirin 75-100mg or Clopidogrel 75mg once a day."
3171444|NCT01400022|Active Comparator|Cortisone|
3171445|NCT01400022|Experimental|UVA1 phototherapy|
3171446|NCT01400009|Placebo Comparator|Placebo|Subjects in this group will receive a placebo tablet (Lactose 100 mg) for the duration of the study
3171447|NCT01400009|Active Comparator|Vitamin D|Subjects in this arm will receive a dose of 50,000 IU of vitamin D3, followed by weekly doses of 10,000 IU of vitamin D3
3171448|NCT01399996|Placebo Comparator|Yogurt smoothie without probiotic.|
3171449|NCT01399996|Experimental|Probiotic added post fermentation.|
3171450|NCT01399996|Experimental|Probiotic added pre-fermentation.|
3171451|NCT01399996|Experimental|A capsule containing the probiotic.|
3171452|NCT01399983||pulmonary hypertension|patients with pulmonary hypertension and with exercise-induced pulmonary hypertension take part
3171453|NCT01399970|Other|Outpatient Consultation Arm (OCA)|Conventional in Office Care
3171454|NCT01399970|Experimental|Mobile Teleconsultation Arm (MTA)|Mobile Teledermatology Care
3171455|NCT01399957||pwMS prescribed dalfampridine-ER|Anyone prescribed D-ER per usual clinical care was recruited into this observational study. All those willing to participate were consented and observed pre-drug and for a 14week period with two follow-up visits scheduled at 12 and 18months.
3171456|NCT01399931||Early-stage Hodgkin Lymphoma Patients|Early-stage Hodgkin Lymphoma (HL) patients presenting bulky nodal lesions treated with ABVD and consolidation radiotherapy
3171457|NCT01399918|Experimental|everolimus and bevacizumab|This is a single-institution, single-arm phase II trial of everolimus in combination with bevacizumab in patients with advanced non-clear cell RCC, who have not received prior VEGF-.or mTOR-targeted therapy. A separate cohort of patients with non-clear cell RCC with papillary features will be enrolled in order to gather information regarding the efficacy given the rarity of these entities.
3171458|NCT01399905|Experimental|High carbidopa followed by low carbidopa|450 mg of carbidopa per day for four weeks followed by 75 mg of carbidopa per day for four weeks
3171459|NCT01399905|Experimental|Low carbidopa followed by high carbidopa|75 mg of carbidopa per day for four weeks followed by 450 mg of carbidopa per day
3171460|NCT01399879||Healthy Volunteers|
3171461|NCT01399866|Placebo Comparator|Placebo|50 mg capsule,single dose, twice, one week apart, by mouth
3171462|NCT01399866|Active Comparator|D-cycloserine|50 mg capsule,single dose, twice, one week apart, by mouth
3171463|NCT01399853|Experimental|160U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 120 children aged 12-36 months old on day0,28
3171464|NCT01399853|Experimental|320U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 120 children aged 12-36 months old on day0,28
3171465|NCT01399853|Experimental|640U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 120 children aged 12-36 months old on day0,28
3171466|NCT01399853|Experimental|(without adjuvant) 640U /0.5ml in children (12-36months)|inactivated vaccine(vero cell) against EV71 of (without adjuvant) 640U /0.5ml in 120 children aged 12-36 months old on day0,28
3171467|NCT01399853|Experimental|160U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 120 infants aged 6-11 months old on day0,28
3171468|NCT01399853|Experimental|320U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 120 infants aged 6-11 months old on day0,28
3171469|NCT01399853|Experimental|640U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 120 infants aged 6-11 months old on day0,28
3171470|NCT01399853|Experimental|(without adjuvant) 640U /0.5ml in infants (from 6 to 11 months|inactivated vaccine(vero cell) against EV71 of (without adjuvant) 640U /0.5ml in 120 infants aged 6-11 months old on day0,28
3171471|NCT01399853|Placebo Comparator|0/0.5ml placebo in children (from 12 to 36 months old)|0/0.5ml placebo in 120 children aged 12-36 months old on day0,28
3171472|NCT01399853|Placebo Comparator|0/0.5ml placebo in infants (from 6 to 11 months old)|0/0.5ml placebo in 120 infants aged 6-11 months old on day0,28
3171473|NCT01399840|Experimental|Arm 1: BMN 673|Arm 1 will enroll patients with either AML or MDS
3171474|NCT01399840|Experimental|Arm 2: BMN 673|Arm 2 will enroll patients with either CLL or MCL
3171475|NCT01399827|Active Comparator|Omega-3 Fatty Acids|1060 mg EPA Omega-3 Fatty Acids
3171476|NCT01399827|Placebo Comparator|Placebo|
3171477|NCT01399814|Active Comparator|standard fluid regimen group|perioperative fluid treatment
3171478|NCT01399814|Experimental|restricted fluid regimen group|perioperative fluid treatment
3171479|NCT01399801|Experimental|hemodynamicaly guided LV lead placement|optimized left ventricular lead placement
3171480|NCT01399801|Active Comparator|Standard lead placement|Standard LV lead placement with no measurements to guide LV lead placement
3171481|NCT01399788|Active Comparator|1.0|Test Myrin P Forte Contains 150mg Rifampicin, 75mg Isoniazid, 275mg Ethambutol, 400mg Pyrazinamide
3171482|NCT01399788|Active Comparator|2.0|Reference Single drug reference preparations contain Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
3171483|NCT01399775|Experimental|immediate implantation|Immediately after tooth extraction, dental implant is inserted.
3171484|NCT01399775|Other|Delayed implantation|Four months after extraction, Dental implant is inserted.
3171485|NCT01399762||mechanical recanalization|Patients with acute stroke being treated with endovascular devices for mechanical recanalization (no restriction to specific endovascular devices)
3171486|NCT01399749|Experimental|Autologous ASC implantation|Treatment with autologous ASC
3171487|NCT01399749|Active Comparator|Autologous Chondrocytes implantation|Treatment with autologous chondrocytes
3171529|NCT01399450|Experimental|paliperidone add on|paliperidone add on
3171600|NCT01398878|Active Comparator|Intervention work schedule|Residents in the Intensive Care Unit perform shifts less than 16 hours in length and have at least 8 hours off between shifts
3171601|NCT01398852|Experimental|CXL Treatment|All eyes to be treated with riboflavin and UV light
3171488|NCT01399736|Active Comparator|FFR-guided revascularisation strategy|In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of >0.80 will not be treated.
3171489|NCT01399736|Placebo Comparator|randomised to guidelines group|In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
3171490|NCT01399723|Experimental|Amoxicillin 45mg/kg 12 hourly|
3171491|NCT01399723|Active Comparator|Benzyl Penicillin 50,000IU/kg 6 hourly|
3171492|NCT01399697|Experimental|A|
3171493|NCT01399697|Active Comparator|B|
3171494|NCT01399684|Experimental|MEGF0444A + mFOLFOX-6 + Bevacizumab|Participants will receive MEGF0444A + mFOLFOX-6 (oxaliplatin, folinic acid, and 5-fluorouracil) regimen + bevacizumab. Participants will receive oxaliplatin for up to 8 cycles (Cycle = 14 days) and 5-fluorouracil, folinic acid, bevacizumab and MEGF0444A will be administered until disease progression or unacceptable toxicity for a maximum of up to 52 cycles.
3171495|NCT01399684|Placebo Comparator|Placebo + mFOLFOX-6 + Bevacizumab|Participants will receive MEGF0444A matching placebo + mFOLFOX-6 regimen + bevacizumab. Participants will receive oxaliplatin for up to 8 cycles and 5-fluorouracil, folinic acid, bevacizumab and placebo will be administered until disease progression or unacceptable toxicity for a maximum of up to 52 cycles.
3171496|NCT01399658|Experimental|Image-Guided Brachytherapy|Image-guided brachytherapy
3171497|NCT01399645|Experimental|Liraglutide-Metformin|"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day until the end of the study.~All subjects will be given metformin with a starting dose of 500 mg in one tablet twice daily given before or during meals for the duration of the study."
3171498|NCT01399645|Experimental|Insulin-Metformin|"Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU. The patients will be taught to increase their insulin dose by 1 unit each day until achieving an FPG ≤ 7.0 mmol/L.~All subjects will be given metformin with a starting dose of 500 mg in one tablet twice daily given before or during meals for the duration of the study."
3171499|NCT01399632|Experimental|High Fat and Low Carbohydrate Diet|
3171500|NCT01399632|Experimental|Low Fat and High Carbohydrate Diet|
3171501|NCT01399619|Experimental|BI201335 12W|patient to receive two capsules of BI 201335 once a day for 12 weeks and pegIFN/RBV for 24 or 48 weeks
3171502|NCT01399619|Experimental|BI 201335 24W|patient to receive two capsules of BI 201335 once a day for 24 weeks and PegIFN/RBV for 24 or 48 weeks
3171503|NCT01399619|Experimental|BI 201335 24 W|patient to receive one capsule of BI 201335 once a day for 24 weeks and pegIFN/RBV for 24 or 48 weeks
3171504|NCT01399606|Experimental|BF2.649|
3171505|NCT01399593|Experimental|Eculizumab|Patients were to receive eculizumab 1200 mg prior to allograft transplantation (Day 0, starting approximately one hour prior to kidney allograft reperfusion), eculizumab 900 mg (Days 1, 7, 14, 21, and 28), and eculizumab 1200 mg (Weeks 5, 7 and 9). All doses of eculizumab were administered intravenously: the median infusion time was 39 minutes.
3171506|NCT01399593|No Intervention|Standard of Care|Patients received standard of care (SOC) prophylactic therapy for acute AMR according to the SOC choice at each participating investigative site, which could have included any combination of plasmapheresis (PP) and intravenous immunoglobulin (IVIg). Patients randomized to SOC who were diagnosed with AMR could have received eculizumab for the treatment of AMR after initially receiving PP and/or IVIg.
3171507|NCT01399580|Placebo Comparator|Group A - Placebo QD|
3171508|NCT01399580|Active Comparator|Group B - Low dose Atrasentan QD|
3171509|NCT01399580|Active Comparator|Group C - High dose Atrasentan QD|
3171510|NCT01399567|Experimental|Algorithm|The NH pain management algorithm is a series of decision-making tools that begins with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain. The algorithm is coupled with intense diffusion strategies (e.g., education, consultation, boosters) to increase adoption of these evidence-based practices
3171511|NCT01399567|Active Comparator|Control|Control sites received staff education for pain assessment and management comprised of four one-hour classes
3171512|NCT01399554|No Intervention|Assessment Only|
3171513|NCT01399554|Experimental|Weekly Exercise Counseling Intervention|
3171514|NCT01399541||Under and over 65 years|
3171515|NCT01399528||Beaumont Hospital, Dublin, Ireland|
3171516|NCT01399528||St. James' Hospital, Dublin, Ireland|
3171517|NCT01399528||Hôpital Erasme, Brussels, Belgium|
3171518|NCT01399528||Duke Medical Centre, North Carolina, USA|
3171519|NCT01399528||The Institute of Neurology/University College London, UK|
3171520|NCT01399515|Active Comparator|Valproic acid|
3171521|NCT01399515|No Intervention|Control|
3171522|NCT01399502|Active Comparator|Self-help advice|Each email will contain a self-help strategy for coping with depressive symptoms. The email will contain information about why the strategy will be effective, tips for implementing the strategy and overcoming barriers, and how to set a goal to implement the strategy. Strategies are based on previous research published by the trial co-ordinators.
3171523|NCT01399502|Placebo Comparator|Depression information|Each email will contain different information about depression, such as symptoms, risk factors, prevalence.
3171524|NCT01399489|Experimental|Exercise training|Individuals randomized to this arm get 48 sessions of personal training in a state of the art fitness facility
3171525|NCT01399489|No Intervention|Control|Individuals in the control arm are expected to continue to live normally, following their doctor's advice but not engage in any formal exercise training.
3171526|NCT01399476|Experimental|Endoscopic Myotomy|
3171598|NCT01398891|Experimental|Positive Psychology Exercises|
3171530|NCT01399372|Active Comparator|Arm I|Patients receive rituximab IV over 5 hours or per institutional guidelines on days 1 and 15, methotrexate IV over 2 hours on days 2 and 16, vincristine sulfate IV on days 2 and 16 (of courses 1 and 2 only), and procarbazine hydrochloride orally (PO) on days 2-8. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive consolidation therapy comprising cytarabine IV over 3 hours on days 1-2. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.
3171531|NCT01399372|Experimental|Arm II|Patients receive rituximab, methotrexate, vincristine sulfate, and procarbazine hydrochloride as in arm I. After completing chemotherapy, patients without progressive disease undergo low-dose whole brain radiotherapy once daily, 5 days a week, for approximately 2.5 weeks (13 fractions total). Patients then receive consolidation cytarabine as in arm I.
3171532|NCT01399359||Women who decide not to take a SERM|Women participate in the counseling session, questionnaire 1, and questionnaire 2, and the online questionnaire.
3171533|NCT01399359||Women who decide to take a SERM|Women participate in the counseling session, questionnaire 1 and questionnaire 2.
3171534|NCT01399346|Experimental|1 bolus of insulin aspart 18 IU|Subcutaneous administration of insulin aspart as one bolus of 18 IU at one injection site.
3171535|NCT01399346|Experimental|9 bolus of insulin aspart a 2 IU|Subcutaneous administration of insulin aspart as 9 separately and simultaneously applied bolus of 2 IU at 9 separate injection sites
3171536|NCT01399333|Active Comparator|Group 1|full liquid diet utilizing meal replacements with PDCAAS of 1.0
3171537|NCT01399333|Active Comparator|Group 2|full liquid diet utilizing protein supplements with PDCAAS of 0.5-0.99
3171538|NCT01399333|Active Comparator|Group 3|full liquid diet utilizing protein supplement with a PDCAAS less than 0.5
3171539|NCT01399320|Experimental|cyanoacrylate dressing,excesion|we excise the sinus tip then apply cyanoacrylate dressing and watch for healing
3171540|NCT01399307|Other|Elective Liposuction|
3171541|NCT01399281||Biologics alone or methotrexate alone|This group mainly refer to children with polyarticular course JIA treated with methotrexate ± biologics,
3171542|NCT01399281||Biologics and MTX|JIA treated with a combination of biologic and MTX (including any other add on therapy e.g. cyclosporine, leflunomide etc). This group mainly refer to children with polyarticular course JIA treated with MTX ± biologics
3171543|NCT01399281||NSAIDs and/or steroid injections alone|This group refers to children with mostly oligoarticular persistent course who are usually NOT treated with second line agents and have a more benign course.
3171544|NCT01399268|Experimental|Steroid|Hydrocortisone 100 mg IV Q 8hrs x3
3171545|NCT01399268|Placebo Comparator|Control|Saline IV Q8hr x3
3171546|NCT01399255|Experimental|Listro™ Arm|Insulin Lispro (Listro™); 100 U/mL, DispoPen 3.0 mL.
3171547|NCT01399255|Active Comparator|Humalog® Arm|Insulin Lispro (Humalog®; 100 U/mL), Humalog® Kwik Pen™ 3.0 mL.
3171548|NCT01399242|Active Comparator|Certican, prednisona, EC-MPS|Twenty patients will be selected at 16 weeks of renal transplantation to convert a immunosuppression to certican,prednisone and myfortic. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation
3171549|NCT01399242|No Intervention|Tacrolimus,Prednisona, EC-MPS|Twenty patients will be selected at 16 weeks of renal transplant to continue use EC-MPS,Tacrolimus and Prednisone. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation
3171550|NCT01399229||Pregnant, Preterm, In Labor|Gestation Age at or less than 36 weeks, clinically determined to be in labor
3171551|NCT01399229||Pregnant, Preterm, Nonlaboring|Gestation Age at or less than 36 weeks, clinically determined to not be in labor
3171552|NCT01399229||Pregnant, Term, Nonlaboring|Gestation Age more than 36 weeks, clinically determined to not be in labor
3171553|NCT01399216|Experimental|Fucoidan supplement|
3171554|NCT01399216|Placebo Comparator|Placebo|
3171555|NCT01399203||percutaneous coronary intervention|The investigators reviewed all consecutive patients who were undergoing percutaneous coronary intervention
3171556|NCT01399190||Bevacizumab|Participants will receive bevacizumab in combination with capecitabine and oxaliplatin.
3171557|NCT01399164|Experimental|Fortified Bread|A single serving of 14C-B12 fortified bread
3171558|NCT01399151|Experimental|Vitamin D - Treatment 1|400 IU/day Vitamin D
3171559|NCT01399151|Experimental|Vitamin D- Treatment 2|2,000 IU/day Vitamin D
3171560|NCT01399151|Experimental|Vitamin D- Treatment 3|5,000 IU/day Vitamin D
3171561|NCT01399138|Experimental|Blueberry Powder|A blueberry smoothie will be consumed at the breakfast and dinner meals.
3171562|NCT01399138|Placebo Comparator|Placebo|A placebo smoothie will be consumed at the breakfast and dinner meals.
3171563|NCT01399125|Experimental|Rivastigmine patch|Once-daily target patch size 10 cm²
3171564|NCT01399125|Active Comparator|Rivastigmine capsules|Twice-daily target dose of 6 mg oral capsule
3171565|NCT01399112|Experimental|Electronic Decision Support System|The Electronic Decision Support System (EDSS) is a 5-module computer program aimed to assess, motivate, educate, solicit preferences, and provide feedback and referrals for people with severe mental illness. The program provides: a) a personalized assessment of the individual's smoking, b) information to improve knowledge of smoking risks and treatment benefits, c) interactive exercises to personalize the impact of smoking, improve attitudes about quitting, and increase self-efficacy for seeking smoking cessation treatment, and d) a video patient vignette to develop social norms for smoking cessation treatment and increase self-efficacy. Usability testing among people with severe mental illness established that the system was comprehensible, easy to use, and took 30-90 minutes to complete.
3171599|NCT01398878|No Intervention|Traditional work schedule|Residents in the intensive care unit perform overnight shifts in excess of 24 hrs every fourth night
3171602|NCT01398839|Sham Comparator|Sham Control|
3171566|NCT01399112|Active Comparator|thetruth.com website|"Participants who are assigned to use the web-based thetruth.com website will be asked to navigate through the website as they wish. The home page of thetruth.com site has links to access video games, fact sheets, and videos that highlight negative aspects of cigarettes or tobacco companies. Thetruth.com website is not structured and participants can utilize whatever aspects of the website they wish and in any order they wish to view them.~Individuals will use the computer with a research staff member present who can provide assistance if needed. The sections of the two programs website that are used and the time spend on each portion of the program will be recorded. Participants who use TheTruth.com will be given a referral for assistance in quitting smoking if requested."
3171567|NCT01399099|Experimental|All Study Participants|Half of the abdomnioplasty incision was treated with the embrace device. Half of the abdomnioplasty incision was treated according to the investigator's standard of care. Participant served as his own control.
3171568|NCT01399086||Fulvestrant|
3171569|NCT01399073||Patients with Neglect|
3171570|NCT01399073||Patients with Hemianopsia|
3171571|NCT01399073||Healthy age-matched controls|
3171572|NCT01399047|Active Comparator|Mycophenolate Mofetil|
3171573|NCT01399047|Placebo Comparator|Placebo liquid|
3171574|NCT01399034||MicroRNA study|Obese group (+ periodontitis group) Non-obese group (+ periodontitis group)
3171575|NCT01399034||DNA methylation study|Periodontitis group Healthy periodontium group
3171576|NCT01399021|Other|Flat Davol drain|both arms will have flat davol drains placed at the end of the parotidectomy surgery
3171577|NCT01399008|Experimental|Arhalofenate 400 mg|Arhalofenate 400 mg plus allopurinol 300 mg
3171578|NCT01399008|Experimental|Arhalofenate 600 mg|Arhalofenate 600 mg plus allopurinol 300 mg
3171579|NCT01399008|Active Comparator|Allopurinol|Placebo plus Allopurinol 300 mg
3171580|NCT01398995|Experimental|90 minutes|Basal insulin infusion reduced to 50% of normal 90 minutes prior to exercise
3171581|NCT01398995|Experimental|60 minutes|Basal insulin infusion reduced to 50% of normal 60 minutes prior to exercise
3171582|NCT01398995|Experimental|30 minutes|Basal insulin infusion reduced to normal 30 minutes prior to exercise
3171583|NCT01398995|Experimental|Start|Basal insulin infusion reduced to 50% of normal at the start of exercise
3171584|NCT01398982|Placebo Comparator|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
3171585|NCT01398982|Experimental|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
3171586|NCT01398969|Experimental|Fresh Human Biotherapy|Patients in this arm will receive Fresh HBT enema. They will be followed for 13 weeks to assess the cure or recurrence of CDI. All other procedures between the two arms will be identical.
3171587|NCT01398969|Experimental|Frozen-and-Thawed Human Biotherapy|Patients in this arm will receive Frozen-and-Thawed HBT enema. They will be followed 13 weeks to assess the cure or recurrence of CDI. All other procedures between the two arms will be identical.
3171588|NCT01398956|Experimental|Levetiracetam|Twice daily (morning and evening) orally
3171589|NCT01398943|Experimental|COPD Patients|"Patients with COPD~AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid~BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)"
3171590|NCT01398943|Experimental|Controls|"Healthy age- and sex- matched controls~AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid~BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)"
3171591|NCT01398930|Active Comparator|Group I was treated with etoricoxib|
3171592|NCT01398930|Active Comparator|Group II was treated with acupuncture and etoricoxib|
3171593|NCT01398930|Sham Comparator|Group III was treated with sham acupuncture and etoricoxib.|
3171594|NCT01398917|Active Comparator|short-term stenting|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
3171595|NCT01398917|Active Comparator|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
3171596|NCT01398904||Body dysmorphic disorder (BDD) Participants|Participants must be 18 years or older with a primary diagnosis of body dysmorphic disorder (BDD), a BDD Yale-Brown Obsessive Compulsive Scale (BDDY-BOCS) score of >20, and a primary facial/head concern. Participants must have the ability to provide informed consent and understand study staff.
3171597|NCT01398904||Healthy Controls|Males and females 18 years of age or older with ability to provide informed consent and understand study staff.
3171604|NCT01398787|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color randomly assigned to one eye, with phemfilcon A contact lens with color in the fellow eye for contralateral wear
3171605|NCT01398787|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color randomly assigned to one eye, with lotrafilcon B contact lens with color in the fellow eye for contralateral wear
3171606|NCT01398761|Experimental|Intervention|nurses, residents, PAs, and attendings from the two pilot services
3171607|NCT01398748|Active Comparator|Intranasal GSH 100mg/ml|Study participant will be provided with monthly supply of study medication and will be asked to intake 100mg/ml of intranasal glutathione (n=15) An amount of 1ml with a frequency 3x per days and duration of 12 weeks with a dosage of 2100mg
3171608|NCT01398748|Active Comparator|Intranasal glutathione 200mg/ml|Study participant will be provided with monthly supply of study medication and will be asked to intake 200/ml of intranasal glutathione (n=15) An amount of 1ml with a frequency 3x per days and duration of 12 weeks with a dosage of 4200mg
3171609|NCT01398748|Placebo Comparator|Saline intranasal delivery|Study participant will be provided with monthly supply of study medication and will be asked to intake Intranasal saline delivery (n=15) An amount of 1ml with a frequency 3x per day with a duration of 12 weeks
3171610|NCT01398748|No Intervention|Watchful waiting|No intervention, watchful waiting only (n=4)
3171611|NCT01398722|Active Comparator|Intensive insulin therapy|Intensive insulin therapy(Blood glucose target: 110-150 mg/dL)
3171612|NCT01398722|Active Comparator|Conventional insulin therapy|Conventional insulin therapy(Blood glucose target: 150-180 mg/dl)
3171613|NCT01398709|Active Comparator|Slow rewarming strategy|Slow rewarming strategy (0.24 degrees C/min)
3171614|NCT01398709|Active Comparator|Fast rewarming strategy|Fast rewarming strategy (0.5 degrees C/min)
3171615|NCT01398696|Active Comparator|Patient Information Leaflets|Patient Information Leaflets (PIL) is given to the patient during consultation
3171616|NCT01398696|Placebo Comparator|usual consultation without PIL|no particular intervention during consultation for the patient.
3171617|NCT01398670|Experimental|Lispro arm|Lispro and Lispro Mix 75/25 /Lispro Mix 50/50
3171618|NCT01398670|Active Comparator|Humalog® arm|Humalog® and Humalog® Mix75/25 / Humalog® Mix50/50
3171619|NCT01398657|Experimental|Adjuvant Androgen-Deprivation Therapy|Cryotherapy with Short-term Adjuvant Androgen-Deprivation Therapy
3171620|NCT01398657|No Intervention|No adjuvant therapy|Cryotherapy without any adjuvant therapy
3171621|NCT01398644|Active Comparator|Phlebotomy -intervention phlebotomy|Patients are treated with phlebotomy if ferritin level >50 ug/l
3171622|NCT01398644|Experimental|Erythrocytapheresis|Patients are treated with erythrocytapheresis if serum ferritin level >50ug/l
3171623|NCT01398631||Study Group|All included patients presented with chest pain at the emergency room within the inclusion period.
3171624|NCT01398618|Experimental|4M-RMP|adult household contacts with latent tuberculosis infection receiving 4-month rifampicin preventive therapy
3171625|NCT01398618|Active Comparator|9M-INH|adult household contact with latent tuberculosis infection receiving 9-month isoniazid preventive therapy
3171626|NCT01398605|Experimental|moderate exercise training|
3171627|NCT01398605|Experimental|intensive exercise training|
3171628|NCT01398605|No Intervention|Control|
3171629|NCT01398592|Experimental|Vildagliptin|Experimental
3171630|NCT01398592|Active Comparator|Sitagliptin|Active comparator (drug)
3171631|NCT01398579|Active Comparator|Group A|Group A: WLE followed by AFI followed by NBI followed by pCLE.
3171632|NCT01398579|Active Comparator|Group B|Group B: WLE followed by NBI followed by AFI followed by pCLE.
3171633|NCT01398566|Experimental|Gaming|members of this group will play SuperBetter for 6 weeks (averaging 10 min per day of play for 6 week period)
3171634|NCT01398553|Experimental|Armeo Spring|
3171635|NCT01398553|Active Comparator|conventional physiotherapy|
3171636|NCT01398540|Experimental|elderly|subjects are at least 60 years old (with no upper age limit), receiving 2 immunisations with IXIARO
3171637|NCT01398540|Experimental|young|subjects 18 to 40 years old, receiving 2 immunisations with IXIARO
3171638|NCT01398527|No Intervention|LTC Osteoporosis Toolkit Only|Homes will receive the LTC osteoporosis toolkit only and will be required to attend an online webinar to outline the toolkit contents.
3171639|NCT01398527|Active Comparator|Educ sessions & LTC Osteoporosis toolkit|LTC homes will receive the LTC osteoporosis toolkit, on line webinar. Three educational sessions lead by an osteoporosis expert will also take place, 1 on-site visit and 2 webinars.
3171640|NCT01398514|Experimental|Active medication|Escitalopram 10mg/day
3171641|NCT01398514|Placebo Comparator|Placebo|Matched pill placebo
3171642|NCT01398501|Experimental|Post-SCT Sorafenib|Sorafenib will be given as maintenance therapy after allo HCT to patients with FLT3-ITD AML.
3171643|NCT01398488|Active Comparator|Conventional Patient education|Conventional Patient education by health care professionals.
3171644|NCT01398488|Experimental|Patient education via Tablet computer|Patient education after lung transplantation via Tablet computers. An electronic patient questionnaire via tablet computer will be collected in addition.
3171645|NCT01398475|Experimental|LY3009104 Reference Formulation|8 milligrams (mg) LY3009104 (two 4-mg phosphate salt capsules), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
3171646|NCT01398475|Experimental|LY3009104 Test Formulation 1|8 mg LY3009104 (one 8-mg smaller particle free base tablet), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
3171647|NCT01398475|Experimental|LY3009104 Test Formulation 2|8 mg LY3009104 (one 8-mg larger particle free base tablet), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
3171648|NCT01398475|Experimental|LY3009104 Test Formulation 2 + Meal|8 mg LY3009104 (one 8-mg larger particle free base tablet), administered orally with high-fat/high calorie meal, once only. There will be a washout period of 5 to 7 days between doses of study drug.
3171649|NCT01398462|Experimental|CWP232291|
3171650|NCT01398449|Experimental|B|After esophagectomy, patients in Arm B will receive adjuvant chemotherapy, followed by elective nodal irradiation (ENI)
3171652|NCT01398436|Experimental|Catheter tip in right atrium|In this group a central venous catheter will be advanced for its entire length unless arrhythmias develop.Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography.
3171653|NCT01398436|No Intervention|Catheter tip in superior vena cava|In this group a central venous catheter will be inserted for 15 cm in accordance with standard practice. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
3171654|NCT01398423|Active Comparator|Active control|Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
3171655|NCT01398423|Experimental|INV-144|INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
3171656|NCT01398410|Experimental|Rabeprazole 5 mg|
3171657|NCT01398410|Experimental|Rabeprazole 10 mg|
3171658|NCT01398384|Active Comparator|Nitric Oxide|nitric oxide for inhalation
3171659|NCT01398384|Placebo Comparator|Placebo|inhalation gas
3171660|NCT01398371|Active Comparator|Stable digoxin therapy|Participants need to have been receiving digoxin therapy for at least 3 months at a dose that results in digoxin plasma levels of 0.4-0.8 on 2 consecutive blood tests (at least 1 weeks apart) prior to randomisation. The dose of digoxin must remain stable for at least 2 weeks prior to randomisation.
3171661|NCT01398371|Experimental|Digoxin withdrawal|Participants will receive a placebo for 4 weeks.
3171662|NCT01398358|No Intervention|Usual Head Start Exposure|Children will attend their usual Head Start classroom and receive the usual educational interventions provided in that classroom.
3171663|NCT01398358|Experimental|Parents of Preschoolers Series (POPS)|Children attend Head Start preschool. Within the classroom, they receive a series of lessons about nutrition and obesity prevention delivered by an Extension Educator in collaboration with the classroom teacher. Parents are invited to attend a series of classes about nutrition and obesity prevention.
3171664|NCT01398358|Experimental|POPS + Incredible Years Series (IYS)|Children attend Head Start preschool. Within the classroom, they receive a series of lessons about nutrition and obesity prevention delivered by an Extension Educator in collaboration with the classroom teacher. Parents are invited to attend a series of classes about nutrition and obesity prevention. In the classroom, children also receive a series of lessons about emotional and behavioral self-regulation delivered by a trained mental health specialist. The parents also are invited to classes about child behavioral and emotional self-regulation delivered by a mental health specialist.
3171665|NCT01398345|Active Comparator|Exercise and Respiratory Training|
3171666|NCT01398332||Aortic pathologies|Indication for aortic endovascular stent graft repair
3171667|NCT01398319|Other|Group Brief Alcohol Intervention|The number of alcohol related incidents for the year prior the initiation of the BAI will be compared to the number of alcohol related incidents when Airmen were exposed to the BAI
3171668|NCT01398306||Group A|Patients with clear cell renal cell carcinoma with metastases.
3171669|NCT01398306||Group B|Patients with low grade neuro-endocrine tumours with metastases.
3171670|NCT01398293|Experimental|A|
3171671|NCT01398293|Experimental|B|
3171672|NCT01398293|Active Comparator|C|
3171673|NCT01398293|Placebo Comparator|D|
3171674|NCT01398280|Experimental|Aminocaproic Acid (ACA)|Subjects will treat their facial skin twice daily for up to 12 weeks with 5-6 visits and 2 telephone visits. Investigator and subject will be blinded. Tape strip samples will be collected from facial skin at each visit to assess KLK activity and LL-37 expression.
3171675|NCT01398280|Placebo Comparator|Vehicle cream|Subjects will apply vehicle twice daily for up to 12 weeks with 5-6 visits and 2 telephone visits. Investigator and subject will be blinded. Tape strip samples will be collected from facial skin at each visit to assess KLK activity and LL-37 expression.
3171676|NCT01398267|Experimental|1|
3171677|NCT01398267|Placebo Comparator|2|
3171678|NCT01398254|Other|TRA|Transradial Access
3171679|NCT01398254|Other|TFA|Transfemoral Access
3171680|NCT01398241|Experimental|Active|
3171681|NCT01398241|Placebo Comparator|Placebo|
3171682|NCT01398228|Other|Group 1|Group 1 will receive quality improvement initiatives first, after 6 months of baseline initiation.
3171683|NCT01398228|Other|Group 2|Group 2 will receive quality improvement initiatives second, after 6 months of the intervention initiation for Group 1.
3171684|NCT01398228|Other|Group 3|Group 3 will receive quality improvement initiatives third, after 6 months of the intervention initiation for Group 2.
3171685|NCT01398228|Other|Group 4|Group 4 will receive quality improvement initiatives forth, after 6 months of the intervention initiation for Group 3.
3171686|NCT01398215||transvaginal NOTES|
3171687|NCT01398202|Active Comparator|Vitamin D3 (20 microgram/day)|
3171688|NCT01398202|Active Comparator|25-hydroxyvitamin D (7 microgram/day)|
3171689|NCT01398202|Active Comparator|25-hydroxyvitamin D3 (20 micogram/day)|
3171690|NCT01398202|Placebo Comparator|Placebo|
3171691|NCT01398189|Experimental|clozapine|patients with refractory schizophrenia or schizoaffective disorder
3171692|NCT01398176|Experimental|3 ounces of mushrooms|3 ounces of mushrooms consumed daily for 4 weeks
3171693|NCT01398176|Experimental|6 ounces of mushrooms|6 ounces of mushrooms consumed daily for 4 weeks
3171694|NCT01398163|Experimental|1 = Tested product|
3171695|NCT01398163|Active Comparator|2 = Control product|
3171696|NCT01398163|No Intervention|3 = No product|
3171697|NCT01398150|Placebo Comparator|Sweetened Beverage|looks like and is given in the same way as the experimental treatment but contains no active ingredient
3171698|NCT01398150|Experimental|Cranberry Beverage|15 ounce bottle of cranberry beverage consumed daily for 70 days
3171699|NCT01398137||Ragweed allergic subjects|
3171700|NCT01398111|Active Comparator|Treatment R2|
3171701|NCT01398111|Active Comparator|Treatment R1|
3171702|NCT01398111|Placebo Comparator|Placebo|
3171703|NCT01398111|Experimental|Treatment T|
3171704|NCT01398098|Experimental|COLOKIT®|
3171705|NCT01398085|Active Comparator|Radioactive iodine (RAI) ablation Arm|Patients will be randomised to receive Radioactive iodine (RAI) ablation I131 1.1 GBq
3172377|NCT01393327|No Intervention|no respiratory and exercise therapy|continuation of usual lifestyle
3171706|NCT01398085|No Intervention|No Radioactive iodine (No-RAI) ablation|Patients will be randomised to receive No Radioactive iodine (No-RAI) ablation
3171707|NCT01398072|Active Comparator|Moxifloxacin|
3171708|NCT01398072|Active Comparator|Azithromycin|
3171709|NCT01398072|Active Comparator|Doxycycline|
3171710|NCT01398072|Placebo Comparator|Placebo|
3171711|NCT01398059|Experimental|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
3171712|NCT01398059|Experimental|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
3171713|NCT01398059|Experimental|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
3171714|NCT01398046|Active Comparator|Dasatinib|
3171715|NCT01398046|Experimental|Dasatinib plus Rabeprazole|
3171716|NCT01398046|Experimental|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|
3171717|NCT01398033|Active Comparator|Drug-coated balloon|"pre-dilatation of the target lesion with a non-coated balloon.~treatment of the target lesion with the paclitaxel-coated balloon"
3171718|NCT01398033|Placebo Comparator|non-coated balloon|Treatment of the target lesion with plain balloon angioplasty.
3171719|NCT01398020|Active Comparator|Standard bowel prep|Subject will receive standard bowel prep prior to colonoscopy.
3171720|NCT01398020|Experimental|2L Bi-Peglyte|Subjects will be asked to take 2L Bi-Peglyte + 15mg bisacodyl for bowel prep the day before colonoscopy.
3171721|NCT01398007|No Intervention|Conventional syringe|Conventional syringe
3171722|NCT01398007|Experimental|Camouflage syringe|The camouflage syringe is divided into three parts: head, body and tail. Head consists of bristles to apply topical anesthesia. The body holds the normally used conventional syringe and presents with a slot to check the aspiration results. The tail hides the conventional syringe loaded with the local anesthetic solution. This syringe is made up of cold-cure acrylic with a colorful toy-like look.
3171723|NCT01397994|Active Comparator|Nicorandil test arm|Nicorandil is given with atenolol therapy.
3171724|NCT01397994|Active Comparator|Atenolol control arm|Atenolol 50 mg OD is given.
3171725|NCT01397981|Experimental|Walking modification|Changing kinematics for walking
3171726|NCT01397968|Experimental|YKP3089|
3171727|NCT01397968|Placebo Comparator|Placebo|Placebo capsule
3171728|NCT01397955||Group 1|Drug (incl. Placebo)
3171729|NCT01397942|Experimental|Diet intervention - Ancient vegatables|A healthy Nordic diet with high content of bitter strong tasting vegetables and cabbages.
3171730|NCT01397942|No Intervention|Control Nordic diet|A diet habitually consumed in the Nordic countries
3171731|NCT01397942|Experimental|Diet intervention - Modern Vegetables|A healthy Nordic diet with high content of sweet and mild tasting vegetables and cabbages.
3171732|NCT01397929|Experimental|Drug: BAL101553 at MTD|
3171733|NCT01397929|Experimental|Drug: BAL101553 at 50% of MTD|
3171734|NCT01397916||CLL-patients|
3171735|NCT01397916||Controls|
3171736|NCT01397903||Group 1|"Inpatients and outpatients diagnosed with major depressive disorder as per the DSM-IV criteria who had poor disease control during antidepressant treatment and have completed 4 weeks of add-on drug therapy at enrolment in the study.~The percentage of patients with CGI-I score ≤ 2 at study Visit (4 weeks after the commencement of add-on treatment)."
3171737|NCT01397890|Other|1|Add-on treatment
3171738|NCT01397890|Other|2|Add-on treatment
3171739|NCT01397877|Experimental|stratum 1|Patients with low grade disease (grade 1 or 2) with positive or negative mutational status
3171740|NCT01397864||Hereditary Angioedema|
3171741|NCT01397851|Experimental|Treatment: Insecticide-treated net|Smallholder farmers in the treatment group are informed that they won a raffle, and receive a free insecticide-treated net
3171742|NCT01397851|No Intervention|Control|Smallholder farmers in the control group are informed that they had a chance to win an insecticide-treated mosquito net in a raffle, but did not end up winning
3171743|NCT01397838|Experimental|Pro-Bone|
3171744|NCT01397825|Experimental|Safety Lead-in|Alisertib 50 mg, enteric coated tablets (ECT), orally, twice daily (BID), on Days 1 to 7 followed by a 14-day rest period in 21-day cycles plus rituximab 375 mg/m^2, intravenous (IV), infusion on Day 1 of each 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
3171745|NCT01397825|Experimental|Dose Escalation, Alisertib 30 mg|Alisertib 30 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1, plus vincristine 1.4 mg/m^2 (max 2 mg), IV, on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
3171746|NCT01397825|Experimental|Dose Escalation, Alisertib 40 mg|Alisertib 40 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
3171747|NCT01397825|Experimental|Dose Escalation, Alisertib 50 mg|Alisertib 50 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
3171782|NCT01397565|Experimental|Minilaparoscopic cholecystectomy|Patients in this arm will undergo laparoscopic cholecystectomy using minilaparoscopic instruments
3171748|NCT01397825|Experimental|Phase 2: Alisertib|Phase 2: Alisertib (MLN8237) at the Recommended Phase 2 Dose, ECT orally twice/day on Days 1-7 & rituximab as an IV infusion on Day 1 & vincristine IV on Days 1 & 8 in a 21 Day cycle for up to 8 cycles was planned but not conducted.
3171749|NCT01397812||1|"Subjects will comprise of patients who are the recipients of a heart transplant within the previous 12 months and are scheduled for a routine endomyocardial biopsy.~Subjects will provide breath samples for the Heartsbreath test using the BreathScanner 1.0. Optionally subjects will provide breath samples using the BreathLink point of care system."
3171750|NCT01397799|Experimental|Treatment|Subjects will be enrolled into a 28-day dose-escalation study. If no DLT's are observed during the first 28 days, subjects are eligible to continue treatment in the Extension Phase and can remain on treatment until toxicity occurs or until disease progression.
3171751|NCT01397786|Experimental|OPC-34712|
3171752|NCT01397773||Hemodialysis group|Patients on chronic hemodialysis program
3171753|NCT01397773||Peritoneal dialysis group|Patients on chronic peritoneal dialysis program
3171754|NCT01397773||Pre-dialysis group|Patients with chronic kidney disease stage-4
3171755|NCT01397773||Control group|Healthy subjects
3171756|NCT01397747||Average risk patients|Subjects will be men and women, 50-84 years of age, inclusive, who are at average risk of developing colorectal cancer.
3171757|NCT01397734|Experimental|Cohort 1|Patients who are receiving Imatinib as part of their standard of care therapy for CML.
3171758|NCT01397734|Experimental|Cohort 2|Patients who are receiving Dasatinib as part of their standard of care therapy for CML.
3171759|NCT01397734|Experimental|Cohort 3|Patients who are receiving Nilotinib as part of their standard of care therapy for CML.
3171760|NCT01397708|Experimental|INXN-1001 in combination with INXN-2001|Intratumoral injections of INXN-2001 (Ad-RTS-hIL-12) at a constant dose in combination with inter-cohort escalating doses of INXN-1001 (activator ligand).
3171761|NCT01397695|Experimental|bevacizumab|
3171762|NCT01397669|Other|HIV infection and non HIV infection|
3171763|NCT01397656|Active Comparator|CPR 30:2|30 chest compressions to 2 ventilations
3171764|NCT01397656|Active Comparator|CPR with Continuous Compressions|Continuous Chest Compressions without ventilation
3171765|NCT01397643|Other|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
3171766|NCT01397643|Other|Operative|Patients in this arm will be managed operatively for their olecranon fracture using either tension band wiring or plate fixation.
3171767|NCT01397630|Experimental|Accelerated Oxytocin Titration|
3171768|NCT01397630|Active Comparator|Gradual Oxytocin Titration|
3171769|NCT01397617|Experimental|NobelActive Internal|NobelActive Internal implant
3171770|NCT01397617|Experimental|NobelActive External|NobelActive External implant
3171771|NCT01397617|Active Comparator|NobelReplace Tapered Groovy|NobelReplace Tapered Groovy implant
3171772|NCT01397604|No Intervention|Saline Placebo|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects."
3171773|NCT01397604|Placebo Comparator|SE Vehicle|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~The SE (squalene) vehicle contains the oil emulsion in which the GLA-SE is solubilized."
3171774|NCT01397604|Active Comparator|GLA-AF|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~GLA-AF contains the study drug in an aqueous solution."
3171775|NCT01397604|Active Comparator|GLA-SE|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~GLA-SE contains the study drug in a squalene oil emulsion."
3171776|NCT01397591|Experimental|Ofatumumab with Bortezomib|Ofatumumab was given intravenously on cycle 1 day 1 at a dose of 300mg, followed by a cycle 1 day 8 dose of 1000mg. During cycles 2 through cycle 6, Ofatumumab was given at a dose of 1000mg on day 1 of each cycle, with no dosing on any other day of the cycle. Bortezomib was given intravenously at a dose of 1.6mg/m2 on days 1, 8, and 15 of each cycle, following the Ofatumumab infusion, if given.
3171777|NCT01397578|Experimental|Part 1: Subcutaneous cohort exp|
3171778|NCT01397578|Experimental|Part 2: Intravenous cohort exp|
3171779|NCT01397578|Placebo Comparator|Part 1: Subcutaneous cohort|Repeating subcutaneous injection
3171780|NCT01397578|Placebo Comparator|Part 2: Intravenous cohort|Repeating intravenous injection
3171781|NCT01397565|Active Comparator|Laparoscopic cholecystectomy|Patients in this arm will undergo conventional laparoscopic cholecystectomy
3171783|NCT01397552|Active Comparator|Dexamethasone|Subjects randomized to receive dexamethasone, will undergo epidural using this medication, however the physician and subject will be blinded
3171784|NCT01397552|Active Comparator|methylprednisolone acetate|Subjects randomized to receive methylprednisolone acetate, will undergo epidural using this medication, however the physician and subject will be blinded
3171785|NCT01397539|Experimental|BIIB037|A single dose of BIIB037 by intravenous infusion.
3171786|NCT01397539|Placebo Comparator|Placebo|A single dose of placebo matching BIIB037 by intravenous infusion.
3171787|NCT01397513|Active Comparator|Aspirin 75mg|
3171788|NCT01397513|Active Comparator|Aspirin 320mg|
3171789|NCT01397500|Active Comparator|Genotropin|"6 months Genotropin (open treatment)~Daily dose:~Male < 45 years: 0,4 mg; ≥ 45 years: 0,2 mg Female < 45 years: 0,5 mg; ≥ 45 years: 0,3 mg Starting with half of the dose for the first 4 weeks."
3171790|NCT01397500|Active Comparator|Testosterone undecannoate|18 weeks testosterone undecanoate/placebo (double-blind treatment) 1000 mg/4 ml at baseline and after 6 weeks
3171791|NCT01397500|No Intervention|control group|No Intervention.
3171792|NCT01397487|Other|one single arm|All patients are included to complete a biopsy of half part of the embryos
3171793|NCT01397474|No Intervention|Control|The fluid management algorithm of the control group is based on the standard care procedure of our ICU as recommended in guidelines: the patient's fluid status is assessed by performing a fluid challenge with a bolus of 250 ml colloids. When the patients is fluid responsive (i.e. showing an increase in stroke volume > 10% ) he will receive an additional bolus of 250 ml of colloids. After each fluid challenge, patients will be revaluated for fluid responsiveness to access need of further fluid administration.
3171794|NCT01397474|Experimental|PPTFM|"The fluid management algorithm of the intervention group uses identical therapy (i.e. fluids) yet targeted at different endpoints (i.e. peripheral perfusion parameters). After evaluation of peripheral perfusion, only patients with a bad peripheral perfusion (i.e. 3 out of 4 criteria considered as bad) will receive a fluid challenge, the same way as in the standard care procedure (i.e. bolus of 250 ml of fluid). After each fluid challenge, patients will be re-evaluated for peripheral perfusion to access further need in fluid challenges. To ensure that no hypovolemia will occur in the intervention group, fluid will be administered irrespectively of peripheral perfusion parameters, if cardiac index falls below a value of 2,5 L/min/m2."
3171795|NCT01397461|Experimental|ozenoxacin 1% cream|1% cream
3171796|NCT01397461|Placebo Comparator|ozenoxacin placebo|cream
3171797|NCT01397461|Active Comparator|retapamulin 1% ointment|1% ointment
3171798|NCT01397448|Experimental|E3810 5 mg|
3171799|NCT01397448|Experimental|E3810 10 mg|
3171800|NCT01397448|Active Comparator|Teprenone 150 mg|
3171801|NCT01397435||Gaucher|We will enroll 15 children who have a confirmed diagnosis of Gaucher disease.
3171802|NCT01397435||Healthy volunteers|We will enroll 15 age and gender matched controls.
3171803|NCT01397422|Placebo Comparator|Treatment A|
3171804|NCT01397422|Active Comparator|Treatment B|Low dose ADS-5102 (amantadine extended release)
3171805|NCT01397422|Active Comparator|Treatment C|A mid-dose ADS-5102 (amantadine extended release)
3171806|NCT01397422|Active Comparator|Treatment D|High dose ADS-5102 (amantadine extended release)
3171807|NCT01397409|Experimental|Stage 1: AGN-150998 4.2 mg|Stage 1: AGN-150998 4.2.mg given as a single intravitreal injection.
3171808|NCT01397409|Experimental|Stage 1: AGN-150998 3.0 mg|Stage 1: AGN-150998 3.0 mg given as a single intravitreal injection.
3171809|NCT01397409|Experimental|Stage 1: AGN-150998 2.0 mg|Stage 1: AGN-150998 2.0 mg given as a single intravitreal injection.
3171810|NCT01397409|Experimental|Stage 1: AGN-150998 1.0 mg|Stage 1: AGN-150998 1.0 mg given as a single intravitreal injection.
3171811|NCT01397409|Experimental|Stage 2: AGN-150998 4.2 mg|Stage 2: AGN-150998 4,2 mg (highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
3171812|NCT01397409|Experimental|Stage 2: AGN-150998 3.0 mg|Stage 2: AGN-150998 3.0 mg (one dose below highest tolerated dose) from Stage 1 given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
3171813|NCT01397409|Active Comparator|Stage 2: ranibizumab 0.5 mg|Stage 2: ranibizumab 0.5 mg given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
3171814|NCT01397409|Experimental|Stage 3: AGN-150998 2.0 mg|Stage 3: AGN-150998 2.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.
3171815|NCT01397409|Experimental|Stage 3: AGN-150998 1.0 mg|Stage 3: AGN-150998 1.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.
3171816|NCT01397409|Active Comparator|Stage 3: ranibizumab 0.5 mg|Stage 3: ranibizumab 0.5 mg given as intravitreal injections every 4 weeks for 16 weeks.
3171817|NCT01397396|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training
3171818|NCT01397396|Placebo Comparator|Sham IMT|Sham Inspiratory Muscle Training
3171819|NCT01397383||Vitamin D deficiency|Patients with low serum vitamin D (25-hydroxy vitamin D < 32 ng/ml)
3171820|NCT01397383||Control group|Patients with normal serum vitamin D level (serum 25-hydroxy vitamin D > 32 ng/ml)
3171821|NCT01397370|Experimental|GLPG0492 oral solution|Multiple ascending doses once daily for 14 days, starting from 5 mg/day
3171822|NCT01397370|Placebo Comparator|Placebo oral solution|Once daily dosing for 14 days
3171823|NCT01397357||suspected Myocardial Ischemia|Patient with diagnosis of suspected coronary artery disease (CAD) or recurrent ischemic symptoms assessed by under-effort angina symptoms and/or cardiac conventional stress test, and the presence of at least two risk factors.
3171824|NCT01397331|Active Comparator|Inhalational anesthesia|Group of patients undergoing the surgery under anesthesia based on inhalational anesthetic
3171825|NCT01397331|Active Comparator|TIVA|Group of patients undergoing the surgery under total intravenous anesthesia
3171826|NCT01397318||Experimental Group|
3171827|NCT01397318||Control Group|
3171828|NCT01397305|Experimental|Modufolin and Pemetrexed|Modufolin ( [6R] 5,10-methylenetetrahydrofolate) and Pemetrexed
3171829|NCT01397279|Active Comparator|Botnia clamp|hyperinsulinemic euglycemic clamp following intravenous glucose tolerance test
3171830|NCT01397279|Active Comparator|hyperinsulinemic euglycemic clamp|hyperinsulinemic euglycemic clamp without previous intravenous glucose tolerance test
3171831|NCT01397266|Active Comparator|Active TMS|active rTMS delivered to the left dorsolateral prefrontal cortex
3171832|NCT01397266|Placebo Comparator|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
3171833|NCT01397253|No Intervention|(Usual) MedTrak system of PCP notification|MedTrak, the information system used by the University of Pittsburgh Medical Center (UPMC), currently notifies PCPs when patients are admitted and discharged from the hospital.
3171834|NCT01397253|Experimental|Automated communication tools|An enhanced version of MedTrak (the present system of PCP notification). Electronic medical record links will be developed and used to allow automated communication with the PCP.
3171835|NCT01397240|Experimental|Albis|Drug: Albis Tab 2 tab, twice a day
3171836|NCT01397240|Placebo Comparator|Placebo|Placebo 2 tab, twice a day
3171837|NCT01397227|Experimental|Cohort 1 (Low Dose)|Ad35.CS.01/Ad26.CS.01 - 1 x 10^10 vp
3171838|NCT01397227|Experimental|Cohort 2 (High Dose)|Ad35.CS.01/Ad26.CS.01 - 5 x 10^10 vp
3171839|NCT01397227|Placebo Comparator|Cohort 1 - Placebo|
3171840|NCT01397227|Placebo Comparator|Cohort 2 - Placebo|
3171841|NCT01397214|Experimental|Megace F|Megace F oral suspension
3171842|NCT01397214|Active Comparator|Megace OS|Megace acetate oral suspension
3171843|NCT01397201|Experimental|BI 54903 LD BID|patient to receive Respimat inhaler containing LD BI54903 plus placebo matching HFA MDI inhaler
3171844|NCT01397201|Experimental|BI 54903 MD BID|patient to receive Respimat inhaler containing MD BI54903 plus placebo matching HFA MDI inhaler
3171845|NCT01397201|Experimental|BI 54903 HD BID|patient to receive Respimat inhaler containing HD BI54903 plus placebo matching HFA MDI inhaler
3171846|NCT01397201|Active Comparator|Fluticasone propionate 220mcg BID|patient to receive Fluticasone HFA MDI inhaler containing 220 mcg ICS plus placebo matching Respimat inhaler
3171847|NCT01397201|Placebo Comparator|Placebo|patient to receive placebo matching Respimat inhaler plus placebo matching HFA MDI inhaler
3171848|NCT01397188|Experimental|PiCCO group|Intervention: Device: Picco- thermodilution catheter
3171849|NCT01397188|Sham Comparator|sham group|No PiCCO Intervention
3171850|NCT01397175|Active Comparator|Biolimus-eluting stent|Biomatrix stent, Biosensors, USA Biomatrix Flex stent, Biosensors, USA
3171851|NCT01397175|Active Comparator|Everolimus-eluting stent|Xience Prime stent, Abbott, USA Xience V stent, Abbott, USA
3171852|NCT01397175|Active Comparator|Zotarolimus-eluting stent|Endeavor resolute, Medtronic, USA Endeavor resolute integrity, Medtronic, USA
3171853|NCT01397162|Experimental|BI 54903 LD BID|BI 54903 low dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.
3171854|NCT01397162|Experimental|BI 54903 MD BID|BI 54903 medium dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.
3171855|NCT01397162|Experimental|BI 54903 HD BID|BI 54903 high dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.
3171856|NCT01397162|Active Comparator|Fluticasone propionate 88 mcg BID|44 mcg Fluticasone propionate 2 puffs BID via HFA MDI plus placebo BI54903 via Respimat inhaler 2 puffs b.i.d.
3171857|NCT01397162|Placebo Comparator|Placebo|Placebo Respimat inhaler 2 puffs b.i.d. and placebo HFA MDI, 2 puffs b.i.d.
3171858|NCT01397149|Experimental|Eltrombopag|In phase II, patients will be randomized (2:1 eltrombopag : placebo) to receive either eltrombopag or placebo to explore the efficacy and confirm the safety of the identified eltrombopag dose from Phase I.
3171859|NCT01397149|Placebo Comparator|Film coated tablet|
3171860|NCT01397123|Experimental|Lifestyle counseling|
3171861|NCT01397110|Active Comparator|Respiratory and exercise therapy|Randomized, prospective, controlled, blinded study of three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional rehabilitation without a specific training program. After 15 weeks training is also offered to patients in the control group.
3171862|NCT01397110|No Intervention|Control group without exercise training|"patients of the control group continue their sedentary lifestyle without given advice for exercise training.~The time before start of rehabilitation (three months) serves as control group. Afterwards patients take part in the training program as well."
3171863|NCT01397097|Experimental|Arm 1|
3171864|NCT01397097|Active Comparator|Arm 2|
3171865|NCT01397084|Other|esomeprazole 20 mg|esomeprazole 20 mg
3171866|NCT01397071|Active Comparator|Ground Beef Patty with Avocado|Test burgers with fresh avocado added just prior to consumption
3171867|NCT01397071|Active Comparator|Ground Beef Patty without Avocado|Test burgers
3171868|NCT01397045|Active Comparator|Video-assisted lung segmentectomy|Patients undergoing VATS segmentectomy
3171869|NCT01397045|Other|Mini thoracotomy|Patients undergoing lung segmentectomy through a mini thoracotomy
3171870|NCT01397032|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
3171871|NCT01397032|Placebo Comparator|Placebo|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns.
3171872|NCT01397019|Experimental|FOLFIRINOX|
3171873|NCT01397006|Experimental|Pregabalin|
3171874|NCT01397006|Placebo Comparator|Placebo|
3171875|NCT01396993||iTOP|Patients undergoing immediate techniques for oncoplastic surgery (level I only parenchmyl rotation and breast undermining as well as level II using complex reduction plastics for nipple-areola-complex movings) and patients with mastectomy and immediate reconstruction
3171876|NCT01396993||BCT|patients undergoing conservative breast surgery
3171877|NCT01396980||dialysis patients|dialysis patients, stabil, dialysis dependancy for more than 3 months, with adequate access
3171878|NCT01396941|Experimental|sleep restriction|The investigators will compare the effects of sleep restriction vs. normal sleep in healthy volunteers, using a randomized crossover study design. Each subject will undergo a period of normal sleep and a period of sleep restriction, separated by a 1-month washout period. Subjects will be randomized to receive either sleep restriction first (later followed by normal sleep) or normal sleep first (later followed by sleep restriction).
3171879|NCT01396928||"J pouch"|"Anastomosis coloanal wiht j pouch reservoir"
3171880|NCT01396928||Transverse coloplasty pouch|Coloanal anastomosis with transverse coloplasty pouch reservoir
3171881|NCT01396915||High or Normal Dietary Protein Intake|
3171882|NCT01396902|Active Comparator|Standard of care|
3171883|NCT01396902|Experimental|Text Messaging|
3171884|NCT01396889|Experimental|Echinacea|0.5ml daily for children 1-2 years old and 2ml daily for children2-5 years old for 3 months
3171885|NCT01396889|Placebo Comparator|Placebo|Placebo
3171886|NCT01396876|Active Comparator|Clown|A clown is present during venipuncture
3171887|NCT01396876|No Intervention|No clown|
3171888|NCT01396863|Active Comparator|First treatment HDF|The patient will receive treatment with pre-dilution hemodiafiltration during the first examination day. During the second examination day the patient will receive treatment with low flux hemodialysis.
3171889|NCT01396863|Active Comparator|First treatment HD|The patient will receive treatment with low flux hemodialysis during the first examination day. During the second examination day the patient will receive treatment with pre-dilution hemodiafiltration.
3171890|NCT01396850||Psychotic Group|
3171891|NCT01396850||Anxiety|
3171892|NCT01396850||Depressed|
3171893|NCT01396850||Control Group|
3171894|NCT01396837|Experimental|RedDress Wound Care System (RD1)|RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit
3171895|NCT01396824||Heart failure|Heart failure patients attending a HF clinic with depressed LVEF (< 45%) or ≥ 1 hospital admission due to HF decompensation.
3171896|NCT01396811|Experimental|Active|Product 33525
3171897|NCT01396811|Placebo Comparator|Placebo|Product 33525 Placebo
3171898|NCT01396798||Children with an acute illness|Children aged 1 month to 16 years of age, which attend the A&E department of UZLeuven with an acute illness episode of maximum 5 days.
3171899|NCT01396785|Experimental|Active|Product 33525
3171900|NCT01396785|Placebo Comparator|Placebo|Product 33525 Placebo
3171901|NCT01396772|Experimental|PREPARE education program|This is a 6-month program that consists of monthly nutrition and physical activity education sessions (2 hours per session) and includes interactive hands-on activities to help you gain knowledge and skills to make positive lifestyle choices. It is a pilot study to test the effectiveness of this type of health-care program in individuals with prediabetes.
3171902|NCT01396772|Other|Control arm|Individuals self-selecting the control arm receive the current standard of care for prediabetes, which is a one-time 2-hour group education session. In addition, the individuals are asked to provide some information at baseline and 6 months and 1 year later. The information collected will include a record of dietary and physical activity habits and whether or not they have developed Type 2 diabetes.
3171903|NCT01396759|Experimental|bubble CPAP|Children will receive bubble CPAP Bubble-CPAP, which requires a source of gas flow (typically 6-8 L/ minute in a neonate), an air-oxygen blender, a humidifier and a T-piece. The expiratory arm is inserted in a bottle of water and the level of CPAP delivered is equivalent to the length of the expiratory tubing that remains under water. Robust equipment is now available at a fraction of the cost of mechanical ventilators. Bubble-CPAP has potential advantages over the mechanical ventilation, such as lower cost, ease of application by nursing staff, lower risk of complications, and has been proposed as an inexpensive method of delivering CPAP in developing countries.
3171904|NCT01396759|Experimental|High flow air/ oxygen mix|High flow air/ oxygen mix is useful in reducing the indication of mechanical ventilation (4); however, there is a lack of randomized studies comparing it with bubble CPAP or with standard flow O2 supplementation by nasal prongs. High flow air/oxygen mix uses flows of 2 litre per kg per minute of blended air / oxygen mix, usually with a low fraction of inspired oxygen (say 25-40%).
3171905|NCT01396759|Active Comparator|Standard O2 supplementation by nasal prongs|Standard O2 supplementation by nasal prongs @ 0.5-2.0 litre per minute
3171906|NCT01396746||People with Post Stroke Conditions|(a) having acquired stroke at least 1 year before testing. (b) Chronic weakness and/or spasticity of the affected side. (c) Independent stair-climbers (with hand-rail). (d) With cognitive level sufficient to comprehend instructions. (e) age range between 40-69. (f) Use of walking aid is permitted as long as the participant is able to walk on a treadmill with hand-rail. (g) No heart failure or other medical conditions that preclude participation in the study.
3171907|NCT01396733|Active Comparator|Low dose group|Patients who will receive 600 mg/day alpha-lipoic acid
3171908|NCT01396733|Active Comparator|High dose group|Patients who will receive 1,200 mg/day alpha-lipoic acid
3171909|NCT01396720|Active Comparator|fluvoxamine|
3171910|NCT01396720|Active Comparator|citalopharm|
3171911|NCT01396707|Experimental|Herceptin+XELOX|
3171912|NCT01396694||all|All patients requiring arthroscopy or arthroplasty
3171913|NCT01396655|Experimental|docetaxel + doxorubicin|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks.
3171914|NCT01396642|Experimental|Topical Emollient|Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
3171915|NCT01396642|No Intervention|Routine Skin Care|Neonates in this group will receive routine skin care as per unit protocol
3171916|NCT01396629||single group|the intra ocular lenses will be loaded in the cartridge.
3171917|NCT01396616|Experimental|Single Arm|The enrolled subject will be implanted with Toric IOL manufactured by AuroLab
3171918|NCT01396590|Active Comparator|6 x 2 mg perampanel|
3171919|NCT01396590|Active Comparator|12 mg Perampanel|
3171920|NCT01396577|Active Comparator|3 x 2-mg perampanel|
3171921|NCT01396577|Active Comparator|6mg perampanel|
3171922|NCT01396564|Active Comparator|Metformin|Randomized patients are given 850 mg of metformin daily, increased to 1700 mg after 12 weeks. Adherence is evaluated and after the first phase, the arm is opened. Fasting plasma glucose concentration, body weight, and blood pressure, fasting plasma lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol), HbA1c are measured during the initial and final week of treatment. Dietary adherence is reinforced.
3171969|NCT01396252|Placebo Comparator|Arm 2: Placebo matching BMS-820836|Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)
3171923|NCT01396564|Active Comparator|Pioglitazone|Randomized patients are given 15 mg of pioglitazone daily, increased to 60 mg after 12 weeks. Adherence is evaluated and after the first phase, the arm is opened. Fasting plasma glucose concentration, body weight, and blood pressure, fasting plasma lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol), HbA1c are measured during the initial and final week of treatment. Dietary adherence is reinforced.
3171924|NCT01396551|Experimental|Transponder implantation|Implantation of anchored Beacon transponder in the lung
3171925|NCT01396525|Experimental|Omnilink Elite™ Peripheral Balloon-Expandable Stent System|
3171926|NCT01396512|Experimental|IMOJEV™ Vaccine Group|Participants will receive a single dose of the Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV™) on Day 0.
3171927|NCT01396512|Active Comparator|CD.JEVAX ™ Vaccine Group|Participants will receive a single dose of the Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine), CD.JEVAX™ on Day 0
3171928|NCT01396499|Experimental|BKM120|Oral BKM120 starting dose 80 mg once daily.
3171929|NCT01396486|Active Comparator|Omega-3/Placebo|Combination Omega-3 and Placebo treatment.
3171930|NCT01396486|Active Comparator|Placebo/Inositol|Combination Placebo and Inositol treatment.
3171931|NCT01396486|Active Comparator|Omega-3/Inositol|Combination Omega-3 and Inositol treatment.
3171932|NCT01396473|No Intervention|control|
3171933|NCT01396473|Experimental|Policy and Environmental Change|
3171934|NCT01396460||bariatric patients|Bariatric post operative patients were compared with morbid obese population
3171935|NCT01396460||control group|morbid obese population
3171936|NCT01396447|Placebo Comparator|Placebo|Participants received placebo orally once a day for 8 weeks.
3171937|NCT01396447|Experimental|Cariprazine 0.75 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2 and cariprazine 0.75 mg orally once a day starting on Day 3 for the remainder of the 8 week treatment period.
3171938|NCT01396447|Experimental|Cariprazine 1.5 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, and cariprazine 1.5 mg orally once a day starting on Day 8 for the remainder of the 8 week treatment period.
3171939|NCT01396447|Experimental|Cariprazine 3.0 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, cariprazine 1.5 mg orally on Days 8-14, and cariprazine 3.0 mg orally once a day starting on Day 15 for the remainder of the 8 week treatment period.
3171940|NCT01396434||Prevenar 13 patients|
3171941|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] High Dose|Higher Dose, tablet, once daily, for six weeks
3171942|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] Middle Dose|Middle Dose, tablet, once daily, for six weeks
3171943|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] Low Dose|Lower Dose, tablet, once daily, for six weeks
3171944|NCT01396421|Placebo Comparator|Placebo|Placebo, once daily, for six weeks
3171945|NCT01396408|Active Comparator|Sunitinib|
3171946|NCT01396408|Active Comparator|Temsirolimus|
3171947|NCT01396395|Experimental|Standard treatment plus nicorandil|The subjects will receive nicorandil 5 milligram (mg ) tablet orally three times daily for a period of 12 weeks along with one of the standard antianginal therapies (such as aspirin, beta-blockers, lipid lowering statins and angiotensin-converting enzyme inhibitors [(ACEIs] as permitted by disease condition /as per standard local practices/prescribed per discretion of investigators).
3171948|NCT01396395|Other|Standard treatment|
3171949|NCT01396382|Experimental|68Ga-DOTATATE PET|Patients will receive a 68Ga-DOTATATE PET scans
3171950|NCT01396369|Active Comparator|Birth control|
3171951|NCT01396369|Experimental|Birth control plus Brevail|
3171952|NCT01396356||ablation procedure|
3171953|NCT01396343||Pediatric MS Case|Demographic and Medical History Questionnaire, Environmental Exposure Questionnaire, Food Frequency Questionnaire, Blood Sample Collection
3171954|NCT01396343||Pediatric Control|Demographic and Medical History Questionnaire, Environmental Exposure Questionnaire, Food Frequency Questionnaire, Blood Sample Collection
3171955|NCT01396330|Other|Stress|
3171956|NCT01396317|Experimental|Tocilizumab|This is a single-arm study. All subjects will receive the active study treatment for 12 months, and will then be evaluated for 3 months of long-term follow-up.
3171957|NCT01396304|Experimental|Restore Calcium Alginate Dressing Silver|Restore Calcium Alginate Dressing Silver under compression wrap
3171958|NCT01396304|Active Comparator|Aquacel Ag Wound Dressing|Aquacel Ag Wound Dressing under compression wrap
3171959|NCT01396291|Experimental|Asenapine|All study participants will first receive open-label asenapine and placebo for 12 to 16 weeks before being randomized. After randomization, participants will receive asenapine or placebo (this is the double-blind period) for up to 26 weeks.
3171960|NCT01396291|Placebo Comparator|Placebo|All study participants will first receive open-label asenapine and placebo for 12 to 16 weeks before being randomized. After randomization, participants will receive asenapine or placebo (this is the double-blind period) for up to 26 weeks.
3171961|NCT01396278|Experimental|BI 54903 LD BID|patient to receive Respimat inhaler containing LD BI54903 plus placebo matching HFA MDI inhaler
3171962|NCT01396278|Experimental|BI 54903 MD BID|patient to receive Respimat inhaler containing MD BI54903 plus placebo matching HFA MDI inhaler
3171963|NCT01396278|Experimental|BI 54903 HD BID|patient to receive Respimat inhaler containing HD BI54903 plus placebo matching HFA MDI inhaler
3171964|NCT01396278|Active Comparator|Fluticasone propionate 440 mcg BID|patient to receive Fluticasone HFA MDI inhaler containing 440 mcg ICS plus placebo matching Respimat inhaler
3171965|NCT01396278|Active Comparator|Fluticasone propioante 88 mcg BID|patient to receive Fluticasone HFA MDI inhaler containing 88 mcg ICS plus placebo matching Respimat inhaler
3171966|NCT01396265|Experimental|Afatinib alone (Reference)|Tablet, Oral administration with 240 mL of water
3171967|NCT01396265|Experimental|Rifampicin + Afatinib (Test)|Tablet, Oral administration with 240 mL of water
3171968|NCT01396252|Experimental|Arm1: BMS-820836|Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)
3172378|NCT01393314|Active Comparator|Honeywell HomMed Telemonitor|
3171970|NCT01396239|Experimental|AVI-4658 (Eteplirsen)|"50 mg/kg eteplirsen for 28 weeks~30 mg/kg eteplirsen for 28 weeks"
3171971|NCT01396239|Placebo Comparator|Placebo / Delayed Treatment|"3a. Placebo 50 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 50 mg/kg of eteplirsen for 4 weeks.~3b. Placebo 30 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 30 mg/kg of eteplirsen for 4 weeks."
3171972|NCT01396226|Experimental|1|A single dose of AZD2927 administered as an iv infusion
3171973|NCT01396226|Placebo Comparator|2|A single dose of placebo administered as an iv infusion
3171974|NCT01396213|Experimental|Larazotide Acetate 0.5 mg|larazotide acetate 0.5 mg capsules TID
3171975|NCT01396213|Experimental|Larazotide Acetate 1 mg|larazotide acetate 1 mg capsules TID
3171976|NCT01396213|Experimental|Larazotide Acetate 2 mg|larazotide acetate 2 mg capsules TID
3171977|NCT01396213|Placebo Comparator|Placebo|placebo capsules TID
3171978|NCT01396200|Experimental|Hydroxychloroquine (Cohort B)|Infusional cyclophosphamide 300mg/m2/day for 4 days IV and dexamethasone 40mg/day orally or IV for 4 days on days 1 through 4. Hydroxychloroquine oral will be given on days 5 through 28 of cycle 1 and every day of all subsequent cycles (to be given with milk or food at approximately the same time each day)
3171979|NCT01396200|Experimental|Rapamycin (Cohort A)|Infusional cyclophosphamide 300 mg/m2/day for 4 days IV and dexamethasone 40 mg/day orally or IV for 4 days on days 3 through 6. Rapamycin oral loading dose will be given on day 1 followed by an oral daily dose for an additional 5 days (days 2 through 6) to be given on an empty stomach at approximately the same time each day suggested 11 am)This dosing schedule is the same for all cycles.
3171980|NCT01396187|Experimental|Treatment|
3171981|NCT01396187|Placebo Comparator|Placebo|
3171982|NCT01396174|Active Comparator|Standard Online Support Group|
3171983|NCT01396174|Experimental|Prosocial Online Support Group|
3171984|NCT01396161|Experimental|30 mg PF-05175157 or Placebo QD|
3171985|NCT01396161|Experimental|100 mg PF-05175157 or Placebo QD|Planned dose might be modified based on emerging safety and PK data.
3171986|NCT01396161|Experimental|200 mg PF-05175157 or Placebo QD|Planned dose might be modified based on emerging safety and PK data.
3171987|NCT01396161|Experimental|100 mg PF-05175157 or Placebo BID|Planned dose might be modified based on emerging safety and PK data.
3171988|NCT01396161|Experimental|xxx mg PF-05175157|Dose will be determined based on results obtained from Arms 1 to 4.
3171989|NCT01396148|Experimental|Children with GIST|children ages 6yrs-<18yrs
3171990|NCT01396148|Experimental|Young adults with GIST|young adults ages 18yrs-<21 yrs
3171991|NCT01396135|Experimental|Single dosing|Single doses of CP-601,927 (1, 2 or 3 mg) or placebo
3171992|NCT01396135|Experimental|Multiple dosing|Multiple doses of CP-601,927 (2 mg BID, 4mg/day) or placebo
3171993|NCT01396122|Experimental|PROSIMA group|Reconstructive surgeries with GYNECARE PROSIMA* were performed in all patients.
3171994|NCT01396109|Active Comparator|Group I|Intervention: Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System
3171995|NCT01396109|Active Comparator|Group II|Intervention: Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with Mesh
3171996|NCT01396083|Experimental|Ranibizumab|
3171997|NCT01396083|Active Comparator|Standard of Care|
3171998|NCT01396070|Experimental|Brentuximab vedotin|Novel antibody-drug conjugate, 1.8 mg/kg intravenously every 3 weeks
3171999|NCT01396057|Experimental|Ranibizumab|Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally
3172000|NCT01396057|Sham Comparator|Dexamethasone|Intravitreal implant as per commercial label (700 μg Dexamethasone; long acting release (LAR) over 6 months
3172001|NCT01396044|Experimental|Electronic checklist|Electronic checklist
3172002|NCT01396044|Experimental|Verbal prompting|Verbal prompting with written checklist
3172003|NCT01396005|Experimental|Methadone + boceprevir|Participants receive standard methadone maintenance therapy (20-150 mg tablets, liquid, or disket, orally, once per day) on Days 1 through 8 + boceprevir (800 mg [4 x 200 mg capsules], orally, every 8 hours) on Days 2 through 7)
3172004|NCT01396005|Experimental|Buprenorphine/naloxone + boceprevir|Participants receive standard buprenorphine/naloxone maintenance therapy (8/2-24/6 mg, tablets, sublingual, once per day) on Days 1 through 8 + boceprevir (800 mg [4 x 200 mg capsules], orally, every 8 hours) on Days 2 through 7
3172005|NCT01395992|Experimental|Asenapine 5 mg|Participants who were randomized to asenapine 5 mg twice per day (BID) during the P05691 study will be assigned to receive asenapine 5 mg BID on this extension study. Participant who were randomized to placebo during the P05691 study will be assigned to receive asenapine 5 mg BID on this extension trial.
3172006|NCT01395992|Experimental|Asenapine 10 mg|Participants who were randomized to asenapine 10 mg BID during the P05691 study will be assigned to receive asenapine 10 mg BID on this extension study.
3172007|NCT01395979|Experimental|Cognitive Processing Therapy for Sexual Risk (CPT-SR)|The CPT-SR condition will be comprised of 10 individual therapy sessions fully integrating sexual risk reduction counseling into cognitive therapy for sexual abuse-related trauma.
3172008|NCT01395979|Active Comparator|Time-Matched Control (TMC)|The TMC will be comprised of sexual risk reduction counseling/education and supportive psychotherapy.
3172009|NCT01395966|Active Comparator|DF289|Ear drops
3172010|NCT01395966|Active Comparator|DF277|Ear drops
3172011|NCT01395966|Experimental|DF289 plus DF277|Ear drops
3172012|NCT01395953|Active Comparator|Buspirone|
3172013|NCT01395953|Placebo Comparator|Placebo|
3172014|NCT01395940|Experimental|KLH-2109, lower dose|
3172015|NCT01395940|Experimental|KLH-2109, higher dose|
3172016|NCT01395927|Experimental|001|Canagliflozin Type=1 unit=mg number=300 form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10,Rifampin Type=2 unit=mg number=300 Form=capsule route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
3172017|NCT01395914|Experimental|100 mg QD|100 mg yellow coated, oval tablet; oral administration once daily
3172018|NCT01395914|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
3172019|NCT01395901|Experimental|Palonosetron and placebo to Ondansetron|Intervention: Drug: Palonosetron
3172020|NCT01395901|Active Comparator|Ondansetron and placebo to Palonosetron|Intervention: Drug: Comparator: Ondansetron
3172021|NCT01395888|Experimental|Relovair|Inhaled long-acting bronchodilator and corticosteroid combination
3172022|NCT01395888|Active Comparator|Tiotropium|Inhaled long-acting anticholinergic
3172023|NCT01395875||COPD patients with moderate exacerbations|COPD patients with COPD-related using ICD-9 codes physician office/outpatient visit with a dispensing for oral corticosteroid (OCS) or antibiotic (ABX) within 5 days of the visit (Phy+Rx)
3172024|NCT01395862||Patients prescribed fluticasone and salmeterol|Patients with asthma prescribed fluticasone and salmeterol for long-term use during study period
3172025|NCT01395849||Patients prescribed fluticasone and salmeterol|Patients with asthma prescribed fluticasone and salmeterol during study period
3172026|NCT01395836||Treatment|"The treatment group will be medically managed based on data obtained from monthly transmissions of the implanted Cardiac Monitor."
3172027|NCT01395836||Control Group|"The control group will be managed in the usual standard of care with physicians blinded to their ICM data."
3172028|NCT01395823|Other|ergocalciferol supplementation|
3172029|NCT01395823|Placebo Comparator|placebo|
3172030|NCT01395810|Experimental|Prophylaxis, high dose (once weekly)|
3172031|NCT01395810|Experimental|Prophylaxis, low dose (once weekly)|
3172032|NCT01395810|Experimental|On-demand|
3172033|NCT01395810|Experimental|Prophylaxis, high dose (every second week)|
3172034|NCT01395797|Placebo Comparator|Placebo - Heroin|Participants will be maintained on 0 mg of Pioglitazone (PIO) prior to sessions assessing the abuse liability of heroin.
3172035|NCT01395797|Experimental|PIO low dose - Heroin|Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of heroin.
3172036|NCT01395797|Experimental|PIO high dose - Heroin|Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of heroin.
3172037|NCT01395797|Placebo Comparator|Placebo - Nicotine|Participants will be maintained on 0 mg of PIO prior to sessions assessing the abuse liability of nicotine.
3172038|NCT01395797|Experimental|PIO Low Dose - Nicotine|Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of nicotine
3172039|NCT01395797|Experimental|PIO High Dose - Nicotine|Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of nicotine
3172040|NCT01395784|Placebo Comparator|Placebo Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Placebo (PCB).
3172041|NCT01395784|Experimental|PIO 15 Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 15 mg.
3172042|NCT01395784|Experimental|PIO 45 Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 45 mg.
3172043|NCT01395771|Experimental|Phone call|New cases and old cases will be randomly categorized into two groups,respectively,one is phone call intervention group, the other is no phone call intervention group.
3172044|NCT01395758|Experimental|tivantinib (ARQ 197) plus erlotinib arm|"Eligible subjects will be randomly assigned to receive erlotinib plus tivantinib (ARQ 197).~Treatment will be open-label and continue until progression of disease, unacceptable toxicity, or another discontinuation criterion is met."
3172045|NCT01395758|Active Comparator|Chemotherapy arm|Investigator's choice of single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered in 3-week cycles according to the approved label until disease progression or unacceptable toxicity. Subjects who discontinued chemotherapy can be switched to the crossover arm (tivantinib plus erlotinib) and continue treatment until disease progression or unacceptable toxicity.
3172046|NCT01395745|Experimental|blisibimod weekly dose|
3172047|NCT01395745|Placebo Comparator|Placebo|
3172048|NCT01395732|Experimental|1|
3172049|NCT01395719|No Intervention|Non remote ischemic conditionin(non-rIC)|Patients receiving kidney transplantation from a deceased donor. This group does not receive remote ischemic conditioning, but has a tourniquet on the leg (not inflated).
3172050|NCT01395719|Experimental|Remote ischemic conditioning (rIC)|Patients receiving kidney transplantation from a deceased donor. This group receives remote ischemic conditioning by inflating a tourniquet on the leg during surgery, before reperfusion of the kidney.
3172051|NCT01395706|Experimental|ICG flourescence technique|This is an uncontrolled, non-randomised, open-label, monocenter clinical trial. A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.
3172052|NCT01395693|Experimental|Salt Lake mask system|
3172053|NCT01395680||cancer adolescent|
3172054|NCT01395667|Experimental|Bevacizumab + CCRT followed by surgery|Bevacizumab 5 mg/kg every 2 weeks + radiotherapy 45~55 Gy/25 fractions, followed by total mesorectal excision
3172055|NCT01395654|Experimental|Standard rechallenge, Slow rechallenge|
3172056|NCT01395641|Experimental|Gene therapy|Intracerebral infusion of AAV2-hAADC viral vector will be performed
3172057|NCT01395615||Cohort|
3172058|NCT01395602|Placebo Comparator|placebo|placebo pill
3172059|NCT01395602|Active Comparator|cabergoline|cabergoline pill
3172060|NCT01395589|Active Comparator|Injectable + oral vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels < 25 ng/mL.
3172061|NCT01395589|Active Comparator|Oral-only Vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels < 25 ng/mL.
3172062|NCT01395563|Experimental|1|pancreatic cancer patients
3172063|NCT01395563|Experimental|2|pancreatic cancer patients
3172064|NCT01395537|Experimental|Lapatinib With Carboplatin and Paclitaxel|
3172065|NCT01395524|Experimental|NKTR-118 12.5mg|
3172066|NCT01395524|Experimental|NKTR-118 25mg|
3172067|NCT01395524|Placebo Comparator|Placebo|
3172113|NCT01395277|Experimental|Low Flavanol first then High Flavanol|"The measurements will be made on all study participants on two separate occasions; 1) before and 2 hours following consumption of a beverage with low flavanol content and 2) before and 2 hours following consumption of a beverage with high flavanol content."
3172114|NCT01395264||Episodic Migraine.|
3172115|NCT01395264||menstrual migraine|
3172068|NCT01395511|Experimental|Acupuncture|"About ten acupuncture points are selected from the following points to be used. Local Acupoints : SI14, SI15, BL10, BL12, BL13, BL14, TE15, GB20, SI9~Distal Acupoints :~Upper extremities: LU6, LU7, LU9, LI11, HT3, SI2, SI3, SI5, SI7, PC4, PC6, TE5~Lower extremities: SP3, SP4, BL59, BL60, BL61, BL62, BL66, KI3, KI4,KI6, KI7, GB40, GB41, LR4~All Acupuncture points were prepared with 70% alcohol pads, and disposable stainless steel needles were used. Most of acupuncture were inserted vertically 1~1.5cm in depth until patient can feel De-Qi. (No more additional stimulation)"
3172069|NCT01395511|No Intervention|Waiting list group|"No Intervention Comparator~The waiting-list group did not receive acupuncture treatment and participants were permitted to receive usual care including physical therapy and exercise and were not permitted to take analgesics and antiphlogistics during the periods."
3172070|NCT01395498||fiberoptic bronchoscopy|patients undergoing fiberoptic bronchoscopy who are not immunocompromized and in whom an opportunistic infection is not suspected.
3172071|NCT01395485|Experimental|Cohort 2|Adolescents - Ages 13 to <17
3172072|NCT01395485|Experimental|Cohort 1|Adolescents - Ages 12 to <13
3172073|NCT01395485|Experimental|Cohort 4|Adults - Ages 18 to <=50
3172074|NCT01395485|Experimental|Cohort 3|Adolescents - Ages 17 to <18
3172075|NCT01395472|Experimental|TBI - Experimental Sample|TBI patients will be submitted to two acute physical exercise protocols in a cycloergometer with one weak of interval (until voluntary exhaustion and 30 minutes in ventilatory threshold I)
3172076|NCT01395472|Active Comparator|Healthy Controls|healthy volunteers will be submitted to two acute physical exercise protocols in a cycloergometer with one weak of interval (until voluntary exhaustion and 30 minutes in ventilatory threshold I)
3172077|NCT01395472|Active Comparator|TBI Controls|Patients will be submitted to a protocol of stretching for 30 minutes
3172078|NCT01395459|No Intervention|control|Care as usual is given.
3172079|NCT01395459|Experimental|IVR only|The participants in this study arm receive calls from an Interactive Voice Response (IVR) call system, to remind them that they are in need of breast, cervical and colon cancer screening, as applicable.
3172080|NCT01395459|Experimental|IVR+PCC|The participants in this study arm receive calls from an Interactive Voice Response (IVR) call system, to remind them that they are in need of breast, cervical and colon cancer screening, as applicable. Furthermore, if remained unscreened, these participants receive person to person follow up telephone calls from a prevention care coordinator (PCC) to address barriers.
3172081|NCT01395446||prolonged neutropenic patients|patients that will undergo treatment for a hematological malignancy expected to result in grade 4 neutropenia of prolonged duration
3172082|NCT01395433|Active Comparator|Treatment A|Conventional escitalopram
3172083|NCT01395433|Experimental|Treatment B|Escitalopram test treatment B
3172084|NCT01395433|Experimental|Treatment C|Escitalopram test treatment C
3172085|NCT01395420|Experimental|1|CAZ104 (2000mg Ceftazidime/500mg Avibactam)
3172086|NCT01395420|Experimental|2|CAZ104 (3000mg Ceftazidime/1000mg Avibactam)
3172087|NCT01395407|Experimental|Cohort A|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Dose level Cohort A (Gy)~21~23~25"
3172088|NCT01395407|Experimental|Cohort B|"Cohort B: resection cavity volume > 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter).~Dose level Cohort B (Gy)~18~20~22"
3172089|NCT01395407|Experimental|Cohort C|"Cohort C: resection cavity volume > 14.1 cc and ≤ 35 cc (3 - 4 cm diameter).~Dose level Cohort C (Gy)~15~17~19"
3172090|NCT01395394|Experimental|BH4 Non-Responders|Participants in this group have PKU and were deemed unresponsive to the drug. They will attend their first study visit, and proceed through the meal challenge without BH4. They will then take BH4 for 2 weeks. The second meal challenge will be performed with the participant's final dose of BH4.
3172091|NCT01395394|Experimental|Healthy Controls|Participants in this group match an enrolled PKU participant in terms of age, gender, and body mass index class. They will participate in a single study visit and will not be given BH4.
3172092|NCT01395394|Experimental|BH4 Responders|Participants in this group will use their already prescribed BH4 with the meal challenge and be assessed at a single study visit. They will take their prescribed BH4 with the meal.
3172093|NCT01395381|Placebo Comparator|Placebo|
3172094|NCT01395381|Experimental|Albendazole|
3172095|NCT01395368||Brain Speed Test|Brain Speed Test
3172096|NCT01395355|Experimental|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
3172097|NCT01395355|Active Comparator|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral weight management techniques.
3172098|NCT01395342|No Intervention|blood pressure and heart rate data|
3172099|NCT01395329|Active Comparator|Nebivolol|
3172100|NCT01395329|Active Comparator|Metoprolol|
3172101|NCT01395329|Placebo Comparator|Placebo|
3172102|NCT01395316|Experimental|Alemtuzumab|Single arm, single cohort study, all subjects will be dosed with alemtuzumab.
3172103|NCT01395303||myocardial infarction|subjects with myocardial infarction in the Tromsø study end point registry
3172104|NCT01395303||type 2 diabetes|subjects with type 2 diabetes in the Tromsø study end point registry
3172105|NCT01395303||stroke|subjects with stroke in the Tromsø study end point registry
3172106|NCT01395303||fracture|subjects with fracture in the Tromsø study end point registry
3172107|NCT01395303||cancer|subjects with cancer in the Tromsø study end point registry
3172108|NCT01395303||death|subjects registered as dead in the Tromsø study end point registry
3172109|NCT01395303||aortic stenosis|subjects with aortic stenosis in the Tromsø study end point registry
3172110|NCT01395303||control group|randomly selected controls from the Tromsø study
3172111|NCT01395290|Experimental|cholecalciferol|cholecalciferol 20.000 IU per week
3172112|NCT01395277|Experimental|High Flavanol first then Low Flavanol|"The measurements will be made on all study participants on two separate occasions; 1) before and 2 hours following consumption of a beverage with high flavanol content and 2) before and 2 hours following consumption of a beverage with low flavanol content."
3172116|NCT01395264||Cluster Headache patients|
3172117|NCT01395264||control (non-headache group)|
3172118|NCT01395251|Other|Prednisolone|Patients with suspicious of rheumatoid arthritis will undergo a prednisolone test with 20 mg per day for 3 days after 2 days of therapy with paracetamol 500 mg twice for 2 days.
3172119|NCT01395238|No Intervention|Wait-List Group|
3172120|NCT01395238|Experimental|Parenting Group|Experimental Condition. Group-based, 8 weekly sessions/2 hours per week.
3172121|NCT01395225||All Patients|There will be no separate cohorts in this study. All patients will have their specimens processed by conventional means and by the study method. The conventional means will be the control for the study method.
3172122|NCT01395212||Cardiac stem cell therapy 5 years ago|
3172123|NCT01395199|Placebo Comparator|Starch pill|Placebo
3172124|NCT01395199|Experimental|Amlodipine|Amlodipine 5mg QD
3172125|NCT01395186|Other|varicocelectomy|varicocelectomy for patients complaining of pain
3172126|NCT01395173|Placebo Comparator|Control|Subject will undergo standard colonoscopy.
3172127|NCT01395173|Active Comparator|Position change|Subject will under go standard colonoscopy, but also with position changes during colonoscope withdrawal.
3172128|NCT01395160||Adult ADHD|
3172129|NCT01395160||Bipolar Disorder|
3172130|NCT01395160||Healthy control|
3172131|NCT01395147|Experimental|Lu AA21004 group|
3172132|NCT01395134|No Intervention|Visualization of the EBSLN and RLN|Visual inspection of the nerves.
3172133|NCT01395134|Experimental|Neuromonitoring of the EBSLN and RLN|Electrical stimulation and monitoring of the nerves' function.
3172134|NCT01395121|Experimental|nilotinib|nilotinib 400mgs oral tablets
3172135|NCT01395108|Placebo Comparator|Placebo|Placebo
3172136|NCT01395108|Active Comparator|Nemonoxacin 125mg|Nemonoxacin 125mg
3172137|NCT01395108|Active Comparator|Nemonoxacin 250mg|Nemonoxacin 250mg
3172138|NCT01395108|Active Comparator|Nemonoxacin 500mg|Nemonoxacin 500mg
3172139|NCT01395108|Active Comparator|Nemonoxacin 750mg|Nemonoxacin 750mg
3172140|NCT01395108|Active Comparator|Nemonoxacin 1000mg|Nemonoxacin 1000mg
3172141|NCT01395095|Experimental|OPTICARE-A|Starts 2 weeks after ending standard cardiac rehabilitation (CR) and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
3172142|NCT01395095|Active Comparator|OPTICARE-B|Standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions)
3172143|NCT01395095|Experimental|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
3172144|NCT01395082||Entire registry group|Participants with potential myopericarditis cases referred to the Registry
3172145|NCT01395069|Active Comparator|Nepafenac 0.1%|
3172146|NCT01395069|Active Comparator|Ketorolac 0.5%|
3172147|NCT01395069|Placebo Comparator|Placebo|
3172148|NCT01395043|Other|TAP-catheter|Each patient receives bilateral TAP-catheters preoperatively.
3172149|NCT01395030|Experimental|Diagnostic (18F-fluoromethylcholine PET/CT)|Patients undergo 18F-fluoromethylcholine PET/CT scan within 14 days of surgical resection.
3172150|NCT01395017|Active Comparator|Group 1|One arm will receive standard of care treatment (ie, GEM 1000 mg/m2 by intravenous [IV] infusion weekly for 3 weeks of a 4-week cycle) plus dasatinib 100 mg by mouth once daily (QD).
3172151|NCT01395017|Placebo Comparator|Group 2|The other arm will receive standard of care treatment (ie, GEM 1000 mg/m2 by intravenous [IV] infusion weekly for 3 weeks of a 4-week cycle) plus matched placebo by mouth once daily (QD).
3172152|NCT01395004|Experimental|Active Drug - GSK2110183|This was an open-label study of oral GSK211083 administered at the maximum tolerated dose of 125 mg once daily.
3172153|NCT01394991|Experimental|001|Epoetin alfa 450 IU/kg once a week (QW) 450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
3172154|NCT01394991|Experimental|002|Epoetin alfa 150 IU/kg 3 times a week (TIW) 150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
3172155|NCT01394978|Other|Control|No treatment.
3172156|NCT01394978|Experimental|ProGEL Pleural Air Leak Sealant|Standard surgical technique plus Progel Pleural Air Leak Sealant.
3172157|NCT01394965|No Intervention|ECG Mapping|
3172158|NCT01394952|Experimental|1.5 mg Dulaglutide|Administered subcutaneously, weekly for up to 8 years
3172159|NCT01394952|Placebo Comparator|Placebo|Administered subcutaneously, weekly for up to 8 years
3172160|NCT01394939|Experimental|Single Agent|JX-594 administered intravenously weekly for 5 weeks followed by up to 3 additional intravenous infusion boosts.
3172161|NCT01394939|Experimental|Combination|JX-594 administered intravenously weekly for 5 weeks followed by up to three additional intravenous infusion boosts in combination with Irinotecan administered every 14 days beginning at Day 9.
3172162|NCT01394926|Experimental|Arm Number 1|
3172163|NCT01394913|Experimental|Reumatocept 25mg|50mg each week for 30 weeks
3172164|NCT01394913|Active Comparator|Enbrel 25mg|50mg each week for 30 weeks
3172165|NCT01394900|Experimental|CNU intervention|African American/Black men who have sex with men (MSM) in same sex intimate relationships in which at least one partner is illicitly using psychostimulants and/or psychoactive substances will receive 4 sessions of CNU intervention
3172166|NCT01394900|Active Comparator|WP intervention|African American/Black men who have sex with men (MSM) in same sex intimate relationships in which at least one partner is illicitly using psychostimulants and/or psychoactive substances will receive 4 sessions of general wellness promotion (WP) intervention
3172167|NCT01394887|Active Comparator|metformin group|this group received 850 mg metformin twice daily, along with recommended diet and exercise
3172168|NCT01394887|Placebo Comparator|placebo group|This group received 850 mg of placebo twice daily, along with a recommended regimen of diet and exercise
3172169|NCT01394874|Experimental|Telephone-linked Communication (TLC)|This group will receive the computer-based telephone counseling.
3172170|NCT01394874|No Intervention|Control|This is the control group. They will receive the exercise class, however, they will not receive the telephone counseling.
3172171|NCT01394861|Experimental|ESD using MASTER Slave Robotic System|
3172172|NCT01394848|Active Comparator|Genous stent group|Genous stent (Endothelial progenitor cell capture stent) insertion in elderly patients with stable coronary artery disease
3172173|NCT01394848|Active Comparator|Xience stent group|Xience Prime V stent (everolimus eluting stent) insertion in elderly patients with stable coronary artery disease
3172174|NCT01394848|Active Comparator|Atorvastatin 20mg group|
3172175|NCT01394848|Active Comparator|Atorvastatin 80mg group|
3172176|NCT01394835|Experimental|Alpha -1 Antitrypsin|
3172177|NCT01394822||Ultrasound results reported|
3172178|NCT01394822||Ultrasound results NOT reported|
3172179|NCT01394809|Experimental|Mental Practice|During motor imagery practice a person imagines performing a movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of movement performance. The guideline offers therapists structure and a strategy to deliver subject-specific imagery, and is based on principles of motor learning.
3172180|NCT01394809|Experimental|Mirror Therapy|Mirror therapy is thought to work by using vision of the intact or good arm to replace or drive proprioception in the affected arm, and so normalise the afferent segment of the movement process.
3172181|NCT01394809|Active Comparator|Relaxation training|The control group will receive therapy as usual. Currently, this means that patients are immobilized during first 3-4 weeks. The control group will receive additional relaxation training during this period to achieve the same total amount of time the therapist spends with the patients of the experimental groups.
3172182|NCT01394796|Active Comparator|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
3172183|NCT01394796|Placebo Comparator|Placebo|No active substance is given.
3172184|NCT01394783|Other|Classic laryngoscope|Phase 1 and 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
3172185|NCT01394783|Other|Videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
3172186|NCT01394770|Experimental|Aliskiren|
3172187|NCT01394770|Active Comparator|Amlodipine|
3172188|NCT01394731|Experimental|Paracetamol 1|
3172189|NCT01394731|Experimental|Paraceatmol 2|
3172190|NCT01394731|Active Comparator|Meperidine|
3172191|NCT01394718|Placebo Comparator|Saline Placebo|Control subjects will receive saline as placebo at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
3172192|NCT01394718|Experimental|Intravenous Acetaminophen|Subjects will receive the first dose of intravenous (IV) acetaminophen (at 15 mg/kg, with maximum doses based on patient age and weight) at the time of skin closure intra-operatively and will continue to receive IV acetaminophen for 42 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
3172193|NCT01394705|Experimental|Standard of Care|
3172194|NCT01394705|Experimental|Intervention|
3172195|NCT01394692|Active Comparator|intraoperative MRI|tumor resection with intraoperative MRI-guidance
3172196|NCT01394692|Active Comparator|conventional group|standard microsurgical tumor resection
3172197|NCT01394679|Active Comparator|18-F-FDG Imaging Agent|18 F FDG followed by PET/CT imaging
3172198|NCT01394679|Experimental|99m Tc-EC-DG imaging agent|99m Tc-EC-DG injection followed by SPECT/CT imaging (target of 20-30 mCi of Tc)and < 1 mg EC-DG
3172199|NCT01394666||CP-CML patients who have failed Imatinib 400 mg daily|
3172200|NCT01394653|Experimental|orally-disintegrating (OD) tablet precedence group|
3172201|NCT01394653|Experimental|conventional tablet precedence group|
3172202|NCT01394640||Healthy Volunteers|Healthy people without any serious comorbidity (no immunosuppressive treatment, no autoimmune disease, no cancer) receiving the same vaccine
3172203|NCT01394640||Onco-hematologic patients|Patients with lymphoma or myeloproliferative diseases or multiple myeloma either receiving chemotherapy or in follow-up or treated with allogeneic hematopoietic stem cell transplant.
3172204|NCT01394627|Experimental|Eplerenone|hypoglycemia (50 mg/dl) with pretreatment with two doses of eplerenone (100 mg of eplerenone per dose)
3172205|NCT01394627|Placebo Comparator|placebo|hypoglycemia of 50 mg/dl plus placebo
3172206|NCT01394614||Narcoleptics exposed to A/H1N1 vaccine|Adjuvanted (ASO3) A/H1N1 pandemic vaccine
3172207|NCT01394614||Narcoleptics unexposed to A/H1N1 vaccine|Narcoleptic subjects who were unexposed (non-vaccinated or vaccinated after onset) to adjuvanted (ASO3) A/H1N1 pandemic vaccine.
3172208|NCT01394588||Cardiac Surgery Patients|Competent Adult Patients going for elective cardiac surgery.
3172209|NCT01394575|Experimental|IMRT-SIB|
3172210|NCT01394562|Experimental|Ferinject (ferric carboxymaltose)|
3172211|NCT01394562|Other|Standard of Care|Standard of care. IV iron is not permitted
3172212|NCT01394549||Cardiology|The study includes all patients hospitalized for acute coronary syndrome during the week selected and who agreed to participate in the study.
3172379|NCT01393314|No Intervention|usual care|
3172213|NCT01394536|Sham Comparator|1|"Sham device - an EAS band placed over the P6 acupoint that will be turned off (inactive)."
3172214|NCT01394536|Active Comparator|2|The second arm will use the ReliefBand (Aeromedix, Jackson, WY), an FDA-approved, reusable, battery-operated electroacustimulation device.
3172215|NCT01394523|Active Comparator|Caudal epidural|The caudal epidural block will be delivered with 1.5ml/kg of 0.25% Bupivacaine up to a maximum of 30 mL.
3172216|NCT01394523|Active Comparator|Rectus sheath|The rectus sheath block will be performed with 0.1ml/kg of 0.25% Bupivacaine on each side at the T9-T10 distribution under ultrasound guidance.
3172217|NCT01394523|Active Comparator|Local|The surgeon will inject either 0.5% Bupivicaine 0.5ml/kg or 0.25% Bupivicaine 1ml/kg at the surgeon's discretion.
3172218|NCT01394510|Experimental|N-acetylcysteine dose study|Subjects will take N-acetylcysteine (NAC) 600 mg twice daily for 2 weeks, then 1200 mg twice daily for an additional 2 weeks. Study procedures will be performed at baseline, after 2 weeks and after 4 weeks.
3172219|NCT01394497|Experimental|NAC procurement protocol|The allocated organ, in addition to the standard procedure, was treated with a systemic NAC infusion before initiating the liver harvesting procedure, and a loco‑regional infusion into the portal vein before cross‑clamping.
3172220|NCT01394497|No Intervention|Standard procurement procedure|Allocated organ was treated according to the centre's standard procurement procedure: a modified double perfusion technique, where donor livers are gravity-perfused in situ via the aorta and portal vein with Celsior solution at 4 °C. After hepatectomy, donor livers were further perfused at the back‑table with Celsior solution and then stored in conventional bags containing the same solution at 4 °C until transplantation.
3172221|NCT01394484|Experimental|Arm 1|Four servings of dairy foods per day for 42 days, followed by washout for 42 days, followed by dietary supplements for 42 days
3172222|NCT01394484|Experimental|Arm 2|Dietary Supplements for 42 days, followed by washout for 42 days, followed by 4 servings of dairy foods for 42 days.
3172223|NCT01394471|Experimental|oxytocin|Twice daily treatment of oxytocin will be administered by subjects
3172224|NCT01394471|Placebo Comparator|Control spray|Self administration twice daily of intranasal spray that does not contain oxytocin
3172225|NCT01394458|Experimental|30 % ethanol/ 4 % sodium citrate group|For patients randomized to the 30% ethanol /4 % sodium citrate group, the lock solution will be provided in pre-filled syringes for single use only. After each dialysis session, the locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. Any remaining 30% ethanol/4% sodium citrate solution in each syringe will be discarded. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.
3172226|NCT01394458|Experimental|Heparin 1000 U/ml|For patients randomized to the heparin group, the heparin will be provided in 10 ml glass vials. Two, 3 ml syringes will be used to draw up the required volume of heparin to fill each lumen. A separate syringe will be used to fill each catheter lumen. The necessary volume should match the lumen volume with no overfill. The locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.
3172227|NCT01394445|Active Comparator|Physostigmine|
3172228|NCT01394445|Placebo Comparator|Placebo|
3172229|NCT01394432|Active Comparator|Group 1 (PCI+SC implantation)|Endocardial Stem cells implantation with Noga system
3172230|NCT01394432|Placebo Comparator|Group 2 (PCI+Placebo)|Placebo
3172231|NCT01394419|Experimental|NAC group|N-acetylcysteine
3172232|NCT01394419|Placebo Comparator|Placebo group|Saline
3172233|NCT01394406|Experimental|Ketamine group|
3172234|NCT01394406|Placebo Comparator|Saline group|
3172235|NCT01394393|Experimental|ECT|Experiential-Cognitive Therapy for Obesity
3172236|NCT01394393|Active Comparator|BCT|Cognitive behavioral treatment program
3172237|NCT01394393|Sham Comparator|NT|Nutritional groups In this condition (NT) the participants enter only 5 weekly nutritional groups held by dietitians.
3172238|NCT01394380|Experimental|artificially sweetened beverages|subjects will be required to consume only artificially-sweetened sodas, water, tea or coffee
3172239|NCT01394380|No Intervention|regular sodas|subjects will continue their usual consumption of sweetened sodas
3172240|NCT01394367|Experimental|Respiratory and exercise therapy|Randomized, prospective, controlled, blinded study of three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional rehabilitation without a specific training program. After 15 weeks training is also offered to patients in the control group.
3172241|NCT01394367|No Intervention|respiratory and exercise therapy|
3172242|NCT01394354|Experimental|1|"Vorinostat. To determine the MTD, dose escalation for Vorinostat will be conducted following the 3 + 3 design The first cohort of 3 patients will be given 100mg/d on days 1-4, 8-11, 15-18. The second cohort of 3 new patients will be treated with Vorinostat 200mg/d. The third cohort will be given Vorinostat 300mg/d. Cycles will be repeated every 28 days. Maximum treatment cycles: 6. Bortezomib will be administered intravenously (i.v.) 1.3mg/m2 BSA an days 1, 8, 15.~Doxorubicin will be administered i.v. with a total dose of 18mg/m2 BSA per cycle (9mg/m2 BSA, d1 and 8).~Dexamethasone will be administered per os (p.o.) with 40mg (first cycle) or 20mg (all other cycles) on d1, 8, 15, and 22."
3172243|NCT01394341|Active Comparator|T2D, Dialysis, Liraglutide|Daily liraglutide treatment Chronic dialysis treatment
3172244|NCT01394341|Placebo Comparator|T2D, Dialysis, Placebo|Daily placebo Chronic dialysis treatment
3172245|NCT01394341|Active Comparator|T2D, Normal kidney function, Liraglutide|Daily Liraglutide treatment Normal kidney function
3172246|NCT01394341|Placebo Comparator|T2D, Normal kidney function, Placebo|Daily placebo treatment Normal kidney function
3172247|NCT01394328||Persons with Dementia|Persons with Dementia are identified by the Modified Blessed Dementia Rating Scale and the IQCODE
3172248|NCT01394289|Experimental|Biological/Vaccine: Lolium allergen extract|Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
3172286|NCT01393951|Experimental|im dose 3|intramuscular (im) vaccination of ASP7374 dose-3
3172287|NCT01393938|Other|Mullerian Duct Anomaly|
3172249|NCT01394276||Tocilizumab|Participants with moderate to severe Rheumatoid arthritis (RA) who had received RoActemra [Tocilizumab (TCZ)] treatment for 6 months prior to initiation of study and are inadequate responders to Disease Modifying Anti-Rheumatic Drugs (DMARDs) and anti-Tumor Necrosis Factors (anti-TNFs) agents were observed. Participants received treatment with TCZ with dose of 8 milligrams per kilogram (mg/kg) body weight, intravenously once every 4 weeks for 12 months according to European Union (EU) approved dosage, and Summary of Product Characteristics (SmPC).
3172250|NCT01394263|Active Comparator|Zoladex goserelin implant.|Zoladex goserelin implant: D, L-lactic and glycolic acids copolymer. Injected subcutaneously into the upper abdominal wall.
3172251|NCT01394263|Experimental|Histrelin Acetate implant|Histrelin hydrogel implant, 3 cm x 3.5 mm, containing 50 mg of histrelin acetate, surgically placed subdermally into the inner aspect of the upper arm.
3172252|NCT01394250|Experimental|Buzzy|If randomized to Buzzy®, the nurse will demonstrate the cold pack and the device just prior to the IV cannulation procedure. The device will be applied with a Velcro strap 5 centimeters proximal to the site of IV cannulation; it will remain in place until the IV cannula is inserted and secured. All nurses that work during the study hours will be trained on the device prior to beginning the study. Training includes direct one-one training with the device including return demonstration.
3172253|NCT01394250|Active Comparator|Topical Lidocaine 4% Cream|If randomized to topical lidocaine cream, subjects will have the cream placed on two or more potential IV sites as soon as possible after the consent procedure is complete. These subjects will undergo IV placement no less than 30 minutes after the cream is applied.
3172254|NCT01394237||Operated by laparoscopic sacrocolpopexy|Patients operated at our institution by laparoscopic sacrocolpopexy between 2003 and 2007
3172255|NCT01394224|Experimental|Levetiracetam IV Infusion (1500 mg)|
3172256|NCT01394224|Experimental|Levetiracetam tablets (1500 mg)|
3172257|NCT01394211|Experimental|Neoadjuvant enzyme inhibitor therapy|"Patients receive pazopanib hydrochloride* PO QD and anastrozole PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients then undergo therapeutic conventional surgery.~NOTE: *Pazopanib hydrochloride is stopped 7-14 days before definitive surgery."
3172258|NCT01394185|Active Comparator|Low Dose Dronabinol, High Dose Dronabinol, and placebo|Participants were administered dronabinol (0 mg/day, 120mg/day and 240mg/day) for 12 days each in a random order
3172259|NCT01394159|Active Comparator|22G ProCore biopsy needle|Using the 22G ProCore needle for sampling pancreatic mass lesions, the tissue obtained will be compared to the standard FNA needle.
3172260|NCT01394159|Active Comparator|22G standard FNA needle|Using the 22G standard fine needle aspiration needle (FNA) for sampling pancreatic mass lesions, the tissue obtained will be compared to the 22 G ProCore needle.
3172261|NCT01394146|Experimental|Subjects with healthy kidney function|
3172262|NCT01394133||HIV+ Female|HIV infected women between 21-40 years of age, not receiving oral contraceptives.
3172263|NCT01394120|Experimental|Tarteted Therapy|
3172264|NCT01394120|Active Comparator|Standard Chemotherapy|
3172265|NCT01394107||Pregnant|"50 pregnant women with physiological ongoing pregnancy and undergoing planned caesarean section, without known coagulation disorders, will be included in to the study.~Inclusion criteria: pregnant women undergoing planned caesarean section, 39th-40th week of pregnancy, age 18-40 years, informed consent."
3172266|NCT01394107||Control|50 healthy women in fertility age (18-40 years) undergoing elective surgery for other than oncology or inflammatory indication, without known risk factors for coagulation disorders, not using hormonal contraception, informed consent.
3172267|NCT01394094|Experimental|Gum Chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
3172268|NCT01394094|No Intervention|Conventional|Conventional postoperative feeding schedule
3172269|NCT01394081|Experimental|Enhanced Engagement and Enrollment (EEE)|Enhanced Engagement and Enrollment (EEE) consists of the outreach worker (interventionalist) engaging the participant in education (about VA resources and medical care), navigating the patient through the VA eligibility, enrollment, and scheduling processes, and using motivational interview to focus on ambivalence about attending a VA appointment.
3172270|NCT01394081|Active Comparator|Administrative Outreach (AO)|Administrative Outreach (AO) consists of the outreach worker giving the participants an application package to VA enrollment or phone number for the scheduling clerk. This intervention does not involve education, patient navigation (guidance through VA eligibility, enrollment, and scheduling processes) or motivational interviews (interviews focused on ambivalence about attending a VA appointment).
3172271|NCT01394055|Active Comparator|RM-131|
3172272|NCT01394055|Placebo Comparator|Placebo|
3172273|NCT01394042|No Intervention|No intervention|All consenting patients will be imaged with the Proxiscan and data compared with MRI, ProstaScint and biopsy data
3172274|NCT01394029||deferasirox|
3172275|NCT01394016|Experimental|LY2835219|
3172276|NCT01394003|Experimental|LY2584702|"Oral dose escalation starting at 25 mg, daily for 28 day cycles in Part A; oral dose escalation starting at 50 mg, twice daily for 28 day cycles in Part B; oral dose with schedule determined by Parts A and B will be administered in Part C (dose confirmation)~Patients who demonstrate clinical benefit may receive treatment beyond two (2) cycles unless one or more of the criteria for discontinuation are met."
3172277|NCT01393990|Experimental|LY2228820|"Administered orally, for two (2) 28-day cycles.~Patients demonstrating clinical benefit may receive treatment beyond 2 cycles until one or more of the criteria for discontinuation are fulfilled."
3172278|NCT01393977|No Intervention|control|Outpatient in hospital
3172279|NCT01393977|Active Comparator|rehabilitation|interventions: rehabilitation
3172280|NCT01393977|Experimental|Stem Cell Transplantation|interventions: stem cell transplantation
3172281|NCT01393964|Experimental|Arm 1: Lenalidomide + Dexamethasone +Elotuzumab|Severe Renal Impairment
3172282|NCT01393964|Experimental|Arm 2: Lenalidomide + Dexamethasone +Elotuzumab|End-stage renal disease
3172283|NCT01393964|Experimental|Arm 3: Lenalidomide + Dexamethasone +Elotuzumab|Normal renal function
3172284|NCT01393951|Experimental|sc dose 1|subcutaneous (sc) vaccination of ASP7374 dose-1
3172285|NCT01393951|Experimental|sc dose 2|subcutaneous vaccination of ASP7374 dose-2
3172288|NCT01393925|Experimental|parecoxib, normal saline|
3172289|NCT01393912|Other|Stratum A Patients|The patients are newly diagnosed Diffuse Intrinsic Pontine Glioma patients. Patients may take crenolanib as an intact tablet or crushed in apple sauce/juice. Currently accruing to dose level 3 (170 mg/m^2).
3172290|NCT01393912|Other|Stratum B Patients|The patients are recurrent, refractory or progressive high-grade glioma including Diffuse Intrinsic Pontine Glioma patients. Patients may take crenolanib as an intact tablet or crushed in apple sauce/juice. Currently accruing to dose level 4 (220 mg/m^2).
3172291|NCT01393899|Placebo Comparator|Placebo BID|
3172292|NCT01393899|Experimental|5mg BID|
3172293|NCT01393899|Experimental|10mg BID|
3172294|NCT01393886|Experimental|Laparoscopic Greater Curvature Plication|Only one treatment arm
3172295|NCT01393873||Bariatric surgery pts with Type 2 DM|Primary bariatric surgery pts with Type 2 DM
3172296|NCT01393860||Aliskiren|Diabetic nephropathy
3172297|NCT01393834|Experimental|Delayed cord clamping|Delayed cord clamping for 30 seconds
3172298|NCT01393834|Experimental|Milking of the cord|Milking of the cord 4 times in 10 seconds
3172299|NCT01393834|No Intervention|Immediate cord clamping|Immediate cord clamping after delivery
3172300|NCT01393821|Experimental|Arm I (lotion)|Patients apply menadione topical lotion BID for 28 days.
3172301|NCT01393821|Placebo Comparator|Arm II (placebo)|Patients apply topical placebo lotion BID for 28 days.
3172302|NCT01393808|Experimental|Paricalcitol|
3172303|NCT01393808|Placebo Comparator|placebo|
3172304|NCT01393795|Placebo Comparator|Tegaderm|
3172305|NCT01393795|Active Comparator|Qutenza|
3172306|NCT01393782|Active Comparator|Angiotensin|The angiotensin arm will receive angiotensin II acetate at an initial dose of 20ng/kg/min, titratable during the study (6 hours) for MAP goals as outlined in the protocol.
3172307|NCT01393782|Placebo Comparator|Control|Control patients will receive placebo intravenously equal in duration, color and volume to the intervention arm's angiotensin II.
3172308|NCT01393769|Experimental|Melphalan|Intra-arterial chemotherapy with melphalan, via direct administration by catheterization of the ophthalmic artery. Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume: a)3 mg for patients under 10 kg and tumour volume size under 1,5 cm3; b)5 mg for patients over 10 kg and tumour volume over 1,5 cm3; c)4 mg in all other situations(tumour volume over 1,5 cm3 in patients under 10 kg or tumour volume under 1,5 cm3 in patients over 10 kg).
3172309|NCT01393756|Experimental|Lenalidomide dose 25 mg|
3172310|NCT01393743|Experimental|Perampanel|Participants received 6 tablets (initially 1 tablet of 2-mg perampanel plus 5 tablets of perampanel matched placebo) and up-titrated weekly in 2-mg increments to a target dose range of 8 mg per day maintaining the blind with administration of 6 tablets per day of either perampanel/placebo.
3172311|NCT01393743|Placebo Comparator|Placebo|Participants received 6 tablets of perampanel matched placebo, once a day.
3172312|NCT01393730|Experimental|Abiraterone+prednisone+dutasteride|Abiraterone acetate 1000mg orally once per day + prednisone 5mg orally once per day for two months, followed by abiraterone 1000mg orally once per day + prednisone 5mg orally once per day + dutasteride 3.5mg orally once per day in 28-day cycles until symptomatic or radiographic progression
3172313|NCT01393717|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses. Patients in the new cohort receive regular study dose of brentuximab vedotin for courses 1 and 2. Patients not achieving CR after 2 courses receive higher-dose brentuximab vedotin IV over 60 minutes on day 1 for 2 additional courses.
3172314|NCT01393704|Active Comparator|High Volume Dilute Vasopressin|20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
3172315|NCT01393704|Active Comparator|Low volume dilute vasopressin|20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
3172316|NCT01393691|Experimental|CBT with parent combined play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
3172317|NCT01393691|Active Comparator|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
3172318|NCT01393678|Experimental|PENNEL|2cap T.I.D
3172319|NCT01393678|Active Comparator|NISSEL|"NISSEL~BDD (biphenylmethyl dicarboxylate) ................25mg~2cap T.I.D"
3172320|NCT01393665|Placebo Comparator|Placebo|
3172321|NCT01393665|Experimental|PENNEL capsule|1cap or 2cap T.I.D
3172322|NCT01393652|Experimental|Cohort 1: Experimental intervention: PF-05105679 or placebo|Cohort 1
3172323|NCT01393652|Experimental|Cohort 2: Experimental intervention: PF-05105679 or placebo|Cohort 2
3172324|NCT01393652|Active Comparator|Cohort 3: Experimental intervention PF-05105679 or placebo and|Cohort 3
3172325|NCT01393639|Experimental|PF-04171327 1 mg QD|
3172326|NCT01393639|Experimental|PF-04171327 5 mg QD|
3172327|NCT01393639|Experimental|PF-04171327 10 mg QD|
3172328|NCT01393639|Experimental|PF-04171327 15 mg QD|
3172329|NCT01393639|Active Comparator|prednisone 5 mg QD|
3172330|NCT01393639|Active Comparator|prednisone 10 mg QD|
3172331|NCT01393639|Placebo Comparator|placebo|
3172332|NCT01393626|Placebo Comparator|Placebo BID|
3172333|NCT01393626|Experimental|5mg BID|
3172334|NCT01393626|Experimental|10mg BID|
3172335|NCT01393613|Experimental|Dose 3 OPC 34712|Higher dose, tablet, once daily, for six weeks
3172336|NCT01393613|Experimental|Dose 2 OPC 34712|Middle dose, tablet, once daily, for six weeks
3172337|NCT01393613|Experimental|Dose 1 OPC 34712|Lower dose, tablet, once daily, for six weeks
3172338|NCT01393613|Placebo Comparator|Placebo|Placebo, once daily, for six weeks
3172339|NCT01393600|Experimental|NBI-98854 12.5 mg|"During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence 1: Placebo once daily dose for Days 1-14 and 12.5 mg NBI-98854 once daily dose for Days 15-28.~Sequence 2: 12.5 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28."
3172340|NCT01393600|Experimental|NBI-98854 50 mg|"During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence 3: Placebo once daily dose for Days 1-14 and 50 mg NBI-98854 once daily dose for Days 15-28.~Sequence 4: 50 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28."
3172341|NCT01393587|Experimental|Experimental|
3172342|NCT01393574|Experimental|Melatonin treatment|Treatment with Melatonin before sleep for 1 month - 3 mg for body weight <40kg, 6mg for body weight >40kg
3172343|NCT01393574|Active Comparator|Stimulants treatment|Treatment with Methylphenidate with a formulary and dose as decided by the treating neurologist, for 1 month.
3172344|NCT01393561|Experimental|Group 1|Fixed dose combination of brompheniramine + phenylephrine.
3172345|NCT01393561|Placebo Comparator|Group 2|Placebo
3172346|NCT01393548|Experimental|brompheniramine + phenylephrine|Fixed dose combination of brompheniramine + phenylephrine
3172347|NCT01393548|Active Comparator|brompheniramine + pseudoephedrine|Fixed dose combination of brompheniramine + pseudoephedrine
3172348|NCT01393522|Active Comparator|Milnacipran|
3172349|NCT01393522|Placebo Comparator|Sugar Pill|
3172350|NCT01393509|Experimental|PU-H71|This Phase 1 trial will be an open-label, dose-escalation study of single-agent PU-H71 in patients with advanced solid malignancies and lymphoma.
3172351|NCT01393496|Experimental|"liberal transfusion triggers"|"liberal guidelines for red blood cell transfusions"
3172352|NCT01393496|Active Comparator|"restrictive transfusion triggers"|"restrictive guidelines for red blood cell transfusions"
3172353|NCT01393483||patients endoscopically resected|In patients with endoscopically resected T1 disease (40 patients in 2 years) if available, we will stain the initial endoscopic tumor specimen, as well as any subsequent specimen obtained at each routine 3(+/- 2) month interval endoscopy.
3172354|NCT01393483||patients treated primarily with surgery|In patients who undergo surgery as their primary therapy, serum will be obtained at the time of surgical resection, and at each subsequent long-term disease status follow-up visit every 4 (+/- 2) months.
3172355|NCT01393483||patients who undergo chemo-radiation prior to surgery|a serum sample will be obtained : 1) prior to initiation of therapy, 2) following the completion of induction chemotherapy, 3) at the time of surgical resection, and 4) at each subsequent long-term disease status follow-up visit every 4 (+/- 2) months. The availability of tissue for staining will determine whether or not patients are evaluable for Group 3.
3172356|NCT01393470||Cohort A (Trial Cohort, Vaccinated during HPV-008)|"Cohort A subjects were previously enrolled in the HPV-008 study, and have received at least 1 dose of the HPV vaccine.~Cohort A subjects have provided written informed consent prior to enrolment to allow retrieval of biospecimens for HPV DNA testing and confirmation of diagnosis.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries."
3172357|NCT01393470||Cohort B1 + B2|"Cohort B1 subjects were previously enrolled in the HPV-008 study and received at least 1 dose of HPV vaccine as cross-over vaccination at the end of the HPV-008 study.~Cohort B1 subjects have provided written informed consent prior to enrolment to allow retrieval of biospecimens for HPV DNA testing and confirmation of diagnosis.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries.~Cohort B2 (Trial Cohort, Non-Vaccinated)"
3172358|NCT01393470||Cohort C (Referent Cohort, Non-Vaccinated)|"Cohort C subjects have not participated in the HPV-008 study but have been enrolled in the Referent Cohort.~Cohort C subjects have not received any HPV vaccination (neither Cervarix, nor Gardasil, nor any experimental HPV vaccine).~Cohort C subjects are partially matched to HPV-008 in terms of the geographical recruitment area.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries."
3172359|NCT01393457|Active Comparator|ldopa + ropinirole low dose|levodopa/carbidopa 800/200 mg/d plus ropinirole 2 mg/d
3172360|NCT01393457|Active Comparator|ldopa + ropinirole high dose|levodopa/carbidopa 800/200 mg/d plus ropinirole 4 mg/d
3172361|NCT01393457|Active Comparator|ldopa|levodopa/carbidopa 800/200 mg/d
3172362|NCT01393457|Placebo Comparator|placebo|Placebo
3172363|NCT01393444|Experimental|Direct Brain Interface Users|"All participants enrolled in the study will undergo Implantation of ECoG sensors on the brain surface to record neural activity. There is no control group. There are no other arms."
3172364|NCT01393431||EBC pH|Observational study
3172365|NCT01393418||Subjects undergoing cardiac surgery|
3172366|NCT01393405|Active Comparator|Methotrexate|25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
3172367|NCT01393405|Placebo Comparator|Placebo|Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
3172368|NCT01393392|Experimental|Intensive, tailored intervention|Participants in the intensive intervention condition will receive eight individual counseling sessions, with a smoking cessation counselor, over three months. Each session will last approximately 45 minutes and occur in the methadone clinic. Participant treatment needs will be assessed during the first session and the intervention will be tailored to the participants' needs. Prior to quitting participants will receive nicotine replacement patches and lozenges and instructions on how to use them.
3172369|NCT01393392|Active Comparator|Control Intervention|Participants randomized to the control intervention will receive a referral to the NJ Quitline (a telephone smoking cessation counseling service). Participants will receive a brochure and information about the referral. Study staff will contact the NJ Quitline for control participants, and a counselor from the Quitline will call control participants.
3172370|NCT01393366|Other|Without AMA|Patient will be follow only like usual practice
3172371|NCT01393366|Other|With AMA|Patient will be follow like usual practice, plus 'Telephone Intervention' every week with a nurse to evaluate physical conditions.
3172372|NCT01393353|Sham Comparator|Computer game|Nintendo Wii
3172373|NCT01393353|Experimental|Cognitive Training with Cogniplus|CogniPlus
3172374|NCT01393340|Placebo Comparator|Placebo|
3172375|NCT01393340|Active Comparator|Omalizumab|
3172376|NCT01393327|Experimental|Respiratory and exercise therapy|Randomized, prospective, controlled, blinded study of postoperative three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional postoperative rehabilitation without a specific training program.
3172380|NCT01393301|Experimental|Behavioral Intervention Arm|Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
3172381|NCT01393301|Other|Control Arm|Enhanced Treatment as Usual (ETAU); enhanced standard smoking cessation treatment and nicotine replacement therapy (NRT).
3172382|NCT01393288|Placebo Comparator|Ondansetron|
3172383|NCT01393288|Placebo Comparator|Lorazepam|
3172384|NCT01393288|Placebo Comparator|Aprepitant|
3172385|NCT01393275|Active Comparator|Rehabilitation intervention group|The group is performing a strength endurance training intervention in addition with rehabilitation exercise intervention.
3172386|NCT01393275|Placebo Comparator|Placebo rehabilitation|The group is performing a strength endurance training intervention in addition with placebo rehabilitation exercise intervention.
3172387|NCT01393262||Healthy Escort|
3172388|NCT01393262||Hand Service patient|
3172389|NCT01393249||ALL, Asparaginase, pancreatitis|Patients that have been scanned and have had blood tests
3172390|NCT01393236||patients|patient characteristics are specified in H-2-2010-011
3172391|NCT01393236||controls|age matched to patients described in protocol H-2-2010-011
3172392|NCT01393223|Active Comparator|LP-08 80mg|4 weekly intravesical administration of LP-08 80mg
3172393|NCT01393223|Active Comparator|LP-08 20mg|4 weekly intravesical administration of LP-08 20mg
3172394|NCT01393223|Placebo Comparator|Normal Saline|Four weekly normal saline intravesical administration
3172395|NCT01393210|Active Comparator|low-calorie diet|Intervention was low-calorie diet only for 12 weeks.
3172396|NCT01393210|Active Comparator|low calorie diet plus beta-glucan|Intervention was low-calorie diet plus BETA-GlLUCAN 1.3D-1.6D 500 mg daily for 12 weeks.
3172397|NCT01393197|Active Comparator|TACE -oil|embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge
3172398|NCT01393197|Experimental|TACE-KMG ( routine dose Chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）
3172399|NCT01393197|Experimental|TACE-KMG( low dose Chemo )|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with low dose Epirubicin （5-10mg/m2）
3172400|NCT01393197|Experimental|TACE-KMG(without chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g)
3172401|NCT01393184|Experimental|Radiotherapy + Nimotuzumab|"Radiotherapy (RT) Technique: IMRT, Rapid Arc, Tomotherapy Total dose: GTV 70 Gy & CTV 60 Gy/33F~Nimotuzumab (Nimo) weekly Nimo (200 mg) × 8, started 1 w before RT"
3172402|NCT01393184|Active Comparator|Radiotherapy (RT)|Radiotherapy (RT) Technique: IMRT, Rapid Arc, Tomotherapy Total dose: GTV 70 Gy & CTV 60 Gy/33F
3172403|NCT01393171|Active Comparator|Polypropylene Mesh|Site-specific cystocele repair with polypropylene mesh augmentation
3172404|NCT01393171|Placebo Comparator|Anterior Colporrhaphy|Anterior vaginal prolapse repair with anterior colporrhaphy with no graft.
3172405|NCT01393171|Active Comparator|Porcine Dermis|Site-specific cystocele repair with porcine dermis augmentation
3172406|NCT01393158|Experimental|Apremilast|One-arm study
3172407|NCT01393145|Experimental|Group 1|
3172408|NCT01393145|Active Comparator|Group 2|
3172409|NCT01393132|Experimental|Thymosin Beta 4 eye drops|It is a preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, six times daily for 28 days
3172410|NCT01393132|Placebo Comparator|Vehicle Control|It is composed of the same excipients as RGN-259 but does not contain Tβ4 for direct instillation into each eye, six times daily for 28 days.
3172411|NCT01393119|Experimental|3000mg GTx-758 daily|loading dose 3000mg GTx-758 daily + maintenance dose of 1000mg
3172412|NCT01393119|Experimental|3000 mg GTx-758 daily|loading dose of 3000mg GTx-758 daily + maintenance dose of 2000mg GTx-758 daily
3172413|NCT01393119|Experimental|1500 mg GTx-758 BID|Loading dose of 1500 mg GTx-758 BID + maintenance dose of 1000mg GTx-758 daily
3172414|NCT01393119|Experimental|1500mg GTx-758 BID|loading dose of 1500mg of GTx-758 BID + maintenance dose of 2000mg GTx-758 daily
3172415|NCT01393106|Experimental|Idelalisib|Participants will receive up to 300 mg of idelalisib twice daily.
3172416|NCT01393093|Active Comparator|TACE -oil|embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge
3172417|NCT01393093|Experimental|TACE-KMG ( routine dose Chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）
3172418|NCT01393093|Experimental|TACE-KMG( low dose Chemo )|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with low dose Epirubicin （5-10mg/m2）
3172419|NCT01393093|Experimental|TACE-KMG(withou chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g)
3172420|NCT01393080|Experimental|Nimotuzumab and TP regimen|"TP Regimen ：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.~Nimotuzumab : 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression."
3172421|NCT01393080|Placebo Comparator|TP Regimen|TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.
3172422|NCT01393067|Active Comparator|study group NEPS|implantation of multiple non-expandable plastic stents
3172423|NCT01393067|Active Comparator|group cSEMS|implantation of a self-expandable metal stent (cSEMS)
3172424|NCT01393041|Other|Angio-Seal VIP|
3172425|NCT01393028|Experimental|Cardiac CT|Cardiac CT (CT calcium and/or CT angiography), followed by stress testing, invasive angiography or neither depending on the CT scan result
3172426|NCT01393028|Other|Standard care|Standard diagnostic management, including stress testing and/or invasive angiography
3172427|NCT01393015|Experimental|FreeO2 system|FreeO2 is a new system that automatically adjusts the oxygen flow delivered to patients in closed-loop based on the SpO2 signal. This system is intended to maintain SpO2 in a predefined target and to adapt oxygen flow to patient's needs.
3172428|NCT01393015|Active Comparator|Rotameter (flowmeter)|A rotameter is a device that measures the flow rate of liquid or gas in a closed tube.
3172429|NCT01393002||INABBRA|Participating hospitals in the INABBRA alliance.
3172522|NCT01392313|Placebo Comparator|Placebo|participants will be given creatinine placebo
3172430|NCT01392989|Experimental|Allogeneic Cytokine Induced Killer Cells|Target dose of ≥ 5 x 106 CD34+ cells/kg of recipient body weight plus an additional 2 x109 mononuclear cells.
3172431|NCT01392976|Experimental|CO-1.01 Formulation B|
3172432|NCT01392976|Active Comparator|CO-1.01 Formulation A|
3172433|NCT01392963|Experimental|Botox, Then Placebo|At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).
3172434|NCT01392963|Experimental|Placebo, Then Botox|At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).
3172435|NCT01392950|Active Comparator|Air Optix Aqua|Compare safety and efficacy using OptiFree Replenish solution
3172436|NCT01392950|Active Comparator|Clariti|Compare safety and efficacy of the lens using OptiFree Replenish solution
3172437|NCT01392937|Active Comparator|All-in-One Light multipurpose|Used All in One light multipurpose with one of five different lens brands: Air Optix Aqua(Ciba Vision Inc.), PureVision (Bausch + Lomb Inc.), Biofinity (CooperVision Inc.), Acuvue Advance and Acuvue 2 (both Johnson & Johnson).
3172438|NCT01392937|Active Comparator|Aquify care|Use Aquify care with one of five different lens brands: Air Optix Aqua(Ciba Vision Inc.), PureVision (Bausch + Lomb Inc.), Biofinity (CooperVision Inc.), Acuvue Advance and Acuvue 2 (both Johnson & Johnson).
3172439|NCT01392924|Experimental|SAR245408|single cohort: SAR245408 administered once daily
3172440|NCT01392911|Active Comparator|10 mg/kg rifampicin|7 Days monotherapy with 10 mg/kg rifampicin followed by 7 days standard TB treatment, i.e. Rifafour® e275 once daily including the standard dose of rifampicin.
3172441|NCT01392911|Experimental|20 mg/kg Rifampicin|7 Days monotherapy with 20 mg/kg rifampicin followed by 7 days combination therapy consisting of 20 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
3172442|NCT01392911|Experimental|25 mg/kg Rifampicin|7 Days monotherapy with 25 mg/kg rifampicin followed by 7 days combination therapy consisting of 25 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
3172443|NCT01392911|Experimental|30 mg/kg Rifampicin|7 Days monotherapy with 30 mg/kg rifampicin followed by 7 days combination therapy consisting of 30 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
3172444|NCT01392911|Experimental|35 mg/kg Rifampicin|7 Days monotherapy with 35 mg/kg rifampicin followed by 7 days combination therapy consisting of 35 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
3172445|NCT01392911|Experimental|40 mg/kg Rifampicin|7 Days monotherapy with 40 mg/kg rifampicin followed by 7 days combination therapy consisting of 40 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
3172446|NCT01392911|Experimental|45 mg/kg Rifampicin|7 Days monotherapy with 45 mg/kg rifampicin followed by 7 days combination therapy consisting of 45mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
3172447|NCT01392911|Experimental|50 mg/kg rifampicin|7 Days monotherapy with 50 mg/kg rifampicin followed by 7 days combination therapy consisting of 50 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
3172448|NCT01392911|Experimental|55 mg/kg Rifampicin|7 Days monotherapy with 55 mg/kg rifampicin followed by 7 days combination therapy consisting of 55 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
3172449|NCT01392898|Experimental|liraglutide|
3172450|NCT01392898|Active Comparator|insulin|
3172451|NCT01392872|Other|sclerosis|
3172452|NCT01392859|Experimental|antihistamine|
3172453|NCT01392859|Placebo Comparator|placebo|
3172454|NCT01392846||Resolute Integrity|Patients receiving Resolute-Integrity stent
3172455|NCT01392833|Active Comparator|steroids|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5, and oral prednisone 0.5 mg/kg every other day for six months followed by oral prednisone 0.2 mg/kg every other day for a further six months.
3172456|NCT01392833|Experimental|steroids plus azathioprine|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5, and oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months followed by oral prednisone 0.2 mg/kg every other day plus azathioprine 50 mg/day for a further six months.
3172457|NCT01392820|Experimental|TC-5214|
3172458|NCT01392820|Placebo Comparator|Placebo|
3172459|NCT01392807|Experimental|Group 1|Normal hepatic function, 25 mg NKTR-118 administered orally
3172460|NCT01392807|Experimental|Group 2|Mild hepatic impairment, 25 mg NKTR-118 administered orally
3172461|NCT01392807|Experimental|Group 3|Moderate hepatic impairment, 25 mg NKTR-118 administered orally
3172462|NCT01392794|Experimental|orally-disintegrating (OD) tablet precedence group|
3172463|NCT01392794|Experimental|conventional tablet precedence group|
3172464|NCT01392781||normoweight PCOS patients|
3172465|NCT01392781||normoweight controls|
3172466|NCT01392781||overweight plus obese PCOS patients|
3172467|NCT01392781||overwqeight plus obese controls|
3172468|NCT01392768|Experimental|Levetiracetam|
3172469|NCT01392768|Placebo Comparator|Placebo|
3172470|NCT01392755|Experimental|1|
3172471|NCT01392755|Experimental|2|
3172472|NCT01392742||Cohort|
3172473|NCT01392729||Cohort|
3172474|NCT01392716|Experimental|Single arm|
3172475|NCT01392703|Other|Dasatinib, 100 mg as tablets + water|Treatment A. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
3172523|NCT01392300|Experimental|DB IncobotulinumtoxinA (Xeomin) (400 U)|IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment
3172476|NCT01392703|Other|Dasatinib, 100 mg as liquid + water|Treatment B. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
3172477|NCT01392703|Other|Dasatinib, 100 mg as tablets in orange juice + water|Treatment C. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
3172478|NCT01392690|No Intervention|Waiting list control - no intervention|No intervention. After the post-test they were offered the prevention program.
3172479|NCT01392690|Experimental|Dominique's handy tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
3172480|NCT01392677|Experimental|Dapagliflozin 10 mg tablet|
3172481|NCT01392677|Placebo Comparator|matching placebo tablet|
3172482|NCT01392651||Women with urinary stress incontinence|
3172483|NCT01392638|Placebo Comparator|sugar pill|Intervention: sugar pill
3172484|NCT01392638|Active Comparator|sildenafil|Intervention: sildenafil citrate
3172485|NCT01392625|Active Comparator|Autologous hMSCs|Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
3172486|NCT01392625|Active Comparator|Allogeneic hMSCs|Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
3172487|NCT01392612|Other|Erythropoietin|all subjects received epo iv.
3172488|NCT01392599|Experimental|Surgery|Patients with CRPS Type II
3172489|NCT01392586|Experimental|Upfront surgery|Upfront surgery followed by systemic treatment
3172490|NCT01392586|Other|Systemic therapy|Systemic therapy possibly followed by local treatment of the breast tumor
3172491|NCT01392573|Experimental|IDegLira + metformin|IDegLira was injected subcutaneously once daily for 26 weeks.
3172492|NCT01392573|Experimental|IDeg + metformin|IDeg was injected subcutaneously once daily for 26 weeks.
3172493|NCT01392560|Experimental|BI 10773|Oral once daily
3172494|NCT01392547|Experimental|rFVIIa|
3172495|NCT01392547|Experimental|vatreptocog alfa|
3172496|NCT01392534||Group 1|
3172497|NCT01392521|Experimental|Arm 1|
3172498|NCT01392495|Experimental|QTI571|Participants received 200 mg or 400 mg every day (qd) based on their highest tolerated dose in CQTI571A2102 (NCT01392469).
3172499|NCT01392482||treatment with antipsychotics|40 LHU covering about 18 millions inhabitants distributed all over Italy with a coverage of nearly 100% of Italian regions. All subjects will be included in the analysis who have received treatment with antipsychotics (typical and / or atypical) between January 1, 2009 and June 30, 2010 and diagnosed with schizophrenia and / or Bipolar Disorder.
3172500|NCT01392469|Experimental|QTI571|
3172501|NCT01392456|Active Comparator|Retentive Anchor Group|23 fully edentulous patients will receive Retentive Anchors (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
3172502|NCT01392456|Active Comparator|Magnet Group|23 fully edentulous patients will receive Magnets (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
3172503|NCT01392456|Active Comparator|Locator Group|23 fully edentulous patients will receive Locator (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
3172504|NCT01392443|Experimental|Ruxolitinib|Ruxolitinib is taken twice daily, unless instructed. ﻿Starting dose 15 mg BID for patients with baseline platelet count of 100,000/μL to 200,000/μL (inclusive) or 20 mg BID for those with baseline platelet count >200,000/μL (approximately 12 hours apart: morning and night), to be increased or decreased per standardized dosing paradigm.
3172505|NCT01392430|No Intervention|Arm A|Continuation of prophylaxis of opportunistic infections
3172506|NCT01392430|Experimental|Arm B|Discontinuation of opportunistic infections
3172507|NCT01392391|Experimental|Exercise|Task-oriented exercise training (aerobic, strength, and balance exercises)
3172508|NCT01392391|Active Comparator|Stroke Care|"Best Medical Care in Jamaica adapted from the American Stroke Association Get with the Guidelines."
3172509|NCT01392378|Experimental|Group 1|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of paracetamol on the day of each vaccination.
3172510|NCT01392378|Experimental|Group 2|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of ibuprofen on the day of each vaccination.the first dose.
3172511|NCT01392378|Experimental|Group 3|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of paracetamol on the day of each vaccination.
3172512|NCT01392378|Experimental|Group 4|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of ibuprofen on the day of each vaccination.
3172513|NCT01392378|Experimental|Group 5|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. This group does not receive any antipyretic medication as part of the study.
3172514|NCT01392365||Crohn' disease|The group of patients whose final diagnosis is Crohn's disease
3172515|NCT01392365||Intestinal tuberculosis|The group of patients whose final diagnosis is intestinal tuberculosis
3172516|NCT01392352|Experimental|Pazopanib|Patients will receive 800mg (2 X 400mg tablets) of pazopanib, to be administered once daily orally for 12 weeks or until development of hypertension (defined as VHyp), whichever occurs first.
3172517|NCT01392339|Experimental|CPAP|CPAP - Continuous Positive Airway Pressure, gold standard treatment to Obstructive Sleep Apnea
3172518|NCT01392326|Experimental|Group 1|Secukinumab (75mg)
3172519|NCT01392326|Experimental|Group 2|Secukinumab (150 mg)
3172520|NCT01392326|Placebo Comparator|Group 3|
3172521|NCT01392313|Experimental|Carnitine|Participants will be given Creatinine supplements
3172524|NCT01392300|Placebo Comparator|DB Placebo Comparator|Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment
3172525|NCT01392287|Experimental|Memantine hydrochloride|Older individuals with DSM IV TR Major Depression, with persistent symptoms of depression despite at least 8 weeks of treatment with standard pharmacotherapy, will be referred for a study of memantine hydrochloride augmentation. Healthy control subjects follow similar study schedule for baseline and endpoint but do not receive memantine hydrochloride.
3172526|NCT01392274||pCLE|This trial will study only one group which will receive a standard ERCP procedure followed by pCLE
3172527|NCT01392235|Experimental|Drug: Famitinib|
3172528|NCT01392222||patients who have had surgery or have scheduled surgery|In this exploratory study we will conduct focus groups and individual interviews with two population segments according to the established methodology of Krueger and Casey [13] and Morgan [14]. We will conduct 4-6 focus groups, two to three within each population segment, to evaluate the process of decision-making to manage papillary microcarcinoma, factors that influenced decision-making, understanding of risk for recurrence and other negative outcomes due to thyroid cancer, information needed to make informed decisions, and what could influence thyroid cancer patients who have had surgery or have scheduled to have surgery to remove their papillary microcarcinomas to consider active surveillance. Individual interviews will be offered and conducted as needed for those patients who are unable to attend a focus group due to scheduling conflicts or other reasons.
3172529|NCT01392222||who chose to not have immediate surgery|In this exploratory study we will conduct focus groups with two population segments according to the established methodology of Krueger and Casey [13] and Morgan [14]. We will conduct 4-6 focus groups, two to three within each population segment, to evaluate the process of decision-making to manage papillary microcarcinoma, factors that influenced decision-making, understanding of risk for recurrence and other negative outcomes due to thyroid cancer, information needed to make informed decisions, and what could influence thyroid cancer patients who have had surgery or have scheduled to have surgery to remove their papillary microcarcinomas to consider active surveillance. Individual interviews will be offered and conducted as needed for those patients who are unable to attend a focus group due to scheduling conflicts or other reasons.
3172530|NCT01392209|Experimental|Bevacizumab & Stereotactic Radiotherapy|This will be a multicenter (MSKCC and UCSF) phase I dose escalation study to determine the maximum tolerated dose (MTD) of hypofractionated stereotactic radiotherapy when administered in combination with a fixed dose of bevacizumab.
3172531|NCT01392196|Other|Single arm|Renal Denervation
3172532|NCT01392183|Experimental|Pazopanib|Pazopanib 800 mg by mouth daily. Quality of Life Assessment - Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
3172533|NCT01392183|Experimental|Temsirolimus|Temsirolimus 25 mg by vein infused over 30-60 minutes weekly. Benadryl 25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus. Quality of Life Assessment - Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
3172534|NCT01392170|Experimental|PEG-IFNá-2a|PEG-IFNá-2a (Pegasys) 45 mcg subcutaneously as single weekly dose.
3172535|NCT01392157|Active Comparator|copper intrauterine device|100 women will be allocated to receive a TCu380A intrauterine device
3172536|NCT01392157|Active Comparator|LNG-releasing intrauterine system|100 women were allocated to receive a LNG-IUS
3172537|NCT01392157|Active Comparator|ENG-releasing implant|100 women will receive an LNG-IUS
3172538|NCT01392144||Nitric Oxide Breath Analysis|Nitric Oxide Breath Test + Questionnaires
3172539|NCT01392131|Active Comparator|Oncoxin will be administered orally|20 patients will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
3172540|NCT01392131|Active Comparator|Supportive treatment|20 patients with hepatocellular carcinoma will receive supportive treatment only
3172541|NCT01392105|Active Comparator|Mesenchymal stem cell treatment group|
3172542|NCT01392105|Placebo Comparator|Control group|All patients were required to have successful revascularization of an infarct-related artery on coronary angiography at the time of randomization. All patients received aspirin (300 mg loading dose, then 100 mg daily) and clopidogrel (600 mg loading dose, then 75 mg daily) with optimal medical therapy according to the American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines for treatment of ST-segment elevation myocardial infarction (STEMI)
3172543|NCT01392079|Experimental|Alemtuzumab|"30 mg alemtuzumab will be administered subcutaneously 3 times weekly for 4 weeks (total of 12 doses of 30 mg alemtuzumab) with premedication (as needed) and infection prophylaxis; combined with oral dexamethasone 40 mg total dose for 4 days every 2 weeks; evaluation at end of cycle (i.e. after 12 doses of 30 mg alemtuzumab).~If CR is documented after week 4 (12 doses of 30 mg alemtuzumab) or 8 (24 doses of 30 mg alemtuzumab), maintenance treatment with alemtuzumab or withdrawal from the study and stem cell transplantation will be instituted at this time point.~After a maximum of three 4-week cycles (total of 36 doses of 30 mg alemtuzumab, in case of interruptions this may take longer than 12 weeks), maintenance treatment with alemtuzumab or withdrawal from the study and stem cell transplantation will be instituted. Maintenance treatment with alemtuzumab will continue for a maximum of two years, with evaluation every three months, unless there is PD."
3172544|NCT01392066||Breast cancer patients and their partners|Patients with breast cancer and their cohabiting partners/spouses
3172545|NCT01392053|No Intervention|Control group|Control Group (CG) that will receive the routine procedures of motherhood, but will be monitored and evaluated at the same time in the intervention group
3172546|NCT01392053|Experimental|Massage Group|Massage Group (GM):receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation
3172547|NCT01392040||Patients in oral anticoagulant therapy|Patients taking oral anticoagulant therapy
3172548|NCT01392014|Active Comparator|dihydroartemisinin-piperaquine|
3172549|NCT01392014|Active Comparator|Dihydroartemisininpiperaquine primaquine|
3172550|NCT01392001||Cohort|
3172551|NCT01391988|Active Comparator|Electric Scalpel Mastectomy|Radical mastectomy with electric scalpel
3172552|NCT01391988|Experimental|Harmonic scalpel mastectomy|Radical Mastectomy with harmonic scalpel
3172553|NCT01391975|Experimental|Surveillance and proactive intervention|
3172554|NCT01391975|No Intervention|Control and reactive intervention|
3172555|NCT01391962|Experimental|Part I|Patients will be randomized to receive cediranib (30 mg) or sunitinib malate (37.5 mg) orally, once a day in 28-day cycles
3172556|NCT01391962|Experimental|Part II|At the time of disease progression patients will cross over to the other treatment arm after a 2-week wash-out period.
3172557|NCT01391949|Experimental|Detailed feedback|Subjects will pedal on the UCFit with a goal of 30 total minutes of daily exercise.
3172558|NCT01391949|Active Comparator|Basic feedback|Subjects will pedal on the UCFit with a goal of 30 total minutes of daily exercise.
3172559|NCT01391936|Other|Tension Band Wiring|Patients in this arm will receive the tension band wiring technique for fixation of their olecranon fracture.
3172560|NCT01391936|Other|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
3172561|NCT01391910||post endoscopic sinus surgery for chronic rhinosinusitis|Patients who have undergone functional endoscopic sinus surgery for treatment of chronic rhinosinusitis and completed a pre-surgery SNOT-20
3172562|NCT01391897||in- and out-patient psychotherapy patients|All included patients are highly selected in- and outpatients in a department of psychosomatic medicine (Germany) undergoing high dose psychotherapy (e.g. group therapy, creative therapy, cbt and psychodynamic psychotherapy).
3172563|NCT01391884||Dialysis, Non-diabetic|Hemodialysis
3172564|NCT01391884||Healthy control|
3172565|NCT01391871||PRO-Kinetic DES|Patients receiving PRO-Kinetic drug-eluting stent
3172566|NCT01391871||Endeavor Resolute DES|Patient receiving Endeavor Resolute zotarolimus-eluting stent
3172567|NCT01391858|Active Comparator|pregabalin|pregabalin (lyrica)
3172568|NCT01391858|Placebo Comparator|placebo|placebo
3172569|NCT01391845|Experimental|UPA, 300UI FSH|patients on COS with 300UI FSHu/GnRH Antagonist protocol and ulipristal acetate use
3172570|NCT01391845|Placebo Comparator|No UPA, 300FSH|patients on COS with 300UI FSHu/GnRH Antagonist protocol and without ulipristal acetate use
3172571|NCT01391845|Experimental|UPA, FSH 225|patients on COS with 225UI FSHu/GnRH Antagonist protocol and ulipristal acetate use
3172572|NCT01391845|Placebo Comparator|no UPA, FSH225|patients on COS with 225UI FSHu/GnRH Antagonist protocol and without ulipristal acetate use
3172573|NCT01391832|Sham Comparator|Sham rTMS|Sham Treatment Intervention: Device: Repetitive Transcranial Magnet Stimulation (sham treatment)
3172574|NCT01391832|Active Comparator|active rTMS|"Active Repetitive Transcranial Magnet Stimulation treatment~Intervention: Device: Active rTMS of dorsolateral pre-frontal cortex"
3172575|NCT01391819|Other|Study cohort|Children age 5 to 13 years at the time of enrollment, selected from schools in Fortaleza.
3172576|NCT01391806||Breast cancer|Patients selected for breast-conserving surgery based on conventional radiological methods, following the criteria recommended by the Norwegian Breast Cancer Group
3172577|NCT01391793|Active Comparator|Adjuvant dexamethasone|
3172578|NCT01391793|Placebo Comparator|Placebo|
3172579|NCT01391780||Group 1|Patients with stress urinary incontinence
3172580|NCT01391780||Group 2|Patients with urgency urinary incontinence.
3172581|NCT01391767||NuOss XC|Bone grafting material used in this group will be NuOss XC.
3172582|NCT01391767||NuOss Particulate|Bone grafting material used in this group will be NuOss Particulate.
3172583|NCT01391754|Experimental|SafeCare with Coached Implementation|Home-based services with the SafeCare model, implemented with in vivo provider coaching as quality control
3172584|NCT01391754|Experimental|SafeCare without Coaching|Home-based services using the SafeCare model, implemented without in vivo coached implementation quality control
3172585|NCT01391754|Experimental|Services As Usual with Coaching|Usual home based services, with in vivo coached implementation quality control
3172586|NCT01391754|Active Comparator|Services As Usual Without Coaching|Usual home based services without in vivo coached quality control
3172587|NCT01391741|Experimental|Walking with visual cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
3172588|NCT01391741|Active Comparator|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4 times a week for 4 weeks.
3172589|NCT01391728|Active Comparator|Lifestyle counseling|
3172590|NCT01391728|No Intervention|Control|
3172591|NCT01391715|Active Comparator|Double dose rabeprazole|Rabeprazole 20m bid per day will be given for 2 weeks
3172592|NCT01391715|Placebo Comparator|standard dose rabeprazole|rabeprazole 20mg per day will bi given for 2 weeks
3172593|NCT01391702||Labouring woman with epidural in situ|Any healthy English-speaking pregnant woman in labour who has received an epidural for pain relief
3172594|NCT01391689|Experimental|Arm I (antineoplastic therapy)|Patients receive diindolylmethane (BioResponse) PO BID for approximately 18 months.
3172595|NCT01391689|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for approximately 18 months.
3172596|NCT01391676||Trabeculectomy|glaucoma patients undergoing trabeculectomy with mitomycin c 0,02%
3172597|NCT01391663|Experimental|Alogliptin 12.5 mg QD|
3172598|NCT01391663|Experimental|Alogliptin 25 mg QD|
3172599|NCT01391663|Experimental|Alogliptin 50 mg QD|
3172600|NCT01391650|Experimental|biomechanic of the knee|
3172601|NCT01391637||HuCNS-SC transplanted subjects in the lead-in phase|Subjects who had HuCNS-SC transplant in the lead-in phase study CL-N01-PMD
3172602|NCT01391624|Experimental|Omega 3|The group was treated with omega 3 fatty acids for 2 months.
3172603|NCT01391624|Placebo Comparator|Placebo|The group received paraffin with dye in order to mimic the visual aspects of omega 3 fatty acid capsules.
3172604|NCT01391611|Experimental|Pazopanib arm|
3172605|NCT01391598|Active Comparator|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
3172658|NCT01391338|Experimental|High dose ASP3652 once daily|
3172659|NCT01391338|Experimental|High dose ASP3652 twice daily|
3172606|NCT01391598|Placebo Comparator|Saline|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
3172607|NCT01391585|Experimental|text message recipients|Patients will be recruited to receive text messages
3172608|NCT01391572|Experimental|A|After esophagectomy, patients in Arm A will receive Large field radiation (tumor bed + ENI (elective nodal irradiation)) + Sequential chemotherapy
3172609|NCT01391572|Active Comparator|B|After esophagectomy, patients in Arm B will receive small field radiation (tumor bed only) + Sequential chemotherapy
3172610|NCT01391559|Experimental|arformoterol|beta-2 agonist bronchodilator
3172611|NCT01391559|Active Comparator|salmeterol|beta-2 agonist bronchodilator
3172612|NCT01391546|Experimental|ZOSTAVAX intramuscular (IM) route|Single dose of 0.65 mL via IM injection
3172613|NCT01391546|Active Comparator|ZOSTAVAX subcutaneous (SC) route|Single dose of 0.65 mL via SC injection
3172614|NCT01391533|Experimental|Dose Escalation|Dose escalation phase: The starting dose of SAR125844 will be 50 mg/m^2 up to 960 mg/m^2
3172615|NCT01391520|Experimental|CRMD001-Deferiprone|CRMD001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days
3172616|NCT01391520|Placebo Comparator|Placebo|3 placebo tablets matching the appearance of the experimental treatment arm (CRMD001) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
3172617|NCT01391507|Placebo Comparator|Placebo|
3172618|NCT01391507|Experimental|20 mg COR-1|
3172619|NCT01391507|Experimental|80 mg COR-1|
3172620|NCT01391507|Experimental|160 mg COR-1|
3172621|NCT01391494|Experimental|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
3172622|NCT01391494|Experimental|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
3172623|NCT01391494|Experimental|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
3172624|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
3172625|NCT01391494|Placebo Comparator|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
3172626|NCT01391494|Experimental|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
3172627|NCT01391494|Experimental|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
3172628|NCT01391494|Experimental|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
3172629|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
3172630|NCT01391494|Placebo Comparator|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
3172631|NCT01391494|Experimental|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
3172632|NCT01391494|Experimental|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
3172633|NCT01391494|Experimental|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
3172634|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
3172635|NCT01391494|Placebo Comparator|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
3172636|NCT01391481|Experimental|Perfluorocarbon|
3172637|NCT01391481|Placebo Comparator|Sterile Water for Injection|
3172638|NCT01391468|Placebo Comparator|Placebo|cornstarch
3172639|NCT01391468|Experimental|Probiotics|probiotics
3172640|NCT01391455|No Intervention|Spermatic Cord in contact with mesh|Where the spermatic cord has been allowed to remain in contact with the mesh.
3172641|NCT01391455|Experimental|Spermatic Cord is isolated from the mesh|The inguinal ligament is interposed between the cord and the mesh and then repaired. This isolates the cord from the mesh and the splinting function of the overlying inguinal ligament.
3172642|NCT01391442|Other|family|each family, composed of 4 characters at least, is studied
3172643|NCT01391429|Experimental|Video decision support tool|Video decision support tool for goals-of-care options
3172644|NCT01391429|No Intervention|Verbal description|Standard verbal description of goals-of-care options provided by an inpatient palliative care team
3172645|NCT01391416||CKD stage 3-4|CKD stage 3-4 from Thai SEEK study
3172646|NCT01391416||hyperhomocysteine group|CKD stage 3-4 from Thai SEEK study
3172647|NCT01391403|Experimental|Artemisinin, anti-toxoplasma|Artemisinin
3172648|NCT01391403|Placebo Comparator|Placebo|Placebo looks like the active drug, with the same dose.
3172649|NCT01391390|Experimental|Melatonin, antioxidant, oxidative stress|Melatonin is an active treatment for TD.
3172650|NCT01391390|Placebo Comparator|Placebo|Placebo look like the active drug, and same dose.
3172651|NCT01391377|Active Comparator|Niacin / Laropiprant|
3172652|NCT01391377|Placebo Comparator|Sugar Pill (Placebo)|
3172653|NCT01391351|Other|Taxol and carboplatin|blood samples in patients receiving Taxol and carboplatin chemotherapy
3172654|NCT01391351|Other|Taxol, carboplatin and avastin|blood samples in patients receiving Taxol, carboplatin chemotherapy with avastin
3172655|NCT01391338|Experimental|Lowest dose ASP3652 twice daily|
3172656|NCT01391338|Experimental|Low dose ASP3652 twice daily|
3172657|NCT01391338|Experimental|Medium dose ASP3652 twice daily|
3172660|NCT01391338|Placebo Comparator|Placebo|
3172661|NCT01391325|Other|Allopurinol|Treatment.
3172662|NCT01391312|Active Comparator|botulinum toxin Type A|Botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.
3172663|NCT01391312|Placebo Comparator|placebo (Normal Saline)|Normal Saline (placebo) injected into the glabellar region on Day 0.
3172664|NCT01391299|Active Comparator|botulinum toxin Type A (40 Units)|Botulinum toxin Type A 40 Units (total dose) injected into bilateral forehead and frown line areas on Day 1.
3172665|NCT01391299|Active Comparator|botulinum toxin Type A (30 Units)|Botulinum toxin Type A 30 Units (total dose) injected into bilateral forehead and frown line areas on Day 1.
3172666|NCT01391299|Placebo Comparator|placebo (Normal saline)|Placebo (Normal saline) injected into bilateral forehead and frown line areas on Day 1.
3172667|NCT01391286|Experimental|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
3172668|NCT01391286|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
3172669|NCT01391273|Experimental|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
3172670|NCT01391273|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
3172671|NCT01391260|Experimental|Radiotherapy Combined With Gefitinib|
3172672|NCT01391247||healthy age machted controls|
3172673|NCT01391247||normal tension glaucoma patients|
3172674|NCT01391247||primary open angle glaucoma patients|
3172675|NCT01391234|Experimental|STAT RT planning and delivery workflow|single arm
3172676|NCT01391221|Experimental|Duloxetine treatment|Subjects with major depression will be entered into the trial and treated with open label duloxetine
3172677|NCT01391208|No Intervention|peptide application|
3172678|NCT01391195|Experimental|Laser therapy and aerobic capacity|Effects of low level laser therapy on aerobic capacity of young women submitted to endurance training
3172679|NCT01391182|Active Comparator|EACA arm|In order to obtain sufficient power, a total of 120 patients will be studied, 60 in each group. The surgeon performing the case, their staff, the anesthesiologist, nurse anesthetist and the patient will be blinded to whether the patient received EACA or placebo. Pharmacy will prepare the EACA dose or the saline. Serum hemoglobin levels with be drawn preoperatively and on post operative days one, two, and three. The first dose will be given in the operating room prior to incision (within 30 minutes of the incision). The second dose will be given four hours after the first dose. Two doses are given due to the short half-life of EACA. The timing of administration of EACA will be recorded.
3172680|NCT01391182|Placebo Comparator|Placebo arm|In order to obtain sufficient power, a total of 120 patients will be studied, 60 in each group. The surgeon performing the case, their staff, the anesthesiologist, nurse anesthetist and the patient will be blinded to whether the patient received EACA or placebo. Pharmacy will prepare the EACA dose or the saline. Serum hemoglobin levels with be drawn preoperatively and on post operative days one, two, and three. The first dose will be given in the operating room prior to incision (within 30 minutes of the incision). The second dose will be given four hours after the first dose. Two doses are given due to the short half-life of EACA. The timing of administration of EACA will be recorded.
3172681|NCT01391169|Active Comparator|1sup group|enforcement of the anastomoses with seromuscular flap
3172682|NCT01391169|Placebo Comparator|2nd group|primary anastomosis without enforcement
3172683|NCT01391156|Experimental|Minoxidil|
3172684|NCT01391156|Active Comparator|MinoxidilFinasteride|
3172685|NCT01391143|Experimental|MGA271|Fc-optimized, humanized monoclonal antibody
3172686|NCT01391130|Experimental|LY2510924 + Sunitinib|LY2510924: 20 milligram administered subcutaneously once daily, given every day of the 6 week cycle. Sunitinib: 50 milligram administered orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment. Treatment cycles will continue until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
3172687|NCT01391130|Active Comparator|Sunitinib|50 milligram administered orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment. Treatment cycles will continue until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
3172688|NCT01391117|Experimental|010|TMC649128 panel 4 arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128 administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.
3172689|NCT01391117|Experimental|001|TMC649128. panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
3172690|NCT01391117|Placebo Comparator|002|placebo. panel 1: 2 participants receive placebo at a q24h regimen.
3172691|NCT01391117|Experimental|003|TMC649128. panel 2 arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
3172692|NCT01391117|Placebo Comparator|004|placebo. panel 2 arm 1: 2 participants receive placebo at a q12h regimen.
3172693|NCT01391117|Experimental|005|TMC649128. panel 2 arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
3172694|NCT01391117|Placebo Comparator|006|placebo. panel 2 arm 2: 2 participants receive placebo at a q24h regimen.
3172695|NCT01391117|Experimental|007|TMC649128 panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
3172696|NCT01391117|Placebo Comparator|008|placebo. panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
3172697|NCT01391117|Placebo Comparator|009|placebo panel 4 arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.
3172698|NCT01391104|Experimental|Sildenalfil|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
3172731|NCT01390831|Experimental|Catheter, Renal Denervation, Ablation|Catheter-based renal denervation and maintenance of anti-hypertensive medications
3172699|NCT01391104|Placebo Comparator|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
3172700|NCT01391091|Active Comparator|Patients without history of migraine|Incidence and prevalence of migraine episodes in the post-ablation period
3172701|NCT01391091|Active Comparator|Patients with history of migraine|Incidence and prevalence of migraine episodes in the post-ablation period
3172702|NCT01391078|Experimental|Sensimed Triggerfish|
3172703|NCT01391078|Active Comparator|Goldmann Applanation Tonometry/Perkins Tonometry|
3172704|NCT01391052|Active Comparator|Norethindrone acetate pretreatment|This arm will receive two cycles of norethindrone acetate before LVN IUS insertion.
3172705|NCT01391052|Other|No pretreatment|LVN IUS is placed without norethindrone acetate pretreatment.
3172706|NCT01391039|Experimental|Contrast perfusion and elastography arm|Intravenous injection of microbubble contrast agent and elastography
3172707|NCT01391026|No Intervention|Usual care|
3172708|NCT01391026|Experimental|Enhanced patient-centered care|Patients will be evaluated and treated in the advanced illness management clinic
3172709|NCT01391013|Experimental|Monotherapy|Monotherapy: darunavir/ritonavir (DRV/r) will be administered for 48 weeks.
3172710|NCT01391013|Experimental|Combination therapy|DRV/r along with 2 nucleoside reverse transcriptase inhibitors (NRTIs) will be administered for 48 weeks and whenever possible, participants should take these medications at the same time. Switch of NRTIs will be allowed in the event of suspected toxicity/intolerance, providing this change can be linked to a documented adverse event (AE)/serious AE.
3172711|NCT01391000|Experimental|Laser CO2|
3172712|NCT01391000|Active Comparator|TENS|
3172713|NCT01390974||Patients treated for ACS|ACS patients who recently underwent stent PCI, who are stable and eligible for prasugrel or clopidogrel therapy.
3172714|NCT01390948|Experimental|Bevacizumab + TMZ Young Patient Cohort (YPC)|Participants aged greater than or equal to (>/=) 6 months and less than (<) 3 years will receive 10 milligrams per kilogram (mg/kg) Bevacizumab every 2 weeks and 150 to 200 milligrams per meter squared (mg/m^2) of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle.
3172715|NCT01390948|Experimental|Main Cohort: Chemoradiation + Bevacizumab + TMZ|Participants will receive a total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks with 75 mg/m^2 TMZ daily for up to 49 days followed by a treatment break of approximately 4 weeks. The treatment break will be followed by an adjuvant treatment phase where participants will receive 150 to 200 mg/m^2 of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle. Bevacizumab will be given concomitantly at a dose of 10 mg/kg every 2 weeks throughout the entire treatment period.
3172716|NCT01390948|Active Comparator|Main Cohort: Chemoradiation + TMZ|Participants will receive a total dose of 54 Gy units delivered in 30 daily fractions of 1.8 Gy over 6 weeks with 75 mg/m^2 TMZ daily for up to 49 days followed by a treatment break of approximately 4 weeks. The treatment break will be followed by an adjuvant treatment phase where participants will receive 150 to 200 mg/m^2 of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle.
3172717|NCT01390935||systolic heart failure|EF under 45%
3172718|NCT01390922||Subjects prescribed botulinum injection|Subjects prescribed botulinum injection
3172719|NCT01390909||Medicaid patients with uncontrolled epilepsy|Database records for patients with 2 or more consecutive changes in anti-epileptic drug (AED) therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or emergency department (ED) visits within the 365 days
3172720|NCT01390909||Medicaid patients with well-controlled epilepsy|Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits
3172721|NCT01390909||Medicaid patients with intermediate epilepsy|Database records for patients who are not classified as uncontrolled or well-controlled
3172722|NCT01390909||Patients in a private health plan with uncontrolled epilepsy|Database records for patients with 2 or more consecutive changes in AED therapy occuring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visits within 365 days
3172723|NCT01390909||Patients in a private health plan with well-controlled epileps|Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits
3172724|NCT01390909||Patients in a private health plan with intermediate epilepsy|Database records for patients who are not classified as uncontrolled or well-controlled
3172725|NCT01390896||Patients prescribed fondaparinux|Patients undergoing general surgery of the lower limb at high risk for venous thromboembolism
3172726|NCT01390883||Patients prescribed fondaparinux|Patients undergoing abdominal surgery in urology, obstetrics and gynecology departments prescribed fondaparinux during study period
3172727|NCT01390870||Patient Survey|Men from the United States aged 50 years or older who initiated medication for EP within the past 12 months.
3172728|NCT01390857||Pediatric patients prescribed valaciclovir|Pediatric patients with chickenpox prescribed valaciclovir during study period.
3172729|NCT01390844|Experimental|Boceprevir|PEG + RBV for 4 weeks followed by BOC + PEG + RBV for 32 weeks. At the Treatment Week 36 visit, participants with undetectable HCV-RNA at Treatment Weeks 8 and 12 will proceed to 36 weeks of post-treatment follow-up. Participants with detectable HCV-RNA at Treatment Week 8 and undetectable HCV-RNA at Treatment Week 12 will continue on BOC + PEG + RBV until Treatment Week 36, receive placebo + PEG + RBV until Treatment Week 48, and then proceed to 24 weeks of post-treatment follow-up. Participants with any HCV-RNA result at Treatment Week 8 and detectable HCV-RNA at Treatment Week 12 will discontinue treatment and proceed to 24 weeks of post-treatment follow-up.
3172730|NCT01390844|Active Comparator|Control|PEG + RBV for 4 weeks followed by BOC placebo + PEG + RBV for 44 weeks. Participants with undetectable HCV-RNA at Treatment Week 12 and at subsequent assays will continue on placebo + PEG + RBV through Treatment Week 48 and proceed to 24 weeks of post-treatment follow-up. Participants with detectable HCV-RNA at Treatment Week 12 may roll over to Cross-Over BOC treatment beginning with Treatment Week 14.
3172732|NCT01390831|No Intervention|anti-hypertensive medications|Maintenance of anti-hypertensive medications
3172733|NCT01390818|Experimental|MSC1936369B and SAR245409 once daily|
3172734|NCT01390818|Experimental|MSC1936369B and SAR245409 twice daily|
3172735|NCT01390805||Subjects with recurrent genital herpes|
3172736|NCT01390792||Subjects prescribed zanamivir|Subjects prescribed zanamivir during study period
3172737|NCT01390779|Experimental|SENSIMED Triggerfish|All subjects enrolled in the trial were housed in a sleep laboratory for 24 hours, during which they underwent SENSIMED Triggerfish recording on one randomly selected eye.
3172738|NCT01390766||Subjects prescribed azathioprine tablet|Subjects prescribed azathioprine tablet during study period after the liver transplantation
3172739|NCT01390753|No Intervention|Preterm formula|
3172740|NCT01390753|Active Comparator|Donor milk + preterm formula|Human milk from a donor bank
3172741|NCT01390753|No Intervention|Breastfeeding + formula|
3172742|NCT01390753|No Intervention|Breasfeeding|
3172743|NCT01390740||Echocardiography|patients with echocardiography
3172744|NCT01390727|Placebo Comparator|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
3172745|NCT01390727|Active Comparator|Device-guided breathing|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
3172746|NCT01390714|Experimental|1|
3172747|NCT01390714|Experimental|2|
3172748|NCT01390701|Experimental|transcutaneous electr. nerve stimulation|
3172749|NCT01390701|Active Comparator|felodipin|
3172750|NCT01390688||Type 2 Diabetes|80 individuals with type 2 Diabetes, confirmed by an OGTT, age 40-65 years, BMI > 18.5 kg/m2 fatsing plasma glucose < 12 mmol/l
3172751|NCT01390688||Impaired glucose tolerance|40 individuals with impaired glucose tolerance. age 40 -65 years, BMI > 18. 5 kg/m2
3172752|NCT01390688||Normal glucose tolerance|80 Individuals without type 2 diabetes Age 40-65 years, BMI >18.5 kg/m2.
3172753|NCT01390662|Active Comparator|Vitamin D3|one tablet of vitamin D3 (70µg) per day for 24 weeks.
3172754|NCT01390662|Placebo Comparator|placebo|one tablet of sugar pill per day for 24 weeks.
3172755|NCT01390649|Experimental|IgPro10|
3172756|NCT01390636||ED-DMT1 and ED/only|Eating Disorder and Type 1 Diabetes and only an Eating Disorder
3172757|NCT01390584|Experimental|Centralized PET review|Centralized PET review of patients after 2 cycles of ABVD induction followed by 4 additional cycles of ABVD (escalated BEACOPP or standard BEACOPP) followed by involved nodal radiotherapy [INRT] of 30-30.6 Gy.
3172758|NCT01390558||Persons with Down Syndrome who use orthotics|Orthotic users
3172759|NCT01390558||Persons with Down Syndrome who do not use orthotics|Non orthotic users
3172760|NCT01390545|Active Comparator|Veltuzumab 80 mg|
3172761|NCT01390545|Active Comparator|Veltuzumab 160 mg|
3172762|NCT01390545|Active Comparator|Veltuzumab 320 mg|
3172763|NCT01390545|Placebo Comparator|Placebo|
3172764|NCT01390519||Afinitor|Afinitor
3172765|NCT01390506|Active Comparator|Sodium-selenite infusion|Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
3172766|NCT01390506|Placebo Comparator|Placebo|0.9% sodium chloride
3172767|NCT01390493|Experimental|neurofeedback, alpha power|
3172768|NCT01390480|Placebo Comparator|Placebo|peanut oil
3172769|NCT01390480|Active Comparator|Vitamin D (Oleovit®)|cholecalciferol
3172770|NCT01390454|Experimental|Tennis elbow patients|These patients have tennis elbow, according to stated inclusion criteria.
3172771|NCT01390454|Active Comparator|Healthy volunteers|Healthy volunteers are selected and paired according to age, sex, socio-professional category and left- or right-handedness.
3172772|NCT01390441|Experimental|Part A: MK-8808 500 mg/m^2 / Extension A: MK-8808 1000 mg|"During the Treatment Period, participants receive one course of MK-8808 (500 mg/m^2) administered intravenously (IV) on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~During the Extension Period, participants receive open-label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, subcutaneously (SC), or intramuscularly (IM) for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
3172773|NCT01390441|Active Comparator|Part A: MabThera® 500 mg/m^2 / Extension A: MK-8808 1000 mg|"During the Treatment Period, participants receive one course of MabThera® (500 mg/m^2) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~During the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
3172774|NCT01390441|Experimental|Part B: MK-8808 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of MK-8808 (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) adminstered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
3172807|NCT01390272|Active Comparator|Arm 2|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months (identical to booster (low) resource intensity component of the titrated intervention). The control arm will utilize the same procedures as the booster level for intervention patients for whom SBP comes under control.
3173030|NCT01388751|Active Comparator|night splinting|Night Splinting for 4 weeks after removal of initial cast
3172775|NCT01390441|Active Comparator|Part B: MabThera® 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of MabThera® (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
3172776|NCT01390441|Experimental|Part B: Rituxan® 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of Rituxan® (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
3172777|NCT01390428|Experimental|Part 1-Mild Hepatic Impairment (HI)|Participants with mild hepatic impairment will receive 200 mg of Grazoprevir once a day for 10 consecutive days during Part 1 of the study.
3172778|NCT01390428|Experimental|Part 1-Healthy Matched to Mild HI|Healthy participants will receive 200 mg of Grazoprevir once a day for 10 consecutive days during Part 1 of the study.
3172779|NCT01390428|Experimental|Part 2-Moderate HI|Participants with moderate hepatic impairment will receive 100 mg of Grazoprevir once a day for 10 consecutive days during Part 2 of the study.
3172780|NCT01390428|Experimental|Part 2-Healthy Matched to Moderate HI|Healthy participants will receive 100 mg of Grazoprevir once a day for 10 consecutive days during Part 2 of the study.
3172781|NCT01390428|Experimental|Part 3-Severe HI|Participants with severe hepatic impairment will receive 50 mg of Grazoprevir once a day for 10 consecutive days during Part 3 of the study.
3172782|NCT01390428|Experimental|Part 3-Healthy Matched to Severe HI|Healthy participants will receive 50 mg of Grazoprevir once a day for 10 consecutive days during Part 3 of the study.
3172783|NCT01390415||Losartan 50 mg|Adults with Type II diabetes mellitus with hypertension and microalbuminuria who received losartan 50 mg for at least 6 months during the period between 1 June 2007 and 31 December 2008.
3172784|NCT01390415||Losartan 100 mg|Adults with Type II diabetes mellitus with hypertension and microalbuminuria who received losartan 100 mg for at least 6 months during the period between 1 June 2007 and 31 December 2008.
3172785|NCT01390402|Experimental|NK Infusion + Chemotherapy|Fludarabine 40 mg/m2 intravenous (IV) daily for 4 days, immediately followed by Busulfan 130 mg/ m2 IV every 24 hours and NK cell infusion IV.
3172786|NCT01390389|Experimental|CoQ10|"Subjects who meet DSM-IV diagnostic criteria for Bipolar Disorder, Current Episode Depressed are assigned to this arm and administered the Coenzyme Q10 intervention. CoQ10 dosing guidelines:~Visit 1 (Baseline) start at 400mg once a day for two weeks~Visit 2 (within 7 days of Baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
3172787|NCT01390389|No Intervention|Control|Subjects without a known psychiatric disorder and/or unstable medical illness are assigned to the control group. The control subjects are not given CoQ10.
3172788|NCT01390376|Experimental|BE 1|DAAOI-1 1g
3172789|NCT01390376|Experimental|BE 2|DAAOI-1 2g
3172790|NCT01390376|Placebo Comparator|starch pill|
3172791|NCT01390363|No Intervention|control|This study arm will receive usual clinical care, but no specific intervention will be made to inform the parent or adolescent that the adolescents is overdue for a routine vaccine.
3172792|NCT01390363|Experimental|Parent Only Group|Parent Only Phone Call
3172793|NCT01390363|Experimental|Parent and Adolescent Group|Parent and Adolescent Phone Call
3172794|NCT01390350|Placebo Comparator|Placebo|
3172795|NCT01390350|Experimental|Canakinumab|
3172796|NCT01390337|Experimental|AC220|
3172797|NCT01390324|Experimental|Fixed-dose combination of naratriptan+naproxen|Fixed-dose combination of naratriptan+naproxen
3172798|NCT01390324|Active Comparator|Naratriptan|Naratriptan
3172799|NCT01390324|Active Comparator|Naproxen|Naproxen
3172800|NCT01390311|Active Comparator|Control Cohort|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight~No Azacitidine will be given"
3172801|NCT01390311|Experimental|Cohort 1 (Starting Dose)|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight~Azacitidine 45 mg/m2 IV on Days 4, 6, 8, and 10 post-DLI."
3172802|NCT01390311|Experimental|Cohort 2|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight~Azacitidine 75 mg/m2 IV on Days 4, 6, 8, and 10 post-DLI."
3172803|NCT01390298||Knee replacement|Adult patients scheduled for elective unicompartmental or total knee replacement surgery
3172804|NCT01390285|Experimental|TENS|
3172805|NCT01390285|Sham Comparator|Sham TENS|
3172806|NCT01390272|Experimental|Arm 1|"The intervention arm includes three levels of resource intensity targeted to improve patients' systolic blood pressure (SBP) [top number of blood pressure measurement].~Medium/level 1 resource intensity: a registered nurse (RN) will provide monthly tailored behavioral support telephone calls + home BP monitoring.~High/level 2 resource intensity: a pharmacist will provide monthly tailored behavioral support telephone calls + home BP monitoring + pharmacist-directed medication management.~Booster (low) resource intensity: a licensed practical nurse (LPN) will provide non-tailored behavioral support telephone calls every two months to patients whose SBP comes under control."
3173031|NCT01388738|Active Comparator|cerebrolysin|IV
3172808|NCT01390259|Experimental|Closed Loop Control (CLC)|"The CLC used a computer to make recommendations for their insulin treatment. This study arm was designed to demonstrate management of glucose using a modular insulin management system based on continuous glucose monitoring and targeted towards the avoidance of hypoglycemic and prolonged hyperglycemic episodes (i.e. control to range). This system was designed to both:~monitor the meal boluses of the patient and correct it in case of observed/predicted under insulinization (avoidance of prolonged hyperglycemia), based on a coarse and subjective knowledge of the meal amount, a precise understanding of the subject's day to day insulin treatment, continuous glucose monitoring, and past insulin injections;~predict and avoid hypoglycemic events, based on continuous glucose reading and past insulin injection."
3172809|NCT01390259|Placebo Comparator|Open Loop|The subject were in charge of their insulin treatment.
3172810|NCT01390246|Active Comparator|Bupropion SR + cessation counseling|"Bupropion SR and smoking cessation counseling Subjects received Bupropion SR 150 mg tablet orally twice daily (BID) for 12 weeks. Subjects were instructed to begin using study medication (bupropion SR 150 mg orally for 3 days, then BID for 4 days) on study visit day 1, which was approximately 1 week prior to their quit date. Thereafter, they were continued to dose Bupropion SR 150 mg tablet orally BID for a total medication treatment of 12 full weeks.~Smoking cessation counseling included 35-minute counseling sessions at each of the first 2 visits and 10 minutes of smoking cessation counseling at subsequent visits, provided by the trained study nurse."
3172811|NCT01390246|Placebo Comparator|Placebo + cessation counseling|"Placebo and smoking cessation counseling Subjects received matching Bupropion SR placebo tablet orally twice daily (BID) for 12 weeks. Subjects were instructed to begin using study medication (matched placebo tablets orally for 3 days, then BID for 4 days) on study visit day 1, which was approximately 1 week prior to their quit date. Thereafter, they were continued to dose matching Bupropion SR placebo tablet orally BID for a total medication treatment of 12 full weeks of therapy.~Smoking cessation counseling included 35-minute counseling sessions at each of the first 2 visits and 10 minutes of smoking cessation counseling at subsequent visits, provided by the trained study nurse."
3172812|NCT01390233|Active Comparator|Urinary Balloon Catheter Only|A urinary balloon catheter will be placed through the cervix into the lower uterine segment and the bulb inflated with 40ml of saline. The catheter will be taped to the patient's thigh and placed under traction using a liter bag of saline. The catheter will be deflated and removed after 6 hours. If spontaneously expelled from the uterus, time of expulsion will be noted. Six hours after insertion of catheter, a digital exam will be performed and Bishop score recorded. If no active labor at time of catheter removal or expulsion, standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.
3172813|NCT01390233|Active Comparator|Prepadil Only|Prepidil Only : Prepidil gel will be inserted into the vaginal fornix according to manufacturer's direction. No oxytocin or other intervention will commence until 6 hours after insertion of gel. Six hours after insertion of gel, digital exam will be performed and Bishop score recorded. If no active labor 6 hours after the administration of gel, standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.
3172814|NCT01390233|Experimental|Combined Urinary Catheter & Prepidil Gel|A urinary balloon catheter will be placed through the cervix into the lower uterine segment and the bulb inflated with 40ml of saline. The catheter will be taped to the patient's thigh and placed under traction using a liter bag of saline. Prepidil gel will be inserted through the catheter into the lower uterine segment, in a dose equivalent to manufacturer's recommendation. No oxytocin or other intervention will commence until 6 hours after insertion of the catheter and administration of prepidil gel (even if catheter is spontaneously expelled). After 6 hours, digital exam will be performed and Bishop score recorded. If no active labor, standardized protocol of oxytocin will commence.
3172815|NCT01390220|Experimental|USL261|5 mg intranasal midazolam
3172816|NCT01390220|Experimental|Placebo|Intranasal placebo
3172817|NCT01390207|Experimental|16mm follicles|
3172818|NCT01390194||subjects with an underlying liver disease|(1)underlying liver disease; (2) have a lesion on a prior imaging study; (3) must be prior standard MR
3172819|NCT01390181|Experimental|Losartan|
3172820|NCT01390168|Experimental|tailored internet-administrated CBT|Behavioral: tailored internet-administrated CBT
3172821|NCT01390168|Active Comparator|waitlist|waitlist
3172822|NCT01390155||1|Patients undergoing temporary myocardial ischemia produced by a one-minute balloon occlusion of the proximal left anterior descending coronary artery.
3172823|NCT01390155||2|Patients undergoing temporary myocardial ischemia produced by a one-minute balloon occlusion of the proximal left circumflex artery.
3172824|NCT01390155||3|Patients undergoing temporary myocardial ischemia produced by a one-minute occlusion of the proximal right coronary artery.
3172825|NCT01390155||4|Patients undergoing temporary myocardial ischemia produced by a one-minute occlusion of the target vessel.
3172826|NCT01390142|Experimental|Control|
3172827|NCT01390142|Active Comparator|RIPer|Remote ischemic preconditioning
3172828|NCT01390142|Active Comparator|RIPer + IPost|Remote ischemic preconditioning and Local ischemic postconditioning
3172829|NCT01390129|Experimental|Control|
3172830|NCT01390129|Active Comparator|Remote ischemic preconditioning|
3172831|NCT01390116|Placebo Comparator|Sugar pill|looks like and is given in the same way as the experimental treatment but contains no active ingredient
3172832|NCT01390116|Experimental|AGE|Encapsulated aged garlic extract, 4 capsules per day, 2.56 g/day
3172833|NCT01390103||Assessment following the hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
3172834|NCT01390077|Experimental|Nitisinone|all subjects will receive open-label nitisinone
3172835|NCT01390064|Experimental|Initial Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms
3172836|NCT01390064|Active Comparator|Escalation Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms
3172837|NCT01390064|Active Comparator|De-escalation Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 100 micrograms
3172838|NCT01390051|Active Comparator|Innohep|Tinzaparin 4500 I.U. sub cutaneous once daily until gestational week 37
3172839|NCT01390051|No Intervention|no treatment|
3173032|NCT01388738|Active Comparator|L-Alpha glycerylphosphorylcholine|IV
3172840|NCT01390038|Experimental|Simpliciti™ Shoulder System|The Simpliciti™ Shoulder System is intended for Total Shoulder Arthroplasty of the shoulder.
3172841|NCT01390025|Experimental|TCN-032|
3172842|NCT01390025|Placebo Comparator|Placebo|
3172843|NCT01390012|Active Comparator|Dexamethasone oral|
3172844|NCT01390012|Active Comparator|Dexamethasone intravenous|
3172845|NCT01389999||Chronic back pain patients|Patients who have had back pain for at least three months.
3172846|NCT01389986|Experimental|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
3172847|NCT01389986|No Intervention|Conventional|Conventional postoperative feeding schedule
3172848|NCT01389973|Experimental|Open-label: ustekinumab 90 mg|
3172849|NCT01389973|Experimental|Double-blind: ustekinumab 45 mg|
3172850|NCT01389973|Experimental|Double-blind: ustekinumab 90 mg|
3172851|NCT01389973|Experimental|Double-blind: ustekinumb 180 mg|
3172852|NCT01389973|Placebo Comparator|Double-blind: placebo|
3172853|NCT01389947||Extracorporeal circulation|Patients who have coronary artery bypass graft performed under extracorporeal circulation
3172854|NCT01389947||Heart beating group|Patients who have a coronary artery bypass graft without extracorporeal circulation
3172855|NCT01389934|Placebo Comparator|Control|Women of this group be infused saline 2 ml / h for 48h.
3172856|NCT01389934|Experimental|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h.
3172857|NCT01389921|Experimental|healthy testpersons|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome.
3172858|NCT01389921|Experimental|patients with non-neurogenic OAB|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome.
3172859|NCT01389921|Other|patients with neurogenic OAB|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome
3172860|NCT01389908|Experimental|schizophrenia|schizophrenia or schizoaffective patients
3172861|NCT01389895|Active Comparator|AMG 557|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99.
3172862|NCT01389895|Placebo Comparator|AMG 557 Placebo|All will receive placebo on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99.
3172863|NCT01389882|Experimental|ventilator assist|
3172864|NCT01389869|Experimental|Tears|Emotional tears of female volunteers while watching sad video clips
3172865|NCT01389869|Placebo Comparator|Saline|Saline collected after being trickled down women's skin below eyes like tears
3172866|NCT01389869|Placebo Comparator|Fasting|Their own overnight fasting plasma of male volunteers
3172867|NCT01389869|Experimental|Prandial|Their own postprandial plasma of male volunteers
3172868|NCT01389856|Experimental|1|Bosentan
3172869|NCT01389856|Placebo Comparator|2|Matching placebo
3172870|NCT01389843||All consecutive hospitalized adult patients|"All consecutive hospitalized adult patients who have 1 and (2 and/or 3)~Symptom and/or sign of heart failure~Lung congestion~Objective finding of LV systolic dysfunction (LVEF), or structural heart disease."
3172871|NCT01389830||Older Latinos With Cancer|Monthly Telephone Survey of Cohort with stage III or greater of breast, colorectal, or prostate cancer up until 12 months.
3172872|NCT01389830||Older Latinos Without Cancer|Single Telephone Survey of Cohort without a history of cancer.
3172873|NCT01389817|Experimental|Symptomatic LHON patients.|Study Arm 1) symptomatic LHON patients. Male and female LHON patients with treatable bilateral optic atrophy. Treat the worse of the 2 eyes if there is a measurable difference in subjective visual functions (visual acuity, peripheral vision).
3172874|NCT01389817|No Intervention|Asymptomatic LHON mutation carriers|Study Arm 2) asymptomatic LHON mutation carriers. Can be male or female; have some dysfunction, with changes occurring over months. Patients in study arm 2 will not be exposed to NIR-LED, but only undergo diagnostic studies.
3172875|NCT01389804||Pediatric Solid Organ Transplant|Parents of pediatric solid organ transplant recipients
3172876|NCT01389791|No Intervention|Roc|Patients in this group receive neither MgSO4 nor priming dose of rocuronium.
3172877|NCT01389791|Active Comparator|priming|patients in this group receive 0.06mg/kg of rocuronium before 0.54mg/kg of rocuronium.
3172878|NCT01389791|Experimental|Mg&priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
3172879|NCT01389791|Active Comparator|MgSO4|Patients in this group receive intravenous MgSO4 before administration of rocuronium.
3172880|NCT01389778|Experimental|Metformin|Subjects treated with metformin.
3172881|NCT01389765|Experimental|LY2216684 administered in fasted then fed state|Period 1: 18 mg LY2216684 administered orally on Day 1, one time only, in fasted state. This will then be followed by a 7 day washout period prior to beginning the second period. Period 2: 18 mg LY2216684 administered orally on Day 1, one time only, in fed state.
3172882|NCT01389765|Experimental|LY2216684 administered in fed then fasted state|Period 1: 18 mg LY2216684 administered orally on Day 1, one time only, in fed state. This will then be followed by a 7 day washout period prior to beginning the second period. Period 2: 18 mg LY2216684 administered orally on Day 1, one time only, in fasted state.
3172883|NCT01389752|Experimental|LY2216684 without Charcoal First, then with Charcoal|Period 1: Single 18mg (2 x 9 mg tablets) oral dose of LY2216684 administered on Day 1 without Activated Charcoal. Periods will be separated by a minimum of 7 days. Period 2: Single 18mg (2 x 9 mg tablets) oral dose of LY2216684 administered on Day 1 with single oral dose of 1 gm/kg of Activated Charcoal administered orally.
3172884|NCT01389752|Experimental|LY2216684 with Charcoal First, then without Charcoal|Period 1: Single 18mg (2 x 9 mg tablets) oral dose of LY2216684 administered on Day 1 with single oral dose of 1 gm/kg of Activated Charcoal administered orally. Periods will be separated by a minimum of 7 days. Period 2: Single 18mg (2 x 9 mg tablets) oral dose of LY2216684 administered on Day 1 without Activated Charcoal.
3173033|NCT01388738|Active Comparator|citicoline|IV and per os
3172885|NCT01389739|Experimental|Exposed to the intervention|Patients in the intervention arm will be exposed to a multi-faceted intervention to improve continuity of care; the intervention includes 4 components: 1) systematic appointments with FP at 3-month interval during the study period; 2) transmission to FP of a standardized comprehensive summary before each appointment; 3)systematic transmission to the oncology team of patients' information resulting from FP visits; 4) development of a priority access to FP for cancer patients
3172886|NCT01389739|No Intervention|Usual care|
3172887|NCT01389726|Experimental|Behavioral Parenting Training|Triple-P Parenting Training Program (group level)
3172888|NCT01389726|Experimental|Cognitive Behavioral Therapy|CBT group-level intervention (Designed by Larry Thompson & Dolores Gallagher Thompson)
3172889|NCT01389726|Active Comparator|Psychosocial-Informational Support|Standard of Care informational support group
3172890|NCT01389713|Active Comparator|High doses|Administration of high doses of gonadotrophins to stimulate ovarian follicular growth
3172891|NCT01389713|Experimental|Clomid|Administration of Clomiphene Citrate to obtain ovarian follicular growth
3172892|NCT01389700|Experimental|SAR279356 dose 1|SAR279356 dose 1, single administration
3172893|NCT01389700|Experimental|SAR279356 dose 2|SAR279356 dose 2, single administration
3172894|NCT01389700|Placebo Comparator|Placebo|Matching placebo, single administration
3172895|NCT01389687|Experimental|Study Group|
3172896|NCT01389674|Experimental|2D-strain echo|After myocard vitality diagnostics with MRI follows a stress echocardiography to determine the LV volumes and EF. The received Data are compare with the MRI-Data(reference)to identify the ideal strain-parameters and Cut-Off-Result for an intraprocedural vitality diagnostic of the different films (endocardial, myocardial and epicardial).
3172897|NCT01389661|Experimental|MSV treatment|MSV treatment: Mesenchymal stem cells from bone marrow expanded by GMP-compliant procedure in IBGM cell production unit in autologous plasma scaffold and implanted in maxillary bone cavities after cyst removal
3172898|NCT01389648|Experimental|Pre Operative|Pre operative chest physiotherapy treatment
3172899|NCT01389648|No Intervention|usual care|
3172900|NCT01389635||Abdominoplasty patients|All patients who underwent abdominoplasty at our institution without concurrent operations
3172901|NCT01389622|Experimental|Arm 1: NADA points and digital pressure|Arm 1: NADA points and digital pressure with urge.
3172902|NCT01389622|Experimental|Arm 2: random points + digital pressure with urge|Arm 2 (20 participants): random points + digital pressure with urge
3172903|NCT01389622|No Intervention|Arm 3 (20 participants): NO acupressure, only advice + support|
3172904|NCT01389609|Experimental|A|Doxazosin 4 mg Japanese marketed IR tablet as a single oral dose under fasted conditions
3172905|NCT01389609|Experimental|B|Doxazosin 4 mg ODT with water as a single oral dose under fasted conditions
3172906|NCT01389609|Experimental|C|Doxazosin 4 mg ODT without water as a single oral dose under fasted conditions
3172907|NCT01389596|Placebo Comparator|Placebo|
3172908|NCT01389596|Experimental|Pregabalin Level 1 (max 150 mg/day)|
3172909|NCT01389596|Experimental|Pregabalin Level 2 (max 600 mg day)|
3172910|NCT01389583|Experimental|AUY922|AUY922
3172911|NCT01389570|Experimental|Acupressure wrist band|The group receiving acupressure wrist band
3172912|NCT01389544|Experimental|Single Arm|
3172913|NCT01389531|Other|Stents|All recruited patients will be receiving a stent during a rigid bronchoscopy procedure.
3172914|NCT01389518|Active Comparator|Paracetamol,Chlorpheniramin,Phenylephrin|
3172915|NCT01389518|Placebo Comparator|Placebo|
3172916|NCT01389505|Active Comparator|Panretinal photocoagulation|Group 1: Panretinal photocoagulation treatment (PRP) at month-0 that can be repeated after month-3.
3172917|NCT01389505|Experimental|Bevacizumab + Panretinal Photocoagulation (PRP)|Group 2: Bevacizumab intravitreous injections plus PRP
3172918|NCT01389492|Other|frozen meat|250 g of frozen meat meal for 4 days
3172919|NCT01389492|Other|frozen meat and wine|250 g of frozen meat and red wine for 4 days
3172920|NCT01389492|Other|fresh meat|250 g of fresh meat meal
3172921|NCT01389492|Other|fresh meat and wine|250 g of fresh meat meal
3172922|NCT01389479|Experimental|Fluviral Group|
3172923|NCT01389479|Active Comparator|Fluzone Group|
3172924|NCT01389466|Experimental|MG1109 - Step 1|
3172925|NCT01389466|Placebo Comparator|Normal Saline - Step 1|
3172926|NCT01389466|Experimental|MG1109 - Step 2|
3172927|NCT01389453|Active Comparator|stem cell transplatation|All experimental group patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7—14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
3172928|NCT01389453|No Intervention|control|The control group gives injection through intravenous and lumbar puncture ways separately in the corresponding time, but the transplantation matter is physiological saline not the stem cell.
3172929|NCT01389440|Experimental|Gemcitabine, Erlotinib and radiotherapy|Gemcitabine + Erlotinib follow by Gemcitabine + Erlotinib + radiotherapy
3172930|NCT01389427|Experimental|Torisel 15 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 15 mg
3172931|NCT01389427|Experimental|Torisel 25 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 25 mg
3172932|NCT01389427|Experimental|Torisel 50 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 50 mg
3172933|NCT01389427|Experimental|Torisel 75 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 75 mg
3172934|NCT01389414|Experimental|Arm A- p-Gemox|"Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once Q2W.~GEMOX chemotherapy will be administered after the administration of panitumumab once Q2W.~Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle."
3172935|NCT01389414|Active Comparator|Arm B-GEMOX|Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
3172936|NCT01389401||reflux laryngitis group pre-treatment|adults with clinical suspicion of Reflux Laryngitis confirmed by 24-hour double probe esophageal monitoring who have not made use of any treatment in the past 15 days.
3172937|NCT01389401||study group - post treatment|adults with reflux laryngitis after 16 weeks of treatment with proton pump inhibitor (omeprazole 40 mg twice a day)and dietary/lifestyle changes that present improvement in symptoms and video laryngoscopic signs of chronic laryngitis
3172938|NCT01389401||control group|healthy controls paired by gender and age that do not present symptoms and videolaryngoscopic signs suggestive of reflux laryngitis
3172939|NCT01389388|Experimental|Rosuvastatin intervention|Patients > 70 years will be given Rosuvastatin of 5 mg a day, uptitering the dose until the LDL level of 1.6-1.8 mmol/l has been reached. Patient <70 years, strat on Rosuvastatin 20 mg a day, uptitered to 40 mg a day, with the LDL of 1.6-1.8 mmol/l. -1.8 mmol/l. The objective is that all the participants should have reached a LDL level of 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
3172940|NCT01389375|Experimental|FemoSeal®|Device: FemoSeal®
3172941|NCT01389375|Experimental|ExoSeal®|Device: ExoSeal®
3172942|NCT01389375|Active Comparator|Manual compression|Other: Manual compression
3172943|NCT01389362|Active Comparator|Chinese Herbal Medicine|2 sachets of Chinese Herbal Medicine to be taken daily
3172944|NCT01389362|Placebo Comparator|Placebo arm|2 sachets to be taken daily
3172945|NCT01389349|Experimental|Acupuncture|
3172946|NCT01389349|Sham Comparator|Sham Control|
3172947|NCT01389336||Add-on Ayurveda - Group|In the Āyurveda add-on-group 20 patients will receive individualized treatment according to the Āyurveda diagnosis which may include manual treatments, massages, dietary advice, specific consideration of selected food items, āyurvedic lifestyle & yoga posture advice and daily self-applied massage on top of standard care.
3172948|NCT01389336||Standard Care|20 Patients will receive the individually adjusted complex conventional standard care according to the current AWMF-guidelines including physiotherapy, occupational therapy, specific pain therapy and psychotherapy.
3172949|NCT01389323|Experimental|Arm 1: Daclatasvir + Peg-Interferon Alfa-2a + Ribavirin|
3172950|NCT01389310||HIV-infected children <18 yrs old - exposed to Atazanavir|
3172951|NCT01389297|Active Comparator|Face-to-face SMART Recovery meetings|Participants in this arm will be asked to attend face-to-face SMART Recovery meetings.
3172952|NCT01389297|Experimental|Overcoming Addictions web app|Participants in this condition will use the Overcoming Addictions web application and not attend face-to-face SMART Recovery meetings.
3172953|NCT01389297|Experimental|Web app + meetings|Participants in this condition will be asked to use both the Overcoming Addictions web application and attend face-to-face SMART Recovery meetings.
3172954|NCT01389284|Experimental|Naproxen Sodium ER (BAYH6689)|1 naproxen sodium extended release (ER) 660 mg tablet and 1 naproxen sodium immediate release (IR) 220 mg placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)
3172955|NCT01389284|Active Comparator|Naproxen Sodium IR (Aleve, BAYH6689)|1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg tablet initially followed by 1 naproxen sodium IR 220 mg tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg tablet eight hours at hour 16 (± 15 min)
3172956|NCT01389284|Placebo Comparator|Placebo|1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg matching placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)
3172957|NCT01389271||Group 1|
3172958|NCT01389258|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
3172959|NCT01389245|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX implants of lengths 8-17 mm
3172960|NCT01389232|Experimental|1|SeriScaffold® Surgical Scaffold
3172961|NCT01389219|No Intervention|Control|Control arm
3172962|NCT01389219|Other|Intervention clusters|Focus is to increase the number of visits by LHWs to the newborn baby and to ensure that this visit occurs within 48-72 hours of birth. The purpose of this visit was the provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation, cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.
3172963|NCT01389206||Standard of care|Observational study to improve the management of PAH patients through an evidence-based approach aimed at achieving optimal WHO functional class (FC) treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi.
3172964|NCT01389193|Experimental|Ibudilast|
3172965|NCT01389193|Placebo Comparator|Placebo|
3172966|NCT01389180|Experimental|BDRC|
3172967|NCT01389180|Experimental|EC|
3172968|NCT01389180|Other|TAU|
3172969|NCT01389167|Experimental|Vivitrol + BDRC|
3172970|NCT01389167|Experimental|Vivitrol + Medical Management|
3172971|NCT01389167|Experimental|Naltrexone (oral)+BDRC|
3172972|NCT01389167|Experimental|Naltrexone (oral) + Medical Management|
3172973|NCT01389154|Experimental|Patients recommended for a lung biopsy.|Patients with a positive diagnosis of a peripheral, less than 3.0 centimeter lung lesion, recommended for bronchoscopic biopsy are eligible to be consented into the study.
3172974|NCT01389141||mid-reproductive age|
3172975|NCT01389141||late reproductive age-1|
3172976|NCT01389141||late reproductive age-2|
3172977|NCT01389128|No Intervention|control group|Control Group (CG): Pregnant women who receive assistance from the protocol CRSM MATER, not being assisted by the physiotherapist, but that will be evaluated at the same time in the intervention group.
3172978|NCT01389128|Experimental|intervention group|Intervention Group (IG): Pregnant women who receive the application protocol using the combination of non-pharmacological resources: standing upright pelvic mobility in the ball (4 to 5 cm), alternating stance associated with lumbosacral massage (6 and cm)and shower (> 7 cm);
3172979|NCT01389115||Liver Cirrhosis|Patient with liver cirrhosis undergoing liver transplant
3172980|NCT01389115||Liver donors|Subjects eligible for organ explant
3172981|NCT01389115||Healthy controls|
3172982|NCT01389102|Placebo Comparator|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
3172983|NCT01389102|Placebo Comparator|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
3172984|NCT01389102|Placebo Comparator|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
3172985|NCT01389102|Active Comparator|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
3172986|NCT01389102|Active Comparator|Estradiol transdermal two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
3172987|NCT01389102|Active Comparator|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
3172988|NCT01389089|No Intervention|Control group|The Control group received ice gel packs and elevation to reduce edema.
3172989|NCT01389089|Experimental|Multi-layer compression bandage|A multi-layer compression bandage was applied to the lower limb and foot of the patient to reduce edema. Additionally, the limb was constantly elevated.
3172990|NCT01389089|Experimental|A-V Impulse compression|An A-V Impulse compression device was used to reduce edema.
3172991|NCT01389076|Experimental|Treatment arm|Low dose methotrexate and Bexxar
3172992|NCT01389063|Active Comparator|Arm A|HAART of subjects in arm A will be intensified with maraviroc during week 1-8.
3172993|NCT01389063|Active Comparator|Arm B|HAART of subjects enrolled in arm B will be intensified with maraviroc during week 9-16
3172994|NCT01389050|No Intervention|Follow-up|Data from these patients will be added to retrospectively gathered data from the PMH radiotherapy data bank (approximately 50 patients). The data collected will be analyzed using descriptive statistics.
3172995|NCT01389050|Experimental|Prospective|
3172996|NCT01389037|Experimental|Health Literacy-focused Self-help|
3172997|NCT01389037|Placebo Comparator|Delayed intervention control|
3172998|NCT01389024|Experimental|Hydroxyurea|treatment with hydroxyurea 20 mg/kg/day increased by 5 mg/kg every 8 weeks to maximum of 35 mg/kg/day or hematologic toxicity or ANC <4000
3172999|NCT01389024|Placebo Comparator|Placebo|Sucrose placebo 0.2 ml/kg/day increased to max of 0.35 ml/kg/day
3173000|NCT01388985|Active Comparator|Standard vaccination schedule|One injection will be given on three different days (day 0, day 7 and day 21 or 28)
3173001|NCT01388985|Experimental|Accelerated vaccination schedule|Two injections will be given on the same day (day 0 and day 7): one on each forearm.
3173002|NCT01388959|Experimental|Single arm|
3173003|NCT01388946|Active Comparator|Ropivacaine 0.75|Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
3173004|NCT01388946|Placebo Comparator|Normal saline|Continuous infusion of normal saline 2 ml/h for 24 hours
3173005|NCT01388933|Experimental|TU-100|15g TU-100 (oral, daily) for 8 consecutive weeks (administered as 5g three times daily)
3173006|NCT01388933|Placebo Comparator|Matching placebo|Matching placebo given 5g three times daily orally for 8 consecutive weeks
3173007|NCT01388920|Experimental|Tesamorelin 2 mg|Tesamorelin 2 mg/day
3173008|NCT01388920|Experimental|Tesamorelin 3 mg|Tesamorelin 3 mg/day
3173009|NCT01388920|Placebo Comparator|Placebo|
3173010|NCT01388907|Experimental|Prevadh film|Patient randomized in this arm have been treated with Prevadh film applied on the uterine surgical sites, at the end of the myomectomy surgery to prevent post-surgey adhesion formation.
3173011|NCT01388907|Active Comparator|Ringer solution|Patients randomized in the Ringer solution group have been treated with Ringer lactate solution directly applied to the uterine surgical sites at the end of the myomectomy surgery.
3173012|NCT01388881|Experimental|Music Education|Music education classes take place three times a week, 50 minutes each. These interventional classrooms will make available keyboard and blockflute.
3173013|NCT01388881|No Intervention|Non-intervention|In this arm, children will be not encourage practicing musical activities and will not have musical classes.
3173014|NCT01388868|Active Comparator|TOF count guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by No. of response to TOF stimulation
3173015|NCT01388868|Experimental|T1/T0 guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by T1 twitch height as compared with control (T0)
3173016|NCT01388868|Experimental|T2/ T0 guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by T2 twitch height as compared with baseline (T0)
3173017|NCT01388855|Experimental|Cholecalciferol|Patients were given two cholecalciferol tablets (10,000 IU each) daily for 30 days.
3173018|NCT01388855|Placebo Comparator|Placebo|Patients were given two cholecalciferol placebo tablets daily for 30 days.
3173019|NCT01388842|Placebo Comparator|Placebo|Controls will receive small pulses of placebo study drug via the INOpulse delivery system. Oxygen saturation will be maintained above 94% by adding oxygen to inspired gas via a loose fitting mask when necessary.
3173020|NCT01388842|Experimental|inhaled nitric oxide|Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air using an INOpulse delivery system for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days. Oxygen saturation will be maintained above 94% by adding oxygen to inspired gas via a loose fitting mask when necessary.
3173021|NCT01388829|Experimental|formulation comparison|formulation comparison
3173022|NCT01388816|Placebo Comparator|Placebo capsule|
3173023|NCT01388816|Experimental|DRL-17822 50 mg|
3173024|NCT01388816|Experimental|DRL-17822 150 mg|
3173025|NCT01388816|Experimental|DRL-17822 300 mg|
3173026|NCT01388790|Experimental|Cetuximab plus cisplatin plus S-1|
3173027|NCT01388777|Experimental|Cryoablation|Cryoablation therapy followed by re-imaging then complete surgical resection.
3173028|NCT01388764|Experimental|L-arginine|
3173029|NCT01388751|No Intervention|no night splinting|
3173034|NCT01388725||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
3173035|NCT01388725||Sepsis|SIRS + infection
3173036|NCT01388712|Placebo Comparator|Placebo|
3173037|NCT01388712|Active Comparator|Probiotics|Lactobacillus reuteri DSM 17938
3173038|NCT01388699||migraine group|female migraineurs with aura
3173039|NCT01388699||control group|healthy women without headache syndrome
3173040|NCT01388686||INABBRA|Participating intensive care units of hospitals in the INABBRA alliance.
3173041|NCT01388673|Experimental|ACE Stapler procedure|ACE Stapler procedure for the treatment of dilated post-surgical gastric anatomy
3173042|NCT01388660|Experimental|Cloas|A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin
3173043|NCT01388660|Active Comparator|Plavix/Astrix|Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin)
3173044|NCT01388647|Experimental|Eribulin, carboplatin, and trastuzumab|During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle. Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle. Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
3173045|NCT01388634||Study cohort|Patients with prolonged length of hospital stay (>5 days) or readmission after ventral hernia repair
3173046|NCT01388634||control group|Patients without prolonged length of hospital stay (>5 days) or readmission after ventral hernia repair
3173047|NCT01388621|Experimental|Experimental arm (A):|"Caelyx 30 mg/m² d1 Carboplatin AUC 5 d1 Panitumumab 6 mg/kg/KG d1 + 15 q4w until progressive disease or for a max. of 6 cycles~OR~Gemcitabine 1000 mg/m² d1 + 8 Carboplatin AUC 4 d1 Panitumumab 9 mg/kg/KG d1 q3w until progressive disease or for a max. of 6 cycles~The backbone chemotherapy (Caelyx or Gemcitabine-based) is specified by the investigator before randomization of a patient."
3173048|NCT01388621|Active Comparator|Standard arm (B):|"Caelyx 30 mg/m² d1 Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles~OR~Gemcitabine 1000 mg/m² d1 + 8 Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles~The backbone chemotherapy (Caelyx or Gemcitabine-based) is specified by the investigator before randomization of a patient."
3173049|NCT01388608||RA patients receiving etanercept|Patients with active rheumatoid arthritis (RA) who are eligible to a treatment with etanercept.
3173050|NCT01388595|Active Comparator|Fluticasone Proprionate|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
3173051|NCT01388595|Active Comparator|Salmeterol|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
3173052|NCT01388595|Placebo Comparator|placebo|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
3173053|NCT01388582|Active Comparator|Combined oral contraceptive|10 women will receive COC during breastfeeding
3173054|NCT01388582|Active Comparator|Levonorgestrel intrauterine system|10 women will receive a LNG-IUS during breastfeeding
3173055|NCT01388582|Active Comparator|Implanon|10 women will receive Implanon during breastfeeding
3173056|NCT01388582|Active Comparator|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive during breastfeeding
3173057|NCT01388556|Experimental|Tango|Twice weekly tango dance classes for 12 months.
3173058|NCT01388556|No Intervention|Control Group|
3173059|NCT01388543|Active Comparator|CYP3A5 Expressors|A pre-screening genetic test determines CYP3A5 expressor status
3173060|NCT01388543|Active Comparator|CYP3A5 Non-expressors|A pre-screening genetic test determines CYP3A5 non-expressor status
3173061|NCT01388530|Experimental|trigeminal nerve stimulation|Open label treatment with trigeminal nerve stimulation in an 8-week trial.
3173062|NCT01388517|Active Comparator|Calcitriol|Repigmentation treatment for the relief of hypopigmented pityriasis alba lesions
3173063|NCT01388517|Active Comparator|Tacrolimus|Treatment for the relief of hypopigmented pityriasis alba lesions
3173064|NCT01388517|Placebo Comparator|Petrolatum|Petrolatum treatment for the relief of hypopigmented pityriasis alba lesions
3173065|NCT01388504|Experimental|sodium nitrite|
3173066|NCT01388504|Placebo Comparator|placebo|sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes
3173067|NCT01388491|Experimental|Treatment I: (DR-102)|21 days of combination active pills (containing 150 mcg desogestrel [DSG]/20 mcg ethinyl estradiol [EE]), followed by 7 days of 10 mcg EE, taken orally for 6 consecutive 28-day cycles
3173068|NCT01388491|Active Comparator|Treatment II|21 days combination active pills (containing 150 mcg DSG/20 mcg EE), taken orally and followed by 7 days of no treatment for a total of 6 consecutive 28-day cycles
3173069|NCT01388478|Experimental|R(+)pramipexole|Each study participant will be given the active study drug, R-pramipexole. There is no placebo arm.
3173070|NCT01388465|Experimental|Mobile phone text message Intervention|Daily assessments with feedback about (1) filling prescription and (2) number of doses taken
3173071|NCT01388465|No Intervention|Control|No TM queries or feedback
3173072|NCT01388452|Experimental|Point of Care HIV RNA PCR|Patients randomized to this arm will be followed prospectively from the time of clinical evaluation in the hospital until 12 months after returning for outpatient care at the KCH HIV clinic. The counselor will collect infant blood for point of care RNA PCR testing, number the sample, and transport it to the central laboratory for processing. Patients determined to be HIV-uninfected or HIV-exposed uninfected will not continue in the study beyond virologic test result disclosure, which will occur as an inpatient at KCH for this arm. If the patient does not return for outpatient care for three months after hospitalization then the patient's participation in the study will end.
3173123|NCT01388023|Active Comparator|smellx|test group- SmellX palatal patch with the herbal formula
3173073|NCT01388452|No Intervention|Standard of Care|"Patients randomized to this arm will be followed prospectively from the time of clinical evaluation in the hospital until 12 months after returning for outpatient care at the KCH HIV clinic. The counselor will collect infant blood for dried blood spot DNA PCR testing, number the sample, and transport it to the central laboratory for processing. If the patient is PD positive then the patient will be offered ART initiation prior to hospital discharge.~Patients determined to be HIV-uninfected or HIV-exposed uninfected will not continue in the study beyond virologic test result disclosure, which will occur as an outpatient at KCH for this arm. If the patient does not return for outpatient care for three months after hospitalization then the patient's participation in the study will end."
3173074|NCT01388439||Oseltamivir exposure|One infant in the Neonatal Intensive Care Unit (NICU) at St. Louis Children's Hospital experienced respiratory decompensation and tested positive for influenza virus type A by fluorescent antibody stain performed on a nasopharyngeal swab. This infant received treatment doses of oseltamivir. Subsequently, 27 other infants received oseltamivir prophylaxis for exposure to influenza virus type A. Exposed infants were those who shared a primary medical team, nursing care, respiratory therapist, physical therapist, or occupational therapist with the influenza A positive infant. Prophylaxis was deemed necessary by the attending neonatologist after consultation with the Infectious Diseases Division of the Department of Pediatrics at the Washington University School of Medicine.
3173075|NCT01388426|Experimental|7eye( Panoptx)™ Moisture chamber glasses|7eye( Panoptx)™
3173076|NCT01388413|Experimental|Weekly Oral Cyclic Antibiotic programme|
3173077|NCT01388413|No Intervention|Classic care|
3173078|NCT01388400|Experimental|Conventional intervention for upper limb reaching|Reaching or holding cones, cups, etc. in all planes with and without gravity or loading
3173079|NCT01388400|Experimental|VR treatment|The Virtual Reality (VR) therapy group received the treatment in the GestureTek VR environment which focused on reaching movements of the affected upper limb using virtual games and a virtual supermarket.
3173080|NCT01388387|Experimental|Tacrolimus pharmacokinetics|
3173081|NCT01388374|No Intervention|General Practitioners Care|Usual medical care provided by a general practitioner at the Primary Out of Hours Emergency Service.
3173082|NCT01388374|Experimental|Nurse Practitioners Care|Medical care provided by the Nurse Practitioner at the Primary Out of Hours Emergency Service.
3173083|NCT01388361|Experimental|IDeg (non-randomised)|
3173084|NCT01388361|Experimental|IDeg + IAsp|
3173085|NCT01388361|Experimental|IDeg + liraglutide|
3173086|NCT01388348|Experimental|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
3173087|NCT01388335|Experimental|warfarin + enzastaurin|"On day 1 of period 1, a single 5 mg oral dose of warfarin will be given, followed by at least a 7-day washout.~Period 2; 500 mg enzastaurin administered orally once daily for at least 19 consecutive days. 5 mg warfarin administered as a single oral dose on day 15.~Safety Extension: Participants are allowed to continue receiving enzastaurin alone until disease progression or other discontinuation criteria are met."
3173088|NCT01388322|Experimental|Enoxaparin|Subcutaneous administration of one dose daily of enoxaparin
3173089|NCT01388322|No Intervention|expectant management|Usual management
3173090|NCT01388309||Cohort|
3173091|NCT01388296||Morbidly obese patients|BMI 40-50 k/m2
3173092|NCT01388296||Morbidly obese|BMI 50-60 k/m2
3173093|NCT01388296||Morbidly obeses|BMI 60-70 k/m2
3173094|NCT01388270|Active Comparator|Evodial|a pre-heparin-coated hemodialysis filter
3173095|NCT01388270|No Intervention|170 H|Conventional filter
3173096|NCT01388257|Experimental|Surgery|Seton drain removal is associated with proctological surgery.
3173097|NCT01388257|Other|Simple seton drain removal|
3173098|NCT01388244|Active Comparator|Screening|Two-step screening process using FRAX risk score assessment followed by DXA scanning for high risk participants.
3173099|NCT01388244|Other|Control|Control arm - Fracture risk assessment by FRAX without any intervention
3173100|NCT01388231|Active Comparator|Manualized CBT Group|The present group is comprised of clinical practitioners performing cognitive-behavioral therapy (CBT) on social phobic patients after receiving structured clinical training on the treatment of social phobia based on the Clark and Wells (1995) model.
3173101|NCT01388231|Active Comparator|CBT Group -Treatment as Usual|The present group is comprised of clinical practitioners performing cognitive-behavioral therapy (CBT) on social phobic patients, while receiving no structured training in the treatment of social phobia.
3173102|NCT01388218||Arm 1 - Daily+Clinical|Order of assessment: Daily PRO + Clinical visit PRO
3173103|NCT01388218||Arm 2 - Clinical+Daily|Order of assessment: Clinical visit PRO + Daily PRO
3173104|NCT01388205|Experimental|Family-based Intervention Arm|
3173105|NCT01388205|No Intervention|Control|
3173106|NCT01388192||Receiving pancreaticoduodenectomy|
3173107|NCT01388179|Active Comparator|Real rTMS treatment|low-frequency rTMS to the left DLPFC (Dorsa-Lateral Pre-Frontal Cortex) prior to high-frequency deep rTMS to the FFA (Fusi-Form Area) through the STS(Superior Temporal Sulcus).
3173108|NCT01388179|Sham Comparator|Sham rTMS treatment|Sham coil which simulate the real coil action
3173109|NCT01388166||Patients with COPD|
3173110|NCT01388153|Experimental|Arm 1|
3173111|NCT01388153|Experimental|Arm 2|
3173112|NCT01388153|Active Comparator|Arm 3|
3173113|NCT01388140||psychiatric inpatients, regardless of clinical diagnoses|
3173114|NCT01388114|Experimental|Electrosensing antibody probing system (e- Ab sensing)|
3173115|NCT01388101|Experimental|LECT2 detection|single-arm study: Electrosensing antibody probing system(e-AB sensor)
3173116|NCT01388088|Active Comparator|Spironolactone|Increases the level of potassium
3173117|NCT01388088|Active Comparator|Amiloride|Increases the level of potassium
3173118|NCT01388088|Placebo Comparator|Placebo|
3173119|NCT01388075|Experimental|Rifampicin|Consecutive treatments with rifampicin and placebo
3173120|NCT01388062|Experimental|virus detection|
3173121|NCT01388049|Experimental|virus detection|
3173122|NCT01388036|Experimental|esmolol infusion|infusion of esmolol during rest and exercise
3173124|NCT01388023|Placebo Comparator|smellx palatal patch|negative control group- SmellX palatal patch with out the herbal formula
3173125|NCT01388023|Active Comparator|chlorhexidine|poositive control group-mouth wash with chlorhexidine 0.125%
3173126|NCT01388023|Active Comparator|listerine|listerine mouth wash
3173127|NCT01388010|Experimental|1 = Test product|Arm 1 - Intervention 1 (probiotics)
3173128|NCT01388010|Other|2 = Control product|Arm 2 - Intervention 2 (control)
3173129|NCT01387997|Experimental|1|
3173130|NCT01387984||Type 2 diabetes mellitus|
3173131|NCT01387971||ocular surface disorders|various ocular surface disorders
3173132|NCT01387958|Experimental|LCQ908|
3173133|NCT01387958|Placebo Comparator|Placebo|
3173134|NCT01387945|No Intervention|HBPM only|
3173135|NCT01387945|Experimental|HBPM+website+patient navigator|
3173136|NCT01387932|Experimental|HepaSphere/QuadraSphere TACE|HepaSphere/QuadraSphere TACE
3173137|NCT01387932|Active Comparator|Conventional TACE|Conventional TACE
3173138|NCT01387919|Experimental|1|healthy young and lean men
3173139|NCT01387906|Experimental|Topical bimatoprost for eyebrows|Topical bimatoprost will be applied to areas of the eyebrow that have diminished eyebrows (hypotrichosis).
3173140|NCT01387893|Experimental|Immediate & Delayed Instruction|Male patients with mild to moderate lower urinary tract symptoms will alternately be assigned to either immediate intervention or delayed intervention groups. Statistical assessments will be performed to establish comparability of baseline characteristics in the two groups.
3173141|NCT01387880|Experimental|Cetuximab, everolimus, irinotecan|
3173142|NCT01387880|Active Comparator|Cetuximab, everolimus and Irinotecan.|"Patients with metastatic colorectal cancer with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan.~Patients with KRAS wildtype colorectal cancer that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, irinotecan and everolimus."
3173143|NCT01387867|Experimental|Strength training|Strength training three times weekly, i.e.supervised strength training twice weekly and un-supervised strength training once weekly for 4 months.
3173144|NCT01387867|Experimental|Nordic Walking|Nordic walking three times weekly, i.e.Nordic walking twice weekly and un-supervised Nordic walking once weekly for 4 months.
3173145|NCT01387867|Active Comparator|Unsupervised home based exercise|The home based unsupervised exercise comprised exercises recommended by the Danish Arthritis Association.
3173146|NCT01387841|Experimental|Yoga group|Yoga intervention with standard antiemetic care
3173147|NCT01387841|Active Comparator|PMRT/Jacobsons Relaxation training|25 minutes of progressive muscle relaxation training will be given to this group with standard antiemetic care
3173148|NCT01387841|No Intervention|Standard antiemetic care|Standard antiemetic care only
3173149|NCT01387828|Active Comparator|Laparoscopy|Includes all patient underwent intervention with a laparoscopic approach, even if converted to open surgery during intervention
3173150|NCT01387828|Active Comparator|Open surgery|Includes all the patients underwent intervention with a laparotomic approach; it does not include patient underwent laparoscopic approach and then converted in laparotomy.
3173151|NCT01387815||Topical Agents|patients with a new topical agent that was not used before or already on treatment with a topical agent and not responding
3173152|NCT01387815||Adalimumab|patients with adalimumab alone or in combination with topical agents
3173153|NCT01387815||Traditional Systemic Agents|patients with a new systemic agent that was not used before alone or in combination with topical agents
3173154|NCT01387802||Non-Biologic arm|Patients that have not responded to the current treatment with an NSAID (Nonsteroidal Anti-Inflammatory Drug) and/or non - biologic DMARD (Disease-Modifying Anti Rheumatic Drug) for peripheral joint involvement and switch to or addition of another NSAID /DMARDS
3173155|NCT01387802||Biologic arm|Patients that have not responded to the current treatment with non biologic DMARDS (Disease-Modifying Anti Rheumatic Drug) /NSAID (Nonsteroidal Anti-Inflammatory Drug) and switch to or addition of adalimumab
3173156|NCT01387789||Scheduled to start adalimumab therapy|Patients diagnosed with rheumatoid arthritis for at least 3 months that previously had not received prior anti-TNF agents.
3173157|NCT01387776||study group|patients coming to clinique OVO in the 1st trimester of pregnancy to undergo prenatal screening
3173158|NCT01387763|Active Comparator|PegIntron <= 60 years|In patients <= 60 years PegIntron is started at low-dose 35 micrograms once weekly. Dose escalation to 50 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 50 micrograms weekly at 12 months and 18 months respectively, dose escalation to 96 micrograms weekly.
3173159|NCT01387763|Active Comparator|Pegasys <= 60 years|In patients <= 60 years Pegasys is started at low-dose 45 micrograms once weekly. Dose escalation to 90 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 90 micrograms weekly at 12 months and 18 months respectively, dose escalation to 135 micrograms weekly.
3173160|NCT01387763|Active Comparator|PegIntron > 60 years|In patients < 60 years PegIntron is started at low-dose 35 micrograms once weekly. Dose escalation to 50 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 50 micrograms weekly at 12 months and 18 months respectively, dose escalation to 96 micrograms weekly.
3173161|NCT01387763|Active Comparator|Pegasys > 60 years|In patients > 60 years Pegasys is started at low-dose 45 micrograms once weekly. Dose escalation to 90 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 90 micrograms weekly at 12 months and 18 months respectively, dose escalation to 135 micrograms weekly.
3173162|NCT01387763|Active Comparator|Hydroxyurea > 60 years|Capsule Hydrea 500-2000 mg orally QD or BID
3173163|NCT01387750|Placebo Comparator|Mentholated Cream|
3173164|NCT01387750|Active Comparator|Mentholated Cream with OGT|
3173165|NCT01387737|Experimental|TA-7284-Low|
3173166|NCT01387737|Experimental|TA-7284-High|
3173167|NCT01387711|Experimental|ingenol mebutate|PEP gel 0.05% once daily exposure
3173168|NCT01387672|Active Comparator|Nitrol|Nitroglycerin Ointment 2% USP
3173169|NCT01387672|Active Comparator|Nitro-Dur|Nitroglycerin Extended Release Patch 160mg
3173170|NCT01387672|Active Comparator|Nitrostat 1|Nitroglycerin 0.3mg Sublingual Tablet
3173171|NCT01387672|Active Comparator|Nitrostat 2|Nitroglycerin 0.6mg Sublingual Tablet
3173172|NCT01387672|Active Comparator|ISMO|Isosorbide Mononitrate 20mg Oral Tablet
3173173|NCT01387672|Placebo Comparator|Placebo|Placebo Ointment
3173174|NCT01387659|Experimental|Transplant recipients|All subjects receive identical drug treatment
3173175|NCT01387646|Other|Control Group|Participants in the control arm will be interviewed at baseline, be given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and will receive abuse and enhanced clinical counseling
3173176|NCT01387633|Experimental|Educational intervention through telephone contact|Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact
3173177|NCT01387633|Active Comparator|Educational intervention group|Educational intervention group for people with diabetes through Diabetes Conversation Maps.
3173178|NCT01387607|Experimental|Pregabalin|
3173179|NCT01387607|Placebo Comparator|Placebo|Matched placebo
3173180|NCT01387594|Experimental|Cohort 1|Interventions prior to treatment. Control arm
3173181|NCT01387594|Experimental|Cohort 2|Interventions prior to and after 3 monthly injections
3173182|NCT01387581||Without MelaFind|Study dermatologists will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.
3173183|NCT01387581||With MelaFind|Study dermatologists will review clinical exam information, 3 high quality digital images, and MelaFind result for each lesion
3173184|NCT01387581||Experts Without MelaFind|PSL Experts, prospectively identified and recruited by the PI after the general recruitment is completed. They will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.
3173185|NCT01387568|Active Comparator|group L|Lidocaine group
3173186|NCT01387568|Placebo Comparator|group P|Placebo group
3173187|NCT01387555|Experimental|Arm A|Patients on Arm A will receive 1 e9 pfu (plaque forming units) total dose of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) on each of six (6) treatments over 18 weeks.
3173188|NCT01387555|Other|Arm B|Patients on the control arm (Arm B) will have best supportive care over 18 weeks.
3173189|NCT01387542|Experimental|Paliperidone Extended Release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
3173190|NCT01387516|Experimental|Motivational Intervention|Motivational Interviewing (MI) will be a 60-90 minutes individual session.The focus is on establishing rapport and building motivation. The counselor explores youth's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancy, and perceptions of self-efficacy. A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
3173191|NCT01387516|Active Comparator|Relaxation Intervention|The Relaxation Therapy intervention is a 60-90 minute individual session. The session encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and as a whole is really a meditation protocol.
3173192|NCT01387516|Experimental|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy (CBT) Intervention is administered during two 90 minute group sessions. The focus is on the interrelationship between thoughts, feelings, and behaviors. It is used to address specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.
3173193|NCT01387516|Active Comparator|Self-Help Programming|"Self Help intervention is administered during two 90 minute group sessions. The intervention modules are based on the principles of Nicotine Anonymous (NicA), to provide those who use nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. Elements incorporated in this intervention include the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine."
3173194|NCT01387503|Experimental|Group 1 - Transplant strategy|Patients randomized to Group 1 will be enlisted for liver transplantation and will undergo liver transplantation within 8 months unless oncological (i.e. extrahepatic disease) or medical (i.e. cardiac insufficiency) will occur
3173195|NCT01387503|No Intervention|Group 2 - Non-transplant strategy|Patients randomized to Group 2 will continue to receive treatments according to their stage of disease, or will undergo only strict follow-up should a complete response after downstaging treatments have been achieved
3173196|NCT01387490|Experimental|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
3173197|NCT01387490|Other|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
3173198|NCT01387477|Experimental|Lactate|infusion of 66 mmol of lactate
3173199|NCT01387477|Active Comparator|glucose|infusion of 33 mmol of glucose
3173200|NCT01387464|Experimental|ISV-303|
3173201|NCT01387464|Active Comparator|Bromday™|
3173202|NCT01387425|Active Comparator|varenicline|varenicline 1 mg BID. The duration of active treatment will be 12 weeks.
3173203|NCT01387425|Placebo Comparator|control group|
3173204|NCT01387412||Genital warts|Those with and without ano-genital warts
3173205|NCT01387399|Experimental|Cisplatin as HIPEC|Phase I dose escalating study of cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion
3173206|NCT01387373|Experimental|chemotherapy|
3173246|NCT01387087|Experimental|Group E|Third lowest dose, all females, fasting
3173207|NCT01387360|Experimental|Supracor|Study arm will consist of patients who have undergone previous cataract surgery with implantation of a monofocal IOL. The Supracor procedure will be performed on the non-dominant pseudophakic eye of these patients.
3173208|NCT01387347|Active Comparator|Thymosin Beta 4|RGN-259 is a preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4
3173209|NCT01387347|Placebo Comparator|Placebo|The placebo solution is composed of the same excipients as RGN-259 but does not contain Tβ4. The Placebo is identical to the RGN-259 eye drops in color, consistency, and odor.
3173210|NCT01387334|Experimental|Resistance Exercise Training Program|
3173211|NCT01387321|Experimental|BYL719|
3173212|NCT01387308|Experimental|A|Fostamatinib 50 mg tablet x 2 (Phase 3 batch)
3173213|NCT01387308|Sham Comparator|B|Fostamatinib 50 mg tablet x 3 (Phase 3 batch)
3173214|NCT01387308|Experimental|C|Fostamatinib 100 mg tablet (new formulation)
3173215|NCT01387308|Experimental|D|Fostamatinib 150 mg tablet (new formulation)
3173216|NCT01387308|Experimental|E|Fostamatinib 50 mg tablet x 2 (Phase 3 batch)
3173217|NCT01387295|Experimental|chemotherapy|
3173218|NCT01387282|Active Comparator|100 mg QD|Investigational: Anamorelin HCl; 100 mg tablets; oral administration QD for 12 weeks, at least 1 hour before the first meal of the day.
3173219|NCT01387282|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
3173220|NCT01387269|Experimental|100 mg QD|Anamorelin HCL 100 mg will be administered daily
3173221|NCT01387269|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
3173222|NCT01387256|Other|mifepristone+misoprostol|200 mg mifepristone + 800 mcg buccal misoprostol
3173223|NCT01387256|Experimental|buccal misoprostol|2 doses of 800 mcg buccal misoprostol
3173224|NCT01387243||60 mg Orlistat|Purchased by consumer
3173225|NCT01387230|Experimental|GSK573719|active drug
3173226|NCT01387230|Placebo Comparator|Placebo|no active drug
3173227|NCT01387217|Experimental|Part A|Part A will be used to confirm the prediction of GSK2018682 PK, assess its effects on lymphocytes, and monitor its safety profile in a single cohort (Cohort 1). Cohort 1 will consist of 4 subjects and explore 4 doses of GSK2018682 in 4 study sessions. In each session, three subjects will receive GSK2018682 and one subject will receive placebo. Thus, when the cohort completes, each subject will receive placebo and 3 doses of GSK2018682.
3173228|NCT01387217|Experimental|Part B|Part B will explore doses to refine the dose-response curve of GSK2018682 on lymphocyte suppression, as allowed by stopping criteria, in 1 or 2 cohorts of up to 15 subjects (Cohort 2 and Cohort 3). In Part B, up to six single ascending doses of GSK2018682 and one dose of placebo will be investigated in up to 8 sessions.
3173229|NCT01387204|Experimental|Single-Dose, 2 mg [14C]GSK1120212|A single 2 mg (2 mg/10mL) oral dose of [14C]GSK1120212 containing approximately 79 μCi of radioactivity will be delivered as a solution.
3173230|NCT01387191||Subjects prescribed epoprostenol|Subjects with pulmonary arterial hypertension prescribed epoprostenol injection during study period
3173231|NCT01387178||COPD patients - risk analysis population|Patient-records from patients aged 40 and older with at least 2 medical claims with a diagnosis of COPD, at least on diagnosis in the 12 months prior to the index date and at least one diagnosis in the post-index date observation period, and at least one prescription claim for either FSC 250 µg/50µg or TIO. Patient records for the risk analysis population will be required to have continuous medical and pharmacy health plan enrollment for at least 12 months before and at least 3 months after the index date. The index date will be defined as the date of the first prescription claim for FSC or TIO (between January 1, 2004 and June 30, 2008).
3173232|NCT01387178||COPD patients - cost analysis population|Patient-records from patients aged 40 and older with at least 2 medical claims with a diagnosis of COPD, at least on diagnosis in the 12 months prior to the index date and at least one diagnosis in the post-index date observation period, and at least one prescription claim for either FSC 250 µg/50µg or TIO. The cost analysis population is a subset of the risk analysis population. Patient records for the cost analysis population will be required to have continuous medical and pharmacy health plan enrollment for at least 12 months before and at least 12 months after the index date. The index date will be defined as the date of the first prescription claim for FSC or TIO (between January 1, 2004 and September 30, 2007).
3173233|NCT01387165||Patients|males and females between 18 and 75 years of age who been diagnosed with T2DM as defined by the American Diabetes Association
3173234|NCT01387152||Very low dose stress test protocol|Patients admitted to New York Presbyterian Hospital (NYPH)-Columbia University Medical Center with chest pain but normal or nondiagnostic electrocardiograms and at least 3 negative troponins taken 4 or more hours apart, and undergo exercise or pharmacologic stress testing using a very low dose (<6 mCi) of Tc99m tetrofosmin or sestamibi with imaging performed using acquisitions with an Alcyone camera.
3173235|NCT01387139|Active Comparator|Ketamine Alone|1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
3173236|NCT01387139|Experimental|Ketamine Co-Administered with Propofol|0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
3173237|NCT01387126|Experimental|Novel fibre supplement|The full dose of the study intervention is 15 grams per day.
3173238|NCT01387126|No Intervention|Weight management program|
3173239|NCT01387113||Acute ischemic stroke patients|All acute ischemic stroke patients receiving IV rt-PA within 6 hours of symptom onset
3173240|NCT01387100|Experimental|Physical Therapist/Occupational Therapist Intervention|This group will be assigned a physical therapist or occupational therapist to meet with followed by 2 phone consultations.
3173241|NCT01387100|No Intervention|Control|This is the control group. This group will not receive the vocational rehabilitation intervention from an occupational or physical therapist. They will receive written information regarding job accommodations and disability advocacy.
3173242|NCT01387087|Experimental|Group A|Lowest dose, all males, fasting
3173243|NCT01387087|Experimental|Group B|Second lowest dose, all males, fasting
3173244|NCT01387087|Experimental|Group C|Third lowest dose, all males, fasting
3173245|NCT01387087|Experimental|Group D|Middle dose, all males, fasting
3173819|NCT01382875|Experimental|Multi-disciplinary management program|
3173247|NCT01387087|Experimental|Group F|Third highest dose, all males, fasting then fed
3173248|NCT01387087|Experimental|Group G|Second highest dose, all males, fasting
3173249|NCT01387087|Experimental|Group H|Highest dose, all males, fasting
3173250|NCT01387087|Experimental|Group I|Second highest dose, all females, fasting
3173251|NCT01387087|Placebo Comparator|Placebo Group A|all male, fasting
3173252|NCT01387087|Placebo Comparator|Placebo Group B|all male, fasting then fed
3173253|NCT01387087|Placebo Comparator|Placebo Group C|all female, fasting
3173254|NCT01387074||botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
3173255|NCT01387061|Experimental|hepatic resection|
3173256|NCT01387048|Experimental|Skinoren gel 15 %, topical|primary treatment 12 weeks with Skinoren gel®, followed by maintenance therapy with Skinoren gel® for another 24 weeks,
3173257|NCT01387048|Active Comparator|Differin Gel 0.1%|primary 12 weeks therapy with Differin gel®, followed by maintenance therapy with Differin gel® for another 24 weeks.
3173258|NCT01387048|Experimental|Skinoren|primary 12 weeks therapy with Skinoren gel®, followed by observation only for another 24 weeks,
3173259|NCT01387022|Experimental|Tenofovir, lamivudine and efavirenz|
3173260|NCT01387022|Active Comparator|Zidovudine, lamivudine and efavirenz|
3173261|NCT01386996|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
3173262|NCT01386996|Active Comparator|Charcoal and Symbicort Turbuhaler|
3173263|NCT01386996|Experimental|Budesonide/formoterol Easyhaler|
3173264|NCT01386996|Active Comparator|Symbicort Turbuhaler|
3173265|NCT01386983||Early 5ARI Initiation|Patients with EP receiving either 5ARI monotherapy or combination therapy (AB + 5ARI) with early initiation of 5ARI (within 30 days of initiation of AB)
3173266|NCT01386983||Late 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with late initiation of 5ARI (within 31 to 180 days after initiation of AB)
3173267|NCT01386970|Active Comparator|HIV-negative|This group was used to compare intracellular ZDV- and 3TC-triphosphate concentrations to the HIV-infected group and in men versus women.
3173268|NCT01386970|Active Comparator|HIV-infected|This group was started on ZDV-3TC based therapy. Intracellular ZDV- and 3TC-triphosphate concentrations were compared in men versus women and the HIV-negative group.
3173269|NCT01386957||Study group|children aged 6 months - 18 years, diagnosed with an initial episode of INS occurring from the first of July 2011 to the 31st of june 2013.
3173270|NCT01386944||Neupro® Treatment|Routine treatment (1,2,3 mg/24 h) as per approved label in the European Union (EU).
3173271|NCT01386931||Cytopathologist present during EUS-FNA|"Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.~After EUS-FNA is performed all slides will be sent to the pathology department. The slides will be sent for review regardless of which arm the patient is randomized into, and they will be reviewed by experienced cytopathologists for the purpose of determining the final diagnoses."
3173272|NCT01386931||Cytopathologist absent during EUS-FNA|"In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).~After EUS-FNA is performed all slides will be sent to the pathology department. The slides will be sent for review regardless of which arm the patient is randomized into, and they will be reviewed by experienced cytopathologists for the purpose of determining the final diagnoses."
3173273|NCT01386918|Experimental|Low frequency left (LFL) sided rTMS|LFL rTMS was administered at an intensity of 115% resting motor threshold at 1HZ for 20 minutes. The treatment targeted the left temporoparietal cortex (TPC).
3173274|NCT01386918|Experimental|Priming stimulation|Priming stimulation was administered as follows: 10 minutes of 6 Hz at 90% resting motor threshold (RMT) administered to the left temporoparietal cortex followed by 10 minutes of 1 Hz stimulation at 115% RMT.
3173275|NCT01386918|Sham Comparator|Sham Control|Sham stimulation was applied with identical parameters to those for the LFL condition but with the coil angled at 90 degrees off the scalp in a single wing tilt position.
3173276|NCT01386892||Healthy Volunteer|Healthy Volunteer without lung disease
3173277|NCT01386879|Experimental|TaperGuard Evac ETT|Trachea will be intubated with Mallinckrodt™TaperGuard™ Evac Endotracheal Tube with a suction port to facilitate removal of secretions from the region of the trachea below the vocal cords and above the inflated ETT cuff
3173278|NCT01386879|Experimental|Teleflex ISIS ETT|Trachea will be intubated with Teleflex ISIS HVT Cuffed Tracheal Tube with Subglottic Secretion suction port to facilitate removal of secretions from the region of the trachea below the vocal cords and above the inflated ETT cuff
3173279|NCT01386879|Active Comparator|Standard ETT|Control group of patients will be intubated with a standard ETT without a suction port above the cuff (The Mallinckrodt Intermediate Hi-Lo Endotracheal Tube)
3173280|NCT01386866|Experimental|A|
3173281|NCT01386853|Experimental|Pitavastatin|
3173282|NCT01386853|Active Comparator|Atorvastatin|
3173283|NCT01386840|No Intervention|Severe Pneumonia - Hospital Management|"Those randomized to hospital management will be monitored by health personnel for at least 48 hours for clinical deterioration and parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, Clinical deterioration, Other signs eg. comorbid conditions, Assessment of adherence, Adverse event.~Mothers, whose children are discharged after 48 hours, will be counseled to continue with oral treatment prescribed for a period of 7 days and will be advised to return to healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card"
3173327|NCT01386554|Experimental|40 U Acthar|Acthar (Repository Corticotropin Injection) 40 U (1.0 mL) two times per week
3173370|NCT01386125|Placebo Comparator|Placebo|Participants receive matching placebo nasal spray BID for 16 weeks
3173371|NCT01386112|Experimental|EUR-1100 1.5 mg|
3173372|NCT01386112|Experimental|EUR-1100 3.0 mg|
3173373|NCT01386112|Placebo Comparator|placebo|
3173374|NCT01386099|Experimental|PSN821|
3173284|NCT01386840|Experimental|Severe Pneumonia - Home Management|"For those randomized to home management, first dose will be administered by the mother/caretaker under supervision at health facility. The health personnel will assess the parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, clinical deterioration, Other signs eg. co-morbid conditions, Assessment of adherence, Adverse event when they visit the home after 24 hours, 72 hours and on day 8th.~Mothers will be advised to return to the healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card with contact Numbers."
3173285|NCT01386827|Active Comparator|A) primary immunization with MB-JEV|Volunteers immunized with MB-JEV
3173286|NCT01386827|Active Comparator|Primary and booster MBJEV vaccinations|Booster immunization with MB-JEV of vaccinees primed with MB-JEV
3173287|NCT01386827|Active Comparator|C) primary immunizations with Ixiaro|Primary immunization with Ixiaro 2 dose
3173288|NCT01386827|Active Comparator|S) Ixiaro booster to MBJEV primed|Actual study group:Booster immunization with Ixiaro to those primed previously with MB-JEV
3173289|NCT01386801||People with Diabetes Mellitus Type II|500 subjects will have T2D
3173290|NCT01386801||Healthy|500 persons who do not have T2D, hypertension or hypercholesterol
3173291|NCT01386788||Smoke Inhalation patients|Closed space fire, Soot deposits, Altered mental status Blood specimen before intravenous antidote treatment (cyanide measurement) Known delay between end of smoke exposure and blood sampling
3173292|NCT01386775||HED Affected Males|
3173293|NCT01386775||Controls|
3173294|NCT01386762|Experimental|Exercise intervention|6 months of intense multimodal training.
3173295|NCT01386749|No Intervention|Control|
3173296|NCT01386749|Experimental|Treatment|receive 6 months LMHFV
3173297|NCT01386736|Active Comparator|Vitamin D|Subjects will randomly be assigned to Vitamin D drops versus placebo drops.
3173298|NCT01386736|Placebo Comparator|Placebo|Subjects will randomly be assigned to Vitamin D drops versus placebo drops.
3173299|NCT01386723||Discontinuation of eltrombopag|ITP subjects who have discontinued the use of eltrombopag
3173300|NCT01386710|Experimental|Arm 2|Drug: Bevacizumab and Carboplatin
3173301|NCT01386710|Experimental|Arm 1|Drug: Bevacizumab and Carboplatin
3173302|NCT01386684||Patients with Prostate Cancer|Patients with prostate cancer who were receiving treatment with leuprolide acetate (Lupron).
3173303|NCT01386671|Experimental|Metformin glycinate|Metformin glycinate is a new biguanide, for this study the dose administrated will be 1050.6 mg OD for a month, and 1050.6 mg BID for 11 moths.
3173304|NCT01386671|Active Comparator|Metformin Hydrochloride|Metformin Hydrochloride is the biguanide most used, for this study the dose administrated will be 850 mg OD for a month, and 850 mg BID for 11 months.
3173305|NCT01386658|Experimental|Icatibant|Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
3173306|NCT01386645|Active Comparator|Low GI diet|low glycemic index diet
3173307|NCT01386645|Placebo Comparator|High GI diet placebo|high glycemic index diet plus placebo
3173308|NCT01386645|Active Comparator|High GI diet NAC|high glycemic index diet plus N-acetylcysteine
3173309|NCT01386632|Active Comparator|DCA (dichloroacetate) Treatment|DCA orally 12.5mg/kg or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m^2 IV over 30-60 minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
3173310|NCT01386632|Placebo Comparator|Placebo|Placebo orally or per G-tube BID for 8 weeks in conjunction with Cisplatin 100 mg/m^2 IV over 30-60 minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
3173311|NCT01386619|Experimental|NK cell DLI|
3173312|NCT01386606|Experimental|Androxal 6.25 mg|Androxal 6.25 mg/day
3173313|NCT01386606|Experimental|Androxal 12.5 mg|Androxal 12.5 mg/day
3173314|NCT01386606|Experimental|Androxal 25 mg|Androxal 25 mg/day
3173315|NCT01386606|Active Comparator|AndroGel|AndroGel 5G topical testosterone
3173316|NCT01386593|Other|(A) Baseline|
3173317|NCT01386593|Other|(B) Inhibition|
3173318|NCT01386593|Other|(C) Induction|
3173319|NCT01386580|Experimental|2B3-101 Single Agent Dose Escalation|Patients in single agent dose escalation arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
3173320|NCT01386580|Experimental|2B3-101 in combination with trastuzumab|HER2+ breast cancer patients with brain metastases will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. As long as 2B3-101 is well tolerated, the remaining 95% of the infusion could thereafter be administered over the next 60 min, resulting in a total infusion time of 90 minutes. The infusion of trastuzumab will then follow 30 minutes after the completion of the 2B3-101 infusion.
3173321|NCT01386580|Experimental|2B3-101 solid tumor expansion|Patients in the breast, Small Cell Lung Cancer and melanoma dose expansion arms will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
3173322|NCT01386580|Experimental|2B3-101 glioma expansion|Patients in the single agent glioma dose expansion arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
3173323|NCT01386567|Experimental|Androxal|Androxal (enclomiphene citrate)12.5 mg or 25 mg
3173324|NCT01386567|Active Comparator|Testim (topical testosterone)|
3173325|NCT01386554|Experimental|80 U Acthar|Acthar (Repository Corticotropin Injection) 80 U (1.0 mL) two times per week
3173326|NCT01386554|Placebo Comparator|1.0 mL Placebo|Placebo (1.0 mL) two times per week
3173375|NCT01386099|Placebo Comparator|Placebo|
3173328|NCT01386541|Active Comparator|BYK324677|"Dose group I: total daily dose 2 mg (1 mg BID or 2 mg SID)~Dose group II: total daily dose 4 mg (2 mg BID or 4 mg SID)~Dose group III: total daily dose 6 mg (3 mg BID or 6 mg SID)~In each dose group 12 subjects (8 subjects BYK324677, 4 subjects placebo) are planned.~Within each dose group, the subjects will be randomised to either BYK324677 or placebo at a ratio of 2:1.~Within each verum group, the subjects will be randomised to one of the 2 treatment sequences (BID/SID or SID/BID, ratio 1:1) and treated in a cross-over manner."
3173329|NCT01386541|Placebo Comparator|Placebo|
3173330|NCT01386528|Experimental|Patients enrolled in trial|New patients will be included as well as transferred patients from Paradigm™ 2 or Paradigm™ 4 trial
3173331|NCT01386411||Women with Breast Cancer|The proposed investigation is a prospective cohort study. Women with newly diagnosed breast cancer will decide whether to undergo BRCA testing either before or after completion of local surgical treatment.
3173332|NCT01386385|Experimental|Arm I (RT, veliparib, carboplatin, paclitaxel)|Patients undergo 3D-CRT and receive veliparib, carboplatin, and paclitaxel as in Phase I induction and consolidation therapy.
3173333|NCT01386385|Active Comparator|Arm II (3D-CRT, placebo, carboplatin, paclitaxel)|Patients undergo 3D-CRT as in arm I. Patients also receive placebo PO BID on days 1-43 and carboplatin and paclitaxel as in Phase I. Within 4-6 weeks after completion of chemotherapy and radiation therapy, patients receive placebo on days 1-7 and carboplatin and paclitaxel as in Phase I.
3173334|NCT01386372|Experimental|Tolvaptan|
3173335|NCT01386372|Active Comparator|standard therapy|
3173336|NCT01386359||Adult de novo EBV-seropositive kidney-transplant recipients|Adult de novo EBV-seropositive kidney-transplant recipients treated with Nulojix (belatacept)
3173337|NCT01386346|Experimental|All subjects|"Azacitidine Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.~Oxaliplatin on Day 1 130mg/m2 Epirubicin on Day 1 50mg/m2 Capecitabine 625 mg/m2"
3173338|NCT01386333|Experimental|Oxytocin 24IU|Oxytocin 24 IU administered intranasally twice daily for 1 week
3173339|NCT01386333|Experimental|Oxytocin 48 IU|48 IU of intranasal oxytocin administered twice daily for 1 week
3173340|NCT01386333|Experimental|72 IU oxytocin|72 IU of intranasal oxytocin administered twice daily for 1 week
3173341|NCT01386333|Placebo Comparator|Saline nasal spray|
3173342|NCT01386320|Active Comparator|Ultrasound guided ankle block|Subjects in this arm will be given an ultrasound guided ankle block prior to foot surgery.
3173343|NCT01386320|Active Comparator|Medial forefoot block|Subjects in this arm will be given a nerve-stimulator guided forefoot block prior to anaesthesia and forefoot surgery
3173344|NCT01386294|Experimental|Tenofovir 1% vaginal gel|Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
3173345|NCT01386294|Placebo Comparator|Universal placebo gel|Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
3173346|NCT01386281||Group 1|Drug (incl. Placebo)
3173347|NCT01386268||Group 1|
3173348|NCT01386255|Active Comparator|baclofen|Baclofen suspension
3173349|NCT01386255|Placebo Comparator|placebo|Identical palcebo suspension
3173350|NCT01386242|Experimental|The first group|Recombinant anti-tumor and anti-virus protein for injection, twice per week
3173351|NCT01386242|Experimental|The second group|Recombinant anti-tumor and anti-virus protein for injection, three times per week
3173352|NCT01386242|Placebo Comparator|Placebo group|Saline Injection, three times per week
3173353|NCT01386242|Experimental|The third group|High dose of recombinant anti-tumor and anti-virus protein for injection, three times per week
3173354|NCT01386229|Active Comparator|Ketamine|
3173355|NCT01386229|Active Comparator|Etomidate|
3173356|NCT01386216|Experimental|Bone Marrow Cell Concentrate|Bone Marrow Cell Concentrate Prepared Using the Magellan System
3173357|NCT01386203||Lung Cancer|
3173358|NCT01386203||Lung Cancer after therapy|
3173359|NCT01386203||COPD controls|
3173360|NCT01386190|Experimental|Exercise Group|Caregivers will be taught progressive exercises to use with their infants from hospital discharge to 1 year of age.
3173361|NCT01386190|Active Comparator|Control|Both the control and the intervention groups will be guided in implementing structured social interaction.In the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
3173362|NCT01386177|Experimental|doxazosin, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
3173363|NCT01386164|Experimental|Gardasil®|
3173364|NCT01386164|Experimental|Cervarix®|
3173365|NCT01386151|Active Comparator|Study drug|Keratinocyte growth factor (KGF) will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11.
3173366|NCT01386151|Placebo Comparator|Placebo|Saline will be used as a placebo comparator
3173367|NCT01386138|Experimental|RBT+WHIC|Participants met in groups for 2 hours thrice weekly (M/W/F). During the first hour, the counselor facilitated discussion of 1 of the 12 RBT module topics, repeated three times during the course of the 12-week intervention (as in RBT). A patient-led group served the purpose of mutual support during the second hour. The counselor facilitated but did not have direct discussion in these latter groups. The four WHC modules were incorporated into the RBT sessions.
3173368|NCT01386138|Active Comparator|Psycho-education|Participants met in groups for 2 hours thrice weekly (M/W/F). During the first hour, the counselor facilitated discussion of 1 of the 12 RBT module topics, repeated three times during the course of the 12-week intervention (as in RBT). A patient-led group served the purpose of mutual support during the second hour. The counselor facilitated but did not have direct discussion in these latter groups.
3173369|NCT01386125|Experimental|Mometasone Furoate Nasal Spray (MFNS)|Participants receive mometasone furoate nasal spray (MFNS) 200 mcg twice daily (BID) for 16 weeks
3173376|NCT01386086|Experimental|Aripiprazole|aripiprazole used adjunctively to antidepressants in patients with resistant postpartum depression
3173377|NCT01386073|Active Comparator|FreshKote|
3173378|NCT01386073|Placebo Comparator|Systane|
3173379|NCT01386060|Experimental|Mindfulness Meditation Training|Participants receive the 6-week meditation training intervention between the 1st and 2nd study visits.
3173380|NCT01386060|No Intervention|Waitlist Control|Participants receive no intervention between the 1st and 2nd study visits. They receive the training between the 2nd and 3rd study visits only.
3173381|NCT01386047|Experimental|iCPR randomized providers|The physician population for the proposed study will comprise primary care providers (physicians, internal medicine residents, or licensed nurse practitioners; practicing in the outpatient primary care clinics at Mount Sinai Medical Center. The iCPR tool will automatically trigger for providers randomized into the iCPR intervention arm when they initiated an encounter for a patient that meets the criteria for possible evaluation of Strep Pharyngitis or Pneumonia.
3173382|NCT01386047|No Intervention|Control providers|The physician population for the proposed study will comprise primary care providers (physicians, internal medicine residents, or licensed nurse practitioners; practicing in the outpatient primary care clinics at Mount Sinai Medical Center. These providers will conduct visits for Strep Pharyngitis and Pneumonia in their manner (usual care).
3173383|NCT01386034|Experimental|Citrulline/Placebo|
3173384|NCT01386034|Experimental|Placebo/Citrulline|
3173385|NCT01386021||Prior recipients of allografts for CABG|
3173386|NCT01386008|Other|enfilcon A + senofilcon A|Simultaneous wearing of daily wear contact lenses - investigational enfilcon A contact lenses in one eye and comparator senofilcon A worn in the other
3173387|NCT01385995|Active Comparator|Continuous Positive Airway Pressure (CPAP)|
3173388|NCT01385995|Sham Comparator|Sham-Continuous Positive Airway Pressure (CPAP)|
3173389|NCT01385982|Other|Actionable Test Results|"Creating standardized policies and procedures around actionable test results (ATR) management, and implementing them network-wide:~Defining the levels of severity and urgency for clinically significant test results~Network-wide policy for test result follow-up by the responsible providers, documentation and escalation processes to assure timely communication.~Standardized policies for the time frames and nature of communication of test result alerts.~Establish criteria for appropriate ATR management by the responsible provider.~Feedback performance including provider, practice and service report cards"
3173390|NCT01385969||Standard Practice|
3173391|NCT01385969||Syringe recoil|
3173392|NCT01385969||Pressure Transducer|
3173393|NCT01385956|Experimental|SOM 230 LAR and Gemcitabine|"Combination Therapy: Dose escalation of SOM 230 LAR and standard treatment with gemcitabine. Treatment will be administered on an outpatient basis. Gemcitabine is administered by IV infusion. The dose should be based on the patient's actual baseline body weight; the dose will be recalculated if there is a weight change of > 10% from baseline. The dose of gemcitabine will be given over 30 minutes, weekly every 3 weeks followed by 1 week rest period.~SOM 230 LAR will be administered as an intramuscular dose determined by the dosing schema, every month."
3173394|NCT01385943||Skin Cancer|Patients from dermatology practices throughout Europe that have a skin lesion or tumor requiring a biopsy for diagnosis.
3173395|NCT01385930|Experimental|Lifestyle counseling|Lifestyle counseling
3173396|NCT01385930|No Intervention|Control group|Control group
3173397|NCT01385891|Experimental|children with advanced leukemia|
3173398|NCT01385878|Active Comparator|Phacoemulsification with 1.8mm incision|Microcoaxial phacoemulsification was performed using a 1.8mm clear corneal incision
3173399|NCT01385878|Active Comparator|Phacoemulsification with 2.2mm incisi|Microcoaxial phacoemulsificaiton will be performed through 2.2mm incision
3173400|NCT01385865|Experimental|Mulberry leaf extract|
3173401|NCT01385865|Placebo Comparator|Placebo|
3173402|NCT01385852|Active Comparator|Longitudinal U/S - low fluidic|ASPIRATION FLOW RATE - 25 CC/MIN, BOTTLE HEIGHT - 90 CMS, LONGITUDINAL ULTRASOUND
3173403|NCT01385852|Active Comparator|Torsional U/S - low fluidic|ASPIRATION FLOW RATE - 25 CC/MIN, BOTTLE HEIGHT - 90 CMS, TORSIONAL ULTRASOUND
3173404|NCT01385852|Active Comparator|Longitudinal U/S - high fluidic|ASPIRATION FLOW RATE - 40 CC/MIN, BOTTLE HEIGHT - 110 CMS, LONGITUDINAL ULTRASOUND
3173405|NCT01385839|Experimental|alopecia areata|pts will have one area (or ½ of a large area) treated by hair transplant and another (or the other ½) treated by simple irritation with a large gauge sterile hypodermic needle
3173406|NCT01385826|Experimental|adalimumab|Anti-tumor necrosis factor alpha monoclonal antibody
3173407|NCT01385826|Placebo Comparator|placebo|placebo
3173408|NCT01385813||Pregnant women who develop preeclampsia|pregnant women who develop preeclampsia (n =43) compared to pregnant women fulfilling a normotensive pregnancy (n= 86).
3173409|NCT01385800|Placebo Comparator|Placebo|Intradermal injection, 1 x 8 administrations 2 weeks apart
3173410|NCT01385800|Experimental|ToleroMune Grass Dose 1|Intradermal injection 1 x 8 administrations 2 weeks apart
3173411|NCT01385800|Experimental|ToleroMune Grass Dose 2|Intradermal injection 1 x 8 administrations 2 weeks apart
3173412|NCT01385800|Experimental|ToleroMune Grass Dose 3|Intradermal injection 1 x 8 administrations 2 weeks apart
3173413|NCT01385774|Active Comparator|Intervention group: Angioplasty|Angioplasty with or without stent of the iliac artery
3173414|NCT01385774|Active Comparator|Control: Supervised Exercise Therapy|Supervised exercise therapy by a physiotherapist
3173415|NCT01385761||Laryngeal Mask airway (LMA)|children weighing 20 to 30 kg
3173416|NCT01385761||Intubating Laryngeal Airway (ILA-SP)|Children weighing 20-30 kg
3173417|NCT01385748|Active Comparator|Clonidine Lauriad® 50µg|50µg muco-adhesive buccal tablets, once de day, every day up to 8 weeks
3173418|NCT01385748|Active Comparator|Clonidine Lauriad® 100µg|100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
3173419|NCT01385748|Placebo Comparator|Placebo Lauriad®|Placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
3173420|NCT01385735|Placebo Comparator|Placebo|Placebo 1 Tbl per day, 12 week (84 days) duration
3173421|NCT01385735|Active Comparator|Rasagiline|Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
3173461|NCT01385449|Experimental|interscalene block|interscalene block
3173949|NCT01381939||ICP and spontanius delivery|
3173422|NCT01385709||Sertraline|Therefore, patients who are already taking psychotropic medications, and therefore are currently in treatment for a psychiatric illness, will be recruited. The specific psychiatric diagnoses anticipated in the subject pool include the conditions that sertraline is indicated to treat, including Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, and Social Anxiety Disorder. Patients must be female, between the ages of 18-40, taking either sertraline on a daily basis for at least one week. Exclusion criteria include 1) currently pregnant or breastfeeding, 2) concurrent use of any form of hormonal birth control, including oral contraceptive pills, Norplant or Depo-provera, 3) hepatic or renal disease, 4) irregular menstrual cycles.
3173423|NCT01385709||Lithium|Therefore, patients who are already taking psychotropic medications, and therefore are currently in treatment for a psychiatric illness, will be recruited. The specific psychiatric diagnoses anticipated in the subject pool include the conditions that lithium is indicated to treat, including Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, and Social Anxiety Disorder. Patients must be female, between the ages of 18-40, taking lithium on a daily basis for at least one week. Exclusion criteria include 1) currently pregnant or breastfeeding, 2) concurrent use of any form of hormonal birth control, including oral contraceptive pills, Norplant or Depo-provera, 3) hepatic or renal disease, 4) irregular menstrual cycles.
3173424|NCT01385696|Experimental|group A|Genuair first, HandiHaler second
3173425|NCT01385696|Experimental|group B|HandiHaler first, Genuair second
3173426|NCT01385683|Active Comparator|Arm A|Dabigatran then dabigatran and clarithromycin
3173427|NCT01385683|Active Comparator|Arm B|Clarithromycin and dabigatran and dabigatran
3173428|NCT01385657|Experimental|Cohort 1|
3173429|NCT01385657|Experimental|Cohort 2|
3173430|NCT01385644|Experimental|1*10^6 MSC / kg|Placental MSC
3173431|NCT01385644|Experimental|2*10^6 MSC / kg|Placental MSC
3173432|NCT01385631|Placebo Comparator|Atorvastatin plus Placebo|50/100 patients are randomized to Atorvastatin 80 mg per day plus placebo.
3173433|NCT01385631|Experimental|Atorvastatin plus Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
3173434|NCT01385618||high responder|females with >15 follicles or E2>3000 after treatment with gonadotropins
3173435|NCT01385618||low responder|patients with <3 follicles or no response to treatment with gonadotropins
3173436|NCT01385618||control|females with an indication for treatment because of male subfertility
3173437|NCT01385605||female patients|ICSI treatment because of male subfertility
3173438|NCT01385592|Experimental|AFQ056 100 mg|
3173439|NCT01385592|Placebo Comparator|Placebo|
3173440|NCT01385579|No Intervention|usual care|Patients assigned to the usual care arm may be referred for colorectal cancer screening by their providers per usual health center protocol and practice. They receive no additional outreach by the preventive care care manager.
3173441|NCT01385579|Experimental|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit
3173442|NCT01385566|Active Comparator|Full Dose Subcutaneous|Participants will receive a full dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Nine participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1.
3173443|NCT01385566|Experimental|1/3 Dose Subcutaneous|Participants will receive a 1/3 dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
3173444|NCT01385566|Experimental|Full Dose Intradermal|Participants will receive a full dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
3173445|NCT01385566|Experimental|1/3 Dose Intradermal|Participants will receive a 1/3 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
3173446|NCT01385566|Experimental|1/10 Dose Intradermal|Participants will receive a 1/10 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
3173447|NCT01385566|Experimental|1/27 Dose Intradermal|Participants will receive a 1/27 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
3173448|NCT01385553|Active Comparator|Individual Drug Counseling|
3173449|NCT01385553|Experimental|Fathers for Change|
3173450|NCT01385540||Task-based fMRI|
3173451|NCT01385527|Experimental|Weekly Internet survey w medication|Weekly survey via email plus topical triamcinolone
3173452|NCT01385527|Active Comparator|Topical triamcinolone only|Standard of care
3173453|NCT01385514||company A-Training Base No.1|
3173454|NCT01385514||company A-Training Base No.2|
3173455|NCT01385514||company A-Training Base No.3|
3173456|NCT01385501|No Intervention|routine care|
3173457|NCT01385501|Experimental|Educational intervention group|
3173458|NCT01385488|Experimental|self-monitoring|participants will use bioelectrical impedance to self-monitor arm volume at home
3173459|NCT01385488|No Intervention|completion of forms|participants will complete self-report forms
3173460|NCT01385475|Experimental|Control|
3173462|NCT01385449|Experimental|interscalene catheter|interscalene catheter
3173463|NCT01385436||HPV HSIL cervical carcinoma|
3173464|NCT01385423|Experimental|IL-15 Patients with AML|Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML) treated with preparative regimen and Intravenous Recombinant Human IL-15 (rhIL-15)
3173465|NCT01385410|Active Comparator|CPS, cell phone based peer support|Cell phone base peer mother support for continued exclusive breastfeeding
3173466|NCT01385410|Active Comparator|PSG, group meeting based peer support|Group based peer Cell phone base peer mother support for continued exclusive breastfeeding
3173467|NCT01385410|No Intervention|Control|Current standard of care and support (national health system)
3173468|NCT01385397|Experimental|Preceptorship and virtual community|
3173469|NCT01385384|Other|NeuRx|
3173470|NCT01385371|Experimental|SCH 697243|
3173471|NCT01385371|Placebo Comparator|Placebo|
3173472|NCT01385358|Experimental|Thoracoscopically Assisted Surgical Ablation|This arm will have an index thoracoscopically assisted surgical ablation.
3173473|NCT01385358|Active Comparator|Catheter Ablation|This is an active comparator arm where study subjects will undergo conventional catheter ablation.
3173474|NCT01385345|Active Comparator|Vitamin D3 high dose|200,000 units (time 0) followed by (100,000 units) at months 1.5, 3 and 5. Participants will also have daily 1,000 units per day to mirror the control arm and maintain double blinding.
3173475|NCT01385345|Placebo Comparator|Vitamin D3|Participants will have a placebo liquid (to mirror the active arm high dose Vitamin D3) and also have daily 1,000 units Vitamin D3.
3173476|NCT01385332|Active Comparator|Early luteal phase -COH-|We perform an standard antagonist protocol beginning the second day of the menstrual cycle compared with an antagonist protocol beginning in the early luteal phase.
3173477|NCT01385332|Active Comparator|Late folicular phase - COH -|We perform an standard antagonist protocol beginning the second day of the menstrual cycle compared with an antagonist protocol beginning in the late follicular phase.
3173478|NCT01385319|Active Comparator|bare metal stent|
3173479|NCT01385319|Experimental|Endeavor sprint stent|
3173480|NCT01385306|Experimental|1|
3173481|NCT01385293|Experimental|Study arm|BKM120 at 100mg orally daily
3173482|NCT01385280|Experimental|Arm I|Patients receive oral therapeutic estradiol once daily on days 1-3, twice daily on days 4-7, and thrice daily on days 8-90. Beginning on day 98, patients receive oral exemestane once daily in the absence of disease progression or unacceptable toxicity. Also laboratory biomarker analysis and enzyme-linked immunosorbent assay will be taken for correlative studies.
3173483|NCT01385267||Diamniotic twin gestations|
3173484|NCT01385254||siblings and mothers of Very Low Birth Weight infants|50 older siblings (closest in age) and mothers of very low birthweight (VLBW) infants, born at <33 weeks gestation and <1500 grams at birth
3173485|NCT01385254||siblings and mothers of healthy infants|50 siblings (closest in age) and mothers of healthy, full-term infants (between 38-42 weeks gestation and lacking medical conditions that require a hospital stay past the mother's discharge date)
3173486|NCT01385241|Experimental|Received video intervention|The group of women who received an Ipod Touch with the video loaded onto it and told to view it at least once a week for the first 4 weeks, and as often as desired in weeks 5-12.
3173487|NCT01385241|No Intervention|Did not receive video|This group does not receive the video intervention during the study period, and will complete surveys at baseline, 30 days and 90 days for comparison to the intervention group.
3173488|NCT01385228|Experimental|"Dose Level Xa"|once daily pazopanib for Days 1-21 in combination with docetaxel given IV on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.
3173489|NCT01385228|Experimental|"Dose Level Xb"|once daily oral administration of pazopanib for Days 3-19 in combination with docetaxel given intravenous administration on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.
3173490|NCT01385215|Placebo Comparator|Placebo|
3173491|NCT01385215|Placebo Comparator|Nasal Aerosol Immunization|
3173492|NCT01385215|Placebo Comparator|Nasal Droplet Immunization|
3173493|NCT01385215|Placebo Comparator|Intramuscular Immunization|
3173494|NCT01385202|Experimental|THERMOCOOL® SMARTTOUCH™ Catheter|
3173495|NCT01385189|Experimental|Cohort 1|10 μg Na-GST-1/Alhydrogel vs. 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
3173496|NCT01385189|Experimental|Cohort 2|30 μg Na-GST-1/Alhydrogel vs. 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
3173497|NCT01385189|Experimental|Cohort 3|30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
3173498|NCT01385189|Experimental|Cohort 4|100 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
3173499|NCT01385189|Experimental|Cohort 5|100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
3173500|NCT01385176|Experimental|Therapy|
3173501|NCT01385176|No Intervention|Control|Control group will be implanted with study system, but will receive no therapy until 6-month cross-over.
3173502|NCT01385163|No Intervention|Control - VSLA|the wait control sample for the economic intervention
3173503|NCT01385163|Other|Control - Mental Health|treatment as usual based on standard psychosocial services in the area
3173504|NCT01385163|Experimental|Voluntary Savings/Loans Assoc|
3173505|NCT01385163|Experimental|Cognitive Processing Therapy|
3173506|NCT01385137|Experimental|Arm I|Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity.
3173507|NCT01385137|Placebo Comparator|Arm II|Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity.
3173508|NCT01385124|Experimental|Oral Cannabidiol|Oral Cannabidiol 10 mg twice daily will be given from conditioning starting day and until day +30 after allogeneic transplantation. Dose can be doubled every 7 days if no significant side effects documented.
3173509|NCT01385111|Active Comparator|Arm A|EBUS centered
3173510|NCT01385111|Experimental|Arm B|EUS centered
3173511|NCT01385098|Experimental|Vitamin D3 and Calcium|Dietary supplement of vitamin D3 and calcium
3173512|NCT01385085||No natural sunlight|one group works in a basement with no natural sunlight
3173513|NCT01385085||Low level of Natural Sunlight|the second group work in offices with unopenable windows.
3173514|NCT01385085||High level of Natural Sunlight|The third group works outdoors.
3173515|NCT01385072|Experimental|Double matched sibling transplantation|"Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.~Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS."
3173516|NCT01385059|Experimental|Arm I (neoadjuvant enzyme inhibitor and prostatectomy)|Patients receive axitinib PO BID on days 1-28. Patients then undergo prostatectomy and pelvic lymph node dissection. Treatment continues in the absence of disease progression or unacceptable toxicity.
3173517|NCT01385059|Active Comparator|Arm II (surgery)|Patients undergo prostatectomy and pelvic lymph node dissection at 5-6 weeks after biopsy confirmation of prostate cancer.
3173518|NCT01385046|Experimental|physical activity and nutrition|
3173519|NCT01385033|Experimental|Part I, Healthy Elderly (HE) and AD Participants|HE and AD participants will receive a single intravenous (IV) dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part I of the study
3173520|NCT01385033|Experimental|Part II, Healthy Young, HE and AD Participants|Healthy Young, HE and AD participants will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part II of the study
3173521|NCT01385033|Experimental|Part III, Participants with aMCI|Participants with aMCI will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part III of the study
3173522|NCT01385020|Experimental|Gemfibrozil & red yeast rice (LipoCol)|The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects
3173523|NCT01384994|Experimental|FOLFOX + Panitumumab|
3173524|NCT01384994|Active Comparator|FOLFOX|
3173525|NCT01384981|Active Comparator|pulmonary rehabilitation with NIV|Patients receiving nocturnal non-invasiv Ventilation during a 3-week pulmonary Rehabilitation program.
3173526|NCT01384981|Sham Comparator|pulmonary rehabilitation without NIV|Patients receiving no nocturnal non-invasiv Ventilation during a 3-week pulmonary Rehabilitation program.
3173527|NCT01384968|Experimental|Beetroot juice|beetroot juice (170 mL, 8 mmol nitrate)
3173528|NCT01384968|Placebo Comparator|Nitrate-depleted beetroot juice|140 mL ...0 nitrate. Beetroot juice
3173529|NCT01384955||exercise|subjects diagnosed and treated in the Centre of Corrective and Compensatory Gymnastics in Bielsko - Biala, Poland, between 1983 and 1994, with scoliosis - specific exercise program
3173530|NCT01384955||control|age and condition - matched subjects, who were diagnosed at the same time, in the same clinic, and by the same physician, and prescribed the same method of physiotherapy, but did not start the exercise treatment
3173531|NCT01384942|Experimental|Meaning-Based Bereavement Group|
3173532|NCT01384942|Active Comparator|Conventional Bereavement Group|
3173533|NCT01384929||ICU patients|All patients present in the ICU on the selected days
3173534|NCT01384916|Experimental|Yoga|
3173535|NCT01384916|Active Comparator|Health education|
3173536|NCT01384903|Experimental|KW-3357|
3173537|NCT01384903|Active Comparator|Plasma-derived antithrombin|
3173538|NCT01384890|Experimental|VMAT with CBCT|Volumetric modulated arc therapy (VMAT) with cone-beam computed tomography position (CBCT) verification
3173539|NCT01384890|Active Comparator|VMAT with kV-ray|Volumetric modulation arc therapy (VMAT) with kV-ray position verification
3173540|NCT01384877|Experimental|Lidocaine|Lidocaine
3173541|NCT01384877|Placebo Comparator|Placebo (D5W)|Placebo first as compared with lidocaine first
3173542|NCT01384864|Experimental|treatment|fluorescent imaging with proflavine
3173543|NCT01384851|Experimental|Next Generation Emulsion|Next Generation Emulsion Multi-Dose Eye Drop (9963X) is a sterile, buffered, aqueous and emulsion topical ophthalmic product formulated for the relief of ocular surface irritation and symptoms of dryness. The Next Generation Emulsion 9963X formulation is an oil-in-water aqueous emulsion intended to replenish deficient aqueous and lipid components and stabilising the tear film.
3173544|NCT01384851|Active Comparator|Refresh Dry Eye Therapy|A preserved multi-dose formulation for use in treating dry eye symptomatology. The key ingredients are Castor oil, Polysorbate 80, Carbomer 1342 and Glycerin. Refresh Dry Eye Therapy® Lubricant Eye Drops contains emulsified castor oil, which enhances the natural oily superficial tear layer on the ocular surface. By stabilizing and supplementing the lipid layer, castor oil may retard evaporation of surface moisture.
3173545|NCT01384851|Active Comparator|Refresh Contacts|Solution contains carboxymethylcellulose sodium (carmellose), sodium chloride, boric acid, sodium borate, potassium chloride, calcium chloride, magnesium chloride, Purite®, sodium hydroxide, and purified water. This product is registered as a CE Mark medical device. Refresh Contacts Comfort drops providing soothing relief from tired, dry eyes. Although intended for contact lens wearers, the primary indication is for relief of dry eyes as is being studied in this investigation.
3173546|NCT01384838|Other|Counseling|Patients are to receive identical counseling for ideal nutritional, lifestyle, physical activity.
3173547|NCT01384838|Experimental|Controlled physical activity|"All patients are to receive identical counseling for ideal nutritional, lifestyle, physical activity.~Patients randomized to Arm 2 will additionally undergo a controlled and observed program of physical activity for a period of 6 months. Thereafter the patients are expected to adhere to a comparable, unobserved exercise program at home."
3173548|NCT01384825||MS|Subjects with Multiple Sclerosis
3173549|NCT01384825||HC|Healthy Controls
3173550|NCT01384825||OND|"Subjects with Other Neurodegenerative Diseases, including both other non-inflammatory neurodegenerative diseases (OND) and other inflammatory neurodegenerative diseases (ONDi)"
3173551|NCT01384812|Placebo Comparator|Isoton sodium chloride|
3173552|NCT01384812|Active Comparator|Prostin E2 (dinoprostone)|
3173592|NCT01384539|Experimental|Cholecalciferol|Cholecalciferol 4000 IU capsule by mouth daily x 1 month then 2000 IU capsule by mouth daily x 5 months
3173593|NCT01384539|Experimental|Calcitriol|Calcitriol 0.25 mcg capsule by mouth daily x 1 month then 0.5 mcg capsule by mouth daily x 5 months
3173594|NCT01384526||history of hormone therapy|
3173595|NCT01384526||no history of hormone therapy|
3173553|NCT01384760|Active Comparator|Lifestyle modification program|"At the 1st session, the dietitian carried out a complete behavioral assessment, with emphasis on patient's current eating and lifestyle patterns, specific eating-related behaviors, knowledge of risks associated with current eating patterns, and concerns and feelings about specific lifestyle changes. In the subsequent follow up visit, the dietitian reviewed the 7-day food diaries to ensure nutritional adequacy and treatment compliance, and also offered recommendations for controlling caloric intake.~Patients were encouraged to see an exercise instructor who designed an individualized suitable exercise regime with cardiovascular and resistance exercises for the patients to perform at home. Subjects were encouraged to perform 30-minute aerobic exercise 2-3 times a week."
3173554|NCT01384760|Placebo Comparator|Simple lifestyle advice|Subjects in control group received simple lifestyle advice from a clinician at baseline and month 6. This was a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects were encouraged to perform regular 30-minute exercise 2 to 3 times per week. This was to resemble routine clinical practice.
3173555|NCT01384747|Experimental|Fimasartan|Initial dose will be started with 60mg per day. At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
3173556|NCT01384747|Placebo Comparator|Placebo|Initial dose will be started with 60mg per day. At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
3173557|NCT01384734|Experimental|Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir|Treatment Group 1
3173558|NCT01384734|Experimental|Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir|Treatment Group 2
3173559|NCT01384734|Experimental|Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir|Treatment Group 3
3173560|NCT01384734|Experimental|Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir|Treatment Group 4
3173561|NCT01384734|Active Comparator|Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir|Treatment Group 1 (reference arm)
3173562|NCT01384708|Experimental|treatment|imaging with proflavine
3173563|NCT01384695|Experimental|Fluorescein|Confocal imaging using contrast agent fluorescein
3173564|NCT01384695|Experimental|Proflavine hemisulfate|confocal imaging using contrast agent proflavine
3173565|NCT01384682|No Intervention|No change|continue their current cART regimen
3173566|NCT01384682|Active Comparator|Replace N(t)RTI drugs with Maraviroc|Replace N(t)RTI drugs with MVC at a dose of 150mg bid (MVC 300mg bid can be used at the discretion of the Investigator if the PI/r is fosamprenavir/r) and continue the PI/r
3173567|NCT01384682|Active Comparator|Replace PI/r drugs with Maraviroc|Replace PI/r drugs with MVC at a dose of 300mg bid and continue 2N(t)RTI.
3173568|NCT01384669||Group 1|papillary thyroid microcarcinoma without lymph node metastasis
3173569|NCT01384669||Group 2|papillary thyroid microcarcinoma with lateral lymph node metastasis
3173570|NCT01384656|Experimental|GIK group|
3173571|NCT01384656|Placebo Comparator|Control group|
3173572|NCT01384643|Experimental|Propofol group|
3173573|NCT01384643|Placebo Comparator|Control group|
3173574|NCT01384630|Other|Single group|
3173575|NCT01384617|Experimental|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
3173576|NCT01384617|Active Comparator|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
3173577|NCT01384591|Experimental|Losartan and placebo N-acetylcysteine|losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
3173578|NCT01384591|Placebo Comparator|Placebo losartan and placebo N-acetylcysteine|Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
3173579|NCT01384591|Experimental|N-acetylcysteine and placebo losartan|N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
3173580|NCT01384578|Experimental|pentoxiphylline and Vitamin E|
3173581|NCT01384578|Active Comparator|Vitamin E|
3173582|NCT01384565|Active Comparator|G-CSF+EPO|
3173583|NCT01384565|Placebo Comparator|Placebo|
3173584|NCT01384552|Active Comparator|Normal Weight, Unrestrained - Standard|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
3173585|NCT01384552|Active Comparator|Normal Weight, Restrained - Single Serving|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
3173586|NCT01384552|Active Comparator|Normal Weight, Restrained - Standard|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
3173587|NCT01384552|Active Comparator|Overweight, Unrestrained - Single Serving|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
3173588|NCT01384552|Active Comparator|Overweight, Unrestrained - Standard|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
3173589|NCT01384552|Active Comparator|Overweight, Restrained - Single Serving|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
3173590|NCT01384552|Active Comparator|Overweight, Restrained - Standard|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
3173591|NCT01384552|Active Comparator|Normal Weight, Unrestrained - Single Serving|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
3173947|NCT01381939||Induction of labor in ICP|Induction of laborin women with ICP
3173596|NCT01384513|Experimental|Treatment (Allogeneic PBSCT)|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 60 minutes on days -11 to -8 and busulfan IV over 3 hours on days -10 to -9. Patients undergo TBI on day -6. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients undergo DLI on day -6 and CD-34+ allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID on days -1 to 28."
3173597|NCT01384500|Experimental|Saline in tube cuff|Use of sterile saline to inflate tracheal tube cuff
3173598|NCT01384500|No Intervention|Air in tube cuff|No intervention (control) - patient cohort, using air to inflate tracheal tube cuff.
3173599|NCT01384487||Normal Eyes|Eyes without disease
3173600|NCT01384487||Eyes with Glaucoma|
3173601|NCT01384487||Eyes with Retinal Disease|
3173602|NCT01384487||Eyes with Corneal Disease|Including post keratorefractive surgery
3173603|NCT01384474||CRM training of surgical teams|CRM : Crew resource Management
3173604|NCT01384474||No CRM training of surgical teams|CRM : Crew resource Management
3173605|NCT01384461||Cohort|
3173606|NCT01384448|Experimental|Initial Stress Echocardiography|
3173607|NCT01384448|Experimental|Initial Coronary CT Angiography|
3173608|NCT01384435|Experimental|KPS-0373, lowest dose|
3173609|NCT01384435|Experimental|KPS-0373, 2nd lowest dose|
3173610|NCT01384435|Experimental|KPS-0373, 2nd highest dose|
3173611|NCT01384435|Experimental|KPS-0373, highest dose|
3173612|NCT01384435|Placebo Comparator|Placebo|
3173613|NCT01384422|Experimental|GLPG0634 100 mg bid oral capsules|
3173614|NCT01384422|Experimental|GLPG0634 200 mg qd oral capsules|
3173615|NCT01384422|Placebo Comparator|Placebo oral capsules|
3173616|NCT01384409|Experimental|KW-3357|
3173617|NCT01384396|Experimental|KW-3357|
3173618|NCT01384383|Experimental|Arm 1|Response-Guided Therapy with GS-5885 30 mg plus GS-9451 200 mg, plus PEG and RBV for 6 or 12 weeks.
3173619|NCT01384383|Experimental|Arm 2|Response-Guided Therapy with PEG and RBV for 24 weeks.
3173620|NCT01384370||AHPV positive and negative subjects|
3173621|NCT01384357||ultrasound,lymphadenopathy|
3173622|NCT01384344|Active Comparator|witness|no mnesic complaint
3173623|NCT01384344|Experimental|Alzheimer disease with apathy|Alzheimer's disease according to criteria of NINCDS-ADRDA with apathy
3173624|NCT01384344|Experimental|Alzheimer's disease without apathy|Alzheimer's disease according to criteria of NINCDS-ADRDA without apathy
3173625|NCT01384331|Active Comparator|Group 1 Marvelon ,placebo|"7 days daily intake of oral capsule containing Marvelon ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules containing starch for 21 day treatment Cycle"
3173626|NCT01384331|Active Comparator|Marvelon|"21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~for one cycle of 21 days"
3173627|NCT01384331|Active Comparator|NuvaRing|21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days Treatment will be for 21 days
3173628|NCT01384331|Placebo Comparator|Starch capsule|21 days daily oral placebo capsules Treatment will be for one 21 day cycle
3173629|NCT01384318||Cuffed ETT|Patients intubated with cuffed endotracheal tubes.
3173630|NCT01384292|Experimental|1 (part A and B)|Oral treatment
3173631|NCT01384292|Experimental|2 (part A and B)|Oral treatment
3173632|NCT01384292|Placebo Comparator|3 (part A only)|Oral treatment
3173633|NCT01384279|Experimental|metformin, topiramate|
3173634|NCT01384266||Subjects undergoing Cataract Surgery|Subjects undergoing routine cataract surgery
3173635|NCT01384253|Experimental|Phase I: Dose escalation|In preparation for the study, patients screened and eligible will have a peritoneal catheter placed and the evening prior to the injection of the labeled antibody will receive furosemide. Herceptin will be administered IV followed by a single IP infusion of ²¹²Pb-TCMC-Trastuzumab. Serial sampling of blood, urine, and dosimetry will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antitumor effects.
3173636|NCT01384240|Experimental|Proflavine Hemisulfate|
3173637|NCT01384227|Experimental|Proflavine Hemisulfate|
3173638|NCT01384214|Experimental|1|botulinum toxin Type A
3173639|NCT01384201||Confocal Laser Endomicroscopy|OGD by Confocal Endomicroscopy
3173640|NCT01384201||White light endoscopy|OGD by whitelight endoscopy
3173641|NCT01384188|Experimental|E1|ONO-5334
3173642|NCT01384188|Experimental|E2|ONO-5334
3173643|NCT01384175|Active Comparator|intravenous analgesia|Patients received postoperative analgesia by intravenous fentanyl 10 µg/ml 3-8 mL/h.
3173644|NCT01384175|Active Comparator|epiduaral infusion|Patients received epidural analgesia intraoperatively with ropivacaine 0.75% 1 mg/kg and fentanyl 1 µg/kg followed by continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL postoperatively.
3173645|NCT01384175|Active Comparator|patient-controlled epidural analgesia|In addition to epidural anesthesia and epidural infusion, postoperatively patients received patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
3173646|NCT01384162|Experimental|sNN0029, ICV infusion|
3173647|NCT01384149|Active Comparator|standart slt|gonioscopic selective laser trabeculoplasty
3173648|NCT01384149|Experimental|external slt|perilimbal ,above trabecular meshwork 180 degrees ,100 laser dots
3173649|NCT01384136||High risk pregnancy|
3173650|NCT01384136||"|Control - Normal low risk pregnancies"|
3173651|NCT01384110|Experimental|Brown Seaweed Lemon Tea|Single administration of lemon tea containing 500 mg of brown seaweed powder and 50 g of sucrose
3173652|NCT01384110|Placebo Comparator|Placebo lemon tea|Single administration of placebo lemon tea containing 50 g of sucrose
3173653|NCT01384097||Conventional care|patients treated by conventional haemodynamic care intraoperatively
3173654|NCT01384097||Haemodynamic algorithm|patients treated within a goal-directed haemodynamic algorithm intraoperatively
3173948|NCT01381939||Induction of labor in women with no ICP|No ICP
3173655|NCT01384084|Experimental|POP repair plus mini-sling|Patients affected by urogenital prolapse and urinary incontinence, who are candidates for pelvic organ prolapsed repair using sacropexy, will receive sacropexy plus anti-incontinence procedure (mini-sling).
3173656|NCT01384084|Active Comparator|pelvic organ prolapse repair|Patients affected by urogenital prolapsed and urinary incontinence, who are candidates for pelvic organ prolapsed repair using sacropexy, will receive sacropexy alone.
3173657|NCT01384071|Experimental|Unstable shoes (MBT)|MBT shoes (Masai Barefoot Technology, Switzerland)
3173658|NCT01384071|Sham Comparator|Stable shoes (Adidas)|Adidas stable shoes (Adidas Bigroar2)
3173659|NCT01384058|Active Comparator|Ezetimibe 10mg/d|intake of ezetimibe 10mg per day for six weeks after wash-out
3173660|NCT01384058|Active Comparator|Simvastatin 20 mg per day|intake of simvastatin 20 mg per day for six weeks after wash-out
3173661|NCT01384058|Active Comparator|Ezetimibe 10 mg/d and Simvastatin 20mg/d|intake of ezetimibe 10 mg and simvastatin 20 mg per day for six weeks after wash-out
3173662|NCT01384045|No Intervention|Usual Care|Patients continue to receive usual diabetes care without outreach by health promotions staff.
3173663|NCT01384045|Experimental|Arm 1-Health Promotoin Outreach|Active outreach by health promotion staff to send diabetes report card and schedule services including laboratory testing and visits.
3173664|NCT01384032|Experimental|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
3173665|NCT01384032|Experimental|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
3173666|NCT01384032|Experimental|High saturated fat plus DHA diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
3173667|NCT01384019|Experimental|DP-TA|distal protection and thrombus aspiration during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)
3173668|NCT01384019|Placebo Comparator|c-PCI|conventional PCI without DP-TA during primary percutaneous coronary intervention for ST-elevation myocardial infarction
3173669|NCT01384006||Control|standard pancreas allograft recipients
3173670|NCT01384006||Study|recipients of extended donor criteria pancreas allografts
3173671|NCT01383993|Experimental|1.0|Immunocompromised children aged 2 to <15 and 12 to <15 years weighing <50 kg who are at high risk for systemic fungal infection.
3173672|NCT01383993|Experimental|2.0|Immunocompromised children aged 12 to <15 years weighing more than 50 kg who are at high risk for systemic fungal infection.
3173673|NCT01383980|No Intervention|Control|Tube feeds are held night prior to elective surgery (standard of care)
3173674|NCT01383980|Experimental|Continuous Feeding|Tube feeds are continued up until surgery. Subjects with a nasogastric tube will have their stomach contents emptied prior to surgery.
3173675|NCT01383967|Experimental|LY2979165 Part A, Cohort 1|20 mg LY2979165 administered orally, daily for 14 days
3173676|NCT01383967|Experimental|LY2979165 Part A, Cohort 2|60 mg LY2979165 administered orally, daily for 14 days
3173677|NCT01383967|Experimental|LY2979165 Part A, Cohort 3|100 mg LY2979165 administered, orally daily for 14 days
3173678|NCT01383967|Experimental|LY2979165 Part A, Cohort 4|150 mg LY2979165 administered orally, daily for 14 days
3173679|NCT01383967|Experimental|LY2979165 Part B, Cohort 5|Dose to be determined by safety review of doses administered in Part A, administered, orally daily for 14 days
3173680|NCT01383967|Placebo Comparator|Placebo|Administered orally, daily for 14 days in a ratio of 3:1 in each Cohort of Part A
3173681|NCT01383967|Experimental|LY2979165 Part A, Cohort 6|250 mg LY2979165 administered orally, daily for 14 days
3173682|NCT01383967|Experimental|LY2979165 Part A, Cohort 7|400 mg LY2979165 administered orally, daily for 14 days
3173683|NCT01383954|Other|Diclofenac gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
3173684|NCT01383941||Subjects with Mild to Severe Asthma|This is an epidemiologic, multi-center, cross-sectional study to define the phenotypic characteristics of Difficult-to-Treat asthma, among children receiving one year of guidelines-based therapy for asthma and rhinitis/rhinosinusitis.
3173685|NCT01383928|Experimental|IXAZOMIB + Lenalidomide + Dexamethasone|
3173686|NCT01383915||inpatients|
3173687|NCT01383902|Other|dessert / chocolate|
3173688|NCT01383889|Other|Treading mill exercise|Pregnant women in this group will perform treadmill exercise during 20 minutes. The intensity of exercise will be maintained between 60% and 80% of maximum heart rate by Karvonen formula, in addition to the subjective perception of exertion on the modified Borg scale (moderate intensity).
3173689|NCT01383889|Other|Stationary bicycle exercise|Pregnant women in this group will perform exercise using a stationary bicycle. The intensity of exercise will be maintained between 60% and 80% of maximum heart rate by Karvonen formula, in addition to the subjective perception of exertion on the modified Borg scale (moderate intensity).
3173690|NCT01383876|Active Comparator|Collar|Hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
3173735|NCT01383499|Experimental|Treatment B|patients inhale 2 puffs (medium dose) once daily in the evening via Respimat inhaler
3173691|NCT01383876|Experimental|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
3173692|NCT01383850|Active Comparator|NCPAP + standard air|
3173693|NCT01383850|Experimental|NCPAP + Heliox|
3173694|NCT01383837|Experimental|STYLEnS|Multifamily Group HIV/STI Prevention intervention or Single Family Dyad (youth and a parent)
3173695|NCT01383837|Active Comparator|Health Promotion|Health Promotion Intervention - Adolescents only
3173696|NCT01383824|Other|Silent™ Hip|A short cementless, femoral component for use in total hip arthroplasty
3173697|NCT01383811|Active Comparator|Moderate Intensity Aerobic Exercise|
3173698|NCT01383811|Other|Wait List/Usual Care|The subjects in this group will continue to receive the usual treatment that they were on at the time of enrollment through the wait list period of 12 weeks. Subsequently they will receive the 12 weeks of aerobic exercise program intervention
3173699|NCT01383798|Placebo Comparator|Placebo|Red capsule (50 mg) lactose
3173700|NCT01383798|Experimental|Ferrous sulfate|
3173701|NCT01383785|Active Comparator|GROUP A|Intracoronary full bolus dose of abciximab proximal to thrombus occlusion
3173702|NCT01383785|Experimental|GROUP B|Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter
3173703|NCT01383785|Experimental|GROUP C|Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter
3173704|NCT01383772|Experimental|Visual fields|One arm study. All patients will receive laser treatment following visual field testing.
3173705|NCT01383759|Experimental|Bortezomib/Dexamethasone (BD) , STC & Maintenance BD|This is a pilot study to gain information and estimate the toxicity/tolerability of 1-3 cycles of BD, followed by HDM/ASCT, and maintenance therapy with BD in patients with MIDD associated with multiple myeloma and AL amyloidosis.
3173706|NCT01383746|Experimental|1|Yttrium microsphere injection
3173707|NCT01383733|Experimental|Single Arm|
3173708|NCT01383720|Experimental|Lotus Valve System|Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis
3173709|NCT01383707|Experimental|Bevacizumab + mFOLFOX-6|Participants will receive combination therapy of bevacizumab 5 mg/kg IV dose and mFOLFOX-6 (Levofolinic acid, 5-FU and oxaliplatin) on Day 1 of every 2 weeks' cycle for 5 cycles (Cycle 1-5), followed by 1 cycle (Cycle 6) of mFOLFOX6 alone (preoperative treatment phase). After 3 weeks of preoperative treatment phase, participants satisfying the surgical criteria for hepatic resectability will undergo a liver metastasectomy. Thereafter participants will receive combination therapy of mFOLFOX-6 + bevacizumab for another 6 cycles (Cycle 7-12); (post-operative treatment phase) followed by bevacizumab alone for 52 weeks (26 cycles) (maintenance therapy).
3173710|NCT01383694|Experimental|Piperine Dose 1|Piperine 1 mM
3173711|NCT01383694|Experimental|Piperine Dose 2|Piperine 150 microM
3173712|NCT01383681||All Participants|This was a retrospective chart review in patients with spasticity in the Spanish population. There was no treatment in this study.
3173713|NCT01383668|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sirolimus PO QD on days 1-28 and gold sodium thiomalate IM on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3173714|NCT01383655|Experimental|Magnesium|i.v. magnesium infusion 40mg/kg in 20 min
3173715|NCT01383655|Placebo Comparator|Placebo|i.v. 0.9 % NaCl
3173716|NCT01383642||individuals age >=70|
3173717|NCT01383629|No Intervention|No counselling|normal preoperative procedures prior to vitrectomy surgery
3173718|NCT01383629|Experimental|Preoperative counselling|Counselling to patient about what to expect during vitrectomy surgery under local anaesthesia
3173719|NCT01383616|Active Comparator|Unipedicular kyphoplasty|Balloon kyphoplasty achieves reduction of the vertebral compression fracture using a balloon tamp inserted into the vertebral body by a transpedicular approach, followed by fixation of the fracture fragments with polymethylmethacrylate (PMMA) bone cement. In this arm only vertebral body pedicle was entered to deliver bone cement.
3173720|NCT01383616|Active Comparator|Bipedicular Kyphoplasty group|Balloon kyphoplasty achieves reduction of the vertebral compression fracture using a balloon tamp inserted into the vertebral body by a transpedicular approach, followed by fixation of the fracture fragments with polymethylmethacrylate (PMMA) bone cement. In this arm two pedicles were entered to deliver bone cement.
3173721|NCT01383603|Experimental|Cat-PAD|
3173722|NCT01383590|Experimental|Cat-PAD|
3173723|NCT01383577|Experimental|Single hemorrhoidal ligation|Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each session of treatment.
3173724|NCT01383577|Experimental|Triple hemorrhoidal ligation|The three major hemorrhoidal groups are ligated in the first session of ligation. The three following monthly appointments of patients of this arm are for sham hemorrhoidal ligations and final revision.
3173725|NCT01383564|Active Comparator|CPAP group|CPAP group
3173726|NCT01383564|Placebo Comparator|non CPAP group|non CPAP group
3173727|NCT01383551|Experimental|"Becoming Parents intervention"|"A Becoming Parents Programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
3173728|NCT01383551|No Intervention|Usual prenatal education|Attend usual prenatal classes which will be provided by the midwives in the hospital.
3173729|NCT01383538|Experimental|FOLFIRINOX Plus IPI-926|
3173730|NCT01383525|Experimental|Direct Selective Trabeculoplasty|Treatment by an Automated Direct Selective Trabeculoplasty device
3173731|NCT01383512|Experimental|Rehabilitation robotics|Subjects will be practicing an Armeo Spring rehabilitation program in addition to their usual care (1.5h/day,5d/week) 1h/day 5d/week 4 weeks.
3173732|NCT01383512|Active Comparator|Self-rehabilitation|Subject will associated to there classical care 1 hours, 5 days per week during 4 weeks, of self rehabilitation.
3173733|NCT01383512|Other|Healthy volunteer|20 healthy volunteer will be recruiting and using ARMEO Spring. All volunteer will repeat 5 times the same program on the medical device.
3173734|NCT01383499|Experimental|Treatment A|patients inhale 2 puffs (low dose) once daily in the evening via Respimat inhaler
3173736|NCT01383499|Experimental|Treatment C|patients inhale 2 puffs (high dose) once daily in the evening via Respimat inhaler
3173737|NCT01383499|Placebo Comparator|Treatment D|patients inhale 2 puffs of placebo inhalation solution matching tiotropium once daily in the evening via Respimat inhaler
3173738|NCT01383486|Experimental|Naproxen Sodium ER (BAYH6689) or Advil IR|Eligible subjects were provided with 24 Advil immediate-release (IR) caplets containing 200 mg Ibuprofen and Naproxen Sodium extended release (ER) tablets containing 660 mg Naproxen Sodium. Upon a single incidence of pain, subjects were instructed to review both packages and choose one product to use. Subject were not offered any additional instructions for use beyond what is on the packages.
3173739|NCT01383473||Leukemia Patients|6-12 year old pediatric oncology patients' perceptions of their school experiences pre and post cancer diagnosis will be done through interviews and drawings.
3173740|NCT01383473||Solid Tumor Patients|6-12 year old pediatric oncology patients' perceptions of their school experiences pre and post cancer diagnosis will be done through interviews and drawings.
3173741|NCT01383460|Active Comparator|G-CSF+EPO|
3173742|NCT01383460|Placebo Comparator|Placebo|
3173743|NCT01383447|Experimental|Treatment (entinostat and imatinib mesylate)|Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3173744|NCT01383421||Participants With RA Receiving Adalimumab|"Participants with RA who were prescribed adalimumab based on current clinical practice criteria (regardless of participation in the study), with the first dose corresponding to the Enrollment/Baseline visit.~All participants were offered to participate in the PSP while treated with ADA for their RA."
3173745|NCT01383408|Sham Comparator|healthy individual|healthy individual with no lung disease and no history of cancer including lung cancer
3173746|NCT01383408|Experimental|lung cancer|patients with histologically confirmed lung cancer, but no history of other cancer
3173747|NCT01383408|Experimental|breast cancer|patients with histologically confirmed breast cancer, but no history of other cancer
3173748|NCT01383408|Experimental|ovarian cancer|patients with histologically confirmed ovarian cancer, but no history of other cancer
3173749|NCT01383395|Experimental|simvastatin/cilostazol|simvastatin 40 mg on day 1 and 6, cilostazol 100 mg from day 2 to day 6
3173750|NCT01383356|Experimental|Linagliptin/Metformin medium dosecombo|patient to receive a single medium dose combination tablet containing Linagliptin and Metformin once daily
3173751|NCT01383356|Active Comparator|Linagliptin plus Metformin medium dose|patient to receive two individual tablets: Linagliptin and Metformin (medium dose)
3173752|NCT01383343|Experimental|Treatment (FOLFIRI and bevacizumab)|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1, leucovorin calcium IV over 2 hours on day 1, fluorouracil IV continuously over 46 hours on days 1-2, bevacizumab IV over 30-90 minutes on day 1, and sorafenib tosylate PO QD or BID on days 3-6 and 10-13*. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3173753|NCT01383330|Experimental|Megace|800mg
3173754|NCT01383330|Active Comparator|DW-ES(A)|625mg
3173755|NCT01383330|Active Comparator|DW-ES(B)|625mg
3173756|NCT01383317|Active Comparator|RIPC|A tourniquet on the thigh will be inflated to 300 mmHg for 5 minutes then deflated for 5 minutes. This will be repeated three times
3173757|NCT01383317|Sham Comparator|Sham RIPC|A tourniquet on the thigh will be inflated to 15 mmHg for 5 minutes then deflated for 5 minutes. This will be repeated three times
3173758|NCT01383291||Pelvic floor prolapse|Those who underwent prolift and those who underwent IVS
3173759|NCT01383278|Experimental|Computer-directed 5 A's intervention for smoking|
3173760|NCT01383278|Active Comparator|Screening and resource provision|
3173761|NCT01383265|Experimental|Water method and chromoendoscopy|Combined water method with chromoendoscopy using 0.008% IC solution for screening colonoscopy
3173762|NCT01383265|Active Comparator|Water method|Control method will use plain water with the water method for screening colonoscopy
3173763|NCT01383252|Experimental|Water method|Water infusion in lieu of air insufflation for screening and surveillance colonoscopy
3173764|NCT01383252|Active Comparator|Air method|Air insufflation for screening and surveillance colonoscopy
3173765|NCT01383239|Active Comparator|Immediate postoperative therapy|Patients will be randomized into one of two groups: immediate postoperative therapy versus 6-week delay
3173766|NCT01383239|Active Comparator|postoperative therapy delayed for 6 weeks|Patients will be randomized into one of two groups: immediate postoperative therapy versus 6-week delay.
3173767|NCT01383226|Other|Thoracic endosonography|Thoracic endosonography, either endobronchial or esophageal ultrasound controlled needle aspiration, is a minimally invasive diagnostic technique.
3173768|NCT01383213|Experimental|CPAP (group A)|group A will be treated with CPAP using a helmet, initial PEEP of 10 cmH20 and an FiO2 set in order to maintain SpO2 ≥92%
3173769|NCT01383213|Active Comparator|oxygen therapy (group B)|group B (standard treatment) will be treated with oxygen therapy by Venturi mask with an FiO2 set in order to maintain SpO2 ≥92%.
3173770|NCT01383200|Active Comparator|Tetracaine R/Lidocaine L|Participant's Right or Left eye will receive 0.5% Tetracaine drop, at 10 minutes and 5 minutes, prior to LASIK.
3173771|NCT01383200|Active Comparator|Tetracaine L/Lidocaine R|Participant's Right or Left eye will receive 2% lidocaine gel, at 10 minutes and 5 minutes, prior to LASIK.
3173772|NCT01383187|Experimental|DE graft and PRP concentrate|Patients enrolled in this arm receive the innovative treatment methods consisting of application of DE graft together with PRP concentrate.
3173773|NCT01383187|Active Comparator|Standard treatment group|PAtients included into this arm will receive a standard treatment for deep-burn injuries, i.e. DE graft without the application of the PRP concentrate.
3173774|NCT01383174|Experimental|Peer Support Program|Nuevo Amanecer is the peer support program. Participants receive the peer support program as soon as possible after randomization.
3173775|NCT01383174|No Intervention|Wait-list Control|Waits six months, and at the end of the six months is offered the option of participating in the peer support program.
3173776|NCT01383161|Active Comparator|Curcumin|Theracurmin (180mg/day)
3173777|NCT01383161|Placebo Comparator|Placebo|Sugar Pill
3173778|NCT01383148|Experimental|Arm 1 - TG4010 + first line therapy|First-line therapy and maintenance therapy
3173779|NCT01383148|Active Comparator|Arm 2 : Placebo + first line therapy|First-line therapy and maintenance therapy
3173780|NCT01383122|Active Comparator|Active device|Functional pulsed electromagnetic field device
3173781|NCT01383122|Placebo Comparator|Placebo - inactive device|Inactive pulsed electromagnetic field device
3173782|NCT01383109|Experimental|Pyronaridine|All subjects will receive a single dose of Pyronaridine
3173783|NCT01383096|Active Comparator|Cohort 1 - Treatment A: OZ439 800mg PIB, fed|OZ439 800 mg (as free base) as powder in a bottle (PIB)for reconstitution in a suspension prior to administration. Administered 30 minutes after a standard fatty breakfast.
3173784|NCT01383096|Experimental|Cohort 1 - Treatment D: OZ439 800 mg Prototype F1 fasted|OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered fasted.
3173785|NCT01383096|Experimental|Cohort 2 - Treatement H: OZ439 800 mg Prototype F2 fasted|OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered fasted.
3173786|NCT01383096|Experimental|Cohort 3 - Treatement K: OZ439 400mg Prototype F1 fasted|Best Prototype Solution - OZ439 400 mg as prototype solution formulation 1. Administered fasted.
3173787|NCT01383096|Experimental|Cohort 1 - Treatement B: OZ439 800mg PIB fasted|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.
3173788|NCT01383096|Experimental|Cohort 1 - Treatment C:OZ439 800mg PIB with milk|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.
3173789|NCT01383096|Experimental|Cohort 3 - Treatment J: OZ439 800mg Prototype F1 fasted|Best Prototype Solution - OZ439 800 mg (as free base) as prototype solution formulation 1. Administered fasted.
3173790|NCT01383096|Experimental|Cohort 1 - Treatement E: OZ439 800mg Prototype F1 with milk|OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered with milk.
3173791|NCT01383096|Experimental|Cohort 2 - Treatement F: OZ439 800 mg PIB fasted|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.
3173792|NCT01383096|Experimental|Cohort 2 - Treatement G: OZ439 800mg PIB with milk|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.
3173793|NCT01383096|Experimental|Cohort 2 - Treatement I: OZ349 800mg Prototype F2 with milk|OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered with milk.
3173794|NCT01383083||iloprost|In the adult patient group, iloprost acceptable target dose is 2.5 ug 4-6 times/day according to the patient's compliance. Because of the concern of safety and tolerability, during the first 4 weeks of treatment, patients receive 2.5 ug twice daily. After 4 weeks, this is increased to the target dose, if iloprost is well tolerated.
3173795|NCT01383070|No Intervention|Lactational Conseling|The existing staff of the hospitals will be provided training in IYCF by BPNI. They will be encouraged to set up their own systems to continue counseling during the ante natal period, at delivery and during the immunization visits. The participants will be asked to come for the same schedule of visits as in the intervention group where their data will be collected.
3173796|NCT01383070|Experimental|Lactation Counseling by Cell Phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
3173797|NCT01383057|Experimental|Femtosecond Laser|
3173798|NCT01383044|Experimental|EVL + carvedilol|EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
3173799|NCT01383044|Active Comparator|carvedilol|carvedilol 6.25-12.5 mg per day
3173800|NCT01383031|Active Comparator|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
3173801|NCT01383031|Active Comparator|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC（conventional laparoscopic cholecystetomy）by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
3173802|NCT01383018||AMS penile prosthesis receipients|Men for whom an AMS penile prosthesis is recommended
3173803|NCT01383005||Kaletra (LPV/r) QD as First Kaletra Treatment|HIV-infected participants treated with lopinavir/ritonavir once daily (LPV/r QD) from ≥3 months to <2 years who had not been treated with any of the following: LPV/r twice daily (BID), a protease inhibitor, or a ritonavir-boosted protease inhibitor.
3173804|NCT01383005||Kaletra (LPV/r) QD from Kaletra BID|HIV-infected participants treated with LPV/r from ≥3 months to <2 years who had initiated on LPV/r BID and at any time within this period (but at least 3 months before inclusion in the study) had changed dosing from BID to QD.
3173805|NCT01382992||Early Stage|
3173806|NCT01382992||Late Stage|
3173807|NCT01382979|Experimental|Alcohol education and prevention|AlcoholEdu is an online course designed to prevent alcohol misuse and related problems among college freshmen.
3173808|NCT01382979|No Intervention|Control|Control group.
3173809|NCT01382966||Single group|Maintenance hemodialysis patients of minimal 6 months of hemodialysis duration; free of malignancy, infection and autoimmune disease; age over 18 years
3173810|NCT01382940|Experimental|Rituximab|Rituximab intravenous (IV) infusions were administered over a 4.25-hour period on Day 1, and over a 2-hour period on Day 15 (first course) and on Days 168 and 182 (second course). All participants continued to receive methotrexate as prescribed by their treating physician. Premedication included methylprednisolone, an antihistamine and acetaminophen.
3173811|NCT01382927||General Anesthesia|
3173812|NCT01382927||Spinal Anesthesia|
3173813|NCT01382914|Experimental|chlorhexidine 0.12 %|
3173814|NCT01382901|Experimental|Intravenous (IV) Iron|
3173815|NCT01382901|Placebo Comparator|Placebo|
3173816|NCT01382888|Active Comparator|Heparin 2,400 IU /ml Cutaneous Spray|Patients are randomized to receive the active comparator heparin 2,400 IU/ml cutaneous spray for 24 weeks
3173817|NCT01382888|Placebo Comparator|Placebo Cutaneous Spray|Patients are randomized to receive placebo cutaneous spray for 24 weeks
3173818|NCT01382875|No Intervention|Conventional care program|
3173820|NCT01382862|No Intervention|Regular Care|Regular care for suspected stroke in Berlin consists of an ambulance with paramedics only, and neither computed tomography (CT) nor point-of-care diagnostics. In Berlin, emergency physicians are involved in prehospital care only in cases of special medical emergencies such as severe instability of vital parameters or loss of consciousness.
3173821|NCT01382862|Active Comparator|Stroke Emergency Unit Mobile (STEMO)|The STEMO is equipped with a CT-scanner, a point-of-care laboratory and the infrastructure for tele-radiological as well as videoconferencing support. STEMO is operated by a team of experienced neurologists (n=6, half-time positions, with additional formal training in emergency medicine according to the requirements of the Berlin Medical Board), paramedics of the fire brigade (n=3, two years formal training in emergency care) and radiology technicians (n=3, three years formal training in radiology assistance and three months formal training in emergency care).
3173822|NCT01382849||CAA positive microbleeders|Cerebral amyloid angiopathy (CAA) positive microbleeders
3173823|NCT01382849||probable CAA macrobleeders|
3173824|NCT01382849||CAA negative microbleeders|
3173825|NCT01382836||Black inner city children with persistent asthma|
3173826|NCT01382836||Black inner city non-atopic healthy children|
3173827|NCT01382823|Experimental|Femtosecond Laser|
3173828|NCT01382810|Active Comparator|Altaire Gel forming solution|
3173829|NCT01382810|Placebo Comparator|Refresh Tears|
3173830|NCT01382797|Placebo Comparator|Placebo|Capsules for oral administration
3173831|NCT01382797|Experimental|ALKS 37|Capsules for oral administration
3173832|NCT01382771|Active Comparator|Intra-articular corticosteroid injection|Intra-articular corticosteroid injection in conjunction with confirmatory anesthetic medial branch blocks
3173833|NCT01382771|Placebo Comparator|Intra-articular saline injection|Intra-articular saline injections with confirmatory anesthetic medial branch blocks
3173834|NCT01382758||Acute kidney injury|The group of patients who develop acute kidney injury as defined by the pediatric RIFLE criteria.
3173835|NCT01382758||No acute kidney injury|The patients who do not develop acute kidney injury
3173836|NCT01382745|Experimental|Nimotuzumab|Patients will receive weekly injections of Nimotuzumab (200mg/injection) for 12 weeks and standard external beam radiotherapy
3173837|NCT01382732|Experimental|Carbetocin|"Protocol A (carbetocin + placebo) Carbetocin: 100ug (1mL) + Ringer's Lactate 10mL directly into the vein in no less than two minutes.~Ringer's Lactate 4mL applied to a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr"
3173838|NCT01382732|Active Comparator|Oxytocin|Protocol B (oxytocin + placebo) Ringer's Lactate 11mL directly into the vein in no less than two minutes. Oxytocin 20 U (4mL) diluted in a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr
3173839|NCT01382719|Placebo Comparator|Placebo|Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.
3173840|NCT01382719|Experimental|bremelanotide arm 1|Low dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
3173841|NCT01382719|Experimental|bremelanotide arm 2|Middle dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.25 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
3173842|NCT01382719|Experimental|bremelanotide arm 3|High dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
3173843|NCT01382706|Experimental|Treatment|Patients receive docetaxel IV over 1 hour on day 1 and lapatinib ditosylate PO QD on days 1-21. Courses repeat every 21 days until disease progression or unacceptable toxicity.
3173844|NCT01382693|Experimental|TimeSlips group storytelling program|
3173845|NCT01382693|Active Comparator|Standard care activity program|
3173846|NCT01382680|Active Comparator|Classic guidewires|Conventional guidewires used in combination as preferred by the investigating ERCP specialist
3173847|NCT01382680|Active Comparator|New guidewire (G240)|Primary use of the new guidewire (G240)
3173848|NCT01382667||GLP-2 and symptom evaluation|Before starting and at the end of the chemotherapy, along with a blood withdrawal for GLP-2 evaluation, a GSRS (gastrointestinal symptom rate scale) questionnaire will be filled by each patient to account for GI symptoms. In addition, minor complaints such as warm sensation after chemotherapy, susceptibility to nausea under specific condition, sweating and weakness will scored by visual analog score (VAS). Lastly, the NCI-CTC score for mucositis will be performed.
3173849|NCT01382654|Experimental|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
3173850|NCT01382654|Experimental|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
3173851|NCT01382654|Experimental|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
3173852|NCT01382654|Experimental|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
3173853|NCT01382654|Active Comparator|azelastine 0.1%|nasal spray 2 sprays in each nostril for a total of 3 doses
3173854|NCT01382641|Other|Hoya AF-1 IOL|
3173855|NCT01382641|Other|Revital Vision|
3173856|NCT01382628||Preulcerative plantar foot lesion|An area on the plantar foot, usually at the location of a bony prominence, that presents with erythema, significant hyperkeratosis, or thin, shiny skin.
3173857|NCT01382628||Plantar ulcer no history of amputation|Plantar ulceration without a history of amputation or require an amputation.
3173858|NCT01382628||Plantar ulcer and digital amputation|Plantar ulceration who will be undergoing a digital amputation.
3173859|NCT01382628||Plantar ulcer and transmet amputation|Plantar ulceration who will be undergoing a transmetatarsal amputation.
3173860|NCT01382628||Plantar ulceration and choparts|Plantar ulceration who will be undergoing Chopart's or more proximal amputation.
3173861|NCT01382615||Healthy Volunteers|Healthy volunteers who have agreed to have a bone marrow and/or blood harvest as part of a donation to a transplant recipient.
3173862|NCT01382615||Patients with multiple myeloma|Patients undergoing routine blood draw and bone marrow aspirates as part of their ongoing follow-up care for myeloma at the Norris Cotton Cancer Center of DHMC.
3173863|NCT01382602|Experimental|AMDC-USR|Subjects received 1 or 2 treatments of 150 million AMDC-USR delivered via transurethral intrasphincteric injection. After completing 12 months follow-up subjects were unblinded. Subjects were followed for 2 years after initial AMDC-USR treatment.
3173864|NCT01382602|Placebo Comparator|Placebo|Subjects received 1 or 2 treatments of placebo delivered via transurethral intrasphincteric injection. After completing 12 months follow-up subjects were unblinded and could elect to receive open-label AMDC-USR treatment. Subjects that received unblinded AMDC-USR treatment were followed for 2 years after initial placebo treatment.
3173865|NCT01382589|Experimental|Arm A: Afamelanotide + NB-UVB|Subject in this arm will receive both afamelanotide implants (one implant administered every 28 days, 6 implants in total) and NB-UVB light (administered thrice weekly, 72 treatments in total)
3173866|NCT01382589|Active Comparator|Arm B: NB-UVB alone|Subjects in this arm B will receive NB-UVB light only (administered thrice weekly, 72 treatments in total)
3173867|NCT01382576||PCOS patients|
3173868|NCT01382576||PCOS patients and healthy controls|There are two groups in this study. One group is PCOS patients and other group is healthy controls.
3173869|NCT01382550||VTE subjects|"subjects with a recent (<3 months) first VTE event undergoing long-lasting OAT or 12-month OAT~Exclusion criteria: missing data during the follow-up; contraindications to or lack of compliance to oral anticoagulation (OAT), lack of informed consent; history of previous VTE event; indication for continuous oral anticoagulation (e.g., an artificial heart valve or chronic atrial fibrillation); events occurring during pregnancy, malignancy, puerperium, oral contraceptive intake, hormone replacement therapy; deficiencies of Prot. C and Prot S or combined inhibitor deficiencies."
3173870|NCT01382537|Active Comparator|A|
3173871|NCT01382537|Placebo Comparator|B|
3173872|NCT01382524||Stabilization system A|A commercialized stabilization dressing using a winged PIV catheter.
3173873|NCT01382524||Stabilization System B|A commercialized stabilization device using a non-winged PIV catheter
3173874|NCT01382498|Placebo Comparator|Placebo|Placebo tablets will be administered to the patients in Placebo arms daily for three months.
3173875|NCT01382498|Experimental|Calcium dobesilate|Calcium dobesilate as 500 mg tablets will be administered once to the patients daily.
3173876|NCT01382485|Active Comparator|AICBG harvesting group|Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
3173877|NCT01382485|Experimental|RIA harvesting group|Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
3173878|NCT01382472|Experimental|Rosuvastatin|40 mg rosuvastatin pre PCI and daily during hospital stay
3173879|NCT01382472|Other|Historical data (KOMPIS)|Patients from the KOMPIS trial (n=44) will be used as historical controls. They received no statins omn the first day. Low dose simvastatin during hospital stay.
3173880|NCT01382459||type 1 DM children- intervention group|will have home visits and trainings at school
3173881|NCT01382459||type 1 DM children- control group|will receive the standard care at the clinic
3173882|NCT01382446|Active Comparator|Standard Oral Care Regimen|Current oral care protocol includes the use of 1.5% H2O2-coated swabs every four hours, toothbrushing with toothpaste every 12 hours, and use of continuous subglottic suction apparatus.
3173883|NCT01382446|Experimental|Chlorhexidine Oral Care Regimen|This study will compare our current oral care practice with the use of Chlorhexidine Gluconate 0.12% (Peridex, 3M Corporation) Twice daily in addition to regularly scheduled oral care as a means to decrease the incidence of VAP utilizing evidence-based strategies.
3173884|NCT01382433|Experimental|Chronic Cannabis Users|
3173885|NCT01382433|Experimental|Control|Neurotypical subjects
3173886|NCT01382420|Active Comparator|Adrenalectomy group|patients who undergo adrenalectomy
3173887|NCT01382420|No Intervention|Control group|patients who receive conservative treatment
3173888|NCT01382407||Cetuximab|All patients who started treatment with ERBITUX® (cetuximab), as a single agent or in combination with chemotherapy.
3173889|NCT01382394||Sepsis Group, Heart failure group|"The first group will include 60 patients with the diagnosis of acute decompensated heart failure.~The second group will include 60 patients with the diagnosis of sepsis."
3173890|NCT01382368|Experimental|Sildenafil|
3173891|NCT01382355||Kidney transplant|
3173892|NCT01382342|Experimental|rasagiline|Participants in this arm will receive 1 mg of rasagiline daily for the six month duration of the study.
3173893|NCT01382342|Placebo Comparator|Placebo|Participants in this group will receive 1 mg of placebo daily for the six month duration of the study.
3173894|NCT01382329|Experimental|Treatment group I / Intramuscular|85 subjects to receive 2 intramuscular vaccinations at Dose A on Days 1 and 22
3173895|NCT01382329|Experimental|Treatment group II / Intramuscular|85 subjects to receive 2 intramuscular vaccinations at Dose B on Days 1 and 22
3173896|NCT01382329|Experimental|Treatment group III / Subcutaneous|85 subjects to receive 2 subcutaneous vaccinations at Dose A on Days 1 and 22
3173897|NCT01382329|Experimental|Treatment group IV / Subcutaneous|85 subjects to receive 2 subcutaneous vaccinations at Dose B on Days 1 and 22
3173898|NCT01382316|Experimental|Making Alcoholics Anonymous Easier|Six session, group format intervention, consisting of introductory session, four core sessions (sponsorship, principles not personalities, spirituality, living sober), and return to introductory session as MAAEZ graduate
3173899|NCT01382316|Active Comparator|Usual care|Usual group sessions on education about alcohol and drug problems
3173900|NCT01382303|Active Comparator|Pentoxifylline|Pentoxifylline 400mg three times a day
3173901|NCT01382303|Placebo Comparator|Placebo|placebo tablet
3173902|NCT01382277|Experimental|Rosuvastatin 20 mg|Rosuvastatin 20 mg for 76 weeks.
3173903|NCT01382264|Experimental|CADS|
3173904|NCT01382251||Patient|Patients undergoing ambulatory surgery
3173905|NCT01382251||Caregiver|Spouse, family members, or friends identified as the patient's primary source of support in the community.
3173906|NCT01382238|Experimental|Single arm|Subjects will have a screening visit within 30 days prior to the first dose of study drug, five treatment periods containing a single dose of study drug, followed by 48 hours of serial PK collection. In the 5 treatment periods subjects will receive DTG granule formulation 1) directly to mouth; 2) with purified water; 3) with Contrex brand water; and 4) with milk-based infant formula. They will also receive the current 50 mg tablet formulation administered with tap water. These treatments will be administered in a random order. Subjects will check out of the unit on Day 3 after the 48 hour PK sample in each period. Study periods will be separated by at least 5 days. Subjects will have a follow-up visit 5-7 days after last dose of DTG given.
3173907|NCT01382225|Experimental|Sodium Hyaluronate|Sodium Hyaluronate Ophthalmic Solution, 0.18%, 1-2 drops instilled in each eye 3-6 times a day for 14 days
3173908|NCT01382225|Placebo Comparator|Vehicle|Inactive ingredients, 1-2 drops instilled in each eye 3-6 times a day for 14 days
3173909|NCT01382212|Experimental|Paricalcitol|Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.
3173910|NCT01382199|Experimental|Ven100|Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
3173911|NCT01382186||Purposive Sampling|Purposive sampling was used to identify a sample of 33 Veterans who have been Personally Authenticated for the SM feature on MHV. Participants were recruited from each site (Tampa, Boston). Women were purposively recruited to ensure females were represented in data findings.
3173912|NCT01382186||Random Sampling|Random sampling was used to conduct a quantitative survey with 819 veterans to explore their experiences using secure messaging.
3173913|NCT01382160|Experimental|adalimumab|40 mg every two weeks, by subcutaneous way
3173914|NCT01382147|Experimental|S-HAM|S-HAM (S-HAMescalated for younger patients and S-HAMbasis for elderly patients)
3173915|NCT01382147|Active Comparator|TAD-HAM (younger) or HAM-HAM (elderly)|is TAD-9 - HAM for younger patients (with 2 mandatory induction cycles) and HAM (- HAM) for the elderly patients with the second HAM cycle only applied in the case of inadequate blast clearance (> 5%) in the day 16 bone marrow aspirate
3173916|NCT01382134|Placebo Comparator|Placebo group|Subjects will be given placebo daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15 microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.
3173917|NCT01382134|Active Comparator|Aspirin group|Subjects will be given aspirin 100mg daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.
3173918|NCT01382121|Experimental|Peer modeling|Participants watch a video geared to increase confidence in ability to preform fitness test. Male participants will watch a video of a male adolescent completing the fitness test and talking about coping mechanisms used to preform to the best of his ability. Female participants will watch a video of a female adolescent completing the fitness test and talking about coping mechanisms used to preform to the best of her ability.
3173919|NCT01382121|Active Comparator|Control|Participants watch a video unrelated to the fitness test and self-efficacy. The video depicts healthy food and nutrition options.
3173920|NCT01382108||Normal participants|
3173921|NCT01382108||Meibomian Gland Dysfunction|
3173922|NCT01382095|Experimental|Group A|
3173923|NCT01382095|Experimental|Group B-1|
3173924|NCT01382095|Experimental|Group B-2|
3173925|NCT01382095|Experimental|Group C|
3173926|NCT01382082||subjects with breast cancer|
3173927|NCT01382082||subjects with lymphoma|
3173928|NCT01382082||subjects without cancer|
3173929|NCT01382069|Placebo Comparator|Placebo|Placebo
3173930|NCT01382069|Experimental|Dimethandrolone Undecanoate|DMAU group with different doses 100, 200 and 400 groups
3173931|NCT01382056|Experimental|Mixed beans (higher amount)|Participants may be randomized to foods containing 0.6 cup of mixed beans daily 5 times per week for 8 weeks
3173932|NCT01382056|Experimental|Mixed beans (lower aomunt)|Participants may be randomized to foods containing 0.3 cup of mixed beans daily, 5 times per week for 8 weeks.
3173933|NCT01382056|Active Comparator|Control foods|pulse-free control foods consumed daily, 5 days per week for 8 weeks
3173934|NCT01382043||Endeavor Segment group|
3173935|NCT01382043||Excel Segment Group|
3173936|NCT01382030|Experimental|Treatment Arm|All patients receive 4 cycles of EIA chemotherapy pre- and postoperatively. There is no further observation arm. The study is non-randomized.
3173937|NCT01382017|Placebo Comparator|Placebo|Placebo arm
3173938|NCT01382017|Experimental|Lasosamide 200|Lacosamide 200 mg
3173939|NCT01382017|Experimental|Lacosamide 400|Lacosamide 400 mg
3173940|NCT01382017|Active Comparator|Carbamazepine 600|Carbamazepine 600 mg
3173941|NCT01382004|Active Comparator|Penicillin-G-Benzathine|penicillin-G-Benzathine : 50,000 UI/Kg single dose(maximum 2.4 million units IM)
3173942|NCT01382004|Experimental|Azithromycin|Azithromycin: 30 mg/kg single dose (Maximum: 2.000 mg.)
3173943|NCT01381991|Experimental|i-scan-EGD|Examination of GE junction using conventional WL as well as i-scan mode
3173944|NCT01381965|Active Comparator|Eyes with macular hole|
3173945|NCT01381952|Experimental|Reduced radiation dose (ClarityIQ)|Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology
3173946|NCT01381952|Active Comparator|Normal radiation dose (AlluraXper)|Normal dose DSA with conventional X-ray technology.
3173950|NCT01381926|Experimental|Exenatide then Placebo|"Study participants in phase1 will receive the study drug, exenatide, at a dose of 5mg subcutaneously twice daily 30 minutes before meals for one month. During the second month of the study, the dose of exenatide will be increased to 10mg subcutaneously twice daily before meals for one month. During the third month of the study, no study medication will be given and this will serve as a wash out period prior to the second phase of the study (placebo). During the fourth and fifth months, study participants will get placebo alternatives to exenatide 5mg and exenatide 10mg, respectively, subcutaneously twice daily before meals."
3173951|NCT01381926|Active Comparator|Placebo then Exenatide|"Study participants in phase1 will receive the saline placebo, at a dose of 5mcg subcutaneously twice daily 30 minutes before meals for one month. During the second month of the study, the saline placebo will be increased to 10mcg subcutaneously twice daily before meals for one month. During the third month of the study, no treatment will be given and this will serve as a wash out period prior to the second phase of the study. During the fourth month study participants will receive Exenatide 5mcg twice daily with meals. During the fifth month, study participants will receive exenatide 10mcg, subcutaneously twice daily before meals."
3173952|NCT01381900|Experimental|Canagliflozin 100mg|Each participant will receive 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
3173953|NCT01381900|Experimental|Canagliflozin 300mg|Each participant will receive 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
3173954|NCT01381900|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
3173955|NCT01381887|Placebo Comparator|001|Placebo Treatment A: Form=capsule route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
3173956|NCT01381887|Experimental|002|"Canagliflozin 300mg/Placebo Treatment B: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
3173957|NCT01381887|Experimental|003|Canagliflozin 300mg Treatment C: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
3173958|NCT01381887|Experimental|004|"Canagliflozin 300mg/Canagliflozin 150mg Treatment D: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1 unit=mg number=150 form=capsule route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
3173959|NCT01381874|Experimental|Abiraterone acetate + Prednisone or Prednisolone|Abiraterone acetate + Prednisone or Prednisolone Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use. All drugs are taken once daily.
3173960|NCT01381874|Experimental|Abiraterone acetate + Prednisone/Prednisolone + Exemestane|Abiraterone acetate + Prednisone/Prednisolone + Exemestane Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
3173961|NCT01381874|Experimental|Exemestane|Exemestane Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
3173962|NCT01381861|Experimental|TRC105|
3173963|NCT01381848|Experimental|001|Doripenem Type=exact number unit=mg/kg number=5 form=solution for injection route=intravenous use once on Day 1 for patients <8 weeks CA.,Doripenem Type=exact number unit=mg/kg number=8 form=solution for injection route=intravenous use once on Day 1 for patients >=8 weeks CA.
3173964|NCT01381835|Experimental|001|TMC435 150 mg capsule once daily for 7 days
3173965|NCT01381822|Experimental|TH-302 Dose escalation|The initial dose of TH-302 will be 240 mg/m2. A Dose Level minus 1 and 2 will be built into the study in the event that subjects experience excessive toxicity at Dose Level 1. Dose escalation will continue with approximately 40% increases from the previous dose level; however lower dose increases of 20-39% may be implemented after consultation between the Investigators, Medical Monitor and Sponsor with the percent increase dependent on the current dose level and the cumulative safety data.
3173966|NCT01381809|Experimental|Epoetin alfa|Group 1: Epoetin alfa type = range unit= IU/Kg number= 337.5 to 1050 IU/Kg form= solution for injection route= subcutaneous use weekly injections (max 40 000 IU per week for first 8 weeks of treatment max 80 000 IU per week later) using pre-filled 1mL 40 000 IU syringes for 24 to 48 weeks
3173967|NCT01381809|Placebo Comparator|No treatment|Group 2: Placebo form= solution for injection route= subcutaneous use weekly injections for 24 to 48 weeks
3173968|NCT01381796|Active Comparator|Treatment A - NP101|
3173969|NCT01381796|Active Comparator|Treatment C - oral sumatriptan succinate|
3173970|NCT01381796|Experimental|Treatment B - NP101B|
3173971|NCT01381796|Experimental|Treatment D - NP101D|
3173972|NCT01381783|Other|Topical anesthesia|
3173973|NCT01381770|Experimental|Platelet-derived repairing factors|
3173974|NCT01381744|Experimental|Group 3: 6 mcg Flagellin/F1/V|12 subjects will receive 6 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
3173975|NCT01381744|Experimental|Group 4: 10 mcg Flagellin/F1V|12 subjects will receive 10 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
3173976|NCT01381744|Experimental|Group 2: 3 mcg Flagellin/F1/V|12 subjects will receive 3 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
3173977|NCT01381744|Experimental|Group 1: 1 mcg Flagellin/F1/V|12 subjects will receive 1 microgram (mcg) of Flagellin/F1/V or placebo on Day 0 and Day 28.
3173978|NCT01381731|Experimental|Diquafosol tetrasodium ophthalmic solution 2%|topical ophthalmic solution
3173979|NCT01381731|Placebo Comparator|Placebo|saline ophthalmic solution
3173980|NCT01381718|Experimental|Arm I|Participants receive modafinil orally (PO) once daily (QD) on days 1-42.
3173981|NCT01381718|Placebo Comparator|Arm II|Participants receive placebo PO QD on days 1-42.
3173982|NCT01381692|Active Comparator|Arm I (rituximab, bortezomib, dexamethasone)|Patients receive rituximab IV over 30-60 minutes on days 1, 8, 15, and 22 (of courses 1 and 4 only) and bortezomib IV or SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3175389|NCT01371513||PSA level|more than 2.5ng/ml
3173983|NCT01381692|Experimental|Arm II (temsirolimus, rituximab, bortezomib, dexamethasone)|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and rituximab, bortezomib, and dexamethasone as in arm I. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3173984|NCT01381679||All participants|Participants in whom LDL-C target levels have not been achieved and for whom ezetimibe therapy has been chosen.
3173985|NCT01381666|Experimental|INS316|inhalation via nebulizer given for 2 doses for 60 minutes each
3173986|NCT01381666|Placebo Comparator|hypertonic saline 3% sodium chloride solution|inhalation via nebulizer given for 2 doses for 60 minutes each
3173987|NCT01381653|Experimental|Motivational Interviewing|Eight 30-minute sessions utilizing Motivational Interviewing will be delivered to reduce substance use and sexual risk in a group of high risk young men who have sex with men.
3173988|NCT01381640|Active Comparator|Marketed paracetamol|Marketed formulation
3173989|NCT01381640|Experimental|Experimental paracetamol formulation|Experimental formulation
3173990|NCT01381627|Active Comparator|Remifentanil|
3173991|NCT01381627|Experimental|Dexmedetomidine|
3173992|NCT01381614||Occurance of severe adverse event claims in subjects|Presence or absence of common severe treatment related adverse events (based on existence of claims) in patients with metastatic RCC. Common severe adverse event defined as Grade 3 or higher with >=5% frequency of occurance as reported in product label.
3173993|NCT01381601||Severe adverse event claims in subjects with metastatic RCC|Presence or absence of common severe treatment related adverse events (based on existence of claims) in patients with metastatic RCC. Common severe adverse event defined as Grade 3 or higher with >=5% frequency of occurence as reported in product label.
3173994|NCT01381588||Post menopausal women|Post menopausal women between 50 to 80
3173995|NCT01381575|Experimental|Cervarix 1 Group|Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
3173996|NCT01381575|Experimental|Cervarix 2 Group|Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
3173997|NCT01381575|Experimental|Cervarix 3 Group|Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
3173998|NCT01381562|Experimental|GSK2251052 750mg|q12h administered via IV infusion, plus saline placebo
3173999|NCT01381562|Experimental|GSK2251052 1500mg|q12h administered via IV infusion, plus saline placebo
3174000|NCT01381562|Active Comparator|Meropenem 1G|q8h administered via IV infusion, plus saline placebo
3174001|NCT01381549|Experimental|GSK2251052 750mg|q12h administered via IV infusion, plus saline placebo
3174002|NCT01381549|Experimental|GSK2251052 1500mg|q12h administered via IV infusion, plus saline placebo
3174003|NCT01381549|Active Comparator|imipenem-cilastatin|500 mg imipenem monohydrate and 500 mg cilastatin sodium; q6h administered via IV infusion, plus saline placebo
3174004|NCT01381536|Experimental|GSK1550188 1mg/kg or 10mg/kg|one shot IV
3174005|NCT01381523||Study-treatment naive insured adults with migraine|Adult health care plan members with a pharmacy claim for a combination product of sumatriptan and naproxen sodium (SumaRT/Nap) and propensity score matched controls with a pharmacy claim for a single-entity triptan
3174006|NCT01381523||Insured adults with migraine who switch study treatment|Adult health plan members with a pharmacy claim for SumaRT/Nap following at least one single-entity triptan pharmacy claim in the previous 6 months and propensity-score matched controls who switched from one single-entity triptan to another
3174007|NCT01381510||Adherent BPH patients|Patients with benign prostatic hyperplasia (BPH) who are adherent to 5-alpha reductase inhibitor (5ARI) therapy based on a medication possession ratio (MPR). Analyses will be conducted with threshold adherence levels of 70%, 75% and 80%
3174008|NCT01381510||Non-adherent BPH patients|Patients with BPH who are not adherent to 5ARI therapy based on an MPR and threshold levels of less than 70%, less than 75% and less than 80%
3174009|NCT01381497||Employed migraine sufferers|Diagnosed adult migraine sufferers who are employed at least 30 hours per week during a daytime shift
3174010|NCT01381484|No Intervention|Placebo|This group received placebo gel and requested to apply periorbital area and over the face for 3 months.
3174011|NCT01381484|Experimental|Study group|This group received La Jolie Gel and requested to apply periorbital area and over the face for 3 months.
3174012|NCT01381471||COPD|Patients with a diagnosis code of COPD
3174013|NCT01381458||COPD patients receiving pharmacotherapy|COPD patients age 40 years and older receiving pharmacotherapy to treat their COPD and an index event of COPD hospitalization or ER visit.
3174014|NCT01381445|Experimental|GW870086 0.2% &amp; GW870086 2%|GW870086 0.2%, 2% &amp; placebo each applied to an identified area for 42 days.
3174015|NCT01381445|Experimental|GW870086 2% &amp; Clobetasol Propionate|GW870086 2% &amp; placebo applied to an identified area for 42 days, while Clobetasol Propionate is applied to an area for 21 days
3174016|NCT01381432||Subjects prescribed azathioprine tablet|Subjects prescribed azathioprine tablet during study period after the lung transplantation
3174017|NCT01381419|Experimental|Part A, Cohort 1|In Cohort 1, four subjects (two on active and two on placebo for first dose, and then three on active and one on placebo for subsequent doses) will be included. Subjects will be dosed at least 30 minutes apart over the dosing day and only doses administered where the predicted plasma concentration will remain below those corresponding to the MABEL.
3174055|NCT01381120|Active Comparator|Narcotic Painkiller|Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
3174056|NCT01381107|Experimental|ALKS 5461 (ALKS 33 and buprenorphine)|
3174057|NCT01381107|Placebo Comparator|Placebo|
3174058|NCT01381094|Experimental|AKB-6548 240 mg|
3174059|NCT01381094|Experimental|AKB-6548 370 mg|
3174060|NCT01381094|Experimental|AKB-6548 500 mg|
3174061|NCT01381094|Experimental|AKB-6548 630 mg|
3174062|NCT01381094|Placebo Comparator|Placebo|
3174018|NCT01381419|Experimental|Part A, cohort 2|In Cohort 2, 10 subjects will be included (8 active : 2 placebo). Dosing will start once the previous cohort (Cohort 1) has completed the Treatment Phase. For Cohort 2 and any subsequent cohorts, dosing will take place on two different days when a new dose is administered such that no more than one subject receives the agreed ascending dose on the first dosing day. Doses may be split in up to three divided doses given 2 to 3 hours apart. Dosing for the first four sessions in each cohort will be staggered over 2 days. On the first day of each dosing session, only one subject will receive the highest dose for that dosing session and at least one subject each will receive placebo. The remaining subjects in the cohort will be dosed on the second day according to the randomisation plan.
3174019|NCT01381419|Experimental|Part B|Part B of the study will consist of a Screening Visit (up to 30 days before the dosing session), three PET scans (where possible, all three scans may be performed in one visit when subject is admitted overnight) and a Follow-up Visit. Each subject will receive an oral dose of study drug. The dose may be split in up to three divided doses given 2 to 3 hours apart.
3174020|NCT01381406||COPD patients|Patients who are at least 40 years of age and diagnosed with COPD using ICD-9 codes of 491.xx, 492.xx, and 496.xx in an administrative claims database.
3174021|NCT01381393||Ibandronate|The subjects with osteoporosis in postmenopausal women
3174022|NCT01381380|Other|single-arm studies|Manual therapy for one group
3174023|NCT01381367|Experimental|Vaccine|Enrolled COPD patients receiving PPSV23 pneumococcal vaccine
3174024|NCT01381367|Placebo Comparator|Normal saline|Enrolled COPD patient receiving placebo normal saline
3174025|NCT01381354|Experimental|Combined intervention|Combination intervention consisting of the following: structured modified paleolithic diet, Progressive Exercise, Neuromuscular Electrical Stimulation designed to facilitate the adoption of multiple therapeutic lifestyle behaviors associated with superior health outcomes.
3174026|NCT01381341|Experimental|linifanib|
3174027|NCT01381328||RAL Group|HIV-1 infected patients failing to a RALTEGRAVIR-containing regimen
3174028|NCT01381315|Other|Sentinel lymph node biopsy|During surgery, 1.0 mCi of technetium-99m sulfur colloid will be injected into sub-dermal subareolar aspect of the affected breast. The KUMC Nuclear Medicine Department will be responsible for performing the injection of the isotope and dilution of the isotope using saline to a final volume of 4.0 ml or less.
3174029|NCT01381315|Other|Axillary lymph node biopsy|
3174030|NCT01381302||Parkinson|Early onset of disease
3174031|NCT01381276|Experimental|Cassava Treatment 1|Single meal containing bio-fortified, high carotenoid cassava without oil.
3174032|NCT01381276|Experimental|Cassava Treatment 2|Single meal containing bio-fortified, high carotenoid cassava with oil.
3174033|NCT01381276|Active Comparator|Cassava Treatment 3|Single meal containing low carotenoid cassava with oil and retinyl palmitate.
3174034|NCT01381263|Experimental|Behavioural medicine|
3174035|NCT01381263|Active Comparator|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
3174036|NCT01381250|Experimental|Treatment|The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur & Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
3174037|NCT01381224||Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection.
3174038|NCT01381211|Active Comparator|Yttrium-90 radioembolization (90Y-RE)|
3174039|NCT01381211|Active Comparator|Transarterial chemoembolization with drug eluting beads|Transarterial chemoembolization is performed with drug eluting beads, polyvinyl alcohol-based microspheres (DC Beads, Biocompatibles) loaded with the chemotherapeutic agent doxorubicin.
3174040|NCT01381198|Active Comparator|Distal rectus femoris transfer|Single-event multilevel surgery with a concomitant distal rectus femoris transfer
3174041|NCT01381198|No Intervention|No distal rectus femoris transfer|Single-event multilevel surgery without distal rectus femoris transfer
3174042|NCT01381185|No Intervention|Standard therapy|standard dose of 100mg aspirin qd and 1x75mg Clopidogrel will be given
3174043|NCT01381185|Active Comparator|ASA/CLP increase|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd
3174044|NCT01381172|Experimental|Treatment|The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.
3174045|NCT01381172|Other|Control|The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.
3174046|NCT01381159|Experimental|Motivational Communication|Up to 3 x 30 minute brief MC sessions within 4-6 week period
3174047|NCT01381159|Placebo Comparator|Control|Usual care
3174048|NCT01381146|Experimental|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
3174049|NCT01381146|Other|TAU|treatment as usual -- participants have access to all other jail programs and services
3174050|NCT01381133|Experimental|CBOP without ACC|
3174051|NCT01381133|Experimental|CBOP with ACC|
3174052|NCT01381133|Experimental|MET/CBT 7 without ACC|
3174053|NCT01381133|Experimental|MET/CBT 7 with ACC|
3174054|NCT01381120|Experimental|VESIcare + Narcotic Painkiller|VESIcare: Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
3174063|NCT01381081|Experimental|platelet-rich plasma intra-articular knee injections|a single intra-articular injection of PRP in knee osteoarthritis
3174064|NCT01381081|Active Comparator|Corticosteroid intra-articular knee injections|a betamethasone and bupivacaine intra-articular injection
3174065|NCT01381068|Experimental|Monitored Arm|The end tidal CO2 sensor is placed in the respiratory circuit and the monitor is visible to the resuscitation team. The resuscitation team is instructed to adjust ventilation to keep EtCO2 levels between 40-55.
3174066|NCT01381068|Placebo Comparator|Control Arm|The end tidal CO2 sensor is placed in th respiratory circuit. The monitor is covered so the resuscitation team can not see the display. The resuscitation team is instructed to provide ventilation according to clinical judgment.
3174067|NCT01381055|Experimental|Pentoxifylline plus antimony|
3174068|NCT01381055|Placebo Comparator|Placebo plus antimony|
3174069|NCT01381029||HIV positive|HIV positive, receiving Influenza vaccine as standard of care.
3174070|NCT01381016|Other|Group 1 - Normal Weight|"Group 1: Normal weight (BMI 18-25 kg/m2)~Subjects were instructed to apply 0.1 mg/d transdermal estrogen (Estradiol) for one month. Pituitary response was assessed to determine how estradiol administration altered pituitary sensitivity to Gonadotropin-releasing hormone - GnRH. Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary."
3174071|NCT01381016|Experimental|Group 2 - Obese|"Group 2: Obese (BMI >30 kg/m2)~Subjects were instructed to apply 0.1 mg/d transdermal estrogen (Estradiol) for one month. Pituitary response was assessed to determine how estradiol administration altered pituitary sensitivity to Gonadotropin-releasing hormone - GnRH. Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary."
3174072|NCT01381003|Experimental|pCCLchimGp91s lentiviral vector transduced CD34+ cells|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
3174073|NCT01380990|Experimental|EF1αS-ADA lentiviral vector transduced patient Cd34+ cells|
3174074|NCT01380977|Experimental|Impact of Crime group intervention|
3174075|NCT01380977|Active Comparator|Treatment as usual|
3174076|NCT01380964||DMD patients|DMD Patients
3174077|NCT01380964||Control patients|Control patients
3174078|NCT01380951|Experimental|telbivudine|
3174079|NCT01380938|No Intervention|Arm C. Standard duration|"Patients will be randomly assigned in 3:3:1 ratio to three treatment arms. In the standard treatment group (Arm C), patients will be treated for 24 weeks independently of the HCV RNA status at week 4 with Peginterferon alpha-2a at a dose of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 800 mg/day.~Patients enrolled in Arm C will be treated for standard 24 weeks duration of treatment."
3174080|NCT01380938|Experimental|Arm A|"Patients enrolled in Arm A will receive Peginterferon alpha-2a at a dosage of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 1000 mg/day for patients with a body weight < 75 kg or 1200 mg/day for those with a body weight > 75 kg.~Patients with week 4 viral clearance (labelled as rapid virological responders, RVR) will be allocated to 12 week treatment duration (Arm A), whereas those without RVR will be treated for 24 weeks (Arm A)"
3174081|NCT01380938|Experimental|Arm B|"Patients enrolled in Arm B will receive Peginterferon alpha-2a at a dosage of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 800 mg/day.~Patients with week 4 viral clearance (labelled as rapid virological responders, RVR) will be allocated to 12 week treatment duration (Arm B), whereas those without RVR will be treated for 48 weeks (Arm B)"
3174082|NCT01380912||breast cancer|"Patients operated with mastectomy and axillary dissection, who are randomised to injection of methylprednisoloneacetate in the cavity~Patients operated with mastectomy and axillary dissection, who are randomised to injection of saline solution in the cavity~Patients operated with mastectomy and Sentinel Node Operation, who are randomised to injection of methylprednisoloneacetate in the cavity~Patients operated with mastectomy and Sentinel Node Operation, who are randomised to injection of saline solution in the cavity"
3174083|NCT01380899||PD alpha-synuclein|
3174084|NCT01380899||PPS alpha-synuclein|
3174085|NCT01380886|Experimental|Infant formula, alternate protein source|Experimental infant formula with alternate protein source
3174086|NCT01380886|Active Comparator|Infant formula powder|Infant formula powder
3174087|NCT01380873|Experimental|Group1|
3174088|NCT01380873|Experimental|Group2|
3174089|NCT01380873|Experimental|Group3|
3174090|NCT01380860|Experimental|Mesh|The patients allocated to this arm of the study will have mesh (Covidien France: mono filament polyester bidimensional knit) implanted in association with their colostomy.
3174091|NCT01380860|Active Comparator|No mesh|The patients allocated to this arm of the protocol will not receive mesh implantation with their colostomy.
3174092|NCT01380847||Renal allograft nephropathy|To evaluate urine from KTRs during the first year post-transplantation to assess whether mRNA levels of genes involved in EMT/fibrogenesis can diagnose and predict CAN, and identify patients at risk of chronic allograft dysfunction
3174093|NCT01380834|Active Comparator|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
3174094|NCT01380834|Placebo Comparator|Placebo group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
3174095|NCT01380821||SPECT|Patients clinically indicated to undergo myocardial SPECT in our institution.
3174096|NCT01380808|Experimental|experimental arm|capecitabine and pseudomonas aeruginosa combination
3174097|NCT01380795|Other|Circulating Tumor Cell|blood sample CTC monitoring and CTC EGFR/K-ras status determination
3174098|NCT01380782|Experimental|Bevacizumab Naive|Bevacizumab naive subjects
3174099|NCT01380782|Experimental|Prior Bevacizumab|Patients previously treated with bevacizumab
3174100|NCT01380769|Experimental|CRLX101|
3174101|NCT01380769|Other|Best supportive care|
3174102|NCT01380756|Experimental|Arm 1- Dose Escalation|The dose escalation will be conducted in 2 parts. Group 1 will consist of 8 cohorts and Group 2 will consist of 5 cohorts. The dose escalation is aimed at determining the maximum tolerated dose (MTD) of AMG 900.
3174247|NCT01379729|Active Comparator|Group B|Patients that are candidates for islet cell transplantation
3174103|NCT01380756|Experimental|Arm 2- Dose Expansion|The dose expansion part of the study will begin after completion of the dose escalation phase and will consist of 20 subjects with acute myelogenous leukemia.
3174104|NCT01380743|Experimental|Cohort 1, Duvoglustat 50 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 50 milligram (mg) oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
3174105|NCT01380743|Experimental|Cohort 2, Duvoglustat 100 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 100 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
3174106|NCT01380743|Experimental|Cohort 3, Duvoglustat 250 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 250 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
3174107|NCT01380743|Experimental|Cohort 4, Duvoglustat 600 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 600 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
3174108|NCT01380730|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
3174109|NCT01380730|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
3174110|NCT01380730|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3174111|NCT01380730|Experimental|Evolocumab 105 mg Q2W|Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3174112|NCT01380730|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3174113|NCT01380730|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3174114|NCT01380730|Experimental|Evolocumab 350 mg Q4W|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3174115|NCT01380730|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3174116|NCT01380717|Active Comparator|Standard treatment|Patients with CKD 3-4, hypertension, treated for 18 months with beta-blocker and if needed ACE-inhibitor or ARB.
3174117|NCT01380717|Active Comparator|Intensive vasodilation|Patients with CKD 3-4 and hypertension, randomized to treatment with calcium channel blocker and if needed ACE-inhibitor or ARB for 18 months
3174118|NCT01380704|Experimental|Active|
3174119|NCT01380704|Placebo Comparator|Placebo|
3174120|NCT01380691|Experimental|Sequence 1|Period 1: 18 mg LY2216684 administered orally once daily for 8 days. On day 6, participant will be administered 2 cups of alcohol containing beverage, to be taken orally one time. On day 8, participant will be administered 2 cups of Alcohol placebo containing beverage, to be taken orally, one time. There will be a 7 day washout period between periods 1 and 2. Period 2: LY2216684 Placebo administered orally once daily for 8 days. On day 6, participant will be administered 2 cups of alcohol containing beverage, to be taken orally one time. On day 8, participant will be administered 2 cups of Alcohol placebo containing beverage, to be taken orally, one time.
3174121|NCT01380691|Experimental|Sequence 2|Period 1: LY2216684 Placebo administered orally once daily for 8 days. On day 6, participant will be administered 2 cups of alcohol containing beverage, to be taken orally one time. On day 8, participant will be administered 2 cups of Alcohol placebo containing beverage, to be taken orally, one time. There will be a 7 day washout period between periods 1 and 2. Period 2: 18 mg LY2216684 administered orally once daily for 8 days. On day 6, participant will be administered 2 cups of alcohol containing beverage, to be taken orally one time. On day 8, participant will be administered 2 cups of Alcohol placebo containing beverage, to be taken orally, one time.
3174122|NCT01380691|Experimental|Sequence 3|Period 1: 18 mg LY2216684 administered orally once daily for 8 days. On day 6, participant will be administered 2 cups of Alcohol placebo containing beverage, to be taken orally one time. On day 8, participant will be administered 2 cups of alcohol containing beverage, to be taken orally, one time. There will be a 7 day washout period between periods 1 and 2. Period 2: LY2216684 Placebo administered orally once daily for 8 days. On day 6, participant will be administered 2 cups of Alcohol placebo containing beverage, to be taken orally one time. On day 8, participant will be administered 2 cups of alcohol containing beverage, to be taken orally, one time.
3174123|NCT01380691|Experimental|Sequence 4|Period 1:LY2216684 Placebo administered orally once daily for 8 days. On day 6, participant will be administered 2 cups of Alcohol placebo containing beverage, to be taken orally one time. On day 8, participant will be administered 2 cups of alcohol containing beverage, to be taken orally, one time. There will be a 7 day washout period between periods 1 and 2. Period 2: 18 mg LY2216684 administered orally once daily for 8 days. On day 6, participant will be administered 2 cups of Alcohol placebo containing beverage, to be taken orally one time. On day 8, participant will be administered 2 cups of alcohol containing beverage, to be taken orally, one time.
3174124|NCT01380678|Active Comparator|bevacizumab|intralesional bevacizumab injection
3174125|NCT01380678|Active Comparator|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
3174126|NCT01380665|Other|There is one group of 100 patients|50 of these patients will receive a total hip replacement; 50 patients will receive a total knee replacement;
3174127|NCT01380652|Experimental|rehabilitation with vibration training|
3174128|NCT01380652|No Intervention|rehabilitation without vibration training|
3174129|NCT01380639|Experimental|Rehabilitation with vibration training|
3174130|NCT01380639|No Intervention|Rehabilitation without vibration training|
3174131|NCT01380626|Experimental|exercise training|
3174132|NCT01380613|Active Comparator|Workshop Control|Participants receive HIV/STDs risk reduction information.
3174248|NCT01379703||Single patients group|Single HIV-1 infected patients group
3174133|NCT01380613|Experimental|Intervention Workshop|Participants learn skills to cope with depressive symptoms and stress as well as safer sex and injection skills.
3174134|NCT01380600|Other|single arm; Dose escalation|Dose escalation 1e6 pfu/kg bw, 1e7 pfu/kg bw, 3e7 pfu/kg bw of Recombinant Vaccinia GM-CSF JX-594
3174135|NCT01380587||Acute Lymphoblastic Leukemia|We will invite patients with newly diagnosed acute lymphoblastic leukemia in the Department of Hematology, who had not received anticancer therapy and regardless the subtype and immunophenotype of the disease.
3174136|NCT01380561|Experimental|Single Arm Study|asimadoline
3174137|NCT01380548|Placebo Comparator|Placebo|
3174138|NCT01380548|Placebo Comparator|Iron alone|
3174139|NCT01380548|Experimental|Low-dose 5-aminolevulinic acid|
3174140|NCT01380548|Experimental|Medium-dose 5-aminolevulinic acid|
3174141|NCT01380548|Experimental|High-dose 5-aminolevulinic acid|
3174142|NCT01380535|Experimental|ECP+Corticosteroids+Cyclosporine or Tacrolimus|ECP UVADEX dose (TBD) administered during Wks 2-10 (2x/wk), Wks 11-18 (2x/wk every 2 wks), and Wks 19-26 (2x/wk every 4 wks) along with corticosteroids at a dose of 1.0 mg/kg prednisone, or equivalent, daily, tapered to 0.125 mg/kg daily by Wk 24 and maintained at that dose until Wk 28.
3174143|NCT01380535|Active Comparator|Corticosteroids/Cyclosporine/Tacrolimus|1.0 mg/kg prednisone, or equivalent, daily, tapered to 0.125 mg/kg daily by Wk 24 and maintained at that dose until Wk 28 administered with cyclosporine or Tacrolimus (dose of cyclosporine and Tacrolimus should be consistent with local institutional practice).
3174144|NCT01380522|Experimental|A|Subjects received kali product under fed conditions
3174145|NCT01380522|Active Comparator|B|Subjects received Searle product under fed conditions
3174146|NCT01380509|Experimental|A|Subjects received kali product under fasting conditions
3174147|NCT01380509|Active Comparator|B|Subjects received Searle product under fasting conditions
3174148|NCT01380496|Active Comparator|B|Subjects received the Oclassen Pharmaceuticals Inc. formulated product.
3174149|NCT01380496|Active Comparator|C|Subjects received the Oclassen Pharmaceuticals Inc. formulated product.
3174150|NCT01380496|Experimental|A|Subjects received the Par formulated product
3174151|NCT01380483|Experimental|A|Subjects received the Par formulated product
3174152|NCT01380483|Active Comparator|B|Subjects received the Oclassen Pharmaceuticals formulated product.
3174153|NCT01380470||Chronic Obstructive Pulmonary Disease|Group of patients seen in consultation not previously diagnosed with COPD, both sexes, aged between 40 and 70 years.
3174154|NCT01380457|Experimental|A|Subjects received the test formulated product manufactured by Pharmaceutics International, Inc. and marketed by Par Pharmaceutical, Inc. under fasting conditions
3174155|NCT01380457|Active Comparator|B|Subjects received the reference listed drug manufactured by Banner Pharmacaps, Inc. and marketed by Unimed Pharmaceutical, Inc.
3174156|NCT01380444|Active Comparator|1|Gamma3 Intramedullary Nails
3174157|NCT01380444|Active Comparator|2|Sliding Hip Screws
3174158|NCT01380431|Experimental|A|Subjects received the Par formulated product.
3174159|NCT01380431|Active Comparator|B|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
3174160|NCT01380431|Active Comparator|C|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
3174161|NCT01380418||Study group|Obese BMI>30 18-85 years old
3174162|NCT01380405|No Intervention|without health education|the normal practices without specific intervention
3174163|NCT01380405|Experimental|individual health education|"The study intervention is an individual education in the correct use of inhalers and it will be carried out in so-called inhalation workshops. The room in which the inhalation workshop will be located has to meet the necessary comfort conditions for the patient to feel relaxed and be able to carry out learning. The lesson included inhalation devices, explanatory leaflets"
3174164|NCT01380405|Experimental|health education group|"The study intervention is education in group in the correct use of inhalers and it will be carried out in so-called inhalation workshops. The room in which the inhalation workshop will be located has to meet the necessary comfort conditions for the patient to feel relaxed and be able to carry out learning. In addition to the necessary furniture and teaching material that will be required (slide projector, over-head-projector, projection screen, video, etc.), the physical space given over to this purpose should consist of an area in which material can be left which will be used to complete the teaching and patient information (inhalation devices, explanatory leaflets, small monographs, slides, etc.)."
3174165|NCT01380379|Experimental|Life skills and self-defense training|Women will participate in a therapeutic group which covers education, skills, and empowerment activities.
3174166|NCT01380366|Other|Patients consent to rHGH study|Patients consent to be given growth hormone (rHGH) for their short bowel syndrome.
3174167|NCT01380353|Experimental|Breast Group|Diclofenac epolamine patch applied to the breast
3174168|NCT01380353|Experimental|Abdomen Group|Diclofenac epolamine patch applied to the abdomen
3174169|NCT01380340|Experimental|Seniors early intervention driving group|The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
3174170|NCT01380340|No Intervention|Matched comparison group|The subjects will be recruited from a parallel service and will be paired with similar subjects in the experimental group.
3174171|NCT01380327|Experimental|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Glycerinated German cockroach (Blatella germanica) allergen extract administered sublingually with a maximally tolerated dose of 420 microliters daily
3174172|NCT01380327|Placebo Comparator|Placebo|Placebo administered sublingually not to exceed the maximally tolerated dose of either 1.) 420 microliters daily (placebo - low dose randomization) or 2.) 840 microliters twice daily (placebo - high dose randomization)
3174173|NCT01380327|Experimental|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Glycerinated German cockroach (Blatella germanica) allergen extract administered sublingually with a maximally tolerated dose of 840 microliters taken twice daily
3174174|NCT01380314|Experimental|1|Miltefosine 150 mg x day + Imiquimod 5%
3174175|NCT01380314|Placebo Comparator|2|Miltefosine 150 mg x day + Placebo
3174176|NCT01380301|Experimental|Miltefosine and Antimony|Miltefosine 1,5 to 2,5 mg x k x d during 14 days simultaneously with meglumine antimoniate 20 mg x kg x d during 10 days
3174177|NCT01380301|Active Comparator|Miltefosine alone|Miltefosine 1,5 to 2,5 mg x kg x d during 14 days
3174178|NCT01380288|Active Comparator|without white matter change|
3174179|NCT01380288|Active Comparator|with white matter change group|
3174180|NCT01380275|Experimental|Docetaxel and Irinotecan (DI)|"Combination chemotherapy of Docetaxel and Irinotecan (DI) in recurrent or refractory bone and soft tissue sarcomas.~Docetaxel and Irinotecan (DI) have different biologic targets, mode of action and mechanism of resistance. Preclinical studies have demonstrated an additive or synergistic effect of irinotecan and taxanes when used in combination in human.~Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1 Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8 Therapy consists of 3-week cycles comprising weekly treatment for 2 weeks (docetaxel on D1 and irinotecan on D1 and D8) followed by 1-week rest, and will be continued in the absence of disease progression or unacceptable toxicity."
3174181|NCT01380262||Low Dose Doxycycline|Patients with metastatic colorectal cancer, qualified to either cetuximab or panitumumab based systemic treatment (either monotherapy or with chemotherapy) receiving a 100 mg of doxycycline daily
3174182|NCT01380249|Experimental|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12 mg, 2.24 mg, 3.5 mg and 14 mg, 28 mg and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or the patient is refractory to it.
3174183|NCT01380223|Experimental|Dose-escalation Cohort 1|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
3174184|NCT01380223|Experimental|Dose-escalation Cohort 2|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
3174185|NCT01380223|Experimental|Dose-escalation Cohort 3|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
3174186|NCT01380223|Experimental|Dose-escalation Cohort 4|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
3174187|NCT01380197|Active Comparator|Randomizing particiipants to Morphine|Randomizing participants to Morphine or Nubain for treatment of Sickle Cell Pain Crisis
3174188|NCT01380197|Active Comparator|Randomization to Nubain|Randomization toNubain or Morphine for the management of Pain Crisis in Sickle Cell patients
3174189|NCT01380184|Experimental|Ridaforolimus 40 mg|
3174190|NCT01380171||Cleft lip/palate|Patients who have had surgical intervention for cleft lip/palate since 1998 at Children's Healthcare of Atlanta at the Center for Craniofacial Disorders
3174191|NCT01380158|Experimental|Pessary use during pregnancy|Device: Cup pessary
3174192|NCT01380158|No Intervention|Expectant management|Expectant Management + weekly intramuscular progesterone injections
3174193|NCT01380145|Experimental|recMAGE-A3 Protein + AS15 Adjuvant|Subjects received a total of 8 pre- and post-auto-SCT immunizations with recMAGE-A3 + AS15.
3174194|NCT01380132|Experimental|Anal injection of Nasha Dx|
3174195|NCT01380119|Experimental|V7|Oral pill containing heat-killed Mycobacterium vaccae
3174196|NCT01380119|Placebo Comparator|Placebo pill|Identically appearing placebo pills
3174197|NCT01380106|Active Comparator|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
3174198|NCT01380106|Active Comparator|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15mg once daily for days 1-21 out of a 28 cycle
3174199|NCT01380093|Placebo Comparator|Placebo|
3174200|NCT01380093|Active Comparator|MS Contin (morphine sulfate, controlled release)|
3174201|NCT01380093|Experimental|EMBEDA (morphine sulfate / naltrexone hydrochloride)|
3174202|NCT01380080|Experimental|Arm A: Empiric|Study treatment for Arm A participants is the strategy of initiating study-provided or other FDA-approved or tentatively approved antiretroviral treatment as soon as possible following randomization and within no more than 3 days following randomization plus a 4-drug anti-tuberculosis treatment (ATT) regimen (defined as rifampin/isoniazid/ethambutol/pyrazinamide) as soon as possible following randomization and within no more than 7 days following initiation of antiretroviral therapy. After 2 months (or 8 weeks), the 4-drug ATT will be followed with 4 months (or 16 weeks) of 2-drug ATT (defined as rifampin/isoniazid). All participants will be followed through week 96. Drug provision by or through the study will be through week 48 only
3174203|NCT01380080|Experimental|Arm B: IPT|Study treatment for Arm B participants is the strategy of initiating study-provided or other FDA-approved or tentatively approved antiretroviral therapy as soon as possible following randomization and within no more than 3 days following randomization and of initiating anti-TB treatment (ATT) only when indicated according to local standard practice and at the discretion of the site investigator. All participants will be followed through week 96. Drug provision by or through the study will be through week 48 only. Pyridoxine is provided by the sites to all participants while they are receiving isoniazid (INH).
3174204|NCT01380067||Group A|the patients were subjected laparoscopic purse-string knot for closing the internal hernia opening
3174205|NCT01380067||Group B|the lateral umbilicus ligament was used to cover the internal hernia opening after the laparoscopic purse-string knot
3174206|NCT01380054||patients with pulmonary hypertension|
3174207|NCT01380028|Placebo Comparator|placebo|The aim of this prospective multicenter randomized, double blind, is to evaluate in patients with chronic subdural hematoma, compared with placebo, the efficacy of postoperative corticosteroid treatment orally for approximately 2 months on the rate of clinical recurrence
3175930|NCT01368055|Experimental|Intermediate Risk|72.5 Gy/CGE
3174208|NCT01380028|Active Comparator|oral corticosteroids|The aim of this prospective multicenter randomized, double blind, is to evaluate in patients with chronic subdural hematoma, compared with placebo, the efficacy of postoperative corticosteroid treatment orally for approximately 2 months on the rate of clinical recurrence
3174209|NCT01380015|Placebo Comparator|Placebo Control|Participants will consume two cups of commercial spearmint tea per day (300 mL in the morning and 300 mL in the evening, providing a total of approximately 20 mg of rosmarinic acid per day) for a total of 4 months.
3174210|NCT01380015|Experimental|Experimental|Participants will consume two cups of a high rosmarinic acid spearmint tea per day (300 mL in the morning and 300 mL in the evening, providing a total of approximately 300 mg of rosmarinic acid per day) for a total of 4 months.
3174211|NCT01379989|Active Comparator|Carboplatin plus PLD|Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/ m2 followed by carboplatin AUC 5.
3174212|NCT01379989|Experimental|Trabectedin plus PLD|Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/m2 infusion followed by trabectedin 1.1 mg/m2 infusion.
3174213|NCT01379976|Placebo Comparator|CHT cisplatin containing + placebo|
3174214|NCT01379976|Experimental|CHT cisplatin containing + acetyl-L-carnitina|
3174215|NCT01379963||Cohort|
3174216|NCT01379950||periodontitis|patients diagnosed with periodontal disease
3174217|NCT01379937|Experimental|GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group|Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
3174218|NCT01379937|Experimental|GSK1562902A Formulation 1 - Havrix / Havrix Jr Group|Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
3174219|NCT01379937|Active Comparator|GSK1562902A Formulation 2 - Havrix / Havrix Jr Group|Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
3174220|NCT01379937|Active Comparator|Havrix / Havrix Jr Group|Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
3174221|NCT01379924|Experimental|Non Randomized|These are those mothers in the group who choose not to be randomized into the study, or the fathers who participate who are not randomized into the study.
3174222|NCT01379924|Experimental|Modules|Patient takes part in 5 one on one modules during the first year of child's life aimed at educational attainment, budgeting, child development, safety in the home and substance abuse.
3174223|NCT01379924|Experimental|Control|
3174224|NCT01379911|Active Comparator|Yogurt with added inulin|Yogurt with 6g of added inulin
3174225|NCT01379911|Placebo Comparator|Regular yogurt|Regular yogurt without added inulin
3174226|NCT01379898|Active Comparator|Phenoxybezamine|Phenoxybenzamine (capsules 10 mg, once to twice daily) is administered orally, starting 2-3 weeks before planned resection of PCC.
3174227|NCT01379898|Active Comparator|Doxazosin|Phenoxybenzamine (slow release tablets 4 or 8 mg, once to twice daily) is administered orally, starting 2-3 weeks before planned resection of PCC.
3174228|NCT01379885|Active Comparator|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
3174229|NCT01379885|Experimental|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
3174230|NCT01379872||Study Protocol A - IMRT Post Prostatectomy|"Prospective TROG 08.03 (RAVES) Participants~Prospective Participants (NOT participating in TROG 08.03 (RAVES))~Retrospective TROG 08.03 (RAVES) Participants~Participating in dosimetric evaluation and toxicity/QoL study~Participating in dosimetric evaluation only"
3174231|NCT01379872||Study Protocol B - IMRT Anal Cancer|"Retrospective Patient Datasets~Prospective Participants (dosimetric evaluation and toxicity/QoL study)"
3174232|NCT01379872||Study Protocol C - IMRT Nasopharynx|"Retrospective Patient Datasets~Prospective Participants (dosimetric evaluation and toxicity/QoL study)~Post-Treatment Prospective Participants (toxicity/QoL and cost study)"
3174233|NCT01379872||Study Protocol D - IGRT Intact Prostate|"Patients with prostate cancer~- A sample of 30 patients from at least 10 centres that are to be treated for intermediate risk prostate cancer will be enrolled. The sample will be selected to comprise at least 10 patients that will undergo non-IGRT, 10 that will undergo IGRT with fiducials and planar imaging, and 10 that will undergo IGRT with volumetric imaging."
3174234|NCT01379846|Experimental|TAK-816|
3174235|NCT01379846|Active Comparator|ActHIB|
3174236|NCT01379833||Subjects|Subjects are patients with CIDP
3174237|NCT01379833||Controls|Controls are age-matched people without CIDP
3174238|NCT01379807|Experimental|panitumumab + docetaxel + cisplatino|
3174239|NCT01379781|Experimental|Behavioral Intervention for PPD|Behavioral Intervention for PPD delivered over 3 in-person sessions.
3174240|NCT01379781|No Intervention|Treatment As Usual|Referred to Treatment in the Community.
3174241|NCT01379768|Active Comparator|Lotrafilcon A|Lotrafilcon A contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon A contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
3174242|NCT01379768|Active Comparator|Lotrafilcon B|Lotrafilcon B contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon B contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
3174243|NCT01379768|No Intervention|No lens wear|No contact lens wear for the duration of the study. One 8-hour sleep at 1 week, followed by an 8-hour sleep 4 weeks later.
3174244|NCT01379742|Active Comparator|Iodine-125 standard 18 g needle|Rapidstrand
3174245|NCT01379742|Active Comparator|20 g needle|Thin Strand
3174246|NCT01379729|Active Comparator|Group A|Patients with loss of long-term function after intraportal implantation
3174249|NCT01379690||Control|Controls were selected from patients with diabetes on consultation during the year 2005-2010 in specialist clinic, without a previous hip fracture. There was no followup period for these patients. Instead the A1C value upon the point of consultation was used to reflect glycaemic control at the point of consultation
3174250|NCT01379690||Case|All patients with treated diabetes admitted with primary diagnosis hip fractures from 2005-2010 to Changi General Hospital was included in the study. The A1C at the point of admission was used to reflect the glycaemic control at that point in time. This was a retrospective study and there was no subsequent follow up on patients after the point of admission
3174251|NCT01379677|Other|Single arm|This is an Head to Head Comparison between Rubidium-82 PET and Tc-99m-MIBI SPET with CTA as gold standard. All the patients will undergo the three imaging protocols.
3174252|NCT01379664|Experimental|Isoflurane|Isoflurane is to be administered to patients in this arm during surgery
3174253|NCT01379664|Experimental|Sevoflurane|Sevoflurane is to be administered to patients in this arm during surgery
3174254|NCT01379651|Experimental|Specific oral tolerance induction|Specific oral tolerance induction consisted in the administration of increasing amounts of food antigen
3174255|NCT01379651|No Intervention|control|controls were kept on an egg-free diet for 6 months
3174256|NCT01379638||cardiac output|Adult patients undergoing cardiac surgery with normothermic cardiopulmonary bypass
3174257|NCT01379625|Active Comparator|Medium Chain Triglyceride (MCT)|Subjects randomized to consume 20% of energy from MCT
3174258|NCT01379625|Experimental|Triheptanoin|Subject randomized to consume 20% of energy from triheptanoin.
3174259|NCT01379612||Rectal cancer patients in chemoradiation|
3174260|NCT01379599|Experimental|Brief motivation intervention|Brief motivation intervention was implemented with enrollees identified with heroin and cocaine use who were allocated to the experimental group. The aim was to test the ability of a peer-delivered intervention to reduce risk of HIV and STIs related to sexual behaviors (condom use and sex while high on drugs.
3174261|NCT01379599|No Intervention|control group|Care as usual.
3174262|NCT01379586|Experimental|E|ONO-4053
3174263|NCT01379586|Placebo Comparator|P|Placebo
3174264|NCT01379573|Experimental|Pregnant women with previous child with cardiac neonatal lupus|400 mg/day Hydroxychloroquine
3174265|NCT01379560|Experimental|unoprostone isopropyl (2 drop)|
3174266|NCT01379560|Experimental|unoprostone isopropyl (3 drop)|
3174267|NCT01379547|Active Comparator|Conventional Treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice
3174268|NCT01379547|Experimental|procalcitonin-guided antibiotics treatment|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin-guided algorithm.
3174269|NCT01379534|Experimental|TKI258|1 treatment arm (single agent TKI258), with patients classified into 2 groups based on their FGFR2 mutation status
3174270|NCT01379521|Experimental|everolimus + TACE|everolimus 7.5mg/day by mouth + transcatheter arterial chemoembolization (TACE)
3174271|NCT01379521|Placebo Comparator|placebo + TACE|Placebo by mouth + transcatheter arterial chemoembolization (TACE)
3174272|NCT01379508|Experimental|Arm 1|
3174273|NCT01379508|Active Comparator|Arm 2|
3174274|NCT01379495|No Intervention|Usual Care|Burns victims will receive information according to the service routine
3174275|NCT01379495|Experimental|educational program+telephone follow up|Burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
3174276|NCT01379482|Experimental|Multimodal treatment|Neoadjuvant systemic chemotherapy followed by cytoreductive surgery, hyperthermic intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy
3174277|NCT01379469|Active Comparator|Drug-Carbamazepine (Tegretol XR)|One arm receives Drug-Carbamazepine (Tegretol XR).All subjects have severe liver disease due to alpha-1-antitrypsin deficiency.
3174278|NCT01379469|Placebo Comparator|Drug-Carbamazepine (Tegretol XR) Placebo|One arm receives Carbamazepine (Tegretol-XR) placebo.All subjects have severe liver disease due to alpha-1-antitrypsin deficiency.
3174279|NCT01379456|Experimental|physiotherapy|exercises
3174280|NCT01379456|No Intervention|conventional treatment|care as usual
3174281|NCT01379443|Active Comparator|Parental reports of their children|Parental report of family-centered processes of care (MPOC) Parent mental health Parent perceived social support
3174282|NCT01379443|No Intervention|Integration of service provider teams|Network co-alition teams were measured using the Integration of Human Services Measure, the Partnership Synergy Measure and a Network Capacity Measure were employed at the CEO level.
3174283|NCT01379430|Experimental|Group 1|Intramuscular arm
3174284|NCT01379430|Experimental|Group 2|Intradermal arm
3174285|NCT01379417|Placebo Comparator|Maltodextrin|Maltodextrin
3174286|NCT01379417|Active Comparator|Probiotic B lactis/B longum|Bifidobacterium lactis + Bifidobacterium longum
3174287|NCT01379417|Active Comparator|Probiotic B longum|Bifidobacterium longum
3174288|NCT01379417|Active Comparator|Probiotic B lactis|Bifidobacterium lactis
3174289|NCT01379391|Active Comparator|TPO|Patients received myeloablative Allo-HSCT with platelet lower than 20G/L on +14d post-transplantation. Patient enrolled in TPO arm will recieved Recombinant Human Thrombopoietin (rHTPO) treatment fro 14 days.
3174290|NCT01379391|No Intervention|TPO-Free Arm|No TPO intervention
3174291|NCT01379365|Experimental|Treatment|
3174292|NCT01379352||High MELD group|Preoperative MELD score greater than 20
3174293|NCT01379352||Low MELD group|Preoperative MELD score lesser than 20
3174294|NCT01379339|Experimental|Cabazitaxel 10mg/m2|"Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
3174334|NCT01379053||Staphylococcus Patients|Patients suspected of having Methicillin-resistant and/or methicillin-susceptible staphylococcus aureus.
3174335|NCT01379053||Control|Healthy volunteer
3174295|NCT01379339|Experimental|Cabazitaxel 12.5mg/m2|"Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
3174296|NCT01379339|Experimental|Cabazitaxel 15mg/m2|"Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
3174297|NCT01379339|Experimental|Cabazitaxel 17.5mg/m2|"Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
3174298|NCT01379339|Experimental|Cabazitaxel 20mg/m2|"Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
3174299|NCT01379326|Experimental|Mebendazole|
3174300|NCT01379313|Active Comparator|1:2 group|conventional I:E ratio group, inspiratory time : expiratory time = 1:1
3174301|NCT01379313|Experimental|1:1 group|1:1 I:E ratio group, inspiratory time : expiratory time = 1:1
3174302|NCT01379313|Experimental|2:1 group|inverse ratio group, inspiratory time : expiratory time = 2:1
3174303|NCT01379313|Active Comparator|1:2 PEEP group|I:E ratio of 1:2 with external PEEP of 5 cm H2O
3174304|NCT01379300|Experimental|Dabigatran|Single 150-mg dose of dabigatran etexilate
3174305|NCT01379300|Experimental|Rivaroxaban|Single 20-mg dose of rivaroxaban
3174306|NCT01379300|No Intervention|No intervention|No study drug will be administered
3174307|NCT01379287|Experimental|Patients with Advanced Solid Tumors|The trial was initially designed as a 3 hour IV infusion of iso-fludelone every 3 weeks with three dose-escalation stages (12 patients), however it has been amended to study iso-fludelone administered over 6 hours (+/- 30 minutes) every 3 weeks schedule.
3174308|NCT01379274|Experimental|lenalidomide and azacitidine combination|Lenalidomide and azacitidine combination to be utilized in patients who did not respond to 3 months of lenalidomide monotherapy.
3174309|NCT01379261|Active Comparator|Hypothermia treatment|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
3174310|NCT01379261|No Intervention|Standard treatment|Standard treatment
3174311|NCT01379248|Experimental|thrombus aspiration|Manual thrombus aspiration with dedicated catheter (Export, Medtronic Inc. Minneapolis, Minnesota, USA)
3174312|NCT01379248|No Intervention|no thrombus aspiration|
3174313|NCT01379235|Experimental|Intervention group|Intervention group: will receive 12 weeks of pilatis exercise 3 times a week.
3174314|NCT01379235|Other|control group|The control group will be offered the same intervention (pilatis exercise) at the end of the study period.
3174315|NCT01379222|Experimental|ENGAGE PAS De Novo Subjects|The Endurant Stent Graft System Bifurcated device is administered to patients diagnosed with an abdominal aortic or aortoiliac aneurysm who are considered candidates for endovascular repair, per the FDA approved Instructions For Use (IFU).
3174316|NCT01379209|Experimental|RGI-2001|Dose escalation group in part 1 of this study will include 3 to 6 patients each group and up to 7 dose groups. In part 2 of this study the best dose or doses determined from part 1 will be administered in up to 30 persons.
3174317|NCT01379196|Experimental|Azithromycin PO three times weekly|Tablets Azithromycin 500 mg PO three times weekly for three months
3174318|NCT01379183|Active Comparator|Erythromycin|Erythromycin 200 mg i.v. suspension, Barium Sulfate Solution, and Magnetic Resonance Imaging
3174319|NCT01379183|Placebo Comparator|Placebo|Matching placebo i.v. suspension, Barium Sulfate Solution, and Magnetic Resonance Imaging
3174320|NCT01379170|Experimental|Type 2 diabetes, de novo hypothyrodism treatment|Type 2 diabetic patients with de novo hypothyroidism will be included in this arm and will receive 3 months of treatment with Euthyrox (standard protocol).
3174321|NCT01379157|Active Comparator|Conventional arm|Infusion of 0.5 g of imipenem for 0.5 hr every 6 hr for 3-5 days
3174322|NCT01379157|Experimental|Extended infusion arm|Infusion of 1 g of imipenem for 4 hr every 8 hr for 3-5 days
3174323|NCT01379144|Experimental|latanoprost 75 ug|
3174324|NCT01379144|Experimental|latanoprost 100 ug|
3174325|NCT01379144|Experimental|latanoprost 125 ug|
3174326|NCT01379144|Active Comparator|latanoprost 50 ug|
3174327|NCT01379131||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
3174328|NCT01379105|Other|electromyography|The electrical activity of the femoral bicep muscle of the right thigh was recorded by a four channel EMG system with using superficial bipolar active electrodes (pre-amplified) with acquisition software and signal processing. The sampling frequency was 2,000 Hz, and the amplifier had a high-pass filter at 20 Hz and a low-pass filter at 500 Hz; a 12-bit analogical converter and computer completed the system
3174329|NCT01379092|Experimental|Breast biopsy specimen imaging & comparison of image quality|Each subject's explanted tissue will serve as both the control (standard analysis) and the experimental analysis of the quality of the images.
3174330|NCT01379079|Experimental|aspirin at bedtime|
3174331|NCT01379079|Active Comparator|aspirin on awakening|
3174332|NCT01379066||Tuberculosis Patients|Suspected Tuberculosis patients
3174333|NCT01379066||Control|Healthy volunteers
3174336|NCT01379040||Cystic Fibrosis Patients|Patients with Cystic Fibrosis, some having Pseudomonas aeruginosa, some not.
3174337|NCT01379040||Control|Healthy volunteers
3174338|NCT01379027|No Intervention|a treatment as usual (TAU) control condition|Participants will receive recruitment information, go on the study website to enroll and complete assessments over the study web site but will not receive the study intervention.
3174339|NCT01379027|Experimental|Pure self-help Internet CBT for depression|Participants will receive TAU plus access to the study website for the self-help Internet CBT for depression, consisting of access to the Internet site without any contact with therapist
3174340|NCT01379027|Experimental|Guided self-help Internet CBT|Participants will receive TAU plus Guided self-help Internet CBT, consisting of access to the Internet site plus brief, periodic telephone contacts with therapists
3174341|NCT01379027|Experimental|Stepped-Care Internet CBT condition|This consists of a Stepped-Care Internet CBT condition, starting with TAU + Pure self-help CBT and progressing to Guided self-help CBT if adequate progress is not observed early on
3174342|NCT01379014|Experimental|Decision Aid Tool|Intervention group - receives the decision aid tool in booklet form and is introduced to it by an investigator.
3174343|NCT01379014|No Intervention|Control|The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
3174344|NCT01379001|Experimental|Young|Young healthy controls, aged 21-35
3174345|NCT01379001|Experimental|Older|Older healthy controls, aged 65-80
3174346|NCT01378988|Experimental|Dose level 1|Dexmedetomidine 0.7 mcg/kg loading dose and 0.5 mcg/kg/hr maintenance infusion
3174347|NCT01378988|Experimental|Dose level 2|Dexmedetomidine 1.0 mcg/kg loading dose and 0.75 mcg/kg/hr maintenance infusion
3174348|NCT01378975|Experimental|Cohort 1: Previously Untreated Participants|Participants who had not received previous treatment for brain metastases [i.e., had never received brain stereotactic radiotherapy (SRT), whole-brain radiotherapy (WBRT), surgery, or any other treatment for their brain metastases] received Vemurafenib 960 milligram (mg) tablet orally, twice daily (BID) from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant's safety, death, reasons deemed by the investigator, or study termination by the Sponsor.
3174349|NCT01378975|Experimental|Cohort 2: Previously treated Participants|Participants who were previously treated with brain SRT, WBRT, or surgery for their brain metastases and have progressed following this treatment, received Vemurafenib 960 milligram (mg) tablet orally, BID from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant's safety, death, reasons deemed by the investigator, or study termination by the Sponsor.
3174350|NCT01378962|Experimental|Single Arm|
3174351|NCT01378949|Active Comparator|PsCB Group|Ultrasound-Guided Psoas Compartment Block will be used in patients for pain relief after THA
3174352|NCT01378949|Active Comparator|FICB Group|Ultrasound-Guided Fascia Iliaca Compartment Block will be used in patients for pain relief after THA
3174353|NCT01378949|Active Comparator|Patient-Controlled Analgesia|Patient-controlled analgesia will be used for pain relief after THA
3174354|NCT01378936|Experimental|MI plus IOC group intervention|
3174355|NCT01378936|Experimental|Motivational Interview only|
3174356|NCT01378923|Experimental|Values-based mindfulness group|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
3174357|NCT01378923|Other|Treatment as usual|has access to standard jail interventions and programs
3174358|NCT01378910|Experimental|Change of 3rd drug to maraviroc|Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
3174359|NCT01378884|Experimental|Domeperidone|Patients to receive Domperidone for treatment of Gastroparesis
3174360|NCT01378871|Experimental|Anitbody Therapy|Treatment with Imtox-25 intravenously over 4 hours every other day for 4 doses. Hospital admission is required during this treatment.
3174361|NCT01378858|Experimental|Varenicline treatment as usual (TAU)|Subjects in the TAU arm will self administer varenicline for 12 weeks.
3174362|NCT01378858|Experimental|Varenicline directly observed therapy|Subjects in the directly observed therapy (DOT) arm will receive varenicline directly administered by methadone clinic nurses 4-6 times per week at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.
3174363|NCT01378845|Placebo Comparator|Prostavasin|
3174364|NCT01378845|Active Comparator|Prostavasin + Bosentan|
3174365|NCT01378806|Experimental|Intervention|A 12-week intensive intervention on nutrition and exercise education and coping skills training (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
3174366|NCT01378793|No Intervention|Standard of Care|Participants will be asked to continue doing whatever their healthcare providers advise for their insomnia, but not to start any new treatments during the study. They will also be given a sleep hygiene handout as a standard of care. After six weeks, they will be reassessed and then provided the opportunity to engage in the web-based acupressure intervention.
3174367|NCT01378793|Active Comparator|Relaxation Acupressure|In addition to being given a sleep hygiene handout as a standard of care, participants will be asked to apply pressure on each of following points (bilaterally where indicated). There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes done once daily.
3174368|NCT01378793|Active Comparator|Stimulating Acupressure|In addition to being given a sleep hygiene handout as a standard of care, participants will be asked to apply pressure on each of following points (bilaterally where indicated). There are 6 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 10 points to stimulate. Each of the 10 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 30 minutes done once daily.
3174369|NCT01378780|Active Comparator|Intervention for diet, exercise|This group will receive the educational intervention for healthy diet and increased physical activity
3174460|NCT01378052||urothelial carcinoma pateints|
3176250|NCT01365663|Experimental|Cohort 3|1.0 mg/kg in Healthy Subjects
3174370|NCT01378780|Other|Control|This group will get a skin cancer awareness educational message. At the end of the study this group will also receive the diet and exercise intervention but outcomes will not be measured after the crossover.
3174371|NCT01378767|Active Comparator|Krill oil capsules|Two grams per day daily for 21 days
3174372|NCT01378767|Placebo Comparator|Coconut oil capsules|Two grams per day for 21 days
3174373|NCT01378754|Experimental|6.5 milligram per kilogram of Fospropofol (Lusedra®)|
3174374|NCT01378754|Experimental|10 milligram per kilogram of Fospropofol (Lusedra®)|
3174375|NCT01378754|Experimental|12 milligram per kilogram of Fospropofol (Lusedra®)|
3174376|NCT01378741|Active Comparator|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
3174377|NCT01378741|Active Comparator|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
3174378|NCT01378728||Patients with chronic or acute wounds.|Patients with chronic or acute wounds.
3174379|NCT01378715|Active Comparator|Rosuvastatin|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
3174380|NCT01378715|No Intervention|Control|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to no-pretreatment with rosuvastatin.
3174381|NCT01378702|Experimental|Iscucin populi strength F, G and H|1 ampoule two times/week subcutaneously. Week 1-4: strength F. Week 5-8: strength G. Week 9-12: strength H.
3174382|NCT01378702|Experimental|Viscum Mali e planta tota D3, D2, 2%|1 ampoule two times a week subcutaneously. Week 1-4: D3. Week 4-8: D2. Week 9-12: 2%.
3174383|NCT01378702|Placebo Comparator|Placebo|1 ampoule two times a week subcutaneously
3174384|NCT01378689|Experimental|Online video|Participants in this arm are shown a brief video (~5 minutes) after ordering a refill for their glucocorticoid use. The video includes real patients telling their own story about the possible side effects of prolonged use of glucocorticoids.
3174385|NCT01378689|No Intervention|No video|
3174386|NCT01378676|Placebo Comparator|Matching Placebo|
3174387|NCT01378676|Experimental|Active Drug Low Dose|
3174388|NCT01378676|Experimental|Active Drug Mid Dose|
3174389|NCT01378676|Experimental|Active Drug High Dose|
3174390|NCT01378663||Post congenital cardiac surgery pain management|All patients that underwent congenital cardiac surgery from 2004 till 2010 and required PCA or NCA.
3174391|NCT01378650|Experimental|Cilostazol group|Administration of Cilostazol 100mg twice a day for 4 weeks
3174392|NCT01378650|Placebo Comparator|Placebo group|placebo drug twice a day for 4 weeks.
3174393|NCT01378637|Experimental|AMES Leg treatment|An investigational device flexes and extends the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the foot. The subject's task is to assist the motion of the device by pulling or pushing with the foot. Feedback of ankle torque or the electrical signal produced by the muscles (EMG) while the subject is assisting the motion is provided during the 30 treatment sessions.
3174394|NCT01378624|Experimental|Bronchoscopy|
3174395|NCT01378611|Placebo Comparator|active control group|The active control group is stimulated with: Output current 0.25 milliampere, Pulse width 0.1 milliseconds, Frequency 1 Hz, Duty cycle: 14 sec on 60 min off (duty cycle <0.5%)
3174396|NCT01378611|Experimental|treatment group|The high stimulation group is stimulated with output current 0.25 milliampere, Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off in the treatment group the current was stepwise increased with two week intervals to the maximally tolerated output current (maximum 1.75 mA).
3174397|NCT01378585|Experimental|Treatment 1|Test drug treatment: 3 x 490 mg DLBS1033 daily
3174398|NCT01378585|Placebo Comparator|Treatment 2|Placebo treatment: 3 x 1 tablet daily
3174399|NCT01378559||Penis prosthesis cohort|
3174400|NCT01378533|Experimental|AC-T（dose-dense）|AC-T(dose-dense) EPI（Pharmorubicin） CTX（cyclophosphamide） PTX（Paclitaxel） G-CSF
3174401|NCT01378533|Experimental|chemotherapy:PC|PTX（Paclitaxel） CBP（carboplatin）
3174402|NCT01378520|Experimental|ketoconazole|600 mg ketoconazole
3174403|NCT01378520|Placebo Comparator|inert powder|inert powder in capsule
3174404|NCT01378507|Experimental|Endoscopic Submucosal Dissection|Single-arm for ESD procedure and retrospective surgical procedure(Laparoscopy, Open surgery)data collection
3174405|NCT01378494||HIV+|HIV+ patients that entered the 1917 Clinic at UAB as naive to ART
3174406|NCT01378481|Experimental|Treatment (vorinostat, surgery, FSRT)|Patients receive high-dose vorinostat PO at 48, 27, and 3 hours prior to surgery. Beginning 2-6 weeks later, patients receive vorinostat PO QD on days 1-3 in weeks 1-2and undergo fractionated stereotactic body radiation therapy on days 1-5 in weeks 1-2. Treatment continues in the absence of disease progression or unacceptable toxicity.
3174407|NCT01378468||Patients with first ischemic stroke|
3174408|NCT01378455|Experimental|ICHTP group|In ICHTP (interactive computerized handwriting training program) group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software
3174409|NCT01378455|Active Comparator|THTP group|The THTP (traditional handwriting training program)group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
3174410|NCT01378442|Experimental|high level training group|receive high frequency fitness training program(Frequency: three times a week, Duration: 40 minutes).
3174411|NCT01378442|Experimental|low level training group|will receive low frequency fitness training program(Frequency: 1-2 times a week, Duration: 40 minutes).
3174412|NCT01378442|No Intervention|control|No intervention, but maintain usual physical activities
3174413|NCT01378429|Experimental|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
3174414|NCT01378429|Placebo Comparator|Placebo|
3174415|NCT01378416|Experimental|1|
3174416|NCT01378390|Experimental|ASCs|Intralesional dose of 20 million cells at baseline with a possible second administration of 40 million cells in case of incomplete fistula closure following week 12 assessment.
3174588|NCT01377129|Experimental|Double bundle|These patients are operated using a double bundle technique.
3174417|NCT01378390|Sham Comparator|Placebo|Instillation of saline solution into the fistulous tract, following identical tract preparation process as for the investigational treatment group.
3174418|NCT01378377|Experimental|Pimasertib 45 mg+Temsirolimus 12.5 mg|
3174419|NCT01378377|Experimental|Pimasertib 45 mg+Temsirolimus 25 mg|
3174420|NCT01378377|Experimental|Pimasertib 75 mg+Temsirolimus 25 mg|
3174421|NCT01378364|Experimental|AbGn-168H very low dose i.v.|subject to receive a single very low dose of AbGn-168H intravenously (i.v.) or placebo
3174422|NCT01378364|Experimental|AbGn-168H low dose i.v.|subject to receive a single low dose of AbGn-168H intravenously (i.v.) or placebo
3174423|NCT01378364|Experimental|AbGn-168H medium dose i.v.|subject to receive a single medium dose of AbGn-168H intravenously (i.v.) or placebo
3174424|NCT01378364|Experimental|AbGn-168H high dose i.v.|subject to receive a single high dose of AbGn-168H intravenously (i.v.) or placebo
3174425|NCT01378364|Experimental|AbGn-168H very low dose s.c.|subject to receive a single very low dose of AbGn-168H subcutaneously (s.c.) or placebo
3174426|NCT01378364|Experimental|AbGn-168H medium dose s.c.|subject to receive a single medium dose dose of AbGn-168H subcutaneously (s.c.) or placebo
3174427|NCT01378338||Typical reflux symptom by EGD|Total 2000 subjects who has Typical reflux symptom by EGD
3174428|NCT01378325|Experimental|Phenylephrine|PHenylephrine infusion started at 0.75 microgram per kg per mL started at spinal injection till delivery
3174429|NCT01378325|Placebo Comparator|Saline|Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
3174430|NCT01378312|Placebo Comparator|Placebo Arm|
3174431|NCT01378312|Active Comparator|AERAS 402 Arm|
3174432|NCT01378299|Experimental|Arm 1: Testosterone Cypionate|All patients who qualify for the study will receive testosterone cypionate
3174433|NCT01378286|Experimental|artesunate/amodiaquine|"artesunate (AS) / amodiaquine (AQ) as fixed dose combination~1 tablet of AS 25mg/ AQ 67,5mg or AS 50mg/AQ 135mg or AS 100mg/ AQ 270mg or 2 tablets of AS 100mg/ AQ 270mg dose according to bodyweight Once daily 3 days of treatment"
3174434|NCT01378286|Active Comparator|chloroquine|150mg tablets 25mg/kg in 3 days (10mg/kg on day 1 and 7,5 mg/kg on days 2 and 3) dose according to bodyweight Once daily 3 days of treatment
3174435|NCT01378273|Placebo Comparator|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
3174436|NCT01378273|Experimental|Epo 1000 U/kg followed by 400 U/kg|Subjects will receive 6 doses of intravenous Epo 1000 U/kg/dose at 48 hour intervals from the time of enrollment. Following the high dose period, subjects will receive subcutaneous Epo 400 U/kg/dose three times a week until 32-6/7 weeks postmenstrual age.
3174437|NCT01378260||Surgical Bypass|use of synthetic or endogenous (vein) or composite graft to treat lesions in the superficial femoral, common femoral, or popliteal artery
3174438|NCT01378260||Endovascular Therapy|angioplasty and/or stent to treat lesions in the superficial femoral or popliteal artery
3174439|NCT01378260||Medical Management|"Documentation of the following in the medical record:~i. Walking/physical therapy to improve endurance was recommended; ii. For tobacco users, tobacco cessation was recommended; iii. Prescribing pentoxifylline (Trental) or cilostazol (pletal) iv. Ongoing care by physician for treatment of claudication"
3174440|NCT01378247|No Intervention|Treatment as usual|Pharmacological treatment, patient information and counselling according to international and national guidelines by health professionals specialized in heart failure.
3174441|NCT01378247|Experimental|Family Focused Nursing|Family Focused Nursing and treatment as usual
3174442|NCT01378234|Experimental|EDPP Intervention|Receive EDPP transitional care intervention from social worker upon hospital discharge
3174443|NCT01378234|No Intervention|Usual Care|Receive usual care upon hospital discharge
3174444|NCT01378221||Group 1|cardiac surgery patients age 65 years and less
3174445|NCT01378221||Group 2|cardiac surgery patients aged 75 years and over
3174446|NCT01378208|Experimental|Normal weight|Body Mass Index between 18-25 kg/m2 Age between 18-35 years male
3174447|NCT01378195|Experimental|CBT-based|CBT-based program (Cognitive Behavioral Therapy) with video, workbook, and website
3174448|NCT01378195|Active Comparator|Educational/Resources Materials|Educational/Resources Materials: video, workbook, and website.
3174449|NCT01378169||SIRS patients|Every patient, without exclusion criteria, presenting with SIRS during an hospitalization in ICU.
3174450|NCT01378156|Experimental|JS7 plasmid DNA and MVA62B vaccines|All subjects receive JS7 plasmid DNA (at 1 and 9 weeks) and MVA62B vaccines (17 and 25 weeks), followed (in 2 months after last vaccination) by a 12-week treatment interruption phase. Subjects reinstitute therapy after the treatment interruption and are followed for 6 months.
3174451|NCT01378143|Experimental|OCZ103-OS, mFOLFOX6 or FOLFIRI|OCZ103-OS in combination with mFOLFOX6 or FOLFIRI as standard of care
3174452|NCT01378117|Experimental|Sitagliptin + SSI prn|Sitagliptin once daily plus supplemental doses of lispro if needed.
3174453|NCT01378117|Experimental|Sitagliptin and glargine+ SSI|Sitagliptin 50-100mg po once a day and SQ glargine insulin once daily + acqhs correctional doses of lispro if needed for elevated blood glucose
3174454|NCT01378117|Active Comparator|Glargine and Lispro + SSI|Glargine once daily and lispro before meals + acqhs supplemental insulin lispro as needed for elevated blod glucose
3174455|NCT01378104|Experimental|80% dosage group of peginterferon alfa 2a|This group patients will treated the same full dose (180ug/week) of peginterferon alfa 2a during the first 12 weeks and then reduce the 75% dose (135ug/week) of peginterferon alfa 2a during remnant 36 weeks. At a result, these patients treated with 80% dosage of originally prescribed peginterferon alfa-2a for standard 48 weeks of treatment.
3174456|NCT01378104|Active Comparator|100% dosage group of peginterferon alfa 2a|These group patients would be treated with standard dose 180 ug/week for 48 weeks.
3174457|NCT01378091|Experimental|Lenalidomide, Docetaxel, Prednisone|Subjects will receive this drug combination during a treatment phase and an extension phase.
3174458|NCT01378078|Sham Comparator|sham|patients receive sham tDCS stimulation
3174459|NCT01378078|Active Comparator|active|active transcranial direct current stimulation
3174461|NCT01378052||healthy controls|Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
3174462|NCT01378039|Other|Budesonide|patients who gave their agreement were randomised to 3 months treatment with either inhaled budesonide (400 µg BD) or placebo
3174463|NCT01378013||Elective sugery|"Patients entering into elective surgery. These will be divided into three subgroups:~A. Patients with cancer. This will include patients with malignancy of the gastrointestinal and colorectal tract (including those excised by microsurgery) cancer of the breast or solid tumours of the kidney.~B. Patients with benign diseases of the bowel requiring surgery e.g. inflammatory bowel disease C. Benign surgical conditions, usually operated on in a day surgery setting. These will specifically be of the biliary tree (gall stones) and the anterior abdominal wall (e.g. Hernia surgery)"
3174464|NCT01378013||Acute (emergency) surgery|"Patients presenting to Accident and emergency under the care of the general surgery on call team will be recruited into this study group. This study group will have the following subgroups:~A. Acute abdominal pain, as per the previous ethical clearance B. Patients with acute sepsis thought to be of surgical origin. C. Patients suffering major trauma with an Injury severity score of >15, multiple injuries, who require surgery or who have >1 organ system that is failed or who are admitted to the intensive care department."
3174465|NCT01378000||UFH,once a day|
3174466|NCT01378000||heparin Calcium,every 12 hours|
3174467|NCT01378000||dextran,Salviae,once a day|
3174468|NCT01378000||UFH,continuous intravenous infusion,|
3174469|NCT01377987|Experimental|Acetazolamide|
3174470|NCT01377987|Placebo Comparator|Sugar pill|
3174471|NCT01377974|Active Comparator|Standard Treatment|Meglumine antimoniate as recommended by the Brazilian Ministry of Health
3174472|NCT01377974|Experimental|Tested Intervention|Miltefosine as the tested intervention
3174473|NCT01377961|Active Comparator|Arm1: Metabolic Syndrome Volunteers|
3174474|NCT01377961|Active Comparator|Arm 2:Previously Diagnosed diabetic patients|
3174475|NCT01377948|Other|ACT with RAGE-Control|all subjects are assigned to this arm. This is an open feasability proof of concept trail with a single experimental group with all subjects receiving the intervention being studied.
3174476|NCT01377935||Patients exposed to Saxagliptin|
3174477|NCT01377935||Patients exposed to OAD in classes other than DPP4 inhibitors|OAD - Oral Antidiabetic Drug
3174478|NCT01377922|Placebo Comparator|Placebo|Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
3174479|NCT01377922|Experimental|Amifampridine Phosphate|Amifampridine, 30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets), for 2 weeks.
3174480|NCT01377909|Experimental|statin|
3174481|NCT01377883|Sham Comparator|Standard intervention|"Preparation and information: the doctor and nurse explained the steps of the procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.~Memory change and positive reinforcement: medical staff present spoke to the child positively and offered prizes, among which the child could choose.~Volunteer attendance: as part of the control session, receiving no particular instructions in relation to the child's potential pain during the procedure."
3174482|NCT01377883|Experimental|clown care|Cognitive coping: encouraging a child to cope with the challenge. Imagery: a cognitive technique used to encourage the child to cope with the pain and distress of the procedure by imagining a pleasant object or experience Empowerment: the child is made to feel empowered by controlling the actions of the clown Reflecting emotions: the clown, sensing the state of the child, plays it out in an exaggerated fashion.
3174483|NCT01377870|Placebo Comparator|cell free media|15 patients with relapsing remitting multiple sclerosis who receive cell free media
3174484|NCT01377870|Experimental|mesenchymal stem cell reciepiants|Patients with relapsing remitting multiple sclerosis who underwent intravenous injection of mesenchymal stem cells
3174485|NCT01377857|Experimental|Opt-In|Opt-in refers to a default of no test - patients must ask for the test in order to receive it. Patients are informed of the availability of rapid testing. They are tested only if they request the test.
3174486|NCT01377857|Experimental|Opt-Out|Opt-out has a default to test - patients are informed that they will receive a rapid HIV screening test unless they decline it. Patients will be tested unless they decline.
3174487|NCT01377857|Experimental|Active Choice|In the active choice treatment, there is no default; patients must actively accept or actively decline the test.
3174488|NCT01377857|Experimental|$1 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
3174489|NCT01377857|Experimental|$5 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
3174490|NCT01377857|Experimental|$10 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
3174491|NCT01377857|Experimental|Early Questionnaire|At a time that does not interfere with patients' medical care, patients will be approached by a member of the research team to consent to and complete a short (3 minutes) questionnaire. The questionnaire is designed to elicit two things: subjective risk of infection (e.g., What are the chances you have HIV? [Not possible, Unlikely, Possible, Likely, Certain]) and objective risk of infection (e.g., In the past year, have you given anyone drugs or money for sex?). The questionnaire will be administered as one of two timing treatments - a) at the beginning of care, before the patient is offered an HIV test (Early questionnaire) or b) after the patient has been offered an HIV test (Late questionnaire).
3174532|NCT01377545|Active Comparator|Local Anesthetic Via Catheter|30mL of Lidocaine (local Anesthetic) will be injected via a perineural catheter at hour 0.
3174533|NCT01377545|Active Comparator|Local Anesthetic Via Needle|30mL of Lidocaine (local Anesthetic) will be injected via a needle at hour 0.
3174534|NCT01377519|Active Comparator|MR Guided Focused Ultrasound|
3174535|NCT01377519|Placebo Comparator|Placebo MR Guided Focused Ultrasound|
3174589|NCT01377103|Placebo Comparator|Placebo|Placebo Gel
3174492|NCT01377857|Experimental|Late Questionnaire|At a time that does not interfere with patients' medical care, patients will be approached by a member of the research team to consent to and complete a short (3 minutes) questionnaire. The questionnaire is designed to elicit two things: subjective risk of infection (e.g., What are the chances you have HIV? [Not possible, Unlikely, Possible, Likely, Certain]) and objective risk of infection (e.g., In the past year, have you given anyone drugs or money for sex?). The questionnaire will be administered as one of two timing treatments - a) at the beginning of care, before the patient is offered an HIV test (Early questionnaire) or b) after the patient has been offered an HIV test (Late questionnaire).
3174493|NCT01377857|Experimental|FITD Questionnaire|"There will be two versions of the early questionnaire: one standard Early questionnaire, and one with an additional question: If you were offered an HIV test as part of your routine health care at no cost, would you get tested? The two questionnaires will be otherwise identical."
3174494|NCT01377857|Experimental|Free|When offering the HIV test, study staff will inform subjects that the ED is offering HIV testing (and that the test is also free); no monetary incentive will be offered.
3174495|NCT01377844|Placebo Comparator|EGT0001442|EGT0001442 20 mg capsule, daily, 96 weeks
3174496|NCT01377844|Placebo Comparator|Placebo|Placebo
3174497|NCT01377818|Experimental|ventilation|Group program of positive pressure ventilation noninvasive
3174498|NCT01377818|Experimental|exercise training|"The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:~d. 20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.~e. Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)"
3174499|NCT01377818|Experimental|exercise training and ventilation|Group of exercise training program and noninvasive positive pressure ventilation
3174500|NCT01377805||Multiple Sclerosis patients|Multiple sclerosis patients
3174501|NCT01377792|Active Comparator|5 ml|
3174502|NCT01377792|Active Comparator|10 ml|
3174503|NCT01377779|Experimental|Intercoat treatment|women treated by Intercoat gel following hysteroscopy for retained products of conception
3174504|NCT01377779|Placebo Comparator|Control group|No additional treatment following hysteroscopy was performed
3174505|NCT01377753|Experimental|1|Eligible subjects will undergo MRthermal image guided laser ablation of all biopsy proven areas of prostate cancer using one or multiple laser probes during a single procedure lasting approximately two hours in duration.
3174506|NCT01377688||Diabetics with PKD|Diagnoses of diabetes type 2 with progressive kidney disease (slope of eGFR decline between -15 to -3 ml/min/1.73m2 per year, estimated by calculating an eGFR for each creatinine using the 4-variable Modification of Diet in Renal Disease Study [MDRD] equation and conducting a simple ordinary least squares regression from these values to evaluate changes over time to derive each individuals' slope of eGFR, annualized using test dates)
3174507|NCT01377675||Usual curriculum education program|Third year internal medicine residents
3174508|NCT01377662|Placebo Comparator|Placebo|
3174509|NCT01377662|Experimental|OND-PR002 and MPh-IR|
3174510|NCT01377649||Control|Age matched control subjects without PAD
3174511|NCT01377649||Patients with PAD|
3174512|NCT01377636|Experimental|Isoproterenol, BIS, forearm test|30 consecutive patients scheduled for EP studies under general anesthesia will participate in the study. Patients with neuromuscular disease precluding the use of succinylcholine will be excluded. The only other exclusions will be patient or cardiologist refusal. No attempts will be made to alter concurrent patient medication.
3174513|NCT01377623|Placebo Comparator|Placebo group|Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
3174514|NCT01377623|Experimental|Dexmedetomidine group|Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
3174515|NCT01377610|Active Comparator|Buprenorphine|Standard 7-day buprenorphine induction and gradual taper from 8 mg to 0 mg followed on day 15 by Vivitrol injection
3174516|NCT01377610|Active Comparator|Oral naltrexone|The naltrexone arm is a modification of our current inpatient naltrexone induction procedure, consisting of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses. Followed on day 8 by Vivitrol injection.
3174517|NCT01377597|Experimental|ranibizumab intravitreal injection|
3174518|NCT01377584|Experimental|Patients in the Couple-oriented intervention|Patients randomly assigned to the couple-oriented (CO) group will attend two face to face sessions with their partner and participate in an individual telephone follow-up session.
3174519|NCT01377584|Other|Patients in Usual Care|Patients will not attend any intervention sessions.
3174520|NCT01377584|Experimental|Patients in the Patient-oriented intervention|Patients randomly assigned to the patient-oriented (PT) group will attend two face to face sessions and participate in a telephone follow-up session.
3174521|NCT01377584|Experimental|Partners in the Couple-oriented intervention|Partners randomly assigned to the couple-oriented (CO) group will attend two face to face sessions with the patient and participate in an individual telephone follow-up session.
3174522|NCT01377584|Other|Partners in Usual Care|Partners will not attend any intervention sessions.
3174523|NCT01377584|Experimental|Partners in the Patient-oriented intervention|Partners randomly assigned to the patient-oriented (PT) group will not attend any intervention sessions.
3174524|NCT01377571|Experimental|Rotavin2H|2 doses of Rotavin-M1 vaccine, 106.3FFU/dose, 2-month separation between doses
3174525|NCT01377571|Experimental|Rotavin2L|2 doses of Rotavin-M1 vaccine, 106.0FFU/dose, 2-month interval between doses
3174526|NCT01377571|Experimental|Rotavin3H|3 doses of Rotavin-M1 vaccine, 106.3FFU/dose, 1-month interval between doses
3174527|NCT01377571|Experimental|Rotavin3L|3 doses of Rotavin-M1, 106.0FFU/dose, 1-month interval between doses
3174528|NCT01377558|Experimental|Aerobic endurance training intervention|Aerobic endurance training
3174529|NCT01377558|Experimental|Strength endurance training intervention|Strength endurance training
3174530|NCT01377558|Experimental|Combined training intervention|Combined aerobic endurance training and strength endurance training intervention
3174531|NCT01377558|No Intervention|Control group|control group
3174536|NCT01377506|Experimental|Lifestyle counseling|Diabetes Prevention Program Lifestyle Balance Intervention delivered by lay health educator
3174537|NCT01377506|Active Comparator|Cognitive Training|Adaptation of SeniorWise Memory Training program for delivery by lay health educator, matched in duration and contact to the other study arm
3174538|NCT01377493|Placebo Comparator|placebo|
3174539|NCT01377493|Active Comparator|POs-Ca|
3174540|NCT01377493|Active Comparator|POs-Ca+F|
3174541|NCT01377480|Experimental|Posaconazole|Posaconazole (POS) 400 mg (10 mL) oral suspension twice daily for 60 days
3174542|NCT01377480|Placebo Comparator|Placebo|Posaconazole placebo (10 mL) oral suspension twice daily for 60 days
3174543|NCT01377480|Experimental|Posaconazole + Benznidazole|Posaconazole 400 mg (10 mL) oral suspension twice daily for 60 days and benznidazole (BNZ) 100 mg oral tablet twice daily (200-mg daily dose) for 60 days
3174544|NCT01377480|Active Comparator|Benznidazole + Placebo|Posaconazole placebo (10 mL) oral suspension twice daily for 60 days and benznidazole 100 mg oral tablet twice daily (200-mg daily dose) for 60 days
3174545|NCT01377467|Experimental|Denosumab|60 mg denosumab s.c. at baseline and after 6 months
3174546|NCT01377467|No Intervention|Control|No treatment
3174547|NCT01377441|Experimental|Ibuprofen|Eligible subjects will be randomized to one of the two treatment group in a 1:1 ratio to receive either IV ibuprofen or matching placebo.
3174548|NCT01377441|Placebo Comparator|Placebo/Saline solution|Eligible subjects will be randomized to one of the two treatment group in a 1:1 ratio to receive either IV ibuprofen or matching placebo
3174549|NCT01377428|Experimental|Indacaterol|Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
3174550|NCT01377428|Active Comparator|Formoterol|Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
3174551|NCT01377415|Active Comparator|bupivacaine|a continuous flow of 5 mg/ml bupivacaine 2 ml/h 48 h
3174552|NCT01377415|Placebo Comparator|saline|saline 9 mg/ml infusion 2 ml/h 48 h
3174553|NCT01377402||Chest pain|Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).
3174554|NCT01377389|Experimental|Ipilimumab + ADT|Ipilimumab 10 mg/kg intravenous (IV) Weeks 5, 9, 13, and 17 plus Androgen Deprivation Therapy (ADT) of either Leuprolide 7.5 mg intramuscular (IM) , Goserelin 3.6 mg subcutaneous (SQ) or Degarelix 80 mg SQ once a month for 8 months beginning Week 1.
3174555|NCT01377376|Experimental|ARQ 197|ARQ 197 and Erlotinib
3174556|NCT01377376|Placebo Comparator|Placebo|Placebo and Erlotinib
3174557|NCT01377363||Not treatment|Locally recurrent breast carcinoma or metastatic
3174558|NCT01377350|Experimental|"Pneumedicares monitoring system"|"Single arm study - Pneumedicares monitoring system is used for monitoring heart failure patients"
3174559|NCT01377337|Active Comparator|Sodium bicarbonate|1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR.
3174560|NCT01377337|Placebo Comparator|0.9% NaCl|1 ml/kg of 0.9% NaCl (Blinded label)
3174561|NCT01377324|Experimental|Single arm|Fluoroestradiol-PET is performed at baseline, after 1 month, and 3 months
3174562|NCT01377311|Experimental|1|Patients suffering from unilateral limbal stem cell insufficiency. Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
3174563|NCT01377298|Experimental|Pazopanib|Single arm study, pazopanib
3174564|NCT01377285|Experimental|ARB & Pentoxifylline|angiotensin receptor blockers(ARB)and Pentoxifylline 400mg tablet (If CKD3 1# BID(Bi in die=two times a day); CKD4 1# QD(quaque die=one time a day); CKD5(estimated Glomerular filtration rate,eGFR<15ml/min/1.73 m2) 1# QOD(Every other day).
3174565|NCT01377285|Active Comparator|ARB & Placebo|angiotensin receptor blockers(ARB) and Placebo tablet(If CKD3 1# BIDBi in die=two times a day); CKD4 1# QD(quaque die=one time a day); CKD5(estimated Glomerular filtration rate,eGFR<15ml/min/1.73 m2) 1# QOD(Every other day).
3174566|NCT01377259||1Tissue oxygenation change|Spinal anesthesia may result different changes of tissue oxygenation in blocked area ( upper extrimities ) and non-blocked area ( lower extrimities). The changes of tissue oxygenation saturation between upper and lower extremities in patients under spinal anesthesia for orthopedic surgery
3174567|NCT01377259||2Tissue oxygenation change|The changes of tissue oxygenation saturation between upper and lower extremities in patients under spinal anesthesia for cesarean section
3174568|NCT01377246|Placebo Comparator|Saline solution.|
3174569|NCT01377246|Experimental|Octrotide-LAR|
3174570|NCT01377233|Experimental|Zicronapine open-label lead-in 10 mg daily|
3174571|NCT01377233|Experimental|Zicronapine 10 mg daily|
3174572|NCT01377233|Experimental|Zicronapine 20 mg once weekly|
3174573|NCT01377233|Experimental|Zicronapine 30 mg once weekly|
3174574|NCT01377233|Experimental|Zicronapine 45 mg once weekly|
3174575|NCT01377207|Experimental|Female Arm|Female gender diagnosed with ST segment Elevation Myocardial Infarction (STEMI)
3174576|NCT01377207|Active Comparator|Male Arm|Male Gender diagnosed with ST segment Elevation Acute Myocardial Infarction (STEMI)
3174577|NCT01377194|Experimental|1|40mg Levomilnacipran ER
3174578|NCT01377194|Experimental|2|80mg of Levomilnacipran ER
3174579|NCT01377194|Placebo Comparator|3|Placebo
3174580|NCT01377181||group A|the patients were accepted laparoscopic purse-string knot closing the internal hernia opening only
3174581|NCT01377181||group B|the patients were accepted the lateral umbilicus ligament covering the internal hernia opening region after the laparoscopic purse-string knot
3174582|NCT01377168|Placebo Comparator|Placebo pill|Daily oral placebo.
3174583|NCT01377168|Active Comparator|NTX|Daily oral naltrexone.
3174584|NCT01377155|Other|Insulin determir|
3174585|NCT01377142||Laparoscopic sacral hysteropexy|Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance
3174586|NCT01377142||Vaginal mesh hysteropexy|Vaginal Mesh Hysteropexy using the Uphold device which includes Sacrospinous Ligament Fixation
3174587|NCT01377129|Active Comparator|Single Bundle|These patients are operated using a single bundle technique.
3176251|NCT01365663|Experimental|Cohort 4|1.5 mg/kg in Healthy Subjects
3174590|NCT01377103|Active Comparator|Testosterone Supplementation|Testosterone Gel
3174591|NCT01377090||SSc DU-history subgroup|Systemic sclerosis patients with history of digital ulcers
3174592|NCT01377090||SSc with No-DU-history subgroup|Systemic sclerosis patients with no history of digital ulcers
3174593|NCT01377077|Experimental|epidermal 1mm grafting|Epidermal skin biopsies of 1mm diameter
3174594|NCT01377077|Experimental|dermal 1mm grafting|dermal skinbiopsies of 1mm diameter
3174595|NCT01377077|Experimental|dermal 1,5mm grafting|dermal skinbiopsies of 1,5mm diameter
3174596|NCT01377077|Active Comparator|epidermal 1,5mm grafting|epidermal skinbiopsies of 1,5mm diameter
3174597|NCT01377064|Experimental|Physical activity group|Subjects will participant in physical activity program
3174598|NCT01377064|Active Comparator|Standard care group|This group will not receive a physical activity intervention
3174599|NCT01377051|Active Comparator|Bronchodilator|Indacaterol maleate 300 mcg will be administered by a third independent investigator following a randomization list.
3174600|NCT01377051|Placebo Comparator|Placebo|Will be administered with the same device by a third independent investigator
3174601|NCT01377038|Active Comparator|Duloxetine|Phenotype assessment prior to and after treatement with duloxetine 20-30 mg oral daily for eight weeks.
3174602|NCT01377038|Active Comparator|Diclofenac|Phenotype assessment prior to and after treatment with topical diclofenac four times daily
3174603|NCT01377025|Experimental|Sorafenib blinded Phase|400 mg Sorafenib bid until PD
3174604|NCT01377025|Placebo Comparator|Placebo blinded Phase|Two tbl. in the morning and two tbl. in teh evening until PD
3174605|NCT01377025|Experimental|Sorafenib Open Phase|400 mg Sorafenib bid until PD
3174606|NCT01377012|Experimental|AIN457 10mg/kg-75mg|Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks
3174607|NCT01377012|Experimental|AIN457 10mg/kg-150mg|Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks
3174608|NCT01377012|Placebo Comparator|Placebo|Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (>= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24
3174609|NCT01376999|Experimental|Step Down|Step Down: We begin the COS (controlled ovarian stimulation) with 150 IU of FSH-r until 7th day of stimulation. This day we make an adjustment reducing the dose if necessary.
3174610|NCT01376999|Active Comparator|Step Up|Step up: We begin the COS (controlled ovarian stimulation) with 75 IU of FSH-r until 7th day of stimulation.This day we make an adjustment increasing the dose if necessary.
3174611|NCT01376986|Experimental|Activation|All those determined fit for service or who are granted postponement will be included in the activation intervention. The physical activation intervention will be implemented between the call-up and start of military service. The activation group utilises an ICT platform that will be developed.
3174612|NCT01376986|No Intervention|control|no access to the activation platform
3174613|NCT01376973||group A|Not received any oral device (Control)
3174614|NCT01376973||Group B and Group C|Group B - Used Michigan Occlusal Splint (MOS); Group C - Used Planas Oral Appliance (POA).
3174615|NCT01376960|Active Comparator|single shot popliteal fossa block|
3174616|NCT01376960|Active Comparator|ankle blocks|
3174617|NCT01376947||Nulliparous|Nulliparous women who were submitted to IUD device insertion
3174618|NCT01376947||Multiparous with no cesaraen section|Multiparous women with no cesarean sections that were submitted to IUD device insertion
3174619|NCT01376947||Mulitparous with cesarean section|multiparous women with a cesarean section that were submitted to IUD insertion
3174620|NCT01376908|Experimental|Kuvan® + Phe-restricted diet|Subjects will be treated with Kuvan® tablets once daily along with Phe-restricted diet therapy.
3174621|NCT01376908|Other|Phe-restricted diet alone|Subjects will follow a Phe-restricted diet alone.
3174622|NCT01376895|Experimental|POWER|Power is a 3 session intervention delivered through the internet in real time by a trained health educator. It focuses on reducing HIV risk. Each session last from 1 to 2 hours.
3174623|NCT01376895|Active Comparator|Power Health|Power Health is a 1 session general health promotion program designed to be delivered via the internet in real time by a trained health educator. The sessions focus on healthy life styles, cardiovascular health, and prostate health. Participants also receive information regarding safe sex.
3174624|NCT01376882|Experimental|Acute withdrawal|Chronic intervention 100 mg caffeine capsules 3 times per day for 14 days. Acute intervention of placebo capsule on day 15.
3174625|NCT01376882|Experimental|Acute caffeine-independent of withdrawal|Chronic intervention of placebo capsules 3 times per day for 14 days. Acute intervention of 100 mg caffeine capsule on day 15.
3174626|NCT01376882|Experimental|Chronic abstinence|Chronic intervention of placebo capsules 3 times per day for 14 days. Acute intervention of placebo capsule on day 15.
3174627|NCT01376882|Experimental|Acute caffeine-in state of withdrawal|Chronic intervention of 100 mg caffeine capsule 3 times per day for 14 days. Acute intervention of 100 mg caffeine capsule on day 15.
3174628|NCT01376869|Active Comparator|102mg extract 1 hops|Equivalent to 0.5g dry weight
3174629|NCT01376869|Active Comparator|410mg extract 1 hops|Equivalent to 2g dry weight
3174630|NCT01376869|Active Comparator|79mg extract 2 hops|Equivalent to 0.5g dry weight
3174631|NCT01376869|Active Comparator|316mg extract 2 hops|Equivalent to 2g dry weight
3174632|NCT01376869|Placebo Comparator|Placebo|
3174633|NCT01376856||PET/CT and surgical biopsy group|person who performed PET/CT and surgical biopsy of mediastinal lymph node for diagnosis of primary lung cancer of metastatic lung cancer
3174634|NCT01376843||Health care workers|health care workers who performed TST or Quantiferon-TB Gold In tube assay before
3174635|NCT01376830||COPD patients|
3174636|NCT01376817|Experimental|Omega 3|
3174637|NCT01376817|Active Comparator|MCT / LCT|
3174638|NCT01376804|Experimental|Valganciclovir|Participants received a once daily oral dose (solution or tablets) of valganciclovir starting within 10 days of kidney transplant for up to 200 days post-transplant. Dose (in milligrams) was calculated using the algorithm [7 * Body Surface Area * Creatinine Clearance].
3174639|NCT01376778|Active Comparator|CMV hyperimmune globulin - Cytogam®|Infusion of Cytogam®, Cytomegalovirus Immune Globulin Intravenous (Human) (CMV-IGIV)
3174640|NCT01376778|Placebo Comparator|Placebo|IV 5% albumin diluted 1 to 9 with 5% Dextrose in water (D5W)
3174641|NCT01376765|Experimental|Cohort 1|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine received with aluminum hydroxide adjuvant (Alhydrogel®), without adjuvant, or placebo in 2 intramuscular doses, 28 days apart, at 5 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine {(SARS vaccine with aluminum hydroxide adjuvant (Alhydrogel®)}; 4 subjects receive placebo.
3174642|NCT01376765|Experimental|Cohort 3|SARS vaccine with adjuvant, without adjuvant, or placebo; l in 2 intramuscular doses, 28 days apart, at 45 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine (SARS vaccine with adjuvant); 4 subjects receive placebo.
3174643|NCT01376765|Experimental|Cohort 2|SARS vaccine with adjuvant, without adjuvant, or placebo in 2 intramuscular doses, 28 days apart, at 15 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine (SARS vaccine with adjuvant) 4 subjects receive placebo.
3174644|NCT01376752|Active Comparator|maximal cytoreductive surgery without HIPEC|
3174645|NCT01376752|Experimental|maximal cytoreductive surgery with HIPEC|
3174646|NCT01376739||Group 1|
3174647|NCT01376726|Experimental|Previous HIV Vaccine Trial Participants (Group 1)|"Participants will receive the study vaccine administered as one 0.5 mL intramuscular injection (IM) in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
3174648|NCT01376726|Experimental|No Previous HIV Vaccine Trial (Group 2)|"Participants will receive the study vaccine administered as one 0.5 mL IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
3174649|NCT01376713|Experimental|Ofatumumab alone|Patients with melanoma unresectable stage III B (T1- 4a, N2b-c), stage III C or stage IV (AJCC 2009) will be included in this study. Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks. Tumor imaging is performed at wk 4 (screening for rapid disease progression), 8, 16 and 24. In case of PD, patients will have the opportunity to receive at least 3 cycles of ofatumumab q4w in combination with DTIC (1000 mg/m2) q4w (see Arm2).
3174650|NCT01376713|Experimental|Ofatumumab plus Dacarbazine|Patients will be treated with a combination of DTIC (1000 mg/m2) q4w plus ofatumumab (1000mg) qw for 8 wks, and thereafter q4w.Tumor imaging is performed at wk 8, 16 and 24.
3174651|NCT01376700|Experimental|ADVATE - Prophylactic Regimen|Weekly infusions of ADVATE. Study visits (physical examination, lab tests including FVIII inhibitor tests) every week during the first 10 exposure days (EDs), every 5 weeks during the next 10 EDs and every 10 weeks thereafter.
3174652|NCT01376687||Pain free|No pain in the cervical spine
3174653|NCT01376687||Pain|Pain of 3 or greater on a VAS scale for the cervical spine
3174654|NCT01376661||Active Surveillance/ Prostate Cancer|
3174655|NCT01376622||Chronically Transfusion Patients|Patients with transfusion dependent anemia (excluding sickle cell disease), ages 2-25, on Deferasirox chelation therapy, to be monitored over 2 years.
3174656|NCT01376622||Controls|Normal controls, ages 2-25, with no known brain abnormality or endocrine dysfunction.
3174657|NCT01376596|Experimental|CBT-based Intervention|Contrast the impact of a CBT intervention for the treatment of social anxiety in schizophrenia with standard care (care as usual)
3174658|NCT01376596|Active Comparator|Treatment as usual|Usual care received by patients at clinic/hospital - randomized to a wait list to receive the CBT intervention at the end of the group that received the intervention immediately
3174659|NCT01376570|Experimental|Contingency Management arm|The Contingency Management arm will receive the abstinence-reinforcing contingency management intervention.
3174660|NCT01376570|Active Comparator|Control arm|The Control arm will receive the performance feedback intervention.
3174661|NCT01376557|Experimental|Treatment A|
3174662|NCT01376557|Experimental|Treatment B|
3174663|NCT01376557|Experimental|Treatment C|
3174664|NCT01376557|Experimental|Treatment D|
3174665|NCT01376557|Placebo Comparator|Placebo|
3174666|NCT01376544|Active Comparator|Assist control ventilation|Assist control ventilation
3174667|NCT01376544|Active Comparator|Pressure support ventilation|
3174668|NCT01376531||acute renal failure|patients at intensive care unit with definition of acute renal failure and the need for continuous veno-venous hemodialysis
3174669|NCT01376518||respiratory failure|patients with respiratory failure and need of high positive end-expiratory pressure ventilation.
3174670|NCT01376505|Experimental|HER-2 Vaccine|"combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with nor-MDP and ISA 720~This escalation arm has completed. The trial has moved on to the extension arm"
3174671|NCT01376505|Experimental|EXTENSION HER-2 Vaccine at OBD|"Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with nor-MDP and ISA 720 at dose level cohort 2~This extension arm is ongoing"
3174672|NCT01376492||001|Functioning assessment The functioning will be assessed with 2 scales (Personal and Social Performance Scale (PSP) and Brief Psychiatric Rating Scale)
3174673|NCT01376492||002|Quality of sleep assessment The quality of sleep will be assessed with 2 scales (Pittsburgh Sleep Quality Index (PSQI) and Epworth scale)
3174674|NCT01376479|Experimental|INV21 Low Dose|
3174675|NCT01376479|Experimental|INV21 High Dose|
3174676|NCT01376466||patients with acute appendicitis|Patients who have been clinically diagnosed to have acute appendicitis
3174677|NCT01376453|Experimental|Sorafenib Dose Escalation|Pre-operative Continuous 5-FU, and Sorafenib with External Radiation Therapy. Dose level -1 will only be evaluated if dose level 1 exceeds MTD. The sorafenib and infusional 5-FU will only be given Day 1-5(Monday-Friday) with radiation only.
3174678|NCT01376440|Experimental|Household water treatment|household water treatment with 1.25% sodium hypochlorite
3174679|NCT01376440|No Intervention|control|"Usual practice (the use of Jerrican for water storage, which is considered as safe storage)"
3174877|NCT01375075|Experimental|100 mg LY2484595|Administered orally once daily for 12 weeks
3174680|NCT01376414||Non specific upper abdominal pain|Cohort is patients who present to the Emergency Department with primary complaint of upper abdominal pain without obvious cause.
3174681|NCT01376388|Experimental|GSK573719/GW642444|125/25mcg
3174682|NCT01376362|Experimental|Interferon gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
3174683|NCT01376349|Experimental|Arm I low dose DHEA|Participants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone [DHEA]) gel once daily (QD), at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
3174684|NCT01376349|Experimental|Arm II high dose DHEA|Participants apply a high dose (6.5 mg) of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
3174685|NCT01376349|Placebo Comparator|Arm III placebo|Participants apply a vaginal placebo gel QD, at bed time, for 12 weeks. There is an Optional Continuation Phase (for placebo arm only): Participants apply a high dose of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
3174686|NCT01376336|Experimental|Safe storage device|This arm will be assigned a safe water storage device.
3174687|NCT01376336|No Intervention|Control|This arm of the trial will receive nothing until the end of the trial.
3174688|NCT01376323|Experimental|GSK256073 1mg bid|GSK256073 1mg capsule taken orally twice a day
3174689|NCT01376323|Experimental|GSK256073 2mg qd|GSK256073 2 x 1mg capsule taken orally once a day
3174690|NCT01376323|Experimental|GSK256073 5mg bid|GSK256073 5mg capsule taken orally twice a day
3174691|NCT01376323|Experimental|GSK256073 10mg qd|GSK256073 2 x 5mg capsule taken orally once a day
3174692|NCT01376323|Experimental|GSK256073 10mg bid|GSK256073 10mg capsule taken orally twice a day
3174693|NCT01376323|Experimental|GSK256073 20mg qd|GSK256073 2x 10mg capsule taken orally once a day
3174694|NCT01376323|Experimental|GSK256073 25mg bid|GSK256073 25mg capsule taken orally twice a day
3174695|NCT01376323|Experimental|GSK256073 50mg qd|GSK256073 2x 25mg capsule taken orally once a day
3174696|NCT01376323|Placebo Comparator|Placebo|Matching placebo capsules taken orally either once a day or twice a day
3174697|NCT01376323|Active Comparator|Sitagliptin 100mg qd|Commercially available Sitagliptin 100mg capsules taken once a day
3174698|NCT01376310|Experimental|Cohort A|Subjects on GSK1120212 Monotherapy and have been treated less than 24 weeks in their parent study.
3174699|NCT01376310|Experimental|Cohort B|Subjects on GSK monotherapy who have been treated for 24 weeks or greater in their parent study. Also, subjects entering this study from any GSK1120212 combo trial.
3174700|NCT01376297|Experimental|Netupitant and Palonosetron plus dexamethasone|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
3174701|NCT01376297|Active Comparator|Aprepitant and Palonosetron plus dexamethasone|Oral aprepitant hard capsule 125 mg (on Day 1) + 80 mg daily (for the following two days) and oral palonosetron soft capsule 0.50 mg (on Day 1) given with oral dexamethasone at each scheduled chemotherapy cycle.
3174702|NCT01376284||Subjects prescribed dutasteride capsules|Subjects with BPH prescribed dutasteride capsules during study period
3174703|NCT01376271||Subjects prescribed paroxetine tablets|Subjects with SAD prescribed paroxetine tablets during study period
3174704|NCT01376258||Patients adherent to 5-alpha reductase inhibitor (5ARI)|Patients with benign prostate hyperplasia (BPH) who are adherent (as measured by a medication possession ratio (MPR)) based on 3 MPR threshold values of 70%, 75% and 80%
3174705|NCT01376258||Patients who are non-adherent to 5ARI therapy|Patients with BPH who are not adherent to 5ARI therapy as measured by 3 MPR threshold values of 70%, 75%, and 80%
3174706|NCT01376245|Experimental|fluticasone furoate/vilanterol|Inhaled corticosteroid/long acting beta-agonist
3174707|NCT01376245|Placebo Comparator|placebo|matching placebo
3174708|NCT01376232|Experimental|GSK1278863|100 mg of GSK1278863
3174709|NCT01376232|Experimental|GSK1278863 + food|100 mg of GSK1278863 given with a high fat meal
3174710|NCT01376232|Experimental|GSK1278863 + Gemfibrozil|GSK1278863A 100mg + Gemfibrozil 600mg steady state
3174711|NCT01376219||All patients|All patients entered in the study
3174712|NCT01376206||Subjects prescribed ALLERMIST|Subjects with allergic rhinitis prescribed ALLERMIST during study period
3174713|NCT01376193||Subjects prescribed naratriptan tablets|Subjects with migraine headache prescribed naratriptan tablets during study period
3174714|NCT01376180||Subjects prescribed lamotrigine tablet|Subjects with epilepsy prescribed lamotrigine tablet during study period
3174715|NCT01376167|Experimental|Tafenoquine 50mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 50mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
3174716|NCT01376167|Experimental|Tafenoquine 100mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 100mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
3174717|NCT01376167|Experimental|Tafenoquine 300mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 300mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
3174718|NCT01376167|Experimental|Tafenoquine 600mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 600mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
3174719|NCT01376167|Active Comparator|Primaquine 15mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 15mg Primaquine once daily Days 2-15.
3174720|NCT01376167|Placebo Comparator|Chloroquine only|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered.
3174878|NCT01375075|Experimental|500 mg LY2484595|Administered orally once daily for 12 weeks
3174721|NCT01376167|Experimental|Tafenoquine 300mg (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 300mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
3174722|NCT01376167|Active Comparator|Primaquine 15mg (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 15mg Primaquine once daily Days 2-15
3174723|NCT01376167|Placebo Comparator|Chloroquine only (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered
3174724|NCT01376154||Subjects prescribed lamivudine tablet|Subjects with hepatitis B virus-induced liver cirrhosis prescribed lamivudine tablet during study period
3174725|NCT01376141||Subjects prescribed IMIGRAN|Subjects with migraine disorders prescribed IMIGRAN during study period
3174726|NCT01376128||Subjects prescribed PAXIL|Pediatric subjects with panic disorder prescribed PAXIL during study period
3174727|NCT01376115||Subjects administered nelarabine|Subjects with T-cell acute lymphocytic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) prescribed nelarabine during study period
3174728|NCT01376102||BONVIVA(ibandronate)|Patients administrated ibandronate injection with postmenopausal osteoporosis
3174729|NCT01376089|Other|Arm 1-Iodixanol|
3174730|NCT01376089|Active Comparator|Arm 2-Iopamidol|
3174731|NCT01376076|Experimental|1|Sequential, Multiple Dose, titration from 1.5mg to 18mg once daily dose of cariprazine
3174732|NCT01376076|Placebo Comparator|2A|Double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35
3174733|NCT01376076|Placebo Comparator|2B|Double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35
3174734|NCT01376063|Experimental|FG-4592|
3174735|NCT01376050|Active Comparator|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 milliWatts (mW) 635 nanometer (nm) light emitting diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center, and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
3174736|NCT01376050|Placebo Comparator|Placebo Laser|Placebo Laser has the same appearance and application as the Erchonia MLS but does not emit an therapeutic output.
3174737|NCT01376037|Placebo Comparator|inactive placebo laser device|The inactive placebo laser device looks identical to the active laser device, but does not emit any therapeutic light output.
3174738|NCT01376037|Active Comparator|Erchonia ML Scanner (MLS)|The Erchonia ML Scanner (MLS) is a low level laser light therapy device comprising 4 independent rotating diodes, each emitting 17mW 635nm of red laser light. The diodes are mounted in scanner devices positioned 120 degrees apart from each other, tilted at a 30 degree angle. The Erchonia® MLS is activated for 20 minutes per arm during which time the 4 rotating diodes create a spiraling circle pattern that is totally random and independent from the others. These patterns overlap each other to guarantee total coverage within the target area. The total laser energy the test subject is exposed to per treated arm is approximately 3.94 joules per square centimeter. Six procedures are administered evenly across 2 weeks.
3174739|NCT01376011|Experimental|healthy young|
3174740|NCT01376011|Experimental|healthy old|
3174741|NCT01375998||Group 1|
3174742|NCT01375985|Experimental|AVI-7100|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
3174743|NCT01375985|Experimental|Placebo|Vehicle
3174744|NCT01375972|Experimental|SP treatment|S-1 plus cisplatin combination chemotherapy
3174745|NCT01375972|Active Comparator|GP treatment|Gemcitabine plus Cisplatin combination chemotherapy
3174746|NCT01375959|Experimental|resveratrol|
3174747|NCT01375959|Placebo Comparator|placebo|
3174748|NCT01375946|Experimental|AG200-15 location|The subject will wear AG200-15 for 7 days and be exposed to one of 5 external conditions (normal, treadmill, cold water, whirlpool, dry sauna).
3174749|NCT01375933|Active Comparator|NicVAX - Phase 3 Lot|NicVAX - Phase 3 Lot
3174750|NCT01375933|Active Comparator|NicVAX - Commercial Lot|NicVAX - Commercial Lot
3174751|NCT01375920|Active Comparator|Metyrapone, daily medication|500 milligrams Metyrapone to be taken orally twice daily for 3 weeks.
3174752|NCT01375920|Placebo Comparator|placebo|a matched placebo will be given for patients to take twice daily
3174753|NCT01375907|Experimental|Rotavin|Rotavin-M1 vaccine, 10e6.3FFU/dose, 2 doses, 1 month between doses
3174754|NCT01375894|Active Comparator|depresive patients|30 patients suffering from depression
3174755|NCT01375894|Experimental|Schizophrenia patients|30 Schizophrenia patients
3174756|NCT01375881||001|darunavir/ritonavir plus background regimen darunavir/ritonavir oral use in naive and experienced patients at approved dosages
3174757|NCT01375868|Experimental|Vaccine Silgard|vaccination with tetravalent antiviral vaccine, 3 doses
3174758|NCT01375855|Active Comparator|Polimeric-PES|Arm receiving polimeric stent (Taxus)
3174759|NCT01375855|Active Comparator|Non-Polimeric PES|Arm receiving non-polimeric PES (axxion)
3174760|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.01 mg/kg|Participants will receive intravenous (IV) infusion of atezolizumab 0.01 milligrams per kilogram (mg/kg) every 3 weeks (q3w) until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
3174761|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.03 mg/kg|Participants will receive IV infusion of atezolizumab 0.03 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
3174762|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.1 mg/kg|Participants will receive IV infusion of atezolizumab 0.1 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
3174763|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.3 mg/kg|Participants will receive IV infusion of atezolizumab 0.3 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
3174879|NCT01375075|Placebo Comparator|Placebo|Administered orally once daily for 12 weeks
3174764|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 1 mg/kg|Participants will receive IV infusion of atezolizumab 1 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
3174765|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 3 mg/kg|Participants will receive IV infusion of atezolizumab 3 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
3174766|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 10 mg/kg|Participants will receive IV infusion of atezolizumab 10 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
3174767|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 20 mg/kg|Participants will receive IV infusion of atezolizumab 20 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
3174768|NCT01375842|Experimental|Expansion Cohort (Atezolizumab)|Participants will receive IV infusion of atezolizumab q3w up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first. The dose which result in total drug exposure less than or equal to (</=) exposures achieved at the MTD or maximum administered dose (MAD), will be selected for expansion cohort.
3174769|NCT01375829|Experimental|Treatment (ixabepilone, temsirolimus)|Patients receive ixabepilone IV over 3 hours on day 1 and temsirolimus IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3174770|NCT01375816|Active Comparator|FOLFIRI 1 or m FOLFIRI3-Bevacizumab|"FOLFIRI 1-Bevacizumab:~Day 1 H0 : Bevacizumab 5 mg/kg, 30-90 min infusion H+1: Irinotecan 180 mg/m² in 250 ml NaCl 0.9%, 1h infusion Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) over 2h H + 3: 5-FU bolus 400 mg/m², 15 min infusion H + 3.5: 5-FU continuous infusion 2400 mg/m² 46-h infusion End of cycle: day 14~modified FOLFIRI3-Bevacizumab H0 :Bevacizumab 5 mg/kg, 30-90 min infusion H+1:Irinotecan 90 mg/m² in 250 ml NaCl 0.9%, 1h infusion H+1: Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) 2-h infusion H + 3: 5-FU continuous infusion 2400 mg/m² 46-h infusion Day 3 (H+49) H0 Irinotecan 90 mg/m² in 250 ml NaCl 0.9%, 1h infusion End of cycle: day 14"
3174771|NCT01375816|Experimental|FUPEP-Bevacizumab|"Day 1 H0 :Bevacizumab 5 mg/kg, 30-90 min infusion H +1 :PEP02 80 mg/m² , 1h30 infusion. The infusion time could be reduced to 1h from cycle 2 if no acute infusion reaction has occured in cycle 1.~H +1 : Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) , 2-h infusion H +3 : 5-FU continuous infusion 2400 mg/m² 46-h infusion End of cycle: day 14"
3174772|NCT01375803|Experimental|1|3g/day
3174773|NCT01375803|Experimental|2|6g/day
3174774|NCT01375803|Placebo Comparator|Placebo beverage|0g/day
3174775|NCT01375790|Experimental|Exercise with Whole-body vibration platform|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm). Training volume and intensity we will increase systematically over six weeks according to the overload principle.
3174776|NCT01375790|Active Comparator|Exercise|The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli, during a six weeks training period (3sessions/week). Training volume and intensity we will increase systematically over six weeks according to the overload principle
3174777|NCT01375777|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
3174778|NCT01375777|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
3174779|NCT01375777|Active Comparator|Ezetimibe|Participants received 10 mg ezetimibe orally once a day for 12 weeks.
3174780|NCT01375777|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3174781|NCT01375777|Experimental|Evolocumab 105 mg Q2W|Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3174782|NCT01375777|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3174783|NCT01375777|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3174784|NCT01375777|Experimental|Evolocumab 350 mg Q4W|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3174785|NCT01375777|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3174786|NCT01375764|Active Comparator|Ezetimibe|Participants received placebo subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
3174787|NCT01375764|Experimental|Evolocumab + Ezetimibe|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
3174788|NCT01375764|Experimental|Evolocumab 280 mg|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3174789|NCT01375764|Experimental|Evolocumab 350 mg|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3174790|NCT01375764|Experimental|Evolocumab 420 mg|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3174791|NCT01375751|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 4 weeks for 12 weeks.
3174792|NCT01375751|Experimental|Evolocumab 350 mg|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3174793|NCT01375751|Experimental|Evolocumab 420 mg|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3174794|NCT01375738|Active Comparator|Gastroduodenostomy|Arm 1: undergo gastroduodenostomy after distal gastrectomy for gastric cancer
3174795|NCT01375738|Experimental|Roux-en Y gastrojejunostomy|Arm 2: undergo Roux-en Y gastrojejunostomy after distal gastrectomy for gastric cancer
3174796|NCT01375725||Coumadin (warfarin)|Subjects currently receiving coumadin (warfarin) treatment.
3174797|NCT01375712|Active Comparator|Fermented milk|Fermented milk containing Lactobacillus casei strain Shirota, 65 ml in a bottle, consume 1 bottle per day.
3174798|NCT01375712|Placebo Comparator|Placebo|Non-fermented milk without Lactobacillus casei strain Shirota, 65 ml in a bottle, consume 1 bottle per day.
3174799|NCT01375699|Experimental|Sildenafil + doxorubicin|"Patients receive sildenafil citrate PO QD* beginning at least 2 days prior to scheduled first dose of doxorubicin hydrochloride and continuing until 2 weeks after last scheduled dose of doxorubicin hydrochloride. Patients also receive doxorubicin hydrochloride IV as clinically indicated and as prescribed by treating provider.~NOTE: *Patients receive sildenafil citrate PO TID on days that doxorubicin hydrochloride is also administered."
3174800|NCT01375699|Active Comparator|Doxorubicin-based chemotherapy|Patients receive doxorubicin hydrochloride IV as clinically indicated and as prescribed by treating provider.
3174801|NCT01375686||Those at Risk for Type 2 diabetes|All subjects will be at risk for diabetes based on the American Diabetes Association (ADA) Standard of Care Guidelines.
3174802|NCT01375673|Experimental|Arm 1|Exercise
3174803|NCT01375673|No Intervention|Arm 2|Usual Care
3174804|NCT01375660|Placebo Comparator|Arm 1|Placebo: One capsule weekly
3174805|NCT01375660|Experimental|Arm 2|50K vitamin D2: One capsule weekly
3174806|NCT01375647|Experimental|Rotarix + No IPV|Randomized to receive rotarix vaccine but no IPV boost
3174807|NCT01375647|Experimental|Rotarix + with IPV boost|Randomized to receive both rotarix vaccine and IPV boost
3174808|NCT01375647|No Intervention|No Rotarix + No IPV|Randomized to receive neither rotarix vaccine nor IPV boost
3174809|NCT01375647|Experimental|No Rotarix + with IPV boost|Randomized to receive no rotarix vaccine but to receive IPV boost
3174810|NCT01375634|Placebo Comparator|Placebo|Normal saline
3174811|NCT01375634|Experimental|Midazolam|Midazolam
3174812|NCT01375608|Other|decitabine|active treatment
3174813|NCT01375582|Experimental|Drop Administration|
3174814|NCT01375569|Experimental|TRC105 in Liver Cancer|TRC105 is an experimental cancer drug designed to slow or stop the growth of tumors. It does this by preventing the growth of new blood vessels that feed these tumors. This drug is being used to test the safety and effectiveness to treat liver cancer that has not responded to standard therapy. TRC105 will be given as an intravenous infusion every two weeks.
3174815|NCT01375504|Active Comparator|Dietary Counseling|The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
3174816|NCT01375504|Other|Mindfulness Training Program|The mindfulness training program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
3174817|NCT01375491|Experimental|Doxycycline|Participants with DM2 receiving doxycycline 100mg BID
3174818|NCT01375491|Placebo Comparator|Placebo|Pills prepared identical to doxycycline.
3174819|NCT01375478||Cohort|
3174820|NCT01375465|Other|Dior|One arm observational registry using the Dior paclitaxel eluting balloon for the treatment of de novo ostial bifurcated lesions.
3174821|NCT01375452|Active Comparator|Femara|
3174822|NCT01375452|Experimental|Letrozole|
3174823|NCT01375439|Other|Active search of lower genital tract infections|"Active search of lower genital tract infections~Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome."
3174824|NCT01375413|Experimental|Integrated dual task training|Integrated dual task training delivered by a physiotherapist. In this training mode walking practice will be combined with simultaneously carrying out cognitive discrimination, verbal fluency and memory tasks.
3174825|NCT01375413|Active Comparator|Consecutive task training|Consecutive task gait training delivered by a physical therapist. In this training mode, walking practice will be conducted separately, focusing on the motor task only. Training of cognitive discrimination, verbal fluency and memory tasks will be done consecutively while the subjects are sitting.
3174826|NCT01375387|Experimental|Lacosamide 100 mg, Japanese|1 Lacosamide 100 mg tablet plus 3 placebo tablets
3174827|NCT01375387|Experimental|Lacosamide 100 mg, Chinese|1 Lacosamide 100 mg tablet plus 3 placebo tablets
3174828|NCT01375387|Experimental|Lacosamide 200 mg, Japanese|2 Lacosamide 100 mg tablets plus 2 placebo tablets
3174829|NCT01375387|Experimental|Lacosamide 200 mg, Chinese|2 Lacosamide 100 mg tablets plus 2 placebo tablets
3174830|NCT01375387|Experimental|Lacosamide 400 mg, Japanese|4 Lacosamide 100 mg tablets
3174831|NCT01375387|Experimental|Lacosamide 400 mg, Chinese|4 Lacosamide 100 mg tablets
3174832|NCT01375387|Placebo Comparator|Placebo Comparator, Japanese|4 placebo tablets
3174833|NCT01375387|Placebo Comparator|Placebo Comparator, Chinese|4 placebo tablets
3174834|NCT01375374|Experimental|Lacosamide|commercial 50 mg (pinkish) and 100 mg (yellow) tablets
3174835|NCT01375361|Experimental|Inhaled Albuterol|Patients identified to have Cardiogenic Pulmonary Edema, will receive 2.5mg of Albuterol nebulizer on enrollment in the study and again at 4 hours. Patients will be monitored on telemetry in the emergency department during and after study drug administration. Although study drug administration will cease after 4 hours, we will continue to record ongoing data during the patient's hospitalization.
3174836|NCT01375361|Placebo Comparator|Inhaled Placebo.|Patients identified to have Cardiogenic Pulmonary Edema will receive 2.5mg Normal saline inhaled (Placebo) on enrollment and at 4 hours in the emergency department. Patient will be monitor on telemetry in the emergency department during and after placebo administration.
3174837|NCT01375348|Active Comparator|Remifentanil|"Investigate the effect of remifentanil on cognitive function in healthy volunteers by use of experimental pain models:~tonic muscle pain induced by the tourniquet pain model~cognitive tests~recording of brain activity by use of 64 channel cap"
3174880|NCT01375075|Active Comparator|10 mg Atorvastatin|Administered orally once daily for 12 weeks
3174838|NCT01375348|Placebo Comparator|Placebo infusion|"To blind the study and use as comparator in the investigation of the effect of remifentanil on cognitive function in healthy volunteers by use of experimental pain models:~tonic muscle induced pain by the tourniquet pain model~cognitive tests~brain activity by use of a 64 channel cap"
3174839|NCT01375335|Experimental|Dobutamine|
3174840|NCT01375322|Active Comparator|Co-Diovan® Group|The starting dose of Co-Diovan® was 1 capsule (contains 1/2 tablet) (valsartan/ hydrochlorothiazide 40 mg/ 6.25 mg) every morning and could be adjusted up to 2 capsules (contains 1 tablet per capsule) (valsartan/ hydrochlorothiazide 160 mg/ 25.0 mg) every morning if patients did not achieve the criteria of SBP<130 mmHg and DBP< 80 mmHg during treatment period
3174841|NCT01375322|Experimental|Amtrel® Group|The starting dose of Amtrel® was 1 capsule (contains 1/2 tablet) (amlodipine / benazepril hydrochloride 2.5 mg/ 5 mg) every morning and could be adjusted up to 2 capsules (contains 1 tablet per capsule) (amlodipine / benazepril hydrochloride 10 mg/ 20 mg) every morning if patients did not achieve the criteria of SBP<130 mmHg and DBP< 80 mmHg during treatment period
3174842|NCT01375309|Active Comparator|Active|Bifidobacterium bifidum
3174843|NCT01375309|Placebo Comparator|Placebo|Dextrin without Bifidobacterium bifidum
3174844|NCT01375296|Experimental|SES|including two types of China-made SES, i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
3174845|NCT01375296|Other|medicine|
3174846|NCT01375283||lung cancer surgery|
3174847|NCT01375270|Experimental|Glucotoxicity Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest, isocaloric meal feeding, and experimental elevation of blood glucose."
3174848|NCT01375270|No Intervention|Control Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest and isocaloric meal feeding."
3174849|NCT01375270|Experimental|Lipotoxicity Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest, isocaloric meal feeding, and experimental elevation of blood free fatty acids."
3174850|NCT01375257|Active Comparator|Guideline treatment with parenteral antibiotics|Guideline treatment with parenteral antibiotics
3174851|NCT01375257|Experimental|Oral treatment with antibiotics|Oral treatment with antibiotics based on resistens pattern
3174852|NCT01375244|Experimental|A|Subjects received the Par formulated product.
3174853|NCT01375244|Active Comparator|B|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
3174854|NCT01375231|Active Comparator|Measured Resection of patellofemoral joint|The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
3174855|NCT01375231|Active Comparator|Measured resection of patella|The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
3174856|NCT01375218|Active Comparator|Plastizote Brace|
3174857|NCT01375218|Active Comparator|Pavlik Brace|
3174858|NCT01375205|Active Comparator|Standard of Care|Subjects will apply Johnson&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&Johnson cleanser.
3174859|NCT01375205|Experimental|Cetaphil Restoraderm|Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
3174860|NCT01375179|Experimental|KRP203|"Experimental~Edit~Experimental"
3174861|NCT01375179|Placebo Comparator|Placebo|Placebo
3174862|NCT01375166||Diabetic retinopathy|Patients with early insulin dependent diabetes and no or mild non-proliferative retinopathy
3174863|NCT01375166||healthy|healthy control subjects
3174864|NCT01375153|Placebo Comparator|Placebo|0,9% NaCl administered as a continuous intravenous infusion during four hours.
3174865|NCT01375153|Active Comparator|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours.
3174866|NCT01375140|Experimental|Ruxolitinib + Lenalidomide|Ruxolitinib 15 mg orally twice daily continuously + Lenalidomide orally 5 mg/day on days 1-21, followed by 7 days of no therapy (28-day cycle). Prednisone will be added for patients who have not responded after 3 cycles of therapy. Prednisone 30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued.
3174867|NCT01375127||Subjects from Study A3921009|
3174868|NCT01375127||Subjects from Study A3921030|
3174869|NCT01375114|Experimental|Panax Ginseng|Panax ginseng 400 mg by mouth twice a day from Day 1-29 for first 30 participants in Part 1. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
3174870|NCT01375114|Experimental|Ginseng (Part 2)|Panax ginseng 400 mg by mouth twice a day from Day 1-29. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
3174871|NCT01375114|Placebo Comparator|Placebo (Part 2)|Oral placebo twice daily for 4 weeks. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
3174872|NCT01375101|Active Comparator|quercetin|quercetin is one of flavonoids , and having therapeutical anti-inflammatory and antioxidant action
3174873|NCT01375101|Placebo Comparator|placebo|placebo capsul is produced with lactose for using in placebo/ control group.
3174874|NCT01375088|Placebo Comparator|placebo mouth wash|10 patients swish & swallow 15 ml placebo mouth wash for at least 5 min from the first session of radiotherapy until the last session
3174875|NCT01375088|Active Comparator|propolis|10 patients swish & swallow 15 ml propolis mouth wash for at least 5 min from the first session of radiotherapy until the last session
3174876|NCT01375075|Experimental|30 mg LY2484595|Administered orally once daily for 12 weeks
3174881|NCT01375075|Experimental|100 mg LY2484595 + 10 mg Atorvastatin|Administered orally once daily for 12 weeks
3174882|NCT01375062|No Intervention|tissue from biopsies|
3174883|NCT01375049|Experimental|Aztreonam for Inhalation Solution (AZLI)|Participants will receive one 28-day course of AZLI, then will be followed for a 24-week period (through Day 196).
3174884|NCT01375023|Experimental|Anti-Thymocyte Globulin+radiotherapy|triple negative breast cancer patients treated with radiation and Anti-Thymocyte Globulin iv
3174885|NCT01375010|Placebo Comparator|Group A|Placebo vitamin D3 capsule daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 1000 IU.
3174886|NCT01375010|Experimental|Group B|2000 IU vitamin D3 daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 3000 IU.
3174887|NCT01374997|Other|patients with Fabry disease|detection of this disease in end-stage renal failure patients, transplant or hemodialysis
3174888|NCT01374984||Subjects treated with VIGIV.|"Subjects treated with VIGIV deployed from the US Strategic National Stockpile for any of the following conditions:~Eczema vaccinatum.~Progressive vaccinia.~Severe generalized vaccinia.~Vaccinia infections in individuals who have skin conditions.~Aberrant infections induced by vaccinia virus (except in cases of isolated keratitis)."
3174889|NCT01374971|Other|Certolizumab Pegol (CZP)|Certolizumab Pegol (CZP) liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks with arthroscopic synovial tissue biopsy pre- and post-treatment.
3174890|NCT01374945|No Intervention|SOC preparation and colonoscopy|
3174891|NCT01374945|Experimental|Miniprep and Clearpath|
3174892|NCT01374932|Experimental|CPAP (see below)|Adult patients with asthma who require treatment with CPAP because of OSAS (RDI> = 20 events per hour). CPAP will be administered according to SEPAR guidelines and tailored to individual characteristics
3174893|NCT01374919|Other|ferumoxytol|IV administration of 1020 mg of ferumoxytol in 15 minutes
3174894|NCT01374906|Experimental|10 mg LAR dose|Randomization was stratified based on Screening mUFC to ensure balanced distribution of disease severity in the two dose arms.
3174895|NCT01374906|Experimental|30 mg LAR dose|Randomization was stratified based on Screening mUFC to ensure balanced distribution of disease severity in the two dose arms.
3174896|NCT01374893|Active Comparator|Exercise|
3174897|NCT01374893|Placebo Comparator|Control group|Usual care
3174898|NCT01374880||Dyspnea cohort|Dyspnea cohort
3174899|NCT01374880||Stable chronic heart failure|Stable chronic heart failure
3174900|NCT01374880||Valvular heart disease|Valvular heart disease
3174901|NCT01374880||Ventricular assist device|Ventricular assist device
3174902|NCT01374880||Cardiac arrest|Cardiac arrest
3174903|NCT01374880||Cardiac rehabilitation|Cardiac rehabilitation
3174904|NCT01374854|Experimental|Stem Cell Infusion|
3174905|NCT01374854|Active Comparator|traditional therapy control|
3174906|NCT01374841|Experimental|Stem Cell Transplant+Cyclophosphamide|patients with high-risk hematologic malignancies will receive hematopoietic stem cell transplantation from haploidentical donors after treatment with cyclophosphamide
3174907|NCT01374828|Experimental|Ketolorac|
3174908|NCT01374815|Experimental|The Online Advocate|
3174909|NCT01374802|Experimental|BI 201335|capsule for oral administration
3174910|NCT01374802|Experimental|Darunavir 400 mg|tablet for oral administration
3174911|NCT01374802|Experimental|Ritonavir 100 mg|tablet for oral administration
3174912|NCT01374789|Experimental|Arm A (GemCis + Panitumumab)|gemcitabine + cisplatin + panitumumab
3174913|NCT01374789|Active Comparator|Arm B (GemCis)|gemcitabine + cisplatin
3174914|NCT01374763|Active Comparator|Oxycodone|Drug: prolonged-release oxycodone
3174915|NCT01374763|Active Comparator|Oxycodone/naloxone|Prolonged-release oxycodone/naloxone
3174916|NCT01374750|Active Comparator|m-TOR inhibitor free|Immunosuppressive drug
3174917|NCT01374750|Experimental|Sirolimus|Immunosuppressive drug
3174918|NCT01374737|Other|dexmedetomidine, children|
3174919|NCT01374724|Experimental|Ban & Informational Pamphlet|Following 8.5 weeks of cessation subjects are given an informational pamphlet on tobacco cessation and relapse prevention.
3174920|NCT01374724|Experimental|Ban & Tailored Pamphlet|After 8.5 weeks of tobacco use cessation during Basic Military Training subjects are provided a tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force
3174921|NCT01374724|Experimental|Ban & Tailored Pamphlet & Intervention|After 8.5 weeks of tobacco use cessation during Basic Military Training subjects are provided a tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force. In addition they are given a face to face relapse prevention intervention.
3174922|NCT01374711|Placebo Comparator|placebo|LPS will be administered twice on days 1 and 7. In between placebo will be administered on days 2, 4 and 6 subcutaneously.
3174923|NCT01374711|Active Comparator|GM-CSF|LPS will be administered twice on days 1 and 7. In between GM-CSF will be administered on days 2, 4 and 6 subcutaneously.
3174924|NCT01374711|Active Comparator|IFN-y|LPS will be administered twice on days 1 and 7. In between IFN-Y will be administered on days 2, 4 and 6 subcutaneously.
3174925|NCT01374698|Active Comparator|Aspirin|All patients who meet the eligibility criteria will be randomized in a 1:1 manner to receive, before the coronary percutaneous procedure, an oral aspirin reload (325 mg)or placebo.
3174926|NCT01374698|No Intervention|No intervention|No intervention
3174927|NCT01374672||Correlative studies|DNA and RNA extracted from biopsy samples are analyzed for methylation changes and transcription changes by ligation-mediated PCR and mass-array genotyping.
3174974|NCT01374269|Active Comparator|NSAID|Naproxen 500 mg per day by 10 days or Celecoxib 200 mg per day by 10 days and Acetaminophen 1,5 a 2 g as rescue
3174975|NCT01374256||Combination therapy|Patients with Acinetobacter baumannii bacteremia treated with combination therapy of imipenem and sulbactam
3174976|NCT01374256||Not combination therapy|Patients with Acinetobacter baumannii bacteremia not treated with combination therapy of imipenem and sulbactam
3175021|NCT01373905|Active Comparator|Sustained lung inflation|recruitment was done using CPAP of 30 Cm/ H2o for 30 seconds
3174928|NCT01374659||Study patients|Study patients with histologically proven DTC were studied. All patients had previously undergone total thyroidectomy and more than one session of postoperative RI therapy. After the last RI therapy session, all patients showed increasing pathological Tg levels (Tg > 9-10 ng/ml) after TSH stimulation (TSH > 30 mU/l). However, neither tumor recurrence nor metastasis could be detected in any patient by post-therapeutic [131I] scanning, neck US, or chest radiography. Patients with obvious cervical pathology or positive fine-needle aspiration cytology (FNAC) were excluded from the study. The work was approved by our Institutional Review Board and written informed consent was obtained from each patient.
3174929|NCT01374633|Experimental|1:patient with severe traumatic brain|
3174930|NCT01374620|Experimental|Paclitaxel Dose escalation|"A standard dose escalation strategy will be used including 3 to 6 patients at each dose level (Paclitaxel dose escalation + fixed dose of cyclophosphamide)~+ blood collection"
3174931|NCT01374620|Experimental|Cohort extension|"An additional 10 patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose~+ blood collection"
3174932|NCT01374594||Healthy adults|
3174933|NCT01374594||Type 2 diabetes|
3174934|NCT01374581|Experimental|Artemether/Lumefantrine|Tablets 20 mg/120 of Artemether/Lumefantrine will be given to 124 trial patients
3174935|NCT01374581|Experimental|Artesunate/Amodiaquine|Tablets 25mg/67,5 mg of Artesunate/Amodiaquine will be given to 124 trial patients.
3174936|NCT01374581|Active Comparator|Quinine + Clindamycin|Quinine tablet 125mg + Clindamycin syrup 75mg/5ml will be given to 60 children.
3174937|NCT01374568|Active Comparator|sitagliptin|Sitagliptin
3174938|NCT01374568|Placebo Comparator|Placebo|Placebo
3174939|NCT01374542||Respiratory endoscopy patients|Patients undergoing respiratory endoscopy at Singapore General Hospital
3174940|NCT01374516|Experimental|CYD Dengue Vaccine Group|Participants will receive a dose of CYD dengue vaccine at 0, 6, and 12 months, respectively.
3174941|NCT01374516|Placebo Comparator|Control Group|Participants will receive a dose of placebo vaccine at 0, 6, and 12 months, respectively.
3174942|NCT01374503|Experimental|ALX-0651|
3174943|NCT01374503|Placebo Comparator|Placebo|
3174944|NCT01374490|Experimental|Crofelemer|
3174945|NCT01374477||Adolescent with preeclampsia|Patients < 19 years old who delivered in our institution (vaginal birth or cesarean) that developed a hypertensive disorder of pregnancy.
3174946|NCT01374477||Normal adolescent|Patients < 19 years old who delivered in our institution (vaginal birth or cesarean) without developing a hypertensive disorder of pregnancy.
3174947|NCT01374464|Active Comparator|High Volume, High Concentration|
3174948|NCT01374464|Active Comparator|High Volume, Low Concentration|
3174949|NCT01374464|Active Comparator|Low Volume, High Concentration|
3174950|NCT01374464|Active Comparator|Low Volume, Low Concentration|
3174951|NCT01374451|Experimental|Paseriotide LAR + Everolimus|everolimus 10 mg once daily po in combination with pasireotide LAR 60 mg every 28 days (q28d) im
3174952|NCT01374451|Experimental|Everolimus|everolimus 10 mg once daily po alone
3174953|NCT01374438|Experimental|MSDC-0160 capsules|MSDC tablets contained in #00 capsules
3174954|NCT01374438|Placebo Comparator|Placebo capsules|Placebo tablets contained in #00 capsules
3174955|NCT01374425|Experimental|Bevacizumab + mFOLFOX6|Participants will receive bevacizumab plus mFOLFOX6 by intravenous (IV) infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity. Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to oxaliplatin, with bevacizumab continued in 3-week cycles.
3174956|NCT01374425|Experimental|Bevacizumab + FOLFIRI|Participants will receive bevacizumab plus FOLFIRI by IV infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity. Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to irinotecan, with bevacizumab continued in 3-week cycles.
3174957|NCT01374412||osteoporosis|patients with benign osteoporosis
3174958|NCT01374399|Experimental|resistance and endurance exercise|
3174959|NCT01374399|Active Comparator|relaxation|
3174960|NCT01374386|No Intervention|Usual Physical Activity|Participants in this arm are do not have access to Exergames, only usual physical activity at the gym
3174961|NCT01374386|Experimental|Exergaming|Participants in this arm will have access to usual physical activity at the gym as well as access to Exergaming equipment (video games that require physical activity)
3174962|NCT01374373|Other|Open Label|One arm open label
3174963|NCT01374360||Receiving Soliris|PNH patients of any age, including minors, that are receiving Soliris
3174964|NCT01374360||Not receiving Soliris|PNH patients of any age, including minors, that are not receiving Soliris
3174965|NCT01374347||One dose, Repeat doses|First group recives one dose Second group receives several doses
3174966|NCT01374347||One dose, several doses|15 patients will take one dose of 20 mg cialis, and will have a second brain SPECT 24 hours after cialis administration. 15 other patients (age and risk factor matched) will be prescribed 5 mg of cialis once daily for 7 days, and a second SPECT study will be performed 24 hours after the last dose.
3174967|NCT01374321|Placebo Comparator|Placebo|
3174968|NCT01374321|Experimental|TRO40303|
3174969|NCT01374308|Experimental|NASVAC|NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
3174970|NCT01374308|Active Comparator|Pegylated interferon alpha 2b|Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
3174971|NCT01374295|Experimental|video|If randomized to this arm patient watches a 3 minute video
3174972|NCT01374295|Active Comparator|standard education|If randomized to this arm patient receives standard verbal education from healthcare provider.
3174973|NCT01374269|Experimental|Excercise|One group will be assigned to protocolized back pain exercise, three times a week for 4 weeks. This program is carried out by physiotherapists from participating institutions who wish to participate in research and who will be given a training which will standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. Treatment, type of exercises, exercise tolerance and adverse reactions will be registered
3174977|NCT01374230|Experimental|E1 Tibial bearing|All patients undergoing primary total knee replacement surgery will receive a tibial bearing made of E1 polyethylene, which is the material being monitored in this study.
3174978|NCT01374217|Experimental|Tadalafil (Cialis)|Subject will take tadalafil(cialis) in combination with with Lenalidomide and dexamethasone (Rd) or Biaxin/Lenalidomide/ dexamethasone (BiRd)
3174979|NCT01374191|Active Comparator|onabotulinum toxin type-A|1 injection of Btx-A, or up to 4 injections of Btx-A during the 1-year study period if pain recurs
3174980|NCT01374191|Placebo Comparator|placebo|saline
3174981|NCT01374191|Active Comparator|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
3174982|NCT01374178|Experimental|LY2963016|A single 0.5-unit per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously.
3174983|NCT01374178|Active Comparator|Lantus|A single 0.5-U/kg dose of Lantus will be administered subcutaneously.
3174984|NCT01374165||Low dose SANGUINATE™|"160 mg/kg of SANGUINATE™.~SANGUINATE™ (PEG-bHb-CO) an OTA is composed of three moieties, polyethylene glycol, bHb and carbon monoxide that act in a specific manner to promote the delivery of oxygen to tissue. SANGUINATE™ was not developed to be used as a blood substitute. It is instead an oxygen transfer agent intended to functionally deliver and release oxygen to hypoxic tissues."
3174985|NCT01374165||High dose of SANGUINATE™|"320 mg/kg of SANGUINATE™.~SANGUINATE™ (PEG-bHb-CO) an OTA is composed of three moieties, polyethylene glycol, bHb and carbon monoxide that act in a specific manner to promote the delivery of oxygen to tissue. SANGUINATE™ was not developed to be used as a blood substitute. It is instead an oxygen transfer agent intended to functionally deliver and release oxygen to hypoxic tissues."
3174986|NCT01374152|Experimental|Perfetti|Cognitive sensory motor training method for upper extremities rehabilitation every working day, totally training not less than 600 minutes within 4 weeks.
3174987|NCT01374152|No Intervention|conventional rehabilitation|conventional occupational therapy method for upper extremities rehabilitation every working day, totally training not less than 600 minutes within 4 weeks.
3174988|NCT01374139|Experimental|Cohort 1|
3174989|NCT01374139|Experimental|Cohort 2|
3174990|NCT01374126|Experimental|Azithromycin-Artesunate|
3174991|NCT01374126|Active Comparator|Control (artesunate alone)|
3174992|NCT01374113|Experimental|Group 1|Subjects with moderate renal impairment
3174993|NCT01374113|Experimental|Group 2|Subjects with severe renal impairment
3174994|NCT01374113|Experimental|Group 3|Matched subjects with normal renal function
3174995|NCT01374100|Active Comparator|Standard Exercise|See methods below - standard strength and endurance training
3174996|NCT01374100|Experimental|Qigong exercise|See methods below - medical QiGong therapy session
3174997|NCT01374087|Experimental|Brachytherapy + Triptorelin 22.5 mg|Brachytherapy: Low or high dose rate. Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
3174998|NCT01374087|Active Comparator|Brachytherapy|Brachytherapy: Low or high dose rate.
3174999|NCT01374074||White GERD|"Participants who self-identify as not-Hispanic or Latino and White and have been diagnosed by a physician with gastroesophageal reflux disease and do not have Barrett's esophagus."
3175000|NCT01374074||African American GERD|"Participants who self-identify as not-Hispanic or Latino and African American and have been diagnosed by a physician with gastroesophageal reflux disease and do no have Barrett's esophagus."
3175001|NCT01374074||White BE|"Participants who self-identify as not-Hispanic or Latino and White and have been diagnosed by a physician with Barrett's Esophagus."
3175002|NCT01374074||African American BE|"Participants who self-identify as not-Hispanic or Latino and African American and have been diagnosed by a physician with Barrett's Esophagus."
3175003|NCT01374061|Active Comparator|1: Classical intubation|
3175004|NCT01374061|Experimental|2: Glidescope intubation|
3175005|NCT01374035|Experimental|Participating GPs|GPs working at randomly selected GP centers/offices within the region that are invited to participate and signs a written informed consent to participate. (N=30-40)
3175006|NCT01374035|No Intervention|Control group|GPs working at randomly selected GP centers/office within the region that are not invited to participate, will form the control group. (N=30-40)
3175007|NCT01374022|Experimental|ART Strategy|maximum alveolar recruitment plus PEEP titration
3175008|NCT01374022|Active Comparator|ARDSNet Strategy|standard strategy (ARDSNet)
3175009|NCT01373996||Wireless|Measuring of invasive arterial blood pressure through HMW10 Wireless System.
3175010|NCT01373996||Wired|Measuring of invasive arterial blood pressure through conventional wired technology.
3175011|NCT01373983|Other|ziconotide|
3175012|NCT01373970|Placebo Comparator|Placebo|
3175013|NCT01373970|Active Comparator|PPI + Placebo|PPI followed by cross over to placebo
3175014|NCT01373957||1|Patients hospitalized and diagnosed with UA, STEMI or NSTEMI
3175015|NCT01373944||Stress Only SPECT MPI with Anger Camera|Patients undergoing clinically-indicated stress-only sestamibi studies who are imaged on the traditional Anger camera
3175016|NCT01373944||Stress Only SPECT MPI with SD Camera|Patients undergoing clinically-indicated stress-only sestamibi studies who are imaged on the Spectrum Dynamics camera system.
3175017|NCT01373931|Experimental|OC + LY2216684 First, Then OC + Placebo|28 day Lead-in period of Ortho Cyclen (OC) (28 day packet), followed by randomization to OC administered orally once daily for 28 days + 18 mg of LY2216684 administered concomitantly orally once daily for 21 days, followed by OC administered orally once daily for 28 days + placebo administered concomitantly orally once daily for 21 days.
3175018|NCT01373931|Experimental|OC + Placebo First, Then OC + LY2216684|28 day Lead-in period of Ortho Cyclen (OC) (28 day packet), followed by randomization to OC administered orally once daily for 28 days + placebo administered concomitantly orally once daily for 21 days, followed by OC administered orally once daily for 28 days + 18 mg of LY2216684 administered concomitantly orally once daily for 21 days.
3175019|NCT01373918|Experimental|low dose intravenous fat emulsion|Subjects in this arm will receive approximately 1 g/kg/d IV of intravenous soybean oil (Intralipid).
3175020|NCT01373918|Active Comparator|standard dose intravenous fat emulsion|Subjects in this arm will receive approximately 3 g/kg/d IV of intravenous soybean oil (Intralipid).
3176252|NCT01365663|Experimental|Cohort 5|2.0 mg/kg in Healthy Subjects
3175022|NCT01373905|Active Comparator|Stepwise PEEP elevation|Recruitment was done using stepwise elevation of PEEP followed by determination of the alveolar collapsing pressure
3175023|NCT01373892|Active Comparator|Surgery|Slevve vs. Roux-Y
3175024|NCT01373892|No Intervention|Healthy lean volunteers|
3175025|NCT01373879|Experimental|Group 1A|Adults (18-50 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
3175026|NCT01373879|Experimental|Group 1B|Adults (18-50 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME TRAP
3175027|NCT01373879|Experimental|Group 2A|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
3175028|NCT01373879|Experimental|Group 2B|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
3175029|NCT01373879|Active Comparator|Group 2C|Children (2-6 years old) vaccinated with human diploid cell rabies vaccine
3175030|NCT01373879|Experimental|Group 3A|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
3175031|NCT01373879|Experimental|Group 3B|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
3175032|NCT01373879|Active Comparator|Group 3C|Children (2-6 years old) vaccinated with human diploid cell rabies vaccine
3175033|NCT01373866|Experimental|Multimodal MRI-guided rTMS|
3175034|NCT01373866|Active Comparator|Conventional T3-P3 rTMS|
3175035|NCT01373853|Experimental|Femtec Groupe A|In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery
3175036|NCT01373853|Active Comparator|Manual Group B|Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
3175037|NCT01373840||healthy controls|
3175038|NCT01373840||patients with focal dystonias|
3175039|NCT01373827||MC1 Subjects|
3175040|NCT01373801|Active Comparator|Control|
3175041|NCT01373801|Experimental|GuardaCare|
3175042|NCT01373775||Revisit|HF patients who revisit the emergency department before the next appointment date.
3175043|NCT01373775||Non-revisit|HF patients who follow up on the appointment date.
3175044|NCT01373762|Experimental|Exercise Videogame Bike|Families in this group will receive an interactive exercise videogame bike (ie. the Active Cycle) to keep in their home for three months.
3175045|NCT01373762|Other|Stationary Bike|Families will receive a stationary bike to keep in their home for three months. It is required that the family places the stationary bike (Active Cycle without video game controllers) in front of a television.
3175046|NCT01373749|Experimental|NOS|NO inhalation was performed in the first stage(<48h) of PPHN, NO inhalation was replaced by sildenafil in the second stage(>48h).
3175047|NCT01373749|Placebo Comparator|NO|NO inhalation was performed during the whole treatment procedure of PPHN. There is no other methods given to treat PPHN during the therapy course.
3175048|NCT01373723|Experimental|invitation letter|to participate in the screening
3175049|NCT01373723|Experimental|Invitation letter, informative leaflet and phone call reminder|to participate in the screening
3175050|NCT01373723|Experimental|Invitation letter and informative leaflet|to participate in the screening
3175051|NCT01373710|Experimental|Trastuzumab intrathecal|
3175052|NCT01373697|Active Comparator|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
3175053|NCT01373697|Active Comparator|Ibuprofen|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
3175054|NCT01373684|Experimental|Peginterferon alfa-2a add on|All patients are all currently being treated with long-term NA treatment. PEG-IFN will be given in a dose of 180 μg per week s.c. for a total duration of 48 weeks starting at week 0.
3175055|NCT01373684|Active Comparator|Nucleoside analogue|All patients are all currently being treated with long-term Nucleos(t)ide analogue treatment and will continue using this medication during the duration of the study.
3175056|NCT01373671|Other|Mammography exam|Siemens DBT scan
3175057|NCT01373658|Experimental|Yinyi stent|
3175058|NCT01373645|Experimental|Yinyi stent|subjects with Yinyi stent implantation
3175059|NCT01373632|Experimental|Firebird 2 stent group|the patients who receive Firebird 2 stent
3175060|NCT01373632|Active Comparator|Excel stent group|the patients who receive Excel stent
3175061|NCT01373619|Experimental|IVABRADINE, HEART FAILURE WITH NORMAL EF|Patient on hemodialysis with Heart failure with normal ejection fraction treated with ivabradine titrated to 7.5 mg BID to assess changes in echocardiography diastolic function and NYHA class and 6-minutes walking test
3175062|NCT01373606|Experimental|Terlipressin|
3175063|NCT01373593|Experimental|lidocaine|lidocaine block
3175064|NCT01373593|Placebo Comparator|Placebo|
3175065|NCT01373580|Experimental|Raindrop|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near vision.
3175066|NCT01373567|Experimental|TINEFCON|Tablets of 700 mg.
3175067|NCT01373554|Placebo Comparator|Placebo|
3175068|NCT01373554|Experimental|Oltipraz|
3175069|NCT01373541|Active Comparator|InFat group|Infant formula with structured triglycerides (high palmitic acid content at the sn-2 position)
3175070|NCT01373541|Active Comparator|Control group|Infant formula with standard vegetable blend (low palmitic acid content at the sn-2 position)
3175071|NCT01373541|No Intervention|Referance group|Human milk breastfeeding
3175072|NCT01373528|Experimental|Budesonide|
3175073|NCT01373515|Experimental|Cohort 1; 1x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 1x10E7 DCP-001.
3175074|NCT01373515|Experimental|Cohort 2; 2.5x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 2.5x10E7 DCP-001.
3175075|NCT01373515|Experimental|Cohort 3; 5x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 5x10E7 DCP-001.
3175150|NCT01373086|Active Comparator|Eplerenone|Eplerenone 50mg twice daily + matching placebo of LFF269
3175076|NCT01373515|Experimental|Cohort 4; 5x10E7 DCP-001|n=3; patients, matched for HLA-A2, receiving 4 bi-weekly vaccinations of 5x10E7 DCP-001. Or, in case this turned out toxic, this group will receive the Maximum Tolerated Dose.
3175077|NCT01373502|Experimental|DES Limus Carbostent Coronary Stent|
3175078|NCT01373502|Active Comparator|Taxus Liberté Coronary Stent|
3175079|NCT01373489|No Intervention|Usual Care|The usual care group received the current standards of care at the study clinics.
3175080|NCT01373489|Experimental|Technology Assisted Case Management|The TACM group used the FORA 2-in-1 Telehealth system for diabetes management intervention to link a case manager to patients with poorly controlled type 2 diabetes in real time.
3175081|NCT01373476|Experimental|Qideng Mingmu capsule|High dosage group,Middle dosage group,Low dosage group.
3175082|NCT01373476|Placebo Comparator|Placebo|Placebo group
3175083|NCT01373463|Experimental|Arm A|"Patients will be given the drugs pemetrexed and carboplatin~Radiation~Participants evaluated for response~Lobectomy surgery"
3175084|NCT01373463|Experimental|Arm B|"Patients will be given the drugs pemetrexed and cisplatin~Radiation~Participants evaluated for response~Lobectomy surgery"
3175085|NCT01373450|Experimental|OXM → Lg-0.6 → Pbo → Lg-1.2|Participants received Oxyntomodulin 3.0 pmol/kg/min in the first, Liraglutide 0.6 mg in the second, Placebo in the third, and Liraglutide 1.2 mg in the fourth period
3175086|NCT01373450|Experimental|Lg-0.6 → Pbo → OXM → Pbo|Participants received Liraglutide 0.6 mg in the first, Placebo in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Placebo in the fourth period
3175087|NCT01373450|Experimental|Pbo → OXM → Lg-0.6 → Pbo|Participants received Placebo in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
3175088|NCT01373450|Experimental|Lg-0.6 → OXM → Pbo → Lg-1.2|Participants received Liraglutide 0.6 mg in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Placebo in the third and Liraglutide 1.2 mg in the fourth period
3175089|NCT01373450|Experimental|OXM → Pbo → Lg-0.6 → Pbo|Participants received Oxyntomodulin 3.0 pmol/kg/min in the first; Placebo in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
3175090|NCT01373450|Experimental|Pbo → Lg-0.6 → OXM → Lg-1.2|Participants received Placebo in the first, Liraglutide 0.6 mg in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Liraglutide 1.2 mg in the fourth period
3175091|NCT01373437||Intubate|
3175092|NCT01373424||Cervical dystonia|People diagnosed with cervical dystonia
3175093|NCT01373424||Laryngeal dystonia|People diagnosed with laryngeal dystonia
3175094|NCT01373424||Other voice disorders|People diagnosed with a voice disorder other than laryngeal dystonia - enrollment for this group is complete
3175095|NCT01373424||Craniofacial dystonia|People diagnosed with craniofacial dystonia (including blepharospasm, meige syndrome, and oromandibular dystonia)
3175096|NCT01373424||Limb dystonia|People diagnosed with limb dystonia
3175097|NCT01373424||All other isolated dystonias|People diagnosed with any isolated dystonia not listed in descriptions of other cohorts
3175098|NCT01373424||Myoclonus dystonia|People diagnosed with myoclonus dystonia
3175099|NCT01373424||Dopa-responsive dystonia|People diagnosed with dopa-responsive dystonia
3175100|NCT01373411|Placebo Comparator|Placebo|Placebo twice daily. Study drug will be started within 48 hours of CABG.
3175101|NCT01373411|Active Comparator|ticagrelor 90 mg|Taken twice daily. Study drug will be started within 48 hours of CABG.
3175102|NCT01373385||Surgical|Patients receiving a surgical procedure for vesicoureteral reflux at Connecticut Children's Medical Center.
3175103|NCT01373372|Experimental|Functional Dyspepsia cohort|Cohort of subjects with functional dyspepsia
3175104|NCT01373372|Other|Control cohort|Control group of subjects with no functional dyspepsia
3175105|NCT01373359|Experimental|Sublingual misoprostol|400 µg powdered misoprostol administered sublingually; IM placebo
3175106|NCT01373359|Active Comparator|Oxytocin|10 IU IM oxytocin; placebo powder
3175107|NCT01373346|Experimental|Long limb Roux-en Y reconstruction|Long limb Roux-en Y reconstruction means that the length of Roux limb and biliopancreatic limb are longer than conventional reconstruction method after gastrectomy.
3175108|NCT01373320|Experimental|Early Intervention|Participants in this group are nested in churches which were randomly assigned to the treatment group.
3175109|NCT01373320|No Intervention|Delayed Intervention|Participants in this group are nested in churches which were randomly assigned to the wait-list control group. They receive an educational luncheon focused on stress reduction during the intervention window for the Early Intervention group, and subsequently receive the intervention(s) for their selected target health behaviors at a later date.
3175110|NCT01373307|Experimental|Early Intervention|Participants are nested in churches which were randomly assigned to receive the intervention first.
3175111|NCT01373307|No Intervention|Delayed Intervention|Wait-list control group. Participants are nested in churches which were randomly assigned to receive the intervention at a later date. Delayed Intervention participants receive an educational luncheon addressing stress reduction during the window of no intervention.
3175112|NCT01373294|Experimental|A: Combination Arm|"Bacille Calmette-Guerrin (BCG) and lenalidomide.~Participants were assigned to receive BCG or BCG and lenalidomide based on their cancer. This group received BCG + lenalidomide)"
3175113|NCT01373294|Active Comparator|B: Control Arm|"Bacille Calmette-Guerrin (BCG) only.~Participants were assigned to receive BCG or BCG and lenalidomide based on their cancer.~This group was not eligible to receive the combination of BCG + lenalidomide."
3175114|NCT01373281|Experimental|Dengue Vaccine Group|Participants will receive CYD dengue vaccine at 0, 6, and 12 months
3175115|NCT01373281|Placebo Comparator|Control Group|Participants will receive a placebo vaccine at 0, 6, and 12 months
3175116|NCT01373255|Experimental|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
3175117|NCT01373255|No Intervention|No intervention|no intervention prior to cesarean
3175118|NCT01373242|Experimental|Peanut ( liquid peanut extract) SLIT|All subjects will receive peanut SLIT upon enrollment for at least the first 48 months. After the desensitization DBPCFC after at least 48 months of treatment, subjects will be randomized off treatment from 1 to 17 weeks. Subjects will then undergo another DBPCFC.
3175119|NCT01373229|Experimental|Lenalidomide + Plerixafor+ Rituximab|"Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.~Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.~Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) <100.0 x 109 / L.~Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:~Cohort 1: 0.24 mg/kg~Cohort 2: 0.32 mg/kg~Cohort 3: 0.42 mg/kg~Cohort 4: 0.54 mg/kg~Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.~Subjects will then continue single agent lenalidomide until disease progression."
3175120|NCT01373216|Experimental|Exenatide|Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving perioperatively i.v. exenatide on top of standard treatment
3175121|NCT01373216|No Intervention|Control|Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving standard treatment
3175122|NCT01373190||Epilepsy Group|Individuals diagnosed with Partial/Focal Onset Epilepsy ICD9CM 345.4 and/or 345.5
3175123|NCT01373190||Control Group|Individuals who do not have the diagnosis of Epilepsy and have no history of seizure disorders
3175124|NCT01373177||BSID II - Bayley III|Receive BSID-II testing 4-8 weeks before Bayley-III testing
3175125|NCT01373177||Bayley III - BSID II|Receive Bayley-III testing 4-8 weeks before BSID-II testing
3175126|NCT01373164|Experimental|Phase 1b: 80 mg Galunisertib + Gemcitabine|"Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
3175127|NCT01373164|Experimental|Phase 1b: 160 mg Galunisertib + Gemcitabine|"Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
3175128|NCT01373164|Experimental|Phase 1b: 300 mg Galunisertib + Gemcitabine|"Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
3175129|NCT01373164|Experimental|Phase 2: Recommended dose of Galunisertib + Gemcitabine|"Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
3175130|NCT01373164|Experimental|Phase 2: Placebo + Gemcitabine|"Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
3175131|NCT01373151|Placebo Comparator|Arm 1|BMS-945429 Placebo/BMS-945429+Methotrexate+Adalimumab Placebo
3175132|NCT01373151|Experimental|Arm 2|BMS-945429 + Methotrexate + Adalimumab Placebo
3175133|NCT01373151|Experimental|Arm 3|BMS-945429 + Methotrexate + Adalimumab Placebo
3175134|NCT01373151|Experimental|Arm 4|BMS-945429 + Methotrexate + Adalimumab Placebo
3175135|NCT01373151|Experimental|Arm 5|BMS-945429 + Methotrexate/Methotrexate Placebo + Adalimumab Placebo
3175136|NCT01373151|Experimental|Arm 6|BMS-945429 + Methotrexate/Methotrexate Placebo+Adalimumab Placebo
3175137|NCT01373151|Active Comparator|Arm 7|Adalimumab + Methotrexate
3175138|NCT01373138|Experimental|Desloratadine and pseudoephedrine ER tablets 5/240 mg|Desloratadine and pseudoephedrine ER tablets 5/240 mg of Dr. Reddy's Laboratories Limited
3175139|NCT01373138|Active Comparator|Clarinex D 24-hour|Clarinex D-24 of Schering Corporation Inc USA
3175140|NCT01373125||Radiofrequency Ablation (RFA)|Participants in this group are greater than or equal to 12 months status post radiofrequency ablation (RFA).
3175141|NCT01373125||Radiofrequency Ablation Longitudinal (RFAL)|Participants in this group are part of a longitudinal portion of the study and are enrolled prior to their first radiofrequency ablation procedure and followed at 6 and 12 months after completion of RFA.
3175142|NCT01373125||Gastroesophageal Reflux Disease (GERD)|Participants in this group have been diagnosed with gastroesophageal reflux disease.
3175143|NCT01373125||Asymptomatic Controls (AC)|Participants in this group are asymptomatic controls and enrolled as part of the comparison group.
3175144|NCT01373112|Experimental|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
3175145|NCT01373112|Experimental|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
3175146|NCT01373099|Experimental|Static Spacer|Patients in this group will be randomized to a static, nonarticulating, antibiotic-impregnated cement spacer.
3175147|NCT01373099|Experimental|Articulating spacer|Patients in this group will be randomized to an articulating antibiotic-impregnated cement spacer.
3175148|NCT01373086|Experimental|LFF269 low dose|LFF269 low dose + Matching Placebo to Eplerenone 50mg during 4 week double blind period
3175149|NCT01373086|Experimental|LFF269 high dose|LFF269 high dose + Matching Placebo to Eplerenone 50mg
3175151|NCT01373086|Placebo Comparator|Placebo|Placebo of LFF269 high dose + Placebo of Eplerenone 50 mg
3175152|NCT01373073|Experimental|Experimental Human Milk Fortifier|Experimental human milk fortifier to be added to human milk
3175153|NCT01373073|Active Comparator|Control Human Milk Fortifier|Control human milk fortifier to be added to human milk
3175154|NCT01373060|Experimental|ASP1941 group|
3175155|NCT01373060|Placebo Comparator|placebo group|
3175156|NCT01373047|Experimental|Intrahepatic anti-CEA designer T cells|
3175157|NCT01373034|Experimental|Soy Dietary Fiber|
3175158|NCT01373034|Placebo Comparator|Rice powder|
3175159|NCT01373021|Placebo Comparator|F|Fentanyl+Normal saline
3175160|NCT01373021|Experimental|D|Fentanyl+Dexmedetomidine
3175161|NCT01373008|Experimental|Inhaled QVAR|Inhaled QVAR 100 mic via aerochamber twice daily until 3 month post discharge
3175162|NCT01373008|Placebo Comparator|Inhaled placebo|Inhaled nonmedicated MDI [metered dose inhaler] in a similarly marked aerosol chamber using the same delivery technique, obtained from the drug manufacturer
3175163|NCT01372995|Experimental|Enteral vitamin D3 50,000 IU|An arm where subjects receive 50,000 IU of Vitamin D for 5 days.
3175164|NCT01372995|Experimental|Enteral Vitamin D3 100,000 IU|Arm where subjects receive 100,000 IU of Vitamin D for 5 days
3175165|NCT01372995|Placebo Comparator|Inactive Substance|Arm where patients receive inactive substance for 5 days.
3175166|NCT01372982|Active Comparator|Femara|
3175167|NCT01372982|Experimental|Letrozole|
3175168|NCT01372969|Experimental|Cx601|
3175169|NCT01372956||Dyslipidemia|
3175170|NCT01372943|Experimental|synthetic stool|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
3175171|NCT01372930|Experimental|Etanercept|
3175172|NCT01372930|Placebo Comparator|saline|
3175173|NCT01372917||Allomax|The cohort consists of immediate breast reconstruction patients who have AlloMax placed at the time of their tissue expander based immediate breast reconstruction.
3175174|NCT01372904|Experimental|Dexamethasone|
3175175|NCT01372891||Patients underging PCI|
3175176|NCT01372865|Experimental|Mometasone|
3175177|NCT01372865|Active Comparator|Nasonex®|
3175178|NCT01372852||T2DM patients|newly diagnosed T2DM patients and untreated with any drugs.
3175179|NCT01372852||Non-diabetic Control Group|
3175180|NCT01372839|Active Comparator|Atorvastatin|80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
3175181|NCT01372839|Other|Usual care|statin dose should not be higher than that described in exclusion criteria.
3175182|NCT01372826|Experimental|NKTR118 Group1|Normal Renal Function
3175183|NCT01372826|Experimental|NKTR118 Group 2|Moderate Renal Function
3175184|NCT01372826|Experimental|NKTR118 Group 3|Severe Renal Impairment
3175185|NCT01372826|Experimental|NKTR118 Group 4|End-Stage Renal Disease
3175186|NCT01372813|Other|Clear Cell Renal Carcinoma|Clear cell renal cancer is a highly vascular tumor characterized by mutations in the von Hippel-Lindau (VHL) gene in the majority of patients, an alteration that leads to overexpression vascular endothelial growth factor (VEGF) as well as other genes such as transforming growth factor-alpha, platelet derived growth factor and glucose transporter 1. Patients received ZD6474 300 mg/day by mouth daily on days 1-28.
3175187|NCT01372800||volunteer|
3175188|NCT01372787||Arm I|
3175189|NCT01372774|Active Comparator|Arm I - WBRT|Patients undergo whole brain radiotherapy (WBRT) once a day, 5 days a week, for approximately 3 weeks. Patient observation/follow up occurs at week 12 and months 6, 9, 12, 16 and 24 post registration/randomization. Event monitoring occurs every 6 months until 5 years post registration/randomization.
3175190|NCT01372774|Experimental|Arm II - SRS|Patients undergo stereotactic radiosurgery (SRS) using a gamma knife or a linear accelerator procedure. Patient observation/follow up occurs at week 12 and months 6, 9, 12, 16 and 24 post registration/randomization. Event monitoring occurs every 6 months until 5 years post registration/randomization.
3175191|NCT01372761|Placebo Comparator|Normal Saline|
3175192|NCT01372761|Experimental|ZGN-433|
3175193|NCT01372748|Active Comparator|Standard CPR|American Heart Association (AHA)recommended cardiopulmonary resuscitation (CPR) of 30 compressions with brief pause for 2 ventilations
3175194|NCT01372748|Experimental|Continuous chest compressions|Continuous compression CPR
3175195|NCT01372722|Experimental|Sham then Stimulation|
3175196|NCT01372722|Experimental|Stimulation then Sham|
3175197|NCT01372709||Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Adult male and female patients will be consecutively screened for the study. Eligible patients must meet all of the inclusion criteria and none of the exclusion criteria.
3175198|NCT01372696|Other|Tissue sample|Patients who consent to participate in this study will have a small sample of their polyp and normal tissue sent for molecular testing.
3175199|NCT01372683|Experimental|Test cereal 1|Oat based breakfast cereal
3175200|NCT01372683|Experimental|Test cereal 2|2nd Oat based breakfast cereal
3175201|NCT01372683|Experimental|Leading oat based RTE cereal|3rd oat based breakfast cereal
3175202|NCT01372670|Experimental|Hydroxyzine|Hydroxyzine given TID
3175203|NCT01372670|Placebo Comparator|Sugar Pill|Placebo given 3 times per day
3175204|NCT01372657||cataract patients|cataract patients
3175205|NCT01372644|Experimental|ADH, ALH, LCIS, SOM 230|Women who meet eligibility criteria.
3175206|NCT01372631|Experimental|Pressure assessment|30 patients undergoing lumpectomy, mastectomy or reduction mammoplasty will be enrolled to assess the ideal pressure that should be applied when taking optical measurements.
3175207|NCT01372631|Experimental|Random and Systematic Errors|40 patients undergoing lumpectomy or mastectomy will be enrolled to assess the random and systematic errors of the miniature spectral imaging system.
3175208|NCT01372631|Experimental|Sensitivity and Specificity Assessment|150 patient undergoing lumpectomy, mastectomy or reduction mammoplasty will be enrolled in order to determine the sensitivity and specificity of the miniature spectral imaging system.
3176253|NCT01365663|Placebo Comparator|Saline 0.9%|
3175209|NCT01372618|Experimental|SOM 230/Pasireotide|Treatment with SOM230 600mcg twice daily for 20 days.
3175210|NCT01372605|Experimental|Collaborative depression care|Measurement-Based Care: Decision support from paraprofessional to HIV medical provider around initiating and monitoring antidepressant treatment.
3175211|NCT01372605|Other|Enhanced usual care|Usual care. Enhanced through pre-study training of providers, provision of psychiatric diagnostic information at enrollment to HIV provider, and availability of best-practices guidelines for reference in clinic.
3175212|NCT01372592||Degenerative|Patients being treated for degenerative spine conditions.
3175213|NCT01372592||Deformity|Patients being treated for a deformity spine condition.
3175214|NCT01372592||Trauma|Patients being treated for a trauma related spine condition.
3175215|NCT01372579|Experimental|Treatment (neoadjuvant chemotherapy)|Patients receive eribulin mesylate IV over 2-5 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3175216|NCT01372566|Experimental|Platelet Rich Plasma|Concentrated blood platelets from subject will be injected multiple times into the superficial layer of either their arm (Part 1) or one side of their upper face and cheek (Part 2).
3175217|NCT01372566|Placebo Comparator|Sterile Saline|Sterile saline will be injected multiple times into the superficial layer of either their arm (Part 1) or one side of their upper face and cheek (Part 2)that has not been injected with PRP.
3175218|NCT01372553||Family history risk stratification|primary care patients who receive risk stratification and clinical decision support based upon the family health history they entered in to MeTree
3175219|NCT01372540|Experimental|1 A: Arry-520 + Carfilzomib|Arry-520 starting dose .75 mg/m^2 intravenous (IV) on Days 1, 2, 15 and 16; Carfilzomib IV 20/27 mg/m^2/day on Days 1 ,2, 8, 9 and 15, 16; and Dexamethasone 4 mg oral/IV on Days 1, 2, 8, 9 and 15, 16.
3175220|NCT01372540|Experimental|1B Arry-520 MTD + Carfilzomib|Arry-520 MTD IV with dose escalate of Carfilzomib IV starting at 20/36 mg/m^2/day; and Dexamethasone 4 mg oral/IV.
3175221|NCT01372540|Experimental|2 A: Dose Expansion Group|Arry-520 MTD from 1B + Carfilzomib MTD from 1B; and Dexamethasone 4 mg oral/IV.
3175222|NCT01372540|Experimental|2B Dose Expansion Group|Arry-520 either at MTD from 1A or one dose level lower; Carfilzomib MTD from 1A; and Dexamethasone 4 mg oral/IV on Days 1, 2, 8, 9 and 15, 16.
3175223|NCT01372527|Experimental|TopCare Intervention|"The TOP-CARE intervention will be based on a medical informatics platform that:~Identifies all patients eligible for any of the three cancer screening programs~Links patients with a specific clinician~Offers a visit-independent method for clinicians to review panels of their eligible patients~For patients due for one or more cancer screenings, clinicians will access a web-based informatics tool to:~Screen their panel based upon risk~Defer patients, document exclusions, and update the EHR~Order a screening test with patient information material based upon the patient's risk profile and automatically initiate the process of:~Informing the patient by letter of the need to schedule a test, educating the patient with respect to the benefits of cancer screening, and properly documenting the transaction in the patient's EHR, or~Referral to a patient navigator for patients most likely to benefit from this more intensive approach"
3175224|NCT01372527|Active Comparator|Augmented Standard Care|In augmented standard care control practices, we will implement a system that includes: 1) a population-based perspective to identify all eligible patients overdue for screening, 2) an automated, centralized process to contact selected patients by letter, 3) a result management system that automatically tracks test scheduling and completion, 4) a web-based, easily accessible tool allowing practice personnel to contact patients not completing testing, and 5) use of patient navigators for high risk patients not responding to initial outreach. In the control arm, the process of escalating the reminder intervention from a letter, to contact by phone call, to a patient navigator, will occur in a standard algorithmic fashion without provider input.
3175225|NCT01372514||suspected thromboembolic disease|Patients with thromboembolic disease according to diagnostic tests (MDTC with angiography, scintigraphy V/Q, dimer d, ecografia doppler, etc. ) required by the physician.
3175226|NCT01372501|Experimental|Experimental: Device|All patients will be implanted with the Endobarrier Liner device
3175227|NCT01372488|Active Comparator|Study group|Study group will be provided with suture removal instructions and suture removal kit and asked to consider removing their own sutures
3175228|NCT01372488|Placebo Comparator|Control group|Control group will be asked to have their sutures removed as they normally would (see family doctor or clinic)
3175229|NCT01372475|Active Comparator|Hymovis Viscoelastic Hydrogel|Intra-articular Injection
3175230|NCT01372475|Placebo Comparator|Placebo|Phosphate Buffered Saline Intra-articular Injection
3175231|NCT01372462|Experimental|NIOV - Room air|Subjects exercise using the NIOV device powered by compressed air (room air, 21% O2).
3175232|NCT01372462|Experimental|NIOV - Oxygen|Subjects exercise using the NIOV device powered by compressed medical oxygen (100% O2).
3175233|NCT01372462|Active Comparator|Nasal Cannula Oxygen|Subjects exercise using a standard nasal cannula using medical oxygen (100% O2).
3175234|NCT01372462|No Intervention|No treatment|Control arm. Subjects exercise without using supplemental oxygen or NIOV.
3175235|NCT01372449|Active Comparator|Memantine|
3175236|NCT01372449|Placebo Comparator|Placebo|Placebo Comparator
3175237|NCT01372436||1|children in high-school
3175238|NCT01372436||2|children in primary school
3175239|NCT01372423|Active Comparator|AMITIZA|Manufactured by Sucampo Pharmaceuticals (24 mcg administered for 7 days)
3175240|NCT01372423|Placebo Comparator|Placebo|Manufactured by Anchen Pharmaceuticals (24 mcg administered for 7 days)
3175241|NCT01372423|Experimental|Lubiprostone|Manufactured by Anchen Pharmaceuticals (24 mcg administered for 7 days)
3175242|NCT01372410|Active Comparator|Tiotropium|18 mcg, inhaled long acting muscarinic antagonist
3175243|NCT01372410|Experimental|GSK573719|inhaled medication
3175244|NCT01372410|Placebo Comparator|Placebo|inactive/excipients only
3175245|NCT01372384|Experimental|Single Arm|
3175246|NCT01372371|Active Comparator|Vancomycin|
3175247|NCT01372371|Active Comparator|Vancomycin and Gentamycin|
3175248|NCT01372371|Active Comparator|Intravenous Antibiotic|
3175249|NCT01372358|Experimental|Ciprofloxacin|Ciprofloxacin Extended Release Tablets of Dr. Reddy's Laboratories Limited
3175250|NCT01372358|Active Comparator|CIPRO®XR|CIPRO® XR (Bayer Health Care, Bayer Pharmaceuticals Corporation) Tablets
3175251|NCT01372345|Experimental|Ciprofloxacin|Ciprofloxacin Extended Release Tablets of Dr. Reddy's Laboratories Limited
3175252|NCT01372345|Active Comparator|CIPRO®XR|CIPRO® XR (Bayer Health Care, Bayer Pharmaceuticals Corporation) Tablets
3175253|NCT01372332||Normal subjects|Age-related (+ 5 years of age) and gender-matched normal subjects.
3175254|NCT01372332||Patients with homonymous hemianopia|Patients with homonymous visual field defects
3175255|NCT01372319||Glaucoma Patients (OAG, Aulhorn stages II - IV)|Manifest glaucoma (OAG, Aulhorn stages II - IV) with advanced binocular visual loss, as obtained by semi-automated kinetic perimetry (SKP), no study medication
3175256|NCT01372319||Normal subjects|male+female > 18 years
3175257|NCT01372306|Experimental|Galantamine|Galantamine Hydrobromide Tablets of Dr. Reddy's
3175258|NCT01372306|Active Comparator|Reminyl|Reminyl 4 mg tablets of Janssen Pharmaceutical Products
3175259|NCT01372280|Experimental|Galantamine|Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
3175260|NCT01372280|Active Comparator|Reminyl|Reminyl 4 mg tablets of Janssen Pharmaceutical Products
3175261|NCT01372267|Experimental|CBT for pain|
3175262|NCT01372267|Active Comparator|Psychoeducational control group|This group is designed to be an active control which provides detailed information about substance us and chronic pain without providing any CBT or other specific therapy.
3175263|NCT01372254|Active Comparator|Standard smoking cessation treatment (ST)|Participants will receive a standard, group smoking cessation treatment based on the most recent clinical practice guideline from USDHHS, Treating Tobacco Use and Dependence. Treatment will be delivered in five, 90-minute individual sessions, and 2, 4, 8, 16, and 26 weeks post quit.
3175264|NCT01372254|Experimental|Behavioral Activation for Substance Abusing Smokers (BA-DAS)|The BA-DAS treatment protocol will incorporate elements of the ST and NRT along with behavioral activation strategies, modified for smoking. Treatment will consist of five, 90-minute individual sessions and 2, 4, 8, 16, and 26 weeks post-quit.
3175265|NCT01372241|Experimental|Early Intervention|This group served as the treatment group for analysis of the primary outcome.
3175266|NCT01372241|No Intervention|Delayed Intervention|This group served as a wait-list control group, eventually receiving the intervention after the treatment group completed the intervention and the primary outcomes were assessed for both groups.
3175267|NCT01372228|Experimental|Inherited Metabolic Disorder Patients|Recipients are treated with hematopoietic stem cell infusion from living donors
3175268|NCT01372202|Active Comparator|Arm A|Paclitaxel with Cisplatin along with Radiotherapy and followed by Esophagectomy
3175269|NCT01372202|Active Comparator|Arm B|Cisplatin or Oxaliplatin with 5-Fluorouracil along with Radiotherapy and followed by Esophagectomy
3175270|NCT01372202|Active Comparator|Arm C|Cisplatin with 5-Fluorouracil along with Radiotherapy and followed by Esophagectomy
3175271|NCT01372189||colorectal cancer|Patients with colorectal carcinoma during conventional endoscopic imaging.
3175272|NCT01372189||colorectal adenoma|Patients with colorectal adenoma during conventional endoscopic imaging.
3175273|NCT01372176|Experimental|Early Goal-Directed Nutrition|
3175274|NCT01372176|Active Comparator|ASPEN-guidelines|
3175275|NCT01372163|Experimental|2 mg PF-05190457 or Placebo BID|
3175276|NCT01372163|Experimental|10 mg PF-05190457 or Placebo BID|
3175277|NCT01372163|Experimental|40 mg PF-05190457 or Placebo BID|Dose and dose frequency may be adjusted based on emerging safety and PK data.
3175278|NCT01372163|Experimental|150 mg PF-05190457 or Placebo BID|Dose and dose frequency may be adjusted based on emerging safety and PK data.
3175279|NCT01372163|Experimental|5 mg PF-05190457 or Placebo QD|Dose and dose frequency may be adjusted based on emerging safety and PK data.
3175280|NCT01372163|Experimental|50 mg PF-05190457 or Placebo QD|Dose and dose frequency may be adjusted based on emerging safety and PK data.
3175281|NCT01372163|Experimental|xxx mg PF-05190457 or Placebo|Dose and dose frequency to be determined based on emerging safety and PK data.
3175282|NCT01372150|Experimental|DVS SR|
3175283|NCT01372150|Other|Fluoxetine|Active control for assay sensitivity
3175284|NCT01372150|Experimental|Placebo|
3175285|NCT01372137|Experimental|NOX-H94|Group A: single 15 minutes IV infusion of 0.3 mg/kg NOX-H94 Group B: single 15 minutes IV infusion of 0.6 mg/kg NOX-H94 Group C: single 15 minutes IV infusion of 1.2 mg/kg NOX-H94 Group D: single 15 minutes IV infusion of 2.4 mg/kg NOX-H94 Group E: single 15 minutes IV infusion of 4.8 mg/kg NOX-H94 Group F: single / repeated SC injection of NOX-H94 over a treatment period of 2 weeks Group G: multiple doses of NOX-H94 as a 15 minutes IV infusion over a treatment period of 2 weeks Group H: multiple doses of NOX-H94 as a 15 minutes IV infusion over a treatment period of 2 weeks
3175286|NCT01372137|Placebo Comparator|Glucose 5%|Group A to Group H get NOX-H94 or Placebo
3175287|NCT01372124|Experimental|NOX-E36|All subjects included in this study will receive the same dose of NOX E36.
3175288|NCT01372098|Experimental|NFP + IPV intervention|The protocol for number and timing of visits will be the same for both NFP+IPVI and Standard Care, as follows: weekly for the first four visits, every other week for the remainder of the pregnancy, every week for six weeks in the postpartum and every other week until the infant is 21 months old after which it is once a month for the last three months. We recognize that the intervention might prompt the nurse and mother to alter the regular visit schedule if IPV is present.
3175289|NCT01372098|No Intervention|NFP (standard care)|"The NFP nurses currently receive some training regarding IPV, but it is minimal. Between intake and when the child is 3 months and 12 months old, there is a brief instruction that the nurse assess for IPV. If the client acknowledges current abuse when completing the Abuse Assessment Screen, the nurse should assist her to evaluate threats to personal safety and make referrals as needed. There is a prompt to be mindful of client safety, and to make referrals as needed."
3175290|NCT01372085|Experimental|Part A: 25 mg RF|A single 25 mg dose of LY2548702 Reference Formulation (RF)
3175291|NCT01372085|Placebo Comparator|Part A: Placebo|Placebo taken orally
3175325|NCT01371981|Experimental|Intensification II, Arm C|Patients receive cytarabine IT on day 1, MA chemotherapy as in Induction II, Arm A (HR patients), and sorafenib tosylate PO on days 7-34.
3176254|NCT01365650|Experimental|Ketorolac Tromethamine|
3175292|NCT01372085|Experimental|Part B: Sequence 1|A single 10 mg dose of LY2548702 Test Formulation (TF) during the first intervention period, followed by placebo in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
3175293|NCT01372085|Experimental|Part B: Sequence 2|Placebo during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
3175294|NCT01372085|Experimental|Part B: Sequence 3|A single 10 mg dose of LY2548702 Test Formulation (TF) during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
3175295|NCT01372085|Experimental|Part B: Sequence 4|A single 10 mg dose of LY2548702 Test Formulation (TF) during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by placebo in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
3175296|NCT01372072|Active Comparator|Humidification|Patients in this arm of the trial will receive humidification with the non-invasive ventilation.
3175297|NCT01372072|No Intervention|NIV without humidifivation|As per usual practice patients in this arm will not have humidification with their NIV
3175298|NCT01372059|Experimental|Rhythm and music therapy|Since 1993 The RGRM Method is a concept launched in both health and medical care. The method is mainly designed to help people with injuries and diseases of the central nervous system.
3175299|NCT01372059|Active Comparator|Therapeutic riding|Therapeutic riding can be useful for individuals with neurological and muscular impairments. The goal of therapeutic riding as professional treatment is to improve neurological functioning and to achieve functional gains and enhance life skills.
3175300|NCT01372059|Other|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
3175301|NCT01372046|Experimental|Enhanced|A external consultant works with the team to develop skills and trains an in-house coach
3175302|NCT01372046|Experimental|Trainer|External consultant provides booster session
3175303|NCT01372046|Experimental|Standard|Receive agency training
3175304|NCT01372033|Experimental|CBT|Use of cognitive behavioral therapy focused on social skill development and interpersonal relationships
3175305|NCT01372020|Sham Comparator|control group|
3175306|NCT01372020|Experimental|neuromuscular electrical therapy|
3175307|NCT01372007|Experimental|Lanreotide Autogel 120mg|
3175308|NCT01372007|Placebo Comparator|Placebo|
3175309|NCT01371994|Experimental|Solifenacin succinate|Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily.
3175310|NCT01371994|Placebo Comparator|Placebo|Participants received matching placebo tablets once a day for 12 weeks.
3175311|NCT01371981|Experimental|Induction I, Arm A|Patients receive cytarabine IT on day 1 and ADE chemotherapy comprising cytarabine IV over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5; and etoposide IV over 1-2 hours on days 1-5.
3175312|NCT01371981|Experimental|Induction I, Arm B|Patients receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV on days 1, 4, and 8.
3175313|NCT01371981|Experimental|Induction I, Arm C|Patients receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A and sorafenib tosylate PO on days 11-28.
3175314|NCT01371981|Experimental|Induction I, Arm D|Patients receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. If patients are determined to be HR FLT3/ITD+ no later than the end of Induction I they will be eligible to participate in Arm C.
3175315|NCT01371981|Experimental|Induction II, Arm A (HR patients)|Patients receive cytarabine IT on day 1 and MA chemotherapy comprising high-dose cytarabine IV over 1-3 hours on days 1-4, and mitoxantrone IV over 15-30 minutes on days 3-6.
3175316|NCT01371981|Experimental|Induction II, Arm A (LR patients)|Patients receive cytarabine IT and ADE chemotherapy as in Induction I Arm A.
3175317|NCT01371981|Experimental|Induction II, Arm B (HR patients)|Patients receive MA chemotherapy as in Induction II, Arm A (HR patients) and bortezomib IV on days 1, 4, and 8.
3175318|NCT01371981|Experimental|Induction II, Arm B (LR patients)|Patients receive cytarabine IT, ADE chemotherapy, and bortezomib as in Induction I Arm B.
3175319|NCT01371981|Experimental|Induction II, Arm C|"Patients receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV over 1-2 hours on days 1-5, and sorafenib tosylate PO on days 9-36.~Maintenance: Patients receive sorafenib tosylate PO starting on day 40-80 after completion of intensification II or SCT for one year."
3175320|NCT01371981|Experimental|Intensification I, Arm A|Patients receive cytarabine IT on day 1 and AE chemotherapy comprising high-dose cytarabine IV over 1-3 hours, and etoposide IV over 1-2 hours on days 1-5.
3175321|NCT01371981|Experimental|Intensification I, Arm B|Patients receive cytarabine IT and AE chemotherapy in Intensification II, Arm A, and bortezomib IV on days 1, 4, and 8.
3175322|NCT01371981|Experimental|Intensification I, Arm C|Patients receive cytarabine IT and AE chemotherapy in Intensification II, Arm A, and sorafenib tosylate PO on daily on days 6-33.
3175323|NCT01371981|Experimental|Intensification II, Arm A (LR)|Patients receive cytarabine IT on day 1 and MA chemotherapy as in Induction II, Arm A (HR patients).
3175324|NCT01371981|Experimental|Intensification II, Arm B (LR)|Patients receive cytarabine IT on day 1, MA chemotherapy as in Induction II, Arm A (HR patients), and bortezomib IV on days 1, 4, and 8.
3175326|NCT01371981|Experimental|Intensification II, Arms A and B|Patients receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, and 9 and asparaginase IM on days 2 and 9.
3175327|NCT01371968|Experimental|alfentanil|patient will received a dose of alfentanil in which the dose of alfentanil is determined by response of previously tested patient using Dixon up and down methods
3175328|NCT01371955||diabetic nephropathy group|patient with diabetic nephropathy, defined as Albuminuria > 30 mg/day or urinary Albumine/ creatinine ratio > 3 mg/mmol ; or GFR estimated by MDRD less than 60 ml/min.1,73m². With no other etiology of diabetic nephropathy.
3175329|NCT01371955||diabetic retinopathy group|patient with diabetic retinopathy defined as showing at least one micro aneurysm on retinography. Without nephropathy defined as above
3175330|NCT01371955||no complication group|patient without diabetic nephropathy or retinopathy
3175331|NCT01371929||ICU patients who become septic|Patients considered to be at risk of becoming septic based upon his/her clinical presentation during admittance or transfer to an ICU will be tested for the presence of plasma iNOS using our PliNOSa test on the day of ICU entry and their sepsis status will be followed for three days to determine if they develop sepsis, severe sepsis, or septic shock. Approximately, 50% of the enrolled patients are expected to develop sepsis, severe sepsis, or septic shock.
3175332|NCT01371929||ICU patients who do not become septic|Patients considered to be at risk of becoming septic based upon his/her clinical presentation during admittance or transfer to an ICU will be tested for the presence of plasma iNOS using our PliNOSa test on the day of ICU entry and their sepsis status will be followed for three days to determine if they develop sepsis, severe sepsis, or septic shock. Approximately, 50% of the enrolled patients are expected NOT to develop sepsis, severe sepsis, or septic shock.
3175333|NCT01371916||ESAT-6 positive|
3175334|NCT01371916||ESAT-6 negative|
3175335|NCT01371890||Intradialytic hypertension|Patients with systolic blood pressure increases > 10 mmHg during 4/6 hemodialysis sessions
3175336|NCT01371877|Experimental|Vitamin D3 4000 IU|"Subjects will be randomized 1:1 to high dose vitamin D defined as 4000 IU per day for 3 months.~Subjects will be given Vitamin D3 supplementation at 4000 IU daily."
3175337|NCT01371877|Active Comparator|Vitamin D3 600 IU|"Subjects will be randomized 1:1 to low dose vitamin D as defined as 600 IU per day for 3 months.~Subjects will be given Vitamin D3 supplementation at 600 IU daily"
3175338|NCT01371864||Pediatric Cardiothoracic Team|This group consists of members of the cardiothoracic surgery team: The attending physician, the fellow physician, the nurses, and the physician assistants.
3175339|NCT01371864||Critical Care Team|This group consists of the nurses and physicians who work in the pediatric intensive care unit and the neonatal intensive care unit caring for patients who require cardiothoracic surgery.
3175340|NCT01371864||Subspecialty Team|This group consists of physicians and nurses from pediatric cardiology and pediatric anesthesiology who care for children who require cardiothoracic surgery.
3175341|NCT01371864||Parent|This group consists of the parent or legal guardian of the pediatric patient who requires cardiothoracic surgery.
3175342|NCT01371851|Experimental|Doxazosin|Doxazosin extended release will be administered initially at 4 mg/day. On day 8 the dose is increased to 8 mg/day and the participant is maintained on the study until the end of the trial.
3175343|NCT01371851|Placebo Comparator|Placebo|Participants will be maintained on placebo (cellulose) throughout the trial.
3175344|NCT01371838|Experimental|Ceftaroline|
3175345|NCT01371838|Active Comparator|Ceftriaxone plus placebo|
3175346|NCT01371825|Experimental|Open-Label sebelipase alfa|All subjects received IV infusions of sebelipase alfa during the open-label treatment period. Subjects received a starting dose of 0.35 mg/kg once weekly (qw) and, after demonstrating acceptable safety and tolerability after at least 2 infusions at this dose, began receiving the per-protocol dose of 1 mg/kg qw. Thereafter, subjects were to continue receiving a dose of 1 mg/kg qw for the duration of the treatment period. However, in the event of disease progression (based on protocol-defined criteria) at any time during treatment with 1 mg/kg qw, an individual subject could receive a dose increase to 3 mg/kg qw and; if necessary, a subsequent dose increase to 5 mg/kg qw (after review and approval by a Safety Committee). Subjects receiving long-term treatment on a stable qw dose could be switched to an every other week (qow) dosing schedule at the same total dose (mg/kg) per infusion.
3175347|NCT01371812|Experimental|Cohort 1|Interlocking design with Cohort 2. Single dose; treatment period over 2 days such that one subject will receive GSK2239633 and one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK2239633 from 150mg, to 600mg, to 1200mg and 1200mg with a FDA high fat/high calorie meal, will be administered over the 13 week long study allowing adequate washout period between doses.
3175348|NCT01371812|Experimental|Cohort 2|Interlocking design with Cohort 1. Single dose; treatment period over 2 days such that one subject will receive GSK2239633 and one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK2239633 from 300mg, to 900mg, and 1500mg, will be administered over the 13 week long study allowing adequate washout period between doses.
3175349|NCT01371799|Experimental|Study drug at 4mg|GSK1034702 at 4mg
3175350|NCT01371799|Experimental|Study drug at 8mg|GSK1034702 at 8mg
3175351|NCT01371799|Placebo Comparator|Placebo|Placebo
3175352|NCT01371786|Experimental|ciclesonide nasal aerosol|A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister followed by a washout period of 120 hours and a radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
3175353|NCT01371786|Active Comparator|mometasone|A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle followed by a washout period of 120 hours and a radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
3175354|NCT01371773|Experimental|Left-sided double lumen tube|
3175355|NCT01371760|Experimental|Intervention|The patients will undergo PTA of the extracranial cerebral veins
3175356|NCT01371760|Sham Comparator|Controls|The patients will undergo sham procedure
3175357|NCT01371747|Experimental|Stratum 1: 8.4 g/d patiromer|Participants with baseline serum potassium > 5.0 to 5.5 mEq/L (milliequivalent)
3175358|NCT01371747|Experimental|Stratum 1: 16.8 g/d patiromer|Participants with baseline serum potassium > 5.0 to 5.5 mEq/L
3175359|NCT01371747|Experimental|Stratum 1: 25.2 g/d patiromer|Participants with baseline serum potassium > 5.0 to 5.5 mEq/L
3175360|NCT01371747|Experimental|Stratum 2: 16.8 g/d patiromer|Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
3175361|NCT01371747|Experimental|Stratum 2: 25.2 g/d patiromer|Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
3175362|NCT01371747|Experimental|Stratum 2: 33.6 g/d patiromer|Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
3175363|NCT01371734|Experimental|Experimental Arm 1 - high dose|
3175364|NCT01371734|Experimental|Experimental Arm 2 - low dose|
3175365|NCT01371734|Placebo Comparator|Placebo Arm|
3175366|NCT01371721|Experimental|Desvenlafaxine Succinate Sustained-Release|
3175367|NCT01371708|Experimental|Desvenlafaxine Succinate Sustained-Release|
3175368|NCT01371682|Other|Session 1|Ropinirole manufactued at Crawley will be compared to that manufactured at Aranda
3175369|NCT01371682|Other|Session 2|Ropinirole manufactured at Crawley will be compared to that manufactured at Aranda.
3175370|NCT01371669||IPAH or CPEPH|Idiopathic pulmonary arterial hypertension (IPAH) or pulmonary hypertension associated with chronic post-embolic pulmonary hypertension (CPEPH)
3175371|NCT01371656|Experimental|Arm I (levofloxacin)|Patients receive levofloxacin PO or IV over 60-90 minutes once or twice daily beginning on day 3 during 2 consecutive courses of chemotherapy or beginning on day -2 during HSCT and continuing until blood counts recover.
3175372|NCT01371656|No Intervention|Arm II (standard of care)|Patients receive established standard of care and receive chemotherapy or HSCT as patients in Arm I.
3175373|NCT01371643|Active Comparator|Medical treatment by Octreotide LAR|Medical therapy with Octreotide LAR 30 mg/month for 3 months preceding surgery
3175374|NCT01371643|Active Comparator|Surgical debulking followed by Octreotide LAR|Surgical debulking of pituitary tumor followed by Octreotide LAR if not surgically cured
3175375|NCT01371630|Experimental|Inotuzumab Ozogamycin + Low-Intensity Chemotherapy|"Phase I:~Inotuzumab Ozogamycin on Day 2 and 8 of Cycles 1 and 3, and in Cycles 2 and 4. Cyclophosphamide twice a day Days 1 - 3 for Cycles 1, 3, 7, and 9. Vincristine on Day 1 and 8 of Cycles 1, 3, 7, and 9 . Rituximab on Day 1 and 8 for Cycles 1 and 3, and Cycles 2 and 4. Intrathecal methotrexate on Day 2 of Cycles 1 and 3 and on Day 8 of Cycles 2 and 4, and Intrathecal Ara-C on Day 8. Peg-filgrastim on Day 4.~Blinatumomab by vein on Days 1-29 of Cycles 5-6 and 11-12.~Phase II:~Inotuzumab Ozogamycin: 0.6mg/m2 per cycle in cycles 2 and 4 with 0.3mg/m2 given on days 2 and 8. Methotrexate on Day 1. Ara-C twice a day on Days 2 and 3. Rituximab on Day 2 and 8 of cycles 2 and 4. Peg-filgrastim on Day 4. Citrovorum rescue beginning 12 hrs post MTX completion.~Maintenance Therapy (3 years):~6-Mercaptopurine twice a day twice a day for three years. Methotrexate weekly for three years. Vincristine once a month for 1 year. Prednisone daily for 5 days every month for 1 year."
3175376|NCT01371617|Experimental|IPI-926|Single Arm, Phase 2 trial evaluating the safety and efficacy of IPI-926 in patients with myelofibrosis
3175377|NCT01371604|Experimental|IDX184 50 mg + Peg-IFN/RBV|IDX184 50 mg and matching placebo once daily plus peginterferon alfa-2a (Peg-IFN) weekly and ribavirin (RBV) daily for 12 weeks followed by Peg-IFN weekly and RBV daily for an additional 12 or 36 weeks.
3175378|NCT01371604|Experimental|IDX184 100 mg + Peg-IFN/RBV|IDX184 100 mg once daily plus Peg-IFN weekly and RBV daily for 12 weeks followed by Peg-IFN weekly and RBV daily for an additional 12 or 36 weeks.
3175379|NCT01371591|Active Comparator|Pill Cam, clinical evaluation|"This group receives standard of care plus Pill Cam (Video Capsule Endoscopy, VCE). VCE will be read immediately by site PI or co-PI and by site GI doctor. However, if PillCam appears normal or shows a low-risk problem and the patient is stable medically, then the patient will be discharged home. If the patient is discharged, patient will be called to get an endoscopy as an outpatient within 3 days. Patient will be monitored for a minimum of 4 hours. Repeat CBC every 4 hours. If the patient has stable Blood Pressure and pulse for 4 plus hours then the subject will be discharged home with a follow up (standard of care) EGD within 3 days."
3175380|NCT01371591|Placebo Comparator|Pill Cam, archived|"This group also receives standard of care plus Pill Cam (Video Capsule Endoscopy,VCE). VCE video will be archived and read at a later date. Patient will be admitted. VCE will not be used for clinical decisions. Same day or next day (<24 hour) Endoscopic examination of the upper GI tract will be offered to all patients within 24 hours, and hemostasis therapy will be applied as necessary. All patients in this group will be admitted for next day endoscopy in the hospital. This is standard of care."
3175381|NCT01371578|Experimental|Arm 2|"AM Dosing: One GS-5885 30 mg tablet, two GS-9451 100 mg tablets, orally with RBV and with food.~PM Dosing: RBV with food.~PEG, 180 µg, will be administered weekly by subcutaneous injection for the specified period of time (see Study Design). Pegasys® prefilled syringes (Hoffman-La Roche) will be supplied by Gilead Sciences."
3175382|NCT01371565|Experimental|mifepristone|
3175383|NCT01371552|Experimental|delefilcon A|Part 1: Delefilcon A contact lenses, followed by filcon II 3 contact lenses and narafilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
3175384|NCT01371552|Active Comparator|filcon II 3|Part 1: Filcon II 3 contact lenses, followed by narafilcon A contact lenses and delefilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
3175385|NCT01371552|Active Comparator|narafilcon A|Part 1: Narafilcon A contact lenses, followed by filcon II 3 contact lenses and delefilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
3175386|NCT01371539|Other|Lotrafilcon B / Comfilcon A|Lotrafilcon B contact lenses worn first, with comfilcon A contact lenses worn second. Both products worn bilaterally on a daily wear basis for one week each.
3175387|NCT01371539|Other|Comfilcon A / Lotrafilcon B|Comfilcon A contact lenses worn first, with lotrafilcon B contact lenses worn second. Both products worn bilaterally on a daily wear basis for one week each.
3175388|NCT01371526|Experimental|Synacthen|active treatment
3175390|NCT01371487|Experimental|Treatment A|GSK1120212 Dose /Treatment 2.0 mg/Fasted
3175391|NCT01371487|Experimental|Treatment B|GSK1120212 Dose /Treatment 2.0 mg/high fat, high calorie meal
3175392|NCT01371474||Patients prescribed PAXIL|Patients with depression or in a depressed state starting PAXIL at 20 mg/day during study period
3175393|NCT01371461||Patients prescribed PAXIL|Patients with depression or depressed state prescribed PAXIL during study period
3175394|NCT01371448||Patients prescribed PAXIL for long-term use|Patients with depression/depressed state or panic disorder prescribed PAXIL during study period
3175395|NCT01371435||Patients prescribed PAXIL|Patients with depression/depressed state or panic disorder prescribed PAXIL during study period
3175396|NCT01371422|Experimental|A1 (PVB)|PVB technique will be utilized for injection of the anaesthetic under the skin before the procedure.
3175397|NCT01371422|Placebo Comparator|A2 (Placebo)|The placebo is an inactive substance that looks identical to the test intervention but contains no active ingredients and will be administered the same as the PVB by a local skin injection, but no advancement of the needle to the paravertebral space will be made to avoid unnecessary risks.
3175398|NCT01371409|Experimental|active cTBS|
3175399|NCT01371409|Sham Comparator|Sham cTBS|
3175400|NCT01371396|Other|Hispanic subjects|Subjects will identify as Hispanic ethnicity.
3175401|NCT01371396|Other|African American subjects|Subjects will self-identify as African American in origin.
3175402|NCT01371383|Experimental|omega-3 fatty acids|
3175403|NCT01371383|Placebo Comparator|Placebo|
3175404|NCT01371370|Experimental|Resistance exercise training|Lower-body exercises 3 times per wk for 12 wk
3175405|NCT01371370|Experimental|Hypocaloric diet|This arm involves 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
3175406|NCT01371370|Experimental|Resistance exercise training & diet|Lower-body exercise training and diet
3175407|NCT01371370|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 wk.
3175408|NCT01371357|Experimental|TEST1|2.4 g/day of guanidinoacetic acid
3175409|NCT01371357|Experimental|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogen citrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
3175410|NCT01371357|Experimental|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
3175411|NCT01371357|Experimental|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
3175412|NCT01371344|Experimental|Part A: Heart Transplant (Tacrolimus granules)|In Part A of the study, participants who are heart transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
3175413|NCT01371344|Experimental|Part A: Liver Transplant (Tacrolimus granules)|In Part A of the study, participants who are liver transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
3175414|NCT01371344|Experimental|Part A: Kidney Transplant (Tacrolimus granules)|In Part A of the study, participants who are kidney transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
3175415|NCT01371344|Experimental|Part B: All Participants (Tacrolimus capsules)|In Part B of the study, participants who are heart, kidney or liver transplant recipients and who are converted from tacrolimus granules-based immunosuppression regimen, receive tacrolimus capsules twice daily for 1 month and thereafter receive commercially available tacrolimus capsules.
3175416|NCT01371331|Experimental|Tacrolimus granules|oral
3175417|NCT01371318|Experimental|OWEMR|Medical centers will be randomized to use the Online Wound Electronic Medical Record to enhance care of patients with diabetic foot ulcers
3175418|NCT01371318|No Intervention|Standard of Care|Medical/wound centers will be randomized to continue routine care of patients with diabetic foot ulcers
3175419|NCT01371305|Experimental|BG00011|Participants will receive 8 consecutive weekly doses of BG00011
3175420|NCT01371305|Placebo Comparator|Placebo|Participants will receive 8 consecutive weekly doses of placebo.
3175421|NCT01371292|Experimental|Transformational teaching condition|Teachers allocated to this condition will receive the transformational teaching intervention.
3175422|NCT01371292|Active Comparator|Standard practice control condition|Teachers allocated to this condition will not receive the transformational teaching intervention. Instead they will take part in a parallel workshop offered by their respective school board (unrelated to transformational leadership training).
3175423|NCT01371266|Active Comparator|Honey|60.7 grams daily orally times 14 days
3175424|NCT01371266|Active Comparator|CHO|50 grams daily orally times 14 days
3175425|NCT01371266|Active Comparator|High Fructose Corn Syrup|65.7 grams daily orally times 14 days
3175426|NCT01371253|Experimental|Nintendo Wii traning|Balance training
3175427|NCT01371253|Placebo Comparator|EVA-soles|
3175428|NCT01371227|Experimental|JNS002|JNS002 30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
3175429|NCT01371214|Experimental|Group 1|PLIÉ exercise program 30-45 minutes, 2-3 days/week for 18 weeks followed by 18 weeks of usual care (20-minutes of chair-based exercises 2-5 days/week).
3175430|NCT01371214|Active Comparator|Group 2|Usual care (20 minutes of chair-based exercises 2-5 days/week) for 18 weeks followed by the PLIÉ exercise program 30-45 minutes/day, 2-3 days/week for 18 weeks.
3175431|NCT01371201|Experimental|Sunitinib|sunitinib 37.5 mg per day
3175432|NCT01371201|Placebo Comparator|Placebo|Placebo 37.5 mg per day
3175433|NCT01371188||Controls|Healthy male volunteers, non-smokers, 20-40yo, living in the city of Mendonça, São Paulo-Brazil.
3175434|NCT01371188||Sugarcane Workers|Healthy male volunteers, non-smokers, 20-40yo, sugarcane workers, living in the city of Mendonça, São Paulo-Brazil.
3175479|NCT01370941|Placebo Comparator|Drug B: Placebo|B: 5 drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
3175435|NCT01371175|Experimental|Group A|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
3175436|NCT01371175|Experimental|Group B|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
3175437|NCT01371175|Experimental|Group C|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intradermally. Vaccine:Placebo =18/3
3175438|NCT01371175|Experimental|Group D|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
3175439|NCT01371175|Experimental|Group E|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
3175440|NCT01371175|Experimental|Group F|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
3175441|NCT01371175|Experimental|Group G|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
3175442|NCT01371175|Experimental|Groups C2/D2/E2 (Subgroups of C,D,E)|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and Month 12+ (volunteers offered second MVA/placebo more than 12 months (late boost) after their enrollment into their original treatment assignment) delivered ID, SC, or IM according to original randomization. Vaccine:Placebo = blinded ratio, maximum in C2/D2/E2 = 16.
3175443|NCT01371175|Experimental|Group F2/G2 (Subgroup of F and G)|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and Month 12+ (volunteers offered second MVA/placebo more than 12 months (late boost) after their enrollment into their original treatment assignment) delivered either SC or IM according to original randomization. Vaccine:Placebo = blinded ratio, maximum in F/G= 29.
3175444|NCT01371162|Experimental|A1 Healthy Volunteers|
3175445|NCT01371162|Placebo Comparator|A2|
3175446|NCT01371162|Experimental|B1 HCV Infection|
3175447|NCT01371162|Placebo Comparator|B2|
3175448|NCT01371149|No Intervention|Physician led ventilator set up|Patients will be set up on non-invasive ventilation as per the current gold standard physician led approach
3175449|NCT01371149|Experimental|parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
3175450|NCT01371136|Experimental|Curricular Trained|"Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an easy, medium and hard level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver."
3175451|NCT01371136|No Intervention|conventional residency training|These residents proceed through surgical residency training as usual
3175452|NCT01371123||On long-term PN|
3175453|NCT01371123||Never been on TPN|
3175454|NCT01371110|Active Comparator|Ketamine|Study participants will receive a one-time intravenous infusion of 0.5 mg/kg racemic ketamine hydrochloride
3175455|NCT01371110|Sham Comparator|Midazolam|Study participants will receive a one-time intravenous infusion of 0.045 mg/kg midazolam
3175456|NCT01371097|No Intervention|Control Group|
3175457|NCT01371097|Experimental|Treatment group|
3175458|NCT01371084|Experimental|Physical activity treatment group|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
3175459|NCT01371084|Placebo Comparator|Wait List Control|
3175460|NCT01371071||CIS or early relapsing-remitting MS|
3175461|NCT01371058|Active Comparator|routine dual antiplatelet|asprin 300mg/d for 1 month followed by 100mg/d chronically； clopidogrel 75mg/d for 1year.
3175462|NCT01371058|Experimental|high maintenance clopidogrel|aspirin 300mg/d for 1 month followed by 100mg/d chronically; clopidogrel 150mg/d for 1 month followed by 75mg/d for at least 1 year.
3175463|NCT01371058|Experimental|policosanol plus dual antiplatelet|asprin 300mg/d for 1 month followed by 100mg/d chronically; clopidogrel 75mg/d for at least 1 year; Policosanol 40mg/d for 6months.
3175464|NCT01371045||Acromegaly|Patients carrying the diagnosis of acromegaly who are on long-acting somatostatin for at least 3 months prior to study enrollment.
3175465|NCT01371045||Carcinoid Syndrome|Patients carrying a diagnosis of carcinoid syndrome who are taking long-acting somatostatin for at least 3 months prior to study enrollment.
3175466|NCT01371045||Healthy Controls|
3175467|NCT01371032|Active Comparator|Video-Miller laryngoscope|using the screen (Video laryngoscopy group)
3175468|NCT01371032|Active Comparator|Direct laryngoscopy|without use the screen (Direct laryngoscopy group)
3175469|NCT01371019||Women with preterm delivery|
3175470|NCT01371019||Women without preterm delivery|
3175471|NCT01371006|Experimental|BI201335 low dose Efavirenz|low dose Efavirenz
3175472|NCT01371006|Experimental|BI201335 high dose Efavirenz|normal dose Efavirenz
3175473|NCT01370980||Study population|Adults (18 years old or more) with one of the following oral oncology treatments: letrozole, exémestane, imatinib, sunitinib, nilotinib, evérolimus, déférasirox
3175474|NCT01370967||Study formula-fed only|
3175475|NCT01370967||Human milk-fed only|
3175476|NCT01370967||Mixed-fed using study formula only|
3175477|NCT01370954||CerefolinNAC®|Subjects diagnosed with Early Memory Loss who have been prescribed CerefolinNAC® daily.
3175478|NCT01370941|Active Comparator|Drug A: Chymosin|A: 5 drops of Chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
3175480|NCT01370928|Experimental|Prototype colonoscope|The new colonoscope to be tested
3175481|NCT01370928|Active Comparator|Standard colonoscope|The standard colonoscope used world-wide today.
3175482|NCT01370915|Experimental|Pregabalin|Patients receive oral placebo 150 mg 1hour prior to septal surgery, and 12 hours later
3175483|NCT01370915|Placebo Comparator|Placebo|Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
3175484|NCT01370902|Experimental|Single-dose (SD) trial part (i.v.)|
3175485|NCT01370902|Experimental|Single-dose (SD) trial part (s.c.)|
3175486|NCT01370902|Experimental|Multiple-dose (MD) trial part (s.c.)|
3175487|NCT01370889|Experimental|Basic Science (resveratrol)|Patients receive resveratrol PO QD for 12 weeks.
3175488|NCT01370876|Experimental|Oxaliplatin/5-FU|
3175489|NCT01370863|Experimental|SPD557|
3175490|NCT01370863|Placebo Comparator|Placebo|
3175491|NCT01370850||Normal|Normal results from the clinical exam and free of ocular pathology.
3175492|NCT01370850||Glaucoma|Clinical exam results consistent with glaucoma; visual field defects consistent with glaucoma and/or structural damage consistent with glaucoma.
3175493|NCT01370850||Retina|Clinical exam results consistent with retina pathology.
3175494|NCT01370837|Experimental|Healthy controls|
3175495|NCT01370837|Experimental|Diabetes|Patients with diabetes mellitus without polyneuropathy.
3175496|NCT01370837|Experimental|Polyneuropathy|Patients with diabetes and polyneuropathy.
3175497|NCT01370824||Basal cell carcinoma|"- Population: Eligible are patients (men and women) ≥18 years of age who visit the outpatient department of dermatology of the Maastricht University Medical Centre because of a clinically suspected BCC.~- Inclusion criteria: All patients aged 18 years or older, otherwise healthy, with ≤ three primary (no previous treatment) clinically determined BCC.~- Exclusion criteria: Patients using immunosuppressive drugs. Genetic skin cancer disorders. Earlier treatments at the same site. Age under 18 years. More than 3 clinical suspected BCCs. Not capable of informed consent."
3175498|NCT01370811|Placebo Comparator|OC oral solution treatment D|Placebo
3175499|NCT01370811|Experimental|OC oral solution treatment C|High dose oxybutynin and clonidine
3175500|NCT01370811|Experimental|OC oral solution treatment A|Low dose oxybutynin and clonidine
3175501|NCT01370811|Experimental|OC oral solution treatment B|Intermediate dose oxybutynin and clonidine
3175502|NCT01370798|Experimental|promestriene|Children with severe hypospadias treated with promestriene 1%
3175503|NCT01370798|Placebo Comparator|Placebo|Control group, children with severe hypospadias treated with Placebo.
3175504|NCT01370772|Active Comparator|Standard R-FC arm|"Standard R-FC arm 6 cycles every 28 days~Cycle 1:~Rituximab : 375 mg/m² i.v on day 1~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days For patients with Leucocyte count > 25* G/L : rituximab in two equal doses at D1, D2~Cycle 2-6:~Rituximab: 500 mg/m² i.v on day 1, repeated every 28 days~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days"
3175505|NCT01370772|Experimental|DenseR-FC arm|"DenseR-FC arm =1 prephase R Dense course +6 R-FC courses~Prephase:~- Rituximab: 500 mg on day 0, 2000 mg on days 1, 8, and D15 For patients with Leucocyte count > 25* G/L : rituximab 250 mg D-1, D0 prephase~Cycle 1-6 (cycle 1 beginning at D22):~Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days"
3175506|NCT01370759|Experimental|Colon-targeted cleaning capsule|
3175507|NCT01370746||Cross-Sectional Study Group|Cross-sectional comparison of perceived barriers to adherence to post-transplant immunosuppressant regimens in parents/legal guardians of children 0-11 years versus adolescents 12-21 years
3175508|NCT01370746||Longitudinal Study Group|Subset of Cross-Sectional Study Group to evaluate whether perceived barriers to adherence increase with time during the first year following transplantation
3175509|NCT01370733|Experimental|Active sTMS|Treatment with the NEST-1 Device
3175510|NCT01370733|Sham Comparator|Sham|Treatment with a sham (inactive) device, identical in sound and appearance to the NEST-1 Device
3175511|NCT01370720|Active Comparator|Recoclix (CM&D Pharma Limited)|Recoclix: two tablets per day for 12 weeks
3175512|NCT01370720|Placebo Comparator|Placebo|IBS patients
3175513|NCT01370707|Active Comparator|Metformin|
3175514|NCT01370707|Experimental|CJ-30001/CJ-30002|
3175515|NCT01370694|Experimental|MK-8808 Combination Therapy|Participants received MK-8808 375 mg/m^2 intravenously (IV) + cyclophosphamide 750 mg/m^2 IV + vincristine 1.4 mg/m^2 IV (maximum dose of 2 mg IV) on Day 1 each cycle, plus prednisolone 40 mg/m^2, orally on Days 1 to 5 of each cycle for a maximum of 8 cycles. Participants receiving clinical benefit could remain on MK-8808 375 mg/m^2 IV starting 8 weeks after last dose of combination therapy, every 2 months for up to 2 years.
3175516|NCT01370681|Experimental|Group1|
3175517|NCT01370681|Experimental|Group2|
3175518|NCT01370668|Experimental|Functional remediation|"Patients assigned to the experimental treatment will receive standard psychiatric care and will be enrolled in the neurocognitive intervention program composed of 21 sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.~The program will be performed in an 8-to-10 patient group conducted by 2 experienced neuropsychologists. with previous experience with bipolar patients (at least 3 years) and specific training on patients' group management."
3175519|NCT01370668|Active Comparator|Psychoeducation|The group psychoeducation is a tested (Colom et al, 2003) and manualized intervention (Vieta and Colom, 2006) consisting on 21 sessions of 90 minutes, aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences and lifestyle regularity. The program will be performed in an 8-10 patient group conducted by 2 experienced psychologists with previous experience with bipolar patients and specific training on patients' group management. The structure of each session consists of a 30 to 40 minute speech on the topic of the day, followed by an exercise related to the issue (eg. drawing a life chart, writing a list of potential triggering factors) and a discussion.
3175520|NCT01370668|Active Comparator|Treatment as Usual|This arm will not receive any sort of add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
3175647|NCT01369732|Placebo Comparator|Saline group|We administrate the saline single bolus (5ml, intravenously) 30 min before the commencement of ischemia.
3175521|NCT01370655|Experimental|MK-7145 6 mg (Treatment A)|MK-7145 3 mg (three x 1-mg MK-7145 capsules administered orally) and placebo to HCTZ (two 12.5-mg capsules) then three x 1-mg MK-7145 capsules 4 hours later, daily for 4 weeks.
3175522|NCT01370655|Experimental|MK-7145 3 mg (Treatment B)|MK-7145 3 mg (one 2mg MK-7145 and one MK-7145 placebo capsule) then one 1-mg MK-7145 capsule and two MK-7145 placebo capsules 4 hours later and placebo to HCTZ (2 capsules once daily) daily for 4 weeks.
3175523|NCT01370655|Active Comparator|Hydrochlorothiazide 25 mg (Treatment C)|HCTZ 25 mg (two 12.5-mg capsules) and placebo to MK-7145 (one 3-mg capsule) then placebo for MK-7145 (one 3-mg capsule) 4 hours later daily for 4 weeks.
3175524|NCT01370655|Placebo Comparator|Placebo (Treatment D)|Placebo to MK-7145 (2 x 3-mg capsules) and placebo to HCTZ 25 mg (2 capsules) then placebo to MK-7145 (2 x 3-mg capsules) 4 hours later daily for 4 weeks
3175525|NCT01370642|Experimental|Vaniprevir 12 Week Arm|Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) and then 12 weeks of placebo to vaniprevir along with 24 weeks of treatment with peg-IFN and RBV.
3175526|NCT01370642|Experimental|Vaniprevir 24 Week Arm|Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV.
3175527|NCT01370642|Active Comparator|Control Arm|Participants on this arm receive 24 weeks of treatment with placebo to vaniprevir along with 48 weeks of treatment with peg-IFN and RBV.
3175528|NCT01370629||All participants|Participants treated with vernakalant IV in acute care and inpatient hospital settings
3175529|NCT01370616|Experimental|Ertapenem sodium|Participants received 1.0 g intravenous (IV) ertapenem sodium as a single daily dose at Hour 0 infused over a 30-minute interval , and IV piperacillin/tazobactam-matching placebo at Hours 8 and 16 infused over a 30-minute interval, for 5 to 28 days. Participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
3175530|NCT01370616|Active Comparator|Piperacillin/tazobactam sodium|Participants received 4.5 g IV piperacillin/tazobactam at Hours 0, 8, and 16 infused over a 30-minute interval, for 5 to 28 days. Participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
3175531|NCT01370603|Active Comparator|Ezetimibe and atorvastatin|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including 10 mg ezetimibe, 40 mg atorvastatin, and placebo to ezetimibe/atorvastatin.
3175532|NCT01370603|Experimental|Ezetimibe/atorvastatin combination|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including ezetimibe/atorvastatin 10 mg/40 mg, placebo to ezetimibe, and placebo to atorvastatin.
3175533|NCT01370590|Active Comparator|Ezetimibe and atorvastatin|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including 10 mg ezetimibe, 20 mg atorvastatin, and placebo to ezetimibe/atorvastatin.
3175534|NCT01370590|Experimental|Ezetimibe/atorvastatin combination|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including ezetimibe/atorvastatin 10 mg/20 mg, placebo to ezetimibe, and placebo to atorvastatin.
3175535|NCT01370577||1|Total 300 subjects who was diagnosed with asthma
3175536|NCT01370564|Other|Daily diuretic adjustment|Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
3175537|NCT01370551|Experimental|Gynoflor|This study consists only of this arm.
3175538|NCT01370538|Experimental|Esomeprazole 20 mg|
3175539|NCT01370538|Placebo Comparator|Placebo|
3175540|NCT01370525|Experimental|Esomeprazole 20 mg|
3175541|NCT01370525|Placebo Comparator|Placebo|
3175542|NCT01370512|Active Comparator|Droxidopa / Pyridostigmine|
3175543|NCT01370512|Placebo Comparator|Droxidopa|
3175544|NCT01370512|Placebo Comparator|Pyridostigmine|
3175545|NCT01370499|Experimental|LY2216684|12 mg to 18 mg Administered orally, once daily for 52 weeks
3175546|NCT01370486|Active Comparator|melatonin|
3175547|NCT01370486|Placebo Comparator|placebo|
3175548|NCT01370460|Experimental|Tranexamic Acid|Topical tranexamic acid (2g/100mL) applied during unilateral total knee arthroplasty.
3175549|NCT01370460|Placebo Comparator|Placebo|100mL 0.9% NS, applied topically
3175550|NCT01370447|Experimental|EPI-743 Treatment|Single treatment arm; All enrolled subjects will be treated with EPI-743
3175551|NCT01370434|No Intervention|VAD combination|"vincristine 0.4mg iv on D1-4~doxorubicin 9mg/m2 iv on D1-4~dexamethasone 40mg/d po on D1-4,9-12,17-20~Many physicians use vincristine, doxorubicin, and dexamethasone (VAD) for three to four months as induction therapy (Alexandrian et al, 1990). VAD produces partial response (PR) in about 50% patients, with complete response (CR) observed in 5%-10% patients (Kyle et al, 2004)."
3175552|NCT01370421||Knee OA patients undergoing Total Knee Arthroplasty (TKA)|Participants will be 50 years or older, diagnosed with Osteoarthritis of the knee and be scheduled for a unilateral total knee replacement surgery.
3175553|NCT01370408|Experimental|Palonosetron|"All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation~Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV on the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO"
3175554|NCT01370395||Left ventricular function|According to the result of the echocardiographic exam, the patients will be divided into subgroups with (LV-EF>=55%) and without preserved ejection fraction (LV-EF<55%).
3175555|NCT01370382||Time interval|"Patients are divided according to the interval between the onset of chest pain symptoms and presentation at the hospital in an early(<4 hours) and late(> = 4 hours) group."
3175556|NCT01370369|Experimental|Single Testosterone Dose (Inner Thigh)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the inner thigh followed by a seven day washout period.
3175557|NCT01370369|Experimental|Single Testosterone Dose (Abdomen)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the abdomen followed by a seven day washout period.
3175558|NCT01370369|Experimental|Single Testosterone Dose (shoulder/upper arm)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the shoulder/upper arm.
3175559|NCT01370369|Experimental|Testosterone 1.25|Subjects received testosterone gel 2% at dose of 1.25 mL (one stroke) applied once daily for 10 consecutive days to the shoulder/upper arm.
3175560|NCT01370369|Experimental|Testosterone 2.50|Subjects received testosterone gel 2% at dose of 2.50 mL (two strokes) applied once daily for 10 consecutive days to the shoulder/upper arm.
3175561|NCT01370369|Experimental|Testosterone 3.75|Subjects received testosterone gel 2% at dose of 3.75 mL (three strokes) applied once daily for 10 consecutive days to the shoulder/upper arm.
3175562|NCT01370356|Active Comparator|Varenicline Tartrate|
3175563|NCT01370356|Placebo Comparator|Placebo|
3175564|NCT01370343|Experimental|PF-04991532 alone|
3175565|NCT01370343|Experimental|PF-04991532 + cyclosporine|
3175566|NCT01370317|Experimental|MK-1029|
3175567|NCT01370317|Placebo Comparator|Placebo|
3175568|NCT01370304|Experimental|active rTMS and active Venlafaxine|
3175569|NCT01370304|Experimental|active rTMS and sham Venlafaxine|
3175570|NCT01370304|Sham Comparator|sham rTMS and active Venlafaxine|
3175571|NCT01370291|Active Comparator|active Risperidone and active rTMS|active Risperidone and active rTMS for the first-episode schizophrenia patients
3175572|NCT01370291|Experimental|active rTMS and sham Risperidone|active rTMS and sham Risperidone for the first-episode schizophrenia
3175573|NCT01370291|Sham Comparator|sham rTMS and active Risperidone|sham rTMS and active Risperidone for the first-episode schizophrenia patients
3175574|NCT01370278|Active Comparator|Normal Saline|Normal saline sprayed into stent/airway tubes then suctioned out through bronchoscope.
3175575|NCT01370278|Active Comparator|Sodium Bicarbonate|Sodium bicarbonate sprayed into stent/airway tubes then suctioned out through bronchoscope.
3175576|NCT01370265|Active Comparator|Regadenoson, then Adenosine|Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the first intervention period. Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the second intervention period (after washout period). Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered.
3175577|NCT01370265|Active Comparator|Adenosine, then Regadenoson|Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the first intervention period. Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered. After a washout period, Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the second intervention period.
3175578|NCT01370252||scope technique|
3175579|NCT01370252||open technique|
3175580|NCT01370239|Experimental|Hu3S193|Single arm
3175581|NCT01370226|Active Comparator|CBI|Computer delivered Brief Intervention
3175582|NCT01370226|Active Comparator|TBI|Therapist delivered Brief Intervention
3175583|NCT01370226|No Intervention|EUC|Enhanced Usual Care
3175584|NCT01370213|Experimental|High-Risk Acute Myeloid Disease|Patients with high risk acute myeloid disease treated with preparative regimen including Fludara, Cytoxan and total body irradiation followed by haploidentical donor NK cells, Interleukin-2, rabbit anti-thymocyte globulin, and same donor TCR α/β-depleted cells infusion.
3175585|NCT01370200|Active Comparator|4% citrate|4% trisodium citrate, starting infusion rate 180 ml/h Interventions according to postfilter ionized calcium, change in 10 ml/h step
3175586|NCT01370200|Active Comparator|15% citrate|15% trisodium citrate, starting infusion rate 50 ml/h Interventions according to postfilter ionized calcium, change in 10 ml/h step
3175587|NCT01370187|No Intervention|Control|Control group
3175588|NCT01370187|Experimental|Montelukast|4mg Montelukast daily for 2 months
3175589|NCT01370174|Active Comparator|Induced Step Training (IST)|The IST group will receive waist-pulls in both the left and right lateral directions by a motorized pulling system to produce stepping.
3175590|NCT01370174|Active Comparator|Hip Strength Training (HST)|The HST group will have muscle strength training, to include hip abduction (AB) and adduction (AD) resistance exercises.
3175591|NCT01370174|Active Comparator|Combined Induced Step and Hip Strength Training|This training group consists of combined induced step training (IST) and hip AB-AD strength training (HST).
3175592|NCT01370174|Placebo Comparator|Standard Flexibility and Relaxation (SFR)|The SFR group will perform a flexibility and relaxation program involving minimal-intensity exercises.
3175593|NCT01370161|Experimental|TIPS treatment|TIPS will be performed as soon as possible once the patients are enrolled in the study, always within the first 72 hours after the diagnostic endoscopy (preferably in the first 24 hours).
3175594|NCT01370161|Active Comparator|Medical treatment|Patients will be treated with non-selective beta-blockers (either propranolol or nadolol). In case of contraindications or intolerance to beta-blockers, patients will not receive pharmacological treatment (beta-blockers but also mononitrate) and the only treatment to prevent rebleeding will be endoscopic band ligation.
3175595|NCT01370148|Experimental|Subjects with severe hepatic impairment|
3175596|NCT01370148|Active Comparator|Subjects with normal hepatic function|
3175597|NCT01370135|Experimental|Lucentis (Ranibizumab)|
3175598|NCT01370122||Subjects exposed to radiation|
3175599|NCT01370122||Subjects not exposed to radiation|
3175600|NCT01370109||Penn Site|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
3175601|NCT01370109||Vanderbilt University Medical Center|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
3175602|NCT01370109||Case Medical Center|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
3175603|NCT01370109||University of Wisconsin at Madison|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
3175604|NCT01370083|Experimental|Stroke: TPPT|Adults with dysphagia post stroke (within 4-16 weeks of onset) who have radiographically confirmed difficulties with thin liquid bolus control. Individuals will complete 24 sessions of tongue-pressure-profile training over 8-12 weeks.
3175648|NCT01369732|Experimental|erythropoietin group|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
3175605|NCT01370083|Active Comparator|Stroke: TPSAT Control|Individuals with dysphagia (within 4-16 weeks post stroke) who demonstrate difficulties with thin liquid control on videofluoroscopy. Individuals will complete 24 sessions of tongue-pressure strength-and-accuracy training over 8-12 weeks.
3175606|NCT01370070|Experimental|MK-2206|
3175607|NCT01370057|Experimental|Treatment Group|Treatment with bracing
3175608|NCT01370057|No Intervention|Control Group|Watchful waiting without bracing
3175609|NCT01370044|Experimental|Verum|Verum arm receiving Carbogen
3175610|NCT01370044|Placebo Comparator|Placebo|Placebo arm receiving oxygen
3175611|NCT01370031|Experimental|Clenil® Modulite® via AeroChamber Plus™|Clenil® Modulite® administered via AeroChamber Plus™ spacer
3175612|NCT01370031|Active Comparator|Clenil® Modulite® via Volumatic™|Clenil® Modulite® administered via Volumatic™ spacer
3175613|NCT01370031|Experimental|Clenil® Modulite® via AeroChamber Plus™ plus charcoal block|Clenil® Modulite® administered via AeroChamber Plus™ spacer plus charcoal block
3175614|NCT01370031|Active Comparator|Clenil® Modulite® via Volumatic™ plus charcoal block|Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block
3175615|NCT01370018|Experimental|alpha-1-Proteinase Inhibitor|Although Zemaira® (alpha-1-Proteinase Inhibitor) treatment is the standard treatment for patients with too little alpha-1-Proteinase Inhibitor, its use in HIV-1 patients has not been established. This pilot study was performed to show that Zemaira® treatment can be used in HIV-1 patients to elevate alpha-1-Proteinase Inhibitor and has the added benefit of elevating CD4 cells.
3175616|NCT01370005|Experimental|BI 10773 low dose|BI 10773 low dose once daily
3175617|NCT01370005|Experimental|BI 10773 high dose|BI 10773 high dose once daily
3175618|NCT01370005|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
3175619|NCT01369979||Patients with chronic liver disease|"Inclusion criteria~Age between 40 and 70 years~BMI between 20 and 26~Exclusion Criteria~Diabetes mellitus~Glucose intolerance~Medical treatment of portal hypertension~People who have undergone surgery for obesity~Pregnancy"
3175620|NCT01369979||Healthy subjects|"Inclusion criteria~Age between 40 and 70 years~BMI between 20 and 26~Exclusion Criteria~Diabetes mellitus~Glucose intolerance~Medical treatment of portal hypertension~People who have undergone surgery for obesity~Pregnancy"
3175621|NCT01369940||NICHD Fetal Growth Study - Twin Gestations|"Women with dichorionic twin gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2012-2013) in this prospective cohort study.~Intervention: No intervention"
3175622|NCT01369901|Experimental|Group A|Functional exercise
3175623|NCT01369901|Active Comparator|Group B|Stretching exercise
3175624|NCT01369888|Experimental|IL-15 following Young TIL (0.25 mcg)|0.25 mcg/kg/day x 10
3175625|NCT01369888|Experimental|IL-15 following Young TIL (0.50 mcg)|0.50 mcg/kg/day x 10
3175626|NCT01369888|Experimental|IL-15 Following Young TIL (1 mcg)|1 mcg/kg/day x 10
3175627|NCT01369888|Experimental|IL-15 Following Young TIL (2 mcg)|2 mcg/kg/day x 10
3175628|NCT01369875|Experimental|Standard Young TIL|"Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0~Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)~Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)~Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6"
3175629|NCT01369875|Experimental|ECCE Young TIL|"Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0~Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)~Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)~Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6"
3175630|NCT01369862|Placebo Comparator|SPGNH buffer|SPGNH buffer administration by liquid nasal spray
3175631|NCT01369862|Experimental|GHB16L2|Dose level ~7.0 log10 fTCID50/strain/person
3175632|NCT01369849|Experimental|Treatment (Akt inhibitor MK2206, bendamustine, rituximab)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22 (days 1, 8, 15, 22, and 29 of course 1); rituximab IV on day 1 (day 8 of course 1); and bendamustine hydrochloride IV over 30-60 minutes on days 1-2 (days 8-9 of course 1). Treatment repeats every 28 days (35 days for course 1 and 84 days for course 6) for 6 courses in the absence of disease progression or unacceptable toxicity.
3175633|NCT01369836|Experimental|20 mg soft gelatin capsule|
3175634|NCT01369836|Experimental|40 mg (20 mg*2) soft gelatin capsule|
3175635|NCT01369836|Active Comparator|Placebo|
3175636|NCT01369810||1|All patients who was on treatment with fixed combination asthma or COPD therapy by January 1 2010
3175637|NCT01369797|No Intervention|reference|"reference group, where every patient will benefit: of the same GGA at home as those of the  specific intervention  group. The GGA results will not be supplied to the family practioner."
3175638|NCT01369797|Experimental|specific intervention|"specific intervention group, where every patient will benefit: of an GGA at home. According to the frailties or the detected morbidity, a specific plan of intervention will be established for the person. all the preventive actions will be coordinated by UPSAV."
3175639|NCT01369784||refractory/relapsed LDCBG|patients with refractory/relapsed diffuse large B-cell lymphoma
3175640|NCT01369771|Experimental|Tafluprost 0.0015%|Open, one arm study. Patients who have been using latanoprost 0.005% eye drops (Xalatan®) as their prior medication (at least 6 months) and who fulfil all the inclusion criteria including the specified ocular symptoms and signs, will switch from latanoprost to the assigned preservative-free tafluprost 0.0015% (Taflotan®)eye drops for twelve (12) months.
3175641|NCT01369758|Experimental|Intrauterine pathology, myomectomy|Subjects with intrauterine fibroids and/or polyps will undergo intrauterine pathology removal using the MyoSure Tissue Removal System; myomectomy procedure.
3175642|NCT01369745|Active Comparator|Prednisolone|Prednisolone 2.7 mg daily for 12 weeks
3175643|NCT01369745|Active Comparator|dipyridamole|Dipyridamole 360 mg daily for 12 weeks
3175644|NCT01369745|Active Comparator|prednisone|Prednisone 5 mg daily for 12 weeks
3175645|NCT01369745|Experimental|Z102 (2.7/360)|Prednisolone 2.7 mg plus dipyridamole 360 mg daily for 12 weeks
3175646|NCT01369745|Placebo Comparator|placebo|Placebo daily for 12 weeks
3175649|NCT01369719|Experimental|Osveral|20 mg/kg oral osveral daily
3175650|NCT01369719|Active Comparator|desferal|40mg/kg desferal for 6 nights in a week subcutaneously
3175651|NCT01369706|Other|Hand-held metal detector|Exposure to two hand-held metal detectors
3175652|NCT01369693|Active Comparator|General Portion 1 g pouch|
3175653|NCT01369693|Active Comparator|Catch Licorice Portion 1 g pouch|
3175654|NCT01369693|Active Comparator|Catch Licorice Portion Mini 0.5 g pouch|
3175655|NCT01369693|Active Comparator|Catch Licorice Portion Dry Mini 0.3 g pouch|
3175656|NCT01369680|Experimental|Ketamine 0.25 mg/kg/dose|The first three subjects were administered 0.25 mg/kg/dose oral ketamine.
3175657|NCT01369680|Experimental|Ketamine 0.5 mg/kg/dose|The second group of three subjects were administered 0.5 mg/kg/dose oral ketamine.
3175658|NCT01369680|Experimental|Ketamine 1 mg/kg/dose|The third group of three subjects were administered 1 mg/kg/dose oral ketamine.
3175659|NCT01369680|Experimental|Ketamine 1.5 mg/kg/dose|The fourth group of three subjects were administered 1.5 mg/kg/dose oral ketamine.
3175660|NCT01369667|Active Comparator|vitamin D|Capsule, one taken daily
3175661|NCT01369667|Placebo Comparator|Placebo|Capsule, one taken daily
3175662|NCT01369654|Experimental|Computerized decision aid|
3175663|NCT01369641|Experimental|Experimental Ear - Sodium Thiosulfate (STS)|Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.
3175664|NCT01369641|Placebo Comparator|Comparator Ear - Placebo|Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.
3175665|NCT01369628|Experimental|Arm 1|"1 arm with the 3 following dose regimens:~Regimen 1: Atacicept 25 mg weekly for 12 weeks~Regimen 2: Atacicept 75 mg weekly for 12 weeks~Regimen 3: Atacicept 150 mg weekly for 12 weeks"
3175666|NCT01369615|Experimental|Oxycodone HCl controlled-release|Oxycodone hydrochloride controlled-release tablets
3175667|NCT01369602|Experimental|healthy controls|healthy subjects (creatinine clearance > 90 mL/min)
3175668|NCT01369602|Experimental|ESRD / severe renal insufficiency|Severe (creatinine clearance 15 to 29 mL/min) OR ESRD (creatinine clearnace <15 mL/min OR requiring dialysis)
3175669|NCT01369602|Experimental|Moderate renal impairment|Moderate (creatinine clearance = 30 to 59 mL/min)
3175670|NCT01369602|Experimental|Mild renal impairment|Mild (creatinine clearance = 60 to 89 mL/min)
3175671|NCT01369589|Experimental|P-552 oral rinse|P-552 oral rinse (10 mL volume containing 5 mg of P-552)
3175672|NCT01369589|Placebo Comparator|Placebo|Vehicle oral rinse (10 mL)
3175673|NCT01369576|Placebo Comparator|Placebo|Usual sleep apnea and CPAP care Sleep apnea OSR Medical Treatment Plan©
3175674|NCT01369576|Experimental|zopiclone|Sleep apnea OSR Medical Treatment plan ©
3175675|NCT01369550|Placebo Comparator|High-oleic sunflower oil-containing foods|Subjects will consume 3 servings of foods containing high-oleic sunflower oil plus 3x500 mg high-oleic sunflower oils softgels per day.
3175676|NCT01369550|Active Comparator|Eicosapentaenoic acid|Subjects will consume 3 x 500 mg eicosapentaenoic acid ethyl ester in softgels plus 3 servings of high-oleic sunflower oil-containing foods per day
3175677|NCT01369550|Experimental|SDA soybean oil-containing foods|Subjects in this arm will consume 3 servings of SDA soybean oil-containing foods plus 3 x 500 mg high-oleic sunflower oil softgels per day.
3175678|NCT01369537||adults > 65 yrs undergoing noncardiac surgery|
3175679|NCT01369524||ICUpatient with need of fluid|age > 18 - haemodynamic monitoring - informed consent - admission on ICU
3175680|NCT01369511|Placebo Comparator|Placebo|Administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
3175681|NCT01369511|Experimental|35 mg LY2495655|LY2495655: 35 milligrams (mg) administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
3175682|NCT01369511|Experimental|105 mg LY2495655|LY2495655: 105 mg administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
3175683|NCT01369511|Experimental|315 mg LY2495655|LY2495655: 315 mg administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
3175684|NCT01369498|Experimental|Simtuzumab 200 mg|Participants in stage 1 of study will receive simtuzumab 200 mg for up to 28 weeks.
3175685|NCT01369498|Experimental|Simtuzumab 700 mg|Participants in stage 1 of study will receive simtuzumab 700 mg for up to 28 weeks.
3175686|NCT01369498|Experimental|Simtuzumab 200 mg+ruxolitinib|In stage 2, participants on stable doses of ruxolitinib will receive simtuzumab 200 mg for at least 24 weeks.
3175687|NCT01369498|Experimental|Simtuzumab 700 mg+ruxolitinib|In stage 2, participants on stable doses of ruxolitinib will receive simtuzumab 700 mg for at least 24 weeks.
3175688|NCT01369485|Active Comparator|Active Treatment group|VERV™ System
3175689|NCT01369485|Sham Comparator|Sham Treatment Group|Sham version of (VERV™ System)
3175690|NCT01369472|Experimental|Dilatrend SR capsule 8mg|
3175691|NCT01369472|Experimental|Dilatrend SR capsule 16mg|
3175692|NCT01369472|Experimental|Dilatrend SR capsule 32mg|
3175693|NCT01369472|Experimental|Dilatrend SR capsule 64mg|
3175694|NCT01369472|Experimental|Dilatrend SR capsule 128mg|
3175695|NCT01369459|Experimental|Family Counseling with MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
3175696|NCT01369459|No Intervention|Historical Control|
3175697|NCT01369446||Women undergoing IVF treatment|
3175698|NCT01369433|Experimental|tivozanib RCC|Subjects who participated in a Phase 2 monotherapy study in RCC and showed tolerablity and clinical benefit will be allowed access to tivozanib (AV-951).
3175699|NCT01369433|Experimental|tivozanib + temsirolimus|Subjects who participated in a Phase 1b study and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951) + temsirolimus combination.
3175700|NCT01369433|Experimental|tivozanib + paclitaxel|Subjects who participated in a Phase 1b study and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951) + paclitaxel combination.
3175701|NCT01369433|Experimental|tivozanib solid tumors - QTC|Subjects who participated in a Phase 1 and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951).
3175702|NCT01369433|Experimental|tivozanib + capecitabine|After Ph 1b study tolerable to Tivo + Xeloda®
3175703|NCT01369433|Experimental|tivozanib Advanced RCC|After biomarker study tolerable to Tivo
3175704|NCT01369407||Enrolled Subjects|Enrolled subjects participate for up to 2 years
3175705|NCT01369394|Experimental|Tailored information|Individuals assigned to the experimental group will receive individually-tailored educational messages.
3175706|NCT01369394|Active Comparator|Untailored information|Individuals assigned to the control group will receive generic, untailored educational messages.
3175707|NCT01369381|Experimental|Airtraq laryngoscope|The Airtraq is an alternative indirect laryngoscope that appears to cause less cervical spine motion during intubation that conventional direct laryngoscopy (Macintosh blade)
3175708|NCT01369381|Active Comparator|Macintosh laryngoscope|This arm constitutes intubation with a conventional direct laryngoscopy with a Macintosh blade which has been shown to result in cervical spine extension, particularly in the upper cervical segments.
3175709|NCT01369368|Experimental|1|Azacitidine, valproic acid, all-trans retinoic acid, hydroxyurea, eventually donor leukocyte infusions
3175710|NCT01369355|Placebo Comparator|001|Participants who were responders to Intravenous (IV) infusion of ustekinumab induction will be randomized to receive a single dose of placebo subcutaneously (SC) every 4 weeks (q4w).
3175711|NCT01369355|Experimental|002|Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 milligram (mg) SC every 12 weeks (q12w).
3175712|NCT01369355|Experimental|003|Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 mg SC every 8 weeks (q8w).
3175713|NCT01369355|Experimental|004|Participants who were nonresponders to IV ustekinumab induction will receive a single dose of ustekinumab 90 mg SC and one placebo IV at week 0, if then respond will continue to receive one ustekinumab 90 mg SC q8w.
3175714|NCT01369355|Experimental|005|Participants who were nonresponders to IV placebo induction will receive a single dose of ustekinumab 130 mg IV and one placebo SC at week 0, if then respond will continue to receive one ustekinumab 90 mg SC at week 8 then q12w.
3175715|NCT01369355|Placebo Comparator|006|Participants who were responders to IV placebo induction will receive one dose of placebo SC q4w.
3175716|NCT01369342|Placebo Comparator|Placebo IV|Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
3175717|NCT01369342|Experimental|Ustekinumab 130 milligram (mg)|Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
3175718|NCT01369342|Experimental|Ustekinumab approximately (~) 6 milligram per kilogram (mg/kg)|Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg) 390 mg (weight > 55 kg and <= 85 kg) and 520 mg (weight > 85 kg).
3175719|NCT01369329|Placebo Comparator|001|Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
3175720|NCT01369329|Experimental|002|Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
3175721|NCT01369329|Experimental|003|Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg) 390 mg (weight > 55 kg and <= 85 kg) and 520 mg (weight > 85 kg).
3175722|NCT01369316|Experimental|Circumferential Submucosal Incision Resection|
3175723|NCT01369316|Active Comparator|Endoscopic Mucosal Resection|Patients randomised into this arm will receive the conventional treatment Endoscopic Mucosal Resection in which the sessile lesion is injected and snared by piecemeal technique.
3175724|NCT01369303|Experimental|Daily dosing|Tenofovir 1% gel will be inserted each day or evening at about the same time with the last study-sex 12 hours after the final dose
3175725|NCT01369303|Experimental|BAT24 dosing|Tenofovir 1% gel will be inserted 1 hour before and 1 hour after sex
3175726|NCT01369303|Experimental|Pericoital dosing|Tenofovir 1% gel will be inserted either 1 hour before sex OR 1 hour after sex
3175727|NCT01369290||Drug 1|Venlafaxine
3175728|NCT01369290||Drug 2|Bupropion
3175729|NCT01369290||Drug 3|Escitalopram
3175730|NCT01369290||Drug 4|Duloxetine
3175731|NCT01369290||Psychotherapy|Cognitive behaviour therapy
3175732|NCT01369277|Experimental|Japanese cohort|A total of 12 Japanese healthy subjects will be allocated to receive 3 ascending single doses (100 mg, 300 mg and 750 mg) of PF-04991532 or placebo through 3 dosing periods in a randomization ratio of 3:1.
3175733|NCT01369277|Experimental|Weterner Cohort|9 western healthy subjects will be enrolled to receive 2 single ascending doses (300 mg and 750 mg) of PF-04991532 through 2 dosing periods.
3175734|NCT01369264|Experimental|True Left High Frequency|True left high frequency repetitive transcranial magnetic stimulation
3175735|NCT01369264|Placebo Comparator|Passive sham left high frequency|Passive sham left high frequency repetitive transcranial magnetic stimulation
3175736|NCT01369251|Experimental|Hygiene with water and soap|
3175737|NCT01369251|Active Comparator|Usual alcohol care|
3175738|NCT01369238|Experimental|Bee Venom Acupuncture & zaltoprofen|
3175739|NCT01369238|Active Comparator|zaltoprofen|
3175740|NCT01369238|Active Comparator|Bee Venom Acupuncture|
3175741|NCT01369225|Experimental|0.5 mg/kg AAB-003|
3175742|NCT01369225|Experimental|1 mg/kg AAB-003|
3175743|NCT01369225|Experimental|2 mg/kg AAB-003|
3175744|NCT01369225|Experimental|4 mg/kg AAB-003|
3175745|NCT01369225|Experimental|8 mg/kg AAB-003|
3175746|NCT01369212|Experimental|Tenofovir|Tenofovir 192 weeks
3175794|NCT01368887|Active Comparator|3|Calcipotriol Monotherapy
3175795|NCT01368887|Active Comparator|4|Nicotinamide Monotherapy
3175747|NCT01369212|Experimental|Peginterferon-alfa 2a and tenofovir|A combination of peginterferon-alfa 2a plus tenofovir for 24 weeks and then tenofovir only for 168 weeks
3175748|NCT01369199|Experimental|Peginterferon and entecavir|A combination of 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon.
3175749|NCT01369186|Active Comparator|Morphine|Vendal 5 mg i.v. bolus injection
3175750|NCT01369186|Placebo Comparator|Placebo|Sodium chloride 0.9% i.v. bolus injection
3175751|NCT01369173|Active Comparator|Mexican Menu|24 days, all foods and drinks provided, menu consists of traditional mexican meals
3175752|NCT01369173|Active Comparator|US diet|24 days, all foods and drinks provided, menu consists of foods commonly eaten in contemporary United States
3175753|NCT01369160||1|Chronic Transfusion
3175754|NCT01369160||2|hydroxyurea
3175755|NCT01369160||3|matched sibling donor stem cell transplantation (MSD-SCT)
3175756|NCT01369160||4|standard comprehensive care (SCC, control)
3175757|NCT01369147|Experimental|Parenteral nutrition energy dose at 0.6x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake [from parenteral nutrition (PN) + dextrose-containing IV fluids (> 500 mL/day) + propofol/clevidipine + any enteral feedings) at 0.6 x resting energy expenditure (REE).
3175758|NCT01369147|Active Comparator|Parenteral nutrition energy dose at 1.0 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake [from parenteral nutrition (PN) + dextrose-containing IV fluids (> 500 mL/day) + propofol/clevidipine + any enteral feedings) at 1.0 x resting energy expenditure (REE).
3175759|NCT01369147|Experimental|Parenteral nutrition energy dose at 1.3 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake [from parenteral nutrition (PN) + dextrose-containing IV fluids (> 500 mL/day) + propofol/clevidipine + any enteral feedings) at 1.3 x resting energy expenditure (REE).
3175760|NCT01369121|Experimental|Xerecept|All patients will receive hCRF (XERECEPT)
3175761|NCT01369108|Experimental|Flowable composite|Flowable composite
3175762|NCT01369108|Active Comparator|Conventional composite|Highly filled conventional composite restorative
3175763|NCT01369095|Active Comparator|Arm 1: Duloxetine / Escitalopram + BMS-820836 placebo|
3175764|NCT01369095|Experimental|Arm 2: BMS-820836 (0.25 mg) + BMS-820836 placebo|
3175765|NCT01369095|Experimental|Arm 3: BMS-820836 (0.50 mg) + BMS-820836 placebo|
3175766|NCT01369095|Experimental|Arm 4: BMS-820836 (1.0 mg) + BMS-820836 placebo|
3175767|NCT01369095|Experimental|Arm 5: BMS-820836 (2.0 mg) + BMS-820836 placebo|
3175768|NCT01369082||CIT Islet Transplantation Recipients|"Subjects who received an islet-cell transplant for Type 1 Diabetes (T1D) while enrolled in one of the Clinical Islet Transplantation (CIT) parent studies and continue to have islet graft function. All subjects will continue immunosuppressive medications under CIT08. Detailed follow-up evaluations including but not limited to islet function will occur on an annual basis.~The immunosuppressive medications (e.g., tacrolimus, sirolimus, cyclosporine, mycophenolate mofetil [MMF], mycophenolic sodium) in this study are obtained by prescription unless provided by the study through the drug distributor. Generic brands are allowed, when available. Antibacterial, antifungal, and antiviral prophylaxis, insulin therapy, and other standard therapies will be provided per site-specific practices."
3175769|NCT01369069|Experimental|IV insulin drip with target glucose 80 mg/dL - 130 mg/dL|The intervention arm will have a targeted glucose concentration of 80-130 mg/dL. IV insulin drip will be titrated to keep glucose concentration in this range.
3175770|NCT01369069|Active Comparator|Sub Q insulin to keep glucose less than 180 mg/dL|This standard care arm will get sub q insulin sliding scale to keep glucose concentration less than 180 mg/dL
3175771|NCT01369056|Experimental|Advanced Adherence Counseling (AdvAdh)|Please see the Intervention Description section
3175772|NCT01369056|No Intervention|Control|Standard of care (including counseling regarding antiretroviral treatment adherence) received by HIV/AIDS patients at the study clinic
3175773|NCT01369043|Active Comparator|Vitamin E and Vitamin C|4 weeks with Vitamin E and Vitamin C supplementation with no exercise and 4 weeks of supplementation with prescribed exercise.
3175774|NCT01369043|No Intervention|Placebo|Placebos instead of the Vitamin E and Vitamin C supplements
3175775|NCT01369030||Deplin®|Subjects with depression who have been prescribed Deplin® daily.
3175776|NCT01369017|Active Comparator|Anakinra|All subjects will undergo 2 CCRE challenges. Each subject will be given either anakinra or placebo prior to CCRE challenge
3175777|NCT01369017|Placebo Comparator|Placebo|Normal saline injection
3175778|NCT01369004|Experimental|Daily self-weighing + feedback/lessons|Participants will be instructed to weigh daily and they will receive a smart scale for daily monitoring of weighing via the website bodytrace.com. They will also receive weekly emailed lessons with content related to behavioral weight control (e.g., How to control portion sizes, How to develop an exercise routine) as well as weekly emailed feedback from a registered dietitian on their daily weighing and weight loss progress.
3175779|NCT01369004|No Intervention|Delayed Intervention Control Group|Participants will receive the same components of the experimental group with the exception of the weekly feedback after the 6-month study period is complete.
3175780|NCT01368991|Active Comparator|Kryptonite|Sternal closure with stainless steel and kryptonite
3175781|NCT01368991|Active Comparator|Conventional Closure|Sternal closure with stainless steel wires
3175782|NCT01368978|Experimental|Test (with the InsuPatch device)|Device use
3175783|NCT01368978|No Intervention|Control (without the InsuPatch device)|
3175784|NCT01368965|Experimental|Ulthera® System treatment|
3175785|NCT01368952|Active Comparator|Pure Prone Positioning|Sleeping in prone position by pure prone positioning device, which consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
3175786|NCT01368952|No Intervention|Baseline|No intervention for sleep position
3175787|NCT01368926|Experimental|Part 1|
3175788|NCT01368926|Experimental|Part 2|
3175789|NCT01368913||Patients treated with orally disintegrating tablet|
3175790|NCT01368913||Patients treated with tablets|
3175791|NCT01368900|Experimental|Ulthera System Treatment|Ulthera treatment to the upper face.
3175792|NCT01368887|Experimental|1|DPS-102
3175793|NCT01368887|Placebo Comparator|2|Vehicle
3175796|NCT01368874|Active Comparator|Group A|Ulthera® System treatment of the submental and submandibular regions at two treatment depths, and the lower neck region at one treatment depth.
3175797|NCT01368874|Active Comparator|Group B|Ulthera® System treatment of skin above the jawline, as well as the submental, submandibular and lower neck regions.
3175798|NCT01368874|Active Comparator|Group C|Ulthera® System treatment of the submental, submandibular, and the lower neck regions at two treatment depths.
3175799|NCT01368861||control|water and normal physical comfort provided by mom
3175800|NCT01368861||sucrose|sugar and normal physical comfort provided by mom
3175801|NCT01368861||physical intervention|physical intervention using the 5 S's and water
3175802|NCT01368861||physical intervention and sucrose|Physical intervention using the 5 S's and sugar water
3175803|NCT01368835|Experimental|Ulthera treatment|
3175804|NCT01368809|Active Comparator|Fentanyl|Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
3175805|NCT01368809|Placebo Comparator|Saline Solution|Saline Solution 2 ml at induction, 1-2 ml boluses as needed
3175806|NCT01368796|Active Comparator|Trivalent Influenza vaccine subunit|The seasonal vaccine (Agriflu, Novartis) contains egg-derived, inactivated and detergent split versions of the 3 influenza strains (tri-valent). It is given into the muscle of the upper arm at a dose of 0.5 mL.
3175807|NCT01368796|Active Comparator|Adjuvanted Tri-valent Influenza Vaccine|The adjuvanted vaccine (Fluad, Novartis) is made with an immune-stimulator (MF59) that contains squalene oil microdroplets and two surfactants, Tween 80 and Span 65. It is given into the muscle of the upper arm at a dose of 0.5 mL.
3175808|NCT01368796|Active Comparator|Intradermal Tri-valent Influenza vaccine|(Intanza 15ug, Sanofi Pasteur) is an inactivated, split-virion influenza vaccine. Strains are grown in fertilized hen's eggs, inactivated with formalin and split using Triton X-100 detergent, as for TIV. The syringe is attached to a micro-needle injection system (Beckton Dickinson) that limits the depth of injection to just under the skin. It is given into the skin over the upper arm at a dose of 0.1 mL.
3175809|NCT01368796|Active Comparator|Trivalent Split-virion Influenza vaccine|Vaxigrip, Sanofi Pasteur is an inactivated, split-virion Influenza vaccine. The 3 influenza strains are grown on fertilized eggs, concentrated, purified in a sugar-like solution, detergent split, and inactivated by formaldehyde, then diluted in phosphate buffered salt solution. A dose of 0.5 mL is given into the muscle of the arm.
3175810|NCT01368783|Experimental|atazanavir|400 mg/day for 2 days
3175811|NCT01368783|Experimental|Atazanavir and Tenofovir|
3175812|NCT01368783|Experimental|Atazanavir and Ritonavir|
3175813|NCT01368783|Experimental|Atazanavir + tenofovir + ritonavir|
3175814|NCT01368770|Experimental|Coronary CTA|Coronary CTA using standard protocols
3175815|NCT01368770|Active Comparator|Stress MPI SPECT|Stress-rest MPI SPECT using standard protocols
3175816|NCT01368744||OSNA Breast Cancer System|
3175817|NCT01368731|No Intervention|nil prophylactic coagulation|
3175818|NCT01368731|Active Comparator|Prophylactic coagulation|
3175819|NCT01368718|Other|Active/Sham CPAP|
3175820|NCT01368705|Active Comparator|Control Group|
3175821|NCT01368705|Experimental|Intervention Group 1|
3175822|NCT01368705|Experimental|Intervention Group 2|
3175823|NCT01368692|Active Comparator|neutral shoulder|neutral shoulder position during subclavian vein catheterization
3175824|NCT01368692|Experimental|shoulder retraction|position of shoulder retraction during subclavian vein catheterization
3175825|NCT01368679|Experimental|Endoprothesis Scitech|"The endoprothesis of SCITECH is a self-expandable stent mixed (laser cut and wire plotted) covered with polyester fabric. The delivery system has lower profile than the existing market and this approach allows the passage of the delivery system through the femoral artery with ease and without dissection. Fixation has proximal and distal securing lower rates of leakage and displacement.~The delivery system is done by linear drive or screw diameters greater than 30mm"
3175826|NCT01368666|Experimental|Perceval S Valve Prosthesis|Patients who underwent replacement of diseased or malfunctioning native aortic valve with the Perceval S Valve prosthesis
3175827|NCT01368653|Active Comparator|Standard treatment|In this arm, smokers receive a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling sessions to help them quit smoking
3175828|NCT01368653|Experimental|Standard treatment+practice quitting|In this arm, participants receive standard treatment (a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling session) and an experimental treatment that involves practice quitting 7 times prior to a target quit date (for 4-12 hours per day) and returning to smoking by puffing smoke without inhaling.
3175829|NCT01368653|Experimental|Very low nicotine cigarettes|In this condition, smokers from both the Standard treatment and the Standard treatment+practice quitting arms who have smoked in the last 7-days at a 4-week post-target-smoking-cessation-date follow-up interview may be randomly assigned to this group. Those assigned to this group will receive a 6-week supply of cigarettes that contain tobacco with very low levels of nicotine (in regular or menthol flavors) to smoke instead of regular cigarettes containing nicotine. This treatment is designed to help people stop smoking after slipping (returning to smoking) during an attempt to stop smoking
3175830|NCT01368653|No Intervention|Advice and encouragement only|In this condition, smokers from both the Standard treatment and the Standard treatment+practice quitting arms who have smoked in the last 7-days at a 4-week post-target-smoking-cessation-date follow-up interview may be randomly assigned to this condition. Those in this arm will receive advice and encouragement to try to stop smoking again after they have slipped (returned to smoking) during a stop smoking attempt.
3175831|NCT01368640||healthy adults|The study will cover 130 healthy adults. 65 men and 65 women in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
3175832|NCT01368627|Experimental|Supralimus® Sirolimus-Eluting Coronary Stent|
3175833|NCT01368614|Experimental|AVAPS-AE|AVAPS-AE Mode of ventilation
3175834|NCT01368614|Active Comparator|Respironics OmniLab Advanced BiPAP S mode|OmniLab Advanced BiPAP S Mode of ventilation
3175835|NCT01368614|Active Comparator|Respironics OmniLab Advanced CPAP mode|OmniLab Advanced CPAP Mode of ventilation
3175885|NCT01368315|Placebo Comparator|Placebo|Cream (Vehicle only)
3175886|NCT01368315|Active Comparator|Active comparator|Cream
3175887|NCT01368315|No Intervention|No intervention|
3175836|NCT01368601|Active Comparator|CPAP (positive airway pressure)|To evaluate if continuous positive airway pressure(CPAP) on the lung undergoing lobectomy can decrease the inflammatory response PPC (postoperative pulmonary complications).
3175837|NCT01368601|No Intervention|Control without CPAP|
3175838|NCT01368588|Active Comparator|Arm I|Patients undergo high-dose radiotherapy of the prostate and seminal vesicles using intensity-modulated radiotherapy (IMRT)* or 3D-conformal radiation therapy (3D-CRT)* once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo permanent prostate implant (PPI) brachytherapy or high-dose rate brachytherapy (I 125 or Pd 103 may be used as the radioisotope).
3175839|NCT01368588|Experimental|Arm II|Patients undergo whole-pelvic radiotherapy (WPRT)* (3D-CRT or IMRT) once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo brachytherapy as in arm I.
3175840|NCT01368575|Active Comparator|subgroup B1|subgroup B1 will receive CABG combined with MV repair with annuloplasty rigid ring
3175841|NCT01368575|Active Comparator|subgroup B2|B2 - CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus
3175842|NCT01368575|Active Comparator|subgroup A2|CABG combined with MV repair with remodeling annuloplasty rigid ring
3175843|NCT01368575|Active Comparator|subgroup A1|only CABG
3175844|NCT01368575|Active Comparator|subgroup B3|patients in subgroup B3 will be performed CABG and MV replacement with preservation of subvalvular apparatus
3175845|NCT01368562|Experimental|Arm 1|Methylnaltrexone
3175846|NCT01368549||Metanx®|Subjects with Diabetic Peripheral Neuropathy who have been prescribed Metanx® daily.
3175847|NCT01368536|Experimental|Valturna|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks.
3175848|NCT01368536|Active Comparator|Valturna + Amlodipine|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks.
3175849|NCT01368536|Active Comparator|Valturna + chlorthalidone|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks.
3175850|NCT01368523|Experimental|nilotinib|
3175851|NCT01368510|Experimental|OCD Active CBT|Adults with obsessive-compulsive disorder (OCD) will be treated with cognitive-behavioral therapy (CBT) from the time of enrollment.
3175852|NCT01368510|Active Comparator|OCD Waitlist|Adults with OCD will receive waitlist treatment at enrollment. Nonresponders will cross over to CBT.
3175853|NCT01368510|No Intervention|Healthy Control|Healthy control adults will be given no intervention.
3175854|NCT01368497|Experimental|Entecavir and peginterferon|Entecavir for 8 weeks followed by 40 weeks of both entecavir and peginterferon
3175855|NCT01368484|Placebo Comparator|Sunflower oil|
3175856|NCT01368484|Experimental|Docosahexanoic acid|
3175857|NCT01368471|Experimental|MGuard|MGuard stent will be deployed
3175858|NCT01368471|Active Comparator|BMS or DES|A regular bare metal stent or drug-eluting stent will be deployed
3175859|NCT01368458|Experimental|Conversion to mono therapy|Conversion from 2 to 1 antipsychotic
3175860|NCT01368458|No Intervention|control|No change in antipsychotics
3175861|NCT01368445|Active Comparator|MP03-36 Nasal Spray|azelastine hydrochloride 0.15%
3175862|NCT01368445|Active Comparator|MP03-36 and Placebo Nasal Spray|azelastine hydrochloride 0.15% and Placebo
3175863|NCT01368445|Active Comparator|Azelastine 0.1%, Nasal Spray|Azelastine 0.1%, Nasal Spray
3175864|NCT01368445|Placebo Comparator|Placebo Nasal Sapray|0mg, 2 sprays per nostril twice daily AM & PM)
3175865|NCT01368432|Placebo Comparator|Placebo|Daily for 12 weeks
3175866|NCT01368432|Experimental|Escitalopram|Escitalopram 10 mg or 20 mg daily for 12 weeks
3175867|NCT01368419|Experimental|Treatment|
3175868|NCT01368406|Experimental|wellness program|12-week weight management intervention in patients with severe mental disorders. In the 1-hour weekly group sessions topics like dietary choices, lifestyle, physical activity and self-esteem were discussed with outpatients and their relatives
3175869|NCT01368406|No Intervention|treatment as usual|patients were on regular visits on psychiatrist
3175870|NCT01368393|Experimental|Electroacupuncture|
3175871|NCT01368393|Active Comparator|Sham acupuncture|
3175872|NCT01368380|Experimental|Psychological Intervention|
3175873|NCT01368380|No Intervention|Usual care|
3175874|NCT01368367|Active Comparator|Intensive exercise group|
3175875|NCT01368367|Placebo Comparator|Stretch exercise only|
3175876|NCT01368354|Active Comparator|CLTS Arm|To induce behavioural changes by confronting the community with their open defecation behaviour. This will lead to voluntary construction and use of latrines and improved hygiene behaviour. CLTS involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination.
3175877|NCT01368354|No Intervention|Control arm|
3175878|NCT01368341|Active Comparator|Doxycycline|Doxycycline, 100 mg, tablets, b.i.d., 14 days
3175879|NCT01368341|Active Comparator|Penicillin|Phenoxymethylpenicillin tablets 650 mg. 2 tablets t.i.d. 14 days
3175880|NCT01368341|Active Comparator|Amoxicillin|Amoxicillin 500 mg capsula, t.i.d., 14 days
3175881|NCT01368328|Placebo Comparator|Placebo|
3175882|NCT01368328|Active Comparator|Chromium nicotinate 50 mcg|
3175883|NCT01368328|Active Comparator|Chromium nicotinate 200 mcg|
3175884|NCT01368315|Experimental|CT327|Cream
3175888|NCT01368302|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to normalize threat-related attention biases.
3175889|NCT01368302|Placebo Comparator|Placebo|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns.
3175890|NCT01368289||Colonic Polyps|Patients who present with colonic polyps >20mm
3175891|NCT01368276|Active Comparator|GM-CSF|Granulocyte macrophage colony-stimulating factor (GM-CSF) was administered at a dose of 125 μg/m²/day subcutaneously for 14 consecutive days followed by 14 days of rest, in 28-day treatment cycles for up to 12 months or until a complete response, occurrence of an unacceptable toxicity, death or another criterion for withdrawal from treatment was met. Participants who demonstrated a partial response after being on treatment for 12 months could continue to be treated until disease progression or another treatment discontinuation criterion was met.
3175892|NCT01368276|Experimental|Talimogene Laherparepvec|Talimogene laherparepvec was administered at a concentration of 10⁸ plaque forming units (PFU)/mL injected into 1 or more skin or subcutaneous tumors on Days 1 and 15 of each 28-day cycle for up to 12 months or until a complete response, occurrence of an unacceptable toxicity, death or another criterion for withdrawal from treatment was met. Participants who demonstrated a partial response after being on treatment for 12 months could continue to be treated until disease progression or another treatment discontinuation criterion was met.
3175893|NCT01368263|Experimental|Group 1 (Ki67 <10%, E2 <= 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Neoadjuvant treatment repeats every 28 days for a total of 16-18 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Recommendations for postsurgical treatment will be based on PEPI score and physician discretion.
3175894|NCT01368263|Experimental|Group 2 (Ki67 >= 10%, E2 <= 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Patients receive standard neoadjuvant chemotherapy in the absence of disease progression or unacceptable toxicity. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Postsurgical treatment at physician discretion.
3175895|NCT01368263|Experimental|Group 3 (E2 > 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Patients receive standard neoadjuvant therapy at the discretion of the physician. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Postsurgical treatment at physician discretion.
3175896|NCT01368250||1|Elderly patients with symptomatic severe aortic stenosis, deemed at high risk for conventional aortic valve replacement
3175897|NCT01368237||Patients|Patients awaiting invasive coronary angiography
3175898|NCT01368224|Placebo Comparator|Maltodextrin|
3175899|NCT01368224|Experimental|Lactobacillus paracasei NCC 2461 (ST 11)|1x1010 CFU of Lactobacillus paracasei NCC 2461 (ST 11)
3175900|NCT01368224|Experimental|Lactobacillus paracasei+ Bifidobacterium longum|1x1010 CFU of Lactobacillus paracasei NCC 2461 (ST 11) + 1x1010 CFU of Bifidobacterium longum (NCC3001)
3175901|NCT01368211|Active Comparator|Mirasol first, then Reference|This study arm will receive first a 2-4-day-old Mirasol-treated platelets transfusion and then a reference 2-4-day-old untreated platelets transfusion (Mirasol-Reference sequence).
3175902|NCT01368211|Active Comparator|Reference first, then Mirasol|This study arm will receive first a reference 2-4-day-old untreated platelets transfusion and then a 2-4-day-old Mirasol-treated platelets transfusion (Reference-Mirasol sequence).
3175903|NCT01368198|Active Comparator|Ocular Emulsion|An Ocular Emulsion
3175904|NCT01368198|Active Comparator|OPTIVE™|An OPTIVE™
3175905|NCT01368185||All Participants|Participants with hypertension who had been treated with MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg) for at least three months
3175906|NCT01368172|Experimental|Physical Activity Guidelines|Participants randomized to this arm received training/guidance on following the physical activity guidelines for adults with spinal cord injury
3175907|NCT01368172|No Intervention|Control|
3175908|NCT01368159|Active Comparator|pressure centred at 25 mm Hg|
3175909|NCT01368159|Active Comparator|pressure between 20 and 36 mm Hg|
3175910|NCT01368159|Placebo Comparator|pressure between 10 and 15 mm Hg|
3175911|NCT01368146|Experimental|IV Clear™|
3175912|NCT01368146|Active Comparator|Tegaderm CHG™|
3175913|NCT01368146|Placebo Comparator|Control Vehicle Dressing|
3175914|NCT01368120|Experimental|IV Clear™|
3175915|NCT01368120|Active Comparator|Tegaderm CHG™|
3175916|NCT01368120|Placebo Comparator|Vehicle Control Dressing|
3175917|NCT01368107|Placebo Comparator|Placebo Arm|the patients will receive Placebo before the 1st and during the 3rd CT cycle (N=6)
3175918|NCT01368107|Experimental|CYT107 treatment before CT|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle and the placebo during the 3rd CT cycle (N=6)
3175919|NCT01368107|Experimental|CYT107 treatment during CT|patients will receive the placebo before the 1st CT cycle and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (N=6)
3175920|NCT01368107|Experimental|CYT107 treatment before and during CT|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (N=6).
3175921|NCT01368094|Active Comparator|Standard drainage|
3175922|NCT01368094|Experimental|Short drainage|
3175923|NCT01368081|Experimental|BI 10773 low dose|BI 10773 low dose tablet once daily
3175924|NCT01368081|Experimental|BI 10773 high dose|BI 10773 high dose tablet once daily
3175925|NCT01368081|Active Comparator|Metformin|Metformin tablets 500-2250 mg a day (twice or three times per day)
3175926|NCT01368068|Experimental|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial.
3175927|NCT01368068|Active Comparator|Escitalopram|10mg of escitalopram will be taken by participants daily for the duration of the 12 week trial period.
3175928|NCT01368068|Placebo Comparator|Placebo|Placebo arm containing sweetener has been approved and will be used as placebo arm.
3175929|NCT01368055|Experimental|Low Risk|70 Gy/CGE
3175931|NCT01368042||Chronic Kidney Disease, Secondary Hyperpathyroidism|All eligible participants treated with paricalcitol iv according to the approved Summary of Product Characteristics (SmPC)
3175932|NCT01368029|Experimental|LGG|Lactobacillus rhamnosus GG (LGG) containing 1x10^10 LGG per capsule will be given to volunteers with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day on an outpatient basis.
3175933|NCT01368029|Placebo Comparator|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis.
3175934|NCT01368016|Experimental|Experimental NRT|A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits.
3175935|NCT01368016|Active Comparator|Nicotine GUM|A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits.
3175936|NCT01368003|Experimental|STA9090 with Dutasteride|STA9090 with Dutasteride
3175937|NCT01368003|Experimental|STA9090|STA9090
3175938|NCT01367990|Experimental|Norepinephrine|
3175939|NCT01367977||Ehlers-Danlos patients|Patients with diagnosed or suspected Classic or Hypermobile Ehlers-Danlos Syndrome
3175940|NCT01367964|Experimental|ACTH treatment|Infants with a Type 3 EEG (pre-hypsarhythmia) will be treated with ACTH for 2 weeks.
3175941|NCT01367951|Experimental|Surgical fixation|"The fractures will be reduced and stabilized by use of plates and screws~Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.~Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.~Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted."
3175942|NCT01367951|No Intervention|non-operative|"Mechanical ventilation: Patients in respiratory distress will receive endotracheal intubation, and placed on mechanical ventilation. PEEP will be utilized as needed, at the discretion of the ICU and respiratory therapy team.~Other conservative means/Pulmonary toilet:Patients will receive aggressive pulmonary toilet (suctioning of ET tube as needed), chest physiotherapy (as per standard local protocol), and will have the head of the bed elevated to 30° unless contraindicated (ie unstable C-spine injury).~Pain control:Epidural catheters, intercostal nerve block, PCA, IV/PO pain medication"
3175943|NCT01367938||OMNI Apex Ultracongruent Knee Device|
3175944|NCT01367925||Cruciate Substituting Tibial Insert|
3175945|NCT01367925||Posterior Stabilized Tibial Insert|
3175946|NCT01367912|No Intervention|Progesterone only group|received a single daily application of vaginal progesterone gel beginning from the day of OPU and continued at least until pregnancy was ruled out by a negative serum ß-hCG measurement performed on the 14th day after embryo transfer with no E2 added
3175947|NCT01367912|Active Comparator|Progesterone+Early Estradiol group|received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
3175948|NCT01367912|Active Comparator|Progesterone+Late estradiol group|received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel
3175949|NCT01367899||CONSERVE® Plus hip resurfacing|Recipients/C Plus (IDE)study
3175950|NCT01367886|Other|Fesoterodine|Females with overactive bladder symptoms will be given Fesoterodine 4 mg. daily for six weeks.
3175951|NCT01367873|Placebo Comparator|Placebo|
3175952|NCT01367873|Experimental|VIA-3196|Multiple, single-dose, ascending dosing groups (cohorts) will be evaluated.
3175953|NCT01367873|Experimental|VIA-3196 with Food|Second, single dose administered after a standard high-fat breakfast.
3175954|NCT01367873|Placebo Comparator|Placebo with Food|
3175955|NCT01367860|Active Comparator|OMicro|This group will be formed by randomization, which gets out surgery to open microdiscectomy
3175956|NCT01367860|Experimental|SJet|This group will be formed by randomization, and receive the discectomy procedure addressed by the technique of Percutaneous Diskectomy SpineJet
3175957|NCT01367847|Active Comparator|HNC|Helping the Noncompliant Child (McMahon & Forehand), a well-established behavioral parent training program for parents of 3 to 8 year old children with externalizing problems
3175958|NCT01367847|Experimental|TE-HNC|Standard HNC Program plus Technology-Enhancement (smartphones, which are being used for mid-week video calls to check-in re: skill-building, videotaping of family practice of skills at home, daily surveys re: skills practice & child behavior, reminders re: practice & sessions.
3175959|NCT01367834|Experimental|Growth Hormone|Subjects in the somatotropin (growth hormone, GH) arm will receive GH injections from 12-24 months of life.
3175960|NCT01367834|No Intervention|Control|Subjects will receive no GH or placebo.
3175961|NCT01367821||Patients with obstructive jaundice|Patients with obstructive jaundice
3175962|NCT01367821||Healthy volunteers|Healthy volunteers
3175963|NCT01367808|Placebo Comparator|Placebo|
3175964|NCT01367808|Active Comparator|Vorikonazole|
3175965|NCT01367808|Active Comparator|Posakonazole|
3175966|NCT01367795||palliative tumor disease|Patients in a known palliative setting with symptoms due to tumor growth.
3175967|NCT01367782|Active Comparator|Active repetitive Transcranial Stimulation|Each patient will be given 12 stimulation sessions, over a period of 4 weeks, and then a maintenance phase consisting of 8 stimulation sessions for the first 4 weeks and additional 4 stimulation sessions during the following 4 weeks.
3175968|NCT01367782|Sham Comparator|Sham Stimulation|The control arm group will receive sham stimulations in identical treatment and maintenance schedules.
3175969|NCT01367769||Thrombosis|"Patients with acute, idiopathic or provoked, unilateral proximal DVT (involving the popliteal vein or further proximal veins) and SVT of the lower-extremity detected with duplex ultrasound.~Age and sex matched controls (volunteers)"
3175970|NCT01367756|Experimental|1|
3175971|NCT01367756|Placebo Comparator|2|
3175972|NCT01367743|Active Comparator|epinephrine|
3175973|NCT01367743|Active Comparator|norepinephrine|
3175974|NCT01367730||osteoporosis and osteopenia|Subjects will be stratified based on DXA BMD T-scores.
3176255|NCT01365650|Experimental|Oxymetazoline Hydrochloride|
3175975|NCT01367717|Active Comparator|Creatine Monohydrate|Each of the 25 subjects took Creatine Monohydrate.
3175976|NCT01367717|Active Comparator|Creatine Ethyl Ester|Each of the 25 subjects took Creatine Ethyl Ester.
3175977|NCT01367704|Active Comparator|Control School|Control schools (where the coaches do not receive the Coaching Boys into Men (CBIM) training until following academic year 'wait list control')
3175978|NCT01367704|Experimental|Intervention School|Intervention schools (where coaches receive the CBIM training at start of sports season)
3175979|NCT01367678|Experimental|Laryngeal Mask Airway Supreme|Directly measured mucosal pressures
3175980|NCT01367678|Experimental|i-Gel|Directly measured mucosal pressures
3175981|NCT01367665|Experimental|Single Arm|
3175982|NCT01367652|Active Comparator|Letrozole|2.5 mg tablet
3175983|NCT01367652|Active Comparator|Femara|2.5 mg tablet
3175984|NCT01367639|Experimental|intervention|Inquiry Based Stress Reduction (IBSR) program
3175985|NCT01367626|Active Comparator|letrozole|2.5 mg tablet
3175986|NCT01367626|Active Comparator|Fermara|2.5 mg tablet
3175987|NCT01367613|Experimental|Arm 1|
3175988|NCT01367600|Experimental|Arm 1|
3175989|NCT01367587|Experimental|Arm 1|
3175990|NCT01367574|Experimental|Arm 1|
3175991|NCT01367574|Experimental|Arm 2|
3175992|NCT01367574|Experimental|Arm 3|
3175993|NCT01367561|Experimental|Arm 1|
3175994|NCT01367561|Experimental|Arm 2|
3175995|NCT01367561|Placebo Comparator|Arm 3|
3175996|NCT01367548|Experimental|Arm 1|
3175997|NCT01367548|Placebo Comparator|Arm 2|
3175998|NCT01367535|Experimental|Arm 1|
3175999|NCT01367535|Experimental|Arm 2|
3176000|NCT01367535|Active Comparator|Arm 3|
3176001|NCT01367535|Placebo Comparator|Arm 4|
3176002|NCT01367522|Experimental|Arm 1|
3176003|NCT01367509|Experimental|Arm 1|SC Methylnaltrexone (MNTX)
3176004|NCT01367496|Experimental|Arm 1|
3176005|NCT01367496|Experimental|Arm 2|
3176006|NCT01367496|Experimental|Arm 3|
3176007|NCT01367496|Experimental|Arm 4|
3176008|NCT01367483|Experimental|Arm1|MNTX active treatment
3176009|NCT01367470|Active Comparator|VSL#3 probiotic preparation|30 mothers in the last 4 weeks of gestation and in the first month of breastfeeding will be given (after obtaining their informed consent) 1 sachet per day of probiotics (VSL#3) during the last four weeks of pregnancy and the first month of breastfeeding for four weeks under the usual fasting dosage scheme (1 sachet before meal).
3176010|NCT01367470|Placebo Comparator|Placebo VSL#3|30 mothers in the last 4 weeks of gestation and in the first month of breastfeeding will be given (after obtaining their informed consent) a placebo comparable to VSL#3 during the last four weeks of pregnancy and the first month of breastfeeding for four weeks under the usual fasting dosage scheme (1 sachet/day, before meal)
3176011|NCT01367457||Patients that received treatment with Temsirolimus|Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
3176012|NCT01367444|Experimental|SAR422459 (Dose 1)|Starting dose of SAR422459 given through subretinal injection
3176013|NCT01367444|Experimental|SAR422459 (Dose 2)|Escalating dose of SAR422459 given through subretinal injection
3176014|NCT01367444|Experimental|SAR422459 (Dose 3)|Maximum tolerated dose (MTD) of SAR422459 given through subretinal injection
3176015|NCT01367431||20 mg|Single dose 20 mg Xanthohumol
3176016|NCT01367431||60 mg|Single dose 60 mg Xanthohumol
3176017|NCT01367431||180 mg|Single dose 180 mg Xanthohumol
3176018|NCT01367418|Experimental|Thoracic Epidural Analgesia (TEA)|TEA is used for perioperative pain management, having been used both intra- and postoperatively, up to 48 h.
3176019|NCT01367418|Active Comparator|Patient controlled analgesia (PCA)|PCA is the standard of pain management and is usually used for up to 48 h postoperative for pain management following radical prostatectomy.
3176020|NCT01367405|Experimental|surgical decompression|surgical decompression within 24 hours post-injury
3176021|NCT01367405|Active Comparator|Conservative treatment|Normal conservative treatment without surgical intervention
3176022|NCT01367392|Experimental|interventional procedure|The patients undergo the required interventional procedure, biopsy or ablation
3176023|NCT01367379||Physician of internal medicine in Taipei city hospital|
3176024|NCT01367366||Mediastinal malignant lymphadenopathy|
3176025|NCT01367353|Experimental|ovarian cancer|
3176026|NCT01367340|Experimental|Exercise and physical activity|
3176027|NCT01367340|Active Comparator|Exercise only|
3176028|NCT01367327|Experimental|Exercise with music|Loaded sit-to-stand exercise with music for 6 weeks
3176029|NCT01367327|Active Comparator|Exercise without music|Loaded sit-to-stand exercise without music for 6 weeks
3176030|NCT01367314|Experimental|NVC-422 Dermal Gel, 1.5%|
3176031|NCT01367314|Experimental|NVC-422 Dermal Gel, 0.5%|
3176032|NCT01367314|Experimental|NVC-422 Dermal Gel, 0.1%|
3176033|NCT01367301|Experimental|Treatment (paclitaxel, carboplatin, radiotherapy)|"CHEMOTHERAPY (weeks 1-9, 14-22): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 14-22.~RADIATION THERAPY (weeks 8-16): Patients undergo external beam pelvic radiation therapy once a day, 5 days a week for 5 weeks during weeks 8-13. Patients then undergo HDR brachytherapy or IMRT once weekly during weeks 14-16."
3176034|NCT01367288|Experimental|A (Neoadjuvant therapy + Zometa)|Patients will be treated every 3 weeks (+/- 2 days ) for 8 cycles in total. The 4 first cycles : Zometa 4 mg (in a 15 min. infusion) + doxorubicin (60 mg/m²) + cyclophosphamide (600 mg/m²). The 4 last cycles with Zometa 4 mg (in a 15 min. infusion) + docetaxel (100 mg/m²)
3176035|NCT01367288|Active Comparator|B (Neoadjuvant therapy)|Patients will be treated every 3 weeks (+/- 2 days) for 8 cycles in total. The 4 first cycles : doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²). The 4 last cycles with docetaxel (100 mg/m²)
3176036|NCT01367275|Experimental|Brivanib + Irinotecan|Brivanib 800 mg orally daily Days 1-14, and Irinotecan intravenously 180 mg/m^2 on Day 1.
3176037|NCT01367262|Experimental|Radiolabeled LY2886721|Single 25 mg oral dose containing 80 microcuries of radiolabeled LY2886721
3176038|NCT01367249|Experimental|Bromfenac Ophthalmic Solution|Bromfenac ophthalmic solution 0.07% one drop into study eye, once daily (QD) starting the day before cataract surgery and continued for 14 days post surgery for a total of 16 days.
3176039|NCT01367249|Placebo Comparator|Placebo|One drop of placebo into study eye, once daily (QD) starting the day before cataract surgery and continued for 14 days post surgery for a total of 16 days.
3176040|NCT01367236|Active Comparator|standard care|"treatment with:~atazanavir 300 mg daily~ritonavir 100 mg daily~tenofovir 245 mg daily*~emtricitabine 200 mg daily* * as the fixed dose combination Truvada™"
3176041|NCT01367236|Active Comparator|Novel therapeutic approach|"darunavir 800 mg daily~ritonavir 100 mg daily~lamivudine 300 mg daily**~abacavir 600 mg daily**~maraviroc 150 mg once daily ** as the fixed dose combination Kivexa ™"
3176042|NCT01367223|Experimental|solution of amino acids with glutamine|Group 1 as the experimental group who will be administered a solution of amino acids supplemented with glutamine
3176043|NCT01367223|Other|amino acids solution without glutamine|Group 2:control group will be administered a solution of amino acids (Aminoven Infant® or Vamin®) not supplemented with glutamine
3176044|NCT01367210|Experimental|MARAVIROC, DARUNAVIR/r|"Treatment simplification from a standard combined antiretroviral therapy including 3 drugs to Maraviroc plus Darunavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy"
3176045|NCT01367210|Sham Comparator|current ART with 3 drugs|Patients on HAART with three drugs and HIV RNA below 50 copies/mL
3176046|NCT01367197|No Intervention|No intervention|Observation only
3176047|NCT01367197|Experimental|Exercise training group|Group exercise training, three times weekly high-intensity
3176048|NCT01367158|Experimental|3ABCWY|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of the same in current study
3176049|NCT01367158|Experimental|2ABCWY|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of Tdap in current study
3176050|NCT01367158|Experimental|3ABx2CWY|two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of the same in current study
3176051|NCT01367158|Experimental|2ABx2CWY|two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of Tdap in current study
3176052|NCT01367158|Experimental|3ABCWY+OMV|Two doses Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus outer membrane vesicles (OMV) in previous study and one dose of the same in current study
3176053|NCT01367158|Experimental|2ABCWY+OMV|Two doses Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus outer membrane vesicles (OMV) in previous study and one dose of Tdap in current study
3176054|NCT01367158|Experimental|3ABCWYqOMV|Two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of outer membrane vesicles (qOMV) in previous study and one dose of the same in current study
3176055|NCT01367158|Experimental|2ABCWYqOMV|Two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of outer membrane vesicles (qOMV) in previous study and one dose of Tdap in current study
3176056|NCT01367158|Active Comparator|3B|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine in previous study and one dose of the same in current study
3176057|NCT01367158|Active Comparator|2B|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine in previous study and one dose of Tdap in current study
3176058|NCT01367158|Active Comparator|1ACWY|One dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine followed by one dose of placebo and one dose of Tdap in current study
3176059|NCT01367145|Active Comparator|Omacor|
3176060|NCT01367145|Placebo Comparator|Placebo|
3176061|NCT01367119|Active Comparator|Ketamine|Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic prior to electroconvulsive therapy (ECT).
3176062|NCT01367119|Active Comparator|Methohexital|Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic prior to electroconvulsive therapy.
3176063|NCT01367106|Experimental|exposed offspring|
3176064|NCT01367106|Other|controls|
3176065|NCT01367093||ICU patients admitted for severe illness|
3176066|NCT01367080|Experimental|A Group|"1st administration - DWETR10~2nd administration - DWETR25"
3176067|NCT01367080|Experimental|B Group|"1st administration - DWETR25~2nd administration - DWETR10"
3176068|NCT01367067||Psychometric Questionnaire|Adult inpatients and outpatients with a clinical indication of any part of the body who have been referred to Charité for MR imaging and have filled out a psychometric questionnaire
3176069|NCT01367067||No Psychometric Questionnaire|Adult inpatients and outpatients with a clinical indication of any part of the body who have been referred to Charité for MR imaging and did not fill out a psychometric questionnaire
3176070|NCT01367054|Experimental|Metformin|500 mg
3176071|NCT01367041|Experimental|Bone loss|Postmenopausal women with osteoporosis, whole body vibration will be applied at 40 Hz, 2mm amplitude, 30+30s
3176072|NCT01367041|Experimental|Normal|Postmenopausal women without osteoporosis, whole body vibration will be applied at 40 Hz, 2mm amplitude, 30+30s
3176073|NCT01367028|Other|A: Trastuzumab+Docetaxel|
3176074|NCT01367028|Experimental|B: Trastuzumab+Docetaxel+Bevacizumab|
3176075|NCT01367028|Experimental|C: Trastuzumab+Docetaxel+NPLD|
3176076|NCT01367028|Experimental|D: Trastuzumab+Docetaxel+NPLD+Bevacizumab|
3176077|NCT01367015|Experimental|Early Feeding|Early feeding group received minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours after randomization followed by regular feeding with feed increments of 20ml/kg/day to reach 150 ml/kg.
3176078|NCT01367015|Active Comparator|Late feeding|Late feeding group was kept NPO for a period of 48 hours after randomization followed by minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours and thereafter received regular feeding with feed increments of 20ml/kg/day till full enteral feeds of 150 ml/kg/day were achieved
3176079|NCT01367002|Active Comparator|Carboplatin/Paclitaxel|Chemotherapy
3176080|NCT01367002|Experimental|Trastuzumab|Monoclonal antibody
3176081|NCT01366989||Total Ankle Arthroplasty with calcaneal stem|Patients received the TAA with calcaneal stem between 12/6/05 & 11/13/07 at approximately 28 sites.
3176082|NCT01366976|Placebo Comparator|Placebo|
3176083|NCT01366976|Active Comparator|Acetaminophen|Acetaminophen will ge given as 1g every 6 hours for 4 doses over a 24 hours study period
3176084|NCT01366963||Normal Controls / Healthy Volunteers|Age and gender matched individuals without postural orthostatic tachycardia syndrome
3176085|NCT01366963||Patients with Postural Tachycardia Syndrome (POTS)|Individuals with Postural Tachycardia Syndrome
3176086|NCT01366950|Experimental|Excercise group|
3176087|NCT01366950|No Intervention|Reference|
3176088|NCT01366924|No Intervention|Muscle protein turnover and intracellular signaling at rest|Muscle protein turnover and intracellular signaling are measured at rest for comparison to post-exercise muscle metabolism.
3176089|NCT01366924|Active Comparator|Muscle metabolism after endurance exercise|Post-exercise muscle protein metabolism was measured to determine if endurance exercise affects muscle metabolism compared to rest.
3176090|NCT01366924|Experimental|Muscle Metabolism after endurance exercise|Muscle metabolism response to endurance exercise with essential amino acid supplementation
3176091|NCT01366924|Experimental|Muscle anabolism after endurance exercise|Muscle anabolism after endurance exercise with essential amino acid supplementation.
3176092|NCT01366911||stem cell QCT testing|
3176093|NCT01366898|Experimental|Chemotherapy|
3176094|NCT01366885|Experimental|Intervention during pregnancy|5000 IU Vitamin D3 to be given to the mother during pregnancy. 7000 IU Vitamin D3 to be given during breast feeding if breast feeding. If not breastfeeding, infant to be given 400 IU Vitamin D3 during first year of age, then increased to 1000 IU D3 until completion of research trial.
3176095|NCT01366859|Experimental|Whey Protein (Immunocal®)|The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
3176096|NCT01366859|Placebo Comparator|Placebo: Rice Protein|The control or placebo study arm will consist of thirty children who will receive a dose of 0.5 g/kg of weight a day up to 18 kg of weight a day or a dose of 10 g/day for those over 18 kg for three months.
3176097|NCT01366846|Experimental|Peanut avoidance after continuous peanut consumption|These participants were the peanut consumption group of the ITN032AD (LEAP) study
3176098|NCT01366846|Experimental|Continued peanut avoidance|These participants were the peanut avoidance group of the ITN032AD (LEAP) study
3176099|NCT01366833|Active Comparator|Self-expanding stent alone|All patients in Arm A will receive self-expanding stent alone
3176100|NCT01366833|Experimental|Brachytherapy and Stent therapy|
3176101|NCT01366820|Experimental|NNZ-2566|20 mg/kg intravenous bolus infusion of NNZ-2566 over 10 minutes followed by a continuous intravenous infusion of 6 mg/kg/h (n=133) intravenous infusion of NNZ-2566 for a total of 72 consecutive hours.
3176102|NCT01366820|Placebo Comparator|Sodium Chloride (0.9%) for Injection|Intravenous bolus infusion of Sodium Chloride (0.9%) for Injection over 10 minutes followed by a continuous intravenous infusion of Sodium Chloride (0.9%) for Injection for a total of 72 consecutive hours.
3176103|NCT01366794|Experimental|Type 2 diabetes|Administration of macronutrients in type 2 diabetes
3176104|NCT01366794|Experimental|Healthy volunteers|Administration of macronutrients in healthy volunteers
3176105|NCT01366781|Experimental|Healthy males|Meal ingestion in healthy males
3176106|NCT01366781|Experimental|Healthy females|Meal ingestion in healthy females
3176107|NCT01366768|Experimental|Oral amino acid mixture|Oral administration of amino acid mixture in healthy volunteers
3176108|NCT01366768|Experimental|Intravenous amino acid administration|Intravenous infusion of amino acid mixture in healthy volunteers
3176109|NCT01366742||HPV Cohort|Sexually active young women aged 12 to 22 years of age without a previous history of CIN. Women are not eligible for entry if pregnant or known immunosuppression.
3176110|NCT01366729|Experimental|TheraTogs|
3176111|NCT01366729|Active Comparator|Cane walking|
3176112|NCT01366716|Experimental|Voucher CM|Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
3176113|NCT01366716|Experimental|Cash CM|Participants in the cash CM condition will be assigned to the identical 12-week escalating schedule of reinforcement, except that the contingencies will be provided in cash rather than vouchers, and no negotiation process will be involved (although counselors may recommend how clients might best spend their money).
3176114|NCT01366716|No Intervention|Non-CM Control|Participants in the non-CM control condition will provide urine specimens during the 12-week period as do the two experimental conditions, but will receive no contingent rewards other than praise from the RAs.
3176115|NCT01366703||heart failure patients|stable heart failure patients, NYHA 1-2, EF > 35%, no AF, No OAC, CHADS score >2
3176116|NCT01366690|Experimental|Peer Support|Peer supporter assigned to participant.
3176117|NCT01366690|No Intervention|Standard of Care|No peer assigned. Current standard of care.
3176118|NCT01366677|Experimental|Yoga Therapy|
3176119|NCT01366664|Experimental|001|Treatment sequence 1 Treatment Period 1 (stable dose of terazosin [2 to 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2 to 10 mg] + placebo administered orally once daily for 5 days)
3176120|NCT01366664|Experimental|002|Treatment sequence 2 Treatment Period 1 (stable dose of terazosin [2 to 10 mg] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2 to 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days)
3176154|NCT01366430|Active Comparator|Gefoni manenuver|Gefoni manenuver for Geotropic HC-BPPV
3176121|NCT01366651|Experimental|Doripenem|Doripenem Type=exact number unit=mg/kg number=10 form=solution for injection route=intravenous use every 8 hours for 2 days (total of 5 doses) for patients <12 weeks of age.Doripenem 500-mg sterile powder will be supplied for the study in single use glass vials.,Doripenem Type=exact number unit=mg/kg number=30 form=solution for injection route=intravenous use every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to <1 year of age. Doripenem 500-mg sterile powder will be supplied for the study in single use glass vials.
3176122|NCT01366638|Experimental|Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks), followed by PR until Week 24 or Week 48. Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
3176123|NCT01366638|Experimental|Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
3176124|NCT01366638|Experimental|Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.
3176125|NCT01366625|Experimental|Renal Denervation|Renal Denervation and maintenance of anti-hypertensive medications and continuous positive airway pressure therapy
3176126|NCT01366625|No Intervention|Maintenance of Medications|Maintenance of anti-hypertensive medications and continuous positive airway pressure therapy
3176127|NCT01366612|Active Comparator|Group 1|FLUDARABINE AND BUSULFAN
3176128|NCT01366612|Experimental|Group 2|FLUDARABINE, BUSULFAN AND LOW DOSE TOTAL BODY IRRADIATION
3176129|NCT01366599||Patients enrolled in IHCIS in 2006|Patients enrolled in IHCIS in 2006
3176130|NCT01366573|Experimental|GSK1521498 &amp; alcohol|GSK1521498 20 mg and alcohol (0.5g/kg ethanol mixed with orange juice)
3176131|NCT01366573|Experimental|GSK1521498 & orange juice|GSK1521498 20 mg and orange juice approximately matching alcoholic beverage for volume and colour
3176132|NCT01366573|Experimental|Placebo &amp; alcohol|Placebo and alcohol (0.5g/kg ethanol mixed with orange juice)
3176133|NCT01366573|Placebo Comparator|Placebo &amp; orange juice|Placebo and orange juice approximately matching alcoholic beverage for volume and colour
3176134|NCT01366560|Experimental|GSK962040|The subjects will be administered GSK962040 125 mg tablet as a single dose on Day 1 of study treatment visit. After 2 hours, the subjects will be administered wireless motility capsule. The subjects will be observed for expulsion of WMC in stool. Each subject will attend the clinical unit for two study treatment visits which will be separated by at least one week.
3176135|NCT01366560|Placebo Comparator|Placebo|The subjects will be administered placebo tablet as a single dose on Day 1 of study treatment visit. After 2 hours, the subjects will be administered wireless motility capsule. The subjects will be observed for expulsion of WMC in stool. Each subject will attend the clinical unit for two study treatment visits which will be separated by at least one week.
3176136|NCT01366547|Experimental|Single Arm|Subjects will be randomized in a three-way crossover design to receive a single dose of each of two different tablet formulations of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg or dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg). There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
3176137|NCT01366534|Experimental|Ad35.CS.01 Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered one dose of Ad35.CS.01 vaccine at Month 0, and 2 doses of GSK257049 at Months 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
3176138|NCT01366534|Experimental|GSK257049 Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered 3 doses of GSK257049 vaccine at Months 0, 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
3176139|NCT01366534|Experimental|Control Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were volunteers who did not receive any immunization but were subjected to the sporozoite challenge. The duration of the study was approximately 8 months for infectivity control subjects.
3176140|NCT01366521|Experimental|Mepolizumab 250 mg subcutaneous (SC)|250 mg subcutaneous (SC)
3176141|NCT01366521|Experimental|Mepolizumab 125 mg subcutaneous (SC)|125 mg subcutaneous (SC)
3176142|NCT01366521|Experimental|Mepolizumab 12.5 mg subcutaneous (SC)|12.5 mg subcutaneous (SC)
3176143|NCT01366521|Experimental|Mepolizimab 75 mg intravenously (I.V.)|75 mg intravenously (I.V.)
3176144|NCT01366508|Other|Visit B|At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at ~11:00 and at ~13:00. During this period the subject will be required to remain in the unit.
3176145|NCT01366508|Other|Visit A|At approximately 13:00 the subject will be given a standard high calorie lunch that the subject is required to finish
3176146|NCT01366495|Experimental|Project Bridge|Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
3176147|NCT01366495|No Intervention|Treatment As Usual|Passive referral to HIV community treatment provider.
3176148|NCT01366482|Experimental|Drug-eluting balloon|
3176149|NCT01366482|Experimental|Plaque excision followed by a drug-eluting balloon|
3176150|NCT01366482|Experimental|Non-Randomized Arm (severely calcified lesions)|Subjects with severe calcification will be assigned to a non-randomized arm and treated with plaque excision followed by a drug-eluting balloon
3176151|NCT01366456|Active Comparator|Shingigu|Treat with Shingigu
3176152|NCT01366456|Active Comparator|Charcoal|Treat with Charcoal
3176153|NCT01366443||women pregnant|Healthy pregnant women between 15 or greater weeks gestation reporting with signs or symptoms of rupture of membranes.
3176155|NCT01366430|Active Comparator|sham maneuver|sham maneuver for geotropic HC-BPPV
3176156|NCT01366430|Active Comparator|barbecue maneuver|barbecue maneuver for geotropic HC-BPPV
3176157|NCT01366404||FFR|Patients who had FFR measurement
3176158|NCT01366391|Other|Metformin|study parallel with one arm only.
3176159|NCT01366378|Experimental|Arm 1|methylnaltrexone (MNTX)
3176160|NCT01366365|Experimental|Arm 1|IV methylnaltrexone (MNTX)
3176161|NCT01366365|Placebo Comparator|Arm 2|placebo
3176162|NCT01366352|Experimental|Arm 1|MNTX tablet
3176163|NCT01366352|Experimental|Arm 2|MNTX tablet
3176164|NCT01366339|Experimental|Arm 1|Oral methylnaltrexone
3176165|NCT01366339|Experimental|Arm 2|Oral methylnaltrexone
3176166|NCT01366339|Experimental|Arm 3|Oral methylnaltrexone
3176167|NCT01366339|Placebo Comparator|Arm 4|Oral placebo
3176168|NCT01366326|Experimental|Arm 1|Methylnaltrexone bromide
3176169|NCT01366313|Experimental|Paracetamol|initial doses was 1.5g g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
3176170|NCT01366313|Experimental|Morphine|Initial doses of morphine was 5mg, with dose adjustment intervals of 1 mg .
3176171|NCT01366313|Experimental|Paracetamol-morphine|The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
3176172|NCT01366300|Active Comparator|Intravenous lidocaine infusion|Intravenous lidocaine infusion during total intravenous anesthesia with propofol administered by target controlled infusion
3176173|NCT01366300|Placebo Comparator|Intravenous 0.9% saline infusion|Intravenous 0.9% saline infusion during total intravenous anesthesia with propofol administered by target controlled infusion
3176174|NCT01366287|Experimental|Suspension/fasted|
3176175|NCT01366287|Experimental|Tablet/fasted|
3176176|NCT01366287|Experimental|Tablet/fed|
3176177|NCT01366274|Active Comparator|Usual method of MHI|
3176178|NCT01366274|Experimental|Protective MHI|
3176179|NCT01366261|Experimental|semirigid thoracoscopy|Semirigid instrument which we compare was autoclavable Olympus LTF-160 (Olympus Tokyo, Japan). Handle and its controls were similar to flexible fiberoptic bronchoscope, with the insertion portion composed of 22 cm long rigid part and distal 5 cm flexible tip with angulation range 1600 up / 1300 down. The external diameter of insertion portion was 7 mm with 2,8 mm inner channel diameter. The instrument was compatible with Olympus EVIS Exera 160 and 145 and EVIS 100 and 140 video processors and light sources, otherwise employed in video-bronchoscopy. Forceps, which we used was flexible FB-55CD-1 Olympus forceps with 5 mm long cusps and diameter, which fitted the diameter of inner channel of semirigid thoracoscope.
3176180|NCT01366261|Active Comparator|rigid thoracoscopy|The rigid instrument was autoclavable OP EndoEYE WA50120A (Olympus Tokyo, Japan) video thoracoscope. The length of the instrument was 29 cm with 00 direction of view and 700 field of view. The external diameter of the instrument was 10 mm with 5,2 mm inner channel diameter. The instrument was compatible with Olympus Visera OTV-S7V and EVIS Exera II CV-180 video processors. Cusps of rigid forceps had outer diameter 5 mm and length 10 mm.
3176181|NCT01366248||IO Clinic Breast Cancer Patients|Includes patients who are receiving care for their breast cancer at participating Seattle area IO clinics.
3176182|NCT01366248||CSS Match-Control Patients|For each IO clinic patient, an average of two (up to four) matched comparison cases will be recruited from the Washington State Cancer Surveillance System (CSS). Matched comparison cases from CSS will be identified by CSS and confirmed by the FHCRC investigator.
3176183|NCT01366235|Experimental|Southeast Asians|
3176184|NCT01366235|Experimental|Korean|
3176185|NCT01366235|Experimental|Caucasians|
3176186|NCT01366235|Experimental|Africans|
3176187|NCT01366222|Placebo Comparator|Placebo|
3176188|NCT01366222|Active Comparator|Food concentrates (FC)|Food concentrates (FC) was including fruit and vegetable, fish and probiotics.
3176189|NCT01366209|Active Comparator|Active Arm|
3176190|NCT01366209|Placebo Comparator|Placebo Arm|
3176191|NCT01366196|Placebo Comparator|Control Group (C)|Patients in the control group will receive a placebo tablet with a sip of water one hour prior to surgery and a placebo tablet twice a day for a total of two weeks.
3176192|NCT01366196|Experimental|Pregabalin Group (P)|Patients in the treatment group will receive 150 mg of pregabalin with a sip of water one hour prior to surgery, and then 150 mg daily (75 mg BID) for a total of two weeks.
3176193|NCT01366183||Observational (quality of life questionnaire)|"Patients receive chemotherapy comprising carboplatin, paclitaxel, and filgrastim (regimen 1) or carboplatin alone (regimen 2) every 21 days for 4 courses according to their physicians and/or patients' choice. Patients may undergo surgery and/or further chemotherapy at the discretion of treating physician. Patients undergo blood sample collection at baseline and periodically during course 1 for pharmacokinetic studies.~Patients' quality of life is assessed by the FACT-O, the FACT-Ntx subscale, the IADL, and the Ability to Complete Social Activity questionnaires at baseline, prior to courses 1 and 3, and then 3-6 weeks after completion of course 4. Nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment are also assessed."
3176194|NCT01366144|Experimental|Treatment (veliparib, paclitaxel, carboplatin)|"Patients receive veliparib* PO BID on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~NOTE: * All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day)."
3176195|NCT01366131|Experimental|A|
3176196|NCT01366131|Experimental|B|
3176197|NCT01366118|Experimental|TT tailored Ch plus IMRT|
3176198|NCT01366105|No Intervention|Dry Dressing|Incisions that were dressed with a sterile dry dressing at end of operation.
3176199|NCT01366105|Experimental|Negative Pressure Wound Therapy|Incisions dressed with a V.A.C. (NPWT) postoperatively.
3176247|NCT01365676|Active Comparator|GAMALINE® 45-55 years old|Climacteric women with PMS symptoms
3176248|NCT01365663|Experimental|Cohort 1|0.25 mg/kg in Healthy Subjects
3176249|NCT01365663|Experimental|Cohort 2|0.5 mg/kg in Healthy Subjects
3176200|NCT01366092|Experimental|Interleukin-2|Each study participant will receive daily subcutaneous IL-2 (1 x 106 IU/m2/day) for self-administration for 12 weeks, followed by a 4-week hiatus. IL-2 will be typically administered on an outpatient basis. After completing the 16 week study (12 weeks of IL-2 study treatment and a mandatory 4 weeks off-IL-2), patients experiencing clinical benefit (complete or partial response; as well as minor response not meeting NIH criteria for partial response) with an acceptable toxicity profile will be permitted to continue extended-duration treatment indefinitely at the discretion of the treating physician.
3176201|NCT01366079|Experimental|Position change|Position change group
3176202|NCT01366079|Active Comparator|Left lateral|Left lateral position
3176203|NCT01366066|Active Comparator|TMNS treatment - Stress incontinence|Women with stress incontinence treated with active TMNS (vibration)
3176204|NCT01366066|No Intervention|No treatment - stress incontinence|Women with stress incontinence NOT treated with TMNS (vibration)
3176205|NCT01366066|Active Comparator|TMNS treatment - Urge incontinence|Women with stress incontinence treated with TMNS (vibration)
3176206|NCT01366066|No Intervention|No treatment - urge incontinence|Women with urge incontinence NOT treated with TMNS (vibration)
3176207|NCT01366053||Prostate Cancer|Males who have been diagnosed with Prostate Cancer and are experiencing PSA rise, while taking androgen agonist therapy.
3176208|NCT01366014|Experimental|ARRY-371797|
3176209|NCT01366014|Active Comparator|Oxycodone HCl ER|
3176210|NCT01366014|Placebo Comparator|Placebo|
3176211|NCT01366001|Experimental|ALKS 33-BUP|
3176212|NCT01366001|Experimental|ALKS 33|
3176213|NCT01366001|Placebo Comparator|Placebo|
3176214|NCT01365936|Active Comparator|menotrophin|In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
3176215|NCT01365936|Active Comparator|recombinant FSH|Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
3176216|NCT01365923|Active Comparator|Remifentanil group|Remifentanil group : remifentanil effect site-TCI 2-4ng/ml
3176217|NCT01365923|Active Comparator|Dexmedetimidine group|Dexmedetomidine group: remifentanil effect site-TCI 2-4ng/ml + dexmedetomidine 0.5mcg/kg
3176218|NCT01365910|Experimental|Treatment (enzyme inhibitor)|Patients receive linifanib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3176219|NCT01365897|Placebo Comparator|Placebo|Control Group
3176220|NCT01365897|Experimental|Modafinil 200mg|Modafinil 200mg taken orally.
3176221|NCT01365871|Active Comparator|basal injection|basal injection of anesthetics
3176222|NCT01365871|Active Comparator|basal + apical injection|basal + apical injection of anesthetics
3176223|NCT01365858|Experimental|Virtual reality-based cognitive training|
3176224|NCT01365858|Active Comparator|Cognitive rehabilitation (without extra computer training)|
3176225|NCT01365845|Active Comparator|1|Conventional photon plan
3176226|NCT01365845|Experimental|2|3D-Proton/Conventional plan or 3D-proton only
3176227|NCT01365832|Experimental|Sleep apnea|"Participants with Obstructive Sleep Apnea (OSA).This arm will undergo a pre-treatment blood draw, six months of Continuous Positive Airway Pressure (CPAP) to treat OSA, and a post-treatment blood draw 3 and 6 months later.~Intervention: Procedure: Continuous Positive Airway Pressure (CPAP)"
3176228|NCT01365819|Placebo Comparator|Sugar pill|Placebo
3176229|NCT01365819|Experimental|Varenicline|Varenicline (Chantix (R))
3176230|NCT01365793|Experimental|Rapid rehydration using 0.45% saline replacement fluid|This arm will involve more rapid intravenous fluid treatment which will include a second 10cc/Kg bolus of 0.9% saline and assume a 10% fluid deficit. 0.45% saline will be used as the replacement fluid for this arm.
3176231|NCT01365793|Experimental|Rapid rehydration using 0.9% saline replacement fluid|This arm will involve more rapid intravenous fluid treatment which will include a second 10cc/Kg bolus of 0.9% saline and assume a 10% fluid deficit. 0.9% saline will be used as the replacement fluid.
3176232|NCT01365793|Experimental|Slower rehydration using 0.45% saline intravenous fluid|This arm will involve slower rehydration (assumed 5% fluid deficit and no additional fluid bolus) with 0.45% saline used as the replacement fluid.
3176233|NCT01365793|Experimental|Slower rehydration using 0.9% saline intravenous fluid|This arm will involve slower rehydration (assumed 5% fluid deficit and no additional fuid bolus) with 0.9% saline used as the replacement fluid.
3176234|NCT01365780|Active Comparator|With HBOT|Patients, who receive hyperbaric Oxygen Therapy after their surgical treatment
3176235|NCT01365780|No Intervention|Without HBOT|"Patients who receive the same surgical treatment of their radius fracture than the patients of the group with HBOT, but no hyperbaric oxygen therapy (comparison group)"
3176236|NCT01365767||Crohn Disease|Patients with Crohns Disease referred to referred to a Magnetic Resonance Imaging Scan.
3176237|NCT01365754|Active Comparator|A|A - Fusion
3176238|NCT01365754|Active Comparator|B|B - Dynamic (new)
3176239|NCT01365741|No Intervention|Standard administration of Efient|The test person will ingest Efient in supine position, and remain supine during 2 hours, mimicing the way Efient is used for pre-PCI treatment today
3176240|NCT01365741|Active Comparator|Upright administration of Efient|The test person will ingest Efient in an upright position, and remain supine during 2 hours.
3176241|NCT01365715|Experimental|Preoperative embolization|32 patients with spinal metastasis/metastases will undergo arteriography and receive transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
3176242|NCT01365715|Active Comparator|Control group|32 patients with spinal metastasis/metastases will undergo arteriography of spinal metastasis/metastases without receiving transcatheter arterial embolization prior to surgery.
3176243|NCT01365702||Tiotropium in TB destroyed lung|
3176244|NCT01365676|Experimental|GAMALINE® + HIPERICIN® 25-44 years old|Fertile women 24-44 years old with PMS symptoms
3176245|NCT01365676|Active Comparator|GAMALINE® 25-44 years old|Fertile women 24-44 years old with PMS symptoms
3176246|NCT01365676|Experimental|GAMALINE® + HIPERICIN® 45-55 years old|Climacteric women with PMS symptoms
3176256|NCT01365650|Experimental|Fluticasone Propionate|
3176257|NCT01365637|Experimental|Cohort 1 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
3176258|NCT01365637|Experimental|Cohort 2 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
3176259|NCT01365637|Experimental|Cohort 3 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo either twice or thrice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
3176260|NCT01365637|Experimental|Cohort 4 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo either twice or thrice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
3176261|NCT01365624|Experimental|Ketorolac tromethamine|
3176262|NCT01365611|Experimental|Ketorolac tromethamine|
3176263|NCT01365598|Placebo Comparator|Placebo|Non-active drug
3176264|NCT01365598|Experimental|Low dose primaquine (PQ1)|Lowest experimental dose of primaquine base: 0.1mg/kg
3176265|NCT01365598|Experimental|Intermediate dose primaquine (PQ2)|Intermediate experimental dose of primaquine base: 0.4mg/kg
3176266|NCT01365598|Active Comparator|Reference dose primaquine (PQ-R)|WHO-recommended dose of primaquine base: 0.75mg/kg
3176267|NCT01365585||Sildenafil ≥20mg three times daily|Subjects receiving sildenafil ≥20mg three times daily for the treatment of PAH
3176268|NCT01365572|Active Comparator|Xience V, drug-eluting stent|randomized implantation for DES restenotic lesion
3176269|NCT01365572|Active Comparator|Endeavor Resolute, drug-eluting stent|randomized implantation for DES restenotic lesion
3176270|NCT01365559|Experimental|Group A: Carfilzomib & Non-IMiD containing regimen|Bortezomib is replaced with carfilzomib in a combined regimen identical to the patient's previous regimen. Regimen cannot include thalidomide or lenalidomide.
3176271|NCT01365559|Experimental|Group B: Carfilzomib & IMiD containing regimen.|Bortezomib is replaced with carfilzomib in a regimen that includes IMiDs (lenalidomide or thalidomide). Thus, the regimen is carfilzomib in an IMiD-containing regimen.
3176272|NCT01365546|Experimental|human VWF/FVIII concentrate|
3176273|NCT01365533|Active Comparator|Roflumilast|
3176274|NCT01365533|Placebo Comparator|Placebo|
3176275|NCT01365520|Experimental|N8|
3176276|NCT01365507|Experimental|IDegAsp Simple|
3176277|NCT01365507|Experimental|IDegAsp Step wise|
3176278|NCT01365494|Active Comparator|Group A-Zagreb|Purified Chick Embryo Cell Inactivated Rabies Vaccine, administered intramuscularly (IM) according to the 2-1-1 (Zagreb) schedule (i.e., 2 doses of vaccine administered on day 0 and 1 dose of vaccine each administered on day 7 and day 21)
3176279|NCT01365494|Active Comparator|Group B-Essen|Purified Chick Embryo Cell Inactivated Rabies Vaccine, administered IM according to the 1-1-1-1-1 (Essen) schedule (i.e., 1 dose of vaccine administered on day 0, 3, 7, 14, and 28)
3176280|NCT01365481|Experimental|valsartan|Valsartan starting dose: ≥18 kg to <35 kg is 40 mg, ≥35 kg to <80 kg is 80 mg, ≥80 kg to ≤160 kg is 160 mg for 1 week then Valsartan maintenance dose: ≥18 kg to <35 kg is 80 mg, ≥35 kg to <80 kg is 160 mg, ≥80 kg to ≤160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study.
3176281|NCT01365468|Experimental|Everolimus (RAD001)|enrolled patients received everolimus (RAD001) in an open label manner. Recommended starting dose of everolimus depend on body surface area, starting from 2.5 mg once daily to 7.5 mg once daily.
3176282|NCT01365455|Experimental|AIN457 150 mg|AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week
3176283|NCT01365455|Experimental|AIN457 300 mg|AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week
3176284|NCT01365455|Placebo Comparator|placebo|placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
3176285|NCT01365455|Experimental|AIN457 150mg from Placebo|Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase because they were PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
3176286|NCT01365455|Experimental|AIN457 300mg from Placebo|Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase. PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
3176287|NCT01365442||Consenting, eligible participants|All consenting eligible participants in the study area will receive the oral cholera vaccine
3176288|NCT01365429|Experimental|EVLP Group|EVLP Group are those recipient lung transplant patients that received donor lungs that had been placed on the XPS™ with Steen Solution™ and undergone ex-vivo lung perfusion before being transplanted.
3176289|NCT01365429|No Intervention|Control Group|Control Group are those recipient lung transplant patients that receive donor lungs via conventional transplant.
3176290|NCT01365403|Experimental|Single Arm|
3176435|NCT01364467|Active Comparator|Guaifenesin|
3176291|NCT01365390||Cohort A|Subjects aged < 6 years who are registered in primary care clinics of any of the participating countries (Estonia, Lithuania, Poland, Romania and Slovenia).
3176292|NCT01365377|Experimental|Booklet|Referent member of the family is designated to receive a written detailed information on Critical care.
3176293|NCT01365377|No Intervention|No booklet|daily information to the family is given as usual.
3176294|NCT01365364|Active Comparator|PLM group|Individuals with increased periodic leg movement index (>5)
3176295|NCT01365364|Active Comparator|Non-PLM group|Individuals with PLM index <5
3176296|NCT01365351||Growth hormone|Children with growth hormone deficiency
3176297|NCT01365338|Placebo Comparator|Placebo|
3176298|NCT01365338|Experimental|PF-04958242 - 0.075mg|
3176299|NCT01365338|Experimental|PF-04958242 - 0.15mg|
3176300|NCT01365325|Experimental|handled echocardiography|home monitoring care program based on clinical and electrocardiographic evaluations and periodical handled echocardiographic examinations
3176301|NCT01365325|Active Comparator|home monitoring program|home monitoring care program based on clinical and electrocardiographic evaluations
3176302|NCT01365312|Experimental|Ethanol|Assigned intervention is a 70% ethanol lock, placed every 72 hours for 15 minutes, for the duration of the PICC line.
3176303|NCT01365312|Placebo Comparator|Heparinized saline|Intervention is to place a heparinized saline lock every 72 hours for 15 minutes, for the duration of the line.
3176304|NCT01365286|Active Comparator|Ivabradine-Placebo|
3176305|NCT01365286|Active Comparator|Placebo-Ivabradine|
3176306|NCT01365273|No Intervention|Bridal Veil together with staples|Standard of care. Bridal Veil is fixed over the graft with staples.
3176307|NCT01365273|Active Comparator|Mepitel One|Device, dressing
3176308|NCT01365260|Experimental|MM-II|
3176309|NCT01365260|Active Comparator|DurolaneTM|hyaluronic acid
3176310|NCT01365247|Experimental|COPE|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure
3176311|NCT01365247|Active Comparator|RPT|Relapse Prevention Therapy
3176312|NCT01365247|Active Comparator|Active Monitoring Control Group|
3176313|NCT01365234|Experimental|20066 Lead|Non-randomized study. Intervention: Device: Pacing Lead
3176314|NCT01365221|Experimental|Patients who have received loading dose of clopidogrel|
3176315|NCT01365221|Active Comparator|Patients who have not received loading dose of clopidogrel|
3176316|NCT01365208||advanced nasopharyngeal carcinoma|
3176317|NCT01365195|Placebo Comparator|Control|"Loading and Infusion:~Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate"
3176318|NCT01365195|Active Comparator|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
3176319|NCT01365195|Active Comparator|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
3176320|NCT01365182|Other|BF+SUPPORT|
3176321|NCT01365182|Other|BF+PHONE|
3176322|NCT01365182|No Intervention|Usual Care|
3176323|NCT01365169||Exercise Adherence Arm (Arm 1)|
3176324|NCT01365169||Dehydration Risk Arm (Arm 2)|
3176325|NCT01365169||Swallowing Exercise Adherence Arm (Arm 3)|
3176326|NCT01365169||Smoking Cessation Adherence Arm (Arm 4)|
3176327|NCT01365169||Pre-Pilot|
3176328|NCT01365169||Pancreas Cancer Group|
3176329|NCT01365156|Experimental|EPLND + Chemoradiation|Group 1: Extraperitoneal laparoscopic lymphadenectomy followed by chemoradiation therapy
3176330|NCT01365156|Active Comparator|Chemoradiation|Group 2: standard-of-care chemoradiation therapy only
3176331|NCT01365143|Active Comparator|Open Radical Prostatectomy|
3176332|NCT01365143|Active Comparator|Robotic radical prostatectomy|
3176333|NCT01365130|Experimental|real drug|patients will receive Jevtana 25mg/m2, IV every 21 days until disease progression or unacceptable toxicity
3176334|NCT01365117|Experimental|Cohort 1|
3176335|NCT01365117|Experimental|Cohort 2|
3176336|NCT01365104|Experimental|Healthy young|Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.
3176337|NCT01365104|Experimental|healthy old|Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.
3176338|NCT01365091|Experimental|Arm 1: Treatments A,B/B,A|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.~Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A)."
3176339|NCT01365091|Experimental|Arm 2: Treatments C,D/D,C|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.~Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C)."
3176340|NCT01365091|Experimental|Arm 3: Treatments E, F/F,E|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.~Period 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E)."
3176341|NCT01365091|Experimental|Arm 4: Treatments G,H/H,G|"Period 1: Participants received a single oral dose of saxagliptin , 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.~Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G)."
3176342|NCT01365078|Experimental|Echium oil (SDA-rich oil)|
3176343|NCT01365078|Placebo Comparator|High-oleic acid sunflower oil (HOSO)|low in SDA
3176344|NCT01365065|Experimental|Vorinostat|Vorinostat 400mg ( 4 X 100mg ) orally daily for 14 days
3176345|NCT01365052|Experimental|Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|
3176346|NCT01365052|Placebo Comparator|Placebo|
3176347|NCT01365039|Experimental|Test lens|Test contact lens will be worn on a daily disposable wear basis.
3176348|NCT01365039|Active Comparator|SofLens lens|The currently marketed Bausch + Lomb SofLens daily disposable contact lens. Worn on a daily disposable wear basis.
3176349|NCT01365026|Experimental|PVS intervention|
3176350|NCT01365026|No Intervention|Control group|
3176351|NCT01365013|Experimental|Lifestyle counseling|
3176352|NCT01365013|Active Comparator|control group|
3176353|NCT01365000|Experimental|NKTR118 Formulation 1|Fasted
3176354|NCT01365000|Experimental|NKTR118 Formulation 2|Fasted
3176355|NCT01365000|Experimental|NKTR118 Formulation 3|Fasted
3176356|NCT01365000|Experimental|NKTR118 Formulation 1a|Fed
3176357|NCT01365000|Experimental|NKTR118 Formulation 3a|FED
3176358|NCT01364987|Experimental|ASP015K and Mycophenolate Mofetil|
3176359|NCT01364974|Experimental|Group A|low dose, all male
3176360|NCT01364974|Experimental|Group B|medium dose, all male
3176361|NCT01364974|Experimental|Group C|high dose, all male
3176362|NCT01364974|Experimental|Group D|medium dose, all female
3176363|NCT01364974|Placebo Comparator|Placebo|
3176364|NCT01364961|Placebo Comparator|Cellulose capsules|
3176365|NCT01364961|Experimental|Resveratrol capsules|
3176366|NCT01364948|Experimental|Coconut oil application|The oil (coconut oil) was applied by the trained nurse to the entire body surface of infant except the face two times a day starting at 12 hrs of life. Four ml of coconut oil was applied using both hands of the caregiver in four strokes. First stroke was from the clavicles over the chest and abdomen till the groin, second from the front of thighs over the knee and leg upto the sole, the third one from the shoulders over the arm and forearm till the palm continuing medially over the forearm and arm till the axilla and the final stroke was used for the back, starting from the upper back, continuing over the back of the thighs till the heel. Just prior to the first application, and thereafter prior to the subsequent applications the TEWL was recorded using the portable closed chamber evaporimeter. The oil application was continued twice daily (every 12 hrs at the same time as the hour of birth e.g. 11 am and 11pm) till the completion of the seventh day (168 hrs of life).
3176367|NCT01364948|No Intervention|No Oil Application|Babies in this group were not subjected to oil application. TEWL measurement was recorded every 12 hrs for the first week of life, at the same time as the hour of birth.
3176368|NCT01364922|Experimental|Open-label Hydrocodone/Acetaminophen Extended Release|Hydrocodone/acetaminophen extended release, 2 tablets twice daily
3176369|NCT01364922|Experimental|Double-blind Hydrocodone/Acetaminophen Extended Release|Hydrocodone/acetaminophen extended release, 1 tablet twice daily
3176370|NCT01364922|Placebo Comparator|Double-blind Placebo|Placebo, 1 tablet twice daily
3176371|NCT01364909|Placebo Comparator|Control (usual practice)|
3176372|NCT01364909|Experimental|Exercise|
3176373|NCT01364896||Inflammatory bowel disease, Immunosuppressive agent|Men and women 18 years + with a histological diagnosis of IBD (ulcerative colitis or Crohn's disease) who are undergoing a colonoscopy prior to starting a non-corticosteroid immunosuppressive agent
3176374|NCT01364883|Experimental|Group 1|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16
3176375|NCT01364883|Experimental|Group 2|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24
3176376|NCT01364883|Experimental|Group 3|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, MVA ME-TRAP boost W8, MVA ME-TRAP boost W12
3176377|NCT01364883|Experimental|Group 4|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24
3176378|NCT01364883|Experimental|Group 5|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16
3176379|NCT01364883|Experimental|Group 6|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W12
3176380|NCT01364883|Experimental|Group 7|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
3176381|NCT01364870|Active Comparator|Active TENS|High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
3176382|NCT01364870|Placebo Comparator|Placebo TENS|"Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working."
3176383|NCT01364870|No Intervention|Standard Care|"Subjects randomized to Standard Care will be given no TENS unit."
3176384|NCT01364857|Other|PWS cohort|search for polymorphisms of RASA1 gene
3176385|NCT01364844|Experimental|DS7423|
3176436|NCT01364454|Experimental|Eligible patients' paper-based reminder|
3176437|NCT01364454|No Intervention|Control group|
3176438|NCT01364441|Placebo Comparator|P|
3176386|NCT01364818||Placebo Comparator: Placebo|No treatment/ performance of somatosensory task (cortical metrics) without any intervention. The somatosory task will be performed before any intervention/at the midpoint/ and finally at the end.
3176387|NCT01364818||Active Comparator: Active Medication|Treatment (memantine, lurasidone)/ performance of somatosensory task (cortical metrics) with intervention. The somatosory task will be performed before any intervention has started/at the midpoint/ and finally at the end.
3176388|NCT01364805|Experimental|PK Intravenous Vitamin C and Gemcitabine|Week 1: 2 visits for escalating doses of intravenous ascorbic acid (IV C). First dose 25 gm followed by 50 gm 2nd visit. Week 2: 3 visits escalating doses of IV C, 75 grams, 100 grams, and 125 grams. Week 3: 2 visits pharmacokinetic evaluation of intravenous ascorbic acid alone at 125 grams; return to the infusion clinic the following morning for a 24 hour blood draw; 2nd visit receive the first infusion of gemcitabine chemotherapy for PK evaluation of gemcitabine alone. Week-4: gemcitabine and IV C co-administered for pharmacokinetics of both drugs to assess for PK variability related to drug-drug interactions. Subjects will return to the infusion clinic the following morning for 24 hour blood draw.
3176389|NCT01364792|Experimental|Valaciclovir|The patients in the experimental group will be treated with 4 times 2 grams valaciclovir per day for seven days.
3176390|NCT01364792|Placebo Comparator|Placebo|Patient receives placebo four times a day for seven days.
3176391|NCT01364753||Pilots|No intervention; observational study
3176392|NCT01364740|Experimental|PMP-300E, In-Lab PSG|PMP-300E, A 7-channel (nasal pressure, effort, snoring, SpO2, pulse rate, body position and movement) Level 3 portable monitor (11.2 x 3.3 x 5.5cm, 80g, Pacific Medico Co., LTD) to measure sleep-related breathing will be tested against conventional gold-standard In-Lab Polysomnography (sleep study)
3176393|NCT01364727|Experimental|Amrubicin|Amrubicin 35mg/m2 IV days 1-3 every 3 weeks
3176394|NCT01364714||ICU survivors|Male ICU survivors 12 month after discharge
3176395|NCT01364714||Controls|Age and gender matched controls
3176396|NCT01364701|Active Comparator|Maximal dose sildenafil|4 tablets of sildenafil 100mg are given for on demand use
3176397|NCT01364701|Active Comparator|Tadalafil 20mg maximal dose|4 tablets of tadalafil 20mg are given for on demand use
3176398|NCT01364701|Active Comparator|Combination half dose|4 tablets of sildenafil 50mg and tadalafil 10mg are given for on demand use
3176399|NCT01364688|Experimental|Treatment|oral alfacalcidol
3176400|NCT01364688|No Intervention|Control|No drug
3176401|NCT01364675|Experimental|Metformin+Enalapril+Simvastatin|
3176402|NCT01364675|Placebo Comparator|Placebo tablet|
3176403|NCT01364662|Experimental|1|
3176404|NCT01364662|Experimental|2|
3176405|NCT01364662|Experimental|3|
3176406|NCT01364662|Experimental|4|
3176407|NCT01364649|Experimental|Vortioxetine|Vortioxetine 10 mg, tablets, orally, once daily for 1 week, then dose adjustment to a maximum 20 mg, tablets, orally, once daily for up to 7 weeks. At week 8, vortioxetine placebo-matching capsules, orally, once daily for 1 week only.
3176408|NCT01364649|Active Comparator|Escitalopram|Escitalopram 10 mg, tablets, orally, once daily for 1 week, then escitalopram dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks. At week 8, escitalopram 10 mg, capsules, capsules, orally, once daily for 1 week only.
3176409|NCT01364636||Acute Heart Failure|Patients admitted to emergency room in Acute Heart Failure at Hospital PróCardíaco and Hospital Universitario Antonio Pedro
3176410|NCT01364623|Experimental|Low dose TBS-2|
3176411|NCT01364623|Experimental|Medium dose TBS-2|
3176412|NCT01364623|Experimental|High dose TBS-2|
3176413|NCT01364610|Active Comparator|Standard Care|Group 1 will have standard catheter based pH-metry. All participants will answer a questionnaire assessing tolerance and satisfaction of both the siting and placement methods and the 24 hour monitoring period.
3176414|NCT01364610|Active Comparator|Bravo pH Monitoring System|Group 2 will undergo unsedated peroral placement of the Bravo capsule. All participants will answer a questionnaire assessing tolerance and satisfaction of both the siting and placement methods and the 24 hour pH monitoring period.
3176415|NCT01364597|Experimental|Brivaracetam|Subjects entering this study from the previous study must be able to tolerate at least 0.4 mg/kg of brivaracetam twice daily (bid) if ≥8 years of age or at least 0.5 mg/kg bid if <8 years of age.
3176416|NCT01364584|Experimental|Exenatide|Pre-dosed inject-able pen (an automatic device which injects under the skin) 10 mcg twice a day of exenatide for 2.5 months
3176417|NCT01364584|Placebo Comparator|Placebo|Pre-dosed inject-able pen (an automatic device which injects under the skin) 10 mcg twice a day of placebo for 2.5 months
3176418|NCT01364571|Experimental|1|SA4Ag vaccine low dose
3176419|NCT01364571|Experimental|2|SA4Ag vaccine mid dose
3176420|NCT01364571|Experimental|3|SA4Ag vaccine high dose
3176421|NCT01364571|Placebo Comparator|4|Placebo
3176422|NCT01364558|Experimental|Diazepam Nasal Spray Suspension|Diazepam Nasal Suspension - 10 mg
3176423|NCT01364558|Experimental|Diazepam Nasal Spray Solution|Diazepam Nasal Spray Solution - 10 mg
3176424|NCT01364558|Active Comparator|Diazepam injection|Diazepam injection IV - 5 mg
3176425|NCT01364545|Other|Ketone ester drink Vs placebo drink|Ketone ester drink Vs placebo drink (cross over study - all patients will recieve both)
3176426|NCT01364532|Experimental|Transulnar arterial access|Transulnar arterial access for coronary angiography, ad-hoc or elective PCI
3176427|NCT01364532|Active Comparator|Transradial arterial access|Transradial arterial access for coronary angiography, ad-hoc or elective PCI
3176428|NCT01364519|Experimental|Arm 1|
3176429|NCT01364519|Placebo Comparator|Arm 2|
3176430|NCT01364506|Experimental|Water exercise|
3176431|NCT01364506|No Intervention|Control|
3176432|NCT01364493|Experimental|Trastuzumab+Capecitabine+Oxaliplatin|"Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Oxaliplatin 130mg/m2 d1; q3w, 6 cycles"
3176433|NCT01364480|Experimental|Brain-Machine Interface Users|All participants enrolled in the study will undergo Implantation of NeuroPort Arrays in the motor cortex. There is no control group.
3176434|NCT01364467|Placebo Comparator|Placebo|Placebo is provided by the sponsor and is identical in composition to the treatment only lacking active drug.
3176440|NCT01364428|Experimental|IDeg 200 U/mL|
3176441|NCT01364428|Experimental|IDeg 100 U/mL|
3176442|NCT01364415|Experimental|Pasireotide LAR|
3176443|NCT01364402|Experimental|Erythropoietin|
3176444|NCT01364402|Placebo Comparator|Placebo|
3176445|NCT01364389|Experimental|ACZ885|On day 1, patients received a single intravenous dose of ACZ885 3mg/kg along with a placebo intravenous infusion in a double dummy manner to maintain the blind. On day 15, partial and complete responders continued in the open label phase of this treatment arm where they were eligible to receive one re-dose of ACZ885 upon confirmed disease flare. Non-responders started a 20 mg dose cycle of prednisone or prednisolone followed by standard steroid tapering.
3176446|NCT01364389|Experimental|AIN457|On day 1, patients received a single intravenous dose of AIN457 3mg/kg along with a placebo intravenous infusion in a double dummy manner to maintain the blind. On day 15, partial and complete responders continued in the open label phase of this treatment arm where they were eligible to receive one re-dose of AIN457 upon confirmed disease flare. Non-responders started a 20 mg dose cycle of prednisone or prednisolone followed by standard steroid tapering.
3176447|NCT01364389|Other|Prednisone|On day 1, patients received daily oral doses of prednisone 20 mg along with daily oral placebo doses to in a double-dummy manner to maintain the blind. On day 15, partial and complete responders continued in the study and tapered their steroid treatment according to standard care. Non-responders were discontinued from the study.
3176448|NCT01364376|Active Comparator|FOLFOX|
3176449|NCT01364376|Experimental|SOX|
3176450|NCT01364363|Other|Total Body Irradiation/VP16|Acute Leukemias, Myelodysplastic syndromes
3176451|NCT01364363|Other|Cytoxan/Total Body Irradiation|Chronic Leukemias, Bone Marrow Failure States, Lymphomas, Hodgkin's Disease
3176452|NCT01364363|Other|Busulfan/Cytoxan|Acute Leukemia, Myelodysplastic syndromes, Chronic Leukemias, Bone Marrow Failure states
3176453|NCT01364363|Other|BEAM (BCNU, etoposide, Ara-C, melphalan)|Lymphomas, Hodgkin's Disease
3176454|NCT01364363|Other|Total Lymphoid Irradiation|For patients with Multiple Myeloma, or prior autologous transplantation, or age in excess of 55
3176455|NCT01364363|Other|Cladribine/Melphalan|For patients with Multiple Myeloma, or prior autologous transplantation, or age in excess of 55
3176456|NCT01364363|Other|FLAG (fludarabine, Ara-C, G-CSF)|For patients undergoing a second allogeneic transplant
3176457|NCT01364350||TODAY cohort|The cohort of participants diagnosed with type 2 diabetes ages 10 to <18 and obese at time of diagnosis who participated in the TODAY clinical trial are recruited, consented and followed.
3176458|NCT01364337|Active Comparator|DASH diet|
3176459|NCT01364337|Active Comparator|lower carbohydrate DASH diet|
3176460|NCT01364324||Gastrectomy|Twenty gastrectomized patients with pulmonary TB, treated with standard first line anti-TB drugs(isoniazid/rifampicin/ethambutol/pyrazinamide), administered daily, orally
3176461|NCT01364324||Non-gastrectomy|Twenty non-gastrectomized patients with pulmonary TB, treated with standard first line anti-TB drugs(isoniazid/rifampicin/ethambutol/pyrazinamide), administered daily, orally
3176462|NCT01364298|Experimental|Gabapentin/B-complex|
3176463|NCT01364298|Active Comparator|Pregabalin|
3176464|NCT01364259|Placebo Comparator|Placebo|Placebo and SRS
3176465|NCT01364259|Experimental|Amifostine|Amifostine and CyberKnife stereotactic radiosurgery
3176466|NCT01364246|Experimental|Human umbilical cord mesenchymal stem cells transplantation|Intervention group
3176467|NCT01364233|Other|MotifMesh|
3176468|NCT01364220|Experimental|Rosuvastatin|Rosuvastatin 20mg tablet, once daily, for 14 days
3176469|NCT01364220|Placebo Comparator|Placebo|Placebo tablet, once daily, for 14 days
3176470|NCT01364207|Experimental|Caffeinated Coffee 1st Visit, Decaffeinated Coffee 2nd Visit|Participants will be given an 8 oz cup of caffeinated coffee on their first visit and 8 oz cup of decaffeinated coffee on their second visit.
3176471|NCT01364207|Experimental|Decaffeinated Coffee 1st Visit, Caffeinated Coffee 2nd Visit|Participants will be given an 8 oz cup of decaffeinated coffee on their first visit and 8 oz cup of caffeinated coffee on their second visit.
3176472|NCT01364194|Active Comparator|0.25% Bupivacaine|Periarticular injection with 20 ml of 0.25% bupivacaine before wound closure.
3176473|NCT01364194|Placebo Comparator|0.9% normal saline|Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
3176474|NCT01364181|Experimental|Udenafil|Udenafil 50mg qd po
3176475|NCT01364168||First ever acute ischemic stroke|Patients over 18 years and without prior stroke according to WHO criteria, displaying an ischemic stroke, onset within the last 7 days, language German
3176476|NCT01364155|Experimental|600 mg LIM-0705 BID for 28 days|
3176477|NCT01364155|Placebo Comparator|Placebo LIM-0705 for 28 days|
3176478|NCT01364142||thoracic surgery|Patients undergoing thoracic surgery in which one lung ventilation is needed.
3176479|NCT01364129|Experimental|Telemedicine|Participants in this group have digital images of their retina captured with a non-mydriatic camera and are encouraged to see an eye care provider yearly.
3176480|NCT01364129|No Intervention|Traditional Surveillance|Participants in this group are encouraged to see an eye care provider each year for a diabetic eye exam.
3176481|NCT01364090|Active Comparator|Standard Treatment Duration (24 weeks)|Subjects with detectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 24 and follow-up for an additional 24 weeks following treatment completion (48 weeks in total).
3176482|NCT01364090|Experimental|Shortened Treatment Duration (12 Weeks)|Subjects with undetectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 12 and follow-up for an additional 24 weeks following treatment completion (36 weeks in total).
3176483|NCT01364077|Active Comparator|Ivabradine|
3176484|NCT01364077|Placebo Comparator|Control|
3176485|NCT01364064|Active Comparator|Conventional adjuvant Temozolomide|TMZ d 1-5 of 28-d cycle 6 cycles
3176486|NCT01364064|Experimental|Dose intensive Temozolomide|TMZ d 1-21 of 28-d cycle 6 cycles
3176487|NCT01364051|Experimental|Treatment (cediranib maleate, selumetinib)|Patients receive cediranib maleate PO QD and selumetinib PO QD or BID on days 1-28 (days 8-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Courses may be extended to 12 weeks after 1 year of study treatment.
3176488|NCT01364025|Experimental|uterosacral ligament suspension|uterosacral ligament suspension colpopexy sutures will be placed bilaterally at the time of hysterectomy
3176489|NCT01364025|No Intervention|hysterectomy alone|
3176490|NCT01364012|Experimental|Bevacizumab + Paclitaxel/Carboplatin|Participants will receive bevacizumab on Day 1 of each 3-week cycle in combination with paclitaxel and carboplatin for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive bevacizumab on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
3176491|NCT01364012|Active Comparator|Placebo + Paclitaxel/Carboplatin|Participants will receive bevacizumab matching placebo on Day 1 of each 3-week cycle in combination with paclitaxel and carboplatin for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive bevacizumab matching placebo on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
3176492|NCT01363999|Experimental|1|
3176493|NCT01363999|Experimental|2|
3176494|NCT01363999|Experimental|3|
3176495|NCT01363999|Experimental|4|
3176496|NCT01363986|Experimental|Trastuzumab Monotherapy|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.), followed by weekly doses of 2 mg/kg i.v. for up to 18 weeks.
3176497|NCT01363973|Experimental|Sensory stimulation|Transcutaneous electrical stimulation at 75% of motor threshold
3176498|NCT01363973|Experimental|Motor stimulation|Transcutaneous electrical stimulation at motor threshold
3176499|NCT01363960||neonates with retinopathy of prematurity|"all neonates meet the criteria:~a BW of less than 1501 gram (g)~born at a GA of 34 weeks (wk) or less and~selected infants with an unstable clinical course were included"
3176500|NCT01363947|Experimental|Dose Escalation Cohort (DNIB0600A)|Participants will receive IV infusions of DNIB0600A at doses ranging from 0.2 milligrams/kilogram (mg/kg) to 2.8 mg/kg q3w until dose-limiting toxicity (DLT) is reached, or up to 28 cycles.
3176501|NCT01363947|Experimental|Expansion Cohort (DNIB0600A)|Participants will receive 2.4 mg/kg, by IV infusion, of DNIB0600A q3w for up to 26 cycles.
3176502|NCT01363934|Experimental|Group A|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
3176503|NCT01363934|Experimental|Group B|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
3176504|NCT01363934|Experimental|Group C|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
3176505|NCT01363934|Experimental|Group D|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
3176506|NCT01363934|Active Comparator|Darbepoetin alfa 30ug/kg by IV|Darbepoetin alfa 30ug/kg once intravenously
3176507|NCT01363934|Experimental|Group H|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
3176508|NCT01363934|Experimental|Group I|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
3176509|NCT01363934|Experimental|Group J|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
3176510|NCT01363934|Experimental|Group K|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
3176511|NCT01363934|Active Comparator|Darbepoetin alfa 30ug/kg by SC|Darbepoetin alfa 30ug/kg once subcutaneously
3176512|NCT01363921|Experimental|Dialysis treatment with HCO1100|
3176513|NCT01363908|Experimental|SPD602 (26 mg/kg)|Oral SSP-004184AQ taken once daily for 48 weeks
3176514|NCT01363908|Experimental|SPD602 (36 mg/kg)|Oral SSP-004184AQ taken once daily for 48 weeks. Starting dose based on transfusion burden and iron overload status. Doses may range from 8-60mg/kg/day depending on clinical response.
3176515|NCT01363908|Experimental|SPD602 (16 mg/kg)|A single dose given in the initial pharmacokinetic phase.
3176516|NCT01363895|Active Comparator|Percutaneous closure of LAA|Percutaneous closure of LAA
3176517|NCT01363895|Active Comparator|Catheter ablation of AF|Catheter ablation of AF
3176518|NCT01363882|Active Comparator|Standard NIV|Noninvasive ventilation (NIV) will be initiated and managed as per current standard of practice guided by the American Academy of Neurology (AAN) Practice Parameters (updated in 2009), in all subjects with amyotrophic lateral sclerosis (ALS) and a forced vital capacity of <50% predicted. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months, but will not influence management of the NIV.
3176519|NCT01363882|Experimental|Sleep study titrated NIV|ALS subjects in this arm, who are offered NIV for Forced Vital Capacity (FVC) <50% as per AAN Practice Parameters, will have their initial level of NIV determined polysomnographically. They will be followed with sleep studies at 1 month, 3 months and 6 months to reassess NIV efficacy and NIV will be adjusted as necessary to optimize parameters of oxygenation and ventilation.
3176520|NCT01363869|Experimental|Green tea extracts 2 gm/day|Green tea extracts 2 gm/day for 14 days
3176521|NCT01363869|Experimental|Green tea extracts 4 gm/day|Green tea extracts 4 gm/day for 14 days
3176522|NCT01363869|Experimental|Green tea extracts 6 gm/day|Green tea extracts 6 gm/day for 14 days
3176523|NCT01363856||First ever acute stroke|Patients over 18 years and without prior stroke according to WHO criteria, displaying an ischemic stroke, onset within the last 7 days, language German
3176524|NCT01363843|Experimental|treatment|"Induction therapy - Modified FOLFOX6 - Oxaliplatin 85 mg/m2 + Leucovorin 400 mg/m2 IV, followed by 5-FU 400 mg/m2 IV, followed 5-FU 2400 mg/m2 IV by continuous infusion over 46 hours - Repeat q14 days x 8 cycles~Concurrent Chemoradiation~50.4 Gy Radiation in 28 fractions (45 Gy IMRT, 5.4 Gy 3D conformal boost)~Surgery"
3176525|NCT01363830|Experimental|Two-Week Post-Operative Restriction|Restrict bending, lifting, and twisting for two-weeks following discectomy.
3176526|NCT01363830|Active Comparator|Six-Week Post-Operative Restriction|Restrict bending, lifting, and twisting for six-weeks following discectomy.
3176527|NCT01363817|Experimental|Escalation Phase: BMS-906024|BMS-906024 escalating doses starting at 0.3 mg solution for intravenous (IV) administration once weekly continuously until disease progression or unacceptable toxicity
3176528|NCT01363817|Experimental|Expansion Phase: BMS-906024 + Dexamethasone|BMS-906024 maximum tolerated dose (To be determined) solution for IV administration once weekly and Dexamethasone 20mg/day tablet by mouth (Oral) for 3-4 days every week for 3-4 weeks per cycle continuously until disease progression or unacceptable toxicity
3176576|NCT01363440|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4|Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks.
3176679|NCT01362686|Experimental|Rivastigmine|See intervention note.
3176529|NCT01363804|Experimental|Tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
3176530|NCT01363778|Experimental|tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
3176531|NCT01363765|Experimental|Xpert MTB/Rif|Sputum specimens arriving during intervention period will be submitted to this technology, a real-time automated polymerase chain reaction test
3176532|NCT01363765|Active Comparator|Sputum smear|Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining
3176533|NCT01363752|Active Comparator|Advagraf + MMF + Steroids|Without sirolimus
3176534|NCT01363752|Experimental|Advagraf + MMF + Steroids + Sirolimus|With sirolimus; MMF withdrawn on Day 28; Sirolimus introduced on Day 28
3176535|NCT01363726||2|Jewish and Bedouin children < 5 years of age in southern Israel
3176536|NCT01363713|Experimental|1|
3176537|NCT01363700|Experimental|1|
3176538|NCT01363700|Placebo Comparator|2|
3176539|NCT01363700|Active Comparator|3|
3176540|NCT01363687|Experimental|Remote ischemic postconditioning group|Recipients receive remote ischemic postconditioning after declamping of renal artery during kidney transplantation
3176541|NCT01363687|No Intervention|Control group|Patients who have a deflated cuff placed on the upper limb free of arteriovenous fistula during the surgery
3176542|NCT01363661|Experimental|Molsidomine|Coruno (molsidomine 16 mg tablet; per os; once daily)
3176543|NCT01363661|Placebo Comparator|Placebo|Placebo (16 mg tablet; once a day)
3176544|NCT01363648|Experimental|Choline alfoscerate|choline alfoscerate 400mg, 3 times a day, for 12 weeks.
3176545|NCT01363648|Placebo Comparator|placebo (for choline alfoscerate )|placebo tablet, 3 times a day, for 12 weeks.
3176546|NCT01363635||severe sepsis|severe sepsis/septic shock, organ failure, ICU death
3176547|NCT01363622||SGA|SGA (small for gestational age)
3176548|NCT01363622||LGA|LGA (large for gestational age)
3176549|NCT01363622||AGA|AGA (appropriate-for-gestational-age)
3176550|NCT01363609|Experimental|Liraglutide|12 week treatment with liraglutide in fixed dosage
3176551|NCT01363609|Active Comparator|Insulin glargine|12 week treatment, once daily, with insulin glargine. Dosage based on fasting blood glucose measurements
3176552|NCT01363609|Other|before start of treatment period|before start of the treatment period, one day with tests will be performed. During this test a GLP-1 receptor antagonist will be administered In the group with obesity and planned gastric bypass surgery, the GLP-1 receptor agonist will be administered during 1 test before and 1 test after the surgery
3176553|NCT01363596||Natural Procreative Technology (NPT)|Patients who are treated or who consider being treated with Natural Procreative Technology (NPT) for infertility or history of spontaneous abortion.
3176554|NCT01363583|Active Comparator|epoprostenol, Flolan®|Measurement on the effect of epoprostenol on lactate/pyruvate ratio measured by cerebral microdialysis
3176555|NCT01363583|Placebo Comparator|normal saline|Effect of saline on the lactate/pyruvate ratio measured by cerebral microdialysis
3176556|NCT01363570|Other|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
3176557|NCT01363557|Experimental|Arm A : Gefitinib + WBRT|Arm A : WBRT and Concurrent Gefitinib followed by Gefitinib Maintenance
3176558|NCT01363557|Experimental|Arm B : Gefitinib|Arm B : Gefitinib alone
3176559|NCT01363544|Experimental|Neurofeedback|
3176560|NCT01363544|Experimental|Exercise|
3176561|NCT01363544|Active Comparator|methylphenidate|optimum dose of methylphenidate (assessed by a double blind placebo-controlled procedure)
3176562|NCT01363531|Active Comparator|Direct antibiotic treatment|The doctor gives to patient an antibiotic prescription for his respiratory infection, which he should start immediately.
3176563|NCT01363531|No Intervention|No antibiotic treatment|The doctor doesn't give to patient an antibiotic prescription for his respiratory infection.
3176564|NCT01363531|Experimental|Delayed antibiotic prescription 1|The doctor gives to patient an antibiotic prescription for his respiratory infection with the advice to use it if needed, in case of worsening of symptoms or not improving.
3176565|NCT01363531|Experimental|Delayed antibiotic prescription 2|The doctor leaves the antibiotic prescription, for the respiratory infection of the patient, at the reception of the primary care center 3 days after the first medical visit. This prescription can be collected by patient if he needed, in case of worsening of symptoms or not improving.
3176566|NCT01363518||Operative|Operative group would have had surgery to treat their broken humerus.
3176567|NCT01363518||Nonoperative|Nonoperative group would have been treated with a brace, no surgery.
3176568|NCT01363505||Acute CHF patients|Acute CHF patients with BARD Intra-abdominal pressure monitors in ICU
3176569|NCT01363492|Experimental|Replagal 0.2 mg/kg every other week (EOW)|
3176570|NCT01363479|Experimental|Oral palonosteron plus dexamethasone|Oral palonosetron (Aloxi 0.50 mg softgel capsule) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
3176571|NCT01363479|Active Comparator|I.V. palonosetron plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
3176572|NCT01363466|Experimental|with hysterectomy|
3176573|NCT01363466|No Intervention|without hysterectomy|
3176574|NCT01363453||Patients with Ulcerative Colitis|
3176575|NCT01363440|Active Comparator|Macular Laser Photocoagulation Treatment (Control)|Participants received macular laser treatment at baseline and as-needed at visits at which laser re-treatment criteria were met, but no more frequently than every 12 weeks.
3176577|NCT01363440|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8|Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks for 5 visits followed by injections every 8 weeks.
3176578|NCT01363427||Crohn's disease|Patients with initially diagnosed Crohn's disease
3176579|NCT01363414|Experimental|Artificial tear|One drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
3176580|NCT01363414|Placebo Comparator|Control|one drop of sterile 0.9% sodium chloride solution in the other eye
3176581|NCT01363401|Experimental|Test group|Treatment group with HYNR-CS inj.
3176582|NCT01363401|Experimental|Control group|No treatment with HYNR-CS inj.
3176583|NCT01363388|Placebo Comparator|Placebo|
3176584|NCT01363388|Experimental|CCX168|Active study medication
3176585|NCT01363375||normal foot|Subjects with normal foot structure
3176586|NCT01363375||flat foot|Subjects with flat foot structure.
3176587|NCT01363375||high arch foot|Subjects with high arch foot structure.
3176588|NCT01363362|Experimental|glaucoma patients|Glaucoma patients undergoing selective laser trabeculoplasty for further IOP reduction
3176589|NCT01363349|Experimental|CYP-1020|Dose titration 15-35mg/day for 6 months
3176590|NCT01363349|Active Comparator|Risperidone|Dose titration 2-6mg/day for 6 months
3176591|NCT01363336||Group 1|
3176592|NCT01363323|Experimental|Arm 1|
3176593|NCT01363323|Experimental|Arm 2|
3176594|NCT01363323|Experimental|Arm 3|
3176595|NCT01363323|Placebo Comparator|Arm 4|
3176596|NCT01363323|Active Comparator|Arm 5|
3176597|NCT01363310|Active Comparator|Quetiapine XR|
3176598|NCT01363310|Active Comparator|Escitalopram|
3176599|NCT01363297|Experimental|Inotuzumab Ozogamicin|
3176600|NCT01363284|Experimental|Duloxetine|The first week of the treatment is the placebo treatment. The effect of placebo will be taken into consideration for further evaluation the duloxetine effect on clinical pain and descending pain inhibition capabilities.
3176601|NCT01363271||complicated skin and skin structure infections (cSSSI)|Identified through a pre-specified list of ICD-9 codes in study protocol.
3176602|NCT01363271||Pneumonia|Identified through a pre-specified list of ICD-9 codes in study protocol.
3176603|NCT01363258|Experimental|Care-resistant mouth care (MOUTh)|These nursing home residents with dementia receive mouth care from study personnel who use strategies to reduce care-resistant behavior (Managing Oral Hygiene Using Threat Reduction or MOUTh) while providing evidence-based mouth care.
3176604|NCT01363258|Active Comparator|Evidence Base Mouth Care|Nursing home residents with dementia received mouth care from study personnel who were trained in evidence-based mouth care only.
3176605|NCT01363245|Experimental|Hospital phone counseling|multisession telephone counseling by hospital/study's smoking cessation staff
3176606|NCT01363245|Active Comparator|Fax-to-quit|Faxed referral to the state Quitline, which will then perform phone outreach as per Quitline protocol
3176607|NCT01363232|Experimental|BKM120 + MEK162|
3176608|NCT01363206|Experimental|Single arm open label|GM-CSF and Ipilimumab
3176609|NCT01363180||Control|
3176610|NCT01363180||Trauma-exposed without PTSD|
3176611|NCT01363180||Trauma-exposed with PTSD|
3176612|NCT01363167|Active Comparator|400 IU Cholecalciferol - Vitamin D|
3176613|NCT01363167|Placebo Comparator|Placebo|Placebo contains Fractionated Coconut Oil
3176614|NCT01363154|Active Comparator|Mozart K448|Treatment: music exposure to Mozart K448
3176615|NCT01363154|Placebo Comparator|Beethoven's Für Elise|Placebo: music exposure to Beethoven's Für Elise for piano
3176616|NCT01363154|No Intervention|No music exposure|Control: no music exposure
3176617|NCT01363141|Active Comparator|Regular AGE Diet|Regular AGE Diet
3176618|NCT01363141|Active Comparator|Low AGE Diet|One year reduction in dietary AGE intake
3176619|NCT01363128|Experimental|Hyper-CVAD + Ofatumumab|"Hyper-CVAD + Ofatumumab (odd courses)~Hyper-CVAD + High Dose Methotrexate + Cytarabine + Ofatumumab (even courses)"
3176620|NCT01363115|Experimental|OJ fortified with Ca and VitD|Regular OJ fortified with Calcium (350 mg/8 fluid oz serving) and Vitamin D3 (100 IU/8 fluid oz serving): one 8 fluid oz serving three times/day (treatment) in combination with nutritional counseling
3176621|NCT01363115|Active Comparator|OJ without VitD and Ca|Regular OJ without Calcium or Vitamin D3: one 8 fluid oz serving three times/day (control)
3176622|NCT01363102|No Intervention|Control group|Group will undergo usual mobilization per standard SICU care
3176623|NCT01363102|Experimental|Study Group|Patient mobilization discussed on rounds, SOMS score goal created, specific attempt to mobilize patient and achieve goal throughout day.
3176624|NCT01363089|Experimental|Ketorolac tromethamine|
3176625|NCT01363089|Experimental|Oxymetazoline hydrochloride|
3176626|NCT01363076|Experimental|Ketorolac Tromethamine (15 mg)|Ketorolac Tromethamine - single dose (15 mg) administered intranasally (IN) for subjects weighing <50 kg.
3176627|NCT01363076|Experimental|Ketorolac Tromethamine (30 mg)|Ketorolac Tromethamine - single dose (30 mg) administered intranasally (IN) for subjects weighing ≥50 kg.
3176628|NCT01363063|Experimental|Ketorolac tromethamine (Part A)|
3176629|NCT01363063|Experimental|Ketorolac tromethamine (Part B)|
3176630|NCT01363050|Experimental|Ketorolac tromethamine|
3176631|NCT01363037|Experimental|Dapivirine-Maraviroc Vaginal Ring|
3176632|NCT01363037|Placebo Comparator|Placebo Vaginal Ring|
3176633|NCT01363037|Active Comparator|Maraviroc Vaginal Ring|
3176634|NCT01363037|Active Comparator|Dapivirine Vaginal Ring|
3176635|NCT01363024|Experimental|A|
3176636|NCT01363011|Experimental|E/C/F/TDF (Cohort 1)|"Participants who have not received prior antiretroviral (ARV) treatment and who are virologically unsuppressed at baseline will initiate treatment with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) single-tablet regimen (STR) for up to 96 weeks.~Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of E/C/F/TDF was received in the applicable country."
3176677|NCT01362686|Experimental|Donepezil|See intervention note.
3176678|NCT01362686|Experimental|Galantamine|See intervention note.
3176637|NCT01363011|Experimental|COBI+PI+2 NRTI (Cohort 2)|"Participants who have received prior ARV treatment and who are virologically suppressed at baseline will continue their treatment regimen, switching the regimen's pharmacoenhancer component from ritonavir to cobicistat (COBI), and continuing their existing protease inhibitor (PI; either atazanavir (ATV) or darunavir (DRV)) plus 2 nucleoside reverse transcriptase inhibitor (NRTI) regimen for up to 96 weeks.~Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of cobicistat was received in the applicable country."
3176638|NCT01362998|Active Comparator|Preservative free morphine|This group will receive 3mg of preservative free morphine epidurally during the procedure.
3176639|NCT01362998|Active Comparator|Fentanyl infusion|This group will receive an epidural infusion of fentanyl (60 micrograms per hour), which will be started during the Cesarean section and which will continue for the next two days.
3176640|NCT01362972||plerixafor + granulocyte colony stimulating factor (G-CSF)|Patients who receive plerixafor+granulocyte colony stimulating factor (G-CSF) for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
3176641|NCT01362972||plerixafor + G-CSF + chemotherapy|Patients who receive plerixafor+granulocyte colony stimulating factor (G-CSF)+chemotherapy for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
3176642|NCT01362972||granulocyte colony stimulating factor (G-CSF) + chemotherapy|Patients who receive granulocyte colony stimulating factor (G-CSF) + chemotherapy for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
3176643|NCT01362972||granulocyte colony stimulating factor (G-CSF) alone|Patients who receive granulocyte colony stimulating factor (G-CSF) alone for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
3176644|NCT01362959|Experimental|Nicotine patch|
3176645|NCT01362959|Placebo Comparator|Control patch|The control product is a look-alike patch compared to the test product, containing no nicotine or other active substances.
3176646|NCT01362946|Experimental|Reward-Emphasized treatment|This treatment consisted of behavior therapy modified to match the unique learning styles of children with CPCU. This was accomplished by emphasizing rewards and de-emphasizing punishments. This treatment was administered using a summer treatment program.
3176647|NCT01362946|Active Comparator|Standard treatment|This treatment consisted of standard behavior therapy, in which reward and punishment components were used in a balanced manner, as is typically done in outpatient settings. This treatment was administered using a summer treatment program.
3176648|NCT01362933||VTE treatment in cancer patient|All patients with cancer present in the clinic, hospital, out patient diagnosed with a VTE during the 6 previous months.
3176649|NCT01362920||Sepsis or Septic shock cohort|
3176650|NCT01362920||Non-sepsis or non-Septic shock cohort|
3176651|NCT01362907|Other|Delefilcon A / etafilcon A|Delefilcon A contact lenses worn first, with etafilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
3176652|NCT01362907|Other|Etafilcon A / delefilcon A|Etafilcon A contact lenses worn first, with delefilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
3176653|NCT01362894|Other|nelfilcon A / etafilcon A|Nelfilcon A lenses worn first, with etafilcon A lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
3176654|NCT01362894|Other|etafilcon A / nelfilcon A|Etafilcon A lenses worn first, with nelfilcon A lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
3176655|NCT01362829||Patients with severe sepsis|Patients who are admitted to medical ICU with severe sepsis
3176656|NCT01362816||Palliative care cancer patients|"Inclusion criteria are:~Patient has a cancer diagnosis (radiological, histological, cytological or operative evidence), local, loco-regional or metastatic disease, defined as a palliative care patient; enrolled in a palliative care programme, age 18 years or older, able to provide written informed consent, able to complete the data collection tool, preferably without help, available for follow up registration"
3176657|NCT01362803|Experimental|Arm 1|Phase 1: AZD6244 PO BID x 28 DAYS
3176658|NCT01362803|Experimental|Arm 2|Phase 2: AZD6244 PO BID x 28 DAYS
3176659|NCT01362790|Experimental|1|Regimen A pilot (closed)
3176660|NCT01362790|Experimental|2|Regimen B pilot (closed)
3176661|NCT01362790|Experimental|3|Regimen A phase 2 peritoneal mesothelioma
3176662|NCT01362790|Experimental|4|Regimen A phase 2 pleural mesothelioma
3176663|NCT01362790|Experimental|5|Regiman A Dose de-escalation
3176664|NCT01362790|Experimental|6|Regimen A pancreatic adenocarcinoma pilot
3176665|NCT01362790|Experimental|7|Regimen A lung adenocarcinoma pilot
3176666|NCT01362777|Experimental|In-Patient Rehabilitation|"Sessions of rehabilitation contains :~Individualized exercise training~Educational activities~Dietary advices"
3176667|NCT01362777|Active Comparator|Educational activities alone|"Out-patient control arm contains only :~-Educational activities"
3176668|NCT01362764|Other|001|Abiraterone acetate tablets Type=exact unit=mg number= 250 form=tablet route=oral use as a single dose
3176669|NCT01362764|Other|002|Abiraterone acetate suspension Formulation 1 Type=exact unit=mg/mL number=25 form=oral suspension route=oral use as a single dose of 10 mL
3176670|NCT01362764|Other|003|Abiraterone acetate suspension Formulation 2 Type=exact unit=mg/mL number=25 form=oral suspension route=oral use as a single dose of 10 mL
3176671|NCT01362751||Nursing home residents|In this study, patients from both the somatic and the psychogeriatric department are included. For the primary endpoint 'successful rehabilitation' only the patients from the somatic departments are included.
3176672|NCT01362738|Active Comparator|Ablation of PV and extra-PV triggers|Conventional approach which includes pulmonary vein isolation (PVI) and ablation of extra-pulmonary triggers
3176673|NCT01362738|Active Comparator|LAA isolation along with the conventional ablation strategy|LAA isolation along with the conventional ablation strategy
3176674|NCT01362725|Experimental|Spinal cord stimulation|
3176675|NCT01362699|Experimental|JNJ-31001074|
3176676|NCT01362699|Placebo Comparator|Placebo|
3176680|NCT01362673|Experimental|Single dose|
3176681|NCT01362673|Experimental|Multiple dose|
3176682|NCT01362660||Infants with potential exposure in utero|
3176683|NCT01362634|Experimental|CAPI Intervention|an interviewer-administered comprehensive health and social risk assessment intervention
3176684|NCT01362634|Experimental|ACASI Intervention|self-administered comprehensive health and social risk assessment intervention
3176685|NCT01362634|No Intervention|Control|waitlist control condition
3176686|NCT01362621||Children 6 to less than 12 years of age|
3176687|NCT01362608|Experimental|Canakinumab and placebo matching to triamcinolone acetonide|ACZ885H
3176688|NCT01362608|Active Comparator|Triamcinolone acetonide 40 mg|ACZ885H
3176689|NCT01362595|Other|Leucine|No alternative treatment arm
3176690|NCT01362582|No Intervention|Chemotherapy, Nutritional Care|"5-Fluorouracil (5-FU) 2000mg/m2 IV (24-hour)/folinic acid (FA) 200mg/m2 IV (30 min) will be administered weekly over four weeks with additional oxaliplatin 85 mg/m2 IV (2-hour) on days 8 and 22. Therapy will be interrupted between days 23 to 42. The next cycle will be started on day 43.~Subjects in the control group receive Best Supportive Nutritional Care. BSNC is defined as nutritional consultation and recommendation by experienced ecotrophologists."
3176691|NCT01362582|Experimental|PN, Chemotherapy, Nutritional Care|"5-Fluorouracil (5-FU) 2000mg/m2 IV (24-hour)/folinic acid (FA) 200mg/m2 IV (30 min) will be administered weekly over four weeks with additional oxaliplatin 85 mg/m2 IV (2-hour) on days 8 and 22. Therapy will be interrupted between days 23 to 42. The next cycle will be started on day 43.~Patients receive also Best Supportive Nutritional Care defined as nutritional consultation and recommendation by experienced ecotrophologists.~Intervention: Supportive Parenteral Nutrition"
3176692|NCT01362569||predialytic renal insufficiency|Patents without renal replacement therapy
3176693|NCT01362569||hemodialysis/hemofiltration patients|patients undergoing regular hemodialysis/hemofiltration
3176694|NCT01362569||peritoneal dialysis patients|patients undergoing peritoneal dialysis
3176695|NCT01362569||acute renal failure|patients with acute renal failure
3176696|NCT01362569||post renal transplantation|patients after renal transplantation
3176697|NCT01362569||healthy controls|control group
3176698|NCT01362556|Placebo Comparator|Sodium Chloride|Group receiving sodium chloride 0.9% after arterial blood gas analysis in cardiac arrest.
3176699|NCT01362556|Active Comparator|Sodium Bicarbonate|Group receiving targeted sodium bicarbonate 8% therapy after arterial blood gas analysis in cardiac arrest.
3176700|NCT01362543|Active Comparator|Stress Management|
3176701|NCT01362543|Active Comparator|Cognitive restructuring|
3176702|NCT01362530|Experimental|Aprepitant Regimen|"Cycle 1:~Participants 12 to 17 years of age, Day 1: aprepitant 125 mg capsule orally (PO) + ondansetron, Days 2 to 3: aprepitant 80 mg capsule PO. Participants 6 months to <12 years of age, Day 1: aprepitant powder for suspension (PFS), 3.0 mg/kg (up to 125 mg) + ondansetron, Days 2 to 3: aprepitant PFS, 2.0 mg/kg (up to 80 mg).~Optional Cycles 2-6:~Open-label aprepitant administered in the same manner as in Cycle 1."
3176703|NCT01362530|Placebo Comparator|Control Regimen|Cycle 1: Participants 12 to 17 years of age, Day 1: matching placebo for aprepitant 125 mg capsule oral (PO) + ondansetron Days 2 to 3: matching placebo for aprepitant 80 mg capsule PO. Participants 6 months to <12 years of age, Day 1: matching placebo PFS: 3.0 mg/kg (up to 125 mg) + ondansetron, Days 2 to 3: matching placebo PFS: 2.0 mg/kg (up to 80 mg). Optional Cycles 2-6: Open-label aprepitant administered in the same manner as in Cycle 1.
3176704|NCT01362517|Experimental|Quinvaxem|
3176705|NCT01362504||Clinical sepsis|
3176706|NCT01362504||Proven sepsis|
3176707|NCT01362504||Control group|healthy neonates
3176708|NCT01362491|Experimental|Treatment A|
3176709|NCT01362491|Active Comparator|Treatment B|
3176710|NCT01362491|Placebo Comparator|Treatment C|
3176711|NCT01362478||Case group|
3176712|NCT01362478||Control group|
3176713|NCT01362465|Experimental|Cardiac Resynchronization Therapy (CRT)|Implanting device to measure delays between paced chambers in heart failure patients.
3176714|NCT01362452|Experimental|Double Umbilical Cord Blood (UCB)|"Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.~Starting dose level of T-cells not to exceed 106/m2.~The investigational component of the treatment plan of this study is the infusion of CD19-specific T cells derived from cord blood (CB) to be infused Day +42 to Day +100 following stem cell transplantation. The transplant component of the treatment plan will include CB transplant regimens that are commonly use for CB transplantation."
3176715|NCT01362452|Experimental|Single Umbilical Cord Blood (UCB)|"Single UCB unit arm does not start enrollment until Dose Level A2 in the double UCB unit arm has been deemed safe.~Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.~Starting dose level of T-cells not to exceed 106/m2.~The investigational component of the treatment plan of this study is the infusion of CD19-specific T cells derived from cord blood (CB) to be infused Day +42 to Day +100 following stem cell transplantation. The transplant component of the treatment plan will include CB transplant regimens that are commonly use for CB transplantation"
3176716|NCT01362439|Experimental|Paliperidone ER|
3176717|NCT01362426||001|paliperidone palmitate Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
3176718|NCT01362400|Active Comparator|ARM 1: IPI 504 + Docetaxel|Drug: IPI-504 plus Docetaxel
3176719|NCT01362400|Placebo Comparator|Placebo + Docetaxel|Placebo plus Docetaxel
3176720|NCT01362387|No Intervention|Group 1|Women assigned to Group 1 will receive the standard post-abortion follow-up currently used at bpas and will be undertaken as usual by staff at the treating clinic
3176721|NCT01362387|Experimental|Group 2|Follow-up after medical abortion using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test.
3176722|NCT01362374|Experimental|Arm A (Ipatasertib + Docetaxel)|Participants will receive ipatasertib at a starting dose of 100 milligrams (mg) once daily for 14 consecutive days (beginning on Day 2) in combination with docetaxel on Day 1, in 21-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurs first.
3176830|NCT01361594|Active Comparator|Intensive insulin treatment|Intensive insulin treatment (BG target: 100-140 mg/dL)
3176723|NCT01362374|Experimental|Arm B (Ipatasertib + mFOLFOX6)|Participants will receive ipatasertib at a starting dose of 100 mg once daily for 7 consecutive days (beginning on Day 1) in combination with mFOLFOX6 chemotherapy (comprising of oxaliplatin, leucovorin, and 5-FU) on Day 1, in 14-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurs first.
3176724|NCT01362374|Experimental|Arm C (Ipatasertib + Paclitaxel)|Participants will receive ipatasertib at a dose of 600 mg once daily for 21 consecutive days (beginning on Day 1) in combination with paclitaxel on Days 1, 8, and 15, in 28-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurs first.
3176725|NCT01362374|Experimental|Arm D (Ipatasertib + Enzalutamide)|Participants will receive ipatasertib at a dose of 400 mg once daily alone for 8 days, then from Day 9, ipatasertib will be administered in combination with enzalutamide once daily for 27 days (Cycle 1 duration = 35 days). Participants will receive both ipatasertib and enzalutamide once daily continuously in subsequent 28-days cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurs first. Higher (up to 600 mg) or lower dose of ipatasertib may be evaluated in subsequent cycles depending upon safety, tolerability, and pharmacokinetics of the first cycle.
3176726|NCT01362361|Experimental|Arm A|mFOLFOX6 + BIBF 1120
3176727|NCT01362361|Placebo Comparator|Arm B|mFOLFOX6+placebo
3176728|NCT01362348|Experimental|pazopanib eye drops|pazopanib topical ocular administration
3176729|NCT01362335||patients, that are having a routine surgical procedure.|
3176730|NCT01362322|Experimental|BOOSTRIX NEW GROUP|Subjects, aged 10 to 15 years, received one dose of Boostrix™ vaccine administered using a new syringe presentation (prefilled syringes from a different manufacturer) in the deltoid of the non-dominant arm, at Day 0.
3176731|NCT01362322|Active Comparator|BOOSTRIX PREV GROUP|Subjects, aged 10 to 15 years, received one dose of Boostrix™ vaccine administered using a previous syringe presentation (single dose vial or a prefilled disposable syringe without a needle) in the deltoid of the non-dominant arm, at Day 0.
3176732|NCT01362309|Placebo Comparator|Placebo|Inert filler in matched pill.
3176733|NCT01362309|Active Comparator|d-cycloserine 50 mg|50 mg d-cycloserine.
3176734|NCT01362296|Experimental|GSK1120212|Oral once daily
3176735|NCT01362296|Active Comparator|docetaxel|IV once every 3 weeks
3176736|NCT01362283||Hypertension|Subject who meet eligible criteria
3176737|NCT01362270|Experimental|Verum Acupuncture|"Subjects will receive verum, or real, acupuncture."
3176738|NCT01362270|Sham Comparator|Sham acupuncture|Subjects will receive sham acupuncture therapy using the Streitberger needle at the same points and on the same schedule as patients in the treatment group. Streitberger needles are blunt tipped and retract into themselves rather than penetrating the skin.
3176739|NCT01362257|Experimental|14C-GSK573719 Oral Solution|single dose of 1000µg
3176740|NCT01362257|Experimental|14C-GSK573719 IV Solution|single dose of 65µg
3176741|NCT01362244|Experimental|Treatment Periods 1-8|Part A comprises eight outpatient visits (Visits 1 - 8). For six of these visits, subjects will receive a dose of either 750 mg mepolizumab or placebo. Dosing occurs in four week intervals. Assessment for entry into Part B will take place at the last visit in Part A (Visit 8). Subjects not eligible for Part B will have study exit procedures performed and be discontinued.
3176742|NCT01362244|Other|Run In period|10-14 day run in period to assess the patients suitability for entry into Part A of the trial.
3176743|NCT01362244|No Intervention|Treatment periods 9-13|Subjects eligible for Part B will attend the clinic for up to 5 more outpatient visits (Visits 9 - 13) for assessments. Visits occur every four weeks. There is no dosing in Part B. At the point when each subject meets Study Exit criteria, study exit procedures will be performed and the subject will exit the study.
3176744|NCT01362231|Experimental|GS-6624 125mg|
3176745|NCT01362231|Experimental|Experimental: GS-6624 200mg|
3176746|NCT01362218|Experimental|Fixed Dose Combination Pill|A fixed dose combination of acetylsalicylic acid, simvastatin, and ramipril Intervention: Drug: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)
3176747|NCT01362218|Active Comparator|Simvastatin|Simvastatin given together with the reference drugs ramipril and acetylsalicylic acid
3176748|NCT01362205|Experimental|Dexmedetomidine|Dexmedetomidine titrated to achieve predefined goals on selected components of the MINDS score using the minimum amount of medication possible. Blinded study medication will be started at a rate determined by the MINDS score. The maximum infusion rate is 1.4 μg/kg per hour. Uncontrolled SAWS/D symptoms, will be treated with open label lorazepam according to the MINDS score algorithm. Persistent SAWS/D symptoms despite maximum infusion rate of study medication treatment limiting symptoms while receiving higher infusion rates of study medication, ancillary therapies will be administered according to the MINDS score algorithm, at the discretion of the treating physician.
3176749|NCT01362205|Placebo Comparator|Placebo|Blinded placebo study drug administration in equal volume per hour as active study medication arm.
3176750|NCT01362192|Other|532 nm KTP Laser Treatment|
3176751|NCT01362179||unstimulated BM donors|Observational (non-interventional) study.
3176752|NCT01362179||filgrastim-mobilized PBSC donors|Observational (non-interventional) study.
3176753|NCT01362153|Experimental|001|Golimumab IV infusions of 2 mg/kg golimumab on Days 1 and 85.
3176754|NCT01362153|Experimental|002|Golimumab SC injection of 100 mg every 4 weeks through Week 20
3176755|NCT01362140|Experimental|Darbepoetin alfa|Participants received darbepoetin alfa 500 µg every three weeks (Q3W) for 24 weeks in the double-blind treatment period, and continued to receive darbepoetin alfa 500 µg Q3W during the active treatment period for an additional 48 weeks.
3176756|NCT01362140|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection every 3 weeks (Q3W) for 24 weeks during the double-blind treatment period. From week 25 participants received darbepoetin alfa 500 µg Q3W during the active treatment period for 48 weeks.
3176757|NCT01362127|Active Comparator|Radiochemotherapy|Radiochemotherapy + Surgery
3176758|NCT01362127|Active Comparator|Chemotherapy|Chemotherapy + surgery
3176831|NCT01361594|Active Comparator|Conventional insulin treatment|Conventional insulin treatment (BG target: 141-180 mg/dl)
3176832|NCT01361581||ACD (acid-citrate-dextrose)|
3176833|NCT01361581||4% trisodium citrate|
3176834|NCT01361581||unfractionated heparin (UFH)|
3176759|NCT01362114|Experimental|Sihogayonggolmoryeo-tang extract|"name of product: 'SIHOGAYONGGOLMORYU TANG EXTRACT GRAN'~standard code for item: 200005676~shape, type: extract(brown)~usage, content: adults;three times a day, each taken before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36months after manufacture~macufacturing company: KyungBangnShinYak inc."
3176760|NCT01362114|Placebo Comparator|Placebo; corn flour,|"raw material: total contents(500㎎); cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)~shape, type: extract(brown)~usage, dose: adults: three times a day, 1 sack before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36 months after manufacture~manufacturing company: KyungBangnShinYak inc."
3176761|NCT01362101|Active Comparator|Traditional behavioral intervention|
3176762|NCT01362101|Active Comparator|Mindfulness behavioral intervention|
3176763|NCT01362088||CVVH patients|
3176764|NCT01362075|Experimental|Local infiltration analgesia|
3176765|NCT01362075|Active Comparator|Interscalene catheter|
3176766|NCT01362062||RA Cohort|Participants with active RA who had an inadequate clinical response to current non-biologic disease modifying anti-rheumatoid drug (DMARD) and/or anti-tumor necrosis factor (anti-TNF) therapy being treated with tocilizumab according to the routine clinical practice and in line with prescribing information will be observed for a total duration of 12 months.
3176767|NCT01362049|Active Comparator|'Eligible' Subject Group - STAB|"Subjects between the ages of 21-55 years with low back pain >12 months who are eligible for Treatment-Based Classification (TBC) stabilization exercises based on current criteria:~straight leg raise > 90 degrees~aberrant trunk movement with trunk forward flexion~positive prone instability test AND/OR~passive lumbar mobility testing that is judged to be hypermobile at any level."
3176768|NCT01362049|Active Comparator|'Ineligible' Subject Group - STAB|Subjects between the ages of 21-55 years with low back pain >12 months who are not eligible for the TBC-based stabilization exercises based on current criteria
3176769|NCT01362049|Active Comparator|'Eligible' Subject Group - MSI|"Subjects between the ages of 21-55 years with low back pain >12 months who are eligible for Treatment-Based Classification (TBC) stabilization exercises based on current criteria:~straight leg raise > 90 degrees~aberrant trunk movement with trunk forward flexion~positive prone instability test AND/OR~passive lumbar mobility testing that is judged to be hypermobile at any level."
3176770|NCT01362049|Active Comparator|'Ineligible' Subject Group -MSI|Subjects between the ages of 21-55 years with low back pain >12 months who are not eligible for the TBC-based stabilization exercises based on current criteria
3176771|NCT01362036|Experimental|TXA127 sc injectable|All cohorts will recieve TXA127; Cohorts receive either 300, 600, or 900 ug/kg daily
3176772|NCT01362023|No Intervention|control|Control pupils follow their usual activities
3176773|NCT01362023|Experimental|lifestyle counseling|"In 3 academic years, the intervention program consisted of three components:~Classroom practice by HPA to highlight healthy lifestyle habits~Teaching practice by HPA using books designed to include the nutritional objectives~Parental activities included with their children~In each of 12 activities (1 h/activity), the classroom practice consisted of three components:~Experimental development of activities regarding each healthy lifestyle habit~Assessment of activity performed in classroom~An activity developed for use at home"
3176774|NCT01362010|Experimental|Topical Minocycline Foam FXFM244 - 4%|Active ingredient: Minocycline Concentration: 4% Route: Topical Dosage schedule: Once daily, evening.
3176775|NCT01362010|Experimental|Topical Minocycline Foam FXFM244 - 1%|Active ingredient: Minocycline Concentration: 1% Route: Topical Dosage schedule: Once daily, evening.
3176776|NCT01362010|Placebo Comparator|Placebo foam|Active ingredient: None Route: Topical Dosage schedule: Once daily, evening
3176777|NCT01361997|Experimental|Chlorhexidine in isopropyl alcohol|This arm is composed of 545 hospitalized patients with suspected blood stream infection, to test 2% chlorhexidine gluconate in 70% isopropyl alcohol.
3176778|NCT01361997|Experimental|Isopropyl alcohol|This arm is composed of 572 hospitalized patients with suspected blood stream infection, to test 70% isopropyl alcohol.
3176779|NCT01361984|Experimental|Brovana (nebulized arformoterol)|Brovana (nebulized arformoterol) treatment for 2 weeks
3176780|NCT01361984|Experimental|Serevent (Salmeterol dry powder inhaler)|Serevent (Salmeterol dry powder inhaler) treatment for 2 weeks
3176781|NCT01361958|Experimental|T1 received 0.625 mg NOMAC + 1.5 mg E2|
3176782|NCT01361958|Experimental|T2 received 1.25 mg NOMAC + 1.5 mg E2|
3176783|NCT01361958|Experimental|T3 received 2.5 mg NOMAC + 1.5 mg E2|
3176784|NCT01361958|Experimental|T4 received 2.5 mg NOMAC + Lactose|
3176785|NCT01361945|Experimental|AUY922|Single Arm
3176786|NCT01361932|Experimental|Video of ED Discharge Instructions|
3176787|NCT01361932|No Intervention|Control (usual standard of care)|
3176788|NCT01361919|Experimental|Feedback During CPR Training and Testing|"A feedback defibrillator (ZOLL R series) will be used at teaching, immediate testing and 12 week (retention) testing. A simulation manikin with an attached accelerometer pad on its sternum will be used to collect CPR performance data. Subjects will be told to perform compressions on top of the accelerometer pad and will be taught to use and follow the audio and visual feedback to optimize their CPR performance. After training, the raw data collected by the accelerometer will be used as a demonstration and training tool, to correct the subjects' performance by visually demonstrating the difference between ideal and suboptimal CPR performance. Testing will be carried out with the use of a feedback defibrillator."
3176789|NCT01361919|Active Comparator|Feedback during CPR Training Not Testing|"A feedback defibrillator will be used for teaching, with a standard no feedback defibrillator used at immediate and 12 week (retention) testing to assess if the techniques the students' learned during training are transferable to devices without feedback. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest."
3176829|NCT01361607|Placebo Comparator|Placebo (GA-0034)|Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorings.
3176790|NCT01361919|Placebo Comparator|No Feedback Group|"A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur."
3176791|NCT01361906|No Intervention|Untreated control|Untreated control
3176792|NCT01361906|Experimental|Sensomotoric training|Treatment with Sensomotoric training
3176793|NCT01361893|Other|Lifestyle Counseling|Parents who qualify for the study will be asked to participate in the survey portion of the study. informed consent will be obtained. After completing the survey each parent will be asked if they would be willing to participate in and additional interview (focus group or semi-structured in-debth interview) at a later date.
3176794|NCT01361880|Other|Reduce infant mortality|The overall purpose of this study is to develop and evaluate a systematic approach to improve African-American parental behaviors specifically with regards to the infant sleep environment
3176795|NCT01361867|Other|Robot-induced perturbations|The subject walks on a treadmill with his/her legs strapped to a robotic system (Lokomat by Hocoma AG) that generates mechanical perturbations aimed to modify the subject's walking pattern.
3176796|NCT01361854|Experimental|polysomnography for suspicion of SDB|adults, suspects of suffering from sleep disordered-breathing, who must undergo a diagnostic polysomnography
3176797|NCT01361841|Other|ophtalmic solution,|Travoprost, latanoprost and bimatoprost, ophthalmic solution are topical medications used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. they are synthetic prostaglandin F 2α analogue (and prodrug for bimatoprost) that works by increasing the outflow of aqueous fluid from the eyes.
3176798|NCT01361828||Patients with choroidal neovascularization|CNV due to Age-Related Macular Degenerations and Myopia were included.
3176799|NCT01361815|Other|H-Coil Deep TMS Treatment|
3176800|NCT01361802|Active Comparator|Ambroxol Spray 2.5mg|Ambroxol Spray Low Dose
3176801|NCT01361802|Active Comparator|Ambroxol Spray 5mg|Ambroxol Spray Medium Dose
3176802|NCT01361802|Active Comparator|Ambroxol Spray 10mg|Ambroxol Spray High dose
3176803|NCT01361802|Placebo Comparator|Placebo Spray|Placebo Spray
3176804|NCT01361789|Active Comparator|COXIB|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
3176805|NCT01361789|Active Comparator|Dexamethasone|dexamethasone 8 mg iv
3176806|NCT01361789|Active Comparator|COXIB and dexamethasone|combination of coxib AND dexamethasone
3176807|NCT01361776|Active Comparator|TBE vaccine at 0+30 days|This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later
3176808|NCT01361776|Active Comparator|TBE vaccine at 0+7+21 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later
3176809|NCT01361776|Active Comparator|TBE vaccinte at 0+30+90 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later
3176810|NCT01361776|Active Comparator|younger participants|This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later
3176811|NCT01361763|Experimental|Dabigatran|
3176812|NCT01361763|Active Comparator|Antiplatelets|
3176813|NCT01361750|Experimental|gastirc tube group|conduit will be perfomed by narrowed gastric tube
3176814|NCT01361750|No Intervention|control group|conduit will be traditional subtotal stomach without any surgical modification
3176815|NCT01361737||preeclampsia|"Control group: 86 healthy women not developing preeclampsia (PE)~Case group: 43 women developing PE"
3176816|NCT01361724|Other|One on one with a PT|The participant will work one-on-one with a trained for PT for 3 days a week for four weeks.
3176817|NCT01361724|Other|Group exercise class|The participant will be in a group exercise class. That will meet 3 days a week for 4 weeks.
3176818|NCT01361724|Other|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
3176819|NCT01361711|Experimental|Treatment (monoclonal antibody therapy)|Patients receive alemtuzumab SC three times a week in weeks 1-18 and ofatumumab IV over 4-6 hours on day 1 of weeks 3, 5, 7, 9, 11, 13, 15, and 17.
3176820|NCT01361698|Experimental|IMR program|The program is organised into 11 curriculum topic areas: recovery strategies, practical facts about mental illness, the stress-vulnerability model, building social support, using medication effectively, drug and alcohol use, reducing relapses, healthy lifestyle, coping with stress, coping with problems and symptoms, and getting your needs met in the mental health system. In this Danish trial IMR will be implemented in group format with 10 patients assigned to each group and two IMR facilitators, and the IMR program will require nine months of weekly sessions to complete.
3176821|NCT01361698|No Intervention|Treatment as usual|Patients randomised to the control group will get 'treatment as usual' only. This means individual adapted interdisciplinary treatment including medication, individual support, occupational therapy, psycho-education and group therapy.
3176822|NCT01361646|Experimental|LC350189|
3176823|NCT01361646|Active Comparator|Febuxostat|
3176824|NCT01361646|Placebo Comparator|Placebo|
3176825|NCT01361633|Experimental|Medication|250 mg d-cycloserine
3176826|NCT01361633|Placebo Comparator|Sugar Pill|
3176827|NCT01361620|Other|Aspirin|All subjects took 7-10 days of 81 mg aspirin
3176828|NCT01361607|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligram [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
3176835|NCT01361568|Experimental|CR845|Peripheral kappa opioid receptor agonist
3176836|NCT01361568|Placebo Comparator|Placebo|Matched Placebo
3176837|NCT01361555|Experimental|Arm 1: Placebo + BMS-820836 (0.5 mg/day)|
3176838|NCT01361555|Experimental|Arm 2: Placebo + BMS-820836 (1 mg/day)|
3176839|NCT01361555|Experimental|Arm 3: Placebo + BMS-820836 (2 mg/day)|
3176840|NCT01361542|Experimental|Anti TNF|Anti TNF alpha therapy including either infliximab or etanercept with data obtained before and after the study duration.
3176841|NCT01361529|Experimental|safty test|FLP,dose escalation,MTD
3176842|NCT01361516|Experimental|Intravenous sedation, General anaesthesia|IV sedation-ESWL under spontaneous respiration GA - ESWL under controlled respiration
3176843|NCT01361503||Autism Spectrum Disorder (ASD)|
3176844|NCT01361503||Controls|
3176845|NCT01361477||patient|complication, refusal ICU admission, adverse event
3176846|NCT01361464|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib orally twice daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3176847|NCT01361425|Experimental|methildopa|pregnant women with stable severe pre-eclampsia will use methildopa (1,5g/day)
3176848|NCT01361425|Placebo Comparator|placebo|stable pregnant women with severe preeclampsia will use placebo
3176849|NCT01361412|Experimental|ToleroMune Ragweed 4|
3176850|NCT01361412|Experimental|ToleroMune Ragweed Regimen 3|
3176851|NCT01361412|Experimental|ToleroMune Ragweed Regimen 2|
3176852|NCT01361412|Placebo Comparator|Placebo|Placebo
3176853|NCT01361412|Experimental|ToleroMune Ragweed Regimen 1|
3176854|NCT01361399|Experimental|Arm 1|
3176855|NCT01361399|Active Comparator|Arm 2|
3176856|NCT01361399|Active Comparator|Arm 3|
3176857|NCT01361399|Placebo Comparator|Arm 4|
3176858|NCT01361386||1|
3176859|NCT01361373|Active Comparator|DOPAMINE|Sinemet up to 10 mg/kg/day
3176860|NCT01361373|Placebo Comparator|Placebo|placebo
3176861|NCT01361360||control|
3176862|NCT01361360||hypercapnia|
3176863|NCT01361347|Placebo Comparator|placebo|"rice/soy/oat milkdrink, masked"
3176864|NCT01361347|Experimental|milk|cow's milk
3176865|NCT01361334|Experimental|Pazopanib|Pazopanib treatment
3176866|NCT01361321||patients after GBR procedure|The study will comprise of patients who already underwent a routine Guided Bone Regeneration (GBR) procedure in order to augment a bony ridge before dental implant insertion. The patients will be followed up in order to determine bone quality and quantity formed after the usage of routinely used bone substitutes during GBR procedure.
3176867|NCT01361308|Experimental|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate)
3176868|NCT01361308|Placebo Comparator|Placebo Capsules|Placebo Capsules
3176869|NCT01361295|Active Comparator|PVI with PVAC gold|Patient for pulmonal vein isolation using the PVAC Gold Catheter. Intervention.
3176870|NCT01361295|Active Comparator|PVI with Cooled-RF|Patient for pulmonal vein isolation using the Cooled-RF catheter.
3176871|NCT01361282||Triple Procedure|All qualifying patients will have received DSAEK with concurrent cataract extraction and intraocular lens placement. Data collection will occur between 6-18 months post-operation.
3176872|NCT01361269|Experimental|Fosmidomycin and clindamycin treatment|All the subject will be given fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
3176873|NCT01361256|Experimental|WA- NG Telescope Prothesis|Implantable Miniature Telescope for end stage AMD (Age-related Macular Degeneration)
3176874|NCT01361243|Experimental|NOURISH+|Participants will receive a 6-week face-to-face intervention, NOURISH+. Weekly topics teach parents skills to role model and encourage healthy lifestyle behaviors for their children.
3176875|NCT01361243|Placebo Comparator|Wellness Group|"Participants will receive an in-person Family Wellness Night followed by 6 mailings of information regarding pediatric overweight and obesity."
3176876|NCT01361230|Experimental|Protocol|Using sedation monitoring and protocol
3176877|NCT01361230|No Intervention|Control|Standard practice
3176878|NCT01361217|Experimental|Fluoxetine DDI|Only arm in the study. Successive Control (Study Days 1 and 3) and fluoxetine multiple-dose treatment (Study Days 16 and 18) Sessions.
3176879|NCT01361204|Experimental|Theanine|Experimental Comparator, theanine Taking 4 tablets of theanine two times daily for 16 days Placebo Comparator, sucrose Taking 4 tablets of sucrose two times daily for 16 days
3176880|NCT01361178|No Intervention|Transplant patients who do not receive SQ IVIG|Patients participating in the observational arm of the study who do not need to receive IgG replacement.
3176881|NCT01361178|Active Comparator|Transplant patients who receive SQ IVIG|Patients participating in the observational arm of the study who are randomized to receive a dosage of SQ IVIG due to low IgG level.
3176882|NCT01361152|Experimental|Fixed-bearing group|Fixed-bearing group
3176883|NCT01361152|Experimental|Mobile-bearing group|Mobile-bearing group
3176884|NCT01361126|Experimental|On-demand|The routine prophylactic therapy interval is targeted at every 7 days.
3176885|NCT01361126|Experimental|Prophylactic|On-demand subjects will receive rIX-FP only for the treatment of a bleeding episode.
3176886|NCT01361113|Other|Single Arm Neoadjuvant Pazopanib|Pazopanib 800 mg PO once daily for 8 weeks
3176887|NCT01361100|Experimental|Oncoral test|
3176888|NCT01361074|Experimental|In Vivo Exposure|
3176889|NCT01361074|Experimental|Augmented Reality Exposure|
3176890|NCT01361061||patients with liver cirrhosis|
3176891|NCT01361048|Active Comparator|oral metronidazole|control arm
3176892|NCT01361048|Experimental|neo penotran forte|neo penotran forte vaginal suppository twice a day for 7 days
3176893|NCT01361048|Experimental|neo penotran forte once a day|neo penotran forte vaginal suppository once a day for 7 days
3176894|NCT01361035|No Intervention|No communication training|Physicians enrolled in the control arm do not undergo training in health literacy, cancer screening and shared decision making
3176895|NCT01361035|Other|Cancer risk ommunication skills training|Physicians enrolled in the intervention arm undergo training in health literacy, cancer screening and shared decision making
3176896|NCT01361022|Active Comparator|Brotizolam tablet|Brotizolam tablets 250mcg : at least 6 and 24 subjects will be enrolled in the pre-study and main study, respectively
3176897|NCT01361022|Experimental|Lendormin tablet|Lendormin tablets 250mcg: at least 6 and 24 subjects will be enrolled in the pre-study and main study, respectively
3176898|NCT01361009||pramipexole group|It's a open-label, non-intervention,observation post marketing surveillance to observe the safety and efficacy of pramipexole in real world.
3176899|NCT01360996|Experimental|3 mg DRSP/20 μg EE--normal weight|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~Normal weight -BMI 18-24.9 kg/ m2"
3176900|NCT01360996|Experimental|3 mg DRSP/20 μg EE- Overweight|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~BMI 25-29.9 kg/ m2"
3176901|NCT01360996|Experimental|3 mg DRSP/20 μg EE- Grade 1 obese|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~BMI 30-34.9 kg/ m2"
3176902|NCT01360957|Placebo Comparator|Water flavored placebo|to be given orally in a dosage of 30 ml trice daily for 60 days
3176903|NCT01360957|Experimental|Black cumin water extract as a traditional medicine|Black cumin water extract as a traditional medicine to be given orally in a dosage of 30 ml trice daily for 60 days
3176904|NCT01360944|Experimental|LAS 41004, variant 1, once daily|variant 1, once daily
3176905|NCT01360944|Experimental|LAS41004, variant 2, once daily|variant 2, once daily
3176906|NCT01360944|Experimental|LAS41004, variant 3, once daily|variant 3, once daily
3176907|NCT01360944|Experimental|LAS41004, variant 4, once daily|variant 4, once daily
3176908|NCT01360944|Experimental|LAS41004, variant 5, once daily|variant 5, once daily
3176909|NCT01360944|Experimental|LAS41004, variant 6, once daily|variant 6, once daily
3176910|NCT01360944|Placebo Comparator|reference|once daily, 100microgram
3176911|NCT01360944|Active Comparator|reference, once daily|once daily
3176912|NCT01360931||Lung Cancer group|Subject with histological confirmation of lung cancer
3176913|NCT01360931||Control group|Subjects with no diagnosis of lung cancer
3176914|NCT01360918|Active Comparator|Usual care|
3176915|NCT01360918|Active Comparator|Pulmonary vein isolation|
3176916|NCT01360866|Experimental|1|Drug: OPC-34712 + ADT
3176917|NCT01360853|Experimental|Arm A: Combination|Arm A: Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle, + ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
3176918|NCT01360853|Active Comparator|Arm B: Gemcitabine only|Arm B: Gemcitabine only, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
3176919|NCT01360840|Placebo Comparator|Placebo + Standard of care (SoC)|
3176920|NCT01360840|Experimental|EMD 525797 750 mg + SoC|
3176921|NCT01360840|Experimental|EMD 525797 1500 mg + SoC|
3176922|NCT01360827|Experimental|Arm 1 (Part 1)|
3176923|NCT01360827|Experimental|Arm 2 (Expansion cohorts -Part 2 and Part 2a)|
3176924|NCT01360814|Experimental|GROUP A (multidisciplinary intervention)|Patients receive six 90-minute sessions of a multidisciplinary structured intervention comprising physical therapy, education, a cognitive-behavioral intervention, discussion and support, spiritual reflection, and a relaxation exercise over 2-4 weeks. Caregivers are invited to sessions 1, 3, 4, and 6. Patients may also receive brief telephone contact during the 6 month follow-up period.
3176925|NCT01360814|Active Comparator|GROUP B (standard medical care)|Patients receive standard medical care only. Patients may also receive brief telephone contact during the 6 month follow-up period.
3176926|NCT01360788||Healthy control subjects|Subjects with a significant smoking history (more than 10 pack-years) and a normal lung function.
3176927|NCT01360788||Asymptomatic GOLD stage I COPD patients|GOLD stage I COPD (post-bronchodilator forced expiratory volume in 1 second [FEV1] > 80% predicted and FEV1/ forced vital capacity [FVC] < 0.7 and a smoking history > 10 pack-years) were recruited. A Medical Research Council (MRC) dyspnea score ≥ 2 was used to define the presence of symptoms (dyspnea). Concretely, this group did not present any respiratory symptoms, with a MRC dyspnea score of 1/5.
3176928|NCT01360788||Symptomatic GOLD stage I COPD patients|GOLD stage I COPD (post-bronchodilator forced expiratory volume in 1 second [FEV1] > 80% predicted and FEV1/ forced vital capacity [FVC] < 0.7 and a smoking history > 10 pack-years) were recruited. A Medical Research Council (MRC) dyspnea score ≥ 2 was used to define the presence of symptoms (dyspnea) in this group.
3176929|NCT01360775|Experimental|nutritional counseling|Supervision and monitoring of nutritional status of patients in the home care program, after making nutritional advice
3176930|NCT01360775|No Intervention|Not nutritional counseling|
3176931|NCT01360762|Experimental|Pentamidine Secondary Prophylaxis (PSP)|"Patients with co-infection of human immunodeficiency virus (HIV)and visceral leishmaniosis (VL), having being treated for VL, are allocated to pentamidine secondary prophylaxis, to prevent VL relapses. The treatment period is of 12 months, plus an extended treatment period of 0 to 6 months depending on the immunosuppression status, plus 12 months follow-up after the extended treatment period."
3176932|NCT01360749|Experimental|Lambdalina and placebo|Eligible patients will receive lambdaline (lidocaine cream 40 mg/g) in Left Lower Extremity and placebo in Right Lower Extremity.
3176933|NCT01360749|Experimental|Placebo and lambdalina|Eligible patients will receive placebo in Left Lower Extremity and lambdaline (lidocaine cream 40 mg/g) in Right Lower Extremity.
3176934|NCT01360736|Experimental|Safety Planning - Military (SAFE-MIL)|Brief Safety Planning Using Stanley and Brown (2012) Model
3176935|NCT01360736|No Intervention|E-CARE|Treatment As Usual and Assessment Services of Study; Control Condition
3176936|NCT01360723||urothelial carcinoma|Pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists.
3176937|NCT01360723||Healthy controls group|Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
3176938|NCT01360710|Experimental|Moxonidine|
3176939|NCT01360710|Active Comparator|Irbesartan|
3176940|NCT01360697|Experimental|JADE- JA|Use the JADE portal to monitor the delivery of structured care.
3176941|NCT01360697|Active Comparator|Usual care|Patients will receive usual care in between two annual comprehensive assessments.
3176942|NCT01360671|Experimental|Sildenafil|iv sildenafil
3176943|NCT01360658|Experimental|Intravenous immunoglobulins|Intravenous immunoglobulins
3176944|NCT01360645|Experimental|Phase B|"Drug: OPC-34712 + ADT~Drug: Placebo + ADT"
3176945|NCT01360645|Placebo Comparator|Phase A|Intervention: Drug: Placebo + ADT
3176946|NCT01360632|Experimental|Phase B|"Drug: OPC-34712 + ADT~Drug: Placebo + ADT"
3176947|NCT01360632|Placebo Comparator|Phase A|Drug: Placebo + ADT
3176948|NCT01360606|Other|SBRT|
3176949|NCT01360593|Other|Gem, Xeloda, SBRT|
3176950|NCT01360567|Placebo Comparator|B formula|placebo
3176951|NCT01360567|Experimental|A formula|Green tea extract
3176952|NCT01360554|Experimental|A|Blinded active PF-00299804 + blinded placebo comparator (erlotinib)
3176953|NCT01360554|Active Comparator|B|Blinded active comparator (erlotinib) + blinded placebo PF-00299804
3176954|NCT01360541|Experimental|Radiofrequency ablation|Endoscopic radiofrequency ablation of BE
3176955|NCT01360541|Active Comparator|Surveillance|Endoscopic surveillance and PPI treatment
3176956|NCT01360528||Extremely low birth weight|Extremely low birth weight under 1000 gram
3176957|NCT01360528||Very low birth weight|Between 1000-1500 gram babies
3176958|NCT01360528||Low birth weight|Between 1500-2500 gram
3176959|NCT01360476|Active Comparator|Vitamin D|
3176960|NCT01360476|Placebo Comparator|placebo|
3176961|NCT01360463|Experimental|Behavioral and Drug Risk Counseling|Participants assigned to this arm will receive bi weekly Behavioral and Drug Risk Counseling (BDRC) counseling for six months.
3176962|NCT01360463|Active Comparator|Treatment as Usual|Participants assigned to this arm will receive methadone treatment without and alterations.
3176963|NCT01360450|Experimental|Treatment|Interventions: Infants will receive intravenous or oral clonidine(Duraclon) for the treatment of pain and sedation: Duration: (Clonidine HCL) 1 mcg/kg/dose q4 either iv or po.
3176964|NCT01360450|Placebo Comparator|Control|Intervention: Infants will receive place (saline) (if receiving it IV) or orally (sterile water) if receiving it orally
3176965|NCT01360437|Active Comparator|Prasugrel|
3176966|NCT01360437|Experimental|Ticagrelor|
3176967|NCT01360424|Experimental|teriparatide|
3176968|NCT01360411||Pancreatic lesions|"Any patient with a solid pancreatic lesion of unknown histology may be recruited. Cystic lesions are not included.~Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively."
3176969|NCT01360411||Intramural upper GI-lesions|Patients with intramural lesions discovered by endoscopy or other imaging modalities are recruited. Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively.
3176970|NCT01360411||Lymph nodes|Patients with visible mediastinal lymph nodes or retroperitoneal lymph nodes in patients with inflammatory or malignant diseases are recruited. Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively.
3176971|NCT01360398|Other|Cohort|COPD male and female patients between 40 and 85 years of age, recruited among the patients of the Southampton General Hospital and referring practices.
3176972|NCT01360385||Central Retinal Vein Occlusion|CRVO-patients with planned treatment with intravitreal injections of ranibizumab, who receive three monthly injections of ranibizumab and a 3 month follow-up period, during which ranibizumab injections are provided as needed.
3176973|NCT01360372|Active Comparator|Methylnaltrexone|
3176974|NCT01360372|Placebo Comparator|saline placebo injection|
3176975|NCT01360359|Experimental|Core Stabilization|"8-week core stabilization program in 3 stage that emphasizes use of specific local trunk stabilizing muscles to restore active control and stability to the trunk.~8-week exercise program, 1-2 sessions/ week, 30-60 minute sessions"
3176976|NCT01360359|Active Comparator|Trunk Motion and Fitness|"8-week exercise program in 3 stages emphasizing spine motion, general trunk flexibility and strengthening and cardiovascular fitness.~8-week exercise program, 1-2 sessions/ week, 30-60 minute sessions"
3176977|NCT01360346|Experimental|Enteral Sedation (EN)|Melatonin, Hydroxyzine, and Lorazepam. At every work shift, it will be checked the possibility to decrease the Lorazepam and then the Hydroxyzine dosage to quickly obtain and continuously maintain a RASS level = 0
3176978|NCT01360346|Active Comparator|Intravenous Sedation (IV)|Intravenous propofol or midazolam administration at the ICU admission to discharge at the compatible lowest level with harsh ICU environment. At every shift nurses are requested to give intravenous lowest dosage to obtain RASS=0
3176979|NCT01360333|Other|Tap water, sodium chloride, carbohydrate rich fluid|
3176980|NCT01360320|Experimental|Green tea extract|
3176981|NCT01360320|Placebo Comparator|Placebo|
3176982|NCT01360307||Major Depressive Disorder Patients|
3176983|NCT01360294||Asthma with small airway disease|
3176984|NCT01360294||Asthma without small airway disease|
3176985|NCT01360281|Experimental|ECR|
3176986|NCT01360281|No Intervention|Control|
3176987|NCT01360281|Experimental|NMES|
3176988|NCT01360255||Patients treated with TACE|Patients treated with transarterial chemoembolisation (TACE) are included in this clinical trial
3176989|NCT01360242|Active Comparator|MIMI procedure (two-step strategy)|Thrombus aspiration is performed to achieve TIMI-3 flow. Once TIMI-3 flow is restored and sustained for > 10 minutes, the initial procedure is stopped regardless of the presence of any residual stenosis. A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
3176990|NCT01360242|Sham Comparator|Immediate Stenting (one-step strategy)|The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
3176991|NCT01360229|Sham Comparator|Randomized Subjects receive a sham acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
3176992|NCT01360229|Active Comparator|Randomized Subjects receive real acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
3176993|NCT01360216|Experimental|LARC education and training|Clinicians and contraceptive educators practicing in clinics assigned to this arm receive a special half-day Continuing Medical Education (CME/CEU) accredited LARC education and training session.
3176994|NCT01360216|No Intervention|Standard practice- control|Clinicians and contraceptive educators practicing in clinics assigned to this arm do not receive special LARC training and education session. Standard practice will be followed at clinics assigned to the control arm.
3176995|NCT01360203|No Intervention|Current Care|Patients will receive the current care provided to heart failure patients at each of the study sites
3176996|NCT01360203|Experimental|Care Transition Intervention|Care transition intervention beginning prior to discharge and through six months post-discharge.
3176997|NCT01360190|Active Comparator|fluoxetine|
3176998|NCT01360190|Placebo Comparator|placebo|
3176999|NCT01360177|Experimental|Radioactive Iodide and PET/CT|
3177000|NCT01360164|Experimental|Human umbilical cord mesenchymal stem cells transplantation|Participants will be given umbilical cord mesenchymal stem cells transplantation with a 1 year follow-up.
3177001|NCT01360151|Experimental|experimental|Arm 1 : combination treatment of ranibizumab(Lucentis) and verteporfin(Visudyne) injection
3177002|NCT01360151|Active Comparator|active comparator|Arm 2 : Treatment of verteporfin(Visudyne)
3177003|NCT01360151|No Intervention|normal control group|Arm 3 : normal control group
3177004|NCT01360138|Active Comparator|midline approach|cervical epidural steroid injection with 18G Touhy epidural needle by midline approach
3177005|NCT01360138|Active Comparator|paramedian approach|cervical epidural steroid injection with 18G Touhy epidural needle by paramedian approach
3177006|NCT01360086|Experimental|Perioperative CT with 5FU-Cisplatine-Cetuximab|6 cycles of intravenous Cetuximab (500mg/m²), Cisplatine (50mg/m²) and LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks. Surgery was planned 3-4 weeks after the end of neaodjuvant CT and postoperative CT, with the same regimen, planned for 6-8 weeks after surgery.
3177007|NCT01360073||Cases|Cases with nonfatal MI or coronary death
3177008|NCT01360073||Controls|Age, sex, and calendar-year matched controls sampled from the original study cohort to be a round number of at least four times the number of cases
3177009|NCT01360060||Group N|parturients who had undergone Cesarean section under the diagnosis of non-preeclampsia
3177010|NCT01360060||Group P|parturients who had undergone Cesarean section under the diagnosis of preeclampsia
3177011|NCT01360047||Cases|Cases with nonfatal MI or coronary death
3177012|NCT01360047||Controls|Age, sex, and calendar-year matched controls sampled from the original study cohort to be a round number of at least four times the number of cases
3177013|NCT01360034|Experimental|Nifedipine|108 patients will receive nifedipine as tocolytic for 48 hours.
3177014|NCT01360034|Experimental|Indomethacin|108 patients will receive indomethacin as tocolytic for 48 hours.
3177015|NCT01360021|Active Comparator|1 Symbicort/inhaler|Symbicort BA MDI 2x160/4.5 μg twice daily
3177016|NCT01360021|Active Comparator|Symbicort/inhaler|Symbicort AC pDMI 2x160/4.5 μg twice daily
3177017|NCT01360021|Active Comparator|Budesonide/inhaler|Budesonide AC pMDI 2x160 μg twice daily
3177018|NCT01360008||Cryo ablation|Patients with first Ablation of atrial fibrillation treated by cryo ablation
3177019|NCT01360008||RF ablation|Patients with first Ablation of atrial fibrillation treated by Radio frequency ablation
3177020|NCT01359982|Experimental|RRx-001|
3177021|NCT01359969|Experimental|Recombinant Human C1 Inhibitor|Patients presented to the clinic within 5 hours of onset received rhC1INH 50 U/kg body weight up to a maximum of 4200 U.
3177022|NCT01359956|Experimental|A1|combination chemotherapy without interferon
3177023|NCT01359956|Experimental|A2|combination chemotherapy with interferon
3177024|NCT01359956|Active Comparator|B1|single agent dacarbazine without interferon
3177025|NCT01359956|Experimental|B2|single agent dacarbazine plus interferon
3177026|NCT01359943|Experimental|secukinumab 10 mg/kg i.v. loading|secukinumab 10mg/kg i.v. loading at Weeks 0, 2 and 4, and placebo s.c. at weeks 0, 1, 2, 3 and 4, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 8
3177027|NCT01359943|Experimental|secukinumab 150 mg s.c. loading|secukinumab 150mg s.c. loading at Weeks 0, 1, 2, 3 and 4, and placebo i.v. at weeks 0, 2 and 4, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 8
3177028|NCT01359943|Placebo Comparator|placebo|placebo at Weeks 0, 1, 2, 3, 4, 8 & 12, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 16
3177029|NCT01359930|Active Comparator|Naltrexone and Bupropion SR|
3177030|NCT01359930|Placebo Comparator|Placebo|
3177031|NCT01359917||autologous fat transfer|patients received fat transfer for HIV lipodystrophy
3177032|NCT01359917||polylactic acid|treatment with polylactic acid (PLA) for HIV lipodystrophy
3177033|NCT01359917||bio-alcamid|bio-alcamid injections
3177034|NCT01359904|Active Comparator|high dialysate bath|additive is put in the dialysate to increase the concentration of glucose to 10mmol/l
3177035|NCT01359904|No Intervention|Standard dialysate glucose concentration|Standard 5.5 mmol/L dialysate glucose concentration.
3177036|NCT01359891||Cohort 1|"All patients >18 years admitted to the University Hospital Graz, Austria, with positive blood cultures tested in the Microbiology Laboratory, Department of Internal Medicine, Medical University Graz, or the Institute for Hygiene, Microbiology and Environmental Medicine, Medical University Graz, are screened for study inclusion. Patients eligible for the study have to have Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Enterococcus faecium, Enterococcus faecalis, Streptococcus pneumoniae, Klebsiella pneumoniae or medically relevant fungi / viral pathogens identified as causative pathogen.~The estimated total number of patients included in this first study cohort will be 500."
3177075|NCT01359644|Experimental|Treatment B: PSI-7977 + Daclatasvir|Genotype 2 or 3
3177076|NCT01359644|Experimental|Treatment C: PSI-7977 + Daclatasvir|Genotype 1a or 1b
3177077|NCT01359644|Experimental|Treatment D: PSI-7977 + Daclatasvir|Genotype 2 or 3
3177078|NCT01359644|Experimental|Treatment E: PSI-7977 + Daclatasvir + Ribavirin|Genotype 1a or 1b
3177037|NCT01359891||Cohort 2|"All patients >18 years admitted to the University Hospital Graz, Austria, will be screened for study inclusion if the attending emergency department physicians on the very first visit suspects bacteremia/fungemia/sepsis and consecutively orders blood cultures. Patients will be included in this second cohort if these initially taken blood culture turns positive (n=200) or stays negative (n=50) at the Microbiology Laboratory, Department of Internal Medicine, Medical University Graz. As soon as the number of 50 is reached for the control group enrollment will be stopped for this group.~As soon as the proposed number of 250 patients is reached enrolment for this second cohort will be stopped. Patients enrolled in cohort 2 may also be consecutively enrolled in cohort 1."
3177038|NCT01359891||Validation Cohort|To verify the employed Presage™ST2 assay established in our study laboratory for its intended use, a total number of 70 left over plasma samples obtained from septic patients which have prior been tested for sST2 with the same assay at the Department of Laboratory Medicine, Barmherzige Brueder Linz, Austria, will be retested. This cohort therefore serves as a validation cohort.
3177039|NCT01359878|Experimental|Fibrinogen Concentrate|
3177040|NCT01359878|Placebo Comparator|Placebo|Isotonic Saline
3177041|NCT01359865|No Intervention|Lumbar plexus Block|This group will recieve pre-operative lumbar plexus block plus general anesthesia
3177042|NCT01359852|Experimental|001|"[11C] JNJ-42491293 + JNJ-40411813 Part C:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan,[11C] JNJ-42491293 + JNJ-40411813 Part D:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain,[11C] JNJ-42491293 Part A: [11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.,[11C] JNJ-42491293 Part B:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection have a 90 minute PET scan and have arterial and venous blood sampling."
3177043|NCT01359839|Experimental|Relaxation Response Mind Body Intervention|The Relaxation Response (RR) Mind Body Intervention Arm receives the Behavioral: Relaxation Response and Cognitive Behavioral Therapy Intervention which is a RR based Mind Body Group consisting of 1½ hour group classes held weekly for 8 weeks, in a conference room at the health center.
3177044|NCT01359826|Experimental|Milnacipran|Patients administered milnacipran will receive a dose escalation to 50 mg twice a day over 12 days and continued at this dose until week 6. If tolerated and a 15% improvement in fatigue from baseline is achieved by assessment on the FSS, then patients will continue taking 50 mg twice a day until the end of the study on day 98 (week 14). Otherwise, the dose of milnacipran will be titrated upward to 100 mg twice a day over 12 days and continued at this dose until day 98 (week 14).
3177045|NCT01359826|Placebo Comparator|Placebo|Placebo tablets administered orally twice a day for 14 weeks.
3177046|NCT01359813|No Intervention|Usual treatment|intravenous injection of Human Albumin. 1,5g/kg on first day and 1g/kg on third day
3177047|NCT01359813|Experimental|Human Albumin|1,5g/kg on first day and 1g/kg on third day.
3177048|NCT01359800||Treatment-naive HIV+ subjects|
3177049|NCT01359800||HAART-treated HIV+ subjects|
3177050|NCT01359787|Active Comparator|Mapracorat 0.01% Ointment|Lowest concentration
3177051|NCT01359787|Active Comparator|Mapracorat 0.03% Ointment|Middle concentration
3177052|NCT01359787|Active Comparator|Mapracorat 0.1% Ointment|Highest concentration
3177053|NCT01359787|Placebo Comparator|Vehicle without active|
3177054|NCT01359774|Other|Healthy volunteers|
3177055|NCT01359774|Other|Huntington patients|
3177056|NCT01359761|Experimental|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Post Admission Cognitive Therapy Individual Sessions; Up to Two (2) Inpatient Booster Sessions; Up to Four (4) Telephone Booster Sessions Following Psychiatric Discharge; 12-Months Case Management
3177057|NCT01359761|No Intervention|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services; 12-Months Case Management
3177058|NCT01359748|Other|Wrist Size <= 14.25 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
3177059|NCT01359748|Other|Wrist Size >=14.26 <16.50 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
3177060|NCT01359748|Other|Wrist size >=16.5 <17.75 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
3177061|NCT01359748|Other|Wrist Size >=17.75 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
3177062|NCT01359735|Active Comparator|HP802-247|allogeneic, growth arrested keratinocytes and fibroblasts: final concentration of 5.0 M cells/mL with a ratio of 1:9 keratinocytes:fibroblasts, applied weekly
3177063|NCT01359735|Active Comparator|Bacitracin Ointment|bacitracin antibiotic ointment
3177064|NCT01359722|Experimental|N-Acetylcysteine|N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.
3177065|NCT01359722|Placebo Comparator|Control|This group will receive only the infusion of saline in the same doses and infusion rate.
3177066|NCT01359709|Experimental|Contingency Management|
3177067|NCT01359709|Placebo Comparator|Noncontingent control|
3177068|NCT01359696|Experimental|A|
3177069|NCT01359683|Other|A|This is a prospective observational study. 100 patients in one arm scheduled for cardiac surgery will be enrolled. ECG tracings will be obtained when subject is at rest, in supine position, before induction of anesthesia (within 24 hours prior to induction), after induction of general anesthesia, right before emergence from anesthesia (or before transportation to the ICU if the subject remains intubated), and within 24 hours post-operatively; additional ECG readings may be obtained during the surgery if deemed necessary.
3177070|NCT01359670|Experimental|Tadalafil|
3177071|NCT01359670|Experimental|Sildenafil|
3177072|NCT01359657|Experimental|Arm A: Anti-CXCR4 (BMS-936564)+Lenalidomide+Dexamethasone|
3177073|NCT01359657|Experimental|Arm B: Anti-CXCR4 (BMS-936564)+Bortezomib+Dexamethasone|
3177074|NCT01359644|Experimental|Treatment A: PSI-7977 + Daclatasvir|Genotype 1a or 1b
3177079|NCT01359644|Experimental|Treatment F: PSI-7977 + Daclatasvir+ Ribavirin|Genotype 2 or 3
3177080|NCT01359644|Experimental|Treatment G: PSI-7977 + Daclatasvir|"Hepatitis C virus genotype 1, treatment-naive patients~Genotype 1a or 1b"
3177081|NCT01359644|Experimental|Treatment H: PSI-7977 + BMS-790052 + Ribavirin|"Hepatitis C virus genotype 1, treatment-naive patients~Genotype 1a or 1b"
3177082|NCT01359644|Experimental|Treatment I: PSI-7977 + Daclatasvir|"Patients who experienced telaprevir/boceprevir treatment failure~Genotype 1a or 1b"
3177083|NCT01359644|Experimental|Treatment J: PSI-7977 + Daclatasvir + Ribavirin|"Patients who experienced telaprevir/boceprevir treatment failure~Genotype 1a or 1b"
3177084|NCT01359618|Experimental|Part A 1|TC-5214
3177085|NCT01359618|Experimental|Part A 2|TC-5214 placebo
3177086|NCT01359618|Experimental|Part B 1|TC-5214 8 mg + moxifloxacin placebo
3177087|NCT01359618|Experimental|Part B 2|TC-5214 supratherapeutic dose + moxifloxacin placebo
3177088|NCT01359618|Active Comparator|Part B 3|TC-5214 placebo + moxifloxacin 400 mg
3177089|NCT01359618|Placebo Comparator|Part B 4|TC-5214 placebo + moxifloxacin placebo
3177090|NCT01359605|Experimental|varespladib methyl|
3177091|NCT01359592|Active Comparator|PET Negative: R-CHOP|R-CHOP x 3 Cycles
3177092|NCT01359592|Experimental|PET Positive: IFRT +Zevalin|Standard IFRT+ Zevalin IV per ABW
3177093|NCT01359579|Experimental|Subjects with mild renal impairment|
3177094|NCT01359579|Experimental|Subjects with moderate renal impairment|
3177095|NCT01359579|Experimental|Subjects with normal renal function|
3177096|NCT01359579|Experimental|Subjects with severe renal impairment|
3177097|NCT01359566|Active Comparator|Arbaclofen placarbil 15 mg BID|Arbaclofen placarbil (XP19986 SR4) 15 mg every morning and every evening
3177098|NCT01359566|Active Comparator|Arbaclofen placarbil 30 mg BID|Arbaclofen placarbil (XP19986 SR4) 30 mg every morning and every evening
3177099|NCT01359566|Active Comparator|Arbaclofen placarbil 45 mg BID|Arbaclofen placarbil (XP19986 SR4) 45 mg every morning and every evening
3177100|NCT01359566|Placebo Comparator|Placebo|Placebo every morning and every evening
3177101|NCT01359553||Knee pain|Group with knee pain problems referred to an arthroscopy.
3177102|NCT01359540||APEX Modular|APEX Modular Stem group
3177103|NCT01359540||ARC Stem|ARC Stem group
3177104|NCT01359527||Hip Resurfacing|
3177105|NCT01359527||Total Hip Arthroplasty|
3177106|NCT01359514|Active Comparator|Duloxetine|
3177107|NCT01359514|Active Comparator|Pregabalin|
3177108|NCT01359501|Experimental|Chinese medical treatment|
3177109|NCT01359501|Placebo Comparator|Placebo|
3177110|NCT01359488|Experimental|VRS-317 Safety Arm 1|"VRS-317 Single injection SC of dose level 1 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume"
3177111|NCT01359488|Experimental|VRS-317 Safety Arm 2|"VRS-317 Single injection SC of dose level 2 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume"
3177112|NCT01359488|Experimental|VRS-317 Safety Arm 3|"VRS-317 Single injection SC of dose level 3 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume"
3177113|NCT01359488|Experimental|VRS-317 Safety Arm 4|"VRS-317 Two injections SC of dose level 4 (based on 90 kg patient)~Placebo Two SC injection Dose matched to treatment volume"
3177114|NCT01359488|Experimental|VRS-317 Safety Arm 5|"VRS-317 Two injections SC of dose level 5 (based on 90 kg patient)~Placebo Two SC injections Dose Volume matched to active treatment volume"
3177115|NCT01359475|Experimental|Acetal crown|Clinical performance of acetal crowns for treatment of primary molars
3177116|NCT01359462|Experimental|Tolvaptan 15mg tablet|
3177117|NCT01359449|Experimental|Menactra® Vaccine Group|Meningococcal vaccine naive participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate vaccine (Menactra®) at 12 months of age and at 18 months of age concomitantly with routine vaccines administered as per provincial schedule
3177118|NCT01359449|Active Comparator|Menjugate® Vaccine Group|Meningococcal vaccine naive participants will receive MenC vaccine (Menjugate) given concomitantly at 12 months of age with routine vaccines administered as per provincial schedule.
3177119|NCT01359436|Experimental|Electrosensing antibody probing system (e- Ab sensing)|
3177120|NCT01359423|Experimental|long coverage|Primary long full coverage stenting
3177121|NCT01359423|Active Comparator|short spot|primary short spot stenting
3177122|NCT01359410|Active Comparator|Stapled transection with mesh reinforcement|Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)
3177123|NCT01359410|No Intervention|Stapled transection without mesh reinforcement|
3177124|NCT01359397|Active Comparator|Herceptin -|
3177125|NCT01359397|Experimental|Herceptin +|
3177126|NCT01359384||affected patients|25 patients suffering from severe immune deficiency under immunoglobulin therapy
3177127|NCT01359384||non-affected patients|25 matched controls not suffering from severe immune deficiency
3177128|NCT01359371||Volunteer Telephone Cessation Couseling|The cohort is discharged veteran smokers who received the standard-of-care Tobacco Tactics intervention while in the hospital.
3177129|NCT01359345|Experimental|A|The patients with renal failure in whom Gadollinume has being used
3177130|NCT01359332|Experimental|hypothermia|
3177131|NCT01359332|No Intervention|control|
3177132|NCT01359319|Experimental|650 mg (single dose only)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
3177133|NCT01359319|Experimental|1,950 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
3177353|NCT01357850|Placebo Comparator|GSK716155-matched placebo|GSK716155-matcued placebo
3177134|NCT01359319|Experimental|2,925 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
3177135|NCT01359319|Experimental|4,875 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
3177136|NCT01359319|Experimental|6,000 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
3177137|NCT01359280|Experimental|Adherence Counseling + Text Messages|Participants receive one office-based adherence counseling session and 4 phone-delivered counseling sessions focused on antiretroviral adherence strategies using a model of behavioral self regulation skills building. Participants also receive follow-up medication reminder text messages delivered by cell phone.
3177138|NCT01359280|Experimental|Adherence Counseling Only|Participants receive one office-based adherence counseling session and 4 phone-delivered counseling sessions focused on antiretroviral adherence strategies using a model of behavioral self regulation skills building.
3177139|NCT01359280|Placebo Comparator|General Health Counseling Only|Participants receive one office-based counseling session and 4 phone-delivered counseling sessions focused on general health and nutrition strategies using a model of behavioral self regulation skills building.
3177140|NCT01359280|Placebo Comparator|General Health Messages + Text Messages|Participants receive one office-based counseling session and 4 phone-delivered counseling sessions focused on general health and nutrition strategies using a model of behavioral self regulation skills building. Participants also receive follow-up medication reminder text messages delivered by cell phone.
3177141|NCT01359267|Experimental|Imaging|
3177142|NCT01359254|Experimental|Conditioning Regimen I|Arm I contains fludarabine, melphalan, and antithymocyte globulin (ATG)
3177143|NCT01359254|Experimental|Conditioning Regimen II|Arm II contains fludarabine, busulfan, antithymocyte globulin (ATG), and total body irradiation (TBI).
3177144|NCT01359241|Experimental|closed-loop insulin delivery|Subcutaneous insulin delivery adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
3177145|NCT01359241|Active Comparator|Usual diabetes treatment regimen|Usual non-insulin glucose-lowering medications
3177146|NCT01359228|Experimental|Rifaximin|rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
3177147|NCT01359228|Placebo Comparator|sugar pill|Placebo 1 tablet three times a day for 14 days.
3177148|NCT01359215||Treatment|Children who received an anesthetic prior to age 2
3177149|NCT01359215||Control|Children who have never been anesthetized
3177150|NCT01359202|Active Comparator|Niastase RT|Niastase RT 80ug/kg IV bolus
3177151|NCT01359202|Placebo Comparator|Placebo|saline IV bolus
3177152|NCT01359189|Experimental|Suspected Primary Prostate Cancer|Patients with suspected prostate cancer will be evaluated for initial proof of concept and feasibility of a scintigraphic rectal probe (ProxiScanTM) utilizing a PSMA receptor radiopharmaceutical (ProstaScint®). To explore the adjunctive benefit/feasibility of PSMA distribution in the normal prostate versus prostate cancer gland utilizing TRUS and CT/SPECT hybrid imaging, biopsy negative patients will be considered as normal controls. This is an exploratory, open label trial and randomization is not required. Subject blinding is not needed and investigator blinding in not possible.
3177153|NCT01359176||Healthy volunteers|
3177154|NCT01359163|Active Comparator|Femulen commercial tablets|
3177155|NCT01359163|Experimental|Femulen reformulated tablets|
3177156|NCT01359150|Experimental|Treatment Group 1: 10 mg BID CP-690,550 (100 subjects).|CP-690,550 will be administered for 4 weeks, vaccines will be administered at week 4. CP-690,550 will then continue for another 5 weeks at which point the immune response will be evaluated.
3177157|NCT01359150|Placebo Comparator|Treatment Group 2:Placebo CP-690,550 (100 subjects).|Placebo will be administered for 4 weeks, vaccines will be administered at week 4. Placebo will then continue for another 5 weeks at which point the immune response will be evaluated.
3177158|NCT01359137|Experimental|Probation as usual|Routine supervision with no deferred jail condition.
3177159|NCT01359137|Experimental|Deferred jail|Discretionary deferred jail in response to violations of probation conditions.
3177160|NCT01359137|Experimental|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) which uses non-discretionary brief jail sanctions for probation violations.
3177161|NCT01359124||Water Treadmill|These subjects will participate in three monitored exercise sessions per week for 8 weeks using a water-based treadmill.
3177162|NCT01359124||Land Treadmill|These subjects will participate in three monitored exercise sessions per week for 8 weeks using a land-based treadmill.
3177163|NCT01359124||Exercise Cycle|These subjects will participate in three monitored exercise sessions per week for 8 weeks using an upright exercise cycle.
3177164|NCT01359098|Active Comparator|Ciprodex Otic Suspension|Ciprodex Sterile Otic Solution (Alcon, Inc.)
3177165|NCT01359098|Experimental|Ciprodexa Otic Foam|Ciprodexa Otic Foam (0.3% Ciprofloxacin, 0.1% Dexamethasone otic foam)
3177166|NCT01359085|Active Comparator|Pregabalin|
3177167|NCT01359085|Active Comparator|ISBPB|Interscalene brachial plexus block
3177168|NCT01359072|Experimental|Immediate Intervention Treatment|
3177169|NCT01359072|Experimental|Wait list|
3177170|NCT01359059|Active Comparator|IV-PCA (Patient-controlled analgesia) morphine|
3177171|NCT01359059|Active Comparator|Patient controlled epidural analgesia (PCEA) fentanyl|
3177172|NCT01359046|Experimental|silver SPC|Subjects randomized to receive silver-impregnated SPC.
3177173|NCT01359046|Active Comparator|standard SPC|subjects randomized to receive standard SPC.
3177174|NCT01359033||MINAP cohort|The Myocardial Ischaemia National Audit Project (MINAP) was established in 1999, in response to the national service framework (NSF) for coronary heart disease, to examine the quality of management of heart attacks (myocardial infarction) in hospitals in England and Wales.
3177175|NCT01359033||RIKS-HIA cohort|The Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) has been established to record clinical and treatment information for all patients admitted to the coronary care units in Sweden from 1995.
3177176|NCT01359020|Experimental|Ibuprofen|10 milligram per kilo, oral administration
3177177|NCT01359020|Active Comparator|Acetaminophen|10 milligram per kilo, oral administration
3177178|NCT01359020|Active Comparator|Dipyrone|10 milligram per kilo, oral administration
3177179|NCT01359007|Experimental|FOLFIRINOX|Combination of drugs (Irinotecan, Oxaliplatin, Leucovorin, and 5-Fluorouracil (5-FU)) known as FOLFIRINOX every 2 weeks for 4 treatments. At the end of 4 cycles, patients will be re-evaluated for resectability by CT scan within 28 days of the last dose of chemo. If found amendable to surgery, patient will proceed with resection, and type of resection (R0 or R1) will be recorded.
3177180|NCT01358981|Experimental|LY2881835|"Two cohorts of healthy subjects will receive single oral doses of LY2881835 in up to 3 of the 4 periods in Part A (dose escalation: 0.5 mg, 1.5 mg, subsequent doses determined based on review of safety, tolerability, glycaemic response and available pharmacokinetic (PK) data from the first 2 dose levels). One cohort of subjects with Type 2 Diabetes Mellitus (T2DM) will receive single oral doses of LY2881835 in up to 2 of the 3 periods in Part B (dose escalation: starting dose based on review of safety, tolerability, glycaemic response and available PK data from Part A).~There is a washout period of at least 5 days between doses."
3177181|NCT01358981|Placebo Comparator|placebo|"Two cohorts of healthy subjects will receive a single oral dose of placebo in 1 of the 4 periods in Part A. One cohort of subjects with T2DM will receive a single oral dose of placebo in 1 of the 3 periods in Part B.~There is a washout period of at least 5 days between doses."
3177182|NCT01358968|Experimental|LY2603618|"Single 50 mg oral dose of desipramine on day 1 of study period 1. Single 275 mg intravenous infusion of LY2603618 followed by single 50 mg oral dose of desipramine on day 1 of study period 2. Patients may then receive additional doses of LY2603618 in combination as follows: 1000 mg/m^2 intravenous dose of gemcitabine on days 1, 8 and 15 and 230 mg intravenous dose of LY2603618 on days 2, 9 and 16 of 28 day cycles OR 500 mg/m^2 intravenous dose of pemetrexed on day 1 and 275 mg intravenous dose of LY2603618 on day 2 of 21 day cycles.~Patients will be allowed to continue to receive the combination therapy until fulfilling of the criteria for discontinuation, such as unacceptable toxicity or disease progression."
3177183|NCT01358955|Active Comparator|Group cognitive intervention|The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
3177184|NCT01358955|Active Comparator|Home-based cognitive intervention|The participants will do their homework for 30 minutes every business days for 12 weeks.
3177185|NCT01358955|No Intervention|Wait list Control|They will participate in cognitive intervention after ending this study.
3177186|NCT01358942||Cohort|
3177187|NCT01358929|Experimental|1|
3177188|NCT01358929|Placebo Comparator|2|
3177189|NCT01358916|No Intervention|Usual information policy|No specific intervention
3177190|NCT01358916|Other|Antibiotic therapy guidelines|
3177191|NCT01358903|Experimental|A|
3177192|NCT01358903|Experimental|B|
3177193|NCT01358890|Experimental|B|Subjects will be supplied with low carbohydrate diet for 12 weeks.
3177194|NCT01358890|Experimental|A|Subjects will be supplied with calories restricted diet for 12 weeks
3177195|NCT01358877|Experimental|Pertuzumab + Trastuzumab + Chemotherapy|Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m^2 + epirubicin 90-120 mg/m^2 or doxorubicin 50 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m^2 for 3 cycles, 75 mg/m^2 in first cycle and 100 mg/m^2 in subsequent cycles, or 75 mg/m^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m^2 or epirubicin 90-120 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).
3177196|NCT01358877|Placebo Comparator|Placebo + Trastuzumab + Chemotherapy|Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram [mg/kg] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m^2) + epirubicin 90-120 mg/m^2 or doxorubicin 50 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m^2 for 3 cycles, 75 mg/m^2 in first cycle and 100 mg/m^2 in subsequent cycles, or 75 mg/m^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m^2 or epirubicin 90-120 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m^2 + carboplatin AUC 6 (up to 900 milligrams [mg]).
3177197|NCT01358864|Active Comparator|Placebo/PegIFN/RBV|patient to receive two capsules identical to those containing BI201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks
3177198|NCT01358864|Experimental|BI201335 12 weeks|patient to receive two capsules containing BI 201335 once a day for 12 weeks and PegIFN/RBV for 48 weeks
3177199|NCT01358864|Experimental|BI201335 24 weeks|patient to receive two capsules containing BI 201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks
3177200|NCT01358851|Experimental|1|Drug Las41005
3177201|NCT01358851|Other|2|Cryotherapy
3177202|NCT01358838|Active Comparator|laser|
3177203|NCT01358838|No Intervention|no laser|
3177204|NCT01358825|Experimental|Infanrix hexa Group|Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix hexa™ (DTPa-HBV-IPV/Hib) administered intramuscularly in study NCT00307034.
3177205|NCT01358825|Experimental|Infanrix-IPV/Hib Group|Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix-IPV/Hib™ (DTPa-IPV/Hib) administered intramuscularly in study NCT00307034.
3177206|NCT01358812|Experimental|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
3177207|NCT01358786|No Intervention|no quilting sutures but drains|
3177208|NCT01358786|Experimental|quilting sutures and drains|
3177209|NCT01358786|Experimental|quilting sutures but no drains|
3177210|NCT01358773|Other|Lifestyle counseling|Obese adolescents are encouraged to improve their lifestyle
3177211|NCT01358760|Placebo Comparator|Placebo|
3177212|NCT01358760|Experimental|0.25% DHEA|
3177213|NCT01358760|Experimental|0.5% DHEA|
3177214|NCT01358747|Active Comparator|Standard arm|Induction treatment: Patients will be treated by a BEACOPPesc regimen every 3 weeks for 4 cycles. A PET will be performed after 2 cycles of chemotherapy (PET2) with no decisional value, and after 4 cycles with decisional value. Consolidation treatment: depends on the reviewed PET4 result. In case of PET4 negative result, patient will received 2 additional cycles of BEACOPPesc, whatever the result of the PET2. In case of PET4 positive, the patient will be considered in treatment failure and proposed to a salvage therapy after pathologic confirmation of failure by biopsy of the hypermetabolic residual mass when possible.
3177215|NCT01358747|Experimental|Experimental arm|"Induction treatment: Patients will be treated by a BEACOPPesc regimen every 3 weeks for 2 cycles followed by a PET scan (PET2).~After PET2 central review:~In case of positive PET2, the induction treatment will be completed by 2 additional cycles of BEACOPPesc~In case of negative PET2, the induction treatment will be completed by 2 cycles of ABVD delivered every 4 weeks. The first cycle of ABVD will start at day 21 of the second cycle of BEACOPPesc.~Consolidation treatment: depends on the reviewed PET4 result In case of PET4 negative result, consolidation treatment will depends on PET2 results:~If PET2 was positive, patient will received 2 additional cycles of BEACOPPesc delivered every 3 weeks~If PET2 was negative, patient will received 2 additional cycles of ABVD delivered every 4 weeks In case of PET4 positive, the patient will be considered as treatment failure."
3177216|NCT01358734|Experimental|Lenalidomide in combination with azacitidine|Repeated cycles of azacitidine 75 mg/m^2/day subcutaneous (SC) on Days 1-7 and lenalidomide 50 mg/day by mouth (PO) on Days 8-28 followed by a 14-day break plus best supportive care
3177217|NCT01358734|Experimental|Lenalidomide - single agent|Lenalidomide 50 mg PO daily for 28 days for the first 2 cycles and lenalidomide 25 mg daily for 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg daily PO plus best supportive care
3177218|NCT01358734|Experimental|Azacitidine-single agent|Repeated cycles of azacitidine 75mg/m^2/day subcutaneous on Days 1-7 followed by a 21-day break plus best supportive care
3177219|NCT01358721|Experimental|Arm 1: BMS-936558|
3177220|NCT01358721|Experimental|Arm 2: BMS-936558|
3177221|NCT01358721|Experimental|Arm 3: BMS-936558|
3177222|NCT01358721|Experimental|Arm 4: BMS-936558|(treatment naive)
3177223|NCT01358708|Experimental|LACTEOL® 340 mg|
3177224|NCT01358708|Placebo Comparator|PLACEBO|
3177225|NCT01358695|Placebo Comparator|Placebo Comparator|
3177226|NCT01358695|Experimental|Dose 1|Dose 1
3177227|NCT01358695|Experimental|Dose 2|Dose 2
3177228|NCT01358695|Experimental|Dose 3|Dose 3
3177229|NCT01358695|Experimental|Dose 4|Dose 4
3177230|NCT01358695|Experimental|Dose 5|Dose 5
3177231|NCT01358669|Active Comparator|Denosumab|In this study we explore the potential for giving a medication (denosumab) that may prevent the loss of bone around the hip replacement implant
3177232|NCT01358669|Placebo Comparator|Placebo|Placebo
3177233|NCT01358656|Active Comparator|Single Bundle Reconstruction|Subjects will undergo single bundle acl reconstruction
3177234|NCT01358656|Active Comparator|Double bundle reconstruction|Subjects will undergo double bundle acl reconstruction
3177235|NCT01358643|Other|P90X + Sparkpeople|"For six weeks of the study participants will use the P90X tools and for the other six weeks participants will use Sparkpeople tools.~Sparkpeople is a web based diet and exercise program in which the participant can track their diet and exercise progress and read and post messages to a large online community of others who are also trying to lose weight.~P90X is A DVD based home exercise program that guides the participant through a daily exercise routine."
3177236|NCT01358643|Other|P90X + BodyMedia Fit|"For six weeks participants will use the P90X tools and for the other six weeks participants will use the BodyMedia Fit Device.~P90X is a DVD based home exercise program that guides the participant through a daily exercise routine.~BodyMedia Fit is a program in which the participants wears a small device on their arm that measures their physical activity and allows you to upload detailed physical activity data to a web site to help them track your progress."
3177237|NCT01358643|Other|BodyMedia Fit + Sparkpeople|"For six weeks participants will use the BodyMedia Fit devise and for the other six weeks participants will use the Sparkpeople program.~BodyMedia Fit is a program in which the participants wears a small device on their arm that measures their physical activity and allows you to upload detailed physical activity data to a web site to help them track your progress.~Sparkpeople is A web based diet and exercise program in which the participant can track their diet and exercise progress and read and post messages to a large online community of others who are also trying to lose weight"
3177238|NCT01358617||Biomarker analysis|Archived tissue microarray samples are analyzed for ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) expression by UCHL1 monoclonal antibody and peroxidase technique.
3177239|NCT01358591|Sham Comparator|Control Breakfast|Normal calcium breakfast.
3177240|NCT01358591|Experimental|High calcium breakfast|High calcium breakfast.
3177241|NCT01358578|Experimental|AIN457 150mg|AIN457 150mg
3177242|NCT01358578|Experimental|AIN457 300mg|AIN457 300mg
3177243|NCT01358578|Placebo Comparator|Placebo|Placebo
3177244|NCT01358578|Active Comparator|Etanercept|Etanercept
3177245|NCT01358578|Experimental|AIN457 150mg from Placebo|Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase
3177355|NCT01357837|Experimental|75 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
3177246|NCT01358578|Experimental|AIN457 300mg from Placebo|Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase
3177247|NCT01358565|Active Comparator|Mild and Moderate Hepatic Dysfunction|Patients with mild and moderate hepatic dysfunction
3177248|NCT01358565|Active Comparator|Healthy Volunteers|Healthy volunteers
3177249|NCT01358552||Néevo®/NéevoDHA®|Subjects who have been prescribed Néevo/NéevoDHA® daily.
3177250|NCT01358539|Experimental|Pain education|Patients receiving pain education
3177251|NCT01358539|No Intervention|No Pain education|Control group, patients receiving no pain education
3177252|NCT01358526|Experimental|OXN|Oxycodone/Naloxone Controlled-release Tablets (OXN)
3177253|NCT01358526|Placebo Comparator|Placebo|Placebo tablets to match OXN
3177254|NCT01358513||Control Patients|Patients with normal aortic valves
3177255|NCT01358513||Aortic sclerosis|To undergo PET imaging and follow up with CT and echo for 2 years
3177256|NCT01358513||Mild Aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
3177257|NCT01358513||Moderate Aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
3177258|NCT01358513||Severe aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
3177259|NCT01358500|Experimental|Fentanyl|
3177260|NCT01358487|Active Comparator|Online self-help mood management course|Online self-help mood management course based on cognitive behavioral therapy and social cognitive theory, plus automated online follow ups using email reminders and incentives for completing follow-ups
3177261|NCT01358487|Experimental|Online self-help course plus live follow-up if needed|Intervention and automated follow ups with incentives as in the active comparator condition. The experimental procedure is adding live phone follow-ups if participant does not complete online assessment surveys at 1, 3, and 6 months in response to automated emails.
3177262|NCT01358474||PD Subjects|Subjects diagnosed with Parkinson's disease (PD)
3177263|NCT01358474||At-risk for PD|Subjects at-risk for developing PD (e.g., those with idiopathic rapid eye movement sleep disorder (iRBD) and those who are heterozygous or homozygous for Gaucher's disease (GBA) mutations)
3177264|NCT01358474||Healthy Controls|Healthy volunteers
3177265|NCT01358461||Patients with vagal syncopes|Patients with vagal syncopes (n=120 : 60 adults & 60 children)
3177266|NCT01358461||Subjects controls without vagal syncopes|Subjects controls without vagal syncopes (n=120:60 adults & 60 children
3177267|NCT01358448|No Intervention|Newsletter|
3177268|NCT01358448|Experimental|Growth Monitoring|
3177269|NCT01358448|Experimental|Growth Monitoring plus Family-based Behavioral Counseling|
3177270|NCT01358435|Experimental|Wosulin 70/30|Wosulin 70N /30R is a recombinant Human Insulin with 30 % Regular Insulin Human Neutral and 70% Isophane Insulin, 600 nmol/ml, 100 IU/ml.
3177271|NCT01358435|Active Comparator|Novolin 70/30|Novolin 70/30 is a Recombinant Human Insulin with 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection
3177272|NCT01358422||In Patients|
3177273|NCT01358409|Experimental|Nebivolol|Nebivolol (Bystolic® by Forest/Mylan) is a third-generation beta-blocker; it selectively blocks β1-adrenergic receptors and increases peripheral vasodilation.
3177274|NCT01358396||HBA1c|
3177275|NCT01358357|Experimental|Lurasidone 20-80 mg flexible dose|
3177276|NCT01358357|Placebo Comparator|Placebo|
3177277|NCT01358344|Experimental|Standard Percentage|
3177278|NCT01358344|Experimental|High Percentage|
3177279|NCT01358331|Experimental|MK-8353|capsules, orally administered every day in 28-day cycles
3177280|NCT01358318|Placebo Comparator|Control|
3177281|NCT01358318|Experimental|Soy Protein|
3177282|NCT01358318|Experimental|Soy Fiber|
3177283|NCT01358318|Experimental|Soy Protein and Soy Fiber|
3177284|NCT01358305|Active Comparator|Whey Protein Isolate|
3177285|NCT01358305|Experimental|Protein Blend (soy, whey and casein)|
3177286|NCT01358292|Experimental|Semi-extended surgical technique|The experimental technique for implanting an intramedullary tibia nail is with the knee in 10-20 degrees of flexion.
3177287|NCT01358292|Active Comparator|Standard Surgical Technique|The standard surgical technique in intramedullary tibia nailing is with the knee in almost 90 degrees of flexion.
3177288|NCT01358279|Experimental|migraine|
3177289|NCT01358266|Active Comparator|Ophthalmic solution low dose|
3177290|NCT01358266|Active Comparator|Ophthalmic solution medium dose|
3177291|NCT01358266|Active Comparator|Ophthalmic solution high dose|
3177292|NCT01358253|Active Comparator|HyperCVAD|"Consolidation:~HyperCVAD(odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses.~Maintenance:~6-Mercaptopurine+Methotrexate for 24 months. Vincristine+Prednisone for the first 12 months. L-asparaginase in month 3 and 9."
3177293|NCT01358253|Experimental|R-HyperCVAD|"Consolidation:~R-HyperCVAD(odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses.~Maintenance:~6-Mercaptopurine+Methotrexate for 24 months. Vincristine+Prednisone for the first 12 months. L-asparaginase in month 3 and 9. Rituximab in month 6 and 12."
3177294|NCT01358240|Experimental|Econazole Nitrate Foam 1%|Study medication
3177295|NCT01358240|Placebo Comparator|Vehicle Foam|Placebo medication
3177296|NCT01358240|Active Comparator|Econazole Nitrate Cream 1%|Econazole Nitrate Cream 1%
3177297|NCT01358240|Sham Comparator|Placebo Cream|Placebo Cream
3177298|NCT01358227|Experimental|PR104|
3177299|NCT01358214||Patients treated with a surgical mesh|This arm of study patients is defined by patients treated with a TiLOOP® Tape mesh between 2007 and 2009 at the Franziskus Krankenhaus, Berlin. The sample of the treated population represents the patient population for which the medical device is intended. To minimize selection bias without compromising patients' rights and welfare, all treated patients will be invited. These patients will be asked to participate in the validation of the questionnaire on quality of life. In addition to this safety and effectiveness of the surgical mesh implantation will be collected
3177354|NCT01357837|Placebo Comparator|Matching Placebo|Once daily oral administration of matching placebo for 4 weeks.
3177300|NCT01358214||Intended to be treated with a mesh|This arm of the study populations is defined by patients in whom a clinical anamnesis independent of the requirements of this study suggests that a sub-urethral sling operation is indicated. These patients will be asked to participate in the validation of the questionnaire on quality of life.
3177301|NCT01358214||Non-symptomatic Population|This arm of the study population is defined by women that show no symptoms of incontinence. They will be asked to participate in the validation of the questionnaire on quality of life.
3177302|NCT01358188||Gaucher disease group|Subjects will include individuals with GD
3177303|NCT01358188||Control group|Controls will include healthy individuals and individuals with primary immune dysfunction
3177304|NCT01358175|Experimental|Secukinumab 10 mg/kg i.v. / 75 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
3177305|NCT01358175|Experimental|Secukinumab 10 mg/kg i.v. / 150 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
3177306|NCT01358175|Placebo Comparator|Placebo|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
3177307|NCT01358162|Experimental|SQ109|300 mg of SQ109, orally, given daily for 14 consecutive days
3177308|NCT01358162|Placebo Comparator|Placebo|Placebo given orally, daily for 14 consecutive days
3177309|NCT01358149|Placebo Comparator|placebo|cocoa-based food 1
3177310|NCT01358149|Active Comparator|Treatment 1|cocoa-based food 2
3177311|NCT01358136||Hemithyroidectomy|Patients with benign nontoxic goiter who have an indication for hemithyroidectomy
3177312|NCT01358110|Experimental|Early palliative care consultation|Early palliative care consultation for ED patients with advanced cancer.
3177313|NCT01358110|Other|Care as usual|Care as usual, may or may not receive palliative care consultation
3177314|NCT01358097||Patients with HPV positive tumors|
3177315|NCT01358097||Patients with HPV negative tumors|
3177316|NCT01358097||Control|
3177317|NCT01358084|Experimental|Arm A: NGR-hTNF + Best Supportive Care|NGR-hTNF + Best Supportive Care
3177318|NCT01358084|Placebo Comparator|Arm B: Placebo + Best Supportive Care|Placebo + Best Supportive Care
3177319|NCT01358071|Experimental|Arm A: NGR-hTNF+ anthracycline|NGR-hTNF+Pegylated Liposomal Doxorubicin or Doxorubicin
3177320|NCT01358071|Active Comparator|Arm B: anthracycline|Pegylated Liposomal Doxorubicin or Doxorubicin
3177321|NCT01358058|Experimental|Proton radiation therapy|Single arm study delivering fractionated proton therapy over 6 week (54-59.4 Gy(RBE))
3177322|NCT01358045|Active Comparator|Solaraze|
3177323|NCT01358045|Active Comparator|Solaraze + Silkis|
3177324|NCT01358045|Active Comparator|Silkis|
3177325|NCT01358045|No Intervention|No treatment|
3177326|NCT01358032|Experimental|Cognitive behavioral program|an in-home cognitive behavioral program on managing concerns about falling and associated activity avoidance in frail community-dwelling older people facilitated by trained community nurses.
3177327|NCT01358032|No Intervention|Control group|no program, only care as usual
3177328|NCT01358019|Experimental|LY2523355|
3177329|NCT01358006|Experimental|001|JNJ-40411813 Cohort 1: Type=2 to 3 unit=mg number=200 to 300 form=capsule route=oral use.Capsule(s) taken in the fed state Capsule(s) taken in the fed state.,JNJ-40411813 Cohort 2: Type=up to 7 unit=mg number=up to 700 mg form=capsule route=oral use. Capsule(s) taken in the fed state.
3177330|NCT01357993|Experimental|001|JNS001 18 mg 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
3177331|NCT01357980|Experimental|Dysport 750 U (15 injection sites)|
3177332|NCT01357980|Placebo Comparator|Placebo (15 injection sites)|
3177333|NCT01357980|Experimental|Dysport 750 U (30 injection sites)|
3177334|NCT01357980|Placebo Comparator|Placebo (30 injection sites)|
3177335|NCT01357967|Experimental|Seroquel XR adjunctive|"The quetiapine XR adjunct group will be titrated up to 300mg. Initial dosing will begin at 50mg on Day 1 and 2, increased to 150mg on Day 3 and 4. Further adjustments will be able to be made upwards or downwards within the recommended dose range of 50mg to 300mg depending upon the clinical response and tolerance of the patient. Seroquel XR will be administered daily in the evening.~The dosage of SSRIs will be maintained as low (es-citalopram 5mg, paxil CR 6.25mg, fluoxetine 10mg, and sertraline 25mg)."
3177336|NCT01357967|Active Comparator|SSRI monotherapy|active comparator
3177337|NCT01357954|Experimental|Targeted Training|
3177338|NCT01357954|Other|Control|
3177339|NCT01357941||Prior VTE minor transient risk factor|Pregnant women with a single prior VTE episode that was either unprovoked or associated with a minor transient risk factor - Prophylaxis with fixed-dose LMWH
3177340|NCT01357941||Prior VTE major transient risk factor|Pregnant women with a single prior VTE episode that was provoked by a major transient risk factor - Surveillance
3177341|NCT01357928||Healthy Volunteers|
3177342|NCT01357915|Experimental|GSK149203A S- Group|Male subjects who received 3 doses of GSK Biologicals' candidate GSK149203A vaccine according to a 0-1-6 month schedule in the primary study 108890 (NCT00435396).
3177343|NCT01357915|Other|GSK149203A S+ Group|Male subjects who were assessed as being naturally infected with Cytomegalovirus (CMV) at the screening visit of the primary study 108890 (NCT00435396).
3177344|NCT01357902|Experimental|Lamictal|Chinese healthy male subjects were randomized to receive single dose of either 5 mg lamotrigine dispersible/chewable tablets or 25mg compressed/standard tablets.
3177345|NCT01357889|Active Comparator|process 2 albiglutide|albiglutide 30mg from process 2 drug substance
3177346|NCT01357889|Active Comparator|process 3 albiglutide|albiglutide 30mg from process 3 drug substance
3177347|NCT01357876|Other|Type two diabetics|Type two diabetics
3177348|NCT01357863||Patients on second line treatment|Patients treated with Lapatinib-capecitabine immediately after first Trastuzumab-containing regimen progression
3177349|NCT01357863||Patients on third or more lines treatment|Patients treated with Lapatinib-capecitabine after 2 or more lines of treatment after first Trastuzumab-containing regimen progression
3177350|NCT01357850|Experimental|GSK716155 (3.75mg)|GSK716155 (3.75mg)
3177351|NCT01357850|Experimental|GSK716155 (15mg)|GSK716155 (15mg)
3177352|NCT01357850|Experimental|GSK716155 (30mg)|GSK716155 (30mg)
3177356|NCT01357837|Experimental|200 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
3177357|NCT01357837|Experimental|400 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
3177358|NCT01357824||Patients admitted for elective surgery|The patient admitted for elective surgery can be included, and will both the case and control, as we intubate the same patient twice, with and without Sellick´s maneuver.
3177359|NCT01357811|Active Comparator|digoxin|
3177360|NCT01357811|Experimental|eliglustat with digoxin|
3177361|NCT01357798|Active Comparator|Btx-A: Active Comparator|Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
3177362|NCT01357798|Placebo Comparator|Placebo Comparator|0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
3177363|NCT01357772|Experimental|Tamoxifen|tamoxifen at daily dose of 5 mg for a total treatment time of 3 years
3177364|NCT01357772|Placebo Comparator|placebo|placebo at daily dose of 5 mg for a total treatment time of 3 years
3177365|NCT01357759|Experimental|Escalating doses of MORAb-022|Subjects with RA will be randomized into Cohorts 8 to 11, with each cohort consisting of five RA subjects per cohort (four active and one placebo).
3177366|NCT01357759|Placebo Comparator|Placebo|Subjects with RA will be also randomized into Cohorts 8 to 11, with each cohort consisting of five RA subjects per cohort (four active and one placebo).
3177367|NCT01357733|Other|Interim FDG PET/CT|Single arm study with diagnostic imaging study as the intervention.
3177368|NCT01357720|Experimental|Quinvaxem|
3177369|NCT01357720|Active Comparator|Tritanrix Hib/HepB + Quinvaxem|
3177370|NCT01357707||West Syndrome (idiopathic)|Patients with idiopathic infantile seizures
3177371|NCT01357694|Experimental|psychotherapeutic contacts|
3177372|NCT01357694|No Intervention|control group|
3177373|NCT01357681|Experimental|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) p.o. Month 02:800 mg /day (400-0-400) p.o. Month 03 -12: 1200 mg /day (600-0-600) p.o.
3177374|NCT01357681|Placebo Comparator|Placebo|Placebo
3177375|NCT01357668||Patients with JIA who are treated with Abatacept|Patients with JIA who are treated with Abatacept according to physicians'/families' decisions
3177376|NCT01357655|Active Comparator|Arm 1: Dasatinib|
3177377|NCT01357655|Experimental|Arm2: Dasatinib + BMS-833923|Dasatinib for 1 year followed by dasatinib plus BMS-833923 for 2 years followed by dasatinib alone for approximately 2 years; depending on response
3177378|NCT01357642|Experimental|Arm T|Arm T is the experimental treatment arm consisting of 2 x 125 mcg/inhalations of E004, QID, with 4-6 hr intervals
3177379|NCT01357642|Placebo Comparator|Arm P|Placebo comparator as 2×Placebo QID, with 4-6 hr intervals
3177380|NCT01357642|Active Comparator|Arm A|Active comparator, Primatene Mist, 2×220 mcg/inhalation, QID, with 4-6 hr intervals
3177381|NCT01357616|Experimental|AZARGA|Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension, 1 drop in the affected eye(s) dosed twice daily (9AM and 9PM) for 8 weeks. Both eyes were dosed unless there was a potential safety issue to the patient in the opinion of the Investigator.
3177382|NCT01357616|Active Comparator|AZOPT + Timolol|Brinzolamide 1% ophthalmic suspension, 1 drop instilled in the affected eye(s), followed by Timolol 0.5% ophthalmic solution, 1 drop instilled in the affected eye(s). Approximately 10 minutes separated the 2 instillations. The study drugs were instilled twice daily (9AM and 9PM) for 8 weeks. Both eyes were dosed unless there was a potential safety issue to the patient in the opinion of the Investigator.
3177383|NCT01357603|Experimental|Glaritus arm|Insulin glargine (Glaritus: 100 U/ml), Penfill® cartridges 3.0ml
3177384|NCT01357603|Active Comparator|Lantus arm|Insulin glargine (Lantus: 100 U/ml), Penfill® cartridges 3.0ml
3177385|NCT01357577|Experimental|Arm 1: TAU + CBT|The experimental group will receive treatment as usual (TAU) plus cognitive behavioral therapy (CBT).
3177386|NCT01357577|No Intervention|Arm 2: TAU|"The no intervention group will receive treatment as usual (TAU)."
3177387|NCT01357564|Other|Arm 1|Comparison of attention control versus customized intervention activity.
3177388|NCT01357551|Experimental|Maintenance intervention|Participants receive a theoretically-informed maintenance intervention for 42 weeks, followed by 14 weeks of no intervention contact to examine sustainability. The maintenance intervention involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
3177389|NCT01357551|No Intervention|Usual care|Participants receive usual care for 56 weeks
3177390|NCT01357538|Active Comparator|Posiformin 2 %|Eye ointment applied to the eye lid
3177391|NCT01357538|Placebo Comparator|Placebo|corresponding vehicle, eye ointment applied to the eye lid
3177392|NCT01357525|Other|Stereotactic Body Radiotherapy|
3177393|NCT01357512|Experimental|MRI done|Subjects with MRI prior prostate biopsies
3177394|NCT01357512|No Intervention|no MRI|No MRI before prostate biopsies
3177395|NCT01357499||control group|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg but without inflating the cuff and without stimulating the muscle. Now 25 minutes will have to pass by before beginning the coronary angioplasty.
3177396|NCT01357499||intervention group 1|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. There will be no electrical muscle stimulation in this group.
3177397|NCT01357499||intervention group 2|A Blood pressure cuff and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle
3177398|NCT01357486|Experimental|A|patients receiving sorafenib 400 mg - twice a day
3177399|NCT01357486|Experimental|B|patients receiving pravastatin 40 mg - once a day
3177400|NCT01357486|Experimental|C|patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
3177401|NCT01357486|Other|D|patients receiving best supportive care
3177402|NCT01357447|Experimental|Dornase alfa (Pulmozyme)|Dornase alfa is a highly purified solution of recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.
3177403|NCT01357447|Placebo Comparator|Saline|Normal saline 0.9% solution
3177404|NCT01357434||Adolescents|Participants 12-21 years old.
3177405|NCT01357421|Experimental|TT301|Investigational drug TT301
3177406|NCT01357421|Placebo Comparator|Placebo|Normal saline
3177407|NCT01357408||REVEAL XT device|Subjects implanted at time of admission for HF or to be implanted within 14 days of discharge from HF hospitalization for clinical indications>
3177408|NCT01357395|Experimental|Amuvatinib|Amuvatinib 300 mg PO TID + standard-of-care platinum-etoposide
3177409|NCT01357382|No Intervention|low fat diet|replace high fat, energy dense foods with foods rich in whole grains, fruits and vegetables. The macronutrient distribution of this diet will be approximately 55% carbohydrate, 15% protein and 30% fat. Individuals will also be instructed to reduce sodium intake to < 2300 mg / day and in individuals with hypertension, < 1500 mg / day.
3177410|NCT01357382|Experimental|low carbohydrate diet|restrict carbohydrate consumption to < 20 grams / day while not restricting caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' to increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
3177411|NCT01357369||Ondansetron/Cefazolin treatment|Pregnant women undergoing uncomplicated cesarean section deliveries who have consented to participate, and will receive Ondansetron and Cefazolin in the course of their clinical care will have PK blood samples drawn.
3177412|NCT01357356|Experimental|SER120 (750 ng/day)|SER120 (750 ng/day)
3177413|NCT01357356|Experimental|SER120 (1000 ng/day)|SER120 (1000 ng/day)
3177414|NCT01357356|Experimental|SER120 (1500 ng/day)|SER120 (1500 ng/day)
3177415|NCT01357356|Placebo Comparator|Placebo|Placebo
3177416|NCT01357343|Active Comparator|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping
3177417|NCT01357343|Active Comparator|Chiropractic care|Chiropractic adjustments and active and passive physical modalities.
3177418|NCT01357343|Active Comparator|Integrated Chiropractic and Acupuncture|
3177419|NCT01357330|Experimental|Dose Escalation|Dose escalation phase The starting dose of SAR245408 will be 25-mg once daily (up to 200-mg). The starting dose of MSC1936369B will be 15- mg once daily (up to 90-mg)
3177420|NCT01357317|Active Comparator|Lanthanum Carbonate|Lanthanum Carbonate: initial dose 500 mg TID with meals, titrated at monthly intervals in 500 mg increments or decrements, with goal of returning to normal the level of the abnormal baseline marker(s) of phosphorus homeostasis (serum phosphorus, PTH or TRP). Normality for this marker will be defined as serum phosphorus of 2.6-4.6 mg/dl, PTH of 10-65pg/ml and TRP>=80%.
3177421|NCT01357317|Active Comparator|Calcium Acetate|Calcium Acetate: initial dose 667 mg TID with meals, titrated at monthly intervals in 667 mg increments or decrements, with goal of returning to normal the level of the abnormal baseline marker(s) of phosphorus homeostasis. The maximum daily intake of elemental calcium should not exceed 1500 mg in order to comply w/recommendations from K-DOQI [5](this is approximately equal to three 667mg tablets of calcium acetate TID).
3177422|NCT01357317|Active Comparator|Dietary instructions|Dietary instructions consisting of pamphlets describing foods high in phosphorus and consultation with a renal dietitian if necessary, with the goal of return to normal the level of the abnormal marker of phosphorus homeostasis. Rescue therapy with a phosphorus binder of the treating physician's choice will be allowed in patients who fail to normalize elevated baseline serum phosphorus levels after 3 months following dietary instructions.
3177423|NCT01357304|Experimental|Group treatment and PAR|
3177424|NCT01357304|No Intervention|Usual care|
3177425|NCT01357291|Experimental|Recidivism Reduction Program|Inmates who were assigned to the RRP intervention.
3177426|NCT01357291|Active Comparator|Business-as-usual|Business-as-usual are those inmates not assigned to RRP and who receive standard inmate programming.
3177427|NCT01357278|Experimental|Rehabilitation and patient education|"Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.~Patient education will be offered every eight week."
3177428|NCT01357278|No Intervention|Patient education|Patient education will be offered every eight week.
3177429|NCT01357265|Other|1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
3177430|NCT01357252|Experimental|vildagliptin|
3177431|NCT01357252|Placebo Comparator|placebo|
3177432|NCT01357239|Experimental|25 mg bid|
3177433|NCT01357239|Experimental|50 mg bid|
3177434|NCT01357239|Experimental|100 mg bid|
3177435|NCT01357239|Placebo Comparator|Placebo|
3177436|NCT01357226||All patients over the age of 18|
3177437|NCT01357213|Placebo Comparator|Arm 2|Placebo in all three cohorts
3177438|NCT01357213|Experimental|Arm 1|XOMA 3AB in 3 dose levels/cohorts A, B or C.
3177439|NCT01357200||critically ill obese adults|Age ≥ 18 years, body mass index (BMI) ≥ 30, in intensive care unit (ICU) requiring tube feeding ≥ 3 days
3177440|NCT01357187|Other|Control|
3177441|NCT01357187|Experimental|Treatment|
3177442|NCT01357174||All Participants|Infants who were vaccinated with ROTATEQ™
3177443|NCT01357161|Experimental|Part 1: MK-1775 225 mg + paclitaxel +carboplatin|During the open-label run-in, participants receive 225 mg MK-1775 twice daily (BID) starting on Day 1 of Cycle 1 (cycle=21 days) for a total of 5 doses. Participants receive MK-1775 in combination with paclitaxel (175 mg/m2) and carboplatin (area under the curve [AUC] 5).
3177444|NCT01357161|Experimental|Part 2: MK-1775 225 mg + paclitaxel +carboplatin|During Part 2, participants receive 225 mg MK-1775 BID starting on Day 1 of each 21 day cycle for a total of 5 doses. Participants receive MK-1775 in combination with paclitaxel (175 mg/m2) and carboplatin (AUC 5).
3177445|NCT01357161|Placebo Comparator|Part 2: Placebo + paclitaxel +carboplatin|During Part 2, participants receive matched placebo to MK-1775 BID starting on Day 1 of each 21 day cycle for a total of 5 doses. Participants receive placebo in combination with paclitaxel (175 mg/m2) and carboplatin (AUC 5).
3177446|NCT01357148||Participants treated with sitagliptin phosphate/metformin HCl|
3177599|NCT01356095|No Intervention|Control|
3177447|NCT01357135||Metformin + Sitagliptin|Participants taking metformin + sitagliptin (Januvia®/Xelevia®) as prescribed in routine clinical practice.
3177448|NCT01357135||Metformin + Sulfonylurea|Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride.
3177449|NCT01357135||Sitagliptin +/- Other Antihyperglycemic Medication|Participants taking sitagliptin +/- other antihyperglycemic medication (other than metformin) as prescribed in routine clinical practice. These other antihyperglycemic medications could include: insulin, glinides, sulfonylurea, glitazone, an alpha-glucosidase inhibitor, or combinations thereof.
3177450|NCT01357122|Experimental|NCI Insertion|
3177451|NCT01357122|Active Comparator|Standard Forceps Insertion|
3177452|NCT01357109|Experimental|Bosentan|
3177453|NCT01357109|Placebo Comparator|Placebo|
3177454|NCT01357096|No Intervention|Comparison group|
3177455|NCT01357096|Experimental|Integrated health care team|
3177456|NCT01357083||Major Depression Disorder|This study is analytical cross-sectional and randomized. Two groups of depressed patients and healthy subjects were selected.The individual were submitted to a medical examination, and responded to the Beck depression inventory (BDII-II). Those, who got a score above 20, were included in the depressed group. Among this group, 50 patients were chosen randomly. those who obtained a depressive score below 9, 50 of them were chosen and they were included in the healthy group. The control group was chosen to match to the depressed patients for education, social occasion, occupational and economical situation. All of the subjects were interviewed psychiatrically, and the depression disorder was confirmed on the basis of the DSM criteria. eight out of 50 depressed patients were excluded from the study due to suffering from other psychiatric disorders .
3177457|NCT01357070|Active Comparator|Brocco-sprout homogenate|
3177458|NCT01357070|Sham Comparator|Alfalfa sprout homogenate|
3177459|NCT01357057||Derivation cohort|Arm 1: Derivation cohort (from 2003 to 2007)
3177460|NCT01357057||Validation cohort|Arm 2: Validation cohort (from 2008 to 2009)
3177461|NCT01357044|Active Comparator|Plant extracts|
3177462|NCT01357044|Placebo Comparator|Placebo|
3177463|NCT01357031|Experimental|Melatonin|Melatonin 3 mg at bedtime
3177464|NCT01357031|Placebo Comparator|Placebo|Placebo
3177465|NCT01357031|Active Comparator|Amitriptyline|Amitriptyline 25 mg
3177466|NCT01357018||patients with rheumatoid arthritis|
3177467|NCT01357018||patients with ankylosing spondylitis|
3177468|NCT01357005||Schizophrenia Family|
3177469|NCT01356992|Active Comparator|Clexane® (enoxaparin - Sanofi)|
3177470|NCT01356992|Experimental|Versa® (enoxaparin - Eurofarma)|
3177471|NCT01356979||Patients underwent medical thoracoscopy|Patients who require medical thoracoscopy for undiagnosed exudative pleural effusion by other clinical or radiological investigations.
3177472|NCT01356966|Experimental|Tetrahydrobiopterin + Folate|Male subjects with hypertension and chronic kidney disease stage 2 or 3 will receive Tetrahydrobiopterin (6R-BH4) 200 mg twice daily and folic acid 1 mg daily
3177473|NCT01356966|Placebo Comparator|Placebo + Folate|Male subjects with hypertension and chronic kidney disease stage 2 or 3 will receive 2 placebo pills twice daily and folic acid 1 mg daily
3177474|NCT01356953|Experimental|Aerobic Exercise|
3177475|NCT01356940|Active Comparator|dalfampridine ER 10mg bid-placebo|4 week administration of dalfampridine ER 10mg bid followed by 2 week washout and 4 weeks of placebo control
3177476|NCT01356940|Placebo Comparator|placebo-dalfampridine ER 10mg bid|placebo tablet administered bid for four weeks followed by 2 week washout and 4 weeks of dalfampridine ER 10mg bid
3177477|NCT01356927||DMPA|DMPA given at the time of mifepristone for medical abortion
3177478|NCT01356927||Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone for medical abortion
3177479|NCT01356914|Experimental|Treatment A: BMS-914392|
3177480|NCT01356914|Experimental|Treatment B: BMS-914392|
3177481|NCT01356914|Experimental|Treatment C: BMS-914392|
3177482|NCT01356914|Placebo Comparator|Treatment D: Placebo|
3177483|NCT01356901||Treatment naïve and pre-treated CHB patients|subanalysis with migrant and non-migrant patients
3177484|NCT01356888|Active Comparator|Abbott Laboratories - Xience Prime DES|
3177485|NCT01356888|Experimental|Biotronik - Orsiro DES|
3177486|NCT01356875|Experimental|HIDRA/VPA|In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycles of hydralazine and valproic acid.
3177487|NCT01356875|Active Comparator|best supportive care (BSC)|The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
3177488|NCT01356862|Experimental|PASIREOTIDE|INTRAMUSCULAR INJECTION OF PASIREOTIDE 60 MG
3177489|NCT01356862|Placebo Comparator|PLACEBO|INTRAMUSCULAR INJECTION OF PLACEBO
3177490|NCT01356849|Placebo Comparator|Group A - Placebo QD|
3177491|NCT01356849|Active Comparator|Group B - Low dose Atrasentan QD|
3177492|NCT01356849|Active Comparator|Group C - High dose Atrasentan QD|
3177493|NCT01356836||Good-poor collateral|Patients who had good and poor collaterals formed 2 groups
3177494|NCT01356836||Good collateral, Poor collateral|
3177495|NCT01356823|Experimental|30μg HPV|Participants in this arm would receive 30μg HPV vaccines which contains 20μg HPV 16 antigen and 10μg HPV 18 antigen
3177496|NCT01356823|Experimental|60μg HPV|Participants in this arm would receive 60μg HPV vaccines which contains 40μg HPV 16 antigen and 20μg HPV 18 antigen
3177497|NCT01356823|Experimental|90μg HPV|Participants in this arm would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
3177498|NCT01356823|Placebo Comparator|hepatitis B vaccine|Participants in this arm would receive hepatitis B vaccine.
3177499|NCT01356810|Placebo Comparator|Standard Care|Delirium management defined by the attending physician.
3177500|NCT01356810|Experimental|Environmental Intervention|
3177501|NCT01356797|Active Comparator|hyperbaric bupivacaine|
3177502|NCT01356797|Experimental|hypobaric levobupivacaine with fentanyl|
3177503|NCT01356784|Experimental|Tailored Physical Activity|
3177504|NCT01356784|Active Comparator|"Chronic Pain Self-management Programme"|
3177505|NCT01356784|Other|Health Counselling|
3177506|NCT01356771|Other|Control Group|
3177507|NCT01356771|Other|Tailored Intervention|We will mail three separate pamphlets created specifically for the participant. The information in the pamphlets will be based on answers from the first survey.
3177508|NCT01356758||Psoriasis topical treatment|Psoriasis topical treatment. No systemic drugs.
3177509|NCT01356758||Psoriasis biological treatment|Psoriasis biological treatment. Anti-Tnf and anti-il12/23.
3177510|NCT01356758||Severe atopic dermatitis|Severe atopic dermatitis
3177511|NCT01356758||Control|No intervention. No inflammatory skin disease.
3177512|NCT01356745|Experimental|premixed 50% nitrous oxide and oxygen|
3177513|NCT01356745|Placebo Comparator|medical air|
3177514|NCT01356732|Experimental|Sufentanil|
3177515|NCT01356706||CRLM|patients with colorectal liver metastases (CRLM) who undergo their primary surgery at UZ. Leuven (single-center academic study)
3177516|NCT01356693|Experimental|Active drug|Bromelin. Extract from Ananas comosus, 3,3g on vehicle (methylparaben, propylparaben, honey from apis mellifera, sodium benzoate, ethylic alcohol, water) 5ml.
3177517|NCT01356693|Placebo Comparator|Placebo|Placebo comparator with the same characteristics of experimental drug, 5ml, single dose.
3177518|NCT01356680|Active Comparator|Arm A|2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy IF-RT irrespective of FDG-PET results after chemotherapy
3177519|NCT01356680|Experimental|Arm B|2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy IN-RT if FDG-PET is positive after chemotherapy; 2 cycles BEACOPPescalated plus 2 cycles ABVD and treatment stop if FDG-PET is negative after chemotherapy
3177520|NCT01356667|Active Comparator|Treatment-As-Usual|Substance Abuse treatment typically received
3177521|NCT01356667|Experimental|DARTNA|12-week DARTNA program
3177522|NCT01356654|Sham Comparator|SHAM TDCS|
3177523|NCT01356654|Active Comparator|True TDCS|
3177524|NCT01356641|Experimental|Antibiotic treatment alone|"Intravenous administration:~Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7mg/kg once daily~Oral administration of:~Amoxicillin/clavulanic acid 50/12.5 mg/kg/day (in three doses)"
3177525|NCT01356641|Active Comparator|Appendectomy|Routine appendectomy either laparoscopic or open depending on the surgeon's preference
3177526|NCT01356628|Experimental|PD-0332991|PD-0332991 in the Treatment in Patients with Advanced Hepatocellular Carcinoma
3177527|NCT01356615|Experimental|enoxaparin|enoxaparin sodium (Clexane) (40 mg) followed prospectively for 3 months (36 dialyses)
3177528|NCT01356615|Active Comparator|standard unfractionated heparin|standard unfractionated heparin followed prospectively for 3 months (36 dialyses)
3177529|NCT01356602|Experimental|Canakinumab, pre-filled syringes (PFS)|Patients on this arm received 150 mg subcutaneously (s.c.) at randomization and upon new flare. The doses were provided as pre-filled syringes. The patients were given 3 injections: two placebo and one active drug.
3177530|NCT01356602|Active Comparator|Canakinumab, lyophilizate (LYO)|The patients on this arm received 150 mg s.c. at randomization and upon new flare. The doses were provided as lyophilized powder and had to be reconstituted with water for injection before application. The patients were given 3 injections: two placebo and one active drug.
3177531|NCT01356602|Active Comparator|Triamcinolone Acetonide|The patients on this arm received 40 mg intramuscular (i.m.) at randomization and upon new flare. The patients were given 3 injections: two placebo and one active drug.
3177532|NCT01356589||Cohort|
3177533|NCT01356563|Experimental|clinical pharmacist intervention|
3177534|NCT01356563|No Intervention|usual care|Patients randomized to usual care group will receive routine review of medication by outpatient department pharmacists and nurse.
3177535|NCT01356550|Experimental|Healthy subjects|
3177536|NCT01356550|Experimental|Hepatic impairment|
3177537|NCT01356537||Gaucher's Disease under VPRIV|
3177538|NCT01356524|Active Comparator|Supplementary progesterone|Women with mid-luteal progesterone levels that are less than 15 ng/dl will receive higher doses of supplementary progesterone
3177539|NCT01356524|No Intervention|No additional progesterone|No additional progesterone given to women with mid-luteal progesterone levels below 15 ng/dl
3177540|NCT01356511|Experimental|Prednisone group|Patients in the PDN arm received PDNorally at 1.0mg/kg body weight daily for 4 consecutive weeks.
3177541|NCT01356511|Experimental|Dexamethasone group|DXM was administered orally at 40 mg daily for 4 consecutive days and then stopped
3177542|NCT01356498|Experimental|q2 RCT|Pegloticase every 2 wk arm of Randomized Controlled Trial(RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
3177543|NCT01356498|Experimental|q4 RCT|Pegloticase every 4 wk arm of Randomized Controlled Trial (RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
3177544|NCT01356498|Experimental|Placebo in RCT|Placebo arm in Randomized Controlled Trial (RCT), received pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in OLE
3177545|NCT01356485|Experimental|MP4CO|Escalating doses of MP4CO, administered intravenously
3177546|NCT01356485|Placebo Comparator|Saline|Normal saline (0.9% sodium chloride solution)
3177547|NCT01356472|No Intervention|Linezolid alone|the control group is designed for linezolid alone treated MRSA VAP (standard treatment).
3177548|NCT01356459|Experimental|Intervention|Patients in this arm will have Mepilex dressings applied to their sacrum and heels
3177549|NCT01356459|No Intervention|Control|Patients in this arm will have standard care
3177550|NCT01356446|No Intervention|before surgical checklist|
3177551|NCT01356446|Active Comparator|after implementation surgical checklist|
3177552|NCT01356433|Other|arm1, vitamin C treated first|Arm 1(50cases): intervention with oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.
3177553|NCT01356433|Other|Arm 2 control first|
3177554|NCT01356420|Experimental|Cholesterol supplementation|All new subjects will come to their first visit with an least 3 weeks of stable cholesterol intake. Typically and preferably this will include egg yolk as cholesterol supplement, but in some instances e.g. intolerance to egg yolk it may include a new encapsulated cholesterol preparation, Sloesterol.
3177555|NCT01356407|Experimental|PICOPREP|"Split Dose method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day before the colonoscopy."
3177556|NCT01356407|Active Comparator|PEG-ELS|PEG-ELS was used according to the approved labeled dosage and administration instructions. Only received one dose of 2 boxes (6 packets), administrated on the day of colonoscopy examination.
3177557|NCT01356381|Experimental|vildagliptin|
3177558|NCT01356381|Experimental|Placebo|
3177559|NCT01356368|Experimental|Cisplatin,Docetaxel,Gemzar, Premetrexed|Patients will receive treatment for up to six cycles of the assigned regimen unless there is disease progression or unacceptable toxicities. After treatment, the patients will be seen every 2 months for the first year, then every 3 months for the second year and every 6 months afterwards.
3177560|NCT01356355|Experimental|Herbmed plus|One capsule twice a day daily till ureteral stent in situ
3177561|NCT01356355|Placebo Comparator|Placebo|One capsule twice a day daily till ureteral stent in situ
3177562|NCT01356355|Active Comparator|Tolterodine|One capsule twice a day daily till ureteral stent in situ
3177563|NCT01356342|Experimental|AdimFlu-S 2010-2011, 6 months~<3 years|
3177564|NCT01356342|Experimental|AdimFlu-S 2010-2011,3~<9 years|
3177565|NCT01356342|Experimental|AdimFlu-S 2010-2011,9~<18 years|
3177566|NCT01356329|Experimental|Lovenox|Group A : Low Molecular Weight Heparin (LMWH), LovenoxTM (Enoxaparin)
3177567|NCT01356329|Experimental|Heparin|Group B:HeparinTM (Unfractionated Heparin)
3177568|NCT01356316|Experimental|AdimFlu-S Influenza Vaccine|
3177569|NCT01356303|Experimental|Cisplatin, Docetaxel|Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of D5W or NS administered as a 1-hour intravenous infusion, followed by cisplatin at dose of 75 mg/m2administered as a 2-hour intravenous infusion every 3 weeks per cycle for 4-6 cycles
3177570|NCT01356277|Experimental|Multi-component Intervention|"Multi-component Intervention consisting of:~Adherence Support Team (patient, parent, Coach)~standardized education on immunosuppressive medications~identification of adherence barriers~Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals~'Action-Focused Problem-Solving' to address barriers selected as most important by the patient~text message, email, or visual cue dose reminders"
3177571|NCT01356277|No Intervention|Attention control|Control group study visits were conducted at the same intervals as intervention visits and consisted of the Coach engaging in active listening and providing non-specific support only. Adherence was NOT discussed with control participants.
3177572|NCT01356264|Experimental|multimodal prehabilitation begun preop|The prehabilitation program will begin several weeks preop and continue in the postoperative period
3177573|NCT01356264|Active Comparator|Multimodal prehabilitation begun postop|The prehabilitation program will begin after the surgery.
3177574|NCT01356251|Experimental|Surgical group with mesothelioma|The study proposed here has two parts: part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life through a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. In part 2, patients are invited to participate in an Internet-based discussion group.
3177575|NCT01356251|Experimental|Non Surgical group with mesothelioma|The study proposed here has two parts: part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life through a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. In part 2, patients are invited to participate in an Internet-based discussion group
3177576|NCT01356238|Experimental|MRC media|Use MRC media in the human IVF-ET program
3177577|NCT01356238|Active Comparator|Sydney IVF media|Use Sydney IVF media in the human IVF-ET program
3177578|NCT01356225|Experimental|Intranasal Ketorolac tromethamine|
3177579|NCT01356225|Placebo Comparator|Intranasal placebo|
3177580|NCT01356212|Experimental|Regimen A: Ketorolac tromethamine (Gentle Sniff - Upright)|Gentle sniff-inhalation with the volunteer upright for dosing and imaging
3177581|NCT01356212|Experimental|Regimen B: Ketorolac tromethamine (Vigorous Sniff - Upright)|Vigorous sniff-inhalation with the volunteer upright for dosing and imaging
3177582|NCT01356212|Experimental|Regimen C: Ketorolac tromethamine (Gentle Sniff - Semi-supine)|Gentle sniff-inhalation with the volunteer semi-supine for dosing and imaging
3177583|NCT01356199|Experimental|ARTRONAT|
3177584|NCT01356199|Placebo Comparator|PLACEBO|
3177585|NCT01356186|Experimental|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Sessions of Post Admission Cognitive Therapy Delivered Preferably Over 3 Consecutive Days of Inpatient Stay
3177586|NCT01356186|No Intervention|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services
3177587|NCT01356173|Experimental|A|
3177588|NCT01356160|Active Comparator|Arm 1|RGT with GS-5885 30 mg QD + GS-9451 200 mg QD + PEG/RBV
3177589|NCT01356160|Placebo Comparator|Arm 2|RGT with GS-5885 30 mg QD + GS-9451 placebo QD + PEG/RBV
3177590|NCT01356147|Sham Comparator|Sham placebo|No therapy will be given to placebo arm. Respiratory therapist will shield infant from view and nebulize saline solution into incubator rather than into ventilator circuit.
3177591|NCT01356147|Active Comparator|Dornase alfa|Dornase alfa 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
3177592|NCT01356134||Multiple sclerosis and or Ehlers-Danlos|Patients with suspected or confirmed cases of Ehlers Danlos Syndrome and or Multiple Sclerosis
3177593|NCT01356134||Age matched normals|Age matched normals
3177594|NCT01356121|Active Comparator|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
3177595|NCT01356121|Active Comparator|Propofol|Propofol will be initiated with a 0.5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
3177596|NCT01356121|No Intervention|No Sedation|No sedation given in this group
3177597|NCT01356095|Active Comparator|PALM-Plus control|Health centers randomized to Palm-Plus intervention in larger trial this trial is embedded in, but not receiving the adherence intervention.
3177598|NCT01356095|Experimental|Adherence intervention|Intervention arm.
3177600|NCT01356082||Arterial blood pressure line|Patients receiving an arterial blood pressure line
3177601|NCT01356069|Experimental|SB-APP Psychotherapy|Patients, who signed the informed consent, were randomly assigned to SB-APP in addition to TAU (n=18) or to TAU alone (n=17) groups. The SB-APP group received the usual treatment plus SB-APP (40 weekly sessions) for 10 or 11 months. At the term of the first year (T12) the TAU group continued with the TAU management with supportive weekly session whilst the SB-APP group was carried on with the psychiatric, nurse, educational management without any individual psychological support. The number of sessions performed by the two groups in the first year (T0-T12) was programmed to be almost the same to reduce the number of sessions bias comparing the specific quality of treatments.
3177602|NCT01356069|Active Comparator|TAU treatment|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators. The medication was administered according to the APA guidelines [18] for good clinical practice with regard to BPD.
3177603|NCT01356056||Kinesia HomeView Monitoring|Uses Kinesia HomeView at home once per week
3177604|NCT01356056||Control|Assessed in the clinic every 4 weeks using traditional methods
3177605|NCT01356043|Experimental|Free combination of S-amlodipine and Telmisartan|Subjects received S-amlodipine 5mg and Telmisartan 80mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
3177606|NCT01356043|Active Comparator|S-amlodipine monotherapy|Subjects received S-amlodipine 5mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
3177607|NCT01356030|Active Comparator|EUS-FNA|
3177608|NCT01356030|Active Comparator|ERCP Brushing and Biopsy|
3177609|NCT01356017|Experimental|Free combination of Telmisartan and S-amlodipine|Subjects received Telmisartan 80mg and S-amlodipine 5mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
3177610|NCT01356017|Active Comparator|Telmisartan monotherapy|Subjects received Telmisartan 80mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
3177611|NCT01356004|Experimental|chicken pox vaccine, efficacy|
3177612|NCT01356004|Placebo Comparator|saline, efficacy|
3177613|NCT01355991|Active Comparator|Anticholinergic Agent|
3177614|NCT01355991|Active Comparator|Long Acting Beta 2 Agonist|
3177615|NCT01355978|Experimental|Noninvasive Open Ventilation System|Portable noninvasive open ventilator & nasal interface.
3177616|NCT01355965|Experimental|Cohort 1 - One dose of cells|Subjects receive one dose of 1x108 cells on day 0 followed by one dose of 1x109 autologous transfected anti-mesothelin CAR T cells on day 7.
3177617|NCT01355965|Experimental|Cohort 2 - three doses of cells|receive three doses of 1x108 cells on day 0, 2, 4 (Monday-Wednesday-Friday (MWF) of Cycle 1) followed by three doses of 1x109 T cells on day 7, 9, 11 (MWF of Cycle 2). Total target dose for Cohort 2 is 3.3x109 cells.
3177618|NCT01355952|Experimental|Alpha Lipoic Acid|taking 1800mg daily (600mg 3 times per day) Alpha Lipoic Acid (ALA) open-label for 10 weeks.
3177619|NCT01355939||Abdominal surgery after prior VHR with barrier-coated mesh|
3177620|NCT01355939||Abdominal surgery after prior VHR with nonbarrier-coated mesh|
3177621|NCT01355939||Lap adhesiolysis during abdominal surgery after prior VHR|
3177622|NCT01355939||Open adhesioloysis during abdominal surgery after prior VHR|
3177623|NCT01355926|Experimental|Flexible Fiber-based CO2 Laser|In the CO2 excised group, the resection will be performed at 15W, at a distance of 1cm from the tissue. Here too, if required, the bipolar will be used to achieve hemostasis The study will focus on post operative pain and quality of life outcomes for both surgical interventions.
3177624|NCT01355926|Experimental|electrocautery resection|In the electrocautery excised group, the cut and coagulation modes used will be each at 25 Malis power setting. First, cut mode will be used to mark out the lesion. Subsequently, coagulation mode will be used for excision. Bipolar cautery will then be used at 25 Malis for hemostasis. The study will focus on post operative pain and quality of life outcomes for both surgical interventions.
3177625|NCT01355900|Other|I tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before incision, deflation- after bone cement set.
3177626|NCT01355900|Other|II tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before cement application, deflation- after bone cement set.
3177627|NCT01355900|Other|III tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before incision, deflation- after wound closure
3177628|NCT01355900|Other|IV control group|Do not use volume loading test. Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before cement application, deflation- after bone cement set.
3177629|NCT01355874|Experimental|Iferanserin|
3177630|NCT01355874|Experimental|Placebo|
3177631|NCT01355874|Experimental|Iferanserin + Placebo|
3177632|NCT01355861|Experimental|1|Exercise group 1: Negative work exercise
3177633|NCT01355861|Other|2|Exercise group 2: Negative work exercise (delayed start for single-arm crossover trial)
3177634|NCT01355848|Experimental|Brief Intervention|The brief intervention consists of stepped care protocol, including building rapport, functional analysis of suicidal behavior, and crisis planning
3177635|NCT01355848|No Intervention|care as usual|Patients randomized to the care as usual arm will not receive the brief intervention.
3177636|NCT01355835|Active Comparator|[STNmono]|Conventional stimulation on subthalamic contacts
3177637|NCT01355835|Experimental|[STN+SNr]|Combined subthalamic and nigral stimulation
3177638|NCT01355822|Placebo Comparator|Placebo|
3177639|NCT01355822|Experimental|PETN|Pentalong, Actavis Germay: 80 mg twice a day
3177640|NCT01355809|Active Comparator|Inhalation Nitrogen/Oxygen|Nitrogen/Oxygen (65%/35%)
3177641|NCT01355809|Experimental|Inhalation Helium/Oxygen|Helium/Oxygen (65%/35%)
3177642|NCT01355809|Experimental|Inhalation gas|Medicinal oxygen 100% via NIV with FiO2 of 0.35
3177643|NCT01355796|Experimental|Aerosolized Hypertonic xyltiol|"Drug~Aerosolized xylitol (5 ml) twice daily for 14 days"
3178131|NCT01352299|Active Comparator|Macintosh|Laryngoscopy performed with Macintosh Laryngoscope
3177644|NCT01355796|Active Comparator|Hypertonic saline|Aerosolized 7% hypertonic saline (4 ml) twice daily for 14 days
3177645|NCT01355783|Active Comparator|E7777 + CHOP Chemotherapy|
3177646|NCT01355783|Active Comparator|CHOP alone|
3177647|NCT01355757|Experimental|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
3177648|NCT01355757|Active Comparator|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
3177649|NCT01355744||Spider bite patients|All patients treated for an actual spider bite by a Swiss physician during study period.
3177650|NCT01355731||Registered Nurse|This is quality improvement study that is descriptive and is utilizing a convenience sample of direct care registered nurses employed full-time for at least one year at St. Jude Children's Research Hospital.Participants will take a onetime researcher generated therapeutic boundaries questionnaire which will describe behaviors and attitudes regarding therapeutic boundaries.
3177651|NCT01355718||Repaglinide|
3177652|NCT01355705|Experimental|Amrubicin + Lenalidomide + Dexamethasone|"Amrubicin will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.~Concurrent therapeutic medications:~Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14~Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)~Other drugs:~Aspirin: 81 or 325 mg daily oral~Pegfilgrastim subcutaneous on Day 2"
3177653|NCT01355692|Experimental|Laser therapy|
3177654|NCT01355679|Experimental|Guided therapy|A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
3177655|NCT01355666|Experimental|DermaTherapy® Linen group|The DermaTherapy® Linen group uses bed sheets and underpads made with DermaTherapy® fabric.
3177656|NCT01355653|Experimental|Treatment A|thermal therapy
3177657|NCT01355653|Active Comparator|Treatment B|ThermaCare Lower Back/Hip heatwrap
3177658|NCT01355640|Experimental|breast-feeding group|Mothers console their babies by breast-feeding during heel lance.
3177659|NCT01355640|Experimental|non-nutritive sucking|"Every mother was given a vacuum pacifier( the brand is Goodbaby) to console her baby during heel lance."
3177660|NCT01355640|No Intervention|control group|A research nurse also explained the study to the control group parents. Standard clinic procedure for infant injection was also implemented. Mothers in control group also lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed.
3177661|NCT01355627|Experimental|TachoSil®|
3177662|NCT01355627|Active Comparator|Current practice group|
3177663|NCT01355614|Experimental|QAX576|
3177664|NCT01355614|Other|Infliximab|
3177665|NCT01355601|Experimental|Group 1 - Control A|Nutritional beverage containing varying types and levels of carbohydrates
3177666|NCT01355601|Experimental|Group 2 - Experimental A|Nutritional Beverage with varying types and levels of carbohydrates
3177667|NCT01355588|Experimental|Ketorolac Tromethamine|
3177668|NCT01355588|Experimental|Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)|
3177669|NCT01355588|Experimental|Ketorolac Tromethamine with 5% Lidocaine HCl|
3177670|NCT01355588|Experimental|Ketorolac Tromethamine with 6% Lidocaine HCl|
3177671|NCT01355575|Experimental|A: Rifaximin first then standard care|Rifaximin for 6 weeks in addition to standard care, followed by 12 weeks of standard care only.
3177672|NCT01355575|Experimental|B: Standard care first then Rifaximin|Standard care for 6 weeks then Rifaximin for 6 weeks in addition to standard care, followed by 6 weeks of standard care only.
3177673|NCT01355549|Experimental|Platelet-rich plasma therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
3177674|NCT01355536||Preterm birth group|Women with prior preterm birth
3177675|NCT01355536||Term birth group|Women with prior term birth
3177676|NCT01355523|Active Comparator|Melatonin|6 mg oral melatonin daily
3177677|NCT01355523|Placebo Comparator|Placebo|6 mg oral placebo daily
3177678|NCT01355497|Experimental|GTx-024|subjects will be randomized to receive GTx-024 for the duration of the trail
3177679|NCT01355497|Placebo Comparator|placebo|subjects will be randomized to receive placebo for the duration of the trial
3177680|NCT01355484|Experimental|GTx-024|subject will receive GTx-024 treatment for the duration of the trial
3177681|NCT01355484|Placebo Comparator|Placebo|subject will receive placebo for the duration of the trial
3177682|NCT01355471|Experimental|CD07805/47 gel|
3177683|NCT01355471|Placebo Comparator|Placebo|
3177684|NCT01355458|Experimental|CD07805/47 gel|
3177685|NCT01355458|Placebo Comparator|Placebo|
3177686|NCT01355445|Active Comparator|Vincristine / Irinotecan|Vincristine, Irinotecan Vincristine :1.5 mg/m² (max 2mg), IV Irinotecan : Irinotecan 50 mg/m²/d, IV
3177687|NCT01355445|Experimental|Vincristine / Irinotecan / Temozolomide|Vincristine, Irinotecan, Temozolomide
3177688|NCT01355432||Propofol|
3177689|NCT01355419||obstructive sleep apnea, CPAP|moderate to severe obstructive sleep apnea requiring CPAP therapy
3177690|NCT01355406|Other|PAD|This is a prospective single-arm multi-center clinical trial designed to evaluate the safety and efficacy of the Flexible Stenting Solutions Flext Stent® Femoropopliteal stenting system in subjects with lower limb peripheral arterial desease (PAD). Subjects targeted for enrollment must have a single de-novo lesion located in the superficial femoral artery and/or proximal popliteal artery with at > 70% stenosis. Subjects must meet all enrollment criteria and provide written informed consent prior to participation in the study.
3177691|NCT01355393|Experimental|Stage I (HER-2/neu peptide vaccine and rintatolimod)|Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses).
3177692|NCT01355393|Active Comparator|Stage II, Arm I (HER-2/neu peptide vaccine and sargramostim)|Patients receive synthetic HER-2/neu peptide vaccine admixed with GM-CSF ID.
3177693|NCT01355393|Experimental|Stage II, Arm II (HER-2 vaccine, sargramostim, rintatolimod)|Patients receive synthetic HER-2/neu peptide vaccine admixed with GM-CSF and rintatolimod ID
3177694|NCT01355380||Group 1|Drug (incl. Placebo)
3177695|NCT01355367|Experimental|Arm 1|
3177696|NCT01355354|Experimental|1|Digoxin
3177697|NCT01355354|Experimental|2|Fostamatinib
3177698|NCT01355341|Experimental|HERBMED PLUS|Herbal formulation of four constituents i.e.Varuna,Yav,Aghada,Kadali as per ayurvedic literature.
3177699|NCT01355328|Experimental|laser|
3177700|NCT01355328|No Intervention|control|
3177701|NCT01355302|Experimental|Phase Ib: Cohort 1 and 2 and 3|"Phase Ib: Cohort 1; 200 mg E7050 + 80 mg/m2 cisplatin + 1000 mg/m2 capecitabine~Cohort 2; 300 mg E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine Cohort 3; 400 mg E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine"
3177702|NCT01355302|Active Comparator|Phase II: Arm 1; E7050 + cisplatin+ capecitabine|Phase II: Arm 1; MTD E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine
3177703|NCT01355289|Placebo Comparator|Placebo (Core Study)|Placebo, will be administered orally, once daily for up to 21 days.
3177704|NCT01355289|Active Comparator|Avatrombopag 10 mg (Core Study)|Avatrombopag 10 mg, will be administered orally, once daily, preferably with food for up to 21 days.
3177705|NCT01355289|Active Comparator|Avatrombopag 20 mg (Core Study)|Avatrombopag 20 mg, will be administered orally, once daily, preferably with food for up to 21 days.
3177706|NCT01355289|Active Comparator|Avatrombopag 30 mg (Core Study)|Avatrombopag 30 mg, will be administered orally, once daily, preferably with food for up to 21 days.
3177707|NCT01355289|Experimental|Avatrombopag (Open-Label Extension)|Avatrombopag will be initiated at a dose of 20 mg, once daily in the open-label extension (OLE) period. The avatrombopag dose will be titrated up or down in accordance with the participant's individual response, within the range of a minimum of 5 mg and a maximum of 50 mg for up to 48 weeks.
3177708|NCT01355276|Experimental|1|
3177709|NCT01355276|Active Comparator|2|
3177710|NCT01355263|Experimental|iron tablet, vitamin a capsule|children in Group I received a 200,000 IU vitamin A capsule just one time initially; Group II received ferrous sulfate (element Fe 1-2 mg/kg•day) once a day for 6 months;.
3177711|NCT01355237||OCC Patients|Patients being treated for chronic low back pain at the Osher Clinical Center of Brigham and Women's Hospital
3177712|NCT01355237||Comparison|Patients being treated for chronic low back pain at Brigham and Women's Hospital, other than at Osher Clinical Center
3177713|NCT01355224|No Intervention|No risk feedback|No obesity risk information given (control)
3177714|NCT01355224|Experimental|Genetic risk feedback|Only personal genetic risk information provided
3177715|NCT01355224|Experimental|Lifestyle risk feedback|Only personal lifestyle risk information provided
3177716|NCT01355224|Experimental|Both genetic or lifestyle risk feedback|Personal genetic and lifestyle information provided
3177717|NCT01355198|Experimental|Cysteine/glycine|Subjects will be studied before and after receiving oral cysteine (as n-acetylcysteine) and glycine for 2 weeks
3177718|NCT01355159|Experimental|Folic Acid 4 mg|Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
3177719|NCT01355159|Placebo Comparator|Placebo|Women will be randomised in a 1:1 ratio to folic acid 4.0 mg or placebo
3177720|NCT01355146||Fabry's Disease under Replagal|
3177721|NCT01355120|Experimental|a human immunoglobulin|Four infusions (i.v.) of 3mg/kg Ipilimumab in week 1, week 4, week 7 and week 10
3177722|NCT01355107||chronic hcv, no liver cirrhosis, no HCC|patients with chronic hepatitis c- infection: no cirrhosis of the liver (= Desmet IV), no HCC - suspected lesion in the liver
3177723|NCT01355107||chronic hcv, liver cirrhosis, no HCC|patients with hcv- associated cirrhosis of the liver, but with no HCC - suspected lesions in the liver
3177724|NCT01355107||hcv-infection, HCC|patients with hcv- associated HCC
3177725|NCT01355094|Active Comparator|"Stampede VAC"|"Calgary-home-made Stampede VAC system with only closed drain bulb suction"
3177726|NCT01355094|Experimental|KCI AbThera|commercial AbThera vacuum assisted abdominal closure at 125 mmHg suction
3177727|NCT01355081|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.
3177728|NCT01355081|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.
3177729|NCT01355081|Placebo Comparator|Placebo|Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.
3177730|NCT01355068|Active Comparator|Treatment A|Epanutin Infatabs 50 mg (sourced from Germany), 1 x 50 mg (REFERENCE)
3177731|NCT01355068|Experimental|Treatment B|Dilantin Infatabs 50 mg (sourced from Australia), 1 x 50 mg (TEST)
3177732|NCT01355042||Severe Sepsis and Septic Shock|
3177733|NCT01355042||Other Critical Ill with or without Shock|Severe Trauma, Neurological Injury, Other Shock (not Septic)
3177734|NCT01355016|Experimental|MDT-637|Active formulation
3177735|NCT01355016|Placebo Comparator|Placebo|Matched Placebo Comparator
3177736|NCT01355003||All Participants|Participants who were vaccinated with GARDASIL™ by their physician
3177737|NCT01354990||Participants treated with sitagliptin|
3177738|NCT01354977|Experimental|Resveratrol|Each participant will receive a 28 days' supply of resveratrol capsules on day 0.
3177739|NCT01354964|Experimental|Vitamin D|Vitamin D
3177740|NCT01354951|Experimental|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|This is a non-randomized, Phase II study examining the tolerance profile (primary endpoint) as well as the secondary endpoints of QOL changes, efficacy and the correlation of post-treatment MRI findings with post-treatment biopsy outcomes in men with early stage low volume prostate cancer treated with focal brachytherapy.
3177789|NCT01354561|Active Comparator|respiratory disease group|Respiratory disease group consisting of hospitalized children with acute viral bronchiolitis
3177790|NCT01354548|Experimental|TheraBite grupp|
3178220|NCT01351610|Experimental|Group A|
3177741|NCT01354938||Acute Exacerbation of Chronic Bronchitis (AECB)|Participants with a diagnosis of chronic bronchitis and signs and symptoms of an acute exacerbation who were prescribed Klaricid XL (500 mg of modified release clarithromycin) at a dose of one tablet once a day or two tablets once a day based on physician's decision of severity of symptoms per routine clinical care.
3177742|NCT01354925|Active Comparator|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. .
3177743|NCT01354925|Active Comparator|Standard treatment during Ramadan|Standard of care according to physicians choice
3177744|NCT01354860|Experimental|Moxibustion treatment plus usual care|
3177745|NCT01354860|No Intervention|usual care alone|
3177746|NCT01354847||cardiac surgery patients|cardiac surgery patients scheduled for elective complex cardiac surgery
3177747|NCT01354834||hMG|
3177748|NCT01354821|Active Comparator|Endovascular therapy branched|Endovascular therapy branched or fenestrated stent-graft
3177749|NCT01354821|Other|Open surgical repair|Open surgical repair or aortic replacement with revascularization of visceral arteries
3177750|NCT01354808|Active Comparator|DAPT|
3177751|NCT01354808|Experimental|TAPT|
3177752|NCT01354795|Experimental|1.EUS-FNA with or without suction|During EUS FNA is performed, with or without self-retracting 10-mL syringe
3177753|NCT01354795|Experimental|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet into the needle or injecting air
3177754|NCT01354782|Experimental|Roflumilast|(This is a pharmacokinetic study)
3177755|NCT01354769||Non-intubated patients|
3177756|NCT01354769||Intubated patients|
3177757|NCT01354756||bariatric population|obese patients in whom a bariatric surgery is planified
3177758|NCT01354743|Other|Dysport|Dysport injections into the glabella and orbicularis oculi muscles with dose based on muscle mass
3177759|NCT01354730||Exposed cohort|The woman received AdimFlu-S (A/H1N1) vaccination between 2009/10 and 2010/02. The woman was pregnant at the time of vaccination.
3177760|NCT01354730||Unexposed cohort|The woman was gestation after April 2009.
3177761|NCT01354717|Active Comparator|Brand Carac|Treatment of actinic keratosis with active ingredient
3177762|NCT01354717|Active Comparator|Generic 0.5% 5-fluorouracil cream|Treatment of actinic keratosis with active ingredient
3177763|NCT01354717|Placebo Comparator|Placebo|treatment of actinic keratosis with placebo cream
3177764|NCT01354704|Active Comparator|lovenox|patient under lovenox 4000 IU
3177765|NCT01354704|Active Comparator|enoxa|patients under Enoxa 4000 IU
3177766|NCT01354704|No Intervention|total knee replacement|patients undergoing total knee replacement
3177767|NCT01354704|No Intervention|total hip replacement|patient undergoing total knee replacement
3177768|NCT01354691|Experimental|ladostigil hemitartrate|
3177769|NCT01354678|Active Comparator|group of bone marrow cell therapy|
3177770|NCT01354678|Sham Comparator|group of sham therapy|
3177771|NCT01354665||Group 1|
3177772|NCT01354652|Experimental|entecavir|"Oral 0.5mg/day until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18.~Participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
3177773|NCT01354652|Active Comparator|lamivudine|"Oral 100mg/day lamivudine until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18.~Participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
3177774|NCT01354652|No Intervention|no NRTI group|hepatitis C virus associated LC patients for the calculation of lactic acidosis incidence
3177775|NCT01354639||Group 1|Group 1 : conventional open thyroidectomy group (papillary thyroid carcinoma patient who underwent conventional open bilateral total thyroidectomy procedure and postoperative low dose RAI therapy)
3177776|NCT01354639||Group 2|Group 2 : robotic thyroidectomy group (papillary thyroid carcinoma patient who underwent robotic bilateral total thyroidectomy procedure and postoperative low dose RAI therapy)
3177777|NCT01354626|Experimental|High fat diets|High-fat-Low-protein or High-fat-high-protein
3177778|NCT01354626|Other|Control group|Low-protein-low-fat (according to healthy eating guidelines)
3177779|NCT01354613|Experimental|HFpEF|25 patients with clinically diagnosed heart failure with preserved ejection fraction, confirmed by Framingham criteria, with EF > 50% and without evidence of active ischemia or known severe CAD, valvular or pericardial disease, infiltrative or hypertrophic cardiomyopathy, cor pulmonale, severe pulmonary disease, or primary renal disease. Subjects will receive amlodipine, oral administration for a period of 12 weeks.
3177780|NCT01354613|Experimental|Pulmonary Disease|20 patients with pulmonary disease and no clinical evidence of cardiovascular disease
3177781|NCT01354613|Experimental|LVH/HTN|20 subjects with known left ventricular hypertrophy and clinically diagnosed hypertension without the diagnosis of heart failure.
3177782|NCT01354613|Placebo Comparator|HFpEF placebo|25 patients with clinically diagnosed heart failure with preserved ejection fraction, confirmed by Framingham criteria, with EF > 50% and without evidence of active ischemia or known severe CAD, valvular or pericardial disease, infiltrative or hypertrophic cardiomyopathy, cor pulmonale, severe pulmonary disease, or primary renal disease. Subjects will be administered a placebo for a period of 12 weeks.
3177783|NCT01354600|Other|Energy Balance|
3177784|NCT01354600|Other|Positive Energy Balance|
3177785|NCT01354587|Active Comparator|Hizentra|Compare IgG levels and site reaction in subjects transitioning from Vivaglobin to Hizentra
3177786|NCT01354574|Experimental|High Glycemic Index meals|Three days of run-in diet with meals containing high glycemic index carbohydrates followed by test day with breakfast meal containing high glycemic index carbohydrates.
3177787|NCT01354574|Experimental|Low Glycemic Index meals|Three days of run-in diet with meals containing low glycemic index carbohydrates followed by test day with breakfast meal containing low glycemic index carbohydrates.
3177788|NCT01354561|Sham Comparator|control group|Physiotherapy in the control group were also done at hospital, in dorsal decubitus position at 30-degree elevation, all receiving the same treatment given for the paediatric inpatients, except nasotracheal suction, which was not performed due to ethical reasons.
3177791|NCT01354548|No Intervention|Conventional treatment|
3177792|NCT01354535|Active Comparator|Cable plating with strut|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
3177793|NCT01354535|Active Comparator|isolated plating|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
3177794|NCT01354522|Active Comparator|TAC|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
3177795|NCT01354522|Experimental|TCX|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
3177796|NCT01354509||Current protocol group|Patients treated with current standards based on physician discretion.
3177797|NCT01354509||Normothermia group|Normothermia protocol, using Hydrogel cooling Pads(Arctic Sun) applied for 96 hrs starting upon admission to the ICU
3177798|NCT01354496|Experimental|Cohort 1 - LY2409021 reference form|Single 20 mg LY2409021 reference form administered orally in the fasted state
3177799|NCT01354496|Experimental|Cohort 1 - LY2409021 medium test form fed|Single 20 mg LY2409021 test form with medium particle size administered orally immediately after ingestion of a standardized high-fat meal
3177800|NCT01354496|Experimental|Cohort 1 - LY2409021 medium test form fasted|Single 20 mg LY2409021 test form with medium particle size administered orally in the fasted state
3177801|NCT01354496|Experimental|Cohort 2 - LY2409021 low test form fasted|Single 20 mg LY2409021 test form with low particle size administered orally in the fasted state
3177802|NCT01354496|Experimental|Cohort 2 - LY2409021 medium test form fasted|Single 20 mg LY2409021 test form with medium particle size administered orally in the fasted state
3177803|NCT01354496|Experimental|Cohort 2 - LY2409021 high test form fasted|Single 20 mg LY2409021 test form with high particle size administered orally in the fasted state
3177804|NCT01354483|Experimental|Treatment Group A|Umbilical cord blood mononuclear cell, 1.6 million
3177805|NCT01354483|Experimental|Treatment Group B|Umbilical cord blood mononuclear cell, 3.2 million
3177806|NCT01354483|Experimental|Treatment Group C|Umbilical cord blood mononuclear cell, 6.4 million
3177807|NCT01354483|Experimental|Treatment Group D|Umbilical cord blood mononuclear cell, 6.4 million; mehtylprednisolone
3177808|NCT01354483|Experimental|Treatment Group E|Umbilical cord blood mononuclear cell, 6.4 million; methylprednisolone; 6 week course of lithium carbonate tablet
3177809|NCT01354470|Experimental|Modafinil|
3177810|NCT01354470|Placebo Comparator|placebo (cornstarch)|
3177811|NCT01354457|Experimental|Epratuzumab and 90Y-Epratuzumab|Escalating dose schedule with 5 cohort. For each cohort 3 patients will receive Radio-immunotherapy (RIT ) at Day 1 and Day 8 ± 2 First cohort : 92,5 MBq/m² of 90Y-DOTA-hLL2 associated with hLL2 Second cohort : 185 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Third cohort : 277,5 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Fourth cohort : 370 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Fifth cohort : 462.5 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2
3177812|NCT01354444|Active Comparator|Carvedilol|Carvedilol is a is a beta-blocker. Beta-blockers are generally used to reduce the workload on the heart and help it to beat more regularly.
3177813|NCT01354444|Placebo Comparator|Placebo|Non active substance
3177814|NCT01354431|Experimental|Arm 1: nivolumab - 0.3 mg/kg|
3177815|NCT01354431|Experimental|Arm 2: nivolumab - 2.0 mg/kg|
3177816|NCT01354431|Experimental|Arm 3: nivolumab - 10.0 mg/kg|
3177817|NCT01354418|Experimental|Phenylephrine HCl Extended Release - Fasted|Single dose phenylephrine HCl extended release tablet administered under fasted conditions on Day 1 in one of four study periods
3177818|NCT01354418|Experimental|Phenylephrine HCl Extended Release - Fed|Single dose phenylephrine HCl extended release tablet administered after a high-fat, high-calorie breakfast on Day 1 in one of four study periods
3177819|NCT01354418|Active Comparator|Phenylephrine HCl Immediate Release - Fasted|Three single doses of phenylephrine HCl immediate release tablet four hours apart, with the first dose administered under fasted conditions on Day 1 in one of four study periods
3177820|NCT01354418|Active Comparator|Phenylephrine HCl Immediate Release - Fed|Three single doses of phenylephrine HCl immediate release tablet four hours apart, with the first dose administered after a high-fat, high-calorie breakfast on Day 1 in one of four study periods
3177821|NCT01354405||Lanreotide|
3177822|NCT01354392|Experimental|AZD1152|
3177823|NCT01354379|Active Comparator|Fluzone 15 mcg HA 200 mcl IN by Pipette|
3177824|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 200 mcl IN by Pipette|
3177825|NCT01354379|Active Comparator|Fluzone 15 mcg HA 200 mcl IN by Nasal Spray|
3177826|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 200 mcl IN by Nasal Spray|
3177827|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 400 mcl IN by Nasal Spray|
3177828|NCT01354366||Control|Marketed hypoallergenic infant formula containing a probiotic
3177829|NCT01354366||Experimental 1|An investigational hypoallergenic infant formula with a different protein content, containing the same probiotic as the control
3177830|NCT01354366||Experimental 2|An investigational hypoallergenic infant formula with a different protein content, without a probiotic
3177831|NCT01354353|Active Comparator|Aripiprazole|Part A: Continue current prescribed dosing regimen -- Study Day 1 to discharge (Study Day 21). Part B: Continue current prescribed dosing regimen -- Study Day 1 to discharge (Study Day 23, 25 or 28 based on adaptive design)
3177832|NCT01354353|Experimental|Part A: 160 mg LY2140023|Administered orally, twice daily for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
3177833|NCT01354353|Experimental|Part A: 240 mg LY2140023|Administered orally, twice daily for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
3177834|NCT01354353|Experimental|Part A: 320 mg LY2140023|Administered orally, twice daily for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
3178004|NCT01353313|Placebo Comparator|Placebo|Saline placebo
3177835|NCT01354353|Experimental|Part A: 400 mg LY2140023|Administered orally, twice daily for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
3177836|NCT01354353|Experimental|Part A: 480 mg LY2140023|Administered orally, twice daily for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
3177837|NCT01354353|Experimental|Part B: LY2140023|If doses up to or equal to 400 mg twice daily are not tolerated, Part B of the study may be started. The dose of LY2140023 will be titrated in the same subject from highest dose that was tolerated in Part A, with the intention to reach a dose of 480 mg LY2140023.
3177838|NCT01354340|Experimental|Limicol simple dose|
3177839|NCT01354340|Experimental|Limicol double doses|
3177840|NCT01354340|Placebo Comparator|Placebo|
3177841|NCT01354327|Experimental|Limicol|
3177842|NCT01354327|Placebo Comparator|Placebo|
3177843|NCT01354314|Experimental|Fluconazole|Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine
3177844|NCT01354314|Experimental|Paroxetine|Paroxetine 20 mg orally once per day; placebo in place of fluconazole
3177845|NCT01354314|Experimental|Paroxetine and Fluconazole|Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
3177846|NCT01354314|Placebo Comparator|Placebo|Placebo in place of both fluconazole and paroxetine
3177847|NCT01354301|Experimental|Thymoglobulin and everolimus|single dose antithymocyte globulin, reduced concentration tacrolimus, everolimus starting at day 2 posttransplant and prednisone
3177848|NCT01354301|Experimental|Basiliximabe and everolimus|basiliximab, reduced concentration tacrolimus, everolimus starting at day 2 posttransplant and prednisone
3177849|NCT01354301|Active Comparator|Basiliximabe and mycophenolate|basiliximab, reduced concentration tacrolimus, mycophenolate and prednisone.
3177850|NCT01354288|Experimental|Therapeutic education|
3177851|NCT01354288|No Intervention|Classical management|
3177852|NCT01354275|Active Comparator|GnRH Agonist|oral contraceptive pill and GnRH Agonist IVF/ICSI cycle
3177853|NCT01354275|Active Comparator|GnRH Agonist Arm|Oral contraceptive pill and day 21 GnRH agonist began, Day 3 of menstruation 150 IU FSH will be started. If 3 or more follicle reach >17 mm hCG will be administered.
3177854|NCT01354262|Experimental|Lower dose vitamin D|Fixed daily doses of 600 IU vitamin D oral supplementation.
3177855|NCT01354262|Experimental|Higher dose vitamin D|50,000 IU supplementation bi-monthly.
3177856|NCT01354262|No Intervention|Control Group|Patients will be followed from baseline to 12 and 24 week follow up. Patients do not receive any research treatment or intervention beyond the standard care of their diabetes. This group are patients with normal levels of Vitamin D.
3177857|NCT01354249|Placebo Comparator|water|Patients will receive water 3h before operation in the same volume of the study group
3177858|NCT01354249|Experimental|whey protein plus carbohydrate|The CHO-P group will receive 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
3177859|NCT01354236||School dropouts|Students who quit school without graduation
3177860|NCT01354236||Controls|Normally enrolled students matched for age, gender, school and educational level
3177861|NCT01354223|Experimental|stenfilcon A contact lens|Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode
3177862|NCT01354223|Active Comparator|ocufilcon B contact lens|Randomized to ocufilcon B contact lens worn in a daily wear, daily disposable mode
3177863|NCT01354210|No Intervention|Standard of care only|The SOC for ART adherence consists of viewing a 20-minute animated tutorial which explains the importance of adherence to antiretroviral medication. It is specifically designed for viewers who have no science background and is appropriate for adolescents and young adults.
3177864|NCT01354210|Experimental|Intervention|This study will test a tailored, personalized SMS Text Message Reminder intervention to improve adherence to ART among non-adherent YLH. Participants will use their own cell phones for receipt of the intervention. Participants will have the option to choose a tailored personalized message that may be changed as requested throughout the study period (six months). Taking advantage of the Intelecare technology, participants will be asked to send a text message response indicating that that have successfully (or not) taken their meds per schedule. No identifying patient information will be included in the SMS text to protect patient confidentiality.
3177865|NCT01354197||All ICU admission patients|All ICU admission to surgical intensive care unit at cohort time
3177866|NCT01354184|Experimental|CRD007 10 mg tablet|
3177867|NCT01354184|Experimental|CRD007 25 mg tablet|
3177868|NCT01354184|Experimental|CRD007 40 mg tablet|
3177869|NCT01354184|Placebo Comparator|CRD007 matching placebo tablet|
3177870|NCT01354171|No Intervention|TRUS guided biopsy|
3177871|NCT01354171|Experimental|MRI Assisted TRUS guided biopsy|
3177872|NCT01354158|Experimental|Droxidopa|The dose-titration response to ascending doses of Droxidopa (placebo, 100mg, 200mg, 400mg) will be measured four separate days.
3177873|NCT01354145|Experimental|Chondroitin sulfate (Condrosan)|CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
3177874|NCT01354145|Active Comparator|Celecoxib|CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
3177875|NCT01354132|Active Comparator|n-acetyl-cysteine|N-Acetyl cysteine effervescent tablets in water 2 in am and 1 in pm for 28 weeks
3177876|NCT01354132|Placebo Comparator|Placebo|matching effervescent tablets in water 2 in am and 1 in pm
3177877|NCT01354119|Active Comparator|Early intervention|Early intervention: stent-graft just after acute phase
3177878|NCT01354119|No Intervention|Conservative|Conservative: medial follow-up without early intervention
3177879|NCT01354106|Experimental|3M Kind Removal Silicone Tape|"investigational medical Silicone tape, 1 x 1.5 sample, applied on time, worn for 24 hours."
3177880|NCT01354106|Other|3M Micropore Medical Tape|"Commercially available Medical Paper Tape, 1 x 1.5 sample, applied on time, worn for 24 hours. Study Control."
3177881|NCT01354093||MacTel Type 2 20 mg/day dose group|Participants will have macular telangiectasis type 2 as confirmed by the reading center. Participants will take 20 mg of zeaxanthin per day.
3177882|NCT01354093||MacTel Type 2 10 mg/day dose group|Participants will have macular telangiectasia type 2 as confirmed by the reading center. Participants will take 10 mg of zeaxanthin per day.
3177883|NCT01354080|Experimental|tensegrity massage|In this group of patients massage sessions based on the tensegrity method were applied.
3177884|NCT01354080|Active Comparator|classical massage|In this group of patients classical massage sessions were applied
3177885|NCT01354067|Active Comparator|Control group|The control group will receive standardized patient education four times, once every two weeks, during the eight week intervention period.
3177886|NCT01354067|Experimental|High-repetitive single limb training|The experimental group will receive a high-repetitive single limb exercise regime, three times a week for two months. In addition, the exercise group will receive patient education at four occasions during the intervention period.
3177887|NCT01354054|Experimental|High frrequency TENS|100 Hz TENS, 100 usec
3177888|NCT01354054|Experimental|Low frequency TENS|4 Hz, 100 usec TENS
3177889|NCT01354054|Experimental|Placebo TENS|100 Hz, 100 usec, set at motor minus 10% then ramps to off in 45 sec, 40 minutes
3177890|NCT01354054|No Intervention|Control|Age matched controls, no intervention
3177891|NCT01354041|No Intervention|Treatment-as-usual|Participants in the Treatment as usual (TAU) arm will not receive any specific Fear of Cancer Recurrence (FCR) intervention during the study period. However, they will be offered an optional full-day workshop at the end of the study.
3177892|NCT01354041|Experimental|Acceptance and Commitment Therapy|"Participants in the intervention arm will receive seven sessions of a mindfulness and values-based living intervention, led by a trained licensed facilitator, conducted in groups of 10-12 participants and include components specifically designed to reduce FCR. The intervention arm will include six weekly 90 minute group sessions and one followup 90 minute group session booster session held three weeks later. The group sessions will be interactive and experiential and include homework practice for generalizing skills."
3177893|NCT01354028|Experimental|Massage therapy|Massage therapy for 10 minutes during quiet alert state following 9 AM feeding. Actigraph in place to measure sleep for 3 hours.
3177894|NCT01354028|No Intervention|No massage therapy|This was a crossover trial with two arms. On one day, infants received massage therapy for 10 minutes. On the other day, infants were monitored as usual with the Actigraph to measure sleep efficiency, but received no massage therapy. This was the control or no intervention arm.
3177895|NCT01354015|Experimental|Use of messaging system|Use of DRMS
3177896|NCT01354015|No Intervention|Usual Care|Usual Care
3177897|NCT01354002||Protocol Participants|All participants enrolled on protocols
3177898|NCT01353989||>60 years|
3177899|NCT01353989||< 40 years|
3177900|NCT01353976|Experimental|Econazole Nitrate Foam 1%|Study medication
3177901|NCT01353976|Placebo Comparator|Vehicle Foam|Placebo medication
3177902|NCT01353963||1|
3177903|NCT01353950||Adult Cystic Fibrosis Patients|Adults with Cystic Fibrosis will be followed longitudinally for 2 years
3177904|NCT01353937|No Intervention|Standard of Care|All patients will be receiving the Standard of Care treatments regardless of whether or not they are receiving study drug.
3177905|NCT01353937|Active Comparator|Novel Combination Therapy|AMD3100 (Plerixafor) injection with Regranex Gel topical application
3177906|NCT01353937|Active Comparator|Becaplermin (Regranex Gel)|Topical application
3177907|NCT01353924|Active Comparator|Bet v 1aF1 + Bet v 1aF2 -Alum|
3177908|NCT01353924|Placebo Comparator|Alum-Placebo|
3177909|NCT01353911|Experimental|Grazoprevir 100 mg|TN non-cirrhotic (NC) participants receive Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
3177910|NCT01353911|Experimental|Grazoprevir 200 mg|TN NC participants receive Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
3177911|NCT01353911|Experimental|Grazoprevir 400 mg|TN NC participants receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
3177912|NCT01353911|Experimental|Grazoprevir 800 mg|TN NC participants receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
3177913|NCT01353911|Active Comparator|Boceprevir 800 mg|TN NC participants start a 4 week lead-in with Peg-IFN + RBV, then receive Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.
3177914|NCT01353911|Experimental|Grazoprevir 400 mg/100 mg|As the result of an interim analysis, TN NC participants assigned to the 400 mg grazoprevir group were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV and will remain in the study.
3177915|NCT01353911|Experimental|Grazoprevir 800 mg/100 mg|As the result of an interim analysis, TN NC participants assigned to the 800 mg grazoprevir group were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV and will remain in the study.
3177916|NCT01353911|Experimental|OL Grazoprevir 100 mg|TN cirrhotic participants receive open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
3177917|NCT01353898|Experimental|MK-1972 50 mg once daily (Part I)|Ten capsules containing a total daily dose of 50 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
3177918|NCT01353898|Experimental|MK-1972 200 mg once daily (Part I)|Ten capsules containing a total daily dose of 200 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
3177919|NCT01353898|Experimental|MK-1972 800 mg once daily (Part I)|Ten capsules containing a total daily dose of 800 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
3177920|NCT01353898|Experimental|MK-1972 25 mg twice daily (Part I)|Ten capsules containing a total daily dose of 25 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part I)
3177921|NCT01353898|Experimental|MK-1972 100 mg twice daily (Part I)|Ten capsules containing a total daily dose of 100 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part I)
3177922|NCT01353898|Placebo Comparator|Placebo twice daily (Part I)|Ten capsules containing placebo were taken orally, twice per day for 10 days (Part I)
3177923|NCT01353898|Experimental|MK-1972 800 mg twice daily (Part II)|Ten capsules containing a total daily dose of 800 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part II)
3177924|NCT01353898|Placebo Comparator|Placebo twice daily (Part II)|Ten capsules containing placebo were taken orally, twice per day for 10 days (Part II)
3177925|NCT01353885||Anterior Approach THA|500 Patients will be included who have received a total hip arthroplasty using the Anterior Approach. The anterior approach to total hip arthroplasty refers to an internervous approach to the hip, where the incision is made from the middle of the iliac crest, then curved distally and laterally to the anterior superior iliac spine (Kelmanovich et al., 2003). To optimize feasibility and applicability of our results, we will not standardize the use of cemented components, the implant manufacturer, or the femoral head size. Surgeons will use the manufacturer specific guides for insertion of the total hip arthroplasty.
3177926|NCT01353885||Posterior Approach THA|100 patients will be enrolled who have received a total hip arthroplasty using the posterior approach. The posterior approach is performed by making a curved incision posteriorly on the greater trochanter (Jolles & Bogoch, 2004). The fascia lata is then incised and the fibers of the gluteus maximus split using dissection (Jolles & Bogoch, 2004). To ensure the feasibility and applicability of our findings, we will not standardize the use of cemented components, the implant manufacturer, or the femoral head size used in the posterior approach.
3177927|NCT01353885||Anterolateral Approach THA|100 patients will be enrolled who have had a total hip arthroplasty using the anterolateral approach. An anterolateral approach to THA utilizes an intermuscular approach by incising the patient posteriorly and distally to the anterior superior iliac spine, extending distally to the greater trochanter along the shaft of the femur (Kelmanovich et al., 2003). To optimize the feasibility and applicability of our results, the implant manufacturer, femoral head size or the use of cemented components will not be standardized in this study.
3177928|NCT01353872|Experimental|Sports Drinks|3 drinks : Nutrattente (before each match) / Nutraperf (during each match) / Nutrarecup (after each match)
3177929|NCT01353872|Placebo Comparator|Placebo|3 drinks : Nutrattente placebo (before each match) / Nutraperf placebo(during each match) / Nutrarecup placebo (after each match)
3177930|NCT01353859|Experimental|Single Arm|
3177931|NCT01353846|Active Comparator|Natural cycle|
3177932|NCT01353846|Active Comparator|Artificial cycle|"Drugs: Agonist GnRH Acetate Triptoreline Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose. Estradiol Valerate, orally Initially 4 pills daily during 4 days, and after increase the dose to 6 mg orally daily.~Natural micronized progesterone, 400 mg/12 hours vaginal administration"
3177933|NCT01353833|Placebo Comparator|IL2-4|
3177934|NCT01353833|Experimental|IL2-2|1 millions IU of IL-2 per day
3177935|NCT01353833|Experimental|IL2-3|3 millions IU of IL-2 per day
3177936|NCT01353833|Experimental|IL2-1|0.33 millions IU of IL-2 per day
3177937|NCT01353820|Active Comparator|1 = Tested product|
3177938|NCT01353820|Sham Comparator|2 = Control product|
3177939|NCT01353807|Active Comparator|Fish oil supplementation|These women received 4 1-g capsules of fish oil per day providing 2,7 grams long chain n-3 fatty acids per day, from gestation week 30 until delivery
3177940|NCT01353807|Placebo Comparator|Olive oil|These women received 4 1-g capsules with olive oil per day from gestational week 30 until delivery
3177941|NCT01353807|No Intervention|No oil supplement|These women received no capsules with oil
3177942|NCT01353794||Group 1|
3177943|NCT01353781|Experimental|AZD5363|Ascending doses of AZD5363 administered orally to patients to define the maximum tolerated dose (MTD)
3177944|NCT01353768||No treatment|zanamivir aqueous solution administered previously as part of the Compassionate Use Program
3177945|NCT01353755|Experimental|recombinant Phleum (rPhleum) allergen cocktail|The recombinant Phleum (rPhleum) allergen cocktail is prepared by mixing equivalent volumes of each single allergen adsorbate. The recombinant Phleum (rPhleum) allergen cocktail contains Phleum pratense (Phl p) allergens: Type 1, 2, 5 and 6 at equimolar quatities. The total protein concentration in the highest strength is 200μg protein per 1mL aluminium hydroxide suspension.
3177946|NCT01353755|Placebo Comparator|Placebo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
3177947|NCT01353742|Active Comparator|Lamivudine and Adefovir dipivoxil|One 100mg Lamivudine tablet and One 10mg Adefovir dipivoxil tablet
3177948|NCT01353742|Experimental|Fixed dose combination|One capsule (100mg lamivudine and 10mg adefovir dipivoxil)
3177949|NCT01353729|Experimental|Treatment A|Treatment A will include combination of zanamivir 600 mg IV plus placebo for moxifloxacin
3177950|NCT01353729|Experimental|Treatment B|Treatment A will include combination of zanamivir 1200 mg IV plus placebo for moxifloxacin
3177951|NCT01353729|Experimental|Treatment C|Treatment C will include zanamivir placebo plus placebo for moxifloxacin
3177952|NCT01353729|Experimental|Treatment D|Treatment D will include moxifloxacin plus zanamivir placebo
3177953|NCT01353716|Experimental|Cohort 1|Healthy subjects matched to the renal impaired subjects by gender, age and body mass index to the renal impaired subjects. There will be a screening visit within 30 days of dose, a single dose of study drug and a follow-up visit 7-10 days after the dose of study drug.
3177954|NCT01353716|Experimental|Cohort 2|Subjects with severe renal impairment. There will be a screening visit within 30 days of dose, a single dose of study drug and a follow-up visit 7-10 days after the dose of study drug.
3177955|NCT01353703|Experimental|Group A|Subjects will receive Infanrix hexa™ at 6, 10 and 14 weeks of age
3177956|NCT01353703|Active Comparator|Group B|Subjects will receive Infanrix hexa™ at 2, 4 and 6 months of age
3177957|NCT01353690|Experimental|AMDC|
3177958|NCT01353677||HSCT recipients|"Adult (≥ 18 years), or pediatric (≥ 2 years and < 18 years) allogeneic HCT recipient (related, unrelated, or CBU) at participating pilot study transplant centers.~Signed informed consent form from adult patient or parent/guardian of pediatric patient.~Patient must have a valid mailing address within the United States to receive QOL surveys.~Ability to speak and read English.~Patients with access to a telephone."
3177959|NCT01353664|Experimental|Romidepsin|This study is an open-label, single-arm study. The study is divided into the Screening Period, Treatment Period, and Follow-up Period.
3177960|NCT01353651|Experimental|Endovascular treatment|
3177961|NCT01353651|Active Comparator|Open repair treatment|
3178093|NCT01352611|Experimental|baclofen, intrathecal|A single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
3177962|NCT01353638|Other|Arm A|Arm A includes 14 patients. In treatment period 1, arm A receives standard PDF with the interventional drug alanyl-glutamine-dipeptide as add-on. As it is a cross-over study design, in treatment period 2, group A receives standard PDF without add-on.
3177963|NCT01353638|Other|Arm B|Arm B includes 14 patients who in treatment period 1 receive standard PDF without the investigational drug. As it is a cross-over study design, in treatment period 2 arm B receives standard PDF with alanyl-glutamine-dipeptide as add-on.
3177964|NCT01353625|Experimental|CC-115|
3177965|NCT01353599|Experimental|Asmanex|Study participants will receive inhaled Mometasone Furoate (Asmanex) 220mcg once daily for 8 weeks.
3177966|NCT01353586|Experimental|nMARQ™ System|The nMARQ™ System (Circular and Crescent Mapping and Ablation Catheters as well as the Multi-Channel Radiofrequency Generator) as part of the Multi-Electrode Irrigated Pulmonary Vein (PV) Isolation System will serve as a treatment method for subjects undergoing radiofrequency catheter ablation for drug refractory, symptomatic Paroxysmal Atrial Fibrillation (PAF). The study later included a Subpopulation Neurological Assessments (SNA) substudy which is a prospective, non-randomized, controlled, acute assessment to compare subjects treated with the nMARQ™ System against control subjects treated with the NAVISTAR® THERMOCOOL® Irrigated Tip Catheter.
3177967|NCT01353573|Active Comparator|Fixed Gantry Radiosurgery|Single fraction radiosurgery will be prescribed using a Fixed Gantry Linear Accelerator
3177968|NCT01353573|Experimental|Robotic Radiosurgery|Single fraction radiosurgery will be prescribed using a robotic linear accelerator
3177969|NCT01353560||New patients of Osher Clinical Center|
3177970|NCT01353547||Received anti-TNFa therapy|Received anti-TNFa therapy
3177971|NCT01353547||First-degree relative of MS patients|First-degree relative (child, parent or sibling) of a diagnosed MS patient
3177972|NCT01353547||Referred by the Partners MS Center|Referred by the Partners MS Center
3177973|NCT01353534|Experimental|Group 1|3.8 mcg with AS03 adjuvant at D0 and 21
3177974|NCT01353534|Experimental|Group 2|15 mcg at D0 and 21
3177975|NCT01353534|Experimental|Group 3|15 mcg + 50 mcg VEP at D0 and 21
3177976|NCT01353534|Experimental|Group 4|30 mcg + 50 mcg VEP at D0
3177977|NCT01353521|Experimental|Contrast-enhanced ultrasound|
3177978|NCT01353508|Experimental|LCZ696 to Valsartan - Heart Failure (HF) cohort|Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.
3177979|NCT01353508|Experimental|Valsartan to LCZ696 - HF Cohort|Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.
3177980|NCT01353508|Experimental|LCZ696 to Valsartan - Hypertension (HTN) cohort|Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.
3177981|NCT01353508|Experimental|Valsartan to LCZ696 - HTN cohort|Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.
3177982|NCT01353482|Active Comparator|Phase II only - Arm I|If the patient is randomised into the Vorinostat arm they will be given Pemetrexed (500mg/m2 iv) and Cisplatin (75mg/m2 iv) on day one of a 21 day cycle plus the dose of Vorinostat determined in the phase I study.
3177983|NCT01353482|Placebo Comparator|Phase II only - Arm 2|If the patient is randomised into the placebo arm they will be given Pemetrexed (500mg/m2 iv) and Cisplatin (75mg/m2 iv) on day one of a 21 day cycle with the placebo for the same number of days as in the vorinostat arm.
3177984|NCT01353469|Experimental|Insuman Comb 25|Insuman Comb 25 will be self-injected subcutaneously twice daily 30-45 minutes before breakfast and dinner. The dose will be adjusted individually by monitoring the blood glucose values and symptoms, and following China guideline.
3177985|NCT01353469|Active Comparator|Novolin® 30R|Novolin® 30R will be self-injected subcutaneously twice daily within 30 minutes before breakfast and dinner. The dose will be adjusted individually by monitoring the blood glucose values and symptoms, and following China guideline and the package insert of Novolin® 30R
3177986|NCT01353456|Active Comparator|Dexmedetomidine|
3177987|NCT01353456|Placebo Comparator|Normal saline|
3177988|NCT01353443|No Intervention|Group A|Monofilament absorbable MonoPlus® suture material will be used for closing of the midline incision.
3177989|NCT01353443|Other|Group B|Abdominal wall closure with monofilament absorbable MonoPlus® suture material and onlay placement of Optilene® Mesh Elastic fixed by sutures.
3177990|NCT01353443|No Intervention|Group C|Monofilament, absorbable MonoMax suture material will be used for the closure of the abdominal cavity.
3177991|NCT01353430||VCP families|Patients with a personal or family history of VCP associated disease.
3177992|NCT01353417||Renal allograft|
3177993|NCT01353404|Experimental|fenofibrate 65mg, fed condition, per oral|
3177994|NCT01353404|Experimental|fenofibrate 65mg, fasting condition, per oral|
3177995|NCT01353404|Active Comparator|fenofibrate 160mg, fed condition, per oral|
3177996|NCT01353391|Active Comparator|Metformin|
3177997|NCT01353391|Placebo Comparator|Placebo|
3177998|NCT01353378|Experimental|dexmedetomidine|intravenously injecting 0.125microgram/kg and 0.25microgram/kg within 10 minutes as soon as the operation begins respectively.
3177999|NCT01353352|Other|Cervical spine injury|We enrolled consecutive alert adults who were in stable condition and who presented with potential cervical spine injury after acute blunt trauma, including patients with posterior neck pain and those presenting by ambulance with immobilization of the cervical spine.
3178000|NCT01353339|Placebo Comparator|sugar pill|
3178001|NCT01353339|Active Comparator|levofloxacin|
3178002|NCT01353326|Active Comparator|Cementless Hip Resurfacing|Patients randomized into the Cementless Hip Resurfacing Group will have their hip resurfaced with the cementless Cormet / Corin Hip Resurfacing System.
3178003|NCT01353326|Active Comparator|Cemented Hip Resurfacing|Patients randomized into the Cemented Hip Resurfacing Group will have their hip resurfaced with the cemented Conserve Plus Total Resurfacing Hip System.
3178005|NCT01353313|Experimental|Hydrocortisone|hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents)
3178006|NCT01353287||TAVI live case or video-taped transmission|
3178007|NCT01353287||TAVI without transmission|
3178008|NCT01353274||Patients with hypertension|
3178009|NCT01353261||Elective Cases|Patients with stable CAD undergoing PCI
3178010|NCT01353261||AMI Cases treated with clopidogrel|Patient with AMI undergoing PCI
3178011|NCT01353261||AMI Cases treated with prasugrel|Patients with AMI undergoing PCI
3178012|NCT01353248|Active Comparator|Arm 1|GS-5885, GS-9451 and Tegobuvir in combination with ribavirin (Copegus®) for 24 weeks.
3178013|NCT01353248|Active Comparator|Arm 2|GS-5885, GS-9451 and Tegobuvir in combination with ribavirin (Copegus®) for 12 or 24 weeks.
3178014|NCT01353235|Sham Comparator|usual care|
3178015|NCT01353235|Active Comparator|Prednisolone|1mg/kg/day prednisolone for the entire ICU stay and a maximum of 10 days
3178016|NCT01353222|Experimental|DN24-02|Subjects received infusion of DN24-02, at 2-week intervals, for a total of 3 infusions.
3178017|NCT01353222|Other|Standard of Care|Subjects randomized to the control arm were treated per standard of care, which in this patient population is generally observation, as there is currently no evidence that treatment with non-cisplatin containing chemotherapy is beneficial in the adjuvant setting for this patient population.
3178018|NCT01353209|Experimental|Letrozole|
3178019|NCT01353209|Placebo Comparator|Placebo|
3178020|NCT01353196||stenosis|carotid stenosis
3178021|NCT01353196||no stenosis|no stenosis
3178022|NCT01353183|Experimental|Colonic biopsies|Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy
3178023|NCT01353170|Experimental|Prevalent hd patients|Patients undergoing three consecutive cross-over hd session with 3 different dialysate calcium concentrations
3178024|NCT01353157||patients with elective cardiac surgery|
3178025|NCT01353144|No Intervention|esomeprazole|esomeprazole (40 mg/day) for 8 weeks
3178026|NCT01353144|Active Comparator|esomeprazole plus aspirin|esomeprazole (40 mg/day) plus aspirin (100 mg/day) for 8 weeks
3178027|NCT01353131||ECG Screening|1000 patients with moderate to high risk determined by stratification algorithm based on the electronic analysis of 69,088 routine 12-lead ECGs performed in a large medical institution during a 6 month period by combining previously established indices of abnormal repolarization (wide QRS-T angle) with validated measures of myocardial damage (Selvester QRS score) excluding those > 70 years of age or with LV ejection fraction ≤ 35%, or at a high risk of dying within 3 years from cancer, end stage cardiac, pulmonary, renal, immunologic or neurologic diseases excluded on clinical data obtained through medical record.
3178028|NCT01353118|No Intervention|gastric bypass|Group A: Patients will undergo gastric bypass surgery within 3 months after randomisation without any pre operative optimisation of glycaemic control.
3178029|NCT01353118|Active Comparator|Gastric bypass 2|Gastric bypass 2 (Group B):Patients will undergo gastric bypass 3-6 months after randomisation. During this period the group will receive modern best medical care based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines. Glycaemic optimisation will be achieved in a gradual manner with particular attention to the avoidance of hypoglycaemia
3178030|NCT01353118|No Intervention|Best medical care|Group C: Obese patients with T2DM (who choose not to have surgery) will be treated with best medical care based on the ADA/EASD guidelines including anti-diabetes/obesity pharmacotherapy, access to a trained dietician and exercise programme.
3178031|NCT01353105|Experimental|Ex vivo lung transplantation|single-group studies
3178032|NCT01353092|Experimental|Active PEMF twice daily|"Re5 treatment helmet using Pulsating ElectroMagnetic Field:~Intervention: 30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon"
3178033|NCT01353092|Active Comparator|Active PEMF once daily|"Re5 treatment helmet using Pulsating ElectroMagnetic Field:~Intervention: 30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)"
3178034|NCT01353079|Experimental|Short Ragweed Pollen Allergenic Extract|
3178035|NCT01353079|Placebo Comparator|Glycero-COCAs|
3178036|NCT01353066|Active Comparator|Intensive Medical Treatment|
3178037|NCT01353066|Experimental|Intensive medical treatment (IMM)+RYGBP|
3178038|NCT01353053||Tacrolimus, Everolimus|Immunosuppression is the same for all patients in the study until the period between the 3rd and 5th weeks, when patients will be randomized to initial regimen and remain or be converted to everolimus tacrolimus.
3178039|NCT01353040|Experimental|AVI-6003|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
3178040|NCT01353040|Placebo Comparator|Placebo|Normal saline
3178041|NCT01353027|Placebo Comparator|Placebo|
3178042|NCT01353027|Experimental|AVI-6002|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
3178043|NCT01353014|Experimental|Dietary advice with genetic information|This group will receive dietary advice for caffeine, vitamin C, sugar and sodium based on genetic information.
3178044|NCT01353014|Active Comparator|General dietary recommendations|This group will receive general dietary recommendations for caffeine, vitamin C, sugar and sodium from recognized health institutions (caffeine: Health Canada; sugar: the World Health Organization; vitamin C and sodium: the Institute of Medicine).
3178045|NCT01353001|Experimental|Diet Only|
3178046|NCT01353001|Experimental|Diet plus Aerobic Training|
3178047|NCT01353001|Experimental|Diet plus Resistance Training|
3178048|NCT01352988|Experimental|Fumaric acid esters|
3178049|NCT01352962|Experimental|Arm 1|Standard of Care plus escalating dosesof Lenalidomide
3178050|NCT01352936||Experimental Group|
3178051|NCT01352936||Control Group|
3178052|NCT01352923|Experimental|peripheral blood|healthy voluntary donors
3178053|NCT01352910|Experimental|effective rTMS|
3178054|NCT01352910|Sham Comparator|Sham rTMS|
3178055|NCT01352884|Experimental|Stage 1|Stage 1 will identify the recommended Stage 2 dose using a dose-escalation process. Dose-escalation will continue until either a maximum tolerated dose is established, or a therapeutic dose is reached.
3178056|NCT01352884|Experimental|Stage 2|Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood specimens will be evaluated for pharmacodynamic markers/activity at specified timepoints throughout the study.
3178057|NCT01352871||Concentration / meditation|The subject will try to influence the innate immune response by concentration / meditation in advance of and during endotoxemia
3178058|NCT01352858|Experimental|TolDC|Experimental arm - TolDC administered arthroscopically
3178059|NCT01352858|Placebo Comparator|Control|Arthroscopy & saline irrigation alone
3178060|NCT01352845|Experimental|rLP2086|
3178061|NCT01352845|Placebo Comparator|Control|Steril normal saline solution
3178062|NCT01352832|Experimental|Interactive DVD|"Patients randomized to this arm will receive a DVD DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate stories through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor."
3178063|NCT01352832|Placebo Comparator|Usual Care|Patients randomized to this arm receive their usual care.
3178064|NCT01352806|Experimental|fluoroscopy, palpation, ultrasound|in the same subject we will compare the accuracy of identifying the intralaminar space by three technique, fluoroscopy, ultrasound, palpation.
3178065|NCT01352793|Experimental|rLP2086 vaccine|rLP2086 vaccine
3178066|NCT01352793|Other|control|The control treatment will be HAVRIX vaccine at month 0 and 6 and a normal saline injection at month 2.
3178067|NCT01352780|No Intervention|usual care|Motivational interviewing
3178068|NCT01352767|Experimental|InsuPad Device|Use of the InsuPad which heats the injection site.
3178069|NCT01352767|No Intervention|CONTROL|no treatment
3178070|NCT01352741|Experimental|Tapentadol Prolonged Release|Tapentadol Prolonged Release (100 - 500 mg per day) Oral administration twice daily
3178071|NCT01352741|Active Comparator|Tapentadol Prolonged Release with Pregabalin|Tapentadol Prolonged Release (100 - 300 mg per day) with Pregabalin (150 - 300 mg per day) Both administered orally twice a day.
3178072|NCT01352728|Experimental|TACE+Axitinib|
3178073|NCT01352715|Experimental|Arm A: LPV/r plus RAL|Participants were administered LPV/r plus RAL orally twice daily throughout follow-up.
3178074|NCT01352715|Experimental|Arm B: LPV/r plus best available NRTIs|"Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs (listed below) throughout follow-up-~FTC/TDF orally twice daily~ABC/3TC/ZDV orally twice daily~ABC/3TC orally once daily~3TC/ZDV orally twice daily~ABC 300mg orally twice daily or 600 mg once daily~3TC orally twice daily~ZDV orally twice daily"
3178075|NCT01352702|Experimental|Arm 1|Dabigatran Therapy
3178076|NCT01352702|Active Comparator|Arm 2|Phenprocoumon Therapy
3178077|NCT01352689|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 80mg/S-Amlodipine 2.5mg
3178078|NCT01352689|Experimental|Free combination Therapy|Co-administration of single oral doses of a 80mg tablet of Telmisatan and a 2.5 mg tablet of S-Amlodipine
3178079|NCT01352663|Experimental|Wockhardt's Insulin Analogue (Recomb)|Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
3178080|NCT01352663|Active Comparator|Lantus®|Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
3178081|NCT01352650|Active Comparator|Cohort 1A|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5
3178082|NCT01352650|Active Comparator|Cohort 1B|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10
3178083|NCT01352650|Active Comparator|Cohort 2A|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5
3178084|NCT01352650|Active Comparator|Cohort 2B|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 2 decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 4 decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10
3178085|NCT01352650|Active Comparator|Cohort 3A|Cycle 1: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 3: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5
3178086|NCT01352650|Active Comparator|Cohort 3B|Cycle 1: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 2: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 4: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10
3178087|NCT01352637|Placebo Comparator|Placebo + Prolonged Imaginal Exposure|Drug: Placebo (sugar pill) + Prolonged Imaginal Exposure (PE) PTSD treatment
3178088|NCT01352637|Placebo Comparator|Placebo + VR exposure|Drug: Placebo (sugar pill) + Virtual Reality Exposure (VR) PTSD treatment
3178089|NCT01352637|Active Comparator|DCS + Prolonged Imaginal Exposure|Drug: 50mg DCS (D-Cycloserine ) + Prolonged Imaginal Exposure (PE) PTSD treatment
3178090|NCT01352637|Active Comparator|DCS+VR exposure|Drug: 50mg DCS (D-Cycloserine ) + Virtual Reality Exposure (VR) PTSD treatment
3178091|NCT01352624|Experimental|Experimental|$teps for Achieving Financial Empowerment ($AFE)
3178092|NCT01352624|No Intervention|Usual Care|Veterans in control arm will receive usual care at VA
3178261|NCT01351298|Placebo Comparator|Saline spray|
3178094|NCT01352598|Other|Stereotactic Body Radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
3178095|NCT01352585||Anagrelide hydrochloride|
3178096|NCT01352572|Experimental|antidepressant response|antidepressant response are refered the patients having a 50 ≤ Decrease rate(%) of HAM-D score
3178097|NCT01352572|Active Comparator|antidepressant non-response|antidepressant non-response are refered the patients having a 50 > Decrease rate(%) of HAM-D score
3178098|NCT01352559|Experimental|responders|50 ≤ Decrease rate(%) of HAM-D score
3178099|NCT01352559|Active Comparator|non-responders|nonresponders is a patients having 50 > Decrease rate(%) of HAM-D score
3178100|NCT01352546|Experimental|BOTOX|intravaginal Botox injections and progressive dilation under anesthesia to cure vaginismus.
3178101|NCT01352533|Active Comparator|Running polypropylene closure|Half of every linear wound will be closed with running polypropylene sutures. This technique is Standard of Care.
3178102|NCT01352533|Experimental|Tissue Adhesive (Derma-Bond)|The experimental half of the wound will be randomized to receive closure with tissue adhesive alone.
3178103|NCT01352533|Experimental|Subcuticular polyglactin-910 combined with tissue adhesive|The experimental half of the wound will be randomized to receive closure with running subcuticular polyglactin-910 combined with tissue adhesive.
3178104|NCT01352520|Experimental|SGN-35|1.8 mg/kg intravenously Day 1 of 21-day cycle.
3178105|NCT01352507|Experimental|Tadalafil then Sildenafil|"20 mg tadalafil taken orally, as needed, for 8 weeks, followed by 100 mg sildenafil taken orally, as needed, for an additional 8 weeks. There is a washout period of 7-10 days between treatments.~At the end of the two 8-week treatment periods, participants will be allowed to enter an 8-week extension phase on their preferred medication for erectile dysfunction (ED)."
3178106|NCT01352507|Active Comparator|Sildenafil then Tadalafil|"100 mg sildenafil taken orally, as needed, for 8 weeks, followed by 20 mg tadalafil taken orally, as needed, for an additional 8 weeks. There is a washout period of 7-10 days between treatments.~At the end of the two 8-week treatment periods, participants will be allowed to enter an 8-week extension phase on their preferred medication for ED."
3178107|NCT01352494|Experimental|docetaxel/gemcitabine|All the patients are locally advanced breast cancer. Patients with a measurable lesion at chest CT. (at least 1 measurable lesion)
3178108|NCT01352481|Experimental|Intervention group|
3178109|NCT01352481|No Intervention|Control group|
3178110|NCT01352468|Experimental|Multifaceted Cognitive Training|Cognitive Training with 4 different tasks each of which gets progressively more difficult as children obtain proficiency.
3178111|NCT01352468|Sham Comparator|Sham Cognitive Training|Cognitive Training with 4 different tasks which does not get progressively more difficult throughout training
3178112|NCT01352455|Experimental|5 days per week hemodialysis|5 days per week, 2 hours 20 minutes per session versus 3 days per week, 4 hours per session
3178113|NCT01352442|Experimental|AcuFocus Corneal Inlay|The AcuFocus Corneal Inlay ACI 7000PDT, which is a small medical device, will be surgically implanted in one eye of each subject.
3178114|NCT01352429||Phase 1 Feasibility|
3178115|NCT01352429||Phase 2 Registration|
3178116|NCT01352416|Active Comparator|CABG surgery with Ranolazine|Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Ranolazine 1000 mg (2-500mg tablets) twice daily. If intolerant to the study drug due to adverse effects,or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice daily.
3178117|NCT01352416|Placebo Comparator|CABG surgery with placebo|Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Placebo 1000mg mg (2-500mg tablets)twice daily. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily.
3178118|NCT01352416|Active Comparator|Heart Valve surgery with Ranolazine|Patient will undergo heart Valve surgery and will receive, Ranolazine1000mg (2-500 mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice a day.
3178119|NCT01352416|Placebo Comparator|Heart Valve surgery with placebo|Patient will undergo heart Valve surgery and will receive, Placebo 1000mg (2-500mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice a day.
3178120|NCT01352403|Other|intensive life style intrvention|intensive life style intervention over 18 months including movement, psychological meetings and change in food intake
3178121|NCT01352403|Other|gastric bypass|
3178122|NCT01352390|Active Comparator|Control Condition|A basic reminder mailing will prompt each subject to receive a health test as specified on the mailing
3178123|NCT01352390|Experimental|Artwork Prompt Condition|A basic reminder mailing will prompt each subject to give their child a reminder postcard to color
3178124|NCT01352364|Experimental|deaf children|
3178125|NCT01352351|Experimental|Breastfeeding promotion intervention|"Intervention:~Group breastfeeding counseling during monthly microcredit borrower group meetings~Weekly cell phone messages about breastfeeding"
3178126|NCT01352351|No Intervention|No intervention|The no intervention group will participate in their regular microcredit borrower group meetings, but will not receive breastfeeding counseling or cell phone messages.
3178127|NCT01352338|Experimental|lenalidomide, endoxan, prednisone|"lenalidomide 25mg, oral therapy, once a day, 4 weeks cycles. Lenalidomide is used 3 of the 4 weeks.~Lenalidomide is combined with endoxan and prednisone"
3178128|NCT01352325|Experimental|system constellations seminar (exp. group)|Study participants randomized to this group receive the intervention (system constellation seminar) 4 months prior to the control group
3178129|NCT01352325|Experimental|system constellations seminar (control group)|Study participants randomized to this group receive the intervention (system constellations seminar) 4 months after the experimental group.
3178130|NCT01352312|Experimental|Treatment (pentostatin, bendamustine, ofatumumab)|Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, pentostatin IV on day 1, and ofatumumab IV on day 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3178132|NCT01352299|Active Comparator|McCoy|Laryngoscopy performed with MacCoy Laryngoscope
3178133|NCT01352299|Active Comparator|Miller|Laryngoscopy performed with Miller Laryngoscope
3178134|NCT01352299|Active Comparator|TrueView|Laryngoscopy performed with TrueView Laryngoscope
3178135|NCT01352286|Experimental|Autologous Genetically modified T cells|Patients with advanced myeloma and who are candidates for autologous stem cell transplants, or syngeneic stem cell transplants (SSCT), will be eligible. Prior to full screening on this study, patients will undergo prescreening to evaluate HLA-A type and presence of NY-ESO-1c259T/LAGE antigen. Patients will undergo a steady-state mononuclear cell apheresis for T cell collection, with an optional second collection. Once mononuclear cells have been collected, patients (or donors in the case of SSCT) will then undergo hematopoietic stem cell mobilization. Patients will receive a dose >0.1-1 x 10¹º anti-CD3/anti-CD28-costimulated autologous T cells which have been genetically modified to express high affinity NY-ESO-1c259 TCRs.
3178136|NCT01352273|Experimental|MEK162 + RAF265|
3178137|NCT01352260||Cardiac Disease|Total Aortic Arch Replacement
3178138|NCT01352247|Experimental|Unicompartmental Knee Replacement|"TOPKAT will be pragmatic in terms of implant selection for the knee replacement operation. Providing the inclusion criteria are met, surgeons will be entirely free to use an implant of their choice or will use the current implants used at their institution. Implant type used on each patient will be recorded.~A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure."
3178139|NCT01352247|Experimental|Total Knee Replacement|"TOPKAT will be pragmatic in terms of implant selection for the knee replacement operation. Providing the inclusion criteria are met, surgeons will be entirely free to use an implant of their choice or will use the current implants used at their institution. Implant type used on each patient will be recorded.~A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position."
3178140|NCT01352234|Experimental|Group A|Acetylsalicylic Acid 160mg administered at bedtime
3178141|NCT01352234|Active Comparator|Group B|Acetylsalicylic Acid 80mg administered at bedtime
3178142|NCT01352221|Experimental|ST10|ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day
3178143|NCT01352221|Placebo Comparator|Placebo|Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day
3178144|NCT01352208|Experimental|ASP9521|
3178145|NCT01352195|Active Comparator|Usual Care (UC)|This condition will comprise a single, high quality booklet that is currently in dissemination: NCI's Clearing the Air (NCI, 2003).
3178146|NCT01352195|Active Comparator|Standard Repeated Mailings (Stand-RM)|Stand-RM will be the same 8 Forever Free booklets (edited for cessation) distributed over 12 months as in our preliminary studies.
3178147|NCT01352195|Active Comparator|Intensive Repeated Mailings (Inten-RM)|Inten-RM will add two additional booklets to extend the intervention out to 18 months, plus additional monthly contacts.
3178148|NCT01352182|Experimental|Pioglitazone hydrochloride|
3178149|NCT01352182|No Intervention|Normal standard care|
3178150|NCT01352130|Active Comparator|Ondansetron|Patients given Ondansetron
3178151|NCT01352130|Active Comparator|Granisetron|Patients given Granisetron
3178152|NCT01352117|Active Comparator|Arm A: ART alone or with delayed ET|Participants were prescribed ART (co-formulated efavirenz/emtricitabine/tenofovir disoproxil fumarate, EFV/FTC/TDF) for 96 weeks. Arm A participants who experienced KS progression on ART alone could receive ET in addition to EFV/FTC/TDF in Step 2 of the study.
3178153|NCT01352117|Experimental|Arm B: ART with immediate ET|Participants were prescribed ART (co-formulated efavirenz/emtricitabine/tenofovir disoproxil fumarate, EFV/FTC/TDF) for 96 weeks with immediate ET for up to 16 weeks.
3178154|NCT01352104|Experimental|waiting-intervention-course|
3178155|NCT01352091|Experimental|Switch to Zoladex + AI for 3-2 years|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
3178156|NCT01352091|Experimental|TAM|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
3178157|NCT01352078||Non Healing Ulcer|
3178158|NCT01352065|Experimental|BOSENTAN|
3178159|NCT01352065|Experimental|AMBRISENTAN|
3178160|NCT01352065|Placebo Comparator|PLACEBO|
3178161|NCT01352052|No Intervention|waiting list assignment|6 months waiting list assignment followed by the 2-week interdisciplinary rehabilitation programme
3178162|NCT01352052|Active Comparator|Intervention: interdisciplinary rehabilitation programme|A two-weeks non-residential, group-based, psycho-educative treatment course conducted by an interdisciplinary team.
3178163|NCT01352039|Experimental|Heparin Sodium - Eurofarma|
3178164|NCT01352039|Active Comparator|Heparin Sodium - APP Pharmaceuticals|
3178165|NCT01352026|Experimental|Metformin|
3178166|NCT01352013|Placebo Comparator|Colored olive oil|
3178167|NCT01352013|Active Comparator|Omega-3 (oil)|
3178168|NCT01352000|Active Comparator|Usual Care (UC)|Receive Quitline services
3178169|NCT01352000|Active Comparator|Repeated Mailings (RM)|Receive the 8 Forever Free booklets sent by mail at regular intervals over a period of 12 months
3178170|NCT01352000|Active Comparator|Massed Mailings (MM)|Receive all 8 booklets in a single mailing
3178171|NCT01351961|Other|Elderly hypertensive patients with mnemonic subjective|"Elderly hypertensive patients with mnemonic subjective without dementia. Interventions :~blood sampling brain MRI Assessment of cognitive functions brain MRI and TEP cerebral Electrocardiogram and blood pressure Pulse wave velocity Quality of life questionnaire Urine sample Vascular explorations"
3178172|NCT01351948|Experimental|Group 1|AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
3178173|NCT01351948|Experimental|Group 2|AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
3178174|NCT01351948|Experimental|Group 3|AdCh63 AMA1 + AMA1-C1/Alhydrogel®
3178175|NCT01351948|Experimental|Group 4|AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909
3178176|NCT01351948|Experimental|Group 5|AdCh63 AMA1 + MVA AMA1
3178177|NCT01351935|Experimental|AVL-292|
3178178|NCT01351922||A|
3178179|NCT01351909|Experimental|Treatment (veliparib, cyclophosphamide)|Patients receive veliparib orally PO QD and cyclophosphamide PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3178180|NCT01351896|Experimental|Arm I (Concurrent PCV13 and lenalidomide)|Patients receive low-dose lenalidomide PO once daily on days 1-28. Treatment repeats every 28 days for at least 24 courses in the absence of disease progression or unacceptable toxicity. Patients also receive PCV13 IM on days 78 and 134 (courses 3 and 5).
3178181|NCT01351896|Experimental|Arm II (Sequential PCV13 and lenalidomide)|Patients receive PCV13 IM on days 1 and 78 (courses 1 and 3). Patients also receive low-dose lenalidomide as in arm 1 beginning on day 106 (course 4).
3178182|NCT01351883|No Intervention|Standard enteral nutrition supplement|regular standard enteral nutrition(SEN) was made by hospital for patient
3178183|NCT01351870|Active Comparator|Standard Fractionation Regimen|"1.8 Gy daily, 5 fractions per week~Cranio-spinal axis:~23.4 Gy in 13 fractions of 1.8 Gy~Posterior fossa:~30.6 Gy in 17 fractions of 1.8 Gy"
3178184|NCT01351870|Experimental|Hyperfractionated radiotherapy|"1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week~Craniospinal axis:~36 Gy in 36 fractions of 1 Gy~Posterior fossa:~24 Gy in 24 fractions of 1 Gy~Tumour Bed:~8 Gy in 8 fractions of 1 Gy"
3178185|NCT01351857|Other|Transition Coordinator|A Transition Coordinator, a Certified Diabetes Educator, will provide transition support and the link between pediatric and adult diabetes care. The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
3178186|NCT01351857|No Intervention|Current Standard of Care|Subjects in the control group will transition to adult care equal to the intervention group and will differ only by exclusion of Transition Coordinator. Control group will receive the current standard of diabetes care otherwise unchanged. Three months following randomization, subjects in the control group will be referred to the adult endocrinologist in the same way as subjects in the intervention group
3178187|NCT01351844|Active Comparator|Education and exercise intervention|"The intervention module will contain a brief series of slides with a voice-over. An occupational therapist will review recommended exercises."
3178188|NCT01351844|Placebo Comparator|Education and general exercise|"The control module will contain a brief series of slides with a voice-over. A physical therapist with experience in treating breast cancer patients will demonstrate a series of 4-5 general stretching and toning exercises."
3178189|NCT01351831|Experimental|Rehabilitation with strength training|
3178190|NCT01351831|Active Comparator|Rehabilitation without strength training|
3178191|NCT01351818||Growth hormone|Patients with a condition
3178192|NCT01351805|Experimental|Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
3178193|NCT01351805|Experimental|Vitamin D|Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.
3178194|NCT01351805|Placebo Comparator|placebo|Subjects will receive placebo pill.
3178195|NCT01351805|Experimental|Vitamin D and Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
3178196|NCT01351792|Experimental|Foster®|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
3178197|NCT01351792|Active Comparator|Symbicort® Turbohaler®|Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
3178198|NCT01351779||Progressive glaucoma|Patients with primary open angle glaucoma identified to have an optic disc hemorrhage
3178199|NCT01351766|Experimental|Behavioral Activation Treatment for Smoking|BATSY includes standard smoking cessation strategies and identifying life areas, values, and daily activities to help manage mood. Participants will complete between group exercises and will also monitor and plan daily activities in line with their values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period.
3178200|NCT01351753|Active Comparator|Metformin|
3178201|NCT01351753|Experimental|Metformin + Orlistat|
3178202|NCT01351753|Experimental|Metformin + Topiramate|
3178203|NCT01351753|Experimental|Topiramate|
3178204|NCT01351753|Experimental|Metformin + Topiramate + Orlistat|
3178205|NCT01351753|Placebo Comparator|Placebo|
3178206|NCT01351740|Experimental|Switch|switch to unboosted atazanavir 400mg daily with the same nucleoside (NRTI) backbone
3178207|NCT01351740|Active Comparator|Continuation|continue on current regimen of atazanavir/ritonavir 300mg/100mg with the same nucleoside (NRTI) backbone
3178208|NCT01351727||Seniors with Seizures|Seniors aged 65 or older with newly diagnosed seizures (consistent with epilepsy) or epilepsy as of October, 2010.
3178209|NCT01351714|Other|D3 resection|Radical D3 resection of the right colon through the use of preoperative MDCT angiography
3178210|NCT01351688|Experimental|AZD3514|Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD)
3178211|NCT01351675|Placebo Comparator|Placebo|
3178212|NCT01351675|Experimental|Bardoxolone Methyl|
3178213|NCT01351662|Experimental|Self management program|"The Arthritis Self-Management Program (ASMP) will be administered to 15 African American lupus patients participating in an ongoing SLE Clinic Database Project at the Medical University of South Carolina (MUSC). Fifteen other patients will serve as controls and receive usual care."
3178214|NCT01351649|Other|attention control|Sessions with school nurse to discuss health-promoting topics and after-school health-promoting workshop. Physical activity and healthy eating were not addressed.
3178215|NCT01351649|Experimental|physical activity|
3178216|NCT01351636|Experimental|Arotinolol Hydrochloride|Antihypertensive medications plus arotinolol hydrochloride
3178217|NCT01351636|Placebo Comparator|Non arotinolol group|Antihypertensive medications without arotinolol hydrochloride
3178218|NCT01351623|Experimental|Carfilzomib|A single arm, open-label, single institution phase 2 clinical trial is planned.
3178219|NCT01351610|Experimental|Group B|
3178221|NCT01351597|Experimental|docetaxel/ oxaliplatin|All the patients are recurrent or metastatic breast cancer. Patients with a measurable lesion.
3178222|NCT01351571||Cohort|
3178223|NCT01351558|No Intervention|Control|No intervention for 12 weeks
3178224|NCT01351558|Active Comparator|Knee muscle strengthening exercises|
3178225|NCT01351558|Active Comparator|Upper extremity strengthening exercises|
3178226|NCT01351558|Active Comparator|Cardiovascular fitness exercises|
3178227|NCT01351545||Unlicensed CBU|The cohort includes recipients of any age receiving unlicensed cryopreserved cord blood units (CBUs) for designated indications.
3178228|NCT01351532|Experimental|Lifestyle counseling, smoking cessation drug|
3178229|NCT01351532|Active Comparator|Lifestyle counseling|
3178230|NCT01351519|Experimental|Aminolevulinic Acid (AL)|
3178231|NCT01351493|Active Comparator|Nitric oxide gel|
3178232|NCT01351493|Placebo Comparator|placebo|
3178233|NCT01351480|Other|abatacept|open label use of abatacept for 12 months
3178234|NCT01351467||Parkinson's disease patients|People diagnosed with Parkinson's disease by a physician
3178235|NCT01351454|Active Comparator|ACT HEALTHY|ACT HEALTHY is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001) and Life Steps, an HIV medication adherence intervention (Safren, Otto, & Worth, 1999). ACT HEALTHY is based on the belief that the best way to improve mood, remain sober, increase medication adherence, and make long-term life changes is by changing and increasing one's activity level. Treatment includes 16 individual sessions over a 12-week period.
3178236|NCT01351454|Placebo Comparator|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, & Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
3178237|NCT01351441|Other|Age 65 years or over AND at least 5 chronic medications|
3178238|NCT01351428|Experimental|NICOM group|Vasodilator therapy begins when SVR increases by 20% or greater than baseline. Therapy is titrated according to hemodynamic profile and clinical signs and symptoms.
3178239|NCT01351415|Experimental|Bevacizumab + Standard of Care|Participants will receive bevacizumab on Day 1 of every 21-days cycle along with standard of care (Erlotinib or Docetaxel or Pemetrexed) as second line treatment, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).
3178240|NCT01351415|Active Comparator|Standard of Care|Participants will receive investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).
3178241|NCT01351389|Active Comparator|Brief Motivational Intervention (BMI)|
3178242|NCT01351389|Active Comparator|Brief Advice|
3178243|NCT01351376|Placebo Comparator|Placebo|CDT + inactive LLL
3178244|NCT01351376|Active Comparator|LLL combined with CDT|CDT + active LLL
3178245|NCT01351363|Experimental|Electrical pain threshold measrement patients|
3178246|NCT01351350|Experimental|MLN0128P 30 mg QW|MLN0128 and paclitaxel (MLN0128P): MLN0128 30 mg, capsule, orally, once weekly (QW) + paclitaxel 80 mg/m^2, 1 hour infusion, on days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
3178247|NCT01351350|Experimental|MLN0128P 40 mg QW|MLN0128 40 mg, capsule, orally, once a week (QW) + paclitaxel 80 mg/m^2, 1 hour infusion, on days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
3178248|NCT01351350|Experimental|MLN0128P 6 mg QD×3d QW|MLN0128 6 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
3178249|NCT01351350|Experimental|MLN0128P 7 mg QD×3d QW|MLN0128 7 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
3178250|NCT01351350|Experimental|MLN0128P 8 mg QD×3d QW|MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
3178251|NCT01351350|Experimental|MLN0128P 9 mg QD×3d QW|MLN0128 9 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
3178252|NCT01351350|Experimental|MLN0128P 10 mg QD×3d QW|MLN0128 10 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
3178253|NCT01351350|Experimental|MLN0128P 7 mg QD×5d QW|MLN0128 7 mg, capsule, orally, once daily 5 days on/2 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
3178254|NCT01351350|Experimental|MLN0128P 8 mg QD×3d QW HER2-|MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on days 1, 8 and 15 of a 4-week cycle in human epidermal growth factor receptor 2 negative (HER-) cancer patients until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.
3178255|NCT01351350|Experimental|MLN0128PH 8 mg QD×3d QW HER2+|MLN0128 + paclitaxel + trastuzumab (MLN0128PH): MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on days 1, 8 and 15 plus trastuzumab 4 mg/kg loading dose on day 1 followed by 2 mg/kg, intravenous each week of a 4-week cycle in HER+ cancer patients until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.
3178256|NCT01351337|Other|intraoperative functional monitoring|intraoperative functional monitoring
3178257|NCT01351324|Experimental|SFA|Oral dose of palmitic acid (SFA) given as a chocolate-flavoured drink every 30 min (0-390 min) with a continuous infusion of heparin (60-390 min).
3178258|NCT01351324|Experimental|SFA + LC n-3 PUFA|Oral dose of palmitic acid and DHA-rich fish oil (SFA + LC n-3 PUFA) given as a chocolate-flavoured drink every 30 min (0-390 min) together with a continuous infusion of heparin (60-390 min).
3178259|NCT01351311|Experimental|Exercise Group|Resistance exercise with swiss ball and drug treatment
3178260|NCT01351311|Other|Control Group|Drug treatment
3178262|NCT01351298|Experimental|Decongestant|
3178263|NCT01351298|Experimental|Decongestant and local anesthetic|
3178264|NCT01351285|Experimental|Sevo group|undergoing sevoflurane-remifentanil anesthesia
3178265|NCT01351285|Active Comparator|Des group|undergoing desflurane-remifentanil anesthesia
3178266|NCT01351285|Active Comparator|Pro group|undergoing propofol-remifentanil anesthesia
3178267|NCT01351272|Experimental|methylphenidate, non-retard|
3178268|NCT01351259|Experimental|Pneumatic device, tapered cuff|Intervention: continuous control of cuff pressure using a pneumatic device, tapered polyurethane cuff
3178269|NCT01351259|Experimental|Pneumatic device, cylindrical cuff|Continuous control of cuff pressure using a pneumatic device in patients intubated with cylindrical polyurethane cuffed tracheal tubes
3178270|NCT01351259|Active Comparator|Routine care, tapered cuff|Routine care of cuff pressure using a manometer, tapered polyurethane cuff
3178271|NCT01351259|Active Comparator|Routine care, cylindrical cuff|Routine care of cuff pressure using a manometer, cylindrical polyurethane tracheal cuff
3178272|NCT01351246|Experimental|Intervention|
3178273|NCT01351220|Active Comparator|Basic dissemination|
3178274|NCT01351220|Active Comparator|Organizational dissemination|
3178275|NCT01351207|Active Comparator|pork sausages and hash brown potatoes plus eggs|
3178276|NCT01351207|Placebo Comparator|pork sausages and hash brown potatoes plus egg-free pudding|
3178277|NCT01351207|Placebo Comparator|pork sausages and hash brown potatoes|
3178278|NCT01351194|Experimental|RFA group|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
3178279|NCT01351194|Experimental|HR group|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
3178280|NCT01351181|Experimental|Exercise advice|Behavioural
3178281|NCT01351181|Other|Normal Care|Normal care
3178282|NCT01351168|Placebo Comparator|Sugar pill|
3178283|NCT01351168|Active Comparator|Levodopa|
3178284|NCT01351168|Experimental|Zolpidam second dose|
3178285|NCT01351168|Experimental|Zolpidam first dose|
3178286|NCT01351155|Active Comparator|polyurethane foam (Allewyn adesive)|Polyurethane foam is applied as skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
3178287|NCT01351155|Active Comparator|polyurethane film (Tegaderm)|The polyurethane film is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
3178288|NCT01351155|Active Comparator|Hydrocolloid (Duoderm)|Hydrocolloid is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
3178289|NCT01351155|No Intervention|Control|In this no-intervention arm, any skin protective dressing devices is applied before NIV starting
3178290|NCT01351129|Experimental|Formulation 1|
3178291|NCT01351129|Experimental|Formulation 2|
3178292|NCT01351129|Experimental|Formulation 3|
3178293|NCT01351116|Experimental|EBR plus HDRIB|External Beam Radiation (EBR) plus High Dose Rate Intraluminal Brachytherapy (HDRIB)
3178294|NCT01351116|Active Comparator|EBR|External Beam Radiation (EBR)
3178295|NCT01351103|Experimental|LGK974|
3178296|NCT01351103|Experimental|LGK974 in combination with PDR001|
3178297|NCT01351090|Experimental|Ketorolac tromethamine (5%)|
3178298|NCT01351090|Experimental|Ketorolac tromethamine (15%)|
3178299|NCT01351090|Placebo Comparator|Placebo|
3178300|NCT01351077|Experimental|CHICA DevScreen Module|This arm will get the CHICA Developmental Screening Module
3178301|NCT01351077|No Intervention|CHICA DevScreen Control|This arm will get CHICA without the developmental screening module
3178302|NCT01351064|Experimental|CHICA ADHD Module|This arm received The CHICA ADHD Module
3178303|NCT01351064|No Intervention|CHICA ADHD Control|This arm received CHICA without the ADHD module
3178304|NCT01351051||No endometriosis|
3178305|NCT01351051||Superficial endometriosis|
3178306|NCT01351051||Endometrioma|
3178307|NCT01351051||Deep infiltrating endometriosis|
3178308|NCT01351038|Experimental|treatment|3 cycles(repeated q21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Capecitabine 500mg/m² bid d1-d21 Panitumumab 9mg/kg i.v. d1
3178309|NCT01351025|Experimental|Arm A: atorvastatin / placebo|"At study entry (week 0), participants continued the entry boosted PI-based antiretroviral regimen (not provided by the study) and initiated atorvastatin at a daily dose of 10 mg for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, the dose of atorvastatin was increased to 20 mg daily at the week 4 visit. At week 20, atorvastatin was stopped for a 4-week washout period.~At week 24, placebo was started for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, the placebo dose was doubled at week 28. At week 44, the placebo was stopped to allow for another 4-week washout period."
3178310|NCT01351025|Experimental|Arm B: placebo / atorvastatin|"At study entry (week 0), participants continued the entry boosted PI-based antiretroviral regimen (not provided by the study) and initiated placebo for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, the dose of placebo was doubled at the week 4 visit. At week 20, the placebo was stopped for a 4-week washout period.~At week 24, atorvastatin was started at a daily dose of 10 mg for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, the dose of atorvastatin was increased to 20 mg daily at week 28. At week 44, atorvastatin was stopped to allow for another 4-week washout period."
3178311|NCT01351012|Placebo Comparator|Corn and safflower oil|
3178312|NCT01351012|Active Comparator|Canola oil|
3178313|NCT01351012|Active Comparator|High oleic acid canola oil|
3178314|NCT01351012|Active Comparator|DHA enriched high oleic acid canola oil|
3178315|NCT01351012|Active Comparator|Flax and safflower oil|
3178316|NCT01350999|Experimental|TAK-085 2 g|TAK-085 2 g, orally, once daily for up to 52 weeks.
3178317|NCT01350999|Experimental|TAK-085 4 g|TAK-085 2 g, orally, twice daily for up to 52 weeks.
3178318|NCT01350999|Active Comparator|EPA-E 1.8 g|Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.
3178319|NCT01350986|Experimental|Directive|
3178320|NCT01350986|Active Comparator|Non-Directive|
3178321|NCT01350973|Experimental|TAK-085 2 g|TAK-085 2 g, orally, once daily for up to 12 weeks.
3178322|NCT01350973|Experimental|TAK-085 4 g|TAK-085 2 g, orally, twice daily for up to 12 weeks.
3178323|NCT01350973|Experimental|EPA-E 1.8 g|Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.
3178324|NCT01350960|Placebo Comparator|saline 0.9%|
3178325|NCT01350960|Experimental|Cohort 1|0.5 mg/kg in Healthy Subjects
3178326|NCT01350960|Experimental|Cohort 2|1.5 mg/kg in Healthy subjects
3178327|NCT01350960|Experimental|Cohort 3|5.0 mg/kg in Healthy subjects
3178328|NCT01350960|Experimental|Cohort 4|10 mg/kg in Healthy subjects
3178329|NCT01350960|Experimental|Cohort 5|TBD mg/kg in FH subjects
3178330|NCT01350947|Experimental|All patients|All participants enrolled.
3178331|NCT01350934|Experimental|Fosamax Plus|Participants received alendronate 70 mg plus vitamin D3 5600 IU in a combination tablet (FOSAMAX PLUS D) once weekly for 6 months (base study), and then once weekly for another 6 months (extension study).
3178332|NCT01350934|Active Comparator|Calcitriol|Participants received calcitriol 0.25 μg once daily orally for 6 months (base study), and then once daily orally for another 6 months (extension study).
3178333|NCT01350908|Other|Blood sampling|
3178334|NCT01350895||Experimental Group|
3178335|NCT01350895||Control Group|
3178336|NCT01350882|Experimental|A|Patients randomized into the arm blind A. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
3178337|NCT01350882|Placebo Comparator|B|Patients randomized into the arm blind B. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
3178338|NCT01350869||Xience stent|Real world patients treated with XIENCE stents
3178339|NCT01350856|Active Comparator|Artesunate 2|Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
3178340|NCT01350856|Experimental|Artesunate 4|Artesunate 4 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
3178341|NCT01350843|Experimental|Orange Juice|Juice high in flavonoids
3178342|NCT01350843|Placebo Comparator|Orange Drink|Sugars matched, low flavonoids orange drink
3178343|NCT01350830|Active Comparator|pre-trasversalis mesh repair group|
3178344|NCT01350830|Active Comparator|trans-inguinal preperitoneal patch group|
3178345|NCT01350817|Active Comparator|Docetaxel|
3178346|NCT01350817|Experimental|Erlotinib|
3178347|NCT01350804|Experimental|AIN457 10mg/kg - 75 mg|Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks
3178348|NCT01350804|Experimental|AIN457 10mg/kg - 150 mg|Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks
3178349|NCT01350804|Placebo Comparator|Placebo|Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (>= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.
3178350|NCT01350804|Active Comparator|Abatacept|Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).
3178351|NCT01350791||Promus Element stent|Patients receiving Promus Element stents
3178352|NCT01350778||Biomatrix stent|patients treated with Biomatrix stent
3178353|NCT01350765|Experimental|Intervention|This would be the interventional arm of the study, where the LHWs would receive additional training for identification and management of birth asphyxia, lbw, and sepsis.
3178354|NCT01350765|Active Comparator|Control|This would be the comparative group of the study in which the LHWs would perform the usual routine tasks assigned to them by their program.
3178355|NCT01350752|No Intervention|Control|"In Cameroon: Existing practice (with microscopy widely available)~In Nigeria: Expected practice (RDTs will be provided with basic instructions)"
3178391|NCT01350505|Placebo Comparator|Arm 2|Dim white light
3178392|NCT01350505|Experimental|Arm 3|Red light
3178393|NCT01350505|Experimental|Arm 4|Orange light
3178356|NCT01350752|Active Comparator|Provider Intervention|"Cameroon: Introduce malaria RDTs with basic provider training and job aids on malaria diagnosis and treatment. This involved 1-day training on: 1) Malaria Diagnosis; 2) Rapid Diagnostic Testing; 3) Malaria Treatment. These modules explain that all febrile patients should be tested for malaria; procedures for using an RDT; that confirmed cases of uncomplicated malaria should be treated with an ACT; and test-negative patients should not be given an antimalarial.~Nigeria: Introduce malaria RDTs with provider training and job aids on malaria diagnosis and treatment. This involved a 2-day training workshop and support visits. The training covered the following topics: causes and symptoms of malaria; demonstration on how to use an RDT; updated malaria guidelines; and communications skills. The training used a combination of seminars and facilitated small-group work, such as a treatment algorithm game, problem-solving exercises, self-developed participatory drama and role-playing."
3178357|NCT01350752|Active Comparator|Extended intervention|"Cameroon: Introduce malaria RDTs with basic provider training and job aids on malaria diagnosis and treatment AND enhanced provider training on improving quality of care. Clinicians received 3-days of training: the first day was identical to the basic intervention, while the remainder of the course covered three additional modules targeting improvements in quality of care: 4) Adapting to Change; 5) Professionalism; 6) Communicating Effectively.~Nigeria: Introduce malaria RDTs with provider training and job aids on malaria diagnosis and treatment AND School-based malaria education intervention (with drama, peer-health education and distribution of health education materials). In addition, teachers and Peer Health Educators were offered support to hold malaria events in which parents, guardians, and other community members could participate in the same types of activities."
3178358|NCT01350739|Other|intraumbilical incision|an intraumbilical vertical incision is made
3178359|NCT01350739|Other|infraumbilical incision|incision is done in circular fashion at the inferior boarder of umbilicus
3178360|NCT01350726||Normal control|Subjects without liver cirrhosis and normal volunteers.
3178361|NCT01350726||Cirrhosis group|Subjects with liver cirrhosis.
3178362|NCT01350713|Experimental|povidone iodine|
3178363|NCT01350713|Active Comparator|cold water|treatment by cold water after burn
3178364|NCT01350700||Patients that were treated in MW2004-011-02 study with Debrase|
3178365|NCT01350700||Patients that were treated in MW2004-011-02 with SOC|
3178366|NCT01350674|Experimental|EBUS|patients undergoing EBUS
3178367|NCT01350661||Asthma control level assessment|
3178368|NCT01350622|Experimental|Pennsaid|Active Pennsaid and oral placebo
3178369|NCT01350622|Active Comparator|Oral Diclofenac|Oral diclofenac and placebo lotion (2.3% DMSO solution)
3178370|NCT01350609|Experimental|Nifedipine/Candesartan (fixed dose)|
3178371|NCT01350609|Active Comparator|Nifedipine/Candesartan (loose)|
3178372|NCT01350596|Active Comparator|Reference Drug|
3178373|NCT01350596|Active Comparator|Test Drug|
3178374|NCT01350583|Experimental|Sodium Bicarbonate Therapy|Dose Escalation
3178375|NCT01350570|Experimental|acupuncture group 1|Acupoints ST25 and BL25 will be used in the group. ST25 locate at the abdomen, while BL25 locate at the back.
3178376|NCT01350570|Experimental|acupuncture group 2|Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
3178377|NCT01350570|Experimental|acupuncture group 3|All acupoints used in acupuncture group1 and acupuncture group2 will be used in this group.
3178378|NCT01350570|Active Comparator|Loperamide|Loperamide will be used as an active comparator to the acupuncture groups.
3178379|NCT01350557|No Intervention|Control group|Patients receive only usual hospital care
3178380|NCT01350557|Other|Subacute care group|Patients receive hospital usual care and subacute care. Subacute care consisted of geriatric consultation, a rehabilitation program, and early discharge planning.
3178381|NCT01350557|Experimental|Comprehensive care group|Patients receive not only the subacute care (geriatric consultation, rehabilitation program, and discharge planning), but also health-maintenance interventions to prevent falls, consult on nutrition, and manage depression.
3178382|NCT01350544|No Intervention|Wait-list control|Participants in the wait-list control group will not receive the intervention until after the 6-month follow-up assessment.
3178383|NCT01350544|Experimental|treatment advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with AIDS Project Los Angeles' (APLA) social service programs, as necessary.
3178384|NCT01350531|Experimental|Skills training|
3178385|NCT01350531|Experimental|Contingency Management|
3178386|NCT01350518|Placebo Comparator|Study prepared meals and placebo|Participants will have meals designed specifically for them based on their caloric needs. Participants will choose a weeks worth of meals (from a menu) and pick them up from the Clinical Research Unit twice a week. Participants will not receive any fiber (Benefiber) supplementation in their TrueLemon mixture.
3178387|NCT01350518|Active Comparator|Nutritional Counseling with fiber|Participants receiving nutritional education will have two individual sessions (spaced approx. 2 weeks apart). The nutritional sessions will focus on knowledge, self-regulation, motivation, experience and environment. Participants will receive fiber (Benefiber) supplementation as the fiber intervention in their TrueLemon mixture .
3178388|NCT01350518|Placebo Comparator|Nutrition counseling and placebo|Participants receiving nutritional education will have two individual sessions (spaced approx. 2 weeks apart). The nutritional sessions (interventions) will focus on knowledge, self-regulation, motivation, experience and environment.Participants will receive no fiber supplementation in their TrueLemon mixture .
3178389|NCT01350518|Active Comparator|Study prepared meals and fiber|Participants will have meals designed specifically for them based on their caloric needs. Participants will choose a weeks worth of meals (from a menu) and pick them up from the Clinical Research Unit twice a week. Participants will receive fiber (Benefiber) supplementation as the fiber intervention in their TrueLemon mixture.
3178390|NCT01350505|Active Comparator|Arm 1|White room light
3178394|NCT01350505|Experimental|Arm 5|Yellow light
3178395|NCT01350492|Experimental|Arm 1|Resistance exercise training
3178396|NCT01350492|No Intervention|Arm 2|Waitlist Control
3178397|NCT01350479||MRSA colonized|Residents with history of MRSA in the past year
3178398|NCT01350479||Not MRSA colonized|Residents without history of MRSA in the past year
3178399|NCT01350466||FESS patients|
3178400|NCT01350466||Controls|
3178401|NCT01350453|Experimental|LifeCIT|Participants will be asked to aim to wear the C-MIT for 9 hours a day for 5 days/week, including 4-6 hours of structured activities per day: two 30-60 minute sessions of web-based activities and 3-4 hours practicing everyday activities.
3178402|NCT01350453|Active Comparator|Standard Care|
3178403|NCT01350440|Experimental|IVIG|Intravenous Immune Globulin
3178404|NCT01350427|Experimental|Leucine|
3178405|NCT01350427|Experimental|BCAA|
3178406|NCT01350427|Placebo Comparator|Placebo|
3178407|NCT01350414||Alair Group|Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02, NCT00231114)
3178408|NCT01350401|Experimental|NY-ESO-1/LAGE-1 and HLA-A*02 Positive Subjects|
3178409|NCT01350388|Active Comparator|Febuxostat|80 mg/day of febuxostat for 24 weeks
3178410|NCT01350388|Placebo Comparator|Placebo|1 placebo tablet per day for 24 weeks
3178411|NCT01350375|Placebo Comparator|Saline|
3178412|NCT01350375|Active Comparator|Botox|
3178413|NCT01350362|Experimental|Tideglusib 1000 mg Q.D.|Group dosed with 1000 mg once daily for 26 weeks/extension
3178414|NCT01350362|Experimental|Tideglusib 1000 mg Q.O.D.|Group dosed with 1000 mg once every other day for 26 weeks/extension
3178415|NCT01350362|Experimental|Tideglusib 500 mg Q.D.|Group dosed with 500 mg once daily for 26 weeks/extension
3178416|NCT01350362|Placebo Comparator|Placebo|Once daily administration for 26 weeks/extension
3178417|NCT01350349|Experimental|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
3178418|NCT01350349|Active Comparator|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
3178419|NCT01350336|Experimental|Alair|Alair system
3178420|NCT01350323|Active Comparator|Type 3 NV|Wet-AMD related type 3 neovascularization
3178421|NCT01350323|Active Comparator|Type 2 NV|Wet-AMD related type 2 neovascularization
3178422|NCT01350323|Active Comparator|Type 1 NV|Wet-AMD related type 1 neovascularization
3178423|NCT01350323|Other|Controls|Aqueous sample (0.1ml) in patients undergoing cataract extraction
3178424|NCT01350310|Experimental|Intramyocardial Injections|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Electromechanical mapping will be used to identify viable myocardium and intramyocardial injections in the target areas will be performed with NOGA catheter. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure.
3178425|NCT01350310|Active Comparator|Intracoronary Injections|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Patients will undergo myocardial perfusion scintigraphy and CD34+ cells will be injected intracoronary in the artery supplying segments of reduced viability. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure.
3178426|NCT01350310|Active Comparator|Ischemic heart disease|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Electromechanical mapping will be used to identify viable myocardium and intramyocardial injections in the target areas will be performed with NOGA catheter. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure
3178427|NCT01350297|Experimental|Patients|Patients
3178428|NCT01350284|Experimental|Dietary supplementation|3g of cinnamon or placebo control were added to a test-meal.
3178429|NCT01350271|Placebo Comparator|Placebo|Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
3178430|NCT01350271|Active Comparator|Mebendazole polymorph A and C 500 mg|Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
3178431|NCT01350271|Experimental|Mebendazole polymorph C 500 mg|Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
3178432|NCT01350258|Experimental|Transplant Treatment Group|All patients treated on this research study.
3178433|NCT01350245|Experimental|TJU 2 Step Regimen|All patients treated on this trial will have hematological malignancies that are in remission at the time of the transplant. Their diseases would be expected to relapse with standard therapy alone.
3178434|NCT01350232|Experimental|HSCT|"Subjects receive the preparative regimen in 2 steps. The first step will be with fludarabine and cytarabine and a low dose of total body irradiation. This will be followed by the first step of the transplant graft - the donor lymphocytes. The second step of the chemotherapy will be two doses of cyclophosphamide. This will then be followed by the second step of the transplant graft - the stem cells.~Only subjects with prior alloimmunization against donor will receive desensitization. Subjects who demonstrate alloimmunization against the HLA of the donor will receive bortezomib and rituximab in combination with plasmapheresis prior to the admission for transplant."
3178435|NCT01350219|Experimental|Cord blood stem cell|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations.
3178513|NCT01349803|Active Comparator|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
3178514|NCT01349790|Experimental|NewGam|Each participant received 1 g/kg NewGam intravenously on 2 consecutive days.
3178515|NCT01349777|Experimental|Pregrel®|clopidogrel
3178436|NCT01350206|Experimental|HR group|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
3178437|NCT01350206|Experimental|TACE group|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
3178438|NCT01350193|Active Comparator|Saline Nasal Irrigation|Saline Nasal Irrigation is actively being used as the standard of care. It does not contain any active ingredients.
3178439|NCT01350193|Experimental|Manuka Honey Irrigation|Manuka Honey Irrigation involves the experimental treatment of manuka honey nasal irrigation.
3178440|NCT01350167|Active Comparator|Triphasic CT|Triphasic CT of the abdomen with and without contrast every 12 months with alpha-fetoprotein every 6 months.
3178441|NCT01350167|Active Comparator|Ultrasound|Ultrasound of the upper left quadrant with alpha-fetoprotein testing every 6 months.
3178442|NCT01350154|Experimental|Sildenafil (Revation) 20 mg|This arm will receive sildenafil for 4 weeks followed by 2 weeks washout and 4 weeks placebo.
3178443|NCT01350154|Experimental|Placebo|This arm will receive placebo for 4 weeks followed by 2 weeks washout and 4 weeks sildenafil
3178444|NCT01350141|Placebo Comparator|Treatment A|
3178445|NCT01350141|Experimental|Treatment B|
3178446|NCT01350141|Experimental|Treatment C|
3178447|NCT01350128|Experimental|PT001 MDI (Dose 1)|PT001 MDI
3178448|NCT01350128|Experimental|PT001 MDI (Dose 2)|PT001 MDI
3178449|NCT01350128|Experimental|PT001 MDI (Dose 3)|PT001 MDI
3178450|NCT01350128|Experimental|PT001 MDI (Dose 4)|PT001 MDI
3178451|NCT01350128|Active Comparator|Ipratropium Bromide HFA Inhalation Aerosol|Ipratropium Bromide HFA Inhalation Aerosol
3178452|NCT01350128|Placebo Comparator|Placebo MDI|PT001 Placebo MDI
3178453|NCT01350115|Active Comparator|LDE225|Participants received 400 mg once daily.
3178454|NCT01350115|Placebo Comparator|Placebo|Participants received matching placebo.
3178455|NCT01350102|Active Comparator|Bacitracin wound care dressing alone|Bacitracin wound care dressing alone
3178456|NCT01350102|Active Comparator|Bacitracin with Vit C|Bacitracin wound care dressing with Vitamin C supplementation
3178457|NCT01350102|Active Comparator|AmeriGel® wound care dressing alone|AmeriGel® wound care dressing alone
3178458|NCT01350102|Active Comparator|AmeriGel® with Vit C|AmeriGel® wound care dressing with Vitamin C supplementation
3178459|NCT01350089|Placebo Comparator|Placebo|
3178460|NCT01350089|Active Comparator|Comparator 1 (with alcohol)|
3178461|NCT01350089|Active Comparator|Comparator 2 (with alcohol and coffeine)|
3178462|NCT01350089|Experimental|Comparator 3 (with alcohol and energy drink)|
3178463|NCT01350076|Active Comparator|control group|Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
3178464|NCT01350076|Experimental|study group|"Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index"
3178465|NCT01350063|Experimental|Aquatabs and Safe Storage Vessel|Households in this group will receive Aquatabs for water purification, a safe water storage container to prevent contamination during storage in the home, and training and encouragement to treat and safely store their water using the provided products.
3178466|NCT01350063|Experimental|Safe Storage Vessel|Households in this group will receive a safe water storage container, and training and encouragement to safely store their water using the provided products. If our study shows that treatment of tubewell water at the household level is effective in protecting children's health, they will receive a six-month supply of water treatment tablets at the end of the study.
3178467|NCT01350063|Other|Standard practice|Households in this group will not receive any water treatment or storage intervention during the study. They will continue their usual water collection and storage practices. If our study shows that treatment and safe storage of tubewell water at the household level is effective in protecting children's health, they will receive the same safe water storage container as Groups 1 and 2 as well as a six-month supply of water treatment tablets at the end of the study.
3178468|NCT01350050|Active Comparator|articaine|Pharyngeal anesthesia with articaine 4% or placebo should randomly and double-blindly applied in turns for every volunteer. In details: 3 ml of Articaine 4%solution or placebo (NaCl 0,9%) will be sprayed into the pharynx 5 minutes before beginning of gastroscopy. Also gastroscope will be lubricated with articaine (or placebo) gel(prepared by adding 4% articaine or 0,9%NaCl in placebo grope to Endopurin® endoscopic lubricant at the day of study).
3178469|NCT01350050|Placebo Comparator|placebo|Pharyngeal anesthesia with placebo or articaine 4% should be randomly and double-blindly applied in turns for every volunteer. In details: 3 ml of placebo or Articaine 4% solution should be sprayed into the pharynx 5 minutes before beginning of gastroscopy. Also gastroscope will be lubricated with placebo(or articaine) gel(prepared by adding 4% articaine or 0,9%NaCl in placebo grope to Endopurin® endoscopic lubricant at the day of study).
3178470|NCT01350037|Active Comparator|remifentanil|sedative mixture for PCS consisting of propofol 10mg/ml 20 ml and remifentanil 50 mkg/ml 5 ml
3178471|NCT01350037|Active Comparator|alfentanil 0.04 mg/ml|sedative mixture for PCS consisting of propofol10 mg/ml 20 ml,alfentanil 0.5 mg/ml 2 ml, NaCL 9 mg/ml 3 ml
3178472|NCT01350037|Active Comparator|alfentanil 0.08 mg/ml|sedative mixture for PCS consisting of propofol 10 mg/ml 20 ml, alfentanil 0.5 mg/ml 4 ml,NaCl 9mg/ml 1ml
3178473|NCT01350024|Active Comparator|Frontal Nerve Block|Patients will receive a frontal nerve block for anesthesia
3178474|NCT01350024|Active Comparator|Subconjucntival Injection|Patients will receive a subconjunctival injection for anesthesia
3178516|NCT01349777|Active Comparator|Plavix®|clopidogrel
3178601|NCT01349205|Placebo Comparator|0.9 NS Saline|Control group of randomized study.
3178475|NCT01350011|Active Comparator|Innovative System (IS)|The innovative intervention uses the treatment system to support motivational counseling treatment entrance and treatment utilization. It has two components, a Motivational Intervention component via Expert System Counseling, and a Treatment Component that incorporates both pharmacological and behavioral long-term components. An innovative aspect of the IS is the use of the pharmacist as an intervention agent, who queries participants on their readiness to quit smoking, encourages involvement in the motivational intervention and in treatment, and who, along with the counselors, is available to answer medication questions.
3178476|NCT01350011|Active Comparator|Standard Treatment Control|After a baseline interview, patients in this condition will be given a packet of brochures on quitting, including descriptions of self-quitting and help-lines. Participants in this condition will continue to have access to their primary care providers, and through that system have access to pharmacotherapy for smoking cessation, if they wish to receive it. They will receive written instructions on how to approach their primary care provider about smoking cessation medication, and a written description of the medications used in smoking cessation and a list of those that are available to them through the public health system. At each assessment, patients will be queried about their use of these resources.
3178477|NCT01349998|Experimental|Safety Population|
3178478|NCT01349985|Experimental|AGATE|To evaluate whether AGATE, a smartphone medication reminder and assessment system, effectively measures and enhances medication adherence in the context of naltrexone treatment for problem drinking.
3178479|NCT01349985|Active Comparator|SASED|The control condition for the proposed study is a smartphone alcohol and side-effects diary (SASED, a smartphone alcohol and side effects diary).
3178480|NCT01349972|Experimental|Arm I (alvocidib, cytarabine, mitoxantrone hydrochloride)|Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Patients who achieve complete or partial response to the first course (completion of all doses) may receive a second course of treatment or high-dose cytarabine after 21-63 days following blood count recovery, and/or undergo allogeneic bone marrow transplant.
3178481|NCT01349972|Active Comparator|Arm II (cytarabine, daunorubicin hydrochloride)|Patients receive cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients who have residual disease on day 14 may receive additional cytarabine for 5 days and daunorubicin hydrochloride for 2 days.
3178482|NCT01349959|Experimental|Treatment (entinostat and azacitidine)|Patients receive azacitidine SC on days 1-5 and 8-10, and entinostat PO on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may continue azacitidine and entinostat in combination with hormonal therapy, at treating physician discretion, or undergo event monitoring.
3178483|NCT01349933|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive 200 mg Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3178484|NCT01349920||Infliximab 5 mg/kg|Infliximab treatment and endoscopy.
3178485|NCT01349907|Experimental|Asenapine/Asenapine|Participants treated with asenapine in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg twice per day (BID), then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7. After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
3178486|NCT01349907|Experimental|Placebo/Asenapine|Participants treated with placebo in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg BID, then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7. After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
3178487|NCT01349894||SNaP® Wound Care System|
3178488|NCT01349881|Placebo Comparator|eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets, PO, daily for 3 years. Sulindac placebo, 1 tablet, PO, daily for 3 years.
3178489|NCT01349881|Experimental|Eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo one tablet PO daily for 3 years.
3178490|NCT01349881|Experimental|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
3178491|NCT01349881|Experimental|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
3178492|NCT01349868|Experimental|PT005 MDI (Dose 1)|PT005 MDI (Dose 1)
3178493|NCT01349868|Experimental|PT005 MDI (Dose 2)|PT005 MDI (Dose 2)
3178494|NCT01349868|Experimental|PT005 MDI (Dose 3)|PT005 MDI (Dose 3)
3178495|NCT01349868|Placebo Comparator|Placebo MDI|Placebo MDI
3178496|NCT01349868|Active Comparator|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 12 μg
3178497|NCT01349868|Active Comparator|Formoterol Fumarate 24 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 24 μg
3178498|NCT01349855|Experimental|Cohort 1|Dose Level 1
3178499|NCT01349855|Experimental|Cohort 2|Dose Level 2
3178500|NCT01349842|Experimental|Circulating Tumor Cells|Centralized determination of CTC by CellSearch® technology (Veridex), the only technology currently validated in clinical practice for the early evaluation of response to chemotherapy of breast cancers. This evaluation is performed by blood sampling comparing the CTC level before the first injection of each new line of chemotherapy. Chemotherapy can only be continued in the case of a positive CTC response. Discontinuation of chemotherapy can also be decided by the clinician on the basis of other clinical or radiological arguments.
3178501|NCT01349842|Other|Clinical and radiological criteria|Management of chemotherapy according to the usual clinical and radiological criteria adopted by the patient's attending physician.
3178502|NCT01349829|Experimental|HAVpur|
3178503|NCT01349829|Active Comparator|Havrix|
3178504|NCT01349816|Experimental|PT003 (Dose 1)|PT003 MDI Dose 1
3178505|NCT01349816|Experimental|PT003 (Dose 2)|PT003 MDI Dose 2
3178506|NCT01349816|Experimental|PT003 (Dose 3)|PT003 MDI Dose 3
3178507|NCT01349816|Experimental|PT003 (Dose 4)|PT003 MDI Dose 4
3178508|NCT01349816|Experimental|PT001|PT001 MDI
3178509|NCT01349816|Experimental|PT005|PT005 MDI
3178510|NCT01349803|Experimental|PT005 MDI|PT005 MDI
3178511|NCT01349803|Experimental|PT001 MDI|PT001 MDI
3178512|NCT01349803|Experimental|PT003 MDI|PT003 MDI
3178517|NCT01349764||No vitamin D replacement|The control arm will not receive vitamin D replacement, but patients in both study arms will receive care consistent with best care practices for stone disease. All patients will be evaluated by the stone clinic clinical nutritionist and full nutritional evaluation will be performed. All patients will be advised to maintain adequate hydration (>2L/day), no-added salt diet (Na 80-100mmol/day), low protein diet (1 g/kg/day). Patients with hyperoxaluria will be advised to follow low-oxalate diet. All patients will be advised to maintain moderate calcium intake; 800-1200mg/day.
3178518|NCT01349764||Vitamin D3 tabs|The active arm of randomization will receive vitamin D repletion in the form of oral vitamin D3 tablets 10 000 IU twice/ week for 8 consecutive weeks, followed by a maintenance dose of 1 000 IU daily for further 22 months.
3178519|NCT01349751|Active Comparator|isobaric levobupivacaine|spinal isobaric levobupivacaine
3178520|NCT01349751|Active Comparator|hyperbaric levobupivacaine|hyperbaric levobupivacaine
3178521|NCT01349738||Positive Group|Positive for ASB
3178522|NCT01349738||Negative Group|Negative for ASB
3178523|NCT01349725|Experimental|ARRY-502|
3178524|NCT01349725|Placebo Comparator|Placebo|
3178525|NCT01349712||Coumadin (warfarin)|Subjects are required to be currently receiving coumadin (warfarin) treatment.
3178526|NCT01349699|Active Comparator|Iron loading|Subjects will receive 1.25 mg/kg iron sucrose intravenously 1 hour before endoxin administration 2ng/kg.
3178527|NCT01349699|Active Comparator|Iron chelation|Subjects will receive 30mg/kg deferasirox orally 2 hours before endotoxin administration 2ng/kg.
3178528|NCT01349699|Placebo Comparator|Placebo|Subjects will receive placebo instead of iron chelation or iron loading before endotoxin administration
3178529|NCT01349686|Experimental|Oral intake of fluids|Intake of oral fluids during labour.
3178530|NCT01349686|Placebo Comparator|Fasting|No intake of oral fluids during labour.
3178531|NCT01349673|Experimental|Budesonide foam|2mg/25ml BID for 2 weeks followed by 2mg/25ml QD for 4weeks
3178532|NCT01349660|Experimental|BKM120/Bevacizumab|"Phase I:~BKM 120 orally (PO) once daily (dose is 60mg or 80mg). Bevacizumab: 10mg/kg intravenous (IV) every 2 weeks~Phase II:~BKM 120 orally (PO) once daily - dose is optimal dose determined in Phase I. Bevacizumab: 10mg/kg intravenous (IV) every 2 weeks"
3178533|NCT01349647|Experimental|Vaccine and Chemotherapy|This is a pilot trial evaluating the safety and immunogenicity of a pentavalent vaccine for patients with small cell lung cancer (SCLC). Patients with SCLC who have completed all planned initial therapy and have maintained a partial or complete response will be enrolled.
3178534|NCT01349647|Experimental|Vaccine Alone|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.
3178535|NCT01349634|No Intervention|Comparison group|This arm will use the salt that is on the open market, which is primarily non-iodized salt. Iodized salt may enter in these communities through the normal trade route. No active interference with salt trade will occur in these communities.
3178536|NCT01349634|Experimental|Early delivery of iodized salt|Iodized salt that is produced nationally for the open market (which meets only about 10% of national needs) will be directed to these communities through the normal trade system or by direct delivery to the communities.
3178537|NCT01349621||Standard and polarized light colposcopy|Standard and polarized light colposcopy
3178538|NCT01349608|Experimental|Health coaching|
3178539|NCT01349595|Experimental|Bortezomib|Bortezomib is a type of targeted chemotherapy
3178540|NCT01349595|No Intervention|Standard Post-transplant Treatment|Mayo Clinic standard post kidney transplant follow-up.
3178541|NCT01349582|Active Comparator|flow diversion|
3178542|NCT01349582|Active Comparator|Best standard treatment|
3178543|NCT01349582|Other|Registry for flow diversion|Flow diversion when randomization between flow diversion and best standard treatment is not possible and the only alternative is flow diversion for compassionate use. In this case there will be no random allocation but the patient will be entered into a registry
3178544|NCT01349569|Experimental|Myeloma Vaccine, Prevnar-13 Vaccine, & Lenalidomide|
3178545|NCT01349556|Experimental|Tretinoin pre-treatment|
3178546|NCT01349543|Experimental|Viral Challenge|
3178547|NCT01349530|Experimental|Anticoagulation clinic care|Monitoring by CREATIF
3178548|NCT01349530|Active Comparator|Usual care|Monitoring by GP.
3178549|NCT01349517|Other|MIE Group|The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)
3178550|NCT01349517|Other|Three-incision esophagectomy group|The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)
3178551|NCT01349517|Other|Ivor-Lewis esophagectomy group|The patients in this group would underwent Ivor-Lewis esophagectomy
3178552|NCT01349517|Other|Sweet esophagectomy group|The patients in this group would underwent Sweet esophagectomy.
3178553|NCT01349504||Mesalmine|
3178554|NCT01349491|Experimental|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated.
3178555|NCT01349491|Placebo Comparator|Placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion.
3178556|NCT01349478|Experimental|study arm|
3178557|NCT01349465|Other|Group 1: TMC 435 - Patients With SVR at LPVPS|Patients with sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) [Phase IIb or Phase III] in which they received a TMC435-containing regimen for the treatment of HCV infection.
3178558|NCT01349465|Other|Group 2: TMC 435 - Patients With No SVR at LPVPS|Patients with no sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) [Phase IIb or Phase III] in which they received a TMC435-containing regimen for the treatment of HCV infection.
3178559|NCT01349452|Experimental|Ganciclovir|
3178560|NCT01349452|Sham Comparator|Artificial tear|
3178561|NCT01349439|Experimental|Propranolol + Memory Reactivation|This arm involves recalling the traumatic event after administration of propranolol
3178562|NCT01349439|Experimental|Placebo + Memory reactivation|This arm involves recalling the traumatic event after administration of a placebo
3178600|NCT01349205|Experimental|Caffeine and Sodium Benzoate 20 mg/kg IV|Group 2 of randomized study
3178563|NCT01349439|Experimental|Placebo + No Memory Reactivation|This arm involves administration of a placebo without recalling the traumatic event
3178564|NCT01349439|Experimental|Propranolol + No Memory Reactivation|This arm involves administration of propranolol without recalling the traumatic event
3178565|NCT01349439|Other|Open-label Propranolol + Memory Reactivation|All participants terminating the double-blind phase of the study will receive open-label reconsolidation blockade treatment with propranolol combined with recall of the traumatic event for six weeks.
3178566|NCT01349426|Experimental|LigaSure|"Arm 1~Patients undergoing lung surgery"
3178567|NCT01349426|Active Comparator|Automatic Staplers|"Arm 2~Patients undergoing lung surgery"
3178568|NCT01349413|Placebo Comparator|Placebo|Identical looking placebo (once daily)
3178569|NCT01349413|Experimental|Esomeprazole 20mg daily|Esomeprazole 20mg daily Oral for 8 weeks
3178570|NCT01349400|Experimental|watchful waiting|"After informed consent and randomization into the watchful waiting group patients will receive standardized verbal information and written instructions on symptoms of acute incarceration. In case of acute symptoms they will be told to visit a physician immediately. On follow-up visits at 1 month, 12 months and 24 months the hernia size will be determined by physical examination, and the pain/ discomfort and the functional status will be monitored.~Control intervention/ reference test:~Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided. Divergent types of repair are permitted but have to be documented."
3178571|NCT01349400|Active Comparator|Hernia repair|Intervention: Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided. Divergent types of repair are permitted but have to be documented.
3178572|NCT01349387|Experimental|Arm1|"During their visit of consultation on the follow-up to the type 2 diabetes, les patients will be selected on the basis of active metformin treatment at a dose greater than or equal to 1400 mg/day. Patients will have to achieve a 10 ml blood sample. The blood will be processed by Ficoll gradient centrifugation to remove the red cells and isolate circulating leukocytes: this stage will be conducted in the CERITD. Analysis on circulating leukocytes and in particular the quantification of expressions of isoforms A and B of the INSR1 by quantitative RT - PCR gene will be conducted in the laboratory of the Professor Marc Peschanski (unit INSERM 861 I - STEM of Evry).~After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31."
3178573|NCT01349374|Experimental|Group1|healthy volunteers
3178574|NCT01349374|Experimental|group2|Unaffected siblings of MODY patients
3178575|NCT01349374|Experimental|Group3|Type2 Diabetic patients
3178576|NCT01349374|Experimental|Group4|MODY patients
3178577|NCT01349361|Experimental|Daylight-PDT|
3178578|NCT01349348|Experimental|Tolvaptan 15mg|Tablet;15mg/tab
3178579|NCT01349348|Experimental|Tolvaptan 7.5mg|Tablet;7.5mg/tab
3178580|NCT01349348|Placebo Comparator|Placebo|Tolvaptan 0mg/tab
3178581|NCT01349335|Experimental|1. tolvaptan|15 mg, P.O., Qd, for 7 days,
3178582|NCT01349335|Experimental|2 tolvaptan|30 mg, P.O., Qd, for 7 days,
3178583|NCT01349335|Experimental|3. Placebo|30mg,P.O.,Qd, for 7 days.
3178584|NCT01349322|Active Comparator|Arm I|Patients undergo standard whole-breast radiotherapy (WBI) comprising intensity-modulated radiation therapy (IMRT) or three-dimensional conformal radiotherapy (3D-CRT) 5 days a week for 3-5 weeks followed by a sequential radiotherapy boost to the lumpectomy area 5 days a week for 1-1½ weeks in the absence of disease progression or unacceptable toxicity.
3178585|NCT01349322|Experimental|Arm II|Patients undergo accelerated hypofractionated WBI comprising IMRT or 3D-CRT with a concurrent boost to the lumpectomy area 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity.
3178586|NCT01349309|Experimental|Swallowing Exercise Group|Swallowing Exercise Group: This arm will undergo the protocol that involves intensive swallowing exercises to begin at the start of the cancer treatment. Those patients randomized to the intensive therapy protocol will be required to participate in weekly swallowing therapy sessions either in person or over the phone and perform the learned swallowing exercises three times a day. In addition, these patients will document their swallowing practice on a daily basis.
3178587|NCT01349309|No Intervention|Control|Control Arm: This arm will receive the standard of care which provides swallowing evaluation and treatment once symptoms of swallowing dysfunction are experienced by the patient.
3178588|NCT01349296|Experimental|BIBF 1120 + RAD001|
3178589|NCT01349283|Experimental|HepavaxGene Stratum 1a|Subjects of mothers with chronic hepatitis B (positive for both HBsAg and hepatitis B envelope antigen - HBeAg)
3178590|NCT01349283|Active Comparator|Comparator vaccine Stratum 1a|Subjects of mothers with chronic hepatitis B (positive for both HBsAg and HBeAg)
3178591|NCT01349283|Experimental|HepavaxGene Stratum 1b|Subjects of mothers with chronic hepatitis B (positive for HBsAg only)
3178592|NCT01349283|Active Comparator|Comparator vaccine Stratum 1b|Subjects of mothers with chronic hepatitis B (positive for HBsAg only)
3178593|NCT01349283|Experimental|HepavaxGene Stratum 2|Subjects of mothers without chronic hepatitis B (negative for both HBsAg and HBeAg)
3178594|NCT01349283|Active Comparator|Comparator vaccine Stratum 2|Subjects of mothers without chronic hepatitis B (negative for both HBsAg and HBeAg)
3178595|NCT01349270|Experimental|immunoglobulin|patient who received monthly 2g/kg cure of intravenous Immunoglobulin during 6 months
3178596|NCT01349270|Active Comparator|prednisone|patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
3178597|NCT01349231|Experimental|Ketamine|Ketamine will be given at a dose of 0.5mg/kg over 40 minutes. This dose is identical to that used in previous anti-depressant studies of ketamine.
3178598|NCT01349218|Experimental|Blood sample drawn from a vein and from a heel stick|0.5 ml will be drawn from a vein when an IV is started for the surgery or from an IV already in place. The blood will be placed into a heparinized, 1 ml syringe for venous blood gas analysis. A second blood sample, 0.3 ml will be drawn into a capillary pipette from a heel stick for capillary blood gas analysis.
3178599|NCT01349205|Experimental|Caffeine and Sodium Benzoate 10 mg/kg IV|Group 1 of randomized study.
3178602|NCT01349192|Experimental|Treatment|Subjects are treated with two oral antibiotics, topical antibiotics, and are instructed to use environmental decontamination techniques.
3178603|NCT01349192|No Intervention|Observational|Subjects are tracked and not treated for their MRSA. If the subject reaches a protocol defined exacerbation within the first 28 days then they will be treated per choice of their primary Pulmonologist.
3178604|NCT01349153|Active Comparator|Facebook-based Self-help Comparison|Participants will receive a pedometer and twelve weekly messages with links to Internet resources that have educational materials related to exercise and cancer survivorship.
3178605|NCT01349153|Experimental|Facebook-based Messages/Website|Participants will receive a pedometer, twelve weekly messages, and be encouraged to participate in sixteen Facebook group discussions and use a website for exercise goal-setting and tracking activity.
3178606|NCT01349140|Experimental|Nerve Block|The dominant side (left or right) will be randomized to one of two treatment groups: the higher or lower concentration of the local anesthetic EXPAREL. The non-dominant contralateral side will receive the other possible treatment. The volume of each and every single-injection femoral nerve block will be 30 mL (standard for femoral nerve blocks is 30-40 mL).3 Since volume will remain constant, we will vary the dose of EXPAREL by varying concentration (volume x concentration = dose). Of note, EXPAREL may be mixed with normal saline to vary the concentration. Randomization will be based on computer-generated codes. Randomization will be in blocks of two, and stratified by sex.
3178607|NCT01349127|Active Comparator|20µg Vitamin D3|Arm will receive per day one gelatin capsule containing 20µg (800IU) of vitamin D3 (Cholecalciferol).
3178608|NCT01349127|Active Comparator|20µg Vitamin D3 + 500 mg Calcium|Arm will receive per day one gelatin capsule containing 20µg (800IU) of vitamin D3 (Cholecalciferol) and one tablet of calcium carbonate containing 500mg of calcium.
3178609|NCT01349127|Placebo Comparator|Placebo|Arm will receive one gelatin capsule containing 0µg (0IU) of vitamin D3 (Cholecalciferol).
3178610|NCT01349114|Active Comparator|aliskiren 300 mg once daily for 12 weeks|aliskiren 300 mg daily
3178611|NCT01349114|Placebo Comparator|Sugar pill/ placebo|Patients were double-blind placebo-controlled randomized to either aliskiren 300 mg once daily or sugar pill/ placebo
3178612|NCT01349101|Experimental|Myeloablative HSCT|Myeloablative Hematopoietic Stem Cell Transplantation (HSCT): Patients will receive myeloablative transplants or nonmyeloablative transplants depending on their disease type.
3178613|NCT01349101|Experimental|Reduced Intensity HSCT|Reduced Intensity Hematopoietic Stem Cell Transplantation (HSCT): Patients who have received a previous transplant, patients who have received dose limiting radiation, and patients with a DLCO <45% will receive the reduced intensity conditioning regimen.
3178614|NCT01349088|Experimental|Motesanib|Eligible patients will be enrolled to receive ixabepilone, capecitabine, plus motesanib.
3178615|NCT01349075||TheraSphere|
3178616|NCT01349062|Other|"Kallunk oxide (Immunotherapy)"|"The participants will be received a daily regimen of Kallunk oxide(Immunotherapy) ."
3178617|NCT01349049|Experimental|PLX3397|Subjects will be dosed at the maximum tolerated dose.
3178618|NCT01349049|Experimental|oral dose of 800 mg/day of PLX3397|Level 0
3178619|NCT01349049|Experimental|oral dose of 1000 mg/day PLX3397|Level 1
3178620|NCT01349049|Experimental|oral dose of 1200 mg/day PLX3397|Level 2
3178621|NCT01349049|Experimental|oral dose of 1400 mg/day PLX3397|Level 3
3178622|NCT01349049|Experimental|oral dose of 2000 mg/day PLX3397|Level 4
3178623|NCT01349049|Experimental|oral dose of 3000 mg/day PLX3397|Level 5
3178624|NCT01349049|Experimental|oral dose of 4000 mg/day PLX3397|Level 6
3178625|NCT01349049|Experimental|oral dose of 5000 mg/day PLX3397|Level 7
3178626|NCT01349036|Experimental|PLX3397-Cohort 1|10 patients with recurrent glioblastoma who require reoperation will be treated with PLX3397 for 7 days prior to surgery and their tumor tissue will be evaluated for pharmacokinetic levels and pharmacodynamic effects.
3178627|NCT01349036|Experimental|PLX3397-Cohort 2|30 patients will be orally dosed with PLX3397 continuously on 28 day cycles.
3178628|NCT01349023|Experimental|Standard Energy content/Standard ED|
3178629|NCT01349023|Experimental|Standard Energy content/Reduced ED|
3178630|NCT01349023|Experimental|Reduced Energy content/Standard ED|
3178631|NCT01349023|Experimental|Reduced Energy content/Reduced ED|
3178632|NCT01349010|Placebo Comparator|Placebo|Placebo Arm: Placebo 1 tablet bid. p.o
3178633|NCT01349010|Active Comparator|Probucol|Probucol Arm: Imported Probucol 250 mg (1 tablet) bid. p.o
3178634|NCT01348997|Active Comparator|Project Onward website + 16 person social network|
3178635|NCT01348997|Active Comparator|Project Onward website + 8 person social network|
3178636|NCT01348984|Active Comparator|group 1|group 1 = transdermal fentanyl patch
3178637|NCT01348984|Placebo Comparator|group 2|placebo patch
3178638|NCT01348971|Experimental|Sodium nitrate|Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
3178639|NCT01348971|Placebo Comparator|Placebo|Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
3178640|NCT01348958|Experimental|Post-operative knee replacement|Subjects that have had a hemi knee replacement of one knee at least 8 weeks ago had the post-operative knee scanned using the orthopedic hip application and the Lunar orthopedic knee application.
3178641|NCT01348945|Experimental|Stump Preserving ACL Surgery|Patients of partial tear ACL injury fulfilling inclusion criteria received stump preserving ACL surgery, entered conventional ACL reconstruction rehabilitation program
3178642|NCT01348945|Active Comparator|ACL Reconstruction|Patients with complete tear ACL injury received ACL reconstruction entered conventional ACL rehabilitation program
3178643|NCT01348932||Asthma|The relationship between single nucleotide polymorphisms of chitinase 3-like 1 gene, YKL-40 serum levels and adult asthma
3178644|NCT01348919|Experimental|CEP-18770 in Combination With Lenalidomide and Dexamethasone|
3178645|NCT01348906|Experimental|Intermittent normoxia|Repeated brief normoxic reperfusion during cardioplegia arrest in adult valve replacement
3178646|NCT01348893|No Intervention|Physical education as usual|High school physical education curriculum established by the school, including competitive sports, aerobic and anaerobic activities, balance and coordination skills. Yoga is not a component of the curriculum.
3178647|NCT01348893|Experimental|Yoga during physical education|
3178648|NCT01348880|Experimental|Arm1|
3178649|NCT01348880|Placebo Comparator|Arm2|
3178650|NCT01348867|No Intervention|Usual Care|These 120 controls will undergo a comprehensive assessment at baseline then again at 12 months, which is similar to the intervention group. However, in between these 2 time points the 'control' patients will receive usual care and hence will not be monitored under the structured care protocol by a diabetes nurse consultant led team.
3178651|NCT01348867|Experimental|Structured Care|"120 patients will be randomised to the structured care group, and these patients will receive repeated follow-ups and contact with the structured care team in between the two comprehensive assessments at week 0 and week 52.~Patients will be seen by Diabetes Nurse Consultant at week 0, 6, 12, 24 38 during the year. At each visit, clinical and laboratory measurements will be performed; treatment compliance and self care will be assessed and medications will be adjusted to optimise metabolic and cardiovascular risk factors control.~Patients will be seen by the doctors in their clinic follow up at week 0, 24 and 52.~Technical service assistance will telephone patient at week 18, 30 and 44 to reinforce patient to take medications, attend clinical follow up."
3178652|NCT01348854|Experimental|Natural Astigmatism|Use of the iFS Femtosecond Laser System to make arcuate incisions to correct naturally occurring corneal astigmatism in eyes with no prior history of ophthalmic surgery. May include eyes with cataracts.
3178653|NCT01348854|Experimental|Post Cataract with Residual Astigmatism|Use of the iFS Femtosecond Laser System to make arcuate incisions to correct residual astigmatism in eyes that have undergone cataract extraction. May also include eyes with residual astigmatism following implantation of a phakic intraocular lens implanted.
3178654|NCT01348841|No Intervention|Control Arm|Usual care is care as currently delivered to clients with chronic wounds in the community.
3178655|NCT01348841|Experimental|Intervention Arm|"Systematic referral to MDWCT and comprehensive primary care:~Intervention consists of systematic referral to MDWCT in conjunction with comprehensive primary care.Systematic referral to, and follow up, by MDWCTs, co-ordinated by the CM, will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4."
3178656|NCT01348802|Experimental|Push + Pull|Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.
3178657|NCT01348802|Placebo Comparator|Pull|Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
3178658|NCT01348789|Experimental|Hair2Go (Mē)|Treatment with Hair2Go (Mē)device
3178659|NCT01348776|Experimental|Hair2Go (Mē)|Subjects treated with Hair2Go (Mē) Device
3178660|NCT01348763|Experimental|Truvada, Darunavir/r and Maraviroc|Participants will be taking Truvada, Darunavir/r before entering the study. On day 1 they will add maraviroc then on day 11 they will stop the Truvada
3178661|NCT01348750|Other|Group A|This group receives 6 Healing Touch & Guided Imagery treatments in addition to standard medical care.
3178662|NCT01348750|No Intervention|Group B|This group receives standard medical care but NO Healing Touch and Guided Imagery.
3178663|NCT01348737|Experimental|AZD3839|Oral Treatment
3178664|NCT01348737|Placebo Comparator|AZD3839 Placebo|Oral Treatment
3178665|NCT01348724|Experimental|[14C] NKTR-118|
3178666|NCT01348672||1. ARMD Study arm|"The ARMD study arm (n=150) consists of 3 groups. The groups are organised according to established risk criteria for clinical progression (AREDS, 2003).~Group 1A (n=50); Early stage ARMD with low risk of progression; several small drusen, or a few medium-sized drusen, in one or both eyes. One eye will be randomly selected for the study.~Group 2A (n=50); Intermediate ARMD with high risk of progression to advanced ARMD; many medium-sized drusen, or one or more large drusen, in one or both eyes. More severely affected eyewill be selected for the study.~Group 3A (n=50); In one eye only, either a break-down of light-sensitive cells and supporting tissue in the central retinal area (i.e. geographic atrophy), or abnormal and fragile blood vessels under the retina (i.e. choroidal neovascular membrane formation). The fellow eye is at high risk of progression to advanced ARMD. The fellow eye will be selected for the study."
3178667|NCT01348672||2. POAG study arm|"Patient groups are organised according to established risk criteria for clinical progression (EMGT, 2003).~Group 1P (n=36); Stable, early to moderate, treated patients with POAG. Early to moderate POAG is defined as having an untreated IOP prior to treatment of >21mmHg and a repeatable visual field defect with a Mean Deviation of <12dB and/or documented but stable ONH appearance, consistent with a diagnosis of glaucoma.~Group 2P (n=36); Early to moderate, treated patients with normal tension glaucoma (NTG). Normal Tension Glaucoma is defined using the same criteria as POAG but with an untreated IOP of <21mmHg throughout the day. This group has NTG and is thought to be at increased risk of vascular dysfunction due to loss of ONH perfusion.~Group 3P (n=36); Early to moderate, treated patients with POAG or NTG with recurrent disc hemorrhage (indicative of progression)."
3178668|NCT01348672||3. DR study arm|"DR patient groups are organised according to established risk factors for the clinical progression of DR (increasing from Groups 1 A to 3 A, ETDRS, 1991). We will recruit 41 patients per group (Klein et al, 1984).~Group 1D (n=41); Type 2 diabetic patients with no, or minimal, clinically visible DR. These patients are at low risk of developing sight-threatening DR.~Group 2D (n=41); Type 2 diabetic patients with microaneurysms and / or hard exudates within 2 disc diameters of the fovea and no clinical evidence of retinal thickening. These patients are at increased risk of developing DME.~Group 3D (n=41); Type 2 diabetic patients with the typical features of moderate-to-severe DR i.e. venous beading, intra-retinal microvascular abnormalities (IRMA) and dark blot intra-retinal haemorrhages. These patients are at a much increased risk of developing proliferative DR and/or ischemic maculopathy."
3178669|NCT01348659|Active Comparator|7.2% NaCl/hydroxyethyl starch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) (Hyperhaes®, Fresenius Kabi)
3178670|NCT01348659|Active Comparator|0.9% NaCl|250 ml of NaCl 0.9% (Natriumklorid Braun 9 mg/ml)
3178671|NCT01348646|Other|Lifestyle counseling|
3178712|NCT01348334|Active Comparator|Vypromesh®(Ethicon,USA)|Vypromesh®(semiabsorbable multiflament mesh;non-absorbable Polypropylene+absorbable Poliglactin)
3178672|NCT01348633||Sub-study 1|The Quantitative, Doppler SD-OCT Blood Flow Technology will be validated and calibrated by manipulating end-tidal blood gases using the computer-controlled gas sequencer (Slessarev et al, 2005) in 15 healthy controls. Homeostatic inner retina blood flow values and the magnitude of vascular reactivity will be compared between Doppler SD-OCT blood flow technology and the Canon Laser Blood Flowmeter, an established standard, at specific locations within the retinal vascular tree.
3178673|NCT01348633||Sub-study 2|The Quantitative, Hyper-Spectral Imaging Derived Oxygen Saturation Maps of the major retinal vessels and capillary beds will be validated and calibrated in human volunteers using our novel and exact technique that allows the precise control of the partial pressure of oxygen (PO2) to induce controlled and safe levels of hypoxia. Oxygen saturation values will be compared to measured PO2 values (i.e. recognized standard) for various levels of hypoxia and will be used to provide in-sight into the properties of the data output e.g. effective operating range, linearity of response. At the end of the study, subjects will be returned to normoxic conditions to assess reproducibility of oxygen saturation maps.
3178674|NCT01348633||Sub-study 3|Subjects with symptoms of branch and central retinal artery and vein occlusion within the past 2 months will be used to validate the Doppler SD-OCT blood flow technology and the hyperspectral imaging derived oxygen saturation maps. In cases of central retinal vein and artery occlusion, imaging values (i.e. inner retinal and choroidal blood flow, oxygen saturation values of the major retinal vessels and the capillary beds of the retina and ONH) will be compared between the affected and unaffected eyes. In cases of branch occlusion, imaging values will be compared between the affected and unaffected quadrants of the affected eye and between the affected and unaffected eyes. The difference in inner retinal and choroidal blood flow for each eye will be calculated and compared between eyes.
3178675|NCT01348633||Sub-study 4|Calibration for retinal melanin, crystalline lens absorption, macular pigment, morphological variation and pre-retinal autofluorescence in healthy subjects (n=20 per decade, range 40 to 80yrs). Established reflectometric techniques to derive absorption values and autofluorescence techniques will be used to calculate correction values for each parameter that influences the hyper-spectral retinal and ON oxygen saturation imaging data (Keilhauer and Delori, 2006; Delori et al, 2007).
3178676|NCT01348633||Sub-study 5|Establishment of a database of healthy control imaging values (n=20 per decade, range 40 to 80yrs). A database of healthy control values will be established for each technology taking into account extraneous factors such as age (range 40 to 70 years) and gender. The healthy control database will be compared to the results of each individual patient in the prospective study phase of this proposed Research Program (see Prospective Study Phase, 3, Control group). Statistical confidence limits for abnormality at each time point, and for progression overtime, will be established. Measurements will be repeated at separate visits to establish repeatability.
3178677|NCT01348620|Experimental|Single port laparoscopic device|
3178678|NCT01348620|Active Comparator|Four-port laparoscopic device|
3178679|NCT01348607|Experimental|Arm I - methylphenidate hydrochloride|Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.
3178680|NCT01348607|Experimental|Arm II -modafinil|Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.
3178681|NCT01348607|Placebo Comparator|Arm III placebo|Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.
3178682|NCT01348594||Vitamin D deficient|
3178683|NCT01348594||Vitamin D sufficient|
3178684|NCT01348581|Experimental|Marigen Wound Dressing|
3178685|NCT01348568|Experimental|Low glycemic index diet with canola oil bread|Subjects will be given whole wheat bread which includes canola oil, and advised to follow a diabetic diet using low glycemic index foods.
3178686|NCT01348568|Active Comparator|high fiber diet|Subjects will be given whole wheat bread, and advised to follow a healthy high fiber diabetic diet.
3178687|NCT01348555|Experimental|V0162|
3178688|NCT01348555|Placebo Comparator|Placebo|
3178689|NCT01348542|Active Comparator|Trazodone|
3178690|NCT01348542|Active Comparator|Cognitive Behavioral Therapy|
3178691|NCT01348529|Experimental|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
3178692|NCT01348516|Experimental|KM-023|
3178693|NCT01348516|Placebo Comparator|Placebo for KM-023|
3178694|NCT01348503|Experimental|Open Label, Single Arm|Dose escalation of lenalidomide in combination with sorafenib at standard doses in patients with advanced, unresectable hepatocellular carcinoma.
3178695|NCT01348490|Experimental|Ruxolitinib (INCB018424)|
3178696|NCT01348477|Experimental|Elliptical domed mesh technique|84 adult patients with primary uncomplicated inguinal hernia, treated with an open preperitoneal elliptical mesh technique
3178697|NCT01348477|Active Comparator|Lichtenstein technique|84 adult patients with primary uncomplicated inguinal hernia treated with the Lichtenstein technique (gold standard)
3178698|NCT01348464||lifestyle, wound satisfaction|single site access three site access for appendectomy
3178699|NCT01348451|Experimental|surgery|A sequential design of five groups will be utilized to reduce risk to subjects. The first group (Group A) will include six subjects and the subsequent groups will include three subjects per group. Each group represents both different inclusion criteria and location of surgery.
3178700|NCT01348438|Other|Single arm study|
3178701|NCT01348425|Experimental|Longer Stents|
3178702|NCT01348425|Experimental|Shorter Stents|
3178703|NCT01348412|Experimental|ARM A|Hepatic artery infusion through an implanted arterial catheter of the combination of raltitrexed (3 mg/m ²) and oxaliplatin (100 mg/m ²) every 21 days.
3178704|NCT01348412|Active Comparator|ARM B|Intravenous standard chemotherapy.
3178705|NCT01348399||XIENCE PRIME stents|
3178706|NCT01348386|Experimental|KOH 10%|Treatment consists of the application of topical 10% KOH in an aqueous solution.
3178707|NCT01348386|Experimental|KOH 15%|Treatment consists of the application of topical 15% KOH in an aqueous solution
3178708|NCT01348386|Placebo Comparator|PLACEBO|100 milliliters of saline solution
3178709|NCT01348373||GENOUS EPC-coated stent|Patients treated with GENOUS EPC-coated stent
3178710|NCT01348360||NOBORI stent|
3178711|NCT01348347|Experimental|Volasertib|Patient to receive low, middle and high doses of Volasertib IV
3178805|NCT01347801|Active Comparator|2A-4|TNF and IVGTT
3178713|NCT01348334|Active Comparator|Ultrapromesh®(Ethicon,USA)|Ultrapromesh®(semiabsorbable monofilament mesh;non-absorbable Polypropylene+absorbable polyglecaprone).
3178714|NCT01348334|Active Comparator|Prolene light mesh®(Johnson&Johnson,USA)|Prolene light mesh®(cpp-Condensed monofilament non absorbable polypropylene mesh)
3178715|NCT01348321|Experimental|Azithromicine plus levamisole|
3178716|NCT01348321|Experimental|Azithromicin|
3178717|NCT01348308|Active Comparator|Maraviroc|Maraviroc 300, 600 or 1200mg per day
3178718|NCT01348308|Placebo Comparator|Placebo|Placebo 300, 600 or 1200mg per day
3178719|NCT01348295||Mechanically ventilated children|All children under 16 years of age who are needing mechanical ventilation for any reason.
3178720|NCT01348282|Experimental|Lithium|Lithium group: Patients who will initiate therapy with lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
3178721|NCT01348282|Active Comparator|Rivastigmine|rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
3178722|NCT01348282|No Intervention|Control group|Patients who will not initiate treatment
3178723|NCT01348269|Active Comparator|Aclasta|
3178724|NCT01348269|Placebo Comparator|NaCl Solution|
3178725|NCT01348256|No Intervention|Observation|Observation after standard treatment
3178726|NCT01348256|Experimental|Dendritic cells vaccine|Adjuvant treatment with dendritic cells vaccine after standard treatment
3178727|NCT01348243|Experimental|Clodronate 200 mg|
3178728|NCT01348243|Active Comparator|Clodronate 100 mg|
3178729|NCT01348230||prior preterm delivery at 24-32 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
3178730|NCT01348230||prior preterm delivery at 32-34 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
3178731|NCT01348230||prior preterm delivery at 34-36 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
3178732|NCT01348217|Active Comparator|ARM A|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph nodes:~Radiotherapy 40 Gy, in 20 fractions / 4 weeks: PTV (1cm in every direction)~Boost 10 Gy in 5 fr: PTV = +1cm.~Chemotherapy FOLFOX 4: 6 treatments in 3 courses concomitant to the radiotherapy (D1, D15, D29)"
3178733|NCT01348217|Experimental|ARM B|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph nodes:~40 Gy in 20 fractions / 4 weeks, PTV (1cm in every direction)~Boost 26 Gy in 13 fr: PTV = +1cm.~Chemotherapy: FOLFOX 4: 6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43)."
3178734|NCT01348204|Experimental|quercetin|health food supplement
3178735|NCT01348191||Elective caesarean section|"Population: ten pregnant women, scheduled for elective caesarean section with a term pregnancy ( > 37 weeks).~Inclusion criteria~Elective caesarean section~Term pregnancy > 37 weeks~Age > 18 years~Exclusion criteria~Previous caesarean scar~Gestational age < 37 weeks~Maternal temperature > 37.8 degrees Celsius~Meconium stained liquor~Foetal distress~Maternal diabetes~Seropositivity~Use of thyroid medication~Maternal thyroid disease~Age < 18 years"
3178736|NCT01348178||developmental dysplasia of the hip, PAO|All patients who underwent periacetabular osteotomy from 1999-2007 at the University Hospital of Aarhus
3178737|NCT01348165|Experimental|BI 137882 Dose 1|Powder for oral solution
3178738|NCT01348165|Experimental|BI 137882 Dose 2|Powder for oral solution
3178739|NCT01348165|Experimental|BI 137882 Dose 3|Powder for oral solution
3178740|NCT01348165|Experimental|BI 137882 Dose 4|Powder for oral solution
3178741|NCT01348165|Experimental|BI 137882 Dose 5|Powder for oral solution
3178742|NCT01348165|Experimental|BI 137882 Dose 6|Powder for oral solution
3178743|NCT01348165|Experimental|BI 137882 Dose 7|Powder for oral solution
3178744|NCT01348165|Experimental|BI 137882 Dose 8|Powder for oral solution
3178745|NCT01348165|Experimental|BI 137882 Dose 9|Powder for oral solution
3178746|NCT01348165|Placebo Comparator|Placebo|Powder for oral solution
3178747|NCT01348152|Placebo Comparator|Placebo|Placebo TID
3178748|NCT01348152|Experimental|DAIKENCHUTO (TU-100) 15 g/day|TU-100 5g TID
3178749|NCT01348139|Experimental|1|AZD3199 800 µg inhaled via single inhaler device (SID), single dose
3178750|NCT01348139|Experimental|2|AZD3199 880 µg inhaled via SID, single dose
3178751|NCT01348139|Experimental|3|AZD3199 1400 µg inhaled via SID, single dose
3178752|NCT01348139|Experimental|4|AZD3199 300 µg inhaled via Turbuhaler inhaler, single dose
3178753|NCT01348139|Experimental|5|AZD3199 1200 µg inhaled via Turbuhaler inhaler, single dose
3178754|NCT01348139|Placebo Comparator|6|Placebo inhaled via Turbuhaler inhaler and SID, single dose
3178755|NCT01348126|Active Comparator|Single agent docetaxel|
3178756|NCT01348126|Experimental|Combination of ganetespib and docetaxel|
3178757|NCT01348113|Experimental|Brief Alcohol Intervention|
3178758|NCT01348113|No Intervention|No intervention|
3178759|NCT01348100|Experimental|Iloperidone 50 mg crystalline formulation - Phase A|Participants received a crystalline formulation of iloperidone 50 mg in a depot intramuscular (IM) injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.
3178760|NCT01348100|Experimental|Iloperidone 125 mg crystalline formulation - Phase A|Participants received a crystalline formulation of iloperidone 125 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.
3178761|NCT01348100|Experimental|Iloperidone 250 mg crystalline formulation - Phase B|Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
3178762|NCT01348100|Experimental|Iloperidone 250 mg microparticle formulation - Phase B|Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
3178763|NCT01348100|Experimental|Iloperidone 250 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
3178764|NCT01348100|Experimental|Iloperidone 500 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 500 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
3178765|NCT01348100|Experimental|Iloperidone 625 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
3178766|NCT01348087|Experimental|AFQ056 100 mg (Bid)|All patients initiated treatment with AFQ056 at a starting dose of 25 milligram (mg) twice daily. The dose was titrated from 25mg bid to 50mg bid, 75mg bid and 100mg bid at weekly intervals. Dose adjustments (up- and down titrations) were permitted as needed to manage any tolerability issues and to ensure that patients reach their highest tolerated dose not to exceed 100mg bid.
3178767|NCT01348074|Experimental|Double dose|Re-initiation with warfarin at twice the usual maintenance dose the first 2 days, then maintenance dose.
3178768|NCT01348074|No Intervention|Usual maintenance dose|Usual maintenance dose from Day 1, i.e. no postoperative loading dose.
3178769|NCT01348061||Elderly Healthy Control (EHV)|No clinically significant deviation from healthy in medical history, physical examination, ECGs, MRI and clinical laboratory determinations for their respective age group.
3178770|NCT01348061||Progressive Supranuclear Palsy (PSP)|A diagnosis of possible or probable PSP according to clinical criteria of National Institute of Neurologic Diseases and Stroke - the Society for PSP plus a MRI at screening to exclude other potential causes of parkinsonism as well as a mild-to-moderate stage of disease severity according to a score of 1 to 3 in Golbe Staging System.
3178771|NCT01348061||Alzheimer's Disease (AD)|A diagnosis of probable AD Based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association and The Diagnostic and Statistical Manual of Mental Disorders as determined by a mini-mental state examination (MMSE) score of 16 to 26, inclusive.
3178772|NCT01348048|Experimental|Specialised palliative care (SPC) group|Patients continue with their standard treatment (typically they receive treatment in one or more hospitals departments and from their GP). In addition, they are offered a consultation in the SPC out-patient clinic (or at home if the patient cannot attend the hospital) as soon as possible and no more than one week after randomization. If possible, each patient will have at least two contacts to the SPC in the trial period.
3178773|NCT01348048|No Intervention|Standard care group|Patients continue with their standard treatment. They are instructed to contact either their GP or their hospital department if they feel that additional treatment or care is needed.
3178774|NCT01348035||Water Load Group|Water load group: 2.5 ~ 3 L water intake daily for 12 months (50ml/Kg body weight/day). When large amount water intake is not sustainable, patients can reduce the amount of water intake to the levels as much as large he or she can sustain.
3178775|NCT01348035||Non-Water Loaded Group|Non-water load group: The patients are free to access water intake, as they like.
3178776|NCT01348022||Xience V stent|unprotected Left Main Coronary Artery stenting treated with Xience V stent
3178777|NCT01348009|Experimental|Tesetaxel-capecitabine-cisplatin|
3178778|NCT01347996|Experimental|histamine dihydrochloride and IL-2|histamine and IL-2 subcutaneous injections
3178779|NCT01347970|Experimental|Arm I (beta-adrenergic/alpha-1 adrenergic blocker)|Patients receive low-dose carvedilol PO QD or BID for 24 months.
3178780|NCT01347970|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD or BID for 24 months.
3178781|NCT01347957|Experimental|Nitric Oxide (NO) Gel|
3178782|NCT01347957|Placebo Comparator|Placebo Gel|
3178783|NCT01347931|Experimental|NIOV System|Noninvasive ventilation and oxygen delivered via NIOV System oxygen using an open nasal interface. Connected to standard portable oxygen cylinder
3178784|NCT01347931|Active Comparator|Standard Oxygen Therapy|Supplemental oxygen using standard oxygen cannula connected to a portable oxygen cylinder.
3178785|NCT01347918||control|Healthy controls
3178786|NCT01347918||IBS|Patients that fulfil the Rome III criteria for irritable bowel syndrome (IBS)
3178787|NCT01347905||Obese women and men|Obese women and men undergoing restrictive bariatric surgery. Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
3178788|NCT01347892||DeNovo NT Subject|Subjects who have received or who are scheduled to receive a DeNovo NT Graft for repair of a cartilage lesion in the ankle.
3178789|NCT01347879|Experimental|Visonac cream with PDT|active treatment with light dose of 37 Joule/cm2
3178790|NCT01347879|Placebo Comparator|Vehicle cream with PDT|Placebo treatment, Light dose 37 Joule/cm2
3178791|NCT01347866|Experimental|Arm D: PF-05212384 + PD-0325901|
3178792|NCT01347866|Experimental|Arm C: PF-05212384 + irinotecan|
3178793|NCT01347853|Experimental|Ketorolac tromethamine|
3178794|NCT01347853|Placebo Comparator|Placebo|
3178795|NCT01347840||All Subjects|This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.
3178796|NCT01347827||on pump|Coronary artery bypass grafting (CABG)with with cardiopulmonary bypass
3178797|NCT01347827||off pump|off-pump CABG surgery
3178798|NCT01347801|Placebo Comparator|2C - 1|TNF and OGTT and saline
3178799|NCT01347801|Active Comparator|2C - 2|TNF and OGTT and GLP-1
3178800|NCT01347801|Placebo Comparator|2C - 3|TNF and IVGTT and saline
3178801|NCT01347801|Active Comparator|2C - 4|TNF and IVGTT and GLP-1
3178802|NCT01347801|Placebo Comparator|2A-1|Saline infusion and OGTT
3178803|NCT01347801|Placebo Comparator|2A-2|Saline and IVGTT
3178804|NCT01347801|Active Comparator|2A-3|TNF and OGTT
3178806|NCT01347801|Experimental|1C|OGTT and corresponding IVGTT
3178807|NCT01347788|Experimental|Cohort 1|Dose level 0: cabozantinib 40 mg daily
3178808|NCT01347788|Experimental|Cohort 2|Dose level -1: cabozantinib 20 mg daily
3178809|NCT01347788|Experimental|Expansion cohort|Dose level 0: cabozantinib 40 mg daily
3178810|NCT01347775|Sham Comparator|Sham inspiratory muscle training|Patients in the sham group used the threshold trainer (Threshold at IMT device URES HS730, Respironics, New Jersey, Inc, Cedar Grove, NJ, USA), with the diaphragm removed.
3178811|NCT01347775|Experimental|Inspiratory muscle training|Inspiratory muscle training will be by a threshold trainer (Threshold at IMT device URES HS730, Respironics, New Jersey, Inc, Cedar Grove, NJ, USA), a commercially available spring-loaded inspiratory muscle training device. It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
3178812|NCT01347762|Experimental|Nabilone|nabilone titrated to 2 mg daily
3178813|NCT01347762|Placebo Comparator|Placebo|Placebo
3178814|NCT01347749|Experimental|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
3178815|NCT01347749|Active Comparator|Present Centered Therapy for PTSD|This is a more standard from of group psychotherapy (talk therapy) which focusses on current symptoms and stressors
3178816|NCT01347736|Experimental|Treatment (pain therapy)|Patients undergo scrambler therapy for approximately 30 minutes. Treatment continues for 10 days in the absence of pain progression or unacceptable toxicity.
3178817|NCT01347723|Experimental|Supportive care (pain therapy)|Patients undergo scrambler therapy for 30 minutes daily for up to 10 consecutive days. Treatment continues in the absence of unacceptable toxicity.
3178818|NCT01347710|Experimental|Flurpiridaz F18|Open-label study of a single dose of Flurpiridaz F18 injection for PET MPI compared to a single dose of 99mTc sestamibi or tetrofosmin for SPECT MPI in patients with suspected or known coronary artery disease referred for coronary catheterization
3178819|NCT01347697|Experimental|Porcine collagen implant|Reconstruction with an acellular porcine collagen implant.
3178820|NCT01347697|Active Comparator|Gluteus maximus flap|Reconstruction with a gluteus maximus myocutaneous flap.
3178821|NCT01347684|Active Comparator|Standard care using current drugs|Standard care with drug intervention
3178822|NCT01347684|Experimental|Behavioral therapy, splint therapy and physical therapy|Using rehabilitation for comparing use of drug
3178823|NCT01347671|Active Comparator|25 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 25 µg GRT6005 per day
3178824|NCT01347671|Active Comparator|75 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 75 µg GRT6005 per day
3178825|NCT01347671|Active Comparator|200 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 200 µg GRT6005 per day
3178826|NCT01347671|Placebo Comparator|Matching Placebo|Participants allocated to this treatment arm will receive a dose of matched placebo once a day.
3178827|NCT01347658|Experimental|Etravirine + echinacea|etravirine + root of Echinacea purpurea
3178828|NCT01347645|Active Comparator|1|Experimental Irinotecan plus E7820
3178829|NCT01347645|Active Comparator|2|FOLFIRI alone
3178830|NCT01347632|Other|BV pre treatment|Open Label Study. All participants had BV and took metronidazole 500 mg po BID for 7 days.
3178831|NCT01347619|Active Comparator|Arm 1. Toolkit only with Web Access|NHs in this arm will receive the toolkit only and web access to the materials.
3178832|NCT01347619|Active Comparator|Arm 2.Toolkit, Audit/Feedback, Education|NHs in the second arm will receive the toolkit, web access, periodic audit and feedback reports of antipsychotic prescribing to NH leadership, and faxed educational messages adapted from the AHRQ atypical antipsychotic CERSG to prescribers.
3178833|NCT01347619|Active Comparator|Arm 3. All above plus academic detailing|NHs in the third arm will receive the previous items plus face-to-face academic detailing.
3178834|NCT01347593|Experimental|ceftizoxime (cefizox) injection|ceftizoxime (cefizox) as single dose of 1 g at the interval of 30-60 minutes before the incision
3178835|NCT01347580|Experimental|Ticagrelor|Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
3178836|NCT01347580|Experimental|Placebo|Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
3178837|NCT01347567|Experimental|BNP + Health Management|Subjects will provide information from home regarding weight,signs and symptoms, and will perform BNP self testing. This information including BNP results will be used by the investigator as an aid to treatment decisions. BNP results are blinded to subjects.
3178838|NCT01347567|Active Comparator|Health Management|Subjects will provide information from home regarding weight, signs and symptoms, and will perform BNP self testing . BNP results will be blinded to the investigator and subject; weight, signs and symptoms will be used by the investigator as an aid to treatment decisions
3178839|NCT01347567|Placebo Comparator|Control|Subject will provide information from home regarding weight, signs and symptoms and will perform BNP self testing. All these data will be blinded to the investigator. BNP results will be blinded to the subject.
3178840|NCT01347554|Active Comparator|Xience V stent group|Xience V (Everolimus eluting stent) insertion in patients with acute myocardial infarction
3178841|NCT01347554|Active Comparator|Endeavor resolute group|Endeavor resolute (Zotarolimus eluting stent) insertion in patients with acute myocardial infarction
3178842|NCT01347541|Experimental|Stepped care|Combination of behavioral therapy and drug therapy
3178843|NCT01347541|Active Comparator|Standard care provided to injured trauma survivors|
3178844|NCT01347528|Experimental|TELEmonitoring intervention|
3178845|NCT01347528|No Intervention|Usual care|
3178846|NCT01347515|Placebo Comparator|FOO250|FOO250 ppm, the standard virgin olive oil
3178847|NCT01347515|Active Comparator|FOO500|Olive oil enriched with its own broad-spectrum phenolic compounds; FOO500 ppm
3178908|NCT01347086|Placebo Comparator|Matching placebo (high dose)|Single dose of matching placebo
3178848|NCT01347515|Active Comparator|FOO750|Olive oil enriched with its own broad-spectra phenolic compounds; FOO750 ppm
3178849|NCT01347502||HCPs with smartphone|healthcare providers in MICU who have smart cellular phones
3178850|NCT01347502||HCP with non-smart phones|healthcare providers in MICU who have non-smart cellular phones
3178851|NCT01347476||patients older than 70 years|
3178852|NCT01347476||patients 70 years or younger|
3178853|NCT01347463|No Intervention|Traditional|
3178854|NCT01347450|Experimental|Cocoa, Placebo|
3178855|NCT01347437|No Intervention|Condition|In the comparison condition, participants will receive MEMS only.
3178856|NCT01347437|Experimental|Positive STEPS|"Participants will receive one on one Positive STEPS counseling sessions (~1 hour sessions per week for 5 weeks).~Participants will receive motivational reminders to take medications sent via text message to their cell phones.~Participants will receive the Medication Event Monitoring Systems (MEMS) pill cap monitoring device to measure antiretroviral medication adherence."
3178857|NCT01347424|Experimental|Test group|
3178858|NCT01347424|Active Comparator|control group|
3178859|NCT01347411|No Intervention|Control|Usual treatment
3178860|NCT01347411|Experimental|CPAP|Treatment with CPAP
3178861|NCT01347398|Experimental|MicroMESAM|Sleep study made by MicroMESAM system
3178862|NCT01347398|Active Comparator|PSG|Sleep study made by PSG (polysomnography)
3178863|NCT01347385|Experimental|Barbed suture|
3178864|NCT01347385|Active Comparator|Traditional suture material|
3178865|NCT01347359|Experimental|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, either face-to-face or by telephone.
3178866|NCT01347359|Active Comparator|Control - Standard of care|"Standard of care is at the discretion of the treating rheumatologist."
3178867|NCT01347333|Other|liver metastases|Oligometastases (1-3) with aggregate tumor diameter < 6 cm Metastases from neuroendocrine tumors with functional endocrine syndromes
3178868|NCT01347333|Other|Primary Liver Tumors|Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma
3178869|NCT01347320|No Intervention|No preoperative MRI|control arm of the study
3178870|NCT01347320|Active Comparator|MRI group|preoperative MRI
3178871|NCT01347307|Other|SBRT for Benign Extradural Spine Tumors|Benign extradural spine tumors such as chordomas, meningiomas, schwannomas, neurofibromas, paragangliomas, and arteriovenous malformations (AVMs).
3178872|NCT01347307|Other|SBRT for Vertebral/Paraspinal Metastases|Vertebral and/or paraspinal metastases, with or without prior surgery and/or fractionated radiotherapy
3178873|NCT01347294|Experimental|Bleomycin + Fibrovein|
3178874|NCT01347294|Active Comparator|Bleomycin|
3178875|NCT01347294|Experimental|Natrium Tetradecyl Sulphate (Fibrovein )|
3178876|NCT01347281|Experimental|[18F]HX4 PET|Injection of [18F]HX4
3178877|NCT01347268|Experimental|withdrawing GnRH agonists|
3178878|NCT01347268|Experimental|GnRH antagonist administration|
3178879|NCT01347255|Experimental|LEO 90100 cutaneous spray ointment|LEO 90100 cutaneous spray, ointment, is a new product containing calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate).
3178880|NCT01347255|Active Comparator|LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone|Vehicle cutaneous spray, ointment, with betamethasone 0.5 mg/g (as dipropionate)
3178881|NCT01347255|Placebo Comparator|LEO 90100 Cutaneous Spray, Ointment, Vehicle|LEO 90100 vehicle served as a negative control for the two cutaneous spray ointments with active ingredients.
3178882|NCT01347255|Active Comparator|Daivobet® Ointment|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
3178883|NCT01347203|Experimental|Treatment A|DPOC-4088 prolonged release tablet 100 mg (Formulation A= 16 hr release formulation)
3178884|NCT01347203|Experimental|Treatment B|DPOC-4088 prolonged release tablet 200 mg (Formulation A= 16 hr release formulation)
3178885|NCT01347203|Experimental|Treatment C|DPOC-4088 prolonged release tablet 100 mg (Formulation B= 20 hr release formulation)
3178886|NCT01347203|Experimental|Treatment D|DPOC-4088 prolonged release tablet 200 mg (Formulation B= 20 hr release formulation)
3178887|NCT01347190|Experimental|Liquid API|
3178888|NCT01347190|Placebo Comparator|Placebo|
3178889|NCT01347177|Experimental|Zirconia-based adhesive bridges|Patients in this group will be treated with the employment of zirconia-based adhesive bridges to replace the missing tooth/teeth.
3178890|NCT01347177|Experimental|Metal-based adhesive bridges|Patients in this group will be treated with the employment of metal-based adhesive bridges.
3178891|NCT01347164|Experimental|Life coaching sessions|6 2-hour counseling session with trained therapist/counselor. The sessions deal with coping and stress reduction as well as sexual health.
3178892|NCT01347164|Active Comparator|HIV counseling session|One 60-minute counseling session, based on standard HIV counseling content.
3178893|NCT01347151|Experimental|Glide scope|
3178894|NCT01347151|Experimental|Pentax airway scope|
3178895|NCT01347138|Experimental|case management|case management regulary
3178896|NCT01347138|No Intervention|Control|usual care
3178897|NCT01347125|Experimental|ImCardia|Aortic Stenosis patients candidates for Aortic Valve Replacement (AVR) implanted with the ImCardia device
3178898|NCT01347125|No Intervention|AVR control group|Aortic stenosis patients candidates for aortic valve replacement
3178899|NCT01347112|Active Comparator|Varenicline|varenicline 1.0 mg twice daily for 12 weeks
3178900|NCT01347112|Placebo Comparator|Sugar Pil|Varenicline look alike sugar pill twice daily for 12 weeks
3178901|NCT01347099|Experimental|Internet CBT|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks.
3178902|NCT01347099|Placebo Comparator|Support therapy|10 weeks. Therapist support contact through e-mail.
3178903|NCT01347086|Experimental|BI 207127 NA (low dose)|Single dose of BI 207127 NA
3178904|NCT01347086|Placebo Comparator|Matching placebo (low dose)|Single dose of matching placebo
3178905|NCT01347086|Experimental|BI 207127 NA (medium dose)|Single dose of BI 207127 NA
3178906|NCT01347086|Placebo Comparator|Matching placebo (medium dose)|Single dose of matching placebo
3178907|NCT01347086|Experimental|BI 207127 NA (high dose)|Single dose of BI 207127 NA
3178909|NCT01347073|Experimental|HPN-100|Switch over from sodium phenylbutyrate to open label HPN-100 oral liquid over 10 days then open label, long term treatment for 12 months
3178910|NCT01347060||Medicare-eligible subjects with asthma|Asthma subjects at least 65 years of age enrolled in a large Medicare managed care health plan.
3178911|NCT01347034|Active Comparator|External Beam Radiation Therapy (RT)|Arm A - University of Florida - External Beam Radiation Therapy (RT) - As outlined in Intervention Description
3178912|NCT01347034|Experimental|External Beam RT + DC Injection|Arm B - Moffitt Cancer Center - External Beam RT + Autologous Dendritic Cells (DC) Injection - As outlined in Intervention Description
3178913|NCT01347021|Active Comparator|sacrospinous, pelvic prolapse.|Women with pelvic prolapse grade III/IV were randomly allocated to the sacrospinous colpopexy (25 women) or high uterosacral (26 women)
3178914|NCT01347021|Active Comparator|uterosacral , pelvic prolapse.|Women with pelvic prolapse grade III/IV were randomly allocated to the sacrospinous colpopexy (25 women) or high uterosacral (26 women)
3178915|NCT01347008|Active Comparator|Sildenafil citrate|Oral Sildenafil citrate, 50mg, b.i.d.
3178916|NCT01347008|Placebo Comparator|Sugar pill|Placebo pill (identical to Sildenafil citrate 50mg), b.i.d.
3178917|NCT01346995|Experimental|Experimental Knee Pain|Experimental knee pain induced by injections of 1 ml hypertonic saline in to the infrapatellar fat pad
3178918|NCT01346995|Active Comparator|Control|non-painful injections of isotonic saline into the infrapatellar fatpad.
3178919|NCT01346982|Experimental|Silimarine|darunavir + ritonavir + silimarine
3178920|NCT01346969|Active Comparator|Group 1|
3178921|NCT01346969|Placebo Comparator|Group 2|
3178922|NCT01346969|Placebo Comparator|Group 3|
3178923|NCT01346969|Placebo Comparator|Group 4|
3178924|NCT01346943|Experimental|AAA Stent Graft System|Altura Medical AAA Stent Graft System
3178925|NCT01346930|Experimental|Macitentan|Macitentan tablet, 10 mg, once daily
3178926|NCT01346917|Experimental|Lidocaine|
3178927|NCT01346917|Placebo Comparator|Placebo|
3178928|NCT01346891||Hyponatremia Group (Cases)|Patients over 21 years old, with confirmed antecedent of thiazide-induced hyponatremia who required hospitalization with a serum sodium concentration lower than 125 meq/L.
3178929|NCT01346891||Good Thiazide Tolerance (Controls)|Patients over 21 years old, who have consumed thiazide diuretics for more than 2 years, with a serum sodium concentration persistently over 135 meq/L.
3178930|NCT01346865|Experimental|cilostazol|cilostazol 100mg
3178931|NCT01346865|Placebo Comparator|dual therapy group|Placebo
3178932|NCT01346852||Pediatric participants|Pediatric participants (age 4 to 17) with a diagnosis of asthma
3178933|NCT01346852||Adult participants|Adult participants (age 18 and older) with a diagnosis of asthma
3178934|NCT01346839|Experimental|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
3178935|NCT01346839|No Intervention|Usual Care Control|"The usual care at MEDVAMC consists of providers using an advanced EHR and its notification system (the View Alert system) that immediately alerts providers about clinically significant events. The system relies primarily on computerized notification (alerts) displayed prominently through a View Alert window that is displayed in the EHR every time a provider signs on or switches between patient records. The system does not require providers to read alerts, and providers do have an option of ignoring the View Alert window to bypass it. At SWHS there is a navigation program for patients who have received a cancer diagnosis by tissue biopsy. However, currently there is no routine tracking of patients if they do not show for their scheduled appointments and tests at SWHS."
3178936|NCT01346826|Active Comparator|2 hours-infusion group|Number of patients: 57 (Standard 2 hours-infusion group)
3178937|NCT01346826|Experimental|1 hour-infusion group|Number of patients: 59 (1 hour-infusion group)
3178938|NCT01346826|Experimental|30 minutes-infusion group|Number of patients: 59 (30 minutes-infusion group)
3178939|NCT01346800|Experimental|Prasugrel 10mg po|
3178940|NCT01346800|Experimental|Prasugrel 10mg po + ritonavir 100mg po|
3178941|NCT01346787|Experimental|Carfilzomib Cyclophosphamide Dexamethasone|The treatment period includes administration of Carfilzomib Cyclophosphamide Dexamethasone for 9 courses. In order to assess the toxicity of treatment, patients will attend the study centre visits at each scheduled carfilzomib administration. The response will be assessed after each cycle.
3178942|NCT01346774|Experimental|Cranberry powder capsules|"TheraCran® cranberry: based upon proanthocyanidin content, the four cranberry capsules are equivalent to two 8-ounce servings of cranberry juice.~Participants were directed to take two capsules by mouth twice each day (once in the morning and once in the evening) starting at time of discharge for 4-6 weeks, or until their return for their post-operative doctor's visit. Participants were instructed to drink an 8 oz glass of water while taking the capsule with or without food."
3178943|NCT01346774|Placebo Comparator|Placebo capsules|Placebo: participants were directed to take two capsules by mouth twice each day (once in the morning and once in the evening) starting at time of discharge for 4-6 weeks, or until their return for their post-operative doctor's visit. Participants were instructed to drink an 8 oz glass of water while taking the capsule with or without food.
3178944|NCT01346761|Experimental|Telephone genetic counseling|Participants randomly assigned to telephone counseling are mailed packets that included a sealed envelope containing an educational brochure about hereditary breast and ovarian cancer (HBOC) genetic counseling with visual aids. At the time of their session, participants open their envelope and counselors use the visual aids to explain breast-ovarian cancer genetics and administer BRCA1/BRCA2 genetic counseling. Women receiving in-person counseling are given these same materials during their session at the community clinic. In-person and telephone counseling are delivered by the same five board-certified genetic counselors.
3178980|NCT01346449|Active Comparator|Calorie information absent|
3178981|NCT01346449|Experimental|Visual cue present|
3178982|NCT01346436|Active Comparator|Robotic|Use of daVinci surgical system (Intuitive Surgical Inc, Sunnyvale, CA) for the treatment of complex pelvic floor dysfunction
3178945|NCT01346761|Active Comparator|In-person genetic counseling|In-person BRCA1/BRCA2 genetic counseling is delivered by board-certified genetic counselors using a guide-line-concordant semistructured protocol that allows for personalization of counseling and is similar to that used by others. All sessions are audiotaped for treatment fidelity assessments. In-person and telephone counseling are delivered by the same five board-certified genetic counselors.
3178946|NCT01346748|Experimental|Statin|
3178947|NCT01346735||ICU infections|Infections acquired during the ICU stay
3178948|NCT01346722|Other|Group A|zinc biofortified rice-based diet (Diet-ZBfR) will be compared with conventional rice-based diet (Diet- CR)
3178949|NCT01346722|Other|Group B|zinc biofortified rice-based diet (Diet-ZBfR) will be compared with a rice-based diet plus zinc fortificant (Diet-CR+Z)
3178950|NCT01346709||In-patient Adult Non-obstetricSurgical|"Consecutive patients admitted to participating centres undergoing surgery Non-obstetric in-hospital surgical procedure, elective or emergent, under general anaesthesia (alone or in combination with regional/neuraxial anaesthesia), neuraxial anaesthesia or plexus block (with and without sedation).~All eligible patients undergoing surgery within the seven day study period will be recruited wherever possible."
3178951|NCT01346696|Experimental|OsseoSpeed™ TX implants|OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.
3178952|NCT01346683|Experimental|OsseoSpeed TX|OsseoSpeed TX implants of lengths 8-17 mm
3178953|NCT01346670|Experimental|LipoCol and Mevacor|To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor Tablet after single oral administration in healthy subjects using a 2x2 crossover design
3178954|NCT01346657|Experimental|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects
3178955|NCT01346644|Active Comparator|No probiotics|Infant formula with no probiotics
3178956|NCT01346644|Experimental|Probiotic|Infant formula supplemented with probiotic
3178957|NCT01346631|Experimental|paleolithic diet|Subjects will adhere to a paleolithic diet for the duration of three months
3178958|NCT01346618||children ages 4-17 years|Participants are children and youth ages 4-17 years (inclusive) who performed or will perform a X-ray of the left hand for bone age assessment as part of any clinical work up, within 2 months of enrollment in this study.
3178959|NCT01346605||CCTA patients|Prior stress SPECT with intermediate to high likelihood to be referred to the cardiac catheterization laboratory for an invasive coronary angiogram or patients presenting with chest pain and clinical indication of Coronary CT Angiography and an initial calcium score above 300
3178960|NCT01346592|Active Comparator|aTIV (6 to <72 months)|Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29
3178961|NCT01346592|Active Comparator|Comparator TIV (6 to <72 months)|Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29
3178962|NCT01346592|Active Comparator|TIV (6 to <72 months)|Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29
3178963|NCT01346553|Experimental|ESVV treatment|using ESVV device
3178964|NCT01346540|Experimental|BIBF 1120|VEGF inhibitor
3178965|NCT01346540|Placebo Comparator|Placebo|BIBF 1120 placebo
3178966|NCT01346527||Type 2 diabetes|"Women will be diagnosed with type 2 DM (pre-gestational, White classification B or C class). Since the majority of women with B or C class DM are on insulin therapy in our clinic, we will recruit only women on insulin therapy (i.e. no oral diabetes medications).~HbA1C ≤ 8 for greater than 3 months32, 33.~All women will have confirmed singleton pregnancies.~Receive care at the Women's Health Clinic at Barnes Jewish Hospital.~Pre-pregnancy BMI is anticipated to be >30 (i.e. obese) from the data regarding the patient population of our clinic. Women with pre-pregnancy BMI between 23-40 will be included."
3178967|NCT01346527||Healthy, obese pregnant controls|"No diagnosis of type 1 or 2 diabetes or previous gestational DM.~Women with pre-pregnancy BMI between 30-45: control participants will be BMI matched to women with DM.~A normal routine, standard of care 1 hour 50 gram gestational diabetes screen.~Receive care at the Women's Health Clinic at Barnes Jewish Hospital.~Patients will have a singleton pregnancy with no fetal abnormalities (as determined by routine standard of care ultrasonography)."
3178968|NCT01346527||Healthy, Lean Controls|No diagnosis of type 1 or 2 diabetes or previous gestational DM. 2) Women with pre-pregnancy BMI between 21-25.9 3) A normal routine, standard of care 1 hour 50 gram gestational diabetes screen.
3178969|NCT01346514|Experimental|Arm 1: Addiction/Housing Case Management(AHCM)|The AHCM condition provided individual case management, delivered at the VA and in the community, designed to assist homeless Veterans with SUD issues who may be unable to take advantage of housing opportunities available in the VA due to difficulty navigating multiple services and maintaining stability with respect to SUD and co-occurring mental health conditions.
3178970|NCT01346514|Active Comparator|Arm 2: Housing Support Group(HSG)|The HSG condition involved a weekly drop-in housing support group.
3178971|NCT01346501||Adalimumab|"Participants with Rheumatoid Arthritis (RA) who continued adalimumab treatment after completion of study M06-859, participated in the observational period of studies P12-069 and P12-707.~Other name for adalimumab is Humira."
3178972|NCT01346501||Non-adalimumab|Patients who discontinued adalimumab treatment after completion of the study M06-859.
3178973|NCT01346488||Adalimumab|Participants with RA treated with adalimumab who are either engaged in paid work for more than 35 hours per week (paid workers) or those who are either engaged in paid work for less than 35 hours per week or who perform basic activities of daily life other than paid work (home workers).
3178974|NCT01346475|Active Comparator|valacyclovir|
3178975|NCT01346475|Experimental|high dose valacyclovir|
3178976|NCT01346462|Experimental|PaCT|The Patient-Centered Transition Arm
3178977|NCT01346462|No Intervention|Control|Control group patients will receive routine care from the admitting hospital, including routine patient management, and discharge planning.
3178978|NCT01346449|Active Comparator|Visual cue absent|
3178979|NCT01346449|Experimental|Calorie information present|
3178983|NCT01346436|Active Comparator|Laparoscopy|Use of standard laparoscopy for the treatment of complex pelvic floor dysfunction
3178984|NCT01346423|Experimental|Intervention group|Treatment team with a physician, a physiotherapist, a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The patient meets at the outpatient clinic three times; at baseline, after 2 weeks and after 3 months. One year after baseline the patient has a telephone-follow-up. At baseline, the patient and the team works out a rehabilitation plan and in this process a new visual, educational tool is central.
3178985|NCT01346423|Active Comparator|Controll group|The brief intervention is a standardized intervention based on the studies by Indahl and Hagen. Therapist treatment manuals will be written for the intervention. The essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. Unless symptoms and clinical findings indicate some serious disease, the patients will be informed about the good prognosis, and the importance of staying active to avoid development of muscle dysfunction.
3178986|NCT01346410|Experimental|A|Stereotactic Radiation to Pancreas
3178987|NCT01346397||cyclosporine group|cyclosporine group - after alemtuzumab induction cyclosporine was administered
3178988|NCT01346397||tacrolimus group|tacrolimus group - after alemtuzumab induction tacrolimus was administered
3178989|NCT01346384||intracuff pressure N2O|measured intracuff pressure of LT with N2o during operative period
3178990|NCT01346371|Placebo Comparator|Refresh Tears® eye drops|Must add drops twice a day every day during trial enrollment.
3178991|NCT01346371|Experimental|Bepreve® 1.5% solution|Must add drops twice a day every day while enrolled in trial.
3178992|NCT01346358|Experimental|IMC-CS4 Weight Based Dosing|Participants receiving IMC-CS4 intravenously (weight based dosing)
3178993|NCT01346358|Experimental|IMC-CS4 Non-Weight Based Dosing|Participants receiving IMC-CS4 intravenously (non-weight based dosing)
3178994|NCT01346332||Anesthetization|
3178995|NCT01346319|Active Comparator|Testosterone undecanoate|
3178996|NCT01346319|Placebo Comparator|Placebo|
3178997|NCT01346306|Experimental|DCS 1|
3178998|NCT01346306|Experimental|DCS 2|
3178999|NCT01346293|Experimental|Study Group 1|Participants will receive concomitantly a dose of DTap-IPV, a dose of M-M-R®II, and a dose of VARIVAX® vaccine on Day 0
3179000|NCT01346293|Experimental|Study Group 2|Participants will receive concomitantly a dose of DAPTACEL®, a dose of IPOL®, a dose of M-M-R®II, and a dose of VARIVAX® vaccines on Day 0
3179001|NCT01346293|Experimental|Study Group 3|Participants will receive concomitantly a dose of DTap-IPV with or without a dose of M-M-R®II and a dose of VARIVAX® on Day 0
3179002|NCT01346293|Experimental|Study Group 4|Participants will receive concomitantly a dose of DAPTACEL® vaccine, a dose of IPOL® vaccine with or without a dose of M-M-R®II and a dose of VARIVAX® vaccines on Day 0
3179003|NCT01346267|Experimental|Arm I- Real Acupressure bands|Patients wear Sea-Band acupressure wristbands on each wrist beginning approximately 30 minutes prior to the first cisplatin-containing chemotherapy course and continually for 24 hours after the last chemotherapy dose (acute phase), and for a maximum of 7 days or until the next chemotherapy course starts (delayed phase). Patients are allowed to take bands off intermittently (up to 4 times a day, for no more than 15 minutes each time) to relieve pressure or to bathe. Patients also receive standard of care anti-emetic prophylaxis comprising granisetron, ondansetron, or dexamethasone during chemotherapy according to institutional or physician preference.
3179004|NCT01346267|Sham Comparator|Arm II- Placebo Acupressure Bands|Patients wear placebo wristbands on each wrist and receive standard of care anti-emetic prophylaxis during chemotherapy as patients in arm I.
3179005|NCT01346254|Experimental|Vildagliptin|16 patients randomized into this arm will receive vildagliptin (Galvus) 50mg orally once daily
3179006|NCT01346254|Experimental|Pioglitazone|16 patients randomized into this arm will receive pioglitazone (Actos) 30mg orally once daily
3179007|NCT01346254|Placebo Comparator|Placebo|16 patients randomized into this arm will receive placebo medication orally once daily
3179008|NCT01346215|Experimental|Actparin® - Laboratorio Bergamo|
3179009|NCT01346215|Active Comparator|Heparin sodium - APP Pharmaceuticals|
3179010|NCT01346202||chronic pain|260 consecutive patients with verified chronic pain syndromes
3179011|NCT01346189|Active Comparator|Physician Incentives|"(with adherence feedback)~Quarterly payments to physician combined based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL with daily patient statin adherence information made available."
3179012|NCT01346189|Active Comparator|Patient Incentives|"(with adherence feedback)~Quarterly payments to patient based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL."
3179013|NCT01346189|Active Comparator|Physician and Patient Combined Incentives|"(with adherence feedback)~Quarterly payments shared evenly by physician and patient based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL. Physicians will receive daily information about patients' statin adherence."
3179014|NCT01346189|No Intervention|Usual Care|
3179015|NCT01346176|Experimental|Positive default|Patients in this arm will receive AD forms where specific life-extending interventions will be provided unless patients specifically opt-out from such selections
3179016|NCT01346176|Experimental|Negative default|Patients in this arm will receive AD forms where specific life-extending interventions will not be provided unless patients specifically opt-into such selections
3179017|NCT01346176|Experimental|Forced Choice|Patients in this arm will receive AD forms in which they must actively choose whether to receive each intervention.
3179018|NCT01346163|Active Comparator|PF-03654746|H3 receptor antagonist currently being developed for the treatment of cognitive impairment associated with schizophrenia (CIAS) as well as with Alzheimer's disease.
3179019|NCT01346163|Placebo Comparator|Placebo|
3179020|NCT01346150||Stratum A|SCID, ADA-SCID, and XSCID who received a transplant
3179021|NCT01346150||Stratum B|Leaky SCID, Omenn Syndrome, and Reticular Dysgenesis who received a transplant
3179022|NCT01346150||Stratum C|SCID who received PEG ADA or gene therapy
3179023|NCT01346137|Experimental|meloxicam|15 mg versus 30 mg per day P.O for 15 days, during 3 menstrual cycles
3179024|NCT01346124|Experimental|IMPT|High dose IMPT
3179025|NCT01346111||generation cohort|Included 5 hospitals from Buenos Aires, Argentina
3179026|NCT01346098|Experimental|GROUP B|At the time of surgery the surgeon will directly assess pancreatic consistency and the pancreatic duct size. In the presence of a soft pancreas and a small duct (diameter <3 mm), the patient will be randomly assigned to receive either a pancreaticoduodenectomy with pancreatic anastomosis (group A) or a total pancreatectomy with IAT (group B).
3179027|NCT01346098|Active Comparator|GROUP A|
3179028|NCT01346085|Experimental|CNI-free single-group|
3179029|NCT01346072|Other|Tolvaptan|Single arm study
3179030|NCT01346059|Placebo Comparator|Saline|The saline arm will receive normal saline through the catheter as a placebo.
3179031|NCT01346059|Experimental|Vancomycin|The vancomycin arm will receive vancomycin solution through the catheter.
3179032|NCT01346046||Those with Type 2 diabetes|270 subjects with Type 2 diabetes
3179033|NCT01346046||Non diabetic|30 healthy subjects
3179034|NCT01346033||Those with Type 2 diabetes|All subjects have been diagnosed with type 2 diabetes.
3179035|NCT01346020||CLL|
3179036|NCT01346007|Active Comparator|patients|Children with idiopathic nephrotic syndrome in remission treated with low-dose prednisolone and/or mycophenolate mofetil and/or cyclosporine A
3179037|NCT01346007|Active Comparator|controls|
3179038|NCT01345994|Experimental|Acupuncture - local|acupuncture on forearm only
3179039|NCT01345994|Experimental|acupuncture - distal|acupuncture on both arm and leg
3179040|NCT01345981|Experimental|lidocaine 20 mg|intravenous lidocaine
3179041|NCT01345981|Experimental|lidocaine 40 mg|intravenous lidocaine 40 mg
3179042|NCT01345981|Placebo Comparator|normal saline|2 ml
3179043|NCT01345968|Placebo Comparator|NaCl 0.9%|
3179044|NCT01345968|Experimental|Ferinject|
3179045|NCT01345942|Experimental|A food|
3179046|NCT01345942|Experimental|B without food|
3179047|NCT01345929|Experimental|CXA-201 as treatment for cUTI|CXA-201 IV infusion (1500mg q8) for 7 days
3179048|NCT01345929|Active Comparator|Levofloxacin as treatment for cUTI|Levofloxacin IV infusion (750mg qd) for 7 days
3179049|NCT01345916|Experimental|CHF 1535 100/6 NEXT Dry Powder Inhaler®|CHF1535 100/6 NEXT DPI® 1 inhalation bis in day (b.i.d) (daily dose BDP 200/FF 12 µg)
3179050|NCT01345916|Active Comparator|CHF1535 100/6 pMDI|CHF1535 100/6 pressurisedMeterDoseInhaler 1 inhalation b.i.d (total daily dose BDP 200/FF 12 µg)
3179051|NCT01345916|Active Comparator|beclomethasone dipropionate DPI|beclomethasone dipropionate 100 µg DPI, 1 inhalation b.i.d (total daily dose BDP 200 µg)
3179052|NCT01345903|Experimental|Treatment (surgery)|Patients undergo robotic-assisted surgery using the da Vinci robot
3179053|NCT01345890|Experimental|electrical stimulation|stroke patients
3179054|NCT01345877|Other|gender|
3179055|NCT01345864|Other|Cohort A|Parallel design with 5 unique treatment groups Donepezil tablets and matching placebo tablets may be overencapsulated as needed.
3179056|NCT01345851|Experimental|Treatment (dose-escalation of RT)|Patients undergo image-guided hypofractionated RT over 35 minutes 5 days a week for 2 weeks followed by 5 fractions of hypofractionated RT boost. Patients also receive standard carboplatin and paclitaxel for 3 weeks.
3179057|NCT01345838||Dysplasia|Patients with developmental dysplasia of the hip undergoing PAO
3179058|NCT01345825|Experimental|resistance training|
3179059|NCT01345812|Active Comparator|urine-derived FSH|Follicle stimulating hormone
3179060|NCT01345812|Active Comparator|recombinant FSH|Follicle stimulation hormone
3179061|NCT01345799|Experimental|TRK-170 Low Dose|
3179062|NCT01345799|Experimental|TRK-170 Middle Dose|
3179063|NCT01345799|Experimental|TRK-170 High Dose|
3179064|NCT01345799|Placebo Comparator|Placebo|
3179065|NCT01345786|Experimental|Commercial NOMAC-E2, Part 1|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Participants in Part 1 were from Site 1."
3179066|NCT01345786|Active Comparator|Phase 3 NOMAC-E2, Part 1|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program (Batch A), either on the first day of Period 2 and Period 4 (for participants randomized to Sequence 1) or on the first day of Period 1 and Period 3 (for participants randomized to Sequence 2). Participants in Part 1 were from Site 1."
3179067|NCT01345786|Experimental|Commercial NOMAC-E2, Part 2|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Participants in Part 2 were from Site 2."
3179068|NCT01345786|Active Comparator|Phase 3 NOMAC-E2, Part 2|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program (Batch B), either on the first day of Period 2 and Period 4 (for participants randomized to Sequence 1) or on the first day of Period 1 and Period 3 (for participants randomized to Sequence 2). Participants in Part 2 were from Site 2."
3179069|NCT01345773||Patients receiving gastric cancer surgery|
3179070|NCT01345760||Basal Cell Carcinoma|
3179071|NCT01345760||Squamous Cell Carcinoma|
3179072|NCT01345760||Actinic Keratosis|
3179073|NCT01345760||healthy non-lesional skin|
3179074|NCT01345747|Experimental|laryngeal tube|laryngeal tube suction has suction port
3179075|NCT01345747|Experimental|endotracheal tube|
3179076|NCT01345734||Liraglutide|
3179077|NCT01345721|Experimental|MenACWY (2 primary + 1 booster dose)|Subjects who had previously received two primary doses of MenACWY-CRM vaccine (at 6-8 months and 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
3179133|NCT01345279||cisplatin|
3179134|NCT01345279||cisplatin + topotecan|
3179135|NCT01345279||cisplatin + paclitaxel|
3179078|NCT01345721|Experimental|MenACWY (1 primary + 1 booster dose)|Subjects who had previously received one primary dose of MenACWY-CRM vaccine (at 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
3179079|NCT01345721|Experimental|MenC (1 primary dose)+MenACWY (1 booster dose)|Subjects who had previously received one primary dose of the comparator MenC vaccine (at 12 months of age) in parent study, were administered one booster dose MenACWY-CRM vaccine in this extension study.
3179080|NCT01345695||Treatment|Data collected on persons living in the catchment area for a WHP telemedicine center
3179081|NCT01345695||Control|Data collected on persons living in the catchment area where there is not a WHP telemedicine center
3179082|NCT01345682|Experimental|Afatinib (BIBW 2992)|Once daily
3179083|NCT01345682|Active Comparator|Methotrexate|Weekly
3179084|NCT01345669|Experimental|Afatinib (BIBW 2992)|Once daily
3179085|NCT01345669|Placebo Comparator|Placebo|Once daily
3179086|NCT01345656|Experimental|Arm 1|
3179087|NCT01345656|Experimental|Arm 2|
3179088|NCT01345656|Experimental|Arm 3|
3179089|NCT01345656|Experimental|Arm 4|
3179090|NCT01345656|Placebo Comparator|Arm 5|
3179091|NCT01345656|Active Comparator|Arm 6|
3179092|NCT01345643|Experimental|Hemoglobin level based on WCPT Score|According to WCPTS, the patient's hemoglobin level will be maintained not less than 7,8,9,or 10g/dL. Determination of whether a patient need red blood cells transfusion is based on WCPT Score.
3179093|NCT01345643|Active Comparator|Hemoglobin level 100g/L|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
3179094|NCT01345630|Experimental|Maraviroc|Maraviroc 150 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for emtricitabine/tenofovir once daily.
3179095|NCT01345630|Active Comparator|Emtricitabine/tenofovir|Emtricitabine/tenofovir 200/300 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for maraviroc once daily.
3179096|NCT01345617||cystic fibrosis patients|cystic fibrosis patients
3179097|NCT01345617||non-cystic fibrosis patients|non-cystic fibrosis patients
3179098|NCT01345604|Placebo Comparator|Saline|
3179099|NCT01345604|Active Comparator|Ropivicaine|
3179100|NCT01345591|Experimental|Fat Grafting|Twenty (20) subjects who have had severe facial trauma, 18 years of age and older enrolled to clinical trial will receive Fat grafting intervention procedure
3179101|NCT01345578|Experimental|Hepatocyte Transplantation|See Below
3179102|NCT01345565|Experimental|Hepatocyte Transplantation|See Below
3179103|NCT01345552|Other|SBRT|
3179104|NCT01345539|Other|SBRT|
3179105|NCT01345526|Experimental|Metastatic colorectal cancer, Doxycycline, Vitamin K1 Cream|
3179106|NCT01345526|Placebo Comparator|Metastatic colorectal cancer, Doxycycline, Cream|
3179107|NCT01345513||Solid Tumor Cancer|
3179108|NCT01345500|Experimental|Higher Carbohydrate/Lower Fat Diet|
3179109|NCT01345500|Experimental|Lower Carbohydrate/Higher Fat Diet|
3179110|NCT01345500|Active Comparator|Individualized Counseling|
3179111|NCT01345487|Other|Low Vegetable Protein|Meal with 10 E% protein from fava beans/split peas
3179112|NCT01345487|Experimental|High Vegetable protein|Meal with 20 E% protein from fava beans/split peas
3179113|NCT01345487|Experimental|High Animal Protein|Meal with 20 E% protein from pork/beef
3179114|NCT01345461||Healthy adult volunteers|Twelve healthy adult volunteers (6 men, 6 women)
3179115|NCT01345435|Experimental|Telemonitoring group|"A Smart Care PC, blood glucose meter and body composition analyzer will be provided~transmitting the results to the Smart Care Server via Smart Care PC~At Smart care Center,care manager will provide remote blood glucose monitoring and individual diabetes case management"
3179116|NCT01345435|Experimental|Telemonitoring & Telemedicine group|"A Smart Care PC, blood glucose meter and body composition analyzer will be provided~transmitting the results to the Smart Care Server via Smart Care PC~At Smart care Center,care manager will provide remote blood glucose monitoring and individual diabetes case management~taking telemedicine through video telephone instead of visiting hospital"
3179117|NCT01345435|Other|Control group|"Blood glucose meter and body composition analyzer will be provided~Self-monitoring Blood Glucose (SMBG)"
3179118|NCT01345422|Experimental|Wii Balance Board|Wii Balance Board Training
3179119|NCT01345396|Experimental|Education|
3179120|NCT01345396|No Intervention|No education|
3179121|NCT01345383||Current smokers|
3179122|NCT01345370||Stupp protocole|All subjects enrolled must be treated according to the Stupp schedule : surgical resection followed by Temozolomide (TMZ) chemotherapy with concomitant radiotherapy, and then 6 cycles of adjuvant Temzolomide.
3179123|NCT01345357|Experimental|CEP-9722 in combination with Gemcitabine and Cisplatin|Study drugs will be administered in cycles of 21 days for up to 6 cycles. CEP-9722 treatment will be initiated at cycle 2. After cycle 3, patients may discontinue gemcitabine and/or cisplatin for reasons of tolerability, at the discretion of the investigator.
3179124|NCT01345344|Experimental|Cognitive-Behavioral Therapy|Practicing certain strategies such as relaxation and changing negative thoughts about pain.
3179125|NCT01345344|Active Comparator|Education|Giving information about pain and how to change perceptions of pain.
3179126|NCT01345344|No Intervention|Healthy Controls|No intervention
3179127|NCT01345331|Experimental|Real Stimulation|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain.
3179128|NCT01345331|Sham Comparator|Sham|The sham treatment will use the same equipment as the real treatment, but the participant will not receive any real stimulation to the ear.
3179129|NCT01345318|Experimental|Open-label Treatment|
3179130|NCT01345292|Experimental|12027-027|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
3179131|NCT01345292|Active Comparator|310158077046|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
3179132|NCT01345292|Placebo Comparator|037000003212|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
3179136|NCT01345266|Other|Inhalation Profiling|All subjects have Inhaltion profiling, there are no other arms.
3179137|NCT01345253|Experimental|Belimumab|10mg/kg
3179138|NCT01345253|Placebo Comparator|Placebo|placebo
3179139|NCT01345240|Experimental|RTS,S Regimen A Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3179140|NCT01345240|Experimental|RTS,S Regimen A Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. In addition, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3179141|NCT01345240|Experimental|RTS,S Regimen A Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3179142|NCT01345240|Experimental|RTS,S Regimen B Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3179143|NCT01345240|Experimental|RTS,S Regimen B Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3179144|NCT01345240|Experimental|RTS,S Regimen B Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3179145|NCT01345240|Experimental|RTS,S Regimen C Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3179304|NCT01344083|Active Comparator|Olopatadine hydrochloride|
3179146|NCT01345240|Experimental|RTS,S Regimen C Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3179147|NCT01345240|Experimental|RTS,S Regimen C Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3179148|NCT01345240|Active Comparator|Engerix B Regimen A Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the Engerix-B Vaccination Regimen A. This regimen included 3 doses of Engerix B™ co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™ at Weeks 0, 4 and 8, and 2 doses of Rotarix™, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. Engerix B™ was administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3179149|NCT01345240|Active Comparator|Engerix B Regimen B Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the Engerix-B Vaccination Regimen B. This regimen included 3 doses of Engerix B™ co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™ vaccine, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. Engerix B™ was administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3179150|NCT01345227|Experimental|Intra BM islet infusion|single intra BM islet infusion at the level of the iliac crest will be performed in patients having contraindications for intraportal infusion
3179151|NCT01345214|Experimental|E|
3179152|NCT01345188|Active Comparator|Ranolazine|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
3179153|NCT01345188|Placebo Comparator|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
3179154|NCT01345175|Experimental|Pts receiving Rifaximin|This group will receive rifaximin 400mg bid for 4 weeks. At 1 - 24 months after completion of the phase III portion of the trial, patients will be contacted by phone and given the option of receiving metronidazole in a followup, single arm study in which all patients receive the antibiotic. Patients who wish to participate will be mailed a drug prescription for a 3 week course of metronidazole 500mgs tid as well as the BFI forms and stool diary. Pretreatment and post treatment BFI scores will be collected and analyzed for change in bowel function as was done in the initial Phase III study.
3179155|NCT01345175|Placebo Comparator|Pts receiving placebo|This group will receive a placebo bid for 4 weeks. At 1 - 24 months after completion of the phase III portion of the trial, patients will be contacted by phone and given the option of receiving metronidazole in a followup, single arm study in which all patients receive the antibiotic. Patients who wish to participate will be mailed a drug prescription for a 3 week course of metronidazole 500mgs tid as well as the BFI forms and stool diary. Pretreatment and post treatment BFI scores will be collected and analyzed for change in bowel function as was done in the initial Phase III study.
3179156|NCT01345162|Other|ketorolac|Patients will be given intraoperative analgesia with Ketorolac and tramadol before the the end of surgery, then Ketorolac postoperative 10mg 1cp x 3/die, from the day of surgery for 4 days after surgery.
3179157|NCT01345162|Other|acetaminophene+tramadol|Patients will be given intraoperative analgesia with Ketorolac and tramadol before the the end of surgery, then postoperative Patrol (acetaminophene 325mg+tramadol 37,5mg) 1cp x 3/die for 4 days after surgery.
3179158|NCT01345149|Experimental|Diet + Exercise|"Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.~Exercise: Individual counselling"
3179159|NCT01345149|Experimental|Exercise|Exercise: Individual counselling
3179160|NCT01345149|No Intervention|Control|Standard treatment without intervention.
3179161|NCT01345136|Experimental|RAD001 Treatment|All subjects will be given RAD001 for 1 year (12 months).
3179162|NCT01345123|Experimental|Decision Aid with Health Coaching|
3179163|NCT01345123|Experimental|Decision Aid only|
3179164|NCT01345123|No Intervention|No condition specific support|
3179165|NCT01345097|Experimental|Younger Group|
3179166|NCT01345097|Experimental|Elderly Group|
3179209|NCT01344772|Active Comparator|Total hip replacement|Displaced femoral neck fracture treated with total hip replacement through a posterior approach.
3179210|NCT01344759|Active Comparator|Propofol|
3179211|NCT01344759|Active Comparator|Dexmedetomidine|
3179167|NCT01345084|Experimental|Radiation therapy, cisplatin and nimotuzumab|"Nimotuzumab - (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes. Pre-drugs are optional, at the investigator's discretion)- 200 mg, IV, weekly doses during the radiation therapy until completing 6 months.~Radiation therapy- 66 -70 Gy, external,fractions of 2 Gy per day, 5 days a week~Cisplatin - 75 mg/m2, IV, Doses every 3 weeks (a total of three doses)"
3179168|NCT01345084|Active Comparator|Radiation therapy and cisplatin|"Radiation therapy: 66- 70 Gy, fractions of 2 Gy per day, 5 days a week~Cisplatin:75 mg/m2, IV, doses every 3 weeks (a total of three doses)"
3179169|NCT01345071||RA patients|RA patients with active disease or current use of anti-TNF. Treatment is according to treat to target principles.
3179170|NCT01345058|Experimental|Lacosamide + Low-Dose Levetiracetam|Participants received lacosamide 50 mg twice a day for one week followed by 100 mg twice daily added to low dose levetiracetam ≤1500 mg/day (polytherapy) for 6 months in patients with breakthrough seizures on low-dose levetiracetam.
3179171|NCT01345058|Other|Control Group (High-Dose Levetiracetam)|Historical chart review of patients whose dose of levetiracetam was raised to high dose levetiracetam >1500 mg/day (monotherapy) after a breakthrough seizure. No intervention was administered in the study.
3179172|NCT01345045|Experimental|ABT-639|ABT-639 twice daily for 6 weeks
3179173|NCT01345045|Active Comparator|pregabalin|pregabalin starting dose twice daily for week one then titrated up to maintenance dose twice daily for duration of the study
3179174|NCT01345045|Placebo Comparator|Placebo|Placebo twice daily for 6 weeks
3179175|NCT01345032|Experimental|Home visits|Nutritional follow-up after discharge, conducted as nutritional counselling performed as in-person counselling in the participants homes
3179176|NCT01345032|Experimental|Telephone consultation|Nutritional follow-up after discharge, conducted as nutritional counselling performed as telephone consultation
3179177|NCT01345032|No Intervention|Control|No follow-up after discharge
3179178|NCT01345019|Active Comparator|Zoledronic acid|Participants received zoledronic acid 4 mg intravenously plus placebo to denosumab subcutaneous injection once every 4 weeks until the required number of events was reached.
3179179|NCT01345019|Experimental|Denosumab|Participants received denosumab 120 mg subcutaneous injection and placebo to zoledronic acid intravenously once every 4 weeks until the required number of events was reached.
3179180|NCT01345006|Experimental|MA09-hRPE|Patients will undergo subretinal injection of MA09-hRPE
3179181|NCT01344993|Experimental|MA09-hRPE|"Experimental: Subretinal injection of MA09-hRPE~Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
3179182|NCT01344980|Experimental|Stainless steel MGH|Patients in this study arm will have their flexor tendon laceration repaired using stainless steel suture (size 3-0) in an MGH repair technique. They will then undergo aggressive early active range of motion rehabilitation post-operatively.
3179183|NCT01344980|Active Comparator|Polypropylene DOLL|Patients in this study arm will have their flexor tendon laceration repaired using polypropylene suture (size 3-0) in a double-locking loop repair technique. They will then undergo aggressive early active range of motion rehabilitation post-operatively.
3179184|NCT01344967|Experimental|Zometa, Bone Suppression, Active Ingredient|
3179185|NCT01344954|Experimental|25mg TB-402|
3179186|NCT01344954|Experimental|50mg TB-402|
3179187|NCT01344954|Active Comparator|10mg QD Rivaroxaban|
3179188|NCT01344941||Group 1|The first group will comprise individuals who have received a St. Jude HIV-1 vaccine and who have exhibited sustained immune responses
3179189|NCT01344941||Group 2|Groups 2 will be HIV-1-infected. The first visit of individuals in groups 2 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.
3179190|NCT01344941||Group 3|Groups 3 will be HIV-1-uninfected. The first visit of individuals in groups 3 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.
3179191|NCT01344928|Experimental|HIT training|
3179192|NCT01344928|Active Comparator|Aerobic exercise training|
3179193|NCT01344915|Active Comparator|Knee brace|
3179194|NCT01344915|Active Comparator|Locked knee brace|
3179195|NCT01344902|Experimental|Hexaminolevulinate|
3179196|NCT01344889||Cohort|
3179197|NCT01344876|Experimental|OPB-51602|OPB-51602 1, 2, 4 and 6 mg/day oral once daily (QD) in a 4 week cycle
3179198|NCT01344863|Experimental|1|
3179199|NCT01344863|Active Comparator|2|
3179200|NCT01344837||Observational|Archived serum and tumor tissue samples are analyzed for synuclein-γ (SNCG) expression and other biomarker expression, including TP53 (p53), HER-2, folate receptor alpha (FOLR1), estrogen receptor (ER), progesterone receptor (PR), phosphatase and tensin homolog (PTEN), phosphorylated AKT (pAKT), pERK, and p16 by microarray analysis, IHC assays, and western blot. Results are then compared with patients' existing clinical, demographic, and pathology data, including history of breast cancer (metachronous) or breast cancer diagnosed at the same time as the endometrial cancer (synchronous).
3179201|NCT01344824|Other|Single Arm Trial|Bevacizumab, Carboplatin, and Pemetrexed disodium, with option for second line erlotinib hydrochloride
3179202|NCT01344811|Experimental|Telemonitoring group|"A Smartphone, body composition analyzer and Pedometer will be provided~transmitting the results to the Smart Care Server via Smartphone~At Smart care Center,care manager will provide remote body weight and activity monitoring and individual obesity case management"
3179203|NCT01344811|Other|Control group|"A weighing scale and Pedometer will be provided~recording in a self diary of body weight and the number of steps"
3179204|NCT01344798|Experimental|Dose level 1|AAV1-gamma-sarcoglycan vector dose level: 3x10e9 vg/100µl
3179205|NCT01344798|Experimental|Dose level 2|AAV1-gamma-sarcoglycan vector dose level: 1.5x10e10 vg/100µl
3179206|NCT01344798|Experimental|Dose level 3|AAV1-gamma-sarcoglycan vector dose level: 4.5x10e10 vg/300µl
3179207|NCT01344785||Patients with a intertrochanteric fracture|Patients with a intertrochanteric fracture, n=100
3179208|NCT01344772|Active Comparator|Internal fixation|Displaced femoral neck fracture treated with internal fixation using two parallel cannulated screws.
3179305|NCT01344070|Active Comparator|Reference formulation of each drug|Innovator formulation
3179212|NCT01344746||Snoring group|"Subjects with snoring and AHI ≥ 20 episodes/h (severe SDB).~Snorers with AHI < 20 episodes/h and ≥ 5 episodes/h (moderate SDB)~Snorers with AHI < 5 episodes/h and ≥ 1 episodes/h (mild SDB)"
3179213|NCT01344746||Non-snoring group|"When testing serum and urinal samples, healthy children without snoring will be chosen as controls.~When testing lymphoid tissue samples, patients with recurrent infectious tonsillitis (at least five tonsillar infections in less than 6 months) but without snoring will be selected as controls before surgery and recruited to the study, because adenotonsillar tissue can't be obtained from normal children for obvious ethical reasons."
3179214|NCT01344733||MDD|Patients with treatment resistant major depressive disorder will be evaluated in order to assess the presence of hypomanic symptoms as cause of resistance.
3179215|NCT01344720|Active Comparator|etoricoxib|etoricoxib up to 60mg/day as monotherapy
3179216|NCT01344720|Active Comparator|etoricoxib plus controlled-release oxycodone|combination treatment of etoricoxib (30 mg/day) plus controlled-release oxycodone (10 mg/day)
3179217|NCT01344694||patient with liver fat|30 patients with liver fat
3179218|NCT01344694||excess of visceral fat|50 pts. with excess of visceral fat
3179219|NCT01344694||control|30 control subjects
3179220|NCT01344681|Experimental|Arm A|Micafungin sodium
3179221|NCT01344681|Active Comparator|Arm B|Itraconazole
3179222|NCT01344668|Other|Standard Diabetes Education|Standard Diabetes Education
3179223|NCT01344668|Other|Enhanced Diabetes Education|Enhanced Diabetes Education
3179224|NCT01344655|Experimental|Formoterol 12 μg pMDI (Atimos®)|
3179225|NCT01344655|Active Comparator|Salmeterol 25 µg pMDI HFA (Serevent™)|
3179226|NCT01344655|Placebo Comparator|Matched Placebo|
3179227|NCT01344629|Experimental|Telmisartan80mg/Amlodipin5mg FDC|single-dose, four-period replicated crossover design
3179228|NCT01344629|Experimental|Telmisartan80mgtab + Amlodipin5mg tab|single-dose, four-period replicated crossover design
3179229|NCT01344616|No Intervention|usual clinical care|usual clinical care with no intervention
3179230|NCT01344616|Experimental|lifestyle counseling|computer-based clinical support to patient
3179231|NCT01344603||epidural|
3179232|NCT01344603||standard|
3179233|NCT01344590|Active Comparator|saline lock maintenance|Standard saline lock maintenance
3179234|NCT01344590|Experimental|ethanol maintenance|Instillation of 70% pharmaceutical grade ethanol solution into the central line in a volume calculated to fill the catheter lumen and hub.
3179235|NCT01344577||Group1#|bone graft material used: Apatos Cortical® (porcine cortical bone 600-1000 µm)
3179236|NCT01344577||Group2#|bone graft material used: MP3® (porcine cortic-cancellous collagenated bone mix 600-1000 µm)
3179237|NCT01344577||Group3#|control group
3179238|NCT01344564|Other|ADT|All subjects receive ADT, degarelix acetate for 3 months followed by one 3 month leuprolide depot.
3179239|NCT01344551|Active Comparator|High Flavanol|High Flavanol cocoa drink containing 495mg cocoa
3179240|NCT01344551|Placebo Comparator|Low Flavanol|Low Flavanol cocoa drink (23mg)
3179241|NCT01344538|Experimental|Ginger Root Extract|
3179242|NCT01344538|Placebo Comparator|Lactose Capsule|
3179243|NCT01344525|No Intervention|Control group|Nutritional counselings every 6 months, no further intervention
3179244|NCT01344525|Experimental|"low-calorie-diet (LCD)-based lifestyle intervention"|12 months multidisciplinary weight loss program including three months low-calorie formula diet (800 kcal) (OPTIFAST®52 program)
3179245|NCT01344525|Experimental|Laparoscopic gastric sleeve intervention|
3179246|NCT01344525|Experimental|Conventional bariatric surgery|Gastric Banding and Gastric Bypass
3179247|NCT01344512|Experimental|Patients treated with Ceftazidime|
3179248|NCT01344512|Experimental|Patients treated with Ciprofloxacin|
3179249|NCT01344512|Experimental|Patients treated with Voriconazole|
3179250|NCT01344499|Experimental|Adept|1000ml Adept will be left in the abdomen and measured over time
3179251|NCT01344499|Active Comparator|Ringer-lactate|1000 ml of Ringer lactate left in the abdomen and measured over time
3179252|NCT01344486|Experimental|Full conditioing|Intervention by alteration of laparoscopic gas with addition of oxygen and nitrous oxide, regulation of humidification and temperature (32°C), injection of 5mg Dexamethasone and application of Hyalobarrier Gel Endo (Nordic Pharma) at the surgical wound
3179253|NCT01344486|Active Comparator|carbon dioxide|induction pneumoperitoneum with carbon dioxide 100%
3179254|NCT01344473|Experimental|Casein phosphopeptide in the form of TM|Experimental group will be given TM to use daily for 12 weeks
3179255|NCT01344473|No Intervention|No intervention|Standard oral care
3179256|NCT01344460|Experimental|Arm 1|
3179257|NCT01344447|Experimental|Arm 1|
3179258|NCT01344421||hip dysplasia|Patients with hip dysplasia
3179259|NCT01344421||Healthy people|Enrolled from the patients acquaintance circle
3179260|NCT01344408|Experimental|Computer-training|The computer-training program, Move it to improve it was installed in the participants homes using an internet-connected computer with a web camera connected to a cloud-based specifically adapted interactive training program.
3179261|NCT01344408|Experimental|Printed instructions|A training program delivered as printed instructions
3179262|NCT01344395|Experimental|RK-group|
3179263|NCT01344395|Active Comparator|K-group|
3179264|NCT01344382|Experimental|CRAFT|All parents will be scheduled for 12 individual Community Reinforcement and Family Training for parents (CRAFT-P) training sessions within 120 days and allowed to use up to 6 additional emergency sessions at any time up to the 12-mo follow-up. The first session will last 90 min; the remaining sessions will be 50 - 60 min in duration. Emergency sessions typically last 30 - 60 min and are used to assist the parent with crisis situations during the treatment period (e.g., adolescent violence, arrest) or for booster sessions after.
3179301|NCT01344109||Breast cancer patients|Newly diagnosed patients with breast cancer presenting with operable breast tumor prior to initiation of of neoadjuvant chemotherapy (choice of chemotherapy will be the the treating physician's discretion)
3179302|NCT01344109||Healthy volunteers|Adult women without a cancer diagnosis.
3179303|NCT01344083|Experimental|T1210|
3179265|NCT01344382|Active Comparator|Al-Anon Facilitation|All parents will be scheduled for 12 individual Alanon/Naranon Facilitation Training (ANF) sessions within 120 days and allowed to use up to 6 additional emergency sessions at any time up to the 12-mo follow-up. The first session will last 90 min; the remaining sessions will be 50 - 60 min in duration. Emergency sessions typically last 30 - 60 min and are used to assist the parent with crisis situations during the treatment period (e.g., adolescent violence, arrest) or for booster sessions after.
3179266|NCT01344369|Experimental|Investigational Test Product|Norethindrone/Ethinyl Estradiol 0.4 mg/0.035 mg Chewable Tablets (Teva)
3179267|NCT01344369|Active Comparator|Reference Listed Drug|FEMCON® Fe 0.4 mg/0.035 mg Chewable tablets (Warner Chilcott)
3179268|NCT01344356|Other|Benign Tumors|Benign head and neck tumors will be treated with SBRT
3179269|NCT01344356|Other|Malignant Tumors|Malignant Head and Neck Tumors will be treated with SBRT.
3179270|NCT01344343|Experimental|Accelerated hip fracture surgery|Arrival in the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair
3179271|NCT01344343|No Intervention|Standard care|Surgical hip fracture repair according to the standard timing
3179272|NCT01344330||Screening colonoscopy patients|Men and women age 50 to 75 scheduled for screening colonoscopy
3179273|NCT01344317||Caffeine group|Premature infants below 30 weeks of gestation who receive Caffeine treatment
3179274|NCT01344317||Caffeine and Doxapram group|Premature infants below 30 weeks of gestation who receive Caffeine and Doxapram treatment
3179275|NCT01344317||Group with no treatment|Premature infants below 30 weeks of gestation with no stimulating treatment
3179276|NCT01344304|No Intervention|Standard therapy|The patients are treated with 5HT3-receptor antagonist + dexamethasone during the first course, then treated with aprepitant / fosaprepitant + 5HT3-receptor antagonist + dexamethasone
3179277|NCT01344304|Experimental|Aprepitant / Fosaprepitant therapy|The patients are treated with aprepitant / fosaprepitant + 5HT3-receptor antagonist + dexamethasone during first and second courses.
3179278|NCT01344278|Experimental|Lifestyle Counseling|
3179279|NCT01344278|No Intervention|Control|
3179280|NCT01344265||consecutive patients|there is only one group in our study
3179281|NCT01344252|Experimental|Topical|
3179282|NCT01344252|Active Comparator|subtenon|
3179283|NCT01344239|Experimental|Limb RIPC|The limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
3179284|NCT01344239|No Intervention|convention|Adult patients undergoing elective open abdominal aortic aneurysm repair received no treatment after induction of anaesthesia
3179285|NCT01344213|Active Comparator|Pregabalin|Oral single-dose of pregabalin (150 mg) and 1 capsule of placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
3179286|NCT01344213|Active Comparator|Celecoxib|Oral single-dose of celecoxib (400 mg) and 1 capsule of placebo (C) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
3179287|NCT01344213|Active Comparator|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
3179288|NCT01344213|Placebo Comparator|Placebo|Oral single-dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
3179289|NCT01344200|Active Comparator|Dose Timing Cohort|"1. All patients and CSF Dose timing Cohort (Oral celecoxib 10 mg/kg pharmacokinetic profile)~Mean Total and unbound plasma concentration ug/L at approximately the following time intervals (mins): 30, 60, 90, 120, 180, 300, 900~Mean CSF concentration ug/L at approximately the following time intervals (mins): 60, 120, 180, 300 and 900~Ratio CSF/unbound plasma concentration at approximately the following time intervals (mins): 60, 120, 180, 300 and 900~This information will be used to determine plasma and CSF mean +/- SD values for Maximum concentration (Cmax [ug/L]); Area under concentration curve from time 0 to infinity (AUC (0-∞) [ug/L∙h]); Apparent oral volume of distribution (Vd/F [L/kg]); Apparent oral clearance (CL/F [L∙h-1∙kg-1] and terminal elimination half -life (t1/2 [h]). A median value will be determined for time to maximum concentration (tmax[h])"
3179290|NCT01344200|Active Comparator|Dose Escalation Cohort|"2. Dose escalation cohort (Oral celecoxib 6 mg/kg and 14 mg/kg pharmacokinetic profile)~Mean Total and unbound plasma concentration ug/L at approximately the following time intervals (mins): 60,180 and 300~Mean CSF concentration ug/L at approximately 180 minutes~Ratio CSF/unbound plasma concentration at approximately 180 minutes~This information in conjunction with the pharmacokinetic profile established in the dose timing cohort (10 mg/kg) will be used to predict plasma and CSF values for tmax, Cmax, AUC, Vd/F, CL/F and t1/2 for 6 and 14 mg/kg oral doses respectively."
3179291|NCT01344187|Experimental|riboflavin solution and KXL System|Subjects will receive riboflavin solution followed by UVA irradiation for 4 minutes
3179292|NCT01344187|Placebo Comparator|placebo solution and KXL System|Subjects will receive placebo solution followed by UVA irradiation for 4 minutes
3179293|NCT01344174|Other|glucocorticoids treatment|
3179294|NCT01344161|Placebo Comparator|Lactose|
3179295|NCT01344161|Experimental|Vitamin D|
3179296|NCT01344148|Experimental|Anti- TB therapy HAART|
3179297|NCT01344135|Placebo Comparator|Group 1 (placebo control)|60 clinically stable COPD patients with muscle atrophy, eligible for out-patient pulmonary rehabilitation
3179298|NCT01344135|Experimental|Group 2 (nutritional intervention)|60 clinically stable COPD patients with muscle atrophy, eligible for out-patient pulmonary rehabilitation
3179299|NCT01344122|Active Comparator|KPI training only|Study sites randomized to this arm will receive a knowledge, perceptions and information (KPI) training for community correctional and treatment staff to address knowledge, perceptions, and information regarding local resources about MAT.
3179300|NCT01344122|Experimental|KPI plus OLI|Study sites randomized to this arm will receive the KPI training plus a Organizational Linkage Intervention (OLI) that will: (a) establish a local Pharmacotherapy Exchange Council (PEC) among agencies important for the implementation of MAT in community corrections; (b) facilitate a strategic planning process within the PEC to increase the availability of MAT for opiate and/or alcohol dependent individuals who are on probation/parole; and (c) identify a community corrections coordinator in one of the local agencies to operationalize and implement the strategic plan.
3179306|NCT01344070|Active Comparator|generic formulation a|one of the several generic formulations in the market, randomly selected for each drug
3179307|NCT01344070|Active Comparator|generic formulation b|second of the several generic formulations in the market, randomly selected for each drug
3179308|NCT01344070|Active Comparator|generic formulation c|third of the several generic formulations in the market, randomly selected for each drug
3179309|NCT01344057|Other|Sub unit, Inactivated, MF59C.1 Adjuvanted Influenza Vaccine|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
3179310|NCT01344044|Active Comparator|BCI treatment|BCI treatment will commence during the week of the Baseline.
3179311|NCT01344044|Other|Wait-list control|BCI treatment will commence 8 weeks after Baseline
3179312|NCT01344044|Experimental|BCI pilot arm|This is a experimental arm to test out the safety and effectiveness of BCI in improving ADHD symptoms. This pilot arm is necessary as the BCI device, incorporating dry electrode sensors and intervention game, is newly developed and have not been tested out in children with ADHD. This preliminary study will also allow us to test out the treatment protocol (24 sessions of BCI training over 8 weeks) to see if it is efficacious.
3179313|NCT01344031|Experimental|Arm A (anastrozole and Akt inhibitor MK2206)|"Patients receive anastrozole PO on days 1-28. Beginning in course 2, patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
3179314|NCT01344031|Experimental|Arm B (Akt inhibitor MK2206 and anastrozole)|"The RPTD of Akt inhibitor MK2206 with anastrozole is determined after 3 courses, administered as in Arm A.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
3179315|NCT01344031|Experimental|Arm C (Akt inhibitor MK2206 and fulvestrant)|"Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22, fulvestrant IM on day 1and day 15 of course 1 and then on day 1 of each course in each subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
3179316|NCT01344031|Experimental|Arm D (Akt inhibitor MK2206, anastrozole, fulvestrant)|"Patients receive Akt inhibitor MK2206 PO as in Arm A, anastrozole PO on days 1-28 and fulvestrant IM on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
3179317|NCT01344018|Active Comparator|Surgery alone|En-bloc resection of surrounding tissues and organs when located within 1 to 2 cm from the surface tumor, even when not infiltrated.
3179318|NCT01344018|Experimental|Preoperative radiotherapy followed by en-bloc surgery|3D-CRT or IMRT to a dose of 50.4 Gy/28 daily fractions
3179319|NCT01343992|Active Comparator|Bedrest|Patients will rest in bed ten minutes after the embryo transfer.
3179320|NCT01343992|Experimental|No bed rest|Patients will not rest after the embryo transfer.
3179321|NCT01343979||positive|Patients with clinically suspected H1N1 infection confirmed by positive H1N1 PCR
3179322|NCT01343979||negative|Patients with clinically suspected H1N1 infection and negative H1N1 PCR
3179323|NCT01343966|Experimental|Part 1: Subcutaneous cohort exp|
3179324|NCT01343966|Experimental|Part 2: Intravenous cohort exp|
3179325|NCT01343966|Placebo Comparator|Part 1: Subcutaneous cohort|Repeating subcutaneous injection
3179326|NCT01343966|Placebo Comparator|Part 2: Intravenous cohort|Repeating intravenous infusion
3179327|NCT01343953|Experimental|Cord Blood Transplantation|
3179328|NCT01343940|Experimental|Dulce family partner intervention|"Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services."
3179329|NCT01343940|Active Comparator|Safety intervention|Participating family is assigned a safety specialist who will provide the parent with guidance, equipment and instruction to reduce risk of newborn injury during transport (car seat) and while sleeping (Pack-and-Play).
3179330|NCT01343927|Active Comparator|Yoga|12 weeks of weekly yoga classes plus 40 weeks of either drop-in classes or home practice.
3179331|NCT01343927|Active Comparator|Physical Therapy|15 individual physical therapy sessions over 12 weeks plus 40 weeks with either 5 booster sessions or home practice.
3179332|NCT01343927|Active Comparator|Education|"The Back Pain Helpbook which gives exercises and tips for self-care pain management."
3179333|NCT01343914||Cohort|
3179334|NCT01343901||Bevacizumab|Participants with metastatic colorectal cancer (mCRC) with exclusively liver or liver and lung metastases, who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases will be observed.
3179335|NCT01343888|Active Comparator|PegIFN/RBV|PegIFN/RBV for 48 weeks
3179336|NCT01343888|Experimental|BI 201335 for 12 or 24 weeks|BI 201335 once daily low dose for 12 or 24 weeks in combination with PegIFN/RBV for 24 or 48 weeks
3179337|NCT01343888|Active Comparator|Placebo and PegIFN/RBV|Placebo (oral) once daily plus PegIFN/RBV (subcutaneous injection/oral) for 24 weeks, followed by PegIFN/RBV alone up to Week 48.
3179338|NCT01343875||surgery, biceps tear|
3179339|NCT01343862|Experimental|D- Cycloserine|
3179340|NCT01343862|Placebo Comparator|sugar pill|
3179341|NCT01343849||Suspected Breast cancer subjects|
3179342|NCT01343836|Experimental|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte implantation) injection with eccentric exercises
3179343|NCT01343836|Placebo Comparator|Saline injection|Intratendinous saline injection with eccentric exercises
3179344|NCT01343823|Active Comparator|ecallantide 10mg|Administered as one 3 mL SC injection containing 10 mg ecallantide and one 3 mL SC injection of matching placebo.
3179345|NCT01343823|Placebo Comparator|placebo|Administered as two SC 3 mL injections
3179346|NCT01343823|Active Comparator|ecallantide 60mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
3179347|NCT01343823|Active Comparator|ecallantide 30mg|Administered as one 3 mL SC injection containing 30 mg ecallantide and one 3 mL SC injection of matching placebo.
3179445|NCT01343238|Experimental|Diet and Exercise|12 week diet and exercise behavioral modification by dietician and physical therapist
3179348|NCT01343810|Experimental|Meditation|Both arms will undergo 8-weeks of Mindfulness-Based Stress Reduction (MBSR) training. The experimental arm will be randomly assigned to practice meditation immediately following the emotional stress task in the lab during the post-MBSR lab visit.
3179349|NCT01343810|Active Comparator|No meditation|Both arms will undergo 8-weeks of Mindfulness-Based Stress Reduction (MBSR) training. The active comparator arm will be randomly assigned to not practice meditation, but rather listen to a non-meditative audio track of equal length, immediately following the emotional stress task in the lab during the post-MBSR lab visit.
3179350|NCT01343784|Active Comparator|Standard Voiding Trial|Subjects in this group will undergo backfill-assisted voiding trial that involves infusing 300ml of fluid in the bladder, removing the catheter and allowing the patient to void. All subjects will be asked to use visual analog scale (VAS) to assess their force of stream (FOS) and the voided amount as well as post-void residual (PVR) (measured by the bladder ultrasound) will be measured and recorded. Subjects will be discharged without a catheter if the voided amount is more than 200ml, or 2/3rds of the infused volume (300ml).
3179351|NCT01343784|Experimental|Force of Stream Voiding Trial|Subjects in this group will undergo backfill-assisted voiding trial that involves infusing 300ml of fluid in the bladder, removing the catheter and allowing the patient to void. All subjects will be asked to use visual analog scale (VAS) to assess their force of stream (FOS) and the voided amount as well as post-void residual (PVR) (measured by the bladder ultrasound) will be measured and recorded. Subjects in the FOS group will be discharged home without a catheter if they are able to void any amount and report an FOS of at least 50% their typical FOS based on a visual analog scale
3179352|NCT01343771|Placebo Comparator|Placebo|
3179353|NCT01343771|Active Comparator|DHEA + ERT|
3179354|NCT01343758|Active Comparator|5% dextrose in normal saline|This group will receive a bolus of normal saline that contains 5% dextrose
3179355|NCT01343758|No Intervention|Normal Saline Bolus|
3179356|NCT01343745|Placebo Comparator|Placebo|Placebo pMDI
3179357|NCT01343745|Experimental|Low dose|BDP/formoterol pMDI low dose
3179358|NCT01343745|Experimental|High dose|BDP/Formoterol pMDI high dose
3179359|NCT01343732|No Intervention|healthy volunteeres|this arm will undergo only EEG measurement
3179360|NCT01343732|Active Comparator|real - low frequency|this arm will receive DTMS treatment with low frequency
3179361|NCT01343732|Active Comparator|real - high frequency|this arm will receive DTMS treatment with high frequency
3179362|NCT01343732|Sham Comparator|sham - low / high frequency|this arm will receive DTMS sham treatment with low or high frequency
3179363|NCT01343719|Experimental|BI 661051 low dose, low|solution for oral administration, single dose
3179364|NCT01343719|Experimental|BI 661051 low dose, medium|solution for oral administration, single dose
3179365|NCT01343719|Experimental|BI 661051 low dose, high|solution for oral administration, single dose
3179366|NCT01343719|Experimental|BI 661051 medium dose, low|solution for oral administration, single dose
3179367|NCT01343719|Experimental|BI 661051 medium dose, medium|solution for oral administration, single dose
3179368|NCT01343719|Experimental|BI 661051 medium dose, high|solution for oral administration, single dose
3179369|NCT01343719|Experimental|BI 661051 high dose, low|solution for oral administration, single dose
3179370|NCT01343719|Experimental|BI 661051 high dose, medium|solution for oral administration, single dose
3179371|NCT01343719|Experimental|BI 661051 low dose|tablet
3179372|NCT01343719|Experimental|BI 661051 medium dose|tablet
3179373|NCT01343719|Placebo Comparator|Placebo|solution for oral administratrion
3179374|NCT01343706|Experimental|BI 409306 dose 1|Solution for oral administration
3179375|NCT01343706|Experimental|BI 409306 dose 2|Solution for oral administration
3179376|NCT01343706|Experimental|BI 409306 dose 3|Solution for oral administration
3179377|NCT01343706|Experimental|BI 409306 dose 4|Solution for oral administration
3179378|NCT01343706|Experimental|BI 409306 dose 5|Immediate release solid oral dosage
3179379|NCT01343706|Experimental|BI 409306 dose 6|Immediate release solid oral dosage
3179380|NCT01343706|Experimental|BI 409306 dose 7|Immediate release solid oral dosage
3179381|NCT01343706|Experimental|BI 409306 dose 8|Immediate release solid oral dosage
3179382|NCT01343706|Experimental|BI 409306 dose 9|Immediate release solid oral dosage
3179383|NCT01343706|Experimental|BI 409306 dose 10|Immediate release solid oral dosage
3179384|NCT01343706|Experimental|BI 409306 dose 11|Immediate release solid oral dosage
3179385|NCT01343706|Experimental|BI 409306 dose 12|Immediate release solid oral dosage
3179386|NCT01343706|Placebo Comparator|Placebo|Solution for oral administration
3179387|NCT01343706|Placebo Comparator|Placebo 2|Immediate release solid oral dosage
3179388|NCT01343693||Anterior cervical discectomy and fusion|Any subject with DDD, tumor, deformity ot trauma to the cervical spine in which the investigator determines the subject will require an ACDF using the MaxAn Plate.
3179389|NCT01343680|Active Comparator|10U/l heparin|
3179390|NCT01343680|Experimental|normal saline|
3179391|NCT01343667|Other|GFRS EPD|Carotid artery stenting with Gore Flow Reversal System embolic protection device
3179392|NCT01343667|Other|GEF EPD|Carotid artery stenting with Gore Embolic Filter embolic protection device
3179393|NCT01343654|Experimental|Text messaging|Participants randomized to this arm will receive a mobile phone if needed, and the 12 week personalized text messaging/EMA intervention
3179394|NCT01343654|Active Comparator|Treatment as usual|Participants randomized to this arm will receive treatment as usual in the ID clinics and in the communities for nonadherence and drug use problems
3179395|NCT01343641|Experimental|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck & Co, Inc.
3179396|NCT01343641|Placebo Comparator|Placebo|Inactive Pill used as a comparator
3179397|NCT01343628|Placebo Comparator|Placebo, Atomoxetine|
3179398|NCT01343628|Active Comparator|Atomoxetine, Placebo|
3179399|NCT01343615|Active Comparator|carotid stenting|
3179400|NCT01343615|Active Comparator|carotid endarterectomy|
3179401|NCT01343602|Experimental|mod. Constraint-Induced Movement Therapy|CIMT at home is applied in the patients' home over the course of four weeks including (i.e. 20 consecutive days) 2 hours of daily training together with an instructed non-professional coach (e.g. family member) applying shaping techniques.
3179402|NCT01343602|Other|Therapy as usual|Patients in this arm will receive usual care dose-matched to the intervention group (250-300 minutes).
3179403|NCT01343563|Active Comparator|Low frequency to High|For the first six weeks, subjects randomized to this group will receive low frequency stimulation. At the six week point, the low frequency group subjects will be crossed over to high frequency for the remaining six weeks.
3179404|NCT01343563|Active Comparator|High frequency|Subjects randomized to this group will receive high frequency stimulation for the entire 12 weeks of the first phase of this study.
3179405|NCT01343550|Experimental|Creativity group for persons diagnosed with BPD|
3179406|NCT01343537|Experimental|Monitoring|
3179407|NCT01343524||all subjects|all subjects who are enrolled in an industry-sponsored study that utilizes a sponsor-supplied spirometer.
3179408|NCT01343511|Experimental|Rehabilitation plus hCB-MNCs treatment|Participants will be given rehabilitation therapy plus human cord blood mononuclear cells transplantation with a 6 months follow-up.
3179409|NCT01343511|Experimental|Rehabilitation plus hCB-MNCs and hUC-MSCs therapy|Participants will be given rehabilitation therapy plus combination of hCB-MNCs together with hUC-MSCs transplantation with a 6 months follow-up.
3179410|NCT01343498|Experimental|BEZ235|
3179411|NCT01343485|No Intervention|Control, standard care for HPV vaccine|Study participants in control sites will receive standard care for HPV vaccine administration and follow-up per PPFA protocol
3179412|NCT01343485|Experimental|Intervention, computer reminder system|Study participants in the intervention sites will receive standard care for HPV vaccine administration per PPFA protocol, reminder messages for subsequent vaccination appointments, and real-time determination of financial assistance for HPV vaccine.
3179413|NCT01343472|Experimental|WISP supervision|Parolee supervised under WISP parole model.
3179414|NCT01343472|Active Comparator|Parole-as-usual|Parolees supervised under Washington State's parole-as-usual
3179415|NCT01343459|Experimental|IOERT followed by hypofractionated WBRT|HIOB: IOERT of 11.1 Gy followed by WBRT with 15 times 2.7 Gy per fraction.
3179416|NCT01343446||Patients with Diabetes|Patients with diabetes suffer from sleep impairment or not
3179417|NCT01343433||Control group|Chamber allocation will determine which patient receives bright light therapy. We selected four patient chambers at the Intensive Care Unit, each with the capacity of two patient beds. In two chambers patients will receive bright light therapy. Patients in the other two rooms are only exposed to environmental light
3179418|NCT01343433||Treatment group (bright light therapy)|Chamber allocation will determine which patient receives bright light therapy. We selected four patient chambers at the Intensive Care Unit, each with the capacity of two patient beds. In two chambers patients will receive bright light therapy. During our study, light therapy will be applied with instrument 'Litepod' (manufactured by Goodlite, Donker Curtiusstraat 7/407, Amsterdam), which gives an intensity of 10000 lux at a distance of 22 centimetres.Patients will receive bright light therapy for three hours in the morning, from eight o'clock till eleven o'clock.
3179419|NCT01343420|Active Comparator|Dog Hair Extract, ALK-Abelló, Inc.|
3179420|NCT01343407|Experimental|60 mg MK-1029|Part II - Participants will receive 60 mg MK-1029 in one out of four study periods
3179421|NCT01343407|Experimental|500 mg MK-1029|Part II - Participants will receive 500 mg MK-1029 in one out of four study periods
3179422|NCT01343407|Placebo Comparator|Placebo|Part II - Participants will receive placebo to MK-1029 in two out of four study periods
3179423|NCT01343394|Experimental|Biologic; Autologous Cell Injection|
3179424|NCT01343381|Active Comparator|Hepalean Heparin|
3179425|NCT01343381|Active Comparator|PPC Heparin|
3179426|NCT01343368|Experimental|Interventional - Received Leuprolide|Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
3179427|NCT01343368|Active Comparator|Observational Arm|Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
3179428|NCT01343342|Experimental|capsules omega-3|Omega-3 supplementation (3g EPA+DHA/d)
3179429|NCT01343329|Experimental|Subjects Receiving Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment.
3179430|NCT01343329|Active Comparator|Subjects receiving Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
3179431|NCT01343316||Transgastric tube|Nasogastric (NG tube)
3179432|NCT01343316||Transpyloric tube - Tiger2|Self-propelled by paristaltic waves of the stomach
3179433|NCT01343316||Transpyloric tube - Syncro BlueTube|Magnetically placed
3179434|NCT01343303|Experimental|001|JNJ-39439335 2 x 5 mg tablets once daily for 21 days
3179435|NCT01343303|Experimental|002|JNJ-39439335 2 x 25 mg tablets once daily for 21 days
3179436|NCT01343303|Other|003|Naproxen 500 mg capsule every 12 hours for 21 days
3179437|NCT01343303|Placebo Comparator|004|Placebo Placebo tablet/capsule every 12 hours for 21 days
3179438|NCT01343290|Experimental|001|Canagliflozin Type = 1 unit = mg number = 300 form = tablet route = oral use. Single tablet taken with or without a meal during 2 treatment periods
3179439|NCT01343277|Experimental|Trabectedin|
3179440|NCT01343277|Active Comparator|Dacarbazine|
3179441|NCT01343251||HeRO Graft|patients who are evaluated and receive a HeRO Graft implant for hemodialysis
3179442|NCT01343251||Control|control group of non-HeRO patients who are evaluated but do not receive a HeRO Graft for any reason
3179443|NCT01343238|Experimental|Diet|12 week diet modification intervention by dietician
3179444|NCT01343238|Experimental|Exercise|12 week physical exercise modification intervention by physical therapist
3179446|NCT01343238|No Intervention|Control|Standard procedure
3179447|NCT01343225|Active Comparator|atripla|comparator
3179448|NCT01343225|Experimental|darunavir ritonavir raltegravir|experimental
3179449|NCT01343212||newly diagnosed HCC|"Subjects with newly diagnosed untreated hepatocellular carcinoma (HCC) will be enrolled.~Subjects with the following conditions will be excluded:~liver cancer other than HCC, treated HCC, post major abdominal surgery, contraindications to liver tumor biopsy, contraindications to local percutaneous treatment of liver tumors, low quality ARFI measurement"
3179450|NCT01343186|Other|Arm 1|
3179451|NCT01343186|Other|Arm 2|
3179452|NCT01343186|Other|Arm 3|
3179453|NCT01343186|Other|Arm 4|
3179454|NCT01343173|Experimental|Patients|
3179455|NCT01343160|Other|GORE VIABIL® Biliary Endoprosthesis|Placement of GORE VIABIL® Biliary Endoprosthesis to establish duct patency
3179456|NCT01343147|Other|Deep hyperthermia|Microwave diathermy
3179457|NCT01343147|Other|Superficial hyperthermia|Hot packs
3179458|NCT01343134||Retinal detachment cohort|
3179459|NCT01343121|Other|sample collection|"This is a single arm study. Patients will be seen on day 1, 8, 15 and 22 and will have the following samples collected:~Pre gemcitabine urine sample~Blood sample 30 minutes post Gemcitabine infusion~Urine and blood sample 2 hours post Gemcitabine infusion"
3179460|NCT01343095|No Intervention|Usual Care|Usual Care between 10pm-6am
3179461|NCT01343095|Active Comparator|Earplugs|Application of foam earplugs from 10pm-6am nightly for seven nights or until ICU discharge.
3179462|NCT01343095|Active Comparator|Earplugs and Headphones|Foam Earplugs and Noise canceling headphones applied from 10pm-6am nightly for 7 nights or until ICU discharge.
3179463|NCT01343082|Experimental|1|DE-111 ophthalmic solution
3179464|NCT01343069|No Intervention|before surgical checklist|
3179465|NCT01343069|Active Comparator|after implementation surgical checklist|
3179466|NCT01343056|Active Comparator|Office Staff follow up education|"A designee in the office staff shall be assigned to follow up with the patient for for behavioral goal setting attainment. The office staff will call patients monthly to monitor goal attainment. It will be suggested that they phone the participant monthly but researchers will observe how and if they provide follow up.~The intervention is the follow up goal attainment and office staff have been trained on elements of goal attainment."
3179467|NCT01343056|Active Comparator|Peer follow up education|"A person with diabetes trained as a peer shall meet the participant at their 6 week follow up visit and then call the participant monthly to monitor behavioral goal attainment.The intervention is the follow up goal attainment and peers have been trained on elements of goal attainment."
3179468|NCT01343056|Active Comparator|Usual Care|ADA Recognition maintains the standard that a follow up to diabetes education must occur from 3-6 month post education. This one phone call will be made by the diabetes educator. The intervention is the diabetes educator making a phone call to the patient to ask how they are doing.
3179469|NCT01343056|Active Comparator|Educator support follow up|A diabetes educator will provide follow up support and make monthly call to the patient to ascertain behavioral goal setting attainment. The diabetes educator uses behavioral goal setting as an education intervention. The educator calls patient to determine goal attainment. That is the intervention.
3179470|NCT01343043|Experimental|Cohort 1 treated with NY-ESO-1 T Cells|High NY-ESO-1 expression and the use of cyclophosphamide plus fludarabine. (COMPLETE)
3179471|NCT01343043|Experimental|Cohort 2 treated with NY-ESO-1 T Cells|Low NY-ESO-1 expression and the use of cyclophosphamide plus fludarabine.
3179472|NCT01343043|Experimental|Cohort 3 treated with NY-ESO-1 T Cells|High NYESO-1 expression and the use of cyclophosphamide only for lymphodepletion rather than fludarabine. (COMPLETE)
3179473|NCT01343043|Experimental|Cohort 4 treated with NY-ESO-1 T Cells|High NY-ESO-1 expression and the use of reduced dose cyclophosphamide plus fludarabine regimen.
3179474|NCT01343030||Patients with implants|Patients with silicone implants and fat grafting.
3179475|NCT01343017|Other|Increased tidal volume (IVT)|In the group with increased tidal volume (IVT), initial plateau pressure (Pplateau) will be monitored and then tidal volume will be increased until Pplateau was 0.04 cm H2O/kg over the initial Pplateau. The PETCO2 will be then adjusted to 4.5 kPa with a flexible corrugated hose placed between the Y-piece of the anaesthesia circle system and the heat and moisture filter (HME) attached to the endotracheal tube.
3179476|NCT01343017|Other|Normal tidal volume (NVT), with PEEP|In the group with normal tidal volume (NVT), a PEEP to10 cmH2O will be applied. When required, VT will then adjusted to maintain PETCO2 at 4.5 kPa
3179477|NCT01343004|Placebo Comparator|Placebo|Placebo identical in appearance to BA058 study drug
3179478|NCT01343004|Experimental|BA058 80 mcg (abaloparatide)|
3179479|NCT01343004|Active Comparator|teriparatide|Blinded until after randomization, then open-label
3179480|NCT01342991|Active Comparator|Milligan-Morgan Haemorrhoidectomy|Control arm
3179481|NCT01342991|Experimental|Laser Haemorrhoidectomy|This new method of haemorrhoidectomy is being compared to the standard Milligan-Morgan Haemorrhoidectomy.
3179482|NCT01342978||oropharyngeal cancer case|208 oropharyngeal cancer cases were enrolled
3179483|NCT01342978||partner or spouse of case|110 partners of patients with oropharyngeal cancer were enrolled
3179484|NCT01342978||control|A convenience group of 106 non-cancer controls were enrolled at some study sites at cancer screening events
3179485|NCT01342965|Experimental|Erlotinib|Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity.
3179486|NCT01342965|Active Comparator|Chemotherapy|Participants received gemcitabine 1250 mg/m^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first.
3179487|NCT01342952|Experimental|Ambrisentan|Open label, flexible dosing from 2.5 mg to 10 mg (not to exceed 0.25 mg/kg) per day
3179488|NCT01342939||MODY2|Also called GCK (glucokinase) MODY. They have a specific mutation in the GCK gene.
3179489|NCT01342939||MODY3|Also called HNF1 alfa MODY. They have a specific mutation in the HNF1 alfa gene.
3179490|NCT01342939||Healthy control subjects|
3179491|NCT01342926|Experimental|GSK933776 3 mg/kg|3 mg/kg administration of GSK933776 via intravenous infusion
3179602|NCT01342315|Experimental|Active|Product 33525
3179492|NCT01342926|Experimental|GSK933776 6 mg/kg|6 mg/kg administration of GSK933776 via intravenous infusion
3179493|NCT01342926|Placebo Comparator|Placebo|Placebo via intravenous infusion
3179494|NCT01342926|Experimental|GSK933776 15 mg/kg|15 mg/kg administration of GSK933776 via intravenous infusion
3179495|NCT01342913|Experimental|Fluticasone Furoate/Vilanterol|Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA)
3179496|NCT01342913|Active Comparator|Fluticasone Propionate/Salmeterol|Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA
3179497|NCT01342900|No Intervention|standard care|The data from the InSPectra Monitor in the Control group will be inaccessible for the Investigator since this is not a part of their daily medical practice
3179498|NCT01342900|Active Comparator|Treatment group,|The data given by the monitor will be available for the Investigator and used to apply the optimization protocol
3179499|NCT01342887|Experimental|Treatment (immunosuppression, enzyme inhibitor, and chemo)|Patients receive cyclosporine IV continuously on days 5-9. Patients also receive pravastatin sodium PO every 6 hours on days 1-10, etoposide IV continuously on days 5-9, and mitoxantrone hydrochloride IV continuously on days 5-9. Treatment repeats for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR/CRi may receive 2 additional courses in the absence of disease progression or unacceptable toxicity.
3179500|NCT01342874||Inositol group|Inositol dietary exposure 4000 mg/day
3179501|NCT01342874||Control group|folic acid 400 mcg/day
3179502|NCT01342861|Sham Comparator|Observational period|A first period of follow-up on the 400 patients was designed to survey and evaluate current nutrition administration policy
3179503|NCT01342861|Experimental|Intervention period|The second period of follow-up on the 400 patients was designed to evaluate the impacts of adding milky food to the breakfast and of educating health care professionals on the early detection of undernutrition.
3179504|NCT01342835|Active Comparator|drug: propofol|Drug:Propofol and sevoflurane The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
3179505|NCT01342835|Active Comparator|Sevoflurane group:sevoflurane|Drug:Sevoflurane and Propofol Mask induction is perform with sevoflurane (4-6%) follow by 1.5-2% sevoflurane in a 50:50 mixture of N2O and O2.
3179506|NCT01342822||PROMUS Element™|All patients enrolled will be randomized 2:1 to receive the PROMUS Element™ stent (N=1987)
3179507|NCT01342822||Xience™ Prime stent|All patients enrolled will be randomized 2:1 to receive the PROMUS Element™ stent (N=1987) versus the Xience™ Prime Stent (N=993).
3179508|NCT01342809|Experimental|Follow up|Close follow up from written guidelines, supervision provided.
3179509|NCT01342809|No Intervention|Usual Treatment|
3179510|NCT01342796|Experimental|Arm 1|
3179511|NCT01342796|Active Comparator|Arm 2|
3179512|NCT01342770|Experimental|Treatment (pioglitazone hydrochloride)|Patients receive pioglitazone hydrochloride PO QD for 14-42 days. Patients then undergo surgery.
3179513|NCT01342757|Experimental|Arm I|"Patients receive vorinostat once daily on days -7 to -1 (course 1 only) and days 8-14 and 22-28 and temozolomide on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients undergo magnetic resonance spectroscopic imaging at baseline and at approximately 1 and 8 weeks on treatment. Patients also undergo a survey administration of Inventory of Depression Symptomatology Self-Reported (IDS-SR) assessment at baseline and periodically during study."
3179514|NCT01342744|Experimental|Metformin|Metformin (850mg) 1 tab oral twice a day
3179515|NCT01342744|Placebo Comparator|Placebo|Placebo 1 tab oral twice a day
3179516|NCT01342731|Experimental|Tigecycline|Tigecycline 100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 d
3179517|NCT01342718|Experimental|GJS/Duolac7S|GJS: Real herbal extract granule/Duolac7S: Real probiotics
3179518|NCT01342718|Placebo Comparator|GJS-P/Duolac7S|GJS-P: Placebo herbal extract granule/Duolac7S: Real probiotics
3179519|NCT01342718|Placebo Comparator|GJS/Duolac7S-P|GJS: Real herbal extract granule/Duolac7S-P: Placebo probiotics
3179520|NCT01342718|Placebo Comparator|GJS-P/Duolac7S-P|GJS-P: Placebo herbal extract granule/Duolac7S-P: Placebo probiotics
3179521|NCT01342705|Experimental|phlebotomy|
3179522|NCT01342705|No Intervention|control|
3179523|NCT01342692|Active Comparator|Azacitidine alone|
3179524|NCT01342692|Experimental|Azacitidine +Valproic acid|
3179525|NCT01342692|Experimental|Azacitidine +Lenalidomide|
3179526|NCT01342692|Experimental|Azacitidine + Idarubicine|
3179527|NCT01342679|Experimental|dasatinib|
3179528|NCT01342666|Experimental|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
3179529|NCT01342666|Placebo Comparator|Cucumber consumption|Daily consumption of 300g of cucumber.
3179530|NCT01342653|Experimental|NIPS plus HIPEC plus adjuvant chemotherapy|
3179531|NCT01342640|Experimental|Single Arm|
3179532|NCT01342627|Experimental|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to protocol.~In case of disease progression Sorafenib administration will be discontinued."
3179533|NCT01342614|Active Comparator|Fosinopril group|Fosinopril group received fosinopril, 10mg, once per day.
3179534|NCT01342614|Experimental|Metformin group|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
3179535|NCT01342601|Active Comparator|Ectoin products|
3179536|NCT01342601|Placebo Comparator|Placebo products|
3179537|NCT01342588|Experimental|Electrical stimulation|Only arm of the study, the experimental
3179538|NCT01342575|Experimental|Intra-operative maneuver group|
3179539|NCT01342562|Experimental|DXM-bupivacaine|
3179540|NCT01342562|Placebo Comparator|saline-bupivacaine|
3179541|NCT01342549|Active Comparator|Arm 1|sodium valproate
3179542|NCT01342549|Active Comparator|Arm 2|naltrexone
3179543|NCT01342536|Experimental|lifestyle counseling (OHDC)|Oh Happy Day Class (OHDC) is a culturally-specific, 12-week cognitive behavioral group counseling intervention designed for African American adults experiencing depression
3179544|NCT01342536|Active Comparator|lifestyle counseling (CWD)|Coping with Depression Course (CWD) is a 8-week cognitive behavioral group counseling depression intervention
3179545|NCT01342523|Experimental|No CIS/No loz/No Email/Lite Website/Brief Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, No nicotine lozenge, No motivational emails, lite website, brief mailed booklet"
3179546|NCT01342523|Experimental|CIS/No loz/No email/Lite Website/Brief booklet|"This arm of the project will address the following question:~Does the following treatment provide efficacy relative to others:~CIS calls, no NRT lozenge, no motivational email, Lite website, Brief mailed booklet"
3179547|NCT01342523|Experimental|no CIS/Loz/No email/lite website/brief booklet|"This arm of the project will address the following question:~Does this combination of services achieve effectiveness compared to others:~No CIS phone counseling, NRT lozenge, no motivational email, lite website, brief mailed booklet"
3179548|NCT01342523|Experimental|No CIS/no loz/email/lite website/brief booklet|"This arm of the project will address the following question:~Does this combination of services lead to greater abstinence:~No CIS counseling calls, no NRT lozenge, motivational emails, lite website, brief mailed booklet."
3179549|NCT01342523|Experimental|No CIS/No loz/No email/Full website/Brief booklet|"This arm of the project will address the following question:~Does this combination of services lead to greater abstinence?~No CIS counseling, no NRT lozenge, no motivational email, full website, brief mailed booklet"
3179550|NCT01342523|Experimental|No CIS/No loz/No email/lite website/full booklet|"This arm seeks to answer the question:~Does this combination of services achieve efficacy compared to others:~No CIS counseling, no NRT lozenge, no motivational email, lite website, full mailed booklet"
3179551|NCT01342523|Experimental|CIS/Loz/No email/Lite website/Brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, lite website, brief mailed booklet"
3179552|NCT01342523|Experimental|CIS/No loz/Emails/Lite Website/Brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, motivational emails, lite website, brief mailed booklet"
3179553|NCT01342523|Experimental|CIS/No loz/no email/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, No motivational emails, full website, brief mailed booklet"
3179554|NCT01342523|Experimental|CIS/No loz/no email/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, No motivational emails, lite website, full mailed booklet"
3179555|NCT01342523|Experimental|No CIS/Loz/emails/Lite Website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, lite website, brief mailed booklet"
3179556|NCT01342523|Experimental|No CIS/Loz/No emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, lite website, full mailed booklet"
3179557|NCT01342523|Experimental|No CIS/Loz/No emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, full website, brief mailed booklet"
3179558|NCT01342523|Experimental|no CIS/no loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, full website, brief mailed booklet"
3179559|NCT01342523|Experimental|no CIS/no loz/emails/lite web/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, lite website, full mailed booklet"
3179560|NCT01342523|Experimental|no CIS/no loz/no email/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, No motivational emails, full website, full mailed booklet"
3179561|NCT01342523|Experimental|CIS/loz/emails/lite website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, lite website, brief mailed booklet"
3179562|NCT01342523|Experimental|CIS/loz/no email/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, full website, brief mailed booklet"
3179563|NCT01342523|Experimental|CIS/loz/no email/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, lite website, full mailed booklet"
3179564|NCT01342523|Experimental|CIS/no loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, full website, brief mailed booklet"
3179565|NCT01342523|Experimental|CIS/no loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, lite website, full mailed booklet"
3179566|NCT01342523|Experimental|CIS/no loz/no email/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, No motivational emails, full website, full mailed booklet"
3179567|NCT01342523|Experimental|No CIS/loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, full website, brief mailed booklet"
3179568|NCT01342523|Experimental|No CIS/loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, lite website, full mailed booklet"
3179603|NCT01342315|Experimental|Placebo|Product 33525 Placebo
3179604|NCT01342302|Other|Couples Intervention|Single arm study design
3179569|NCT01342523|Experimental|No CIS/loz/no emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, full website, full mailed booklet"
3179570|NCT01342523|Experimental|no CIS/no loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, full website, full mailed booklet"
3179571|NCT01342523|Experimental|CIS/loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, full website, brief mailed booklet"
3179572|NCT01342523|Experimental|CIS/loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, lite website, full mailed booklet"
3179573|NCT01342523|Experimental|No CIS/loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, full website, full mailed booklet"
3179574|NCT01342523|Experimental|CIS/no loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, full website, full mailed booklet"
3179575|NCT01342523|Experimental|CIS/Loz/no Emails/Full Website/Full Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, full website, full mailed booklet"
3179576|NCT01342523|Experimental|CIS/Loz/Emails/Full Website/Full Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, full website, full mailed booklet"
3179577|NCT01342510|Experimental|Lidocaine|Lidocaine 50 mg in a 10 cc syringe
3179578|NCT01342510|Experimental|Magnesium|Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe
3179579|NCT01342510|Experimental|Lidocaine/Magnesium|Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe
3179580|NCT01342510|Placebo Comparator|Control|0.9% saline in a 10 cc syringe
3179581|NCT01342497|Experimental|BBR-012|
3179582|NCT01342497|Placebo Comparator|Placebo|
3179583|NCT01342484|Experimental|linagliptin low dose|linagliptin low dose for children once daily
3179584|NCT01342484|Experimental|linagliptin high dose|linagliptin high dose for children once daily
3179585|NCT01342484|Placebo Comparator|placebo|matching placebo for each linagliptin dose once daily
3179586|NCT01342471|Active Comparator|30-min walk|"Instructed to use brisk walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Participants were permitted to exercise in one long bout (30 min) or divide the exercise into multiple bouts as long as the bout length was 10 min or greater."
3179587|NCT01342471|Experimental|TV commercial stepping|"Instructed to stand and briskly step in place, or briskly walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Rather than exercising continuously for at least 10-minute bouts, participants performed multiple (~9 or 10), short (~3-5 min) bouts, conveniently incorporated into their daily TV viewing time."
3179588|NCT01342458|Experimental|Intervention Group|Daily use of the intervention Flexible footwear (Moleca®) for 6 months, for at least 42 hours/week (approximately 6 hours/day, 7 days/week). The Moleca® shoe (Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a low-cost women's double canvas, flexible, flat, walking shoe without heels, with a 5-mm anti-slip rubber sole and a 3-mm flat insole of ethylene vinyl acetate that provides only protection but no correction. The mean weight of the shoe is 0.172±0.019 kg (range 0.091 to 0.182 kg), depending on size. This minimalist footwear is commonly worn by the elderly of all social classes and its average cost is US$ 6.25.
3179589|NCT01342458|No Intervention|Control Group|During the intervention period, patients from the Control Group (CG) were instructed not to wear Flexible footwear (Moleca®) or other similar minimalist footwear. During everyday activities, the CG group was only permitted to wear a standard, neutral tennis shoe. At the end of the intervention period, all CG participants also received one pair of Moleca® shoes at no cost.
3179590|NCT01342445|Experimental|lisdexamfetamine dimesylate|All participants will be assessed across five conditions (baseline, placebo, 30-mg, 50-mg, & 70-mg) in a double-blind, crossover design
3179591|NCT01342432|Experimental|Balance reeducation plus exercise|exercises that challenge postural control are performed in addition to general exercises for stretch and strength of abdominal and paraspinal muscles
3179592|NCT01342432|Other|General exercise only|general exercise for stretch and strength of paraspinal and abdominal muscles
3179593|NCT01342380||Seroquel|Participants who received Seroquel
3179594|NCT01342380||Pioglitazone|Participants who received pioglitazone
3179595|NCT01342367|Experimental|Oral Androgen Therapy|Subjects will receive two oral hormonal drugs (bicalutamide with dutasteride or bicalutamide with finasteride)
3179596|NCT01342354|Experimental|Stereotactic Radiation|Escalating doses of SBRT in three doses over ten days.
3179597|NCT01342341|Experimental|Parafon Forte first, then Placebo|Experimental: Forty moderate to heavy social alcohol users (women=10-25 drinks/week, men=14-30 drinks/week) will receive either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (1st intervention; 14 days), followed by a washout (7 days), and then followed by placebo (2nd intervention; 14 days).
3179598|NCT01342341|Placebo Comparator|Placebo first, then Parafon Forte|Experimental: Forty moderate to heavy social alcohol users (women=10-25 drinks/week, men=14-30 drinks/week) will receive placebo (1st intervention; 14days) followed by a washout (7 days), and then followed by either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (2nd intervention; 14 days).
3179599|NCT01342328|Placebo Comparator|Control|For this arm, the volunteer subject will receive a saline infusion during the sleep session.
3179600|NCT01342328|Experimental|Dexmedetomidine (DEX)|For this arm, the volunteer subject will receive a DEX infusion for sedation during the sleep session.
3179601|NCT01342328|Experimental|Propofol|For this arm, the volunteer subject will receive a propofol infusion for sedation during the sleep session.
3179605|NCT01342276|Experimental|vHFC|Patients will get to participate in the interactive heart failure website (vHFC).
3179606|NCT01342276|No Intervention|Usual Care|Patients will not get to participate in the interactive heart failure website (vHFC).
3179607|NCT01342263|No Intervention|Usual Care|Does not get to participate in the interactive chronic disease website.
3179608|NCT01342263|Experimental|iCDM|The iCDM will support patient self-management through collaborative planning and goal setting, education and skill development, support for behaviour change, and regular patient monitoring with follow-up. For each chronic condition, we have outlined sample patient signs and symptoms to be monitored, frequency of patient provider contact and frequency of patient prompt questions on their condition. The main premise of the iCDM is that only those patients who generate 'alerts' will be contacted by the iCDM nurse allowing for the potential to manage more patients than through traditional means of required patient follow-up regardless of patient condition . Across these five diseases are the following cross-cutting features: nutrition therapy, exercise therapy, psychological support, medication adherence and smoking cessation.
3179609|NCT01342250|Experimental|Conventional plus hUC-MSCs treatment (low dose)|
3179610|NCT01342250|Experimental|conventional therapy plus hUC-MSCs treatment （medium dose）|
3179611|NCT01342250|Experimental|conventional therapy plus hUC-MSCs treatment （high dose）|
3179612|NCT01342237|Experimental|topotecan|
3179613|NCT01342224|Experimental|tadalafil and vaccination|Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV). This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine.
3179614|NCT01342211|Placebo Comparator|Treatment A|
3179615|NCT01342211|Experimental|Treatment B|
3179616|NCT01342211|Experimental|Treatment C|
3179617|NCT01342211|Experimental|Treatment D|
3179618|NCT01342211|Experimental|Treatment E|
3179619|NCT01342198|Experimental|1|Single Dose Pregabalin Controlled Release
3179620|NCT01342198|Experimental|2|Single Dose Pregabalin Controlled Release with Multiple Doses of Erythromycin
3179621|NCT01342185|Experimental|Medical ozone therapy with tianyi|
3179622|NCT01342185|Active Comparator|medical ozone therapy with humares|
3179623|NCT01342185|Placebo Comparator|Diammonium glycyrrhizinate Capsules|
3179624|NCT01342172|Experimental|Lenalidomide|capsules for oral administration
3179625|NCT01342159|Active Comparator|Intravitreal bevacizumab injection|
3179626|NCT01342159|Active Comparator|Intravitreal Triamcinolone injection|
3179627|NCT01342159|Active Comparator|intravitreal bavacizumab with triamcinolone|
3179628|NCT01342133||Newborns|
3179629|NCT01342133||Mothers|
3179630|NCT01342120||Quetiapine|Quetipine users
3179631|NCT01342120||All other atypical antipsychotics|All other atypical antipsychotics users
3179632|NCT01342120||Risperidone|Risperidone users
3179633|NCT01342120||Olanzapine|Olanzapine users
3179634|NCT01342107|Experimental|FID 114675A|Contact lens soaked overnight in an investigational multi-purpose disinfecting solution randomly assigned to one eye, with contact lens removed directly from the blister pack assigned to the fellow eye for contralateral wear. Both products worn for one day, 16 hours.
3179635|NCT01342107|Active Comparator|Blister Pack|Contact lens removed directly from the blister pack randomly assigned to one eye, with contact lens soaked overnight in an investigational multi-purpose disinfecting solution assigned to the fellow eye for contralateral wear. Both products worn for one day, 16 hours.
3179636|NCT01342094|Experimental|DE-111 ophthalmic solution|DE-111 ophthalmic solution (one drop at a time, once daily) and Placebo ophthalmic solution (one drop at a time, BID) in both eyes.
3179637|NCT01342094|Active Comparator|Timolol ophthalmic solution 0.5%|Timolol ophthalmic solution 0.5% (one drop at a time, BID) and Placebo ophthalmic solution (one drop at a time, once daily) in both eyes.
3179638|NCT01342081|Experimental|1|DE-111 ophthalmic solution
3179639|NCT01342081|Active Comparator|2|Tafluprost ophthalmic solution 0.0015%
3179640|NCT01342081|Active Comparator|3|Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
3179641|NCT01342055|Experimental|Group 1 : Megace 800mg - Apetrol ES 650mg - Apetrol ES 675mg|
3179642|NCT01342055|Experimental|Group 2 : Apetrol ES 650mg - Apetrol ES 675mg -Megace 800mg|
3179643|NCT01342055|Experimental|Group 4: Megace 800mg - Apetrol ES 675mg - Apetrol ES 650mg|
3179644|NCT01342055|Experimental|Group 5: Apetrol ES 650mg - Megace 800mg - Apetrol ES 675mg|
3179645|NCT01342055|Experimental|Group 3: Apetrol ES 675mg - Apetrol ES 650mg - Megace 800mg|
3179646|NCT01342055|Experimental|Group 6 : Apetrol ES 675mg - Megace 800mg - Apetrol ES 650mg|
3179647|NCT01342042|Active Comparator|Metformin|
3179648|NCT01342042|Active Comparator|exenatide-4|
3179649|NCT01342029|Experimental|Ranolazine|147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
3179650|NCT01342029|Placebo Comparator|Placebo|147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
3179651|NCT01342016|Experimental|tacrolimus group|tacrolimus capsule + leflunomide placebo
3179652|NCT01342016|Active Comparator|leflunomide group|tacrolimus placebo + leflunomide tablet
3179653|NCT01342003||Subtype 1a|subtype 1a patients treated with peginterferon plus ribavirin
3179654|NCT01342003||subtype 1b|subtype 1b patients treated with peginterferon plus ribavirin
3179655|NCT01341990|Experimental|FID 114675A|Multi-purpose disinfecting solution used per protocol-specified instructions for cleaning, rinsing, disinfecting/storing, and reinserting study contact lenses
3179656|NCT01341990|Active Comparator|ReNu MultiPlus|Multi-purpose solution used per protocol-specified instructions for cleaning, rinsing, disinfecting/storing, and reinserting study contact lenses
3179657|NCT01341977|Experimental|Alcon MPDS|Alcon Multi-Purpose Disinfecting Solution (MPDS)
3179658|NCT01341977|Active Comparator|ReNu Fresh Multi-Purpose Solution|ReNu Fresh Multi-Purpose Solution
3179659|NCT01341964|Experimental|Higher dose aspirin group|Clopidogrel 600 mg plus aspirin 325mg
3179660|NCT01341964|Active Comparator|Low dose aspirin group|Clopidogrel 600mg plus aspirin 81mg
3179661|NCT01341951|Experimental|G-CSF therapy in acute liver failure and alcoholic hepatitis|G-CSF therapy given in cases with acute liver failure and alcoholic hepatitis
3179662|NCT01341938|Experimental|lozenges (4 mg), Phone, Self-help|Commit® nicotine lozenges (4 mg)
3179663|NCT01341938|Experimental|LSH: Nicotine Lozenge, Self Help|Commit® nicotine lozenges (4 mg)
3179664|NCT01341938|Experimental|ASH: Counseling, Self Help|
3179665|NCT01341925|Placebo Comparator|Placebo Supplement and No PEP|Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
3179666|NCT01341925|Experimental|Omega-3 and PEP|"Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
3179667|NCT01341925|Experimental|Omega-3 and No PEP|Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
3179668|NCT01341925|Experimental|Placebo Supplement and PEP|"Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
3179669|NCT01341912|Experimental|Human-cl rhFVIII|Recombinant FVIII derived from a human cell line.
3179670|NCT01341899|Experimental|stem cell transplantation|
3179671|NCT01341886|Active Comparator|metformin|patients who receive metformin in addition to levothyroxine
3179672|NCT01341886|Placebo Comparator|levothyroxine|patients who receive only levothyroxine
3179673|NCT01341873|Experimental|Group I (FCI)|FCs receive 4 sessions of an APN FCI beginning during the admission for transplant and continuing for up to 100 days after transplant.
3179674|NCT01341873|Other|Group II (control)|FCs receive standard supportive care.
3179675|NCT01341860||controls|control group with a BMI of less thatn 25kg/m2
3179676|NCT01341860||obese group|Obese patients with BMI 25-30 kg/m2
3179677|NCT01341847|Active Comparator|Water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of the colonoscope during insertion since the scope is inserted into the anus until reach the cecum. Water will be infused as needed under endoscopist judgement through the adaptor on biopsy channel with endoscopic washer pump. The usual air insufflation will be used during colonoscope withdrawal to facilitate mucosal examination and perform any other intervention, such as biopsy
3179678|NCT01341847|Other|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
3179679|NCT01341834|Experimental|LBH589-RAD001|LBH589-RAD001, single arm dose finding study
3179680|NCT01341808|Experimental|IBD patients|"Patients diagnosed with IBD~-> receive Epaxal Berna (virosomal hepatitis A vaccine)"
3179681|NCT01341782|Experimental|Paricalcitol|Participants received paricalcitol at an initial dose of 2 µg, and maxacalcitol placebo administered 3 times per week at each hemodialysis via intravenous catheter for 12 weeks. After 2 weeks the dose could be adjusted ± 1 µg based on protocol-specified criteria up to a maximum of 7 µg.
3179682|NCT01341782|Active Comparator|Maxacalcitol|Participants received maxacalcitol at an initial dose of 5 µg (iPTH < 500 pg/mL at Screening) or 10 µg (iPTH ≥ 500 pg/mL at Screening), and paricalcitol placebo administered 3 times per week at each hemodialysis via intravenous catheter for 12 weeks. After 2 weeks the dose could be adjusted ± 2.5 µg based on protocol-specified criteria up to a maximum of 20 µg.
3179683|NCT01341769|Placebo Comparator|Control Test Food|Snack base
3179684|NCT01341769|Experimental|Experimental Test Food 1|Snack Base containing ingredient 1
3179685|NCT01341769|Experimental|Experimental Test Food 2|Snack base containing ingredient 2
3179686|NCT01341769|Experimental|Experimental Test Food 3|Snack base containing ingredients 1 and 2
3179687|NCT01341756|Experimental|Radiotherapy for gastric cancer|Single arm study
3179688|NCT01341743|Active Comparator|A|oral entecavir 1mg daily for 104 weeks
3179689|NCT01341743|Active Comparator|B|oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
3179690|NCT01341743|Active Comparator|C|oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
3179691|NCT01341730|Active Comparator|Atorvastatin 20 mg|"After the subject take PET CT, he or she is randomized to either  Atorvastatin 20 mg group or  Atorvastatin 20 mg+ Pioglitazone 30 mg. The  Atorvastatin 20 mg group is to take atorvastatin 20 mg and take follow up PET CT in 3 months"
3179692|NCT01341730|Experimental|Atorvastatin 20 mg + Pioglitazone 30 mg|"After the subject take PET CT, he or she is randomized to either  Atorvastatin 20 mg group or  Atorvastatin 20 mg+ Pioglitazone 30 mg. The  Atorvastatin 20 mg + Pioglitazone 30 mg group is to take atorvastatin 20 mg + pioglitazone 30 mg and take follow up PET CT in 3 months"
3179693|NCT01341717|Experimental|Sitagliptin along with metformin and insulin|
3179694|NCT01341717|Active Comparator|Glimepiride as an active comparator to Sitagliptin|
3179695|NCT01341704|Experimental|MSP3-LSP/AlOH|Synthetic polyprotein of 96 amino acids (186-276 in 3D7 strain) manufactured by solid-phase synthesis by SYNPROSIS, France; lyophilized product was formulated extemporaneously with aluminum hydroxide (Reheis). 30 microgram per dose; three dose schedule on study day 0, 28 and 56 for primary series
3179696|NCT01341704|Placebo Comparator|Control|Primary series: Verorab Rabies vaccine; Secondary/Booster series: 0.9% NaCL/Normal Saline
3179697|NCT01341691|Placebo Comparator|Placebo 20mg|
3179698|NCT01341691|Active Comparator|K2CG 60 mg extender|
3179699|NCT01341691|Active Comparator|K2CG 60 mg|
3179700|NCT01341691|Active Comparator|K2CG 20mg extender|
3179701|NCT01341691|Active Comparator|K2CG 20mg|
3179702|NCT01341691|Placebo Comparator|Placebo 60mg|
3179703|NCT01341678|Other|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
3180313|NCT01337401|Placebo Comparator|Blinded Placebo|
3179704|NCT01341678|Other|Restricted Phosphorus Diet|Diet containing 750mg of phosphorus per day and administration of a phosphate binder (lanthanum carbonate)
3179705|NCT01341678|Other|High Phosphorus Diet|Diet containing 3000mg of phosphorus per day and phosphorus supplementation (NeutraPhos)
3179706|NCT01341652|Experimental|pTVG-HP vaccine with GM-CSF|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
3179707|NCT01341652|Active Comparator|GM-CSF alone|rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
3179708|NCT01341639|Experimental|V419|V419 + RotaTeq + Prevenar 13 + ProQuad
3179709|NCT01341639|Active Comparator|INFANRIX hexa|INFANRIX hexa + RotaTeq + Prevenar 13 + ProQuad
3179710|NCT01341626|Experimental|Treatment Foster Care Oregon (TFCO)|Youth are placed individually in well-trained and supervised foster homes. Basic components include: (a) daily telephone contact with TFCO parents using the Parent Daily Report; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation.
3179711|NCT01341626|Active Comparator|Group Care|Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%).
3179712|NCT01341613|Experimental|Cardioviva™ supplement capsule|
3179713|NCT01341613|Placebo Comparator|Placebo capsule|
3179714|NCT01341600|Experimental|Clopidogrel in poor metabolizers|"Healthy subjects who have been genotyped for CYP2C19*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 poor metabolizers (PM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
3179715|NCT01341600|Experimental|Clopidogrel in intermediate metabolizers|"Healthy subjects who have been genotyped for CYP2C19*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 intermediate metabolizers (IM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
3179716|NCT01341600|Experimental|Clopidogrel in extensive metabolizers|"Healthy subjects who have been genotyped for CYP2C19*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 extensive metabolizers (EM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
3179717|NCT01341600|Experimental|Omeprazole/Clopidogrel in PM|PM participants who have completed Arm 1 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
3179718|NCT01341600|Experimental|Omeprazole/Clopidogrel in IM|IM participants who have completed Arm 2 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
3179719|NCT01341600|Experimental|Omeprazole/Clopidogrel in EM|EM participants who have completed Arm 3 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
3179720|NCT01341587|No Intervention|Control|Provider-driven care, based in office, no special diabetes management; Patient self-monitoring of blood glucose (SMBG)
3179721|NCT01341587|Active Comparator|Intervention|"Home diabetes monitoring by patient using cellular enabled glucometer to communicate information and receive feedback.~Care provider can access raw and analyzed patient data; Physician receives report summary."
3179722|NCT01341574|Experimental|Early phase, experimental|Neglect patients, randomized in the experimental group (Prism adaptation, optical shift of 10 degrees) in the early phase after stroke.
3179723|NCT01341574|Experimental|Delayed phase, experimental|Neglect patients, randomized in the experimental group (Prism adaptation, optical shift of 10 degrees) in the delayed phase after stroke.
3179724|NCT01341574|Placebo Comparator|Early phase, placebo|Neglect patients, randomized in the placebo group (Prism adaptation, optical shift of 0 degrees) in the early phase after stroke.
3179725|NCT01341574|Placebo Comparator|Delayed phase, placebo|Neglect patients, randomized in the placebo group (Prism adaptation, optical shift of 0 degrees) in the delayed phase after stroke.
3179726|NCT01341574|Experimental|Delayed phase postural, experimental|Neglect patients, randomized in the experimental group (Prism adaptation, optical shift of 10 degrees) in the delayed phase after stroke. In this group, postural aspects are taken into account.
3179727|NCT01341561||weaning patients|
3179728|NCT01341548|Active Comparator|Civamide Nasal Solution 0.01%|
3179729|NCT01341548|Placebo Comparator|Vehicle Solution|
3179730|NCT01341535|Experimental|adaptive DPBN|"This patient group will be treated by adaptive dose-painting-by-numbers, while patients in the control arm will receive standard treatment.~Patients will have a 50 % chance of being allocated to the experimental arm and a 50 % chance of being allocated to the control arm."
3179731|NCT01341535|Active Comparator|standard IMRT|"This patient group will be treated by standard intensity-modulated radiotherapy (IMRT), while patients in the experimental arm will receive adaptive dose-painting-by-numbers.~Patients will have a 50 % chance of being allocated to the experimental arm and a 50 % chance of being allocated to the control arm."
3179732|NCT01341522|Active Comparator|Control|Control
3179733|NCT01341522|Experimental|MRI|experimental
3179734|NCT01341509|Active Comparator|FHL tendon transferred|Surgical group in which the FHL tendon was transferred
3179735|NCT01341509|Active Comparator|FHL tendon not transferred|
3179736|NCT01341496|Experimental|1|autologous tumor vaccine plus chemotherapy
3179737|NCT01341470|Experimental|Single dose LY2495655|Single 70 mg dose LY2495655 administered intravenously
3179738|NCT01341470|Experimental|Multiple dose 17.5 mg LY2495655|17.5 mg of LY2495655 administered subcutaneously every 2 weeks for 8 weeks (total of 5 doses)
3179739|NCT01341470|Experimental|Multiple dose 140 mg LY2495655|140 mg of LY2495655 administered subcutaneously every 2 weeks for 8 weeks (total 5 doses)
3179740|NCT01341470|Experimental|Multiple dose 420 mg LY2495655|420 mg dose of LY2495655 administered subcutaneously every 2 weeks for 8 weeks (total 5 doses)
3179741|NCT01341470|Placebo Comparator|Single dose placebo|single dose administered intravenously
3179742|NCT01341470|Placebo Comparator|Multiple dose placebo|subcutaneous dose administered subcutaneously every 2 weeks for 8 weeks (total of 5 doses)
3179743|NCT01341457|Experimental|LY2603618+gemcitabine|"Gemcitabine 1000 mg/m^2 administered intravenously on days 1, 8 and 15 of at least one 28-day cycle. LY2603628 170 or 230 mg administered intravenously on days 2, 9 and 16 of at least one 28-day cycle.~Patients experiencing benefit may continue on the combination therapy until discontinuation criteria are met."
3179744|NCT01341444|Experimental|Prevena Incision Management System|Negative Pressure Therapy Device
3179745|NCT01341444|Placebo Comparator|Standard of Care for Surgical Incisions|Sterile gauze and a non-penetrable barrier
3179746|NCT01341431|Experimental|bee venom|
3179747|NCT01341431|Placebo Comparator|saline|
3179748|NCT01341418|Active Comparator|Suprapatellar approach|surgical approach for intramedullary nailing of the tibia
3179749|NCT01341418|Active Comparator|Infrapatellar approach|surgical approach for intramedullary nailing of the tibia
3179750|NCT01341405|Experimental|CG100649 2 mg|capsule, once daily
3179751|NCT01341405|Experimental|CG100649 4 mg|capsule, 4 mg, once daily for 28 days
3179752|NCT01341405|Active Comparator|celecoxib 200 mg|capsule, once daily
3179753|NCT01341392|Experimental|CKD-501 0.5mg|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
3179754|NCT01341392|Experimental|CKD-501 Amlodipine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
3179755|NCT01341392|Experimental|Amlodipine 10mg|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
3179756|NCT01341379|Experimental|N-carbamylglutamate (Carbaglu)|
3179757|NCT01341366|Experimental|Fast-track perioperative program|
3179758|NCT01341366|Active Comparator|Traditional perioperative program|
3179759|NCT01341353|Active Comparator|Antiarrythmic Drugs|
3179760|NCT01341353|Experimental|ablation|
3179761|NCT01341340|Experimental|Everolimus Eluting BVS|Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS)
3179762|NCT01341327||Left Main disease|Consecutive patients with unprotected LMCA diseases at participating centers will be evaluated for the entry into the study.
3179763|NCT01341301|Experimental|Allogeneic HSCT|"CONDITIONING: Patients undergo Total Body Irradiation (TBI) twice daily (BID) on days -10 to -7. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients receive DLI on day -6 and undergo cluster of differentiation 34 (CD34+) selected allogeneic HSCT on day 0~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO on days -1 with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID or PO on days -1 to 28."
3179764|NCT01341288|Experimental|Implant|Robotic implantation of brachytherapy seeds to treat prostate cancer
3179765|NCT01341275|Experimental|birth, lower dose booster|Adolescents who received their first dose of hepatitis B vaccine at or before day 7 of life who received a 10 ug dose of hepatitis B vaccine as a booster
3179766|NCT01341275|Experimental|birth, higher dose booster|Adolescents who received their first dose of hepatitis B vaccine at or before day 7 of life who received a 20 ug dose of hepatitis B vaccine as a booster
3179767|NCT01341275|Experimental|4 weeks, lower dose booster|Adolescents who received their first dose of hepatitis B vaccine at or after 4 weeks of life who received a 10 ug dose of hepatitis B vaccine as a booster
3179768|NCT01341275|Experimental|4 weeks, higher dose booster|Adolescents who received their first dose of hepatitis B vaccine at or after 4 weeks of life who received a 20 ug dose of hepatitis B vaccine as a booster
3179769|NCT01341249|Experimental|DW224aa|DW224aa given by oral administration
3179770|NCT01341249|Active Comparator|DW224a|DW224aa given by oral administration
3179771|NCT01341236|Active Comparator|continuous nutrition|
3179772|NCT01341236|Active Comparator|bolus nutrition|
3179773|NCT01341197||Subjects undergoing bidirectional endoscopy and fecal tests|Subjects participating in the health check-up at National Taiwan University Hospital (Health Management Center)
3179774|NCT01341197||Patients with screening detected GI tract cancers|Patients with screening detected GI tract cancer, such as throat cancer, esophageal cancer, gastric cancer and colorectal cancers, from other screening sites in Taiwan and were referred to the National Taiwan University Hospital for confirmatory diagnosis and treatment.
3179775|NCT01341184|Experimental|Group 1|16 subjects: TMC207 400mg orally on days 1 and 29, rifabutin 300mg orally, every day on day 20-41
3179776|NCT01341184|Experimental|Group 2|16 subjects: TMC207 400mg orally on days 1 and 29, rifampin 600mg orally, every day on day 20-41
3179777|NCT01341171||tamoxifen or aromatase inhibitors|
3179778|NCT01341158|Experimental|Experimental arm|
3180314|NCT01337388||Cohort|
3179779|NCT01341145|Experimental|Aerobic Exersice|12-week moderate aerobic exercise program
3179780|NCT01341145|Active Comparator|Relaxation|12-week at home progressive muscle relaxation program
3179781|NCT01341132||Suspected Liver Disease|"Alpha-feto protein > 400 ng / mL or~prior ultrasound with mass suspicious for hepatic malignancy or.~clinical risk of hepatocellular carcinoma or~prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma"
3179782|NCT01341106|Experimental|Treatment Arm|Patients will be treated with entecavir
3179783|NCT01341093|Active Comparator|usual care|
3179784|NCT01341093|Experimental|educational program+telephone follow up|
3179785|NCT01341080|Experimental|Varenicline|
3179786|NCT01341080|Placebo Comparator|Sugar pill|
3179787|NCT01341067||Basal insulin, approved oral medications|
3179788|NCT01341054|Experimental|mouthwash with Chamomilla extract 1%|The Chamomile recutita mouthwash 1% was administered two times daily for 30 days.
3179789|NCT01341054|Experimental|mouthwash with Chamomilla extract 2%|The Chamomile recutita mouthwash 2% was administered two times daily for 30 days.
3179790|NCT01341054|Active Comparator|standard oral care protocol|The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12%; oral hygiene teaching. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.
3179791|NCT01341054|Experimental|mouthwash with Chamomilla extract 0.5%|The Chamomile recutita mouthwash 0.5% was administered two times daily for 30 days, starting on the first day of chemotherapy.
3179792|NCT01341041|Experimental|chlorine dioxide|2 arms
3179793|NCT01341041|Active Comparator|saline|one time wash with 50-100cc of normal saline
3179794|NCT01341028|Active Comparator|Roux-en-Y gastric bypass (LRYGBP)|Twelve subjects underwent laparoscopic Roux-en-Y gastric bypass
3179795|NCT01341028|Experimental|LRYGBP plus gastric fundus resection|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass plus gastric fundus resection
3179796|NCT01341015|Experimental|ultrasound for fracture|All patients receive ultrasound for potential ankle fracture.
3179797|NCT01341002|Experimental|SCVO2 < 70%|guidelines transfusion + SCVO2 < 70%
3179798|NCT01341002|Active Comparator|currently intervention|guidelines transfusion
3179799|NCT01340989|Experimental|4% oxygen|addition of 4% oxygen to the CO2 pneumoperitoneum
3179800|NCT01340989|Experimental|full conditioning|full conditioning of the peritoneal cavity by the laparoscopic gas: 4% oxygen, 10% nitrous oxide, humidification and set temperature of 32°C
3179801|NCT01340989|Active Comparator|CO2 pneumoperitoneum|standard laparoscopy with CO2 pneumoperitoneum
3179802|NCT01340976|Experimental|LY2787106 Dose Escalation|Part A: Dose escalation starting at 0.3 mg/kg, intravenously (IV), day one of up to three 21-day cycles.
3179803|NCT01340976|Experimental|10 mg/kg LY2787106|Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator.
3179804|NCT01340976|Experimental|10 mg/kg LY2787106+Iron|Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles with daily oral iron supplementation. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator.
3179805|NCT01340963||Class I|Structurally normal heart, no bundle branch block
3179806|NCT01340963||Class II|Mild symptoms, bundle brunch block or hemi-block on resting surface electrocardiogram, normal cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction as relaxation deficit (type I), none or mild global left ventricular systolic dysfunction
3179807|NCT01340963||Class III|Overtly symptomatic, enlarged cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction, global systolic dysfunction, ventricular tachycardia, atrio-ventricular block (any degree)
3179808|NCT01340950|Active Comparator|Better-Penetrating ART|zidovudine 300 mg orally every 12 hours lamivudine 300 mg orally daily nevirapine 200 mg orally every 12 hours
3179809|NCT01340950|Active Comparator|Worse-Penetrating ART|tenofovir disoproxil fumarate 300 mg orally daily lamivudine 150 mg orally every 12 hours efavirenz 600 mg orally daily
3179810|NCT01340937|Experimental|V419 Lot A|V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
3179811|NCT01340937|Experimental|V419 Lot B|V419 (Lot B) 0.5 mL IM at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
3179812|NCT01340937|Experimental|V419 Lot C|V419 (Lot C) 0.5 mL IM at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
3179813|NCT01340937|Active Comparator|Control|Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age
3179814|NCT01340911|Active Comparator|Part 1A, Cohorts 1-6|"Approximately 48 healthy male subjects will be enrolled into 6 separate cohorts (8 subjects per cohort). Each Cohort of subjects will be dosed sequentially, approximately one week apart, at escalating doses. Within each cohort, 6 subjects will be randomized to receive a single dose of SRT3025, and 2 will be randomized to receive a single dose of placebo.~The following are the planned doses for Cohorts 1-6, with Cohort 1 being the lowest dose and Cohort 6 being the highest dose: 50, 150, 500, 1000, 2000, and 3000mg of SRT3025. Dose level may be altered as appropriate during the study based on real time analysis of the safety, tolerability, and /or PK data. Dose adjustment may involve an increase or decrease in dose or dividing the total daily dose allowing for twice-daily dosing. Total daily dosing will not exceed 3000mg."
3179815|NCT01340911|Active Comparator|Part 1B, Cohorts 7-8|One to two of the doses administered in Part 1A may be selected for administration with food, based on expected changes in SRT3025 exposures with food, as well as safety, tolerability, and PK data from Part 1A. If initiated, the effect of a single dose of SRT3025 with a moderate fat/calorie meal may be initiated concurrently with a cohort in Part 2 of the study. Approximately 6 subjects would be enrolled into each cohort in Part 1B.
3180315|NCT01337375|Experimental|A/B|
3179816|NCT01340911|Active Comparator|Part 2A, Cohorts 9-11|Approximately 16-24 healthy subjects will be enrolled into 2 to 3 cohorts (8 subjects per cohort) in Part 2A. Within each cohort, 6 subjects will be randomized to receive multiple doses of SRT3025, and 2 will be randomized to receive multiple doses of placebo. The repeat dosing component of the study will be initiated, and doses selected, based on the evaluation of safety, tolerability, and PK data from Part 1A. Subjects in Part 2A will be randomized to receive 14 consecutive days of dosing with SRT3025 or matched-placebo. Subjects in these Cohorts will be dosed sequentially (in the fasted state) approximately two weeks apart.
3179817|NCT01340911|Active Comparator|Part 2B, Cohorts 12-13|If initiated, the effect of repeat doses of SRT3025 with moderate fat/calorie meals would occur in Part 2B (Cohorts 12 and 13). Each of these cohorts would enroll approximately 6 subjects.
3179818|NCT01340898|Experimental|Group A|Subjects who receive 3 primary doses and 1 booster dose of the investigational vaccine, (3 doses at 2, 4 and 6 months of age followed by a booster dose at 15-18 months of age).
3179819|NCT01340898|Experimental|Group B|Subjects who receive 1 primary dose and 1 booster dose of the investigational vaccine, (1 dose at 6 months of age followed by a booster dose at 15-18 months of age)
3179820|NCT01340898|Experimental|Group C|Subjects who receive 1 dose of the investigational vaccine, at 15-18 months of age
3179821|NCT01340885|Active Comparator|atomoxetine|Strattera 10-30 mg b.i.d.
3179822|NCT01340885|Active Comparator|rivastigimine|Exelon 1.5-4.5 mg b.i.d.
3179823|NCT01340885|Placebo Comparator|Placebo|sugar pill
3179824|NCT01340872|Experimental|ST10|ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day
3179825|NCT01340872|Placebo Comparator|Placebo|Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day
3179826|NCT01340859|Experimental|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Sessions of Post Admission Cognitive Therapy Delivered Preferably Over 3 Consecutive Days of Inpatient Stay
3179827|NCT01340859|No Intervention|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services
3179828|NCT01340846|Experimental|Part A|Warfarin dosed at 15mg
3179829|NCT01340846|Experimental|Part B|Ketoconazole dosed at 400mg
3179830|NCT01340846|Experimental|Part C|Gemfibrozil dosed at 600mg
3179831|NCT01340846|Experimental|Part D|GSK2118436 dosed alone
3179832|NCT01340833|Experimental|Study Medication|GSK2118436
3179833|NCT01340820|Experimental|AERAS-422 Low dose|>=10^5 to < 10^6 CFU
3179834|NCT01340820|Experimental|AERAS-422 High Dose|>=10^6 CFU
3179835|NCT01340820|Active Comparator|BCG Tice|BCG Tice 1-8 x 10^5 CFU
3179836|NCT01340807|Experimental|Prosthetic Feet|Randomized to 4 different prosthetic feet (SACH, SAFE, TALUX, and Proprio Foot)
3179837|NCT01340794|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28 (days 1-14 of courses 1 and 2). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3179838|NCT01340781||Hospitalized medical patients|"Adult age 18-65 years old admitted to the general medical floors at MetroHealth Medical Center who are expected to stay a minimum of 48 hours.~Potential subjects cannot have a known diagnosis of OSA, a tracheostomy, respiratory failure requiring noninvasive ventilation, currently pre or post surgical intervention, or clinically unstable patients with plans for transfer to a higher acuity of care or transferred from intensive care."
3179839|NCT01340768|Experimental|Sitagliptin|Sitagliptin 100mg taken orally once daily with or without metformin
3179840|NCT01340768|Active Comparator|Sulfonylurea Therapy|Usual sulfonylurea therapy with or without metformin
3179841|NCT01340755|Experimental|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
3179842|NCT01340742|Active Comparator|1|Arm remote preconditioning
3179843|NCT01340742|Placebo Comparator|2|Control group.
3179844|NCT01340729|Experimental|TPI 287|Starting dose TPI 287 of 125 mg/m2 intravenous (IV) for 3 weeks of 4 week schedule.
3179845|NCT01340716|Active Comparator|stretching exercise|patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style.
3179846|NCT01340716|Experimental|Tai Chi Chuan exercise|patients in this group held weekly classes of two stretching for 12 weeks.
3179847|NCT01340703|Other|optic disc pit maculopathy|
3179848|NCT01340690|Active Comparator|ω-3 fatty acids suspension|2 bags of Esprico(R) suspension each day. Each 4ml suspension bag includes 400mg eicosapentaenoic acid (EPA), 40mg docosahexaenoic acid (DHA), 5.4 mg gamma-linolenic acid (GLA), 80 mg magnesium, 5 mg zinc and consists of linseed oil, xylitol, sea fish oil with high portion of omega-3-acids, magnesium citrate, vegetable oil, orange flavour, evening primrose oil, zink gluconate, soya lecithin, citric acid, acesulfame k (E950)
3179849|NCT01340690|Placebo Comparator|placebo suspension|2 bags of Esprico (R) placebo suspension. Includes no ω-3 fatty acids, no ω-6 fatty acids, no magnesium and no zinc, but other vegetable oils, orange flavor, etc.
3179850|NCT01340677|Experimental|001|Canagliflozin 100 mg Type=1 unit=mg number=100 form=tablet route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.,Canagliflozin 300 mg Type=1 unit=mg number=300 form=tablet route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.,Canagliflozin 50 mg Type=1 unit=mg number=50 form=tablet route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
3179851|NCT01340664|Experimental|Canagliflozin 50 mg bid|Each patient will receive 50 mg canagliflozin twice daily for 18 weeks.
3179852|NCT01340664|Experimental|Canagliflozin 150 mg bid|Each patient will receive 150 mg canagliflozin twice daily for 18 weeks
3179853|NCT01340664|Placebo Comparator|Placebo|Each patient will receive matching placebo twice daily for 18 weeks
3179854|NCT01340651|Experimental|Ruxolitinib 25 mg SR/10, 15, or 20 mg IR|Participants began administration with 25 mg ruxolitinib sustained release (SR) once daily (QD). After 8 weeks, if there was inadequate efficacy, the dose level could be titrated to 50 mg SR QD or 25 mg SR every other day (QOD) alternating with 50 mg SR QOD. At Week 16, participants transitioned to ruxolitinib 10, 15, or 20 mg immediate release (IR) orally twice daily. Participants who continued to demonstrate benefit in the opinion of the investigator could remain on ruxolitinib IR until the last participant completed Week 36 or the commercial availability of ruxolitinib IR, whichever was earlier; the dose received was based on platelet counts at the time of transition.
3179855|NCT01340638|Active Comparator|Cookgas|This group will be assigned to use cookgas mask
3179856|NCT01340638|Active Comparator|LMA mask|This group will be assigned to use LMA mask
3179857|NCT01340625|Experimental|Investigational Test Product|Norethindrone/Ethinyl Estradiol 0.4 mg/35 mcg Chewable Tablets (Teva)
3179858|NCT01340625|Active Comparator|Reference Listed Drug|Ovcon® 35 Fe 0.4 mg/35 mcg Chewable Tablets (Warner Chilcott)
3179859|NCT01340612|Active Comparator|coiling|
3179860|NCT01340612|Active Comparator|coiling plus stenting|
3179861|NCT01340599|Experimental|Arm I (Polyphenon E)|Patients receive defined green tea catechin extract PO once daily QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.
3179862|NCT01340599|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.
3179863|NCT01340586|Experimental|Group A: Apixaban|
3179864|NCT01340586|Experimental|Group B: Apixaban|
3179865|NCT01340573||Genotype 1 CHC Participants|
3179866|NCT01340573||Non-genotype 1 CHC participants|
3179867|NCT01340547|Other|Single Arm|Single Arm, non-blinded, non-randomized
3179868|NCT01340534|Experimental|Oxygen 80% FIO2|Group of 181 patients that will receive supplemental oxygen 80% FIO2 during surgery (cesarean) and two hours after the procedure.
3179869|NCT01340534|Placebo Comparator|Use of air (no oxygen during surgery)|Group of 181 patients that will not receive supplemental oxygen during surgery (cesarean).
3179870|NCT01340508|Experimental|Intensity modulated Radiotherapy|Intensity modulated radiotherapy, dose escalation, rectal cancer, volumetric modulated arc therapy
3179871|NCT01340495|Experimental|Proton Radiation|Radiation therapy with proton beam
3179872|NCT01340482|Experimental|KRN23|Escalating doses of KRN23 (0.05, 0.10, 0.30 and 0.60 mg/kg) will be administered SC every 28 days (up to 4 doses)
3179873|NCT01340469|Active Comparator|study|Probiotics supplementation .
3179874|NCT01340469|Placebo Comparator|control|The control group received daily placebo liquid .
3179875|NCT01340456|Experimental|Rifampicin 10 mg QD|
3179876|NCT01340456|Experimental|Rifampicin 20 mg QD|
3179877|NCT01340456|Experimental|Rifampicin 100 mg QD|
3179878|NCT01340443||Cohort|
3179879|NCT01340430|Experimental|FEC-paclitaxel-trastuzumab|fluorouracil 600 mg/m2; epirubicin 90 mg/m2; cyclophosphamide 600 mg/m2 for 4 cycles followed by paclitaxel 80 mg/m2/week in combination with trastuzumab for 12 weeks
3179880|NCT01340417|Experimental|one label|Measurements of melatonin levels in urine, blood, milk.
3179881|NCT01340404|Experimental|Stem Cell Transplantation|
3179882|NCT01340404|Active Comparator|Transfusion program|
3179883|NCT01340391|Experimental|splinting method|A new splinting method has been invented. This is a study using the splint / cast in treatment of distal radius fractures.
3179884|NCT01340365|Other|Usual Care|
3179885|NCT01340365|Experimental|Tai Chi|Individuals will take part in community-based Tai Chi classes twice a week for 6 months as well as practice Tai Chi outside of class twice a week for the same 6 month period.
3179886|NCT01340352||study group: previous preterm labor|
3179887|NCT01340352||control group:previous term delivery|
3179888|NCT01340339|Experimental|BILITRON BED®|Super-LED reverse phototherapy
3179889|NCT01340339|Active Comparator|BILIBERÇO®|Fluorescent Reverse Phototherapy
3179890|NCT01340326|Active Comparator|Valsartan,high dose|high dose group (valsartan up to 320 mg/day)
3179891|NCT01340326|Other|Valsartan, usual dose|usual dose group (valsartan 80 mg/day)
3179892|NCT01340313||Group 1|4 times evaluation according to doses in 1 group
3179893|NCT01340300|Active Comparator|Exercise training|Exercise training with exercise physiologist
3179894|NCT01340300|Active Comparator|Exercise training with metformin|Exercise training with exercise physiologist with oral metformin
3179895|NCT01340300|Active Comparator|Metformin|Metformin
3179896|NCT01340300|Active Comparator|Control|Educational information
3179897|NCT01340287|Active Comparator|1 = Tested product|
3179898|NCT01340287|Sham Comparator|2 = Control product|
3179899|NCT01340274|Active Comparator|Treatment as Usual|"Clients will receive 12 sessions of Treatment as usual , delivered 1 session per week for 12 consecutive weeks."
3179900|NCT01340274|Experimental|CRAFT Treatment|"Clients will receive 12 sessions of CRAFT, delivered 1 session per week for 12 consecutive weeks."
3179901|NCT01340261||Pediatric Pain Rehab Patients|
3179902|NCT01340248|Experimental|Dilatrend 64mg capsule|"* Randomized, open-label, single dose, two-period, two-way, crossover study~group : Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet~group : Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting"
3179903|NCT01340235|Experimental|Oral erythromycin|Oral erythromycin
3179904|NCT01340209|Experimental|Tiotropium Respimat (low dose)|Tiotropium low dose once daily delivered with Respimat inhaler
3179905|NCT01340209|Experimental|Tiotropium Respimat (high dose)|Tiotropium high dose once daily delivered with Respimat inhaler
3179906|NCT01340209|Placebo Comparator|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
3179907|NCT01340196|Experimental|sequence 1|tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through day 22 (morning dose on day 22 only)
3179908|NCT01340183|Experimental|AZD5099|IV Dose
3179909|NCT01340183|Placebo Comparator|Placebo|IV Dose
3179910|NCT01340170|Experimental|Soft bone drilling protocol|A soft bone drilling protocol will be used in bone quality 3 and 4
3179911|NCT01340170|Active Comparator|Standard drilling protocol|A standard drilling protocol will be used in bone quality 1 and 2
3179912|NCT01340157|Experimental|Fasting|Treatment A: 1200mg fexinidazole administered in fasting conditions by oral route
3179913|NCT01340157|Experimental|Meal 1: Plumpy Nuts|Treatment B: 1200mg fexinidazole administered in fed conditions (meal 1) by oral route
3179914|NCT01340157|Experimental|Meal 2: Rice + beans|Treatment B: 1200mg fexinidazole administered in fed conditions (meal 2) by oral route
3179915|NCT01340144||PFC Sigma PS TKA|one group received primary TKA using the PFC Sigma PS TKA
3180316|NCT01337375|Experimental|C/D|
3179916|NCT01340144||PFC Sigma HP PS TKA|One group received primary TKA using the PFC Sigma HP PS TKA.
3179917|NCT01340131|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 40mg/S-Amlodipine 5mg Intervention
3179918|NCT01340131|Active Comparator|Free combination Therapy|Co-administration of single oral doses of a 40mg tablet of Telmisatan and a 5 mg tablet of S-Amlodipine
3179919|NCT01340118|Experimental|Budesonide|Patients with FeNO level greater than 25 ppb were randomly allocated to one of two groups. Randomisation was stratified by baseline FeNO. In one group (treatment group), participants were assigned to once daily treatment with 400 µg budesonide. In the other group (non-treatment group), participants did not receive any medication.
3179920|NCT01340118|No Intervention|remain untreated|
3179921|NCT01340105|Experimental|Microwave|
3179922|NCT01340105|Active Comparator|Radiofrequency|
3179923|NCT01340092|Active Comparator|Family Navigator|Family navigation
3179924|NCT01340092|No Intervention|Standard Care|standard care
3179925|NCT01340079|Experimental|Virtual world|Virtual world delivery method
3179926|NCT01340079|Active Comparator|face to face|face to face method of health education
3179927|NCT01340066|Experimental|UISH001|
3179928|NCT01340066|Placebo Comparator|Matching placebo|
3179929|NCT01340053|Placebo Comparator|Placebo|
3179930|NCT01340053|Experimental|Low Dose|
3179931|NCT01340053|Experimental|Mid Dose|
3179932|NCT01340053|Experimental|High Dose|
3179933|NCT01340040|Experimental|MEDI-573|MEDI-573
3179934|NCT01340027|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once a day for 12 weeks
3179935|NCT01340027|Active Comparator|Mirabegron 25 mg|Participants received mirabegron 25 mg tablets orally once a day for 12 weeks
3179936|NCT01340027|Active Comparator|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks
3179937|NCT01340027|Active Comparator|Solifenacin 2.5 mg|Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks
3179938|NCT01340027|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg tablets orally once a day for 12 weeks
3179939|NCT01340027|Active Comparator|Solifenacin 10 mg|Participants received solifenacin 10 mg tablets orally once a day for 12 weeks
3179940|NCT01340027|Experimental|Solifenacin 2.5 mg and Mirabegron 25 mg|Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
3179941|NCT01340027|Experimental|Solifenacin 2.5 mg and Mirabegron 50 mg|Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
3179942|NCT01340027|Experimental|Solifenacin 5 mg and Mirabegron 25 mg|Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
3179943|NCT01340027|Experimental|Solifenacin 5 mg and Mirabegron 50 mg|Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
3179944|NCT01340027|Experimental|Solifenacin 10 mg and Mirabegron 25 mg|Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
3179945|NCT01340027|Experimental|Solifenacin 10 mg and Mirabegron 50 mg|Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
3179946|NCT01340014|Other|AZARGA/COSOPT|1 drop AZARGA instilled in each eye twice a day for 7 days, followed by 1 drop COSOPT instilled in each eye twice a day for 7 days. A 48-hour washout period separated the two treatment periods.
3179947|NCT01340014|Other|COSOPT/AZARGA|1 drop COSOPT instilled in each eye twice a day for 7 days, followed by 1 drop AZARGA instilled in each eye twice a day for 7 days. A 48-hour washout period separated the two treatment periods.
3179948|NCT01340001|Sham Comparator|Sham Electrical stimulation of the nucleus basalis of Meynert|Deep brain stimulation
3179949|NCT01340001|Experimental|Electrical stimulation of the nucleus basalis of Meynert|Deep brain stimulation
3179950|NCT01339988|Experimental|Busulfan/Cyclophosphamide|
3179951|NCT01339975||Group A. Surgically treated patients|Patients having a radical or partial nephrectomy.
3179952|NCT01339975||Group B. Patients treated with targeted therapies|Patients treated by RCC-directed targeted therapy
3179953|NCT01339962||Non-Interventional Study|Outcomes Research Study
3179954|NCT01339949|Experimental|24 Gy radiation|
3179955|NCT01339949|Sham Comparator|Sham 24 Gy radiation|
3179956|NCT01339936|Experimental|Investigational eye drop|Formulation 1: Carboxymethylcellulose sodium, glycerin and polysorbate 80 based eye drops formulated for the relief of ocular surface irritation and symptoms of dryness
3179957|NCT01339923|Experimental|B_2h3h5_11|Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.
3179958|NCT01339923|Experimental|B_3h5_11|Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.
3179959|NCT01339923|Experimental|B_68_11|Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.
3179960|NCT01339923|Experimental|B_02_2_5|Subjects, 2-5 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
3179961|NCT01339923|Experimental|B_02_6_10|Subjects, 6-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
3179962|NCT01339923|Experimental|BC_35_12|Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
3179963|NCT01339923|Experimental|C_35_12|Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 and 15 months of age.
3179964|NCT01339910|Experimental|Reduced Intensity Conditioning (RIC)|One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
3179965|NCT01339910|Active Comparator|Myeloablative Conditioning Regimen (MAC)|One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
3179966|NCT01339897|Active Comparator|5 mg/N6022|Injectable formulation, given at doses per cohort of 5 mg given QD each day over 7 days.
3179967|NCT01339897|Placebo Comparator|Placebo|Injectable formulation normal saline
3179968|NCT01339897|Active Comparator|10mg/N6022|Injectable formulation, given at doses of 10 mg given QD each day over 7 days.
3179969|NCT01339897|Active Comparator|20mg/N6022|Injectable formulation, given at doses per cohort of 20 mg given QD each day over 7 days.
3179970|NCT01339884|Active Comparator|Resveratrol, 1g daily|15 participants will receive resveratrol 1g daily
3179971|NCT01339884|Active Comparator|Resveratrol, 5g daily|15 participants will receive resveratrol, 5g daily
3179972|NCT01339871|Experimental|Pazopanib + Vorinostat|Starting doses Pazopanib 400 mg orally daily and Vorinostat 100 mg orally daily
3179973|NCT01339858|Experimental|N-Acetyl Cysteine|NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 480 mg of NAC. Dosing will begin at 480 mg/d and titrated up by 480 mg/d each week until a maximum dose of 2880 mg/d (BID) is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose.
3179974|NCT01339858|Placebo Comparator|Sugar Pill|matched placebo
3179975|NCT01339845|Active Comparator|Vaccine arm|Thirty clusters (approximately 80,000 people) will receive cholera vaccine alone
3179976|NCT01339845|Active Comparator|Vaccine plus hygiene and safe water arm|Thirty clusters (approximately 80,000 people)will receive both cholera vaccine and behaviour change
3179977|NCT01339845|No Intervention|Non-intervention arm|30 neighbourhoods(approximately 80,000 people) will continue their standard habits and practices
3179978|NCT01339832||Cohort|
3179979|NCT01339819|Experimental|Arm 1|Dabigatran Therapy
3179980|NCT01339819|Active Comparator|Arm 2|Phenprocoumon Therapy
3179981|NCT01339806|Other|Standard of Care for mTBI Provider Arm|Arm 1: Psychoeducational Control Group. Individuals assigned to arm 1 will receive psychoeducational materials specifically adapted for persistent management of symptoms and routine follow-up with medical providers (every three weeks). Additionally, subjects assigned to this group will receive medical care (e.g., psychopharmacological management of depression) and/or referral for symptom management (e.g., vestibular rehabilitation) of non-cognitive complaints, consistent with the current standard of care treatment model for managing post-concussive symptoms (see Figure below adapted with permission from authors; Brenner et al., 2009).
3179982|NCT01339806|Experimental|Computer Based Therapy Group|"Arm 2: Non-therapist directed computerized cognitive rehabilitation. Individuals assigned to treatment arm 2 will receive ten hours of in-clinic, computerized treatment per week throughout the 6-week treatment trial. Participants will be scheduled for 2 hours per day, proctored by clinic staff (certified recreation therapist or neuropsychology technician) who will be responsible for recording daily performance, providing positive reinforcement of participation, and effort. Computer programs selected for this treatment trial include both skill-specific training (e.g., attention processes) and general cognitive activation. These computer programs are commercially available and advertised as brain fitness or brain training."
3179983|NCT01339806|Experimental|Cognitive Rehab Group|"Arm 3: Therapist-directed individualized cognitive rehabilitation. Individuals assigned to treatment arm 3 will receive 10 hours of individual and group cognitive rehabilitation treatment (including homework assignments) per week conducted by credentialed speech therapists and occupational therapists. The treatment components will include five hours of weekly individual therapy (one-hour sessions; two hours focused on compensatory strategies and three hours focused on restorative strategies), two hours of weekly group therapy (one hour sessions focused on compensatory strategies), and three hours of weekly computer-based homework proctored by clinic staff who will be responsible for recording performance, and providing positive reinforcement of participation and effort."
3179984|NCT01339806|Experimental|Cognitive and Psychological Based Rehab|"Arm 4: Integrated interdisciplinary cognitive rehabilitation combined with cognitive-behavioral psychotherapy. Individuals assigned to treatment arm 4 will receive 10 hours of individual and group treatment per week conducted by credentialed therapists and doctoral-level psychologists. The treatment components will include four hours of weekly 1 hr individual therapy sessions; 2 hrs of cognitive rehabilitation, 1 hr of cognitive rehab & 1 hr of individual psychotherapy targeting anxiety/combat stress symptoms including relaxation training & exposure therapy and cognitive-behavioral principles, 3 hrs of weekly group therapy & three hours of weekly homework including 30-mins relaxation training, 30-mins cognitive-behavioral psychotherapy homework, and 2 hrs of computerized cognitive rehabilitation exercises proctored by clinic staff."
3179985|NCT01339780|Experimental|Breast Cancer|
3179986|NCT01339780|Experimental|Prostate Cancer|
3179987|NCT01339754|Experimental|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
3179988|NCT01339741|Active Comparator|Vitamin D|
3179989|NCT01339741|Placebo Comparator|Placebo|
3179990|NCT01339702||"Pre-implementation cohort (before)"|This cohort is a combination of retrospective and some prospective severe TBI patients cared for in the EMS systems of Arizona BEFORE implementation of the national prehospital TBI management guidelines
3179991|NCT01339702||"Post-implementation cohort (after)"|"This cohort is a comprised of prospective severe TBI patients cared for in the EMS systems of Arizona AFTER training EMS providers in the implementation of the national prehospital TBI management guidelines. It is intended that these patients will receive the bundle of care specified in the TBI Guidelines."
3179992|NCT01339689|Experimental|Ganaxolone|active
3179993|NCT01339689|Placebo Comparator|Placebo|non-active
3179994|NCT01339676|Experimental|1|Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D
3179995|NCT01339676|Placebo Comparator|2|Identically appearing once weekly peroral capsules
3180039|NCT01339351|No Intervention|Usual Psychosocial Care|Participants are free to use any psychosocial care available to cancer patients. No restrictions to participation in other groups or services.
3179996|NCT01339663|Experimental|Treatment (dose-escalation, T-APC boost, CTL)|"INFUSION I: Patients receive high-dose cyclophosphamide IV on day days -4 and -3 and low-dose IL-2 SC BID on days 0-14. Patients also receive CTL IV on day 0.~INFUSION II: Beginning 6-48 hours later, patients receive high-dose cyclophosphamide, low-dose IL-2, and CTL as in Infusion I. Patients also receive T-APC vaccine IV within 18-36 hours following CTL infusion and in week 4, and IL-2 SC BID on days 0-14 following second T-APC vaccination."
3179997|NCT01339650|Experimental|ABT-767|ABT-767 monotherapy
3179998|NCT01339637||Diabetes risk factors|Very dark skin subjects with with diabetes risk factors
3179999|NCT01339624|Active Comparator|NASAL FENTANYL,|
3180000|NCT01339624|Active Comparator|KETOROLAC + MORPHINE|
3180001|NCT01339611|Experimental|Educational Program|Patients who are going to use of oral anticoagulant will participate in an individual orientation, using instructional material (slides and illustrative booklet) during hospitalization period and the telephone follow-up at a week and four weeks after discharge
3180002|NCT01339611|Other|usual care|Patients who are going to use of oral anticoagulant will have usual orientation from the health service (illustrative booklet) during hospitalization time. No telephone follow-up after discharge.
3180003|NCT01339598|Sham Comparator|Sham transcranial direct current stimulation|
3180004|NCT01339598|Active Comparator|Transcranial direct current stimulation|
3180005|NCT01339598|Active Comparator|Different transcranial direct current stimulation montage|
3180006|NCT01339585|Experimental|Timing of tDCS|
3180007|NCT01339585|Experimental|Alternative timing of tDCS|
3180008|NCT01339572|Experimental|Plerixafor|All subjects will receive filgrastim as part of their primary mobilization regimen. If a subject does not meet minimum peripheral blood CD34+ cell count levels or fails to adequately collect a threshold number of CD34+ cells, plerixafor will be added to the mobilization regimen.
3180009|NCT01339572|Active Comparator|Observation|All subjects will receive filgrastim as part of their primary mobilization regimen. If the subject meets minimum peripheral blood CD34+ cell count levels or adequately collects a threshold number of CD34+ cells, plerixafor will not be added to the mobilization regimen.
3180010|NCT01339559|Experimental|Brivaracetam|Brivaracetam with a maximum of 200 mg/day
3180011|NCT01339546||Study population|All ambulatory visits for otitis media, myringotomy tube insertion, skin rash or trauma among children age 5 or under during the periods of study
3180012|NCT01339533|Experimental|APRV ls|APRV low stretch will titrate Plow to maintain release volumes between 4 and 8 cc/kg.
3180013|NCT01339533|Active Comparator|AC/VC Conventional Ventilation|Standard volume control ventilation with the ARDS Net protocol.
3180014|NCT01339533|Experimental|APRV h|APRV Habashi protocol which sets Plow equal to 0.
3180015|NCT01339520|Experimental|Scorecard|Score of points for variables.
3180016|NCT01339520|No Intervention|Control|Standard of care for diabetes subjects
3180017|NCT01339507||Bepreve|Subjects with a history of allergic conjunctivitis.
3180018|NCT01339507||Lastacaft|Subjects with a history of allergic conjunctivitis.
3180019|NCT01339494|Active Comparator|arginine supplementation|Oral L-arginine supplementation will be administered to subjects with MELAS for 48 hours at a dose of 10 grams per M2 per day. Arginine will be given every 4 hours.
3180020|NCT01339494|Active Comparator|citrulline supplementation|Oral L-citrulline supplementation will be administered to subjects with MELAS for 48 hours at a dose of 10 grams per M2 per day. Citrulline will be given every 4 hours
3180021|NCT01339481||Subjects with RA initiating abatacept treatment regimen|Subjects naïve to both abatacept and belatacept
3180022|NCT01339468|Experimental|Arm 1|Intravenous Prograf therapy followed by oral Advagraf therapy
3180023|NCT01339468|Active Comparator|Arm 2|Intravenous Prograf therapy followed by oral Prograf therapy
3180024|NCT01339455|Experimental|AHSCT|All patients undergo autologous hematopoietic stem cell transplantation in a two stage process.
3180025|NCT01339442|Experimental|Dose Level 1 - Phase 1A|"BKM120 80 mg PO daily.~Fulvestrant 500 mg IM on Days 1 & Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
3180026|NCT01339442|Experimental|Dose Level 2 - Phase IA|"BKM120 100 mg PO daily.~Fulvestrant 500 mg IM on Days 1 & Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
3180027|NCT01339442|Experimental|Phase IB|"BKM120 (dose to be determined in Phase IA)PO 5 days on/ 2 days off per week.~Fulvestrant 500 mg IM on Days 1 & Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
3180028|NCT01339442|Experimental|Cohort C|"BKM120 (dose determined in Phase IA) PO daily.~Fulvestrant 500 mg IM on Day 1 and Day 15 during Cycle 1 then monthly on Day 1 of subsequent cycles."
3180029|NCT01339429|Experimental|simplified Negative Pressure Wound Therapy|The simplified Negative Pressure device will be placed on subjects selected from the hospital ward and meeting the eligibility criteria.
3180030|NCT01339416||HIV infected cohort|HIV infected patients in the HIV cohorts at the three participating hospitals
3180031|NCT01339403||HIV infected|No study specific intervention, non-interventional trial
3180032|NCT01339403||HIV-uninfected|No study specific intervention, non-interventional trial
3180033|NCT01339390|Experimental|Arm 1: MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE! program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
3180034|NCT01339390|Active Comparator|Arm 2: MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the primary care provider (PCP) to determine if the person would benefit from a weight loss program, and to refer them to MOVE! if they and the patient agree that it would be beneficial. The MOVE! program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
3180035|NCT01339377|Experimental|AO-1000 Treatment|Oxygen-ozone treatment with the AO-1000 device
3180036|NCT01339364|Active Comparator|Didactic Lecture|
3180037|NCT01339364|Experimental|Lecture plus Case Disscussion|
3180038|NCT01339364|Experimental|Lecture plus Small Group Education|
3180174|NCT01338519||PCOS and hirsutism|
3180040|NCT01339351|Experimental|Therapeutic Group by teleconference|ten 90 minute group sessions by teleconference. Lead by social workers. Sessions focus on information, story sharing and coping.
3180041|NCT01339338|Experimental|warm media|Subjects undergo HSG using a warm media heated with a 37℃ water-bathing
3180042|NCT01339338|No Intervention|cold media|the contrast media under room temperature without heat
3180043|NCT01339325|Active Comparator|LESS cholecystectomy|Laparo-endoscopic single site cholecystectomy, the entire surface of the patient's abdomen is covered by plaster at the end of the operation. Patient does not know which kind of procedure he underwent before discharge.
3180044|NCT01339325|Active Comparator|Standard LAP-CHOLE|Standard laparoscopic cholecystectomy. The entire surface of the patient's abdomen is covered by plaster at the end of the operation. Patient does not know which kind of procedure he underwent before discharge.
3180045|NCT01339325|Active Comparator|LESS Cholecystectomy not blind|Laparo-endoscopic single site cholecystectomy. The patient is aware of the procedure he underwent.
3180046|NCT01339312|Experimental|VRVg Vaccine Group 1|Participants aged 18 years or older will receive Purified Vero Rabies Vaccine Serum Free (VRVg)
3180047|NCT01339312|Experimental|VRVg Vaccine Group 2|Participants aged 10 to 17 years will receive Purified Vero Rabies Vaccine Serum Free (VRVg)
3180048|NCT01339312|Active Comparator|Verorab Vaccine Group 1|Participants aged 18 years or older will receive Verorab Vaccine
3180049|NCT01339312|Active Comparator|Verorab Vaccine Group 2|Participants aged 10 to 17 years will receive Verorab Vaccine
3180050|NCT01339299|Experimental|recombinant luteinizing hormone|150 IU r-LH, recombinant luteinising hormone, from treatment day 1 (stimulation day 1) until day of r-hCG administration (normally treatment day 10 to 14)
3180051|NCT01339299|Active Comparator|recombinant human chorionic gonadotrofin|25 IU of r-hCG from treatment day 1 (stimulation day 1) until day of r-hCG administration (normally treatment day 10 to 14 )
3180052|NCT01339286|Experimental|atomoxetine|
3180053|NCT01339273|Experimental|TAP block|Patients in this arm will receive ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
3180054|NCT01339273|Active Comparator|Local anaesthetic infiltration|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
3180055|NCT01339260|Experimental|Netupitant and Palonosetron+dexamethasone-cycle 1|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle
3180056|NCT01339260|Active Comparator|Palonosetron+dexamethasone-cycle 1|Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle
3180057|NCT01339260|Experimental|Netupitant and Palonosetron+dexamethasone-multicycle extension|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle
3180058|NCT01339260|Active Comparator|Palonosetron+dexamethasone-multicycle extension|Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle
3180059|NCT01339247|Active Comparator|Paxil CR Reference|Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, in Period 1, followed by Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada, in Period 2
3180060|NCT01339247|Active Comparator|Paxil CR Test|Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada, in Period 1, followed by Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, in Period 2
3180061|NCT01339234|Experimental|Body-weight supported treadmill training|
3180062|NCT01339221||Cohort A|Children confirmed with G1 and/or P[8] cases from the RotaBel study
3180063|NCT01339221||Cohort B|Children hospitalized for severe gastroenteritis in the study hospitals and tested positive for rotavirus
3180064|NCT01339208|Experimental|Telemedicine Diabetes Intervention|
3180065|NCT01339195|Experimental|Behavioral|Behavioral: French adaptation of NINDS-Canadian Stroke Network battery
3180066|NCT01339182|Experimental|Pegylated-Somatropin, 10mcg/kg|
3180067|NCT01339182|Experimental|Pegylated-Somatropin, 30mcg/kg|
3180068|NCT01339182|Experimental|Pegylated-Somatropin, 60mcg/kg|
3180069|NCT01339182|Experimental|Pegylated-Somatropin, 120mcg/kg|
3180070|NCT01339182|Experimental|Pegylated-Somatropin, 200mcg/kg|
3180071|NCT01339169|Experimental|YF476 treatment|
3180072|NCT01339156|Experimental|P3914|
3180073|NCT01339156|Placebo Comparator|Placebo|
3180074|NCT01339143|Active Comparator|Pioglitazone|pioglitazone: 15mg, QD, PO, 16 weeks
3180075|NCT01339143|Experimental|vildagliptin|vildagliptin 50mg,BID,PO,16 weeks
3180076|NCT01339130|Other|behavioral and physiological tests|Computerized tests and Electrophysiological measurements
3180077|NCT01339117|Experimental|High fermentable substrate diet|High fermentable substrate diet provided for two days
3180078|NCT01339117|Experimental|Low fermentable substrate diet|Low fermentable substrate diet provided for two days
3180079|NCT01339104|Experimental|Regorafenib|
3180080|NCT01339091|Experimental|Dalbavancin|
3180081|NCT01339091|Active Comparator|Vancomycin with possible switch to oral linezolid|
3180082|NCT01339078|Active Comparator|Plastic stenting|Patients will be randomized towards plastic stenting.
3180083|NCT01339078|Experimental|Kaffes stenting|Patients will be randomized towards Kaffes stenting.
3180084|NCT01339065|Active Comparator|Ketamine|will be given low sub-anesthetic doses of Ketamine 0.5mg/kg.
3180085|NCT01339065|Placebo Comparator|Placebo|will get placebo treatment
3180175|NCT01338506|Experimental|COPE Therapy|Combined prolonged exposure therapy for PTSD with cognitive behavioral therapy for substance use.
3180176|NCT01338506|Active Comparator|Treatment as usual|Current standard treatment available through the Department of Veteran's Affairs.
3180086|NCT01339052|Experimental|Cohort 1: Surgical subjects|"Subjects scheduled for surgery~BKM120: 100 mg once daily, orally, for 8-12 days prior to surgery~Surgery: Surgery~BKM120: 100 mg once daily, orally, for 28-day cycles~Patients continued treatment until disease progression or unacceptable toxicity."
3180087|NCT01339052|Experimental|Cohort 2: Non-surgical subjects|"Subjects not candidates for surgery~BKM120: 100 mg once daily, orally, for 28-day cycles~Patients continued treatment until disease progression or unacceptable toxicity."
3180088|NCT01339039|Experimental|Part 1|Maximum Tolerated Dose Determination of Plerixafor (3 weeks on, 1 week off) and Bevacizumab (every 2 weeks)
3180089|NCT01339039|Experimental|Part 2|Surgical Arm: Safety evaluation of Plerixafor (3 weeks on, 1 week off) and Bevacizumab (every 2 weeks)
3180090|NCT01339039|Experimental|Part 3|Safety and tolerability of Plerixafor (daily) at MTD dose from Part 1 and Bevacizumab (every 2 weeks)
3180091|NCT01339026|Active Comparator|Prasugrel|Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
3180092|NCT01339026|Active Comparator|Clopidogrel|Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
3180093|NCT01339013|Active Comparator|AnaConDa|
3180094|NCT01339000|Experimental|Arm A -Sequence 1 Immunizations|Receive vaccine of Sequence 1 first, then vaccines of Sequence 2, 7 weeks later, after receiving interleukin-7 (IL-7)
3180095|NCT01339000|Experimental|Arm B - Sequence 2 Immunizations|Receive vaccines of Sequence 2 first then vaccines of Sequence1, 7 weeks later, after receiving IL-7
3180096|NCT01338987|Active Comparator|NIH Arm 1a|Lupron and first transplant and FLT imaging at NIH
3180097|NCT01338987|Active Comparator|NIH Arm 1b|No lupron (men only are randomized) with first transplant and FLT imaging at NIH
3180098|NCT01338987|Experimental|CNMC arm|FLT scan alone in children at CNMC only
3180099|NCT01338987|Experimental|NIH Arm 2|Second transplant with lupron and FLT imaging
3180100|NCT01338987|Active Comparator|UOK Arm 1a|Lupron and first transplant at UOK
3180101|NCT01338987|Active Comparator|UOK Arm 1b|No lupron (men only are randomized) with first transplant at UOK
3180102|NCT01338987|Experimental|Arm 3|Healthy Volunteer
3180103|NCT01338961|No Intervention|Normothermic CPB|Standard management. Patients will be kept at normothermia throughout the procedure (>36oC).
3180104|NCT01338961|Active Comparator|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC.
3180105|NCT01338935|Experimental|Part I|Ascending dose tolerance, PK, and estimation of ED95 for CW 002
3180106|NCT01338935|Experimental|Part II|Safety, efficacy and PK of increasing bolus doses and infusions of CW 002, and exploration of Neostigmine reversal
3180107|NCT01338935|Experimental|Part III|Intubation with CW 002 and Neostigmine reversal
3180108|NCT01338922|Experimental|Insulin pump therapy (CSII)|Continuous subcutaneous insulin infusion therapy using different devices with marketing approval and different insulins
3180109|NCT01338922|Active Comparator|Multiple daily injection therapy (MDI)|Multiple daily injection therapy using different devices with marketing approval and different insulin types
3180110|NCT01338909|Experimental|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
3180111|NCT01338909|Active Comparator|Clopidogrel|Clopidogrel 150mg/day starting from Day 1 until Day 5
3180112|NCT01338896|Experimental|Sequence A-B|4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 h, test product PR 2.2.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 h reference patch PR 2.1.1)
3180113|NCT01338896|Experimental|Sequence B-A|4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 h reference patch PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 h, test product PR 2.2.1)
3180114|NCT01338883|Experimental|CVC 100 mg + Truvada|
3180115|NCT01338883|Experimental|CVC 200 mg + Truvada|
3180116|NCT01338883|Active Comparator|Sustiva + Truvada|
3180117|NCT01338870|Placebo Comparator|Placebo|Placebo for PF-04991532 and sitagliptin
3180118|NCT01338870|Experimental|25 mg PF-04991532|
3180119|NCT01338870|Experimental|75 mg PF-04991532|
3180120|NCT01338870|Experimental|150 mg PF-04991532|
3180121|NCT01338870|Experimental|300 mg PF-04991532|
3180122|NCT01338870|Active Comparator|Sitagliptin 100 mg|
3180123|NCT01338857|Experimental|Sorafenib (Nexavar)|Sorafenib will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.
3180124|NCT01338844|Experimental|D-Chiro-inositol|Patients will receive 1.2g/day of D-chiro-inositol
3180125|NCT01338844|Active Comparator|Myo-inositol|Patients will receive 4g/day of myo-inositol
3180126|NCT01338831|Experimental|Breast & Prostate Cancer Group|Dose Escalation
3180127|NCT01338831|Experimental|Breast Cancer Group|Dose Expansion
3180128|NCT01338831|Experimental|Prostate Cancer Group|Dose Expansion
3180129|NCT01338831|Experimental|Uterine Leiomyoma Group|Dose Expansion
3180130|NCT01338818|Experimental|Ritalin LA|All participants started with Ritalin LA 20 mg/day and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 40, 60 or 80 mg/day).
3180131|NCT01338805|Experimental|BGG492|
3180132|NCT01338792|Experimental|Treatment (chemotherapy and enzyme inhibitor)|Patients receive oxaliplatin IV over 2 hours and pemetrexed disodium IV on day 1. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
3180133|NCT01338779||Group 1 - kidney tolerant|Renal allograft recipients showing functional tolerance (normal and stable renal function) after discontinuation of immunosuppressive medications for at least 1 year (or based on the investigator's discretion).
3180177|NCT01338493||lumbar spinal arthroplasty + Maverick™|Patients requiring total disc replacement
3180178|NCT01338480|Experimental|video|Participants in the intervention group watched an educational video illustrating informed consent information
3180179|NCT01338480|No Intervention|control|Participants in the control group read an informed consent document.
3180134|NCT01338779||Group 2 - acceptor|Enrollment for group 2 was closed. Renal transplant recipients with functioning allografts (not on dialysis) who had not received immunosuppressive medications for at least 1 year (or at investigator's discretion) but who had moderately impaired or gradually deteriorating renal function, defined as creatinine clearance (CrCl) < 40 mL/min and/or creatinine > 50% above baseline value, and thus did not qualify for group 1.
3180135|NCT01338779||Group 3 - kidney graft loss|Enrollment for group 3 is closed. These were renal transplant recipients who had subsequently rejected and lost function of their transplanted kidney.
3180136|NCT01338779||Group 4 - kidney monotherapy|Renal transplant recipients showing stable and normal renal function after receiving only prednisone 10 mg/day for at least 1 year (or based on the investigator's discretion).
3180137|NCT01338779||Group 5 - kidney standard immunotherapy|Enrollment for group 5 is closed. Stable renal transplant recipients currently on standard immunosuppression.
3180138|NCT01338779||Group 6 - kidney chronic rejector|Enrollment for group 6 is closed. Chronic allograft nephropathy group.
3180139|NCT01338779||Group 7 - kidney identical twin|Enrollment for group 7 is closed.
3180140|NCT01338779||Group 8 - living kidney donors|Corresponding to recipients in group 1 or 4.
3180141|NCT01338779||Group 9 - healthy controls|Enrollment for group 9 is closed.
3180142|NCT01338779||Group 10 - liver tolerant|Enrollment for group 10 is closed. Liver allograft recipients with functional tolerance (stable and normal liver function) after cessation of immunosuppressive medications for at least three years (or at investigator's discretion).
3180143|NCT01338779||Group 11 - liver standard immunotherapy|Enrollment for group 11 is closed. Subjects with a liver transplant who never had an attempt made to discontinue gradually their immunosuppression and who are currently taking standard immunosuppressive medications and have stable and normal liver allograft function after at least 1 year of receiving these drugs.
3180144|NCT01338766|Experimental|Surgery|Decompression using the iO-Flex® system
3180145|NCT01338740||Switch from Adalimumab to Infliximab|Moderately to severely active Crohn's disease patients with primary non-response or loss of response to Adalimumab, will switch to Infliximab.
3180146|NCT01338727|Experimental|Breastfeeding Peer Counseling|
3180147|NCT01338727|No Intervention|Standard Care|
3180148|NCT01338714|Experimental|A foumula|Compound Herbal Formula (RHD-1)
3180149|NCT01338714|Placebo Comparator|B formula|dilute Compound Herbal Formula
3180150|NCT01338701|Experimental|Auricular (Ear) Acupuncture|Auricular (Ear) Acupuncture is administered in a step-wise, algorithmic acupuncture approach in which needles are inserted at specific auricular landmarks. The sequence and location of needled points is determined by the participant's severity of headache pain at presentation and response to needling. Between six and nine points are needled in each treatment session depending on the individual's response (i.e., a decrease or persistence of headache pain). In-dwelling ASP needles are inserted at the end of each session. Participants are instructed to remove the needles after 3 days, or sooner if pain or redness developed at a needle site. Ten 45-minute acupuncture treatment sessions are administered over 6 weeks.
3180151|NCT01338701|Experimental|Traditional Chinese Acupuncture (TCA)|A semi-standardized form of Traditional Chinese Acupuncture (TCA) is administered, incorporating the insertion of up to 22 acupuncture needles associated with each individual participant's: (1) primary headache pattern (up to three pairs of points); (2) secondary headache pattern (up to 2 pairs of points); (3) Ah-Shi or tender points (up to 4 points); (4) constitutional points (source points on two meridians); and, (5) up to 2 pairs of additional points from a selected list. Point selection was reassessed every two weeks per TCM diagnostic and treatment principles. While the majority of points were located on the limbs, points also included local points of tenderness to the head, as well as the front and back of the torso. Ten 60-minute TCA sessions are administered over 6 weeks.
3180152|NCT01338701|Other|Usual Care|All study participants continue to receive routine usual care for their TBI, headaches and associated symptoms as determined by their clinical team.
3180153|NCT01338688||Td ,Td and TIG|
3180154|NCT01338675|Experimental|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
3180155|NCT01338662||Group A-1|"study enroll number 3n+1 (N=0,1,2...)~initial treatment- amantadine~add levodopa when the patient become to need further treatment."
3180156|NCT01338662||Group A-2|"study enroll number 3n+2 (N=0,1,2...)~initial treatment: amantadine~add dopamine agonist when the patient become to need further treatment."
3180157|NCT01338662||Group B|"study enroll number 3n+3 (N=0,1,2...)~initial treatment: dopamine agonist~add levodopa when the patient become to need further treatment. but cannot use amantadine"
3180158|NCT01338649|Active Comparator|Bright White|Exposure to bright white light treatment.
3180159|NCT01338649|Placebo Comparator|Dim red light|Exposure to dim red light treatment.
3180160|NCT01338636|Other|Exercise-induced PAH|Open-label ambrisentan
3180161|NCT01338623|Experimental|Tansulosine|
3180162|NCT01338610|Experimental|ESBA105|ESBA105 ophthalmic solution, 1 drop in each eye 3 times per day for 4 weeks
3180163|NCT01338610|Placebo Comparator|Vehicle|ESBA105 vehicle, 1 drop in each eye 3 times per day for 4 weeks
3180164|NCT01338597|Experimental|standard|3 trocars are needed. two in the circumareolar region and one in the parasternal region. the dissection area begins from the trocar site and extends to the neck.
3180165|NCT01338597|Experimental|limited dissection|the dissection is reduced by creating a long tunnel from the trocar site and the dissection area confined in the upper chest wall and in the neck.
3180166|NCT01338584|Experimental|Pelvic floor muscle training, post prostatectomy|Pelvic floor muscle training will be taught on the day of admission
3180167|NCT01338571||Healthly children|Children will be given yogurt twice a day for four weeks. The dose for an adult is 8 ounces of yogurt twice a day. The dose will be scaled to the children based upon surface area dosing charts, but will not exceed a resistant starch load of 1 gram per year of age plus 10 grams10.
3180168|NCT01338558|Experimental|K-RAS mutated|
3180169|NCT01338558|Experimental|K-RAS native A|
3180170|NCT01338558|Active Comparator|K-RAS native B|
3180171|NCT01338545||Cohort|
3180172|NCT01338532|Active Comparator|Supervised exercise + patient education|
3180173|NCT01338532|Active Comparator|Patient education|
3180180|NCT01338467|Experimental|EYEOP Treatment|Open label, all subject treated by the EYEOP device
3180181|NCT01338454|Active Comparator|tranexamic acid|TA administered intravenously over a 5 min period at delivery of the anterior shoulder
3180182|NCT01338454|No Intervention|saline|10 mL of saline was administered intravenously over a 5 min period at delivery of the anterior shoulder
3180183|NCT01338441|Experimental|Erythromycin|
3180184|NCT01338441|Placebo Comparator|Placebo|
3180185|NCT01338428|Active Comparator|Brochure|
3180186|NCT01338428|Experimental|Enhanced AAA Sexual Assault Education|
3180187|NCT01338415|Experimental|bosentan 2mg/kg b.i.d.|Patients who received 2 mg/kg bosentan twcie daily (b.i.d.) during the FUTURE 3 core study and continued with the same dose regimen during the extension study
3180188|NCT01338415|Experimental|bosentan 2mg/kg t.i.d.|Patients who received 2 mg/kg bosentan 3 times a day (t.i.d.) during the FUTURE 3 core study and continued with the same dose regimen during the extension study
3180189|NCT01338402|Other|AIR OPTIX® AQUA|Lotrafilcon B contact lenses worn in both eyes on a daily wear basis for one week in Phase 1.
3180190|NCT01338402|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color randomly assigned to one eye, with phemfilcon A contact lens with color in the fellow eye for contralateral wear. Both products worn on a daily wear basis for 4 weeks in Phase 2. A replacement phemfilcon A lens was dispensed at the Week 2 visit.
3180191|NCT01338402|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color randomly assigned to one eye, with lotrafilcon B contact lens with color in the fellow eye for contralateral wear. Both products worn on a daily wear basis for 4 weeks in Phase 2. A replacement phemfilcon A lens was dispensed at the Week 2 visit.
3180192|NCT01338389|Experimental|CITICOLINE|Daily oral administration of 800 mg citicoline
3180193|NCT01338389|Placebo Comparator|Placebo|Daily oral administration of placebo
3180194|NCT01338376|Experimental|Structured Education Group|Subjects received structured diabetes education
3180195|NCT01338376|Active Comparator|Conventional Care Group:|Subjects received conventional diabetes education
3180196|NCT01338363||All first time users of esomeprazole|
3180197|NCT01338363||All first time users of other PPIs|
3180198|NCT01338363||All first time users of H2-receptor antagonists|
3180199|NCT01338350|Experimental|1|
3180200|NCT01338350|Placebo Comparator|2|
3180201|NCT01338337|No Intervention|Support treatment|Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed.
3180202|NCT01338337|Experimental|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
3180203|NCT01338311|Active Comparator|salbutamol|
3180204|NCT01338311|Placebo Comparator|placebo|200mcg twice daily for a total of 7 doses
3180205|NCT01338298|Active Comparator|Aripiprazole|
3180206|NCT01338298|Placebo Comparator|Placebo|
3180207|NCT01338142|Placebo Comparator|CCC|Crystalline calcium carbonate (CCC)
3180208|NCT01338142|Experimental|ACC|Amorphous calcium carbonate (ACC)
3180209|NCT01338129|Experimental|vitamin c|administration of vitamin c for 45 days following ankle fracture operation
3180210|NCT01338129|Placebo Comparator|placebo|placebo pills
3180211|NCT01338116|Experimental|Management by TREAT/PCR|The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly.
3180212|NCT01338116|No Intervention|Usual management|Patients will be managed by physicians as in regular clinical practice.
3180213|NCT01338103|Experimental|Rituximab|
3180214|NCT01338090||89Zr-bevacizumab|
3180215|NCT01338077|Experimental|Sodium alginate|Oral suspension, 50 mg/ml
3180216|NCT01338077|Active Comparator|Omeprazole|20 mg/cap
3180217|NCT01338064||exposed workers|At least six months of occupational exposure to Caesar stone
3180218|NCT01338025|Active Comparator|Arm A, non-suppressive HAART regimen|"In Step 1, subjects were randomized to continue their non-suppressive HAART regimen.~In Step 2, subjects either began a new HAART regimen, continued randomized treatment, or discontinued therapy while remaining on follow-up, as decided by their provider."
3180219|NCT01338025|Active Comparator|Arm B, 3TC or FTC monotherapy|"In step 1, subjects were randomized to receive 3TC or FTC (the choice of 3TC or FTC was left to the provider).~In Step 2, subjects either began a new HAART regimen, continued randomized treatment, or discontinued therapy while remaining on follow-up, as decided by their provider."
3180220|NCT01338012|Experimental|sipuleucel-T|Men with metastatic castrate resistant prostate cancer previously treated with sipuleucel-T in the androgen dependent setting in the Dendreon P-11 study. Subjects received one infusion of sipuleucel-T every two weeks for for a total of three infusions.
3180221|NCT01337999||HE-4 levels, healthy premenopausal women|
3180222|NCT01337986|Active Comparator|Group A: Dalfampridine/Placebo|
3180223|NCT01337986|Active Comparator|Group B: Placebo/Dalfampridine|
3180224|NCT01337973|Experimental|Arm 1: MI-CBT|MI-CBT (six sessions during acute treatment phase integrating motivational interviewing and cognitive behavioral approaches)
3180225|NCT01337973|Experimental|Arm 2: MI-CBT+CC|MI-CBT+CC (acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention)
3180226|NCT01337973|Active Comparator|Arm 3: E-TAU|E-TAU (enhanced treatment as usual - includes brief session and provision of resources)
3180305|NCT01337440|Active Comparator|UDCA pretreatment|"Ursodeoxycholic Acid (UDCA) for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
3180227|NCT01337960|Experimental|Arm 1|Seated robot training group. Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
3180228|NCT01337960|Experimental|Arm 2|Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
3180229|NCT01337960|Active Comparator|Arm 3|Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
3180230|NCT01337947||exercise training|12 weeks of exercise treatment/program for DM1 subjects
3180231|NCT01337934|Placebo Comparator|Lactated Ringer|Patients randomized for this group will receive 500 ml of lactated Ringer solution in early phase of sepsis or septic shock (less than six hour from sepsis onset) if mean arterial pressure was under 65mmHg, or blood lactate concentration higher than 4 mmol/L or base excess under - 4mmol/L until the target of central venous pressure of 8 mmHg or higher or recovery of hypotension.
3180232|NCT01337934|Active Comparator|Albumin|Patients randomized for Albumin group will receive 500 ml of 4% Albumin solution in early phase of sepsis (less than six hour from sepsis onset) if mean arterial pressure was under 65mmHg or blood lactate concentration higher than 4 mmol/L or base excess under - 4mmol/L until the target of central venous pressure of 8 mmHg or higher or recovery of hypotension.
3180233|NCT01337921|Experimental|Multi-strain Synbiotic|Multi-strain probiotic with prebiotics
3180234|NCT01337921|Active Comparator|Multi-strain Probiotic|Multi-strain Probiotic without prebiotics.
3180235|NCT01337895|Active Comparator|Lifestyle counselling|These participants will be assigned to a 500 kcal/day energy-restricted diet that is low in dairy products (no more than 1 serving per day).
3180236|NCT01337895|Experimental|High dairy|These participants will be assigned a 500 kcal/day energy-restricted diet that is high in dairy (4 or more servings per day).
3180237|NCT01337882|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust (approximate PM10 concentration 300 mcg/m3) during intermittent exercise
3180238|NCT01337882|Experimental|Biodiesel exhaust exposure|1 hour exposure to dilute biodiesel exhaust (approximate PM10 concentration 300 mcg/m3) during intermittent exercise
3180239|NCT01337869|Active Comparator|Bascom Cleft Lift Technique|
3180240|NCT01337869|Active Comparator|Limberg Flap Technique|
3180241|NCT01337856|Other|WHO alcohol handrub protocol|handrubbing with alcohol using the standard 7-step technique (WHO alcohol handrub protocol)
3180242|NCT01337856|Other|CDC alcohol handrub protocol|Handrubbing with alcohol covering all hand surfaces in no particular order (CDC alcohol handrub protocol)
3180243|NCT01337856|Other|Chlorhexidine handwashing|chlorhexidine handwashing using the standard 7-step technique (WHO handwashing protocol)
3180244|NCT01337843|Active Comparator|Control Group|Control Group participants will receive a well-regarded book for back pain patients.
3180245|NCT01337843|Experimental|Wellnes Workbook|Participants will receive the Wellness Workbook, a web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase their physical activity and manage stress with relaxation and mindfulness training
3180246|NCT01337830|Experimental|Ariva® Silver Wintergreen|Subjects allow study product lozenge to dissolve in the mouth, smoke a cigarette, then answer questionnaires about the effect of the product on both their desire to smoke and on cigarette taste.
3180247|NCT01337830|Active Comparator|Silver Wintergreen|Subjects allow comparator product lozenge to dissolve in the mouth, smoke a cigarette, then answer questionnaires about the effect of the product on both their desire to smoke and on cigarette taste.
3180248|NCT01337817|Experimental|Ariva Silver Wintergreen|Subjects allow study product lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
3180249|NCT01337817|Active Comparator|Ariva Wintergreen|Subjects allow study comparator lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
3180250|NCT01337804|Experimental|Zegerid-Prilosec|Participants receive Zegerid in Period 1 and Prilosec in Period 2, with a 10- to 21-day washout between study drug administrations.
3180251|NCT01337804|Experimental|Prilosec-Zegerid|Participants receive Prilosec in Period 1 and Zegerid in Period 2, with a 10- to 21-day washout between study drug administrations.
3180252|NCT01337791|No Intervention|control|
3180253|NCT01337791|No Intervention|telbivudine|
3180254|NCT01337778|Active Comparator|Primary Care for DILs|Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced gender-based violence. A comprehensive health examination for mothers-in-law will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
3180306|NCT01337440|Active Comparator|Sitagliptin pretreatment|"Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
3180307|NCT01337427|Placebo Comparator|Placebo for 48 weeks, BIIB017 for 48 weeks|Placebo every 2 weeks for 48 weeks followed by 125 mcg BIIB017 SC every 2 or 4 weeks for 48 weeks.
3180308|NCT01337427|Experimental|BIIB017 every 2 weeks for 96 weeks|125 mcg BIIB017 SC every 2 weeks for 96 weeks.
3180309|NCT01337427|Experimental|BIIB017 every 4 weeks for 96 weeks|125 mcg BIIB017 SC every 4 weeks for 96 weeks.
3180310|NCT01337414|Experimental|VMS diary booklet|
3180255|NCT01337778|Experimental|Standard Care plus Dil Mil Intervention|The Dil Mil intervention will be implemented during the second and third trimesters of the daughter-in-law's (DILs) pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with mothers-in-law (MILs), and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce gender-based violence (GBV) and protect and promote their family's health.
3180256|NCT01337765|Experimental|BEZ235 + MEK162|
3180257|NCT01337752|Experimental|BHQ880|
3180258|NCT01337752|Placebo Comparator|BHQ880 Placebo|
3180259|NCT01337739|Placebo Comparator|Placebo Comparator|Continuous infusion of placebo during operative procedure
3180260|NCT01337739|Active Comparator|Active Comparator|Administration of Dexmedetomidine
3180261|NCT01337726|Active Comparator|Illness Management Only|
3180262|NCT01337726|Experimental|Combined Psychotherapy & Illness Management|
3180263|NCT01337713|Experimental|Swedish Massage|
3180264|NCT01337713|Sham Comparator|Light Touch|
3180265|NCT01337700|Experimental|Milnacipran|
3180266|NCT01337700|Placebo Comparator|Placebo|
3180267|NCT01337687|Experimental|Oxytocin|
3180268|NCT01337687|Placebo Comparator|Placebo|
3180269|NCT01337674|Experimental|Panel A: MK-4618 + Met → PBO + Met|Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.
3180270|NCT01337674|Experimental|Panel A: PBO + Met → MK-4618 + Met|Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.
3180271|NCT01337674|Experimental|Panel B: MK-4618 + Amlo → PBO + Amlo|Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.
3180272|NCT01337674|Experimental|Panel B: PBO + Amlo → MK-4618 + Amlo|Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.
3180273|NCT01337661||COPD subjects|Adult male and female subjects with COPD
3180274|NCT01337648||TBI prior to stem cell transplantation|
3180275|NCT01337635|Active Comparator|Standard dose vitamin D|Treatment with cholecalciferol 400 IU daily at home.
3180276|NCT01337635|Active Comparator|High dose vitamin D|Treatment with ergocalciferol 300,000 IU (6 capsules of 50,000 IU) as a single oral dose observed in clinic.
3180277|NCT01337622|Experimental|No routine check for gastric residuals|
3180278|NCT01337622|Active Comparator|Routine check for gastric residuals|
3180279|NCT01337609|Experimental|GanedenBC30|Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.
3180280|NCT01337609|Placebo Comparator|Sugar pill|Arm 2 will take placebo (sugar pill) for 60 days.
3180281|NCT01337609|Other|Ganeden BC30, Sugar pill|Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.
3180282|NCT01337596|Experimental|Single dose 1 mg LY2951742|Administered single subcutaneous injection
3180283|NCT01337596|Experimental|Single dose 5 mg LY2951742|Administered single subcutaneous injection
3180284|NCT01337596|Experimental|Single dose 25 mg LY2951742|Administered single subcutaneous injection
3180285|NCT01337596|Experimental|Single dose 75 mg LY2951742|Administered single subcutaneous injection
3180286|NCT01337596|Experimental|Single dose 200 mg LY2951742|Administered single subcutaneous injection
3180287|NCT01337596|Experimental|Single dose 600 mg LY2951742|Administered single subcutaneous injection
3180288|NCT01337596|Placebo Comparator|Single dose placebo|Administered single subcutaneous injection
3180289|NCT01337596|Placebo Comparator|Multiple dose placebo|Administered subcutaneously every 2 weeks for 6 weeks (4 doses)
3180290|NCT01337596|Experimental|150 mg LY2951742|Administered subcutaneously every 2 weeks for 6 weeks (4 doses)
3180291|NCT01337583|Experimental|Dapivirine|Vaginal ring containing 25mg of dapivirine
3180292|NCT01337583|Placebo Comparator|Placebo Ring|Vaginal ring containing no drug substance
3180293|NCT01337570|Experimental|Dapivirine|Vaginal ring containing 25mg of dapivirine
3180294|NCT01337570|Placebo Comparator|Placebo Ring|Vaginal ring containing no drug substance
3180295|NCT01337557|Experimental|Bepotastine|
3180296|NCT01337544|Experimental|IL-15 STIMULATED NK CELLS|
3180297|NCT01337531|Experimental|gonadotropin|recombinant or highly purified gonadotropin
3180298|NCT01337531|Active Comparator|Gonadotropins|recombinant versus highly purified gonadotropin
3180299|NCT01337518|Experimental|EZN-4176|
3180300|NCT01337505|Experimental|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 doxorubicin equivalents of 165, 260, and 325 mg/m2)will be administered as a 30 minute IVI on Day 1 of each cycle.
3180301|NCT01337492|Experimental|Sorafenib|
3180302|NCT01337479||Participants of specific phase III entecavir studies|Those who participated in the specific Phase III entecavir studies as described; all had Hepatitis B infections
3180303|NCT01337466|Experimental|[124I]FIAU|single dose study of [124I]FIAU in healthy volunteers or subjects with prosthetic joint infection who will undergo PET-CT scanning
3180304|NCT01337453||Flu-like symtoms, incidence|The frequency of FLS will be estimated by number of patients and number of Botox treatments.
3180311|NCT01337414|Active Comparator|Usual Care (e.g. Amsler grid monitoring)|
3180312|NCT01337401|Experimental|Blinded Cediranib|
3180317|NCT01337362|Active Comparator|Patients with hypoglycemia awareness|Patients who have symptoms when the blood sugar level is low
3180318|NCT01337362|Experimental|patients with hypoglycaemic unawareness.|Patients who do not feel any symptoms when the blood sugar levels are low
3180319|NCT01337349|Placebo Comparator|Sugar Pill|Placebo control Group with sugar pill three times daily for 6 months
3180320|NCT01337349|Experimental|Pentoxifylline|Pentoxifylline 400mg tablets to be taken three times daily for 6 months
3180321|NCT01337336||COPD patients with comorbid depression/anxiety|Patients aged 40 and over with COPD and comorbid depression/anxiety. Managed care enrolees (aged >40 years) having newly initiated drug therapy with FSC or AC during the identification period (01/01/2004 to 06/30/2008) to treat COPD with a medical or pharmacy claim for depression before and 60 days post index date were the target population. The first fill date of FSC or AC was the index date.
3180322|NCT01337323||New prescription for fluticasone furoate nasal spray|patients receiving their first prescription for fluticasone furoate nasal spray and who have active seasonal allergic rhinitis with a history of using another intranasal steriod (INS) and other concomitant allergic rhinitis medications to treat their seasonal allergy symptoms.
3180323|NCT01337310|Experimental|Tesetaxel|Tesetaxel administered orally once every 21 days for at least 2 cycles
3180324|NCT01337297|Placebo Comparator|sham-tDCS|the electrodes are positioned in the same manner as the active-tDCS, activated for 20 s (time to climb ramp of the current until reach the current intensity used in the experiment), enough to produce the sensation of itch, and turned off until the end of the session.
3180325|NCT01337297|Experimental|active-tDCS|low-intensity transcranial Direct Current Stimulation (tDCS)applied over the dorsolateral prefrontal cortex
3180326|NCT01337271|Active Comparator|PSV|
3180327|NCT01337271|Experimental|NAVA|
3180328|NCT01337258||Men at increased risk for Prostate Cancer (PCA)|
3180329|NCT01337245|Experimental|Antivenom|For comparison with historical mortality rate, all patients prospectively enrolled will receive antivenom (Snake [Micrurus] North American immune F(ab')2 Equine) for treatment of coral snake bite.
3180330|NCT01337232|Active Comparator|1 session per week|
3180331|NCT01337232|Experimental|2 sessions per week|
3180332|NCT01337219|Other|Arm A|experimental treatment (Nebcinal/Aeroneb Idehaler pocket) - 6day-wash out period - standard treatment (Tobi/Pari LC Plus)
3180333|NCT01337219|Other|Arm B|standard treatment (Tobi/Pari LC Plus) - 6day-wash out period - experimental treatment (Nebcinal/Aeroneb Idehaler)
3180334|NCT01337206|Experimental|Stenting Arm|Stenting Arm
3180335|NCT01337206|Active Comparator|Dilation Arm|Dilation Arm
3180336|NCT01337193|Active Comparator|Pelvic floor muscle exercises|Three pelvic floor muscle exercises will be performed with verbal cueing from the instructor.
3180337|NCT01337193|Experimental|Pelvic floor exercises with biofeedback|Pelvic floor exercises will be performed with biobeedback cueing.
3180338|NCT01337180||Main study group|"Inclusion criteria: Employment at one of the plants (SiC I) and (SiC II) in Porsgrunn. Both administrative/office workers and workers in the production and maintenance departments will be invited to participate. Non-smokers and smokers and male and female workers will be included in the main study group (study A).~Sputum part of study: nonsmokers."
3180339|NCT01337167|Experimental|V419|V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.
3180340|NCT01337167|Active Comparator|Control|Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.
3180341|NCT01337154|Experimental|Tamibarotene|Subjects will receive tamibarotene, 6 mg/m2, divided as twice daily orally starting 1 week before chemotherapy and continuing through all 6 cycles and through the duration of the study. Chemotherapy will include paclitaxel (IV; 200 mg/m2) and carboplatin (IV; AUC=6)administered once every 3 weeks for up to 6 cycles.
3180342|NCT01337154|Placebo Comparator|Placebo|Subjects will take an equal number of placebo tablets as the group receiving tamibarotene divided as twice daily orally, starting 1 week before chemotherapy and continuing through all 6 cycles and through the duration of the study. Paclitaxel (IV; 200 mg/m2) and carboplatin (IV; AUC=6) will be administered once every 3 weeks for up to 6 cycles.
3180343|NCT01337141|Experimental|Interventional telematic|80 patients will be included in this arm. They will receive 5 telematic visits (Telecare system) and 2 face to face visits.
3180344|NCT01337141|Other|Control|80 patients will be included in this arm. They will receive 7 face-to-face visits (not telematic).
3180345|NCT01337128|Experimental|Carotid endarterectomy (CEA)|Patients with carotid stenosis who are randomly assigned to a carotid endarterectomy.
3180346|NCT01337128|Experimental|Carotid Stenting (CAS)|Patients with carotid stenosis who are randomly assigned to a carotid stenting.
3180347|NCT01337128|No Intervention|matched control group|Matched control group.
3180348|NCT01337115|Active Comparator|Continuous femoral nerve block (CFNB)|A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
3180349|NCT01337115|Experimental|Single shot SNB plus CFNB|A single shot sciatic nerve block (SNB) is performed before surgery with 25ml of 0.2% ropivacaine in addition to the continuous femoral nerve block (CFNB) performed in the control group before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in Post anesthesia care unit (PACU) and maintained for 48h
3180350|NCT01337102|Other|Physician to receive results|Arm 1 Physician to receive the results of the Lung QoL scale
3180351|NCT01337102|Other|Physician Does Not Receive Results|Arm 2 Physician does not receive the results of the Lung QoL scale
3180389|NCT01336816|Placebo Comparator|Placebo Wintergreen|Subjects allow study placebo lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
3180390|NCT01336803|Experimental|Feraheme|Intravenous injection of Feraheme, 5 mg Fe/kg
3180391|NCT01336803|Active Comparator|Control|MR imaging without Feraheme
3180352|NCT01337089|Experimental|Non-comparative, open-label Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray, in the morning and evening, up to a maximum of 10 sprays per day for 6 months. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligrams [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
3180353|NCT01337076|Other|cochlear implant|
3180354|NCT01337063|No Intervention|Pre-intervention|Usual care regarding medication reconciliation as currently practiced at each participating site.
3180355|NCT01337063|Experimental|Intervention|Improved medication reconciliation process using continuous quality improvement methods, mentored implementation, and an implementation guide.
3180356|NCT01337050|Experimental|A|PF-03446962
3180357|NCT01337037||standard VATS group|patients undergo standard VATS lobectomy using non-modified equipments,without limits of staples
3180358|NCT01337037||modified equipments group|patients undergo VATS lobectomy with modified VATS lobectomy equipments designed designed according to the experience of chinese lobectomy surgery: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.).
3180359|NCT01337037||less staples group|patients undergo VATS lobectomy with at most 4 staples used.
3180360|NCT01337037||open group|patients undergo lobectomy by thoracotomy approach
3180361|NCT01337024||Control group|Healthy volunteers, examined with ECG without any treatment (controls)
3180362|NCT01337024||100 BoNT/A|patients with neurogenic detrusor overactivity, examined with ECG, injection of 100 units BoNT/A
3180363|NCT01337024||300 BoNT/A|patients with neurogenic detrusor overactivity, examined with ECG, injection of 300 units BoNT/A
3180364|NCT01337011|Experimental|intra-coronary administration|Application of stem cells using the intra-coronary route.
3180365|NCT01337011|Experimental|intra-myocardial administration|Application of stem cells using the intra-myocardial route.
3180366|NCT01336972|Experimental|Group A - eGFR > 60 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM [8 hours later]) to the maximally tolerated dose.
3180367|NCT01336972|Experimental|Group B - eGFR 30 to 60 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM [8 hours later]) to the maximally tolerated dose.
3180368|NCT01336972|Experimental|Group C - eGFR < 30 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM [8 hours later]) to the maximally tolerated dose.
3180369|NCT01336959|Experimental|Open Label - BCT197|
3180370|NCT01336959|Experimental|Randomized double-blind BCT197|
3180371|NCT01336959|Placebo Comparator|Randomized double-blind BCT 197 Placebo|
3180372|NCT01336946|Experimental|health promotion program|Psycho education and behavioural group sessions and supervised walking sessions will be performed.
3180373|NCT01336946|No Intervention|Control group|No intervention will be performed in this control group.
3180374|NCT01336933|Experimental|Treatment|"A Treatment: Cyclophosphamide,Etoposide, Vincristine and Prednisone (CEOP) B Treatment: Pralatrexate (P)~A cycles (CEOP) of the treatment regimen are 14 days, followed by  B cycles (P) which are 21 days, followed by 7 days of rest for a total of 42 days per course, unless criteria are met for stopping or holding treatment or to a maximum of 6 courses.~Patients with Complete Response (CR) or Partial Response (PR), per investigators discretion, may then undergo hematopoietic stem cell collection and administration of standard preparative regimen followed by hematopoietic stem cell transplantation."
3180375|NCT01336920|Experimental|Treatment (carfilzomib)|Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3180376|NCT01336907||naive CNV subjects|Newly diagnosed CNV, before any treatment (naïve)
3180377|NCT01336907||previously diagnosed CNV subjects|Previously diagnosed CNV if last treatment is older than 4 months (reactivated)
3180378|NCT01336894|Active Comparator|Arm I (SR+Brachytherapy)|Patients undergo sublobar resection comprising either a wedge resection or anatomical segmentectomy with or without intraoperative brachytherapy comprising an iodine I 125 implant at the resection margin.
3180379|NCT01336894|Experimental|Arm II (SBRT)|Patients undergo 3 fractions of stereotactic body radiation therapy at 2-8 days apart.
3180380|NCT01336881||Correlative (tissue analysis)|Archived tumor tissue samples are analyzed for hepatoblastoma and other liver tumor biomarkers by microRNA array profiling and exome sequencing. Results are then compared with patients' clinical data.
3180381|NCT01336855||HIV Positive|HIV-1 positive subjects
3180382|NCT01336855||HIV negative subjects|HIV-1 seronegative control group
3180383|NCT01336842|Experimental|Phase I dose-escalation|Drug: panobinostat Drug: cisplatin Drug: pemetrexed Other: Biomarker studies
3180384|NCT01336829|Experimental|001|ETR/telaprevir Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18 and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
3180385|NCT01336829|Experimental|002|telaprevir/ETR Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18 and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
3180386|NCT01336829|Experimental|003|TMC278/telaprevir Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18 and TMC278 25 mg once daily from Day 8 to Day 18.
3180387|NCT01336829|Experimental|004|telaprevir/TMC278 Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18 and TMC278 25 mg once daily from Day 8 to Day 18.
3180388|NCT01336816|Experimental|Ariva Silver Wintergreen|Subjects allow study product lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
3180392|NCT01336777||Insulin resistant group|there is no intervention
3180393|NCT01336777||Insulin sensitive group|There is no intervention
3180394|NCT01336764|Experimental|Active|individual coping self-statements and stimulus guided paced breathing.
3180395|NCT01336764|Sham Comparator|Control|Coping self statements and breathing retraining will be replaced with undirected passive behaviors such as listening to music.
3180396|NCT01336751|Experimental|Insulin glargine|"Lantus (insulin glargine) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by Self-monitoring blood glucose (SMBG).~The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator."
3180397|NCT01336751|Active Comparator|Lispro mix|"Humalog Mix 75/25 (lispro mix) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by self-monitoring blood glucose (SMBG).~The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator."
3180398|NCT01336738|Placebo Comparator|Placebo|Matching placebo for PF-04991532 and Sitagliptin
3180399|NCT01336738|Experimental|150 mg PF-04991532|
3180400|NCT01336738|Experimental|450 mg PF-04991532|
3180401|NCT01336738|Experimental|750 mg PF-04991532|
3180402|NCT01336738|Active Comparator|Sitagliptin 100 mg|
3180403|NCT01336725||Morbid obesity|All attending learning and mastery courses for persons with morbid obesity
3180404|NCT01336712|Experimental|Myeloablative Haploidentical Transplant|Haplo transplant
3180405|NCT01336699|Experimental|Cohort D|WRSs2 vaccine 1x10^6 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^6 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
3180406|NCT01336699|Experimental|Cohort E|WRSs2 vaccine 1x10^7 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^7 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
3180407|NCT01336699|Experimental|Cohort A|WRSs2 vaccine 1x10^3 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^3 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
3180408|NCT01336699|Experimental|Cohort B|WRSs2 vaccine 1x10^4 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^4 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
3180409|NCT01336699|Experimental|Cohort C|WRSs2 vaccine 1x10^5 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^5 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
3180410|NCT01336686|Experimental|Arhalofenate 400 mg|
3180411|NCT01336686|Experimental|Arhalofenate 600 mg|
3180412|NCT01336686|Placebo Comparator|Placebo|
3180413|NCT01336660|Experimental|Equine F(ab')2 antivenom|Intensive care support and Equine F(ab')2 antivenom
3180414|NCT01336660|Placebo Comparator|Placebo|Intensive care support plus placebo
3180415|NCT01336647|Experimental|Group A|Group A Low-Dose Ha44 Gel 0.37% w/w topically administered to head and scalp.Single application for 10 minutes.
3180416|NCT01336647|Experimental|Group B|Group B High-Dose Ha44 Gel 0.74% w/w. Topically administered to hair and scalp. Single application for 10 minutes of duration.
3180417|NCT01336647|Placebo Comparator|Group C|Group C Placebo/ vehicle Ha44 Gel. Topically administered to hair and scalp.Single application for 10 minutes of duration.
3180418|NCT01336634|Experimental|Cohort A|Subjects will receive dabrafenib 150mg BID and will continue on treatment until disease progression, death, or unacceptable adverse event. Subjects receiving and adequately tolerating dabrafenib as a single agent and who continue to meet the inclusion and exclusion criteria will have the option to switch to dabrafenib (150 mg BID) and trametinib (2 mg once daily) combination treatment within 4 weeks of radiologic disease progression with prior approval from a GSK medical monitor
3180419|NCT01336634|Experimental|Cohort B|Subjects enrolled in Cohort B will receive dabrafenib 150 mg BID in combination with trametinib 2 mg once daily and will continue on treatment until disease progression, death, or unacceptable adverse event.
3180420|NCT01336634|Experimental|Cohort C|Subjects enrolled in Cohort C will receive dabrafenib 150 mg BID in combination with trametinib 2 mg once daily and will continue on treatment until disease progression, death, or unacceptable adverse event
3180421|NCT01336621|Experimental|Retigabine IR|Open label flexible dose between 300 mg/day (Minimum) and 1200 mg/day (maximum).
3180422|NCT01336608|Experimental|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
3180423|NCT01336608|Experimental|vilanterol|Inhaled long acting beta-agonist
3180424|NCT01336608|Placebo Comparator|placebo|Placebo
3180425|NCT01336595|Experimental|Zirconium Femoral Component|Oxidized zirconium femoral component of Genesis II TKR system is used.
3180426|NCT01336595|Active Comparator|Cobalt Chrome|Cobalt-Chromium Femoral component of Genesis II system is used.
3180427|NCT01336582|Experimental|docetaxel|
3180428|NCT01336582|Active Comparator|Taxotere|Docetaxel-PM 75 mg/m2 (70 mg/m2 for age of ≥ 65) Taxotere 75mg/m2 (70 mg/m2 for age of ≥ 65)
3180429|NCT01336569|Experimental|DuoTrav|Travoprost 0.004%/timolol maleate 0.5% fixed combination, one drop to the study eye nightly for up to 6 weeks
3180430|NCT01336543|Experimental|Active Treatment|"ACTIVE TREATMENT intervention below:~NSCLC (Non-Small Cell Lung Cancer)~PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 60 mg/m2 days 1-3 and 29-31)~Radiation 59.4 Gy with 2 cycles of PE~(Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~(Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
3180431|NCT01336530|Experimental|Tepilta®|
3180432|NCT01336530|Active Comparator|Oxetacaine|
3180433|NCT01336530|Active Comparator|Antacids|
3180434|NCT01336530|Placebo Comparator|Placebo|
3180435|NCT01336465|Experimental|rhuMAb Beta7|
3180436|NCT01336465|Placebo Comparator|placebo|
3180531|NCT01335841|Active Comparator|2D and anatomical landmarks|
3180437|NCT01336452|Other|CCRTx|consecutive patients who plan to undertake CCRTx due to advanced hepatocellular carcinoma
3180438|NCT01336439|Active Comparator|M group|A total of 25U of botulinum toxin type A was injected into each side masseter muscle in this arm.
3180439|NCT01336439|Active Comparator|MT group|A total of 25U of botulinum toxin type A was injected into each side masseter and temporal muscle in this arm.
3180440|NCT01336413|Active Comparator|Arm 1|Pregnenolone
3180441|NCT01336413|Placebo Comparator|Arm 2|Placebo
3180442|NCT01336400||PGD-FISH|"Following couples opting for preimplantation genetic diagnosis on the basis of FISH:~couples suffering a complex chromosomal rearrangement (CCR)~couples with X-linked recessive disorders~couples that carry a balanced chromosomal rearrangement"
3180443|NCT01336400||PGD-PCR|"Following couples opting for preimplantation genetic diagnosis on the basis of PCR:~-couples at risk for the transmission of monogenic diseases"
3180444|NCT01336387|Experimental|Arm I (retinoid 9cUAB30)|Participants receive retinoid 9cUAB30* PO on days 1-28.
3180445|NCT01336387|Placebo Comparator|Arm II (placebo)|Participants receive placebo* PO on days 1-28.
3180446|NCT01336374||Greened Vacant Lot|A cluster of vacant lots is greened. People living around this area make up this cohort.
3180447|NCT01336374||Control Site|The control site is a cluster of vacant lots that will not be greened. The people living around these lots make up the control group.
3180448|NCT01336361||Physical Therapists|Physical Therapists who are members of the American Physical Therapy Association (APTA) and live in the United States .
3180449|NCT01336348|Experimental|prasugrel|Prasugrel 60 mg loading dose
3180450|NCT01336348|Active Comparator|Tirofiban|Tirofiban will be at a bolus only of 25uM or followed by 2 hour infusion
3180451|NCT01336335|Experimental|CPAP|OSA treatment with CPAP
3180452|NCT01336335|No Intervention|control|no intervention
3180453|NCT01336322|Active Comparator|Metformin|Metformin 850 mg bid
3180454|NCT01336322|Active Comparator|Sitagliptin|Sitagliptin 100 mg qd
3180455|NCT01336322|Active Comparator|Sitagliptin+Metformin|Sitagliptin 100 mg qd plus Metformin 850 mg bid
3180456|NCT01336309||Focus Group|We conducted three focus groups per site, at three sites, with around eight people each. These data were used to guide refinement and selection of the items we developed for Phase III data collection. We will administer the Yoga Research Tool.
3180457|NCT01336309||Cognitive Interviews|We conducted cognitive interviews at three different sites, with about ten in each group. These data were used to guide refinement and selection of the items we developed for Phase III data collection. We collected this data via a large, online survey and administered the Yoga Research Tool.
3180458|NCT01336309||Survey Prototype Administration|We administered a prototype of the study measure to a large group of yoga students, with about 450 total participants. These data were used to further inform the refinement and selection of items to be used in the final measure.
3180459|NCT01336309||Reliability and Validity Testing|We are conducting yoga classes at community partner facilities near each site, with about ten participants in each class. Participants at each class will complete the study measure and related questionnaires, in order to test the reliability and validity of the study measure.
3180460|NCT01336296|Active Comparator|Myfortic preload|Initiation of mycophenolic acid (Myfortic) 2 weeks prior to transplantation (with Simulect induction at time of transplant)
3180461|NCT01336296|Active Comparator|Myfortic standard|mycophenolic acid (Myfortic) at time of transplant with Thymoglobulin induction
3180462|NCT01336283|Active Comparator|COPD with emphysema|Analyze what type of training is more appropriate and beneficial as the patient characteristics that apply to you.
3180463|NCT01336283|Active Comparator|COPD non-emphysema|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
3180464|NCT01336270||MELANOMA 10mm|patients with a melanoma larger than 10mm or with cutaneous metastasis
3180465|NCT01336270||STAGE III MELANOMA|stage III melanoma patients who shall undergo a regional lymph node dissection
3180466|NCT01336270||SENTINEL NODE PROCEDURE|retrospective study of patients who underwent a sentinel node procedure
3180467|NCT01336270||STAGE IV MELANOMA|stage IV patients achieves of inoperable melanomas the stage(stadium) III or IV that must receive in treatment(processing) a chemotherapy (by the dacarbazine or by the cisplatin or by the inhibitor of B-raf) and carrier of at least two cutaneous metastases
3180468|NCT01336257|Experimental|Electronic Reminder|alert from SEBASTIAN decision support system
3180469|NCT01336257|No Intervention|control|
3180470|NCT01336244|Experimental|GLPG0778 ascending doses|Multiple ascending doses for 13 days, ranging from 50 mg twice daily upto a maximum to be determined during escalation.
3180471|NCT01336244|Placebo Comparator|Placebo|Twice daily for 13 days, matching the scheme of the multiple ascending dose.
3180472|NCT01336231||patients group|Patients with a metastatic kidney cancer and must beginning a treatment by antiangiogenic
3180473|NCT01336218|Experimental|1|Fostamatinib
3180474|NCT01336218|Experimental|2|Rifampicin
3180475|NCT01336205|Experimental|1|Oral Treatment
3180476|NCT01336205|Active Comparator|2|Oral treatment
3180477|NCT01336192|No Intervention|Best supportive care|Best supportive care
3180478|NCT01336192|Experimental|Maintenance gemcitabine|Maintenance therapy of gemcitabine alone
3180479|NCT01336179|Experimental|Miswak, dental plaque and gingivitis|
3180480|NCT01336179|Active Comparator|Toothbrush, dental plaque and gingivitis|
3180481|NCT01336166|Experimental|split-virion, non-adjuvanted vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
3180482|NCT01336166|Experimental|split-virion, non-adjuvanted vaccine of 30 μg|split-virion, non-adjuvanted H1N1 vaccine of 30 μg.
3180483|NCT01336166|Experimental|split-virion, non-adjuvanted vaccine of 45 μg|split-virion, non-adjuvanted H1N1 vaccine of 45 μg.
3180484|NCT01336166|Placebo Comparator|Placebo control|Placebo control
3180485|NCT01336153|Experimental|MLC601|MLC601 (NeuroAideTM) is a TCM which is used extensively in China to improve recovery after stroke. It combines several herbal and animal components.
3180486|NCT01336153|Placebo Comparator|Placebo|
3180487|NCT01336140|Experimental|Aminophylline|75 mg of intravenous aminophylline.
3180488|NCT01336140|Placebo Comparator|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
3180489|NCT01336127|Experimental|occupational therapy|10 weeks occupational therapy according to a protocol (OTiP protocol) based on the Dutch guidelines of occupational therapy in Parkinson's disease
3180490|NCT01336127|No Intervention|No occupational therapy|Patients and their caregivers in the control group will have no occupational therapy intervention until their last measurement has taken place (6 months).
3180491|NCT01336101|Other|SFA stenting|
3180492|NCT01336088|Experimental|ADX48621|
3180493|NCT01336088|Placebo Comparator|ADX48621 Matching Placebo|
3180494|NCT01336075|Active Comparator|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic radiofrequency ablation
3180495|NCT01336075|Active Comparator|Percutaneous ablation|Percutaneous radiofrequency catheter ablation
3180496|NCT01336062|Experimental|Nanoparticle Albumin-Bound Paclitaxel|The study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;
3180497|NCT01336049|Experimental|Nimotuzumab|
3180498|NCT01336023|Experimental|IDeg|
3180499|NCT01336023|Experimental|IDegLira|
3180500|NCT01336023|Experimental|Lira|
3180501|NCT01336010|Experimental|Group A - 8 weeks therapy|8 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 2 weeks of therapy.
3180502|NCT01336010|Experimental|Group B - 16 weeks therapy|16 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 4 weeks of therapy.
3180503|NCT01336010|Experimental|Group C - 24 weeks therapy|24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 6 weeks of therapy.
3180504|NCT01336010|Experimental|Group D - 32 weeks (gt1) or 24 weeks (gt 2/3)|32 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 8 weeks of therapy (genotype 1) or 24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 8 weeks of therapy.
3180505|NCT01336010|Experimental|Group E - 48 weeks (gt 1) or 24 weeks (gt 2/3)|48 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 12 weeks of therapy (genotype 1) or 24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 12 weeks of therapy (genotype 2/3).
3180506|NCT01336010|No Intervention|Untreated Group|Observation only. No treatment for hepatitis C administered. Subjects who have undetectable HCV RNA at baseline, do not wish to commence treatment or are ineligible for treatment.
3180507|NCT01335997|Experimental|ERN/LRPT/SIM → ERN/LRPT+SIM|Weeks 0-4 (Period 1): Participants will take ERN/LRPT/SIM 1 g/10 mg and SIM-matching placebo tablets daily; Weeks 5-12 (Period 2): Participants will be advanced to ERN/LRPT/SIM 2 g/20 mg and SIM-matching placebo tablets daily; Weeks 13-20 (Period III): Participants will crossover to ERN/LRPT 2 g + SIM 20 mg coadministration treatment.
3180508|NCT01335997|Active Comparator|ERN/LRPT+SIM → ERN/LRPT/SIM|Weeks 0-4 (Period I): Participants will take ERN/LRPT co-administered with SIM (ERN/LRPT 1g + SIM 10 mg tablets) daily; Weeks 5-12 (Period II): Participants will be advanced to ERN/LRPT 2 g + SIM 20 mg daily; Weeks 13-20 (Period III): Participants will crossover to the ERN/LRPT/SIM 2 g/20 mg combination treatment and SIM-matching placebo tablets.
3180509|NCT01335984|Experimental|Telemonitoring group|The subjects who are assigned in the Telemonitoring group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring group require site visit once per 2 months (8weeks)
3180510|NCT01335984|Experimental|Telemonitoring & Telemedicine group|The subjects who are assigned in the Telemonitoring & Telemedicine group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring & Telemedicine group take remote medical treatment through video telephone instead of visiting study site.
3180511|NCT01335984|Other|Control group|The subjects who are assigned in the Control group require site visit once per 2 months (8weeks)
3180512|NCT01335971|Active Comparator|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
3180513|NCT01335971|Active Comparator|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
3180514|NCT01335971|Placebo Comparator|Placebo|Microcrystalline cellulose
3180515|NCT01335958|Experimental|A|
3180516|NCT01335945|Other|Cryoablation|Freezing of the celiac plexus
3180517|NCT01335932|Experimental|IV Ganciclovir|5mg/kg IV twice daily for 5 days, then followed by either IV ganciclovir or oral valganciclovir once daily until hospital discharge
3180518|NCT01335932|Placebo Comparator|Placebo|normal saline IV twice daily for 5 days, then followed by either IV normal saline or oral placebo once daily until hospital discharge
3180519|NCT01335919||Neonate|Subjects admitted for surgery or to the pediatric intensive care unit (PICU) or neonatal intensive care unit (NICU) who require daily and/or multiple blood samples for hemoglobin measurement.
3180520|NCT01335906|Experimental|Evidence-based informed consent|
3180521|NCT01335906|No Intervention|Usual information|
3180522|NCT01335893|Experimental|ICG injection group|This group will receive a single dose of ICG, diluted in saline solution, prior to surgery. Then, during their surgery, they will be imaged with the camera and imaging probe we have developed.
3180523|NCT01335880|Active Comparator|Promotion I|Three month time horizon
3180524|NCT01335880|Experimental|Promotion II|One week time horizon
3180525|NCT01335867|Experimental|Vigabatrin|
3180526|NCT01335867|Placebo Comparator|Placebo|
3180527|NCT01335854|No Intervention|Usual Care|Usual care for 3 months. This consists of a phone call after one week of treatment, and clinic appointments at the sleep center following one month and three months of CPAP treatment.
3180528|NCT01335854|Experimental|Web-Access to CPAP Data|Usual care and web-based access to CPAP adherence data for 3 months. Participants in this group will be asked to review their CPAP use daily in the first week of treatment and as desired over the next 3 months by accessing a password protected website.
3180529|NCT01335854|Experimental|Web-Access to CPAP Data & Incentive|Usual care and web-based access to CPAP data for 3 months with financial incentives. Participants in this group will be asked to review their CPAP use daily in the first week of treatment and as desired over the next 3 months by accessing a password protected website. Financial incentive terminated after 1 week.
3180530|NCT01335841|Experimental|3D fluoroscopy and navigation station|
3180532|NCT01335828|Other|echography/elastography|
3180533|NCT01335815||elective knee and limb endoprothesis|
3180534|NCT01335802||Subclinical hypothyroidim|Women having subclinical hypothyroidism and/or TPOab-positive.
3180535|NCT01335802||Controls|Women having normal levels of TSH and TPOab-negative.
3180536|NCT01335789|Active Comparator|Oxytocin|intranasal administration
3180537|NCT01335789|Placebo Comparator|saline|intranasal administration
3180538|NCT01335776|Experimental|Cognitive Behavior Therapy|Cognitive Behavior Therapy for insomnia consists of stimulus control therapy, sleep restriction therapy, cognitive therapy and relaxation.
3180539|NCT01335776|Experimental|Mindfulness-Based Stress Reduction|The program consists of three primary components: theoretical material related to relaxation, meditation, and the mind-body connection; experiential practice of meditation and yoga and home based practice; group process focused on problem solving and support.
3180540|NCT01335763|Other|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of <=5.5mmol/L
3180541|NCT01335750|Experimental|Multipurpose Solution #1|B&L Renu Fresh Multipurpose Solution
3180542|NCT01335750|Experimental|Multipurpose Solution #2|OptiFree Replenish Multipurpose Solution
3180543|NCT01335750|Experimental|Multipurpose Solution #3|Ciba ClearCare Multipurpose Solution
3180544|NCT01335750|Active Comparator|Multipurpose Solution #4|Saline Solution
3180545|NCT01335737|Experimental|aerobic training|12 weeks of aerobic training, 4 times/week
3180546|NCT01335737|Placebo Comparator|wait list control|wait list control condition, 12 weeks + 4 to parallel the deconditioning protocol in active intervention group
3180547|NCT01335724|Experimental|Diclofenac diethylamine 1.16% gel|
3180548|NCT01335724|Placebo Comparator|placebo gel|
3180549|NCT01335711|Experimental|IMP_C/C IL28B|C/C IL28B subjects to whom IMP will be administrated prior to SOC
3180550|NCT01335711|Active Comparator|SOC_C/C IL28B|C/C IL28B subjects to whom only SOC will be administrated
3180551|NCT01335711|Experimental|IMP_non-C/C IL28B|non-C/C IL28B subjects to whom IMP will be administrated prior to SOC
3180552|NCT01335711|Active Comparator|SOC_non-C/C IL28B|non-C/C IL28B subjects to whom only SOC will be administrated
3180553|NCT01335698|Experimental|Stage 1: Atazanavir + Ritonavir|Participants received atazanavir powder orally (dosed by weight: 5 to <10 kg=150 mg, 5 to <10 kg=200 mg, 10 to <15 kg=200 mg, 15 to <25 kg=250 mg, 25 to <35 kg=300 mg) once daily for 24 to 48 weeks or a weight ≥35 kg. Participants also received ritonavir once daily for 24 to 48 weeks or weight ≥35 kg in the form of 80-mg/mL solution, orally (dosed by weight 5 to <25 kg=80 mg, 25 to <35 kg=100 mg); 100-mg capsule, orally (dosed by weight 25 to <35 kg=100 mg); or 100-mg tablet, orally (dosed by weight 25 to <35 kg=100 mg)
3180554|NCT01335685|Experimental|Arm A: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 4, 8, 11, 22, 25, 29, 32 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle for up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 23 maintenance cycles; overall up to 32 cycles [34 months]).
3180555|NCT01335685|Experimental|Arm A: Ixazomib 3.7 mg|Ixazomib 3.7 mg, capsules, orally, on Days 1, 4, 8, 11, 22, 25, 29, 32 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 10 maintenance cycles; overall up to 19 cycles [21 months]).
3180556|NCT01335685|Experimental|Arm B: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 15 maintenance cycles; overall up to 27 cycles [25 months]).
3180557|NCT01335685|Experimental|Arm B: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 cycle plus melphalan 6 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 49 maintenance cycles; overall up to 61 cycles [58 months]).
3180558|NCT01335685|Experimental|Arm B: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m^2, tablets orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 12 maintenance cycles; overall up to 24 cycles [24 months]).
3180559|NCT01335685|Experimental|Arm C: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 8, 15, 22, and 29 plus melphalan 9 mg/m^2, tablets orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 30 maintenance cycles; overall up to 39 cycles [40 months]).
3180560|NCT01335685|Experimental|Arm C: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15, 22, and 29 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 12 maintenance cycles; overall up to 21 cycles [24 months]).
3180616|NCT01335217|Other|Open-label TNS treatment|There is only one arm in this open label treatment of MDD co-occuring with PTSD.
3181010|NCT01332487||Early initiation of 5ARI therapy|Patients starting 5ARI therapy within 30 days of initiating AB therapy
3180561|NCT01335685|Experimental|Arm D: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 22, and 29 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally, on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 28 maintenance cycles; overall up to 37 cycles [38 months]).
3180562|NCT01335672||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
3180563|NCT01335659||ostial lesion|ostial lesion will be evaluated by IVUS and FFR
3180564|NCT01335646|Active Comparator|Surgery|
3180565|NCT01335646|Active Comparator|Non-operative|
3180566|NCT01335620|Other|Truvada plus Raltegravir|Single arm study
3180567|NCT01335607|Active Comparator|Part A: Samatasvir cap→tab→tab; Part B: cap|Part A: Samatasvir capsule as a single dose on Day 1 (fasting state) followed by samatasvir tablet as a single dose on Day 8 (fasting state) followed by samatasvir tablet as a single dose on Day 15 (fed state); Part B: samatasvir capsule as a single dose on Day 1 (fed state)
3180568|NCT01335607|Active Comparator|Part A: Samatasvir tab→cap→tab; Part B: cap|Part A: Samatasvir tablet as a single dose on Day 1 (fasting state) followed by samatasvir capsule as a single dose on Day 8 (fasting state) followed by samatasvir tablet as a single dose on Day 15 (fed state); Part B: samatasvir capsule as a single dose on Day 1 (fed state)
3180569|NCT01335581|Experimental|Laser treatment|Laser treatment added to microdermabrasion and topical lightening agent regimen
3180570|NCT01335568|Experimental|surgery|chronic liver insufficiency, cirrhosis
3180571|NCT01335555||Patients Pre and Post-chemotherapy|
3180572|NCT01335542|Active Comparator|Epidural Pathway (PCEA+FNB)|
3180573|NCT01335542|Active Comparator|Peri-Articular Injection|
3180574|NCT01335529|Experimental|Boceprevir, PegIFN alfa 2b, Ribavirin|"Standard Treatment :~Peg-Interferon (PegIFN) alfa 2b by subcutaneous injection 1,5 µg/kg/week~Ribavirin capsules 200mg: dosage delivered in weight categories (< 65 kg: 800 mg ; 65-80 kg: 1000 mg; 81-105 kg: 1200mg; > 105 kg: 1400mg)~Three-drug-regimen:~Peg-Interferon alfa 2b by subcutaneous injection 1,5 µg/kg/week~Ribavirin capsules 200mg: dosage delivered in weight categories like in standard treatment~Boceprevir tablets 200mg: 800 mg 3 times a day (2400 mg/j) with food"
3180575|NCT01335503|Active Comparator|AN-PEP with low caloric meal|
3180576|NCT01335503|Active Comparator|AN-PEP with high caloric meal|
3180577|NCT01335503|Placebo Comparator|Placebo with low caloric meal|
3180578|NCT01335503|Placebo Comparator|Placebo with high caloric meal|
3180579|NCT01335490|Experimental|Biolite Cook Stove|Provision of two cook stoves to each subject. Each stove burns wood fuel, but more efficiently than a traditional three stone fire.
3180580|NCT01335490|Experimental|LPG Cook Stove|Provision of a two-burner liquified petroleum gas stove to each subject, along with fuel needed for the family during the follow up period.
3180581|NCT01335490|No Intervention|Control|
3180582|NCT01335477|Placebo Comparator|placebo|patient receives capsules identical to those containing active drug
3180583|NCT01335477|Experimental|BIBF 1120|patient receives capsules containing BIBF 1120 twice a day
3180584|NCT01335464|Experimental|BIBF 1120|patient receives capsules containing BIBF 1120 twice a day
3180585|NCT01335464|Placebo Comparator|placebo|patient receives capsules identical to those containing active drug
3180586|NCT01335451|Experimental|Active|Each cohort will have 6 subjects that will receive AZD5213
3180587|NCT01335451|Placebo Comparator|Placebo|Each cohort will have 2 subjects that will receive placebo
3180588|NCT01335438|Experimental|Cementless Nexgen CR|Cementless fixation of Nexgen CR TKR
3180589|NCT01335438|Active Comparator|Cemented Nexgen CR|Cemented fixation of Nexgen CR TKR
3180590|NCT01335412||IXIARO exposed group|Male and female active duty U.S. military personnel ≥ 17 years of age who either received at least one dose of IXIARO
3180591|NCT01335412||Comparison group|Male and female active duty U.S. military personnel ≥ 17 years of age who either received at least one dose of JE-VAX
3180592|NCT01335399|Active Comparator|Lenalidomide + Dexamethasone|
3180593|NCT01335399|Experimental|Lenalidomide + Dexamethasone + Elotuzumab|
3180594|NCT01335386|Experimental|KLYX|
3180595|NCT01335386|Active Comparator|Glycerine|
3180596|NCT01335373||Group 1|
3180597|NCT01335360||Subjects >80kg|As above
3180598|NCT01335360||Subjects <70kg|As above
3180599|NCT01335360||Subjects 70-80kg|As above
3180600|NCT01335347|Experimental|Experimental Low Dose|Biological: One dose of a live replication incompetent adenovirus given in a capsule
3180601|NCT01335347|Experimental|Experimental Medium Dose|"Biological: One or two doses of replication incompetent adenovirus given in a capsule~Other: Placebo capsules of the same size and shape"
3180602|NCT01335347|Experimental|Experimental High Dose|Biological: One dose of replication incompetent adenovirus in a capsule
3180603|NCT01335347|Placebo Comparator|Placebo Control|Capsules of the same size and shape as the experimental
3180604|NCT01335321|Active Comparator|Hylan GF-20 alone|This arm will receive a knee infiltration with 6ml of Hylan GF-20 only
3180605|NCT01335321|Experimental|Triamcinolone|This arm will receive a knee infiltration with 6ml of Hylan GF-20 associated with 1ml of triamcinolone
3180606|NCT01335308|Active Comparator|Standard Care with Education Materials|Measure height and weight only. usual care
3180607|NCT01335308|Experimental|Moderate Dose Motivational Interviewing|MI delivered by PCP, 4 sessions
3180608|NCT01335308|Experimental|Higher Dose Motivational Interviewing|MI delivered by PCP, 4 sessions plus MI delivered by RD, 6 sessions
3180609|NCT01335269|Experimental|Treatment arm|BI 853520 once daily in a dose escalation schedule
3180610|NCT01335256|Experimental|Arm 1|
3180611|NCT01335243|Experimental|TLIF surgery|
3180612|NCT01335230||10 HIV mono-infected subjects|10 subjects infected with HIV only
3180613|NCT01335230||10 HCV mono-infected subjects|10 subjects infected with HCV only
3180614|NCT01335230||10 HIV/HCV co-infected subjects|10 subjects infected with both HIV and HCV
3180615|NCT01335230||10 control subjects|10 subjects without HIV, HCV, or both
3180617|NCT01335204|Experimental|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle. Bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
3180618|NCT01335191|Experimental|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0 and Week 3.
3180619|NCT01335191|Placebo Comparator|Placebo|Two subcutaneous injections of placebo at Day 0 and Week 3.
3180620|NCT01335178|Experimental|Intervention|Participants received the behavioral intervention, which was designed to motivate parents to protect their children from tobacco smoke exposure
3180621|NCT01335165|Experimental|TT30 (ALXN1102 Formulation)|IV: 0.1, 0.3, and 1.0 mg/kg
3180622|NCT01335165|Experimental|TT30 (ALXN1103 Formulation)|"IV: 3.0, 6.0, and 10.0 mg/kg~SC: 1.0 and 3.0 mg/kg"
3180623|NCT01335152|Experimental|Web-based workbook|Participants will use one chapter of the web-based workbook each week for 10 weeks. The workbook consists of stress management education, cognitive behavioral interventions and relaxation training exercises.
3180624|NCT01335152|No Intervention|Waitlist control group|Participants will no intervention for the first 10 weeks of the study and then will receive the web-based intervention.
3180625|NCT01335139|Experimental|SCIT + Placebo|Subcutaneous immunotherapy (SCIT) + sublingual immunotherapy (SLIT) placebo
3180626|NCT01335139|Experimental|SLIT + Placebo|Sublingual immunotherapy (SLIT) + subcutaneous immunotherapy (SCIT) placebo
3180627|NCT01335139|Placebo Comparator|Placebo + Placebo|Sublingual immunotherapy (SLIT) placebo + subcutaneous immunotherapy (SCIT) placebo
3180628|NCT01335126|Experimental|Test|
3180629|NCT01335100||ambulatory CP|ambulatory children with cerebral palsy undergoing Botulinum toxin injections to lower limbs
3180630|NCT01335100||controls|age and gender matched sibilings
3180631|NCT01335087|Active Comparator|Lifestyle|Standard care for OSA: lifestyle, and sleep hygiene counselling
3180632|NCT01335087|Experimental|Continuous positive airway pressure CPAP|CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling
3180633|NCT01335087|No Intervention|Reference|This group will be followed according to cardiovascular protocols and will be evaluated as a reference group.
3180634|NCT01335074|Experimental|Temsirolimus + Sorafenib|
3180635|NCT01335061|Other|BeneFIX|
3180636|NCT01335048|Experimental|Atorvastatin-Clopidogrel group|Patients who receive Atorvastatin 80 mg/day and Clopidogrel 150 mg/day
3180637|NCT01335048|Active Comparator|Clopidogrel group|Patients who receive clopidogrel 150 mg daily
3180638|NCT01335035|Experimental|ICL670|
3180639|NCT01335022|Experimental|Cardiovascular Disease Education|6 lectures on cardiovascular disease were given over a 2 month time period
3180640|NCT01335009|Experimental|MORAb-004, 2 mg/kg|Biologic (monoclonal antibody)
3180641|NCT01335009|Experimental|MORAb-004, 4 mg/kg|Biologic (monoclonal antibody)
3180642|NCT01334983|Experimental|REST|Participants instructed in individualized Rapid Easy Strength Training and pedometer-based walking programs
3180643|NCT01334983|No Intervention|Wait list control|Participants instructed in REST after completing week 8 outcome measures
3180644|NCT01334957|Experimental|Intravenous ibuprofen|Intravenous ibuprofen (800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 10 minute Treatment Period.
3180645|NCT01334944|Experimental|Intravenous ibuprofen|Intravenous ibuprofen (400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 5-10 minute Treatment Period.
3180646|NCT01334931|Experimental|Large field of view|Patients will have coronary angiography performed with large field of view lens
3180647|NCT01334931|Active Comparator|Medium field of view|Patients will have coronary angiography performed with medium field of view lens
3180648|NCT01334918|Experimental|Single Photon Emission Computed Tomography (SPECT)|"Resting SPECT imaging was performed prior to regadenoson stress SPECT~imaging. Imaging was conducted with one of two radiotracers (99mTc sestamibi or tetrofosmin). Regadenoson 0.4 mg was administered prior to stress SPECT as a single bolus injection."
3180649|NCT01334918|Experimental|Multidetector Computed Tomography (MDCT)|Multidetector Computed Tomography (MDCT), composed of CCTA and regadenoson CTP. Regadenoson stress CTP was performed prior to rest CCTA/CTP imaging. Regadenoson 0.4 mg was administered prior to stress CTP as a single bolus injection. The rest CCTA/CTP was performed at least 30 minutes after completion of the stress CTP, after resolution of any symptoms brought on by the regadenoson infusion and after the participant's heart rate had returned to baseline.
3180650|NCT01334905|Experimental|Part A group|fasted condition then fed condition
3180651|NCT01334905|Experimental|Part B group|fed condition then fasted condition
3180652|NCT01334892|Active Comparator|L-CsA|Twice daily inhalation of 2.5 ml/10 mg L-CsA for 96 weeks
3180653|NCT01334892|Placebo Comparator|L-CsA placebo|Twice daily inhalation of 2.5 ml aerosolised placebo (carrier) for 96 weeks (24 months)
3180654|NCT01334879|Active Comparator|With Loading Doses|5 patients will receive intravitreal injections every 30 days (+/- 7 days) for the first 4 months and every month thereafter until month 12 (maximum of 12 injections)
3180655|NCT01334879|Active Comparator|Physician Discretion|5 patients will receive intravitreal ranibizumab every 30 days (+/- 7 days) on as needed basis based on the criteria defined in the study.
3180656|NCT01334853||Cohort 1|50 eosinophilic subjects to be evaluated
3180657|NCT01334853||Cohort 2|50 non-eosinophilic subjects to be evaluated
3180658|NCT01334840|Experimental|BW|Bicarbonated mineral water without meal
3180659|NCT01334840|Experimental|BW with meal|Bicarbonated mineral water with meal
3180660|NCT01334840|Active Comparator|CW|Mineral water low in mineral content (control) without meal
3180661|NCT01334840|Active Comparator|CW with meal|Mineral water low in mineral content (control) with a meal
3180662|NCT01334801||Aortic Stenosis|Restricted aortic valve motion and a peak Doppler aortic velocity > 2.5 m/sec blood draw
3180663|NCT01334801||Aortic regurgitation|Echocardiographic and Doppler evaluation revealing aortic regurgitation with data adequate to calculate regurgitant volume
3180664|NCT01334801||Aortic valve replacement|Mechanical or biological aortic valve replacement
3181835|NCT01326455|Active Comparator|Clo-Sur P.A.D.|
3180665|NCT01334801||Mitral regurgitation|Echocardiographic and Doppler evaluation revealing mitral regurgitation with data adequate to calculate regurgitant volume
3180666|NCT01334801||Mitral valve replacement|Mechanical or biological mitral valve replacement
3180667|NCT01334801||Hypertrophic cardiomyopathy|Patients with known hypertrophic cardiomyopathy who are referred for clinically indicated echocardiography
3180668|NCT01334801||Severe TR with pacemaker / ICD lead|Patients referred for clinically indicated echocardiography who have severe tricuspid regurgitation associated with a pacemaker or defibrillator lead documented by echocardiography
3180669|NCT01334801||Prosthetic valve dysfunction|Patients with prior heart valve replacement or repair referred for clinically indicated echocardiography who demonstrate stenosis, regurgitation, dehiscence.
3180670|NCT01334801||Normal controls|Patients with no heart murmur or history of valve replacement, stenosis, regurgitation, or hypertrophic cardiomyopathy
3180671|NCT01334801||Left ventricular assist device patients|Patients with previously implanted LVAD
3180672|NCT01334801||Renal dialysis patients|Patients on hemodialysis, peritoneal dialysis, or chronic kidney disease with dialysis fistula to be created.
3180673|NCT01334788|Experimental|sleep deprivation|These are subjects who are randomized to undergo sleep deprivation.
3180674|NCT01334788|Other|Normal sleep|These are subjects who are randomized to sleep normally.
3180675|NCT01334775|Experimental|Experimental - Cousin Biotech Adhesix|Placement of a self-adhering (sutureless) surgical mesh in open anterior inguinal hernia repair
3180676|NCT01334775|Active Comparator|Conventional - Cousin Biotech Biomesh P8|Placement of the conventional (sutured) surgical mesh in open anterior inguinal hernia repair
3180677|NCT01334762|Experimental|Letrozole/IUI|Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
3180678|NCT01334762|Active Comparator|CC/IUI|Patients received 100 mg CC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
3180679|NCT01334749||Acute Stroke|Patients over 18 years and without pre-stroke dementia, displaying an ischemic or hemorrhagic stroke, onset within the last 72 hours, language German
3180680|NCT01334736|Placebo Comparator|Usual care|
3180681|NCT01334736|Active Comparator|Lung Age|
3180682|NCT01334736|Active Comparator|Contingency Management|
3180683|NCT01334736|Active Comparator|Lung age + Contingency Management|
3180684|NCT01334723||Acute Urinary Retention|This subset of the Integrated Health Care Information Solutions (ICHIS) benign prostate hyperplasia (BPH) study population was used to assess acute urinary retention as a clinical outcome.
3180685|NCT01334723||Prostate Surgery|This subset of the ICHIS BPH study population was used to assess surgery as a clinical outcome.
3180686|NCT01334710|Experimental|Sorafenib and OSI-906|This is a single arm phase II trial designed to evaluate the effect of adding OSI-906 to sorafenib in patients with hepatocellular cancer. The study is designed to evaluate the safety of the regimen in the first six patients.
3180687|NCT01334697|Experimental|Cardiotrophin-1|
3180688|NCT01334697|Placebo Comparator|Placebo|
3180689|NCT01334684|Other|Metformin|"At study entry, all oral hypoglycemic agents will be discontinued for 5 days and then metformin (2,550 mg/daily) will be given for 3 months. Fasting plasma glucose will be measured at baseline and 3 months after metformin treatment. Patients will be stratified according to the median value of metformin efficacy as indicated by fasting glucose change after metformin treatment (i.e. baseline fasting glucose minus 3-month fasting glucose).~So, two subgroups of patients will be obtained, defined as relatively high responders (individual fasting glucose change > median value) or relatively low responders (individual fasting glucose change < median value) to metformin monotherapy."
3180690|NCT01334671|Experimental|group 1, Atorvastatin|STEMI patients will be randomly divided into three groups Group 1 which has been give 80mg atorvastatin before PCI will be administered with atorvastatin 40mg per day for one month,then 20mg per day until the end of the trial
3180691|NCT01334671|Experimental|group 2 , Atorvastatin|Group 2 will be administered with atorvastatin 40mg per day for one month,then 20mg per day until the end of the trial
3180692|NCT01334671|Experimental|group 3 , Atorvastatin|Group 3 will be administered with atorvastatin 20mg per day until the end of the trial
3180693|NCT01334658|Active Comparator|Balanced Salt Solution (BSS®)|Subjects who received Balanced Salt Solution.
3180694|NCT01334658|Active Comparator|Glucose-bicarbonate-Ringer Lactate (GBRL)|Subjects who received glucose-bicarbonate-Ringer Lactate.
3180695|NCT01334632|Active Comparator|Continuous interscalene block|Continuous interscalene block with bolus ropivacaine 0.5% and then continuous infusion of ropivacaine 0.2% 4 - 6 ml/h, associated with paracetamol and ibuprofen. Each group will contain 60 patients.
3180696|NCT01334632|Placebo Comparator|PCA morphine|Patients with iv self-administration of morphine, associated with paracetamol and ibuprofen. Each group will contain 60 patients.
3180697|NCT01334619|Other|ropivacaine volume titration|
3180698|NCT01334606|Experimental|Nano: 4mm x 32G Pen Needle|Subjects will use the 4mm x 32G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.
3180699|NCT01334606|Experimental|Short: 8mm x 31G Pen Needle|Subjects will use the 8 mm x 31G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.
3180700|NCT01334593||Rectal Cancer|
3180701|NCT01334580|Active Comparator|Methadone Drug Counseling|Methadone Drug Counseling is provided by skilled drug counselors over a 12 week period and focuses on cessation of illicit drugs
3180702|NCT01334580|Experimental|Cognitive-Behavioral Therapy for Pain and Opioid Dependence|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
3180703|NCT01334567|Experimental|Tenofovir DF|
3180704|NCT01334554|Experimental|Sildenafil|Sildenafil 20 mg three times a day
3180705|NCT01334554|Placebo Comparator|Placebo|placebo
3180706|NCT01334541||SAFE VET|
3180707|NCT01334541||E-CARE|
3180708|NCT01334528||OEF/OIF Veterans mTBI|Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF) Veterans with a history of mild traumatic brain injury (mTBI) with persistent self-reported symptoms.
3180709|NCT01334515|Experimental|Disease measured by standard radiographic criteria|Treatment (hu14.18-Interleukin 2(IL2) fusion protein and isotretinoin). Patients receive sargramostim (SC [preferred]) or IV over 2 hours on days 1-2 and 8-14, hu14.18-IL2 fusion protein IV over 4 hours on days 4-6, and isotretinoin PO twice daily on days 11-24. Treatment repeats every 28 days for 4-10 courses in the absence of disease progression or unacceptable toxicity. Patients in stratum-1 who achieve stable disease (SD) after course 4 are removed from protocol therapy. Patients in stratum-2 who achieve SD after course 4 receive 2 additional courses of study treatment. Patients may undergo blood and bone marrow sample collection periodically for correlative studies.
3180710|NCT01334515|Experimental|Disease evaluable only by I-MIBG or BM histology|Treatment (hu14.18-Interleukin 2(IL2) fusion protein and isotretinoin). Patients receive sargramostim (SC [preferred]) or IV over 2 hours on days 1-2 and 8-14, hu14.18-IL2 fusion protein IV over 4 hours on days 4-6, and isotretinoin PO twice daily on days 11-24. Treatment repeats every 28 days for 4-10 courses in the absence of disease progression or unacceptable toxicity. Patients in stratum-1 who achieve stable disease (SD) after course 4 are removed from protocol therapy. Patients in stratum-2 who achieve SD after course 4 receive 2 additional courses of study treatment. Patients may undergo blood and bone marrow sample collection periodically for correlative studies.
3180711|NCT01334502|Experimental|everolimus and RCHOP|Patients registered to the study will receive an assigned dose of everolimus by mouth and RCHOP for a maximum of six cycles. Each cycle is a total of 21 days. RCHOP consists of 375 mg/m2 IV rituximab, 750 mg/m2 IV cyclophosphamide, 50 mg/m2 IV doxorubicin, 1.4 mg/m2 IV vincristine and 100 mg/m2 by mouth QD prednisone. The study includes a Phase I component to determine the maximum tolerated dose of everolimus and the second component determines the feasibility of therapy administered to lymphoma patients.
3180712|NCT01334489|No Intervention|Usual management|Usual management of monochorionic pregnancy without the pessary placement
3180713|NCT01334489|Other|Arabin Cervical Pessary|"The pessary will be inserted 24 hours after fetal surgery in the exploration room. This procedure does not need anaesthesia and it does not need to be done in a surgery room. During the following explorations the correct placement of the pessary is assessed, and if it does not, it can be easily adjusted.~The pessary will be removed at 37 weeks of gestation, or before if any unexpected event occurs."
3180714|NCT01334463||mTBI+PTSD|History of active duty-related mild TBI and history of active duty-related PTSD
3180715|NCT01334463||mTBI Only|History of active duty-related mild TBI and no history of active duty-related PTSD
3180716|NCT01334463||PTSD Only|No history of active duty-related mild TBI and history of active duty-related PTSD
3180717|NCT01334463||No mTBI, No PTSD|No history of active duty-related mild TBI and no history of active duty-related PTSD
3180718|NCT01334450|Active Comparator|High Frequency TMS to prefrontal cortex|
3180719|NCT01334450|Active Comparator|Low Frequency TMS to Prefrontal cortex|
3180720|NCT01334450|Sham Comparator|Sham TMS on Prefrontal Cortex|
3180721|NCT01334424|Placebo Comparator|no propofol|induction anesthesia with midazolam 0.2 - 0.3 mg/kg
3180722|NCT01334424|Experimental|propofol induction|induction anesthesia with propofol 2 - 2.5 mg/kg
3180723|NCT01334424|Experimental|propofol maintenance|induction anesthesia with midazolam 0.2 - 0.3 mg/kg and maintain anesthesia with propofol 2 mg/kg.h (maintenance dose)
3180724|NCT01334424|Experimental|propofol induction and maintenance|induction anesthesia with propofol 2 - 2.5 mg/ kg and maintain anesthesia with propofol 2 mg/kg.h (maintenance dose)
3180725|NCT01334398||Initial Treatment Group|
3180726|NCT01334398||Deferred Treatment Group|
3180727|NCT01334385||OEF/OIF Veterans through VA ECHCS|
3180728|NCT01334372|No Intervention|Treatment as Usual|Treatment as usual (TAU) outpatient care will consist of existing outpatient clinical practices utilized in the Mental Health Clinic.
3180729|NCT01334372|Experimental|CAMS|First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
3180730|NCT01334359|Experimental|Treatment Group|Participants randomized to the afterschool intervention
3180731|NCT01334359|Placebo Comparator|Wait List Group|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
3180732|NCT01334346|Active Comparator|Neutral Shoe|Conventional, non-minimalist, footwear.
3180733|NCT01334346|Experimental|Partial minimalist shoe|
3180734|NCT01334346|Experimental|Full minimalist|
3180735|NCT01334333|Active Comparator|Prograf®|Prograf® is a twice daily formulation of tacrolimus
3180736|NCT01334333|Experimental|Advagraf®|Advagraf® is a once daily formulation of tacrolimus
3180737|NCT01334320|Experimental|elective neck dissection|patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
3180738|NCT01334320|No Intervention|wait and see|patient underwent primary tumor excision transorally as initial treatment, and without a cervical intervention
3180739|NCT01334307|Experimental|Lung Volume Reduction Coil (LVRC)|Lung Volume Reduction Coil (LVRC)
3180740|NCT01334307|Placebo Comparator|Control|Standard of Care
3180741|NCT01334294||1. Received therapy for CNV|
3180742|NCT01334281||Blood: Undergoing Desensitization|Transplant subjects give blood at specified time points. Sensitization to HLA antigens is a barrier to transplant. Several U.S. institutions have protocols for desensitization where patients are treated with IV immunoglobulins (IVIg) and plasmapheresis (PP) to reduce circulating HLA-directed antibody levels. Labs provide doctors information on circulating donor-specific antibody (DSA) levels. These results are the main indicator whether to proceed with transplant. However, no information is given on the fate of the B cells that produce the DSA.
3180743|NCT01334281||Blood: NOT Undergoing Desensitization|Transplant subjects give blood at specified time points. Sensitization to HLA antigens is a barrier to transplant. Several U.S. institutions have protocols for desensitization where patients are treated with IV immunoglobulins (IVIg) and plasmapheresis (PP) to reduce circulating HLA-directed antibody levels. Labs provide doctors information on circulating donor-specific antibody (DSA) levels. These results are the main indicator whether to proceed with transplant. However, no information is given on the fate of the B cells that produce the DSA.
3180744|NCT01334268|Active Comparator|Taxus Liberte Paclitaxel-Eluting Coronary Stent System|Subjects will be randomized to be treated with Taxus Liberte Paclitaxel-Eluting Coronary Stent System by an interactive voice response system (IVRS).
3180745|NCT01334268|Experimental|Medtronic Resolute (Zotarolimus-eluting stent)|Subjects will be randomized to be treated with Medtronic Resolute (Zotarolimus-eluting stent) by an interactive voice response system (IVRS).
3180746|NCT01334255|Experimental|0.5 mg of iSONEP (sonepcizumab/LT1009)|iSONEP (sonepcizumab/LT1009) is a humanized murine monoclonal antibody to sphingosine 1-phosphate
3180747|NCT01334255|Experimental|2.0 mg of iSONEP (sonepcizumab/LT1009)|iSONEP (sonepcizumab/LT1009) is a humanized murine monoclonal antibody to sphingosine 1-phosphate
3180748|NCT01334242|Experimental|LX4211|400 mg of LX4211 administered orally
3180749|NCT01334242|Placebo Comparator|Placebo|Nonidentical placebo administered orally
3180750|NCT01334229|Experimental|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
3180751|NCT01334229|Placebo Comparator|Placebo|Placebo for 6 weeks
3180752|NCT01334216|Active Comparator|CHICA Smoking Cessation Module|This arm had the CHICA smoking cessation module turned on
3180753|NCT01334216|Placebo Comparator|CHICA Placebo|This arm had CHICA without the smoking cessation module
3180754|NCT01334203|Experimental|Ranolazine|
3180755|NCT01334203|Placebo Comparator|Placebo|
3180756|NCT01334177|Experimental|Treatment (immunotherapy and monoclonal antibody therapy)|Patients receive cetuximab IV over 60-120 minutes on days -28, -21, -14, -7 of weeks -4 to -1. Patients then receive cetuximab IV on days 1, 8, 15, and 22 and TLR8 agonist VTX-2337 SC on days 1, 8, 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3180757|NCT01334164|Experimental|Recovery Management Checkup (RMC)|Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
3180758|NCT01334164|Active Comparator|Outcome Monitoring|Outcome monitoring only, however participates are still able (and do) enter treatment on their own.
3180759|NCT01334151|Active Comparator|Humalog®|Humalog®, administered subcutaneously on 1 occasion
3180760|NCT01334151|Experimental|BIOD- 105|BIOD- 105 administered subcutaneously on 1 occasion
3180761|NCT01334151|Experimental|BIOD-107|BIOD-107 administered subcutaneously on 1 occasion
3180762|NCT01334138|Experimental|4-week diet, low in sodium|The study subjects go on a 4-week diet, low in sodium.
3180763|NCT01334125|Experimental|Metformin|Metformin 1000 mg once daily by mouth for 9 months
3180764|NCT01334125|Placebo Comparator|Placebo|2 capsules once daily by mouth for 9 months
3180765|NCT01334112|Experimental|Axitinib|Oral Axitinib (5mg, twice daily) will be administered to all patients
3180766|NCT01334099|Experimental|Radiation combined with CP-675,206|
3180767|NCT01334086|Experimental|Aprepitant|
3180768|NCT01334073|Experimental|Axitinib plus everolimus|
3180769|NCT01334060|No Intervention|CML HLA A2-|
3180770|NCT01334060|No Intervention|AML HLA A2-|
3180771|NCT01334060|Experimental|AML HLA A2+|
3180772|NCT01334060|Experimental|CML HLA A2+|
3180773|NCT01334047|Experimental|DC vaccine|Dendritic cells loaded with amplified ovarian cancer stem cell mRNA, hTERT and Survivin.
3180774|NCT01334034|Experimental|Dose levels 1-7|
3180775|NCT01334021||Breast Cancer Registry Study for Molecular Predictive Testing|Patients scheduled for biopsy or surgery of a primary tumor site for suspected or proven invasive breast cancer of clinical Stage I to III.
3180776|NCT01334008|Other|Blood sampling|
3180777|NCT01333995|No Intervention|Usual Health Message|No intervention mothers will recieve standard maternal and child care education
3180778|NCT01333995|Sham Comparator|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
3180779|NCT01333982|Experimental|Referral compliance|Health workers will receive a basic maternal, newborn and child health training under the MNCS programme. Newborn sepsis management training will be organised for the study. The Bangladesh Perinatal Society (BPS) will take the lead in developing and implementing the training programme with support from Saving Newborn Lives (SNL) and other partners.Referral slips will be used in the intervention unions for all the sick newborns identified so that they seek care on a timely fashion.
3180780|NCT01333982|Experimental|Neonatal sepsis|Existing health delivery systems in the community level in managing neonatal sepsis.
3180781|NCT01333969|Active Comparator|Ishcemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components).
3180782|NCT01333969|No Intervention|Control|In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
3180783|NCT01333956|Placebo Comparator|Control|Patients will receive 0mg of pregabalin
3180784|NCT01333956|Experimental|50mg Arm|Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of post-operative day (POD)14 and one capsule at bedtime POD15, POD16.
3180785|NCT01333956|Experimental|100mg Arm|Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
3181112|NCT01331863|Experimental|single arm surgery|Airway and/or pulmonary Vessels Transplantation
3180786|NCT01333956|Experimental|150mg Arm|Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
3180787|NCT01333943|Experimental|Experimental|Saphenous (Adductor Canal) Nerve Block
3180788|NCT01333943|Active Comparator|Control|Femoral Nerve Block
3180789|NCT01333930|Experimental|Test product (Active O2)|
3180790|NCT01333930|Placebo Comparator|Placebo (Adelholzener Mineralwasser)|
3180791|NCT01333917|Experimental|Curcumin|4g Curcumin C3 tablet daily
3180792|NCT01333904|Experimental|PUR118|
3180793|NCT01333891|Active Comparator|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
3180794|NCT01333891|Active Comparator|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
3180795|NCT01333891|Active Comparator|Suction Cup|suction force of 25, 50, 75, and 100 mmHg
3180796|NCT01333878|Experimental|Open-Label Subcutaneous Abatacept|Open-Label Subcutaneous Abatacept
3180797|NCT01333865|Experimental|Memantine (Namenda) Treatment|
3180798|NCT01333852|Active Comparator|Paclitaxel, placebo|Paclitaxel 175mg/m² q21d until disease progression, unacceptable toxicity or consent withdrawal
3180799|NCT01333852|Experimental|Paclitaxel plus metformin|Paclitaxel 175mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal
3180800|NCT01333839|Active Comparator|standard exercise intervention|12 weeks of endurance exercise training
3180801|NCT01333839|Active Comparator|modified exercise intervention|combined endurance + strength exercise training
3180802|NCT01333839|Active Comparator|modified 2 exercise intervention|combined endurance + strength exercise training + oral protein supplements
3180803|NCT01333826|Experimental|Unconditional cash transfers|Monthly cash transfers given to households with school aged girls with no strings attached. Transfer amounts randomized within this arm.
3180804|NCT01333826|Experimental|Conditional Cash Transfer|Monthly cash transfers given to households with school aged girls conditional on regular school attendance (80%). Transfer amounts randomized within this arm.
3180805|NCT01333826|No Intervention|Control Group|No cash transfer program implemented in this group.
3180806|NCT01333813|Experimental|Engerix-B Kinder Group|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 7-8 years of age.
3180807|NCT01333800|Active Comparator|Ciclesonide|
3180808|NCT01333800|Placebo Comparator|Beclomethasone|
3180809|NCT01333787|Active Comparator|Dietary Fiber Mixture|The dietary fiber mixture was composed of six different types of fibers. It was used for treatment of chronic constipation in children.
3180810|NCT01333787|Placebo Comparator|Maltodextrine|Blinded control group
3180811|NCT01333774||Group 1|
3180812|NCT01333761|Experimental|TCD/Cardiox FDS/TEE testing|All patients enrolled will be evaluated with TCD and Cardiox FDS and TEE for the presence of RTLS.
3180813|NCT01333748|Experimental|patients group|Patients with ovarian and/or breast cancer
3180814|NCT01333748|Other|control population|control population without history of breast and/or ovarian cancer
3180815|NCT01333735||Patients with chemotherapy group|Patients with breast or colon cancer must beginning a chemotherapy (colon group was ended)
3180816|NCT01333735||Patients without chemotherapy group|patient with breast or colon cancer should not receive chemotherapy (colon group was ended)
3180817|NCT01333722|Placebo Comparator|Placebo|placebo, 1 oral tablet every 12 hours
3180818|NCT01333722|Experimental|Hydrocodone/Acetaminophen Extended Release|hydrocodone/acetaminophen extended release, 1 oral tablet every 12 hours
3180819|NCT01333709|Experimental|Arm A: immediate rectal surgery|"Very good responder patients will be randomly assigned to proctectomy within 2-4 weeks after the end of the induction chemotherapy."
3180820|NCT01333709|Other|Arm B: RCT Cap 50 and then rectal surgery|"Very good responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy)."
3180821|NCT01333709|Other|Arm C: RCT Cap 50 and then rectal surgery|"Good or poor responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy)."
3180822|NCT01333709|Experimental|Bras D: RCT Cap 60 and then rectal surgery|"Good or poor responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 60 grays (2Gy/day, 5 days a week, 6 weeks, boost 14 Gy)."
3180823|NCT01333696|Experimental|Pemetrexed|500 mg/m2, repeated every 3 weeks until disease progression or intolerable toxicity
3180824|NCT01333683||Control|Normal subjects
3180825|NCT01333683||AH|Arterial hypertension patients
3180826|NCT01333670|Experimental|Prontosan wound irrigation solution|
3180827|NCT01333670|Active Comparator|Standard care|
3180828|NCT01333657||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
3180829|NCT01333657||Sepsis|"sepsis: SIRS plus infection;~severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
3180830|NCT01333644||HIV-Infection|Treated HIV-infected individuals with an undetectable HIV RNA level (< 75 copies RNA/mL, untreated HIV-infected individuals, and HIV-uninfected individuals.
3180831|NCT01333631|Experimental|Valporoic acid + chemoradiotherapy|
3180832|NCT01333618|Experimental|curving introducer|
3180833|NCT01333618|Placebo Comparator|straight introducer|
3181011|NCT01332487||Delayed initiation of 5ARI therapy|Patients starting 5ARI therapy more than 30 days but less than 6 months from the initiation of AB therapy
3181159|NCT01331564|Placebo Comparator|Control|
3180834|NCT01333605|Experimental|IGEV regimen|Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles
3180835|NCT01333592|Experimental|KAD-1229|
3180836|NCT01333579|Active Comparator|Active rTMS|1Hz active rTMS delivered to the unaffected hemisphere
3180837|NCT01333579|Placebo Comparator|Placebo rTMS|1Hz placebo rTMS delivered to the vertex
3180838|NCT01333566|Experimental|Intervention Group|
3180839|NCT01333566|Placebo Comparator|Control Group|
3180840|NCT01333553||Image-guided remove Port Wine Stain|Image-guided surgery remove Port Wine Stain
3180841|NCT01333540|Experimental|Active|Escalating Doses of TD-1211
3180842|NCT01333540|Placebo Comparator|Placebo|
3180843|NCT01333527|Experimental|Group A (early ROM)|Group A (early ROM) will use the sling for comfort only
3180844|NCT01333527|Active Comparator|Group B (usual care)|Group B (usual care) will be immobilized in a sling for 6 weeks.
3180845|NCT01333514|Experimental|Carbohydrate based prandial insulin dosing|Subjects will received prandial insulin based on the amount of carbohydrates consumed.
3180846|NCT01333514|Active Comparator|Usual Care Prandial insulin dosing|Subjects will received prandial insulin if they consume 50% or more of their meal-tray as is the usual care.
3180847|NCT01333501|Experimental|Fingolimod|0.5 mg in capsules for oral administration once daily
3180848|NCT01333501|Active Comparator|Interferon beta 1b|250 μg injected s.c. every other day
3180849|NCT01333488|No Intervention|Conventional Therapy|
3180850|NCT01333488|Experimental|Hypothermia|Subjects will have their core body temperatures lowered to 34C.
3180851|NCT01333488|Experimental|Hypothermia plus supplemental magnesium sulfate infusion|
3180852|NCT01333475|Experimental|TAC1:MK-2206 & AZD6244 in Pts with Colorectal Ca|Cycle = 28 days:MK-2206:90 mg PO days 1, 8, 15, and 22 AZD6244 Hydrogen sulfate: 75 mg PO QD (every day) MK-2206 + AZD6244: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
3180853|NCT01333475|Experimental|TAC1A:MK-2206 & AZD6244 in Pts with Colorectal Ca|"Cycle = 28 days:MK-2206:135 mg PO days 1, 8, 15, and 22 AZD6244 Hydrogen sulfate: 100 mg PO QD~MK-2206 + AZD6244: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression."
3180854|NCT01333462|Placebo Comparator|Phosphate Buffered Saline (PBS) IN|
3180855|NCT01333462|Active Comparator|Fluzone 4 mcg HA IN|
3180856|NCT01333462|Active Comparator|Fluzone 15 mcg HA IM|
3180857|NCT01333462|Experimental|NB-1008 4 mcg HA 5% W805EC|
3180858|NCT01333462|Experimental|NB-1008 4 mcg HA 10% W805EC|
3180859|NCT01333462|Experimental|NB-1008 4 mcg HA 15% W805EC|
3180860|NCT01333462|Experimental|NB-1008 4 mcg HA 20% W805EC|
3180861|NCT01333462|Active Comparator|Fluzone 10 mcg HA IN|
3180862|NCT01333462|Experimental|NB-1008 10 mcg HA 5% W805EC|
3180863|NCT01333462|Experimental|NB-1008 10 mcg HA 10% W805EC|
3180864|NCT01333462|Experimental|NB-1008 10 mcg HA 15% W805EC|
3180865|NCT01333462|Experimental|NB-1008 10 mcg HA 20% W805EC|
3180866|NCT01333449|Experimental|Single Arm|Decitabine 20mg/m^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
3180867|NCT01333436|Experimental|Diabetic participants|Diabetic participants with normal to moderately high LDL-C
3180868|NCT01333436|Experimental|Nondiabetic participants|Non-diabetic participants with normal to moderately high LDL-C
3180869|NCT01333423|Experimental|Doxil + Seliciclib|Doxil (Liposomal doxorubicin) 40 mg/m2 intravenous (IV) over 2 -3 hours on Day 4 and Seliciclib starting dose 200 mg orally twice a day on Days 1 - 3 of 28 day cycle
3180870|NCT01333410|Active Comparator|0.1% tacrolimus ointment|
3180871|NCT01333410|Active Comparator|0.1% mometasone furoate cream|
3180872|NCT01333397|Experimental|Dysport RU 20 U|
3180873|NCT01333397|Experimental|Dysport RU 50 U|
3180874|NCT01333397|Experimental|Dysport RU 75 U|
3180875|NCT01333397|Active Comparator|Dysport (Azzalure) 50 U|
3180876|NCT01333397|Placebo Comparator|Placebo|
3180877|NCT01333371|Active Comparator|closed reduction with percutaneous k-wire fixation and casted|
3180878|NCT01333371|Active Comparator|open reduction internal fixation with a volar locked plate|
3180879|NCT01333332|Experimental|Capecitabine, Radiation|
3180880|NCT01333306|Experimental|tDCS and cognitive training|
3180881|NCT01333293|Experimental|Omalizumab|
3180882|NCT01333293|Placebo Comparator|Placebo|
3180883|NCT01333280|Experimental|Double Trouble (DTR) group|Double Trouble in Recovery groups
3180884|NCT01333280|Active Comparator|Treatment as usual|Treatment as usual while on a waiting list for DTR groups
3180885|NCT01333267|Experimental|PTHrP group|Subjects receive PTHrP(1-36) starting with doses of 2 picomoles (pmols)/kg/hr for one week. Subsequent dosing groups are determined by the response to PTHrP doses.
3180886|NCT01333267|Experimental|PTH dosing group|Subjects receive PTH(1-34) starting with doses of 2 picomoles (pmols)/kg/hr for one week. Subsequent dosing groups are determined by the response to PTH doses.
3180914|NCT01333059|Placebo Comparator|Sedative Intervention|"At cycling time for midazolam, the continuous infusion of midazolam will be stopped by the bedside nurse. The nurse will start a pump containing a syringe labeled Study Drug M which will contain the placebo drug (normal saline). The switch to Study Drug M will occur twice daily at 0800 and 2000 for a period of 3 hours each. At cycling time for fentanyl, the continuous infusion of fentanyl will be stopped by the bedside nurse. The pump containing a syringe labeled Study Drug F, which will contain the placebo drug (normal saline), will be started. The switch Study Drug F will occur twice daily at 1400 and 0200 for a period of 3 hours each."
3180887|NCT01333254|No Intervention|Indwelling urinary catheter|Patients in this group with hip fracture will get an indwelling catheter at arrival to the orthopaedic ward. The patients with arthrosis get the indwelling catheter in the morning at the day of surgery. In both cases the indwelling catheter is inserted after shower with skin disinfectant. The catheter system is kept close. The catheter will be removed in the morning on day 2 after surgery. The patients are bladder-scanned every four-hour until normal bladder function is recaptured. If the bladder volume exceeds 400ml and the patient is unable to urinate, the patient will be re-catheterised. The procedure of the patients in this arm is in accordance with common practice in the Orthopaedic clinic.
3180888|NCT01333254|Experimental|Intermittent urinary catheterisation|Patients randomised to this arm will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 400 ml urine in the bladder, the patient will be intermittent catheterised.
3180889|NCT01333241|Experimental|Lifestyle behavior intervention|The 6-month lifestyle behavior intervention includes group education and individual teaching and coaching.
3180890|NCT01333228|Experimental|Endothelial Progenitors Cells|Autologous bone marrow-derived endothelial progenitor cells
3180891|NCT01333215||Group 1|Depressed older suicide non-attempters
3180892|NCT01333215||Group 2|Depressed older suicide attempters
3180893|NCT01333202|Experimental|Fresh lime|Those who were randomly assigned to receive fresh lime were instructed to use it every time they began to crave cigarettes and as often as they needed. Fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible. All participants in this group had to report the number of fresh lime slices used per day in the self-report card.
3180894|NCT01333202|Active Comparator|Nicotine gum|"The dosage of nicotine gum used in this group was primarily based on the participants' FTND scores. Those with FTND score of 4 or above were given 4-mg nicotine gum. The 2-mg gum was assigned only to light smokers. Appropriate gum use by chew and park technique was instructed to all subjects in this group. They were advised to use the gum whenever they began to crave a cigarette but not to exceed more than 20 pieces per day. All participants in this group also had to report the total number pieces of gum used per day in the self-report card. Like the lime use group, phone calls were also made every 2-3 days during the initial month of study to remind them of technique and record keeping."
3180895|NCT01333189|Experimental|RELOAD: Weight-bearing biofeedback exercise|RELOAD participants participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games. These biofeedback training sessions were provided in addition to the standard of care rehabilitation that the CONTROL group received. Total dose of exercise across groups was matched.
3180896|NCT01333189|Active Comparator|CONTROL: Standard of care exercise|CONTROL participants were provided two weeks of home rehabilitation (6 visits) by a physical therapist. Patients then progressed to outpatient rehabilitation, consisting of 4 weeks of treatment for a total of 6 weeks of standard of care rehabilitation. Total dose of exercise across groups was matched.
3180897|NCT01333176|Experimental|All volunteers have HbA1c test|All candidates receive same procedure
3180898|NCT01333163|Active Comparator|GLP-1|
3180899|NCT01333163|Placebo Comparator|Placebo|
3180900|NCT01333150|Experimental|Propranolol|
3180901|NCT01333150|Experimental|Placebo|
3180902|NCT01333137|Active Comparator|Gemcitabine and Carboplatin|Gemcitabine 1000 mg/m2/day on Days 1 & 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
3180903|NCT01333137|Experimental|P276-00 along with Gemcitabine and carboplatin|P276-00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 & 8 every 21 days.In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
3180904|NCT01333124|Experimental|Radiation: chemoradiotherapy with Gemcitabine|Radiation: chemoradiotherapy with Gemcitabine All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.
3180905|NCT01333111|Experimental|Prophylaxis, high dose (trial duration 52 weeks)|
3180906|NCT01333111|Experimental|Prophylaxis, low dose (trial duration 52 weeks)|
3180907|NCT01333111|Experimental|On-demand (trial duration 28 weeks)|
3180908|NCT01333098|Experimental|mifepristone|1 week mifepristone (followed by 3 weeks open label mifepristone)
3180909|NCT01333098|Placebo Comparator|placebo|1 week placebo(followed by 3 weeks open label mifepristone)
3180910|NCT01333085|Experimental|RAD001-paclitaxel-carboplatin|RAD001: 20,30 or 50 mg PO 9 weekly cycles Paclitaxel: 60 mg/m²IV, in 1 hour, 9 weekly cycles Carboplatin AUC2 IV in 1 hour,9 weekly cycles
3180911|NCT01333072|Active Comparator|Risperidone|Atypical antipsychotic
3180912|NCT01333072|Active Comparator|Aripiprazole|Atypical antipsychotic
3180913|NCT01333059|Active Comparator|Sedative control|"At cycling time for midazolam, the continuous infusion of midazolam will be stopped by the bedside nurse. The nurse will start a pump containing a syringe labeled Study Drug M which will contain the control drug (midazolam). The switch to Study Drug M will occur twice daily at 0800 and 2000 for a period of 3 hours each. At cycling time for fentanyl, the continuous infusion of fentanyl will be stopped by the bedside nurse. The pump containing a syringe labeled Study Drug F, which will contain the control drug (fentanyl), will be started. The switch to Study Drug F will occur twice daily at 1400 and 0200 for a period of 3 hours each."
3180949|NCT01332864|Active Comparator|OMT to the body except the head region|OMT is the intervention that will be applied to areas of somatic dysfunction in any region except the head.
3180915|NCT01333046|Experimental|Antigen-Escalation Stage|"The first stage will be an antigen-escalation stage using a fixed total dose of cells (5 x 10^6 cells/m^2 x 2) to evaluate the safety of the T cells primed against PRAME pepmix, and then SSX pepmix, and then MAGE A4 pepmix, and then NY-ESO pepmix, and then SURVIVIN pepmix."
3180916|NCT01333046|Experimental|Dose-Escalation Study Stage|The second stage will be a dose-escalation study, beginning with the same total dose of cells used in the antigen escalation phase (5 x 10^6 cells/m2 x 2). This second stage will evaluate the safety of T cells specific for all 5 tumor associated antigens.
3180917|NCT01333046|Experimental|azacytidine and multiTAA T cells Stage|This phase will administer aza intravenously at a dose of 75 mg/m2 after premedication with an anti-emetic such as ondansetron po or IV (up to a maximum dose of 16 mg ondansetron or equivalent). This phase will determine whether infusion of TAA-specific T cells (at dose level 2 - 1x10^7) targeting multiple tumor antigens in combination with azacytidine is safe, and whether CTL infusions (with or without azacytidine) increase the spectrum of epitopes/antigens targeted by endogenous T cells (epitope spreading).
3180918|NCT01333046|Experimental|Pediatric multiTAA T cells Stage|This phase will give patients < 18 years old two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10^7 cells/m2. This phase will test the safety and efficacy of multiTAA-specific T cells in pediatric patients with active HL/NHL.
3180919|NCT01333033|Experimental|Arm I (FOLFOX regimen)|Patients receive modified FOLFOX-6 therapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously on days 1-5. Treatment repeats every 14 days for 3 courses. Patients then undergo PET/CT scan. Patients with responsive disease (tumor metabolic activity decreased by >= 35%) receive 3 additional courses of FOLFOX-6 therapy and undergo concurrent RT (3D-conformal or intensity-modulated) once daily, 5 days a week, for approximately 6 weeks. Patients without responsive disease (tumor metabolic activity did not decrease by 35%) cross over to Arm II during RT.
3180920|NCT01333033|Experimental|Arm II (carboplatin + paclitaxel + radiation)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 2 courses. Patients then undergo PET/CT scan. Patients with responsive disease (tumor metabolic activity decreases >= 35%) continue to receive carboplatin IV over 30 minutes and paclitaxel IV over 1 hour once weekly for 5 weeks and undergo RT (3D-conformal or intensity-modulated) once a day, 5 days a week, for approximately 6 weeks. Patients without responsive disease (metabolic activity did not decrease by 35%) cross over to Arm I during RT
3180921|NCT01333020|Experimental|transglutaminase cross-linking of emulsion|The impact of enzyme cross linking of the protein stabilising the test emulsion on gastric emptying rate will be assessed. In this crossover study the subjects will also consume ( on a separate day)an emulsion of the same formulation but not cross-linked.
3180922|NCT01333007||Cohort|
3180923|NCT01332994|Experimental|1|
3180924|NCT01332994|Experimental|2|
3180925|NCT01332981||Cohort|
3180926|NCT01332968|Active Comparator|Rituximab+Chemotherapy|Participants will receive either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.
3180927|NCT01332968|Experimental|Obinutuzumab+Chemotherapy|Participants will receive either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.
3180928|NCT01332955|Experimental|Telaprevir-pegIFN alfa-2a-ribavirine|Single Group Assignment
3180929|NCT01332942|Placebo Comparator|Placebo|
3180930|NCT01332942|Experimental|Molidustat (BAY85-3934) 5 mg|
3180931|NCT01332942|Experimental|Molidustat (BAY85-3934) 10 mg|
3180932|NCT01332942|Experimental|Molidustat (BAY85-3934) 25 mg|
3180933|NCT01332942|Experimental|Molidustat (BAY85-3934) 50 mg|
3180934|NCT01332942|Experimental|Molidustat (BAY85-3934) 75 mg|
3180935|NCT01332929|Experimental|Bevacizumab|first level dose : 5 mg/kg Second level dose : 10 mg/kg Third level dose : 15 mg/kg
3180936|NCT01332916|Experimental|patients aged 45 and over group|patients aged 45 and over with breast cancer and should receive an adjuvant chemotherapy
3180937|NCT01332916|Active Comparator|healthy volunteers (controls) aged 45 and over|healthy volunteers (controls) aged 45 and over
3180938|NCT01332903|Experimental|1|[14C] AZD5069
3180939|NCT01332890|Experimental|Sequence 1|
3180940|NCT01332890|Experimental|Sequence 2|
3180941|NCT01332890|Experimental|Sequence 3|
3180942|NCT01332890|Experimental|Sequence 4|
3180943|NCT01332890|Experimental|Sequence 5|
3180944|NCT01332890|Experimental|Sequence 6|
3180945|NCT01332877|Experimental|enriched breakfast|high carbohydrate, high protein breakfast providing 600 kcal, 50% carbohydrate, 20% protein, 30% fat
3180946|NCT01332864|Active Comparator|OMT to the head and rest of body|OMT is the intervention that will be applied to areas of somatic dysfunction as well as to the head using a compression of the fourth ventricle (CV4) technique.
3180947|NCT01332864|Placebo Comparator|Light touch|Light touch will be applied to the head region for 10 minutes with the patient at rest in the supine position.
3180948|NCT01332864|Experimental|OMT with CV4 to head|OMT is the intervention using the CV4 technique to the head region for 10 minutes with patient at rest.
3180950|NCT01332851|Experimental|Promoting First Relationships (PFR)|"PFR is a strengths-based 10 week in-home parenting intervention based on attachment theory. Each week has a theme for discussion, an activity, and time for joining - checking in with the parent, listening to their concerns and establishing a positive, supportive relationship. The sessions include handouts which focus on the content area covered that day and applying a topic to their relationship with their child. The provider also videotapes playtime between parent and child. On alternate weeks, the provider watches the video with the parent, reflecting on both the parent's and the child's needs. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent identify her own feelings and needs around parenting."
3180951|NCT01332851|Active Comparator|Resource & Referral|This condition consists of 1) Resource and Referral assistance provided over the phone, and 2) Local Services Resource Packet. The participant receives a phone call from a Resource and Referral Specialist to conduct a needs assessment to identify the particular needs or concerns of the family (such as housing needs, mental health, tangible goods). If a need is identified, the Referral and Referral Specialist will provide the family with local information regarding the stated need. The R&R provider makes two follow-up check in calls with the families. In addition, families can call the Research and Referral Specialist if additional needs arise. The resource packet includes information organized by type of need or resource. These packets are updated regularly as services change over time.
3180952|NCT01332838|Experimental|Sigvaris special compression stocking|
3180953|NCT01332838|Active Comparator|Standard Compression|
3180954|NCT01332825|No Intervention|olfactory dysfunction|subjects diagnosed with olfactory dysfunction
3180955|NCT01332825|No Intervention|normal olfaction, no saline|no smell dysfunction, not randomized to saline nasal irrigation for 7 days
3180956|NCT01332825|Other|normal olfaction|normal olfaction, randomized to saline nasal irrigation for 7 days
3180957|NCT01332812|Experimental|Dexamethasone, POCD, psycological tests|"Subjects will be randomly assigned in two groups: For the Dexamethasone group, 8mg of dexamethasone will be administered intravenously before the induction of general anesthesia. For Control Group, no Dexamethasone will be administered.~Tests for evaluation of quality of life, depressive symptoms and neuropsychological battery to assess general mental status, learning, attention, visuospatial perception, immediate memory, operational and executive skills and recall, including processing speed. This assessment will be applied before surgery, and 3, 7, 21, 90 and 180 days after surgery."
3180958|NCT01332812|Sham Comparator|Control, POCD, psycological tests|"Subjects will be randomly assigned in two groups: For the Dexamethasone group, 8mg of dexamethasone will be administered intravenously before the induction of general anesthesia. For Control Group, no Dexamethasone will be administered.~Tests for evaluation of quality of life, depressive symptoms and neuropsychological battery to assess general mental status, learning, attention, visuospatial perception, immediate memory, operational and executive skills and recall, including processing speed. This assessment will be applied before surgery, and 3, 7, 21, 90 and 180 days after surgery."
3180959|NCT01332799|Active Comparator|Allopurinol|
3180960|NCT01332799|Placebo Comparator|Placebo (sugar pill)|
3180961|NCT01332786|Experimental|Tigecycline|
3180962|NCT01332773|Experimental|Artery first group|"The basic principle of the artery first approach is the early identification of the SMA at its origin at the aorta with the further resection then being guided by its anatomic course.~The dissection is carried cephalad along the aorta until the origin of the SMA is reached. The posterior and right aspect of the SMA is then dissected over a few centimeters. On the right side of the SMA a replaced or accessory right hepatic artery, if present, will be identified and preserved. This maneuver should be done, if infiltration of the SMA is suspected as the procedure can be terminated at this point. Once the situation at the SMA is assessed and resectability is confirmed resection will be done."
3180963|NCT01332773|Active Comparator|Conventional Group|A wide Kocher manoeuver is performed to fully mobilize the duodenum and the head of the pancreas. The colonic mesentery on the right side is separated from the anterior surface of the duodenum and the head of the pancreas. The size of the tumor and its relation to the superior mesenteric artery, the celiac trunk, the mesentery, the portal vein, and the superior mesenteric vein is assessed. If resectability is given a Kausch-Whipple's resection is performed.
3180964|NCT01332760|Active Comparator|narrow diameter heavy dental tool|periodontal tools for dental scaling and cleaning provided that have a narrow diameter (8mm) made of heavy material (steel).
3180965|NCT01332760|Experimental|light large diameter dental tool|periodontal tools for scaling and tooth cleaning provided with large diameter (11mm) handle made of light weight material
3180966|NCT01332747|Experimental|Safoof e Muhazzil in its conventional powder form|safoof e muhazzil in its conventional powder form 5 gms twice daily given orally
3180967|NCT01332747|Experimental|compressed tablet of safoof e muhazzil|compressed tablet of safoof e muhazzil is given in equivalent dose orally
3180968|NCT01332747|Active Comparator|atorvastatin|atorvastatin 10mg daily as a standard control
3180969|NCT01332734||severe sepsis and septic shock|
3180970|NCT01332721|Experimental|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
3180971|NCT01332708|Experimental|Obese and overweight subjects|The participants are overweight and obese people with and without metabolic syndrome that will participate in diet groups.
3180972|NCT01332695|Experimental|ST101|ST101 oval tablets
3180973|NCT01332695|Placebo Comparator|Placebo|oval tablets to match ST101 tablet
3180974|NCT01332682|Experimental|Resistance Training and Nutrition Counseling|
3180975|NCT01332682|Other|Nutrition Counseling|
3180976|NCT01332669|Active Comparator|chemoembolization|HCC patients received chemoembolization
3180977|NCT01332669|Other|Historical use of c-TACE using Lipiodiol and doxorubicin|The control arm will be of the patients that have been treated historically in the centers with conventional TACE (that is Lipiodiol plus doxorubicin).
3180978|NCT01332656|Experimental|Arm A|Ombrabulin, Paclitaxel and Carboplatin
3180979|NCT01332656|Placebo Comparator|Arm B|Placebo, Paclitaxel and Carboplatin
3181009|NCT01332500||adult migraineurs with/without aura|Adult migraine patients >18-65 years who have initiated treatment for migraine with Treximet ™ or other orally administered triptan.
3180980|NCT01332643|Active Comparator|Test|The test group will consist of patients undergoing blastocyst biopsy followed by vitrification (embryo freezing), and in which the biopsied cells will be analyzed with a comprehensive chromosome analysis technique (array Comparative Genome hybridization or aCGH) and only one chromosomally normal embryo will be replaced in a thawed cycle.
3180981|NCT01332643|No Intervention|control|The control group will consist of patients in which one embryo will be replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patient does not become pregnant, successive embryo transfers of frozen embryos will be performed, but not as part of the study.
3180982|NCT01332630|Experimental|TPI 287|TPI 287 administered at 160 mg/m2 by vein on Day 1 and repeated every three weeks. Day 1 of each subsequent cycle is equivalent of day 22 of the previous cycle; pre TPI 287: Dexamethasone 6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, Dexamethasone 10 mgby vein may be given 30-60 minutes prior to treatment with TPI 287, Benadryl 12.5-25 mg IV push over 30-60 minutes, and Ranitidine 1mg/kg IV over 30-60 minutes.
3180983|NCT01332617|Experimental|Treatment with combination therapy|Treatment with combination therapy of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine, and Methylprednisolone.
3180984|NCT01332604|Experimental|A|
3180985|NCT01332604|Experimental|B|
3180986|NCT01332591|Active Comparator|Complete revascularization|"Percutaneous coronary intervention of non-infarct coronary arteries"
3180987|NCT01332591|No Intervention|Conservative management|standard guideline-based medical therapy
3180988|NCT01332578|Experimental|Test Product|Paracetamol, phenylephrine and ascorbic acid to be administered in 150 milliliters (mL) of hot water.
3180989|NCT01332578|Active Comparator|Paracetamol tablet|Two paracetamol 500 mg tablets to be administered with 150 mL of hot water.
3180990|NCT01332565|Experimental|Single Arm|All subjects will receive a 50 mg single dose of GSK1349572
3180991|NCT01332552|Experimental|Part 1: Single dose escalation|GSK2485852 planned single doses are placebo, 70 mg, 420 mg, 70 mg with food
3180992|NCT01332552|Experimental|Part 2: Repeat dose escalation|GSK2485852 planned repeat doses are placebo, 420mg BID, 420mg TID, 630mg BID
3180993|NCT01332552|Experimental|Part 3: GSK2485852 + Ritonavir|GSK2485852 single dose 70mg, 210 mg +Ritonavir 100mg x 1 day; GSK2485852 210mg + Ritonavir 100mg single dose x 3 days;
3180994|NCT01332539||drug-resistant partial epilepsy|
3180995|NCT01332539||controlled partial epilepsy|
3180996|NCT01332526||Patients with BMI> 30 and metabolic syndrome ( ATP III).|Patients with BMI> 30 and metabolic syndrome ( ATP III).
3180997|NCT01332526||Patient with BMI> 30 without metabolic syndrome.|Patient with BMI> 30 without metabolic syndrome.
3180998|NCT01332526||Normal healthy control|healthy persons( without renal disease, cardiovascular diseases, diabetes mellitus, BMI < 25;normotensives ).
3180999|NCT01332526||Patients with CKD stage III and uric acid < 7 mg/dl|"Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid < 7 mg/dl.~without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressives agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)"
3181000|NCT01332526||Patients with CKD stage III and uric acid > 7 mg/dl|"Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid > 7 mg/dl~without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)"
3181001|NCT01332526||Patient with asymptomatic hyperuricemia|Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function
3181002|NCT01332526||Hemodialysis patients|"Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function Hemodialysis patients.~CKD: nondiabetic nephropathy~duration hemodialysis 3-48 months~Hb-11-13 g/dl~well controlled hypertension ( < 140/90 mmHg)~without ACEi, ARB, allopurinol treatment~residual diuresis will be estimated for last 48 hours-between mid and next dialysis"
3181003|NCT01332513|Experimental|ABFCED sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 milligram (mg) twice daily (BID) dosing of ezogabine modified release (MR) tablet in periods A, B, C, D and E and will receive 200 mg three times daily (TID) dosing of ezogabine immediate release (IR) tablet in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
3181004|NCT01332513|Experimental|BCADFE sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
3181005|NCT01332513|Experimental|CDBEAF sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
3181006|NCT01332513|Experimental|DECFBA sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
3181007|NCT01332513|Experimental|EFDACB sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
3181008|NCT01332513|Experimental|FAEBDC sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
3181012|NCT01332474||JCP|treatment of Equinus Foot due to Lower Limb Spasticity in Juvenile Cerebral Palsy Patients Aged 2-year or Older
3181013|NCT01332461||COPD Patients|Patients over the age of 40 with a COPD-related hospital or ER visit
3181014|NCT01332448||Orlistat 120|Orlistat 120mg tid
3181015|NCT01332448||Orlistat 60|Orlistat 60 mg tid
3181016|NCT01332448||Placebo|No active drug
3181017|NCT01332435||Early 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with early initiation of 5ARI (within 30 days of initiation of AB)
3181018|NCT01332435||Late 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with late initiation of 5ARI (more than 30 days but less than 6 months after initiation of AB)
3181019|NCT01332422||Pediatric patients prescribed ADOAIR|Pediatric patients with asthma prescribed ADOAIR during study period
3181020|NCT01332409||Patients prescribed salmeterol and fluticasone|Patients with chronic obstructive pulmonary disease prescribed salmeterol and fluticasone during study period
3181021|NCT01332396||Patients prescribed TYKERB|Patients with HER2 overexpressing inoperable or recurrent breast cancer
3181022|NCT01332383||Patients prescribed AMERGE|Patients with migraine disorders prescribed AMERGE during study period
3181023|NCT01332370||Adults with Type 2 Diabetes|Subjects with a diagnosis (ICD-9 code) of diabetes
3181024|NCT01332357||Fluticasone propionate/salmeterol combination ED MD|Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the ED physician
3181025|NCT01332357||Fluticasone propionate/salmeterol combination OP MD|Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the OP physician
3181026|NCT01332344||Asthma patients treated with inhaled corticosteroids|Asthma subjects newly prescribed inhaled corticosteriods
3181027|NCT01332331|Experimental|Low Dose Ambrisentan|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
3181028|NCT01332331|Experimental|High Dose Ambrisentan|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
3181029|NCT01332318|Placebo Comparator|Placebo|XP13512 Placebo + Diphenhydramine Placebo
3181030|NCT01332318|Experimental|XP13512 1200 mg|XP13512 1200 mg/day + Diphenhydramine Placebo
3181031|NCT01332318|Experimental|XP13512 1800 mg|XP13512 1800 mg/day + Diphenhydramine Placebo
3181032|NCT01332318|Active Comparator|Placebo + Diphenhydramine|XP13512 Placebo + 50 mg Diphenhydramine
3181033|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 600 mg|GEn (XP13512/GSK1838262) 600 mg
3181034|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 1200 mg|GEn (XP13512/GSK1838262) 1200 mg
3181035|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 1800 mg|GEn (XP13512/GSK1838262) 1800 mg
3181036|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 2400 mg|GEn (XP13512/GSK1838262) 2400 mg
3181037|NCT01332305|Placebo Comparator|Placebo|Placebo
3181038|NCT01332292|Active Comparator|COHORT 1 RANDOMISATION A|(8-11 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Day 2-13 = home dosing
3181039|NCT01332292|Placebo Comparator|COHORT 1 RANDOMISATION B|(8-11 years old) Repeat dose session: matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
3181040|NCT01332292|Active Comparator|COHORT 2 RANDOMISATION A|(5-7 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
3181041|NCT01332292|Placebo Comparator|COHORT 2 RANDOMISATION B|(5-7 years old) Repeat dose session: Matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
3181042|NCT01332279|Experimental|Treatment (enzyme inhibitor and radiation therapy)|Patients receive RAD001 PO and erlotinib hydrochloride PO QD. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo EBRT BID 5 days a week for 5 weeks.
3181043|NCT01332266|Active Comparator|Active Comparator; Phase IB: Cohort 1,2,and 3|"Phase Ib:~Cohort 1; 200 mg E7050 + 250 mg/m2 cetuximab Cohort 2; 300 mg E7050 + 250 mg/m2 cetuximab Cohort 3; 400mg E7050 + 250mg/m2 cetuximab~Phase II: Arm 1; MTD E7050 + 250 mg cetuximab Arm 2; 250 mg cetuximab~Interventions: Drug cetuximab"
3181044|NCT01332266|Active Comparator|Phase II|"Phase II:~Arm 1; MTD E7050 + 250 mg/m2 cetuximab Arm 2; 250 mg/m2 cetuximab"
3181045|NCT01332253|Experimental|Intravenous Ibuprofen|
3181046|NCT01332253|Placebo Comparator|Normal Saline|
3181047|NCT01332240|Experimental|Endosonography|Endoscopic ultrasonography (EBUS-TBNA +/- EUS-FNA) for invasive mediastinal nodal staging
3181048|NCT01332227|Experimental|Atazanavir/Ritonavir + Raltegravir|Atazanavir + Ritonavir (heat-stable) + Raltegravir
3181049|NCT01332227|Other|Atazanavir/Ritonavir + Tenofovir/Emtricitabine|"Reference~Atazanavir + Ritonavir (heat-stable) + Tenofovir/Emtricitabine"
3181050|NCT01332214|Experimental|AZD2820|
3181051|NCT01332214|Placebo Comparator|Placebo|
3181052|NCT01332201|Experimental|Advagraf|
3181053|NCT01332201|Active Comparator|Prograf|
3181054|NCT01332188|Experimental|AC-170 0.05%|
3181055|NCT01332188|Experimental|AC-170 0.1%|
3181056|NCT01332188|Experimental|AC-170 0.24%|
3181057|NCT01332188|Placebo Comparator|AC-170 0%|
3181058|NCT01332175|Active Comparator|Provent|
3181059|NCT01332175|Placebo Comparator|Placebo-Provent|
3181060|NCT01332175|Active Comparator|CPAP|
3181061|NCT01332162|Experimental|Biventricular pacing|All patients will be pacing during two years
3181062|NCT01332162|Active Comparator|No Pacing during the first year|No Pacing during the first year. In the second year all patients will be pacing
3181063|NCT01332149|Experimental|300 mg/day pregabalin (Lyrica)|Patient take pregabalin capsule twice a day
3181064|NCT01332149|Placebo Comparator|Placebo|
3181065|NCT01332136||Endoscopic sinus surgery|Patients electing endoscopic sinus surgery for chronic rhinosinusitis
3181066|NCT01332136||Medical management|Continued medical management for symptoms of chronic rhinosinusitis
3181067|NCT01332123|Experimental|Alignment perturbations|The following modifications will be applied to the prostheses: increased foot plantar flexion, increased foot dorsal flexion, increased foot supination, increased foot pronation (always 2 degrees from the neutral position)
3181068|NCT01332110|Experimental|Knee abduction moment-reducing footwear|Footwear that is known to decrease knee abduction moments of force in healthy subjects. May include orthotics, or footwear that allows relative movement between the heel section of the outsole and rest of the shoe.
3181069|NCT01332110|Placebo Comparator|Control footwear|Standard, off-the-shelf running shoes with no mechanical modifications.
3181070|NCT01332097|Experimental|Treatment A|single 75mg oral dose of BCT197 capsules + single oral dose of prednisone placebo capsules
3181071|NCT01332097|Placebo Comparator|Treatment B|single oral dose of BCT197 placebo capsules + single oral dose of prednisone placebo capsules
3181072|NCT01332097|Active Comparator|Treatment C|single oral dose of BCT 197 placebo capsules + single oral dose of 40mg prednisone capsules
3181073|NCT01332097|Experimental|Treatment D|single oral dose of 20mg dose of BCT197 capsules
3181074|NCT01332097|Placebo Comparator|Treatment E|single oral dose of BCT 197 placebo capsules
3181075|NCT01332097|Experimental|Treatment F|single oral dose of 20 mg dose of BCT197 capsules on Day 1 and Day 6
3181076|NCT01332097|Placebo Comparator|Treatment G|single oral dose of BCT 197 placebo capsules on Day 1 and Day 6
3181077|NCT01332097|Experimental|Treatment H|single oral dose of 75mg dose of BCT197 capsules on Day 1 and Day 6
3181078|NCT01332097|Placebo Comparator|Treatment I|single oral dose of BCT 197 placebo capsules on Day 1 and Day 6
3181079|NCT01332084|Experimental|hypoallergenic wheat cereals|HA wheat cereal used in a SOTI test
3181080|NCT01332071|Active Comparator|Avandamet test product|Test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 miligrams (mg) + 1000 mg in Period 1, followed by a 7-day washout period during which no medication was administered, followed by reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 mg + 500 mg in Period 2
3181081|NCT01332071|Active Comparator|Avandamet reference product|Reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 miligrams (mg) + 500 mg in Period 1; followed by a 7-day washout period during which no medication was administered; followed by test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 mg + 1000 mg in Period 2
3181082|NCT01332058|Experimental|Motivational Interviewing (MI)|
3181083|NCT01332045|Sham Comparator|Saline boluses in nerve catheter|A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
3181084|NCT01332045|Active Comparator|Continuous saphenous nerve block|Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
3181085|NCT01332032||Reminder Letter|"A letter sent to women reminding them that are coming due or overdue for a mammogram. It contains a reminder that their primary care provider (PCP) recommends mammography screening every 1-2 years. It urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. Repeat Booster letters will be sent in subsequent years to those failing to get a mammogram."
3181086|NCT01332032||Reminder Call|"A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a mammogram within 2 weeks, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offer to schedule a mammogram for her. Repeat Booster letters will be sent and repeat scheduler calls made in subsequent years to those failing to get a mammogram."
3181087|NCT01332032||Counselor Call|"A reminder letter as above is sent first. If a woman does not call in to schedule a mammogram within 2 weeks, a second letter is sent along with a mammography educational booklet. The second letter also reiterates a reminder that her PCP recommends screening every 1-2 years, and offers a special number to call to schedule. If a woman does not schedule within 8-10 days, a counselor will call. The protocol script included tailored barriers counseling, correction of misinformation and motivational interviewing. Repeat booster letters will be sent and repeat counselors calls made in subsequent years to those failing to get a mammogram. techniques. Average calls last 20-30 minutes."
3181088|NCT01332019|Experimental|peginterferon beta-1a Q4W|125 µg peginterferon beta-1a administered by subcutaneous (SC) injection every 4 weeks (Q4W) for at least 2 years and up to 4 years.
3181089|NCT01332019|Experimental|peginterferon beta-1a Q2W|125 μg peginterferon beta-1a administered by SC injection every 2 weeks (Q2W) for at least 2 years and up to 4 years.
3181090|NCT01332006|Experimental|Intra-bone injection|Intra-bone transplantation of hematopoietic stem cells from cord blood
3181091|NCT01331993|Experimental|1|Treatment order : A, B, C
3181092|NCT01331993|Experimental|2|Treatment order : B, C, A
3181093|NCT01331993|Experimental|3|Treatment order : C, A, B
3181094|NCT01331993|Experimental|4|Treatment order : A, C, B
3181095|NCT01331993|Experimental|5|Treatment order : B, A, C
3181096|NCT01331993|Experimental|6|Treatment order : C, B, A
3181097|NCT01331980||cystic fibrosis|children aged 6-12 years of age and Tanner stage 1 with a diagnosis of cystic fibrosis
3181098|NCT01331980||healthy controls|children ages 6-12 years and Tanner stage 1 without cystic fibrosis or other chronic disease that affects bone health
3181099|NCT01331967|Experimental|Pioglitazone, Placebo|
3181100|NCT01331954|Experimental|HIFU|
3181101|NCT01331941|Experimental|Group 1|Cancer subjects with normal renal function.
3181102|NCT01331941|Experimental|Group 3|Cancer subjects with moderate renal impairment.
3181103|NCT01331941|Experimental|Group 4|Cancer subjects with severe renal impairment.
3181104|NCT01331941|Experimental|Group 2|Cancer subjects with mild renal impairment.
3181105|NCT01331928|Experimental|Capecitabine, Oxaliplatin, Docetaxel , Gastric cancer|
3181106|NCT01331915|Experimental|Theravac|Theravac® is a recombinant adenylate cyclase toxin from Bordetella pertussis that has been detoxified by mutation of its catalytic domain, and which has been coupled to the Tyrosinase.A2 epitope YMDGTMSQV.
3181107|NCT01331902|Experimental|Adenosine Followed by Nicorandil|
3181108|NCT01331902|Experimental|Nicorandil Followed by Adenosine|
3181109|NCT01331889||Potassium concentration|plasma potassium concentrations in the Fluid Management System (FMS) reservoir, arterial blood, and central venous blood
3181110|NCT01331876|Experimental|reference therapy|20 OCD patients following 15 sessions of the reference CBT (Bouvard,2006)
3181111|NCT01331876|Experimental|experimental therapy|20 OCD patients following 15 sessions of reference CBT associated with a new psychopedagogic task developed by our team.
3181113|NCT01331850|Experimental|Previous null responders (Cohort B): Group 4|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 4 will receive RO5024048 1000 mg twice a day and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
3181114|NCT01331850|Experimental|Previous null responders (Cohort B): Group 5|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 5 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
3181115|NCT01331850|Experimental|Previous null responders (Cohort B): Group 6|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 6 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks. In addition, patients in Group 6 will receive another 24 weeks of Pegasys plus Copegus treatment.
3181116|NCT01331850|Experimental|Previous partial responders (Cohort A): Group 1|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 1 will receive RO5024048 1000 mg twice a day and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
3181117|NCT01331850|Experimental|Previous partial responders (Cohort A): Group 2|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 2 will receive Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
3181118|NCT01331850|Experimental|Previous partial responders (Cohort A): Group 3|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 3 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
3181119|NCT01331837|Active Comparator|Etanercept|
3181120|NCT01331837|Experimental|Tocilizumab|
3181121|NCT01331824|Experimental|Amrubicin|35 mg/m2/day intravenously
3181122|NCT01331798|Experimental|Test: TissuGlu Adhesive|Patients received the TissuGlu Adhesive Treatment
3181123|NCT01331798|Active Comparator|Control|Control Arm received no TissuGlu- Standard of Care received.
3181124|NCT01331785|Experimental|Midodrine|
3181125|NCT01331772|Other|Control arm|Dietetic follow-up only
3181126|NCT01331772|Experimental|Intervention arm|Dietetic + adapted physical activity
3181127|NCT01331759|Experimental|Immediate Neuropattern™|The experimental group will undergo Neuropattern™ stress diagnostics immediately after inclusion in the study.
3181128|NCT01331759|Placebo Comparator|Later Neuropattern™|The control group will undergo Neuropattern™ stress diagnostics three months after inclusion in the study.
3181129|NCT01331746|Experimental|APD515|Active APD515 treatment 20 mg qds for 7 days
3181130|NCT01331746|Placebo Comparator|Placebo|
3181131|NCT01331733||hMG-HP|Patients with a condition
3181132|NCT01331733||hMG-HP + GnRH antagonist|Patients with a condition
3181133|NCT01331720||FSH:LH 1:1 - Treatment Group A|"Patients with a condition~LH (luteinizing hormone)"
3181134|NCT01331720||FSH:LH 3:2 - Treatment Group B|Patients with a condition
3181135|NCT01331720||FSH:LH 3:1 - Treatment Group C|Patients with a condition
3181136|NCT01331720||FSH:LH 3:0 - Treatment Group D|Patients with a condition
3181137|NCT01331720||Initially FSH:LH 3:0 and on S6 FSH:LH 1:1 - Treatment Group E|Patients with a condition
3181138|NCT01331707|Active Comparator|Promus Element|
3181139|NCT01331707|Active Comparator|Resolute Integrity|
3181140|NCT01331694||COPD|copd patients 65 years and older
3181141|NCT01331681|Experimental|Intravitreal Aflibercept Injection 2Q4|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
3181142|NCT01331681|Experimental|Intravitreal Aflibercept Injection 2Q8|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
3181143|NCT01331681|Active Comparator|Macular Laser Photocoagulation (Control)|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
3181144|NCT01331668||renal allograft donors and recipients|All de novo renal allograft recipients transplanted at the University Hospitals Leuven
3181145|NCT01331655|Experimental|Arm 1|
3181146|NCT01331655|Experimental|Arm 2|
3181147|NCT01331655|Active Comparator|Arm 3|
3181148|NCT01331642||Observation|Patients from the first day of life with Gaucher Disease based on biochemical and/or genetic criteria or high-grade suspicion for Gaucher disease.
3181149|NCT01331629|Experimental|ART-THERAPIE|supported in art therapy with other supportive care available in the facility
3181150|NCT01331629|No Intervention|standard group|standard care (supportive care available in each facility)
3181151|NCT01331616|Experimental|Bevacizumab (Avastin)|
3181152|NCT01331603||MDS and primary myelofibrosis patients|patients with in iron overloaded MDS patients (low and high risk ), and also patients with primary myelofibrosis. The risk stratification of these patients will be calculated according to the IPSS (International Prognostic Scoring System).
3181153|NCT01331590|Experimental|G-CSF + Ifosfamide + Etoposide + Dexamethasone + Mesna|"G-CSF = 10 mcg/kg/d SQ starting on day 1 and continuing until ANC >=1000/mcL x 2 days~Ifosfamide = 3330 mg/m2/d CIVI over 24 hours on Days 4-6~Etoposide = 150 mg/m2 IV over 2 hours BID on Days 4-6~Dexamethasone = 5 mg/m2 PO or IV BID on Days 4-10~Mesna = 2660 mg/m2/d continuous IV infusion over 24 hours on Days 4-6. 2000 mg/m2 continuous IV infusion over 12 hours on Day 7 to be started immediately after completion of ifosfamide."
3181154|NCT01331577|Experimental|Cognitive behavioural Intervention|
3181155|NCT01331577|Experimental|Integrative Kinesiology Intervention|
3181156|NCT01331577|No Intervention|Waiting-List control group|
3181157|NCT01331564|Experimental|electronic intervention group 2|(e-intervention 2) receives a behavioral intervention through a website during pregnancy and until 18 months postpartum
3181158|NCT01331564|Experimental|electronic intervention group 1|(e-intervention 1) receives a behavioral intervention through a website during pregnancy. During the postpartum period this arm receives the same non-weight-related information as the control arm
3181160|NCT01331551||men with inflammatory bowel disease|Men between the ages of 18-55 with inflammatory bowel disease who are taking mesalamine medication.
3181161|NCT01331538||adolescents with TMD|adolescents with temporomandibular dysfunction
3181162|NCT01331538||No TMD|adolescents without temporomandibular dysfunction
3181163|NCT01331525|Experimental|Single stage non-randomised|"Patients will receive Carboplatin and Etoposide. Both Chemotherapy drugs will be delivered as a 21 day cycle (q21) with up to a maximum of 6 cycles delivered according to response unless progressive disease (RECIST Version 1.0) and or excessive toxicity.~Ipilimumab will be administered at a dose of 10mg/kg IV on day 1 of cycles 3-6 of Chemotherapy.~In the absence of immune related progression of disease or unacceptable toxicity, subsequent maintenance doses of Ipilimumab will be delivered every 12 weeks starting at week 30 at a dose of 10 mg/kg until unacceptable toxicity or immune related disease progression"
3181164|NCT01331499|Experimental|Bipolar Sealer|Standard of care blood sparing techniques with bipolar sealer
3181165|NCT01331499|Active Comparator|Control|Standard of care blood sparing techniques without the use of bipolar sealer
3181166|NCT01331486|Placebo Comparator|Placebo|Placebo capsule
3181167|NCT01331486|Active Comparator|Low dose|
3181168|NCT01331486|Active Comparator|Mid dose|
3181169|NCT01331486|Active Comparator|High dose|
3181170|NCT01331473|Active Comparator|Carotid Artery Stenting without Protection|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and without embolic protection device
3181171|NCT01331473|Active Comparator|Carotid Artery Stenting with Proximal Protection|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and with a proximal embolic protection device provided by the GORE Neuro Protection System
3181172|NCT01331460|Experimental|RBT Experimental|
3181173|NCT01331460|Active Comparator|Case-Management: Treatment as Usual|
3181174|NCT01331408|Experimental|Macrolane VRF30|Injection of Macrolane VRF30 in buttocks
3181175|NCT01331395|No Intervention|IVF-No Acupuncture|IVF with no Traditional Chinese Medicine: Acupuncture
3181176|NCT01331395|Active Comparator|IVF-Acupuncture|IVF with Traditional Chinese Medicine: Acupuncture
3181177|NCT01331382|Experimental|250mg trans- resveratrol|
3181178|NCT01331382|Experimental|250mg trans-resveratrol with 20mg piperine|
3181179|NCT01331382|Placebo Comparator|Placebo|
3181180|NCT01331369|Active Comparator|Control|Usual care. It means routine medical care that include free demand consultation and free medicines.
3181181|NCT01331369|Experimental|Intervention|Intensification of care. Besides routine medical care that include free demand consultation and free medicines, subjects were invited to have 6 structured medical encounters based on a social-psychological approach. Doctors must follow a protocol to conduct the encounter that have around 30 minutes each.
3181182|NCT01331356|Experimental|Injection of botulinum toxin type A|
3181183|NCT01331330|Active Comparator|Group B|Low Programming
3181184|NCT01331330|Experimental|Group A|Normal Programming
3181185|NCT01331317|Other|Paricalcitol|Crossover study between paricalcitol and placebo
3181186|NCT01331304|Other|Li + APT|Study participants will take lithium in addition to any other medications recommended by the study physician.
3181187|NCT01331304|Other|QTP + APT|Study participants will take quetiapine in addition to any other medications recommended by the study physician.
3181188|NCT01331291|Experimental|Arm A|Patients who are surgical candidates. Participants are given oral bosutinib, 400mg daily, for 7-9 days prior to resection. After at least 10 days elapsed post-operatively, bosutinib dosing was resumed.
3181189|NCT01331291|Experimental|Arm B|Patients that are not surgical candidates. Participants are given oral bosutinib, 400 mg daily in 28 day cycles until disease progression, intolerability or withdrawal of consent.
3181190|NCT01331278|Active Comparator|Custom Cutting Blocks|
3181191|NCT01331278|Active Comparator|Computer Assisted Surgery|
3181192|NCT01331265||no treatment|
3181193|NCT01331252|Experimental|supine body position|Consecutive patients admitted with severe tetanus to the tetanus intensive care ward will be eligible to be included in the study. An envelope for the next study number will be opened in which patients will be randomly allocated to either semi-recumbent (30 degree) or supine (0 degree) body position
3181194|NCT01331252|Experimental|semi-recumbent|Consecutive patients admitted with severe tetanus to the tetanus intensive care ward will be eligible to be included in the study. An envelope for the next study number will be opened in which patients will be randomly allocated to either semi-recumbent (30 degree) or supine (0 degree) body position
3181195|NCT01331239|Experimental|LCI699|Ascending dose from 2mg bid or 5 mg bid, up to 30 mg bid
3181196|NCT01331226|Experimental|3 session telephone counseling|
3181197|NCT01331226|Experimental|1 session telephone counseling|
3181198|NCT01331226|Active Comparator|written materials|
3181199|NCT01331213|Active Comparator|Pregabalin|Subjects randomized to this arm received a single dose of pregabalin 200mg orally.
3181200|NCT01331213|Placebo Comparator|Placebo|Subjects randomized to this arm received a single dose of placebo orally.
3181201|NCT01331187|Active Comparator|Usual care|Usual care diagnostics. No routinely ultrasound examination
3181202|NCT01331187|Experimental|Routinely ulasonography|Patients will routinely be examined with ultrasound at admittance in addition to usual care diagnostics
3181203|NCT01331174|Experimental|High dose PSW groups|The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W. These settings were based on the fact that applications with mean power below 20W minimize the thermal effects
3181204|NCT01331174|Placebo Comparator|Placebo|A placebo group was also established, in which the PSW device was turned on but kept in stand-by mode during 19 minutes without any electrical current being applied in the patients
3181205|NCT01331174|No Intervention|Control|The control group was composed of patients that were not submitted to any form of treatment and all patients were instructed to maintain their daily activities
3181206|NCT01331161|Experimental|Older group|Participants between the ages of 60-79
3181207|NCT01331161|Experimental|Younger group|Participants between the ages of 25-40
3181208|NCT01331148|Active Comparator|Vitamin D|10,000 IU per caplet, with vitamin D dose based on weight, ranging from 240,000 IU to 600,000 IU. Patients will receive calcium/vitamin D daily soft chew as well.
3181209|NCT01331148|Placebo Comparator|Placebo|placebo only, all patients will receive calcium/vitamin D chew
3181210|NCT01331135|Experimental|sirolimus treatment|Dose escalation of sirolimus with starting dose at 1 mg/m2 and increasing to a possible 3 mg/m2.
3181211|NCT01331122|Experimental|droxidopa|Northera (2R,3S)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid L-DOPS L-threo-dihydroxyphenylserine Droxidopa SM-5688
3181212|NCT01331122|Placebo Comparator|placebo|placebo
3181213|NCT01331109|Experimental|Milnacipran|oral administration, twice daily dosing
3181214|NCT01331096||Anesthetic drugs manually administrated|
3181215|NCT01331096||Automated anesthesia delivery system|
3181216|NCT01331083|Experimental|PX-866|
3181217|NCT01331070|Experimental|PATIENT|Patients, half with moderate (GOLD II) and half with severe (GOLD III) COPD
3181218|NCT01331070|Other|Accepts Healthy Volunteers|Control arm with the same intervention
3181219|NCT01331057||1:Sri Lankais|Children aged of four to six years old, in the nursery school and if their first language is unique : tamil.
3181220|NCT01331057||2: Algerian|Children aged of four to six years old, in the nursery school and if their first language is unique : arabic.
3181221|NCT01331057||3: Mali|Children aged of four to six years old, in the nursery school and if their first language is unique : SONINKE.
3181222|NCT01331044|Experimental|RUTF|Ready to use Therapeutic Food (RUTF) Plumpy nut.
3181223|NCT01331044|Active Comparator|Khichuri - Halwa|Cereal Legume
3181224|NCT01331031||Adolescents|Adolescents between 10 and 20 years of age and enrolled in a municipal school system.
3181225|NCT01331018|Experimental|Treatment (hematopoietic stem progenitor cells)|"STEM CELL MOBILIZATION FOR CELL COLLECTION: Patients receive filgrastim SC BID for 5-6 days (on days 1-6 of mobilization). Patients receive plerixafor SC QD on days 4-6 of mobilization. PBSC count will be checked daily starting on day 4 of mobilization. Patients who have a PBSC count of >= 5 CD34+ cells/mcL will undergo up to 2 apheresis collections on consecutive days.~BONE MARROW HARVEST FOR CELL COLLECTION: Patients with inadequate PBSC counts undergo bone marrow harvest for collection of stem/progenitor cells.~REINFUSION: Patients receive methylprednisolone IV or prednisone PO on days -1 to 7 followed by a rapid taper over approximately 1 week and undergo reinfusion of genetically modified hematopoietic stem/progenitor cells on day 0."
3181226|NCT01331005|Placebo Comparator|Placebo|Placebo will be given three times per day for one year
3181227|NCT01331005|Active Comparator|nepafenac 0.1% drops|Nepafenac drops will be given three times per day for one year
3181228|NCT01330992|Experimental|Ocular Light or Dark Exposure|Ocular Light or Dark Exposure
3181229|NCT01330966|Experimental|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
3181230|NCT01330953|Placebo Comparator|Placebo|Single intravenous placebo dose.
3181231|NCT01330953|Experimental|30 mg LY2928057 (Cohort 1)|Day 1: single 30-milligram (mg) LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 30-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 30-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 30 mg LY2928057.
3181232|NCT01330953|Experimental|100 mg LY2928057 (Cohort 2)|Day 1: single 100-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 100-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 100-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 100 mg LY2928057.
3181233|NCT01330953|Experimental|300 mg LY2928057 (Cohort 3)|Day 1: single 300-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 300-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 300-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 300 mg LY2928057.
3181234|NCT01330953|Experimental|1000 mg LY2928057 (Cohort 4)|Day 1: single 1000-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 1000-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 1000-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 1000 mg LY2928057.
3181235|NCT01330940|Placebo Comparator|Water drinking|32 ounces of water/24 hours
3181236|NCT01330940|Active Comparator|orange soda drinking|32 ounces orange soda
3181237|NCT01330927|Experimental|VA106483 0.5 mg|
3181238|NCT01330927|Experimental|VA106483 1 mg|
3181239|NCT01330927|Experimental|VA106483 2 mg|
3181240|NCT01330927|Experimental|VA106483 4 mg|
3181241|NCT01330927|Placebo Comparator|Sugar pill|
3181242|NCT01330914||Gastric Bypass Surgery Patients|Obese men and women undergoing gastric bypass surgery
3181243|NCT01330901|Experimental|Ustekinumab|Ustekinumab 90 mg subcutaneously at week 0, 4 and 16
3181244|NCT01330888||Group 1|ARNG Chaplains
3181245|NCT01330849|Experimental|Toolkit intervention|
3181246|NCT01330849|No Intervention|Waiting List Control Group|Children eligible for the study according to the inclusion criteria, but randomly allocated to the waiting list control group are promised to receive the intervention AFTER the study is finished.
3181247|NCT01330823|Active Comparator|L-Carnitine|L-Carnitine 4 g daily for Intervention
3181248|NCT01330823|Placebo Comparator|Placebo|Placebo (tartaric acid)
3181249|NCT01330810|Active Comparator|C3 tablet|4g C3 tablet
3181250|NCT01330810|Active Comparator|Meriva|2g Meriva powder
3181251|NCT01330797||LOCS III|Cohort is composed of cases with a diagnosis of wet age-related macular degeneration and those that received intravitreal ranibizumab
3181252|NCT01330784||hMG-HP|Patients with a condition
3181253|NCT01330771||hMG-HP/r-FSH|Patients with a condition
3181254|NCT01330758|Active Comparator|40 mg AZD8931 wet granulation tablet formulation|
3181255|NCT01330758|Experimental|40 mg AZD8931 roller compacted tablet formulation|
3181256|NCT01330745|Other|aortic valve replacement|
3181257|NCT01330732||1|Main group: patients examined in scoliosis clinic for kyphosis with recent lateral spine X-rays.
3181258|NCT01330719|Experimental|Diseased periodontal treatment|Scaling and root planing along with systemic antibiotics (Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days).
3181259|NCT01330719|Active Comparator|Conventional periodontal treatment|Standard periodontal prophylaxis
3181260|NCT01330706|Experimental|Sterile Saline solution|The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
3181261|NCT01330693|Active Comparator|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children
3181262|NCT01330693|Placebo Comparator|Placebo|Sugar pill
3181263|NCT01330680|Experimental|Coffee|
3181264|NCT01330680|Active Comparator|Decaffeinated coffee|
3181265|NCT01330667|Experimental|Formula Supplementation|Participants will supplement feedings with early limited formula following nursing.
3181266|NCT01330667|No Intervention|Control|Participants will be instructed to continue exclusively breastfeeding with no formula supplementation.
3181267|NCT01330654|Active Comparator|Beta blocker|These patients will be randomized to receive a standard dose of metoprolol (50mg) starting two weeks prior to surgery
3181268|NCT01330654|No Intervention|Control|This arm will receive no additional treatment prior to surgery
3181269|NCT01330641|Active Comparator|Anterior injection Route|Group of patients injected with medication using the anterior route
3181270|NCT01330641|Active Comparator|Posterior Injection|Group of patients receiving injection through a posterior route
3181271|NCT01330641|Active Comparator|Lateral Injection|Group of patients receiving subacromial injection through a lateral route
3181272|NCT01330628|Experimental|Laser atherectomy and PTA|laser, then balloon angioplasty
3181273|NCT01330628|Active Comparator|Balloon angioplasty|
3181274|NCT01330615|Active Comparator|Cryotherapy with EMLA|EMLA applied before cryotherapy
3181275|NCT01330615|Placebo Comparator|Cryotherapy with placebo analgesia|Placebo cream applied instead of EMLA
3181276|NCT01330602|Experimental|Lifestyle counseling|"All participants randomised into the IMPRESS Intervention group will undergo tailored health profiling.This individual assessment will be carried out within the clinic setting.~The key elements of the IMPRESS intervention include:~Promoting a healthy lifestyle~Supporting lifestyle and risk modification~Encouraging active self-management of risk and chronic disease~Improving coordination of care~Pharmacological therapy All the individuals in the intervention group will receive a comprehensive report on their risk status and ideal goals."
3181277|NCT01330602|No Intervention|Usual care arm|"Usual Care Following the assessment of absolute cardiovascular risk, usual care participants will be provided a report outlining areas in which improvements could be made for the prevention of atherosclerotic burden.~No restrictions will be made in respect to usual care management. As such, the prescription of standard medications for primary prevention of atherosclerotic burden based on individual risk factors is anticipated in 20-30% of usual care participants.~At 18 months and three years those in the usual care arm will be invited to undergo repeat CIMT measurements, pathology, absolute risk score calculation and health-related questionnaires as part of the structured study follow-up"
3181278|NCT01330589|Experimental|AB: Placebo (A); St. Johns Wort (B)|Receive placebo for 7 days, 7 days washout and 7 days of St. Johns Wort
3181279|NCT01330589|Experimental|BA: St. Johns Wort (B); Placebo (A)|Receive St. Johns Wort for 7 days, 7 days washout and 7 days of placebo
3181280|NCT01330576|Placebo Comparator|Standard treatment of care at normothermia|Control group: Standard treatment of care at normothermia
3181281|NCT01330576|Experimental|cooling blanket/mattress|Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress
3181282|NCT01330563|Experimental|CKD-501|"Subjects received Ketoconazole 200 mg twice daily for 5 days in one period and in the other period, Subjects don't receive Ketoconazole.~In addition, The CKD-501 is administered on day 5"
3181283|NCT01330563|Experimental|ketoconazole|"Subjects received Ketoconazole 200 mg twice daily for 5 days in one period and in the other period, Subjects don't receive Ketoconazole.~In addition, The CKD-501 is administered on day 5"
3181284|NCT01330550|Experimental|high fiber sugar free biscuit.|High fiber sugar free biscuit will regulate Blood sugars.
3181285|NCT01330524|Active Comparator|Avastin and Triamcinolone|
3181286|NCT01330524|Placebo Comparator|Placebo|
3181287|NCT01330511||Bilateral Hydronephrosis Grade I-II|Patients with Bilateral Hydronephrosis Grade I-II
3181288|NCT01330511||Bil. Hydronephrosis Grade III-IV, Other|Patient with Bilateral Hydronephrosis Grade III-IV and others with any hydronephrosis and distended bladder or MCKD
3181289|NCT01330511||Unilateral Hydronephrosis Grade I-II|Patients with Unilateral Hydronephrosis Grades I-II
3181290|NCT01330511||Unilateral Hydronephrosis Grade III-IV|Patients with Unilateral Hydronephrosis Grade III-IV
3181291|NCT01330498||Tysabri (natalizumab) infusing|Patients with relapsing forms of MS who participated in 001-001-TY and are currently still infusing with Tysabri (natalizumab).
3181292|NCT01330485|Experimental|ART|Affect Regulation Training
3181293|NCT01330485|Active Comparator|CFT-C|common factor based therapy control condition
3181294|NCT01330485|Other|WLC|wait list control
3181295|NCT01330472|Active Comparator|Xanax XR tablets 3 mg (sourced from Caugus)|Xanax XR tablets 3 mg (sourced from Caugus), 1 x 3 mg (REFERENCE)
3181296|NCT01330472|Experimental|Xanax XR tablets 3 mg (sourced from Barceloneta),|Xanax XR tablets 3 mg (sourced from Barceloneta), 1 x 3 mg (TEST)
3181297|NCT01330459|Active Comparator|Hydrocodone/acetaminophen|Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure.
3181298|NCT01330459|Placebo Comparator|Placebo|Subject will receive placebo 45-90 minutes prior to abortion procedure.
3181299|NCT01330446|Experimental|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
3181300|NCT01330446|Placebo Comparator|Placebo|1 Placebo by mouth every morning for a 28 day cycle.
3181386|NCT01329874|No Intervention|Buccal infiltration, Lingual infiltration|
3183021|NCT01317849|Experimental|vitamin supplements|
3181301|NCT01330433|No Intervention|No CoSeal Surgical Spray|A patient randomized to the No CoSeal Surgical Spray group will not have CoSeal Surgical Spray applied at the end of their first staged procedure.
3181302|NCT01330433|Experimental|CoSeal Spray Group|CoSeal Spray will be applied at the end of the first staged procedure in patients randomized to the experimental group.
3181303|NCT01330420|Experimental|Relaxation Response Resiliency Program for Depression|"The Relaxation Response Resiliency Program for Depression (3RP-D) is a low-cost, easily replicable, 6-session, 1.5 hour, mind body intervention.~The 3RP-D was designed to promote resiliency by reducing the harmful effects of stress through the elicitation of the relaxation response, and through skill training to enhance positive attitudes and beliefs, nutrition, exercise, recuperative sleep, social support, and coping. Specific interventions include: cognitive behavioral therapy (CBT), enhancing social support (SS), cultivating positive attitudes and beliefs (CPE), and promoting Healthy Lifestyle Habits(HL). The 3RP-D program has been manualized for use by group facilitators and health center patients."
3181304|NCT01330407|Experimental|gp2|Cultured Epidermal Autografts
3181305|NCT01330407|Active Comparator|gp1|cryopreserved skin allografts.
3181306|NCT01330394|Sham Comparator|sham-tDCS control|simulate control for transcranial Direct Current Stimulation
3181307|NCT01330394|Active Comparator|active tDCS|active transcranial Direct Current Stimulation
3181308|NCT01330381|Experimental|prucalopride|drug
3181309|NCT01330381|Placebo Comparator|Placebo|
3181310|NCT01330381|Active Comparator|PEG 4000|4-20g administered as an oral solution once daily
3181311|NCT01330355|Experimental|Besivance|Besifloxacin 0.6% ophthalmic suspension
3181312|NCT01330355|Active Comparator|Gatifloxacin|Gatifloxacin 0.3% ophthalmic solution
3181313|NCT01330342||HIV patients without lymphoma|HIV-infected subjects on cART without a diagnosis of lymphoma
3181314|NCT01330342||HIV patients with lymphoma|HIV seropositive individuals with lymphoma
3181315|NCT01330329|Experimental|SBT + technology system (SBT+FIT)|Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention.
3181316|NCT01330329|Experimental|Standard behavioral treatment (SBT)|Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program.
3181317|NCT01330316|Experimental|BI 201335 for 24 weeks|BI 201335 once daily dose for 24 weeks in combination with PegIFN/RBV for 24 or 48 weeks
3181318|NCT01330303|Active Comparator|tamsulosin - Reference|Reference drug administration followed by Test drug administration
3181319|NCT01330303|Active Comparator|tamsulosin - Test|Test drug administration followed by Reference drug administration
3181320|NCT01330290||Neupro® Treatment|Routine treatment (2, 4, 6, 8, 10, 12, 14, 16 mg/24 hours) as per approved label in European Union (EU)/in accordance with the terms of the local marketing authorization for Neupro®
3181321|NCT01330277||Observation|Patients from the first day of life with Hunter Disease based upon biochemical and/or genetic criteria or who are profoundly suspicious for Hunter disease
3181322|NCT01330264||Dyad|
3181323|NCT01330251||Patients with diabetes having Roux-en-Y gastric bypass|
3181324|NCT01330251||Patients without diabetes having Roux-en-Y gastric bypass|
3181325|NCT01330251||Control subjects (patients having gastroscopy, no surgery)|
3181326|NCT01330238|Active Comparator|Zoledronic acid|Single infusion of 5 mg zoledronic acid I.V.
3181327|NCT01330238|Placebo Comparator|Placebo|Single infusion of 100 ml isotonic NaCl-solution I.V.
3181328|NCT01330199|Experimental|TDF 150mg + MVC 150mg|Subjects will receive a single dose of tenofovir 150 mg and maraviroc 150 mg.
3181329|NCT01330199|Experimental|TDF 300mg + MVC 300mg|Subjects will receive a single dose of tenofovir 300 mg and maraviroc 300 mg.
3181330|NCT01330199|Experimental|TDF 600mg +MVC 600mg|Subjects will receive a single dose of tenofovir 600 mg and maraviroc 600 mg.
3181331|NCT01330199|Experimental|FTC 100mg + RAL 200mg|Subjects will receive a single dose of emtricitabine 100 mg and raltegravir 200 mg.
3181332|NCT01330199|Experimental|FTC 200mg + RAL 400mg|Subjects will receive a single dose of emtricitabine 200 mg and raltegravir 400 mg.
3181333|NCT01330199|Experimental|FTC 400mg + RAL 800mg|Subjects will receive a single dose of emtricitabine 400 mg and raltegravir 800 mg.
3181334|NCT01330186||Anal cancer|
3181335|NCT01330173|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity.
3181336|NCT01330160||cohort of stroke patients|patients, over 40 years old and without dementia, displaying an hemorrhagic or an ischemic stroke, with a sus-tentorial localization, and included 72h before the onset of symptoms
3181337|NCT01330147||Tonsillectomy|Subjects undergoing tonsillectomy for non-cancer reasons including operations for: recurrent tonsillitis, asymmetric tonsils, snoring surgery or obstructive sleep apnoea.
3181338|NCT01330134|Experimental|lidocaine onto skin prior to lidocaine subcutaneous injection|1-2ml of 1% lidocaine dripped onto the surface of the skin immediately prior to subcutaneous injection of 1% lidocaine.
3181339|NCT01330134|Active Comparator|lidocaine subcutaneous injection alone|1% lidocaine subcutaneous injection alone by standard approach
3181340|NCT01330121|Active Comparator|Pharmacist Counseling|"Pharmacist Counseling includes but is not limited to:~Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic & non-glycemic goal levels Explaining the importance of compliance with medications & appointments Educating on the basics of nutrition and physical activity"
3181341|NCT01330121|No Intervention|Standard therapy|Standard therapy: Nurses distribute a education pamphlet on diabetes
3181342|NCT01330108|Experimental|Ambrisentan|patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
3181343|NCT01330095|Active Comparator|Eearly administration|Administration of Bifidobacterium within 48h after birth
3181344|NCT01330095|Active Comparator|Late administration|Administration of Bifidobacterium more than 48h after birth
3181345|NCT01330082|Experimental|Photodynamic therapy|will be treated by PDT using Light-emitting diod(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark) in the presence of toluidine blue O (TBO)
3181346|NCT01330082|Experimental|Light-emitting diode Irradiation|will be treated only by using Light-emitting diode(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark)
3181347|NCT01330082|Experimental|applying photosensitizer|will be treated only by toluidine blue O
3181348|NCT01330056|Active Comparator|FOPS|"Functional organ preservation surgery (FOPS) group as a first-line treatment modality~Postoperative RT or CRT may be included for the patients of this group"
3181349|NCT01330056|Active Comparator|CRT|"Concurrent chemoradiotherapy or radiotherapy group as a first-line treatment modality~Salvage surgery may be applied for the patients for persistent or recurrent cancers after CRT or RT"
3181350|NCT01330043|Active Comparator|Non-extended treatment|"26 weeks of CBT~10 weeks of combination bupropion plus nicotine patch~Additional 16 weeks of bupropion plus nicotine patch if increased craving or depression scores or varenicline if smoking at 10 weeks"
3181351|NCT01330043|Experimental|Extended treatment|"26 weeks of CBT~10 weeks of combination bupropion plus nicotine patch~Additional 16 weeks of bupropion plus nicotine patch if increased craving or depression scores or varenicline if smoking at 10 weeks~24 additional weeks of CBT"
3181352|NCT01330030|Experimental|Drug Selegiline|6 mg selegiline patch (transdermal) worn for 24 hours for 8 weeks
3181353|NCT01330030|Placebo Comparator|Matching placebo|matching placebo worn 24 hours for 8 weeks
3181354|NCT01330017|Experimental|PE 10 mg|
3181355|NCT01330017|Experimental|PE 20 mg|
3181356|NCT01330017|Experimental|PE 30 mg|
3181357|NCT01330017|Experimental|PE 40 mg|
3181358|NCT01330017|Placebo Comparator|Placebo|
3181359|NCT01330004||Hemodialysis patients|
3181360|NCT01329991|Active Comparator|oral dose of 200 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
3181361|NCT01329991|Active Comparator|oral dose of 400 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
3181362|NCT01329991|Active Comparator|oral dose of 800 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
3181363|NCT01329991|Active Comparator|oral dose of PLX5622-dose to be determined|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
3181364|NCT01329991|Placebo Comparator|Placebo Comparator|2 patients per cohort will be randomly assigned to take placebo. 8 patients total will be randomized to take placebo in this study.
3181365|NCT01329978|Experimental|SOF+PEG+RBV 12 weeks|Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks.
3181366|NCT01329978|Experimental|SOF+PEG+RBV 24 weeks|Participants were randomized to receive sofosbuvir+PEG+RBV for 24 weeks.
3181367|NCT01329978|Experimental|SOF+PEG+RBV 12 week/Rerandomization Group|Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks, then were rerandomized to receive sofosbuvir only or sofosbuvir+RBV for 12 additional weeks.
3181368|NCT01329965|Experimental|LPS|LPS will be injected at a dose of 0.6 ng/kg body weight through a catheter by a trained GCRC staff member involved with this study.
3181369|NCT01329965|Placebo Comparator|Saline|A saline solution will be injected through a catheter by a trained GCRC staff member involved with this study.
3181370|NCT01329952||Current intravenous drug users|Those who were actively injecting drugs at the time of their hepatitis C treatment.
3181371|NCT01329952||Past drug users|Those who stopped injecting drugs intravenously at least 6 months prior to the start of treatment for hepatitis C
3181372|NCT01329939|Experimental|Obese atopic asthmatics, montelukast|Obese/overweight (BMI 85%ile or above for children and > 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive montelukast in a double blinded fashion.
3181373|NCT01329939|Placebo Comparator|Lean atopic asthmatics, placebo|Normal weight (BMI less than 85%ile or above for children and < 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive placebo in a double blinded fashion.
3181374|NCT01329939|Active Comparator|Lean atopic asthmatics, montelukast|Normal weight (BMI less than 85%ile or above for children and < 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive montelukast in a double blinded fashion.
3181375|NCT01329939|Placebo Comparator|Obese atopic asthmatics, Placebo|Obese/overweight (BMI 85%ile or above for children and > 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive placebo in a double blinded fashion.
3181376|NCT01329926||Neural stem cells|
3181377|NCT01329913|Experimental|GT1-HCV 200 mg|
3181378|NCT01329913|Experimental|GT1-HCV 400 mg|
3181379|NCT01329913|Experimental|GTI-HCV 800 mg|
3181380|NCT01329913|Experimental|GT3-HCV 200 mg|
3181381|NCT01329913|Experimental|GT3-HCV 400 mg|
3181382|NCT01329913|Experimental|GT3-HCV 800 mg|
3181383|NCT01329900|Experimental|Ofatumumab + Stem Cell Collection|Ofatumumab 1000 mg by vein on Day 1 and 2000 mg by vein on Day 8. Ifosfamide 3.33 gm/m2 by vein on Days 2, 3, and 4 continuously. Etoposide 150 mg/m2 by vein over 2 hours every 12 hours for 6 doses. Mesna 2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts). Mesna 2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide). After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose. G-CSF 6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis. Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
3181384|NCT01329887|Other|administration of ketanserin|
3181385|NCT01329874|No Intervention|Gow gates ,conventional block injection|Patients will be selected from a group with acute irreversible pulpitis in mandibular molars. Half of the patients randomly selected for receiving gow gates block injection and half will receive traditional inferior block injection by 3.6 ml Lidocaine plus epinephrine.Teeth with no response to anesthetizing will be randomly divided into two group of either buccal or lingual infiltration.
3181387|NCT01329861|Experimental|Internet delivered CBT|Internet delivered cognitive behavioral intervention, 8 weeks treatment.
3181388|NCT01329861|No Intervention|Control condition|Wait-list condition, received treatment after post-treatment assessment.
3181389|NCT01329848||discomfort symptoms|level of discomfort symptoms while performing near work
3181390|NCT01329835|Experimental|Written information via brochure|Written information by a brochure
3181391|NCT01329835|No Intervention|standard care|standard prenatal care
3181392|NCT01329835|Experimental|Lifestyle counseling|Psycho-education based on principles of motivational interviewing and positive reinforcement
3181393|NCT01329822|Experimental|Caloric restriction group|CR group were educated by a dietitian to reduce their usual energy intake to 1400 kcal/day (-500 kcal/day, -26% from baseline) for weight reduction and the recommended macronutrient composition was the 50-55% of energy intake as carbohydrate, 15-20% as protein and 20-25% as fat. Daily energy intake and nutrient composition were determined using a computer-aided nutritional analysis program (CAN-Pro 3.0; Korean Nutrition Society, Seoul, South Korea).
3181394|NCT01329822|No Intervention|Control group|Control group - ad libitum diet
3181395|NCT01329809|Experimental|JX-594 Intravenous infusion|JX-594 will be administered intravenously to patients with measurable intra-hepatic disease who are not eligible for intratumoral injection of JX-594.
3181396|NCT01329809|Experimental|JX-594 Intratumoral Injection|JX-594 will be injected directly into the liver tumor of patients who have at least two measurable intra-hepatic tumors, one of which must be at least 1.5cm in diameter and safety injectable.
3181397|NCT01329796|Experimental|Pertubation with Endole® (lignocaine)|Three treatments were to be given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
3181398|NCT01329796|Placebo Comparator|Placebo|Pertubation with Ringer solution, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
3181399|NCT01329783||EuroSIDA sub-cohort|HIV infected patients in the EuroSIDA cohort who meet the entry criteria for maraviroc pivotal clinical trials (MOTIVATE 1 and MOTIVATE 2)
3181400|NCT01329770|Experimental|Ascorbic Acid and alpha-tocopherol|Two daily doses of the combination of antioxidants, administered at breakfast and dinner
3181401|NCT01329770|Placebo Comparator|Placebo|Two daily doses of placebo, administered at breakfast and dinner
3181402|NCT01329757|Active Comparator|GH|Administration of a daily dose of GH (0.4mg)for 1 year
3181403|NCT01329757|Placebo Comparator|Placebo|Administration of a daily dose of placebo for 1 year
3181404|NCT01329744|Experimental|Treatment|Recombinant IGF-I
3181405|NCT01329744|Placebo Comparator|Placebo|
3181406|NCT01329731|Active Comparator|Test|1.25% fluoride (elmex® gelée)
3181407|NCT01329731|Placebo Comparator|Control|0% fluoride (negative control)
3181408|NCT01329718|Experimental|CRC Group|
3181409|NCT01329705|Active Comparator|Control|All patients will be treated with the current standard of care including onabotulinum toxin
3181410|NCT01329705|Experimental|Dynasplint|Patients in the experimental Dynasplint group will be treated with the current standard of care, including onabotulinum toxin, and use the Ankle Dorsiflexion Dynasplint
3181411|NCT01329692|Experimental|Lifestyle counseling|"This is a seven-week group education, counseling, nutrition, exercise, and journaling program of the Duke Metabolic and Weight Loss Surgery Center designed to help postoperative bariatric surgery patients who are failing to progressively lose weight resume an expected pattern of weight loss and improved overall outcome.~Weeks 1 and 2 consist primarily of a review of current dietary habits. Weeks 3, 4, & 5 introduces counseling, with specific emphasis on emotional aspects of eating and behavioral modification strategies. Week 6 focuses on the metabolic impact of exercise, and includes an exercise session with a personal trainer. Week 7 incorporates a question and answer session with a sharing of discoveries, as well as an option for additional individual follow-up as needed."
3181412|NCT01329692|No Intervention|RYGB regular post-op care|Regular care and follow-up after RYGB surgery
3181413|NCT01329679|Experimental|5 Hour Energy|
3181414|NCT01329679|Placebo Comparator|Placebo|
3181415|NCT01329666|Experimental|50,000 IU Vitamin D3|
3181416|NCT01329666|Placebo Comparator|Placebo (inactive Vitamin D3)|
3181417|NCT01329653|Experimental|aerobic training|12 weeks of aerobic training, 4X/week
3181418|NCT01329653|Placebo Comparator|wait list control|wait list control condition, 12 weeks to parallel the active intervention group
3181419|NCT01329640|Experimental|Paclitaxel, trastuzumab, doxorrubicin, ciclophosphamide|
3181420|NCT01329627|Experimental|Paclitaxel/doxorubicin/cyclophosphamide|
3181421|NCT01329614|Experimental|Nicotine Replacement Therapy, 7mg dose|
3181422|NCT01329614|Experimental|Nicotine Replacement Therapy, 21mg dose|
3181423|NCT01329614|Placebo Comparator|Nicotine Replacement Therapy, Placebo|
3181424|NCT01329614|Experimental|Nicotine Replacement Therapy, 42mg dose|
3181425|NCT01329601|Experimental|Cognitive Intervention|StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
3181426|NCT01329601|Active Comparator|Booklet-based training|Home based training of episodic memory using paper-pencil exercizes
3181427|NCT01329588|Placebo Comparator|Sugar pill|
3181428|NCT01329588|Experimental|Treatment arm|
3181429|NCT01329562|Active Comparator|Treximet|"Subjects randomized to Group A will be provided with 1 tablet of Treximet to be taken at onset of menstrual migraine headache pain.~All subjects will be provided with 1 tablet of Treximet for treatment of persistent or recurring headache between 2 and 24 hours following treatment with study medication at headache onset."
3181430|NCT01329562|Placebo Comparator|Placebo|"Subjects randomized to Group B will be provided with 1 tablet of placebo to be taken at onset of menstrual migraine headache pain.~All subjects will be provided with 1 tablet of Treximet for treatment of persistent or recurring headache between 2 and 24 hours following treatment with study medication at headache onset."
3181431|NCT01329549|Experimental|BIBF 1120 (low) + Carboplatin + PLD|BIBF 1120 (low dose) + carboplatin (AUC5 mg/mL*min) + PLD (30 mg/m2)
3181432|NCT01329549|Experimental|BIBF 1120 (medium) + Carboplatin + PLD|BIBF 1120 (medium dose) + carboplatin (AUC5 mg/mL*min) + PLD (30 mg/m2)
3181433|NCT01329549|Experimental|BIBF 1120 (high) + Carboplatin + PLD|BIBF 1120 (high dose) + carboplatin (AUC5 mg/mL*min) + PLD (30 mg/m2)
3183022|NCT01317849|Placebo Comparator|Placebo|
3181434|NCT01329536||AD Patients with Agitation|Patients with a diagnosis of probable Alzheimer's Disease who show signs of agitation based on the Cohen-Mansfield Agitation Inventory
3181435|NCT01329536||AD Patients without Agitation|Patients with a diagnosis of probable Alzheimer's Disease who do not show signs of agitation based on the Cohen-Mansfield Agitation Inventory and are matched in both age and gender to the AD Patients with Agitation
3181436|NCT01329523||Subjects with AD|Subjects with a diagnosis of dementia
3181437|NCT01329523||Family Members|Younger biological family members of the patients with dementia
3181438|NCT01329523||Control Group|Individuals without dementia matched in age to the patients with a dementia diagnosis
3181439|NCT01329510|Experimental|methylphenidate|
3181440|NCT01329497|Experimental|interventional group|
3181441|NCT01329484|Experimental|Cognitive training|
3181442|NCT01329484|Experimental|Reminiscence therapy|
3181443|NCT01329484|Other|Control|This group will receive neither of the above interventions or any other similar interventions
3181444|NCT01329471||Umbilical cord blood|
3181445|NCT01329458||Focal liver lesions|Focal liver lesions: patients discovered with new, uncharacteristic focal liver lesions at standard ultrasound
3181446|NCT01329445||DeNovo NT patient|Patients who have received or who are scheduled to receive a DeNovo NT graft for repair of 1-2 knee cartilage lesions.
3181447|NCT01329432|Sham Comparator|take care|In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing
3181448|NCT01329432|Experimental|InSurE|infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration
3181449|NCT01329419||adefovir dipivoxil|Patients administrated adefovir at the site
3181450|NCT01329406|Experimental|Milnacipran|If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The milnacipran arm will take milnacipran at 200mg/day (100mg twice daily).
3181451|NCT01329406|Placebo Comparator|Placebo|If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The placebo group will take 1 tablet twice daily.
3181452|NCT01329393|Experimental|Benefits Management|Money-management intervention consisting of brief advice on budgeting, assessment of ability to follow a budget, and assessment of need for a representative payee.
3181453|NCT01329393|Active Comparator|Illness Management and Recovery|
3181454|NCT01329380||Humira|those with an exposure
3181455|NCT01329367|Active Comparator|Control group|"Control group: Subjects will receive Nutritional education together with weight management counselling for overweight and obesity.~-10 weekly personal interviews with a registered nutritionist for body weight control."
3181456|NCT01329367|Experimental|Protein group|"Protein group: Participants will receive Nutritional education and personalised structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of legumes and fish (protein rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
3181457|NCT01329367|Experimental|Antioxidant group|"Antioxidant group: Participants will receive Nutritional education and personalized structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of fruits and vegetables (antioxidant rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
3181458|NCT01329354|Experimental|Autologous effector lymphocytes|
3181459|NCT01329341|Experimental|Arm 1|Service Dogs
3181460|NCT01329315|Active Comparator|BMI-T|Brief Motivational Intervention (BMI-T): social worker/therapist-delivered intervention (25-minute tailored structured module).
3181461|NCT01329315|Active Comparator|BMI-C|Computer-delivered intervention (BMI-C): computerized tailored 25-minute intervention.
3181462|NCT01329315|No Intervention|DPB|Drug Prevention Booklet (DPB)- National Institute on Drug Abuse (NIDA)-developed drug prevention booklet to address preventing marijuana initiation, and marijuana use.
3181463|NCT01329302|Active Comparator|Group A: Direct aspiration|
3181464|NCT01329302|Active Comparator|Follicular Flushing|
3181465|NCT01329289|Experimental|SOM230 with Bortezomib and Dexamethasone|
3181466|NCT01329276|Other|Symbicort® forte Turbohaler®|
3181467|NCT01329276|Placebo Comparator|Placebo (lactose)|
3181468|NCT01329263|Experimental|Nonmenthol|Participants switch from menthol to non-menthol cigarettes.
3181469|NCT01329263|No Intervention|Menthol|Participants smoke own brand of menthol cigarettes.
3181470|NCT01329250|Experimental|Moxifloxacin|Moxifloxacinin escalating dose
3181471|NCT01329237|Other|dynamic physical exercise OCT|dynamic physical exercise and optical coherence tomography imaging
3181472|NCT01329224||TAM patients|All consecutive patients under chronic ASA treatment (100mg/d) seen at our outpatient clinic.
3181473|NCT01329211||Gastroparesis Patients|
3181474|NCT01329211||Gastroparesis Patients' Caregivers|
3181475|NCT01329198|Active Comparator|Delayed Activation - Deep Brain Stimulation (DBS)|"Delayed Activation stimulation in which no electrical charge is delivered through the Neuropace RNS (responsive neurostimulation) system for the first 59 days. On Day 60, all subjects will be programmed to receive active stimulation.~There will be a one month post-operative period during which stimulation is not turned on.~One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.~By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.~Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days."
3181521|NCT01328808|Experimental|group 2 Pain management|"In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.~In preterm and term neonates with a GA of less than 28 weeks 15 mg/kg dose of APAP will be given every 12 hrs by an intravenous infusion over 30-minute"
3181522|NCT01328782|Active Comparator|The group receiving oral pain medicine|This group will receive Oxycodone with Acetaminophen orally
3181476|NCT01329198|Active Comparator|Immediate Activation - Deep Brain Stimulation (DBS)|"Active stimulation through the Neuropace RNS (responsive neurostimulation) system at settings to maximally reduce tic frequency & severity, while limiting potential stimulation-induced side-effects.~There will be a one month post-operative period during which stimulation is not turned on.~One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.~By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.~Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days."
3181477|NCT01329185|Placebo Comparator|Placebo|Eligible consenting kidney transplant donors who are randomized to receive placebo will be given 1 placebo in morning and 1 in evening for 14 days prior to transplant date
3181478|NCT01329185|Experimental|Valganciclovir|Eligible consenting kidney transplant donors who are randomized to the experimental arm of the study will receive 450mg of Valganciclovir twice a day for 14 days prior to the transplant date
3181479|NCT01329172|Experimental|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 (PUFA n-3)
3181480|NCT01329172|Placebo Comparator|placebo|sun flower oil
3181481|NCT01329133|Active Comparator|DBS of subthalamic nucleus|
3181482|NCT01329133|Active Comparator|DBS of ventral striatum|
3181483|NCT01329120||Pectus excavatum|Patients who has undergone minimally invasive repair of pectus excavatum
3181484|NCT01329120||Pectus carinatum|Patients who has undergone open surgical repair of pectus carinatum
3181485|NCT01329107|No Intervention|No intervention|Standard Care
3181486|NCT01329107|Experimental|Multimodal intervention|Intervention group will be assigned to specific decribed multimodal intervention
3181487|NCT01329094||Patients with severe mental illness|In-patients and out-patients with severe mental illness attending treatment at Aarhus University Hospital, Risskov.
3181488|NCT01329094||Healthy controls|Healthy controls recruited from staff members at Aarhus University Hospital, Risskov
3181489|NCT01329081|Experimental|Six weeks strength training in teams and patient education|
3181490|NCT01329081|Experimental|Supervised home training with focus on activities|
3181491|NCT01329068|Active Comparator|Individual consult|regular individual consult
3181492|NCT01329068|Active Comparator|group medical consult|regular group medical consult
3181493|NCT01329055||Hemodialysis patients|
3181494|NCT01329029|Active Comparator|Roflumilast|concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
3181495|NCT01329029|Placebo Comparator|Placebo|concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
3181496|NCT01329016|Active Comparator|GDM Subjects|Women with GDM requiring treatment
3181497|NCT01329016|No Intervention|Non-pregnant Type 2 Diabetes Milletus Subjects|Non-pregnant women with Type 2 diabetes mellitus who plan to use metformin treatment
3181498|NCT01329016|No Intervention|Healthy Pregnant Women|Healthy pregnant women with normal 1-hour glucose tolerance test
3181499|NCT01329003||exposed workers|At least six months of occupational exposure to Caesar stone
3181500|NCT01328977|Active Comparator|emails, book|
3181501|NCT01328977|Active Comparator|didactic teaching from experts|
3181502|NCT01328977|Experimental|personal coaching by development profs|
3181503|NCT01328964||Children Ages 4-11 with asthma|Children ages 4 to 11 with a diagnosis of asthma receiving a prescription for an asthma therapy
3181504|NCT01328951|Experimental|Early Erlotinib|Participants will receive blinded erlotinib as 150 mg PO once daily in the maintenance setting until disease progression, death, or unacceptable toxicity. Those who demonstrate disease progression may be unblinded to receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. Participants may be observed during a final SFU period after discontinuation from study treatment.
3181505|NCT01328951|Placebo Comparator|Late Erlotinib|Participants will receive blinded placebo tablets PO once daily in the maintenance setting until disease progression, death, or unacceptable toxicity. Those who demonstrate disease progression may be unblinded to receive second-line erlotinib as 150 mg PO once daily until disease progression, death, or unacceptable toxicity. Participants may be observed during a final SFU period after discontinuation from study treatment.
3181506|NCT01328938|Experimental|Stage I - Arm I: GCPGC I (3.6mg)|GCPGC 3.6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)
3181507|NCT01328938|Experimental|Stage I - Arm II: GCPGC II (6mg)|GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)
3181508|NCT01328938|Experimental|Stage II - Arm I: GCPGC|"GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1).~The recommended dose in Stage II was determinated as GCPGC 6mg in Stage I."
3181509|NCT01328938|Active Comparator|Stage II - Arm II: Neulasta|Neulasta 6mg, sc, once at Day 3 per cycle (in patients receiving chemotherapy at Day 1)
3181510|NCT01328925|Experimental|Nitazoxanide Oral Suspension|Nitazoxanide Oral Suspension 100 mg/5 ml
3181511|NCT01328925|Placebo Comparator|Placebo Oral Suspension|Placebo Oral Suspension
3181512|NCT01328912|Experimental|Remote ischemic preconditioning stimulus|
3181513|NCT01328912|Placebo Comparator|Control|
3181514|NCT01328899|Experimental|Lung Volume Reduction Coil (LVRC)|Lung Volume Reduction Coil (LVRC)
3181515|NCT01328886|Experimental|Omalizumab|
3181516|NCT01328873|Experimental|Laboratory testing|All patients will receive the lab testing on bronchoscopy specimens
3181517|NCT01328860|Experimental|Biologic; Stem Cells|
3181518|NCT01328834|Experimental|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase
3181519|NCT01328821|Placebo Comparator|Part A|"Single ascending dose administration of four doses of CTP-499 as tablets under fasting condition.~8 subjects per dose group will be enrolled with a 3:1 randomization of active drug to placebo.~Dose levels: 600mg -> 1200mg -> 1800mg -> 2400mg"
3181520|NCT01328821|Active Comparator|Part B|Part B will consist of a single 400 mg dose of an immediate release capsule of CTP-499 administered under fasting conditions. In Part B 6 subjects will be enrolled.
3181651|NCT01327729|Active Comparator|YPEG-IFN α-2a one week|this arm will be treated with: YPEG-IFN α-2a 180mcg/ week for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks
3181523|NCT01328782|Active Comparator|The group receiving bupivacaine and oral pain medicine|This group will receive an intra-articular shot during surgery and will then be sent to the recovery room to receive pain medication as needed.
3181524|NCT01328782|Active Comparator|The group receiving ropivacaine and oral pain medicine|This group will receive an intra-articular shot of ropivacaine during surgery and will be sent to the recovery room to receive pain medicine as needed.
3181525|NCT01328769|Active Comparator|Febuxostat|Investigational
3181526|NCT01328769|Placebo Comparator|Placebo|Placebo
3181527|NCT01328756|Experimental|Lisdexamfetamine Dimesylate|
3181528|NCT01328743|No Intervention|Treatment as usual|Treatment as usual in an HIV primary care setting. Participants receive assessment of alcohol use but not counseling or advice regarding drinking.
3181529|NCT01328743|Experimental|Brief Alcohol Intervention|Participants receive 3 face-to-face sessions of counseling on alcohol use and 2 follow-up phone calls
3181530|NCT01328730|Experimental|Firebird 2 stent group|patients who were implated with Firebird 2 SES
3181531|NCT01328730|Active Comparator|Cypher Stent Group|patients who were implanted with Cypher SES
3181532|NCT01328717|Experimental|Intended Users of the System|Subjects with diabetes used Contour Link Investigational Blood Glucose Monitoring System
3181533|NCT01328704||Triathletes|Group of individuals who are participating in a triathlon training program at the Avera Sports Institute
3181534|NCT01328678||Alopecia Areata|Individuals with Alopecia Areata (AA)
3181535|NCT01328665|Experimental|Expressive Writing|Affectionate Writing Intervention for 20 minutes per day, 2 times per week, 6 weeks.
3181536|NCT01328665|No Intervention|No writing|Control Group -- No writing
3181537|NCT01328652|Experimental|Proton Pump Inhibitor|Treatment with dexlansoprazole 60 mg once daily for 3 months
3181538|NCT01328639|Active Comparator|Usual Care|Participants in this arm will be actively screened for depression and will receive the usual standard care for diabetes from their family physicians based on available clinical practice guidelines.
3181539|NCT01328639|Experimental|TeamCare Depression Intervention|Participants in this arm will be actively screened for depression, and will receive care for depression and diabetes based on the collaborative teamcare model for the management of diabetes and co-morbid depression.
3181540|NCT01328626|Experimental|Arm A (CLL/SLL subjects)|Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) subjects
3181541|NCT01328626|Experimental|Arm B (NHL subjects)|Non-Hodgkin lymphoma (NHL) subjects
3181542|NCT01328587|Experimental|1|Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 50mg/day (East Asian ancestry 25mg/day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
3181543|NCT01328574|Experimental|Single Arm - TRC105 in Urothelial Carcinoma|TRC105 15 mg/kg/dose every two weeks
3181544|NCT01328548||Nursing Home Elderly Cases|Non-ambulatory nursing home residents >= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs (single nucleotide polymorphisms). A case will be considered failure to mount a high response.
3181545|NCT01328548||Nursing Home Elderly Controls|Non-ambulatory nursing home residents >= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs. A control will be a participant who mounted an adequate response as defined in primary outcomes.
3181546|NCT01328548||Community dwelling seniors|Community dwelling seniors ages 60-75 will be enrolled as a control group for the laboratory testing. They will be vaccinated and will provide pre- and post-vaccination blood. If nursing home residents do not show a response it is important to know that it is not a failure of the laboratory's measurement of immunogenicity.
3181547|NCT01328535|Experimental|Treatment (individualized chemotherapy)|Patients with an established biorhythm receive TMZ PO on recommended day for 5 days. Treatment repeats every 21-42 days until disease progression or unacceptable toxicity. Patients without an established biorhythm receive TMZ PO on days 1-5. Courses repeat every 28 days until disease progression or unacceptable toxicity.
3181548|NCT01328522|Experimental|SAR153191 drug product 1|"SAR153191 drug product 1 in a single injection.~Methotrexate (stable dose) and folic/folinic acid are continued as background therapy."
3181549|NCT01328522|Experimental|SAR153191 drug product 2|"SAR153191 drug product 2 in a single injection.~Methotrexate (stable dose) and folic/folinic acid are continued as background therapy."
3181550|NCT01328509||Sepsis|Patients with sepsis
3181551|NCT01328509||Control|Patients with no clinical evidence of sepsis, but who are critically ill
3181552|NCT01328496|Other|Research Arm|"Participant with high-risk hematologic malignancies undergoing Hematopoietic Cell Transplantation, who do not have a suitable Human Leukocyte Antigen -matched related/sibling donor, Matched Unrelated Donor or Killer immunoglobulin receptors ligand mismatched haploidentical donor identified, will receive a single UCB unit.~Intervention: Preparative Regimen"
3181553|NCT01328496|Other|Observation Arm|"Patients requiring two UCB units will be eligible for UCBT01 on the observational arm.~Intervention: Preparative Regimen"
3181554|NCT01328483|No Intervention|No Intrapartum Oropharyngeal (IP-OP) Suction|Neonates randomized to No IP-OP group received supportive treatment as per standard unit protocols. They were also assessed as vigorous or non-vigorous and received care according to NRP 2005.
3181555|NCT01328483|Experimental|Intrapartum Oropharyngeal (IP-OP) suction|The neonates randomized to IP-OP group were provided oropharyngeal suctioning at the delivery of head before the delivery of shoulder, using suction machine at a negative pressure of 100mm of Hg or Dee Lee's suction trap in the event of electricity failure or non availability of suction machine.Subsequently, all the neonates born through MSAF were assessed by pediatrician as vigorous or non vigorous and provided care as per NRP guidelines 2005.
3181556|NCT01328470|Active Comparator|clopidogrel 75 mg/day|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 75 mg/day for 14 days.
3181557|NCT01328470|Active Comparator|clopidogrel 150 mg/day|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 150 mg/day for 14 days.
3181558|NCT01328470|Active Comparator|adjunctive cilostazol|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive co-administration of adjunctive cilostazol (100 mg twice daily) and clopidogrel (75 mg/day; [group 3, 20 patients]) for 14 days.
3181559|NCT01328470|Active Comparator|75mg clopidogrel|control group undergoing PCI for stable angina will be also maintained on clopidogrel (75 mg/day for 14 days).
3181560|NCT01328444|Experimental|GSK 573719 + GW642444 125/25|125mcg/25mcg nDPI
3181561|NCT01328444|Experimental|GSK 573719 +GW642444 62.5/25|62.5mcg/25mcg nDPI
3181562|NCT01328444|Experimental|GSK 573719 125|125mcg nDPI
3181563|NCT01328444|Experimental|GSK 573719 62.5|62.5 mcg nDPI
3181564|NCT01328444|Experimental|GW 642444 25|25mcg nDPI
3181565|NCT01328444|Placebo Comparator|Plb|Plb nDPI
3181566|NCT01328431|No Intervention|Standard Care|Subjects receive a brochure for the state's Smokers' Quitline only.
3181567|NCT01328431|Experimental|SBIRT+NRT|Subjects receive a 6 week course of NRT, a motivational Brief Negotiated Interview, and a facilitated referral to the state's Smokers' Quitline.
3181568|NCT01328418|Other|Achondroplasia lengthening|
3181569|NCT01328405|Experimental|Air-Q LMA|Air-QⓇ intubating laryngeal mask (Mercury Medical, Clearwater, Fl.)
3181570|NCT01328405|Experimental|Proseal LMA|LMA-Proseal TM (LMA North America, San Diego, Ca.)
3181571|NCT01328379|Active Comparator|Dalfampridine-ER 5mg|5mg, twice daily
3181572|NCT01328379|Active Comparator|Dalfampridine-ER 10mg|10mg, twice daily
3181573|NCT01328379|Placebo Comparator|Placebo|placebo, twice daily
3181574|NCT01328366||Participants with severe psoriasis|The participants had severe disease as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and had not responded to standard systemic therapies.
3181575|NCT01328353|No Intervention|control group|Control group arm follows usual care
3181576|NCT01328353|Experimental|Intervention group arm 1|Intervention group arm 1 receives aprn/telephone care coordination
3181577|NCT01328353|Experimental|Intervention group arm 2|Intervention group arm 2 receives aprn/telephone/video care coordination
3181578|NCT01328340|Active Comparator|High-speed power training|Volunteers randomized into SHPT will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength for leg press (LP) and seated knee extension (KE) exercises.
3181579|NCT01328340|Active Comparator|Slow-speed strength training|Volunteers randomized into STR will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength for LP and KE exercises.
3181580|NCT01328340|No Intervention|Control|Volunteers randomized into CON will undergo a placebo exercise intervention consisting of lower extremity range of motion and flexibility exercises performed 2 times per week with the assistance of the research staff.
3181581|NCT01328301|Experimental|Speed-dependent treadmill training (SDT)|Subjects underwent short interval of walking trials with stepwise increases in the treadmill speed
3181582|NCT01328301|Active Comparator|speed-stable treadmill training|Control subjects received gait training on the treadmill with a steady speed.
3181583|NCT01328288||1|long-term follow-up of HIV-infected children
3181584|NCT01328275||1|long-term follow-up of HIV-infected patients on ART
3181585|NCT01328262|Experimental|Hemoglobin dose|The subjects in this group receive an amount red blood cells that has been calculated from the patients' body surface area (BSA).
3181586|NCT01328262|Active Comparator|Standard treatment|The subjects in this group receive the prescribed number of red cell units.
3181587|NCT01328249|Experimental|Doxorubicin and cyclophosphamide followed by eribulin mesylate|
3181588|NCT01328236|Experimental|V-DD single arm|"INDUCTION THERAPY: V-DD induction therapy for 6 cycles，28 Days per Cycle. Bortezomib - 1.3 mg/m2 IV, Days 1, 4, 8 , 11 of every treatment; Liposomal Doxorubicin - 30 mg/m2 IV, Day 4 of every treatment; Dexamethasone - 40 mg/d IV, Days 1 - 4 of every treatment.~Maintenance treatment for 4 cycles,28 Days per Cycle. Thalidomide - 100mg Qn ; Bortezomib - 1.3 mg/m2 IV ,Days 1, 4, 8 and 11 of every treatment; Dexamethasone - 40 mg/d IV ,Days 1 - 4; Interferon - 300 u Qod,（Specially for IgA type）. Interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
3181589|NCT01328223||radiotherapy efficacy|"Concurrent stage with RT: sorafenib 400mg twice daily~Maintenance stage after RT: sorafenib 400mg twice daily Treatment can be continued until the occurrence of clinical or radiologic progression, the occurrence of either unacceptable adverse events, death, or any criteria met for removal from the protocol treatment. Basically, minimum maintenance duration of 6 months is recommended, not mandatory."
3181590|NCT01328210|Experimental|blood letting|Blood letting was performed immediately after baseline assessment and after 4 weeks. First blood removal consisted of 400ml, second blood removal was tailored according to subsequent serum ferritin levels between 300- 400 ml.
3181591|NCT01328210|No Intervention|waiting list control|This group received no specific treatment but was offered treatment after termination of the 6-week study phase
3181592|NCT01328197|Experimental|Treovance|
3181593|NCT01328184|Experimental|Reference|multiple doses of Microgynon
3181594|NCT01328184|Active Comparator|Test|multiple doses of Microgynon + BI 10773
3181595|NCT01328171|Experimental|A (FOLFOXIRI + Panitumumab)|FOLFOXIRI + Panitumumab
3181596|NCT01328171|Active Comparator|B (FOLFOXIRI)|FOLFOXIRI
3181597|NCT01328158||Lopinavir/Ritonavir|Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated
3181598|NCT01328145|Active Comparator|ASA|
3181599|NCT01328145|Placebo Comparator|Placebo|
3181600|NCT01328132|Active Comparator|Saline|
3181601|NCT01328132|Experimental|25% albumin|
3181602|NCT01328119|Other|hemodialysis patients|conventional hemodialysis patients
3181603|NCT01328106|Experimental|1|
3181604|NCT01328093|Experimental|LY2140023|Double Blind Phase: 40 mg administered orally, given twice daily for 24 weeks. Dose may be adjusted to a minimum of 20 mg and a maximum of 80 mg. Open Label Phase: 40 mg administered orally, given twice daily for an additional 28 weeks.
3181710|NCT01327378||Control, normal glucose tolerance|Healthy Control subjects, N=10 OGTT,120 min <7.8 mmol/L
3181605|NCT01328093|Active Comparator|Aripiprazole|Double Blind Phase: 15 mg administered orally, given once daily for 24 weeks. Dose can be adjusted to a minimum of 10 mg or a maximum of 30 mg. Open Label Phase: LY2140023, 40 mg administered orally, given twice daily for an additional 28 weeks.
3181606|NCT01328080|Experimental|Targeted UV-B (Left)|Targeted UV-B on left side of the scalp.
3181607|NCT01328080|Experimental|Targeted UV-B (Right)|Targeted UV-B on right side of the scalp.
3181608|NCT01328067|Active Comparator|Treatment|MR guided Focused Ultrasound
3181609|NCT01328067|Active Comparator|Surgery|Myomectomy
3181610|NCT01328054|Experimental|lapatinib/placebo|This is a crossover study where subjects will receive placebo that mimics lapatinib for 2 days and lapatinib for 2 days. Subjects will not know when they are receiving placebo vs. lapatinib.
3181611|NCT01328041|Experimental|dolutegravir|dolutegravir plus background antiretroviral therapy optimised at Day 8
3181612|NCT01328028||Group A|Subjects diagnosed with invasive cervical cancer
3181613|NCT01328015|Active Comparator|Oxybuynin, hyperhidrosis|
3181614|NCT01328015|Placebo Comparator|placebo - sugar pill|
3181615|NCT01328002|Experimental|Milnacipran|oral administration, twice daily dosing
3181616|NCT01328002|Placebo Comparator|Placebo|oral administration, twice daily dosing
3181617|NCT01327989||Solitaire™ FR device|Eligible subjects treated with the Solitaire™ FR device.
3181618|NCT01327976|Active Comparator|vBloc (Active Device)|The treatment group will receive a functional device that will deliver charge to the vagus nerve during the study period
3181619|NCT01327976|Sham Comparator|Sham (Non-active Device)|The control group will receive a functional, but non-active device that will deliver no charge to the vagus nerve during the study period
3181620|NCT01327963|Experimental|Transoral Incisionless Fundoplication|"Intervention:~Transoral Incisionless Fundoplication:~With patient in general anesthesia. The EsophyX device is introduced through the mouth, over a standard endoscope, into the stomach. Multiple gastro -esophageal plications are performed, apposing the fundus to the distal part of the esophagus and repositioning the GEJ below the diaphragm, into the abdomen. multiple prolene fasteners are used to sescure and keep in place the plications."
3181621|NCT01327950||Superficial Femoral Lesions|Patients undergoing percutaneous treatment of Superficial Femoral Artery lesions
3181622|NCT01327937|Active Comparator|Apligraf Group|Apligraf group - Applied at Day 0, Weeks 1-4 (maximum of 5 applications) Also cross-over at Week 4 for Control NPTH group - Apligraf applied at Week 4, Weeks 5-8 (maximum of 5 applications)
3181623|NCT01327937|Placebo Comparator|Standard of Care Dressing Group|Standard of care dressing regimen - Foam dressing (eg, Mepilex) and 4 layered compression system (eg, Profore)
3181624|NCT01327924||Norditropin NordiFlex® users|
3181625|NCT01327911|Experimental|Ciliary Neurotrophic Factor (CNTF)/NT-501|Biological/Vaccine:NT-501 implant
3181626|NCT01327898|Experimental|1|empowerment theory-based small group discussion
3181627|NCT01327898|Active Comparator|2|single session individual resilience counseling
3181628|NCT01327885|Experimental|Arm A|
3181629|NCT01327885|Active Comparator|Arm B|
3181630|NCT01327872|Experimental|Treatment A|
3181631|NCT01327872|Experimental|Treatment B|
3181632|NCT01327872|Experimental|Treatment C|
3181633|NCT01327872|Experimental|Treatment D|
3181634|NCT01327859|Experimental|Prior Donepezil 5mg|
3181635|NCT01327859|Experimental|Prior Donepezil 10mg|
3181636|NCT01327859|Placebo Comparator|Prior Placebo|
3181637|NCT01327846|Experimental|Canakinumab Dose 50 mg|"Pivotal Phase:~Blinded Canakinumab 50 mg quarterly subcutaneous + standard of care therapy.~Extension Phase:~Blinded canakinumab 50 mg quarterly subcutaneous + standard of care therapy, switched to open-label canakinumab 150 mg quarterly subcutaneous + standard of care therapy after 9 months."
3181638|NCT01327846|Experimental|Canakinumab Dose 150 mg|"Pivotal Phase:~Blinded Canakinumab 150 mg quarterly subcutaneous + standard of care therapy.~Extension Phase:~Blinded canakinumab 150 mg quarterly subcutaneous + standard of care therapy, switched to open-label canakinumab 150 mg quarterly subcutaneous + standard of care therapy after 9 months."
3181639|NCT01327846|Experimental|Canakinumab Dose 300 mg|"Pivotal Phase:~Blinded Canakinumab 300 mg quarterly subcutaneous (with one additional dose at week 2) + standard of care therapy.~Extension phase:~Blinded canakinumab 300 mg quarterly subcutaneous + standard of care therapy, switched to open-label canakinumab 150 mg quarterly subcutaneous + standard of care therapy after 9 months."
3181640|NCT01327846|Placebo Comparator|Placebo|"Pivotal Phase:~Blinded matching placebo quarterly subcutaneous + standard of care therapy.~Extension Phase:~Blinded matching placebo quarterly subcutaneous + standard of care therapy, switched to open-label canakinumab 150 mg quarterly subcutaneous + standard of care therapy after 9 months."
3181641|NCT01327833||Cardiac Arrest|
3181642|NCT01327820||Open aortic aneurysm repair|
3181643|NCT01327820||Endovascular aortic aneurysm repair|
3181644|NCT01327820||Infra-inguinal lower limb revascularisation|
3181645|NCT01327807||Cystinsosis patients|Those with a diagnosis of cystinosis.
3181646|NCT01327794||Group 1|Participants in this correlative study (CALGB 151006) were enrolled in CALGB 80303, which was a national, multi-center, double-blind phase III study that randomly assigned patients (1:1) with advanced pancreatic cancer to gemcitabine plus bevacizumab vs gemcitabine plus placebo. Blood samples were collected from consenting participants in CALGB 80303 at the time of study registration at respective institutions and shipped to the CALGB Pathology Coordinating Office for storage (Columbus, OH).Baseline serum 25-hydroxyvitamin D (25[OH]D) levels were measured and examined associations between baseline 25(OH)D levels and progression-free survival and OS using the Cox rank score test.
3181647|NCT01327781|Experimental|Treatment (Z-endoxifen hydrochloride)|Patients receive Z-endoxifen hydrochloride PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3181648|NCT01327768|Experimental|OECs, Medicine, Rehabilitation|Stroke patients are received intracerebral implantation of Olfactory ensheathing cells(OECs), Antiplatelet Medication, and Rehabilitation.
3181649|NCT01327755|Experimental|Selenium|
3181650|NCT01327755|Placebo Comparator|Placebo|
3181711|NCT01327365|Experimental|Sheathless group|patient randomized to the sheathless guiding catheter group
3181652|NCT01327729|Active Comparator|YPEG-IFN α-2a Ten days|this arm will be treated with: YPEG-IFN α-2a 180mcg/10 days for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks
3181653|NCT01327729|Active Comparator|YPEG-IFN α-2a two weeks|"The third group will be treated with:~YPEG-IFN α-2a 180mcg/ 2 weeks for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks."
3181654|NCT01327703|Experimental|Panzytrat® 25,000|
3181655|NCT01327703|Active Comparator|Kreon® 25,000|
3181656|NCT01327690|No Intervention|Wait List|Wait Period corresponding in length to treatment period
3181657|NCT01327690|Experimental|EFT (Emotional Freedom Techniques)|EFT group therapy sessions.
3181658|NCT01327690|Active Comparator|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
3181659|NCT01327677|Active Comparator|Pro re nata (PRN) fentanyl|A nurse can give the patient up to 3 doses of fentanyl intravenously (through a vein) each hour whenever a patient indicates that he or she is in pain.
3181660|NCT01327677|Active Comparator|Intravenous Patient-controlled Analgesia (IVPCA) fentanyl|Fentanyl will be given with a Patient Controlled Analgesia (PCA) pump.
3181661|NCT01327664|Experimental|AIN457 300mg s.c every 2 weeks|
3181662|NCT01327651|Active Comparator|Daily dosing|Participants will receive oral FTC/TDF daily.
3181663|NCT01327651|Experimental|Time-driven dosing|Participants will receive oral FTC/TDF twice weekly with a post-exposure dose.
3181664|NCT01327651|Experimental|Event-driven dosing|Participants will receive oral FTC/TDF before and after a potential exposure to HIV infection.
3181665|NCT01327638||Patients with SpA/AS and etoricoxib treatment|
3181666|NCT01327638||Patients with SpA/AS and other COX-2 inhibitor treatment|
3181667|NCT01327638||Patients with SpA/AS and nsNSAIDs treatment|
3181668|NCT01327625|Experimental|Azithromycin|Patient who are diagnosed as bronchiolitis obliterans according to the WHO criteria
3181669|NCT01327612|Experimental|Combination Treatment|Combination treatment: Conatumumab Q2W or Q3W + ongoing chemotherapy or ganitumab.
3181670|NCT01327612|Experimental|Monotherapy Treatment|Monotherapy treatment: Conatumumab Q2W or Q3W; or AMG 479 Q3W or Q4W
3181671|NCT01327599|Experimental|DUOTRAV®|Travoprost 0.004%+Timolol 0.5% ophthalmic solution, 1 drop to the study eye(s) once a day at 8:00 PM for 12 weeks
3181672|NCT01327586|Experimental|ATM|Advisor-Teller Money Manager
3181673|NCT01327586|Active Comparator|Individual Drug Counseling|
3181674|NCT01327573|Experimental|Eculizumab|"eculizumab will be given in addition to standard immunosuppression regimen (oral tacrolimus, MMF [mycophenolate mofetil~], prednisone)"
3181675|NCT01327573|No Intervention|no additional therapy|patients in this arm will receive standard immunosuppression regimen (oral tacrolimus, MMF, prednisone only, no additional therapy
3181676|NCT01327547|Experimental|1.0|
3181677|NCT01327547|Placebo Comparator|2|
3181678|NCT01327534|Experimental|prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
3181679|NCT01327534|Active Comparator|clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
3181680|NCT01327508|Experimental|TRIGEN SURESHOT Distal Targeting|TRIGEN SURESHOT Distal Targeting Instrumentation is utilized to find screw holes.
3181681|NCT01327508|Active Comparator|Standard Nailing Instrumentation.|Free-hand technique utilizes x-rays to find screw holes
3181682|NCT01327495|Placebo Comparator|Arm 1: Placebo|Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
3181683|NCT01327495|Active Comparator|Arm 2:1.25g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
3181684|NCT01327495|Active Comparator|Arm 3: 2.5g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
3181685|NCT01327495|Active Comparator|Arm 4: 5g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
3181686|NCT01327495|Active Comparator|Arm 5: 10g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
3181687|NCT01327495|Active Comparator|Arm 6: 15g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
3181688|NCT01327482|Experimental|All|All patients were part of the intervention arm, as this was a pharmacokinetic study. All women took Raltegravir 400mg orally, twice daily for 3 weeks.
3181689|NCT01327469|Experimental|Albendazole 400mg|albendazole, 1 x 400mg
3181690|NCT01327469|Experimental|Albendazole 2 x 400mg|albendazole, 2 x 400mg
3181691|NCT01327469|Experimental|Mebendazole 500mg|mebendazole, 1 x 500mg
3181692|NCT01327469|Experimental|Mebendazole 2 x 500mg|mebendazole, 2x 500mg
3181693|NCT01327469|Experimental|Pyrantel-oxantel + mebendazole|pyrantel-oxantel (10mg/kg)+ mebendazole (500mg)
3181694|NCT01327456|Experimental|Self-Management Intervention|participants who receive the one-on-one self-management intervention
3181695|NCT01327456|No Intervention|Usual Care|group receives no additional education or intervention then they would as usual care of their COPD
3181696|NCT01327443|Other|Weight loss|10% weight loss in 24 weeks time period through nutritional counseling.
3181697|NCT01327443|Active Comparator|Exercise without weight loss|24 weeks under direct supervision.
3181698|NCT01327443|No Intervention|Control|No change in usual exercise levels or food intake.
3181699|NCT01327430|Experimental|Phospholipid supplementation|Supplementation of milk phospholipid
3181700|NCT01327417||Depressed|Patients with Major Depressive Disorder
3181701|NCT01327417||Healthy Controls|
3181702|NCT01327404||Depressed|Patients with Major Depressive Disorder
3181703|NCT01327404||Diabetic|Patients with Type 2 Diabetes
3181704|NCT01327404||Diabetic/Depressed|Patients with both diabetes and major depressive disorder
3181705|NCT01327404||Healthy Controls|
3181706|NCT01327391|Active Comparator|On line Hemodiafiltration|Hemodialysis patients treated with on line hemodiafiltration technic
3181707|NCT01327391|Other|hemodialysis|Hemodialysis patients treated with conventional hemodialysis technic using high flux dialyzers
3181708|NCT01327378||Dialysis, normal glucose tolerance|Chronic dialysis treatment, N=10 OGTT,120 min < 7.8 mmol/L
3181709|NCT01327378||Dialysis, impaired glucose tolerance|Chronic dialysis treatment, N=10 OGTT,120 min 7.7<11.1 mmol/L
3181712|NCT01327365|Active Comparator|Conventional group|patients randomized to the conventional guiding catheter group
3181713|NCT01327352|Experimental|Oshadi D|"2 dose levels of Oshadi D in 2 food regimen will be administered as following:~Subjects will receive placebo on the morning of day 1 during fast. Late breakfast will be provided 4 hours following placebo administration.~On day 8 a single dose of 180mg Oshadi D will be administrated during fast. Late breakfast will be provided 4 hours following drug administration~On day 16 subjects will be administered with 360mg of Oshadi D during fast. Late breakfast will be provided 4 hours following drug administration.~On day 24, 180mg of Oshadi D will be administrated immediately after breakfast.~On day 32, subject will be administered with 360mg of Oshadi immediately after breakfast."
3181714|NCT01327339||Subjects eligible for REQUIP prescription|Male and female subjects who were considered appropriate to be prescribed REQUIP according to the prescribing information will be included in this study.
3181715|NCT01327326|Active Comparator|TMD patients|"Intervention:~Drug: Naltrexone~Drug: placebo"
3181716|NCT01327326|Active Comparator|Healthy controls|"Intervention:~Drug: Naltrexone~Drug: placebo"
3181717|NCT01327313|Experimental|EMD525797 250 milligram (mg)|
3181718|NCT01327313|Experimental|EMD525797 500 mg|
3181719|NCT01327313|Experimental|EMD525797 1000 mg|
3181720|NCT01327313|Experimental|EMD525797 1500 mg|
3181721|NCT01327300|Active Comparator|Mesalamine|This group received the drug Mesalamine for 12 weeks then a wash out for 3 weeks prior to crossing over to the placebo arm.
3181722|NCT01327300|Placebo Comparator|Placebo|This group will receive the Placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
3181723|NCT01327287||Trauma patients eligible to receive thoracic epidural|Patients admitted to the hospital suffering from blunt thoracic injury and who meet inclusion/exclusion criteria and receive thoracic epidural for pain
3181724|NCT01327287||Control Arm|Trauma patients eligible to receive thoracic epidural but did not receive thoracic epidural for pain
3181725|NCT01327274|Experimental|Treatment Arm|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI > 3.5) will undergo the interventional treatment arm by having outpatient surgery and the Magnetic MIni-Mover Magnimplant procedure is performed during which the magnetic implant is surgically placed. After 2 years of treatment with the implanted magnet and brace treatment, the Magnetic Mini-Mover Magnimplant will be explanted. After surgery and recovery, all subjects will be fitted for an orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo 3MP treatment for 18-24 months, enough to attempt to improve their PSI (< 3.25).
3181726|NCT01327261|Experimental|Levodopa + benserazide (test formulation)|A randomized-sequence, open-label, 2-period crossover study assessing relative bioavailability of two drug products containing the association levodopa + benserazide.
3181727|NCT01327261|Active Comparator|Levodopa + benserazide (reference formulation)|
3181728|NCT01327248||affected patients|20 Patients suffering from bronchiolitis obliterans
3181729|NCT01327248||non-affected patients|20 matched controls not suffering from bronchiolitis obliterans
3181730|NCT01327235|Active Comparator|Endostar|
3181731|NCT01327235|Active Comparator|Cisplatin|
3181732|NCT01327235|Experimental|Endostar and Cisplatin|
3181733|NCT01327222|Experimental|bevacizumab|three-monthly intravitreal bevacizumab, followed by PRN monthly injection on the basis of the detection of any fluid on the optical coherence tomography
3181734|NCT01327222|No Intervention|control|monthly follow-up
3181735|NCT01327209||Patients with diabetes|
3181736|NCT01327183|Experimental|20 mg/kg RO4905417 before PCI|
3181737|NCT01327183|Experimental|5 mg/kg RO4905417 before PCI|
3181738|NCT01327183|Placebo Comparator|Placebo before PCI|
3181739|NCT01327170|Active Comparator|Subthreshold diode micropulse laser|Subthreshold diode micropulse laser in patients with chronic central serous chorioretinopathy
3181740|NCT01327170|Sham Comparator|Sham|Sham group simulating the laser treatment
3181741|NCT01327157|Placebo Comparator|Visual Analog Scale (VAS)|"Initial consultation, dental cleaning and performing the visual analog scale. Consultation three months after achieving visual analog scale final~VAS and dental cleaning at the first query.~VAS at the last query. In the second period (91-180 days) that participants have been moved from the Placebo group (VAS) to the Experimental group(Occlusal Adjustment)."
3181742|NCT01327157|Experimental|Occlusal adjustment|In all consultations, was performed VAS and occlusal adjustment. Three sessions of intervention are doing. The Gnathostatic models were performed in the first and last query. To reach a terminal axis of rotation of the jaw the patient to perform the act of swallowing for 3 times, and after palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth and started the adjustment following the rules of Guichet with a cylindrical drill with a thin cut.. The rules to guide the occlusal adjustment selective grinding were in this sequence: Occlusal adjustment to the centric relation: with sliding towards anterior; with sliding towards the medium line; with sliding opposite to the medium line; No sliding.
3181743|NCT01327144|Experimental|Famciclovir 500mg|1 tablet each 8 hours for 7 days
3181744|NCT01327144|Active Comparator|Aciclovir 400mg|2 tablets of Aciclovir 400 mg each 4 hours for 7 days
3181745|NCT01327118|Placebo Comparator|Isoton sodium chloride|
3181746|NCT01327118|Active Comparator|Prostaglandin F2alpha|
3181747|NCT01327105|Experimental|TVU|
3181748|NCT01327092|No Intervention|Literacy Group|Families in the Literacy Group (control group)will receive a program which seeks to promote literacy by providing developmentally appropriate books and other reading-related materials to children and encouraging mothers to develop an interest in reading with their child. After enrollment and randomization, CHIP staff will visit these control group homes, assess the mother's interest in and barriers to reading with her child, council mothers about the importance of literacy and reading books to their child, and children will be given age appropriate books and other materials to promote literacy.
3181784|NCT01326858|Placebo Comparator|Vehicle|Olopatadine hydrochloride ophthalmic solution vehicle, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic solution, 0.7% and ketotifen fumarate ophthalmic solution, 0.025%, Periods 2 and 3, as randomized
3181836|NCT01326442|Experimental|diet only|low glycemic index diet, calorie restricted with exercise 3 times per week.
3181749|NCT01327092|Experimental|Injury Intervention Group|Injury Intervention Group: In homes of children who are randomized to the injury intervention arm of the trial, a comprehensive survey of injury hazards in living spaces will be undertaken. In addition to quantifying hazards, the area of living spaces will be obtained to allow the determination of both the number and density (number of hazards per 100 sq ft) of injury hazards. If one or more injury hazards are identified, they will be removed and/or modified to reduce exposure and injury risk. The intervention is focused on areas in living spaces below 1 meter (~39 inches) in height from (the 75th percentile in height or eye-level for a 3-year old US male toddler) which might be easily reached or climbed on by children less than 4 years
3181750|NCT01327079|Experimental|Group 1|"Gestational age less than 29 weeks We will substitute for one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
3181751|NCT01327079|Experimental|Group 2|"Gestational age greater then 29 weeks We will substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
3181752|NCT01327066|Experimental|Droxidopa - Therapeutic|Droxidopa 600 mg
3181753|NCT01327066|Experimental|Droxidopa - Supratherapeutic Dose|Droxidopa 2000 mg
3181754|NCT01327066|Placebo Comparator|Placebo|Placebo
3181755|NCT01327066|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg dose
3181756|NCT01327053|Experimental|LDE225 200 mg|The study is double blinded and will enroll at least 50 evaluable patients in the 200 mg LDE225 arm. The efficacy and safety of LDE225 will be analyzed separately in each group. Patients who meet all the inclusion and none of the exclusion criteria will be treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.
3181757|NCT01327053|Experimental|LDE225 800 mg|The study is double blinded and will enroll at least 100 evaluable patients in the 800 mg LDE225 arm. The efficacy and safety of LDE225 will be analyzed separately in each group. Patients who meet all the inclusion and none of the exclusion criteria will be treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.
3181758|NCT01327040|Experimental|sensitization duration 1.375h|This group will experience a 1.375h sensitization duration prior to the 12h light exposure
3181759|NCT01327040|Experimental|sensitization duration 5.5h|This group will experience a 5.5h sensitization duration prior to the 12h light exposure
3181760|NCT01327040|Experimental|sensitization duration 22h|This group will experience a 22h sensitization duration prior to the 12h light exposure
3181761|NCT01327040|Experimental|sensitization duration 0.33h|This group will experience a 0.33h sensitization duration prior to the 12h light exposure
3181762|NCT01327027|Experimental|Vasopressin, Arginine, ADH|We will test how vasopressin affects emotional responses to facial stimuli in healthy men and women.
3181763|NCT01327027|Placebo Comparator|Sterile Salilne|Sterile saline will be administered intranasally and emotional responses to facial stimuli measured.
3181764|NCT01327014|Placebo Comparator|Placebo group|
3181765|NCT01327014|Experimental|1,200 mg/day of XZK group|
3181766|NCT01327014|Experimental|2,400 mg/day of XZK group|
3181767|NCT01326988||Patients requiring spinal anesthesia for lower limb surgery|Patients of at least 18 years of age undergoing spinal anesthesia for elective lower limb surgery will be recruited. Therefore inclusion and exclusion criteria are the same as for traditionally administered spinal anesthesia as below. Additionally we will exclude those patients who are incapable of providing fully informed consent, patients who are currently enrolled in other studies and patients with communication difficulties
3181768|NCT01326975||EAdi 1|babies in this group will first receive CPAP through IF-CPAP for 30 minutes. After another 45 minutes, they will be switched to HFNC for 30 minutes. EAdi will be recorded for the last 15 minutes of each 30 minutes period.
3181769|NCT01326975||EAdi 2|babies in this group will first receive CPAP through HFNC for 30 minutes. After another 45 minutes, they will be switched to IF-CPAP for 30 minutes. EAdi will be recorded for the last 15 minutes of each 30 minutes period.
3181770|NCT01326962|Experimental|Single Arm|
3181771|NCT01326949|Active Comparator|ET+NSBB|"Endoscopic treatment(ET)- Endoscopic variceal ligation (EVL)~Non-selective beta blocker(NSBB)-Propranolol.~Anticoagulation(AT)- Heparin followed by warfarin."
3181772|NCT01326949|Active Comparator|TIPS|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS.
3181773|NCT01326936|Experimental|Unworked VP|Online education using typical virtual patient (VP) approach. Five unworked VPs presented to subjects for study.
3181774|NCT01326936|Experimental|Guided Learning|Online education replaces two unworked VPs in Arm 1 with identical worked example VPs (case studies) for learners to study
3181775|NCT01326923|Other|Single arm|Single arm Phase II Study Induction Chemo then Concurrent Chemoradiotherapy with Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
3181776|NCT01326910|Experimental|19306-127|Experimental Topical cream applied twice daily (or as needed)
3181777|NCT01326910|Other|19306-137|Marketed Topical cream applied twice daily (or as needed)
3181778|NCT01326897|Active Comparator|Comparison Group|Comparison group participants will be given health education materials.
3181779|NCT01326897|Experimental|Intervention`|This group will receive the intervention (Healthy Homes/Healthy Families) as described below.
3181780|NCT01326884|Other|1|Endovascular Repair
3181781|NCT01326871|Experimental|ALT-801 with Cisplatin and Gemcitabine (Phase Ib and Phase II)|
3181782|NCT01326871|Experimental|ALT-801 and Gemcitabine (Phase II only)|
3181783|NCT01326858|Experimental|Olopatadine, 0.7%|Olopatadine hydrochloride ophthalmic solution, 0.7%, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic vehicle and ketotifen fumarate ophthalmic solution, 0.025%, Periods 2 and 3, as randomized
3181832|NCT01326468|Experimental|Cohort B - Temsirolimus|Temsirolimus with Erbitux and radiation therapy
3181833|NCT01326455|No Intervention|Terumo Control|
3181785|NCT01326858|Active Comparator|Zaditor|Ketotifen fumarate ophthalmic solution, 0.025%, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic solution, 0.7% and olopatadine hydrochloride ophthalmic solution vehicle, Periods 2 and 3, as randomized
3181786|NCT01326845|Experimental|Deferasirox am|Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food
3181787|NCT01326845|Experimental|Deferasirox pm|Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal
3181788|NCT01326832||Primoris|50 patients included in RSA cohort of total of 350 anticipated Primoris cases
3181789|NCT01326806|Experimental|Sex Education + Standard Care|Participating mothers will receive sex education information while their child is having a physical exam.
3181790|NCT01326806|Active Comparator|Hygiene & Nutrition Education + Standard Care|Participating mothers will receive information on hygiene and nutrition while their child is having a physical exam.
3181791|NCT01326806|No Intervention|No Education + Standard Care|Participating mothers who are passive controls will not receive any additional information while their child is having a physical exam.
3181792|NCT01326780|Experimental|1.2% Facial Cream|1.2% JNJ 10229570-AAA
3181793|NCT01326780|Experimental|2.4% Facial Cream|2.4% JNJ 10229570-AAA
3181794|NCT01326780|Experimental|3.6% Facial Cream|3.6% JNJ 10229570-AAA
3181795|NCT01326780|Placebo Comparator|0% Facial Cream|Vehicle control
3181796|NCT01326767|Active Comparator|Paclitaxel dosing according to SmPC|
3181797|NCT01326767|Experimental|Individualized pharmacokinetically driven paclitaxel dosing|In the first treatment cycle, the Paclitaxel dose is adapted depending on the age and the gender of the patient. In the treatment cycles 2-6 the Paclitaxel dose is adapted based on individual PK data and toxicities.
3181798|NCT01326754|Other|Artemether-lumefantrine|
3181799|NCT01326754|Other|Artesunate-amodiaquine|
3181800|NCT01326754|Other|Dihydroartemisinin-piperaquine|
3181801|NCT01326728||Allogeneic Stem Cell Transplant|Allogeneic hematopoietic stem cell transplantation (or allotransplant; donor blood stem cells)
3181802|NCT01326702|Experimental|Treatment (veliparib, bendamustine hydrochloride, rituximab)|"Patients receive veliparib PO BID on days 1-7 and bendamustine hydrochloride IV over 30-60 minutes on days 1-2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Once the maximum-tolerated dose is determined, a cohort of patients receives veliparib and bendamustine hydrochloride as above and rituximab IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3181803|NCT01326689|Experimental|KW-2246|
3181804|NCT01326689|Placebo Comparator|Placebo|
3181805|NCT01326676|Experimental|polypill|Red Heart Pill Version 1 and Red Heart Pill Version 2.
3181806|NCT01326676|Active Comparator|usual medication|participants continuing to receive cardiovascular disease medications as separate tablets prescribed by their usual physician
3181807|NCT01326663|Active Comparator|divalproex sodium|
3181808|NCT01326663|Placebo Comparator|sugar pill|
3181809|NCT01326650|Experimental|Vitamin D|daily vitamin D supplement
3181810|NCT01326650|Placebo Comparator|placebo|daily placebo supplement
3181811|NCT01326624||NYHA class III or IV|"Patients with NYHA class III or IV during the past month and one or more of the following:~Hospitalization for cardiac decongestion and stabilization.~Advanced heart failure receiving intravenous diuretics/inotropics in an outpatient clinic.~Awaiting cardiac transplantation"
3181812|NCT01326624||left ventricular ejection fraction ≤ 35%|"Patients with left ventricular ejection fraction ≤ 35% and either one of the following:~Coronary revascularization within 3 calendar months prior to enrollment.~Heart failure of non-ischemic origin diagnosed within 3 calendar months prior to enrollment."
3181813|NCT01326624||Awaiting ICD re-implantation|
3181814|NCT01326624||Acute myocardial infarction|Patients hospitalized with acute myocardial infarction and Killip Class III/IV.
3181815|NCT01326611|Active Comparator|Clarithromycine Group: Active Comparator|Drug: Clarithromycin intravenous clarithromycin (10 mg/kg twice a day for 10 days)
3181816|NCT01326611|Placebo Comparator|Placebo Group: Placebo Comparator|Drug: D5W Dose given daily, IV same volume that Clarithromycin would be to equal 10 mg/kg for first 10 days.
3181817|NCT01326598||T2DM patients with A1C<7.0%|
3181818|NCT01326585|Experimental|Dexamethasone|Subjects receive intravenous intraoperative dexamethasone
3181819|NCT01326585|Placebo Comparator|Saline solution|Subjects receive intravenous intraoperative normal saline solution
3181820|NCT01326572||female, male, HIV, lung disease|All participants in the University of Pittsburgh Multicenter AIDS Cohort Study are eligible for this protocol. All participants in the UCSF Women's HIV study are eligible and all Men from the UCLA men's HIV study are eligible
3181821|NCT01326559|Experimental|Experimental 1|Induction chemotherapy using Docetaxel, Cisplatin and 5-FU for week 1 to week 9 and followed by concurrent chemoradiation plus cetuximab from week 10 to week 16
3181822|NCT01326546|Active Comparator|Therapeutic HBV vaccine Joint Entecavir|Therapeutic HBV vaccine Joint Entecavir group：Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
3181823|NCT01326546|Placebo Comparator|Empty liposome Joint Entecavir|Placebo comparator: Inject placebo (empty liposome) 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
3181824|NCT01326533|Experimental|hydroxychloroquine|Thirteen weeks of daily hydroxychloroquine following FSIGTT testing
3181825|NCT01326533|Placebo Comparator|Placebo|Thirteen weeks of daily placebo following FSIGTT testing
3181826|NCT01326520|Experimental|Phospholipid enriched dairy product|
3181827|NCT01326520|Placebo Comparator|dairy product|
3181828|NCT01326494|Active Comparator|Arm 1 Oral Cortico Steroid|A filled prescription will be given to be used upon early onset of symptoms.
3181829|NCT01326494|No Intervention|Usual care for Asthma treatment|monitor the readmission of URTI induced asthma in children over a 12 month period
3181830|NCT01326481|Experimental|Single|All patients received TRC105 + capecitabine
3181831|NCT01326468|Experimental|Cohort A - Temsirolimus with Cisplatin|Temsirolimus with cisplatin, Erbitux and radiation therapy
3181834|NCT01326455|Active Comparator|Terumo Fast Release|
3181837|NCT01326442|Active Comparator|supplemented|2000 IU vitamin D3 plus 1.8 g EPA + DHA
3181838|NCT01326429||Hypernatremia|Patients admitted to the emergency department with a serum sodium exceeding 145 mmol/L.
3181839|NCT01326429||Hyponatremia|Patients admitted to the emergency room with a serum sodium below 135 mmol/L.
3181840|NCT01326416|Active Comparator|S: Nutritional Supplementation alone|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g of L-Leucine and 9 g of L-arginine), to distribute during each of the 3 main meals.
3181841|NCT01326416|Active Comparator|A: Physical Reconditioning alone|Physical reconditioning sessions led by a trainer three times a week for 6 months.
3181842|NCT01326416|Active Comparator|AS: Physical Reconditioning + Nutritional Supplementation|Association for six months of a specific nutritional supplementation by 21 g of L-Leucine and 9 g of L-arginine per day (to distribute during each of the 3 main meals) and of physical reconditioning sessions three times a week.
3181843|NCT01326416|No Intervention|C: Lifestyle counseling|Usual advice given in consultation on the need for a balanced diet and regular physical activity
3181844|NCT01326403|Experimental|Group A|Patients will receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.
3181845|NCT01326403|Experimental|GROUP B|Patients will receive IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.
3181846|NCT01326403|Placebo Comparator|GROUP C|A control group will only receive placebo in the emergency room and in the OR.
3181847|NCT01326351|Experimental|Regenerative Injection Therapy|
3181848|NCT01326351|Sham Comparator|Dry needle|
3181849|NCT01326351|Active Comparator|Exercise|
3181850|NCT01326338|Experimental|Nitazoxanide Suspension|Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years
3181851|NCT01326338|Placebo Comparator|Placebo Suspension|Placebo Oral Suspension 5 ml for patients aged 1-3 years and Placebo Oral Suspension 10 ml for patients aged 4-11 years
3181852|NCT01326325|Experimental|Ketamine|Ketamine PANFARMA
3181853|NCT01326325|Placebo Comparator|Not Ketamine|NaCl
3181854|NCT01326312|Experimental|GTX 758|GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
3181855|NCT01326312|Experimental|GTx-758|GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
3181856|NCT01326312|Active Comparator|Lupron Depot|Luteinizing Hormone Releasing Hormone Agonist
3181857|NCT01326299|Active Comparator|Nutritional ingredient|Dissolve in water and consume with meal
3181858|NCT01326299|Placebo Comparator|Carbohydrate|dissolve in water and consume with meal
3181859|NCT01326299|Experimental|#1 Nutrtitional ingredient + Fiber|Dissolve in water and consume with meal
3181860|NCT01326299|Experimental|#2 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
3181861|NCT01326299|Experimental|#3 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
3181862|NCT01326286||Open Radical Prostatectomy|262
3181863|NCT01326286||Robotic Radical Prostatectomy|1303
3181864|NCT01326286||Intensity-Modulated Radiotherapy|638
3181865|NCT01326286||Interstitial Brachytherapy|171
3181866|NCT01326286||combined EBRT and Brachytherapy|143
3181867|NCT01326286||Active Surveillance|448
3181868|NCT01326286||Various other treatments|300
3181869|NCT01326260||THAM Patients|Patients who were managed with the use of THAM
3181870|NCT01326260||Non-THAM Patients|Patients who did not use THAM but were resuscitated with crystalloids and colloids and may have received sodium bicarbonate for the treatment of acidosis
3181871|NCT01326247|No Intervention|0.9% NaCl solution|
3181872|NCT01326234|Active Comparator|Personalized Feedback|The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
3181873|NCT01326234|Sham Comparator|Treatment as Usual|Practitioners are able to provide normal care with regard to smoking; participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred.
3181874|NCT01326221||1|Single dose of Truvada
3181875|NCT01326208|Experimental|Acute Lung Injury / ARDS|Patient under mechanical suffering from ALI or ARDS
3181876|NCT01326195|Experimental|Skills|Cognitive-Behavioral Dating Violence and HIV Prevention Group
3181877|NCT01326195|Active Comparator|Health Promotion|Psycho-educational Dating Violence and HIV Prevention group
3181878|NCT01326182|Experimental|MAADRE|Group-based intervention combining asthma education and cognitive behavioral treatment for depressive symptoms
3181879|NCT01326182|Active Comparator|MAAS|Group-based treatment combining asthma education and general information regarding child health
3181880|NCT01326169|Active Comparator|Standard care|No intervention
3181881|NCT01326169|Experimental|Counseling|Telephone-delivered counseling
3181882|NCT01326156|Experimental|Avon patellofemoral replacement|Knee arthroplasty with insertion of patellofemoral joint replacement.
3181883|NCT01326156|Active Comparator|PFC Sigma CR total knee replacement|Knee arthroplasty with total (tricompartmental) knee replacement.
3181884|NCT01326143||ORM Narval MRD|
3181885|NCT01326130|Active Comparator|Chronic care management 1|Content of chronic care model implemented in territory 1 and level of implementation
3181886|NCT01326130|Active Comparator|Chronic care management 2|Content of chronic care model implemented in territory 2 and level of implementation
3181887|NCT01326130|Active Comparator|Chronic care management 3|Content of chronic care model implemented in territory 3 and level of implementation
3181888|NCT01326130|Active Comparator|Chronic care management 4|Content of chronic care model implemented in territory 4 and level of implementation
3181889|NCT01326130|Active Comparator|Chronic care management 5|Content of chronic care model implemented in territory 5 and level of implementation
3181890|NCT01326130|Active Comparator|Chronic care management 6|Content of chronic care model implemented in territory 6 and level of implementation
3181891|NCT01326117|Experimental|tadalafil|
3181892|NCT01326104|Experimental|TTRNA-xALT & TTRNA-DCs|TTRNA-xALT 3 x 10^7/kg by intravenous injection once. TTRNA-DCs 1 x 10^7 by intradermal injection every 2 weeks for 3 total doses.
3181893|NCT01326091|No Intervention|Standard Positioning|
3181894|NCT01326091|Active Comparator|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
3181895|NCT01326078|Experimental|propofol nanoemulsion|3-4 mg/kg of propofol nanoemulsion will be administered by 1mL per 5 seconds, adjustment dose can be given.
3181896|NCT01326078|Active Comparator|propofol lipid emulsion|3-4 mg/kg will be administered by 1 ml per 5 seconds.
3181897|NCT01326052|Experimental|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
3181898|NCT01326052|Active Comparator|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
3181899|NCT01326039|Active Comparator|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
3181900|NCT01326039|Placebo Comparator|saline|perineural isotonic saline 20 ml
3181901|NCT01326026|Experimental|IDeg Simple|
3181902|NCT01326026|Experimental|IDeg Step wise|
3181903|NCT01326013||Blinded, Prospective Arm|Diagnostic accuracy for higher prevalence targets will be evaluated in prospectively collected, anonymized, leftover, stool specimens.
3181904|NCT01326013||Blinded, Pre-selected Arm|For targets that exhibit lower prevalence rates in the intended use population, banked, pre-selected, positive clinical specimens will be tested.
3181905|NCT01326000|Experimental|KRAS WT A|
3181906|NCT01326000|Active Comparator|KRAS WT B|
3181907|NCT01326000|Experimental|KRAS mutant A|
3181908|NCT01326000|Active Comparator|KRAS mutant B|
3181909|NCT01325987|Placebo Comparator|sugar pill|Subjects with vitamin D deficiency (serum 25(OH)D <20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
3181910|NCT01325987|Experimental|vitamin D2|Subjects with vitamin D deficiency (serum 25(OH)D <20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
3181911|NCT01325948||Patients with COPD|
3181912|NCT01325935|Experimental|Short-term DAPT group|1,200 patients to be newly registered: Undergo 3-month (+ 30 days) DAPT (aspirin and clopidogrel)
3181913|NCT01325935|No Intervention|Long-term DAPT group|1,200 patients to be appropriated from E-Japan post-marketing surveillance who meet all inclusion criteria and do not fall under any exclusion criteria of the present clinical study: Undergo 12-month DAPT (aspirin and clopidogrel)
3181914|NCT01325922|Other|50/50% Tilt|
3181915|NCT01325909|Active Comparator|Exercise|
3181916|NCT01325909|No Intervention|No Exercise|
3181917|NCT01325896|Other|All patients are receiving PEG-Intron|
3181918|NCT01325870|Experimental|ACD-CPR +ITD|Active Compression Decompression CPR with the ResQPRO device and ResQPOD ITD device.
3181919|NCT01325870|Experimental|S-CPR + ITPR|
3181920|NCT01325870|Active Comparator|S-CPR|
3181921|NCT01325857|Experimental|Group B|Group B = Nerve block group
3181922|NCT01325857|Placebo Comparator|Group L|Group L = Local wound infiltration group
3181923|NCT01325857|Active Comparator|Group C|Group C = Control group
3181924|NCT01325844|No Intervention|G group|G group = General anesthesia group
3181925|NCT01325844|Experimental|G+E group|G+E group = General anesthesia + epidural anesthesia group
3181926|NCT01325831|Experimental|transcranial magnetic stimluation|
3181927|NCT01325831|Sham Comparator|rTMS_sham|
3181928|NCT01325818|Active Comparator|1:pravastatin, 2:rosuvastatin|"Active Comparator Drug:pravastatin~Active Comparator Drug:rosuvastatin"
3181929|NCT01325805|Experimental|Structured Weight Loss|Women randomized to this arm will meet with a registered dietician regularly for review of calorie recommendations and food diary. As well as regular clinic visits to measure patients weight.
3181930|NCT01325805|Active Comparator|Routine Weight Loss Counseling|Patients are counseled by a physicians about the impact of maternal weight on fertility and pregnancy outcomes.
3181931|NCT01325792||GORE® BIO-A® Tissue Reinforcement|Single-staged open complex ventral incisional repair of primary or recurrent anterior abdominal wall hernia.
3181932|NCT01325779|Active Comparator|subcutaneous heparin|
3181933|NCT01325779|Active Comparator|subcutaneous enoxaparin|
3181934|NCT01325766|Active Comparator|Yoga (immediate start) group|This arm will start yoga sessions immediately after screening and will continue sessions for 8 weeks. This group will then continue with home yoga for an additional 8 weeks.
3181935|NCT01325766|Active Comparator|Yoga (waitlist) group|This arm will continue regular CF therapies for 8 weeks and will start yoga sessions at week 9.
3181936|NCT01325753|Experimental|Treatment (cryoablation)|Patients undergo CT-guided CA.
3181937|NCT01325740|Active Comparator|STX107 10 mg|
3181938|NCT01325740|Placebo Comparator|Placebo|
3181939|NCT01325740|Active Comparator|STX107 30 mg|
3181940|NCT01325727|Experimental|Brief computerized feedback|Brief computerized feedback
3181941|NCT01325727|Active Comparator|Resources only|
3181942|NCT01325714|Experimental|Arm 1: PAVeD Intervention|In the experimental arm, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
3181943|NCT01325714|Active Comparator|Arm 2: Enhanced Usual Care|In the comparison arm, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.
3181944|NCT01325701|Experimental|PCI-32765: 560 mg|Treatment Group 1: Subjects received 560 mg of ibrutinib once daily, on a continuous basis.
3181945|NCT01325701|Experimental|PCI-32765: 840 mg|Treatment Group 2: Subjects received 840 mg of ibrutinib once daily, on a continuous basis.
3181946|NCT01325688|Experimental|Group 1|PEP005 0.05% gel applied and occluded with an aluminium disk for up to three consecutive days
3181947|NCT01325688|Experimental|Group 2|PEP005 0.05% Gel applied and occluded with an OpSite(TM) disk up to three consecutive days
3181948|NCT01325688|Experimental|Group 3|PEP005 0.05% applied with no occlusion for up to three consecutive days
3181949|NCT01325675|Experimental|Interval training|Interval training
3181950|NCT01325675|No Intervention|Control|Live as usual
3181951|NCT01325662||Continuous drip sampling|Sampling at ~0.6 cc / hour (~1.2 cc / 2 hours, or lowest feasible rate given technical requirements and volume requirements for core analytes assays)
3181952|NCT01325662||Intermittent sampling|Sampling at 4 cc every 2 hours (+ 2 cc dead space clearance, total = 6 cc / 2 hours)
3181953|NCT01325649||advanced rectal cancer|Patients with carcinoma of the middle rectum with positive mrCRM (≤ 1 mm), with cT3 low rectal carcinoma, and with cT4 Tumors Arm 1 Long course radiochemotherapy before total mesorectal excision Arm 2 total mesorectal excision without radiochemotherapy
3181954|NCT01325636|Experimental|CD4 and CD8 T cell|Injection of specific CD4 and CD8 T cell
3181955|NCT01325623|Other|Model 106 VNS Therapy System|Model 106 VNS Therapy System includes a new Seizure Detection Algorithm (SDA) and corresponding Automatic Magnet Mode (AMM) feature.
3181956|NCT01325597|Experimental|Combined training|Training with functional electrical stimulation added by inspiratory muscle training.
3181957|NCT01325597|Experimental|Electrical stimulation|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks
3181958|NCT01325597|Experimental|Inspiratory muscle training|IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure
3181959|NCT01325597|No Intervention|Control group|No intervention.
3181960|NCT01325584|Experimental|Omegaven (compassionate use)|This is a compassionate use study. All participants will receive intravenous Omegaven (10% fish oil emulsion) with parenteral nutrition for 4 weeks.
3181961|NCT01325571|Experimental|tacrolimus group|
3181962|NCT01325571|Placebo Comparator|placebo group|
3181963|NCT01325545||Cryptogenic stroke|Patients with stroke of unknown cause after comprehensive conventional evaluation
3181964|NCT01325545||Stroke of known cause|Patients with stroke of known cause determined by comprehensive conventional evaluation
3181965|NCT01325532|Experimental|Active CES|"Active CES: The FW-100 Cranial Stimulator headset was placed on the scalp over the two dorsolateral prefrontal cortex areas. The power knob was turned to maximum setting. The waveform contains a 15000Hz square wave carrier from 0-4 mAmp. The first 15Hz modulating signal provides 50msec of on and 16.7msec of off time (total 66.7msec, 50% duty cycle). A second 500Hz modulating signal changes the on time series of 15000Hz pulses (750 pulses/50msec) into 25 smaller bursts of 15 pulses of the 15000Hz carrier signal, for 375 pulses in 50msec. The consecutive positive burst and off time is followed by an opposite negative burst and off time, balancing the current component to zero. Output voltage ranges from 0-40V, positive and negative. CES automatically shut off after 20 mins."
3181966|NCT01325532|Sham Comparator|Sham CES|Shame CES: The sham devices were modified to not deliver current to the headset. The current from the active device departs from the posts at the top of the device into the headsets, creating a loop when the headset is worn by the subject with the wet electrode sponges. This loop is eliminated in the sham devices by wrapping wire around the posts, thus containing the loop within the device, with no electricity leaving the headsets. This approach allows the loop to be maintained, and therefore all of the device's green and yellow amperage lights still light up, protecting the blind.
3181967|NCT01325519|No Intervention|no intervention control group|control subjects
3181968|NCT01325519|Experimental|experimental intervention group|video decision aid viewed by subjects
3181969|NCT01325506||Prostatectomy subjects|
3181970|NCT01325493|Placebo Comparator|Normal Saline|Normal Saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
3181971|NCT01325493|Active Comparator|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
3181972|NCT01325480||Patients with heart failure and wide QRS|Patients undergoing a cardiac resynchronization therapy procedure
3181973|NCT01325454||Patients with parapneumonic effusions|Patients with pleural effusions of unknown causes admitted to Taipei Medical University Hospital were included if parapneumonic effusion was diagnosed as one associated with pneumonia according to the criteria of the American Thoracic Society (ie, patients with newly acquired respiratory symptoms, fever, and abnormal breath sounds, plus a new lung infiltrate seen on a chest radiograph).
3181974|NCT01325441|Experimental|BBI608 and Paclitaxel|Patients will receive BBI608 orally continuously at dose levels specified for their respective dose cohorts. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
3181975|NCT01325428|Experimental|Afatinib once daily (OD)|Patients receive afatinib monotherapy once daily until progression of their disease
3181976|NCT01325415|Experimental|A|NKTR-118 25 mg (1x25 mg tablet + 5x placebo tablets)
3181977|NCT01325415|Experimental|B|NKTR-118 150 mg (6x25 mg tablet)
3181978|NCT01325415|Placebo Comparator|C|NKTR-118 placebo (6x placebo tablets)
3181979|NCT01325415|Active Comparator|D|Moxifloxacin (1 x 400 mg tablet)
3181980|NCT01325402|Experimental|Part 1 Cohort 1|Patients with mild to moderate Alzheimer's Disease
3181981|NCT01325402|Experimental|Part 1 Cohort 2|Patients with mild to moderate Alzheimer's Disease. To run if Maximum Detective Mass is detected in cohort 1.
3181982|NCT01325402|Experimental|Part 2|Healthy Volunteers
3181983|NCT01325389|Experimental|Myo+Mel|Patients are treated with 2g of myo + 3mg of melatonin daily
3181984|NCT01325389|Placebo Comparator|Placebo|
3181985|NCT01325376|No Intervention|Self directed|
3182030|NCT01325038|Active Comparator|extra protein supplement|isometric training with addition of extra protein
3182451|NCT01321840|Experimental|Treatment|This group will be treated with SART.
3181986|NCT01325376|Active Comparator|Technology assisted health behavior|The intervention arm will have access to a dynamic online environment with social networking and device data uploads that include activity data, weight data and laboratory data at frequent intervals to nudge optimal health behavior.
3181987|NCT01325363|Experimental|Schizophrenia|Schizophrenic patients
3181988|NCT01325363|Experimental|Control|Neurotypical subjects
3181989|NCT01325350|Experimental|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
3181990|NCT01325350|Experimental|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
3181991|NCT01325350|Experimental|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
3181992|NCT01325350|Placebo Comparator|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
3181993|NCT01325350|Active Comparator|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
3181994|NCT01325337|Experimental|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
3181995|NCT01325337|Experimental|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
3181996|NCT01325337|Experimental|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
3181997|NCT01325337|Placebo Comparator|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
3181998|NCT01325337|Active Comparator|minoxidil 5% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
3181999|NCT01325324|Other|Study group|Study group
3182000|NCT01325311|Experimental|Arm I (cholecalciferol, genistein)|Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
3182001|NCT01325311|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
3182002|NCT01325298|Active Comparator|20 Minute UV-X Light Treatment Duration|"20 Minute UV-X Light Treatment Duration~Note: UV-X is the trademark of Peschke GmbH"
3182003|NCT01325298|Active Comparator|30 Minute UV-X Light Treatment Duration|30 Minute UV-X Light Treatment Duration
3182004|NCT01325272||preterm newborn|
3182005|NCT01325272||term newborn|
3182006|NCT01325259|Experimental|Alzheimer's disease|30 patients suffering from Alzheimer's disease
3182007|NCT01325259|Experimental|Mild Cognitive Impairment|20 patients suffering from Mild Cognitive Impairment
3182008|NCT01325259|Experimental|Control|15 subjects with no cognitive impairment
3182009|NCT01325233|Experimental|PG2 Injection|Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
3182010|NCT01325233|Placebo Comparator|Placebo|Powder for Injection, 500 ml normal saline, tiw, 2 weeks
3182011|NCT01325220|Active Comparator|STX209 5 mg BID|
3182012|NCT01325220|Active Comparator|STX209 10 mg BID|
3182013|NCT01325220|Active Comparator|STX209 10 mg TID|
3182014|NCT01325220|Placebo Comparator|Placebo|
3182015|NCT01325207|Experimental|intravenous trastuzumab infusions|A Phase I single dose study (H0407g) of intravenous trastuzumab infusions ranging from 10-500 mg resulted in dose-dependent pharmacokinetics (PK) with serum clearance of trastuzumab decreasing with an increasing dose at doses <250 mg. PK modeling of trastuzumab concentration-time data from 7 patients that were administered doses of 250 mg and 500 mg had in a mean halflife of 5.8 days (range 1-32 days).
3182016|NCT01325194|Experimental|CNS prophylaxis|
3182017|NCT01325181|Active Comparator|Low-fluence PDT with Verteporfin|Half the regular laser fluence PDT(Visudyne®; Novartis); a total light energy of 25J/cm2, a light dose rate of 300mW/cm2. If subretinal fluid was sustained after primary treatment, rescue treatment(ranibizumab injection) was considered
3182018|NCT01325181|Active Comparator|Ranibizumab|Consecutive Intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months. If subretinal fluid was sustained after primary treatment, rescue treatment(low-fluence photodynamic therapy) was considered
3182019|NCT01325168|Experimental|study group|32 PTSD patients intervention: Drug: syntocinon nasal spray / placebo nasal spray nasal OT - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
3182020|NCT01325168|Other|control group|control group - 30 healthy control subjects intervention: Drug: syntocinon nasal spray / placebo nasal spray nasal OT - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
3182021|NCT01325142||ONJ|Patient with cancer involving the bone treated with osteoclast inhibitor (bisphosphonate) and has developed ONJ
3182022|NCT01325142||No ONJ|Patient with cancer involving the bone treated with osteoclast inhibitor (bisphosphonate) and has NOT developed ONJ
3182023|NCT01325116|Active Comparator|Control|Usual post-STEMI care
3182024|NCT01325116|Experimental|Intervention|Recurrent, personalized, educational reminders sent via post on behalf of the interventional cardiologist to the patient and their family physician urging long-term adherence to secondary prevention medications post-STEMI. A copy of the letter will be provided to the patient to take to their pharmacist.
3182025|NCT01325103|Experimental|Stem Cell Transplantation|Patients with spinal cord injury that will undergo autologous bone marrow stem cell transplantation.
3182026|NCT01325090|Experimental|BOTOX|Patients will receive in one session multiple intradermal injections of Botox, in order to cover the whole painful area
3182027|NCT01325090|Placebo Comparator|PLACEBO|Patients will receive in one session multiple intradermal injections of placebo , in order to cover the whole painful area
3182028|NCT01325077|Experimental|Conventional model, Study model|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
3182029|NCT01325051|No Intervention|Raltegravir|To test raltegravir to see if it can be detected in gastrointestinal tissue of healthy men.
3182031|NCT01325038|Active Comparator|extra food supplement|isometric exercise with addition of extra food and calories: one fast food meal/day
3182032|NCT01325025|Other|Patients|Patients with a metachromatic leukodystrophy
3182033|NCT01325025|Other|Control|Epileptic population
3182034|NCT01325012|Active Comparator|Subgluteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle.
3182035|NCT01325012|Active Comparator|Popliteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
3182036|NCT01324999|Experimental|Sarcoid Associated Pulm. Hypertension|Single-arm open-label proof of concept study of tadalafil in patients with sarcoidosis associated pulmonary hypertension.
3182037|NCT01324986|Active Comparator|Nissen fundoplication|
3182038|NCT01324986|Active Comparator|Toupet fundoplication|
3182039|NCT01324973|Experimental|eWellness program|A comprehensive program that delivers web-based, evidence-based weight management; and structured peer supports. The program is designed to meet the needs of individuals with mental illness.
3182040|NCT01324973|No Intervention|Control group|Care as usual
3182041|NCT01324960|Experimental|Ceplene® / IL2 + Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene (EpiCept Corporation, Tarrytown, NY) at 0.5 mg subcutaneous twice daily and human recombinant IL-2 (aldesleukin; Novartis) 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
3182042|NCT01324960|Active Comparator|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
3182043|NCT01324947|Experimental|Pomalidomide|Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
3182044|NCT01324934|Active Comparator|Study Group|immunosuppressive treatment consisting of ATG-Fresenius/TAC/MMF or Myfortic
3182045|NCT01324934|No Intervention|Control Group|immunosuppressive treatment consisting of TAC, MMF or Myfortic, and corticosteroids.
3182046|NCT01324921|Placebo Comparator|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
3182047|NCT01324921|Active Comparator|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
3182048|NCT01324921|Experimental|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
3182049|NCT01324908|Experimental|Treatment (Treg predictor of response to ECP)|Patients undergo ECP twice a week for 4 weeks and then twice a week every 2 weeks for 8 weeks.
3182050|NCT01324882|Experimental|Study Arm|This is the group who will have a colonoscopy with the Olympus Technically Improved Colonoscope.
3182051|NCT01324882|Active Comparator|Control|This is the group who will have a colonoscopy with the traditional colonoscope Olympus CF-H180.
3182052|NCT01324869|Experimental|Group A|Patients will receive an intravitreal injection of 0.5mg KH902 in the study eye at the first month, following the fixed injection, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.
3182053|NCT01324869|Experimental|Group B|Patients will receive continuously monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye; following the initial 3-month fixed-dosing phase of the trial, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.
3182054|NCT01324856|Experimental|Pancreaticogastro anastomosis|
3182055|NCT01324856|Active Comparator|Pancreaticojejuno anastomosis|
3182056|NCT01324830|Experimental|arm A|14 days once a day oral intake of BI 847325 followed by 7 days break in 3-week cycles
3182057|NCT01324830|Experimental|arm B|5 days once daily oral intake of BI 847325 followed by 2 days break, repeated every week
3182058|NCT01324817||Hopitalized|Patients admitted to the hospital
3182059|NCT01324804||CABG - subjects|only one group
3182060|NCT01324791|Active Comparator|laparoscopic antireflux surgery|
3182061|NCT01324791|Active Comparator|endoscopic full-thickness-gastroplication|
3182062|NCT01324778|Experimental|A|
3182063|NCT01324778|Active Comparator|B|
3182064|NCT01324765|Experimental|TARGET|12-session affect regulation therapy for PTSD
3182065|NCT01324765|Active Comparator|SGT|12 session supportive group therapy
3182066|NCT01324752|Experimental|PA21 and Losartan with food|
3182067|NCT01324752|Experimental|No PA21; Losartan with food|
3182068|NCT01324752|Experimental|PA21 with food and Losartan 2 hrs later|
3182069|NCT01324739|Active Comparator|B-type natriuretic peptide|the effect of B-type natriuretic peptide on glucose metabolism will be compared with placebo during an intravenous glocose tolerance test
3182070|NCT01324739|Placebo Comparator|Placebo|comparison of the effect of b-type natriuretic peptide on glucose metabolism and placebo
3182071|NCT01324713||Males|
3182072|NCT01324713||Females|
3182073|NCT01324700|Active Comparator|High severity group: Escitalopram|Participants with Baseline score of 20 or above on the 17-item Hamilton Rating Scale for Depression (HRSD) AND 3 or more courses of oral corticosteroids in the past 12 months were stratified into high severity group. Then these participants were further stratified into escitalopram group.
3182074|NCT01324700|Active Comparator|Low severity group: Escitalopram|Participants with Baseline HRSD score of less than 20 AND fewer than 3 courses of oral corticosteroids in the past 12 months were stratified into low severity group. Then these participants were further stratified into escitalopram group.
3182075|NCT01324700|Placebo Comparator|High severity group: Placebo|Participants with Baseline score of 20 or above on the 17-item Hamilton Rating Scale for Depression (HRSD) AND 3 or more courses of oral corticosteroids in the past 12 months were stratified into high severity group. Then these participants were further stratified into placebo group.
3182076|NCT01324700|Placebo Comparator|Low severity group: Placebo|Participants with Baseline HRSD score of less than 20 AND fewer than 3 courses of oral corticosteroids in the past 12 months were stratified into low severity group. Then these participants were further stratified into placebo group.
3182077|NCT01324687||Control|Group without access to telemedicine in the home for acute care issues.
3182078|NCT01324687||Telemedicine care|Cohort with access to telemedicine in the home for acute care issues.
3182079|NCT01324674|Placebo Comparator|Placebo group|Is the group of subjects that will take placebo
3182080|NCT01324674|Experimental|experimental group|Is the group of subjects that will take Bach´s Flower remedies
3182081|NCT01324661|No Intervention|Control|Individuals who receive the ball during a computerized ball tossing game about the same number of times as the other players in the game.
3182082|NCT01324661|Other|Ostracism|Participant would receive the ball of a ball-tossing game once or twice in the beginning and then never again for the duration of the game.
3182083|NCT01324648|Experimental|TG + GP TAU|
3182084|NCT01324648|Experimental|UG + GP TAU|
3182085|NCT01324648|Active Comparator|GP TAU|
3182086|NCT01324635|Experimental|Arm A (panobinostat, multiple fractions of SBRT)|Patients receive panobinostat PO thrice weekly for 2 weeks and undergo 10 fractions of SBRT over 2 weeks (recurrent gliomas) OR 30 fractions of SBRT over 6 weeks (high grade meningiomas).
3182087|NCT01324635|Experimental|Arm B (panobinostat, stereotactic radiosurgery)|Patients receive panobinostat as in Arm A and undergo a single fraction of stereotactic radiosurgery on day 1 of week 1.
3182088|NCT01324622|Active Comparator|Laminectomy|Control
3182089|NCT01324622|Active Comparator|Laminoplasty|Treatment group
3182090|NCT01324596|Active Comparator|Arm A: R-CHOP|Participants receive 6 cycles of conventional R-CHOP chemotherapy on a standard 21 day schedule: Rituximab 375mg/m2 intravenous Cyclophosphamide 750mg/m2 Intravenous Doxorubicin 50mg/m2 Intravenous Vincristine intravenous Prednisolone 100mg od orally
3182091|NCT01324596|Experimental|Arm B: RB-CHOP|"Participants in this arm will receive 1 cycle of conventional R-CHOP chemotherapy, followed by 5 cycles of R-CHOP:~Cyclophosphamide 750mg/m2 Intravenous Doxorubicin 50mg/m2 Intravenous Vincristine intravenous bortezomib - Intravenous Prednisolone 100mg od orally"
3182092|NCT01324583|Experimental|Arm 1|"Patients will receive cabazitaxel as the dose of corresponded level~1-hour intravenous infusion every 3 weeks plus prednisolone 10 mg orally given daily: Dose Level Cabazitaxel Dose Level -1: 15 mg/m², Level 1: 20 mg/m², Level 2: 25 mg/m²"
3182093|NCT01324570|Experimental|Overall BTDS|Buprenorphine transdermal system
3182094|NCT01324557|Experimental|CSII|Optimized subcutaneous insulin infusion by means of continuous subcutaneous insulin infusion (CSII)
3182095|NCT01324557|No Intervention|MDI|MDI: Control Optimized subcutaneous insulin by multiple daily injections (MDI)
3182096|NCT01324544|Experimental|Buprenorphine IV|Buprenorphine IV
3182097|NCT01324531|Active Comparator|Bankart repair|
3182098|NCT01324531|Active Comparator|Bankart repair and remplissage|
3182099|NCT01324518|Experimental|Low dose of ORM-12741|
3182100|NCT01324518|Experimental|High dose of ORM-12741|
3182101|NCT01324518|Placebo Comparator|Placebo|
3182102|NCT01324505|Experimental|One-sequence cross-over arm|
3182103|NCT01324492|Experimental|RAD001|
3182104|NCT01324479|Experimental|INC280|
3182105|NCT01324466|Placebo Comparator|Vehicle|Vehicle
3182106|NCT01324466|Active Comparator|Active|Active NB-001(0.3%)
3182107|NCT01324453|Experimental|Post conditioning + PCI|
3182108|NCT01324453|Active Comparator|Standard PCI|
3182109|NCT01324440|Experimental|V710 without MAA|
3182110|NCT01324440|Active Comparator|V710 with MAA|
3182111|NCT01324427|Experimental|virtual medical visit|"This is a pilot trial involving a maximum of 84 patients undergoing either allogeneic or autologous stem cell transplant aimed at determining the feasibility and acceptance of a virtual medical visit by patients and health care personnel. During this pilot trial we expect to perform 84 virtual medical visits using telemedicine."
3182112|NCT01324401|No Intervention|Control|The subjects randomized to the observational control group will have follow-up visits every 6 months. Each visit will involve a medical history and physical examination. These subjects are then offered to cross-over to active treatment.
3182113|NCT01324401|Experimental|Peanut OIT|The subjects randomized to the active treatment group will receive defatted peanut flour per protocol.
3182114|NCT01324388|Experimental|LY2189265 + Lisinopril|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Days 1, 8, 15, and 22 of Part 1 of the study.~Lisinopril: Dose as prescribed by participant's established course of therapy, oral, daily dosing throughout Part 1 of the study."
3182115|NCT01324388|Placebo Comparator|Placebo + Lisinopril|"Placebo: 1.5 milligrams (mg), subcutaneous (SC), on Days 1, 8, 15, and 22 of Part 1 of the study.~Lisinopril: Dose as prescribed by participant's established course of therapy, oral, daily dosing throughout Part 1 of the study."
3182116|NCT01324388|Experimental|LY2189265 (Treatment 1)/Metoprolol + LY2189265 (Treatment 2)|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Day 1 of Treatment 1 and on Day 5 of Treatment 2 in Part 2 of the study.~Metoprolol: 100 mg, oral, on Days 1 through 7 of Treatment 2 in Part 2 of the study.~There was a washout period of at least 21 days between the LY2189265 and metoprolol doses of each treatment period (Day 1 of Treatment 1 to Day 1 of Treatment 2 in Part 2 of the study)."
3182117|NCT01324388|Experimental|Metoprolol + LY2189265 (Treatment 2)/LY2189265 (Treatment 1)|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Day 5 of Treatment 2 and on Day 1 of Treatment 1 in Part 2 of the study.~Metoprolol: 100 mg, oral, on Days 1 through 7 of Treatment 2 in Part 2 of the study.~There was a washout period of at least 21 days between the LY2189265 and metoprolol doses of each treatment period (Day 7 of Treatment 2 to Day 1 of Treatment 1 in Part 2 of the study)."
3182118|NCT01324375||THA (total hip arthroplasty)|Patients undergoing THA, preoperatively heat tested
3182119|NCT01324362|Active Comparator|Fluticasone propionate|
3182120|NCT01324362|Active Comparator|Fluticasone propionate/salmeterol combination|
3182121|NCT01324349|Experimental|Veriset Hemostatic Patch|Veriset Hemostatic Patch
3182122|NCT01324349|Active Comparator|Fibrin Sealant (TachoSil®)|Fibrin Sealant (TachoSil®)
3182123|NCT01324336||4-17 years, receiving 6-MP|
3182124|NCT01324323|Experimental|Romidepsin and rifampin|"Romidepsin 14 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.~Rifampin 600 mg oral once daily on Days 4-8"
3182125|NCT01324310|Experimental|Romidepsin and ketoconazole|"Romidepsin 8 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.~Ketoconazole 400 mg oral once daily on Days 4-8"
3182126|NCT01324297||Healthy Control|Caucasian males and females between 19 and 30 years of age.
3182127|NCT01324297||First Episode Psychosis|Caucasian males and females between 19 and 30 years of age within twelve months of initial DSM IV TR diagnosis of schizophreniform psychosis, schizophrenia, schizoaffective disorder or psychotic disorder NOS.
3182128|NCT01324284|Experimental|Lubiprostone|Lubiprostone with PEG solution versus Placebo with PEG solution
3182129|NCT01324284|Placebo Comparator|lubiprostone versus placebo|
3182130|NCT01324271|Experimental|Tympanostomy tube placement|placement of tympanostomy tube under local anesthesia in office/clinic setting
3182131|NCT01324258|Experimental|GSK1120212|Part 1-Dose escalation will be conducted to assess PK after single dosing and safety, tolerability, PK and efficacy of GSK1120212 in Japanese subjects with solid tumors using a continuous daily dosing schedule.
3182132|NCT01324258|Experimental|GSK1120212+Gemcitabine|Part 2-Further evaluate the safety, tolerability, PK, and efficacy of GSK1120212 in combination with gemcitabine in subjects with non-small cell lung cancer, pancreatic cancer, biliary cancer, urothelial cancer or other tumor types for which 4-week schedule of gemcitabine has been approved using the recommended dose from Part 1 (single agent).
3182133|NCT01324245|Experimental|Enalapril|2.5 mg every 12 hours for two doses
3182134|NCT01324232|Placebo Comparator|Placebo|
3182135|NCT01324232|Experimental|AVP-923-45|
3182136|NCT01324232|Experimental|AVP-923-30|
3182137|NCT01324232|Experimental|AVP-923-20|
3182138|NCT01324219|Active Comparator|Staff|
3182139|NCT01324219|Experimental|Resident|
3182140|NCT01324193|Other|Pre-diaylsis patients|Chronic Kidney Disease patients not receiving dialysis getting pomegrante Supplementation
3182141|NCT01324193|Other|Dialysis patients|Chronic Kidney Disease patients receiving dialysis getting pomegranate supplementation
3182142|NCT01324180|Experimental|VLPD Regimen|Induction will consist of vincristine, dexamethasone, doxorubicin and PEG asparaginase (so called VPLD - dexamethasone is substituted for prednisone and PEG asparaginase is substituted for L-asparaginase) in combination with metformin. Eligible patients will receive 24 hours of metformin followed by induction. Intrathecal chemotherapy with standard dose cytarabine will be administered at the start of each cycle, with central nervous system (CNS) therapy afterwards determined by findings on staging lumbar puncture.
3182143|NCT01324141|Experimental|1|Chemo + Radiation
3182144|NCT01324128|Experimental|PA21 (2.5 g tablet)|
3182145|NCT01324128|Active Comparator|Sevelamer carbonate|
3182146|NCT01324128|Other|PA21-1 (1.25 g tablet)|
3182147|NCT01324102|Active Comparator|1. Yoga therapy|The intervention is an 8 week Yoga therapy class adapted to the specific needs of the veteran. The class meets two times per weeks for 90 minutes. A series of poses are instructed, with adaptations used as provided by a physical therapist.
3182148|NCT01324102|No Intervention|2. Wait list|The comparative intervention is an 8 week wait list control group for which there is no intervention provided within the study protocol.
3182149|NCT01324089|Active Comparator|Arm 1|Resveratrol 2.5 grams x 1 dose
3182150|NCT01324089|Experimental|Arm 2|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
3182151|NCT01324089|Other|Arm 3|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
3182152|NCT01324050|Experimental|Internet-based Psychodynamic Therapy|
3182153|NCT01324050|Active Comparator|Internet-delivered therapist support|
3182154|NCT01324037|Experimental|clinically suspected upper extremity deep vein thrombosis|Patients with suspected upper extremity DVT
3182155|NCT01324024|Experimental|Lisdexamfetamine, then placebo|Participants first received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks followed by a 2-week washout, then they received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks.
3182156|NCT01324024|Experimental|Placebo, then Lisdexamfetamine|Participants first received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks followed by a 2-week washout, then they received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks.
3182157|NCT01324011|Experimental|Family-based intervention|Special intervention (20 weekly group-based sessions) to be compared with a delayed intervention control group.
3182158|NCT01324011|Other|Delayed intervention controls|The delayed intervention controls will continue with usual care (if patients with diabetes)and at the end of the experimental period (6 months), they will receive a 6-session weight loss intervention delivered over a 2 month period.
3182159|NCT01323998||5ARI monotherapy|Patients with BPH receiving 5ARI monotherapy
3182160|NCT01323998||AB monotherapy|Patients with BPH receiving AB monotherapy
3182161|NCT01323998||Early combination (5ARI + AB) therapy|Patients receiving early initiation of combination therapy with a 5ARI plus AB. Early initiation defined as starting 5ARI therapy within 30 days of initiating AB therapy
3182162|NCT01323998||Delayed combination (5ARI + AB) therapy|Patients receiving delayed initiation of combination therapy with a 5ARI plus AB. Delayed initiation defined as starting 5ARI therapy more than 30 days but less than 6 months after initiating AB therapy
3182163|NCT01323985|Experimental|GSK2315698|Intravenous infusion single dose
3182164|NCT01323972|Experimental|GSK 257049-Lot 1 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine from the commercial scale lot 1 (formulation 1 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
3182165|NCT01323972|Experimental|GSK 257049-Lot 2 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine, from the commercial scale lot 2 (formulation 2 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
3182166|NCT01323972|Experimental|GSK 257049-Lot 3 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine, from the commercial scale lot 3 (formulation 3 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
3183023|NCT01317836||Patients having pancreatic cystic lesion|
3182167|NCT01323972|Experimental|GSK 257049-Pilot Group|Healthy male or female children aged 5 to 17 received 3 doses of the GSK 257049 vaccine from the pilot scale (pilot formulation of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
3182168|NCT01323959|Experimental|BOOSTRIX POLIO GROUP|Healthy subjects who had received one booster dose Boostrix™ Polio vaccine in the NCT01277705 study received one additional booster dose of Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
3182169|NCT01323959|Experimental|BOOSTRIX+POLIORIX GROUP|Healthy subjects who had received one booster dose of the co-administered Boostrix™ and Poliorix™ vaccines in the NCT01277705 study received one booster dose Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
3182170|NCT01323959|Experimental|REVAXIS GROUP|Healthy subjects who had received one booster dose of Revaxis® vaccine in the NCT01277705 study received one booster dose of Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
3182171|NCT01323946|Experimental|Group A|
3182172|NCT01323933|Experimental|AB0024|"The starting dose for Part A will be 1 mg/kg. Subsequent doses of 3, 10, and 20 mg/kg are planned. Three to 6 patients will be enrolled using a 3 + 3 design. Doses of AB0024 will be administered on Days 1, 15, 29, and 43 to characterize the safety, tolerability, and PK.~The dose expansion phase of the study will begin upon completion of the dose escalation phase. Up to 20 patients will be enrolled into one or two cohorts of Part B. The first expansion cohort will be dosed up to the MTD defined as the highest dose level with an observed incidence of DLT in <33% of patients enrolled from Part A."
3182173|NCT01323920|Experimental|Velcade/Tac/MTX|"Drug: Bortezomib. Other Names: Velcade. Bortezomib 1.3 mg/m^2 IV~Drug: Tacrolimus. Tacrolimus 0.05 mg/kg PO bid~Drug: Methotrexate. Methotrexate 15 mg/m^2 IV"
3182174|NCT01323907|Experimental|Omegaven|Omegaven IV lipid emulsion administration for infants with life threatening parenteral nutrition associated liver disease
3182175|NCT01323881|Experimental|intermittent theta burst stimulation|
3182176|NCT01323881|Placebo Comparator|sham stimulation|
3182177|NCT01323855|Experimental|Part 1: Severe Renal Impairment|Participants with severe CRI, defined as creatinine clearance of <30 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
3182178|NCT01323855|Experimental|Part 2: Moderate Renal Impairment|Participants with moderate CRI defined as creatinine clearance of ≥30 and <50 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
3182179|NCT01323855|Experimental|Part 2: Mild Renal Impairment|Participants with mild CRI, defined as creatinine clearance of ≥50 and ≤80 mL/min/1.73m^2, were treated with a single tablet of 5 mg preladenant, administered orally
3182180|NCT01323855|Experimental|Part 1: Normal Renal Function|Participants with normal renal function, defined as creatinine clearance of >80 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
3182181|NCT01323855|Experimental|Part 2: Normal Renal Function|Participants with normal renal function, defined as creatinine clearance of >80 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
3182182|NCT01323842||rule in renal colic|ED patients with abdominal/flank pain where a diagnosis of renal colic is being considered and undergoing formal imaging while in the ED
3182183|NCT01323816||Traditional|ICU staffed by a resident, pulmonary fellow and attending
3182184|NCT01323816||Non-Traditional|ICU staffed by Nurse Practitioners as the direct care deliverer, a pulmonary fellow, and an attending
3182185|NCT01323790|Experimental|1|Oral treatment
3182186|NCT01323790|Experimental|2|Oral treatment
3182187|NCT01323790|Placebo Comparator|3|Oral treatment
3182188|NCT01323777|Experimental|ReSTOR +3.0|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
3182189|NCT01323764|Active Comparator|Radionuclide SPS|Radionuclide Shunt Patency Study
3182190|NCT01323751|Experimental|Treat Regimen|ACY-1215 Bortezomib Dexamethasone
3182191|NCT01323738|No Intervention|Treatment as Ususal|Patients participate in the Treatment as Usual including a non-specific information group.
3182192|NCT01323738|Experimental|Psychoeducation|Intervention group
3182193|NCT01323725|Experimental|Team-based financial incentives|Team-based financial incentives
3182194|NCT01323712|Placebo Comparator|Placebo|
3182195|NCT01323699|Experimental|Behavioral Therapy|
3182196|NCT01323686|Experimental|Imaging guided LV lead placement|
3182197|NCT01323686|No Intervention|Empiric LV lead placement|LV lead placement using standard clinical routine.
3182198|NCT01323673|Active Comparator|Clobetasol Propionate 0.05%|
3182199|NCT01323673|Placebo Comparator|Vehicle|
3182200|NCT01323660|Experimental|GSK573719/GW642444 125/25|125mcg/25mcg nDPI
3182201|NCT01323660|Experimental|GSK573719/GW642444 62.5/25|62.5mcg/25mcg nDPI
3182202|NCT01323660|Experimental|GSK573719/ 125|125mcg nDPI
3182203|NCT01323660|Experimental|GSK573719 62.5|62.5mcg nDPI
3182204|NCT01323660|Experimental|GW642444 25|25mcg nDPI
3182205|NCT01323660|Placebo Comparator|Placebo|Plb nDPI
3182206|NCT01323647|Experimental|Group A|Subjects in this group will receive the GSK Biologicals' IPV vaccine at 18 months of age. Subjects will also receive a dose of DTPa/Hib (Infanrix+Hib) as part of the local standard of care.
3182207|NCT01323647|Active Comparator|Group B|Subjects in this group will receive only a booster dose of GSK Biologicals' DTPa/Hib vaccine (Infanrix+Hib) as part of the local standard of care and will not be associated with any study endpoint.
3182208|NCT01323634|Experimental|Fluticasone Furoate / GW642444 (vilanterol)|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
3182209|NCT01323634|Active Comparator|Fluticasone Propionate / salmeterol|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
3182210|NCT01323621|Experimental|Fluticasone Furoate / GW642444 (vilanterol)|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
3182211|NCT01323621|Active Comparator|Fluticasone Propionate / salmeterol|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
3182212|NCT01323608|Placebo Comparator|Placebo|
3182358|NCT01322607|Other|Arm 1: High-Intensity Program|High-intensity treadmill-based exercise
3182213|NCT01323608|Experimental|Low Vitamin D Group|Subjects in this group will receive the equivalent of 400 IU/day.
3182214|NCT01323608|Experimental|Intermediate Vitamin D group|
3182215|NCT01323608|Experimental|High Vitamin D Group|
3182216|NCT01323595|Experimental|Celecoxib|Celecoxib will be given for 6 days after surgery
3182217|NCT01323595|Placebo Comparator|Sugar pill|Sugar pill for 6 days after surgery.
3182218|NCT01323582|Active Comparator|erythromycin|200mg/5ml elixir administered orally three times a day half an hour prior to meals.
3182219|NCT01323582|Experimental|Azithromycin|The dose of Azithromycin was determined based on our dose response curve obtained on 10 healthy subjects who were given three different doses of Azithromycin, 50 mg, 100 mg and 133 mg and underwent breath testing to determine the gastric emptying half-time. These doses were determined based on a maximum safe dosage per day of Azithromycin of 400 mg given the medication would then be administered three times daily before meals. The appearance of the medication (azithromycin) and administration period was then identical to that of Erythromycin, i.e. 5ml elixir administered orally three times a day half an hour prior to meals. The total daily dosage of Azithromycin was determined after obtaining the dose- response analysis.
3182220|NCT01323569|Placebo Comparator|Placebo|
3182221|NCT01323569|Experimental|Sativex 4 sprays|
3182222|NCT01323569|Experimental|Sativex 8 sprays|
3182223|NCT01323569|Experimental|Sativex 16 sprays|
3182224|NCT01323569|Active Comparator|Marinol low dose|
3182225|NCT01323569|Active Comparator|Marinol high dose|
3182226|NCT01323556|Experimental|Exposure with fear augmentation|exposure-based CBT, including interoceptive exposure and in-vivo exposure with fear augmentation by interoceptive exercises (e.g. hyperventilation)
3182227|NCT01323556|Experimental|Exposure without fear augmentation|exposure-based CBT, including interoceptive and in-vivo exposure without fear augmentation during in-vivo exposure
3182228|NCT01323543|Experimental|Elaspine™|Impantation of Elaspine™ device
3182229|NCT01323530|Experimental|Schedule 1|
3182230|NCT01323530|Experimental|Schedule 2|
3182231|NCT01323517|Experimental|Ipilimumab, Melphalan and Dactinomycin|This is a single-institution phase II trial with a primary outcome of progression free survival (PFS).
3182232|NCT01323504|Experimental|Music therapy group|Local care with music
3182233|NCT01323504|No Intervention|control group|Local care without music
3182234|NCT01323491||routine smokers|would-be non-smokers, no actual nicotine replacement therapy
3182235|NCT01323478|Experimental|Vortioxetine|
3182236|NCT01323465|Experimental|Sequence 1A|Sativex and rifampicin
3182237|NCT01323465|Experimental|Sequence 1B|Sativex and rifampicin
3182238|NCT01323465|Experimental|Sequence 2C|Sativex and ketoconazole
3182239|NCT01323465|Experimental|Sequence 2D|Sativex and ketoconazole
3182240|NCT01323465|Experimental|Sequence 3E|Sativex and omeprazole
3182241|NCT01323465|Experimental|Sequence 3F|Sativex and omeprazole
3182242|NCT01323452||Chronic HBV patients|Patients with chronic hepatitis B Treated for at least 3 months No HIV, HCV or HDV.
3182243|NCT01323439||Axium™ MicroFX™ PGLA Treated Subjects|This observational evaluation will evaluate early experience using the Axium™ MicroFX™ PGLA COILS as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ Bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol
3182244|NCT01323426|Experimental|periurethral injection|Periurethral injection of autologous muscle fibers
3182245|NCT01323413||stroke|acute ischemic stroke patients
3182246|NCT01323400|Experimental|Pazopanib|"Pazopanib (800 mg/day) + Best supportive care according to the investigator's judgement.~Pazopanib treatment is started on the day after randomization until radiological progression according to RECIST or until documented toxicity. In case of radiological progression, pazopanib may be continued (if the investigator wishes so) if a clinical benefit (pain reduction, 1 point increase in performance status) is observed."
3182247|NCT01323400|Other|Best supportive care|Best supportive care according to the investigator's judgment. Upon progression, compassionate treatment by pazopanib is possible according to eligibility criteria.
3182248|NCT01323387|Other|Treatment|Interbody fusions with Anterior Plating
3182249|NCT01323374|Experimental|Droxidopa 200mg TID|
3182250|NCT01323374|Experimental|Droxidopa 400mg TID|
3182251|NCT01323374|Experimental|Droxidopa 600mg TID|
3182252|NCT01323374|Active Comparator|Carbidopa 25mg TID|
3182253|NCT01323374|Active Comparator|Carbidopa 50 mg TID|
3182254|NCT01323374|Experimental|Droxidopa/carbidopa 200mg/25mg TID|
3182255|NCT01323374|Experimental|Droxidopa/carbidopa 400mg/25mg TID|
3182256|NCT01323374|Experimental|Droxidopa/carbidopa 600mg/25mg TID|
3182257|NCT01323374|Experimental|Droxidopa/carbidopa 200mg/50mg TID|
3182258|NCT01323374|Experimental|Droxidopa/carbidopa 400mg/50mg TID|
3182259|NCT01323374|Experimental|Droxidopa/carbidopa 600mg/50mg TID|
3182260|NCT01323374|Placebo Comparator|Placebo TID|
3182261|NCT01323361|No Intervention|Non-immunosupressed|Normal population
3182262|NCT01323348|Experimental|Diabetes Educational Intervention|Study participants in the intervention group will receive a diabetes management educational intervention at baseline and at follow-up visits. For those on an annual follow-up schedule, educational intervention will take place at baseline and 12 months. For those whose standard care involves more frequent, than annual, visits the educational intervention will take place no more than once every 12 weeks.
3182263|NCT01323348|No Intervention|Standard Care|Usual care
3182264|NCT01323309||Individual Meaning-Centered Psychotherapy (IMCP)|
3182265|NCT01323309||standard Individual Supportive Psychotherapy (ISP)|
3182266|NCT01323309||enhanced usual care (EUC)|
3182267|NCT01323296|Active Comparator|Ferumoxytol|Patients will be administered intravenous ferumoxytol 1 - 3 days following myocardial infarction after baseline cardiac magnetic resonance scanning.
3182268|NCT01323296|No Intervention|Control|Subjects who have suffered myocardial infarction will undergo cardiac magnetic resonance imaging at the same time points as those in the 'ferumoxytol' arm but will not receive ferumoxytol or placebo.
3182450|NCT01321853|No Intervention|Usual Care Group|Admitted post home health care with no intervention.
3182269|NCT01323283|Active Comparator|Omega-3 supplementation|50 % of all included children will be randomized to this arm and administered capsules containing an omega-3 fatty acid composition.
3182270|NCT01323283|Placebo Comparator|Placebo|50 % of included children will be randomized to this arm and will be administered placebo capsules for the 15 week intervention.
3182271|NCT01323270|Experimental|rLP2086|rLP2086 and Repevax
3182272|NCT01323270|Placebo Comparator|Saline and Repevax|Saline and Repevax
3182273|NCT01323257|Experimental|001|TMC435 150 mg capsule once daily for 7 days (Trt A C D)
3182274|NCT01323257|Experimental|002|erythromycin 500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
3182275|NCT01323257|Experimental|003|erythromycin 500 mg tablets three times a day for 7 days (Trt C)
3182276|NCT01323257|Experimental|004|TMC435 50 mg capsule once daily for 7 days (Trt F)
3182277|NCT01323257|Experimental|005|Darunavir 2 x 400 mg tablet once daily for 7 days (Trt E F)
3182278|NCT01323257|Experimental|006|Ritonavir 100 mg tablet once daily for 7 days (Trt E F)
3182279|NCT01323244|Experimental|TMC435|TMC435 Type=exact number unit=mg number=150 form=capsule route=oral use once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
3182280|NCT01323231|Experimental|Communities in Schools Services|Communities in Schools services include case management, mental health services, mentorship services, after school programs, and academic assistance.
3182281|NCT01323205|Experimental|JNJ-40411813 (Part A)|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.
3182282|NCT01323205|Experimental|JNJ-40411813 (Part B)|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 10 weeks.
3182283|NCT01323205|Experimental|Placebo and JNJ-40411813 (Part B)|Placebo capsule (s) orally twice daily with a meal for 4 weeks followed by JNJ-40411813 according to tolerability dose range increased from 50 mg to 150 mg twice daily with a meal to 6 weeks.
3182284|NCT01323192|Experimental|JNS001|
3182285|NCT01323192|Placebo Comparator|Placebo|
3182286|NCT01323179||Strong opioids|Patients taking strong opioids preoperatively
3182287|NCT01323179||Weak opioids|Patients taking weak opioids preoperatively
3182288|NCT01323179||Opioid native|Patients not taking opioids preoperatively
3182289|NCT01323166||Excision of the levator muscle|The abdominal part of the operation is performed as an TME and the perineal part of the operation is performed with the intent to get a cylindrical specimen thus removing part of or the entire levator muscle with the specimen
3182290|NCT01323166||Traditional perineal operation|The abdominal part of the operation performed as a TME. The perineal operation performed with the intent of removing the tumour with CRM free of tumour and the levator left in place
3182291|NCT01323153|Experimental|Dalcetrapib|
3182292|NCT01323153|Placebo Comparator|Placebo|
3182293|NCT01323140|Experimental|TMTS treatment|Following a lead-in dose-proportionality phase (Days 1-2) and a site-to-site bioavailability phase (Days 2-9), subjects were dosed for efficacy analysis beginning on Day 9 at dose level B (a single 48 cm2 testosterone matrix transdermal system). Based on pharmacokinetic (PK) analysis of blood samples drawn on Day 16, on Day 22 subjects could be dose-titrated up to dose level C (one 28 cm2 plus one 48 cm2 TMTS), down to dose level A (one 28 cm2 TMTS), or remain at dose level B. Subjects at all dose levels were pooled for primary efficacy analysis on Days 29/30.
3182294|NCT01323127||Chronic back pain|This group of patients has had chronic back pain for longer than 3 months.
3182295|NCT01323127||Non chronic back pain|This group of patients is hospitalized for cardio physical therapy, and has no lumbar-pelvic complications. Patients are selected from the hospitalized population according to age, sex, and BMI in order to match chronic back pain patients.
3182296|NCT01323114|Active Comparator|Medical Control Group|Control group of patients who will receive conventional medical treatment for type 2 diabetes, along with regular dietary and diabetic education, under the monitoring of the study endocrinologist.
3182297|NCT01323114|Experimental|Surgical Treatment Group|Experimental group in which patients will undergo the laparoscopic duodenal bypass procedure along with regular dietary and diabetic education, under the monitoring of the study endocrinologist.
3182298|NCT01323101|Sham Comparator|Control|No doxycycline
3182299|NCT01323101|Experimental|Doxycycline|
3182300|NCT01323088|Other|Control|Standard care control (no-exercise)
3182301|NCT01323088|Active Comparator|Aerobic Exercise|
3182302|NCT01323088|Active Comparator|Resistance Exercise|
3182303|NCT01323075||Renal insufficiency group|Patients in this group have renal insufficiency as defined by a creatinine clearance of < 30 ml/min without dialysis. These patients do not have diabetes.
3182304|NCT01323075||Diabetic group|These patients have diabetes, but not renal insufficiency.
3182305|NCT01323075||Non-exposed group|These patients have neither a neurological nor a metabolic disease and a creatine clearance of > 90 ml/min
3182306|NCT01323062|Other|Single-arm trial|Single-arm trial
3182307|NCT01323049|Active Comparator|Positive pressure extubation|Positive pressure extubation will be used for patients waking up from general anesthesia in this group
3182308|NCT01323049|Active Comparator|Aspiration/suction extubation|Aspiration/suction extubation will be used for patients waking up from general anesthesia in this group
3182309|NCT01323036|Experimental|Krill Oil|
3182310|NCT01323036|Experimental|Fish Oil|
3182311|NCT01323010|Experimental|Albuterol - Experimental|Albuterol dosages during the first hour include 900 mcg (up to 15 kg), 1200 mcg (> 15 to 20 kg), 1500 mcg (> 20 to 25 kg) and 1800 mcg (> 25 kg).
3182312|NCT01323010|Active Comparator|Albuterol - Control|Albuterol dosages during the first hour include either 600 mcg (up to 25 kg) or 1200 mcg (> 25 kg).
3182313|NCT01322997|Experimental|Myomo + RTP|This group will be administered a regimen comprised of repetitive task specific practice (RTP) in conjunction with use of the robotic brace described elsewhere in this record.
3182314|NCT01322997|Active Comparator|Myomo|Patients in this group will only be administered the robotic brace described elsewhere in this record.
3182315|NCT01322997|Active Comparator|RTP only|Patients in this group will be administered repetitive task specific practice (RTP), emphasizing use of their affected arms during performance of valued, functional tasks.
3182316|NCT01322984|Active Comparator|Normal controls|Normal children and youths
3182317|NCT01322984|Experimental|ASD|Children and youths diagnosed with autism spectrum disorder (ASD)
3182318|NCT01322971|Active Comparator|Metronidazole|Patients randomized to the metronidazole arm will receive metronidazole 500mg orally twice daily for seven days.
3182319|NCT01322971|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive placebo orally twice daily for seven days(control arm
3182320|NCT01322958||At Risk of Ectopic Pregnancy|Women who present to the emergency department at UCSF who are at risk of ectopic pregnancy.
3182321|NCT01322945||Endonasal surgery|Single cohort of patients undergoing endonasal surgery
3182322|NCT01322919|Experimental|Myopic Treatment Arm|Patients treated in this arm will have preoperative measurements that indicate a myopic condition of the eye in conjunction with a presbyopic condition
3182323|NCT01322919|Experimental|Hyperopic Treatment Arm|Patients treated in this arm will have preoperative measurements that indicate a hyperopic condition of the eye in conjunction with a presbyopic condition
3182324|NCT01322906|Other|Group A|Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
3182325|NCT01322893||Blood sampling.|Blood samples will be taken before start of treatment, at month 1, month 3, month 4 and month 6.
3182326|NCT01322880|Other|Control Arm|The project, administered by the International Rescue Committee (IRC), involved 25 village savings and loans association (VSLA) groups across the province. The VSLA groups initially formed through local members of the community designated as community based facilitators (CBF).
3182327|NCT01322880|Experimental|Treatment Group|"Half of the VSLA participants were invited to participate in an additional set of discussion groups to be attended along with their spouse. All participants were informed that due to space constraints, only half of the members would be able to attend. In each VSLA, individuals drew numbers from a bag or hat, and those with winning slips were the ones who entered the discussion groups with spouses."
3182328|NCT01322867|Active Comparator|Reference Drug|
3182329|NCT01322867|Active Comparator|Test Drug|
3182330|NCT01322854|Experimental|IMRT + integrated boost|28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed by an integrated boost
3182331|NCT01322854|Other|Conventional RT + sequential boost|Conventional radiotherapy of the whole breast in 28 fractions to a dose of 50.4 Gy and a consecutive boost in 8 fractions to a total dose of 66.4 Gy
3182332|NCT01322841|Active Comparator|CHICA Diagnosis Module|This arm had the CHICA screening module turned on
3182333|NCT01322841|Placebo Comparator|CHICA Placebo|This arm had CHICA but no additional module
3182334|NCT01322828|Active Comparator|Single incision repair of distal bicep tendon rupture|In this treatment arm patients will have a single incision technique used to repair their distal bicep tendon rupture
3182335|NCT01322828|Active Comparator|Double incision repair of distal bicep tendon rupture|In this treatment arm, patients will have a double incision technique used to repair their distal bicep tendon rupture.
3182336|NCT01322815|Experimental|Chemotherapy and GI-4000|"Standard chemotherapy and bevacizumab 40 yeast units (YU) GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks"
3182337|NCT01322815|Experimental|GI-4000 and bevacizumab|maintenance with GI-4000 and bevacizumab for patients who have completed first-line chemotherapy
3182338|NCT01322802|Experimental|Treatment (pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine)|Patients receive pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine ID monthly for 3 months.
3182339|NCT01322789|Experimental|Intravenous mesenchymal stem cell|This group wil receive 8 intravenous infusions of mesenchymal stem cells. Four infusions 1 week apart and 4 infusions a month apart
3182340|NCT01322776|Experimental|Bortezomib,Fludarabine,Cyclophosphamide|
3182341|NCT01322750||With CTCs|Those individuals whom are identified with CTCs
3182342|NCT01322750||Without CTCs|Those individuals whom present and did not have CTCs
3182343|NCT01322737|Experimental|SUMO Tissue Access and Resection System|
3182344|NCT01322724|Active Comparator|Warm water|Body temperature (95-100 degrees F) water
3182345|NCT01322724|Experimental|Cool water|Room temperature (68-73 degrees F) water
3182346|NCT01322711|Active Comparator|Atorvastatin|"Each day accordingly to randomization patients allocated to Atorvastatin received a pill of 40 mg of atorvastatin. In diabetic patients the concomitant aspirin treatment include a previous 30 days treatment with 100 mg daily of aspirin.~All patients followed the diet used in the placebo group."
3182347|NCT01322711|Placebo Comparator|Diet|Low-fat diet with mean macronutrient profiles that were close to the present Adult Treatment Panel III guidelines (7% energy from saturated fat and, 200 mg dietary cholesterol per day)
3182348|NCT01322698||The study population|The target population includes patients in ICUs at the Nîmes and Montpellier University hospitals. This is a population of non-neutropenic patients (polynuclear neutrophils > 500/mm3) at risk of developing invasive candidiasis.
3182349|NCT01322685||Health Group|
3182350|NCT01322685||Tuberculosis Group|Tuberculosis or lung cancer group
3182351|NCT01322659|Active Comparator|Helmet NPPV|Weaning from mechanical ventilation with noninvasive positive pressure ventilation (NPPV)delivered by means of the helmet
3182352|NCT01322659|Sham Comparator|ETT IMV|Weaning from mechanical ventilation with standard invasive mechanical ventilation (IMV) delivered by means of the endotracheal tube (ETT)
3182353|NCT01322646|Active Comparator|Driver Training|Driver Education Program Practice driving on a driving simulator Provision of the CarChipPro to the family
3182354|NCT01322646|Experimental|STEER Program|Driver Education STEER Program
3182355|NCT01322633||Pantoprazole|Patients who received treatment with pantoprazole tablets for at least 240 days within a 12-month period from 2000 through 2003.
3182356|NCT01322633||Other proton pump inhibitors|Patients who received treatment with any other proton pump inhibitor for at least 240 days within a 12-month period from 1996 through 2003.
3182357|NCT01322620||A|
3182359|NCT01322607|Other|Arm 2: Low-Intensity Program|Low-intensity lifestyle intervention (group exercise)
3182360|NCT01322594|Experimental|MEDI2338 10 MG|MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump
3182361|NCT01322594|Experimental|MEDI2338 30 MG|MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
3182362|NCT01322594|Experimental|MEDI2338 100 MG|MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
3182363|NCT01322594|Experimental|MEDI2338 300 MG|MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
3182364|NCT01322594|Experimental|MEDI2338 1000 MG|MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
3182365|NCT01322594|Placebo Comparator|Placebo|Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
3182366|NCT01322503|Experimental|Norovirus Challenge|
3182367|NCT01322503|Experimental|Norovirus challenge|
3182368|NCT01322490|Experimental|PROSTVAC-V/F-TRICOM + GM-CSF|"PROSTVAC-V-TRICOM~PROSTVAC-F-TRICOM~GM-CSF"
3182369|NCT01322490|Experimental|PROSTVAC-V/F-TRICOM + GM-CSF placebo|"PROSTVAC-V-TRICOM~PROSTVAC-F-TRICOM~GM-CSF placebo"
3182370|NCT01322490|Placebo Comparator|Placebo Control|PROSTVAC V/F Placebo + GM-CSF Placebo
3182371|NCT01322477||Hepatocellular Carcinoma|Patients with advanced HCC
3182372|NCT01322464|Experimental|Group 1 Fasted-Fed|"4 sprays Sativex in fasted state, followed by wash-out followed by 4 sprays Sativex in fed state.~Followed by 4 sprays daily in fasted state."
3182373|NCT01322464|Experimental|Group 1 Fed-Fasted|"4 sprays sativex in fed state followed by wash-out followed by 4 sprays Sativex in fasted state.~Followed by 4 sprays daily in fasted state."
3182374|NCT01322464|Experimental|Group 2|2 sprays Sativex daily in fasted state.
3182375|NCT01322464|Experimental|Group 3|8 sprays sativex daily in fasted state.
3182376|NCT01322451|Experimental|Single oral dose, single capsule|
3182377|NCT01322451|Experimental|Single oral dose, two capsules|
3182378|NCT01322438|Experimental|Arm 1|
3182379|NCT01322412||Arm A : physical activity program|Arm A : physical activity program (aerobic and strength training) during the 27 weeks of treatment (chemotherapy and radiotherapy) and conventional follow-up during 27 weeks
3182380|NCT01322412||Arm B : conventional management|Arm B : conventional management during and after treatment
3182381|NCT01322399|Experimental|Structural Integration plus usual care|Each subject in this arm will receive ten Structural Integration treatments at intervals of between one and three weeks, and will also receive usual care for chronic low back pain as standard practice at Spaulding Medford Rehabilitation Clinic, which may include pain medication, exercise and physical therapy. Usual care will be provided on average twice weekly for between 3 and 7 weeks, at the discretion of the clinic's medical director
3182382|NCT01322399|Active Comparator|Usual care|Each subject in this arm will receive care for chronic low back pain as standard practice at Spaulding Medford Rehabilitation Clinic, which may include pain medication, exercise and physical therapy. Usual care will be provided on average twice weekly for between 3 and 7 weeks, at the discretion of the clinic's medical director
3182383|NCT01322386|Experimental|Oral Vancomycin|Vancocin
3182384|NCT01322373||Healthy control subjects (HC)|Subjects who met criteria as healthy control subjects and completed Orasi Protocol ADG-08-01.
3182385|NCT01322373||Alzheimer's disease subjects (AD)|Subjects with a diagnosis of DAT according to DSM-IV-TR criteria who completed Orasi Protocol ADG-08-01.
3182386|NCT01322360|Other|Morphine Sulfate|oral solution (10 mg/5 mL or 20 mg/5 mL) or tablets (15 mg or 30 mg)given based on based on the current pediatric prescribing guidelines
3182387|NCT01322347|Active Comparator|Soluble Ferric Pyrophosphate (SFP) in dialysate|11 micrograms (µg) of iron / deciliter (dL) of dialysate.
3182388|NCT01322347|Placebo Comparator|Standard Dialysate|0 micrograms (µg) of iron / deciliter (dL) of dialysate.
3182389|NCT01322334|Experimental|Singing exercises|
3182390|NCT01322321|Experimental|ACZ885|
3182391|NCT01322321|Placebo Comparator|Placebo|
3182392|NCT01322308|Placebo Comparator|sugar pill|tablet similar to comparator
3182393|NCT01322308|Active Comparator|pioglitazone|30 mg tablets QD (taken once daily)
3182394|NCT01322282|Experimental|ODT with Water|Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken with 240 mL of water
3182395|NCT01322282|Experimental|ODT Without Water|Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken without 240 mL of water
3182396|NCT01322282|Active Comparator|FCT with Water|Marketed Cetirizine 10 mg Film-Coated Tablet (FCT) taken with 240 mL of water
3182397|NCT01322269|Experimental|HQK-1001 (30 mg/kg)|
3182398|NCT01322269|Experimental|HQK-1001 (40 mg/kg)|
3182399|NCT01322269|Experimental|HQK-1001 (50 mg/kg)|
3182400|NCT01322256|Experimental|Included patients|"Patients included in the study according to stated inclusion and exclusion criteria~Intervention: Bone scintigraphy Intervention: Leukoscan Intervention: PET / CT Intervention: Bone biopsy Intervention: Bloodwork"
3182401|NCT01322243|Other|Dietary Intervention: Fasted State|Participants will be randomized to a dietary intervention of a fasted or fed group upon admission.
3182402|NCT01322243|Other|Dietary Intervention: Fed State|Participants will be randomized to a dietary intervention of a fasted or fed group upon admission
3182403|NCT01322230|Experimental|Control|Screen shots with voiceover and no interactivity
3182404|NCT01322230|Experimental|WISEMD Original|Learner control of pacing through multi-media content
3182405|NCT01322230|Experimental|Social Networking|social networking features (Forum and Social Presence)
3182406|NCT01322230|Experimental|Social Networking plus Emotional Design|Social networking features plus user interface enhancements
3182407|NCT01322217||AMTU Clients|All HIV-infected adolescents and young adults engaged in care at sites newly participating in ATN III and their affiliates who are between 12 and 24 years of age, inclusive, are aware of their HIV status and understand written and/or verbal English will be eligible for inclusion in the study. In addition, new patients who have their initial clinic visit within the enrollment period will also be eligible for participation.
3183024|NCT01317823|Active Comparator|Bishop score|
3182408|NCT01322204|Experimental|1|Neonates 0-30 days, no more than 2,000 grams, receiving mechanical ventilation.
3182409|NCT01322191|Experimental|1|Random assignment to a single dose of morphine 0.1 mg/kg infused by syringe pump over 10 minutes; urine and blood sample frozen at -80 degrees Celsius
3182410|NCT01322152|Experimental|wXELIRI regimen|
3182411|NCT01322139|Placebo Comparator|High dose placebo and oral moxifloxacin placebo|24 or 36 placebo sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
3182412|NCT01322139|Active Comparator|Low dose Sativex and oral moxifloxacin placebo|8 Sativex sprays (4 sprays twice daily) + 16 or 28 placebo sprays (8 or 14 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
3182413|NCT01322139|Active Comparator|High dose Sativex and oral moxifloxacin placebo|24 or 36 Sativex sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
3182414|NCT01322139|Active Comparator|High dose placebo and single oral moxifloxacin 400 mg tablet|24 or 36 placebo sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
3182415|NCT01322126|Experimental|ultrasound ,without ultrasound|ultrasound group will be passed the neuraxial anesthesia with ultrasound,the secoud group will be passed the neuraxial anesthesia without ultrasound .
3182416|NCT01322113||Na+, K+-ATPase/DLC system in BD|Bipolar patients in the various phases of the disease.
3182417|NCT01322087|Experimental|Nutritional intervention|
3182418|NCT01322074||Total knee arthroplasty|Patients operated with elective, unilateral total knee arthroplasty.
3182419|NCT01322061|Active Comparator|Vitamin C|
3182420|NCT01322061|Placebo Comparator|mirinda|
3182421|NCT01322048|Experimental|Adrenergic Blockade|Propranolol and Clonidine
3182422|NCT01322048|Placebo Comparator|Placebo|Placebo
3182423|NCT01322022|Experimental|Parent Training|Behavioral Intervention
3182424|NCT01322022|Active Comparator|Parent Education|5 Sessions of individual parent education
3182425|NCT01322009|Experimental|Drug|Probenecid and N-acetyl cysteine will be administered at standard doses for the first 4 days after TBI.
3182426|NCT01322009|Placebo Comparator|Placebo|Placebos will be prepared for the two experimental drugs and administered at identical time periods.
3182427|NCT01321996|Other|68Ga-DOTANOC PET/CT in patients with IPF and NSIP|one arm study: all patients were studied by 68Ga-DOTANOC PET/CT
3182428|NCT01321970|Other|Severe coronary artery disease|Patients in this group have coronary artery disease with a stenosis of >70%.
3182429|NCT01321970|Other|Coronary artery disease|Patients in this group have coronary artery disease with stenosis < 70%.
3182430|NCT01321957|Active Comparator|FOLFOX+Bevacizumab|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
3182431|NCT01321957|Experimental|FOLFOX+Bevacizumab+Irinotecan|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
3182432|NCT01321944|No Intervention|Usual clinical care|Usual clinical care provided by health care system
3182433|NCT01321944|Experimental|DTS intervention|Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP that encourages the smoker to quit, and offers a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC), free nicotine patches, and referral to additional treatment resources including the state's free telephone quitline.
3182434|NCT01321931|Experimental|NRT 60|A 6 mg dose of an experimental Nicotine Replacement Therapy (NRT) given every hour for 11 hours, with a 36-hour washout between visits
3182435|NCT01321931|Active Comparator|NFG 60|A 4 mg dose of a marketed Nicotine Fruit Gum (NFG) given every hour for 11 hours, with a 36-hour washout between visits
3182436|NCT01321931|Experimental|NRT 90|A 6 mg dose of NRT given every 90 minutes for 10.5 hours, with a 36-hour washout between visits
3182437|NCT01321931|Active Comparator|NFG 90|A 4 mg dose of NFG given every 90 minutes for 10.5 hours, with a 36-hour washout between visits
3182438|NCT01321931|Active Comparator|NIQ 60|A 4 mg dose of marketed nicotine mint lozenge (NIQ), given every hour for 11 hours, with a 36-hour washout between visits
3182439|NCT01321918|Other|Case subjects|
3182440|NCT01321918|Other|Control subjects|
3182441|NCT01321905|Experimental|Ergocalciferol|"Patients younger than 16 years of age are administered 35,000 IU ergocalciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.~Patients 16 or more years of age are administered 50,000 IU ergocalciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
3182442|NCT01321905|Experimental|Cholecalciferol|"Patients younger than 16 years of age are administered 35,000 IU cholecalciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.~Patients 16 or more years of age are administered 50,000 IU cholecalciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
3182443|NCT01321905|No Intervention|Control|Patients continue their ordinary vitamin supplementation without getting extra vitamin D supplements.
3182444|NCT01321892||Squamous cell carcinoma|Patients included in this study will be receiving surgical treatment for their biopsy-proven squamous cell carcinoma.
3182445|NCT01321879|Experimental|Telavancin|10 or 7.5 mg/kg intravenous daily
3182446|NCT01321866|Experimental|Experimental arm|Patients in this arm will have angioplasty of a fistula stenosis using a cutting balloon
3182447|NCT01321866|Active Comparator|Standard arm|Patients in this arm will have angioplasty of a fistula stenosis using a non-cutting balloon.
3182448|NCT01321853|Experimental|Machine and NCC|Medications dispensed to subject via MD2 machine and nurse care coordination used to coordinate care among providers and fill machine at least every 2 weeks.
3182449|NCT01321853|Experimental|Medplanner and NCC|Medications loaded in medplanner by nurse care coordinator who coordinates care among providers and visits subject at least every 2 weeks
3183025|NCT01317823|Active Comparator|transvaginal ultrasound|
3182452|NCT01321840|No Intervention|No treatment|This group will not be treated with SART but will regularly be examined by a gynecologist to detect sudden aggravation of the disease.
3182453|NCT01321827|Experimental|Itraconazole group|Itraconazole 200 mg BD for 4 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
3182454|NCT01321827|Active Comparator|Glucocorticoid group|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
3182455|NCT01321814|Experimental|Cognitive behavioural therapy (CBT)|Patients receiving 6 sessions of CBT conducted by a licensed psychologist. Sessions include psychoeducation, exposure treatment, behavioral activation and applied relaxation.
3182456|NCT01321814|No Intervention|Waiting list|Patient waits for CBT treatment for 6 months.
3182457|NCT01321801|Active Comparator|Pregabalin|Preoperative administration of pregabalin 600mg to patients undergo laparoscopic cholecystectomy.Patients receive oral Pregabalin 300 mg the night before the surgery, and another one dose of 300 mg 1 hour prior to surgery
3182458|NCT01321801|Placebo Comparator|Placebo|Preoperative administration of placebo to patients undergo laparoscopic cholecystectomy.Patients receive oral Placebo the night before the surgery, and another one dose 1 hour prior to surgery.
3182459|NCT01321788||STUDY GROUP|will receive the study drug Innohep ® for 14 days
3182460|NCT01321788||CONTROL|The group that will receive placebo for 14 days
3182461|NCT01321775|Experimental|Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet|
3182462|NCT01321762||1|Pregnant Women with singleton pregnancy
3182463|NCT01321749|Experimental|RIPC+stroke secondary prevension|"Procedure/Surgery: Remote Ischemic Preconditioning (RIPC) The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.~Procedure:stroke secondary prevention(Such as Antiplatelet therapy, Cholesterol-lowering therapymaintain blood pressure and blood sugar normal)"
3182464|NCT01321749|No Intervention|stroke secondary prevention|Procedure:stroke secondary prevention(Such as Antiplatelet therapy, Cholesterol-lowering therapymaintain blood pressure and blood sugar normal)
3182465|NCT01321723|Experimental|PTH analog tablet|PTH(1-31) 5 mg tablet, once daily
3182466|NCT01321723|Placebo Comparator|Placebo|Placebo matching tablet, once daily
3182467|NCT01321723|Active Comparator|Forsteo|Forsteo (teriparatide) 20 mcg SC Injection, once daily
3182468|NCT01321710|Active Comparator|Dietary information & standard care|"Mothers in this arm receive dietary information aimed at reducing postpartum sleep disturbance.~Infants in this arm receive no intervention beyond standard immunization care."
3182469|NCT01321710|Experimental|Sleep hygiene & standard care|"Mothers in this arm receive a sleep hygiene intervention aimed at improving their postpartum sleep.~Infants in this arm receive standard immunization care."
3182470|NCT01321710|Experimental|Sleep hygiene & acetaminophen|"Mothers in this arm receive a sleep hygiene intervention aimed at improving postpartum sleep.~Infants in this arm receive an acetaminophen intervention (12.5mg per kg infant weight, 1 dose 30 minutes prior to immunization and q4-6h thereafter, for a total of 5 doses) to minimize sleep disturbance following immunization."
3182471|NCT01321697||Vulvar Cancer|
3182472|NCT01321671|Experimental|Pregabalin controlled release, 330 mg, 600- 750 calorie|
3182473|NCT01321671|Experimental|Pregabalin controlled release, 330 mg, fasted|
3182474|NCT01321671|Other|Pregabalin immediate release, 300 mg|
3182475|NCT01321658|Experimental|Geriatric intervention|
3182476|NCT01321658|No Intervention|Control|
3182477|NCT01321619|Experimental|Varicell|Drug A(Varicell) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
3182478|NCT01321619|Experimental|Placebo daflon (Drug D)|Drug D (Placebo Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
3182479|NCT01321606|Experimental|Arm 1: Probiotic|subjects will be given a capsule formulation of a 1x10^10 colony-forming units of probiotic L. rhamnosus HN001 to be taken once a day, for 4 weeks
3182480|NCT01321606|Placebo Comparator|Arm 2: Placebo|Placebo identical to the active product will be given
3182481|NCT01321593||hemoglobin determination|emergency unit patients
3182482|NCT01321580|Experimental|Group A|
3182483|NCT01321567||Rabeprazole Sodium|
3182484|NCT01321554|Experimental|Lenvatinib (Randomization Phase)|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
3182485|NCT01321554|Placebo Comparator|Placebo (Randomization Phase)|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
3182486|NCT01321554|Experimental|Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)|Participants will receive lenvatinib 24 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
3182487|NCT01321554|Experimental|Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)|Participants will receive lenvatinib 20 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
3182488|NCT01321541|Experimental|Pixantrone + Rituximab|
3182489|NCT01321541|Active Comparator|Gemcitabine + Rituximab|
3182490|NCT01321528||IBSR Intervention group|30 nurses in the geriatric departments in TASMC
3182491|NCT01321489|Experimental|Sildenafil Citrate 20mg Tablet Sublingual|Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
3182492|NCT01321489|Active Comparator|Viagra ® 50mg tablet Coated|Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
3182493|NCT01321463|Experimental|PH-797804|
3182494|NCT01321463|Placebo Comparator|Placebo|
3182495|NCT01321450||Group A|Preparation with Harmonic WAVE
3182496|NCT01321450||Group B|Preparation with conventional modalities
3182497|NCT01321437|Experimental|Axitinib|Patients receive axitinib PO BID on days 1-28. Treatment repeats every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 14-21 days after completion of treatment. Beginning 28-56 days after surgery, patients receive axitinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
3182498|NCT01321424||Aqueous Dificiency Dry Eye|20 Participants
3182499|NCT01321424||Meibomian Gland Disease Dry Eye|20 Participants
3182500|NCT01321424||Normal Eye|20 Participants
3182501|NCT01321411||1. ARDS/COPD|Critically ill patients with either ARDS or COPD weaning from mechanical ventilation.
3182502|NCT01321411||2. Healthy Volunteers|
3182503|NCT01321398||Critically Ill patients receiving HFO|
3182504|NCT01321359|Placebo Comparator|Vehicle|Vehicle
3182505|NCT01321359|Active Comparator|Active|Active NB-001(0.3%)
3182506|NCT01321346|Experimental|Leukemia Patients|Patients with ALL and AML will be treated in one arm of the study.
3182507|NCT01321346|Experimental|Lymphoma Patients|Patients with NHL or HD will be treated in one arm of the study.
3182508|NCT01321333|Experimental|HuCNS-SC cells|Single dose intramedullary administration of HuCNS-SC cells
3182509|NCT01321320|Experimental|Active stimulation|This group will receive active muscle stimulation for 1 week to the quadriceps muscle - the leg will be randomly assigned.
3182510|NCT01321307||Sorend|Group no. 1 shall receive Sorend following diagnosis of aphtostomatitis or mucositis.
3182511|NCT01321307||Sorend placebo|Group no. 2 shall receive Sorend placebo following diagnosis of aphtostomatitis or mucositis.
3182512|NCT01321294|Active Comparator|Nissen fundoplication|
3182513|NCT01321294|Active Comparator|Toupet fundoplication|
3182514|NCT01321281|Experimental|AquaCal|Osteoarthritis and healthy volunteers
3182515|NCT01321281|Active Comparator|AquaPT|Osteoarthritis
3182516|NCT01321268|Experimental|dietary supplement for cellulite|PUFA, resveratrol, lycopene, beta carotene, lutein
3182517|NCT01321268|Active Comparator|Control|Vitamin E
3182518|NCT01321255|Experimental|FDC Fixed Dose Combination|
3182519|NCT01321255|Active Comparator|Conventional treatment|
3182520|NCT01321242||achieving resting HR goals|Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects achieving resting HR goals, according to ACC/AHA/ACP-ASIM Guidelines
3182521|NCT01321242||non-achieving HR goals|Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects non-achieving HR goals, according to ACC/AHA/ACP-ASIM Guidelines
3182522|NCT01321229||With sleep APNEA|Sleeping Apnea Syndrome (SAS) screening usin an APNEA LINK device within the 10 first days following the admission Diagnosis and medical care by a sleeping disorder qualified specialist
3182523|NCT01321229||Without sleep APNEA|Sleeping Apnea Syndrome (SAS) screening usin an APNEA LINK device within the 10 first days following the admission
3182524|NCT01321216||Hospitalized Gastroenteritis|Children under 5 years of age hospitalized with gastroenteritis
3182525|NCT01321203||Group-A, use of air;|
3182526|NCT01321203||Group-B use of CO2|
3182527|NCT01321190||Low Back Pain|Individuals who experience bothersome low back pain.
3182528|NCT01321190||Headache|Individuals who experience bothersome headaches.
3182529|NCT01321190||Fibromyalgia|Individuals who experience bothersome fibromyalgia-related pain.
3182530|NCT01321177|Experimental|Integrated Treatment|Integrated program of treatments and services delivered by a coordinated team of providers.
3182531|NCT01321177|Active Comparator|Community Care|Standard mental health treatments and services offered at the local agency.
3182532|NCT01321164|Active Comparator|Fumaric acid esters|Fumaric acid esters monotherapy
3182533|NCT01321164|Experimental|fumaric acid esters plus narrow band UVB|Combination therapy of fumaric acid esters plus narrow band type B ultraviolet therapy (UVB)
3182534|NCT01321151|Placebo Comparator|Sugar Pill|Placebo control
3182535|NCT01321151|Experimental|Resveratrol|Intervention
3182536|NCT01321138|Active Comparator|Femoral nerve block|Continuous femoral nerve block with bolus of ropivacaine 0.5% and then continuous infusion of ropivacaine 0.2 % 4 - 6 ml/h, associated with paracetamol and ibuprofen. Each group will contain 30 patients.
3182537|NCT01321138|Placebo Comparator|PCA morphine|Patients with iv morphine with self administration with a PCA-system, associated with paracetamol and ibuprofen.
3182538|NCT01321125|Experimental|Whole group of 30 volunteers|The arm is composed of 30 human volunteers to test 2% chlorhexidine gluconate in 70% isopropyl alcohol (ChloraPrep ®, Enturia, Texas, USA ), hypochlorite 10% of electrochemical production (Except 10% ®, Pisa, Guadalajara, Mexico), and two controls.
3182539|NCT01321125|Experimental|test group of substantivity|The arm is composed of 10 human volunteers to test 2% chlorhexidine gluconate in 70% isopropyl alcohol (ChloraPrep ®, Enturia, Texas, USA ), hypochlorite 10% of electrochemical production (Except 10% ®, Pisa, Guadalajara, Mexico), and 10% povidone-iodine (Isodine Solucion ®, Boehringer-Ingelheim Promeco, Mexico City)
3182540|NCT01321112|Experimental|Conversion arm|After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
3182541|NCT01321099|Experimental|NaFeEDTA|
3182542|NCT01321099|Experimental|Phatase|
3182543|NCT01321099|Experimental|Vitamin C|
3183080|NCT01317511|Experimental|Protein|Protein drink
3182544|NCT01321086|Active Comparator|Motivational Interviewing|Motivational Interviewing (MI) is an effective counseling method in individuals who are less ready to change their behavior. 9 MI sessions will be conducted over the course of the six month intervention.
3182545|NCT01321086|Active Comparator|PACE|Patient-centered Assessment and Counseling for Exercise (PACE) is a protocol that targets known modifiable determinants of behavior change to motivate participants to increase their physical activity (walking).
3182546|NCT01321086|No Intervention|Control|
3182547|NCT01321073|Experimental|DelIVery for Pulmonary Arterial Hypertension Single Arm|All subjects were enrolled for implantation of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection.
3182548|NCT01321060|Active Comparator|Conservative treatment|Conservative treatment group with only drugs.
3182549|NCT01321060|Experimental|Continuous catheter drainage|Once the diameter of the fluid collection is more than 6cm, continuous catheter drainage will be applied.
3182550|NCT01321060|Experimental|Repeated aspiration|Once the diameter of the fluid collection is more than 6cm, aspiration is applied and draw the tube out immediately after aspiration.
3182551|NCT01321047|Active Comparator|Propofol group|the conventional propofol group (P group), sedation was induced by an intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age > 70 or ASA class III-IV).
3182552|NCT01321047|Active Comparator|BPS group|the balanced propofol sedation group (BPS group), both midazolam (0.05 mg/kg body weight; 1 mg if age > 70 or ASA class III-IV) and fentanyl (50 µg; 25 µg if age > 70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, an initial bolus of propofol (0.5 mg/kg body weight) was given intravenously. Sedation was maintained with repeated doses of 10 to 20 mg propofol.
3182553|NCT01321034|Other|Niacin/Laropiprant|Subjects with normal Lp(a) will be use as comparative group for the other two groups, so no placebo group is required is this study
3182554|NCT01321021|Experimental|Losartan, Diphenhydramine, Placebo|placebo controlled crossover study with two arms: Losartan, Diphenhydramine
3182555|NCT01321008|Experimental|Radiation + Chemotherapy|Radiation therapy total dose of 50.4 to 54 Gy over 28 to 30 treatments; CHOP Chemotherapy of Cyclophosphamide 750 mg/m2 intravenous piggyback (IVPB), Doxorubicin 50 mg/m2 IVPB, Vincristine 1.4 mg/m2 (max dose 2 mg) IVPB on Day 1, and Oral Prednisone 100 mg daily days 1-5 for four 21-day cycles.
3182556|NCT01320995|Experimental|Experimental arm|In this arm, perineal ultrasound is used directly after delivery in order to hypothetically better detect anal lesions.
3182557|NCT01320995|No Intervention|Standard arm|No perineal ultrasound immediately after delivery.
3182558|NCT01320982|Active Comparator|minocycline|minocycline
3182559|NCT01320982|Active Comparator|pramipexole|pramipexole
3182560|NCT01320982|Active Comparator|acetylsalicylic acid|acetylsalicylic acid
3182561|NCT01320982|Placebo Comparator|Placebo|Placebo
3182562|NCT01320969|Experimental|Mindfulness-Based Stress Reduction course|an eight week mindfulness-based stress reduction course
3182563|NCT01320969|No Intervention|Waitlist group|waitlist group
3182564|NCT01320956|Experimental|Hypnosis|"Pre operative nurse consultation and Hypnosis:~will have hypnosis"
3182565|NCT01320956|Active Comparator|Control|"Pre operative nurse consultation:~usual nurse consultation without hypnosis"
3182566|NCT01320943|Experimental|Stop TDF|Participants randomized to this arm will stop TDF therapy at baseline.
3182567|NCT01320943|Active Comparator|Continue TDF|Participants randomized to this arm will continue TDF therapy.
3182568|NCT01320930|Active Comparator|Pulmonary rehabilitation|A standardized 7 week rehabilitation program, including physical training and education.
3182569|NCT01320930|Placebo Comparator|Control|Conventional care
3182570|NCT01320917|Active Comparator|LNG-IUS|Insertion of a LNG-IUS device
3182571|NCT01320917|Placebo Comparator|Cu-IUD|Insertion of a Cu-IUD
3182572|NCT01320904|Placebo Comparator|Closed Kinetic Chain and NMES placebo|"During the stimulation period the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.~We used a 10-channel electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings."
3182573|NCT01320904|Other|Closed Kinetic Chain Group|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
3182574|NCT01320891|Experimental|balanced|arm in which the subjects received only balanced solutions
3182575|NCT01320891|Experimental|not balanced|arm in which the subjects received only not balanced solutions that means only normal saline and colloid dissolved in normal saline
3182576|NCT01320878|Active Comparator|iloprost low dose group|iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
3182577|NCT01320878|Active Comparator|iloprost high dose group|iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
3182578|NCT01320878|Placebo Comparator|placebo group|distilled water 2 ml per session
3182579|NCT01320865||Subjects with PAH treated with nilotinib|
3182580|NCT01320852|Active Comparator|Milan Criteria|Patients meeting the Milan Criteria
3182581|NCT01320852|Other|No Milan Criteria|Patients not meeting the Milan Criteria
3182582|NCT01320839||Stroke|People who have had a stroke and have an ankle-foot orthosis.
3182583|NCT01320826||Physician colonoscopists|"All primary care physicians (family physicians and general internists) who perform colonoscopies were approached to voluntarily participate in the APC-Endo study.~All patients having a colonoscopy done by an APC-Endo study physician endoscopist were approached at the time of their endoscopy to consent to the post procedure telephone survey."
3182584|NCT01320813|Experimental|Robot arm|Patients in this arm will have a thyroidectomy performed using a robot-assisted endoscopic technique.
3182585|NCT01320813|Active Comparator|Open surgery|Patients in this arm will have a thyroidectomy using an open surgical technique.
3182586|NCT01320800|Active Comparator|Expert-led CBT|Expert SASS is the Skills for Academic and Social Success protocol delivered by a postdoctoral fellows.
3182587|NCT01320800|Experimental|School Counselor-led CBT|"School Counselor SASS is the Skills for Academic and Social Success protocol delivered by School Counselors.~Intervention: Behavioral: Skills for Social and Academic Success"
3182588|NCT01320800|Active Comparator|Skills for Life|SFL is the Skills for Life Protocol delivered by school counselors. Intervention: Behavioral: Skills for Life
3182589|NCT01320787|Experimental|18F-fluoroacetate|18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.
3182590|NCT01320761|Experimental|Group 1A|"Left side injected first:~Left submental - ATX-101-BA Right submental - ATX-101-BA-free"
3182591|NCT01320761|Experimental|Group 1B|"Right side injected first:~Left submental - ATX-101-BA Right submental - ATX-101-BA-free"
3182592|NCT01320761|Experimental|Group 2A|"Left side injected first:~Left submental - ATX-101-BA-free Right submental - ATX-101-BA"
3182593|NCT01320761|Experimental|Group 2B|"Right side injected first:~Left submental - ATX-101-BA-free Right submental - ATX-101-BA"
3182594|NCT01320748|Experimental|Dual Processing|
3182595|NCT01320748|Active Comparator|Relapse Prevention|
3182596|NCT01320735||Advanced PCa|Participants with advanced PCa
3182597|NCT01320722|Experimental|Vitamin D|Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.
3182598|NCT01320722|Experimental|Probenecid|Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).
3182599|NCT01320722|Experimental|Allopurinol|Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).
3182600|NCT01320722|Placebo Comparator|Placebo- Vitamin D|Placebo soft gel once per week for 8 weeks.
3182601|NCT01320722|Placebo Comparator|Placebo- Uric Acid|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).
3182602|NCT01320709|Experimental|Arm 1|
3182603|NCT01320709|Experimental|Arm 2|
3182604|NCT01320709|Placebo Comparator|Arm 3|
3182605|NCT01320709|Experimental|Arm 4|
3182606|NCT01320696|Experimental|Cohort 1|50 subjects will be randomized 1:1:1:1:1 to 5 dose groups (10 subjects per treatment group) to receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22
3182607|NCT01320696|Experimental|Cohort 2|After a safety data review of the first 50 subjects, a further 225 subjects will be randomized 1:1:1:1:1 to 5 dose groups and will receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22
3182608|NCT01320683|Experimental|Treatment (combination chemotherapy and radioimmunotherapy)|FOLFOX* + BEVACIZUMAB CHEMOTHERAPY: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes. Treatment repeats for up to 12 courses in the absence of disease progression or unacceptable toxicity. RIT: Within 4-12 weeks after completion of post-hepatic resection therapy chemotherapy, patients receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV over 25 minutes. Treatment repeats every 6-10 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. NOTE:*Patients previously failing oxaliplatin regimen receive FOLIFIRI chemotherapy comprising irinotecan hydrochloride IV over 90 minutes, leucovorin calcium over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes. Treatment repeats for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3182609|NCT01320657|Active Comparator|InOvation C|Active Self-ligating Bracket
3182610|NCT01320657|Placebo Comparator|Ovation|Conventional Bracket
3182611|NCT01320657|Experimental|Damon Q|Self-ligating bracket
3182612|NCT01320644||vaginal mesh placement|
3182613|NCT01320605|Experimental|Weekly HP802247 treatment|
3182614|NCT01320579|Experimental|Group 2 Cis-UCA 5% emulsion cream|
3182615|NCT01320579|Placebo Comparator|Group 3 Placebo cis-UCA emulsion cream|
3182616|NCT01320579|Active Comparator|Group 4 Protopic® 0.1% ointment|
3182617|NCT01320579|Experimental|Group 1 Cis-UCA 2.5% emulsion cream|
3182618|NCT01320553|Experimental|SPARC1102 I|1334H 0.15% eye drops will be administered in both eyes at 3 occasions
3182619|NCT01320553|Experimental|SPARC1102 II|1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions
3182620|NCT01320553|Experimental|SPARC1102 III|1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions
3182621|NCT01320553|Placebo Comparator|Vehicle|Placebo eye drops (solution)will be administered in both eyes at 3 occasions
3182622|NCT01320540||Breast Center Patients|Patients newly diagnosed with breast cancer who did or did not have genetic testing (retrospectively and prospectively).
3182623|NCT01320540||Staff from the Lynn Sage Comprehensive Breast Cancer Center|Members of the Northwestern staff to include but not limited the Lynn Sage Comprehensive Breast Cancer Center and/or Breast Cancer Genetics Program provider staff (including physicians, nurses, schedulers, physician assistants and/or genetic counselors).
3182624|NCT01320527|Experimental|Nutriceutical formulation|Nutritional supplement
3182625|NCT01320527|Placebo Comparator|Placebo 1|
3182626|NCT01320527|Placebo Comparator|Placebo 2|
3182627|NCT01320514||Fibrin Sealant (Artiss)|
3182628|NCT01320501|Experimental|Erlotinib|150 mg PO daily
3182629|NCT01320475|Experimental|iv Ketamine|Epidural infusion of levobupivacaine and saline (placebo for sufentanil)and iv infusion of ketamine Up to the third postoperative day (6 PM)
3182630|NCT01320475|Active Comparator|Sufentanil|Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
3182631|NCT01320462|Experimental|Smoking cessation group|Counselling, Pharmacotherapy and Smokers Help Line
3182632|NCT01320462|Other|Control group|Brief informatin about quitting and smokers help line
3183081|NCT01317511|Placebo Comparator|Placebo|water
3182633|NCT01320449|Placebo Comparator|No training + placebo|10 young men being investigated with 10 weeks apart. The will receive placebo injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
3182634|NCT01320449|Active Comparator|No training + EPO|10 young men being investigated with 10 weeks apart. During the 10 weeks participants will receive EPO injections twice a week. Blood samples, blood pressures as well as VO2-mas tests will be obtained during the 10 weeks.
3182635|NCT01320449|Active Comparator|Training + placebo|10 young men will be trained for 10 weeks and investigated before and after. They will receive placebo injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
3182636|NCT01320449|Active Comparator|Training + EPO|10 young men will be investigated with 10 weeks apart. During the ten weeks they will train 3 times a week and receive EPO injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
3182637|NCT01320436|Active Comparator|Treatments arm|Patients allocated for this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (total of 820 mg each,containing 500 mg curcumin ) curcumin twice daily after meals.
3182638|NCT01320436|Placebo Comparator|Control arm|Patients allocated to this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (820gr each) of placebo twice a day after meals.
3182639|NCT01320423|Other|surgery|
3182640|NCT01320397|Experimental|Rostafuroxin 6 micrograms capsules|1 capsule of ROSTAFUROXIN (6 micrograms) once a day before breakfast.
3182641|NCT01320397|Experimental|Rostafuroxin 50 micrograms capsules|1 capsule of ROSTAFUROXIN (50 micrograms) once a day before breakfast.
3182642|NCT01320397|Experimental|Rostafuroxin 500 micrograms|1 capsule of ROSTAFUROXIN (500 micrograms) once a day before breakfast.
3182643|NCT01320397|Experimental|Losartan 50 mg encapsulated|1 capsule containing one cpr of Losartan 50 mg once a day before breakfast.
3182644|NCT01320384|Active Comparator|O2 conventional : standard low flow therapy|in order to obtain a SpO2>92%
3182645|NCT01320384|Experimental|O2-HNF : high flow nasal oxygen therapy|set between 30 to 50 l/min,adjusted in order to obtain a SpO2 >92%.
3182646|NCT01320384|Experimental|O2-HFN/NPPV|cycling of NIV and O2-HDN
3182647|NCT01320371||Barbed sutures|Barbed sutures are self-anchoring, requiring no knots for wound closure.
3182648|NCT01320371||Knotted sutures|Knotted sutures used for traditional surgical closures.
3182649|NCT01320358|Experimental|ECMPS-IEM|
3182650|NCT01320345|Experimental|Fenofibrate|
3182651|NCT01320345|Placebo Comparator|Placebo|
3182652|NCT01320332|Experimental|ASP3291 low dose|
3182653|NCT01320332|Experimental|ASP3291 high dose|
3182654|NCT01320332|Placebo Comparator|Placebo|
3182655|NCT01320319|Placebo Comparator|Placebo|
3182656|NCT01320319|Experimental|Nutritional Supplementation with EPA|This arm will receive the nutritional supplementation of EPA 960mg Three times a day.
3182657|NCT01320306||Subarachnoid hemorrhage|A group of patients suffering aneurismal subarachnoid hemorrhage will participate in a fMRI study.
3182658|NCT01320306||Prophylactic surgical treatment of un-ruptured aneurysms|A retrospective follow-up study of patients who have received prophylactic surgical treatment of un-ruptured aneurysms
3182659|NCT01320306||Conservative treatment|A retrospective follow-up of patients receiving conservative (life stile etc.) treatment of un-ruptured aneurysms.
3182660|NCT01320306||Control group of healthy subjects|Control group of healthy subjects
3182661|NCT01320293|Experimental|Adalimumab 40mg|Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA] Dose administered every other week for 6 months
3182662|NCT01320280|Experimental|BIBW 2992 (Afatinib)|BIBW 2992 (Afatinib) 50mg daily continuously (oral medication)
3182663|NCT01320267|Experimental|SILS right hemicolectomy|Single arm with intervention only.
3182664|NCT01320254|Experimental|Cisplatin, Gemcitabine and Panitumumab|Experimental Arm with cisplatin 25mg/sq.m. at day 1 + 8, gemcitabine 1000mg/ sq.m.at day 1 + 8 and panitumumab 9mg/kg BW at day 1. Cycle will be repeated every 3 weeks.
3182665|NCT01320254|Active Comparator|Cisplatin and Gemcitabine|Cisplatin 25mg/sq.m. at day 1 + 8 and Gemcitabine 1000 mg/sq.m. at day 1 + 8. Cycle will be repeated every 3 weeks.
3182666|NCT01320241|Active Comparator|novel radiation stent|"Patients undergo placement of a novel biliary stent loaded with 125I seeds on day 1.~Intervention: Device: self-expandable 125I radioactive seeds-loaded-stent"
3182667|NCT01320241|Experimental|conventional stent|"Patients undergo placement of a conventional nitinol SEMS on day1.~Intervention: Device: self-expandable biliary nitinol alloys stent"
3182668|NCT01320228|Placebo Comparator|Control|Alli treatment plus placebo (rice flour)
3182669|NCT01320228|Experimental|Capolac|Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
3182670|NCT01320228|Experimental|Flax fiber|Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
3182671|NCT01320228|Experimental|Capolac+Flax fiber|Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
3182672|NCT01320215|Experimental|Robot arm|The patients in this arm will have a robot-assisted promontofixation.
3182673|NCT01320215|Active Comparator|Non-robot arm|The patients in this arm with have a promotofixation via a laparoscopy, but without robot assistance.
3182674|NCT01320202|Active Comparator|Soluble Ferric Pyrophosphate (SFP) in dialysate|11 micrograms (µg) of iron / deciliter (dL) of dialysate.
3182675|NCT01320202|Placebo Comparator|Standard Dialysate|0 micrograms (µg) of iron / deciliter (dL) of dialysate.
3182676|NCT01320189|Experimental|Protein intake of 5 energy percent|
3182677|NCT01320189|Experimental|Protein intake of 15 energy percent|
3182678|NCT01320189|Experimental|Protein intake of 30 energy percent|
3182679|NCT01320176|Experimental|Group A|Subjects received dose A of the investigational HIV vaccine
3182680|NCT01320176|Experimental|Group B|Subjects received dose B of the investigational HIV vaccine
3182681|NCT01320150||PPP|Study Subjects with PPP at followup
3182682|NCT01320150||Non-PPP|Subjects without PPP at followup
3182683|NCT01320137|Other|Allergy Group|Subjects with ages ranging from 18-45 years and inclusive, presenting symptomatic allergy to birch pollen.
3183128|NCT01317186||Group II|Stage 3 Non-diabetic Chronic Kidney Disease
3182684|NCT01320137|Other|Control Group|Subjects with ages ranging from 18-45 years and inclusive, with no known allergies.
3182685|NCT01320124||osteoarthritis, total knee arthroplasty|The main cohort will have a total knee arthroplasty and will not develop a contracture post surgery. We will analyze differntial gene expression in all subjects.
3182686|NCT01320124||contracture post arthroplasty|A small group (1.3%) will develop a contracture post total knee arthroplasty. A second sample will be taken at the time of corrective surgery. The 2 samples will be compared for gene expression in the same subject. This group will also be compared to the main cohort for differential gene expression.
3182687|NCT01320111|Active Comparator|Arm 1: PA|patient is treated with paclitaxel only
3182688|NCT01320111|Experimental|Arm 2: PASO|patient is treated with paclitaxel AND sorafenib
3182689|NCT01320098|Experimental|Home-Based Parenting Program|
3182690|NCT01320098|Experimental|Clinic-Based Parenting Program|
3182691|NCT01320098|Other|Wait-List Control Group|
3182692|NCT01320085|Experimental|BRAFV600 mutant, 45mg bid MEK162|BRAFV600 mutant, 45mg bid MEK162
3182693|NCT01320085|Experimental|NRAS mutant, 45mg bid MEK162|NRAS mutant, 45mg bid MEK162
3182694|NCT01320085|Experimental|BRAFV600 mutant, 60mg bid MEK162|BRAFV600 mutant, 60mg bid MEK162
3182695|NCT01320072||Aspirin-sensitive asthmatics|asthma patients with aspirin allergy
3182696|NCT01320072||aspirin-tolerant asthmatics|asthma patients without aspirin allergy
3182697|NCT01320059|Experimental|Imaging with 18F-PEG6-IPQA|Radioactive injection given by vein before multiple (3) PET scans.
3182698|NCT01320046||Patients with urinary incontinence|Patients attending the urogynecological clinic for urinary incontinence-100 patients. In this group we will recruit patients with UI, and will assess co-existence of VCD
3182699|NCT01320046||Patients with vulvar contact dermatitis|Patients attending the vulvovaginal clinic with vulvar contact dermatitis (100 patients). In this group we will recruit patients with VCD, and will assess co-existence of UI.
3182700|NCT01320046||Age matched control group|"Patients attending the general clinic for annual checkup, which will be matched for age with the two other groups (200 patients).~These patients will be evaluated for symptoms of UI and VCD"
3182701|NCT01320033|Experimental|CD2475/101 40 mg Tablets|CD2475/101 40 mg Tablets
3182702|NCT01320033|Active Comparator|Doxycycline 100 mg Capsules|Doxycycline 100 mg Capsules
3182703|NCT01320033|Placebo Comparator|Placebo Tablet, and Placebo Capsule|Matching Placebo Tablet, Matching Placebo Capsule
3182704|NCT01320020|Experimental|catumaxomab|
3182705|NCT01320007|Experimental|Group 1: Optivol Group|
3182706|NCT01320007|Active Comparator|Group 2: Optivol alarm muted|
3182707|NCT01319994|Experimental|Metformin|Metformin treatment
3182708|NCT01319994|Placebo Comparator|Placebo|Placebo treatment
3182709|NCT01319981|Experimental|Hyper-CMAD + Rituximab|Odd Courses 1, 3, 5, 7: Rituximab 375 mg/m2 IV Day 1 & 8 Courses 1 & 3; Imatinib oral 600 mg days 1-14 Course 1 then continuously; Cyclophosphamide 300 mg/m2 IV every; 12 hours for 6 doses; Mesna 600 mg/m2/day IV Days 1-3; Doxorubicin 50 mg/m2 IV CVC Day 4; VSLI 2.25 mg/M2 IV Day 1 & 8; Pegfilgrastim 6 mg/kg after chemotherapy + G-CSF 10 µg/kg/day; Dexamethasone 40 mg IV or P.O. daily days 1-4 and days 11-14 +/- 3 days.
3182710|NCT01319981|Experimental|Hyper-CVAD|Courses 2, 4, 6, 8: Rituximab 375 mg/m2 IV Day 1 & 8 Courses 2 & 4; Imatinib oral 600 mg; Methotrexate 200 mg/m2 IV over 2 hours followed by 8-0- mg/m2 over 22 hours on Day 1; Solu-Medrol 40 mg IV hours approximately every 12 hours +/- 2 hours for 6 doses days 1-3 +/- 3 days; Decadron 40 mg IV or orally 4 times Days 1-4; Ara-C 3 gm/m2 IV every 2 hours, 4 doses on Days 2-3; Pegfilgrastim 6 mg/kg after chemotherapy + G-CSF 10 mg/kg/day.
3182711|NCT01319968||Postpartum patients|100 postpartum women attending the clinic for their postpartum visit will be evaluated for vaginal atrophy, vaginal symptoms and dyspareunia.
3182712|NCT01319955|Experimental|Influenza vaccine (trivalent inactivated vaccine)|
3182713|NCT01319955|Active Comparator|Inactivated polio vaccine|
3182714|NCT01319942||Unresectable hepatoma|Unresectable hepatoma, unsuitable for transarterial embolization or local failure after transarterial embolization
3182715|NCT01319929|Experimental|LY2828360 then Placebo|80 milligrams (mg) of LY2828360 daily by mouth for 4 weeks: placebo daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments.
3182716|NCT01319929|Experimental|Placebo then LY2828360|Placebo daily by mouth for 4 weeks: LY2828360 daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments.
3182717|NCT01319890||Right Colectomy for colonic tumors|The group of patients enrolled will be patients with biopsy proven right colon tumors, both benign and malignant. These patients will then be subdivided into those having conventional laparoscopic right colectomy and SILS right colectomy
3182718|NCT01319877||First Line Treatment|Participants received bevacizumab in combination with 5-FU based chemotherapy as a first line therapy.
3182719|NCT01319877||Second Line Treatment|Participants received bevacizumab in combination with 5-FU based chemotherapy as a second line therapy.
3182720|NCT01319864|Experimental|Plerixafor, Dose Escalation|Dose escalation of plerixafor administered intravenously in combination with IV cytarabine and IV etoposide in pediatric patients wtih relapsed/refractory AML/ALL.
3182721|NCT01319851|Experimental|Alefacept|Pediatric subjects with non-malignant diseases (NMD) will receive pre-conditioning with alefacept 0.5 mg/kg/dose i.v. with the first dose split on days -40 and -39 and the remaining doses given on days -33, -26, -19, and -12 (e.g. weekly for 5 doses).
3182722|NCT01319838|Experimental|isotretinoin prolongation|Prolonged treatment with isotretinoin, extending standard 6 month duration to 2 years
3182723|NCT01319812|Experimental|Astron Stent Group|"Participants indicated for stenting in iliac atherosclerotic lesions.~Intervention: Device: Astron Stents"
3182724|NCT01319812|Experimental|Pulsar Stent Group|"Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.~Intervention: Device: Pulsar Stents"
3182725|NCT01319799||Surgical aortic valve replacement|Single observational study. Count of microembolic signals during open heart surgery and measurement of properative vs postoperative levels of markers in cerebrospinal fluid of neuronal damge.
3182726|NCT01319786|Other|Low- polyphenol diet|
3182727|NCT01319786|Active Comparator|High-polyphenol diet|
3183129|NCT01317186||Group III|Stage 4 Non-diabetic Chronic Kidney Disease
3182728|NCT01319773|Experimental|cyclosporine ophthalmic emulsion Formulation A (Formulation A)|Parallel-Group Phase (PGP): cyclosporine ophthalmic emulsion Formulation A
3182729|NCT01319773|Experimental|cyclosporine ophthalmic emulsion Formulation B (Formulation B)|PGP: cyclosporine ophthalmic emulsion Formulation B
3182730|NCT01319773|Other|Formulation A and cyclosporine ophthalmic emulsion 0.05%|Paired-Eye Phase (PEP): cyclosporine ophthalmic emulsion Formulation A and cyclosporine ophthalmic emulsion 0.05%
3182731|NCT01319773|Other|Formulation B and cyclosporine ophthalmic emulsion 0.05%|PEP: cyclosporine ophthalmic emulsion Formulation B and cyclosporine ophthalmic emulsion 0.05%
3182732|NCT01319773|Experimental|Formulation A and Formulation B|PEP: cyclosporine ophthalmic emulsion Formulation A and cyclosporine ophthalmic emulsion Formulation B
3182733|NCT01319760|Other|Control|Patients in the control arm will be treated with standard of care for post-PCI STEMI patients in accordance with the the 2004 ACC/AHA Guidelines for the Management of Patients with ST-elevation Myocardial Infarction.
3182734|NCT01319760|Experimental|Impella 2.5|Patients in this arm will be treated in accordance with standard of care, and in addition will receive 24 hours of support with the Impella 2.5 post-PCI for acute myocardial infarction.
3182735|NCT01319747|Active Comparator|Percutaneous therapy|
3182736|NCT01319747|Active Comparator|VATS therapy|
3182737|NCT01319734|Experimental|Vitamin C supplementation plus oral hypoglycemic agents arm|This group will receive vitamin C supplementation 500mg daily for one month and then assessment will done for the patients.
3182738|NCT01319734|Active Comparator|Type 2DM patients receiving oral hypoglycemic agents alone|this group is the control group who receive oral hypoglycemic agents alone
3182739|NCT01319721|Active Comparator|Group LCAG|After extensive excision of recurrent pterygium, intraoperative 0.2 mg/ml MMC (0.02%) for 3 minutes will be applied topically onto the exposed surgical area and then limbal conjunctival autograft for repairing the conjunctival defect.
3182740|NCT01319721|Active Comparator|Group AMG|After excision of recurrent pterygium, intraoperative 0.2 mg/ml MMC (0.02%) for 3 minutes will be applied topically onto the exposed surgical area and then an amniotic membrane graft for repairing the conjunctival defect.
3182741|NCT01319708|Experimental|mild ovarian stimulation|100 mg CC by day 2 till 6, plus antagonist plus gonadotrophin 150-200IO until HCG triggering
3182742|NCT01319708|Active Comparator|conventional ovarian stimulation|300-450 IU of FSH starting by day 2 of menstrual cycle together with a fixed dose of GnRH antagonist starting by day 6 till egg recovery, or same doses using a GnRH agonist long protocol
3182743|NCT01319695|Experimental|corifollitropin alfa|
3182744|NCT01319695|Active Comparator|recombinant follicle stimulating hormone (FSH)|150-300 IU of FSH for ovarian stimulation in women undergoing IVF
3182745|NCT01319682|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
3182746|NCT01319682|Placebo Comparator|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
3182747|NCT01319669|Experimental|Treatment group|rhTPO(recombinant human thrombopoietin) is given on the second, 4th and 9th day of the chemotherapy cycle in a dosage of 15000U once subcutaneously.
3182748|NCT01319669|Active Comparator|Control group|15000U of rhTPO(recombinant human thrombopoietin) is given subcutaneously 6 to 24 hours within the end of chemotherapy cycle, that is, the 8th day for 3 consecutive days (d9 to d11)
3182749|NCT01319656|Active Comparator|Group A|Intervention group(n = 163)
3182750|NCT01319656|Active Comparator|Group B|Delayed intervention (n = 163)
3182751|NCT01319656|No Intervention|Group C|No intervention group (n = 163)
3182752|NCT01319643|Experimental|Oxygenation, rigorous normal|Patients admitted in intensive care unit for 3 days. Administration of the lowest inspiratory fraction dose of oxygen to maintain oxygen peripheral saturation (SpO2) between 94 and 98% or an arterial partial pressure of oxygen (PaO2) between 70 and 100 mmHg. No oxygen addition administer for transports or diagnostic manoeuvres. Conventional clinical criteria for airways control and ventilation technique.
3182753|NCT01319643|No Intervention|Oxygen, free conventional|Patients admitted in intensive care units for 3 days. Administration of oxygen inspiratory fractions to maintain SpO2 over 97%, up to a PaO2 of 150 mmHg. Oxygen addition administer for transports or diagnostic manoeuvres. Conventional clinical criteria for airways control and ventilation technique.
3182754|NCT01319630||Normal Saline|patients with severe sepsis/septic shock randomized to receive 1500 cc of Normal saline bolus as the resuscitation fluid.
3182755|NCT01319630||Albumin|patients with severe sepsis/septic shock randomized to receive 500 cc of Albumin 5% bolus as the resuscitation fluid.
3182756|NCT01319630||HES|patients with severe sepsis/septic shock randomized to receive 500 cc of Hydroxyethyl starch (HES 130kD) bolus as the resuscitation fluid.
3182757|NCT01319617|Experimental|SENSIMED Triggerfish|
3182758|NCT01319604|Experimental|Study device during 3 hours|
3182759|NCT01319604|Experimental|Study device during 6 hours|
3182760|NCT01319604|Experimental|Study device during 9 hours|
3182761|NCT01319604|Experimental|Study device during 12 hours|
3182762|NCT01319604|Experimental|Study device during 15 hours|
3182763|NCT01319604|Experimental|Study device during 18 hours|
3182764|NCT01319604|Experimental|Study device during 21 hours|
3182765|NCT01319604|Experimental|Study device during 24 hours|
3182766|NCT01319604|Active Comparator|Tonometric assessment during 24 hours|
3182767|NCT01319591||CNS lymphoma patients|
3182768|NCT01319578|Active Comparator|Chewing Arm 1|
3182769|NCT01319578|Placebo Comparator|Chewing Arm 2|
3182770|NCT01319578|Active Comparator|Chewing Arm 3|
3182771|NCT01319578|Active Comparator|Chewing Arm 4|
3182772|NCT01319565|Experimental|Cohort 1/ACT|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young TIL + highdose aldesleukin
3182773|NCT01319565|Experimental|Cohort 2/ACT+TBI|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young TIL + highdose aldesleukin + TBI
3182774|NCT01319552|Other|Fresh transfusion|1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
3182775|NCT01319552|Experimental|Old transfusion|1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
3182776|NCT01319539|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy (therapeutic conventional surgery) on day 0. Patient samples will be processed for pharmacological study and laboratory biomarker analysis.
3182777|NCT01319513|Experimental|protein feeding|Participants will complete 2 trials in a cross-over fashion in which they will consume whey protein either as a single bolus or as 10 small divided doses
3182778|NCT01319500||Yasmin|"Users of the drospirenone/ethinylestradiol (DRSP/EE) containing OC Yasmin"
3182779|NCT01319500||Other OCs|"Users of OCs except Yasmin (Other OCs)"
3182780|NCT01319487|Experimental|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
3182781|NCT01319487|Experimental|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
3182782|NCT01319487|Placebo Comparator|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
3182783|NCT01319474|Other|Ultrasound for suspected DVT|Enrolled subjects suspected to have deep vein thrombosis undergo whole-leg compression ultrasound. Those with a normal result undergo clinical follow-up for thrombotic outcomes over the following three months.
3182784|NCT01319461|Placebo Comparator|sterile normal saline injection|
3182785|NCT01319461|Experimental|Hyalgan injection|
3182786|NCT01319448|Active Comparator|Daily proguanil|Standard policy of a supply of proguanil tablets to be taken daily
3182787|NCT01319448|Experimental|IPT with MQ+AS bimonthly|Intermittent Preventive Treatment (IPT) consisting of a bimonthly course of treatment with mefloquine-artesunate (MQ+AS)
3182788|NCT01319448|Experimental|IPT with SP+AQ bimonthly|IPT with bimonthly course of treatment with sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ)
3182789|NCT01319435|Other|Pharmacokinetics of ciprofloxacin|Patients receiving ciprofloxacin following clinical decision by attending physician
3182790|NCT01319422|Experimental|Pomalidomide 2 mg/d on 28 days/28 day cycle|
3182791|NCT01319422|Experimental|Pomalidomide 4 mg/d on 21 days/28 day cycle|
3182792|NCT01319409|Experimental|Anatomic Double-Bundle ACL Reconstruction|Subjects in this arm will undergo anatomic double-bundle ACL reconstruction using an autograft quadriceps tendon with a bone block. The graft will be split into 2 strands, 1 to recreate the posterolateral (PL) bundle, the other to recreate the anteromedial (AM) bundle of the ACL. The bone block will be placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft will be placed in tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle will be fixed with the knee in full extension and the AM bundle will be fixed with the knee at 45 degrees of flexion.
3182793|NCT01319409|Active Comparator|Anatomic Single-Bundle ACL Reconstruction|Subjects in this arm will undergo anatomic single-bundle ACL reconstruction using an autograft quadriceps tendon with a bone block. The graft will not be split. The bone block will be placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free end of the graft will be placed in single tunnel located in the center of the tibial ACL insertion site. The graft will be fixed with the knee at 10 20 20 degrees of flexion.
3182794|NCT01319383|Experimental|Open Label, Translational Research|Vorinostat will be administered to all eligible participants in each step of each phase (period) of the study
3182795|NCT01319370|Placebo Comparator|vehicle of 5% Minoxidl topical foam|vehicel foam in twice daily application in temple and vertex region
3182796|NCT01319370|Active Comparator|5% Minoxidil topical foam|5% Minoxidil topical in twice daily application in temple and vertex region
3182797|NCT01319357|Placebo Comparator|Placebo|Placebo
3182798|NCT01319357|Active Comparator|Saxagliptin|saxagliptin 5 mg/day during 6 weeks
3182799|NCT01319344|Experimental|Eplerenone|
3182800|NCT01319331|Experimental|Alpha-1 Antitrypsin (AAT, Aralast NP)|Alpha-1 Antitrypsin (AAT, Aralast NP) as prescribed for study duration
3182801|NCT01319318||Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
3182802|NCT01319305||BREATHE I participatants|
3182803|NCT01319292||Asthma children|children with asthma symptoms through screening
3182804|NCT01319292||normal children|children without symptoms of asthma
3182805|NCT01319279|Experimental|Normal Hepatic Function|Intervention Drug: Hydrocodone bitartrate extended-release tablet
3182806|NCT01319279|Experimental|Moderate Hepatic Impairment|Intervention Drug: Hydrocodone bitartrate extended-release tablet
3182807|NCT01319266|Experimental|Normal Renal Function|Subjects with normal renal function
3182808|NCT01319266|Experimental|Mild Renal Impairment|Subjects with mild renal impairment (defined by an estimated creatinine clearance of > 50 and up to 80 mL/min)
3182809|NCT01319266|Experimental|Moderate Renal Impairment|Subjects with moderate renal impairment (defined by an estimated creatinine clearance of 30-50 mL/min)
3182810|NCT01319266|Experimental|Severe Renal Impairment|Subjects with severe renal impairment (defined by an estimated creatinine clearance of less than 30 mL/min)
3182811|NCT01319266|Experimental|End Stage Renal Disease (ESRD)|Subjects with ESRD (defined as being on hemodialysis for at least 6 months prior to enrollment and be receiving standard in-center dialysis treatments three times a week)
3182812|NCT01319253||Cayston Only Cohort|This cohort will be on a previously established medication regiment of Cayston inhaled antibiotic alternating regimen every other month.
3182813|NCT01319253||Tobi Only Cohort|This Cohort will be on a previously established medication regiment that includes Tobi inhaled antibiotic regimen alternating every other month.
3182814|NCT01319253||Cayston and Tobi Cohort|This Cohort will be on a previously established medication regiment that includes Cayston and Tobi inhaled antibiotic alternating every other month
3182815|NCT01319240|Experimental|IDegLira|
3182816|NCT01319240|Active Comparator|IDeg|
3182817|NCT01319240|Active Comparator|Lira|
3182818|NCT01319227|Experimental|Hip Arthroplasty, ultra-short stem, conventional cup|Hip replacement with a hydroxy-apatite covered ultra-short uncemented femoral stem and a conventional uncemented acetabular cup with hydroxy-apatite covered porous coating and a moderately cross-linked polyethylene cup liner
3183183|NCT01316809|Experimental|A|Surgical arm
3182819|NCT01319227|Experimental|Hip Arthroplasty, conventional stem, trabecular-titanium cup|Hip replacement with an uncemented tapered femoral stem and an uncemented acetabular cup with trabecular-Titanium backside and E-vitamin-treated polyethylene cup liner
3182820|NCT01319214|Experimental|Inderal, neutral cues|
3182821|NCT01319214|Experimental|Inderal, drug cues|
3182822|NCT01319214|Experimental|Placebo, neutral cues|
3182823|NCT01319214|Experimental|Placebo, drug cues|
3182824|NCT01319201||Impaired glucose regulation|This group of subjects was diagnosed as impaired glucose regulation using oral glucose tolerance test.
3182825|NCT01319201||Type 2 diabetes|This group of subjects was diagnosed as type 2 diabetes using oral glucose tolerance test.
3182826|NCT01319201||Normal glucose regulation|This group of subjects was considered normal regarding glucose metabolism using oral glucose tolerance test.
3182827|NCT01319188|Active Comparator|0.5 mg of ranibizumab|
3182828|NCT01319188|Active Comparator|injection + photodynamic therapy|
3182829|NCT01319188|Sham Comparator|Sham injection|
3182830|NCT01319175|Experimental|Training group|
3182831|NCT01319162||Women with PCOS|All obese women between 18 and 50 years diagnosed with PCOS referred to a weight reduction treatment program at the Sahlgrenska Obesity Center at Sahlgrenska University hospital
3182832|NCT01319162||Women without PCOS|All obese women between 18 and 50 years not diagnosed with PCOS referred to a weight reduction treatment program at the Sahlgrenska Obesity Center at Sahlgrenska University hospital
3182833|NCT01319149||No treatment|Patient records would be extracted from the electronic health record system of Southwest Regional Wound Care Center and placed in a separate bin.
3182834|NCT01319123|Other|wound dressing|The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers.
3182835|NCT01319110|Experimental|CoenzymeQ10|Patients will receive CoenzymeQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
3182836|NCT01319110|Placebo Comparator|Placebo|Patients will receive 20 ml chocolate Ensure (as a placebo) three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). Placebo will be given through pre-existing NG or OG tube.
3182837|NCT01319097|Other|Sorbion Sachet S|Subject will evaluate Sorbion Sachet S dressing for 4 weeks.
3182838|NCT01319084||ARMES group|Surgeons who watch Tilepro program before da Vinci Robotic Surgery.
3182839|NCT01319084||normal group|Surgeons who do not watch Tilepro program before da Vinci Robotic Surgery.
3182840|NCT01319071||Top-level athletes|
3182841|NCT01319071||Control group|
3182842|NCT01319058|Active Comparator|Electrocautery tonsillectomy|Children undergoing tonsillectomy and adenoidectomy for obstructive sleep apnea
3182843|NCT01319058|Active Comparator|Debrider tonsillotomy|Children undergoing debrider tonsillotomy + adenoidectomy for obstructive sleep apnea.
3182844|NCT01319058|Active Comparator|Laser tonsillotomy|Children undergoing laser tonsillotomy + adenoidectomy for obstructive sleep apnea.
3182845|NCT01319045|Experimental|Iloprost|Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.
3182846|NCT01319032||I. Top-level swimmers|
3182847|NCT01319032||II. Control|Other swimmers
3182848|NCT01319019|Experimental|GSK961081 100 mcg QD|
3182849|NCT01319019|Experimental|GSK961081 100mcg BD|
3182850|NCT01319019|Experimental|GSK961081 200mcg QD|
3182851|NCT01319019|Experimental|GSK961081 400mcg QD|
3182852|NCT01319019|Experimental|GSK961081 400mcg BD|
3182853|NCT01319019|Experimental|GSK961081 800mcg QD|
3182854|NCT01319019|Active Comparator|Salmeterol 50mcg BD|
3182855|NCT01319019|Placebo Comparator|Placebo|
3182856|NCT01319006|Experimental|GSK1278863A 100mg (X90=13um)|single dose
3182857|NCT01319006|Experimental|GSK1278863A 100mg (x90=29Um)|single dose
3182858|NCT01319006|Experimental|GSK1278863 100mg (X90=41um)|single dose
3182859|NCT01318993|Experimental|GSK1605786A|500 milligrams twice daily
3182860|NCT01318980|Experimental|Period 1 Cohort 1 - GSK2190915 100mg|Period 1 - GSK2190915 100mg tablet.
3182861|NCT01318980|Experimental|Period 1 Cohort 2 - GSK2190915 100mg plus microtracer|Period 1 - GSK2190915 100mg tablet plus [14C] radiolabelled GSK2190915 microtracer solution.
3182862|NCT01318980|Experimental|Period 2 GSK2190915 100mg to proximal small bowel|100mg of ground half 200mg GSK2190915 tablet administered to the proximal small bowel via Enterion capsule.
3182863|NCT01318980|Experimental|Period 3 GSK2190915 100 mg to distal small bowel|100mg of ground half 200mg GSK2190915 tablet administered to the distal small bowel via Enterion capsule.
3182864|NCT01318980|Experimental|Period 4 - GSK 100mg enteric-coated tablet|100mg enteric-coated GSK2190915 coated tablet.
3182865|NCT01318967|Placebo Comparator|PAH|PAH measure of renal blood flow is first performed on subjects prior to administration of furosemide
3182866|NCT01318967|Active Comparator|MRI after furosemide|After the PAH measurement is complete, subjects receive 20 mg furosemide and undergo BOLD MRI to estimate renal blood flow
3182867|NCT01318954||Subjects on allergen immunotherapy|Measurements of Nitric Oxide by NIOX MINO. This device is now FDA approved.
3182868|NCT01318941||Ranibizumab|
3182869|NCT01318928|Placebo Comparator|Periodontal intervention, sugar pill|Group 1: metronidazole + mechanical treatment in one day, Group 2: Placebo + mechanical treatment in one day Group 3: metronidazole + mechanical treatment on day 1 and 21 Group 4: Placebo + mechanical treatment on day 1 and 21
3182870|NCT01318915|Experimental|Induction (Rituximab and ATG)|Study participants will undergo induction with rituximab and ATG and an initial maintenance therapy with tacrolimus, mycophenolate mofetil (MMF) and sirolimus. MMF will be discontinued on day 12. Participants will be evaluated for eligibility for tacrolimus withdrawal which must be initiated between weeks 26 and 38. Tacrolimus withdrawal must be completed in no fewer than 4 weeks and no more than 8 weeks. Then after at least 26 weeks on sirolimus monotherapy, participants will be evaluated for eligibility for sirolimus withdrawal which must be initiated between weeks 56 and 88. Sirolimus withdrawal must be completed in no fewer than 12 weeks and no more than 26 weeks.
3182871|NCT01318902|Experimental|MLN9708|
3182872|NCT01318889|Experimental|normal saline|mouth wash of normal saline ,three times a day, 10 cc each time
3182873|NCT01318876||BC Children's and Women's Hospital, Vancouver.|
3182874|NCT01318876||University of British Columbia, Vancouver.|
3182875|NCT01318876||Health care workers in Halifax|
3182876|NCT01318876||Health care workers from CHUQ hospitals|
3182877|NCT01318876||Health care workers from Toronto|
3182878|NCT01318876||Centre hospitalier et universitaire de Sherbrooke|
3182879|NCT01318876||The Ottawa General Hospital, Ottawa|
3182880|NCT01318850|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Therapy -Frontal/Executive Program (Delahunty)- (Wykes and Reeder, 2005)
3182881|NCT01318850|Active Comparator|Psychoeducation|Symptom Management Module from the University of California. Liberman & Kopelowicz (1995)
3182882|NCT01318850|Other|Healthy Controls|Healthy controls
3182883|NCT01318837|Experimental|sofilenacin group|
3182884|NCT01318837|No Intervention|control group|age and sex matched patients without OAB symptom who will answer demographic questionaire and OABSS once
3182885|NCT01318824|Placebo Comparator|I=NIPPV|This group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment.
3182886|NCT01318824|Experimental|II=BiPAP|This group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
3182887|NCT01318811|Active Comparator|Dilute heparin|Arm A will receive dilute heparin delivered as an intravenous infusion proximal to the dialysis filter.
3182888|NCT01318811|Active Comparator|Standard concentrated heparin|Arm B will receive standard concentrated heparin and will be delivered as an intravenous infusion proximal to the dialysis filter.
3182889|NCT01318798||Patients with post-operative ARF|"Patients developing acute renal failure (ARF) following liver surgery~ARF was defined according to the RIFLE criteria as an absolute increase in serum-creatinine of more than 0.3 mg/dl above baseline, or an increase of more than 1.5 times the pre-operative baseline value within 48 hours after surgery, or a reduction of urinary output less than 0.5 ml/kg/h for at least 6 hrs."
3182890|NCT01318798||Patients without post-operative ARF|Patients with normal kidney function (without acute renal failure (ARF)) following liver surgery
3182891|NCT01318785|Active Comparator|Compression ArmsleevesType A|Product A: armsleeves of type SoraLife KKl. 2 according to RAL GZ 387
3182892|NCT01318785|Active Comparator|Compression Armsleeves Type B|Product B: armsleeves of type Elvarex KKl. 2 according to RAL GZ 387
3182893|NCT01318772||Fluoroscopy and Angiography Procedure|Patient that have been scheduled for routine diagnostic fluoroscopy and angiography procedures by their physician.
3182894|NCT01318746||Healthy group|15 persons with normal renal function
3182895|NCT01318746||Renal failure|15 persons with renal failure (GFR < 60 ml/min)
3182896|NCT01318733|Experimental|CD07805/47 Gel 0.5%|
3182897|NCT01318720|Experimental|Manipulation|The experimental group is receiving thoracic spine thrust manipulation and cervical spine non-thrust manipulation.
3182898|NCT01318694|Experimental|Treatment Arm A|"Alisporivir (ALV) 600 mg twice daily (BID) with Peginterferon alfa-2a (PEG) and ribavirin (RBV) for 1 week, followed by an additional 23 or 47 weeks according to response-guided treatment duration (RGT):~Participants with a viral load below the level of detection (< LOD) at Week 4 stop study treatment after 24 weeks~Participants with a viral load ≥ LOD at Week 4 complete 48 weeks of study treatment"
3182899|NCT01318694|Experimental|Treatment Arm B|Alisporivir (ALV) 400 mg twice daily (BID) with PEG and RBV for 24 or 48 weeks according to response-guided treatment duration (RGT)
3182900|NCT01318694|Experimental|Treatment Arm C|Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg once daily (QD) for 47 weeks
3182901|NCT01318694|Active Comparator|Treatment Arm D|ALV Placebo with PEG and RBV for 48 weeks
3182902|NCT01318681|Experimental|Pollen provocation with systemic treatment|Subjects are treated with Cetirizine 10 mg after a nasal challenge with a pollen solution
3182903|NCT01318681|Experimental|Pollen provocation with topical treatment|treatment with 25ug fluticasone furoate after a nasal pollen challenge
3182904|NCT01318681|Placebo Comparator|placebo treatment after pollen challenge|Placebo treatment after a nasal challenge with pollen solution
3182905|NCT01318681|No Intervention|control condition|A placebo drug is administered after a sham nasal challenge with a pollen solution
3182906|NCT01318668|Experimental|Nicotine vaccination|18 week treatment with Nicvax
3182907|NCT01318655|Experimental|NKTR-118|
3182908|NCT01318655|Placebo Comparator|Placebo|
3182909|NCT01318642|Active Comparator|Placebo + Gemcitabine|Arm 2: AMG479-placebo IV days 1 and 15 plus gemcitabine 1000mg/m2 IV days 1, 8, and 15 of a 28 day cycle
3182910|NCT01318642|Experimental|AMG 479 20 mg/kg + Gemcitabine|ARM 1: AMG 479 20mg/kg IV days 1 and 15 plus gemcitabine 1000mg/m2 IV days 1, 8, and 15 of a 28 day cycle.
3182911|NCT01318616|Experimental|Training group|
3182912|NCT01318590|Experimental|Celiac bloc|
3182913|NCT01318590|Sham Comparator|Conservative treatment|
3182914|NCT01318564||Group 1: Unit-dose - Pill Bottle|Unit-dose (blister) packages used first week, followed second week by pill bottles usage.
3182915|NCT01318564||Group 2: Pill Bottle - Unit Dose|Pill bottle usage the first week followed second week by Unit-dose (blister) packages.
3182916|NCT01318551|Experimental|Arm 1|
3182917|NCT01318551|Experimental|Arm 2|
3182918|NCT01318551|Experimental|Arm 3|
3182919|NCT01318538|Experimental|Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
3182963|NCT01318252|Placebo Comparator|Vehicle|AL-54478 Vehicle, single dose, followed 7 days later with 14 days of once daily dosing
3182964|NCT01318239|Experimental|Standard Chemotherapy with Avastin|
3182920|NCT01318538|Active Comparator|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
3182921|NCT01318525|Experimental|ALF-5755|
3182922|NCT01318525|Placebo Comparator|Saline solution (0.9% NaCl)|
3182923|NCT01318512||Chronic Kidney Disease|Participants with CKD, not undergoing haemodialysis in clinical practice setting and started treatment with methoxy polyethylene glycol-epoetin beta (MIRCERA) subcutaneously (SC) as per summary of product characteristics (SPC) due to decreased levels of haemoglobin.
3182924|NCT01318499|Experimental|Nepafenac 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
3182925|NCT01318499|Active Comparator|Nepafenac 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
3182926|NCT01318499|Placebo Comparator|Nepafenac Vehicle 0.3%|Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
3182927|NCT01318486|Active Comparator|Heparin free dialysis standard of care|Standard of care: can be either saline flushes or predilution (on-line or bags)
3182928|NCT01318486|Experimental|Heparin free dialysis with Evodial|
3182929|NCT01318473|Other|ActiSight™ Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
3182930|NCT01318460|Active Comparator|Levosimendan|Patients treated with prophylactic administration of levosimendan
3182931|NCT01318460|Placebo Comparator|Placebo group|Patients managed with placebo administration
3182932|NCT01318447|Experimental|CyberKnife SBRT|
3182933|NCT01318434|Experimental|EB-1010 25 mg BID|Experimental Active
3182934|NCT01318434|Experimental|EB-1010 50 mg BID|Experimental Active
3182935|NCT01318434|Active Comparator|SSRI/SNRI|Active Comparator
3182936|NCT01318434|Placebo Comparator|EB-1010 0 mg BID|Placebo comparator
3182937|NCT01318421|Experimental|ELND002|ELND002 sc injection
3182938|NCT01318408|Experimental|Levetiracetam|Levetiracetam was titrated over 4 weeks, with initial dosing of 250 mg bis in die (BID). Dosing was flexible and was based on the prescribing physician's discretion.
3182939|NCT01318395|Active Comparator|Aliskiren|
3182940|NCT01318395|Placebo Comparator|Placebo|
3182941|NCT01318382|Experimental|TOF-Watch SX®|Participants who have undergone elective open or laparoscopic abdominal surgery, received general anesthesia, received at least one dose of non-depolarizing neuromuscular blocker and had the extent of their recovery from NMB monitored by a TOF-Watch SX®.
3182942|NCT01318369|Experimental|Namisol|Namisol (dronabinol) single dose 8 mg
3182943|NCT01318369|Active Comparator|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
3182944|NCT01318356|Experimental|Cognitive behavioral therapy|
3182945|NCT01318356|Experimental|Doxycycline|
3182946|NCT01318356|Placebo Comparator|Placebo|
3182947|NCT01318343||Treatment Group 1|Eight (8) subjects will receive one (1) treatment with the eZ8 Large Applicator.
3182948|NCT01318343||Treatment Group 2|Eight (8) subjects will receive two (2) treatments two (2) months apart with the eZ8 Large Applicator.
3182949|NCT01318343||Treatment Group 3|Four (4) subjects will receive one (1) treatment, six (6) months after the previous treatment with the eZ App 8 large applicator to the abdomen. This is the same applicator that is being evaluated in this study. These subjects have been treated on-site at the Laser & Skin Surgery Center of New York by the study doctor.
3182950|NCT01318317|Experimental|Treatment (cellular adoptive immunotherapy following PBSCT)|Patients receive standard salvage chemotherapy per standard practice and undergo standard mobilization for stem cell collection with Granulocyte-Colony Stimulating Factor (G-CSF) and/or plerixafor. Some patients may also receive rituximab IV within 4 weeks of transplantation. Patients receive standard myeloablative conditioning followed by autologous Peripheral Blood Stem Cell Transplant (PBSCT). Patients then undergo infusion of ex vivo expanded autologous central memory (TCM)-enriched CD8+ T cells expressing CD19-specific chimeric antigen receptor (CAR) on day 2 or 3 after transplantation.
3182951|NCT01318304||Pregnant, HIV- negative|This cohort has completed accrual as of 12/28/11.
3182952|NCT01318304||Pregnant, HIV-positive|
3182953|NCT01318304||Non-pregnant, HIV-negative|This cohort has completed accrual as of 12/28/11.
3182954|NCT01318304||Non-pregnant, HIV-positive|This cohort has completed accrual as of 12/28/11.
3182955|NCT01318291|Placebo Comparator|Control|
3182956|NCT01318291|Experimental|CCRI Group|
3182957|NCT01318278|Active Comparator|Dopamine treatment|Dopamine treatment beginning at 5 mcg/kg/min and titrated by 5 mcg/kg/min to effect up to maximum of 20 mcg/kg/min
3182958|NCT01318278|Active Comparator|Vasopressin treatment|Arginine Vasopressin treatment beginning at 0.01 units/kg/hr and titrated up by 0.01 units/kg/hr to effect up to a maximum of 0.04 units/kg/hr
3182959|NCT01318278|No Intervention|Comparison Arm|Infants who did not require vasopressor support for hypotension during the first 24 hours of life
3182960|NCT01318265|Experimental|Arm1|
3182961|NCT01318252|Experimental|AL-54478|AL-54478 0.005%, single dose, followed 7 days later with 14 days of once daily dosing
3182962|NCT01318252|Active Comparator|Latanoprost|Latanoprost 0.005%, single dose, followed 7 days later with 14 days of once daily dosing
3182965|NCT01318239|Active Comparator|Standard Chemotherapy only|
3182966|NCT01318226|Placebo Comparator|Placebo|Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
3182967|NCT01318226|Experimental|ATx08-001 2.5 mg bid|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg, twice a day approximately every 12 hours over an 8 day period.
3182968|NCT01318226|Experimental|ATx08-001 7.5 mg bid|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
3182969|NCT01318213||Intervention Arm|The intervention will consist of wearing gloves and gowns for all patient contact in the ICUs that are randomized to receive the intervention. During the intervention phases of the study, all healthcare workers (nurses, physicians, nurse extenders, respiratory therapists, social workers etc.) in the intervention group will be required to wear gloves and gowns for patient contact and when entering any patient room. In essence, healthcare workers will apply the CDC Contact Precautions guidelines for ALL patients.
3182970|NCT01318213||Non-intervention - Usual Standard of Care|The non-intervention units will follow their present standard of care. For all of these units, this will consist of healthcare workers following Contact Precautions (gloves and gowns) only for patients known to have antibiotic-resistant bacteria such as VRE and MRSA based on previous admission clinical and surveillance cultures or clinical cultures from the present admission. This represents on average 20-25% of patients on Contact Precautions. For the rest of the patients standard precautions will be followed.
3182971|NCT01318200|Active Comparator|Transarterial Chemoembolization|
3182972|NCT01318200|Active Comparator|CyberKnife SBRT|
3182973|NCT01318187|Experimental|Paracetamol|
3182974|NCT01318187|Active Comparator|Morphine|
3182975|NCT01318161|Experimental|Epidural anesthesia and analgesia|
3182976|NCT01318161|Active Comparator|Patient controlled analgesia|
3182977|NCT01318148|Experimental|Caspofungin|
3182978|NCT01318135|Active Comparator|Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID|
3182979|NCT01318135|Active Comparator|Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID|
3182980|NCT01318135|Active Comparator|Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID|
3182981|NCT01318135|Active Comparator|Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID|
3182982|NCT01318122|Active Comparator|Alogliptin 12.5 mg QD and Pioglitazone 15 or 30 mg QD|
3182983|NCT01318122|Active Comparator|Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD|
3182984|NCT01318109|Active Comparator|Alogliptin 12.5 mg QD and metformin 500mg BID or 750mg TID|
3182985|NCT01318109|Active Comparator|Alogliptin 25mg QD and metformin 500mg BID or 750mg TID|
3182986|NCT01318109|Active Comparator|Metformin 500mg BID or 750mg TID|
3182987|NCT01318096|Experimental|A:Raltegravir + tenofovir+lamivudine|
3182988|NCT01318096|Active Comparator|B:Efavirenz+tenofovir+lamivudine|
3182989|NCT01318083|Active Comparator|Alogliptin 12.5 mg QD and Glimepiride QD or BID|
3182990|NCT01318083|Active Comparator|Alogliptin 25 mg QD and Glimepiride QD or BID|
3182991|NCT01318083|Active Comparator|Glimepiride 1, 2, 3 or 4 mg QD or BID|
3182992|NCT01318070|Experimental|Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD|
3182993|NCT01318070|Experimental|Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD|
3182994|NCT01318070|Active Comparator|Pioglitazone (15mg or 30mg ) QD|
3182995|NCT01318057||Wild-Type|Wild-Type are those individuals who were non-carriers of any functional (loss-of-function)variant in CYP2C9 and/or VKORC1 genes
3182996|NCT01318057||Carriers|Those patients who were identified as having any functional CYP2C9 and/or VKORC1 polymorphism
3182997|NCT01318044|Active Comparator|Propofol group: propofol|
3182998|NCT01318044|Active Comparator|Thiopental group: thiopental|
3182999|NCT01318031|Experimental|DDI|
3183000|NCT01318018||Magnetic Seizure Therapy Group|Patients receiving magnetic seizure therapy for depression
3183001|NCT01318018||Electroconvulsive Therapy Group|Patients receiving electroconvulsive therapy for depression
3183002|NCT01318005|Active Comparator|Ortho-Novum® 1/35|Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.
3183003|NCT01318005|Active Comparator|Ovcon® 35|Ovcon® 35 is an oral contraceptive that contains less progestin.
3183004|NCT01318005|Active Comparator|Microgestin Fe® 1/20|is an oral contraceptive that contains less estrogen.
3183005|NCT01317992|Experimental|Ibudilast|To receive ibudilast 40mg twice daily for 8 weeks.
3183006|NCT01317992|Placebo Comparator|Placebo|To receive placebo twice daily for 8 weeks.
3183007|NCT01317979||Diabetes group I|metabolic surgery, laparoscopicly
3183008|NCT01317966||rhIL-11Combinating Low-dose Rituximab|"rhIL-11 (interleukin-11, Juheli) 50 mcg/kg subcutaneously daily for 14 days~Rituximab 100mcg weekly for 4 weeks"
3183009|NCT01317940|Experimental|Group A (Newly Diagnosed Subjects)|
3183010|NCT01317940|No Intervention|Standard of Care Group A|
3183011|NCT01317940|Experimental|Group B (Early Survivors)|
3183012|NCT01317940|No Intervention|Observation Only - Group B|
3183013|NCT01317940|No Intervention|Group C (Siblings of Group A)|
3183014|NCT01317927|Experimental|Warfarin, Belinostat|Warfarin 5 mg po will be given on Day -14 and Day 3. Belinostat 1000 mg/m² will be given as a 30 minute IV infusion on Days 1 - 5
3183015|NCT01317914|Experimental|Dietary instruction on Gluten Free Diet|
3183016|NCT01317901|Experimental|TRU-016+bendamustine+rituximab|Two dose levels (10 and 20 mg/kg) of TRU 016 combined with rituximab 375 mg/m2 and bendamustine 90 mg/m2 were evaluated during up to 6 cycles (28 days each). TRU-016 was administered by intravenous (IV) infusion on Days 1 and 15 of each cycle. Rituximab was administered by IV infusion on Day 2 of each cycle. Bendamustine was administered by IV infusion on Days 1 and 2 of each cycle. Subjects received study treatment for up to 6 cycles.
3183017|NCT01317888|Experimental|Treated with MAB-425|All patients receive the same treatment of MAb-425 +Iodine 125 in a total of three injections.
3183018|NCT01317875|Experimental|Ruxolitinib|
3183019|NCT01317862|Active Comparator|Transcervical foley catheter|
3183020|NCT01317862|Active Comparator|Prostaglandins|
3183026|NCT01317810||Subjects with Overactive Bladder (OAB)|Combination of new OAB subjects and existing subjects on OAB medication
3183027|NCT01317797|Experimental|Namilumab 150 mg|Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.
3183028|NCT01317797|Experimental|Namilumab 300 mg|Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.
3183029|NCT01317797|Placebo Comparator|Placebo|Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.
3183030|NCT01317784|Experimental|All tests.|Choose from all 16 possible tests.
3183031|NCT01317784|Active Comparator|HIV/HCV|Choice of 10 different HIV and hepatitis C tests in the bundle.
3183032|NCT01317784|Active Comparator|HIV/Syphilis|Choice of 7 different tests for HIV and syphilis.
3183033|NCT01317784|Active Comparator|HIV only|Choice of 4 rapid tests for HIV only.
3183034|NCT01317771||Proximal Biceps Tendon Tenodesis|
3183035|NCT01317758|Placebo Comparator|Group 6|Two doses of sanofi H5N1 antigen 15 mcg plus PBS diluent
3183036|NCT01317758|Placebo Comparator|Group 5|Two doses of sanofi H5N1 antigen 7.5 mcg plus PBS diluent
3183037|NCT01317758|Placebo Comparator|Group 4|Two doses of sanofi H5N1 antigen 3.75 mcg plus Phosphate Buffered Saline (PBS) diluent
3183038|NCT01317758|Experimental|Group 3|Two doses of sanofi H5N1 antigen 15 mcg plus GSK AS03 adjuvant
3183039|NCT01317758|Experimental|Group 1|Two doses of sanofi H5N1 antigen 3.75 mcg plus GSK AS03 adjuvant
3183040|NCT01317758|Experimental|Group 2|Two doses of sanofi H5N1 antigen 7.5 mcg plus GSK AS03 adjuvant
3183041|NCT01317745|Placebo Comparator|Group 5|Two doses of sanofi H5N1 antigen 7.5 mcg plus PBS diluent
3183042|NCT01317745|Placebo Comparator|Group 4|Two doses of sanofi H5N1 antigen 3.75 mcg plus Phosphate Buffered Saline (PBS) diluent
3183043|NCT01317745|Experimental|Group 3|Two doses of sanofi H5N1 antigen 15 mcg plus Novartis MF59 adjuvant
3183044|NCT01317745|Experimental|Group 2|Two doses of sanofi H5N1 antigen 7.5 mcg plus Novartis MF59 adjuvant
3183045|NCT01317745|Experimental|Group 1|Two doses of sanofi H5N1 antigen 3.75 mcg plus Novartis MF59 adjuvant
3183046|NCT01317745|Placebo Comparator|Group 6|Two doses of sanofi H5N1 antigen 15 mcg plus PBS diluent
3183047|NCT01317732|Experimental|MOTIONPOD (TM)|
3183048|NCT01317719||Distal Biceps Ruptures|
3183049|NCT01317706|Active Comparator|Bishop score|
3183050|NCT01317706|Active Comparator|transvaginal ultrasound|
3183051|NCT01317693|Experimental|Treatment LI-ESWT|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
3183052|NCT01317680|Active Comparator|Treatment LI-ESWT|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
3183053|NCT01317680|Placebo Comparator|Sham control|We use the same probe that induces the same sensation on the penis and the same noise yet no energy.
3183054|NCT01317667|Experimental|Group 1|RVEc vaccine 20 μg/dose x 3 doses
3183055|NCT01317667|Experimental|Group 2|RVEc vaccine 50 μg/dose x 3 doses
3183056|NCT01317667|Experimental|Group 3|RVEc vaccine 100 μg/dose x 1 dose
3183057|NCT01317654||Survivors of TBM trial 2001-2005|
3183058|NCT01317641|Experimental|ODM-201 Phase I|
3183059|NCT01317641|Experimental|ODM-201 Phase II Dose 1|
3183060|NCT01317641|Experimental|ODM-201 Phase II Dose 2|
3183061|NCT01317641|Experimental|ODM-201 Phase II Dose 3|
3183062|NCT01317628|Other|Lifestyle counseling|Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.
3183063|NCT01317615|Experimental|RAD001 plus paclitaxel/carboplatin|Participants received RAD001 5 mg orally once daily in combination with carboplatin and paclitaxel for a maximum 4 cycles or until discontinuation.
3183064|NCT01317589|Active Comparator|fentanyl|active pain treatment with fentanyl patch
3183065|NCT01317589|Experimental|methadone|active pain treatment with methadone
3183066|NCT01317576|Experimental|Healthy control|This group will exist of healthy obese that are matched for BMI and age with the type 2 diabetes group and non-alcoholic fatty liver disease group.
3183067|NCT01317576|Experimental|Non-alcoholic fatty liver disease|This group will exist of people that suffer from non-alcoholic fatty liver disease. They will be matched for BMI and age according to the Type 2 diabetes group
3183068|NCT01317576|Experimental|Type 2 diabetes patients|This group will exist of patients that suffer from type 2 diabetes
3183069|NCT01317563|Active Comparator|Antioxidant arm|Two capsules twice daily (total daily dose = Vitamin A 10000 IU, Vitamin C 1200mg, Vitamin E 400 IU, Selenium 300mcg)
3183070|NCT01317563|Placebo Comparator|Placebo arm|two capsules twice daily (total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose)
3183071|NCT01317550|Experimental|Armodafinil + Placebo|Armodafinil orally 150 mg/day + Placebo capsules for 10 weeks
3183072|NCT01317550|Experimental|Minocycline + Placebo|Minocycline orally 100 mg twice/day + Placebo capsules for 10 weeks
3183073|NCT01317550|Experimental|Armodafinil + Minocycline|Armodafinil orally 150 mg/day for 10 weeks + Minocycline orally 100 mg twice/day for 10 weeks
3183074|NCT01317550|Placebo Comparator|Placebos|Placebo Capsules orally once/day for 10 weeks
3183075|NCT01317537|Experimental|Received personal health record|received personal health record access
3183076|NCT01317537|No Intervention|No personal health record|did not receive personal health record
3183077|NCT01317524|Experimental|Homogenized Milk|900 mL homogenized milk is consumed within a mixed meal
3183078|NCT01317524|Experimental|Unhomogenized Milk|900 mL unhomogenized milk is consumed within a mixed meal
3183079|NCT01317524|Experimental|Skimmed Milk|900 mL skimmed milk and 44 g of butter are consumed within a mixed meal
3183082|NCT01317498|Placebo Comparator|Standard Monitoring|The patients in the standard monitoring arm will receive routine laboratory monitoring as provided to all patients in public HIV clinics in Vietnam, including CD4 count, complete blood count, and liver functions tests every 6 months.
3183083|NCT01317498|Active Comparator|Virological Monitoring|The patients in the virological monitoring arm will have routine laboratory monitoring as in the standard monitoring arm and in addition will have a viral load test performed every 6 months while in treatment. The first test will be done 6 months after initiating ART.
3183084|NCT01317485|Experimental|Purulent peritonitis|"Patients with purulent peritonitis are randomised at a 2:1:1 ratio between~Laparoscopic lavage and drainage~Sigmoidectomy with primary anastomosis~Sigmoidectomy with end-colostomy"
3183085|NCT01317485|Experimental|Fecal peritonitis or overt perforation|"Patients with fecal peritonitis or an overt perforation are randomised between~Sigmoidectomy with primary anastomosis~Sigmoidectomy with end-colostomy"
3183086|NCT01317472|Experimental|Dexlansoprazole|Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC).
3183087|NCT01317472|Placebo Comparator|Sugar pill|Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC) or 1 tablet of placebo QAM (1 hour AC).
3183088|NCT01317459|Experimental|Lifestyle counselling|
3183089|NCT01317459|Experimental|No intervention|Care as usual
3183090|NCT01317446|Experimental|amine fluoride/stannous fluoride|Amine fluoride/stannous fluoride mouthrinse in addition to mechanical oral hygiene
3183091|NCT01317446|No Intervention|No rinsing|Mechanical oral hygiene only
3183092|NCT01317433|Experimental|Arm A|Intensified FOLFIRI plus Cetuximab + Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks + skin moisturizers (Dexeryl), sun protection.
3183093|NCT01317433|No Intervention|Arm B|Intensified FOLFIRI plus Cetuximab + skin moisturizers (Dexeryl), sun protection.
3183094|NCT01317420|Experimental|Monotherapy|BI 836845 dose escalation, infusion, once every three weeks, monotherapy
3183095|NCT01317381||ICU patients|Admitted patients to the ICU
3183096|NCT01317368|Active Comparator|TAP block|"TAP block with Ropivacaine~Wound infiltration with Saline"
3183097|NCT01317368|Active Comparator|Wound infiltration|"TAP block with Saline.~Wound infiltration with Ropivacaine."
3183098|NCT01317368|Placebo Comparator|Placebo|"TAP block with Saline.~Wound infiltration with Saline."
3183099|NCT01317355||cancer patients|in and out patients of 5 German university hospitals currently undergoing cancer treatment
3183100|NCT01317342|Active Comparator|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 1 hour
3183101|NCT01317342|No Intervention|Control group: no intervention|Conventional cold storage (IGL-1)
3183102|NCT01317329|Other|Clinically prescribed CPAP therapy|Clinically prescribed CPAP therapy
3183103|NCT01317303|Experimental|PAS25|PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
3183104|NCT01317303|Experimental|cTBS-PAS|40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
3183105|NCT01317303|Experimental|iTBS|190 seconds of intermittent theta-burst stimulation
3183106|NCT01317303|Experimental|cTBS-iTBS|40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation
3183107|NCT01317290|Experimental|linseed oil; young|ALA rich linseed oil to younger subjects (18-35 years)
3183108|NCT01317290|Experimental|linseed oil; older|ALA rich linseed oil to older, normalweight subjects (BMI <25, age 49-69 years)
3183109|NCT01317290|Experimental|linseed oil older, overweight|ALA-rich linseed oil to older, normalweight subjects (BMI >25, age 49-69 years)
3183110|NCT01317290|Experimental|olive oil|n3-PUFA free control oil to normalweight subjects (BMI <25)
3183111|NCT01317277|Experimental|Texting + Psychoeducation|Participants in the individualized Texting for Adherence Building (iTAB) arm will receive daily text messaging reminders for antiretroviral medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Participants will also receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV medications.
3183112|NCT01317277|Active Comparator|Psychoeducation|Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV medications. They will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.
3183113|NCT01317264|Placebo Comparator|Placebo milk drink|
3183114|NCT01317264|Experimental|Millk drink with oat β-glucan|
3183115|NCT01317264|Experimental|Milk drink with barley β-glucan|
3183116|NCT01317264|Experimental|Milk drink with mutant-barley β-glucan|
3183117|NCT01317251|Experimental|Control diet|Diet without dairy products
3183118|NCT01317251|Experimental|Milk diet|Diet with a high content of milk
3183119|NCT01317251|Experimental|Cheese diet|Diet with a high content of cheese
3183120|NCT01317238|Experimental|CJ Vaccination arm|healthy vaccinia-experienced volunteers who received CJ smallpox vaccine
3183121|NCT01317225|Experimental|17 α hydroxyprogesterone caproate|17α-Hydroxyprogesterone caproate.
3183122|NCT01317225|Placebo Comparator|Placebo|Saline solution.
3183123|NCT01317199|Experimental|Phase 1: Dose-escalation of Muscadine Plus Grape Skin Extract|Muscadine Plus Grape Skin Extract (MPX): Phase I Dose-escalation starts at 500mg daily for 1 cycle (28 days), then increased to 1000mg for 2nd cycle, then increased to 2000mg daily for 3rd cycle, then increased to 3000mg daily for 4th cycle, then increased to maximum dose of 4000mg daily for final cycle. Pills given by mouth once daily for 28 days per cycle.
3183124|NCT01317199|Placebo Comparator|Phase 2: Placebo control|Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
3183125|NCT01317199|Experimental|Phase 2: Low-dose MPX|Randomly-assigned participants receive low-dose (500mg) MPX
3183126|NCT01317199|Experimental|Phase 2: High-dose MPX|Randomly-assigned participants receive high-dose (4000mg) MPX
3183127|NCT01317186||Group I|Stage 2 Non-diabetic Chronic Kidney Disease
3183130|NCT01317173||Progressive disease|Serum creatinin level rise more than 2 times
3183131|NCT01317173||Non-progressive disease|Serum creatinin level rise less than 2 times
3183132|NCT01317160|No Intervention|Routine care: Plaster Cast Treatment|Two weeks of postoperative conventional lower limb plaster cast immobilization in 30 degrees of plantarflexion
3183133|NCT01317160|Experimental|Intermittent pneumatic compression (IPC)|Two weeks of calf IPC by Aircast® VenaFlow® Elite System during immobilization in an orthosis Aicast® XP Walker.
3183134|NCT01317147||Gastric bypass patients|
3183135|NCT01317134|Active Comparator|Therapy-naive|"This group consists of patients with a newly diagnosed PH (Class I or IV). First blood sampling takes place before initiation of PH therapy (0 months), the following measurements will be performed after 3, 6, 9 and 12 months under specific therapy.~Initiation of standard therapy is performed directly after baseline visit / study inclusion. No special study medication will be used.~Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood Test"
3183136|NCT01317134|Active Comparator|Under therapy|"This group consists of patients under ERA monotherapy at timepoint of inclusion. Observation period is one year to detect intraindividual changes in endothelial dysfunction measured by L-arginine/NO-metabolites after 0, 3, 6, 9 and 12 months under investigation.~Specific PAH therapy has been started prior to the study for medical reasons and will be continued throughout.~Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood"
3183137|NCT01317134|Active Comparator|Healthy controls|This group consists of healthy individuals. Sex and age matching is intended. Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood
3183138|NCT01317121||Subjects at risk for psychosis|Identification and clinical characterization of subjects with prodromal symptoms will be done in the early diagnosis outpatient center of the University Department of Psychiatry in Hamburg, Germany. Subjects At Risk Mental State (ARMS) for psychosis will be identified if they meet the criteria of the Structured Interview for Prodromal Syndromes (SIPS) (McGlashan et al 2001).
3183139|NCT01317121||Patients with a first episode of schizophrenia|Patients with a first episode of schizophrenia will be recruited from inpatients at the Clinic for Psychiatry and Psychotherapy at the University Hospital (UKE) in Hamburg, Germany. All patients have to meet criteria for DSM-IV and ICD-10 diagnosis for schizophrenia.
3183140|NCT01317121||Healthy control subjects|Healthy control subjects will be recruited from the hospital staff and students at the University Hospital Hamburg-Eppendorf (UKE), Hamburg, Germany. They have to be free from any neurological or psychiatric disorder, according to DSM-IV and ICD-10 criteria.
3183141|NCT01317108|No Intervention|A|Low uPA/PAI-1: Observation
3183142|NCT01317108|No Intervention|B2|High uPA/PAI-1: Observation
3183143|NCT01317108|No Intervention|B3|High uPA/PAI-1: refused randomization
3183144|NCT01317108|Active Comparator|B1|High uPA/PAi-1: CMF chemotherapy
3183145|NCT01317095|Active Comparator|Wire closure is the intervention|Patients will have their sternum closed using stainless steel wires.
3183146|NCT01317095|Active Comparator|Rigid fixation|Patients will have their sternum closed by rigid fixation using Starnalock plates.
3183147|NCT01317069|Experimental|Fluorouracil implant|
3183148|NCT01317030|Experimental|Contact Lens Wear|Senofilcon A Lenses, using Sensitive Eyes Saline Solution and/or Biotrue Multipurpose Solution
3183149|NCT01317030|Placebo Comparator|Non-Contact Lens Wear|
3183150|NCT01317004|Experimental|Fingolimod|Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period.
3183151|NCT01317004|Active Comparator|Multiple Sclerosis Disease Modifying Treatment (MS DMT)|Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months.
3183152|NCT01316991|Active Comparator|Chewing gum|Subject will chew gum at defined intervals
3183153|NCT01316991|Placebo Comparator|No Gum|No chewing gum will be provided to subject
3183154|NCT01316978|Experimental|Experimental|Experimental Ibuprofen
3183155|NCT01316978|Active Comparator|Nurofen|Nurofen Meltlets Orodispersible Tablet
3183156|NCT01316978|Active Comparator|Motrin|Junior Strength Motrin Chewable Tablet
3183157|NCT01316965|Experimental|multifaceted prevention program|
3183158|NCT01316965|No Intervention|usual care|
3183159|NCT01316952||LabRx database Oct. 1st 2004 to Sep. 30th 2009|The study cohort from which cases and controls are drawn is all subjects in the LabRx database between Oct. 1st 2004 to Sep. 30th 2009.
3183160|NCT01316939|Placebo Comparator|Placebo|Placebo
3183161|NCT01316939|Experimental|GSK1605786A once daily|500 milligrams once daily
3183162|NCT01316939|Experimental|GSK1605786A twice daily|500 milligrams twice daily
3183163|NCT01316926|Active Comparator|Paxil CR Reference|Reference drug administration followed by test drug administration
3183164|NCT01316926|Active Comparator|Paxil CR Test|Test drug administration followed by Reference drug administration
3183165|NCT01316913|Experimental|GSK573719/GW642444 125/25|125/25 mcg once-daily
3183166|NCT01316913|Experimental|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
3183167|NCT01316913|Experimental|GSK573719|125 mcg once-daily
3183168|NCT01316913|Active Comparator|tiotropium bromide|18 mcg once-daily
3183169|NCT01316900|Experimental|GSK573719/GW642444 125/25|125/25 mcg once-daily
3183170|NCT01316900|Experimental|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
3183171|NCT01316900|Experimental|GW642444|25 mcg once-daily
3183172|NCT01316900|Active Comparator|tiotropium bromide|18 mcg once-daily
3183173|NCT01316887|Experimental|GSK573719/GW642444|125/25 mcg once-daily
3183174|NCT01316887|Experimental|GSK573719|125 mcg once-daily
3183175|NCT01316887|Placebo Comparator|Placebo|inactive
3183176|NCT01316874|Experimental|AD32 (valrubicin)|800mg, once weekly for 6 weeks
3183177|NCT01316861|Experimental|EMS Acarbose|
3183178|NCT01316861|Active Comparator|Bayer Acarbose|
3183179|NCT01316848|Experimental|Fasted dosing followed by fed dosing|Dosing in the fasted state followed by fed dosing
3183180|NCT01316848|Experimental|Fed dosing followed by fasted dosing|Dosing in the fed state followed by fasted dosing
3183181|NCT01316835||Type 2 Diabetes Mellitus, No treatment|
3183182|NCT01316822|Experimental|ARRY-382|
3183184|NCT01316809|Experimental|B|Non-surgical arm
3183185|NCT01316757|Experimental|Treatment|Patients receive cetuximab IV over 60 minutes, paclitaxel IV over 1 hour, and carboplatin IV over 30 minutes on day 1. Beginning in course 2, patients also receive erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3183186|NCT01316731|Experimental|Exercise|
3183187|NCT01316718|Experimental|Mesalazine Granules|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
3183188|NCT01316718|Placebo Comparator|Placebo Granules|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
3183189|NCT01316692|Experimental|MLN8237|Patients receive oral Aurora A kinase inhibitor MLN8237 every 12 hours on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3183190|NCT01316679||group A|Patients with known HCC
3183191|NCT01316679||Group B|Patients with liver disease but no HCC
3183192|NCT01316679||Group C|Control; patients with no known liver disease or HCC
3183193|NCT01316666||Neurogenic Hypotension|Patients with neurogenic hypotension, which includes those with Pure Autonomic Failure (PAF), Multiple System Atrophy (MSA) and Parkinson Disease (PD)
3183194|NCT01316653|Active Comparator|GROW Smarter|Library based program to promote early literacy
3183195|NCT01316653|Experimental|GROW Healthier|Healthy lifestyle intervention focused on building healthy lifestyle skills for preschool children and participating parents and building new social networks between the intervention group members.
3183196|NCT01316627|Experimental|Crooked Mirror Externalization Therapy|"Of recent, the crooked mirror externalization therapy, developed by Dr. Eda Gorbis, has been put to use with much success (Gorbis 2004). This method involves the use of crooked or fun house mirrors made from highly reflective surfaces that can be bent in different directions, which distort and exaggerate the patient's perceived defects (Gorbis 2005). In turn, this process externalizes or reverses the patient's internalized distorted body image, and allows the patient to habituate to the reflection of the imagined defect that is even more distorted than the internalized image (Rosen et al. 1995)."
3183197|NCT01316627|Active Comparator|Mirror Retraining Method|"In treating BDD, the cognitive-behavioral technique, mirror retraining, uses ordinary and/or magnifying mirrors to amplify the supposed defect, which teaches patients to see their appearance in a more holistic way. Since BDD patients tend to only focus on their perceived flaws when looking in the mirror, and tend to think about their flaws in negative terms, in mirror retraining, patients learn how to change their negative evaluations of their appearance into more objective and nonjudgmental descriptions. Generally, this method is designed to intentionally exaggerate anxiety regarding appearance concerns through exposures with mirrors. However, using exclusively ordinary and/or magnifying mirrors does not address the internal distorted image that many patients with BDD experience (Rosen et al. 1995, Osman et al. 2004, Veale 2004)."
3183198|NCT01316614|Experimental|With Stylet & Without Stylet|There will only be one arm in this study. This arm will undergo EUS-guided FNA with the use of a stylet for half of their FNA passes and without a stylet for the other half. Patients will be exposed to an equal number of passes with and without a stylet. Each pass will be individually assessed by a skilled cytopathologist who is blinded to the technique used. We will compare the adequacy of both techniques to determine whether or not a stylet leads to a higher diagnostic accuracy rate in patients with solid lesions.
3183199|NCT01316588|Experimental|Plastic adesive drape|Intraoperative: Plastic adhesive drape on the chest and bare skin on the leg
3183200|NCT01316588|Experimental|Microbial Sealant|Intraoperative: Microbial Sealant on the leg and bare skin on the chest
3183201|NCT01316575|Experimental|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
3183202|NCT01316575|Active Comparator|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
3183203|NCT01316562||Group 1|Healthy controls
3183204|NCT01316562||Group 2|Patients with an Alzheimer's disease or related disorders
3183205|NCT01316536|Experimental|With Music|This randomized group will receive music
3183206|NCT01316536|Placebo Comparator|Control Arm|Will not receive music but will receive audio loop of recorded ICU sounds
3183207|NCT01316523|Experimental|Lenalidomide + Rituximab|Patients will receive lenalidomide 20 mg daily (oral), on days 1-21 of a 28 day cycle. Rituximab 375 mg/m2 (into the vein) will be administered weekly for 4 doses starting day 15 of cycle 1, to be repeated if patient does not achieve a complete response after cycle 4, on days 1, 8, 15 and 22 of cycle 5.
3183208|NCT01316510|Active Comparator|Bifidobacteria infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge (whichever happens first)
3183209|NCT01316510|Placebo Comparator|Placebo|A dilute formulation of the elemental formula Nutramigen (diluted to look like the probiotic arm).
3183210|NCT01316497|Experimental|Remote ischemic preconditioning (RIPC)|See intervention description
3183211|NCT01316497|Placebo Comparator|Control|
3183212|NCT01316484||No Treatment|Adult subjects with diabetes mellitus and a diagnosis of gastroparesis
3183213|NCT01316471|Experimental|Online Behavioral Intervention|In addition to standard medical care, children and parents in the online behavioral intervention will receive access to the full web-based program including education about chronic pain, training in behavioral and cognitive coping skills, instruction in increasing activity participation, and education about pain behaviors and parental operant strategies using an engaging, interactive format on the Internet.
3183214|NCT01316471|Active Comparator|Online Patient Education|The Online Patient Education group will serve as an attention control condition. In addition to standard medical care, children and parents will be provided with access to a modified version of the study website that will provide information from publicly available educational websites about pediatric chronic pain management.
3183215|NCT01316458|Experimental|imatinib mesylate|
3183216|NCT01316445|Experimental|nasal Midazolam|3 mg of the standard IV solution of midazolam (5 mg/mL) was given via a metered-dose nasal sprayer (6 sprays × 0.1 ml/spray, or 6 × 0.5 mg/spray) divided between the two nostrils within 1-2 min. During the EEG, vital signs (blood oxygen saturation, blood pressure, pulse and respiratory rate) were monitored and a nurse and a physician were available at all times. Subjects were monitored for 2 hours after administration of midazolam to ensure adequate recovery from sedation.
3183217|NCT01316432|Experimental|SQ Bolus Cenderitide|
3183218|NCT01316432|Experimental|SQ Infusion Cenderitide|24 hour SQ infusion of cenderitide
3183219|NCT01316432|Placebo Comparator|Placebo|24 hrs of SQ placebo infusion
3183220|NCT01316419||Patients with essential hypertension|
3183221|NCT01316406|Experimental|ATH008 cream 3%|ATH008 cream 3%
3183222|NCT01316406|Experimental|ATH008 cream 8%|ATH008 cream 8%
3183223|NCT01316406|Placebo Comparator|ATH008 cream placebo|ATH008 cream placebo
3183224|NCT01316393|Experimental|XER2020|mucoprotective product
3183225|NCT01316393|Active Comparator|Saliva Natura|salivary substitute
3183226|NCT01316393|Placebo Comparator|XER2020 placebo|
3183227|NCT01316380|Experimental|tiotropium 5 mcg|once daily delivered via Respimat inhaler
3183228|NCT01316380|Experimental|tiotropium 2.5 mcg|once daily delivered via Respimat inhaler
3183229|NCT01316380|Placebo Comparator|placebo|once daily delivered via Respimat inhaler
3183230|NCT01316367|Active Comparator|Conventional Health Promotion Education (CHPE).|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
3183231|NCT01316367|Experimental|PRECEDE HPE model|
3183232|NCT01316354|Experimental|Beta-glucan|Bread with purified beta-glucan
3183233|NCT01316354|Experimental|Rye kernels|Rye bread with kernels
3183234|NCT01316354|Experimental|White bread|White bread
3183235|NCT01316354|Experimental|Arabinoxylan|Bread with Purified arabinoxylan
3183236|NCT01316341|Experimental|BI10773 low dose Per Os(p.o.)|patient to receive a tablet containing low dose BI10773 Per Os(p.o.) plus one placebo
3183237|NCT01316341|Placebo Comparator|Placebo|patient to receive two placebos
3183238|NCT01316341|Experimental|BI10773 high dose Per Os(p.o.)|patient to receive a tablet containing high dose BI10773 Per Os(p.o.) plus one placebo
3183239|NCT01316328||BC patients after SSPBI|breast cancer (BC) patients following single shot partial breast irradiation (SSPBI) after breast conservative surgery
3183240|NCT01316315|Experimental|Active|N6022 - 5 mg
3183241|NCT01316315|Placebo Comparator|Placebo|Placebo
3183242|NCT01316302|Experimental|Pristiq|Flexible dose, 50-100mg QD
3183243|NCT01316302|Placebo Comparator|Placebo|Matching placebo
3183244|NCT01316276|Experimental|Arikayce|
3183245|NCT01316263|Experimental|PDGFRα mutation negative|Participants with GIST with genotypes that do not have a PDGFRα mutation given 20 milligrams per kilogram (mg/kg) Olaratumab intravenously (IV) every 14 days.
3183246|NCT01316263|Experimental|PDGFRα mutation positive|Participants with GIST with genotypes that have a PDGFRα mutation given 20 mg/kg Olaratumab IV every 14 days.
3183247|NCT01316250|Other|Nilotinib, cytogenetic response|Newly diagnosed CML patients
3183248|NCT01316237|Other|Cohort 1|(N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2) 50 mg GS-6620 or placebo QD in the morning with food [total daily dose (TDD) = 50 mg] for 5 days
3183249|NCT01316237|Other|Cohort 2|"(N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~100 mg GS-6620 or placebo QD in the morning with food (TDD = 100 mg) for 5 days"
3183250|NCT01316237|Other|Cohort 3|"Cohort 3 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~300 mg GS 6620 or placebo QD in the morning with food (TDD = 300 mg) for 5 days"
3183251|NCT01316237|Other|Cohort 4|"Cohort 4 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~100 mg GS 6620 or placebo QD in the morning without food (TDD = 100 mg) for 5 days"
3183252|NCT01316237|Other|Cohort 5|"Cohort 5 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~300 mg GS 6620 or placebo QD in the morning without food (TDD = 300 mg) for 5 days"
3183253|NCT01316237|Other|Cohort 6|"Cohort 6 (N = 10, genotype 2 or genotype 3): (Active drug: 8, Matching Placebo: 2)~900 mg GS 6620 or placebo QD in the morning without food (TDD = 900 mg) for 5 days"
3183254|NCT01316237|Other|Cohort 7|"Cohort 7 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~450 mg GS 6620 or placebo, administered BID with food (TDD = 900 mg) for 5 days"
3183255|NCT01316237|Other|Cohort 9|"Cohort 9 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~900 mg GS 6620 or placebo BID in the with food (TDD = 1800 mg) for 5 days"
3183256|NCT01316237|Other|Cohort 11|"Cohort 11 (N = 10, genotype 1 : (Active drug: 8, Matching Placebo: 2)~Up to 450 mg GS-6620 or placebo as an oral solution, BID, 12 hours apart in the fasted state, 2 hours after a meal (up to TDD = up to 900 mg) for 5 days."
3183257|NCT01316224||Moderate or severe plaque psoriasis|Participants with moderate or severe plaque psoriasis treated with adalimumab
3183258|NCT01316211|Active Comparator|coflex™|Implantation of coflex™ device in assigned patients
3183259|NCT01316211|Active Comparator|Surgical decompression|Surgical decompression in patients with spinal stenosis without stabilization by an additional implant.
3183260|NCT01316198|Experimental|Lutein and zeaxanthin|
3183261|NCT01316198|Experimental|Placebo|
3183262|NCT01316185|Experimental|Group 1|Low Dose for 28 days: n=4
3183263|NCT01316185|Experimental|Group 2|High Dose for 28 days; n=4
3183264|NCT01316172|Experimental|5 Cs|Educational intervention
3183265|NCT01316172|No Intervention|Control|
3183266|NCT01316146|Experimental|CAR.CD30 T cells|Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection (IV) according to the dosing schedules: starting with the lowest cell dose (2×10^7 cells/m2) and then escalate the cell dose to the highest cell dose (2×10^8/m2) as per study design.
3183267|NCT01316133|Experimental|Tacrolimus group|Oral
3183268|NCT01316120|Experimental|HPV Dry first|"Randomization will determine the sequence of the two tests, avoiding potential bias that may advantage the first test. All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic tests"
3183309|NCT01315769||primiparous women|Group 2
3183269|NCT01316120|Experimental|HPV standard transport medium|"Randomization will determine the sequence of the two tests, avoiding potential bias that may advantage the first test. All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic tests"
3183270|NCT01316107|Experimental|ASP group|Concomitant administration of ASP1941 and nateglinide
3183271|NCT01316094|Experimental|ASP group|
3183272|NCT01316094|Placebo Comparator|placebo group|
3183273|NCT01316081|Experimental|Antioxidant Group|500mg Vitamin C 400 I.E. Vitamin E 50 mcg Selenium
3183274|NCT01316081|Placebo Comparator|Placebo Group|identical appearing placebo supplements
3183275|NCT01316068|Experimental|sequencial use of sulodexide|Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks. Then patients will receive 1000 LSU per day orally for 50 weeks.
3183276|NCT01316068|Active Comparator|oral use of sulodexide|Patients allocated to oral group will received 1000 LSU per day orally for 52 weeks
3183277|NCT01316055|Active Comparator|Healthy: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in healthy volunteers
3183278|NCT01316055|Active Comparator|Mild renal: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with mild renal impairment
3183279|NCT01316055|Active Comparator|Moderate renal: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with moderate renal impairment
3183280|NCT01316042|Placebo Comparator|sugar pill|2 pills per day for 12 months
3183281|NCT01316042|Active Comparator|Metformin|2 212.5mg pill/day for 12 months
3183282|NCT01316029||laying-on-of-hands|44,587 Japanese volunteers with/without illness, who were interested in receiving laying-on-of-hands
3183283|NCT01316016|Experimental|Rose hip|
3183284|NCT01316003||Normal subjects|Thirty-seven eyes of 37 individuals without eye diseases
3183285|NCT01315990|Experimental|FOLFIRI + Cetuximab|
3183286|NCT01315964|Active Comparator|plant stanol ester|3 grams of plant stanol esters per day in a margarine product as part of daily diet for 6 months
3183287|NCT01315964|Placebo Comparator|Placebo|a margarine product as part of daily diet, which is not containing plant stanol esters
3183288|NCT01315951|Experimental|Petroleum Jelly|Every patient will be applying petroleum jelly to the affected areas per protocol.
3183289|NCT01315938|Experimental|Abatacept|
3183290|NCT01315925||Newly disgnosed AML|Adult and pediatric patients with newly diagnosed acute myeloid leukemia, both eligible and not eligible for intensive chemotherapy. Since this is a non-interventional study, therapeutic strategies remains related to local guidelines. Will be treated as cases all patients with acute leukemia in first induction developing an Invasive Fungal Infection according to international EORTC criteria for possible/probable/proven infections. Patients who do not develop the infection will be used as a control group.
3183291|NCT01315899|Experimental|ORM-12471 30mg|
3183292|NCT01315899|Placebo Comparator|placebo|
3183293|NCT01315899|Experimental|ORM-12471 100mg|
3183294|NCT01315886|Experimental|SL Fentanyl conversion|"Baseline period: 7-15 episodes of breakthrough cancer pain treated with prior IR opioid medication~Treatment period: Conversion to SL Fentanyl at a Fentanyl:Prior opioid conversion factor of 1:50 (using the estimated Morphine Sulphate Equivalent dose for the prior opioid). SL Fentanyl use was followed for 8-15 episodes of breakthrough cancer pain. SL Fentanyl dose could be titrated between episodes."
3183295|NCT01315873|Experimental|Bortezomib and Bendamustine|
3183296|NCT01315860||Pregnant Females|Pregnant females in their second or third trimester that meet the inclusion and exclusion criteria.
3183297|NCT01315847|Experimental|Healthy Participants (Part I)|Baseline PET imaging of the brain using [11C]MK-4232 tracer (~300 megabecquerel [MBq]) was performed in healthy participants; this PET data served as the baseline for both Period 1 and 2 of Part I. Subsequently in study Part I, Period 1 the healthy participants received a single 1120 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~3 hours post telcagepant dose. In Part I, Period 2 the healthy participants received a single 140 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~2 hours post telcagepant dose. Interval between Part I Period 1 and 2 was to be at least 1 week.
3183298|NCT01315847|Experimental|Participants with Migraine (Part III)|In study Part III, Period 1 baseline PET imaging of the brain using [11C]MK-4232 tracer (~300 MBq) was performed in participants with migraine during a migraine attack (ictal phase). Later in Part III, Period 1 the participants with an ongoing migraine attack (ictal phase) received a single 140 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~2 hours post telcagepant dose. In Part III, Period 2 baseline PET imaging of the brain using [11C]MK-4232 tracer (~300 MBq) was performed in participants with migraine, however, without a migraine attack ongoing (interictal phase). Later in Part III, Period 2 participants with migraine without a migraine attack ongoing (interictal phase) received a single 140 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~2 hours post telcagepant dose. Interval between Part III Period 1 and 2 was to be at least 1 week.
3183299|NCT01315834||Couples coping with CHD|The target group will be 127 male patients and their partners. The couples will be recruited during the patients' first hospitalization for ACS. The participants will complete questionnaires during the hospitalization and again six months later. The patients will also be asked to be weighed and have their blood drawn and at the six-month follow-up for measurement of blood Cholesterol level. Relevant data will be obtained from their medical files.
3183300|NCT01315834||control group|The control group will be 100 couples who are not coping with a life threatening illness. The couples will complete self report questionnaires at one point of time.
3183301|NCT01315821|Experimental|Saccharomyces boulardii|Saccharomyces boulardii 5 million unit/day for 3 months
3183302|NCT01315821|Placebo Comparator|control|Placebo- for 3 months
3183303|NCT01315808||Low risk group|Patients will be stratified based on risk factors significantly contributing to diabetes type 2.
3183304|NCT01315808||Intermediate risk group|
3183305|NCT01315808||High risk group|
3183306|NCT01315795|Experimental|Symptomatic polycystic liver disease (PCLD) patients|Symptomatic polycystic liver disease (PCLD) patients
3183307|NCT01315782||Multi-organ failure|Alveolar dead space on mechanically ventilated patients with severe sepsis or septic shock.
3183308|NCT01315769||non pregnant nulliparous|Group 1
3183310|NCT01315756|No Intervention|Control group|Treatment as usual.
3183311|NCT01315756|Experimental|Few Touch Application (FTA)|"This arm will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user."
3183312|NCT01315756|Experimental|FTA and health counseling|This arm will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via sms from the diabetes nurse which is based on the patient's initiative (via sms). In addition, the diabetes nurse will call the patients three times during this period and discuss progress.
3183313|NCT01315743|Experimental|Intervention|
3183314|NCT01315730|Experimental|Device: Tactile Stimulation|"A new medical grade device (FDA - category exempt) has been newly designed and built at the University of Mississippi within the departments of Communication Sciences & Disorders, Exercise Science, and Computer and Electrical Engineering. The device records either sound waves (via a small standard microphone) or three dimensional accelerometer data from the throat of a stuttering subject. This data is digitally signal processed, and fed back to the user in the form of a small vibrating disk/film that can be held between the fingers or mounted on the skin. This feedback data does not require the subject to attend to the incoming signal."
3183315|NCT01315717||Group 1|Healthy subjects
3183316|NCT01315717||Group 2|Patients with Mild Cognitive Impairment
3183317|NCT01315717||Group 3|Patients with Mild AD
3183318|NCT01315717||Group 4|Patients with Moderate AD
3183319|NCT01315704||Group 1|Patients with Mild Cognitive Impairment
3183320|NCT01315704||Group 2|Patients with Mild Alzheimer's disease or related disorders
3183321|NCT01315704||Group 3|Patients with Moderate Alzheimer's disease or related disorders
3183322|NCT01315691|Experimental|Arikace™|Liposomal amikacin for inhalation
3183323|NCT01315691|Placebo Comparator|Placebo|Placebo for liposomal amikacin for inhalation
3183324|NCT01315678|Experimental|Arikayce™|Arikayce™ is liposomal amikacin for inhalation
3183325|NCT01315678|Active Comparator|TOBI®|TOBI® is tobramycin inhalation solution
3183326|NCT01315665|Experimental|Healthy volunteers|100 grams of raw broccoli sprouts once daily for 5 consecutive days
3183327|NCT01315665|Experimental|Subjects with cystic fibrosis|100 grams of raw broccoli sprouts once daily for 5 consecutive days
3183328|NCT01315652|Experimental|Auto DAS|"Auto-DASNumber of patients with a modification in their treatment between baseline and 6 months visits"
3183329|NCT01315652|Active Comparator|Comorbidities treatment|
3183330|NCT01315639|Other|biomarkers, MRI and CSF|"Longitudinal multicenter study including 1300 subjects with amnestic impairment (MCI, n=650 and AD, n=650) derived from the main French national Memory Resources and Research Centers.~Participants will undergo at baseline and every 6 months a neurological examination, a neuropsychological assessment (and an oculomotor examination for those included from Broca Hospital).~Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
3183331|NCT01315626||Immediately preceding intervention|3 months immediately before the education event. Charts of patients with a primary respiratory complaint will be reviewed so evaluate if they 1) have experienced 3 or more suppurative respiratory infections and 2) have required 3 or more courses of antibiotic therapy for respiratory infection over the period of one year. 4) Whether or not they underwent a HRCT, and if so, and 5) Were the patients diagnosed with BE.
3183332|NCT01315626||3 months after educational event|3 months immediately after the education event. An active assessment will be preformed as per the proposed diagnostic algorithm (attachment B) Patients that meet all criteria in the algorithm are considered at risk for bronchiectasis and based on these criteria, physicians will be encouraged to order HRCT, and the number/ proportion of patients identified with BE will be noted and compared to the other time periods.
3183333|NCT01315626||Seasonal prior year|As respiratory illnesses are commonly seasonal, an assessment of rate of Bronchiectasis diagnosis during the months of Period 2 in the year prior to the educational intervention will also be assessed as described in Period 1
3183334|NCT01315613||Acute pancreatitis|Patients admitted in our institution for an episode of acute pancreatitis
3183335|NCT01315587|Active Comparator|intermittent theta burst stimulation|
3183336|NCT01315587|Active Comparator|repetitive Transcranial Magnetic Stimulation|
3183337|NCT01315587|Placebo Comparator|Sham TMS|
3183338|NCT01315574|Active Comparator|Latanoprost (Xalatan)|7 Patients were randomized to receive BAK-containing Xalatan for treatment of their glaucoma.
3183339|NCT01315574|Active Comparator|Travoprost (Travatan Z)|7 Patients were randomized to receive BAK-free Travatan Z for treatment of their glaucoma.
3183340|NCT01315561|Experimental|acupuncture|MSAT is a treatment method in which the patient is exposed to active or passive movement and exercise during acupuncture, as opposed to conventional acupuncture.
3183341|NCT01315561|Active Comparator|injections of diclofenac|the control group was treated with intramuscular injections of diclofenac(NSAID). All administrations were limited to 1 session
3183342|NCT01315548||Pancreatic adenocarcinoma|Patients diagnosed with solid pancreatic adenocarcinoma masses, with cytological / histologicalconfirmation
3183343|NCT01315548||Chronic pancreatitis|Patients diagnosed with solid pancreatic tumor masses with all the criteria fulfilled to exclude pancreatic cancer
3183344|NCT01315535||Fast Titration|
3183345|NCT01315535||Regular Titration|
3183346|NCT01315535||Fast Tritation Including Mandibular Exercises|
3183347|NCT01315535||Regular Tritation Including Mandibular Exercises|
3183348|NCT01315522|Active Comparator|ComVi stent|ComVi stent (Niti-S stent, ComVi type, Taewoong Medical Inc, Korea)
3183349|NCT01315522|Active Comparator|Uncovered SEMS|uncovered nitinol metal stent (HANAROSTENT, M.I. Tech Co., Ltd., Korea)
3183350|NCT01315496|Experimental|Imunoglobulin G|The enrolled patients will be randomized to receive supplementation of IVIG in ICU within 48 hours after hospital arrival admission for 3 consecutive days.
3183351|NCT01315496|Placebo Comparator|Placebo control|The enrolled patients will be randomized to receive supplementation of placebo (0.9% NaCl) in ICU within 48 hours after hospital arrival admission for 3 consecutive days.
3183352|NCT01315483|Experimental|Low fat, high carb weight loss diet|Ornish-like weight loss dietary pattern
3184051|NCT01310478|Experimental|Endostar combined with mFOLFOX6|
3183353|NCT01315483|Experimental|Low carb, high fat weight loss diet|South-Beach-like weight loss diet pattern
3183354|NCT01315483|No Intervention|Control|Usual care
3183355|NCT01315470|Experimental|neupogen|
3183356|NCT01315470|No Intervention|no intervantion|
3183357|NCT01315457||Alemtuzumab|Patients treated with alemtuzumab
3183358|NCT01315444|Active Comparator|PPI abrupt cessation|Abrupt cessation
3183359|NCT01315444|Active Comparator|PPI gradual step down cessation|Gradual cessation
3183360|NCT01315431|Experimental|Tesetaxel-capecitabine|
3183361|NCT01315418|Active Comparator|1 = Tested product|
3183362|NCT01315418|Sham Comparator|2 = Control product|
3183363|NCT01315392|Active Comparator|delayed closure|wounds packed open with normal saline wet to dry gauze dressings and were returned to the operating room 36 to 72 hours after initial procedure for debridement and definitive closure.
3183364|NCT01315392|Active Comparator|immediate wound closure|traumatic and surgical wounds closed at initial surgical intervention
3183365|NCT01315379||PTSD without TBI|"children and adolescents with a diagnosis of PTSD and without head injury, following a motor vehicle accident.~This group will be treated using the Prolonged Exposure Therapy protocol."
3183366|NCT01315379||PTSD with m-TBI|"children and adolescents with a diagnosis of PTSD and a diagnosis of mild traumatic brain injury, following a motor vehicle accident.~This group will be treated using the Prolonged Exposure Therapy protocol."
3183367|NCT01315366|Active Comparator|High dose vitamin D|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) Ci-Cal D daily, plus a supplement of vitamin D3 EuroD (20,000 IU/wk) for one year.
3183368|NCT01315366|Placebo Comparator|Low dose Vitamin D|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) Ci-Cal D daily, plus a weekly placebo (EURO D Placebo) supplement for one year.
3183369|NCT01315353|Experimental|Arm A: Immediate cryotherapy (HPV test-and-treat)|Participants in Arm A (HPV test-and-treat) had cervical cryotherapy at entry. Post entry, participants in Arm A were seen at regular intervals for the collection of cervical specimens, cytology, and as needed, cervical colposcopy, directed biopsies, and LEEP.
3183370|NCT01315353|Experimental|Arm B: cytology-based strategy|Participants in Arm B followed a cytology-based management plan involving three steps- cytology, colposcopy with directed biopsies, and LEEP (as needed).
3183371|NCT01315353|Experimental|Arm C : Ineligible for randomization to Arm A or B|Participants were eligible for Arm C under the conditions noted in the inclusion criteria. Participants in Arm C had colposcopy and directed biopsies at entry. If CIN2+ was found by biopsy, then LEEP was performed and a follow-up visit 26 weeks after these procedures was scheduled for the collection of cervical specimens, cytology, and as needed, cervical colposcopy, directed biopsies, and LEEP. After the week 26 visit, Arm C participants went off study.
3183372|NCT01315340|Experimental|Glaucoma Patients|
3183373|NCT01315340|Active Comparator|Control subjects|
3183374|NCT01315327|Experimental|Omega-3 Fatty Acids|Omega-3 Fatty Acids (fish oil), flexibly titrated up to 6000 mg/day.
3183375|NCT01315327|Placebo Comparator|Placebo|Olive oil placebo, looks and tastes identical to active intervention.
3183376|NCT01315314|No Intervention|conventional PDF (Stay safe)|
3183377|NCT01315314|Active Comparator|low GDP PDF (Balance)|
3183378|NCT01315301|Active Comparator|Arm-A|Immediate Treatment Group
3183379|NCT01315301|Active Comparator|Arm-B|Deferred Treatment Group-1
3183380|NCT01315301|Active Comparator|Arm-C|Deferred Treatment Group-2
3183381|NCT01315288|Other|Video presentation|
3183382|NCT01315275|Experimental|Ranibizumab|
3183383|NCT01315262|Active Comparator|Viagra 100 mg daily|
3183384|NCT01315262|Active Comparator|Viagra 100mg on demand|
3183385|NCT01315249|Experimental|QVA149|Participants received indacaterol and glycopyrronium (QVA149) and placebo to fluticasone/salmeterol.
3183386|NCT01315249|Active Comparator|fluticasone/salmeterol|Participants received fluticasone/salmeterol and placebo to indacaterol and glycopyrronium (QVA149).
3183387|NCT01315236|Experimental|Arikayce|
3183388|NCT01315236|Placebo Comparator|Placebo|
3183389|NCT01315223|No Intervention|Conventional treatment CHF patients|One hundred and fifty patients with CHF will be treated according to current guidelines (conventional treatment).
3183390|NCT01315223|Experimental|Lung impedence-guided treatment|
3183391|NCT01315210|Experimental|D-Ribose|
3183392|NCT01315210|Placebo Comparator|Placebo|
3183393|NCT01315197|Experimental|massage|The massage Anma has Japanese origin and a protocol was used with smoothing, kneading and pressure points on the bladder meridian.
3183394|NCT01315184|Experimental|Recovery Line Support System|Patients assigned to the Recovery Line Support System will be trained on the system and provided 24-hr access to the system for a four week period, provided with a Recovery notebook, and given reminder calls to contact the system.
3183395|NCT01315184|No Intervention|Treatment as Usual|Patients assigned to the TAU condition will receive any services provided by their buprenorphine provider and any additional services that their provider refers or recommends that patients attend. No additional services will be provided by the study.
3183396|NCT01315171|Experimental|Medium chain supplemented diet|Subjects will have a diet during which all meals are supplemented with 4 tablespoons of medium chain triglyceride oil.
3183397|NCT01315171|No Intervention|Standard group|Subjects will continue with a standard western diabetes diet.
3183398|NCT01315158|Active Comparator|Propofol+Benzo/Opioids|"If the patient is randomized into this arm the recommended Versed and Fentanyl doses are standardized:~Recommended Versed:~a. Prior to intubation~patient is < 50 kg = 1 mg Versed~patient is 50-75 kg = 1.5 mg Versed~patient is > 75 kg = 2 mg Versed~Recommended Fentanyl~Prior to intubation = 0.5 ug/kg~Total procedural dose = 1 ug/kg"
3183399|NCT01315158|Active Comparator|Propofol Alone|"The patients randomized into the sedation with propofol alone are able to cross over if they are unable to be successfully sedated under propofol alone. The the recommended doses before considering crossover are standardized:~Induction Dose: 2-2.5 mg/kg~Maintenance Dose: 0.1-0.2 mg/kg/min"
3183400|NCT01315145|Active Comparator|Percutaneous Lumbar Decompression|Patients receiving percutaneous decompression using the mild® Device Kit.
3183401|NCT01315145|Active Comparator|Lumbar Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
3183402|NCT01315132|Experimental|Allogeneic Transplantation|Matched Sibling Allogeneic Transplantation
3183403|NCT01315093|Experimental|Heparin, Low-Molecular-Weight group|LMWH was administered during an IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders. Drug was started at the beginning of the cycle and stopped at the time of pregnancy test if negative, or continued if pregnancy occurred until the 32th weeks of gestation
3183404|NCT01315093|Active Comparator|Non Heparin, Low-Molecular-Weight group|IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders.
3183405|NCT01315080||Saline|Percutaneous drainage and saline solution irrigation
3183406|NCT01315080||Triamcinolone|Percutaneous drainage and saline solution irrigation plus percutaneous triamcinolone
3183407|NCT01315054|Other|Control arm|Using currently practiced methadone dosage prescription methods
3183408|NCT01315054|Experimental|MMT provider dosage training|Intensive health care provider training on prescribing methadone dosage based on national guidelines
3183409|NCT01315054|Experimental|MMT provider dosage training/counseling|Intensive health care provider training on prescribing methadone dosage, plus providing on-site psychosocial counseling services and peer support to clients .
3183410|NCT01315041|Active Comparator|"Pi medicine"|
3183411|NCT01315041|Placebo Comparator|Placebo|
3183412|NCT01315028|Experimental|Psychological Therapy|Cognitive Interpersonal Therapy (CIT) was a psychological therapy which emphasised assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive-behavioural and interpersonal strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley & Schwannauer, 2006).
3183413|NCT01315028|Active Comparator|Treatment As Usual|All participants continued to receive their usual care from their local community mental health team and other psychological therapies were not withheld during the conduct of the trial.
3183414|NCT01315015|Experimental|Contrast enhanced breast MRI|The additional MRI will take place biennially after the regular screening mammogram for a study period of 6 years.
3183415|NCT01315015|No Intervention|Regular breast cancer screening|No further follow-up until next scheduled screening examination two years later (according to the current Dutch guideline).
3183416|NCT01315002|Active Comparator|Nicotine Patch|Transdermal nicotine patch
3183417|NCT01315002|Placebo Comparator|Placebo patch|Placebo patch
3183418|NCT01314989|Active Comparator|Cyproheptadine|Cross-over study
3183419|NCT01314989|Placebo Comparator|Sugar pill|Cross-over study
3183420|NCT01314976|Experimental|Metronidazole|Active treatment.
3183421|NCT01314976|Placebo Comparator|Placebo|Passive treatment.
3183422|NCT01314963|Experimental|Intraoperative handheld Gamma Camera (pIHGC)|The prototype intraoperative handheld gamma camera (pIHGC)
3183423|NCT01314963|Active Comparator|Gamma probes (GP)|Standard of care intraoperative gamma probes (GP) currently in use.
3183424|NCT01314950|Active Comparator|Best practices primary care|Best practices primary care encompasses the collaborative care intervention tested in a prior clinical trial (Callahan CM et al. JAMA 2006).
3183425|NCT01314950|Experimental|Home based occupational therapy|The intervention group receives all of the components of best practice primary care in addition to a home-based intervention designed to slow functional decline.
3183426|NCT01314937|Experimental|Deworming at 12 months of age|
3183427|NCT01314937|Experimental|Deworming at 18 months of age|
3183428|NCT01314937|Experimental|Deworming at 12 and 18 months of age|
3183429|NCT01314937|Placebo Comparator|Usual care|
3183430|NCT01314924|Experimental|Responders|Patients who present an increase in flow-mediated dilation of brachial artery.
3183431|NCT01314924|Experimental|Non responders|Patients who do not present an increase in flow-mediated dilation of brachial artery.
3183432|NCT01314911|Experimental|Oseltamivir|Participants will receive oseltamivir twice a day for 5 days.
3183433|NCT01314911|Placebo Comparator|Oseltamivir Placebo|Participants will receive oseltamivir placebo twice a day for 5 days.
3183434|NCT01314898|Experimental|Treatment|
3183435|NCT01314885|Experimental|PF-03715455|
3183436|NCT01314885|Experimental|PH-797804|
3183437|NCT01314885|Placebo Comparator|Placebo for PF-03715455|
3183438|NCT01314885|Placebo Comparator|Placebo for PH-797804|
3183439|NCT01314872|Placebo Comparator|Part 1: placebo|Participants received two placebo matching vibegron tablets and one placebo matching tolterodine extended release (ER) capsule, taken orally each morning, for 8 weeks.
3183440|NCT01314872|Experimental|Part 1: vibegron 3 mg|Participants received one vibegron 3 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
3183441|NCT01314872|Experimental|Part 1: vibegron 15 mg|Participants received one vibegron 15 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
3183442|NCT01314872|Experimental|Part 1: vibegron 50 mg|Participants received one vibegron 50 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
3183443|NCT01314872|Experimental|Part 1: vibegron 100 mg|Participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
3183444|NCT01314872|Active Comparator|Part 1: tolterodine ER 4 mg|Participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 8 weeks.
3183445|NCT01314872|Experimental|Part 1: vibegron 50 mg + tolterodine ER 4 mg/vibegron 50 mg|Participants received one vibegron 50 mg tablet and one placebo matching vibegron tablet, taken orally each morning, for 8 weeks. They also received one tolterodine ER 4 mg capsule for the first 4 weeks and one placebo matching tolterodine ER capsule for the second 4 weeks, both taken orally each morning.
3183446|NCT01314872|Placebo Comparator|Part 2: placebo|Participants received two placebo matching vibegron tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 4 weeks.
3183447|NCT01314872|Experimental|Part 2: vibegron 100 mg|Participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 4 weeks.
3183521|NCT01314274|Experimental|bevacizumab|submucosal intranasal bevacizumab on day 0
3183448|NCT01314872|Active Comparator|Part 2: tolterodine ER 4 mg|Participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 4 weeks.
3183449|NCT01314872|Experimental|Part 2: vibegron 100 mg + tolterodine ER 4 mg|Participants received two vibegron 50 mg tablets and one tolterodine ER 4 mg capsule, taken orally each morning, for 4 weeks.
3183450|NCT01314872|Experimental|Extension Study: vibegron 50 mg|Participants in Base Study/Part 1 who received vibegron 50 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received vibegron 3 mg received vibegron 50 mg in the Extension Study. Also, participants in Base Study/Part 1 who received vibegron 50 mg + tolterodine ER for 4 weeks, followed by vibegron 50 mg alone for 4 weeks, remained on vibegron 50 mg in the Extension Study. In the extension, participants received one vibegron 50 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 52 weeks.
3183451|NCT01314872|Experimental|Extension Study: vibegron 100 mg|Participants in Base Study/Part 1 or Part 2 who received vibegron 100 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received vibegron 15 mg received vibegron 100 mg in the Extension Study. In the extension, participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 52 weeks.
3183452|NCT01314872|Experimental|Extension Study: tolterodine ER 4 mg|Participants in Base Study/Part 1 or Part 2 who received tolterodine ER 4 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received placebo also received tolterodine ER 4 mg in the Extension Study. In the extension, participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 52 weeks.
3183453|NCT01314872|Experimental|Extension Study: vibegron 100 mg + tolterodine ER 4 mg|Participants in Base Study/Part 1 who received vibegron 100 mg + tolterodine ER 4 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 2 who received placebo were assigned to the vibegron 100 mg + tolterodine ER 4 mg arm in the Extension Study. In the extension, participants received two vibegron 50 mg tablets and one tolterodine ER 4 mg capsule, taken orally each morning, for 52 weeks.
3183454|NCT01314859|Experimental|Nifedipine|"Oral Treatment with Nifedipine capsules (10 mg)~Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).~Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.~Maximum Duration of the treatment: 48 hours."
3183455|NCT01314859|Active Comparator|Atosiban|"Intravenously Treatment with Atosiban (7.5mg/ml)~Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.~Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.~Maximum Duration of the treatment: 48 hours."
3183456|NCT01314846||Control Group|sequential culture system
3183457|NCT01314846||Co-culture system|
3183458|NCT01314833|Experimental|TC|"Cyclophosphamide 600 mg/m² D1 Docetaxel 75 mg/m² D1~1 cycle = 21 days TC*6 cycles"
3183459|NCT01314833|Experimental|CEF-T|"1st~3rd cycles 5-fluorouracil 500 mg/m2 Epirubicin 90 mg/m2 Cyclophosphamide 500 mg/m2~1 cycle=21 days~4th~6th cycles Docetaxel 100mg/m2~1 cycle=21 days CEF*3-T*3"
3183460|NCT01314833|Experimental|EC-P|"1st~4th cycles: Epirubicin 90 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~5th-8th cycles: Paclitaxel 80mg/m² D1，D8,D15~1 cycle = 21 days~EC*4-P*4"
3183461|NCT01314820|Active Comparator|normal saline injection|20 cc normal saline injection into the knee joint
3183462|NCT01314820|Sham Comparator|sham injection|knee injection without saline
3183463|NCT01314807||patients with COPD|patients who were defined as COPD, based on post-bronchodilator spirometry (GOLD criteria). Patients will have at least 10 pack years
3183464|NCT01314807||smoking controls|patients with at least 10 pack years who have no COPD (based on post-bronchodilator spirometry)
3183465|NCT01314807||non-smoking controls|patients with < 1 pack year who have no COPD (based on post-bronchodilator spirometry)
3183466|NCT01314781|Experimental|solifenacin 5mg, PFMT and WBVT|Patients randomized to group A will receive solifenacin 5mg tablet once daily and a training programme for PFMT and WBVT once a week.
3183467|NCT01314781|Active Comparator|solifenacin 5mg|Subjects randomised to group B will receive solifenacin 5mg tablet once daily.
3183468|NCT01314768|Active Comparator|Brief intervention|Behavioural brief intervention delivered by GP
3183469|NCT01314768|Placebo Comparator|Business as usual|Business as usual according to individual GP
3183470|NCT01314768|Other|Chronic headache control|Screening and outcome control only. Non-intervention Control, screened and followed-up at final time point
3183471|NCT01314768|Other|Population control|Screening and outcome control only. Non-intervention Control, screened and followed-up at final time point
3183472|NCT01314755|Experimental|immune-enhancing feed IMPACT|
3183473|NCT01314755|Active Comparator|control arm|
3183474|NCT01314742|Experimental|Biotene OralBalance® gel Arm|Biotene OralBalance® gel contains antibacterial active ingredients: lactoperoxidase, lysozyme and lactoferrin. These enzymes occur naturally in the human milk and colostrum and have mimicking properties of the human saliva activity in vivo.
3183475|NCT01314742|Placebo Comparator|Sterile Water Arm|Sterile Water moisten cotton tipped applicator
3183476|NCT01314729|Active Comparator|Fiber-reinforced-composite retainer|
3183477|NCT01314729|Active Comparator|composite-wire retainer|
3183478|NCT01314716|Experimental|AZLI-AZLI|Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
3183479|NCT01314716|Placebo Comparator|Placebo-AZLI|Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
3183480|NCT01314677|Experimental|Group A (FDG PET/CT between RT fractions 5-6)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 5-6 (before course 2 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
3183522|NCT01314274|Placebo Comparator|placebo|0.9% NaCl intranasal submucosal on day 0
3183686|NCT01313169|Experimental|EMR reminder + Panel management|EMR reminder + Panel manager
3183481|NCT01314677|Experimental|Group B (FDG PET/CT between RT fractions 10-11)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 10-11 (before course 3 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
3183482|NCT01314677|Experimental|Group C (FDG PET/CT between RT fractions 15-16)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 15-16 (before course 4 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
3183483|NCT01314651|Experimental|Sleep Management|Instructions in stimulus control and sleep restriction.
3183484|NCT01314651|Sham Comparator|Lifestyle Modification|Instructions to change general lifestyle habits (maintain consistent liquid consumption, range of motion exercises, etc.)
3183485|NCT01314638||Single group|Single group, Identical investigations for all subjects
3183486|NCT01314625||one arm|
3183487|NCT01314612|Experimental|Group Intervention|Subjects randomly assigned to this arm of the study will receive the 9-week insomnia and nightmare intervention group once per week for 90 minutes in addition to continuing treatment as usual with medical and mental health providers.
3183488|NCT01314612|No Intervention|Treatment as Usual|This group is randomly assigned to receive only treatment as usual and does not receive the active intervention of the insomnia and nightmare group treatment. This treatment will be made available to these members once the study is completed
3183489|NCT01314599|Experimental|Arm 1|PM01183 will be administered i.v. as a 1-hour infusion through a pump device at escalating doses according to the respective dose level, on Days 1 and 8 of each treatment phase.
3183490|NCT01314586|Placebo Comparator|placebo|placebo pill, diet counseling to comply with NCEP Step I diet
3183491|NCT01314586|Experimental|150 mg/day Beneflax|2 pills taken at breakfast and dinner containing a total of 150 mg secoisolariciresinol (SDG) per day for 12 weeks
3183492|NCT01314586|Experimental|300 mg/day Beneflax|2 pills taken at breakfast and dinner containing a total of 300 mg secoisolariciresinol (SDG) per day for 12 weeks
3183493|NCT01314573|Experimental|Interval maximal exercise|Interval exercise involving repeated Wingate tests (30s durations of maximal exercise on a cycle ergometer).
3183494|NCT01314573|Experimental|Continuous maximal exercise|Continuous exercise of maximal exertion that has been work matched to an initial bout of interval exercise of 4 x 30s of maximal exercise. This exercise is performed on a cycle ergometer.
3183495|NCT01314560|Experimental|1|experimental
3183496|NCT01314508|Other|All patients will be treated with IGF-1 factors|Patients will serve as their own control.
3183497|NCT01314495|Active Comparator|Abatacept|Abatacept administered as a 30 minute intravenous infusion
3183498|NCT01314495|Placebo Comparator|Inactive infusion|Placebo will be administered as a 30 minute intravenous infusion.
3183499|NCT01314482|Experimental|Minocycline|
3183500|NCT01314469||Patients with intermediate uveitis|
3183501|NCT01314456|Experimental|NaviGo|Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
3183502|NCT01314443|Experimental|Placebo + Smoking Cessation|Individuals will quit smoking without use of nicotine replacement therapy (NRT) and ingest a placebo for 7 days
3183503|NCT01314443|Experimental|Supplement + Smoking Cessation|Individuals will quit smoking without the use of nicotine replacement therapy (NRT) and ingest a gamma-tocopherol supplement for 7 days
3183504|NCT01314443|Experimental|Placebo + Nicotine Replacement Therapy|Individuals will quit smoking with the use of nicotine replacement therapy (NRT) and ingest a placebo for 7 days
3183505|NCT01314443|Experimental|Supplement+Nicotine Replacement Therapy|Individuals will quit smoking with the use of nicotine replacement therapy (NRT) and ingest a gamma-tocopherol supplement for 7 days
3183506|NCT01314417|Experimental|Methotrexate|400 μg/100 μL injection
3183507|NCT01314404||KAP/WTP study population|"The participants will range in age from 12 to 50 and will be selected randomly. The study population will be representative of the following categories: men, women, adolescent boys, and adolescent girls.~As our study seeks to take a broad-based view of knowledge related to cervical cancer and HPV, our study population is necessarily wide-ranging. Adolescent boys and girls will be between the ages of 12 and 18; men and women will be older than 18, with at least one child that falls within the adolescent age range."
3183508|NCT01314404||Prevalence study population|"We plan to identify and recruit women diagnosed with cervical cancer who are being treated by a doctor from the department of gynecology of the Hospital Gabriel Touré in Bamako, Mali. These patients will have been previously identified and diagnosed by clinical exam by an obstetrician-gynecologist at Gabriel Touré, and will have been identified as surgical candidates by a doctor.~The subject has expressed a willingness to have a biopsy or other gynecological operation and have a doctor collect tissue samples during a standard medical appointment, has agreed to have blood drawn, was older than 18, and has the capacity to give informed consent."
3183509|NCT01314378|Active Comparator|Cognitive-Behavioral Therapy|
3183510|NCT01314378|Experimental|Mindfulness Training|
3183511|NCT01314352|Experimental|Desloratadine Tablets, 5 mg|Desloratadine Tablets, 5 mg of Dr. Reddy's Laboratories
3183512|NCT01314352|Active Comparator|Clarinex|Clarinex® 5 mg Tablets of Schering-Plough
3183513|NCT01314339|Experimental|Desloratadine Tablets, 5 mg|Desloratadine Tablets, 5 mg of Dr. Reddy's Laboratories
3183514|NCT01314339|Active Comparator|Clarinex|Clarinex® 5 mg Tablets of Schering-Plough
3183515|NCT01314326||Perimetric Glaucoma (PG)|Patients with clinically confirmed abnormal VF and glaucomatous ONH or NFL defect
3183516|NCT01314326||Glaucoma Suspects and Pre-Perimetric Glaucoma (GSPPG) Group|Patients who are at high risk to develop perimetric glaucoma
3183517|NCT01314326||Normal Group|Volunteers with healthy eyes
3183518|NCT01314313|Experimental|PIIA - SAPIEN XT|PIIA is operable group
3183519|NCT01314313|Active Comparator|Control: SAVR|SAVR (surgical aortic valve replacement) is the control arm
3183520|NCT01314300|Experimental|Efficacy of Lidocaine 5% plaster|Treatment of pain by Lidocaine 5% plaster
3183523|NCT01314261|Experimental|ABT-267 (5 mg) once daily + pegIFN/RBV|Participants were given 5 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
3183524|NCT01314261|Experimental|ABT-267 (50 mg) once daily + pegIFN/RBV|Participants were given 50 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
3183525|NCT01314261|Experimental|ABT-267 (200 mg) once daily + pegIFN/RBV|Participants were given 200 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
3183526|NCT01314261|Placebo Comparator|Placebo + pegIFN/RBV|Participants were given matching placebo to ABT-267 once daily in combination with pegIFN/RBV for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
3183527|NCT01314248||children weighing 10 to 15 kg|
3183528|NCT01314222|Other|Arm 1: BMS-954561 40mg or 80mg|"BMS-954561 40mg or 80mg TID to Placebo OR Placebo to 40mg or 80mg TID~Active to Placebo or Placebo to Active (cross-over)"
3183529|NCT01314222|Other|Arm 2: BMS-954561 150mg or 300mg|"BMS-954561 150mg or 300mg TID to Placebo OR Placebo to 150mg or 300mg TID~Active to Placebo or Placebo to Active (cross-over)"
3183530|NCT01314222|Other|Arm 3: Pregabalin 100mg|"Pregabalin 100mg TID to Placebo OR Placebo to 100mg TID~Active to Placebo or Placebo to Active (cross-over)"
3183531|NCT01314209|Experimental|dexmedetomidine|
3183532|NCT01314196|Active Comparator|therapeutic exercises|therapeutic exercises for the shoulder and scapula stabilizers
3183533|NCT01314196|Experimental|progressive resistance training biceps|therapeutic exercises for the shoulder and scapula stabilizers and biceps resistance training.
3183534|NCT01314183|Active Comparator|exercise|Subjects in this arm receive 12 exercise sessions in 9 weeks.
3183535|NCT01314183|Active Comparator|exercise + manual therapy|Subjects in this group receive exercise combined with manual therapy techniques for 12 sessions in 9 weeks.
3183536|NCT01314183|Experimental|exercise + booster|subjects in this arm will receive exercise sessions delivered with booster sessions (8 sessions in the first 9 weeks, 2 sessions at 5 months, 1 session at 8 months, and 1 session at 11 months).
3183537|NCT01314183|Experimental|exercise + manual therapy + booster|Subjects in this arm will receive exercise combined with manual therapy techniques and booster sessions.
3183538|NCT01314170|No Intervention|Susanna Implant|Patients with refractory glaucoma neovascular type or that failed in trabeculectomy will undergo surgery to place implants Susana.
3183539|NCT01314157|Experimental|Physiotherapy treatment technique|"Randomized clinical trial controlling and using at the time of allocation, toss with sealed envelopes, sealed and opaque. The study group will be dealt with technical isostretching and the other group is control group."
3183540|NCT01314144|Experimental|Bupivacaine|Patients will receive intraoperative wound soakage with 20ml of 0.5% bupivacaine with adrenaline by the surgeon before closure and receive a continuous infusion of 4ml/hr of 0.2% bupivacaine delivered by an elastomeric pump the catheter of which will be placed by the surgeon in the wound before closure. Postoperative anlagesia will be provided with oxycodone, paracetamol and diclofenac.
3183541|NCT01314144|No Intervention|Control|Patients will receive morphine up to 0.1mg/kg intraoperatively. Postoperative analgesia will be provided with oxycodone, paracetamol and diclofenac.
3183542|NCT01314131|Experimental|Intervention group|
3183543|NCT01314118|Experimental|001|abiraterone acetate in combination with prednisone Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
3183544|NCT01314105|Experimental|BIBF 1120 L+ Carboplatin + PLD|BIBF 1120 (100 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
3183545|NCT01314105|Experimental|BIBF 1120 M + Carboplatin + PLD|BIBF 1120 (150 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
3183546|NCT01314105|Experimental|BIBF 1120 H + Carboplatin + PLD|BIBF 1120 (200 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
3183547|NCT01314092|Experimental|Group 1|Low dose group
3183548|NCT01314092|Experimental|Group 2|high dose group
3183549|NCT01314066|Experimental|Bevacizumab 5 mg/kg|Receive drug solution as a single dose. Treatment will be given as 90 minute IV infusion.
3183550|NCT01314066|Experimental|Bevacizumab at 10 mg/kg|Receive drug solution as a single dose. Treatment will be given as 90 minute IV infusion.
3183551|NCT01314066|Placebo Comparator|Placebo|In addition to receiving the best standard supportive care for both diagnosis and treatment for individuals diagnosed with severe sepsis, they will receive an IV saline solution.
3183552|NCT01314040|Other|Run in|
3183553|NCT01314040|Experimental|High meat protein diet|
3183554|NCT01314040|Experimental|High dairy protein diet|
3183555|NCT01314040|Experimental|High grain protein diet|
3183556|NCT01314027|Experimental|neoadjuvant + adjuvant chemotherapy|neoadjuvant chemotherapy is based on gemcitabine/oxaliplatin adjuvant therapy is based on gemcitabine
3183557|NCT01314027|Active Comparator|adjuvant chemotherapy|adjuvant therapy is based on gemcitabine
3183558|NCT01314014|Experimental|Imexon|Subjects will be treated on Days 1-5 of 21-day treatment cycles for up to one year. Following pre-treatment with anti-emetics Amplimexon will be given by intravenous infusion over 60 minutes.
3183583|NCT01313858||Participants with Rheumatoid Arthritis|Simponi®-naïve participants with rheumatoid arthritis given Simponi® 50 mg once a month as a subcutaneous injection. Combination use with methotrexate was recommended.
3183584|NCT01313858||Participants with Psoriatic Arthritis|Simponi®-naïve participants with psoriatic arthritis given Simponi® 50 mg once a month as a subcutaneous injection.
3183585|NCT01313858||Participants with Ankylosing Spondylitis|Simponi®-naïve participants with ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.
3183687|NCT01313169|No Intervention|Control|Control
3183559|NCT01314001|Placebo Comparator|Placebo (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
3183560|NCT01314001|Active Comparator|Varenicline (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take active varenicline pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~When taking the active varenicline, subjects will follow the same treatment regimen per the manufacturer.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
3183561|NCT01314001|Active Comparator|Transdermal Nicotine (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & will wear an active transdermal nicotine patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~When wearing the active transdermal nicotine, subjects will follow the same treatment regimen per the manufacturer.~All subjects in this arm will receive smoking cessation counseling during their sessions."
3183562|NCT01314001|Placebo Comparator|Placebo (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
3183563|NCT01314001|Active Comparator|Varenicline (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take active varenicline pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~When taking the active varenicline, subjects will follow the same treatment regimen per the manufacturer.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
3183564|NCT01314001|Active Comparator|Transdermal Nicotine (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & will wear an active transdermal nicotine patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~When wearing the active transdermal nicotine, subjects will follow the same treatment regimen per the manufacturer.~All subjects in this arm will receive smoking cessation counseling during their sessions."
3183565|NCT01313988|Active Comparator|Dose 1|Spread that contains plant sterols and fish oil
3183566|NCT01313988|Active Comparator|Dose 2|Spread that contains plant sterols and fish oil
3183567|NCT01313988|Active Comparator|Dose 3|Spread that contains plant sterols and fish oil
3183568|NCT01313988|Placebo Comparator|Placebo|Placebo spread
3183569|NCT01313988|Active Comparator|Control|Spread that contains plant sterols
3183570|NCT01313975||1|Patients with non-traumatic subarachnoid hemorrhage
3183571|NCT01313975||2|Patients with severe traumatic brain injury
3183572|NCT01313962|Experimental|Flufirvitide-3|
3183573|NCT01313962|Placebo Comparator|Placebo|
3183574|NCT01313949|No Intervention|Usual Care|A total of 90 patients with diabetes will be recruited. Thirty will be selected for the training course and the other 60 will be compared as controls. These controls will receive their usual diabetes care.
3183575|NCT01313949|Experimental|Peer leader training|"Peer leaders are people with diabetes who had volunteered to undertake an extensive program of training. The purpose of this training is to make them effective in the provision of support and advice to their peers on a one-to-one basis via telecommunication.~These diabetes patients will undergo a 32-hour 'Train the trainer' program (4 workshops, 8-hours each) led by health care experts in nutrition, physical activity, psychology and neuro-linguistic program [NLP] trainer to ensure the adequacy of knowledge and skills of these mentors."
3183576|NCT01313936|Experimental|15 mCi/kg of 131I-MIBG|The first cohort for safety will be 3-6 patients treated with vincristine and irinotecan and 15 mCi/kg of 131I-MIBG.
3183577|NCT01313936|Experimental|18 mCi/kg of 131I-MIBG|The second cohort will be 3-6 patients at the same doses of vincristine and irinotecan and 18 mCi/kg of 131I-MIBG.
3183578|NCT01313923|Experimental|Sirolimus (formerly known as Rapamycin)|Subjects with stable pemphigus vulgaris already on treatment with prednisone will be enrolled. Subjects will start taking oral sirolimus and have it up-titrated while decreasing the prednisone dosage. Their disease state will be monitored during this time.
3183579|NCT01313910|Experimental|ImmunoLin®|8-week treatment course
3183580|NCT01313897|Experimental|Velcade for Anti-MM therapy|Day(s) -9,-6,-2 3 doses of Bortezomib at 1.0 mg/m2, i.v.
3183581|NCT01313884|Experimental|Combination Therapy|"Regimen A alternating with Regimen B every 21 days~Regimen A:~Cytoxan 1200mg/m2~Doxorubicin, starting dose 75 mg/m2 to a maximum of 450mg/m2~Vincristine, starting dose 2 mg/m2 to a maximum of 2 mg~Pegfilgrastim, 6 mg subcutaneous within 24 to 48 hours after each cycle~Regimen B:~Irinotecan 50 mg/m2/day x 5 days~Temozolomide 100 mg/m2/day x 5 days followed by 2 weeks treatment-free"
3183582|NCT01313871||All Participants|Adults with a confirmed diagnosis of rheumatoid arthritis
3183685|NCT01313169|Experimental|EMR reminder|EMR reminder
3183688|NCT01313143|Experimental|AOP200704, infusion|
3183586|NCT01313845|Active Comparator|amantadine|administration of intravenous amantadine sulfate 200mg/500ml/bottle 1 bottle infusion over 3 hours, twice a day for consecutive 5 days
3183587|NCT01313845|Placebo Comparator|placebo|administration of 0.9% sodium chloride 500ml/bottle 1 bottle infusion over 3 hours twice a day for consecutive 5 days
3183588|NCT01313832|Experimental|remote ischemic preconditioning|
3183589|NCT01313819|Active Comparator|Group 1|Give IV amantadine first then IV placebo(normal saline) drug
3183590|NCT01313819|Active Comparator|Group 2|Give IV placebo drug first then IV amantadine
3183591|NCT01313806|Active Comparator|Resonator|Treatment with active Resonator device using low level magnetic fields
3183592|NCT01313806|Placebo Comparator|Placebo|
3183593|NCT01313793|Experimental|Sequence 1|Subjects will receive clinical formulation (treatment A) followed by commercializable formulation (treatment B).
3183594|NCT01313793|Experimental|Sequence 2|Subjects will receive commercializable formulation (treatment B) followed by clinical formulation (treatment A).
3183595|NCT01313780|Experimental|'Oxycodone/Naloxone'|Trade name is Targin(fixed combination drug).
3183596|NCT01313780|Active Comparator|Oxycodone|Trade name is Oxycontin(single compound).
3183597|NCT01313767|Experimental|Meditoxin®|Botulinum toxin type A
3183598|NCT01313767|Active Comparator|Botox®|Botulinum Toxin type A
3183599|NCT01313754|Other|Vicryl|These patients will receive the standard monocryl suture on their right sided inguinal incision and then will receive the vicryl material on the left.
3183600|NCT01313754|Experimental|Dermabond|The patients will receive the standard monocryl suture on their right sided inguinal incision and then will receive dermabond skin glue on the left
3183601|NCT01313741|Experimental|Single arm shoulder arthroplasty|
3183602|NCT01313728|Experimental|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks - all subjects participate in both arms in a split-face model
3183603|NCT01313728|Active Comparator|Tretinoin Gel Alone|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks - all subjects participate in both arms in a split-face model
3183604|NCT01313715|Experimental|160U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 45 children aged 13-60 months old on day0,28
3183605|NCT01313715|Experimental|320U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 45 children aged 13-60 months old on day0,28
3183606|NCT01313715|Experimental|640U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 45 children aged 13-60 months old on day0,28
3183607|NCT01313715|Experimental|160U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 45 infants aged 6-12 months old on day0,28
3183608|NCT01313715|Experimental|320U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 45 infants aged 6-12 months old on day0,28
3183609|NCT01313715|Experimental|640U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 45 infants aged 6-12 months old on day0,28
3183610|NCT01313715|Placebo Comparator|0/0.5ml placebo in children|0/0.5ml placebo in 45 children aged 13-60 months old on day0,28
3183611|NCT01313715|Placebo Comparator|0/0.5ml placebo in infants|0/0.5ml placebo in 45 infants aged 6-12 months old on day0,28
3183612|NCT01313702|Experimental|polipillV1|poli pill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
3183613|NCT01313702|Experimental|polipillV2|Polipill versão2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
3183614|NCT01313702|Active Comparator|usual care|
3183615|NCT01313689|Experimental|Ofatumumab|Biological
3183616|NCT01313689|Active Comparator|Physicians' Choice|Physicians' choice of treatment
3183617|NCT01313676|Experimental|fluticasone furoate/vilanterol|Combination of both products in one inhaler
3183618|NCT01313676|Experimental|fluticasone furoate|comparator of individual component
3183619|NCT01313676|Experimental|vilanterol|comparator of individual component
3183620|NCT01313676|Placebo Comparator|placebo|once daily via inhaler
3183621|NCT01313663|Experimental|Pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
3183622|NCT01313663|Active Comparator|Pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
3183623|NCT01313650|Experimental|GSK573719/GW642444|62.5/25mcg
3183624|NCT01313650|Experimental|GSK573719|62.5mcg
3183625|NCT01313650|Experimental|GW642444|25mcg
3183626|NCT01313650|Placebo Comparator|Placebo|Placebo
3183627|NCT01313637|Experimental|GSK573719/GW642444|125/25mcg
3183628|NCT01313637|Experimental|GSK573719|125mcg
3183629|NCT01313637|Experimental|GW642444|25mcg
3183630|NCT01313637|Placebo Comparator|Placebo|Placebo
3183631|NCT01313624|Experimental|AZLI-AZLI|Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
3183632|NCT01313624|Placebo Comparator|Placebo-AZLI|Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
3183633|NCT01313611|Experimental|Rituximab + bendamustine|
3183634|NCT01313598|Experimental|GLPG0187|GLPG0187 for infusion
3183635|NCT01313585||IPDA salbutamol MDI|receive a recorded increase in ICS therapy as BDP Easibreathe at the index date and also receive salbutamol MDI
3183636|NCT01313585||IPDA salbutamol EB|receive a recorded increase in ICS therapy as BDP Easibreathe at the index date and also receive salbutamol Easibreathe
3183637|NCT01313585||IPDI salbutamol EB|initiate ICS therapy as BDP Easibreathe at the index date and also receive salbutamol Easibreathe
3183638|NCT01313585||IPDI salbutamol MDI|initiate ICS therapy as BDP Easibreathe at the index date and also receive salbutamol MDI
3183639|NCT01313572|Experimental|Apadenoson|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson
3183689|NCT01313143|Active Comparator|Esmolol, infusion|
3183640|NCT01313572|Active Comparator|Adenosine|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with the active comparator: adenosine.
3183641|NCT01313559|Active Comparator|Cohort A (pasireotide)|Patients receive pasireotide IM once every 4 weeks
3183642|NCT01313559|Experimental|Cohort B (pasireotide and everolimus)|Patients receive pasireotide as in cohort A and everolimus PO QD
3183643|NCT01313546|Active Comparator|quadriceps|quadriceps muscular contraction
3183644|NCT01313546|Active Comparator|sartorius|stimulation of sartorius muscle through femoral nerve
3183645|NCT01313533|Active Comparator|Lactated Ringers Solution with Arginine|100 ml of LRS with arginine
3183646|NCT01313533|Placebo Comparator|Lactated Ringers Solution|Lactated ringers solution
3183647|NCT01313520|Experimental|Infliximab|3 mg/kg of Infliximab intravenous infusion
3183648|NCT01313520|Placebo Comparator|Placebo|saline via intravenous infusion
3183649|NCT01313507|Experimental|NewGam|Participants received NewGam 200-800 mg/kg intravenously every 3 or 4 weeks for 3 months (5 or 4 total infusions, respectively).
3183650|NCT01313494|Experimental|Roflumilast|Roflumilast 500 μg, tablet, oral, once daily for up to 24 weeks.
3183651|NCT01313494|Placebo Comparator|Placebo|Placebo to roflumilast, tablet, oral, once daily for up to 24 weeks.
3183652|NCT01313481|Experimental|Group exercise|Otago exercise performed in groups
3183653|NCT01313481|Active Comparator|Home exercise|Otago exercise performed as home exercise
3183654|NCT01313468|Experimental|4 x 4 Interval|4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
3183655|NCT01313468|Experimental|1 4 minutes interval|1 x 4 minutes intervals at 90-95% of HR max
3183656|NCT01313468|Experimental|Moderate continuous Training|47 minutes of Moderate continuous Training
3183657|NCT01313442||1|Subjects with a diagnosis of cancer
3183658|NCT01313429|Experimental|1|tumor cell vaccine administered with chemotherapy
3183659|NCT01313416|Experimental|Single arm|Combination CT-011 and Gemcitabine
3183660|NCT01313377|Experimental|ARM A: Gemox 85|Adjuvant chemotherapy for six months with gemcitabine - oxaliplatin 85mg / m² ( GEMOX 85)
3183661|NCT01313377|Other|ARM B:|Observation until progression or death
3183662|NCT01313364|Experimental|All subjects to self-administer 4 IM injections|Subjects will be recruited and stratified into BMI groups: <18.5 kg/m2, 18.5 to 24.9 kg/m2, 25 to 29.99 kg/m2, and >30 kg/m2 all with 20 subjects. To maintain a balance between sexes that is representative of the MS population, approximately 50 to 70% of subjects within each BMI group should be female.
3183663|NCT01313338||Acute coronary syndrome|
3183664|NCT01313325|Experimental|Treatment group|Children between 5-17 years who have balance deficits related to any movement disorder (preferably neuromuscular)
3183665|NCT01313312|Experimental|Total Dysport®|A total of 254 subjects in the open label study received between 1 and 5 intramuscular (i.m) injections of Dysport® according to their individual needs, for a period of up to 12 months. All subjects were administered an appropriate dosage of Dysport® (1000 Units [U] or 500 U) on Day 1 of treatment Cycle 1. At each study visit from Week 12 onwards, subjects were assessed to determine whether a subsequent treatment cycle was required and treatment cycles were administered at intervals of a minimum of 12 weeks apart depending on the subject's safety and efficacy response. From Cycle 2 onwards, a total dose of 1500 U could be administered in subjects requiring treatment with Dysport® in their shoulder and other upper limb muscles. Subjects who showed improvement in their upper limb during the first two treatment cycles were able to receive concomitant injections of Dysport® 500 U into at least one calf muscle, from Cycle 3 onwards as long as the total dose did not exceed 1500 U.
3183666|NCT01313299|Experimental|Dysport 500 U|
3183667|NCT01313299|Experimental|Dysport 1000 U|
3183668|NCT01313299|Placebo Comparator|Placebo|
3183669|NCT01313286|Experimental|LY2608204 Reference, LY2608204 Test|Single oral 80 mg dose of LY2608204 reference formulation in period 1; single oral 80 mg dose of LY2608204 test formulation in period 2. There is a washout period of at least 14 days between dosing periods.
3183670|NCT01313286|Experimental|LY2608204 Test, LY2608204 Reference|Single oral 80 mg dose of LY2608204 test formulation in period 1; single oral 80 mg dose of LY2608204 reference formulation in period 2. There is a washout period of at least 14 days between dosing periods.
3183671|NCT01313273|Other|Arm A|
3183672|NCT01313273|Experimental|Arm B|
3183673|NCT01313260||Epilepsy patients|Epilepsy patients selected before undergoing intracranial EEG recordings
3183674|NCT01313260||control group|Healthy volunteers
3183675|NCT01313247|Placebo Comparator|Placebo pills|Placebo tablets resembling paracetamol 500 mg are given as alternative 2 tablets 4 times daily
3183676|NCT01313247|Active Comparator|oral paracetamol 4 g daily|Patients are given 2 tablets of 500 mg paracetamol on a regular basis 4 times daily
3183677|NCT01313234|Experimental|Education|Educational theory based intervention and systematic daily pain assessment
3183678|NCT01313234|No Intervention|Control|Control group with care as usual
3183679|NCT01313221|Active Comparator|Etanercept 50 mg BIW|Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg etanercept twice weekly for 12 weeks.
3183680|NCT01313221|Experimental|Etanercept 50 mg QW + Topical|Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg etanercept once weekly plus as needed topical agents.
3183681|NCT01313208|Placebo Comparator|Placebo|"Participants received placebo subcutaneous injections once a week for 12 weeks and then open-label etanercept 50 mg subcutaneous injection once weekly for the next 12 weeks.~All participants continued their disease modifying anti-rheumatic drug (DMARD) treatment throughout the 24-week study period."
3183682|NCT01313208|Experimental|Etanercept|"Participants received etanercept 50 mg subcutaneous injection once weekly for 12 weeks and then open-label etanercept 50 mg subcutaneous injection for the next 12 weeks.~All participants continued their DMARD treatment throughout the 24-week study period."
3183683|NCT01313182|Active Comparator|3M Skin and Nasal Antiseptic|Povidone-iodine solution 5% w/w (0.5% available iodine) USP Patient Preoperative Skin Preparation
3183684|NCT01313182|Active Comparator|Bactroban Nasal|Mupirocin calcium ointment, 2%
3183690|NCT01313130||blast-related TBI|100 active duty US military personnel identified clinically as having suffered blast-related TBI
3183691|NCT01313130||non-blast-related TBI|100 active duty US military personnel identified clinically as having suffered non-blast-related TBI. TBI caused by other mechanisms such as motor vehicle crashes, falls, struck by blunt objects etc.
3183692|NCT01313130||other blast-related injuries|100 active duty US military personnel with blast-exposure and other blast-related injuries but no clinical evidence of TBI
3183693|NCT01313130||other non-blast injuries|100 active duty US military personnel with other non-blast injuries and no clinical evidence of TBI
3183694|NCT01313117|Experimental|Alpha lipoic acid|Oral administration three times daily (morning, mid-day, night)
3183695|NCT01313104|Experimental|Screening|See Detailed Description
3183696|NCT01313078|Experimental|Pegaspargase in women with cancer|Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks
3183697|NCT01313065|Experimental|VX15/2503|VX15/2503 monoclonal antibody at a concentration of 0.3 mg/kg - 20 mg/kg to be administered intravenously on a weekly dosing cycle.
3183698|NCT01313052|Experimental|Forensic Assertive Community Treatment (FACT)|Individuals in this arm will receive the services of an Assertive Community Treatment team and close supervision of a judge trained in the FACT model.
3183699|NCT01313052|Active Comparator|Enhanced Treatment as Usual|Individuals in this arm of the study will receive an expedited appointment at a clinic specializing in the treatment of psychotic disorders. These individuals will receive the services of a therapist, psychiatrist, and case manager.
3183700|NCT01313039|Experimental|AZD6244|
3183701|NCT01313026|Active Comparator|PNE first|patients randomised to start with PNE stimulation over 4 weeks. Then the stimulator will be removed and after a wash out period of 4 weeks they will be trained in transanal irrigation
3183702|NCT01313026|Active Comparator|TAI first|Patients randomised to start with transanal irrigation treatment in 8 weeks, thereafter a wash out period of 4 weeks before being implanted with a neuro stimulator
3183703|NCT01313013|Experimental|intervention|question prompt sheet
3183704|NCT01313013|No Intervention|control|no question prompt sheet
3183705|NCT01313000||Autologous fat transfer|
3183706|NCT01312987|Experimental|Nutrition intervention|Receives a month's supply of the nutrition supplement, Plumpy'doz®, in addition to food voucher for each month. Participants were also allowed to attend monthly educational sessions.
3183707|NCT01312987|No Intervention|Control|Receives food vouchers each month.
3183708|NCT01312961|Placebo Comparator|Placebo (for Dupilumab)|Placebo (for Dupilumab) subcutaneous (SC) injection once weekly (qw) for 12 weeks added to background therapy of inhaled corticosteroids/long-acting beta2-adrenergic agonist (ICS/LABA) (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.
3183709|NCT01312961|Experimental|Dupilumab 300 mg qw|Dupilumab 300 mg SC injection qw for 12 weeks added to background therapy of ICS/LABA (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.
3183710|NCT01312948|Experimental|Prototype mask|
3183711|NCT01312935|Experimental|Heparin and PMX-60056|
3183712|NCT01312922|Experimental|PNB01|oral, once daily administration
3183713|NCT01312922|Active Comparator|citalopram|oral, once daily administration
3183714|NCT01312922|Sham Comparator|pipamperone|oral, once daily administration
3183715|NCT01312909|Experimental|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
3183716|NCT01312909|Experimental|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
3183717|NCT01312909|Placebo Comparator|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
3183718|NCT01312883|No Intervention|Treatment as usual|Participants will receive standard postpartum education and discharge materials provided by the hospital and a list of community and Internet resources by mail.
3183719|NCT01312883|Experimental|Behavioral education|Participants will receive behavioral education on postpartum depression and a list of community and Internet resources by mail.
3183720|NCT01312870|Experimental|postoperative nutritional supplements|postoperative nutritional supplements in addition to standard hospital diet
3183721|NCT01312870|Placebo Comparator|standard hospital diet|patients receiving standard hospital diet
3183722|NCT01312857|Experimental|Randomization to panitumumab|Patients whose liver metastases have been completely resected will be randomized Arm A will receive Panitumumab in addition to HAI FUDR/Dexamethasone plus systemic CPT-11/5FU/LV
3183723|NCT01312857|Experimental|Randomization to No Panitumumab|Patients whose liver metastases have been completely resected will be randomized and patients randomized to Arm B will receive HAI FUDR/Dex plus systemic CPT-11/5FU/LV alone.
3183724|NCT01312844|Experimental|Scopolamine|Patients receiving IV scopolamine at ECT treatment
3183725|NCT01312844|Placebo Comparator|Placebo|Patients receiving IV placebo at ECT treatment
3183726|NCT01312831|Experimental|Oral Eligen® B12|Eligen® B12 1000 μg oral tablet taken in the fasted state as a single tablet with 50 mL water. Each dose self-administered daily, for 90 days, after an overnight fast and 1 hour before the morning meal.
3183727|NCT01312831|Active Comparator|IM B12|Commercially available 1000 μg cyanocobalamin administered IM as 1 mL from a vial containing 1000 μg/mL drug administered by study personnel, in the research clinic, in the morning, in the fasted state and at least 1 hour prior to the morning meal on study Days 1, 3, 7, 10, 14, 21, 30, 60 and 90.
3183728|NCT01312818|Experimental|Chemotherapy|Bortezomib IV Vorinostat PO Dexamethasone PO Intrathecal Methotrexate Imatinib Mesylate PO (for Ph+ ALL patients only)
3183729|NCT01312805|Active Comparator|CHICA Control|This arm received CHICA without the asthma module
3183730|NCT01312805|Experimental|CHICA Asthma Module|This arm received the CHICA asthma module
3183862|NCT01311908||Surgery, Roux-en-Y , reflux esophagitis|Patients with roux-en-Y reconstruction (study group)
3183959|NCT01311219|Active Comparator|Plate fixation|Operative Treatment-Plate fixation
3183731|NCT01312792|Experimental|Modified IMCI guideline|Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
3183732|NCT01312792|Active Comparator|Current IMCI guideline|Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
3183733|NCT01312779|Other|All subjects receive implant|Subjects serve as own control
3183734|NCT01312766|Experimental|hMG-IBSA|New hMG preparation.
3183735|NCT01312766|Active Comparator|Menopur|
3183736|NCT01312727|Other|HTIN|HTIN
3183737|NCT01312714|Active Comparator|Cholecalciferol|
3183738|NCT01312714|Placebo Comparator|Placebo|
3183739|NCT01312701||cancer patients|as described patietns with solid cancer about to be treated with anticancer therapies
3183740|NCT01312701||control group|normal populations who domated blood for further use
3183741|NCT01312688|Other|Standard hemodynamic therapy|Standard hemodynamic therapy currently accepted in our ICU
3183742|NCT01312688|Experimental|Early Goal Directed Hemodynamic Therapy|Early Goal Directed Hemodynamic Therapy according to the Surviving Sepsis Campaign Guidelines
3183743|NCT01312675|Experimental|Group A|S.A.F.E.BT plus Standard of Care therapy
3183744|NCT01312675|No Intervention|Group B|Standard of Care therapy alone
3183745|NCT01312662||normal ophthalmological status|
3183746|NCT01312662||opacity of the refractive media|
3183747|NCT01312662||maculopathy|
3183748|NCT01312662||optic neuropathy|
3183749|NCT01312662||chiasmal and postchiasmal visual pathway pathologies|
3183750|NCT01312662||amblyopia (deprivation)|
3183751|NCT01312662||amblyopia (strabism)|
3183752|NCT01312649|Experimental|Arm 1|Healthy volunteers
3183753|NCT01312649|Experimental|Arm 2|Schizophrenia with history of delusions of control
3183754|NCT01312649|Experimental|Arm 3|Schizophrenia without history of delusions of control
3183755|NCT01312649|Experimental|Arm 4|Bipolar disorders
3183756|NCT01312649|Active Comparator|Arm 5|Matched healthy controls
3183757|NCT01312636||A|
3183758|NCT01312623|Experimental|Remote ischemic preconditioning|Remote ischemic preconditioning at the left leg.
3183759|NCT01312623|No Intervention|Control|No ischemic preconditioning
3183760|NCT01312610|Experimental|High flavonone orange juice drink|
3183761|NCT01312610|Placebo Comparator|Control orange juice drink|Juice drink matched for sugar content
3183762|NCT01312597|Experimental|Fruit beverage|
3183763|NCT01312597|Experimental|Control beverage|
3183764|NCT01312584|Placebo Comparator|Non alkalised High Flavanol|Non-alkalised high flavanol cocoa drink containing 1745 mg of total flavanols
3183765|NCT01312584|Active Comparator|Alkalised high Flavanol|Alkalised high flavanol cocoa drink (medium alkalisation) containing 410 mg of total flavanols
3183766|NCT01312584|Active Comparator|Alkalised Low Flavanol|Alkalised low flavanol cocoa drink (heavily alkalised) containing 1.26 mg of total flavanols
3183767|NCT01312571|Active Comparator|Cognitive behavior therapy via the internet|Cognitive behavior therapy via the internet with therapist support.
3183768|NCT01312571|Active Comparator|Attentional retraining|Attentional retraining as described by Nader Amir.
3183769|NCT01312558|Experimental|Prudent diet group|Participants follow CPAP therapy, a prudent diet while receiving counselling to increase their physical activity.
3183770|NCT01312558|Experimental|Mediterranean diet group|Participants follow CPAP therapy, Mediterranean diet, while receiving counselling to increase their physical activity.
3183771|NCT01312545|Experimental|local made implant (3DP)|Enucleation and local made implant (3DP) insertion
3183772|NCT01312545|Experimental|imported implant (Medpor)|Enucleation and imported implant (Medpor) insertion
3183773|NCT01312532|Other|fixed-bearing|fixed-bearing device is a kind of prosthesis
3183774|NCT01312532|Other|mobile-bearing|mobile-bearing device is a kind of prosthesis
3183775|NCT01312519|Active Comparator|Manual bone marrow sampling device|Hollow needle with a t-shaped handle manually pushed into the bone for the purpose of bone marrow aspiration and core biopsy collection. Manual Bone Marrow Sampling Device.
3183776|NCT01312519|Active Comparator|OnControl Bone Marrow System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest. OnControl Bone Marrow Biopsy and Aspiration System.
3183777|NCT01312506||Subjects undergoing a craniotomy|This group will include those subjects who have consented to have either a craniotomy or a laminectomy to resect an intramedullary tumor.
3183778|NCT01312506||Metastases, no craniotomy|These subjects have metastases but have either chosen not to undergo removal of the cancer or their neurosurgeon does not recommend surgical approach or they have been diagnosed with metastatic melanoma but do not have CNS metastases.
3183779|NCT01312506||Healthy Volunteers|Subjects who do not have known melanoma or metastases.
3183780|NCT01312480|Other|Intervention Group|The smoking cessation intervention is a Public Health Services-approved intervention based on the 5A's Model, which includes (1) Ask if the patient smokes, (2) Advise every patient to quit, (3) Assess readiness to quit, (4) Assist in quitting and finding services and (5) Arrange for cessation services and follow up. Practitioners will complete a 5A checklist for each patient in this arm.
3183781|NCT01312480|Other|Control Group|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
3183863|NCT01311908||surgery, traditional gastrojejunostomy|Traditional gastrojejunostomy reconstruction (control group).
3183782|NCT01312467|Experimental|Prevention (metformin hydrochloride)|Patients receive metformin hydrochloride PO QD during week 1 and then BID during weeks 2-12. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.
3183783|NCT01312454|Experimental|AL-59412C Concentration 1|AL-59412C injectable solution, single intravitreal injection
3183784|NCT01312454|Experimental|AL-59412C Concentration 2|AL-59412C injectable solution, single intravitreal injection
3183785|NCT01312454|Active Comparator|Travoprost|Travoprost injectable solution, single intravitreal injection
3183786|NCT01312454|Placebo Comparator|Vehicle|AL-59412C Vehicle, single intravitreal injection
3183787|NCT01312441|Experimental|Ergocalciferol|Ergocalciferol 50,000 IU by mouth once weekly for 6 months
3183788|NCT01312441|Placebo Comparator|Placebo|Placebo by mouth once weekly for 6 months
3183789|NCT01312428|Other|Pelvic Alignment Level (PAL)|Pelvic Alignment Level Instrument Used
3183790|NCT01312428|Other|No Pelvic Alignment Level (PAL)|No Pelvic Alignment Level Instrument Used
3183791|NCT01312415|Experimental|levobupivacaine infiltration|Patients will receive spinal anaesthesia with intrathecal bupivacaine (17.5 or 15 mg) without morphine, and will receive peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% at 8am the following morning.
3183792|NCT01312415|Other|Control|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
3183793|NCT01312402|Active Comparator|Topical Brinzolamide (Azopt)|ophthalmic drop given three times a day
3183794|NCT01312402|Placebo Comparator|placebo ophthalmic drop in 5 mL solution|masked non-active eye drop (absence of Brinzolamide)
3183795|NCT01312389|Experimental|Arm A|10 patients will receive vaccine (OC-L, an autologous vaccine comprised of autologous oxidized tumor cell lysate, admixed with Montanide ISA 51 VG) injected by intradermal/subcutaneous injection in both groin regions.
3183796|NCT01312389|Experimental|Arm B|10 patients will receive vaccine (OC-L, an autologous vaccine comprised of autologous oxidized tumor cell lysate, admixed with Montanide ISA 51 VG) injected by intradermal/subcutaneous injection in both groin regions, administered in combination with intravenous Ampligen.
3183797|NCT01312350|Active Comparator|CCRT only arm|no neoadjuvant chemotherapy before definitive CCRT
3183798|NCT01312350|Experimental|neoadjuvant chemotherapy arm|2 cycles of TPF chemotherapy before definitive CCRT
3183799|NCT01312337|Experimental|Iressa for EGFR wild group|salvage Iressa therapy for patients with EGFR mutation negative NSCLC patients
3183800|NCT01312324|Experimental|neoadjuvant chemotherapy|3 cycles of docetaxel/cisplatin before operation
3183801|NCT01312311|Experimental|weekly docetaxel and cisplatin|Docetaxel 35mg/m2 D1 & D8 Cisplatin 70mg/m2 D1 every 3 weeks maxinum 6 cycles
3183802|NCT01312298|Experimental|General Anesthesia|Patients allocated to this arm will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml in a Target Controlled Infusion (TCI)
3183803|NCT01312298|Active Comparator|Regional anesthesia|Patients will receive intrathecal anesthesia
3183804|NCT01312285|Placebo Comparator|Placebo|
3183805|NCT01312285|Experimental|Resonator Device|
3183806|NCT01312272|Placebo Comparator|Inactive nasal spray|A placebo nasal spray will be prepared to be otherwise identical to the active treatment nasal spray except lacking oxytocin. The ingredients in the inactive nasal spray are mannitol, glycerin, and preserved water.
3183807|NCT01312272|Experimental|Intranasal Oxytocin|Oxytocin nasal spray (40 units/ml) will be administered in a single intranasal dose of 40 IU. Its formula is: oxytocin 1 unit/mg mannitol trituration 0.2Gm + glycerin USP 0.1ml + preserved water 5ml.
3183808|NCT01312259|Active Comparator|Interstim Parameter Frequency 14 HZ|Subjects in this arm will receive 14 Hx as their frequency for the first three months. For the second 3 months, these patients will receive 40 Hz. Six months after the devise has been implanted, the patient has the option to choose which frequency they feel allows for better symptom control, and this is how the devise will be programmed.
3183809|NCT01312259|Experimental|Interstim Parameter Frequency 40 HZ|Subjects in this arm will receive 40 Hz as their frequency for the first three months. For the second 3 months, these patients will receive 14 Hz. Six months after the devise has been implanted, the patient has the option to choose which frequency they feel allows for better symptom control, and this is how the devise will be programmed.
3183810|NCT01312233|Active Comparator|Medical Care|Conventional medical care alone
3183811|NCT01312233|Active Comparator|Dual Care|Unlinked co-occurrence of conventional medical care and chiropractic care
3183812|NCT01312233|Active Comparator|Shared Care|Co-management of medical care and chiropractic care
3183813|NCT01312194|Experimental|One vist group|All patients included in this treatment group will receive the complete endodontic treatment in a single visit.
3183814|NCT01312194|Active Comparator|Two-vist group|All patients included in this treatment group will receive treatment in two visits. The first will be done chemo mechanical root canal preparation, the placement of the intracanal medication the basis of calcium hydroxide and coronal sealing. Ten to twelve days later, this medication is removed and the root canal will be permanently filled.
3183815|NCT01312181|Active Comparator|HealthCall +Motivational Interviewing|Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
3183864|NCT01311895|Experimental|H2O|2 mg IV hydromorphone administered over 2-3 minutes as initial dose
3183865|NCT01311895|Experimental|1+1|"1 mg IV hydromorphone followed by an additional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the following question: Do you want more pain medication?"
3183816|NCT01312181|Active Comparator|Motivational Interviewing (MI)|The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
3183817|NCT01312181|Placebo Comparator|HIV/AIDS health education - DVD control|HIV/AIDS health education - DVD control. The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.
3183818|NCT01312168|No Intervention|Healthy non-OSA control|
3183819|NCT01312168|Experimental|OSA receiving therapeutic CPAP|
3183820|NCT01312168|Sham Comparator|OSA receiving subtherapeutic CPAP|
3183821|NCT01312155||Patients undergoing general anesthesia|
3183822|NCT01312142||patients with difficult weaning|
3183823|NCT01312129|Experimental|Sulfasalazine|Sulfasalazine 1500 mg
3183824|NCT01312129|Placebo Comparator|Placebo|Placebo capsule x 3 doses 12 hours apart
3183825|NCT01312116|Experimental|Internet-delivered CBT|Active treatment: Internet-delivered Cognitive Behavior Therapy, 8 weeks treatment, guided self-help
3183826|NCT01312116|Experimental|Internet-delivered PDT|Active treatment: Internet-delivered Psychodynamic Therapy Active treatment: Internet-delivered Psychodynamic Therapy, 8 weeks treatment, guided self-help
3183827|NCT01312116|No Intervention|Control condition|Wait-list condition, received treatment 3 months after initial treatment period
3183828|NCT01312103|Experimental|Internet Based Safety Decision Aid|
3183829|NCT01312103|Active Comparator|Control Website|
3183830|NCT01312090|Active Comparator|Conventional weight loss treatment group|Eating and physical activity counseling and behavioral therapy for weight loss.
3183831|NCT01312090|Experimental|Cryo group|"Eating and physical activity counseling and behavioral therapy for weight loss will be provided to all subjects.~The subjects in the cryo group will be given whole-body cryotherapy 1-3 times a week for the 4-month-treatment period"
3183832|NCT01312077|Experimental|Levobupivacaine infiltration|Patients will receive spinal anaesthesia with intrathecal bupivacaine, and will receive peri- and intraarticular surgical site infiltration during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure and this will be left in situ in the wound. The catheter will be sited under the fascia lata exiting antero-superior to the incision. A bacterial filter will be attached and it will be connected to an elastomeric pump which will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.
3183833|NCT01312077|Other|Control|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.2 mg).
3183834|NCT01312064|Active Comparator|rituximab and everolimus|Patients of the study arm will receive rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus will be given with an initial dose of 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
3183835|NCT01312064|Active Comparator|thymoglobulin and tacrolimus|The control arm will receive thymoglobulin induction and tacrolimus-based immunosuppressive therapy. The dose of thymoglobulin would be 1.0mg/kg/d for 3 days25. The first dose of thymoglobulin will be administered before graft kidney reperfusion, and so is rituximab. All patients will receive corticosteroid therapy as usual. The initial daily dose of tacrolimus will be 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation. The doses of tacrolimus will be adjusted to target the whole blood trough levels between 8 to 12 ng/ml during the first 30 days after transplantation, and tapered to 6 to 10 ng/ml at 6 months.
3183836|NCT01312051||Protocol 1|Healthy, overweight 11 to 17 year old black and white adolescents
3183837|NCT01312051||Protocol 2|Healthy, normal-weight 11 to 17 year old black and white adolescents
3183838|NCT01312051||Protocol 3|Healthy, normal-weight 8 to 12 year old black and white adolescents
3183839|NCT01312051||Protocol 4|Healthy, overweight 11 to 17 year old black and white adolescents
3183840|NCT01312038|Experimental|simethicone|125 mg tablet
3183841|NCT01312038|Placebo Comparator|placebo|chewable calcium tablet
3183842|NCT01312025|Placebo Comparator|conventional laparoscopic cholecystectomy|
3183843|NCT01312025|Active Comparator|modified laparoscopic cholecystectomy|
3183844|NCT01312012|Experimental|The effectiveness and feasibility, using antiviral therapy|Experimental: Subjects receive tenofovir disoproxil fumarate (TDF) oral use prior to delivery in pregnant women with positive serum HBeAg and HBsAg and high HBV DNA levels > 10^8copies / mL, to reduce the rate of mother to infant transmission of HBV infection, and also to monitor the safety of the therapy.
3183845|NCT01312012|No Intervention|Control|Subjects receive no intervention, but with blood tests for mothers and infants before and after delivery, as a comparative group to experimental arm.
3183846|NCT01311999||IGRA-positive group|The subjects who have positive results of interferon-gamma release assay
3183847|NCT01311999||IGRA-negative group|The subjects who have negative results of interferon-gamma release assay
3183848|NCT01311986||Patients with atopic dermatitis|
3183849|NCT01311986||Patients with nummular eczema|
3183850|NCT01311986||Normal control|
3183851|NCT01311973||Renal Function Group #1|Creatinine clearance > 90 mL/min
3183852|NCT01311973||Renal Function Group #2|Creatinine clearance 60-69 mL/min
3183853|NCT01311973||Renal Function Group #3|Creatinine clearance 50-59 mL/min
3183854|NCT01311973||Renal Function Group #4|Creatinine clearance 40-49 mL/min
3183855|NCT01311973||Renal Function Group #5|Creatinine clearance 30-39 mL/min
3183856|NCT01311973||Renal Function Group #6|Creatinine clearance 20-29 mL/min
3183857|NCT01311973||Renal Function Group #7|Creatinine clearance < 20 mL/min (not on dialysis)
3183858|NCT01311960|Experimental|bevacizumab eye drop|
3183859|NCT01311960|Experimental|placebo normal saline eye drop|
3183860|NCT01311934||HBV-infected|
3183861|NCT01311934||HCV-infected|
3183957|NCT01311232||Control|Patients without HBV reactivation
3183866|NCT01311882|Experimental|MK-4305 40 mg|Day 1 and Day 8- 4 x 10 mg MK-4305 and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 4 x 10 mg MK-4305
3183867|NCT01311882|Experimental|MK-4305 20 mg|Day 1 and Day 8- 2 x 10 mg MK-4305 and 2 x 10 mg MK-4305 matching placebo and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 2 x 10 mg MK-4305 and 2 x 10 mg MK-4305 matching placebo
3183868|NCT01311882|Active Comparator|Zopiclone 7.5 mg|Day 1 and Day 8- 1 x 7.5 mg zopiclone and 4 x 10 mg MK-4305 matching placebo; Days 2-7- 4 x 10 mg MK-4305 matching placebo
3183869|NCT01311882|Placebo Comparator|Placebo|Day 1 and Day 8- 4 x 10 mg MK-4305 matching placebo and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 4 x 10 mg MK-4305 matching placebo
3183870|NCT01311869|Active Comparator|EGCG ( Green Tea extract)|40 subjects will receive 800 mg EGCG orally per day for 6 months versus 40 subjects will receive Brown Rice pill for 6 months
3183871|NCT01311869|Placebo Comparator|Brown Rice pills|40 subjects will receive 800 mg brown rice pills orally per day for 6 months versus 40 subjects will receive EGCG capsule for 6 months
3183872|NCT01311856||Standard Arm (mail/telephone)|
3183873|NCT01311856||Internet Arm|
3183874|NCT01311830|Active Comparator|Telephone Counseling|
3183875|NCT01311830|Placebo Comparator|Written Materials|
3183876|NCT01311817|Placebo Comparator|Saline Patch|1mL saline applied to the vaccine patch
3183877|NCT01311817|Experimental|Bacteria plus CT|0.95mL bacterial vector plus 0.05mL cholera toxin
3183878|NCT01311804|Experimental|periarticular parecoxib sodium|patients will be given periarticular parecoxib sodium injection
3183879|NCT01311804|Active Comparator|intravenous parecoxib sodium|intravenous parecoxib sodium will be given during total knee arthroplasty
3183880|NCT01311791|Experimental|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure.
3183881|NCT01311791|Active Comparator|Standard Medical Therapy|as per protocol
3183882|NCT01311778|Placebo Comparator|Placebo|Subjects will receive placebo
3183883|NCT01311778|Experimental|CBD 400 mg|Subjects will receive 400 mg CBD
3183884|NCT01311778|Experimental|CBD 800mg|Subjects will receive 800 mg CBD
3183885|NCT01311765|Active Comparator|8 day-antibiotherapy|Duration of antibiotic therapy limited to 8 days: Antibiotics received for up to 8 days following surgery for postoperative peritonitis in patients hospitalised in intensive care unit
3183886|NCT01311765|No Intervention|15 day-antibiotherapy|Antibiotics received for up to15 days following surgery for postoperative peritonitis in patients hospitalised in intensive care unit corresponding to usual practice and recommendations
3183887|NCT01311739|Experimental|10 mg Eligen® B12 (Cyanocobalamin/SNAC)|A single oral dose of Eligen® B12, cyanocobalamin/SNAC (5 mg cyanocobalamin/100 mg SNAC) administered in the fasted state as 2 tablets taken with 50 mL of water resulting in a total dose of 10 mg cyanocobalamin and 200 mg SNAC.
3183888|NCT01311739|Experimental|5 mg Eligen® B12 (Cyanocobalamin/SNAC)|A single oral dose of Eligen® B12, cyanocobalamin/SNAC (5 mg cyanocobalamin/100 mg SNAC) administered in the fasted state as a tablet taken with 50 mL of water resulting in a total dose of 5 mg cyanocobalamin and 100 mg SNAC.
3183889|NCT01311739|Active Comparator|5 mg Oral Cyanocobalamin|A single oral dose of cyanocobalamin alone (5 mg cyanocobalamin, commercial: VITALABS, INC) administered in the fasted state as a tablet taken with 50 mL of water resulting in a total dose of 5 mg cyanocobalamin.
3183890|NCT01311739|Active Comparator|1 mg Intravenous Cyanocobalamin|A single intravenous (IV) dose of cyanocobalamin (1 mg cyanocobalamin) administered in the fasted state. Each subject will receive a 1 mL IV injection of a 1 mg/mL (1000 μg/mL) solution resulting in a total dose of 1 mg cyanocobalamin.
3183891|NCT01311713|Experimental|(Part 1): CEP-9722|
3183892|NCT01311713|Experimental|(Part 2): CEP-9722|
3183893|NCT01311700|Active Comparator|Early metoprolol initiation strategy|
3183894|NCT01311700|No Intervention|Delayed metoprolol initiation strategy|
3183895|NCT01311687|Experimental|Oral Pomalidomide plus Low-Dose Dexamethasone|"For Subjects ≤ 75 years of age:~4 mg pomalidomide will be administered by mouth on Days 1-21 of each 28-day treatment cycle until disease progression and 40 mg low-dose dexamethasone will be administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression~For Subjects > 75 years of age:~4 mg pomalidomide will be administered by mouth on Days 1-21 of each 28-day treatment cycle until disease progression and 20 mg low dose dexamethasone will be administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression"
3183896|NCT01311687|Active Comparator|High-Dose Dexamethasone|"For Subjects ≤ 75 years of age:~40 mg high-dose dexamethasone will be administered by mouth once per day on Days 1 through 4, 9 through 12, and 17 through 20 of a 28-day cycle until disease progression~For Subjects > 75 years of age:~20 mg high-dose dexamethasone will be administered by mouth once per day on Days 1 through 4, 9 through 7, and 17 through 20 of a 28-day cycle until disease progression"
3183897|NCT01311674|Active Comparator|Schedule 1|
3183898|NCT01311674|Experimental|Schedule 2|
3183899|NCT01311661|Experimental|Olodaterol medium daily dose|Olodaterol medium daily dose given either as once daily or split into two low doses daily or placebo only in randomised sequence of three cross-over treatment phases
3183900|NCT01311661|Experimental|Olodaterol high daily dose|Olodaterol high daily dose given either as once daily or split into two medium doses daily or placebo only in randomised sequence of three cross-over treatment phases
3183901|NCT01311648|Experimental|Arm 1|PTPs prophylaxis treatment 25-50 IU/kg at least 2x/week. PUPs 15 -50 IU/kg at least 1x/week.
3183902|NCT01311635|Experimental|Treatment A|
3183903|NCT01311635|Experimental|Treatment B|
3183904|NCT01311635|Experimental|Treatment C|
3183905|NCT01311635|Experimental|Treatment D|
3183906|NCT01311622|Experimental|warfarin|
3183907|NCT01311622|Experimental|warfarin and fostamatinib|
3183908|NCT01311609|Experimental|Systane|Systane Lubricant Eye Drops
3183909|NCT01311596||No icons|"Clinic - Children who are established patients, 4-18 years old, and presented to the NeuroDevelopmental Science Center for a follow-up office visit during the first 2 weeks of the study period~Lab -Patients 4-18 years old with a documented diagnosis who were seen in the NeuroDevelopmental Science Center and were given a prescription for lab work during the first 2 weeks of the study period"
3183958|NCT01311219|Active Comparator|No surgery|Non-operative Treatment
3183910|NCT01311596||Icons|"Clinic - Children who are established patients, 4-18 years old, and presented to the NeuroDevelopmental Science Center for a follow-up office visit during the last 2 weeks of the study period~Lab - Patients 4-18 years old with a documented diagnosis who were seen in the NeuroDevelopmental Science Center and were given a prescription for lab work during the last 2 weeks of the study period"
3183911|NCT01311583|Active Comparator|usual care plus Teach Back intervention|Trained nurses will provide Teach Back to the intervention group. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
3183912|NCT01311583|No Intervention|usual care|"All participants will experience the current practice of discharge teaching: daily interaction with the interdisciplinary team members via rounds, counseling on diet and medications with a dietician and pharmacist when referred, view the Heart Failure Discharge Video, and receive a Congestive Heart Failure education package which includes the Heart and Stroke Managing Congestive Heart Failure booklet."
3183913|NCT01311570|Experimental|Buprenorphine|
3183914|NCT01311557|Experimental|Adacel Vaccine Group 1|Participants enrolled at 10 to < 11 years of age
3183915|NCT01311557|Experimental|Adacel Vaccine Group 2|Participants enrolled at 11 to < 12 years of age
3183916|NCT01311531|Active Comparator|TriMed fragment-specific fixation|
3183917|NCT01311531|Active Comparator|TriMed volar locking plate|
3183918|NCT01311518|Placebo Comparator|Placebo|
3183919|NCT01311518|Active Comparator|Drug: Thymosin Beta 4 injectable|
3183920|NCT01311505|Active Comparator|A|Test
3183921|NCT01311505|Active Comparator|B|Reference
3183922|NCT01311492|Placebo Comparator|Healthy Lifestyle Program|The purpose of the healthy lifestyle group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest.
3183923|NCT01311492|Active Comparator|Physical Activity Intervention|The physical activity program includes aerobic, strenth, flexibility and balance training.
3183924|NCT01311479|Active Comparator|Osteopathic Manipulation|"Patients will be evaluated and examined by an Osteopathic physician. This examination will consist of full osteopathic structural exam, and a focused examination of the sacroiliac joint and the surrounding musculature.~Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction."
3183925|NCT01311479|Active Comparator|Massage Therapy|Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment.
3183926|NCT01311466|Experimental|Liver transplantation|The liver transplantation will be performed as described by the standard protocol, Liver Transplantation Protocol (Version 2006) at the Oslo University Hospital
3183927|NCT01311440|Experimental|Modified Atkins diet treatment|12 weeks of Modified Atkins diet treatment, recording seizures
3183928|NCT01311440|No Intervention|No intervention|12 weeks seizure record
3183929|NCT01311427|Active Comparator|Group education|The control condition received standard group education, which met in small groups two times weekly for 60 minutes over 12 weeks.
3183930|NCT01311427|Experimental|8-form Yang-style Tai chi program|This arm tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in small groups two times weekly for 60 minutes over 12 weeks.
3183931|NCT01311414|Experimental|cafedrine/theodrenalin|
3183932|NCT01311401||Rehania village (Kfar Rehania)|Circassian community
3183933|NCT01311401||Kama village (Kfar Kama )|Circassian community
3183934|NCT01311375|Experimental|w3 supplement + capsule CA-D|Mor DHA :w3 supp will be given to this group + capsule Ca(500 mg)-D(200 micro gram)
3183935|NCT01311375|Placebo Comparator|placebo+ CA-D|placebo in the same color,shape,size
3183936|NCT01311362||CYP2C19 wild type|"CYP2C19 wild type =extensive metaboliser~Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~Administration of St. Johns wort: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
3183937|NCT01311362||CYP2C19 mutant|"CYP2C19 *2/*2 or *2/*3 or *3/*3 = poor metaboliser~Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~Administration of St. Johns wort: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
3183938|NCT01311349||1|A listing of all isolates meeting the inclusion criteria will be maintained.
3183939|NCT01311336|Active Comparator|Loratadine|Loratadine 10 mg once a day for 7 days beginning the day of pegfilgrastim treatment in patients with pegfilgrastim-induced back and leg pain during the previous treatment cycle
3183940|NCT01311336|Placebo Comparator|Placebo|Placebo once a day for 7 days beginning the day of pegfilgrastim treatment in patients with pegfilgrastim-induced back and leg pain during the previous treatment cycle
3183941|NCT01311323|Experimental|PCI with DES implantation|Percutaneous Coronary Intervention Implantation of Drug-Eluting Stents
3183942|NCT01311323|Active Comparator|CABG|Coronary Artery Bypass Grafting.On-pump or Off-pump CABG
3183943|NCT01311310|Experimental|remote ischemic preconditioning|
3183944|NCT01311297||Perioperative ovarian cancer patients|
3183945|NCT01311297||Pregnant patients|
3183946|NCT01311297||Female healthy volunteers|
3183947|NCT01311284|Active Comparator|Macintosh|
3183948|NCT01311284|Active Comparator|Mcgrath|
3183949|NCT01311284|Active Comparator|Airtraq Nasotracheal|
3183950|NCT01311271|Sham Comparator|Sham rTMS-Sham rTMS|Sham rTMS for 2 weeks
3183951|NCT01311271|Experimental|Sham rTMS-Real rTMS|Sham rTMS in the first week and real rTMS in the second week
3183952|NCT01311271|Experimental|Real rTMS-Real rTMS|Real rTMS for 2 weeks
3183953|NCT01311245|Experimental|Stage-tailored|At baseline and three months later
3183954|NCT01311245|Experimental|Non-stage-tailored|At baseline and three months later
3183955|NCT01311245|No Intervention|Control group|Assessment only
3183956|NCT01311232||Case|Patients with HBV reactivation
3183960|NCT01311219|Active Comparator|Intramedullary pinning|Operative Treatment-Intramedullary Pinning
3183961|NCT01311206|Experimental|PBFR|Partial Blood Flow Restriction (PBFR) during Low-Intensity Exercise.
3183962|NCT01311206|Active Comparator|PBFR control|Low-Intensity Exercise without partial blood flow restriction.
3183963|NCT01311193|Experimental|light therapy|Morning bright light treatment (at 8000 lux for 40min, daily during 3 weeks)
3183964|NCT01311180|Experimental|Sensoril®|
3183965|NCT01311180|Placebo Comparator|Placebo|
3183966|NCT01311167|Experimental|Dexamethasone|
3183967|NCT01311167|Placebo Comparator|Placebo|
3183968|NCT01311141|Experimental|Doripenem i.v.|no comparator, PK study
3183969|NCT01311128|Experimental|Heart rate and blood pressure determination|All subjects have the same conditions (T-line, blood pressure cuff, and radial artery catheter), in order to compare them within-subjects.
3183970|NCT01311115|Experimental|Group commitment contracts|"In addition to education and counseling, the intervention includes the following components:~Each participant is encouraged to deposit his cigarette money on a weekly basis, to be returned only if the smoker quits successfully within three months.~The project gives a series of two matching contributions of 150 baht each to participants who meet certain deposit requirements.~Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt."
3183971|NCT01311115|Active Comparator|Education and counseling|Participants in this group receive educational pamphlets about quitting smoking and one-time, group counseling from a nurse trained in smoking cessation counseling.
3183972|NCT01311102|Experimental|2% Lidocaine liquid|1.33cc of 2% liquid lidocaine infused in endo cervix and endometrium
3183973|NCT01311102|Placebo Comparator|Normal Saline|1.33cc of normal saline infused in endo cervix and endometrium
3183974|NCT01311089||Robotic thyroidectomy group|Robotic thyroidectomy group is the patient group who underwent robot-assisted endoscopic thyroid surgery using a gasless, trans-axillary approach.
3183975|NCT01311089||conventional open thyroidectomy group|Conventional open thyroidectomy group is th patient group who underwent thyroid surgery via neck incision.
3183976|NCT01311076|Experimental|TAK-329 50 mg|
3183977|NCT01311076|Experimental|TAK-329 200 mg|
3183978|NCT01311076|Active Comparator|Insulin 0.2 U/kg|
3183979|NCT01311076|Placebo Comparator|Placebo|
3183980|NCT01311024||Sibling vaccinated with PCV GSK1024850A|"Older sibling of a child vaccinated with Pneumococcal conjugate vaccine GSK1024850A in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)~NOTE: the primary analysis cohort include siblings of the PCV-vaccinated according to infant schedules (excluding siblings of catch-up vaccinated children)"
3183981|NCT01311024||Control-vaccinated sibling|"Older sibling of a child vaccinated with control vaccine (hepatitis B vaccine or hepatitis A vaccine) in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)~NOTE: the primary analysis cohort include siblings of the PCV-vaccinated according to infant schedules (excluding siblings of catch-up vaccinated children)"
3183982|NCT01310998|Experimental|schizophrenic disorder|
3183983|NCT01310998|Experimental|other psychotic disorder|
3183984|NCT01310998|Experimental|no mental disorder|
3183985|NCT01310933||Kikuchi's disease|
3183986|NCT01310933||Malignant lymphoma|
3183987|NCT01310920||sick sinus syndrome|
3183988|NCT01310920||control|
3183989|NCT01310907||sinus node dysfunction|
3183990|NCT01310907||Atrioventricular block|
3183991|NCT01310907||control|
3183992|NCT01310894|Experimental|TOOKAD® Soluble|TOOKAD® Soluble, lyophilized formulation, given at a dose of 4mg/Kg.
3183993|NCT01310894|No Intervention|Active Surveillance|Active surveillance is one of the management strategy in men who have low-risk prostate cancer
3183994|NCT01310881|Experimental|Dose 1|
3183995|NCT01310881|Experimental|Dose 2|
3183996|NCT01310881|Experimental|Dose 3|
3183997|NCT01310881|Experimental|Dose 4|
3183998|NCT01310881|Experimental|Dose 5|
3183999|NCT01310881|Experimental|Dose 6|
3184000|NCT01310881|Experimental|Dose 7|
3184001|NCT01310868|Experimental|5-ALA and Gliadel wafers|This is a single arm feasibility study to evaluate the safety and tolerability of combining 2 technologies (5-ALA and Gliadel wafers) in the surgical management of patients with GBM.
3184002|NCT01310855|Active Comparator|Cediranib & Gefitinib|Cediranib maleate 30mg od orally and gefitinib 500mg od orally. Each cycle of treatment lasts 6 weeks. Treatment will continue until confirmation of progression, patient decision or the development of unacceptable toxicity (if there is radiological progression only treatment can continue if the investigator has the opinion that the patient is receiving benefit.
3184003|NCT01310855|Placebo Comparator|Cediranbib & placebo|Cediranib maleate 30mg od orally and placebo 500mg od orally. Each cycle of treatment lasts 6 weeks. Treatment will continue until confirmation of progression, patient decision or the development of unacceptable toxicity (if there is radiological progression only treatment can continue if the investigator has the opinion that the patient is receiving benefit.
3184004|NCT01310842||Pilot Smoking Cessation|4 weeks nicotine patch therapy, self-help materials, and 5 in-person counseling sessions.
3184005|NCT01310842||Smoking Cessation|4 weeks nicotine patch therapy, self-help materials, and 7 in-person counseling sessions.
3184006|NCT01310829||Virtual Reality|Board-eligible or board-certified genetic counselors and students evaluate a virtual reality-based intervention using questionnaires and physiological measurements.
3184007|NCT01310816|Active Comparator|IPI-926|IPI-926
3184008|NCT01310816|Placebo Comparator|Sugar Pill|Placebo Arm, sugar pill
3184009|NCT01310803|Experimental|Maintenance therapy|Chemotherapeutic: EN3329-301 (VALSTAR)
3184010|NCT01310803|Other|No Maintenance (Standard of care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
3184011|NCT01310777|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months
3184012|NCT01310777|Active Comparator|Brinz|Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months
3184013|NCT01310777|Active Comparator|Brim|Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye 2 times a day for 6 months
3184014|NCT01310764|Sham Comparator|Mitomycin C|Those with trabeculectomy and intraoperative application of mitomycin C.
3184015|NCT01310764|Active Comparator|Bevacizumab|Those with trabeculectomy and adjunctive intraoperative subconjunctival injection of bevacizumab.
3184016|NCT01310751|Experimental|iloprost nebuliser solusion|50 ng/kg/min
3184017|NCT01310751|Placebo Comparator|distilled water|2ml
3184018|NCT01310738|Active Comparator|Meglumine antimoniate|Antimoniate of N-methylglucamine 20mg/kg/d, I.V. for 20 consecutive days.
3184019|NCT01310738|Experimental|Liposomal Amphotericin B|Liposomal amphotericin B 3mg/kg/d I.V. for 7 consecutive days.
3184020|NCT01310738|Experimental|Amphotericin B|Amphotericin B deoxycholate 1mg/kg/d I.V. for 14 consecutive days. This arm was suspended in September 19th, 2012, because of a relevant excess of adverse events and serious adverse events associated with this experimental intervention in comparison with the active comparator and the other two experimental arms. The suspension of this study arm was supported by a DSMB statement.
3184021|NCT01310738|Experimental|Combination therapy|Liposomal amphotericin B 10mg/kg/d, I.V. single dose on day 0 plus Antimoniate of N-methylglucamine 20mg/kg/d for 10 consecutive days on days 1 to 10.
3184022|NCT01310712|Experimental|oxybutynin|patients will receive in the end of the treatment, 10 mg of oxybutynin a day
3184023|NCT01310712|Placebo Comparator|Placebo|Placebo
3184024|NCT01310699|Experimental|High Definition NBI Colonoscopy|Use of high definition narrow band imaging colonoscopy during examination for polyp detection. The same intervention is used on both arms: the Olympus Colonoscope CFHQ190AL, a technically improved colonoscope with close focus high definition narrow band imaging.
3184025|NCT01310699|Placebo Comparator|High Definition White Light Colonoscopy|Use of high definition white light colonoscopy during examination for polyp detection. The same intervention is used on both arms: the Olympus Colonoscope CFHQ190AL, a technically improved colonoscope with close focus high definition narrow band imaging.
3184026|NCT01310686||Wet AMD Non-Responders to Anti-VEGF|
3184027|NCT01310673|Active Comparator|Allopurinol|
3184028|NCT01310673|Placebo Comparator|Placebo|
3184029|NCT01310660||Nulliparous|
3184030|NCT01310647|Experimental|Testosterone|Transdermal testosterone (20µg/day) from day 24 of the previous cycle until day 2 of the ICSI cycle
3184031|NCT01310647|Experimental|Estradiol|Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle
3184032|NCT01310647|Experimental|CombEq|"(150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI~Estradiol valerate 4 mg/day during 10 days, starting the second day of the cycle prior to the ICSI cycle."
3184033|NCT01310634|Experimental|Comprehensive intervention|Parents of hospitalized neonates received Comprehensive intervention program.
3184034|NCT01310634|Other|Conventional treatment|Usual educational program
3184035|NCT01310621|No Intervention|No Lavage|Neonate randomized to this group will be managed as per the standard protocol in the neonatal ward. The evaluation of respiratory distress will be done using Downe's score at hourly intervals till 24 hrs, followed by 2 hourly intervals till 72 hrs and finally 4 hourly intervals till resolution of clinical distress.
3184036|NCT01310621|Experimental|Surfactant Lavage|The diluted surfactant is instilled into endotracheal tube over a period of 15 to 20 seconds. Once the instillation is complete, 5 manual breaths will be provided and infant will be repositioned supine. The suction catheter will be inserted and advanced to a position approximately 5mm past the end of endotracheal tube. Suction will be activated for no more than 10 seconds and would be temporarily halted earlier if the oxygen saturation value falls by > 5% of the prelavage value. The same shall be resumed once prelavage oxygen saturation has been restored. The infant's bed will now be moved back to horizontal position. Once the neonate is STABLE, suctioning will be again repeated. The total retrieved volume is measured and recorded.This procedure will be done in both right and left lateral decubitus position
3184037|NCT01310608|Experimental|A-View|
3184038|NCT01310608|No Intervention|No A-View|
3184039|NCT01310595|Experimental|Manual mobilization on cervical spine|Manual mobilization given on cervical spine with infra-red therapy and self exercise and advice pamphlet.
3184040|NCT01310595|Active Comparator|Infra-red radiation therapy|Infra-red radiation therapy with self exercise pamphlet given to patients with chronic mechanical neck pain.
3184041|NCT01310582|Active Comparator|Desflurane|During the surgery the subjects were given Desflurane, general anesthesia, that will keep the patient asleep during the surgery. The dosage form was inhalation gas, dosage equivalent to 1 MAC, frequency was once and the duration was throughout the surgery (30-45 minutes).
3184042|NCT01310582|Active Comparator|Sevoflurane|During the surgery the subjects were given Sevoflurane, general anesthesia, that will keep the patient asleep during the surgery. The dosage form was inhalation gas, dosage equivalent to 1 MAC, frequency was once and the duration was throughout the surgery (30-45 minutes).
3184043|NCT01310556||coronary artery disease|patients with coronary artery disease
3184044|NCT01310543|Experimental|Teens and Toddlers|The T&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
3184045|NCT01310543|No Intervention|Comparison|Girls in the comparison group will continue with their normal afternoon of schooling, which is missed by girls attending the T&T intervention for the 20 weeks of their attendance.
3184046|NCT01310530|Experimental|Partial Breast Proton Therapy|Two weeks of daily proton therapy delivered to the lumpectomy site.
3184047|NCT01310517||Radial Coronary Angiography|The subjects enrolled in this study will be adults referred for radial coronary angiography with left ventriculography for clinical indications.
3184048|NCT01310504|Active Comparator|Non peritoneal dialysis patient|
3184049|NCT01310504|Active Comparator|Peritoneal dialysis patient|
3184050|NCT01310491|No Intervention|Usual Care|
3184052|NCT01310465|Experimental|Experimental group|Three days postoperatively, patients in this group are given one infusion of zoledronic acid intravenously.
3184053|NCT01310465|Placebo Comparator|Placebo Comparator|Three days postoperatively, patients in this group are given one infusion of sodium chloride intravenously.
3184054|NCT01310452|Active Comparator|neutral protamine insulin, metformin|NPH insulin once daily plus oral metformin twice or thrice daily during 26 weeks
3184055|NCT01310452|Experimental|insulin detemir, metformin|Insulin detemir once daily plus oral metformin twice or thrice daily during 26 weeks
3184056|NCT01310439||ADHD adolescents and adults|30 adolescents and adults diagnosed with Combined-subtype AD/HD
3184057|NCT01310426||anal sphincter damage|After assessing women after vaginal delivery, a comparison will be made between those with anal sphincter damage and those women without.
3184058|NCT01310413|Experimental|Influenza A (H5N1) adjuvanted 6-<36M Group|Subjects aged at enrolment between 3 and 36 months, 36 months excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly. For children aged up to 12 months, 12 months excluded (< 12 months), Dose 1 was administered in the left anterolateral thigh and Dose 2 in the right anterolateral thigh. For children older than (>=) 12 months, Dose 1 was administered in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
3184059|NCT01310413|Experimental|Influenza A (H5N1) Virus monovalent vaccine 3-<9Y Group|Subjects aged at enrolment between 3 and 9 years, 9 years excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
3184060|NCT01310413|Experimental|Influenza A (H5N1) Virus monovalent vaccine 9-<18Y Group|Subjects aged at enrolment between 9 and 18 years, 18 years excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
3184061|NCT01310413|Placebo Comparator|Placebo 6-<36M Group|Subjects aged at enrolment between 3 and 36 months, 36 months excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly. For children aged up to 12 months, 12 months excluded (< 12 months), Dose 1 was administered in the left anterolateral thigh and Dose 2 in the right anterolateral thigh. For children older than (>=) 12 months, Dose 1 was administered in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
3184062|NCT01310413|Placebo Comparator|Placebo 3-<9Y Group|Subjects aged at enrolment between 3 and 9 years, 9 years excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
3184063|NCT01310413|Placebo Comparator|Placebo 9-<18Y Group|Subjects aged at enrolment between 9 and 18 years, 18 years excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
3184064|NCT01310413|Experimental|Placebo/Influenza A (H5N1) adjuvanted Group|Subjects in this group were those who were administered the saline placebo solution in the Blinded Phase of the study (either in the Placebo 6-<36M, Placebo 3-<9Y or Placebo 9-<18Y Group). These were subjects aged at enrolment between 6 months and 18 years, 18 years excluded, who had received 2 doses of saline placebo at Days 0 and 21 in the Blinded Phase of the study, as per described in the descriptions of the Placebo 6-<36M, Placebo 3-<9Y and Placebo 9-<18Y groups. After consenting to participating to the Unblinded Phase of the study, these subjects received in addition 2 doses of Influenza A (H5N1) Virus monovalent vaccine at Days 385 (Day U0) and Day 385 + 21 days (Day U21). Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly. Dose 1 of was administered in the deltoid region of the non-dominant arm and Dose 2 in the deltoid region of the dominant arm.
3184065|NCT01310400|Experimental|Inflexal 0.5 mL|
3184066|NCT01310400|Experimental|Inflexal 0.25 mL|
3184067|NCT01310400|Experimental|Agrippal 0.25 mL|
3184068|NCT01310387|Experimental|active pain management|active pain management (APM) by specialized nurses for cancer pain
3184069|NCT01310361|Experimental|Amoxicillin|Once-daily Therapy for Streptococcal Pharyngitis With Amoxicillin
3184070|NCT01310361|Active Comparator|Benzathin Penicillin G|Once-daily Therapy for Streptococcal Pharyngitis With Intramuscular Benzathin Penicillin G
3184071|NCT01310348|Placebo Comparator|Very low magnitude vibration|Very low magnitude vibration
3184072|NCT01310348|Experimental|Training|The whole-body vibration (WBV) training
3184073|NCT01310335|Experimental|Training|The whole-body vibration (WBV) training
3184074|NCT01310322|Experimental|1|AZD5423 iv
3184075|NCT01310322|Experimental|2|AZD5423 inhalation, Spira
3184076|NCT01310322|Experimental|3|AZD5423 inhalation I-neb
3184077|NCT01310322|Experimental|4|AZD5423 oral
3184078|NCT01310309||EXecutive Registry|A prospective controlled registry to analyze the clinical efficacy and safety at mid and long-term follow-up in patients with MVD treated with the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS).
3184079|NCT01310296|Other|Radiolabeled Lofexidine Oral Solution|Participants will receive a radiolabeled lofexidine oral solution followed by safety evaluations, and plasma, urine and fecal sampling for up to 216 hours post dose.
3184080|NCT01310296|Experimental|Lofexidine Intravenous Solution|Participants will receive 200 mcg of lofexidine in an intravenous solution infusion over 200 minutes followed by 72 hours of safety evaluation and plasma sampling.
3184081|NCT01310283|No Intervention|control group|Conventional pediatric dental care.
3184082|NCT01310270|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation
3184083|NCT01310270|Placebo Comparator|Placebo|
3184084|NCT01310257||Knee osteoarthritis|Patients will have osteoarthritis (OA) of the knee defined and scored radiologically in Study 1. Patients in Study 2 will also have OA of the knee, but a clinical diagnosis will suffice. All patients will report knee pain.
3184085|NCT01310244|Experimental|Single arm, open label|
3184086|NCT01310231|Active Comparator|Metformin|Metformin plus standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
3184087|NCT01310231|Placebo Comparator|Placebo|Placebo and standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
3184088|NCT01310218|Other|extended postoperative dressing|Bulky dressing for 2 weeks
3184089|NCT01310218|Other|short postoperative dressing|2 day bulky dressing followed by bandaid.
3184090|NCT01310205||Hepatitis C treatment|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
3184091|NCT01310205||non cirrhotic subjects|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
3184092|NCT01310192|Experimental|1|Investigational Imaging Device
3184093|NCT01310179|Experimental|Ad/PNP and fludarabine monophosphate|Ad/PNP will be injected three times into the tumor over 2 days followed by three daily intravenous infusions of F-araAMP (fludarabine monophosphate). Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
3184094|NCT01310166|Experimental|Fingolimod|
3184095|NCT01310153|Active Comparator|Prone Positioning|Newly born infant placed in prone position (face up) for the first 30 60 seconds of life after delivery by Cesarean birth.
3184096|NCT01310153|Active Comparator|Supine Positioning|newly born infant placed in supine position (face down) for the first 30 60 seconds of life after delivery by Cesarean birth.
3184097|NCT01310140||Major Depressive Disorder|
3184098|NCT01310140||Major Depressive Disorder with Psychotic Features|
3184099|NCT01310127|Experimental|Bromday|Patients receiving Bromday self-administered one drop of bromfenac 0.09% daily as a topical ophthalmic drop three days prior to cataract surgery, on the day of cataract surgery and 21 days post operatively.
3184100|NCT01310127|Active Comparator|Nevanac|Patients in this arm self-administered nepafenac topical ophthalmic drops three times daily beginning 3 days prior to cataract surgery, on the day of surgery and for 21 days postoperatively in addition to usual cataract procedure.
3184101|NCT01310114|Experimental|Cohort 1|1 unit PDA001 [approximately 2 x 108 cells] in 240 mL per infusion on Day 1.
3184102|NCT01310114|Experimental|Cohort 2A - Experimental|1 unit PDA001 [approximately 2 x 108 cells] or placebo in 240 mL per infusion on Day 1
3184103|NCT01310114|Experimental|Cohort 2B - Experimental|4 units PDA001 [approximately 8 x 108 cells] or placebo in 240 mL per infusion on Day 1
3184104|NCT01310101|Experimental|Ofatumumab plus dexamethasone|
3184105|NCT01310088|Experimental|Lifestyle counseling|Treatment protocol The Children's Obesity Clinic Department of Paediatrics Holbaek Hospital, University of Copenhagen Denmark
3184106|NCT01310088|No Intervention|Control|Healthy age and gender matched control subjects. Recruited from school visits.
3184107|NCT01310075|Experimental|Alloderm Mesh|Alloderm Mesh - 6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
3184108|NCT01310075|Experimental|Surgimend Mesh|Surgimend Mesh - 10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
3184109|NCT01310075|No Intervention|Control (no mesh)|
3184110|NCT01310049|Experimental|LP0058 oral solution (0.050 mg/mL)|LEO 32731
3184111|NCT01310049|Experimental|LP0058 oral solution (0.200 mg/mL)|LEO 32731
3184112|NCT01310049|Placebo Comparator|LP0058 oral solution (placebo)|Placebo
3184113|NCT01310049|Experimental|LP0058 capsule 1-120 mg|LEO 32731
3184114|NCT01310049|Placebo Comparator|LP0058 capsule (placebo)|Placebo
3184115|NCT01310036|Experimental|Single Arm|
3184116|NCT01310023||Static Cohort|HIV-uninfected children < 12 years of age at the time of enrollment, born of HIV-infected mothers
3184117|NCT01310023||Dynamic Cohort|HIV-uninfected children born of HIV-infected mothers enrolled from prior to birth through ≤ 72 hours of age
3184118|NCT01310023||Reference Cohort|HIV-uninfected children born to a mother HIV uninfected at the time of the child's birth enrolled at 1, 3, 5, or 9 years of age(± 3 months) at the time of the study visit
3184119|NCT01310023||Young Adult Cohort|Former Dynamic and Static Cohort participants ≥ 18 years of age.
3184120|NCT01310010|Experimental|Dasatinib|
3184121|NCT01309997|Experimental|Arm I (enzyme inhibitor)|Patients receive imatinib mesylate PO QD for 6 months in the absence of progression of sclerosis or unacceptable toxicity.
3184122|NCT01309997|Experimental|Arm II (monoclonal antibody)|Patients receive rituximab IV on days 1, 8, 15, and 22. A second treatment cycle is repeated at 3 months for a total of 8 doses of rituximab in the absence of progression of sclerosis or unacceptable toxicity.
3184123|NCT01309984|Active Comparator|arm 1|
3184124|NCT01309984|Active Comparator|arm 2|
3184125|NCT01309971||Questionable occlusal lesions|
3184126|NCT01309958||intervention|design instruments and test feasibility of an intervention aimed at increasing the proportion on non-invasive treatment for early caries
3184127|NCT01309945|Active Comparator|Arm 1: Duloxetine 30mg|
3184128|NCT01309945|Placebo Comparator|Arm 2: BMS-820836 placebo|
3184129|NCT01309945|Experimental|Arm 3: BMS-820836 0.5-2.0 mg/day|
3184130|NCT01309945|Active Comparator|Arm 4: Duloxetine 30mg|
3184131|NCT01309945|Placebo Comparator|Arm 5: Duloxetine placebo|
3184132|NCT01309932|Experimental|A1: pegIFNλ+BMS-790052+Placebo for BMS-650032+Ribavirin|Part A
3184133|NCT01309932|Experimental|A2: pegIFNλ+BMS-650032+Placebo for BMS-790052+Ribavirin|Part A
3184814|NCT01305018|Experimental|Exercise and BCAA|
3184134|NCT01309932|Active Comparator|A3: pegIFNα-2a+PBO for BMS-790052+PBO for BMS-650032+RBV|Part A
3184135|NCT01309932|Experimental|A4: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (24 weeks)|Part B
3184136|NCT01309932|Experimental|A5: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (16 weeks)|Part B
3184137|NCT01309932|Experimental|A6: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (24 weeks)|Part B
3184138|NCT01309932|Experimental|A7: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (16 weeks)|Part B
3184139|NCT01309919|Active Comparator|IUD Arm|Subjects who receive an IUD within 48 hours of delivery (vaginal or cesarean birth)
3184140|NCT01309919|Other|Diary Arm|Subjects who will not have an IUD placed postpartum; they may use another form of contraception, or no form at all
3184141|NCT01309893|Experimental|Investigational Lens|Bausch & Lomb investigational silicone hydrogel contact lens for 1 week; then issued Air Optix Aqua Lens for 1 week.
3184142|NCT01309893|Active Comparator|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens for 1 week; then issued Investigational Lens for 1 week.
3184143|NCT01309880|Active Comparator|Air Optix Aqua|Ciba Vision daily wear contact lens
3184144|NCT01309880|Experimental|Test Lens|Investigational silicone hydrogel contact lens
3184145|NCT01309854|Experimental|pioglitazone|
3184146|NCT01309854|Experimental|pioglitazone and fostamatinib|
3184147|NCT01309841|Experimental|1|Oral treatment
3184148|NCT01309841|Experimental|2|Oral treatment
3184149|NCT01309841|Placebo Comparator|3|Oral treatment
3184150|NCT01309828|Experimental|Azilsartan Medoxomil + Chlorthalidone|United States and Europe: Azilsartan medoxomil 20 mg plus chlorthalidone 12.5 mg fixed dose combination tablets, titrated up to azilsartan medoxomil 40 mg plus chlorthalidone 25 mg orally, once daily for up to 52 weeks.
3184151|NCT01309828|Active Comparator|Olmesartan Medoxomil + Hydrochlorothiazide|United States: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 40 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks. Europe: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 20 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks.
3184152|NCT01309815||Cancer in elderly people|other
3184153|NCT01309802|No Intervention|placebo|no intervention
3184154|NCT01309802|Active Comparator|onabotulinum toxin type-A|up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
3184155|NCT01309789|Experimental|1|Sequential
3184156|NCT01309789|Experimental|2|Combination
3184157|NCT01309789|Experimental|3 Brentuximab vedotin/CH-P|Combination
3184158|NCT01309776|Experimental|Tianeptine|
3184159|NCT01309776|Active Comparator|Escitalopram|
3184160|NCT01309763|Active Comparator|AFFITOPE AD03|s.c. injection
3184161|NCT01309763|Experimental|AFFITOPE AD03 + Alum|s.c. injection
3184162|NCT01309750||C. diff|Patients with Clostridium difficile colitis admitted to the intensive care unit will be the study group.
3184163|NCT01309737|Experimental|Active Treatment 10 mg BID|
3184164|NCT01309737|Experimental|Active Treatment 5 mg BID|
3184165|NCT01309737|Placebo Comparator|Placebo Treatment|
3184166|NCT01309724|No Intervention|Control|No measurements are made on the control group.
3184167|NCT01309724|Experimental|USCOM|Patients undergo hemodynamic measurements with the ultrasound cardiac output monitor (USCOM). Fluid resuscitation is guided by USCOM measurements.
3184168|NCT01309711||HIE|Moderate of severe neonatal encephalopathy
3184169|NCT01309698|Experimental|Treatment Sequence 1|
3184170|NCT01309698|Experimental|Treatment Sequence 2|
3184171|NCT01309698|Experimental|Treatment Sequence 3|
3184172|NCT01309698|Experimental|Treatment Sequence 4|
3184173|NCT01309698|Experimental|Treatment Sequence 5|
3184174|NCT01309698|Experimental|Treatment Sequence 6|
3184175|NCT01309672|Experimental|Abiraterone acetate + prednisone|"Abiraterone, 1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); to be taken daily~Prednisone, 5 mg, oral, 5 mg twice daily"
3184176|NCT01309659|Experimental|Immediate Intervention Group|Subjects randomized to the immediate treatment group will be scheduled to begin treatment with IV iron infusion immediately (or within 2 business days). They will receive 200mg IV iron sucrose a week for 5 weeks followed by 19 weeks of follow up.
3184177|NCT01309659|Experimental|Wait List Control|Subjects randomized to the wait list control group will have an observation visit at week 6 and week 12. After that they will begin treatment with IV iron infusion. They will receive 200mg IV iron sucrose a week for 5 weeks followed by 7 weeks of follow up
3184178|NCT01309646|Experimental|Infanrix-IPV+Hib Group|Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.
3184179|NCT01309646|Active Comparator|Infanrix IPV Group|Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.
3184180|NCT01309633|Experimental|Arm A|"1) Arm A~Day -6 to Day 0 (total 7 days):~Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
3184231|NCT01309217|Active Comparator|Usual Care|The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. See below for a complete description.
3184181|NCT01309633|Experimental|Arm B|"Arm B~Day -6 to Day 0 (total 7 days):~Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
3184182|NCT01309620|Placebo Comparator|Placebo|
3184183|NCT01309620|Experimental|Zinc supplement|
3184184|NCT01309607|Experimental|Pre-operative Therapy|Neoadjuvant paclitaxel/carboplatin/lapatinib x 12 weeks
3184185|NCT01309594|Experimental|Hematopoietic stem cell transplantation|Extraction of bone marrow cells from HIV positive patients with advanced liver cirrhosis and transplant their bone marrow back into the patients
3184186|NCT01309581|Experimental|Ketamine|Participants receiving ECT for depression will be randomized 1:1 to either ketamine (experimental condition) or methohexital (standard anesthetic).
3184187|NCT01309581|Active Comparator|Methohexital|Participants receiving ECT for depression will be randomized 1:1 to either ketamine (experimental condition) or methohexital (standard anesthetic).
3184188|NCT01309568||Investigational testing|Pending the outcome of culture, the subject may be treated with an approved antiviral medication at the doctors discretion.
3184189|NCT01309542|Experimental|DVS|
3184190|NCT01309529||thoracic surg, epidural, urine retention|
3184191|NCT01309516|Experimental|Complex Intervention (LTP-TH)|The 12 sessions of complex intervention (LTP-TH) will be delivered to mothers.
3184192|NCT01309516|No Intervention|Control group|Control group will receive standard postnatal follow-up.
3184193|NCT01309503||Normal hearing|Children and adults
3184194|NCT01309503||Unilateral hearing loss|
3184195|NCT01309503||Severe hearing loss high frequencies|
3184196|NCT01309503||Adult CI users|Unilateral and bilateral CI
3184197|NCT01309503||Bilateral CI users|"Children and adults~Sequential CIs~Simultaneous CIs"
3184198|NCT01309490|Experimental|Ribavirin, nucleoside analog|
3184199|NCT01309477|Experimental|ADVAGRAF|All subjects in the study will take the Tacrolimus Sustained-release Capsules (ADVAGRAF) orally at the basis of low dose prednisone treatment
3184200|NCT01309451|Active Comparator|Bevacizumab alone|
3184201|NCT01309451|Active Comparator|Combined group|Bevacizumab plus Ozurdex
3184202|NCT01309438|Experimental|Normal renal function|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
3184203|NCT01309438|Experimental|Mild renal impairment|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 5 mg rivaroxaban on Day 5) followed, up to 14 days later, by Treatment Period 3 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
3184204|NCT01309438|Experimental|Moderate renal impairment|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 5 mg rivaroxaban on Day 5) followed, up to 14 days later, by Treatment Period 3 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
3184205|NCT01309425|Experimental|001|tapentadol (CG5503) ER 25-mg TRF 25mg TRF single oral dose
3184206|NCT01309425|Experimental|002|tapentadol (CG5503) ER 50-mg TRF 50mg TRF single oral dose
3184207|NCT01309425|Experimental|003|tapentadol (CG5503) ER 100-mg TRF 100mg TRF single oral dose
3184208|NCT01309425|Experimental|004|tapentadol (CG5503) ER two 100-mg TRF 200mg TRF single oral dose
3184209|NCT01309412|Experimental|Siltuximab|Siltuximab 5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
3184210|NCT01309399|Active Comparator|teriparatide|six weeks of teriparatide
3184211|NCT01309399|Placebo Comparator|placebo|placebo identical in appearance to teriparatide
3184212|NCT01309386|Experimental|Tapentadol ER|Tapentadol extended-release (ER) (JNS024ER) oral tablets 100 to 400 milligram (mg) daily for 8 weeks (maximum dose could be up to 500 mg daily), as per Investigator's discretion.
3184213|NCT01309386|Active Comparator|Morphine SR|Morphine sustained-release (SR) oral tablets 30 to 120 mg daily for 8 weeks (maximum dose could be up to 140 mg daily), as per Investigator's discretion.
3184214|NCT01309373||001|Patient assessment 2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
3184215|NCT01309360|Active Comparator|group A : 40ml Prilocaine 1%|40 outpatients : 40ml Prilocaine 1% were administered for axillary plexus block
3184216|NCT01309360|Active Comparator|group B : 30ml Prilocaine 1%|40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
3184217|NCT01309360|Active Comparator|group C : 20ml Prilocaine 1%|40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block
3184218|NCT01309321|Experimental|Perinatal Handwashing Intervention Arm|
3184219|NCT01309321|Active Comparator|Neonatal Health Promotion|
3184220|NCT01309308|Experimental|The membranes swept group|This group will have a sweeping of the membranes after the 38th of gestation at hospital, in order to reduce the latency period until labor. Sweeping of the membranes is done by the insertion of examiners finger between the decidua and fetal membranes and by the circular movement of the finger, the membranes are detached from the decidua.
3184221|NCT01309308|Sham Comparator|No sweeping group|This group will not have sweeping of the membranes, will only have vaginal ultrasound
3184222|NCT01309295||Cohort|
3184223|NCT01309282||Rituximab|Sero-positive [Rheumatoid Factor (RF) and/or anti-Cyclic Citrullinated Peptide (CCP+)] rheumatoid arthritis (RA) patients, who had initiated therapy with Rituximab (MabThera) following lack of response or intolerance to a single tumour necrosis factor (TNF)-inhibitor will be included in this arm
3184224|NCT01309269||Cohort|
3184225|NCT01309256||R-robot group|retrospective robot group
3184226|NCT01309256||P-robot group|prospective robot group
3184227|NCT01309256||P-laparoscopic group|prospective laparoscopic group
3184228|NCT01309243|Experimental|FTC/RPV/TDF|
3184229|NCT01309243|Experimental|EFV/FTC/TDF|
3184230|NCT01309230|Experimental|Vigil™|intradermal autologous Vigil™ (1.0 x 10^7 cells/injection; maximum of 12 vaccinations)
3184232|NCT01309217|Experimental|Tobacco Tactics Intervention|"At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals."
3184233|NCT01309204|Experimental|Brinz/Brim|Vehicle, 1 drop instilled in each eye, followed by Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension, 1 drop instilled in each eye. A 10-minute waiting period separated the instillations. Study drugs were instilled twice a day for 6 months.
3184234|NCT01309204|Active Comparator|Brinz+Brim|Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye, followed by Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye. A 10-minute waiting period separated the instillations. Study drugs were instilled twice a day for 6 months.
3184235|NCT01309191|Experimental|Minoxidil|Patients received Minoxidil (same strength as sold over the counter) twice a day for 8 weeks.
3184236|NCT01309191|Placebo Comparator|Placebo|Placebo arm
3184237|NCT01309178|Active Comparator|Amitriptyline|After the experience with the treatment of 18 CF-patients phase IIa study), the medication will be therefore 25 mg daily in two doses (2 x 12,5 mg). Because of a higher rate of side effects (tiredness, dry mucous membrane) the higher dose of 50 mg (2 x 25 mg) is not chosen first, but will be adapted after 2 weeks of treatment.
3184238|NCT01309178|Placebo Comparator|Mannite|The placebo will be given 25 mg daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
3184239|NCT01309165|Experimental|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10 one-hour sessions intervention format. Participants randomized to the CO-OP group will continue to receive usual out-patient services, such as physiotherapy or speech-language therapy, but will receive CO-OP instead of usual occupational therapy.
3184240|NCT01309165|Active Comparator|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
3184241|NCT01309139|Experimental|Treatment A: Tiotropium medium dose|Oral inhalation daily for 21 days
3184242|NCT01309139|Experimental|Treatment A: BI 54903 high dose|Oral inhalation daily for 21 days
3184243|NCT01309139|Experimental|Treatment B: Tiotropium medium dose|Oral inhalation daily for 21 days
3184244|NCT01309139|Experimental|Treatment C: BI 54903 high dose|Oral inhalation daily for 21 days
3184245|NCT01309126|Experimental|Arm 1: Imprime PGG + cetuximab|Biological/Vaccine + Drug
3184246|NCT01309126|Active Comparator|Arm 2: cetuximab|Drug
3184247|NCT01309113|Placebo Comparator|Placebo of VAC BNO 1095|1 tablet of placebo in the morning, 1 tablet of placebo in the evening
3184248|NCT01309113|Active Comparator|10 mg VAC BNO 1095|1 tablet of VAC BNO 1095 10 mg in the morning, 1 tablet of placebo in the evening
3184249|NCT01309113|Active Comparator|20 mg VAC BNO 1095|1 tablet of VAC BNO 1095 10 mg in the morning, 1 tablet of VAC BNO 1095 10 mg in the evening
3184250|NCT01309100|Experimental|Investigational Lens|Bausch & Lomb investigational silicone hydrogel lens.
3184251|NCT01309100|Active Comparator|Acuvue Oasys Lens|Johnson & Johnson Acuvue Oasys contact lens.
3184252|NCT01309100|Active Comparator|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens.
3184253|NCT01309074|Experimental|Pregabalin|Pregabalin is an antiepileptic medication which has been found in double blind placebo controlled trials to be effective and safe in the treatment of primary generalized anxiety disorder. It has an indication for the treatment of this condition in Europe & Canada but not in the US.
3184254|NCT01309074|Active Comparator|Sertraline|Sertraline is an SSRI found to be an effective treatment of generalized anxiety disorder in controlled trials. It does not have an indication for this in this country.
3184255|NCT01309048|Experimental|Patients with painful bone metastasis|Patients with bone metastasis causing pain
3184256|NCT01309035|Active Comparator|With Tourniquet|Total Knee Arthroplasty. Surgery performed during use of a tourniquet.
3184257|NCT01309035|Experimental|Without Tourniquet|Total Knee Arthroplasty. Surgery performed without use of a tourniquet.
3184258|NCT01309009|Experimental|Nepadutant High Dose|
3184259|NCT01309009|Experimental|Nepadutant Low Dose|
3184260|NCT01309009|Placebo Comparator|Placebo|
3184261|NCT01308996|Experimental|INFUSE® Bone Graft|
3184262|NCT01308996|Active Comparator|Autogenous bone graft|
3184263|NCT01308983|Other|Amiloride|
3184264|NCT01308970|Experimental|Stress Management Group 1|
3184265|NCT01308970|Experimental|Stress Management Group 2|
3184266|NCT01308970|Experimental|Stress Management Group 3|
3184267|NCT01308957|Experimental|Long chain omega-3 fatty acids|
3184268|NCT01308957|Placebo Comparator|Corn oil|
3184269|NCT01308957|No Intervention|Young healthy controls|Young subjects' muscle mass and physical function will be evaluated once (i.e., during baseline testing only). The data in young subjects will be used to determine the magnitude of the aging-induced decline in muscle mass and physical function in the older subjects prior to starting the interventions.
3184270|NCT01308944|Experimental|Arm 1|"Propranolol 40mg po orally twice daily to begin at least 48 hours prior to surgical debulking. This will ideally be titrated in order to maintain a heart rate between 60 and 80 without hypotension.~After surgery, the patient will resume the propranolol once tolerating clear liquids in the hospital and will remain on them until completion of chemotherapy.~After completion of chemotherapy, the patient will be weaned off the medication over the following two weeks."
3184271|NCT01308931||Tubal ligation|Patients who elect to have tubal ligation
3184272|NCT01308931||Essure|Group that elects to have Essure placement
3184273|NCT01308931||Levonorgestrel IUD|Patients that elect to have a levonorgestrel intra-uterine device placement
3184274|NCT01308918||GlideScope DLT intubation|Patients having a thoracic surgery (non cardiac) via either thoracoscopy or thoracostomy. Patients were all 18 years old or over, and have read, understood and signed an informed consent at the preoperative evaluation or on surgery morning.
3184275|NCT01308905|Experimental|FLT-PET|"Patients will be managed per COG protocol ANBL00B1 (low risk, LR), ANBL0521 (intermediate risk, IR), ANBL0531 (high risk, HR) or other future neuroblastoma studies according to their risk group (risk assignment, treatment schema and protocols are available in COG website). The following is a brief description of the treatment.~Low risk patients: observation only.~Intermediate risk patients: chemotherapy stratified according to risk sub-groups followed by surgical resection.~High risk patients: 6 courses of induction chemotherapy, surgical resection and high dose chemotherapy with autologous stem cell transplant (SCT), involved field radiation and 6 months of Isotrenitoin.~PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection)."
3184276|NCT01308892|Active Comparator|High flavaonol chocolate|
3184277|NCT01308892|Placebo Comparator|Low flavanol chocolate|
3184278|NCT01308879|Experimental|Weekly feedback|After clinical questionnaires are entered into the system (CFStm), an automated online report is available weekly to clinicians in the experimental group that shows current mental health status of youths, alerts, and trends over time based on youth, caregiver, and clinician responses. Reports also show some clinical data on caregivers.
3184279|NCT01308879|Other|No feedback|Clinicians in the control group do not have access to weekly feedback. Instead, they receive reports every 90 days after the youth is enrolled in CFStm. Because the average duration of CFS enrollment was 3.8 months, many youths would have been discharged before the first 90-day report became available three months after treatment start. Thus, we considered the 90-day feedback group to be essentially a no-feedback group.
3184280|NCT01308866|No Intervention|Control|Usual care
3184281|NCT01308866|Experimental|Intervention|Intervention arm using a share-decision tool for cardiovascular patients
3184282|NCT01308840|Experimental|Panitumumab|Panitumumab 6mg/kg on days 1 and 15 of every cycle (28 days); Gemcitabine 1000mg/m2 on days 1 and 15 of every cycle (28 days); Oxaliplatin 85mg/m2 on days 1 and 15 of every cycle (28 days)
3184283|NCT01308827||Children with suspected pneumococcal invasive disease|
3184284|NCT01308814|Placebo Comparator|Placebo|Placebo patches for 12 months and placebo pills for 12 days every 2 months.
3184285|NCT01308814|Experimental|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months and oral micronized progesterone (200 mg/day) for 12 days every two months.
3184286|NCT01308801|Experimental|active rTMS + rehabilitation exercise|14 weeks of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise
3184287|NCT01308801|Placebo Comparator|placebo rTMS + rehabilitation exercise|14 weeks of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise
3184288|NCT01308788||aqueous suppressant|aqueous suppressant treated
3184289|NCT01308788||aqueous outflow|aqueous outflow treated
3184290|NCT01308775|Active Comparator|SIS.NET, Routine Follow up|
3184291|NCT01308762|Experimental|IMM-101|"Patients received an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28. Doses used were:~'Heat killed whole cell M. obuense (IMM-101) 0.1 mg', 'Heat killed whole cell M. obuense (IMM-101) 0.5 mg', or 'Heat killed whole cell M. obuense (IMM-101) 1.0 mg'"
3184292|NCT01308749|Placebo Comparator|Placebo|Intervention: Drug: placebo
3184293|NCT01308749|Active Comparator|Oxytocin|Intervention: Drug: Syntocinon® Nasal Spray
3184294|NCT01308736|Active Comparator|varenicline|
3184295|NCT01308736|Placebo Comparator|placebo pill|
3184296|NCT01308723|Experimental|Part I|
3184297|NCT01308723|Experimental|Part II (A)|
3184298|NCT01308723|Active Comparator|Part II (B)|
3184299|NCT01308697|Active Comparator|Operative|Operative intervention
3184300|NCT01308697|Active Comparator|Non Operative Treatment|Non Operative management
3184301|NCT01308684|Experimental|1|
3184302|NCT01308684|Experimental|2|
3184303|NCT01308671|Active Comparator|varenicline|On 3 day after received clopidogrel 75mg/day, Varenicline group will be administered with varenicline 0.5mg Qd,after 3 days, 0.5mg Bid,after 7days,1mg Bid .And received counseling and psychosocial support.
3184304|NCT01308671|Other|Blank|Blank group will be only administered with Counseling and psychosocial support,beside antiplatelet etc.conventional therapy for 14 days.
3184305|NCT01308658|Experimental|001|Darunavir (DRV) 2x400-mg DRV tablet or 800-mg tablet on Day 3
3184306|NCT01308658|Experimental|002|ritonavir 100-mg once daily on Day 1 to Day 5
3184307|NCT01308632|Experimental|Temozolamide, irinotecan|"Phase I trial:~TMZ will be administered in a fixed schedule as follows:~TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.~100 mg/m2 in a morning single dose on days 8 and 22~CPT-11 starting dose:~100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)~One cycle = 28 days~CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 ."
3184308|NCT01308619|Active Comparator|Oracea®|Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules
3184309|NCT01308619|Active Comparator|placebo|placebo
3184310|NCT01308606|Experimental|001|TMC435 gelatin capsule Single intake of one 150-mg capsule without food
3184311|NCT01308606|Experimental|002|TMC435 HPMC capsule Single intake of one 150-mg capsule without food
3184312|NCT01308606|Experimental|003|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule without food
3184313|NCT01308606|Experimental|004|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after standardized breakfast
3184314|NCT01308606|Experimental|005|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after high-fat breakfast
3184315|NCT01308593|Active Comparator|Juvederm XC|Juvederm XC
3184316|NCT01308593|Active Comparator|Botox|Medication used to block neuromuscular transmission
3184317|NCT01308580|Experimental|Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.
3184318|NCT01308580|Experimental|Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.
3184319|NCT01308567|Experimental|Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until disease progression (DP), unacceptable toxicity or participant's refusal.
3184320|NCT01308567|Experimental|Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.
3184321|NCT01308567|Active Comparator|Docetaxel 75 mg/m^2|Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.
3184322|NCT01308554|Placebo Comparator|Sterile normal saline|Control group will receive sterile normal saline in the block
3184323|NCT01308554|Active Comparator|Marcaine|Study group will receive a bilateral TAP block using 20 ml of Marcaine 2,5 mg/ml on each side.
3184324|NCT01308541|Active Comparator|LUSEDRA (arm 1)|
3184325|NCT01308541|Active Comparator|LUSEDRA (arm 2)|
3184326|NCT01308541|Active Comparator|Propofol (arm 3)|
3184327|NCT01308528|Experimental|Sodium enoxaparin|Endocris - 40 mg/0,4mL
3184328|NCT01308528|Experimental|sodium enoxaparin Clexane|Clexane - 40 mg/ 0,4mL
3184329|NCT01308515|Other|Posterior Stabilized|Patients who received a PS (Posterior Stabilized) Tibial Bearing.
3184330|NCT01308515|Other|Anterior Stablized|Patients who received an AS (Anterior Stabilized) Tibial Bearing
3184331|NCT01308502|Experimental|Probe|Children with airway obstruction
3184332|NCT01308489|Experimental|Arm I (posterior spinal tumor resection)|Patients undergo posterior spinal tumor resection on day 0.
3184333|NCT01308489|Experimental|Arm II (anterior and posterior spinal tumor resection)|Patients undergo anterior and posterior tumor resection on day 0.
3184334|NCT01308476||SMS group|
3184335|NCT01308476||control group|
3184336|NCT01308450||Single Arm, Non ADHD Control Group|Single site, single visit study. Subjects will be administered Standard Rating Scales (Defined) and the Quotient ADHD System Test (Adolescent and Adult Version). Subject's assessed to be Non-ADHD will be eligible to have their Quotient tests added to the Quotient Adolescent and Adult Normative Database.
3184337|NCT01308437|Experimental|Wosulin (N or 70/30 with R)|Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
3184338|NCT01308437|Active Comparator|Novolin® (N or 70/30 with R)|Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
3184339|NCT01308424|Experimental|BTL TML HSV|
3184340|NCT01308424|Placebo Comparator|Matching Placebo|
3184341|NCT01308411|Experimental|50% reduction in ICS dose|All patients will reduce their inhaled corticosteroid dose by 50%
3184342|NCT01308385||Patients with pectus excavatum|
3184343|NCT01308372||1|For this group of patients, the cardiovascular risk will be evaluated by several tools: the SCORE scale, the Framingham 2008 scale d'Agostino and the 1998 scale Wilson ;
3184344|NCT01308359|Experimental|glucose 5%|glucose 5%
3184345|NCT01308359|Active Comparator|saline|saline
3184346|NCT01308346|Experimental|Bioresorbable Vascular Scaffold (BVS)|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)
3184347|NCT01308346|Active Comparator|XIENCE V® or XIENCE PRIME®|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) or XIENCE PRIME®
3184348|NCT01308333||XLHED children|
3184349|NCT01308333||XLHED adults|
3184350|NCT01308333||Control children|
3184351|NCT01308333||Control adults|
3184352|NCT01308320|Placebo Comparator|saline|control group
3184353|NCT01308320|Active Comparator|F1 group|F1 group : fentanyl 1 mcg/kg
3184354|NCT01308320|Active Comparator|F1.5 group|F1.5 group : fentanyl 1.5 mcg/kg
3184355|NCT01308320|Active Comparator|F2 group|F2 group : fentanyl 2 mcg/kg
3184356|NCT01308307|Experimental|one arm|
3184357|NCT01308294|Experimental|Group 1|2 vaccine injections in same limb (vaccine 1 : NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2 : Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)
3184358|NCT01308294|Experimental|Group 2|2 vaccine injections in different limbs (vaccine 1: NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2: Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)
3184359|NCT01308294|Experimental|Group 3|2 vaccine injections in different limbs (vaccine 1: NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2: Melan-A peptide + IMP321 + Montanide)
3184360|NCT01308281|Experimental|PCI with IVUS guidance|PCI(percutaneous coronary intervention) with IVUS(IntraVascular UltraSound) group
3184361|NCT01308281|Active Comparator|PCI without IVUS guidance|PCI(percutaneous coronary intervention) group
3184362|NCT01308255|Experimental|Infliximab Arm|For those randomised to the infliximab arm, infliximab will be administered at a dose of 3mg/kg according to the standard treatment protocol.
3184363|NCT01308255|Placebo Comparator|Steroid/Placebo Arm|Patients randomised to this arm will receive an IV infusion of 250mg methylprednisolone at week 0 & those without an adequate clinical response after 26 wks will receive additional steroid as IM methylprednisolone 120mg. Patients on this arm will receive an IV placebo infusion of 250ml of 9mg/l NaCl.
3184364|NCT01308242|Experimental|Treatment|Patients enrolled will receive Renvela for a 3 month time frame.
3184365|NCT01308229|Experimental|Nile PAX®|
3184366|NCT01308216|Experimental|Transcranial low level laser therapy|Transcranial laser therapy is applied by automatic scanning over both hemispheres and the patients undergoing also a standard rehabilitation program based on therapeutic exercises.
3184367|NCT01308216|Active Comparator|Control|The patients undergoing only a standard rehabilitation program based on therapeutic exercises.
3184368|NCT01308203|Experimental|Extended release niacin /laropiprant|The patients will be randomized to one of two arms. The intervention is with the extended release niacin laropiprant combination, that is an add on of the usual medication that the primary care physician gave them to treat their lipid disorder (statin, ezetimibe or the combination of both).
3184369|NCT01308203|Placebo Comparator|placebo|The patients will received placebo added to the usual therapy their primary care physician gave them to treat their lipid disorder (statin, ezetimibe or the combination of both).
3184370|NCT01308190|Active Comparator|Chemoradiotherapy+TEM|Preoperative chemotherapy: capecitabine 825 mg/m2 every 12 hours orally, plus Radiotherapy (50.4 Gy). After 6-8 weeks, transanal endoscopic microsurgery (TEM)is done
3184371|NCT01308190|Other|Total Mesorectal Excision|Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer
3184372|NCT01308177|Placebo Comparator|PPI+placebo|
3184373|NCT01308177|Active Comparator|PPI+ES|
3184374|NCT01308164|Experimental|MD logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
3184375|NCT01308164|No Intervention|Control Group|Regular treatment, no change will be made in the insulin pump setting during the study (unless there is a medical need or any safety concern) Only segment 2 of the study, which is conducted as RCT (randomized controlled trial) , will include control group
3184376|NCT01308151|Experimental|Experimental Arm|Culturally Adapted Manualised Cognitive Behavioral Therapy (CBT) Sessions will be offered weekly in the first month and then fortnightly.
3184377|NCT01308151|No Intervention|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
3184378|NCT01308138|Experimental|ExerciseTr|
3184379|NCT01308138|Experimental|Remote ischemic preconditioning group|
3184380|NCT01308138|No Intervention|Control patient group|
3184381|NCT01308112|Experimental|Supplemental iron|
3184382|NCT01308112|Placebo Comparator|Placebo|
3184383|NCT01308099||POTS & Controls|"Participants will have a physical prior to the study day and collect urine for 24 hours.~On the study day the following procedures take place:~After blood samples taken (about 2 tbsp), the subject will lie down. A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The arm blood pressure cuff will be inflated 60 points above the highest number on your normal blood pressure for five minutes. The blood pressure and forearm blood flow will be recorded. At the end of 5 minutes, the cuff will be released and the measurements of blood pressure and calf blood flow will be repeated. The brachial artery diameter and flow will be measured at baseline, during cuff inflation and for 3 minutes after deflation.~The study lasts about 2 hours."
3184384|NCT01308086|Active Comparator|FOLFOX 4 - 6months or XELOX -6months|
3184385|NCT01308086|Experimental|FOLFOX4 -3months or XELOX -3months|
3184386|NCT01308073||EMIC 2 dialysis|Patients on ICU requiring dialysis for acute renal insufficiency
3184387|NCT01308060|Experimental|Botulinum Toxin type A|During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo
3184388|NCT01308060|Placebo Comparator|Placebo|During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo
3184389|NCT01308047|Experimental|bupivacaine S75:R25|3 ml for subarachnoid block
3184390|NCT01308047|Active Comparator|bupivacaine (S50:R50)|3 ml subarachnoid block
3184391|NCT01308034|Experimental|association sunitinib radiotherapy|
3184392|NCT01308021|Experimental|gpASIT400|gpASIT+TM 400 µg
3184393|NCT01308021|Experimental|gpASIT800|gpASIT+TM 800 µg
3184394|NCT01308021|Placebo Comparator|Placebo|
3184395|NCT01308008|Experimental|Arm 1|Initial on-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with nurse telephonic behavioral support
3184396|NCT01308008|Active Comparator|Arm 2|Initial on-site flex and toning program continued on follow-up along with health education
3184397|NCT01307995||GDM|Patients with Gestational Diabetes Mellitus found during pregnancy by means of 75g OGTT
3184398|NCT01307995||NGT|Pregnant patients with normal glucose tolerance as observed in 75g OGTT
3184399|NCT01307982|Active Comparator|Fundoplication|During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
3184400|NCT01307982|Active Comparator|Gastrojejunal (GJ) feeding tube|Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
3184401|NCT01307969|Experimental|Anesthetic efficacy|Local anesthetics were injected at the apex of the maxillary right canine.
3184402|NCT01307956|Experimental|Treatment (panitumumab, chemotherapy, radiation)|Patients receive panitumumab IV over 1 hour on day 1. Patients also receive oxaliplatin IV and leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1 (FOLFOX chemotherapy). Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Within 24 hours of the start of chemotherapy, patients undergo radiation therapy 5 days a week for 5.5 weeks. Patients then undergo surgery within 6-8 weeks after completion of radiation therapy. Patients with residual disease receive 4 additional courses of FOLFOX chemotherapy on days 1, 15, 29, and 42.
3184403|NCT01307943|Experimental|Mindfulness Based Stress Reduction|"Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat at the completion of the eight sessions to review and consolidate experience with the various mindfulness practices. The MBSR concepts and techniques will emphasize portability. Participants will be encouraged to find moments throughout their day in which to practice the techniques. The language used to describe mindfulness practices will be accessible to youth. Mindfulness concepts will be linked with tag phrases like breathing break, autopilot, and choice points. Homework will emphasize experiential, concrete tasks (notice five new things today; eat one meal mindfully this week)."
3184404|NCT01307943|Active Comparator|Usual Care|The control group will be youth receiving therapies and programs already used at the site. The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
3184482|NCT01307332|Experimental|MabCampath-1h|Single arm, single cohort study, all subjects will be dosed with alemtuzumab.
3184405|NCT01307930|Experimental|Anidulafungin|Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
3184406|NCT01307917|Experimental|healthy controls high flavonoid|20 healthy adolescents (12-21 years old) receiving the flavonoid-rich capsule/supplement
3184407|NCT01307917|Active Comparator|healthy controls low flavonoid|20 healthy adolescents (12-21 years old) receiving the placebo
3184408|NCT01307917|Experimental|T1DM or T2DM high flavonoid|20 adolescents (12-21 years old) with Type 1 diabetes mellitus or Type 2 diabetes mellitus receiving the capsule/supplement
3184409|NCT01307917|Active Comparator|T1DM or T2DM low flavonoid|20 adolescents (12-21 years old) with Type 1 diabetes mellitus or Type 2 diabetes mellitus receiving the placebo
3184410|NCT01307904|Active Comparator|dates|Each healthy and diabetic subjects received 50 grams equivalent of carbohydrates of the tested dates, On five separate days.
3184411|NCT01307904|Active Comparator|sugar|Each healthy and diabetic subjects received 50 grams of glucose
3184412|NCT01307891|Experimental|Abraxane + Tigatuzumab|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles. Patients will be evaluated for response every 8 weeks. Patients with disease progression will be taken off the study.
3184413|NCT01307891|Experimental|Abraxane alone|Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals. Patients will have the option to crossover to the combination arm based upon the pre-clinical data.
3184414|NCT01307878|Experimental|arm A|chemotherapy ± targeted therapy before resection of primary colorectal cancer
3184415|NCT01307878|No Intervention|arm B|resected the primary colorectal cancer and then given chemotherapy ± targeted therapy
3184416|NCT01307865|Experimental|Sculptra Aesthetic|Patients receiving Sculptra Aesthetic
3184417|NCT01307852|Experimental|In Vivo Dosimetry|Modified endorectal device capable of real-time dose measurement during prostate radiation therapy
3184418|NCT01307839|Active Comparator|5% lidocaine patch|If the patient chooses to participate, the resident will place the patch over the lower lumbar area of the back.
3184419|NCT01307839|Placebo Comparator|placebo patch|If the patient chooses to participate, the resident will place the patch over the lower lumbar area of the back.
3184420|NCT01307826|Experimental|tensegrity massage|In this group of patients massage sessions based on the tensegrity method were applied.
3184421|NCT01307826|Active Comparator|classical massage|In this group of patients 10 classical massage sessions were applied
3184422|NCT01307813|Experimental|Endoscopic suturing device|Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.
3184423|NCT01307800|Experimental|80 mg LY2140023|40 mg LY2140023 administered orally, twice daily (BID) for up to 7 weeks of treatment.
3184424|NCT01307800|Experimental|40 mg LY2140023|20 mg LY2140023 administered orally, BID for up to 7 weeks of treatment.
3184425|NCT01307800|Experimental|10 mg LY2140023|5 mg LY2140023 administered orally, BID for up to 7 weeks of treatment.
3184426|NCT01307800|Placebo Comparator|Placebo|Administered orally, BID for up to 7 weeks of treatment.
3184427|NCT01307787|Experimental|fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component.
3184428|NCT01307787|No Intervention|waiting list control group|The waiting-list control group was allowed to enter the FIT program for rehabilitation after the study period.
3184429|NCT01307761||Patients with thyroid nodule received US-FNA exam|Patients with thyroid nodules which underwent head and neck ultrasound(US) examination and US-FNA cytology at Department of Otolaryngology, Far Eastern Memorial Hospital, Taipei, Taiwan. No patient included in this series had a previous diagnosis of thyroid malignancy before US exam.
3184430|NCT01307748|Experimental|stress reducing aroma|aroma with reported stress reducing effects
3184431|NCT01307748|Placebo Comparator|Placebo aroma 1|
3184432|NCT01307748|Placebo Comparator|Placebo aroma 2|
3184433|NCT01307735||Myocarditis negative on CMR|Patients with suspected myocarditis referred for CMR and not fulfilling at least 2 of the 3 CMR criteria (Lake Louise Criteria)for myocarditis.Lake Louise Criteria are edema, hyperaemia, and necrosis/fibrosis.
3184434|NCT01307735||Myocarditis positive on CMR|Patients with suspected myocarditis referred for CMR and fulfilling at least 2 of the 3 CMR criteria (Lake Louise Criteria)for myocarditis.Lake Louise Criteria are edema, hyperaemia, and necrosis/fibrosis.
3184435|NCT01307722|Experimental|Patients under LA distensibility-guiding management|The management of guide group will be adjusted by LA distensibility, including the adjustments of inotropic agents, diuretics, beta-blocker, ACEI, and AIIB.
3184436|NCT01307722|No Intervention|patients under conservative monitor and management|This group will be treated by conventional management and traditional echocardiography can be performed as in-charge doctor request. Renal function will be checked 1 time per 3 months.
3184437|NCT01307683|Active Comparator|Mindful Moms|Based on the Mindful Motherhood Training (developed by Cassandra Vieten, PhD), Mindfulness-Based-Eating and Awareness Training (MB-EAT) (developed by Jean Kristeller, PhD), and other mindfulness- and acceptance-based interventions
3184438|NCT01307683|No Intervention|Comparison Group|Usual prenatal care
3184439|NCT01307657|Other|clopidogrel 600 mg loading dose|
3184440|NCT01307644|Experimental|Web-based only (WO) weight intervention|A comprehensive lifestyle modification intervention for healthy eating and activity delivered by web only to facilitate Phase I weight loss (weekly messages baseline to 6 months), Phase 2 guided weight loss and weight maintenance (bi-weekly hot topics news, 6-18 months) and Phase 3 self-managed weight maintenance (6 monthly and 3 bi-monthly new content, 18-30 months).
3184441|NCT01307644|Experimental|WO & peer-led discussion board (WD)|Includes WO intervention, including all 3 Phases for weight loss and weight maintenance, supplemented with peer-lead discussion board. A peer leader will facilitate the asynchronous discussion group. The primary purpose of this group is to provide support, increase self-efficacy (role modeling by successful women and leader) and discuss progress toward goals.
3184537|NCT01307020|Experimental|DKP-TRIS high dose - TRAM.HCl high dose|
3184442|NCT01307644|Experimental|WO & professional email counseling (WE)|Includes WO intervention, including all 3 Phases for weight loss and weight maintenance, supplemented with professional email-counseling by experienced counselor who will review women's web-logs of eating, activity, weight and goal-setting on web-site and send e-mail feedback.
3184443|NCT01307631|Experimental|Treatment (Akt inhibitor MK2206|Patients receive Akt inhibitor MK2206 PO once weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3184444|NCT01307618|Experimental|Arm I (vaccine therapy)|Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.
3184445|NCT01307618|Experimental|Arm II (vaccine therapy, IL-12)|Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.
3184446|NCT01307605|Active Comparator|Rituximab|Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
3184447|NCT01307605|Active Comparator|Rituximab plus Lenalidomide|Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
3184448|NCT01307579|Experimental|Arm I (caspofungin acetate)|Patients receive caspofungin acetate IV over 1 hour QD beginning within 24-72 hours following the last dose of chemotherapy for each course and continuing until ANC > 100-500/uL following the nadir or the next chemotherapy course begins.
3184449|NCT01307579|Active Comparator|Arm II (fluconazole)|Patients receive fluconazole IV over 1-2 hours or PO QD beginning within 24-72 hours following the last dose of chemotherapy for each course and continuing until ANC > 100-500/uL following the nadir or the next chemotherapy course begins.
3184450|NCT01307566|Experimental|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure (CPAP)
3184451|NCT01307553||PCS Group|
3184452|NCT01307540|Experimental|Active light therapy|oral mucosa is exposed to a light source (broad band of wavelengths, 400-800 nm)
3184453|NCT01307540|Placebo Comparator|Inactive light therapy|Oral mucosa is exposed to a extremely low-intensity light which is assumed to have no effect.
3184454|NCT01307501|Other|Cryoablation|Freezing of the tumor(s)
3184455|NCT01307488|Experimental|ATV/r+3TC|Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
3184456|NCT01307488|Active Comparator|ATV/r+2 NRTIs|Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
3184457|NCT01307475||Proband Group|Patients identified with FSS or a related condition
3184458|NCT01307475||Family Group|Persons who are genetically or legally related to a person with FSS or related condition
3184459|NCT01307475||Other Affected Individuals Group|Persons who have had significant and meaningful contact with a person with FSS or related condition but do not qualify for family group enrolment
3184460|NCT01307462|Experimental|Treatment (BOS therapy)|Patients receive fluticasone propionate inhaled PO BID, azithromycin PO 3 days a week, and montelukast sodium PO QD. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
3184461|NCT01307449|Experimental|Older Group|Participants between the ages of 60-89
3184462|NCT01307449|Experimental|Younger Group|Participants between the ages of 25-40 years
3184463|NCT01307436|Experimental|Group A|Epaxal + concomitant administration of DTPaHibIPV, MMR, OPV
3184464|NCT01307436|Experimental|Group B|Epaxal, with administration of DTPaHibIPV, MMR, OPV one month later
3184465|NCT01307436|Active Comparator|Group C|Havrix 720 + concomitant administration of DTPaHibIPV, MMR
3184466|NCT01307423|Experimental|Apremilast 20mg|Apremilast 20mg twice daily, orally
3184467|NCT01307423|Experimental|Apremilast 30mg|Apremilast 30mg twice daily, orally
3184468|NCT01307423|Placebo Comparator|Placebo + 20mg Apremilast|Placebo + 20mg Apremilast tablets administered twice daily
3184469|NCT01307423|Placebo Comparator|Placebo + 30mg Apremilast|Placebo + 30mg Apremilast tablets administered twice daily
3184470|NCT01307410||with CAD|Patients with hypertension and dyslipidemia with prior CAD
3184471|NCT01307410||without CAD|Patients with hypertension and dyslipidemia without prior CAD
3184472|NCT01307397|Experimental|Vemurafenib|Participants will receive vemurafenib at a dose of 960 milligrams (mg) twice daily (bid) until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
3184473|NCT01307384||Continuum Acetabular System|Patients receiving primary hip arthroplasty using the Continuum Metal on Polyethylene Acetabular System
3184474|NCT01307371||Diabetes|Patients with diabetes.
3184475|NCT01307371||non-diabetes|Patients without diabetes.
3184476|NCT01307358|Experimental|Manual Toothbrush + Sonicare Interproximal Cleaning Prototype|Manual Toothbrush + Sonicare Interproximal (IP) Cleaning Prototype
3184477|NCT01307358|Active Comparator|Manual Toothbrush|Manual Toothbrush
3184478|NCT01307358|Active Comparator|Manual Toothbrush + Floss|Manual Toothbrush + Floss
3184479|NCT01307358|Active Comparator|Manual Toothbrush + Waterpik Ultra Water Flosser|Manual Toothbrush + Waterpik Ultra Water Flosser
3184480|NCT01307345|No Intervention|Monitoring Alone|Research assistants will phone or text participants and request videorecordings of breathalyzer samples up to 21 times per week. Participants will receive compensation for each valid videorecording that occurs within the requested one-hour time frame, and bonus compensation each time all requested videorecordings are submitted within the timeframe over a 7-day period, and/or if >90% of prompts are returned over the study period.
3184481|NCT01307345|Experimental|Monitoring plus contingency management for abstinence|Participants assigned to this condition will receive the same monitoring schedule outlined above, plus the same payment for compliance. In addition, they will receive contingent reinforcement for submission of videorecordings that demonstrate negative breath alcohol samples. For each sample submitted that reads below the cut point, participants will receive vouchers for payment.
3184483|NCT01307319|Experimental|BDP HFA 80 mcg/day|Participants/parents administer 40 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
3184484|NCT01307319|Experimental|BDP HFA 160 mcg/day|Participants/parents administer 80 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
3184485|NCT01307319|Placebo Comparator|Placebo nasal aerosol once daily|Participants/parents administer placebo (a spray with no medication in each nostril) once daily for 15 days.
3184486|NCT01307306|Experimental|Metformin|
3184487|NCT01307306|Experimental|Insulin|
3184488|NCT01307306|No Intervention|Control|
3184489|NCT01307293|Experimental|Cognitive Behavior Therapy|6-12 sessions of Cognitive Behavior Therapy to address PTSD symptoms and parenting issues related to premature infants.
3184490|NCT01307293|No Intervention|Placebo comparison|Education regarding NICU parenting issues.
3184491|NCT01307280|Experimental|Basic HEALTH|Participants received the bookHEALTH manual and eHEALTH tools, the basic Internet component of the intervention
3184492|NCT01307280|Experimental|Interactive Internet|Intervention intensity increased in RCT2, which included bookHEALTH and an interactive version of eHEALTH that provided tailored computerized feedback whenever participants submitted weekly assessments.
3184493|NCT01307280|Experimental|Behavioral Counseling|RCT3 included bookHEALTH, the interactive version of eHEALTH, and telephonic coaching support provided by trained health lifestyle coaches every 2 weeks alternating between a telephone call (typically 15 to 20 minutes) and a personalized e-mail. The coaches used motivational interviewing, helped participants solve problems, and reinforced their successes.
3184494|NCT01307267|Experimental|Portion A|PF-05082566 single agent in patients with advanced cancer
3184495|NCT01307267|Experimental|Portion B|PF-05082566 in combination with rituximab in patients with Non-Hodgkin's Lymphoma
3184496|NCT01307254||Non alcoholic fatty liver disease|
3184497|NCT01307254||control|
3184498|NCT01307241||one cohort|Adult patients with ALL attending at the Instituto Nacional de Cancerologia Mexico.
3184499|NCT01307228|Experimental|Full-serve evidence service|"The full-serve evidence service consists of:~database (Health Systems Evidence) access;~monthly e-mail alerts; and~full-text article availability."
3184500|NCT01307228|Active Comparator|Self-serve evidence service|"Participants allocated to the self-serve evidence service will receive only database access, which is already publicly available at www.healthsystemsevidence.org"
3184501|NCT01307215|Experimental|20mLs of 0.5% ropivacaine per side|
3184502|NCT01307215|Experimental|30mLs of 0.33% ropivacaine per side|
3184503|NCT01307215|Experimental|40mLs of 0.25% ropivacaine per side|
3184504|NCT01307202|Experimental|Gabapentin|Gabapentin 600 mg will be given per oral two hours preoperatively and 200 mg three times daily after surgery (600 mg/day).
3184505|NCT01307202|Placebo Comparator|Placebo|Placebo will match the the gabapentin pill and will be given orally.
3184506|NCT01307189|Active Comparator|Tiotropium|
3184507|NCT01307189|Placebo Comparator|Placebo|
3184508|NCT01307176|Experimental|Home exercise program|Balance and walking exercise program
3184509|NCT01307150||Before and after treatment|SCORAD of each patient before and after treatment.
3184510|NCT01307137|Experimental|Telehealth (TAP)|
3184511|NCT01307137|Experimental|Peer-led care (PC)|
3184512|NCT01307124|Active Comparator|standard dose|Arm 1:LPV/r Standard dose BW 25-35 kg 300/75 mg BW >35-50 kg 400/100 mg
3184513|NCT01307124|Experimental|low dose|Arm 2:Low dose BW 25-35 kg 200/50 mg BW >35-50 kg 300/75 mg
3184514|NCT01307111|Experimental|Misoprostol|Misoprostol 400 micrograms inserted buccally or vaginally, per the participants desire.
3184515|NCT01307111|Placebo Comparator|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
3184516|NCT01307098|Experimental|Cohort 1|Cohort 1: Weekly IV infusions of Dose A of SBC-102 (sebelipase alfa)
3184517|NCT01307098|Experimental|Cohort 2|Cohort 2: Weekly IV infusions of Dose B of SBC-102 (sebelipase alfa)
3184518|NCT01307098|Experimental|Cohort 3|Cohort 3: Weekly IV infusions of Dose C of SBC-102 (sebelipase alfa)
3184519|NCT01307085|Experimental|preconditioning|Adult patients undergoing elective pulmonary lobectomy were received a remote ischemic preconditioning group after induction of anaesthesia.
3184520|NCT01307085|No Intervention|conventional|Adult patients undergoing pulmonary lobectomy were received no treatment after induction of anaesthesia.
3184521|NCT01307072||Never-treated group|The patients who had no previous ophthalmic examination until the first visit when vitreous surgery was prescribed
3184522|NCT01307072||The non-compliant group|The patients with a history of missing ophthalmic examination over a one year period
3184523|NCT01307072||The compliant group|The patients who had ophthalmic examinations at least once a year
3184524|NCT01307046|Experimental|MK-0954A|Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks.
3184525|NCT01307046|Active Comparator|Losartan|Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks.
3184526|NCT01307033|Active Comparator|MK-954H (L50/H12.5)|One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will then receive open label MK-0954A (L100/H12.5) orally, once daily for 44 weeks (extension)
3184527|NCT01307033|Experimental|MK-0954A (L100/H12.5)|One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will continue to receive MK-0954A orally, once daily for 44 week extension
3184528|NCT01307020|Placebo Comparator|Placebo|
3184529|NCT01307020|Active Comparator|Ibuprofen|
3184530|NCT01307020|Active Comparator|TRAM.HCl high dose|
3184531|NCT01307020|Active Comparator|TRAM.HCl low dose|
3184532|NCT01307020|Active Comparator|DKP-TRIS high dose|
3184533|NCT01307020|Active Comparator|DKP-TRIS low dose|
3184534|NCT01307020|Experimental|DKP-TRIS low dose - TRAM.HCl low dose|
3184535|NCT01307020|Experimental|DKP-TRIS low dose - TRAM.HCl high dose|
3184536|NCT01307020|Experimental|DKP-TRIS high dose - TRAM.HCl low dose|
3184538|NCT01307007|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0
3184539|NCT01307007|Active Comparator|Iron Dextran Injection|Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
3184540|NCT01306994||Syndrome Group|Individuals with Freeman-Sheldon, Sheldon-Hall, distal arthrogryposis type 1, or distal arthrogryposis type 3
3184541|NCT01306994||Control Group|Healthy individuals
3184542|NCT01306981|Experimental|Ranibizumab|
3184543|NCT01306981|Placebo Comparator|Saline|
3184544|NCT01306968|No Intervention|Standard TBI Care|Routine post-concussive symptoms (PCS) care as practiced within Departments of Defense (DoD)
3184545|NCT01306968|Experimental|HBO2 Group|Routine PCS care supplemented with hyperbaric oxygen (HBO2) at the dose of 1.5 ATA for 60 minutes administered over 40 sessions given daily Monday through Friday
3184546|NCT01306968|Sham Comparator|Sham Group|Routine PCS care supplemented with an otherwise identical sham hyperbaric air exposure at 1.2 atmospheres absolute (ATA)
3184547|NCT01306968|No Intervention|PTSD With no History of TBI|Subjects who have been diagnosed with PTSD but have no diagnosed or suspected brain injuries. This group does not receive HBO2.
3184548|NCT01306955|Active Comparator|methylprednisolone|patients who received methylprednisolone
3184549|NCT01306955|Placebo Comparator|dextrose water 5%|patients who received dextrose water 5% as placebo
3184550|NCT01306942|Experimental|Dasatinib + trastuzumab + paclitaxel|Eligible patients will be enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days. Dasatinib will be administered orally in two dose levels 100 and 140 mg once daily (QD) (a -1 dose level is included just in case dose de-escalation is needed). Treatment will be repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occurs. Only in the phase I, the first cycle will last 38 days.
3184551|NCT01306929|Experimental|pridopidine|45mg bid
3184552|NCT01306916||Group 1 of 1|diagnosis of primary and secondary hyperparathyroidism scheduled to undergo parathyroid resection.
3184553|NCT01306903|Experimental|MECC|Minimal extracorporeal circuit
3184554|NCT01306903|Placebo Comparator|MOPS|
3184555|NCT01306903|Placebo Comparator|Super MOPS|
3184556|NCT01306890||sipuleucel-T|
3184557|NCT01306877|Experimental|EEA Hemorrhoid and Prolapse Stapling Set|
3184558|NCT01306877|Active Comparator|Endosurgery Proximate PPH03 Stapling Set|
3184559|NCT01306864|Experimental|Hemospray Treatment|Hemospray Kit
3184560|NCT01306851|Active Comparator|Fibrin glue|
3184561|NCT01306838|Experimental|Treatment|The treatment arm is given early enteral supplementation with MicroLipid and Fish oil.
3184562|NCT01306838|Active Comparator|Control Group|Routine care
3184563|NCT01306799||Barrett's Esophagus, Erosive Esophagitis, GERD|
3184564|NCT01306786|Active Comparator|Quadruple therapy|"First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d"
3184565|NCT01306786|Active Comparator|Triple Therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
3184566|NCT01306773|Active Comparator|H1N1 convalescent plasma and oseltamivir|Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma
3184567|NCT01306773|Active Comparator|Oral Oseltamivir alone|Oseltamivir 75mg bid during ICU hospitalization
3184568|NCT01306760|Experimental|Ketamine|Ketamine used as the anaesthetic during ECT.
3184569|NCT01306760|Active Comparator|Propofol|Propofol, the standard anaesthetic, used during ECT.
3184570|NCT01306747|Experimental|Chronic Pain Self-Management|
3184571|NCT01306747|No Intervention|Control group|
3184572|NCT01306734||Gradient cooling group|Study group receiving gradient cooling during the procedure using extracorporeal circulation (ECC). The procedure is used routinely in the department and is not an experimental procedure. A maximum of 10 degrees celsius is allowed between the measured nasopharyngeal body temperature and the heater-cooler unit of the ECC-machine, when cooling or rewarming.
3184573|NCT01306734||Crash cooling group|Study group receiving rapid cooling using extracorporeal circulation. The protocol for rapid cooling is using routinely in the department and is not an experimental procedure. When cooling, the investigators aim for maximal difference in temperature between the heater-cooler unit of the ECC-machine.
3184574|NCT01306721|Active Comparator|FEX 60 mg|"Study medications is administered one hour before or two hours after a meal twice a day.~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination)~Double-blind treatment period:~1 tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg /pseudoephedrine 60 mg (fixe dose combination)"
3184575|NCT01306721|Experimental|FEX 60 mg/PSE 60 mg|"Study medications is administered one hour before or two hours after a meal twice a day.~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination~Double-blind treatment period:~1 tablet of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 60 mg / pseudoephedrine 60 mg (fixe dose combination)"
3184576|NCT01306721|Experimental|FEX 60 mg/PSE 120 mg|"Study medications is administered one hour before or two hours after a meal twice a day.~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination)~Double-blind treatment period:~2 tablets of fexofenadine 30 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 30 mg"
3184577|NCT01306708|Active Comparator|nimesulide|Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral non-steroidal anti-inflammatory (nimesulide 100 mg, twice per day, for 14 days);
3184620|NCT01306409|Experimental|A|Sequential application of different ESA
3184578|NCT01306695|Experimental|NYUCI|New York University Caregiver Intervention (NYUCI) in addition to community-based case management using community health workers.
3184579|NCT01306695|Other|CHW|Community-based case management using community health workers (CHWs).
3184580|NCT01306682|Active Comparator|Trivalent Influenza vaccine|0.5ml of TIV will be administered into deltoid muscle of non dominant arm
3184581|NCT01306682|Placebo Comparator|Normal saline|0.5ml of normal saline administered into deltoid muscle of non dominant arm
3184582|NCT01306669|Active Comparator|Trivalent influenza vaccine|Single dose administration of trivalent influenza vaccine prior to onset of influenza season
3184583|NCT01306669|Placebo Comparator|Normal saline|
3184584|NCT01306656|Experimental|Group 1|10,000 IU Vitamin D3 plus a multivitamin with 400 IU vitamin D
3184585|NCT01306656|Placebo Comparator|Group 2|Placebo plus a multivitamin with 400 IU vitamin D
3184586|NCT01306643|Experimental|Idelalisib|
3184587|NCT01306630|Other|tivozanib + capecitabine|
3184588|NCT01306617|Experimental|ABT-450/r (250/100 mg) and ABT-333 plus RBV in treatment-naïve|ABT-450/r (250/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID for 12 weeks in treatment-naïve participants.
3184589|NCT01306617|Experimental|ABT-450/r (150/100 mg) and ABT-333 plus RBV in treatment-naïve|ABT-450/r (150/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID for 12 weeks in treatment-naïve participants.
3184590|NCT01306617|Experimental|ABT-450/r (150/100 mg) and ABT-333 plus RBV in non-responders|ABT-450/r (150/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID in previous non-responders to pegylated interferon (pegIFN) and RBV.
3184591|NCT01306604||Observation|Patients from the first day of life with Niemann Pick Type C syndrome NPC1/NPC2 or profound suspicion for Niemann Pick Type C syndrome NPC1/NPC2 disease
3184592|NCT01306591|Active Comparator|Bevacizumab 1|
3184593|NCT01306591|Active Comparator|Bevacizumab 2|
3184594|NCT01306578|Active Comparator|IVIG group|20 children randomized to receive IVIG for 5 days at a dose of 0.4 g/kg/day
3184595|NCT01306578|Active Comparator|Plasma Exchange|21 children randomized to receive 5 sessions of 1 volume plasma exchange per day for 5 consecutive days
3184596|NCT01306565|Active Comparator|High dose atorvastatin|Three 80mg daily doses of atorvastatin
3184597|NCT01306565|Experimental|Low dose Atorvastatin|80mg atorvastatin followed by two 20mg daily atorvastatin
3184598|NCT01306552|Active Comparator|Student-intervention only group|"Schools randomized to intervention only (arm 1) will agree to visit the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?).~One school class of students will visit the parcours once during a school day. The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
3184599|NCT01306552|Active Comparator|Multi-component intervention|Schools randomized to the student-parent intervention arm also will agree to visit the KARUNA e.V. smoking prevention parcours. In addition, the schools will agree to have one parents' night presented by trained health coaches informing parents about smoking prevention topics in youth during the school year. Trained health coaches will give an evaluated smoking prevention presentation for parents at the parents' nights at the end of the first school year. Also, participating parents will receive information about successful ways to prevent smoking and promote smoking cessation in their children once by mail.
3184600|NCT01306552|Active Comparator|Control Group|Schools randomized to the control school will be offered to participate in the nutrition and exercise prevention program offered by KARUNA e.V. during the 2-year study.
3184601|NCT01306539|Experimental|Deep Brain Stimulation|Parkinson's patients with deep brain stimulation in the subthalamic nucleus.
3184602|NCT01306526||Moderate to Severe OSA|
3184603|NCT01306513|Experimental|cells|
3184604|NCT01306500|Experimental|Gastric lavage Group|In neonates randomized to intervention Group (gastric lavage group) gastric lavage was done in the labor room after initial stabilization
3184605|NCT01306500|No Intervention|No gastric lavage|Neonates randomized to 'No gastric lavage group' will receive supportive treatment as per standard unit protocol.
3184606|NCT01306487||Macular hole patients|The patients who underwent vitreous surgery for idiopathic macular hole.
3184607|NCT01306474||Prednisone|profess to convinced 1-1.5mg/Kg.d
3184608|NCT01306474||methotrexate to band prednisone|profess to convinced 7.5-15mg/w, concoction prednisone profess to convinced 0.5-1mg/Kg.d
3184609|NCT01306461|Active Comparator|Timolol and Tafluprost|Concomitant administration of preservative-free timolol and tafluprost eye drops
3184610|NCT01306461|Experimental|Fixed Dose Combination of tafluprost and timolol|Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops
3184611|NCT01306448|Experimental|vibrating capsule|
3184612|NCT01306435|Experimental|Laser Group|
3184613|NCT01306435|Placebo Comparator|Placebo Group|
3184614|NCT01306422|Placebo Comparator|Stage 2: Placebo|Placebo product, twice-daily, 65 minutes before breakfast and dinner
3184615|NCT01306422|Active Comparator|Stage 2: H.g.PE 1110 mg b.d.|Hoodia gordonii Purified Extract (H.g.PE) formulated product (1110 mg), twice-daily, 65 minutes before breakfast and dinner
3184616|NCT01306422|Placebo Comparator|Stage 1: placebo, breakfast & dinner|Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
3184617|NCT01306422|Active Comparator|Stage 1: H.g.PE 1110 mg breakfast/dinner|Hoodia gordonii purified extract (H.g.PE) formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
3184618|NCT01306422|Placebo Comparator|stage 1: Placebo breakfast/lunch|Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
3184619|NCT01306422|Active Comparator|Stage 1: H.g.PE 1110 mg breakfast/lunch|Hoodia gordonii purified extract (H.g.PE) formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
3184621|NCT01306396|Other|Intervention group|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake about 50%.
3184622|NCT01306396|No Intervention|Control group|"Families participating in the control group are given only one dietary counseling based on the references of the DGE at the beginning of the study if they wish."
3184623|NCT01306383|Active Comparator|SODIS Bottles given|Caregivers in the intervention group were given two 2-litre plastic bottles. Bottle was filled with available water and placed in direct sunlight for a minimum of 6 hours. Water was consumed the next day while second bottle was being consumed.
3184624|NCT01306383|Active Comparator|Usual practices|Caregivers in this group were asked to maintain their usual practices regarding drinking water so that disease rates could be compared with the SODIS arm
3184625|NCT01306370|Experimental|Tranexamic acid|Tranexamic acid is a synthetic derivative of the amino acid lysine. It inhibits fibrinolysis by blocking the lysine binding sites on plasminogen and facilitates the coagulation process.
3184626|NCT01306370|Experimental|Fibrin glue BSTC|It is homologous fibrin glue from a single blood donor.
3184627|NCT01306370|Experimental|Tissucol|It is fibrin glue commercialized from multiple donors.
3184628|NCT01306370|Other|Habitual haemostasis|Electrocoagulation of blood vessels was performed during surgery in all patients (routine hemostasis)
3184629|NCT01306357||Zomacton® with Zomajet® needle-free device|Zomacton® 4 mg delivered by percutaneous transjection (needle-free) using the Zomajet® 2 Vision device or Zomacton® 10 mg delivered by percutaneous transjection (needle-free) using the Zomajet® Vision X needle-free device.
3184630|NCT01306344||Patients|Heterogeneous groups of patients (age, gender)
3184631|NCT01306344||Nurses|Heterogeneous groups of nurses (age, gender, working experience)
3184632|NCT01306344||Physicians|Heterogeneous groups of physicians (age, gender, working experience)
3184633|NCT01306331|Active Comparator|Conceptrol|
3184634|NCT01306331|Experimental|Amphora|
3184635|NCT01306318|Experimental|1|
3184636|NCT01306318|Active Comparator|2|
3184637|NCT01306305|Experimental|Elderly|Elderly subjects aged over 60 years
3184638|NCT01306305|Experimental|Adults|Adults from 18 to 60 years old inclusive
3184639|NCT01306292|Experimental|SonoVue|Ultrasound contrast agent under development
3184640|NCT01306292|Placebo Comparator|Placebo|normal saline 0.9% for injection used as the comparator
3184641|NCT01306279||Cystic Fibrosis, infection|Cystic Fibrosis patients with an infective exacerbation
3184642|NCT01306266|Active Comparator|rizatriptan|initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo
3184643|NCT01306266|Placebo Comparator|Placebo|Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg
3184644|NCT01306253|Experimental|Elderly|Elderly subjects aged over 60 years
3184645|NCT01306253|Experimental|Adults|Adults from 18 to 60 years old inclusive
3184646|NCT01306240|Experimental|Early strategy|Intratracheal poractant alpha (Curosurf®) after tracheal intubation
3184647|NCT01306240|Active Comparator|Delayed strategy|Nasal Continous Positive Airways Pressure. Intratracheal poractant alpha as a rescue treatment if FiO2 > 60%
3184648|NCT01306227|Placebo Comparator|water|Oral treatment with water for 6 weeks
3184649|NCT01306227|Experimental|L-Thyroxine|Oral treatment with L-Thyroxine for 6 weeks
3184650|NCT01306214|Experimental|BI 10773 low dose|BI 10773 low dose once daily
3184651|NCT01306214|Experimental|BI 10773 high dose|BI 10733 high dose once daily
3184652|NCT01306214|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
3184653|NCT01306201||In-patient Volunteers|In-patients from the hospital who choose to participate in the study
3184654|NCT01306188||Breast cancer|Metastatic breast cancer
3184655|NCT01306188||Lung cancer|Metastatic lung cancer
3184656|NCT01306175|Experimental|Digoxin alone (Reference)|Tablet, oral administration with 240 mL water
3184657|NCT01306175|Experimental|Digoxin plus BI 10773 (Test)|Tablets, oral administration with 240 mL water
3184658|NCT01306162|Experimental|A: Dabigatran alone (Reference)|Capsule, oral administration with 240 mL water
3184659|NCT01306162|Experimental|B: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
3184660|NCT01306162|Experimental|C: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
3184661|NCT01306162|Experimental|D: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
3184662|NCT01306162|Experimental|E: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
3184663|NCT01306136|Experimental|Prolonged Exposure|
3184664|NCT01306136|Active Comparator|Usual care|
3184665|NCT01306123|Experimental|Nascobal nasal spray (cyanocobalamin USP)|One single administration of intranasal cyanocobalamin (initially)
3184666|NCT01306123|Active Comparator|Vitamin B12-ratiopharm N, injection solution|One single injection of IM cyanocobalamin (initially)
3184667|NCT01306097|Experimental|Zinc sulfate|daily zinc supplementation for 3 months. (10mg daily for under 1 years old children and 20mg daily for above 1 years old children)
3184668|NCT01306058|Experimental|Sorafenib & TRC105 in Hepatocellular CA|CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day
3184669|NCT01306045|Active Comparator|A|Erlotinib
3184670|NCT01306045|Active Comparator|B|AZD6244
3184671|NCT01306045|Active Comparator|C|MK-2206
3184672|NCT01306045|Active Comparator|D|Lapatinib
3184673|NCT01306045|Active Comparator|E|Sunitinib
3184674|NCT01306045|Other|F|NOS (not otherwise specified)
3184675|NCT01306032|Experimental|Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
3184676|NCT01306032|Experimental|Triple-negative Breast Cancer: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
3184815|NCT01305018|Experimental|Exercise and Leucine|
3184816|NCT01305018|Placebo Comparator|Exercise and Placebo|
3184677|NCT01306032|Experimental|BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
3184678|NCT01306032|Experimental|BRCA- positive Ovarian Cancer: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
3184679|NCT01306032|Experimental|Non-Hodgkin's: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
3184680|NCT01306032|Experimental|Non-Hodgkin's: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
3184681|NCT01306019|Experimental|1|Gene Therapy
3184682|NCT01306006|Active Comparator|MV-for-all|Measles vaccine provided to all children aged 9 months -3 years of age
3184683|NCT01306006|No Intervention|National policy|Measles vaccine provided to children aged 9-11 months, if there are sufficient children to open a measles vaccine vial.
3184684|NCT01305941|Experimental|Everolimus +Vinorelbine + trastuzumab|daily everolimus plus weekly (Days 1, 8, and 15) vinorelbine and trastuzumab
3184685|NCT01305928|Active Comparator|Fax|
3184686|NCT01305928|Experimental|Warm Hand-off|
3184687|NCT01305915|No Intervention|Control|participant will receive standard print material
3184688|NCT01305915|Experimental|Intervention|patient will receive standard print material and a single session group psychoeducational intervention (GBOT)
3184689|NCT01305902|No Intervention|walking recommendations|Participants assigned to this condition will be instructed to wear a pedometer daily and scheduled for weekly meetings over for the next 12 weeks. Each week, they will be congratulated if they walked the target goal on any days, and encouraged to meet the goals for the upcoming week. However, they will not receive any tangible reinforcement for walking. The meetings will be brief (about 15 minutes) and will include discussions and handouts related to the health benefits of walking.
3184690|NCT01305902|Experimental|contingency management for walking|Participants assigned to this condition will be asked to wear a pedometer daily and scheduled for weekly meetings over for the next 12 weeks. The meeting duration and structure will be similar to that in the standard treatment condition including the handouts, with one exception. Participants in this condition will earn tangible reinforcement in the form of prizes for walking the target number of steps per day.
3184691|NCT01305889|Experimental|problem solving therapy|subjects will receive 12 weeks of weekly problem solving therapy
3184692|NCT01305889|Experimental|sertraline|12 weeks of sertraline
3184693|NCT01305876|Experimental|one group with yoga intervention|one group with yoga intervention
3184694|NCT01305863|Active Comparator|Propaten graft|Untreated Propaten vascular graft
3184695|NCT01305863|Experimental|ASC-Coated ePTFE graft|ASC Coated BARD IMPRA® ePTFE Vascular Graft
3184696|NCT01305850|Active Comparator|Aliskiren|
3184697|NCT01305850|Active Comparator|Aliskiren plus Losartan|
3184698|NCT01305850|Active Comparator|Enalapril plus Losartan|
3184699|NCT01305850|Placebo Comparator|placebo|
3184700|NCT01305837|Experimental|methylprednisolone|all patients will be treated with the active drug methylprednisolone 500 mg in 3 days every month for 60 weeks.
3184701|NCT01305824|Active Comparator|PRT 201 (10 micrograms)|
3184702|NCT01305824|Placebo Comparator|Placebo|
3184703|NCT01305824|Active Comparator|PRT-201 (30 micrograms)|
3184704|NCT01305811|Experimental|Bi-weekly acupuncture treatment|Bi-weekly acupuncture treatment
3184705|NCT01305811|Active Comparator|Wait list|Wait list for 2 months followed by weekly acupuncture for 4 months
3184706|NCT01305798|Experimental|Control Arm|The control arm will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment.
3184707|NCT01305798|Experimental|Active Choice and Default Option Arm|The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email.
3184708|NCT01305798|Experimental|Active Choice Only Arm|The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
3184709|NCT01305772|Experimental|Surgery|Patients who underwent surgery after research PET/CT scans and subsequent radiation therapy with panitumumab administration
3184710|NCT01305772|Active Comparator|Radiation Therapy|Patients who underwent radiation therapy only, in conjunction with panitumumab therapy.
3184711|NCT01305759||YoungTKA|Adults under 60 years who are having primary TKA
3184712|NCT01305759||YOUNGTHA|Adults under 60 years who are having primary THA
3184713|NCT01305759||PAOAarhus|Adults under 60 years who are having primary PAO
3184714|NCT01305746|Experimental|A-623 high dose weekly|High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
3184715|NCT01305746|Experimental|A-623 low dose weekly|Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
3184716|NCT01305746|Experimental|A-623 high dose every 4 weeks|High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
3184717|NCT01305733|Active Comparator|local infiltration analgesia|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
3184718|NCT01305733|Placebo Comparator|saline injection|The normal saline injection are used in the control group in the same manner than in the RKA group.
3184810|NCT01305044|Experimental|Tai Chi Chih|The Tai Chi Chih classes were 60 minutes sessions, held three times a week, over twelve weeks. The classes were led by an instructor who was certified and licensed in the Tai Chi Chih form.
3184812|NCT01305031|Experimental|Room air|Initiation of resuscitation with 21% Oxygen, adjustments to the inspired oxygen concentration (increased 10%) will be made every 60 seconds for infants to achieve a target SpO2 range of 85-92%
3184719|NCT01305707|Experimental|C-ECT and Pharmacotherapy|Consolidation treatment with ECT will be considered finished after 9 months of being started, at which time patients will stay only on the pharmacological treatment they already had. The study will be completed within 15 months of patient inclusion (six months after the end of C-ECT). Patient assessment and follow-up will be conducted by participant researchers. Blind rater will conduct clinical and adverse effects ratings. A neuropsychologist will conduct neuropsychological assessments.
3184720|NCT01305707|Active Comparator|Pharmacotherapy|Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet.
3184721|NCT01305694|Experimental|MSC|Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with relapsed/refractory aplastic anemia.
3184722|NCT01305681|Active Comparator|LoFric® catheters|LoFric® catheters during clean intermittent catheterization will be compared to non-LoFric® catheters during clean intermittent catheterization
3184723|NCT01305668||Emphysema phenotype|
3184724|NCT01305668||No-Emphysema phenotype|
3184725|NCT01305655|Experimental|Glucarpidase arm|In the NOPHO ALL-2008 protocol patients with delayed methotrexate elimination (DME) in high-dose methotrexate treatments should be given Glucarpidase (50 ie/kg) with-in 60 hours from start of the methotrexate treatment.
3184726|NCT01305642|Experimental|Individualized fortification of breast milk|
3184727|NCT01305629|Experimental|Intervention Condition|Twelve sessions of spiritual self schema counseling, adapted to target target medication adherence and substance use.
3184728|NCT01305629|Active Comparator|Education Condition|Eight sessions of education with content designed to mirror the information covered in the intervention condition.
3184729|NCT01305616|Active Comparator|Group 1, glaucoma and cataract|Group1 were those patients with visually significant cataract (less than grade 2) and mild to moderate open angle glaucoma
3184730|NCT01305616|Sham Comparator|Group2, cataract patients|This group included those patients with visually significant cataract and normal other eye examination.
3184731|NCT01305603|Active Comparator|Dual TAP block|Dual TAP block on one side on the abdomen. Classical (or single) TAP on the contra lateral side of the abdomen; supplemented with a sham injection to ensure double blindness.
3184732|NCT01305603|Active Comparator|Classical (or single) TAP block|Dual TAP block on one side on the abdomen. Classical (or single) TAP on the contra lateral side of the abdomen; supplemented with a sham injection to ensure double blindness
3184733|NCT01305590|Other|Survey|"We will survey participants to see if they would prefer more commitment, in the form of a Take-Medication-Get-Paid plan; less commitment, in the form of an Attend-Clinic-Get-Paid plan; or if they would prefer to designate their own levels of commitment."
3184734|NCT01305577|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3184735|NCT01305577|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3184736|NCT01305577|Experimental|Deoxycholic Acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3184737|NCT01305564|Experimental|Denali inferior vena cava filter|All subjects enrolled will receive the Denali vena cava filter.
3184738|NCT01305551|Experimental|Treatment A-Saxagliptin+Metformin XR|5mg Saxagliptin + 500 mg Metformin XR Tablets, once on Day 1 only, administered together in the fasted state.
3184739|NCT01305551|Experimental|Treatment B-Saxagliptin/Metformin XR FDC|5mg Saxagliptin / 500 mg Metformin XR FDC tablet, once on Day 1 only, administered in the fasted state.
3184740|NCT01305551|Experimental|Treatment C-Saxagliptin+Metformin XR|5mg Saxagliptin + 500 mg Metformin XR Tablets, once on Day 1 only, administered together in the fed state.
3184741|NCT01305551|Experimental|Treatment D-Saxagliptin/Metformin XR FDC|5mg Saxagliptin / 500 mg Metformin XR FDC tablet, once on Day 1 only, administered in the fed state.
3184742|NCT01305538|Other|Arm 1 BMS-954561 40mg or 80mg|"Arm description: BMS-954561 40mg or 80mg three times daily (TID) to Placebo OR Placebo to 40mg or 80mg TID.~Arm type: Active to Placebo or Placebo to Active (cross-over)"
3184743|NCT01305538|Other|Arm 2 BMS-954561 150mg or 300mg|"Arm description: BMS-954561 150mg or 300mg TID to Placebo OR Placebo to 150mg or 300mg TID~Arm type: Active to Placebo or Placebo to Active(cross-over)"
3184744|NCT01305525||Spinal Cord Stimulation|
3184745|NCT01305512|Experimental|SPARC1028|
3184746|NCT01305499|Experimental|A: 5AC days 1-10 / entinostat days 3, 10|Arm A will be given an overlapping schedule of drugs with 5AC given at 50mg/m2 subcutaneously daily for 10 days on days 1 - 10 of a 28 day cycle and entinostat given at a flat dose of 8 mg orally on days 3 and 10.
3184747|NCT01305499|Experimental|B: 5AC days 1-10 / entinostat days 10,17|In Arm B the agents will be administered sequentially with 5AC given at 50mg/m2 subcutaneously daily for 10 days on days 1 - 10 of a 28 day cycle followed by entinostat at a 8 mg flat dose on days 10 and 17.
3184748|NCT01305486||XenMatrix|
3184749|NCT01305473||Sepramesh Group|
3184750|NCT01305460|Experimental|Azacitidine intensified dose|
3184751|NCT01305447|Experimental|Exercise Maintenance|"Randomization and Group-Mediated Cognitive Behavioural therapy (GMCB) sessions will begin on week 8 of the program. Topics of self-regulation related to exercise (Social cognitive theory of self-regulation, Albert Bandura, 1991) will be discussed: monitoring, scheduling, goal setting, coping, overcoming barriers, rewards, social support.~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) intervention strategies over the phone to continue to enhance the GMCB principles on how to maintain exercise behavior."
3184811|NCT01305044|Active Comparator|Health Education Classes|Health Education classes were 60 minute sessions that occurred three times a week, over twelve weeks. These classes were taught by specialists in the class topic and focused on topics related to aging (e.g., sleep quality, nutrition, pain, etc.).
3184813|NCT01305031|Active Comparator|100% Oxygen|Initiation of resuscitation with 100% Oxygen and achieve oxygen saturation in the preset limits 85-92%
3184752|NCT01305447|Experimental|Ex. Maintenance + relapse prevention|"The same topics of self-regulation related to exercise maintenance(Social cognitive theory of self-regulation, Albert Bandura, 1991) will be discussed: monitoring, scheduling, goal setting, coping, overcoming barriers, rewards, social support.~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) intervention strategies over the phone to continue to enhance the Group-Mediated Cognitive Behavioural therapy (GMCB) principles on how to maintain exercise behavior.~Participants in this arm will also receive the Brandon et al. (2004) Forever Free smoking relapse prevention booklets."
3184753|NCT01305447|Active Comparator|relapse prevention|"Randomization and group discussion sessions will begin on week 8 of the program. Topics of women's health, unrelated to exercise will be discussed (control).~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to continue to maintain contact time.~Participants in this arm will also receive the Brandon et al. (2004) Forever Free smoking relapse prevention booklets."
3184754|NCT01305447|Active Comparator|Contact Control|"Randomization and group discussion sessions will begin on week 8 of the program. Topics of women's health, unrelated to exercise will be discussed (control).~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to continue to maintain contact time."
3184755|NCT01305434|Other|Placebo then mulberry leaf|These patients receive placebo for two weeks, then 1 week washout, then two weeks of mulberry leaf extract.
3184756|NCT01305434|Other|Mulberry leaf then placebo|These patients receive mulberry leaf extract for two weeks, then 1 week washout, then two weeks of placebo.
3184757|NCT01305408|Placebo Comparator|Placebo|Participants began taking placebo to match armodafinil and following the same titration procedure. Treatment was administered for a total of 8 weeks.
3184758|NCT01305408|Experimental|Armodafinil 150 mg/day|Participants began taking armodafinil at a dosage of 50 mg/day; the dosage was increased by 50 mg/day on days 2 and 4, up to a dosage of 150 mg/day. Treatment was administered for a total of 8 weeks.
3184759|NCT01305395|Experimental|Early Intervention Arm|Initiate sirolimus within 6 months of heart transplant
3184760|NCT01305395|Experimental|Late Intervention Arm: Group 2A|Initiate sirolimus after CAV is diagnosed by angiogram
3184761|NCT01305395|Experimental|Retrospective Arm: Angiogram group|Start sirolimus after CAV diagnosed is by angiogram
3184762|NCT01305395|Experimental|Late Intervention Arm: Group 2B|Start sirolimus after CAV is diagnosed by IVUS
3184763|NCT01305395|Experimental|Retrospective Arm: Intravascular Ultrasound|Sirolimus after CAV is diagnosed by IVUS
3184764|NCT01305382||Heart Transplant Cohort|This group consist of transplant subjects within 10 years of heart transplant
3184765|NCT01305382||Heart Failure Sub group|Consist of subjects with advanced heart failure (NYHA class III and IV)
3184766|NCT01305382||Healthy Volunteer|This groups consist of healthy individuals
3184767|NCT01305356|Active Comparator|Autologous bone graft|Standard Rigid Fixation + Autologous bone graft
3184768|NCT01305356|Experimental|Augment(tm) Injectable Bone Graft|Standard rigid fixation + Augment(tm) Injectable Bone Graft (beta-TCP/bovine collagen matrix + rhPDGF-BB)
3184769|NCT01305343||Surgical treatment|This observational study is examining the outcomes of standard surgical treatments for adult spinal deformity.
3184770|NCT01305317|Experimental|lipitor|atorvastatin 20mg daily
3184771|NCT01305304||1|"15 healthy male veteran runners (marathon, triathlon, orienteering) aged between 40 and 65 years with a history of competitive running at a national level during a period of at least 5 years, implicating normally a runner career with at least 50km per week over more than 10 years"
3184772|NCT01305304||2|15 healthy male volunteers, matched for age and bmi, without a history of competitive physical exercise (i.e. sedentary controls)
3184773|NCT01305291|Placebo Comparator|tea only without fibersol-2|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects (11).~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling (11).~The beverage will be consumed at 10 am.~Blood samples will be taken at specified time points prior to after the treatments."
3184774|NCT01305291|Active Comparator|tea only with fibersol-2 (10 g)|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects.~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling (11).~The beverage will be consumed at 10 am.~Blood samples will be taken at specified time points prior to and after the treatments.~Ingredient only test will be done without the meal to determine independent effects of Fibersol-2."
3184775|NCT01305291|Placebo Comparator|tea without fibersol-2 and meal|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects.~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.~The test meal and beverage will be consumed at 10 am.~The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).~Tea containing test materials will accompany the meal.~Blood samples will be taken at specified time points prior to and after the treatments."
3184776|NCT01305291|Experimental|tea with 5 g fibersol-2 and meal|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects.~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.~The test meal and beverage will be consumed at 10 am.~The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).~Tea containing test materials will accompany the meal.~Blood samples will be taken at specified time points prior to and after the treatments."
3184777|NCT01305291|Experimental|tea with 10 g fibersol-2 and meal|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects.~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.~The test meal and beverage will be consumed at 10 am.~The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).~Tea containing test materials will accompany the meal.~Blood samples will be taken at specified time points prior to and after the treatments."
3184778|NCT01305278|No Intervention|Control|No Wii balance gaming undertaken
3184779|NCT01305278|Active Comparator|Wii during vestibular rehab only|To start Wii Balance Gaming from the beginning of vestibular rehabilitation.
3184780|NCT01305278|Active Comparator|Wii whilst on waiting list and rehab|Wii Balance Gaming whilst on waiting list for vestibular rehabilitation. To continue with Wii Balance Gaming until end of vestibular rehabilitation.
3184781|NCT01305265|Active Comparator|intervention|Endotracheal tube will be adjusted to 22-26 cm H20 pressure immediately post intubation using a cuff manometer
3184782|NCT01305265|No Intervention|control|endotracheal tube cuff will be inflated using standard technique
3184783|NCT01305252|Active Comparator|tadalafil alone|tadalafil 40mg QD(Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated).
3184784|NCT01305252|Active Comparator|tadalafil and treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation & gradually increasing to 9 breaths.Each breath provides approximately 6 mcg of treprostinil.Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated.
3184785|NCT01305239||Postmenopausal ER+ patients treated by Aromasin.|
3184786|NCT01305226|Experimental|Test - THR-100|120 subjects are to be recruited into the trial, with patients randomized in a 1:1 allocation ratio to THR-100 and Streptokinase 60 subjects are to be recruited into Test arm, and administered 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
3184787|NCT01305226|Active Comparator|Streptokinase|120 subjects are to be recruited into the trial, with patients randomized in a 1:1 allocation ratio to THR-100 and Streptokinase Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
3184788|NCT01305213|Experimental|Arm I (bevacizumab)|Patients receive bevacizumab as in Arm II. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3184789|NCT01305213|Experimental|Arm II (bevacizumab, fosbretabulin tromethamine)|Patients receive bevacizumab IV over 30-90 minutes and fosbretabulin tromethamine IV over 10-20 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3184790|NCT01305200|Placebo Comparator|Arm I (placebo)|Patients rinse and gargle with placebo over 1 minute QID beginning the first day (about day -7) of the conditioning regimen. Treatment continues until day 20 post-transplantation.
3184791|NCT01305200|Experimental|Arm II (supersaturated calcium phosphate rinse)|Patients rinse and gargle with supersaturated calcium phosphate rinse over 1 minute QID beginning on the first day (about day -7) of the conditioning regimen. Treatment continues until day 20 post-transplantation.
3184792|NCT01305187|Experimental|Hyaluronic Acid Filler - Medical Device|
3184793|NCT01305174|Active Comparator|Balloon expandable stent arm|"First placement of the sheath and successful passage of a 0.018 or 0.035 guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the balloon-expandable stent (Visi-Pro™, ev3 Endovascular, Inc., Plymouth, MN, USA), which was premounted on a balloon catheter, was deployed by inflation of the balloon. The nominal stent diameter had to approximate the reference vessel diameter of the target lesion. Postdilation was permitted"
3184794|NCT01305174|Active Comparator|Selfexpanding stent arm|"First placement of the sheath and successful passage of a 0.018 or 0.035 guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the the self-expanding stent (Protege™, ev3 Endovascular, Inc., Plymouth, MN, USA), which had to exceed in the nominal diameter the reference vessel diameter at least by 1 mm, was released. Postdilation was mandatory. The inflated postdilation-balloon should approximate the reference vessel diameter."
3184795|NCT01305148|Experimental|Randomized - Genetic|Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
3184796|NCT01305148|No Intervention|Randomized - Clinical|Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from clinical information alone through the warfarindosing.org website
3184797|NCT01305148|Experimental|Registry|Subjects who are followed 30 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
3184798|NCT01305135|Experimental|azacitidine 75mg/m²/d + idarubicin 5mg/m²/d|"phase I : palier 1 have 10 patients and palier 2 have to 10 patients.~palier 1: Ida 5mg/m²/d (D8) + AZACITIDINE 75mg/m²/d (D1-D7)"
3184799|NCT01305135|Experimental|Azacitidine 75mg/m²/d + idarubicin 10mg/m²/d|palier 2: Ida 10mg/m²/d (D8)+ Azacitidine 75mg/m²/d (D1-D7)
3184800|NCT01305122|Other|OMS grade II glioma|neurocognitive tests
3184801|NCT01305109|Experimental|Oral Rotavirus Vaccine 116E (ORV 116E)|Oral Rotavirus Vaccine 116E (ORV 116E), 10^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5 mL at 4 week intervals
3184802|NCT01305109|Placebo Comparator|Placebo|3 doses of 0.5 mL at 4 week intervals
3184803|NCT01305096|Experimental|Yoga group|Participants in this group will take part in six to eight weeks of yoga classes. The classes will be held once a week and each class will be approximately one hour long. The classes will consist of yoga inversions, sun salutations and other yoga postures with deep breathing.
3184804|NCT01305096|No Intervention|Control group|Matched control
3184805|NCT01305083|Active Comparator|Udenafil|Active Ingredient
3184806|NCT01305083|Placebo Comparator|Placebo|Placebo
3184807|NCT01305070|Active Comparator|Standart balloon angioplasty|Admiral Xtreme, Invatec
3184808|NCT01305070|Active Comparator|Paclitaxel-eluting balloon arm|In.Pact Admiral, Invatec
3184809|NCT01305057|Experimental|Evaluation of P-IP on hydration and barrier function|Effects of P-IP on improvement of skin hydration and TEWL were examined.
3184817|NCT01305005||hyperpiesia|patients who underwent phacoemulsification surgery with hyperpiesia
3184818|NCT01305005||diabetes mellitus|patients who underwent phacoemulsification surgery with diabetes mellitus
3184819|NCT01305005||hyperpiesia and diabetes mellitus|patients who underwent phacoemulsification surgery with hyperpiesia and diabetes mellitus
3184820|NCT01304992|Experimental|Lupin Protein|Lupin protein (cultivar: Lupinus angustifolius Boregine; incorporated in a drink)
3184821|NCT01304992|Active Comparator|Reference protein|Reference Protein (75% sodium caseinate (EM7; DMV international) and 25% milk protein (Megglosat HP; Meggle), incorporated in a drink)
3184822|NCT01304992|No Intervention|Wash out|Wash out (four weeks without any intervention between interventional periods)
3184823|NCT01304979|No Intervention|Usual care alone|Subjects receive usual care alone before and after spine fusion surgery
3184824|NCT01304979|Experimental|Active Intervention|Acupuncture therapies, ear seeds, acupuncture treatment and gua sha, designed to reduce pain and facilitate recovery for low back spine fusion patients.
3184825|NCT01304979|Sham Comparator|Control Arm|Indirect therapies with same encounter time and timing as direct care group.
3184826|NCT01304953|Placebo Comparator|P+P|
3184827|NCT01304953|Experimental|P+T|
3184828|NCT01304953|Placebo Comparator|S+P|
3184829|NCT01304953|Experimental|S+T|
3184830|NCT01304927|Active Comparator|Cholecalciferol + calcium|Group of intervention: Each man will receive 300,000 IU (7500 ug) Cholecalciferol (VD3) orally once after blood and semen sampling and performed DXA scan. Thereafter they will receive VD tablets of 1,400 IU (35 ug) + 500 mg calcium daily for 3 months. At 3 months a clinical control and blood sampling will be performed, followed by continued daily intake of 1400 IU VD3 + 500 mg calcium. At end of treatment at five months after inclusion the men deliver two semen samples, have a blood sample drawn and a DEXA scan performed.
3184831|NCT01304927|Placebo Comparator|placebo|Group receiving placebo: Each man will receive placebo oral mixture once after blood- and semen sampling and performed DXA scan. Thereafter they will receive placebo tablets daily for 3 months. At 3 months a clinical control and blood sampling will be performed, followed by continued daily intake of placebo. At end of treatment at five months after inclusion the men deliver two semen samples, have a blood sample drawn and a DEXA scan performed.
3184832|NCT01304914||Healthy, term-delivered babies|
3184833|NCT01304901|Active Comparator|1-Montelukast|Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.
3184834|NCT01304901|Placebo Comparator|2- Placebo|Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
3184835|NCT01304888|Experimental|Food basket w/o nutrition education|
3184836|NCT01304888|Experimental|Food basket + nutrition education|
3184837|NCT01304888|Experimental|Control|
3184838|NCT01304888|Experimental|Cash + health and nutrition education|
3184839|NCT01304862|Experimental|Self-management intervention|
3184840|NCT01304862|Active Comparator|Educational Videos about Healthy Living|
3184841|NCT01304849|Experimental|Primary|Patients with aHL will receive 2 cycles of ABVD and undergo interim PET-2 scan- those with positive scans will receive 4 additional cycles of Esc BEACOPP while those with negative scans will receive 4 additional cycles of ABVD.
3184842|NCT01304836|Active Comparator|10 Days of Steroids|Advagraf + Basiliximab + MMF + Steroids (10 days)
3184843|NCT01304836|Experimental|Optional Steroid bolus only|Advagraf + Basiliximab + MMF + Steroids (bolus only)
3184844|NCT01304823|Active Comparator|glucose|intraduodenal perfusion of glucose (29.3 g glucose per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min)
3184845|NCT01304823|Active Comparator|glucose + lactisole|intraduodenal perfusion of glucose (29.3 g glucose per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min) + 450 ppm lactisole
3184846|NCT01304823|Active Comparator|mixed liquid meal|intraduodenal perfusion of a mixed liquid meal (20.20 g carbohydrate, 4.92 g fat and 6.25 g protein per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min)
3184847|NCT01304823|Active Comparator|mixed liquid meal + lactisole|intraduodenal perfusion of a mixed liquid meal (20.20 g carbohydrate, 4.92 g fat and 6.25 g protein per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min) + 450 ppm lactisole
3184848|NCT01304823|Placebo Comparator|saline + lactisole|saline (0.9 %; rate: 2.5 mL/min for 180 min) + 450 ppm lactisole
3184849|NCT01304810||NicVAX|NicVAX vaccine
3184850|NCT01304810||Placebo vaccine|Placebo vaccine
3184851|NCT01304797|Experimental|MM-302|
3184852|NCT01304797|Experimental|MM-302 in Combination with Trastuzumab|
3184853|NCT01304797|Experimental|MM-302 in Combination with Trastuzumab q3w|
3184854|NCT01304797|Experimental|MM-302 in Combination with Trastuzumab and Cyclophosphamide|
3184855|NCT01304784|Experimental|Arm 1|"Regimen follows a 3-week treatment cycle.~Cisplatin 80mg/m2 given on day 1 by IV infusion over two hours every three weeks.~Capecitabine 1000 mg/m2 given orally twice daily for fourteen days each 3-week cycle.~Up to six 3-week cycles of Cisplatin and Capecitabine to be administered. Trastuzumab given as 8 mg/kg loading dose at week 1 over 90 minutes followed by 6 mg/kg every 3 weeks over 30-90 minutes.~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Trastuzumab (every 3 weeks) and MM-111 (weekly) will continue until disease progression, unacceptable toxicity, or withdrawal of consent."
3184856|NCT01304784|Experimental|Arm 2|"Regiment follows a 4-week treatment cycle.~The following Lapatinib and Trastuzumab regimen will be given in combination with MM-111 in the following order:~Trastuzumab 4 mg/kg loading dose week 1 over 90 minutes~Followed by Trastuzumab 2 mg/kg weekly thereafter~Lapatinib 1000 mg by mouth (PO) daily~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
3184893|NCT01304498|Experimental|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
3184894|NCT01304498|Active Comparator|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
3184895|NCT01304485|Experimental|Sodium Acetate C11 PET Imaging|
3184857|NCT01304784|Experimental|Arm 3|"Regimen follows a 4-week treatment cycle Paclitaxel dosing should begin first dose on cycle 1 day 1. Paclitaxel will be administered at 80 mg/m2 weekly, as an IV infusion over 60 minutes. The infusion should be prepared as directed in the Paclitaxel package insert. All patients receiving Paclitaxel should be premedicated as per the local institutional guidelines.~Trastuzumab will be administered via IV over 90 minutes at a 4 mg/kg loading dose for the first infusion followed by weekly infusion of 2 mg/kg over 60 minutes thereafter.~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
3184858|NCT01304784|Experimental|Arm 4|"4-week treatment cycle. Lapatinib given orally. Paclitaxel dosing on cycle 1 day 1. Paclitaxel given at 80 mg/m2 weekly, as an IV infusion over 60 minutes. The infusion should be prepared as directed in the Paclitaxel package insert. All patients receiving Paclitaxel should be premedicated as per the local institutional guidelines.~Trastuzumab given via IV over 90 minutes at a 4 mg/kg loading dose for the first infusion followed by weekly infusion of 2 mg/kg over 60 minutes thereafter.~MM-111 given over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
3184859|NCT01304784|Experimental|Arm 5|"Docetaxel, trastuzumab and MM-111 3-week treatment cycles with therapies given in the following order: 1) docetaxel, 2) trastuzumab, and 3) MM-111~Docetaxel given as an IV infusion over 60 minutes every three weeks. The infusion should be prepared as directed in the Docetaxel package insert and any institutional guidelines. All patients receiving Docetaxel should be pre-medicated as per the local institutional guidelines.~The first dose of trastuzumab is a loading dose of 8 mg/kg administered over 90 minutes followed by every three week dosing at 6 mg/kg over 60 minutes via IV infusion.~The first dose of MM-111 given over 90 minutes followed by 3 week dosing over 60 minutes in the absence of infusion-related reactions"
3184860|NCT01304771|Active Comparator|Synbiotic AKSB|Participants (healthy > 65 year old persons) will be randomized to take the synbiotic AKSB. All participants will also receive inactivated trivalent Influenza vaccine while being on the AKSB. We will assess safety of the AKSB in this setting. We will also assess the stool microbiology in relation to vancomycin-resistant enterococcus and probiotic strain enterococcus. We will also assess influenza vaccine response in patients on AKSB
3184861|NCT01304771|Placebo Comparator|Talc Placebo|Participants (healthy > 65 year old persons) will be randomized to take the placebo. All participants will also receive inactivated trivalent Influenza vaccine while being on the placebo. We will also assess the stool microbiology in relation to vancomycin-resistant enterococcus. We will also assess influenza vaccine response in patients on placebo.
3184862|NCT01304758|Experimental|ExAblate Treatment|
3184863|NCT01304745|Experimental|Physical traning in group|
3184864|NCT01304745|Experimental|Educational and counselling group|
3184865|NCT01304745|No Intervention|Control group|
3184866|NCT01304719|Experimental|Computer Assisted home visitation|Home visitation with computer modules added
3184867|NCT01304719|Experimental|Home Visitation TAU|Home Visitation Treatment as Usual
3184868|NCT01304719|No Intervention|Community Referral|Community Referral
3184869|NCT01304706|Experimental|Fluocinolone Acetonide|
3184870|NCT01304693|Experimental|ESBA1008|ESBA1008 solution, single intravitreal injection
3184871|NCT01304693|Active Comparator|LUCENTIS|Ranibizumab 0.5 mg, single intravitreal injection
3184872|NCT01304654||ALI/ARDS oncologic patients|Consecutively admitted patients at GRAACC's PICU with malignancy diagnosis according to IDC-10, in a 24mo consecutive period, under mechanical ventilation for over 24h and with ALI/ARDS criteria, not younger than 29 days or older than 17 years 11 months
3184873|NCT01304641||Atorvastatin Initiators|
3184874|NCT01304641||Simvastatin Initiators|
3184875|NCT01304628|Experimental|PL-3994 (4 escalating doses)|
3184876|NCT01304628|Placebo Comparator|Placebo|
3184877|NCT01304615|Active Comparator|Web-Based|Participants will receive a web-based behavioral intervention that decreases dietary energy density and increases physical activity combined with a life skills training program. Life skills training topics include stress management, coping with change, time management, and thoughts and emotions in weight control.
3184878|NCT01304615|Experimental|Web-Based plus Culinary Training|Participants will receive a web-based behavioral intervention that decreases dietary energy density and increases physical activity combined with a hands-on culinary skills training program designed to increase food purchasing and meal self-preparation and consumption of meals low in energy density.
3184879|NCT01304602|Experimental|Irinotecan + BKM120|Irinotecan + BKM120 at the assigned cohort dose level.
3184880|NCT01304589|Experimental|Milnacipran|This was an 18-week, open-label, flexible-dose exploratory trial where eligible patients were treated with 200 mg/day of milnacipran (or the maximum tolerated dose) for a total of 12 weeks. The study design involved 3 phases: screening and baseline assessment, dose escalation and stable-dose phase. All women received 12 weeks of stable dose treatment after a 6-week dose-escalation period for a total of 18 weeks of drug exposure.
3184881|NCT01304576|Experimental|patient with right parietal lesions|
3184882|NCT01304576|Active Comparator|patient with left parietal lesions|
3184883|NCT01304563|Active Comparator|IM15|15 mcg TIV 2010/2011 influenza vaccine delivered via intramuscular injection (control)
3184884|NCT01304563|Active Comparator|ID1|Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection (MicronJet)
3184885|NCT01304563|Active Comparator|ID2|Higher low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection (MicronJet)
3184886|NCT01304563|Active Comparator|INT|Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device
3184887|NCT01304537|Experimental|Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 40 mg/kg throughout the study.
3184888|NCT01304537|Experimental|Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 60 mg/kg throughout the study.
3184889|NCT01304537|Experimental|Alpha-1 Antitrypsin 80mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 80 mg/kg throughout the study.
3184890|NCT01304524|Experimental|VGX 3100|
3184891|NCT01304524|Placebo Comparator|Placebo|
3184892|NCT01304511||Participants Treated|Women undergoing controlled ovarian COH for ART
3184896|NCT01304472|Experimental|Prasugrel|Prasugrel 10mg per day
3184897|NCT01304472|Active Comparator|Clopidogrel|
3184898|NCT01304446|Experimental|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
3184899|NCT01304433||1|hydroxyethyl starch (HES) 130/0.42
3184900|NCT01304394|Other|parenteral nutrition solution|
3184901|NCT01304381|Experimental|Integrated care|Multidisciplinary approach and collaboration between specialist palliative and heart failure (HF) caregivers in a shared structured person-centred and identity-promoting homecare
3184902|NCT01304381|No Intervention|control|Usual care is performed for the control group
3184903|NCT01304368|Active Comparator|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
3184904|NCT01304368|No Intervention|Waiting list|Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
3184905|NCT01304355||Controls|Healthy Control Subjects
3184906|NCT01304355||IBS Group|Subjects diagnosed with IBS
3184907|NCT01304342|Active Comparator|Remifentanil|Remifentanil 1 microgram/kg/h along with propofol infusion
3184908|NCT01304342|Active Comparator|Fentanyl|Fentanyl 200 micrograms intranasally
3184909|NCT01304342|Placebo Comparator|Normal saline|Normal saline intravenously and intranasally
3184910|NCT01304329|Experimental|treatment A, reference|1 tablet BI 10773, oral administration with 240 ml water
3184911|NCT01304329|Experimental|treatment B, reference|1 tablet simvastatin, oral administration with 240 ml water
3184912|NCT01304329|Experimental|treatment C, test|1 tablet BI 10773 + 1 tablet simvastatin, oral administration with 240 ml water
3184913|NCT01304316|Experimental|Kovacaine Nasal Spray|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 6 sprays of 0.1 mL - total of 18 mg tetracaine HCl and 0.3 mg oxymetazoline HCl followed by 12 sprays of 0.1 mL - total of 36 mg tetracaine HCl and 0.6 mg oxymetazoline HCl
3184914|NCT01304303|Experimental|SPARC1023 I|
3184915|NCT01304303|Experimental|SPARC1023 II|
3184916|NCT01304290|No Intervention|Control|
3184917|NCT01304290|Experimental|Glucose/Insulin Clamp|
3184918|NCT01304277|Experimental|Replagal® (0.2 mg/kg, IV, EOW)|"Screening period of approximately 14 days during which all patients received 1 infusion of 0.2 mg/kg Replagal RB (Week 0)~Treatment period of 14 weeks during which all patients received 7 infusions of 0.2 mg/kg Replagal AF"
3184919|NCT01304264||combination topical glaucoma treatment|timolol or dorzolamide add on latanoprost monotherapy
3184920|NCT01304251|Active Comparator|Short-term fasting|short term fasting (i.e. 24 hours before and 24 hours after administration of chemotherapy) in 20 breast cancer patients
3184921|NCT01304251|Placebo Comparator|Healthy nutrition|20 breast cancer patients eat according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy.
3184922|NCT01304238||lepirudin|lepirudin treated subjects
3184923|NCT01304238||danaparoid|danaparoid treated subjects
3184924|NCT01304238||argatroban|argatroban treated subjects
3184925|NCT01304238||fondaparinux|fondaparinux treated subjects
3184926|NCT01304225|Active Comparator|100ms single-shot|Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion
3184927|NCT01304225|Experimental|20ms multiple-shot|Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion
3184928|NCT01304225|Experimental|20ms multiple-shot, barely visible|Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
3184929|NCT01304212|Active Comparator|femoral block|
3184930|NCT01304212|Experimental|local infiltration + femoral nerve block|Combination of local infiltration with drugs and femoral nerve block
3184931|NCT01304212|Active Comparator|several drugs local infiltration|
3184932|NCT01304199||Adult Cancer Survivors|"Intervention:~Behavioural:~Questionnaires for patient/family caregiver interview"
3184933|NCT01304186|Experimental|Tailored Information|Participants in this arm receive the computer-based tailored information application that focuses on improving health literacy related to treatment of HIV infection.
3184934|NCT01304160|Experimental|strereotactic radiotherapy, gemcitabine|stereotactic radiotherapy (30Gray in 5 fractions) followed by gemcitabine
3184935|NCT01304147|Experimental|Ketamine|Subjects randomized to this arm will receive the active study medication, intranasal ketamine.
3184936|NCT01304147|Placebo Comparator|Placebo|Subjects randomized to this arm will receive intranasal saline.
3184937|NCT01304134|Experimental|Oxycodone i.v.|To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)
3184938|NCT01304134|Active Comparator|Morphine i.v.|To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)
3184939|NCT01304121|Experimental|Bioactive glass|Resorbable bioactive glass granules
3184940|NCT01304108|Experimental|Order Set|"Insertion of VTE-P Order Set tollgate in all active admission and transfer orders."
3184941|NCT01304108|Experimental|Clinical Decision Support Pop-up|Deploy rules-based pop-up that reminds ordering clinicians when patients do not have an active VTE-P plan.
3184942|NCT01304108|Active Comparator|Usual Care|Usual care, without the experimental additions
3184943|NCT01304095|Active Comparator|Ranolazine|Ranolazine in addition to standard of care medical therapy
3184944|NCT01304095|No Intervention|Standard of Care|
3184945|NCT01304082|Placebo Comparator|normal saline|
3184946|NCT01304082|Active Comparator|lidocaine|
3184947|NCT01304082|Experimental|alkalinized lidocaine|
3184948|NCT01304069|Placebo Comparator|Placebo|
3184949|NCT01304069|Active Comparator|Selecoxib|
3184950|NCT01304069|Active Comparator|Etoricoxib|
3184951|NCT01304056||Critically ill patients|Patients that are treated in intensive care unit and given ventilatory therapy.
3184952|NCT01304056||Interventional volunteer group|Healthy volunteers
3184953|NCT01304030|Experimental|Experimental Group|The experimental group receives Empathy Training. The control Group receives residency training as usual
3184954|NCT01304030|Active Comparator|Control Group|The control group receives residency training as usual
3184955|NCT01304017|Experimental|Virtual Reality Therapy|The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing.
3184956|NCT01304017|Active Comparator|Traditional Therapy|The traditional therapy will include exercises for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
3184957|NCT01304004|Experimental|Experimental drinking yogurt|
3184958|NCT01304004|Placebo Comparator|Placebo drinking yogurt|
3184959|NCT01303991|Experimental|Hexvix PDT|
3184960|NCT01303978|Experimental|APD421 starting dose|
3184961|NCT01303965|Experimental|Open Label, Single Arm|Use sirolimus and tacrolimus as GvHD prophylaxis with sirolimus and lenalidomide as post-transplant maintenance
3184962|NCT01303952|Experimental|Eculizumab|
3184963|NCT01303939||Glaucoma Patients|Patients who were outliers from the AARV or ADREV Studies.
3184964|NCT01303939||Control Patients|Age, gender and race matched group of healthy individuals with no ocular diseases.
3184965|NCT01303926|Active Comparator|Cisplatin and Pemetrexed|
3184966|NCT01303926|Active Comparator|Carboplatin paclitaxel bevacizumab|
3184967|NCT01303913||Walking desaturation group|COPD patients that at the end of 6MWT have SO2 nadir <88-90%
3184968|NCT01303913||Walking No-desaturation group|COPD patients that at the end of 6MWT have SO2 nadir >88-90%
3184969|NCT01303887|Active Comparator|R-CVP|Repeated every 21 days for up to 8 cycles with response assessment after 4 cycles. Responders (PR/CR) after 8 cycles will receive Rituximab maintenance therapy for 2 years (12 bi-monthly cycles).
3184970|NCT01303887|Experimental|R-FC|Repeated every 21 days for 4 cycles. Responders (PR/CR) after 4 cycles will receive 4 further cycles of Rituximab only. Responders after 8 cycles will receive Rituximab maintenance therapy for 2 years (12 bi-monthly cycles).
3184971|NCT01303874|Experimental|Combination Therapy|Methotrexate & Etanercept
3184972|NCT01303874|Placebo Comparator|Single-agent therapy|Methotrexate (MTX)
3184973|NCT01303861|Active Comparator|varenicline|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline.
3184974|NCT01303861|Active Comparator|Nicotine Patches only|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation nicotine patches(assessed at Session P2). They will continue to receive only nicotine patches.
3184975|NCT01303861|Active Comparator|Nicotine Patches with Nicotine Inhaler|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will continue to receive nicotine patches and will receive a nicotine inhaler to use as needed after their quit date.
3184976|NCT01303861|Active Comparator|varenicline with bupropion|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline in combination with bupropion.
3184977|NCT01303848||Healthy probands|Healthy probands, age between 18 and 40 years
3184978|NCT01303835|Experimental|Naltrexone|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
3184979|NCT01303835|Placebo Comparator|Placebo|Randomized patients received placebo to be taken every night before bed.
3184980|NCT01303822|Experimental|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
3184981|NCT01303809|Active Comparator|ERAS|The perioperative management of the patients in this arm will be according to a fast-track protocol designed by the investigators. The preoperative component of this program is the same as routine practice. Intraoperative and postoperative components which are different to routine practice are as described in the intervention section. This protocol is based on current literature regarding Enhanced Recovery After Surgery (ERAS).
3184982|NCT01303809|No Intervention|non ERAS|The perioperative management of patients in this arm will be according to routine practice currently implemented at our institution.
3184983|NCT01303796|Experimental|Arm A|Sapacitabine and decitabine
3184984|NCT01303796|Active Comparator|Arm C|Decitabine
3184985|NCT01303783|Experimental|Nifedipine GITS 20 mg|Subjects received 20 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
3184986|NCT01303783|Experimental|Nifedipine GITS 30 mg|Subjects received 30 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
3184987|NCT01303783|Experimental|Nifedipine GITS 60 mg|Subjects received 60 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
3184988|NCT01303783|Experimental|Candesartan cilexetil 4 mg|Subjects received 4 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
3184989|NCT01303783|Experimental|Candesartan cilexetil 8 mg|Subjects received 8 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
3184990|NCT01303783|Experimental|Candesartan cilexetil 16 mg|Subjects received 16 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
3184991|NCT01303783|Experimental|Candesartan cilexetil 32 mg|Subjects received 32 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
3184992|NCT01303783|Experimental|Nifedipine/candesartan 20/4 mg|Subjects received the combination of 20 mg of nifedipine GITS/4 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
3184993|NCT01303783|Experimental|Nifedipine/candesartan 20/8 mg|Subjects received the combination of 20 mg of nifedipine GITS/8 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
3184994|NCT01303783|Experimental|Nifedipine/candesartan 20/16 mg|Subjects received the combination of 20 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
3184995|NCT01303783|Experimental|Nifedipine/candesartan 30/8 mg|Subjects received the combination of 30 mg of nifedipine GITS/8 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
3184996|NCT01303783|Experimental|Nifedipine/candesartan 30/16 mg|Subjects received the combination of 30 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
3184997|NCT01303783|Experimental|Nifedipine/candesartan 30/32 mg|Subjects received the combination of 30 mg of nifedipine GITS/32 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
3184998|NCT01303783|Experimental|Nifedipine/candesartan 60/16 mg|Subjects received the combination of 60 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
3184999|NCT01303783|Experimental|Nifedipine/candesartan 60/32 mg|Subjects received the combination of 60 mg of nifedipine GITS/32 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
3185000|NCT01303783|Placebo Comparator|Placebo|Subjects received placebo (3 tablets and 1 capsule) once daily for 8 weeks
3185001|NCT01303770|Experimental|Cognitive intervention group|Cognitive rehabilitation program designed to be tested in this study
3185002|NCT01303770|Active Comparator|Control group|
3185003|NCT01303757|Experimental|Low glycemic load diet|Low glycemic load diet
3185004|NCT01303757|Active Comparator|Low fat diet|Low fat diet
3185005|NCT01303744|Experimental|CHF 5074 1x|oral tablet, multidose
3185006|NCT01303744|Experimental|CHF 5074 2x|oral tablet, multidose
3185007|NCT01303744|Experimental|CHF 5074 3x|oral tablet, multidose
3185008|NCT01303744|Placebo Comparator|Placebo|placebo, oral tablet, multidose
3185009|NCT01303731|Active Comparator|Standard dose Marcaine Spinal 0.5% Heavy|Standard group - will receive spinal anesthesia induced by Marcaine Spinal 0.5% Heavy 12.5 mg (2.5 ml).
3185010|NCT01303731|Experimental|Minidose of Marcaine Spinal 0.5% Heavy|Minidose group - will receive spinal anesthesia induced by Marcaine Spinal 0.5% Heavy 7.5 mg (1.5 ml) diluted in 0.75ml of patient's CSF (0.25 ml)with addition of Fentanyl 12.5 mcg (total 2.5 ml)
3185011|NCT01303718|Experimental|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
3185012|NCT01303718|Active Comparator|Standard of Care|Usual care (no CardioFit System implant)
3185013|NCT01303705|Experimental|Cyclophosphamide - Cohort 1|Cyclophosphamide 300 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
3185014|NCT01303705|Experimental|Cyclophosphamide - Cohort 2|Cyclophosphamide 600 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
3185015|NCT01303705|Experimental|Cyclophosphamide - Cohort 3|Cyclophosphamide 900 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
3185016|NCT01303692||A|Total of 250 prostate cancer patients receiving GnRH agonist
3185017|NCT01303692||B|Total of 250 prostate cancer patients receiving GnRH agonist plus anti-androgen agent
3185018|NCT01303679|Active Comparator|paclitaxel-bevacizumab|Paclitaxel, 80mg/m² at d1, d8, d15 bevacizumab, 10 mg/kg at d1, d15
3185019|NCT01303679|Experimental|exemestane-bevacizumab|exemestane, 25 mg daily dose bevacizumab, 15mg/kg every 3 weeks
3185020|NCT01303666|Active Comparator|TI of the knee|
3185021|NCT01303666|Active Comparator|Intra-articular CSI|
3185022|NCT01303640|Active Comparator|Biolimus-eluting stent|Biolimus-eluting stent
3185023|NCT01303640|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent
3185024|NCT01303627|Active Comparator|ultiva,remifentanil,opioid,analgesic|Remifentanil:1.5ng/ml remifentanil infusion maintained at the end of the surgery
3185025|NCT01303627|No Intervention|control|Control:Remifentanil stopped at the end of the surgery
3185026|NCT01303614|Active Comparator|Lidocaine-Prilocaine cream|
3185027|NCT01303614|Placebo Comparator|Placebo|purified water, ethylene glycol stearate, palm, palm stearate, polyethylene glycol, liquid paraffin, benzoic acid
3185028|NCT01303601|Experimental|olanzapine|
3185029|NCT01303601|Placebo Comparator|placebo|
3185030|NCT01303588|No Intervention|Waiting Group|
3185031|NCT01303588|Active Comparator|Qigong|
3185032|NCT01303588|Active Comparator|Yoga|
3185033|NCT01303575|Experimental|HIV, STI, and Pregnancy Prevention Curriculum|
3185034|NCT01303575|Active Comparator|Control curricula: Science Education|No sexual health elements
3185035|NCT01303562|Placebo Comparator|Placebo muffin made with no whole grains|
3185036|NCT01303562|Active Comparator|Test muffin made with whole oats|
3185037|NCT01303562|Active Comparator|Test muffin made with whole barley|
3185038|NCT01303549|Experimental|Anidulafungin|Anidulafungin IV once a day: initial dose 200 mg/day, following doses 100 mg/day.
3185039|NCT01303549|Active Comparator|Liposomal Amphotericin B|Liposomal amphotericin B once a day: 3 mg/kg/day
3185040|NCT01303536|Experimental|obsessive compulsive disorder|obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
3185041|NCT01303510|Experimental|Group A|Adults from 18 to 60 years old inclusive
3185042|NCT01303510|Experimental|Group B|Elderly subjects aged over 60 years
3185043|NCT01303497|Other|Arm A : Paclitaxel|administration of paclitaxel drug during cycle of 28 days (6 cycles Max) + blood sample on day 1, 8, 15, 29 and 57
3185044|NCT01303497|Other|Arm B : Paclitaxel + Bevacizumab|"administration of paclitaxel drug during per cycle of 28 days (6 cycles Max) + Bevacizumab every two weeks during paclitaxel cycles then every 3 weeks during P cycles until disease progression or inacceptable toxicity~+ blood sample on day 1, 8, 15, 29 and 57"
3185045|NCT01303484|Placebo Comparator|MDn|Maltodextrin
3185046|NCT01303484|Active Comparator|B-GOS|Prebiotic
3185047|NCT01303471|Experimental|opioïd|Different levels of remifentanyl of each group during nociceptive stimulation
3185048|NCT01303458|Experimental|Intervention arm|Study subjects will receive the Basic Needs Surveillance (BNS) intervention.
3185049|NCT01303458|No Intervention|Control arm|Study subjects in the control arm will receive the standard of care.
3185050|NCT01303445|Active Comparator|Treatment A|Aggrenox alone
3185051|NCT01303445|Experimental|Treatment B|Aggrenox and omeprazole
3185052|NCT01303445|Active Comparator|Treatment C|Omeprazole alone
3185053|NCT01303445|Experimental|Treatment D|Aggrenox and omeprazole
3185054|NCT01303432|Experimental|Mobilee yogurt|Subjects eating daily on yogurt supplemented with Mobilee
3185055|NCT01303432|Placebo Comparator|Placebo yogurt|Subjects receiving daily a standard yogurt
3185056|NCT01303419|Active Comparator|CE-BMRI|Subject will undergo bilateral CE-BMRI as per usual clinical practice within 30 days after the new breast cancer diagnosis.
3185057|NCT01303419|Experimental|DE-CEDM|Subject will undergo bilateral DE-CEDM examination within 8 weeks after the CE-BMRI exam.
3185058|NCT01303406|Placebo Comparator|Placebo|"Following the body weight, patients will be allocated to one of the following regimen:~Placebo Patients < 45 kg - 3 tablets 3 times a day with meals~Placebo Patients > 45 kg - 5 tablets 3 times a day with meals"
3185059|NCT01303406|Experimental|idebenone|"Following the body weight, patients will be allocated to one of the following regimen:~Idebenone Patients < 45 kg - 3 tablets 3 times a day with meals~Idebenone Patients > 45 kg - 5 tablets 3 times a day with meals"
3185060|NCT01303393||Surgery for colorectal cancer|Patients that had surgery for colorectal cancer without receiving a stoma, and their next of kin.
3185061|NCT01303380|Experimental|Canakinumab|
3185062|NCT01303367||antipsychotic agents|
3185063|NCT01303367||non-antipsychotic agents|
3185064|NCT01303354|Experimental|DXM 4 mg|Dexamethasone 4 mg
3185065|NCT01303354|Experimental|DXM 8 mg|Dexamethasone 8 mg
3185066|NCT01303354|Experimental|DXM 12 mg|Dexamethasone 12 mg
3185067|NCT01303341|Experimental|Treatment (riluzole and sorafenib tosylate)|Patients receive riluzole PO BID and sorafenib tosylate PO QD or BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3185068|NCT01303328|Experimental|Treatment group|
3185069|NCT01303328|Placebo Comparator|Placebo group|
3185070|NCT01303315|Other|GLP-1 receptor agonist therapy|Group A: Subjects on GLP-1 receptor agonist therapy only. After run in of 12 weeks on GLP-1 receptor agonist therapy, Patients with HbA1c < 7.5 are moved to Group A, continue GLP-1 receptor agonist therapy, and then start the Evaluation Period These patients will not be implanted with the TANTALUS system.
3185071|NCT01303315|Experimental|GLP-1 receptor agonist and TANTALUS|Group B: subjects on GLP-1 receptor agonist therapy and TANTALUS therapy After run in of 12 weeks on GLP-1 receptor agonist therapy, Patients with HbA1c > 7.5 are moved to Group B, continue GLP-1 receptor agonist therapy, implanted with TANTALUS within 4 weeks, and then start the Evaluation Period
3185072|NCT01303315|Active Comparator|Subjects on TANTALUS therapy only|Group C: subjects on TANTALUS therapy only After run in of 12 weeks on GLP-1 receptor agonist therapy, patients intolerant to low dosage of GLP-1 receptor agonist therapy will be implanted with the TANTALUS system
3185073|NCT01303302|Active Comparator|GCM stimulation|The patient will be implanted with a gastric contractility modulation (GCM) stimulation system using the TANTALUS System for treatment of type 2 diabetic patients.
3185074|NCT01303302|Sham Comparator|Device off|The TANTALUS System is implanted but is off
3185075|NCT01303289|Experimental|Group 1|The group 1 will receive the experimental product T-Diet plus Standard for 3 months.
3185076|NCT01303289|Active Comparator|Group 2|The group 2 will receive the control product Jevity (Abbott Laboratories) for 3 months.
3185077|NCT01303276||Anti-VEGF group|Patients who are clinically indicated for the intravitreal injection of ranibizumab
3185078|NCT01303276||Age-matched controls|Group of healthy participants who will be age and gender matched
3185079|NCT01303263|Other|Intervention Group|Residents Randomized to Receive Educational Intervention
3185080|NCT01303263|No Intervention|Control Group|Residents randomized not to receive a teaching intervention.
3185081|NCT01303250|Experimental|Group 1|A balanced hydroxyethyl starch 130/0.4 will be used
3185082|NCT01303250|Active Comparator|Group 2|A balanced crystalloid will be used
3185083|NCT01303224|Experimental|Ibodutant low dose|Oral tablet, to be given once daily in fasting conditions.
3185084|NCT01303224|Experimental|Ibodutant intermediate dose|Oral tablet, to be given once daily in fasting conditions.
3185085|NCT01303224|Experimental|Ibodutant high dose|Oral tablet, to be given once daily in fasting conditions.
3185086|NCT01303224|Placebo Comparator|Placebo|Oral tablet, to be given once daily in fasting conditions.
3185087|NCT01303211||serogroup A meningococcal disease|Cases of serogroup A meningococcal disease
3185088|NCT01303211||Community controls|Healthy members of the community controls matched with cases for age, sex and place of residence
3185089|NCT01303211||Hospital controls|Patients admitted to the hospital with an acute illness other than meningitis or septicemia
3185090|NCT01303198|Active Comparator|CPAP|Use of CPAP as treatment for sleep apnea
3185091|NCT01303198|Active Comparator|APAP|Use of APAP as treatment for sleep apnea
3185092|NCT01303185||Experimental Group|
3185093|NCT01303185||Control Group|
3185094|NCT01303172|Active Comparator|gemcitabine chemotherapy|Patients in the control arm will receive normal standard of care - up to 12 cycles of Gemcitabine. Dosing of Gemcitabine is as per the normal orescribing information for pancreatic cancer.
3185095|NCT01303172|Experimental|IMM-101 in addition to gemcitabine|"Patients in the experiemental arm will recieve IMM-101 in addition the current standard of care, namely chemotherapy (Gemcitabine). The treatment regimen with IMM-101 will be every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.~For patients in the active group, chemotherapy (GEM) will begin at least 14 days after first dose of IMM-101.~Chemotherapy plus IMM-101 will be offered until intolerable toxcity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks)."
3185096|NCT01303159|Experimental|Radiofrequency probe (ENDOHPB)|"Intervention:~The EndoHPB is an endoscopic bipolar catheter designed to ablate tissue in malignant tumors within luminal structures, such as the biliary tree or pancreatic ducts. EndoHPB can be deployed via an ERCP or Percutaneous Transhepatic Cholangiographic (PTC) route. By using radiofrequency (RF) energy to heat the tissue in the duct prior to insertion of the stent, the surrounding tissue becomes coagulated and this may delay tumour growth and the time before the stent lumen becomes blocked. Thereby, allowing increased periods between the need for intervention and further stent deployment"
3185097|NCT01303146|Experimental|Enzyme replacement therapy|intravenous infusion 100U/kg every other week for 18 months
3185098|NCT01303133||Adults with Down Syndrome ages 30+|We will be recruiting healthy adults with Down syndrome ages 30 and over. Participants cannot have a diagnosis of dementia.
3185099|NCT01303120|Active Comparator|Femoral Nerve Block|
3185100|NCT01303120|Active Comparator|Combined Nerve Blocks|
3185101|NCT01303120|Active Comparator|Patient-controlled analgesia|
3185102|NCT01303107|Active Comparator|bupivacaine S50:R50|3 ml subarachnoid block
3185103|NCT01303107|Experimental|bupivacaine S75:R25|3 ml for subarachnoid block
3185104|NCT01303094|Other|Continuation of Trabectedin|patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle, every 3 weeks until progression/ toxicity
3185105|NCT01303094|Other|"Drug holiday therapy"|patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle and he stops the drug until progression and re-challenge
3185106|NCT01303081|Active Comparator|Usual Care|Participants will be offered free smoking cessation programs, and be provided web-based education regarding the health and economic benefits of smoking cessation. Participants will also have the opportunity to submit weekly reports on their smoking habits. They will be informed that they will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days and 3 months (among those eligible).
3185107|NCT01303081|Experimental|Individual Rewards|Same as USUAL CARE arm, plus financial incentive as follows: if participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators.
3185108|NCT01303081|Experimental|Fixed Deposits|Same as USUAL CARE arm, plus financial incentive as follows: participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
3185109|NCT01303081|Experimental|Chosen Deposits|Same as USUAL CARE, plus financial incentive as follows: participants will choose their deposit amount (XX = chosen deposit); this same amount will be returned upon success (that is, quit smoking by the target quit date, and having this confirmed by cotinine or anabasine tests). If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. The default deposit will be set to a certain monetary amount for consistency with other arms, and participants can increase or decrease this amount until they reach the amount they want to deposit.
3185110|NCT01303081|Experimental|Competitive Deposits (Pari-Mutuel)|"Same as USUAL CARE, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, and the payout for quitting on this arm will be Y x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
3185111|NCT01303068|Experimental|CF patients, 13C urea breath test kit|CF patients with Pseudomonas infection tested with 13C urea breath test
3185112|NCT01303068|Active Comparator|Healthy controls, 13C urea breath test kit|Healthy subjects using 13C urea breath test kit
3185113|NCT01303055|Experimental|Alogliptin|Alogliptin 25 mg
3185114|NCT01303055|Active Comparator|Metformin|Metformin 750 mg
3185115|NCT01303042|Experimental|Insulin lispro mix 50/50|
3185116|NCT01303029|Active Comparator|Control|Gemcitabine+erlotinib
3185117|NCT01303029|Experimental|Experimental|Gemcitabine+erlotinib+capecitabine
3185118|NCT01303016|Experimental|Nutrition supplement|Receives a month's supply of the nutrition supplement, Chispuditos, in addition to a voucher for 1lb of powdered milk each month and a voucher for 1lb of sugar every other month.
3185119|NCT01303016|No Intervention|Control|Receives a voucher for 1lb of powdered milk each month and a voucher for 1lb of sugar every other month. Participants in the control group will receive the nutrition supplement, Chispuditos, for one year after the study is complete.
3185120|NCT01303003|Experimental|Treatment Arm 1|Bilateral TAP block consisting of 40cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
3185121|NCT01303003|Active Comparator|Treatment Arm 2|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
3185122|NCT01302990|Experimental|5 micrograms H1 VLP|
3185123|NCT01302990|Experimental|13 micrograms H1 VLP|
3185124|NCT01302990|Experimental|28 micrograms H1 VLP|
3185125|NCT01302990|Active Comparator|45 micrograms Fluzone|
3185126|NCT01302990|Placebo Comparator|Placebo|
3185127|NCT01302977|Experimental|Fetal intervention|Composed of fetuses that undergo to fetal tracheal occlusion at 26-28 weeks.
3185128|NCT01302977|No Intervention|Control|Composed of fetuses that do not undergo fetal intervention
3185129|NCT01302964|Experimental|Mirtazapine|The starting dose for subjects is 7.5 mg daily. The maximum daily dose will be 45 mg.
3185130|NCT01302964|Placebo Comparator|Placebo|Subjects randomized to placebo arm will receive capsules identical in size and appearance to those subjects receiving study drug. Placebo capsules contain inactive ingredients.
3185131|NCT01302951|Experimental|Moxifloxacin|Moxifloxacin 400 mg i.v.
3185132|NCT01302951|No Intervention|No drug|2 Patients were included as controls- no MXF given
3185133|NCT01302938|Experimental|Tolterodine ER|
3185134|NCT01302938|Placebo Comparator|Placebo|
3185135|NCT01302925|Experimental|PEP005 Gel 0.05%/2 days|Subjects will be exposed to investigational product for 2 consecutive days.
3186659|NCT01291849|Experimental|remifentanil for intranasal surgery|
3185136|NCT01302925|Experimental|PEP005 Gel 0.015%/3 days|Subjects will be exposed to investigational product for 3 consecutive days.
3185137|NCT01302899|Experimental|Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)+HCTZ/Ram+Ali/Ram|"Period 1(Day 1 to end of week 6): 1 tablet ramipril 10 mg once daily (o.d.) + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule Hydrochlorothiazide (HCTZ) 25 mg o.d.~Period 2 (Weeks 7 to 12): 1 tablet ramipril 10 mg o.d.+ 1 tablet aliskiren 150 mg in 1st week of period; thereafter, 2 tablets aliskiren 150mg o.d.+ 1 capsule HCTZ 25 mg o.d.~Period 3 (Weeks 13 to 18): 1 tablet ramipril 10 mg o.d. + 2 tablets aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d.~Period 4 (Weeks 19 to 26): 1 tablet ramipril 10 mg o.d. + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d."
3185138|NCT01302899|Experimental|Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)/Ram+Ali + HCTZ/Ram|"Period 1(Day 1 to end of week 6): 1 tablet ramipril 10 mg once daily (o.d.) + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule Hydrochlorothiazide (HCTZ) 25 mg o.d.~Period 2 (Weeks 7 to 12): 1 tablet ramipril 10 mg o.d.+ 1 tablet aliskiren 150 mg in 1st week of period; thereafter, 2 tablets aliskiren 150mg o.d.+ 1 capsule placebo to HCTZ 25 mg o.d.~Period 3 (Weeks 13 to 18): 1 tablet ramipril 10 mg o.d. + 2 tablets aliskiren 150mg o.d. + 1 capsule HCTZ 25 mg o.d.~Period 4 (Weeks 19 to 26): 1 tablet ramipril 10 mg o.d. + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d."
3185139|NCT01302886|Experimental|BHQ880|
3185140|NCT01302873|Experimental|BGG492|
3185141|NCT01302873|Placebo Comparator|Placebo|
3185142|NCT01302860|Experimental|Canakinumab|Canakinumab s.c. injection (2 mg/kg) was administered every 8 weeks.
3185143|NCT01302847|Experimental|Cohort I: Adolescents 12 to younger than 18 years of age|DTG film-coated tablets
3185144|NCT01302847|Experimental|Cohort IIA: Children 6 to younger than 12 years of age|DTG film-coated tablets
3185145|NCT01302847|Experimental|Cohort IIB: Children 6 to younger than 12 years of age|DTG granules for suspension or DTG dispersible tablets
3185146|NCT01302847|Experimental|Cohort III: Children 2 to younger than 6 years of age|DTG granules for suspension or DTG dispersible tablets
3185147|NCT01302847|Experimental|Cohort III-DT: Children 2 to younger than 6 years of age|DTG dispersible tablets
3185148|NCT01302847|Experimental|Cohort IV: Children 6 months to younger than 2 years of age|DTG granules for suspension or DTG dispersible tablets
3185149|NCT01302847|Experimental|Cohort IV-DT: Children 6 months to younger than 2 years of age|DTG dispersible tablets
3185150|NCT01302847|Experimental|Cohort V-DT: Infants 4 weeks to younger than 6 months of age|DTG dispersible tablets
3185151|NCT01302834|Experimental|Arm I|Patients undergo image-guided intensity-modulated radiation therapy (IMRT) once daily on days 1-4 and twice daily on day 5 weekly for 6 weeks. Patients also receive high-dose cisplatin IV over 1-2 hours on days 1 and 22.
3185152|NCT01302834|Active Comparator|Arm II|Beginning 1 week prior to IMRT, patients receive cetuximab IV over 2 hours. Patients then receive cetuximab IV over 1 hour once weekly for 7 weeks. Patients undergo IMRT as in arm I.
3185153|NCT01302821|Experimental|Radiotherapy|AMT positron emission tomography with integrated computed tomography (PET/CT)scanning in metastatic breast cancer patients to identify tumors with increased AMT uptake due to up-regulated IDO expression.
3185154|NCT01302795|Experimental|Canakinumab|Canakinumab s.c. 150-300mg Week 0, (2), 8
3185155|NCT01302769|Experimental|battlefield auricular acupuncture|battlefield auricular acupuncture
3185156|NCT01302769|No Intervention|placebo|
3185157|NCT01302743|Active Comparator|Metformin|oral extended-release Metformin 1000 mg once a day for 90 days
3185158|NCT01302743|Experimental|Cinnamon Bark|Cinnamon Bark 1000 mg once a day for 90 days
3185159|NCT01302743|Experimental|Cinnulin PF|Cinnulin PF 500 mg once a day for 90 days
3185160|NCT01302717|Active Comparator|Right ventricular pacing|
3185161|NCT01302717|Experimental|Left ventricular pacing|
3185162|NCT01302691|Experimental|L50/H12.5/A5|Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.
3185163|NCT01302691|Active Comparator|L50 + A5|Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.
3185164|NCT01302652||GH deficient after acromegaly cure (on GH replacement)|Men and women with growth hormone deficiency following cure of acromegaly who are receiving growth hormone treatment.
3185165|NCT01302652||GH deficient after acromegaly cure (not on GH replacement)|Men and women with growth hormone deficiency following cure of acromegaly who are not receiving growth hormone treatment.
3185166|NCT01302639|Experimental|EGCG and resveratrol|
3185167|NCT01302639|Experimental|EGCG, resveratrol and genistein|
3185168|NCT01302639|Placebo Comparator|placebo|
3185169|NCT01302626||1: Surgery alone or combined with (chemo)radiotherapy|"Fresh frozen tumor tissue and normal tissue;~Recording of clinical characteristics, imaging, surgery features.~After treatment: FU at 2-3 weeks post surgery, 3,6,12,24 and 36 months post-surgery"
3185170|NCT01302626||2: Radiotherapy alone|"(including stereotactic radiotherapy)~Before start RT (during staging):Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Day 0 (before start RT): Recording of clinical characteristics, imaging, and radiotherapy features;~Day 8-12 (during RT): Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
3185171|NCT01302626||3: Sequential chemotherapy and radiotherapy|"Day -30 (before start CT):~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, and chemotherapy features.~Day 0 (before start RT):~Recording of clinical characteristics, imaging, and radiotherapy features.~Scoring of toxicity.~Day 8-12 (during RT):~Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
3185172|NCT01302626||4: Concurrent chemoradiotherapy with induction chemotherapy|"Day -30 until-18 (before start CT):~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, and chemotherapy features.~Day 0 (before start RT):~Recording of clinical characteristics, imaging, and radiotherapy features.~Scoring of toxicity.~Day 8-12 (during RT):~Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
3185219|NCT01302353|Experimental|Arm 11 (0.1451ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1451ml/kg.
3185173|NCT01302626||5: Concurrent chemoradiotherapy without induction chemotherapy|"Day 0 (before start CRT):~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, chemotherapy features, and radiotherapy features.~Day 8-12 (during CRT):~Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
3185174|NCT01302626||6: Stage IV lungcancer, any systemic therapy & supportive care|"Day 0:~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, surgery or any systemic (MoAb) features.~After treatment: FU at 2-3 weeks post treatment, 3,6,12,24 and 36 months post-treatment"
3185175|NCT01302613|Other|arm one|RT + Chemo + surgery
3185176|NCT01302600|Experimental|Olesoxime|100 patients in this arm. liquid suspension
3185177|NCT01302600|Placebo Comparator|Placebo|50 patients enrolled in this arm. liquid suspension
3185178|NCT01302587||Albuterol MDI|All participants in this study will receive an albuterol MDI inhaler.
3185179|NCT01302574|Placebo Comparator|mixed liquid meal|500 mL mixed liquid meal + 50 mg 13C-sodium-acetate
3185180|NCT01302574|Active Comparator|mixed liquid meal + lactisole|500 mL mixed liquid meal + 50 mg 13C-sodium-acetate + 450 ppm lactisole
3185181|NCT01302561|Placebo Comparator|Sugar Pill|
3185182|NCT01302561|Experimental|Galactooligosaccharide 5 g|
3185183|NCT01302548|Experimental|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
3185184|NCT01302548|Active Comparator|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
3185185|NCT01302535|Active Comparator|Yoga group with supervision/trainer|
3185186|NCT01302535|Active Comparator|Yoga at home|
3185187|NCT01302535|No Intervention|Control|No changes will be made for the participants in the control group, but they will undergo the same measurements and evaluations as the intervention groups.
3185188|NCT01302509|Active Comparator|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
3185189|NCT01302496|Experimental|TriMix-DC and Ipilimumab|
3185190|NCT01302483|Experimental|Kovacaine Nasal Spray|3% tetracaine HCL with 0.05% oxymetazoline HCL - Delivered via 3 sprays (100 uL) in each nostril
3185191|NCT01302483|Active Comparator|Lidocaine Injection|.5 to 1 catridge of 2% lidocaine HCL with 1:100,000 epinephrine
3185192|NCT01302470|Active Comparator|Robotic placement of CS lead|CS leads placed epicardially in the area of increased dyssynchrony as demonstrated by low dose dobutamine stress testing.
3185193|NCT01302470|Active Comparator|Transvenous placement of CS lead|CS lead will be placed transvenously
3185194|NCT01302457||Healthy Same Subjects|The control group will be 19 years or older and be randomly picked from from volunteer staff at Saint Elizabeth Regional Medical Center. This is a prospective study that will look at the similarities and difference of both groups. This will help us determine if there is a need to improve oral hygiene protocol given to burn/intensive care patients. Each group will consist of 25 subjects
3185195|NCT01302457||Health Volunteers|"The control group will be 19 years or older and be randomly picked from volunteer staff at Saint Elizabeth Regional Medical Center.~DESIGN This is a prospective study that will look at the similarities and difference of both groups. This will help us determine if there is a need to improve oral hygiene protocol given to burn/intensive care patients. Each group will consist of 25 subjects"
3185196|NCT01302444|Active Comparator|Tadalafil|first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort
3185197|NCT01302444|Placebo Comparator|Placebo|first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks
3185198|NCT01302431|Experimental|Nurse-Led Manualised Telephone support|Participants assigned to this arm of the study will receive 4 nurse-led telephone support calls over a three month time-frame
3185199|NCT01302431|No Intervention|Usual care|Participants randomised to this arm of the study will receive their usual care which comprises caregivers calling nurse specialists when they needs advice and support
3185200|NCT01302418||Symptomatic|Individuals with signs and symptoms of an acute respiratory tract infection where it is suspected that such signs and symptoms are caused by a respiratory virus infection.
3185201|NCT01302405|Experimental|PRI-724|
3185202|NCT01302392|Active Comparator|Best Supportive Care|
3185203|NCT01302392|Experimental|Carfilzomib|
3185204|NCT01302379|Active Comparator|Metformin + lifestyle intervention|
3185205|NCT01302379|Active Comparator|Placebo + lifestyle intervention|
3185206|NCT01302379|Active Comparator|Metformin + standard dietary guidelines|
3185207|NCT01302379|Placebo Comparator|Placebo + standard dietary guidelines|
3185208|NCT01302366|Experimental|Sea cucumber extract|TBL12 is administered orally at a dose of 2 units (of 20 mL each) twice a day, in 4-week cycles, until disease progression or there is sign of disease progression.
3185209|NCT01302353|Experimental|Arm 1 (0.0024 ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0024ml/kg.
3185210|NCT01302353|Experimental|Arm 2 (0.006ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.006ml/kg.
3185211|NCT01302353|Experimental|Arm 3 (0.012ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.012ml/kg.
3185212|NCT01302353|Experimental|Arm 4 (0.02ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.02ml/kg.
3185213|NCT01302353|Experimental|Arm 5 (0.0301ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0301ml/kg.
3185214|NCT01302353|Experimental|Arm 6 (0.0391ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0391ml/kg.
3185215|NCT01302353|Experimental|Arm 7 (0.0508ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0508ml/kg.
3185216|NCT01302353|Experimental|Arm 8 (0.066ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.066ml/kg.
3185217|NCT01302353|Experimental|Arm 9 (0.0859ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0859ml/kg.
3185218|NCT01302353|Experimental|Arm 10 (0.1116ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1116ml/kg.
3185220|NCT01302353|Experimental|Arm 12 (0.1886ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1886ml/kg.
3185221|NCT01302353|Experimental|Arm 13 (0.2452ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.2452ml/kg.
3185222|NCT01302353|Experimental|Arm 14 (0.3188ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.3188ml/kg.
3185223|NCT01302353|Experimental|Arm 15 (0.4144ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.4144ml/kg.
3185224|NCT01302353|Experimental|Arm 16 (0.5387ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.5387ml/kg.
3185225|NCT01302340|Active Comparator|Delta-THC|THC will be administered twice daily during three consecutive days per treatment block(0.75 or 1.5 mg twice daily)
3185226|NCT01302340|Placebo Comparator|placebo|Placebo will be administered twice daily during three consecutive days per treatment block.
3185227|NCT01302327|Experimental|Exenatide|
3185228|NCT01302314|Experimental|cognitive rehabilitation|
3185229|NCT01302275|Experimental|oxcarbazepine|Oxcarbazepine is gradually increased during 21 days from 300 mg x 1 daily to 2400 mg, and kept on that dose ( 2400 mg) for three weeks.
3185230|NCT01302275|Placebo Comparator|placebo|
3185231|NCT01302262||Healthy smokers|Healthy male and female smokers. Each subject will undergo PET scan (along with craving and anxiety questionnaires) on two conditions - Smoking and Non-smoking - on two separate visits.
3185232|NCT01302249|Experimental|AR-12286|AR-12286 Ophthalmic Solution 0.5%
3185233|NCT01302249|Active Comparator|Timolol|Timolol maleate ophthalmic solution 0.5%
3185234|NCT01302236|Experimental|Eplerenone|
3185235|NCT01302223||Minor Burns|Total burn surface area less than 5% of second and third degree.
3185236|NCT01302223||Major Burns.|Total Burn Surface Area more than 25% of second and third degree, and less than 50%.
3185237|NCT01302210|Experimental|Intervention|Active surveillance testing for MRSA and decolonization of positive subjects
3185238|NCT01302210|No Intervention|control|Usual standard of care
3185239|NCT01302184|Experimental|Experimental Group|Lokomat®
3185240|NCT01302184|Active Comparator|Control Group|Treadmill training
3185241|NCT01302171|Experimental|Peripheral|Half the patients will be randomised to the non-interventional part of the trial. In this subgroup of patients will be randomised 1:1 to 5 day course of subcutaneous placebo injections or a 5 day course of G-CSF(Granocyte™) subcutaneous injections
3185242|NCT01302171|Experimental|Interventional arm|In the subgroup of the interventional arm patients will be randomised 1:1 to receive a 5 day course of subcutaneous G-CSF (Granocyte™) injections and bone marrow aspiration at day 5, they will then receive either stem cells or placebo via intracoronary injection
3185243|NCT01302145|Experimental|ASP1941 + metformin|Oral
3185244|NCT01302145|Placebo Comparator|Placebo + metformin|Oral
3185245|NCT01302119|Experimental|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%
3185246|NCT01302119|Placebo Comparator|Solution Vehicle|Solution Vehicle
3185247|NCT01302106|Experimental|Arm 1|Clofarabine combined with low dose Ara-C
3185248|NCT01302093|Experimental|Experimental Tablet|A single 100 mg dose of an experimental Racecadotril Film-Coated Tablet (FCT)
3185249|NCT01302093|Active Comparator|Marketed Capsule|A single 100 mg dose of a marketed Racecadotril capsule
3185250|NCT01302080||Sertraline-treated|inception cohort of enrolled subjects beginning treatment for one of the study qualifying disorders with sertraline
3185251|NCT01302080||pyschotherapy only|inception cohort of enrolled subjects beginning treatment for one of the study qualifying disorders with psychotherapy
3185252|NCT01302067|Experimental|Fesoterodine 8mg|
3185253|NCT01302067|Experimental|Fesoterodine 4mg|
3185254|NCT01302067|Placebo Comparator|Placebo|
3185255|NCT01302054|Experimental|Fesoterodine|
3185256|NCT01302054|Placebo Comparator|Placebo|
3185257|NCT01302041|Experimental|Enzalutamide|Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.
3185258|NCT01302028|Active Comparator|Healthy volunteers with normal renal function|Oral
3185259|NCT01302028|Experimental|T2DM patient with normal renal function|Oral
3185260|NCT01302028|Experimental|T2DM patient with mild renal impairment|Oral
3185261|NCT01302028|Experimental|T2DM patient with moderate renal impairment|Oral
3185262|NCT01302028|Experimental|T2DM patient with severe renal impairment|Oral
3185263|NCT01302015|Experimental|RNL-Vascostem®|drug name and ingredients : RNL-Vascostem[Autologous adipose tissue derived mesenchymal stem cells] dosage : Intramuscular infusion, 5 x 10e6 cells/kg
3185264|NCT01302002|Experimental|Metformin Pre-Surgery|Patients will take metformin twice a day for three weeks prior surgery
3185265|NCT01301989|Placebo Comparator|Sleep Education Control|"The control group receives a low intensity intervention that provides information about sleep and the benefits of adequate sleep. We will give parents the National Sleep Foundation's handout, Information about Children's Sleep for Parents and Teachers (in English and Spanish)."
3185266|NCT01301989|Experimental|Sleep Counselor Intervention|"The sleep counselor visits are to assess the family's understanding of their child's sleep problems; help parents recognize the child's sleep deficiency; discuss how sleep problems affect behavior, learning, and health; and reassure parents that the sleep counselor can help them with these problems.~Additionally, sleep counselors: review parent's sleep goals to monitor changes to the child's bedtime routine and sleep environment; help them solve problems with implementation; provide positive feedback to help the parent recognize success; and help parents set additional goals for improving sleep."
3185267|NCT01301963|Active Comparator|Arm I|Patients receive G-CSF SC QD on days 1-4.
3185268|NCT01301963|Experimental|Arm II|Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.
3185269|NCT01301950|Active Comparator|TruMatch® Personalized Solutions|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using TruMatch® Personalized Solutions (Custom Patient Instrumentation)
3185270|NCT01301950|Active Comparator|Conventional Total Knee Replacement|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments
3185271|NCT01301937|Active Comparator|High continuous dose|Meglumine antimoniate 20 mg/kg/day for 30 continuous days
3185272|NCT01301937|Active Comparator|Low continuous dose|Meglumine antimoniate 5 mg/kg/day for up to 120 continuous days according to clinical cure
3185273|NCT01301924|Active Comparator|High dose|High dose: 20 days of 20 mg/kg/day meglumine antimoniate
3185274|NCT01301924|Experimental|Low dose|Low dose: 30 days of 5 mg/kg/day meglumine antimoniate
3185275|NCT01301911|Experimental|Cipatinib|Each subject will receive a single dose of cipatinib on treatment day 1, followed by 4-day observation period, and then will receive cipatinib once daily in cycles consisting of 21 days.
3185276|NCT01301898|Experimental|GC1111_0.5mg/kg|
3185277|NCT01301898|Experimental|GC1111_1.0mg/kg|
3185278|NCT01301898|Active Comparator|Elaprase_0.5mg/kg|
3185279|NCT01301885||Endometriosis|Women (19-38 years of age) with surgically confirmed endometriosis
3185280|NCT01301885||Healthy women|Healthy women (32-48 years of age), symptom free, existence of endometriosis ruled out during laparoscopy for tubal ligation
3185281|NCT01301872|Other|1|All patients meet ALI/less severe ARDS criteria
3185282|NCT01301859|Active Comparator|TIP Adherence Intervention|The TIP program is a brief, individualized intervention designed as an adjunct to pharmacotherapy for depression prescribed by a primary care physician. The key to the intervention is the involvement of the older adult in creating an adherence strategy tailored to his/her barriers and needs.
3185283|NCT01301859|Placebo Comparator|Usual Care|Treatment as usual in a primary care setting
3185284|NCT01301846||Wheelchair users|People who have a wheelchair for home and community use.
3185285|NCT01301833|Experimental|teneligliptin|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )
3185286|NCT01301833|Experimental|teneligliptin and glinide|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide
3185287|NCT01301833|Experimental|teneligliptin and biguanide|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide
3185288|NCT01301833|Experimental|teneligliptin and alpha-glucosidase inhibitor|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor
3185289|NCT01301820|Other|ARM A|maintenance study treatment: azacitidine sc 75 mg/m²/d (d1- d7) in first cycle: months 1,3,5,7,9 ,11 then lenalidomide 10mg/d (d1- d21) months 2,4,6,8,10,12
3185290|NCT01301820|Other|ARM B|maintenance study treatment: lenalidomide 10mg/d (d1- d21)in first cycle and months 1,3,5,7,9 ,11 then azacitidine sc 75 mg/m²/d (d1- d7) months 2,4,6,8,10,12
3185291|NCT01301807|Experimental|Carfilzomib + Panobinostat|Carfilzomib starting dose 20 mg/m^2 by vein over 30 minutes on days 1, 2, 8, 9, 15, and 16; Panobinostat starting dose 15 mg orally 3 times/week for first 2 weeks every 28 day cycle.
3185292|NCT01301807|Experimental|Dose Expansion - Bortezomib Sensitive|Carfilzomib MTD and Panobinostat MTD from Phase I.
3185293|NCT01301807|Experimental|Dose Expansion - Bortezomib Refractory|Carfilzomib MTD and Panobinostat MTD from Phase I.
3185294|NCT01301807|Experimental|Dose Expansion - Carfilzomib Refractory|Carfilzomib MTD and Panobinostat MTD from Phase I.
3185295|NCT01301807|Experimental|Dose Expansion - Carfilzomib + Panobinostat + Dexamethasone|Carfilzomib MTD and Panobinostat MTD from Phase I. Dexamethasone 40 mg on days 1, 8, 15, and 21.
3185296|NCT01301781|Experimental|BLI801 laxative|BLI801 laxative - oral solution
3185297|NCT01301781|Placebo Comparator|Placebo|BLI801 placebo - oral solution
3185298|NCT01301768|Experimental|Group Education|Group educational workshops about dietary habits in the first trimester because it is when organogenesis occurs and therefore when the iodine deficiency in the mother is an important risk in the development of the fetal central nervous system.
3185299|NCT01301768|No Intervention|Usual care|Women in the control group receive the usual care during the pregnancy
3185300|NCT01301755||1|
3185301|NCT01301742|Active Comparator|BI 10773|Subject to receive one single dose BI 10773
3185302|NCT01301742|Experimental|BI 10773 plus gemfibrozil|Subject to receive one single dose BI 10773 plus 600 mg gemfibrozil bid for 5 days
3185303|NCT01301729|Experimental|Trastuzumab|Participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams per meter square (mg/m^2), every 3 weeks or paclitaxel 90 mg/m^2 once a week until progression of disease, occurrence of intolerable toxicity, the participant discontinues the study or dies.
3185304|NCT01301716|Experimental|A|
3185305|NCT01301716|Experimental|B|
3185306|NCT01301716|Experimental|C|
3185307|NCT01301703|Active Comparator|Tdap vaccination|Patients and controls will be vaccinated with BOOSTRIX (Tdap vaccine)
3185308|NCT01301690||Neck masses|Neck mass received US and US-FNA
3185309|NCT01301677|Active Comparator|Hydrocortisone|
3185310|NCT01301677|Experimental|2PX+|strontium chloride hexahydrate in a penetration enhancing vehicle
3185311|NCT01301677|Experimental|2PX-|strontium chloride hexahydrate without a penetration enhancing vehicle
3185312|NCT01301651|Experimental|virtual reality balance training|balance board training with virtual reality intervention
3185313|NCT01301651|Experimental|conventional balance training|physical therapy conventional balance training
3185314|NCT01301651|No Intervention|control group|No physical therapy
3185315|NCT01301625||MitraClip Implant|Eligible patients undergoing a MitraClip procedure in Australia and New Zealand
3185316|NCT01301612|Active Comparator|Radiation therapy and Cisplatin|Cisplatin, 40 mg/m2, IV - Weekly doses for 6 weeks Pelvic radiation therapy, 45 Gy External, Fractions of 1.8 Gy per day, 5 days a week Dose boosts,15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week Brachytherapy (if indicaed), 40 Gy at spot A(low dose rate), Intracavitary 1 or 2 separate fractions for 1 to 3 weeks. 28 Gy at spot A, (high dose rate) Intracavitary,4 fractions of 7.0 Gy once or twice a week.
3185373|NCT01301261|Active Comparator|4 mg/kg of sugammadex|4 mg/kg of sugammadex are given when a posttetanic count 1-3 appears
3185317|NCT01301612|Experimental|Nimotuzumab and|"Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks.~Nimotuzumab, 200 mg, Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes, Weekly doses for 14 weeks.~Pelvic radiation therapy, 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts, 15 Gy ± 5%, External,Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week~Brachytherapy (In case there is indication, should it be performed, not to be longer than the expected 70 days for the entire radiation therapy), 40 Gy at spot A (low dose rate) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks 28 Gy at spot A (high dose rate), Intracavitary, 4 fractions of 7.0 Gy once or twice a week."
3185318|NCT01301599|Experimental|combination group|combination therapy of alpha blocker and 5-alpha-reductase inhibitor medication
3185319|NCT01301599|Active Comparator|alpha blocker group|alpha blocker monotherapy
3185320|NCT01301599|Active Comparator|5 ARI group|5 alpha-reductase inhibitor group
3185321|NCT01301586|Active Comparator|Oral antibiotic plus soy extract|
3185322|NCT01301586|Active Comparator|Oral antibiotic|
3185323|NCT01301573||rAAV-GAD Treated Subjects|rAAV-GAD treated subjects who are being observed for long-term effects of the gene therapy product which they received from participating in a previous clinical study.
3185324|NCT01301560|Experimental|Radiosurgery arm|Radiosurgery before palliative chemotherapy
3185325|NCT01301560|No Intervention|Observation arm|No radiotherapy or local treatment until specific symptoms or sign developed
3185326|NCT01301534||T-Con|1. Nurse initiated Telephone Consult (T-Con)
3185327|NCT01301534||Mail-Out|2. Mail-0ut Letter to the patient
3185328|NCT01301534||Education|3. Provider, Nurse and Technician Education with point-of-care patient referrals , Exam Room Flyer
3185329|NCT01301534||Control group|4. Control group (i.e. usual care)
3185330|NCT01301521|Experimental|Cinnulin PF|Will take (by mouth) 2 gelatin capsules that contains 1 gram (2-500 mg capsules) water-soluble cinnamon extract (Cinnulin PF) once a day for 1 year plus 1 year of follow-up plus standard of care aggressive lifestyle therapy.
3185331|NCT01301521|Placebo Comparator|Placebo|Will take (by mouth) 2 placebo capsules (gelatin capsule filled with wheat bran) once a day for 1 year plus 1 year of follow-up plus standard of care aggressive lifestyle therapy.
3185332|NCT01301508|Experimental|AN2898 ointment, 1%, vs. ointment vehicle|"AN2898 ointment applied twice daily for 6 weeks to one target lesion, and AN2898 ointment vehicle applied twice daily for 6 weeks to a second target lesion.~Treatments will be randomly assigned to target lesions A and B."
3185333|NCT01301508|Experimental|AN2728 ointment, 2%, vs. ointment vehicle|"AN2728 ointment applied twice daily for 6 weeks to one target lesion, and AN2728 ointment vehicle applied twice daily for 6 weeks to a second target lesion.~Treatments will be randomly assigned to target lesions A and B."
3185334|NCT01301495|Experimental|HANAROSTENT covered Esophageal Stent|
3185335|NCT01301482|Experimental|battlefield auricular acupuncture|
3185336|NCT01301482|No Intervention|placebo|
3185337|NCT01301469|Experimental|1|6% HES 130/0.42 in plasma adapted Ringer's solution (balanced solution)
3185338|NCT01301469|Active Comparator|2|HES 130/0.4 in a saline solution
3185339|NCT01301456|Placebo Comparator|Treatment Arm 1 (Stage 1A)|
3185340|NCT01301456|Experimental|Treatment Arm 2 (Stage 1A)|
3185341|NCT01301456|Experimental|Treatment Arm 3 (Stage 1A)|
3185342|NCT01301456|Experimental|Treatment Arm 4 (Stage 1A)|
3185343|NCT01301456|Placebo Comparator|Treatment Arm 5 (Stage 1B)|
3185344|NCT01301456|Experimental|Treatment Arm 6 (Stage 1B)|
3185345|NCT01301456|Experimental|Treatment Arm 7 (Stage 1B)|
3185346|NCT01301456|Experimental|Treatment Arm 8 (Stage 1B)|
3185347|NCT01301456|Placebo Comparator|Treatment Arm 9 (Stage 2)|
3185348|NCT01301456|Experimental|Treatment Arm 10 (Stage 2)|
3185349|NCT01301456|Experimental|Treatment Arm 11 (Stage 2)|
3185350|NCT01301456|Experimental|Treatment Arm 12 (Stage 2)|
3185351|NCT01301456|Experimental|Treatment Arm 13 (Stage 2)|
3185352|NCT01301443|Experimental|Subretinally Injected RetinoStat|Subretinally injected RetinoStat
3185353|NCT01301430|Experimental|H-1 parvovirus (H-1PV)|
3185354|NCT01301417||ColonRing™|Adult Patients who underwent a laparoscopic or open colorectal resection with the creation of an anastomosis using the ColonRing™ in routine clinical practice
3185355|NCT01301404|No Intervention|control|patient receive nothing
3185356|NCT01301404|Experimental|carbohydrate drink|10%carbohydrate drink
3185357|NCT01301391|Experimental|Milciclib|Milciclib Maleate capsules
3185358|NCT01301378|Active Comparator|KeraSys Tissue Patch Graft|20 patients needing a Molteno 3 glaucoma drainage shunt implant will receive the KeraSys patch graft
3185359|NCT01301378|Active Comparator|Tutoplast tissue patch graft|20 patients need Molteno 3 glaucoma drainage surgery will receive tutoplast patch graft
3185360|NCT01301352|No Intervention|Nasojejunal feeding (control)|
3185361|NCT01301352|Experimental|Nasogastric feeding (intervention)|
3185362|NCT01301339||failed and passed physical fitness test|520 subjects who have failed their Air Force physical fitness test and 520 volunteers who have passed their physical fitness test both within the last 6 months
3185363|NCT01301326|Experimental|subthreshold laser treatment|
3185364|NCT01301326|Active Comparator|threshold laser treatment|
3185365|NCT01301313|Experimental|Levosimendan|
3185366|NCT01301313|Active Comparator|Conventional intensified inotropic treatment|
3185367|NCT01301300|Active Comparator|Glenbrook Hospital|Immediate implementation of the disinfecting cap, no baseline contamination assessment, historical infection data only.
3185368|NCT01301300|Active Comparator|Evanston, Highland Park, Skokie Hospitals|"Phase 1: Assess baseline contamination rate for patients with PICC catheters for 3-12 months.~Phase 2: Implement intervention. Assess contamination 3-12 months. Phase 3: (optional): Remove cap asses contamination rate (3-6 months)"
3185369|NCT01301287|Experimental|Chlorella|
3185370|NCT01301274|Active Comparator|Hypotonic|Subjects in this arm will receive 0.45% NaCl/5% dextrose intravenous maintenance fluids.
3185371|NCT01301274|Experimental|Isotonic|Subjects in this arm will receive 0.9% NaCl/5% dextrose intravenous maintenance fluids.
3185372|NCT01301261|Active Comparator|sugammadex 2 mg/kg|2 mg/kg of sugammadex are given when a response of two counts of train of four are present
3185374|NCT01301261|Active Comparator|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg are given three minutes after the injection of cis-atracurium
3185375|NCT01301248|Active Comparator|Radiotherapy/Cisplatin(GroupA)|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)
3185376|NCT01301248|Experimental|Radiotherapy/Cisplatin/Cetuximab(GroupB)|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
3185377|NCT01301235||Subjects with mitochondrial disease|
3185378|NCT01301222|Experimental|octreotide|octreotide arm 100mcg for 5 days. control has no octreotide
3185379|NCT01301209||treatment|patients undergoing treatment
3185380|NCT01301196|Experimental|Behaviour change|Attendance at 3-h workshop
3185381|NCT01301183|Experimental|Rh IGF-1 + Transdermal estradiol|RhIGF-1 with transdermal 17-beta estradiol
3185382|NCT01301183|Placebo Comparator|Placebo + Transdermal estradiol|Placebo and transdermal 17-beta estradiol
3185383|NCT01301157|Experimental|25ug M518101|
3185384|NCT01301157|Placebo Comparator|Vehicle|
3185385|NCT01301157|Active Comparator|Dovonex|
3185386|NCT01301157|Experimental|50ug M518101|
3185387|NCT01301131|Experimental|Probiotic|80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily
3185388|NCT01301131|No Intervention|control|
3185389|NCT01301105|Placebo Comparator|Health Enhancement Program (HEP)|Intervention designed to be effective and structurally equivalent to Mindfulness Based Stress Reduction (MBSR) but without a mindfulness component. Designed as an active control for MBSR to isolate mindfulness as an active ingredient.
3185390|NCT01301105|Active Comparator|Mindfulness Based Stress Reduction (MBSR)|
3185391|NCT01301092|Experimental|Part A: LY2189265 intravenous|Single intravenous (IV) dose, starting at 0.1 milligrams (mg) of LY2189265. Dose may be increased to 0.2 mg or decreased to 0.05 mg for subsequent patients, dependent on safety assessments of the first 3 patients.
3185392|NCT01301092|Experimental|Part B: LY2189265 subcutaneous, intravenous|Patients are randomized to 2 sequences of 2 treatments. Single 1.5 mg subcutaneous (SC) dose of LY2189265 in Period 1; single intravenous (IV) dose of LY2189265 (determined by Part A IV arm data) in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.
3185393|NCT01301092|Experimental|Part C: LY2189265 subcutaneous, intramuscular|Patients are randomized to 2 sequences of 2 treatments. Single 0.75 mg subcutaneous (SC) dose of LY2189265 in Period 1; single 0.75 mg intramuscular (IM) of LY2189265 in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.
3185394|NCT01301079|Active Comparator|Ketamine|"A cardioscope, a capnograph, a pulse oximeter, and a noninvasive blood pressure meter were used to monitor the patients. Propofol (2-4 mg/kg), remifentanil (1 μg/kg), and atracurium (0.5 mg/kg) were administered for intubation. Atracurium was titrated to maintain muscle relaxation. Anesthesia was maintained with remifentanil, 0.8% isoflurane, and 50% oxygen without nitrous oxide. Infusion of the solutions was continued until skin closure.~The patients in group ketamine received remifentanil (0.4 μg/kg/min) and ketamine (5 μg/kg/min).~Remifentanil was administered as necessary until skin closure. Neostigmine was used for antagonizing the neuromuscular block."
3185395|NCT01301079|Placebo Comparator|Saline|"A cardioscope, a capnograph, a pulse oximeter, and a noninvasive blood pressure meter were used to monitor the patients. Propofol (2-4 mg/kg), 1 μg/kg remifentanil, and atracurium (0.5 mg/kg) were administered for intubation. Atracurium was titrated to maintain muscle relaxation. Anesthesia was maintained with remifentanil, 0.8% isoflurane, and 50% oxygen without nitrous oxide. Infusion of the solutions was continued until skin closure.~The patients in group saline received remifentanil (0.4 μg/kg/min) and saline solution.~Remifentanil was administered as necessary until skin closure. Neostigmine was used for antagonizing the neuromuscular block."
3185396|NCT01301066|Experimental|Pitavastatin 4 mg QD|
3185397|NCT01301066|Active Comparator|Pravastatin 40 mg QD|
3185398|NCT01301053|Other|Current UVA intensive care insulin protocol without brakes|Studies the safety and feasibility of the continuous glucose monitor in 10 critically ill patients for 7 days and uses the current UVA intensive care insulin for insulin management for 12 hours.
3185399|NCT01301053|Active Comparator|Current UVA intensive care insulin protocol with brakes|"Studies the safety and feasibility of the continuous glucose monitor in 10 critically ill patients for 7 days. Uses the current UVA intensive care insulin protocol for insulin management for 12 hours with the addition of brakes that reduce insulin administration based on continuous glucose monitoring data between hourly reference glucose data."
3185400|NCT01301040|Active Comparator|Epirubicin/Cyclophosphamide|Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles
3185401|NCT01301040|Active Comparator|docetaxel/cyclophosphamide|Treatment Arm 2: TC - docetaxel (Taxotere) (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.
3185402|NCT01301027|Active Comparator|Pioglitazone|15 mg/day pioglitazone for 2 weeks, then 30 mg/day for remaining 24 weeks
3185403|NCT01301027|Placebo Comparator|Placebo|1 placebo pill a day matching the pioglitazone treatment for 26 weeks
3185404|NCT01301001|Placebo Comparator|Placebo oral capsule|Placebo capsule daily in first intervention period and Gabapentin capsule 3000 mg daily in in second intervention (after washout period)
3185405|NCT01301001|Active Comparator|Gabapentin|Gabapentin capsule 3000 mg daily in first intervention period and Placebo capsule in second intervention (after washout period)
3185406|NCT01300988|Active Comparator|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
3185407|NCT01300988|Placebo Comparator|Placebo|Aprepitant (Emend®) placebo for 14 days
3185408|NCT01300975|Experimental|Intralesional antimony|3 intralesional injections of antimony at D1, D3 and D7
3185409|NCT01300975|Active Comparator|Cryotherapy|Liquid nitrogen until freezing at DF1 and D14
3185410|NCT01300975|Placebo Comparator|Topical cream|topical treatment 3 times a day during 21 days with an emollient cream
3185411|NCT01300962|Experimental|BYL719 ARM B|Treatment with BYL719 and Capecitabine
3185412|NCT01300962|Experimental|BKM120 ARM A|Treatment with BKM120 and capecitabine
3185413|NCT01300962|Experimental|ARM C|BKM 120 plus capecitabine plus trastuzumab
3185414|NCT01300962|Experimental|ARM D|BKM120 plus capecitabine plus lapatinib
3185415|NCT01300936||patients with abdominal wall hernias|
3185416|NCT01300923|Active Comparator|Acamprosate|The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 60kg and 1332 mg per day for those less weighing less than 60kg.
3185417|NCT01300923|No Intervention|Autism Spectrum Disorder|This baseline comparison group will participated in only the psychophysiological and biomarker portion of subject characterization.
3185418|NCT01300910|Active Comparator|1|One group of men will undergo a circumcision using the Shang Ring and men are to return for regular follow-up visits to evaluate pain and wound healing. . The Shang Ring will be removed at 7 days, and the last scheduled follow-up visit is at 60 days.
3185419|NCT01300910|Active Comparator|2|One group of men will undergo a conventional circumcision using a WHO recommended surgical technique, either the forceps-guided method or the dorsal slit method. Men are to return for regular follow-up visits to evaluate pain and wound healing, with the last scheduled follow-up visit at 60 days.
3185420|NCT01300897||Healthy Volunteer|healthy volunteers will serve as controls. In each subject the cortical evoked potentials, transcranial motor evoked potentials and translumbosacral motor evoked potentials will be measured.
3185421|NCT01300897||Constipated patients|Patients with chronic constipation and rectal hypersensitivity or hyposensitivity and/or dyssynergic defecation.In each subject the cortical evoked potentials, transcranial motor evoked potentials and translumbosacral motor evoked potential will be measured
3185422|NCT01300884||healthy volunteers|
3185423|NCT01300884||patients with fecal incontinence|
3185424|NCT01300884||patients with constipation|
3185425|NCT01300871||Postmenopausal Women on Endocrine Therapy|Postmenopausal women with Breast Cancer that undergo Endocrine Therapy.
3185426|NCT01300858|Experimental|EGEN-001|
3185427|NCT01300845|Active Comparator|Humidification|
3185428|NCT01300845|Experimental|No Humidification|
3185429|NCT01300832|Experimental|Duplex scan|Subjects undergo preoperative and post-operative duplex scanning of the lower extremities
3185430|NCT01300819|Placebo Comparator|Placebo|
3185431|NCT01300819|Experimental|Rotigotine|
3185432|NCT01300806||myHERO SBIRT|
3185433|NCT01300806||clinician administered SBIRT|
3185434|NCT01300780|Active Comparator|Experimental|The participants from the placebo group received a placebo (Talco pharma SM-200-Henrifarma produtos químicos e farmacêuticos LTDA, São Paulo, SP, Brazil) and participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil). All the participants were watched to ensure that they took the drugs or placebo 1 h before treatment. The drugs were similar in appearance. A second dose of placebo or etoricoxib (60 mg) was administered 24 h after the first dose. At the time the participants were required to take the second dose of the medicine, the research auxiliary called him/her and asked him/her to take the medicine.
3185435|NCT01300780|Placebo Comparator|placebo group|The participants from the placebo group received a placebo (Talco pharma SM-200-Henrifarma produtos químicos e farmacêuticos LTDA, São Paulo, SP, Brazil) and participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil). All the participants were watched to ensure that they took the drugs or placebo 1 h before treatment. The drugs were similar in appearance. A second dose of placebo or etoricoxib (60 mg) was administered 24 h after the first dose. At the time the participants were required to take the second dose of the medicine, the research auxiliary called him/her and asked him/her to take the medicine.
3185436|NCT01300767|Experimental|Lotrafilcon B|Lotrafilcon B commercially marketed contact lens randomly assigned to one eye, with balafilcon A commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW) modality.
3185437|NCT01300767|Active Comparator|Balafilcon A|Balafilcon A commercially marketed contact lens randomly assigned to one eye, with lotrafilcon B commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW) modality.
3185438|NCT01300754|Active Comparator|Dextrose|
3185439|NCT01300754|Active Comparator|Lidocaine|
3185440|NCT01300754|Active Comparator|Usual Care|
3185441|NCT01300741|Experimental|Lotrafilcon B|Lotrafilcon B commercially marketed contact lens randomly assigned to one eye, with galyfilcon A commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW modality).
3185442|NCT01300741|Active Comparator|Galyfilcon A|Galyfilcon A commercially marketed contact lens randomly assigned to one eye, with lotrafilcon B commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW modality).
3185443|NCT01300728|Experimental|intravenous immunoglobulin (IVIG)|IVIG (NewGam 10%)at 0.4 g/kg
3185444|NCT01300728|Placebo Comparator|Saline solution|0.9% saline solution
3185445|NCT01300715|Active Comparator|MBRF|
3185446|NCT01300702||lung cancer surgery|Patients undergoing thoracotomy for lung cancer
3185447|NCT01300676|Active Comparator|Tualang Honey|Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.
3185448|NCT01300676|No Intervention|Group 2|Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia.
3185449|NCT01300663||post-surgery symptom experience|women with vulvar intraephitelial neoplasia or vulvar cancer
3185450|NCT01300650|Experimental|Anakinra|
3185451|NCT01300637|Active Comparator|metformin|metformin intervention group
3185452|NCT01300637|Placebo Comparator|placebo|placebo-controlled
3185527|NCT01300039||Control group, no H. pylori|Patients who underwent upper endoscopy and found to not have H. pylori, and then would not receive antibiotics
3185453|NCT01300624|Experimental|Verb Network Strengthening Treatment|Verb Network Strengthening Treatment (VNeST) tasks involve the retrieval of nouns related to a target verb. For example, for the verb measure, participants would come up with people who measure and what they measure (e.g., carpenter/lumber, chef/sugar). They would then answer questions related to why, where, and when these things might occur (e.g., for carpenter/measure, they might say to get the right length of board, (why) at a construction site, (where) and when building a house (where). Cues and assistance are provided to the participants when they are unable to complete any given task. As the participants improve, cues are reduced.
3185454|NCT01300611|Experimental|TXA127 300 mcg/kg/day|Treatment group 1 (300 mcg/kg/day) of a two-arm, dose-escalation pilot feasibility trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect.
3185455|NCT01300611|Experimental|TXA127 1000 mcg/kg/day|Treatment group 2 (1000 mcg/kg/day) of a two-arm, dose-escalation pilot feasibility trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect.
3185456|NCT01300585|Other|MRI|All patients on study will undergo an MRI of the breast(s).
3185457|NCT01300572|Experimental|Treatment (90Y-BC8, allogeneic PBSC or bone marrow transplant)|"PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.~GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180."
3185458|NCT01300559|Experimental|Treatment Group|Tissuelink device plus Unipolar electrocautery will be used in this arm of the study.
3185459|NCT01300559|No Intervention|No treatment|Unipolar electrocautery without Tissuelink device will be used in this arm of the study.
3185460|NCT01300546|Active Comparator|Sumatriptan/Naproxen Sodium|In Treatment Period, subjects randomized to Sumatriptan/Naproxen Sodium will be provided with 14 tablets of Sumatriptan/Naproxen Sodium to treat migraine within 1 hour of onset on 14 or fewer days per month. Subjects will be provided with 14 tablets of Sumatriptan/Naproxen Sodium per month for rescue of persistent or recurring headache.
3185461|NCT01300546|Active Comparator|Naproxen Sodium|In Treatment Period, subjects randomized to Naproxen Sodium 500mg will be provided with 14 tablets of Naproxen Sodium to treat migraine within 1 hour of onset on 14 or fewer days per month. Subjects will be provided with 14 tablets of Naproxen Sodium per month for rescue of persistent or recurring headache.
3185462|NCT01300520|No Intervention|Target Tape|Including target tape in the procedure
3185463|NCT01300520|Other|Control|Without target tape in the procedure
3185464|NCT01300468|Experimental|Dose-escalation|
3185465|NCT01300455|Experimental|Suvorexant (40 mg)|In Period 1, suvorexant (40 mg tablets) administered orally once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. Period 2 consists of placebo administered once daily for 4 consecutive days in the evening.
3185466|NCT01300455|Placebo Comparator|Placebo|In Period 1, placebo administered orally once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. In Period 2, suvorexant (40 mg tablets) administered once daily for 4 consecutive days in the evening.
3185467|NCT01300442|Experimental|Control|The transcutaneous electrical diaphragmatic stimulation will be applied in healthy and COPD subjects.
3185468|NCT01300442|Experimental|Chronic Obstructive Pulmonary Disease|The intervention will be the TEDS in patients with Chronic Obstructive Pulmonary Disease (COPD)
3185469|NCT01300429||patients with Non Small Cell Lung cancer|This is a protocol to obtain and/or analyze tissue specimens of patients with NSCLC harboring an activating ALK inversion or translocation that have had a previous clinical response to tyrosine kinase inhibitor therapy and subsequently experience progressive disease. The tissue will be used to identify changes in the ALK gene that are acquired during treatment with an ALK TKI and may account for acquired resistance.
3185470|NCT01300416||With Gastro-Intestinal (GI) symptoms|
3185471|NCT01300416||Without GI symptoms|
3185472|NCT01300403|Experimental|FLUTTER|Since this was a crossover study, all patients performed all interventions in a randomized order.
3185473|NCT01300403|Experimental|ELTGOL|Since this was a crossover study, all patients performed all interventions in a randomized order.
3185474|NCT01300403|Active Comparator|CONTROL|Since this was a crossover study, all patients performed all interventions in a randomized order.
3185475|NCT01300390||End-stage liver disease pre-transplant|Patients with end-stage liver disease (non-fulminant) awaiting liver transplant
3185476|NCT01300377|Active Comparator|Bupivacaine / Lidocaine|Lidocaine/Bupivacaine mixture - 5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
3185477|NCT01300377|Active Comparator|Lidocaine|Lidocaine - 10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
3185478|NCT01300364|Placebo Comparator|sugar pill|
3185479|NCT01300364|Active Comparator|reboxetine (NRI)|
3185480|NCT01300364|Active Comparator|citalopram (SSRI)|
3185481|NCT01300351|Experimental|Fulvestrant 500mg|Fulvestrant 500mg (2 syringes of Fulvestrant 250mg), Fulvestrant 500 mg i.m. every 28 (+/- 3) days plus an additional 500 mg on day 14 (+/-3) of first month only
3185482|NCT01300351|Active Comparator|Fulvestrant 250mg|Fulvestrant 250mg (1 syringe of fulvestrant 250mg + 1 syringe matching placebo), Fulvestrant 250 mg and matching placebo i.m. every 28 (+/- 3) days plus an additional 2 placebo syringes on day 14 (+/-3) of first month only
3185483|NCT01300338|Experimental|Blood pressure with telemetry|Home blood pressure monitor with telemetry
3185484|NCT01300338|Active Comparator|Blood pressure without telemetry|Home blood pressure self monitor without telemetry.
3185485|NCT01300325|Placebo Comparator|0.9% saline|patients receive every 6 hours the nebulized 0.9% saline (placebo comparator) (group I) or the 3% HS (group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
3185486|NCT01300325|No Intervention|3% hypertonic saline|Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
3185487|NCT01300312|Experimental|1|
3185488|NCT01300312|Active Comparator|2|
3185489|NCT01300299|Experimental|All subjects|Subjects will receive chemotherapy after stereotactic body radiation therapy.
3185490|NCT01300286|Experimental|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
3185491|NCT01300273|Experimental|Ketosteril|
3185492|NCT01300260|Experimental|LY2189265 then Placebo|"LY2189265 (Dulaglutide) then Placebo: A single 1.5 milligram (mg) subcutaneous (SC) injection of LY2189265 on Day 1 in Period 1, followed by a single SC injection of Placebo on Day 1 in Period 2.~On Day 3 of each period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose bolus (0.3 gram/kilogram [g/kg] over approximately 2 minutes). Three hours later, participants were administered a second IV dextrose bolus of 25 g of 50% dextrose or a suitably adjusted dose according to glycemic status (20 g of 50% dextrose for participants with 3-hour glucose between 5.2 and 10 millimole/liter [mmol/L] or 15 g of 50% dextrose for participants with 3-hour glucose >10 mmol/L), followed by a 20% dextrose at the set infusion rate of 600 milliliter/hour [mL/h] for 35 minutes. Fifteen minutes after the start of the 20% dextrose infusion, an IV 1-mg glucagon bolus was administered.~There was a washout period of at least 28 days between Periods 1 and 2."
3185493|NCT01300260|Experimental|Placebo then LY2189265|"Placebo then LY2189265 (Dulaglutide): A single subcutaneous injection of Placebo on Day 1 in Period 1, followed by a single 1.5 milligrams (mg) subcutaneous injection of LY2189265 on Day 1 in Period 2.~On Day 3 of each period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose bolus (0.3 gram/kilogram [g/kg] over approximately 2 minutes). Three hours later, participants were administered a second IV dextrose bolus of 25 g of 50% dextrose or a suitably adjusted dose according to glycemic status (20 g of 50% dextrose for participants with 3-hour glucose between 5.2 and 10 millimole/liter [mmol/L] or 15 g of 50% dextrose for participants with 3-hour glucose >10 mmol/L), followed by a 20% dextrose at the set infusion rate of 600 milliliter/hour [mL/h] for 35 minutes. Fifteen minutes after the start of the 20% dextrose infusion, an IV 1-mg glucagon bolus was administered.~There was a washout period of at least 28 days between Periods 1 and 2."
3185494|NCT01300247|Experimental|Obinutuzumab + Fludarabine + Cyclophosphamide|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab (1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6), fludarabine (25 mg/m^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6), and cyclophosphamide (250 mg/m^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6).
3185495|NCT01300247|Experimental|Obinutuzumab + Bendamustine|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab (1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6) and bendamustine (90 mg/m^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6).
3185496|NCT01300234|Experimental|A (TDF tablets)|Tenofovir disoproxil fumarate (TDF) tablets
3185497|NCT01300234|Active Comparator|B (ADV tablets)|Adefovir dipivoxil (ADV) tablets
3185498|NCT01300221||Group 1|Subjects who are healthy normal children.
3185499|NCT01300221||Group 2|Subjects who have congenital heart disease.
3185500|NCT01300221||Group 3|Subjects who have sickle cell disease
3185501|NCT01300221||Group 4|Subjects who have Duchenne muscular dystrophy
3185502|NCT01300221||Group 5|Patients who have Marfan syndrome and other aortic disease
3185503|NCT01300208|Experimental|Cohort 1|CC-11050 (50 milligrams twice per day and Placebo)
3185504|NCT01300208|Experimental|Cohort 2|CC-11050 (100 milligrams twice per day and Placebo)
3185505|NCT01300208|Experimental|Cohort 3|CC-11050 (200 milligrams twice per day and Placebo)
3185506|NCT01300195||lung cancer surgery|Patients undergoing video-assisted thoracic surgery
3185507|NCT01300182|Experimental|Whole body vibration therapy|Whole body vibration therapy on top of conventional physiotherapy treatment.
3185508|NCT01300182|Active Comparator|Control|Conventional post-operative physical therapy rehabilitation exercises.
3185509|NCT01300169|Experimental|CAMS--Collaborative Driver-Treatment|"The Collaborative Assessment and Management of Suicidality (CAMS) is a suicide-specific clinical intervention that targets and treats patient-defined suicidal drivers over the course of clinical care."
3185510|NCT01300169|Active Comparator|Enhanced Care as Usual--E-CAU|This control group treatment will reflect current clinical practices for treating suicidal soldiers in the research site setting. These are providers were on site clinicians who provided care according to their usual and customary practices for working with suicidal risk within outpatient care.
3185511|NCT01300156|Experimental|ESHAOx arm|Patients who are planned to be treated with ESHAOx chemotherapy
3185512|NCT01300143|Active Comparator|TACE|Patients will be treated by 2 or 3 cures of hyperselective TACE. The first one at week 0 and the second one at week 8. If required, a third cure of TACE could be done at week16.
3185513|NCT01300143|Experimental|TACE + RTC|Patients will be treated by one cure of TACE at week 0. Then, patients will be treated within two weeks by external conformational radiotherapy of 54 grey fractioned in 18 sessions during 3-4 weeks.
3185514|NCT01300130|Experimental|low docosahexaenoic acid formula|
3185515|NCT01300130|Experimental|medium docosahexaenoic acid formula|
3185516|NCT01300130|Experimental|high docosahexaenoic acid formula|
3185517|NCT01300130|Active Comparator|human milk|
3185518|NCT01300117||with extracorporeal circulation|Patients undergoing cardiac surgery with the use of an extracorporeal circulation
3185519|NCT01300117||without extracorporeal circulation|Patients undergoing cardiac surgery without the use of extracorporeal circulation (OPCAB)
3185520|NCT01300104|Experimental|Exercise and whole grain rye|
3185521|NCT01300104|Active Comparator|No prescriptions|
3185522|NCT01300078|Experimental|MF101 10 grams/day|
3185523|NCT01300078|Experimental|MF101 15 grams/day|
3185524|NCT01300052|Experimental|AN2728 ointment, 2%|AN2728 ointment, 2%
3185525|NCT01300052|Placebo Comparator|Ointment Vehicle|Ointment Vehicle
3185526|NCT01300039||Antibiotics for H. pylori|Patients who underwent upper endoscopy and were found to have H. pylori, and were then to be treated with antibiotics for eradication of H. pylori
3185528|NCT01300026|Experimental|Part II Dose Expansion|Dose selected from Part I dose exploration
3185529|NCT01300026|Experimental|Part I Dose Exploration|The AMG 319 doses proposed for this study are 25, 50, 100, 200, 300 and 400 mg administered by mouth once daily.
3185530|NCT01300013|Experimental|Omecamtiv mecarbil|
3185531|NCT01300013|Placebo Comparator|Placebo|
3185532|NCT01300000|Active Comparator|Human Milk|ad lib
3185533|NCT01300000|Active Comparator|Milk based standard infant formula|ad lib
3185534|NCT01300000|Experimental|Milk based investigational infant formula|ad lib
3185535|NCT01299987|Experimental|Intraoperative radiotherapy|single arm with intraoperative radiotherapy
3185536|NCT01299974|Other|Parents and Residents in Session|Parents and Residents in Session
3185537|NCT01299961|Experimental|Subcutaneous Abatacept|All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.
3185538|NCT01299948|Active Comparator|prednisolone|5 mg prednisolone per os daily administration
3185539|NCT01299948|Placebo Comparator|placebo|The placebo is designed to the equal look like the study medication.
3185540|NCT01299935|Experimental|Stress reduction|Stress reduction program utilizing the Transcendental Meditation (TM) technique
3185541|NCT01299935|Active Comparator|health education|health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
3185542|NCT01299922|Experimental|cyclosporine+mycophenolic acid+prednison|Triple therapy
3185543|NCT01299922|Active Comparator|mycophenolic acid + prednison|Mycophenolic acid+prednison 106 weeks
3185544|NCT01299909|Active Comparator|Mindfulness Training for Smokers|MTS participants will receive 8 classes of training in mindfulness meditation, access to the MTS website, and 2 weeks of nicotine patches.
3185545|NCT01299909|Active Comparator|Integrated Training for Smokers|ITS participants will receive 8 classes of training in smoking cessation strategies, access to the Freedom From Smoking online program, and 2 weeks of nicotine patches.
3185546|NCT01299909|Other|Quitline|Quitline participants will consist of participants who elect not to participate in the high-intensity treatments (Mindfulness Training for Smokers; Integrated Training for Smokers. This Quitline group is a Non-Randomized, Treatment as Usual group.
3185547|NCT01299896|Active Comparator|Usual Care|Participants will continue to receive all the care currently offered in the VAPHS, including medications for smoking cessation and use of the in-person or telephone counseling options for quit smoking classes. For veterans with a co-pay, incurred fees with be reimbursed.
3185548|NCT01299896|Active Comparator|Coordinated Care|A CTQ Coordinator will coordinate the delivery of smoking related care.
3185549|NCT01299883|Active Comparator|Cancer and CVD Education|Participants receive education about both cancer and CVD risk factors and their relationship to dietary and physical activity health behaviors.
3185550|NCT01299883|Active Comparator|CVD Education|Participants receive education about CVD risk factors and their relationship to dietary and physical activity health behaviors.
3185551|NCT01299870|Active Comparator|AED treatment plus placebo|
3185552|NCT01299870|Experimental|Keishibukuryogan|
3185553|NCT01299844|No Intervention|Standard Care|
3185554|NCT01299844|Experimental|Diabetes Peer Counseling|
3185555|NCT01299831|Experimental|72 hour fast|
3185556|NCT01299831|Experimental|12 hours fast|
3185557|NCT01299831|Experimental|12 hour fast, growth hormone bolus|
3185558|NCT01299831|Experimental|72 hour fast, inhibition of lipolysis|
3185559|NCT01299818||spinal surgery|patients who undergo spinal surgery
3185560|NCT01299805|Experimental|Vortioxetine|Vortioxetine 20 mg, encapsulated tablet, orally, once daily for up to 14 days.
3185561|NCT01299805|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 14 days.
3185562|NCT01299792||one arm; neurogenic bladder dysfunction|evaluation of the clinical utility of bladder wall thickness as a diagnostic tool in patients with spinal cord injury
3185563|NCT01299779|Active Comparator|PEG-ELS|
3185564|NCT01299779|Active Comparator|PEG-SD|
3185565|NCT01299766|Experimental|Behavior Activation|BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
3185566|NCT01299766|Placebo Comparator|Supportive Therapy (ST)|ST is a person-centered treatment in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
3185567|NCT01299753|Placebo Comparator|Control|
3185568|NCT01299753|Experimental|Beta blockade|
3185569|NCT01299740|Other|Control Group|Treatment as usual
3185570|NCT01299740|Experimental|Research Group|Participation in the DBT skills group
3185571|NCT01299727|Experimental|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
3185572|NCT01299727|Experimental|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
3185573|NCT01299727|Experimental|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
3185574|NCT01299701|Experimental|ASA404|
3185575|NCT01299675||Chronic Performance|Subjects enrolled prior to or within 30 days post implant of SureScan pacing system. In office follow-up visits required every 6 months.
3185576|NCT01299675||Multiple MRI Scan Characterization|Subject enrolled into study at the time of MRI Scan indication. Subject followed per clinic standard of care.
3185577|NCT01299662|Experimental|Poly ICLC|One 1.6 mg subcutaneous injection of the adjuvant, poly ICLC, in the upper arm.
3185578|NCT01299649||Non-contrast echocardiography|Non-contrast echocardiography
3185579|NCT01299649||Contrast Echocardiography|Contrast Echocardiography
3185580|NCT01299636|Experimental|PM060184|
3185581|NCT01299623|Active Comparator|Evidential Group|Participants in this group will receive education about breast cancer prevention and specific information about African American women and breast cancer risk.
3185633|NCT01299311|Active Comparator|NEAT|4 days of NEAT (everyday activities)
3187594|NCT01285492|Experimental|QVA149|QVA149 110/50 μg once a day (o.d)
3185582|NCT01299623|Active Comparator|Non-Evidential Group|Participants in this group will receive general information about breast cancer prevention without anything specific to African American women.
3185583|NCT01299610|Experimental|GW870086 2.0% &amp; 0.2%|GW870086 2.0%, GW870086 0.2% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
3185584|NCT01299610|Experimental|GW870086 2.0% & FP 0.05%|GW870086 2.0%, FP 0.05% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
3185585|NCT01299610|Experimental|GW870086 0.2% & FP 0.05%|GW870086 0.2%, FP 0.05% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
3185586|NCT01299597|Experimental|Cohort 1: Atorvastatin|single dose session with Atorvastatin with PK samples collected up to 72h post dose, then 14 days repeat dose session with SB649868 with Atorvastatin single dose co-administered on day 8 (same time as SB649868) and on day 12 (2 hours before SB649868).
3185587|NCT01299597|Experimental|Cohort 2: Simvastatin|single dose session with Simvastatin with PK samples collected up to 24h post dose, then 14 days repeat dose session with SB649868 with Simvastatin single dose co-administered on day 12 (same time as SB649868) and on day 14 (2 hours before SB649868).
3185588|NCT01299584||Remifentanil|Patients administrated remifentanil at the site
3185589|NCT01299571||Dutasteride|Patients administrated dutasteride at the site
3185590|NCT01299558|Other|Treatment period 1|Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder given once daily in the morning on Day 1 of Treatment period 1
3185591|NCT01299558|Other|Treatment Period 2|Single IV dose of FF (250mcg) given over 20 mins on Day 1 of Treatment period 2
3185592|NCT01299558|Other|Treatment Period 3|Single IV dose of GW642444M (55mcg) given over 60 mins on Day 1 of Treatment period 3
3185593|NCT01299545||a single group of patients -200 expected|polyarthrite rhumatoid patients
3185594|NCT01299532|Experimental|Macrolane VRF30|
3185595|NCT01299519|Experimental|Weight Loss|Half of the subjects in the weight loss arm will lose 5% of their weight through a low-calorie diet, and half will also lose 10% and 15% body weight.
3185596|NCT01299519|Active Comparator|Weight Maintenance|Subjects in the weight maintenance arm will maintain a steady body weight (plus or minus 2% of initial body weight) for six months.
3185597|NCT01299506||Trabectedin|The administration of chemotherapy regimen with trabectedin will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
3185598|NCT01299506||Conventional care|This includes other palliative chemotherapy or biological therapy or best supportive care.
3185599|NCT01299493|Experimental|Interventional|Access to systems-level interventions to increase colorectal cancer screening.
3185600|NCT01299493|No Intervention|Usual Care|Practices will receive access to intervention components after outcomes data collection is complete.
3185601|NCT01299480|Experimental|Group 1|rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
3185602|NCT01299480|Experimental|Group 2|rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
3185603|NCT01299480|Experimental|Group 3|rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
3185604|NCT01299480|Experimental|Group 4|rLP2086 at visits 1 and 3, saline at visits 2 and 5
3185605|NCT01299480|Experimental|Group 5|rLP2086 at visits 3 and 5, saline at visits 1 and 2
3185606|NCT01299467|Experimental|Dose 1 (0.5 hours)|
3185607|NCT01299467|Experimental|Dose 1 (8 hours)|
3185608|NCT01299467|Placebo Comparator|Dose 1 (placebo)|
3185609|NCT01299467|Experimental|Dose 2 (0.5 hr)|
3185610|NCT01299467|Experimental|Dose 2 (8 hours)|
3185611|NCT01299467|Placebo Comparator|Dose 2 (placebo)|
3185612|NCT01299454|Active Comparator|Normal|
3185613|NCT01299454|Active Comparator|Mild|
3185614|NCT01299454|Active Comparator|Moderate|
3185615|NCT01299454|Active Comparator|Severe|
3185616|NCT01299441||OLT patients intubated with ECOM ETT|Patients undergoing liver transplantation and intubated with ECOM endotracheal tube (ETT).
3185617|NCT01299428|Active Comparator|cerebral oxygenation|
3185618|NCT01299415|Experimental|ASA404 + Fluvoxamine|ASA404 + Fluvoxamine (Core Phase), ASA404 + either paclitaxel or docetaxel or paclitaxel plus carboplain chemotherapy combination (Extension Phase)
3185619|NCT01299402|Experimental|Soulera Herbal Blend|
3185620|NCT01299402|Placebo Comparator|Placebo Blend|
3185621|NCT01299389|Experimental|Paliperidone palmitate|
3185622|NCT01299389|Placebo Comparator|Placebo|
3185623|NCT01299376|Experimental|L50/H12.5/A5→L50/H12.5/A5|One combination tablet containing L50 mg, H12.5 mg, and A5 mg, orally, once daily, for up to 8 weeks (double-blind treatment period). Participants continue with once daily L50/H12.5/A5 for 44 weeks during open label extension.
3185624|NCT01299376|Active Comparator|L50/H12.5→L50/H12.5/A5|One combination tablet containing L50 mg and H12.5 mg, orally, once daily, for up to 8 weeks during double-blind treatment period. Participants then receive once daily L50/H12.5/A5 for 44 weeks during open-label extension
3185625|NCT01299363|No Intervention|No dilator use|
3185626|NCT01299363|Active Comparator|Dilator use|Women randomized to vaginal dilators will be given instructions to perform softening exercises from postoperative weeks 4 to 8
3185627|NCT01299350|No Intervention|Usual|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged according to routine clinical practice based on symptoms, physical examination and other data that the cardiologist deems appropriate, except for Nt-proBNP.
3185628|NCT01299350|Experimental|Nt-proBNP guided|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops >30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies
3185629|NCT01299337||placebo|Subjects will be randomized either receiving T3 or placebo.
3185630|NCT01299324|Experimental|BMAC Infusion|Infusion of autologous bone marrow aspirate concentrated nucleated sells into the coronary sinus
3185631|NCT01299324|No Intervention|Control|Standard of care only. No infusion
3185632|NCT01299311|No Intervention|Inactivity|4 days of inactivity, mainly sitting
3185634|NCT01299311|Active Comparator|Exercise|4 days of inactivity combined with 1 hour of exercise
3185635|NCT01299298|Experimental|mipomersen|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose
3185636|NCT01299298|Placebo Comparator|placebo|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose
3185637|NCT01299285|Experimental|LY3009104|Single 10-milligram (mg) oral dose containing 100 microcuries of 14C-labeled LY3009104
3185638|NCT01299272|Experimental|LY2216684 + SSRI|"Acute Open-label (OL) Period: Participants received a starting dose of 12 milligrams (mg) LY2216684, administered orally, once daily for at least 2 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI). Then, based on efficacy and tolerability, the dose could be increased to 18 mg (and decreased back to 12 mg) over the next 6 weeks.~Stabilization OL Period: Participants meeting remission criteria continued on the same dose of LY2216684 for an additional 12 weeks. Participants who discontinued early during either OL Period were discontinued abruptly from LY2216684.~Double-blind (DB) Randomized Withdrawal Period: At 20 weeks, participants meeting criteria for randomization continued their current dose of LY2216684 for another 24 weeks. Participants who completed this period or discontinued early were randomized to abrupt (placebo for 2 weeks) or tapered (12 mg LY2216684 for 4 days, 6 mg LY2216684 for 4 days, then placebo for 6 days) discontinuation of LY2216684."
3185639|NCT01299272|Placebo Comparator|Placebo + SSRI|"Acute Open-label (OL) Period: Participants received a starting dose of 12 milligrams (mg) LY2216684, administered orally, once daily for at least 2 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI). Then, based on efficacy and tolerability, the dose could be increased to 18 mg (and decreased back to 12 mg) over the next 6 weeks.~Stabilization OL Period: Participants meeting remission criteria continued on the same dose of LY2216684 for an additional 12 weeks. Participants who discontinued early during either OL Period were discontinued abruptly from LY2216684.~Double-blind (DB) Randomized Withdrawal Period: At 20 weeks, participants meeting criteria for randomization were tapered from their LY2216684 dose to placebo following the regimen of 12 mg for 7 days, 6 mg for 7 days, and placebo for the remaining 22 weeks. Participants who completed this period or discontinued early continued to receive placebo for an additional 2 weeks"
3185640|NCT01299259|Experimental|Text Message Reminders|Subjects randomized to the the intervention group will receive a total of 4 text messages on days 2 through 5 to remind them to schedule and attend a PCP follow-up appointment
3185641|NCT01299259|No Intervention|Control Group|The control group will not receive any additional reminders to follow-up with PCP.
3185642|NCT01299246|Experimental|improving self-care|
3185643|NCT01299233||control group|age matched healthy controls
3185644|NCT01299233||Glaucoma|patients with diagnosis of primary open angle glaucoma
3185645|NCT01299207||CAD treated with Xience stents|Patients with CAD who undergo successful stenting with the Xience drug-eluting stent will represent the patient population.
3185646|NCT01299194|Active Comparator|ATORVASTATIN|Atorvastatin 80mg once daily for 3 months, 1.5 month wash out, then Placebo for 3 months
3185647|NCT01299194|Placebo Comparator|PLACEBO|Placebo 3 months, then washout for 1.5 months, then Atorvastatin 80mg once daily
3185648|NCT01299181|Active Comparator|Atorvastatin|Atorvastatin 80mg once daily
3185649|NCT01299181|Placebo Comparator|Placebo|Placebo
3185650|NCT01299168||Kidney Transplant Biopsies for Cause|The study population includes patients with a functioning kidney transplant undergoing a biopsy for clinical indications as standard of care to determine the cause of their graft dysfunction (deterioration in graft function, delayed graft function, proteinuria).
3185651|NCT01299155|Experimental|ReSTOR +3|Bilateral implantation of a ReSTOR +3 Intraocular Lens (IOL) Model SN6AD1
3185652|NCT01299155|Active Comparator|LENTIS MPlus|Bilateral implantation of a LENTIS MPlus Intraocular Lens (IOL) Model
3185653|NCT01299142|Experimental|FGI-101-1A6|Intervention: Drug-FGI-101-1A6
3185654|NCT01299142|Placebo Comparator|Placebo|Intervention: Drug-Placebo
3185655|NCT01299116|Other|Preference SARC|Participants received one of a variety of oral contraceptives or DMPA
3185656|NCT01299116|Experimental|Randomized LARC|"Participants receive one of the following interventions:~Implanon® or Nexplanon®; ParaGard®; Mirena®"
3185657|NCT01299116|Active Comparator|Randomized SARC|Participants received one of a variety of oral contraceptives or DMPA
3185658|NCT01299103|Active Comparator|Single Treatment|Treatment of facial wrinkle with one treatment only
3185659|NCT01299103|Active Comparator|Double Treatment|Treatment of facial wrinkle with two treatments
3185660|NCT01299103|Active Comparator|Triple treatment|Treatment of facial wrinkle with three treatments
3185661|NCT01299090|Experimental|Treatment Group|All subjects enrolled were in the treatment group.
3185662|NCT01299077||Lumbar disc degenerative disease|Triple therapy (MBL+ MYO+ NSAIDs) which prescribed by doctors (Drs) based on disease condition
3185663|NCT01299064||Buddhist Clergy and Laypersons|
3185664|NCT01299051|Active Comparator|Steps to Health|Steps to Health worksite weight management program at Duke.
3185665|NCT01299051|Experimental|Steps to Health Plus!|Steps to Health Plus! worksite weight management program at Duke. Also known as Pathways to Change.
3185666|NCT01299051|No Intervention|Observational Comparison|Observational comparison group consisting of employees who are eligible for the study but do not take part will also be used in analyses (approximately 1500 subjects).
3185667|NCT01299038|Active Comparator|Group 1|Rosuvastatin 20mg taken orally once a day for 4 weeks
3185668|NCT01299038|Active Comparator|Group 2|Rosuvastatin 40mg taken orally once a day for 4 weeks
3185669|NCT01299025|No Intervention|Control|Participants allocated as controls receive no treatment. They may be physically active as usual.
3185670|NCT01299025|Experimental|Training with Nintendo Wii Fit|Training 6 weeks with Nintendo Wii Fit, 30 minutes 2 times per week
3185671|NCT01298999|Experimental|YF476|YF476 (gastrin-receptor antagonist)
3185672|NCT01298999|Placebo Comparator|Placebo|Placebo pill (identical in appearance to YF476 pills)
3185673|NCT01298986|Active Comparator|Pulmonary Vein Isolation|Patients who have paroxysmal or persistent atrial fibrillation but whose left atrium is < /= 5.0
3185729|NCT01298622||OCD parents|
3185730|NCT01298609|Active Comparator|Suprathreshold Stimulation|Patients will be stimulated at supra-sensory threshold levels for two weeks using occipital stimulation
3187595|NCT01285492|Active Comparator|Tiotropium|tiotropium 18 μg o.d.
3185674|NCT01298986|Experimental|Hybrid procedure for patients with a left atrium < /= 5.0 cm|A combined procedure where the cardiac surgeon will place the ablation lesions on top of the heart and the electrophysiologist will place the lesions inside the heart. 3D mapping with be used to guide the procedure. The left atrial appendage will be surgically managed.
3185675|NCT01298986|Active Comparator|Cox Maze Procedure|All lesions of the Cox Maze procedure will be completed as originally described by Dr. James Cox using crypthermia. Patients will be randomized if there left atrium is >5.0 cm but < 6.1 cm and are experiencing paroxysmal or persistent atrial fibrillation
3185676|NCT01298986|Experimental|Hybrid Procedure|A collaborative approach between electrophysiologist and surgeons for patients with a left atrium <5.0 cm and < 6.1 cm where the surgeon will epicardially place the ablation lesions and the electrophysiologist will place the lesion lines endocardially. 3D mapping will be used and the left atrial appendage will be surgically managed.
3185677|NCT01298973|Experimental|Saline|One group will receive Saline to irrigate the wound
3185678|NCT01298973|Experimental|Viscoat|One group will receive Viscoat to close the surgical wound
3185679|NCT01298960|Experimental|rGH Group|
3185680|NCT01298960|No Intervention|Non rGH group|
3185681|NCT01298947|Active Comparator|Laser atherectomy and drug-coated balloon|Laser atherectomy and Paclitaxel-coated balloon angioplasty in treatment of instent lesions of femoropopliteal arteries
3185682|NCT01298947|Active Comparator|Drug eluting Ballon PTA|Paclitaxel-coated balloon angioplasty
3185683|NCT01298934|Experimental|LBH589|Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
3185684|NCT01298921|Active Comparator|Continous Flow Oxygen|
3185685|NCT01298921|Experimental|Oxygen Demand Valve|
3185686|NCT01298908|Other|Operative treatment|vein stripping
3185687|NCT01298908|Other|Laser ablation|Ultrasound guided laser ablation
3185688|NCT01298908|Other|Foam sclerotherapy|Ultrasound guided foam sclerotherapy
3185689|NCT01298895||PEX group|The first group consisted of 47 eyes with cataract complicated with pseudoexfoliation syndrome (PEX).
3185690|NCT01298895||control group|The control group included 177 eyes with uncomplicated cataract in eyes without other ocular pathology
3185691|NCT01298882|Experimental|Diacerein|
3185692|NCT01298882|Placebo Comparator|Placebo|
3185693|NCT01298869||Chronic kidney disease|Chronic kidney disease stage IV and V
3185694|NCT01298856|Active Comparator|hydrotherapy|hydrotherapy and ankle taping and land based exercise
3185695|NCT01298856|Active Comparator|land-based|land-based and ankle taping program
3185696|NCT01298843|Other|Study of Blood Levels of Ceftaroline Fosamil|Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital
3185697|NCT01298830|Experimental|GLP-1 CellBeads|
3185698|NCT01298817|Experimental|Soy, Prepared Meals|Soy-based meal replacement weight loss group with additional meals provided
3185699|NCT01298817|Active Comparator|Non soy prepared meals|Non-soy based meal replacement weight loss group with additional meals provided
3185700|NCT01298804|Experimental|Problem Solving Education|
3185701|NCT01298804|No Intervention|Control|
3185702|NCT01298791|Experimental|Provider sitting|Providers seated during communication through hospitalization
3185703|NCT01298791|Experimental|Provider standing (control)|Providers standing during communication through hospitalization
3185704|NCT01298778|Placebo Comparator|Standard of care|Spinal consists of duramorph 150 mcg combined with fentanyl and bupivacaine in conjunction with placebo capsules 2 PO q 6 hrs x 4 doses in first 24 hrs postop. Ibuprofen given as standard of care.
3185705|NCT01298778|Active Comparator|Acetaminophen and increased dose of Duramorph|Spinal consists of duramorph 300 mcg combined with fentanyl and bupivacaine in conjunction with Acetaminophen 1 Gm PO q 6 hrs x 4 doses in first 24 hrs postop. Ibuprofen given as standard of care.
3185706|NCT01298765|Experimental|BEMA Buprenorphine|buprenorphine buccal soluble film
3185707|NCT01298752|Experimental|Mapracorat|Mapracorat ophthalmic suspension
3185708|NCT01298752|Placebo Comparator|Vehicle|Vehicle of mapracorat ophthalmic suspension
3185709|NCT01298726|Other|PHARMACEUTICAL CARE|
3185710|NCT01298726|Other|HEALTH USUAL CARE|
3185711|NCT01298713|Active Comparator|A|Tamoxifen 20mg/d
3185712|NCT01298713|Experimental|B|Tamoxifen 20mg/d + RAD001 10mg/d
3185713|NCT01298700|Active Comparator|bimatoprost 0.01% ophthalmic solution|One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
3185714|NCT01298700|Active Comparator|bimatoprost 0.03% ophthalmic solution|One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
3185715|NCT01298687|Experimental|Trav 0.00013%|Travoprost Ophthalmic Solution, 0.00013%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
3185716|NCT01298687|Experimental|Trav 0.00033%|Travoprost Ophthalmic Solution, 0.00033%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
3185717|NCT01298687|Experimental|Trav 0.001%|Travoprost Ophthalmic Solution, 0.001%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
3185718|NCT01298687|Experimental|Trav 0.00267%|Travoprost Ophthalmic Solution, 0.00267%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
3185719|NCT01298687|Active Comparator|TRAVATAN|Travoprost Ophthalmic Solution, 0.004%, 1 drop administered in each eye at 8 pm for 5 days, with 1 drop of vehicle administered at all other timepoints (2-hour intervals)
3185720|NCT01298687|Placebo Comparator|Vehicle|Travoprost vehicle, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
3185721|NCT01298661|Other|Healthy Young Subjects|Subjects apparently healthy, with age of 18 to 27 years old.
3185722|NCT01298661|Other|Healthy Elderly subjects|Subjects apparently healthy, with age of 60 to 75 years old.
3185723|NCT01298661|Other|COPD Patients|Patients with clinical and spirometric diagnosis of COPD
3185724|NCT01298648||Humira|Participants who were prescribed Humira per approved prescribing information of Humira in Japan.
3185725|NCT01298635|Active Comparator|trab|
3185726|NCT01298635|Active Comparator|phacotrab|
3185727|NCT01298622||controls|
3185728|NCT01298622||OCD patients|
3185731|NCT01298609|Sham Comparator|minimal stimulation|Patients will be stimulated at minimal stimulation for two weeks using occipital stimulation
3185732|NCT01298609|Active Comparator|Subthreshold Stimulation|Patients will be stimulated at sub-sensory threshold stimulation for two weeks using occipital stimulation
3185733|NCT01298596|Experimental|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
3185734|NCT01298596|Experimental|Loop Electrosurgical Excision Procedure|Loop Electrosurgical Excision Procedure (LEEP) uses a low-voltage electrified wire loop to cut out diseased part of cervix
3185735|NCT01298583|Experimental|ankle tracking|subjects track a target with ankle movement
3185736|NCT01298583|No Intervention|ankle movement|
3185737|NCT01298570|Active Comparator|Regorafenib + FOLFIRI|regorafenib 160 mg + FOLFIRI
3185738|NCT01298570|Placebo Comparator|Placebo + FOLFIRI|Placebo + FOLFIRI
3185739|NCT01298557||Traumatic brain injured patients|This group consists of participants who suffered a traumatic brain injury an average of 4 months to 4 years prior to testing. Patients must not have history of prior head injury, substance abuse, psychiatric illness, or contraindications to MRI.
3185740|NCT01298557||Controls (no traumatic brain injury)|This group consists of participants who do not have a history of brain trauma. Furthermore, controls must not suffer from substance abuse, psychiatric illness, or have contraindications to the MRI.
3185741|NCT01298544|Other|All subjects|
3185742|NCT01298531|Active Comparator|etanercept|Group A: etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
3185743|NCT01298531|Placebo Comparator|etanercept-placebo|Group B: placebo subcutaneous (SC) injections once weekly for (how many) weeks follwed by etanercept 50 mg SC injections once weekly.
3185744|NCT01298518|Experimental|PF-04620110|
3185745|NCT01298518|Placebo Comparator|placebo|
3185746|NCT01298505|Experimental|PF-03654764 2.5mg plus fexofenadine 60mg|
3185747|NCT01298505|Experimental|PF-03654764 5mg plus fexofenadine 60mg|
3185748|NCT01298505|Placebo Comparator|placebo|
3185749|NCT01298492|Experimental|Open-Label Treatment|Subjects eligible for this study will have completed the 12 week double blind induction period in study A7281006 and will be stratified by responders or non responders based on change in CDAI in that study, without unblinding treatment assignment from study A7281006. Additionally, subjects who have completed study A7281008
3185750|NCT01298479||Group 1|All subjects
3185751|NCT01298466|Experimental|Pregabalin|Open label study. All patients fulfilling the protocol inclusion/exclusion criteria will receive pregabalin in a flexible-dosing regimen.
3185752|NCT01298401|Experimental|Arm A|Dose level -1A (Ganitumab 6 mg/kg, Capecitabine 825mg/m2)
3185753|NCT01298401|Experimental|Arm B|Dose level 1A (Ganitumab 12 mg/kg, Capecitabine 825mg/m2)
3185754|NCT01298401|Experimental|Arm C|Dose level 2A (Ganitumab 20 mg/kg, Capecitabine 825mg/m2)
3185755|NCT01298401|Experimental|Arm D|Dose level -1B (Ganitumab 6 mg/kg, Capecitabine 625mg/m2)
3185756|NCT01298401|Experimental|Arm E|Dose level 1B (Ganitumab 12 mg/kg, Capecitabine 625mg/m2)
3185757|NCT01298401|Experimental|Arm F|Dose level 2B (Ganitumab 20 mg/kg, Capecitabine 625mg/m2)
3185758|NCT01298362||AIs as first line therapy|Patients in postmenopausal status, with ER-positive early breast cancer, treated with an AI as first line therapy for 12 months.
3185759|NCT01298362||AIs after chemotherapy|Patients in postmenopausal status, with ER-positive early breast cancer, treated with an AI as maintenance therapy for 12 months after initial treatment with anthracycline- and/or taxane-based chemotherapy (chemotherapy treatment duration: 1-6 months).
3185760|NCT01298349||schizophrenic patients|
3185761|NCT01298349||normal population|
3185762|NCT01298336|Experimental|Clarithromycin|
3185763|NCT01298336|Experimental|Moxifloxacin|
3185764|NCT01298323|Active Comparator|Vandetanib Control|Control - treatment 300mg vandetanib opel label
3185765|NCT01298323|Experimental|Experimental|Experimental - treatment 300mg vandetanib opel label
3185766|NCT01298310|Active Comparator|Xylocaine_1mg|1 injection of Xylocaine (1 mg/mL)
3185767|NCT01298310|Active Comparator|Xylocaine_10mg|1 injection of Xylocaine (10 mg/mL)
3185768|NCT01298310|Placebo Comparator|Placebo|1 injection of placebo
3185769|NCT01298297|Active Comparator|Buprenorphine + Placebo|
3185770|NCT01298297|Placebo Comparator|Morphine + Placebo|
3185771|NCT01298284|No Intervention|EVL\GVS Alone|Endoscopic ligation treatment in the 2nd prevention of gastroesophageal variceal bleeding in patients with HCC
3185772|NCT01298284|Active Comparator|EVL\GVS Combined Propranolol|"Propranolol and endoscopic ligation treatment is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.~<EVL\GVS Combined Propranolol>"
3185773|NCT01298271|No Intervention|Cyanoacrylate|Endoscopic Cyanoacrylate Injection treatment of primary prevention GVB
3185774|NCT01298271|Active Comparator|Propranolol|Propranolol is used for primary prevention of GVB
3185775|NCT01298258|Placebo Comparator|placebo|control group
3185776|NCT01298258|Experimental|Aliskiren|Aliskiren 150 mh
3185777|NCT01298245||Case: diabetic retinopathy|Patients with diabetes who have received ophthalmic fundus examination within 6 months before the study and those with known positive results of diabetic retinopathy
3185778|NCT01298245||Control: no diabetic retinopathy|Patients with diabetes who have received ophthalmic fundus examination within 6 months before the study and those without known positive results of diabetic retinopathy
3185779|NCT01298232|No Intervention|EMAT-guided therapy|electromechanical activation time (EMAT, obtain by phonocardiogram, Audicor, USA)
3185780|NCT01298232|No Intervention|Symptomatic-guided therapy|HF therapy guided by clinical symptoms
3185781|NCT01298219|Experimental|2|
3185782|NCT01298219|Placebo Comparator|1|
3185783|NCT01298206||H1N1 not exposed controls|For every enrolled H1N1 case, the study will enroll 2 sex matched controls. On the date of enrollment of a case, 2 sex-matched controls will be located from the same clinic from which the case was enrolled. Enrolled controls will then be verified to be free from influenza infection at the time of enrollment by RT-PCR.
3185835|NCT01297803|Active Comparator|Mitomycin_c application after sclera flapdissection|
3187596|NCT01285479||prescribed fingolimod 0.5 mg/day|
3185784|NCT01298206||H1N1 exposed Cases|A swab will be collected from cases to verify presence of pandemic influenza. Testing positive for influenza A/H1N1 by RT PCR to be enrolled will be confirmed as a case. The participant will be presented with a questionnaire that will capture exposure data through a group of variables assessing underlying health conditions, symptoms, use of influenza vaccine, travel, occupational setting, and other demographic variables. Cases will be contacted once during the study.
3185785|NCT01298193|Experimental|Aprepitant|"Observational phase (first cycle):~Day 0 (Dexamethasone 8mg) Day 1 (5-HT3 antagonist, Ondansetron: 8 mg x2, Granisetron: 1mg x2,Tropisetron: 5 mg, Dexamethasone 24 mg).~• Chemotherapy: Docetaxel 75mg/m2 and Cyclophosphamide 600mg/m2 Days 2 and 3 (Dexamethasone 16 mg).~Efficacy phase (second cycle):~Day 0 (Dexamethasone 8mg) Day 1 (Aprepitant: 125 mg,5-HT3 antagonist, Ondansetron: 8 mg x2, Granisetron: 1mg x2, Tropisetron: 5 mg, Dexamethasone 12 mg).~Chemotherapy: Docetaxel 75mg/m2 and Cyclophosphamide 600mg/m2 Days 2 and 3 (Aprepitant: 1 capsule of 80 mg daily, Dexamethasone 8 mg)."
3185786|NCT01298180|Experimental|SPW|Children presenting a Prader-Willi Syndrome
3185787|NCT01298180|Experimental|GHD|Patient deficient in Growth Hormone
3185788|NCT01298180|Experimental|SPW-B|Patient with Prader-Willi Syndrome who has Biopsy
3185789|NCT01298180|Experimental|T|Patient Control
3185790|NCT01298180|Experimental|SPW-GH-B|Patient with Prader-Willi Syndrome taking growth Hormone and who has biopsy
3185791|NCT01298167|Active Comparator|Cyanoacrylate Superior/Inferior|This arm contains data from only the Cyanoacrylate used on superior ½ of wounds & inferior ½ of wounds in randomized patients to determine the impact of Cyanoacrylate tissue glue versus Fast Absorbing Gut suture.
3185792|NCT01298167|Active Comparator|Fast Absorbing Gut Suture Superior/Inferior|This arm contains data from only the Fast Absorbing Gut Suture used on superior ½ of wounds & inferior ½ of wounds in randomized patients to determine the impact of Cyanoacrylate tissue glue versus Fast absorbing gut suture.
3185793|NCT01298154|Experimental|Intact Pea Protein (20 g)|
3185794|NCT01298154|Experimental|Hydrolyzed Pea Protein (20 g)|
3185795|NCT01298154|Experimental|Intact Whey Protein|
3185796|NCT01298154|Experimental|Hydrolyzed Whey Protein|
3185797|NCT01298154|Experimental|Water|
3185798|NCT01298141|Experimental|Replagal®|All eligible patients may receive Replagal produced by the bioreactor process (AF Replagal) on this treatment plan until AF Replagal is commercially available for the patient, the patient's participation is discontinued, or the study is discontinued, whichever comes first.
3185799|NCT01298128|Experimental|NuvaRing|NuvaRing for IVF pre-treatment
3185800|NCT01298128|Active Comparator|Combined oral contraceptive pill|OCP for IVF pre-treatment
3185801|NCT01298115||Stage 5 chronic kidney disease|Incident patients commencing renal replacement therapy or conservative care
3185802|NCT01298102|Experimental|influenza vaccine|Pandemrix vaccine (Influenza A/H1N1 2009)to be injected to renal transplant patients, haemodialyzed patients, and controls
3185803|NCT01298076|Active Comparator|AVASTIN|intravitreal bevacizumab
3185804|NCT01298076|Active Comparator|OZURDEX|intravitreal dexamethasone
3185805|NCT01298063|Experimental|Afatinib Group A, B (2), D|healthy subjects, mild and moderate liver impaired subjects to receive one single dose treatment containing the highest dose afatinib
3185806|NCT01298063|Experimental|Afatinib Group B (3), D|healthy subjects, moderate liver impaired subjects to receive one single dose treatment containing the medium dose of afatinib
3185807|NCT01298063|Experimental|Afatinib Group B (1), D|healthy subjects, moderate liver impaired subjects to receive one single dose treatment containing the low dose of afatinib
3185808|NCT01298050||Extracorporeal Membrane Oxygenation|All patients have to start ECMO under CPR, by insertion of peripheral VA cannulas.
3185809|NCT01298024|Experimental|Early neuromusclar exercise|
3185810|NCT01298024|Active Comparator|Treatment as usual (late training)|
3185811|NCT01298011|Experimental|Gemcitabine & Abraxane Pancreatic Cancer|
3185812|NCT01297998|Experimental|gemcitabine , cisplatin|
3185813|NCT01297959|Experimental|E-101 Solution 300 GU/mL|
3185814|NCT01297959|Placebo Comparator|Saline solution|
3185815|NCT01297946|Placebo Comparator|Open-loop|Conventional continuous subcutaneous insulin infusion (CSII) therapy
3185816|NCT01297946|Experimental|Dual-hormone closed-loop|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. The infusion rates are based on continuous glucose sensor reading and a control algorithm.
3185817|NCT01297920|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 3 times a day for 3 months
3185818|NCT01297920|Active Comparator|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, 1 drop instilled in each eye 3 times a day for 3 months
3185819|NCT01297920|Active Comparator|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, 1 drop instilled in each eye 3 times a day for 3 months
3185820|NCT01297907||Crohn's Patients|Random Crohn's Disease Patients that can perform Methacholine Challenge Test (MCT)
3185821|NCT01297907||Negative MCT|Patients evaluated for functional cough who had negative Methacholine Challenge Test (MCT)
3185822|NCT01297894|Active Comparator|colistin|Colistimethate sodium 2.5-5mg/kg iv
3185823|NCT01297894|Active Comparator|colistin plus fosfomycin|colistimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
3185824|NCT01297881||Caucasian outpatients with respiratory symptoms|all consecutive new Caucasian outpatients with respiratory symptoms like dyspnoea, cough, sputum but without diagnosis who are being examined for the first time.
3185825|NCT01297868||exercise group|
3185826|NCT01297855|Active Comparator|Colistin|Colistate
3185827|NCT01297855|Experimental|Colistin plus Rifampicin|Colistate Rifampin
3185828|NCT01297842|Experimental|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
3185829|NCT01297842|Active Comparator|Meropenem or Imipenem|Meropenem or Imipenem o.5 or 1 gram 3 to 4 times a day for 7 to 14 days
3185830|NCT01297829|Active Comparator|IV Caldolor|
3185831|NCT01297829|Placebo Comparator|Placebo|
3185832|NCT01297816|Placebo Comparator|placebo|100mg-
3185833|NCT01297816|Placebo Comparator|minocyclin|
3185834|NCT01297803|Active Comparator|Mitomycin_c application before sclera flap dissection|
3185931|NCT01297088|Experimental|Arm 1|
3185836|NCT01297790||Asthma|Subjects with asthma more than 18 years old with minimal or no smoking history and evidence of bronchial hyperreactivity
3185837|NCT01297790||Chronic obstructive pulmonary disease|Subjects with diagnosis of COPD who must be ex smokers and have evidence of airflow obstruction on breathing tests.
3185838|NCT01297790||Healthy Volunteers|Healthy non smoking adults.
3185839|NCT01297790||Healthy smokers|Current smokers with normal breath tests (spirometry)
3185840|NCT01297790||Chronic cough|Subjects with idiopathic chronic cough.
3185841|NCT01297777|Experimental|Imatinib mesylate|Imatinib mesylate 300 or 400 mg daily for 12 months.
3185842|NCT01297764|Experimental|carfilzomib for MML|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone - This study will be conducted as an open-label Phase I/II, single-center study in which subjects will receive carfilzomib, lenalidomide, vorinostat and dexamethasone, for relapsed and/or refractory multiple myeloma. Study treatment will be administered in sequential cohorts, with 3-6 subjects in each cohort. Treatment will be administered in 28-day cycles, with the fourth week as a rest week, for 12 cycles or until disease progression or unacceptable toxicity develops.
3185843|NCT01297738|Experimental|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a liquid meal which is high in fat and sugar (Nutridrink®)
3185844|NCT01297738|Experimental|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume this caloric surplus with their meals, which results in an increase in meal size.
3185845|NCT01297738|Experimental|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a liquid meal which has a high fat and sugar content(Nutridrink®). Subjects consume the Nutridrink 3 times a day in between meals. which results in an increase in meal frequency.
3185846|NCT01297738|Experimental|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
3185847|NCT01297738|No Intervention|Control group|Subjects will not follow any diet but their own ad-libitum, healty diet.
3185848|NCT01297725|Experimental|Right sharp, left blunt|Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
3185849|NCT01297725|Experimental|Right blunt, left sharp|Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.
3185850|NCT01297712|Active Comparator|Hi Line|This arm is examined with latest generation HDTV colonoscopes
3185851|NCT01297712|No Intervention|Classic Line|control group undergoing colonoscopy with older generation scope currently in use in most centers
3185852|NCT01297699|Experimental|Tocilizumab|
3185853|NCT01297699|Placebo Comparator|Sterile 0.9% Sodium Chloride|
3185854|NCT01297686|Experimental|Exercise|Multi-element exercise protocol involving static and dynamic stretches, deep massage, and balance training.
3185855|NCT01297686|Active Comparator|Standard of Care|This arm will consist of a single injection of a corticosteroid, followed by stretching exercises for the calf.
3185856|NCT01297673||Spinal cord injury|Patients with neurogenic lower urinary tract dysfunction due to spinal cord injury with regular urodynamic examination
3185857|NCT01297660||patients with SCI for at least 5 years|Ages Eligibility: minimum 18 years Genders Eligibility: female and male
3185858|NCT01297647|Experimental|Spinal cord injured|Patients with neurogenic lower urinary tract infection (Spinal Cord Injury,MS,M. Parkinson)
3185859|NCT01297634|Other|Botulinum Toxin Type-A 1U|
3185860|NCT01297634|Other|Botulinum Toxin Type-A 2U|
3185861|NCT01297634|Other|Botulinum Toxin Type-A 3U|
3185862|NCT01297621|Experimental|Breast reduction|Breast hypertrophy women allocated to this arm will undergo reduction mammaplasty
3185863|NCT01297621|Other|Control|Patients in this arm will be assessed twice, without surgical intervention
3185864|NCT01297608|Experimental|treatment|
3185865|NCT01297608|Placebo Comparator|placebo|
3185866|NCT01297595|Experimental|crizotinib|
3185867|NCT01297582|Experimental|E|
3185868|NCT01297582|Placebo Comparator|P|
3185869|NCT01297569|Experimental|Ranibizumab|
3185870|NCT01297556|No Intervention|Control group|Patients in this group will receive conventional treatment for IBS, including anti-diarrhea agents, laxatives, bulking agents and anti-spasmodic.
3185871|NCT01297556|Experimental|Treatment|Patients in this group will receive conventional treatment for IBS, but in addition will receive 6 weeks of CBT
3185872|NCT01297543|Experimental|Consolidation Group A|Low dose CLT-008 (human myeloid progenitor cells)
3185873|NCT01297543|Experimental|Consolidation Group B|Intermediate dose CLT-008 (human myeloid progenitor cells)
3185874|NCT01297543|Experimental|Consolidation Group C|Intermediate dose CLT-008 (human myeloid progenitor cells), no G-CSF
3185875|NCT01297543|Experimental|Consolidation Group D|High dose CLT-008 (human myeloid progenitor cells)
3185876|NCT01297543|Active Comparator|Induction Group A1 (cytarabine 7+3)|G-CSF
3185877|NCT01297543|Experimental|Induction Group A2 (cytarabine 7+3)|Intermediate dose CLT-008 (human myeloid progenitor cells)
3185878|NCT01297543|Experimental|Induction Group A3 (cytarabine 7+3)|High dose CLT-008 (human myeloid progenitor cells)
3185879|NCT01297543|Active Comparator|Induction Group B1 (cytarabine HIDAC)|G-CSF
3185880|NCT01297543|Experimental|Induction Group B2 (cytarabine HIDAC)|Intermediate dose CLT-008 (human myeloid progenitor cells)
3185881|NCT01297543|Experimental|Induction Group B3 (cytarabine HIDAC)|High dose CLT-008 (human myeloid progenitor cells)
3185882|NCT01297530|Experimental|Arm 1|
3185883|NCT01297517|Experimental|Brinzolamide/Brimonidine|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, one drop instilled in each eye three times a day for 3 months
3185884|NCT01297517|Active Comparator|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, one drop instilled in each eye three times a day for 3 months
3185885|NCT01297517|Active Comparator|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, one drop instilled in each eye three times a day for 3 months
3186366|NCT01294072|Experimental|Arm 1: Curcumin alone|Subjects take curcumin orally.
3185886|NCT01297504||Palivizumab|Infants at risk for respiratory syncytial virus infection received palivizumab prescribed in accordance with the terms of the local marketing authorization.
3185887|NCT01297491|Experimental|Squamous BKM120 100mg qd|Diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease.
3185888|NCT01297491|Experimental|Non-Squamous BKM120 100mg qd|Diagnosed patients with non-squamous NSCLC that progressed after one or two prior antineoplastic therapy lines for metastatic disease.
3185889|NCT01297465|Active Comparator|Gonal-f® Plus Pergoveris®|
3185890|NCT01297465|Experimental|Pergoveris®|
3185891|NCT01297452|Experimental|BKM120 (days 1 - 21) + paclitaxel + carboplatin|This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered with paclitaxel + carboplatin on both a 21-day cycle with growth factor support (Group 1)
3185892|NCT01297452|Experimental|BKM120 (days 1 - 28, ) + paclitaxel + carboplatin|This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered + paclitaxel with carboplatin on a 28-day cycle with growth factor support and a 28-day cycle (Group 2).
3185893|NCT01297452|Experimental|BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)|EXPANSION COHORT A BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT A.
3185894|NCT01297452|Experimental|BKM120 (days 1 - 21) + paclitaxel + carboplatin exp B|Expansion Cohort B will be restricted to patients with tumors known to harbor PTEN mutation or homozygous deletion. The regimen in Expansion Cohort B will be the same regimen established in Group 1 of the protocol, with BKM120 (now called buparlisib) at 100 mg/day per oral + paclitaxel (175 mg/m2) + carboplatin (AUC 5), both given intravenously (IV) on day 1 of a 21-day cycle
3185895|NCT01297439|Other|group M|"Normal delivery without pushing maneuver suctioning of fetal nose and mouth during delivery"
3185896|NCT01297439|Experimental|group C|"Pushing maneuver on the fetal head"
3185897|NCT01297426||Group 1|Lean and obese, diabetic and non diabetics
3185898|NCT01297413|Experimental|Stem cells|All subjects will receive allogeneic adult mesenchymal bone marrow stem cells
3185899|NCT01297400|Experimental|MEBO Wound Ointment (MEBO)|
3185900|NCT01297400|Active Comparator|Standard of care|
3185901|NCT01297387||Revascularization of limb ischemia|Procedure/Surgery
3185902|NCT01297374|Experimental|dietetic counseling|
3185903|NCT01297374|Experimental|physical activities|
3185904|NCT01297374|Experimental|Lifestyle counseling|
3185905|NCT01297361|Other|Plasma Vitamin B12 and Folic acid levels|Blood sample was drawn
3185906|NCT01297348||Lybrel®|Current users of 90 ug levonorgestrel / 20 ug ethinyl estradiol - cases and controls (i.e., women diagnosed with new venus thromboembolism [VTE] and women not diagnosed with VTE).
3185907|NCT01297348||Other OCs containing 20μg of ethinyl estradiol|Current users of oral contraceptives containing 20μg of ethinyl estradiol - cases and controls (i.e. women diagnosed with new VTE and women not diagnosed with VTE)
3185908|NCT01297335|Experimental|Intrathecal Clonidine|Subject will receive one time Clonidine injection via lower lumber interspace. Clonidine (Duraclon), 100 μg/ml, 1.5 ml will be diluted to 2 ml with preservative free saline, and total of 150 μg will be delivered. Supine and sitting blood pressures and heart rate will be measured at 10 minute intervals until 60 minutes after clonidine administration, then at 15 minutes for next 3 hours.
3185909|NCT01297322|Active Comparator|Manual compression|
3185910|NCT01297322|Experimental|VASCADE™ Vascular Closure System|
3185911|NCT01297309|Experimental|NPSP558|titration of 25, 50, 75 or 100 μg
3185912|NCT01297283|Experimental|Leadless ECG first|Measurement of pacing thresholds are done first with the support of a leadless ECG provided by the implanted device
3185913|NCT01297283|Active Comparator|Programmer ECG first|Measurements of pacing thresholds are done first with the support of the programmer ECG
3185914|NCT01297270|Active Comparator|PegIFN/RBV|48 weeks
3185915|NCT01297270|Experimental|BI 201335 for 24 weeks|BI 201 335 QD dosing in combination with IFN/RBV
3185916|NCT01297270|Experimental|BI201335 for 12 weeks|BI 201335 QD doing in combination with PEFG IFN/RBV
3185917|NCT01297270|Placebo Comparator|Placebo|
3185918|NCT01297244|Experimental|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
3185919|NCT01297231||Breast cancer|This prospective study will recruit patients with stage 0-3 breast cancer who have had or are scheduled for a breast MRI prior to treatment.
3185920|NCT01297218|Experimental|NEUROSTEM®-AD|
3185921|NCT01297205|Experimental|PNEUMOSTEM®|
3185922|NCT01297192|Other|Treatment Arm 1|The effect of mirabegron on the pharmacokinetics of solifenacin
3185923|NCT01297192|Other|Treatment Arm 2|The effect of solifenacin on the pharmacokinetics of mirabegron
3185924|NCT01297166|Experimental|LEO 27989 ointment|
3185925|NCT01297153|Active Comparator|Aphakia|"The patient is randomly assigned for aphakia / pseudophakia. This is done only after vitrectomy. If it is aphakia,IOL will not be implanted.Aphakia will be corrected with aphakic glasses / contact lenses. Bilateral aphakes are given both contact lenses and glasses. So when they do not wear contact lenses they can put on aphakic glasses. Unilateral aphakes are given only contact lenses. Contact lenses should be fitted in the eye in OT immediately after the operation.~Aphakic glasses :~Prescribed within 2 weeks of surgery for both eyes."
3185926|NCT01297153|Active Comparator|Pseudophakia|The patient is randomly assigned for aphakia / pseudophakia. This is done only after vitrectomy. Hydrophobic Acrysof IOL is implanted.All pseudophakic children will be refracted and given the residual correction within a month of surgery.
3185927|NCT01297140|Experimental|questionary|
3185928|NCT01297127||Cohort|
3185929|NCT01297114||Participants aged 60-70|Participants age 60-70 will receive Florbetaben PET tracer to identify presence of amyloid burden.
3185930|NCT01297114||Participants aged 20-30|Younger participants will not undergo PET scanning that will be studied with other methods.
3185932|NCT01297075|Experimental|Outreach visits|Practices allocated to outreach visits may receive up to three outreach visits in order to motivate and support general practice clinics in implementing two chronic care programmes for chronic obstructive Pulmonary disease and Type 2 diabetes.
3185933|NCT01297075|No Intervention|Control (late intervention)|These practices are allocated to outreach visits after the initial evaluation stops at 12 months.
3185934|NCT01297062|Experimental|Exenatide|
3185935|NCT01297062|Placebo Comparator|Placebo|
3185936|NCT01297062|Active Comparator|Moxifloxacin|
3185937|NCT01297049|Experimental|Lifestyle counseling|
3185938|NCT01297036|Active Comparator|Reference arm|Treated with Reference (Aricept, 10 mg donepezil tablet)
3185939|NCT01297036|Experimental|Test arm|Treated with Test (Neuropezil, 10 donepezil ODT, orally disintegrating tablet)
3185940|NCT01297023|Experimental|calcium phosphate|
3185941|NCT01297023|Experimental|vitamin d|
3185942|NCT01297023|Experimental|calcium phosphate and vitamin d|
3185943|NCT01297023|Placebo Comparator|placebo|
3185944|NCT01297010|Placebo Comparator|Dexamethasone|Children randomized to this group received a 10 ml syringe containing dexamethasone (0.15 mg / kg) at the beginning of the procedure.
3185945|NCT01297010|Placebo Comparator|Dexamethasone and ondasetron|Children randomized to this group received a 10 ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling) and ondansetron (0.1 mg / kg dose of 4mg ceiling)at the beginning of the procedure.
3185946|NCT01296997|Experimental|calcium phosphate|
3185947|NCT01296997|Placebo Comparator|placebo|
3185948|NCT01296984||Extralevator APR|The perineal part of the APR is done with the intent to create a cylindrically shaped specimen thus removing part of or the entire levator muscle with the specimen.
3185949|NCT01296984||Traditional APR|The perineal part of the APR is performed with the intent to remove the tumour with CRM free of tumour and the levator left in place.
3185950|NCT01296971|Experimental|A|genotype 1, treatment-naive
3185951|NCT01296971|Experimental|B|genotype 2 and 3, treatment-naive
3185952|NCT01296971|Experimental|C|all genotypes, non-responders or relapses
3185953|NCT01296958|Experimental|Targeted screening|Screening for intestinal tapeworm carrier followed by treatment with niclosamide as indicated.
3185954|NCT01296958|Active Comparator|Education|Community education about Taenia solium prevention.
3185955|NCT01296945|Active Comparator|Kiosk|
3185956|NCT01296945|Active Comparator|Paper|
3185957|NCT01296945|Active Comparator|Kiosk PLUS paper|
3185958|NCT01296945|Active Comparator|kiosk PLUS web|
3185959|NCT01296932|Experimental|Patients with relapsed CLL|Patients with relapsed CLL after at least two prior treatment regimens will receive BI 836826.
3185960|NCT01296919||Sinus drainage|Adult patients with chronic rhinosinusitis who failed treatment with antibiotics and topical corticosteroids and underwent endoscopic sinus surgery. Preoperative evaluation included paranasal sinus CT scans. The diagnosis was confirmed by endoscopic examination showing purulent and/or mucopurulent discharge in the middle and/or superior meatus.
3185961|NCT01296906|Experimental|Population-based Reminder/Recall|Recall is performed centrally by public health departments for all children in need of immunizations in a geographic area.
3185962|NCT01296906|Experimental|Practice-based Reminder/Recall|Reminder/Recall is performed by individual private practices for their patients who appear in need of immunizations.
3185963|NCT01296893|No Intervention|Delayed exercise control|Participants asked to maintain usual lifestyle and provided with abbreviated version of intervention upon completion of end of study testing.
3185964|NCT01296893|Experimental|Exercise|Aerobic exercise Intervention as per below
3185965|NCT01296880||LCM group|Patients who are having lacosamide (LCM) added to their anti-epileptic drug regimen
3185966|NCT01296880||control group|Patients who are NOT having lacosamide (LCM) added to their anti-epileptic drug regimen
3185967|NCT01296854|No Intervention|Standard|The patients randomized into this arm of the study will not have spa therapy.
3185968|NCT01296854|Experimental|Spa Therapy|The patients randomized into this arm of the study will have 3 weeks of spa therapy
3185969|NCT01296841|No Intervention|Standard encounter|"Standard in-house clinical visit between patient and physician."
3185970|NCT01296841|Experimental|Telemedicine Encounter|Remote clinical appointment between patient and physician.
3185971|NCT01296828||MOUTH BREATHING CHILDREN|
3185972|NCT01296815|No Intervention|HAART|Patients received antiretroviral treatment according to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
3185973|NCT01296815|Experimental|HAART+ Bevacizumab injection|Patients received antiretroviral treatment according to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Patients received 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) in the target lesion every 2 weeks. Bevacizumab was injected using an insulin syringe in a submucosal plane. The volume injected was based on the size of the target lesion; the dose was 0.2 mL (5 mg) per cm2.
3185974|NCT01296802|Placebo Comparator|Placebo|
3185975|NCT01296802|Experimental|Dexfenfluramine|Dexfenfluramine HCL
3185976|NCT01296789|Active Comparator|Tissue perfusion guided protocol|Active comparator group, where parameters of tissue perfusion are used to guide hemodynamic therapy
3185977|NCT01296789|Other|Usual Care|Usual Care
3185978|NCT01296776|Active Comparator|whole-body electromyostimulation|20 min of whole-body electromyostimulation with sequences of 6 sec of current and 4 sec at 85 Hz performed during low-intensity/low amplitude movements. 3 sessions / 14 days for 12 months
3185979|NCT01296776|Placebo Comparator|wellness control group|Low intensity, low frequency exercise that focus on well being. 1 session/week for 10 weeks. 10 blocks of exercise with intermittent periods of 100 weeks of rest
3186012|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 as Single Agent|Participants (Cohorts A, B, C, D, G, H, T, T2, and X) will receive GDC-0032 until disease progression.
3186013|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 + Midazolam|Participants (Cohort C) will receive GDC-0032 in combination with midazolam.
3186100|NCT01295918|Placebo Comparator|L. reuteri, Antibiotic, diarrhoea|L. reuteri will be ingested by patients on antibiotic therapy, effect of probiotic on AAD will be assessed.
3185980|NCT01296763|Experimental|Irinotecan, Cisplatin, Olaparib, then add Mitomycin-C|A 3+3 dose escalation design will be used starting with dose 1. The maximally tolerated dose is defined as the highest dose for which at most 1 out of 6 patients experiences a DLT. We will use 3 patients per dose cohort. If 0 of 3 patients have a DLT (see section 5a) then the escalation will be continued at the next dose level. If 1 of 3 patients have a DLT then three more patients will be enrolled at this dose. If 1 of 6 patients has a DLT then the dose escalation will continue. If 2 or more of the first 3 patients, or >2 of 6 patients treated have a DLT at the dose level, we will reduce the dose to the previous dose level of Olaparib for the phase 2 and then test Mitomycin C (phase 1 dose 5). If DLTs are observed at our dose 1 regimen, we will reduce the duration of Olaparib from day 1 and day 8 to just day 1 (dose level -1) and we will not test Mitomycin C in the trial.
3185981|NCT01296750|Active Comparator|Early Physiotherapy|Physiotherapy to begin within 1 day post op.
3185982|NCT01296750|No Intervention|Late Physiotherapy|Physiotherapy to start 6 weeks post op
3185983|NCT01296724|Other|newborn with digestive pathology|Preterm or term newborn admitted in paediatric intensive care unit with an urethral catheter and digestive pathology
3185984|NCT01296724|Other|Newborn without digestive pathology|Preterm or term newborn admitted in paediatric intensive care unit with an urethral catheter and without digestive pathology
3185985|NCT01296711|Experimental|CDP6038|
3185986|NCT01296698|Placebo Comparator|Placebo|0 mg Oral NRT, up to 4 times per hour for 12 weeks
3185987|NCT01296698|Experimental|Nicotine|1 mg Oral NRT, up to 4 times per hour for 12 weeks
3185988|NCT01296685||oxygenator with arterial filter|
3185989|NCT01296685||arterial filter|
3185990|NCT01296672|Experimental|Finasteride|Finasteride 5mg tablets every day by mouth for 3 months
3185991|NCT01296672|Placebo Comparator|Placebo|Placebo 5mg tablet every day by mouth for 3 months
3185992|NCT01296659|Experimental|AIM Arm|Ridaforolimus combined with doxorubicin/ifosfamide/mesma (AIM)
3185993|NCT01296659|Experimental|TG Arm|Ridaforolimus combined with docetaxel and gemcitabine (TG)
3185994|NCT01296646|Active Comparator|Arm 1|Sweet Liker, High Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions
3185995|NCT01296646|Active Comparator|Arm 2|Sweet Liker - Low Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions
3185996|NCT01296646|Active Comparator|Arm 3|Sweet Disliker - High Craver. Half of this group will be on naltrexone the other half will be on Placebo. All subjects will receive Brenda Therapy Sessions
3185997|NCT01296646|Active Comparator|Arm 4|Sweet Disliker - Low Craver; half of this group will be on naltrexone the other half on placebo. All subjects will receive Brenda Therapy Sessions
3185998|NCT01296633|Experimental|Medtable|The Medtable is a patient education tool used for collaborative planning. The Medtable focuses patients on how to take their medication and prompts them to anchor this task to familiar routines. The tool serves as an external workspace that helps provider and patient jointly visualize how to integrate constraints from medications (e.g., which can be taken together; dose spacing) and patients' routine (e.g., typical meal times) in order to create an optimal daily schedule. The completed Medtable shows providers how patients are thinking about taking their medications, allowing them to clear up any confusion. It encourages teach-back and teach-to-goal strategies recommended for patients with low health literacy. Completing the Medtable helps patients implement as well as create plans by encouraging them to think about when and where they will actually take their medication. It also provides a template developed with their providers that could help patients load pill organizers at home.
3185999|NCT01296633|Active Comparator|Usual care|Patients in the usual care condition at both research sites will receive the medication counseling and communication that is standard of care at these sites. This includes a medication reconciliation process, where patients are given a card with list of medications that is periodically checked. This provides an opportunity for providers to correct patient knowledge of their medications, and is similar to the process of creating a list for the Medtable. However, the Medtable also encourages patients and providers to collaborate in order to organize this list in terms of the patient's routine to create a patient-specific, concrete plan for taking the medications.
3186000|NCT01296620|Experimental|Experimental 1|
3186001|NCT01296620|Experimental|Experimental 2|
3186002|NCT01296620|Placebo Comparator|Placebo|
3186003|NCT01296607|Other|Urocortin 2|This arm studies the onset/ offset of action and the reproducibility of effect on forearm blood flow of of intra-arterial Urocortin 2 in the presence and absence of a saline washout between incremental doses.
3186004|NCT01296607|Other|Urocortin 3|This arm studies the onset/ offset of action and the reproducibility of effect on forearm blood flow of of intra-arterial Urocortin 3 in the presence and absence of a saline washout between incremental doses.
3186005|NCT01296594|Active Comparator|Usual Care|
3186006|NCT01296594|Experimental|usual care with cell phone monitoring and CM|In the CM condition, patients will carry a cell phone and record and send in time- and date-stamped self videos of medication ingestion.
3186007|NCT01296581|Experimental|X-82|
3186008|NCT01296568|Experimental|LY2603618|"Single 250 mg intravenous dose of LY2603618 containing [14C] LY2603618.~After the completion of a minimum 7 day wash out period, patients may receive additional doses of LY2603618 in combination as follows:~Gemcitabine 1000 mg/m2 on Days 1, 8, and 15 with 230 mg LY2603618 being administered on days 2, 9 and 16 of a 28-day cycle OR~Pemetrexed 500 mg/m2 on day 1 and 275 mg LY2603618 on day 2 of a 21-day cycle~Patients will be allowed to continue to receive the combination therapy until fulfilling one of the criteria for discontinuation, such as unacceptable toxicity or disease progression."
3186009|NCT01296555|Experimental|Phase I, Stage 1: GDC-0032 as Single Agent|Participants with locally advanced or metastatic solid tumors will receive increasing doses of GDC-0032 administered orally daily in 28-day cycles. Dose escalation decisions will be based upon the observed incidence of DLTs.
3186010|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 + Fulvestrant|Participants (Cohorts F, J, K, L, and M) will receive GDC-0032 in combination with fulvestrant until disease progression.
3186011|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 + Letrozole|Participants (Cohorts E, N, P, Q, R, and S) will receive GDC-0032 in combination with letrozole until disease progression.
3186098|NCT01295931|Experimental|IC-Green + Imaging|Indocyanine Green (IC-Green) Injections + Imaging
3186014|NCT01296555|Experimental|Phase II: GDC-0032 + Fulvestrant|Post-menopausal females with locally advanced or metastatic HER2-negative, hormone receptor-positive breast cancer will receive GDC-0032 in combination with fulvestrant until disease progression.
3186015|NCT01296542||VIGAMOX|Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection
3186016|NCT01296542||Besivance|Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection
3186017|NCT01296529||HIV monoinfection|Evidence should include a copy of a laboratory report of testing positive for HIV antibodies and/or HIV viral RNA, and a negative antibody test for HCV
3186018|NCT01296529||HCV monoinfection|Evidence should include a copy of a laboratory report of testing positive for HCV antibodies and HCV viral RNA, and a negative antibody test for HIV
3186019|NCT01296529||HIV and HCV coinfection|Evidence should include a copy of a laboratory report of testing positive for HIV or HIV viral RNA, and positive tests for HCV antibodies and HCV RNA.
3186020|NCT01296529||HIV/HCV coinfection with HCV clearance|Evidence should include a copy of a laboratory report of testing positive for HIV or HIV viral RNA, a positive tests for HCV antibodies, and undetectable HCV RNA without hepatitis C treatment (spontaneous clearance) or >6 months after hepatitis therapy (sustained virologic response)
3186021|NCT01296516|Placebo Comparator|Control Group|A group matched for age and BMI will be selected to serve as control subjects in this study.
3186022|NCT01296516|Active Comparator|Face-to-face group|Participants randomized to the face-to-face intervention will attend motivational meetings held once per week in Phase I and biweekly in Phase II. Behavioral sessions will be led by a trained interventionist and will take place at Pennington Biomedical Research Center.
3186023|NCT01296516|Active Comparator|Telehealth Group|Participants randomized to the Telehealth intervention will receive behavioral counseling through Trestletree, phone system.
3186024|NCT01296503|Active Comparator|Dexamethasone (Arm A)|Sixty days (D+60) after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days)
3186025|NCT01296503|Experimental|Thalidomide and Dexamethasone (Arm B)|"D+60 after ASCT: dexamethasone plus thalidomide 200 mg by mouth daily for 12 months or until disease progression.~The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event."
3186026|NCT01296490|Experimental|Stress test|The men will run on a treadmill for 10 minutes until exhaustion. Blood will be drawn before, 5 minutes after and an hour after the test.
3186027|NCT01296477||Asthma IQ Primary Care Tool|
3186028|NCT01296477||Usual Asthma Care in Primary Care|
3186029|NCT01296464|Experimental|Stalevo|levodopa/carbidopa/entacapone
3186030|NCT01296464|Placebo Comparator|Placebo|
3186031|NCT01296451|Experimental|Arm A, group1|Intervention: MVA-NSmut. Administration schedule: 1 dose MVA-NSmut 2 x 10^8 pfu. Subjects: 4 healthy volunteers
3186032|NCT01296451|Experimental|Arm A, group 2|"Interventions: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.~Subjects: 10 healthy volunteers"
3186033|NCT01296451|Experimental|Arm B, group 1|"Interventions: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 14 and 1 dose MVA-NSmut 2 x 10^8pfu at week 22, after starting PEG-IFN and ribavirin therapy.~Subjects: 5 patients"
3186034|NCT01296451|Experimental|Arm B, group 2|"Interventions: AdCh3NSmut; MVA-NSmut.. Administration schedule: 1 dose AdCh3NSmut 2.5 x 1010vp at week 2 and 1 dose MVA-NSmut 2 x 108pfu at week 10, after starting PEG-IFN and ribavirin therapy.~Subjects: 5 patients"
3186035|NCT01296451|Experimental|Arm C, group 1|"Interventions: AdCh3NSmut; MVA-NSmut Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 0 and 1 dose MVA-NSmut 2 x 10^8pfu at week 8.~Subjects: 4 patients"
3186036|NCT01296451|Experimental|Arm A, group 3|"Interventions: AdCh3NSmut; MVA-NSmut Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 0, 1 dose MVA-NSmut 2 x 10^8pfu at week 8, 1 dose AdCh3NSmut 2.5 x 10^10vp at week 16 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 24.~Subjects: 5 healthy volunteers"
3186037|NCT01296451|Experimental|Arm A, group 4|"Intervention: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp (at least 6 months after they were initially enrolled) and 1 dose MVA-NSmut 2 x 10^8 pfu 8 weeks later.~Subjects: up to 5 healthy volunteers who were previously in group A2"
3186038|NCT01296451|Experimental|Experimental: Arm A, group5|"Intervention: AdCh3NSmut1. MVA-NSmut. Administration schedule:1 dose AdCh3NSmut1 2.5 x 10^10vp at week 0, 1 dose MVA-NSmut 2 x 10^8 pfu at week 8 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 40.~Subjects: 5 healthy volunteers"
3186039|NCT01296451|Experimental|Arm A, group 6|"Interventions: AdCh3NSmut1. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^7 pfu at week 8.~Subjects: 5 healthy volunteers"
3186040|NCT01296451|Experimental|Arm A, group 7|"Interventions: AdCh3NSmut1; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^6 pfu at week 8.~Subjects: 5 healthy volunteers"
3186041|NCT01296438|Experimental|Treatment sequence 1|
3186042|NCT01296438|Active Comparator|Treatment sequence 2|
3186043|NCT01296412|Experimental|Sitagliptin +/- glimepiride|Sitagliptin 100 mg tablet orally once daily for 26 weeks. Participants continued their stable dose of metformin >=1500 mg orally daily. Participants may have received glimepiride orally for glycemic control.
3186044|NCT01296412|Active Comparator|Liraglutide|Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin >=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.
3186045|NCT01296399||Bare metal stent|patients, with a patent previously deployed intra coronary bare metal stent, receiving intra coronary bare metal stent, for de-novo stenosis
3186046|NCT01296399||Drug eluting stent|patients, with a patent previously deployed intra coronary bare metal stent, receiving intra coronary drug eluting stent, for de-novo stenosis
3186047|NCT01296386|Experimental|IC84, 75 µg w/ Alum|75 µg w/ Alum (microgram with Alum)
3186048|NCT01296386|Experimental|IC84, 75 µg w/o Alum|75 µg w/o Alum (microgram without Alum)
3186049|NCT01296386|Experimental|IC84, 200 µg w/ Alum|200 µg w/ Alum (microgram with Alum)
3186050|NCT01296386|Experimental|IC84, 200 µg w/o Alum|200 µg w/o Alum (microgram without Alum)
3186051|NCT01296373||HIV-1-infected, off ART|HIV-1-infected, antiretroviral naive or off antiretroviral therapy for at least 12 months with CD4+ T-cell counts less than or equal to 350 cells/µL who are about to commence combination antiretroviral therapy
3186052|NCT01296360|Active Comparator|>14 months to <2 years|IXIARO 0.25 ml i.m. (milliliter, intramuscular)
3186053|NCT01296360|Active Comparator|>3 years - <18 years|IXIARO 0.5 ml i.m (milliliter, intramuscular)
3186054|NCT01296347|No Intervention|Saline|Patients will receive a placebo infusion of 0.9% sodium chloride, which will start 10 minutes prior to the start of the operation and continue for 96 hours.
3186055|NCT01296347|Experimental|ketamine|Patients will receive intravenous ketamine, starting 10 minutes prior to surgery and will continue for 96 hours
3186056|NCT01296334|Experimental|morphine low dose|morphine infusion 10 mg over a 210 min period
3186057|NCT01296334|Experimental|morphine high dose|morphine infusion 20 mg over a 210 min period
3186058|NCT01296334|Experimental|buprenorphine low dose|buprenorphine infusion 0.3 mg over a 210 min period
3186059|NCT01296334|Experimental|buprenorphine high dose|buprenorphine infusion 0.6 mg over a 210 min period
3186060|NCT01296334|Placebo Comparator|placebo|placebo (normal saline) infusion 0.6 mg over a 210 min period
3186061|NCT01296321|Experimental|Tailored Internet-delivered CBT|Behavioral: Tailored Internet-delivered CBT
3186062|NCT01296321|Active Comparator|Waitlist|Waitlist.
3186063|NCT01296308||type 2 diabetics with neuropathy|
3186064|NCT01296295|Experimental|Spirometry and lifestyle counseling|Intervention group: The intervention is to give brief structured smoking cessation advice combined with a detailed and structured discussion of the spirometric results.
3186065|NCT01296295|No Intervention|Lifestyle counseling|No intervention group: the patients of the control group will receive a brief structured smoking cessation advice.
3186066|NCT01296282||Heart failure patients|
3186067|NCT01296269|Experimental|Vasopressin|vasopressin condition
3186068|NCT01296269|Experimental|oxytocin|oxytocin condition (syntocinon)
3186069|NCT01296269|Placebo Comparator|placebo|
3186070|NCT01296256|Experimental|Bendamustine-EAM|
3186071|NCT01296243|Experimental|Tesetaxel once every 3 weeks|
3186072|NCT01296230|Experimental|Hormone/semen measurements before and after varicocelectomy|We will measure sex-hormone and semen quality in patients both before and after varicocelectomy. The purpose is to asses if preoperative hormone levels are predictive for who will have improved semen quality after surgery.
3186073|NCT01296217|Experimental|lymph nod detection|
3186074|NCT01296204|Experimental|BB4 antibody-Iodine 131|
3186075|NCT01296191|Active Comparator|VIGAMOX|Subjects undergoing cataract surgery, randomized to the VIGAMOX group
3186076|NCT01296191|Active Comparator|Besivance|Subjects scheduled for cataract surgery, randomized to the Besivance group
3186077|NCT01296165||Travellers visiting India|People that are older than 18 years and planning to visit India for a period of at least 5 days will be approached by the personal at the travel clinics to participate in the study. Informed consent will be obtained prior to enrolling subjects.
3186078|NCT01296152|Experimental|Depo-medroxyprogesterone acetate (DMPA)|At study entry/ Day 0, subjects will receive depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
3186079|NCT01296139|Experimental|A|All subjects will receive 7.5 mg/kg Fe
3186080|NCT01296113|Experimental|A|
3186081|NCT01296100|Experimental|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
3186082|NCT01296100|Experimental|Lifestyle counseling (physical activity)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
3186083|NCT01296087|Experimental|TC-6987|
3186084|NCT01296087|Placebo Comparator|Placebo|
3186085|NCT01296074|Experimental|Corticosteroid|Methylprednisolone will be given during cardiopulmonary bypass.
3186086|NCT01296061||Failed Kidney Transplant|Adults ≥ 18 years, initiating chronic dialysis
3186087|NCT01296048||Body Analysis|
3186088|NCT01296035|Experimental|Panitumumab and Gemcitabine|Panitumumab and Gemcitabine
3186089|NCT01296022|Active Comparator|Subcutaneous ICD|Subcutaneous Implantable Cardioverter Defibrillator
3186090|NCT01296022|Active Comparator|Transvenous ICD|Transvenous Implantable Cardioverter Defibrillator
3186091|NCT01296009|Experimental|traditional Chinese medicine|The pregnancy rate in traditional Chinese medicine group is higher than the control group
3186092|NCT01295970|Active Comparator|Radiosurgery (SRS)|
3186093|NCT01295970|Active Comparator|Surgery|
3186094|NCT01295957|Active Comparator|reminiscence therapy, story telling|24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. Refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography. Three main variables contributed to successful reminiscing: individuality, evaluation and structure.
3186095|NCT01295957|Placebo Comparator|comparison|control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, but they didn't participate in reminiscence sessions to rule out the possibility that improvement in quality of life was due only to attention received and social stimulation.
3186096|NCT01295957|No Intervention|control|control group was administered counseling and informal social contacts in bi-weekly sessions of one hour,
3186097|NCT01295944|Experimental|1|The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued, but bevacizubab may be continued at the descretion of the treating physician.
3186099|NCT01295918|No Intervention|Placebo, antibiotic, diarrhea|
3186101|NCT01295905|Experimental|delefilcon A|Investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for 3 months.
3186102|NCT01295905|Active Comparator|narafilcon B|Commercially marketed contact lenses worn in both eyes on a daily wear, daily disposable basis for 3 months.
3186103|NCT01295892|Placebo Comparator|placebo|placebo (transdermal gel)
3186104|NCT01295892|Experimental|Estrogen|1mg of 17B-estradiol/day (transdermal gel)
3186105|NCT01295879|Experimental|Ergocalciferol|Subjects will take Ergocalciferol (vitamin D), 50,000 IU's orally per week for 8 weeks
3186106|NCT01295866||nasal nitric oxide, atypy status|
3186107|NCT01295853|Active Comparator|t3 sympathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
3186108|NCT01295853|Active Comparator|t4 sypathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
3186109|NCT01295840|No Intervention|CRT therapy|Cardiac Resynchronization Therapy Defibrillator (CRT-D)
3186110|NCT01295827|Experimental|Part A: Pembrolizumab 1 mg/kg (Closed)|Participants receive pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of each cycle, at dose of 1 mg/kg
3186111|NCT01295827|Experimental|Part A: Pembrolizumab 3 mg/kg (Closed)|Participants receive pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of each cycle, at dose of 3 mg/kg
3186112|NCT01295827|Experimental|Part A: Pembrolizumab 10 mg/kg (Closed)|Participants receive pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of each cycle, at dose of 1 mg/kg
3186113|NCT01295827|Experimental|Part B: Pembrolizumab MEL (Closed)|Participants receive pembrolizumab IV infusion over 30 minutes on Day 1 of each cycle.
3186114|NCT01295827|Experimental|Part C: Pembrolizumab NSCLC (Closed)|Participants receive pembrolizumab IV infusion over 30 minutes on Day 1 of each cycle
3186115|NCT01295827|Experimental|Part D: Pembrolizumab MEL Low Dose (Closed)|participants receive pembrolizumab IV infusion over 30 minutes every 3 weeks at dose determined during dose escalation
3186116|NCT01295827|Experimental|Part D: Pembrolizumab MEL High Dose (Closed)|Participants receive pembrolizumab IV infusion over 30 minutes every 3 weeks at dose determined during dose escalation
3186117|NCT01295827|Experimental|Part E: Pembrolizumab NSCLC Low Dose (Closed)|Participants receive pembrolizumab IV infusion over 30 minutes every 3 weeks at dose determined during dose escalation
3186118|NCT01295827|Experimental|Part E: Pembrolizumab NSCLC Med. Dose (Closed)|Participants receive pembrolizumab IV infusion over 30 minutes every 3 weeks at dose determined during dose escalation
3186119|NCT01295827|Experimental|Part E: Pembrolizumab NSCLC High Dose (Closed)|Participants receive pembrolizumab IV infusion over 30 minutes every 3 weeks at dose determined during dose escalation
3186120|NCT01295827|Experimental|Part F: Pembrolizumab NSCLC PD-L1 Low Dose (Closed)|Participants receive pembrolizumab IV infusion over 30 minutes every 3 weeks at dose determined during dose escalation. All participants were changed over to a 200 mg fixed dose of pembrolizumab IV every 3 weeks based on analysis of safety and efficacy data.
3186121|NCT01295827|Experimental|Part F: Pembrolizumab NSCLC PD-L1 High Dose (Closed)|Participants receive pembrolizumab IV infusion over 30 minutes every 2 or 3 weeks at dose determined during dose escalation. All participants were changed over to a 200 mg fixed dose of pembrolizumab IV every 3 weeks based on analysis of safety and efficacy data.
3186122|NCT01295814|Experimental|adalimumab|Adalimumab 80mg subcutaneous loading dose followed by 40 mg subcutaneous every 2 weeks for 12 weeks
3186123|NCT01295814|Placebo Comparator|Inactive drug|Placebo in identical syringe subcutaneous every 2 weeks for 12 weeks
3186124|NCT01295801||Linezolid+vitamin B6|
3186125|NCT01295801||Linezolid|
3186126|NCT01295788|Experimental|Simultaneous RT-CGM and Pump Initiation|The experimental group will initiate RT-CGM at the same time as they begin insulin pump therapy.
3186127|NCT01295788|Active Comparator|Delayed RT-CGM Initiation|The control group will use standard pump therapy until the 6 month study visit at which time RT-CGM will be initiated.
3186128|NCT01295775|Active Comparator|Sulodexide group|50 mg of sulodexide a day will be administered by oral route (1+1 capsule/day) for 360 days
3186129|NCT01295775|Placebo Comparator|Placebo group|Sulodexide placebo will be administered at the same schedule (1+1 capsule/day) and for the same lengths of time (for 360 days) as Sulodexide group
3186130|NCT01295762|Other|Type of neuroblastoma|Neonatal stages I Localized immediately resectable stages Localized immediately unresectable stages High-risk neuroblastoma Relapsed neuroblastoma
3186131|NCT01295749|Active Comparator|ventilation by laryngeal tube|ventilation by laryngeal tube and continuous chest compression
3186132|NCT01295749|Sham Comparator|ventilation by bag valve mask|ventilation by bag valve mask and interrupted chest compression
3186133|NCT01295736|Active Comparator|Actif arm|Sildenafil 20mg TID during 90 days
3186134|NCT01295736|Placebo Comparator|Sugar pill|Placebo pills TID during 90 days
3186135|NCT01295723|Experimental|Intraoperative Electron Radiation Therapy|A single dose of electron irradiation given at the surgical site during the operation to remove the cancerous tumor will replace the usual 5-8 days of localized radiation. Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days post operatively.
3186136|NCT01295710|Active Comparator|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-12 hours 3 days prior to transplantation
3186137|NCT01295710|Placebo Comparator|Placebo|250 mL normal saline, IV infusion over 6-12 hours 3 days prior to transplantation
3186138|NCT01295697|Experimental|EZN-2208|Cytotoxic Agent
3186189|NCT01295333|Experimental|experimental approach|early and systematic traitment
3186139|NCT01295684|Placebo Comparator|placebo|Base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage.
3186140|NCT01295684|Experimental|Cranberry Juice|Base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day.
3186141|NCT01295671|Active Comparator|Sugar-Sweetened Beverages|Provision of beverages: Sugar-sweetened beverages
3186142|NCT01295671|Experimental|Artificially-sweetened Beverages|Provision of beverages: Artificially-sweetened beverages
3186143|NCT01295671|Experimental|Unsweetened Beverages|Provision of beverages: Unsweetened beverages
3186144|NCT01295658||Cancer Survivors|"This is a broad observational study conducted online at www.cancerexperienceregistry.org, or via pen and paper survey obtained by calling the cancer support helpline at 888-793-9355~Any individual who has ever received a cancer diagnosis, regardless of disease type, stage, treatment, and time since diagnosis, can take part in this study."
3186145|NCT01295645|Experimental|Standard of Care + Cidofovir|Cidofovir 0.5 mg/kg IV 3 x week for 4 weeks
3186146|NCT01295645|Active Comparator|No Cidofovir|Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
3186147|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-2206 90 mg|
3186148|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-2206 135 mg|
3186149|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 90 mg|
3186150|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 135 mg|
3186151|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 200 mg|
3186152|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-2206 135 mg|
3186153|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-2206 200 mg|
3186154|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
3186155|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
3186156|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
3186157|NCT01295619|Experimental|I-020805|This was a prospective, open, multi-center, single-arm study to investigate I-020805 in patients following elective cranial surgery. If they met the inclusion/ exclusion criteria, they receive I-020805 after suturing of the dura. If necessary, autologous grafts were to be used to augment dural closure.
3186158|NCT01295606|No Intervention|Cefazolin, antibiotic prophylaxis|All included patients will received iv cefazolin
3186159|NCT01295593|Experimental|valproic acid combined with CdA|valproic acid, oral daily intake, combined with 2-chlorodeoxyadenosine administered intravenously for 4 cycles
3186160|NCT01295580|Active Comparator|Hyaluronic acid, stabilized|
3186161|NCT01295580|Active Comparator|Hyaluronic acid|
3186162|NCT01295567|Placebo Comparator|placebo|
3186163|NCT01295567|Experimental|dipyridamole|
3186164|NCT01295554||Peripheral arterial disease|Peripheral arterial disease
3186165|NCT01295541||4 months of observation|CVICU
3186166|NCT01295528||Blood Pressure, Heart Rate, Monitor|
3186167|NCT01295515|Experimental|1|Interferon treatment
3186168|NCT01295502|Experimental|Treatment (radiation, cisplatin, paclitaxel, carboplatin)|Patients receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 and undergo extended-field radiotherapy daily 5 days a week for 6 weeks followed by brachytherapy. Beginning 4-6 weeks after completion of chemoradiation, patients receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3186169|NCT01295489||Group A (IP catheter removed)|Archival formalin-fixed, paraffin-embedded tumor (collected during previous surgery), peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolation) samples are collected before course one and blood (for cell, plasma, and serum isolations) is collected before courses two and three for translational research.
3186170|NCT01295489||Group B (IP catheter in place)|Archival formalin-fixed, paraffin-embedded tumor (collected during previous surgery), peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolation) samples are collected before course one and peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolations) before courses two and three for translational research.
3186171|NCT01295450|Active Comparator|Vitamin Complex|A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
3186172|NCT01295450|Experimental|Apevinat BC|"Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily."
3186173|NCT01295437|Active Comparator|Vypro II mesh|A partly absorbable polypropylene-polyglactin mesh (50g/m2).
3186174|NCT01295437|Active Comparator|Premilene LP|A lightweight polypropylene mesh (55 g/m2)
3186175|NCT01295437|Placebo Comparator|Premilene mesh|A conventional polypropylene mesh (82 g/m2)
3186176|NCT01295424||Single group study|
3186177|NCT01295411|Other|schizophrenia PATIENTS|
3186178|NCT01295398|Other|conventional jet-nebulizer|(particles diameter of 4-5 µm)
3186179|NCT01295398|Experimental|a jet-nebulizer adapted for infants|(particles diameter of 2-2.5 µm),
3186180|NCT01295398|Experimental|a mesh-nebulizer adapted for infants|(particles diameter of 2-2.5 µm).
3186181|NCT01295385|Experimental|healthy volunteers|
3186182|NCT01295385|Active Comparator|patients with a diabetic cardiomyopathy|
3186183|NCT01295372|Experimental|Zicronapine|
3186184|NCT01295372|Active Comparator|Risperidone|
3186185|NCT01295359|Experimental|Trained Group|This group will receive the usual care of the hospital and a ground walking training program associated with respiratory exercises.
3186186|NCT01295359|No Intervention|Usual Care Group|This group will only receive the usual care of the hospital, including physical therapy
3186187|NCT01295346||Traumatic Brain Injury|Patients who present to the health care facility with mild or moderate traumatic brain injury (Glasgow Coma Scale 9-15) within 4 hours of injury
3186188|NCT01295333|Other|conventional approach|conventional traitment
3186190|NCT01295320|Experimental|GSK1437173A Group|Subjects who received 2 doses of HZ vaccine in the intermediate dose study group in study 108494 (NCT00434577). No treatment was given in this current study (NCT01295320).
3186191|NCT01295307|Experimental|Single Arm|Induction therapy with clofarabine/cytarabine. Post-remission therapy with either allogeneic HCT after conditioning with clofarabine/melphalan if a donor is available, or clofarabine/cytarabine if no donor is available
3186192|NCT01295294|Experimental|tranexamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive treatments with tranexamic acid
3186193|NCT01295294|Experimental|mefenamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive treatments with mefenamic acid
3186194|NCT01295294|Placebo Comparator|placebo + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive placebo
3186195|NCT01295281|Experimental|LoFric POBE 2.0 - PVC|First period (7 days) use of LoFric POBE 2.0 followed by second period (7 days) use of LoFric PVC
3186196|NCT01295281|Experimental|LoFric PVC - POBE 2.0|First period (7 days) use of LoFric PVC followed by second period (7 days) use of LoFric POBE 2.0.
3186197|NCT01295268|Active Comparator|Emu Oil|
3186198|NCT01295268|Placebo Comparator|inert oil|
3186199|NCT01295229|Active Comparator|Lifestyle Intervention|
3186200|NCT01295229|Active Comparator|Surgery|
3186201|NCT01295216|Experimental|Intervention|Pre-hypertensive subjects who receive mHealth support for 12 months
3186202|NCT01295216|No Intervention|Control|Individuals who receive the usual primary health care
3186203|NCT01295203|No Intervention|Control group|The control group were not given access to the intervention website and received no additional information.
3186204|NCT01295190||Propofol|Patients receiving Propofol during cardiopulmonary bypass.
3186205|NCT01295190||Sevoflurane|Patients receiving sevoflurane during cardiopulmonary bypass
3186206|NCT01295177|Placebo Comparator|vehicle cream|Intervention: Placebo cream vehicle. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream (cream with the same constitution but without insulin). The placebo cream vehicle was used for 8 weeks.
3186207|NCT01295177|Placebo Comparator|cream insulin|Intervention: insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with insulin cream (cream with the same constitution but with insulin). The insulin cream was used for 8 weeks.
3186208|NCT01295164|Active Comparator|Group 1|Measurement of aberrations in patients with keratoconus of grade 1
3186209|NCT01295164|Active Comparator|Group 2|patients with keratoconus of grade 2
3186210|NCT01295164|Experimental|Group 3|patients with keratoconus of grade 3
3186211|NCT01295164|Experimental|Group 4|patients with keratoconus of grade 4
3186212|NCT01295151|Experimental|TNF-blocking drug|
3186213|NCT01295151|Experimental|Abatacept|
3186214|NCT01295151|Active Comparator|Rituximab|
3186215|NCT01295138|Experimental|Lactulose group|Group receives 48 hours of lactulose post Caesarean section.
3186216|NCT01295138|No Intervention|Non-lactulose group|Group receives no lactulose post Caesarean section.
3186217|NCT01295125|Experimental|XenMATRIX|Use of XenMATRIX mesh to repair hernia
3186218|NCT01295125|Active Comparator|Native tissue|Repair with participants native tissue
3186219|NCT01295112|Sham Comparator|Group 1|Active bevacizumab (Avastin®) and Sham Ozurdex®
3186220|NCT01295112|Active Comparator|Group 2|Active bevacizumab (Avastin®) and Active Ozurdex®
3186221|NCT01295099|Active Comparator|5-Fluorouracil|Patients with small keloidal scars to have intralesional 5FU injected
3186222|NCT01295099|Active Comparator|Radiotherapy|Large keloid scars undergo extralesional excision and radiotherapy
3186223|NCT01295099|Active Comparator|TAC|
3186224|NCT01295086|Experimental|Her-TEX|
3186225|NCT01295073|Active Comparator|A|Oral Trientine 1500mg x 1 week before cataract surgery and 3 days post surgery
3186226|NCT01295073|Placebo Comparator|B|Oral Placebo x 1 week before cataract surgery and 3 days post surgery
3186227|NCT01295060|Experimental|Octreotide Implant|
3186228|NCT01295047|Active Comparator|ATENOLOL|ATENOLOL 75MG FOR 4 WEEKS
3186229|NCT01295047|Active Comparator|VERAPAMIL|240MG VERAPAML FOR 4 WEEKS
3186230|NCT01295047|Active Comparator|PERINDOPRIL|4MG PERINDOPRIL FOR 4 WEEKS
3186231|NCT01295034|Placebo Comparator|conventional vitamin D treatment|Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
3186232|NCT01295034|Experimental|tiered/titrated vitamin D dosing|Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
3186233|NCT01295008||Patients with the classic form|
3186234|NCT01295008||Fabry disease and healthy controls|
3186235|NCT01294995|Experimental|Tea-flavor Liquor, taken with meal|including 12 males and 11 females
3186236|NCT01294995|Placebo Comparator|Guizhou Meijiao Liquor, taken with meal|including 11 males and 11 females
3186237|NCT01294982|Experimental|1.6 g AOBO-001 Group|AOBO-001 400 mg Oral Capsules
3186238|NCT01294982|Experimental|3.2 g AOBO-001 Group|AOBO-001 400 mg Oral Capsules
3186239|NCT01294982|Placebo Comparator|Placebo|Matching Placebo Capsules
3186240|NCT01294969|Experimental|AL-4943A|One drop per day in both eyes
3186241|NCT01294956|Experimental|FID 115958D|Lubricant Eye Drop
3186242|NCT01294956|Active Comparator|Refresh Liquigel|Lubricant Eye Drop
3186243|NCT01294943||Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
3186244|NCT01294930||hip fracture|Patients operated for hip fracture, giving informed consent
3186245|NCT01294917|Experimental|Investigational MPS|AMO Investigational MPS.
3186246|NCT01294917|Active Comparator|Clear Care|Peroxide-based lens care regimen.
3186247|NCT01294917|Active Comparator|Opti-Free RepleniSH|Multi-purpose disinfecting solution (Alcon).
3186248|NCT01294904||renal transplant patients|Patients undergoing transplantation
3186419|NCT01293643|Experimental|clindamycin/ketoconazole combination|
3186249|NCT01294904||dialysis patients|hemodialysis patients and peritoneal dialysis patients. Before and after a dialysis session
3186250|NCT01294904||patients with renal insufficiency|outpatient patients with chronic kidney disease stage 2, 3 and 4
3186251|NCT01294904||Chronic kidney disease|outpatient cohort. Those with mild renal insufficiency
3186252|NCT01294891||Control|Age matched healthy subjects
3186253|NCT01294891||Sickle Cell Patients|Patients with established SCD
3186254|NCT01294891||Paroxysmal Nocturnal Hemoglobinuria patients|Patients with PNH
3186255|NCT01294878|Experimental|treatment with omalizumab|Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used
3186256|NCT01294865||septic|Infants having clinical suspected late-onset neonatal sepsis enrolled in the study. Blood samples for suPAR were obtained before initiating antibiotic treatment and at the end of the treatment with other laboratory tests.
3186257|NCT01294865||non-septic|Infants without any clinical or hematological septic signs. Blood samples will be taken only once.
3186258|NCT01294852|Experimental|immediate bolus surfactant|
3186259|NCT01294852|Experimental|post-resuscitation surfactant|
3186260|NCT01294839|Experimental|RVOTs|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in RVOTs arm, the RV lead of this group patients will be implanted in right ventricular outflow tract septum,the accumulated ventricular pacing percentage should be over 80% by adjusting AV delays.
3186261|NCT01294839|Experimental|AAI|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in AAI arm, the RV lead of this group patients will be implanted in right ventricular apex.
3186262|NCT01294839|Active Comparator|RVA|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in RVA arm, the RV lead of this group patients will be implanted in right ventricular apex, the accumulated ventricular pacing percentage should be over 80% by adjusting AV delays.
3186263|NCT01294826|Experimental|AUY922 plus Cetuximab|
3186264|NCT01294813|Experimental|Bronchoscopy-EIT|Patients who routinely undergo bronchoscopy will be measured by EIT directly before, directly after and 10, 30, 60 minutes after bronchoscopy with a rubber belt which is placed around their chest. The EIT measurements will take 1-2 minutes; the total examination will last 1.5 hours.
3186265|NCT01294800|Experimental|Preladenant 2 mg|Participants will receive preladenant 2 mg taken orally twice daily (BID), one tablet in the morning and one tablet in the evening, for 12 weeks.
3186266|NCT01294800|Experimental|Preladenant 5 mg|Participants will receive preladenant 5 mg taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
3186267|NCT01294800|Experimental|Preladenant 10 mg|Participants will receive preladenant 10 mg taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
3186268|NCT01294800|Placebo Comparator|Placebo|Participants will receive a placebo to preladenant tablet taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
3186269|NCT01294787|Experimental|indacaterol and glycopyrronium bromide (QVA149)|QVA149 delivered once daily via single-dose dry powder inhaler.
3186270|NCT01294787|Placebo Comparator|placebo|Placebo, delivered once daily via single-dose dry powder inhaler.
3186271|NCT01294787|Active Comparator|tiotropium|Tiotropium delivered once daily via HandiHaler® device.
3186272|NCT01294774|Experimental|KRP203 - 1.2 mg|
3186273|NCT01294774|Placebo Comparator|Placebo to KRP203 - 1.2 mg|
3186274|NCT01294761|Experimental|Raltegravir, Darunavir/r|"An arm to change the regimen from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD~to: Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID"
3186275|NCT01294761|No Intervention|Tenofovir, Emtricitabine, Lopinavir/r|An arm continuing on the same regimen before the randomization as Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD
3186276|NCT01294748|Experimental|MiStent DES|The MiStent SES is a sirolimus-eluting absorbable polymer stent for coronary artery revascularization.
3186277|NCT01294748|Active Comparator|Endeavor DES|The Endeavor DES is an everolimus-eluting durable polymer stent for coronary artery revascularization.
3186278|NCT01294735|Experimental|Part A, MK-4827 + temozolomide dose escalation cohort|
3186279|NCT01294735|Experimental|Part B, MK-4827 + temozolomide melanoma cohort|
3186280|NCT01294735|Experimental|Part B, MK-4827 + temozolomide glioblastoma multiforme cohort|
3186281|NCT01294709|Experimental|Telcagepant/ Placebo|Participants receive single oral dose of 600 mg (two 300 mg capsules or two bioequivalent 280 mg tablets) or 900 mg telcagepant (three 300 mg capsules) in Period 1 and single oral dose of two capsules or tablets of placebo for telcagepant (or three capsules of placebo for telcagepant) in Period 2 of the crossover. Each treatment period is separated by a washout of 96-240 hours.
3186282|NCT01294709|Experimental|Placebo/Telcagepant|Participants receive single oral dose of two capsules or tablets of placebo for telcagepant (or three capsules of placebo for telcagepant) in Period 1 and a single oral dose of 600 mg (two 300 mg capsules or two bioequivalent 280 mg tablets) or 900 mg telcagepant (three 300 mg capsules) in Period 2 of the crossover. Each treatment period is separated by a washout of 96-240 hours.
3186283|NCT01294696||All Enrolled Participants|All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
3186284|NCT01294683|Experimental|Sequence 1: MK-0524B 2g/40g→MK-0524A 2g + Simvastatin 40 mg|After a 2-week placebo run-in, participants received extended release (ER) niacin/laropiprant (N/LRPT) 1 g/20 mg combination tablet (MK-0524B) once daily for 4 weeks, then ERN/LRPT/Simvastatin (SIM) 2 g/40 mg combination tablet once daily for 8 weeks. Participants then received ERN/LRPT 2 g (MK-0524A) co-administered with SIM 40 mg once daily for 8 weeks.
3186285|NCT01294683|Experimental|Sequence 2: MK-0524A 2g + Simvastatin 40 mg→ MK-0524B 2g/40g|After a 2-week placebo run-in, participants received ERN/LRPT 1 g (MK-0524A) co-administered with SIM 20 mg once daily for 4 weeks then received ERN/LRPT 2 g (MK-0524A) co-administered with SIM 40 mg once daily for 8 weeks. Participants then received ERN/LRPT/SIM 2 g/40 mg combination tablets (MK-0524B) once daily for 8 weeks.
3186286|NCT01294670|Experimental|Vorinostat and Etoposide|This is a multi-center, open label, phase I/II trial of escalating doses of vorinostat in combination with etoposide.
3186287|NCT01294657||HE Group|Health Education [HE] - Counseling, referrals to resources + self-help materials; 2 HE interventions at Baseline + 6 month visits.
3186288|NCT01294657||MAPS Group|Motivation And Problem Solving (MAPS) - HE + 12 telephone counseling sessions over 1-year period (average 1 call/month).
3186289|NCT01294644|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3186290|NCT01294644|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3186291|NCT01294644|Experimental|Deoxycholic Acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3186292|NCT01294631|Experimental|001|"Canagliflozin 300 mg once daily and HCTZ 25 mg once daily Period 1: canagliflozin tablets oral 300 mg once daily on Days 1 to 7 followed 14 days later by Period 2.~Period 2: HCTZ tablets oral 25 mg once daily for Days 1 to 28 followed by canagliflozin tablets oral 300 mg once daily taken with HCTZ tablets oral 25 mg once daily on Days 29 to 35.."
3186293|NCT01294618|Experimental|nilotinib + pegylated interferon alpha 2a (PEG-IFN).|
3186294|NCT01294605|Experimental|Group A|
3186295|NCT01294605|Experimental|Group B|
3186296|NCT01294605|Active Comparator|Group C|
3186297|NCT01294592|Active Comparator|Dutasteride plus tamsulosin|Dutasteride plus tamsulosin arm + lifestyle advice
3186298|NCT01294592|Experimental|Watchful waiting with escalation to tamsulosin|Watchful waiting with escalation to tamsulosin
3186299|NCT01294579|Experimental|ofatumumab and bendamustine|"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase and 1000 mg IV every 2 months for 2 years.~Bendamustine 90 mg/m2 was given on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)"
3186300|NCT01294566|Experimental|Cohort 1|GSK1322888 (1 mg, 2 mg, 5 mg, 10 mg; 6 subjects) and Placebo (32 subjects)
3186301|NCT01294566|Experimental|Cohort 2|GSK1322888 (20 mg, 40 mg, 80 mg, and dose to be determined; 6 subjects) and Placebot (2 subjects)
3186302|NCT01294553||rosiglitazone/metformin group|Korean subjects who are administered rosiglitazone/metformin according to the prescription information
3186303|NCT01294540|Experimental|Experimental: 1|
3186304|NCT01294540|Placebo Comparator|Placebo Comparator: 2|
3186305|NCT01294527|Experimental|Implant|Implant of the WiCS-LV system
3186306|NCT01294514||Healthy Volunteers|Healthy volunteers ASA Class 1
3186307|NCT01294501|Experimental|Fever assessment and management|Medication administration educational module for low literacy subjects on how to administer common medications appropriately and safely.
3186308|NCT01294488|Experimental|Phone Consultation|Therapists receive phone consultation for 6 months during the course of the project.
3186309|NCT01294488|Experimental|Remote Real-Time Consultation|Therapists receive consultation for 6 months via polycommunication technology.
3186310|NCT01294475|Experimental|Cell Phone Enhanced Parent Training|Cell phones will be provided to mothers participating in Planned Activities Training.
3186311|NCT01294462|Experimental|1|Ticagrelor (AZD6140)
3186312|NCT01294462|Active Comparator|2|Clopidogrel
3186313|NCT01294449||MADIT-CRT ICD|
3186314|NCT01294449||MADIT-CRT CRT-D|
3186315|NCT01294436|Experimental|Open label treatment|
3186316|NCT01294423|Experimental|1|Dapagliflozin 5 mg
3186317|NCT01294423|Experimental|2|Dapagliflozin 10 mg
3186318|NCT01294423|Placebo Comparator|3|
3186319|NCT01294410|Experimental|Cohort 1: Induction|Placebo or Anti-IP-10 Antibody
3186320|NCT01294410|Experimental|Cohort 2: Induction|Placebo or Anti-IP-10 Antibody
3186321|NCT01294410|Experimental|Cohort 3: Induction|Placebo or Anti-IP-10 Antibody
3186322|NCT01294410|Experimental|Maintenance|Placebo or Anti-IP-10 Antibody
3186323|NCT01294410|Other|Open Label|
3186324|NCT01294397|Experimental|Etanercept + Denosumab|Participants received etanercept 50 mg subcutaneously once weekly for 25 weeks. On study day 8, participants were administered a single 60 mg subcutaneous injection of denosumab.
3186325|NCT01294384|Experimental|New Eye Drop Formulation 1|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.
3186326|NCT01294384|Experimental|New Eye Drop Formulation 2|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.
3186327|NCT01294384|Active Comparator|Refresh Tears®|1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
3186328|NCT01294371||Leuprorelin|"Patients with genital endometriosis received leuprorelin (Lucrin Depot®) in accordance with the respective marketing authorization/manufacturer's directions. All participants received leuprorelin for up to 6 months intramuscularly at a dose of 3.75 mg once a month. If intramuscular administration was not possible, leuprorelin was injected subcutaneously at a dose of 3.75 mg once a month. The first injection was to be carried out on the 3rd day of a menstrual period.~Accepted options for add-back therapy included: monophasic combined low-dose products for hormonal replacement therapy; combined oral contraceptives; and, if use of hormones was not possible, phytoestrogens with calcium products."
3186329|NCT01294358|Experimental|1|gemcitabine dose escalation
3186330|NCT01294345||personalized genomics|genetic/genomic syndromes
3186331|NCT01294319|Experimental|Sedentary young adults, SMCP|Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone
3186332|NCT01294319|Experimental|Endurance-trained young athletes, SMCP|Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone
3186333|NCT01294319|Experimental|Sedentary young adults, MSPC|Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone
3186334|NCT01294319|Experimental|Endurance-trained young athletes, MSPC|Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone
3186335|NCT01294319|Experimental|Sedentary young adults, CPSM|Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone
3186336|NCT01294319|Experimental|Endurance-trained young athletes, CPSM|Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone
3186337|NCT01294319|Experimental|Sedentary young adults,PCMS|Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone
3186338|NCT01294319|Experimental|Endurance-trained young athletes,PCMS|Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone
3186339|NCT01294306|Experimental|Treatment (Akt inhibitor MK2206, erlotinib hydrochloride)|Patients receive Akt inhibitor MK2206 PO QOD of a 28-day course, and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3186340|NCT01294293|Experimental|Treatment (TLR8 agonist VTX-2337, PLD, and Paclitaxel)|Patients receive TLR8 agonist VTX-2337 SC on days 3, 10, and 17 and pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 or TLR8 agonist VTX-2337 SC on days 1, 8, and 15 and paclitaxel IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3186341|NCT01294280||Ancillary-Correlative (IHC)|Previously collected tissue samples are analyzed by IHC.
3186342|NCT01294267|Other|Circulatory Support System|Percutaneous use of left ventricular assist device, Impella 2.5 Circulatory Support System to facilitate mapping and ablation of ongoing VT by maintaining near-normal hemodynamics, reducing myocardial workload and preservice organ perfusion.
3186343|NCT01294254|Experimental|experimantal: wound site will be treated with Oleogel-S10|"The patients will be randomised in a ratio of 1:1 with regard to the part of the skin graft donor site that is treated with Oleogel-S10.~Arm A: application of Oleogel-S10 towards the periphery of the body, i.e. the lower part of the leg~Arm B: application of Oleogel-S10 towards the centre part of the body, i.e. the upper part of the leg~Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)~Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site"
3186344|NCT01294254|Active Comparator|Moist wound healing dressing alone|Treatment with moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site
3186345|NCT01294241|Experimental|Oleogel-S10|The eligible wound (half) was topically treated with Oleogel-S10 and covered with a non-adhesive wound dressing (Mepilex®) on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
3186346|NCT01294241|Other|Non-adhesive wound dressing|Mepilex® soft silicone faced polyurethane foam dressing was used as non-active comparator. The eligible wound (half) was covered with Mepilex® as control on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
3186347|NCT01294215|Experimental|Arm 1|
3186348|NCT01294202|Experimental|AT13387 and imatinib|AT13387 administered on days 1, 8 and 15, imatinib administered daily
3186349|NCT01294189||ICU-patients that died on the ICU|ICU-patients (post-operative and non operative patients) will be enrolled in the study. All patients are followed until their death on the ICU.
3186350|NCT01294176|Active Comparator|Oral Lipoic Acid|Lipoic acid is a natural antioxidant available as an oral dietary supplement. A higher than average dose of 1200mg will be administered in this trial.
3186351|NCT01294176|Placebo Comparator|Avicel™|The placebo is Avicel™ (microcellulose crystal) and 4.3 mg quercetin (a bioflavanoid).
3186352|NCT01294163|Experimental|Xenon|
3186353|NCT01294163|Active Comparator|Sevoflurane|
3186354|NCT01294163|Active Comparator|Total intravenous anaesthesia|
3186355|NCT01294150|Active Comparator|UroLift System|The treatment group subjects underwent the UroLift system procedure. The subject was blinded to his randomization into control or treatment group. Unblinding will occurred at 3 months post procedure after the assessments were completed. Between 3 and 12 month follow-up assessments, a subject was allowed to retreat with the UroLift system if he met the retreatment inclusion and exclusion criteria. Subjects that went on to UL retreatment within the first 12 months started their follow-up schedule over and were considered treatment failures. All UL subjects will be followed a minimum of 5 years.
3186356|NCT01294150|Sham Comparator|Cystoscopy|The control group subjects underwent a cystoscopy procedure. The subject was blinded to his randomization into the control or treatment group. Unblinding will occurred at 3 months post procedure, after follow-up assessments were completed. Between 3 and 12 month follow-up assessments, a subject was allowed to crossover and undergo a UL procedure if he met crossover inclusion and exclusion criteria. Subjects crossing over will then be followed for 5 years post-treatment. The subject can also be treated by other approved therapies, or receive no treatment at all, which would require participation through 12 months.
3186357|NCT01294150|Active Comparator|Crossover|Between 3 and 12 month follow-up assessments, a subject was allowed to crossover and undergo a UL procedure if he met crossover inclusion and exclusion criteria. Subjects crossing over will then be followed for 5 years post-treatment. The subject can also be treated by other approved therapies, or receive no treatment at all, which would require participation through 12 months.
3186358|NCT01294137|Active Comparator|ventilatory polygraphy|
3186359|NCT01294124||No Tinnitus|The absence of tinnitus will be based on the participants' responses to questions 8a, 9c, and 9d of the Post-Deployment Health Assessment (PDHA).
3186360|NCT01294124||Tinnitus|The presence of tinnitus will be based on the participants' responses to questions 8a, 9c, and 9d of the Post-Deployment Health Assessment (PDHA).
3186361|NCT01294111|Experimental|Tai Chi training|Participation in a group of 15 patients, completing a 60 minutes tai chi training programme twice-weekly for 16 weeks.
3186362|NCT01294111|No Intervention|Control|Living as usual, following ordinary care plans and personal activities. Participants will be called to hospital for data collection. Participants are asked not to start any of the activities Tai Chi, Qui Gong or Yoga during the study period.
3186363|NCT01294098|No Intervention|PCA only|this group will only get a pain control anesthesia pump to use for post-operative pain
3186364|NCT01294098|Experimental|PCA and femoral nerve block|this group will be receiving a femoral nerve block during surgery and have a PCA post-operatively
3186365|NCT01294098|Experimental|PCA + hematoma block|patient will receive hematoma block during surgery
3186367|NCT01294072|Experimental|Arm 2: Curcumin with plant exosomes|Subjects take curcumin conjugated with plant exosomes.
3186368|NCT01294072|Experimental|Arm 3: no treatment|
3186369|NCT01294059|Placebo Comparator|Sugar pill|One sugar pill twice daily over 6 weeks
3186370|NCT01294059|Active Comparator|Milnacipran|Milnacipran 50 mg bid over 6 weeks
3186371|NCT01294046|Experimental|Deep brain stimulation of SPG for migraine|Electrical SPG for Treatment of Migraine
3186372|NCT01294033|Placebo Comparator|Fractional inspired oxygen 0.21|Cardiopulmonary exercise test performed by subject on Fractional inspired oxygen 0.21
3186373|NCT01294033|Active Comparator|Fractional inspired oxygen 0.28|Cardiopulmonary exercise test performed on supplemental oxygen (Fractional inspired oxygen 0.28)
3186374|NCT01294020|Experimental|Tacrolimus Prolonged Release|Participants receive tacrolimus prolonged release once daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus prolonged release once daily up to end of Part B of the study.
3186375|NCT01294007|Experimental|Study Graft Composite|
3186376|NCT01294007|Active Comparator|Control Graft Composite|
3186377|NCT01293981||Lumbar Degenerative Disc Disease|
3186378|NCT01293968|Experimental|5cc Ibuprofen100mg,10 cc Diphenhydramine25mg,10 cc AlMgS550mg|
3186379|NCT01293968|Active Comparator|100 cc Diphenhydramine, 25 mg and 100 cc AlMgS 550 mg|
3186380|NCT01293955|Experimental|JOINS 200mg|One tablet of JOINS 200mg is administered three times a day for 1 year. The subjects who consent to participate in an extension study are treated with JOINS 200mg for another 1 year.
3186381|NCT01293955|Placebo Comparator|Placebo|One tablet of Placebo is administered three times a day for 1 year. The subjects who consent to participate in an extension study are treated with Placebo for another 1 year.
3186382|NCT01293942|Experimental|IXO+A|IXO regimen with Avastin
3186383|NCT01293929||Non- obese group|
3186384|NCT01293929||Obese group|
3186385|NCT01293916|Active Comparator|Double leg spica cast|The current accepted treatment is the double leg spica cast in the treatment of pediatric diaphyseal femur fractures.
3186386|NCT01293916|Experimental|Single leg spica casts|The study group is the single leg spica cast group
3186387|NCT01293903|Experimental|Qiliqiangxin capsule|
3186388|NCT01293903|Placebo Comparator|Placebo|
3186389|NCT01293890||COPD patients with hospital admission for exacerbation|
3186390|NCT01293877|Other|LGP|Patient underwent surgery for morbid obesity treatment between 18 to 60 years, and BMI of 40 ore more will divided in two groups, one hundred will be schedule for laparoscopic gastric plication. Our theory for this arm is that the procedure can offer the same results than the second arm with less cost and safety, reversibility included.
3186391|NCT01293877|Other|LSG|The patients in a total of one hundred will be schedule for laparoscopic sleeve gastrectomy. The is our control for development of the study.
3186392|NCT01293825|Experimental|Medication Adherence Bipolar Disorder|There was only one group in this study. All participants received the study drug Ziprasidone.
3186393|NCT01293812|Experimental|sucrose po|"88% sucrose solution (Syrup B.P.). The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution."
3186394|NCT01293812|Placebo Comparator|placebo po|"The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
3186395|NCT01293799|Experimental|The follow-up group|The intervention in the follow-up group consists of regular tests of the patients´ theoretical and practical skills regarding peritoneal dialysis. The test goals should be passed. If not, retraining will be given if needed til the goals are reached. The peritonitis rate in this group will be compared with that of the control group.
3186396|NCT01293799|No Intervention|Control group|Patients randomised to the control group will be treated according to the routines of the clinic.
3186397|NCT01293786||Kidney transplant recipients|
3186398|NCT01293786||Chronic kidney disease|
3186399|NCT01293773|Active Comparator|Taxus Element|Patients treated with paclitaxel-eluting stent (Taxus Element, Boston Scientific, MN)
3186400|NCT01293773|Active Comparator|Xience Prime|Patients treated with Everolimus-eluting stent (Xience Prime, Abbott, IL)
3186401|NCT01293773|Active Comparator|Integrity Resolute|Patients treated with ABT 578-eluting stent (Integrity Resolute, Medtronic, MA)
3186402|NCT01293760|Other|6 weeks interval insertion|IUD is inserted 6 weeks following c-section delivery of baby and placenta
3186403|NCT01293760|Experimental|Immediate insertion|IUD is inserted immediately following c-section delivery of baby and placenta
3186404|NCT01293747|Experimental|Estradiol 0.5 mg/Progesterone 15 mg microspheres|Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension
3186405|NCT01293747|Experimental|Estradiol 1 mg/Progesterone 20 mg microspheres|Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension
3186406|NCT01293734|Experimental|cold type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in cold type
3186407|NCT01293734|Experimental|heat type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in heat type.
3186408|NCT01293734|Experimental|Asthenia type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in Asthenia type.
3186409|NCT01293734|Active Comparator|Western medicine control group|
3186410|NCT01293721|No Intervention|control|
3186411|NCT01293721|Experimental|Treatment|Receive vibration therapy
3186412|NCT01293708||80+ year olds|All 80+ year old that had had an ICU stay of >=24 hrs.
3186413|NCT01293695|Active Comparator|Hypnosis|Receives 5 weeks of hypnotic relaxation therapy
3186414|NCT01293695|Placebo Comparator|Structured Attention|Meets with therapist for five weekly sessions, but receives no hypnotic relaxation therapy
3186415|NCT01293682|Experimental|Calcitriol|Calcitriol 45mcg/week
3186416|NCT01293669|Experimental|TC-6987|
3186417|NCT01293669|Placebo Comparator|Placebo|
3186418|NCT01293656||CD and UC participants|All participants with CD or UC visiting their physician over a period of one year, newly and already diagnosed, regardless of treatment pattern.
3186420|NCT01293643|Active Comparator|tetracycline hydrochloride/amphotericin B combination|
3186421|NCT01293630|Experimental|Cohort - 1 through 5|AVE8062 combined with paclitaxel and carboplatin will be administered once every 3 weeks
3186422|NCT01293617|Placebo Comparator|Gelatin|
3186423|NCT01293617|Experimental|Blackberries|
3186424|NCT01293604|Experimental|Whole Grain Barley Diet|A controlled diet containing at least 4 daily servings of whole grain barley.
3186425|NCT01293604|Active Comparator|Whole Grain Oats Diet|A diet containing at least 4 servings of whole grain oats.
3186426|NCT01293604|Other|Low Whole Grain Diet|A control diet containing 0.7 daily servings of whole grain.
3186427|NCT01293591|Other|Control|270 kcal White bread with 15 g margarine
3186428|NCT01293591|Other|Garlic Treatment|270 kcal white bread with 15 g margarine and 5 g crushed garlic
3186429|NCT01293578|No Intervention|Usual Care|Clinicians will present diabetes medication options to patients, in their usual way.
3186430|NCT01293578|Experimental|Diabetes Medication Decision Aid|In the decision aid arm, clinicians will use the diabetes medication decision aid cards (if they choose) when discussing diabetes medication options with their patients.
3186431|NCT01293565||HED Affected Males|
3186432|NCT01293565||Male Controls|
3186433|NCT01293552|Placebo Comparator|Control|blank vehicle formulation
3186434|NCT01293552|Experimental|Dose 1|Dose 1
3186435|NCT01293552|Experimental|Dose 2|Dose 2
3186436|NCT01293552|Experimental|Dose 3|Dose 3
3186437|NCT01293552|Experimental|Dose 4|Dose 4
3186438|NCT01293539|Other|Intraocular Retinoblastoma Patients|Single group assignment of patients with intraocular retinoblastoma, unilateral or bilateral.
3186439|NCT01293526|Experimental|Experimental 1|Patients who respond will have their leads placed based on study measurements.
3186440|NCT01293526|Experimental|Control|Leads will be placed using standard procedures.
3186441|NCT01293526|Experimental|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
3186442|NCT01293487|Experimental|Arm 1|
3186443|NCT01293474||glaucoma patients|patients with diagnosis of primary open angle glaucoma
3186444|NCT01293474||control group|age matched healthy controls
3186445|NCT01293461|Experimental|CBX129801|
3186446|NCT01293461|Placebo Comparator|Placebo|
3186447|NCT01293448|Experimental|Intervention|CryoBalloon ablation of esophageal tissue in patients scheduled for esophagectomy for reasons unrelated to the objective of the study.
3186448|NCT01293435||1|
3186449|NCT01293422|Experimental|Rifampicin|
3186450|NCT01293409|Placebo Comparator|Placebo|The amount of photic energy of light is considered to be non-therapeutical
3186451|NCT01293409|Experimental|Intermediate dose|"The amount of photic energy of bright light is considered to be intermediate"
3186452|NCT01293409|Experimental|High dose bright light|The amount of photic energy of bright light is considered to be fully therapeutic
3186453|NCT01293396|Active Comparator|Biphasic Insulin Aspart 30|
3186454|NCT01293396|Active Comparator|Biphasic Insulin Aspart 70|
3186455|NCT01293396|Active Comparator|Insulin Aspart|
3186456|NCT01293383|Other|LEO 90105|
3186457|NCT01293383|Other|Vehicle|
3186458|NCT01293370||vocational rehabilitation|Admitted and discharged psychiatric patients receiving vocational rehabilitation
3186459|NCT01293357|Experimental|Patches|
3186460|NCT01293344|Experimental|Men and Mediterranean diet|Men who are assigned to a 4 weeks experimental diet formulated to be concordant with characteristics of the traditional Mediterranean diet.
3186461|NCT01293344|Experimental|Women and Mediterranean diet|Women who are assigned to a 4 weeks experimental diet formulated to be concordant with characteristics of the traditional Mediterranean diet.
3186462|NCT01293331||Study Cohort (Case )|Participants will be examined for fever in dengue endemic regions
3186463|NCT01293318||Acute pancreatitis|
3186464|NCT01293305|Experimental|Chondroitin Sulfate + Glucosamine sulfate|Pharmaceutical form capsule.
3186465|NCT01293305|Experimental|Chondroitin Sulfate + Glucosamine Sulfate|Oral powder.
3186466|NCT01293305|Active Comparator|Condroflex®|Pharmaceutical form capsule.
3186467|NCT01293305|Active Comparator|CONDROFLEX®|Oral powder
3186468|NCT01293279||HCV Patients who are treatment naive|Han ethnic Chinese male or female ≥ 18 years old with recent a confirmation of anti-HCV-antibody positive and HCV RNA positive but antiviral or interferon treatment naive at the time this study starts from 28 university affiliated hospital throughout China.
3186469|NCT01293266|Active Comparator|Propofol|Anesthesia is changed from Sevoflurane to Propofol after obtaining baseline blood gas analysis from the heart catheterisation sheath.
3186470|NCT01293266|No Intervention|Sevoflurane|Sevoflurane anesthesia is maintained after obtaining a baseline blood gas analysis.
3186471|NCT01293253|Experimental|Stair walking|Participants of this group is encouraged to use the stairs for 10 minutes a day at the workplace
3186472|NCT01293253|Active Comparator|Control|Receives a health examination before and after the intervention period, and are advised to stay active
3186473|NCT01293240|Experimental|Lotrafilcon B|
3186474|NCT01293214|Experimental|Transplantation|Subjects will undergo single or multiple limb transplantation
3186475|NCT01293201|Experimental|STAHIST Investigational Medical Product|STAHIST Tablet, dosed one tablet BID
3186476|NCT01293201|Placebo Comparator|Placebo|Placebo tablet, identical appearance to IMP, dosed one tablet BID
3186477|NCT01293188||Biopresthetic aortic valve replacement.|
3186478|NCT01293175|Experimental|Whole grains|Subjects will consume whole grains every day for two months
3186479|NCT01293175|No Intervention|Control|Subjects will consume their habitual diet
3186480|NCT01293162||placebo|
3186481|NCT01293149|Experimental|Ropivacaine plus clonidine|Ropivacaine plus clonidine for femoral block
3186482|NCT01293149|Active Comparator|Ropivacaine|Ropivacaine alone for femoral block
3186483|NCT01293136||intravenous opioids|
3186484|NCT01293136||femoral nerve block|
3186485|NCT01293123|Experimental|Raltegravir|
3186486|NCT01293123|Active Comparator|Efavirenz|
3186487|NCT01293097|Active Comparator|Intensive statin therapy|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
3186488|NCT01293097|Other|Usual care|Usual care, but statin dose should not be higher than that described in exclusion criteria.
3186489|NCT01293084|Experimental|7% saline|5 mL of 7% saline was inhaled once over a 20 minute period.
3186490|NCT01293084|Placebo Comparator|0.12% saline|5mL 0.12% saline inhaled once during 20 minutes
3186491|NCT01293071|Active Comparator|Mixing arm|Antibiotic rotation, each consecutive initiated antibiotic treatment a different class (one of 3 classes: cephalosporins, piperacillin-tazobactam, carbapenems)
3186492|NCT01293071|Active Comparator|Cycling|Antibiotic rotation, every 1.5 month a different preferred antibiotic treatment from a different class (one of 3 classes: cephalosporins, piperacillin-tazobactam, carbapenems) is used for empiric treatment.
3186493|NCT01293058|Other|Intravenous|The investigators administered intravenous naloxone for our opioid overdose patients
3186494|NCT01293058|Other|Intranasal|The investigators administered intranasal naloxone for treatment of our patients
3186495|NCT01293045|Experimental|HC Group|Group of volunteers fed with Hydrolyzed Collagen
3186496|NCT01293045|Active Comparator|CT Group|Group of volunteers fed with wheat proteins
3186497|NCT01293032|Experimental|Group 1 (RS < 11)|"Patients with a Recurrence Score (RS) less than 11 (RS <11) are assigned to Group 1, neoadjuvant hormonal therapy either tamoxifen (pre-menopausal women) or an aromatase inhibitor (post-menopausal women) for 4-6 months in the absence of disease progression or unacceptable toxicity.~Treatment:~Neoadjuvant therapy~Therapeutic conventional surgery~Laboratory biomarker analysis/Correlative studies~Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System~Hormonal therapy:~Tamoxifen Citrate (pre-menopausal women) OR~Aromatase Inhibition Therapy (post-menopausal women)"
3186498|NCT01293032|Experimental|Group 2 Arm 1 (RS 11-25)|"Patients with an intermediate RS (11-25) assigned to Group 2. Randomized to Arm 1, neoadjuvant hormonal therapy as in Group 1.~Treatment:~Neoadjuvant therapy~Therapeutic conventional surgery~Laboratory biomarker analysis/Correlative studies~Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System~Hormonal therapy:~Tamoxifen Citrate (pre-menopausal women) OR~Aromatase Inhibition Therapy (post-menopausal women)"
3186499|NCT01293032|Experimental|Group 2 Arm 2 (RS 11-25)|"Patients with an intermediate RS(11-25) assigned to Group 2. Randomized to Arm 2, neoadjuvant chemotherapy 6-8 courses of anthracycline/taxane based regimen over 4-6 months in the absence of disease progression or unacceptable toxicity.~Treatment:~Neoadjuvant therapy~Therapeutic conventional surgery~Laboratory biomarker analysis/Correlative studies~Gene Expression Analysis/Oncotype DX Gene Expression Profiling System~Systemic chemotherapy"
3186500|NCT01293032|Experimental|Group 3 (RS > 25)|"Patients with a high RS (> 25) assigned to Group 3, neoadjuvant chemotherapy as in Group 2 Arm 2.~Treatment:~Neoadjuvant therapy~Therapeutic conventional surgery~Laboratory biomarker analysis/Correlative studies~Gene Expression Analysis/Oncotype DX Gene Expression Profiling System~Systemic chemotherapy"
3186501|NCT01293019|Experimental|Experimental|Osteopathic treatment
3186502|NCT01293019|Placebo Comparator|Placebo|Sham osteopathic treatment
3186503|NCT01293019|Active Comparator|Usual care|Classic treatment of cystic fibrosis patients
3186504|NCT01293006|Experimental|Suvorexant first, then placebo|"During Period 1, participants <65 years of age were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening and participants ≥65 years of age were administered a 30-mg oral dose of~suvorexant once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening."
3186505|NCT01293006|Experimental|Placebo first, then suvorexant|"During Period 1, participants <65 years of age received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening and participants ≥65 years of age received one placebo tablet matching~suvorexant, orally, once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening."
3186506|NCT01292993|Experimental|Treatment A|400 mg LX4211
3186507|NCT01292993|Experimental|Treatment B|1000 mg metformin
3186508|NCT01292993|Experimental|Treatment C|400 mg LX4211 + 1000 mg metformin
3186509|NCT01292967|Placebo Comparator|Low flavanol|Low-flavanol chocolate contained 48 mg of cocoa flavanols. macro- and micro-nutrient matched with active comparator
3186510|NCT01292967|Active Comparator|High-flavanol with sugar|High-flavanol chocolate made with added sugar containing 251 mg of cocoa flavanols
3186511|NCT01292967|Active Comparator|High flavanol Maltitol|High-flavanol chocolate made with the sugar substitute maltitol containing 266 mg cocoa flavanols
3186512|NCT01292954|Active Comparator|Low dose blueberry|
3186513|NCT01292954|Active Comparator|medium dose blueberry|
3186514|NCT01292954|Active Comparator|high dose blueberry|
3186515|NCT01292954|Placebo Comparator|control|
3186516|NCT01292941|Active Comparator|Active comparator/Yellow catheter|SpeediCath coated catheter
3186517|NCT01292941|Experimental|NonCE marked intermittent catheter/red|
3186518|NCT01292941|Experimental|NonCE marked intermittent catheter/green|
3186519|NCT01292941|Experimental|NonCE marked intermittent catheter/Blue|
3186520|NCT01292928|Experimental|Stent|Stent implantation into SFA/PPA
3186521|NCT01292915||1|
3186522|NCT01292902|Active Comparator|healthy volunteers|
3186523|NCT01292902|Other|chronic heart failure|
3186524|NCT01292889||Seasonal Affective Disorder|Consists of Individuals with Seasonal Affective Disorder
3186525|NCT01292889||Subsyndromal Seasonal Affective Disorder|Consists of individuals who do not meet SAD criteria,but present more symptoms for the disorder than do controls.
3186526|NCT01292889||Major Depressive Disorder|Consists of individuals who have MDD.
3186527|NCT01292889||Controls|Consists of individuals who do not present symptoms of SAD or MDD.
3186528|NCT01292876|Other|Extracellular Matrix|Implantation of Extracellular Matrix
3186529|NCT01292863|Active Comparator|Conventional peritoneal dialysis solution|Subjects will be randomized to perform dialysis with the conventional peritoneal dialysis solution for 3 months. At the end of three months mesothelial cell shedding and apoptosis will be measured.
3186530|NCT01292863|Experimental|Novel biocompatible dialysis solution Delflex neutral pH|
3186531|NCT01292850||Healthy Volunteers|15 healthy volunteers were recruited
3186532|NCT01292837|Experimental|Levetiracetam|Twice daily (morning and evening) orally
3186533|NCT01292824|No Intervention|Standard liver transplant care|Liver Transplantation as per Standard of Care
3186534|NCT01292824|Experimental|ITX 5061|Liver Transplantation as per Standard of Care + ITX5061
3186535|NCT01292811|Experimental|Functional electrical Stimulation|The functional electrical stimulation for the treatment group will begin by designing a stimulation protocol that can generate the palmar and/or the lateral grasp on demand. In other words, the stimulation sequence (protocol) will be developed for each patient individually using either Compex Motion or HEWHS stimulator; this will allow the patient, who otherwise cannot grasp, to do so with the system. Both stimulators will be used to deliver the same FES therapy. Stimulation parameters are: 1) balanced, biphasic, current regulated electrical pulses; 2) pulse amplitude from 8 to 50 mA (typical values 17-26 mA); 3) pulse width from 250 to 300 μs; and 4) pulse frequency from 20 to 70 Hz (typical value 25 to 40 Hz).
3186536|NCT01292811|Other|Control Group|"The Control group will receive conventional occupational therapy pertaining to hand function [15].~The conventional therapy represents control activities against which the FES therapy will be assessed. The conventional occupational therapy includes: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training."
3186537|NCT01292798|Experimental|0.5mg and 2.0mgRanibizumab|Three consecutive intravitreal ranibizumab 0.5mg injections followed by three consecutive intravitreal ranibizumab 2.0mg injections if specific criteria is met.
3186538|NCT01292785||Transsexual|Female-to-Male and Male-to-Female Transsexuals receiving hormonal therapy
3186539|NCT01292785||Healthy control subjects|receiving no hormonal therapy
3186540|NCT01292746|Experimental|Erchonia ML Scanner (MLS)|Erchonia MLS employs four diodes emitting 10 milliwatts (mW) 635 nanometer (nm) red laser light
3186541|NCT01292733|Experimental|Ovarian Cancer Screening|CA125 tumor marker, Transvaginal Ultrasound, Health Status Questionnaires
3186542|NCT01292720|Placebo Comparator|Placebo|Placebo (herbal oil)
3186543|NCT01292720|Experimental|Vitamin D|
3186544|NCT01292707|Active Comparator|Control|Prescribing staff in control facilities will receive the standard package of RDT training that is being provided by NMCP in Tanzania
3186545|NCT01292707|Active Comparator|HW|Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial.
3186546|NCT01292707|Active Comparator|HWC|The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
3186547|NCT01292694|Experimental|Losartan|Angiotensin II AT1 receptor antagonist which blocks the actions of angiotensin II
3186548|NCT01292694|Experimental|Captopril|ACE inhibitor which blocks the formation of angiotensin II
3186549|NCT01292694|Placebo Comparator|Placebo Tablet|A placebo tablet will be provided by the Vanderbilt Investigational Drug Service for these studies.
3186550|NCT01292681|Other|Multi-modality imaging|
3186551|NCT01292668|Experimental|Group I|Patients apply methyl-5-aminolevulinate hydrochloride (MAL) cream on the lesions and the surrounding normal skin. Beginning 3 hours later, patients undergo laser light treatment for 3-5 minutes.
3186552|NCT01292668|Experimental|Group II|Patients apply MAL cream on the lesions and the surrounding normal skin. Beginning 3 hours later, patients undergo light emitting diode treatment for 5-10 minutes.
3186553|NCT01292655|Experimental|Arm A1 (Escalation): BMS-906024|BMS-906024 solution intravenously as specified
3186554|NCT01292655|Experimental|Arm A2 (Expansion): BMS-906024|BMS-906024 solution intravenously as specified
3186555|NCT01292655|Experimental|Arm B1 (Escalation): BMS-906024|BMS-906024 solution intravenously as specified
3186556|NCT01292655|Experimental|Arm B2 (Expansion): BMS-906024|BMS-906024 solution intravenously as specified
3186557|NCT01292642|Experimental|Treatment|Cognitive behavioral therapy (CBT) plus transdermal patch nicotine replacement therapy (NRT) to treat co-occurring nicotine and cannabis dependence during a 10-week study.
3186558|NCT01292629|Experimental|Investigational intraocular lens|iSert 251 intraocular lens
3186559|NCT01292603|Experimental|1|
3186560|NCT01292603|Experimental|2|
3186561|NCT01292603|Experimental|3|
3186562|NCT01292590|Experimental|High fat meal|
3186563|NCT01292577|Experimental|CET/PT|Behavioral Intervention: Participants will receive adapted Cognitive Enhancement Therapy/Personal Therapy.
3186564|NCT01292577|Active Comparator|Treatment as Usual|Behavioral Intervention: Participants will receive treatment as usual.
3186565|NCT01292564|Active Comparator|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
3186566|NCT01292564|Placebo Comparator|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
3186567|NCT01292551|Active Comparator|Bosentan|
3186568|NCT01292551|Placebo Comparator|Placebo|
3186569|NCT01292538|Experimental|Erchonia GLS 532nm|532nm green laser light therapy.
3186570|NCT01292538|Sham Comparator|Placebo laser|Sham light output with no therapeutic benefit
3186571|NCT01292525|Active Comparator|Tacrolimus|
3186572|NCT01292525|Experimental|Withdrawal of Tacrolimus|
3186656|NCT01291901|Placebo Comparator|Placebo|Single intradermal dose of placebo (vehicle). An open label study extension will offer up to two additional doses of active NP2 between weeks 4-10 following the previous dose.
3186657|NCT01291875|Experimental|Intensive periodontal treatment|
3186573|NCT01292512|Experimental|Interventiongroup|"A) Professional level. B) Patient level.~Intervention~Professional level:~GPs receive updated information on bereavement related symptoms, how to identify complicated grief, and the DPM of coping.~GPs receive suggestions on how to provide psycho-educational support for the patient.~GPs are informed about the results of the initial assessment of their patient prognostic screening for complicated grief.~Patient level:~Patients receive updated information on bereavement related symptoms, the DPM of coping and suggestions on when to seek professional help.~Patients are informed of the results of their initial assessment of their prognostic grief screening.~Patients are encouraged to contact their GP if they worry about handling their bereavement reaction."
3186574|NCT01292512|No Intervention|Control group|Treatment as usual (in the Danish health care system).
3186575|NCT01292499|No Intervention|Pharmacological treatment|Pharmacological treatment consists of the administration of a single antidepressant drug. The treatment will be administered as currently done by the mental health center, taking into due account patient's age, general health, previous response to antidepressant drugs, comorbidity, and potential side effects of drugs.
3186576|NCT01292499|Experimental|Psychotherapy|Will receive psychotherapy as well (10 sessions). Psychoterapy will consist of 10 weekly sessions, lasting about 50 minutes each. Psychotherapy will begin after 4‐6 weeks from the beginning of the pharmacological treatment, to allow drugs to be effective. The overall list of visits scheduled for the patients is defined during the second psychiatric visit, to allow a reasonable planning of all of the appointments required for that particular patient. Psychotherapists will be free to follow the approach they were trained.
3186577|NCT01292499|Experimental|Psychoeducation|Will receive psychoeducation as well, with phone monitoring and regular follow‐ups. Psychoeducation does not simply mean making the patient aware of depression etiology and drugs effect. In fact, patients should receive additional counselling about how to integrate the pharmacological treatment in their daily routine and to solve possible problems, in order to allow them to be actively and constantly involved in the treatment they are going to receive. Patients will receive 7 sessions of psychoeducation and 7 phone calls during the first 5 months. In addition, all of the patients will receive a brochure explaining the most important aspects of their disorder.
3186578|NCT01292499|Experimental|Psychoeducation and psychotherapy|Will receive both psychoeducation and psychotherapy sessions.
3186579|NCT01292486|Experimental|Patients with multiple myeloma|Multiple myeloma patients who receive autologous stem-cell transplants, collected using the Spectra Optia Apheresis System, following myeloablative therapy. The study is limited to subjects who are expected demonstrate normal neutrophil recovery.
3186580|NCT01292473|Experimental|Placebo|Placebo subcutaneously (sc) every 4 weeks
3186581|NCT01292473|Experimental|Omalizumab 75 mg|Omalizumab 75 mg sc every 4 weeks
3186582|NCT01292473|Experimental|Omalizumab 150 mg|Omalizumab 150 mg sc every 4 weeks
3186583|NCT01292473|Experimental|Omalizumab 300 mg|Omalizumab 300 mg sc every 4 weeks.
3186584|NCT01292460|Active Comparator|Preservative-free timolol|
3186585|NCT01292460|Experimental|Preservative-free FDC and placebo|
3186586|NCT01292460|Active Comparator|Preservative-free tafluprost|
3186587|NCT01292460|Experimental|Preservative-free FDC|
3186588|NCT01292447|Placebo Comparator|Control Group|Will receive placement of inert glycerin gel on ectocervix and in cervical canal prior to IUD placement.
3186589|NCT01292447|Experimental|Study Group|Will receive placement of 2% lidocaine gel on ectocervix and in cervical canal prior to IUD placement.
3186590|NCT01292434|Experimental|Lunch in the Bag Intervention|Lunch is in the Bag behavioral intervention: Parents receive a behavioral intervention that includes handouts/newsletters sent to parents from the early care and education (ECE) center, classroom activities and projects, an implementation support calendar, and teacher training.
3186591|NCT01292434|No Intervention|Control|Parents received no specific nutrition education intervention at the ECE center, other than usual practice.
3186592|NCT01292421|Placebo Comparator|Arm I|Participants consume placebo HBV-EPV on days 0, 14, 28, and 56.
3186593|NCT01292421|Experimental|Arm II|Participants consume HBV-EPV expressing HBsAg on days 0 and 28 and placebo HBV-EPV on days 14 and 56.
3186594|NCT01292421|Experimental|Arm III|Participants consume HBV-EPV expressing HBsAg on days 0, 28, and 56 and placebo HBV-EPV on day 14.
3186595|NCT01292421|Experimental|Arm IV|Participants consume HBV-EPV expressing HBsAg on days 0, 14, 28, and 56.
3186596|NCT01292408|Experimental|Daily HCQ|Between tumor biopsy and surgery, during 2-3 weeks, breast cancer patients will take daily HCQ, an anti-malaria and anti-rheumatic drug that precludes tumor cells from surviving hypoxia by inhibiting the process of autophagy in these cells
3186597|NCT01292395|Experimental|Protein level 1|
3186598|NCT01292395|Experimental|Protein level 2|
3186599|NCT01292395|Experimental|Protein level 3|
3186600|NCT01292382|Sham Comparator|rTMS versus Sham|rTMS: active coil Sham: inactive coil
3186601|NCT01292382|Active Comparator|rTMS versus sham|rTMS group: active coil Sham group: inactive coil
3186602|NCT01292369||Breast cancer|Women diagnosed with breast cancer by a positive biopsy test after mammography.
3186603|NCT01292369||Breast control|Women with negative biopsy result done due to a suspicious mammography exam.
3186604|NCT01292369||Colon cancer|Men and women diagnosed with colon cancer by a positive colonoscopy and biopsy.
3186605|NCT01292369||Colon control|Men and women with negative colonoscopy and biopsy tested due to complaints indicating the possibility of colon cancer.
3186606|NCT01292356|Experimental|cetuximab|
3186607|NCT01292317|Active Comparator|intravenous hydration|intravenous application of 0.9% saline
3186608|NCT01292317|Active Comparator|oral hydration only|
3186609|NCT01292304|Experimental|Tolvaptan|Tolvaptan 15 mg tablet once daily for 7 days followed by Tolvaptan 30 mg (two 15 mg tablets) once daily according to efficacy and tolerability
3186610|NCT01292278||aSAH|consecutive patients with spontaneous or aneurysmal subarachnoid hemorrhage
3186611|NCT01292278||control group|no neurological disease but spinal anesthesia
3186612|NCT01292265|Experimental|CZP 200 mg|Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
3186613|NCT01292252|Experimental|Treatment|Teriparatide treatment
3186614|NCT01292252|Placebo Comparator|Placebo|Placebo treatment
3186615|NCT01292239|Experimental|TMC435 100 mg 12 Wks + PR 24/48|Participants received TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment was stopped at Week 24 for participants who achieved HCV RNA < 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable HCV RNA at Week 12. All other participants continued PR until Week 48.
3186616|NCT01292239|Experimental|PBO 12 Wks + PR 48|Participants received placebo (PBO) once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.
3186617|NCT01292226|Experimental|Mycophenolate Mofetil Monotherapy|Participants received an initial dose of mycophenolate mofetil (MMF), 1 gram (g), orally (PO), twice per day (BID), within 5 days of transplant for 24 weeks. Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.
3186618|NCT01292213||Cases|Subjects diagnosed with chronic cough who are undergoing general anaesthesia and bronchoscopy/BAL as part of the diagnostic process for chronic cough.
3186619|NCT01292213||Controls|Subjects without respiratory symptoms who are undergoing general anaesthesia for elective surgery or endoscopy of non-respiratory-related conditions.
3186620|NCT01292200|Experimental|watch DVD and small group discussion|Participants will watch the video in a group and discuss the video.
3186621|NCT01292200|Placebo Comparator|watch video only|watch a 22 minutes long video at home by herself.
3186622|NCT01292187|Experimental|Oral calcitonin at dinner-or bedtime|Intervention: Oral calcitonin at dinnertime or oral calcitonin at bedtime. Postmenopausal subjects with osteopenia were treated for one year (also with vitamin D and calcium supplements) to determine if oral calcitonin tablets would prevent the loss of bone mineral density compared with placebo. Randomization to active or placebo was done 2:1. After randomization, further randomization was done to divide each arm into two groups, one in which dosing was at dinnertime and the other in which dosing was at bedtime to determine if food affected efficacy or safety.
3186623|NCT01292187|Experimental|Oral placebo at dinner- or bedtime|Intervention: oral placebo at dinnertime or oral placebo at bedtime
3186624|NCT01292174|Experimental|Group 1 - lowest dosage|120 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
3186625|NCT01292174|Experimental|Group 2 - middle dosage level|240 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
3186626|NCT01292174|Experimental|Group 3 - highest dosage level|480 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
3186627|NCT01292161|Other|Silymarin|Silymarin drived from Silybum marianum (milk thistle), a flowering member of the daisy family, may benefit liver function in people infected with the hepatitis C virus.
3186628|NCT01292135|Experimental|PCI-32765 plus fludarabine/cyclophosphamide/rituximab (FCR)|
3186629|NCT01292135|Experimental|PCI-32765 plus bendamustine/rituximab (BR)|
3186630|NCT01292122|Experimental|VCT-01-treated STSG donor site wound|Application of VCT-01 to STSG donor site wound at Day 0
3186631|NCT01292109||PICOPREP®|
3186632|NCT01292083|Experimental|Treatment|See Detailed Description
3186633|NCT01292070|Experimental|Control-Experimental arm|Each subject will serve as their own control with the left arm receiving the control protein (Histamine prick, intradermal diluent and intradermal CAT) and right arm receiving the experimental protein (GFD).
3186634|NCT01292057|Active Comparator|Aripiprazole|Medication
3186635|NCT01292057|Placebo Comparator|Sugar pill|
3186636|NCT01292044|Experimental|The study population|The study population consists of patients for whom an echo-guided fine-needle aspiration was performed for one or more thyroid nodes, and for whom surgical node excision is required.
3186637|NCT01292031|Experimental|Colistin|Colistin 4.5 MU/iv.plus Colistin 3 MU/iv./8 h. 30 minutes infusion
3186638|NCT01292031|Active Comparator|Meropenem|Meropenem 2 g/iv/ 8 h. 30 minutes infusion
3186639|NCT01292005|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
3186640|NCT01292005|Placebo Comparator|Placebo|Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
3186641|NCT01291992||Continuous EEG Monitoring|Immediately after surgery, while still sedated and in the cardiac surgery recovery unit, 9 sticker electrodes applied to the skin just below the hairline, which record brain activity onto a computer. The EEG will be recorded for 24 hours. This brain activity (EEG) will later be interpreted by a neurologist who will be looking for evidence of seizure activity in the brain waves. Other relevant information: age, sex, the nature of other health problems, drugs used, complications and whether or not seizures are found will be stored on our computer for further evaluation.
3186642|NCT01291979|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
3186643|NCT01291979|Placebo Comparator|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
3186644|NCT01291966|Experimental|Motivational interview|
3186645|NCT01291953|Experimental|Screening|Opportunist Screening asymptomatic patients. Taking the arterial pulse. Will invite patient to realize an ECG, if pulse is irregular
3186646|NCT01291953|Active Comparator|Control|Case finding of patient whith symptoms of atrial fibrilation. Taking the arterial pulse. ECG if pulse is irregular
3186647|NCT01291940|Experimental|Pediatric Moisturizer Intervention|Apply one of four moisturizers to one arm daily for four weeks.
3186648|NCT01291940|Experimental|Adult Moisturizer Intervention|Apply moisturizer to one arm once a day for four weeks.
3186649|NCT01291940|No Intervention|Adult Control|No intervention.
3186650|NCT01291927|Experimental|Pancreas-sparing duodenectomy|
3186651|NCT01291927|Active Comparator|Pancreaticoduodenectomy|
3186652|NCT01291914|Experimental|FX005|
3186653|NCT01291914|Placebo Comparator|Placebo 1 (Carrier)|
3186654|NCT01291914|Placebo Comparator|Placebo 2 (Diluent)|
3186655|NCT01291901|Experimental|Active NP2|Single intradermal dose of active NP2. An open label study extension will offer up to two additional doses of active NP2 between weeks 4-10 following the previous dose.
3186658|NCT01291875|Active Comparator|Supragingival biofilm control|
3186660|NCT01291823|Experimental|Concomitant Gefitinib and radiotherapy|Patients received Gefitinib and radiation therapy
3186661|NCT01291810|Experimental|TNF Kinoid|
3186662|NCT01291810|Placebo Comparator|Placebo|
3186663|NCT01291797||Neonates with congenital heart disease|The case group will consist of newborns born between 32 and 41 weeks gestation diagnosed with a congenital cardiac anomaly requiring surgical repair during their hospitalization and managed in the Mount Sinai Neonatal Intensive Care Unit. The control arm will include newborns born between 32 and 41 weeks without congenital cardiac anomalies. Both groups will undergo a neurological screening assessment and receive an AEEG to look at sleep wake cycles.
3186664|NCT01291784|Experimental|monoclonal antibody to TGF-beta|starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
3186665|NCT01291771|Other|comparator|One group of patients with no myocardial ischemia on non invasive testing will be followed up for 2 years
3186666|NCT01291771|Experimental|coronary angiography group|One group of patients with myocardial ischemia on non invasive testing will undergo coronary angiography and measure of FFR + CFR to detect myocardial microvascular disease
3186667|NCT01291758||GWI|Veterans of the 1990-1991 Persian Gulf War who have autonomic, neurological and other symptoms
3186668|NCT01291758||HC|Healthy veterans of the 1990-1991 Persian Gulf War
3186669|NCT01291745||Patients with MYELODYSPLASTIC SYNDROMES|Patients diagnosed with MDS according to FAB, WHO and IPSS classifications. Patients who necessitate to start a treatment (i.e. EPO, Lenalidomide, Azacytidine).
3186670|NCT01291732|Experimental|BI 135585 XX|single dose of BI 135585
3186671|NCT01291732|Placebo Comparator|matching placebo|single dose of matching placebo
3186672|NCT01291719|Experimental|insulin and glucose infusion|trial of experimental technique in outpatient setting; the group under study will be comprised of type 1 and type 2 diabetic individuals ; they will have automated treatment using algorithm which regulates balancing infusions of glucose and/or insulin intravenously without manual intervention; blood glucose target of 80-180 mg/dl will be guide for the automated system
3186673|NCT01291706||Mild TBI with mild lesions on CT scan|Negative predictive value of transcranial doppler for patients with mild to moderate traumatic brain injury and mild brain lesions on initial CT scan (TCDB II)
3186674|NCT01291693|Experimental|Personal counseling|
3186675|NCT01291693|Experimental|Computer generated feedback letters|
3186676|NCT01291693|No Intervention|Control group|Treatment as usual
3186677|NCT01291680||Pre - delivery pregnant women|Participants in the study will be pregnant women attending the obstetric ER for routine term followup. This evaluation is generally conducted at week 39-41 of pregnancy. The current study will focus on women attending a regular followup, not considered to be at high risk.
3186678|NCT01291654|Experimental|Paracetamol|Babies with hsPDA will be treated with paracetamol 15 mg/kg/dose x 4/day for three days
3186679|NCT01291654|Experimental|NSAID|Babies with hsPDA will be randomized to treatment with IV indomethacin 17 mcg/kg/hr x 36 hr
3186680|NCT01291641|Experimental|Group A|HMGCoA reductase inhibitor continued
3186681|NCT01291641|Experimental|Group B|HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID
3186682|NCT01291641|Experimental|Group C|HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID + Cilostazol 100 mg PO, BID
3186683|NCT01291628|Experimental|socks containing copper-oxide fibers|
3186684|NCT01291615|Experimental|Gemcitabine group|800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
3186685|NCT01291615|Experimental|S-1 group|S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks
3186686|NCT01291602|Experimental|NXL104|Six Japanese subjects to receive single and repeated 500 mg IV infusions of NXL104
3186687|NCT01291602|Placebo Comparator|Placebo|Three Japanese subjects to receive placebo IV doses
3186688|NCT01291602|Experimental|Ceftazidime NXL104 (CAZ104)|Six Japanese subjects to receive single and repeated IV infusions of 500 mg NXL104 with 2000 mg ceftazidime
3186689|NCT01291589|Experimental|Cognitive-behavioral counseling|
3186690|NCT01291576|Active Comparator|Rectal/colorectal segmental resection|
3186691|NCT01291576|Active Comparator|Rectal nodule excision|
3186692|NCT01291563|Experimental|001|TMC207 8 tablets of TMC207 (100 mg/tablet) on Day 1
3186693|NCT01291563|Placebo Comparator|002|TMC207 placebo 8 tablets of TMC207 placebo on Day 1
3186694|NCT01291563|Active Comparator|003|Moxifloxacin 1 capsule of moxifloxacin (400 mg/capsule) on Day 2
3186695|NCT01291563|Placebo Comparator|004|Moxifloxacin placebo 1 capsule of moxifloxacin placebo on Day 2
3186696|NCT01291550||Nerodegenerative diseases|Patients with parkinsonism and patients with dementia
3186697|NCT01291550||Controls|
3186698|NCT01291550||ADHD|Subjects diagnosed with ADHD
3186699|NCT01291537|Experimental|Duodopa|
3186700|NCT01291537|Active Comparator|Best medical treatment|
3186701|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, 400-500 calorie|
3186702|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, 600- 750 calorie|
3186703|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, bedtime|
3186704|NCT01291524|Other|Pregabalin immediate release, 300 mg|Reference Treatment
3186705|NCT01291511|Experimental|Iloperidone|After meeting all entry criteria, completing a 1-week open-label iloperidone titation period (up to 12 mg/day), followed by a 14-24 week open-label iloperidone flexible dose-stabilization period (up to 24 mg/day), approximately 260 patients will be randomized to one of two arms in a 1:1 ratio of iloperidone (flexible dosing 8-24 mg/day) to placebo. Post-randomization double-blind study medication will be administered orally twice daily for up to 26 weeks to evaluate relapse prevention. Subsequently, during the extension period, after a 1-week mock double-blind titration, open-label iloperidone (8-24 mg/day) is administered for up to 51 weeks to evaluate long-term safety.
3186706|NCT01291511|Placebo Comparator|Iloperidone (including Placebo)|Post-randomization matching placebo is administered orally bid during the double-blind period.
3186707|NCT01291498|Other|HIFU Treatment|High Intensity Focused Ultrasound. This is not a comparative study
3186765|NCT01291108|Active Comparator|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1.
3186708|NCT01291485|Experimental|Lifestyle counseling|Intervention includes education about HIV and medication adherence, motivational interviewing, cognitive behavioral techniques, and problem-solving strategies to improve HIV medication adherence and clinical outcomes.
3186709|NCT01291485|No Intervention|Treatment as Usual|
3186710|NCT01291472|Other|ketorolac|Ketorolac will be given to all patients as a part of routine medical care
3186711|NCT01291459|Experimental|single arm|Maraviroc/raltegravir/emtricitabine/tenofovir 24 weeks followed by Maraviroc/Raltegravir 24 weeks
3186712|NCT01291446|Sham Comparator|High flatulogenic diet|3-day diet containing fermentable residues
3186713|NCT01291433|Experimental|PENTOCLO|Association pentoxifylline, tocopherol and clodronate
3186714|NCT01291433|Placebo Comparator|Placebo|Triple placebo
3186715|NCT01291407|Experimental|S-1,peroral BID,capsule|
3186716|NCT01291381|Active Comparator|Dermatophagoides pteronyssinus extract|Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
3186717|NCT01291381|Active Comparator|Pharmacotherapy|Persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
3186718|NCT01291355|Experimental|Specific maternal position|"women allocated to intervention group will be invited to adopt a posture all fours type:support on the knees, torso tilted forward, back stretched for a minimum of 10 minutes. A cushion is placed between the legs of the woman to limit the cuts. According to Dr de Gasquet, author of the description of this posture, the effect on the variety of presentation would be almost immediate."
3186719|NCT01291355|No Intervention|Control|Not specific intervention for this group- Only usual care
3186720|NCT01291342||Preeclampsia|30 preeclamptic pregnant women with gestational age >24 weeks and no chronic medical disorders who are not in labor and their fetus is alive.
3186721|NCT01291342||Normal pregnancy|30 normotensive pregnant women with gestational age >24 weeks and no chronic medical disorders who has no obstetrical problems, not in labor and their fetus is alive.
3186722|NCT01291342||Healthy non-pregnant|30 healthy non-pregnant control women not on medications and has not delivered a baby or conceived during the year before the breath collection
3186723|NCT01291329|Experimental|WJ-MSC|Wharton's jelly- Derived Mesenchymal Stem Cells Transfer
3186724|NCT01291316|Experimental|clobazam|
3186725|NCT01291316|Active Comparator|clonazepam|
3186726|NCT01291316|Placebo Comparator|tolterodine|
3186727|NCT01291303|Experimental|1- optimized ventilation|35 COPD patients ventilated for acute exacerbations in NIV with pressure support mode.
3186728|NCT01291303|Experimental|2-standard setting of ventilation|35 COPD patients ventilated for acute exacerbations in NIV with pressure support mode.
3186729|NCT01291290|No Intervention|Control treatment|Usual transfusion regime to patients with rAAA
3186730|NCT01291290|Experimental|Thrombocyte|Early thrombocyte administration to patients with rAAA
3186731|NCT01291277|Active Comparator|Ligation: 1-week interval|Endoscopic variceal ligation performed at 1-week intervals
3186732|NCT01291277|Active Comparator|Ligation 2-week interval|Endoscopic variceal ligation performed at 2-week intervals
3186733|NCT01291238|Experimental|Healthy lifestyle habits|Increased physical activity and healthy food with decreased sugar and fat content
3186734|NCT01291225|Other|Playground|"The playground arm of the study will consist of playground audits and KAP surveys about playground safety in both Chillicothe and Circleville, Ohio.~The intervention is Playground Safety Renovations and Development."
3186735|NCT01291225|Other|Farms|The Farm Arm will consist of farm audits with safety checklists and KAP surveys about farm safety. The intervention is a Safety Educational Campaign.
3186736|NCT01291212|Active Comparator|Testosterone and FSHr|
3186737|NCT01291212|Active Comparator|testosterone and FSHr-LHr|
3186738|NCT01291199|Experimental|Vardenafil 10 mg bid|
3186739|NCT01291199|Placebo Comparator|Placebo|
3186740|NCT01291186|Experimental|BPV6NO|
3186741|NCT01291186|Experimental|BPV7NO|
3186742|NCT01291186|Experimental|BPV8NO|
3186743|NCT01291186|Experimental|BPV9NO|
3186744|NCT01291186|Experimental|BPV10NO|
3186745|NCT01291186|Experimental|BPV11NO|
3186746|NCT01291186|Active Comparator|BPV6O|
3186747|NCT01291186|Active Comparator|BPV7O|
3186748|NCT01291186|Active Comparator|BPV8O|
3186749|NCT01291186|Active Comparator|BPV9O|
3186750|NCT01291186|Active Comparator|BPV10O|
3186751|NCT01291186|Active Comparator|BPV11O|
3186752|NCT01291173|Experimental|SPD489 30 mg|
3186753|NCT01291173|Experimental|SPD489 50 mg|
3186754|NCT01291173|Experimental|SPD489 70 mg|
3186755|NCT01291173|Placebo Comparator|Placebo|
3186756|NCT01291160|Experimental|Epiflo Treatment|The cohort will comprise of 2 populations: the Treatment Arm of up to 90 subjects; and the Control Arm of up to 90 subjects, in order to collect 120 invaluable subjects. The Treatment Arm includes subjects with DFU who will receive EPIFLO in addition to standard wound care therapy during the Treatment Period.
3186757|NCT01291160|Sham Comparator|Sham Device|The cohort will comprise of 2 populations: the Treatment Arm of up to 90 subjects; and the Control Arm of up to 90 subjects, in order to collect 120 invaluable subjects. Control Arm includes subjects with Diabetic Foot Ulcers who will receive sham units of EPIFLO along with standard wound care therapy during the treatment Period.
3186758|NCT01291147|Active Comparator|Levobupivicaine|
3186759|NCT01291147|Placebo Comparator|0.9% Saline|
3186760|NCT01291134||Cervical Degenerative Disc Disease|
3186761|NCT01291121|Active Comparator|group 1|Intravitreal ranibizumab 0.5mg only group
3186762|NCT01291108|Experimental|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1.
3186763|NCT01291108|Experimental|AGN-210669 + bimatoprost|AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% applied as 1 drop of each treatment in both eyes every evening during Month 2.
3186764|NCT01291108|Experimental|AGN-210669 + bimatoprost vehicle|AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.
3186766|NCT01291108|Experimental|bimatoprost + AGN-210669|bimatoprost ophthalmic solution 0.03% + AGN-210669 0.05% applied as 1 drop of each treatment in both eyes every evening during Month 2.
3186767|NCT01291108|Other|bimatoprost + bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.
3186768|NCT01291095|Active Comparator|CONCURRENT CHEMO-RADIOTHERAPY ARM|Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy).
3186769|NCT01291095|Experimental|ACCELERATED FRACTIONATION RADIOTHERAPY ARM|Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
3186770|NCT01291082||Breast cancer patients|Breast cancer patients
3186771|NCT01291069|Experimental|Tadalafil Citrate|The study subjects will be given Tadalfil citrate, encapsulated, 0.8-1 mg/kg/day in 1 dose orally. Max dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
3186772|NCT01291069|Placebo Comparator|Sugar pill|If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a sugar pill. All patients will receive either study drug or placebo for a total of 20 days.
3186773|NCT01291056|Active Comparator|Clomphine|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
3186774|NCT01291056|Placebo Comparator|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
3186775|NCT01291043|Experimental|Shiatsu Group|
3186776|NCT01291043|No Intervention|Control Group|
3186777|NCT01291030|Experimental|hypomagnesemic + magnesium supplement|The patient group of hypomagnesesemic renal transplant recipients randomized to magnesium supplementation (number = 30). The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion,which are repeated after 6 months.
3186778|NCT01291030|No Intervention|hypomagnesemic without magnesium supplement|The patient group of hypomagnesesemic renal transplantation recipients, randomized to no magnesium supplementation (number = 30). During 6 months, no magnesium supplementation is started, provided that the serum magnesium level remains > 1,2 milligram/deciliter. In case of cramps, intermittent supplementation is allowed, but will be recorded. The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion,which are repeated after 6 months.
3186779|NCT01291030|No Intervention|normomagnesemic without magnesium supplement|In the control group of normomagnesemic renal transplantation recipients (number = 10), only a baseline assessment will be performed. The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion.
3186780|NCT01291017|Experimental|PD0332991|PD0332991 125 mg PO days 1 - 21
3186781|NCT01291004|Experimental|28-day Desogestrel Oral Contraceptive|
3186782|NCT01291004|Active Comparator|28-day Drospirenone Oral Contraceptive|
3186783|NCT01291004|Active Comparator|28-day Levonorgestrel Oral Contraceptive|
3186784|NCT01290991|Other|Bone Graft|Single Arm.. Augment Bone Graft for Osteochondral Defects
3186785|NCT01290978|Active Comparator|ChloraPrep|Applied ChloraPrep on the application site per manufacturer's instruction
3186786|NCT01290978|Active Comparator|DuraPrep|Apply DuraPrep to the application site per manufacturer's instruction
3186787|NCT01290965|Placebo Comparator|Placebo comparator|
3186788|NCT01290965|Active Comparator|SCY-635 30 mg once daily|
3186789|NCT01290965|Active Comparator|SCY-635 100 mg once daily|
3186790|NCT01290965|Active Comparator|SCY-635 300 mg once daily|
3186791|NCT01290965|Active Comparator|SCY-635 100 mg three times daily|
3186792|NCT01290965|Active Comparator|SCY-635 200 mg three times daily|
3186793|NCT01290965|Active Comparator|SCY-635 300 mg three times daily|
3186794|NCT01290952|Experimental|Off-pump bypass surgery|Off-pump coronary artery bypass graft (OPCAB) using mandatory a stabilization device and advisable, but not mandatory, a heart positioner
3186795|NCT01290952|Active Comparator|On-pump bypass surgery|coronary artery bypass graft with cardiopulmonary bypass (CPB/CAB)
3186796|NCT01290939|Experimental|Arm 1|Lomustine 90 mg/m² every 6 weeks (cap. 160 mg) + bevacizumab 10 mg/kg every 2 weeks (at further progression treatment will be according to investigators discretion). In the absence of hematological toxicity > grade 1 during the first cycle the dose of lomustine can be escalated to 110 mg/m² (cap 200 mg) in their second cycle.
3186797|NCT01290939|Active Comparator|Arm 2|Lomustine single agent 110 mg/m² every 6 weeks (cap. 200 mg) (at further progression treatment will be according to investigators discretion).
3186798|NCT01290926|Experimental|Capecitabine & Sorafenib|Sorafenib 200mg in the morning,400mg in the evening; escalation to 400mg twice daily after 1 cycle, Oral, Continuous dosing Capecitabine 850mg/m2 twice daily, Oral Days 1-14, weeks 1-2
3186799|NCT01290913|Experimental|omalizumab, oral desensitization|Patients receive omalizumab along with oral peanut desensitization.
3186800|NCT01290900|Experimental|CXL104|2000 mg NXL104 + 1500 mg Ceftaroline (IV)
3186801|NCT01290900|Experimental|CAZ104|Placebo Infusion (saline) + 2000 mg NXL104 + 3000 mg Ceftazidime (IV)
3186802|NCT01290900|Active Comparator|Moxifloxacin|Moxifloxacin 400mg (1 tablet)
3186803|NCT01290900|Placebo Comparator|Placebo|Placebo Infusion (saline)
3186804|NCT01290887|Experimental|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months.
3186805|NCT01290874|Experimental|Tiotropium|Tiotropium bromide will be evaluated as a treatment for asthma.
3186806|NCT01290874|Active Comparator|Salmeterol or Formoterol|Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
3186807|NCT01290861||pre-manifest HD|
3186808|NCT01290861||early manifest HD|
3186810|NCT01290848|Experimental|Township of Uxbridge|The Take TIME for Your Child's Health campaign will target parents and caregivers of children up to 8 years of age.
3186811|NCT01290848|No Intervention|Township of Guelph/Ermosa|For a control group the investigators have selected a community that is similar in size, household composition, population density, distance from Toronto and economic status to the Township of Uxbridge.
3186812|NCT01290835|Experimental|Stereotactic radiotherapy|Accelerated stereotactic radiotherapy as an adjuvant treatment for early stage breast cancer.
3186813|NCT01290822|Experimental|BiVP Pacing|BIVP optimize AVD, VVD, and LVPS parameters and assess the effect on cardiac output.
3186814|NCT01290822|Active Comparator|AAI Pacing|Traditional atrial (AAI) pacing
3186815|NCT01290809||Prophylactic Cranial Irradiation|NSCLC patients treated with whole brain PCI: cognitive functioning as assessed by neuropsychological tests?
3186816|NCT01290809||no Prophylactic Cranial Irradiation|NSCLC patients not treated with whole brain PCI: cognitive functioning as assessed by neuropsychological tests?
3186817|NCT01290796|Other|Ajust Adjustable Single-Incision Sling|Urinary incontinence sling
3186818|NCT01290783|Active Comparator|FOLFIRI|
3186819|NCT01290783|Experimental|FOLF(HA)iri|
3186820|NCT01290770||obese men|obese men with chest pain like angina
3186821|NCT01290757|Experimental|Dabigatran etexilate 150 mg (T)|Capsugel (T), oral administration
3186822|NCT01290757|Experimental|Dabigatran etexilate 150 mg (R)|Qualicaps (R), oral administration
3186823|NCT01290744|Placebo Comparator|Placebo group|These patients will receive placebo for 12 months after completion of MDT.
3186824|NCT01290744|Experimental|Clofazimine for 12 months after MDT|Patients will be given clofazimine (100mg daily) for 12 months after completion of MDT.
3186825|NCT01290731|Experimental|TMC435 100 mg 12 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24 (PR 24). Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels less than (<) 1.2 log10 IU/mL detectable or undetectable of at Week 4, and undetectable HCV RNA levels at Week 12. All other participants will continue PR until Week 48 (PR 48).
3186826|NCT01290718|Experimental|Single Arm|
3186827|NCT01290705|Experimental|high exercise|High dose, high repetition exercise therapy, 3 times weekly in 12 weeks
3186828|NCT01290705|Experimental|low exercise|low dose, low repetition exercise therapy, 3 times weekly in 12 weeks
3186829|NCT01290692|Experimental|TVI-Brain-1|All patients will receive the full TVI-Brain-1 treatment.
3186830|NCT01290679|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) (PegIFN alpha-2a/b) and ribavirin (Copegus or Rebetol) for 24 or 48 weeks
3186831|NCT01290679|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) (PegIFN alpha-2a/b) and ribavirin (Copegus or Rebetol) for 48 weeks
3186832|NCT01290666||GORE® BIO-A® Fistula Plug|All patients in study receive the GORE® BIO-A® Fistula Plug.
3186833|NCT01290653|Experimental|Dry Needling of trigger point|Deep dry needling will be applied on the upper trapezius myofascial trigger point
3186834|NCT01290653|Experimental|Strain-counterstraing technique|This manual technique will be applied at the upper trapezius.
3186835|NCT01290653|Placebo Comparator|Placebo manual technique|A technique simulating strain-counterstrain, but without any therapeutic manoeuvre will be applied at the upper trapezius site.
3186836|NCT01290640||TC3 TKA|Subjects implanted with a DePuy fixed-bearing Total Condylar III (TC3) TKA
3186837|NCT01290640||PFC RP TC3 TKA|Subjects implanted with a DePuy PFC Rotating Platform TC3 TKA
3186838|NCT01290627||Knee Prosthesis LCS PS RP TKA|Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
3186839|NCT01290627||Knee Prosthesis Sigma PS RP TKA|Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
3186840|NCT01290627||Control|Subjects with normal knees
3186841|NCT01290614|Experimental|Pharmacist intervention|
3186842|NCT01290614|Active Comparator|Control - usual care|Patients assigned to control will continue to receive care from their VA provider.
3186843|NCT01290601|Experimental|Cohort 1 Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
3186844|NCT01290601|Active Comparator|Cohort 1-Chloroquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
3186845|NCT01290601|Experimental|Cohort 2 Tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
3186846|NCT01290601|Active Comparator|Cohort 2 Chloroquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
3186847|NCT01290588||Children of Caucasian descent|Healthy children of Caucasian descent.
3186848|NCT01290588||Adults of Caucasian descent|Healthy adult eyes of Caucasian descent.
3186849|NCT01290588||Children of African-American descent|Healthy children of African-American descent.
3186850|NCT01290588||Adults of African-American descent|Healthy adults of African-American descent.
3186851|NCT01290575|Active Comparator|Arm 1 BMS-820132 or placebo|
3186852|NCT01290575|Active Comparator|Arm 2 BMS-820132 or placebo|
3186853|NCT01290575|Active Comparator|Arm 3 BMS-820132 or placebo|
3186854|NCT01290575|Active Comparator|Arm 4 BMS-820132 or placebo|
3186855|NCT01290575|Active Comparator|Arm 5 BMS-820132 or placebo|
3186856|NCT01290575|Active Comparator|Arm 6 BMS-820132 or placebo|
3186857|NCT01290575|Active Comparator|Arm 7 BMS-820132 or placebo|
3186858|NCT01290575|Active Comparator|Arm 8 BMS-820132 or placebo|
3186859|NCT01290575|Active Comparator|Arm 9 BMS-820132 or placebo|
3187597|NCT01285466|Experimental|BEZ235 + paclitaxel|
3186860|NCT01290562|Experimental|Stereotactic Body Radiotherapy (SBRT)|Cohort 1: Patients with spinal metastases and no prior radiation Cohort 2: Patients with spinal metastases in a previously radiated field Cohort 3: Post-operative patients with spinal metastases
3186861|NCT01290549|Experimental|Polatuzumab Vedotin|Polatuzumab vedotin will be administered by an IV infusion of escalating doses (starting dose of 0.1 mg/kg, potentially to be followed by 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, and 4.0 mg/kg doses) every 3 weeks (q3w) (Day 1 of each 21 day cycle).
3186862|NCT01290549|Experimental|Polatuzumab Vedotin + Rituximab|Polatuzumab vedotin will be administered by an IV infusion q3w (Day 1 of each 21 day cycle). Rituximab was administered by an IV infusion at 375 milligrams per square meter (mg/m^2) body surface area dose q3w.
3186863|NCT01290536|Experimental|Yttrium-90 liver radioembolization|
3186864|NCT01290523|Experimental|Yttrium-90 liver radioembolization|Patients who receive liver-directed therapy with Yttrium-90 glass microspheres (TheraSphere)
3186865|NCT01290510|Experimental|hyaluronic acid sodium salt|
3186866|NCT01290497|Active Comparator|Hyaluronic acid 5 x 2.5 ml|
3186867|NCT01290497|Experimental|Hyaluronic acid 1 X 5 ml|
3186868|NCT01290497|Experimental|Hyaluronic acid 2 x 5 ml|
3186869|NCT01290484|Experimental|Open Label|Sildenafil oral tablet three times daily
3186870|NCT01290471|Experimental|Part 1 Dose Escalation|Dose escalation of U3 1565 will follow a modified 3+3 study design with a starting intravenous (IV) dose of 2 mg/kg. A maximum of 2 new subjects will receive their first dose of U3-1565 per 24-hour period during the dose-escalation phase. Subsequent escalating doses of 8, 16, and 24 mg/kg are planned. Three to 6 subjects will be enrolled in 4 sequential dose level cohorts.
3186871|NCT01290471|Experimental|Part 2a Dose Expansion|For Part 2a, 6 or 12 subjects with advanced solid malignant tumors will be enrolled and treated at the MTD or MAD to further define the safety and tolerability of U3-1565. These additional subjects are expected to permit the detection of relatively rare toxicities that would not likely be observed during the dose escalation part of the study, whose 3+3 design implies a maximum of 6 subjects only will be treated at the MTD or MAD. Six subjects will be treated; however, if toxicities meeting the definition of DLT are observed during the first cycle of treatment, 6 more subjects will be treated for a total of 12 subjects.
3186872|NCT01290471|Experimental|Part 2b Dose Expansion and Anti-tumor Impact|For Part 2b, up to 30 subjects with advanced solid malignant tumors, with a preference for those with advanced ovarian cancer, will be enrolled and treated at the MTD or MAD. This number of subjects should allow demonstrating U3-1565 has anti-tumor impact by showing treatment-induced changes in pharmacodynamic biomarkers and clinical activity. Ovarian cancer may be more likely to be impacted by U3 1565 than other tumors, considering that in this cancer, high levels of HB-EGF have been associated with an unfavorable clinical outcome. Six subjects will be initially treated; at which point, a safety analysis will be conducted after these initial subjects have completed the first cycle of treatment, to allow the reevaluation of the appropriateness of the dosing level.
3186873|NCT01290458|Experimental|Vitamin|
3186874|NCT01290458|Placebo Comparator|Control|
3186875|NCT01290445||Exposed|Infants exposed in utero to varenicline
3186876|NCT01290445||Unexposed|infants exposed in utero to cigarette smoke from maternal smoking
3186877|NCT01290445||Reference|infants not exposed in utero to either varenicline or cigarette smoke from maternal smoking
3186878|NCT01290432|Experimental|Inofolic Plus|Patients are given Inofolic Plus to see if the AMH changes over a period of up to 90 days.
3186879|NCT01290419|Experimental|A: Dose 1 + adjuvant|
3186880|NCT01290419|Experimental|B: Dose 2 + adjuvant|
3186881|NCT01290419|Experimental|C: Dose 3 + adjuvant|
3186882|NCT01290419|Experimental|D: Dose 3 alone|
3186883|NCT01290419|Placebo Comparator|E: Placebo control|
3186884|NCT01290419|Experimental|F: Dose 4 alone|
3186885|NCT01290419|Experimental|G: Dose 4 +adjuvant|
3186886|NCT01290406|Experimental|BEZ235|
3186887|NCT01290393||Exposed vaccinated cohort|Women with last menstrual period between 30 days before and 90 days after any CERVARIX dose. The target sample size of the Exposed vaccinated cohort is 150 subjects.
3186888|NCT01290393||Non-exposed vaccinated cohort|Women with last menstrual period between 120 days and 18 months after the last CERVARIX or GARDASIL dose. The target sample size of the Non-exposed vaccinated cohort is 300 subjects.
3186889|NCT01290380|Experimental|ASA 404 + standard chemotherapy|ASA 404 in combination with in combination with standard chemotherapy (paclitaxel + carboplatin or docetaxel) and a cocktail of caffeine, diclofenac, simvastatin and omeprazole
3186890|NCT01290367|Experimental|High Dose MPCs|Injection of High Dose MPCs with Hyaluronic Acid
3186891|NCT01290367|Experimental|Low Dose MPCs|Injection of Low Dose MPCs with Hyaluronic Acid
3186892|NCT01290367|Sham Comparator|Saline injection|Injection of saline solution.
3186893|NCT01290367|Placebo Comparator|Hyaluronic acid injection|Injection of hyaluronic acid solution
3186894|NCT01290354|Experimental|lapatinib|unlabelled, administered orally
3186895|NCT01290341|Experimental|NAFT-600 ( naftin 2 % gel)|Topical; applied once daily for two weeks
3186896|NCT01290341|Placebo Comparator|Placebo|Topical; applied once daily for two weeks.
3186897|NCT01290328|No Intervention|Standard of care|
3186898|NCT01290328|Experimental|Epoetin alfa|150 units/kg/week
3186899|NCT01290315|Experimental|Ferric Carboxymaltose (FCM)|Intravenous iron
3186900|NCT01290315|Active Comparator|Iron Sucrose / Iron Dextran|Intravenous iron
3186901|NCT01290302|Experimental|Luitpold Azacitidine|
3186902|NCT01290302|Active Comparator|Vidaza®|
3186903|NCT01290289|Active Comparator|Epidura, combined spinal epidura & IV|"Gp 1: received CSE analgesia, 25µg of fentanyl injected intrathecally & a bolus of 10 ml of 0.5% lidocaine injected epidurally.~Gp 2: received CSE analgesia, 25µg of fentanyl injected intrathecally & a bolus of 10 ml of 0.0625% bupivacaine injected epidurally.~Gp 3: received 50µg of E fentanyl analgesia, injected intrathecally & a bolus of 10 ml of 0.5% lidocaine, followed by lidocaine E top-ups.~Gp 4: received 50µg of E fentanyl injected intrathecally and a bolus dose of 10 ml of 0.125% bupivacaine, followed by E bupivacaine top-ups.~Gp 5: 50mg of IV pethidine was administered as a loading dose, followed by 0.5 mg/kg."
3187033|NCT01289483|Active Comparator|fospropofol 2 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 2 mg/kg.
3186904|NCT01290276|Experimental|Ond-PR1 followed by (Ond-PR1 + MPh-IR)|Oral dose of 8 mg of ondansetron pulsatile-release formulation 1 followed by Oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)
3186905|NCT01290276|Experimental|Ond-PR2 followed by (Ond-PR2 + MPh-IR)|Oral dose of 8 mg of ondansetron pulsatile-release formulation 2 followed by Oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
3186906|NCT01290263|Experimental|Amgen 386|Cohort A will assess recurrent Glioblastoma Multiforme (GBM) patients who receive AMG 386 monotherapy at 30mg/kg every week. As of August 1, 2013, Cohort A was closed to new accrual following early interim analysis of first 10 participants enrolled on study. None of these patients had achieved stable disease or response at their initial evaluation after 1-2 months of study therapy. Therefore, study investigators and sponsor agreed that the level of single-agent anti-tumor activity associated with AMG386 for recurrent glioblastoma patients is most likely insufficient to satisfy the stopping rule for low efficacy outlined in Section 14.5 for Cohort A.
3186907|NCT01290263|Experimental|Amgen 386 and Bevacizumab|Cohort B will assess recurrent Glioblastoma Multiforme(GBM) patients who receive AMG 386 plus bevacizumab. Because the maximum tolerated dose of this combination therapy has not yet been established, a 3x3 Phase I study was used to determine the maximum tolerated dose. As of June 6, 2014, the MTD was determined to be AMG386 30 mg/kg administered intravenously every week(dose level +1) in combination with bevacizumab at 10mg/kg administered intravenously every other week. As of July 25, 2014 the Cohort B, Phase II portion of the study was opened to accrual.
3186908|NCT01290250|Experimental|Orange juice based beverage enriched in polyphenols|2 daily doses (250 ml each) during 3 months
3186909|NCT01290250|Placebo Comparator|Orange juice with low levels of polyphenols|2 daily doses (250 ml each) during 3 months
3186910|NCT01290237|Experimental|Vancomycin loading dose|Intervention: administer intravenous vancomycin 30 mg/kg/dose once, followed 8 hours later by 20 mg/kg/dose every 8 hours
3186911|NCT01290237|Active Comparator|Control|No intervention. Administer intravenous vancomycin 20 mg/kg/dose every 8 hours as per hospital guideline.
3186912|NCT01290224|Experimental|Supportive Care|See Detailed Description
3186913|NCT01290211|Experimental|Cohort 1|Twice daily regimen
3186914|NCT01290211|Experimental|Cohort 2|Once daily regimen
3186915|NCT01290198|Placebo Comparator|Vehicle without ANESDERM (lidocaine, prilocaine)|
3186916|NCT01290198|Active Comparator|Vehicle with ANESDERM (lidocaine, prilocaine)|
3186917|NCT01290198|Active Comparator|Fluconazole without ANESDERM (lidocaine, prilocaine)|
3186918|NCT01290198|Active Comparator|Fluconazole with ANESDERM (lidocaine, prilocaine)|
3186919|NCT01290185|Experimental|Coiled Catheter|Placement of the coiled catheter for continuous infusion of local anesthetics close to the femoral nerve: To place coiled catheters ab 18-gauge Tuohy needle (Sonoline Curl Catheter Set, Pajunk® Medizintechnologie GmbH, Geisingen, Germany) of 8 cm length is placed adjacent to the nerve by ultrasound guidance and nerve stimulator control. At this position and after injection of 5 ml dextrose 5% in water to dilate the space the coiled catheter is blindly advanced 2 cm through the needle and the final position verified with ultrasound.
3186920|NCT01290185|Active Comparator|Conventional stimulating Catheter|For the control group a conventional stimulating catheter is placed adjacent to the femoral nerve as follows: To place the simulating catheter an 18-gauge Tuhoy needle s placed adjacenit to the nerve by ultrasound guidance. At this position a stimulation catheter is introduced through the needle and stimulated with a decreasing current from 1 mA to 0.4 mA, with a pulse width 0.1ms to verify the appropriate motor response of the quadriceps muscle. The catheter is slowly advanced 3 cm beyond the needle tip under continuous electric stimulation using a current that is subsequently adapted according to the motor response achieved. If muscles twitches disappear during catheter placement at a current above 1 mA, either the catheter or the needle are manipulated until muscle twitches reappear.
3186921|NCT01290172|Experimental|Somatostatin|Patients in this group receive treatment with Somatostatin for 5 days.
3186922|NCT01290172|Placebo Comparator|Placebo|Patients in this group receive a placebo for 5 days.
3186923|NCT01290159||post heat stroke heat tolerant|
3186924|NCT01290159||post heat stroke heat intolerant|
3186925|NCT01290159||healthy controls|
3186926|NCT01290146|Active Comparator|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
3186927|NCT01290146|Experimental|Levosimendan|"Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~SBP ≥100 mmHg: 0.1 mcg/kg/min"
3186928|NCT01290133|Experimental|Active Drug|
3186929|NCT01290133|Placebo Comparator|Placebo|
3186930|NCT01290094|Experimental|Single Arm|
3186931|NCT01290081|Active Comparator|Active referral|Case management intervention group - study personnel scheduled the TB doctor appointment for the participant, reminded to keep it, and transportation to the clinic was organized when needed.
3186932|NCT01290081|No Intervention|Passive referral|Participants were instructed to schedule an appointment with TB services themselves.
3186933|NCT01290068|Experimental|ReSTOR +3|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL, bilateral implantation
3186934|NCT01290068|Experimental|ReSTOR +3 Toric|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative corneal astigmatism, bilateral implantation, or implanted in 1 eye with AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL in the other eye
3186935|NCT01290068|Active Comparator|Monofocal|Monofocal IOL, bilateral implantation
3186936|NCT01290055|Experimental|Group 1|In group 1, participants will receive the Yellow fever vaccine and will be asked to drink deuterium labeled water for 2 weeks. They will undergo phlebotomy on days 0, 14, 21, weeks 6, 10, 14, 18, 22, 26, 32, 36, 40, 44, 48 and 52.
3186937|NCT01290055|Experimental|Group 2|All participants in Group 2 will receive the yellow fever vaccine and will drink deuterium labeled for 3 weeks and will undergo serial phlebotomy for upto 7 months.
3186938|NCT01290042|Active Comparator|Placebo arm|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
3187186|NCT01288508|Active Comparator|Psyllium|
3186939|NCT01290042|Active Comparator|Active arm|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
3186940|NCT01290029|Experimental|Cinacalcet|Participants received a single, oral dose of 0.25 mg/kg cinacalcet.
3186941|NCT01290016|Active Comparator|Control 6-8 yrs|The group will receive information during the study about diet and exercise but will not receive the intervention till the end of the study protocol.
3186942|NCT01290016|Experimental|2 servings dairy + exercise 6-8 yrs|Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.
3186943|NCT01290016|Experimental|4 servings dairy + exercise 6-8 yrs|Subjects in this group will receive family based counselling to maintain the intake of 4 servings of dairy per day and also receive instruction on how to improve their physical activity.
3186944|NCT01290016|Experimental|4 servings dairy + exercise 9-12 yrs|Subjects in this group will receive family based counselling to maintain the standard recommended intake of 4 servings of dairy per day for 9-14 year olds according to the Canada's Food Guide and also receive instruction on how to improve their physical activity.
3186945|NCT01290016|Active Comparator|Control 9-12 yrs|The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
3186946|NCT01290003|Experimental|Antibiotic Group|Neonates randomized to intervention Group(Antibiotic group)will receive the first line antibiotics (Piperacillin-Tazobactam and Amikacin) as per the unit policy for 72 hours. These neonates will also be monitored by performing sepsis screens and blood culture for development of sepsis.
3186947|NCT01290003|No Intervention|No Antibiotic Group|Neonates randomized to 'No antibiotic group' will receive supportive treatment as per standard unit protocol. These neonates will be monitored by performing sepsis screens and blood culture for development of sepsis.
3186948|NCT01289990|Experimental|BI 10773 low (drug naive)|BI 10773 tablets once daily
3186949|NCT01289990|Experimental|BI 10773 high (drug naive)|BI 10773 tablets once daily
3186950|NCT01289990|Placebo Comparator|Placebo (drug naive)|Placebo tablets matching BI 10773 / Sitagliptin once daily
3186951|NCT01289990|Active Comparator|Sitagliptin 100mg (drug naive)|Sitagliptin once daily
3186952|NCT01289990|Experimental|BI 10773 low (pioglitazone)|BI 10773 tablets once daily
3186953|NCT01289990|Experimental|BI 10773 high (pioglitazone)|BI 10773 tablets once daily
3186954|NCT01289990|Placebo Comparator|Placebo (pioglitazone)|Placebo tablets matching BI 10773 once daily
3186955|NCT01289990|Experimental|BI 10773 low (metformin)|BI 10773 tablets once daily
3186956|NCT01289990|Experimental|BI 10773 high (metformin)|BI 10773 tablets once daily
3186957|NCT01289990|Placebo Comparator|Placebo (metformin)|Placebo tablets matching BI 10773 once daily
3186958|NCT01289990|Experimental|BI 10773 low (metformin+sulfonylurea)|BI 10773 tablets once daily
3186959|NCT01289990|Experimental|BI 10773 high (metformin+sulfonylurea)|BI 10773 tablets once daily
3186960|NCT01289990|Placebo Comparator|Placebo (metformin+sulfonylurea)|Placebo tablets matching BI 10773
3186961|NCT01289977||Phlebotomus group|Those in the Phlebotomus group will have exposure to P. duboscqui sand fly
3186962|NCT01289977||Lutzomyia group|Those placed in this group will receive exposure to L. longipalpis sand fly bites.
3186963|NCT01289964|No Intervention|Waiting list control group|No treatment within the study period, were allowed to continue physiotherapy and medication. Were offered the treatment after finishing the study
3186964|NCT01289964|Active Comparator|Treatment group|Received the 5 cupping treatments, application twice a week, non standardised application - individual determinations of trigger points
3186965|NCT01289951|Experimental|Patients with Child-Pugh C hepatic-cirrhosis.|VIH/VHC coinfected patients with advanced (Child-Pugh C) hepatic cirrhosis.
3186966|NCT01289951|Active Comparator|VIH/VHC coinfected patients without liver damage.|
3186967|NCT01289938|Active Comparator|Metoclopramide|Metoclopramide treatment
3186968|NCT01289938|Active Comparator|Diphenhydramine|Diphenhydramine treatment
3186969|NCT01289925|Experimental|Selenium|
3186970|NCT01289925|Placebo Comparator|Sugar Pill|
3186971|NCT01289912|Experimental|RAD001|RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis.
3186972|NCT01289912|Placebo Comparator|Placebo|Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10.
3186973|NCT01289899|Experimental|Arm A|BR-A-657 120mg or placebo
3186974|NCT01289899|Experimental|Arm B|BR-A-657 360mg or placebo
3186975|NCT01289886|Other|Arm A|BR-A-657 20mg or placebo
3186976|NCT01289886|Other|Arm B|BR-A-657 60mg or placebo
3186977|NCT01289886|Other|Arm C|BR-A-657 120mg or placebo
3186978|NCT01289886|Other|Arm D|BR-A-657 240mg or placebo
3186979|NCT01289886|Other|Arm E|BR-A-657 480mg or placebo
3186980|NCT01289860|Active Comparator|Blueberry drink|30g of blueberry powder (equivalent to 200g fresh blueberries) and 300ml of semi-skimmed milk
3186981|NCT01289860|Placebo Comparator|Control drink|29g of powder consisting of sugars and vitamin C, values of which were matched to that of the blueberry drink, with 1 g of citric acid to match for taste.
3186982|NCT01289847|Experimental|Gammaplex|
3186983|NCT01289834|Active Comparator|Hi-Fatigue Bone Cement|CPT femoral stems fixed with Hi-Fatigue Bone Cement
3186984|NCT01289834|Active Comparator|Palacos Bone Cement|CPT femoral stems fixed with Palacos Bone Cement
3186985|NCT01289821|Experimental|Regorafenib + oxaliplatin/folinic acid/5-FU (mFOLFOX6)|On Day 1, participants received 85 mg/m^2 oxaliplatin as a 2-hour intravenous (IV) infusion and folinic acid (either 400 mg/m^2 D/L‑folinic acid or 200 mg/m^2 L-folinic acid) as a 2-hour IV infusion. Once the initial infusion was completed, participants received 5-FU 400 mg/m^2 IV bolus injection immediately followed by a 5-FU 2400 mg/m^2 IV infusion for 46 hours. The next cycle of mFOLFOX6 was administered on Day 15 to 17. Participants received Regorafenib (Stivarga, BAY73-4506) 160 mg orally (po) once daily (qd) on Days 4 to 10 and Days 18 to 24. One cycle comprised 28 days.
3187187|NCT01288495|Experimental|L-alanine|Subjects will consume l-alanine prior to eating fructose-containing foods.
3186986|NCT01289808|Experimental|glucose 25%|"180 healthy babies born term in the Baruch Padeh Medical Center, Poriya.~There will be three study groups:~Study Group: 60 newborn infants who will receive 1cc 25% Glucose, 2-3 minutes prior red-reflex examination.~Base line (control) Group 1: 60 newborn infants who will receive 1cc Water for Injection (WFI), 2-3 minutes prior red-reflex examination.~Base line (control ) Group 2: 60 newborn infants who will not receive neither glucose nor Water for Injection (WFI), 2-3 minutes prior red-reflex examination"
3186987|NCT01289795||first-ever ischemic stroke|first-ever ischemic stroke according to the WHO definition
3186988|NCT01289782|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alpha-2a (PegIFN alpha-2a) and ribavirin (RBV) for 24 or 48 weeks
3186989|NCT01289782|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition to PegIFNα-2a and RBV for 48 weeks
3186990|NCT01289769|Active Comparator|dexmedetomidine|
3186991|NCT01289769|Placebo Comparator|control|
3186992|NCT01289756|Experimental|CYP2D6 EM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
3186993|NCT01289756|Experimental|CYP2D6 IM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
3186994|NCT01289756|Experimental|CYP2D6 PM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
3186995|NCT01289756|Experimental|CYP2D6 UM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
3186996|NCT01289743|Experimental|Etanercept 25 mg|Etanercept 25 mg subcutaneously twice weekly
3186997|NCT01289730|Experimental|Etanercept 25 mg|Etanercept 25 mg subcutaneously twice a week
3186998|NCT01289704|Experimental|TreSPE|Treatment with treadmill, proprioceptive and stretching exercises
3186999|NCT01289704|Active Comparator|SPE|Proprioceptive and stretching exercises
3187000|NCT01289691|Experimental|Air/Oxygen Mixture|Patients in this group will be ventilated with a mixture of air and oxygen during one lung ventilation.
3187001|NCT01289691|Active Comparator|Oxygen|Patients in this group will be ventilated with only oxygen during one lung ventilation.
3187002|NCT01289678|Experimental|interleukin-2|interleukin-2 therapy during lymphocyte recovery
3187003|NCT01289665|Experimental|Lubricating Gel|
3187004|NCT01289665|Active Comparator|Water|
3187005|NCT01289652||HCV + HIV|
3187006|NCT01289652||HCV|
3187007|NCT01289639|Placebo Comparator|Placebo|matching placebo 1 po qd
3187008|NCT01289639|Experimental|Fenofibrate|micronized fenofibrate 200 mg 1 po qd
3187009|NCT01289639|Experimental|Pioglitazone|pioglitazone 30 mg po qd
3187010|NCT01289613||Children|Children
3187011|NCT01289613||Adults|Adults
3187012|NCT01289600|Active Comparator|Pressure support ventilation, ARDSnet|"Mechanical ventilator is set to pressure support ventilation (6 ml/kg) for 30 min with positive end expiratory pressure (PEEP) set according to the higher arm of the ARDS network consensus."
3187013|NCT01289600|Active Comparator|Pressure control ventilation, ARDSnet|"Mechanical ventilator is set to pressure control ventilation (6 ml/kg) for 30 min with PEEP set according to the higher arm of the ARDS network consensus."
3187014|NCT01289600|Active Comparator|Neurally adjusted ventilatory assist, ARDSnet|"Mechanical ventilator is set to NAVA for 30 min with PEEP set according to the higher arm of the ARDS network consensus."
3187015|NCT01289600|Active Comparator|Neurally adjusted ventilatory assist, titrated|Mechanical ventilator is set to NAVA for 30 min with PEEP titrated using the diaphragm EMG signal.
3187016|NCT01289587|Experimental|Alternative frequency variant|An alternative variant of the DIAfit program (progressive increase of the number of administered PA sessions per week, namely one PA session per week during 4 weeks and then twice a week over a period of 16 weeks)
3187017|NCT01289587|Active Comparator|Standard frequency program|Standard usual program (3 times per week over a period of 12 weeks)
3187018|NCT01289574|Placebo Comparator|Vehicle control cream|
3187019|NCT01289574|Experimental|0.025% ASC-J9 cream|
3187020|NCT01289574|Experimental|0.1% ASC-J9 cream|
3187021|NCT01289561|Experimental|Alcohol self-administration|All participants will participate in seven sessions. In three sessions, each participant will consume a beverage containing alcohol and caffeine. In three separate sessions, participants will consume a beverage containing alcohol and caffeine-placebo. In the final session, all participants may choose which beverage they consume. Participants and research assistants will be blinded to inclusion of caffeine/caffeine-placebo in beverage, but each beverage will be labeled for identification (e.g., A or B).
3187022|NCT01289548|No Intervention|control|patients (both donors and recipients) had a deflated cuff placed on the left lower limb for 30 min
3187023|NCT01289548|Experimental|donor|Donors receive remote ischaemic preconditioning after anaesthesia induction and before surgery started; recipients only have a deflated blood pressure cuff around their leg for 30 minutes.
3187024|NCT01289548|Experimental|recipient|recipients receive remote ischaemic preconditioning after anaesthesia induction and before surgery started; donors only have a deflated blood pressure cuff around their leg for 30 minutes.
3187025|NCT01289535|Experimental|antibody rates|
3187026|NCT01289522|Experimental|cetuximab|Patients receive four cycles of chemotherapy comprising cetuximab IV plus docetaxel IV over 1 hour and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of the fourth cycle of chemotherapy, patients receive a maintenance therapy with cetuximab every 2 weeks. Treatment will be continued until disease progression or unacceptable toxicities according
3187027|NCT01289509|Experimental|Experimental 1|Drug: E5501
3187028|NCT01289509|Experimental|Experimental 2|Drug: E5501
3187029|NCT01289496|Experimental|Peg-interferon alpha-2a, Ribavirin|"Adult patients with chronic hepatitis C and failure of prior treatment with peginterferon plus ribavirin(non-response or relapse).~This is a pilot study with no control group."
3187030|NCT01289483|Active Comparator|fospropofol 6.5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 6.5 mg/kg.
3187031|NCT01289483|Active Comparator|fospropofol 5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 5 mg/kg.
3187032|NCT01289483|Active Comparator|fospropofol 3.5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 3 mg/kg.
3187278|NCT01287897|Experimental|Drug Dose level 1 - SC injection|
3187034|NCT01289457|Experimental|Clofarabine + Idarubicin + Cytarabine|Phase I: Clofarabine Starting dose 15 mg/m2 by vein for 5 days (days 1-5) + Idarubicin 10 mg/m2 by vein on day 1-3 + Cytarabine 1 g/m2 by vein on day 1-5.
3187035|NCT01289457|Experimental|Group 1 CIA|Phase II, Group 1 CIA (Clofarabine + Idarubicin + Cytarabine): Clofarabine MTD based on Phase I by vein on days 1-5; Idarubicin 10 mg/m2 by vein on days 1-3; Cytarabine 1 g/m2 by vein on days 1-5.
3187036|NCT01289457|Experimental|Group 2 FLAI|Phase II, Group 2 FLAI (Fludarabine + Idarubicin + Cytarabine): Fludarabine 30 mg/m2 by vein on days 1-5; Idarubicin 10 mg/m2 by vein on days 1-3; Cytarabine 1 g/m2 by vein on days 1-5.
3187037|NCT01289444|Active Comparator|Healthy Living Control|"Session 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered, with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.~Session 3. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides. The Administered by the trained RA-Control to prevent contamination with the FACE condition."
3187038|NCT01289444|Experimental|FAmily CEntered (FACE) ACP|Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care & when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care & prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
3187039|NCT01289431|Experimental|Mapracorat|
3187040|NCT01289431|Placebo Comparator|Mapracorat Vehicle|
3187041|NCT01289418||Health care workers in Québec|Health care workers from CHUQ hospitals
3187042|NCT01289418||Health care workers in Toronto|Health care workers from the Mount Sinai Hospital
3187043|NCT01289418||Health care workers in Halifax|Health care workers from the Queen Elizabeth Hospital
3187044|NCT01289405|Placebo Comparator|placebo exercices|relaxation exercises and stretching neck, without therapeutic purpose.
3187045|NCT01289405|Active Comparator|phonoaudiologic therapy|isometric and isotonic exercises to improve posture, mobility and muscle tone of the soft palate, pharyngeal constrictor muscles, tip and base of tongue, cheeks and lips.
3187046|NCT01289392|Active Comparator|Continuous Positive Airway Pressure (CPAP)|CPAP is the gold standard treatment
3187047|NCT01289392|Active Comparator|Oral Appliance|Alternative treatment for obstructive sleep apnea patients
3187048|NCT01289392|Active Comparator|Physical Exercise|Aerobic and resistance physical exercises
3187049|NCT01289379|Experimental|HFJV|
3187050|NCT01289366||Patients with IBD|
3187051|NCT01289353|Experimental|ChemoRT|Concurrent Carboplatin and Radiotherapy
3187052|NCT01289340||Polymem (R)|superficial burns treated with Polymem wound dressing until complete wound healing
3187053|NCT01289340||Biaten IBU|burns treated with Biaten IBU until complete wound healing.
3187054|NCT01289340||Hartmen dressing|burns treated with hartman or saline wet dressing until wound healing
3187055|NCT01289327|Active Comparator|propofol|
3187056|NCT01289327|Active Comparator|midazolam+alfentanil|
3187057|NCT01289314|Active Comparator|Total laparoscopic hysterectomy|
3187058|NCT01289314|Active Comparator|Laparoscopic supracervical hysterectomy|
3187059|NCT01289301|Experimental|mTOR-receiving arm|switching from calcineurin-inhibitor-based immunosuppression to mTOR-based immunosuppression
3187060|NCT01289301|Active Comparator|calcineurin-inhibitor keeping arm|continuing calcineurin-inhibitor based immunosuppression
3187061|NCT01289288|Experimental|Mailed printed materials and in-office training|
3187062|NCT01289288|No Intervention|Control|Usual care
3187063|NCT01289275|Experimental|Telephone Counseling|Up to 5 proactive counseling sessions
3187064|NCT01289275|Experimental|Nicotine Patches|8 weeks of nicotine patches
3187065|NCT01289275|Experimental|Telephone Counseling + Patches|5 proactive sessions, 8 weeks patches
3187066|NCT01289275|Active Comparator|Brief hospital counseling|brief in hospital counseling, no proactive sessions or patches
3187067|NCT01289262|Active Comparator|Purse string closure technique|Uterine Kerr incision will be closed with purse string suture.
3187068|NCT01289262|Active Comparator|Continuously locked closure technique|Uterine Kerr incision will be closed with continuously locked closure technique.
3187069|NCT01289249||Children receiving meropenem|Children aged from 3 months to 18 years that receive treatment with meropenem.
3187070|NCT01289236|Placebo Comparator|Placebo|Placebo BID (twice daily, approximately 12 hours apart)
3187071|NCT01289236|Active Comparator|milnacipran 200 mg|200mg- 1 100mg tablet BID (twice daily, approximately 12 hours apart)
3187072|NCT01289236|Active Comparator|milnacipran 100 mg|100mg- 1 50mg tablet BID (twice daily, approximately 12 hours apart)
3187073|NCT01289223|Active Comparator|Treatment of Physicians Choice|Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
3187074|NCT01289223|Experimental|Bendamustine IV|Up to 8 cycles of Bendamustine (120mg/m2 Days 1 and 2, every 21 days (+ 3 days).
3187075|NCT01289210|Other|VTX-2337 plus radiation|
3187076|NCT01289197|No Intervention|No Feedback or services offered.|The Family Check-Up is not offered.
3187077|NCT01289197|Other|Intervention|Family Check Up is offered.
3187078|NCT01289184||control|
3187079|NCT01289184||exposure 2-3 years|
3187080|NCT01289184||exposure 3-5 years|
3187081|NCT01289184||exposure 5-10 years|
3187082|NCT01289184||exposure >15 years|
3187083|NCT01289171|Experimental|Glycolic acid|All who met the study criteria commenced once daily use of 15% glycolic acid lotion.
3187084|NCT01289158||non-classical CMAMMA, classical CMAMMA|
3187085|NCT01289145|Experimental|Intervention|"Participants will be allocated to a motivational intervention, a volitional intervention or the active control group.~The motivational intervention promotes positive outcome expectancies on physical activity. The volitional intervention promotes the formulation of action plans for physical activity. Participants in the active control group, receive a quiz on physical activity and sports."
3187086|NCT01289132|Placebo Comparator|Placebo|
3187087|NCT01289132|Experimental|Azilsartan 5 mg QD|
3187088|NCT01289132|Experimental|Azilsartan 10 mg QD|
3187089|NCT01289132|Experimental|Azilsartan 20 mg QD|
3187090|NCT01289132|Experimental|Azilsartan 40 mg QD|
3187091|NCT01289132|Experimental|Azilsartan 80 mg QD|
3187092|NCT01289132|Active Comparator|Candesartan Cilexetil 8 mg titrated to12 mg QD|
3187093|NCT01289119|Placebo Comparator|Placebo|Participants received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
3187094|NCT01289119|Experimental|Alogliptin Monotherapy|Participants received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
3187095|NCT01289119|Other|Metformin|Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
3187096|NCT01289119|Experimental|Metformin + Alogliptin Add-on Therapy|Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
3187097|NCT01289119|Other|Pioglitazone|Participants continued to receive their stable dose of pioglitazone with or without metformin, and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
3187098|NCT01289119|Experimental|Pioglitazone + Alogliptin Add-on Therapy|Participants continued to receive their stable dose of pioglitazone with or without metformin and also received alogliptin, 25 mg tablets orally once daily for up to 16 weeks.
3187099|NCT01289106|Active Comparator|Arm A|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
3187100|NCT01289106|Experimental|Arm B|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
3187101|NCT01289106|Experimental|Arm C|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
3187102|NCT01289093||laparoscopic ingunal herniotomy|
3187103|NCT01289093||laparoscopic incisional herniotomy|
3187104|NCT01289093||Lichtenstein inguinal herniotomy|
3187105|NCT01289093||laparoscopic umbilical hernia repair|
3187106|NCT01289080|Active Comparator|Group 1|subjects with normal renal function
3187107|NCT01289080|Active Comparator|Group 2|severely renally impaired subjects
3187108|NCT01289067|Other|Satraplatin, Single Arm|
3187109|NCT01289054||Cohort 1 - Pregnancy/Fetal Exposure|
3187110|NCT01289054||Cohort 2 - Interrupted TKI|
3187111|NCT01289041|Experimental|All Patients|
3187112|NCT01289028|Experimental|Nilotinib|nilotinib 400 mg twice daily (bid).
3187113|NCT01289015|Experimental|NAFT-600 ( naftin 2 % gel)|
3187114|NCT01289015|Placebo Comparator|Placebo|
3187115|NCT01288989|Experimental|IMC-3C5|Patients receiving IMC-3C5 intravenously
3187116|NCT01288976||MitraClip Therapy|Patients treated with the MitraClip System.
3187117|NCT01288976||Medical Management|Patients with MR managed non-surgically based on standard hospital clinical practice.
3187118|NCT01288976||Mitral Valve Surgery|Patients with MR managed surgically (repair or replacement) based on standard hospital clinical practice.
3187119|NCT01288963||IL-2 subjects|Subjects receiving IL-2 for advanced melanoma
3187120|NCT01288950|Experimental|Vitamin D3|
3187121|NCT01288950|No Intervention|Placebo|
3187122|NCT01288937|Experimental|Milnacipran|Day 1: 12.5 mg once Day 2 3: 25 mg/day (12.5 mg twice daily) Day 4 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)
3187123|NCT01288937|Placebo Comparator|Placebo|Day 1: 12.5 mg once Day 2 3: 25 mg/day (12.5 mg twice daily) Day 4 7: 50 mg/day
3187124|NCT01288924|Active Comparator|Parecoxib|Parecoxib 2 ml intravenous
3187125|NCT01288924|Placebo Comparator|Control|0.9% sodium chloride 2 ml intravenous
3187126|NCT01288911|Experimental|Enzalutamide|Participants received enzalutamide 160 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.
3187127|NCT01288911|Active Comparator|Bicalutamide|Participants received bicalutamide 50 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.
3187128|NCT01288872|Experimental|Praziquantel|45 women in 3 cohorts (15 early pregnancy: 12-16 weeks gestation; 15 late pregnancy: 30-36 weeks gestation; and 15 lactating nonpregnant women who are 5-7 months (inclusive) postpartum) given praziquantel (PZQ), 60 mg/kg orally in split dose (30 mg/kg each) separated by 3 hours.
3187129|NCT01288859|Experimental|encapsulated curcumin|
3187130|NCT01288859|Experimental|encapsulated curcumin + PQG|PQG means Piperine, Quercetin and Genistein
3187131|NCT01288859|Active Comparator|free cocoa polyphenol|
3187132|NCT01288859|Placebo Comparator|control|
3187133|NCT01288859|Experimental|encapsulated cocoa polyphenols|
3187134|NCT01288859|Active Comparator|free curcumin|Subjects will consume bread added with free curcumin
3187135|NCT01288846||Acutly ill, Medical ward, consent|group of acutely ill patient who uses three or more drugs, must be able to give consent.
3187136|NCT01288833|Experimental|Close focus HD NBI Colonoscopy System|Use of close focus to make optical diagnosis
3187137|NCT01288833|No Intervention|Current HD NBI Colonoscopy System|Use of standard focus for optical diagnosis
3187138|NCT01288820|Experimental|DHP+PQ|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
3187139|NCT01288820|Active Comparator|AS-AQ +PQ|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
3187140|NCT01288807|Experimental|Treatment|Titrated Milnacipram doses
3187141|NCT01288794|Active Comparator|Standard medical treatment plus albumin|The patients will receive standard medical treatment (diuretics) plus weekly albumin infusion
3187142|NCT01288794|Other|Standard medical treatment|The patients will receive the standard medical treatment (diuretics), but non albumin for the therapy of ascites
3187143|NCT01288781|Experimental|Acetazolamide|Arm 1: ACETAZOLAMIDE (250mg) will be given to subjects at fifteen, twenty and thirty two hours post hypoxic exposure (3777m).
3187144|NCT01288781|Placebo Comparator|Placebo|Placebo (LACTOSE MONOHYDRATE) will be given to subjects at fifteen, twenty and thirty two hours post hypoxic exposure (3777m).
3187145|NCT01288768|Active Comparator|Arthroscopy|Knee arthroscopy + Exercise therapy
3187146|NCT01288768|No Intervention|Exercise therapy|Exercise therapy alone
3187147|NCT01288755|Experimental|001|TMC278 One 25 mg tablet once daily for 11 days (TrtA and C)
3187148|NCT01288755|Experimental|002|Raltegravir One 400 mg tablet twice daily for 4 days (Trt B) and for 11 days (TrtC)
3187149|NCT01288742|Experimental|001|TMC435 One 150-mg capsule once daily for 7 days (Trts B and D).
3187150|NCT01288742|Experimental|002|Digoxin One 0.25-mg tablet for 1 day (Trt A)
3187151|NCT01288742|Experimental|003|Digoxin One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
3187152|NCT01288742|Experimental|004|Rosuvastatin One 10-mg tablet for 1 day (Trt C).
3187153|NCT01288742|Experimental|005|Rosuvastatin One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
3187154|NCT01288729|Experimental|Group 1 - Steel Cathetar, then Teflon|Participants will alternate between wearing the Sure-T Steel Infusion Set Catheter for 7 days, then the Quick-Set Teflon for 7 days.They will wear each set twice starting with the Sure-T Steel Infusion Set.
3187155|NCT01288729|Experimental|Group 2 - Teflon Cathetar, the Steel|Participants will alternate between wearing the Quick-Set Teflon catheter for 7 days, then the Quick-Set Teflon for 7 days. They will wear each set twice starting with the Quick-Set Teflon set.
3187156|NCT01288716|Placebo Comparator|Placebo|
3187157|NCT01288716|Active Comparator|Arbaclofen|
3187158|NCT01288690|No Intervention|Wait List Control|This condition is a wait-list control and receives no intervention during the study period, but is offered treatment after the final assessment.
3187159|NCT01288690|Experimental|Narrative Exposure Therapy|Patients in this condition receive 3 sessions of Narrative Exposure Therapy
3187160|NCT01288677|Experimental|001|TMC649128 Escalated doses
3187161|NCT01288664|Experimental|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase for 6 months
3187162|NCT01288638|Experimental|Pulse-based diet|The pulse based-diet will include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils.
3187163|NCT01288638|Placebo Comparator|TLC diet|Grocery gift cards will be provided weekly for 16 weeks to those participants in the placebo group. Recipe booklet will be given to follow Therapeutic Lifestyle Changes (TLC) guidelines, recommended by National Cholesterol Education Program (NCEP) and will be based on lean-meats for the protein source. The recipes will exclude pulses.
3187164|NCT01288625|Experimental|Cytofos group A|Amifostine 500 mg sc, qod, 3 times per week Radiation treatment 30 min after amifostine treatment, 1.8-2.0 Gy/day × 30-35 times
3187165|NCT01288625|Experimental|Cytofos group B|Amifostine 500mg rinsing wash, qod, 3 times per week Radiation treatment 5 min after amifostine treatment, 1.8-2.0 Gy/day × 30-35 times
3187166|NCT01288625|Active Comparator|Control group|Radiation treatment 1.8-2.0 Gy/day × 30-35 times
3187167|NCT01288612|Active Comparator|Sedated Endoscopy|Sedated esophagogastroduodenoscopy with biopsy
3187168|NCT01288612|Active Comparator|Transnasal Endoscopy at Hospital Unit|Unsedated transnasal endoscopy at hospital unit.
3187169|NCT01288612|Active Comparator|Transnasal Endoscopy at Mobile Unit|Unsedated transnasal endoscopy in mobile research van
3187170|NCT01288599|Experimental|Single port access laparoscopy|Single port access laparoscopy for benign adnexal disease.
3187171|NCT01288599|Active Comparator|Conventional laparoscopy|Conventional laparoscopy for benign adnexal disease.
3187172|NCT01288586||Device|Scandinavian Total Ankle Replacement System (STAR Ankle)
3187173|NCT01288573|Experimental|Plerixafor 160 μg/kg|Patients will receive subcutaneous (SC) injection of 160 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
3187174|NCT01288573|Experimental|Plerixafor 240 μg/kg|Patients will receive subcutaneous (SC) injection of 240 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
3187175|NCT01288573|Experimental|Plerixafor 320 μg/kg|Patients will receive subcutaneous (SC) injection of 320 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
3187176|NCT01288560|Active Comparator|Advanced cardiac imaging (PET/CT or CMR)|Patients will undergo cardiac imaging as evaluation of heart failure using 1 of the following alternate/advanced imaging modalities: Positron Emission Tomography (PET/CT), Cardiac Magnetic Resonance (CMR)
3187177|NCT01288560|Active Comparator|Standard cardiac imaging (SPECT)|Patients will undergo standard cardiac imaging procedures for evaluation of heart failure such as single photon emission computed tomography (SPECT).
3187178|NCT01288547|Active Comparator|theobromine|theobromine (700 mg) in capsule
3187179|NCT01288547|Active Comparator|caffeine|caffeine (120 mg) in capsule
3187180|NCT01288547|Placebo Comparator|Placebo capsule|no theobromine or caffeine
3187181|NCT01288547|Active Comparator|theobromine + caffeine|Combined theobromine and caffeine treatment, consisting of 700 mg theobromine and 120 mg caffeine
3187182|NCT01288534|Experimental|Radiation Treatment|
3187183|NCT01288521|Experimental|Tacrolimus + Ketoconazole, Then Tacrolimus alone|Participants first received tacrolimus in combination with with ketoconazole. After a 1-2 week washout they received tacrolimus alone.
3187184|NCT01288521|Experimental|Tacrolimus alone, Then Tacrolimus + Ketoconazole|The participants first received tacrolimus alone. After a 1-2 week washout period they received tacrolimus in combination with ketoconazole.
3187185|NCT01288508|Active Comparator|Supra Fiber|
3187188|NCT01288495|Placebo Comparator|Placebo|Subjects will consume the placebo prior to eating fructose-containing foods.
3187189|NCT01288482|Experimental|Asthma Subjects|
3187190|NCT01288469|Placebo Comparator|Placebo + Atorvastatin 80 mg|Placebo (for alirocumab) subcutaneous (SC) administration every 2 weeks (Q2W) in combination with atorvastatin 80 mg orally once daily for 8 weeks.
3187191|NCT01288469|Experimental|Alirocumab + Atorvastatin 10 mg|Alirocumab 150 mg SC administration Q2W in combination with atorvastatin 10 mg orally once daily for 8 weeks.
3187192|NCT01288469|Experimental|Alirocumab + Atorvastatin 80 mg|Alirocumab 150 mg SC administration Q2W in combination with atorvastatin 80 mg orally once daily for 8 weeks.
3187193|NCT01288443|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
3187194|NCT01288443|Experimental|Alirocumab 50 mg Q2W|Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
3187195|NCT01288443|Experimental|Alirocumab 100 mg Q2W|Alirocumab 100 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
3187196|NCT01288443|Experimental|Alirocumab 150 mg Q2W|Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
3187197|NCT01288443|Experimental|Alirocumab 200 mg Q4W|Alirocumab 200 mg every 4 weeks (Q4W) and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.
3187198|NCT01288443|Experimental|Alirocumab 300 mg Q4W|Alirocumab 300 mg Q4W and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.
3187199|NCT01288430|Experimental|DS-2248|"Study Part 1: DS-2248 oral capsule(s) of increasing strength in a dose escalation study in subjects with advanced solid tumors, administered once daily in 21-day cycles, with no interruption between cycles if no unacceptable treatment-related toxicity or tumor progression is observed.~Study Part 2: DS-2248 oral capsule(s) dose of 4.5 mg/m2, in subjects with non-small cell lung cancer who have developed acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors or whose tumors carry an ALK translocation and are resistant to ALK inhibitor therapy, administered once daily in 21 day-cycles, with no interruption between cycles if no unacceptable treatment-related toxicity or tumor progression are observed."
3187200|NCT01288417|Experimental|boceprevir + raltegravir|9 days of boceprevir 800mg TID; day 10 two doses of boceprevir 800mg and one dose of raltegravir 400mg
3187201|NCT01288417|Active Comparator|raltegravir alone|single dose of raltegravir 400mg
3187202|NCT01288404|Placebo Comparator|Control|topical 0.1% fluorometholone eye drops
3187203|NCT01288404|Active Comparator|Bevacizumab group 1|Bevacizumab 1.25 mg/0.05mL
3187204|NCT01288404|Active Comparator|Bevacizumab group 2|Bevacizumab 2.5 mg/0.1mL
3187205|NCT01288404|Active Comparator|bevacizumab group 3|bevacizumab 3.75 mg/0.15mL
3187206|NCT01288391|Experimental|100 mcg/kg|
3187207|NCT01288391|Experimental|200 mcg/kg|
3187208|NCT01288378|Active Comparator|Empirical|Empirical approach (fever driven) for starting antifungal therapy
3187209|NCT01288378|Experimental|Pre-emptive|Pre-emptive approach (diagnostic driven) for starting antifungal therapy
3187210|NCT01288365|Experimental|Exercise training|Protocol of 3 month exercise training program.
3187211|NCT01288365|No Intervention|Control|Control group
3187212|NCT01288352|No Intervention|Usual care|Usual care closely follows the suggestions laid out in the current European Society of Cardiology (ESC) guidelines for AF treatment. In addition to antithrombotic therapy and therapy of underlying heart disease, usual care usually consists of an initial attempt to control symptoms by rate control therapy. Rhythm control interventions are recommended when symptoms can not be controlled by optimal rate control therapy in the usual care group.
3187213|NCT01288352|Other|early standardised rhythm control|"Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.~Early-onset rhythm control therapy can consist of:~Optimal antiarrhythmic drug therapy (Dronedarone, Amiodarone, Flecainide, Propafenone),~Catheter ablation with the aim of pulmonary vein isolation (PVI),~Antiarrhythmic drug therapy and catheter ablation may be supplemented by early cardioversion in patients with persistent AF.~All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences."
3187214|NCT01288339|Experimental|Panitumumab + FOLFOX (DP)|Panitumumab and FOLFOX will be administered to patients with DP (MMP7+/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
3187215|NCT01288339|Experimental|Panitumumab + FOLFOX (no-DP)|Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
3187216|NCT01288326||A|
3187217|NCT01288313|Experimental|rapeseed oil|
3187218|NCT01288313|Experimental|n-3 margarine and rapeseed oil|
3187219|NCT01288313|Experimental|n-3 margarine|
3187220|NCT01288313|Active Comparator|Olive oil|
3187221|NCT01288300|Active Comparator|Comprehensive diabetes self-management intervention|Diabetes education, self-empowerment training, exercise, patient navigator
3187222|NCT01288300|Other|Control|Diabetes self-management lecture
3187223|NCT01288287||Week 12 Disease Activity Score (DAS) Responders|Patients achieving a reduction from Baseline in a Disease Activity Score 28-joint count (Erythrocyte Sedimentation Rate) [DAS28(ESR)] score of greater than 1.2 points at Week 12
3187224|NCT01288287||Week 12 Disease Activity Score (DAS) Non-Responders|Patients who fail to achieve a reduction from Baseline in a Disease Activity Score 28-joint count (Erythrocyte Sedimentation Rate) [DAS28(ESR)] score of greater than 1.2 points at Week 12
3187225|NCT01288274|Active Comparator|Injection by Health Extension Worker|Women who receive injectable contraceptive from clinic based health extension workers (HEWs) during the study period
3187279|NCT01287897|Experimental|Drug Dose level 2 - SC injection|
3187280|NCT01287884|No Intervention|Venous Blood Gas|All subjects have an ABG and VBG drawn. No intervention.
3187226|NCT01288274|Active Comparator|Injection by Community Health Worker|Women who receive injectable contraceptive through community based distributors from community based reproductive health agents (CBRHAs) during the study period
3187227|NCT01288261|Experimental|Treatment|Paclitaxel, bavituximab, laboratory biomarker analysis and pharmacological study
3187228|NCT01288248|Experimental|Airway laryngeal mask classic|Ventilation with Airway laryngeal mask classic during surgery
3187229|NCT01288248|Active Comparator|endotracheal tube|Ventilation with endotracheal tube during surgery
3187230|NCT01288235|Experimental|Proton Radiotherapy|Proton Radiotherapy
3187231|NCT01288222|Experimental|Unrelated Donor Transplant Patients|Patients with acute myeloid leukemia who have received KIR genotype from an unrelated donor transplant.
3187232|NCT01288209|Experimental|TMC435 100 mg 12 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment will be stopped at Week 24 if participants achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels < 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
3187233|NCT01288209|Experimental|TMC435 100 mg 24 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin ( PR) for 24 weeks (Wks). Treatment will be stopped at Week 24 if participants achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels < 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
3187234|NCT01288196|Experimental|001|CNTO 6785 1 mg/kg IV A single 30-minute IV infusion of CNTO 6785 1 mg/kg
3187235|NCT01288196|Experimental|002|CNTO 6785 3 mg/kg IV A single 30-minute IV infusion of CNTO 6785 3 mg/kg
3187236|NCT01288196|Experimental|003|CNTO 6785 10 mg/kg IV A single 30-minute IV infusion of CNTO 6785 10 mg/kg
3187237|NCT01288196|Placebo Comparator|004|Placebo IV A single 30-minute IV infusion of placebo
3187238|NCT01288196|Experimental|005|CNTO 6785 SC A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
3187239|NCT01288196|Placebo Comparator|006|Placebo SC A single SC dose of placebo administered in up to 3 SC injections
3187240|NCT01288183|Sham Comparator|sham tDCS|sham transcranial direct current stimulation The anode (7 x 5 cm) is placed on the right dorsolateral prefrontal cortex. A large cathode (10 x 10cm) is placed on the left occipital region
3187241|NCT01288183|Active Comparator|active tDCS|active anodal tDCS over the right dorsolateral prefrontal cortex The anode (7 x 5 cm) is placed on the right dorsolateral prefrontal cortex. A large cathode (10 x 10cm) is placed on the left occipital region Intensity of the stimulation: 2 mA Duration of the stimulation: 20 min 10 sessions, 2 per day
3187242|NCT01288170|Other|Nebcinal Tobi|crossover design
3187243|NCT01288170|Other|Tobi Nebcinal|crossover design
3187244|NCT01288157|Experimental|001|Golimumab Single dose of 50 mg subcutaneously
3187245|NCT01288157|Experimental|002|Golimumab Single dose of 100 mg subcutaneously
3187246|NCT01288144|Experimental|Intervention|Quality improvement initiative using computerized decision support
3187247|NCT01288144|No Intervention|Usual care|In control clinics, women will continue to receive usual care.
3187248|NCT01288131|Active Comparator|CSA+MMF|Cyclosporine 100 mg BID combine with Mycophenolate mofetil 750 mg BID for 24 weeks
3187249|NCT01288131|Active Comparator|Cyclophosphamide + pred|Cyclophosphamide 100 mg QD and prednisolone 1.0 mg/kg/day
3187250|NCT01288105|Experimental|Optical Coherence Tomography|Patients enrolled in the study will undergo optical coherence tomography to evaluate the extent of stent strut coverage.
3187251|NCT01288092|Experimental|BEZ235|
3187252|NCT01288079|Experimental|1|TC-5214, 1 mg BID
3187253|NCT01288079|Experimental|2|TC-5214, 4 mg BID
3187254|NCT01288079|Active Comparator|3|Duloxetine 60 mg Q Day
3187255|NCT01288079|Placebo Comparator|4|Placebo
3187256|NCT01288066|Other|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system.
3187257|NCT01288066|Other|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system.
3187258|NCT01288053|Experimental|Allogeneic Stem Cell Therapy|Allogeneic Stem Cell Therapy will be performed after conditioning
3187259|NCT01288040|Experimental|Treadmill exercise|Split-belt treadmill training
3187260|NCT01288027|Experimental|Alglucosidase Alfa|
3187261|NCT01288014||Edlerly Recipients of Zoster Vaccine|Blood samples are collected before and after vaccination in people age 60 or more, who are getting the zoster vaccine as part of their routine health care.
3187262|NCT01288001|Experimental|Ostenil plus|Patient will get Ostenil plus injection and standard treatment of Osteoarthritis
3187263|NCT01287988||Ocriplasmin|Subjects who were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study (TG-MV-006 or TG-MV-007)
3187264|NCT01287988||Placebo|Subjects who were exposed to a single intravitreal injection of placebo in a previous phase III study (TG-MV-006 or TG-MV-007)
3187265|NCT01287975|Active Comparator|Standard Occupational Therapy|Standard Occupational Therapy for Wrist and Hand Training
3187266|NCT01287975|Experimental|BCI Haptic Knob|BCI controlled robotic-assisted training for wrist and hand
3187267|NCT01287975|Experimental|Haptic Knob|Robotic-assisted training for wrist and hand
3187268|NCT01287962|Experimental|Apatinib|750 mg，po，QD； 28 days every cycle
3187269|NCT01287962|Placebo Comparator|Placebo|
3187270|NCT01287949|Experimental|REPEVAX followed by REVAXIS administration|
3187271|NCT01287936|Experimental|SB623|Administration of modified stem cells, SB623
3187272|NCT01287923||DLBCL|DLBCL patients included 075-GOELAMS trial or 075-like patient.
3187273|NCT01287923||Healthy controls|Blood donors from the EFS (French Blood Bank) of Rennes.
3187274|NCT01287923||Septic patients|septic patients included at the Rennes University Hospital.
3187275|NCT01287923||DLBCL in completed remission|DLBCL patients from the 075 GOELAMS study in completed remission.
3187276|NCT01287910|Other|All Patients|All patients undergo the same study procedures
3187277|NCT01287897|Placebo Comparator|Placebo- SC injection|
3187281|NCT01287871||Social media intervention|Women between the ages of 18-70 who have not been diagnosed with any type of cancer and are of African descent or Latina
3187282|NCT01287858|Placebo Comparator|Placebo|Placebo
3187283|NCT01287858|Active Comparator|AC430|AC430
3187284|NCT01287845|Experimental|Arm 1|
3187285|NCT01287845|Experimental|Arm 2|
3187286|NCT01287832|Active Comparator|High dose vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
3187287|NCT01287832|Experimental|High-dose daptomycin|Daptomycin dosed at 8 mg/kg/daily (every 48 hours in end-stage renal disease)
3187288|NCT01287819||APOE4 (+) and APE4 (-)|APOE4 (+) 10 people APOE4 (-) 20 people from 200 participants
3187289|NCT01287806|Sham Comparator|blank control group|
3187290|NCT01287806|Experimental|ulinastatin group|ulinastatin is a multivalent kunitz-type serine protease inhibitor refined from human urine
3187291|NCT01287793|Experimental|high dose tigecycline|
3187292|NCT01287793|Experimental|regular dose tigecycline|
3187293|NCT01287793|Active Comparator|moxifloxacin|
3187294|NCT01287793|Placebo Comparator|placebo|
3187295|NCT01287780|Active Comparator|Collagen-gentamicin sponges|Two sponges of collagen-gentamicin will be inserted into the hip immediately before closure of the wound. Each sponge (10 by 10 cm) contains 280 mg of collagen and 130 mg of gentamicin.
3187296|NCT01287780|No Intervention|No intervention|
3187297|NCT01287767|No Intervention|Control group, ordinary support|Home care as usual.
3187298|NCT01287767|Experimental|A multidimensjonalt support program|•Behavioral (e.g., Psychotherapy, Lifestyle Counseling) The family will receive individual consulting, teaching and problem solving in support groups.
3187299|NCT01287754|Experimental|Single Arm|
3187300|NCT01287741|Active Comparator|Rituximab+Chemotherapy|Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.
3187301|NCT01287741|Experimental|Obinutuzumab+Chemotherapy|Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.
3187302|NCT01287728|Experimental|treatment BY METROMIDAZOLE|
3187303|NCT01287715|Experimental|STOP-arm|Discontinuation of etanercept
3187304|NCT01287715|No Intervention|CONTROL-arm|Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
3187305|NCT01287702|Experimental|Early feeding|patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
3187306|NCT01287702|Active Comparator|Dealyed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL.
3187307|NCT01287689||Patient treated with any IgG|Any marketed SC or IV IgG can be documented
3187308|NCT01287663|Placebo Comparator|no permethrin|
3187309|NCT01287663|Experimental|permethrin|
3187310|NCT01287637|Experimental|Early reversal group|Early reversal of temporary ileostomy
3187311|NCT01287637|Active Comparator|Control group|Standard reversal of temporary ileostomy
3187312|NCT01287624|Experimental|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin)
3187313|NCT01287624|Active Comparator|Gemcitabine, Paclitaxel|GT (gemcitabine and paclitaxel combination)
3187314|NCT01287611|Active Comparator|Purse string closure technique|Eighty four patients were allocated to the study group. Due to expanded Kerr incisions 4 patients in study group did not receive their allocated intervention. In addition, 29 patients in the study group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 51 study group.
3187315|NCT01287611|Active Comparator|Continuously locked closure technique|Eighty four patients were allocated to the control group. Due to expanded Kerr incisions 3 patients in control group did not receive their allocated intervention. In addition, 16 patients in the control group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 65 study group.
3187316|NCT01287598|Experimental|Arm 1|Regorafenib (Stivarga, BAY73-4506) + warfarin + omeprazole + midazolam
3187317|NCT01287598|Experimental|Arm 2|Regorafenib (Stivarga, BAY73-4506) + rosiglitazone
3187318|NCT01287585|Experimental|ADI-PEG 20|Arginine deiminase formulated with polyethylene glycol.
3187319|NCT01287585|Placebo Comparator|Placebo|
3187320|NCT01287572||Conscious sedation group|Pediatric patients 0 to 18 years requiring conscious sedation for procedures done in the pediatric ICU excluding burned patients or patients with severe eczema or other skin disease.
3187321|NCT01287559||Subjects with NEC|Infants in which a possible diagnosis of NEC is suspected
3187322|NCT01287559||Control Infants|Age-matched and illness-severity matched to NEC subjects, controls are infants NOT suspected of having NEC.
3187323|NCT01287546|Experimental|LY2875358|
3187324|NCT01287546|Experimental|LY2875358 + erlotinib|
3187325|NCT01287546|Experimental|LY2875358 at Part A highest dose|
3187326|NCT01287546|Experimental|LY2875358 at Part A highest dose + trametinib|
3187327|NCT01287533|Experimental|Ibandronate treatment|Ibandronate 150mg PO once every 4 weeks
3187328|NCT01287533|Placebo Comparator|Placebo arm|Placebo PO once every 4 weeks
3187361|NCT01287338|Experimental|Lower Puncta Delivery|
3187362|NCT01287338|Experimental|Double Puncta Delivery|
3187363|NCT01287325|Experimental|DNK333|
3187364|NCT01287325|Placebo Comparator|Placebo|
3187365|NCT01287299|Experimental|Low Glycemic Load Diet|Counseled to consume a diet with a low or higher intake of carbohydrate sources that cause rapid or significant intakes in blood glucose. The average glycemic load of the diet should be less than 55 per 1000 calories or greater than 55 per 1000 calories.
3187366|NCT01287299|Experimental|Low Fat Diet|Pregnant women were counseled to consume a diet providing less that 25% of the energy as fat.
3187329|NCT01287520|Experimental|LY2090314/pemetrexed/carboplatin|"In Part A, intravenous (IV) doses of LY2090314 starting at 10 mg will be given on day 1 of cycle 1 (28 days) followed by 10 mg dose of LY2090314, 500 mg/m^2 IV dose of pemetrexed, and 5 or 6 AUC IV dose of carboplatin on day 8 of cycle 1. In Cycle 2, pemetrexed and carboplatin will be given on day 1 at same dose administered in cycle 1. In Cycle 3 and beyond, LY2090314, pemetrexed and carboplatin will be given on day 1 in the same dose administered in cycle 1. Cycles 2 and beyond are 21 days in length. Doses of LY2090314 will be escalated until the maximum tolerated dose is reached. In Part B, dose determined by Part A will be administered.~Patients may continue the combination treatment if they are receiving therapeutic benefit until they fulfill one of the criteria for discontinuation."
3187330|NCT01287507|Placebo Comparator|Placebo|In born VLBW infants with parental consent form signed will be given oral saline daily as placebo until discharge
3187331|NCT01287507|Experimental|Lactoferrin|In born VLBW infants with parental consent form signed will be given oral bovine lactoferrin daily until discharge
3187332|NCT01287494|Experimental|Depression Care Management|"DCM Intervention for Depressed Elders in Primary Care~Treatment guidelines (TG): Eight weeks treatment with Sertraline, another 8 weeks treatment augmentation with Bupropion if patients fail to respond in the initial trial, For more complicated cases, the transfer to psychiatrists is indicated.~Care managers: Screening, Adherence support, psychoeducation and communication.~Psychiatric Consultation"
3187333|NCT01287494|No Intervention|Care as Usual|
3187334|NCT01287481|Experimental|Stress and Emotions|Seeks to reduce stress and physical symptoms by helping individual become aware of their emotions, express them, and resolve emotional difficulties. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
3187335|NCT01287481|Active Comparator|Thoughts and Behaviors|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms of fibromyalgia. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
3187336|NCT01287481|Active Comparator|Brain and Body|Seeks to help individuals improve health by educating about fibromyalgia so that one can better understand and more effectively communicate about their health. It will explain the latest scientific information about fibromyalgia, including its causes, the role of the nervous system and body, various medical and alternative treatments, and how to understand research findings.
3187337|NCT01287468||Experimental Group|
3187338|NCT01287468||Control Group|
3187339|NCT01287455|Active Comparator|vitamin D|vitamin D deficient asthmatic patients receiving vitamin D supplement
3187340|NCT01287455|Placebo Comparator|placebo|vitamin D deficient asthmatic patients receiving placebo
3187341|NCT01287429||acute dyspnea|
3187342|NCT01287416|Experimental|Applied Suicide Intervention Skills Training (ASIST)|"ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The training is designed for anyone (especially those in a position of trust), from professionals and volunteers to members of the community. Participants range from those in caring roles to people concerned about family members or friends. The theory is that suicide can be pre¬vented with the help of prepared caregivers. ASIST is designed to help all caregivers become more willing, ready and able to help persons at risk. Just as CPR skills make physical first aid possible, training in suicide intervention develops the skills used in suicide first aid."
3187343|NCT01287416|Active Comparator|Resilience Retreat|The two days will be divided into cultural activities, sharing circles, small group discussions, story telling and dance. Two First Nations community leaders will be identified to lead each of the two retreats.
3187344|NCT01287403|Placebo Comparator|Refined wheat flour|A negative control flour to serve as a reference.
3187345|NCT01287403|Active Comparator|Esterase wholegrain wheat flour|Wholegrain wheat flour treated with esterases to release phenolics (positive control for phenolic acids)
3187346|NCT01287403|Experimental|Wholegrain wheat flour|Flour with unknown response
3187347|NCT01287403|Experimental|Liquid whole grain wheat flour|Test flour with unknown response.
3187348|NCT01287403|Experimental|Wholegrain barley flour|Test flour with unknown response.
3187349|NCT01287403|Experimental|Liquid wholegrain barley flour|Test flour with unknown response.
3187350|NCT01287390|Active Comparator|standard radiotherapy treatment|These patients receive the normal standard treatment.
3187351|NCT01287390|Experimental|adaptive radiotherapy|These patients receive the adaptive image-guided intensity-modulated radiotherapy (IMRT) for head and neck cancer.
3187352|NCT01287377|Experimental|Pre-Patch and Telephone Counseling|"Nicotine patches (2 weeks' worth) are mailed directly to the subject. Clients will be encouraged to start using these patches PRIOR to their quit date.~Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls."
3187353|NCT01287377|Active Comparator|Post-Patch and Telephone Counseling|"Nicotine patches (2 weeks' worth) are mailed directly to the subject. Clients are encouraged to start using their patches ON their quit date.~Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls."
3187354|NCT01287377|Active Comparator|Telephone Counseling and no patches sent|Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls.
3187355|NCT01287364|Experimental|ciclesonide HFA followed by mometasone|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily in first intervention period, followed by a 7-14 day washout period, after which the second intervention of mometasone nasal inhalation 200 μg once daily will be administered.
3187356|NCT01287364|Active Comparator|mometasone followed by ciclesonide HFA|mometasone nasal inhalation 200 μg once daily in first intervention period followed by a 7-14 day washout period after which the second intervention of ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily will be administered
3187357|NCT01287351||IPDI: Qvar|ICS initiation as Qvar
3187358|NCT01287351||IPDI FP|ICS initiation as fluticasone
3187359|NCT01287351||IPDA Qvar|ICS step-up as Qvar
3187360|NCT01287351||IPDA FP|ICS step-up as fluticasone
3187367|NCT01287286|Experimental|AC-Can|Antrodia cinnamomea and concomitant chemotherapy
3187368|NCT01287286|Placebo Comparator|control|Placebo and concomitant chemotherapy
3187369|NCT01287273||Group A|Transfer at the day of embryo thawing
3187370|NCT01287273||Group B|Transfer of thawed embryos 24-72 hours post thawing
3187371|NCT01287260|Experimental|Arm1|
3187372|NCT01287260|Active Comparator|Arm 2|
3187373|NCT01287247||Cervical Dystonia|The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of cervical dystonia.
3187374|NCT01287247||Blepharospasm|The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of blepharospasm.
3187375|NCT01287234|Other|All Patients|All patients will have an echocardiogram and SonR sensor readings completed.
3187376|NCT01287221|Active Comparator|Rifampicin|Subjects randomized to this arm will receive 300 mg Rifampicin two times a day for 12 months.
3187377|NCT01287221|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo capsules twice daily for 12 months. The capsules will contain riboflavin (vitamin B2).
3187378|NCT01287208|Active Comparator|Unblinded activity monitor|Subjects wear the activity device and can see the data on the device and on a website where the data is uploaded.
3187379|NCT01287208|Placebo Comparator|Blinded activity monitor|Subjects wear a blinded activity device and cannot see the activity on the device and cannot log on to the website where the data gets uploaded.
3187380|NCT01287195|Experimental|Oral OKT3|Participants with ulcerative colitis will receive Oral OKT3 given with Omeprazole once daily for 30 days.
3187381|NCT01287182|Placebo Comparator|Placebo|
3187382|NCT01287182|Active Comparator|Ateronon|
3187383|NCT01287130|Experimental|DL 1|AZD6244 once daily on days 1, 8, 15 and 22. Cetuximab 400 mg/m2 IV loading dose over 120minutes on day 1 and cetuximab 250 mg/m2 IV loading dose over 60 minutes on days 8, 15,22
3187384|NCT01287130|Experimental|DL 2|AZD6244 twice daily on days 1, 8, 15 and 22. Cetuximab 400 mg/m2 IV loading dose over 120minutes on day 1 and cetuximab 250 mg/m2 IV loading dose over 60 minutes on days 8, 15,22
3187385|NCT01287117|Placebo Comparator|Placebo|Participants received placebo subcutaneously every 4 weeks during the 24 week treatment period.
3187386|NCT01287117|Experimental|Omalizumab 75 mg|Participants received omalizumab 75 mg subcutaneously every 4 weeks during the 24 week treatment period.
3187387|NCT01287117|Experimental|Omalizumab 150 mg|Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 24 week treatment period.
3187388|NCT01287117|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24 week treatment period.
3187389|NCT01287104|Experimental|1|Pre-BMT Prep Regimen with Stem Cell and NK Cell Infusions coupled with Induction therapy
3187390|NCT01287091|Experimental|Part 1|
3187391|NCT01287091|Experimental|Part 2|
3187392|NCT01287091|Experimental|Part 3: Group A|
3187393|NCT01287091|Experimental|Part 3: Group B|
3187394|NCT01287065|Experimental|FF(100mcg)/Vilanterol(25mcg) - AM dosing|FF(100mcg)/Vilanterol(25mcg) in the morning (approx 09.00) for 14 days (± 2 days).; placebo in evening (approx 21.00) for 14 days (± 2 days).
3187395|NCT01287065|Experimental|FF(100mcg)/Vilanterol(25mcg) - PM dosing|Placebo in morning (approx 09.00) for 14 days (± 2 days); FF(100mcg)/Vilanterol(25mcg) in evening (approx 21.00) for 14 days (± 2 days).
3187396|NCT01287065|Placebo Comparator|Placebo|Placebo given in morning (approx 09.00) and in evening (approx (21.00) for 14 days (± 2 days).
3187397|NCT01287052|Experimental|Nitrous Oxide|
3187398|NCT01287039|Placebo Comparator|Placebo|Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
3187399|NCT01287039|Experimental|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
3187400|NCT01287026|Experimental|1|Open Label
3187401|NCT01287013|Other|Cone Beam CT|Procedure performed with Xperguide cone-beam Computed Tomography (CT) navigation
3187402|NCT01287013|Other|Conventional CT|Procedure performed with Conventional Computed Tomography (CT) image guidance
3187403|NCT01286987|Experimental|Talazoparib|
3187404|NCT01286974|Experimental|ADME|[14C]linifanib
3187405|NCT01286974|Experimental|Extension|linifanib
3187406|NCT01286961||outpatient colonoscopy, bowel preparation, split dose PEG|adult outpatients who undergo colonoscopy
3187407|NCT01286948|Active Comparator|Levonorgestrel (LNG) gel (Levogel)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
3187408|NCT01286948|Active Comparator|oral LNG (1.5mg)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
3187409|NCT01286935|Experimental|Low Dose (50mg/day)|
3187410|NCT01286935|Experimental|High Dose (100mg/day)|
3187411|NCT01286935|Placebo Comparator|Placebo|
3187412|NCT01286922|Experimental|Interval Training|"The target intensity for the INT group is 2 min at about 95% of baseline VO2max followed by 2 min of recovery at 40-50% of VO2max. Regardless of the training method each participant will be locked into a weekly energy expenditure of 12 kilocalories per kilogram of body weight per week (KKW)."
3187413|NCT01286922|Placebo Comparator|Aerobic Conditioning|During the first AER training condition, we will train all participants at an energy expenditure of 12 kcal/kg/wk (KKW). The target exercise intensity for the AER group will be 50%-70% of baseline V02max.
3187414|NCT01286909|Experimental|LaFlavon|
3187415|NCT01286909|No Intervention|Placebo|
3187416|NCT01286896|Experimental|Sunitinib|Sunitinib is administered in oral capsules of 12.5 mg. Patients will start with a continuous once-daily dose of 37.5 mg.
3187417|NCT01286883||Blood draws|Laboratory studies will be performed at baseline; Cycle 1, Day 1; Cycle 1, Day 7; Cycle 2, Day 1; Cycle 3, Day 1; Cycle 4, Day 1; Cycle 6, Day 1; Cycle 12, Day 1.
3187418|NCT01286870|Other|Reconstruction|"The study population will consist of women aged 18 or over who are undergoing primary breast reconstruction.~The Reconstruction cohort will include subjects with loss of breast tissue due to mastectomy, contralateral breast for post-reconstruction symmetry or subjects with deformities secondary to disease, malignancy, trauma, and congenital deformity. Subjects in this cohort cannot have been implanted with breast implants, but may have tissue expanders. A Becker implant is considered a tissue expander until the port and fill tube have been removed. Women who undergo surgery primarily for a mastopexy will not be part of the reconstruction cohort."
3187419|NCT01286844|Experimental|Cohort 1|Subjects ≥4 and< 12 years. First 6 subjects included, ≥8 and< 12 yrs and weigh ≥21kg, receive 1 SD (10mg) and an 8 day RD period (100mg). Remaining subjects in cohort: Subjects < 21kg receive 2 SD periods (10mg and 50mg), Subjects > 21kg receive 2 SD periods (10mg and 50mg) and an 8 day RD (100mg)
3187420|NCT01286844|Experimental|Cohort 2|Subjects ≥1 and< 4 years, receive 2 SD (5mg and 25mg)
3187421|NCT01286831|Experimental|[14C]GW642444|Single 200μg dose of [14C]GW642444 given on Day 1.
3187422|NCT01286818|Experimental|FOLFIRI plus Ramucirumab (IMC-1121B)|
3187423|NCT01286805|Experimental|Lumbar Plexus Blockade + CSE|The study group will receive a lumbar plexus blockade with 30 mL of 0.25% bupivacaine with 1:200,000 epinephrine, followed by a combined spinal-epidural.
3187424|NCT01286805|Placebo Comparator|Control Group|The control group will receive only a combined spinal-epidural.
3187425|NCT01286779|Experimental|BAX 326|
3187426|NCT01286766|Active Comparator|DCS|DCS: docetaxel with cisplatin with TS-1
3187427|NCT01286766|Active Comparator|DCF|DCF : docetaxel with cisplatin with 5-FU
3187428|NCT01286753|Experimental|Tyrosine Kinase Inhibitor (TKI) Naive|Vemurafenib in participants naive to any prior systemic TKI therapy.
3187429|NCT01286753|Experimental|TKI Experienced|Vemurafenib in participants previously treated with TKI therapy active against vascular endothelial growth factor receptor 2 (VEGFR).
3187430|NCT01286740|Experimental|FTC/RPV/TDF|Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.
3187431|NCT01286727|Placebo Comparator|Normal Saline|Placebo
3187432|NCT01286727|Active Comparator|BB3|
3187433|NCT01286714|Experimental|clips OST|
3187434|NCT01286701|Experimental|Terbinafine Hydrochloride|Terbinafine Hydrochloride Tablets, 250 mg of Dr.Reddy's Laboratories Limited
3187435|NCT01286701|Active Comparator|Lamisil® 250 mg Tablets|Lamisil® 250 mg Tablets of Novartis
3187436|NCT01286688|Experimental|Terbinafine Hydrochloride|Terbinafine Hydrochloride Tablets, 250 mg of Dr.Reddy's Laboratories Limited
3187437|NCT01286688|Active Comparator|Lamisil® 250 mg Tablets|Lamisil® 250 mg Tablets of Novartis
3187438|NCT01286675|Experimental|Eltrombopag|
3187439|NCT01286649|Other|Injection of verum and control|Patients will receive randomized, blinded, injections of BOTH autologous hair follicle cells in medium (verum) and of medium alone (control) into two separate pre-defined treatment areas on their scalp.
3187440|NCT01286636|Experimental|artificial neural network|
3187441|NCT01286636|Active Comparator|Polysomnogram|
3187442|NCT01286610|Other|vibration therapy and electrical muscle stimulation|
3187443|NCT01286597|Experimental|dietary|
3187444|NCT01286584|Active Comparator|varenicline group|
3187445|NCT01286584|Placebo Comparator|placebo group|
3187446|NCT01286571|Experimental|BI 135585 (T)|single dose per subject as tablet formulation after high fat, high caloric meal
3187447|NCT01286571|Experimental|BI 135585 (R)|single dose per subject as tablet formulation after an overnight fast
3187448|NCT01286558|Experimental|80mg telmisartan and 5mg amlodipine FDC|once daily
3187449|NCT01286558|Active Comparator|40mg telmisartan and 5mg amlodipine FDC|once daily
3187450|NCT01286545||Ankylosing spondylitis, long term treatment with infliximab|Patients with ankylosing spondylitis under long term treatment with infliximab within the open label clinical trials EASIC and DIKAS are now followed up in a registration study. No intervention is planned. Patients will be followed up for clinical outcome parameters and for radiographic progression.
3187451|NCT01286532||1|Children (male or female) aged 5 to 11 years inclusive on step 3 asthma combination therapy with ICS(inhalation glucocorticosteroids) and LABA ( long-acting b2-agonist) who have completed at least one valid CACT assessment after the study entry
3187452|NCT01286506||Mechanically ventilated patients|
3187453|NCT01286506||Non-mechanically ventilated patients|
3187454|NCT01286493|Experimental|Rabies vaccines on day 0 and 3|Cell culture Rabies vaccines on day 0 and 3
3187455|NCT01286480|Experimental|Clinic-based Educational Intervention|This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
3187456|NCT01286480|No Intervention|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies. Time-pressured clinic visits limit the opportunity to discuss many of the topics noted above.
3187457|NCT01286467|Experimental|1|
3187458|NCT01286454|Experimental|A|4 mg fesoterodine IR beads in capsule under fasting condition
3187459|NCT01286454|Experimental|B|4 mg fesoterodine 10% coated ER beads in capsule under fasting condition
3187460|NCT01286454|Experimental|C|4 mg fesoterodine 15% coated ER beads in capsule under fasting condition.
3187461|NCT01286454|Experimental|D|4 mg fesoterodine 20% coated ER beads in capsule under fasting condition.
3187462|NCT01286454|Experimental|E|4 mg fesoterodine ER tablets under fasting condition.
3187463|NCT01286454|Experimental|F|4 mg fesoterodine TBD % coated ER beads in capsule under fed condition.
3187464|NCT01286441|Placebo Comparator|Placebo|Placebo for East Indian Sandalwood Oil ointment administered topically twice daily
3187465|NCT01286441|Active Comparator|10% EISO|East Indian Sandalwood Oil ointment, 10% (w/w), applied topically twice daily
3187466|NCT01286441|Active Comparator|20% EISO|East Indian Sandalwood Oil ointment, 20% (w/w), applied topically twice daily
3187467|NCT01286441|Active Comparator|30% EISO|East Indian Sandalwood Oil ointment, 30% (w/w), applied topically twice daily
3187468|NCT01286415|Experimental|Group Cognitive Processing Therapy-Cognitive Only|
3187469|NCT01286415|Active Comparator|Group Present Centered Therapy|
3187470|NCT01286402|Experimental|Bupropion SR (sustained release)|Group receiving bupropion SR medication
3187471|NCT01286402|Placebo Comparator|Placebo|
3187472|NCT01286389|Active Comparator|Conventional medical care|Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)
3187473|NCT01286389|Experimental|caloric restriction +medical care|Nutritional counseling individually and in groups, aiming to promote weight loss (10% of body weight) through caloric restriction, +Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise)
3187474|NCT01286376|Active Comparator|symbiotic|
3187475|NCT01286376|Placebo Comparator|placebo|
3187476|NCT01286363||Brachyfacial|Subjects with a horizontal facial growth pattern
3187477|NCT01286363||Mesofacial|Subjects with a balanced facial growth pattern
3187478|NCT01286363||Dolichofacial|Subjects with a vertical facial growth pattern
3187479|NCT01286350|No Intervention|Control|Participants randomized control will continue with usual clinical care.
3187480|NCT01286350|Experimental|Intervention|"Participants randomized to intervention will receive the FL3X Flexible Lifestyle Empowering Change intervention. Adolescents will be paired with a health coach to help learn strategies for improving diabetes control"
3187481|NCT01286337|Experimental|vessel sealing|axilla dissection using this device
3187482|NCT01286337|Active Comparator|control|standard surgical technique
3187483|NCT01286324|Experimental|Chamomile High Grade Extract|Each capsule contains 90 mg dry extract of chamomile flowering tops [6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet
3187484|NCT01286324|Placebo Comparator|Placebo Tablet|Contained lactose
3187485|NCT01286311|Experimental|Direct-to-patient tailored cardiovascular risk message system|Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.
3187486|NCT01286311|No Intervention|Control|
3187487|NCT01286298|Experimental|Laser gingivectomy|
3187488|NCT01286272|Experimental|Arm A (ofatumumab, bendamustine hydrochloride)|"INDUCTION: Patients receive ofatumumab IV over 2-8 hours on day 1 and bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.~MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive ofatumumab IV over 2-8 hours on day 1. Treatment repeats every 56 days for up to 4 courses."
3187489|NCT01286272|Experimental|Arm B (ofatumumab, bendamustine hydrochloride, bortezomib)|"INDUCTION: Patients receive ofatumumab IV over 2-8 hours on day 1, bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, and bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.~MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive ofatumumab IV over 2-8 hours on day 1 and bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 56 days for up to 4 courses."
3187490|NCT01286259|Experimental|Intervention Arm|
3187491|NCT01286246|Experimental|Vaginal progesterone|
3187492|NCT01286246|Placebo Comparator|Placebo|
3187493|NCT01286233||Group 1: Metformin|850 mg orally twice a day for 5 years
3187494|NCT01286233||Group 2: Placebo|One caplet orally twice a day for 5 years
3187495|NCT01286220|Active Comparator|Dilute bleach baths|Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.
3187496|NCT01286220|Placebo Comparator|Water|Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
3187497|NCT01286207|Experimental|Rizatriptan 5 mg|Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
3187498|NCT01286207|Experimental|Rizatriptan 10 mg|Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
3187499|NCT01286207|Active Comparator|Standard Care|Standard care at onset of migraine attack
3187500|NCT01286194||Experimental 1|
3187501|NCT01286181|Experimental|Device-guided slow breathing|
3187502|NCT01286168|Experimental|Antisepsis Side|A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days. The drainage bulb will be irrigated with 10ml of 0.125% sodium hypochlorite (Dakin's solution) twice a day.
3187503|NCT01286168|Other|Control Side|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
3187504|NCT01286155||with gastroesophageal reflux disease(GERD)|Subjects with gastroesophageal reflux disease (GERD)
3187505|NCT01286155||Non-GERD|Subjects with no history of gastroesophageal reflux disease (GERD)
3187506|NCT01286155||Barrett's esophagus|Subjects with confirmed barrett's esophagus in Olmsted county
3187507|NCT01286142||Influenza treatment with oseltamivir|Patients 24 months of age and younger initially presenting with confirmed or presumed influenza A or B infection treated with oseltamivir.
3187508|NCT01286142||Influenza prophylaxis with oseltamivir|Patients 24 months of age and younger prescribed oseltamivir for influenza prophylaxis
3187509|NCT01286142||Influenza patients with no antiviral treatment|A comparator group of patients 24 months of age and younger presenting with confirmed or presumed influenza A or B and not treated with any influenza antiviral.
3187510|NCT01286129|Active Comparator|Allergic asthmatic|Subjects with allergic asthma will undergo nasal allergen provocations with either house dust mite or cat pelt.
3187511|NCT01286129|Active Comparator|Allergic rhinitic without asthma|Subjects with allergic rhinitis without asthma will undergo nasal allergen provocations with either house dust mite or cat pelt.
3187512|NCT01286116|Experimental|Treatment|Parachute implant
3187513|NCT01286103|Experimental|001|Canagliflozin 300 mg once daily and 150 mg twice daily Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
3187514|NCT01286103|Experimental|002|Canagliflozin 100 mg once daily and 50 mg twice daily Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
3187515|NCT01286090|Experimental|001|Cisapride One 10-mg tablet taken orally 4 times a day for up to 8 weeks.
3187516|NCT01286090|Experimental|002|Placebo One tablet taken orally 4 times a day for up to 8 weeks.
3187517|NCT01286077|Experimental|bortezomib|bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles
3187518|NCT01286077|No Intervention|Non-treated control|no treatment, observation only
3187519|NCT01286064|Experimental|patient with colo-rectal cancer|fluorescence spectra will be mainly characterized by the presence of an emission peaking at 620-630 nm
3187520|NCT01286064|Active Comparator|patient without colo-rectal cancer|fluorescence spectra will be characterized by the absence of an emission peaking at 620-630 nm
3187521|NCT01286051|Active Comparator|Follistim|standard treatment
3187522|NCT01286051|Experimental|Follistim plus single ganirelix injection|
3187523|NCT01286038|Experimental|Eltrombopag Treatment|Phase I: Dose Escalation. Phase II: Treatment at Maximum Tolerated Dose (MTD)
3187524|NCT01286025|Active Comparator|Video modality|
3187525|NCT01286025|Active Comparator|Text modality|
3187526|NCT01286012|Active Comparator|SFP in liquid bicarbonate|
3187527|NCT01286012|Placebo Comparator|Placebo: Conventional Liquid Bicarbonate|Control concentrate lacking SFP does not contain SFP (total iron = 0)
3187528|NCT01285999|Experimental|PROMUS Element|PROMUS Element Everolimus-Eluting Coronary Stent System (PROMUS Element)
3187529|NCT01285999|Active Comparator|TAXUS Liberté|TAXUS Liberté Paclitaxel-Eluting Coronary Stent System (TAXUS Liberté)
3187530|NCT01285986|Experimental|Vein collar at distal anastomosis|Vein collar at the distal anastomosis
3187531|NCT01285986|Experimental|No vein collar at the distal anastomosis|No vein collar at the distal anastomosis
3187532|NCT01285960|Experimental|ExAblate treatment UF V2|ExAblate MRgFUS Treatment
3187533|NCT01285947|Other|Naive Subjects|Subjects who have not previously undergone energy-based dermatologic procedures in the past.
3187534|NCT01285947|Other|Non-Naive Subjects|Subjects who have previously undergone energy-based dermatologic procedures in the past.
3187535|NCT01285934|Experimental|Hematopoietic Stem Cell Transplantation|Patients who meet eligibility and have completed pre-HSCT testing in section 7.0 (study parameters) may be enrolled in the transplant arm and will undergo an Autologous Hematopoietic Stem Cell Transplantation
3187536|NCT01285934|Other|control arm of intensive insulin therapy|The control arm of intensive insulin therapy (IIT) will enroll all patients who meet eligibility but decline HSCT or whose insurance does not approve payment for HSCT before expiration of eligibility (within 5 months of disease onset)
3187537|NCT01285921|Experimental|hippocampal surgery|"Vestibular test before and after hippocampal surgery~Principal criterion:~Research for an asymmetry of the vestibular responses (Caloric test, Vestibular Evoked Myogenic potentials: VEMp, Head Impulse Test: HIT, Eye Rotational Test: ERI). Investigator performs a blind vestibular test (single blind)"
3187538|NCT01285908|No Intervention|Baseline|Baseline values measured at various tilt angles, so that each participant may serve as their own control.
3187539|NCT01285908|Placebo Comparator|Saline infusion|Subjects received a saline IV infusion as a placebo, while measurements were taken at various tilt angles.
3187540|NCT01285908|Active Comparator|Norepinephrine Infusion|Subjects were given an norepinephrine infusion at various tilt angles, while measurements were taken.
3187541|NCT01285882||Representations|
3187542|NCT01285869|Experimental|Multidisciplinar intervention|Patients that will receive the multidimensional intervention during the ambulatory follow-up.
3187543|NCT01285869|No Intervention|Conventional follow up|This is an observation only group and outpatient follow up will be indicated in accordance with usual and customary practices.
3187544|NCT01285856|Active Comparator|buprenorphine|populations of patients treated with HDB will be recruited during consultations at a center for addiction treatment. One hundred and ten patients will be included. Written informed consent will be obtained from each patient. Anonymity will be respected at inclusion and throughout. Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. Treatment efficacy will also be assessed using Handelsman's subjective and objective opiate withdrawal scales. Lastly, polymorphisms of the metabolic enzymes of methadone and HDB will be sought by real-time PCR in a saliva sample, a method which gives similar results without the need for venous blood sampling.
3187588|NCT01285531|No Intervention|Lumbar puncture|The participants randomly assigned to this arm will receive a lumbar puncture using standard procedures and equipment
3187589|NCT01285531|Experimental|Lumbar puncture with the Compass device|The participants randomly assigned to this group will receive a lumbar puncture with the use of the Compass device.
3187590|NCT01285518|Experimental|Treatment|
3187591|NCT01285518|Placebo Comparator|Placebo|0.9% w/v sodium chloride injection, USP
3187592|NCT01285505|Active Comparator|Alprazolam commercial sublingual tablet|
3187545|NCT01285856|Active Comparator|methadone|populations of patients treated with methadone will be recruited during consultations at a center for addiction treatment. One hundred and ten patients will be included. Written informed consent will be obtained from each patient. Anonymity will be respected at inclusion and throughout. Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. Treatment efficacy will also be assessed using Handelsman's subjective and objective opiate withdrawal scales. Lastly, polymorphisms of the metabolic enzymes of methadone and HDB will be sought by real-time PCR in a saliva sample, a method which gives similar results without the need for venous blood sampling.
3187546|NCT01285843|Active Comparator|Quadra Group|
3187547|NCT01285843|Active Comparator|AMIStem Group|
3187548|NCT01285830|Placebo Comparator|Placebo|
3187549|NCT01285830|Active Comparator|Lactobacillus reuteri|
3187550|NCT01285817|Experimental|traetment|
3187551|NCT01285804|Active Comparator|Cuffed ETT|
3187552|NCT01285804|Active Comparator|Uncuffed ETT|
3187553|NCT01285791||patients undergoing laparoscopic adjustable gastric banding|morbid obese patients undergoing laparoscopic adjustable gastric banding will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased.
3187554|NCT01285791||patients undergoing laparoscopic sleeve gastrectomy|morbid obese patients undergoing laparoscopic sleeve gastrectomy will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased
3187555|NCT01285791||patients undergoing laparoscopic gastric bypass|morbid obese patients undergoing laparoscopic gastric bypass will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased
3187556|NCT01285778|Experimental|Panitumumab, mytomicin C, 5-FU, radiation|
3187557|NCT01285765|Experimental|Early-PET-result-adapted treatment|4 to 6 RCHOP21
3187558|NCT01285765|Active Comparator|standard treatment|6 RCHOP21
3187559|NCT01285752|Experimental|1|
3187560|NCT01285752|Experimental|2|
3187561|NCT01285752|Active Comparator|3|
3187562|NCT01285739||NIMV COPD|Patients with chronic obstructive pulmonary disease (COPD), who underwent tracheostomy for acute respiratory failure and who were discharged with tracheostomy but in domiciliary non invasive ventilation
3187563|NCT01285739||IMV COPD|Patients with chronic obstructive pulmonary disease (COPD), who underwent tracheostomy for acute respiratory failure and who were discharged in domiciliary invasive mechanical ventilation (IMV)
3187564|NCT01285713|Experimental|5% Dextrose (D5) in Normal Saline (NS)|10cc/kg D5NS, followed by 30cc/kg NS
3187565|NCT01285713|Active Comparator|Normal Saline (NS)|10cc/kg NS, followed by 30cc/kg NS
3187566|NCT01285700|Active Comparator|Lamazym 25|25 U/kg
3187567|NCT01285700|Active Comparator|Lamazym 50|50 U/kg
3187568|NCT01285687|No Intervention|Standard Analgesic Treatment|
3187569|NCT01285687|Experimental|Standard Analgesic Treatment with Acupuncture|Patients will receive standard analgesic treatment and in addition acupuncture.
3187570|NCT01285674|Experimental|Intra-tympanic steroid injection|
3187571|NCT01285661|Experimental|Proximal DVT|Patients whose veins have recanalized (either at the recruitment or later on during the follow-up) will receive the D-dimer determination before discontinuing sodium warfarin. Veins are defined as recanalized when the vein diameter under maximum compressibility is lower than 4 mm both at the common femoral and at the popliteal vein. In those with negative D-dimer sodium warfarin will be discontinued. These patients will have two further determinations of D-dimer (after 1 and 3 months, respectively). While patients with persistently negative D-dimer will no longer receive sodium warfarin, those in whom D-dimer is positive or reverts to positive values in the following determinations will have their sodium warfarin resumed and no longer discontinued.
3187572|NCT01285648|Other|Cpap|This group joined chest physiotherapy with CPAP via nasal masks for two hours.CPAP was continued from the immediate postoperative day until the second postoperative day, twice a day.
3187573|NCT01285648|Other|Chest Physiotherapy|Chest Physiotherapy consisted of bronchial hygiene techniques and pulmonary expansion, in addition to exercises, and received oxygen supplementation to maintain the pulse oxymetry saturations > 90%.
3187574|NCT01285635|Active Comparator|Docetaxel Alone|
3187575|NCT01285635|Experimental|Pulse Dose AT-101 Arm|
3187576|NCT01285635|Experimental|Metronomic AT-101 Arm|
3187577|NCT01285622||Gynecology patients|female subjects scheduled for elective robotic gynecological surgery under general anesthesia.
3187578|NCT01285609|Experimental|Ipilimumab + Paclitaxel and Carboplatin|"Ipilimumab + Active Chemo Backbone~Ipilimumab: IV solution, intravenous (IV), 10 mg/kg, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)~Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses~Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses"
3187579|NCT01285609|Placebo Comparator|Placebo + Paclitaxel and Carboplatin|"Placebo + Active Chemo Backbone~Placebo: IV solution, IV, 0.9% sodium chloride or 5% dextrose, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)~Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses~Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses"
3187580|NCT01285583|Other|Olesoxime|All patients will receive the IMP as add-on to riluzole 50 mg bid orally, 50 mg morning and evening on an empty stomach ie at least 20 min before the meal.
3187581|NCT01285570|Experimental|Experimental 2|
3187582|NCT01285570|Experimental|experimental 1|
3187583|NCT01285570|Placebo Comparator|Placebo|Placebo comparator daily (QD)
3187584|NCT01285557|Experimental|S-1/cisplatin|
3187585|NCT01285557|Active Comparator|5-FU/cisplatin|
3187586|NCT01285544|Experimental|Lipinon-test formulation of atrovastain - 20mg|
3187587|NCT01285544|Active Comparator|Lipitor- branded formuation of atorvastatin-20mg|
3187593|NCT01285505|Experimental|Alprazolam test sublingual tablet|
3187598|NCT01285466|Experimental|BKM120 + paclitaxel|
3187599|NCT01285466|Experimental|BEZ235 + paclitaxel + trastuzumab|
3187600|NCT01285466|Experimental|BKM120 + paclitaxel + trastuzumab|
3187601|NCT01285453|Experimental|ASA404|
3187602|NCT01285440||Diagnostic Imaging|
3187603|NCT01285427||DNA loci (SeCore vs. SSP UniTray platforms)|
3187604|NCT01285414|Experimental|Verubulin & standard of care (RT & TMZ)|Verubulin, at the dose selected in Part A, plus standard of care Radiation Therapy and Temozolomide
3187605|NCT01285414|Active Comparator|Standard of care (RT & TMZ)|Standard of care Radiation Therapy and Temozolomide
3187606|NCT01285401|Experimental|VigantOL® oil|VigantOL oil plus Rebif in subjects with 25-hydroxy-vitamin D plasma levels below 150 nmol/L
3187607|NCT01285401|Placebo Comparator|Placebo|Placebo daily plus Rebif in subjects with 25-hydroxy-vitamin D plasma levels below 150 nmol/L
3187608|NCT01285401|Experimental|Rebif|Rebif alone in subjects with 25-hydroxy-vitamin D plasma levels equal or higher than 150 nmol/L
3187609|NCT01285388|Experimental|MB12066 10mg|
3187610|NCT01285388|Active Comparator|MB12066 30mg|
3187611|NCT01285388|Active Comparator|MB12066 100mg|
3187612|NCT01285388|Active Comparator|MB12066 150mg|
3187613|NCT01285388|Active Comparator|MB12066 200mg|
3187614|NCT01285388|Placebo Comparator|placebo|
3187615|NCT01285375|Active Comparator|CDC graft perfusion|Flushing of kidney allografts prior to transplantation with UW-solution containing CDC
3187616|NCT01285375|Sham Comparator|Sham perfusion|
3187617|NCT01285362|Active Comparator|Fish Oil Supplementation (Group A)|Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.
3187618|NCT01285362|Placebo Comparator|Placebo Supplementation (Group B)|Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
3187619|NCT01285349|Experimental|Couple-based HIV prevention|
3187620|NCT01285349|Active Comparator|Individual HIV/STI Prevention|
3187621|NCT01285349|Active Comparator|Couple Wellness Promotion|
3187622|NCT01285336|Experimental|The genetic and the functional study|
3187623|NCT01285323|Placebo Comparator|Placebo|Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
3187624|NCT01285323|Experimental|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
3187625|NCT01285310|Experimental|Apremilast 30 mg|
3187626|NCT01285310|Experimental|Apremilast 20 mg|
3187627|NCT01285310|Placebo Comparator|Placebo|
3187628|NCT01285297|Experimental|TMR plus BMAC injection|Injection of bone marrow aspirate concentrate into reversibly ischemic myocardium with transmyocardial revascularization during the same open procedure.
3187629|NCT01285284|Experimental|Music|A previously defined list of songs will be administered by headphones to these patients during the colonoscopy.
3187630|NCT01285284|Sham Comparator|Control|These patients will receive an MP3 device (and headphones) which will be functioning but without volume.
3187631|NCT01285271|Experimental|Xenon|Xenon will be administered for balanced general anesthesia for CABG surgery before and after the extracorporal circulation.
3187632|NCT01285271|Active Comparator|Sevoflurane|Sevoflurane will be administered for balanced general anesthesia for CABG surgery before and after the extracorporal circulation.
3187633|NCT01285258|Other|peripartum|patients whom underwent peripartum hysterectomy
3187634|NCT01285245|Experimental|kineret|
3187635|NCT01285232|Experimental|Anakinra|Anakinra 150 mg/day during four weeks
3187636|NCT01285232|Placebo Comparator|Placebo|Placebo during four weeks
3187637|NCT01285219|Active Comparator|AOB,pegylated filgrastim to filgrastim|patients were administered pegylated filgrastim 100 ug/kg in cycle 1 and ﬁlgrastim 5 ug/kg/d in cycle 2
3187638|NCT01285219|Active Comparator|BOA,ﬁlgrastim to pegylated filgrastim|patients received ﬁlgrastim 5 ug/kg/d in cycle 1 and pegylated filgrastim 100 ug/kg in cycle 2
3187639|NCT01285206|Experimental|Routine practice|
3187640|NCT01285193|Experimental|Breath control|A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
3187641|NCT01285180||DINO|
3187642|NCT01285167||DACOTA|
3187643|NCT01285154||Traditional Steel Triple Osteotomy|Traditional technique
3187644|NCT01285154||Modified Triple Osteotomy|Modified technique
3187645|NCT01285141|Experimental|Vaginal immunisation|CN54gp140 glycoprotein-hsp70 conjugate vaccine
3187646|NCT01285115|Placebo Comparator|Placebo; corn flour,|"raw material total contents(500㎎) cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)~shape, type: extract(brown)~usage, content: adults;three times a day each sack taken before or between meals~dose, standard: for each sack 7.67g~storage : airtight container, stored in room temperature~expiration date : after manufacture 36 month~macufacturing company: KyungBangnShinYak inc."
3187647|NCT01285115|Active Comparator|Gamisoyosan extract|"name of product: KyungBangn-Gamisoyosan-x-gwarip~standard code for item : 200005799~shape, type: extract(grayish brown)~usage, content : adults;three times a day , each sack taken before or between meals~dose, standard: 7.67g for each sack~storage : airtight container, stored in room temperature expiration date : after manufacture 36 month macufacturing company: KyungBangnShinYak inc."
3187648|NCT01285115|Active Comparator|Gamisoyosan extract powder|"name of product: KyungBangn Gamisoyosan~standard code for item: 200005591~shape, type: powder(brown)~usage, content: adults;three times a day each sack taken before or between meals~dose, standard: 7.67g for each sack~storage : airtight container, stored in room temperature~expiration date : after manufacture 36 month~macufacturing company: KyungBangnShinYak inc."
3187649|NCT01285102|Experimental|Arm I|Patients receive irinotecan-eluting beads via hepatic artery embolization every 3 weeks for up to 3 (unilobar disease) or 4 (bi-lobar disease) courses in the absence of disease progression or unacceptable toxicity.
3187650|NCT01285089||A|
3187760|NCT01284231|Experimental|MEDI-565 - Dose Escalation|Up to 15 dose-escalation cohorts will be enrolled
3188496|NCT01278849|Experimental|ASA404 + standard therpy|
3187651|NCT01285076||All Enrolled Participants|Adults with Type 2 DM ≥30 years of age who have been treated with SU monotherapy or SU + MF combination therapy for at least 6 months by a cardiologist, nephrologist, neurologist, or family practice doctor.
3187652|NCT01285063|Experimental|physical activiy & nutrition|"25 kindergarten children in the ages of 4-6 who defined as suffering from overweigh (BMI percentage 85-95) or obesity (above BMI percentage 95).~Non-generalization criteria: children who suffer from obesity due to organic disease or children who take medicine which may influence body weight (e.g., steroids) will be excluded from the research."
3187653|NCT01285050|Other|pre post ART|HCV and HIV viral load pre and post antiretroviral therapy (ART). ART is the intervention and the comparison is the HIV and HCV viral load reductions as determined by RT-PCR after administration of interferon alfa in each instance (before and after ART)
3187654|NCT01285037|Experimental|LY2801653|"This study consists of a dose escalation of LY2801653 (Part A) followed by dose confirmation cohorts in four tumor types (adenocarcinoma of the colon or rectum, head and neck squamous cell carcinoma, uveal melanoma with liver metastasis, and cholangiocarcinoma) (Part B).~Part C consists of dose determination for LY2801653 in combination with cetuximab in participants with head and neck squamous cell carcinoma followed by an expansion cohort.~Part D consists of dose determination for LY2801653 in combination with cisplatin in participants with cholangiocarcinoma followed by an expansion cohort.~Part E consists of dose determination for LY2801653 in combination with gemcitabine and cisplatin.~Part F consists of dose determination for LY2801653 in combination with ramicirumab."
3187655|NCT01285024|No Intervention|Control|No Vitagel used during total hip arthroplasty
3187656|NCT01285024|Experimental|Vitagel|Vitagel applied just prior to closure during total hip arthroplasty
3187657|NCT01285011||Ipp-On|Patient implanted with the Ipp-On
3187658|NCT01284998||B-BOP lock|Subjects who needs a fixation of osteotomy of the basis of the first metatarsal and for whose surgeon has recommended that a B-BOP® Lock plate from INTEGRA be implanted can be enrolled in this study
3187659|NCT01284985||METIS|Patient who has an indication of : Hallux Rigidus, Hallux Limitus with degenerative joint disease, Painful Hallux Valgus, Osteoarthritis, Rheumatoid arthritis, Post-traumatic arthritis and for which surgeon has recommended that a METIS® prosthesis be implanted.
3187660|NCT01284972||HINTEGRA|Patient Implanted with the HINTEGRA Total Ankle Prosthesis more than 2 years ago
3187661|NCT01284959|Experimental|risperidone|Drug: risperidone 3mg, PO two times Groups: risperidone
3187662|NCT01284959|Placebo Comparator|placebo|drug: lactose, PO 3 times group: placebo
3187663|NCT01284959|Experimental|paliperidone ER|drug : Paliperidone ER 6mg PO, two times group: paliperidone ER
3187664|NCT01284946|Experimental|Exjade|Safety and efficacy
3187665|NCT01284933||Acute Ischemic Stroke, TIA|Patients admitted to a specialized stroke service because of an acute ischemic stroke or a transient ischemic attack (TIA).
3187666|NCT01284920|Experimental|dose-escalation cohort-1|MDV3100 low dose arm
3187667|NCT01284920|Experimental|dose-escalation cohort-2|MDV3100 middle dose arm
3187668|NCT01284920|Experimental|dose-escalation cohort-3|MDV3100 high dose arm
3187669|NCT01284920|Experimental|dose-expansion cohort|dose expansion with MDV3100 middle dose
3187670|NCT01284907|Active Comparator|Vit D|
3187671|NCT01284907|Placebo Comparator|Placebo drops|
3187672|NCT01284894|Other|Conventional manometry|
3187673|NCT01284894|Experimental|High resolution manometry|
3187674|NCT01284881||OSAHS|
3187675|NCT01284868|Experimental|Mirabegron|
3187676|NCT01284855|Active Comparator|Low initial dose|This arms corresponds to Nepal national protocol and involves the initial administration of 2 vials of antivenom over one hour followed by the slow infusion of 4 vials over 4 hours
3187677|NCT01284855|Experimental|High initial dose|This arms corresponds to Indian national protocol and involves the initial administration of 10 vials of antivenom over one hour followed by the slow infusion of saline over 4 hours
3187678|NCT01284829|Experimental|adrenal tumors|adrenal tumors
3187679|NCT01284816|Other|severely obese patients|35 patients addressed for severe obesity in the Endocrinology department of Marseille North Hospital before (V1) and 6 months (V2) after bariatric surgery
3187680|NCT01284803|Experimental|experimental arm|
3187681|NCT01284790|Experimental|Cochlear implants|
3187682|NCT01284777||patients|
3187683|NCT01284764|No Intervention|midnight fasting|The patients in this group will have midnight fasting the day before endoscopic examination
3187684|NCT01284764|Active Comparator|Mosapride, low volume of water|The patients in this group will take mosapride and a 500mL water at evening of the day before endoscopic examination.
3187685|NCT01284751||Breast cancer patients|Patients aged 30-70 years having a lumpectomy or mastectomy at the Department of Breast Surgery at Herlev Hospital, Copenhagen, Denmark.
3187686|NCT01284738|Active Comparator|TM patients|thalassemia major (TM) Need transfusion for survive
3187687|NCT01284738|Active Comparator|TI patients|thalassemia intermedia (TI) Patients with TI have a milder clinical phenotype than those with TM
3187688|NCT01284725|Experimental|immunosuppressive treatment discontinuation,|
3187689|NCT01284725|Active Comparator|Continuation of immunosuppressive therapy|with MMF or AZA, with a background therapy with hydroxychloroquine, and possibly low-dose corticosteroids
3187690|NCT01284686|Active Comparator|dopamine|ON DOPA:The patient will take his usual treatment with dopamine
3187691|NCT01284686|Experimental|without dopa|OFF Dopa: The patient will be deprived of his treatment usual dopaminergique for at least 12 hours
3187692|NCT01284660|Active Comparator|I. DHA|Oral ingestion 5 tablets DHA + EPA (daily ingestion DHA 2040 mg and EPA 2710 mg)- (Omega 3 - 950,the Solgar Pharmaceutical Co., Israel).
3187693|NCT01284660|Placebo Comparator|II. Placebo|Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
3187694|NCT01284647|Experimental|Teprenone capsule|
3187695|NCT01284647|Active Comparator|sucralfate|
3187696|NCT01284634|Experimental|GWP42003 200 milligrams (mg)/day Dose|Participants self-administered one x 100 mg GWP42003 capsule twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
3188660|NCT01277640|Placebo Comparator|matched placebo|
3187697|NCT01284634|Experimental|GWP42003 400 mg/day Dose|Participants self-administered two x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
3187698|NCT01284634|Experimental|GWP42003 800 mg/day Dose|Participants self-administered four x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
3187699|NCT01284634|Experimental|Placebo|Participants self-administered one, two or four placebo capsules twice daily, for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]). Each capsule exactly matched the GWP42003 capsules in terms of appearance, size, smell and taste.
3187700|NCT01284621|Experimental|BI 10773|1 tablet per days for 5 days, oral administration with 240 mL water for each treatment
3187701|NCT01284621|Other|Ramipril|1 tablet on day 1 and 2 tablets per day on day 2-5, oral administration with 240 mL water for each treatment
3187702|NCT01284621|Other|BI 10773 + Ramipril|1 tablet BI 10773 and 1 tablet on day 1 and 2 tablets ramipril per day on day 2-5, oral administration with 240 mL water for each treatment
3187703|NCT01284595|Experimental|AZD8931|[14C] AZD8931
3187704|NCT01284582|Experimental|ATH03 Group A|ATH03, 10 µg, 0.2% Alum
3187705|NCT01284582|Experimental|ATH03 Group B|ATH03, 30 µg, 0.2% Alum
3187706|NCT01284582|Experimental|ATH03 Group C|ATH03, 100 µg, 0.2% Alum
3187707|NCT01284569|Experimental|ALX-0061|
3187708|NCT01284569|Placebo Comparator|Placebo|
3187709|NCT01284556|Placebo Comparator|Placebo|placebo tablets
3187710|NCT01284556|Experimental|60 mg group|Patients titrated to 60mg phenobarbital for maintenance period, then titrated down.
3187711|NCT01284556|Experimental|100 mg group|Patients titrated to 100mg phenobarbital maintenance period, then titrated down
3187712|NCT01284543|Active Comparator|Busin glide delivery of donor graft|Use of the Busin glide to insert the donor graft
3187713|NCT01284543|Experimental|Tan EndoGlide for insertion of the donor graft|Use of the Tan EndoGlide for insertion of the donor graft
3187714|NCT01284530|Experimental|Conversion-25|25 mg
3187715|NCT01284530|Experimental|Conversion-50|50 mg
3187716|NCT01284530|Experimental|Conversion-100|100 mg
3187717|NCT01284530|Experimental|Conversion-200|200 mg
3187718|NCT01284517|Experimental|Lurasidone 20-120 mg flexible dose|
3187719|NCT01284517|Placebo Comparator|Placebo|
3187720|NCT01284504|Experimental|Celecoxib|Celecoxib, 200 mg tab
3187721|NCT01284504|Placebo Comparator|Placebo|placebo, tab
3187722|NCT01284491|Active Comparator|Standard of Care (SOC)|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
3187723|NCT01284491|Experimental|PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
3187724|NCT01284478|Other|Dexamethasone Implant|Patients will be treated with the Ozurdex (Dexamethasone Implant)
3187725|NCT01284465|Experimental|Intervention group|Education and patient liaison combination
3187726|NCT01284465|Experimental|Control group|Education only
3187727|NCT01284452|Placebo Comparator|Placebo|Normal saline 50 ml intravenous every 6 hours for 7 days
3187728|NCT01284452|Active Comparator|Hydrocortisone|Hydrocortisone 50 mg intravenous every 6 hours for 7 days
3187729|NCT01284439|Experimental|TearA|
3187730|NCT01284439|Experimental|TearB|
3187731|NCT01284426||Chronic urticaria|Chronic urticaria, Natural history
3187732|NCT01284413|Experimental|S-1, Gemcitabine, Cisplatin|
3187733|NCT01284400|Experimental|Disease management|
3187734|NCT01284400|No Intervention|Usual treatment and care|
3187735|NCT01284387|Experimental|3 μg ACC-001 / QS-21 50 μg IM dose 1|3 μg ACC-001 / QS-21 50 μg IM
3187736|NCT01284387|Experimental|10 μg ACC-001 / QS-21 50 μg IM dose 2|10 μg ACC-001 / QS-21 50 μg IM
3187737|NCT01284387|No Intervention|Placebo - Phosphate buffered saline (PBS) IM dose|Placebo - Phosphate buffered saline (PBS) IM
3187738|NCT01284374||Male Adolescents|Male adolescents, 13-17 years old, who are seen at community adolescent health clinics and are offered HPV vaccine
3187739|NCT01284374||Parents of Male Adolescents|Parents of Male Adolescents, whose adolescents are being seen at community adolescent health clinics and are offered HPV vaccine
3187740|NCT01284374||Health Care Providers for Males 13-17 yo|Health care providers who provide medical care to male adolescents in pediatric and adolescent clinics
3187741|NCT01284361|Experimental|30 cm Intermittent Catheter|Intervention was the test of a 30 cm catheter compared to standard commercial 40 cm catheter in a cross-over design.
3187742|NCT01284361|Active Comparator|40 cm Intermittent Catheter|Active comparator 40 cm commercial catheter was compared to experimental 30 cm catheter in a cross-over design.
3187743|NCT01284348|Experimental|Sotatercept - 15 mg|Sotatercept 15 mg Subcutaneous (SC) Day 1 every 42 days
3187744|NCT01284348|Experimental|Sotatercept 30 mg|Sotatercept 30 mg SC Day 1 every 42 days
3187745|NCT01284335|Experimental|Gemcitabine plus LY573636|
3187746|NCT01284335|Experimental|Docetaxel plus LY573636|
3187747|NCT01284335|Experimental|Temozolomide plus LY573636|
3187748|NCT01284335|Experimental|Cisplatin plus LY573636|
3187749|NCT01284335|Experimental|Erlotinib plus LY573636|
3187750|NCT01284322|Experimental|Fresolimumab|
3187751|NCT01284309|Experimental|Mirabegron|
3187752|NCT01284309|Placebo Comparator|Placebo|
3187753|NCT01284296|Experimental|Digital block|
3187754|NCT01284283|Other|Single|Device: Scandinavian Total Ankle Replacement System (STAR Ankle)
3187755|NCT01284270|Other|All Patients|All patients undergo the same study procedures
3187756|NCT01284257||Enteric coated mycophenolate sodium (EC-MPS) arm|Patients to whom EC-MPS is prescribed by their practitioner.
3187757|NCT01284257||MMF arm|Patients to whom MMF is prescribed by their practitioner.
3187758|NCT01284244|Experimental|Uresta|
3187759|NCT01284244|Sham Comparator|Silastic vaginal ring|
3187803|NCT01283932|Active Comparator|Protonix|Protonix 40 mg DR Tablets of Wyeth Laboratories
3187761|NCT01284231|Experimental|MEDI-565 Dose Expansion Arm 1|20 subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biologic dose
3187762|NCT01284231|Experimental|MEDI-565 Dose Expansion Arm 2|20 subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biologic dose
3187763|NCT01284231|Experimental|MEDI-565 Dose Expansion Arm 3|Subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biological dose
3187764|NCT01284218||Aripiprazole cohort|
3187765|NCT01284218||Other atypical cohort|
3187766|NCT01284218||Other antidepressant cohort|
3187767|NCT01284218||Mood stabilizer cohort|
3187768|NCT01284218||Stimulant cohort|
3187769|NCT01284205|Experimental|MCC|Intravesical Administration of Mycobacterial Cell-Wall DNA Complex
3187770|NCT01284205|Active Comparator|BCG|Intravesical Administration of Bacillus Calmette-Guerin
3187771|NCT01284192|Experimental|ASP3026|Subjects will receive escalated doses of ASP3026 to determine the maximum tolerated dose (MTD)
3187772|NCT01284179|Experimental|Hypnotherapy|Participants will be randomized to either the home hypnotherapy or educational group. The HHT protocol will consist of sequences of two different types of sessions, longer biweekly sessions (LS), each approximately 30-40 minutes in length, and shorter daily sessions (SS), approximately 12 minutes in length. On the first day of each sequence, the patient will listen to the appropriate LS. The patients will listen to the SS on a daily basis in between each LS. Every 2 weeks a new sequence will begin, for a total of 12 weeks of treatment.
3187773|NCT01284179|Other|Educational|Participants will be randomized to receive either home hypnotherapy or an educational program. The control group will receive an educational digital audio program on MP3 players. These digital audio files will contain general information about FCP and FGIDs. These audio files will be similar to the intervention audio files in length. Patients will be instructed to begin listening on the day of randomization. Patients will be instructed to continue their other medical treatment for chest pain during the study. The control group will be assessed at the same times as the HHT group.
3187774|NCT01284166|Experimental|Triple Combination Therapy|Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
3187775|NCT01284140|Experimental|Sleep promotion protocol|Behavioral: 48 hours of sleep and circadian rhythm promotion including timed light exposure.
3187776|NCT01284140|Active Comparator|Usual care|Behavioral: 48 hours of usual care.
3187777|NCT01284127||Deferiprone|All patients must have MRI evidence of superficial siderosis and be treated with deferiprone according to standard of care guidelines.
3187778|NCT01284114|Active Comparator|Aliskiren|
3187779|NCT01284101|Active Comparator|Forceps delivery of donor graft|Using the forceps to insert the donor graft.
3187780|NCT01284101|Experimental|Tan Endoglide for insertion of the donor graft|Use of the Tan Endoglide for insertion of the donor graft.
3187781|NCT01284088|Experimental|PrePex™|Adult male circumcision by the PrePex™ Device
3187782|NCT01284088|Active Comparator|Surgical|Adult male surgical circumcision
3187783|NCT01284075|Experimental|Guided Imagery and Music therapy group (GIMT)|Participants will undergo a standardized regimen of peri-operative guided imagery and music therapy guided by CDs (compact disc). The peri-operative regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
3187784|NCT01284075|Active Comparator|White Noise Group (WN)|Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
3187785|NCT01284075|Active Comparator|No Interventions Group (CP)|Control group (CP) will have no intervention at all and will follow our current peri-operative procedures.
3187786|NCT01284062|Experimental|Arm 1|200 mg PF-05230917, Anrukinzumab active dose level
3187787|NCT01284062|Experimental|Arm 2|400 mg PF-05230917, Anrukinzumab active dose level
3187788|NCT01284062|Experimental|Arm 3|600 mg PF-05230917, Anrukinzumab active dose level
3187789|NCT01284062|Placebo Comparator|Arm 4|Matching placebo - administered at matching dose level 200 mg, 400 mg or 600 mg.
3187790|NCT01284049|Active Comparator|Intralipid 20%®|reference treatment by standard lipid emulsion not enriched in n-3 EFA (Intralipid 20%®)+ vitamin E.
3187791|NCT01284049|Experimental|OMEGAVEN 10%®|Interventional treatment by a lipid emulsion enriched in n-3 EFA (OMEGAVEN 10%®).
3187792|NCT01284036|Other|PF-05230905|9 subjects will participate in each dose cohort. 6 subjects will receive investigational product (PF-05230905) and 3 subjects will receive placebo
3187793|NCT01284023||Controls|Uninjured volunteers
3187794|NCT01284010||Group 1|Diagnostic, complete remission, and germ-line specimens are analyzed for DNA profiling and gene resequencing by the Affymetrix SNP6.0 microarray platform, PCR, and fluorescence in situ hybridization (FISH). Frequency of genetic alterations are performed by the Agilent 2100 Bioanalyzer. Results are then compared with the data already generated from pediatric patients.
3187795|NCT01283997|Placebo Comparator|Placebo Group|1 dose on first day of induction therapy, then every 12 hours for 10 weeks.
3187796|NCT01283997|Experimental|Minocycline Group|200 mg orally for 1 dose, then 100 mg orally every 12 hours for 10 weeks.
3187797|NCT01283984|Experimental|1|AZD2115
3187798|NCT01283984|Placebo Comparator|2|Placebo to AZD2115
3187799|NCT01283971|Experimental|Tocilizumab + Methotrexate|Tocilizumab 8 mg/kg intravenous (IV) every 4 weeks + Placebo to adalimumab subcutaneous (SC) every 2 weeks for 24 weeks. All participants received methotrexate 10-25 mg and folate at least 5 mg/kg weekly.
3187800|NCT01283971|Active Comparator|Adalimumab + Methotrexate|Adalimumab 40 mg SC every 2 weeks + Placebo to tocilizumab IV every 4 weeks for 24 weeks. All participants received methotrexate 10-25 mg and folate at least 5 mg/kg weekly.
3187801|NCT01283945|Experimental|Lucitanib|
3187802|NCT01283932|Experimental|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited
3187804|NCT01283919|Experimental|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited
3187805|NCT01283919|Active Comparator|Protonix|Protonix 40 mg DR Tablets of Wyeth Laboratories
3187806|NCT01283906|Experimental|MuGard|Mucoadhesive Oral Wound Rinse
3187807|NCT01283906|Sham Comparator|Control Rinse|Aqueous Control Rinse.
3187808|NCT01283893||Laparoscopy group|Laparoscopy group: patients who underwent laparoscopic distal gastrectomy with D2 lymphadenectomy
3187809|NCT01283893||Open group|Open group: patients who underwent open distal gastrectomy with D2 lymphadenectomy
3187810|NCT01283867|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets of Dr. Reddy's Laboratories Limited
3187811|NCT01283867|Active Comparator|Cellcept|Cellcept 500 mg tablets of Roche Laboratories Inc.
3187812|NCT01283854|Experimental|Exercise group|Each participant randomised to the exercise group will receive routine, regular antenatal care. In addition, these women will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist.
3187813|NCT01283854|No Intervention|Control group|Women allocated to the control group will not participate in the home-based exercise program, and will continue their normal physical activity throughout pregnancy. This group will receive routine, regular antenatal care, together with the additional outcome assessments at baseline (14 weeks gestation) and cessation of the study (28 weeks gestation).
3187814|NCT01283841|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets of Dr. Reddy's Laboratories Limited
3187815|NCT01283841|Active Comparator|Cellcept|Cellcept 500 mg tablets of Roche Laboratories Inc.
3187816|NCT01283815|Active Comparator|Conservative management|Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
3187817|NCT01283815|Experimental|Laparoscopic appendectomy|Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group
3187818|NCT01283802||IOCUS|
3187819|NCT01283789|Experimental|Lapatinib and RAD-001|"RAD-001 will be administered orally as a once-daily dose of 5 mg (one 5 mg tablet) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD-001 in the morning, at the same time each day.~Lapatinib will be administered orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take lapatinib at bedtime, at the same time each day. Lapatinib should be taken by the patient in a fasting state."
3187820|NCT01283776|Experimental|treatment arm|Cyclophosphamide
3187821|NCT01283763|Experimental|Topical Imiquimod|16 weeks topical Imiquimod
3187822|NCT01283763|Active Comparator|Conization|Large loop excision of the transformation zone
3187823|NCT01283750|No Intervention|Augmented Usual Care|
3187824|NCT01283737|Experimental|DBX|DBX Putty in glass syringe
3187825|NCT01283737|Active Comparator|Mosaicplasty|
3187826|NCT01283724|Experimental|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
3187827|NCT01283711|Experimental|apollo|
3187828|NCT01283698|Experimental|LAS 41004 dosage 1|dosage 1, once daily
3187829|NCT01283698|Experimental|LAS 41004 dosage 2|dosage 2, once daily
3187830|NCT01283698|Experimental|LAS 41004 dosage 3|dosage 3, once daily
3187831|NCT01283698|Placebo Comparator|placebo|once daily
3187832|NCT01283698|Active Comparator|Reference|once daily
3187833|NCT01283659|Active Comparator|Standard imaging (coronary angiography)|Subjects will undergo a coronary angiogram as planned by their attending doctor
3187834|NCT01283659|Active Comparator|Advanced imaging (CTA)|Subjects will undergo a CTA scan first. Based on the CTA results, subjects may or may not proceed to coronary angiography. CTA results will be reviewed by the attending physician.
3187835|NCT01283646|Experimental|Apevitin BC|Children (5 to 6 years): 3.5 ml 3 times a daily Children (7 to 15 years): 5 ml 3 times a daily
3187836|NCT01283646|Active Comparator|Vitamin B Complex + Vitamin C|Children (5 to 6 years): 3.5 ml 3 times a daily Children (7 to 15 years): 5 ml 3 times a daily
3187837|NCT01283633|Experimental|programming with non-experienced nurse|Programming done by an experienced neuromodulation clinician will be compared to the patient satisfaction of a programming session with an inexperienced nurse via remote presence robotics, which will be directed by the experienced clinician
3187838|NCT01283620|Other|Usual Care|
3187839|NCT01283620|Experimental|modified CIMT (mCIMT)|
3187840|NCT01283607|Active Comparator|Digicoach|Women randomized in the Digicoach group will be treated by the Digicoach therapy. Digicoach is an e-health cognitive behavioral therapy with 4-12 weekly sessions especially developed for in vitro fertilization (IVF) women. Digicoach is facilitated by an e-therapist. The investment for the weekly home work assignments is about one and a half hour. Digicoach consist of different modules (e.g. stress reduction, acceptance). Digicoach starts before the hormonal down regulation as the start of the IVF procedure and ends three weeks after the pregnancy test.
3187841|NCT01283607|No Intervention|Control|Women in the control group will get the usual treatment, there will be no additional intervention.
3187842|NCT01283594|Experimental|Tozadenant (SYN115) 60 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
3187843|NCT01283594|Experimental|Tozadenant (SYN115) 120 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
3187844|NCT01283594|Experimental|Tozadenant (SYN115) 180 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
3187845|NCT01283594|Experimental|Tozadenant (SYN115) 240 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
3187846|NCT01283594|Placebo Comparator|Sugar Pill|White-coated, modified-oval placebo tablets.
3187847|NCT01283581|Experimental|Delafloxacin|300 mg IV every 12 hours for 5-14 days
3187969|NCT01282697|Experimental|rapamycin+irinotecan at a given dose|
3187848|NCT01283581|Active Comparator|Vancomycin|15 mg/kg, up to 1250 mg, IV every 12 hours for 5-14 dyas
3187849|NCT01283581|Active Comparator|Linezolid|600 mg IV every 12 hours for 5-14 days
3187850|NCT01283568||1 - Gamaline+Hipericin - fertile women|
3187851|NCT01283568||2- Gamaline+Hipericin - climateric women|
3187852|NCT01283568||3- Gamaline- control - fertile women|
3187853|NCT01283568||4 - Gamaline control - climateric women|
3187854|NCT01283555|Experimental|User-Filled Applicator|
3187855|NCT01283555|Other|Prefilled applicator|
3187856|NCT01283542|Experimental|Pasireotide LAR|
3187857|NCT01283529||Children 0 - 15 years|Children undergoing neurosurgery in general anesthesia
3187858|NCT01283516|Experimental|LDK378: Arm 1A and Arm 1B|NSCLC patients previously treated with an ALK inhibitor
3187859|NCT01283516|Experimental|LDK378: Arm 2|NSCLC patients not previously treated with an ALK inhibitor
3187860|NCT01283516|Experimental|LDK378: Arm 3|Patients with other tumors that are ALK positive other than NSCLC
3187861|NCT01283503|Experimental|BKM120|
3187862|NCT01283490|Active Comparator|DASD Group|Benzocaine 20% will be placed using the DASD for one minute. Immediately after DASD application a needle puncture with a 27 gauge needle to the depth of 3 millimeters will be performed.
3187863|NCT01283490|Sham Comparator|Sonic Vibration (SV)|A modified tooth brush which only allows sonic vibration (SV), that has the appearance and sound of the DASD will be used to apply the benzocaine 20% for one minute. Following application with the SV a needle puncture with a 27 gauge needle to the depth of 3millimeters.
3187864|NCT01283477|Experimental|ACUPUNCTURE|
3187865|NCT01283477|Sham Comparator|SHAM ACUPUNCTURE|
3187866|NCT01283464|Active Comparator|Retinol|Retinol 1.0% cream
3187867|NCT01283464|Active Comparator|Tretinoin|Tretinoin 0.02% cream
3187868|NCT01283451||Exercise|NIRS values of all participants will be measured at baseline and following each 30-60 second exercise.
3187869|NCT01283438|Experimental|Barricaid Device|Intervention: Barricaid Device
3187870|NCT01283438|Active Comparator|Standard of Care|Standard (Limited) Discectomy Only
3187871|NCT01283425|Experimental|Test|InsuPatch use for 3 months.
3187872|NCT01283425|No Intervention|Control|
3187873|NCT01283412|Active Comparator|Arm P|Placebo infusion
3187874|NCT01283412|Experimental|Arm D|Dexmedetomidine infusion
3187875|NCT01283399||Rituximab + Methotrexate|All participants with active refractory RA who were eligible to receive treatment with methotrexate and rituximab in the Investigators' opinion as per the routine clinical practice following inadequate response to a single cycle of anti-TNF therapy.
3187876|NCT01283386|Experimental|A|
3187877|NCT01283386|Active Comparator|B|
3187878|NCT01283373|Experimental|A|Dose escalation cohorts
3187879|NCT01283373|Experimental|B|Dose expansion cohorts
3187880|NCT01283360|Placebo Comparator|HEC Placebo Gel|In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel. Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
3187881|NCT01283360|Active Comparator|Tenofovir 1% Gel|In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel. Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
3187882|NCT01283347|Experimental|18F-DTBZ for Parkinson's Disease|"25 age-matched healthy volunteers will be enrolled. For assessing the correlation between the 18F-DTBZ binding and the severity of disease, the patients with PD will be divided into three groups according to their motor scores: mild, moderate, and advanced. We will enroll 25 patients in each group. Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study, as one screening visit, one imaging visit, and one safety evaluation visit.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
3187883|NCT01283334|Experimental|A|Treatment arm with carboplatin, cetuximab and RAD001
3187884|NCT01283321|Experimental|Group A: RiaSTAP|Human fibrinogen concentrate
3187885|NCT01283321|Active Comparator|Group B: apheresis platelets|single apheresis unit
3187886|NCT01283308|Active Comparator|Standard of Care|Participants randomized to the standard of care group will receive standard lifestyle advice for diabetes prevention consistent with expert recommendations for a healthy lifestyle, including losing 5-10% of their excess body weight, following standard dietary recommendations to reduce calorie and fat intake, and exercising at least 150 minutes per week.
3187887|NCT01283308|Experimental|Lifestyle Intervention|Intervention arm participants will participate in a step-wise model of diabetes prevention with the goal of reducing diabetes risk, primarily through (1) a weight loss of at least 7% and (2) 150 minutes or more per week of moderate level physical activity.
3187888|NCT01283295||Immune complications|Transplant recipients who develop a clinically recognized complication with potential immune etiology or ramifications. Examples include opportunistic infection, rejection, malignancy, alloantibody formation or immunosuppressive drug toxicity.
3187889|NCT01283295||Stable Transplant Recipient|Patients who demonstrate immune stability characterized by stable graft function without evident complication. These patients serve as comparators for Group 1
3187890|NCT01283295||Pre-Transplant Longitudinal|Patients who are candidates for kidney, pancreas, liver or lung transplant will be enrolled and followed longitudinally.
3187891|NCT01283295||Organ Donors|Donors for individuals meeting the criteria for Cohorts 1-3
3188103|NCT01281631|Placebo Comparator|Placebo|normal saline
3187892|NCT01283295||Disease state|Individuals with liver, renal or pulmonary diseases that may lead to the development or organ failure.
3187893|NCT01283295||Normal Volunteers|
3187894|NCT01283282|Active Comparator|Clopidogrel/Placebo|Subjects were randomized to clopidogrel 75 mg daily for 6 weeks. Then immediately transitioned to a placebo daily for 6 weeks.
3187895|NCT01283282|Active Comparator|Placebo/Clopidogrel|Subjects were randomized to a placebo daily for 6 weeks. Then immediately transitioned to clopidogrel 75 mg daily for 6 weeks.
3187896|NCT01283269|Experimental|Memory Support System or Computer|
3187897|NCT01283256||Experimental|
3187898|NCT01283243||HIV patients with normal liver status|HIV patients without abnormal liver function and chronic liver disease
3187899|NCT01283230||chronic liver disease|Any cause of liver disease that involves a process of progressive destruction and regeneration of the liver parenchyma leading to fibrosis and cirrhosis such as hepatitis B, hepatitis C, alcoholic liver disease.
3187900|NCT01283230||Healthy liver and kidney donor|Healthy liver and kidney donor who have normal liver condition
3187901|NCT01283217|Experimental|DS(Docetaxel with S-1)|Docetaxel with S-1
3187902|NCT01283217|Active Comparator|SP(S-1 with cisplatin)|S-1 with cisplatin
3187903|NCT01283204|Active Comparator|SP(S-1 with cisplatin)|"SP <Every 3 weeks>~Day 1~14 : TS-1 80mg/m2/day (PO)~Day 1 : CDDP 60mg/m2/day IVF 2hours~Day 15~21 : Rest"
3187904|NCT01283204|Active Comparator|FL/Tax(Paclitaxel with Leucovorin with 5-FU)|"FL/Tax <Every q 3 weeks>~Day1 : Paclitaxel 175mg/m2 IVF for 2hours~Day1 : Leucovorin 20mg/m2 IVF for 1hour~Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
3187905|NCT01283204|Active Comparator|FL/Doc(Decetaxel with Leucovorin with 5-FU)|"FL/Doc <Every q 3 weeks>~Day1 : Docetaxel 75mg/m2 IVF for 1hour~Day1 : Leucovorin 20mg/m2 IVF for 1hour~Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
3187906|NCT01283204|Active Comparator|FOLFOX(Oxaliplatin with Leucovorin with 5-FU)|FOLFOX <Every q 2 weeks> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1~2 : 5-FU 1200mg/m2 IVF for 24hours
3187907|NCT01283191|Experimental|Behavioral Incentives|Vouchers for complying with target behavior
3187908|NCT01283191|Placebo Comparator|Education Control|Education class
3187909|NCT01283178|Experimental|Arm I|Patients undergo intensity-modulated image-guided adaptive radiotherapy once daily 5 days a week for 6 weeks. Patients also receive cisplatin IV on days 1 and 22. Treatment continues in the absence of disease progression or unacceptable toxicity.
3187910|NCT01283165||health education|This was an intervention follow up Knowledge Attitude and Practice study that investigated the distribution of polyparasitism with schistosomiasis, STHs and P. falciparum among primary schoolchildren.
3187911|NCT01283152|Active Comparator|Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)|
3187912|NCT01283152|Other|Lactulose|Per standard of care
3187913|NCT01283139|Experimental|Sifalimumab 200 milligram (mg)|Sifalimumab 200 milligram (mg) will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
3187914|NCT01283139|Experimental|Sifalimumab 600 mg|Sifalimumab 600 mg will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
3187915|NCT01283139|Experimental|Sifalimumab 1,200 mg|Sifalimumab 1,200 mg will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
3187916|NCT01283139|Placebo Comparator|Placebo|Placebo matching to sifalimumab will be administered intravenously at a fixed dose every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
3187917|NCT01283126|Experimental|Euglycemic and hypoglycemic clamp|Subjects will complete clamp study visit.
3187918|NCT01283100|Experimental|Treatment A|GSK1349572 50mg q24h x 7 days
3187919|NCT01283100|Experimental|Treatment B|GSK2248761 200mg q24h x 7 days
3187920|NCT01283100|Experimental|Treatment C|GSK1349572 50mg q24h x 7 days + GSK2248761 200mg q24h x 7 days
3187921|NCT01283074||Cohort|
3187922|NCT01283061|Experimental|zafirlukast|Zafirlukast Tablets 20 mg of Dr. Reddys Laboratories Limited
3187923|NCT01283061|Active Comparator|Accolate|ACCOLATE tablets manufactured by IPR pharmaceuticals and manufactured for Astrazeneca Pharmaceuticals
3187924|NCT01283048|Experimental|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
3187925|NCT01283035|Experimental|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 will be taken PO once a week for four weeks (one cycle). Treatment will continue for as long as a subject is benefiting from the study drug.
3187926|NCT01283022|Experimental|MVI 200|MVI 200 mcg vaginal insert
3187927|NCT01283009|Active Comparator|Arm 1: Methylprednisolone|Methylprednisolone
3187928|NCT01283009|Placebo Comparator|Arm 2: Inactive substance|Inactive substance
3187929|NCT01282983|Active Comparator|fiber|
3187930|NCT01282983|Placebo Comparator|Placebo|
3187931|NCT01282970|Experimental|BI 135585|once daily doses as oral solution or tablet formulation over 14 days
3187932|NCT01282970|Placebo Comparator|Placebo to BI 135585|once daily doses as oral solution or tablet formulation over 14 days
3187933|NCT01282957|No Intervention|Active Control|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 6 months
3187934|NCT01282957|Experimental|Financial Incentive Group I|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 3 months. If all three devices used daily, participant entered in lottery with 1 in 100 odds of winning $100 and 2 in 10 odds of winning $10. Financial incentive terminated after 3 months. Daily use of devices continues for additional 3 months. (Intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.)
3187935|NCT01282957|Experimental|Financial Incentives Group II|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 3 months. If all three devices used daily, participant entered in lottery with 1 in 100 odds of winning $50 and 2 in 10 odds of winning $5. Financial incentive terminated after 3 months. Daily use of devices continues for additional 3 months. (Intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.)
3188104|NCT01281618||Those with barrett's esophagus|Those with barrett's esophagus: no dysplasia or low grade dysplasia
3187936|NCT01282944|Experimental|Combined Financial Incentive & Peer Network Arm|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Subjects connected with 4 other participants in the same study arm to form a peer network of 5 individuals. Each peer network participant given access to a secure online message board that will allow the 5 participants in each peer network to communicate online. Participants also receive weekly feedback regarding which participants in the peer group achieved their walking goals during the previous week.~Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will be entered in lottery with an approximate 3 in 10 chance of winning $50 and an approximate 3 in 100 chance of winning $200.~Financial incentive and peer network terminated after 4 months. Daily use of pedometer continues for an additional 2 months."
3187937|NCT01282944|No Intervention|Active Control|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects in the Control Group will only receive pedometers and weekly feedback on their performance through the same mechanisms and with the same frequency as participants in the other three study arms. There will be no financial incentives or peer networks in this group."
3187938|NCT01282944|Experimental|Financial Incentive Arm|Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will be entered in lottery with an approximate 3 in 10 chance of winning $50 and an approximate 3 in 100 chance of winning $200. Financial incentive is terminated after 4 months. Daily use of pedometer continues for an additional 2 months.
3187939|NCT01282944|Experimental|Peer Network Arm|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period.~Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals. Each peer network participant will be given access to a secure online message board that will allow the 5 participants in each peer network to communicate online. All participants in a peer network will receive a list of ways in which his or her new network could support each individual's walking goals. Participants will also receive weekly feedback regarding which participants in the peer group were successful in achieving their walking goals during the previous week.~Peer network is terminated after 4 months. Daily use of pedometer continues for an additional 2 months."
3187940|NCT01282918|Other|Study group|Patients without DF (Defibrillation) testing during ICD implantation
3187941|NCT01282918|Other|Control group|Patients with DF testing during ICD implantation (according to standardized procedure)
3187942|NCT01282905||Healthy controls|
3187943|NCT01282905||Ulcerative colitis|
3187944|NCT01282892||patients with NAFLD|
3187945|NCT01282892||excess of visceral fat|
3187946|NCT01282879|Experimental|itraconazole, prophylaxis, Oral solution|For GVHD patients who are required systemic glucocorticoids therapy, itraconazole oral solution will be administered at a dose of 200mg every 12 hours.
3187947|NCT01282866|Experimental|HS treatment|Treatment with HS handpiece
3187948|NCT01282853|Active Comparator|A1|one biopsy specimen taken from gastric antrum was put into RUT kit
3187949|NCT01282853|Experimental|A4|4 biopsy specimens taken from gastric antrum were put into RUT kit
3187950|NCT01282853|Experimental|B1|one biopsy specimen taken from gastric body was put into RUT kit
3187951|NCT01282840|Other|Bladder wall blood perfusion pattern|
3187952|NCT01282827|Experimental|rtACS (Verum condition)|Repetitive transorbital alternating current stimulation (rtACS)
3187953|NCT01282827|Placebo Comparator|Placebo stimulation|no intervention (Sham stimulation)
3187954|NCT01282814|Experimental|Investigational Test Product|Venlafaxine Hydrochloride 150 mg Extended-Release Capsules.
3187955|NCT01282814|Active Comparator|Reference Listed Drug|Effexor® XR 150 mg Extended-Release Capsules
3187956|NCT01282801|Experimental|Investigational Test Product|Venlafaxine Hydrochloride 150 mg Extended-Release Capsules
3187957|NCT01282801|Active Comparator|Reference Listed Drug|Effexor® XR 150 mg Extended-Release Capsules
3187958|NCT01282788|No Intervention|Traditional Diet|Infants in communities randomized to the traditional diet arm will not receive food supplements.
3187959|NCT01282788|Experimental|Cereal|All infants in communities randomized to the Cereal Arm will receive caterpillar cereal from 6-18 months of age.
3187960|NCT01282775|No Intervention|Environment / Usual Care|
3187961|NCT01282775|Other|WEB+ Environment|Web-based weight loss program (WEB) + Environment - Participants have access to a proven Web-based weight loss program with weekly lessons focused on lifestyle behavior changes
3187962|NCT01282775|Other|WEB + Cash Incentive for Weight Loss|Web-based Weight Loss Program + Cash Incentive for Weight Loss - participants have access to a proven web-based weight loss program plus they are paid cash based on the percent weight lost at 12 months compared to baseline.
3187963|NCT01282749|Experimental|SisterTalk Hartford First|12-week group support and film-based healthy lifestyle education program, including information on healthy nutrition and food preparation, increasing activity and exercise, healthy lifestyle behavior modification, and supportive spiritual materials.
3187964|NCT01282749|Other|SisterTalk Hartford Second|Participants received general film series on healthy lifestyles while waiting to participate in the experimental arm.
3187965|NCT01282736|Experimental|Integrative Response Therapy|IRT is based on affect regulation theories of binge eating and adds emphasis on cognitive restructuring techniques. IRT is a 10 session, group-based, guided-self-help treatment that works to decrease binge eating by primarily enhancing emotion coping skills, in addition to transforming faulty interpretations and reducing vulnerabilities (e.g., interpersonal events) that risk overwhelming emotion and problematic cognitions.
3187966|NCT01282736|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy guided self-help (CBT-GSH), based on the restraint model of binge eating, has been adapted from individual format to a 10 session, group-based therapy for the purpose of this study. The book 'Overcoming Binge Eating' is employed in the present study and consists of Part 1, an educational background on BED, and Part 2, a 6 step treatment program to overcome binge eating.
3187967|NCT01282723||Pregnant, In Labor|
3187968|NCT01282710||Pregnant, In Labor|
3187970|NCT01282684|Active Comparator|single oral dose of 200 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
3187971|NCT01282684|Active Comparator|single oral dose of 400 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
3187972|NCT01282684|Active Comparator|single oral dose of 800 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
3187973|NCT01282684|Active Comparator|single oral dose of 1600 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
3187974|NCT01282684|Active Comparator|single oral dose of 1000 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
3187975|NCT01282684|Active Comparator|single oral dose of 1400 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
3187976|NCT01282684|Placebo Comparator|Placebo|2 patients per cohort will be randomly assigned to take placebo. 12 patients total will be randomized to take placebo in this study.
3187977|NCT01282671|Experimental|Breathing exercises|On the fourth postoperative day the patients are randomly assigned to a Treatment group continuing to perform deep breathing exercises for 2 months postoperatively and to a Control group who will perform no breathing exercises after the third postoperative day. Patient management is otherwise similar in the groups. The patients in the Deep breathing group will be instructed to perform breathing exercises (3 x 10 deep breaths) 5 times a day (document compliance) during the two postoperative months.
3187978|NCT01282671|No Intervention|Control group|No breathing exercises.
3187979|NCT01282658||Colorectal cancer|
3187980|NCT01282645||PSI in PEEK|All study subjects have received a Patient Specific Implant (PSI) made of PEEK to repair a cranial defect
3187981|NCT01282632|Experimental|Risperidone|Commence at 0.5 mg once daily Increase, blindly, to 1 mg and then by 1 mg at discretion of clinicians through weeks 1-4 to a maximum of 3 mg.
3187982|NCT01282632|Experimental|Olanzapine|Commence at 2.5 mg once daily Increase to 5.0 mg, blindly, and then by 5 mg at the discretion of the clinician through weeks 1 - 4 to a maximum of 15 mg
3187983|NCT01282619|Experimental|Huperzine A Sustained-Release Tablet|
3187984|NCT01282619|Active Comparator|Huperzine A Tablet|
3187985|NCT01282619|Placebo Comparator|Placebo|
3187986|NCT01282606|Experimental|Drug I: SI-6603 (Low)|
3187987|NCT01282606|Experimental|Drug II: SI-6603 (Middle)|
3187988|NCT01282606|Experimental|Drug III: SI-6603 (High)|
3187989|NCT01282593|Other|CD9 expression level|Impact of CD9 expression level on motility assays
3187990|NCT01282580|Experimental|Dietary fish (canned salmon, albacore)|Fish products: Canned albacore and salmon will be provided at no cost to the patient. Supplies of tuna and salmon will be provided in quantities sufficient for one month of daily intake by the subject. If desired, a subject can request a sufficient amount to allow for preparation of a meal for the family or household at no more than two times per week. Labels or portions of labels from the cans will be collected at the monthly study visits, and canned supplies will be replenished monthly or at more frequent intervals if needed. Subjects will be allowed to keep unused cans.
3187991|NCT01282580|Experimental|Lovaza-Omega 3 fatty acid capsules|Lovaza capsules will be provided at no cost to the patient. Pill bottles will be provided to the patient, with the start date and number of pills recorded. The supplement will be provided in sufficient supply for one month at a time. Pill bottles will be collected at monthly follow-up visits, and any unused capsules will be documented and discarded as biohazardous waste.
3187992|NCT01282567|Other|diabetic patients|
3187993|NCT01282554|Experimental|stimulated group|stimulated group
3187994|NCT01282554|No Intervention|control group|Control group : non stimulated group.
3187995|NCT01282541|Active Comparator|Transconjunctival|
3187996|NCT01282541|Active Comparator|Transcutaneous|
3187997|NCT01282515|Experimental|ELP active|one PDT treatment
3187998|NCT01282515|Active Comparator|topical steroids|
3187999|NCT01282502|Experimental|Midostaurin with chemoradiation|
3188000|NCT01282476|Experimental|Panobinostat/Rituximab|single-arm, open-label; Panobinostat with Rituximab: Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
3188001|NCT01282463|Active Comparator|Docetaxel|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
3188002|NCT01282463|Experimental|Docetaxel + Ramucirumab DP|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
3188003|NCT01282463|Experimental|Docetaxel + IMC-18F1|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
3188004|NCT01282450|Experimental|Single arm|Eligible patients
3188005|NCT01282437|Experimental|Prophylactic Cranial Irradiation|
3188006|NCT01282437|No Intervention|Observation|Patients will not receive PCI, but will be observed and the same items will be measured as in the PCI-arm.
3188007|NCT01282424|Experimental|Idelalisib|Treatment with idelalisib will be continued until tumor progression or development of unacceptable toxicity.
3188008|NCT01282398|Experimental|simvastatin|The experimental group will take simvastatin 40mg for at least two years.
3188009|NCT01282398|Placebo Comparator|placebo|the control group wiil take placebo pills for at least two years.
3188010|NCT01282385|Experimental|simvasatin|"a) patients responding to treatment with beta-blockers, in which she was treated with nadolol Subsequently randomized into two treatment arms, double-blind:~a.1: simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance.~a.2: placebo capsules with external characteristics similar to simvastatin.~b) non-responders to treatment with beta blockers, receive treatment with carvedilol.Subsequently randomized into two treatment arms, double-blind~b.1: simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance.~b.2: placebo capsules with external characteristics similar to simvastatin."
3188011|NCT01282385|Placebo Comparator|placebo|
3188012|NCT01282372||Participants with moderate to severe rheumatic disease|Participants with moderate to severe rheumatic disease (RA, PsA, or AS), who received adalimumab in accordance with approved label
3188013|NCT01282359|Other|Clinical Practice Group|Patients collected in centres randomized as usual clinical practice, who will not receive the limited educational asthma program.
3188014|NCT01282359|Other|"Gold Standard educational group"|Patients will receive a formal program of structured and individualized education, enrolled in centres recognized by using high standard procedures in asthma education.
3188015|NCT01282359|Other|Intervention group|This group will receive a limited educational asthma program (minimal educational intervention)
3188016|NCT01282346|Experimental|SOLX Gold Shunt|
3188017|NCT01282333|Experimental|Treatment (veliparib, gemcitabine hydrochloride, cisplatin)|Patients receive veliparib orally every 12 hours on days 1-12, gemcitabine hydrochloride IV over 30 minutes on days 3 and 10, and cisplatin IV over 60-120 minutes on day 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with suspected or known germline BRCA mutations may continue to receive single-agent veliparib continuously in the absence of disease progression or unacceptable toxicity. Patients may undergo blood, tumor tissue, and hair follicle sample collection periodically for pharmacokinetic and correlative studies.
3188018|NCT01282320|Experimental|Increased Physical Activity|Individually tailored training one hour, 2-3 sessions per week.
3188019|NCT01282320|No Intervention|"Activity as usual (Buisness as usual)"|
3188020|NCT01282307|Experimental|Method Guided Self-Determination|The Method Guided Self-Determination consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
3188021|NCT01282307|No Intervention|Treatment as usual|
3188022|NCT01282294||ETN PROtect|There is only 1 cohort in this case series
3188023|NCT01282281||Individuals aged 14-18 and 19-65 with a diagnosis of BD|
3188024|NCT01282268|Active Comparator|Arbaclofen|
3188025|NCT01282268|Placebo Comparator|Placebo|
3188026|NCT01282255|Experimental|A|
3188027|NCT01282255|Placebo Comparator|B|
3188028|NCT01282242|Experimental|IV rt-PA|open-label
3188029|NCT01282229|Active Comparator|LANAP Quadrant|Treated with LANAP
3188030|NCT01282229|No Intervention|Modified Widman Flap|Quadrant treated with Modified Widman Flap surgery
3188031|NCT01282229|No Intervention|Scaling and Root Planing|Quadrant treated with scaling and root planing alone
3188032|NCT01282229|No Intervention|Coronal Debridement|Quadrant treated with coronal debridement
3188033|NCT01282216|Active Comparator|Hepatitis A vaccine|
3188034|NCT01282216|Active Comparator|PCV 13|
3188035|NCT01282203||Adults requiring anesthesia for surgery|This post-marketing observational study will be conducted in a prospective, multi-centre format. It is a non-interventional, observational study in which Sevorane is prescribed for adult patients undergoing general surgery for induction and maintenance of anesthesia in the usual manner in accordance with the terms of the local marketing authorization. Sevorane is used for induction and maintenance anesthesia by the choice of anesthesiologist. No additional procedures (other than standard of care) shall be applied to the patients. Each patient will be observed from the start of anesthesia through anesthesia end. Markers of myocardial ischemia will be detected up to the first 24 hours after anesthesia (if available). Additionally the correlation between the experience and training background of anesthesiologists and patient related outcomes of general anesthesia with Sevorane as a single anesthetic will be assessed.
3188036|NCT01282190|Experimental|Motivational interview|
3188037|NCT01282164|Experimental|Study patients|patients with growth hormone deficiency or hypothalamic-pituitary disorders underwent fixed-dose glucagon stimulation test (GST), weight-based GST and insulin tolerance test (ITT).
3188038|NCT01282164|Active Comparator|Control|"The control group will consist of healthy volunteers matched to the study group for age, gender, Body mass index (BMI) and estrogen status. Note: Allegheny site is not enrolling in the control group.~Control subjects underwent fixed-dose glucagon stimulation test (GST), weight-based GST and insulin tolerance test (ITT)."
3188039|NCT01282151|Experimental|Taxotere|Docetaxel plus Cisplatin
3188040|NCT01282151|Active Comparator|Pemetrexed|Pemetrexed plus Cisplatin
3188041|NCT01282138|Experimental|Patanol|One drop twice daily in each eye for five days prior to allergen provocation testing, followed by an additional drop in each eye approximately 15 minutes prior to start of testing.
3188042|NCT01282138|Placebo Comparator|Tears Naturale II|One drop twice daily in each eye for five days prior to allergen provocation testing, followed by an additional drop in each eye approximately 15 minutes prior to start of testing.
3188043|NCT01282125||sleep apnea|100 patients suffering from obstructive sleep apnea syndrome
3188044|NCT01282125||controls|100 subjects matching cases to age, sex, and body weight
3188045|NCT01282099||Cardiac patients|Postoperative congenital heart disease patients requiring stay in the PICU
3188046|NCT01282099||non-cardiac patients|non-cardiac patients requiring stay in the PICU
3188047|NCT01282086||Adults requiring anesthesia for surgery|Adult patients requiring general anesthesia for surgery
3188048|NCT01282073|Experimental|Mycophenolate mofetil, low dose steroid|
3188049|NCT01282073|Active Comparator|Cyclosporin, low dose steroid|
3188050|NCT01282047|Experimental|Lenalidomide|
3188051|NCT01282034|Active Comparator|Marrow stimulation|
3188052|NCT01282034|Experimental|Medical device: MaioRegen|
3188053|NCT01281969|Experimental|Group A|
3188054|NCT01281969|Placebo Comparator|Group B|
3188055|NCT01281956|Experimental|Phase I|selective 5HT1A agonist or placebo x3 months
3188056|NCT01281956|Experimental|Phase II|selective 5HT1A agonist or placebo x3 months
3188057|NCT01281943|Experimental|Temsirolimus and Pegylated Liposomal Doxorubicin|Temsirolimus 25mg andPegylated liposomal doxorubicin 25mg/m2
3188058|NCT01281930|Experimental|Wick placement into abscess cavity|
3188059|NCT01281930|Active Comparator|Full packing of abscess cavity|
3188060|NCT01281917|Experimental|Velcade plus Temsirolimus|"Velcade 1.6 mg/m2 weekly (days 1, 8, 15, and 22) Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)~Treat for up to 6 cycles, cycles are 35 days long."
3188105|NCT01281605|Active Comparator|Active titration algorithm|titrate insulin dose by contacting with investigator by telephone weekly.
3188061|NCT01281904|No Intervention|Standard of Care|Participants randomized into the standard of care group will be asked to continue following the instructions of the healthcare provider throughout the 10 week study period. They will not be asked to perform any study intervention.
3188062|NCT01281904|Active Comparator|Relaxation Acupressure|In addition to their standard of care, participants will be asked to apply pressure on each of 9 acupressure points (bilaterally where indicated) that have been carefully selected for their relaxing effect. (There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes done once daily over a period of 6 weeks followed by 4 weeks of intervention wash-out where the participant will be asked to perform no acupressure at all.
3188063|NCT01281904|Active Comparator|Stimulating Acupressure|In addition to their standard of care, participants will be asked to apply pressure on each of 9 acupressure points (bilaterally where indicated) that have been carefully selected for their excitatory effect. (There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. There are 6 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 10 points to stimulate. Each of the 10 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 30 minutes done once daily over a period of 6 weeks followed by 4 weeks of intervention wash-out where the participant will be asked to perform no acupressure at all.
3188064|NCT01281891|Experimental|Local Infiltration Analgesia|Combination of ropivacaine, ketorolac and adrenaline
3188065|NCT01281891|Active Comparator|Intrathecal morphine|Morphine special (preservative-free) injected intrathecally
3188066|NCT01281878|Experimental|Pyridoxal-phosphate|Treatment with pyridoxal-phosphate in increasing dosages every six weeks starting with 5mg/kg body weight up to 20 mg/kg body weight. treatment duration 24 weeks
3188067|NCT01281865|Experimental|Treatment (everolimus and imatinib mesylate)|Patients receive everolimus PO once daily and imatinib mesylate PO once daily on days 1-28. Course repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood and tumor tissue sample collection at baseline and periodically during study for correlative biomarker and protein expression studies.
3188068|NCT01281852|Experimental|Treatment (paclitaxel, cisplatin, veliparib)|Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IV over 1 hour on day 2, and veliparib PO on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3188069|NCT01281839|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
3188070|NCT01281839|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
3188071|NCT01281813|Experimental|001|Darunavir (DRV) 400 milligram (mg) tablet intake of 2 tablets once daily in combination with Ritonavir (rtv)
3188072|NCT01281813|Experimental|002|Darunavir 600 mg tablet intake of 1 tablet twice a day in combination with Ritonavir
3188073|NCT01281813|Experimental|003|Ritonavir 100 mg capsule to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
3188074|NCT01281813|Experimental|004|Ritonavir 100 mg tablet to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
3188075|NCT01281813|Experimental|005|Darunavir 375 mg composed via various tablets (2x 150mg DRV tablets + 1x 75mg DRV tablet) in combination with Ritonavir (1x 100mg rtv tablet) twice daily
3188076|NCT01281813|Experimental|006|Darunavir 375 mg composed via various tablets (2x 150mg DRV tablets + 1x 75mg DRV tablet) in combination with Ritonavir oral solution 80 milligram per milliLitre (mg/mL) (dose dependant on weight) twice daily
3188077|NCT01281813|Experimental|007|Darunavir 375 mg composed via various tablets (2x 150mg DRV tablets + 1x 75mg DRV tablet) in combination with Ritonavir powder for oral suspension prepared as 100mg/10mL (dose dependant on weight) twice daily
3188078|NCT01281813|Experimental|008|Darunavir oral suspension (dose dependant on weight) in combination with Ritonavir 100mg tablet twice daily
3188079|NCT01281813|Experimental|009|Darunavir oral suspension (dose dependant on weight) in combination with Ritonavir oral solution as 80 mg/mL (dose dependant on weight) twice daily
3188080|NCT01281813|Experimental|010|Darunavir oral suspension (dose dependent on weight) in combination with Ritonavir powder for oral suspension prepared as 100 mg/10 mL (dose dependent on weight) twice daily
3188081|NCT01281800|Active Comparator|Cisplatin with pemetrexed|
3188082|NCT01281800|Experimental|Cisplatin with gemcitabine in long infusion|
3188083|NCT01281787|Active Comparator|Losartan|angiotensin II-receptor blocker
3188084|NCT01281787|No Intervention|no treatment|no preventive treatment
3188085|NCT01281787|Active Comparator|Metoprolol|beta-adrenergic antagonist
3188086|NCT01281774|Experimental|CSL112|Multiple ascending intravenous doses of CSL112
3188087|NCT01281774|Placebo Comparator|Placebo|Multiple intravenous infusions of placebo
3188088|NCT01281761|Experimental|cetuximab/irinotecan/simvastatin|"D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- [C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV [over 90min] D1-14 Simvastatin 80mg P.O(continuous, daily)~every 2weeks"
3188089|NCT01281748|Experimental|methylprednisolone|
3188090|NCT01281748|Placebo Comparator|normal saline solution|
3188091|NCT01281722||healthy adults|healthy adults with the age among 20 to 95 years old
3188092|NCT01281722||melanoma cases|the people who are diagnosed melanoma in NTU hospital
3188093|NCT01281696|Experimental|Bevacizumab, etoposide, cisplatin (BEEP)|
3188094|NCT01281683||TACE|
3188095|NCT01281683||RFA|
3188096|NCT01281670|No Intervention|No vibration|
3188097|NCT01281670|Active Comparator|vibration|
3188098|NCT01281657||Prescribed fingolimod 0.5 mg/day|
3188099|NCT01281644|No Intervention|No Laser Treatment|
3188100|NCT01281644|Active Comparator|45-60 J Diode Laser Therapy|Diode laser therapy will be initiated at 45-60 J for 30 ms to 100 ms.
3188101|NCT01281631|Experimental|Low dose NP001|Low drug dose
3188102|NCT01281631|Experimental|High dose NP001|High drug dose
3188106|NCT01281605|Experimental|Usual titration algorithm|contact with investigator only at routine study visit.
3188107|NCT01281592|Experimental|LOR-253 HCl|LOR-253 HCl will be given in ascending doses until the maximum administered dose or appropriate target dose is reached. A biomarker study of up to 10 patients will be conducted upon achieving appropriate dose level.
3188108|NCT01281579|Experimental|001|Canagliflozin 50 mg Tablets oral 50-mg once daily on Day 1 and on Days 4 through 9.
3188109|NCT01281579|Experimental|002|Canagliflozin 100 mg Tablets oral 100-mg once daily on Day 1 and on Days 4 through 9.
3188110|NCT01281579|Experimental|003|Canagliflozin 300 mg Tablets oral 300-mg once daily on Day 1 and on Days 4 through 9.
3188111|NCT01281566|Experimental|001|Cisapride 0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
3188112|NCT01281566|Placebo Comparator|002|Placebo liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
3188113|NCT01281553|Experimental|001|Cisapride 0.2 mg/kg suspension q.i.d.for 8 weeks.
3188114|NCT01281553|Placebo Comparator|002|Placebo Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
3188115|NCT01281540|Experimental|001|Cisapride one 10 mg tablet 4 times a day for 8 weeks
3188116|NCT01281540|Placebo Comparator|002|Placebo one placebo tablet 4 times a day for 8 weeks
3188117|NCT01281527|Experimental|Paliperidone Palmitate|Paliperidone Palmitate 50 - 150 mg eq. every 30 days for 6 months during the core phase and for 12 months during an optional extension phase after the last patient has completed the 6-month core treatment phase or until product will be available on market (whichever comes first)
3188118|NCT01281514|Experimental|Treatment|See Detailed Description
3188119|NCT01281501|Active Comparator|Conventional|Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline
3188120|NCT01281501|Experimental|Pantoprazole|Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole
3188121|NCT01281488|Experimental|Treatment 1 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.018 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
3188122|NCT01281488|Experimental|Treatment 2 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.036 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
3188123|NCT01281488|Experimental|Treatment 3 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.07 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
3188124|NCT01281488|Experimental|Treatment 4 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.14 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
3188125|NCT01281488|Experimental|Treatment 5 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.21 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
3188126|NCT01281475|Experimental|Levodopa|Levodopa is prescribed as a combination of levodopa/carbidopa (4:1) to reduce the peripheral side effects. The dosage used was 15 mg/kg/day in 3 divided doses.
3188127|NCT01281475|Placebo Comparator|Placebo|The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa, so it is not expected to have any effect.
3188128|NCT01281462|Experimental|Ceftaroline fosamil and NXL104 (q8h)|
3188129|NCT01281462|Experimental|Ceftaroline fosamil and NXL104 (q12h)|
3188130|NCT01281462|Active Comparator|Doripenem|
3188131|NCT01281436|Other|Web-based Provider training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
3188132|NCT01281436|Active Comparator|HeartSmartKids with web-based training|The providers assigned to Group 2 will receive the web-based training described in the other arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
3188133|NCT01281410|No Intervention|Standard physiotherapy|Standard Physiotherapy without Inspiratory Muscle Training
3188134|NCT01281410|Experimental|Inspiratory muscle training|Inspiratory muscle training with a device named Respifit in addition to the usual physiotherapy program
3188135|NCT01281397||Patients undergoing elective cardiac surgery|Patients undergoing elective cardiac surgery will be enrolled in study. Data about antiplatelet therapy ingestion prior to surgery will be included.
3188136|NCT01281384|Active Comparator|Standard imaging (echocardiography)|Subjects will undergo their clinically indicated echocardiogram as ordered by their attending physician.
3188137|NCT01281384|Active Comparator|Advanced Imaging (Cardiac MRI)|Subjects will undergo their clinically indicated echo as ordered by their attending physician, plus a cardiac MRI, which will be scheduled within 14 days of the echo.
3188138|NCT01281358|Experimental|HOP-ON intervention|Participants will receive a CD-ROM (or DVD and booklet if no access to computer) highlighting motor skills which could be encouraged with premature infants
3188139|NCT01281358|Active Comparator|SMILES|Participants will received a CD-ROM (or DVD and booklet if no access to a computer) which contains information on interacting with their premature infant
3188140|NCT01281332|Active Comparator|Menopod device|Menopod®
3188141|NCT01281332|Sham Comparator|Sham device|Inactive device.
3188142|NCT01281319||Asymptomatic normal pregnant women|
3188143|NCT01281319||Women with high risk pregnancy|Women at risk for preterm birth or recurrent abortions that are being followed at the high risk pregnancy unit (outpatients clinic, high risk day care center)
3188144|NCT01281319||Women admitted with preterm labor|Women that are admitted to the gynecology department due to pregnancy complications: preterm labor with intact membranes (PTL) or with preterm PROM.
3188661|NCT01277640|Placebo Comparator|universal placebo|
3188145|NCT01281306|Experimental|VAL + AHU 400 mg|Participants were started with AHU377 100 mg + valsartan 160 mg every day (qd) for 1 week, then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for another week, and then were uptitrated to AHU377 400 mg + valsartan 320 mg for the remaining 6 weeks.
3188146|NCT01281306|Experimental|VAL + AHU 200 mg|Participants were started with AHU377 100 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for the remaining 7 weeks.
3188147|NCT01281306|Experimental|VAL + AHU 100 mg|Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 100 mg + valsartan 320 mg for the remaining 7 weeks.
3188148|NCT01281306|Experimental|VAL + AHU 50 mg|Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 50 mg + valartan 320 mg qd for the remaining 7 weeks.
3188149|NCT01281306|Experimental|VAL 320 mg|Participants were started with valsartan 160 mg qd for 1 week and then were uptitrated to valsartan 320 mg qd for the remaining 7 weeks.
3188150|NCT01281306|Experimental|LCZ 400 mg|Participants were started with LCZ696 200 mg qd for 1 week and then were uptitrated to LCZ696 400 mg qd for the remaining 7 weeks.
3188151|NCT01281306|Experimental|Placebo|Participants received matching placebo to LCZ696, AHU377 and valsartan for 8 weeks.
3188152|NCT01281280||VNS Therapy|
3188153|NCT01281280||Best Medical Practice|
3188154|NCT01281267|Experimental|Face transplantation|
3188155|NCT01281254|Placebo Comparator|Placebo plus PLD|Arm B: PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)
3188156|NCT01281254|Experimental|AMG386 plus PLD|Arm A: PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
3188157|NCT01281228|Experimental|exenatide|Infusion of exenatide; loading dose 50 ng/min during 30 min, followed by a maintenance dose 20ng/min for the rest of the tests.
3188158|NCT01281228|Experimental|exenatide + exendin (9-39)|exenatide infusion: loading dose 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the test. And infusion of exendin(9-39) 600pM/kg/min.
3188159|NCT01281228|Placebo Comparator|saline|saline infusion, with the same infusion speed
3188160|NCT01281215|Experimental|Pharmaceutical Education|The patients will receive pharmaceutical education.
3188161|NCT01281215|No Intervention|Control|
3188162|NCT01281202|Active Comparator|CPP-109 Vigabatrin Tablets|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -2 to -4 week Screening/Baseline Phase~During treatment, subjects received 3 CPP-109 Vigabatrin 500 mg Tablets, bid, for 9 weeks~Subjects were provided with on-site, supervised, standardized, manualized Individual Drug Counseling 1x per week for 9 weeks and the first 4 weeks for the follow-up phase (weeks 10-13)"
3188163|NCT01281202|Placebo Comparator|Placebo|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -2 to -4 week Screening/Baseline Phase~During treatment, subjects received Vigabatrin matching placebo tablets, bid, for 9 weeks~Subjects were provided with on-site, supervised, standardized, manualized Indivdiual Drug Counseling 1x per week for 9 weeks and the first 4 weeks for the follow-up phase (weeks 10-13)"
3188164|NCT01281189|Experimental|Dexpramipexole|
3188165|NCT01281189|Placebo Comparator|Placebo|
3188166|NCT01281176|Experimental|Arm I (high- and low-dose vorinostat and carboplatin)|Patients receive high-dose vorinostat PO QD on days 1-3 and low-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive high-dose vorinostat PO QD on days 1-3 and carboplatin IV over 30 minutes on day 3 of all subsequent courses.
3188167|NCT01281176|Experimental|Arm II (high- and low-dose vorinostat and carboplatin)|Patients receive high-dose vorinostat and low-dose vorinostat as in Arm I. After 5 days, patients receive lower-dose vorinostat PO QD on days 1-3 and carboplatin IV over 30 minutes on day 3.
3188168|NCT01281176|Experimental|Arm III (low- and high-dose vorinostat and carboplatin)|Patients receive low-dose vorinostat PO QD on days 1-3 and high-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive vorinostat and carboplatin as in Arm I.
3188169|NCT01281176|Experimental|Arm IV (low- and high-dose vorinostat and carboplatin)|Patients receive low-dose vorinostat and high-dose vorinostat as in Arm III. After 5 days, patients receive vorinostat and carboplatin as in Arm II.
3188170|NCT01281176|Experimental|Arm V (low- and mid-dose vorinostat and paclitaxel)|Patients receive low-dose vorinostat PO QD on days 1-3 and mid-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive mid-dose vorinostat PO QD on days 1-3 and paclitaxel IV over 3 hours on day 3.
3188171|NCT01281176|Experimental|Arm VI (mid- and low-dose vorinostat and paclitaxel)|Patients receive mid-dose vorinostat PO QD on days 1-3 and low-dose vorinostat PO QD on days 8-10. After 5 days, patients receive vorinostat and paclitaxel as in Arm V.
3188172|NCT01281163|Experimental|Treatment (Akt inhibitor MK2206 and lapatinib ditosylate)|Patients receive lapatinib ditosylate PO QD on days 1 and 15-28 of course 1 and on days 1-28 of subsequent courses. Patients also receive AKT inhibitor MK2206 PO QD on days 8, 15, and 22 of course 1 and on days 1, 8, 15, and 22 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3188173|NCT01281150|Experimental|Treatment (veliparib, paclitaxel, carboplatin)|"DOSE-ESCALATION: Patients receive veliparib PO twice daily BID on days 1-5, 8-12, and 15-19 and paclitaxel IV over 1 hour and carboplatin IV over 30 minutes in course 1 and 3 hours in subsequent courses on days 3, 10, and 17. After 4 courses, patients receive paclitaxel and carboplatin on days 3 and 10 only. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (Completed as of 12/2012)~EXPANSION COHORT: Patients receive veliparib PO BID on days 1-21 and paclitaxel IV over 1 hour and carboplatin IV over 3 hours on days 3 and 10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3188174|NCT01281124|Experimental|Treatment (azacitidine)|Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3188175|NCT01281111|Experimental|BG00012 plus ASA|
3188176|NCT01281111|Experimental|BG00012 plus ASA matching placebo|
3188177|NCT01281111|Placebo Comparator|BG00012 Placebo plus ASA|
3188178|NCT01281111|Experimental|BG00012 Placebo plus ASA matching placebo|
3188179|NCT01281111|Experimental|BG00012|modified dose regimen
3188180|NCT01281098|Active Comparator|Panretinal Photocoagulation (PRP)|Group 1: Panretinal photocoagulation treatment (PRP) at week-0 that can be repeated every 6 weeks.
3188181|NCT01281098|Experimental|Pegaptanib + Panretinal Photocoagulation (PRP)|Group 2: Combination treatment of pegaptanib intravitreous injections at weeks 0, 6 and 12 that can be repeated every 6 weeks. Plus PRP after first injection (2 weeks +/- 1 week)and that can be repeated every 12 weeks.
3188182|NCT01281085||No treatment|Shoulder conditions including rotator cuff condition treated conservatively, shoulder instability treated conservatively, diaphyseal humerus fracture or subcapital humerus fracture treated surgically and frozen shoulder
3188183|NCT01281033|Active Comparator|thrombus-aspiration group|In patients in the thrombus-aspiration group, the thrombus-aspiration is manually performed.
3188184|NCT01281033|Experimental|AngioJet Rheolytic Thrombectomy|AngioJet Rheolytic Thrombectomy (RT) System consists of a drive unit console, disposable pump set, and disposable catheter.
3188185|NCT01281020||Treatment with fixed combination|Patients who receive treatment with latanoprost/timolol fixed combination
3188186|NCT01281020||Treatment with unfixed therapy|Patients who receive latanoprost and timolol therapy
3188187|NCT01281007|Experimental|Famciclovir 125 mg|1 tablet every 12 hours for 5 days
3188188|NCT01281007|Active Comparator|Aciclovir 200 mg|1 tablet every 4 hours (excluding nocturnal dose) for 5 days
3188189|NCT01280981|Experimental|Tranexamic acid|Two 650 mg tablets orally 3 times per day with liquids for up to 5 days (not to exceed 3 doses in 1 day or 15 doses during the menstrual period).
3188190|NCT01280968|Experimental|NIC002 Vaccine in Aluminum hydroxide|4 subcutaneous vaccinations were performed over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 100 μg of NIC002 and 0.46 mg aluminum hydroxide.
3188191|NCT01280968|Placebo Comparator|Placebo Vaccine - Aluminum hydroxide|4 placebo injections were administered subcutaneously over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 0.46 mg aluminum hydroxide.
3188192|NCT01280955|Experimental|Transplant Recipients|Transplant recipients from matched sibling donors and dual cord donors. Subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
3188193|NCT01280942|No Intervention|Control|Patients admitted to 4 GHWs designated as controls. Nurses will not be notified when patients on these GHWs satisfy the EWS algorithm. They will also not wear the wireless sensor devices.
3188194|NCT01280942|Experimental|Nurse notification of EWS alert|Patients admitted to 4 GHWs designated as intervention wards at BJH. Nurses will be notified when patients on these wards satisfy the EWS algorithm. Some patients will be asked to wear the wireless remote sensors.
3188195|NCT01280929|Active Comparator|Panretinal Photocoagulation (PRP)|Group 1: Panretinal photocoagulation treatment (PRP) at month-0 that can be repeated after month-3.
3188196|NCT01280929|Experimental|Ranibizumab|Group 2: Intravitreous injections of ranibizumab every 4 weeks at month-0, month-1 and month-2 that can be repeated after month-3.
3188197|NCT01280929|Experimental|Ranibizumab + Panretinal Photocoagulation (PRP)|Group 3: Combination treatment of ranibizumab intravitreous injections plus PRP (2 weeks +/- 1 week after injection), at month-0, month-1 and month-2 that can be repeated after month-3.
3188198|NCT01280916|Experimental|Mind-body intervention|Mindful Awareness in Body-oriented Therapy
3188199|NCT01280916|No Intervention|Treatment as Usual|
3188200|NCT01280903|Experimental|STAR Intervention|Staying Active with Arthritis Intervention
3188201|NCT01280903|Placebo Comparator|Attention-Control|Senior Health Information Intervention
3188202|NCT01280890|Experimental|Staff training using VIPS framework|The staff will be trained to give person-centred care using the VIPS framework
3188203|NCT01280890|Experimental|Staff training using DCM|Staff will be supervised in how to give person-centred care using Dementia Care Mapping
3188204|NCT01280890|Placebo Comparator|Control group|Traditional lectures using films will be given to care staff
3188205|NCT01280877|Experimental|Verum stimulation|Complete treatment with transorbital alternating current stimulation (tACS)
3188206|NCT01280877|Sham Comparator|Sham stimulation|Same electrode montage set-up is used during tACS- and placebo-stimulation. Sham stimulation condition consists of minimal treatment with low intensity/few impulses tACS.
3188207|NCT01280864||Interstitial Cystitis Alone|
3188208|NCT01280864||Irritable Bowel Syndrome Alone|
3188209|NCT01280864||Healthy Controls|
3188210|NCT01280838|Experimental|Theory-based behavioral intervention|Participants in this arm will receive a single-session, theory-based intervention (Hombre Seguro) at baseline that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and Motivational Interviewing (MI) to increase clients' use of condoms with FSWs. The intervention lasts approximately 45 minutes.
3188211|NCT01280838|Active Comparator|Didactic attention-control condition|The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
3188212|NCT01280825||Adult Patients|Adults receiving health care at the University of Chicago Medical Center.
3188213|NCT01280812|Experimental|PA intervention and Maintenance plus|3-month physical activity intervention and 6-month maintenance intervention-Plus program
3188214|NCT01280812|Experimental|PA intervention and Maintenance regular|3-month physical activity intervention and 6-month maintenance - Regular program
3188215|NCT01280812|Active Comparator|Pedometer|Non-intervention group
3188216|NCT01280799|Experimental|Active Treatment|
3188217|NCT01280786|Experimental|Elesclomol Sodium|
3188218|NCT01280773|No Intervention|PSV weaning|Patinens in the PSV group will be weaned using PSV mode.
3188219|NCT01280773|Experimental|NAVA weaning|Patients in NAVA group will eb weaned using NAVA mode.
3188220|NCT01280760||Non invasive ventilation|Non-invasive ventilation after invasive mechanical ventilation weaning
3188221|NCT01280747||1|Eligible fibromyalgia patients receive usual care with pregabalin prior authorization requirements in place
3188222|NCT01280747||2|Eligible fibromyalgia patients receive usual care without pregabalin prior authorization requirements in place
3188662|NCT01277640|Active Comparator|dapivirine|
3188223|NCT01280747||3|Eligible painful diabetic peripheral neuropathy patients receive usual care with pregabalin prior authorization requirements in place
3188224|NCT01280747||4|Eligible painful diabetic peripheral neuropathy patients receive usual care without pregabalin prior authorization requirements in place
3188225|NCT01280734|Active Comparator|Melatonin|Circadin(R) 2 mg tablet 2 hours at 23:00
3188226|NCT01280734|Active Comparator|Zolpidem|Stilnox (R) 10 mg tablet at 23:00
3188227|NCT01280734|Placebo Comparator|Placebo|
3188228|NCT01280721|Experimental|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
3188229|NCT01280708||Capture data|
3188230|NCT01280695|Placebo Comparator|Placebo|Placebo capsule once daily
3188231|NCT01280695|Experimental|MSDC-0602 100 mg|MSDC-0602 capsule 100 mg once daily
3188232|NCT01280695|Experimental|MSDC-0602 250 mg|MSDC-0602 capsule 250 mg once daily
3188233|NCT01280695|Experimental|MSDC-0602 500 mg|MSDC-0602 capsule 500 mg once daily
3188234|NCT01280695|Active Comparator|Pioglitazone 45 mg|Pioglitazone capsule 45 mg once daily
3188235|NCT01280682|Experimental|rituximab|
3188236|NCT01280669|Experimental|Group 1|Intravitreal injections of 440mcg sirolimus (low-dose monthly group)
3188237|NCT01280669|Experimental|Group 2|Intravitreal injections of 880mcg sirolimus (high-dose every other month group)
3188238|NCT01280656||Conventional Interferon Plus Ribavirin|Eligible participants who will receive conventional interferon plus ribavirin for Chronic Hepatitis C (CHC) according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
3188239|NCT01280656||Peginterferon Alfa-2a Plus Ribavirin|Eligible participants who will receive peginterferon alfa-2a plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
3188240|NCT01280656||Peginterferon Alfa-2b Plus Ribavirin|Eligible participants who will receive peginterferon alfa-2b plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
3188241|NCT01280643|Experimental|Arm A|Patients receive FOLFIRI (FOLolinic acid (leucovorin) Fluorouracil (5-FU) IRInotecan (irinotecan)) chemotherapy comprising fluorouracil intravenously (IV) over 46 hours continuously, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
3188242|NCT01280643|Experimental|Arm B|Patients receive FOLFOX (FOL- Folinic acid (leucovorin) F - Fluorouracil (5-FU) OX - Oxaliplatin (Eloxatin)) chemotherapy comprising fluorouracil IV over 46 hours continuously on day 1 and leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
3188243|NCT01280643|Experimental|Arm C|Patients receive FOLFIRI chemotherapy as in Arm A and bevacizumab IV over 30-90 minutes on days 1 and 15.
3188244|NCT01280643|Experimental|Arm D|Patients receive FOLFOX chemotherapy as in Arm B and bevacizumab IV over 30-90 minutes on days 1 and 15.
3188245|NCT01280643|Experimental|Arm E|Patients receive CapeIRI (Capecitabine and Irinotecan) chemotherapy comprising capecitabine orally (PO) twice daily (BID) on days 1-14 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
3188246|NCT01280643|Experimental|Arm F|Patients receive CapeOX (capecitabine (Xeloda) and oxaliplatin (Eloxatin)) chemotherapy comprising capecitabine PO BID on days 1-14 and oxaliplatin IV over 2 hours on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
3188247|NCT01280643|Experimental|ARM G|Patients receive CapeIRI chemotherapy as in Arm E and bevacizumab IV over 30-90 minutes on day 1.
3188248|NCT01280643|Experimental|Arm H|Patients receive CapeOX chemotherapy as in Arm F and bevacizumab IV over 30-90 minutes on day 1.
3188249|NCT01280643|Experimental|Arm I|Patients receive treatment as in Arm D.
3188250|NCT01280617|Experimental|Thymoglobulin 1.25mg/kg dose|The safety and efficacy of low dose Thymoglobulin (1.25mg/kg) as an induction agent in renal transplant subjects.
3188251|NCT01280617|Experimental|Thymoglobulin 0.75mg/kg dose|The safety and efficacy of low dose Thymoglobulin (0.75mg/kg) as an induction agent in renal transplant subjects.
3188252|NCT01280604|Experimental|Intervention 'Fenofibrate 54mg'|Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.
3188253|NCT01280604|No Intervention|Control 'Fenofibrate 160mg'|Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).
3188254|NCT01280591|Experimental|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|
3188255|NCT01280591|Experimental|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|
3188256|NCT01280591|Active Comparator|Naproxen sodium 440 mg (BAYH6689)|
3188257|NCT01280591|Active Comparator|DPH 50 mg|
3188258|NCT01280565|Experimental|masitinib|
3188259|NCT01280565|Active Comparator|dacarbazine|
3188260|NCT01280552|Experimental|ICT-107|Autologous dendritic cells pulsed with immunogenic peptides from tumor antigens
3188261|NCT01280552|Placebo Comparator|Control|Autologous dendritic cells that have not been pulsed with antigens
3188262|NCT01280539|Experimental|TENS|Transcutaneous electrical nerve stimulation will be applied on the impaired hand
3188263|NCT01280539|Sham Comparator|Sham TENS|Sham TENS will be applied to the impaired hand
3188264|NCT01280526|Experimental|Romidepsin dose 10mg/m²|Romidepsin dose 10mg/m²
3188265|NCT01280526|Experimental|Romidepsin dose 12mg/m²|Romidepsin dose 12mg/m²
3188266|NCT01280526|Experimental|Romidepsin dose 14mg/m²|Romidepsin dose 14mg/m²
3188267|NCT01280526|Experimental|Romidepsin dose 8mg/m²|Romidepsin dose 8mg/m²
3188268|NCT01280513|Experimental|High Protein intake|
3188269|NCT01280513|Experimental|Low Protein intake|
3188315|NCT01280149|Experimental|substance P-low dose allergen|Substance P injections with 8 sequential, increasing doses of allergen
3188316|NCT01280149|Experimental|substance P-moderate dose allergen|Substance P with sequential, increasing doses of allergen
3188270|NCT01280500|Placebo Comparator|Group A - Usual Care Controls|Group A will consist of 20 primary care clinics who are part of the Carolinas Healthcare System network but have not yet adopted the Electronic Medical Record System. These practices do use the same billing databases as the remaining clinics, allowing easy identification of asthma patients and their health services utilization patterns. Data from the billing systems will be used to retrospectively populate a database for these clinics from January 2009 forward.
3188271|NCT01280500|Active Comparator|Group B - EMR Control Practices|There are currently 65 primary care practices within the Carolinas Healthcare System network that have electronic medical record with decision support (EAP)access at baseline. These practices will serve as a second level of control for comparison with the intervention groups. Each of these practices is currently using Cerner PowerChart and at the start of the study and will have access to the asthma decision support tools; an electronically generated Asthma Action Plan (AAP); and a built-in system of population management reports which will be pushed to the practices on an on-going basis to help in patient recall and management. The EAP approach to care has been developed with input from clinicians, hospital administrators, hospital information services personnel, and Cerner consultants.
3188272|NCT01280500|Active Comparator|C Integrated Approach to Care|There are 10 practices within the Carolinas Healthcare System (CHS) network that have already received additional training for improving outcomes for patients with chronic diseases termed the Integrated Approach to Care (IAC). This IAC approach developed by CHS is based on the Chronic Care Model (CCM). The IAC approach includes a heavy emphasis on the use of health information technology that practices receive during the initial EAP rollout.
3188273|NCT01280500|Active Comparator|Group D - Shared Decision Making (SDM)|This approach has great potential for improved patient outcomes and provides an additional step in the successful implementation of patient self-management. The research team will develop the SDM intervention during the first 6 months of the study. In particular, the Shared decision making (SDM) intervention will be designed to be deployed within the 4 large clinics that care for the majority of the community's underserved and disadvantaged patients. The SDM intervention development will be overseen by the study advisory board and actively recruit providers from within the clinics for feedback about the intervention.
3188274|NCT01280500|Active Comparator|School Based Care (SBC)|Activities included: spending individual time with students to assess, treat, and monitor and to educate students in proper asthma management; facilitate access to health care and medicine; and communicate with parents.
3188275|NCT01280487|Experimental|Oral ZSTK474|Daily oral dosing for 21 days per cycle
3188276|NCT01280461||Experimental Group|
3188277|NCT01280461||Control Group|
3188278|NCT01280448||Case Group|
3188279|NCT01280448||Control Group|
3188280|NCT01280409|Placebo Comparator|Placebo|Compounded placebo
3188281|NCT01280409|Experimental|Metformin|Compounded metformin as the intervention
3188282|NCT01280396||SGAs|patients receiving SGAs
3188283|NCT01280383|Experimental|non-invasive NAVA|application of non-invasive NAVA in critically ill patients
3188284|NCT01280370||1|1.patients treated in a laparoscopic manner
3188285|NCT01280370||2.|2. patients treated in open operative manner
3188286|NCT01280357|Active Comparator|Monitor Philips 50XM (K954351)|CTG Fetal Monitor If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
3188287|NCT01280357|Experimental|Monica AN24 (K101801)|EHG Fetal Monitor
3188288|NCT01280344|Experimental|0.03 mg/kg BID|Ipamorelin 0.03 mg/kg, BID (2 investigational drug infusions and 1 placebo infusion)
3188289|NCT01280344|Experimental|0.06 mg/kg BID|Ipamorelin 0.06 mg/kg, BID (2 investigational drug infusions and 1 placebo infusion)
3188290|NCT01280344|Experimental|0.06 mg/kg TID|Ipamorelin 0.06 mg/kg, TID (3 investigational drug infusions)
3188291|NCT01280344|Placebo Comparator|Placebo|Matching placebo, TID (3 placebo infusions)
3188292|NCT01280331|Experimental|Q8003 12 mg/8 mg|Combination
3188293|NCT01280331|Active Comparator|Morphine sulfate 24 mg|Single component
3188294|NCT01280331|Active Comparator|Oxycodone HCl 16 mg|Single component
3188295|NCT01280318|Other|1|patients with operable head and neck squamous cell carcinoma
3188296|NCT01280318|Other|2|patients treated by neck ansd head surgery for a non-oncological disease
3188297|NCT01280318|Experimental|3|patients treated before surgery with 3 doses of neoadjuvant cetuximab
3188298|NCT01280305|Experimental|raloxifene|
3188299|NCT01280305|Placebo Comparator|Placebo|
3188300|NCT01280279||group with nocturnal polyuria and nocturia|Patients were enrolled when they had the urine volume at nighttime more than one third of total daily urine volume (NPU) and voided more than two times at nighttime (nocturia)
3188301|NCT01280266|Experimental|Amlodipine-Udenafil (AU) arm|Amlodipine 10mg PO QD for 4 weeks, washout period, then Udenafil 100mg PO QD for 4 weeks
3188302|NCT01280266|Experimental|Udenafil-Amlodipine (UA) arm|Udenafil 100mg PO QD for 4 weeks, washout period, then Amlodipine 10mg PO QD for 4 weeks
3188303|NCT01280240|Active Comparator|Monofer 500 mg|
3188304|NCT01280240|Active Comparator|Monofer 250 mg|
3188305|NCT01280227|Experimental|1|Patients uses the symptom assessment tool SiSom. A summary of their reported symptoms are printed out and given to the pediatrician and nurse before the consultation. The consultation is videotaped.
3188306|NCT01280227|No Intervention|2|"The control group do not use the symptom assessment tool SiSom before the consultation. The control group receives usual care and the consultation is videoptaped."
3188307|NCT01280214|Experimental|Triamcinolone|
3188308|NCT01280201|Experimental|Pazopanib|
3188309|NCT01280188|Experimental|Desmopressin|Day 1 - participants continue desmopressin intranasal. Day 2 up to Day 4 - Desmopressin oral melt to optimum dose. Continue optimum dose for the four week treatment and one year follow-up periods.
3188310|NCT01280175|Experimental|pMDI + charcoal block|BDP/formoterol 100/6 µg pMDI with charcoal ingestion
3188311|NCT01280175|Experimental|pMDI + Aerochamber Plus|BDP/formoterol 100/6 µg with Aerochamber Plus
3188312|NCT01280175|Active Comparator|pMDI|BDP/formoterol 100/g µg pMDI
3188313|NCT01280162|Experimental|3 day therapy|Total dose split over 3 days (3 tablets per day)
3188314|NCT01280162|Experimental|2 day therapy|Total dose split over 2 days (4.5 tablets per day)
3188317|NCT01280149|Experimental|substance P-low/moderate dose allergen|substance P with 16 sequential increasing doses of allergen
3188318|NCT01280149|Active Comparator|substance P-placebo|Placebo injections of substance P and placebo
3188319|NCT01280149|Experimental|placebo-low dose allergen|Placebo injections with 8 sequential increasing low dose allergen injections
3188320|NCT01280149|Placebo Comparator|placebo-placebo|substance P placebo and allergen placebo (weekly)
3188321|NCT01280136|Experimental|It's Your Game Tech|An interactive web-based HIV, sexually transmitted infection (STI), and pregnancy prevention program for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game…Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
3188322|NCT01280123|Experimental|15 mg pioglitazone|15 mg pioglitazone
3188323|NCT01280123|Experimental|45 mg pioglitazone|45 mg pioglitazone
3188324|NCT01280123|Placebo Comparator|Matching Placebo|Placebo
3188325|NCT01280110|Active Comparator|Preserved (BAK 0.006%) lubricating drop|One group will receive preserved lubricating drops 4 times a day for 1 month.
3188326|NCT01280110|Active Comparator|Preservative-free lubricating drops|The second group will receive preservative-free lubricating drops 4 times a day for 1 month.
3188327|NCT01280097||Prospective cohort study|Observational only
3188328|NCT01280084||No labour analgesia/nitrous oxide|Women who use no analgesia during labour or who only used nitrous oxide.
3188329|NCT01280084||Systemic opioids|Women who receive only systemic opioids for analgesia during, either intravenously or intramuscularly
3188330|NCT01280084||Intermediate dose epidural fentanyl|Women who receive a total epidural fentanyl dose less than 150 micrograms
3188331|NCT01280084||High dose epidural fentanyl|Women who receive a total epidural fentanyl dose more than 150 micrograms
3188332|NCT01280071|Experimental|dipyridamole, aminophylline|
3188333|NCT01280058|Experimental|Arm I (wild-type reovirus, carboplatin, paclitaxel)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and wild-type reovirus IV over 60 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3188334|NCT01280058|Experimental|Arm II (carboplatin, paclitaxel)|Patients receive paclitaxel and carboplatin as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.
3188335|NCT01280045|Experimental|AROMATASE INHIBITOR|
3188336|NCT01280045|Active Comparator|GNRH ANALOG|
3188337|NCT01280032|Experimental|Kypho-IORT|
3188338|NCT01280019|Experimental|FRC guided|Patients receive an alveolar recruitment manoeuvre if FRC falls below 94% of baseline FRC
3188339|NCT01280019|Active Comparator|Saturation guided|Patients receive an alveolar recruitment manoeuvre if peripheral oxygen saturation falls below 90%
3188340|NCT01279993|Experimental|Kerato refractive Surgery|
3188341|NCT01279980|Active Comparator|Epidural|Subjects will have an epidural catheter placed to provide postoperative pain relief. This is standard care for those undergoing an enhanced recovery program.
3188342|NCT01279980|Active Comparator|Painbuster|Subjects will have a local anaesthetic wound catheter inserted into the wound at time of surgery rather than an epidural for the provision of postoperative pain relief.
3188343|NCT01279967|No Intervention|A|Arm A is control arm with best supportive care.
3188344|NCT01279967|Experimental|B|Arm B is the treatment arm with best supportive care plus ADI-PEG20.
3188345|NCT01279954|Experimental|open-label abatacept|
3188346|NCT01279954|Experimental|5 mg/kg abatacept|At 6 months subjects will be randomized to receive either 5 mg/kg abatacept or 10 mg/kg abatacept.
3188347|NCT01279954|Experimental|10 mg/kg abatacept|
3188348|NCT01279941|No Intervention|Testing Only|
3188349|NCT01279941|Experimental|Testing & Intervention|
3188350|NCT01279928||Type 1 Diabetes Paediatric|Paediatric patients aged 8-18 with diagnosed Diabetes Mellitis Type 1 attending paediatric clinic at John Hunter Hospital.
3188351|NCT01279915|Experimental|ASP group|ASP0456 receiving group
3188352|NCT01279915|Placebo Comparator|Placebo group|Placebo treatment
3188353|NCT01279902|Experimental|Rituximab plus CHOP Immunochemotherapy|"Interventions: conventional R-CHOP every 3 weeks for 3 cycles~Rituximab 375 mg/M2 IV day 1~Cyclophosphamide 750 mg/M2 IV day1~Vincristine 1.5 mg/M2 (max. 2 mg) IV day1~Prednisolone 50 mg bid day 1-5, every 3 weeks"
3188354|NCT01279889||Cesarean Delivery|Healthy pregnant women having an elective cesarean delivery
3188355|NCT01279876|Active Comparator|Melatonin|
3188356|NCT01279876|Placebo Comparator|Placebo|
3188357|NCT01279850||Pregabalin (Lyrica) capsule|"Patients administered Pregabalin capsule."
3188358|NCT01279837|No Intervention|Usual care|Control (Usual care) group in which patients will receive swallowing and prescribed dietary intervention during the radiotherapy period prescribed by the attending physician.
3188359|NCT01279837|Experimental|High Intensity Pharyngocise|Patients receive twice daily swallowing intervention by a speech language pathologist, consisting of the battery of isometric / isotonic exercises.
3188360|NCT01279837|Active Comparator|Low Intensity Pharyngocise|Patients will receive a one time only swallowing intervention session by a speech language pathologist, instructing them in the battery of isometric / isotonic exercises plus a home practice instruction digital video tape to support self directed practice of this program at home.
3188361|NCT01279824|Active Comparator|Usual Care|Patients will receive behavioral swallowing therapy comprising combination's of treatment strategies / exercises chosen from an approved hierarchy. This formulation of treatment will be designed and applied by the treating clinician.The treatment will be provided daily for a one-hour over a consecutive 3-week period.
3188489|NCT01278888|Active Comparator|PLEACE 1|Anterolateral vs. posterolateral thoracotomy
3188490|NCT01278888|Active Comparator|PLEACE 2|Video assisted thoracic surgery (VATS) vs. anterolateral thoracotomy
3188663|NCT01277627|Active Comparator|Nevirapine|
3188362|NCT01279824|Placebo Comparator|sham NMES|Patients will receive behavioral swallowing therapy comprising combinations of treatment strategies / exercises chosen from an approved hierarchy with the addition of non stimulating electrodes. A faux NMES device will be utilized with an active current display and non stimulating electrodes. The treatment will be provided daily for a one-hour over a consecutive 3-week period.
3188363|NCT01279824|Experimental|NMES therapy|Patients will receive a protocol of standardized behavioral swallowing intervention combined with NMES. This formulation of treatment will be prescribed from a standard protocol and will be applied daily for one-hour over a consecutive 3-week period.
3188364|NCT01279811|Other|Single Arm|Vasopressor Crossover - Dopamine & NORepinephrine
3188365|NCT01279785||Prostate Cancer Patients|Male participants who are scheduled to undergo standard of care prostatectomy for presumed localized prostate cancer at the NIH Clinical Center and have evidence of a recent (within 12 months of study entry) trans-rectal biopsy documenting adenocarcinoma of the prostate.
3188366|NCT01279746||ultrasond compression of deep veins|
3188367|NCT01279733||Microarray Analysis|
3188368|NCT01279720|Experimental|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
3188369|NCT01279707|Experimental|A: Veltuzumab and chemotherapy|Veltuzumab and modified UKALL XII chemotherapy
3188370|NCT01279707|Experimental|B: epratuzumab and chemotherapy|epratuzumab and modified UKALL XII chemotherapy
3188371|NCT01279707|Experimental|C: veltuzumab and epratuzumab and chemotherapy|Veltuzumab and Epratuzumab and modified UKALL XII chemotherapy
3188372|NCT01279681|Active Comparator|Arm A [fluoropyrimidine + bevacizumab (BEV)]|Patients receive either 5FU/LV or Capecitabine, plus BEV. 5FU/LV + BEV is comprised of 5FU IV over 46-48 hours, LV calcium IV over 2 hours, and BEV IV over 10-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Capecitabine + BEV is comprised of capecitabine PO BID on days 1-14 and BEV IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3188373|NCT01279681|Experimental|Arm B [fluoropyrimidine/oxaliplatin (OXAL) + BEV]|Patients receive either mFOLFOX7 plus BEV, or Capecitabine + OXAL (XELOX) plus BEV. mFOLFOX7 + BEV is comprised of OXAL IV over 2 hours, LV calcium IV over 2 hours, and 5FU IV over 46-48 hours on day 1. Patients also receive BEV IV over 10-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. XELOX + BEV is comprised of OXAL IV over 2 hours on day 1 and capecitabine PO BID on days 1-14. Patients also receive BEV IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3188374|NCT01279668|Experimental|Montelukast|
3188375|NCT01279668|Placebo Comparator|Placebo|
3188376|NCT01279655|Experimental|tDCS and training|Transcranial Direct current stimulation (tDCS) is applied together with a bimanual learning task. tDCS is delivered through two gel-sponge electrodes (eldith DC Stimulator, neuroConn GmbH, Ilmenau, Germany) embedded in a saline-soaked solution. tDCS will be applied for 20 min, with a current intensity of 1mA.
3188377|NCT01279655|No Intervention|Control|No intervention is applied
3188378|NCT01279655|Placebo Comparator|Sham tDCS + Training|The training consists of a bimanual training task. tDCS is only applied for a few seconds and will than be ramped-down.
3188379|NCT01279642|Experimental|ultrasound|Use of ultrasound to PICC placement
3188380|NCT01279642|Active Comparator|Control group|PICC placement by inspection and visualization of site
3188381|NCT01279629||Tazarotene 0.1%|
3188382|NCT01279629||Calcipotriol 0.005%|
3188383|NCT01279616|Experimental|Hematopoietic Stem Cell Transplant|Stem cell infusion on Day 0.
3188384|NCT01279603|Experimental|GO-203-2c|
3188385|NCT01279590|Experimental|PPD10558|Dosing will be forced-titrated as follows: 40 mg orally twice daily for 4 weeks and 80 mg orally twice daily for 8 weeks
3188386|NCT01279590|Active Comparator|Atorvastatin|Dosing will be forced titrated as 40 mg orally once daily for 4 weeks, and 80 mg orally once daily for 8 weeks
3188387|NCT01279590|Placebo Comparator|Placebo|Dosing will be 2 placebo capsules twice daily for 12 weeks
3188388|NCT01279577|Experimental|Low dose TSO|Low dose suspension of TSO
3188389|NCT01279577|Experimental|Medium dose TSO|Medium dose suspension of TSO
3188390|NCT01279577|Experimental|High dose TSO|High dose suspension of TSO
3188391|NCT01279577|Placebo Comparator|Placebo|Placebo solution
3188392|NCT01279564|Experimental|ETview|ETview TVT endotracheal tube
3188393|NCT01279564|Sham Comparator|Control|Endotracheal tube
3188394|NCT01279551|Experimental|GTN|In this arm the investigators administer local application of 0.4% nitroglycerin ointment and ketorolac tromethamine 10 mg
3188395|NCT01279551|Active Comparator|Control|In this arm the investigators administer local application of lidocaine cloridrato 2.5% and ketorolac tromethamine 10 mg.
3188396|NCT01279538|Experimental|ASKP1240 lowest dose|
3188397|NCT01279538|Experimental|ASKP1240 low dose|
3188398|NCT01279538|Experimental|ASKP1240 high dose|
3188399|NCT01279538|Experimental|ASKP1240 highest dose|
3188400|NCT01279538|Placebo Comparator|Placebo|
3188401|NCT01279525|Experimental|Multifactorial intervention|Multifactorial intervention to prevent falls
3188402|NCT01279512|Experimental|Metformin reciepiants|Infertile overweight women with PCO who received Metformin
3188403|NCT01279512|Experimental|Acarbose reciepiants|Infertile overweight women with PCO who received Acarbose
3188404|NCT01279499|Active Comparator|SEVO group|Anaesthesia will be induced with IV Propofol (2 mg/kg TW [TW = ideal body weight, IBW + 0.4 * difference to the excess weight]), Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR > 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes.If the positive sympathetic response persists, then Nifedipine 10 mg will be administered sublingual, if HR < 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR > 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of positive sympathetic stress responses that required pharmacologic intervention will be recorded.
3188491|NCT01278875||Acute Coronary Syndrome|Subjects with ACS within 72 hours of clinical presentation
3188492|NCT01278875||Stable CAD subjects|Patients with stable, chronic CAD
3188405|NCT01279499|Active Comparator|SEVO-BIS group|Anaesthesia will be induced with IV Propofol (2 mg/kg TW [TW = ideal body weight, IBW + 0.4 * difference to the excess weight]), Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).Intraoperatively Sevoflurane will be guided by a target BIS of 40 - 50 .Every rise of BP or HR > 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes. If the positive sympathetic response persists, then Nifedipine 10 mg will be administered sublingual, if HR < 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR > 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of positive sympathetic stress responses that required pharmacologic intervention will be recorded.
3188406|NCT01279499|Active Comparator|Propo- Remi group|"General Anaesthesia (GA) will be induced with a continuous IV Propofol (P) infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (R, 1 μg/kg IBW) and succinylcholine (1mg/kg IBW). GA will be maintained with continuous intravenous administration of P at 150-300mcg/kg/min (doses based on ideal body weight).~Every rise of BP or HR > 15% of baseline will be followed by a R bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of R to 1.0 μg/kg/min . If HR < 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR > 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of stress responses that required intervention is recorded."
3188407|NCT01279499|Active Comparator|Propo-Remi-BIS group|"General Anaesthesia (GA) will be induced with a continuous IV Propofol (P) infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (R, 1 μg/kg IBW) and succinylcholine (1mg/kg IBW). GA will be maintained with continuous intravenous administration of P at 150-300mcg/kg/min (IBW).~The depth of anesthesia will be adjusted to accomplish a BIS score 40 -50. If BP or HR is > 15% of baseline will a bolus of R IV (1 μg/kg IBW) will be given and an the infusion rate of R will be increased to 1.0 μg/kg/min . If this response persists and HR < 70/ min, Nifedipine 10 mg will be given s.l. and if HR > 70/ min Diltiazem 10-20 mg IV will be given, followed by esmolol infusion if no response is observed."
3188408|NCT01279473|Experimental|Nilotinib|
3188409|NCT01279460||CKD Cohort of patients with renal insufficiency|patients with renal insufficiency grade II-IV
3188410|NCT01279447|Sham Comparator|Placebo|A sham infrapatellar block performed under US guidance with normal saline
3188411|NCT01279447|Experimental|Infrapatellar nerve block|An infrapatellar nerve block performed under US guidance with 0.25% bupivacaine
3188412|NCT01279434|Experimental|Vitamin E plus Pentoxiphyllin|
3188413|NCT01279434|Active Comparator|Vitamin E|
3188414|NCT01279421|Experimental|Social Network HIV Testing|Participants in this arm will be recruited through social networks and will receive an HIV test.
3188415|NCT01279421|Experimental|Peer Network Intervention|Eight (8) current or former crack users will be recruited to facilitate small networks of crack users in a three-day intervention. They will also facilitate monthly meetings open to all community members regarding HIV prevention and interpersonal violence.
3188416|NCT01279395||naproxen|Patients age 40-70 who fulfill the American College of Rheumatology (ACR) criteria for a diagnosis of primary osteoarthritis are considered eligible. This group has been prescribed naproxen (1000 mg/day) for a minimum of two weeks.
3188417|NCT01279395||diclofenac|Patients age 40-70 who fulfill the ACR criteria for a diagnosis of primary osteoarthritis. The group consists of patients who have been prescribed diclofenac (150 mg/day)for a minimum of two weeks.
3188418|NCT01279395||celecoxib|Patients age 40-70 who fulfill the ACR criteria for a diagnosis of primary osteoarthritis are considered eligible. This group has been prescribed celecoxib (200 mg/day) for a minimum of two weeks.
3188419|NCT01279382|Other|Care as usual (CON)|CON was given to a subgroup of patients as control treatment in IBS treatment
3188420|NCT01279382|Other|Hypnotherapy (HYP)|HYP was given to a subgroup of patients as intervention in IBS treatment
3188421|NCT01279382|Other|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
3188422|NCT01279356||Patients with liver diseases of various etiologies|"viral hepatitis~cholestatic liver diseases~auto-immune hepatitis~NAFLD~ALD~sarcoidosis of the liver"
3188423|NCT01279343|No Intervention|Foley Bulb plus Misoprostol|
3188424|NCT01279343|No Intervention|Misoprostol|
3188425|NCT01279330|No Intervention|Control|Patients receive by mail the materials needed for stool samples.
3188426|NCT01279330|Experimental|Co-signed Letter|
3188427|NCT01279317|Experimental|vinegar co-ingestion|25 ml vinegar is added to glucose containing beverage
3188428|NCT01279317|Placebo Comparator|Placebo co-ingestion|25 ml vinegar is substituted by 25 ml water
3188429|NCT01279304||Group 1. Low risk|"Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:~a. all nodes negative: ycN0~or~Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:~a. only micrometastases in the SN, and no risk factors (grade 3, LVI, tumour size > 3 cm)~or~Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:~no metastases in the post chemo SN"
3188430|NCT01279304||Group 2: Intermediate risk|"Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:~a. 1-3 nodes positive: ypN1~or~Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:~micrometastases in the SN and at least 1 risk factor; or~≤ 2 macrometastases and no risk factor~or~Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:~micrometastases in the post chemo SN and no risk factors (grade 3, LVI, tumour size > 3 cm)"
3188431|NCT01279304||Group 3. High risk|"Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:~a. 4 or more nodes positive: ypN2~or~Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:~≤ 2 macrometastases in the sentinel node prior to primary systemic treatment in the presence of risk factors like Grade 3, lymphangioinvasion, tumour size > 3 cm; or~3 macrometastases, 2 macrometastases and 1 micrometastase, 1 macrometastase and 2 micrometastases.~or~Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:~Micrometastases in the post chemo SN, and at least one risk factor~≤ 3 macrometastases in the post chemo SN; or~2 macrometastases and 1 micrometastase, 1 macrometastase and 2 micrometastases"
3188493|NCT01278875||Control subjects|Healthy individuals
3188432|NCT01279291|Experimental|KHK2866 as monotherapy|Groups of subjects will receive a weekly infusions of KHK2866 as treatment for advanced cancer. If there no severe side effects, the dose will be increased for future subjects. A total of four groups are anticipated. Once an acceptable dose is determined an additional seven subjects will be treated at that dose.
3188433|NCT01279291|Experimental|KHK2866, gemcitabine+carboplatin|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with gemcitabine and carboplatin. The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
3188434|NCT01279291|Experimental|KHK2866, weekly paclitaxel|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with weekly paclitaxel (80 mg/m2). The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
3188435|NCT01279291|Experimental|KHK2866, pegylated liposomal doxorubicin|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with monthly PLD (40 mg/m2). The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
3188436|NCT01279278|No Intervention|Control|
3188437|NCT01279278|Experimental|Co-signed Letter|
3188438|NCT01279265|Active Comparator|Nutramigen Lipil with Enflora|Formula with probiotics (Lactobaccillus Rhamnosus GG)
3188439|NCT01279265|Placebo Comparator|Nutramigen A+|Hypoallergenic formula without probiotics (Lactobaccillus Rhamnosus GG)
3188440|NCT01279252|Experimental|Antibiotic regimen|
3188441|NCT01279239||Poly trauma|20 Patients suffering from poly trauma who meet inclusion criteria would be recruited
3188442|NCT01279239||Healthy control|20 healthy volunteers would be recruited to obtain basal metabonomics fingerprinting
3188443|NCT01279213|Active Comparator|paliperidone clozapine BPRS|patients assigned to clozapine plus paliperidone controls at 6 and 12 weeks
3188444|NCT01279213|Placebo Comparator|clozapine plus placebo BPRS|patients assigned to placebo plus clozapine should show less improvement
3188445|NCT01279200|Active Comparator|Urinary LH Kits|Patients randomized to this arm will monitor ovulation with home-based urinary LH kits (Ovulation Predictor Kits, OPK's).
3188446|NCT01279200|Active Comparator|Midcycle ultrasound + hCG injection|Patients randomized to this arm will undergo ovulation monitoring with midcycle ultrasound and receive hCG injection if evidence of a mature size follicle.
3188447|NCT01279187|Experimental|Teriparatide|demeclocycline HCl (150 mg, four times per day for 3d) followed by a 12 day intermission then 3 more days of demeclocycline HCl (150 mg, four times per day). One day after the last demeclocycline dosage, subjects will be instructed to self-administer teriparatide (or placebo) for 7 weeks. Twenty-five days after the last demeclocycline dosage, subjects will begin their second set of tetracycline labels:(250 mg, four times per day) for three days, followed by 12 days off, and then repeat another 3 days of tetracycline HCl (250 mg, four times per day). On day of the last teriparatide (or placebo) injection, subjects will present for bone core removal and dental implant placement.
3188448|NCT01279187|Placebo Comparator|Control|demeclocycline HCl (150 mg, four times per day for 3d) followed by a 12 day intermission then 3 more days of demeclocycline HCl (150 mg, four times per day). One day after the last demeclocycline dosage, subjects will be instructed to self-administer teriparatide (or placebo) for 7 weeks. Twenty-five days after the last demeclocycline dosage, subjects will begin their second set of tetracycline labels:(250 mg, four times per day) for three days, followed by 12 days off, and then repeat another 3 days of tetracycline HCl (250 mg, four times per day). On day of the last teriparatide (or placebo) injection, subjects will present for bone core removal and dental implant placement.
3188449|NCT01279174|Other|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
3188450|NCT01279174|Experimental|Whole-body-vibration exercises|Patients in this study group will attend whole body vibration exercise sessions of one hour three times a week for six weeks, using the Galileo® Fitness device. Initial training sessions will focus on patient acclimatization, and afterwards improved on muscular capacity and body coordination. During exercise sessions, patients will do 6 training cycles of 3 minutes each. The goals of this treatment are improved proprioception of the ankle and knee joints, as well as optimization of neuronal reactivation of the muscles and thereby improved joint stability. This should also increase endogenous analgesia
3188451|NCT01279161||diabetes|The study will include 1500 children with type 1 diabetes, aged 6-18 years. These will be patients from Diabetes Outpatient Clinics and patients hospitalized in Departments of Paediatrics, Endocrinology and Diabetology in University and Municipal Hospitals from Poland (Białystok, Warszawa, Łódź, Gdańsk, Wrocław, Katowice).
3188452|NCT01279161||control|Reference group will be made of 1500 children from the above mentioned Clinics and Departments in whom type 1 diabetes was excluded. In these children diagnostics procedures will be conducted for reasons other than body weigh related diseases (excluding simple obesity). The children will not receive any treatment that might influence their body weight.
3188453|NCT01279148||Biopsy/Ablation - CONTROL GROUP|The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded by pushing the start button again.
3188494|NCT01278862|Experimental|DVS veneer|veneer made by CAD/CAM method
3188495|NCT01278862|Active Comparator|Conventional veneer|Veneer made by laboratory technician
3188454|NCT01279148||Biopsy/Ablation - STUDY GROUP:|"The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. The physician will then be un-blinded and shown the PercuNav screen and will correct the desired approach path and another screen capture will be taken. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded. At the end of the procedure, and if clinically indicated, a verification CT computed tomography scan will be taken with the needle in place and, sent to the PercuNav. Radiation dosage, due to CT imaging, will also be recorded."
3188455|NCT01279135|Active Comparator|Conventional RT|Patients in this arm will receive conventional radiation with or without chemotherapy
3188456|NCT01279135|Experimental|Tomotherapy based IGRT|Patients in this arm will receive Tomotherapy based IGRT with or without chemotherapy
3188457|NCT01279122|No Intervention|Nanoflex IOL|
3188458|NCT01279109|Experimental|Social network building intervention|Healthy lifestyle intervention focused on building healthy lifestyle skills and reciprocal social ties between the intervention group members
3188459|NCT01279109|Active Comparator|Home visit|Home visits focused on preventable infant injuries
3188460|NCT01279083|Experimental|Concentration 1|
3188461|NCT01279083|Experimental|Concentration 2|
3188462|NCT01279083|Experimental|Concentration 3|
3188463|NCT01279083|Experimental|Concentration 4|
3188464|NCT01279083|Placebo Comparator|Vehicle Solution|
3188465|NCT01279083|Active Comparator|Timolol Maleate Ophthalmic Solution|
3188466|NCT01279070|Experimental|REPYFLEC cognitive remediation training|REPYFLEC cognitive remediation as a Problem solving and Cognitive flexibility group training.
3188467|NCT01279070|Active Comparator|Leisure group|"Leisure group is a stimulating activity focused on socialization through group dynamics, board games, coffee and talk."
3188468|NCT01279057|Experimental|Fluticasone furoate (Lek Pharmaceuticals) nasal spray|
3188469|NCT01279057|Active Comparator|Fluticasone furoate (Veramyst®) nasal spray|
3188470|NCT01279057|Placebo Comparator|Placebo nasal spray|
3188471|NCT01279044|Active Comparator|1|HIV testing with adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)
3188472|NCT01279044|Placebo Comparator|2|HIV testing with information only
3188473|NCT01279031|Experimental|Abbott WHITESTAR Signature System|Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound
3188474|NCT01279031|Experimental|Alcon Infiniti|Alcon Infiniti with the OZIL Torsional Handpiece
3188475|NCT01279018||Patients treated with docetaxel|Patients treated according to the DBCG 07 protocol, that have received docetaxel as part of the adjuvant treatment.
3188476|NCT01279005||20-50 YEARS OLD MSM|
3188477|NCT01278979|Active Comparator|Assessment of perineal tears|Consenting women sustaining perineal tear after child birth
3188478|NCT01278979|Other|Visual and digital assessment|Consenting women that sustained perineal tear after child birth.
3188479|NCT01278966|Experimental|The Modified Atkins Diet|Treatment with the Modified Atkins Diet for 6 months
3188480|NCT01278953|Experimental|TactiCath|Ablation performed using the TactiCath contact force sensing catheter
3188481|NCT01278953|Active Comparator|Control|Ablation performed using a catheter with no contact force sensing capability
3188482|NCT01278940|Experimental|Dendritic Cells (DC) malignant melanoma|22 patients were included in this arm.
3188483|NCT01278940|Experimental|DC vaccine plus IL-2|To improve the efficacy of the DC vaccine, IL-2 was administrated at the vaccination site through direct lymph node injection. 9 patients were included in this arm.
3188484|NCT01278927|Active Comparator|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief (10 minute) personalized introduction to the home-based exercise intervention. On Day 30 post hematopoietic cell transplantation (HCT), participants will meet briefly with the same interventionist when possible. To minimize contamination across intervention conditions, participants randomized to Exercise will be provided with only general advice regarding stress management (i.e., to continue using any techniques they currently use to manage stress). The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant.
3188485|NCT01278927|Active Comparator|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief standardized introduction to the self-administered intervention. On Day 30 post HCT, the interventionist will meet with the participant to answer any questions about the intervention, encourage the continued use of stress management techniques as recommended, and monitor for any adverse reactions to use of the techniques. The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant. Whenever possible, the interventionist meeting with the patient at 30 and 60 days should be the same interventionist who previously met with the patient.
3188486|NCT01278927|Active Comparator|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions. On Day 30 post HCT, the same interventionist will meet with the participant briefly to answer any questions about the interventions, encourage the continued use of the interventions as recommended, and monitor for any adverse reactions. The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant. Whenever possible, the interventionist meeting with the patient at 30 and 60 days should be the same interventionist who previously met with the patient.
3188487|NCT01278927|Other|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive a digital video disc (DVD). The interventionist will briefly discuss the topics of the DVD and elicit questions. To minimize contamination across intervention conditions, participants randomized to the control group will be provided with only general advice about exercise and stress management during treatment (i.e., to maintain any usual patterns of exercise to the extent possible and to continue using any techniques they currently use to manage stress).
3188488|NCT01278901||Cohort of consecutive patients undergoing EGD treated with PPI|Patients positive for helicobacter pylori undergoing EGD, started on PPI therapy for a month, repeated diagnostic tests for Helicobacter pylori after a month of therapy (urease test, histology and breath test)
3188497|NCT01278836|Other|fascio-cutaneous flap|flaps which include skin, subcutaneous tissue, and the underlying fascia.
3188498|NCT01278823|Experimental|surgery|Surgery: laparoscopic roux en y gastric bypass operation
3188499|NCT01278823|Active Comparator|Medical treatment|Medical Treatment: Comprehensive medical management of diabetes including medications, diet intervention, lifestyle modification, exercise regimen
3188500|NCT01278810|Experimental|Icaritin|
3188501|NCT01278797|Active Comparator|Telmisartan/Amlodipine Fixed Dose|Telmisartan/Amlodipine medium fixed dose combination tablet once daily.
3188502|NCT01278797|Active Comparator|Amlodipine Monocomponent|Amlodipine Monocomponent 10mg tablet once daily
3188503|NCT01278784|Experimental|Healthy volunteer|
3188504|NCT01278758|Experimental|ASA404 + standard therpy|
3188505|NCT01278745|Experimental|Rituximab|Rituximab induction/conventional immunosuppression
3188506|NCT01278745|Placebo Comparator|Rituximab Placebo|Rituximab Placebo / conventional immunosuppression
3188507|NCT01278732||untreated persons with suspected hypertension|
3188508|NCT01278719||Antrochaonal polyp; non recurrent type|
3188509|NCT01278719||Antrochoanal polyp; recurrent type|
3188510|NCT01278719||Ethmoidal polyp - non recurrent type|
3188511|NCT01278719||Ethmoidal polyp - recurrent type|
3188512|NCT01278706|No Intervention|no treatment|
3188513|NCT01278706|Experimental|one biopsy, proliferative phase|
3188514|NCT01278706|Experimental|one biopsy, secretory phase|
3188515|NCT01278706|Experimental|two biopsies|
3188516|NCT01278693|Other|placebo|it is as like as L-carnitine in shape
3188517|NCT01278693|Other|L-carnitine|it is kind of supplement
3188518|NCT01278680|No Intervention|Hold-out control|Hold-out control: participants will be asked to refrain from using the walkstations for the duration of the study (90 days).
3188519|NCT01278680|Active Comparator|Personal incentive|Personal incentive: Participants will receive $3 for each time they use the walkstation.
3188520|NCT01278680|Experimental|Charitable incentive|Charitable incentive: $3 will be donated to charity every time the participant uses the walkstation.
3188521|NCT01278654|Active Comparator|Personal incentive|If participants attain their walkstation usage goal, they are entered into bi-weekly lotteries to win money.
3188522|NCT01278654|Active Comparator|Token incentive|Participants who attain their walkstation usage goal will be entered into a bi-weekly prize to win a token reward.
3188523|NCT01278641|Experimental|1|Intervention i arm 1 comprises graded strength resistance training, 75 minutes twice a week for 12 weeks.
3188524|NCT01278641|Experimental|2|Intervention in arm 2 comprises low intensive temperate pool exercise 50 minutes, twice a week for 12 weeks.
3188525|NCT01278641|No Intervention|3|Reference group, continues with normal activities during the study period of 12 weeks.
3188526|NCT01278628|Experimental|Lifestyle modification|
3188527|NCT01278615|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity
3188528|NCT01278602|Experimental|R-ESHAP|Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
3188529|NCT01278589|Experimental|• Plantago asiatica L. extract 5g|
3188530|NCT01278589|Experimental|Plantago asiatica L. extract 10g|
3188531|NCT01278589|Experimental|Plantago asiatica L. extract 20g|
3188532|NCT01278589|Placebo Comparator|Placebo|
3188533|NCT01278576|Experimental|Intramuscular ending Targeting|Botox 200 units placed at the upper 2/10-3/10 length of the GCM
3188534|NCT01278576|Active Comparator|Midbelly Targeting|A total of 200 units will be placed at the four quadrants of the midbelly portion of the GCM.
3188535|NCT01278550||Average risk cohort|Patients having no history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have H. pylori positive OR negative
3188536|NCT01278550||High risk cohort|Patients have history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have successful eradication of H. pylori based on histology
3188537|NCT01278537|Experimental|Empowerment, shared-decision making,|Patients receive a booklet with informations. Assessment of health-related risk factors. Assessment of psychological and physical social support Delirium protection. Early mobilization.
3188538|NCT01278537|No Intervention|control group|
3188539|NCT01278524||Critically ill patients|Patients staying in the ICU on the 25th of January
3188540|NCT01278511|Experimental|Canadian C-Spine Rule|
3188541|NCT01278498|Experimental|escitalopram|prevention of poststroke depression in patients with acute stroke.
3188542|NCT01278498|Placebo Comparator|placebo|prevention of poststroke depression in patients with acute stroke.
3188543|NCT01278485||Sulphonylurea (SU) Monotherapy or SU + Metformin|Participants with Type 2 diabetes that have been treated with SU monotherapy for at least 6 months by a cardiologist, nephrologist, or family practice doctor.
3188544|NCT01278472|Experimental|Single Port Cholecystectomy|Laparoscopic Cholecystectomy with single port transumbilical access
3188545|NCT01278472|Active Comparator|4 Port Cholecystectomy|Laparoscopic Cholecystectomy using 4 separate conventional trocars
3188546|NCT01278459|Experimental|Atorvastatin first|Participants receive 4 week treatment with atorvastatin 20mg/day, followed by 4 week washout, followed by 4 week treatment with placebo.
3188547|NCT01278459|Experimental|Placebo first|Participants receive 4 week treatment with placebo, followed by 4 weeks washout, followed by 4 weeks treatment with atorvastatin 20mg/day.
3188548|NCT01278446|Experimental|Test Formula|New hydrolyzed whey formula
3188549|NCT01278446|Active Comparator|Control Formula|Commercially available hydrolyzed infant formula
3188550|NCT01278433|Experimental|Study Group|Participants receiving their first dose of polio vaccine
3188551|NCT01278420|Other|Tecnis MF|
3188552|NCT01278420|Other|ReSTOR|
3188553|NCT01278407|Placebo Comparator|Placebo - Confirmatory Phase|Participants received donepezil matched placebo tablets orally, once daily for 12 weeks in the confirmatory phase.
3188554|NCT01278407|Experimental|Donepezil 5 mg - Confirmatory Phase|Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 10 weeks in the confirmatory phase.
3188555|NCT01278407|Experimental|Donepezil 10 mg - Confirmatory Phase|Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 4 weeks. Thereafter, the dose was increased to 10 mg for 6 weeks in the confirmatory phase.
3188556|NCT01278407|Experimental|Placebo to Donepezil (5 +10 mg) - Extension Phase|Participants previously receiving donepezil matched placebo up to Week 12 in the Confirmatory Phase, continued placebo until Week 16 (at the beginning of the Extension Phase). Participants received 3 mg of donepezil, and the dose was then increased to 5 mg at Week 18 and to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.
3188557|NCT01278407|Experimental|Donepezil (5 +10 mg) - Extension Phase|Participants previously receiving donepezil (5 mg or 10 mg) up to Week 12 in the Confirmatory Phase, maintained allocated treatment and dosages until Week 24. In the 5 mg group of the Confirmatory Phase, the dose was increased to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.
3188558|NCT01278394|Experimental|Group 1|AN2690 Solution, 5.0%
3188559|NCT01278381||Pancreaticoduodenectomy (PD)|Patients undergoing PD from 2002 to 2010
3188560|NCT01278368|Active Comparator|Preoperative chemotherapy (PCHT)|Patients who underwent pancreatic resection after PCHT.
3188561|NCT01278368|Active Comparator|Control|Patient who underwent pancreatic resection without preoperative therapy
3188562|NCT01278355||Pain Patients|
3188563|NCT01278342|Active Comparator|Sandostatin LAR high dose Alone|All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with controlled GH and IGF-I after 3 months of Sandostatin LAR monotherapy continued to receive Sandostatin LAR 40 mg i.m. every 28 days for an additional 4 months.
3188564|NCT01278342|Experimental|Sandostatin LAR high dose + Pegvisomat|All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with uncontrolled GH and or IGF-I received Sandostatin LAR40 mg every 28 days in combination with weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for a further 4 months
3188565|NCT01278342|Experimental|Sandostatin LAR high dose + Cabergoline|"All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with uncontrolled GH and or IGF-I received Sandostatin LAR 40 mg every 28 days in combination with weekly cabergoline for a further 4 months, with cabergoline doses as follows:~st week: 0.25 mg twice a week (0.50 mg/week)~nd week: 0.50 mg/week twice a week (1 mg/week)~rd week: 0.50 mg four times a week (2 mg/week)~th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)"
3188566|NCT01278329|Experimental|Music|"Mothers in the music group were provided a pre-recorded Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India) with a running duration of approximately 50 minutes and a cassette player with headphones. They were asked to listen to the recorded music daily in the evening just before going to the bed with a minimum of ambient noise."
3188567|NCT01278329|No Intervention|Control|Standard routine ante-natal care.
3188568|NCT01278316|Experimental|Cognitive training|Cognitive Intervention Tasks Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
3188569|NCT01278316|Active Comparator|Control|The control group will perform computerized tasks that utilize cognitive performance, but were not systematically developed to improve cognitive performance.
3188570|NCT01278303|Other|Treatment of Aortic Wall Injury|Repair of aortic wall injury with covered CP Stents
3188571|NCT01278290|Active Comparator|Triptorelin test AND LHRH test|Patients undergo two tests with a test interval of at least 15 days
3188572|NCT01278290|Active Comparator|LHRH test AND Triptorelin test|Patients undergo two test with a test interval of al least 15 days.
3188573|NCT01278277|Placebo Comparator|placebo supplementation|patients will be assigned, in a cross-over design, to placebo or supplement administration
3188574|NCT01278277|Active Comparator|Saffron|Saffron Supplementation 20 mg/die
3188575|NCT01278264|Active Comparator|iTAP-group|Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
3188576|NCT01278264|Active Comparator|aTAP-group|Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
3188577|NCT01278251||Endobutton|
3188578|NCT01278238|Active Comparator|Phenylephrine|
3188579|NCT01278238|Active Comparator|Lower limb compression|
3188580|NCT01278238|Placebo Comparator|Placebo|
3188581|NCT01278225||EEG biofeedback (BF) Group|Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions. After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
3188582|NCT01278225||Wait-List Control (WLC) Group|Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits. After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
3188583|NCT01278212|Experimental|AHF-RT|"accelerated hypofractionated radiotherapy (AHF-RT)~30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy"
3188584|NCT01278199|Other|2|Medicals measures in the treatment of non-severe acute hemoptysis
3188585|NCT01278199|Experimental|1|bronchial artery embolization (BAE)
3188586|NCT01278186|Experimental|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon catheter (SeQuent Please, B. Braun)
3188587|NCT01278186|Experimental|Paclitaxel-eluting stent|Paclitaxel-eluting stent
3188588|NCT01278173|Other|Sabril|
3188664|NCT01277627|Active Comparator|Non-nevirapine|
3188895|NCT01276158|Active Comparator|Doppler|Arterial line placed with doppler guidance
3188589|NCT01278160|Experimental|BIAsp 30 (2:1)|After discontinuation of previous treatment of once daily biphasic insulin aspart 30 (BIAsp 30) or insulin glargine combined with metformin and glimepiride in trial BIAsp-3756, subjects were adminstered BIAsp 30 twice daily with initial dosage split regimen of 2/3 and 1/3 total daily dose before breakfast and before dinner, respectively combined with metformin administered orally with meals
3188590|NCT01278160|Experimental|BIAsp 30 (1:1)|After discontinuation of previous treatment of once daily biphasic insulin aspart 30 (BIAsp 30) or insulin glargine combined with metformin and glimepiride in trial BIAsp-3756, subjects were adminstered BIAsp 30 twice daily with initial dosage split regimen of 1/2 and 1/2 total daily dose before breakfast and before dinner, respectively combined with metformin administered orally with meals
3188591|NCT01278147|No Intervention|controle|patient without fatigue education program
3188592|NCT01278147|Experimental|Education program|the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
3188593|NCT01278134|Experimental|Arm B Extension|All patients in treatment arm B were offered to receive Pegasys/Cogepus therapy for an additional 24 weeks.
3188594|NCT01278134|Experimental|RO5024048 & ritonavir-boosted danoprevir without Ribavirin (B)|
3188595|NCT01278134|Experimental|RO5024048 and ritonavir-boosted danoprevir with Ribavirin (A)|
3188596|NCT01278121|Other|Diet A: High-fat diet|"Diet given for 3 days to reset all of the participants"
3188597|NCT01278121|Active Comparator|Diet B: A carbohydrate-restricted diet|The diet will be given for 10 days, 6 meals a day
3188598|NCT01278108|Experimental|1|single ascending doses
3188599|NCT01278108|Placebo Comparator|2|single dose placebo
3188600|NCT01278108|Experimental|3|multiple dose, 7 days, capsules (dosing depends on outcome of single-dose part; can be once or twice daily).
3188601|NCT01278108|Placebo Comparator|4|multiple dose, capsules, 7 days; scheme to match that of Study Arm 3.
3188602|NCT01278095|Experimental|GLPG0555 solid dispersion, fasting|50 mg as solid dispersion capsule, in fasting condition
3188603|NCT01278095|Experimental|GLPG0555 solid dispersion, fed|50 mg as solid dispersion capsule, after breakfast
3188604|NCT01278095|Experimental|GLPG0555 nanosuspension, fed|50 mg as nanosuspension, given after breakfast
3188605|NCT01278082|Experimental|A|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
3188606|NCT01278082|Placebo Comparator|B|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
3188607|NCT01278056|Experimental|Exjade|
3188608|NCT01278030|No Intervention|Control group|Patients will be implanted according to the standard of care with the LV lead in the traditional LV lead position.
3188609|NCT01278030|Experimental|3D echo-guided LV lead placement group|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on Real-Time 3-Dimensional Echocardiography (RT3DE) will be available to the physician at the time of implant. This location will be used as the target for optimal LV lead placement.
3188610|NCT01278017|Experimental|ceftriaxone|
3188611|NCT01278004|Placebo Comparator|Placebo|Placebo capsule
3188612|NCT01278004|Experimental|Drug|
3188613|NCT01277991|Experimental|Sequence 1|
3188614|NCT01277991|Experimental|Sequence 2|
3188615|NCT01277978||Carbetocin|Women undergoing elective caesarean sectio in regional anesthesia randomised to receive 100 ug Carbetocin (the clinical standard dose) following delivery of the baby.
3188616|NCT01277978||Oxytocin|Women undergoing elective caesarean sectio in regional anesthesia randomised to receive 5 IU oxytocin (the clinical standard dose) following delivery of the baby.
3188617|NCT01277965|Other|50% VO2 max, BFR reduced by 50%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%
3188618|NCT01277965|Other|50% VO2 max,BFR reduced by 80%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%
3188619|NCT01277965|Other|75% VO2 max, BFR reduced by 80%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%.
3188620|NCT01277965|Other|75% VO2 max, pump switched off|Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed.
3188621|NCT01277965|Other|Rest|Patient will be in rest, basal insulin flow rate will not be change.
3188622|NCT01277952|Experimental|DBS Surgery|Deep brain stimulation (DBS) will be the treatment option in this study along with behavioral interventions for participants with severe disability due to Traumatic Brain Injury (TBI) 24 months post their injury, the participants will have severe disabilities in behavioral and emotional self-regulation, cognitive impairments and somatic symptoms.
3188623|NCT01277939|Experimental|Therapeutic Education System (TES)|Experimental (E) condition, the Therapeutic Education System (TES) delivered via effective informational technologies and multimedia learning tools.
3188624|NCT01277939|Active Comparator|Standard Care|The Control (C) condition, Standard Care, consisting of psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
3188625|NCT01277913|Experimental|Vitamin D 1000 IU|vitamin D will be given 1000 IU for 12 months
3188626|NCT01277913|Active Comparator|Vitamin D 500IU|vitamin D 500 IU will be given for 12 months once daily
3188627|NCT01277900||Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
3188628|NCT01277887|Active Comparator|Cognitive-Behavioral Counseling|The intervention consists of 8 sessions provided over 10 weeks. Counseling commences 4 weeks before quitting smoking. Participants will also receive the nicotine patch for 6 weeks starting on the day of quit date.
3188629|NCT01277887|Placebo Comparator|Smoking Cessation Counseling|The intervention consists of 8 sessions provided over 10 weeks. Counseling commences 4 weeks before quitting smoking. Participants will also receive the nicotine patch for 6 weeks starting on the day of quit date.
3188630|NCT01277874|Active Comparator|Nasal CPAP|Standard Nasal CPAP
3188631|NCT01277874|Active Comparator|Oscillatory NCPAP|NCPAP will be given to infant via prongs in the infant's nose. A Bird Industries pneumatic oscillating diaphragm to drive a Bird Industries phasatron which is attached by T-connector to the NCPAP patient circuit.
3188632|NCT01277861|Active Comparator|FENTANYL|FENTANYL
3188633|NCT01277861|Placebo Comparator|SALINE|SALINE
3188634|NCT01277835|Experimental|Lidocaine Infusion|
3188635|NCT01277835|Placebo Comparator|Placebo|Saline Infusion
3188636|NCT01277822|Experimental|Losartan/amlodipine Treatment Arm|One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks.
3188637|NCT01277822|Active Comparator|Amlodipine Treatment Arm|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks.
3188638|NCT01277809|No Intervention|Usual Care|Participants will receive care as usual (Usual Care Group; UCG) that is provided by their long-term care unit.
3188639|NCT01277809|Active Comparator|Interpersonal Interaction|Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program. This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the walking group. This interaction time will occur with the participant stationary, rather than walking with the researcher.
3188640|NCT01277809|Experimental|Walking Program|Participants will walk five times per week under the supervision of a licensed physiotherapist.
3188641|NCT01277770||Kidney Transplant Recipients|Kidney Transplant Recipients at the University of Minnesota since 1984. The study looks at a 10 year followup of steroid-free maintenance immunosuppression, post-transplant infections and evaluation of the DGF nomogram in Thymoglobulin on patients at the University of Minnesota.
3188642|NCT01277757|Experimental|Treatment (Akt inhibitor MK-2206)|Akt Inhibitor MK-2206 mg orally once a week on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3188643|NCT01277744|Experimental|HIPEC + Cisplatin|HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions. Cisplatin 100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the Cisplatin.
3188644|NCT01277731|Experimental|Methylprednisolone replacement|"This study will enroll the patients who were previously experienced dexamethasone-induced hiccup. Patients who experienced dexamethasone-induced hiccup during chemotherapy will enroll to study arm.~Run-in period * Dexamethasone 10mg-20mg q day iv during chemotherapy~▶ measure hiccup and nausea/vomiting severity~Treatment period * Methylprednisolone 60mg-125mg iv during chemotherapy~▶ measure hiccup and nausea/vomiting severity~Response will be evaluated by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE) and NRS to hiccup at 24hrs after start methylprednisolone.~Nausea and vomiting will be assessed as CTCAE 4.0"
3188645|NCT01277718|Experimental|Treatment A first, then Treatment B, followed by Treatment C|Treatment A in Period 1: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliters (mL) room temperature water after at least an 8-hour fast. Treatment B in Period 2: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1, 20 mg rabeprazole will be administered in fasted state followed by one 20-mg tablet of cobimetinib administration orally with 240 mL room temperature water after at least an 8-hour fast. Treatment C in Period 3: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1, 20 mg rabeprazole will be administered in fasted state. Approximately 30 minutes later, participants will be provided a standardized Food and Drug Administration (FDA) high-fat meal, and approximately 30 minutes after starting meal, one 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water. There will be a 13-day washout between cobimetinib doses of each period.
3188646|NCT01277718|Experimental|Treatment A first, then Treatment C, followed by Treatment B|Treatment A in Period 1: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast. Treatment C in Period 2: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1 of the treatment period, 20 mg rabeprazole will be administered in fasted state. Approximately 30 minutes later, participants will be provided a standardized FDA high-fat meal, and approximately 30 minutes after starting meal, one 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water. Treatment B in Period 3: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1 of treatment period, 20 mg rabeprazole will be administered in fasted state followed by one 20-mg tablet of cobimetinib administration orally with 240 mL room temperature water after at least an 8-hour fast. There will be a 13-day washout between cobimetinib doses of each period.
3188647|NCT01277705|Experimental|Group A|
3188648|NCT01277705|Experimental|Group B|
3188649|NCT01277705|Active Comparator|Group C|
3188650|NCT01277692|Experimental|Part 1: Single Dose Escalation in Healthy Subjects|The doses currently planned are 10, 30mg, 100mg, 200mg
3188651|NCT01277692|Experimental|Part 2: Repeat Dose Escalation in Healthy Subjects|The first planned dose is currently 10mg QD and the planned maximum dose is 100mg QD
3188652|NCT01277692|Experimental|Part 3: Single Dose Escalation in HCV Infected Subjects|The planned doses for Part 3 are 5mg, 30mg, and 100 mg.
3188653|NCT01277679|Other|Healthy Volunteer|Healthy Volunteer cohort
3188654|NCT01277679|Other|Heart Failure|Heart Failure cohort
3188655|NCT01277666|Placebo Comparator|Placebo|orally administered
3188656|NCT01277666|Experimental|GSK1605786A 500mg once daily|orally administered
3188657|NCT01277666|Experimental|GSK1605786A 500mg twice daily|orally administered
3188658|NCT01277653||PIVKA-II and AFP 6 months|PIVKA-II and AFP measurement every 6 months
3188659|NCT01277653||tumor maker interval every 6 month|tumor maker interval every 6 month
3188665|NCT01277614|Experimental|Lifestyle counseling|This is a 6-month intervention in which participants with 2 or more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
3188666|NCT01277614|Placebo Comparator|Health Literature|
3188667|NCT01277601|Experimental|TDF+Peg-IFN 48 Weeks|TDF plus Peg-IFN for 48 weeks
3188668|NCT01277601|Experimental|TDF 48 Weeks + Peg-IFN 16 Weeks|TDF plus Peg-IFN for 16 weeks, followed by TDF alone for an additional 32 weeks
3188669|NCT01277601|Active Comparator|TDF 120 Weeks|TDF monotherapy for 120 weeks
3188670|NCT01277601|Active Comparator|Peg-IFN 48 Weeks|Peg-IFN monotherapy for 48 weeks
3188671|NCT01277588||Patient|
3188672|NCT01277588||Physcician|
3188673|NCT01277575|Experimental|Verum stimulation|repetitive transorbital alternating current stimulation (rtACS)
3188674|NCT01277575|Sham Comparator|Placebo stimulation|Sham stimulation (placebo condition) no intervention
3188675|NCT01277562||Breast Cancer|Non-metastatic breast cancer with recent diagnosis of osteopenia or osteoporosis
3188676|NCT01277562||Prostate Cancer|Non-metastatic prostate cancer with recent diagnosis of osteopenia or osteoporosis
3188677|NCT01277549||Non-mobilized donors|In this arm the collection efficiency of mononuclear cells from non-mobilized donors will be studied.
3188678|NCT01277549||G-CSF mobilized donors|In this arm the collection efficiency of CD34+ cells will be studied.
3188679|NCT01277536||hospitalization >24 hours|
3188680|NCT01277523|Experimental|A|
3188681|NCT01277523|Experimental|B|
3188682|NCT01277523|Placebo Comparator|C|
3188683|NCT01277510|Placebo Comparator|Placebo|Participants received standard of care and placebo once daily for 30 weeks during the double-blind phase. During the open-label phase, participants received cinacalcet with standard of care for an additional 30 weeks. The starting dose of cinacalcet was ≤ 0.20 mg/kg based on dry weight, and could be titrated up according to plasma iPTH and serum calcium levels every 4 weeks up to Week 54 to a maximum dose of 4.2 mg/kg.
3188684|NCT01277510|Experimental|Cinacalcet|Participants received standard of care and cinacalcet once daily for 30 weeks during the double-blind phase. The starting dose of cinacalcet was ≤ 0.20 mg/kg based on dry weight, and could be titrated up according to plasma iPTH and serum calcium levels every 4 weeks until Week 24 to a maximum dose of 4.2 mg/kg. During the open-label phase participants continued to receive cinacalcet with standard of care for an additional 30 weeks.
3188685|NCT01277497|Experimental|Sevelamer carbonate|1,600 mg (2 x 800 mg) three times daily with meals for a total of 12 weeks
3188686|NCT01277497|Active Comparator|Calcium acetate|1,334 mg (2 x 667 mg) three times daily with meals for a total of 12 weeks
3188687|NCT01277484|Experimental|Decitabine, MDS treatment, IV injection|For the patients who achieve remission after allogeneic BMT and meet the enrollment criteria, decitabine will be given at a dose of 5mg/kg/day ~ 15mg/kg/day iv over 1 hour for 5 consecutive days starting 42-90 days after transplantation. The drug will be repeated every 4 weeks for up to 12 cycles.
3188688|NCT01277471|Experimental|Arm A: 6 and 2 meals/day|6 meals/day for the first 12 weeks followed by 2 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
3188689|NCT01277471|Active Comparator|Arm B: 2 and 6 meals/day|2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
3188690|NCT01277458||Non white HIV positive men who have sex with men|
3188691|NCT01277445|Placebo Comparator|Placebo|15g/day maltodextrin for 28 days
3188692|NCT01277445|Active Comparator|Prebiotic|Consumption of 15g/day of inulin-fructan for 28 days
3188693|NCT01277432||Psychiatrist interview|"All patients will receive the same assessments as the 'active comparator' arm, but in addition those patients found to have positive symptoms for mild to severe depression by PHQ9 or CESD (PHQ>10 and/or CES>16) and a random sample of subjects with no or mild symptoms will also undergo a face-to-face interview by a trained clinician or psychiatrist using the following instruments:~MINI~SSI-28 (somatization)"
3188694|NCT01277432||Depression screening|"All study participants will undergo a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal.~All patients will also undergo detailed psychological and behavioral assessments using validated questionnaires.~Several specialist questionnaires will also be conducted with all patients, including those on depression, self care and quality of life;~Patient Health Questionnaire (PHQ-9)~Depression Anxiety and Stress Scale (DASS-21)~Diabetes Distress Scale (DDS-17)~Life events questions (Inter-Heart Study)~Diabetes Empowerment Scale (C-DES 20)~Summary of Diabetes Self Care Activities (SDSCA-15)~Euroqol-5D (EQ-5D)"
3188695|NCT01277419||Ankylosing spondylitis|Ankylosing spondylitis according to the modified New York criteria and duration of symptoms ≤10 years
3188696|NCT01277419||Non-radiographic axial spondyloarthritis|Patients with clinical characteristics of axial SpA but not fulfilling the modified New York criteria for which radiographic sacroiliitis is essential. Maximal duration of symptoms: 5 years.
3188697|NCT01277419||Juvenile spondyloarthritis|Patients with juvenile spondyloarthritis (juvenile ankylosing spondylitis, juvenile non-AS-spondyloarthritis).
3188698|NCT01277419||Crohn's disease|Crohn's disease with duration of symptoms ≤5 years
3188699|NCT01277406|Experimental|4SC-201+FOLFIRI|
3188700|NCT01277406|Active Comparator|FOLFIRI|
3188701|NCT01277393||Experimental Group|
3188702|NCT01277393||Control Group|
3188703|NCT01277380||Experimental Group|
3188704|NCT01277380||Control Group|
3188705|NCT01277380||Negative control group|
3188706|NCT01277367|Active Comparator|A|These members will be offered no additional incentives
3188707|NCT01277367|Experimental|B|These members will receive regular communications by Discovery Vitality.
3188708|NCT01277367|Experimental|C|These members will nominate a charity which will benefit financially based on participants' level of physical activity.
3188709|NCT01277367|Experimental|D|These members are entered into a prize draw for a monthly cash prize if they achieve physical activity targets.
3188710|NCT01277367|Experimental|E|These members will receive a direct payment.
3188711|NCT01277367|Experimental|F|These members will be offered the opportunity to choose one of three incentive options at the time of enrollment in the study.
3188712|NCT01277354|Active Comparator|Cognitive Processing Therapy|Participants are seen weekly for six weeks for therapy. At visits 2, 4, and 6 they also complete ratings.
3188713|NCT01277354|Placebo Comparator|Waitlist|Participants come in at the end of weeks 2, 4, and 6 to complete ratings but do not receive therapy.
3188714|NCT01277341|Experimental|Arm No. 1|
3188715|NCT01277341|Experimental|Arm No. 2|
3188716|NCT01277341|Experimental|Arm No. 3|
3188717|NCT01277341|Placebo Comparator|Arm No. 4|
3188718|NCT01277328||Cohort|Cohort
3188719|NCT01277302|Experimental|Ranibizumab 0.5 mg monthly - randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific visual acuity and spectral-domain optical coherence tomography (VA-OCT) stability criteria were met and randomization occurred to the monthly arm. At subsequent monthly visits after randomization, injections were given whether the VA-OCT stability criteria were met or not met. Subjects were to receive 15 ranibizumab 0.5 mg injections.
3188720|NCT01277302|Experimental|Ranibizumab 0.5 mg PRN - randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific VA-OCT stability criteria were met and randomization occurred to the PRN arm. No injection was given at the randomization visit. At subsequent monthly visits after randomization, injections were given if the VA-OCT stability criteria were not met and no injections were given if the VA-OCT stability criteria were met. Subjects could receive between 7 and a maximum of 14 ranibizumab 0.5 mg injections.
3188721|NCT01277302|Experimental|Ranibizumab 0.5 mg monthly - non-randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections and then never met the study-specific VA-OCT stability criteria from month 7 to month 14. Subjects were to receive 15 ranibizumab 0.5 mg injections.
3188722|NCT01277289|Experimental|Ery-dex|Ery-dex (dexamethasone sodium phosphate)is administered as intra-erythrocyte drug at monthly interval
3188723|NCT01277289|Placebo Comparator|Placebo|placebo comparator (sodium chloride instead of dexamethasone sodium phosphate) is administered in infusion at monthly interval.
3188724|NCT01277276||Diagnostic tool|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
3188725|NCT01277250|Other|Usual Care|Standard smoking cessation information provided to all hospitalized patients as part of discharge packet.
3188726|NCT01277250|Experimental|Smoking Cessation Program|"Web-based program tailored to patients who smoke and are hospitalized. Program is tailored to participant's specific hospital experience and other characteristics. E-messages, social support and a transition coach are provided to each participant in this condition."
3188727|NCT01277237|Active Comparator|Omacor|
3188728|NCT01277237|Placebo Comparator|Lactose tablet|
3188729|NCT01277224|Experimental|Movi2 Program|
3188730|NCT01277224|No Intervention|Control|
3188731|NCT01277211|Experimental|ENG-EE (NuvaRing)|Participants were to complete 13 cycles of etonogestrel (ENG) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day ring-free period. Participants used one ring per cycle. Each ring contained 11.7 mg ENG and 2.7 mg EE, and released on average 120 mcg/day of ENG and 15 mcg/day of EE.
3188732|NCT01277211|Active Comparator|DRSP-EE|Participants were to complete 13 cycles of drospirenone (DRSP) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received a total of 21 tablets of DRSP-EE per cycle. Each tablet contained 3 mg DRSP and 30 μg EE.
3188733|NCT01277198||surgery without using a flexible cystoscopy|surgery without using a flexible cystoscopy: patients who did not undergo a flexible cystoscopy during laparoscopic stone surgery
3188734|NCT01277198||surgery with using a flexible cystoscopy|surgery with using a flexible cystoscopy: patients who underwent a flexible cystoscopy during laparoscopic stone surgery
3188735|NCT01277185|Active Comparator|Low Calcium Diet (600-1200 mg/d)|
3188736|NCT01277185|Active Comparator|High Calcium Diet (1100-2300mg/d)|
3188737|NCT01277172|Experimental|Group 1 / PBO-326|This group will be treated three cycles with PBO-326, after the third cycle the patients will receive Mabthera for another three cycles.
3188738|NCT01277172|Active Comparator|Group 2 / Mabthera|This group will be treated three cycles with Mabthera, after the third cycle the patients will receive PBO-326 for another three cycles.
3188739|NCT01277172|Experimental|Group 3 / PBO-326|This group will be treated six cycles with PBO-326
3188740|NCT01277172|Active Comparator|Group 4 / Mabthera|This group will be treated six cycles with Mabthera
3188741|NCT01277159|Experimental|Control Nerve Block. IV Dexamethasone (4 mg).|Control Nerve Block. IV Dexamethasone (4 mg).
3188742|NCT01277159|Experimental|Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
3188743|NCT01277159|Experimental|Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp|Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
3188744|NCT01277159|Experimental|Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (|Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
3188745|NCT01277159|Experimental|Nerve Block with Dexamethasone (4 mg) / block Buprenorphine|Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
3188746|NCT01277146|Experimental|OMP-59R5|
3188747|NCT01277133||Cohort|
3188748|NCT01277120||Cohort|
3188749|NCT01277107|Experimental|Zaleplon AP formulation|Gastric Retentive Dual Release Zaleplon (Zaleplon AP)
3188750|NCT01277107|Placebo Comparator|Placebo|Identical placebo capsule
3188751|NCT01277094|Experimental|1|
3188752|NCT01277094|Placebo Comparator|2|
3188753|NCT01277081|Active Comparator|Paracetamol hot drink|Hot drink containing paracetamol
3188754|NCT01277081|Active Comparator|Paracetamol tablets|Paracetamol tablets
3188755|NCT01277068|Active Comparator|the adjustable gastric banding|
3188756|NCT01277068|Active Comparator|the sleeve gastrectomy|
3188757|NCT01277068|Active Comparator|the gastric bypass|
3188758|NCT01277042|Experimental|Cervarix Group|Subjects received a 3-dose vaccination course of the Cervarix™ vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
3188759|NCT01277042|Active Comparator|Engerix Group|Subjects received a 3-dose vaccination course of the Engerix™-B vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
3188760|NCT01277029||lower urinary tract symptoms|
3188761|NCT01277016|No Intervention|MDex:|"MDex:~Administration of oral melphalan (M) at 0.22 mg/kg and dexamethasone (Dex) at 40 mg daily for 4 consecutive days every 28 days (MDex) until end of therapy"
3188762|NCT01277016|Experimental|BMDex|"BMDex:~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle."
3188763|NCT01277003|Experimental|Aculife Magnetic Wave Therapist|patients with carpal tunnel syndrome treated with Aculife
3188764|NCT01277003|Active Comparator|TENS|patients with carpal tunnel syndrome treated by TENS
3188765|NCT01276990|Placebo Comparator|Placebo|Matching placebo in dosing regimen 1-8
3188766|NCT01276990|Experimental|BI 224436 dosing regimen 1|Dosing regimen 1
3188767|NCT01276990|Experimental|BI 224436 dosing regimen 2|Dosing regimen 2
3188768|NCT01276990|Experimental|BI 224436 dosing regimen 3|Dosing regimen 3
3188769|NCT01276990|Experimental|BI 224436 dosing regimen 4|Dosing regimen 4
3188770|NCT01276990|Experimental|BI 224436 dosing regimen 5|Dosing regimen 5
3188771|NCT01276990|Experimental|BI 224436 dosing regimen 6|Dosing regimen 6
3188772|NCT01276990|Experimental|BI 224436 dosing regimen 7|Dosing regimen 7
3188773|NCT01276990|Experimental|BI 224436 dosing regimen 8|Dosing regimen 8
3188774|NCT01276977|Experimental|Zolmitriptan 5 mg nasal spray|
3188775|NCT01276977|Active Comparator|Eletriptan 40 mg Tablet|
3188776|NCT01276964||1. Women in the fertile age|Healthy women in the fertile age (between 20-45 years) with apparently normal periods
3188777|NCT01276951|Placebo Comparator|Placebo|
3188778|NCT01276951|Active Comparator|6,5g Dose Group|
3188779|NCT01276951|Active Comparator|12g Dose Group|
3188780|NCT01276951|Active Comparator|25g Dose Group|
3188781|NCT01276951|Active Comparator|50g Dose Group|
3188782|NCT01276938|Active Comparator|IORT 21 Gy|Single fraction 21 Gy Intraoperative Radiation Therapy for breast tumors with diameter between 10 and 25 mm
3188783|NCT01276938|Experimental|IORT 18 Gy|Single fraction 18 Gy Intra Operative Radiation Therapy in breast tumors smaller than 10 mm.
3188784|NCT01276925|Active Comparator|B3: Blockade of three nerves|Peripheral nerve blockade of the femoral nerve, the anterior division of the obturator nerve, and the lateral femoral cutaneous nerve with ropivacaine.
3188785|NCT01276925|Active Comparator|B2: Blockade of 2 nerves|"Peripheral nerve blockade of the anterior division of the obturator nerve and the lateral femoral cutaneous nerve with ropivacaine.~Sham blockade of the femoral nerve with saline."
3188786|NCT01276925|Sham Comparator|K: Control group|Sham blockade of the femoral nerve, the anterior division of the obturator nerve, and the lateral femoral cutaneous nerve with saline.
3188787|NCT01276899||Neoadjuvant setting|
3188788|NCT01276899||Metastatic setting|
3188789|NCT01276886||Acute Diverticulitis|
3188790|NCT01276873|Experimental|Closed System|Application of Tracheal aspiration closed system, controlled by the use of Open system to tracheal aspiraiton.
3188791|NCT01276847|Experimental|Ustekinumab|
3188792|NCT01276847|Active Comparator|Etanercept|
3188793|NCT01276847|No Intervention|No treatment|
3188794|NCT01276834|Experimental|everolimus-based immunosuppression|immunosuppression with everolimus, prednisone and mycophenolate
3188795|NCT01276834|Active Comparator|standard immunosuppression|immunosuppression with tacrolimus, prednisone and mycophenolate
3188796|NCT01276821|Placebo Comparator|Standard Treatment|L-Epinephrine and Normal Saline (0.9%)
3188797|NCT01276821|Active Comparator|Study Treatment|L-Epinephrine and Hypertonic Saline (3%)
3188798|NCT01276808|Experimental|Magnetic navigation PCI|These patients will be treated with magnetically navigated percutaneous coronary intervention
3188799|NCT01276808|Active Comparator|Conventional PCI|These patients will be treated with normal standard percutaneous coronary intervention
3188800|NCT01276795|Experimental|Glucose and whey protein|Patients who are randomly allocated to this group will receive a drink made of anhydrous beet dextrose and pressurized whey protein in water (200 g/L + 100g/L). Patients will sip the drink for 4 hours of the 6 hour study.
3188801|NCT01276795|Active Comparator|Glucose only|The patients who are randomly allocated to this arm will receive a drink composed of anhydrous beet dextrose in water (200g/L). They will sip the drink for 4 hours of the 6 hour study.
3188802|NCT01276782|Placebo Comparator|Pregnant SLE|Pregnant SLE patients with autoimmune thyroid antibodies will be randomized to levothyroxine or Placebo
3188803|NCT01276769|Active Comparator|ET|The control arm receive the paclitaxel plus epirubicin
3188804|NCT01276769|Experimental|PC|the experimental arm which receive the paclitaxel combined with carboplatin
3188805|NCT01276756|Active Comparator|Standard of care|Group A: comprises 50 treatment-naive chronic hepatitis c patients who will receive the standard of care treatment: peginterferon Alfa 2a 160 ug once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
3188806|NCT01276756|Experimental|Triple therapy|Group B: comprises 50 treatment-naive chronic HCV patients who will receive oral Nitazoxanide 500 mg twice daily for 4 weeks (lead-in phase) followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (160ug once weekly) and weight-based ribavirin 1000-1200 mg daily (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
3188807|NCT01276743||T1DM|Children and adolescents with T1DM
3188808|NCT01276743||Unaffected Population|Population not known to be affected by T1DM
3188809|NCT01276730|Experimental|Group A|Treatment consists of Interferon, given as a sub-cutaneous injection, 3 times per week for 4 weeks, 20 mg Retinoic Acid tablets, 2 times a day for 30 days. starting from the first day of radiation.
3188893|NCT01276171|Active Comparator|Palpation|Participants will place arterial line using palpation technique
3188894|NCT01276158|Active Comparator|Ultrasound|Arterial line placed with Ultrasound guidance.
3188810|NCT01276730|Active Comparator|Group B|"Treatment consists of radiation and chemotherapy using Cisplatin. Cisplatin, given intravenously, will be administered on the first day of each week, mixed with saline solution, before and after the Cisplatin infusion.~Radiation will be given for a few minutes daily, five days a week, for approximately 5 weeks.~Two weeks after completion of external radiotherapy, subject will receive internal radiation (brachytherapy) once a week for two weeks. For this internal radiation a specially designed instrument will be inserted into the vagina that will be connected to a machine for a few minutes."
3188811|NCT01276717|Experimental|Vorinostat + Carfilzomib|
3188812|NCT01276704|Experimental|flaxseed lignan, SDG|Secoisolariciresinol diglycoside
3188813|NCT01276704|Placebo Comparator|Placebo|Matched Placebo
3188814|NCT01276691|Active Comparator|Acute, Aspirin|81 mg asprin provided 30 minutes prior to firefighting- Acute single dosage
3188815|NCT01276691|Placebo Comparator|Acute, Placebo|Acute single dosage of placebo provided 30 minutes prior to firefighting
3188816|NCT01276691|Active Comparator|Chronic, Aspirin|81 mg asprin provided prior to firefighting- 14 day dosage
3188817|NCT01276691|Placebo Comparator|Chronic, Placebo|14 day dosage of placebo provided prior to firefighting
3188818|NCT01276678||Control|300 healthy controls free from any pharmacologic therapy
3188819|NCT01276678||Suspected CAD - Cardiac Cathetrization|subject's ≥18 years undergoing coronary angiography (inpatient cohort)or who have undergone coronary angiography within 5 years
3188820|NCT01276665|Experimental|Restrictive regimen group|treated with a restrictive fluid regimen of 2ml/kg/h of crystalloids in combination with sympathicomimetics.
3188821|NCT01276665|Active Comparator|Control group|treated according to an internationally accepted standard fluid regimen (6 ml/kg/h of crystalloids and correction of the hypotony with fluid boluses)
3188822|NCT01276652|Active Comparator|Environmental modification|Subjects assigned to this group receive the environmental modification intervention for 48 hours beginning the morning after enrollment.
3188823|NCT01276652|No Intervention|Usual care (randomized)|"Usual care is provided for the first 48 hours. Subsequently, in the initial protocol, subjects received 48 hours of the environmental modification intervention so long as they remained in the ICU during this time. The opportunity to receive the Delayed intervention was later removed from the protocol."
3188824|NCT01276652|No Intervention|Usual care (observational)|Usual care was provided.
3188825|NCT01276639|Experimental|Active Treatment 10 mg BID|
3188826|NCT01276639|Experimental|ActiveTreatment 5 mg BID|
3188827|NCT01276639|Placebo Comparator|Placebo Treatment|
3188828|NCT01276626|Experimental|Bifidobacterium longum|
3188829|NCT01276626|Placebo Comparator|Maltodextrin|
3188830|NCT01276613|Experimental|Intraoperative Gemcitabine|Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min. Drug infusion started 100 minutes prior to complete gross tumor removal in order to have drug administration complete at tumor removal.
3188831|NCT01276613|Experimental|Intraoperative Gemcitabine + Losartan|"Losartan 50 mg by mouth daily for one week and 50 to 100 mg of Losartan by mouth daily for at least 1 week and at most 3 weeks prior to surgical resection.~Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min. Drug infusion started 100 minutes prior to complete gross tumor removal in order to have drug administration complete at tumor removal."
3188832|NCT01276600|Experimental|Arm 1|1 tablet orally weekly
3188833|NCT01276600|Experimental|Arm 2|One tablet orally twice weekly
3188834|NCT01276600|Experimental|Arm 3|Two tablets orally twice weekly
3188835|NCT01276600|Experimental|Arm 4|One tablet orally daily
3188836|NCT01276587|Experimental|Single arm|
3188837|NCT01276561|Active Comparator|Single Incision Splenectomy|Patients will undergo splenectomy through a single incision in the umbilicus regardless of the technique or equipment used
3188838|NCT01276561|Active Comparator|Laparoscopic Splenectomy|Patient will undergo standard laparoscopic splenectomy, port placement is surgeon dependent
3188839|NCT01276548|Experimental|Genexol®-PM plus Carboplatin|
3188840|NCT01276548|Active Comparator|Genexol® plus Carboplatin|
3188841|NCT01276535|Experimental|Erchonia MLS + Erchonia THL|"The Erchonia® MLS contains 5 independent diodes: 4 each emitting 17 milliwatt (mW) 635 nanometers (nm) of red laser light and the fifth diode emitting 17 mW, 405 nm of blue laser light.~The Erchonia THL is a single diode pulsed laser that emits 4.9 milliwatts (mW) of red 635 nanometer (nm) light."
3188842|NCT01276522|Experimental|Canakinumab|A 6-month open-label, single treatment arm study of canakinumab 150 or 300 mg (in case of insufficient response to 150 mg) subcutaneous injection once per month.
3188843|NCT01276509|Placebo Comparator|Placebo-SC Injection|Placebo delivered SC, 3 doses separated by 4 weeks.
3188844|NCT01276509|Experimental|Drug Dose level 1- SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks.
3188845|NCT01276509|Experimental|Drug Dose level 2-SC injection|Drug dose level 2 delievered SC, 3 doses separated by 4 weeks.
3188846|NCT01276509|Experimental|Drug Dose level 3- SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks.
3188847|NCT01276496|Experimental|Treatment (cilengitide, paclitaxel)|"Patients receive cilengitide IV over 1 hour on days* 1, 8, and 15 and paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~NOTE: *Some patients receive cilengitide IV over 1 hour on days 1, 2, 8, 9, 15, and 16."
3188848|NCT01276457|Experimental|Upper everolimus blood target + very low dose cyclosporine|Patients received everolimus orally twice daily at a dose that was adjusted to achieve a drug blood trough level in the range of 8-12 ng/mL. Patients also received a very low dose of cyclosporine (150-300 ng/mL) orally twice daily that was adjusted to maintain a drug blood level of 200 ng/mL 2 hours after the morning dose. Both drugs were taken in the morning and again 12 hours later. The drugs were taken consistently either before, during, or after meals. No grapefruit or grapefruit juice was allowed throughout the study.
3188890|NCT01276184|Experimental|SMS Text Message|Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their scheduled appointment(s) (phone call, letter, etc, as appropriate). Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit.
3188849|NCT01276457|Active Comparator|Standard everolimus blood target + low dose cyclosporine|Patients received everolimus orally twice daily at a dose that was adjusted to achieve a drug blood trough level in the range of 3-8 ng/mL. Patients also received a low dose of cyclosporine (350-500 ng/mL) orally twice daily that was adjusted to maintain a drug blood level of 400 ng/mL 2 hours after the morning dose. Both drugs were taken in the morning and again 12 hours later. The drugs were taken consistently either before, during, or after meals. No grapefruit or grapefruit juice was allowed throughout the study.
3188850|NCT01276444|Active Comparator|Pulmonary artery catheter (PAC)|PAC was used to guide hemodynamic therapy after combined valve repair
3188851|NCT01276444|Active Comparator|COMPLEX|An combination of transpulmonary thermodilution and continuous monitoring of central venous saturation was used to guide hemodynamic therapy after combined valve repair surgery.
3188852|NCT01276431|Other|Buprenorphine transdermal patch|For two age groups: 50-60 years and >= 75 years of age
3188853|NCT01276418|Experimental|Treatment|
3188854|NCT01276405||Cohort|
3188855|NCT01276392||Heparin|10 Patients undergoing continuous renal replacement therapy using heparin for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
3188856|NCT01276392||CiCa|10 Patients undergoing continuous renal replacement therapy using citrate for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
3188857|NCT01276379|Experimental|FOLFIRI (m) or FOLFOX-6 (m) + cetuximab|FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.
3188858|NCT01276366|Active Comparator|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
3188859|NCT01276366|Active Comparator|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
3188860|NCT01276366|Active Comparator|Breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
3188861|NCT01276353|Experimental|1|
3188862|NCT01276353|Active Comparator|2|
3188863|NCT01276340||1|women with urinary incontinence
3188864|NCT01276327|Experimental|1 Linagliptin/Pioglitazone (Test)|Fixed-Dose-Combination-Tablet, oral administration with 240 mL water
3188865|NCT01276327|Experimental|2 Linagliptin + Pioglitazone (Ref)|Tablets, oral administration with 240 mL water for each treatment
3188866|NCT01276327|Experimental|3 Linagliptin/Pioglitazone (Test)|Fixed-Dose-Combination-Tablet, oral administration with 240 mL water
3188867|NCT01276327|Experimental|4 Linagliptin + Pioglitazone (Ref)|Tablets, oral administration with 240 mL water for each treatment
3188868|NCT01276314|Experimental|anti- TNF-a treatment|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF~Fill out the case report form~Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis~Etanercept administration:~The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks"
3188869|NCT01276314|Active Comparator|control group|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF~Fill out the case report form~Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis~Drug administration:~The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose."
3188870|NCT01276301|Experimental|Reference|single dose BI 10773
3188871|NCT01276301|Active Comparator|Test|single dose BI 10773 + single dose verapamil
3188872|NCT01276288|Active Comparator|Reference 1|administration of BI 10773 once daily for 5 days (20 patients)
3188873|NCT01276288|Active Comparator|Reference 2|administration of hydrochlorothiazide (HTC) once daily for 4 days (10 patients)
3188874|NCT01276288|Active Comparator|Reference 3|administration of torasemide (TOR) once daily for 4 days (10 patients)
3188875|NCT01276288|Experimental|Test 1|administration of BI 10773 + HTC once daily for 5 days (10 patients)
3188876|NCT01276288|Experimental|Test 2|administration of BI 10773 + TOR once daily for 5 days (10 patients)
3188877|NCT01276275||Exposure Group 1|First time users of ticagrelor
3188878|NCT01276275||Exposure Group 2|First time users of clopidogrel
3188879|NCT01276275||Exposure Group 3|First time users of prasugrel
3188880|NCT01276262|Placebo Comparator|Treatment A|Monophasic oral contraceptive (Microgynon® 30) with placebo tablets
3188881|NCT01276262|Experimental|Treatment B|Monophasic oral contraceptive (Microgynon® 30) and fostamatinib
3188882|NCT01276249||Fortevo Endograft|All subjects diagnosed with a qualifying AAA suitable for elective endovascular repair, who meet the inclusion/exclusion criteria for the registry, are eligible for enrollment if treated with the Fortevo Endograft.
3188883|NCT01276236|Experimental|Treatment Arm (single-arm study)|The subjects in this arm will receive Maraviroc as treatment, while continuing their current antiretroviral medication regimen.
3188884|NCT01276223|Experimental|Durezol|Difluprednate 0.05% ophthalmic emulsion, 1 drop to the study eye 2 times a day for 4 weeks, followed by 1 drop to the study eye once daily for 1 week to allow for tapering of the steroid exposure.
3188885|NCT01276223|Placebo Comparator|Vehicle|Difluprednate vehicle, 1 drop to the study eye 2 times a day for 4 weeks, followed by 1 drop to the study eye once daily for 1 week.
3188886|NCT01276210|Experimental|Treatment|See Detailed Description
3188887|NCT01276197|Experimental|Arm 1: Story-Telling DVD|Participant will receive a DVD with informational and story-telling components
3188888|NCT01276197|Active Comparator|Arm 2: Non-Storytelling DVD|Participant will receive an informational DVD
3188889|NCT01276184|No Intervention|Usual Care|Participants follow the usual practices for scheduling their follow up visit(s) for vaccination at the clinic. Participants will receive the standard reminder from the clinic for their scheduled appointment(s) (phone call, letter, etc, as appropriate).
3188891|NCT01276171|Active Comparator|Ultrasound|Participants will place arterial line using ultrasound technique
3188892|NCT01276171|Active Comparator|Doppler|Participants will place arterial line using doppler technique
3188896|NCT01276132||Subjects who are designated to receive same-day PCI|
3188897|NCT01276132||Subjects who had been admitted to the hospital after their PCI|
3188898|NCT01276119|Experimental|Cohort A, CDP6038 0.001 mg/kg, iv|
3188899|NCT01276119|Experimental|Cohort B, CDP6038 0.01 mg/kg, iv|
3188900|NCT01276119|Experimental|Cohort C, CDP6038 0.03 mg/kg, iv|
3188901|NCT01276119|Experimental|Cohort D, CDP6038 0.1 mg/kg, iv|
3188902|NCT01276119|Experimental|Cohort E, CDP6038 0.3 mg/kg, iv|
3188903|NCT01276119|Experimental|Cohort G, CDP6038 1.0 mg/kg, iv|
3188904|NCT01276119|Experimental|Cohort I, CDP6038 3.0 mg/kg, iv|
3188905|NCT01276119|Experimental|Cohort K, CDP6038 10.0 mg/kg, iv|
3188906|NCT01276119|Placebo Comparator|Cohort A, Placebo, iv|
3188907|NCT01276119|Placebo Comparator|Cohort B, C, D, E, G, I, K, Placebo, iv|
3188908|NCT01276119|Experimental|Cohort F, CDP6038 0.3 mg/kg, sc|
3188909|NCT01276119|Experimental|Cohort H, CDP6038 1.0 mg/kg, sc|
3188910|NCT01276119|Experimental|Cohort J, CDP6038 3.0 mg/kg, sc|
3188911|NCT01276119|Placebo Comparator|Cohort F, H, J, Placebo, sc|
3188912|NCT01276106|Experimental|AC-201, 25mg|25mg BID for 24 weeks
3188913|NCT01276106|Experimental|AC-201, 50mg|50mg BID for 24 weeks
3188914|NCT01276106|Experimental|AC-201, 75mg|75mg BID for 24 weeks
3188915|NCT01276106|Placebo Comparator|Placebo|Placebo BID for 24 weeks
3188916|NCT01276093|Experimental|PVI ablation|Pulmonary Vein Ablation
3188917|NCT01276093|Active Comparator|Amiodarone medical treatment|Amiodarone medical treatment
3188918|NCT01276080|Experimental|1|Donepezil Hydrochloride 10 mg Tabletof OHM Laboratories, Inc.
3188919|NCT01276080|Active Comparator|2|ARICEPT® (donepezil hydrochloride) 10 mg Tablet of Eisai, Inc.
3188920|NCT01276067|Experimental|1|Donepezil Hydrochloride 10 mg Tabletof OHM Laboratories, Inc.
3188921|NCT01276067|Active Comparator|2|ARICEPT® (donepezil hydrochloride) 10 mg Tablet of Eisai, Inc.
3188922|NCT01276054|Experimental|SNB plus ARM or ALND (+/- SNB) plus ARM|Patients undergo sentinel lymph node biopsy (SNB) and/or axillary lymph node biopsy (ALND) using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node. Patients then undergo an axillary reverse mapping.
3188923|NCT01276054|Active Comparator|SNB or ALND (+/- SNB)|Patients undergo SNB and/or ALND using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node.
3188924|NCT01276041|Experimental|pertuzumab in combination with trastuzumab and paclitaxel|This is a phase II study of pertuzumab in combination with trastuzumab and paclitaxel for the treatment of patients with Stage IV HER2 (+) breast cancer.
3188925|NCT01276028|Experimental|Acupuncture|This group will start acupuncture treatments within 3 weeks of consent and continue to receive up to 20 treatments over a six month period. The number of treatments will be jointly determined by the participant and the acupuncturist.
3188926|NCT01276028|Other|Waitlist|This group of participants will be asked to wait 6 months and will then be allowed to receive acupuncture.
3188927|NCT01276015|Experimental|botulinum toxin A|botulinum toxin A diffusion in cerebral palsy
3188928|NCT01276002|No Intervention|No stenting|Control group, no stenting of the pancreatic duct in case of a disrupted duct
3188929|NCT01276002|Active Comparator|Pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting in this arm
3188930|NCT01275989|Sham Comparator|21|sham acupuncture
3188931|NCT01275989|No Intervention|15|Control
3188932|NCT01275989|Active Comparator|20|intervention
3188933|NCT01275976|Active Comparator|C1-esterase inhibitor|C1-esterase inhibitor, 100 U/kg bodyweight
3188934|NCT01275976|Placebo Comparator|Saline 0.9%|Saline 0.9%
3188935|NCT01275963||Control|Healthy individuals without structural heart disease
3188936|NCT01275963||CAD|Patients with coronary artery disease
3188937|NCT01275963||DCM|Participants with dilated cardiomyopathy
3188938|NCT01275963||HNCM|Patients with hypertrophic non-obstructive cardiomyopathy
3188939|NCT01275963||HOCM|Patients with hypertrophic obstructive cardiomyopathy
3188940|NCT01275963||RCM|Patients with restrictive cardiomyopathy
3188941|NCT01275963||Amyloidosis|Patients with cardiac manifestation of amyloidosis
3188942|NCT01275963||HFPEF|Patients with heart failure with preserved ejection fraction (diastolic heart failure)
3188943|NCT01275937|Other|Esomeprazole|Esomeprazole 40 mg IV daily is given for three days followed by40mg once daily orally for two months.
3188944|NCT01275937|Active Comparator|esomeprazole|esomeprazole 160 mg/day continuous infusion is given for three days followed by 40mg once daily orally for two months.
3188945|NCT01275924|Active Comparator|Tightrope|Treatment with Tightrope Syndesmosis Repair Kit
3188946|NCT01275924|Active Comparator|Syndesmotic screw|Treatment with a quadricortical syndesmotic screw
3188947|NCT01275911|Experimental|Esmolol|
3188948|NCT01275911|Active Comparator|Remifentanil|
3188949|NCT01275898||Beach chair|Patients scheduled for surgical procedure in beach chair position (Shoulder surgery)
3188950|NCT01275898||Sitting position|Patients scheduled for surgical procedure in sitting position (Neurosurgery)
3188951|NCT01275898||Head down position|Patients scheduled for surgical procedure in head down position (daVinci robotic surgery)
3188952|NCT01275898||Prone position|Patients scheduled for surgical procedure in prone position
3188953|NCT01275885|Active Comparator|Vitamin D3 10µg|
3188954|NCT01275885|Active Comparator|Vitamin D3 30µg|
3188955|NCT01275885|Active Comparator|Vitamin D3 40µg|
3188956|NCT01275872|Experimental|Guided Imagery and Progressive Muscle Relaxation|
3188957|NCT01275859|Experimental|Letrozole, Lapatinib|Letrozole 2.5mg po qd + Lapatinib 1500mg po qd for 18-21 wks
3188995|NCT01275521|Active Comparator|optimized medical BPH treatment|
3188996|NCT01275508|Experimental|FITC-Adalimumab|
3189039|NCT01275287|Experimental|Eculizumab arm|"Standard of care for ANCA vasculitis + eculizumab treatment~Standard of care for ANCA vasculitis treatment- depends on severity of disease and individual characteristics and medical history of each patient so this won't be described here."
3188958|NCT01275846|Experimental|Health Guide using AHA protocols|Participants in the study will receive the use of the Intel Health Guide, a telehealth device, with AHA customized heart failure protocols, response algorithms and educational content. Participants interact with the Intel Health Guide device, receiving immediate feedback when transmitting vitals measures and health question responses to a site monitored by their nurse case managers. Nurse case managers review and address concerns raised in vitals and/or question responses through standard care protocols established by their institution. Nurse case managers strive to enhance the participants quality of life, support continuity of care, facilitate provision of services in the appropriate setting to promote positive health outcomes.
3188959|NCT01275833|Experimental|Device programming modifies AV timing|DDD-40-BiV
3188960|NCT01275833|No Intervention|Device programming allows intrinsic AV timing.|VVI-40-RV
3188961|NCT01275820||Nutralin|All 10 subjects in the study will consume the investigational food product.
3188962|NCT01275807|Experimental|acupuncture|10 acupuncture sessions
3188963|NCT01275807|Active Comparator|self care|psychological support, phisical exercice, diet, self care groups
3188964|NCT01275794||1|Patients have an established diagnosis of T2D, Age 35 years and more, Experience of therapy with one OAD during the from 6 months to 5 years before the registration in the Program
3188965|NCT01275781|Experimental|A|[14C]-AZD9742 1000 mg intravenous over 2 hours
3188966|NCT01275768|Experimental|Experimental arm|Insertion and activation of the endo-biliary RF catheter at the site of the stricture before insertion of a Self-expandable Metal Stent (SEMS)
3188967|NCT01275768|Placebo Comparator|Control arm|Insertion and sham activation of the endo-biliary RF catheter at the site of the stricture before insertion of a SEMS
3188968|NCT01275755|Placebo Comparator|Placebo|Each participant received 1 placebo capsule orally every day (QD) during the Run-in Placebo Period (1 week), the Double-blind Treatment Period (4 weeks), and the Run-out Placebo Period (1 week).
3188969|NCT01275755|Experimental|ADL5945 0.25 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally QD for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.25-milligrams (mg) ADL5945 capsule orally QD for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally QD for 1 week.
3188970|NCT01275742|No Intervention|Usual Care|
3188971|NCT01275729|Experimental|Lasix|Pt to get dose of furosemide after meeting entry criteria - dose dependent on previous exposure to diuretics
3188972|NCT01275716|Experimental|Patients who are shown the images|
3188973|NCT01275716|No Intervention|Patients who are not shown the images|
3188974|NCT01275703||patients with PH undergoing exercise testing|
3188975|NCT01275690||subjects with PH undergoing right heart catheterization|
3188976|NCT01275677|Experimental|Arm IA (docetaxel, cyclophosphamide)|Patients receive docetaxel IV over 60 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 6 courses.
3188977|NCT01275677|Experimental|Arm IB (doxorubicin hydrochloride, cyclophosphamide)|Patients receive doxorubicin hydrochloride IV over 15 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 2 or 3 weeks (at the investigator's discretion) for 4 courses. Patients then receive paclitaxel IV over 60 minutes once weekly for 12 doses.
3188978|NCT01275677|Experimental|Arm IIA (docetaxel, cyclophosphamide, trastuzumab)|Patients receive chemotherapy as in Arm IA. Patients also receive trastuzumab IV over 30-90 minutes on day 1. Trastuzumab treatment repeats every 3 weeks for 51 weeks.
3188979|NCT01275677|Experimental|Arm IIB (chemotherapy, trastuzumab)|Patients receive chemotherapy as in Arm IB. Patients also receive paclitaxel IV over 60 minutes weekly and trastuzumab IV over 30-90 minutes weekly for 12 doses. After completion of paclitaxel, patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 13 courses.
3188980|NCT01275664|Experimental|Treatment (granisetron, dexamethasone, aprepitant)|Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.
3188981|NCT01275651||Ancillary-Correlative (AR activity in CRPC)|Previously collected bone marrow tissue and blood samples are analyzed for AR activity, AR splice variations, expression of androgen transport/synthesis/metabolism genes, AKR1C3 protein levels, and testosterone and dihydrotestosterone levels via RT-PCR, SNP microarrays, IHC, gene expression analysis, and mass spectrometry methods.
3188982|NCT01275638|Placebo Comparator|Prednisolone (20 mg/day) for 10 days.|
3188983|NCT01275625|Experimental|Treatment|Single arm study of combivir and maraviroc for 48 weeks
3188984|NCT01275612|Experimental|Cell therapy|
3188985|NCT01275599|Experimental|Open-Label Arm|"The treatment period will include 3 phases:~14 day run-in period~7 day co-administration period~31 day follow-up period"
3188986|NCT01275586|Experimental|Tasigna|Following enrollment each subject will initially receive the drug Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated. Subjects will have his/her dose increased as tolerated dose during the first three months of therapy. The maximum targeted dose is 400mg twice daily.
3188987|NCT01275573|Other|healthy volunteers|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
3188988|NCT01275573|Other|painful Parkinson's disease patients|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
3188989|NCT01275573|Other|painless Parkinson's disease patients|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
3188990|NCT01275560|Experimental|Metronidazole|3 intakes per day during 10 days
3188991|NCT01275560|Active Comparator|Carbosylane|3 intakes per daysduring 10 days
3188992|NCT01275547|Experimental|S-ketamine & midazolam spray|all 20 minutes as a patient controlled analgesia alternating s-ketamine / midazolam
3188993|NCT01275547|Active Comparator|morphine, patient controlled analgesia|morphine as an active comparator as a patient controlled analgesia system
3188994|NCT01275521|Experimental|BONT-A intra-prostatic injection|
3188997|NCT01275495|Experimental|Telephone Assessment and Skill-Building Kit (TASK II)|The TASK II group will fill out a checklist about their needs and concerns, and will receive written tip sheets by mail that address the needs and concerns that they feel are most important. A nurse will call by telephone (lasting about 30 minutes or less) once a week for a total of 8 weeks, with another call at 12 weeks, to provide more information, answer questions, and to discuss more written tip sheets based on the caregiver's needs and concerns.
3188998|NCT01275495|Active Comparator|Information, Support, and Referral (ISR)|The ISR group will receive existing educational materials about stroke and caregiving developed by the American Stroke Association and weekly telephone calls by a nurse (lasting about 30 minutes or less) for a total of 8 weeks, with another call at 12 weeks.
3188999|NCT01275482|Experimental|isolated contractions caused|The investigators do TFM causing isolated contractions in de muscle fibers containing de latent trigger point.
3189000|NCT01275482|Active Comparator|No isolated contraction caused|The investigators don´t cause contraction during the TFM
3189001|NCT01275469|Experimental|GFT505 80mg|
3189002|NCT01275469|Placebo Comparator|Matching placebo|
3189003|NCT01275443|Experimental|300mg TMC278LA|Single gluteal intramuscular injection (300mg) at day 1
3189004|NCT01275443|Experimental|1200mg TMC278LA|Single gluteal intramuscular injection (1200mg) at day 1
3189005|NCT01275443|Experimental|600mg TMC278LA|Single gluteal intramuscular injection (600mg) at day 1
3189006|NCT01275443|Experimental|150mg TMC278LA|This arm was included in the adaptive design of the study, but was not recommended for use based on the review of results from 300mg and 600mg arms by the protocol steering committee
3189007|NCT01275430|Experimental|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
3189008|NCT01275430|Active Comparator|"Blind Placement"|"PICCs will be placed blindly, without the use of any tip location/positioning device."
3189009|NCT01275417||adult|100 volunteers age ranged 18-80 years old
3189010|NCT01275417||children|60 children under 10 years old.
3189011|NCT01275404|Experimental|(SMRP) + nurse practitioner information phone calls|Part A will use focus groups to gain feedback and refine the intervention. Part B will consist of a randomized pilot study where 70 men will be randomly assigned to one of two conditions: Sexual Medicine Rehabilitation (SMRP) plus nurse practitioner information phone calls and monitoring (SMRP+I), or SMRP plus the novel psychological intervention of Acceptance and Commitment Therapy for ED (SMRP+ACT-ED).
3189012|NCT01275404|Experimental|SMRP+ACT-ED|Part A will use focus groups to gain feedback and refine the intervention. Part B will consist of a randomized pilot study where 70 men will be randomly assigned to one of two conditions: Sexual Medicine Rehabilitation (SMRP) plus nurse practitioner information phone calls and monitoring (SMRP+I), or SMRP plus the novel psychological intervention of Acceptance and Commitment Therapy for ED (SMRP+ACT-ED).
3189013|NCT01275391|No Intervention|Treatment as Usual Group 1|Participants will receive treatment as usual and will complete a baseline and 1-month post-visit assessment
3189014|NCT01275391|No Intervention|Treatment as Usual Group 2|Participants will receive treatment as usual and complete only the 1-month post-visit assessment
3189015|NCT01275391|Experimental|Intervention Group 1|Computer Screening, Brief Intervention, Referral toTreatment. Participants will receive the intervention and complete a baseline and 1-month post-visit assessment
3189016|NCT01275391|Experimental|Intervention Group 2|Computer Screening, Brief Intervention, Referral toTreatment Participants will receive the intervention and complete only the 1-month post-visit assessment
3189017|NCT01275378|Active Comparator|Collaborative Care Plus|Collaborative care model with specific theory-based elements to address common reasons for ADHD treatment failure
3189018|NCT01275378|Active Comparator|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
3189019|NCT01275365|No Intervention|Placebo/Low Protein|Placebo injections weekly; 0.8 g/kg/day protein
3189020|NCT01275365|No Intervention|Placebo/High Protein|Placebo injections weekly; 1.3 g/kg/day protein
3189021|NCT01275365|Other|Testosterone/Low Protein|Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
3189022|NCT01275365|Other|Testosterone/High Protein|Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
3189023|NCT01275352|Active Comparator|Arm 1|Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele
3189024|NCT01275352|Active Comparator|Arm 2|Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele
3189025|NCT01275352|Placebo Comparator|Arm 3|Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele
3189026|NCT01275352|Placebo Comparator|Arm 4|Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele
3189027|NCT01275339|Active Comparator|Tadalafil in Diabetic Cohort|
3189028|NCT01275339|Placebo Comparator|Placebo in Diabetic Cohort|
3189029|NCT01275339|Active Comparator|Tadalafil in Non-Diabetic Cohort|
3189030|NCT01275339|Placebo Comparator|Placebo in Non-Diabetic Cohort|
3189031|NCT01275313|Experimental|Custom-Fitted Lightweight Wheelchair & Cushion|Receive a new custom-fitted lightweight wheelchair, skin protection cushion and wheelchair skills training
3189032|NCT01275313|Other|Cushion Only|Receive a skin protection cushion and wheelchair training, but remain in facility-issued wheelchair
3189033|NCT01275300|Placebo Comparator|Phase I, Period B|Period B: 5 days of placebo, followed by a single dose of 600mg niacin.
3189034|NCT01275300|Placebo Comparator|sugar pill|
3189035|NCT01275300|Placebo Comparator|low dose aspirin or placebo|5 days taking either 81 mg aspirin/placebo with at least 10 day washout in between.
3189036|NCT01275300|Active Comparator|Single dose 2 gms Niaspan for 8 days|
3189037|NCT01275300|Placebo Comparator|Celebrex / Placebo|Celebrex 200 mg/Placebo taken for 5 days, two times daily, followed by single dose of 600 mg niacin on day five. At least 10 days in between each dosing period.
3189038|NCT01275287|Active Comparator|Standard of care|Standard of care for ANCA vasculitis treatment- depends on severity of disease and individual characteristics and medical history of each patient so this won't be described here.
3189040|NCT01275274|Active Comparator|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone.
3189041|NCT01275274|Experimental|Retinoic acid|Tretinoin in addition to standard of care
3189042|NCT01275261|No Intervention|Foley catheter|Usual care - patients will have a Foley catheter placed on admission.
3189043|NCT01275261|Experimental|Nursing protocol to avoid Foley Catheter|No catheter will be placed on admission, and a nursing order protocol will be followed to avoid catheterization and avoid complications.
3189044|NCT01275248|Experimental|Ondansetron 0.5 mg|Ondansetron oral tablet 0.5 mg taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
3189045|NCT01275248|Experimental|Ondansetron 0.75 mg|Ondansetron oral tablet 0.75 mg taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
3189046|NCT01275248|Placebo Comparator|Placebo|Placebo oral tablet taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
3189047|NCT01275235||Exposure to Type II Diabetes for two siblings|Two sibling pairs with the same parents, between the ages of 20 to 34 in the Baton Rouge Area, having mother with diabetes while pregnant with one.
3189048|NCT01275222|Experimental|RAD001 + Glivec|
3189049|NCT01275209|Experimental|HCD122|
3189050|NCT01275196|Experimental|Nilotinib|
3189051|NCT01275196|Active Comparator|Imatinib|
3189052|NCT01275183|Experimental|Raltegravir and cisplatin|
3189053|NCT01275170|Experimental|Panel A Mild Renal Impairment|Participants in this arm will not participate in Part II of the study.
3189054|NCT01275170|Experimental|Panel B Healthy Participants|Participants in this arm will not participate in Part II of the study.
3189055|NCT01275170|Experimental|Panel C Moderate Renal Impairment|Participants in this arm will not participate in Part II of the study.
3189056|NCT01275170|Experimental|Panel D Healthy Participants|Participants in this arm will not participate in Part II of the study.
3189057|NCT01275170|Experimental|Panel E Severe Renal Impairment|Panel E participants will receive the probe cocktail (caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg) at Hour 0 in Part 2 of the study.
3189058|NCT01275170|Experimental|Panel F Healthy Participants|Panel F participants will receive the probe cocktail (caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg) at Hour 0 in Part 2 of the study.
3189059|NCT01275170|Experimental|Panel G End Stage Renal Disease with Dialysis|Panel G participants will receive the probe cocktail (caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg) at Hour 0 in Part 2 of the study, during both Period 1 and Period 2.
3189060|NCT01275170|Experimental|Panel H Healthy Volunteers|Panel H participants will receive the probe cocktail (caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg) at Hour 0 in Part 2 of the study.
3189061|NCT01275157|Experimental|LY2452473|15 mg, containing 100 micro curies of 14C labeled LY2452473 taken once only
3189062|NCT01275144|Experimental|LY2216684+lorazepam, placebo+lorazepam|Oral 18 mg doses of LY2216684 on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 1. Oral doses of placebo on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 2. There is a washout period of at least 7 days between dosing periods.
3189063|NCT01275144|Experimental|Placebo+Lorazepam, LY2216684+Lorazepam|Oral doses of placebo on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 1. Oral 18 mg doses of LY2216684 on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 2. There is a washout period of at least 7 days between dosing periods.
3189064|NCT01275131|Active Comparator|Stage 1: Insulin aspart first, then insulin aspart-rHuPH20|"Participants first received 0.15 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4.~After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8."
3189065|NCT01275131|Active Comparator|Stage 1: Insulin aspart-rHuPH20 first, then insulin aspart|"Participants first received 0.15 units per kilogram (U/kg) insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4.~After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart alone as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8."
3189066|NCT01275131|Active Comparator|Stage 3: Insulin aspart first, then insulin aspart + rHuPH20|"Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a sham injection was administered 2.5 hr prior to the 6-hr euglycemic clamp.~After a 5- to 14-day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the 6-hr euglycemic clamp."
3189067|NCT01275131|Active Comparator|Stage 3: Insulin aspart + rHuPH20 first, then insulin aspart|"Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6- hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the euglycemic clamp .~After a 5- to 14- day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a sham injection was administered 2.5 hr prior to the 6-hour euglycemic clamp."
3189068|NCT01275105|Other|Vehicle|
3189069|NCT01275105|Active Comparator|Brimonidine Tartrate 0.01%|
3189070|NCT01275105|Active Comparator|Oxymetazoline HCl 0.025%|
3189071|NCT01275105|Active Comparator|Brimonidine Tartrate 0.025%|
3189072|NCT01275092|Experimental|CorPath robotic-assisted PCI|CorPath 200 robotic-assisted PCI
3189073|NCT01275066|Placebo Comparator|Placebo|
3189074|NCT01275066|Experimental|BMN 110 Weekly|
3189075|NCT01275066|Experimental|BMN 110 Every Other Week|
3189076|NCT01275053|Experimental|Leptin|
3189077|NCT01275040|Experimental|Mobile screening team|The Primary Health Care clinics where the mobile screening team will visit and active screening for DM complications will take place.
3189078|NCT01275040|Active Comparator|No mobile screening team|No mobile team will visit clinics and active screening for DM complications will not be done. Patients and Health Workers will receive Education, same as intervention arm but no enhanced care.
3189079|NCT01275027|Experimental|Nutralin|Individuals with Type 2 Diabetes
3189080|NCT01275027|Placebo Comparator|Placebo|Individuals with Type 2 Diabetes
3189081|NCT01275014|Placebo Comparator|Placebo|
3189082|NCT01275014|Experimental|Dexamethasone|
3189083|NCT01275001||Intervention children|Children who are receiving a Suzuki-like violin instruction through their participation in an Early Childhood/Headstart preschool program
3189084|NCT01275001||Control Group|Preschool-age children who are not receiving Suzuki-like violin instruction
3189085|NCT01274988|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
3189086|NCT01274988|Active Comparator|Standard Control|methadone maintenance treatment
3189087|NCT01274962|Experimental|A - neoadjuvant chemotherapy|Patients in arm A will receive 6 cycles of FOLFOX chemotherapy prior to radiotherapy and surgery as well as 6 cycles of chemotherapy in adjuvant
3189088|NCT01274962|Experimental|Arm B - adjuvant chemotherapy|Patients in arm B will receive 12 cycles of FOLFOX after radiotherapy and surgery
3189089|NCT01274949|Experimental|LI-ESWT|Low intensity shock wave treatment- 12 sessions
3189090|NCT01274936|Experimental|Qishe|
3189091|NCT01274936|Placebo Comparator|Control|Qishe Placebo
3189092|NCT01274923|Sham Comparator|shock wave treatment|
3189093|NCT01274923|Sham Comparator|"MEDISPEC Sham"|"MEDISPEC Probe does not deliver energy but creates same noise and sensation of active probe"
3189094|NCT01274910|Active Comparator|Fish oil group|Treatment Group.
3189095|NCT01274910|Placebo Comparator|Control group|Placebo group
3189096|NCT01274897|Experimental|MenACWY-CRM|Subjects received one dose of MenACWY-CRM conjugate vaccine.
3189097|NCT01274897|Placebo Comparator|Placebo|Subjects received the saline placebo.
3189098|NCT01274884|Active Comparator|Acromioclavicular joint dislocation|Surgery: Arthroscopic repair using the Tightrope fixation device
3189099|NCT01274871||lung cancer surgery|
3189100|NCT01274858||lung cancer surgery|
3189101|NCT01274845|Other|Heliox|
3189102|NCT01274832||Late-treated PD patients|Patients affected by Parkinson Disease, implanted with STN DBS and with an history of disease > 10 years
3189103|NCT01274832||Early-treated PD patients|Patients affected by Parkinson Disease, implanted with STN DBS and with an history of disease <7 years
3189104|NCT01274819|Experimental|Dynamic light|ICU patients exposed to dynamic light during ICU stay
3189105|NCT01274819|No Intervention|Normal Light|control group is exposed to normal light during ICU stay
3189106|NCT01274806|No Intervention|Usual care|
3189107|NCT01274806|Experimental|Physical therapy|
3189108|NCT01274793|Active Comparator|Mosapride|In the control group were orally administered 5 mg mosapride citrate tablet s three times a day for 4 continu ous weeks if no severe adverse effects were found.
3189109|NCT01274793|Experimental|Low-dose acupuncture|In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants
3189110|NCT01274793|Experimental|High-dose acupuncture|In this group,the current was strong enough to reach the patients'tolerance threshold value.
3189111|NCT01274780|Experimental|Darunavir / Ritonavir|
3189112|NCT01274780|Experimental|Atazanavir / Ritonavir|
3189113|NCT01274767||High risk cohort|Patients having history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have a negative test for H. pylori based on histology
3189114|NCT01274767||Average risk cohort|Patients having no history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have H. pylori positive OR negative
3189115|NCT01274754||erythromycin group|Patients of erythromycin group: 25mg/kg erythromycin intravenously 12 hours before surgery and 12 hours after the end of surgery.
3189116|NCT01274754||control group|no administration of erythromycin
3189117|NCT01274741|Active Comparator|Psychotherapy for PTSD/SUD|Participants randomly assigned to this condition will attend 17 sessions of present focused psychotherapy Seeking Safety (described further under Assigned Interventions).
3189118|NCT01274741|Experimental|Integrated psychotherapy for PTSD/SUD|Participants randomly assigned to this arm will receive 17 sessions of Creating Change (described further under Assigned Interventions).
3189119|NCT01274728||ST-elevated myocardial infarction|Those with a condition of chestpain (or equal complains) and ECG changes confirming STEMI.
3189120|NCT01274715|Experimental|Behavioral Health Coaching arm|This is a single-arm, pilot study of a health behavior coaching intervention to consist of 12 sessions of coaching over a 3 month period. There is no control arm for this pilot study.
3189121|NCT01274702|Experimental|Visual Reconstitution Therapy|
3189122|NCT01274702|Active Comparator|Saccadic Eye Movement Training|
3189123|NCT01274689||cohort|cohort of consecutively enrolled patients with lagophthalmos
3189124|NCT01274676|Active Comparator|carotid stenting with MOMA|
3189125|NCT01274676|Active Comparator|Carotid stenting with filter wire EZ|
3189126|NCT01274663|Experimental|10 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
3189127|NCT01274663|Experimental|30 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
3189128|NCT01274663|Experimental|100 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
3189210|NCT01273987|Active Comparator|standard neobladder|
3189129|NCT01274663|Experimental|300 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
3189130|NCT01274663|Experimental|600 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
3189131|NCT01274663|Experimental|800 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
3189132|NCT01274663|Experimental|xxx mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
3189133|NCT01274650|Other|Decubitis Ulcer|Patients admitted to the hospital with decubitus ulcers in the ischial, sacral, or coccyx area.
3189134|NCT01274637|Experimental|low molecular weight heparin|Prophylactic-dose (5000 IU/0.2ml)low molecular weight heparin (LMWH), administered subcutaneously once daily in pre-filled glass syringes for 10 days (+/- 3 days) for a total of 10 (+/-3) study drug injections.
3189135|NCT01274637|No Intervention|Control Group|No treatment control group.
3189136|NCT01274611|Active Comparator|Suction-Curettage|
3189137|NCT01274611|Experimental|Botox|
3189138|NCT01274598|Experimental|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|Lactobacillus rhamnosus GG ATCC 53103 1 x 10^10 twice a day for 28 days
3189139|NCT01274585|Sham Comparator|No active treatment|
3189140|NCT01274585|Experimental|stimulation/treatment|
3189141|NCT01274559|Experimental|Extended-release niacin/laropiprant|ERN/LRPT 1 g (1 tablet for 4 wks) followed by ERN/LRPT 2 g (2 tablets for 8 wks); Each 1-g tablet contains 1 g of ER niacin and 20 mg of laropiprant.
3189142|NCT01274559|Placebo Comparator|Placebo|Matching 1 g Placebo (1 tablet for 4 wks) followed by 2 g placebo (2 tablets for 8 weeks)
3189143|NCT01274546||"In Office"|These subjects will come into the office to perform the consenting process, and complete all evaluations required at the only visit in the study.
3189144|NCT01274546||"Telephone Arm"|These subjects will be consented over the phone and give a verbal consent to participate. They will complete all aspects of the study over the phone except for the knee society score evaluation and the x-ray.
3189145|NCT01274533|Experimental|Lenalidomide|Oral lenalidomide is initiated on Day 1 of Cycle 1 and continues once daily days 1-21 of a 28 day cycle. Subjects may continue participation in the Treatment Phase of the study for 24 months unless disease progression or drug is discontinued for safety reasons.
3189146|NCT01274520|Experimental|Medtronic Portable Bypass System|The Medtronic Portable Bypass System (PBS®) with Model 550 Bioconsole and the BioCal® blood temperature control module will be used for machine perfusion of liver grafts. These products are commercially available and used in clinical practice for cardiopulmonary bypass and extracorporeal membrane oxygenation. The Medtronic system utilizes an atraumatic centrifugal pump that can deliver the flow rates approximating portal venous flow in human livers, and it has modules for online membrane oxygenation, and electronic flow measurement.
3189147|NCT01274520|No Intervention|Matched control group|The proposed study is a matched cohort design. Subjects will be matched with 24 historical control patients who received similar cold stored ECD grafts. Subjects will be matched on known covariates including donor age, donation after cardiac death, steatosis, both warm and cold ischemia times, recipient age, MELD score and disease etiology. Additional analyses will be performed on historical control blood and/or tissue samples previously collected and stored in the study's sample repository.
3189148|NCT01274507|Other|All participants|
3189149|NCT01274481|Experimental|Iloprost|All patients will have their response to Iloprost compared to baseline pre-treatment.
3189150|NCT01274455|Experimental|Therapy|
3189151|NCT01274442|Active Comparator|CONTROL: no dental implants lost|Group of patients who received an implant during a dental implant surgery in the University Hospital in Ghent in 2004-2007, who did not lose their implants.
3189152|NCT01274442|Experimental|CASE: patients lost one or more implants|Group of patients who received an implant during a dental implant surgery in the University Hospital in Ghent in 2004-2007, but who lost one or more implants.
3189153|NCT01274429|Experimental|Open label peanut flour|Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.
3189154|NCT01274403|Experimental|Melphalan, prednisone plus Thalidomide|
3189155|NCT01274403|Active Comparator|Melphalan and Prednisone|
3189156|NCT01274390||Shorter-storage red blood cell units|Red blood cell units stored <= 10 days
3189157|NCT01274390||Longer-storage red blood cell units|Red blood cell units stored >= 21 days
3189158|NCT01274377|Experimental|Recipients Using 3-5/6 Matched Donors|There will be an equal number of subjects (10) receiving transplants from 3-5/6 Human Leukocyte Antigen (HLA) Matched Donors as those receiving transplants from 6/6 HLA Matched Donors for a total of 20 subjects on study.
3189159|NCT01274377|Experimental|Recipients Using 6/6 Matched Donors|There will be an equal number of subjects (10) receiving transplants from 3-5/6 HLA Matched Donors as those receiving transplants from 6/6 HLA Matched Donors for a total of 20 subjects on study.
3189160|NCT01274364|Experimental|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
3189161|NCT01274364|Active Comparator|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
3189162|NCT01274351|Experimental|Nilotinib|
3189163|NCT01274338|Experimental|Arm A (age >= 18, high-dose ipilimumab)|Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (closed accrual as of 4/4/14) (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
3189211|NCT01273974|Experimental|intradermal influenza vaccine|
3189212|NCT01273974|Active Comparator|intramuscular influenza vaccine|
3189292|NCT01273337|Experimental|ALD-401|ALD-401 is derived from Autologous Bone Marrow of the Stroke Subject
3189164|NCT01274338|Experimental|Arm B (age >= 18, recombinant interferon alfa-2b)|Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
3189165|NCT01274338|Experimental|Arm C (age >= 18, low-dose ipilimumab)|Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
3189166|NCT01274338|Experimental|Arm D (age 12-17, high-dose ipilimumab)|Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.
3189167|NCT01274338|Experimental|Arm E (ages 12-17, recombinant interferon alfa-2b)|Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (ages 12-17)
3189168|NCT01274338|Experimental|Arm F (ages 12-17, low-dose ipilimumab)|Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (ages 12-17)
3189169|NCT01274325|Experimental|Sereflo|Sereflo (25/125)
3189170|NCT01274325|Active Comparator|Seretide|Seretide (25/125)
3189171|NCT01274299||Infants|Healthy 0-4 years of age both boys and girls
3189172|NCT01274273|Experimental|Interleukin-2, interferon, bevacizumab|
3189173|NCT01274273|Active Comparator|Interleukin-2 and interferon-alfa|
3189174|NCT01274260|Active Comparator|Experimental Group|Intervention: Subjects in this study group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
3189175|NCT01274260|Placebo Comparator|Placebo Group|Intervention: The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline. The placebo group with receive the masked study drug in infusion rates that mimic the infusions received by the experimental group.
3189176|NCT01274247|Active Comparator|Topical Benzocaine|For infants treated with topical benzocaine prior to the procedure
3189177|NCT01274247|No Intervention|no benzocaine|No benzocaine applied
3189178|NCT01274234|Experimental|COMBO Stent|COMBO Stent
3189179|NCT01274221|Placebo Comparator|Placebo|
3189180|NCT01274221|Active Comparator|SPD489|
3189181|NCT01274208||Gaucher Disease with Hepatitis C|
3189182|NCT01274195|Experimental|Busulfan|
3189183|NCT01274182|Experimental|GP2013|
3189184|NCT01274182|Active Comparator|MabThera|
3189185|NCT01274182|Active Comparator|Rituxan|
3189186|NCT01274156|Active Comparator|shock wave treatment|
3189187|NCT01274156|Sham Comparator|"MEDISPEC Sham"|"MEDISPEC Probe does not deliver energy but creates same noise and sensation of active probe"
3189188|NCT01274143|Active Comparator|Telephone-delivered risk intervention|Participants in this arm receive a personalized telephone-risk assessment intervention provided by a trained cancer risk counselor.
3189189|NCT01274143|Active Comparator|Mailed pamphlet intervention group|Participants in this group receive a mailed pamphlet containing information about familial colorectal cancer risk and screening.
3189190|NCT01274130|Experimental|Ranitidine|
3189191|NCT01274130|Experimental|Verapamil|
3189192|NCT01274117|Placebo Comparator|One-stage transposition of the basilic vein|One-stage transposition of the basilic vein
3189193|NCT01274117|Experimental|Two-stage transposition of the basilic vein|Two-stage transposition of the basilic vein
3189194|NCT01274104|Active Comparator|Vitamin D|Subjects will take 5,000 IU-capsules of vitamin D3 three times a day (for a total of 15,000 IU) for 14 days
3189195|NCT01274104|Placebo Comparator|Control|Subjects will take 3 capsules of placebo every day for 14 days
3189196|NCT01274091|Experimental|P/S-ratio 1.0|"Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:~polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0."
3189197|NCT01274091|Experimental|P/S-ration 0.3|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:. Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
3189198|NCT01274078|No Intervention|conventional food|Regular eating habits during exercise period
3189199|NCT01274078|Active Comparator|Blueberries|Intervention: Addition of blueberries (150g/day) to regular food during the exercise period on days with exercise
3189200|NCT01274065||Psychiatric illnesses|Participants will reside at the South Dakota Developmental Center (SDDC), which serves a unique population of people with developmental disabilities and co-occuring psychiatric disorders.
3189201|NCT01274052||Gestational Diabetes Mellitus|Women with Gestational Diabetes Mellitus
3189202|NCT01274052||Normal Glucose Tolerance|Women with Normal Glucose Tolerance
3189203|NCT01274039||Patient with a trabeculectomy planed|
3189204|NCT01274013||Study Group|Individuals with chronic Hepatitis C
3189205|NCT01274013||Control Group|Healthy individuals
3189206|NCT01274000|Placebo Comparator|placebo group|
3189207|NCT01274000|Experimental|YM060 low-dose group|
3189208|NCT01274000|Experimental|YM060 middle-dose group|
3189209|NCT01274000|Experimental|YM060 high-dose group|
3189213|NCT01273948|Experimental|Bavituximab 3 mg/kg|Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
3189214|NCT01273948|Experimental|Bavituximab 0.3 mg/kg|Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
3189215|NCT01273948|Active Comparator|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
3189216|NCT01273935||Responder|Responder versus Non-Responder as a result of platelet function test
3189217|NCT01273935||Non-Responder|According to the result of platelet function test
3189218|NCT01273922|Placebo Comparator|Low Dose NDV-3 investigational vaccine|15 subjects will receive vaccine and 5 subjects will receive placebo.
3189219|NCT01273922|Placebo Comparator|High Dose NDV-3 investigational vaccine|15 subjects will receive vaccine and 5 subjects will receive placebo
3189220|NCT01273909||Perforator Flap Breast Reconstruction|Patients who undergo perforator flap breast reconstruction with or without concomitant vascularized lymph node transfer
3189221|NCT01273909||Vascularized Lymph Node Transfer|Patients who undergo perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction
3189222|NCT01273896|Experimental|STA-9090|This will be a monotherapy, open-label phase 2 study of STA-9090 in patients who have metastatic breast cancer.
3189223|NCT01273883|Experimental|Magnesium first, then placebo|Magnesium 532 mg daily for 25 days followed by 2 weeks of washout followed by 25 days of placebo.
3189224|NCT01273883|Placebo Comparator|Placebo first, then magnesium|Placebo daily for 25 days followed by 2 weeks of washout followed by magnesium 532 mg daily for 25 days.
3189225|NCT01273857|Sham Comparator|Control|Subjects will undergo standard staged-procedures without cell infusion
3189226|NCT01273857|Experimental|Cell infusion|Subjects will receive transcoronary infusion of autologous cardiosphere-derived cells 1 month after staged shunt procedure
3189227|NCT01273844|Experimental|Bortezomib|Patients will receive two 21-day cycles of induction therapy with vel / dex regimen. Bortezomib 1.3mg/m2 on days 1, 4, 8 and 11 will be given by intravenous bolus injection while Dexamethasone 40 mg/d will be taken orally on days 1-4.
3189228|NCT01273831|Other|atracurium|Patients who underwent general anesthesia received atracurium
3189229|NCT01273831|Other|cisatracurium|Patients who underwent general anesthesia received cisatracurium
3189230|NCT01273818|Active Comparator|gentamicin|80 mg gentamicin topical application intraoperatively
3189231|NCT01273818|Active Comparator|Cefazolin|Application of 1000 mg cefazolin intra venously 1 hour before surgery
3189232|NCT01273818|Active Comparator|gentamicin and cefazolin|1000 mg cefazolin application 1 hour before surgery and topical 80 mg gentamicin intraoperatively
3189233|NCT01273805|Experimental|Hydroxychloroquine 400 mg b.i.d.|Patients received 400 mg hydroxychloroquine orally twice per day. Cycle duration was 4 weeks. Patients remained on treatment indefinitely without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision.
3189234|NCT01273805|Experimental|Hydroxychloroquine 600 mg b.i.d.|Patients received 600 mg hydroxychloroquine orally twice per day. Cycle duration was 4 weeks. Patients remained on treatment indefinitely without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision.
3189235|NCT01273792||Patients with Susac syndrome|
3189236|NCT01273792||Matched healthy controls|
3189237|NCT01273779|Placebo Comparator|Placebo|
3189238|NCT01273779|Experimental|Talactoferrin alfa|
3189239|NCT01273766|Experimental|Arm I|Patients receive oral deferasirox once daily for up to 6 months or until blood counts recover in the absence of disease progression or unacceptable toxicity.
3189240|NCT01273766|No Intervention|control arm|blood tested on healthy patients
3189241|NCT01273766|No Intervention|correlative|treated off study with or without oral deferasirox (patient choice) but lab draws to gather lab analysis
3189242|NCT01273753|Active Comparator|Exercise|After baseline measurements, all subjects will undergo a phase involving intradialytic exercise. Subjects will serve as their own controls.
3189243|NCT01273740|Experimental|External support|Bypass graft with external support
3189244|NCT01273740|Experimental|No external support|Bypass with graft without external support
3189245|NCT01273727|No Intervention|No Ozurdex|Arm 1(control) - Patients who have had epi-retinal membrane peeling and have macular edema at least 3 months (90 days) after surgery. These patients will followed without Ozurdex. The patients will be treated with current standard of care, including topical and intravitreal or subtenon's medication.
3189246|NCT01273727|Experimental|Ozurdex 3 months after surgery|Patients who have had epi-retinal membrane peeling and have residual macular edema 3 months after surgery. These patients will receive an Ozurdex implant
3189247|NCT01273727|Experimental|Ozurdex 6 months or longer after surgery|Patients who have had epiretinal membrane peeling and have residual macular edema at least 6 months after surgery
3189248|NCT01273714|Active Comparator|BST|bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each)
3189249|NCT01273714|Experimental|TT|extracapsular total thyroidectomy
3189250|NCT01273701|Experimental|TSTSU-N|TSTSU-N stands for Treatment for Schedule Two Substance Use, No Telephone Reminding. Subjects will be referred by the Yunlin District Prosecutors Office for one-year psychosocial interventions to get slow prosecutions. After the referral, they will be randomized in a 1:1 ratio to either TSTSU-N group or TSTSU-T group. During the intervention, subjects of TSTSU-N will not receive telephone reminding before each visit.
3189251|NCT01273701|Experimental|TSTSU-T|TSTSU-T stands for Treatment for Schedule Two Substance Use, Telephone Reminding. Subjects will be referred by the Yunlin District Prosecutors Office for one-year psychosocial interventions to get slow prosecutions. After the referral, they will be randomized in a 1:1 ratio to either TSTSU-N group or TSTSU-T group. During the intervention, subjects of TSTSU-T will receive telephone reminding before each visit.
3189293|NCT01273337|Sham Comparator|Sham Comparitor|Sham Bone Marrow harvest and sham dosing procedure.
3189252|NCT01273701|Active Comparator|OPD|OPD stands for Outpatient Department. Subjects in this arm will be methamphetamine users who voluntarily visit psychiatric clinics for treatment of mental disorders in National Taiwan University Hospital, Yunlin Branch. They will be referred to this study by their treating psychiatrists.
3189253|NCT01273688|Active Comparator|Eccentric training only|Eccentric training only active control group (Flex-Bar)
3189254|NCT01273688|Experimental|Eccentric training and elbow brace|Combined eccentric training (Flex-Bar) and elbow brace (Epi-Hit)
3189255|NCT01273662|Experimental|Axitinib|
3189256|NCT01273649|Experimental|ice, rate of force development|to monitor the long term effect of cryotherapy in rate of force development.
3189257|NCT01273623|Experimental|Patients with PAD|Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention who have moderate to severe obstructive intraluminal calcium
3189258|NCT01273610|Experimental|Lapatinib and trastuzumab|Patients receive lapatinib ditosylate PO QD and trastuzumab IV once weekly OR once every 3 weeks. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3189259|NCT01273597||End-stage kidney disease with secondary hyperparathyroidism|Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)
3189260|NCT01273584|Active Comparator|Metformin|"Tablet Metformin 500 mg, starting dose of 1 tablet twice a day with meals, gradually titrated upwards by 1 tablet every week to a maximum dose of 2 tablets three times a day.~Tablets started at recruitment and continued till the delivery of the baby"
3189261|NCT01273584|Placebo Comparator|Placebo|"Tablet Placebo 500 mg, starting dose of 1 tablet twice a day with meals, gradually titrated upwards by 1 tablet every week to a maximum dose of 2 tablets three times a day.~Tablets started at recruitment and continued till the delivery of the baby"
3189262|NCT01273571|Experimental|001|Canagliflozin/Metformin Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8 followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
3189263|NCT01273558|No Intervention|Part 1: no Intervention|In Part 1 of the study, patients will not receive any study drug.
3189264|NCT01273558|Experimental|Part 2: canagliflozin|In Part 2 of the study, patients will receive canagliflozin once daily on Days 1 through 8.
3189265|NCT01273545||001|PRILIGY (dapoxetine hydrochloride) The study will observe characteristics of the patients to whom PRILIGY 30-mg and 60-mg tablets are prescribed in Germany by general practitioners and (separately) by urologists and in Italy by urologists
3189266|NCT01273532|Experimental|001|tapentadol (CG5503) ER 50-mg TRF 100 mg TRF single oral dose
3189267|NCT01273532|Experimental|002|tapentadol (CG5503) ER 100-mg TRF 100mg TRF single oral dose
3189268|NCT01273519||RA, PsA, AS|Participants with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) prescribed Humira (adalimumab) in the usual manner and in accordance with the terms of the local marketing authorization with regards to dose, population and indication.
3189269|NCT01273506|Experimental|001|tapentadol (CG5503) ER 25-mg TRF 50 mg TRF single oral dose
3189270|NCT01273506|Experimental|002|tapentadol (CG5503) ER 50-mg TRF 50 mg TRF single oral dose
3189271|NCT01273493|Experimental|Trabectedin 1.3 mg/m^2 plus Dexamethasone|Control group Trabectedin 1.3 mg/m^2 i.v.will be administered on Day 1. Dexamethasone will be administered 30 minutes prior to trabectedin.
3189272|NCT01273493|Experimental|Trabectedin 0.58 mg/m^2 plus Dexamethasone|Hepatic dysfunction group Trabectedin 0.58 mg/m^2 (or adjusted dose) i.v. will be administered on Day 1. Dexamethasone will be administered 30 minutes prior to trabectedin.
3189273|NCT01273480|Experimental|002|Sequence 2 Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
3189274|NCT01273480|Experimental|001|Sequence 1 Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
3189275|NCT01273467|Experimental|001|CNTO 0007 or placebo (Stage A) a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
3189276|NCT01273467|Experimental|002|CNTO 0007 or placebo (Stage B) a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
3189277|NCT01273454||001|OROS Hydromorphone 8 16 32 mg once a day for 4 weeks
3189278|NCT01273441|Active Comparator|Sequential treatment:|
3189279|NCT01273441|Experimental|Concomitant treatment|
3189280|NCT01273428|Active Comparator|HP011-101|
3189281|NCT01273428|Active Comparator|HP828-101|
3189282|NCT01273428|Other|Standard Care|
3189283|NCT01273415||hormone receptor-positive breast cancer|postoperative hormone receptor-positive breast cancer
3189284|NCT01273402|Experimental|TF2 and IMP288|TF2 will be administered at least 4 days before the radiolabeled IMP-288.
3189285|NCT01273389|Experimental|CNTO 136|CNTO 136 is used in the form of final vialed product, as a single-use, sterile solution in a 2 ml glass vial. Each 1 mL of the solution contains sirukumab 100mg active drug substance, sorbitol, acetate buffer, and polysorbate 20, at a pH of 5.0, without any preservatives.
3189286|NCT01273389|Placebo Comparator|Placebo|
3189287|NCT01273376|Experimental|RX-10100 high dose|"RX-10100~Study drug is to be given orally, in tablet form, twice daily, for 8 weeks"
3189288|NCT01273376|Experimental|RX-10100 low dose|"RX-10100~Study drug is to be given orally, in tablet form, twice daily, for 8 weeks"
3189289|NCT01273376|Placebo Comparator|Placebo|Matching placebo is to be given orally, in tablet form, twice daily, for 8 weeks
3189290|NCT01273363||1|Male and female over 18. Patients with asthma diagnosed in accordance with the Global Initiative for Asthma within 6 months before inclusion into the study and without changes in treatment for 2 months before inclusion
3189291|NCT01273350|Other|Single arm|"Single arm observational study looking at a low risk cohort of individuals with carotid stenosis"
3189294|NCT01273324||ADM|ADM Cup
3189296|NCT01273298|Placebo Comparator|Sugar pill|
3189297|NCT01273272|Experimental|Cognitive Behavioral Therapy (CBT)|Comprehensive, CBT-based, multi-component treatment. Comprehensive CBT intervention in addition to standard treatment
3189298|NCT01273272|Active Comparator|Treatment as usual (TAU)|Standard Treatment (medical and psychosocial)
3189299|NCT01273259|Experimental|200 mg /day arm|
3189300|NCT01273259|Experimental|25 mg/day arm|
3189301|NCT01273246|Experimental|Children Group 1: 200U EV71 vaccine|12 children received 3 doses of 200U EV71 vaccine 28 days apart
3189302|NCT01273246|Placebo Comparator|Children Group 1: Placebo|6 children received 3 doses of placebo 28 days apart
3189303|NCT01273246|Experimental|Children Group 2: 400U EV71 vaccine|12 children received 3 doses of 400U EV71 vaccine 28 days apart
3189304|NCT01273246|Placebo Comparator|Children Group 2: Placebo|6 children received 3 doses of placebo 28 days apart
3189305|NCT01273246|Experimental|Infants Group 1: 100U EV71 vaccine|24 infants received 3 doses of 100U EV71 vaccine 28 days apart
3189306|NCT01273246|Placebo Comparator|Infants Group 1: Placebo|8 infants received 3 doses of placebo 28 days apart
3189307|NCT01273246|Experimental|Infants Group 2: 200U EV71 vaccine|24 infants received 3 doses of 200U EV71 vaccine 28 days apart
3189308|NCT01273246|Placebo Comparator|Infants Group 2: Placebo|8 infants received 3 doses of placebo 28 days apart
3189309|NCT01273246|Experimental|Infants Group 3: 400U EV71 vaccine|24 infants received 3 doses of 400U EV71 vaccine 28 days apart
3189310|NCT01273246|Placebo Comparator|Infants Group 3: Placebo|8 infants received 3 doses of placebo 28 days apart
3189311|NCT01273233|Experimental|Group 1: 200U EV71 vaccine|12 adults received 3 doses of 200U EV71 vaccine 14 days apart
3189312|NCT01273233|Experimental|Group 2: 400U EV71 vaccine|12 adults received 3 doses of 400U EV71 vaccine 14 days apart
3189313|NCT01273233|Placebo Comparator|Group 1: Placebo|6 adults received 3 doses of placebo 14 days apart
3189314|NCT01273233|Placebo Comparator|Group 2: Placebo|6 adults received 3 doses of placebo 14 days apart
3189315|NCT01273207|Experimental|1|Subjects will continue self administration of aerosolized cyclosporine A in solution with propylene glycol using a Sidestream nebulizer with the Invacare Mobilaire compressor at 30 psi at the maximum tolerated dose established during participation on the initial protocol (Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans), 3 times weekly (150 mg to 300 mg inhalation dose, total volume 2.4 to 4.8 ml).
3189316|NCT01273181|Experimental|Ph I:Anti-MAGE A3/12 TCR PBL 5x10e9|"Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase I: The study will begin by evaluating the safety of two ranges of cells, 5x10^9-3x10^10, and greater than 3x10^10-1x10^11 in a standard phase I dose escalation fashion using a 3+3 design."
3189317|NCT01273181|Experimental|Ph I:Anti-MAGE A3/12 TCR PBL 3x10e10|"Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase I: The study will begin by evaluating the safety of two ranges of cells, 5x10^9-3x10^10, and greater than 3x10^10-1x10^11 in a standard phase I dose escalation fashion using a 3+3 design."
3189318|NCT01273181|Experimental|Ph II:Anti-MAGE TCR PBL MTD+HD IL-2|"Phase II:Anti-MAGE A3/12 TCR PBL MTD + HD IL-2, Melanoma, RCC~Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase II:patients will be entered into two cohorts based on histology:cohort 1 will include patients with metastatic melanoma or renal cell cancer; cohort 2 will include patients with other types of metastatic cancer."
3189319|NCT01273181|Experimental|Ph II:Anti-MAGE A3/12 TCR PBL MTD|"Phase II: Anti-MAGE A3/12 TCR PBL MTD + HD-IL2 Other Cancer~Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase II:patients will be entered into two cohorts based on histology:cohort 1 will include patients with metastatic melanoma or renal cell cancer; cohort 2 will include patients with other types of metastatic cancer."
3189320|NCT01273168|Experimental|0|Z-endoxifen will be administered orally once a day in 28-day cycles
3189321|NCT01273155|Experimental|Cohorts1-4|Four cohorts: normal, mild, moderate, and severe hepatic dysfunction
3189322|NCT01273116|Experimental|CWS in Hospital|CWS in Hospital in addition to usual care
3189323|NCT01273103|Experimental|Treatment|[14C]- GSK2248761 200 mg
3189324|NCT01273090|Experimental|Treatment|
3189325|NCT01273077||Evaluation of Rotarix Program|All infants in Nova Scotia DHA 9 and PEI born after October1, 2010 until September 31, 2012 will be eligible for Rotarix immunization as part of the publicly funded immunization program. New Brunswick will serve as the non-intervention control location.
3189326|NCT01273077||Retrospective Surveillance|All laboratory- confirmed cases of rotavirus gastroenteritis and all cause diarrhea admitted to the trial hospitals from 2008-2010 will be entered in the database.
3189327|NCT01273077||Prospective Surveillance|Will begin on December 1, 2010. Data will be collected to identify hospitalizations for all cause diarrhea and rotavirus gastroenteritis at all 3 sites through the first two consecutive rotavirus seasons following vaccination.
3189328|NCT01273077||Safety Intussusception|Each trial hospital will identify cases of severe diarrhea and intussusception in Rotarix vaccine recipients through the first two consecutive rotavirus seasons following vaccination.
3189329|NCT01273077||ED Rotavirus Snap Shot Study|During rotavirus peak season, a prospective study of a sample of children under the age of 2 years presenting with diarrhea with or without vomiting to the ER of participating trial centers will be conducted.
3189330|NCT01273077||KAB Questionnaire for HCP and Parents|Data will be collected by a validated survey given to Parents, Healthcare providers and Program organizers throughout the 2 year program.
3189331|NCT01273064|Experimental|CTS-1027 60 mg + ribavirin + peglyated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027, 60 mg (supplied in a blinded kit containing two bottles of 30 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 120 mg.
3189332|NCT01273064|Experimental|CTS-1027 30 mg + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027 30 mg, supplied in a blinded kit containing one bottle of 30 mg tablets, and one bottle of placebo tablets (in order to maintain blind). One tablet from each of the bottles is taken twice daily, for a total daily dose of 60 mg of CTS-1027.
3189333|NCT01273064|Experimental|CTS-1027 15 mg + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027 15 mg (supplied in a blinded kit containing one bottle each of of 5 mg and 10 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 30 mg.
3189334|NCT01273064|Active Comparator|placebo + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus placebo (supplied in a blinded kit containing two bottles of placebo tablets). One tablet is taken from each of the placebo bottles twice daily, for a total daily dose of 4 tablets.
3189335|NCT01273038|Active Comparator|SenSura|The reference product is the CE marked and launched SenSura product which is commercially available
3189336|NCT01273038|Experimental|Morfeus|The test product is the product with the proposed new Morfeus filter
3189337|NCT01273012|Placebo Comparator|Placebo|The group of patients treated with placebo.
3189338|NCT01273012|Experimental|Infloran|The group of patients treated with Infloran.
3189339|NCT01272999||1|Otitis media cases
3189340|NCT01272986|Placebo Comparator|Healthy patients|
3189341|NCT01272986|Active Comparator|Asymptomatic myocardial Ischemic patients|
3189342|NCT01272986|Active Comparator|Acute Coronary Syndrome Patients|
3189343|NCT01272973|Experimental|Oral 1|
3189344|NCT01272973|Experimental|Oral 2|
3189345|NCT01272973|Experimental|Oral 3|
3189346|NCT01272973|Active Comparator|S.c.|
3189347|NCT01272960|Active Comparator|Interval Insertion|Will receive Mirena at 4-8 weeks post-partum after vaginal delivery.
3189348|NCT01272960|Experimental|Post-Placental Mirena Insertion|Will receive Mirena insertion within 10 minutes of delivery of placenta
3189349|NCT01272947|Experimental|Diclofenac sodium topical gel 1%|
3189350|NCT01272947|Placebo Comparator|placebo|
3189351|NCT01272934|Placebo Comparator|Placebo|
3189352|NCT01272934|Experimental|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%
3189353|NCT01272921|Active Comparator|Bupivacaine|Varying does to determine duration of analgesia following a sciatic nerve block
3189354|NCT01272921|Active Comparator|Ropivacaine|Varying does to determine duration of analgesia following a sciatic nerve block
3189355|NCT01272908|Experimental|Single arm|
3189356|NCT01272895|Experimental|GENOUS stent|
3189357|NCT01272882|Experimental|Adults with ARDS or ALI|Adults with PaO2/FiO2 ratio less than 300. Consented patients will be placed on EIT monitor. The only intervention is the addition of Electrical Impedance Tomography monitoring using the Chest belt with 16 electrodes connected to the EIT device. No changes to standard patient care will occur other than collecting EIT monitor data.
3189358|NCT01272869|Active Comparator|Sensura|SenSura is the reference product and the product is already commercially available
3189359|NCT01272869|Experimental|Morfeus|The test product is the product with the proposed new filter (Morfeus)
3189360|NCT01272856|Experimental|Open Label Abatacept|
3189361|NCT01272843||Carotid endarterectomy patients|
3189362|NCT01272843||Lumbar stenosis laminectomy patients|
3189363|NCT01272830|Experimental|oral Apatone®B|An amalgam of Vitamins C & K3
3189364|NCT01272830|Placebo Comparator|Placebo|Oral capsule of similar appearance and taste without Apatone®B
3189365|NCT01272817|Other|Cladribine + melphalan|Cladribine + melphalan conditioning
3189366|NCT01272817|Other|TLI|Total lymphoid irradiation conditioning
3189367|NCT01272804|Experimental|PF-04937319|
3189368|NCT01272804|Placebo Comparator|Placebo|
3189369|NCT01272791|Experimental|Gemcitabine, bavituximab|Gemcitabine will be administered on Days 1, 8, 15 of each 28-day (4 weeks) cycle until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will receive 3 mg/kg weekly (in addition to gemcitabine) until disease progression or unacceptable toxicities
3189370|NCT01272791|Active Comparator|Gemcitabine|Patients randomized to Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities.
3189371|NCT01272778|Experimental|Lorazepam 0.2 mg|All subjects receive lorazepam 0.2 mg in this crossover design.
3189372|NCT01272778|Experimental|Lorazepam, 0.5 mg|All subjects receive lorazepam 0.5 mg in this crossover design.
3189373|NCT01272778|Experimental|Lorazepam, 1.0 mg|All subjects receive lorazepam 1.0 mg in this crossover design.
3189374|NCT01272778|Experimental|Lorazepam, 2.0 mg|All subjects receive lorazepam 2.0 mg in this crossover design
3189375|NCT01272778|Placebo Comparator|Sugar pill|All subjects receive a sugar pill in this crossover design.
3189376|NCT01272765|Placebo Comparator|Control Group|
3189377|NCT01272765|Experimental|Risperdal Group|Subjects who are on a stable dose of Ripserdal and taking 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
3189378|NCT01272765|Experimental|Seroquel Group|Subjects who are on a stable dose of Seroquel and taking 500 mg of IHBG-10 15 minutes before the three main meals of the day.
3189379|NCT01272765|Experimental|Zyprexa Group|Subjects who are on a stable dose of Zyprexa and taking 500 mg of IHBG-10 15 minutes prior to the three main meals of the day.
3189380|NCT01272752|Experimental|Study Group|Subjects will take 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
3189381|NCT01272752|Placebo Comparator|Control Group|Subjects will take a placebo 15 minutes prior to the three main meals of the day.
3189382|NCT01272739|Experimental|Study Group|Subjects will take 500 mg of the investigational product 15 minutes prior to the 3 main meals of the day.
3189383|NCT01272739|Placebo Comparator|Control Group|Subjects will take a placebo 15 minutes prior to the three main meals of the day.
3189384|NCT01272726||ADHD|Women with symptoms of ADHD. Women who either think they may have ADHD or have been previously diagnosed with ADHD but have not been treated for it.
3189385|NCT01272713|Other|Oxygen therapy|"Standard acute coronary syndrome treatment as per hospital protocol~Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min~In-hospital oxygen as per hospital protocol"
3189386|NCT01272713|Other|No oxygen therapy|"Standard acute coronary syndrome treatment as per hospital protocol~No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%."
3189387|NCT01272700|Experimental|PCV|Peak airway pressure were set to deliver a tidal volume of 10 ml/kg of ideal body weight
3189388|NCT01272700|Active Comparator|VCV|After anesthetic induction, anesthesia maching were set to deliver a tidal volume of 10 ml/kg of ideal body weight
3189389|NCT01272687||Observation|all adult Patients at 18 years with a confirmed diagnosis of Parkinson's disease
3189390|NCT01272674|Active Comparator|exercise training|4 weeks of supervised physical exercise training
3189391|NCT01272674|No Intervention|control|sedentary lifestyle
3189392|NCT01272674|No Intervention|healthy control|
3189393|NCT01272661|Active Comparator|Enhanced Curriculum|New Enhanced Breastfeeding Curriculum with 11 brief modules
3189394|NCT01272661|Active Comparator|Enhanced Curriculum+Breastfeeding Doula|"Enhanced Curriculum + mother selects a support person to learn about breastfeeding with her and support her postpartum (breastfeeding doula)"
3189395|NCT01272661|Active Comparator|Enhanced Curriculum +Father Support|Enhanced Curriculum+ mother provides father-friendly information about breastfeeding to her partner plus an invitation to an educational group for fathers
3189396|NCT01272648|Active Comparator|Rehabilitation|note intervention
3189397|NCT01272648|Placebo Comparator|Control|same radiotherapy but no rehabilitation
3189398|NCT01272635|Experimental|Azythromycin (APRIL) and Prednisolone (OCELOT)|
3189399|NCT01272635|Experimental|Azythromycin (APRIL) and Placebo (OCELOT)|
3189400|NCT01272635|Experimental|Placebo (APRIL) and Prednisolone (OCELOT)|
3189401|NCT01272635|Placebo Comparator|Placebo (APRIL) and Placebo (OCELOT)|
3189402|NCT01272622|Other|Arm I|"Children and adolescents >= 18 years of age new diagnosed with craniopharyngioma~>= 5 years of age and with incomplete resected tumor => randomized in two arms: immediate irradiation after surgery"
3189403|NCT01272622|Other|Arm II|incomplete resection, wait and watch, MRI-controls every 3 months, and irradiation at the time of progression of residual tumor
3189404|NCT01272609|Experimental|LCP + Timolol|Three sessions of LCP in 595 nm (diameter of spot 7mm; duration of shooting 1,5 ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
3189405|NCT01272609|Active Comparator|LCP|Three sessions of LCP in 595 nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure © spaced out of 1 month.
3189406|NCT01272596||Multiple Sclerosis Patients|Patients with Clinically Isolated Syndrome or definite Multiple Sclerosis (either relapsing-remitting or secondary progressive)
3189407|NCT01272583|Other|Sequence A (sitagliptin→placebo)|Cross-over, both arms reveived the same intervention in different order.
3189408|NCT01272583|Other|Sequence B (placebo→sitagliptin)|Cross-over, both arms reveived the same intervention in different order.
3189409|NCT01272570||Aromatase Inhibitor|"Diagnosis of BCa- Histologic confirmed diagnosis of BCa: Stage 0, I, II, or III with no evidence of metastatic disease.~Treatment- AI as clinically indicated (AI may be anastrozole, exemestane or letrozole). Subjects may have had prior tamoxifen or raloxifene. Subjects may have had chemotherapy and/or radiation therapy. Must be within the first year of consecutive AI therapy. If a subject started AI, discontinued, then restarted, they will be accepted into the study as long as the past therapy did not exceed 12 months and the current therapy has not exceeded 12 months."
3189410|NCT01272570||Control|• No Diagnosis of cancer.- Patients must not have a diagnosis of any cancer (Not including a history of thyroid or skin cancer).
3189411|NCT01272557|Active Comparator|Sorafenib 400 mg bid (oral) continuously|Sorafenib 400 mg bid (oral) continuously until progression or unacceptable toxicity).
3189412|NCT01272557|Experimental|q22d: Doxorubicin 60 mg/m2 i.v d1, Sorafenib 400 mg bid d3-19|During trial therapy period in Arm-A treated patients will receive doxorubicin infusion with 60mg/m² on day 1 every 21 days for maximum of 18 weeks (or 6 cycles) until a maximal dose of 360mg/m² are reached. Sorafenib 400mg bid (oral) will be administered from day 3-19 every 21 days during the trial therapy period
3189413|NCT01272544||participation in a dental health program|Group 1 - children who participated to a dental health program Group 2 - children who did not participate to dental health program
3189414|NCT01272544||participation in a preventive program|Group 1 - children who participated to the preventive program Group 2 - children who did not participate
3189415|NCT01272531||lithium|All study subjects will be started on lithium and taken off other medications, such as antidepressants, antipsychotic or other mood stabilizers used to control their mood. They will be stabilized over a 3 month time period, observed for one month, the followed every 2 months for 2 years.
3189416|NCT01272531||valproate|Subjects that do not achieve stabilization or relapse while on lithium monotherapy will be started on valproate (VPA), in an identically designed prospective trial of VPA.
3189417|NCT01272505|Placebo Comparator|conventional SILC|Conventional method of single incision laparoscopic cholecystectomy
3189418|NCT01272505|Active Comparator|HS-SILC|
3189419|NCT01272492|Experimental|Computer Use|Participants use the computer with the infant/toddler nutrition/feeding education modules
3189420|NCT01272492|No Intervention|Control|Only answers survey questions.
3189421|NCT01272479||HCV (+)|Hemodialysis patients with chronic hepatitis C
3189422|NCT01272479||HCV (-)|Hemodialysis patients without chronic hepatitis C
3189423|NCT01272479||Control|Healthy volunteers
3189424|NCT01272466|Experimental|peptides from antiapoptotic proteins|
3189606|NCT01271257|Experimental|hourly misoprostol|20 microgram misoprostol intake per hour
3189425|NCT01272453||Control Group|Data from patients in the control group will be obtained retrospectively from patient medical records and stored image data
3189426|NCT01272453||Prospective Patient Group|Data from patients in the Flash group will be obtained prospectively from scanner consoles and medical records.
3189427|NCT01272427|Experimental|noncaloric beverage|noncaloric sweetened beverage administered 30 min prior to mealtime
3189428|NCT01272427|Experimental|noncaloric beverage (60 min)|noncaloric sweetened beverage administered 60 min prior to mealtime
3189429|NCT01272427|Experimental|glucose beverage|glucose beverage administered 30 min prior to mealtime
3189430|NCT01272427|Experimental|glucose beverage (60 min)|glucose beverage administered 60 min prior to mealtime
3189431|NCT01272427|Experimental|whey protein beverage|whey protein beverage administered 30 min prior to mealtime
3189432|NCT01272427|Experimental|whey protein beverage (60 min)|whey protein beverage administered 60 min prior to mealtime
3189433|NCT01272414|Experimental|BoTox Treatment|Subjects receive BoTox injection to levator complex
3189434|NCT01272414|Placebo Comparator|Saline injection|Saline injection to levator complex
3189435|NCT01272401||Breast cancer patients and survivors|
3189436|NCT01272388|Active Comparator|Tadalafil|
3189437|NCT01272388|Placebo Comparator|Placebo|
3189438|NCT01272375|Experimental|Treatment A PF-04764793|PF-04764793 using inhaler A
3189439|NCT01272375|Experimental|Treatment B PF-04764793|PF-04764793 using inhaler A
3189440|NCT01272375|Experimental|Treatment C PF-04764793|PF-04764793 using inhaler A
3189441|NCT01272375|Experimental|Treatment D PF-04764793|PF-04764793 using inhaler A
3189442|NCT01272375|Experimental|Treatment E PF-04764793|PF-04764793 using inhaler B
3189443|NCT01272375|Experimental|Treatment F PF-04764793|PF-04764793 using inhaler B
3189444|NCT01272375|Experimental|Treatment G PF-04764793|PF-04764793 using inhaler B
3189445|NCT01272362|Experimental|Indacaterol|
3189446|NCT01272349|Experimental|Low oxygen|
3189447|NCT01272349|Sham Comparator|Room Air|
3189448|NCT01272336|Active Comparator|AIH/Sham|Subjects with chronic, motor-incomplete SCI receive AIH and then SHAM
3189449|NCT01272336|Active Comparator|Sham/AIH|Subjects with chronic, motor-incomplete SCI receive SHAM and then AIH
3189450|NCT01272323||Placebo|Subjects previously randomised to receive placebo in study CP005
3189451|NCT01272323||Cat-PAD Group 1|Subjects previously randomised to receive Cat-PAD dose 1 in study CP005
3189452|NCT01272323||Cat-PAD Group 2|Subjects previously randomised to receive Cat-PAD dose 2 in study CP005
3189453|NCT01272310|Experimental|Combination therapy|
3189454|NCT01272297|Experimental|LI-ESWT|Low intensity shock wave treatment- 12 sessions
3189455|NCT01272284|Other|Altis® SIS|Subjects enrolled with Altis® SIS
3189456|NCT01272271||Children|
3189457|NCT01272271||Adults|
3189458|NCT01272258|Experimental|Arm 1|PRO 140
3189459|NCT01272258|Placebo Comparator|Arm 2|Placebo
3189460|NCT01272245|Experimental|Omacetaxine and Cytarabine|Omacetaxine 1.25 mg/m2 SQ every 12 hours x 3 days + Cytarabine 20 mg SQ x 7 days of 4-7 week cycle.
3189461|NCT01272232|Experimental|Lira 3.0 mg|
3189462|NCT01272232|Experimental|Lira 1.8 mg|
3189463|NCT01272232|Experimental|Placebo|
3189464|NCT01272219|Experimental|Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)|
3189465|NCT01272219|Experimental|Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)|
3189466|NCT01272219|Placebo Comparator|Liraglutide Placebo, no Pre-diabetes|
3189467|NCT01272219|Experimental|Liraglutide 3.0mg, Pre-diabetes|
3189468|NCT01272219|Placebo Comparator|Liraglutide Placebo, Pre-diabetes|
3189469|NCT01272206|Experimental|A|
3189470|NCT01272206|Experimental|B|
3189471|NCT01272193|Experimental|IDegAsp OD|
3189472|NCT01272193|Active Comparator|IGlar OD|
3189473|NCT01272180|Experimental|ABCWY+OMV|"Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus Outer Membrane Vesicles (OMV) administered two months apart."
3189474|NCT01272180|Experimental|ABCWY+qOMV|"Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of Outer Membrane Vesicles (qOMV) administered two months apart."
3189475|NCT01272180|Active Comparator|rMenB+OMV|"Subjects in this group received two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine,administered two months apart."
3189476|NCT01272180|Active Comparator|MenACWY|"Subjects in this group received a dose of placebo followed by one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine administered two months later."
3189477|NCT01272154|Experimental|Primary cervical dystonia Patients|
3189478|NCT01272154|Experimental|Primary upperlimb Dystonia Patients|
3189479|NCT01272154|Experimental|Secondary Cervical or Upperlimb Dystonia due to cerebral palsy|
3189480|NCT01272154|Other|Healthy volunteers|
3189481|NCT01272141|Experimental|Arm A: Lapatinib plus Everolimus|
3189482|NCT01272102||Glaucoma|subjects with glaucoma
3189483|NCT01272089|Experimental|Pataday|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once daily for one week
3189484|NCT01272076||Dry AMD and geographic atrophy|Patients diagnosed with dry AMD and geographic atrophy
3189485|NCT01272063||Dry AMD with macular drusen|Patients diagnosed with dry AMD with macular drusen
3189486|NCT01272050|Active Comparator|Arm A: 64 Gy - Radiation Therapy|Arm A: 64 Gy (32 x 2 Gy) without hormonal treatment
3189487|NCT01272050|Active Comparator|Arm B: 70 Gy - Radiation Therapy|Arm B: 70 Gy (35 x 2 Gy) without hormonal treatment
3189488|NCT01272037|Experimental|Arm I (chemotherapy and endocrine therapy)|Patients receive a protocol-approved chemotherapy regimen based on the patient and/or physician preference. Patients then receive a protocol-approved adjuvant endocrine therapy comprising tamoxifen citrate, an aromatase inhibitor (anastrozole, letrozole, or exemestane), or both for 5-10 years in the absence of disease progression or unacceptable toxicity.
3189489|NCT01272037|Experimental|Arm II (endocrine therapy)|Patients receive a protocol-approved endocrine therapy comprising tamoxifen citrate, an aromatase inhibitor (anastrozole, letrozole, or exemestane), or both for 5-10 years in the absence of disease progression or unacceptable toxicity.
3189490|NCT01272024|Active Comparator|Information/Education Group|Assistance in using Symptom Management Toolkit
3189491|NCT01272024|Experimental|Nurse Intervention|Participants are given intensive nurse contacts to reduce uncertainty and maximize problem solving, and later, to transition to the treatment phase of their cancer.
3189492|NCT01272011|Experimental|Phase 1 Arm (Pilot)|Individuals were exposed to intermittent hypoxia and locomotor training to establish our interventions (set up lab, train personnel, develop study protocols/interventions, etc)
3189493|NCT01272011|Experimental|Phase 2 Arm (LTF)|Individuals were exposed to 10 days of intermittent hypoxia to determine the effect of this intervention on ventilatory long-term facilitation, as measured by minute ventilation
3189494|NCT01272011|Other|Phase 3 Arm (Ventilatory Loading)|Individuals were exposed to 10 days of intermittent hypoxia to determine changes in ventilatory loading.
3189495|NCT01271998|Experimental|healthy volunteer|healthy volunteers
3189496|NCT01271985|Active Comparator|PolyPill|PolyPill once daily and Minimal Care
3189497|NCT01271985|Active Comparator|Minimal care|Minimal care.
3189498|NCT01271985|No Intervention|Usual care|Basic primary health care provided by the local physicians and Community Health Workers consistent with the current Iranian Health Care System guidelines.
3189499|NCT01271972|Experimental|Cohort 1|Dose 1
3189500|NCT01271972|Experimental|Cohort 2|Dose 2
3189501|NCT01271972|Experimental|Cohort 3|Dose 3
3189502|NCT01271972|Experimental|Cohort 4|Dose 4
3189503|NCT01271972|Experimental|Cohort 5|Dose 5
3189504|NCT01271972|Experimental|Expansion Cohort 1|Dose 4
3189505|NCT01271972|Experimental|Expansion Cohort 2|Dose 5
3189506|NCT01271946|Other|Diagnostic Procedure|
3189507|NCT01271933|Experimental|Pregabalin|
3189508|NCT01271933|Placebo Comparator|Placebo|
3189509|NCT01271920|Experimental|AUY922 + Trastuzumab|
3189510|NCT01271907|Experimental|Cohort 0|Drosophila generated CTL + SQ IL-2 Drug: 1 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL) (CTL-05), aldesleukin Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
3189511|NCT01271907|Experimental|Cohort 1|2 Experimental Lymphodepleting regimen +Cells+Low dose IL-2 Drug: 2 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL), aldesleukin Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
3189512|NCT01271907|Experimental|Cohort 2|1 Experimental Lymphodepleting regimen +Cells Drug: 3 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL) Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells
3189513|NCT01271894|Experimental|Reduced dose Efavirenz arm|Participants randomized in main study to receive EFV (400 mg once daily; 2 x 200 mg + 1 x placebo once daily) plus tenofovir/emtricitabine (300/200 mg) fixed-dose combination once daily
3189514|NCT01271894|Active Comparator|Normal Efavirenz dose arm|Patients randomized in the main study to receive EFV (600 mg once daily; 3 x 200 mg once daily) plus tenofovir/emtricitabine (300/200 mg) fixed-dose combination once daily
3189515|NCT01271881|Active Comparator|Percutaneous Transluminal Angioplasty (PTA) alone|Intervention: Procedure: PTA alone without use of the GORE VIABAHN
3189516|NCT01271881|Experimental|PTA with covered stent|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
3189517|NCT01271868|Other|Age group 1|Age less than 6 years old
3189518|NCT01271868|Other|Age group 2|Age between 6 to 12 years old
3189519|NCT01271855|Placebo Comparator|Glycerin suppository|Women assigned to this arm receive a glycerin suppository (placebo) every 8 hours after delivery during the first 24 hours postpartum
3189520|NCT01271855|Experimental|Belladonna and opioid suppository|Women assigned to this arm receive a belladonna and opioid (B&O) suppository every 8 hours after delivery during the first 24 hours postpartum
3189521|NCT01271842||Extra corporeal oxygenation|Survivors of ARDS due to influenza A (H1N1)2009 infection who needed an extracorporeal oxygenation at the time of infection
3189522|NCT01271842||No extracorporeal oxygenation|Survivors of ARDS due to influenza A (H1N1) 2009 infection who did not need an extracorporeal oxygenation at the time of infection
3189523|NCT01271829|No Intervention|Control|While on the control arm subjects will be given a meal with no avocado.
3189524|NCT01271829|Active Comparator|Avocado supplement|While on the avocado supplement arm subjects will be given a meal in which a given amount of calories will be replaced by calories contributed by avocados.
3189525|NCT01271829|Active Comparator|Avocado included|While on the avocado included arm subjects will be given a meal in which the calories of avocado will be added to the calories of the control meal.
3189526|NCT01271816||Presymptomatic ARVC gene carriers|ARVC gene positive patients without manifest ARVC after standard screening clinical testing.
3189527|NCT01271803|Experimental|DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 milligrams (mg) cobimetinib once daily (QD) on Days 1-14, followed by 14 days off on Days 15-28 (14/14 dosing schedule) and oral 720 mg vemurafenib twice daily (BID) on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3189528|NCT01271803|Experimental|DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on Days 1-21, followed by 7 days off on Days 22-28 (21/7 dosing schedule) and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3189529|NCT01271803|Experimental|DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3190707|NCT01263496|Experimental|Alogliptin 25 mg QD|
3189530|NCT01271803|Experimental|DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on Days 1-28 (28/0 dosing schedule) and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3189531|NCT01271803|Experimental|DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 28/0 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3189532|NCT01271803|Experimental|DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 80 mg cobimetinib QD on 14/14 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3189533|NCT01271803|Experimental|DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 100 mg cobimetinib QD on 14/14 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3189534|NCT01271803|Experimental|DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 14/14 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3189535|NCT01271803|Experimental|DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 80 mg cobimetinib QD on 14/14 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3189536|NCT01271803|Experimental|Cobimetinib Monotherapy (100 mg or 60 mg)|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule, or oral 100 mg cobimetinib QD on 14/14 dosing schedule of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3189537|NCT01271803|Experimental|CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3189538|NCT01271803|Experimental|CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3189539|NCT01271790|Active Comparator|Arm 1|GS-9451 and Tegobuvir (GS-9190) in combination with Pegasys® and Copegus® for 16 or 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
3189540|NCT01271790|Active Comparator|Arm 2|GS-9451 (active) and Tegobuvir (GS-9190) placebo in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
3189541|NCT01271790|Placebo Comparator|Arm 3|Placebo matching Tegobuvir (GS-9190) and GS-9451 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® will be continued for up to 48 weeks total duration
3189542|NCT01271777|Experimental|GFT505 80mg|
3189543|NCT01271777|Placebo Comparator|Matching placebo|
3189544|NCT01271764|No Intervention|endometrial cancer|
3189545|NCT01271751|Experimental|GFT505 80mg|
3189546|NCT01271751|Placebo Comparator|Matching placebo|
3189547|NCT01271738|Active Comparator|Breast Conserving Surgery (BCS)|
3189548|NCT01271738|Active Comparator|Breast Conserving Surgery with Additional 5 Margins (BCS + M)|
3189549|NCT01271725|Experimental|Afatinib 40mg once daily (OD)|Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
3189550|NCT01271725|Experimental|Paclitaxel 80 mg/m2 weekly|Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
3189551|NCT01271725|Experimental|Vinorelbine 25 mg/m2 weekly|Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
3189552|NCT01271712|Experimental|Regorafenib (Stivarga, BAY73-4506)|Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
3189553|NCT01271712|Placebo Comparator|Placebo|Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
3189554|NCT01271699||Observation|Patients at age 18-50 with a confirmed or probably diagnosis of Multiple Sclerosis according to the McDonald diagnostic criteria for MS
3189555|NCT01271686|Experimental|0.01% bimatoprost|bimatoprost 0.01% one time per day at bedtime for 4 weeks.
3189556|NCT01271673||Women undertaking Breast Self Examination|Women attending Preventive Oncology Clinic during the month of November- December 2010,and undertaking BSE training whose Residential address mentioned as Mumbai and whose Contact number is available.
3189557|NCT01271660|Active Comparator|Pregabalin|"35 randomly allocated patients after a 4-week run-in period, who will take part in a 6-week treatment period with pregabalin.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as standard dose period + 75mg twice a day for a week as tapering period."
3189558|NCT01271660|Placebo Comparator|Placebo|"35 randomly allocated patients after a 4-week run-in period, who will take part in a 6-week treatment period with placebo.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as standard dose period + 75mg twice a day for a week as tapering period."
3189559|NCT01271647|Experimental|chinese herb|
3189560|NCT01271647|Experimental|placebo|
3189561|NCT01271621|Active Comparator|Macintoch group|Intubation with Macintoch Laryngoscope
3189562|NCT01271621|Experimental|Glidescope|Inubation by Glidescope
3189563|NCT01271595|Active Comparator|acupuncture|12 sessions of acupuncture according to TCM
3189564|NCT01271595|Sham Comparator|sham acupuncture|superficial acupuncture at non acupuncture sites
3189607|NCT01271257|Active Comparator|traditional misoprostol|80 microgram misoprostol intake per 4 hours
3189565|NCT01271582|Experimental|FOLFIRI|Patients with colorectal cancer or gastric cancer will be treated with FOLFIRI(Irinotecan, 5FU, leucovorin) regimen upto 12 cycles. (Single arm study)
3189566|NCT01271569|Other|In the treatment arm|
3189567|NCT01271556|Experimental|1, salmeterol, saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to each test day. Salmeterol 50 mcg on days A was administered between 8 AM and 10 AM. Patients and healthy subjects underwent a rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment (salmeterol 50 mcg MDI), and mixed venous blood was withdrawn for measurements of hematocrit (Htc), Hb, and albumin concentration 10 minutes before and 10 minutes after the infusion. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
3189568|NCT01271556|Placebo Comparator|2, placebo, saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Placebo was administered between 8 AM and 10 AM. Patients and healthy subjects underwent a rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment (placeboI), and mixed venous blood was withdrawn for measurements of hematocrit (Htc), Hb, and albumin concentration 10 minutes before and 10 minutes after the infusion. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
3189569|NCT01271556|Active Comparator|3, salmeterol, no saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Salmeterol 50 mcg on days A was administered between 8 AM and 10 AM. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
3189570|NCT01271556|Placebo Comparator|4, placebo, no saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Placebo was administered between 8 AM and 10 AM. 240 and 290 minutes after inhalatory treatment (placebo), pulmonary function tests were performed.
3189571|NCT01271543|Active Comparator|MacIntosh group|
3189572|NCT01271543|Experimental|Shikani optical stylet|
3189573|NCT01271530|Experimental|Exercise|
3189574|NCT01271530|No Intervention|Control|
3189575|NCT01271517|Active Comparator|Insulatard|Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugars
3189576|NCT01271517|Active Comparator|Lantus|Treatment once daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
3189577|NCT01271517|Active Comparator|Levemir|Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
3189578|NCT01271504|Active Comparator|Phase Ib: Cohort 1,2, and 3|Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib
3189579|NCT01271504|Active Comparator|Phase II: Arm 1; E7050 + Sorafenib|Phase II: Arm 1; E7050 + 400 mg Sorafenib Arm 2; 400 mg Sorafenib
3189580|NCT01271491||Cases|Children hospitalized in the ICU with bronchiolitis
3189581|NCT01271491||Controls|Children hospitalized in the general ward with bronchiolitis
3189582|NCT01271478|Experimental|Telmisartan plus Captopril|captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day)
3189583|NCT01271478|Experimental|Telmisartan plus Placebo|telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day) plus 1 tablet of placebo orally twice a day
3189584|NCT01271478|Experimental|Captopril plus Placebo|patients received captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
3189585|NCT01271478|Placebo Comparator|Placebo|2 tablets of placebo orally twice a day
3189586|NCT01271452|Active Comparator|Vistabel®|botulinum toxin type A (Vistabel®)
3189587|NCT01271452|Active Comparator|Bocouture®|botulinum toxin type A (Bocouture®)
3189588|NCT01271439|Experimental|cetuximab|
3189589|NCT01271413|Experimental|Adaptive cognitively stimulating activities|
3189590|NCT01271413|Active Comparator|Non-adaptive cognitively stimulating activities|
3189591|NCT01271387|Experimental|Moderate Hepatic Impairment|
3189592|NCT01271387|Experimental|Mild Hepatic Impairment|
3189593|NCT01271387|Experimental|Healthy Volunteers|
3189594|NCT01271374|Active Comparator|Hyzaar-Treatment Arm B|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
3189595|NCT01271374|Active Comparator|Azor-Treatment A|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
3189596|NCT01271361|Experimental|primary PCI with thrombectomy|thrombectomy before implantation of drug eluting stent
3189597|NCT01271361|Active Comparator|primary PCI without thrombectomy|implantation of a drug eluting stent without thrombectomy
3189598|NCT01271348|Active Comparator|Etoricoxib|
3189599|NCT01271348|Placebo Comparator|Placebo tablet|
3189600|NCT01271335|Experimental|Collagenase (MZ-004)|Local intra-coronary administration of MZ-004 at or into the CTO
3189601|NCT01271309||Acute Myocardial Infarction patients|Patients with thoracic pain lasting at least 20 min and ST changes or left B block, not present in previous ECG.
3189602|NCT01271296|Active Comparator|Liquorice|Liquorice eq to 150 mg glycyrrhizinic acid. Results are compared to a baseline assessment without liquorice/grapefruit juice ingestion.
3189603|NCT01271296|Active Comparator|Grapefruit juice|200 ml pink grapefruit juice three times a day. Results are compared to a baseline assessment without liquorice/grapefruit juice ingestion.
3189604|NCT01271296|No Intervention|Baseline|Baseline assessment without intake of liquorice or grapefruit juice
3189605|NCT01271283|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (by morphological criteria but have persistent minimal residual disease by molecular criteria) or partial response may continue treatment beyond 8 courses. Patients may undergo bone marrow, peripheral blood, and/or lymph node sample collection at baseline and periodically during study for correlative studies.
3189608|NCT01271244|Active Comparator|PTSD Depression Group|Escitalopram 10-20 mg/day
3189609|NCT01271244|Active Comparator|Major Depression Group|Escitalopram 10-20 mg/day
3189610|NCT01271231|Placebo Comparator|Group IP1|
3189611|NCT01271231|Experimental|Group IP2|
3189612|NCT01271231|Active Comparator|Group IP3|
3189613|NCT01271218|Placebo Comparator|Placebo|Participants ingested 2,200 mg/day of a placebo or active dietary supplement. Participants ingested three caplets in the morning and the remaining three caplets in the evening 30-minutes before a meal for 14-weeks. The supplements were prepared in caplet form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.
3189614|NCT01271218|Active Comparator|Active Supplement|Participants were randomly assigned to ingest in a double-blind manner caplets containing a commercially available glucosamine/chondroitin (GC) dietary supplement (Curves Joint and Connective Support™, Curves International, Waco, TX) or a suitable placebo (P). The GC supplement provided a total of 1,500 mg/d of glucosamine, 1,200 mg/d of chondroitin sulfate, 120 mg/d of niacin, 120 mg/d of sodium, 45 mg/d of zinc, 900 mg/d MSM, 300 mg/d of boswellia serrata extract, 180 mg/d of white willow bark extract, and 15 mg/d of rutin powder. Participants ingested three caplets in the morning and the remaining three caplets in the evening 30-minutes before a meal for 14-weeks.
3189615|NCT01271192|Active Comparator|Surgical resection and adjuvant therapy|Patients receive surgical resection and undergo FOLFIRI for 12 cycles, from 2-4 weeks after operation. Patients undergo radiotherapy once daily 5 days a week for 5-6 weeks, from 8-12 weeks after operation
3189616|NCT01271192|Experimental|Neoadjuvant followed by operation|Patients receive neoadjuvant chemoradiotherapy (mFOLFIRI for 5 cycles and undergo radiotherapy as in arm I from the second cycle of FOLFIRI), surgery and FOLFORI for 7 cycles from 2-4 weeks after operation.
3189617|NCT01271179|Active Comparator|sequential perfusion|sequential perfusion of liver grafts with low-viscosity improved Ross solution and high-viscosity UW solution.
3189618|NCT01271179|Placebo Comparator|sole perfusion|sole perfusion of liver grafts with high-viscosity UW solution only
3189619|NCT01271166|Experimental|Glivec®, modified FOLFOX, Avastin®|
3189620|NCT01271153|Active Comparator|Dobutamine|Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours
3189621|NCT01271153|Placebo Comparator|Placebo|An equivalent infusion of placebo will be infused for 2.5 h
3189622|NCT01271140|Experimental|Insulin/dextrose clamp|
3189623|NCT01271114|Experimental|Hypertonic Saline and Terlipressin|
3189624|NCT01271114|Active Comparator|Normal Saline and norepinephrine|
3189625|NCT01271101||anticoagulant|
3189626|NCT01271088|Experimental|N-acetylcysteine|N-acetylcysteine: Experimental N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin
3189627|NCT01271088|No Intervention|Control|Vancomycine and/or amikacin alone
3189628|NCT01271075|Active Comparator|Bilastine A|A: Crossover Bilastine 20 mg, Bilastine 40 mg, Placebo, Bilastine 80 mg
3189629|NCT01271075|Active Comparator|Bilastine B|B: Crossover Bilastine 80 mg, Placebo, Bilastine 40 mg, Bilastine 20 mg
3189630|NCT01271062|Active Comparator|T2DM patients before gastric bypass surgery|oral glucose tolerance test , botnia clamp, preoperative as well as 10 days postoperative and 1 year postoperative, gastric bypass surgery.
3189631|NCT01271062|Active Comparator|Non-diabetic patient before gastric bypass surgery|oral glucose tolerance test , botnia clamp, preoperative as well as 10 days postoperative and 1 year postoperative, gastric bypass surgery.
3189632|NCT01271062|Active Comparator|non diabetic patients, non-bariatric abdominal surgery|oral glucose tolerance test , botnia clamp, elective laparoscopic abdominal surgery.
3189633|NCT01271062|Active Comparator|severely obese T2DM patients following a very low caloric diet|oral glucose tolerance test , botnia clamp, before as well after following a very low caloric diet. Very low caloric diet.
3189634|NCT01271049|Placebo Comparator|Control Food Product|Consumption of placebo food product
3189635|NCT01271049|Experimental|Novel Food Product|Consumption of novel food product
3189636|NCT01271036|Experimental|Formula PD-F-7716|Apply a dime-size amount on each application site as instructed during the 1-week study period
3189637|NCT01271023|Experimental|Closed-Loop Control|The Control to Range algorithm will be used in conjunction with continuous glucose monitoring and insulin pump delivery to manage the subject's blood glucose.
3189638|NCT01271010|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants received rituximab 375 milligrams per square meter (mg/m^2) intravenously (IV) on Day 1 of Cycle 1, then 500 mg/m^2 IV on Day 1 of each subsequent cycle; fludarabine 25 mg/m^2 IV or 40 mg/m^2 orally on Days 1-3 of each cycle and cyclophosphamide 250 mg/m^2 IV or 250 mg/m^2 orally on Days 1-3 of each cycle. Treatment duration was 6 cycles, 28 days each.
3189639|NCT01270997|Experimental|HD203|Subcutaneous injection (SC) HD203 25mg twice a week for 48 weeks
3189640|NCT01270997|Active Comparator|Enbrel|Subcutaneous injection (SC) Enbrel® 25mg twice a week for 48 weeks.
3189641|NCT01270984|Experimental|Luckyvec 400mg film coated tablet|400mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
3189642|NCT01270984|Active Comparator|Glivec 100mg film coated tablet|100mg/tablet, PO, 4 tablets once daily for Period I & II D1(crossover)
3189643|NCT01270971|Experimental|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%
3189644|NCT01270971|Placebo Comparator|Solution Vehicle|Solution Vehicle
3189645|NCT01270958|Experimental|TREATMENT|50 adult patients with Perennial Allergic Rhinities treated with Avamys.
3189646|NCT01270945|Experimental|CV-18C3 and standard of care|CV-18C3 and standard of care
3189647|NCT01270945|Active Comparator|standard of care|Percutaneous revascularization
3189648|NCT01270932|Experimental|Lenalidomide and Dexamethasone|"Lenalidomide:Daily for 21 days of a 28 day cycle~Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4."
3189649|NCT01270919|Other|BioDuct Meniscal Repair Device|BioDuct Meniscal Repair Device
3189650|NCT01270906|Experimental|CHIR-258 (TKI258)|
3189651|NCT01270893|Experimental|Nilotinib and Surgical Resection|
3189652|NCT01270893|Experimental|Nilotinib and Potential Resection|
3189653|NCT01270880|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3189654|NCT01270867|Active Comparator|Merci Retriever|Merci Retriever is the predicate product that received FDA clearance in 2004. Merci Retriever a first generation mechanical thrombectomy device intended to remove clot and restore blood flow in a neurovascular vessel in the setting of acute ischemic stroke.
3189655|NCT01270867|Experimental|Trevo Stentriever|Trevo Retriever is a second generation mechanical thrombectomy device intended to remove clot and restore blood flow in a neurovascular vessel in the setting of acute ischemic stroke. The Trevo Retriever is a type of stent, specifically design to allow for clot integration into the device. The clot in the retriever is then removed and blood flow is restored.
3189656|NCT01270854|Experimental|Plasmalyte|Administration of Plasmalyte A as the standard intravenous fluid during the first 24 hours after arrival to the hospital
3189657|NCT01270854|Active Comparator|Normal Saline|Administration of Normal Saline as the standard intravenous fluid during the first 24 hours after arrival to the hospital
3189658|NCT01270841|Placebo Comparator|Placebo|Placebo
3189659|NCT01270841|Active Comparator|Testim (topical testosterone)|Testim (topical testosterone)
3189660|NCT01270841|Experimental|Androxal 12.5 mg|Androxal 12.5 mg/day
3189661|NCT01270841|Experimental|Androxal 25 mg|Androxal 25 mg/day
3189662|NCT01270828|Experimental|Pregablain CR tablet 82.5 to 660mg|
3189663|NCT01270828|Placebo Comparator|Placebo|
3189664|NCT01270815|Experimental|Pregabalin controlled release, 330 mg, 400 to 500 calories|
3189665|NCT01270815|Experimental|Pregabalin controlled release, 330 mg, 600 to 750 calories|
3189666|NCT01270815|Experimental|Pregabalin controlled release, 330 mg, 800 to 1000 calories|
3189667|NCT01270815|Other|Pregabalin immediate release, 300 mg|Reference
3189668|NCT01270802|Active Comparator|Tenofovir/emtricitabine/efavirenz|Tenofovir/emtricitabine/efavirenz
3189669|NCT01270802|Experimental|Tenofovir/emtricitabine plus raltegravir|Tenofovir/emtricitabine/efavirenz is switched to tenofovir/emtricitabine plus raltegravir
3189670|NCT01270789|Experimental|Liraglutide|
3189671|NCT01270789|Placebo Comparator|Placebo|
3189672|NCT01270776|Experimental|Aqueous Chlorhexidine|The group received skin antisepsis using 2% aqueous chlorhexidine solution.
3189673|NCT01270776|Active Comparator|2% Chlorhexidine 70% isopropyl alcohol|The group will receive skin antisepsis with 2% chlorhexidine solution in alcohol.
3189674|NCT01270763||The Look AHEAD Study|The Look AHEAD Study includes intensive lifestyle intervention treatment, focusing on caloric intake and physical activity, and a treatment arm focused on diabetes support and education.
3189675|NCT01270737|Active Comparator|Whole soy|
3189676|NCT01270737|Active Comparator|daidzein|
3189677|NCT01270737|Placebo Comparator|milk powder|
3189678|NCT01270724|Experimental|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)|Two to four cycles of induction therapy with open label GemPOx followed by consolidation and autologous stem cell transplant (ASCT).
3189679|NCT01270711||Cabergoline users|cohort of patients, who are treated with cabergoline during the study period ( from January 1st, 2006 to July 1st 2012)
3189680|NCT01270698|Experimental|IMMU-130|
3189681|NCT01270685||1|Veterans with spinal cord injuries and disorders
3189682|NCT01270685||2|Comparison group: general Veteran population (without spinal cord injuries or disorders)
3189683|NCT01270685||3|Health care providers with face-to-face contact with Veterans with SCI/D
3189684|NCT01270685||4|Infection control Chiefs/Officers
3189685|NCT01270672|Experimental|carvedilol, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
3189686|NCT01270659|Experimental|Low-FBT|Subject will receive FBT and placebo at a low dose
3189687|NCT01270659|Experimental|High-FBT|Subject will receive the high dose regimen of FBT and a high dose placebo
3189688|NCT01270659|Active Comparator|Low control|"Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl placebo"
3189689|NCT01270659|Active Comparator|High control|"Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl placebo"
3189690|NCT01270646|Experimental|Intraventricular Electrical Activation|
3189691|NCT01270633|Other|Treatment|PriMatrix applied to appropriately debrided wound bed and covered with a non-adherent dressing. Dressings applied to maintain moist wound therapy.
3189692|NCT01270633|Active Comparator|Standard of Care|Non adherent dressing applied to appropriately debrided wound bed and moist wound therapy maintained.
3189693|NCT01270620|Active Comparator|Propofol|Patients will receive propofol as general anesthetics.
3189694|NCT01270620|Active Comparator|Desflurane|Patients will receive desflurane as general anesthetics.
3189695|NCT01270607|Experimental|Acupuncture|
3189696|NCT01270594|Experimental|COPD Counseling Intervention|Pharmacist counseling intervention delivered via telephone.
3189697|NCT01270594|Other|Usual Care|
3189698|NCT01270581|Experimental|High Flow Nasal Cannula|Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7. Newborns randomized to HFNC will be started on a flow rate of 4L/min and supplemental oxygen will be provided to maintain oxygen saturations between 88-93% (experimental group). Once initiated, the gas flow rate will be titrated as needed by the attending neonatologist to ameliorate signs of respiratory distress to a maximum flow rate of 6L/min. The nasal cannula size (0.2 cm or 0.3 mm outer diameter) will determined by the caliber of the subject's nares).
3189746|NCT01270269|Experimental|Behavioral: Phys & Func Rehab|A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.
3189747|NCT01270269|Experimental|Behavioral: Cog/Phys/Func Rehab|A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
3189699|NCT01270581|Active Comparator|Control Group- Bubble Nasal CPAP|NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
3189700|NCT01270568|Experimental|Positive Psychology|8 weekly positive psychology exercises
3189701|NCT01270568|Active Comparator|Relaxation Response|Meditation-based treatment
3189702|NCT01270568|Sham Comparator|Recollection|Recollection of daily events, recorded weekly
3189703|NCT01270555|Experimental|Bupropion|
3189704|NCT01270542|Experimental|Avastin Injection Group (AIG)|Subjects in this group will get single 0.05 mL intravitreal injection of bevacizumab 1.25 mg 3-7 days prior to surgery for tractional retinal detachment secondary to Proliferative Diabetic Retinopathy.
3189705|NCT01270542|Sham Comparator|Sham Injection Group (SIG)|Subjects in this group will get a sham injection 3-7 days prior to surgery for tractional retinal detachment secondary to Proliferative Diabetic Retinopathy.
3189706|NCT01270529|Experimental|CKD Stages 1-4|
3189707|NCT01270529|Experimental|ESRD on Dialysis|
3189708|NCT01270529|Experimental|Kidney Transplant recipients|
3189709|NCT01270516|Placebo Comparator|Control, to be given saline solution|Intervention: This group will be given saline (30 ml every 12 hours) for 10 days
3189710|NCT01270516|Experimental|EPA, eicosapentaenoic acid|This group will be given 1000 mg EPA every 12 hours for 10 days
3189711|NCT01270516|Experimental|HMB, hydroxymethylbutyrate|This arm will be given HMB (1500 mg) every 12 hours for 10 days.
3189712|NCT01270516|Experimental|EPA and HMB|Intervention: This group will be given EPA (1000 mg every 12 hours given via the GI tract) and HMB (1500 mg every 12 hours given via the GI tract) for 10 days.
3189713|NCT01270503|Experimental|Menactra® Group 1|Participants aged 2 to 11 on enrollment
3189714|NCT01270503|Experimental|Menactra® Group 2|Participants aged 12 to 17 on enrollment
3189715|NCT01270503|Experimental|Menactra® Group 3|Participants aged 18 to 55 on enrollment
3189716|NCT01270490|Experimental|Interferon-gamma|
3189717|NCT01270490|No Intervention|No intervention|No adjunctive treatment
3189718|NCT01270477|Experimental|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment in an hyperbaric oxygen treatment chamber on an recognized treatment table.
3189719|NCT01270464|Placebo Comparator|Placebo|Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses.
3189720|NCT01270464|Experimental|Reslizumab - 0.3 mg/kg|0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses
3189721|NCT01270464|Experimental|Reslizumab - 3.0 mg/kg|3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses.
3189722|NCT01270451|Other|Lifestyle group counseling|Included patients will be randomised into two groups: to the intervention group or to the control group.
3189723|NCT01270438|Experimental|Arm I (RO4929097, combination chemotherapy, bevacizumab)|Patients receive FOLFOX6 regimen comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46 hours, and bevacizumab IV over 30-90 minutes on days 1-2. Patients also receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3189724|NCT01270438|Experimental|Arm II (combination chemotherapy, bevacizumab)|Patients receive FOLFOX6 regimen and bevacizumab as in arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3189725|NCT01270412|Experimental|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml of platelet-derived preparation rich in growth factors
3189726|NCT01270412|Active Comparator|Hyaluronic acid|Drug: hyaluronic acid 20 mg / 2 ml Other Name: Arthrease
3189727|NCT01270399||malignant neoplasm's cells|
3189728|NCT01270399||natural cells|
3189729|NCT01270386|Experimental|Apatinib|Apatinib 750 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3189730|NCT01270386|Placebo Comparator|Placebo|Placebo qd p.o., and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3189731|NCT01270373|Active Comparator|FAC x 3 followed by Docetaxel x 3|
3189732|NCT01270373|Experimental|Docetaxel x 3 followed by FAC x 3|
3189733|NCT01270360||asymptomatic subjects with positive FOBT|individuals having undergone a positive faecal occult blood test (FOBT) and a reference colonoscopy
3189734|NCT01270347|Experimental|Aeroquin|Aeroquin, Inhaled Levofloxacin (MP-376)
3189735|NCT01270347|Active Comparator|TIS|Tobramycin Inhalation solution (TIS) [TOBI® Novartis Pharmaceuticals]
3189736|NCT01270334||ph above cutoff|
3189737|NCT01270334||PH under cutoff|
3189738|NCT01270321|Experimental|Arm A (Everolimus alone)|CURRENTLY CLOSED TO ACCRUAL--Everolimus alone followed by Everolimus + Pasireotide at the time of progression
3189739|NCT01270321|Experimental|Arm B (Pasireotide alone)|CURRENTLY CLOSED TO ACCRUAL--Pasireotide alone followed by Everolimus + Pasireotide at the time of progression
3189740|NCT01270321|Experimental|Arm C (Everolimus + Pasireotide)|CURRENTLY CLOSED TO ACCRUAL
3189741|NCT01270308|Experimental|Lansoprazole DR Capsules 30 mg|Lansoprazole DR Capsules 30 mg of Dr.Reddy's Laboratories Limited
3189742|NCT01270308|Active Comparator|Prevacid 30 mg Capsules|Prevacid 30 mg Capsules of TAP Pharmaceuticals Inc. USA
3189743|NCT01270282|Experimental|AM-101 0.81 mg/mL|Gel for injection; single or triple injection
3189744|NCT01270282|Placebo Comparator|Placebo|Gel for injection; single or triple injection
3189745|NCT01270269|No Intervention|Patients (Controls)|Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
3189748|NCT01270256|Active Comparator|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
3189749|NCT01270256|Placebo Comparator|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
3189750|NCT01270243||Control|No tonsilar or adenoid problems
3189751|NCT01270243||Adenotonsillectomy (recurrent)|Recurrent adenotonsillitis
3189752|NCT01270243||Adenotonsillectomy (obstruction)|Upper airway obstruction
3189753|NCT01270230|Experimental|Comparison Group, Standard HIV-CT|The comparison group will receive standardized HIV counseling and testing (HIV-CT), with referrals to case management.
3189754|NCT01270230|Experimental|Intervention Group, Bruthas Counseling|Participants assigned to this arm receive four individual HIV prevention counseling sessions.
3189755|NCT01270217|Experimental|Brief motivational interview|
3189756|NCT01270217|No Intervention|No discussion|
3189757|NCT01270204||Normal Volunteers|Patients older than 55 years of age with no history of voice, swallowing, reflux, or progressive neurologic disease affecting the swallowing mechanism.
3189758|NCT01270204||Patients with Dysphagia|Patients older than 55 years of age with the following condition: Dysphagia (the sensation of swallowing difficulty), globus, gastroesophageal reflux, or any other condition requiring referral for a dynamic swallowing study.
3189759|NCT01270191|Experimental|Exenatide|In the exenatide therapy group, subjects will be instructed in the techniques for injection and be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months. If FPG still greater than 200 mg/dL after 4 weeks of exenatide treatment, they will use insulin for rescue therapy and will be withdrawn from this study.
3189760|NCT01270191|Active Comparator|Humulin-N|In the insulin therapy group (Humulin-N), subjects will be instructed in the techniques for insulin injection and home capillary glucose monitoring. The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
3189761|NCT01270178||Entecavir|
3189762|NCT01270152|Experimental|group 50 mg ascorbic acid|this arm received a dose of 50 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
3189763|NCT01270152|Experimental|group 100mg ascorbic acid|this arm received a dose of 100 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
3189764|NCT01270152|Experimental|group 200mg ascorbic acid|this arm received a dose of 200 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
3189765|NCT01270139|Experimental|Nano group|60 patients in Nano group were treated with transplantation of nanoparticles (NP), particularly with a bioengineered patch that was grown with allogenous stem cells pre-cultivated in the medium with NP. After the admission, patients were examined with QCA, and allocated to the trial. The implantation of the patch onto the artery was undergone by the minimally invasive cardiac surgery (MICS CABG) with fixation of the graft to the epicardial myocardium. MICS CABG implies a beating-heart multi-vessel heart surgery performed through several small incisions under direct vision through an anterolateral mini-thoracotomy in the 4th-6th intercostal spaces. The patients can expect high quality of life resuming all everyday activities within a few weeks of their operation. NP were activated with NIR laser at 7 days after the intervention. Patients were treated with bolus of bivalirudin on the day of NP detonation.
3189766|NCT01270139|Active Comparator|Ferro group|60 patients in Ferro group were managed with transplantation of iron-bearing nanoparticles (NP), particularly with intracoronary infusion of allogenous stem cells or CD68 targeted micro-bubbles pre-cultivated in the medium with iron-bearing NP. Cells and/ or micro-bubbles were infused with QCA- and IVUS-guidance to the target coronary artery via micro-catheter on the day of admission. The destruction of CD68 targeted micro-bubbles was obtained by using a Sonos 5500 machine with an S3 transducer operating in ultraharmonic mode (transmit, 1.3MHz/ receive, 3.6 MHz) with a mechanical index of 1.5 and a depth of 4 cm. The AXIOM Artis dBC (Siemens) magnetic navigation system was used for precise delivery of NP to the atheroma through two permanent computer-controlled external magnets generating a navigational magnetic field of 0.08 Tesla in any direction. NP were detonated with NIR laser under the protection of anti-platelet therapy.
3189767|NCT01270139|Other|Stenting control|In case of control group (stenting control), XIENCE V stent was implanted to 60 patients. Patients with a single de novo native coronary stenosis of less than 12 mm lesion length, more than 50% stenosis and reference diameter of 3.0 mm as assessed by online QCA were stented by a single stent of 3.0 x 18 mm. The procedure of implantation had to be performed according to common interventional practices including the administration of intracoronary nitroglycerine 0.2 mg of glycerol trinitrate or isosorbide dinitrate and intra-arterial heparin (50-100 U/kg body weight). Predilation with a conventional balloon catheter was recommended before DES deployment according to the manufacturer's recommendation. The protocol recommended the study stent should cover 2 mm of non-diseased tissue on either side of the target lesion. Postdilatation was allowed with a balloon that was shorter than was the study device.
3189768|NCT01270126|Experimental|rtACS (Verum condition)|Repetitive transorbital alternating current stimulation (rtACS)
3189769|NCT01270126|No Intervention|Sham stimulation (placebo condition)|A clicking sound was presented and the same electrode montage set-up was used during rtACS- and placebo-stimulation, except that placebo patients received no current (stimulator turned off)
3189770|NCT01270100|Experimental|Recovery management intervention|
3189771|NCT01270087|Other|Adalimumab|
3189772|NCT01270074|Experimental|azithromycin liquid preparation|azithromycin will be given at a dose of 10mg/kg given three times per week from three months of age to three years of age
3189773|NCT01270074|Active Comparator|inert liquid preparation|inert liquid preparation will be given three times per week from three months of age to three years of age
3189774|NCT01270061|Active Comparator|HIV testing|Group 1 (Control) is the current standard of care in HIV testing. A trained counselor provides required information to obtain informed consent for HIV testing and provides rapid HIV testing on site.
3189775|NCT01270061|Experimental|General Health Screening|In Group 2 (Intervention), a theory-based video is used to obtain informed consent for a free general health screening that includes a blood pressure check, blood glucose measurement, and an HIV test.
3189870|NCT01269463|Placebo Comparator|Capsule without active drug|Double blind crossover assignment of the placebo comparator.
3189871|NCT01269450|Active Comparator|Utrogestan|
3189872|NCT01269450|Placebo Comparator|placebo|
3189776|NCT01270048|Experimental|Bunsimgieum extract|"name of product: 'mild-x-gwarip'~standard code for item: 200005689~shape, type: extract(brown)~usage, content: adults;three times a day, each taken before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36months after manufacture~macufacturing company: KyungBangnShinYak inc."
3189777|NCT01270048|Placebo Comparator|Placebo; corn flour,|"raw material: total contents(500㎎); cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)~shape, type: extract(brown)~usage, dose: adults: three times a day, 1 sack before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36 months after manufacture~manufacturing company: KyungBangnShinYak inc."
3189778|NCT01270035|Experimental|ADA 80 mg eow + MTX|
3189779|NCT01270022|Experimental|Implementation|
3189780|NCT01270022|Active Comparator|dissemination|
3189781|NCT01269996|Active Comparator|Metformin followed by gliclazide and protaphane|
3189782|NCT01269996|Active Comparator|Janumet followed by Lantus insulin injection|
3189783|NCT01269983|Experimental|fascial manipolation|8 treatment sessions: 4 of fascial manipulation treatment, and 4 of standard physiotherapy (rexing exercise, stretching, abdominal and paravertebral isometric muscular recruiting)
3189784|NCT01269983|Active Comparator|physiotherapy|8 treatment sessions of standard physiotherapy (rexing exercise, stretching, abdominal and paravertebral isometric muscular recruiting)
3189785|NCT01269970||locally advanced esophageal carcinoma (cT2-3N0/+)|
3189786|NCT01269957||Mouth breathing|
3189787|NCT01269957||Nasal breathing|
3189788|NCT01269944||Medial compartment knee osteoarthritis|Patients with medial compartment osteoarthritis of the knee, as proven by x-rays and clinical examination
3189789|NCT01269931||Group 1 (EBUS-TBNA simulator training)|Group 1 (EBUS-TBNA simulator training): pulmonary medicine trainees with >30 bronchoscopy procedures experience, >nine months of pulmonary fellowship training and no clinical EBUS-TBNA experience (n=4).
3189790|NCT01269931||Group 2 (Clinical EBUS-TBNA training)|Group 2 (Clinical EBUS-TBNA training): pulmonary medicine trainees in the 2nd half of their final year of pulmonary training or recent graduates (within one year), with >50 bronchoscopy procedures experience who completed a one-month elective with the Interventional Pulmonary Medicine (IPM) service with ≥15 and ≤25 EBUS-TBNA procedures experience (n=4).
3189791|NCT01269918|Active Comparator|Remifentanil|Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
3189792|NCT01269918|Active Comparator|Dexmedetomidine|a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
3189793|NCT01269905||Group A|Group A patients received mechanical heart valve replacement MHVR (and were educated in INR self-management using the Coagu-Check monitor.
3189794|NCT01269905||Group B|Group B patients received MHVR and their anticoagulation was managed by their general practitioners.
3189795|NCT01269905||Group C|Group C patients received stentless bioprosthesis, with initial 6 weeks on oral anticoagulation managed by their general practitioners.
3189796|NCT01269892|Other|lactose-free milk|it is kind of nutritional regime
3189797|NCT01269892|Other|conventional milk|it is kind of nutritional regime
3189798|NCT01269879|Active Comparator|Active control (Flexi-Bar only)|Flexi-Bar vibration training only over 12 weeks with three distinct exercises and 10min training twice daily
3189799|NCT01269879|Experimental|Intervention Flexi-Bar + XCO-Trainer|Combination intervention using vibration device Flexi-Bar and XCO-Trainer (oscillating mass witin a tube moved during running 40-60min/week suggested)
3189800|NCT01269866|Other|Cymbalta|Cymbalta 60 to 120 mg
3189801|NCT01269853|Experimental|Arm 2|
3189802|NCT01269853|Experimental|Arm 1|
3189803|NCT01269827|Experimental|pentoxifylline|
3189804|NCT01269827|Placebo Comparator|placebo|
3189805|NCT01269814||Go-home group|The patients with a Rockall score of 0 or 1 will be prescribed medical therapy, and will be scheduled for elective gastroscopy.
3189806|NCT01269801|Active Comparator|Botox Cosmetic|onabotulinumtoxinA for injection
3189807|NCT01269801|Active Comparator|JUVÉDERM|JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel
3189808|NCT01269788|Active Comparator|pH positive-omeprazole|
3189809|NCT01269788|Placebo Comparator|pH positive-placebo|
3189810|NCT01269788|Active Comparator|pH positive-fluoxetine|
3189811|NCT01269788|Active Comparator|pH negative-omeprazole|
3189812|NCT01269788|Active Comparator|pH negative-fluoxetine|
3189813|NCT01269788|Placebo Comparator|pH negative-placebo|
3189814|NCT01269775|Experimental|Face to face lecture|The lecturer allocated 1.5 hours for delivering the lecture by using provided slides about the topic and 0.5 hours for question and answer.
3189815|NCT01269775|Experimental|Internet based teaching|For providing materials for interactive internet-based group the professor's lecture was converted to an interactive electronic content. This content started with a case introduction followed with asking questions and then based on each student's answer a learning pathway would be assigned to his/her.
3189816|NCT01269775|Experimental|Computer based teaching|For providing material for computer-based group the lecture of the same professor was recorded in studio environment and was synchronized with the slides that were similar to those for lecture-based group. Then the lecture and the slides were converted to a CD as a multimedia CD.
3189817|NCT01269762|Experimental|LipoCol Forte|Subject will receive single dose of one, two and four 600 milligram (mg) red yeast rice capsules (LipoCol Forte)and multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days.
3189818|NCT01269749|Other|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
3189873|NCT01269437|Experimental|Budesonide, Novolizer|Budesonide Dry Powder Inhaler
3189874|NCT01269437|Active Comparator|BudesonideTurbuhaler|Budesonide Dry Powder Inhaler
3189819|NCT01269749|Other|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
3189820|NCT01269736|Experimental|Education|Online ECG monitoring education program and strategies to implement and sustain change for nurses
3189821|NCT01269736|No Intervention|Control|Usual in-service education for nurses
3189822|NCT01269723|Active Comparator|Broccoli sprout homogenate|"The broccoli sprouts and water are chopped in a blender until a uniform mix is obtained. Salt or sugar may be added to the shake."
3189823|NCT01269723|Placebo Comparator|alfalfa sprout homogenate|"Alfalfa sprouts and water are chopped in a blender until a uniform mix is obtained. Salt or sugar may be added to the shake."
3189824|NCT01269697|Active Comparator|Nutrof|patient receive the treatment of Nutrof Total
3189825|NCT01269697|Placebo Comparator|Placebo of Nutrof|Patient receive the treatment of the placebo of Nutrof Total
3189826|NCT01269684|Experimental|1|Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
3189827|NCT01269671|Experimental|Melatonin, Peppermint Oil, Simethicone|
3189828|NCT01269671|Placebo Comparator|Sugar pill|
3189829|NCT01269658|Experimental|Azithromycin ophthalmic solution, 1%|
3189830|NCT01269658|Placebo Comparator|Vehicle|
3189831|NCT01269645|Active Comparator|Usual care|"Usual care and provision of National Cancer Institute brochure Taking Part in Cancer Treatment Research Studies. Participants will be asked to read this brochure after completion of the baseline surveys and will be given a copy to take home with them."
3189832|NCT01269645|Experimental|Clinical Trial educational materials|Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
3189833|NCT01269632|Other|HIV infected|young adult infected by HIV
3189834|NCT01269632|Other|HIV uninfected|a control group of HIV uninfected young adult will be included for comparison in physiopathological module (metabolic, cardiovascular, and immunological)
3189835|NCT01269619|Experimental|Dynamic|Use of Dynamic back support
3189836|NCT01269619|Active Comparator|Static|Use of static back support
3189837|NCT01269606|Experimental|Treatment sequence 1 - IM treatment group|
3189838|NCT01269606|Experimental|Treatment sequence 2 - IM treatment group|
3189839|NCT01269606|Experimental|Treatment sequence 1 - IV treatment group|
3189840|NCT01269606|Experimental|Treatment sequence 2 - IV treatment group|
3189841|NCT01269593|Experimental|PET Imaging Using 124 IPUH71|Patients will receive an injection of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71, followed by serial PET scanning and blood draws, over a period of 3 days. Optional with a fourth day of PET scanning is to be pursued, in willing patients.
3189842|NCT01269580||Diabetic|Adult diabetic patients type 1 or 2, with chronic critical ischemia as defined by TASC 2007 criteria
3189843|NCT01269580||Not diabetic|Adult not diabetic with chronic critical ischemia
3189844|NCT01269567|Active Comparator|Drainage|Rectal excision with aspiration pelvic drainage
3189845|NCT01269567|Experimental|No drainage|Rectal excision without aspiration pelvic drainage
3189846|NCT01269554||Children with diarrhea in Bissau|
3189847|NCT01269554||Children without diarrhea in Bissau|
3189848|NCT01269554||Children without diarrhea in Finland|
3189849|NCT01269554||Children with diarrhea in Finland|
3189850|NCT01269554||Adults without diarrhea in Finland|
3189851|NCT01269554||Adults with diarrhea in Finland|
3189852|NCT01269554||Adults without diarrhea in Bissau|
3189853|NCT01269554||Adults with diarrhea in Bissau|
3189854|NCT01269541|Active Comparator|Mupirocin|Topical treatment
3189855|NCT01269541|Active Comparator|Rifampicin+Clindamycine or Trimethoprimsulfa|Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3xVII Trimethoprimsulfa 400mg/80mg 2x2
3189856|NCT01269528||Born in 2007-2008|Methacholine Challenge Test (MCT). Monthly telephone contact. Visits to the study site. Fractional exhaled nitric oxide. Blood test.
3189857|NCT01269528||Born in 2009-2010|Methacholine Challenge Test (MCT). Monthly telephone contact. Visits to the study site. Fractional exhaled nitric oxide. Blood test.
3189858|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 25 weeks ART-|Etoricoxib for 25 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 5 weeks.
3189859|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 2 weeks ART-|Etoricoxib for 2 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
3189860|NCT01269515|No Intervention|Control ART-|No Etoricoxib. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
3189861|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 25 weeks ART+|Etoricoxib for 25 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 5 weeks.
3189862|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 2 weeks ART+|Etoricoxib for 2 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
3189863|NCT01269515|No Intervention|Control ART+|No Etoricoxib. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
3189864|NCT01269502|Experimental|Skin temperature measurement|Regular measurement of skin temperature on feet for one year
3189865|NCT01269502|Active Comparator|Active control|Daily inspection of feet for one year
3189866|NCT01269489||general population|a representative sample from general Slovenian population
3189867|NCT01269476|Experimental|SNX-001|
3189868|NCT01269476|Placebo Comparator|Placebo|
3189869|NCT01269463|Active Comparator|Methylphenidate HCl ER Capsules|Methylphenidate hydrochloride extended release capsules
3190125|NCT01267578|Experimental|peptide vaccination|
3189875|NCT01269424|Active Comparator|Cohort 1|LV gene transfer after concurrent chemo-radiotherapy
3189876|NCT01269424|Active Comparator|Cohort 2|LV gene transfer prior to concurrent chemo-radiotherapy
3189877|NCT01269424|Active Comparator|Cohort 3|Intra patient dose escalation of TMZ in patients with evidence of P140K marked cells
3189878|NCT01269411|Experimental|Treatment (RO4929097 and surgery)|"PART A: Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive oral RO4929097 once daily on days 1-7 and undergo surgery on day 8. Beginning 28 days later, patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3189879|NCT01269398|No Intervention|GO-LIF procedure, posetrior facets fusion|
3189880|NCT01269398|Other|solid fusion, GO-LIF procedure|ability to achieve solid fusion, comibing the GO-LIF procedure for spinal fixation and stabilization with percutaneous posetrior facets fusion
3189881|NCT01269385|Experimental|Arm I|Patients receive PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31; alemtuzumab subcutaneously on days 3, 4, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; and rituximab IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity.
3189882|NCT01269359||radiation|
3189883|NCT01269346|Experimental|1|
3189884|NCT01269333|Active Comparator|fluvoxamine|
3189885|NCT01269333|Experimental|omeprazole|
3189886|NCT01269333|Placebo Comparator|placebo|
3189887|NCT01269307|Active Comparator|1:1 ketamine - propofol mixture|
3189888|NCT01269307|Active Comparator|propofol|propofol
3189889|NCT01269294|Experimental|001|TMC435 2 capsules of 75 mg once daily for 7 days in Treatment A
3189890|NCT01269294|Other|002|Placebo for TMC435 2 placebo capsules once daily for 7 days in Treatment A
3189891|NCT01269294|Other|003|Placebo for moxifloxacin 1 placebo tablet on Day 7 of Treatments A B and D
3189892|NCT01269294|Experimental|004|TMC435 2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
3189893|NCT01269294|Other|005|Placebo for TMC435 4 placebo capsules once daily for 7 days in Treatment C
3189894|NCT01269294|Other|006|Moxifloxacin 1 tablet of 400 mg on Day 7 of Treatment C
3189895|NCT01269294|Placebo Comparator|007|Placebo for TMC435 4 placebo capsules once daily for 7 days in Treatment D
3189896|NCT01269281|Experimental|Sumatriptan Succinate tablets 100 mg|Sumatriptan Succinate tablets 100 mg of Dr.Reddy's Laboratories Limited
3189897|NCT01269281|Active Comparator|Imitrex 100 mg Tablets|Imitrex 100 mg Tablets of Glaxosmithkline
3189898|NCT01269268||active tuberculosis|active TB patients : diagnosed with TB through microbiologic examination
3189899|NCT01269268||healthy control|healthy control : no evidence of respiratory disease, no respiratory symptoms, and no history of close contact of active pulmonary TB patients
3189900|NCT01269255|Experimental|Combination group|
3189901|NCT01269242|Experimental|bindarit 600 mg|
3189902|NCT01269242|Experimental|bindarit 1200 mg|
3189903|NCT01269242|Placebo Comparator|placebo|
3189904|NCT01269216|Active Comparator|5-FU with leucovorin|
3189905|NCT01269216|Active Comparator|TS-1 with Irinotecan|
3189906|NCT01269203|Active Comparator|Curcumin|1000 mg/day Curcumin + 5 -15 mg/day Lenalidomide
3189907|NCT01269203|Placebo Comparator|Placebo|Placebo daily + 5 -15 mg/day Lenalidomide
3189908|NCT01269190|Experimental|Mouth Exam|Oral mucosa in vivo assessment with wide-field and high resolution images obtained using new optical imaging devices composed of cameras and microscopes, and with a topically administered contrast agent.
3189909|NCT01269177||Patients with acute cardiogenic pulmonary edema|
3189910|NCT01269164|Experimental|Face Transplantation|Surgical Procedure Composite Facial Transplant
3189911|NCT01269151|Experimental|Lucentis (Ranibizumab)|
3189912|NCT01269138||Factor VII Deficient Patients|Patients affected by Inherited Factor VII deficiency undergoing treatment for bleeding episodes, surgery , prophylaxis.Any patient with levels of FVII less than 50% of normal or a mutation known to be associated to a FVII deficiency. Any patient with a FVII deficiency for whom treatment of bleeding episodes, prevention related to surgery and primary/secondary prophylaxis is considered necessary by his/her treating physician can be enrolled.
3189913|NCT01269125|Active Comparator|Endometriosis, leuprolide, IVF|Women with stage II endometriosis received GnRH-a (leuprolide) prior to an IVF attempt.
3189914|NCT01269125|Active Comparator|Endometriosis, IVF|Women with mild endometriosis who underwent an IVF attempt without prior administration of GnRH-a.
3189915|NCT01269125|Active Comparator|Tubal infertility, IVF|Women with tubal infertility underwent an IVF attempt.
3189916|NCT01269112|Placebo Comparator|heparin|CVVHDF performed using unfractionated heparin as anticoagulant and Prismasol as reinjection and dialysate fluids
3189917|NCT01269112|Active Comparator|citrate regional anticoagulation|CVVHDF performed using Prismocitrate 18/0 solution (Trisodium citrate 18 mmol/L
3189918|NCT01269099|Active Comparator|Control|Control-group
3189919|NCT01269099|Experimental|IV-PCA|IV-PCA group
3189920|NCT01269086|No Intervention|Usual Care|Traditional care with no systematic assessment of family member´s health problems or risk factors.
3189921|NCT01269086|Experimental|Family Preventive Visit|Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
3189922|NCT01269060|Experimental|Single incision sigmoidectomy|Single incision laparoscopic sigmoidectomy for sigmoid colon cancer
3189923|NCT01269047|Experimental|Pramlintide + Insulin Group|These kids will get Pramlintide (Symlin) along with insulin before breakfast and supper.
3189924|NCT01269047|Experimental|Exenatide + Insulin Group|This group will get Exenatide(Byetta) along with insulin before breakfast and supper.
3189925|NCT01269047|Active Comparator|Insulin monotherapy|This group will be on their regular insulin therapy.
3189926|NCT01269034|Experimental|Part A|Exenatide and long acting insulin before the boost.
3189927|NCT01269034|Active Comparator|Part B|Rapid and long acting insulin before the boost
3189928|NCT01269034|Active Comparator|Part C|long acting insulin+ rapid acting+1.25 mcg Exenatide before the boost
3190708|NCT01263496|Experimental|Alogliptin 50 mg QD|
3189929|NCT01269034|No Intervention|Healthy controls|healthy controls without any medication before the boost.
3189930|NCT01269021|Experimental|mycophenolate mofetil|
3189931|NCT01269021|Active Comparator|Prednisone|
3189932|NCT01268995|Experimental|Cyclosporine A|Patients in this arm will be switched from immunosuppressive therapy with Tacrolimus to Cyclosporine A. Furthermore, patients in this arm will commence insulin treatment with NPH-insulin to reach normoglycemia. After the achievement of normoglycemia the insulin treatment will be continued for three more weeks and than terminated.
3189933|NCT01268995|Active Comparator|Tacrolimus|Patients in this arm will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, patients in this arm will commence insulin treatment with NPH-insulin to reach normoglycemia. After the achievement of normoglycemia the insulin treatment will be continued for three more weeks and than terminated.
3189934|NCT01268982|Experimental|preserved socket|sockets will be filled with DFDBA and covered with absorbable membrane. Primary coverage will be achieved by full thickness mucosal flap advancement over each socket.
3189935|NCT01268969|Active Comparator|excision and krydakis reconstruction|The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
3189936|NCT01268969|Active Comparator|surgical excision and limberg closure|The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia . The fasciocutaneous flap was transposed medially so that the defect would be covered without any tension.
3189937|NCT01268956||Lymphatic progenitor cell|Circulating lymphatic progenitor cell
3189938|NCT01268956||Control|healthy people
3189939|NCT01268943|Experimental|1000mg|capecitabine 1000mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
3189940|NCT01268943|Experimental|1200mg|capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
3189941|NCT01268943|Experimental|1400mg|capecitabine 1400mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
3189942|NCT01268943|Experimental|1500mg|capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
3189943|NCT01268930|Active Comparator|Bipolar coagulation|In this arm, after the complete excision of ovarian endometrioma, ovarian hemostasis is provided by bipolar electrocoagulation.
3189944|NCT01268930|Active Comparator|Hemostatic matrix|In this arm, after complete excision of ovarian endometrioma, ovarian hemostasis is provided by hemostatic matrix.
3189945|NCT01268917|Experimental|preoperative aspirin use|
3189946|NCT01268917|No Intervention|preoperative aspirin nonuse|
3189947|NCT01268904||Pediatric status epilepticus|
3189948|NCT01268891|Placebo Comparator|Placebo|
3189949|NCT01268891|Experimental|Azilect®|
3189950|NCT01268865||HBV-infected|
3189951|NCT01268865||HCV-infected|
3189952|NCT01268852|Active Comparator|Damon|Standard self ligating orthodontic Damon brackets
3189953|NCT01268852|Experimental|Insignia|Innovative self ligating orthodontic bracket
3189954|NCT01268839|Experimental|001|Efavirenz 600mg tablet once daily for 14 days,TMC278 25mg tablet once daily for 14 days,TMC278 25mg tablet once daily for 28 days
3189955|NCT01268826||dosage of the urinary osmolality|dosage of the urinary osmolality
3189956|NCT01268813|Experimental|Exhaled breath uptake blood test|Diabetic patients receiving oral hypoglycemic drug will be tested for biomarkers in their breath and blood samples
3189957|NCT01268813|No Intervention|Exhaled breath and blood test|Breath and blood samples will be collected from healthy volunteers and analyzed using Gas Chromatography-Mass Spectroscopy. The results will be compared to the experimental arm.
3189958|NCT01268800||AML induction|Adults AML patients who were referred for intensive induction therapy
3189959|NCT01268787|Active Comparator|EV 71 vaccine 5ug|EV71 Vaccine 5ug
3189960|NCT01268787|Experimental|EV 71 vaccine 10ug|EV71 vaccine 10ug
3189961|NCT01268761|Experimental|GnRH antagonist|• GnRH antagonist (Cetrorelix 0.25)
3189962|NCT01268761|Placebo Comparator|Placebo (saline solution)|• Placebo (saline solution)
3189963|NCT01268748|Other|4 ports laparoscopic cholecystectomy|
3189964|NCT01268748|Other|One port transumb. laparoscopic surgery|
3189965|NCT01268735|Experimental|Lubricating eyedrops containing HP-guar|
3189966|NCT01268722|Active Comparator|Balloon|
3189967|NCT01268722|Experimental|Stent|
3189968|NCT01268709|Active Comparator|doxepin|
3189969|NCT01268709|Active Comparator|nortriptyline|
3189970|NCT01268709|Placebo Comparator|placebo|
3189971|NCT01268696||control group|healthy volunteers
3189972|NCT01268696||Metabolic group|Patients with metabolic syndrome
3189973|NCT01268683|Experimental|RP-1127 (Glyburide for Injection)|This arm is administered a RP-1127 bolus followed by continuous infusion of RP-1127 for 72 hours
3189974|NCT01268670|Active Comparator|Ibuprofen|Subjects will receive topical LET and oral ibuprofen.
3189975|NCT01268670|Active Comparator|Oxycodone|Subjects will receive topical LET and oral oxycodone.
3189976|NCT01268670|Placebo Comparator|Placebo|Subjects will receive topical LET and oral placebo.
3189977|NCT01268657|Experimental|Cognitive Behavioral Exposure Therapy|
3189978|NCT01268644|Experimental|active open label Leptin|Active open label Leptin for type 1 Diabetes
3189979|NCT01268631|Active Comparator|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks. The assessing person will contact patients by phone every week during the treatment period to receive the pain score for the last 24 hours, so we will have an indication of the effect among patients will discontinue medication. Patients will be asked to visit the clinic during the last week of treatment, for assessment of clinical pain (questionnaires) and pain modulation.
3189980|NCT01268631|Active Comparator|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 4 weeks. Drug should not be taken with meals. Same protocol will be applied as for Duloxetine.
3189981|NCT01268618|Experimental|Probiotic|
3189982|NCT01268618|Placebo Comparator|Placebo|
3189983|NCT01268605|Active Comparator|Restoration with a dentin bonding agent (DBA)|Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.
3189984|NCT01268605|Active Comparator|Restoration with a resin modified glass ionomer liner (RMGI)|Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
3189985|NCT01268592|Experimental|positive cancer diagnosis|female patients diagnosed with cancer who wish to preserve their fertility by vitrifying their oocytes
3189986|NCT01268579|Experimental|ribavirin|This will be a single institution non-randomized study for patients with tonsil and/or base of tongue squamous cell cancer. This is a pilot study to obtain pharmacodynamic data regarding the effects of ribavirin on tonsil squamous cell cancer.
3189987|NCT01268566|Experimental|MEDI-575, 25 mg/kg|MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minutes on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participants withdrawal.
3189988|NCT01268553|Experimental|Active treatment|This is the only arm in the trial. All enrolled subjects will be attempted to transition to inhaled treprostinil. There is no placebo and control arm.
3189989|NCT01268540|Experimental|NHT15|Aspheric Toric Intraocular Lens Models NHT15
3189990|NCT01268540|Active Comparator|FY-60AD|Aspheric Non-toric Intraocular Lens: Model FY-60AD
3189991|NCT01268540|Experimental|NHT30|Aspheric Toric Intraocular Lens Model NHT30
3189992|NCT01268540|Experimental|NHT53|Aspheric Toric Intraocular Lens Models NHT53
3189993|NCT01268527|Experimental|Cohort 1|Three concentrations of E6201 topical gel (0.03%, 0.1%, and 0.2%) and active comparator, calcipotriene cream (0.005%), were applied once daily for 12 days to specific test fields determined at Baseline. The 3 concentrations of E6201 gel were dosed first in Cohort 1 to establish the safety and tolerability prior to dosing in Cohort 2.
3189994|NCT01268527|Experimental|Cohort 2|Three concentrations of E6201 topical gel (0.005%, 0.01%, and 0.05%) and active comparator, calcipotriene cream (0.005%), were applied once daily for 12 days to specific test fields determined at Baseline. Cohort 2 participants were not dosed until all participants in Cohort 1 completed treatment and safety data were collected and evaluated.
3189995|NCT01268501|Experimental|Lotrafilcon B multifocal|Lotrafilcon B multifocal contact lenses worn bilaterally for 3 weeks on a daily wear basis
3189996|NCT01268488|Experimental|Intended Users of the System|Untrained subjects with diabetes obtained capillary fingerstick, palm, and forearm blood and performed Blood Glucose (BG) tests using a Ninja 2 investigational blood glucose meter and the Contour® sensor. This BG monitoring system will not proceed to marketed product.
3189997|NCT01268462|Experimental|Heliox + PEP (Group 1)|
3189998|NCT01268462|Experimental|Oxygen+PEP(Group 2)|
3189999|NCT01268462|Experimental|Heliox ( Group 3)|
3190000|NCT01268462|Active Comparator|Oxygen (Group 4)|
3190001|NCT01268449|Active Comparator|Laser group|
3190002|NCT01268449|Placebo Comparator|Placebo group|Randomly,half of the patients receive placebo.
3190003|NCT01268436||Injectable pain medication|Patients who receive an injectable form of pain medication.
3190004|NCT01268436||Oral pain medication|Patients who receive oral pain medication only
3190005|NCT01268423|Experimental|Early percutaneous tracheostomy|
3190006|NCT01268423|Active Comparator|Prolonged translaryngeal intubation|
3190007|NCT01268410||acute respiratory failure|
3190008|NCT01268397|Active Comparator|open reduction and internal fixation with a volar plate|
3190009|NCT01268397|Active Comparator|closed reduction and plaster treatment|
3190010|NCT01268384|Experimental|FDR_GX|Fixed dose rate gemcitabine plus capecitabine every 3 weeks for 3-9 cycles
3190011|NCT01268371|Active Comparator|Promus Element|Everolimus-eluting stent
3190012|NCT01268371|Active Comparator|Nobori|Biolimus-eluting stent with biodegradable polymer
3190013|NCT01268358|Experimental|Lamazym 6.25|
3190014|NCT01268358|Experimental|Lamazym 12.5|
3190015|NCT01268358|Experimental|Lamazym 25|
3190016|NCT01268358|Experimental|Lamazym 50|
3190017|NCT01268358|Experimental|Lamazym 100|
3190018|NCT01268345|Experimental|Andon|Andon blood glucose test strips with test meter
3190019|NCT01268345|Active Comparator|Lifescan|
3190020|NCT01268332|Experimental|Intravaginal Ring|Insertion of intravaginal ring at enrollment. The intravaginal ring should stay in place for 12 consecutive weeks and will be removed by a physician at the Week 12 study visit.
3190021|NCT01268332|No Intervention|No Intravaginal Ring|Intravaginal ring will not be inserted into participants.
3190022|NCT01268319|Experimental|(+)HR-LCP and EPD|These subjects will meet all angiographic criteria.The target plaque will contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 27 Subjects who meet this criteria will be randomized to standard pre-dilation and stent implantation with an embolic protection device (EPD)in place prior to any angioplasty.
3190023|NCT01268319|Placebo Comparator|(+)HR-LCP and No EPD (standard of care)|These subjects will meet all angiographic criteria.The target plaque will contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 27 Subjects who meet this criteria will be randomized to standard pre-dilation and stent implantation without an embolic protection device (EPD)in place prior to any angioplasty.
3190024|NCT01268319|Placebo Comparator|(-)HR-LCP and No EPD (standard of care)|These subjects will meet all angiographic criteria.The target plaque will NOT contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 54 Subjects who meet this criteria will be assigned (not randomized) to standard pre-dilation and stent implantation without an embolic protection device (EPD)in place prior to any angioplasty.
3190025|NCT01268306|Experimental|B+L Biotrue MPS and B+L PureVision|Successful contact lens wearers switched to B&L BioTrue MPS while wearing B+L PureVision lenses
3190026|NCT01268293|Experimental|1|
3190027|NCT01268280|Experimental|Three-way crossover|2 oral dose levels of CK-2017357 and placebo
3190028|NCT01268267|Experimental|Intended Users of the System|Untrained subjects with diabetes obtained capillary fingerstick, palm, and forearm blood and performed Blood Glucose (BG) tests using an investigational blood glucose monitoring system (development name Ninja 2).
3190029|NCT01268254||red wine|red wine usual consumer versus abstemious
3190030|NCT01268241||Observation|Hemizygous male or heterozygous female patients of any age with genetically confirmed diagnosis of Anderson-Fabry disease.
3190031|NCT01268228||Residual ic ECG ST elevation in SB|
3190032|NCT01268228||Residual ic ECG ST elevation in MB|
3190033|NCT01268215|Experimental|A (two study drugs group)|The standard management + two study drugs (endotracheal instillation of a mixture containing budesonide and Infasurf)
3190034|NCT01268215|Active Comparator|B (one study drug group)|The standard management + one study drug (endotracheal instillation of Infasurf only).
3190035|NCT01268215|Sham Comparator|C (no study drug group)|The standard management only.
3190036|NCT01268202|Experimental|Pravastatin|Pravastatin : 40mg/day during 12 months
3190037|NCT01268189|Experimental|Burn wound patients with donor sites|Oxygen diffusing dressing applied to wound vs standard of care dressing (Xeroform) applied to wound (patient serves as own control as s/he receives 1 dressing on 1 donor site and the other on a 2nd donor site)
3190038|NCT01268176|Active Comparator|Low fat meal|Those subjects who receive a low fat meal prior to vitamin D3 administration
3190039|NCT01268176|Active Comparator|High fat meal|Those subjects who receive a high fat meal prior to vitamin D3 administration
3190040|NCT01268176|Active Comparator|No meal|Those subjects who do not receive a meal and continue to fast. They only receive the vitamin D3 dose.
3190041|NCT01268163|Active Comparator|1|European Taxotere® (Taxotere EU) 60-100 mg/m^2
3190042|NCT01268163|Experimental|3|Hospira Docetaxel Injection 60-100 mg/m^2
3190043|NCT01268163|Active Comparator|2|American Taxotere® (Taxotere US) 60-100 mg/m^2
3190044|NCT01268150|Experimental|Experimental|
3190045|NCT01268137|Active Comparator|stimulation on|At first stage, electrodes will be implanted in all patients, who will be continuously stimulated for several months. After this stage, the random-crossed part of the study will start, and patients who responded to DBS will be randomly distributed in two groups: on stimulation or off stimulation group, for the next three months. Subsequently, patients will be allocated in the other group (on or off, crossed part) for three months
3190046|NCT01268137|Placebo Comparator|Stimulation off|At first stage, electrodes will be implanted in all patients, who will be continuously stimulated for several months. After this stage, the random-crossed part of the study will start, and patients who responded to DBS will be randomly distributed in two groups: on stimulation or off stimulation group, for the next three months. Subsequently, patients will be allocated in the other group (on or off, crossed part) for three months
3190047|NCT01268124|Experimental|Treatment|
3190048|NCT01268111|Experimental|Vitamin D|ERgocalcifoerol 50,000 units q weekly for 8 weeks
3190049|NCT01268111|Placebo Comparator|Placebo|
3190050|NCT01268098|Experimental|25 µg dose|25 µg
3190051|NCT01268098|Experimental|50 µg dose|50 µg
3190052|NCT01268085|Experimental|Radiation Safety Alert|A provider placing an electronic order for a CAT scan will receive a radiation safety pop-up alert with a message about the dangers of cumulative ionizing radiation, the patient's cumulative CAT scan history, and the most recent imaging test from any modality of the same body part.
3190053|NCT01268085|Active Comparator|Control|Parallel control with no intervention
3190054|NCT01268072||Cohort 2|Subjects who are recruited on admission to hospital for AECOPD.
3190055|NCT01268072||Cohort 1|Subjects with COPD who are stable, but at risk of presenting with an AECOPD.
3190056|NCT01268059|Active Comparator|MEDI-575 Dose Determination|
3190057|NCT01268059|Active Comparator|Arm A|
3190058|NCT01268059|Active Comparator|Arm B|
3190059|NCT01268046|Experimental|Young postmenopausal women - estrogen|transdermal estrogen patch OR estradiol oral capsule for 1 month
3190060|NCT01268046|Experimental|Older postmenopausal women - estrogen|transdermal estrogen patch OR estradiol oral capsule for 1 month
3190061|NCT01268046|Placebo Comparator|Young postmenopausal women - placebo|transdermal placebo patch for 1 month or placebo oral capsule for 1 month
3190062|NCT01268046|Placebo Comparator|Older postmenopausal women - placebo|transdermal placebo patch for 1 month or placebo oral capsule for 1 month
3190063|NCT01268033|Experimental|Rituximab|two infusions of Rituximab - at the dose of 375 mg/m²
3190064|NCT01268033|Placebo Comparator|placebo|two infusions of placebo
3190065|NCT01268020|Experimental|[18F]-FMH3-01 PET Imaging|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) or 2 ug of [18F]-FMH3, whichever is greatest.
3190066|NCT01268007||Normal ECG measurements|Observational, un-blinded, non-interventional study designed to collect ECG data on at least one (1) male patient in an outpatient setting.
3190067|NCT01267994|Experimental|Single Arm-Open Label|Single Arm-Open Label use of Anakinra
3190068|NCT01267981|Placebo Comparator|Preparation 1|Standard diet: the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.
3190069|NCT01267981|Active Comparator|Preparation 2|"Standard diet : the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.~500 ml of polyethylene glycol 30 minutes after the ingestion of video-capsule endoscopy."
3190070|NCT01267981|Active Comparator|Preparation 3|"Standard diet : the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.~2 liters of polyethylene glycol between 7 pm and 9 pm.~500 ml of polyethylene glycol, 30 minutes after the ingestion of video-capsule endoscopy."
3190071|NCT01267968|Experimental|Cohort 1|GSK2251052 1500 mg Single dose (i.v., 60 min)
3190072|NCT01267968|Experimental|Cohort 2|GSK2251052 1500 mg IV q12h x 5 doses infused over 60 minutes
3190073|NCT01267955|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3190074|NCT01267942|Experimental|Intravenous intraoperative Enhancin|Patients received a dose of intravenous Enhancin at induction and only oral Paracetamol in the postoperative period.
3190075|NCT01267942|Active Comparator|Postoperative oral Enhancin.|Patients received postoperative oral Enhancin for five days in addition to oral Paracetamol for the same duration. They did not receive an antibiotic during the operation.
3190076|NCT01267929|Experimental|The mirror neurons stimulation based VCD program|The children receive the mirror neurons stimulation based VCD program and practice at home three times a day for six months. The mirror neurons stimulation based VCD program that contained four volumes. The first volume includes activities activities for improving balance in sitting position. The second volume includes activities of sitting to standing. The third volume includes activities for improving balance in standing position. The last one includes activities of sideway walking. The running time of each volume is 30 minutes. The children had been practicing for two weeks per volume. Their parents were trained for practicing their children by VCD program at home and were asked to complete daily record of children's activities. The children were scheduled to meet a pediatric physical therapist once a week to monitor possible side effects.
3190077|NCT01267929|Active Comparator|The conventional physical therapy|The children receive manual physical therapy regularly at the hospital once a week for first two months and twice a month for last four months. The conventional physical therapy technique in this study derive from the manual technique including the Bobath concept, stretching exercise and functional training for 30-45 minutes at a time.
3190078|NCT01267916|Experimental|RR 6 + 0|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
3190079|NCT01267916|Experimental|RR 10 + 0|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
3190080|NCT01267916|Experimental|RR 16 + 0|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
3190081|NCT01267916|Experimental|RR 6 + 5|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
3190082|NCT01267916|Experimental|RR 10 + 5|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
3190083|NCT01267916|Experimental|RR 16 + 5|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
3190084|NCT01267903|Experimental|320U /0.5ml in young adults|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 20 young adults aged 16-22 years old on day0,28
3190085|NCT01267903|Experimental|640U /0.5ml in young adults|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 20 young adults aged 16-22 years old on day0,28
3190086|NCT01267903|Experimental|160U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 20 children aged 5-15 years old on day0,28
3190087|NCT01267903|Experimental|320U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 20 children aged 6-15 years old on day0,28
3190088|NCT01267903|Experimental|640U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 20 children aged 6-15 years old on day0,28
3190089|NCT01267877|Active Comparator|Guideline unfavorable article|
3190090|NCT01267877|Active Comparator|Guideline favorable article|
3190091|NCT01267864|Active Comparator|Metoclopramide|Metoclopramide 10mg IVSS
3190092|NCT01267864|Active Comparator|Ketorolac|Ketorolac 30mg IV
3190093|NCT01267864|Active Comparator|Valproate|1gm IV
3190094|NCT01267838|Active Comparator|T Stenting group|PCI of bifurcation lesion with modified T Stenting.
3190095|NCT01267838|Active Comparator|Culotte stenting group|PCI of bifurcation lesion with Culotte stenting
3190096|NCT01267825|Experimental|CT-guided intervention|CT guided perineural injection of corticosteroid+ bupivicaine Also get typical medical care
3190097|NCT01267825|Active Comparator|Standard medical care|
3190098|NCT01267812|Experimental|Treatment (bortezomib and rituximab)|Patients receive bortezomib SC or IV over 3-5 seconds and rituximab IV on days 1, 8, 15, and 22. Treatment with bortezomib repeats every 3 months for up to 8 courses and treatment with rituximab repeats every 6 months for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3190099|NCT01267799||photocopier exposure|
3190100|NCT01267799||control|
3190101|NCT01267786|Active Comparator|Sevoflurane|1MAC intraoperatively
3190102|NCT01267786|Active Comparator|desflurane|1 MAC intraoperatively
3190103|NCT01267773|Active Comparator|Sequential Treatment|
3190104|NCT01267773|Experimental|Integrated Treatment|
3190105|NCT01267760|Active Comparator|conventional HD|conventional 4-hour HD
3190106|NCT01267747||Atrial fibrillation or flutter patients|Patients with atrial flutter or lone (non valvular), paroxysmal, persistent, or permanent atrial fibrillation consecutively admitted at Internal Medicine, Cardiology and Endocrinology Units.
3190107|NCT01267734|Experimental|EECSS + DDAT|Promus Element stent + double-dose clopidogrel anti-platelet therapy
3190108|NCT01267734|Active Comparator|ZECSS + DDAT|Endeavor Resolute stent + double-dose clopidogrel anti-platelet therapy
3190109|NCT01267734|Experimental|EECSS + TAT|Promus Element stent + triple anti-platelet therapy
3190110|NCT01267734|Active Comparator|ZECSS + TAT|Endeavor Resolute stent + triple anti-platele therapy
3190111|NCT01267721||Study Group|A single group of 100 consecutive patients will undergo additional blood sampling at different time points
3190112|NCT01267708||Study Group|All those tested
3190113|NCT01267682|No Intervention|Usual care|Participants receive standard clinical care
3190114|NCT01267682|Experimental|Treatment|Behavioral: cognitive stimulation
3190115|NCT01267669|Experimental|EVL plus Somatostatin|Emergency EVL plus Somatostatin (250 mcg/hr) infusion for 5 days
3190116|NCT01267669|Placebo Comparator|EVL plus Placebo|Emergency EVL plus placebo infusion for 5 days
3190117|NCT01267643|Experimental|Alefacept|
3190118|NCT01267630||Surgical ICU|Patients are admitted to the surgical ICU of Chiang Mai University Hospital within 48 hours .
3190119|NCT01267617||chronic hemodialysis outpatients|
3190120|NCT01267604|Active Comparator|Recombinant FSH|225IU rFSH
3190121|NCT01267604|Experimental|Recombinant FSH Inositol Melatonin|225IU rFSH, 4g Inositol and 3mg Melatonin
3190122|NCT01267591||control|
3190123|NCT01267591||type 1 diabetes|
3190124|NCT01267591||obesity|
3190126|NCT01267565|Other|intubated and ventilated patients|patients undergoing mechanical ventilation for an anticipated length of more than 48h
3190127|NCT01267565|Other|non intubated patients|non intubated patients with an independant indication of bronchoscopy including an endotracheal aspiration during the procedure
3190128|NCT01267552|Experimental|Non drainage arm|No drains will be placed during operation
3190129|NCT01267552|Active Comparator|Drainage arm|Closed suction drains will be placed during operation
3190130|NCT01267513||normal volunteers|Normal individuals, aged 18 -75
3190131|NCT01267513||Hospitalized patients|Pulmonary and cardiac ICU, Trauma
3190132|NCT01267500|Experimental|Non-surgical therapy|patching or fusion exercises
3190133|NCT01267487|Active Comparator|Fixed doses plus PO protamine|"Intraoperative fixed dose schemes (as in fixed doses plus placebo group) plus continuous infusion of 25mg/hour of protamine during first 6 PO hours"
3190134|NCT01267487|Active Comparator|Titrated doses plus PO protamine|"Same as titrated doses arm, plus continuous infusion of 25mg/ hour of protamine during first 6 PO hours"
3190135|NCT01267487|No Intervention|Fixed doses plus placebo|"Before CPB, fixed heparin dose of 400 Units per kg of body weight to achieve an Activated Coagulation Time (ACT) > 480 seconds.~Reversal of heparin after CPB using 1 : 1 ratio (1 mg of protamine for each 100 units (1mg) of heparin), plus 0.8 mg/kg of protamine at the end of the surgery.~Continuous infusion of placebo (saline 0.9%) during the first 6 PO hours."
3190136|NCT01267487|Active Comparator|Titrated doses plus placebo|"Titrated doses of heparin before and during CPB and reversal with protamine after CPB calculated by the construction of individualized Bull's dose-response curve.~Continuous infusion of placebo (saline 0.9%) during first 6 PO hours."
3190137|NCT01267474|Experimental|Nutritional education|
3190138|NCT01267474|No Intervention|Control|
3190139|NCT01267448|Active Comparator|Saxagliptin + Metformin XR|Saxagliptin 5 mg + Metformin XR 1000 mg will be automatically titrated weekly in 2 weeks to Saxagliptin 5 mg + Metformin XR 2000 daily for a total duration of 12 weeks.
3190140|NCT01267448|Active Comparator|the Control goup Glipizide XL|The control group will receive Sulphonylurea (Glipizide XL 10mg orally) for a total duration of 12 weeks.
3190141|NCT01267435|Other|determining correct tunnel positions|
3190142|NCT01267422|Experimental|rAAV2-ND4|injection
3190143|NCT01267396|Experimental|Sertraline Hydrochloride tablets 100 mg|Sertraline Hydrochloride tablets 100 mg of Dr.Reddy's Laboratories Limited
3190144|NCT01267396|Active Comparator|Zoloft 100 mg Tablets|Zoloft 100 mg Tablets of Pfizer
3190145|NCT01267383|Experimental|Sertraline Hydrochloride tablets 100 mg|Sertraline Hydrochloride tablets 100 mg of Dr.Reddy's Laboratories Limited
3190146|NCT01267383|Active Comparator|Zoloft 100 mg Tablets|Zoloft 100 mg Tablets of Pfizer
3190147|NCT01267370|Active Comparator|Soy polysaccharide fiber|Dietary fiber for treatment of chronic constipation in children
3190148|NCT01267370|Placebo Comparator|purified soy extract, with no fiber)|blinded control group
3190149|NCT01267357||Serous papillary endometrial ca patients|30 patients diagnosed with SP endometrial ca
3190150|NCT01267357||Endometrioid endometrial ca|32 patients diagnosed with Endometrioid endometrial ca
3190151|NCT01267344|Active Comparator|GEMOX|Intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks.
3190152|NCT01267344|Experimental|E-GEMOX|Arm A will receive E-GEMOX with additional intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above.
3190153|NCT01267331|Experimental|stem cells injection|Direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG
3190154|NCT01267331|Placebo Comparator|palcebo intramyocardial injection|Direct intramyocardial injection of placebo containing saline and 5% human serum albumin during CABG.
3190155|NCT01267305|Active Comparator|lung lmwh1|use LMWH once daily after lung resection
3190156|NCT01267305|Experimental|lung lmwh2|use LMWH twice daily after lung resection
3190157|NCT01267305|Experimental|lung Fondaparinux|use Fondaparinux once daily after lung resection
3190158|NCT01267305|Active Comparator|eso lmwh1|use LMWH once daily after esophagectomy
3190159|NCT01267305|Experimental|eso lmwh2|use LMWH twice daily after esophagectomy
3190160|NCT01267305|Experimental|eso Fondaparinux|use Fondaparinux once daily after esophagectomy
3190161|NCT01267292|Experimental|Buspirone plus Methylphenidate|[week 1: Buspirone 30 mg twice a day (9am and 6pm) on Monday through Sunday; no Methylphenidate or Methylphenidate placebo] [week 2: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday; 0mg Methylphenidate (placebo) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday; Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
3190162|NCT01267292|Placebo Comparator|Placebo for Buspirone plus Methylphenidate|[week 1: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; no Methylphenidate or Methylphenidate placebo] [week 2: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
3190163|NCT01267279|Placebo Comparator|Placebo group|
3190164|NCT01267279|Experimental|Study drug group|
3190165|NCT01267266|Experimental|Arm I (saracatinib)|Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3190166|NCT01267266|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Upon progression, patients may crossover to arm I.
3190167|NCT01267253|Experimental|Treatment (brivanib alaninate)|Patients receive brivanib alaninate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3190168|NCT01267240|Experimental|Arm I (capecitabine, vorinostat)|Patients receive capecitabine PO BID and vorinostat PO daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3190169|NCT01267227|Active Comparator|High Dose|Pterostilbene 125 mg twice daily
3190170|NCT01267227|Active Comparator|Low Dose|Pterostilbene 50 mg twice daily
3190171|NCT01267227|Active Comparator|Low Dose Combination|Pterostilbene 50 mg/Grape Extract 100 mg twice daily
3190172|NCT01267227|Placebo Comparator|Placebo|Matching placebo twice daily
3190173|NCT01267214|Experimental|Osteotomy plus Hyalgan|Osteotomy at Week 0 Hyalgan injection at Week 2, 3, 4, 5, 6, 24, 25, 26, 27, 28
3190174|NCT01267214|Other|Osteotomy alone|
3190175|NCT01267201|Experimental|POS formulation #1|
3190176|NCT01267201|Experimental|POS formulation #2|
3190177|NCT01267201|Active Comparator|commercial tablet|
3190178|NCT01267188|Experimental|NBI-98854|Open-label, dose titration of active drug
3190179|NCT01267175|Experimental|X54 pump|All subjects transferred from current pump to X54
3190180|NCT01267162||TDF Treatment|
3190181|NCT01267136|Experimental|Capital® with Codeine Suspension|
3190182|NCT01267136|Active Comparator|Tramadol suspension|
3190183|NCT01267123|Experimental|Trendelenburg position|The endoscopist places the patient in 15° Trendelenberg position immediately prior to the initiation of the colonoscopy.
3190184|NCT01267123|Other|Standard care|The patient will have colonoscopy in the standard horizontal position
3190185|NCT01267110|Experimental|Intervention|
3190186|NCT01267110|Active Comparator|Control|
3190187|NCT01267097|Experimental|Cognitive Behavioural Therapy (CBT)|Group-based lifestyle counseling for parents
3190188|NCT01267097|Experimental|Psycho-Education Program (PEP)|Group-based lifestyle counseling for parents
3190189|NCT01267084|Experimental|Part 1|Patients will receive trabectedin+ketoconazole followed by trabectedin alone. Each cycle will be will be separated by 21 days. Patients will receive 6 total consecutive doses of ketoconazole. Dexamethasone or equivalent steroid will be administered before trabectedin in each cycle.
3190190|NCT01267084|Experimental|Part 2|Patients will receive 1 of 2 treatment sequences; Sequence 1: trabectedin+ketoconazole followed by trabectedin alone or Sequence 2: trabectedin alone followed by trabectedin+ketoconazole. Each cycle will be separated by 21 days. Patients will receive 15 total consecutive doses of ketoconazole. Dexamethasone or equivalent steroid will be administered before trabectedin in each cycle.
3190191|NCT01267071|Experimental|A|GSK962040 (50 mg, SD, oral)
3190192|NCT01267071|Experimental|B|14C GSK962040 (100 μg, SD, iv)
3190193|NCT01267058|Experimental|Group A|Subjects will receive the combined diphtheria, tetanus, acellular pertussis vaccine
3190194|NCT01267058|Active Comparator|Group B|Subjects will receive the acellular pertussis vaccine and one month later the combined diphtheria and tetanus vaccine
3190195|NCT01267058|Active Comparator|Group C|Subjects will receive the combined diphtheria and tetanus vaccine and one month later the acellular pertussis vaccine
3190196|NCT01267045|Experimental|Arm 1|Participants in this arm undergo the mindfulness training intervention through taking part in a Mindfulness-Based Stress Reduction course
3190197|NCT01267045|No Intervention|Arm 2|Treatment as usual for Gulf War Syndrome symptoms (medications, psychotherapy, etc.)
3190198|NCT01267032|Experimental|Arm 1|Integrated Care + Cognitive-Behavioral Treatment for Insomnia
3190199|NCT01267032|Sham Comparator|Arm 2|Integrated Care + Desensitization Treatment for Insomnia
3190200|NCT01267019|Experimental|Arm 1: vivo augmentation|social cognitive training with in vivo augmentation
3190201|NCT01267019|Active Comparator|Arm 2: social cognitive|social cognitive training
3190202|NCT01267019|Active Comparator|Arm 3: non-social skills|non-social skills training
3190203|NCT01267006|Placebo Comparator|Placebo|Part A - Cohort 1 subjects will be administered GSK1325756 matching placebo tablets twice daily following a light meal for one day in accordance with the randomization schedule.
3190204|NCT01267006|Experimental|GSK1325756 200 mg|Part A - Cohort 1 subjects will be administered GSK1325756 200 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule.
3190205|NCT01267006|Experimental|GSK1325756 50 mg|Part A - Cohort 1 subjects will be administered GSK1325756 50 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule.
3190206|NCT01267006|Experimental|GSK1325756 100 mg|Part B - Cohort 2 subjects will be administered GSK1325756 100 mg following a light meal (Fed) or in the fasted state twice daily for one day in accordance with the randomization schedule.
3190207|NCT01266993|Experimental|Group A|Subjects who received Nimenrix (GSK134612 vaccine) in the primary study will receive a booster dose of the same vaccine.
3190208|NCT01266993|Experimental|Group B|Subjects who received Menjugate® in the primary study will receive a booster dose of Nimenrix (GSK134612 vaccine).
3190209|NCT01266980|Experimental|Severe Renal Imparement|Nine subjects with severe renal impairment (as defined by a Clcr<30mL/min) will be recruited for this study. they will receive FF/ GW642444M (200/25mcg) once daily for 7 days.
3190210|NCT01266980|Experimental|Matched healthy volunteers|For each of the 9 renally impaired subjects a healthy control subject (as defined by a Clcr>80mL/min matched to the severe subjects based on gender, ethnicity, body mass index (±15%) and age (±5 years)) will be recuited. They will receive FF/ GW642444M (200/25mcg) once daily for 7 days.
3190211|NCT01266967|Experimental|Single Arm|Single arm with 2 cohorts; Cohort A no previous brain therapy and Cohort B previous brain therapy
3190212|NCT01266954|Experimental|Stage 1|Three to six patients on a medium dose of GSK2141795 for four weeks
3190213|NCT01266954|Experimental|Stage 2|Nine to eighteen subjects on a low, medium or high dose of GSK2141795 for four weeks
3190214|NCT01266941|Experimental|Mild Hepatic Impairment|Mild and moderate hepatic patients will be recruited first, approximately 9 subjects should complete each of these treatment arms.
3190215|NCT01266941|Experimental|Moderate Hepatic Impairment|Mild and moderate hepatic patients will be recruited first, approximately 9 subjects should complete each of these treatment arms.
3190267|NCT01266616|Placebo Comparator|Cohort 1: Placebo|Placebo given as an injection in each upper arm
3190216|NCT01266941|Experimental|Matched healthy volunteers|Once a moderate subject has been recruited, a healthy control subject should be recruited (matched to the moderate subject on gender, ethnicity, body mass index +/-15%, age +/-5 years). In total there will be 9 matched healthy volunteers 1 for each subject with moderate hepatic impairment.
3190217|NCT01266941|Experimental|Severe Hepatic Impairment|Severe subjects will not be enrolled into the study until 9 moderate subjects and their matched control subjects have completed the study and the safety and PK data have been reviewed.
3190218|NCT01266928|Active Comparator|vitaminCE|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
3190219|NCT01266928|No Intervention|no drug|no drug
3190220|NCT01266915||Control group|Normal disease free (non lupus) subjects
3190221|NCT01266915||Diseased Control|
3190222|NCT01266915||Diseased group 1|Those subjects with systemic lupus erythematosus.
3190223|NCT01266915||Diseased group 2|Subjects diagnosed with cutaneous lupus.
3190224|NCT01266902|Experimental|Rilpivirine|Rilpivirine 25 mg once daily
3190225|NCT01266889||study group, control group|
3190226|NCT01266876|Placebo Comparator|Placebo|Placebo SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
3190227|NCT01266876|Experimental|Alirocumab 150 mg Q4W|Alirocumab 150 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
3190228|NCT01266876|Experimental|Alirocumab 200 mg Q4W|Alirocumab 200 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
3190229|NCT01266876|Experimental|Alirocumab 300 mg Q4W|Alirocumab 300 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
3190230|NCT01266876|Experimental|Alirocumab 150 mg Q2W|Alirocumab 150 mg SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
3190231|NCT01266863|Experimental|E test method|
3190232|NCT01266850|Active Comparator|Group 1, RotaTeq® x 3|2, 4 and 6 months of age: RotaTeq®
3190233|NCT01266850|Experimental|Group 5, Rotarix®, RotaTeq® x2|2 months of age: Rotarix®; 4 and 6 months of age: RotaTeq®
3190234|NCT01266850|Active Comparator|Group 4, Rotarix® x 2|2 and 4 months of age: Rotarix®
3190235|NCT01266850|Experimental|Group 2, RotaTeq®, Rotarix® x 2|2 months of age: RotaTeq®; 4 and 6 months of age: Rotarix®
3190236|NCT01266850|Experimental|Group 3, RotaTeq® x 2, Rotarix®|2 and 4 months of age: RotaTeq®; 6 months of age: Rotarix®
3190237|NCT01266837|Other|single arm|Treatment with Everolimus
3190238|NCT01266824|Experimental|Proparacaine|Infants in this group will receive 1 drop of Proparacaine Hydrochloride Ophthalmic Solution (anesthetic eye drop) into each eye prior to receiving mydriatic eye drops
3190239|NCT01266824|No Intervention|Standard of Care|Infants in this arm will not receive Proparacaine Hydrochloride Ophthalmic Solution (anesthetic eye drop) prior to mydriatic eye drops.
3190240|NCT01266811|Experimental|001|Siltuximab Velcade and dexamethasone Given in 21-day treatment cycles Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle Velcade 1.3 mg/m2 IV push on Days 1 4 8 and 11 for Cycles 1-8 and on Days 1 and 8 for Cycles 9 and higher Dexamethasone 20 mg orally on the day of and the day after each Velcade dose
3190241|NCT01266811|Other|002|Placebo Velcade and dexamethasone Given in 21-day treatment cycles Placebo as 1-hour IV infusion on Day 1 of every cycle Velcade 1.3 mg/m2 IV push on Days 1 4 8 and 11 for Cycles 1-8 and on Days 1 and 8 for Cycles 9 and higher Dexamethasone 20 mg orally on the day of and the day after each Velcade dose
3190242|NCT01266798|Experimental|Portal arm|
3190243|NCT01266798|No Intervention|Treatment as usal|
3190244|NCT01266772|Active Comparator|montelukast group|Children with asthma treated with montelukast and budesonide.
3190245|NCT01266772|Placebo Comparator|Placebo group|Children with asthma treated with placebo tablet and budesonide.
3190246|NCT01266759|Experimental|NuvaRing|For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
3190247|NCT01266759|Active Comparator|Norethisterone Acetate|Norethisterone Acetate tablets at a dose of 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
3190248|NCT01266746||Macular hole|The patients of idiopathic macular hole enrolled in the study
3190249|NCT01266746||Macular hole retinal detachment|The patients of macular hole retinal detachment enrolled in the study
3190250|NCT01266746||Myopic traction maculopathy|The patients of macular hole with myopic traction maculopathy enrolled in the study
3190251|NCT01266733|Experimental|Interdisciplinary treatment|
3190252|NCT01266733|No Intervention|Usual treatment|
3190253|NCT01266720|Experimental|Phase 1 study|"Interventions:~Biological: VEGFR1, VEGFR2 Drug: Gemcitabine"
3190254|NCT01266707|Experimental|Vaccine|VEGRF1, VEGFR2
3190255|NCT01266694|Experimental|Cochicine|Colchicine arm: patient receiving 1 mg per day for 14 days
3190256|NCT01266694|Placebo Comparator|Placebo|patients placebo controlled
3190257|NCT01266681|Active Comparator|Amiodarone|this group will be given Amiodarone to maintain sinus rhythm powst cardioversion.
3190258|NCT01266681|Active Comparator|Dronedarone|this group will be given dronedarone to maintain sinus rhythm post DC cardioversion
3190259|NCT01266668||Primary breast DLBCL|Primary breast DLBCL was defined as that involving single extranodal organ (i.e. breast) regardless of the status of nodal disease.
3190260|NCT01266668||Nodal DLBCL|The disease was only limited to the lymph nodes or lymphoid organs without extranodal organ involvements.
3190261|NCT01266655|Experimental|Baclofen|
3190262|NCT01266655|Placebo Comparator|Placebo|
3190263|NCT01266642|Experimental|HF-WBI|Shorter radiation (Group 1), Hypofractionated Whole Breast Irradiation (HF-WBI)
3190264|NCT01266642|Experimental|CF-WBI|Standard radiation (Group 2), Conventionally Fractionated Whole Breast Irradiation (CF-WBI)
3190265|NCT01266629||capsule patients|All patients that will undergo endoscopic capsule
3190266|NCT01266616|Experimental|Cohort 1: Vaccine alone IM/EP|HIV MAG pDNA alone IM/EP
3190268|NCT01266616|Experimental|Cohort 2: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 50 mcg of IL-12 pDNA IM/EP
3190269|NCT01266616|Placebo Comparator|Cohort 2: Placebo|Placebo given as an injection in each upper arm
3190270|NCT01266616|Experimental|Cohort 3: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 250 mcg of IL-12 pDNA IM/EP
3190271|NCT01266616|Placebo Comparator|Cohort 3: Placebo|Placebo given as an injection in each upper arm
3190272|NCT01266616|Experimental|Cohort 4: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 1,000 mcg of IL-12 pDNA IM/EP
3190273|NCT01266616|Placebo Comparator|Cohort 4: Placebo|Placebo given as an injection in each upper arm
3190274|NCT01266616|Experimental|Cohort 5: Vaccine plus IL-12 IM|HIV MAG pDNA plus 1,000 mcg (or highest dose reached) IL-12 pDNA IM
3190275|NCT01266616|Placebo Comparator|Cohort 5: Placebo|Placebo given as an injection in each upper arm
3190276|NCT01266603|Experimental|HDIL-2 + recMAGE-A3 + AS15|HDIL-2 720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle. recMAGE-A3 300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
3190277|NCT01266590|Experimental|LY2216684 + digoxin|Two oral 0.5 mg doses of digoxin separated by 12 hours on day 1, followed by once daily 0.25 mg dose of digoxin on days 2-14. Daily oral 18 mg doses of LY2216684 on days 8-14
3190278|NCT01266564||Cohort|
3190279|NCT01266551|No Intervention|lifestyle counseling|The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring. In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.
3190280|NCT01266538||IBD patients|Patients diagnosed with Inflammatory Bowel Disease (IBD)
3190281|NCT01266538||patients after a Large Bowel Resection|Patients after a Large Bowel Resection, with or without a pouch.
3190282|NCT01266538||Control group|Family members of IBD patients, Patients with Irritable Bowel Syndrome (IBS), Fap (familial polyposis)patients after a large bowel resection, Patient performing screening endoscopy
3190283|NCT01266525|Experimental|SAR110894 - 0.5 mg|SAR110894, 0.5 mg once daily along with Donepezil.
3190284|NCT01266525|Experimental|SAR110894 - 2 mg|SAR110894, 2 mg once daily along with Donepezil.
3190285|NCT01266525|Experimental|SAR110894 - 5 mg|SAR110894, 5 mg once daily along with Donepezil.
3190286|NCT01266525|Placebo Comparator|Placebo|Placebo (for SAR110894) once daily along with Donepezil.
3190287|NCT01266512|Experimental|IMRT & docetaxel-cisplatin|"Concurrent chemo-RT:~Radiotherapy: IMRT - Docetaxel 20mg/m2 + cisplatin 20mg/m2 weekly for 6 weeks -~Resting period: 2 weeks -~Adjuvant chemotherapy: Q3W for 2 cycles Docetaxel 35 mg/m² IV infusion for 1 hour on D1&8 - Cisplatin 35 mg/m² on D1&8 -~Dexamethasone for a total of 3 doses is to be given at a dose of 4 mg at 12 hours, 1 hour before and 12 hours after docetaxel administration"
3190288|NCT01266499|Active Comparator|Group 1: will receive PO Garamycin 80mg x 4/d|will receive PO Garamycin 80mg x 4/d
3190289|NCT01266499|Active Comparator|Group 2 : will receive PO Colistin (Polymyxin E) 100mg x 4/d|
3190290|NCT01266499|Active Comparator|Group 3: will receive both medications|
3190291|NCT01266499|Placebo Comparator|Group 4: will not receive PO treatment|
3190292|NCT01266486|Experimental|Metformin|
3190293|NCT01266473|Experimental|Physiotherapy techniques|Cough Technique vs Forced Expiration Technique
3190294|NCT01266460|Experimental|Treatment (ADXS11-001)|Patients receive live-attenuated Listeria monocytogenes cancer vaccine ADXS11-001 IV over 30 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3190295|NCT01266447|Experimental|Treatment (veliparib, topotecan hydrochloride, filgrastim)|Patients receive veliparib PO twice daily and topotecan hydrochloride IV over 30 minutes once daily on days 1-5. Patients also receive, according to institutional standard, filgrastim SC beginning on day 6, 7, or 8 and continuing until hematopoietic recovery or pegfilgrastim SC on day 6, 7, or 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3190296|NCT01266434|Experimental|simvastatin|
3190297|NCT01266434|Placebo Comparator|B1-6-12|
3190298|NCT01266421||Dienogest (DNG)|Women using DNG for the treatment of endometriosis
3190299|NCT01266421||Other medications|Women using hormonal medications other than DNG for the treatment of endometriosis
3190300|NCT01266408||DRSP/EE/metafolin|Women using oral contraceptives containing drospirenone, ethinylestradiol and metafolin
3190301|NCT01266408||Other OC users|Women using oral contraceptives containing other estrogen/progestogen combinations
3190302|NCT01266369|Experimental|masitinib 3 mg/kg/day|masitinib 3 mg/kg/day
3190303|NCT01266369|Experimental|masitinib 6 mg/kg/day|masitinib 6 mg/kg/day
3190304|NCT01266356||Experimental Group|
3190305|NCT01266356||Control Group|
3190306|NCT01266343||Experimental Group|
3190307|NCT01266343||Control Group|
3190308|NCT01266330|Active Comparator|Low Dairy|<0.5 standard dairy servings/day
3190309|NCT01266330|Experimental|Adequate dairy|3.5 standard dairy servings per day
3190310|NCT01266317|Experimental|Combined PEX, Rituximab and Steroids|"Standard Steroid Treatment: One gm of methylprednisolone I.V., on day 0, followed by 40 mg/day I.V. on days 1-4, and days 6-12 (or the P.O. prednisone equivalent). Methylprednisolone 100 mg I.V. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone I.V. (or P.O. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the principle investigator.~Plasma exchange (PEX) will consist of 1.5x estimated plasma volume exchanges for 3 successive days (0, 1,2) and then, after a one day interval to enable equilibration of autoantibodies sequestered in tissues, two more daily treatments on days 4 and 5.~Rituximab: One gm I.V. will be administered on day 5 (after completion of the last PEX) and day 13."
3190311|NCT01266304||community members|Pittsburgh area community members, including people who attend an integrative medicine clinic and people who attend a conventional medicine clinic.
3190351|NCT01266031|Experimental|Vorinostat and Bevacizumab|"Vorinostat: 400 mg/day by mouth on days 1 to 7 and days 15 to 21 of a 28 day cycle.~Bevacizumab: 10 mg/kg/dose by vein on days 1 and 15 of a 28 day cycle."
3190312|NCT01266291|Other|Treatment with Sabril (vigabatrin)|This is a single arm study. All subjects who are eligible for treatment will begin taking vigabatrin (Sabril) during the third month of the study. Treatment will be in accordance with the FDA-approved prescribing information: upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
3190313|NCT01266278|Experimental|Kinesiotape|Kinesiotape will be applied to the correct shoulder position of the participants.
3190314|NCT01266265||Tyvaso|The Tyvaso group will consist of patients receiving Tyvaso and may be receiving another FDA approved PAH therapy as part of routine care.
3190315|NCT01266265||Control|The control group will consist of patients with no previous Tyvaso exposure and not taking Tyvaso at the time of the Baseline visit, but receiving any other FDA approved PAH therapy as part of routine care.
3190316|NCT01266252|Experimental|Dexmedetomidine|
3190317|NCT01266239|Active Comparator|SES-KB|Sirolimus-eluting stent (SES) is deployed in the main vessel (MV)and subsequent kissing balloon inflation is performed in the bifurcation.
3190318|NCT01266239|Active Comparator|SES-NK|SES is deployed in the MV without kissing balloon inflation.
3190319|NCT01266239|Active Comparator|EES-KB|Everolimus-eluting stent (EES) is deployed in the MV and subsequent kissing balloon inflation is performed in the bifurcation.
3190320|NCT01266239|Active Comparator|EES-NK|EES is deployed in the MV without kissing balloon inflation.
3190321|NCT01266226|Experimental|ACP treated|The patients are going to get an injection of 4mL autologous conditioned plasma under the footprint following an arthroscopic repair of the rotator cuff.
3190322|NCT01266226|Placebo Comparator|Control group|The patients are going to get an injection of 4mL saline solution under the footprint following an arthroscopic repair of the rotator cuff.
3190323|NCT01266213|Experimental|Fulvestrant plus Goserelin|
3190324|NCT01266213|Experimental|Anastrozole plus Goserelin|
3190325|NCT01266213|Active Comparator|Goserelin alone|
3190326|NCT01266200|Active Comparator|Minimal-invasive treatment (Mantis)|Patients, who received a minimal-invasive surgery and the fracture was fixed by a system called Mantis
3190327|NCT01266200|Active Comparator|Conventional technique (XIA)|Patients who received a surgical treatment including one long cut (conventional operation technique) and the fracture was fixed by a conventional system called XIA
3190328|NCT01266187|Experimental|Arm B|"12 weeks FOLFOX + cetuximab -> 4 weeks rest -> surgery~-> 4-8 weeks rest -> 12 weeks FOLFOX + cetuximab"
3190329|NCT01266187|Active Comparator|Arm A|surgery -> 4-8 weeks rest -> 24 weeks FOLFOX + cetuximab
3190330|NCT01266174|Experimental|Eltoprazine|eltoprazine pill 2.5mg bid, eltoprazine pill 5mg bid, eltoprazine 7.5mg bid
3190331|NCT01266174|Placebo Comparator|Placebo|placebo pill 2.5mg bid, placebo pill 5mg bid, placebo 7.5mg bid
3190332|NCT01266161|Experimental|Ibuprofen 600 mg extended release|
3190333|NCT01266161|Placebo Comparator|Placebo|
3190334|NCT01266148|Experimental|Everolimus|Participants started immunosuppressive regimen consisting of low dose CsA, everolimus, MMF and CS. After week 11, the participants regimen consisted of everolimus, MMF and CS.
3190335|NCT01266148|Experimental|Control|Participants received an immunosuppressive regimen consisting of CsA, MMF and CS throughout the study.
3190336|NCT01266135|Experimental|Arm 1: QAX576 10 mg/kg|
3190337|NCT01266135|Placebo Comparator|Arm 2: Placebo|
3190338|NCT01266122|No Intervention|HIV/STI voluntary counseling and testing|Participants enrolled in the control arm will receive study assessments only.
3190339|NCT01266122|Experimental|Behavioral intervention|Participants enrolled in the experimental condition will receive 4 group sessions and 4 individual sessions over 3 months. This intervention focuses on psychosocial concerns and HIV risk for MSM in India.
3190340|NCT01266109|Experimental|CM-FAM|
3190341|NCT01266109|Active Comparator|US|
3190342|NCT01266096|Experimental|newly diagnosed or recurrent head/neck melanoma|This is a two-year microdosing study that will enroll 5 metastatic melanoma patients and 18 malignant brain tumor patients (surgical (n=13) and non-surgical candidates (n=5)). We have already accrued 5 melanoma patients and expect to accrue brain tumor patients within a 1 year period.
3190343|NCT01266083|Experimental|WT1 peptide vaccine|This is a Phase II study evaluating the safety and efficacy of the WT1 peptide vaccine in patients who are in CR from Acute Myeloid Leukemia (AML).
3190344|NCT01266070|Experimental|Dovitinib|500 mg/day on a 5 day on, 2 day off schedule
3190345|NCT01266057|Experimental|Hydroxychloroquine + Sirolimus|Hydroxychloroquine starting dose of 200 mg by mouth every day for a 21 day cycle. Sirolimus starting dose of 2 mg by mouth every day for a 21 day cycle.
3190346|NCT01266057|Experimental|Hydroxychloroquine + Vorinostat|Hydroxychloroquine starting dose of 200 mg by mouth every day for a 21 day cycle. Vorinostat starting dose of 200 mg by mouth per day for a 21 day cycle.
3190347|NCT01266044|Experimental|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
3190348|NCT01266044|Active Comparator|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
3190349|NCT01266044|Other|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
3190350|NCT01266031|Experimental|Bevacizumab|10 mg/kg/dose by vein on days 1 and 15 of a 28 day cycle.
3190389|NCT01265758|Experimental|Telemetric ECG monitoring|Telemetric 14-days Full Disclosure ECG recording.
3190352|NCT01266018|Experimental|Cohort 1: Sensitive Disease|"Cohort 1 comprised subjects with sensitive disease, defined as subjects who were treated with 1 previous line of chemotherapy and maintained an appropriate response for 90 days or more. Subjects received 4 administrations of ADI-PEG 20 (320 IU/m^2) followed by 1 week of follow-up in each treatment cycle."
3190353|NCT01266018|Experimental|Cohort 2: Refractory Disease|"Cohort 2 comprised subjects with refractory disease, defined as subjects who either (a) were treated with 1 previous line of chemotherapy and either had no response or progressed < 90 days after completing treatment or (b) required third-line therapy, i.e., had completed 2 previous lines of chemotherapy, regardless of response. Subjects received 4 administrations of ADI-PEG 20 (320 IU/m^2) followed by 1 week of follow-up in each treatment cycle."
3190354|NCT01266005|Experimental|1|Clevudine 30mg
3190355|NCT01266005|Active Comparator|2|Entecavir 0.5mg
3190356|NCT01265992||Paricalcitol capsules|Patients with secondary hyperparathyroidism associated with Stage 3 - 5 CKD and not yet on dialysis and prescribed paricalcitol capsules in accordance with the terms of the marketing authorization in Sweden.
3190357|NCT01265979||GIST treated with regorafenib/placebo|patients with advanced, metastatic gastro-intestinal stromal tumors treated with regorafenib or placebo
3190358|NCT01265966||Moderate Sedation|Children undergoing moderate sedation for procedures.
3190359|NCT01265966||Deep Sedation|Children undergoing deep sedation for procedures.
3190360|NCT01265953|Experimental|sulforaphane glucosinolate capsules|Four weeks sulforaphane (SFN) glucosinolate capsules: 250 mg of broccoli seed extract (30 mg sulforaphane glucosinolate), 8 capsules (4 capsules B.I.D.) daily
3190361|NCT01265953|Placebo Comparator|Placebo capsules|Four weeks placebo capsules: 8 capsules (4 capsules B.I.D.) daily
3190362|NCT01265940|Experimental|Pazopanib + Vinflunine|
3190363|NCT01265927|Experimental|GRN163L + Trastuzumab|
3190364|NCT01265914|Placebo Comparator|placebo|
3190365|NCT01265914|Experimental|FP-01.1|
3190366|NCT01265901|Active Comparator|Sunitinib|Sunitib as Standard therapy per Label.
3190367|NCT01265901|Experimental|IMA901 plus GM-CSF added to sunitinib after single dose of cy|After 1 cycle of sunitinib, intradermal vaccinations with IMA901 plus GM-CSF as adjuvant after a single dose of cyclophosphamide will be applied for a period of 4 months while continuing treatment with sunitinib
3190368|NCT01265888|Experimental|Dosing Group 1|1 Liter per Minute (LPM)of inhaled nitric oxide via nasal cannula: approximately 5 parts per million (ppm)
3190369|NCT01265888|Experimental|Dosing Group 2|2 LPM of inhaled nitric oxide via nasal cannula: approximately 15 ppm
3190370|NCT01265888|Experimental|Dosing Group 3|4 LPM of inhaled nitric oxide via nasal cannula: approximately 20 ppm
3190371|NCT01265875|Other|human secretin|intravenous secretin administration in escalating doses three times daily for three days. After each infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion.
3190372|NCT01265862|Active Comparator|LMA-Fastrach® and GlideRite® tube|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of LMA-Fastrach®, establishment of ventilation~Evaluation of glottic view through LMA-Fastrach® using fibrescope~Tracheal intubation with the GlideRite® tube through the LMA-Fastrach®~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
3190373|NCT01265862|Experimental|I-gel® and GlideRite® tube|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of I-gel®, establishment of ventilation~Evaluation of glottic view through I-gel® using fibrescope~Tracheal intubation with the GlideRite® endotracheal tube through the I-gel®~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
3190374|NCT01265849|Experimental|LI plus CIZ|LI plus CIZ is given as adjuvant therapy prior to standard of care (SOC).
3190375|NCT01265849|Active Comparator|Standard of Care (SOC)|SOC for previously untreated SCCHN patients is currently surgery followed by either radiotherapy or combined radiochemotherapy depending the patient's risk status for relapse determined at surgery.
3190376|NCT01265849|Experimental|LI + SOC|LI is administered without CIZ to determine the contribution of CIZ to the effects of LI.
3190377|NCT01265836||1|
3190378|NCT01265823|Experimental|Adalimumab|
3190379|NCT01265810|Other|sodium chloride -> supersaturated calcium-phosphate|Patients in this arm start first with sodium chloride 0.9% mouth rinses and go crossover to supersaturated calcium-phosphate mouth rinses.
3190380|NCT01265810|Other|supersaturated calcium-phosphate -> sodium chloride|Patients in this arm start first with supersaturated calcium-phosphate mouth rinses and go crossover to sodium chloride 0.9% mouth rinses.
3190381|NCT01265797|Active Comparator|Cranial Electrostimulator|wears active cranial electrostimulation device for 20 minutes daily for 28 days
3190382|NCT01265797|Sham Comparator|Sham device|wears sham device for 20 minutes daily for 28 days
3190383|NCT01265784|Experimental|TP-434, 1.5 mg/kg q24h|TP-434 was administered intravenously (IV) at a dose of 1.5 milligrams per kilogram of body weight (mg/kg) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). TP-434 treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
3190384|NCT01265784|Experimental|TP-434, 1.0 mg/kg q12h|TP-434 was administered IV at a dose of 1.0 mg/kg every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). TP-434 treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
3190385|NCT01265784|Active Comparator|Ertapenem, 1 g q24h|Ertapenem was administered IV at a dose of 1 gram (g) q24h for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
3190386|NCT01265771|Experimental|Telemetry ordered by a Cardiologist|
3190387|NCT01265771|Experimental|24 hours standard Holter monitoring|
3190388|NCT01265771|Experimental|Telemetry ordered by a Pediatrician|
3190390|NCT01265758|Active Comparator|Standard 24-hours Holter ECG recording|Standard 24-hours Holter ECG recording repeated 3 times unless arrhythmia is diagnosed earlier.
3190391|NCT01265745|Active Comparator|Valortim|Valortim 1mg,5mg,10mg
3190392|NCT01265745|Placebo Comparator|Placebo|Saline solution will be used as the placebo
3190393|NCT01265732|Active Comparator|oral single dose dispersion 100mg|Subjects receive a single dose of PF-04191834 as a dispersion
3190394|NCT01265732|Active Comparator|oral wet milled suspension 100mg|Subjects receive a single dose of PF-04191834 as a suspension
3190395|NCT01265732|Active Comparator|oral wet milled suspension 300mg|Subjects receive a single dose of PF-04191834 as a suspension
3190396|NCT01265719||Latanoprost-treatment group|
3190397|NCT01265719||Non-topical prostaglandin analogue treatment group|
3190398|NCT01265680|Experimental|Erythropoietin|80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital
3190399|NCT01265680|No Intervention|Control|No added administration other than our standard of care.
3190400|NCT01265667|Experimental|CF101 2 mg|
3190401|NCT01265667|Placebo Comparator|Placebo|
3190402|NCT01265654||All patients|Patients with ABC and two lines of hormonal treatment
3190403|NCT01265641|Experimental|1|
3190404|NCT01265641|Experimental|2|
3190405|NCT01265641|Experimental|3|
3190406|NCT01265641|Placebo Comparator|4|
3190407|NCT01265628||Glaucoma|
3190408|NCT01265628||Retinitis pigmentosa (RP)|
3190409|NCT01265628||Anterior Ischemic Optic Neuropathy (AION)|
3190410|NCT01265615|Active Comparator|Paricalcitol treatment|6-8 μg daily per os (orally) without special diet
3190411|NCT01265615|Active Comparator|Calcitriol treatment|2-4 μg daily orally under with dietary restrictions of vitamin D
3190412|NCT01265615|Active Comparator|Cholecalciferol|alendronate sodium/ cholecalciferol capsules with recommended daily allowance equals 1200-2400 IU per day
3190413|NCT01265615|Other|Supplemental|intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
3190414|NCT01265602|Experimental|LAS41007|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
3190415|NCT01265602|Active Comparator|LASW1510|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
3190416|NCT01265602|Placebo Comparator|vehicle|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
3190417|NCT01265589|Placebo Comparator|I=surfactant|Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
3190418|NCT01265589|Experimental|II=surfactant+vitamin A|Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
3190419|NCT01265576|Placebo Comparator|Sorafenib with placebo|Participants randomized to the Control Arm (sorafenib with placebo) receive sorafenib as the standard of care, and placebo for the same periods as participants randomized to the Treatment Arm (sorafenib plus VT-122). Participants randomized to the Control Arm will undergo the same visits and procedures as would the participants randomized to the Treatment Arm.
3190420|NCT01265576|Experimental|Sorafenib plus VT-122|
3190421|NCT01265563|Placebo Comparator|NAC placebo and Silibin placebo|Drug: N-acetylcysteine placebo and Drug: Silibin placebo
3190422|NCT01265563|Experimental|NAC active and Silibin placebo|Drug: N-acetylcysteine and Drug: Silibin placebo
3190423|NCT01265563|Experimental|NAC placebo and Silibin active|Drug: N-acetylcysteine placebo and Drug: Silibin active
3190424|NCT01265563|Experimental|NAC active and Silibin active|Drug: N-acetylcysteine active and Drug: Silibin active
3190425|NCT01265563|Experimental|NAC active and High-dose Silibin active|Drug: N-acetylcysteine active and Drug: Silibin higher dose active
3190426|NCT01265550|Other|Medical Treatment Group|Omeprazole or Omeprazole + baclofen or Omeprazole + desipramine
3190427|NCT01265550|Other|Surgical Treatment Group|Laparoscopic nissen fundoplications
3190428|NCT01265550|Other|Placebo Medical Treatment Group|Omeprazole + placebo
3190429|NCT01265537|Experimental|Low target tacrolimus (Advagraf)|"This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and low-target Advagraf."
3190430|NCT01265537|Active Comparator|Standard target tacrolimus (Advagraf)|"This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and standard target Advagraf."
3190431|NCT01265524|Active Comparator|CLP|Investigational drug: 15 g CLP per day given as capsules
3190432|NCT01265524|Placebo Comparator|Placebo|Placebo, capsules
3190433|NCT01265511|Placebo Comparator|Placebo|Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
3190434|NCT01265511|Active Comparator|SCY-635 600 mg|SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
3190435|NCT01265498|Active Comparator|Obeticholic acid|obeticholic acid
3190436|NCT01265498|Placebo Comparator|Placebo|Placebo
3190437|NCT01265485|Experimental|treatment|
3190438|NCT01265459|Experimental|Durolane 3ml|Durolane 3 ml is an Intraarticular hyaluronic acid
3190439|NCT01265459|Experimental|Durolane 4.5|Durolane 4.5 is an Intraarticular hyaluronic acid
3190440|NCT01265459|Experimental|Durolane 6 ml|Durolane 6 ml is an Intraarticular hyaluronic acid
3190441|NCT01265446|Experimental|Lidocaine 8mg +CPC 2mg|one single dose
3190442|NCT01265446|Active Comparator|Lidocaine 1mg + CPC 2mg|one single dose
3190703|NCT01263509|Experimental|Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID|
3190443|NCT01265433|Experimental|WT-1-vaccine Montanide + GM-CSF|The study will be a randomized phase II trial to determine the 1-year progression free survival after treatment with WT-1 analog peptide vaccine in patients with MPM after completion of combined modality therapy.
3190444|NCT01265433|Active Comparator|Montanide adjuvant + GM-CSF (This arm is closed)|The study will be a randomized phase II trial to determine the 1-year progression free survival after treatment with WT-1 analog peptide vaccine in patients with MPM after completion of combined modality therapy.
3190445|NCT01265420|Experimental|Injectable clostridial collagenase|Patients with thumb 1st web contracture secondary to Dupuytren's disease will be treated with 0.58mg of collagenase
3190446|NCT01265394|Experimental|(18F) Flutemetamol|
3190447|NCT01265368|Experimental|Study medication|
3190448|NCT01265355|Experimental|Anti-rotavirus protein|
3190449|NCT01265355|Placebo Comparator|Maltodextrin|
3190450|NCT01265342|Placebo Comparator|Placebo|
3190451|NCT01265342|Experimental|Beclomethasone|Beclometasone suspension 400 mcg will be administered through a nebuliser twice a day, in the morning and in the evening, for 10 days
3190452|NCT01265329|No Intervention|Control|No sperm selection
3190453|NCT01265329|Experimental|Annexine V negative|Sperm selection with Annexine V protein
3190454|NCT01265303|Other|Catheter ablation|
3190455|NCT01265303|Other|Pacemaker implantation|
3190456|NCT01265303|Other|Pharmacotherapy|
3190457|NCT01265290|Experimental|Telemetric ECG monitoring|Telemetric Full Disclosure ECG monitoring
3190458|NCT01265290|Experimental|24 hours standard Holter monitoring|
3190459|NCT01265277||at home|Infants 0-3 months who will stay at home with a parent
3190460|NCT01265277||child care|Infant 0-3 months who will attend a licensed child care center
3190461|NCT01265264|Experimental|ulodesine Placebo + Allopurinol 300mg|Oral dose administered daily for 84 days.
3190462|NCT01265264|Experimental|ulodesine 5mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
3190463|NCT01265264|Experimental|ulodesine 10mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
3190464|NCT01265264|Experimental|ulodesine 20mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
3190465|NCT01265264|Experimental|ulodesine 40mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
3190466|NCT01265251||Test-retest|Forty-four healthy elderly 60-82 years old
3190467|NCT01265251||Validity|Twenty six patients with various diseases and various ages
3190468|NCT01265251||Feasibility|Twenty seven patients under the preoperative investigation for INPH
3190469|NCT01265186||Ventilated term newborns|Ventilated newborns with a corrected gestational age ≧ 37 weeks of gestation until the 28th day of life respectively ≦ 44 weeks of gestation
3190470|NCT01265186||Control group: healthy term newborns|Control group: healthy newborns with a corrected gestational age ≧ 37 weeks of gestation until the 28th day of life respectively ≦ 44 weeks of gestation
3190471|NCT01265173|Active Comparator|Cefotaxime|iv 2G q 8hrs for general, dose titration if needed (eg.CKD)
3190472|NCT01265173|Experimental|Ceftriaxone|iv 2G q 24hrs
3190473|NCT01265173|Experimental|Ciprofloxacine|iv 400mg q 12hrs for general, dose titration if needed (eg.CKD)
3190474|NCT01265160||the group of Jiangzhuo prescription|
3190475|NCT01265160||the group of fenofibrate|
3190476|NCT01265160||the group of placebo|
3190477|NCT01265147|Active Comparator|Cisplatin|cisplatin combine with IMRT
3190478|NCT01265147|Experimental|Nedaplatin|Nedaplatin combine with IMRT
3190479|NCT01265134||Experimental Group|the healthy elders
3190480|NCT01265134||Control Group|the elders who have fallen once
3190481|NCT01265121|Experimental|CPAP treatment|This acromegalic patients is going to have sleep apnea treated for 3 months with a with a continuous positive air pressure device (CPAP)
3190482|NCT01265121|Placebo Comparator|Nasal adhesive|This acromegalic patients will be treated will an external nasal dilator adhesive intended to serve as a placebo treatment
3190483|NCT01265108|Experimental|Intravenous iron sucrose|Infusion of 200 mg iron sucrose (Venofer) in 100 ml normal (0.9%) saline.
3190484|NCT01265108|Placebo Comparator|Intravenous normal saline|Infusion of 100 ml normal (0.9%) saline.
3190485|NCT01265095||VRE bacteremia|VRE bacteremia patients
3190486|NCT01265082||Patients in remission with pruritus|
3190487|NCT01265082||Patients in remission without pruritus|
3190488|NCT01265069|Active Comparator|high dose dual therapy|Group A - high dose dual therapy (rabeprazole 20 mg qid, amoxicillin 750 mg qid for 14 days)
3190489|NCT01265069|Experimental|concomitant therapy|Group B - concomitant therapy (rabeprazole 20 mg, amoxicillin 1000 mg, metronidazole 500 mg, clarithromycin 500 mg, bid for 10 days).
3190490|NCT01265056|Placebo Comparator|Sugar Pill|Placebo
3190491|NCT01265056|Experimental|Gabapentin|Gabapentin
3190492|NCT01265043|Experimental|OHI|Patients provided with oral hygiene instruction and electric toothbrush
3190493|NCT01265043|Experimental|OHI + CHX mouthrinse|Patients provided with oral hygiene instruction and Corsodyl mouthrinse
3190494|NCT01265043|Experimental|OHI + CHX mouthrinse + assisted brushing|Oral hygiene instruction, Corsodyl mouthrinse, and assisted brushing
3190495|NCT01265030|Experimental|Sirolimus|"Preoperative sirolimus:~loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligram)~starting 24 hours after the initial loading dose, subjects will receive a dose of 4 milligram/meters2 daily; Per Os (PO), by mouth days 2 through 28"
3190496|NCT01265017|Experimental|Active Treatment|"interventions include Estradiol, medroxyprogesterone, hydrocortisone, GH as follows~Estradiol 1mg every 8 hours administered orally~Medroxyprogesterone 2.5 mg every 24 hours administered orally~Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally~Growth hormone 2 mg once a day administered by subcutaneous injection"
3190497|NCT01265017|Placebo Comparator|Placebo|Matching placebo
3190498|NCT01265004||Stitches, rupture of achilles tendon|Patients, in who the achilles tendon rupture was treated with tendon surgery including a special way of stitching to preserve the sliding ability of the tendon.
3190499|NCT01265004||Fibrin-glue, rupture of achilles tendon|Patients, who received a surgical treatment including a fixing of the tendon with fibrin-glue.
3190500|NCT01265004||Stiches and Fibrin-glue|Patients, in who the achilles rupture was treated with stitches and fibrin-glue.
3190501|NCT01264991|Experimental|APM group|
3190502|NCT01264991|Placebo Comparator|Sham group|
3190503|NCT01264978|Experimental|repetitive neuromuscular stimulation|repetitive neuromuscular stimulation of the quadriceps arm are patients actively stimulated at increasing intensity to afford maximal contraction during training sessions
3190504|NCT01264965|Active Comparator|Acetaminophen|
3190505|NCT01264965|Active Comparator|Long Acting Oxycodone|
3190506|NCT01264939|Placebo Comparator|Placebo|Participants received placebo subcutaneously every 4 weeks during the 24 week treatment period.
3190507|NCT01264939|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24 week treatment period.
3190508|NCT01264926||rotator cuff tear, pain|
3190509|NCT01264913||Shift Workers|
3190510|NCT01264913||Day Workers|
3190511|NCT01264900|Experimental|Cognitive Behavioral Therapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment
3190512|NCT01264900|Active Comparator|Supportive Psychotherapy|Twelve weekly 50-minute sessions of individual supportive (client-centered) psychotherapy
3190513|NCT01264887|Experimental|Tapentadol Prolonged Release|Participants allocated to this treatment arm can be flexibly dosed between 100 to 250 mg tapentadol twice daily (50 and 100 mg tablets to be dispensed).
3190514|NCT01264874|Experimental|Vitamin D3|Vitamin D3 administration
3190515|NCT01264874|Placebo Comparator|placebo|matched placebo
3190516|NCT01264861|Experimental|Arm 1:|Arm 1: Eligible subjects will receive escalating doses of safinamide for the 6-week duration of treatment. Each dose level will be last 10-14 days. Doses 200mg and 300mg will have a 3 day intermediate step up dose, 150mg and 250mg dose.
3190517|NCT01264848|Experimental|Balloon angioplasty and/or stenting|Balloon angioplasty and/or stenting of stenosed internal jugular vein and/or azygous vein and/or brachiocephalic vein
3190518|NCT01264822||Treatment Arm 1 Rabeprazole Sodium|
3190519|NCT01264809|Experimental|A : immediate physical activity counseling|Participants randomized in the experimental group (group A) will receive physical activity counseling during a one-to-one consultation at both baseline and 3 months.
3190520|NCT01264809|Active Comparator|B : later physical activity counseling|Exercise consultation will be realised only at 3 months in the control group(group B). Furthermore, patients of group B will not received any physical activity counseling at baseline.
3190521|NCT01264796|Experimental|behavioral intervention, counseling|2hr group education for 6 weeks
3190522|NCT01264796|No Intervention|delyed intervention|control group
3190523|NCT01264783|Experimental|RNS60|RNS60
3190524|NCT01264783|Placebo Comparator|Placebo|Placebo
3190525|NCT01264770|Experimental|Dosing Group A|Oral treatment and subcutaneous injection
3190526|NCT01264770|Experimental|Dosing Group B|Oral treatment and subcutaneous injection
3190527|NCT01264770|Experimental|Dosing Group C|Oral treatment and subcutaneous injection
3190528|NCT01264770|Active Comparator|Dosing Group D|Oral treatment and subcutaneous injection
3190529|NCT01264770|Placebo Comparator|Dosing Group E|Oral treatment and subcutaneous injection
3190530|NCT01264757|Active Comparator|Education|Educational brochure about physical activity provided.
3190531|NCT01264757|Experimental|Pedometer|A pedometer was provided in addition to educational materials.
3190532|NCT01264731|Active Comparator|peptide vaccine plus imiquimod|Peptide Vaccine: Days 1, 8, 15, 36, 57, 78 Imiquimod: Applied daily on days 1-85.
3190533|NCT01264731|Active Comparator|Imiquimod|Imiquimod: Applied daily on days 1-85.
3190534|NCT01264718|No Intervention|Control|After random assignment to the control group, minority low-income parents of a Medicaid/CHIP eligible child will receive only the traditional outreach regarding enrolling in Medicaid/CHIP.
3190535|NCT01264705|Experimental|Bavituximab and Sorafenib|
3190536|NCT01264692|Experimental|Treatment A|ACT-280778
3190537|NCT01264692|Placebo Comparator|Treatment B|Placebo
3190538|NCT01264692|Other|Treatment C|Amlodipine
3190539|NCT01264679|Experimental|Ferumoxytol|When a participant has persistent or recurrent IDA (defined as hemoglobin <12.0 grams [g]/deciliter [dL] and with either transferrin saturation <40% or ferritin <100 nanograms/milliliter), the participant will begin a 7-week treatment period. Participants will receive 2 IV injections of ferumoxytol 7.0 milligrams (mg) iron/kilogram (maximum of 510 mg/dose), the first dose administered on Day 1 and the second on Days 3 through 9 of the Treatment Period.
3190540|NCT01264666|Experimental|Chinese tea flavor liquor|
3190541|NCT01264666|Placebo Comparator|Water|Water combined with meal as control.
3190542|NCT01264666|Placebo Comparator|Chinese Meijiao Liquor|
3190543|NCT01264653|Experimental|experimental group,control group|Intraocular adrenalin,topical mydriatics, experimental group: Intervention: Procedure:refractive cataract surgery with Intraocular adrenalin, control group:refractive cataract surgery with topical mydriatics
3190544|NCT01264640|Experimental|A|Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
3190545|NCT01264627|Experimental|Mindful Breathing (MB)|"The MB intervention is based off of the Mindfulness Based Stress Reduction Program developed by Jon Kabat-Zinn. Participants will be organized into cohorts of eight, and attend eight weekly MB sessions. Mindful breathing consists of closely following the breath, throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, perceptions and events, from a non-evaluative, non-judgmental perspective. No other intervention is included. No FDA drug or device is involved."
3190546|NCT01264627|Other|Usual Care (UC)|Usual Care consists of the standard care made available to participants through their primary physician. No intervention is included. No FDA drug or device is involved.
3190547|NCT01264614|Experimental|Early stage dementia|Individuals with early stage dementia who attended a Adult Day Care Program at least twice a week. Participants engaged in a strengthening exercise program three to five times per week for 10 weeks.
3190548|NCT01264614|Active Comparator|Normative older adults|Normative older adults with no known neurological condition. Participants engaged in a strengthening exercise program three to five times per week for 10 weeks.
3190549|NCT01264601|Experimental|Single Dose|This arm will receive TIV as 2 doses, the first of which will be normal saline administered at approximately 10% of the total age appropriate dose volume, followed 30 minutes later by the full age appropriate dose. For children receiving a 0.25ml dose, a 20%/80% split will be used for ease of administration in drawing up the dose.
3190550|NCT01264601|Experimental|Graded Challenge|Subjects in this arm will receive TIV by standard 10%/90% 2-step graded challenge split of the age appropriate dose, separated by 30 minutes. For children receiving a 0.25ml dose, a 20%/80% split will be used for ease of administration in drawing up the dose.
3190551|NCT01264588|Active Comparator|topical calcium glycerophosphate lotion|
3190552|NCT01264588|No Intervention|standard-of-care|
3190553|NCT01264575|Experimental|BPV6E1|
3190554|NCT01264575|Experimental|BPV7E1|
3190555|NCT01264575|Experimental|BPV8E1|
3190556|NCT01264575|Experimental|BPV9E1|
3190557|NCT01264575|Experimental|BPV10E1|
3190558|NCT01264575|Experimental|BPV11E1|
3190559|NCT01264575|Experimental|BPV6E2|
3190560|NCT01264575|Experimental|BPV7E2|
3190561|NCT01264575|Experimental|BPV8E2|
3190562|NCT01264575|Experimental|BPV9E2|
3190563|NCT01264575|Experimental|BPV10E2|
3190564|NCT01264575|Experimental|BPV11E2|
3190565|NCT01264562||Chemotherapy group|Breast cancer patients treated with chemotherapy
3190566|NCT01264562||Non-chemotherapy group|Breast cancer patients not treated with chemotherapy
3190567|NCT01264562||Healthy controls|Women without a cancer diagnosis, matched for age and education
3190568|NCT01264549|Experimental|PCT guided arm|
3190569|NCT01264549|No Intervention|Control|Standard treatment
3190570|NCT01264536|Experimental|Lactoferrin|Lactoferrin is a freeze-dried protein purified directly from fresh bovine milk.
3190571|NCT01264536|Placebo Comparator|maltodextrin|Maltodextrin is an inert sugar.
3190572|NCT01264510|Other|patients implanted with a Bone-anchored hearing aid(Baha)|
3190573|NCT01264484||Advantage prosthetic heart valve|All patients who were enrolled and implanted with an Advantage valve in the Herzzentrum Nordrhein-Westfalen (Bad Oeynhausen, Germany) and Deutsches Herzzentrum München (Munich, Germany) during the previous Advantage clinical study study and who agree to participate in this long-term follow-up study by informed consent.
3190574|NCT01264471||Gulf War Syndrome patients|Gulf War veterans who have been diagnosed with Gulf War Syndrome.
3190575|NCT01264458||Traumatic Injury|Trauma patients arriving at Saint Mary's Emergency Department
3190576|NCT01264458||Control group|
3190577|NCT01264445|Experimental|Group A|Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.
3190578|NCT01264445|Experimental|Group B|Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.
3190579|NCT01264445|Experimental|Group C|Ad35-GRIN investigational HIV vaccine at Month 0 followed by Adjuvanted GSK investigational HIV vaccine at Months 3 and 4.
3190580|NCT01264445|Experimental|Group D|Adjuvanted GSK investigational HIV vaccine and Ad35-GRIN investigational HIV vaccine co-administered (simultaneous administration with separate injections)at Months 0, 1, and 4.
3190581|NCT01264432|Experimental|Treatment (veliparib, LDRWAR)|Patients receive veliparib PO BID on days 1-21 (days 5-21 of course 1). Patients undergo LDFWAR in BID on days 1 and 5 of weeks 1-3. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
3190582|NCT01264419|Experimental|Single|
3190583|NCT01264406||Exercise Group (20 KKW)|Exercise group will obtain 20 KKW, perform in 4-5 sessions per week for approximately 50-70 minutes per session.
3190584|NCT01264406||Exercise Group (8 KKW)|One exercise group will obtain 8KKW (kcal/kg/week) over 3-4 sessions per wee, which will result in each session lasting approximately 30 minutes
3190585|NCT01264406||Control group|This group will be instructed to maintain their baseline level of exercise.
3190586|NCT01264393|Active Comparator|Shape Up Rhode Island + Online weight loss program + groups|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an internet-based weight loss program, and the option of attending face-to-face group sessions
3190587|NCT01264393|Active Comparator|Shape Up Rhode Island + Online Weight Loss Program|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention in addition to an internet-based weight loss program
3190588|NCT01264393|Active Comparator|Shape Up Rhode Island + Internet Resources|Participants in this arm will receive the Standard Shape Up Rhode Island statewide intervention plus access to internet resources
3190589|NCT01264380|Experimental|1|
3190590|NCT01264380|Experimental|2|
3190591|NCT01264380|Experimental|C|
3190592|NCT01264367|Experimental|1|Clevudine 30mg
3190593|NCT01264367|Active Comparator|2|Clevudine 30mg + peg-interferon 180mcg
3190594|NCT01264354|Experimental|1|Clevudine 30mg
3190595|NCT01264354|Experimental|2|Clevudine 20mg+Adefovir dipivoxil 10mg
3190596|NCT01264354|Experimental|3|Clevudine 20mg
3190597|NCT01264341|Experimental|Bevacizumab combined with temsirolimus|Bevacizumab 10mg/kg intravenous every 2 weeks Temsirolimus 25mg intravenous once weekly
3190598|NCT01264328|Experimental|Panitumumab + Paclitaxel|
3190599|NCT01264315|Other|Lenalidomide in maintenance|
3190600|NCT01264302|Experimental|Finasteride tablets 5 mg|Finasteride tablets 5 mg of Dr.Reddy's Laboratories Limited
3190601|NCT01264302|Active Comparator|Proscar 5 mg Tablets|Proscar 5 mg Tablets of Merck & Co. Inc
3190602|NCT01264289|Experimental|Finasteride tablets 5 mg|Finasteride tablets 5 mg of Dr.Reddy's Laboratories Limited
3190603|NCT01264289|Active Comparator|Proscar 5 mg Tablets|Proscar 5 mg Tablets of Merck & Co. Inc
3190604|NCT01264263||1|
3190605|NCT01264250|Experimental|1|
3190606|NCT01264250|Placebo Comparator|2|
3190704|NCT01263509|Experimental|Alogliptin 25 mg QD and Voglibose 0.2 mg TID|
3190607|NCT01264237|Experimental|Etoricoxib|The study will use an Enriched Enrollment Randomized Withdrawal (EERW) design consisting of a 2-week open-label enrichment phase, during which subjects will receive etoricoxib. Patients who experience at least a 30% reduction in pain intensity will be randomized to either continued treatment with etoricoxib 90 mg qd or matching placebo (at a 1:1 ratio) for 4 weeks.
3190608|NCT01264237|Placebo Comparator|Placebo|The study will use an Enriched Enrollment Randomized Withdrawal (EERW) design consisting of a 2-week open-label enrichment phase, during which subjects will receive etoricoxib, followed by a 4-week randomized, double-blind, placebo-controlled treatment phase, during which subjects will receive either etoricoxib or placebo.
3190609|NCT01264224|Experimental|PAC-14028|
3190610|NCT01264211|Experimental|Diacerein|
3190611|NCT01264211|Placebo Comparator|Placebo|
3190612|NCT01264198|Sham Comparator|Stretching Exercises|The patients will perform twice weekly home based static stretching workout.
3190613|NCT01264198|Experimental|Resistance Training|The patients will perform twice weekly supervised RT for 3 months
3190614|NCT01264185||Asia--Thailand; S. America--Brazil|
3190615|NCT01264185||Africa--Zambia|
3190616|NCT01264172|Active Comparator|PCCP, Proximal femur fracture|Patients, who received a minimal-invasive surgical treatment with the PCCP-plate
3190617|NCT01264172|Active Comparator|Osteosythesis with nails, prox. femur frac.|Patients, who received a minimal-invasive surgical treatment including a osteosynthesis with nails
3190618|NCT01264172|Active Comparator|DHS, proximal femur fracture|Patients, who received a conventional surgical treatment with the dynamic hip screw (DHS)
3190619|NCT01264159|Placebo Comparator|Control|
3190620|NCT01264159|Active Comparator|Lung impedence-guided treatment|
3190621|NCT01264146|Active Comparator|calcaneal plating HBOT|Open reduction and internal fixation of calcaneal fracture + HBOT
3190622|NCT01264146|Placebo Comparator|calcaneal plating|Open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
3190623|NCT01264120|Experimental|Health Psychology Intervention|A 50 minute health psychology behavioural intervention with sessions pre-surgery, post-surgery and at 3 month follow up.
3190624|NCT01264120|No Intervention|Control Group|The control group receive usual care through the bariatric surgery process.
3190625|NCT01264081|Experimental|Lapatinib|Lapatinib will be administered as an oral dose of 500 mg twice daily in the morning and evening one hour before or after meals.
3190626|NCT01264068|No Intervention|Insomnia control|
3190627|NCT01264068|Experimental|Suan Tsao Jen Tang|
3190628|NCT01264068|Experimental|Jia-Wey Shiau-Yau San|
3190629|NCT01264042|Experimental|FeSo4|
3190630|NCT01264029|Experimental|Group A|Movement meditation for 2 hours
3190631|NCT01264029|Active Comparator|Group B|Non-moving sitting meditation for 2 hours
3190632|NCT01264029|Active Comparator|Group C|Mall Walking for 2 hours
3190633|NCT01264029|Active Comparator|Group D|Weekly Discussion
3190634|NCT01264016|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use an investigational blood glucose monitoring system.
3190635|NCT01264003|Active Comparator|1|Antibiotic prohylaxis / Lichtenstein repair
3190636|NCT01263990|No Intervention|Nexfin|Nexfin is used in all patients
3190637|NCT01263977|Experimental|Thermodilution controlled volume management|Volume management based on parameters: GEDI, ELWI, CI
3190638|NCT01263977|Active Comparator|Volume management based on surviving sepsis campaign|volume management based on surviving sepsis campaign guidelines: CVP, Urin output, MAP, ScvO2
3190639|NCT01263964||stroke, troponin elevation|Patients with stroke (proven by cerebral imaging) and troponin elevation undergoing coronary angiogram
3190640|NCT01263964||non-stemi (controll group)|Patients with troponin elevation suggesting non-stemi undergoing coronary angiogram
3190641|NCT01263951|Experimental|Everolimus and sorafenib|All patients will receive everolimus and sorafenib daily.
3190642|NCT01263938|Other|Atorvastatin|
3190643|NCT01263925|Experimental|Alprostadil|Alprostadil (Prostaglandin E1) intravenous and matching Placebo to Pentoxifylline oral
3190644|NCT01263925|Active Comparator|Pentoxifylline|Pentoxifylline oral and matching Placebo to Alprostadil (Prostaglandin E1) intravenous
3190645|NCT01263912|Active Comparator|LCPUFA Supplement|DHA/ARA supplement providing 200 mg/day docosahexaenoic acid (DHA) from DHASCO®-S oil and 200 mg/day arachidonic acid (ARA) from ARASCO® oil (DSM Nutritional Products).
3190646|NCT01263912|Placebo Comparator|A Placebo|400 mg/day corn oil
3190647|NCT01263899|Experimental|SB1518|
3190648|NCT01263886|Experimental|AVE8062 and combination|"Day 1: AVE8062~Day 2: docetaxel followed by cisplatin or paclitaxel followed by carboplatin"
3190649|NCT01263886|Placebo Comparator|Placebo|"Day 1: placebo~Day 2: docetaxel followed by cisplatin or paclitaxel followed by carboplatin"
3190650|NCT01263873|Active Comparator|Mallinckrodt (ETT)|Artifical Airway Device
3190651|NCT01263873|Experimental|Parker Flex Tip (ETT)|Artifical Airway Device
3190652|NCT01263860|Experimental|24-Week treatment group|Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 20 weeks
3190653|NCT01263860|Active Comparator|48-Week treatment group|Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 44 weeks
3190654|NCT01263847|Placebo Comparator|No Galactooligosaccharide|0 g galactooligosaccharide added to calcium-containing yogurt beverage
3190655|NCT01263847|Active Comparator|5 g Galactooligosaccharide|5 g galactooligosaccharide provided in two calcium-containing yogurt beverage (2.5 g in each drink) per day
3190656|NCT01263847|Active Comparator|10 g Galactooligosaccharide|10 g galactooligosaccharide added to two calcium-containing yogurt beverage (5 g in each drink) per day
3190657|NCT01263834|Active Comparator|Mitomycin c|Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
3190658|NCT01263834|Experimental|Bevacizumab|Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
3190705|NCT01263496|Experimental|Alogliptin 6.25 mg QD|
3190706|NCT01263496|Experimental|Alogliptin 12.5 mg QD|
3190659|NCT01263821|Experimental|Arm I|Patients undergo magnetic resonance spectroscopic imaging, functional magnetic resonance imaging (MRI), diffusion-weighted MRI, and perfusion-weighted MRI. Patients then undergo maximum surgical resection followed by intensity-modulated radiation therapy (IMRT) 5 days a week for 6 weeks.
3190660|NCT01263808|Experimental|Indacaterol 150 µg|Indacaterol 150 µg
3190661|NCT01263808|Experimental|Indacaterol 300 µg|Indacaterol 300 µg
3190662|NCT01263808|Experimental|Indacaterol 600 µg|Indacaterol 600 µg
3190663|NCT01263808|Placebo Comparator|Placebo|Placebo
3190664|NCT01263808|Active Comparator|Placebo/moxifloxacin|Placebo/moxifloxacin
3190665|NCT01263782|Experimental|Carboplatin + Pemetrexed|"The chemotherapy will be Carboplatin (AUC 6) and Pemetrexed (500 mg/m2) every 3 weeks for 4 cycles.~Then maintenance Pemetrexed (500 mg/m2 every 3 weeks) will be administered until disease progression or excessive toxicity.~If patients are randomized into one of the arms with a biologic therapy, patients will take the chemotherapy prescribed above, but will also receive the biologic therapy during the same time period."
3190666|NCT01263782|Experimental|Chemo (Carbo/Peme) + Bevacizumab|Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle. Bevacizumab 15 mg/kg by vein on day 1 of each 21 day cycle.
3190667|NCT01263782|Experimental|Chemo (Carbo/Peme)|Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle.
3190668|NCT01263782|Experimental|Chemo (Carbo/Peme) + Cixutumumab|"Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle.~Cixutumumab 20 mg/kg by vein on day 1 of each 21 day cycle."
3190669|NCT01263769|Experimental|Axitinib|Axitinib Starting dose: 5 mg by mouth twice each day for 12 weeks.
3190670|NCT01263756||ASD group|Adolescents and adults with Autism Spectrum Disorders (ASDs).
3190671|NCT01263743|Experimental|This is a single arm study|Relaxation Response training will be given to all participants
3190672|NCT01263730|Active Comparator|Tai Chi Training|The active group will be given 12 weeks of tai chi training
3190673|NCT01263730|No Intervention|Waitlist control group|There is a waitlist control group that will receive the training following a 12 week no treatment period of time
3190674|NCT01263717|Experimental|Tesamorelin|Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
3190675|NCT01263717|Placebo Comparator|Placebo (inactive injection)|Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase
3190676|NCT01263704|Experimental|Rituximab plus Fludarabine and Cyclophosphamide|Elderly participants with chronic lymphocytic leukemia (CLL) will receive combination treatment with low-dose fludarabine and cyclophosphamide combined with standard-dose of rituximab for 6 months. Treatment is followed by a follow up period of 36 months.
3190677|NCT01263691|Active Comparator|BioThrax|BioThrax, 0.5 mL AVA per dose
3190678|NCT01263691|Experimental|AV7909 Formulation 1|0.5 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose
3190679|NCT01263691|Experimental|AV7909 Formulation 2|0.5 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose
3190680|NCT01263691|Experimental|AV7909 Formulation 3|0.25 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose
3190681|NCT01263691|Experimental|AV7909 Formulation 4|0.25 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose
3190682|NCT01263691|Placebo Comparator|Control|Saline control
3190683|NCT01263678|Other|Non-Coaching|Usual care for patients with a diagnosis of spinal stenosis after viewing a DA and completing a survey.
3190684|NCT01263678|Other|Coaching|Patients randomized to coaching group will receive one week post viewing of Decisional Aid.
3190685|NCT01263665|Experimental|25cm Gore VIABAHN|25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface
3190686|NCT01263652|Active Comparator|IMmed|Patients receiving intra-muscular medication and oral placebo
3190687|NCT01263652|Active Comparator|POmed|Patients receiving intra-muscular placebo and oral medication
3190688|NCT01263639|Experimental|Intervention Group, biosketch card|The investigators aim to improve the patient-physician relationship and improve patient satisfaction by providing a biosketch card of the attending orthopaedic trauma surgeon to the patient. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies.
3190689|NCT01263639|Active Comparator|Control group, standard care|"The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The control group will receive the usual/standard care as provided to all orthopaedic trauma admission patients without receiving a biosketch card."
3190690|NCT01263626||Cough as Primary Complaint|"Male and female volunteers 18 years of age and older~Cough as chief complaint~Referred to the GI clinic to evaluate if reflux is the cause of their chief complaint~pH testing for standard of care purposes"
3190691|NCT01263626||Healthy Volunteers|"Male and female volunteers 18 years of age and older~No history of chronic or acute cough and throat clearing~Ability to read a 5th grade script written in English for approximately 20 minutes"
3190692|NCT01263613|Other|Biopsy|biopsy
3190693|NCT01263574|Placebo Comparator|Heparinized Saline|This group will maintain their central lines patent with heparinized saline.
3190694|NCT01263574|Experimental|Ethanol lock solution group|Administration of the 70% ethanol lock solution will occur between cycles of parenteral nutrition. Randomized lock solutions will be administered three days per week. When patients have completed their parenteral nutrition, their central venous catheters will be flushed with 5mL saline, per current standards
3190695|NCT01263561|Active Comparator|trabeculectomy|trabeculectomy filtering surgery
3190696|NCT01263561|Experimental|ExPRESS|ExPRESS miniature glaucoma drainage device
3190697|NCT01263548||Vyvanse|This is an open-label study which means that all study participants will be taking active study medication, Vyvanse.
3190698|NCT01263535|Experimental|SENSIMED Triggerfish|
3190699|NCT01263522|Experimental|Endurance training|
3190700|NCT01263522|Experimental|interval training|
3190701|NCT01263522|Experimental|strength endurance training|
3190702|NCT01263522|Placebo Comparator|control|
3190709|NCT01263496|Active Comparator|Voglibose 0.2-mg TID|
3190710|NCT01263483|Active Comparator|Voglibose 0.2 mg TID|
3190711|NCT01263483|Experimental|Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID|
3190712|NCT01263483|Experimental|Alogliptin 25 mg QD and Voglibose 0.2 mg TID|
3190713|NCT01263470|Placebo Comparator|Placebo|
3190714|NCT01263470|Experimental|Alogliptin 6.25 mg QD|
3190715|NCT01263470|Experimental|Alogliptin 12.5 mg QD|
3190716|NCT01263470|Experimental|Alogliptin 25 mg QD|
3190717|NCT01263470|Experimental|Alogliptin 50 mg QD|
3190718|NCT01263470|Active Comparator|Voglibose 0.2 mg TID|
3190719|NCT01263444|Experimental|Azarga|Brinzolamide 1% / timolol 0.5% Fixed Combination administered as 1 drop in study eye(s) twice a day (8:00 AM and 8:00 PM) for 12 weeks, at a 5 minute interval from the habitual prostaglandin monotherapy.
3190720|NCT01263431|Active Comparator|Hemorrhoidectomy|Excision of hemorrhoid cushions
3190721|NCT01263431|Experimental|Hemorrhoidal dearterialization|Ligation of therminbal branches oh hemorrhoid arteries
3190722|NCT01263418|Experimental|Ofatumumab|
3190723|NCT01263405||Normal|normal volunteers without sarcoma
3190724|NCT01263405||Sarcoma|Sarcoma
3190725|NCT01263392|Active Comparator|Polyvinyl Chloride Catheter|Re-use clean polyvinyl chloride catheters for intermittent catheterization of children with spina bifida.
3190726|NCT01263392|Active Comparator|Hydrophilic catheter|Use hydrophilic catheters (Speedicath) for intermittent catheterization of children with spina bifida.
3190727|NCT01263379|Experimental|LEAES treatment|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)
3190728|NCT01263366|Experimental|Norepinephrine|
3190729|NCT01263353|Experimental|Functional tumors, pre-treated|
3190730|NCT01263353|Experimental|Functional tumors, treatment naïve|
3190731|NCT01263353|Experimental|Nonfunctional tumors, pretreated 1|
3190732|NCT01263353|Experimental|Nonfunctional tumors, pretreated 2|
3190733|NCT01263353|Experimental|Nonfunctional tumors, treatment-naïve 1|
3190734|NCT01263353|Experimental|Nonfunctional tumors, treatment-naïve 2|
3190735|NCT01263340||People with COPD|
3190736|NCT01263327|Experimental|HPV 16/18|Participants in this arm would intramuscularly receive 90mcg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
3190737|NCT01263314|Experimental|MK-8266,0.3 mg|A single dose of 0.3 mg MK-8266 following an 8 hour overnight fasting period.
3190738|NCT01263314|Placebo Comparator|Placebo to MK-8266, 0.3 mg|A single dose of Placebo following an 8 hour overnight fasting period.
3190739|NCT01263314|Experimental|MK-8266, 0.6 mg|A single dose of 0.6 mg MK-8266 following an 8 hour overnight fasting period.
3190740|NCT01263314|Placebo Comparator|Placebo to MK-8266, 0.6 mg|A single dose of Placebo following an 8 hour overnight fasting period.
3190741|NCT01263314|Experimental|MK-8266, 1 mg|A single dose of 1 mg MK-8266 following an 8 hour overnight fasting period.
3190742|NCT01263314|Placebo Comparator|Placebo to MK-8266, 1 mg|A single dose of Placebo following an 8 hour overnight fasting period.
3190743|NCT01263301|Active Comparator|carotid duplex for hemolytic patients wtih SSS|assigned intervention:carotid duplex
3190744|NCT01263301|Active Comparator|carotid duplex for nonhemolytic patients with SSS|
3190745|NCT01263288|Active Comparator|Vitamin D3 (cholecalciferol) 400 IU|
3190746|NCT01263288|Active Comparator|Vitamin D3 (cholecalciferol) 1000 IU|
3190747|NCT01263288|Placebo Comparator|Placebo|
3190748|NCT01263275|Experimental|Active tDCS|
3190749|NCT01263249|Active Comparator|Catheter Anterior to Femoral Nerve|Each subject will have one lower extremity (Right or Left) randomized to receive a perinural catheter, placed anterior to the femoral nerve, with a continuous infusion of local anesthetic and then the outcomes will be measured.
3190750|NCT01263249|Active Comparator|Catheter Posterior to Femoral Nerve|Each subject will have the opposite lower extremity (Right or Left) randomized to receive a perinural catheter, placed posterior to the femoral nerve, with a continuous infusion of local anesthetic and then the outcomes will be measured.
3190751|NCT01263236|Experimental|LY2940094 - single dose|Single oral dose of 2-800 milligram (mg) LY2940094
3190752|NCT01263236|Experimental|LY2940094 - multiple dose|Daily oral dose of 2-200 mg LY2940094 for 14 days
3190753|NCT01263236|Experimental|Placebo|Single oral dose or daily oral dose for 14 days
3190754|NCT01263223|Experimental|LY2216684, placebo, LY or placebo|"Period 1: 18 mg LY2216684 administered orally once daily on days 1-4~Period 2: placebo administered orally once daily on days 1-4~Period 3: 36 mg LY2216684 or placebo administered orally daily on days 1-4"
3190755|NCT01263223|Experimental|Placebo, LY2216684, placebo or LY|"Period 1: placebo administered orally once daily on days 1-4~Period 2: 18 mg LY2216684 administered orally once daily on days 1-4~Period 3: 36 mg LY2216684 or placebo administered orally daily on days 1-4"
3190756|NCT01263210|Active Comparator|Pneumococcal vaccine|Half of the children were randomized to receive heptavalent pneumococcal conjugate vaccine (before this vaccine was included in the national immunization programme).
3190757|NCT01263210|No Intervention|Control|Half of the children were randomized to no vaccination and functioned as controls.
3190758|NCT01263197|Experimental|LY2216684, albuterol, LY221684+albuterol|LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a 7 day washout between each intervention period.
3190759|NCT01263197|Experimental|albuterol, LY2216684+albuterol, LY2216684|Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in third intervention period. There is a 7 day washout between each intervention period.
3190796|NCT01262976|Experimental|Group C|Treatment naïve HIV-positive subjects will receive GSK's investigational vaccine 692342.
3190797|NCT01262976|Placebo Comparator|Group D|Treatment naïve HIV-positive subjects will receive physiological saline.
3190760|NCT01263197|Experimental|LY2216684+albuterol, LY2216684, albuterol|LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in second intervention period, Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a 7 day washout between each intervention period.
3190761|NCT01263197|Experimental|LY2216684, propranolol, LY2216684+propranolol|LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a 7 day washout between each intervention period.
3190762|NCT01263197|Experimental|propranolol, LY2216684+propranolol, LY2216684|Placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in third intervention period. There is a 7 day washout between each intervention period.
3190763|NCT01263197|Experimental|LY2216684+propranolol, LY2216684, propranolol|LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in second intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a 7 day washout between each intervention period.
3190764|NCT01263184||sportive wheelchair users|
3190765|NCT01263184||sportive non disabled|
3190766|NCT01263184||non sportive wheelchair users|
3190767|NCT01263171|Other|Neo-adjuvant chemotherapy|Neo-adjuvant chemotherapy prior to short course pre-operative radiotherapy followed by adjuvant chemotherapy.
3190768|NCT01263158|Experimental|Expectant group|Arrest in labour progress for 2-3 hours and no progress after amniotomy. Expectancy of standard oxytocin treatment for 3 hours.
3190769|NCT01263158|No Intervention|Early oxytocin group|Arrest in labour progress for 2-3 hours and no progress after amniotomy. Oxytocin treatment started within 20 minutes.
3190770|NCT01263145|Experimental|Treatment (Akt inhibitor MK2206 and paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and Akt inhibitor MK2206 PO QD on days 2, 9, and 16. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3190771|NCT01263132|Experimental|F0434|
3190772|NCT01263132|Active Comparator|Gabapentin|
3190773|NCT01263119|Experimental|Warfarin, LY2216684+Warfarin|Single oral dose of 10 mg warfarin on Day 1 in period 1. Oral dose of 18 mg LY2216684 once daily (QD) on Days 1 to 12, with a single oral dose of 10 mg warfarin co-administered on Day 3 in period 2. There is a washout period of at least 14 days between dosing periods.
3190774|NCT01263106|Experimental|Theophylline,LY2216684+Theophylline|Single dose of 200 mg Theophylline on Day 1 in period 1. 18 mg LY2216684 once daily (QD) on Days 1 to 5, with a single dose of 200 mg theophylline co-administered on Day 3 in period 2. There is a washout period of at least 7 days between dosing periods.
3190775|NCT01263106|Experimental|LY2216684+Theophylline, Theophylline|18 mg LY2216684 once daily (QD) on Days 1 to 5, with a single dose of 200 mg theophylline co-administered on Day 3 in period 1. Single dose of 200 mg Theophylline on Day 1 in period 2. There is a washout period of at least 7 days between dosing periods.
3190776|NCT01263093|Experimental|Clopidogrel, LY2216684 + Clopidogrel|Clopidogrel as a single oral 300 mg dose on day 1 in first intervention period, and LY2216684 as an 18 mg oral dose on days 1-3 plus clopidogrel as a single oral 300 mg dose on day 3 in second intervention period (after a 14 day washout period).
3190777|NCT01263093|Experimental|LY2216684 + Clopidogrel, Clopidogrel|LY2216684 as an 18 mg oral dose on days 1-3 plus clopidogrel as a single oral 300 mg dose on day 3 in first intervention period, and clopidogrel as a single oral 300 mg dose on day 1 in second intervention period (after a 14 day washout period).
3190778|NCT01263080|Active Comparator|mirtazapine+folic acid|mirtazapine 30mg QD, folic acid 0.4mg QD
3190779|NCT01263080|Active Comparator|mirtazapine+folic acid placebo|mirtazapine 30mg QD, folic acid placebo 1 tablet QD
3190780|NCT01263080|Active Comparator|mirtazapine placebo+folic acid|mirtazapine placebo 1 tablet QD, folic acid 0.4mg QD
3190781|NCT01263080|Placebo Comparator|mirtazapine placebo+folic acid placebo|mirtazapine placebo 1 tablet QD, folic acid placebo 1 tablet QD
3190782|NCT01263067|Experimental|Lifespan Integration Therapy (LI)|
3190783|NCT01263067|Active Comparator|Waitlist Control- Lifespan Integration|
3190784|NCT01263054|Experimental|TransDiscal System|Kimberly-Clark TransDiscal System in addition to standard medical management
3190785|NCT01263054|Other|Medical Management|Standard medical management
3190786|NCT01263041|Experimental|glutamine, PT, sepsis|enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding up to 30 says post natal age + usual care and medications
3190787|NCT01263041|No Intervention|Control|after been allocated, will receive nothing and observed for the same outcomes
3190788|NCT01263041|Experimental|L-arginine,NEC, PT|enteral or via NG tube dose of 260 mg/kg/day divided every 12 hours from starting feeding up to 30 says post natal age + usual care and medications
3190789|NCT01263028|Experimental|Ergocalciferol supplementation|
3190790|NCT01263015|Experimental|Dolutegravir (N=~394):|Dolutegravir 50mg once daily + abacavir/lamivudine as the fixed-dose combination once daily + Atripla placebo once daily
3190791|NCT01263015|Active Comparator|Atripla (N=~394):|Atripla once daily + Dolutegravir placebo once daily + abacavir/lamivudine as the fixed-dose combination placebo once daily
3190792|NCT01262989|Active Comparator|tamsulosin Reference|Reference drug administration followed by Test drug administration
3190793|NCT01262989|Active Comparator|tamsulosin Test|Test drug administration followed by Reference drug administration
3190794|NCT01262976|Experimental|Group A|HIV-positive subjects on highly active anti retroviral therapy will receive GlaxoSmithKline's (GSK's) investigational vaccine 692342.
3190795|NCT01262976|Placebo Comparator|Group B|HIV-positive subjects on highly active anti retroviral therapy will receive physiological saline.
3190798|NCT01262976|Experimental|Group E|HIV negative subjects will receive GSK's investigational vaccine 692342.
3190799|NCT01262976|Placebo Comparator|Group F|HIV negative subjects will receive physiological saline.
3190800|NCT01262963|Experimental|Study Medication|GSK2118436 suspension
3190801|NCT01262937||Biliary Confocal Imaging|
3190802|NCT01262937||Esophageal Confocal Imaging|
3190803|NCT01262924|Experimental|Group A|dTPa vaccine
3190804|NCT01262924|Experimental|Group B|Pa vaccine
3190805|NCT01262924|Active Comparator|Group C|Tedivax-Adult™/ Td-Rix™
3190806|NCT01262911|Active Comparator|1.0 g SRT2379|Single dose of 1.0g of SRT2379
3190807|NCT01262911|Placebo Comparator|1.0 g Placebo|Single dose of 1.0g of placebo
3190808|NCT01262898|Experimental|GSK962040 (10 mg)|GSK962040 10 mg
3190809|NCT01262898|Experimental|GSK962040 (50 mg)|GSK962040 50 mg
3190810|NCT01262898|Experimental|GSK962040 (125 mg)|GSK962040 125 mg
3190811|NCT01262898|Experimental|Placebo|Placebo
3190812|NCT01262885|Experimental|Part A Cohort 1|GSK2251052 500 mg (6 subjects), Placebo (1 subject)
3190813|NCT01262885|Experimental|Part A Cohort 2|GSK2251052 1000 mg (6 subjects), Placebo (1 subject)
3190814|NCT01262885|Experimental|Part A Cohort 3|GSK2251052 2000 mg (6 subjects), Placebo (1 subject)
3190815|NCT01262885|Experimental|Part A Cohort 2 - fed|GSK2251052 1000 mg (6 subjects), Placebo (1 subject)
3190816|NCT01262885|Experimental|Part B Cohort 1|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
3190817|NCT01262885|Experimental|Part B Cohort 2|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
3190818|NCT01262885|Experimental|Part B Cohort 3|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
3190819|NCT01262885|Experimental|Part A Cohort 4|Placebo (1 subject), GSK2251052 (6 subjects) dose to be determined
3190820|NCT01262872|Experimental|10PP-HD 1d Group|This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation at Day 0. The 10PP vaccine was administered intramuscularly in the non-dominant deltoid.
3190821|NCT01262872|Active Comparator|Prevnar13 1d Group|This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of Prevnar 13™ at Day 0. Prevnar 13™ was administered intramuscularly in the non-dominant deltoid.
3190822|NCT01262872|Experimental|10PP-LD 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its low-dose (LD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, LD formulation, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
3190823|NCT01262872|Experimental|10PP-HD 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, HD formulation, co-administered with the Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
3190824|NCT01262872|Active Comparator|Synflorix 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of Synflorix™ and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the Synflorix™, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. Synflorix™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
3190825|NCT01262872|Active Comparator|Prevnar13 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of Prevnar 13™ and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of Prevnar 13™, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. Prevnar 13™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
3190826|NCT01262872|Experimental|10PP-HD 2+1d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received the GSK 2189242A (or 10PP) vaccine, in its high-dose (HD) formulation, and EPI vaccines according to a 2+1 Schedule. That is, subjects received 2 doses of the 10PP vaccine, HD formulation co-administered with Tritanrix™-Hep B/Hib and Polio Sabin™ at 2-4 months of age (at Day 0 and Month 2), followed by a third dose of the same formulation co-administered with M-Vac™, Stamaril™ and Polio Sabin™ at approximately 9 months of age.. The 2nd doses of Tritanrix™-Hep B/Hib and Polio Sabin™ in EPI vaccines were administered without any pneumococcal vaccine at 3 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
3190874|NCT01262586|Active Comparator|Glimepiride|
3190875|NCT01262573|Experimental|Barbed|Vaginal cuff closure with barbed suture
3190876|NCT01262573|Active Comparator|Smooth|Vaginal cuff closure with smooth suture
3190877|NCT01262560|Active Comparator|Supportive Care|Standard supportive care
3190878|NCT01262560|Experimental|Liquid Manuka Honey|Manuka honey in liquid form
3190827|NCT01262872|Active Comparator|Synflorix 2+1d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received Synflorix™ and EPI vaccines according to a 2+1 Schedule. That is, subjects received 2 doses of the Synflorix™ co-administered with Tritanrix™-Hep B/Hib and Polio Sabin™ at 2-4 months of age (at Day 0 and Month 2), followed by a third dose of Synflorix™ co-administered with M-Vac™, Stamaril™ and Polio Sabin™ at approximately 9 months of age. The 2nd doses of Tritanrix™-Hep B/Hib and Polio Sabin™ in EPI vaccines were administered without any pneumococcal vaccine at 3 months of age. Synflorix™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
3190828|NCT01262859|Experimental|Study Intervention|Induction therapy consists of 3 cycles of bevacizumab 15mg/kg on day 1, cetuximab weekly days 1,8,15 (loading dose of cetuximab 400mg/m2 on cycle 1, day 1, then 250 mg/m2 on all subsequent administrations), cisplatin 75mg/m2 on day 1, docetaxel 75mg/m2 on day 1, repeated every 21 days. After 3 cycles of induction therapy, patients will receive standard radiation 70-74 Gy/ 200 cGy/ daily, 5 days/ week with concurrent weekly cisplatin 30mg/m2, cetuximab 250mg/m2 and bevacizumab 15mg/kg every 3 weeks x 3. There is optional surgery for non-responders in the primary (stable disease) after TPE-A.
3190829|NCT01262846|Active Comparator|Fluzone SD|Fluzone® Standard dose
3190830|NCT01262846|Experimental|Fluzone® High dose|Fluzone® High dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
3190831|NCT01262833||Cases|Patients with erectile dysfunction by ILEF questionnaire
3190832|NCT01262833||Controls|Patients without erectile dysfunction by ILEF questionnaire
3190833|NCT01262820|Experimental|Single Intervention|Subjects will take Pazopanib, 800 mg daily by mouth throughout the time in study
3190834|NCT01262807|Experimental|Exercise|This group will receive instructions on specific exercises to perform after randomization.
3190835|NCT01262807|No Intervention|Standard Care|This group will receive standard care
3190836|NCT01262794|Experimental|CDP6038 0.3 mg/kg|
3190837|NCT01262794|Experimental|CDP6038 1 mg/kg|
3190838|NCT01262794|Experimental|CDP6038 3 mg/kg|
3190839|NCT01262794|Experimental|CDP6038 6 mg/kg|
3190840|NCT01262794|Placebo Comparator|Placebo|
3190841|NCT01262768|Experimental|2D Portion Size Measurment Aids (PSMAs)|The 2D PSMAs are life-size photographs of the 3D PSMAs.
3190842|NCT01262768|Experimental|3D Portion Size Measurement Aids (PSMAs)|The 3D PSMAs include foam rubber replicas of a golf ball, a hockey puck, a tennis ball and a baseball.
3190843|NCT01262755||African Americans|Consists of 450 African Americans living in the zip code surrounding Temple Hospital between the ages of 18 and 80.
3190844|NCT01262742|Active Comparator|Carbetocin 80mcg|
3190845|NCT01262742|Active Comparator|Carbetocin 90mcg|
3190846|NCT01262742|Active Comparator|Carbetocin 100mcg|
3190847|NCT01262742|Active Comparator|Carbetocin 110mcg|
3190848|NCT01262742|Active Comparator|Carbetocin 120mcg|
3190849|NCT01262729|Experimental|Xenon-Arm|Patients in Xenon-Arm will be inhalated with xenon within 2 hours additionally to therapeutical hypothermia after successful cardiopulmonary resuscitation.
3190850|NCT01262729|Active Comparator|MTH|Patients after successful cardiopulmonary resuscitation will be treated only with therapeutical hypothermia
3190851|NCT01262703|Experimental|REVA Medical ReZolve Stent|ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent
3190852|NCT01262690|Experimental|Dose|6 treated, 3 placebos
3190853|NCT01262677|Experimental|pregabalin CR 330 mg|
3190854|NCT01262677|Experimental|pregabalin CR 165 mg|
3190855|NCT01262677|Placebo Comparator|Placebo|
3190856|NCT01262664|Experimental|Prohibitin-TP01|Prohibitin-TP01 starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
3190857|NCT01262651|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligram [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
3190858|NCT01262651|Placebo Comparator|Placebo (GA-0034)|Placebo Comparator: Placebo (GA-0034) Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol: propylene glycol (50:50)
3190859|NCT01262638|Experimental|ETC-1002 120 mg (Group 1)|Subjects with hypercholesterolemia and normal triglycerides
3190860|NCT01262638|Experimental|ETC-1002 80 mg (Group 2)|Subjects with hypercholesterolemia and normal triglycerides
3190861|NCT01262638|Experimental|ETC-1002 40 mg (Group 3)|Subjects with hypercholesterolemia and normal triglycerides
3190862|NCT01262638|Experimental|Placebo (Group 4)|Subjects with hypercholesterolemia and normal triglycerides
3190863|NCT01262638|Experimental|ETC-1002 120 mg (Group 5)|Subjects with hypercholesterolemia and elevated triglycerides
3190864|NCT01262638|Experimental|ETC-1002 80 mg (Group 6)|Subjects with hypercholesterolemia and elevated triglycerides
3190865|NCT01262638|Experimental|ETC-1002 40 mg (Group 7)|Subjects with hypercholesterolemia and elevated triglycerides
3190866|NCT01262638|Experimental|Placebo (Group 8)|Subjects with hypercholesterolemia and elevated triglycerides
3190867|NCT01262625|Experimental|Group A: CCTA Diagnostic|Participants randomized to diagnostic evaluation using CCTA to determine therapeutic course of action.
3190868|NCT01262625|Active Comparator|Group B: SPECT MPI/ICA Diagnostic|Standard-of-care diagnostic assessment using SPECT MPI, possibly followed by diagnostic ICA dependent on SPECT MPI results.
3190869|NCT01262612|Active Comparator|immediate treatment with cediranib|8 patients with ascites and 8 patients with pleural effusion will start immediate treatment with cediranib
3190870|NCT01262612|Active Comparator|start cediranib after 28 days BSC|patients in group B will start with cediranib after one month best supportive care.
3190871|NCT01262599|Sham Comparator|Sham PEMF Device|Patients will receive inactive device
3190872|NCT01262599|Active Comparator|PEMF Device|Patients will receive Ivivi Torino II PEMF Device
3190873|NCT01262586|Experimental|Vildagliptin|
3190879|NCT01262560|Experimental|Lozenge Manuka Honey|Manuka honey in lozenge form
3190880|NCT01262547|Experimental|Dermabrasion-Micrografting|Dermabrasion-Micrografting
3190881|NCT01262547|Active Comparator|Dermabrasion alone|Dermabrasion alone
3190882|NCT01262547|No Intervention|Control|Control
3190883|NCT01262534||1|Clinical profile of patients Comorbidities and associated type of treatments will be collected.
3190884|NCT01262534||2|Quality of Life The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire to analyze the overall quality of life of patients and Dermatology Life Quality Index (DLQI) to analyze the quality of life of patients in dermatological terms).
3190885|NCT01262534||3|Patient Preferences about treatment Patient Benefit Index (PBI) for treatment to record patient preferences regarding psoriasis treatment.
3190886|NCT01262521|Experimental|Dietary nitrate|150 ml tab water with 150 umol/kg sodium-nitrate
3190887|NCT01262521|Placebo Comparator|Water|150 ml Chapelle mineral water
3190888|NCT01262508||Risk Population|Patients being suspected to be at risk of hemodynamic instability due to medical history
3190889|NCT01262495|Other|orchidectomy|as specified in the summary
3190890|NCT01262482|Experimental|Oxaliplatin + Sorafenib|
3190891|NCT01262469|Experimental|Lapatinib + Capecitabine|lapatinib 1250 mg/day (once daily) Capecitabine 2x850 mg/m2/day, days 1-14 during the first cycle and 2x1000 mg/m2/day, days 1-14, every 21 days for following cycles ( if no unacceptable toxicity is observed).
3190892|NCT01262456|Experimental|Desmopressin 50 μg Double-Blind / 100 μg Open-Label|Participants took 1 orally disintegrating tablet of desmopressin 50 μg every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
3190893|NCT01262456|Experimental|Desmopressin 75 μg Double-Blind / 100 μg Open-Label|Participants took 1 orally disintegrating tablet of desmopressin 75 μg every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
3190894|NCT01262456|Placebo Comparator|Placebo Double-Blind / Desmopressin 100 μg Open-Label|Participants took 1 orally disintegrating tablet of placebo every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
3190895|NCT01262443|Experimental|Therapy Cool Flex catheter group|Therapy Cool Flex Catheter . No more available data
3190896|NCT01262430|Active Comparator|OtisMed|
3190897|NCT01262430|Active Comparator|Computer Assisted Surgery (CAS)|
3190898|NCT01262417|Experimental|- Seprafilm group|patients receiving resorbable barrier membrane during the first surgery
3190899|NCT01262417|Other|- No-treatment control group|patients without seprafilm barrier during the first surgery
3190900|NCT01262404||HealthEd,Minfdulness,Compassion|HealthEd receives training health education. Mindfulness receives training in mindfulness meditation. Compassion receives training in compassion meditation.
3190901|NCT01262391|Experimental|treatment group 1|adolescents - lowest group
3190902|NCT01262391|Experimental|treatment group 2|adolescents - middle dose
3190903|NCT01262391|Experimental|treatment group 3|children - lowest dose
3190904|NCT01262391|Experimental|treatment group 4|adolescents - highest dose
3190905|NCT01262391|Experimental|treatment group 5|children - middle dose
3190906|NCT01262391|Experimental|treatment group 6|children - highest dose
3190907|NCT01262378|Other|Harmonic knife|surgery using the Harmonic knife
3190908|NCT01262378|Active Comparator|HF knife|
3190909|NCT01262365|Placebo Comparator|Placebo (Weekly infusion)|Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles
3190910|NCT01262365|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
3190911|NCT01262365|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles
3190912|NCT01262352|Experimental|Treatment Sequence 1|Ivacaftor administered in Treatment Period 1 and placebo administered in Treatment Period 2.
3190913|NCT01262352|Experimental|Treatment Sequence 2|Placebo administered in Treatment Period 1 and ivacaftor administered in Treatment Sequence 2.
3190914|NCT01262339|Active Comparator|Comparator of Hand A intervention vs Hand B|Hand A will receive 100U of BTX-A injected intradermally (SOC) Hand B will receive 100U delivered via iontophoresis.
3190915|NCT01262326|Experimental|Low Carbohydrate Diet|Subjects are placed on a low carbohydrate diet where only 5% of energy intake is derived from dietary carbohydrate.
3190916|NCT01262326|Active Comparator|Low Calorie Diet|Subjects have there caloric intake reduced to 1200 or 1500 kcal/day (women and men respectively).
3190917|NCT01262313|Sham Comparator|Control Group|"The Control group will have an hour-long meeting of instruction by a registered dietitian on using the provided A Healthier You: Everyday Healthy Eating and Physical Activity for Life book, based on the Dietary Guidelines for Americans 2005."
3190918|NCT01262313|Experimental|lifestyle counseling intervention|"This group will participate in the weekly Healthy Creations classes for 8 weeks presented by a Registered Dietitian and a certified fitness trainer. This is a community based lifestyle intervention program."
3190919|NCT01262300|Experimental|VZV vaccine|"Varicella Zoster Virus vaccine (Zostavax), single dose X 1 injection~All subjects in this trial will receive the VZV vaccine. The Investigators will primarily compare immune responses in those that are receiving high dose vs. standard dose vitamin D supplementation and those that have high and low 25-hydroxyvitamin D levels."
3190920|NCT01262287|Experimental|dutasteride|dutasteride (1 mg oral daily dose) for 8-week treatment period
3190921|NCT01262287|Placebo Comparator|Placebo|placebo daily for 8-week treatment period
3190922|NCT01262274|Active Comparator|ANA|
3190923|NCT01262274|Experimental|ANA+UFT|
3190924|NCT01262261|Experimental|Probuphine|patients are first inducted on sublingual buprenorphine then switched to 4 Probuphine Implants
3190925|NCT01262248||patients with colorectal polyps|
3190926|NCT01262235|Experimental|TKM-080301|
3190927|NCT01262222||pts undergoing major surg procedure referred to cardiology|Patients deemed to be at intermediate to high risk for postoperative cardiovascular events by clinical criteria will be the subject of this study. Cardiac risk will be determined according to the Revised Cardiac Risk Index (RCRI). RH-PAT testing and BNP evaluation will take place within 30 days before surgery and may occur on separate days. The blood may be drawn on the day of the RH-PAT testing or at a time of routine blood drawing within the 30 day period. After surgery the patient will be monitored and examined in the PACU for evidence of cardiac events.
3190928|NCT01262209|Experimental|Low Vision Aids|"All patients will receive:~A low vision examination:~Low vision refraction~Distance best corrected visual acuity~Near best corrected visual acuity~Contrast Sensitivity~Quality of life questionnaire~Low vision therapy: to teach strategies for more effective use of remaining vision and use of low-vision devices~Prescribed low vision devices including binocular telescope (2.1x or 3.5x), monocular telescope, 6x telemicroscopes, microscopes, magnifiers, portable CCTV and absorptive filters."
3190929|NCT01262196|Experimental|MP4OX|250-mL dose
3190930|NCT01262196|Placebo Comparator|Control|250-mL of normal saline solution
3190931|NCT01262183|Experimental|Concurrent chemoradiation therapy with panitumumab|
3190932|NCT01262183|Active Comparator|Concurrent chemoradiation therapy without panitumumab|
3190933|NCT01262170|Experimental|CigRx Lozenge|CigRx Lozenge
3190934|NCT01262170|Active Comparator|Tobacco Lozenge|Tobacco Lozenge
3190935|NCT01262157|Sham Comparator|placebo|We use the same probe that induces the same sensation on the penis and the same noise yet no energy
3190936|NCT01262157|Active Comparator|Shock wave therapy|12 treatment sessions twice a week during 9 weeks with an interim of 3 weeks no treatment
3190937|NCT01262144||Case group|
3190938|NCT01262131|Active Comparator|Resonator Protocol A|
3190939|NCT01262131|Active Comparator|Resonator Protocol B|Application of magnetic fields using the Resonator device Protocol B
3190940|NCT01262131|Placebo Comparator|Inactive Resonator|
3190941|NCT01262118|Experimental|CP-690,550 (tasocitinib) 10 mg twice daily (BID)|
3190942|NCT01262118|No Intervention|Healthy Volunteers|No intervention
3190943|NCT01262105|No Intervention|No device|
3190944|NCT01262105|Experimental|Device deployed|
3190945|NCT01262092|Active Comparator|Gabapentin|Buprenorphine will be given along with 2 capsules of gabapentin in the morning and 2 take-home capsules of gabapentin for night.
3190946|NCT01262092|Placebo Comparator|Placebo|Buprenorphine will be given, with 2 capsules of placebo in the morning and 2 take-home capsules of placebo in the evening
3190947|NCT01262079||Group 1: 6-15 years old|
3190948|NCT01262079||Group 2: 16-25 years old|
3190949|NCT01262079||Group 3: 26-35 years old|
3190950|NCT01262079||Group 4: 36-45 years old|
3190951|NCT01262079||Group 5: 46-55 years old|
3190952|NCT01262079||Group 6: 56-65 years old|
3190953|NCT01262079||Group 7: 66-75 years old|
3190954|NCT01262079||Group 8: 76-85 years old|
3190955|NCT01262079||Group 9: > 85 years old|
3190956|NCT01262066|Experimental|LifeSkills workshop intervention|Participants attended 10 1-hr weekly sessions. The content of the groups followed the LifeSkills Workshop manual and Video(Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
3190957|NCT01262066|No Intervention|Enhanced usual care|The Usual Care group received a self-help brochure on BP control developed by the National Heart, Lung, and Blood Institute (NHLBI). In addition, with the participants' permission, their BP readings were sent to their listed physicians, along with the 1-page JNC-7 express summary for the management of high BP.
3190958|NCT01262053|Experimental|Passive Intervention|When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated.
3190959|NCT01262053|Experimental|Invasive Intervention|The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders.
3190960|NCT01262053|Active Comparator|Control|Parallel control with no intervention
3190961|NCT01262040|Experimental|pts having a thorascopic, laparoscopic or robotic procedure|The procedure will begin with washings (peritoneal) and two assessments of the extent of peritoneal disease. First, a four quadrant inspection of the peritoneal cavity under white light, this is the standard of care assessment. Then, a repeat four quadrant inspection of the peritoneal cavity under NBI will be done, this is the only experimental component of the design. White light imaging will always be done first, followed by NBI. For those patients scheduled for thorascopic procedures: The procedure will begin with sampling of pleural effusions when clinically indicated. Then there will be two assessments of the pleural surfaces. First, an inspection of the pleural cavity under white light, this is the standard of care assessment. Then, a repeat inspection under NBI, this is the only experimental component of the design. White light imaging will always be done first, followed by NBI.
3190962|NCT01262027|Experimental|Dovitinib|A complete treatment cycle defined as 28 days or 4 weeks (+/- 2 days). Patients receive a single daily oral dose of 500 mg of dovitinib for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule).
3190963|NCT01262014|Experimental|Experimental single arm|Single arm of pazopanib 800 mg (2x400mg) given as a single agent.
3190964|NCT01261975|Experimental|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial microincision
3190965|NCT01261975|Active Comparator|Coaxial Small Incision Cataract Surgery|2.75 mm standard incision
3190966|NCT01261962|Experimental|Chemotherapy and zinc|Patients in adjuvant chemotherapy supplemented with zinc
3190967|NCT01261962|Placebo Comparator|Chemotherapy placebo|Patients in adjuvant chemotherapy with placebo
3190968|NCT01261962|Other|Control and zinc|Healthy patients supplemented with zinc
3190969|NCT01261962|Other|Control Placebo|Healthy volunteers received placebo
3190970|NCT01261949|Experimental|Combined frontal and temporal rTMS|Combined low frequency frontal and temporal transcranial magnetic stimulation of auditory cortex and right DLPFC
3190971|NCT01261949|Experimental|Temporal low frequency rTMS|temporal low frequency rTMS of auditory cortex
3190972|NCT01261936||women with a diagnosis of CBD|women in the fertile age, with an ascertained diagnosis of CBD, followed up for heavy periods and needing a specific treatment.
3190973|NCT01261923|Experimental|Alitretinoin - Hepatic Insufficiency|metabolism of 30 mg alitretinoin single dose in 8 patients with Hepatic Insufficiency
3190974|NCT01261923|Experimental|Alitretinoin - Hepatic Insufficiency Controls|metabolism of 30 mg alitretinoin single dose in 8 healthy controls.
3190975|NCT01261910|No Intervention|Usual education (standard care)|On the day of the transplant evaluation at the transplant center, participants receive usual transplant education regarding living donor kidney transplant.
3190976|NCT01261910|Experimental|Intensive initial education|On the day of the transplant evaluation at the transplant center, participants receive usual transplant education regarding living donor kidney transplant. In addition, participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
3190977|NCT01261897|Active Comparator|Adductor-Canal-Blockade with Ropivacaine|
3190978|NCT01261897|Placebo Comparator|Adductor-Canal-blockade with saline|
3190979|NCT01261884|No Intervention|Routine prenatal care|
3190980|NCT01261884|Experimental|Exercise support|
3190981|NCT01261884|Experimental|Exercise intervention|
3190982|NCT01261871||Robotic laparoscopic prostatectomy|Patients who are undergoing primary surgical treatment for a diagnosis of prostate operatively will be enrolled. IOP will be measured throughout the case to assess for change. The various techniques employed for a radical prostatectomy will be compared. Patients undergoing RRP (open surgery) will act as controls. Those undergoing LRP (minimally invasive surgery) will be compared with the control group to assess for differences in IOP that may result from the different approaches. three arms will be used for the comparison: open, laparoscopic intraperitoneal approach), and laparoscopic (extraperitoneal approach).
3190983|NCT01261858|Experimental|Stainless steel and Kryptonite|Sternal closure with stainless steel and kryptonite
3190984|NCT01261858|Active Comparator|Stainless steel|Sternal closure with only stainless steel
3190985|NCT01261832|Experimental|Dual antiplatelet therapy for 1 year|Dual antiplatelet therapy for 1 year : dual antiplatelet combination therapy with aspirin and clopidogrel for 1 year
3190986|NCT01261832|Experimental|Triple antiplatelet therapy for 1 month|Triple antiplatelet therapy for 1 month : triple antiplatelet therapy including cilostazol for 1 month and after then, dual antiplatelet therapy for 11 months
3190987|NCT01261832|Experimental|Triple antiplatelet therapy for 6 months|Triple antiplatelet therapy for 6 months : triple antiplatelet combination therapy including cilostazol for 6 months and after then, dual antiplatelet therapy for 6 months and cilostazol
3190988|NCT01261819|Experimental|transurethral laparoscope|These patients had cystoscopy performed with the transurethral laparoscope.
3190989|NCT01261819|Active Comparator|Traditional cystoscopy|"These patients had cystoscopy performed with the traditional cystoscope, which is considered to be the gold standard."
3190990|NCT01261806|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up: 10 session intervention in foster families' homes designed to enhance parental nurturance, synchrony, and provide skills such that parents can help children calm down when overwhelmed.
3190991|NCT01261806|Active Comparator|Developmental Education for Families|10 session intervention in foster families' homes that targets cognitive and motor skills of children
3190992|NCT01261793|Placebo Comparator|Placebo (Weekly infusion)|Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles
3190993|NCT01261793|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles
3190994|NCT01261793|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles
3190995|NCT01261780|Sham Comparator|Sham device|Sham therapy device to area of painful chemotherapy induced peripheral neuropathy (CIPN) for 45 minutes daily x 10 days
3190996|NCT01261780|Active Comparator|MC-5A treatment|MC-5A therapy to the area of painful CIPN for 45 minutes daily for a total of 10 days.
3190997|NCT01261767|Experimental|Anti-IL-20|
3190998|NCT01261767|Placebo Comparator|Placebo|
3190999|NCT01261754|Active Comparator|Metastatic prostate adenocarcinoma|
3191000|NCT01261754|Active Comparator|Healthy Volunteers|
3191001|NCT01261754|Active Comparator|Newly Diagnosed, High-Risk Prosate Cancer Patients|
3191002|NCT01261741|Experimental|Memantine|
3191003|NCT01261741|Placebo Comparator|Placebo|
3191004|NCT01261728|Experimental|Gemcitabine and Cisplatin|This is a Phase II Study of Gemcitabine and Cisplatin (GC) as neoadjuvant chemotherapy in patients with upper tract high-grade urothelial carcinoma who are candidates for radical nephroureterectomy or distal ureterectomy.
3191005|NCT01261715|Active Comparator|Woman with previous ceasarean section - staples|
3191006|NCT01261702|Placebo Comparator|Placebo|Normal saline IV
3191007|NCT01261702|Experimental|Magnesium sulphate|Magnesium sulphate 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
3191008|NCT01261689|Active Comparator|Epidural analgesia|Women will be allocated to the EA group. In the EA group, women are given an EA as soon as they are in labour.
3191009|NCT01261689|Other|Care as-usual pain treatment|Women will be allocated to the care-as-usual group. In this care-as-usual(restrictive) group, women receive pain relief only on their explicit request. If necessary epidural analgesia.
3191010|NCT01261676||Caesarean section|
3191011|NCT01261676||Vaginal birth (control)|
3191012|NCT01261663||NOS intake either at end of meals or as snackings.|
3191013|NCT01261650|Active Comparator|transcranial direct current stimulation|transcranial direct current stimulation of the primary motor cortex
3191014|NCT01261650|Sham Comparator|sham treatment|
3191015|NCT01261637|Experimental|0.25% Ropivicaine|0.25% ropivicaine (maximum 1.5mg/kg)
3191016|NCT01261637|Placebo Comparator|Placebo|20ml saline
3191017|NCT01261624|Experimental|Givinostat 1.0 mg/kg daily|
3191018|NCT01261624|Experimental|Givinostat 1.5 mg/kg daily|
3191019|NCT01261611|Experimental|Dysport RU|"500U (1ml) administered as intramuscular injection on day 1 of treatment cycle 1 and 2.~250U (0.5ml), 500U (1ml) or 750U (1.5ml) administered as intramuscular injection on day 1 of treatment cycle 3.~250U (0.5ml), 500U (1ml), 750U (1.5ml) or 1000U (2ml) administered as intramuscular injection on day 1 of treatment cycle 4 and 5."
3191020|NCT01261611|Active Comparator|Dysport|500U (1ml) injected as intramuscular injection on day 1 of treatment cycle 1.
3191021|NCT01261611|Placebo Comparator|Placebo|1ml administered as, intramuscular injection on day 1 of treatment cycle 1.
3191022|NCT01261598|Other|1|Patients treated with curative and exclusive radiotherapy (60 Gy minimum), with possibly prior chemotherapy
3191023|NCT01261598|Other|2|Patient treated with concomitant chemotherapy and radiotherapy (60 Gy minimum), with possibly prior chemotherapy chemotherapy Treatment
3191024|NCT01261572|Experimental|High dose group|ASP3350 high dose
3191025|NCT01261572|Experimental|Low dose group|ASP3350 low dose
3191026|NCT01261559|No Intervention|Standard CT|Women assigned to undergo CT using the standard dose reduction methods (including bismuth shielding and tube current modulation) but without the Chrysalis device.
3191027|NCT01261559|Experimental|Chrysalis CT|Women assigned to undergo CT using the standard dose reduction methods (including bismuth shielding and tube current modulation) plus application of the Chrysalis device for breast displacement.
3191028|NCT01261546|Experimental|Dexamethasone|"Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~Ranitidine 5 mg/kg IV, q.d. for 2 days~Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days."
3191029|NCT01261546|Placebo Comparator|Placebo|"Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~Ranitidine 5 mg/kg IV, q.d. for 2 days.~Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days."
3191030|NCT01261533|Experimental|FCVB team|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB)
3191031|NCT01261520|Other|Culturally-tailored video|The culturally-tailored video was designed to focus on Chinese women's cultural health beliefs and align with Chinese customs, norms, and values, which includes two segments: 1) a soap-opera and 2) recommendation from a Chinese female physician.
3191032|NCT01261494|Experimental|GFT505 80mg|
3191033|NCT01261494|Placebo Comparator|Matching placebo|
3191034|NCT01261481|Experimental|Tolvaptan Intact Tablet Orally|
3191035|NCT01261481|Experimental|Tolvaptan via Nasogastric Tube|
3191036|NCT01261468|Active Comparator|Active SCS|
3191037|NCT01261468|Sham Comparator|Inactive SCS|
3191038|NCT01261455|Active Comparator|Superior Conjunctival Autograft|Conjunctival autograft following pterygium excision is taken from superior conjunctival tissue.
3191039|NCT01261455|Experimental|Inferior Conjunctival Autograft|Conjunctival autograft following pterygium excision is taken from inferior conjunctival tissue.
3191040|NCT01261442||Diabetic patients with DSPN|
3191041|NCT01261442||Diabetic patients without DSPN|
3191042|NCT01261429|Experimental|Nilotinib|
3191043|NCT01261416||Infants with seizures|
3191044|NCT01261403|Experimental|Group 1|1 Unit of PDA001 or 4 units Vehicle Control intravenous on Day 0 and Day 7
3191045|NCT01261403|Experimental|Group 2|4 Units PDA001 or 4 units Vehicle Control intravenous (Placebo) on Day 0 and Day 7
3191046|NCT01261403|Placebo Comparator|Vehicle control|Placebo - Vehicle Control Arm
3191047|NCT01261390|Placebo Comparator|Conservative Medical Therapy (CMT)|All participants will meet with a research assistant who will provide ~30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breath Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
3191048|NCT01261390|Sham Comparator|Sham PAP (Sham)|"In addition to receiving CMT, participants in this treatment arm will receive a sham-CPAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active PAP arms.~The treatment visit schedule is outlined below.~PAP Initial Set-Up~1-week follow up~1-month follow up~3-month follow up~6-month follow up~9-month follow up (will not occur if on a 6-month follow-up protocol)~It is estimated that each in-person follow-up adherence visit with the PAP specialist would last ~30 minutes."
3191049|NCT01261390|Active Comparator|Active PAP with RT Support (Active-Beh)|"In addition to receiving CMT, participants will receive active-PAP. The treatment visit schedule is outlined below.~PAP Initial Set-Up~1-week follow up (FU)~1-month FU~3-month FU~6-month FU~9-month FU (12-month follow-up protocol only)~All visits will take place with a PAP specialist. All follow-up visits will be anchored to the initial PAP set-up visit. At these visits, using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. Each follow-up visit with the PAP specialist will last 30 minutes."
3191050|NCT01261390|Active Comparator|Active PAP with Behavioral Modification (Active+Beh)|"In addition to receiving CMT and active-PAP, participants will have behavioral intervention sessions to promote PAP adherence. The treatment visit schedule is outlined below:~Visits with Behavioral Interventionist (in addition to active-PAP treatment visits):~PAP Initial Set-Up (in-person, 1-hr)~1-week follow-up (FU) (in-person, 1-hr)~1-month FU~2-month FU~3-month FU~5-month FU~8-month FU (12-month follow-up protocol only)~All follow-up visits will be anchored to the initial PAP set-up visit. PAP treatment visits will occur as outlined in the active-PAP arm.~All behavioral intervention visits will be 30-min phone calls, unless otherwise noted. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training."
3191051|NCT01261377|Active Comparator|Bi-level positive airway pressure (BPAP)|bi-level will be titrated to optimize oxygenation and ventilation.
3191052|NCT01261377|Active Comparator|Nocturnal oxygen|oxygen will be provided as per standard of care.
3191053|NCT01261377|Active Comparator|Continuous positive airway pressure|The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
3191054|NCT01261364|Active Comparator|Treatment as Usual|
3191055|NCT01261364|Experimental|Pharmacogenetic guided treatment|
3191056|NCT01261338|Experimental|olestra|Non-absorbable fat
3191057|NCT01261325|Placebo Comparator|Placebo|Matching placebo tablets administered twice daily
3191058|NCT01261325|Experimental|Brivaracetam 100 mg/ day|Brivaracetam 50 mg/ day administered twice daily.
3191059|NCT01261325|Experimental|Brivaracetam 200 mg/ day|Brivaracetam 100 mg/ day administered twice daily
3191060|NCT01261312|Experimental|Daily Regimen|"SGI-110 daily x5 dosing on a 28-day course~SGI-110 daily x10 dosing on a 28-day course"
3191061|NCT01261312|Experimental|Weekly Regimen|"SGI-110 weekly dosing for three weeks on a 28-day course~SGI-110 twice weekly dosing for three weeks on a 28-day course"
3191062|NCT01261299|Experimental|Carbon-14-labeled carboplatin|Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
3191063|NCT01261273||Stable angina|Patient admitted with stable angina
3191064|NCT01261273||Acute Coronary Syndrome|Patients admitted with Acute Coronary Syndrome
3191065|NCT01261273||Female|Participant female patients
3191066|NCT01261273||Bifurcation|One or more lesions treated during the baseline in bifurcation
3191067|NCT01261273||Insulin Dependent Diabetes Mellitus|Patients that were insulin-dependent diabetes mellitus at admission
3191068|NCT01261273||Non-Insulin Dependent Diabetes Mellitus|Patients that were non-insulin-dependent diabetes mellitus at admission
3191069|NCT01261273||Small Vessels|vessels smaller or equal to 2.75mm
3191070|NCT01261273||NOBORI Long Lesions|Lesions longer or equal to 20mm
3191071|NCT01261273||Renal Insufficiency|Patients that at admission had renal insufficiency (> 2.0 mg/dL - 176 µmol/mL) at admission
3191072|NCT01261273||Elderly|Patients more or equal 80 years old
3191073|NCT01261273||Restenosis|One or more lesions treated during the baseline in were restenotic lesions
3191074|NCT01261273||Multivessel Treatment|Patients who underwent the treatment of more than 1 vessel during the index procedure
3191075|NCT01261273||Complex Lesions|Patients who underwent a PCI on the Left Main Trunk, on a Chronic Total Occluded lesion or located on a Saphenous Vein Graft
3191076|NCT01261273||Overall|Total Population
3191077|NCT01261260|Placebo Comparator|Uridine|1g BID
3191078|NCT01261247|Experimental|Arm I|Patients receive oral panobinostat 3 times weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3191079|NCT01261234|Experimental|Cilostazol group|Continuous administration of cilostazol (unrestricted use of other antiplatelet agents and concomitant drugs)
3191080|NCT01261234|Active Comparator|Non-Cilostazol group|Antiplatelet agent other than cilostazol (unrestricted use of concomitant drugs)
3191081|NCT01261182|Experimental|In School Feeding|
3191082|NCT01261182|Experimental|Take Home Rations|
3191083|NCT01261182|No Intervention|Control|
3191084|NCT01261169||Myfortic|
3191085|NCT01261156|Experimental|Study Arm 1|
3191086|NCT01261156|Experimental|Study Arm 2|
3191087|NCT01261143|Experimental|BK-C-0701, diabetic neuropathy|
3191088|NCT01261143|Active Comparator|alpha lipoic acid, diabetic neuropathy, capsule|
3191089|NCT01261130|Experimental|Part I-A: 10μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation A
3191090|NCT01261130|Experimental|Part I-B: 30μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation B
3191091|NCT01261130|Experimental|Part I-C: 100μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation C
3191092|NCT01261130|Experimental|Part I-D: 10μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation D
3191093|NCT01261130|Experimental|Part I-E: 30μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation E
3191094|NCT01261130|Experimental|Part I-F: 100μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation F
3191095|NCT01261130|Experimental|Part II-A: 10μgNaGST1/Alhydrogel|Part II (endemic area), Formulation A
3191096|NCT01261130|Experimental|Part II-B: 30μgNaGST1/Alhydrogel|Part II (endemic area), Formulation B
3191097|NCT01261130|Experimental|Part II-C: 100μgNaGST1/Alhydrogel|Part II (endemic), Formulation C
3191098|NCT01261130|Experimental|Part II-D: 10μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation D
3191099|NCT01261130|Experimental|Part II-E: 30μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation E
3191100|NCT01261130|Experimental|Part II-F: 100μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation F
3191101|NCT01261130|Active Comparator|Part II-G: Butang® hepatitis B vaccine|Part II (endemic), HepB comparator
3191102|NCT01261117|Active Comparator|intravenous ibuprofen|Extremely low birth weight patients receiving iv ibuprofen
3191103|NCT01261117|Active Comparator|Oral ibuprofen|Extremely low birth weight patients receiving oral ibuprofen
3191104|NCT01261104||Hearing impaired elderly|
3191105|NCT01261104||Hearing impaired adults|
3191106|NCT01261091|Experimental|Early Tracheostomy|Patients randomized to early tracheostomy receive (preferably dilatative) tracheostomy within 3 days from intubation.
3191107|NCT01261091|Active Comparator|Prolonged Intubation|Patients randomized to this arm will be tried to wean off the ventilator and get (an) extubation trial(s) if regarded feasible. In case of failure or non-feasibility, they receive tracheostomy between days 7 to 14 from intubation.
3191108|NCT01261078|Placebo Comparator|Placebo|8 mg bupivacaine only
3191109|NCT01261078|Active Comparator|Epi 25|8 mg of bupivacaine mixed with 25 mcg of epinephrine
3191110|NCT01261078|Active Comparator|Epi 50|8 mg of bupivacaine mixed with 50 mcg of epinephrine
3191111|NCT01261078|Active Comparator|Epi 100|8 mg of bupivacaine mixed with 0.1 mg of epinephrine
3191112|NCT01261078|Active Comparator|Epi 200|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
3191113|NCT01261052|Active Comparator|FMPD/APD intervention|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 33 hours. For the first 13 hours, the original artificial pancreas algorithm FMPD, will be used to control the subject's blood glucose. After 13 hours, the adaptive component or APD will be used to control the subject's blood glucose for the remaining 20 hours.
3191114|NCT01261052|Active Comparator|APD only intervention|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 33 hours. For the entire study, the adaptive component or APD will be used to control the subject's blood glucose.
3191115|NCT01261039|Active Comparator|Solar bed UV-radiation|Solar bed UV-radiation
3191116|NCT01261039|Sham Comparator|Solar bed with UV filter|Solar bed with UV filter
3191117|NCT01261026||Ectopic pregnancy, extra-uterine pregnancy|Ectopic pregnancy, control
3191118|NCT01261026||Abnormal intrauterine pregnancy|
3191119|NCT01261013||keratoconus stage I in whom KeraRing ICRS were implanted|
3191120|NCT01261013||keratoconus stage II in whom KeraRing ICRS were implanted|
3191121|NCT01261013||keratoconus stage III in whom KeraRing ICRS were implanted|
3191122|NCT01261000|Experimental|Pegvisomant|
3191123|NCT01260987|Active Comparator|AK split-face treatment|Split-face treatment of two symmetrical areas with moderate to severe actinic keratoses. One area is treated with conventional PDT the other with fractional laser assisted PDT.
3191124|NCT01260987|Active Comparator|Fractional laser assisted PDT for BCC|Difficult to treat nodular basal cell carcinomas in the face is pretreated with fractional CO2 laser followed by methyl-aminolevulinate PDT.
3191125|NCT01260987|Active Comparator|Konventional PDT for BCC|Difficult to treat nodular basal cell carcinomas in the face is treated with methyl-aminolevulinate PDT.
3191126|NCT01260974|Experimental|Caspofungin|Study group
3191127|NCT01260961|Active Comparator|Docosa Hexanoic Acid|
3191128|NCT01260961|Placebo Comparator|Placebo|
3191129|NCT01260948|Experimental|Investigational Test Product|Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg
3191130|NCT01260948|Active Comparator|Reference Listed Drug|Aricept® Orally Disintegrating Tablets, 10 mg
3191131|NCT01260935|Active Comparator|Arm A|Laparoscopic Hill
3191132|NCT01260935|Active Comparator|Arm B|Laparoscopic Nissen
3191133|NCT01260922|Experimental|Investigational Test Product|Donepezil Hydrochloride 10 mg Orally Disintegrating Tablets
3191134|NCT01260922|Active Comparator|Reference Listed Drug|Aricept® 10 mg Orally Disintegrating Tablets
3191135|NCT01260909||Real-time kV/MV Prostate Imaging|
3191136|NCT01260896|Experimental|Investigational Test Product|150 mg Venlafaxine Hydrochloride Extended-Release Capsules
3191137|NCT01260896|Active Comparator|Reference Listed Drug|150 mg Effexor® XR Extended-Release Capsules
3191138|NCT01260883|Experimental|ketorolac 1 mg/kg|ketorolac 1 mg/kg iv given by 10 min infusion
3191139|NCT01260883|Active Comparator|ketorolac 0.5 mg/kg|ketorolac 0.5 mg/kg iv given by 10 min infusion
3191140|NCT01260883|Sham Comparator|placebo|placebo group received D5W 10 min infusion
3191141|NCT01260870|Experimental|Cotavance|
3191142|NCT01260870|Active Comparator|Standard balloon angioplasty|POBA
3191143|NCT01260844|Experimental|single dose of briakinumab|single dose briakinumab cocktail of CYP substrates
3191144|NCT01260831|Experimental|Intervention Hospitals|hospitals randomized to implement bedsidePEWS documentation system (vital sign assessment record)
3191145|NCT01260831|Active Comparator|Control Hospitals|hospitals randomized to continue with their pre existing documentation system (vital sign assessment record)
3191146|NCT01260818|Experimental|Tranexamic Acid|
3191147|NCT01260818|Placebo Comparator|control group|
3191148|NCT01260805|Active Comparator|Reference Drug|
3191149|NCT01260805|Active Comparator|Test Drug|
3191150|NCT01260792||Children|Children between 5 and 18 years old.
3191151|NCT01260792||Adults|Parents of children between 5 and 18 years old
3191152|NCT01260766|Active Comparator|Active Comparator: Oplon Active Patch|
3191153|NCT01260766|Placebo Comparator|Placebo Comparator: Placebo patch|
3191154|NCT01260753|Experimental|UR-63325|
3191155|NCT01260753|Active Comparator|Fluticasone propionate nasal spray|
3191156|NCT01260753|Placebo Comparator|Placebo|
3191157|NCT01260727|Experimental|Group 1|Participants will receive PENNVAX-G vaccine administered by intramuscular injection (IM) via Biojector 2000 needleless device in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
3191158|NCT01260727|Experimental|Group 2|Participants will receive PENNVAX-G vaccine administered via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
3191159|NCT01260727|Experimental|Group 3: Subgroup 1|Participants will receive PENNVAX-G vaccine administered IM via Biojector 2000 needleless device in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
3191160|NCT01260727|Placebo Comparator|Group 3: Subgroup 2|Participants will receive placebo vaccine for PENNVAX-G administered IM via Biojector 2000 needless device in either deltoid on Days 0 and 28. They will then receive placebo vaccine for MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
3191161|NCT01260727|Experimental|Group 4: Subgroup 1|Participants will receive PENNVAX-G vaccine administered IM via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
3191162|NCT01260727|Placebo Comparator|Group 4: Subgroup 2|Participants will receive placebo vaccine for PENNVAX-G administered IM via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive placebo vaccine for MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
3191163|NCT01260714|Experimental|Treatment (azacitidine, mitoxantrone hydrochloride, etoposide)|Patients receive induction therapy comprising azacitidine SC QD on days 1-7, mitoxantrone hydrochloride IV over 30 minutes, and etoposide IV over 1 hour on days 4-8. Patients may receive up to 2 additional courses of the same treatment as re-induction or consolidation therapy beginning 35-60 days from the start of the previous course.
3191164|NCT01260701|Experimental|Treatment (CLOSED TO ACCRUAL 05/01/13)|Patients receive Akt inhibitor MK2206 PO every other day on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3191165|NCT01260688|Experimental|Arm I|Patients receive oral cediranib maleate once daily and oral dasatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3191166|NCT01260688|Experimental|Arm II|Patients receive cediranib maleate as in arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3191167|NCT01260675||NanoBUP Capsules|Investigational Formulation of Buprenorphine HCl/Naloxone HCl 8 mg/2 mg oral capsules
3191168|NCT01260675||Suboxone Sublingual Tablets|Buprenorphine HCl/Naloxone HCl 8 mg/2 mg sublingual tablets
3191169|NCT01260662|Active Comparator|Propofol|Deep sedation using propofol
3191170|NCT01260662|Experimental|1:1 Propofol/Ketamine|Propofol and ketamine mixed 1:1, given at 0.1 cc/kg as initial bolus, followed by 1/2 that dose every 3 minutes as need for sedation
3191171|NCT01260662|Experimental|4:1 Propofol/Ketamine|Propofol and ketamine mixed 4:1, given at 0.1 cc/kg as initial bolus, followed by 1/2 that dose every 3 minutes as need for sedation
3191172|NCT01260649|Experimental|ketamine|ketamine (0.5 mg/kg) followed by anesthetic agent titrated to sedation and succinylcholine titrated to muscle relaxation Right unilateral ECT at 5-6x seizure threshold three times a week
3191173|NCT01260649|Placebo Comparator|placebo|"IV saline, followed by anesthestic agent titrated to sedation and succinylcholine titrated to muscle relaxation.~Right unilateral ECT at 5-6x seizure threshold three times a week"
3191174|NCT01260636|Experimental|MultiHance contrast agent|MultiHance administered at a dose of 0.1 mmol/kg (0.2 mL/kg)
3191175|NCT01260636|Active Comparator|Magnevist|Magnevist administered at a dose of 0.2 mmol/kg
3191176|NCT01260610|Active Comparator|Tenofovir|
3191177|NCT01260610|Active Comparator|Telbivudine|
3191178|NCT01260610|Experimental|Tenofovir plus Telbivudine|
3191179|NCT01260597|Experimental|Life Style Counseling|For individuals who report being quit, a brief congratulatory message will be delivered, independent of each arm of the study they were randomized to. For individuals who report not being quit and are randomized to the intervention condition, tailored messages are delivered via the IVR system. The automated calls would include an assessment of the individual's interest in another quit attempt and deliver brief, tailored messages to perceived barriers for re-engaging into treatment. The system is programmed to transfer the caller to a live quit line counselor if the individual is willing to re-engage in cessation treatment.
3191180|NCT01260597|Active Comparator|Life Counseling|For individuals who report being quit, a brief congratulatory message will be delivered, independent of each arm of the study they were randomized to. For individuals who report still smoking the IVR will thank them for their time and the call will end.
3191181|NCT01260584|Experimental|Prasugrel|Prasugrel 10 mg film-coated tablet daily dose × 10 days. To maintain blinding, placebo film-coated tablets matching clopidogrel in appearance will be given daily × 10 days to subjects in the prasugrel treatment group. In addition, aspirin 81 mg to 325 mg daily will be taken.
3191182|NCT01260584|Active Comparator|Clopidogrel|Clopidogrel 75 mg film-coated tablet daily dose x 10 days To maintain blinding, placebo film-coated tablets matching prasugrel in appearance will be given daily × 10 days to subjects in the clopidogrel treatment group. In addition, aspirin 81 mg to 325 mg daily will be taken.
3191183|NCT01260571|Experimental|Benzoyl Peroxide and Sulfur|Topical Medications containing benzoyl peroxide and sulfur
3191184|NCT01260558|Active Comparator|Arm 1|Sirolimus-Permanent-Polymer Eluting Stent
3191185|NCT01260558|Active Comparator|Arm 2|Sirolimus-Polymer-free Eluting Stent
3191186|NCT01260545|Experimental|Infusion|A standard 3+3 design will be employed to determine maximum tolerated dose
3191187|NCT01260532||Graves' disease|no intervention
3191188|NCT01260532||Hashimoto's thyroiditis|no intervention
3191189|NCT01260532||Healthy subjects|no intervention
3191190|NCT01260519|Experimental|active arm: heparin|
3191191|NCT01260506|Experimental|VB-111|Antiangiogenic and vascular disruptive agent
3191192|NCT01260493|No Intervention|Conventional care, controlgroup|conventional care, control group
3191193|NCT01260493|Experimental|integrated health care chain|integrated health care chain. Geriatric assessment at emergency department (ED), case manager with multiprofessional team in the community, support for informal caregivers
3191194|NCT01260480|Experimental|[18F]-ML-10|
3191195|NCT01260467|Experimental|memantine arm|
3191196|NCT01260454|Experimental|Qutenza patch|All participants actively treated with Qutenza
3191197|NCT01260441|Active Comparator|Standard CPR|"Individuals will learn the Standard form of CPR (30:2, compressions:breathes) Main data points being collected over various increments are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect and 3) CPR Skills"
3191198|NCT01260441|Active Comparator|Chest Compressions Only CPR|"Individuals will learn the chest compression only form of CPR (no rescue breathes) Main data points being collected at various increments are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect and 3) CPR Skills"
3191199|NCT01260428||healthy active subjects|with and without high altitude intolerance
3191200|NCT01260402|Active Comparator|Epicardial|
3191201|NCT01260402|Experimental|Endocardial|
3191202|NCT01260389|No Intervention|control group|Usual pharmacist care in patients with Chronic Obstructive Pulmonary Disease (COPD).
3191203|NCT01260389|Experimental|pharmaceutical care intervention|A pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
3191204|NCT01260376|Experimental|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
3191205|NCT01260376|No Intervention|Placebo|Placebo tablets will be administered 4 times previous to and during the investigation day
3191206|NCT01260363|Active Comparator|Naropin, Adrenalin, applicationsite|
3191207|NCT01260363|Active Comparator|Femoral nerve block|
3191208|NCT01260350|Experimental|Group 1: SOF+RBV 12 wk: GT 2 or 3, TN|Treatment-naive (TN) participants with genotype (GT) 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
3191209|NCT01260350|Experimental|Group 2: SOF+RBV 12 wk+PEG 4 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks plus PEG 180 µg once weekly for 4 weeks.
3191210|NCT01260350|Experimental|Group 3: SOF+RBV 12 wk+PEG 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks plus PEG 180 µg once weekly for 8 weeks.
3191211|NCT01260350|Experimental|Group 4: SOF+RBV+PEG 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily+weight-based RBV (1000-1200 in a divided daily dose) plus PEG 180 µg once weekly for 12 weeks.
3191212|NCT01260350|Experimental|Group 5: SOF 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily for 12 weeks.
3191213|NCT01260350|Experimental|Group 6: SOF+RBV+PEG 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus PEG 180 µg once weekly for 8 weeks.
3191214|NCT01260350|Experimental|Group 7: SOF+RBV 12 wk: GT 1, TE|Treatment-experienced (TE) participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
3191215|NCT01260350|Experimental|Group 8: SOF+RBV 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
3191216|NCT01260350|Experimental|Group 9: SOF+RBV 12 wk: GT 2 or 3, TE|Treatment-experienced participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
3191217|NCT01260350|Experimental|Group 10: SOF+RBV 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 8 weeks.
3191218|NCT01260350|Experimental|Group 11: SOF+RBV 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus split-dose RBV (800 mg in a divided daily dose) for 12 weeks.
3191219|NCT01260350|Experimental|Group 12: SOF+RBV+LDV 12 wk: GT 1, TE|Treatment-experienced participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus LDV 90 mg once daily for 12 weeks.
3191220|NCT01260350|Experimental|Group 13: SOF+RBV+LDV 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus LDV 90 mg once daily for 12 weeks.
3191221|NCT01260350|Experimental|Group 14: SOF+RBV+GS-9669 12 wk: GT 1, TE|Treatment-experienced participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus GS-9669 500 mg once daily for 12 weeks.
3191222|NCT01260350|Experimental|Group 15: SOF+RBV+GS-9669 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus GS-9669 500 mg once daily for 12 weeks.
3191223|NCT01260350|Experimental|Group 16: LDV/SOF FDC 12 wk: GT 1, fibrosis|Treatment-experienced participants with genotype 1 HCV infection and Stage F4 fibrosis who did not respond to prior treatment will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
3191224|NCT01260350|Experimental|Group 17: LDV/SOF FDC+RBV 12 wk: GT 1, fibrosis|Treatment-experienced participants with genotype 1 HCV infection with Stage F4 fibrosis who did not respond to prior treatment will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
3191225|NCT01260350|Experimental|Group 18: LDV/SOF FDC 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
3191226|NCT01260350|Experimental|Group 19: LDV/SOF FDC 12 wk: GT 2 or 3, TE|Treatment-experienced participants with genotype 2 or 3 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
3191227|NCT01260350|Experimental|Group 20: LDV/SOF FDC+RBV 12 wk: GT 1, hemophiliac|Hemophiliac participants with genotype 1 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
3191228|NCT01260350|Experimental|Group 21: LDV/SOF FDC+RBV 6 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 6 weeks.
3191229|NCT01260350|Experimental|Group 22: LDV/SOF FDC 6 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection were randomized to receive LDV 90 mg/SOF 400 mg FDC once daily for 6 weeks.
3191230|NCT01260337|Active Comparator|Diabetes Support and Education (DSE)|
3191231|NCT01260337|Experimental|Portion controlled diet (PCD)|behavior modification
3191232|NCT01260324||NAION cases|From the study population, patients with a claim associated with an ischemic optic neuropathy diagnosis code were identified as potential NAION cases (n = 3,732). From the potential NAION cases, definite and possible NAION cases were identified using medical record review and a claims algorithm (n=1,283). Data from definite and possible NAION cases contributed to the analysis.
3191233|NCT01260324||Controls|From the study population, patients without a claim associated with an ischemic optic neuropathy diagnosis code were randomly selected as controls (n = 20,000)
3191234|NCT01260311||Patients prescribed with Fesoterodine|Patients diagnosed with Over-active bladder and prescribed with fesoterodine.
3191235|NCT01260298||MC1 Ultrasonic Device|
3191236|NCT01260285|Experimental|Vardenafil|
3191237|NCT01260272|Active Comparator|Alternative Snack Group|This group will receive 100 calorie alternative snack packs to consume three times a day with meals. Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables
3191238|NCT01260272|Experimental|Raisin Group|This group will receive raisins to consume three times a day with meals
3191239|NCT01260259|Experimental|Remote Ischemic Preconditioning (RIPC)|
3191240|NCT01260259|Sham Comparator|Control|
3191241|NCT01260246|Experimental|sitagliptin|sitagliptin 100mg/daily for 6 months
3191242|NCT01260246|Placebo Comparator|placebo|placebo match for 6 months
3191243|NCT01260233|No Intervention|Control|No intervention. Patients will receive standard of care.
3191244|NCT01260233|Experimental|Smoking cessation program|Receives smoking cessation program
3191245|NCT01260220|Active Comparator|Circumferential|Completing a complete circle of RF lesions around the left and right pulmonary veins
3191246|NCT01260220|Experimental|Segmental|Isolating the left and right pulmonary veins through RF lesions with a segmental antral approach.
3191247|NCT01260207|Experimental|IVR group|Patients in this arm will receive IVR follow-up telephone calls at 1,3,6,9 and 12 months post-discharge consisting of predetermined questions related to medication management, smoking cessation, diet, exercise and education as recommended by the ACC/AHA BPG for ACS. Upon completion of the IVR follow-up, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
3191248|NCT01260207|No Intervention|Usual care|Patients in this arm will not receive IVR follow-up. One year after discharge, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
3191249|NCT01260194|Experimental|1|
3191250|NCT01260181|Experimental|Erlotinib|Participants will receive erlotinib 150 millgrams (mg) orally daily until disease progression.
3191251|NCT01260168||Colorectal cancer patients|Subjects will be men and women, 40-90 years of age, inclusive, each with a colonoscopic biopsy-based diagnosis of colorectal cancer (CRC) and/or an intact pre-malignant colorectal lesion large enough to require surgical excision or complex colonoscopic polypectomy.
3191252|NCT01260155|Experimental|Treatment A Fasted|
3191253|NCT01260155|Experimental|Treatment B Fasted|
3191254|NCT01260155|Experimental|Treatment C Food Effect|
3191255|NCT01260142|Experimental|Arm 1|
3191256|NCT01260142|Experimental|Arm 2|
3191257|NCT01260142|Experimental|Arm 3|
3191258|NCT01260129|Experimental|Silodosin 8 mg|
3191259|NCT01260129|Experimental|Silodosin 4 mg|
3191260|NCT01260116||1|Ziprasidone,Zeldox capsule
3191261|NCT01260103|Active Comparator|Temozolomide (TMZ)|Study subjects receive TMZ for 13 cycles
3191262|NCT01260103|Experimental|ANP Therapy|Escalating doses of ANP therapy are given daily for 52 weeks.
3191263|NCT01260090|Experimental|Vagus Nerve Stimulation|"Name of the Device:~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).~FDA Facility Registration Number: 1644487"
3191264|NCT01260090|Sham Comparator|No Stimulation|
3191265|NCT01260077||Experimental group|The sample was composed of 78 individuals (156 ears), 40 females (80 ears) and 38 males (76 ears).
3191266|NCT01260064|Active Comparator|Open appendectomy|The subjects will have open appendectomy procedure.
3191267|NCT01260064|Active Comparator|Metal endoclip|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
3191268|NCT01260064|Active Comparator|Intracorporeal suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
3191269|NCT01260051||Epidural Recipients|
3191270|NCT01260051||Non-Epidural Recipients|
3191271|NCT01260025|Experimental|PEDylated Recombinant Human Endostatin|PEDylated Recombinant Human Endostatin
3191272|NCT01260012|Experimental|praziquantel+antioxidant|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In additions, antioxidant suppliment will be given daily for a period of one year
3191273|NCT01260012|Active Comparator|Praziquantel +placebo 2mths then antioxidant for 10 months|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.
3191274|NCT01260012|No Intervention|Praziquantel therapy with placebo supplement|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for a period of one year.
3191275|NCT01259999|Experimental|Energy dense formula|
3191276|NCT01259986|Experimental|Laser treatment|
3191277|NCT01259973|Experimental|Risperidone|
3191278|NCT01259973|Placebo Comparator|Placebo|
3191279|NCT01259973|Experimental|Haloperidol|
3191280|NCT01259960||BMI < 25|Body Mass Index (BMI) according to WHO definition. BMI < 25 is defined as 'normal weight'.
3191281|NCT01259960||25 <= BMI < 30|Body Mass Index (BMI) according to WHO definition. BMI >= 25 and < 30 is defined as 'overweight'.
3191282|NCT01259960||BMI >= 30|Body Mass Index (BMI) according to WHO definition. BMI >= 30 is defined as 'obese'.
3191283|NCT01259947|Experimental|Lippia alba|
3191284|NCT01259934|No Intervention|Arm A|Observation only - no therapy
3191285|NCT01259934|Experimental|Arm B Interferon 1 year|Interferon Therapy: Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 12 months
3191286|NCT01259934|Experimental|Arm C Interferon 2 years|"Two year arm Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months"
3191287|NCT01259921|Experimental|Neurofeedback|40 sessions of SMR neurofeedback training administered twice weekly
3191288|NCT01259908||Laparoscopic vs open Ygraft|Patients with advanced atherosclerosis in aorto iliac segment operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared on the basis of the operative procedure for the primary endpoint, composite endpoint (all-cause mortality, systemic morbidity and graft thrombosis).
3191289|NCT01259895||Obesity|BMI > 30kg/m2
3191290|NCT01259895||Normal weight|BMI between 19 and 24,9kg/m2
3191291|NCT01259882|Experimental|Cohort 1: Experimental intervention: PF-05089771 or placebo|Cohort 1
3191292|NCT01259882|Experimental|Cohort 2: Experimental intervention: PF-05089771 or placebo|Cohort 2
3191293|NCT01259882|Experimental|Cohort 3: Experimental intervention: PF-05089771 or placebo|Cohort 3
3191294|NCT01259882|Experimental|Cohort 4: Experimental intervention: PF-05089771 or placebo|Cohort 4
3191295|NCT01259882|Experimental|Cohort 5: Experimental intervention: PF-05089771 or placebo|Cohort 5
3191296|NCT01259882|Experimental|Cohort 6: Experimental intervention: PF-05089771 or placebo|Cohort 6
3191297|NCT01259869|Experimental|PX-866|
3191298|NCT01259856|Experimental|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
3191299|NCT01259856|Active Comparator|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
3191300|NCT01259843||Acute Aortic Syndrome|Patients admitted to cardiology, radiology or surgery for a clinical picture suggestive of acute aortic syndrome whose diagnosis was subsequently confirmed in due course of hospitalization by further investigations.
3191301|NCT01259830|Experimental|Arcoxia® 120 mg|
3191302|NCT01259830|Placebo Comparator|Sugar pill|
3191303|NCT01259817|Experimental|PEGASYS|Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously.
3191304|NCT01259817|Active Comparator|Aspirin|81 or 100 mg daily.
3191305|NCT01259804|Experimental|Peanut immunotherapy|Peanut flour
3191306|NCT01259791|Experimental|Statin|Individual-specific statin causing myopathy - i.e., Patients will receive the specific statin previously associated with myopathic symptoms in them (can be any of the following statins: rosuvastatin, atorvastatin, simvastatin, fluvastatin, pravastatin in any of the doses causing symptoms previously).
3191307|NCT01259791|Placebo Comparator|Placebo|Identical placebo to patient-specific statin
3191308|NCT01259765|Active Comparator|VHH|"The active substance is VHH batch 203027."
3191309|NCT01259765|Placebo Comparator|Placebo|Placebo product
3191310|NCT01259752|Experimental|compression stockings|
3191311|NCT01259752|Placebo Comparator|standard non compressive stockings|
3191312|NCT01259739|Experimental|Flavanol rich cocoa|(596 mg), dissolved in water, twice daily intervention
3191313|NCT01259739|Experimental|flavanol poor cocoa drink|( 13mg) dissolved in water, twice daily intervention
3191314|NCT01259726|Placebo Comparator|Placebo|
3191315|NCT01259726|Experimental|VP20621 Low Dose and Placebo|
3191316|NCT01259726|Experimental|VP20621 High Dose and Placebo|
3191317|NCT01259726|Experimental|VP20621 High Dose|
3191318|NCT01259713|Experimental|Liposomal amphotericin B|Liposomal amphotericin B 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
3191319|NCT01259713|Placebo Comparator|Placebo|Placebo to match liposomal amphotericin B twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
3191320|NCT01259700|Experimental|High risk management|
3191321|NCT01259700|Experimental|Salt reduction|
3191322|NCT01259700|Experimental|high risk management and salt reduction|
3191323|NCT01259700|No Intervention|Usual care|
3191324|NCT01259687||Study group|
3191325|NCT01259674|Experimental|AboMeg-B-09 syrup|Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
3191326|NCT01259674|Placebo Comparator|Placebo|Placebo syrup
3191327|NCT01259661|Experimental|Experimental Group|
3191328|NCT01259661|Active Comparator|Control Group|
3191329|NCT01259648|Experimental|0.5 µg / kg remifentanil|Induction anesthesia includes 0.5 µg/kg remifentanil in addition to classic induction anesthesia protocol.
3191330|NCT01259648|Experimental|1.0 µg/kg remifentanil|Induction anesthesia includes 1.0 µg/kg remifentanil in addition to the classic induction protocol.
3191331|NCT01259648|Placebo Comparator|NaCl|An equivalent volume (1 ml for 10 kg of weight) of isotonic 0.9% NaCl is injected in addition to the classic anesthesia induction protocol
3191332|NCT01259635|Experimental|Bio feedback for freezing|When ever freezing occures, a metronom sound will be heard
3191333|NCT01259622|Placebo Comparator|placebo|
3191334|NCT01259622|Experimental|K201|intravenous K201
3191335|NCT01259609|Experimental|Diabetic Macular Edema Group|
3191336|NCT01259609|Active Comparator|Epiretinal Membrane Group|
3191337|NCT01259609|No Intervention|Healthy Control|
3191338|NCT01259596|Active Comparator|Cognitive behavioral therapy|Cognitive-behavioral therapy consists of psychoeducation, relaxation techniques, cognitive therapy, problem-solving, thought stopping, behavioral activation, exposure, coping with pain, sleep, and relapse prevention
3191339|NCT01259596|Active Comparator|Nondirective supportive therapy|Nondirective supportive therapy consists of providing a warm and accepting environment in which a person can reflect on their experiences, thoughts, and feelings
3191340|NCT01259583|Experimental|CO2|CO2 insufflation instead air insufflation in unsedated colonoscopy
3191341|NCT01259583|Experimental|Warm Water irrigation|warm water irrigation during the insertion phase of colonoscopy
3191342|NCT01259570|Active Comparator|Skimmilk enriched with VD encapsulated in CM|
3191343|NCT01259570|Active Comparator|VD will be dissolved in milkfat and homogenized into skimmilk|VD will be dissolved in milkfat and homogenized into skimmilk
3191344|NCT01259570|Active Comparator|3% fat milk wherein the VD will be in CM|3% fat milk wherein the VD will be in CM
3191345|NCT01259570|Active Comparator|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk.
3191346|NCT01259557|Experimental|Botulinum toxin type A(Meditoxin®)|
3191347|NCT01259544|Active Comparator|Di -petide breath tests and ePFT secretin induced|Di peptide breath tests will be performed on subjects with known chronic pancreatitis
3191348|NCT01259544|Active Comparator|c13 di peptide breath tests|Healthy volunteers to compare breath tests results to subjects with chronic pancreatitis
3191349|NCT01259531|Experimental|Silodosin|Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
3191350|NCT01259518|Experimental|Once monthly administration of TRIN2755|
3191351|NCT01259518|Experimental|Once weekly administration of TRIN2755|
3191352|NCT01259505|Experimental|Safety|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3191353|NCT01259492|Experimental|Ritalin LA 40 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2, continued in same dose till week 9. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 40 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14. In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
3191354|NCT01259492|Experimental|Ritalin LA 60 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2 and to 60 mg at week 3. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 60 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14.In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
3191355|NCT01259492|Experimental|Ritalin LA 80 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2 and to 60 mg at week 3 and to 80 mg at week 4. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 60 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14. In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
3191356|NCT01259492|Placebo Comparator|Placebo|Period 1- Placebo controlled Period 2 - The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose (40, 60 or 80 mg). In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
3191357|NCT01259479|Experimental|1|Dose escalation, continuous treatment without DLTs
3191358|NCT01259466|Experimental|Cognitive Behavioral + Nicotine Patch|Cognitive Behavioral Therapy + Nicotine Replacement Patch
3191359|NCT01259466|Active Comparator|Health Education + Nicotine Patch|Health Education + Nicotine Replacement Patch
3191360|NCT01259453|Active Comparator|Standard vaccination schedule|Standard dosing at 0, 1, and 6 months
3191361|NCT01259453|Active Comparator|Accelerated Schedule|Accelerated dosing at 0, 1, and 2 months
3191362|NCT01259440|Active Comparator|Video Teleconferencing Care|Video teleconferencing care
3191363|NCT01259440|Placebo Comparator|Usual Care|Usual Care
3191364|NCT01259427|Experimental|Arm 1: Ending Self Stigma|Ending Self Stigma (ESS): Ending Self Stigma (ESS) is a 9-session small-group (4-8 persons) course designed to help individuals with serious mental Illness (SMI) develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
3191365|NCT01259427|Active Comparator|Arm 2: Health and Wellness Group|Health and Wellness Group: The Health and Wellness group is a 9-session small-group (4-8 persons) course designed for individuals with serious mental illness (SMI). Each session focuses on discussion of specific health and wellness related issues and education on ways to better manage health related concerns (e.g., physical activity/exercise, nutrition, managing fatigue/sleep, tobacco and other substance use, etc).
3191366|NCT01259414|Experimental|group1|Chemoembolization with solvent with specific gravity less than lipiodol
3191367|NCT01259414|Experimental|group2|Chemoembolization with Solvent with specific gravity equivalent to lipiodol
3191368|NCT01259401|Experimental|SIP group|The Sleep Intervention Program group received a sleep education program based on behavioral principles, delivered in 4 individual sessions carried out within the Adult Day Health Care program.
3191369|NCT01259401|Active Comparator|Control group|The Control group received basic sleep education, delivered in 4 individual sessions carried out within the Adult Day Health Care
3191370|NCT01259388|Experimental|Arm 1|One year's treatment of standard therapy plus lithium followed by one year of standard therapy without lithium.
3191371|NCT01259388|Experimental|Arm 2|One year's treatment with standard therapy followed by one year of standard therapy plus lithium.
3191372|NCT01259375|Experimental|All patients|All participants who received Amrubicin.
3191373|NCT01259362|Active Comparator|Transcranial Magnetic Stimulation|Cocaine addicted will receive a 20 day TMSr to right dorsolateral prefrontal cortex.
3191374|NCT01259362|Sham Comparator|Transcranial Magnetic Stimlation|cocaine addicted will receive a 20 day sham TMSr to right dorsolateral prefrontal cortex
3191375|NCT01259349|Experimental|one percent ultrasound|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at one percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
3191409|NCT01259167||BACK group|training with a traditional protocol of Therapeutic Physical Exercise
3191410|NCT01259167||"Group C."|Control group with sedentary people undergoing usual care.
3191376|NCT01259349|Active Comparator|40 percent ultrasound|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at 40 percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
3191377|NCT01259336|Active Comparator|Itraconazole|Role of itraconazole in CCPA
3191378|NCT01259336|Experimental|treatment in cavitary pulmonary aspergillosis|Patients in this arm are given conservative management with antitussives, brochial artery embolisation.
3191379|NCT01259323|Experimental|Cohort 1|
3191380|NCT01259323|Experimental|Cohort 2|
3191381|NCT01259323|Experimental|Cohort 3|
3191382|NCT01259310||Women with epilepsy|Women with epilepsy, age 18-40 years, who express a desire to conceive and have stopped or plan to stop taking birth control.
3191383|NCT01259310||Women without epilepsy|Healthy women, age 18-40 years, who express a desire to conceive and have stopped or plan to stop taking birth control.
3191384|NCT01259297|Experimental|Aliskiren + Amlodipine|"In run-in period (4-5 weeks) , patients on thiazide background therapy and approximately 50% of patients on neither CCB nor thiazide background therapy received Amlodipine 5 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.~In double blind period, patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~Patients randomized to this arm received Aliskiren 300 mg + Amlodipine 5 mg once daily during the double blind period."
3191385|NCT01259297|Experimental|Aliskiren + Hydrochlorothiazide (HCTZ)|"In run-in period (4-5 weeks) , patients on CCB background therapy and approximately 50% of patients on neither thiazide nor CCB background therapy: received Hydrochlorothiazide 12.5/25 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.~In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~Patients randomized to this arm received Aliskiren 300 mg + HCTZ 25 mg once daily."
3191386|NCT01259297|Experimental|Aliskiren + Placebo for Amlodipine|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for Amlodipine 5 mg"
3191387|NCT01259297|Experimental|Aliskiren + Placebo for HCTZ|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for HCTZ 25 mg once daily"
3191388|NCT01259297|Experimental|Amlodipine + Placebo for Aliskiren|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~In double blind period, randomized patients to this arm received Amlodipine 5 mg + placebo for Aliskiren 300 mg once daily"
3191389|NCT01259297|Experimental|HCTZ + Placebo for Aliskiren|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~In double blind period, randomized patients to this arm received HCTZ 25 mg + placebo for Aliskiren 300 mg once daily"
3191390|NCT01259297|Placebo Comparator|Placebo for Aliskiren + Placebo for Amlodipine|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for Amlodipine 5 mg once daily"
3191391|NCT01259297|Placebo Comparator|Placebo for Aliskiren + Placebo for HCTZ|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for HCTZ 25 mg once daily"
3191392|NCT01259284|Experimental|Atorvastatin|1 Atorvastatin capsule daily plus 3 Placebo capsules twice a day orally, 5 days pre-surgery.
3191393|NCT01259284|Experimental|Fish Oil Supplement|3 Fish Oil capsules twice a day plus 1 Placebo capsule daily orally 5 days pre-surgery.
3191394|NCT01259284|Placebo Comparator|Placebo|4 capsules orally every morning and 3 every evening for 5 days pre-surgery.
3191395|NCT01259258|Active Comparator|varicocelectomy with dye|subinguinal varicocelectomy for 40 patients who received 2 ml intratunical space injection of methylene blue before spermatic vein ligation
3191396|NCT01259258|Active Comparator|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
3191397|NCT01259245|Experimental|Tai chi + PRP|Tai chi elements in incorporated into the exercise component of standard pulmonary rehabilitation program. The exercise content was totally identical to the PRP group except 15 minutes of Tai Chi exercises was substituted to 15 minutes of relaxation exercise. The 5 forms of Sun Style of Tai Chi were taught.
3191398|NCT01259245|Active Comparator|PRP|PRP is a formal pulmonary rehabilitation program consisted of physical training including warm up and cool down exercise and aerobic exercises in addition to breathing control exercises, safety precautions for physical training, Thera-Band strengthening exercises and overview of COPD management.
3191399|NCT01259232||schizophrenia patients,untreated|
3191400|NCT01259232||schizophrenia relatives|
3191401|NCT01259232||controls|
3191402|NCT01259219|Experimental|Rifabutin (Mycobutin)|Rifabutin is a red-violet powder souble in chloroform and methanol, sparingly souluble in ethanol, and very slightly soluble in water. Mycobutin capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. Mycobutin capsules for oral administered contain 150mg of rifabutin, USP, per capsule, along with the inactive ingredients microcrystalline cellulose magenesium stearate, red iron oxide3, silica gel, sodium lauryl sulfate, titanium dioxide, and edible white ink.
3191403|NCT01259206||diabetic patients|
3191404|NCT01259206||diabetic patients and healty controls|there are two groups in this study. One group is obese type 2 diabetic patiens and other group is healty controls.
3191405|NCT01259193|Experimental|Sorafenib and Zoledronic Acid|
3191406|NCT01259180|Experimental|Acupuncture group|twice a week, 6 weeks real acupuncture treatment, 12 sessions
3191407|NCT01259180|Sham Comparator|Sham acupuncture group|twice a week, 6 weeks real acupuncture treatment, 12 sessions
3191408|NCT01259180|No Intervention|Control group|observation.
3191411|NCT01259167||JOBA group|training with JOBA® Core Trainer
3191414|NCT01259141|Experimental|Moxifloxacin|
3191415|NCT01259141|Experimental|Cephalosporins and azithromycin|
3191416|NCT01259128|Experimental|SER120 500 ng/day|SER120 Level 1 (500 ng/day)
3191417|NCT01259128|Experimental|SER120 750 ng/day|SER120 Level 2 (750 ng/day)
3191418|NCT01259115|Experimental|Sequence A|BTDS 10 with ketoconazole 200 mg tablets twice daily in period 1 and BTDS 10 with ketoconazole placebo tablets twice daily in period 2.
3191419|NCT01259115|Experimental|Sequence B|BTDS 10 with ketoconazole placebo tablets twice daily in period 1 and BTDS 10 with ketoconazole 200 mg twice daily in period 2.
3191420|NCT01259102|Experimental|No Rest|BTDS 10 with no application site rest period prior to application of second BTDS
3191421|NCT01259102|Experimental|7-Day Rest|BTDS 10 with 7-day rest period prior to application of second BTDS
3191422|NCT01259102|Experimental|14-Day Rest|BTDS 10 with 14-day rest period prior to application of second BTDS
3191423|NCT01259102|Experimental|21-Day Rest|BTDS 10 with 21-day rest period prior to application of second BTDS
3191424|NCT01259102|Experimental|28-Day Rest|BTDS 10 with 28-day rest period prior to application of second BTDS
3191425|NCT01259089|Experimental|Arm I|Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3191426|NCT01259076||Group 1|Participants who are eligible for and have opted to undergo gastric bypass surgery
3191427|NCT01259076||Group 2|Participants who are eligible for but decided not to undergo gastric bypass surgery.
3191428|NCT01259063|Experimental|Pts who failed or relapsed after intravesical BCG|Phase I: Everolimus will be administered as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be administered at the dose determined in Phase .Everolimus will be continued for 12 months in the patients who achieve a CR or a Partial Response. Patients demonstrating a CR (by cystoscopy and cytology) or a Partial Response at their Cycle 12 cystoscopy will be observed with serial cystoscopies every 3 months.
3191429|NCT01259050|Experimental|Zinc and Copper|
3191430|NCT01259024|Experimental|doxorubicin-eluting LC Bead|transarterial chemoembolization using doxorubicin-eluting LC Beads
3191431|NCT01259011|No Intervention|control|Written information on advance directives and the patient's right to have an advance directive is provided to every patient on the first day of dialysis treatment by a social worker at the clinic. A social worker documents whether the patient has an advance directive, a surrogate decision maker, and/or a Do-Not-Resuscitate (DNR) Order on a Comprehensive Interdisciplinary Assessment form. The social worker encourages patients to complete an advance directive and addresses their questions about life-sustaining treatment options. If completed, the advance directive is placed in the medical record.
3191432|NCT01259011|Experimental|SPIRIT intervention|The SPIRIT intervention is a two-session, 1½ hour-long, structured intervention that is composed of six steps (assessing representations, identifying and exploring gaps and concerns, creating conditions for conceptual change, introducing replacement information, summarizing, and setting goals and planning), presented to both patient and surrogate by a trained nurse interventionist in a face-to-face interview format based on the representational approach.
3191433|NCT01258998|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3191434|NCT01258985|Active Comparator|Tai Chi|12 weeks of Tai Chi classes
3191435|NCT01258985|Active Comparator|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of Supervised Home Exercise
3191436|NCT01258972|Active Comparator|Angioplasty POBA|Side Branch balloon angioplasty with main branch DES
3191437|NCT01258972|Experimental|Tryton Side Branch Stent|Side Branch treated with Tryton Side Branch Stent with main branch DES
3191438|NCT01258959||Ophthalmic surgery patients|Patients (men and women) of at least 18 years of age undergoing an ophthalmic procedure on the posterior section of the eye under local anaesthesia, i.e. with a peribulbar block. Inclusion and exclusion criteria for the study are the same as for the peribulbar anaesthesia.
3191439|NCT01258933|Experimental|Ofatumumab|Ofatumumab 300 mg dose 1, then 1,000 mg weekly * 7, (treatment) then 1,000 mg every 2 months beginning on week 12 for a total of 2 years of treatment or until progression (maintenance) of disease. The follow-up period will be the period after completion of maintenance.
3191440|NCT01258920|Experimental|Paliperidone palmitate|Paliperidone palmitate Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
3191441|NCT01258907|Experimental|A|
3191442|NCT01258907|Experimental|B|
3191443|NCT01258907|Placebo Comparator|C|
3191444|NCT01258868|Experimental|1|Celebrex+ tumor cell vaccine
3191445|NCT01258855|Experimental|Arm I (ziv-aflibercept and aldesleukin)|Patients receive ziv-aflibercept IV over at least 1 hour in weeks 1, 3, 5, and 7 (and in week 9 of course 1 only) and high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in weeks 1 and 3 (and in weeks 3 and 5 of course 1 only). Treatment repeats every 8 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising ziv-aflibercept IV on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3191446|NCT01258855|Experimental|Arm II (aldesleukin)|Patients receive high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in weeks 1 and 3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3191447|NCT01258842|Experimental|B. lactis HN019|
3191448|NCT01258842|Placebo Comparator|Placebo|
3191449|NCT01258829|Experimental|Non-invasive haemodynamic optimisation|Optimization of pressure production by the heart, as measured by systolic blood pressure in the systemic circulation
3191450|NCT01258829|Active Comparator|ECHO optimisation|Optimization of AV/VV delay using the guideline recommendations
3191451|NCT01258803|Experimental|Sequence 1|Treatment Period 1: Placebo MDI with spacer; Treatment Period 2: MF/F MDI without spacer; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: F DPI
3192152|NCT01253863|Other|determining damaged tissue|
3191452|NCT01258803|Experimental|Sequence 2|Treatment Period 1: F DPI; Treatment Period 2: MF/F MDI without spacer; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: Placebo MDI with spacer
3191453|NCT01258803|Experimental|Sequence 3|Treatment Period 1: MF/F MDI without spacer; Treatment Period 2: F DPI; Treatment Period 3: Placebo MDI with spacer; Treatment Period 4: MF/F MDI with spacer
3191454|NCT01258803|Experimental|Sequence 4|Treatment Period 1: Placebo MDI without spacer; Treatment Period 2: MF/F MDI with spacer; Treatment Period 3: F DPI; Treatment Period 4: MF/F MDI without spacer
3191455|NCT01258803|Experimental|Sequence 5|Treatment Period 1: MF/F MDI without spacer; Treatment Period 2: F DPI; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: Placebo MDI without spacer
3191456|NCT01258803|Experimental|Sequence 6|Treatment Period 1: MF/F MDI with spacer; Treatment Period 2: Placebo MDI without spacer; Treatment Period 3: MF/F MDI without spacer; Treatment Period 4: F DPI
3191457|NCT01258790|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation|Eight sessions of Repetitive Transcranial Magnetic Stimulation, in the form of Continuous Theta Burst Stimulation, was delivered over the Supplementary Motor Area over 2 days using a Sham TMS coil.
3191458|NCT01258790|Experimental|Active Repetitive Transcranial Magnetic Stimulation|Eight sessions of Repetitive Transcranial Magnetic Stimulation, Continuous Theta Burst Stimulation, was delivered over the Supplementary Motor Area over 2 days using an Active Magstim Figure-8 TMS coil.
3191459|NCT01258777|Experimental|001|200 mg golimumab or placebo Single dose of 200 mg subcutaneously
3191460|NCT01258777|Experimental|002|400 mg golimumab or placebo Single dose of 400 mg subcutaneously
3191461|NCT01258764|Active Comparator|Lisinopril|
3191462|NCT01258764|Active Comparator|Hydrochlorothiazide|
3191463|NCT01258751|Experimental|PF-05212377|
3191464|NCT01258738|Active Comparator|etanercept|In Period 1 : Subjects will receive via a prefilled syringe an active dose equivalent to 1.0ml of Etanercept solution once weekly SC once weekly. Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
3191465|NCT01258738|Placebo Comparator|PLACEBO|In Period 1: Subjects will receive in a prefilled syringe with a PLACEBO dose equivalent to 1.0 ml of placebo solution once weekly SC Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
3191466|NCT01258725|Experimental|amnioinfusion|The investigators propose an open trial comparing baseline Doppler waveforms in the uteroplacental and fetal pulmonary circulation in patients presenting with severe, idiopathic olighydramnios (AFI<5, no apparent ethiopathology), managed either with single or with serial amnioinfusions. The patients will be followed up weekly in the fetomaternal unit, Dept. of ObGyn for measuring AFI repeatedly to assess the need for further infusions. These will be carried out when the AFI falls below 5cm again
3191467|NCT01258712|Experimental|1|
3191468|NCT01258712|Placebo Comparator|2|
3191469|NCT01258699|Experimental|3|BK-C-0701 480mg
3191470|NCT01258699|Experimental|2|BK-C-0701 320mg
3191471|NCT01258699|Active Comparator|1|Thioctacid HR tab 600mg
3191472|NCT01258686|Experimental|silymarin, treatment|
3191473|NCT01258686|Placebo Comparator|placebo|
3191474|NCT01258673|Experimental|Fimasartan/HCTZ combination group|
3191475|NCT01258673|Active Comparator|Fimasartan group|
3191476|NCT01258660|Experimental|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
3191477|NCT01258660|Experimental|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
3191478|NCT01258647|Experimental|Feeding group|The feeding group will include 20 mother/infant dyads. The infants will be between 8 and 10 months of age.
3191479|NCT01258634|Other|Pre-op treatment|
3191480|NCT01258621|Experimental|Laparoscopic Distal Pancreatectomy|
3191481|NCT01258608|Experimental|Sorafenib plus mapatumumab|Mapatumumab 30 milligrams (mg)/kilogram (kg) intravenously on Day 1 of each cycle (i.e. every 21 days) plus sorafenib 400 mg orally twice daily continuously in each cycle until radiologic disease progression or unacceptable toxicity
3191482|NCT01258608|Placebo Comparator|Sorafenib plus Placebo|Placebo intravenously on Day 1 of each cycle (i.e. every 21 days) plus sorafenib 400 mg orally twice daily continuously in each cycle until radiologic disease progression or unacceptable toxicity
3191483|NCT01258595|Experimental|High-Dose Trivalent Inactivated Influenza Vaccine|
3191484|NCT01258595|Active Comparator|Trivalent Inactivated Influenza Vaccine|
3191485|NCT01258582|Experimental|Oral HIV testing|
3191486|NCT01258582|Active Comparator|Fingerstick HIV testing|
3191487|NCT01258569|Active Comparator|Entereg|
3191488|NCT01258569|Placebo Comparator|Placebo|
3191489|NCT01258556|Experimental|Probiotic yogurt|
3191490|NCT01258556|Placebo Comparator|Placebo yogurt.|
3191491|NCT01258543||Non-specific back pain|
3191492|NCT01258530|Experimental|Treatment A|Over-encapsulated oseltamivir 75 mg (1 capsule)
3191493|NCT01258530|Experimental|Treatment B|oseltamivir 75 mg (1 capsule)
3191494|NCT01258517||group 1, group 2, group 3, group 4|administration of beractant with single lumen ET tube administration of poractant with single lumen ET tube administration of beractant with double lumen ET tube administration of poractant with double lumen ET tube
3191495|NCT01258504||CYP2C9 wild type|"CYP2C9 wild type =extensive metaboliser~Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19~Administration of St. Johns Wort: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
3191496|NCT01258504||CYP2C9 mutant|"CYP2C9 *2/*2 or 2*/*3 or *3/*3 = poor metaboliser~Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19~Administration of St. Johns Wort: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
3191497|NCT01258478|Experimental|rehabilitation|Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
3191498|NCT01258478|Sham Comparator|usual care|Usual care before surgery is provided
3191499|NCT01258465|Active Comparator|Pivotal Response Training|A naturalistic behavioral intervention designed to facilitate verbal communication.
3191500|NCT01258465|Active Comparator|Picture Exchange Communication System|Pictorially-based behavioral protocol designed to facilitate communication via picture icons.
3191501|NCT01258452|Experimental|CHF 5074 (fed group)|oral tablet, single dose
3191502|NCT01258452|Experimental|CHF 5074 (fasting group)|oral tablet, single dose
3191503|NCT01258439|Active Comparator|1.Raltegravir plus truvada|Raltegravir 400mg twice daily plus truvada 300mg/200mg once daily for 24 weeks
3191504|NCT01258439|Active Comparator|2. ritonavir boosted darunavir plus truvada|Darunavir 800mg with ritonavir 100mg plus truvada 300mg/200mg once daily for 24 weeks
3191505|NCT01258426||Normal, IGT, T2DM|
3191506|NCT01258413|Experimental|Laparoscopic Radical Hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament are removed + pelvic lymphadenectomy
3191507|NCT01258413|Active Comparator|Abdominal radical hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament are removed + pelvic lymphadenectomy
3191508|NCT01258387|Placebo Comparator|GGF2|Seven dosing cohorts: 2 patients randomized to receive 1 GGF2, 1 placebo; if no drug-related dose-limiting toxicities in GGF2-treated patient, other 4 patients in cohort will be randomized (3:1) and dosed
3191509|NCT01258374||Single arm with dual therapy|Dual therapy RAL 400 mg bid + DRV/r 800/100 mg QD
3191510|NCT01258361||The study population|Patients will be recruited during anesthesia consultations carried out before programmed pelvic or visceral surgeries.
3191511|NCT01258348|Experimental|LY573636 +sunitinib|
3191512|NCT01258335|Active Comparator|Omega 3 Fatty acids|"II. Study arms:~a. Participants in the dry AMD study group will be randomized into two arms with a 4:1 ratio: i. Omega-3-fatty acids 4 gm oral daily (Total:840mg EPA/2520mg DHA) (1:3 ratio of EPA to DHA) ( 6 capsules fatty acids)"
3191513|NCT01258335|Placebo Comparator|Olive Oil|ii. Placebo oral daily (6 softgel capsules, each contains 1100 mg olive oil)
3191514|NCT01258322|Experimental|pioglitazone|
3191515|NCT01258309|Experimental|1|olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution
3191516|NCT01258309|Active Comparator|2|olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution
3191517|NCT01258296|Active Comparator|Active fentanyl patch|25 mcg/hr fentanyl patch
3191518|NCT01258296|Placebo Comparator|Placebo patch|Inactive patch that resembles treatment patch but contains no drug
3191519|NCT01258283||The study population|See inclusion and exclusion criteria.
3191520|NCT01258270|Active Comparator|(AQUACEL® Ag Surgical Dressing|
3191521|NCT01258270|Active Comparator|Standard island gauze and tape dressing|A standard island dressing consists of adhesive tape and gauze.
3191522|NCT01258257|Active Comparator|Lumbar drain (LD) / Tuohy drain|Intervention: Insertion of a lumbar drain All patients in the LD group receives a lumbar drain during anesthesia required for aneurysm treatment. Drainage of CSF is started after the post-procedural CT scan on day one after aneurysm securement.
3191523|NCT01258257|No Intervention|No Lumbar drain (NoLD)|Patients randomized to the control group should not receive a lumbar drain before the planned control angiography to be performed on day 7 to 10 after SAH. If the patient develops hydrocephalus, and no EVD was placed initially for CSF drainage, a lumbar drain may be installed at the discretion of the local investigator. These patients are analyzed in the intention-to-treat analysis, but are not suitable for per-protocol analysis.
3191524|NCT01258244||Audiovisual feedback on CPR|EMS technicians will receive audiovisual feedback from the ZOLL device on depth, frequency, and interruptions to cardiac compressions
3191525|NCT01258231||Cardiac surgery|Adult patients undergoing cardiac surgery
3191526|NCT01258218||Accent MRI Group|
3191527|NCT01258205|Experimental|Part B|One dose level of AMG 139 administered as a multiple doses IV in subjects with mild-severe Crohn's disease.
3191528|NCT01258205|Experimental|Part A|Three dose levels of AMG 139 administered as a multiple doses IV or SC in healthy subjects.
3191529|NCT01258192|Experimental|nab-paclitaxel plus cisplatin|
3191530|NCT01258179||Sepsis Group|Patients suffering from sepsis in the postoperative course after major abdominal surgery
3191531|NCT01258179||Control Group|Patients without suffering sepsis during postoperative follow up after major abdominal surgery
3191532|NCT01258166||Tramuatic ulnar translocation|Patients who suffered a traumatic ulnar translocation following injury.
3191533|NCT01258153|Experimental|Nepadutant Low Dose|
3191534|NCT01258153|Experimental|Nepadutant High Dose|
3191535|NCT01258153|Placebo Comparator|Placebo|
3191536|NCT01258140|Active Comparator|1|Patients examined with normal-dose Computed tomography pulmonary angiography
3191537|NCT01258140|Active Comparator|2|Patients examined with low-dose Computed tomography pulmonary angiography
3191538|NCT01258127||Pemetrexed and Carboplatin|For patients in arm pemetrexed/carboplatin, folic acid (350-1000 μg) must be given daily beginning approximately 5-7 days prior to first dose of pemetrexed and continuing daily until 3 weeks after the last dose of study therapy. Vitamin B12 (1000 μg) will be administered as an intramuscular injection approximately 1 to 2 weeks prior to first dose of pemetrexed and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy. Dexamethasone (4 mg of oral or equivalent) given twice daily should be taken on the day before, the day of, and the day after each dose of pemetrexed, for rash prophylaxis unless medically contraindicated. Patients must receive pemetrexed at day 1 at the dose of 500 mg/m2 as an IV infusion over approximately 10 minutes, then carboplatin target area under the concentration curve (AUC) 6 (i.v. infusion over 30 minutes) on day 1 of a 21-day cycle. A total of four cycles is intended.
3191590|NCT01257776|Active Comparator|Mesenchymal stem cells 0,5 million * weight (kg)|Group of low dose of Mesenchymal stem cells.
3191539|NCT01258127||Vinorelbine and Carboplatin|Patients in arm vinorelbine and carboplatin follow the regimen: The scheduled infusion time is 6-10 minutes for IV vinorelbine at the dose of 25 mg/m2 d1,8, then carboplatin target area under the concentration curve (AUC) 6 (i.v. infusion over 30 minutes) on day 1 of a 21-day cycle. A total of four cycles is intended.
3191540|NCT01258114|Active Comparator|SPA treatment (ST)|"Drug : spa treatment during 18 days soon after randomization the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises) ;~nutritional counseling (french nutritional recommendations booklet) ;~caloric restriction and physical training on demand (non mandatory)."
3191541|NCT01258114|Sham Comparator|Non SPA treatment (NST)|"Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)"
3191542|NCT01258101|Experimental|Peginterferon/Ribavirin 800 mg (24 Weeks)|Participants received peginterferon alfa-2a (PEG-IFNα-2a) 180 mcg once weekly + Ribavirin 800 mg daily for 24 weeks (W).
3191543|NCT01258101|Experimental|Peginterferon/Ribavirin 400 mg (24 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 400 mg daily for 24 W.
3191544|NCT01258101|Experimental|Peginterferon/Ribavirin 800 mg (16 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 800 mg daily for 16 W.
3191545|NCT01258101|Experimental|Peginterferon/Ribavirin 400 mg (16 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 400 mg daily for 16 W.
3191546|NCT01258088|Active Comparator|Cohort 1: AN2728 Ointment|
3191547|NCT01258088|Placebo Comparator|Cohort 1: AN2728 Vehicle|
3191548|NCT01258088|Active Comparator|Cohort 3: AN2728 Ointment|
3191549|NCT01258088|Placebo Comparator|Cohort 3: AN2728 Vehicle|
3191550|NCT01258075|Sham Comparator|Placebo proxy|
3191551|NCT01258075|Experimental|Welchol oral suspension|
3191552|NCT01258062|Experimental|of GelVac™ nasal powder H5N1 influenza vaccine.|
3191553|NCT01258062|Placebo Comparator|Placebo|
3191554|NCT01258049|Experimental|ArTiMist|
3191555|NCT01258049|Active Comparator|Quinine|
3191556|NCT01258036||Fractured Mothers|Fractured Mothers and their daughters
3191557|NCT01258036||Non fractured mothers|Mothers non fractured and their daughters
3191558|NCT01258023|Experimental|transplant recipients|Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation
3191559|NCT01258010|Experimental|Tranexamic acid|Study subjects will be randomized to receive a bolus dose of 30 mg/kg of tranexamic acid administered over 30 minutes starting after the induction of anesthesia followed by a continuous intravenous infusion of tranexamic acid of 16 mg/kg/h administered up to 6 hours after surgery.
3191560|NCT01258010|Placebo Comparator|Normal saline (NaCl 0.9%)|Study subjects will be randomized to receive a bolus dose of normal saline (NaCl 0.9%) of equivalent volume administered over 30 minutes starting after the induction of anesthesia followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
3191561|NCT01257997||Healthy subjects|18-49 year old healthy men and women. Free of significant chronic medical illness and illicit substance abuse. Body mass index from 20 to 27.
3191562|NCT01257984|Experimental|Arm 1|
3191563|NCT01257984|Experimental|Arm 2|
3191564|NCT01257971||1|Patients with hypercholesterolaemia
3191565|NCT01257958|Experimental|19 nor vitamin d|
3191566|NCT01257945|Experimental|Flexibility & Function|Subjects take part in an exercise program based on flexibility and function.
3191567|NCT01257945|Experimental|Aerobic Exercise|Subjects will take part in an aerobic exercise program
3191568|NCT01257945|Other|Home exercise|Standard of care home exercise program
3191569|NCT01257932||Diagnostic Tool|Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
3191570|NCT01257919|Experimental|Azelaic Acid Foam 15%|Dermal application of Azelaic Acid Foam 15%
3191571|NCT01257919|Active Comparator|Azelaic Acid Gel 15%|Dermal application of Azelaic Acid Gel 15%
3191572|NCT01257906|Experimental|CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL|Topical Gel Test Product
3191573|NCT01257906|Active Comparator|ZIANA®|Topical Gel Reference Product
3191574|NCT01257906|Placebo Comparator|Vehicle Control|Topical Gel Placebo
3191575|NCT01257893|Experimental|Aspirin 81 mg|Subjects will take 81 mg aspirin per day for 10-14 consecutive days
3191576|NCT01257893|Placebo Comparator|Placebo|Subjects will take matching placebo capsule (excipient: methylcellulose) for 10-14 consecutive days.
3191577|NCT01257880||Control (absence of PFO)|Persons who have migraine aura and no evidence of PFO, based on transcranial Doppler evaluation.
3191578|NCT01257880||Large PFO|Persons who have migraine aura and large PFO, as assessed by transcranial Doppler evaluation.
3191579|NCT01257867|Experimental|Lithia spring water|Lithia water (active) for 4 weeks then placebo water for 4 weeks
3191580|NCT01257867|Placebo Comparator|Natural spring water|Placebo water for 4 weeks then lithia water (active) for 4 weeks
3191581|NCT01257854||Busulfan, pharmacogenetic, pharmacokinetic, children|Children who receive Busulfan IV and have a pharmacokinetic of Busulfan
3191582|NCT01257841|Placebo Comparator|Fasting alone|
3191583|NCT01257841|Active Comparator|Fasting plus leptin|
3191584|NCT01257828|Placebo Comparator|Placebo|Placebo medication and decompressive cervical spine surgery
3191585|NCT01257828|Experimental|Riluzole|Riluzole in dose 50mg BID for 14 days prior to surgery and 28 days after the decompressive spine surgery
3191586|NCT01257815|Experimental|Ranibizumab 0.5mg|
3191587|NCT01257802|Active Comparator|LUPRON|Monthly depot leuprolide acetate 3.75 mg injection during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
3191588|NCT01257802|Placebo Comparator|Placebo|Monthly placebo injection during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses.
3191589|NCT01257789||gastric bypass patients|Consecutive series of 300 patients undergoing laparoscopic gastric bypass
3191591|NCT01257776|Active Comparator|Mesenchymal stem cells 1 million * weight (kg)|Group of mid dose of mesenchymal stem cells
3191592|NCT01257776|No Intervention|Controlled group|Controlled group with no intervention
3191593|NCT01257763|Experimental|Study device|The study device is a transdermal microneedle array designed to introduce microscopic channels into the skin. The study device arm will receive application of this device.
3191594|NCT01257763|Sham Comparator|Sham device|The sham device will be very similar in appearance to the study device. The sham device arm will receive application of this device.
3191595|NCT01257750|Experimental|Pazopanib|This is a single site, open label, safety and efficacy study of pazopanib (5mg/ml) where all 20 patients with corneal neovascularization in a single arm will receive pazopanib in one eye.
3191596|NCT01257737|Experimental|HPN-100|Participants continued HPN-100 treatment after completion of HPN-100-005SE, HPN-100-007, or HPN-100-012SE.
3191597|NCT01257724|Experimental|Full-serve evidence service|"The full-serve evidence service consists of:~an online searchable database of HIV-relevant systematic reviews;~monthly email updates highlighting new reviews;~access to user-friendly summaries produced by us or by others (when available);~links to scientific abstracts;~peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~an interface for participants to leave comments in the records of systematic reviews in the database;~links to full-text articles (when publicly available); and~access to worksheets that help CBOs find and use research evidence"
3191598|NCT01257724|Active Comparator|Self-serve evidence service|Organizations allocated to the control group will only be provided website access to a listing of systematic reviews that are organized by year of publication with links to the record on PubMed (or another publicly available source when not available on PubMed) and access to worksheets that help community-based organizations find and use research evidence.
3191599|NCT01257711|Other|Radical Distal Subtotal Gastrectomy|Following the removal of the stomach, patient will be randomised to restore the continuity of the intestine with the stomach using either of the two procedure named Roux-en-Y or Billroth II reconstruction by randomisation
3191600|NCT01257698|Active Comparator|Dorzolamide-timolol topical drops|
3191601|NCT01257698|No Intervention|Standard of care|
3191602|NCT01257685||Control Group|
3191603|NCT01257685||NAFLD Group|
3191604|NCT01257672|Experimental|ondansetron|ondansetron, syrup, 0,15 mg/Kg of body weight, 1 dose
3191605|NCT01257672|Active Comparator|domperidon|domperidone, syrup, 0,5 mg/Kg of body weight, one dose
3191606|NCT01257672|Placebo Comparator|placebo|placebo, syrup, one dose
3191607|NCT01257659|Experimental|STARR arm|In this group of patients, the STARR transanal stapling system is used to treat the rectocele.
3191608|NCT01257659|Active Comparator|Elevate arm|In this group of patients, a posterior Elevate mesh is placed transvaginally to treat the rectocele.
3191609|NCT01257646||Recent stroke group|These patients have hemiplegia following a stroke within the last 6 months
3191610|NCT01257646||Old stroke group|The patients have hemiplegia following a stroke that took place at least a year ago
3191611|NCT01257633||The study population|Laryngeal cancer patients requiring surgical tumor resection.
3191612|NCT01257620|Placebo Comparator|Placebo|Placebo
3191613|NCT01257620|Experimental|Probiotic|Life Start Two
3191614|NCT01257607|Experimental|1% MIM-D3 Ophthalmic Solution|
3191615|NCT01257607|Experimental|5% MIM-D3 Ophthalmic Solution|
3191616|NCT01257607|Placebo Comparator|Placebo Ophthalmic Solution|
3191617|NCT01257594|Experimental|No cytoreductive surgery planned|Patients who are not candidates for surgery as part of their routine care will enroll into the medical arm of the trial. They will initiate pulsatile erlotinib dosing and continue therapy until either disease progression or intolerable toxicity.
3191618|NCT01257594|Experimental|Cytoreductive surgery planned|"Patients scheduled for salvage resection as part of their routine care will be considered for this cohort. They will receive 1 pre-operative dose of 2000 mg erlotinib. Resection will occur ≤ 3 hours after the pre-operative dose. After recovery from surgery, patients will resume pulsatile erlotinib dosing."
3191619|NCT01257581|Experimental|Creatine 30gm|"Creatine will be taken as a powder mixed into food or liquid twice a day. Volunteers in this arm will take a total of 30gm of creatine per day for 38 weeks. Volunteers will also take placebo capsules twice a day for 38 weeks.~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.~Creatine is a nutritional supplement and is not approved by the U.S. Food and Drug Administration (FDA) for treating ALS."
3191620|NCT01257581|Experimental|Tamoxifen 40mg|"Tamoxifen will be taken as capsules twice a day. Volunteers in this arm will take a total of 40mg of tamoxifen per day for 38 weeks. Volunteers will also take placebo powder twice a day for 38 weeks.~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.~Tamoxifen is approved by the U.S. Food and Drug Administration (FDA) for breast cancer treatment but is not approved for treating ALS."
3191621|NCT01257581|Experimental|Tamoxifen 80mg|"Tamoxifen will be taken as capsules twice a day. Volunteers in this arm will take a total of 80mg of tamoxifen per day for 38 weeks. Volunteers will also take placebo powder twice a day for 38 weeks.~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.~Tamoxifen is approved by the U.S. Food and Drug Administration (FDA) for breast cancer treatment but is not approved for treating ALS."
3191622|NCT01257568|Other|Rejuvenate Modular Hip System|Rejuvenate Modular Hip
3191623|NCT01257555||Treatment Group|
3191624|NCT01257542|Experimental|Active|
3191625|NCT01257542|Placebo Comparator|Placebo|
3191626|NCT01257529|Experimental|Pregabalin controlled release, 330 mg, low-fat|
3191627|NCT01257529|Experimental|Pregabalin controlled release, 330 mg, medium-fat|
3191628|NCT01257529|Experimental|Pregabalin controlled release, 330 mg, high-fat|
3191629|NCT01257529|Other|Pregabalin immediate release, 300 mg|Reference Treatment
3191630|NCT01257516|Other|Pregabalin immediate release, 300 mg|Reference Treatment
3191631|NCT01257516|Experimental|Pregabalin controlled release, 330 mg|
3191632|NCT01257503|Experimental|Homeopathic cold remedy|5 ml of homeopathic cold remedy given by mouth up to 6 times per day as needed for cold symptoms
3191633|NCT01257503|Placebo Comparator|placebo|5 ml of placebo given by mouth up to 6 times per day as needed for cold symptoms
3191634|NCT01257490|Experimental|Intensive counseling|4 sessions of intensive counseling plus bupropion
3191635|NCT01257490|Active Comparator|Brief Counseling|Brief physician advice to quit plus bupropion
3191636|NCT01257464|Active Comparator|Sitagliptin|
3191637|NCT01257464|Placebo Comparator|Placebo|
3191638|NCT01257451|Experimental|Vildagliptin|
3191639|NCT01257451|Placebo Comparator|Placebo|
3191640|NCT01257438|Experimental|Fluency Plus Endovascular Stent Graft|Fluency Plus Endovascular Stent Graft
3191641|NCT01257438|Active Comparator|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty only
3191642|NCT01257425|Other|Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.|
3191643|NCT01257425|Other|Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.|
3191644|NCT01257412|Experimental|1|
3191645|NCT01257412|Experimental|2|
3191646|NCT01257412|Placebo Comparator|3|
3191647|NCT01257399|Experimental|Asacol®|Import Mesalazine
3191648|NCT01257399|Active Comparator|Mesalazine|Marketed Mesalazine
3191649|NCT01257386|Experimental|Asacol®|Import Mesalazine
3191650|NCT01257386|Active Comparator|Mesalazine|Marketed Mesalazine
3191651|NCT01257373||patiens with Firebird 2 stent|The group of 1300 patients, in which only Fireibrd2 stent is implanted, will be collected. All inclusive patients should be definitely diagnosed type 2 diabetic mellitus （DM）, either before or during the present hospitalization and with complex coronary lesion.
3191652|NCT01257347|Other|Concealment (control)|Clinicians in the control arm will not receive any electronically-monitored medication adherence information (collected via MedSignals pillbox) at the 1-month visit and will be expected to manage hypertension according to their usual care.
3191653|NCT01257347|Experimental|Disclosure (intervention)|"Disclosure of adherence report to clinician:~At clinic visits with patients with uncontrolled hypertension, clinicians in the intervention arm were provided with a quantitative summary of their patients' electronic adherence to antihypertensive medications (collected via MedSignals pillbox)."
3191654|NCT01257334|Experimental|Treatment Group|BI 10773 10 mg, 25 mg administered once daily
3191655|NCT01257334|Placebo Comparator|Control Group|Placebo administered once daily
3191656|NCT01257321||post tonsillectomy|children
3191657|NCT01257295|Placebo Comparator|control|No additions of fiber to a breakfast meal
3191658|NCT01257295|Active Comparator|low viscous, low gelling|low viscous, low gelling fibre added to breakfast meal
3191659|NCT01257295|Active Comparator|high viscous, low gelling|high viscous, low gelling fibre added to breakfast meal
3191660|NCT01257295|Active Comparator|low viscous, high gelling|low viscous, high gelling fibre added to breakfast meal
3191661|NCT01257295|Active Comparator|high viscous, high gelling|high viscous, high gelling fibre added to breakfast meal
3191662|NCT01257295|Active Comparator|fibre supplement|high viscous, high gelling fibre is added, not to the breakfast meal, but as supplement
3191663|NCT01257269||1|Patients with confirmed hereditary TTP due to congenital ADAMTS13 deficiency
3191664|NCT01257269||2|Family members of patients with confirmed hereditary TTP
3191665|NCT01257256||infertile patients|male infertile patients(ICD-9:606),female infertile patients(ICD-9:628)
3191666|NCT01257243|Experimental|DRUG 1|Syrup of oxomemazine, guaifenesin and potassium iodate
3191667|NCT01257243|Active Comparator|DRUG 2|Syrup of guaifenesin
3191668|NCT01257230|Placebo Comparator|placebo|once daily, delivered with Respimat inhaler
3191669|NCT01257230|Experimental|tiotropium low dose|once daily, delivered with Respimat inhaler
3191670|NCT01257230|Experimental|tiotropium high dose|once daily, delivered with Respimat inhaler
3191671|NCT01257217|Experimental|ReSTOR +3|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1 or AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT, lens assignment and model determined by preoperative keratometric astigmatism, bilateral implantation
3191672|NCT01257217|Active Comparator|Acri.LISA|Acri.LISA® 366D IOL or Acri.LISA® 466TD Toric IOL, lens assignment determined by preoperative keratometric astigmatism, bilateral implantation
3191673|NCT01257204|Active Comparator|Control|Placebo + Pegylated interferon alfa-2a + Ribavirin
3191674|NCT01257204|Experimental|12 Week Cohort|Daclatasvir + Pegylated interferon alfa-2a + Ribavirin
3191675|NCT01257204|Experimental|16 Week Cohort|Daclatasvir + Pegylated interferon alfa-2a + Ribavirin
3191676|NCT01257191|Experimental|Carbon Black|
3191677|NCT01257191|Experimental|Diesel Exhaust Particles|
3191678|NCT01257191|Experimental|Fine Concentrated Ambient Particles|
3191679|NCT01257191|Experimental|Ultrafine Concentrated Ambient Particles|
3191680|NCT01257191|Placebo Comparator|Placebo|
3191681|NCT01257178|Experimental|Normal hepatic function|6mg, oral, once on day 1
3191682|NCT01257178|Experimental|Mild hepatic impairment|6 mg, oral, once on day 1
3191683|NCT01257178|Experimental|Moderate hepatic impairment|6 mg, oral, once on day 1
3191684|NCT01257178|Experimental|Severe hepatic impairment|6 mg, oral, once on day 1
3191685|NCT01257165|Experimental|Zopiclone 5 mg|Zopiclone 5 mg pill + placebo pill + placebo drink
3191686|NCT01257165|Experimental|Zopiclone 10 mg|2 x zopiclone 5 mg pills + placebo drink
3191687|NCT01257165|Active Comparator|Ethanol 0.8 g/L|2 x placebo pills + ethanol 50 g/70 kg
3191688|NCT01257165|Placebo Comparator|Placebo|2 x placebo pills + placebo drink
3191689|NCT01257139|No Intervention|dual-agent therapy or docetaxel alone|dual-agent therapy based on Carboplatin (Carboplatin-Pemetrexed for non epidermoid forms, Carboplatin-Gemcitabin for epidermoid forms) or Docetaxel alone, according to PS or age
3191690|NCT01257139|Experimental|dual-agent therapy or docetaxel or best supportive care|dual-agent therapy based on Carboplatin (Carboplatin-Pemetrexed for non epidermoid forms, Carboplatin-Gemcitabin for epidermoid forms) or Docetaxel alone, or best supportive care, allocated on the basis of a simplified geriatric scale, plus a more thorough geriatric evaluation if necessary
3191691|NCT01257126|Experimental|diclofenac potassium|
3191692|NCT01257126|Active Comparator|nimesulide|
3191693|NCT01257113|Experimental|supervised exercise|The group gets 10 supervised exerciseclasses at the physiotherapy clinic in addition to homebased exercises
3191694|NCT01257113|Experimental|homebased exercises|The group gets 1 supervised exerciseclass before they do all their exercises at home
3191695|NCT01257087|Experimental|Intensive glycaemic control|Intensive glycaemic control All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
3191696|NCT01257087|Active Comparator|Conservative glycaemic control|Conservative glycaemic control All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
3191697|NCT01257074|Experimental|Drug 1|Penciclovir 10mg/g
3191698|NCT01257074|Active Comparator|Drug 2|Acyclovir 50mg/g
3191699|NCT01257061|Experimental|Group 1|Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g
3191700|NCT01257061|Active Comparator|Group 2|Dexchlorpheniramine maleate 10 mg/g
3191701|NCT01257048|Placebo Comparator|1|Single Dose evaluation placebo (V5)
3191702|NCT01257048|Active Comparator|2|Single Dose evaluation formoterol (V5)
3191703|NCT01257035||18F-FAZA-PET/CT|
3191704|NCT01257022|Experimental|Family Function Intervention|Familias Unidas Intervention Program
3191705|NCT01257022|No Intervention|Treatment as Usual|Control
3191706|NCT01257009|Other|1|Arm 1: cessation of any statin therapy for at least 6 weeks, then the first sympathetic activity measurement will be done.Subsequently, atorvastatin 20mg is added for 6 weeks. Then the second sympathetic measurement will be performed.
3191707|NCT01257009|Other|2|Patients will receive atorvastatin for 6 weeks, then the first sympathetic measurement will be done. Then atorvastatin will be stopped and 6 weeks the second measurement will be done
3191708|NCT01256996|Experimental|Low-abrasive powder|
3191709|NCT01256983|Experimental|Bright Light Therapy|Bright Light Therapy with 10000 lux beginning at day 21 until day 42
3191710|NCT01256983|Other|Wait-list intervention|Wait-list design Intervention. Bright Light Therapy with 10000 lux beginning at day 63 until day 84, when the 9 study weeks were over.
3191711|NCT01256970||Polycystic Ovary Syndrome.|Polycystic ovary syndrome was diagnosed according to the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria: PCOM, chronic anovulation and hyperandrogenism.
3191712|NCT01256970||Normal Control|Normal control women were women who did not present with any of three PCOS criteria.
3191713|NCT01256957|Active Comparator|Indoor air HEPA filtration|HEPA filters operating in the participant's bedroom and living room.
3191714|NCT01256957|No Intervention|Control|Control
3191715|NCT01256944||Control|The normal reproductive-aged women
3191716|NCT01256944||PCOS|"Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:~Oligo- or anovulation~Clinical and/or biochemical signs of hyperandrogenism~Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)"
3191717|NCT01256931||organ transplant patients|
3191718|NCT01256931||healthy controls|
3191719|NCT01256879|Experimental|formulation 1|cimetidine capsule with hydroxypropyl methylcellulose (HPMC), a type of filler
3191720|NCT01256879|Experimental|formulation 2|cimetidine capsule with magnesium stearate, a type of filler
3191721|NCT01256879|Active Comparator|formulation 3|commercial cimetidine solution
3191722|NCT01256879|Experimental|formulation 4|experimental (non-commercial) cimetidine solution
3191723|NCT01256866|Active Comparator|DEXMEDETOMIDINE, SEDATION|
3191724|NCT01256866|Active Comparator|Midazolam, sedation,|
3191725|NCT01256853|Experimental|MVA Vaccine|
3191726|NCT01256840||Calorie Restricting Group|
3191727|NCT01256840||Normal-eating controls|
3191728|NCT01256840||Obese comparison group|
3191729|NCT01256827||ranibizumab in MARINA/ANCHOR|Exudative AMD patients previously enrolled in the ranibizumab treatment arms of the MARINA or ANCHOR studies with subsequent enrollment into the HORIZON extension study.
3191730|NCT01256814|Experimental|Behaviorial Intervention|SystemCHANGE-HIV is a 10-week, small-group intervention that will promote behavior changes to improve the following: physical activity, sleep behaviors and mental wellness. S
3191731|NCT01256814|Active Comparator|Control|"The control group will receive the manual Symptom Management Manual: Strategies for People Living with HIV/AIDS."
3191732|NCT01256801||cytokine|The patients are randomized to receive the cytokine infusion in the pleural cavity
3191733|NCT01256788|Experimental|Viscosupplementation|Hyaluronic acid injection
3191734|NCT01256788|Placebo Comparator|Saline injection|
3191735|NCT01256775|Placebo Comparator|NCX4016 placebo|NCX4016 placebo b.i.d for 6 months
3191736|NCT01256775|Active Comparator|NCX4016|ncx4016,800 mg b.i.d., on top of aspirin 100 mg o.d.
3191737|NCT01256762|Experimental|Imetelstat + Paclitaxel (with or without bevacizumab)|
3191738|NCT01256762|Experimental|Paclitaxel (with or without bevacizumab) alone|
3191739|NCT01256736|Experimental|Tocilizumab 8mg/kg + DMARDs|
3191740|NCT01256723||J-LESSON Central committee|
3191741|NCT01256710||Trifecta Valve Group|
3191742|NCT01256697|Experimental|Alga Dunaliella Bardawil|
3191743|NCT01256697|Placebo Comparator|Sugar pill|
3191744|NCT01256684|Placebo Comparator|Placebo|
3191745|NCT01256684|Experimental|0.25% DHEA|
3191746|NCT01256684|Experimental|0.5% DHEA|
3191747|NCT01256671|Experimental|DHEA|0.5% DHEA (intravaginal)
3191748|NCT01256658|Experimental|Intervention|Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.
3191749|NCT01256658|Experimental|Control|Participants received COA566 treatment for symptomatic malaria episodes only.
3191750|NCT01256645|No Intervention|restrictive transfusion|No transfusion given to correct anemia unless vital indication is given
3191751|NCT01256645|Experimental|liberal transfusion|transfusions are given in single units until Hb is > 12 mg/dl
3192245|NCT01253226|Placebo Comparator|Placebo every 4 weeks|every 4 weeks for 20 weeks
3191752|NCT01256632|Active Comparator|Subfoveal CNV, secondary to AMD with PVD|20 eyes with Subfoveal Choroidal Neovascularization, secondary to Age Related Macular Degeneration, with Posterior Vitreous Detachment (PVD Positive). All study eyes will receive 0.5mg, of intravitreous monthly injections of Ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
3191753|NCT01256632|Active Comparator|Subfoveal CNV, secondary to AMD w/o PVD|20 eyes with Subfoveal Choroidal Neovascularization, secondary to Age Related Macular Degeneration, without Posterior Vitreous Detachment (PVD Negative). All study eyes will receive 0.5mg, of intravitreous monthly injections of Ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after the first 4 injections, will be on an as needed basis, based on predefined criteria.
3191754|NCT01256619|Active Comparator|marvelon|
3191755|NCT01256606||Positive for fetal aneuploidy|
3191756|NCT01256606||Negative for fetal aneuploidy|
3191757|NCT01256593||Pregabalin (Lyrica) capsule|"Patients administered Pregabalin capsule."
3191758|NCT01256580|Active Comparator|Monotherapy|Bevacizumab (Avastin; Genentech, Inc.)1.25 mg by intravitreal injection on day 0 and then prn (as-needed) based on ophthalmic examination and OCT findings
3191759|NCT01256580|Active Comparator|Combination therapy|Intravitreal injection of bevacizumab 1.25 mg (Avastin; Genentech, Inc.) combined with reduced fluence PDT(Visudyne®; Novartis,) and 200 ug of intravitreal dexamethasone(4mg/ml, American regent, Inc) on Day 0 and then monthly retreatment with bevacizumab as-needed and triple therapy every 3 months as-needed.
3191760|NCT01256567|Experimental|ramucirumab and docetaxel combination|
3191761|NCT01256554|Experimental|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation. Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
3191762|NCT01256541|Experimental|Kristalose|Kristalose as Bowel Evacuant
3191763|NCT01256528|Experimental|Delayed Breast Reconstruction|Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
3191764|NCT01256515|Experimental|Health Education Training Group 1|One form of health education training
3191765|NCT01256515|Active Comparator|Health Education Training Group 2|Another form of health education training
3191766|NCT01256502|Other|Implanted Participants|Participants with breast reconstruction surgery implanted with SERI® Surgical Scaffold.
3191767|NCT01256489|Other|Infliximab|Every patient enrolled in the study will receive monthly infusions of Infliximab throughout the term of the study. Infliximab will be administered intravenously.
3191768|NCT01256476|Experimental|pitavastatin 4 mg once daily (QD)|
3191769|NCT01256476|Active Comparator|pravastatin 40 mg once daily (QD)|
3191770|NCT01256463|No Intervention|Comparison|
3191771|NCT01256463|Experimental|HIV prevention intervention|The HIV prevention intervention will be delivered to HIV-seropositive patients in HIV care and treatment clinics during all routine visits. Health care providers (including physicians, clinical officers, and nurses) will deliver HIV prevention messages on correct and consistent condom use, disclosure of serostatus, partner HIV testing, adherence and alcohol reduction during clinic visits. Health care providers will also assess and treat sexually transmitted infections (STIs), and provide basic contraceptives and brief safer pregnancy counseling.
3191772|NCT01256450|Experimental|BEMA Buprenorphine|buprenorphine buccal soluble film
3191773|NCT01256450|Placebo Comparator|BEMA Placebo|placebo buccal soluble film
3191774|NCT01256437|Experimental|ointment Threolone|Treatment with topical application of combined anti inflammatory and anti bacterial agent.
3191775|NCT01256437|Active Comparator|ointment Synthomycine|ointment once daily for 1 month
3191776|NCT01256437|Placebo Comparator|Aqua cream|
3191777|NCT01256424|Experimental|HAL 5% with illumination|HAL PDT 5%
3191778|NCT01256424|Experimental|HAL 1% with illumination|HAL PDT 1%
3191779|NCT01256424|Experimental|HAL 0.2% with illumination|HAL PDT 0.2%
3191780|NCT01256424|Placebo Comparator|Placebo ointment without illumination|Placebo without illumination
3191781|NCT01256411|Experimental|LCZ696|
3191782|NCT01256398|Experimental|Treatment (chemotherapy, transplant)|See Detailed Description
3191783|NCT01256385|Experimental|Arm A (cetuximab and temsirolimus)|Patients receive temsirolimus IV over 30-60 minutes and cetuximab IV over 1-2 hours once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3191784|NCT01256385|Experimental|Arm B (temsirolimus)|Patients receive temsirolimus as in Arm A. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over to Arm A.
3191785|NCT01256372|Experimental|AP214; dose-level 1|AP214; dose-level 1
3191786|NCT01256372|Experimental|AP214; dose-level 2|AP214; dose-level 2
3191787|NCT01256372|Placebo Comparator|Placebo to AP214|Placebo
3191788|NCT01256359|Experimental|Docetaxel and AZD6244|Docetaxel with AZD6244
3191789|NCT01256359|Experimental|Docetaxel and Placebo|Docetaxel without AZD6244
3191790|NCT01256346||Babies|Preterm newborn infants thought to be 24-32 weeks gestational age.
3191791|NCT01256320|No Intervention|Control Group|no shell egg consumption and usual dietary practices
3191792|NCT01256320|Active Comparator|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
3191793|NCT01256320|Active Comparator|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
3191794|NCT01256307|Experimental|training group|training and educational program
3191795|NCT01256307|Other|control group|
3191882|NCT01255722|Experimental|Iobitridol|Patients were IV injected with a single dose of iobitridol before a coronary CT angiography
3191883|NCT01255722|Active Comparator|Iopromide|Patients were IV injected with a single dose of iopromide before a coronary CT angiography
3191796|NCT01256294|Experimental|Sequence 1 - Branded Tacrolimus / Generic Tacrolimus|In Period 1 (Days 1-14) participants received branded tacrolimus (Prograf) orally twice a day and in Period 2 (Days 15 - 28) participants received generic tacrolimus (Sandoz) orally twice a day. Participants received the same stable dosage of tacrolimus they had been taking prior to enrollment (on a milligram for milligram basis).
3191797|NCT01256294|Active Comparator|Sequence 2 - Generic Tacrolimus / Branded Tacrolimus|In Period 1 (Days 1 - 14) participants received generic tacrolimus (Sandoz) orally twice a day and in Period 2 (Days 15 - 28) participants received branded tacrolimus (Prograf) orally twice a day. Participants received the same stable dosage of tacrolimus they had been taking prior to enrollment (on a milligram for milligram basis).
3191798|NCT01256281|Experimental|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
3191799|NCT01256268|Experimental|Endometrial Cancer|Phase 1A + Cohort 1B - Recurrent or Metastatic Endometrial Cancer. Patients with recurrent or metastatic endometrial cancer with up to 1 prior chemotherapy. Ridaforolimus at the Phase 1A MTD and schedule will be administered with paclitaxel at the Phase 1A MTD (175 mg/m2) IV and carboplatin at the phase 1 MTD (AUC 5 to 6) in mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Treatment will continue until disease progression or adverse events prohibit further therapy.
3191800|NCT01256268|Experimental|Ovarian Cancer|Phase 1 A + Cohort 1B - Recurrent or Metastatic Ovarian Cancer. Patients with platinum-sensitive, recurrent ovarian cancer with up to 2 prior chemotherapy regimens. Ridaforolimus at the phase 1A MTD and schedule will be administered with paclitaxel at the phase 1 MTD (175 mg/m2) IV and carboplatin at the phase 1 MTD (AUC 5 to 6) in mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Treatment will continue until disease progression or adverse events prohibit further therapy.
3191801|NCT01256255||influenza infection|Patients with the diagnosis of influenza infection by standard laboratory technique
3191802|NCT01256242|Experimental|Group 1|Standard Suture Repair + Augment Rotator Cuff
3191803|NCT01256242|Active Comparator|Group 2|Standard Suture Repair
3191804|NCT01256229|Experimental|Developmentally delayed - Hearing aids|This arm contains deaf children that have developmental delays and are randomized to be treated with the conventional therapy, hearing aids.
3191805|NCT01256229|Experimental|Developmentally Delayed - Cochlear implant|This arm contains deaf children that have developmental delays and are randomized to be treated with cochlear implantation.
3191806|NCT01256229|Active Comparator|Not developmentally delayed|This control arm contains deaf children that do not have developmental delays and will be treated with cochlear implantation.
3191807|NCT01256216|Other|Signature Custom Cutting Guides|Patients receiving a Vanguard Total Knee implanted utilizing non implantable Signature Cutting Guides Surgical Technique.
3191808|NCT01256216|Other|CAS (Computer Assisted Surgery)|Patients receiving a Vanguard Total Knee implanted utilizing non implantable Computer Assisted Surgery Technique.
3191809|NCT01256203|Experimental|Sunscreen|Solar Protection Formula SPF® 60 will be applied on the skin of each subject. Applications will be followed by photobiological testings to assess skin protection.
3191810|NCT01256190|Experimental|Fibrocaps + Gelatin sponge|Topical Fibrocaps powder followed by application of gelatin sponge
3191811|NCT01256190|Active Comparator|Gelatin Sponge|approved device for surgical bleeding
3191812|NCT01256177|Experimental|1|
3191813|NCT01256177|Placebo Comparator|2|
3191814|NCT01256164|Experimental|Fibrocaps + Gelfoam|After identification of a Target Bleeding Site (TBS), topical Fibrocaps should be applied using the Fibrospray device for general surgeries; and either the Fibrospray device or direct application for spinal and vascular surgeries, followed by application of Gelfoam and manual pressure with sterile gauze.
3191815|NCT01256164|Active Comparator|Gelfoam|Treatment is Gelfoam followed by manual pressure with sterile gauze. If hemostasis is not achieved within 10 minutes of the Start Time,the subject should be considered a treatment failure and the surgeon should implement additional hemostatic measures.
3191816|NCT01256151|Active Comparator|Alprazolam conventional tablet|Alprazolam conventional tablet
3191817|NCT01256151|Experimental|Alprazolam sublingual tablet|Alprazolam sublingual tablet
3191818|NCT01256138||transplantation|
3191819|NCT01256138||control|
3191820|NCT01256125||Allogene MSCs transplantation|Allogene MSCs transplantation were performed in patients with chronic liver diseases through peripheral vein plus the same medical treatments.
3191821|NCT01256125||control|only medical treatments were performed in patients with chronic liver diseases.
3191822|NCT01256112|Experimental|NAE + Behavioral Intervention|Parents of participants receive training in behavioral support at home, in addition to a standard nutrition and physical activity education (NAE) program.
3191823|NCT01256112|Active Comparator|Nutrition/Activity Education|Parents and participants receive a standard nutrition and physical activity education (NAE) program.
3191824|NCT01256099|Experimental|Guided Internet-CBT for insomnia|
3191825|NCT01256099|Placebo Comparator|Control treatment|
3191826|NCT01256099|Experimental|Guided Internet-CBT for insomnia (9)|(9 weeks instead of 8)
3191827|NCT01256099|Active Comparator|Guided Internet-CBT for depression|
3191828|NCT01256086|Experimental|24 µg Formoterol Novolizer|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
3191829|NCT01256086|Experimental|12µg Formoterol Novolizer|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
3191830|NCT01256086|Active Comparator|24 µg Formoterol Aerolizer|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
3191831|NCT01256086|Active Comparator|12µg Formoterol Aerolizer|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
3191832|NCT01256073|Experimental|IPH2101|
3191884|NCT01255722|Active Comparator|Iomeprol|Patients were IV injected with a single dose of iomeprol before a coronary CT angiography
3191885|NCT01255709|Experimental|Arm T1 Primatene Mist HFA|epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
3192341|NCT01252511|Active Comparator|long biliopancreatic limb, 75 cm|
3191833|NCT01256060|Experimental|Intanasal Oxytocin|A modified dose finding method will be used to determine safety among four dose levels for Intranasal Oxytocin. Half the dose (0.2 IU/kg /dose) is the minimum dose and two intermediate doses will also be evaluated (0.26 and 0.33 IU/kg / dose) Dose-finding escalations will be done in groups of three patients.Three patients will be studied at the first dose level. If none of these patients experience dose limiting toxicity, the dose will be escalated. If one experiences dose limiting toxicity, up to three more will be accrued at the same level. If none of these experience dose limiting toxicity, the dose will be escalated. If one or more of these experience dose-limiting toxicity, entry at that dose level will be stopped. Up to three more patients will be treated at the next lower dose. If zero out of these experience dose limiting toxicity, an additional three patients will be treated at that dose.
3191834|NCT01256047|Active Comparator|group A|preoperative immunonutrition
3191835|NCT01256047|No Intervention|group B|ordinary diet
3191836|NCT01256034|Active Comparator|Group A|preoperative immunonutrition
3191837|NCT01256034|No Intervention|Group B|ordinary diet
3191838|NCT01256021|Experimental|Botulinum Toxin Type A(Meditoxin®)|
3191839|NCT01256008|Placebo Comparator|stage 1 Clinical Management|The group will receive clinical management treatment only each session.
3191840|NCT01256008|Experimental|stage1 CBT|The experimental group will receive CBT
3191841|NCT01256008|No Intervention|stage1 Control group|Participants with breast cancer in the control group received standard medical care, but don't receive any other interventions.
3191842|NCT01255995||Control Patients|Controls without PXF who require cataract surgery
3191843|NCT01255995||Pseudo Exfoliation patients|PXF subjects with or without glaucoma who require cataract surgery
3191844|NCT01255982||1|Diagnosed with bipolar I or II disorder, and with an acute episode of bipolar depression at inclusion
3191845|NCT01255969|No Intervention|Control|
3191846|NCT01255969|Experimental|Exercise|Patients in this arm will undergo to personalized exercise program.
3191847|NCT01255956|Experimental|Rapamycin eluting stent|Patients treated with rapamycin eluting stent (n=100)
3191848|NCT01255956|Experimental|Paclitaxel eluting balloon catheter|Patients treated with paclitaxel eluting balloon catheter (n=100)
3191849|NCT01255943||prevalent hemodialysis patients|These patients are observed in two outpatient dialysis units with a combined census of approximately 175 patients
3191850|NCT01255917||Chronic pancreatitis|
3191851|NCT01255904|Experimental|Arm 1|Oral Chloral and intranasal placebo
3191852|NCT01255904|Experimental|Arm 2|oral placebo and intranasal dexmedetomidine
3191853|NCT01255891|Other|Adjuvant|Adjuvant suppression plus radiation therapy
3191854|NCT01255878|Experimental|stabilization splint|
3191855|NCT01255878|Experimental|Gabapentine|
3191856|NCT01255865||A1|Age group 0 up to 1 month
3191857|NCT01255865||A2|Age group from 1 month to 3 months
3191858|NCT01255865||A3|Age group from 3 months to 1 year
3191859|NCT01255865||B|Age group from older than 1y and younger than 5 years
3191860|NCT01255865||C|Age group from older than 5y and younger than 12 years
3191861|NCT01255865||D|Age group from older than 12 years and younger than 21 years
3191862|NCT01255865||E|Age group older than 21 years
3191863|NCT01255852|Experimental|Atorvastatin group|Patients in atorvastatin group will received 40 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
3191864|NCT01255852|No Intervention|Control group|Patients in control group will receive 20mg atorvastatin daily treatment.
3191865|NCT01255839|Active Comparator|Double-balloon|The Double Balloon Catheter was applied (Atad 5) with 80 ml NaCl installed intrauterine above the intern orificium and 80 ml below in cervix/vagina.
3191866|NCT01255839|Active Comparator|Prostglandin E2|The prostaglandin 2 minprostin (3mg) was applied vaginally
3191867|NCT01255826|Active Comparator|Sustained lung inflation followed by CPAP|"Sustained pressure-controlled inflation using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher & Paykel, Auckland, New Zealand).~This will be followed by early CPAP."
3191868|NCT01255826|Active Comparator|Conventional self inflating bag and mask ventilation|Intermittent bag and mask ventilation using a self-inflating bag with an oxygen reservoir.
3191869|NCT01255813|Placebo Comparator|Placebo|
3191870|NCT01255813|Experimental|Sub-perception|
3191871|NCT01255813|Experimental|Full Stimulation|
3191872|NCT01255800|Experimental|IPI-926 and Cetuximab|"Patients will receive Cetuximab IV every week.~Starting on Day 15 of the first cycle, Patients will take the study drug by mouth every day."
3191873|NCT01255787|Experimental|Placebo|Vortioxetine placebo-matching tablets, orally, once daily for up to 10 weeks.
3191874|NCT01255787|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, tablets, orally, once daily for 8 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily for 2 weeks.
3191875|NCT01255787|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, tablets, orally, once daily for 8 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily for 2 weeks.
3191876|NCT01255787|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, tablets, orally, once daily for 1 week, followed by vortioxetine 20 mg, tablets, orally, once daily for 7 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily, for 2 weeks.
3191877|NCT01255774|Experimental|Ranibizumab|Open Label use of Ranibizumab for wet age related macular degeneration
3191878|NCT01255761|Other|RAPID3 to assess response to Cimzia|"RAPID3 is a subject-based assessment tool used to assess subject's response to Cimzia.~Subjects will be randomized to a patient measure tool, a tool based on patient-report outcomes (RAPID3); using a total score of 30 points"
3191879|NCT01255761|Other|CDAI to assess response to Cimzia|"CDAI is an investigator-based assessment tool used to assess subject's response to Cimzia.~Subjects will be randomized to a clinical measures tool, a tool based on Investigator measures without the need for a lab value (CDAI)"
3191880|NCT01255748||Treatment with Radiation Therapy|Includes 9 different arms to capture patient data by disease site
3191881|NCT01255735||Vocal nodules|Two groups of children who are hoarse and have vocal nodules will be examined to see whether voice therapy is effective as a treatment strategy
3192342|NCT01252511|Active Comparator|long Roux limb, 150 cm|
3191886|NCT01255709|Active Comparator|Arm C Primatene Mist|epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
3191887|NCT01255709|Experimental|Arm T2 Primatene Mist HFA|epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
3191888|NCT01255696|Experimental|ALV003|ALV003 is an orally administered mixture of two recombinant proteases (cysteine endoprotease B-isoform 2 and prolyl endopeptidase) engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues common in gluten.
3191889|NCT01255696|Placebo Comparator|Placebo|Excipients for ALV003 absent the experimental compounds
3191890|NCT01255683||Chronic rhinosinusitis|
3191891|NCT01255670|Active Comparator|penicillin and metronidazole|After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess
3191892|NCT01255670|Placebo Comparator|penicillin and placebo|After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess
3191893|NCT01255657|Experimental|ABT-806 Arm|
3191894|NCT01255644|Experimental|Antiviral drug|
3191895|NCT01255631|Sham Comparator|Sham PEMF device|
3191896|NCT01255631|Active Comparator|PEMF Device|
3191897|NCT01255618||study group, control group|
3191898|NCT01255592|Experimental|1|Treatment arm AZD5069
3191899|NCT01255592|Placebo Comparator|2|Placebo dose.
3191900|NCT01255579|Active Comparator|SF|Extrafine Fluticasone/Salmeterol
3191901|NCT01255579|Active Comparator|FB|Extrafine Formoterol and beclometasone HFA
3191902|NCT01255566||Medical therapy cohort|For patients electing continued medical therapy, medication was prescribed based on the disease process and the judgment of the treating rhinologist. Treatment was not specifically dictated or prescribed by the study protocol.
3191903|NCT01255566||Surgical cohort|For patients electing ESS, surgery was performed by the enrolling rhinologist. In addition, medical management was administered in the perioperative and postoperative periods as dictated by the disease process and the judgment of the treating rhinologist. Treatment was not specifically dictated or prescribed by the study protocol.
3191904|NCT01255527|Active Comparator|Busulfan|
3191905|NCT01255527|Active Comparator|Melphalan|
3191906|NCT01255514|Experimental|VAD|VAD : high dose dexamethasone -> response(CR, PR)-> VAD chemotherapy(vincristine + doxorubicin + dexamethasone)-> PBSC -> aSCT
3191907|NCT01255514|Experimental|PAD|PAD : high dose dexamethasone -> response(MR,NC,PD)-> PAD chemotherapy(bortezomib + doxorubicin + dexamethasone)-> PBSC -> aSCT
3191908|NCT01255501|Experimental|NI-0701|
3191909|NCT01255501|Placebo Comparator|Placebo|
3191910|NCT01255488|Experimental|EBN-Search (without full-text manuscripts)|In the intervention arm research subjects will be provided access to EBN-Search (a fictitious search engine) with nine abstracts relating to the clinical case but no full-text manuscripts.
3191911|NCT01255488|Active Comparator|EBN-Search (with full text manuscripts)|Research subjects will be exposed to 9 abstracts and corresponding full-text manuscripts related to the simulated clinical encounter.
3191912|NCT01255475|Experimental|Intervention|
3191913|NCT01255475|Placebo Comparator|Control|
3191914|NCT01255462|Experimental|LFG316 0.15mg|
3191915|NCT01255462|Experimental|LFG316 0.5mg|
3191916|NCT01255462|Experimental|LFG316 1.5mg|
3191917|NCT01255462|Experimental|LFG316 5mg|
3191918|NCT01255449|Experimental|albuterol|Twenty-six consecutive patients undergoing allogeneic HSCT for hematological malignancies were studied. All patients were in stable clinical conditions at the time of study. All patients received a myeloablative conditioning regimen either including or not including total body irradiation. Spirometry, lung volumes, FOT and lung CT scan were obtained before the start of conditioning treatment and, approximately, two months after HSCT. On each study day, all the above measurements were taken before and 30 min after inhaling four consecutive albuterol doses, of 100 mcg each, through a valved-holding chamber. DLco was measured only after bronchodilator inhalation.
3191919|NCT01255436|Experimental|SMS text reminders|Participants in this arm will receive SMS text messages on top of the usual care they receive from their physicians.
3191920|NCT01255436|Other|Usual Care|Participants in this arm will receive the usual care they receive from their physicians.
3191921|NCT01255423|Experimental|Diclofenac sodium topical gel 1%|
3191922|NCT01255423|Placebo Comparator|Placebo|
3191923|NCT01255410|Experimental|Healthy Adults (Group 1)|Healthy adults will receive a single dose of 10^6 plaque forming unit (PFU) rHMPV-Pa vaccine intranasally.
3191924|NCT01255410|Experimental|Seropositive Children-Vaccine (Group 2)|Seropositive children will receive a single dose of 10^6 PFU rHMPV-Pa vaccine intranasally.
3191925|NCT01255410|Placebo Comparator|Seropositive Children-Placebo (Group 2)|Seropositive children will receive a single dose of placebo vaccine intranasally.
3191926|NCT01255410|Experimental|Seronegative Infants and Children-Vaccine (10^5) (Group 3)|Seronegative infants and children will receive a single dose of 10^5 PFU rHMPV-Pa vaccine intranasally.
3191927|NCT01255410|Placebo Comparator|Seronegative Infants and Children-Placebo (Group 3)|Seronegative infants and children will receive a single dose of placebo vaccine intranasally.
3191928|NCT01255410|Experimental|Seronegative Infants and Children-Vaccine (10^6) (Group 4)|Seronegative infants and children will receive a single dose of 10^6 PFU rHMPV-Pa vaccine intranasally.
3191929|NCT01255410|Placebo Comparator|Seronegative Infants and Children-Placebo (Group 4)|Seronegative infants and children will receive a single dose of placebo vaccine intranasally.
3191930|NCT01255397|Experimental|Male Infertility Protocol|
3191931|NCT01255384||Non Diabetic-Controls|Pregnant women with uncomplicated pregnancy will be followed, their offsprings will be evaluated and followed for 5 years
3191932|NCT01255384||Diabetic Pregnancy|Pregnant women followed in the high risk clinic because of diabetes will be followed and their offspring's will be evaluated and followed for 5 years
3191933|NCT01255371|Active Comparator|Arm A : Lopinavir|"Emtricitabine/tenofovir :~TDF300mg.FTC200mg (Fixed Dose Combination)~1 tablet per day~Lopinavir/ritonavir :~LPV200mg/RTV50mg~2 tablets twice a day"
3191934|NCT01255371|Experimental|Arm B : Atazanavir|"Lamivudine/tenofovir :~3TC300mg/TDF300mg (Fixed Dose Combination)~1 tablet per day~Atazanavir/ritonavir :~ATV300mg/RTV100mg~2 tablets once a day"
3191935|NCT01255358|Experimental|Ery-Dex|Patients treated with monthly treatment of Ery-Dex (dexamethasone sodium phosphate encapsulated in autologous erythrocytes)
3191936|NCT01255345||Adult females with CPP living in Denmark|
3191937|NCT01255332||C13-urea breath test: positive|lansoprazole 30mg bid, amoxicillin 1000mg bid and clarithromycin 500mg bid for 7 days
3191938|NCT01255306||NO IOP|Patients without raised IOP
3191939|NCT01255306||RAISED IOP|Patients with raised IOP
3191940|NCT01255293|Active Comparator|1000 centistoke silicone oil|
3191941|NCT01255293|Active Comparator|5000 centistoke silicone oil|
3191942|NCT01255280|Active Comparator|Information, Motivation, Behavioral skills|The comparison condition will only receive the two IMB risk reduction sessions. The intervention will begin with modules that focus directly with sexual risk reduction practices. It will begin with a discussion of one's sexual history, sexual risk limits, and barriers (e.g., motivation or skills) to staying in their sexual risk limits. This session will also involve a Q&A discussion and the use of a fact sheet regarding HIV acquisition risk behaviors (information). The next session will involve motivational interviewing and the formulation of an individualized behavioral skills plan as needed.
3191943|NCT01255280|Experimental|Behavioral Activation Therapy and Risk Reduction Counseling|This intervention is given to patients in the experimental condition only and is comprised of 10 sessions—1 baseline session focused on orienting and rationale, 2 focused on risk reduction (consistent with the IMB model: information, motivation, and behavioral skills), 6 incorporating behavioral activation therapy/risk reduction counseling, and 1 final session on relapse prevention. Each session will last approximately fifty minutes in length; and will also involve a review of the previous materials,and hence the behavioral activation approach will be woven back into the risk reduction content.
3191944|NCT01255267||Acute coronary syndrome patients|
3191945|NCT01255267||Chronic coronary artery disease patients|
3191946|NCT01255267||Healthy control|
3191947|NCT01255254|Experimental|A: Scaling group|The experimental group will receive oral hygiene instruction (OHI) and full-mouth scaling using standard rigid Gracey curettes (Hu-Friedy® Manufacturing Inc., Chicago, IL, USA) and ultrasonic instrumentation (EMS piezoelectric system, Electro Medical Systems, Nyon, Switzerland) at week 1-2 and at a second reinforcement visit at 6-8 weeks. Subjects will also be instructed to rinse with 10ml of Chlorhexidine 0.2% mouthrinse twice daily for 30 seconds for the duration of the study.
3191948|NCT01255254|No Intervention|B: Control group|The control group will receive no periodontal treatment during the study. After completion of the study, these patients will be given oral hygiene instruction and a full mouth scaling.
3191949|NCT01255241||othopaedic surgical intervention|children with lower limbs deformities
3191950|NCT01255228|Experimental|Low glycemic index diet|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
3191951|NCT01255228|Experimental|diet intervention|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
3191952|NCT01255215|Experimental|Inhaled Nitric Oxide|iNO, a gaseous molecule, will be administered by inhalational route over a maximum period of 72 hours.
3191953|NCT01255215|Placebo Comparator|Room air|Room air will be delivered by air compressor through an indistinguishable mask system.
3191954|NCT01255202||twin preganacies|
3191955|NCT01255189|Experimental|Device: near infrared spectroscopy: invos 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements
3191956|NCT01255176|No Intervention|placebo group|not receive physical therapy intervention, there will only support the achievement of a handbook on the abdomen of the baby.
3191957|NCT01255176|No Intervention|control group|not receive any type of intervention, and infants remain at rest
3191958|NCT01255176|Experimental|Thoracoabdominal rebalancing|infants who receive physical therapy through the application of the handlings of the RTA.
3191959|NCT01255163|Experimental|Exendin-4|Exenatide 5 mcg or 10 mcg SC twice daily
3191960|NCT01255163|Placebo Comparator|Placebo|Placebo SC twice daily
3191961|NCT01255137|Experimental|Adrenal Cortex Neoplasms|Aggressive cancer that starts in the adrenal gland located at the top of the kidneys.
3191962|NCT01255124||Health infants (ClinicalTrials.gov ID: NCT01183611)|The subjects participated in the clinical trial 'The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates' in 2007 (ClinicalTrials.gov ID: NCT01183611).
3191963|NCT01255098||Experimental Group|
3191964|NCT01255098||Control Group|
3191965|NCT01255085|Experimental|10 g of yellow pea fiber|
3191966|NCT01255085|Experimental|20 g of yellow pea fiber|
3191967|NCT01255085|Experimental|10 g of yellow pea protein|
3191968|NCT01255085|Experimental|20 g of yellow pea protein|
3191969|NCT01255085|Experimental|Control Tomato Soup|
3191970|NCT01255072|Active Comparator|Active rTMS + placebo|Patients, free from medication for at least one week (washout of 3 weeks for fluoxetine users) will receive 20 sessions of active rTMS delivered to the left Dorsolateral PreFrontal Cortex. Each patient will take placebo pills for 60 day,starting parallel on the first rTMS day.
3191971|NCT01255072|Sham Comparator|SHAM|Patients, free from medication at least for one week (washout of 3 weeks for fluoxetine users)receiving 20 sessions of Sham TMS delivered to the left dordolateral prefrontal cortex, at the same time this washed out of antidepressives patients start taking Citalopram 20mg/day, for 60 days.
3191972|NCT01255059||Female lung cancer group|Female, non-smoker, non-small cell lung cancer
3191973|NCT01255059||Health control|Female, non-smokers, no lung cancer or other types of cancers` healthy population
3191974|NCT01255046|Active Comparator|Donepezil plus STA-1|
3191975|NCT01255046|Placebo Comparator|Donepezil plus placebo|
3191976|NCT01255033||Pulmonary surgical patients|Patients submitted for scheduled lung surgery requiring one-lung ventilation
3192020|NCT01254747|Active Comparator|Nelfilcon A|Nelfilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
3192437|NCT01251822|Active Comparator|Prucalopride|Prucalopride tablets plus placebo solution
3191977|NCT01255020|Active Comparator|α-Keto Acid plus restricted protein diet|Participants randomized to this group will receive 12 months treatment of α-Keto Acid. The dose of α-Keto Acid is 100mg/kg per day and will divided into three times per day, and the α-Keto Acid will be asked to be taken during the meal. In addition, the participants will be asked to restrict the protein intake. The protein intake is restricted as 1g/kg/d.
3191978|NCT01255020|Placebo Comparator|Placebo plus restricted protein diet|All participants will receive 12 months treatment of placebo, at the same time they will be asked to restrict the protein intake.The dose of placebo is 100mg/kg per day, and the protein intake is restricted as 1g/kg/d.
3191979|NCT01255007|Experimental|Post chemotherapy group|The first group consists of patients with colorectal liver metastases who have had treatment with chemotherapy and are now awaiting surgery. This group would have had Multidetector Liver CT (MDCT) imaging prior to the chemotherapy, and will now undergo post chemotherapy MDCT as part of standard clinical care in addition to Gd-EOB-DTPA enhanced liver MRI and Diffusion Weighted MRI (DW-MRI). The MRI will be performed as an additional imaging investigation after obtaining informed consent.
3191980|NCT01255007|Experimental|Pre and Post Chemotherapy Group|The second group consists of patients with colorectal liver metastases who are due to receive neoadjuvant chemotherapy. This group will be imaged prior to receiving and after receiving chemotherapy. This will all be done prior to surgical resection of their colorectal liver metastases.
3191981|NCT01254994|Active Comparator|Control group|The patients were prescribed the tradition comprehensive medical treatment without entecavir.
3191982|NCT01254994|Experimental|ETV group|All the patients were prescribed the tradition comprehensive medical treatment with entecavir. Entecavir was supplied by the Sino-US Shanghai Squibb Pharmaceutical Co., Ltd. Patients took 0.5 mg entecavir following oral fasting one time per day.
3191983|NCT01254981|Experimental|Nobori|Percutaneous coronary intervention with implantation of coronary stent (Nobori)
3191984|NCT01254981|Experimental|Cypher|Percutaneous coronary intervention with implantation of coronary stent (Cypher)
3191985|NCT01254968||examining group|20 healthy subjects (11 men, 9 women, average age 23.94)
3191986|NCT01254968||control group|6 healthy subjects (3 men, 3 women, average age 23.6)
3191987|NCT01254955||organ transplant patients|
3191988|NCT01254955||healthy controls|
3191989|NCT01254942|Active Comparator|Usual Care|Usual care following hip fracture
3191990|NCT01254942|Experimental|Intervention|Follow-up Fracture Clinic
3191991|NCT01254929||F-18 PET bone scan group|Patients with a diagnosis of cancer and clinical concern for bone metastases. They will undergo an F-18 PET bone scan for diagnostic imaging.
3191992|NCT01254929||Tc-99m MDP bone scan group|Patients with a diagnosis of cancer and clinical concern for bone metastases. They will undergo a Tc-99m MDP bone scan for diagnostic imaging.
3191993|NCT01254916||Patients with chronic rhinosinusitis|
3191994|NCT01254903|Experimental|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation treatment.
3191995|NCT01254890|Experimental|Azacitidine + Sorafenib|Azacitidine (AZA) 75 mg/m^2 subcutaneously (SQ) or intravenously (IV) daily for 7 days; Sorafenib 200 mg orally twice a day.
3191996|NCT01254877|Placebo Comparator|Placebo Ondansetron - sugar pill|Placebo is an oral preparation made to appear and taste like the active drug preparation.
3191997|NCT01254877|Experimental|low dose ondansetron (0.2 mg bid)|
3191998|NCT01254877|Experimental|moderate dose ondansetron (0.8 mg bid)|
3191999|NCT01254864|Experimental|Abiraterone Acetate + Prednisone (AP)|Abiraterone Acetate at 1000 mg orally each day, given in combination with 5 mg of Prednisone orally twice daily.
3192000|NCT01254864|Experimental|Group 1: AP + Sunitinib|AP (Abiraterone Acetate + Prednisone) Plus Sunitinib; Randomized from AP group to receive Sunitinib if disease worsens. Assignment to crossover group AP + Dasatinib with further disease progression.
3192001|NCT01254864|Experimental|Group 2: AP + Dasatinib|AP (Abiraterone Acetate + Prednisone) Plus Dasatinib; Randomized from AP group to receive Dasatinib if disease worsens. Assignment to crossover group AP + Sunitinib with further disease progression.
3192002|NCT01254851|Active Comparator|goal-augmented post-operative care.|Patients in this group will be given a goal number of steps to take on each post-operative day.
3192003|NCT01254851|No Intervention|Usual care|routine post-operative ambulation
3192004|NCT01254825|Experimental|Adductor-Canal-Block, Ropivacain|Adductor-Canal-Block, 30 mL Ropivacain 7,5 mg/mL. Single dose. Ultrasound-guided application. 36 patients
3192005|NCT01254825|Placebo Comparator|Adductor-Canal-Block (ACB) - Saline|Adductor-Canal-Block, Placebo (30 mL Saline). Ultrasound-guided application. 36 patients.
3192006|NCT01254812||Bilateral dual TAP-block|
3192007|NCT01254812||Placebo Bilateral dual TAP-block|
3192008|NCT01254799|Placebo Comparator|Placebo|Women in this arm will receive identical Placebo capsules twice daily for 5 days
3192009|NCT01254799|Active Comparator|Doxycycline|Women in this arm will receive 100 mg doxycycline capsules twice daily for 5 days
3192010|NCT01254786|Active Comparator|CPAP2 - HFPPV group|the non-dependent lung will be ventilated with CPAP of 2 cm H2O for 30 min followed with HFPPV for min.
3192011|NCT01254786|Active Comparator|HFPPV-CPAP2 group|the non-dependent lung will be ventilated with HFPPV for 30 min followed with CPAP of 2 cm H2O for 30 min.
3192012|NCT01254773|Experimental|Bapineuzumab SC Dose 1; 2 mg|
3192013|NCT01254773|Experimental|Bapineuzumab SC Dose 2; 7 mg|
3192014|NCT01254773|Experimental|Bapineuzumab SC Dose 3; 20 mg|
3192015|NCT01254773|Placebo Comparator|Placebo|
3192016|NCT01254760|Other|Investigational multifocal / Commercial multifocal|Investigational multifocal contact lenses worn first, with commercial multifocal contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 5 days.
3192017|NCT01254760|Other|Commercial multifocal / Investigational multifocal|Commercial multifocal contact lenses worn first, with investigational multifocal contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 5 days.
3192018|NCT01254747|Experimental|Delefilcon A|Delefilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
3192019|NCT01254747|Active Comparator|Lotrafilcon B|Lotrafilcon B contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
3192021|NCT01254747|Active Comparator|Narafilcon A|Narafilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
3192022|NCT01254734|Experimental|Arm I|Patients undergo transoral robotic microsurgery.
3192023|NCT01254721|Experimental|1|Seroquel XR tablet
3192024|NCT01254721|Active Comparator|2|Seroquel XR + lithium
3192025|NCT01254708|Active Comparator|Control|Standard of care group. Medication as prescribed by the primary physician would be used by this group. Such medications might include azoles as voriconazole
3192026|NCT01254708|Experimental|liposomal amphotericin B (AmBisome ®)|Inhaled Liposomal preparation of Amphotericin B.
3192027|NCT01254695|Active Comparator|Standard settings|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 210 μsec
3192028|NCT01254695|Experimental|Experimental Setting 1|Amplitude: Sensory threshold Frequency:6.9 Hz Pulse width 210 μsec
3192029|NCT01254695|Experimental|Experimental setting 2|Amplitude: Sensory threshold Frequency:31 Hz Pulse width 210 μsec
3192030|NCT01254695|Experimental|Experimental setting 3|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 330 μsec
3192031|NCT01254695|Experimental|Experimental setting 4|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 90 μsec
3192032|NCT01254682|Active Comparator|Hyaluronic acid sodium salt (1%, 20mg/2ml)|
3192033|NCT01254682|Other|Standard arthroscopic procedure|
3192034|NCT01254669|No Intervention|control, standard of care|Mothers assigned to the Control Group received the low-literacy, standard-practice, HPV-vaccine information sheet
3192035|NCT01254669|Experimental|BNI-brief Negotiated Interview|The BNI intervention addressed mothers' beliefs, values, and concerns about HPV prevention and takes their priorities for health and well-being into account.
3192036|NCT01254656|Experimental|LRV 500mg|
3192037|NCT01254656|Experimental|LRV 750mg +TVD|
3192038|NCT01254656|Active Comparator|EFV|
3192039|NCT01254656|Experimental|LRV 750mg+ DRV/r + OBT|
3192040|NCT01254656|Experimental|LRV 1000mg +DRV/r + OBT|
3192041|NCT01254656|Active Comparator|ETR|
3192042|NCT01254643|Experimental|All Enrolled|9-valent human papillomavirus (9vHPV) L1 VLP vaccine (V503), 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6.
3192043|NCT01254630|Experimental|V212-STM|Participants with STM receiving chemotherapy randomized to receive V212 vaccine given as a 4-dose regimen administered ~30 days apart.
3192044|NCT01254630|Experimental|V212-HM|Participants with HM randomized to receive V212 vaccine given as a 4-dose regimen administered ~30 days apart.
3192045|NCT01254630|Placebo Comparator|Placebo-STM|Participants with STM receiving chemotherapy randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered ~30 days apart.
3192046|NCT01254630|Placebo Comparator|Placebo-HM|Participants with HM randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered ~30 days apart.
3192047|NCT01254617|Experimental|Treatment (lenalidomide and cetuximab)|Patients receive lenalidomide PO QD on days 1-21 and cetuximab IV over 1-2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3192048|NCT01254604|Experimental|Tafluprost|One drop of preservative-free vehicle (contains no active drug) per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for four weeks. Morning dose with vehicle only allows blinding to match twice daily dosing of comparator arm.
3192049|NCT01254604|Active Comparator|Timolol|One drop of preservative-free timolol maleate (0.05%) per eye twice daily (morning and evening) for four weeks.
3192050|NCT01254578|Experimental|Treatment (lenalidomide)|"Patients receive oral lenalidomide once daily on days 1-28. Courses repeat every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo blood and bone marrow biopsies and aspirate collection at baseline and periodically during study for pharmacokinetic and pharmacodynamic studies. Buccal swab samples are also collected at baseline and analyzed for genetic polymorphisms."
3192051|NCT01254565|Experimental|Etelcalcetide|Participants received etelcalcetide administered by intravenous injection at the end of each hemodialysis session three times a week (TIW). The starting dose level was 5 mg; dose escalation was to proceed to 10 and 20 mg pending safety review of the prior cohort.
3192052|NCT01254565|Placebo Comparator|Placebo|Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW).
3192053|NCT01254552|Experimental|Iobitridol|
3192054|NCT01254539|Experimental|Autologous bone marrow stem cells intraspinal transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
3192055|NCT01254539|Experimental|Intrathecal infusion of autologous bone marrow stem cells|Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells.
3192056|NCT01254539|Placebo Comparator|Intrathecal infusion of placebo (saline solution).|Patients were infused 2 ml of saline solution
3192057|NCT01254526|Experimental|A|
3192058|NCT01254526|Experimental|B|
3192059|NCT01254513|Experimental|Arm A - Docetaxel every 3 weeks + Prednisone|"Docetaxel: 60 mg/m²/day at C1 then 70 mg/m²/day for subsequent cycles every 3 weeks~Prednisone 10 mg/day continuously"
3192060|NCT01254513|Experimental|Arm B - Docetaxel weekly + Prednisone|"Docetaxel weekly 35 mg/m²/day on day 1 and day 8 of each cycle (J1 = J21)~Prednisone 10 mg/day continuously"
3192061|NCT01254500||patients with brain lesions|
3192062|NCT01254500||young normal controls|
3192063|NCT01254500||old normal controls|
3192064|NCT01254474|Experimental|MAP 4 procedure|Assess MAP 4 mapping capabilities in cardiac chambers in patients suffering from regular or fibrillating tachycardia's
3192065|NCT01254461|Experimental|A|
3192066|NCT01254461|Experimental|B|
3192067|NCT01254448|Placebo Comparator|Placebo|Subjects will receive a placebo capsule orally once a day for 28 days (Group 1) or 10 days (Group 2).
3192068|NCT01254448|Experimental|TC-5619|Subjects will receive a TC-5619 orally once a day for 28 days (Group 1) or 10 days (Group 2).
3192069|NCT01254435|Active Comparator|'Free' positioning withdrawal|Withdrawal of the colonoscope with the patient positioned at the discretion of the endoscopist
3192116|NCT01254097|Placebo Comparator|Probiotic|Participants are provided in double blinded fashion, probiotic given to take with antibiotics prescribed by their provider.
3192070|NCT01254435|Experimental|'Fixed' position withdrawal|Patient positioned in the left lateral position to visualise the caecum, ascending colon and hepatic flexure; supine to visualise the transverse colon; and in the right lateral position to visualise the splenic flexure, descending colon and the sigmoid colon
3192071|NCT01254422|Experimental|Dengue Vaccine Group|Participants will receive 3 doses of CYD dengue vaccine
3192072|NCT01254422|Placebo Comparator|Control Group|Participants will receive 3 doses of saline
3192073|NCT01254409|Experimental|PRM-151|PRM-151 administered at escalating doses of 1, 5, and 10 mg/kg by 30 minute intravenous (IV) infusion days 1, 3, 5, 8 and 15.
3192074|NCT01254409|Placebo Comparator|Placebo|0.9% saline administered by 30 minute IV infusion Days 1, 3, 5, 8, and 15.
3192075|NCT01254396|Active Comparator|Sildenafil ODT tablet 50 mg, Fasted|Treatment A: Sildenafil ODT tablet 50 mg, administered without water under fasted conditions.
3192076|NCT01254396|Experimental|Sildenafil ODT tablet 50 mg, Fed|Treatment B: Sildenafil ODT tablet 50 mg, administered without water under fed conditions.
3192077|NCT01254383|Active Comparator|Treatment A|Viagra 50 mg tablet, administered with approximately 240 mL water under fasted conditions
3192078|NCT01254383|Experimental|Treatment B|Sildenafil ODT tablet 50 mg, administered without water under fasted conditions
3192079|NCT01254383|Experimental|Treatment C|Sildenafil ODT tablet 50 mg, administered with water under fasted conditions.
3192080|NCT01254370|Experimental|Catioprost|
3192081|NCT01254370|Active Comparator|Travatan Z|
3192082|NCT01254357||YA Burned Subjects|Any person between the years of 19-30 years old treated for a burn injury, having incurred within past 12 months.
3192083|NCT01254344|Experimental|Ertapenem sodium 1 g|Ertapenem sodium 1 g administered intravenously (IV) as a single dose followed by matching placebo to metronidazole administered IV as a single dose
3192084|NCT01254344|Active Comparator|Ceftriaxone sodium 2 g|Ceftriaxone sodium 2 g administered intravenously (IV) as a single dose followed by metronidazole 500 mg administered IV as a single dose
3192085|NCT01254331|Experimental|Single arm|
3192086|NCT01254318||Participants at high risk for IFI|Participants will be considered high risk if they are undergoing high dose chemotherapy for leukemia. This includes, but is not limited to participants with acute myelogenous leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. Participants are also considered to be at high risk for IFI if they have undergone allogeneic hematopoietic stem-cell transplantation.
3192087|NCT01254305|Experimental|1|40 -120 mg/day Levomilnacipran ER capsules, oral administration
3192088|NCT01254305|Active Comparator|2|Randomized to treatment with 1 of 4 Selective Serotonin Reuptake Inhibitors (SSRIs) - Paroxetine, Sertraline, Citalopram or Fluoxetine Oral administration, once daily dosing
3192089|NCT01254305|Placebo Comparator|3|Matching placebo capsules, oral administration
3192090|NCT01254292|Experimental|LCS12 (Skyla, BAY86-5028)|Participants received LCS12 (low dose levonorgestrel [LNG] intrauterine delivery system [IUS]) with an initial in vitro release rate of 12 μg LNG per day for 18 months with optional extension to 36 months
3192091|NCT01254292|Active Comparator|EE30/DRSP (Yasmin, BAY86-5131)|Participants received combined oral contraceptive (COC) tablet Yasmin containing 30 μg ethinyl estradiol (EE) and 3 mg drospirenone (DRSP) for 18 months/19 cycles
3192092|NCT01254279|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously every 3 weeks, in combination with oral prednisone or prednisolone 10 mg daily
3192093|NCT01254266|Experimental|conservative treatment|conservative weight reduction treatment in an inpatient unit.
3192094|NCT01254266|Experimental|bariatric surgery|inpatient program as a pre- and post- operational 'envelope' for bariatric surgeries.
3192095|NCT01254253|Experimental|Group a|no severe cardiac perfusion defects
3192096|NCT01254253|Experimental|Gooup b|reversible cardiac perfusion defects
3192097|NCT01254253|Experimental|Group c|irreversible cardiac perfusion defects
3192098|NCT01254240|Experimental|UVA/B phototherapy treatment|UVA/B phototherapy units, stand alone cabins, patients undress, step in the cabin and receive treatment in a duration of seconds to minutes. The noticable difference between the UVA/B and UVB treatment is only in the settings of the cabin.
3192099|NCT01254240|Active Comparator|UVB phototherapy treatment|UVB phototherapy units, stand alone cabins, patients undress, step in the cabin and receive treatment in a duration of seconds to minutes. The noticable difference between the UVA/B and UVB treatment is only in the settings of the cabin.
3192100|NCT01254227|Experimental|Deferasirox|Deferoxamine combination followed by Deferasirox monotherapy
3192101|NCT01254214|Experimental|tMBSR|telephone-adapted Mindfulness Based Stress Reduction (tMBSR) is an 8-week program of training in mindfulness meditation consisting of two in-person group meetings and 6 conference calls, led by a trained meditation teacher.
3192102|NCT01254214|Active Comparator|Support Group|The Support Group is a group intervention led by a trained facilitator and designed to match the intervention for time, attention and social support
3192103|NCT01254201||Dry Eye|Female patients over the age of 18 years with ocular complaints of dryness, grittiness, irritation, or related symptoms, without any identifiable cause.
3192104|NCT01254201||Fibromyalgia|Female patients over the age of 18 years diagnosed with Fibromyalgia.
3192105|NCT01254201||Healthy Control|Female patients over the age of 18 years with no symptoms of dry eyes and with no known diagnosis of Fibromyalgia.
3192106|NCT01254188|Experimental|Nilotinib|300 mg BID
3192107|NCT01254175|Experimental|rHPIV3cp45 Vaccine|Participants will receive one dose of the rHPIV3cp45 vaccine at baseline and a second dose at Month 6.
3192108|NCT01254175|Placebo Comparator|Placebo Vaccine|Participants will receive one dose of the placebo vaccine at baseline and a second dose at Month 6.
3192109|NCT01254162|Experimental|Placebo Gel|
3192110|NCT01254136|Experimental|Treatment A - INCB007839 300mg BID|This is a single arm, open label study in which all patients will receive a single dose of the investigational product INCB007839 in combination with a standard regimen of trastuzumab and vinorelbine.
3192111|NCT01254123|Active Comparator|Exenatide|
3192112|NCT01254123|Placebo Comparator|Placebo|
3192113|NCT01254110||1|Enterally fed with leucine
3192114|NCT01254110||2|Enterally fed with glutamine
3192115|NCT01254110||3|Enterally fed with protein powder
3192150|NCT01253876|Experimental|Soy milk|
3192117|NCT01254097|Placebo Comparator|Placebo|Participants are provided in double blinded fashion, Look alike placebo given to take with antibiotics prescribed by their provider.
3192118|NCT01254084|Placebo Comparator|Placebo tea|Dietary Supplement: Placebo tea 3 gram twice daily, orally
3192119|NCT01254084|Active Comparator|Gynostemma pentaphyllum Tea|Gynostemma Pentaphyllum tea 3 grams twice daily, orally
3192120|NCT01254071|Experimental|Fixed dose combination product|Fixed Dose Combination capsule containing dutasteride 0.5mg and tamsulosin 0.2 mg
3192121|NCT01254058||Glaucoma Group|
3192122|NCT01254058||Age-Matched Controls|
3192123|NCT01254045|Experimental|placebo, oxytocin 24IU, oxytocin 48IU|intranasal placebo (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
3192124|NCT01254045|Experimental|oxytocin 24IU, placebo, oxytocin 48IU|intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
3192125|NCT01254045|Experimental|oxytocin 48IU, oxytocin 24IU, placebo|intranasal oxytocin (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
3192126|NCT01254045|Experimental|oxytocin 24IU, oxytocin 48IU, placebo|intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
3192127|NCT01254045|Experimental|oxytocin 48IU, placebo, oxytocin 24IU|intranasal oxytocin (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles ; intranasal oxytocin (24 international units) and intranasal placebo (24 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
3192128|NCT01254045|Experimental|placebo, oxytocin 48IU, oxytocin 24IU|intranasal placebo (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
3192129|NCT01254019|Experimental|GSK2402968|6mg/kg
3192130|NCT01254019|Experimental|Placebo|dose-matched
3192131|NCT01253980|Active Comparator|Amoxicillin|Amoxicillin
3192132|NCT01253980|Placebo Comparator|Placebo suspension|Placebo
3192133|NCT01253967||Group A|Subjects who are hospitalised for acute gastroenteritis
3192134|NCT01253967||Group B|Subjects who visit an emergency room for acute gastroenteritis
3192135|NCT01253967||Group C|Subjects who have rotavirus positive laboratory results and developed acute gastroenteritis at least 48 hours after hospitalisation.
3192136|NCT01253954||ICU patients with IFI|1
3192137|NCT01253941|Experimental|Mud Bath therapy|
3192138|NCT01253941|No Intervention|no Mud Bath Therapy|
3192139|NCT01253928|Active Comparator|Pioglitazone 45mg per day|Pioglitazone 45mg qd will be added to the current treatment
3192140|NCT01253928|Placebo Comparator|placebo|placebo qd will be added to current treatment
3192141|NCT01253915|Experimental|Carbon Dioxide|
3192142|NCT01253915|Placebo Comparator|Placebo|
3192143|NCT01253902|Active Comparator|bimatoprost ophthalmic solution 0.01%|One drop of bimatoprost ophthalmic solution 0.01% (Lumigan®) administered to affected eye(s), once daily in the evening for 12 weeks.
3192144|NCT01253902|Active Comparator|travoprost ophthalmic solution 0.004%|One drop of travoprost ophthalmic solution 0.004% (Travatan Z®) administered to affected eye(s), once daily in the evening for 12 weeks.
3192145|NCT01253902|Active Comparator|latanoprost ophthalmic solution 0.005%|One drop of latanoprost ophthalmic solution 0.005% (Xalatan®) administered to affected eye(s), once daily in the evening for 12 weeks.
3192146|NCT01253889|Active Comparator|Oral Glucose with soother|Oral Glucose 25% first given two minutes before the first contact by the physician performing the np-ECHO. A soother will be held in the infant's mouth to ensure that continuous contact is maintained throughout the testing period. Repeat application of solution as per study protocol. No other non-pharmaceutical interventions for stress reduction will be applied. During each np-ECHO, infants have additional handling only if it is required to maintain physiological stability.
3192147|NCT01253889|Placebo Comparator|Oral water with soother|Oral water first given two minutes before the first contact by the physician performing the np-ECHO. A soother will be held in the infant's mouth to ensure that continuous contact is maintained throughout the testing period. Repeat application of solution as per study protocol. No other non-pharmaceutical interventions for stress reduction will be applied. During each np-ECHO, infants have additional handling only if it is required to maintain physiological stability.
3192148|NCT01253889|Active Comparator|Oral glucose with soother and tucking|For the infants randomized to receive facilitated tucking throughout the procedure, the bedside nurse will provide gentle, firm containment of the extremities. The facilitated tucking will commence immediately after the baseline BIIP score is taken, but before the glucose/water is administered.
3192149|NCT01253889|Placebo Comparator|Oral water with soother and tucking|For the infants randomized to receive facilitated tucking throughout the procedure, the bedside nurse will provide gentle, firm containment of the extremities. The facilitated tucking will commence immediately after the baseline BIIP score is taken, but before the glucose/water is administered.
3192153|NCT01253837|Experimental|L19TNFa|"Phase I: Prospective, open-label, dose escalation study.~Phase II: Prospective, single-arm, open-label study, equivalent to the stage 1 of the Simon two-stage phase II design."
3192154|NCT01253824|Experimental|NPC-01|1mg norethisterone and 0.02mg ethinyl estradiol
3192155|NCT01253824|Active Comparator|IKH-01|1mg norethisterone and 0.35mg ethinyl estradiol
3192156|NCT01253811|Experimental|rFXIII 35 IU/kg|
3192157|NCT01253798|Active Comparator|Group training on land|Group training in water and on land are carried out by the same principles, which is to improve general function, and to improve function and strength around the operated hip.
3192158|NCT01253798|Active Comparator|Group training in water|Group training in water and on land are carried out by the same principles, which is to improve general function, and to improve function and strength around the operated hip
3192159|NCT01253759||1|Combined treatment of Transpupillary Thermotherapy and ICG-based photodynamic therapy (PDT)
3192160|NCT01253733|Experimental|SMS and Internet|The SMS and Internet group will receive information, tips, strategies, and questions related to the self management of chronic disease (cystic fibrosis, inflammatory bowel disease, or type 1 diabetes) on a web-based program and via SMS messages.
3192161|NCT01253733|No Intervention|Control|The Control group will receive monthly tip sheets on various health topics for adolescents and young adults.
3192162|NCT01253720|Experimental|PACE CALL/Fit4Life|"Fit4Life intervention activities:~Website: Provides weekly nutrition, physical activity, and weight loss information.~Counseling Calls: Participants and their parents will get phone calls from their Health Coach to assess progress & problems.~Health Coach Question & Answer: Participants will be assigned a Health Coach that they can contact at any time to ask questions or express any concerns.~Text & Picture Messages: Participants will receive daily text messages to help remind them of being healthy. Messages will relate to the weekly topics and general checking in questions.~Parent Materials: Parents will receive a packet of printed materials that relate to parenting skills regarding being a healthy role model for their child and healthy eating and exercise tips."
3192163|NCT01253720|No Intervention|Control|The Control group will receive monthly mailings on basic nutrition and physical activity information.
3192164|NCT01253707|Experimental|Dose Escalation|
3192165|NCT01253694|Experimental|Patients with 3-5 consecutive Avastin injections|These patients will receive 0.5 mg of intravitreal Ranibizumab monthly for 6 months.
3192166|NCT01253694|Experimental|Patients with 6 or more consecutive injections of Bevacizumab|Patients will receive 0.5 mg of intravitreal Ranibizumab during the first 6 months.
3192167|NCT01253681|Experimental|AMG 386, paclitaxel and carboplatin|15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
3192168|NCT01253668|Experimental|Arm 1|Patients receive oral brivanib alaninate daily in the absence of disease progression or unacceptable toxicity.
3192169|NCT01253655|Experimental|PF-05212365|
3192170|NCT01253642|Experimental|Treatment (antiangiogenesis, chemosensitizer, chemotherapy)|Patients receive phenelzine sulfate PO QD on days -7 to -4, and then BID on days -3 to 21. Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for at least 12 weeks in the absence of disease progression or unacceptable toxicity.
3192171|NCT01253629|Experimental|25 mg bid AFQ056|1 capsule of 25 mg and 1 capsule of placebo per intake
3192172|NCT01253629|Experimental|50 mg bid AFQ056|2 capsules of 25 mg per intake
3192173|NCT01253629|Experimental|100 mg bid AFQ056|1 capsule of 100 mg and 1 capsule of placebo per intake
3192174|NCT01253629|Placebo Comparator|Placebo|2 capsules of placebo per intake
3192175|NCT01253616|Experimental|VNS plus tones|
3192176|NCT01253603|Experimental|1|QAW039 capsules once daily for 28 days
3192177|NCT01253603|Experimental|2|Placebo to QAW039 capsules once daily for 28 days
3192178|NCT01253603|Experimental|3|Fluticasone propionate inhaler twice daily for 28 days
3192179|NCT01253590||post op cancer patients experiencing atrial fibrillation|This small study aims to assess the feasibility and acceptance of remote cardiac monitoring of postoperative cancer patients experiencing atrial fibrillation and will collect continuous data on heart beat over a period of 4-6 weeks upon discharge.
3192180|NCT01253577|Active Comparator|Drug Coated|Sinus stent coated with steroid
3192181|NCT01253577|Placebo Comparator|Non coated|Sinus stent without drug coating
3192182|NCT01253564|Experimental|Single Arm|
3192183|NCT01253551|Experimental|001|Treatment sequence AB Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6 with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10 with a morning dose of raltegravir and a morning and afternoon dose of telaprevir on Day 11.
3192184|NCT01253551|Experimental|002|Treatment sequence BA Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6 with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10 with a morning dose of raltegravir and a morning and afternoon dose of telaprevir on Day 11.
3192185|NCT01253525|Experimental|Ramucirumab (IMC-1121B ) and Pacitaxel|Each treatment cycle is 4 weeks (28 days)
3192186|NCT01253512|Experimental|THR-18 0.25mg/kg|Treatment with combination with Tissue Plasminogen Activator (tPA) treatment
3192187|NCT01253512|Placebo Comparator|Placebo treatment|Treatment in combination with Tissue Plasminogen Activator (tPA) treatment
3192188|NCT01253512|Experimental|THR-18 0.5mg/kg|Treatment in combination with Tissue Plasminogen Activator (tPA) treatment
3192189|NCT01253499|Experimental|TRx0037|Double blind placebo controlled study of TRx0037 in healthy elderly volunteers to assess safety, tolerability, bioavailability and pharmacokinetics
3192190|NCT01253486|Experimental|Disease-related expressive writing|Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period
3192191|NCT01253486|Active Comparator|Traditional expressive writing|Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period
3192192|NCT01253486|Sham Comparator|Neutral writing|Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
3192193|NCT01253486|No Intervention|Control condition|Participants in the control condition do not receive any intervention and complete only the assessments
3192194|NCT01253473|Active Comparator|ipratropium/albuterol|1 puff 4 times daily
3192195|NCT01253473|Experimental|Budesonide|budesonide 180 ug 2 puffs 4 times daily + ipratropium/albuterol 1 puffs four times daily
3192196|NCT01253473|Experimental|budesonide/formoterol|budesonide/formoterol 160/4.5 ug 2 puffs 4 times daily + ipratropium/albuterol 1 puffs four times daily
3192197|NCT01253460|Experimental|Cyclophosphamide, Rituximab + Sapacitabine|After Sapacitabine 350 mg orally Days 1-3, Cyclophosphamide 250 mg/m2 IV 2 hours, followed by Rituximab 375 mg/m2 IV Day 3, Course 1, and 500 mg/m2 Day 1, subsequent courses.
3192198|NCT01253447|Experimental|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 200 mg orally once a week for each 28 day treatment cycle
3192199|NCT01253434|Experimental|1|
3192200|NCT01253434|Experimental|2|
3192201|NCT01253434|Experimental|3|
3192202|NCT01253434|Experimental|4|
3192203|NCT01253434|Experimental|5|
3192204|NCT01253421|Active Comparator|MDD-amisulpride|Subjects experiencing a current episode of major depression who are randomized to receive amisulpride
3192205|NCT01253421|Placebo Comparator|MDD-placebo|Subjects experiencing a current episode of major depression who are randomized to receive placebo
3192206|NCT01253421|Active Comparator|HC-amisulpride|Subjects having no history of mental disorder (healthy controls, HC) who are randomized to receive amisulpride
3192207|NCT01253421|Placebo Comparator|HC-placebo|Subjects having no history of mental disorder who are randomized to receive placebo
3192208|NCT01253408|Experimental|Dronabinol 2.5 mg bid|Dronabinol 2.5 mg will be taken orally with water twice per day for two days.
3192209|NCT01253408|Experimental|Dronabinol 5 mg bid|Dronabinol 5 mg will be taken orally with water twice per day for two days.
3192210|NCT01253408|Placebo Comparator|Placebo|Placebo will be taken orally with water twice per day for two days.
3192211|NCT01253395|Experimental|Strength training|Supervised strength training.
3192212|NCT01253395|Active Comparator|Aerobic exercise|Supervised aerobic exercise.
3192213|NCT01253382|Active Comparator|ecallantide|
3192214|NCT01253382|Placebo Comparator|placebo|phosphate buffered saline
3192215|NCT01253369|Experimental|Pazopanib|Pazopanib was given at a dose of 800 mg orally once per day for 28 day cycles (+/- 3 days). Patients received treatment as long as they were receiving clinical benefit.
3192216|NCT01253356|No Intervention|No IABP|Standard of care and no IABP
3192217|NCT01253356|Active Comparator|Intra-Aortic Balloon Pump (IABP)|Standard of care, IABP inserted < or = 3 hours before noncardiac surgery, maintained for > or = 12-24 hours after surgery
3192218|NCT01253343||inpatient high aggression|
3192219|NCT01253343||inpatient low aggression|
3192220|NCT01253330|No Intervention|Comparison 1st|Not enrolled in the CMSText website text messaging system during last 3 months of study participation.
3192221|NCT01253330|Experimental|Participant 1st|Enrollment in the CMSText website text messaging system during first 3 months of study participation.
3192222|NCT01253317|Experimental|rhIGF-1|Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the OLE.
3192223|NCT01253304|Experimental|Normal hepatic function|LY2189265: A single, subcutaneous (SC) 1.5-milligram (mg) injection on Day 1 in participants with normal hepatic function
3192224|NCT01253304|Experimental|Mild hepatic impairment|LY2189265: A single, SC 1.5-mg injection on Day 1 in participants with mild hepatic impairment (Child-Pugh A)
3192225|NCT01253304|Experimental|Moderate hepatic impairment|LY2189265: A single, SC 1.5-mg injection on Day 1 in participants with moderate hepatic impairment (Child-Pugh B)
3192226|NCT01253304|Experimental|Severe hepatic impairment|LY2189265: A single, SC-1.5 mg injection on Day 1 in participants with severe hepatic impairment (Child-Pugh C)
3192227|NCT01253291|Experimental|30mg/120 mg LY2127399|Subjects in the 30 mg every 4 weeks arm of lead in study will receive 30 mg every four weeks until the safety of the 120 mg every 4 weeks dose is confirmed in the lead in study.
3192228|NCT01253291|Experimental|120 mg LY2127399|Subjects in the 60 mg every 4 weeks, 120 mg every 4 weeks and 120 mg every 2 weeks arms of the lead in study will receive 120 mg every 4 weeks as these patients will enroll in this study after the safety of the 120 mg every 4 weeks dose in the lead in study is confirmed.
3192229|NCT01253278|Experimental|20 mg LY2393910|
3192230|NCT01253278|Experimental|60 mg LY2393910|
3192231|NCT01253278|Experimental|150 mg LY2393910|
3192232|NCT01253278|Experimental|450 mg LY2393910|
3192233|NCT01253278|Placebo Comparator|Placebo|
3192234|NCT01253265|Experimental|30 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
3192235|NCT01253265|Experimental|80 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
3192236|NCT01253265|Experimental|180 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
3192237|NCT01253265|Placebo Comparator|Placebo|Placebo is administered subcutaneously in the same manner as active drug in each dose group
3192238|NCT01253265|Experimental|120 mg LY2439821|Administered subcutaneously at 240 mg as a single loading dose followed by 120 mg every week
3192239|NCT01253252|Experimental|Specific procedure|"A [18F] Fluorodeoxyglucose PET Scan Imaging will be added to their conventional follow up (CT scan, usual blood sampling, ECG…) i.e. within one month before endovascular surgery (inclusion visit), at one month and 6 month of follow-up.~Furthermore, blood sampling for biological investigations (biological markers of the inflammation, proteolysis and coagulation potentially related to morphology and evolution of AAA) will be done."
3192240|NCT01253239||TECNIS/ReZoom|Patients who received a TECNIS multifocal IOL in one eye and a ReZoom multifocal IOL in the opposite eye.
3192241|NCT01253239||TECNIS/TECNIS|Patients who received TECNIS multifocal IOLs in both eyes
3192242|NCT01253226|Experimental|30 mg LY2127399|30 mg LY2127399 every 4 weeks for 20 weeks (6 doses of study drug)
3192243|NCT01253226|Experimental|60 mg LY2127399|60 mg LY2127399 every 4 weeks for 20 weeks (6 doses of study drug)
3192244|NCT01253226|Experimental|120 mg LY2127399|120 mg LY2127399 every 4 weeks for 20 weeks (6 doses of study drug)
3192246|NCT01253226|Experimental|120mg Q2W LY2127399|Initial loading dose of 240 mg LY2127399 followed by 120 mg every 2 weeks for 20 weeks (10 doses of study drug)
3192247|NCT01253226|Placebo Comparator|Placebo every 2 weeks|every 2 weeks for 20 weeks
3192248|NCT01253213|Experimental|BR55|
3192249|NCT01253200|Experimental|Blazer® Open-Irrigated Ablation Catheter|Patients treated with the Blazer® Open-Irrigated Ablation Catheter
3192250|NCT01253200|Active Comparator|Control Catheter|Patients treated with an open-irrigated radiofrequency ablation catheter that has received FDA market approval for the treatment of type 1 atrial flutter( Biosense Webster ThermoCool® ablation catheters (NaviStar™, EZ Steer, or SF) or St. Jude Medical ablation catheters (Therapy™ Cool Path™ or Safire BLU™),
3192251|NCT01253187|Experimental|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|single oral administration of 1 film-coated SHT00186D tablet (YAZ), containing 0.020 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)
3192252|NCT01253187|Experimental|EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)|single oral administration of 1 film-coated SHT04532B tablet, containing 0.020 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
3192253|NCT01253187|Experimental|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated SHT04532C tablet, containing 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
3192254|NCT01253174|Experimental|EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|single oral administration of 1 film-coated SHT470FA tablet (Yasmin with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
3192255|NCT01253174|Experimental|EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|single oral administration of 1 film-coated SHT04532A tablet (with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
3192256|NCT01253174|Active Comparator|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated tablet SHT04532C, containing 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
3192257|NCT01253161|Experimental|Pasireotide LAR Treatment|The investigational drug used in this study is pasireotide long acting release (LAR) 60 mg.
3192258|NCT01253148|Experimental|Arterial Injection of 90-Y Microspheres|Intrahepatic Arterial Injection of 90-Y Glass Microspheres as First-Line Treatment For Cholangiocarcinoma
3192259|NCT01253135|Placebo Comparator|Control|White Petrolatum
3192260|NCT01253135|Other|Test article|Vehicle (fibrinogen)
3192261|NCT01253122|Experimental|TRx0037|
3192262|NCT01253122|Active Comparator|TRx0014|
3192263|NCT01253109||SENSIMED Triggerfish|
3192264|NCT01253096|Experimental|L19IL2|
3192265|NCT01253070|Experimental|Treatment (daunorubicin, cytarabine, sorafenib tosylate)|"INDUCTION THERAPY: Daunorubicin hydrochloride 60 mg/m^2/day by IV push or short IV on days 1-3, cytarabine 100 mg/m^2/day by continuous IV on days 1-7, and sorafenib tosylate orally every 12 hours on days 1-7.~CONSOLIDATION THERAPY - Every 28 days for 2 cycles: Cytarabine 2 g/m^2/day by IV on days 1-5 and sorafenib tosylate 400 mg orally every 12 hours on days 1-28.~MAINTENANCE - Every 28 days for up to 12 cycles: Sorafenib tosylate 400 mg orally every 12 hours on days 1-28."
3192266|NCT01253057||Experimental Group|
3192267|NCT01253057||Control Group|
3192268|NCT01253044|Experimental|Acceptance and Commitment Therapy|12 weeks of individually delivered Acceptance and Commitment Therapy
3192269|NCT01253044|Active Comparator|Present Centered Therapy|12 weeks of individually delivered Present Centered Therapy
3192270|NCT01253031||Group 1|young normal hearing
3192271|NCT01253031||Group 2|older normal hearing
3192272|NCT01253031||Group 3|older hearing impaired
3192273|NCT01253018|Experimental|Robot Therapy|12 weeks of robotic therapy
3192274|NCT01253018|Active Comparator|Transition to Task Training|12 weeks of task specific practice combined with robotic therapy
3192275|NCT01252992||1:paradoxical reaction negative (RP-)|control group with tuberculosis but without paradoxical reaction
3192276|NCT01252992||1:paradoxical reaction negative (RP+)|group with tuberculosis and paradoxical reaction
3192277|NCT01252979|Experimental|Medium Chain Triglyceride|
3192278|NCT01252966|Experimental|Cognitive Training|Participants in this arm received computerized cognitive training in addition to nicotine patch and smoking cessation counseling.
3192279|NCT01252966|Placebo Comparator|Control Training|Participants in this arm received computerized control training in addition to nicotine patch and smoking cessation counseling
3192280|NCT01252953|Experimental|Anacetrapib|
3192281|NCT01252953|Placebo Comparator|Placebo anacetrapib|
3192282|NCT01252940|Experimental|FTC/RPV/TDF|Participants will switch from their existing treatment regimen to the emtricitabine (FTC)/rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF) single-tablet regimen (STR) at the beginning of the study.
3192283|NCT01252940|Experimental|SBR/Delayed Switch|Participants will stay on baseline regimen (SBR; their existing treatment regimen of PI+RTV plus 2 NRTIs) at the beginning of the study through Week 24, and may switch to the FTC/RPV/TDF STR (Delayed Switch) at the Week 24 visit.
3192284|NCT01252927|Experimental|ASIST intervention|The gatekeeper training intervention group received the Applied Suicide Intervention Skills Training (ASIST) 10.0 in addition to TAU. ASIST is a two-day (fourteen hour), intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The intervention was offered to students on a weekend and was conducted by three senior ASIST trainers and one junior trainer, with two trainers assigned to each training group.
3192285|NCT01252927|No Intervention|Control group: training as usual|Training as usual consisted of didactic teaching and a tutorial with case-based examples around suicide risk factors in their first year of medical school. Third- and fourth-year students may also have the opportunity to practice their skills with real patients during their clerkship rotations or in the emergency department.
3192286|NCT01252914|Experimental|One iStent Supra Stent and medication|The study assesses the efficacy and safety of one iStent Supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma
3192287|NCT01252888|Experimental|Two iStent devices and medication|Implantation of two iStents through small temporal clear corneal incision
3192340|NCT01252524|Experimental|Calcium polycarbophil|Calcium polycarbophil 625 mg PO TID before each meal with 8 oz of water for 6 months
3192288|NCT01252875|Other|LDL-C to100 mg/dL (+/-10 mg/dL)|"Target : 100 mg/dL (+/-10 mg/dL):~Patients recruited in this arm will receive statin +/-other lipid lowering therapy in order to reach a LDL-C concentration of 100 mg/dL(+/-10 mg/dL)."
3192289|NCT01252875|Other|LDL-C < 70 mg/dL|70 mg/dL: Patients recruited in this arm will receive statin +/-other lipid lowering therapy in order to reach a LDL-C concentration of less than 70 mg/dL.
3192290|NCT01252862|Experimental|Two iStents devices|Two iStents devices will be implanted
3192291|NCT01252849|Experimental|First Arm: One iStent, medication|Device: One iStent, medication
3192292|NCT01252849|Experimental|Second Arm: Two iStents, medication|Device: Two iStent devices, medication
3192293|NCT01252849|Experimental|Third Arm: Three iStents, medication|Device: Three iStent devices, medication
3192294|NCT01252836|Placebo Comparator|Control|Treatment with Tegaderm
3192295|NCT01252836|Experimental|AWBAT-D|Application of AWBAT-D on donor site.
3192296|NCT01252823|Experimental|Implantable loop recorder (ILR) in hemodialysis patients|implantation of loop recorder in hemodialysis patients
3192297|NCT01252810|Experimental|GE 145 320mg I/ml injection|
3192298|NCT01252810|Active Comparator|Iopamidol 370mg I/ml injection|
3192299|NCT01252797|Active Comparator|Stereotactic Radiosurgery (15 Gy)|Group A: If the tumor which will be surgically removed is at least 2 cm and up to 4 cm in maximum diameter, then this group will receive Dose Level II (15 Gy) of radiation: stereotactic radiosurgery (SRS) followed by surgery to remove the tumor.
3192300|NCT01252797|Experimental|Stereotactic Radiosurgery (12Gy)|Group B: If the tumor which will be surgically removed is larger than 4 cm and up to 6 cm in diameter, then this group will receive Dose Level I (12 Gy) of radiation: stereotactic radiosurgery (SRS) followed by surgery to remove the tumor.
3192301|NCT01252771|Experimental|PKM report and algorithm|Phosphate kinetic modeling was performed and displayed in graphical form laboratory results and an estimated phophorus protein ratio
3192302|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 1|
3192303|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 2|
3192304|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 3|
3192305|NCT01252758|Placebo Comparator|placebo|
3192306|NCT01252758|Active Comparator|Ventolin HFA dose 1|
3192307|NCT01252758|Active Comparator|Ventolin HFA dose 2|
3192308|NCT01252745|Experimental|10.0 mg of TBS-1, 4.0% T.I.D.|TBS-1 syringes pre-filled with 125 μL 4.0% gel to deliver 5.0 mg of Testosterone per nostril (intra-nasal) given t.i.d. at 2100, 0700, and 1300 hours. (total dose 30 mg/day)
3192309|NCT01252745|Experimental|13.5 mg of TBS-1, 4.5% B.I.D|TBS-1 syringes pre-filled with 150 μL 4.5% gel to deliver 6.75 mg of Testosterone per nostril (intra-nasal) given b.i.d. at 2100 and 0700 hours. (total dose 27.0 mg/day)
3192310|NCT01252745|Experimental|11.25 mg of TBS-1, 4.5% T.I.D|TBS-1 syringes pre-filled with 125 μL 4.5% gel to deliver 5.625 mg of Testosterone per nostril (intra-nasal) given t.i.d. at 2100, 0700, and 1300 hours. (total dose 33.75 mg/day)
3192311|NCT01252732|Experimental|Single-Dose IV Oritavancin Diphosphate|
3192312|NCT01252732|Active Comparator|IV Vancomycin|
3192313|NCT01252719|Experimental|Single-Dose IV Oritavancin Diphosphate|
3192314|NCT01252719|Active Comparator|IV Vancomycin|
3192315|NCT01252693|Experimental|Ozarelix|
3192316|NCT01252693|Active Comparator|Goserelin|
3192317|NCT01252680|Experimental|Group 1: Healive+Healive|75 subjects to receive two doses of Healive 6 months apart
3192318|NCT01252680|Experimental|Group 2: Healive+Havrix|75 subjects to receive one dose of Healive and another dose of Havrix 6 months apart
3192319|NCT01252680|Experimental|Group 3: Havrix+Havrix|75 subjects to receive two doses of Havrix 6 months apart
3192320|NCT01252680|Experimental|Group 4: Havrix+Healive|75 subjects to receive one dose of Havrix and another dose of Healive 6 months apart
3192321|NCT01252667|Experimental|Treatment (chemotherapy and low-dose TBI before PBSCT)|"CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0."
3192322|NCT01252654||1 IntraLase flaps|Patients who have undergone flap creation with IntraLase laser
3192323|NCT01252654||2 Visumax flaps|Patients who have undergone flaps created with Visumax laser
3192324|NCT01252641|Experimental|SB-728-T|Subjects will receive one intravenous infusion of SB-728-T
3192325|NCT01252628|Experimental|PX-866 (SCCHN)|Phase 2 (Squamous Cell Carcinoma of the Head and Neck)
3192326|NCT01252628|Active Comparator|Cetuximab (SCCHN)|Phase 2 (Squamous Cell Carcinoma of the Head and Neck)
3192327|NCT01252628|Experimental|PX-866 (CRC)|Phase 2 (Colorectal Carcinoma)
3192328|NCT01252628|Active Comparator|Cetuximab (CRC)|Phase 2 (Colorectal Carcinoma)
3192329|NCT01252615|Experimental|patient only|Patient with the ICD is involved in the intervention
3192330|NCT01252615|Experimental|patient and partner|patient with the ICD and intimate partner are involved in the intervention
3192331|NCT01252602||Prenatally depressed|Women who tested positive for prenatal depression with a score of > 12 on the Edinburgh Postnatal Depression Scale
3192332|NCT01252602||Not Prenatally Depressed|Women who tested not depressed on the prenatal depression scale with a score < 13
3192333|NCT01252589||Adults with CML|Adult patients (18 years of age or older) with confirmed diagnosis of CML
3192334|NCT01252576||women with and without sexual dysfunction|women with and without female sexual dysfunction
3192335|NCT01252563||Amlodipine 10mg Tablet|Subjects taking Amlodipine 10mg Tablet.
3192336|NCT01252550|Active Comparator|Activia®|Activia® (125g/pot)
3192337|NCT01252550|Placebo Comparator|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
3192338|NCT01252537||Initiation of antituberculosis therapy|Patients initiating treatment for tuberculosis with and without HIV co-infection in primary health care centres in Ethiopia
3192339|NCT01252524|Placebo Comparator|Placebo|A placebo tablet PO TID before each meal with 8 oz of water for 6 months.
3192343|NCT01252498||Radiotherapy|Patients receiving radiotherapy or chemoradiotherapy for head and neck cancer
3192344|NCT01252472||Flomax|Male patients scheduled for cataract surgery with current or past use of Flomax
3192345|NCT01252472||Control|Male adult patients scheduled for cataract surgery with no history of Flomax use
3192346|NCT01252459|Experimental|Arm A: AA-PET based target volume delineation|Experimental intervention (Arm A): High-precision re-irradiation. Target volume delineation based on AA-PET.
3192347|NCT01252459|Active Comparator|Arm B: T1Gd-MRI based target volume delineation|Control intervention (Arm B): High-precision re-irradiation. Target volume delineation based on T1Gd-MRI.
3192348|NCT01252446||ADHD|The sample of 187 children and adolescent in the age of 6 to 17 years referred to the Child and Adolescent Clinic, Haugesund, Norway during the period of one year and diagnosed in ICD 10 system as ADHD.
3192349|NCT01252433|Experimental|Entree energy density 100%|100% energy density
3192350|NCT01252433|Experimental|Entree energy density 85%|85% energy density
3192351|NCT01252433|Experimental|Entree energy density 75%|75% energy density
3192352|NCT01252407|Experimental|tens|
3192353|NCT01252394||Hemodialysis patients|
3192354|NCT01252381|Active Comparator|Vitamin D|
3192355|NCT01252381|Placebo Comparator|Calcium tablet|
3192356|NCT01252368||RAS active drugs|ACE inhibitors and sartanes
3192357|NCT01252368||healthy participants|
3192358|NCT01252355|Experimental|Teriflunomide 7 mg + IFN-beta|Teriflunomide 7 milligram (mg) once a day concomitantly with IFN-beta therapy.
3192359|NCT01252355|Experimental|Teriflunomide 14 mg + IFN-beta|Teriflunomide 14 mg once a day concomitantly with IFN-beta therapy.
3192360|NCT01252355|Placebo Comparator|Placebo + IFN-beta|Placebo (for teriflunomide) once a day concomitantly with IFN-beta therapy.
3192361|NCT01252342|Experimental|Intramyometrial oxytocin|
3192362|NCT01252342|Placebo Comparator|Intramyometrial Saline|
3192363|NCT01252329|Active Comparator|Elective lymph node treatment arm|Patients entering this arm will undergo selective nodal dissection of the draining lymph nodes with subsequent radiation and/or chemotherapy if indicated.
3192364|NCT01252329|No Intervention|Clinical observation arm|Patients who enter into this arm will undergo regular, periodic clinical nodal observation with subsequent evaluation and treatment if indicated upon discovery of a palpable lymph node.
3192365|NCT01252316|Active Comparator|Standard CPR|"Individuals will learn the Standard form of CPR (30:2, compressions:breathes) Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect 3) CPR Skills"
3192366|NCT01252316|Active Comparator|Recruitment with Volunteers|UPHS volunteer subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
3192367|NCT01252316|Active Comparator|Recruitment with Nurses|UPHS Nurse subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
3192368|NCT01252316|Active Comparator|Chest Compressions Only CPR|"Individuals will learn the chest compression only form of CPR (no rescue breathes) Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect 3) CPR Skills"
3192369|NCT01252303|Experimental|Nutrisystem|Group will receive Nutrisystem meals in addition to the behavioral weight loss program.
3192370|NCT01252303|Active Comparator|Control|Group will receive a behavioral weight loss program only.
3192371|NCT01252290|Experimental|Lovaza™|Lovaza™ (two 1 gram capsules twice daily) for six months
3192372|NCT01252277|Experimental|Lovaza™|Lovaza™ (two 1 gram capsules twice daily) for six months
3192373|NCT01252264||Individuals with craniofacial anomalies|Individuals who have a craniofacial anomaly (head, face, or eye disorder)
3192374|NCT01252264||Control Subjects|Family members of individuals with a craniofacial anomaly
3192375|NCT01252251|Experimental|RAD001 and pasireotide LAR|This study will be an open-label, single-arm, phase II study of RAD001 and pasireotide LAR.
3192376|NCT01252238|Placebo Comparator|Valsartan and Aliskiren|Valsartan 150 mg and Aliskiren (150 mg followed by force titration to 300 mg)
3192377|NCT01252238|Experimental|Aliskiren|
3192378|NCT01252238|Placebo Comparator|Placebo Group|Only taking Amlodipine
3192379|NCT01252225|Active Comparator|Nebulised Lidocaine followed by Placebo throat spray|
3192380|NCT01252225|Active Comparator|Nebulised Placebo followoed by Lidocaine Throat Spray|
3192381|NCT01252225|Placebo Comparator|Nebulised placebo followed by placebo throat spray|
3192382|NCT01252212|Experimental|Receiving SMS alerts|The patients randomized to this arm will have a SMS message sent to them regarding medication adherence for antiretroviral medications, anti-hypertensive medications, anti-depressants, hyperglycemic controlling medications and hypercholesterolemia controlling medications as well as life style supportive suggestions.
3192383|NCT01252212|Active Comparator|No SMS messages|The patients randomized to this arm will have a SMS message sent to them regarding healthy life style supportive suggestions.
3192384|NCT01252199|Experimental|cαStx1/cαStx2|
3192385|NCT01252199|Placebo Comparator|Control|
3192386|NCT01252186|Experimental|91-day Levonorgestrel Oral Contraceptive|Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10 µg EE monotherapy in each 91-day cycle for a total of two 91-day cycles.
3192387|NCT01252186|Active Comparator|28-day Levonorgestrel Oral Contraceptive|Participants received 21 days of active combination tablets containing 150 µg LNG/30 µg EE, followed by no treatment for 7 days in each 28-day cycle for a total of six 28-day cycles.
3192388|NCT01252186|Active Comparator|28-day Desogestrel Oral Contraceptive|Participants received 21 days of active combination tablets (containing 150 µg desogestrel (DSG)/30 µg EE, followed by no treatment for 7 days in each 28-day cycle for a total of six 28-day cycles.
3192389|NCT01252160|Experimental|QUTENZA|Cutaneous patch
3192390|NCT01252134|Other|Synergi, then Biotrue, then OTE|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
3192391|NCT01252134|Other|Synergi, then OTE, then Biotrue|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
3192392|NCT01252134|Other|Biotrue, then OTE, then Synergi|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
3192393|NCT01252134|Other|Biotrue, then Synergi, then OTE|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
3192394|NCT01252134|Other|OTE, then Biotrue, then Synergi|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
3192395|NCT01252134|Other|OTE, then Synergi, then Biotrue|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
3192396|NCT01252121|Other|Systane, Hialid, Unisol|1 drop Systane in study eye at Visit 2, 1 drop Hialid in study eye at Visit 3, 1 drop Unisol in study eye at Visit 4, with a minimum of 24 hours between each visit.
3192397|NCT01252121|Other|Systane, Unisol, Hialid|1 drop Systane in study eye at Visit 2, 1 drop Unisol in study eye at Visit 3, 1 drop Hialid in study eye at Visit 4, with a minimum of 24 hours between each visit.
3192398|NCT01252121|Other|Hialid, Systane, Unisol|1 drop Hialid in study eye at Visit 2, 1 drop Systane in study eye at Visit 3, 1 drop Unisol in study eye at Visit 4, with a minimum of 24 hours between each visit.
3192399|NCT01252121|Other|Hialid, Unisol, Systane|1 drop Hialid in study eye at Visit 2, 1 drop Unisol in study eye at Visit 3, 1 drop Systane in study eye at Visit 4, with a minimum of 24 hours between each visit.
3192400|NCT01252121|Other|Unisol, Systane, Hialid|1 drop Unisol in study eye at Visit 2, 1 drop Systane in study eye at Visit 3, 1 drop Hialid in study eye at Visit 4, with a minimum of 24 hours between each visit.
3192401|NCT01252121|Other|Unisol, Hialid, Systane|1 drop Unisol in study eye at Visit 2, 1 drop Hialid in study eye at Visit 3, 1 drop Systane in study eye at Visit 4, with a minimum of 24 hours between each visit.
3192402|NCT01252108|Experimental|Treatment|All subjects receive SQ109
3192403|NCT01252095|Experimental|PG545|
3192404|NCT01252082|Active Comparator|Scalig and Rootplaning|patients will receive scaling and root planing therapy
3192405|NCT01252082|No Intervention|control|patients in control group will not receive periodontal treatment in the time period of the study
3192406|NCT01252069|Experimental|A|PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ended by a drug free period until return of menses.
3192407|NCT01252069|Experimental|B|PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of progestin (oral tablets) during 3 periods each ended by a drug free period until return of menses.
3192408|NCT01252056|No Intervention|Control|
3192409|NCT01252056|Active Comparator|Probucol|Probucol treatment
3192410|NCT01252056|Active Comparator|Combination|Probucol and Cilostazol
3192411|NCT01252043||cohort|cholestatic children without esophageal variceal bleeding
3192412|NCT01252043||study|cholestatic children with esophageal variceal bleeding
3192413|NCT01252043||cholestatic children without EV|cholestatic children without esophageal variceal bleeding
3192414|NCT01252030|Experimental|intervention|stimulation of physical activity by messages sent through e mail or SMS; in combination with monitoring of physical activity with physical activity monitors
3192415|NCT01252030|Placebo Comparator|control|no stimulation of physical activity
3192416|NCT01252017|Experimental|Nilotinib|
3192417|NCT01252004||TT Syndrome|Will be included over a period of one year, prospectively, all patients newly diagnosed
3192418|NCT01251991|Experimental|Combinatorial treatment|
3192419|NCT01251991|Active Comparator|Single treatment: Psyllium husks|
3192420|NCT01251991|Active Comparator|Single treatment: Isolated soy protein|
3192421|NCT01251991|Placebo Comparator|Control|
3192422|NCT01251978|Active Comparator|High dose Ranibizumab|6 patients will receive 3 injections of Ranibizumab (2 mg) a month apart.
3192423|NCT01251978|Active Comparator|Standard Dose Ranibizumab|6 patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.
3192424|NCT01251965|Experimental|Ruxolitinib|"Phase I - Starting dose of Ruxolitinib 50 mg by mouth twice a day for 28 day cycle.~Phase II - MTD reached in Phase I."
3192425|NCT01251952|Experimental|Denileukin Diftitox (Ontak)|Denileukin Diftitox (Ontak) administered Post Autologous Transplantation.
3192426|NCT01251939||Treatment with ibuprofen|Gestational age <32 weeks and <1500 g, postnatal age older than 48 hours and echocardiographic evidence of hemodynamically significant PDA
3192427|NCT01251939||Controls|Gestational age <32 weeks and <1500 g, postnatal age older than 48 hours and without significant PDA
3192428|NCT01251874|Experimental|Treatment (veliparib, F 18 fluorothymidine, carboplatin)|Patients receive carboplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-7 or 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo fluorothymidine PET scan and peripheral blood cell and tumor tissue collection periodically for correlative studies.
3192429|NCT01251861|Active Comparator|Arm A (observation and bicalutamide)|Patients undergo observation on weeks 1-12. Patients then receive bicalutamide PO QD on weeks 13-44. Patients with a PSA decline of >= 50% may continue on bicalutamide until week 72 in the absence of disease progression or unacceptable toxicity.
3192430|NCT01251861|Experimental|Arm B (Akt inhibitor MK2206 and bicalutamide)|Patients receive Akt inhibitor MK2206 PO once per week on weeks 1-44 and bicalutamide PO QD on weeks 13-44. Patients with a PSA decline of >= 50% may continue on Akt inhibitor MK2206 and bicalutamide until week 72 in the absence of disease progression or unacceptable toxicity.
3192431|NCT01251848|Active Comparator|Treatment A|
3192432|NCT01251848|Active Comparator|Treatment B|
3192433|NCT01251848|Experimental|Treatment C|
3192434|NCT01251835|Active Comparator|Sitaxsentan|
3192435|NCT01251835|Experimental|Sitaxsentan plus Rifampin|
3192436|NCT01251822|Experimental|PEG 3350|PEG 3350 plus electrolytes in solution plus placebo tablets
3192438|NCT01251809|Experimental|PEG-rASNase 500|500 U/m2 BSA at day 0
3192439|NCT01251809|Experimental|PEG-rASNase 1000|1000 U/m2 BSA at day 0
3192440|NCT01251809|Experimental|PEG-rASNase 1500|1500 U/m2 at day 0
3192441|NCT01251809|Active Comparator|Oncaspar|2000 U/m2 at day 0
3192442|NCT01251796|Experimental|ARQ 197 and Erlotinib|ARQ 197 and erlotinib hydrochloride
3192443|NCT01251783|Active Comparator|Infant Formula|Infant Formula without lactobaillus or Metlin or Metlos
3192444|NCT01251783|Active Comparator|Fully breast milk|Group non randomized with fully breast milk
3192445|NCT01251783|Experimental|Metlin+Metlos+Lactobacillus GG|Infant Formula added with Metlin+Metlos (6g/L) and Lactobacillus GG 0.3x107UFC
3192446|NCT01251783|Active Comparator|Metlin+Lactobacillus GG|Infant Formula added with Metlin (6g/L) + Lactobacillus GG 0.3x107 UFC
3192447|NCT01251783|Active Comparator|Metlos+Lactobacillus GG|Infant Formula added with Metlos (6g/L)+Lactobacillus GG 0.3x107UFC
3192448|NCT01251783|Active Comparator|Lactobacillus GG|Infant Formula added with Lactobacillus GG 0.3x107UFC without Metlin or Metlos
3192449|NCT01251770|Experimental|half saline|Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.
3192450|NCT01251770|Active Comparator|third saline|Subjects in this arm will receive 0.3% NaCl/dextrose 5% intravenous (IV) maintenance fluids.
3192451|NCT01251757|No Intervention|Usual Care (UC)|Participants in this arm received their usual care with no restrictions.
3192452|NCT01251757|Active Comparator|Interactive Voice Recognition (IVR)|automated phone calls
3192453|NCT01251757|Active Comparator|Enhanced IVR (IVR+)|automated phone calls & Educational mailings and follow-up for nonadherence
3192454|NCT01251744|Experimental|CMV Mothers' Group|Pregnant subjects with confirmed primary CMV infection.
3192455|NCT01251744|Experimental|CMV Infant Group|Offspring of the CMV Mothers' Group, also tested for CMV infection.
3192456|NCT01251731|Experimental|Treatment Group 1|
3192457|NCT01251731|Experimental|Treatment Group 2|
3192458|NCT01251731|Experimental|Treatment Group 3|
3192459|NCT01251731|Experimental|Treatment Group 4|
3192460|NCT01251718||Donepezil Hydrochloride|
3192461|NCT01251692|Experimental|1|A retrospective chart review of 26 eyes of 23 patients with recurrent corneal erosions treated by PTK from 1996 to 2000 was performed. All eyes had failed to respond to conventional therapy. Data regarding the preoperative and postoperative best-corrected visual acuity (BCVA), spherical equivalent (SE), symptomatic relief, incidence of recurrence, and complications arising from the laser treatment were analyzed. The mean duration of symptoms prior to PTK was 18 months (range, 8 to 36 months). The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser. Mean postoperative follow-up was 12 years (range, 10 to 14 years).
3192462|NCT01251679|No Intervention|Control|Control: nutrition, physical activity and smoking cessation education
3192463|NCT01251679|Experimental|Hand washing|Intervention 1: hand washing education and material
3192464|NCT01251679|Experimental|Hand washing and surgical mask|Intervention 2: hand washing education and material AND paper surgical face masks
3192465|NCT01251666|Other|Magstream + Oc Sensor + Hemoccult II|"Each patient will perform all three tests:~Magstream: 2 samples (each on a different stool)~OC Sensor: 2 samples (each on a different stool)~Hemoccult II: 6 samples (2 samples per stool, on 3 different stools)~Each test will be considered as positive if at least one sample is positive (cutoff for Magstream 55 ng/ml and for OC Sensor 150 ng/ml).~Screening will be considered as positive if at least one of the three tests is positive, leading to a colonoscopy"
3192466|NCT01251653||Afatinib and docetaxel|
3192467|NCT01251653||Afatinib and gemcitabine|
3192468|NCT01251640|Experimental|Arm 1|
3192469|NCT01251627|Experimental|Decitabine|Eligible patients will recieve Dacogen 20mg/m2 in 1 hour iv infusion for 5 days every 28 days (1 cycle)plus Best Supportive Care.A total of 6 courses is planned.
3192470|NCT01251614|Experimental|Adalimumab 0.4 mg/kg|In Period A participants received a single subcutaneous loading dose of adalimumab 0.4 mg/kg (up to a maximum of 20 mg) at Week 0 followed by every other week dosing beginning at Week 1. To maintain the blind, participants also received weekly dosing of methotrexate placebo tablets. Participants who were non-responders in Period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.4 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.4 mg/kg eow.
3192471|NCT01251614|Experimental|Adalimumab 0.8 mg/kg|In Period A participants received a single subcutaneous loading dose of adalimumab 0.8 mg/kg (up to a maximum of 40 mg) at Week 0 followed by every other week dosing beginning at Week 1. To maintain the blind, participants also received weekly dosing of methotrexate placebo tablets. Participants who were non-responders in Period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.8 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.8 mg/kg eow.
3192511|NCT01251315|Active Comparator|FT061452, 6000mg high dose|Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
3192512|NCT01251302||Prospective Cohort|Patient presenting with chest pain or anginal equivalent and receiving a resulted age, sex and gene expression score (ASGES) to assist in diagnosis.
3192513|NCT01251302||Retrospective Cohort|Patients presenting with chest pain or anginal equivalent who did not receive an age, sex and gene expression score (ASGES) to assist in diagnosis. Note: this cohort was historical.
3192560|NCT01250886|Active Comparator|Lactated Ringer's solution|Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
3192472|NCT01251614|Active Comparator|Methotrexate|Participants received 0.1 mg/kg methotrexate at Baseline (Week 0), and up to 0.4 mg/kg weekly (maximum dose of 25 mg/week) in Period A. Participants also received adalimumab placebo as a single subcutaneous loading dose at Week 0, followed by every other week (eow) dosing from Week 1. Participants who were non-responders in period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.8 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.8 mg/kg eow.
3192473|NCT01251601||Raltegravir in Pregnancy|HIV positive pregnant women currently on raltegravir as part of combination antiretroviral therapy
3192474|NCT01251588||MACI|autologous cultured chondrocytes on porcine collagen membrane implant received in previous MACI00206 study
3192475|NCT01251588||Microfracture|Microfracture treatment received in previous MACI00206 study
3192476|NCT01251575|Experimental|Treatment (fludarabine, transplant, immunosuppression)|"CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2. Patients also undergo total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation.~IMMUNOSUPPRESSION: Patients receive sirolimus PO QD on days -3 to 180 with taper to day 365; cyclosporine PO BID on days -3 to 150 with taper to day 180; and mycophenolate mofetil PO TID on days 0-30 and then BID to day 100 with taper to day 150."
3192477|NCT01251562|Experimental|intravenous injection|
3192478|NCT01251549|Experimental|Experimental: A|A group of paraplegics.
3192479|NCT01251536|Other|Arm B - standard dose of cetuximab|Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab 250 mg/m2 weekly. No comparison between arms was planned.
3192480|NCT01251536|Experimental|Arm A - dose escalation of cetuximab|Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly.
3192481|NCT01251523|Active Comparator|PACE Plus|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
3192482|NCT01251523|Active Comparator|PACE|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
3192483|NCT01251523|No Intervention|Control|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
3192484|NCT01251510||Healthy adults|
3192485|NCT01251510||Type 2 diabetes|
3192486|NCT01251471|Experimental|Escitalopram|Escitalopram, p.o., 10 mg/d; optional 20 mg/d after 2 weeks for 8 weeks
3192487|NCT01251458|Experimental|Torisel|
3192488|NCT01251432||chronic otitis media|adults who have had tympanostomy tube(s) inserted for chronic otitis media
3192489|NCT01251432||Eustachian tube dysfunction|adults who have had tympanostomy tube(s) inserted for the clinical diagnosis of Eustachian tube dysfunction
3192490|NCT01251419|Experimental|Testimonial and Union Arm|The testimonial and union arm will receive the same letter as the testimonial treatment arm but with the addition of the union affiliation of the employee giving the testimonial.
3192491|NCT01251419|Experimental|Control|The control arm will receive a letter signed by our partner company's Chief Medical Officer, explaining the health and monetary benefits of switching from brand name prescription medication to generic prescription medication.
3192492|NCT01251419|Experimental|Testimonial Treatment Arm|The testimonial treatment arm will receive the exact same letter as the control arm, but the letter will feature an employee's testimonial along with the first name, last initial, city and state of the employee giving the testimonial.
3192493|NCT01251406|Placebo Comparator|Placebo|Subcutaneous administration for daily for 8 hours a day for 10 days
3192494|NCT01251406|Experimental|rhNRG-1 Dose 1|Subcutaneous administration for daily for 8 hours a day for 10 days
3192495|NCT01251406|Experimental|rhNRG-1 Dose 2|Subcutaneous administration for 8 hours a day for 10 days
3192496|NCT01251393|Experimental|Biperiden|Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
3192497|NCT01251393|Placebo Comparator|Placebo|Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
3192498|NCT01251380|Experimental|Dysport|Dysport was injected into either one or both lower limbs in up to 4 cycles of treatment, a minimum of 12 weeks apart and up to a maximum of 40 weeks apart. Doses varied from 5 Units (U)/Kg to 20 U/kg for one leg, or from 10 U/Kg to 30 U/kg for two legs, with a maximum dose of no more than 30 U/Kg overall, or 1000 U, whichever was reached first.
3192499|NCT01251367|Experimental|Dysport®|Dysport® is injected into lower limbs across 4 cycles of treatment, a minimum of 12 weeks between 2 injections. Doses vary from 1000 U to 1500 U.
3192500|NCT01251354|Experimental|BN83495|
3192501|NCT01251341|Experimental|Compassion Meditation Group|
3192502|NCT01251341|Active Comparator|Health Education and Wellness Group|
3192503|NCT01251341|Experimental|Mindful Attention Training|
3192504|NCT01251328|Active Comparator|General anaesthesia|General anaesthesia is performed under standardized conditions
3192505|NCT01251328|Active Comparator|Sedation|Sedation is performed under standardized conditions
3192506|NCT01251315|Placebo Comparator|Placebo low dose|Placebo for low dose group given as a single dose.
3192507|NCT01251315|Active Comparator|N Acetyl cysteine, 600mg (low dose)|N-Acetyl Cysteine (NAC)600 mg (low dose) given as a single dose.
3192508|NCT01251315|Active Comparator|Proimmune 200(FT061452)|Proimmune 200(FT061452) low dose group 3000 mg given as a single dose.
3192509|NCT01251315|Placebo Comparator|Placebo high dose|Placebo given to high dose group given as a single dose.
3192510|NCT01251315|Active Comparator|N Acetyly cysteine, 1200mg (high dose)|N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
3192514|NCT01251276|Experimental|Modified Process Hepatitis B Vaccine in Base Study|Participants who received 3 doses of Modified Process Hepatitis B Vaccine in the Base Study were eligible to receive a single challenge dose of Modified Process Hepatitis B Vaccine on Day 1 of the Challenge Dose Study
3192515|NCT01251276|Experimental|ENGERIX-B™ Vaccine in Base Study|Participants who received 3 doses of ENGERIX-B™ vaccine in the Base Study were eligible to receive a single challenge dose of Modified Process Hepatitis B Vaccine on Day 1 of the Challenge Dose Study
3192516|NCT01251263|Other|Group 1|Cyclic OC users prior to initiating study OC. Estradiol or placebo given in a certain sequence depending on the randomization.
3192517|NCT01251263|Other|Group 2|Spontaneous ovulation group prior to initiating study OC. Estradiol or placebo given in a certain sequence depending on the randomization.
3192518|NCT01251250|Experimental|Arm I|Patients receive oral Azadirachta indica once daily on days 1-28. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3192519|NCT01251237|Experimental|Moviprep Orange|All patients receive 2 litres of NRL0706 solution.
3192520|NCT01251224|Active Comparator|Education Group|This group will receive IPM education at baseline, and then the full IPM intervention after completing the study.
3192521|NCT01251224|Experimental|IPM Group|This group will receive the full IPM intervention at baseline.
3192522|NCT01251211|Active Comparator|botulinum toxin type A|botulinum toxin type A will be injected subcutaneously in the painful area (maximum 300 units)
3192523|NCT01251211|Placebo Comparator|sodium chloride 9 %|sodium chloride 9 % will be used as a neutral placebo
3192524|NCT01251198||Acute coronary Syndrome|Patients affected are patients with acute coronary syndrome with ST segment elevation ST (myocardial infarction) in 48 hospitalized in one of the centers (emergency, ambulance, intensive care unit, cardiac catheterization lab).
3192525|NCT01251185|Experimental|CHF|Single-arm, open label, subjects with Congestive Heart Failure, with ischemic etiology.
3192526|NCT01251172|Experimental|Treatment (RO4929097 after autologous stem cell transplant)|"STEM CELL TRANSPLANTATION AND CHEMOTHERAPY: Patients undergo standard mobilization and collection of autologous peripheral stem cells (>= 4.0 x 10^6 CD34+ cells/kg). Patients then receive high-dose melphalan IV on days -3 and -2 and undergo autologous stem cell transfusion on day 0. Patients with progressive disease, stable disease, partial response, stringent complete response, or complete response are taken off study; patients with residual/persistent disease (VGPR) continue to therapeutic treatment.~THERAPEUTIC TREATMENT: Beginning 100-110 days after transplantation, patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3192527|NCT01251146|Experimental|Bisoprolol|
3192528|NCT01251146|Active Comparator|Atenolol|
3192529|NCT01251133|Experimental|LBVH0101|
3192530|NCT01251133|Active Comparator|Hiberix|
3192531|NCT01251120|Experimental|1|
3192532|NCT01251120|Active Comparator|2|
3192533|NCT01251107|Experimental|Arm B|BEACOPP (Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) for 4 escalated cycles followed by 4 standard cycles
3192534|NCT01251107|Active Comparator|Arm A|ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 6 to 8 cycles
3192535|NCT01251081|Experimental|extra high volume hemofiltration|extra high volume hemofiltration (85 mL/kg/h, EHVHF)
3192536|NCT01251081|Sham Comparator|high volume hemofiltration|high volume hemofiltration (50 mL/kg/h, HVHF)
3192537|NCT01251068|Experimental|gest age, cerebral ,somatic oxygenation measurement|
3192538|NCT01251055|Placebo Comparator|Placebo|
3192539|NCT01251055|Experimental|GlyT-1 inhibitor-1|GlyT-1 inhibitor-1 4000 mg/day
3192540|NCT01251042|Experimental|Sangvia and retransfusion|
3192541|NCT01251042|Sham Comparator|Sangvia and no retransfusion|
3192542|NCT01251029|Experimental|sugar pil and saline|
3192543|NCT01250990|Active Comparator|Niacin|Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
3192544|NCT01250990|Placebo Comparator|Placebo|Placebo tablet with 50 mg niacin for the first 4 weeks to maintain blinding of the study team and subjects, changed to pure placebo after that.
3192545|NCT01250977|Placebo Comparator|Adherence|
3192546|NCT01250977|Placebo Comparator|Side Effects|
3192547|NCT01250977|Placebo Comparator|Smoking behavior|
3192548|NCT01250977|Placebo Comparator|Cognitive Assessments|
3192549|NCT01250964|Active Comparator|Wound-assisted lens injection|Wound-assisted lens injection is considered neither superior or inferior to wound-directed lens injection.
3192550|NCT01250964|Active Comparator|Wound-directed lens injection|Wound-directed lens injection is neither considered superior nor inferior to wound-assisted lens injection.
3192551|NCT01250951|Experimental|Deferasirox|
3192552|NCT01250938|Experimental|ESI - Community Outreach|All families receive the same Early Social Intervention - Community Outreach (ESI-CO) treatment for 3 months in addition to 6 months of community resource support.
3192553|NCT01250925|Active Comparator|OPTI-FREE® RepleniSH®|33 participants will be assigned to use this lens care regimen during the six-week assessment period
3192554|NCT01250925|Active Comparator|Clear Care®|33 participants will be assigned to use this lens care regimen during the six-week assessment period
3192555|NCT01250925|Active Comparator|ReNu MultiPlus® MultiPurpose Solution|33 participants will be assigned to use this lens care regimen during the six-week assessment period
3192556|NCT01250912|Experimental|Imaging Tracer|No arms, the Radio tracer will be used in all subjects imaging tests.
3192557|NCT01250899|No Intervention|Vitamin D Sufficient|HIV-infected men and women with HIV-1 viral load <200 copies/mL on stable ART and 25(OH)D level ≥30ng/mL receive no intervention.
3192558|NCT01250899|Experimental|Vitamin D Insufficient|HIV-infected men and women with HIV-1 viral load <200 copies /mL on stable ART and 25(OH)D level <30ng/mL receive 50,000 IU twice weekly for 5 weeks followed by 2000 IU daily to complete 12 weeks.
3192559|NCT01250886|Placebo Comparator|Normal saline solution|Blood sample is obtained from patient in either forearm immediately before a Normal saline solution administered on the same site. The volume of fluid administration is calculated by means of Holliday and Segar formula.
3192561|NCT01250886|Active Comparator|Acetate Ringer's solution|Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
3192562|NCT01250873|Experimental|LY2216684/sertraline/LY2216684+sertraline|"Period 1: 18 mg oral dose of LY2216684 on days 1-3~Period 2: 50 mg oral dose of sertraline on day 4, followed by 100 mg oral dose of sertraline on days 5 to 10~Period 3: 18 mg oral dose of LY2216684 and 100 mg oral dose of sertraline on days 11-13"
3192563|NCT01250860|Sham Comparator|Control Group|Control DoboMed group - only specific active exercises: symmetrical positions for exercising; asymmetrical active movements; thoracic spine kyphotization; transverse plane derotation; apical area involvement; concave ribs mobilization; exteroceptive facilitation; respiration-directed movements of the thorax and spine; three-dimensional displacement of vertebra; active autocorrection.
3192564|NCT01250860|Experimental|Experimental group|"Experimental DoboMed and Kaltenborn manual therapy. Suitable techniques were chosen according to manual examination: cervical spine; thoracic spine; lumbar spine; costovertebral articles; pelvis position. During the 15 sessions in group DK we used:derotational manual terapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method; the manual techniques used in continuation study were different from techniques in pilot study."
3192565|NCT01250847|Experimental|Seroquel-XR|The subjects At-Risk Mental States will be treated with Quetiapine(Seroquel-XR) from baseline to end of trial.
3192566|NCT01250847|Experimental|Schizophrenia Comparator|The subject with schizophrenia will be treated with standard treatment
3192567|NCT01250847|No Intervention|Healthy Control Comparator|The subjects will not be required to treat
3192568|NCT01250834|Experimental|LY2189265 + Atorvastatin|"Period 1: Participants received a single 40-milligram (mg) oral dose of atorvastatin on Day 1, followed by a 7- to 10-day washout period between Period 1 and Period 2.~Period 2: Participants received a single 1.5-mg subcutaneous dose of LY2189265 on Day 1, followed by a single 40-mg oral dose of atorvastatin on Day 3."
3192569|NCT01250821|Experimental|Ovulation induction|
3192570|NCT01250795|Experimental|15 ug HAI-05 plus Alhydrogel|vaccine
3192571|NCT01250795|Experimental|45 ug HAI-05 plus Alhydrogel|vaccine
3192572|NCT01250795|Experimental|90 ug HAI-05 plus Alhydrogel|vaccine
3192573|NCT01250795|Experimental|90 ug HAI-05 in saline|vaccine
3192574|NCT01250795|Placebo Comparator|Saline|placebo
3192575|NCT01250782|Placebo Comparator|Physiological Serum|
3192576|NCT01250782|Active Comparator|Glutamine|
3192577|NCT01250769|Active Comparator|Manual Toothbrush 1|Manual Toothbrush used for 1 minute twice a day
3192578|NCT01250769|Active Comparator|Manual Toothbrush 2|Manual Toothbrush used for 2 minutes twice a day
3192579|NCT01250769|Experimental|Manual Toothbrush + Interproximal Cleaning 1|Manual Toothbrush used twice a day for 2 minutes plus Interproximal Cleaning Device used once a day
3192580|NCT01250769|Experimental|Manual Toothbrush + Interproximal Cleaning 2|Manual Toothbrush used twice a day for 2 minutes plus Interproximal Cleaning Device used twice a day
3192581|NCT01250756|Experimental|1|Experimental
3192582|NCT01250756|Experimental|2|Active comparator
3192583|NCT01250743|Experimental|Ascorbic Acid (Vitamin C)|
3192584|NCT01250730|Experimental|1.0|This study will consist of three cohorts: PF-02341066 150 mg treatment group (n = 6), PF-02341066 250 mg treatment group (n = 6) and PF-02341066 400 mg treatment group (n = 6).
3192585|NCT01250717|Experimental|Docetaxel Followed by Radical Prostatectomy|Docetaxel,Dexamethasone,Estramustine,Zoladex,Casodex,Prostatectomy
3192586|NCT01250691||hospital acquired pneumonia|
3192587|NCT01250691||isolated rooms|
3192588|NCT01250691||ward-type ICU|
3192589|NCT01250678||neurocognitive impaired|MS patients treated with natalizumab who at the beginning of the study suffer from cognitive impairment
3192590|NCT01250678||neurocognitive non-impaired|MS patients treated with natalizumab who at the beginning of the study do not suffer from cognitive impairment
3192591|NCT01250665||clinically isolated syndrome|In this study the term clinically isolated syndrome (CIS) is defined according to the Task Force on Differential Diagnosis in MS, as a monophasic presentation of neurological symptoms with suspected underlying inflammatory demyelinating disease (Miller 2008).
3192592|NCT01250665||remitting, relapsing MS|remitting relapsing MS according to the criteria by Poser (Poser 1983) or McDonald (McDonald 2001)
3192593|NCT01250652|Active Comparator|Levocetirizine|24 patients will received 20 mg Levocetirizine daily
3192594|NCT01250652|Experimental|Levocetirizine plus Hydroxyzine|24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
3192595|NCT01250626||a single-group study|Pediatric OPD, age < 18 y/o.
3192596|NCT01250600|Experimental|Remote-care|Home exercise monitored by the remote care system
3192597|NCT01250600|Active Comparator|Control|Home exercise under expert's instruction
3192598|NCT01250587|Experimental|PDC31|
3192599|NCT01250574||Postoperative infections|
3192600|NCT01250574||Bacterial infections in the GI tract|
3192601|NCT01250548|Active Comparator|2|
3192602|NCT01250548|Placebo Comparator|Apremilast|Placebo Compared to apremilast arm
3192603|NCT01250535|Experimental|Warfarin plus lovastatin|Warfarin plus lovastatin
3192604|NCT01250535|Placebo Comparator|Warfarin plus placebo|Warfarin plus placebo
3192605|NCT01250509|Experimental|CALMM|Participants receiving the 'Craving and Lifestyle Management through Mindfulness' intervention, i.e. program that combines stress reduction with mindful eating practices.
3192606|NCT01250509|No Intervention|Waitlist Control|Participants were waitlisted for the intervention during the experimental phase.
3192607|NCT01250496|Experimental|Aminophylline|75 mg of intravenous aminophylline.
3192608|NCT01250496|Placebo Comparator|Placebo|Matching normal saline placebo (sterile salt water).
3192609|NCT01250483||BPH|men aged more than 40 years who presented with BPH/LUTS and showed negative results of transrectal prostate biopsy before the period of AB medication
3192610|NCT01250483||prostate cancer|men aged more than 40 years who presented with BPH/LUTS and showed positive results of transrectal prostate biopsy before the period of AB medication
3192656|NCT01250236||placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
3193170|NCT01246414||Non-asthmatic controls|Non-asthmatic controls
3192611|NCT01250470|Experimental|Treatment (vaccine therapy)|"Patients receive Montanide ISA-51/survivin peptide vaccine SC followed by sargramostim SC on day 0. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~TREATMENT EXTENSION: After completion of study treatment, select patients may receive additional doses of Montanide ISA-51/survivin peptide vaccine SC and sargramostim SC. Treatment repeats every 3 months in the absence of disease progression or unacceptable toxicity."
3192612|NCT01250457|Experimental|Topical timolol|topical Timolol 0.5% solution applied twice daily
3192613|NCT01250444|Experimental|Inspiratory Muscle Training|It will me performed a loaded training of ventilatory muscles in patients with Hypertension. Its is done with the practice of breathing exercises associated to an training device, specific for this kind of intervention.
3192614|NCT01250431|Experimental|EFT (Emotional Freedom Techniques)|10 sessions of EFT.
3192615|NCT01250431|No Intervention|Wait List|10 week wait period.
3192616|NCT01250418|Active Comparator|Ketamine Group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
3192617|NCT01250418|No Intervention|No ketamine|No ketamine added to anesthesia regimen
3192618|NCT01250405|Active Comparator|Cinacalcet|
3192619|NCT01250405|Placebo Comparator|Placebo|
3192620|NCT01250392|Other|Control Arm|The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment.
3192621|NCT01250392|Experimental|Active Choice Only Arm|The active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
3192622|NCT01250379|Active Comparator|1|
3192623|NCT01250379|Experimental|2|
3192624|NCT01250366|Experimental|Arm 1: INX-08189 (9 mg) or Placebo|
3192625|NCT01250366|Experimental|Arm 2: INX-08189 (25 mg) or Placebo|
3192626|NCT01250366|Experimental|Arm 3: INX-08189 (50 mg + 9 mg) or Placebo|
3192627|NCT01250366|Experimental|Arm 4: INX-08189 (50 mg) or Placebo|
3192628|NCT01250366|Experimental|Arm 5: INX-08189 (9 mg) or Placebo + Ribavirin|
3192629|NCT01250366|Experimental|Arm 6: INX-08189 (25 mg) or Placebo + Ribavirin|
3192630|NCT01250366|Experimental|Arm 7: INX-08189 (100 mg) or Placebo|
3192631|NCT01250353|Experimental|conjunctival autograft|The conjunctival autograft was performed after the pterygium surgery like usual technique.
3192632|NCT01250353|Experimental|latex biomembrane application|The latex biomembrane was applied after pterygium surgery to recover the bare sclera area. This device was closed to conjunctiva with running suture anchored at some places to episclera. The sutures was removed at fourteenth day after surgery.
3192633|NCT01250340|Experimental|Aspirin|100 mg/day for 30 days
3192634|NCT01250340|Placebo Comparator|Placebo|1 cp /day for 30 days
3192635|NCT01250327|Experimental|Melody|insertion of a pulmonic valved stent
3192636|NCT01250327|Active Comparator|Bare stent|insertion of a bare metal stent
3192637|NCT01250327|Active Comparator|Surgery|conventional surgery methode.
3192638|NCT01250314|Other|With fracture|Patients with fracture
3192639|NCT01250314|Other|Without fracture|Patients without fracture
3192640|NCT01250301|Experimental|De-nicotinised cigarettes + standard treatment|
3192641|NCT01250301|Active Comparator|Standard treatment|
3192642|NCT01250288||Consumers|Consumers (patients or their designated proxies) who have registered to use the personal health management technology platform offered by the Brooklyn Health Information Xchange (BHIX) or Long Island Patient Information Xchange (LIPIX).
3192643|NCT01250288||Providers|Providers who are authorized to view the data entered by consumers in either (1) BHIX's personal health management system, along with BHIX health information exchange data; OR LIPIX's secure messaging system (SMS), along with LIPIX health information exchange data.
3192644|NCT01250275|Experimental|Acute Phase: traditional canola oil|Participants will receive banana bread containing traditional canola oil once weekly during the 5-week schedule
3192645|NCT01250275|Active Comparator|Acute Phase: high oleic canola oil|Participants will receive banana bread containing high oleic canola oil once weekly during the 5-week schedule
3192646|NCT01250275|Active Comparator|Acute Phase: soybean oil|Participants will receive banana bread containing soybean oil once weekly during the 5-week schedule
3192647|NCT01250275|Active Comparator|Acute Phase: high linoleic safflower oil|Participants will receive banana bread containing high linoleic safflower oil once weekly during the 5-week schedule
3192648|NCT01250275|Active Comparator|Acute Phase: coconut oil|Participants will receive banana bread containing coconut oil once weekly during the 5-week schedule
3192649|NCT01250275|Experimental|Chronic Phase: traditional canola oil|A total of 25 participants with peripheral arterial disease will be assigned foods containing traditional canola oil for a total of 8 weeks
3192650|NCT01250275|Active Comparator|Chronic Phase: safflower oil|A total of 25 participants with peripheral arterial disease will be assigned foods containing an oil mixture representing the typical western diet for a total of 8 weeks
3192651|NCT01250262|Active Comparator|Standard care|Subjects will receive normal medical care and follow up during the four month study period if assigned to this group.
3192652|NCT01250262|Active Comparator|Isolated Lumbar Resistance Exercise Program|Lumbar extension exercise protocol to increase strength and reduce pain.
3192653|NCT01250262|Active Comparator|Total Body Resistance Exercise Program|Training protocol for 1 set for each exercise: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl
3192654|NCT01250249|Active Comparator|BCG Vaccine - Intradermal injection|"Subjects must be in the age group of 0 - 14 years of age.~2. Subject's parent should be able to understand and have to sign the informed consent form after being explained by the investigator. They must be aware of the experimental nature of the therapy, its potential benefits, side effects and risks.~3. Ability to comply with the schedule of treatment and follow-up.~4. Absence of BCG scar~5. Tuberculin negative~6. No evidence of any other infection~7. No evidence of skin disease~Skin testing with tuberculin is not generally carried out before giving BCG but when performed, those who are found to be positive reactors need not to be immunized"
3192655|NCT01250236||verum|brimonidine 0.1% eye drops twice daily
3192657|NCT01250210|Experimental|AG200-15|Drug intervention with levonorgestrel and ethinyl estradiol : AG200-15 a transdermal contraceptive system containing 2.60 mg of levonorgestrel and 2.30 mg of ethinyl estradiol.
3192658|NCT01250210|Experimental|AG200|Drug intervention with levonorgestrel and ethinyl estradiol: AG200 a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.92 of ethinyl estradiol.
3192659|NCT01250210|Experimental|AG200LE|Drug intervention with levonorgestrel and ethinyl estradiol: AG200LE a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.28 mg of ethinyl estradiol.
3192660|NCT01250197|Experimental|Formulation A|AR-12286 Ophthalmic Solution Formulation A
3192661|NCT01250197|Experimental|Formulation B|AR-12286 Ophthalmic Solution Formulation B
3192662|NCT01250184|Active Comparator|Physical Therapy|Twelve sessions, 3 per week.
3192663|NCT01250184|Active Comparator|Lidocaine injection|Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
3192664|NCT01250184|Experimental|Lidocaine injection + physical therapy|Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
3192665|NCT01250171|Experimental|Secukinumab 10 mg/kg|Patients received a single dose of secukinumab 10 mg/kg infused intravenously over a 2 hour period.
3192666|NCT01250171|Experimental|Canakinumab 10 mg/kg|Patients received a single dose of canakinumab 10 mg/kg infused intravenously over a 2 hour period.
3192667|NCT01250171|Placebo Comparator|Placebo|Patients received a single placebo infusion intravenously over a 2 hour period.
3192668|NCT01250158|Experimental|Liver-PILP kit|Liver-PILP kit
3192669|NCT01250145|Experimental|LY333334 + placebo|"Part A:~Both a placebo and an 80 microgram active patch will be applied to the same arm for at least 6 hours daily, test arms will be alternated daily, for 22 days~Part B:~Induction phase: Both a placebo and an 80 microgram active patch will be applied to the same arm for at least 6 hours daily, test arms will be alternated daily, 4 times a week for 3 weeks~Rest phase: 2 weeks with no patch application~Challenge phase: 80 microgram active patch given once for at least 6 hours"
3192670|NCT01250132|Other|Moderate to severe Traumatic Brain Injury|"Assessment of hypopituitarism. Blood tests at different moments:~day 0~when leaving intensive care unit~month 3~month 12"
3192671|NCT01250119|Experimental|Single Arm|
3192672|NCT01250106|Experimental|Probiotic capsule|
3192673|NCT01250106|Placebo Comparator|placebo capsule|
3192674|NCT01250080|Experimental|Glutamine|
3192675|NCT01250080|Sham Comparator|Control|
3192676|NCT01250054|Other|Lotrafilcon B / Comfilcon A|Lotrafilcon B multifocal contact lenses worn first, with comfilcon A multifocal contact lenses worn second. Each product worn bilaterally on a daily wear basis for one week.
3192677|NCT01250054|Other|Comfilcon A /Lotrafilcon B|Comfilcon A multifocal contact lenses worn first, with lotrafilcon B multifocal contact lenses worn second. Each product worn bilaterally on a daily wear basis for one week.
3192678|NCT01250041|Active Comparator|femoral block|
3192679|NCT01250041|Experimental|saphenous block|
3192680|NCT01250015||control|given standard nhs advice leaflet
3192681|NCT01250015||interventional|given standard nhs advice leaflet with numerical information and pictograms
3192682|NCT01250002|Active Comparator|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
3192683|NCT01250002|Placebo Comparator|Placebo|Placebo will receive the same volume of saline infusion.
3192684|NCT01249989|Experimental|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
3192685|NCT01249989|Experimental|Simultaneous MBC Condition|Participants in the simultaneous condition will target FV+, Sed- and PA+ simultaneously. Participants will wear accelerometers and enter diet and sedentary activity 5 days/week on their Smartphone. All 3 goal thermometers will be activated from the outset of prescription (FV, Sed, PA). In week 1-2, participants will close 1/3 of the gap between their baseline FV, Sed, and PA behavior and their goals. In week 3-4 participants will close 2/3 of the gap, and 100% of their goals in weeks 5-6. Participants will maintain their target behaviors for FV, Sed and PA through week 12.
3192686|NCT01249989|Active Comparator|Stress Management Control|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
3192687|NCT01249976|Experimental|catheter-spearing diagnostic methods|experimental
3192688|NCT01249963|Experimental|Experimental Group|Patients of this group will receive 400 ml per day of T-Diet plus Atémpero product during 28 days.
3192689|NCT01249963|Active Comparator|Control Diet|Patients of this group will receive 2 packets (76 g) per day of AlitraQ (Abbott) product during 28 days.
3192690|NCT01249950||adolescents|adolescents with morbid obesity
3192691|NCT01249937|Placebo Comparator|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
3193472|NCT01244204|Placebo Comparator|Placebo|
3192692|NCT01249937|Active Comparator|Ranibizumab and Triamcinolone acetonide|"Recent research has discovered that persons with wet or dry ARMD show an immune response, as if the body is fighting off an infection. The body creates a complex immune response to the growth of blood vessels into the eye tissue, which triggers side effects. It is believed that preventing this inflammation can lead to greater visual gains and a need for fewer treatment injections.~Animal studies have shown that Triamcinolone Acetonide, a corticosteroid (class of drugs that reduce inflammation) can prevent damage to vision from this inflammation. The hypothesis is that treatment with both Ranibizumab and Triamcinolone Acetonide will allow even greater vision improvements than Ranibizumab treatment alone for wet age-related macular degeneration."
3192693|NCT01249924|Other|CPAP Group|CPAP Treatment
3192694|NCT01249924|Other|Control Group|Routine care
3192695|NCT01249911|Experimental|Lreuteri|Group of 130 infants allocated to receive L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.
3192696|NCT01249911|Placebo Comparator|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
3192697|NCT01249872|Active Comparator|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Group A patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline. Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
3192698|NCT01249872|Active Comparator|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Group B patients receive an epidural bolus dose of 1mg of morphine intra-operatively (45 min before the estimated end of the surgery). Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
3192699|NCT01249872|Active Comparator|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Group C patients receive an epidural bolus dose 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
3192700|NCT01249872|Active Comparator|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Group D patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline, epidurally. Postoperatively,patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
3192701|NCT01249872|Active Comparator|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Group E patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 1mg of morphine.Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
3192702|NCT01249872|Active Comparator|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Group F patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 2 mg of morphine. Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
3192703|NCT01249859||Signet ring cell carcinoma|
3192704|NCT01249859||non signet ring cell adenocarcinoma|
3192705|NCT01249846|Experimental|Arm 1|Each one of the two selected periodontal pockets (target pockets) will be randomized to the Frequent PerioChip® treatment or to the Routine PerioChip®.
3192706|NCT01249846|Placebo Comparator|Arm 2|Each one of the two selected target pockets will be randomized to the Frequent PerioChip® treatment or to the Frequent Placebo Chip treatment.
3192707|NCT01249833|Active Comparator|Oseltamivir|Added to standard of care for influenza
3192708|NCT01249833|No Intervention|Standard of care alone|Standard of care for influenza
3192709|NCT01249820|Experimental|group A|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
3192710|NCT01249820|Experimental|group B|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
3192711|NCT01249807||1|Patients, Family, Community member
3192712|NCT01249794|No Intervention|Best available treatment|
3192713|NCT01249794|Experimental|non invasive ventilation|
3192714|NCT01249781||resilience in caregivers whose child with ALL|
3192715|NCT01249768||Cohort|The cohort will consist of 150 patients with a hypokinetic rigid syndrome and a disease duration of maximum 36 months
3192716|NCT01249755||delirious patients|The cohort is divided in delirious and non-delirious patients
3192717|NCT01249690|Experimental|PAD|
3192718|NCT01249690|Experimental|TAD|
3192719|NCT01249677|Experimental|insulin glargine|patients with type 2 diabetes on previous therapy with metformin were examined before and after eight weeks of treatment with insulin glargin, aimed to normalize fasting plasma glycaemia
3192720|NCT01249664|Experimental|Arm 1|
3192721|NCT01249664|Sham Comparator|Arm 2|
3192722|NCT01249651|Other|1|One arm: esomeprazole 40 mg
3192723|NCT01249638|Experimental|Cap+Bev until PD followed by CAPIRI +Bev|"Capecitabine + Bevacizumab~In case of Progression Escalation to:~Capecitabine + Irinotecan + Bevacizumab"
3192724|NCT01249638|Active Comparator|Capiri + Bev|Capecitabine + Irinotecan + Bevacizumab
3192725|NCT01249625|Active Comparator|N95 Respirator|The investigators are comparing the 3M 1860 N95 respirator against the Precept 15320 medical mask.
3192726|NCT01249625|Active Comparator|Medical/surgical mask|The investigators are comparing the Precept 15320 medical/surgical mask against the 3M 1860 N95 respirator.
3192727|NCT01249612|Placebo Comparator|Control treatment|Elbow joint icing using two plastic bags with crushed ice
3192728|NCT01249612|Active Comparator|Active treatment|Knee joint icing using two plastic bags with crushed ice
3192729|NCT01249586|Placebo Comparator|Traditional teaching|A traditional class of blindness prevention.
3192730|NCT01249573|Experimental|fascia therapy|arm where fascia therapy is used as a treatment for an acute ankle distortion
3192731|NCT01249573|Experimental|transcutaneous fibrolysis|arm where transcutaneous fibrolysis is used as a treatment for an acute ankle distortion
3193078|NCT01247077|Active Comparator|placebo|Placebo and thyroxin + methimazole
3192732|NCT01249573|Placebo Comparator|placebo|arm where placebo therapy is used as a treatment for an acute ankle distortion
3192733|NCT01249560||raltegravir|"To illustrate the cause and effect relationship between the abnormalities of the distribution(casting) of the molecules of co-activation and the rate of apoptose, we compare also 2 groups: a first group of patients with a rate of apoptose normal ( n=10 ), and another group of patients having a rate of apoptose aggravated ( n=10 ).~20 eligible patients will receive their treatment to J1 and will be estimated for the residual concentration of the raltegravir ®, the antiretroviral activity, the tolerance and the observance at the treatments of the study in the visits of evaluation of M1, M2, M3, M6, M12, and / or in case of premature stop(ruling) of the try(essay). Every visit will give rise to a clinical evaluation of the patient. The arisen of unwanted events"
3192734|NCT01249547|Experimental|axitinib arm|
3192735|NCT01249534||Patients after gastroesophageal cancer surgery|
3192736|NCT01249508|Experimental|implemented nutrition label|A one-group pre-/post-design is used for the evaluation of the university canteen-based nutrition labeling program. This means that all participants of the program are exposed to the nutrition label implemented in the university canteen. The subject essentially serves as its own control based on pre-test behaviour. The nutrition label implemented is a star rating label calculated and assigned to each meal offered at the university canteens and based on the content of energy, saturated fat, sodium and fibre (expressed as vegetable portion).
3192737|NCT01249482||Late eradication|Group B (n=100) will be given rabeprazole 20 mg qd for 8 weeks and discontinued for 2 weeks. Then, H. pylori eradication with triple therapy will be given for one week, followed by rabeprazole 20 mg qd for 7 weeks.
3192738|NCT01249482||Negative HP|For patients with negative H. pylori infection (n=100), proton-pump inhibitor with rabeprazole 20 mg qd will be given for 8 weeks and discontinued.
3192739|NCT01249482||Early eradication|Group A (n=100) will be given initial H. pylori eradication with triple therapy for one week, followed by proton-pump inhibitor with rabeprazole 20 mg qd for 7 weeks.
3192740|NCT01249469|Placebo Comparator|Vehicle|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand.
3192741|NCT01249469|Experimental|Skin whitening cosmetic product|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand.
3192742|NCT01249456||Femara(Letrozole)|
3192743|NCT01249443|Experimental|Treatment (carboplatin, paclitaxel)|"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Before February 1, 2013, patients also received vorinostat PO once daily on days 1-5 with paclitaxel and carboplatin."
3192744|NCT01249430|Experimental|Treatment (azacitidine, mitoxantrone, etoposide, cytarabine)|Patients receive azacitidine IV over 30 minutes on days 1-8 and mitoxantrone hydrochloride IV over 10 minutes, etoposide phosphate IV over 30-60 minutes, and cytarabine IV over 6 hours on days 3-8. Treatment continues for 1 course in the absence of disease progression or unacceptable toxicity.
3192745|NCT01249417|Experimental|Dysport 10 U/Kg|10 U/Kg per lower limb. Either one or both lower limbs can be treated. Total volume injected, 2ml per leg.
3192746|NCT01249417|Experimental|Dysport 15 U/Kg|15 U/Kg per lower limb. Either one or both lower limbs can be treated. Total volume injected, 2ml per leg.
3192747|NCT01249417|Placebo Comparator|Placebo|Total volume to be injected per lower limb - 2ml. Either one or both lower limbs can be treated.
3192748|NCT01249404|Experimental|Dysport® 1000 U, IM|1000 U, I.M. (in the muscle), on day 1 (single treatment cycle)
3192749|NCT01249404|Experimental|Dysport® 1500 U, IM|1500 U, I.M., on day 1 (single treatment cycle)
3192750|NCT01249404|Placebo Comparator|Placebo|I.M., on day 1 (single treatment cycle)
3192751|NCT01249391|Active Comparator|Intervention (splinting)|Splinting of nominated joint in this group
3192752|NCT01249391|No Intervention|Control|Observation and usual treatment only.
3192753|NCT01249378|Active Comparator|10 g non emulsified of milk fat|They are compared using the repeated measurements taken within subjects
3192754|NCT01249378|Active Comparator|40 g non emulsified of milk fat|The subjects receive three sequences of different breakfasts. They are compared using the repeated measurements taken within subjects.
3192755|NCT01249378|Active Comparator|40 g finely emulsified of milk fat|The subjects receive three sequences of different breakfasts. They are compared using the repeated measurements taken within subjects.
3192756|NCT01249365|Experimental|HPV vaccine|Healthy female subjects aged 26 years and above, who received control vaccine in the primary study NCT00294047, were administrated 3 intramuscular injections of Cervarix vaccine into the deltoid of the non-dominant arm, according to a 0, 1, 6-month schedule in the current study.
3192757|NCT01249352|Active Comparator|STANDARD CHEMORADIATION|"Cisplatin 75 mg/m2, IV IV doses on D1 of each chemotherapy cycle, for 4 cycles Fluorouracil 1000 mg/m2, IV IV doses in a 24-hour continuous infusion, from D1 to D4 of each chemotherapy cycle, for 4 cycles.~Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day Equivalent to 28 fractions for 5 and a half weeks."
3192758|NCT01249352|Experimental|CHEMORADIATION + NIMOTUZUMAB|"Nimotuzumab 200 mg, IV weekly IV doses for up to 26 weeks. Cisplatin 75 mg/m2, IV IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.~Fluorouracil 1000 mg/m2, IV IV dose in a 24-hour continuous infusion, from D1 to D4 of each chemotherapy cycle, for 4 cycles.~Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day Equivalent to 28 fractions for 5 and a half weeks."
3192759|NCT01249339|Active Comparator|General 1 g pouch|Oral pouch 0.3-1g, single dose. One pouch administered over 30 minutes.
3192760|NCT01249339|Active Comparator|Catch Licoice 1 g pouch|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
3192761|NCT01249339|Active Comparator|Catch Licorice Mini 0.5 g pouch|Oral pouch 0.5g, single dose. One pouch administered over 30 minutes.
3192762|NCT01249339|Active Comparator|Catch Licorice dry mini 0.3 g pouch|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
3192763|NCT01249300||Dysphagia|Patients with CVA which causes dysphagia
3192764|NCT01249274|Placebo Comparator|Placebo|Matched placebo pills to be taken twice daily
3192765|NCT01249274|Experimental|Progesterone|100 mgs progesterone twice daily
3192766|NCT01249261|Placebo Comparator|Placebo/Risedronate|Placebo years 1-5, Risedronate 5mg/day years 6 & 7, no drug year 8
3192767|NCT01249261|Active Comparator|Risedronate|Risedronate 5mg years 1-7, no drug year 8
3192768|NCT01249248||Male basketball players|
3192769|NCT01249248||Female basketball players|
3192770|NCT01249248||Baseball players|
3192771|NCT01249248||Softball players|
3192772|NCT01249248||Football players|
3192773|NCT01249248||Female vollyball players|
3192774|NCT01249248||Male soccer players|
3192775|NCT01249248||Female soccer players|
3192776|NCT01249235|Active Comparator|Patch|The operative eye will be patched.
3192777|NCT01249235|Experimental|Bandage Contact Lens|The operative eye will have a bandage contact lens
3192778|NCT01249222|No Intervention|conventional treatment|
3192779|NCT01249222|Experimental|Plasmapheresis|
3192780|NCT01249209|Other|lifestyle advice|
3192781|NCT01249196|Placebo Comparator|Placebo|
3192782|NCT01249196|Experimental|SK-PC-B70M 200mg bid|
3192783|NCT01249196|Experimental|SK-PC-B70M 300mg bid|
3192784|NCT01249196|Other|Donepezil|
3192785|NCT01249183|Experimental|1- VAXIGRIP and REPEVAX concomitantly|
3192786|NCT01249183|Active Comparator|2-REPEVAX 28 days after VAXIGRIP|
3192787|NCT01249170|Other|First year fellow|
3192788|NCT01249170|Other|Second Year Fellow|
3192789|NCT01249157|Experimental|MRI and PEM scans|All consenting patients who are to have staging breast MRI, will be offered 18FDG PEM (Positron Emission Mammography) within 30 days. If the patient had a previous breast MRI that was done within 30 days at an outside institution, this MRI can be used if a radiologist determines that it is an adequate study. The surgery date will not be affected by the additional PEM evaluation. All imaging will be done and reviewed by MSKCC breast imagers. MRI and PEM findings suggestive of malignancy will be prospectively recorded in both the ipsilateral and contralateral breast.
3192790|NCT01249144|Active Comparator|Tecnis Z9002 Intraocular Lens (IOL)|
3192791|NCT01249144|Active Comparator|Softec HD Intraocular Lens (IOL)|
3192792|NCT01249131|Experimental|Treatment A first, then Treatment B, followed by Treatment C|Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliter (mL) room temperature water after at least an 8-hour fast, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard Food and Drug Administration (FDA) high-fat meal, in third intervention period. The washout period between each period will be a minimum of 10 days.
3192793|NCT01249131|Experimental|Treatment A first, then Treatment C, followed by Treatment B|Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib administered will be orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
3192794|NCT01249131|Experimental|Treatment B first, then Treatment A, followed by Treatment C|Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in third intervention period.
3192795|NCT01249131|Experimental|Treatment B first, then Treatment C, followed by Treatment A|Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
3192796|NCT01249131|Experimental|Treatment C first, then Treatment A, followed by Treatment B|Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
3192797|NCT01249131|Experimental|Treatment C first, then Treatment B, followed by Treatment A|Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
3192798|NCT01249118|Experimental|Part 1: GDC-0973 IV Infusion First, Then GDC-0973 Capsules|Participants will receive single dose of GDC-0973 2 milligrams (mg) IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
3192799|NCT01249118|Experimental|Part 2: GDC-0973 IV Infusion First, Then GDC-0973 Capsules|Participants will receive single dose of GDC-0973 2 mg IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
3192800|NCT01249118|Experimental|Part 2: GDC-0973 Capsules First, Then GDC-0973 IV Infusion|Participants will receive single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in first intervention period followed by single dose of GDC-0973 2 mg IV infusion in second intervention period. The washout period between each period will be a minimum of 10 days.
3192801|NCT01249105|Experimental|Part 1|Patients with recurrent glioblastoma multiforme (GBM) who require reoperation.
3192802|NCT01249105|Experimental|Part 2|Participants with GBM and with anaplastic glioma
3192803|NCT01249092|Experimental|Pentoxifylline 400 mg TID|This study is an open label pilot with only one arm.
3192804|NCT01249079||Schizophrenia Family|
3192805|NCT01249027||Observational|Single arm prospective, observational, single-arm, open-label, multicenter, postapproval registry study using XIENCE V® Everolimus Eluting Coronary Stent System (EECSS).
3192806|NCT01249014|No Intervention|Control|No peri-operative warming.
3192807|NCT01249014|Experimental|Warmed fluids|Patients will receive warmed i.v. fluids administered pre- and intra-operatively.
3192808|NCT01249014|Experimental|Warmed fluids and warm air|Patients will receive warmed i.v. fluids administered pre- and intra-operatively, and warmed air blown into a blanket covering the body intra-operatively.
3192809|NCT01249001|Experimental|Group 1|This group will receive oral aprepitant on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the capsule on the first day of the second study cycle of chemotherapy.
3192810|NCT01249001|Experimental|Group 2|This group will receive an aprepitant capsule on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the oral aprepitant on the first day of the second study cycle of chemotherapy.
3192811|NCT01248988||Synflorix Group|Infants and children who received at least one dose of Synflorix™ as a part of routine practice at a private clinic or hospital
3192812|NCT01248975|Experimental|FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)|FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)
3192813|NCT01248975|Active Comparator|FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)|FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)
3192814|NCT01248975|Placebo Comparator|FP/SAL 250/50mcg BID plus placebo BID|P/SAL 250/50mcg BID plus placebo BID
3192815|NCT01248962|Experimental|Standard 30-minute infusion|This is a non-blinded randomized study comparing standard 30-minute infusion carboplatin to extended 3-hour infusion carboplatin in women with recurrent, ovary, fallopian tube, and primary peritoneal cancer who will be treated with a carboplatin containing chemotherapy regimen.
3192816|NCT01248962|Experimental|extended 3-hour infusion|This is a non-blinded randomized study comparing standard 30-minute infusion carboplatin to extended 3-hour infusion carboplatin in women with recurrent, ovary, fallopian tube, and primary peritoneal cancer who will be treated with a carboplatincontaining chemotherapy regimen.
3192817|NCT01248949|Experimental|MEDI3617 SINGLE AGENT TOTAL|Participants will receive MEDI3617 via intravenous (IV) infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
3192818|NCT01248949|Experimental|MEDI3617 + BEVACIZUMAB Q3W ESCALATION|Participants will receive MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
3192819|NCT01248949|Experimental|MEDI3617 + BEVACIZUMAB Q2W TOTAL|Participants will receive MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.
3192820|NCT01248949|Experimental|MEDI3617 + PACLITAXEL TOTAL|Participants will receive MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.
3192821|NCT01248949|Experimental|MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL|Participants will receive MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
3192822|NCT01248936|Experimental|Overall Trial|Participants received vemurafenib 960 milligram (mg) orally two times a day for up to one year. Participants were treated until disease progression, unmanageable toxicity most probably attributable to vemurafenib, withdrawal of consent, and study termination by the sponsor
3192823|NCT01248923|Experimental|ARRY-520 (Schedule 1) + bortezomib + G-CSF|
3192824|NCT01248923|Experimental|ARRY-520 (Schedule 1) + bortezomib + dexamethasone + G-CSF|
3192825|NCT01248923|Experimental|ARRY-520 (Schedule 2) + bortezomib + dexamethasone + G-CSF|
3192826|NCT01248910|Experimental|Alpine Skiing|
3192827|NCT01248910|No Intervention|Control group|
3192828|NCT01248897||erbB2+/Her2 Breast Cancer Patients|erbB2+/Her2 Breast Cancer Patients Treated with Lapatinib and Other Anti-erbB2/Her2 Therapy
3192829|NCT01248884|Experimental|GSK217744 Group 1|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of GSK217744 formulation A vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The GSK217744 and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
3192830|NCT01248884|Experimental|GSK217744 Group 2|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of GSK217744 formulation B vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The GSK217744 and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
3192831|NCT01248884|Active Comparator|Infanrix hexa Group|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of Infanrix hexa™ vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The Infanrix hexa™ and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
3192832|NCT01248871|Active Comparator|SEVO|sevoflurane-remifentanil/sufentanil combination
3192833|NCT01248871|Active Comparator|SERE|volatile agent only during reperfusion
3192834|NCT01248871|Active Comparator|propofol|propofol-remifentanil/sufentanil
3192876|NCT01248468|Placebo Comparator|Placebo|1 placebo tablet matching sumatriptan 100mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets
3192877|NCT01248455|Experimental|anti-KIR in Smoldering Multiple Myeloma Patients|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
3192878|NCT01248442|Experimental|Cholecalciferol|
3192879|NCT01248442|Placebo Comparator|Placebo|
3192835|NCT01248858|Experimental|GSK2126458 and GSK1120212|The first combination schedule that will be tested involves giving both GSK2126458 and GSK1120212 continuously once a day in the morning until the subjects withdraw from the study. Other dosing schedules with both drugs will also be tested and these schedules are described below GSK2126458 will be dosed twice per day (morning and evening) continuously and GSK1120212 will be dosed once a day in the morning on a continuous schedule. Subjects will be treated with both drugs and remain in the study as long as they are benefiting from therapy. Another schedule that will be tested involves giving GSK2126458 twice each day (morning and evening) on an intermittent schedule (4 days of treatment, 10 days rest, then 4 days treatment, 10 days rest). GSK1120212 will be dosed once each day in the morning on a continuous schedule. Subjects will be treated with both drugs as long as they are benefiting from therapy.
3192836|NCT01248832|Experimental|Telephone Counseling|
3192837|NCT01248832|Active Comparator|Self-help Materials|
3192838|NCT01248819|Active Comparator|Instillation|Instillation of Ropivacaine 100 mg in the abdominal cavity
3192839|NCT01248819|Experimental|Nebulization|Nebulization of Ropivacaine 60 mg in the abdominal cavity
3192840|NCT01248806||Smokers or former smokers, Aged ≥ 50|Men and women current daily smokers or former smokers, Aged ≥ 50
3192841|NCT01248793|Experimental|Placebo|
3192842|NCT01248793|Experimental|Golimumab|
3192843|NCT01248780|Experimental|Golimumab + methotrexate (MTX)|Participants will receive golimumab 50 mg as subcutaneous (SC) (under the skin) injections administered every 4 weeks for up to 48 weeks. In addition, participants will receive a stable dose of MTX.
3192844|NCT01248780|Experimental|Placebo + methotrexate (MTX)|Participants will be administered Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48. In addition, participants will receive a stable dose of MTX.
3192845|NCT01248754|Experimental|18F-DOPA PET imaging|Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
3192846|NCT01248741|Experimental|HDR prostate brachytherapy|
3192847|NCT01248728|Active Comparator|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea high-EPA (HP) (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2.
3192848|NCT01248728|Placebo Comparator|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2.
3192849|NCT01248715|Experimental|Oseltamirvir|These patients will receive early oseltamivir plus current, standard empiric antibacterial therapy.
3192850|NCT01248715|No Intervention|Standard of care|These patients will be treated with the current, standard care, including currently recommended antibiotics or antiviral therapy based on national recommendations from the IDSA/ATS guidelines for management of hospitalized patients with CAP and ACIP antiviral use guidelines for hospitalized patients with confirmed of suspect influenza, per clinician discretion. In addition these patients with have a NP swab collected for influenza PCR testing and clinical information will be extracted from the medical record.
3192851|NCT01248702|Experimental|Critical Pathway|
3192852|NCT01248702|No Intervention|Standard Practice|
3192853|NCT01248689|Active Comparator|concentration profile 1|"IOP will be measured under this order of sevoflurane concentrations:~7%, 5%, 2%, 0.5%"
3192854|NCT01248689|Active Comparator|concentration profile 2|"IOP will be measured under this order of sevoflurane concentrations:~7%, 2%, 5%, 0.5%"
3192855|NCT01248689|Active Comparator|concentration profile 3|"IOP will be measured under this order of sevoflurane concentrations:~7%, 0.5%, 5%, 2%"
3192856|NCT01248663|Active Comparator|antecolic reconstruction|After completion of pancreaticoduodenectomy and reconstruction of the pancreaticojejunostomy and hepaticojejunostomy, the reconstruction of the intestinal passage will be conducted by performing an antecolic duodeno-jejunostomy
3192857|NCT01248663|Experimental|retrocolic reconstruction|After completion of pancreaticoduodenectomy and reconstruction of the pancreaticojejunostomy and hepaticojejunostomy, the reconstruction of the intestinal passage will be conducted by performing a retrocolic duodeno-jejunostomy
3192858|NCT01248650|Active Comparator|TRK-820 5 μg|Taking TRK-820 5μg(two 2.5μg soft capsules) once on the first day of hospitalization by oral route
3192859|NCT01248650|Active Comparator|TRK-820 2.5μg|Taking TRK-820 2.5μg(one 2.5μg soft capsule) once on the first day of hospitalization by oral route
3192860|NCT01248637||Pimonidazole hydrochloride|Oral pimonidazole is administered at a dose of 0.5gm/m2 once approximately 24 hrs prior to surgery
3192861|NCT01248624|Active Comparator|Early Palliative Care Referral|The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
3192862|NCT01248624|Placebo Comparator|Conventional Cancer Care|This control arm receives standard cancer care.
3192863|NCT01248611|Experimental|fentanyl|cancer patients with pain
3192864|NCT01248585|Active Comparator|Dexamethasone|2 x 4 mg dexamethasone tablets taken once daily for 5 days
3192865|NCT01248585|Placebo Comparator|Placebo|2 placebo tablets taken once daily for 5 days
3192866|NCT01248572|Experimental|Softec HD IOL|
3192867|NCT01248546||Digital mammography|
3192868|NCT01248520|Placebo Comparator|General health information|Pregnant women receiving text messages containing general health messages without including information regarding the importance of the influenza vaccination
3192869|NCT01248520|Active Comparator|Influenza and general health information|Pregnant women receiving text messages with influenza facts and the importance of the influenza vaccination, as well as general health messages Intervention: Text messages with influenza facts
3192870|NCT01248494|Experimental|BEZ235 + Letrozole|
3192871|NCT01248494|Experimental|BKM120 + Letrozole|
3192872|NCT01248494|Experimental|Intermittent BKM120 + Letrozole|
3192873|NCT01248481||Group 1|
3192874|NCT01248468|Experimental|Aspirin, acetaminophen and caffeine|AAC: 2 tablets, each containing acetaminophen 250 mg, aspiring 250 mg, caffeine 65 mg and 1 placebo tablet matching sumatriptan 100 mg tablets
3192875|NCT01248468|Active Comparator|Sumatriptan (100 mg)|1 tablet containing sumatriptan 100 mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets
3192880|NCT01248429||Patient treated by TKI|Any patient with solid tumor and treated by Thyrosine Kinase Inhibitor for at least 1 week
3192881|NCT01248416|Active Comparator|Aromatase Inhibitor|Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
3192882|NCT01248416|Active Comparator|Growth Hormone|Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
3192883|NCT01248416|Active Comparator|Aromatase Inhibitor and Growth Hormone|Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
3192884|NCT01248403|Active Comparator|paclitaxel + placebo|"Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.~+ Placebo (2 tablets / day) d1-d28"
3192885|NCT01248403|Experimental|paclitaxel + RAD001|"Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.~+ RAD001 10mg (2 x5 mg tablets / day) d1-d28"
3192886|NCT01248390|Experimental|Interactive Metronome therapy|Fifteen one-hour training sessions using Interactive Metronome system, in addition to treatment as usual.
3192887|NCT01248390|No Intervention|Treatment as Usual|Standard of care symptom management.
3192888|NCT01248377||Cephalosporins allergic patients|
3192889|NCT01248364|Experimental|BI 10773 Arm|BI 10773 high dose once daily
3192890|NCT01248351|Experimental|autologous stored platelets|
3192891|NCT01248338|Active Comparator|metoprolol, tablets|metoprolol succinate 50-100 mg orally daily for one year
3192892|NCT01248338|Experimental|nebivolol|nebivolol 5 mg capsule once daily for one year
3192893|NCT01248325|Experimental|Luffa Operculate Nasal Solution 5mg/mL|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
3192894|NCT01248325|Active Comparator|Saline Solution (NaCl 0,9%)|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
3192895|NCT01248312||morbidly obese|BMI >45
3192896|NCT01248312||thin patients|BMI <45
3192897|NCT01248299|Experimental|Chemotherapy plus best supportive care|Chemotherapy plus best supportive care with follow up at each cycle of the treatment with FU-CDDP; LV5FU2-CDDP; FOLFOX; TPF
3192898|NCT01248299|Active Comparator|Best supportive care|Best supportive care with follow up every 6 weeks
3192899|NCT01248286|Experimental|Whole grain rice|
3192900|NCT01248286|Active Comparator|Refined grain rice|
3192901|NCT01248273|Experimental|immunization|This trial will investigate the safety and immune responses following immunization with the unimolecular pentavalent Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21. This is a phase I study to assess toxicity and immunogenicity.
3192902|NCT01248260|Experimental|Higher-strength folic acid|Higher-strength folic acid (4mg).
3192903|NCT01248260|No Intervention|Low-strength folic acid|Low-strength (0.8mg) folic acid (standard of care)
3192904|NCT01248247|Experimental|Group 1 - Erlotinib|Erlotinib 150 mg by mouth each day of a 28 day cycle.
3192905|NCT01248247|Experimental|Group 2 - Erlotinib + MK-2206|"Erlotinib 150 mg by mouth each day of a 28 day cycle.~MK-2206 135 mg by mouth every week of a 28 day cycle."
3192906|NCT01248247|Experimental|Group 3 - AZD6244 + MK-2206|AZD6244 100 mg by mouth daily of a 28 day cycle. MK-2206 100 mg by mouth every week of a 28 day cycle.
3192907|NCT01248247|Experimental|Group 4 - Sorafenib|Sorafenib 400 mg by mouth twice a day for a 28 day cycle.
3192908|NCT01248234|Active Comparator|Propofol|Propofol alone will be used to put an elderly hypertensive patient to sleep for surgery.
3192909|NCT01248234|Active Comparator|Etomidate|Etomidate alone will be used to put an elderly hypertensive patient to sleep.
3192910|NCT01248234|Active Comparator|Propofol and Etomidate|A combination of Etomidate and Propofol will be used to put an elderly hypertensive patient to sleep for surgery.
3192911|NCT01248221|Experimental|Healthy subjects|The subject will consume the test meal containing [13C]-Spirulina platensis and 99mTc sulfur colloid, after which gastric emptying will be assessed simultaneously by scintigraphy and breath tests. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
3192912|NCT01248221|Experimental|Dyspeptic subjects|The subject will consume the test meal containing [13C]-Spirulina platensis and 99mTc sulfur colloid, after which gastric emptying will be assessed simultaneously by scintigraphy and breath tests. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
3192913|NCT01248208|Experimental|FluMist (LAIV) group|Patients age 2-49 years WITHOUT a history of asthma symptoms or treatment within the past 12 months will receive intranasal FluMist.
3192914|NCT01248208|Experimental|Flu shot (TIV) group|"Patients 6 months to 2 yrs or > 49 years or WITH a history of asthma symptoms / treatment within the past 12 months will receive intramuscular influenza vaccination. History/Treatment of asthma in the past 12 months is defined as follows:~wheezing in the past 12 months~use of inhaled corticosteroids (ICS), combined ICS / long acting beta agonist (LABA), or oral steroid in the past 12 months~emergency room or acute care visit or hospitalization for asthma or wheezing in the past 12 months."
3192915|NCT01248195|Other|Phase I: 1 arm 'amisulpride open label'|For 4 weeks, all patients will be treated with amisulpride open label.
3192916|NCT01248195|Active Comparator|Phase II: 'amisulpride double blind'|Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'amisulpride double blind'
3192917|NCT01248195|Active Comparator|Phase II 'olanzapine double blind'|Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'olanzapine double blind'
3192918|NCT01248195|Other|Phase III: 1 arm 'clozapine open label'|Patients who do not meet remission criteria during phase II (6-week double blind amisulpride vs olanzapine), flow to phase III, where only 1 arm is available: 'clozapine open label'
3193076|NCT01247090|Active Comparator|Group 2: Vasopressin - Low Dose|0.30 mU per kg per minute
3192919|NCT01248195|Experimental|Psychosocial intervention|Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Psychosocial Intervention' arm.
3192920|NCT01248195|No Intervention|Psychosocial Intervention phase: 'TAU'|Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Treatment as usual' arm.
3192921|NCT01248169||Hydralazine|This group will receive administration of the antihypertensive Hydralazine for the attempted control of their blood pressure and stabilization of their hemodynamic state.
3192922|NCT01248169||Labetalol|This group will receive administration of the antihypertensive Labetalol for the attempted control of their blood pressure and stabilization of their hemodynamic state.
3192923|NCT01248156||Intervention|Patients with persistent, long standing persistent and paroxysmal AF, who will receive ablation at sites that potentially maintain human AF.
3192924|NCT01248156||Control|Patients with persistent, long standing persistent and paroxysmal AF, who receive conventional ablation as determined by the operator at each site, and based upon Heart Rhythm Society guidelines.
3192925|NCT01248143|Experimental|Green tea|
3192926|NCT01248143|Experimental|FPP|
3192927|NCT01248130|Active Comparator|Omega-3 Fatty Acid Treatment|
3192928|NCT01248130|Placebo Comparator|Placebo (Sugar Pill)|
3192929|NCT01248117|Experimental|Previously Treated|With prior anti-vegf therapy, only, no sooner than 30 days prior to enrollment into trial
3192930|NCT01248117|Experimental|Treatment-Naive|Treatment-Naive: no previous treatment for PCV
3192931|NCT01248104|Active Comparator|Tranexamic Acid|
3192932|NCT01248104|Active Comparator|Aminocaproic Acid|
3192933|NCT01248091|Placebo Comparator|Placebo gel|
3192934|NCT01248091|Experimental|Nitroprusside Gel|
3192935|NCT01248078|Active Comparator|Cefazolin A|administered before skin incision
3192936|NCT01248078|Active Comparator|Cefazolin B|after umbilical cord clamping
3192937|NCT01248078|Placebo Comparator|saline solution|administered before skin incision
3192938|NCT01248065|Placebo Comparator|Ciclesonide + placebo|
3192939|NCT01248065|Experimental|Ciclesonide + Vitamin D|
3192940|NCT01248052|Experimental|LY2979165 (Part A)|single oral doses at dose levels ranging from 20 to 1000 mg
3192941|NCT01248052|Placebo Comparator|Placebo (Part A)|single oral dose
3192942|NCT01248052|Experimental|LY2979165 - low dose (Part B)|single oral low dose of LY297165 (dose to be determined by Part A)
3192943|NCT01248052|Experimental|LY2979165 - high dose (Part B)|single oral high dose of LY2979165 (dose determined from Part A)
3192944|NCT01248052|Placebo Comparator|Placebo - Part B|single oral dose
3192945|NCT01248039||Total arthroplasty|Patients with osteoarthrosis going for hip or knee arthroplasty
3192946|NCT01248026|Experimental|Buttermilk|
3192947|NCT01248026|Placebo Comparator|Placebo|
3192948|NCT01248000||classical Hodgkin lymphoma|All cases of classical Hodgkin lymphoma diagnosed between 2006 and 2008 in the province of Modena, Reggio Emilia, Parma and Ferrara will be considered eligible for this study.
3192949|NCT01247987|Active Comparator|Blastocyst cryopreservation|Subjects randomly assigned to this arm of the study will have all of their embryos cryopreserved at the blastocyst stage, followed by thaw and transfer in a subsequent menstrual cycle.
3192950|NCT01247987|Experimental|Bipronuclear oocyte cryopreservation|Subjects randomly assigned to this arm of the study will have all of their bipronuclear oocytes cryopreserved, followed by thaw, extended culture, and transfer in a subsequent menstrual cycle.
3192951|NCT01247974|Experimental|CorMatrix ECM for Pericardial Closure|Pericardial closure with CorMatrix ECM
3192952|NCT01247974|No Intervention|Control|No Pericardial Closure
3192953|NCT01247961|Experimental|10 mg intravenous dexamethasone|Subjects randomized to intervention arm will receive single dose of 10 mg intravenous dexamethasone.
3192954|NCT01247961|Placebo Comparator|Placebo|Equal volume of normal saline administered as a single intravenous dose at enrollment.
3192955|NCT01247948|Experimental|navigation assisted spine surgery|
3192956|NCT01247935|Experimental|Acupuncture|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
3192957|NCT01247935|Experimental|transcutaneous electrical stimulation|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
3192958|NCT01247935|No Intervention|Control|patient are monitored for pain and discomfort
3192959|NCT01247922|Experimental|Erlotinib|Participants who received erlotinib in a continuous oral dose of 85 mg/m^2 per day until dose modification, interruption or study discontinuation occurred.
3192960|NCT01247909|Experimental|Ceftriaxone|Ceftriaxone in infants with sepsis and bacterial meningitis
3192961|NCT01247909|Active Comparator|Penicillin and gentamicin|Penicillin and Gentamicin in infants with sepsis and bacterial meningitis
3192962|NCT01247896|Experimental|Active|
3192963|NCT01247896|Placebo Comparator|Placebo|
3192964|NCT01247883|Active Comparator|single dose PF-04634817 tablet|subjects receive a single dose of PF-04634817 as a tablet
3192965|NCT01247883|Active Comparator|single dose PF-04634817 solution|subjects receive a single dose of PF-04634817 as a solution
3192966|NCT01247870|Experimental|Metformin|Metformin 1 g twice daily for 28-35 days
3192967|NCT01247870|Placebo Comparator|Placebo|Matched placebo capsules
3192968|NCT01247857|Active Comparator|Preoperative Nebulization|Nebulization of 30 mg of Ropivacaine in the peritoneal cavity before surgery
3192969|NCT01247857|Active Comparator|Postoperative Nebulization|Nebulization of 30 mg of Ropivacaine in the peritoneal cavity after surgery
3192970|NCT01247857|Placebo Comparator|Control|Nebulization of normal saline 3 ml before and after surgery
3192971|NCT01247844|Other|Day 7|removal of Shang Ring at 7 days
3192972|NCT01247844|Other|Day 14|removal of Shang Ring at 14 days
3192973|NCT01247844|Other|Day 21|removal of Shang Ring at 21 days
3192974|NCT01247831|Other|glaucoma patients|All of the patients treated with SLT need further IOP reduction for control of their glaucoma.
3192975|NCT01247818|Experimental|PH-10 Treatment (High Dose Cohort)|
3192976|NCT01247818|Experimental|PH-10 Treatment (Mid Dose Cohort)|
3192977|NCT01247818|Experimental|PH-10 Treatment (Low Dose Cohort)|
3192978|NCT01247818|Placebo Comparator|Vehicle Control|
3192979|NCT01247805|Experimental|Treatment A|Revatio: 1 x 20 mg IR oral tablet.
3192980|NCT01247805|Experimental|Treatment B|2 x 10 mg sildenafil citrate IR oral tablet.
3192981|NCT01247805|Experimental|Treatment C|2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).
3192982|NCT01247792|No Intervention|"Before"|No Intervention Observation of current practice
3192983|NCT01247792|Other|"After"|SOPs for decision-making and communication Assessment of practice after implementation of SOPs
3192984|NCT01247779|Active Comparator|Standard Coelioscopy|gynecologic surgery - standard coelioscopy
3192985|NCT01247779|Experimental|Robot-assisted coelioscopy|gynecologic surgery - robot assisted coelioscopy
3192986|NCT01247766||Patients with rheumatoid arthritis (RA) who receive abatacept|
3192987|NCT01247766||Patients with RA who receive BDM drugs|biologic disease-modifying (BDM)
3192988|NCT01247766||Patients with RA who receive non-biologic DMARDs|disease-modifying anti-rheumatic drugs (DMARDs)
3192989|NCT01247753|Experimental|Intervention|
3192990|NCT01247753|No Intervention|Control|
3192991|NCT01247740|Experimental|1|three chamber bag for parenteral nutrition containing lipids, glucose, amino acids and electrolytes
3192992|NCT01247740|Active Comparator|2|compounded monobag including lipids, glucose, amino acids and electrolytes
3192993|NCT01247714|Active Comparator|Group 1|The group 1 will receive the experimental product T-Diet plus Diabet NP for the first month followed by a reference diet corresponding to a current marketed product (Glucerna SR, Abbott) for the second month, then the patients will receive a control product non specific for diabetic patients (T-Diet plus Standard)for the third month, and finally a specific diet for diabetic patients (Novasource, Nestlé Healthcare Nutrition)for the fourth month.
3192994|NCT01247714|Active Comparator|Group 2|The group 2 will receive a reference diet corresponding to a current marketed product (Glucerna SR, Abbott)for the first month, followed by the experimental product T-Diet plus Diabet NP for the second month, then the patients will receive a specific diet for diabetic patients (Novasource, Nestlé Healthcare Nutrition)for the third month, and finally a control product non specific for diabetic patients (T-Diet plus Standard)for the fourth month
3192995|NCT01247701|Experimental|Umbilical Cord Blood Transplant Treatment Plan|Busulfan, Cyclophosphamide, Fludarabine, Cord Blood Stem Cell Infusion
3192996|NCT01247688|Experimental|Umbilical Cord Blood Transplant Treatment Plan|Cytoxan, Fludarabine, Total Body Irradiation (TBI), Cord Blood Stem Cell Infusion
3192997|NCT01247675|Experimental|ACP-001, 0.02 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.02 mg hGH/kg/week for 4 weeks
3192998|NCT01247675|Experimental|ACP-001, 0.04 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.04 mg hGH/kg/week for 4 weeks
3192999|NCT01247675|Experimental|ACP-001, 0.08 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.08 mg hGH/kg/week for 4 weeks
3193000|NCT01247675|Active Comparator|Omnitrope, 0.04 mg hGH/kg/wk|Once daily subcutaneous injection of human Growth Hormone (Omnitrope) equivalent to 0.04 mg hGH/kg/week for 4 weeks
3193001|NCT01247662||ASD group|
3193002|NCT01247662||ADHD group|
3193003|NCT01247662||Normally developing control group|
3193004|NCT01247649|Experimental|Study group|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
3193005|NCT01247636|Experimental|Home-exercise|
3193006|NCT01247610||ADHD group|
3193007|NCT01247610||Control group|
3193008|NCT01247571|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3193009|NCT01247558||Test Cohort|100 randomized subjects administered Metanx®
3193010|NCT01247558||Control Cohort|400 subjects with diabetes mellitus meeting the same inclusion and exclusion criteria as the test cohort who have not been treated with Metanx®.
3193011|NCT01247545|Placebo Comparator|Control|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
3193012|NCT01247545|Active Comparator|Remote ischaemic conditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
3193013|NCT01247532|Experimental|Waitlist|
3193014|NCT01247519|No Intervention|observation|
3193015|NCT01247519|Experimental|Intervention|
3193016|NCT01247506||1|tumor tissues of HCC patients
3193017|NCT01247506||2|paired nontumor tissues of HCC patients
3193018|NCT01247480||Breast cancer patients|
3193019|NCT01247467||Breast Tumor|Breast Tumor Blocks
3193020|NCT01247454|Other|academic detailing|All arms will receive this intervention
3193021|NCT01247454|Experimental|Electronic Health Record (EHR) prompt|One intervention arm will receive the EHR prompt along with the academic detailing
3193022|NCT01247454|Experimental|EHR prompt and patient prompt|The final arm will receive this combined intervention plus the academic detailing
3193023|NCT01247428|Experimental|MiStent SES|The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
3193024|NCT01247415||Anaphylaxis|Anaphylaxis: these patients will have to meet at least level 3 of diagnostic certainty according to the Brighton Collaboration criteria for anaphylaxis
3193025|NCT01247415||Allergic-like reactions|Allergic-like reactions: These patients will have to have displayed at least one sign or symptom of an allergic reaction (any of the minor or major criteria of anaphylaxis) but will exclude patients with conjunctivitis who will belong to the ORS group
3193077|NCT01247090|Placebo Comparator|Group 3: Placebo|No Dose
3193026|NCT01247415||ORS cases|ORS cases: According to the Public Health Agency case definition, these patients should have presented a bilateral conjunctivitis plus ≥1 of the seven respiratory symptoms (cough, wheeze, chest tightness, difficulty breathing, difficulty swallowing, hoarseness or sore throat) that started within 24 hrs of vaccination, with or without facial oedema (no restriction for duration) (ref: Public Health Agency of Canada: User Guide: Report of Adverse Events Following Immunization (AEFI) Appendix III National Case Definitions of AEFIs of Special Interest: oculo-respiratory Syndrome. http://www.phac-pc.gc.ca/im/aefi_guide/ann3-eng.php
3193027|NCT01247415||Controls|Controls will be individuals who received the pH1N1 vaccine but did not present any of the above mentioned adverse events after their vaccine.
3193028|NCT01247402|Active Comparator|Paclitaxel eluting balloon|Freeway 0.035 Paclitaxel eluting balloon (3 microgram Paclitaxel/mm2)
3193029|NCT01247402|Active Comparator|Standard balloon angioplasty|standard balloon angioplasty
3193030|NCT01247389|Active Comparator|midline incision|
3193031|NCT01247389|Active Comparator|transverse incision|
3193032|NCT01247376|No Intervention|No Cooling and compression|
3193033|NCT01247376|Experimental|Intervention with cooling and compression|
3193034|NCT01247363|Experimental|LY2608204|Oral capsules of LY2608204 given once daily at a starting dose of 160mg, which may be titrated in 3 dose escalations to 240mg, 320mg and 400mg, with a 7-day treatment duration at each dose level for up to 28 days total treatment.
3193035|NCT01247350|Experimental|2 mg LY3009104 (Cohort 1)|2mg administered once on day 1 (single dose)
3193036|NCT01247350|Experimental|5 mg LY3009104 (Cohort 2)|5mg administered once on day 1 (single dose)
3193037|NCT01247350|Experimental|10 mg LY3009104 (Cohort 3)|10 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
3193038|NCT01247350|Experimental|14 mg LY3009104 (Cohort 4 )|14 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
3193039|NCT01247350|Placebo Comparator|Placebo|administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
3193040|NCT01247337|Experimental|Single arm chemotherapy treatment|
3193041|NCT01247324|Active Comparator|Interferon beta-1a 44 mcg SC|Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
3193042|NCT01247324|Experimental|Ocrelizumab|Ocrelizumab 600 mg intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.
3193043|NCT01247311|Active Comparator|1.|"1,25 Vitamin D (0.50ug *3 per week)~This is a prospective randomized double blind placebo controlled study of 125 stable CKD subjects examining the impact of vitamin D supplementation (1,25 vitamin D or 25 vitamin D formulations) compared to placebo on arterial stiffness and other parameters of vascular health"
3193044|NCT01247311|Active Comparator|2.|"25 Vitamin D (5000IU * 3 per week)~This is a prospective randomized double blind placebo controlled study of 125 stable CKD subjects examining the impact of vitamin D supplementation (1,25 vitamin D or 25 vitamin D formulations) compared to placebo on arterial stiffness and other parameters of vascular health"
3193045|NCT01247311|Placebo Comparator|3.|Placebo given orally 3xweek for six months
3193046|NCT01247298|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive stereotactic body radiation therapy (SBRT) which is 3 radiation treatments at 15 Gy, for a total of 45 Gy. Patients will be given Trans-Arterial Chemoembolization (TACE), prior to enrollment. (TACE is not performed as part of this clinical study, even though it is part of the inclusion criteria.)
3193047|NCT01247285|Experimental|Investigational Test Product|90 mg Fluoxetine Hydrochloride Capsules (Teva)
3193048|NCT01247285|Active Comparator|Reference Listed Drug|90 mg PROZAC WEEKLY® Capsules (Eli Lilly)
3193049|NCT01247272|Active Comparator|Reference Listed Drug|90 mg PROZAC WEEKLY® Capsules (Eli Lilly)
3193050|NCT01247272|Experimental|Investigational Test Product|90 mg Fluoxetine Hydrochloride Capsules (Teva)
3193051|NCT01247259|Active Comparator|SLIT-mono|
3193052|NCT01247259|Active Comparator|SLIT-poly|
3193053|NCT01247246|Placebo Comparator|Placebo|
3193054|NCT01247246|Active Comparator|SCV-07 0.1mg/kg|
3193055|NCT01247246|Active Comparator|SCV-07 0.3mg/kg|
3193056|NCT01247246|Active Comparator|SCV-07 1.0mg/kg|
3193057|NCT01247233|Active Comparator|Standard or Hypofractionated radiotherapy|"Whole breast RT, 50Gy + boost 16Gy. Whole breast hypofractionated RT without boost, either 40Gy or 42,5Gy."
3193058|NCT01247233|Experimental|Accelerated Partial Breast Irradiation (APBI)|APBI using 3D CRT technique, in 5 days, 38.5 Gy to the tumor bed .
3193059|NCT01247220|Experimental|Peripheral Laser + Ranibizumab|Angiography-directed peripheral laser + ranibizumab
3193060|NCT01247220|Active Comparator|Ranibizumab|Ranibizumab
3193061|NCT01247207|Experimental|Ataluren|Ataluren Oral suspension taken 3 times per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20mg/kg in the evening).
3193062|NCT01247194|Active Comparator|Cohort A|"PPI-461 50 mg~or placebo"
3193063|NCT01247194|Active Comparator|Cohort B|"PPI-461 100 mg~or placebo"
3193064|NCT01247194|Active Comparator|Cohort C|"PPI-461 200 mg~or placebo"
3193065|NCT01247181|Experimental|Mobile phone text message|
3193066|NCT01247181|Active Comparator|No Mobile phone text message|Usual care provided at clinic
3193067|NCT01247168|Experimental|1|
3193068|NCT01247155||first day review|
3193069|NCT01247155||non-first day review|
3193070|NCT01247142||Invasive pulmonary aspergillosis (IPA)|Patients with proven or probable invasive pulmonary aspergillosis (IPA) (EORTC/MSG criteria) or putative IPA (Blot et al. Am J Respir Crit Care Med 2012)
3193071|NCT01247142||Controls|Patients without signs of infection.
3193072|NCT01247129|Experimental|SIEA,delay procedure,widening of diameter|
3193073|NCT01247103|Placebo Comparator|Part A: single ascending dose|AZD4316: single oral dose, with 1 group with/without food
3193074|NCT01247103|Placebo Comparator|Part B: multiple ascending dose|AZD4316: multiple oral doses
3193075|NCT01247090|Active Comparator|Group 1: Vasopressin - Very Low Dose|0.15 mU per kg per minute
3193079|NCT01247077|Placebo Comparator|selenium|selenium + methimazole + thyroxin
3193080|NCT01247064|Experimental|Nebulized 3% Saline|
3193081|NCT01247064|Placebo Comparator|Nebulized 0.9% Normal Saline|
3193082|NCT01247051|Experimental|Precoating|
3193083|NCT01247051|Active Comparator|Standard priming|
3193084|NCT01247038|Experimental|Metal on ceramic articulation|The arm consists of patients with Ceramic femoral heads articulating with metal acetabular cups
3193085|NCT01247038|Active Comparator|Metal-on-metal|The arm consists of patients with Metal femoral heads articulating with metal acetabular cups
3193086|NCT01247025||Veterans|Veterans receiving mental health services at the Eastern Colorado Healthcare System (ECHCS)/Denver Veterans Affairs Medical Center (VAMC)
3193087|NCT01247012|Active Comparator|Lipid minimization|
3193088|NCT01247012|Experimental|Omegaven|
3193089|NCT01246999|Active Comparator|Live Attenuated Influenza vaccine|LAIV 0.2 ml will be given intranasally followed by LAIV 0.2 mg given intranasally 28 days later
3193090|NCT01246999|Active Comparator|Trivalent Influenza Vaccine 2010-2011|TIV will be given in a dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 8 years intramuscularly followed by a second dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 9 years intramuscularly 28 days later
3193091|NCT01246999|Active Comparator|TIV followed by LAIV|TIV will be given in a dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 9 years intramuscularly followed by LAIV given in a dose of .2 ml intranasally 28 days later
3193092|NCT01246999|Active Comparator|LAIV followed by TIV|LAIV will be given in a dose of .2 ml intranasally followed by a dose of TIV given in a dose of .25 ml 2 years to 36 months or .5 ml 37 months to 9 years intramuscularly 28 days later
3193093|NCT01246986|Experimental|160 mg LY2157299|"Per the protocol, following an interim analysis, the decision was taken to no longer randomize participants to the 160 mg LY2157299 arm. As of May 25,2012, all newly enrolled participants will receive 300 mg LY2157299.~160 mg LY2157299 given daily for 14 days followed by 14 days of rest. This on/off schedule constitutes a cycle of 28 days. Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
3193094|NCT01246986|Experimental|300 mg LY2157299|300 mg LY2157299 given daily for 14 days followed by 14 days of rest. This on/off schedule constitutes a cycle of 28 days. Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
3193095|NCT01246986|Experimental|160 mg LY2157299 + 800 mg Sorafenib|During each 28-day cycle: 160 mg LY2157299 given daily for 14 days followed by 14 days of rest. 800 mg Sorafenib will be given daily for 28 days. Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
3193096|NCT01246986|Experimental|300 mg LY2157299 + 800 mg Sorafenib|During each 28-day cycle: 300 mg LY2157299 given daily for 14 days followed by 14 days of rest. 800 mg Sorafenib will be given daily for 28 days. Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
3193097|NCT01246986|Experimental|80 mg LY2157299 + 8 mg/kg Ramucirumab|During each 28-day cycle: 80 mg LY2157299 given twice a day for 14 days followed by 14 days of rest. 8 mg/kilogram (kg) ramucirumab will be given daily for 15 days. Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
3193098|NCT01246986|Experimental|150 mg LY2157299 + 8 mg/kg Ramucirumab|During each 28-day cycle: 150 mg LY2157299 given twice a day for 14 days followed by 14 days of rest. 8 mg/kg ramucirumab will be given daily for 15 days. Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
3193099|NCT01246973|Experimental|curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
3193100|NCT01246973|Placebo Comparator|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
3193101|NCT01246960|Experimental|Ramucirumab|"Oxaliplatin 85 milligrams per square meter (mg/m^2) given on Day 1 of a 2-week cycle~Leucovorin 400 mg/m^2 given on Day 1 of a 2-week cycle~5-Fluorouracil (5-FU) 400 mg/m^2 bolus given on Day 1 of a 2-week cycle~5-FU 2400 mg/m^2 continuously given over 46-48 hours on Day 1 of a 2-week cycle~Ramucirumab 8 milligrams per kilogram (mg/kg) given on Day 1 of a 2-week cycle~Participants will receive study treatment every 2 weeks until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
3193102|NCT01246960|Placebo Comparator|Placebo|"Oxaliplatin 85 mg/m^2 given on Day 1 of a 2-week cycle~Leucovorin 400 mg/m^2 given on Day 1 of a 2-week cycle~5-FU 400 mg/m^2 bolus given on Day 1 of a 2-week cycle~5-FU 2400 mg/m^2 continuously given over 46-48 hours on Day 1 of a 2-week cycle~Placebo given on Day 1 of a 2-week cycle~Participants will receive study treatment every 2 weeks until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
3193103|NCT01246947|Active Comparator|Mitral surgery alone|Mitral valve surgery randomization for no repair of the moderate tricuspid regurgitation
3193104|NCT01246947|Active Comparator|Mitral surgery w/Tricuspid valve repair|Mitral valve surgery with randomization to repair the moderate tricuspid regurgitation
3193105|NCT01246934|No Intervention|COMPLICATION|
3193106|NCT01246921|Active Comparator|fluticasone proprionate 0.05 %|Group reveiving 12 months NB-UVB phototherapy twice a week in combination with fluticasone proprionate 0.05 % cream in an intermittent scheme
3193107|NCT01246921|No Intervention|no intervention|Group receiving 12 months NB-UVB phototherapy twice weekly, without any topical treatment
3193108|NCT01246908|Experimental|CX157 (TriRima)|CX157 (TriRima) in a reversible monoamine oxidase inhibitor (MAOI)
3193109|NCT01246908|Placebo Comparator|Placebo|
3193110|NCT01246895||Experimental|Microfracture with BST-CarGel
3193111|NCT01246895||Control|Microfracture without BST-CarGel
3193112|NCT01246882|Experimental|Augmented activity feedback|Feedback three times per week about 10-m walking speed, plus amount and types of physical activity measured using wireless bilateral ankle sensors that detect bouts of walking and cycling speed, duration, and distance.
3193113|NCT01246882|Active Comparator|speed-only feedback|Feedback three times per week about overground walking speed over 10 meters.
3193114|NCT01246843||metastatic Renal Cell Carcinoma without treatment|patients with metastasized RCC who did not receive treatment
3193169|NCT01246414||Non-allergic asthma|Patients with non-allergic asthma
3193115|NCT01246843||mRCC with treatment|"patients with metastastic renal cell cancer or GIST who are on treatment with Sunitinib or Sorafenib for~≥ 8 weeks"
3193116|NCT01246830||3D cephalometric analysis|
3193117|NCT01246830||2D cephalometric analysis|
3193118|NCT01246804|Experimental|ginkgo biloba + raltegravir|15 days ginkgo biloba 120mg BID + raltegravir 400mg SD
3193119|NCT01246804|Active Comparator|raltegravir|single dose raltegravir 400mg
3193120|NCT01246791|Experimental|NPC-01|Single oral administration of NPC-01
3193121|NCT01246778||With/without sunitinib|Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction during 200 minutes.
3193122|NCT01246778||With/without sunitinib IP|Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction and ischemia/reperfusion
3193123|NCT01246765||Pregnant women using atypical antipsychotic(s)|Pregnant women who have taken at least one type of atypical antipsychotic at some point during this pregnancy.
3193124|NCT01246765||Pregnant women not using atypical antipsychotics|Pregnant women who have not taken an atypical antipsychotic during pregnancy.
3193125|NCT01246752|Experimental|Human Stem Cell Transplantation|Patients receive an allogenic stem cell transplantation from an HLA-matched unrelated or related donor
3193126|NCT01246752|Active Comparator|Consolidating Chemotherapy|Patients receive a standard chemotherapy as consolidation therapy
3193127|NCT01246739|No Intervention|Follow-up|Patients who are diagnosed with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), who are followed only.
3193128|NCT01246739|Experimental|Surgery|Patients diagnosed with adrenal tumour and with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), operated with adrenalectomy
3193129|NCT01246713|Placebo Comparator|Acetaminophen solid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
3193130|NCT01246713|Active Comparator|Acetaminophen liquid formulation|Subjects in this arm will receive a 15mg/kg dose of a liquid acetaminophen formulation.
3193131|NCT01246700|Experimental|Group A|Participants received 12 weeks of Sensory Attention Focused Exercise, then received 12 weeks of no exercise.
3193132|NCT01246700|Experimental|Group B|Participants received no treatment for 12 weeks, then received Sensory Attention Focused Exercise for 12 weeks.
3193133|NCT01246687|Experimental|e-Intervention group|Receive stage-specific dietary intervention via the website & standard care at the outpatient clinic.
3193134|NCT01246687|No Intervention|Control group|Continue with the standard diabetes care at the outpatient clinic without getting access to the web-based intervention.
3193135|NCT01246674||Hypothesis generating study|Consecutive total hip arthroplasty patients
3193136|NCT01246648|Active Comparator|chronic periodontitis|
3193137|NCT01246648|Active Comparator|agressive periodontitis|
3193138|NCT01246648|Active Comparator|healthy patients|
3193139|NCT01246635|Experimental|TRUFIT CB with accelerated rehab.|
3193140|NCT01246635|Experimental|TRUFIT CB with standard rehab.|
3193141|NCT01246635|Active Comparator|• Microfracture with rehabilitation|
3193142|NCT01246622|Experimental|Treatment (biological therapy)|Patients receive lenalidomide PO on days 6-26 and cytarabine IV over 3 hours on days 1-5. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
3193143|NCT01246596|Active Comparator|chronic periodontitis|
3193144|NCT01246596|Active Comparator|aggressive periodontitis|
3193145|NCT01246596|Active Comparator|healthy patient (orthodontics extraction)|
3193146|NCT01246583|Experimental|Treatment Group A|
3193147|NCT01246583|Placebo Comparator|Treatment Group B|
3193148|NCT01246583|Experimental|Treatment Group C|
3193149|NCT01246583|Placebo Comparator|Treatment Group D|
3193150|NCT01246570|Experimental|Maintenance program|"Patients will attend a motivational exercise session once monthly. They will also be tested (exercise test with measurement of peak oxygen uptake) every third months."
3193151|NCT01246570|Active Comparator|Control|Usual care. The patients will receive the usual care provided by the hospital and community health services
3193152|NCT01246544||Data collection group: physicians|Online survey for physicians/members of the innovation alliance Berlin-Brandenburg (INABBRA)
3193153|NCT01246531||Urolithiasis|Case arm: men above fifty years-old with urolithiasis
3193154|NCT01246531||Control|Control arm: men above fifty years-old without urolithiasis
3193155|NCT01246518|Active Comparator|MOB015 for 3 months|
3193156|NCT01246518|Active Comparator|MOB015 for 9 months|
3193157|NCT01246492|Placebo Comparator|45g glucose|glucose water
3193158|NCT01246492|Active Comparator|45g glucose + 150mg aspartame|glucose water aspartame
3193159|NCT01246492|Active Comparator|45g glucose + 20 mg saccharin|glucose water saccharin
3193160|NCT01246492|Active Comparator|45g glucose + 85mg asculfame - K|glucose water aseulfame- k
3193161|NCT01246479|Other|No treatment|subjects will be followed up on immunity (analysis of blood samples) and safety
3193162|NCT01246466|Experimental|AtriCure Bipolar System combined with a catheter ablation|procedure using the AtriCure Bipolar System plus a catheter ablation
3193163|NCT01246453|Active Comparator|urokinase|
3193164|NCT01246453|Active Comparator|Alteplase|
3193165|NCT01246440|Experimental|Catumaxomab|
3193166|NCT01246427|Experimental|BRN01|"A 2 to 4 weeks run-in period is planned, during which all patients receive single blinded hot flash evaluation treatment which is actually a placebo (2 tablets every morning and every evening during 2 to 4 weeks). At the end of this period, the hot flash score is calculated. If the score is ≥10, the patient can be randomized to one of the 2 arms:~Experimental: BRN01~Placebo Comparator: Placebo"
3193167|NCT01246427|Placebo Comparator|Placebo|"A 2 to 4 weeks run-in period is planned, during which all patients receive single blinded hot flash evaluation treatment which is actually a placebo (2 tablets every morning and every evening during 2 to 4 weeks). At the end of this period, the hot flash score is calculated. If the score is ≥10, the patient can be randomized to one of the 2 arms:~Experimental: BRN01~Placebo Comparator: Placebo"
3193168|NCT01246414||Allergic asthma|Patients with allergic asthma
3193171|NCT01246401|Active Comparator|Extended-Release Naltrexone|Participants will receive intramuscular (IM) injections of Naltrexone once monthly for 6 months, the first injection being prior release
3193172|NCT01246401|Placebo Comparator|Placebo|Participants will receive IM injections of Placebo once monthly for 6 months, the first injection being prior release
3193173|NCT01246388||Chronic Liver Disease|
3193174|NCT01246362|Placebo Comparator|Control|Given placebo tablets preoperatively
3193175|NCT01246362|Active Comparator|Etoricoxib|Given etoricoxib preoperatively
3193176|NCT01246349|Experimental|Motivational Interviewing Group|For the Motivational Interviewing (MI) treatment group, a clinical psychology doctoral student trained in Motivational Interviewing administered six individual motivational interviewing treatment sessions, each 30 minutes in length.
3193177|NCT01246349|Active Comparator|Control Group|The comparison group received six social skills training sessions instead of Motivational Interviewing (MI).
3193178|NCT01246336||Patients with parkinsonism|Patients suffering from Parkinson's disease or parkinsonism
3193179|NCT01246336||Healthy controls|Patients not suffering from Parkinson's disease or any other neurological disorder
3193180|NCT01246323|Active Comparator|combined anesthesia|Patients will receive spinal and general anesthesia for benign laparoscopy gynecological surgery
3193181|NCT01246323|No Intervention|Control|
3193182|NCT01246310|Experimental|Inositol|
3193183|NCT01246310|Placebo Comparator|Placebo|
3193184|NCT01246297|Other|Control|Usual Care
3193185|NCT01246297|Active Comparator|Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of twice weekly exercise classes with an educational component.
3193186|NCT01246284|Active Comparator|A|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
3193187|NCT01246284|Active Comparator|B|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
3193188|NCT01246284|Active Comparator|C|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
3193189|NCT01246284|Placebo Comparator|D|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment.
3193190|NCT01246271||Sub urethral sling|
3193191|NCT01246271||sus with anterior vainal wall repair|
3193192|NCT01246258||Test group|Standard tests of balance function
3193193|NCT01246232|Experimental|Amisulpride|400mg, 2 x 200mg amisulpride capsules for the first 4 weeks, then the option of titrating up to 800mg, 4 x 200mg amisulpride capsules for the remaining 8 weeks.
3193194|NCT01246232|Placebo Comparator|Placebo|400mg, 2 x 200mg amisulpride capsules, or 2 matching placebo capsules for the first 4 weeks, then the option of titrating up to 800mg, 4 x 200mg amisulpride capsules, or 4 matching placebo capsules for the remaining 8 weeks.
3193195|NCT01246219|Experimental|GH treatment|4 years of GH treatment
3193196|NCT01246219|Placebo Comparator|Placebo|1 year treatment with placebo followed by optional 3 years of GH treatment
3193197|NCT01246219|No Intervention|Non treatment group|
3193198|NCT01246206|Experimental|Tacrolimus and Thymoglobulin|Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis
3193199|NCT01246193|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 80mg/S-Amlodipine 2.5mg
3193200|NCT01246193|Active Comparator|Combination Therapy|Co-administration of single oral doses of a 80mg tablet of Telmisatan and a 2.5 mg tablet of S-Amlodipine
3193201|NCT01246167|Active Comparator|Conservative|Active physiotherapy and self-training
3193202|NCT01246167|Active Comparator|Philos locking plate|After operative treatment active physiotherapy and self-training
3193203|NCT01246167|Active Comparator|Epoca prosthesis|After operative treatment active physiotherapy and self-training
3193204|NCT01246154||EXERCISE TOLERANCE|
3193205|NCT01246141||Repair group|patients in repair group underwent tricuspid repair for functional tricuspid regurgitation.
3193206|NCT01246141||replacement group|In this group, patients underwent tricuspid valve replacement for functional tricuspid regurgitation.
3193207|NCT01246102|Experimental|1|starting at 20 mg/m2
3193208|NCT01246089|Experimental|Ranabizumab|Myopic eyes with retinal neovascularization
3193209|NCT01246076|Experimental|Lenalidomide|"Lenalidomide 50 mg/day for two 28 day cycles.~Patients who have bone marrow aplasia as defined by a cellularity of <10% will be observed till counts recover. If patients do not progress following 2 cycles of HD lenalidomide, they will receive low dose lenalidomide 10 mg daily for 12 cycles."
3193210|NCT01246063|Experimental|Phase I - Part 1|"Dose Level 0: Carfilzomib IV (20 mg/m2) D1&D2 of C1 and carfilzomib IV (27 mg/m2)D8, D9, D15, D16 of C1. Carfilzomib IV (27 mg/m2) D1, D2, D8, D9, D15, D16 C2. Carfilzomib IV (27 mg/m2)D1, D2, D8, D15, D22 C3-6. PLD IV (30 mg/m2)D8 C1-6.~Dose Level 1: Carfilzomib IV (20 mg/m2) D1&D2 of C1 and carfilzomib IV (36 mg/m2)D8, D9, D15, D16 of C1. Carfilzomib IV (36 mg/m2) D1, D2, D8, D9, D15, D16 C2. Carfilzomib IV (36 mg/m2)D1, D2, D8, D15, D22 C3-6. PLD IV (30 mg/m2)D8 C1-6.~Dose Level 2: Carfilzomib IV (20 mg/m2) D1&D2 of C1 and carfilzomib IV (45 mg/m2)D8, D9, D15, D16 of C1. Carfilzomib IV (45 mg/m2) D1, D2, D8, D9, D15, D16 C2. Carfilzomib IV (45 mg/m2)D1, D2, D8, D15, D22 C3-6. PLD IV (30 mg/m2)D8 C1-6.~Dose Level 3: Carfilzomib IV (20 mg/m2) D1&D2 of C1 and carfilzomib IV (56 mg/m2)D8, D9, D15, D16 of C1. Carfilzomib IV (56 mg/m2) D1, D2, D8, D9, D15, D16 C2. Carfilzomib IV (56 mg/m2)D1, D2, D8, D15, D22 C3-6. PLD IV (30 mg/m2)D8 C1-6."
3193211|NCT01246063|Experimental|Phase I - Part 2|"Dose Level 0: Carfilzomib IV (MTD - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (MTD - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (MTD - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.~Dose Level 1: Carfilzomib IV (1 dose level above MTD) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (1 dose level above MTD) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (1 dose level above MTD) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.~Dose Level 2: Carfilzomib IV (2 dose levels above MTD) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (2 dose levels above MTD) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (2 dose levels above MTD) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib."
3193618|NCT01243125|Placebo Comparator|Saline|
3193212|NCT01246063|Experimental|Phase 2|Carfilzomib IV (MTD - Phase 1 Part 2) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (MTD - Phase 1 Part 2) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (MTD - Phase 1 Part 2) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.
3193213|NCT01246050|Active Comparator|Arm 1|CBOC Providers who have received HF Training
3193214|NCT01246050|No Intervention|Arm 2|CBOC Providers in the same CBOC who have not received HF Training
3193215|NCT01246037|Experimental|First placebo|First half year placebo, second half year bisoprolol
3193216|NCT01246037|Experimental|First Bisoprolol|First half year bisoprolol, second half year placebo
3193217|NCT01246024|Experimental|Hypoxia|
3193218|NCT01246011|Experimental|Heparin PF4 antibody positive -Drug (argatroban and warfarin)|Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive argatroban and warfarin
3193219|NCT01246011|No Intervention|Heparin PF4 antibody positive no drug|Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive no medication
3193220|NCT01246011|No Intervention|Heparin PF4 antibody negative|Post-CABG heparin PF4 antibody negative with no signs or symptoms of HIT randomized to receive no medication
3193221|NCT01245998|Active Comparator|dalteparin 5000 I.U./24 h s.c.|
3193222|NCT01245998|Active Comparator|dalteparin 15000 I.U./24 h s.c.|
3193223|NCT01245985|Experimental|treatment arm|patients receive induction chemotherapy with TPF for a maximum of 3 cycles followed by radioimmunotherapy with cetuximab as intensity-modulated radiotherapy (IMRT) plus carbon ion boost
3193224|NCT01245972|No Intervention|Control|No treatment administered
3193225|NCT01245972|Experimental|PDL Setting 1|PDL Setting 1: 15 J/cm2, 3ms pulse length, no dynamic cooling, 7mm spot size, 10% overlap between the pulses, 2 passes
3193226|NCT01245972|Experimental|PDL Setting 2|PDL Setting 2: 7.5 J/cm2, 3ms pulse length, no dynamic cooling, 10mm spot size, 10% overlap between the pulses, 2 stacked pulses
3193227|NCT01245959|Experimental|Induction chemotherapy and concurrent chemoradiotherapy|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
3193228|NCT01245959|Active Comparator|Concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
3193229|NCT01245946|Experimental|Photodynamic therapy|
3193230|NCT01245946|Experimental|Conventional therapy|
3193231|NCT01245920|Experimental|FDBA + Membrane Group|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
3193232|NCT01245920|Active Comparator|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
3193233|NCT01245907|Experimental|Applied relaxation|Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
3193234|NCT01245907|No Intervention|Waiting-list/control|No intervention for 10 weeks but the same registrations and diaries and forms as the interventional group
3193235|NCT01245894|Active Comparator|Low-dose Rosuvastatin|5mg Rosuvastatin/day
3193236|NCT01245894|Active Comparator|High-dose Rosuvastatin|Rosuvastatin 40mg/day
3193237|NCT01245881|Experimental|Treatment group|Broad-spectrum UV block plus non-ablative 1,550-nm fractional treatment
3193238|NCT01245881|Active Comparator|Control group|
3193239|NCT01245868|Experimental|Bupivacaine|Bupivacaine as used routinely
3193240|NCT01245868|Placebo Comparator|Lidocaine added to bupivacaine|lidocaine is added to bupivacaine
3193241|NCT01245855|No Intervention|PGE1 group and control group|the control group: received only the conventional medications, the PGE1 group: received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
3193242|NCT01245842|No Intervention|Usual care|
3193243|NCT01245842|Experimental|Exercise group|
3193244|NCT01245829|Placebo Comparator|Matt|A standard non antimicrobial laminated chart which will form the control group (group 1).
3193245|NCT01245829|Experimental|Cellomed|Observation charts coated in a laminate with antimicrobial properties (Cellomed) will form group 2.
3193246|NCT01245816|Experimental|Eflornithine plus Sulindac|Eflornithine 500 mg and Sulindac 150 mg
3193247|NCT01245816|Active Comparator|Elfornithine plus Placebo|Eflornithine 500 mg and Placebo
3193248|NCT01245816|Active Comparator|Sulindac plus Placebo|Sulindac 150 mg and Placebo
3193249|NCT01245803|Experimental|rosuvastatin,one month,lipid lowering|additional rosuvastatin(10mg) is given at 18hr and 4-6hr before PCI
3193250|NCT01245803|Placebo Comparator|sugar pill, one month|sugar pill is given 18-24hr and 4-6hr before PCI as control
3193251|NCT01245790|Experimental|1|Healthy subjects (Stage 1)
3193252|NCT01245790|Experimental|2|Mild renal impairment (Stage 2)
3193253|NCT01245790|Experimental|3|Moderate renal impairment (Stage 2)
3193254|NCT01245790|Experimental|4|Severe renal impairment (Stage 2)
3193255|NCT01245790|Experimental|5|End stage renal disease (Stage 1)
3193256|NCT01245777|Experimental|ferric carboxymaltose|Hb> 11 g/dl and Ferritin < 35 (controlled by CRP): 500mg to correct iron deficiency Hb ≥ 10 and < 11g/dl; Ferritin < 35 (controlled by CRP): 700 mg Hb ≥9 and < 10 g/dl; Ferritin < 35 (controlled by CRP): 800 mg Hb < 9g/dl; Ferritin < 35 (controlled by CRP): 900 mg
3193257|NCT01245764|Experimental|GARDASIL™ 9 to 12 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
3193258|NCT01245764|Experimental|GARDASIL™ 13 to 15 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
3193619|NCT01243112|Experimental|Lidocaine w/ Epi|0.2ml 1% Lidocaine with Epinephrine (1:100,000)
3193259|NCT01245764|Experimental|GARDASIL™ 16 to 26 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
3193260|NCT01245764|Placebo Comparator|Placebo 9 to 12 Years Old|Placebo to GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. After database lock and unblinding for study Phase A, participants will have the option to receive GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase B.
3193261|NCT01245751|Experimental|Group 1: Booster Dose Participants ≥70 years of age|Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study V211-004 NCT00007501)
3193262|NCT01245751|Experimental|Group 2: First Dose Participants ≥70 years of age|Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age
3193263|NCT01245751|Experimental|Group 3: First Dose Participants ≥60 and <70 years of age|Herpes zoster history-negative participants ≥60 and <70 years of age who have never received Zoster Vaccine, Live
3193264|NCT01245751|Experimental|Group 4: First Dose Participants ≥50 and <60 years of age|Herpes zoster history-negative participants ≥50 and <60 years of age who have never received Zoster Vaccine, Live
3193265|NCT01245738||Participants|Participants admitted to participating tertiary cardiac care centers who experienced a first coronary event.
3193266|NCT01245725|Experimental|Tirofiban (Aggrastat)|
3193267|NCT01245725|Placebo Comparator|Placebo|
3193268|NCT01245712|Experimental|Proton-Beam PBI Treatment|Accelerated Partial Breast Irradiation (APBI): Two 3.4 Gy fractions administered per day, separated by at least 6 hours for a total of 34 Gy delivered in 10 fractions (5 - 6 days in a row).
3193269|NCT01245686|Active Comparator|One-on-one counseling|Participants in this arm will receive 4 intensive one-on-one counseling sessions (either in person or on the phone) and 3 brief maintenance sessions.
3193270|NCT01245686|Active Comparator|Web counseling|Participants in this arm will receive 4 intensive counseling sessions over the web. They will also receive 3 maintenance sessions over the web.
3193271|NCT01245673|Experimental|Prevnar, T Cells, Lenalidomide, MAGE A-3|
3193272|NCT01245660|Experimental|Patient|
3193273|NCT01245647|Placebo Comparator|Sugar Pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
3193274|NCT01245647|Active Comparator|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
3193275|NCT01245634|Experimental|A|
3193276|NCT01245634|Placebo Comparator|B|
3193277|NCT01245621|Active Comparator|Early entry group|Early entry group will begin the intervention at time of diagnosis of advanced cancer
3193278|NCT01245621|Active Comparator|Later entry group|Later entry group will begin the intervention 12 weeks after enrollment in the study.
3193279|NCT01245608|Experimental|Polypill|Single daily dose of PolyPill and 6-monthly visits
3193280|NCT01245608|No Intervention|Control|Only 6-monthly visits
3193281|NCT01245595|Active Comparator|Aminophylline|Patients to receive aminophylline 5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
3193282|NCT01245595|Placebo Comparator|Placebo|Normal Saline Placebo
3193283|NCT01245582|Experimental|SECOX regimen|Oxaliplatin (Eloxatin) 85mg/m2 , 2 hour infusion, day 1 Capecitabine (Xeloda) 850 mg/m2 BID orally daily, from day 1 to 7 Sorafenib (Nexavar) 400 mg BID orally daily, from day 1 to 14 (continuously)
3193284|NCT01245582|Active Comparator|Sorafenib alone|Sorafenib (Nexavar) 400 mg BID orally daily, from day 1 to 14 (continuously)
3193285|NCT01245569|Experimental|Foster®|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
3193286|NCT01245569|Active Comparator|Seretide® Accuhaler®|Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
3193287|NCT01245556|Experimental|BMS-908662 or Ipilimumab (A)|
3193288|NCT01245556|Experimental|BMS-908662 or Ipilimumab (B)|
3193289|NCT01245543|Experimental|AC480IV|Dose range finding study
3193290|NCT01245543|Experimental|Docetaxel|Dose range finding study in subjects with solid tumors
3193291|NCT01245530|Active Comparator|Aricept|Intervention: Drug: Aricept
3193292|NCT01245530|Experimental|INM-176|Intervention: Drug: INM-176
3193293|NCT01245517|Experimental|Dietary Phosphorus Education Program|
3193294|NCT01245504||Lower-limb amputee|Subjects with at least one lower limb amputated at teh trans-tibial level
3193295|NCT01245465|Experimental|Profermin|Daily oral intake of a food for special medical purposes (Profermin)
3193296|NCT01245452|Experimental|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
3193297|NCT01245452|Active Comparator|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
3193298|NCT01245439|Experimental|1|
3193299|NCT01245426|Experimental|GW870086 2mg|GW870086 2mg once daily in the morning for 27 ± 2 days
3193300|NCT01245426|Experimental|GW870086 4mg|GW870086 4mg once daily in the morning for 27 ± 2 days
3193301|NCT01245426|Placebo Comparator|Placebo|Placebo once daily in the morning for 27 ± 2 days
3193302|NCT01245426|Experimental|GW870086 1mg|GW870086 1mg once daily in the morning for 27 ± 2 days
3193303|NCT01245426|Experimental|GW870086 3mg|GW870086 3mg once daily in the morning for 27 ± 2 days
3193304|NCT01245413|Active Comparator|SenSura Adhesive (device)|Sensura is a commercially available adhesive, that is designed to collect output from a stoma.
3193305|NCT01245413|Experimental|Athena adhesive|Athena = new test adhesive. The Athena baseplate is intended for collecting output from a stoma.
3193306|NCT01245400|Experimental|Z-Lig|Z-Lig Anterior Cruciate Ligament Reconstruction (ACLR) graft implantation performed under anesthesia during an arthroscopic procedure.
3193307|NCT01245400|Active Comparator|Allograft|Allograft bone/tendon graft implantation performed under anesthesia during an arthroscopic procedure.
3193308|NCT01245387||Macugen|
3193309|NCT01245374|Experimental|Nordiflex Norditropin®|Individually adjusted dose administered with Norditropin NordiFlex® for 6 weeks. Dosage depended on age, weight, etiologies and according to the summary of product characteristics (SPC)
3193310|NCT01245361|Experimental|Infliximab|Group I: Infliximab 3 mg/kg wk 0,2,6
3193311|NCT01245361|Placebo Comparator|sodium chloride|RA 1 solution for infusion, intravenous use Sterile normal saline 0.9% sodium chloride
3193312|NCT01245348||Schizophrenia|Patient with schizophrenia
3193313|NCT01245348||Bipolar|Patient with bipolar disorder
3193314|NCT01245335|Active Comparator|BMAC Treatment|Intervention- Injection of 40 ml of autologous bone marrow concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
3193315|NCT01245335|Placebo Comparator|Placebo Injection|Injection of placebo (diluted peripheral blood) into ischemic tissue of the lower extremity
3193316|NCT01245322|Active Comparator|Lactobacilli|different lactobacilli.
3193317|NCT01245309|Experimental|scratching|endometrial scratching prior ivf cycle
3193318|NCT01245309|Placebo Comparator|PLACEBO|PLACEBO PROCEDURE
3193319|NCT01245296|Other|Early cord clamping (ECC)|Early cord clamping consisted of early (< 10 s) clamping of the umbilical cord and obtaining blood gas samples after clamping.
3193320|NCT01245296|Other|Delayed cord clamping (DCC)|Delayed cord clamping consisted of delayed (> 180 s) clamping of the umbilical cord and obtaining blood gas samples before clamping (within 30 seconds).
3193321|NCT01245283|Active Comparator|Wait-list Non-exercise Control (CON)|Subjects will continue to participate in their normal activities and clinical care during the four month study period if assigned to this group.
3193322|NCT01245283|Active Comparator|Concentric Focused RX (CRX)|Training protocol for 1 set of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
3193323|NCT01245283|Active Comparator|Eccentric Focused RX (ERX)|"The Human Dynamics Laboratory features prototype equipment that increases resistance loads during the eccentric phase of the contraction while assistance is provided by the machine during the concentric phase. One set of each exercise - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press."
3193324|NCT01245270|Experimental|Bilberry capsule first, then control cap|"Volunteers will be given a single capsule of 0.47 grams of mirtoselect (a concentrated bilberry extract) followed by a 14 day washout period then a single control placebo capsule.~First Intervention (1 day), Washout (14 days), Second Intervention (1 day)"
3193325|NCT01245270|Experimental|Control capsule first, then bilberry cap|"Volunteers will be given a single control placebo capsule followed by a 14 day washout period the a single capsule of 0.47 grams of mirtoselect (a concentrated bilberry extract)~First Intervention (1 day), Washout (14 days), Second Intervention (1 day)"
3193326|NCT01245257||Alcoholic Hepatitis|Patients with alcoholic hepatitis
3193327|NCT01245244|Experimental|Morphine|
3193328|NCT01245244|Placebo Comparator|Placebo|
3193329|NCT01245205|Experimental|Treatment (Akt inhibitor MK2206 and lapatinib ditosylate)|Patients receive Akt inhibitor MK2206 PO QOD for 28 days (35 days for course 1) and lapatinib ditosylate PO QD or BID on days 1-28 (days 9-35 for course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3193330|NCT01245179|Experimental|Panobinostat|All patients will receive Panobinostat at specified dose levels and dosing schedules.
3193331|NCT01245166|Active Comparator|Acarbose|
3193332|NCT01245166|Experimental|Metformin/Acarbose|
3193333|NCT01245153|Experimental|Rectal Balloon Training|Subjects in combined RBT and PFMT group are taught Foley catheter insertion technique. The catheter is inserted into the rectum until the lower end of the balloon is 1 cm inside from the anus. Then the balloon is blown with clean water. Subjects will contract pelvic floor muscle in standing position by contracting the pelvic floor muscle, hold and count 1 to 5, then relax and count 1 to 5. Subjects are instructed to do the exercise 15 times/set, 3 sets/day, every day for 6 weeks.
3193334|NCT01245153|Active Comparator|Control group|Patients receive Pelvic floor muscle training without inserting any kinds of equipment.
3193335|NCT01245140|Active Comparator|Active|to receive study drug (alitretinoin, 20 patients)
3193336|NCT01245140|Placebo Comparator|Placebo|to receive placebo (dummy drug, 10 patients)
3193337|NCT01245127|Experimental|Canakinumab|"Canakinumab 150 mg (or 2 mg/kg for patients weighing <40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).~At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing <40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing <40 kg) every 8 weeks beginning at Week 8.~Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.~If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks."
3193338|NCT01245101|Experimental|Raltegravir and then Observation|The total duration of the study will be 40 weeks. This will include Part 1 (16 weeks) followed by Part 2 (8 weeks) followed by the crossover to Part 2 (16 weeks). During Part 1 participants in Group A will receive open-label raltegravir in addition to their established antiretroviral regimen while Group B participants will continue taking their established antiretroviral regimen for 16 weeks. After completion of Part 1, both groups will enter Part 2 that will consist of a washout period of 8 weeks during which both groups will only take their established antiretroviral regimen without raltegravir. This will be followed by Part 3 during which the two study groups will undergo a crossover with respect to the treatment assignment during Part 1 so that Group A will continue to receive their established antiretroviral regimen while Group B will receive open-label raltegravir in addition to their established antiretroviral regimen for 16 weeks.
3193380|NCT01244815|Experimental|Asenapine 2.5 mg twice daily (BID)|Participants receive asenapine 2.5 mg BID for 21 days.
3193381|NCT01244815|Experimental|Asenapine 5.0 mg BID|Participants receive asenapine 2.5 mg BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive asenapine 5.0 mg BID for the remainder of the 21-day treatment period.
3193473|NCT01244191|Experimental|Tivantinib and erlotinib|Tivantinib 720 mg daily (360 mg twice a day) in combination with 150 mg of erlotinib, given once a day
3193339|NCT01245101|Active Comparator|Observation and then Raltegravir|The total duration of the study will be 40 weeks. This will include Part 1 (16 weeks) followed by Part 2 (8 weeks) followed by the crossover to Part 2 (16 weeks). During Part 1 participants in Group A will receive open-label raltegravir in addition to their established antiretroviral regimen while Group B participants will continue taking their established antiretroviral regimen for 16 weeks. After completion of Part 1, both groups will enter Part 2 that will consist of a washout period of 8 weeks during which both groups will only take their established antiretroviral regimen without raltegravir. This will be followed by Part 3 during which the two study groups will undergo a crossover with respect to the treatment assignment during Part 1 so that Group A will continue to receive their established antiretroviral regimen while Group B will receive open-label raltegravir in addition to their established antiretroviral regimen for 16 weeks.
3193340|NCT01245088|Experimental|chondroitin sulfate|400 mg (one table) TID
3193341|NCT01245075|Active Comparator|Deep Brain Stimulation|Stimulator setting is ON
3193342|NCT01245075|Sham Comparator|Placebo|Stimulator setting is OFF
3193343|NCT01245062|Experimental|GSK1120212|MEK inhibitor
3193344|NCT01245062|Active Comparator|Chemotherapy|Investigator Choice of DTIC or paclitaxel
3193345|NCT01245062|Experimental|Crossover|MEK inhibitor after documented progression on Chemotherapy Arm
3193346|NCT01245049|Experimental|BOOSTRIX POLIO GROUP|Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Boostrix™ Polio vaccine co-administered with Priorix™ vaccine at Day 0. Boostrix™ Polio vaccine was administered intramuscularly in the deltoid muscle of the left arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arm or as an intramuscular injection into the deltoid muscle of the right arm.
3193347|NCT01245049|Active Comparator|REPEVAX GROUP|Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Repevax™ vaccine co-administered with Priorix™ vaccine at Day 0. Repevax™ vaccine was administered intramuscularly in the deltoid muscle of the arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arn or as an intramuscular injection into the deltoid muscle of the right arm.
3193348|NCT01245036|Active Comparator|Glucocorticoid arm|Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 6 weeks (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 6 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
3193349|NCT01245023|Active Comparator|laparoscopy|laparoscopic adhesiolysis and application of Sprayshield spray to prevent further adhesions
3193350|NCT01245023|Placebo Comparator|placebo-control|anaethesia and skin incisions without laparoscopy or related procedures
3193351|NCT01245010|Experimental|Water|Water and education provision
3193352|NCT01245010|Active Comparator|Control|Education only
3193353|NCT01244997|Experimental|Immediate implant placement|This arm is an immediate placement of a dental implant following tooth extraction.
3193354|NCT01244997|Active Comparator|Delayed Implant|This is the traditional method for implants. This arm will be done following a healing of the area.
3193355|NCT01244984|Experimental|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
3193356|NCT01244984|Experimental|Fluticasone Furoate|Inhaled corticosteroid
3193357|NCT01244971|Active Comparator|Acarbose|
3193358|NCT01244971|Active Comparator|Exercise|
3193359|NCT01244971|Experimental|Exercise + Acarbose|
3193360|NCT01244958|Active Comparator|Rituximab 1000 mg|Administration of 1000 mg Rituximab in Part I, followed by either re-treatment with 1000 mg Rituximab or with 500 mg Rituximab in Part II of the study
3193361|NCT01244958|Placebo Comparator|Placebo|Administration of Placebo in Part I followed by re-treatment with either 1000 mg Rituximab or with 500 mg Rituximab in Part II of the study
3193362|NCT01244945|Experimental|L. reuteri DSM 17938|
3193363|NCT01244945|Placebo Comparator|Placebo|
3193364|NCT01244906|Experimental|Reduced Intensity Allogeneic Stem Cell Transplantation|All patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
3193365|NCT01244893|Other|Acuvue Advance Plus prePQ/Acuvue Advance Plus postPQ|Acuvue Advance Plus silicone hydrogel contact lens manufactured prior to process qualification will be worn first and Acuvue AdvancePlus silicone hydrogel contact lens manufactured after process qualification will be worn second.
3193366|NCT01244893|Other|Acuvue Advance Plus postPQ/Acuvue Advance Plus prePQ|Acuvue Advance Plus silicone hydrogel contact lens manufactured prior to process qualification worn first and Acuvue Advance Plus silicone hydrogel contact lens manufactured after process qualification worn second.
3193367|NCT01244880|Experimental|Saline/PF-02545920|Treatments are co-administered
3193368|NCT01244880|Experimental|Ketamine/PF-02545920|Treatments are co-administered
3193369|NCT01244880|Placebo Comparator|Saline/Placebo|Treatments are co-administered
3193370|NCT01244880|Experimental|Ketamine/Placebo|Treatments are co-administered
3193371|NCT01244867|Experimental|20 microgram H5 VLP vaccine + Alhydrogel|
3193372|NCT01244867|Experimental|30 micrograms H5 VLP vaccine + Alhydrogel|
3193373|NCT01244867|Experimental|45 micrograms H5 VLP vaccine + Alhydrogel|
3193374|NCT01244867|Experimental|45 micrograms H5 VLP vaccine|
3193375|NCT01244867|Placebo Comparator|Placebo|
3193376|NCT01244854|Other|Arm 1|Enhanced Usual Care; patients receive care as usual, with additional mailings on wellness newsletter topics
3193377|NCT01244841|No Intervention|Standard care|Randomised to standard post MI care and length of hospital stay decided by treating physician.
3193378|NCT01244841|Active Comparator|Early discharge|Randomised patient where all post MI investigations, treatment, follow-up plans and information will be performed within 3 days, and the patients are thereafter discharged.
3193379|NCT01244828|Experimental|Asenapine|Asenapine 5 mg twice daily (BID) for the first week of treatment, then either 5 mg or 10 mg BID.
3193382|NCT01244815|Experimental|Asenapine 10.0 mg BID|Participants receive asenapine 2.5 mg BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. On Day 5 and 6 participants receive asenapine 5.0 mg BID. On Day 7 participants receive asenapine 5.0 mg in the morning and 10.0 mg in the evening. Participants receive asenapine 10.0 mg BID for the remainder of the 21-day treatment period.
3193383|NCT01244815|Placebo Comparator|Placebo|Participants receive placebo BID for 21 days.
3193384|NCT01244802||Group 1: 18 to 45 years of age|Between the ages of 18 and 45 at the time of yellow fever vaccination
3193385|NCT01244802||Group 2: 55 years of age and above|Aged 55 or greater at the time of yellow fever vaccination
3193386|NCT01244789|Active Comparator|Observation|postoperative observation only
3193387|NCT01244789|Experimental|Combination chemotherapy|postoperative 6 courses of 3 weekly iv carboplatin-paclitaxel combination chemotherapy
3193388|NCT01244776|Experimental|Acellular corneal matrix|
3193389|NCT01244763|Experimental|Experimental Drug|
3193390|NCT01244750||First line TKI treatment: Imatinib|Diagnosed CML patients who receive first line TKI treatment: Imatinib
3193391|NCT01244750||First line TKI treatment: Nilotinib|Diagnosed CML patients who receive first line TKI treatment: Nilotinib
3193392|NCT01244750||First line TKI treatment: Dasatinib|Diagnosed CML patients who receive first line TKI treatment: Dasatinib
3193393|NCT01244750||Imatinib treated patients|Imatinib treated patients if their study index date is between January 2, 2008 and September 30, 2010
3193394|NCT01244737|Experimental|New diagnosis of brain tumor|In children with a new diagnosis of central nervous system tumor, a PET scan will be performed using [18F] FLT.
3193395|NCT01244737|Experimental|Possible recurrent brain tumor|In children in whom there is concern for recurrent central nervous system tumor, a PET scan will be performed using [18F] PET.
3193396|NCT01244737|Experimental|Brain tumor response to chemotherapy|In children with a newly diagnosed central nervous system tumor who will be treated with post-operative chemotherapy, a PET scan will be performed using [18F] FLT before the start and after two cycles of chemotherapy.
3193397|NCT01244724|Experimental|Lexapro|escitalopram 10 mg or 20 mg/d
3193398|NCT01244711|Experimental|Quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
3193399|NCT01244698|Other|Antibiotics until Drain Removal|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil until the final drain is removed. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin.
3193400|NCT01244698|Experimental|Early discontinuation of antibiotics|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics.
3193401|NCT01244685|Active Comparator|probe|Patients in the 'goal-directed fluid' Lactated Ringers solution according to ideal body weight for the first 24 hours. The fluids will be changed after the first 24 hours and continued until the patient is tolerating a regular diet. The Deltex CardioQ esophageal probe will be evaluated every 15 minutes in the Post Anesthesia Care Unit (PACU) by the Anesthesia service. Stroke Volume (SV), Flow Time Corrected (FTc), and Peak Velocity (PV) will be measured. A short FTc (<330 ms) indicative of hypovolemia will receive a 3cc/kg fluid challenge with Lactated Ringers crystalloid solution over 5 minutes. A SV increase of >10% will receive a further 3cc/kg fluid challenge. A SV increase of <10% will not receive further fluid challenge.
3193402|NCT01244685|No Intervention|Standard Fluid|Patients in the 'standard fluid' group will receive Lactated Ringers solution for 24 hours post-operatively at 1 times maintenance rate according to ideal body weight. Then the fluids will be changed to physiologic maintenance with D5½NS at the same rate. Fluids will be decreased by ½ once the patient is tolerating a clear liquid diet, and then discontinued once the patient is tolerating a regular diet.
3193403|NCT01244672|Active Comparator|Trans-anal dearterialization|24 patients were assigned to the Transanal hemorrhoidal dearterialization with mucopexy arm, which is a Doppler guided procedure for suture ligation of hemorrhidal arteries rather than excisional
3193404|NCT01244672|Active Comparator|Ferguson|17 patients were randomized to Ferguson method, which is the operative gold standard for hemorrhoids. This is an excisional surgery.
3193405|NCT01244659|Experimental|Tacrolimus from EMS|Group 1: Tacrolimus from EMS + Myfortic® + Steroids
3193406|NCT01244659|Active Comparator|Prograf|Group 2: Prograf® + Myfortic® + Steroids
3193407|NCT01244646||1|Patients with Diabetes Mellitus Type 2
3193408|NCT01244633|Experimental|Ecopipam|Active treatment
3193409|NCT01244620|Experimental|Treatment A|sitaxsentan 100 mg QD for 6 days (Treatment A)
3193410|NCT01244620|Experimental|Treatment B|tadalafil 40 mg QD for 6 days
3193411|NCT01244620|Experimental|Treatment C|sitaxsentan 100 mg QD co-administered with tadalafil 40 mg QD for 6 days
3193412|NCT01244620|Experimental|Treatment D|sitaxsentan 100 mg QD co-administered with sildenafil 20 mg TID for 6 days
3193413|NCT01244607|Placebo Comparator|Placebo|
3193414|NCT01244607|Experimental|NI-0801|
3193415|NCT01244594|Experimental|High cadence, low resistance|Subjects in this arm will cycle with functional electrical stimulation at a higher cadence (speed) and a lower resistance.
3193416|NCT01244594|Experimental|Low cadence, high resistance|Subjects in this arm will cycle with functional electrical stimulation at a lower cadence (speed) and a higher resistance.
3193417|NCT01244581|Experimental|Amoxicillin-clavulanate|Oral amoxicillin-clavulanate 40 mg/kg/day divided in two daily doses for 7 days
3193418|NCT01244581|Placebo Comparator|Placebo|
3193419|NCT01244568|No Intervention|Usual care|
3193420|NCT01244568|Experimental|Prostate cancer treatment DESI|
3193421|NCT01244555|Experimental|Massage treatment|
3193422|NCT01244555|Experimental|Ultrasound|
3193423|NCT01244555|No Intervention|Wait-list|
3193424|NCT01244542|Experimental|Patients with schizophrenia|
3193425|NCT01244542|Active Comparator|Healthy controls|controls matched with patients on age, sex and education level
3193470|NCT01244217|Experimental|Age 2 - 11 years (and over 10.5 kg)|Patients between 2 and 11 years (and over 10.5 kg)
3193426|NCT01244529|Other|galy A Plus/ galy A / seno A|"Pair 1: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8)."
3193427|NCT01244529|Other|galy A Plus / seno A / galy A|"Pair 1: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 3: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
3193428|NCT01244529|Other|galy A / galy A Plus / seno A|"Pair 1: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8)."
3193429|NCT01244529|Other|galy A / seno A / galy A Plus|"Pair 1: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 3: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
3193430|NCT01244529|Other|seno A / galy A / glay A Plus|"Pair 1: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 2: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
3193431|NCT01244529|Other|seno A / galy A Plus / galy A|"Pair 1: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 2: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: galy A -subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
3193432|NCT01244516|Other|galyfilcon A|Subjects that were randomized to receive the galyfilcon A lens with a base curve of 8.30 throughout the entire course of the study.
3193433|NCT01244516|Other|lotrafilcon B|Subjects that were randomized to wear lotrafilcon B lens throughout the course of the study.
3193434|NCT01244516|Other|comfilcon A|Subjects that were randomized to wear comfilcon A lens throughout the course of the study.
3193435|NCT01244503|Experimental|Sodium Octanoate Breath Test|Only subjects with metabolic syndrome and suspected non alcoholic fatty liver disease will undergo breath test. They must not have any other liver disease.
3193436|NCT01244490|Experimental|Extended-release Guanfacine Hydrochloride|
3193437|NCT01244490|Other|Atomoxetine Hydrochloride|Active Reference
3193438|NCT01244490|Placebo Comparator|Placebo|
3193439|NCT01244477|Experimental|Arm 1: CPT-C Group|Participants in group CPT-C
3193440|NCT01244477|No Intervention|Arm 2: Waitlist Control Group|Participants randomly assigned to the Waitlist Control Group (who will participate in CPT-C after 12 weeks).
3193441|NCT01244464|Experimental|Study Group|
3193442|NCT01244438|Experimental|FP-1039|FP-1039
3193443|NCT01244425|Experimental|FS VH S/D 500 s-apr|Fibrin Sealant, Vapor Heated, Solvent/Detergent treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), not to exceed 20mL per participant. Hemostasis will be assessed at 4, 6, 8 and 10 minutes after application of the study treatment.
3193444|NCT01244425|Active Comparator|Manual compression - Control|A dry surgical gauze swab will be used to apply by hand an even light pressure onto the oozing resection surface of the liver. Hemostasis will be assessed at 4, 6, 8 and 10 minutes after application of the study treatment.
3193445|NCT01244386||Inflammatory bowel disease|Patients with inflammatory bowel disease requiring CT for clinical purposes will be studied.
3193446|NCT01244373||Patients with senile cataract|Patients with senile cataract
3193447|NCT01244360|Placebo Comparator|Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
3193448|NCT01244360|Active Comparator|Dietary Supplement: resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
3193449|NCT01244347|Experimental|folic acid 4 mg|
3193450|NCT01244347|Active Comparator|folic acid 0.4 mg|
3193451|NCT01244334|Active Comparator|Difluprednate Ophthalmic Emulsion 0.05%|
3193452|NCT01244334|Active Comparator|Prednisolone acetate suspension 0.1%|
3193453|NCT01244321||CoSeal Group|Subjects with indication for LVAD implantation, meeting the requirements for LVAD implantation. Patients for whom LVAD removal is anticipated not earlier than 6 weeks after LVAD implantation.
3193454|NCT01244321||CoSeal Control Group|Subjects who had a LVAD for more than 6 weeks.
3193455|NCT01244295|Experimental|Complicated Grief Treatment|Targeted psychotherapy for complicated grief
3193456|NCT01244295|Active Comparator|Interpersonal Therapy|Standard IPT is a comparator treatment
3193457|NCT01244282|Experimental|All Participants|fMRI studies with sensory stimulation in the presence of 0 mg, 250 mg, 350 mg, and 510 mg cumulative doses of ferumoxytol
3193458|NCT01244269|Experimental|Methylphenidate 10|Methylphenidate 10mg three times daily for a total of 7 doses.
3193459|NCT01244269|Placebo Comparator|Placebo 10|Placebo capsule three times daily for a total of 7 doses.
3193460|NCT01244269|Experimental|Methylpheindate 20|Methylphenidate 20mg three times daily for a total of 7 doses.
3193461|NCT01244269|Placebo Comparator|Placebo 20|Placebo capsule three times daily for a total of 7 doses.
3193462|NCT01244256|Experimental|Treatment with Clotrimazole + Gentamicin + Beclomethasone|
3193463|NCT01244256|Active Comparator|Treatment with Clotrimazole + Gentamicin|
3193464|NCT01244243|Experimental|Active therapy|All subjects receive the same active robotic therapy, there is no placebo arm, as a key goal of this study is to define predictors of response to active treatment.
3193465|NCT01244230|Experimental|Age 6 months - 2 years|Patients between 6 months and 2 years old - Type: Experimental
3193466|NCT01244230|Experimental|Age 2 - 11 years|Patients between 2 and 11 years (and under 10.5 kg)
3193467|NCT01244230|Experimental|Age 2 - 11 years (and over 10.5 kg)|Patients between 2 and 11 years (and over 10.5 kg)
3193468|NCT01244217|Experimental|Age 6 months - 2 years|Patients between 6 months and 2 years old
3193469|NCT01244217|Experimental|Age 2 - 11 years|Patients between 2 and 11 years (and under 10.5 kg)
3193474|NCT01244191|Active Comparator|Placebo and erlotinib|Tivantinib placebo given twice a day in combination with 150 mg of erlotinib, given once a day
3193475|NCT01244178|Experimental|Tight Glucose Control Hyperinsulinemic Group|
3193476|NCT01244178|Experimental|Non-Tight Glucose Control Hyperinsulinemic Group|
3193477|NCT01244178|Active Comparator|Standard Insulin Protocol Group|
3193478|NCT01244165|Other|Cytrix|Observational Study
3193479|NCT01244165|Other|Control Group|Patients with similar indications who were treated at the same centers using other products
3193480|NCT01244152|Experimental|Intervention|
3193481|NCT01244152|Active Comparator|Control Group|
3193482|NCT01244139|Experimental|Active study drug|Treatment
3193483|NCT01244139|Experimental|Comparator|Dummy drug
3193484|NCT01244126|Active Comparator|IM morphine|0.1 mg/kg morphine IM
3193485|NCT01244126|Active Comparator|IV morphine|0.1 mg/kg morphine IV
3193486|NCT01244126|Active Comparator|fentanyl IN|Intranasal fentanyl 2 mcg/kg IN
3193487|NCT01244100|Experimental|PL2200|
3193488|NCT01244074|Experimental|biofeedback|
3193489|NCT01244061|Experimental|Varenicline|
3193490|NCT01244061|Placebo Comparator|Placebo|
3193491|NCT01244035|Experimental|Part I - Sequence ABC|Treatment A in Period 1, Treatment B in Period 2, and Treatment C in Period 3
3193492|NCT01244035|Experimental|Part I - Sequence ACB|Treatment A in Period 1, Treatment C in Period 2, and Treatment B in Period 3
3193493|NCT01244035|Experimental|Part I - Sequence BCA|Treatment B in Period 1, Treatment C in Period 2, and Treatment A in Period 3
3193494|NCT01244035|Experimental|Part I - Sequence BAC|Treatment B in Period 1, Treatment A in Period 2, and Treatment C in Period 3
3193495|NCT01244035|Experimental|Part I - Sequence CAB|Treatment C in Period 1, Treatment A in Period 2, and Treatment B in Period 3
3193496|NCT01244035|Experimental|Part I - Sequence CBA|Treatment C in Period 1, Treatment B in Period 2, and Treatment A in Period 3
3193497|NCT01244035|Experimental|Part II - Sequence DEF|Treatment D in Period 1, Treatment E in Period 2, and Treatment F in Period 3
3193498|NCT01244035|Experimental|Part II - Sequence DFE|Treatment D in Period 1, Treatment F in Period 2, and Treatment E in Period 3
3193499|NCT01244035|Experimental|Part II - Sequence EFD|Treatment E in Period 1, Treatment F in Period 2, and Treatment D in Period 3
3193500|NCT01244035|Experimental|Part II - Sequence EDF|Treatment E in Period 1, Treatment D in Period 2, and Treatment F in Period 3
3193501|NCT01244035|Experimental|Part II - Sequence FDE|Treatment F in Period 1, Treatment D in Period 2, and Treatment E in Period 3
3193502|NCT01244035|Experimental|Part II -Sequence FED|Treatment F in Period 1, Treatment E in Period 2, and Treatment D in Period 3
3193503|NCT01244022||Colorectal cancer patients|Patients with pathohistologically verified colorectal cancer or adenoma with epithelial dysplasia
3193504|NCT01244009|Experimental|MK-4827|All Participants
3193505|NCT01243996|Experimental|Infant treated with high dose ibuprofen|
3193506|NCT01243983|Experimental|LX211|
3193507|NCT01243983|Placebo Comparator|Placebo|
3193508|NCT01243970|Active Comparator|phenylephrine infusion|
3193509|NCT01243970|Active Comparator|Ephedrine infusion|
3193510|NCT01243957|Experimental|LY2216684 + fluoxetine|"LY2216684: 18 mg, oral, daily on days 1, 2, and 3 and days 25-27~Fluoxetine: 60 mg, oral, daily for 7 days (days 4 -10) then 20 mg, daily for 17 days (days 11-27)"
3193511|NCT01243944|Experimental|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg once a day (QD) to 25 mg BID based on safety and efficacy
3193512|NCT01243944|Other|Best Available Therapy|Best Available Therapy (BAT) will be selected by the Investigator for each subject. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
3193513|NCT01243931|Experimental|Surgery|OCT is assisting in surgery guidance.
3193514|NCT01243918|Experimental|VNI/Optiflow, Immunodeficient patients|VNI = non invasive ventilation
3193515|NCT01243918|Experimental|Optiflow/VNI, Immunodeficient patients|VNI = non invasive ventilation
3193516|NCT01243918|Experimental|Ospal/Optiflow, Immunocompetent patients|
3193517|NCT01243918|Experimental|Optiflow/Ospal, Immunocompetent patients|
3193518|NCT01243905|Active Comparator|Family psychoeducation plus TAU|Family psychoeducational therapy in addition to treatment as usual for the child (TAU)
3193519|NCT01243905|Placebo Comparator|Treatment as usual|Treatment as usual for the child (TAU)
3193520|NCT01243892||Cohort 1: IGHD participants|Isolated growth hormone deficient (IGHD) participants who initiated somatropin (Deoxyribonucleic acid [DNA] origin) (recombinant human growth hormone [rhGH]) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
3193521|NCT01243892||Cohort 2: ISS participants|Idiopathic short stature (ISS) participants who initiated somatropin (DNA origin) (rhGH) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
3193522|NCT01243879|No Intervention|Fasting with stimuli|Fasting in the presence of food-related stimuli
3193523|NCT01243879|No Intervention|Fasting without stimuli|Fasting in the absence of food-related stimuli
3193524|NCT01243866|Experimental|Early treatment|comprehensive dental treatment
3193525|NCT01243866|No Intervention|Regualr treatment|Regular treatment consisted of children who would be on a waiting list for regular dental treatment at KFAFH for at least 8 months
3193526|NCT01243853|Active Comparator|Alpha-galactosidase|
3193527|NCT01243853|Placebo Comparator|Placebo|
3193528|NCT01243827|Experimental|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP <140/90 mmHg.
3193610|NCT01243177|Active Comparator|Carbamazepine-Controlled Release (CBZ-CR)|
3193529|NCT01243827|Experimental|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP <140/90 mmHg.
3193530|NCT01243814|Active Comparator|supartz|active intervention arm
3193531|NCT01243814|Placebo Comparator|saline injection|placebo intervention arm
3193532|NCT01243801|Active Comparator|Epidural ketamine|"Bolus of epidural ketamine during the induction of anesthesia~Epidural infusion of ketamine during the first 48 h after surgery~Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine and fentanyl"
3193533|NCT01243801|Active Comparator|Intravenous ketamine|"Bolus of intravenous ketamine administered during the induction of anesthesia~Intravenous infusion during the first 48 hours after surgery~Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine plus fentanyl"
3193534|NCT01243801|Placebo Comparator|Placebo|"Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine and fentanyl"
3193535|NCT01243788|Active Comparator|Ipratropium/Albuterol|Ipratropium/Albuterol 36/206ug QID
3193536|NCT01243775|Experimental|Belotaxel plus Belloxa|Belotaxel 60 mg/m2 3 weekly (day 1) Belloxa 70 mg/m2 3 weekly (day 2)
3193537|NCT01243762|Experimental|Dalotuzumab 7.5 mg/kg + MK-0752 1800 mg|Participants in Part 1 of the study receive dalotuzumab 7.5 mg/kg intravenously (IV) weekly + MK-0752 1800 mg orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy.
3193538|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-0752 1800 mg|Participants in Parts 1 and 2 of the study receive dalotuzumab 10 mg/kg IV weekly + MK-0752 1800 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
3193539|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 90 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK-2206 90 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
3193540|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 135 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 135 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
3193541|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 150 mg|Participants in Parts 1 and 2 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 150 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
3193542|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 200 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 200 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
3193543|NCT01243762|Experimental|Dalotuzumab + Ridaforolimus|Participants in Part 2 of the study receive dalotuzumab 10 mg/kg IV weekly + ridaforolimus 20 mg PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy.
3193544|NCT01243736|No Intervention|Standard prep|One group will receive the standard bowel preparation, which consists of eating no solid foods after 7 p.m. the evening prior to the capsule endoscopy test and being able to consume clear liquids up to 4 hours prior to the capsule endoscopy test
3193545|NCT01243736|Active Comparator|Combination Prep|"The other group will receive the combination bowel preparation, which consists of taking the standard bowel preparation plus:~drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~lying on your right side for 30 minutes following the swallowing of the capsule endoscope."
3193546|NCT01243723|Experimental|Eductyl suppository|
3193547|NCT01243723|Placebo Comparator|Placebo suppository|
3193548|NCT01243710|Experimental|Taurolidine with heparin|
3193549|NCT01243710|Active Comparator|Heparin|
3193550|NCT01243697|Experimental|desogestrel|Tablets of 75 µg, once daily during 112 days
3193551|NCT01243684|Active Comparator|Healty volunteers|
3193552|NCT01243684|Experimental|Patients|
3193553|NCT01243671|Experimental|Adalimumab|Adalimumab 160 mg at Week 0, 80 mg at Week 2 and 40 mg every other week (eow) starting at Week 4 to Week 50, subcutaneous injection. After Week 52, participants could continue the treatment with 40 mg eow until the day before approval of adalimumab for intestinal Behçet's disease in Japan.
3193554|NCT01243658|Experimental|Oxytocin|Oxytocin
3193555|NCT01243658|Placebo Comparator|Placebo|Placebo
3193556|NCT01243619|Experimental|FLT PET|This is a single arm trial, in which all patients receive three FDG-PET scans and three FLT-PET scans, before, during and after pre-operative chemoradiation for esophageal cancer.
3193557|NCT01243606|Experimental|Single Diagnosis Treatment Protocols|Four disorder-specific cognitive-behavioral treatments will be conducted in accordance with treatment manuals of demonstrated efficacy. SDPs will be matched to the principal anxiety disorder diagnosis.
3193558|NCT01243606|Experimental|Unified Protocol|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders will be individually administered in accordance with a treatment protocol.
3193559|NCT01243606|No Intervention|Waitlist Control|Waitlist participants will not receive treatment during a 16-week waitlist period, but will receive the treatment of their choice immediately following the 16 week waiting period.
3193560|NCT01243593|Experimental|Treatment Group|
3193561|NCT01243593|Active Comparator|Control Group|
3193562|NCT01243580|Active Comparator|Ortho-Cyclen®|Ortho-Cyclen® is a comparator drug intervention
3193563|NCT01243580|Experimental|AG200-15|AG200-15 is an investigational transdermal contraceptive delivery system that is a drug intervention
3193564|NCT01243567|Active Comparator|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
3193565|NCT01243567|Active Comparator|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
3193611|NCT01243164|Experimental|Wheelchair Skills Training Program|A standardized wheelchair skills training program to teach 32 specific wheelchair skills.
3193612|NCT01243151|Placebo Comparator|A|
3193613|NCT01243151|Experimental|B|
3193614|NCT01243151|Experimental|C|
3193615|NCT01243151|Experimental|D|
3193616|NCT01243151|Experimental|E|
3193617|NCT01243125|Experimental|NVC-422|
3193566|NCT01243554|Experimental|Exercise training|Supervised exercise training at the hospital during pregnancy: the women will attend at least 2 weekly sessions consisting of aerobic exercise (walking on treadmills), strength training (for upper body, back, abdomen and legs) as well as pelvic floor muscle exercises. Each session is 60 minutes and lead by a physiotherapist or experienced exercise physiologist. The women will also go through motivational interviewing sessions throughout the intervention period and are encouraged to do home exercise training in addition to the exercise at the hospital
3193567|NCT01243554|No Intervention|Control|Usual care as provided by the health services in Norway. The investigators will not advice the women to be inactive
3193568|NCT01243541|Experimental|Arm I|Patients wear an Elasto-Gel cold glove and sock on their dominant hand and foot every two weeks on days the patient is scheduled for paclitaxel.The glove and sock is worn for 15 minutes prior to paclitaxel infusion, 3 hours during treatment, and for 15 minutes after completion of chemotherapy for a total of 210 minutes.
3193569|NCT01243541|Experimental|Arm II|Patients wear an Elasto-Gel cold glove and sock on their non-dominant hand and foot every two weeks on days the patient is scheduled for paclitaxel. The glove and sock is worn for 15 minutes prior to paclitaxel infusion, 3 hours during treatment, and for 15 minutes after completion of chemotherapy for a total of 210 minutes.
3193570|NCT01243528||Patients in neurological rehabilitation|Patients suffering from a neurological disease
3193571|NCT01243515||Chronic Kidney Disease|minimum 7 subjects (male and female)
3193572|NCT01243515||Healthy subjects|minimum 3 subjects (male and female)
3193573|NCT01243502|Experimental|0.01% CT327 (or placebo)|Six (of eight) subjects received a single topical dose of 0.01% CT327 followed by a 7 day wash-out period. The subjects then received a single topical dose of CT327 on five consecutive days. Two subjects received placebo.
3193574|NCT01243502|Experimental|0.001% CT327 (or placebo)|Six (of eight) subjects received a single topical dose of 0.001% CT327 followed by a 7 day wash-out period. The subjects then received a single topical dose of CT327 on five consecutive days. Two subjects received placebo.
3193575|NCT01243489|Other|patient diary|compliance supporting measure: patients uses patient diary from month 6 to 12
3193576|NCT01243489|Other|"Information service Leben mit CML"|"compliance supporting measure: patient uses the Information service Leben mit CML"
3193577|NCT01243476|Experimental|lenalidomide|Experimental treatment branch with Lenalidomide 5 mg/day (oral use)
3193578|NCT01243476|Placebo Comparator|placebo|Placebo branch (oral use)
3193579|NCT01243450|Active Comparator|Active generic|Treatment of acne for 12 weeks with generic tretinoin
3193580|NCT01243450|Placebo Comparator|Placebo|Treatment of acne for 12 weeks with Placebo
3193581|NCT01243450|Active Comparator|Brand|Treatment of acne over 12 weeks with tretinoin Brand
3193582|NCT01243437|Experimental|ciprofloxacin|
3193583|NCT01243437|Active Comparator|doxycycline|
3193584|NCT01243424|Experimental|linagliptin|patient to receive linagliptin or glimepiride placebo overencapsulated tablet QD
3193585|NCT01243424|Active Comparator|glimepiride 1-4 mg QD|patient to receive glimepiride 1-4 mg or linagliptin placebo tablet QD
3193586|NCT01243411|Experimental|AA4500|collagenase clostridium histolyticum
3193587|NCT01243398|Experimental|Gefitinib 500mg once daily|Gefitinib 500mg once daily
3193588|NCT01243398|Placebo Comparator|Placebo|Gefitinib 500mg once daily
3193589|NCT01243385|Other|Metformin|Metformin at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
3193590|NCT01243372||Correlative (BRAF V600E mutation analysis)|Previously collected formalin-fixed and paraffin-embedded baseline tumor samples are analyzed for BRAF V600E mutation. Mutation status is correlated with clinical response and outcome data from patients enrolled on CALGB-C80405.
3193591|NCT01243359|Experimental|Treatment (sunitinib malate, bevacizumab)|Patients receive sunitinib malate PO on days 1-28 and bevacizumab IV over 30-90 minutes on day 29. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3193592|NCT01243346|Experimental|Crenolanib (CP-868,596)|
3193593|NCT01243333|Experimental|Diagnostic (multi-tracer PET scans)|Patients undergo PET scans with fludeoxyglucose F 18, fluorine F 18 fluorothymidine, and water O-15 tracers at baseline and within 7 days of completion of 1 or 2 (if the course is less than 3 weeks) therapeutic agent courses.
3193594|NCT01243320|Experimental|10ppm Oral Silver|Oral Dose of 10ppm
3193595|NCT01243320|Experimental|32ppm Oral Silver|Oral Dose of 32ppm
3193596|NCT01243307|Experimental|CT327 treatment period 1|Subjects in Group 1 will receive CT327 during treatment/testing period 1 and placebo during treatment/testing period 2
3193597|NCT01243307|Experimental|CT327 treatment period 2|Subjects in Group 2 will receive placebo during treatment/testing period 1 and CT327 during treatment/testing period 2
3193598|NCT01243294|Active Comparator|SenSura|"CE marked and launched (The letters CE do not represent any specific words, though may have initially stood for Communauté Européenne (European Community) or Conformité Européenne (European Conformity). By affixing the CE marking to a product, the manufacturer declares that it meets EU safety and health and environmental requirements."
3193599|NCT01243294|Active Comparator|New ostomy appliance (SS)|SS = New ostomy appliance. Due to company confidentiality the product is just called SS and this is not short for any other names.
3193600|NCT01243281|Active Comparator|drug combination|
3193601|NCT01243268||Patients with essential hypertension|
3193602|NCT01243255||1|Patients with hypercholesterolemia on lipid lowering pharmacological treatment
3193603|NCT01243242|Experimental|METADOXINE|Eligible subjects will be randomly assigned to receive MG01CI (1,400 mg)
3193604|NCT01243242|Placebo Comparator|Placebo|Eligible subjects will be randomly assigned to receive Placebo (1,400 mg)
3193605|NCT01243216|Experimental|Ultrasound Group|Patients in the Ultrasound Group will have a pre-procedure ultrasound of the spine prior to needle placement
3193606|NCT01243216|No Intervention|No Ultrasound Group|Patients in the No Ultrasound Group will not have a pre-procedure ultrasound of the spine performed prior to needle placement.
3193607|NCT01243203|Placebo Comparator|Placebo|patient will receive placebo pills
3193608|NCT01243190|Experimental|Ofatumumab|Loading dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).
3193609|NCT01243177|Experimental|Lacosamide|
3193620|NCT01243112|Experimental|Bupivacaine with epi|0.2 ml 0.25% Bupivacaine with epinephrine (1:200,000)
3193621|NCT01243112|Experimental|Low dose Lido and Bupi w/ Epi|0.2ml 0.5% Lidocaine + 0.125% Bupivacaine with Epinephrine (1:150,000)
3193622|NCT01243112|Experimental|High Dose Lido and Bupi with epi|0.2ml 1% Lidocaine + 0.25% Bupivacaine with Epinephrine (1:150,000)
3193623|NCT01243099||In-stent (BMS) restenosis|
3193624|NCT01243099||De-novo coronary lesion|
3193625|NCT01243086|Placebo Comparator|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
3193626|NCT01243086|Active Comparator|Ranibizumab and OZURDEX|Recent research has discovered that persons with wet or dry ARMD show an immune response, as if the body is fighting off an infection. The body creates a complex immune response to the growth of blood vessels into the eye tissue, which triggers side effects. It is believed that preventing this inflammation can lead to greater visual gains and a need for fewer treatment injections. Animal studies have shown that Triamcinolone Acetonide, a corticosteroid (class of drugs that reduce inflammation) can prevent damage to vision from this inflammation. The hypothesis is that treatment with both Ranibizumab and OZURDEX will allow even greater vision improvements than Ranibizumab treatment alone for wet age-related macular degeneration.
3193627|NCT01243073|Experimental|imetelstat|Induction dosing of 9.4 mg/kg weekly, followed by intermittent maintenance dosing.
3193628|NCT01243060|Experimental|Almorexant 100mg|Subjects will receive a one-time dose of Almorexant 100mg.
3193629|NCT01243060|Experimental|Almorexant 200mg|Subjects will receive a one-time dose of Almorexant 200mg.
3193630|NCT01243060|Active Comparator|Zolpidem|Subjects will receive a one-time dose of Zolpidem 10mg.
3193631|NCT01243060|Placebo Comparator|Placebo|Subjects will receive a one-time dose of Placebo.
3193632|NCT01243047|Active Comparator|Arm A|Continuous erlotinib administration (21-day cycle). Erlotinib dose given at 100mg daily
3193633|NCT01243047|Active Comparator|Arm B|Intermittent erlotinib administration (21-day cycle). Erlotinib dose given at 150mg.
3193634|NCT01242995||pancreatobiliary disorders/thin scope|All patients will be evaluated with cholangioscopy and/or pancreatoscopy using the thin scope.
3193635|NCT01242982|Experimental|Operation|Closed reduction and operated for fixation with 2 antegrade intramedullary Kirschner wires.
3193636|NCT01242982|Active Comparator|Conservative treatment|Treated conservatively with reduction and then Plaster of Paris.
3193637|NCT01242956|Experimental|Verum group|video-based training after stroke
3193638|NCT01242956|Placebo Comparator|Placebo group|non-video group
3193639|NCT01242943|Experimental|L19SIP I131|"Phase I: Multicentre, open-label, two-step single-arm dose escalation study in sequential cohorts of patients with cancer.~Phase II: Prospective, open-label, single-arm, multicentre study of 131I-L19SIP, given at the RD as determined in phase I."
3193640|NCT01242930|Experimental|Imetelstat (7.5 mg/kg)|Imetelstat (7.5 mg/kg) with or without lenalidomide standard of care
3193641|NCT01242930|Experimental|Imetelstat (9.4 mg/kg)|Imetelstat (9.4 mg/kg) with or without lenalidomide standard of care
3193642|NCT01242917|Placebo Comparator|Placebo|
3193643|NCT01242917|Experimental|CCX354-C 100mg twice daily|
3193644|NCT01242917|Experimental|CCX354-C 200mg once daily|
3193645|NCT01242904|Experimental|bimodal solution|200 mls of 30% glucose in sterile water is added by the patient to the usual icodextrin day dwell, to create the bimodal solution intraperitoneally
3193646|NCT01242904|Active Comparator|icodextrin|200 mls of icodextrin is added by the patient to the usual icodextrin day dwell
3193647|NCT01242878||healthy volunteers|ethnically matched people who do not have sickle cell disease
3193648|NCT01242878||patients|sickle cell disease patients
3193649|NCT01242865|Other|Attention and Interpretation Therapy|
3193650|NCT01242852|Experimental|Additional diagnostic tests|Participants in the experimental arm will undergo standard hysteroscopy with treatment-on-the spot of predefined intrauterine abnormalities. In two of the participating clinics, also a 'Saline Infusion Sonography' (SIS) will be performed, 1 week before the hysteroscopy. After the additional diagnostic test(s), standard IVF/ICSI treatment will be initiated.
3193651|NCT01242852|No Intervention|Routine fertility workup|Patients allocated to the conventional strategy will be scheduled for IVF and undergo standard treatment, without SIS or hysteroscopy.
3193652|NCT01242839|Experimental|CACICOL20|Arm that receives CACICOL20 treatment each 2 days for 3 months/until closure of the ulcer
3193653|NCT01242839|Placebo Comparator|Placebo|The placebo is applicated each 2 days on patient cornea for 3 months/ until ulcer closure.
3193654|NCT01242839|Experimental|CACICOL20 and Placebo|Patient applies the treatment each 2 days for 3 months or until closure of the ulcer. This treatment is alternatively CACICOL20 or Placebo : so the patient receives CACICOL20 each 4 days. CACICOL20 and placebo strips are strictly similar and cannot be identified.
3193655|NCT01242826|Experimental|A|
3193656|NCT01242813|Experimental|Canakinumab|This was an open-label, single treatment arm, multicenter study of monthly canakinumab 150 mg (2 mg/kg for patient ≤ 40 kg) subcutaneous injections in patients with active recurrent or chronic TRAPS.
3193657|NCT01242800|Active Comparator|Arm I|Patients receive standard palliative therapy, if needed, to address symptoms such as tumor ulceration, pain, bulky adenopathy causing arm symptoms, and other similar situations. Therapy may consist of radiotherapy alone, surgery alone, or a combination of both.
3193658|NCT01242800|Experimental|Arm II|Patients undergo surgery comprising breast-conserving therapy (BCT) or total mastectomy according to patient and treating physician preference. Free surgical margins must be achieved with re-excision or mastectomy for patients undergoing BCT. After completion of BCT, patients undergo radiotherapy once a day, 5 days per week. Patients who had mastectomy undergo radiotherapy at the discretion of treating physician.
3193659|NCT01242787|Active Comparator|Entecavir 0.5 mg|Entecavir 0.5 mg
3193660|NCT01242787|Experimental|LB80380|Optimal dose of LB80380 (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)
3193661|NCT01242774|Experimental|Panobinostat|
3193662|NCT01242761||Symptomatic rotator cuff tear|Patients with symptomatic rotator cuff tears presenting to hospital clinic after having ultrasound exam in community with indications for surgery
3193663|NCT01242748|Experimental|Degarelix 240 mg/480 mg|
3193664|NCT01242748|Active Comparator|Goserelin acetate|
3193665|NCT01242735|Experimental|Exercise|12-week moderate-intensity behavioral exercise intervention (AE)
3193666|NCT01242735|Active Comparator|Health and Wellness|12-week health and wellness education control (HEC)
3193667|NCT01242722||1|Two experimental and/or intervention groups under 1 arm.
3193668|NCT01242696||Coronary artery stenting|All subjects who are candidates for coronary artery stenting, signed the Informed Consent Form and are eligible to receive a TAXUS Element stent will be evaluated for enrollment in this study.
3193669|NCT01242683|Experimental|Case-Management for Behavior Change|Individual and group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator. 12 month of intensive intervention followed by 12 months of maintenance intervention.
3193670|NCT01242683|Experimental|Case-Management plus Home Visits|Community health worker lifestyle support for weight loss strategies conducted in participants' homes and neighborhood. Also, receive individual and group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator. 12 month of intensive intervention followed by 12 months of maintenance intervention.
3193671|NCT01242683|Placebo Comparator|Usual Primary Care|Continuation of usual primary care managed by the participants' usual physician or nurse practitioner source of care.
3193672|NCT01242670|Experimental|Ross River Virus Vaccine|Subjects will be randomized in equal numbers (1:1:1) to receive one of three different lots of the vaccine on Day 1, Day 22 and Day 181. (The study is blinded with regard to which vaccine lot is administered to a subject but all subjects will receive 3 injections with a 2.5 µg aluminum hydroxide adjuvanted dose of RRV vaccine.)
3193673|NCT01242657|No Intervention|Brief Advice|Standard of care arm with no intervention; includes standard communication regarding youth tobacco cessation such as a brief discussion and printed materials
3193674|NCT01242657|Active Comparator|Not On Tobacco (N-O-T) Program|Teens randomized to this arm participated in the N-O-T program, a proven teen cessation program.
3193675|NCT01242657|Experimental|Quit & Fit|Teens randomized to this arm participated in the Not On Tobacco (N-O-T) program with an added physical activity module.
3193676|NCT01242644|Experimental|pain pump , injectable medication|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour;
3193677|NCT01242644|Active Comparator|saline pain pump , injectable medication|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline administered at 4 mL/hour
3193678|NCT01242644|Active Comparator|injectable medication only|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected and no pain pump.
3193679|NCT01242631|Experimental|Everolimus 10 mg daily|
3193680|NCT01242618|Experimental|engineered nasal cartilage graft|Biological intervention: autologous nasal chondrocytes expanded in vitro and cultured in a collagen Type I/III scaffold
3193681|NCT01242605|Experimental|single armed|This is not a randomised trial, there is only one study group. All patients will receive cisplatin/gemcitabine chemotherapy in addition to oral daily dosing of selumetinib
3193682|NCT01242592|Experimental|Homeopathy|
3193683|NCT01242592|Placebo Comparator|Placebo|
3193684|NCT01242579|Active Comparator|Maraviroc Vaginal Gel|Drug: Maraviroc dosage form: vaginal gel dosage: 2.5g frequency: once daily duration: 11 days
3193685|NCT01242579|Active Comparator|Dapivirine Vaginal Gel|Drug: Dapivirine dosage form: vaginal gel dosage: 2.5g dapivirine frequency: once daily duration: 11 days
3193686|NCT01242579|Placebo Comparator|Matching Placebo Gel|Drug: placebo dosage form: vaginal gel dosage: 2.5g placebo frequency: once daily duration: 11 days
3193687|NCT01242579|Experimental|Maraviroc/Dapivirine Gel|Drug: Maraviroc/Dapivirine dosage form: combination vaginal gel dosage: 2.5g - Maraviroc 0.1%, Dapivirine 0.05% frequency: once daily duration: 11 days
3193688|NCT01242566|Experimental|temozolomide|Administration of temozolomide 150-200 mg/m2/day for 5 consecutive days every 4 weeks for a maximum of 12 cycles or until disease progression or prohibited toxicity
3193689|NCT01242553||Normal|Normal results from clinical exam and free of ocular pathology.
3193690|NCT01242553||Retina|Clinical exam results consistent with retina pathology
3193691|NCT01242553||Glaucoma|Clinical exam results consistent with glaucoma and visual field defects consistent with glaucoma.
3193692|NCT01242553||Cornea|Clinical exam results consistent with cornea pathology.
3193693|NCT01242527|Placebo Comparator|placebo|
3193694|NCT01242527|Experimental|Epanova 2 g|
3193695|NCT01242527|Experimental|Epanova 3 g|
3193696|NCT01242527|Experimental|Epanova 4 g|
3193697|NCT01242514|Experimental|A|Oral treatment
3193698|NCT01242514|Experimental|B|Oral treatment
3193699|NCT01242514|Experimental|C|Oral treatment
3193700|NCT01242501|Experimental|60 Min. Risk Reduction Counseling|Single 60 min theory-based counseling session delivered in STI clinic setting in Cape Town South Africa.
3193701|NCT01242501|Active Comparator|20-min single session education|Single brief HIV/STI education only session for men and women receiving sexually transmitted infection clinic services in South Africa.
3193702|NCT01242488|Experimental|CDP6038 60 mg sc every 2 weeks plus methotrexate|
3193703|NCT01242488|Experimental|CDP6038 60 mg sc every 4 weeks plus methotrexate|
3193704|NCT01242488|Experimental|CDP6038 120 mg sc every 2 weeks plus methotrexate|
3193705|NCT01242488|Experimental|CDP6038 120 mg sc every 4 weeks plus methotrexate|
3193706|NCT01242488|Experimental|CDP6038 240 mg sc every 2 weeks plus methotrexate|
3193707|NCT01242488|Experimental|CDP6038 240 mg sc every 4 weeks plus methotrexate|
3193708|NCT01242488|Active Comparator|Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate|
3193709|NCT01242488|Placebo Comparator|Placebo sc every 2 weeks plus methotrexate|
3193710|NCT01242488|Placebo Comparator|Placebo sc every 4 weeks plus methotrexate|
3193762|NCT01242085|Active Comparator|control group|control group will have standard instrumentation of their knee replacement
3193711|NCT01242475|Experimental|0.1µg/0.1 mL C-Tb|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
3193712|NCT01242475|Active Comparator|2TU Tuberculin PPD RT 23 SSI|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
3193713|NCT01242462|Active Comparator|AB|2 hours of treatment with conventional ventilation strategy, then crossover to 2 hours of treatment with mid-frequency ventilation strategy
3193714|NCT01242462|Active Comparator|BA|2 hours of treatment with mid-frequency ventilation strategy, then crossover to 2 hours of treatment with conventional ventilation strategy
3193715|NCT01242423|Experimental|superficial 2nd degree burn|Group A (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who have sustained a superficial 2nd degree burn on ≥1% and ≤30% of the surface of the body.
3193716|NCT01242423|Experimental|deep 2nd degree burn|Group B (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who have sustained a deep 2nd degree burn on ≥1% and ≤30% of the surface of the body.
3193717|NCT01242423|Experimental|skin excision for the purpose of a skin graft|Group C (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of BBS.
3193718|NCT01242410|No Intervention|Expectant Management|
3193719|NCT01242410|Experimental|Placement of cervical pessary since 23 weeks until 37 weeks|
3193720|NCT01242397|Other|CRT ON|After implant, patients will be randomized to CRT pacing ON vs OFF in crossover fashion with 3 months in each period
3193721|NCT01242397|Other|CRT- OFF|After implant, patients will be randomized to CRT pacing OFF vs ON in crossover fashion with 3 months in each period
3193722|NCT01242384|No Intervention|Expectant Management|
3193723|NCT01242384|Experimental|Placement of cervical pessary since 23 weeks until 37 weeks|
3193724|NCT01242371|Active Comparator|Probiotic Supplement|Probiotic supplement 1 tablet by mouth daily for 14 weeks after 2 week placebo run-in
3193725|NCT01242371|Placebo Comparator|Identical-appearing Placebo|Identical appearing placebo 1 tablet by mouth daily for 14 weeks after 2 week placebo run-in
3193726|NCT01242358|Experimental|Capnography|Arm with capnographic monitoring
3193727|NCT01242358|Placebo Comparator|Standard monitoring|Standard monitoring
3193728|NCT01242345|No Intervention|No Intervention|Standard monitoring.
3193729|NCT01242345|Experimental|Capnography|Arm with capnographic monitoring
3193730|NCT01242332|No Intervention|placebo|po 2 hrs before surgery
3193731|NCT01242332|Experimental|Pregabalin|75 mg po 2 hrs before surgery
3193732|NCT01242319||Multi-modal practice intervention|15 intervention practices receive academic detailing, patient activation computer kiosk, decision supported PDA, and coronary risk factor management toolbox
3193733|NCT01242319||Usual care|15 practices receive academic detailing reviewing the ATP III cholesterol management guidelines
3193734|NCT01242306|Placebo Comparator|BMS arm|bare metal stent arm
3193735|NCT01242306|Active Comparator|SES arm|sirolimus eluting stent arm
3193736|NCT01242293|Active Comparator|0.9% Saline with glucose 5%|rate of infusion is 125cc/h
3193737|NCT01242293|Active Comparator|Ringer lactate|rate of infusion is 250cc/h
3193738|NCT01242293|Active Comparator|Ringer lactate - Controls|rate of infusion is 125cc/h
3193739|NCT01242280|Active Comparator|Self-expandable esophageal stent|"The patient will receive a self-expandable esophageal stent (SX-Ella-Danis) without endoscopical guidance but under slight sedation. An immediate X-ray will be done to assess the correct placement of the stent.~After a maximum of 7 days, the stent will be removed by using the specifically designed devices."
3193740|NCT01242280|Active Comparator|Sengstaken-Blakemore tube|The esophageal tamponade will be done as described elsewhere. The gastric content will be checked hourly and the correct placement of the tube will be checked by an immediate X-ray. The esophageal balloon will be inflated a maximum of 24 hours.
3193741|NCT01242267|Other|Thalidomide with melphalan|Safety/Efficacy -
3193742|NCT01242254|Experimental|Group A|Patients will receive an intravitreal injection of KH902 0.5mg/eye/time monthly, after 3-time treatment patients will go on an as needed (PRN) dosing phase till week 52
3193743|NCT01242254|Experimental|Group B|Patients will receive an intravitreal injection of KH902 2.0mg/eye/time monthly, after 3-time treatment patients will go on an as needed (PRN) dosing phase till week 52
3193744|NCT01242241|Other|Non-obese|Non-obese children categorized as those with a body mass index(BMI)between 25-84th percentile
3193745|NCT01242241|Active Comparator|Obese children|Obese children are categorized as those with a body mass index >95th percentile
3193746|NCT01242228|Experimental|ASP group|Concomitant administration of ASP1941 and DPP-4 inhibitor
3193747|NCT01242215|Experimental|ASP group|ASP1941 and sulfonylurea
3193748|NCT01242215|Placebo Comparator|Placebo group|placebo and sulfonylurea
3193749|NCT01242202|Experimental|ASP group|Concomitant administration of ASP1941 and α- glucosidase inhibitor
3193750|NCT01242176|Experimental|BI 10773 Final Formulation|one single film-coated tablet in the morning
3193751|NCT01242176|Experimental|BI 10773 XX Trial Formulation 2|one single dose tablet in the morning
3193752|NCT01242150|Experimental|NCPAP Helmet|Infants with mild Acute Respiratory Failure who need NCPAP
3193753|NCT01242150|Active Comparator|NCPAP facial mask|Infants with mild Acute Respiratory failure who need NCPAP
3193754|NCT01242137||Extensive metabolizers|
3193755|NCT01242137||Intermediate mtabolizers|
3193756|NCT01242137||Poor metabolizers|
3193757|NCT01242124|Experimental|side-to-side stapled esophagogastric anastomosis arm|
3193758|NCT01242124|Active Comparator|circular-stapled esophagogastric anastomosis arm|
3193759|NCT01242111|Experimental|BMN 110|
3193760|NCT01242098||Fostair switch cohort|Seretide patients who, at an index date, had a step down in therapy (reduction in ICS dose of ≥50%) and switch to Fostair
3193761|NCT01242098||Seretide continuation cohort|Seretide patients who, at an index date, had a step down in therapy (reduction in ICS dose of ≥50%) and continue on Seretide
3193763|NCT01242085|Experimental|trumatch group|the trumatch patient will have custom instruments made from preop CT scans
3193764|NCT01242072|Experimental|PaCE|Palifosfamide, Carboplatin and Etoposide
3193765|NCT01242059|Experimental|Control Tomato Soup|
3193766|NCT01242059|Experimental|10 g of yellow pea fiber|
3193767|NCT01242059|Experimental|20 g of yellow pea fiber|
3193768|NCT01242059|Experimental|10 g of yellow pea protein|
3193769|NCT01242059|Experimental|20 g of yellow pea protein|
3193770|NCT01242046|Experimental|Caffeine|Participants will ingest a tablet with 400 mg caffeine
3193771|NCT01242046|Placebo Comparator|Placebo|Participants will ingest an inert placebo tablet
3193772|NCT01242033|Experimental|one cup red raspberries|treatment meal consists of one cup red raspberries
3193773|NCT01242033|Experimental|two cups red raspberries|treatment meal consists of two cups red raspberries
3193774|NCT01242033|Experimental|four cups red raspberries|treatment meal consists of four cups red raspberries
3193775|NCT01242033|Placebo Comparator|bread|treatment meal consists of two slices white bread
3193776|NCT01242033|Active Comparator|vitamin C|treatment meal consists of two slices white bread and 200 mg vitamin C in the form of supplemental ascorbic acid
3193777|NCT01242020|Other|Lean Healthy Subjects|"Lean defined as (BMI ≥18 and ≤25)"
3193778|NCT01242020|Other|Obese Healthy Subjects|Obese grade I-II defined as (BMI>30 and ≤35)
3193779|NCT01241994|No Intervention|basal hemodialysis|
3193780|NCT01241994|Active Comparator|AASD|
3193781|NCT01241981||Digital Breast Tomosynthesis|Digital Breast Tomosynthesis
3193782|NCT01241968|Active Comparator|A|A - Treatment group. Patients in this group receive actual shockwave therapy.
3193783|NCT01241968|Placebo Comparator|B|Placebo group. This group of patients undergo the same procedure as the treatment group, however shockwaves are not delivered to the heart.
3193784|NCT01241955|No Intervention|verbal description of CPR|verbal description of CPR
3193785|NCT01241955|Experimental|Video decision aid|Video decision aid of CPR
3193786|NCT01241942|Experimental|EVLP with STEEN Solution™|The perfusion of the lungs will be performed using STEEN Solution™ and then physiologically assessed. Lungs deemed suitable will be transplanted after Ex-vivo Perfusion w/ STEEN Solution™.
3193787|NCT01241942|Active Comparator|Conventional Lung transplant|No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
3193788|NCT01241929|Experimental|video decision aid|Video decision aid arm
3193789|NCT01241929|No Intervention|Usual Care -- Verbal Description Arm|Verbal description of CPR (i.e., without the video).
3193790|NCT01241916|Experimental|Static-progressive splint|
3193791|NCT01241916|Experimental|Dynamic Splint|
3193792|NCT01241903|Experimental|Crestor|
3193793|NCT01241903|Placebo Comparator|sugar pill|
3193794|NCT01241890||Children with Cystic Fibrosis, care as usual|Treatment according to the Dutch Central Guidance Committee (CBO) guidelines for CF. Assessments: home monitoring, symptoms, lung function, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
3193795|NCT01241877|Experimental|astaxanthin|
3193796|NCT01241877|Placebo Comparator|placebo|
3193797|NCT01241864|Experimental|Allogenic islet cells (human, U. Chicago)|
3193798|NCT01241851|Active Comparator|Aerobic exercise|
3193799|NCT01241851|Active Comparator|Resistance exercise|
3193800|NCT01241851|No Intervention|Control|
3193801|NCT01241838|Placebo Comparator|Normal left ventricular size|Postoperative patient with normal left ventricular size
3193802|NCT01241838|Active Comparator|Left ventricular hypertrophy|Postoperative patient with left ventricular hypertrophy
3193803|NCT01241825|Active Comparator|1.|The subject group will chew sugarless chewing gum for a specific amount of time while undergoing capsule endoscopy.
3193804|NCT01241825|Placebo Comparator|2.|The control group will not chew chewing gum while undergoing capsule endoscopy.
3193805|NCT01241812|Experimental|A.|10 weeks of partially supervised lower limb muscle strengthening targeting the following muscles groups: quadriceps, hamstrings, hip abductors.
3193806|NCT01241812|No Intervention|B|
3193807|NCT01241799|Experimental|1|Pancreatic biopsy with stylet in then stylet out
3193808|NCT01241799|Experimental|2|Pancreatic biopsy with stylet out then stylet in
3193809|NCT01241773|Experimental|001|TMC435 Two 75 mg capsules once daily for 14 days
3193810|NCT01241773|Experimental|002|efavirenz One 600 mg tablet once daily for 14 days
3193811|NCT01241773|Experimental|003|TMC435 + efavirenz Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet once daily for 14 days
3193812|NCT01241773|Experimental|004|TMC435 Two 75 mg capsules once daily for 7 days
3193813|NCT01241773|Experimental|005|raltegravir One 400 mg tablet twice daily for 7 days
3193814|NCT01241773|Experimental|006|TMC435 + raltegravir Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
3193815|NCT01241760|Experimental|001 T(q8h) / PR|Telaprevir (T) 750 mg (2 oral tablets) every 8 hours for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
3193816|NCT01241760|Experimental|002 T(b.i.d.) / PR|Telaprevir (T) 1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
3193817|NCT01241747|Experimental|Supervised Exercise|Supervised program consisting of graded treadmill walking, with progressive increments in exercise duration from 15 to 40 minutes at an exercise intensity of 40% of exercise capacity.
3193818|NCT01241747|Active Comparator|Control|Light resistance training without any walking
3193819|NCT01241734|Experimental|Revlimid (Lenalidomide) in Combination|Study of Lenalidomide in Combination with Rituximab, Ifosphamide, Etoposide, and Carboplatin (RICE-R) as Salvage Therapy with Single Agent Lenalidomide as Maintenance Therapy Post-Autologous Stem Cell Transplantation
3193820|NCT01241721|Experimental|Positron Emission Mammography (PEM)|Positron Emission Mammography (PEM)
3193821|NCT01241708|Experimental|Tandem Transplantation with Melphalan and Bortezomib|Tandem autologous hematopoietic stem cell transplantation with melphalan followed by melphalan and bortezomib in patients with multiple myeloma
3193822|NCT01241695|Experimental|Test|Diben DRINK (200 ml) / a diabetes-specific oral nutritional supplement
3193823|NCT01241695|Placebo Comparator|Control|Fresubin(R) energy fibre DRINK / an isoenergetic standard oral nutritional supplement
3193824|NCT01241682|Experimental|DC immunotherapy + CTX|Patients with mesothelioma who are fit enough to be treated with chemotherapy and enough tumor material was available are asked for participation in this study. After 4 cycles of Alimta chemotherapy, a leukapheresis is performed of which the monocytes are used for differentiation to DCs using different cytokines. The procedure to grow DCs in vitro and pulse them with tumor lysate is performed according to our earlier performed phase I study that was approved by our local ethics committee. Three doses of properly pulsed autologous DCs (MesoCancerVac) are then re-injected every two weeks. Patients will be treated with a low dose of CTX for seven day in a row the week before the 1st vaccination, the weeks in between the 2nd, and for one week after the 3rd vaccination.
3193825|NCT01241669|Experimental|Arm 1|
3193826|NCT01241669|Experimental|Arm 2|
3193827|NCT01241656|Experimental|Mail DVD|
3193828|NCT01241656|Experimental|Invite to SMA to view and discuss DESI|
3193829|NCT01241656|Experimental|SMA and DVD|
3193830|NCT01241656|No Intervention|Encouraged to talk to physician|
3193831|NCT01241643|Experimental|CYT107|repeated cycles of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
3193832|NCT01241643|No Intervention|Control|Control arm with possible CYT107 injection after 12 months of study participation
3193833|NCT01241617|Active Comparator|Duet TRS|Endo GIA with integrated Duet TRS
3193834|NCT01241617|Active Comparator|Endo GIA|Endo GIA stapler with Single Use Loading units
3193835|NCT01241591|Experimental|CP 690,550 5 mg BID+Placebo BIW|
3193836|NCT01241591|Experimental|CP 690,550 10 mg BID+Placebo BIW|
3193837|NCT01241591|Active Comparator|Placebo BID+Etanercept 50 mg BIW|
3193838|NCT01241591|Placebo Comparator|Placebo BID+Placebo BIW|
3193839|NCT01241578|Experimental|Mobile Phone Intervention|Participants receive a behavioral intervention via mobile phone and brief in-person counseling sessions.
3193840|NCT01241565|Experimental|ENDO GIA™ Stapler with TRI-STAPLE™ Technology|Single arm study, all patients will receive the study device.
3193841|NCT01241552|Experimental|MK-3415 + SOC|Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI
3193842|NCT01241552|Experimental|MK-6072 + SOC|Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI
3193843|NCT01241552|Experimental|MK-3415A + SOC|Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI
3193844|NCT01241552|Placebo Comparator|Placebo + SOC|Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI
3193845|NCT01241539|Experimental|Dabigatran etexilate 110 mg|Capsule, oral
3193846|NCT01241539|Experimental|Dabigatran etexilate 75 mg|Capsule, oral
3193847|NCT01241539|Experimental|Dabigatran etexilate 150 mg|Capsule, oral
3193848|NCT01241526|Experimental|Disease management program|
3193849|NCT01241526|Active Comparator|Usual site management|
3193850|NCT01241513|Experimental|N-acetyl-L-Cysteine|N-Acetyl-L-Cysteine
3193851|NCT01241513|Placebo Comparator|Placebo|placebo
3193852|NCT01241500|Experimental|ON 01910.Na + best supportive care (BSC)|Patients will receive ON 01910.Na 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards and best supportive care (BSC).
3193853|NCT01241500|No Intervention|Best supportive care (BSC)|Patients will receive best supportive care (BSC).
3193854|NCT01241487|Experimental|1|valsartan/amlodipine
3193855|NCT01241474|Experimental|Fish oil|
3193856|NCT01241474|Placebo Comparator|Maize (corn) oil|
3193857|NCT01241461|Experimental|LY2584702|
3193858|NCT01241448|Placebo Comparator|Placebo|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
3193859|NCT01241448|Experimental|2.5 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
3193860|NCT01241448|Experimental|10 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
3193861|NCT01241448|Experimental|20 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
3193862|NCT01241435|Experimental|LY2216684|Single oral dose of 18mg
3193863|NCT01241422|Experimental|Treatment A: JNJ 40929837|
3193864|NCT01241422|Placebo Comparator|Treatment B: Placebo|
3193865|NCT01241422|Other|Treatment C: Montelukast|
3193866|NCT01241409|Experimental|Treatment sequence ABC|
3193867|NCT01241409|Experimental|Treatment sequence ACB|
3193868|NCT01241409|Experimental|Treatment sequence BAC|
3193869|NCT01241409|Experimental|Treatment sequence BCA|
3193870|NCT01241409|Experimental|Treatment sequence CAB|
3193871|NCT01241409|Experimental|Treatment sequence CBA|
3193872|NCT01241396||001|Any MMY treatment Any line of treatment for MMY
3193873|NCT01241383|Experimental|Bosentan|Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
3193874|NCT01241370||Lean healthy subjects|Homeostasis Model Assessment score (HOMAs) ≤ 2, Body Mass Index (BMI) ≤ 28 kg/m2
3193875|NCT01241370||Insulin-resistnat subjects|HOMAs > 2, BMI > 28 kg/m2
3193876|NCT01241370||Type 2 diabetic patients|
3193877|NCT01241357||Observation only|This study has a single arm and no intervention.
3193878|NCT01241344|Active Comparator|CMX001|"Adults: 200mg CMX001 given as four 50mg tablets orally either QW OR BIW.~Peds: 4mg/kg (NTE a total single dose of 200mg) given using a 5 mg/mL liquid formulation taken orally either QW OR BIW"
3193879|NCT01241344|Placebo Comparator|Placebo|"Adults: Two matching placebo tablets taken orally QW OR BIW.~Peds: Matching liquid placebo taken orally QW OR BIW"
3193880|NCT01241331|Experimental|BLI1100|BLI1100 topical cream
3193881|NCT01241331|Placebo Comparator|Vehicle cream|Vehicle topical cream
3193882|NCT01241318|Experimental|Chlorhexidine cord care|Mothers located in health facility catchment areas assigned to this arm will apply chlorhexidine to their infants daily until three days after the cord completely separates.
3193883|NCT01241318|Active Comparator|Dry cord care|Mothers in health facility catchment areas assigned to this arm will use dry cord care - keeping their babies' umbilical stumps clean and dry - as per normal routine standard of care and in accordance with Zambia Ministry of Health policy.
3193884|NCT01241292|Experimental|BMS-901608 (Elotuzumab) 10mg|
3193885|NCT01241292|Experimental|BMS-901608 (Elotuzumab) 20mg|
3193886|NCT01241279|Experimental|Crystalens AO|A silicone multi-piece accommodating intraocular lens
3193887|NCT01241279|Active Comparator|SoftPort LI61AO|A silicone multi-piece foldable aspheric intraocular lens
3193888|NCT01241266||1|Target subject population are the consecutive patients hospitalized due to peptic ulcer bleeding. Subjects should be: ≥18 years; admitted to the hospital with an overt upper GI bleed (hematemesis/coffee ground vomiting, melena, hematochezia and other clin
3193889|NCT01241253|No Intervention|Cross-over study|beans and rice in a 50 gram carbohydrate dose
3193890|NCT01241240|Experimental|Triple Combination Therapy|Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
3193891|NCT01241240|Active Comparator|Combigan®|Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
3193892|NCT01241227||Chronic liver disease|All patients with chronic liver disease followed using FibroScan and non-invasive markers
3193893|NCT01241214|Experimental|Investigational drug - Dose 1|
3193894|NCT01241214|Experimental|Investigational drug - Dose 2|
3193895|NCT01241214|Experimental|Investigational drug - Dose 3|
3193896|NCT01241214|Experimental|Investigational Drug - Dose 4|
3193897|NCT01241214|Other|Active Matching Reference|
3193898|NCT01241214|Placebo Comparator|Matching Placebo|
3193899|NCT01241201|Placebo Comparator|Placebo|placebo for probiotic treatment
3193900|NCT01241188|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
3193901|NCT01241188|Active Comparator|2 TU Tuberculin PPD RT 23 SSI|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
3193902|NCT01241175|Experimental|magnesium sulfate|
3193903|NCT01241175|Placebo Comparator|normal saline|
3193904|NCT01241162|Experimental|Single arm study|Biological/Vaccine: Autologous dendritic cell vaccine with adjuvant
3193905|NCT01241149|Active Comparator|Normal pH, abnormal Impedance|After 24hr pH-metry and impedance, those patients with normal pH (i.e. DeMeester score <14.7) but with abnormal impedance scores will be offered anti-reflux surgery
3193906|NCT01241149|Placebo Comparator|Abnormal pH|After 24hr pH-metry and impedance, those with abnormal pH scores (i.e. DeMeester score >14.7)will be offered anti-reflux surgery
3193907|NCT01241136|Placebo Comparator|Open traditional pilonidal cystectomy|traditional complete wide-excision pilonidal cystectomy
3193908|NCT01241136|Experimental|Minimal invasive pilonidal cystotomy|Using only Keyes Trephines to unroof and curette the pilonidal cyst cavity
3193909|NCT01241123|Placebo Comparator|Traditional Ambulation regimen|All patients will receive pedometers to record the total amount of ambulation. These patients will ambulate without limitations or goals. Most surgeons request that post-operative patients ambulate at least 2 to 3 times a day.
3193910|NCT01241123|Active Comparator|Walkers|All patients will receive pedometers to record the total amount of ambulation. Patients in the experimental group will have assigned nursing staff assisting in ambulation in these patients at least three times a day.
3193911|NCT01241110|Active Comparator|azitromicin,PID treatment,ofluxacin|
3193912|NCT01241097|Experimental|high-dose simvastatin, combined, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
3193913|NCT01241084|Placebo Comparator|Placebo|Antileukotrienes+Placebo
3193914|NCT01241084|Active Comparator|Lactobacillus reuteri|Antileukotrienes+Lactobacillus reuteri
3193915|NCT01241071|Experimental|Myofascial treatment|Myofascial release techniques of different muscles implicated in low back pain
3193916|NCT01241071|Placebo Comparator|Placebo|
3193917|NCT01241045||misoprostol|"2 groups:-~Group 1:-those with Ph<5. (n=50).~Group 2:-those with Ph > or=5. (n=50). -Each group is subdivided into another two groups:-~Group 1A (n=25). - Group 1B (n=25).~Group 2A (n=25). - Group 2B (n=25).~All the women in group 1A and group 2A will receive intravaginal misoprostol tablets moistened with 3 ml of 5% acetic acid, and all the women in group 1B and group 2B will receive intravaginal misoprostol tablets moistened with water, 400 micrograms every 4 hours for a maximum of 5 doses within 24 hours. If the patient will not have adequate uterine contractions, the same regimen will be repeated over the following 24 hours"
3193918|NCT01241032|Experimental|Udenafil|Udenafil 200mg
3193919|NCT01241032|Active Comparator|Udenafil + Alcohol|Udenafil 200mg + Alcohol
3193920|NCT01241019|Experimental|Topiramate|Newborns with hypoxic ischemic encephalopathy treated with mild hypothermia and topiramate
3193921|NCT01241019|No Intervention|Control|Newborns with hypoxic ischemic encephalopathy treated with mild hypothermia
3193922|NCT01241006|Active Comparator|Dexamethasone|Single dose of Dexamethasone 12 mg PO and 4 days of placebo capsules
3193923|NCT01241006|Active Comparator|Prednisone|Prednisone 60mg PO capsules for 5 days
3193924|NCT01240993|Active Comparator|Parent Education|PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs (e.g., health care, child care, housing and education). The PE counselor will also provide a choice of pamphlets on age-related parenting topics each week from a series of pamphlets designed specifically for this study.
3194279|NCT01238419|Experimental|Physiotulle|
3193925|NCT01240993|Experimental|Mothers and Toddlers Program|This intervention is an introductory, short-term, supportive, psychodynamic therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing. Mothers meet with an individual, MBT-trained psychodynamically-oriented therapist for 12 sessions. The intervention is conducted a clinic where mothers are enrolled in treatment for their substance abuse.
3193926|NCT01240980|Experimental|BMS-903452 (0.1 mg) or Placebo - A1|(Healthy Subjects)
3193927|NCT01240980|Experimental|BMS-903452 (0.6 mg) or Placebo - A2|(Healthy Subjects)
3193928|NCT01240980|Experimental|BMS-903452 (3.0 mg) or Placebo - A3|(Healthy Subjects)
3193929|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - A4|(Healthy Subjects)
3193930|NCT01240980|Experimental|BMS-903452 (30 mg) or Placebo - A5|(Healthy Subjects)
3193931|NCT01240980|Experimental|BMS-903452 (60 mg) or Placebo - A6|(Healthy Subjects)
3193932|NCT01240980|Experimental|BMS-903452 (120 mg) or Placebo - A7|(Healthy Subjects)
3193933|NCT01240980|Experimental|BMS-903452 (0.6 mg) or Placebo - B1|(Subjects with type 2 Diabetes Mellitus)
3193934|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - B2|(Subjects with type 2 Diabetes Mellitus)
3193935|NCT01240980|Experimental|BMS-903452 (120 mg) or Placebo - B3|(Subjects with type 2 Diabetes Mellitus)
3193936|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - A11|(Healthy Subjects)
3193937|NCT01240980|Experimental|BMS-903452 (60 mg) or Placebo - A12|(Healthy Subjects)
3193938|NCT01240954|Active Comparator|OSIRIS|
3193939|NCT01240954|Experimental|OSIRIS other concentration 1|
3193940|NCT01240954|Experimental|OSIRIS other concentration 2|
3193941|NCT01240941|Experimental|MK-2206|MK-2206 maximum tolerated dose found from Phase Ib trial (under a separate NCT number) taken orally on a weekly basis
3193942|NCT01240928|Experimental|MK-2206 + exemestane +/- goserelin|Oral MK-2206 and oral exemestane and subcutaneous goserelin (for pre-menopausal participants only)
3193943|NCT01240915|Experimental|Cohort 1|The first 9 subjects will be recruited into Cohort 1 and will receive either placebo (n=3) or MultiStem low dose (n=6) as an intravenous infusion on Day 1. The first five patients enrolled constitute a subgroup of Cohort 1 and these patients will receive multiple doses, once every day for 7 days for 3 doses (Day 1 and Weeks 1 & 2).
3193944|NCT01240915|Experimental|Cohort 2|This group will receive either placebo (n=3) or MultiStem high dose (n=6) as an intravenous infusion on Day 1. The subjects then receive the opposite dose of study medication at Week 8.
3193945|NCT01240915|Experimental|Cohort 3|These subjects (total n=88 evaluable patients) will receive either Placebo or MultiStem (1:1 randomization) as an intravenous infusion on Day 1. In addition all subjects in Cohort 3 will receive a single infusion of either MultiStem or Placebo at Week 8, depending on their randomization schedule. A total of ~22 patients will receive an additional infusion of MultiStem, ~44 patients will receive the alternative blinded therapy to that which they received for Day 1 infusion, and ~22 patients will receive an additional infusion of placebo.
3193946|NCT01240902|Experimental|Extreme Risk: TAVI Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Iliofemoral Access
3193947|NCT01240902|Experimental|Extreme Risk: TAVI Non-Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Non-Iliofemoral Access
3193948|NCT01240902|Experimental|High Risk: TAVI|High Risk Surgical Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
3193949|NCT01240902|Active Comparator|High Risk: SAVR|High Risk Surgical Patients: Surgical Aortic Valve Replacement (SAVR)
3193950|NCT01240889|Active Comparator|montelukast|luekotriene inhibitor
3193951|NCT01240889|Active Comparator|Fluticasone|Nasal steroid
3193952|NCT01240876|Experimental|CEP-37247|
3193953|NCT01240876|Placebo Comparator|Matching placebo|
3193954|NCT01240863|Placebo Comparator|Placebo|Participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the treatment period, participants were administered placebo tablets every 12 hours that matched the dosage deemed successful for managing their pain during the titration period. A step-wise, double-blind schedule to tamper off active drug was implemented during the first 2 weeks of the 12-week, double-blind, placebo-controlled treatment period to reduce the risk of withdrawal effects in participants randomly assigned to placebo.
3193955|NCT01240863|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the 12-week, double-blind, placebo-controlled treatment period, participants randomly assigned to hydrocodone ER were administered tablets every 12 hours at the dosage deemed successful for managing their pain during the titration period.
3193956|NCT01240850|Active Comparator|Prednisone|
3193957|NCT01240850|Experimental|Methotrexate+Prednisone|
3193958|NCT01240837|Active Comparator|glucose|
3193959|NCT01240837|Active Comparator|sucrose|
3193960|NCT01240837|Experimental|palm sugar|
3193961|NCT01240824|Experimental|BCG + aminophylline|Bacillus Calmette-Guerin (BCG) plus one of three escalating doses of aminophylline administered intravesically.
3193962|NCT01240811|No Intervention|Control-No IUD|Healthy volunteers not at risk of pregnancy and not using any hormonal contraception.
3193963|NCT01240811|Experimental|Levonorgestrel IUS|Healthy volunteers seeking contraception with IUD. Randomized to LNG IUS.
3193964|NCT01240811|Experimental|Copper T380A IUD|Healthy volunteers seeking contraception with IUD. Randomized to Copper T380A IUD.
3193965|NCT01240798||Depression, anxiety|
3193966|NCT01240785|Active Comparator|Metformin|Metformin 500 mg 1-2 tablets twice daily according to plasma glucose values
3193967|NCT01240785|Active Comparator|insulin|NPH insulin once or twice daily and/or insulin lispro or aspart according to preprandial and postprandial glucose values
3193968|NCT01240772|Experimental|DGALM|doppler-guided arterial ligation with mucopexy
3193969|NCT01240772|Active Comparator|SH|stapled haemorrhoidopexy according to Longo
3193970|NCT01240759|Experimental|S-707106 Dose A|One S-707106 A tablet + 3 Placebo A tablets
3194280|NCT01238419|Placebo Comparator|Urgotul|
3193971|NCT01240759|Experimental|S-707106 Dose B|One S-707106 B tablet + 3 Placebo A tablets
3193972|NCT01240759|Experimental|S-707106 Dose C|S-707106 Dose C = Four S-707106 B tablets
3193973|NCT01240759|Active Comparator|Metformin|The standard of care dose of metformin for the individual patient + 3 Placebo A tablets
3193974|NCT01240746|Active Comparator|Group 1: Licensed 2010-2011 TIV|Participants will receive the Licensed 2010-2011 Trivalent Influenza Vaccine containing the primary B strain.
3193975|NCT01240746|Experimental|Group 2: Investigational TIV|Participants will receive the Investigational Trivalent Influenza Vaccine containing the alternate B strain
3193976|NCT01240746|Experimental|Group 3: Investigational QIV|Participants will receive the investigational Quadrivalent Influenza Vaccine
3193977|NCT01240720|Experimental|I131-F16SIP|"Phase I: Multicentre, open-label, two-step singlearm dose escalation study in sequential cohorts of patients with cancer.~Phase II: Prospective, open-label, single-arm, multicentre study of 131I-F16SIP, given at the RD of 55.5 mCi/m2, as determined in phase I."
3193978|NCT01240707|Other|LF tests, Fiberoptic bronchoscopy|Spirometry, Peak Expiratory Flow (PEF). Bronchoscopic assessment of soot in central airways.
3193979|NCT01240694|Experimental|CEP-33457|200 mcg of CEP-33457
3193980|NCT01240681|Other|FLT PET and BOLD MRI scan|All subjects will have the study intervention of FLT PET and BOLD MRI at baseline and after the first cycle of chemotherapy
3193981|NCT01240668||Hyponatremia Patients|Euvolemic or hypervolemic hyponatremia with serum sodium ≤130 mmol/L
3193982|NCT01240655|Experimental|LCL161 + Paclitaxel|
3193983|NCT01240642|Experimental|ASA404|
3193984|NCT01240629|Experimental|Arm I|Patients receive doxorubicin-GnRH agonist conjugate AEZS-108 intravenously (IV) over 2 hours once every 21 days (21 days = 1 cycle). Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3193985|NCT01240590|Experimental|Ph I Level -1: Cisplatin + Crolibulin|75mg/m(2) Cisplatin + 8 mg/m(2) Crolibulin
3193986|NCT01240590|Active Comparator|Ph I Level 1: Cisplatin + Crolibulin|75mg/m(2) Cisplatin + 13 mg/m(2) Crolibulin
3193987|NCT01240590|Active Comparator|Ph I Level 2: Cisplatin + Crolibulin|100mg/m(2) Cisplatin + 13 mg/m(2) Crolibulin
3193988|NCT01240590|Active Comparator|Ph II Level 3: Cisplatin + Crolibulin|100mg/m(2) Cisplatin + 20 mg/m(2) Crolibulin
3193989|NCT01240590|Active Comparator|Ph II Level 4: Cisplatin|100mg/m(2) Cisplatin
3193990|NCT01240551|Active Comparator|Mets via NaF-18 PET/CT|Patients with known bone metastases (i.e. mets).
3193991|NCT01240551|Active Comparator|No-Mets via NaF-18 PET/CT|Patients with no clinical evidence of bone metastases
3193992|NCT01240538|Experimental|Treatment (virus and chemotherapy)|Patients receive wild-type reovirus IV over 60 minutes QD on days 1-5. Some patients also receive cyclophosphamide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3193993|NCT01240525|Other|CD4 DLI|Patients will receive trial product manipulated CD4 DLI post transplant as trial treatment.
3193994|NCT01240525|Other|No DLI|Patients will receive no DLI post transplant as trial treatment.
3193995|NCT01240512|Active Comparator|High Dose Arm|4000 IU/day Vitamin D3 (cholecalciferol) supplementation
3193996|NCT01240512|Active Comparator|Low Dose Arm|400 IU/day Vitamin D3 (cholecalciferol) supplementation
3193997|NCT01240499|Experimental|Health-At-Every-Size (HAES)|
3193998|NCT01240499|Active Comparator|Social Support (SS)|
3193999|NCT01240499|No Intervention|Control|
3194000|NCT01240460|Experimental|1|Twice-daily dosing (every 12 hours) XL765
3194001|NCT01240460|Experimental|2|Once-daily dosing XL147
3194002|NCT01240460|Experimental|3|Once-daily dosing XL765
3194003|NCT01240447|Other|Best support treatment|
3194004|NCT01240447|Experimental|Racotumomab vaccine|
3194005|NCT01240434|Active Comparator|Fascia closure of the surgical trocars|Arm in which all the surgical trocar orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone)
3194006|NCT01240434|No Intervention|Trocar site without closure|All the orifices of the trocar site are left open, closing only the skin.
3194007|NCT01240408|Experimental|Treatment group 1|10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
3194008|NCT01240408|Experimental|Treatment group 2|10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
3194009|NCT01240395|Experimental|MBCT intervention|
3194010|NCT01240395|No Intervention|Control group|
3194011|NCT01240382|Experimental|3% DE-089|
3194012|NCT01240382|Active Comparator|0.1% HA|
3194013|NCT01240369||VEGF-C low|
3194014|NCT01240369||VEGF-C high|
3194015|NCT01240369||miR-326 low|
3194016|NCT01240369||miR-326 high|
3194017|NCT01240356|Experimental|Phase I: Healthy Volunteers|Subjects without history of Central Nervous System Disease will receive 2-hours of hands-free 2-megahertz (MHz) transcranial Doppler ultrasound insonation continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
3194018|NCT01240356|Experimental|Phase II: 0-3 hour Patients|Ischemic stroke patients who present between 0-3 hours will receive 2-hours of hands-free 2-MHz transcranial Doppler ultrasound Continuously to the intracranial vessels.
3194019|NCT01240304|Experimental|Gemcitabine, radiation therapy, surgery|
3194020|NCT01240291|Experimental|alanyl-glutamine|Intravenous alanyl-glutamine (0.5 g/kg body weight/day)
3194021|NCT01240291|Placebo Comparator|normal saline|Intravenous placebo (normal saline; 0.9 %)
3194022|NCT01240265|Experimental|Vitamin D 150,000 units once|Single dose of vitamin D3 150,000 IU given orally once
3194023|NCT01240265|Experimental|Vitamin D 5000 units daily|Vitamin D3 5000 IU daily given orally for 28 days
3194024|NCT01240252|Experimental|Type 2 Diabetes Mellitus Subjects|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
3194025|NCT01240252|Experimental|Overweight or Obese Subjects with Normal Glucose Tolerance|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
3194118|NCT01239537||GSK H1N1 vaccine|Previously received 2 dose schedule of GSK H1N1 vaccine
3194026|NCT01240252|Placebo Comparator|Non-Obese Control Subjects|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
3194027|NCT01240239||telephone group|The telephone group must be healthy adults scheduled for an ENT surgery.
3194028|NCT01240239||telemedicine group|This group if qualified will randomly be chosen to be in the telemedicine group.
3194029|NCT01240239||pre-anesthesia consultation|This will be the group that will be randomized to the pre-anesthesia clinic.
3194030|NCT01240226|Experimental|A|
3194031|NCT01240226|Experimental|B|
3194032|NCT01240213|Active Comparator|Vitamin D|2000 IU per day of Vitamin D
3194033|NCT01240213|Placebo Comparator|Placebo|
3194034|NCT01240200|Active Comparator|Vial & Syringe (Period 1) / Pen (Period 2)|Crossover phase: patients randomized to the sequence: Insulin glargine vial and syringe in Period 1 and Insulin glargine SoloSTAR pen in Period 2.
3194035|NCT01240200|Experimental|Pen (Period 1) / Vial & Syringe (Period 2)|Crossover phase: patients randomized to the sequence: Insulin glargine SoloSTAR® pen in Period 1 and Insulin glargine vial and syringe in Period 2.
3194036|NCT01240187|Experimental|Experimental 1|
3194037|NCT01240187|Experimental|Experimental 2|
3194038|NCT01240174|Other|Intervention Arm|Single arm in the study of doctors receiving feedback about their antibiotic prescribing rate for acute bronchitis.
3194039|NCT01240161||Patients with high grade gliomas|All subjects will have radiographically suspected or surgically proven de novo high grade gliomas. There are no control patients.
3194040|NCT01240148|Experimental|1|150 μL intradermal injection of 1 μmol/L AZD3161
3194041|NCT01240148|Experimental|2|150 μL intradermal injection of 6 μmol/L AZD3161
3194042|NCT01240148|Experimental|3|150 μL intradermal injection of 30 μmol/L AZD3161
3194043|NCT01240148|Active Comparator|4|150 μL intradermal injection of 10 mg/mL Lidocaine
3194044|NCT01240148|Placebo Comparator|5|150 μL intradermal injection of AZD3161 placebo
3194045|NCT01240135|Other|FID 114576A / renu fresh|FID 114675A used for contact lens care per protocol-specified instructions for 14 days, followed by a minimum 1-day washout period, after which renu fresh used for contact lens care for an additional 14 days.
3194046|NCT01240135|Other|renu fresh / FID 114675A|Renu fresh used for contact lens care per protocol-specified instructions for 14 days, followed by a minimum 1-day washout period, after FID 114675A used for contact lens care for an additional 14 days.
3194047|NCT01240122|Active Comparator|Biotrue MPS|
3194048|NCT01240122|Experimental|Investigational MPS|
3194049|NCT01240109|Active Comparator|propofol|
3194050|NCT01240109|Active Comparator|sevoflurane|
3194051|NCT01240096|Active Comparator|Mirtazapine|mirtazapine 15 mg daily
3194052|NCT01240096|Placebo Comparator|Placebo|Placebo once daily
3194053|NCT01240083|Experimental|Thetaburst Stimulation|1: Thetaburst stimulation: right DLPFC continuous TBS followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 stimuli, 80% motorthreshold
3194054|NCT01240083|Experimental|High frequency rTMS|2: Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC, 110% motor threshold, followed by 1000 stimuli of 10 Hz over the left DLPFC , 110% motorthreshold
3194055|NCT01240083|Experimental|Placebo Stimulation|3: Sham Stimulation (Sham coil): right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
3194056|NCT01240070|Active Comparator|Usual Care|Clinical practice in type 2 diabetes treatment
3194057|NCT01240070|Active Comparator|Intensive Care|Intensive multi-factorial treat-to-target intervention, according to international guidelines, that includes both lifestyle intervention and a step-wise strategy for pharmacological treatment with a treat-to-target approach.
3194058|NCT01240057|Placebo Comparator|expectant management during pregnancy|watchful waiting during pregnancy
3194059|NCT01240057|Experimental|fetal endoluminal tracheal occlusion|fetoscopic balloon occlusion at 27 to 30 weeks of gestation
3194060|NCT01240044|No Intervention|Control Group|In this group the newborns remained at rest 20 minutes and receive no intervention of respiratory therapy.
3194061|NCT01240044|Experimental|Physical Therapy|In this group the newborns are submitted to the mechanical vibrator.
3194062|NCT01240044|Experimental|Thoracoabdominal rebalancing|In this group the newborns receive the thoracoabdominal rebalancing.
3194063|NCT01240018|Placebo Comparator|Placebo|
3194064|NCT01240018|Active Comparator|High dose Lb. casei|
3194065|NCT01240005|Experimental|DCIK|
3194066|NCT01239992|Experimental|Niacin/ Laropiprant|
3194067|NCT01239979||Stable, Unstable , control|
3194068|NCT01239953|Active Comparator|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon (SeQuent Please, B. Braun)
3194069|NCT01239953|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent (Xience Prime, Abbott Vascular)
3194070|NCT01239940|Active Comparator|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon (SeQuent Please, B. Braun)
3194071|NCT01239940|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent (Xience Prime, Abbott Vascular)
3194072|NCT01239888|Active Comparator|Oxytocin|
3194073|NCT01239888|Active Comparator|Oxytocin and Tibolone|
3194074|NCT01239888|Placebo Comparator|Placebo|
3194075|NCT01239875|Experimental|Arm A|Patients receive pneumococcal polyvalent vaccine intramuscularly in weeks -4, 2, and 10. Patients undergo cryoablation followed by dendritic cell vaccine (CA-DC) intratumorally in weeks 0, 2, 4, 6, 10, 14, 18, and 22.
3194076|NCT01239875|Experimental|Arm B|Patients receive pneumococcal polyvalent vaccine as in arm A. Patients also receive autologous dendritic cell-tumor fusion vaccine (TL-DC) intradermally in weeks 0, 2, 4, 6, 10, 14, 18, and 22.
3194119|NCT01239524|Other|DE-group|surgical denervation by excising 1 cm of proximal thoracodorsal nerve
3194120|NCT01239524|Other|IN group|thoracodorsal nerve is saved intact
3194121|NCT01239511|Placebo Comparator|Placebo group|placebo capsule 2# t.i.d./day
3194122|NCT01239511|Experimental|Treatment Group A|150 mg STA-2, 2 capsules t.i.d., after meal (900 mg STA-2 total dose per day)
3194222|NCT01238796|Experimental|End stage renal disease|Subjects with end stage renal disease
3194077|NCT01239862|Experimental|Autologous cell transplantation|We conducted a prospective, non-randomized, single-center longitudinal study in five patients. Inclusion criteria were age 18−50 years, chronic and accelerated silicosis, forced expiratory volume in 1s <60% and >40%, forced vital capacity ≥60% and arterial oxygen saturation >90%. BMDMCs were administered through bronchoscopy (2×107 cells) into both lungs. Physical examination, laboratory evaluations, quality of life questionnaires, thoracic computed tomography scans, lung function tests, and perfusion scintigraphy were performed before the beginning of treatment and up to 360 days after BMDMC (Bone Marrow Derived Mononuclear Cells) therapy. Additionally, whole-body and planar scans were evaluated 2 and 24 h after instillation.
3194078|NCT01239836|Experimental|Self-management|
3194079|NCT01239836|Sham Comparator|General Health Lecture|
3194080|NCT01239836|Experimental|Combined workshop and self-management|
3194081|NCT01239836|Experimental|Workshop|
3194082|NCT01239823|Experimental|Whole Body Vibration Training|The subjects will participate in a 12-week whole body vibration exercise program with 2 sessions (1/2 hour) per week.
3194083|NCT01239823|Experimental|Exercise without vibration|The subjects will participate in a 12-week exercise program with 2 sessions (1/2 hour) per week.
3194084|NCT01239810||Control group|Receiving no treatment
3194085|NCT01239810||hyaluronic acid|treatment group receiving intraarticular hyaluronic acid
3194086|NCT01239797|Active Comparator|Lenalidomide + Dexamethasone|
3194087|NCT01239797|Experimental|Lenalidomide + Dexamethasone +Elotuzumab|
3194088|NCT01239784|Experimental|All Subjects|A total of 20 children and their parents will be recruited for this study. Ten children will have had the Glenn procedure and 10 infants will have had the arterial switch operation.
3194089|NCT01239771|Experimental|1|TC-5214
3194090|NCT01239771|Placebo Comparator|2|Placebo matched to TC-5214
3194091|NCT01239758|Experimental|ACE-031 (Extension of cohort 1 from core study, A031-03)|
3194092|NCT01239758|Experimental|ACE-031 (Extension of cohort 2 from core study, A031-03)|
3194093|NCT01239758|Experimental|ACE-031 (Extension of cohort 3 from core study, A031-03)|
3194094|NCT01239745||1|
3194095|NCT01239732|Experimental|Bevacizumab + Paclitaxel + Carboplatin|Participants will receive bevacizumab 15 mg/kg IV on Day 1 every 3 weeks from Cycle 1 to Cycle 36 (initially concurrent with chemotherapy, then continued as a single agent following the completion of chemotherapy), or until protocol defined disease progression or until unacceptable toxicity (whichever occurred first). Participants will receive paclitaxel 175 mg/m^2 IV on Day 1 every 3 weeks or 80 mg/m^2 IV every week and carboplatin (AUC 5-6) IV on Day 1 every 3 weeks for a minimum of 4 and maximum of 8 cycles (including up to 4 pre-surgical cycles), or until protocol defined disease progression, or unacceptable toxicity (whichever occurred first).
3194096|NCT01239719|Experimental|Dexamethasone + Clemastine|Dexamethasone + clemastine fumarate cream
3194097|NCT01239719|Active Comparator|Dexamethasone|Dexamethasone 0.5 mg
3194098|NCT01239706|Experimental|NTx 265|
3194099|NCT01239693|Active Comparator|IFA group|Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
3194100|NCT01239693|Active Comparator|MMN group|Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients' Children from 6 to 18 months of age: None
3194101|NCT01239693|Experimental|LNS group|Women during pregnancy: 1 sachet of LNS-P&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
3194102|NCT01239680|Placebo Comparator|Ringer's Lactate and Placebo for Glutamine|Ringer's Lactate 1 liter once over 6 hours
3194103|NCT01239680|Experimental|Ringer's Lactate with 25 grams Glutamine|Ringer's Lactate with 25 grams Glutamine (1 liter) once over 6 hours
3194104|NCT01239667|Experimental|Life style counseling|Individual oriented rehabilitation plan in collaboration with the patient followed by measuring health related quality of life and self care behavior
3194105|NCT01239654|Active Comparator|everolimus|everolimus-eluting stent
3194106|NCT01239654|Active Comparator|zotarolimus|zotarolimus-eluting stent
3194107|NCT01239615||healthy volunteers|
3194108|NCT01239602||Normal control|
3194109|NCT01239602||with Stem cell therapy plus G-CSF|
3194110|NCT01239602||G-CSF along|
3194111|NCT01239589||1|patients admitted as for an acute bipolar manic episode and treated with quetiapine IR
3194112|NCT01239589||2|patients admitted as for an acute bipolar manic episode and treated with quetiapine XR
3194113|NCT01239563|Experimental|Thymoglobulin|Thymoglobulin induction group
3194114|NCT01239563|Active Comparator|Basiliximab|Basiliximab induction - 20 mg, day 0 and day 4
3194115|NCT01239550|Experimental|Insulin Detemir Treatment|"Insulin detemir treatment: Insulin detemir will be administered subcutaneously, once daily. Dose ranges from approximately 0.1 U/kg up to 0.6 u/kg or higher. The dosing regimen will employ a strategy similar to the 303algorithm, where, with close interaction with study personnel (rather than self-titration), bedtime insulin dosing will be titrated up by 3 units until AM fasting sugars within the prescribed protocol range are achieved (90-110 mg/dl). Subjects will have contact with study personnel on weekly basis for glycemia monitoring and adjustments. Similarly, documented hypoglycemia (blood sugars less than 70) will trigger a dose reduction, and it is expected that with weight loss, tolerable insulin dosages will drift downward. The treatment period is 24 weeks."
3194116|NCT01239550|No Intervention|Comparator: No insulin|"The main hypothesis is that diabetes can be changed  with early and careful insulinization capturing effects on brain function ultimately leading to weight loss. . Seek to determine in a quantitative manner whether insulin detemir restores brain dopamine neurotransmission, a control group not treated with insulin is required. The strength of this study is our ability to test the specific molecular (D2R, DAT, functional MRI responses) and integrated output (functional brain responses, mood, cognitive function, reward responses etc.) of CNS dopaminergic pathways in order to shed unprecedented light upon mechanisms of detemir action in obesity and diabetes."
3194117|NCT01239537||Baxter H1N1 vaccine|Previously received 2 dose schedule of Baxter H1N1 vaccine
3194123|NCT01239511|Experimental|Treatment Group B|300 mg STA-2, 2 capsules t.i.d., after meal (1800 mg STA-2 total dose per day)
3194124|NCT01239511|Experimental|Treatment Group C|450 mg STA-2, 2 capsules t.i.d., after meal (2700 mg STA-2 total dose per day)
3194125|NCT01239498|Experimental|Saline + Lidocaine/Adrenaline|
3194126|NCT01239498|Placebo Comparator|Lidocaine/Adrenaline only|
3194127|NCT01239485|Experimental|Irinotecan|
3194128|NCT01239472|No Intervention|tacrolimus|Kidney transplant patients with living donors starting with the use of tacrolimus, mycophenolate sodium and prednisone without induction.
3194129|NCT01239472|Active Comparator|everolimus|Kidney transplant patients with living donors starting with the use of tacrolimus, mycophenolate sodium and prednisone without induction, and converted for use of mycophenolate sodium, everolimus, and prednisone after 90 days of kidney transplantation.
3194130|NCT01239459|Experimental|Severe impaired renal function|Subjects with severe renal impairment as defined by Cockroft-Gault formula
3194131|NCT01239459|Experimental|Normal renal function|Subjects with normal renal function as defined by Cockroft-Gault formula
3194132|NCT01239433||mechanically ventilated patients|ICU patients on mechanical ventilation. Daily endotracheal suctioning performed to reduce secretions. Data recorded during these therapeutic interventions.
3194133|NCT01239407|No Intervention|Treatment as usual|"The treatment as usual arm consists of two phone or in-person interviews:~Patients are asked questions about their mental health, their views of mental health, and how they cope with their mental health (including any treatment they might be receiving).~Patients are asked the same questions 6 months after the initial interview."
3194134|NCT01239407|Experimental|Culturally focused psychiatric consultation|"The consultation is comprised of 3 visits:~1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).~1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.~2. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).~3. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person)."
3194135|NCT01239394|Other|ofatumumab|single-arm, open-label, interventional
3194136|NCT01239381|Experimental|SBRT-Proton|Stereotactic body radiotherapy by proton radiation
3194137|NCT01239368|Experimental|Phase 1|Phase I Dose escalation- Closed
3194138|NCT01239368|Experimental|Cohort A|Th1/Tc1.Rapa Prevention of Relapse
3194139|NCT01239368|Experimental|Cohort B|Th1/Tc1.Rapa for Relapsed Multiple Myeloma
3194140|NCT01239355|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive oral Akt inhibitor MK2206 on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3194141|NCT01239342|Experimental|Arm I (Akt inhibitor MK2206)|Akt inhibitor MK2206 200 mg orally (PO) on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who are progression free after 1 year may receive a 12 week study drug supply of Akt inhibitor MK2206.
3194142|NCT01239342|Experimental|Arm II (Everolimus)|Everolimus 10 mg orally once daily (PO QD) on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3194143|NCT01239329||Complex multiple disabilities|People with complex multiple disabilities, living in a care institution participating in the Governor Kremers Centre (GKC.)
3194144|NCT01239316|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
3194145|NCT01239303|Active Comparator|citrulline|
3194146|NCT01239303|Placebo Comparator|alanine|
3194147|NCT01239277|Experimental|protein (elderly)|
3194148|NCT01239277|Experimental|protein and carbohydrate (elderly)|
3194149|NCT01239277|Experimental|protein and carbohydrate (young)|
3194150|NCT01239277|Experimental|protein and leucine (elderly)|
3194151|NCT01239251||breast cancer patients taking endocrine therapy|Breast cancer patients, currently taking adjuvant endocrine therapy will be equipped with a GlowCap device for a period of 30 days. The GlowCap will become part of their medication taking routine.
3194152|NCT01239238||Care as usual|Therapy is guided based on symptoms and lung function. Assessments: home monitoring, symptoms, lung function, FeNO, asthma control, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
3194153|NCT01239225|Experimental|Abdominal ultrasound|Abdominal ultrasound
3194154|NCT01239199|Experimental|Exhaled NO|
3194155|NCT01239186||Oligozoospermia|infertile patients presenting a reduced sperm count (less than 20 Millions of spermatozoa/ml)
3194156|NCT01239173|Active Comparator|1|Post-traumatic stress disorder patient receiving propanolol 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
3194157|NCT01239173|Placebo Comparator|2|Post-traumatic stress disorder receiving placebo 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
3194158|NCT01239173|Active Comparator|3|Controls receiving propanolol 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
3194159|NCT01239173|Placebo Comparator|4|Controls receiving placebo 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
3194160|NCT01239160|Experimental|Advanced PCD|The use of an advanced PCD device to reduce and maintain limb volume
3194161|NCT01239160|Active Comparator|Simple PCD|The use of the Simple PCD is to reduce and maintain limb volume
3194162|NCT01239147|Other|Whole grain diet|
3194163|NCT01239147|Other|Refined grain diet|
3194164|NCT01239134|Experimental|TRX518|
3194165|NCT01239121|Experimental|HIE-Enhanced Medication Reconciliation|Health Information Exchange (HIE)-Enhanced Medication Reconciliation for Veterans admitted to James J Peters VA hospital units 6B, 7B, 7C, and 8B (each unit crossing over between intervention and control every 3-4 months)
3194219|NCT01238809||1|
3194220|NCT01238796|Experimental|Normal renal function|Subjects with normal renal function
3194221|NCT01238796|Experimental|Severe renal impairment|Subjects with severe renal impairment
3194166|NCT01239121|Active Comparator|Optimal Medication Reconciliation without HIE|Optimal Medication Reconciliation without Health Information Exchange (HIE) for Veterans admitted to James J Peters VA hospital units 6B, 7B, 7C, and 8B (each unit crossing over between intervention and control every 3-4 months)
3194167|NCT01239121|Other|Pilot HIE-Enhanced Outpatient Medication Reconciliation|Health Information Exchange (HIE)-Enhanced Medication Reconciliation for Veterans seen as outpatients in Geriatrics Primary care clinic
3194168|NCT01239095|Experimental|Green Tea and Milk Thistle Supplements|Patients will receive green tea extract and milk thistle extract supplements for one week prior to surgery and for 30 days after surgery.
3194169|NCT01239082|Other|Arm 1|Colonoscopy (one time screening)
3194170|NCT01239082|Other|Arm 2|FIT (annually)
3194171|NCT01239069|Experimental|DE-110 ophthalmic suspension high dose|
3194172|NCT01239069|Experimental|DE-110 ophthalmic suspension low dose|
3194173|NCT01239069|Placebo Comparator|Placebo|
3194174|NCT01239056||Pancreatic Pseudocysts|All adult patients who have a clinical indication to undergo an endoscopic drainage of a pancreatic pseudocyst.
3194175|NCT01239043|Experimental|Menomune® vaccine group|Participants received Menomune® vaccine in MTA29 (NCT00874549)
3194176|NCT01239043|Experimental|Menactra® vaccine group|Participants received Menactra® vaccine in trial MTA29 (NCT00874549)
3194177|NCT01239030|Active Comparator|10 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 10 mg
3194178|NCT01239030|Active Comparator|15 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 15 mg
3194179|NCT01239030|Active Comparator|20 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 20 mg
3194180|NCT01239030|Active Comparator|40 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 40 mg
3194181|NCT01239030|Placebo Comparator|Placebo|Placebo Capsules
3194182|NCT01239017|Experimental|Dose 1|SC REGN475 Dose 1 and IV Placebo
3194183|NCT01239017|Experimental|Dose 2|SC REGN475 Dose 2 and IV Placebo
3194184|NCT01239017|Experimental|Dose 3|SC REGN475 Dose 3 and IV Placebo
3194185|NCT01239017|Experimental|Dose 4|SC Placebo and IV REGN475 Dose 4
3194186|NCT01239017|Placebo Comparator|Dose 5|SC Placebo and IV Placebo
3194187|NCT01239004|Placebo Comparator|Placebo|
3194188|NCT01239004|Experimental|Colesevelam|
3194189|NCT01238991|Experimental|ACC-001 (3 micrograms) + QS-21|Active vaccine dose of 3 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
3194190|NCT01238991|Experimental|ACC-001 (10 micrograms) + QS-21|Active vaccine dose of 10 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
3194191|NCT01238991|Experimental|ACC-001 (30 micrograms) + QS-21|Active vaccine dose of 30 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
3194192|NCT01238978|Experimental|Vildagliptin|
3194193|NCT01238978|Active Comparator|other Oral Antidiabetic Drug in a different therapeutic class|
3194194|NCT01238965|Experimental|Arm I|Patients receive oral panobinostat 3 times a week. Patients also receive leucovorin calcium IV over 2 hours on days 1 and 15 followed by fluorouracil IV continuously over 46 hours on days 1-2 and 15-16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3194195|NCT01238939|Experimental|Treatment|
3194196|NCT01238926|Experimental|PD vitamin supplementation|
3194197|NCT01238926|Experimental|PD exercise intervention|
3194198|NCT01238926|Experimental|PD vitamin + exercise|
3194199|NCT01238926|No Intervention|PD control|
3194200|NCT01238913||benign esophageal lesions|All patients who have a benign esophageal lesion where it is medically indicated that they receive a stent.
3194201|NCT01238900||benign biliary strictures|All patients who have a medical indication for an ERCP to place a stent in their benign biliary strictures
3194202|NCT01238887|Placebo Comparator|microcrystalline cellulose|
3194203|NCT01238887|Active Comparator|Hydroxycitric acid|2800 mg divided in three doses per day
3194204|NCT01238887|Active Comparator|Hydroxycitric Acid|5400 mg divided into three doses per day
3194205|NCT01238874|No Intervention|No intervention|Mostly observational study with 1 patient global assessment.
3194206|NCT01238861|Placebo Comparator|Eosinophilic phenotype (EOS+) Placebo|EOS+ (defined as ELEN Index [proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent] positive and/or FeNO [fraction of exhaled nitric oxide] greater than or equal to [>=] 50 parts per billion [ppb]) participants received matching placebo injections subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
3194207|NCT01238861|Experimental|EOS+ Benralizumab (2 mg)|EOS+ participants received single benralizumab 2 milligram (mg) injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
3194208|NCT01238861|Experimental|EOS+ Benralizumab (20 mg)|EOS+ participants received single benralizumab 20 mg injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
3194209|NCT01238861|Experimental|EOS+ Benralizumab (100 mg)|EOS+ participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
3194210|NCT01238861|Placebo Comparator|Non-eosinophil phenotype (EOS-) Placebo|EOS- (defined as ELEN Index negative and FeNO <50 ppb) participants received matching placebo subcutaneous every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
3194211|NCT01238861|Experimental|EOS- Benralizumab (100 mg)|EOS- participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
3194212|NCT01238848|Experimental|Hypertonic|Nebulized hypertonic saline (sodium chloride 3%) + albuterol
3194213|NCT01238848|Active Comparator|Normal|Normal saline (sodium chloride 0.9%) + albuterol
3194214|NCT01238835|Experimental|TAVR-TA|Transcatheter valve replacement with transapical access
3194215|NCT01238822|Placebo Comparator|Placebo|
3194216|NCT01238822|Active Comparator|Low Dose Methylphenidate|Low dose: 18 mg methylphenidate
3194217|NCT01238822|Active Comparator|Medium Dose Methylphenidate|Medium Dosage: 36 mg if more than 50 kg and 27 mg if less than 50 kg
3194218|NCT01238822|Active Comparator|High Dose Methylphenidate|54 mg if more than 50 kg and 36 mg if less than 50 kg
3194223|NCT01238783|Experimental|AL-15469A 0.5% and AL-65150.3% Ophthalmic Suspension|
3194224|NCT01238783|Experimental|AL-15469A 0.5%|
3194225|NCT01238783|Experimental|AL-6515 0.3%|
3194226|NCT01238783|Placebo Comparator|Vehicle|
3194227|NCT01238770|Experimental|Cyclophosphamid + Pazopanib|Cyclophosphamid + Pazopanib
3194228|NCT01238757|Active Comparator|Non-Invasive Pressure support|"in this arm, non-invasive pressure support will be recorded under 3 conditions:~with the initial Expiratory Trigger Setting (ETS) with ETS +15% with ETS -15%"
3194229|NCT01238757|Active Comparator|NAVA|"Neurally Adjusted ventilatory Assist is a ventilation mode where the ventilator is piloted by the electrical activity of the diaphragm. Ventilation is triggered and cycled off by the electrical activity of the diaphragm, the pressure delivered being proportional to this activity.~The proportion named gain is chosen to obtain under NAVA the same peak pressure than during Presure Support"
3194230|NCT01238744|Placebo Comparator|Study I: control drink|
3194231|NCT01238744|Experimental|Study I: flaxseed drink|
3194232|NCT01238744|Active Comparator|Study II: flaxseed drink|
3194233|NCT01238744|Experimental|Study II: flaxseed tablets|
3194234|NCT01238731||Valve replacement|Patients undergoing valve replacement for severe valve disease will be screened for study entry
3194235|NCT01238718|Active Comparator|lidocaine|
3194236|NCT01238718|Placebo Comparator|normal saline|
3194237|NCT01238705|Active Comparator|Felodipine,Irbesartan,Sexual Dysfunction|
3194238|NCT01238705|Active Comparator|Felodipine,Metoprolol,Sexual Dysfunction|
3194239|NCT01238692|Experimental|LBH589|
3194240|NCT01238692|Experimental|LBH589 plus Rituximab|
3194241|NCT01238679|Experimental|PF-04958242|
3194242|NCT01238679|Placebo Comparator|Placebo|
3194243|NCT01238640|Experimental|Code STD|"An experimental 2 mg nicotine product coded STD"
3194244|NCT01238640|Experimental|Code STE|"An experimental 2 mg nicotine product coded STE"
3194245|NCT01238640|Active Comparator|Nicorette Microtab|A comparative 2 mg marketed nicotine product called Nicorette Microtab
3194246|NCT01238627|Experimental|Nicotine Sublingual Tablet Mint (NSTM)-2|Experimental 2 mg NSTM
3194247|NCT01238627|Active Comparator|Microtab-2|2 mg Nicotine tablet
3194248|NCT01238627|Experimental|NSTM-4|Experimental 4 mg Nicotine Sublingual Tablet Mint
3194249|NCT01238627|Active Comparator|Microtab-4|2 x 2 mg Nicotine tablet
3194250|NCT01238614|Experimental|PSF-JIT|Mothers in this arm receive prescreening questions and clinicians receive just-in-time handouts to aid in diagnosis.
3194251|NCT01238614|Experimental|PSF|Mothers in this arm receive screening questions on the prescreener form
3194252|NCT01238614|Placebo Comparator|Control|Mothers in this arm receive no maternal depression CHICA additional care
3194253|NCT01238588|Other|Sevelamer Carbonate (Renvela)|Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
3194254|NCT01238575|Experimental|Extended-release guanfacine|
3194255|NCT01238575|Placebo Comparator|Inactive placebo|
3194256|NCT01238562|Experimental|YPEG-Filgrastim, 10mcg/kg|
3194257|NCT01238562|Experimental|YPEG-Filgrastim, 20mcg/kg|
3194258|NCT01238562|Experimental|YPEG-Filgrastim, 30mcg/kg|
3194259|NCT01238562|Experimental|YPEG-Filgrastim, 45mcg/kg|
3194260|NCT01238562|Experimental|YPEG-Filgrastim, 60mcg/kg|
3194261|NCT01238549||Spinal Cord Injury|Participants with SCI
3194262|NCT01238536|Experimental|Epidural Steroid injection|"Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.~Intervention: Epidural steroid with local anesthetic injection~2cc of .25 - 1% lidocaine and glucocorticoid (Kenalog 40-120 mg, depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg)"
3194263|NCT01238536|Active Comparator|Epidural local anesthetic injection|Intervention: Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
3194264|NCT01238523|Experimental|Long leg cast in full extension|Long leg cast in full extension with instructions to begin immediate weight bearing as tolerated on the injured extremity
3194265|NCT01238523|Experimental|Long leg cast with 45 degrees of flexion|Long leg cast with 45 degrees of flexion at the knee with instructions not to bear weight on the injured extremity
3194266|NCT01238510|Active Comparator|Provisional fKBT|Stent technique that final kissing balloon technique(fKBT) is performed if side branch flow was aggravated to TIMI0-2 after stent deployment
3194267|NCT01238510|Active Comparator|Routine fKBT|Stent technique that fKBT was mandatory irrespective of side branch flow after stenting.
3194268|NCT01238497||Registry 1 - SOURCE XT|Registry 1: All patients implanted with a SAPIEN XT valve, via Transfemoral access using NovaFlex (for 23mm and 26mm valve), or via Transapical access using Ascendra2 (23mm, 26mm and 29mm valve)
3194269|NCT01238497||Registry 2 - Ascendra+|Registry 2: All patients implanted with a SAPIEN XT Valve, via Transapical or Transaortic access using Ascendra+ delivery system (23mm, 26mm and 29mm valve)
3194270|NCT01238497||Registry 3 - NovaFlex+ 29 mm|Registry 3: All patients implanted with a SAPIEN XT valve, 29mm only, via Transfemoral access using NovaFlex+
3194271|NCT01238484|Active Comparator|Control|Patients in the control group will be treated with the current standard of care including shoe modification and home stretching exercises.
3194272|NCT01238484|Experimental|Experimental|Patients assigned to the experimental group will receive the current standard of care as well as the Ankle Dorsiflexion Dynasplint.
3194273|NCT01238471|Experimental|Propranolol|Oral propranolol for premature infants allocated to this arm by randomization
3194274|NCT01238471|Placebo Comparator|Oral sucrose 5%|Placebo: Oral sucrose 5% for premature infants allocated to control arm by randomization
3194275|NCT01238458|Experimental|[18F]AV-45 PET amyloid binding imaging|
3194276|NCT01238432||Inpatient population|Children with asthma who are admitted to the hospital with an exacerbation.
3194277|NCT01238432||Outpatient population|Children with asthma who have not been admitted to the hospital with an exacerbation.
3194278|NCT01238432||Healthy controls|Children without asthma or any other chronic condition.
3194281|NCT01238406|Experimental|MD-logic Artificial Pancreas (MDLAP) system|Use of the closed loop MD-logic Artificial Pancreas(MDLAP)System
3194282|NCT01238406|Active Comparator|Standard treatment with insulin pump|Standard treatment with sensor augmented pump therapy
3194283|NCT01238393|Experimental|Ranibizumab|('intravitreal ranibizumab' )
3194284|NCT01238380||Diabetes diagnosed under 30 years|Patients currently under 50 years of age diagnosed with diabetes under 30 years.
3194285|NCT01238367|Experimental|recombinant factor VIII (N8)|
3194286|NCT01238354|Active Comparator|Without friend|Being in the weight loss programme without friend or family member
3194287|NCT01238354|Experimental|With friend|Having the friend or family member stay together with the patient for 2-3 days for every 3 week stay at the clinic in the weight loss programme
3194288|NCT01238341||Pancreatobiliary disease|Patients who have altered gastric anatomy who need an ERCP with an overtube for evaluation of pancreatobiliary disease.
3194289|NCT01238328|Experimental|Transplantation|
3194290|NCT01238315|Other|HuCNS-SC|
3194291|NCT01238302|Placebo Comparator|Conventional group|
3194292|NCT01238302|Experimental|PRP group|
3194293|NCT01238289|Placebo Comparator|Control group|This arm continues with standard care at community clinic
3194294|NCT01238289|Experimental|Peer Education|This group receives 8 weeks of peer led self management education classes and subsequent monthly support groups for a total of 10 months
3194295|NCT01238250||16p11.2 Deletions|Individuals with documented 16p11.2 deletions.
3194296|NCT01238250||16p11.2 Duplications|Individuals with documented 16p11.2 duplications
3194297|NCT01238250||1q21.1 Deletions|Individuals with documented 1q21.1 deletions
3194298|NCT01238250||1q21.1 Duplications|Individuals with documented 1q21.1 duplications
3194299|NCT01238250||Single Gene Variants|Individuals with documented pathogenic or likely pathogenic variants in a gene related to autism spectrum disorder and/or developmental delay
3194300|NCT01238237|Experimental|Cetuximab|
3194301|NCT01238224|Placebo Comparator|Placebo|A single dose of placebo is administered 30 min before a mixed meal.
3194302|NCT01238224|Active Comparator|Tadalafil|A single dose of tadalafil 20 mg is administered 30 min before a mixed meal.
3194303|NCT01238211|Experimental|Treatment (daunorubicin hydrochloride, cytarabine, dasatinib)|"INDUCTION THERAPY (course 1): Patients receive daunorubicin hydrochloride IV on days 1-3, cytarabine IV continuously over 168 hours on days 1-7, and dasatinib PO QD on days 8-21. Patients with responsive disease on day 21 undergo consolidation therapy, and patients with non-responsive disease on day 21 (bone marrow cellularity >= 20% and leukemia blasts >= 5%) receive a second course of induction therapy.~INDUCTION THERAPY (course 2): Patients receive daunorubicin hydrochloride IV on days 1-3, cytarabine IV continuously over 120 hours on days 1-5, and dasatinib PO QD on days 6-19. Patients achieving complete response receive consolidation therapy.~CONSOLIDATION THERAPY: Patients receive high-dose cytarabine IV over 3 hours on days 1, 3, and 5, and dasatinib PO QD on days 6-26 or 7-27. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients in complete remission receive continuation therapy."
3194304|NCT01238172|Experimental|Arm A - MEAL Program Intervention|Patients will receive dietary education and telephone counseling sessions over 24 months.
3194305|NCT01238172|Experimental|Arm B - Prostate Cancer Foundation Booklet|Patients receive information about diet, nutrition, exercise and cancer. Patients also receive regularly scheduled newsletters.
3194306|NCT01238159|Experimental|CCRT+MIDLE|Patients who are planned to be treated with CCRT plus MIDLE chemotherapy. CCRT means concurrent chemoradiation, and MIDLE represent systemic chemotherapy.
3194307|NCT01238146|Experimental|Arm I|Patients receive obatoclax mesylate IV over 3 hours on days 1-3, rituximab IV over 4-8 hours on day 1, and bendamustine hydrochloride IV over 30 minutes on days 1-2.
3194308|NCT01238146|Experimental|Arm II|Patients receive rituximab and bendamustine hydrochloride as in arm I.
3194309|NCT01238133|Experimental|Treatment (RO4929097, paclitaxel, carboplatin, surgery)|Patients receive gamma-secretase inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17, paclitaxel IV over 60 minutes on days 1, 8, and 15 (day -1 of course one), and carboplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Within 4 weeks after completion of neoadjuvant therapy, patients undergo definitive breast surgery.
3194310|NCT01238120|Active Comparator|Placebo and Home-Based Exercise|200mg placebo (taken twice a day at least 8 hours apart) for a period of 6 weeks and a progressive walking and resistance band exercise program called Exercise for Cancer Patient (EXCAP) for a period of 6 weeks.
3194311|NCT01238120|Active Comparator|Ibuprofen 200mg BID, Home-Based Exercise|200mg ibuprofen (taken twice a day at least 8 hours apart) and a progressive walking and resistance band exercise program called Exercise for Cancer Patient (EXCAP) for a period of 6 weeks.
3194312|NCT01238120|Placebo Comparator|Placebo|200mg placebo (taken twice a day at least 8 hours apart) for a period of 6 weeks.
3194313|NCT01238120|Active Comparator|Ibuprofen 200 mg BID|200mg ibuprofen (taken twice a day at least 8 hours apart) for a period of 6 weeks.
3194314|NCT01238107|Experimental|High dose|
3194315|NCT01238107|Experimental|Low dose|
3194316|NCT01238107|Placebo Comparator|Placebo|
3194317|NCT01238094|Experimental|FOLFIRI or XELIRI/simvastatin|FOLFIRI or XELIRI/simvastatin
3194318|NCT01238068|Active Comparator|Gamma nail, fracture stabilization, better walking|
3194319|NCT01238055|Experimental|Docetaxel + Sunitinib|Docetaxel and Sunitinib
3194320|NCT01238055|Active Comparator|Docetaxel|Docetaxel only
3194321|NCT01238042|Experimental|Light Dose Escalation|Light Dose escalated from 150 joules/cm to 200 joules/cm
3194322|NCT01238029|Experimental|Capecitabine, Lapatinib, Vinorelbine|
3194323|NCT01238016|Other|device|Device implant and EEG recording
3194324|NCT01238003||Hospitalized patients|
3194325|NCT01237977|Experimental|Botulinum toxin type A(Meditoxin®)|
3194326|NCT01237977|Active Comparator|Botulinum toxin type A(Botox®)|
3194327|NCT01237964|Experimental|Xiaflex ( Collagenase use)|all 10 patients will be selected from out burn's clinic pool and will be injected using collagenase
3194565|NCT01236326|Active Comparator|Conventional LDN|
3194566|NCT01236313||TEE report|Cardiac surgery patients requiring TEE
3194328|NCT01237951|Experimental|GemBuMel|"Gemcitabine 1875 mg/m^2 IV (75 mg/ m2 bolus followed by 1800 mg/m^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.~Busulfan 32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan area under curve (AUC) 4,000 by vein on Days -8 to -5 as an outpatient or inpatient.~Melphalan 60 mg/m^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.~Palifermin 60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~Palifermin 60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient.~Dexamethasone 8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.~Stem Cell Transplant: On Day 0, stem cells returned to body by vein over 30-60 minutes."
3194329|NCT01237938|Experimental|Low Glycemic Diet|
3194330|NCT01237925|Experimental|Dexchlorpheniramine 1% gel|
3194331|NCT01237925|Active Comparator|Dexchlorpheniramine 1% cream|
3194332|NCT01237899|Experimental|1 mg LY2623091|Daily by mouth for 7 days
3194333|NCT01237899|Experimental|10 mg LY2623091|Daily by mouth for 7 days
3194334|NCT01237899|Experimental|100 mg LY2623091|Daily by mouth for 7 days
3194335|NCT01237899|Experimental|Up to 200 mg LY2623091|Daily by mouth for 7 days
3194336|NCT01237899|Placebo Comparator|Placebo|Daily by mouth for 7 days
3194337|NCT01237899|Active Comparator|50 mg Eplerenone|Daily by mouth for 7 days
3194338|NCT01237873|Experimental|Ali/Amlo|Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg
3194339|NCT01237847|Other|Wait List|
3194340|NCT01237847|Experimental|2 phone sessions|
3194341|NCT01237847|Experimental|4 phone sessions|
3194342|NCT01237834||Heavy smokers, 15 or more cigarettes/day|Nicotine dependent.
3194343|NCT01237834||Light smokers (chippers)|Less than 2 cigarettes/day, at least 2 days/week. Non nicotine-dependent.
3194344|NCT01237834||Non smokers|
3194345|NCT01237821|Active Comparator|BenzaClin|Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with > or equal to 15 inflammatory lesions, > or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments
3194346|NCT01237821|Active Comparator|effaclar|Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with > or equal to 15 inflammatory lesions, > or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments
3194347|NCT01237808|Active Comparator|Standard arm|6 cycles of chemotherapy (low-dose cytarabine and etoposide) without ATRA
3194348|NCT01237808|Experimental|Investigational arm|6 cycles of chemotherapy (low-dose cytarabine and etoposide) with ATRA (All-trans-Retinoic acid)
3194349|NCT01237795|Experimental|0.01% fluorosurfactant|An experimental formula for denture hygiene containing 0.01% fluorosurfactant.
3194350|NCT01237795|Experimental|1.0% chloramine T|An experimental formula for denture hygiene containing 1.0% chloramine T.
3194351|NCT01237795|Experimental|0.2% chloramine T|An experimental formula for denture hygiene containing 0.2% chloramine T.
3194352|NCT01237795|Active Comparator|Proprietary dentifrice.|A proprietary denture-specific dentifrice.
3194353|NCT01237782|Experimental|Propolis solution|A proprietary denture cleanser with propolis as the active agent.
3194354|NCT01237782|Placebo Comparator|Saline solultion|Physiologic saline solution.
3194355|NCT01237769|Active Comparator|Vitamin D|All patients will be instructed to exercise and lose weight according to the NCEP-ATP III diet. The participants will be randomized in an open manner into one of the following 2 treatment groups: a) cholecalciferol (VitD3) (2200 IU/day) plus lifestyle measures or b) only lifestyle measures. Recruitment will be completed within one year. The reassessment of the patients will be done 3 months after starting of treatment.
3194356|NCT01237769|Active Comparator|Lifestyle measures|
3194357|NCT01237756|Experimental|pediatric|
3194358|NCT01237730|Active Comparator|Cefuroxime group|Use the cefuroxime as prophylactic antiobiotics, according to the clinical guideline.
3194359|NCT01237730|Experimental|Tailored antibiotics group|Tailored antibiotic is selected according to the patient's oropharyngeal microorganisms.
3194360|NCT01237717||normotensive subjects|subjects without hypertension, and without diabetes, ischemic heart disease, major arrhythmia, heart failure, secondary hypertension, high grade renal disease,
3194361|NCT01237717||Hypertensive subjects|"subjects with hypertension,~currently not treated at least within 6 months~without diabetes, ischemic heart disease, major arrhythmia, heart failure, secondary hypertension, high grade renal disease,"
3194362|NCT01237704|Active Comparator|Traditional rehabilitation (TR)|
3194363|NCT01237704|Active Comparator|Transcutaneous electrical stimulation (ES)|
3194364|NCT01237691|Experimental|HOPE supervision|Parolee supervised under California's new HOPE parole model.
3194365|NCT01237691|Active Comparator|Parole-as-usual|Parolees supervised under California parole-as-usual.
3194366|NCT01237678|Experimental|IMGN901 with carboplatin and etoposide|Patients will receive IMGN901 along with carboplatin and etoposide for up to 6 cycles and then be able to continue on IMGN901 alone until no further benefit or toxicity.
3194367|NCT01237678|Active Comparator|Carboplatin and Etoposide|Patients will receive Carboplatin and etoposide for up to 6 cycles.
3194368|NCT01237665|Experimental|IXO regimen|single-group
3194369|NCT01237652||ISH and normotensive|This is a prospective cohort study to compare the incidence of perioperative myocardial ischemia between ISH and normotensive patients admitted for elective non-cardiac surgery. To reduce the number of confounding factors for perioperative myocardial ischemia, RCRI Class I or II patients will be recruited.
3194370|NCT01237652||ISH, Normotensive|This is a prospective cohort study to compare the incidence of perioperative myocardial ischemia between ISH and normotensive patients admitted for elective non-cardiac surgery. To reduce the number of confounding factors for perioperative myocardial ischemia, RCRI Class I or II patients will be recruited.
3194371|NCT01237639|Experimental|Restrictive Red blood cell Transfusion|Transfusion Trigger of 70g/L with an aim to maintain Hemoglobin between 80-90g/L
3194372|NCT01237639|Active Comparator|Liberal Red blood Cell Transfusion|Transfusion Trigger of 90g/L with an aim to maintain Hemoglobin between 100-110g/L
3194373|NCT01237613|Experimental|Artelon|This is an open, prospective study with an anticipated enrollment of 10 patients with chronic or repeat Achilles tendon rupture undergoing surgical repair augmented with Artelon® Tissue Reinforcement.
3194374|NCT01237600|Experimental|Cultivated limbal transplantation|
3194375|NCT01237587|Experimental|Duloxetine|"Blinded treatment period: 30mg or 60mg once daily for 13 weeks~Open label extension: 30mg or 60mg Duloxetine once daily for 26 weeks~Taper period: 30mg Duloxetine or placebo once daily for 1 week."
3194376|NCT01237587|Placebo Comparator|Placebo|"Blinded treatment period:Placebo once daily for 13 weeks~Open label extension: 30mg or 60mg Duloxetine once daily for 26 weeks~Taper period: 30mg Duloxetine or placebo once daily for 1 week."
3194377|NCT01237574||Patients|Patients with chronic alcoholic and/or metabolic liver disease
3194378|NCT01237561|Experimental|spirometry, patient activation tool|"Receive Portable Spirometer~Spirometry training of staff~Provide clinician with web-based COPD interactive guideline tool~Provide clinician with patient activation tool~Train clinicians (tools, integration into workflow)~Academic Detailing"
3194379|NCT01237561|No Intervention|Usual Care|Spirometer and spirometry training of staff
3194380|NCT01237548||All participants|Normal People who have smoked Water-pipe, at least once before.
3194381|NCT01237535|Experimental|Luteal support with progesterone only|Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel)Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.
3194382|NCT01237535|Experimental|Luteal support with estrogen + progesterone|Luteal support with estrogen + progesterone [(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg].
3194383|NCT01237535|No Intervention|No luteal support|
3194384|NCT01237522|Active Comparator|Homozygote for the A270S wildetype|
3194385|NCT01237522|Active Comparator|Homo- or heterozygote for A270S minor alleles|
3194386|NCT01237509||group1|Patients with T1D
3194387|NCT01237496|Experimental|1|
3194388|NCT01237483|Other|Erbitux Radiotherapy|Radiotherapy during 5 weeks and concurrent Erbitux once a week.
3194389|NCT01237470|Experimental|Desarda group|Patients with primary inguinal hernia operated using the Desarda technique
3194390|NCT01237470|Experimental|Lichtenstein group|Patients with primary inguinal hernia operated using the Lichtenstein technique.
3194391|NCT01237457|Experimental|Treatment|
3194392|NCT01237444|Experimental|lopinavir/ritonavir plus lamivudine|"ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"
3194393|NCT01237444|Active Comparator|lopinavir/ritonavir plus two nucleosides|"ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype"
3194394|NCT01237431|Experimental|liver transplanted patients|Target group to confirm the hypothesis. Transplantation has to be between 6 an 24 Month before participation.
3194395|NCT01237431|Active Comparator|kidney transplanted patients|Control group, age, gender and medication matched. Transplantation has to be between 6 an 24 Month before participation.
3194396|NCT01237418||Myocardial Infarction|Any patient over 18 years admitted for myocardial infarction (MI) of less than 48 hours, characterized by the typical rise and fall of troponin or CPKMb
3194397|NCT01237405||Knee Osteoarthritis|"Unilateral or bilateral knee osteoarthritis on radiograph associated with knee pain on most days of any one-month in the last year in at least one knee.~Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi)."
3194398|NCT01237392|Active Comparator|Contact Ultrasonic Debridement Device|
3194399|NCT01237392|Active Comparator|Standard Sharp Debridement|
3194400|NCT01237379||Health Controls|
3194401|NCT01237379||Bipolar Patients with High-Risk of Mania|
3194402|NCT01237379||Bipolar Patients with Ultra-High Risk|
3194403|NCT01237379||First Manic Episode Bipolar Youth|
3194404|NCT01237366|Experimental|Reslient Affective Processing Therapy (RAPT)|
3194405|NCT01237366|No Intervention|Attention-Control|Participants will complete 7 sessions where they will be asked to write about neutral topics and complete psychological measures for the purposes of matching for attention and reimbursement.
3194406|NCT01237353|Experimental|betaine hydrochloride and rabeprazole|
3194407|NCT01237340|Experimental|Saizen®|
3194408|NCT01237327|Active Comparator|1|
3194409|NCT01237327|Experimental|2|
3194410|NCT01237314||Glargine Group|After baseline titration of metformin, this group will take glargine along with metformin.
3194411|NCT01237314||Exenatide Group|After baseline titration of metformin, this group will take exenatide along with metformin.
3194412|NCT01237314||Glargine and Exenatide Group|After baseline titration of metformin, this group will take glargine and exenatide along with metformin.
3194413|NCT01237301|Active Comparator|CGM Group|Wear an unblinded CGM for 16 weeks.
3194414|NCT01237301|Active Comparator|SMBG Group|Use SMBG 4 to 7 times a day for 16 weeks.
3194415|NCT01237288|Experimental|Z-521|
3194416|NCT01237275|Experimental|SSRI treated group|SSRI treated group are depressive patients treated with fluoxetine, paroxetine or sertraline
3194417|NCT01237262|Active Comparator|TNF alfa inhibitors|Male and female adult patients with a diagnosis of moderate to severe psoriasis (when PASI score is > 10 and BSA is > 10%). The overall study enrolment plan is 20 patients. Patients will be screened before the beginning of clinical trial by blood sample in order to exclude major contraindications to use of anti TNF α drugs.
3194418|NCT01237249|Active Comparator|MPV followed by Revlimid/Low Dose Dexamethasone (Rd)|Melphalan/Prednisone/Velcade (MPV) followed by Revlimid/Low Dose Dexamethasone (Rd)
3194419|NCT01237249|Experimental|Alternating MPV with Revlimid/Low Dose Dexamethasone|Alternating Velcade/Melphalan/Prednisone (MPV) with Revlimid/Low Dose Dexamethasone (Rd)
3194420|NCT01237236|Experimental|LEE011|
3194421|NCT01237223|Placebo Comparator|Placebo|In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In single blind run-in (4 weeks) and double blind treatment period (8 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily.
3194422|NCT01237223|Active Comparator|Aliskiren 150 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."
3194423|NCT01237223|Active Comparator|Amlodipine 2.5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."
3194424|NCT01237223|Active Comparator|Amlodipine 5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."
3194425|NCT01237223|Experimental|Aliskiren/amlodipine 150/2.5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period."
3194426|NCT01237223|Experimental|Aliskiren/amlodipine 150/5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."
3194427|NCT01237197|Experimental|Exenatide, then Open-Label Exenatide|Exenatide 5 micrograms (mcg): administered with injection twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study (5 months)
3194428|NCT01237197|Placebo Comparator|Placebo, then Open Label Exenatide|Placebo injection twice a day for three months; Exenatide open label 5mcg twice a day for one month and up-titrated to 10mcg twice a day for remaining two months of study.
3194429|NCT01237184||biocortical fixation|Bi-cortically fixed implants intentionally engaging sinus floor beyond up to 1-2mm without graft but using stopper drill and self-threading concept
3194430|NCT01237184||unicortical fixation|Short implants placed in proximity of the sinus without sinus floor involvement
3194431|NCT01237184||indirect sinus lift|implants engaging both crest and sinus floor but with green stick fracture
3194432|NCT01237171||Sub-lobar resection with Cesium-131|All enrolled patients will undergo sub-lobar resection and brachytherapy implant with Cesium-131 in an effort to study and quantify recurrence/control patterns.
3194433|NCT01237158||healthy controls|
3194434|NCT01237158||bipolar disorder type I|
3194435|NCT01237145||non-EAA, pigeon|subject with BAL because of diseases not suspected to be EAA
3194436|NCT01237145||EAA, pigeon|Bird fanciers with a typical clinical presentation suspected for pigeon induced EAA
3194437|NCT01237119|Experimental|Liraglutide|A once-daily glucagon-like peptide 1 (GLP-1) analogue. Currently has regulation approval for use in type 2 diabetics (ref: guidelines)
3194438|NCT01237119|Placebo Comparator|Placebo|Liraglutide-Placebo manufactured by Novo Nordisk.
3194439|NCT01237106|Experimental|In Vitro Maturation (IVM)|
3194440|NCT01237080|Experimental|Fastrach|50 persons beeing intubated using the Fastrach.
3194441|NCT01237080|Experimental|GlideScope|50 persons beeing intubated using the GlideScope.
3194442|NCT01237067|Experimental|Group 1|Dose esc: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis
3194443|NCT01237067|Experimental|Group 2A|Randomized: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
3194444|NCT01237067|Experimental|Group 2B|Randomized: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
3194445|NCT01237054|Experimental|Imaging in MGUS, SMM, and MM|Participants will have three imaging studies on separate days: a standard positron emission tomography/computed tomography scan (18-FDG PET/CT), a PET/CT scan with an experimental sodium fluoride-based drug (18-NaF PET/CT), and magnetic resonance imaging (DCE-MRI).
3194446|NCT01237041|Experimental|Niacin First|Subjects receive niacin on day 1 then cross over to receive placebo on day 2.
3194447|NCT01237041|Experimental|Placebo First|Subjects receive placebo on day 1 then cross over to receive niacin on day 2
3194448|NCT01237028|Experimental|oral calcitriol|Calcio®
3194449|NCT01237028|No Intervention|placebo|
3194450|NCT01237002||Group 1|117 patients with cumulative clamping time between 60 and 120 minutes
3194451|NCT01237002||Group 2|72 patients with cumulative clamping time longer than 120 minutes
3194452|NCT01236989|Experimental|Anatomical resection|
3194453|NCT01236989|Active Comparator|Non-anatomical resection|
3194454|NCT01236976|Experimental|Intervention Group|"Participants in Group A will receive a triad of interventions comprising body weight supported treadmill training (BWSTT), functional electrical stimulation (FES)-assisted cycling, and trunk and upper and lower extremity exercise. These interventions will be provided at the spinal unit.~It is neither feasible nor desirable that every participant receives identical intervention because of the expected differences in impairments and activity limitations that he/she experiences. Project staff will use their clinical judgment to select exercises suitable for each participant and to progress them as appropriate. All exercises selected will be documented in the participant source notes."
3194455|NCT01236976|Other|Control Group|"Participants in Group B will receive an upper body strength and fitness program. This program may be provided at the spinal unit, or an appropriately equipped gymnasium as approved by the SCIPA Full-On Project Committee. It will be based on the Burn Rubber Burn (BRB) exercise program already established in Sydney. BRB is a circuit-based exercise program incorporating resistance and cardiovascular training. For this protocol, the circuit will comprise several stations using different pieces of equipment.~The participants will be supervised by a therapist and/or clinical exercise instructor and exercises will be progressed as appropriate to build strength and endurance. Guidelines for the content and delivery of exercises will be clearly outlined in a handbook to ensure standardisation across sites."
3194456|NCT01236963|Experimental|Essential oils mouthrinse|Subjects use the essential oils mouthrinse
3194457|NCT01236963|Active Comparator|Dental floss|Subjects use dental floss
3194458|NCT01236950|Experimental|Delmopinol mouthrinse|Subjects use the delmopinol mouthrinse
3194459|NCT01236950|No Intervention|Control|Subjects with no use of mouthrinse
3194460|NCT01236950|Experimental|Essential oils mouthrinse|Subjects using the essential oils mouthrinse
3194461|NCT01236937|Active Comparator|Bellows-based breath hold biopsy|CT guided biopsy is preformed with the use a bellows-based breath
3194462|NCT01236937|No Intervention|No Bellows-based breath hold.|CT guided biopsy is preformed without the use a bellows-based breath
3194463|NCT01236924|Experimental|Lifestyle counseling|
3194464|NCT01236911||Calcium after moderate-severe TBI|Patients with moderate -severe TBI with less as 24 hrs , admitted in emergency. We will measure seric calcium to compare the differences between both groups
3194465|NCT01236898|Experimental|NPC-09|Period 1: NPC-09 800mg single oral dosing NPC-09 800mg three times oral dosing a day Period 2: NPC-09 800mg three times oral dosing a day for 5 consecutive days
3194466|NCT01236885|Experimental|Supportive care (Glucommander)|Patients receive blood glucose management with IV insulin using Glucommander.
3194467|NCT01236872|Experimental|Beetroot juice|250ml beetroot juice ingestion
3194468|NCT01236872|Placebo Comparator|Water|250ml low-nitrate water placebo
3194469|NCT01236859|Placebo Comparator|placebo|The patients in the placebo group received equal numbers of identical looking placebo 2 h before operation
3194470|NCT01236859|Active Comparator|gabapentin|Patients in the gabapentin group received two capsules of gabapentin 300 mg (Neurontin®, Pfizer) at 2 h before operation.
3194471|NCT01236846|Placebo Comparator|Plain Yogurt Drink|Daily intake of unfortified yogurt drink(500 ml) for 12 weeks
3194472|NCT01236846|Experimental|VDR Genotype (aa)|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
3194473|NCT01236846|Experimental|VDR Genotype (AA)|Daily intake of yogurt drink fortified (500 ml) with 1000 IU vitamin D for 12 weeks
3194474|NCT01236846|Experimental|VDR genotype (Aa)|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
3194475|NCT01236833|No Intervention|Fasting|
3194476|NCT01236833|Active Comparator|Lactated Ringer's Solution|
3194477|NCT01236820||Normal|Healthy population
3194478|NCT01236820||CKD Patients|Chronic Kidney Disease, in Stage III-V
3194479|NCT01236820||HD patients|End-stage renal disease patients undergoing hemodialysis
3194480|NCT01236807|Active Comparator|MR Inform|Management guided by the result of the MR perfusion scan. Possible intervention: coronary artery revascularization.
3194481|NCT01236807|Active Comparator|FFR Inform|Management guided by the result of FFR measurement. Possible intervention: coronary artery revascularization.
3194482|NCT01236794|Experimental|Lifestyle and Exercise Intervention|
3194483|NCT01236781|Experimental|Group A: Screening|Group A comprises 500 asymptomatic women with no history of breast cancer who are scheduled for routine screening of the breasts with FFDM.
3194484|NCT01236781|Experimental|Group B: Diagnostic Enriched Population|Approximately 50 asymptomatic women with no history of breast cancer who have been informed of positive (abnormal) findings from a recent (within 30 days) FFDM screening will be recruited to Group B prior to their diagnostic imaging (e.g., diagnostic FFDM and/or ultrasound and/or other).
3194485|NCT01236768|Experimental|AG200-15|Thin transdermal contraceptive delivery system (TCDS) that gives systemic exposure of levonorgestrel (LNG) and ethinyl estradiol (EE)
3194486|NCT01236768|Active Comparator|Levora|oral contraceptive containing 150mcg of LNG and 30mcg of EE
3194487|NCT01236755|Experimental|from single-vision glasses to ortho-k|Children will be required to wear single-vision glasses for the first 7 months of the study and will be switched to wear ortho-k lenses in the next 7 months
3194488|NCT01236742|Experimental|single-vision glasses and ortho-k lenses|Children who are currently wearing ortho-k lenses at night for correction of refractive errors will be switched to wear single-vision glasses for the first 7 months and then switched back to ortho-k lenses for the next 7 months
3194489|NCT01236742|Active Comparator|ortho-k lenses|Children who are currently wearing ortho-k lenses at night for the correction of refractive errors will continue with the current treatment and serve as the first control group
3194490|NCT01236742|Other|single-vision glasses|Children who are currently wearing single-vision spectacles in the daytime for correcting their refractive errors will continue with the current treatment and serve as the second control group
3194491|NCT01236729||Knee replacement recipients|Patients (aged 75 years or over) with late-stage arthritis who have undergone or are undergoing primary knee replacement
3194492|NCT01236716|Experimental|Albumin paclitaxel plus carboplatin|Treatment of Albumin paclitaxel plus carboplatin
3194493|NCT01236716|Active Comparator|Gemcitabine plus carboplatin|Treatment of Gemcitabine plus carboplatin
3194567|NCT01236300|Experimental|Cellvizio system|
3194494|NCT01236703||ICU patients|ICU patients (post-operative and none operative patients) will be enrolled in the study. They are followed up until the end of ICU stay or, for a maximum of 60 days.
3194495|NCT01236677||Community acquired pneumonia,age≥14 ys|Patients with community acquired pneumonia,age≥14 ys and less than one week after the onset of symptoms, without pregnancy,breast-feeding,HIV infection,recent 90-day hospitalized history and in nursing homes or rehabilitation hospitals
3194496|NCT01236664|Experimental|Memory Training|
3194497|NCT01236664|Active Comparator|Control workshop|
3194498|NCT01236651|Experimental|meperidine and duration of 1st stage of labor|meperidine 100mg i.v in 1st stage of labor and calculate the duration of the 1st stage of labor
3194499|NCT01236651|Experimental|drotaverine and duration of 1st stage of labor|drotaverine 40mg i.v in 1st stage of labor and calculate the duration of the 1st stage of labor
3194500|NCT01236638|Experimental|Momelotinib|
3194501|NCT01236625||No adhesiolysis|All patient undergoing elective laparotomy or laparoscopy with no need for adhesiolysis during the procedure.
3194502|NCT01236625||Adhesiolysis|All patient undergoing elective laparotomy or laparoscopy requiring adhesiolysis during the procedure.
3194503|NCT01236612|Experimental|Immunization + bloodstage challenge|
3194504|NCT01236612|Active Comparator|Immunization + mosquito challenge|
3194505|NCT01236612|Placebo Comparator|Control - Bloodstage challenge|
3194506|NCT01236612|Placebo Comparator|Control - Mosquito challenge|
3194507|NCT01236599|No Intervention|traditional care|Preterm Infants were placed under a radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel), dried off and wrapped up in a sterile preheated field
3194508|NCT01236599|Experimental|Polyethylene bag with previous drying|infants were placed under the radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel), dried off, and wrapped up in a polyethylene bag, leaving their faces discovered as well as the access at umbilical catheters or veined access.
3194509|NCT01236599|Experimental|Polyethylene bag without previous drying|Preterm infants were placed under a radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel) and without previous body drying (only the head was dried), were wrapped up with the polyethylene bag, leaving their faces discovered as well as the access to umbilical catheters or veined access
3194510|NCT01236573|Experimental|Group 1 - CD8 + TIL expressing IL-12 1x10^6|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of interleukin-12 (IL-12) gene-transduced tumor infiltrating lymphocytes (TIL).
3194511|NCT01236573|Experimental|Group 2 - CD8 + TIL expressing IL-12 3x10^6|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3194512|NCT01236573|Experimental|Group 3 - CD8 + TIL expressing IL-12 1x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3194513|NCT01236573|Experimental|Group 4- CD8+TIL expressing IL-12 3x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3194514|NCT01236573|Experimental|Group 5 - Bulk TIL expressing IL-12 1x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3194515|NCT01236573|Experimental|Group 6 - Bulk TIL expressing IL-12 3x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3194516|NCT01236573|Experimental|Group 7- Bulk TIL expressing IL-12 1x10^8|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3194517|NCT01236573|Experimental|Group 8 - Bulk TIL expressing IL-12 3x10^8|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3194518|NCT01236573|Experimental|Group 9 - Bulk TIL expressing IL-12 1x10^9|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3194519|NCT01236573|Experimental|Group 10- Bulk TIL expressing IL12 3x10^9|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3194520|NCT01236573|Experimental|Group 11 - Bulk TIL expressing MTD 1x10^9 (Phase 2)|Maximum tolerated dose (MTD). Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3194521|NCT01236560|Experimental|Arm I (vorinostat)|Patients undergo RT 5 days a week for 6 weeks and receive vorinostat at the maximum-tolerated dose determined in the feasibility study.
3194522|NCT01236560|Experimental|Arm II (vorinostat and temozolomide)|Patients undergo RT as in arm I and receive temozolomide PO once daily for 42 days beginning on day 5 of RT.
3194523|NCT01236560|Experimental|Arm III (vorinostat and bevacizumab)|Patients undergo RT as in arm I and receive bevacizumab IV over 30-90 minutes on days 22 and 36.
3194524|NCT01236560|Experimental|Arm IV (vorinostat and temozolomide)|Patients receive RT and temozolomide as in phase II, arm II.
3194525|NCT01236560|Experimental|Arm V (vorinostat, bevacizumab, temozolomide)|Patients receive treatment as in phase II, arm I or phase II, arm III, whichever was established as the superior chemoradiotherapy arm in phase II.
3194561|NCT01236352|Experimental|Phase 2 (Cohort 12): BMS-911543 (200 mg)|BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response
3194562|NCT01236339|Experimental|TIPS|TIPS with GORE® VIATORR® TIPS Endoprosthesis
3194563|NCT01236339|Active Comparator|LVP|"Large Volume Paracentesis~*A subject may be crossed-over from large volume paracentesis to TIPS with GORE® VIATORR® TIPS Endoprosthesis if the subject has completed their six month study visit and has met the criteria for cross-over (LVP failure)."
3194526|NCT01236547|Experimental|Arm I (paclitaxel, pazopanib hydrochloride, IMRT)|Patients receive paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD for 2-3 weeks. Patients then receive concurrent paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD for 6-7 weeks (or until radiation treatment is completed) and IMRT 5 days per week for 6.5 weeks (total of 66 Gy in 33 fractions). Beginning 25-31 days after the completion of IMRT, patients receive paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD. Treatment repeats every 3 weeks for 4 courses (for patients with no measurable disease) or continues in the absence of disease progression or unacceptable toxicity (for patients with measurable disease).
3194527|NCT01236547|Active Comparator|Arm II (paclitaxel, placebo, IMRT)|Patients receive paclitaxel IV over 1 hour once weekly and placebo PO QD for 2-3 weeks. Patients then receive concurrent paclitaxel IV over 1 hour once weekly and placebo PO QD for 6-7 weeks (or until radiation treatment is completed) and IMRT 5 days per week for 6.5 weeks (total of 66 Gy in 33 fractions). Beginning 25-31 days after the completion of IMRT, patients receive paclitaxel IV over 1 hour once weekly and placebo PO QD. Treatment repeats every 3 weeks for 4 courses (for patients with no measurable disease) or continues in the absence of disease progression or unacceptable toxicity (for patients with measurable disease).
3194528|NCT01236534|Active Comparator|Lubiprostone|
3194529|NCT01236534|Placebo Comparator|Sugar pill|
3194530|NCT01236521|Experimental|Arm 1: Pharmacological (PHARM)|Subjects in the Pharmacological (PHARM) arm will receive at least 8 contacts with the nurse care managers (NCM) over the trial period. Participants will have an initial visit at baseline to assess their current and past treatments for chronic lower back pain, pain intensity, and pain-related limitations. Patients' opioids will be adjusted and/or co-analgesics (or adjuvants) will be initiated. During follow-up calls, patients' pain severity, response to treatment, adherence, adverse effects, and desire to change current treatment will be assessed. Follow-up NCM telephone contacts will occur at 2 and 4 weeks after baseline, and months 2, 3, 4, 6, and 9 months. On average, these calls last between 10 to 20 minutes. Detailed logs will be kept of the timing and content of patient contacts.
3194531|NCT01236521|Experimental|Arm 2: Behavioral treatment (BEH)|Veterans randomized to behavioral treatment arm (BEH) will receive a series of 8 pain self-management/coping skills training sessions delivered by one of three primary-care based clinical psychologists. Since optimal application of non-pharmacological interventions for pain involves tailoring to patient needs, participants will be introduced to a menu of self-management and coping skills rather than receive a prescribed program. Delivery of the behavioral intervention will employ a flexible approach that is easily adapted to individual preferences and perceived need for learning specific pain coping skills. Tailoring will include the selection of relevant content and skills and assessment of readiness to change behaviors.
3194532|NCT01236508|Experimental|Nuclear imaging|PET/CT imaging with F-18 fluorodeoxyglucose
3194533|NCT01236495|Experimental|spinal morphine 0.2 mg|spinal morphine 0.2 mg
3194534|NCT01236495|Active Comparator|spinal morphine 0.3 mg|spinal morphine 0.3 mg
3194535|NCT01236482|Active Comparator|Oxytocin|
3194536|NCT01236482|Experimental|Oxytocin - ergometrine|
3194537|NCT01236469||Retrospective Patients|Pediatric (21 years of age or younger) patients who received a CryoValve SG Aortic Valve distributed during the 2000 to 2003 period as an aortic valve replacement.
3194538|NCT01236443|Experimental|HPPH|3 mg/m2
3194539|NCT01236430|Active Comparator|Ezetimibe 10mg and Atorvastatin 10mg|Ezetimibe 10mg tablet and Atorvastatin 10mg tablet coadministered
3194540|NCT01236430|Experimental|10mg Ezetimibe/10mg Atorvastatin|10mg Ezetimibe/10mg atorvastatin combination tablet
3194541|NCT01236430|Active Comparator|Ezetimibe 10mg and Atorvastatin 80mg|Ezetimibe 10mg tablet and Atorvastatin 80mg tablet coadministered
3194542|NCT01236430|Experimental|10mg Ezetimibe/80mg Atorvastatin|Ezetimibe/atorvastatin 10mg/80mg combination tablet
3194543|NCT01236417|Experimental|Exercise|Subjects will be participating in a home-based flexibility and exercise program
3194544|NCT01236404|Experimental|PB1023 Injection|Subcutaneous injection PB1023
3194545|NCT01236404|Placebo Comparator|Placebo (0.9% Sodium Chloride Injection)|Subcutaneous Injection Placebo
3194546|NCT01236391|Experimental|Participants received PCI-32765 560 mg daily|Participants were enrolled and received 560 mg/day dose, stratified into 2 groups based on prior bortezomib exposure.
3194547|NCT01236378|Experimental|sirolimus|Subjects must be taking sirolimus (1 mg tablet formulation) with or without concomitant medications, unless specifically excluded below, for prophylaxis of renal rejection.
3194548|NCT01236365|Experimental|Atorvastatin|
3194549|NCT01236365|Placebo Comparator|Placebo|
3194550|NCT01236352|Experimental|Phase 1 (Cohort 1): BMS-911543 (5 mg)|BMS-911543 5 mg capsule by mouth twice daily for 12 months or greater depending on response
3194551|NCT01236352|Experimental|Phase 1 (Cohort 2): BMS-911543 (10 mg)|BMS-911543 10 mg capsule by mouth twice daily for 12 months or greater depending on response
3194552|NCT01236352|Experimental|Phase 1 (Cohort 3): BMS-911543 (20 mg)|BMS-911543 20 mg capsule by mouth twice daily for 12 months or greater depending on response
3194553|NCT01236352|Experimental|Phase 1 (Cohort 4): BMS-911543 (40 mg)|BMS-911543 40 mg capsule by mouth twice daily for 12 months or greater depending on response
3194554|NCT01236352|Experimental|Phase 1 (Cohort 5): BMS-911543 (80 mg)|BMS-911543 80 mg capsule by mouth twice daily for 12 months or greater depending on response
3194555|NCT01236352|Experimental|Phase 1 (Cohort 6): BMS-911543 (120 mg)|BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response
3194556|NCT01236352|Experimental|Phase 1 (Cohort 7): BMS-911543 (160 mg)|BMS-911543 160 mg capsule by mouth twice daily for 12 months or greater depending on response
3194557|NCT01236352|Experimental|Phase 1 (Cohort 8): BMS-911543 (200 mg)|BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response
3194558|NCT01236352|Experimental|Phase 1 (Cohort 9): BMS-911543 (240 mg)|BMS-911543 240 mg capsule by mouth twice daily for 12 months or greater depending on response
3194559|NCT01236352|Experimental|Phase 1 (Cohort 10): BMS-911543 (320 mg)|BMS-911543 320 mg capsule by mouth twice daily for 12 months or greater depending on response
3194560|NCT01236352|Experimental|Phase 2 (Cohort 11): BMS-911543 (120 mg)|BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response
3194564|NCT01236326|Active Comparator|LESS-DN|
3194568|NCT01236274||Antipsychotic agents AND MI|In the self-controlled case series study, patients who experienced a myocardial infarction and received an antipsychotic agent during up to standard (UTS) follow-up in the GPRD will be included and will act as their own control.
3194569|NCT01236274||Myocardial Infarction|In the case-control study, all cases with a first recorded occurrence of MI during up to standard (UTS) follow-up in the GPRD will be identified
3194570|NCT01236274||No Myocardial Infarction|In the case-control study, a control group with subjects who never experienced a myocardial infarction will be matched to cases (5:1) by age, gender, General Practitioner and registration in the GPRD on the date of MI of the case
3194571|NCT01236261||Fungemia|Patients with a fungal isolate from a blood culture
3194572|NCT01236248|Experimental|Prevention Program|Girls and their mothers who are assigned to participate in a tobacco, alcohol, and other drug use prevention program aimed at young girls.
3194573|NCT01236248|No Intervention|No Prevention Program|Girls and their mothers who are assigned to participate in questionnaires only.
3194574|NCT01236235||ARV-naïve HIV patients initiated on ATV/RTV-based therapy|"Anti-retroviral (ARV)-naïve HIV patients initiated on ATV/RTV-based therapy between 2008-2010~One cohort being observed for 3 different countries"
3194575|NCT01236222|No Intervention|Control group|
3194576|NCT01236222|Experimental|Cycling to school|
3194577|NCT01236209|Active Comparator|web page|"Control group:~Information web page with some mindfulness exercises"
3194578|NCT01236209|Experimental|Webpage and situational feedback|"Intervention group:~have access to the same web-page with information about coping with pain and relaxation and are completing 3 diaries and receiving personalized feedback for 4 weeks at home through a smartphone."
3194579|NCT01236196|Experimental|Arm 1 - Telephone CBT|telephone cognitive behavior therapy for pain management
3194580|NCT01236196|Active Comparator|Arm 2 - telephone education|telephone pain education
3194581|NCT01236170||Group 1|Veterans with spinal cord injury or amputated limbs who use a wheelchair as their primary source of mobility
3194582|NCT01236157||Chest Pain|All patients that call to the SAMU-ACS because of chest pain are included
3194583|NCT01236144|Experimental|AC220 Intervention|
3194584|NCT01236144|Experimental|Plerixafor Intervention|
3194585|NCT01236144|Experimental|Ganetespib|
3194586|NCT01236131||Endometrial biospy samples|The Endometrial Biopsy samples will be provided by women enrolled in the University of Pittsburgh IRB PRO10010112 and PRO10010159
3194587|NCT01236118|Experimental|30 milligrams (mg) LY2439821|Participants will start receiving LY2439821 30 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).
3194588|NCT01236118|Experimental|80 mg LY2439821|Participants will start receiving LY2439821 80 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).
3194589|NCT01236118|Experimental|160 mg LY2439821|Participants will start receiving LY2439821 160 mg once every 2 weeks for the first 3 doses and then once every 4 weeks until Week 44.
3194590|NCT01236105|Experimental|6 mg LY2624803 Alone Morning Dosing|Participants received 6 milligrams (mg) LY2624803 alone orally (po) at approximately 0800 hours following an overnight fast.
3194591|NCT01236105|Experimental|6 mg LY2624803 Morning Dosing + Activated Charcoal|Participants received 6 mg LY2624803 po at approximately 0800 hours following an overnight fast, followed 1 hour later by a single po dose of 1 gram per kilogram (g/kg) body weight of activated charcoal, mixed with caffeine-free diet cola.
3194592|NCT01236105|Experimental|6 mg LY2624803 Alone Evening Dosing|Participants received 6 mg LY2624803 alone po at approximately 2200 hours following a 4-hour fast.
3194593|NCT01236079|Experimental|Assisted Referral & IVR|
3194594|NCT01236079|No Intervention|Usual Care|
3194595|NCT01236066||Study Group|Australian children aged < 5 years who have been vaccinated with RotaTeq or Rotarix from 2007 to 2009 as well as all children aged < 5 years hospitalised for all-cause gastroenteritis, rotavirus gastroenteritis or bronchiolitis.
3194596|NCT01236053||UK GPRD 1993-2008|The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993. Subjects are excluded from the GPRD cohort if they have a cancer diagnosis or a history of cancer prior to the cohort entry date.
3194597|NCT01236040|Experimental|Group A|Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval.
3194598|NCT01236040|Experimental|Group B|Subjects will receive 2 doses of a formulation of GSK2592984A vaccine at a 21-day interval.
3194599|NCT01236040|Placebo Comparator|Group C|Subjects will receive 2 doses of a placebo at a 21-day interval.
3194600|NCT01236040|Experimental|Group D|Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval.
3194601|NCT01236040|Experimental|Group E|Subjects will receive 2 doses of a formulation of GSK2340274A vaccine at a 21-day interval.
3194602|NCT01236040|Experimental|Group F|Subjects will receive 2 doses of a formulation of GSK2340273A vaccine at a 21-day interval.
3194603|NCT01236027||HIV-negative women|HIV-negative women who agree to have specimens collected for validation of laboratory procedures
3194604|NCT01236014||Eltrombopag & standard of care|
3194605|NCT01236014||Romiplostim & standard of care|
3194606|NCT01236014||Standard of care|
3194607|NCT01236001||Vimpat® treatment|Patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® on/after enrollment.
3194608|NCT01235988||Eltrombopag & standard of care|
3194609|NCT01235988||Standard of care|
3194610|NCT01235975|Experimental|Group A|
3194611|NCT01235975|Active Comparator|Group B|
3194612|NCT01235962|Experimental|pazopanib|Pazopanib oral agent, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.
3194613|NCT01235962|Placebo Comparator|placebo|placebo matching pazopanib 200 mg tablets, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.
3194614|NCT01235949|Experimental|Group IIBU|Immediate ibuprofen group: subjects receiving immediate ibuprofen treatment after each primary vaccine dose
3194615|NCT01235949|Active Comparator|Group DIBU|Delayed ibuprofen group: subjects receiving delayed ibuprofen treatment after each primary vaccine dose
3194616|NCT01235949|Active Comparator|Group NIBU|No ibuprofen group: subjects receiving no prophylactic ibuprofen treatment after each primary vaccine dose
3194617|NCT01235949|Experimental|Group IPARA|Immediate paracetamol group: subjects receiving immediate paracetamol treatment after each primary vaccine dose
3194618|NCT01235949|Experimental|Group DPARA|Delayed paracetamol group: subjects receiving delayed paracetamol treatment after each primary vaccine dose
3194619|NCT01235949|Active Comparator|Group NPARA|No paracetamol group: subjects receiving no prophylactic paracetamol treatment after each primary vaccine dose
3194620|NCT01235949|Experimental|Group IIBU-IIBU|1/3 of the subjects from the primary IIBU group receiving immediate ibuprofen treatment after booster vaccination
3194621|NCT01235949|Experimental|Group IIBU-DIBU|1/3 of the subjects from the primary IIBU group receiving delayed ibuprofen treatment after booster vaccination
3194622|NCT01235949|Experimental|Group IIBU-NIBU|1/3 of the subjects from the primary IIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
3194623|NCT01235949|Experimental|Group DIBU-IIBU|1/3 of the subjects from the primary DIBU group receiving immediate ibuprofen treatment after booster vaccination
3194624|NCT01235949|Experimental|Group DIBU-DIBU|1/3 of the subjects from the primary DIBU group receiving delayed ibuprofen treatment after booster vaccination
3194625|NCT01235949|Experimental|Group DIBU-NIBU|1/3 of the subjects from the primary DIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
3194626|NCT01235949|Experimental|Group NIBU-IIBU|1/3 of the subjects from the primary NIBU group receiving immediate ibuprofen treatment after booster vaccination
3194627|NCT01235949|Experimental|Group NIBU-DIBU|1/3 of the subjects from the primary NIBU group receiving delayed ibuprofen treatment after booster vaccination
3194628|NCT01235949|Active Comparator|Group NIBU-NIBU|1/3 of the subjects from the primary NIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
3194629|NCT01235949|Experimental|Group IPARA-NPARA|subjects from the primary IPARA group receiving no paracetamol treatment after booster vaccination
3194630|NCT01235949|Experimental|Group DPARA-IPARA|subjects from the primary DPARA group receiving immediate paracetamol treatment after booster vaccination
3194631|NCT01235949|Experimental|Group NPARA-IPARA|subjects from the primary NPARA group receiving immediate paracetamol treatment after booster vaccination
3194632|NCT01235936|Experimental|AKB-6548|
3194633|NCT01235923|Active Comparator|three times weekly Epo|Epo 400 units/kg three times weekly given subcutaneously for 4 weeks
3194634|NCT01235923|Active Comparator|weekly Epo|1,200 units/kg given once a week subcutaneously for 4 weeks
3194635|NCT01235910|Other|1|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
3194636|NCT01235897|Experimental|Maximum tolerated dose|
3194637|NCT01235884|Active Comparator|Lactobacillus reuteri|Dietary Supplement
3194638|NCT01235884|Placebo Comparator|Placebo|Dietary Supplement
3194639|NCT01235871|Experimental|SB1578|
3194640|NCT01235871|Placebo Comparator|Placebo|
3194641|NCT01235858|Other|Gown group|Anesthesiologists wearing sterile gown for epidural insertion
3194642|NCT01235858|Other|No Gown group|Anesthesiologists not wearing gown for epidural insertion
3194643|NCT01235845|Experimental|DC-DCIK|
3194644|NCT01235832|Active Comparator|Lower-Fat Diet|The Lower-Fat diet will provide ~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.
3194645|NCT01235832|Active Comparator|Moderate Fat Diet|This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
3194646|NCT01235832|Experimental|Avocado Diet|The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
3194647|NCT01235819|Active Comparator|Insulin alone|Type 1 DM only on Insulin
3194648|NCT01235819|Active Comparator|Insulin and Exenatide|Newly detected Type 1 DM on Insulin and exenatide
3194649|NCT01235819|Active Comparator|Insulin and Sitagliptin|Newly detected Type 1 DM using Insulin and Sitagliptin
3194650|NCT01235806|Other|MRI|MRI of the scaphoid bone fracture suspicion
3194651|NCT01235793|Experimental|DRBEAT Regimen|
3194652|NCT01235767|Experimental|ASF supplement pre-pregnancy to term|Supplement of animal-source foods rich in iron, zinc, vitamin A, and vitamin B12
3194653|NCT01235767|Experimental|ASF Supplement mid-gestation to term|Supplement of animal-source foods rich in iron, zinc, vitamin A, and vitamin B12
3194654|NCT01235767|No Intervention|Routine prenatal care|Nutrition education and iron-folate supplements during pregnancy
3194655|NCT01235754|Placebo Comparator|placebo gel|placebo transdermal gel
3194656|NCT01235754|Experimental|testosterone gel|transdermal testosterone gel
3194657|NCT01235741|Experimental|Group A|Pramlintide+Metreleptin
3194658|NCT01235741|Placebo Comparator|Group B|Placebo
3194659|NCT01235728|Experimental|Treatment Sequence 1|Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D.
3194660|NCT01235728|Experimental|Treatment Sequence 2|Participants were randomized to received MK-0873 on lower lesion A and vehicle on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D.
3194661|NCT01235728|Experimental|Treatment Sequence 3|Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D.
3194662|NCT01235728|Experimental|Treatment Sequence 4|Participants were randomized to receive MK-0873 on lower lesion A and vehicle on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D.
3194663|NCT01235728|Experimental|Treatment Sequence 5|Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D.
3194664|NCT01235728|Experimental|Treatment Sequence 6|Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D.
3194665|NCT01235728|Experimental|Treatment Sequence 7|Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D.
3194666|NCT01235728|Experimental|Treatment Sequence 8|Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D.
3194667|NCT01235715|Active Comparator|Evicel|Evicel is a fibrin sealant used for hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical. It has been shown to stop bleeding in 2 minutes or less. Evicel is a combination of a biologic activated component containing human fibrinogen and topical thrombin that functions on wet, actively bleeding tissue. It is a bioresorbable and biocompatible agent.
3194668|NCT01235715|No Intervention|no evicel|Patients will receive standard treatment for bleeding as practiced at the Hospital for Special Surgery.
3194669|NCT01235689|Experimental|Tight Control Management|"Participants randomized to receive management of disease activity using criteria based on Crohn's Disease Activity Index (CDAI), high sensitivity C-reactive protein (hs-CRP), fecal calprotectin, and corticosteroid use.~Participants received customized therapy that could include prednisone, adalimumab, and azathioprine. Participants who randomized at Week 9 meeting success criteria started with no therapy; participants who randomized prior to Week 9 or who randomized at Week 9 but did not meet the success criteria began treatment with adalimumab.~Therapy was escalated according to pre-specified tight control criteria: At Key Visit 1 the success criteria were CDAI < 150, hs-CRP, < 5 mg/L, fecal calprotectin < 250 μg/g, and absence of prednisone use. At Key Visits 3, 4, and 5 (every 12 weeks after Key visit 1), the criteria were CDAI < 150, hs-CRP < 5 mg/L, fecal calprotectin < 250 μg/g, and absence of prednisone during the preceding week."
3194670|NCT01235689|Active Comparator|Clinically Driven Management|"Participants randomized to receive management of disease activity using criteria based on Crohn's Disease Activity Index (CDAI) and corticosteroid use.~Participants received customized therapy that could include prednisone, adalimumab, and azathioprine.~Participants who randomized at Week 9 meeting success criteria started with no therapy; participants who randomized prior to Week 9 or who randomized at Week 9 but did not meet the success criteria began treatment with adalimumab.~Therapy was escalated according to pre-specified failure criteria using less stringent criteria:~At Key Visit 1 the criteria for management of disease activity were a CDAI decrease ≥ 70 (CR-70) compared to Baseline or CDAI < 200 at 1 week prior to the visit. At Key Visits 3, 4, and 5 (every 12 weeks after Key visit 1), the criteria for a change in treatment were a CDAI decrease of ≥ 100 (CR-100) compared to Baseline or CDAI < 200, and absence of prednisone during the preceding week."
3194671|NCT01235676|Experimental|Diet|Calorie restriction to reduce weight gain
3194672|NCT01235676|Experimental|Exercise|Exercise to reduce weight gain
3194673|NCT01235663|Experimental|advisory support|advisory support for six months to prolong the breast-feeding period
3194674|NCT01235650||Spinal fusion|Patients who underwent complex surgical procedures (spinal fusions) which necessitated arterial line placement and intermittent arterial blood gas analysis
3194675|NCT01235637|Active Comparator|Alfentanil|
3194676|NCT01235637|Sham Comparator|Sufentanil|
3194677|NCT01235624|Other|patient|Patient suffering of adRP that accept to participate at this study have a blood prelevement for genetic analysis (intervention)
3194678|NCT01235598|Other|Placebo followed by Certolizumab Pegol (CZP)|Placebo, saline solution for sc injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
3194679|NCT01235598|Experimental|Certolizumab Pegol (CZP)|Certolizumab Pegol (CZP) 400 mg for subcutaneous injection at Weeks 0, 2 and 4 followed by 200 mg 2-weekly from Week 6 to Week 40
3194680|NCT01235585|Experimental|Bitopertin oral dose level 1|
3194681|NCT01235585|Experimental|Bitopertin oral dose level 2|
3194682|NCT01235585|Placebo Comparator|Placebo|
3194683|NCT01235572|Experimental|Health services research (early discharge, outpatient care)|Patients are discharged within 72 hours after completion of chemotherapy and undergo standard outpatient care by a RN, PA, or resident/fellow at a local facility or the study center approximately 3 times per week, as clinically indicated for up to 45 days.
3194684|NCT01235559|Placebo Comparator|Placebo|
3194685|NCT01235559|Experimental|bitopertin [RO4917838] 1|
3194686|NCT01235559|Experimental|bitopertin [RO4917838] 2|
3194687|NCT01235546|Placebo Comparator|Placebo and standard of care|250 cc normal saline
3194688|NCT01235546|Experimental|Azithromycin and Standard of care|500 mg Azithromycin in 250 cc normal saline
3194689|NCT01235533|Experimental|N-3 fatty acids|Participants in this arm were received three capsules of n-3 fatty acids. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g。
3194690|NCT01235533|Placebo Comparator|Placebo|Participants in this arm were received three identical capsules per day. All capsules included olive oil.
3194691|NCT01235520|Experimental|1|
3194692|NCT01235520|Experimental|2|
3194693|NCT01235520|Placebo Comparator|3|
3194694|NCT01235507|Experimental|Single Arm|
3194695|NCT01235494|Experimental|polarised 3 helium|inhaled gas
3194696|NCT01235481|Experimental|Exercise DVD|Exercise DVD to be used by participants 30-60 minutes, once daily to facilitate maintenance exercise training
3194697|NCT01235481|Other|Usual Care|Participants advised to perform maintenance exercise training 30-60 minutes, once daily without benefit of exercise DVD
3194698|NCT01235468|Experimental|CB expnasion|ex-vivo expansion of cord blood for transplantation
3194699|NCT01235455||Group 1|
3194700|NCT01235442|Experimental|etanercept and clobetasol|Etanercept 50 mg twice weekly x 12 weeks + clobetasol propionate foam (weeks 11 and 12) then Etanercept 50 mg once weekly x 12 weeks + clobetasol propionate foam (weeks 23 and 24)
3194701|NCT01235442|Experimental|etanercept|Etanercept 50 mg twice weekly x 12 weeks then Etanercept 50 mg once weekly x 12 weeks
3194702|NCT01235429|Experimental|Educational|Participants will receive 12 diabetes self-management educational lessons in a small group setting located within the participating communities and delivered by trained community health workers.
3194703|NCT01235429|Active Comparator|Delayed education|The delayed education group will receive the same intervention after the intervention group has completed the educational lessons and all participants have completed the follow-up assessments.
3194704|NCT01235416|Active Comparator|AMG 706 50mg|50 mg, once daily. (Cohort 1)
3194705|NCT01235416|Active Comparator|AMG 706 75mg|75 mg, twice daily. (Cohort 2)
3194706|NCT01235416|Active Comparator|AMG 706 125mg|125 mg, once daily. (Cohort 3)
3194707|NCT01235403|Experimental|Lacosamide|Flexible dosing between 200mg/day and 400mg/day
3194708|NCT01235390|Experimental|5 g of walnuts|
3194709|NCT01235390|Experimental|40 g of walnuts|
3194710|NCT01235377|Active Comparator|Favor Chlorthalidone|Providers randomized to Favor Chlorthalidone will have agreed to prescribe chlorthalidone for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. This cluster designation applies only for patients for whom there is equipoise; providers are expected to deviate if medically indicated for individual patients
3194711|NCT01235377|Active Comparator|Favor Hydrochlorothiazide|Providers randomized to Favor Hydrochlorothiazide will have agreed to prescribe hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. This cluster designation applies only for patients for whom there is equipoise; providers are expected to deviate if medically indicated for individual patients
3194712|NCT01235364|Experimental|Digital|The patient was randomized to digital insertion of the Foley catheter
3194713|NCT01235364|Experimental|Speculum|
3194714|NCT01235351|Active Comparator|Clopidogrel 75 mg daily|
3194715|NCT01235351|Experimental|Clopidogrel 150 mg daily|
3194716|NCT01235351|Experimental|Clopidogrel 225 mg daily|
3194717|NCT01235351|Experimental|Clopidogrel 300 mg daily|
3194718|NCT01235338|Experimental|LDX (SPD489) + Venlafaxine XR (Effexor XR)|
3194719|NCT01235338|Experimental|Venlafaxine XR + LDX|
3194720|NCT01235325|Placebo Comparator|Placebo oil capsule|Banner Pharmacaps Europe
3194721|NCT01235325|Experimental|phylloquinone (1000 mcg)|Banner Pharmacaps Europe
3194722|NCT01235312||Healthy subjects|
3194723|NCT01235312||Patients suffering from Diabetes mellitus|
3194724|NCT01235312||Patients suffering from peripheral arterial occlusive disease|
3194725|NCT01235299||Healthy subjects|
3194726|NCT01235299||Subjects suffering from Diabetes mellitus|
3194727|NCT01235299||Subjects suffering from peripheral arterial occlusive disease|
3194728|NCT01235286|Experimental|remote ischemic preconditioning|
3194729|NCT01235273|Experimental|GH replacement therapy|
3194730|NCT01235273|Placebo Comparator|Placebo|
3194731|NCT01235260||001|Becaplermin users A cohort of becaplermin users (ie patients with diabetes treated with becaplermin)
3194732|NCT01235260||002|Becaplermin nonusers A cohort of becaplermin nonusers (ie patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
3194733|NCT01235247|Experimental|reminders, no reminder|
3194734|NCT01235234|Experimental|CF101 0.1 mg|
3194735|NCT01235234|Experimental|CF101 1 mg|
3194736|NCT01235234|Placebo Comparator|Placebo|
3194737|NCT01235221|Experimental|BIIB041 (Fampridine-SR)|Participants take 10 mg sustained-release tablets of fampridine twice daily for up to 27 months or until the product is commercially available.
3194738|NCT01235208|Experimental|Eurodiet treatment|
3194739|NCT01235195|Active Comparator|Sertraline 50 mg capsules|
3194740|NCT01235195|Active Comparator|Sertraline 50 mg tablet|
3194741|NCT01235182||acute dyspnea, field, diagnostic|All patients with shortness of breath as the primary complaint (defined as eitherthe sudden onset of dyspnea without history of chronic dyspnea or an increase in the severity of chronic dyspnea and were age >18 years.
3194742|NCT01235169|Experimental|Proximal Femoral Nail Antirotation|Proximal Femoral Nail Antirotation(PFNA) with cement augmentation
3194743|NCT01235143|Experimental|desflurane anesthesia|maintenance anesthesia with desflurane
3194744|NCT01235143|Active Comparator|sevoflurane|maintenance anesthesia with sevoflurane
3194745|NCT01235130|Active Comparator|OMEGA-3|Long-Chain N-3 polyunsaturated fatty acids (OMEGA-3)
3194746|NCT01235130|Placebo Comparator|Placebo|Placebo soybean oil
3194747|NCT01235104||Total nephrectomy|
3194748|NCT01235091|Other|Standard|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing
3194749|NCT01235091|Experimental|SI/WWE|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing along with Well-Woman Exam
3194750|NCT01235091|Experimental|SI/WWE/PD|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing along with Well-Woman Exam and Peer-delivered Enhanced Intervention
3194751|NCT01235078||Intraosseous vascular access|subjects with urgent vascular access needs in whom intraosseous vascular access has been attempted and/or established.
3194752|NCT01235065|Active Comparator|direct laryngoscope|emergency intubation with direct laryngoscopy technique
3194753|NCT01235065|Active Comparator|video laryngoscope|emergency intubation with video laryngoscopy technique
3194754|NCT01235052|Experimental|TEP with 18F-FMISO|TEP with 18F-FMISO
3194755|NCT01235039|Experimental|Formulation A|VIAject®25 for subcutaneous application
3194756|NCT01235039|Experimental|Formulation B|VIAject®7 for subcutaneous application
3194757|NCT01235039|Experimental|Formulation C|Insulin Lispro for subcutaneous application
3194758|NCT01235026|Experimental|Synbiotic|"Dietary Supplement: Synbiotic: combination of the prebiotic Oligofructose with the probiotic Bifidobacterium animalis subsp. lactis Bb12"
3194759|NCT01235026|Placebo Comparator|Placebo|Dietary supplement: placebo: maltodextrin
3194760|NCT01235013|Experimental|Maraviroc|
3194761|NCT01235013|No Intervention|Control|Patients continue with their usual treatment
3194762|NCT01235000||2010-11 influenza vaccine recipients|Participants of an earlier clinical trial (TITRE II) to evaluate prime-boost response across B lineages in 2009-10
3194763|NCT01234987||Breast cancer|
3194764|NCT01234987||Colon cancer|
3194765|NCT01234987||Lung Cancer|
3194766|NCT01234974|Experimental|Pasireotide|Pasireotide 60 mg day 1 every 28 days
3194767|NCT01234961|Experimental|Redesigning Daily Occupations|The ReDO intervention focuses on how people compose their everyday lives. Supporting people in how to change and modify their patterns of daily occupations is a new intervention method for people with stress-related disorders, but it has been shown to be effective in improving quality of life and self-rated health in other target groups. The basic idea is that re-structuring of an individual's lifestyle and pattern of daily occupations will lead to a healthier balance between the occupations of everyday life, and that this balance will promote wellness and improved work capacity. The program is group based and comprises 16 weeks, with sessions 2 x 2 hours per week, followed by 3-4 booster sessions.
3194768|NCT01234961|Active Comparator|Care as usual|Standard rehabilitation provided by the Social Insurance Office, such as stress management, physical therapy, mindfulness training.
3194769|NCT01234948||Chronic periodontitis patients|Chronic periodontitis patients had at least one site per quadrant with clinical probing depth (CPD) > 5mm and radiographic evidence of bone loss
3194770|NCT01234948||Generalised chronic gingivitis patients|Generalised chronic gingivitis patients presented with bleeding on probing (BOP) at > 30% of sites, CPDs < 4mm and no evidence of bone loss
3194771|NCT01234948||Periodontally healthy subjects|Healthy subjects had < 10% sites with BOP and no sites with CPD > 3mm
3194772|NCT01234935|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3194773|NCT01234935|Experimental|Arm II|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15 and oral dasatinib once daily on days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity. NOTE: *Courses with dasatinib repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.
3194774|NCT01234922|Experimental|Arm I|Patients receive oral benazepril hydrochloride once daily on days 1-7.
3194775|NCT01234922|Experimental|Arm II|Patients receive oral lisinopril once daily on days 1-7.
3194776|NCT01234922|Experimental|Arm III|Patients receive oral ramipril twice daily on days 1-7.
3194777|NCT01234922|Experimental|Arm IV|Patients receive oral losartan potassium once daily on days 1-7.
3194778|NCT01234909||Atopic dermatitis|Pediatric patients ages 1-18 years old with atopic dermatitis
3194779|NCT01234896|Experimental|Nicotine Gum 6|6 mg Nicotine medicated gum
3194780|NCT01234896|Active Comparator|Nicotine Gum 4|4 mg Nicotine Gum
3194781|NCT01234896|Active Comparator|Nicotine Gum 2|2 mg Nicotine Gum
3194782|NCT01234896|Active Comparator|Nicotine Lozenge|4 mg Nicotine Lozenge
3194783|NCT01234883|Experimental|multiple electrolyte solution|Subjects were randomized to receive either multiple electrolyte solution or saline. These solutions were administered IV at 10-20 mL/kg until the subject appeared clinically rehydrated as assessed by the clinician. The selected dose for these solutions is considered standard of care when treating clinical dehydration in children and is consistent with product labeling.
3194784|NCT01234883|Active Comparator|saline|Subjects were randomized to receive either multiple electrolyte solution or saline. These solutions were administered IV at 10-20 mL/kg until the subject appeared clinically rehydrated as assessed by the clinician. The selected dose for these solutions is considered standard of care when treating clinical dehydration in children and is consistent with product labeling.
3194785|NCT01234870|Experimental|Ischemic heart disease patients|Patients with suspected ischemic heart disease prospectively recruited for first pass myocardial perfusion MRI. All subject to receive Gadolinium infusion of 0.075 mmol/kg at rate of 4 ml/sec. Adenosine administered at a rate of 0.14 mg/kg/min for a duration of 4 minutes to induce stress.
3194786|NCT01234857|Experimental|Part A: ridaforolimus + dalotuzumab|Approximately 15 patients will be enrolled to the ridaforolimus-dalotuzumab combination treatment arm. Subsequent Patients are randomly assigned in a 1:1 ratio to treatment with the ridaforolimus (20 mg daily five days a week)/dalotuzumab (intravenous infusion 10 mg/kg once weekly) combination therapy or cross-over to exemestane single-therapy treatment.
3194787|NCT01234857|Active Comparator|Part A: exemestane|Exemestane 25 mg daily; single-agent therapy.
3194788|NCT01234857|Experimental|Part B: ridaforolimus + dalotuzumab|Patients are randomly assigned in a 1:1 ratio to treatment with the ridaforolimus (20 mg daily five days a week)/dalotuzumab (intravenous infusion 10 mg/kg once weekly) combination therapy or cross-over to one of two single-therapy treatments (ridaforolimus alone or dalotuzumab alone). With the implementation of Amendment 3, this study arm will not be opened.
3194789|NCT01234857|Experimental|Part B: ridaforolimus|Ridaforolimus; 40 mg daily five days a week, single-agent therapy. With the implementation of Amendment 3, this study arm will not be opened.
3194790|NCT01234857|Experimental|Part B: dalotuzumab|Dalotuzumab intravenous infusion 10 mg/kg weekly; single-agent therapy. With the implementation of Amendment 3, this study arm will not be opened.
3194791|NCT01234844|Other|care of guinea pigs|"Each patient serves as own control receiving pet therapy and usual occupational therapy on alternate days."
3194792|NCT01234831|Other|Active Screening|Patients randomized to active screening will have two nasal swabs collected daily for 3 days, for both nucleic acid amplification and culture (CHROMagar)assays.
3194793|NCT01234831|Other|Passive Screening|Patients randomized to passive screening will not actively be identified for testing but may be tested using culture-based algorithm by care team.
3194794|NCT01234818|Experimental|LNG-IUS, endometrial hyperplasia|
3194795|NCT01234805|Experimental|Supportive care (yoga therapy)|Patients participate in yoga classes comprising postures, deep relaxation, breathing practices, and meditation twice weekly for 75 minutes during weeks 1-6. Patients then practice yoga at home twice weekly for 45 minutes during weeks 7-12.
3194796|NCT01234792|Experimental|NIC-6|6 mg Experimental nicotine gum
3194797|NCT01234792|Active Comparator|NIC-4|4 mg Nicotine Gum
3194798|NCT01234792|Active Comparator|NIC-2|2 mg Nicotine Gum
3194799|NCT01234779|Experimental|A|
3194800|NCT01234779|Experimental|B|
3194801|NCT01234779|Active Comparator|C|
3194802|NCT01234779|Placebo Comparator|D|
3194803|NCT01234766|Experimental|Single Arm|Subjects will receive bendamustine and rituximab, followed by 90-yttrium (Y) Ibritumomab Tiuxetan
3194804|NCT01234753|No Intervention|Usulal care|Usual care by a visit to physician at the hospital out-patient clinic
3194805|NCT01234740|Experimental|Arm I|Patients undergo intracerebral microdialysis during debulking craniotomy or stereotactic biopsy. Beginning 24 hours later, patients receive oral bafetinib twice daily for 1 day. Beginning at least 2 weeks after surgery, patients continue to receive oral bafetinib twice daily in the absence of disease progression or unacceptable toxicity.
3194806|NCT01234727||Diabetes|Patients with Type 1 or Type 2 diabetes requiring insulin.
3194807|NCT01234714||Major liver resection|This single Cohort/Group will include all consecutive patients that received pre-operative Magnetic Resonant Imaging (MRI) and underwent major liver resection (>=3 segments).
3194808|NCT01234701||Primary liver tumors, non-cirrhotic|This single Cohort/Group will include all consecutive patients that received pre-operative Magnetic Resonance Imaging (MRI) and underwent resection for primary liver tumors.
3194809|NCT01234688|Experimental|Exercise training|Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
3194810|NCT01234688|No Intervention|Control|Patients allocated to the control group remained in regular dialysis treatment during the same timeframe.
3194811|NCT01234675|Placebo Comparator|Placebo/milnacipran|Drug: Placebo, then milnacipran
3194812|NCT01234675|Placebo Comparator|milnacipran/placebo|Drug: milnacipran then placebo
3194813|NCT01234662|Active Comparator|Group 1|Spinal anesthesia + intrathecal opioid bolus (SPA)
3194814|NCT01234662|Active Comparator|Group 2|CSE + epidural opioid bolus (CSE)
3194815|NCT01234662|Experimental|Group 3|CSE + continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs (CSEPCEA)
3194816|NCT01234649|Experimental|Metformin XR plus liraglutide|Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated
3194817|NCT01234649|Active Comparator|Metformin XR plus placebo|Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
3194818|NCT01234636|Active Comparator|cis9,trans 11 CLA oil|50 volunteers on cross over design , receiving 4g/day of cis9,trans11 CLA
3194819|NCT01234636|Placebo Comparator|Placebo oil|50 volunteers cross over design, placebo oil 4g/day
3194820|NCT01234623||UCB eyedrops, single arm|One-centre pilot study, open, non randomized.
3194821|NCT01234610|Experimental|Exercise|Exercise
3194822|NCT01234610|No Intervention|Control|No exercise
3194823|NCT01234597|Active Comparator|Arm A: Without Continous Glucose Monitoring (CGM) sensor|"Run-in phase: insulin glargine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer .~Treatment phase: insulin glulisine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer. Then, adjustment of the dosage is performed by the treating physician"
3194824|NCT01234597|Experimental|Arm B: Continous Glucose Monitoring (CGM) sensor|"Run-in phase: insulin glargine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer .~Treatment phase: the patients are connected to a CGM sensor. Insulin glulisine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer. Then, adjustment of the dosage is performed by the national coordinator based on the data collected in the past previous days of CGM sensor monitoring."
3194825|NCT01234584|Experimental|Group A|23 implants using SPK Abutments
3194826|NCT01234584|Active Comparator|Group B|implants using CPK Abutments
3194827|NCT01234558|Placebo Comparator|Normal Saline|IV placebo
3194828|NCT01234558|Experimental|GLYX-13, 1 mg/kg|
3194829|NCT01234558|Experimental|GLYX-13, 5 mg/kg|
3194830|NCT01234558|Experimental|GLYX-13, 10 mg/kg|
3194831|NCT01234545||A|
3194832|NCT01234532|Experimental|entinostat & anastrozole neoadjuvant|"Neoadjuvant entinostat daily on days 1, 8, 15, 22, and 29 + anastrozole daily on days 4-29 followed by surgery ie either lumpectomy or mastectomy.~Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery."
3194833|NCT01234519|Experimental|Phase 1 - Cohort 1|"Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).~Patients will be enrolled in cohorts of 3 at a specified AEZS-108 dose beginning with 160mg/m^2. Enrollment will be suspended until all members of a cohort have been observed for dose limiting toxicities (DLT) for a period of 3 weeks (1 cycle of AEZS-108) from initial treatment with AEZS-108. Dose escalation will proceed within each cohort according to a specific scheme where DLT is defined."
3194834|NCT01234519|Experimental|Phase 1 - Cohort 2|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
3194835|NCT01234519|Experimental|Phase 1 - Cohort 3|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
3194879|NCT01234246||Partners|Partners of patients with colorectal cancer are included
3194836|NCT01234519|Experimental|Phase 1 - Cohort 4|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
3194837|NCT01234519|Experimental|Phase 2|AEZS-108 at MTD to determine efficacy in up to 40 patients.
3194838|NCT01234506|Active Comparator|secoisolariciresinol diglucoside|Secoisolariciresinol diglucoside (SDG) supplementation as 0.8g/day of BeneFlax containing 300 mg SDG. 1000 IU vitamin D as standard of care.
3194839|NCT01234506|Placebo Comparator|Placebo|An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
3194840|NCT01234493|Active Comparator|fixation|Syndesmosis fixation with one 3.5mm fully threaded screw
3194841|NCT01234493|Active Comparator|no fixation|No syndesmosis fixation
3194842|NCT01234467|Experimental|Bendamustine, Rituximab|This is a single arm intervention where patients will receive bendamustine at a dose of 120 mg/m^2 infused over 60 minutes in days 1 and 2 of each 21 day cycle along with rituximab 375 mg/m^2 after bendamustine on day 1 of each cycle. Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 3 at baseline were allowed to receive bendamustine at a dose of 90 mg/m^2 daily with a dose increase to 120 mg/m^2 daily if their ECOG improved.
3194843|NCT01234454|Experimental|Risperidone Treatment Group|A two-week cross-titration phase followed randomization when patients started treatment with Risperidone in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose was 6mg/day or highest dose tolerated.
3194844|NCT01234454|Experimental|Olanzapine Treatment Group|A two-week cross-titration phase followed randomization when patients started treatment with Olanzapine in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose 20mg/day (or the highest dose tolerated) for 8 weeks, following 4 weeks of baseline Thiothixene.
3194845|NCT01234454|No Intervention|Thiothixene|Subjects were first stabilized on open-label Thiothixene for four weeks, target dose 25 mg per day. Patients were then randomized to either Risperidone or Olanzapine treatment for 8 weeks.
3194846|NCT01234441|Sham Comparator|Control|This group of patients will receive a non-nutritive beverage, and no exercise.
3194847|NCT01234441|Active Comparator|Protein|This group of patients will ingest 30 grams of a liquid whey protein supplement during the first hour of their dialysis session
3194848|NCT01234441|Active Comparator|Protein + Exercise|This group will ingest 30 grams of a liquid whey protein supplement as well as exercise for 30-45 minutes during their dialysis treatment
3194849|NCT01234428|Other|surgery|
3194850|NCT01234415|Experimental|Patient|
3194851|NCT01234402|Experimental|Ramucirumab DP + Capecitabine|Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the patient.
3194852|NCT01234402|Experimental|IMC-18F1 + Capecitabine|Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the patient.
3194853|NCT01234402|Active Comparator|Capecitabine*|"Crossover Study:~* At the discretion of the investigator, patients will be eligible to receive either ramucirumab DP or IMC-18F1 in combination with capecitabine, after radiographic disease progression while on capecitabine. The investigator will decide which investigational product will be given.~Cycles repeat every 21 days until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the patient."
3194854|NCT01234389|Other|H. pylori positive patients|
3194855|NCT01234389|Other|H. pylori negative patients|
3194856|NCT01234376||Control patients|
3194857|NCT01234376||Patients with eosinophilic esophagitis|
3194858|NCT01234363|Experimental|Magnetic Resonance Elastography, Supersonic Shear Imaging|Magnetic Resonance Elastography and Supersonic Shear Imaging
3194859|NCT01234350||Firmagon|
3194860|NCT01234350||GnRH Agonist|
3194861|NCT01234337|Experimental|Sorafenib (Nexavar, BAY43-9006) + Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
3194862|NCT01234337|Placebo Comparator|Placebo + Capecitabine|Capecitabine was administered orally at a dose of 1,000 mg/m^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
3194863|NCT01234324|Experimental|Arm 1: ECX + Panitumumab|
3194864|NCT01234324|Active Comparator|Arm 2: EXC alone|
3194865|NCT01234311|Placebo Comparator|placebo|Matching placebo
3194866|NCT01234311|Experimental|tasquinimod|Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
3194867|NCT01234298|Experimental|SPD489 Low-Dose|
3194868|NCT01234298|Experimental|SPD489 High-Dose|
3194869|NCT01234298|Placebo Comparator|Placebo|
3194870|NCT01234285|Experimental|intravenous heparin aPTT 40-50 seconds|Patients 11-15: IV heparin, target aPTT range 40-50 seconds
3194871|NCT01234285|Experimental|intravenous heparin|Patients 26-40: IV heparin, target range aPTT 50-60 seconds
3194872|NCT01234285|Experimental|Intravenous heparin|Patients 41-55 IV heparin, target aPTT range 60-70 seconds
3194873|NCT01234285|Active Comparator|sq heparin three times a day|Patients 1-10 will receive subcutaneous heparin three times a day
3194874|NCT01234272|Experimental|ITM-IVPCA|ITM-IVPCA:intrathecal morphine and IV-fentanyl patient controlled analgesia
3194875|NCT01234272|Active Comparator|PCEA|PCEA:epidural PCA(patient controlled analgesia)
3194876|NCT01234259|Experimental|Study group|Device: Venus Freeze (MP)2 V2 system
3194877|NCT01234259|Sham Comparator|control group:|Sham comparator
3194878|NCT01234246||Patients with colorectal cancer|Patients with colorectal cancer are included
3194880|NCT01234233|No Intervention|Group 1|Control group - no intervention: no preoperative warming
3194881|NCT01234233|Active Comparator|Group 2 - 10 min prewarming|10 min prewarming preoperatively
3194882|NCT01234233|Active Comparator|Group 3 - 20 min prewarming|20 min prewarming preoperatively
3194883|NCT01234233|Active Comparator|Group 4 - 30 min prewarming|30 min prewarming preoperatively
3194884|NCT01234220||Adrenal Venous Sampling (AVS)|Patients with Primary Aldosteronism (PA) undergoing AVS to discriminate PA forms with unilateral from bilateral excess aldosterone production.
3194885|NCT01234207|Active Comparator|Randomized Order of Interventions 1|Randomized to first wear standard, non-free-form, non-customized PAL spectacles, then second, crossover to wear individually customized free-form surfaced PAL spectacles
3194886|NCT01234207|Active Comparator|Randomized Order of Interventions 2|Randomized to first wear individually customized free-form surfaced PAL spectacles, then second, crossover to wear standard, non-free-form, non-customized PAL spectacles
3194887|NCT01234194|Active Comparator|Group 1|
3194888|NCT01234194|Active Comparator|Group 2|
3194889|NCT01234181|Experimental|BMSCs transplantation|
3194890|NCT01234181|Sham Comparator|No BMSCs transplantation|
3194891|NCT01234155|No Intervention|Control|
3194892|NCT01234155|Experimental|Exercise - Continuous Walking|
3194893|NCT01234155|Experimental|Exercise - Interval Walking|
3194894|NCT01234142|Experimental|Cohort 1|
3194895|NCT01234142|Experimental|Cohort 2|
3194896|NCT01234142|Experimental|Cohort 3|
3194897|NCT01234142|Experimental|Cohort 4|
3194898|NCT01234129||zoledronic acid or not zoledronic acid|patients with multiple myeloma will be treated with cytoreductive therapy following by zoledronic acid or not.
3194899|NCT01234129||zoledronic acid or not zoledronic acid|patients with multiple myeloma will be treated with cytoreductive therapy following by stem cell transplant and did not received zoledronic acid
3194900|NCT01234129||zoledronic acid|Patients with multiple treated with cytoreductive therapy following by stem cell transplant will be planned to received zoledronic acid
3194901|NCT01234116|Active Comparator|Kaletra|Arm 1: Kaletra two tabs twice a day + Truvada one pill once a day.
3194902|NCT01234116|Active Comparator|Raltegravir|Arm 2: Raltegravir 400 mg, one pill twice a day + Truvada one pill once a day.
3194903|NCT01234103|Experimental|Preventing sexual health risks|The over goal is to prevent STIs, unintended pregnancies, and related behaviors including sexual risk, alcohol and other substance misuse
3194904|NCT01234103|Other|Improving nutrition, fitness and injury prevention|The goals are: (1) maintain and improve nutrition and physical fitness through healthier lifestyle and food choices; (2) reduce the risk of sports or physical training injuries and learning how to treat injuries; and (3) Learn to recognize stress and the steps you can take to reduce stress
3194905|NCT01234090||Persons with Aphasia|
3194906|NCT01234077|No Intervention|ECG recording|In-laboratory vs. in-home recordings
3194907|NCT01234064|Active Comparator|Graduated Compression Stockings|
3194908|NCT01234064|Other|No Graduated Compression Stockings|
3194909|NCT01234051|Experimental|Docetaxel, oxaliplatin, palliative chemotherapy|
3194910|NCT01234038|Experimental|Part 1 Cohort 1|
3194911|NCT01234038|Experimental|Part 1 Cohort 2|
3194912|NCT01234038|Experimental|Part 2 Arm A|
3194913|NCT01234038|Experimental|Part 2 Arm B|
3194914|NCT01234025|Experimental|Part 1 Cohort 1|
3194915|NCT01234025|Experimental|Part 1 Cohort 2|
3194916|NCT01234025|Experimental|Part 2 Arm A|
3194917|NCT01234025|Experimental|Part 2 Arm B|
3194918|NCT01234012|Experimental|Treatment: IMF-001|100 or 200 mcg will be administered to patients subcutaneously every 2 weeks for 6 injections.
3194919|NCT01233999|Placebo Comparator|Botox|single-drug dosage comparison cross-over study
3194920|NCT01233986||Case group - Large artery atherosclerosis|
3194921|NCT01233986||Control group-Small vessel occlusion|
3194922|NCT01233973|No Intervention|control subjects|verbal narrative of advance care planning
3194923|NCT01233973|Experimental|intervention group|video decision aid viewed by subjects
3194924|NCT01233960|Experimental|Prochymal|Infusions of Prochyaml on days 42-45, 84-87, and 126-129 after first infusion in Protocol 603. Each infusion of PROCHYMAL (remestemcel-L) will contain 200 million cells.
3194925|NCT01233947|Experimental|AFP464|74 mg/m2 AFP464 administered as a 3 hour IV infusion on Days 1 and 8 of a 21-day cycle.
3194926|NCT01233947|Experimental|AFP464 + Faslodex|AFP464 administered as a 3 hour IV infusion on Days 1 and 8 of a 21-day cycles and Faslodex administered per package label.
3194927|NCT01233934|Active Comparator|Dexchlorpheniramine 1% Cream|
3194928|NCT01233934|Experimental|Dexchlorpheniramine 1% Gel|
3194929|NCT01233921|Experimental|Arm I (palifermin)|Patients receive palifermin IV on days 1-3 in the absence of unacceptable toxicity.
3194930|NCT01233921|Active Comparator|Arm II (no palifermin)|Patients do not receive palifermin.
3194931|NCT01233908||PTSD|Patients which underwent surgical repair for primary rhegmatogenous retinal detachment and developed an associated posttraumatic stress disorder
3194932|NCT01233908||PTSD - negative|Patients which underwent surgical repair for primary rhegmatogenous retinal detachment and did not develope an associated posttraumatic stress disorder
3194933|NCT01233895|Experimental|AVE1642/ AVE1642 with Velcade|
3194934|NCT01233882|Experimental|Healthy Volunteers|
3194935|NCT01233882|Experimental|Mild Renal Impairment|
3194936|NCT01233882|Experimental|Moderate Renal Impairment|
3194937|NCT01233882|Experimental|Severe Renal Impairment|
3194938|NCT01233869|Experimental|Cohort A|
3194939|NCT01233869|Experimental|Cohort B|
3194940|NCT01233869|Placebo Comparator|Cohort C|
3194941|NCT01233843|Other|Drug and radiation|Radiotherapy : 70 grays , fractionization : 2Gy/day, 5 days / week, for 7 weeks . Concurrent administration of Carboplatin: 70 mg/m2/day (day 1 until day 4)and 5FU 600 mg/m2/day (day 1 until day 4). Weeks 1; 4; 7.
3194987|NCT01233583||Anti TNF-alpha|patients in whom decision to treat with anti TNF-alpha(adalimumab-etanercept-infliximab) by their dermatologist
3194942|NCT01233843|Experimental|drug and radiation|"Induction chemotherapy by Docetaxel 100mg/m2, day 1; cisplatin 100mg/m2, day 1; 5-Fluorouracil 1000mg/m2 (from day 1 to day 5), for a total of three cycles .Those cycles are administrated at day 1; day 22, day43.~This induction chemotherapy is followed ( for responders or stable disease patients)by radiotherapy (70 grays for 7 weeks) and concurrent Erbitux( weekly administration)."
3194943|NCT01233830|Experimental|1|
3194944|NCT01233830|Placebo Comparator|2|
3194945|NCT01233817|Experimental|Spinal muscular atrophy|Children and adolescents with diagnosis of SMA type II or III. The intervention group (the only arm/group in this pilot study) receives a home-based, supervised, 12-week progressive strength-training program.
3194946|NCT01233804|No Intervention|Opting in|Currently, pregnant women have to sign a consent stating that they want the influenza vaccine (at the clinics where the study is being conducted). Therefore, this group is the same as usual care. However, women will then be asked if they would like to take part in parts 2 and 3 of the study.
3194947|NCT01233804|Experimental|Opting Out|Women will sign a consent form only if they do not want to receive the flu vaccine.
3194948|NCT01233791|Experimental|Vaginal Diazepam Suppository|Patients in this arm will be asked to use one vaginal suppository every night for 28 days
3194949|NCT01233791|Placebo Comparator|Vaginal Placebo Suppository|Patients will be asked to use one vaginal suppository every night for 28 days
3194950|NCT01233778|Experimental|Canola Oil|
3194951|NCT01233778|Experimental|High Oleic Acid Canola + DHA|
3194952|NCT01233778|Experimental|High Oleic Canola Oil|
3194953|NCT01233778|Experimental|Flax & Safflower Oil (60:40)|
3194954|NCT01233778|Experimental|Safflower & Corn Oil (75:25)|
3194955|NCT01233765||Control volunteers with periodontal health|Control volunteers with periodontal health
3194956|NCT01233765||Patient volunteers with chronic periodontitis|Patient volunteers with chronic periodontitis
3194957|NCT01233752||Group A|Homozygous patients,using PCA administration with morphine chlorhydrate for postoperative analgesia, for the more frequent allele of the polymorphism A118G of OPRM1 gene
3194958|NCT01233752||Group B|Both homozygous and heterozygous patients,using PCA administration with morphine chlorhydrate for postoperative analgesia, for the less frequent allele of the polymorphism A118G of OPRM1 gene
3194959|NCT01233739|Placebo Comparator|Placebo|
3194960|NCT01233739|Experimental|Chondroitin sulfate|Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
3194961|NCT01233726|Experimental|T-DIET PLUS DIABET IR|Patients of this group will receive T-Diet plus Diabet IR as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
3194962|NCT01233726|Active Comparator|ISOSOURCE PROTEIN FIBRE|Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
3194963|NCT01233726|Active Comparator|GLUCERNA SELECT|Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
3194964|NCT01233713|Active Comparator|Primary anastomosis|Primary anastomosis refers to a colonic resection with primary anastomosis and covering ileostomy, followed by a stoma reversal operation.
3194965|NCT01233713|Active Comparator|Hartmann's operation|Hartmann's operation is the surgical resection of the rectosigmoid colon with closure of the rectal stump and end colostomy, followed by a stoma reversal operation.
3194966|NCT01233700|Experimental|Motivational Interviewing|Subjects will receive two, individual telephone sessions with an interventionist, each lasting approximately 30-45 minutes. The sessions will focus on assisting subjects to delineate their reasons for or against proceeding with living organ donation and assisting subjects to resolve any lingering concerns about their decisions regarding donation.
3194967|NCT01233700|Active Comparator|Enhanced Standard Care|Subjects will receive two individual telephone sessions with an interventionist, each lasting approximately 30-45 minutes. The sessions will focus on providing educational information to subjects regarding healthy lifestyle issues (healthy eating, diet, exercise, quitting smoking).
3194968|NCT01233700|No Intervention|Standard Care|Subjects will receive the standard care and education provided by the Living Donor Program at their medical center.
3194969|NCT01233687|Experimental|AMG 102 and erlotinib|Combination of AMG 102 and erlotinib
3194970|NCT01233674||patients referred for standard of care MRI|
3194971|NCT01233661|Experimental|short AVD pacing|short AVD pacing
3194972|NCT01233661|No Intervention|prior (stable) programming|prior (stable) programming
3194973|NCT01233648|Active Comparator|AF|
3194974|NCT01233648|Active Comparator|SR|
3194975|NCT01233635|Experimental|A Group 1 no drug|Patients who have not taken ACE/ARB, randomized to no drug.
3194976|NCT01233635|Experimental|A Group 2|Patients who have not taken ACE/ARB, randomized to take cozaar.
3194977|NCT01233635|Experimental|B|Patients currently taking ACE/ARB will have their prescription changed to cozaar.
3194978|NCT01233622|Experimental|Vildagliptin (metformin + glimepiride)|
3194979|NCT01233622|Placebo Comparator|Placebo (metformin + glimepiride)|
3194980|NCT01233609|Active Comparator|Valproic Acid|Subjects who receive valproic acid
3194981|NCT01233609|Placebo Comparator|Placebo|Subjects who receive placebo
3194982|NCT01233596|Active Comparator|Monocanalicular intubation|Monocanalicular intubations (MCI; n=35 eyes) through the inferior canaliculus intubations performed under general anaeshesia in children between 10 and 36 months of age suffering from congenital nasolacrimal duct obstruction (CNLDO).
3194983|NCT01233596|Active Comparator|Bicanalicular intubation|Bicanalicular intubation (BCI; n=35 eyes) performed under general anaeshesia in children between 10 and 36 months of age suffering from congenital nasolacrimal duct obstruction (CNLDO).
3194984|NCT01233583||Betamethasone/Calcipotriol (Dovobet)|patients in whom decision to treat with Dovobet by their dermatologist
3194985|NCT01233583||Acitretin (neotigason)|patients in whom decision to treat with neotigason by their dermatologist
3194986|NCT01233583||narrow-band UVB|patients in whom decision to treat with narrow band UVB by their dermatologist
3194988|NCT01233570|Experimental|Topical tacrolimus|Once daily topical application
3194989|NCT01233557||Bone Metastases|
3194990|NCT01233544|Experimental|Stereotactic body radiation therapy|Colorectal liver metastases treated by SBRT
3194991|NCT01233544|Active Comparator|Radiofrequency ablation|Colorectal liver metastases treated by RFA
3194992|NCT01233531|Other|A--Monthly cash transfers|Monthly cash transfer payments
3194993|NCT01233531|Other|B--No cash transfers|No cash transfers.
3194994|NCT01233518|Active Comparator|Single arm study|Patients will receive cCTA, ICA, FFR, and cFFR per protocol.
3194995|NCT01233505|Experimental|Treatment (veliparib, capecitabine, oxaliplatin)|Patients receive veliparib PO twice daily and capecitabine PO twice daily on 1-7 and 15-21, and oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3194996|NCT01233453|Active Comparator|the everolimus eluting ® stent|the everolimus eluting XIENCE-V®, XIENCE-Prime® or PROMUS® stent
3194997|NCT01233453|Active Comparator|Biolimus A9 stent|the Biolimus A9 eluting NOBORI® stent
3194998|NCT01233440|Experimental|Cohort 1|25 IU/kg dose
3194999|NCT01233440|Experimental|Cohort 2|50 IU/kg dose
3195000|NCT01233440|Experimental|Cohort 3|75 IU/kg dose
3195001|NCT01233414|Experimental|Parent Training|
3195002|NCT01233414|Active Comparator|Psychoeducation|
3195003|NCT01233401||Mothers|
3195004|NCT01233401||Other Infant Caregivers|Includes fathers, grandparents, and other adults who are infant caregivers
3195005|NCT01233388||Text message surveillance|enroll for text message surveillance
3195006|NCT01233375|Experimental|CO-1.01|
3195007|NCT01233362|Active Comparator|Arm 1: Adults; 14 days interval|89 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
3195008|NCT01233362|Active Comparator|Arm 2: Adults; 28 days interval|89 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
3195009|NCT01233362|Active Comparator|Arm 3: children; 14 days interval|89 children (1-17 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
3195010|NCT01233362|Active Comparator|Arm 4: children; 28 days interval|89 children (1-17 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
3195011|NCT01233362|Active Comparator|Arm 5: Adults; 14 days Interval|15 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
3195012|NCT01233362|Active Comparator|Arm 6: Adults; 28 days interval|15 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
3195013|NCT01233349|Experimental|Litramine|
3195014|NCT01233349|Placebo Comparator|Placebo|
3195015|NCT01233323||All study patients (single arm study)|All eligible patients will be included in the only study arm and will undergo study testing.
3195016|NCT01233297|Active Comparator|Antibiotics|Azithromycin (10 mg/kg once a day for 3 days)
3195017|NCT01233297|Placebo Comparator|Placebo|Placebo mixture (once a day for 3 days)
3195018|NCT01233284|Experimental|tiotropium low dose once daily|once daily, delivered by the Respimat® inhaler
3195019|NCT01233284|Experimental|tiotropium medium dose once daily|once daily, delivered by the Respimat® inhaler
3195020|NCT01233284|Experimental|tiotropium high dose once daily|once daily, delivered by the Respimat® inhaler
3195021|NCT01233284|Placebo Comparator|Placebo once daily|once daily, delivered by the Respimat® inhaler
3195022|NCT01233271|Experimental|1|Space TGC system with incorporated eMPC advised insulin titration to establish glycaemic control
3195023|NCT01233258|Experimental|Arm 1: rFVIII on demand first CS/EP then CS/ADJ|Participants received on-demand treatment with recombinant factor VIII (rFVIII, BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months, followed by cross-over to study drug assayed by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months.
3195024|NCT01233258|Experimental|Arm 2: rFVIII on demand first CS/ADJ then CS/EP|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/ADJ for 6 months, followed by cross-over to study drug assayed by CS/EP for 6 months.
3195025|NCT01233258|Experimental|Arm 3: rFVIII prophylaxis low-dose first CS/EP then CS/ADJ|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII(BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
3195026|NCT01233258|Experimental|Arm 4: rFVIII prophylaxis low-dose first CS/ADJ then CS/EP|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.
3195027|NCT01233258|Experimental|Arm 5: rFVIII prophylaxis high-dose first CS/EP then CS/ADJ|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
3195028|NCT01233258|Experimental|Arm 6: rFVIII prophylaxis high-dose first CS/ADJ then CS/EP|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII(BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.
3195029|NCT01233245||Group 1|
3195030|NCT01233232|Placebo Comparator|1|Placebo dose
3195031|NCT01233232|Experimental|2|Treatment arm AZD5069 50mg
3195032|NCT01233232|Experimental|3|Treatment arm AZD5069 80mg
3195033|NCT01233219||Group A|Homozygous patients for the more frequent allele of the polymorphism A118G of OPRM1 gene
3195034|NCT01233219||Group B|Both homozygous and heterozygous patients for the less frequent allele of the polymorphism A118G of OPRM1 gene
3195035|NCT01233206|Experimental|Experimental group|Patients receiving metformin pretreatment and co-administration
3195036|NCT01233206|Placebo Comparator|Control group|Placebo
3195037|NCT01233193|Experimental|Intervention|The intervention group receive an pharmacist intervention (health education, Home Blood Pressure Monitoring and Referral to physician as needed) This group will be followed for 6 months
3195038|NCT01233193|No Intervention|Control|The control group receive usual care in the community pharmacy
3195039|NCT01233180|Active Comparator|Gua Sha|Single Gua Sha treatment of the neck and shoulder region.
3195040|NCT01233180|Active Comparator|Thermotherapy|Single use of a mud heat pad on the neck and shoulder region.
3195041|NCT01233167|Experimental|clopidogrel|
3195042|NCT01233167|Placebo Comparator|placebo|
3195043|NCT01233167|Experimental|steply discontinued clopidogrel|
3195044|NCT01233154|Experimental|L. paracasei|L. paracasei
3195045|NCT01233154|Experimental|L. acidophilus + B. lactis|L. acidophilus + B. lactis
3195046|NCT01233141||one group only|all participants
3195047|NCT01233128||polypoidal choroidal vasculopathy|patients who were treated for polypoidal choroidal vasculopathy with intravitreal injections of 0.5 mg of ranibizumab monthly for 3 months
3195048|NCT01233115||polypoidal choroidal vasculopathy|patients who were treated for polypoidal choroidal vasculopathy with combined photodynamic therapy and intravitreal bevacizumab injections
3195049|NCT01233102|Active Comparator|Conserved Therapy|Conserved Therapy
3195050|NCT01233102|Experimental|Interventional Therapy|"Patients with liver cirrhosis will be randomly divided into three groups.~1. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group.2. Umbilical cord MSCs will be infused to patients intravenously for another group. The control group will receive conserved therapy. The efficacy of different interventional therapies will be compared."
3195051|NCT01233089|Experimental|CARE|Investigational single-vision contact lenses worn bilaterally on a daily wear basis and replaced monthly
3195052|NCT01233089|Active Comparator|AIR OPTIX AQUA|Commercially available single-vision contact lenses worn bilaterally on a daily wear basis and replaced monthly
3195053|NCT01233089|Active Comparator|AIR OPTIX AQUA MULTIFOCAL|Commercially available multifocal contact lenses worn bilaterally on a daily wear basis and replaced monthly
3195054|NCT01233076|Other|Nelfilcon A / Narafilcon B|Nelfilcon A worn first, with narafilcon B worn second. Each product worn bilaterally in a daily wear, daily disposable basis for one week.
3195055|NCT01233076|Other|Narafilcon B / Nelfilcon A|Narafilcon B worn first, with nelfilcon A worn second. Each product worn bilaterally in a daily wear, daily disposable basis for one week.
3195056|NCT01233063|Experimental|Alive2|Lifestyle Intervention delivered via email and web
3195057|NCT01233063|Experimental|Alive2 plus automated phone/print|All of Arm 1 components, plus biweekly tailored automated phone coaching plus monthly tailored automated print materials.
3195058|NCT01233063|Placebo Comparator|Control|Monthly emailed newsletter on other aspects of wellness, excluding diet and physical activity
3195059|NCT01233050|Active Comparator|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative Skin Antisepsis Preparation
3195060|NCT01233050|Active Comparator|Iodine Povacrylex/74% Isopropyl Alcohol|Preoperative Skin Antisepsis Preparation
3195061|NCT01233024|Placebo Comparator|Low fiber control|no treatment dinner bar, no treatment breakfast bar
3195062|NCT01233024|Experimental|Promitor soluble corn fiber|12g in dinner bar, 11g in breakfast bar
3195063|NCT01233024|Experimental|FiberSym resistant starch|12g in dinner bar, 11g breakfast bar
3195064|NCT01233024|Experimental|Orafti P95 fructooligosaccharide|12g in dinner bar, 11g in breakfast bar
3195065|NCT01233024|Experimental|Orafti HPX inulin|12g in dinner bar, 11g in breakfast bar
3195066|NCT01232998||Patient Satisfaction with nursing care|
3195067|NCT01232998||satisfaction of waiting time for first time visit|
3195068|NCT01232998||patient satisfaction|
3195069|NCT01232985|Experimental|RD047-26|Study Device
3195070|NCT01232972|Experimental|oocyte freezing|includes any women who elects to preserve her fertility by vitrifying her unfertilized eggs.
3195071|NCT01232959|Experimental|Transvaginal Surgery|Gallbladder will be removed through the vagina
3195072|NCT01232946|Experimental|Iiraglutide|Type 2 diabetic subjects will be assigned to 3 months of treatment with 1.8mg liraglutide administered once daily in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
3195073|NCT01232946|Experimental|insulin detemir|Type 2 diabetic subjects will be assigned to 3 months of treatment with insulin detemir administered twice daily in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
3195074|NCT01232946|Experimental|Liraglutide plus insulin detemir|Type 2 diabetic subjects will be assigned to 3 months of treatment with a combination of liraglutide and insulin detemir in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
3195075|NCT01232933|Experimental|VPS System|Use of navigational VPS system to place catheter
3195076|NCT01232920|Active Comparator|Methotrexate|
3195077|NCT01232920|Active Comparator|Mycophenolate mofetil|
3195078|NCT01232907|Experimental|L-Carnitine|This study has a single subject design. Each subject acts as its own control. All subjects will go through intervention phase (treatment with L-Carnitine).
3195079|NCT01232894|Experimental|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
3195080|NCT01232894|Active Comparator|Long-acting beta2-agonist|Participants' current long-acting beta2-agonist (LABA) bronchodilator therapy
3195081|NCT01232881||Tumor and Serum Collection|"Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.~Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib."
3195082|NCT01232868|Other|Age 25-40|Trivalent Influenza vaccine given to age 25-40
3195083|NCT01232868|Other|Age ≥65|Trivalent Influenza vaccine given to age≥65
3195084|NCT01232829|Experimental|Treatment (RO4929097)|"Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.~Patients may undergo tumor biopsy at baseline and on days 16 or 17 of course one for biomarker and other correlative studies. Blood samples may also collected at baseline and periodically during study for pharmacokinetic and angiogenesis marker studies."
3195085|NCT01232816||Delayed graft function|These are patients in whom dialysis is required following transplantation.
3195086|NCT01232816||Immediate function|These are patients in whom no dialysis is required and creatinine declines by >20% in the first 24 hours following transplantation.
3195087|NCT01232803|Active Comparator|2% N-9 gel|Rectal application of 2% N-9 gel
3195088|NCT01232803|Placebo Comparator|HEC placebo gel|Rectal application of HEC placebo gel
3195089|NCT01232803|No Intervention|no-treatment arm|no intervention
3195090|NCT01232803|Experimental|Tenofovir 1% gel|rectal application of Tenofovir 1% gel
3195091|NCT01232790|Experimental|Group A: Intervention/Placebo|Group A first receives the commercially available sustained release form of N-acetylcysteine, then the matching placebo capsules both administered at 1200mg twice a day for 3 full days, along with 1200mg once on the evening prior to and once on the morning following the 3 days (8 total doses over 5 days).
3195092|NCT01232790|Placebo Comparator|Group B: Placebo/Intervention|Group B first receives the placebo and then receives a commercially available sustained release form of N-Acetylcysteine. In each arm, the capsules are both administered at 1200mg twice a day for 3 full days, along with 1200mg once on the evening prior to and once on the morning following the 3 days (8 total doses over 5 days).
3195093|NCT01232777|Active Comparator|Bevacizumab (Avastin) 0.75mg/0.03cc|1/3 of study participants will be randomized to this treatment in one eye (study eye) and the other eye will receive laser (fellow eye)
3195094|NCT01232777|Active Comparator|Bevacizumab (Avastin) 0.625mg/0.025cc|1/3 of patients will be randomized to this treatment in 1 eye (study eye) and the other eye will receive laser (fellow eye).
3195095|NCT01232777|Active Comparator|Laser ablation|1/3 of study participants will be randomized to this treatment in both eyes (study eye and fellow eye)
3195096|NCT01232764|Experimental|Multi-disciplinary wound care team|Stepped wedge study design i.e. start date of exposure is randomized.
3195097|NCT01232738|Experimental|rasagiline|Treated for 12 months with rasagiline 2mg orally, once daily.
3195098|NCT01232725|Experimental|Donor Human Milk|VLBW infants randomized to be fed donor human milk, fortified as appropriate, for all feedings for which maternal milk is not available, including infants who receive no maternal milk
3195099|NCT01232725|Experimental|Preterm Formula|VLBW infants randomized to receive preterm infant formula for any feedings for which maternal milk is unavailable, including infants receiving no maternal milk
3195100|NCT01232712|Experimental|ImMucin|Treatment with ImMucin and rhGMCSF (recombinant human granulocyte-monocyte colony stimulating factor)
3195101|NCT01232699|Active Comparator|Internet Obesity Treatment|Participants will attend weekly class sessions on line and track food and exercise in an on-line journal.
3195102|NCT01232699|Experimental|Internet Obesity Treatment with MI|Participants will attend weekly classes on line, record food and exercise in an on-line journal, and will have no more than 6 individual motivational interviewing sessions.
3195103|NCT01232699|Experimental|Contingent MI|Intervention is the same as for the MI arm, however participants will only receive MI if meeting certain treatment participation conditions.
3195104|NCT01232686|No Intervention|Control area|In the control areas we will monitor the prevalence and treatment of communicable diseases without giving the participants online access to disease surveillance information
3195105|NCT01232686|Experimental|Intervention area|In these areas we will give study participants online access to epidemiological data for communicable diseases
3195106|NCT01232673|Experimental|BMAC treatment active group|Collection of 240ml from both illiac crests, followed by gradient density centrifugation, resulting in obtaining 40ml of BMAC. This ammount is applied by one ml per injection into the critical limb ischemia along the calf vessels.
3195107|NCT01232673|No Intervention|Control Study Group|Standard treatment group of patients with CLI after surgical or interventional revascularisation will serve as control.
3195108|NCT01232660|Active Comparator|Delayed|Delayed addition of hydroxychloroquine in patients with discordant CD4+ cell responses to suppressive HAART
3195109|NCT01232660|Experimental|Immediate|Immediate addition of hydroxychloroquine in patients with discordant CD4+ cell responses to suppressive HAART
3195110|NCT01232647|Active Comparator|Vitamin k1|1.0 mg of vitamin K1 (phylloquinone) and placebo MK4 will be given to one of the treatment arm for 18 months
3195111|NCT01232647|Placebo Comparator|placebo vitamin K1 and MK4|placebo pill of both vitamin K1 and MK4 given for 18 months to the control arm
3195112|NCT01232647|Active Comparator|Menatetrenone MK4|45 mg MK4 given daily and placebo vitamin K1 will be given to one of treatment arm for 18 months
3195113|NCT01232634||All Subjects|
3195114|NCT01232621|Experimental|Physician introduction|Physicians will introduce Research Coordinators (RCs) by name to SDMs and acknowledge patient eligibility to participate in a study using a standardized script.
3195115|NCT01232621|Active Comparator|Non-physician introduction (usual approach)|RCs will either introduce themselves or be introduced by a non-physician member of the health care team.
3195116|NCT01232608|Experimental|Exercise|12 months of exercise training
3195117|NCT01232608|No Intervention|Control|Normal follow-up by primary physician
3195118|NCT01232595|Experimental|LFF571 (POC)|
3195119|NCT01232595|Active Comparator|Vancomycin (POC)|
3195120|NCT01232595|Experimental|LFF571 Dose level 1 (cohort 2)|
3195121|NCT01232595|Experimental|LFF571 Dose level 2 (cohort 2)|
3195122|NCT01232595|Experimental|LFF571 Dose level 3 (cohort 2)|
3195123|NCT01232595|Experimental|LFF571 Dose level 4 (cohort 2)|
3195124|NCT01232569|Experimental|Tocilizumab 162 mg sc|Patients will receive tocilizumab 162 mg subcutaneously (sc) every 2 weeks for 24 weeks.
3195125|NCT01232569|Placebo Comparator|Placebo sc|Patients will receive placebo subcutaneously (sc) every 2 weeks for 24 weeks.
3195126|NCT01232556|Experimental|1|Inotuzumab ozogamicin+rituximab
3195127|NCT01232556|Active Comparator|2|Investigator's choice of (1) rituximab+gemcitabine, or (2) rituximab+bendamustine
3195128|NCT01232543|Experimental|Product 0405|Topical Active Investigational Product 0405
3195129|NCT01232530||Safety Active Surveillance Group|For the active surveillance, all age groups, including children less than 5 years of age, will be identified from the census database and encouraged to attend the health facility whenever sick. Those with a diagnosis of malaria and treated with an antimalarial drug will be actively monitored for AEs.
3195280|NCT01231581|Active Comparator|Placebo plus Gemcitabine|Placebo administered orally plus gemcitabine IV
3195327|NCT01231347|Active Comparator|AMG 479 20 mg/kg + gemcitabine|Arm 3: AMG 479 20 mg/kg IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
3195130|NCT01232530||Safety Passive Surveillance Group|For the people under passive surveillance, sick subjects attending the health facilities, diagnosed with malaria and treated with an antimalarial drug will be identified from the census database. The treatment administered will be recorded in a drug exposure log book and the patients will be encouraged to report passively any AE/ADR.
3195131|NCT01232530||Early Pregnancy Exposure to ACTs Group|All the pregnant women identified during the repeat surveys will be included in a pregnancy cohort. At the time the pregnant woman is identified, her possible exposure to ACTs will be extracted from the drug exposure log book or elicited by history. Births identified through the repeat surveys or any other outcome of pregnancy will be retrospectively matched with antimalarial treatment exposure, particularly during the first trimester of the pregnancy.
3195132|NCT01232530||ACT Effectiveness Monitoring Group|"Besides monitoring AEs and ADRs, data on the effectiveness of ACTs when used in real life conditions and on a large scale will be collected in the active surveillance area. For patients with a microscopically confirmed diagnosis of malaria, clinical symptoms and a blood sample for thick and thin blood smears, will be collected before antimalarial treatment, at day 28 after treatment and at any unscheduled visit. Treatment administration will not be supervised."
3195133|NCT01232504|Experimental|rhGM-CSF group|subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) once daily
3195134|NCT01232504|Active Comparator|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) and 2-3μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) each
3195135|NCT01232504|Active Comparator|rhG-CSF group|subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) once daily
3195136|NCT01232491|Active Comparator|Control|Insulin detemir (Levemir®) 100 U/mL, was injected subcutaneously once daily with the evening meal or at bedtime as add-on to subject's pre-trial treatment of metformin for 26 weeks. Subjects did not receive dietary consultation except for basic dietary advice at baseline. Insulin doses were individually adjusted.
3195137|NCT01232491|Experimental|Dietician|Insulin detemir (Levemir®) 100 U/mL, was injected subcutaneously once daily with the evening meal or at bedtime as add-on to subject's pre-trial treatment of metformin for 26 weeks. Subjects received dietary consultation according to local standard during 3 face-to-face meetings and 3 phone contacts. Insulin doses were individually adjusted.
3195138|NCT01232478|Experimental|Comprehensive Adherence Program (CAP)|The comprehensive adherence program emphasizes the patient's active, collaborative role in identifying adherence barriers and solving them to improve adherence to prescribed treatment regimens. Problem-solving sessions will be used to address barriers to adherence that are identified by the adolescent. The intervention also includes provision of a written, Prescribed Treatment Plan, assessment and remediation of gaps in Knowledge of Disease Management, and evaluation and re-instruction/re-training of skills needed to perform daily treatments.
3195139|NCT01232478|Experimental|Standard Care (SC)|Standard care (SC) for adolescents and young adults seen in outpatient CF clinics in Year 1 of the Study. CAP intervention during Year 2 of the Study.
3195140|NCT01232465||IVF|those individuals undergoing conventional IVF to inseminate their retrieved eggs
3195141|NCT01232465||ICSI|those individuals whose eggs were fertilized via intracytoplasmic sperm injection (ICSI)
3195142|NCT01232452|Experimental|Pemetrexed + Cisplatin + Cixutumumab|"Induction Treatment: Pemetrexed 500 mg/m^2 plus cisplatin 75 mg/m^2 plus cixutumumab 20 mg/kg given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for patients with significant tumor size reduction, after sponsor approval.~Maintenance Therapy: Pemetrexed 500 mg/m^2 plus cixutumumab 20 mg/kg given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met."
3195143|NCT01232452|Active Comparator|Pemetrexed + Cisplatin|"Induction Treatment: Pemetrexed 500 mg/m^2 plus cisplatin 75 mg/m^2 given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for patients with significant tumor size reduction, after sponsor approval.~Maintenance Therapy: Pemetrexed 500 mg/m^2 given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met."
3195144|NCT01232439|Experimental|opioid receptor kappa antagonist|
3195145|NCT01232426|Experimental|Operative|operative treatment of a Mallet fracture with a biodegradable Meniscus Arrow®
3195146|NCT01232426|Active Comparator|Conservative|Conservative treatment of a Mallet fracture with a Mallet splint
3195147|NCT01232413|Placebo Comparator|Treatment A|Placebo
3195148|NCT01232413|Experimental|Treatment B|ASP1941 low dose
3195149|NCT01232413|Experimental|Treatment C|ASP1941 high dose
3195150|NCT01232413|Active Comparator|Treatment D|Moxifloxacin
3195151|NCT01232400|Experimental|esmolol|Esmolol will be used preferentially to control hypertension.
3195152|NCT01232400|No Intervention|Standard care|Standard care for SAH includes other hypertensives such as nicardipine.
3195153|NCT01232387||Fetomaternal hemorrhage - Mothers|Mothers in Mother-baby pairs in which the testing for fetomaternal hemorrhage on the mother's blood demonstrates the presence of fetal cells.
3195154|NCT01232387||Fetomaternal hemorrhage - Babies|Babies in Mother-baby pairs in which the testing for fetomaternal hemorrhage on the mother's blood demonstrates the presence of fetal cells.
3195155|NCT01232374|Experimental|Nimotuzumab plus chemo-irradiation|Nimotuzumab，chemotherapy(cisplatin )，radiotherapy
3195156|NCT01232374|Placebo Comparator|Placebo plus chemo-irradiation|Placebo，chemotherapy(cisplatin)，radiotherapy
3195157|NCT01232361||Methylphenidate|"Subjects will be stratified by medication, HIV status and HIV antiretroviral therapy as follows:~Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant (prescribed) efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a (prescribed) protease inhibitor (PI)* with concomitant ritonavir (at boosting doses) or lopinavir/ritonavir.~*PI may be any of the following: atazanavir, darunavir, fosamprenavir, indinavir, saquinavir or tipranavir"
3195281|NCT01231568|Experimental|Cohort 1 Treatment Sequence 1|Subjects will receive two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 1 and two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
3195491|NCT01230138|Experimental|FP187 - TID|FP187 250mg TID (total daily dose of 750mg)
3195158|NCT01232361||Amphetamine / dextroamphetamine|"Subjects will be stratified by medication, HIV status and HIV antiretroviral therapy as follows:~Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant (prescribed) efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a (prescribed) protease inhibitor (PI)* with concomitant ritonavir (at boosting doses) or lopinavir/ritonavir.~*PI may be any of the following: atazanavir, darunavir, fosamprenavir, indinavir, saquinavir or tipranavir"
3195159|NCT01232348||Symbicort|Those with an exposure
3195160|NCT01232322||Pulmicort Respules|Those with an exposure
3195161|NCT01232309|Active Comparator|High Dose Chitin-Glucan|Daily oral dose of 4.5 g of chitin-glucan
3195162|NCT01232309|Active Comparator|Low Dose Chitin-Glucan|Daily oral dose of 1.5 g chitin-glucan
3195163|NCT01232309|Experimental|Low Dose Chitin-Glucan + Olive Extract|Daily oral dose of 1.5 g chitin-glucan + 135 mg olive extract
3195164|NCT01232309|Placebo Comparator|Placebo|Placebo (Rice Flour)
3195165|NCT01232296|Experimental|TKI258|capsule
3195166|NCT01232296|Experimental|Sorafenib|tablet
3195167|NCT01232283|Experimental|Apremilast|Participants were initially randomized 2:1 and received apremilast 30 mg twice a day (BID). Participants maintained dosing through Week 32. At Week 32, responders, those with a Psoriasis Area Severity Index response -≥75 (PASI-75) and partial responders (≥PASI-50) were re-randomized 1:1 to apremilast 30 mg BID or matching placebo (treatment withdrawal). Participants could resume apremilast 30 mg BID at the time of loss of 50% of improvement in PASI score response which was observed at Week 32 compared to baseline), and no later than Week 52. At Week 52, the non-responders (<PASI-50) had the option of adding topical therapies and/or phototherapy to their treatment regimen. Those re-randomized to apremilast 30 mg BID continued dosing through Week 52. At Week 52, participants continued treatment with apremilast 30 mg BID.
3195168|NCT01232283|Placebo Comparator|Placebo|Participants will be initially randomized to placebo, identically matching during Weeks 0-16. At Week 16, Placebo participants will be switched to receive apremilast 30 mg BID. All participants will maintain Apremilast dosing through Week 32. At Week 32, participants originally randomized to placebo at baseline (Week 0) and are considered non-responders i( < PASI-50) will have the option of adding topical therapies and/or phototherapy to their Apremilast treatment regimen. At Week 52, all participants will continue treatment with apremilast 30 mg BID. Participants will be followed and evaluated for safety and efficacy for up to an additional 4 years (years 2 through 5).
3195169|NCT01232270|Active Comparator|fentanyl|
3195170|NCT01232270|Placebo Comparator|saline|
3195171|NCT01232257|Experimental|Healthy volunteers|
3195172|NCT01232257|Experimental|CKD patients|Patients with CKD stage 3-4 (GFR 15-60 ml/min)
3195173|NCT01232257|Experimental|Hemodialysis patients|
3195174|NCT01232257|Experimental|Peritoneal dialysis patients|
3195175|NCT01232244||Healthy young males|
3195176|NCT01232231|Active Comparator|decolonization treatment|topical antiseptic, intranasal antimicrobial, and oral antimicrobial that have activity against MRSA in addition to education regarding personal hygiene and environmental cleaning
3195177|NCT01232231|Other|education|No decolonization treatment in addition to education regarding personal hygiene and environmental cleaning
3195178|NCT01232218|Active Comparator|Current Standard Treatment|Current standard treatment for hemiplegic shoulder pain will be provided to this group.
3195179|NCT01232218|Experimental|Standard treatment + study technique|Participants will receive current standard treatment for hemiplegic shoulder pain PLUS an additional stretching/strengthening technique. Both groups will be allotted the same treatment time.
3195180|NCT01232205|Active Comparator|micronutrient antioxidant|Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium
3195181|NCT01232205|Placebo Comparator|Control|
3195182|NCT01232192|No Intervention|Antenatal model|
3195183|NCT01232192|Experimental|Antenatal Model|
3195184|NCT01232179|Active Comparator|conventional prp|
3195185|NCT01232179|Active Comparator|targeted PRP|
3195186|NCT01232166|Experimental|Endobronchial Intubation, Auscultation|In this arm, the endotracheal tube will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. The study anesthesiologists will then perform bilateral auscultation of the lungs only, with the patient's thorax and head covered with blankets to blind participants to thorax movements and ETT insertion depth (Group Auscultation, n=20)
3195187|NCT01232166|Active Comparator|Endobronchial Intubation, Observation|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform observation and palpation of symmetric chest movements without auscultation of the lungs, with the patient's head covered with blankets to blind participants to ETT insertion depth (Group Observation, n=20);
3195188|NCT01232166|Active Comparator|Endobronchial intubation, tube depth|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then estimate ETT position by observing the ETT cm scale without lung auscultation, with the patient's thorax covered by blankets to blind participants to thorax movements (Group Tube Depth, n=20)
3195189|NCT01232166|Active Comparator|Endobronchial intubation, all three|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform a combination of auscultation, observation and tube depth
3195190|NCT01232166|Experimental|Endotracheal Intubation, Auscultation|In this arm, the endotracheal tube will be positioned in the trachea, 2,5-4cm above the carina under direct visualization through a fiberoptic bronchoscope. The study anesthesiologists will then perform bilateral auscultation of the lungs only, with the patient's thorax and head covered with blankets to blind participants to thorax movements and ETT insertion depth (Group Auscultation, n=20)
3195282|NCT01231568|Experimental|Cohort 1 Treatment Sequence 2|Subjects will receive two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 1 and two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
3195191|NCT01232166|Active Comparator|Endotracheal Intubation, observation|In this arm, the endotracheal tube (ETT) will be positioned in the trachea, 2,5-3cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform observation and palpation of symmetric chest movements without auscultation of the lungs, with the patient's head covered with blankets to blind participants to ETT insertion depth (Group Observation, n=20);
3195192|NCT01232166|Active Comparator|Endotracheal intubation, tube depth|In this arm, the endotracheal tube (ETT) will be positioned in the trachea, 2,5 - 4 cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then estimate ETT position by observing the ETT cm scale without lung auscultation, with the patient's thorax covered by blankets to blind participants to thorax movements (Group Tube Depth, n=20)
3195193|NCT01232166|Active Comparator|Endotracheal intubation, all three|In this arm, the endotracheal tube (ETT) will be positioned 2,5-4cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform a combination of auscultation, observation and tube depth
3195194|NCT01232153|Active Comparator|NIV preoxygenation|
3195195|NCT01232153|No Intervention|Classical preoxygenation|
3195196|NCT01232140|Experimental|CRP-guided antibiotic treatment|If CRP> 50 mg/l a patient receive antibiotic treatment, whereas in those patients with CRP =< 50 mg/l antibiotic treatment is withheld.
3195197|NCT01232140|Other|GOLD strategy-antibiotic treatment|According to the GOLD strategy a patient with an AECOPD should prescribed antibiotic treatment if a patient has symptoms of increased dyspnea, increased sputum production and change of sputum color. Two of these three criteria should be present, however change in sputum production is obligatory.
3195198|NCT01232127|Other|Atazanavir/ritonavir (300/100 mg) + TDF + ≥ 1 NRTI|The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
3195199|NCT01232127|Other|Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (20)|FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
3195200|NCT01232127|Other|Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (40)|FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
3195201|NCT01232101|Active Comparator|covered self expandable metallic stents|Patients with bile malignant bile duct strictures are randomized to covered or uncovered stent
3195202|NCT01232101|Active Comparator|Uncovered self expandable metallic stent|
3195203|NCT01232088||Data collection group: ICU physicians|Online survey for ICU physicians (members of the European Society of Intensive Care Medicine (ESICM)).
3195204|NCT01232075|Experimental|Extended letrozole regimen|
3195205|NCT01232075|Active Comparator|Clomiphene citrate regimen|
3195206|NCT01232049|Experimental|A|Pitavastatin 4mg
3195207|NCT01232049|Experimental|B|Valsartan 320mg
3195208|NCT01232049|Experimental|C|Pitavastatin 4mg + Valsartan 320mg
3195209|NCT01232036|Active Comparator|A|Reference
3195210|NCT01232036|Experimental|B|Test
3195211|NCT01232036|Placebo Comparator|C|Placebo
3195212|NCT01232023|Experimental|100mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
3195213|NCT01232023|Experimental|200mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
3195214|NCT01232023|Experimental|400mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
3195215|NCT01232023|Experimental|800mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
3195216|NCT01232010|Experimental|Healthy Volunteers|
3195217|NCT01232010|Experimental|Patients with severe renal impairment|
3195218|NCT01231997|Experimental|Healthy Volunteers|
3195219|NCT01231997|Experimental|Patients with mild renal impairment|
3195220|NCT01231997|Experimental|Patients with moderate renal impairment|
3195221|NCT01231997|Experimental|Patients with severe renal impairment|
3195222|NCT01231984|Experimental|4 mm vs. 8 mm|Subjects randomized to this study arm first used either the 4 mm x 32G Pen Needle or the 8mm x 31G Pen Needle for 12 weeks (Period 1), then switched to the alternate pen needle (PN) for another 12 weeks (Period 2). Order of PN use was randomly determined.
3195223|NCT01231984|Experimental|4 mm vs. 12.7 mm|Subjects randomized to this study arm first used either the 4 mm x 32G Pen Needle or the 12.7mm x 29G Pen Needle (PN) for 12 weeks (Period 1), then switched to the alternate PN for another 12 weeks (Period 2). Order of PN use was randomly determined.
3195224|NCT01231971||Cognitively Normal (CN)|150 newly enrolled participants with no apparent memory problems, and CN participants followed from the ADNI1 study
3195225|NCT01231971||Early Mild Cognitive Impairment (EMCI)|100 newly enrolled early amnestic MCI participants, and approximately 200 EMCI participants will be followed from the ADNI-GO study
3195226|NCT01231971||Late Mild Cognitive Impairment (LMCI)|150 newly enrolled late MCI participants, and LMCI participants followed from the ADNI1 study
3195227|NCT01231971||Alzheimer's Disease (AD)|150 newly enrolled mild AD participants
3195228|NCT01231971||Significant Memory Concern (SMC)|100 newly enrolled participants with Significant Memory Concern (SMC)
3195229|NCT01231919|Experimental|Treatment (Akt inhibitor)|Patients receive oral Akt inhibitor MK2206 every other day (schedule 1) OR once weekly (schedule 2) on days 1-28. Treatment repeats every 28 days for up 12 courses (1 year) in the absence of disease progression or unacceptable toxicity.
3195230|NCT01231906|Experimental|Arm I (combination chemotherapy)|"INDUCTION THERAPY: Patients receive vincristine sulfate (IV) on day 1 in weeks 1, 2, 5, 6, 9, and 10; doxorubicin hydrochloride IV on days 1 and 2 and cyclophosphamide IV over 30-60 minutes on day 1 in weeks 1, 5, and 9; and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 in weeks 3, 7, and 11.~CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 7, 8, 9, 10, 13, 14, 17, 18, 21, and 22; doxorubicin hydrochloride IV on days 1 and 2 in weeks 1 and 9; cyclophosphamide IV over 30-60 minutes on day 1 in weeks 1, 7, 9, 13, 17, and 21; and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 in weeks 3, 5, 11, 15, and 19."
3195325|NCT01231347|Active Comparator|AMG 479 12 mg/kg dose + gemcitabine|Arm 2: AMG 479 12 mg/kg IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
3195688|NCT01228838|Placebo Comparator|Placebo liquid|
3195231|NCT01231906|Experimental|Arm II (combination chemotherapy, topotecan hydrochloride)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 5, 6, 9, 10, 11 and 12; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 9; cyclophosphamide IV over 15-60 minutes on days 1-5 in weeks 1 and 9, and on day 1 of weeks 5 and 11; ifosfamide and etoposide as in arm I; and doxorubicin hydrochloride IV on days 1 and 2 in weeks 5 and 11.~CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 7-10, 13-16, 19, and 20; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1, 7, and 15; cyclophosphamide IV over 15-60 minutes on days 1-5 in weeks 1, 7, and 15, and on day 1 in weeks 9, 13, and 19; ifosfamide IV over 1 hour and etoposide IV over 1- 2 hours on days 1-5 in weeks 3, 5, 11, 17, and 21; and doxorubicin hydrochloride IV on days 1 and 2 in weeks 9,13, and 19."
3195232|NCT01231893|Experimental|olfactory ensheathing cell recipient|
3195233|NCT01231893|Active Comparator|control|
3195234|NCT01231880|Experimental|Four monthly IPT|IPT give once a school term (every four months)
3195235|NCT01231880|Experimental|Monthly IPT|IPT given every month
3195236|NCT01231880|Placebo Comparator|Placebo|No active drug in the placebo
3195237|NCT01231854|Active Comparator|Ciclosporingroup|
3195238|NCT01231854|Active Comparator|Alitretinoingroup|
3195239|NCT01231841|Experimental|rATG + Cyclosporine|Patients receive anti-thymocyte globulin IV daily over 4-24 hours on days 1-5. Beginning on day 6, patients receive oral cyclosporine twice daily for 6 months followed by a taper. Treatment continues in the absence of disease progression or unacceptable toxicity
3195240|NCT01231828|Experimental|Carnitine|Versus placebo.
3195241|NCT01231828|Experimental|Lactulose|Versus placebo
3195242|NCT01231815|Experimental|PET|15O-H2O PET
3195243|NCT01231815|Experimental|MRI|MRI
3195244|NCT01231802|Experimental|Arm 1: Eniluracil/5-FU/Leucovorin|Arm 1: (weekly, 28-day cycle): Approximately eighty subjects will orally self-administer eniluracil approximately 13 hr (range of 11-16 hr) before receiving 5 FU and leucovorin. The next day they will orally self-administer 5-FU and leucovorin. On the third day, they will orally self-administer leucovorin. The regimen is taken once per week for three consecutive weeks followed by one-week off-treatment.
3195245|NCT01231802|Active Comparator|Arm 2: Capecitabine|Arm 2: (bid daily, 21-day cycle): Approximately sixty subjects will self-administer oral capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
3195246|NCT01231789|Sham Comparator|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min.
3195247|NCT01231789|Experimental|RIPC treatment|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
3195248|NCT01231776|No Intervention|control group|
3195249|NCT01231776|Active Comparator|acupuncture preoperative|acupuncture before operation for one week
3195250|NCT01231776|Active Comparator|acupuncture in hospital|acupuncture all the time in hospital
3195251|NCT01231763||Healthy volunteers|
3195252|NCT01231750|Active Comparator|0.1% Capsaicin Cream|0.1% capsaicin cream spread 8cm x 15cm on abdomen, once, 45 minutes prior to exercise
3195253|NCT01231750|Placebo Comparator|Placebo Cream|Inactive cream, 4cm spread 8cm x 15cm on the abdomen, once, 45 minutes prior to exercise
3195254|NCT01231737|Active Comparator|Prulifloxacin|
3195255|NCT01231724|Active Comparator|Allstate Nasal Spray|
3195256|NCT01231724|Placebo Comparator|Placebo Nasal Spray|
3195257|NCT01231711|Experimental|Vets Prevail|N=50. Participants were recent veterans (deployed after September 11, 2001) of operations in Iraq and Afghanistan who were experiencing depression/distress symptoms at the time of screening (CES-D > 8) but who were not considered to be inappropriate for a health promotion intervention (CES-D > 35 indicating severe depressed mood or exhibiting self-harm risk).
3195258|NCT01231698|Experimental|esmolol|
3195259|NCT01231698|Other|control|
3195260|NCT01231685|Active Comparator|ritonavir-boosted protease inhibitor|
3195261|NCT01231685|Experimental|Raltegravir|
3195262|NCT01231672||Septic shock patients|
3195263|NCT01231659|Experimental|Everolimus + Letrozole|Everolimus 10 mg + Letrozole 2.5 mg
3195264|NCT01231646||Lamotrigine|No intervention
3195265|NCT01231646||Valproate|No intervention
3195266|NCT01231633|Experimental|Group 1|Subjects randomized to this arm will receive one initial treatment with Ozurdex then treated with Avastin if needed.
3195267|NCT01231633|Active Comparator|Group 2|Subjects randomized to this arm will receive one initial treatment with Avastin then treated with Avastin if needed.
3195268|NCT01231620|Experimental|Intravenous (IV) Zanamivir 300mg Twice Daily|300mg of IV zanamivir infusion twice daily plus oral oseltamivir placebo twice daily
3195269|NCT01231620|Experimental|Intravenous (IV) Zanamivir 600mg Twice Daily|600mg of IV zanamivir infusion twice daily plus oral oseltamivir placebo twice daily
3195270|NCT01231620|Active Comparator|Oral Oseltamivir 75mg Twice Daily|75mg oral oseltamivir twice daily plus intravenous placebo zanamivir twice daily
3195271|NCT01231607|Active Comparator|1mg Finasteride|1mg finasteride active plus dutasteride placebo, by mouth once daily
3195272|NCT01231607|Active Comparator|0.02mg Dutasteride|0.02mg dutasteride active plus finasteride placebo, by mouth once daily
3195273|NCT01231607|Active Comparator|0.1mg Dutasteride|0.1mg dutasteride active plus finasteride placebo, by mouth once daily
3195274|NCT01231607|Active Comparator|0.5mg Dutasteride|0.5mg dutasteride active plus finasteride placebo, by mouth once daily
3195275|NCT01231607|Placebo Comparator|Placebo|1mg finasteride placebo plus dutasteride placebo, by mouth once daily
3195276|NCT01231594|Experimental|Cohort A|Subjects who have received </= 8 weeks of GSK2118436 monotherapy in the parent study
3195277|NCT01231594|Experimental|Cohort B|Subjects who have received >8 weeks of continuous treatment with GSK2118436 either as monotherapy or combination therapy with another approved anti-cancer agent
3195278|NCT01231594|Experimental|Cohort C|Subjects who have received >8 weeks of continuous treatment with GSK2118436 in combination with a MEK inhibitor, GSK1120212
3195279|NCT01231581|Experimental|GSK1120212 plus Gemcitabine|GSK1120212 administered orally plus gemcitabine IV
3195283|NCT01231568|Experimental|Cohort 2 Treatment Sequence 1|Subjects will receive two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 1 and two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
3195284|NCT01231568|Experimental|Cohort 2 Treatment Sequence 2|Subjects will receive two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 1 and two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
3195285|NCT01231555|Experimental|GSK2248761 100 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
3195286|NCT01231555|Experimental|GSK2248761 200 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
3195287|NCT01231555|Active Comparator|Efavirenz 600 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
3195288|NCT01231542|Experimental|Arm 1|Subjects will have a screening visit within 30 days prior to the first dose of study drug, three treatment periods, and a follow-up visit 7-14 days after the last dose of study drug. Subjects enrolled in Arm 1 will receive GSK1349572 50 mg once daily for 7 days, GSK1348572 50 mg twice daily for 7 days, and GSK1349572 50 mg twice daily in combination with rifampin 600 mg once daily for 14 days.
3195289|NCT01231542|Experimental|Arm 2|Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug. Subjects in Arm 2 will receive GSK1349572 50 mg once daily for 7 days and GSK1349572 50 mg once daily in combination with rifabutin 300 mg once daily for 14 days.
3195290|NCT01231529|Experimental|Part 1 Cohort 1|8 subjects with moderate hepatic impairment defined by a Child-Pugh score of 7 to 9 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug.
3195291|NCT01231529|Experimental|Part 1 Cohort 2|8 healthy subjects matched by gender, age and BMI to the subjects in Cohort 1 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug.
3195292|NCT01231529|Experimental|Part 2 Cohort 3|8 subjects with mild hepatic impairment defined by a Child-Pugh score of 5 to 6 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug. This cohort will only be done if the AUC from Cohort 1 is greater than or equal to 2 times the AUC from Cohort 2.
3195293|NCT01231529|Experimental|Part 2 Cohort 4|8 healthy subjects matched by gender, age and BMI to the subjects in Cohort 3 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug. This cohort will only be done if the AUC from Cohort 1 is greater than or equal to 2 times the AUC from Cohort 2.
3195294|NCT01231516|Experimental|GSK1349572 + Raltegravir Placebo|Subjects will receive GSK1349572 50mg once daily plus raltegravir placebo twice daily.
3195295|NCT01231516|Active Comparator|Raltegravir + GSK1349572 Placebo|Subjects will receive raltegravir 400mg twice daily plus GSK1349572 placebo once daily.
3195296|NCT01231503|Experimental|RTS,S Neo-10-14 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) when ≤ 7 days of age and at 10 and 14 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
3195297|NCT01231503|Experimental|RTS,S Neo-10-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) when ≤ 7 days of age and at 10 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanri xHepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
3195298|NCT01231503|Experimental|RTS,S 6-10-14 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 14 weeks of age In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
3195299|NCT01231503|Experimental|RTS,S 6-10-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
3195326|NCT01231347|Placebo Comparator|Placebo + gemcitabine|Arm 1: AMG 479-placebo IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
3195300|NCT01231503|Experimental|Engerix-B Neo/RTS,S 6-10-26 Group|Subjects received one dose of Engerix-B (HBV) when ≤ 7 days of age followed by 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 26 weeks of age In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E and HBV vaccines were administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
3195301|NCT01231503|Experimental|RTS,S 10-14-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 10, 14 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
3195302|NCT01231503|Experimental|RTS,S 14-26-9M Group|Subjects received 3 doses of RTS,S/AS01E (or GSK257049) at 14 and 26 weeks of age and at 9 months of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when below ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
3195303|NCT01231503|Active Comparator|Engerix-B Neo Group|Subjects in this group received one dose of Engerix-B (HBV) ≤ 7 days of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when below ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The HBV vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
3195304|NCT01231490|Experimental|Active|
3195305|NCT01231490|Placebo Comparator|Placebo|
3195306|NCT01231477||Volunteers|Healthy volunteers not submitted to anesthesia nor surgery.
3195307|NCT01231477||Sevoflurane Group|This group was submitted to inhalational anesthesia with sevoflurane and otorhinolaryngological surgery.
3195308|NCT01231464|Placebo Comparator|placebo|vehicle placebo nasal spray
3195309|NCT01231464|Experimental|FFNS|fluticasone furoate nasal spray
3195310|NCT01231451|Experimental|All Subjects|All Subjects will receive the same intervention
3195311|NCT01231438|Experimental|Renvela|Treatment for 2 weeks
3195312|NCT01231438|Experimental|Etalpha|Vit D Treatment for 2 weeks
3195313|NCT01231425||With usual concomitant treatment|Two observational cohorts of patients will be evaluated: with and without concomitant analgesic/ antiinflammatory drugs. The objective is evaluate that both therapies (drugs and acupuncture) could be used as adjunctive therapy in order to maximize the analgesia that could be reached
3195314|NCT01231425||Without usual concomitant treatment|This group include patients that are not been treated with analgesic drugs at the beginning of the study. As an observational and naturalistic study any indicated treatment is allowed in any time
3195315|NCT01231412|Active Comparator|Arm I (MMF and CSP)|Patients receive FLU IV over 30 minutes on days -4 to -2. Patients also receive CSP PO BID on days -3 to 96 with taper to day 150 and MMF PO TID daily on days 0-29 and then BID on days 30-150 with taper to day 180. Patients undergo allogeneic PBSCT on day 0 following the TBI.
3195316|NCT01231412|Experimental|Arm II (MMF, CSP, and Sirolimus)|Patients receive FLU and CSP as in Arm I and sirolimus PO QD on days -3 to 150 with taper to day 180. Patients also receive MMF PO TID on days 0-29 and then BID on days 30-40. MMF will then be discontinued without taper unless GVHD or disease relapse/progression occurs. Patients undergo allogeneic PBSCT on day 0 following the TBI.
3195317|NCT01231412|Experimental|Arm 0 (CSP and Sirolimus)|Patients receive CSP orally (PO) twice daily (BID) on days -3 to 96 with taper to day 150 and and sirolimus PO once daily (QD) on days -3 to 150 with taper to day 180. Arm removed as of 14-Sep-2011
3195318|NCT01231399|Experimental|Arm I|Patients receive fluorouracil IV continuously over 46 hours, leucovorin calcium IV over 2 hours, and oxaliplatin IV over 2 hours on day 1. Patients also receive oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3195319|NCT01231373|Experimental|polidocanol injectable foam, 0.125%|
3195320|NCT01231373|Experimental|polidocanol injectable foam, 0.5%|
3195321|NCT01231373|Experimental|polidocanol injectable foam, 1.0%|
3195322|NCT01231373|Placebo Comparator|Vehicle|
3195323|NCT01231360|Active Comparator|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
3195324|NCT01231360|Active Comparator|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
3195328|NCT01231334|Active Comparator|Aczone® Gel 5% plus Differin® 0.3% Gel|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
3195329|NCT01231334|Active Comparator|Duac® Topical Gel plus Differin® 0.3% Gel|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks.
3195330|NCT01231321|Experimental|adalimumab|Adalimumab / pre-filled syringe 40 mg/0.8 ml
3195331|NCT01231308|Active Comparator|Lifestyle modification|Intensive nutritional/exercise counseling for weight loss by lifestyle modification in addition to optimum medical treatment.
3195332|NCT01231308|Experimental|Roux-en-Y-Gastric Bypass|A laparoscopic gastric bypass will be performed in the treatment of type 2 diabetes in Overweight-to-Moderately Obese Patients
3195333|NCT01231295||Memory problems|Group with clinically validated memory problems
3195334|NCT01231295||Reference group|Group without memory problems
3195335|NCT01231282|Experimental|diffusion-weighted MRI|MRI
3195336|NCT01231269|Experimental|MRI|diffusion-weighted MRI
3195337|NCT01231256|Experimental|preventive health consultation|Half participants randomized to a one hour preventive health consultation with their own general practitioner and a follow up consultation 3 months later
3195338|NCT01231256|No Intervention|Control|Controls are not offered preventive health consultations, but had questionnaires as the intervention arm
3195339|NCT01231243|Active Comparator|35% hydrogen peroxide control|The tooth bleaching will be performed using a high hydrogen peroxide concentration (35%) without light-activation with LED/light device
3195340|NCT01231243|Active Comparator|20% hydrogen peroxide|The tooth bleaching will be performed with a low hydrogen peroxide concentration (20%) without light activation with a LED/laser device
3195341|NCT01231243|Experimental|35% hydrogen peroxide + light|The tooth bleaching will be performed with a high hydrogen peroxide concentration (35%) associated with LED/laser light activation
3195342|NCT01231243|Experimental|20% hydrogen peroxide + light|The tooth bleaching will be performed with a low hydrogen peroxide concentration (20%) associated with LED/laser light activation
3195343|NCT01231230|Experimental|fluticasone/salmeterol|participants were treated fluticasone/salmeterol,
3195344|NCT01231230|Experimental|salmeterol|participants were treated with salmeterol
3195345|NCT01231230|Experimental|fluticasone|participants were treated with fluticasone
3195346|NCT01231230|Placebo Comparator|placebo inhalation|participants were treated with placebo
3195347|NCT01231217|Other|green (or white) tea|Patients are recommended to drink green (or white) tea but are not allowed to consume any coffee
3195348|NCT01231217|Other|coffee|Patients are recommended to drink coffee but are not allowed to consume any tea
3195349|NCT01231204|Placebo Comparator|Placebo Infusion|Patients will be randomized to receive a continuous infusion of Normal Saline via a Paravertebral Nerve Block.
3195350|NCT01231204|Active Comparator|Ropivicaine 0.4% Infusion|Patients will be randomized to receive a continuous infusion of 0.4% Ropivicaine via a Paravertebral Nerve Block.
3195351|NCT01231191|Active Comparator|IV Acetaminophen|Intraoperative IV acetaminophen administered
3195352|NCT01231191|Placebo Comparator|IV Placebo|Intraoperative IV normal saline administered
3195353|NCT01231178|Active Comparator|Alginate based beverage|
3195354|NCT01231178|Placebo Comparator|Control beverage|
3195355|NCT01231165|Experimental|Amiloride,nitrates,clopidogrel,aspirin,statins|Comparative Efficacious Research
3195356|NCT01231165|Active Comparator|Nitrates, clopidogrel, aspirin, statins|Comparative Efficacious Research
3195357|NCT01231139|Experimental|Paracetamol|Paracetamol dissolved in 0.9% Sodium Chloride
3195358|NCT01231139|Placebo Comparator|0.9% Sodium Chloride|0.9% Sodium Chloride
3195359|NCT01231126|Placebo Comparator|spontaneous vaginal deliveries|
3195360|NCT01231126|Placebo Comparator|elective caesarians|
3195361|NCT01231126|Experimental|induced vaginal delivery by misoprostol|
3195362|NCT01231126|Experimental|caesarians section with induction attempt|
3195363|NCT01231113|Active Comparator|artesunate-amodiaquine arm|A co-blistered pack of amodiaquine and artesunate.The 452 pregnant women in this arm will receive artesunate-amodiaquine tablets(artesunate 4mg/kg and amodiaquine 10mg/kg in twelve hourly doses over 3 days
3195364|NCT01231113|Experimental|Dihydroartemisinin-piperaquine arm|a fixed-dose combination to be administered to the other 452 pregnant women in this arm at an estimated total dosing of 6.75mg/kg dihydroartemisinin and 55mg/kg piperaquine over 3 days
3195365|NCT01231100|Experimental|HCUE-guided care|Hand-carried ultrasound echocardiography
3195366|NCT01231100|No Intervention|Standard care|
3195367|NCT01231074|Experimental|Psychotropic/metformin (PIW)|"Inclusion Criteria:Psychotropic/metformin (PIW) Cohort: Children aged 10-17 years on psychotropic* medication with reported weight gain defined by 1 of the following: 1. >5% weight increase from the start of medication to 3 months on medication 2. Crossing into the 95th percentile for BMI 3. Crossing into the 85-95th percentile plus one obesity related complication~The subject will have to be on one of these medications in addition to the criteria above to be eligible for the study: haloperidol, perphenazine, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, thioridazine, fluphenazine, loxapine, mesoridazine, thiothixene or trifluoperazine"
3195368|NCT01231074|Experimental|Obese/metformin (OME)|Obese/metformin (OME) cohort: Children 10-17 years old with BMI >95th percentile and fasting insulin level>21.7U/L
3195369|NCT01231061|Experimental|Arm A: SBRT|
3195370|NCT01231061|Experimental|Arm B: Radiosurgery|
3195371|NCT01231009|Active Comparator|Corticosteroids|Patients receive for 7 days intravenous corticosteroids, dexamethasone, and they continue receiving for 7 days corticosteroids per os
3195372|NCT01231009|Placebo Comparator|Vestibular exercises|Patients perform for 15 days certain vestibular exercises under suspicion of an expert physiotherapist
3195446|NCT01230502|Active Comparator|Group 2 Donor Specific Regulation (DSR) +; standard of care|Subjects that are Donor Specific Regulation (DSR) positive and randomized (1:1) to Group 2 will remain on standard of care immunosuppression.
3195492|NCT01230138|Experimental|FP187- BID|FP187 375mg BID (total daily dose of 750mg)of 750mg administered as 375mg BID
3195373|NCT01230996|Experimental|Dose escalation study|This is a dose escalation study of IMRT for women with locally advanced cervical cancer. Three dose levels will be investigated, (although, the first dose level is considered to be the equivalent to a standard pelvic dose with parametrial boost). Before moving to the next dose level it must be confirmed by the Chief Investigator that the Maximum Administrable Dose (MAD) has not been met in the previous dose level (see section 6.3). If MAD is reached before dose level 3 the study will stop. All patients enrolled on the study will undergo the same procedures at the same time points, regardless of the dose level they are being given (see section 5).
3195374|NCT01230983|Experimental|Treatment 1: (No HD MTX / No Zinecard)|Closed 09/2000 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), methotrexate/cytarabine), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, IT methotrexate /cytarabine radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), IT methotrexate/cytarabine)
3195375|NCT01230983|Active Comparator|Treatment 2: (No HD MTX / Zinecard)|Closed 09/2000 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), methotrexate/cytarabine, dexrazoxane hydrochloride (Zinecard or DZR)), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, dexrazoxane hydrochloride (Zinecard or DZR), IT methotrexate /cytarabine, radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), IT methotrexate/cytarabine)
3195376|NCT01230983|Active Comparator|Treatment 3: (HD MTX / No Zinecard)|Closed 09/2001 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), leucovorin calcium (LCV), HD methotrexate/cytarabine), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, leucovorin calcium (LCV), HD methotrexate /cytarabine radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), HD methotrexate/cytarabine)
3195377|NCT01230983|Active Comparator|Treatment 4: (HD MTX / Zinecard)|Closed 09/2001 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), leucovorin calcium (LCV), HD methotrexate/cytarabine, dexrazoxane hydrochloride (Zinecard or DZR)), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, HD methotrexate /cytarabine, dexrazoxane hydrochloride (Zinecard or DZR), radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), HD methotrexate/cytarabine)
3195378|NCT01230970|Experimental|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
3195379|NCT01230957|Experimental|Group 1|Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
3195380|NCT01230957|Experimental|Group 2|Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
3195381|NCT01230957|Experimental|Group 3|Participants will receive a dose High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
3195382|NCT01230957|Experimental|Group 4|Participants will receive a dose High-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
3195383|NCT01230957|Placebo Comparator|Group 5|Participants will receive a dose Placebo (0.9% normal saline) on Day 0, 7, and 30, respectively.
3195384|NCT01230957|Experimental|Group 6|Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 180, respectively.
3195385|NCT01230957|Experimental|Group 7|Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 30, and 180, respectively.
3195386|NCT01230944|Active Comparator|Laparoscopic Nissen|Laparoscopic Nissen fundoplication
3195387|NCT01230944|Active Comparator|Open Nissen|Open (conventional) Nissen fundoplication
3195388|NCT01230931|Experimental|Vitagel|The group of patients will receive the vitagel spray intra-operatively, along with all the other standards of care.
3195389|NCT01230931|No Intervention|No Vitagel|This group of patients will receive the standard of care for hemostasis in acetabular surgery (electrocautery/ligation of bleeding vessels, fracture reduction and stabilization, cell-saver, lap packing). They will not receive the vitagel product.
3195390|NCT01230918|Experimental|Diagnostic Imaging|A single dose of 800 to 1100 mBq of 99mTc-NC100692 radiopharmaceutical will be injected. Serial cardiac nuclear imaging will be done over a 3 hour period.
3195391|NCT01230905|Other|MPI nuclear scan|Nuclear MPI for CAD for prostate cancer subjects undergoing treatment and development of normal comparison.
3195392|NCT01230892|Active Comparator|Nebivolol|
3195393|NCT01230892|Active Comparator|Atenolol|
3195394|NCT01230879|Experimental|60 - 70 years old|EFR and TDM
3195395|NCT01230879|Experimental|71 - 80 years old|EFR and TDM
3195396|NCT01230879|Experimental|81 - 95 years old|EFR and TDM
3195397|NCT01230866|Other|Proton Radiation Hypofractionation|5 fractions (7.6 Gy(RBE) x 5)
3195398|NCT01230866|Active Comparator|Proton Radiation Standard Fractionation|44 fractions (1.8 Gy(RBE) x 44)
3195399|NCT01230853|Active Comparator|Active Comparator: A|
3195400|NCT01230853|Placebo Comparator|Placebo Comparator A|
3195401|NCT01230853|Active Comparator|Active Comparator: B|
3195402|NCT01230853|Placebo Comparator|Placebo Comparator B|
3195403|NCT01230840|Placebo Comparator|placebo|Control cookies will contain no wheat dextrin and will be taken 3 times daily for 2 weeks.
3195404|NCT01230840|Experimental|wheat dextrin|wheat dextrin (formulated according to the supporter's established method), will be baked in cookies providing three doses per day (≈5 gram of wheat dextrin in each dose)for 2 weeks.
3195405|NCT01230827|Experimental|CNTO 148 (Golimumab)|All patients will receive golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 12. Patients who have a clinical response at Week 16 and who are randomly allocated to golimumab, will receive 30 mg per square meter every 4 weeks through Week 48. Patients will continue to receive golimumab 30 mg per square meter after Week 48 in a long-term extension until Week 248. All patients will receive their fixed dose of commercial methotrexate throughout the study duration.
3195489|NCT01230151|Active Comparator|Clinical|Stimulation settings predetermined clinically (Clinical)
3195490|NCT01230151|Experimental|Model|stimulation settings derived from a patient-specific computer-based model (Model)
3195406|NCT01230827|Placebo Comparator|Placebo|All patients will receive golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 12. Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive placebo every 4 weeks through Week 48. However, patients receiving placebo and who will have lack/loss of clinical response will be eligible to receive golimumab 30 mg per square meter every 4 weeks through Week 48. At Week 48, patients do not have a clinical response will begin to receive golimumab 30 mg per square meter in a long-term extension until Week 248 and patients who have a clinical response will be discontinued from the study. All patients will receive their fixed dose of commercial methotrexate throughout the study duration.
3195407|NCT01230814|Experimental|Arm 1|Intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) nightly for 5 consecutive nights each month; 117 Subjects.
3195408|NCT01230814|Placebo Comparator|Arm 2|Placebo suppositories nightly for five consecutive nights each month; 117 Subjects.
3195409|NCT01230801|Experimental|BMN 701|IV infusion
3195410|NCT01230788|Experimental|rituximab|study drug given
3195411|NCT01230775|Experimental|Anagrelide retard|"Week 1:~1x1 tablet/d of Anagrelide retard (1 tablet = 2mg; total dose = 2mg/d will be administered in week 1.~Week 2 Anagrelide retard: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.~Week 3 - Week 4 Anagrelide retard In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.~Maintenance Phase Anagrelide retard During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range.~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/d"
3195412|NCT01230775|Placebo Comparator|Placebo|"Week 1:~x1 tablet/d of Placebo will be administered in week 1.~Placebo:~x1 tablet/d of placebo will be administered in week 2.~Placebo:~In week 3 and week 4 the maximum dose is 4 tablets per day.~Placebo:~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/d"
3195413|NCT01230762|Experimental|001|dapoxetine 60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
3195414|NCT01230749|Experimental|JNJ-41443532 250 mg|Participants will receive JNJ-41443532 250 mg in morning and evening for 28 days.
3195415|NCT01230749|Experimental|JNJ-41443532 1000 mg|Participants will receive JNJ-41443532 1000 mg (4 X 250 mg) in morning and evening for 28 days.
3195416|NCT01230749|Active Comparator|Pioglitazone|Participants will receive pioglitazone 30 mg in morning for 28 days.
3195417|NCT01230749|Placebo Comparator|Placebo|Participants will receive matching placebo for JNJ-41443532 and pioglitazone for 28 days.
3195418|NCT01230736|Experimental|DuoTrav|One drop in study eye(s) once daily for 8 weeks
3195419|NCT01230723|Active Comparator|Arm 1|Everolimus-Eluting Stent
3195420|NCT01230723|Active Comparator|Arm 2|Zotarolimus-Eluting-Stent
3195421|NCT01230710|Experimental|Erlotinib|Participants received erlotinib 150 mg orally once a day for 48 weeks.
3195422|NCT01230697||Sofanenib and Hypophosphatemia|Patients with advanced renal cells carcinoma and hepatocarcinoma in treatment with Sorafenib
3195423|NCT01230684|Other|Endoleak imaging|In the single arm all participants are recieving both imaging techniques; CEUS and CTA
3195424|NCT01230671|Experimental|Yoga|Patients in this arm will receive yoga therapy
3195425|NCT01230671|Placebo Comparator|No yoga|Patients will not have yoga in this arm
3195426|NCT01230645|Experimental|RV568 treatment group|
3195427|NCT01230645|Placebo Comparator|Placebo treatment group|
3195428|NCT01230632|Experimental|Dietary Supplement|3 days high fat food
3195429|NCT01230619|Experimental|RV568 treatment group|
3195430|NCT01230619|Placebo Comparator|Placebo treatment group|
3195431|NCT01230606||overnight|Subjects that stay overnight at the hospital.
3195432|NCT01230606||Next Day Discharge|Subjects that are discharged on the same day of the procedure.
3195433|NCT01230593|Active Comparator|Hot Compress|"Hot Compress"
3195434|NCT01230593|Active Comparator|Tobrex|"Hot Compress, Tobrex Drops, Tobrex Ointment"
3195435|NCT01230593|Active Comparator|Tobradex|"Hot Compress, Tobradex Drops, Tobradex Ointment"
3195436|NCT01230580|Experimental|Protease Inhibitor Monotherapy|Ritonavir-boosted protease inhibitor
3195437|NCT01230580|Active Comparator|Control|Standard-of-care triple-therapy regimen
3195438|NCT01230554|Experimental|Prism I|Bausch & Lomb daily disposable cosmetic tint contact lens
3195439|NCT01230541|Placebo Comparator|Placebo|Placebo
3195440|NCT01230541|Active Comparator|Udenafil|Udenafil daily tablet
3195441|NCT01230515||Caregiver|Family members will be asked to complete a demographic survey, an assessment of the patient's current pain, and a series of questionnaires including: Caregiver Pain Medicine Questionnaire, the Stressful Caregiving Adult Reactions To Experiences of Dying Scale, and the Caregivers' Self Efficacy in Pain Management Questionnaire. Upon completion of the questionnaires, patients and caregivers will be interviewed separately.
3195442|NCT01230515||Hospice staff|Hospice staff will be asked to complete the Pain Knowledge and Attitudes survey. They will also complete the Technology Acceptance Model (TAM) questionnaire to assess the perceived utility of an opioid titration order sheet to help manage pain control. A demographic survey will also be completed.
3195443|NCT01230515||Referring physician|Referring physicians will be asked to complete the Pain Knowledge and Attitudes survey as well as the TAM questionnaire and Demographic Survey.
3195444|NCT01230515||Patient|Demographic information includes education, marital status, number in household, and employment status will be obtained from patient. Clinical data will be obtained from the patient's medical records. Information to be obtained will include information about the type of cancer, stage of disease, time since diagnosis, current treatment for cancer, type of pain, time since onset of pain, and time of first opioid prescription. The patient will also take a pain assessment survey.
3195445|NCT01230502|Active Comparator|Group 3: Donor Specific Regulation (DSR) -, standard of care|Subjects who test Donor Specific Regulation (DSR) negative will not be randomized to possible tacrolimus withdrawal, and will remain on standard of care immunosuppression.
3195447|NCT01230502|Experimental|Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy|"Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy:~Subjects that are Donor Specific Regulation (DSR) positive and randomized (1:1) to Group 1 will begin a taper off tacrolimus for 6 months, after repeat DSR testing at 6 months subject will either discontinue tacrolimus if they remain DSR negative or remain at reduced dose if converted to DSR positive"
3195448|NCT01230489|No Intervention|Standard Care|This group will undergo the current standard of care for post operative exit sites at the involved institutions. This group will act as the control or the group to which the interventional group will be compared too.
3195449|NCT01230489|Experimental|MediHoney|This study group will have the dry 2 x 2 dressing replaced with a honey 2 x 2 dressing. Additionally all indentations in the exit site wound will be filled with honey ointment prior to the application of the dressing.
3195450|NCT01230476|Experimental|Cetuximab and chemotherapy|2 cycles of neoadjuvant cisplatin and 5FU (3 weekly), given with weekly cetuximab, followed by 7 doses of weekly cisplatin and cetuximab concurrent with radiotherapy
3195451|NCT01230463|Active Comparator|15 mg ketorolac IV|
3195452|NCT01230463|Active Comparator|30 mg ketorolac IV|
3195453|NCT01230450|Experimental|Single-incision Mini-slings (SIMS- Ajust)|AjustTM has polypropylene fixing anchors (one is fixed and the other adjustable) which are anchored onto the obturator membrane. The pulley like system enables adjustment of the tension once the arms have been anchored. Once in place, the anchors rest at right angles to insertion which is claimed to reduce the chances of anchor dislodgment
3195454|NCT01230450|Other|standared med urethral sling (SMUS)|standard med urethral sling (SMUS)TVT-O, was done as originally described by Deleval et al.
3195455|NCT01230437||asthmatic patients taking montelukast|asthma with or without rhinitis
3195456|NCT01230424|Experimental|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
3195457|NCT01230424|Placebo Comparator|Sodium Chloride|0.9% Sodium chloride injection as Placebo will be given into the study knee once every 12 weeks for a total of 8 injections.
3195458|NCT01230411|Placebo Comparator|placebo|IV saline administration as placebo
3195459|NCT01230411|Experimental|Ibuprofen|IV ibuprofen
3195460|NCT01230385|Experimental|Lersivirine 500 mg QD fasted (wet granulated tablet)|
3195461|NCT01230385|Experimental|Lersivirine 500 mg QD fed (wet granulated tablet)|
3195462|NCT01230385|Experimental|Lersivirine 750 mg QD fasted (wet granulated tablet)|
3195463|NCT01230385|Experimental|Lersivirine 750 mg QD fed (wet granulated tablet)|
3195464|NCT01230385|Active Comparator|Lersivirine 500 mg QD fasted (dry granulated tablet)|
3195465|NCT01230359|Experimental|Vitamin B6 and magnesium|
3195466|NCT01230359|Placebo Comparator|Tang powder group|
3195467|NCT01230346|Experimental|Arm I|Patients receive a culturally-informed adapted motivational interviewing telephone call.
3195468|NCT01230346|Experimental|Arm II|Patients participate in a controlled condition comprising a health habits intervention group.
3195469|NCT01230346|Active Comparator|Arm III|Patients receive usual care comprising a standard scheduling phone call and proceed with normal GCRA process.
3195470|NCT01230320|Experimental|Simplified (S) technique|"Complete dentures fabricated according to a simplified technique, divided into the following four sessions:~Maxillary and mandibular casts will be obtained from irreversible hydrocolloid impressions made in stock trays.~Record bases will be adjusted according to vertical dimension and centric relation measurements, without facebow transfer. Casts will be mounted in a semi-adjustable articulator using standardized measures and artificial teeth will be selected.~Trial dentures will be evaluated for esthetics and maxillomandibular relationships.~Insertion of finished dentures."
3195471|NCT01230320|Active Comparator|Conventional (C) technique|"Complete dentures fabricated according to a conventional technique:~Initial impression and the obtainment of custom trays;~Final impression with border molding using compound;~Facebow transfer;~Determination of maxillomandibular relationship;~Try-in of anterior teeth;~Try-in of posterior teeth;~Insertion of finished dentures."
3195472|NCT01230307|Active Comparator|Vitamin D|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
3195473|NCT01230307|Placebo Comparator|Placebo|A placebo loading dose will be given followed by two placebo tablets daily for 6 months.
3195474|NCT01230294||control|participants without structural heart disease
3195475|NCT01230294||CHF|patients with chronic heart failure of the left ventricle affecting the right heart
3195476|NCT01230294||PAH|patients with pulmonary arterial hypertension without left ventricular dysfunction
3195477|NCT01230281|Experimental|Black bean seed coat extract|Daily 1000 mg oral Black bean seed coat extract is given to each subject for 2 weeks from Day2 after measuring antioxidative marker without intervention on Day1.
3195478|NCT01230268|Experimental|Mulberry fruit extract|Daily 1000 mg oral Mulberry fruit extract is given to each subject for 2 weeks from Day2 after measuring antioxidative marker without intervention on Day1.
3195479|NCT01230255|Experimental|Percutaneous catheter decompression|Ultrasound guided percutaneous catheter drainage of free intra-peritoneal fluid or blood
3195480|NCT01230255|Active Comparator|Open abdominal decompression|Surgical treatment of elevated intra-abdominal pressure through traditional open abdominal decompression
3195481|NCT01230229|Active Comparator|Stenting|Active treatment group
3195482|NCT01230229|Placebo Comparator|Conservative treatment|Best medical treatment
3195483|NCT01230216|Active Comparator|intensive blood pressure control|systolic blood pressure less than 120 mmHg
3195484|NCT01230216|Active Comparator|standard blood pressure control|systolic blood pressure less than 140 mmHg
3195485|NCT01230203|Other|Computed tomography scan versus color duplex ultrasound|
3195486|NCT01230190|Active Comparator|Probiotic mixture|participants daily ingest a selected probiotic mixture for a period of 3 months
3195487|NCT01230190|Placebo Comparator|Placebo mixture|controls daily ingest a placebo mixture for a period of 3 months.
3195488|NCT01230177||Etanercept (genetical recombination)|Among the patients with rheumatoid arthritis (only for patients with an inadequate response to prior conventional therapy), the patients who will have changed regimen from 10 mg twice a week administration to 25 mg once a week administration.
3195636|NCT01229202|Active Comparator|bevacizumab arm|
3195493|NCT01230138|Experimental|FP187-LD-BID|FP187 250mg BID (total daily dose of 500mg)
3195494|NCT01230138|Placebo Comparator|Placebo|Placebo treatment
3195495|NCT01230138|Experimental|Open, flexible dosing treatment arm|Open treatment using a flexible dosing schedule for 8 weeks with maximum dose of 750mg FP187 and with a total dosing of 20 weeks. All investigations following same schedule.
3195496|NCT01230125|Experimental|Mapracorat|Ophthalmic suspension 3%
3195497|NCT01230125|Placebo Comparator|Vehicle|Vehicle of mapracorat ophthalmic suspension
3195498|NCT01230099|Experimental|Supportive Information Team Group|Protocolized information and support meetings led by palliative care clinicians
3195499|NCT01230099|No Intervention|Usual Care Group|
3195500|NCT01230086|Active Comparator|ICD implantation only|ICD Implantation without testing of defibrillation threshold testing
3195501|NCT01230086|Active Comparator|Modified upper limit of vulnerability testing|"Modified testing of upper limit of vulnerability"
3195502|NCT01230086|Active Comparator|VF-Induction|traditional VF-induction with T-Wave shock
3195503|NCT01230073|Active Comparator|ICD traditional follow-up|ICD with traditional follow-up in the outpatient clinic
3195504|NCT01230073|Active Comparator|Home-Monitoring|Home-Monitoring
3195505|NCT01230060|Experimental|enVista|enVista One-Piece Hydrophobic Acrylic Intraocular Lens
3195506|NCT01230047|Experimental|Psychoeducational Course|In this arm, clients receive the psychoeducational course.
3195507|NCT01230047|No Intervention|Treatment-as-usual/Waiting list|Clients assigned to this condition will receive treatment-as-usual (TAU) and be placed on a waiting list.
3195508|NCT01230034|Experimental|Imidapril|10 and 20 mg/day, pill
3195509|NCT01230034|Active Comparator|Ramipril|5 and 10 mg/day, pill
3195510|NCT01230021|Experimental|recombinant factor XIII|
3195511|NCT01230008||Radiotherapy in mediastinal lymphoma|Adjuvant radiotherapy or not (control group) in patients treated with R-CHOP
3195512|NCT01230008||Radiotherapy in mediastinal lymphoma|Radiotherapy will no be administered in patients treated with R-CHOP
3195513|NCT01230008||Radiotherapy in primary mediastinal lymphoma|Patients with primary mediastinal lymphoma will be treated with R-CHOP as induction therapy, if complete response is achieved, they were allocated to received or no (control group) adjuvatn radiotherapy, 3.5 G to mediastinal site.
3195514|NCT01229995|Active Comparator|Prefabricated Abutment|
3195515|NCT01229982|Experimental|L-PPDS|
3195516|NCT01229969|Experimental|NeuroCom EquiTest® System|Measure balance assessment (test for Sensory Organization Test (SOT) and Limit of Stability (LOS).
3195517|NCT01229969|Experimental|Wii Fit|Determine if the Wii Fit is valid and feasible in detecting balance problems in older adults
3195518|NCT01229943|Experimental|Arm I (octreotide acetate and everolimus)|Patients receive 28-day cycles until progression or unacceptable toxicity consisting of: everolimus 10 mg PO QD on days 1-28 and octreotide acetate 20 mg IM on day 1.
3195519|NCT01229943|Experimental|Arm II (octreotide acetate, everolimus, and bevacizumab)|Patients receive 28-day cycles until progression or unacceptable toxicity consisting of: everolimus 10 mg PO QD on days 1-28, octreotide acetate 20 mg IM on day 1 and bevacizumab 10 mg/kg IV on days 1 and 15.
3195520|NCT01229904|Experimental|Arm 1|patients with PTSD are randomized to either entering immediately a 6 week treatment with music therapy, or being in the delay group that enters the treatment arm after 6 weeks. This is a delayed entry RCT.
3195521|NCT01229891|Placebo Comparator|Plain yogurt drink|daily intake of two bottle (250 mL) plain yogurt drink
3195522|NCT01229891|Experimental|vitamin D-fortified yogurt drink|daily intake of two bottle yogurt drink fortified with 500 IU vitamin D/250 mL
3195523|NCT01229891|Experimental|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 mL
3195524|NCT01229878|Active Comparator|Arm 1|Hemodialysis Patients randomized to take Vitamin D supplements
3195525|NCT01229878|Placebo Comparator|Arm 2|Hemodialysis Patients randomized to take placebo pills
3195526|NCT01229865|Experimental|VB-111|antiangiogenic and vascular disruptive agent
3195527|NCT01229852|Experimental|Active DSF-rTMS|Active rTMS treatment.
3195528|NCT01229839|Experimental|infusion group|Infusion of anticancer agent followed by Embolization
3195529|NCT01229839|Experimental|lipiodol chemotherapy group|Infusion of mixture of anticancer agent and lipiodol followed by Embolization
3195530|NCT01229813|Active Comparator|bevacizumab and erlotinib (KRAS WT)|
3195531|NCT01229813|Active Comparator|bevacizumab (KRAS WT)|
3195532|NCT01229813|Active Comparator|bevacizumab (KRAS mutated)|
3195533|NCT01229813|Active Comparator|low dose capecitabine (KRAS mutated)|
3195534|NCT01229800|Active Comparator|Split dose PEG|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes.
3195535|NCT01229800|Active Comparator|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
3195536|NCT01229774|Experimental|Etoricoxib|
3195537|NCT01229774|Active Comparator|Diclofenac|
3195538|NCT01229761|Active Comparator|infant cotrimoxazole|
3195539|NCT01229761|Placebo Comparator|infant placebo|
3195540|NCT01229761|Active Comparator|exclusive breastfeeding for 6 months|
3195541|NCT01229761|Active Comparator|exclusive breastfeeding for 12 months|
3195542|NCT01229748|Experimental|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth.(Liddle, 2002) considered in the U.S. and abroad as an empirically supported Best Practice treatment for teen substance abuse and delinquency (USDHHS 2002; Drug Strategies 2003; NIDA 1999; Rigter et al 2004).
3195543|NCT01229748|Experimental|Family Motivational Interviewing|Motivational Interviewing (MI; Miller 1983; Miller & Rollnick 1991), is a client-centered treatment designed to strengthen clients' commitment and empower them to change their substance use behavior (Miller & Rollnick 2002).
3195544|NCT01229748|Other|Standard Care|The standard care condition will represent typical services for teens with alcohol problems in the community: assessment and referral for treatment
3195545|NCT01229735|Experimental|Levetiracetam|250 mg and 500 mg levetiracetam tablet; titration from 1000 mg/day (500 mg bid) to 3000 mg/day (1500 mg bid) levetiracetam with treatment duration up to 52 weeks
3195546|NCT01229735|Active Comparator|Topiramate|25 mg and 100 mg topiramate tablet; titration from 100 mg/day (50 mg bid) to 400 mg/day (200 mg bid) topiramate with treatment duration up to 52 weeks
3195547|NCT01229722|Active Comparator|Beeper|Patients randomized to the control arm (Beeper) will receive the standard of care at each clinic visit. The subjects will bring their HIV medications every 3 weeks (MEMS measure, pill count) and questioned on their adherence to antiretroviral therapy (ART) in the past 7 days. They will not receive any text messages addressing their adherence to ART between each study visit. Their providers will not be receiving any adherence reports but will be asked to assess their adherence at at the start of the trial (Time 1 or T1) and at subsequent clinic visit scheduled according to a frequency defined by standard of care.
3195548|NCT01229722|Experimental|Cell Phone|Participants will receive a text message reminder via ARemind at scheduled intervals, with varying frequency. They will also be subject to a remote adherence assessment, over text messages, interactive voice response (IVR), or a remote pill count with assistance over the phone from a counselor. Those who demonstrate lower adherence rates may receive a call from a counselor.
3195549|NCT01229709|Experimental|Mindfulness Based Tinnitus Reduction|
3195550|NCT01229709|No Intervention|Tinnitus Counseling Only Control|Control group subjects will have had treatment as usual (TAU) care from the UCSF Audiology Clinic which includes Tinnitus Counseling (TC) at least three-months prior to enty into the study.
3195551|NCT01229696|Active Comparator|At Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.
3195552|NCT01229696|Active Comparator|5cm Above Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
3195553|NCT01229683||Shoulder Surgery|Patients will be given an interscalene nerve block and then strength and sensation of the hand and forearm will be tested to determine if the block is helping to anesthetize these areas.
3195554|NCT01229670|Experimental|aerobic intermittent group|aerobic intermittent group
3195555|NCT01229670|Experimental|aerobic continuous group|aerobic continuous group
3195556|NCT01229670|No Intervention|control|home exercise group
3195557|NCT01229644|Experimental|Cohort A|Adult newly diagnosed glioma (both low and high grade) patients, who are able to to take Crenolanib (CP-868,596) for at least 3 days prior to surgical resection.
3195558|NCT01229644|Experimental|Cohort B|Adult patients with recurrent high grade glioma, including patients treated with bevacizumab. Patients are treated with Crenolanib (CP-868,596) continuously until they fulfill one of the criteria for study discontinuation.
3195559|NCT01229644|Experimental|Cohort C|Adult patients with biopsy proven low grade glioma who have residual measurable disease. Patients are treated with Crenolanib (CP-868,596) continuously until they fulfill one of the criteria for study discontinuation.
3195560|NCT01229631|Placebo Comparator|Supplementation with non-active|Subjects will be supplemented with placebo capsules (3 capsules am & 3 capsules pm)
3195561|NCT01229631|Active Comparator|Dietary supplementation with Juice plus+|Subjects will be supplemented with Juice plus+ capsules (3 capsules am & 3 capsules pm)
3195562|NCT01229618|Experimental|1|0.14 ml/kg bw - hyperpolarized pyruvate
3195563|NCT01229618|Experimental|2|0.28 ml/kg bw - hyperpolarized pyruvate
3195564|NCT01229618|Experimental|3|0.43 ml/kg bw - hyperpolarized pyruvate
3195565|NCT01229605|Experimental|Single Arm|Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
3195566|NCT01229592|Experimental|Ethanol|Every three day lock using Ethanol in all the lumen of the Catheter
3195567|NCT01229592|Active Comparator|Heparine|Every three day lock using Heparine in all the lumen of the Catheter
3195568|NCT01229579|Experimental|Zinc Supplement|2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc
3195569|NCT01229579|No Intervention|Placebo|2.5 ml supplement syrup daily without elemental zinc
3195570|NCT01229566|Active Comparator|Active Comparator|Active comparator
3195571|NCT01229566|Placebo Comparator|Placebo|Placebo control
3195572|NCT01229566|Experimental|AKR-963|Investigational drug
3195573|NCT01229553|Experimental|Decolonization group|The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
3195574|NCT01229540|No Intervention|Lifestyle counseling|
3195575|NCT01229527|Experimental|Remifentanil RS1|
3195576|NCT01229527|Experimental|Remifentanil RS2|
3195577|NCT01229527|Active Comparator|Meperidine|
3195578|NCT01229514||Exposure to anesthesia|
3195579|NCT01229514||Normal controls|
3195580|NCT01229488|No Intervention|No Arms|Project was withdrawn before starting
3195581|NCT01229475|Active Comparator|Stepwise approach|Stepwise approach for repeat AF ablation
3195582|NCT01229475|Active Comparator|Linear ablation|Linear ablation for repeat procedure in patients with recurrent atrial fibrillation
3195583|NCT01229462|Other|Combigan®|One drop of brimonidine tartrate/timolol combination ophthalmic solution (Combigan®) and one drop of brimonidine tartrate/timolol fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
3195584|NCT01229462|Active Comparator|Alphagan® and Timolol Concurrent|One drop of brimonidine tartrate ophthalmic solution (Alphagan®) and one drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
3195585|NCT01229449|Experimental|Ibuprofen/acetaminophen (lower dose)|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet
3195586|NCT01229449|Experimental|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg
3195587|NCT01229449|Active Comparator|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®)
3195588|NCT01229449|Active Comparator|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra)
3195589|NCT01229449|Placebo Comparator|Placebo|Two placebo tablets
3195590|NCT01229436|Experimental|Xiapex Injection|
3195591|NCT01229423|Experimental|LATISSE®|bimatoprost 0.03% (LATISSE®)
3195592|NCT01229410|Experimental|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
3195593|NCT01229410|Experimental|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
3195594|NCT01229397|Active Comparator|Inflexal V 0.25 mL x 2|
3195595|NCT01229397|Experimental|Inflexal V 0.5 mL x 1|
3195596|NCT01229384|Experimental|Positive Airway Pressure Nebulization|Will administer nebulized medications using Positive Airway Pressure Nebulization
3195597|NCT01229384|Active Comparator|Standard Nebulization|Current standard of administering nebulized medications without positive airway pressure
3195598|NCT01229371|Active Comparator|Subjects ≥18 to ≤60 Years - CSL HA Antigen|Inflexal V influenza vaccine (CSL HA Antigen) 2010 Group A will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011 containing per 0.5 mL i.m. dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
3195599|NCT01229371|Active Comparator|Subjects >60 Years - CSL HA Antigen|Inflexal V influenza vaccine (CSL HA Antigen) 2010 Group B will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011 containing per 0.5 mL i.m. dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
3195600|NCT01229371|Experimental|Subjects ≥18 to ≤60 Years - AdImmune HA Antigen|Inflexal V influenza vaccine (AdImmune HA Antigen) 2010/2011 Group C will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 containing per 0.5 mL i.m.dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
3195601|NCT01229371|Experimental|Subjects >60 Years - AdImmune HA Antigen|Inflexal V influenza vaccine (AdImmune HA Antigen) 2010/2011 Group D will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 containing per 0.5 mL i.m.dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
3195602|NCT01229358|Experimental|Silver Eluting Dressing|Acticoat Absorbant™ applied as post-operative dressing
3195603|NCT01229358|Active Comparator|Standard Guaze|Standard dry gauze applied as post-operative dressing
3195604|NCT01229345|Experimental|Breakfast & exercise|
3195605|NCT01229345|Experimental|Breakfast & no exercise|
3195606|NCT01229345|Experimental|No breakfast & exercise|
3195607|NCT01229345|No Intervention|No breakfast & no exercise|
3195608|NCT01229332|Placebo Comparator|Carbidopa|
3195609|NCT01229332|Placebo Comparator|Placebo|
3195610|NCT01229319|Experimental|cryo + imiquimod to Left|Cryotherapy alone to Right arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Left arm
3195611|NCT01229319|Experimental|Cryo + imiquimod to Right|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
3195612|NCT01229306|Experimental|reisolation of all PV and additional anterior line|
3195613|NCT01229306|Placebo Comparator|reisolation of all pulmonary veins|
3195614|NCT01229293|Experimental|Resurfacing Total Hip Arthroplasty|A hip replacement that leaves most of the underlying bone intact and mimics the natural biomechanical features of the hip joint. Articular surface replacement ASR, DePuy posterolateral approach used (RTHA)
3195615|NCT01229293|Active Comparator|Standard Total Hip Arthroplasty (THA)|A standard 28 mm head uncemented THA
3195616|NCT01229280|Experimental|Darisec(R) 7.5 mg|
3195617|NCT01229280|Active Comparator|Enablex(R) 7.5 mg|
3195618|NCT01229267|Experimental|V212 Consistency Lot 1|Participants randomized to receive V212 consistency Lot 1 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
3195619|NCT01229267|Experimental|V212 Consistency Lot 2|Participants randomized to receive V212 consistency Lot 2 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
3195620|NCT01229267|Experimental|V212 Consistency Lot 3|Participants randomized to receive V212 consistency Lot 3 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
3195621|NCT01229267|Experimental|V212 High Antigen Lot|Participants randomized to receive V212 High Antigen Lot given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
3195622|NCT01229267|Placebo Comparator|Placebo|Participants randomized to receive matching placebo given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
3195623|NCT01229254|Experimental|Amiodarone|Participants on betrixaban 30 mg and concomitant baseline amiodarone
3195624|NCT01229254|Experimental|Betrixaban 60 mg|Participants with lower weights
3195625|NCT01229254|Experimental|Betrixaban 90 mg|Participants with higher weights
3195626|NCT01229241|Other|levobupivacaine|
3195627|NCT01229241|Other|ropivacaine|
3195628|NCT01229228|Experimental|Naproxen Test (lower dose)|200-mg
3195629|NCT01229228|Experimental|Naproxen Test (upper dose)|400-mg (2 x 200-mg)
3195630|NCT01229228|Active Comparator|Naprosyn 250 mg|
3195631|NCT01229228|Active Comparator|Naprosyn 500 mg|
3195632|NCT01229228|Placebo Comparator|Placebo|
3195633|NCT01229215|Experimental|FCFD4514S|
3195634|NCT01229215|Sham Comparator|sham|
3195635|NCT01229202|Active Comparator|standard of care|standard of care for trabeculectomy surgery
3195637|NCT01229189|Experimental|Maternal and Neonatal Intervention Arm|Pregnant women will be individually randomized; a daily dose of vitamin D in 4000 IU will be given to Intervention group, started at 20-22 weeks of pregnancy till the time of delivery. The infants of this group will further stratify into two groups, one group will receive 400 IU of Vitamin D for 6 months as Intervention.
3195638|NCT01229189|Placebo Comparator|Maternal and Neonatal Control Arm|
3195639|NCT01229176|Experimental|Vi-CRM, Adults|Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine
3195640|NCT01229176|Active Comparator|Vi-PS, Adults|Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine
3195641|NCT01229176|Experimental|Vi-CRM, Children|Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
3195642|NCT01229176|Active Comparator|Vi-PS, Children|Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine
3195643|NCT01229176|Experimental|Vi-CRM, Older infants|Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
3195644|NCT01229176|Active Comparator|PNC13, Older infants|Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
3195645|NCT01229176|Experimental|Vi-CRM, Infants|Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
3195646|NCT01229176|Active Comparator|PNC13, Infants|Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine
3195647|NCT01229150|Active Comparator|KRAS Mut 2|KRAS Mutant patients randomized to combination therapy arm
3195648|NCT01229150|Active Comparator|KRAS Mut 1|KRAS Mutant patients randomized to monotherapy arm
3195649|NCT01229150|Active Comparator|WT KRAS 1|Wild-Type KRAS patients randomized to monotherapy arm
3195650|NCT01229150|Active Comparator|WT KRAS 2|Wild-Type KRAS patients randomized to combination therapy arm
3195651|NCT01229137||Right Ventricular Cohort|Right Ventricle wtih SRD-1 conversion
3195652|NCT01229137||Left Ventricular Cohort|Left Ventricle with SRD-1 conversion
3195653|NCT01229137||Right Atrium Cohart|Right atrium cohort with SRD-1 conversion
3195654|NCT01229111|Experimental|Treatment (cediranib maleate and modified FOLFOX)|Patients receive cediranib maleate PO QD on days 1-14 and modified FOLFOX6 comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1.
3195655|NCT01229098|Experimental|LEO 80185|
3195656|NCT01229085|Experimental|Test|mometasone 0,1% + salicylic acid 5%
3195657|NCT01229072|Experimental|1|Heparin Blausiegel
3195658|NCT01229072|Active Comparator|2|Liquemine
3195659|NCT01229059||lipid infusion|healthy lean humans before and after lipid infusion
3195660|NCT01229046|Active Comparator|ticarcillin-clavulanate|5 doses of IV ticarcillin-clavulanate infants < 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
3195661|NCT01229033|Active Comparator|Ablation|Ablation of atrial tachycardia
3195662|NCT01229033|Active Comparator|Cardioversion|Cardioversion of atrial tachycardia
3195663|NCT01229020||COPD patients|Patients diagnosed with COPD, by the pulmonologist at the institute,who are referred to undergo ventilation/perfusion scans.
3195664|NCT01229007|Experimental|Biostate|
3195665|NCT01228994|Active Comparator|Baclofen 30 mg/day|Baclofen medication
3195666|NCT01228994|Placebo Comparator|Placebo pill|placebo pill
3195667|NCT01228994|Active Comparator|Baclofen 60 mg/day|Baclofen medication high dose
3195668|NCT01228981||Type-2 Diabetic Retinopathy|
3195669|NCT01228968||Volunteers|Volunteers will have a range of body mass index from 19 - 45 kilogram per square meter. In order to fit in the magnetic resonance scanner subjects must weigh less than 300 pounds.
3195670|NCT01228955||Yoga Group|Group will enter a 10 week yoga class
3195671|NCT01228942|Other|Platinum Sensitive|Treatment with platinum-based therapy; COXEN prediction model chooses secondary agent if doublet
3195672|NCT01228942|Other|Platinum resistent|single agent based on Coxen prediction model
3195673|NCT01228929|Experimental|Normal|Subjects with no clinical diagnosis or symptoms of dry eye.
3195674|NCT01228929|Experimental|Aqueous Deficiency Dry Eye (ADDE)|Subjects with low tear volume measured by Schirmer's test less than 10 mm.
3195675|NCT01228929|Experimental|Meibomian Gland Dysfunction (MGD)|Subjects having mild to moderate Meibomian Gland Dysfunction by slit lamp evaluation.
3195676|NCT01228916|Experimental|Tobacco Cessation and Secondhand Smoke Reduction|Community based interventions to raise awareness regarding secondhand smoke exposure, clean indoor air laws, smokefree homes, risks of tobacco use and benefits of cessation; include talks, healthcare provider training, radio public service announcements and talk shows, tleevision interviews, cessation classes and individual sessions, health fairs, community marches for smokefree spaces, materials and resources for assisting in tobacco use cessation, estsablishing smokefree homes, adhering to smokefree laws
3195677|NCT01228916|No Intervention|Delayed Intervention Control|Assessment only during comparison period (no interventions will be provided over and above any secular trends in communities); delayed intervention will be provided at end of 1 year comparison period
3195678|NCT01228903|Placebo Comparator|Control|Patients who are randomized to this group will received placebo tablets. Placebo tables do not contain an active ingredient. This group will be used as a baseline group to compare the effects of lowering uric acid on vascular function.
3195679|NCT01228903|Active Comparator|Allopurinol|Patients who are randomized to this group will receive allopurinol tablets. Allopurinol is a medicine that lowers uric acid levels. The effects of lowering uric acid on vascular function outcomes will be assessed and compared to the control group.
3195680|NCT01228890|Experimental|CATCH-IT 2-R Arm|Primary care/Internet based depression prevention intervention (CATCH-IT 2-R) with a family component.
3195681|NCT01228890|Active Comparator|Attention Monitoring Psycho-education (AMPE) Arm|
3195682|NCT01228877|Experimental|Exercise|Adduction, Abduction and Squat exercise three times a week for 16 weeks
3195683|NCT01228864|Experimental|Brody Belt|
3195684|NCT01228864|Active Comparator|Conventional Urinary Drainage bag|
3195685|NCT01228851|Experimental|Balance Training|Balance training using Wii Fit Balance Board
3195686|NCT01228838|Experimental|NGX-1998, 10% w/w capsaicin|
3195687|NCT01228838|Experimental|NGX-1998, 20% w/w capsaicin|
3195689|NCT01228825||CABG without CPB|Patients undergoing coronary artery bypass graft (CABG) without Cardiopulmonary bypass ( CPB)
3195690|NCT01228825||CABG with CPB|Patients undergoing coronary artery bypass graft (CABG) with cardiopulmonary bypass (CPB)
3195691|NCT01228812||RA patients|Patients with Rheumatoid Arthritis
3195692|NCT01228812||Healthy subjects|Healthy subjects matched for age and sex
3195693|NCT01228799|Active Comparator|Trabeculectomy|Trabeculectomy with Mitomycin C
3195694|NCT01228799|Active Comparator|Canaloplasty|Canaloplasty with implant of suture
3195695|NCT01228786||Group A|~ 20 sporadic PHPT patients
3195696|NCT01228786||Group B|~10 normocalcemic euthyroid patients (control tissue)
3195697|NCT01228773|Experimental|A|"Providing tailored web-based care program(Health Navigation®), which provides various information related to the CRF.~Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue etc."
3195698|NCT01228773|Other|B|Attention control arm: Providing usual care for CRF. Three months later, as attention control, they will be provided tailored web-based care program(Health Navigation®), which provides various information related to the CRF.
3195699|NCT01228760|Experimental|Dose level 1|
3195700|NCT01228760|Experimental|Dose level 2|
3195701|NCT01228760|Experimental|Dose level 3|
3195702|NCT01228760|Experimental|Dose level 4|
3195703|NCT01228760|Experimental|Dose level 5|
3195704|NCT01228760|Experimental|Dose level 5A|
3195705|NCT01228760|Experimental|Dose level 6|
3195706|NCT01228760|Experimental|Dose level 7|
3195707|NCT01228760|Experimental|Dose level 8|
3195708|NCT01228760|Experimental|Dose level 9|
3195709|NCT01228760|Experimental|Chemotherapy-naïve subjects|
3195710|NCT01228760|Experimental|Chemotherapy exposed subjects|
3195711|NCT01228747|Placebo Comparator|Placebo|Matching placebo for 28 weeks
3195712|NCT01228747|Experimental|Levetiracetam|Levetiracetam treatment with flexible dosing of 1000 mg/day or 2000 mg/day or 3000 mg/day for 28 weeks
3195713|NCT01228734|Experimental|Cetuximab + FOLFOX-4|All eligible subjects will receive cetuximab in combination with FOLFOX-4 chemotherapy regimen. FOLFOX-4 chemotherapy regimen consists of a combination of oxaliplatin with 5-fluorouracil (5-FU)/folinic acid (FA). Cetuximab will be administered first followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin, FA will be administered and then 5- FU treatment until progression of disease, withdrawal of consent, or unacceptable toxicity.
3195714|NCT01228734|Active Comparator|FOLFOX-4|All eligible subjects will receive FOLFOX-4 chemotherapy regimen. FOLFOX-4 chemotherapy regimen consists of a combination of oxaliplatin with 5-FU/ FA. Oxaliplatin will be administered first or simultaneously with FA followed by 5-FU until progression of disease, withdrawal of consent, or unacceptable toxicity.
3195715|NCT01228708|Active Comparator|Intervention|Patients from half the GP practices in Ringkoebing-Skjern municipality that participates in an active implementation of a guideline for COPD
3195716|NCT01228708|No Intervention|Control group|Patients from the half of the GP practice in Ringkoebing-Skjern that do not participate in the active implementation of a guideline for COPD. The GPs are however in postgraduate training groups with intervention groups GPs
3195717|NCT01228708|No Intervention|External control|Patients with GP practice in neighboring county Ikast-Brande where there have been no information or contact at all from the investigators
3195718|NCT01228695||steroid treatment|
3195719|NCT01228682||Patients who are treated with Samsca.|
3195720|NCT01228669|Experimental|A|
3195721|NCT01228669|Experimental|B|
3195722|NCT01228669|Placebo Comparator|C|
3195723|NCT01228656|Experimental|-mometasone furoate associated with salicylic acid|
3195724|NCT01228656|Active Comparator|-mometasone furoate|
3195725|NCT01228643|Experimental|Norzyme®|
3195726|NCT01228643|Active Comparator|Creon®|
3195727|NCT01228630|Experimental|Cloratadd-D|Loratadine 5 mg + 120 mg of sulfate pseudoephedrina and coated tablet of placebo (identical to comparator drug). The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
3195728|NCT01228630|Active Comparator|Allegra-D|Loratadine 5 mg + 120 mg of sulfate pseudoephedrina and coated tablet of placebo (identical to test drug). The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
3195729|NCT01228617|Experimental|A1 Short, no buffer|Nicotine / not yet marketed
3195730|NCT01228617|Experimental|A2 Short, low buffer|Nicotine / not yet marketed
3195731|NCT01228617|Experimental|A3 Short, high buffer|Nicotine / not yet marketed
3195732|NCT01228617|Experimental|B1 Long, no buffer|Nicotine / not yet marketed
3195733|NCT01228617|Experimental|B2 Long, low buffer|Nicotine / not yet marketed
3195734|NCT01228617|Experimental|B3 Long, high buffer|Nicotine / not yet marketed
3195735|NCT01228617|Active Comparator|R = Nicotine Gum|Nicorette® Gum
3195736|NCT01228604|Experimental|Methylphenidate|
3195737|NCT01228591|Other|Acuvue Advance Plus/ Acuvue Advance|Acuvue Advance Plus contact lenses worn first period and Acuvue Advance contact lenses worn second.
3195738|NCT01228591|Other|Acuvue Advance/Acuvue Advance Plus|Acuvue Advance contact lenses worn first period and Acuvue Advance Plus contact lenses worn second.
3195739|NCT01228578|Experimental|Multivitamins (B,C,E)|
3195740|NCT01228578|Placebo Comparator|Placebo|
3195741|NCT01228565|Placebo Comparator|Placebo|Radiotherapy+Erbitux+Placebo
3195742|NCT01228565|Experimental|OTD70DERM|Radiotherapy+Erbitux+OTD70DERM®
3195743|NCT01228552|Active Comparator|Topical, intra-oral ketoprofen gel|
3195744|NCT01228552|Placebo Comparator|Placebo gel|
3195745|NCT01228539|Experimental|TARGET|Affect regulation psychotherapy for PTSD
3196823|NCT01220830|Experimental|RFQMR on Multiple Sclerosis lesions|
3195746|NCT01228539|Active Comparator|Prolonged Exposure|Cognitive behavioral therapy for PTSD with trauma memory exposure
3195747|NCT01228513|Active Comparator|0.01% ointment|Lowest concentration
3195748|NCT01228513|Active Comparator|0.03% ointment|Middle concentration
3195749|NCT01228513|Active Comparator|0.1% ointment|Highest concentration
3195750|NCT01228513|Placebo Comparator|Placebo (vehicle without active)|No active ingredient
3195751|NCT01228500|Experimental|Experimental Arm (Internal Control)|"One-half of ulcer receives negative pressure wound therapy~One-half of ulcer receives a fetal bovine collagen bioscaffold (PriMatrix, TEI Biosciences, Boston, MA) in addition to the same negative pressure wound therapy"
3195752|NCT01228487||Acute knee pain|Patients with a history of knee pain < 6 months. The radiologic and arthroscopic OA stadium is less or equal II°. n=20.
3195753|NCT01228487||Chronic knee pain|Clinical manifestation of knee joint OA, radiological and arthroscopic III° or more. n=20
3195754|NCT01228487||Control group|Patients coming for post- primary repair of the cruciate ligament, having no inflammation and no sign of OA. n=10
3195755|NCT01228474|Experimental|SET|Single embryo transfer
3195756|NCT01228474|Active Comparator|DET|Double embryo transfer
3195757|NCT01228461||AYA with Fatigue and Hodgkin Lymphoma|
3195758|NCT01228448|Experimental|Participants 1-39|PET Scan done right after one radiation treatment is complete and will take 15-20 minutes. After undergoing their first PET scan, participants will have the option to undergo 1-2 additional scans throughout radiation treatment in the same manner as the first scan.
3195759|NCT01228435|Experimental|ALK-inhibitor naive|No prior exposure to ALK-inhibitor
3195760|NCT01228435|Experimental|ALK-inhibitor pre-treated|Prior exposure to ALK inhibitor
3195761|NCT01228422||1|test interferon - blausiegel
3195762|NCT01228422||2|reference interferon - Roferon A (Roche)
3195763|NCT01228409|Other|Low dose Acitretin (17.5 mg)|
3195764|NCT01228383|Experimental|CL184+PVRV|CL184 with rabies vaccine (PVRV)
3195765|NCT01228383|Active Comparator|HRIG+PVRV|HRIG with rabies vaccine
3195766|NCT01228383|Placebo Comparator|Placebo+PVRV|Placebo with rabies vaccine (PVRV)
3195767|NCT01228383|Experimental|CL184+HDCV|CL184 with rabies vaccine (HDCV)
3195768|NCT01228383|Placebo Comparator|Placebo+HDCV|Placebo with rabies vaccine (HDCV)
3195769|NCT01228370|Experimental|Silodosin|Silodosin 8mg once a day for 12 weeks
3195770|NCT01228357|Experimental|SSRI treated group|SSRI treated group is patients treated with fluoxetine, paroxetine, or sertraline
3195771|NCT01228357|Active Comparator|non-SSRI treated group|non-SSRI treated group is patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine
3195772|NCT01228344||Artemether-lumefantrine|
3195773|NCT01228331|Active Comparator|Arm I intensification (cytarabine)|"LR-S patients receive HD cytarabine IV 4 x 3 g over 12 hours daily on days 29-31 and pegaspargase IV over 2 hours on days 31, 52, and 80.~LR-I and precursor B-cell ALL HR-S and HR-I patients receive HD cytarabine IV 2.500 over 3 hours twice daily on days 29-31 and 106-108 and pegaspargase IV over 2 hours on days 31, 53, 67, and 108.~Followed by standard consolidation therapy regarding to stratification containing:~methotrexate, cyclophosphamide, thioguanin, mercaptopurine, etoposide phosphate, amsacrine, cytarabine, methylprednisolone, dexamethasone, vincristine sulfate; whole-brain radiation therapy only if indicated in patients with cns involvement or T-cell ALL"
3195774|NCT01228331|Active Comparator|Arm II intensification (clofarabine)|"LR-S patients receive clofarabine* IV 5 x 40 mg over 2 hours every day on days 29-33 and pegaspargase IV over 2 hours on days 33, 52, and 80.~LR-I and precursor B-cell ALL HR-S and HR-I patients receive clofarabine* IV over 2 hours on days 29-33 and pegaspargase IV over 2 hours on days 33, 53, 67, and 108.~Followed by standard consolidation therapy regarding to stratification containing:~methotrexate, cyclophosphamide, thioguanin, mercaptopurine, etoposide phosphate, amsacrine, cytarabine, methylprednisolone, dexamethasone, vincristine sulfate; whole-brain radiation therapy only if indicated in patients with cns involvement or T-cell ALL"
3195775|NCT01228331|Active Comparator|Arm III reinduct.(doxorubicin hydrochl.)|"LR-S patients receive doxorubicin hydrochloride IV 30 mg/m2 over 24 hours on days 1 and 8.~LR-I, HR-S and HR-I Patients receive doxorubicin hydrochloride IV 30 mg/m2 over 24 hours on days 1, 8, 22, and 29.~Followed by standard reinduction and maintenance therapy containing:~cyclophophamide, cytarabine, thioguanine, mercaptopurine, methotrexate and pegaspargase, dexamethasone, vincristine sulfate"
3195776|NCT01228331|Active Comparator|Arm IV reinduct.(daunorubicin hydrochl.)|"LR-S patients receive daunorubicin hydrochloride IV 36 mg/m2 over 24 hours on days 1 and 8.~LR-I, HR-S and HR-I Patients receive daunorubicin hydrochloride IV 36 mg/m2 over 24 hours on days 1, 8, 22, and 29.~Followed by standard reinduction and maintenance therapy containing:~cyclophophamide, cytarabine, thioguanine, mercaptopurine, methotrexate and pegaspargase, dexamethasone, vincristine sulfate"
3195777|NCT01228318|Experimental|Zoledronic acid|Subjects in this arm will receive 5 milligram (mg) per 100 milliliter (mL) solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.
3195778|NCT01228318|Placebo Comparator|Placebo|Subjects in the placebo arm will receive placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered iv over 15-30 minutes under the supervision of study personnel.
3195779|NCT01228305|Experimental|Acetaminophen|Subjects will be randomly assigned to treatment using a permuted-block randomization algorithm. Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children >=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to <2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
3195780|NCT01228305|Placebo Comparator|Placebo|Subjects will be randomly assigned to treatment using a permuted-block randomization algorithm. Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children >=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to <2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
3195781|NCT01228292|Active Comparator|Standard Anticoagulation|Hemodialysis is performed using standard anticoagulation using unfractionated heparin if no contra-indications for the use of heparin exist. If contra-indications for heparin exist a heparin coated hemofilter (Evodial) will be used. The use of unfractionated heparin or no heparin (with coated hemofilter) is a decision to be taken before every hemodialysis.
3195782|NCT01228292|Experimental|Citrasate|Hemodialysis is performed with Citrasate
3195783|NCT01228279|Active Comparator|DIANEAL|One group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with the same type of solution for another 12 weeks.
3195784|NCT01228279|Active Comparator|EXTRANEAL|The other group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with DIANEAL solution during the day and the non-glucose-based solution, EXTRANEAL, during the night
3195785|NCT01228266|Experimental|autologous mesenchymal stem cell|A single infusion of up to 2 million cells per Kg of autologous mesenchymal stem cells vs suspension media. The treatment will be reversed at 6 months
3195786|NCT01228253|No Intervention|1|Safe voluntary.
3195787|NCT01228253|No Intervention|2|patient with psychotrauma but without PSTD and without any psychiatric trouble at the time of inclusion
3195788|NCT01228253|No Intervention|3|patient with psychotrauma and PTSD (post-traumatic stress disorder) and in full remission at the time of inclusion
3195789|NCT01228253|No Intervention|4.3|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
3195790|NCT01228253|Sham Comparator|4.2|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
3195791|NCT01228253|Experimental|4.1|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
3195792|NCT01228240|Experimental|Metformin, Apo-metformin|
3195793|NCT01228227|Active Comparator|ROSUVASTATIN|
3195794|NCT01228227|Experimental|ATORVASTATIN|
3195795|NCT01228214|Experimental|Amiloride,nitrates,clopidogrel,aspirin|Comparative Efficacious Research
3195796|NCT01228214|Placebo Comparator|Placebo,nitrates,clopidogrel,aspirin|Comparative Efficacious Research
3195797|NCT01228201|Experimental|Aerboic interval training|
3195798|NCT01228201|Active Comparator|Moderate continuous training|
3195799|NCT01228188|Experimental|Idiopathic Full Thickness Macular Hole|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole occurs with a minimum diameter exceeding 400 um.
3195800|NCT01228175|Active Comparator|Varenicline|Varenicline
3195801|NCT01228175|Placebo Comparator|Microcrystal Cellulose|Microcrystal cellulose placebo
3195802|NCT01228162|Experimental|general anaesthesia|patients receiving general anaesthesia and rocuronium bromide for muscle relaxation
3195803|NCT01228162|Active Comparator|spinal anaesthesia|patients receiving spinal anaesthesia without muscle relaxation
3195804|NCT01228149|Active Comparator|Diamox/DexaEDO|Patients receive Diamox (oral acetazolamide) starting 28 days Prior to trabeculectomy. 7 days preoperatively DexaEDO (dexamethasone) eyedrops without preservatives are applied additionally. Patient will undergo trabeculectomy.
3195805|NCT01228149|Experimental|Cosopt S|Patients receive Cosopt S (dorzolamide/timolol) eye drops starting 28 days before trabeculectomy.
3195806|NCT01228136|Active Comparator|Tranexamic acid|
3195807|NCT01228136|Placebo Comparator|Placebo|
3195808|NCT01228123|Active Comparator|CVVH arm|
3195809|NCT01228123|Active Comparator|IHD arm|
3195810|NCT01228110|Active Comparator|Corticosteroid group|This group was entitled to receive hydrocortisone 200 mg loading bolus followed by an intravenous infusion (300 mg in 500 ml 0.9% saline) at a rate of 12.5 mg/hour for 7 days
3195811|NCT01228110|Placebo Comparator|Placebo group|This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug).
3195812|NCT01228097||Gastric Bypass|Participants who receive gastric bypass surgery.
3195813|NCT01228097||Principally Restrictive Surgery|Participants who receive gastric banding or sleeve gastrectomy surgery.
3195814|NCT01228097||Weight Stable|Participants who remain weight stable.
3195815|NCT01228084|Experimental|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
3195816|NCT01228071|Experimental|40 mg daily dose of testosterone gel 2%|testosterone gel 2%
3195817|NCT01228058||Adult trauma patients|Patients admitted to the emergency department (ED) as the highest level of acuity following a traumatic injury at three Level 1 trauma centers in the United States (UT Houston, UC San Francisco, Oregon Health Center).
3195818|NCT01228045|Experimental|Trastuzumab in Combination with TS-ONE and cisplatin|The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
3195819|NCT01228032|Experimental|Intervention|
3195820|NCT01228032|No Intervention|Control|referral only
3195821|NCT01228019||All participants|Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)
3195822|NCT01228006|Experimental|Treatment|NatusGerin
3195823|NCT01228006|Placebo Comparator|Control|Gelatin capsules identical to drug test
3195824|NCT01227993|Experimental|Finasteride|Participants are treated with 5 mg oral finasteride daily when they have clinically significant subretinal fluid accumulation, defined as any subretinal fluid in the macula with a volume of at least 0.1 microliter and causing visual change such as reduced acuity, metamorphopsia, or microperimetry deficits.
3195825|NCT01227980|Active Comparator|Pexacerfont|Pexacerfont was given orally as a loading dose of 300 mg/day for 1 week, followed by 100mg/day for 16-20 days
3195826|NCT01227980|Placebo Comparator|Placebo|Oral placebo was given during the 1-week loading dose phase, and during the next 16-20 days
3195827|NCT01227967|Experimental|Combination Therapy|Amantadine, Ribavirin, Oseltamivir
3195828|NCT01227967|Active Comparator|Oseltamivir monotherapy|Oseltamivir
3195829|NCT01227954|Other|WBRT with Hippocampal Avoidance|Whole brain radiotherapy (WBRT) with hippocampal avoidance using intensity-modulated radiation therapy (IMRT)
3195830|NCT01227941|Experimental|Part A: MK-4827 + pegylated liposomal doxorubicin|MK-4827 and pegylated liposomal doxorubicin combination. Dose escalation/confirmation in participants with advanced solid tumors
3195831|NCT01227941|Experimental|Part B: MK-4827 + pegylated liposomal doxorubicin|MK-4827 and pegylated liposomal doxorubicin combination at 1 or 2 dose levels of MK-4827 to be determined from the results of Part A. Ovarian Cancer Cohort
3195832|NCT01227928|Experimental|pazopanib|experimental medication
3195833|NCT01227928|Placebo Comparator|placebo|placebo comparator
3195834|NCT01227915|Experimental|Test|tobramycin 0.3% + dexamethasone 1% - União Química Lab
3195835|NCT01227915|Active Comparator|Comparator|tobramycin 0.3% + dexamethasone 1% - Alcon Lab
3195836|NCT01227902|Experimental|Retigabine IR|Open Label flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
3195837|NCT01227889|Experimental|GSK2118436|Subjects in this arm will receive GSK2118436 150 mg twice daily.
3195838|NCT01227889|Active Comparator|Dacarbazine (DTIC)|Subjects will receive intravenous dacarbazine (DTIC) 1000 mg/m2 every 3 weeks
3195839|NCT01227889|Experimental|Crossover|Subjects who initially receive DTIC will be allowed to receive GSK2118436 after initial progression.
3195840|NCT01227876|Experimental|Test|Ster ® (prednisolone 1% ophthalmic suspension - União Química)
3195841|NCT01227876|Active Comparator|Comparator|Pred Fort ® (prednisolone 1% ophthalmic suspension - Allergan)
3195842|NCT01227863|Experimental|Test|Dexamethasone + neomycyn + polimixyn B
3195843|NCT01227863|Active Comparator|Comparator|Dexamethasone + neomycyn + polimixy B
3195844|NCT01227850||Parenteral nutrition patients.|
3195845|NCT01227837|Sham Comparator|placebo|use of placebo in control group
3195846|NCT01227837|Experimental|omega 3|use of omega 3 2 gr/day for 6 months
3195847|NCT01227824|Experimental|GSK1349572 (N=~394)|GSK1349572 50mg once daily + raltegravir placebo twice daily + NRTI background therapy once daily
3195848|NCT01227824|Active Comparator|raltegravir (N=~394)|raltegravir 400mg twice daily + GSK1349572 placebo once daily + NRTI background therapy once daily
3195849|NCT01227811|Active Comparator|Enablex(R) 15 mg , single dose|
3195850|NCT01227811|Experimental|Darifenacin 15 mg tablets, single dose|
3195851|NCT01227798|Placebo Comparator|Placebo|100 mM sodium Chloride and 25 mM sodium phosphate at pH 7.0 +/- 0.2
3195852|NCT01227798|Active Comparator|Infergen|15mcg subcutaneous injection at fill volume of 0.5mL
3195853|NCT01227785||INCEPTA ICD and CRT-D|ICD and CRT-D indicated patients were included in the study. Overall patient population, CRT-D or ICD populations, and patients experiencing or not experiencing a protocol-defined heart failure event were included (dependent on outcomes measured).
3195854|NCT01227772|Experimental|Weekly Cohort|The gastric cancer vaccine (OTSGC-A24) will be administered at a dose of 1 mg once a week
3195855|NCT01227772|Experimental|2-weekly cohort|The gastric cancer vaccine (OTSGC-A24) will be administered at the dose of 1 mg every 2 weeks.
3195856|NCT01227772|Experimental|3-weekly cohort|The gastric cancer vaccine (OTSGC-A24)will be administered at 1 mg very 3 weeks
3195857|NCT01227759|Experimental|Verum|
3195858|NCT01227759|No Intervention|Untreated|
3195859|NCT01227759|Placebo Comparator|Vehicle|
3195860|NCT01227746||Tumor biopsies|
3195861|NCT01227733||Breast Tumor|Breast Tumor Blocks
3195862|NCT01227720|Experimental|A NSL2L|Experimental Nicotine Replacement Therapy (NRT)(L) 2 mg
3195863|NCT01227720|Active Comparator|B Lozenge|Marketed Nicotine Lozenge 2 mg
3195864|NCT01227720|Experimental|C NSL4M|Experimental NRT (M) 4 mg
3195865|NCT01227720|Active Comparator|D Lozenge|Marketed Nicotine Lozenge 4 mg
3195866|NCT01227720|Experimental|E NSL4L|Experimental NRT (L) 4 mg
3195867|NCT01227720|Experimental|F NSL4H|Experimental NRT (H) 4 mg
3195868|NCT01227707|Experimental|Single Arm|
3195869|NCT01227694|Experimental|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias Avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
3195870|NCT01227681|Experimental|high dose G-CSF|high dose group: 3.3ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
3195871|NCT01227681|Active Comparator|low dose G-CSF|low dose group: 1.65ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
3195872|NCT01227681|Placebo Comparator|placebo|Sodium Chloride (NaCl) 0.9 %
3195873|NCT01227668|Experimental|Aripiprazole|
3195874|NCT01227668|Placebo Comparator|Placebo|
3195875|NCT01227655|Experimental|BIA 9-1067 25 mg once daily (QD).|BIA 9-1067, OPC, Opicapone 25 mg once daily (QD).
3195876|NCT01227655|Experimental|BIA 9-1067 50 mg once daily (QD).|BIA 9-1067, OPC, Opicapone 50 mg once daily (QD).
3195877|NCT01227655|Placebo Comparator|Placebo|PLC, Placebo
3195878|NCT01227642|Experimental|pre-implant transrectal ultrasound images and planning|Transrectal ultrasound session will be performed at a separate session prior to the implant.
3195879|NCT01227629|Experimental|dabigatran 50 mg twice daily (bid)|Dabigatran: one capsule in the morning and 1 capsule in the evening. Twice daily (bis in die = bid).
3195880|NCT01227629|Experimental|dabigatran 50 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. Acetylsalicylic acid (ASA) once daily (quaque dies = qd) in the morning.
3195881|NCT01227629|Experimental|dabigatran 50 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
3195882|NCT01227629|Experimental|dabigatran 150 mg bid|Dabigatran: one capsule in the morning and 1 capsule in the evening
3195883|NCT01227629|Experimental|dabigatran 150 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
3195884|NCT01227629|Experimental|dabigatran 150 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
3195885|NCT01227629|Experimental|dabigatran 300 mg bid|Dabigatran: one capsule in the morning and 1 capsule in the evening
3195886|NCT01227629|Experimental|dabigatran 300 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
3195887|NCT01227629|Experimental|dabigatran 300 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
3195888|NCT01227629|Active Comparator|warfarin|once daily, dosed to target International Normalised Ratio (INR) 2.0 to 3.0
3195889|NCT01227616|Experimental|Ferumoxytol|Intravenous (IV) iron
3195890|NCT01227616|Active Comparator|IV Iron Sucrose|Intravenous (IV) iron
3195891|NCT01227603|Experimental|Nifedipine-candesartan FDC|Each subject received single fixed dose combination of 60 mg nifedipine and 32 mg candesartan orally.
3195892|NCT01227603|Active Comparator|Nifedipine and candesartan|Each subject received one dose of nifedipine GITS 60 mg and candesartan 32 mg (2 x 16 mg tablet) as loose combination, orally.
3195893|NCT01227603|Active Comparator|Nifedipine|Each subject received one dose of nifedipine GITS 60 mg orally.
3195894|NCT01227603|Active Comparator|Candesartan|Each subject received one dose of candesartan 32 mg (2 x 16 mg tablet), orally.
3195895|NCT01227590|Experimental|Pharmacokinetics single-arm|The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
3195896|NCT01227577|Experimental|Nilotinib|Participants received 300 mg twice daily (b.i.d.). Dose increases to 400 b.i.d. were permitted, per Investigator's discretion.
3195897|NCT01227564|Experimental|ACC-001 3 μg/ QS-21 50 μg|
3195898|NCT01227564|Experimental|ACC-001 10 μg/ QS-21 50 μg|
3195899|NCT01227564|Placebo Comparator|Placebo- Phosphate buffered saline (PBS)|
3195900|NCT01227551|Experimental|Intratumoral injection|Each patient will receive 4 separate Coxsackievirus A21 (CVA21) administrations in the first 8 days on trial (Days 1, 3, 5 and 8), followed by a fifth dose 2 weeks later (Day 22) and further administrations at 3 weekly intervals (Days 43, 64, 85, 106 and 127, up to a maximum of 10 sets of injections) until confirmed disease progression or development of excessive toxicity. Subjects with stable disease or better at Day 127 were eligible to receive up 9 more sets of CVA21 administrations under an extension protocol (VLA-008).
3195901|NCT01227538||Stimulated urinary C peptide|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
3195902|NCT01227512|Experimental|Tolvaptan 15-60mg|Oral tablet without fluid restriction. After the initial dose, daily dose may be titrated based on response.
3195903|NCT01227512|Active Comparator|Fluid Restriction|Placebo tablet with prescribed fluid restriction. After the initial dose, level of fluid restriction may titrated based response.
3195904|NCT01227486||Obese patients for planned surgery and endotracheal intubation|
3195905|NCT01227473|Experimental|mindfulness prediabetes education group|The mindfulness-based diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the mindfulness-based diabetes prevention group, the instruction will be enhanced with instruction in mindfulness.
3195906|NCT01227473|Active Comparator|conventional prediabetes education group|The conventional diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the conventional diabetes prevention group, the instruction will be enhanced with group exercises and discussions.
3195907|NCT01227460|Experimental|Sitagliptin|
3195908|NCT01227460|Placebo Comparator|Sugar Pill|
3195909|NCT01227434|Experimental|Surgical Group|PD 0332991 125 mg daily for 7 days prior to an indicated, intended surgical resection as clinical care for progression, and then resume drug at the same dose after recovery from surgery on a repeating schedule of 21 consecutive days of drug followed by a 7 day break off therapy (cycle length is 28 days). Treatment will be repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients will be given the option to continue on study past 12 cycles, up to a maximum of 24 cycles.
3195910|NCT01227434|Experimental|Non-surgical group|Patients not in need of surgery treated with PD 0332991 125 mg daily for 21 consecutive days followed by a 7 day break off therapy (cycle length is 28 days). Treatment will be repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients will be given the option to continue on study past 12 cycles, up to a maximum of 24 cycles.
3195911|NCT01227421|Active Comparator|Nitazoxanide, Placebo|300 mg nitazoxanide tablet and 1 placebo tablet twice daily for 5 days
3195912|NCT01227421|Active Comparator|Nitazoxanide, Nitazoxanide|Two 300 mg nitazoxanide tablets(600mg) twice daily for 5 days
3195913|NCT01227421|Placebo Comparator|Placebo|2 placebo tablets twice daily for 5 days
3195914|NCT01227408|Experimental|Metronomic Chemotherapy|Doxorubicin will be administered as an intravenous bolus, careful intravenous injection. PPX will be administerd as an intravenous 10 mins. infusion. Capecitabine and methotrexate will be taken orally twice a day. Cyclophosphamide will be taken orally once a day.
3195915|NCT01227395||Azithromycin|Patients taking Azithromycin.
3195916|NCT01227382|Other|ERCP with Cholangiopancreatoscopy|The subjects who have been scheduled for an Endoscopic Retrograde Cholangiopancreatography (ERCP) with Cholangiopancreatoscopy for evaluation of a bile duct or pancreatic duct stricture sampling.
3195917|NCT01227369||Bisphosphonates|Korean postmenopausal osteoporosis patients with bisphosphonate treatment
3195918|NCT01227356|Experimental|imatinb + pegIntron|
3195919|NCT01227343||Female Smokers|Healthy females who smoke 10-30 cigarettes per day for the past 2 years and meet criteria for nicotine dependence.
3195920|NCT01227343||Female Non-smokers|Healthy females who do not currently smoke cigarettes.
3195921|NCT01227343||Male Smokers|Healthy males who smoke 10-30 cigarettes per day for the past 2 years and who meet criteria for nicotine dependence.
3195922|NCT01227343||Male - Non-Smokers CLOSED|WE ARE NO LONGER RECRUITING MALE NON-SMOKERS
3195923|NCT01227330|Experimental|Medication adherence intervention|Receives 12-week behavioral feedback intervention to improve adherence to statin medication
3195924|NCT01227330|No Intervention|Control|No intervention
3195925|NCT01227330|Active Comparator|Attention-control|Receives visits on the same schedule as the intervention group, with health education that is unrelated to medications or cholesterol
3195926|NCT01227317||Acute dyspnea in ED|Acute severe shortness of breath (SOB) in emergency Department (ED) with suspicion of acute heart failure (AHF) or Pulmonary Embolism (PE)or Community-acquired pneumonia (CAP) or acute Exacerbation of chronic obstructive pulmonary disease (AE COPD)
3195927|NCT01227304|Experimental|Test of volume responsiveness using crystalloids|
3195928|NCT01227291|Experimental|SYL040012|SYL040012 Ophthalmic drop administration
3195929|NCT01227278|Placebo Comparator|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
3195930|NCT01227278|Experimental|Benralizumab 100 mg|Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
3195931|NCT01227265|Experimental|Preladenant 2 mg|Participants received 2 mg as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extension trial or return for a follow-up visit two (2) weeks later.
3195932|NCT01227265|Experimental|Preladenant 5 mg|Participants received 5 mg as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extension trial or return for a follow-up visit two (2) weeks later.
3195933|NCT01227265|Placebo Comparator|Placebo|Participants received preladenant-matching placebo as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extention trial or return for a follow-up visit two (2) weeks later.
3195934|NCT01227252|Experimental|LY2886721|
3195935|NCT01227252|Placebo Comparator|Placebo|
3195936|NCT01227239|Experimental|1|
3195937|NCT01227226|Active Comparator|Refresh tears|Allergan's Refresh tears artificial tear
3195938|NCT01227226|Active Comparator|Systane Ultra|Alcon's Systane Ultra artificial tear
3195939|NCT01227226|Active Comparator|Visine|Visine artificial tear
3195940|NCT01227226|Active Comparator|Blink tears|AMO's blink tears artificial tear
3195941|NCT01227187|Experimental|Xigris|Xigris used as anticoagulant in patients treated with hemodialysis.
3195942|NCT01227174|Experimental|Propofol sedation|Patients will be undergo procedural sedation using propofol.
3195943|NCT01227161||ultrasonography children|American Society of Anesthesiologists (ASA) I-II children between the age 0-7, undergoing elective urological surgery, such as inguinal hernia repair, orchiopexy, ureteroneocystostomy
3195944|NCT01227148|Experimental|Tightly glucose conntrol|
3195945|NCT01227148|Active Comparator|Conventional glucose control|
3195946|NCT01227109||With infection|This group consist of cancer patients with a bacterial infection
3195947|NCT01227109||Without infection|This is a group of cancer patients without infection
3195948|NCT01227096||Electro-acupuncture, Control|
3195949|NCT01227096||Preconditioning, No preconditioning|
3195950|NCT01227083||1|Asthma control test check AQLQ(Asthma Quality of Life Questionnaire)after being cAQOL(Computerized Asthma specific quality of life)
3195951|NCT01227083||2|Asthma control test check cAQOL(Computerized Asthma specific quality of life)after being AQLQ(Asthma Quality of Life Questionnaire)
3195952|NCT01227070||Asthmatic|
3195953|NCT01227070||Healthy Control|
3195954|NCT01227057|Experimental|Arm 1: Cognitive Rehabilitation|Cognitive rehabilitation and exposure therapy for hoarding
3195955|NCT01227057|Active Comparator|Arm 2: Case Management|Case management
3195956|NCT01227044|Active Comparator|NTX + MM/MC|Naltrexone + Medical Management/Medication Coaching
3195957|NCT01227044|Placebo Comparator|Placebo + MM/MC|Placebo plus Medical Management/Medication Coaching
3195958|NCT01227018|Experimental|STA-9090|Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3195959|NCT01227005|Active Comparator|Whole Blood|Whole Blood plus pooled platelets
3195960|NCT01227005|Active Comparator|Component Therapy|Red blood cells, plasma, platelets
3195961|NCT01226992|Experimental|Fecal Transplant|2 weeks of oral vancomycin pre-treatment followed by single dose fecal transplant administered by rectal enema. Fecal transplant (slurry) consists of 50 grams healthy donor stool blended in 500ml of Normal Saline.
3195962|NCT01226992|Active Comparator|Oral Vancomycin Taper|2 weeks of oral vancomycin pre-treatment followed by 6-week taper of oral vancomycin
3195963|NCT01226979|Experimental|HDRBT|Radiation: High-dose endorectal brachytherapy The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer.
3195964|NCT01226966||A|
3195965|NCT01226953|Active Comparator|Arm 1|
3195966|NCT01226953|Active Comparator|Arm 2|
3195967|NCT01226927|Active Comparator|Continuous infusion rate|Patients received a continuous infusion of 0.2% ropivacaine at 10.1 mL/hr via their femoral nerve catheter.
3195968|NCT01226914|Experimental|EVICEL|
3195969|NCT01226901|Experimental|MK-4827 once daily|MK-4827
3195970|NCT01226875|Active Comparator|A (Narrow focus, LP)|A (Narrow focus): stone is in lower pole of kidney and SWL using narrow focus on lithotripter
3195971|NCT01226875|Active Comparator|B (Wide focus, LP)|B: stone is in lower pole of kidney and SWL using wide focus on lithotripter
3195972|NCT01226875|Active Comparator|C (Narrow focus, no LP)|C: stone is in no-lower pole of kidney and SWL using narrow focus on lithotripter
3195973|NCT01226875|Active Comparator|D (Wide focus, no LP)|D: stone is in no-lower pole of kidney and SWL using wide focus on lithotripter
3195974|NCT01226862||Hub Hospital|Hub Hospital Cohort: Joint Commission-certified Primary Stroke Centers where patients are treated using hospital-based stroke teams and pathways; these hospital personnel also provide telemedicine consultation to satellite hospitals.
3195975|NCT01226862||Spoke Hospital|Spoke Hospital Cohort: non-stroke center certified sites, where patients are treated at an in-network telestroke community hospital using telemedicine technology with consultation provided by physicians from a hub hospital.
3195976|NCT01226862||Control Hospital|Control Hospital Cohort: non-stroke center certified sites with no telemedicine services.
3196824|NCT01220817|Active Comparator|1 POMx capsule|1 POMx capsule daily
3195977|NCT01226849|Experimental|Single Arm|"bortezomib, rituximab, ifosphamide, etoposide, carboplatin~Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended"
3195978|NCT01226836|Experimental|Living Well with COPD for Pulmonary Rehabilitation|
3195979|NCT01226823|Placebo Comparator|Placebo|obstetrical monitoring plus placebo
3195980|NCT01226823|Experimental|Ursodeoxycholic acid|obstetrical monitoring plus active drug
3195981|NCT01226797|Placebo Comparator|Placebo|
3195982|NCT01226797|Active Comparator|PF-04136309|
3195983|NCT01226784|Active Comparator|Physcial exercise|
3195984|NCT01226784|Active Comparator|Relaxation exercise|
3195985|NCT01226771|Experimental|"Group A (Loading)"|PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
3195986|NCT01226771|Experimental|"Group B (Priming)"|Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
3195987|NCT01226771|Active Comparator|"Group C (Standard-of-Care)"|PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
3195988|NCT01226758|Experimental|FLU-v with adjuvant|
3195989|NCT01226758|Placebo Comparator|Placebo|Adjuvant only placebo
3195990|NCT01226745|Experimental|ONO-4641 0.15 milligram (mg) - 0.15 mg|
3195991|NCT01226745|Experimental|ONO-4641 0.10 mg - 0.10 mg|
3195992|NCT01226745|Experimental|ONO-4641 0.05 mg - 0.05 mg|
3195993|NCT01226745|Experimental|Placebo - ONO4641 0.15 mg|
3195994|NCT01226745|Experimental|Placebo - ONO4641 0.10 mg|
3195995|NCT01226745|Experimental|Placebo - ONO4641 0.05 mg|
3195996|NCT01226732|Experimental|Dose Level 1|Hsp90 Inhibitor AUY922: 22mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
3195997|NCT01226732|Experimental|Dose Level 2|Hsp90 Inhibitor AUY922: 28mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
3195998|NCT01226732|Experimental|Dose Level 3|Hsp90 Inhibitor AUY922: 40mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
3195999|NCT01226732|Experimental|Dose Level 4|Hsp90 Inhibitor AUY922: 55mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
3196000|NCT01226732|Experimental|Dose Level 5|Hsp90 Inhibitor AUY922: 70mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
3196001|NCT01226732|Experimental|Dose Level 6|Hsp90 Inhibitor AUY922: 70mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1250mg/m2 PO BID d 1-14 of 21-day cycles
3196002|NCT01226719|Experimental|FOLFOXIRI+panitumumab regimen|"All patients will receive the FOLFOXIRI/panitumumab regimen, with drugs administered in the following order:~Panitumumab~Oxaliplatin~Irinotecan~Leucovorin~5-Fluorouracil"
3196003|NCT01226706|Placebo Comparator|Placebos|Placebo injected into the detrusor at Day 1,
3196004|NCT01226706|Experimental|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
3196005|NCT01226693|Experimental|Sequence 1|
3196006|NCT01226693|Experimental|Sequence 2|
3196007|NCT01226693|Experimental|Sequence 3|
3196008|NCT01226693|Experimental|Sequence 4|
3196009|NCT01226693|Experimental|Sequence 5|oral, 6mg, single dose
3196010|NCT01226693|Experimental|Sequence 6|oral, 6mg, single dose
3196011|NCT01226680|Experimental|Tasocitinib 0.005% QD|
3196012|NCT01226680|Experimental|Tasocitinib 0.003% QD|
3196013|NCT01226680|Placebo Comparator|Vehicle for Tasocitinib|
3196014|NCT01226667|Active Comparator|Flexible Dose|flexibly dosed pregabalin given BID (75-300 mg/d) increased gradually over 4 weeks then maintained at that same dosing for 4 weeks
3196015|NCT01226667|Active Comparator|Fixed Dosing|75 mg BID for one week and increased to 150 mg BID for 7 weeks
3196016|NCT01226654|Other|MS Patients|All subjects enrolled in this study will undergo MRI studies. A computerized neuropsychological battery of tests will be administered.
3196017|NCT01226654|Other|Healthy Patients|Patients enrolled in this study will undergo MRI studies. A computerized neuropsychological battery of tests will be administered.
3196018|NCT01226641|Experimental|Telemedecine|CPAP treatment with telemedicine system
3196019|NCT01226641|Active Comparator|Standard Care|Standard care, including CPAP
3196020|NCT01226628|Experimental|Cohort A|Phase 1: 3 patients will receive 60,000 human umbilical tissue-derived cells (hUTC)
3196021|NCT01226628|Experimental|Cohort B|Phase 1: 3 patients will receive 120,000 hUTC
3196022|NCT01226628|Experimental|Cohort C|Phase 1: 3 patients will receive 300,000 hUTC
3196023|NCT01226628|Experimental|Cohort D|Phase 1: 3 patients will receive 560,000 hUTC
3196024|NCT01226628|Experimental|Cohort E|Phase 1: 6 patients will receive 300,000 hUTC
3196025|NCT01226628|Experimental|Cohort F|Phase 1: 6 patients will receive either 60,000 or 300,000 hUTC
3196026|NCT01226628|Experimental|Cohort G|Phase 1: 6 patients will receive either 60,000 or 300,000 hUTC
3196027|NCT01226628|Experimental|Phase 2a|Up to 38 patients will receive one of two optimal doses as selected from the Phase 1 portion of the study
3196028|NCT01226615|Experimental|1|Chondroitin sulphate
3196029|NCT01226615|Placebo Comparator|2|Placebo
3196030|NCT01226602|Experimental|1|Adenosinladder; Ticagrelor (180 mg), Adenosinladder ; Theophylline (5 mg/kg), Adenosinladder
3196031|NCT01226602|Placebo Comparator|2|Adenosinladder; Placebo, Adenosinladder; Theophylline (5 mg/kg), Adenosinladder
3196032|NCT01226576|Experimental|Treatment|ExAblate Treatment Arm
3196033|NCT01226563|Experimental|IK-5001|IK-5001 Sodium Alginate Calcium Gluconate intracoronary injection
3196034|NCT01226563|Placebo Comparator|Saline Solution|Saline Solution intracoronary injection
3196035|NCT01226550|Experimental|cytoreductive surgery and HIPEC|
3196036|NCT01226537|Active Comparator|Diabetes Mellitus type 1 taurine|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
3196037|NCT01226537|Placebo Comparator|Diabetes mellitus type 1 placebo|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
3196038|NCT01226537|Active Comparator|Diabetes type 2 taurine|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
3196039|NCT01226537|Placebo Comparator|Diabetes type 2 placebo|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
3196040|NCT01226524|Experimental|Traditional Chinese Medicine|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulations, i.e. Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan
3196041|NCT01226511|Experimental|Duloxetine|30-120 mg flexible dosing once daily for 10 weeks. At the end of the 10 week blinded treatment period, participants may participate in an 18 week extension
3196042|NCT01226511|Placebo Comparator|Placebo|Administered once daily for 10 weeks. At the end of the 10 week blinded treatment period, placebo participants receive duloxetine in the 18 week extension
3196043|NCT01226498|Experimental|Fresh blood auto-transfusion|
3196044|NCT01226498|Experimental|Old blood auto-transfusion|
3196045|NCT01226485|Experimental|RXDX-109 Experimental|"Part A (dose escalation: advanced solid tumors) - Daily dosing with RXDX-109~Part B (dose escalation: advanced solid tumors) - Twice Daily dosing with RXDX-109 (if necessary based on pharmacokinetic, pharmacodynamic and safety data)~Part C (dose expansion: advanced solid tumors) - Dose and frequency as determined by parts A and B of the study~Part D (dose expansion: advanced basal cell carcinoma) - Dose and frequency as determined by parts A and B of the study"
3196046|NCT01226472|Experimental|KW-0761|
3196047|NCT01226459|Experimental|Minoxidil Foam|5% Minoxidil Topical Foam
3196048|NCT01226459|Placebo Comparator|Vehicle Foam|Vehicle Topical Foam
3196049|NCT01226446|Experimental|Addition of Vitamin D to Peg-interferon plus Ribavirin|
3196050|NCT01226420|Experimental|Alefacept|Alefacept iv
3196051|NCT01226407|Experimental|Single Arm for CG200745|any progrossive solid cancer
3196052|NCT01226394|No Intervention|surveillance|
3196053|NCT01226394|Experimental|laparotomy plus HIPEC.|
3196054|NCT01226355|Experimental|NOYA|implant NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stents Intervention: Device: stent
3196055|NCT01226355|Active Comparator|Firebird2|implant Firebird2 drug-eluting stents Intervention: Device: stent
3196056|NCT01226342|Experimental|TCEMS|Patients who will receive transcutaneous electrical muscle stimulation
3196057|NCT01226329|Experimental|RQP-MH|Participants in the intervention arm will receive three Patient Activation and Self-Management education sessions, plus a fourth booster session if they show difficulty mastering the content of the first three trainings.
3196058|NCT01226329|Active Comparator|Comparison Group|"Participants in this arm will receive a pamphlet in either Spanish or English called Managing Your Mental Health Care."
3196059|NCT01226316|Experimental|Part A and B Schedule 1, Continuous dosing|Part A: Ascending doses of AZD5363 administered orally, every day to define the maximum tolerated dose. Part B: Dose expansion phase, at the defined maximum tolerated dose or recommended dose from Part A.
3196060|NCT01226316|Experimental|Parts A,B,C,D Schedule 2, Intermittent dosing|Part A: Ascending doses of AZD5363 administered orally, twice daily, on a 7-day repeating regimen (4 days on, 3 days off and 2 days on, 5 days off), to define the maximum tolerated dose. Part B: Dose expansion phase, at the defined maximum tolerated dose or recommended dose from Part A (4 days on, 3 days off and 2 days on, 5 days off). Part C and D: AZD5363 orally, twice daily on an intermittent regimen (4 days on, 3 days off).
3196061|NCT01226316|Experimental|Parts A and B Schedule 3, Intermittent dosing.|"Part A: Ascending doses of AZD5363 administered orally, twice daily, on an alternative weekly regimen. Initiation of Schedule 3 is dependant on emerging clinical data.~Part B: Dose expansion phase, at the defined maximum tolerated dose or recommended dose from Part A"
3196062|NCT01226316|Experimental|Parts E and F, Intermittent dosing with Fulvestrant|Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment to cessation of therapy combined with background therapy of fulvestrant at its licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter to cessation of therapy.
3196063|NCT01226303|Experimental|standard risk|are defined as those patients with a WBC less than 10x10 9 /L at presentation
3196064|NCT01226303|Active Comparator|high risk|are defined as those patients whose highest treatment WBC is equal to or greater than 10x10 9 /L at presentation
3196065|NCT01226290|Experimental|VizAblate treatment|VizAblate System: subject acts as her own control
3196066|NCT01226277|Experimental|A|
3196067|NCT01226251||Healthy adults|Subjects consulting a bad breath clinic at the Department of Periodontology, KULeuven
3196068|NCT01226238|Experimental|Online self-help|Provision of online self-help while waiting for psychotherapy
3196069|NCT01226238|No Intervention|Waiting list alone|Waiting for psychotherapy alone
3196070|NCT01226225|Experimental|Aerobic interval training|
3196071|NCT01226225|Active Comparator|Moderate endurance training|
3196072|NCT01226212|Experimental|Synbiotic|Synbiotic (Synergy 1/B. longum)
3196073|NCT01226212|Placebo Comparator|Placebo|maltodextrose
3196074|NCT01226186|Active Comparator|Nurse dispensed oral morphine solution.|
3196075|NCT01226186|Active Comparator|Self medicated oral morphine solution.|
3196076|NCT01226160|Experimental|Face-down posturing group|Postoperative face-down positioning for 10 days after surgery.
3196077|NCT01226160|Active Comparator|Non-posturing group|avoid a face-up position for 10 days after surgery
3196078|NCT01226134|Experimental|1.Itopride Group|The itopride group will receive itopride 150mg per day(50mg TDS)for four weeks
3196079|NCT01226134|Placebo Comparator|2.Control placebo group|The control group will receive placebo tablets for four weeks
3196080|NCT01226121|Active Comparator|Day 1 manipulation|Finger manipulation one day following Clostridial collagenase injectable
3196081|NCT01226121|Active Comparator|Day 2 manipulation|Finger manipulation two days following Clostridial collagenase injectable
3196082|NCT01226121|Active Comparator|Day 4 manipulation|Finger manipulation four days following Clostridial collagenase injectable
3196083|NCT01226108|Active Comparator|antinitus patch|One patch per day, Duration: three weeks, Administration: behind the ear
3196084|NCT01226095||Osteoarthritic patients|Patients male or female, age ≥ 18 having clinical or radiological evidence of osteoarthritis
3196085|NCT01226082|Experimental|Transcranial Direct Current Stimulation|
3196086|NCT01226069|Active Comparator|Glycerine Magnesium Sulphate paste|
3196087|NCT01226069|Active Comparator|Hirudoid cream|Topical Mucopolysaccharide polysulphate
3196088|NCT01226069|Experimental|No application|Patient will not receive any topical application to apply on the phlebitis site. The outcome assessor will monitor regularly at pre-determined schedule as patients in other active arms.
3196089|NCT01226056|Experimental|RAD001 in combination with sorafenib|
3196090|NCT01226043|Experimental|Lantus (insulin glargine) vial & syringe|10 mL vial, 1000 U per vial for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.
3196091|NCT01226043|Experimental|Lantus (insulin glargine) SoloSTAR pen|3 mL SoloSTAR pre-filled disposable insulin delivery device (pen), 300 U per device for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.
3196092|NCT01226030|Experimental|M2ES 7.5mg|M2ES 7.5mg
3196093|NCT01226030|Experimental|M2ES 15mg|M2ES 15mg
3196094|NCT01226030|Experimental|M2ES 30mg|M2ES 30mg
3196095|NCT01226030|Experimental|M2ES 60mg|M2ES 60mg
3196096|NCT01225991|Experimental|Milnacipran, active drug, open-label|All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day, or to their maximum tolerated dose in the course of the first week. The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day). Final efficacy assessments will be made at the termination visit, and the study medication will be tapered down following 12 weeks of drug treatment.
3196097|NCT01225978||GeneInsight Clinic (GIC)|The Group/Cohort in this study are geneticists, physicians, and genetic counselors who are using the GeneInsight Clinic (previously known as Patient Genome Explorer) to receive and store genetic test reports and variant update information.
3196098|NCT01225965|Experimental|EIL05, Inhalation|
3196099|NCT01225965|Placebo Comparator|Placebo, 0,9% NaCl|
3196100|NCT01225952|Experimental|Crystalens AO|Bausch & Lomb silicone multi-piece accommodating IOL is a modified plate haptic lens
3196101|NCT01225952|Active Comparator|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
3196102|NCT01225952|Active Comparator|AMO Tecnis Multifocal|A foldable hydrophobic acrylic IOL,(Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL
3196103|NCT01225939|Experimental|1|Single Oral dose AZD8329 tablet (fasting)
3196104|NCT01225939|Experimental|2|Single Oral dose AZD8329 solution (fasting)
3196105|NCT01225939|Experimental|3|Single Oral dose AZD8329 tablet (Fed)
3196106|NCT01225926|Experimental|Toric T3 - T9|AcrySof IQ Toric IOL surgically implanted in the capsular bag of the eye following cataract removal. Both eyes were implanted, with the second eye implanted at least 1 week after and within 1 month of the first eye.
3196107|NCT01225926|Active Comparator|IQ SN60WF|AcrySof IQ IOL surgically implanted in the capsular bag of the eye following cataract removal. Both eyes were implanted, with the second eye implanted at least 1 week after and within 1 month of the first eye.
3196108|NCT01225913|Active Comparator|Asthma observational study arm|Asthmatics in this arm may be on varying dose of inhaled fluticasone 100-500mcg/salmeterol 50mcg bid via Advair MDI or equivalent dose via Diskus bid or Symbicort (budesonide 80-160mcg/formoterol 4.5mcg bid)or Dulera 100-200mcg mometasone/5 mcg formoterol bid, tiotropium 18mcg capsule daily. This is an observational study and additional pharmacologic intervention may include antibiotic and tapering doses of corticosteroids.
3196109|NCT01225887|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3196110|NCT01225874|Experimental|Stratum 3|Patients receive oral dexamethasone twice daily on days 1-28; vincristine sulfate IV on days 1, 8, 15, and 22; pegaspargase intramuscularly (IM) on day 4, 5, or 6; cytarabine intrathecally (IT) on day 1; and methotrexate IT on day 8 (some patients also receive methotrexate IT on days 15 and 22).
3196111|NCT01225874|Experimental|Stratum 4|Patients receive oral prednisone twice daily on days 1-28; vincristine sulfate IV on days 1, 8, 15, and 22; IM SC-PEG E. coli asparaginase on days 2, 5, 8, 12, 15, and 19; daunorubicin hydrochloride IV over 15-20 minutes on days 8, 15, and 22; and methotrexate IT on days 1 and 8 (some patients also receive methotrexate IT on days 15 and 22).
3196112|NCT01225835|Experimental|Menotrophin|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met. Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.
3196158|NCT01225575|Active Comparator|co.don chondrosphere®, 3-7 spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group A is 3-7 spheroids/cm2 defect"
3196113|NCT01225835|Active Comparator|Follitrophin Alpha|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met. Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.
3196114|NCT01225822|Experimental|BIBR 1048 50 mg bis in die(b.i.d)|BIBR 1048 50 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus one placebo matching enoxaparin 0 mg once a day for the treatment period
3196115|NCT01225822|Experimental|BIBR 1048 150 mg b.i.d|BIBR 1048 150 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
3196116|NCT01225822|Experimental|BIBR 1048 225 mg b.i.d|BIBR 1048 225 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
3196117|NCT01225822|Experimental|BIBR 1048 300 mg quaque die(q.d)|BIBR 1048 150 mg q.d once a day plus placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
3196118|NCT01225822|Active Comparator|Enoxaparin 40 mg subcutaneous(s.c)|placebo matching BIBR 1048 0 mg twice a day plus enoxaparin 40 mg s.c once a day for the treatment period
3196119|NCT01225809||AD01with or without adjuvant|Patients who have received at least one immunization of AD01 with or without adjuvant during AFF001
3196120|NCT01225796|Experimental|Sodium bicarbonate|This group will receive oral sodium bicarbonate 650mg three times daily for 6 months.
3196121|NCT01225796|No Intervention|Control|This group will not receive any sodium bicarbonate.
3196122|NCT01225770|Experimental|Green tea|Gargling with green tea
3196123|NCT01225770|Active Comparator|water|Gargling with water
3196124|NCT01225757|Experimental|Echocardiography|These patients will have echocardiography guided fluid management
3196125|NCT01225757|Active Comparator|Traditional fluid management|Fluid management will be guided by monitoring of central venous pressure and urine output.
3196126|NCT01225744|Experimental|Cetuximab plus Irinotecan, Oxaliplatin and UFT|Cetuximab plus Irinotecan, Oxaliplatin, UFToral
3196127|NCT01225731|Experimental|Part 1: Tildrakizumab 5 mg|Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4
3196128|NCT01225731|Experimental|Part 1: Tildrakizumab 25 mg|Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4
3196129|NCT01225731|Experimental|Part 1: Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4
3196130|NCT01225731|Experimental|Part 1: Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4
3196131|NCT01225731|Placebo Comparator|Part 1: Placebo|Participants receive placebo, SC, at Weeks 0 and 4
3196132|NCT01225731|Experimental|Part 2: Tildrakizumab 5 mg|Participants receive tildrakizumab 5 mg, SC, every 12 weeks for up to 36 weeks
3196133|NCT01225731|Experimental|Part 2: Tildrakizumab 25 mg|Participants receive tildrakizumab 25 mg, SC, every 12 weeks for up to 36 weeks
3196134|NCT01225731|Experimental|Part 2: Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg, SC, every 12 weeks for up to 36 weeks
3196135|NCT01225731|Experimental|Part 2: Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg, SC, every 12 weeks for up to 36 weeks
3196136|NCT01225731|No Intervention|Part 3: Tildrakizumab 5 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
3196137|NCT01225731|No Intervention|Part 3: Tildrakizumab 25 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
3196138|NCT01225731|No Intervention|Part 3: Tildrakizumab 100 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
3196139|NCT01225731|No Intervention|Part 3: Tildrakizumab 200 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
3196140|NCT01225731|No Intervention|Part 3: Placebo Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
3196141|NCT01225705|Experimental|Raltegravir|45 patients will receive open label raltegravir, in addition to the common backbone tenofovir and emtricitabine
3196142|NCT01225705|Active Comparator|Atazanavir/ritonavir|45 patients will receive open label atazanavir/ritonavir
3196143|NCT01225679||polysomnography|Overnight supervised polysomnography (Embla System®) was performed in a sleep laboratory, which included capnometry. Arterial blood gas analysis was performed by radial arterial puncture. Ventilatory response to progressive hypercapnia was measured using the Read breathing technique. Briefly, subjects rebreathed into an air tight 5-L bag containing a mixture of 8% carbon dioxide (CO2) and 40% oxygen (O2). The spirometer technology used to monitor ventilation was based on a bi-directional rotating vane principle (flow sensitive). A continuous record of CO2 concentration in the expired gas was obtained by a CO2 analyzer within the circuit. The ventilatory hypercapnic drive was calculated from the slope produced by changes in ventilation (L. min-1) and changes in end-tidal PCO2.
3196144|NCT01225666|Experimental|Weekly low dose|MOD-4023
3196145|NCT01225666|Experimental|Weekly middle dose|MOD-4023
3196146|NCT01225666|Experimental|Weekly high dose|MOD-4023
3196147|NCT01225666|Experimental|Every-other week dose|MOD-4023
3196148|NCT01225653|Experimental|Latanoprost|Topical treatment with latanoprost
3196149|NCT01225653|Placebo Comparator|Placebo|Placebo arm
3196150|NCT01225640|Experimental|PNU-100480 600 mg BID|
3196151|NCT01225640|Experimental|PNU-100480 1200 mg QD|
3196152|NCT01225640|Active Comparator|RHZE|conjugated tablet with 4 drug combination of RHZE, Rifafour® e275 will be used in countries where can be sourced locally
3196153|NCT01225627|Experimental|Coordinated discharge|Patients will receive support by discharge coordinator for activities associated with discharge and immediate post-discharge care.
3196154|NCT01225627|Placebo Comparator|Control|Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
3196155|NCT01225614|Experimental|bipap ventilation|
3196156|NCT01225614|Active Comparator|Standard care|Standard care and ventilation if occurrence of absolute criteria of ventilation (cf infra).
3196157|NCT01225601||Histocytosis|Adult with isolated pulmonary Langerhans cell histiocytosis (pulmonary LCH)
3196159|NCT01225575|Active Comparator|co.don chondrosphere®,10-30spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group B is 10-30 spheroids/cm2 defect"
3196160|NCT01225575|Active Comparator|co.don chondrosphere®,40-70spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group C is 40-70 Spheroids/cm2 defect"
3196161|NCT01225562|Experimental|1|Oral Treatment
3196162|NCT01225562|Experimental|2|Oral Treatment
3196163|NCT01225562|Placebo Comparator|3|Oral Treatment
3196164|NCT01225549|Experimental|1|AZD5423 75ug
3196165|NCT01225549|Experimental|2|AZD5423 300ug
3196166|NCT01225549|Active Comparator|3|Budesonide 200 microgram
3196167|NCT01225549|Placebo Comparator|4|Placebo
3196168|NCT01225536|Experimental|ARQ 736|
3196169|NCT01225523|Active Comparator|Preoperative chemotherapy followed by surgery|
3196170|NCT01225523|Active Comparator|Perioperative chemotherapy with surgery|
3196171|NCT01225510|Experimental|Primary Cohort|
3196172|NCT01225510|Experimental|Exploratory Cohort|
3196173|NCT01225497|Active Comparator|Standard eccentric exercise|Participants randomised to this group shall complete 180 repetitions a day of Alfredsons heel drop protocol. This has been accepted as standard management for mid-portion Achilles pain in the first instance.
3196174|NCT01225497|Experimental|Eccentric exercise as able|Participants randomised to this group shall carry out exactly the same eccentric exercises as per Alfredsons heel drop protocol. However, these individuals will be instructed to do what they can.
3196175|NCT01225484|Active Comparator|CFNB, periarticular infiltration|
3196176|NCT01225484|Active Comparator|Intraarticular catheter, periarticular infiltration|
3196177|NCT01225458|Placebo Comparator|exclusive nephrology follow-up|"250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring."
3196178|NCT01225458|Experimental|geriatric follow-up|"250 patients will be included and randomized in the geriatric follow-up arm. They will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients.~About geriatric evaluation Patients randomized in this arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status."
3196179|NCT01225445|Experimental|Treatment|ramipril 2.5 mg daily
3196180|NCT01225445|No Intervention|Control|
3196181|NCT01225432|Experimental|Gait Training|
3196182|NCT01225406||third line naive|Children on second line or other regimen who switch or start third line regimen
3196183|NCT01225406||third line experienced|children who are on third line regimen
3196184|NCT01225393|Experimental|A|
3196185|NCT01225393|Active Comparator|B|
3196186|NCT01225393|Placebo Comparator|C|
3196187|NCT01225380|Experimental|Arm 1|GS-9190 and GS-9256 in combination with Pegasys® and Copegus® for 16 or 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
3196188|NCT01225380|Experimental|Arm 2|GS-9256 (active) and placebo matching GS-9190 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
3196189|NCT01225380|Placebo Comparator|Arm 3|Placebo matching GS-9190 and placebo matching GS-9256 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® will be continued for up to 48 weeks total duration
3196190|NCT01225367||pulmonary doppler|
3196191|NCT01225354|Experimental|Calcium hydroxylapatite|Subject will be treated at baseline and, if needed, at 2 weeks.
3196192|NCT01225341|Experimental|onabotulinumtoxinA/placebo|Patients will be injected every 3 months with onabotulinumtoxinA for a period of 12 months. At the 12 month visit, patients will receive injections of saline.
3196193|NCT01225341|Placebo Comparator|Bacteriostatic normal saline/ onabotulnimtoxinA|Patients will be injected every 3 months with saline for a period of 12 months. At the 12 month visit, patients will receive injections of onabotulnimtoxinA.
3196194|NCT01225328|Experimental|Intervention|Telephone-delivered Behavioral Activation/Problem Solving (BA/PS) intervention
3196195|NCT01225315|Experimental|Setipiprant - Dose 1|100 mg b.i.d.
3196196|NCT01225315|Experimental|Setipiprant - Dose 2|500 mg b.i.d.
3196197|NCT01225315|Experimental|Setipiprant - Dose 3|1,000 mg b.i.d
3196198|NCT01225315|Placebo Comparator|Matching Placebo|Oral placebo
3196199|NCT01225302|Experimental|Arm A|
3196200|NCT01225302|Experimental|Arm B|
3196201|NCT01225289|Active Comparator|with Multiple Sclerosis/ vitamin A|Patients with MS confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A
3196202|NCT01225289|Placebo Comparator|with Multiple Sclerosis/ placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo per day
3196203|NCT01225276|Experimental|Dosage Arm 1|NewGam 10% 0.4 g/kg
3196204|NCT01225276|Experimental|Dosage Arm 2|NewGam 10% 1.0 g/kg
3196205|NCT01225276|Experimental|Dosage Arm 3|NewGam 10% 2.0 g/kg
3196206|NCT01225276|Placebo Comparator|Dosage Arm 4|Placebo 0.9% Saline
3196207|NCT01225263|Experimental|Simvastatin and vitamin D|Participants in this arm will receive simvastatin + vitamin D.
3196208|NCT01225263|Placebo Comparator|"Placebo Sugar Pill"|"Participants in this arm will take placebo pills, which look like the simvastatin and vitamin D. A placebo pill has no active medication in it, and is like taking a sugar pill."
3196209|NCT01225250|Experimental|Polydioxanone (PDS) plates|15 subjects will be randomized to receive a caudal septal extension graft using a PDS plated cartilagenous graft
3196298|NCT01224652|Experimental|irinotecan|irinotecan 150 mg/m2 on Days 1 and 15 of a 28-day cycle
3196210|NCT01225250|Other|Non-plated cartilagenous graft|15 subjects will be randomized to receive a cartilagenous caudal septal extension fgraft
3196211|NCT01225237|Experimental|ramosetron group|
3196212|NCT01225237|Placebo Comparator|Placebo group|
3196213|NCT01225224|Experimental|ASP015K Single Japanese Group|
3196214|NCT01225224|Experimental|ASP015K Single Caucasian Group|
3196215|NCT01225224|Placebo Comparator|Placebo Single Japanese Group|
3196216|NCT01225224|Placebo Comparator|Placebo Single Caucasian Group|
3196217|NCT01225224|Experimental|ASP015K Multiple Group|
3196218|NCT01225224|Placebo Comparator|Placebo Multiple Group|
3196219|NCT01225211|Placebo Comparator|Cohort 1: Placebo|Participants homozygous (HO) for the F508del-CF transmembrane conductance regulator gene (CFTR) mutation received lumacaftor matched placebo once daily (qd) (Day 1 through Day 14), followed by lumacaftor matched placebo qd in combination with ivacaftor matched placebo every 12 hours (q12h) (Day 15 through Day 21).
3196220|NCT01225211|Experimental|Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 150 mg q12h|Participants homozygous for the F508del-CFTR mutation received 200 milligram (mg) of lumacaftor (LUM) qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 150 mg of ivacaftor (IVA) q12h (Day 15 through Day 21).
3196221|NCT01225211|Experimental|Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h|Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 15 through Day 21).
3196222|NCT01225211|Placebo Comparator|Cohort 2 and 3: Placebo (HO and HE)|Participants homozygous or heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo qd (Day 1 through Day 28), followed by lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 29 through Day 56).
3196223|NCT01225211|Experimental|Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
3196224|NCT01225211|Experimental|Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 400 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
3196225|NCT01225211|Experimental|Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO&HE)|Participants homozygous or heterozygous for the F508del-CFTR mutation received 600 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 600 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
3196226|NCT01225211|Experimental|Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone q12h (Day 1 through Day 28), followed by 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
3196227|NCT01225211|Placebo Comparator|Cohort 4: Placebo|Participants heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 1 through Day 56).
3196228|NCT01225211|Experimental|Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h|Participants heterozygous for the F508del-CFTR mutation received 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 1 through Day 56).
3196229|NCT01225198|Placebo Comparator|Placebo Group|Liquid placebo with identical packaging and flavoring to the real supplement.
3196230|NCT01225198|Experimental|Vitamin/Mineral Supplement Group|Multi-vitamin/mineral supplement designed for this study for children and adults with autism spectrum disorders.
3196231|NCT01225185||Patients undergoing shoulder surgery|"This observational study will compare cerebral blood flow autoregulation in patients undergoing surgery in either the supine lateral position or the semi-recumbent or beach chair position. The choice of patient positioning is not randomized but based on usual surgical considerations."
3196232|NCT01225172|Experimental|BMS-754807|
3196233|NCT01225172|Experimental|BMS-754807 + letrozole|
3196234|NCT01225159|Experimental|Tight glycaemic control (TGC)|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
3196235|NCT01225159|Placebo Comparator|Conventional glycaemic control (Control)|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
3196236|NCT01225146|Active Comparator|Treatment Experienced (Cohort 1|"Previously treated with 6 or more intravitreal ranibizumab with persistent edema followed in RAVE 1 (FVF3348s).~Cohort 1 patients will receive 1 dose of ranibizumab 2.0 mg, followed by PRN based on pre-defined retreatment criteria"
3196237|NCT01225146|Active Comparator|Treatment Naive (Cohort 2)|Treatment naïve. Cohort 2 patients will receive 6 doses of ranibizumab 2.0 mg, followed by PRN based on pre-defined re-treatment criteria.
3196238|NCT01225133|Active Comparator|Complex Ayurvedic Treatment|In the Āyurveda arm treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
3196239|NCT01225133|Active Comparator|Conventional Care|Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
3196240|NCT01225120|Experimental|Gait Training|
3196241|NCT01225107|Placebo Comparator|Inert Placebo Capsule|
3196242|NCT01225107|Experimental|Cranberry Extract|
3196295|NCT01224665|Active Comparator|Arm I|therapeutic conventional surgery therapeutic standard lymphadenectomy
3196296|NCT01224665|Experimental|Arm II|therapeutic conventional surgery therapeutic extended lymphadenectomy
3196297|NCT01224652|Experimental|paclitaxel|Paclitaxel 70 mg/m2 on Days 1, 8 and 15 of a 28-day cycle
3196243|NCT01225094|Experimental|curcumin|Patients will take the study medication (500 mg x 4 capsules, twice daily [BID]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg., and then another 2000 mg dose 6 hours after the repair. Final dose (2000 mg)is administered morning after repair.
3196244|NCT01225094|Placebo Comparator|placebo|The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.
3196245|NCT01225081|Experimental|ASP group|ASP1941 and pioglitazone
3196246|NCT01225081|Placebo Comparator|Placebo group|placebo and pioglitazone
3196247|NCT01225068|Experimental|Milnacipran|milnacipran 50 mg bid; can be increased to 100 mg bid
3196248|NCT01225068|Placebo Comparator|Placebo|Placebo
3196249|NCT01225055|Experimental|Teriparatide|Teriparatide alone with sham vibration
3196250|NCT01225055|Experimental|Vibration|Vibration alone with placebo-teriparatide
3196251|NCT01225055|Experimental|Teriparatide and vibration|Teriparatide with vibration applied in conjuction
3196252|NCT01225042|Experimental|probiotics|Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks
3196253|NCT01225042|Placebo Comparator|placebo|Carrier material powder of identical appearance
3196254|NCT01225029|No Intervention|Standard Fluids|Term neonates receive total fluids of 60 mL/kg/day on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
3196255|NCT01225029|Experimental|Restricted Fluids|Term neonates receive total fluids of 40 mL/kg/day on day of life (DOL) 1. Preterm neonates receive total fluids of 60 mL/kg/day on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved
3196256|NCT01224977|Other|azithromycin|
3196257|NCT01224964|Active Comparator|Montelukast|
3196258|NCT01224964|Active Comparator|long-acting beta2-mimetic|
3196259|NCT01224951|Active Comparator|Qvar 100|"Patients will be randomized to receive either the active arm (3/4) or a SABA as rescue medication (1/4). The patient will be asked to take Qvar 100 (2puffs) in the morning and in the evening.~Daily dose (400 microgram)."
3196260|NCT01224951|No Intervention|Control|Patients are allowed to use their SABA as rescue medication only. During the last 4 weeks, the patients will receive 400 microgram of Qvar.
3196261|NCT01224938||Asthma patients|Asthmatics of all classes of severity will be included.
3196262|NCT01224938||Healthy control population|A healthy control population will be included to compare with the asthmatics.
3196263|NCT01224925|Active Comparator|Dycal - calcium hydroxide material|Pulp capping with Dycal
3196264|NCT01224925|Active Comparator|WMTA - White Mineral Trioxide Aggregate|Pulp capping with Mineral Trioxide Aggregate
3196265|NCT01224912|Experimental|Internet Deliviered CBT for Insomnia|Cognitive behavioral self-help method for insomnia via the Internet
3196266|NCT01224899|Experimental|Surgery|
3196267|NCT01224899|No Intervention|Control|
3196268|NCT01224886|Experimental|Sedentary obese|
3196269|NCT01224886|Experimental|Sedentary normal weight|
3196270|NCT01224886|No Intervention|Athletes|
3196271|NCT01224860|Experimental|Telmisartan|
3196272|NCT01224860|Experimental|Losartan|
3196273|NCT01224847|Active Comparator|Tetracaine gtt|Pre-Intravitreal injection - 1 gtt Tetracaine topically
3196274|NCT01224847|Active Comparator|Tetraciane gtt + Lidocaine pledget|1 gtt Tetracaine pre-IVT injection + application Lidocaine pledget to injection site
3196275|NCT01224847|Active Comparator|Cocaine gtt alone|1 gtt pre-IVT injection
3196276|NCT01224834|Placebo Comparator|1|
3196277|NCT01224834|Experimental|2|
3196278|NCT01224821|Experimental|Tositumomab and Iodine I-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
3196279|NCT01224808|Experimental|Experimental|
3196280|NCT01224795|Experimental|Peramivir|Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to < 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
3196281|NCT01224795|Placebo Comparator|Placebo|Placebo Peramivir, administered intravenously.
3196282|NCT01224782||Chronic Kidney Disease, Secondary Hyperparathyroidism|All eligible participants with chronic kidney disease stage 3 and 4 and secondary hyperparathyroidism treated with Zemplar (paricalcitol) capsules according to the local marketing authorization
3196283|NCT01224769||bendamustine +/- rituximab|
3196284|NCT01224756|Experimental|Tinoridine HCl 100 mg (2 capsules) TID|
3196285|NCT01224756|Placebo Comparator|Placebo TID|
3196286|NCT01224743|Placebo Comparator|Placebo|Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.
3196287|NCT01224743|Experimental|Blend 2|Blend 2 - combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends
3196288|NCT01224743|Experimental|Blend 1|Blend 1 - combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends
3196289|NCT01224730|Experimental|Perifosine 100 mg|Perifosine 100 mg orally daily under Fed and Fasted conditions
3196290|NCT01224717|Experimental|PTH134|
3196291|NCT01224717|Placebo Comparator|Placebo|
3196292|NCT01224717|Active Comparator|Forsteo|
3196293|NCT01224678|Placebo Comparator|Placebo|Patients receive oral placebo once daily for 12 months.
3196294|NCT01224678|Experimental|Vitamin D|Patients receive oral vitamin D (2000 IU) once daily for 12 months.
3196825|NCT01220817|Experimental|3 POMx capsules daily|
3196299|NCT01224639|Experimental|Group 1: Low Dose; SC|TDV-1: 8 x 10^3 Plaque Forming Units (PFU), TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, TDV-4: 2 x 10^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.
3196300|NCT01224639|Experimental|Group 2: Low Dose; ID|TDV-1: 8 x 10^3 PFU, TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, TDV-4: 2 x 10^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.
3196301|NCT01224639|Experimental|Group 3: High Dose; SC|TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, TDV-4: 3 x 10^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.
3196302|NCT01224639|Experimental|Group 4: High Dose; ID|TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, TDV-4: 3 x 10^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.
3196303|NCT01224639|Placebo Comparator|Placebo (SC)|Phosphate buffered saline administered subcutaneously in a volume of 0.5 mL.
3196304|NCT01224639|Placebo Comparator|Placebo (ID)|Phosphate buffered saline administered intradermally in a dose volume of 0.1 mL.
3196305|NCT01224626||Zyvox (linezolid)|Patients who have been treated with Zyvox (linezolid).
3196306|NCT01224613|Active Comparator|Intanza - self-administered|Self-administered intradermal influenza vaccine
3196307|NCT01224613|Active Comparator|Intanza - nurse-administered|Nurse-administered intradermal influenza vaccine
3196308|NCT01224600||1|patient with newly diagnosed PAD (< 1 year)
3196309|NCT01224587|Experimental|1|D1000078 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172),AstraZeneca,Mölndal, Sweden , under fasting condition
3196310|NCT01224587|Experimental|2|D1000082 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fasting condition
3196311|NCT01224587|Experimental|3|D1000083 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden ,under fasting condition
3196312|NCT01224587|Experimental|4|D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden , under fasting condition
3196313|NCT01224587|Experimental|5|D100083 marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fed condition
3196314|NCT01224587|Experimental|6|D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca, Mölndal, Sweden , under fed condition
3196315|NCT01224561||Constitutional thinness|Women with a a body mass index of less than 16.5 kg/m2
3196316|NCT01224561||Healthy Volonteer|Women with a body mass index between 20 and 25 kg/m2
3196317|NCT01224548|Experimental|vegan group|participants from sites of this group will receive vegan nutritional intervention starting from Feb 2011
3196318|NCT01224548|No Intervention|control group|participants from sites of the control group will not receive the same nutritional information until June 2011
3196319|NCT01224535|Experimental|Maize porridge with Amaranth|Maize porridge enriched with amaranth grain flour at 70:30 maize/amaranth ratio (80g/day)
3196320|NCT01224535|Active Comparator|Maize flour with multiple micronutrients|Maize porridge fortified with a multiple micronutrient powder (MixMe™)
3196321|NCT01224535|Placebo Comparator|Maize Porridge|Plain maize porridge group
3196322|NCT01224522|Experimental|Visionaire|the group who will be operated by the use of Visionaire patient matched cutting blocks
3196323|NCT01224522|Active Comparator|Standard Surgical technique|The group who will be operated by means fo standard surgical technique
3196324|NCT01224509|Experimental|Mifepristone|
3196325|NCT01224509|Active Comparator|Non-treatment|
3196326|NCT01224496|Experimental|Treatment with Chinese herbal concoction|"Patients must have a marrow study to confirm diagnosis of MDS, AA or MF. MDS is classified according to the WHO criteria and scored according to IPSS. The AA group is further classified into AA, SAA or VSAA . MF is defined by the Italian criteria and risk stratified by the Lilles Scoring system. Diagnosis of thal intermedia and major is based on previously done Hb electrophoresis and severity of disease is assessed by degree of anaemia.and frequency of blood transfusions~TCM diagnosis: Syndrome differentiation according to TCM theory will be assessed as a baseline by experienced TCM collaborators and classified into one of the few defined syndromes as follows~Yin deficiency of spleen and kidney~Yang deficiency of spleen and kidney~Deficiency of both Yin and Yang~Stagnation of dampness and poison in the blood~Excessive heat and poison"
3196327|NCT01224470|Active Comparator|bupivacaine|0.5% bupivacaine 1.2 mL + normal saline 0.8 mL = total 2 mL
3196328|NCT01224470|Placebo Comparator|saline|
3196329|NCT01224444||All adenomatous polyps|Standard polypectomy snare of adenomatous polyps (included serrated adenomas) from ≤5mm to ≤20mm.
3196330|NCT01224431|Experimental|needleless injection of buffered lidocaine|needleless injection of buffered lidocaine prior to lumbar puncture
3196331|NCT01224431|Placebo Comparator|normal saline via needleless injection|needleless injection of normal saline prior to lumbar puncture
3196332|NCT01224418|Experimental|Tacrolimus group|
3196333|NCT01224405|Active Comparator|Treatment arm|ten docetaxel cycles + maintenance androgen deprivation.
3196334|NCT01224405|Experimental|suspension arm|Ten Docetaxel cycles + stop androgen deprivation therapy
3196335|NCT01224405|Experimental|intermittent arm|Intermittent Docetaxel
3196336|NCT01224405|Active Comparator|Continuous arm|Continuous Docetaxel
3196337|NCT01224392|Active Comparator|Concomitant chemoradiotherapy|Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends
3196338|NCT01224392|Experimental|Radiotherapy with boost|Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor
3196339|NCT01224379|Other|"Arm1: topping off system"|"The intervention group will receive a topping off system (PLIF -posterior intervertebral fusion- connected with a flexible pedicle screw system above the fusion)."
3196340|NCT01224379|Other|Arm 2: monosegmental PLIF|The control group receives a monosegmental PLIF. This is the current standard therapy for many pathologies in the lumbar spine (e.g. Spondylolisthesis)
3196341|NCT01224366|Experimental|Vildagliptin|
3196342|NCT01224366|Placebo Comparator|Placebo|
3196343|NCT01224353|Placebo Comparator|Thioctacid Oral Placebo Tablet|
3196344|NCT01224353|Active Comparator|Thioctacid Oral Tablet|
3196386|NCT01224067|Placebo Comparator|Placebo|Participant will receive placebo for 8 weeks.
3197280|NCT01217931|Experimental|Group 4|Everolimus + possible Pazopanib
3196345|NCT01224340|Experimental|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
3196346|NCT01224340|Experimental|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path. The player got points for collected fishes but also credits for time of flying and speed.
3196347|NCT01224340|Experimental|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
3196348|NCT01224327|Experimental|umbilical cord mesenchymal stem cells|Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
3196349|NCT01224327|Active Comparator|Conserved therapy|Patients received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
3196350|NCT01224314|Active Comparator|dialysis fluid potassium high|potassium concentration in the dialysis fluid 1 mmol/L higher than usual
3196351|NCT01224314|Active Comparator|dialysis fluid potassium low|potassium concentration in the dialysis fluid 1 mmol/L lower than usual
3196352|NCT01224301|Experimental|School based flu vaccine: High intensity|Interventions: Parents in high intensity schools have access to school-based flu vaccine clinics and 3 or more communications from schools about influenza illness, influenza vaccine, and school based clinics.
3196353|NCT01224301|Experimental|School based flu vaccine: Low intensity|Interventions: Parents in low intensity schools have access to school-based flu vaccine clinics and less than 3 communications from schools about influenza illness, influenza vaccine, and school based clinics.
3196354|NCT01224301|No Intervention|Standard of Care|Control Schools did not have any in school seasonal influenza vaccine clinics. Parents of children in control schools got no notification from the schools and sought seasonal influenza vaccines for their children as they normally would.
3196355|NCT01224288|Experimental|DCE-CT Scans|DCE-CT = Dynamic contrast enhanced CT - DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
3196356|NCT01224275|Experimental|Group antenatal care|The first arm is midwife which allocated to group based antenatal care. They have education in this model of care and follow up meeting to secure the intervention
3196357|NCT01224275|No Intervention|Individual antenaal care|the second arm include midwife which allocated to traditional care as control group.
3196358|NCT01224262|Experimental|Fluzone + 0.45 mg LIQ001|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (0.45mg)
3196359|NCT01224262|Experimental|Fluzone + 1.8 mg LIQ001|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (1.8mg)
3196360|NCT01224262|Active Comparator|Fluzone|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)
3196361|NCT01224249|Active Comparator|Fish and shellfish|
3196362|NCT01224249|No Intervention|Control|Assessment only
3196363|NCT01224236|Experimental|iron supplementation|2 mg/kg/day of elemental iron as a multivitamin with iron solution
3196364|NCT01224236|Sham Comparator|control|multivitamin solution without iron
3196365|NCT01224223||acute asthma exaecerbtion patients|Patients experiencing acute exacerbation of their asthma
3196366|NCT01224223||chronic asthma group|Two groups are being enrolled. The first group is chronic asthma patients with FEV1 below 80% and FEV1/FVC ratio reduced by 5%
3196367|NCT01224210|Other|Ambrisentan|Open Label Ambrisentan
3196368|NCT01224197|Experimental|001|TMC435 100 or 200 mg capsule one single dose
3196369|NCT01224197|Experimental|002|TMC435 100 or 200 mg capsule once daily for 5 days
3196370|NCT01224184|Active Comparator|Nutrition|Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
3196371|NCT01224184|Experimental|Young Women's|Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (Principal Investigator (PI): Dr. Wendee M. Wechsberg).
3196372|NCT01224171|Placebo Comparator|Placebo|Participants received placebo intravenous infusion at Weeks 0, 2 and 6.
3196373|NCT01224171|Experimental|Vedolizumab|Participants received 300 mg intravenous vedolizumab at Weeks 0, 2, and 6.
3196374|NCT01224145|Experimental|Drug: Bupivacaine Collagen Sponge|4, 5x5 bupivacaine collagen sponges
3196375|NCT01224132|No Intervention|Probiotics|
3196376|NCT01224132|No Intervention|skim milk powder, dextrose|
3196377|NCT01224119|Experimental|Amplex (synthetic bone graft)|
3196378|NCT01224119|Active Comparator|Autograft bone|
3196379|NCT01224106|Experimental|Gantenerumab 105 mg (Parts 1 and 2)|Participants with Alzheimer's disease will receive gantenerumab 105 milligrams (mg) by SC injection every 4 weeks (q4w) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who complete the Week 104 visit will be given an option to continue the treatment received during Part 1 for 2 additional years in Part 2.
3196380|NCT01224106|Experimental|Gantenerumab 225 mg (Parts 1 and 2)|Participants with Alzheimer's disease will receive gantenerumab 225 mg by SC injection q4w for 104 weeks or approximately 2 years during Part 1 of the study. Participants who complete the Week 104 visit will be given an option to continue the treatment received during Part 1 for 2 additional years in Part 2.
3196381|NCT01224106|Placebo Comparator|Placebo (Parts 1 and 2)|Participants with Alzheimer's disease will receive placebo SC injection q4w for 104 weeks or approximately 2 years during Part 1 of the study. Participants who complete the Week 104 visit will be given an option to continue the treatment received during Part 1 for 2 additional years in Part 2.
3196382|NCT01224093||First line|
3196383|NCT01224093||Relapsed/refractory|
3196384|NCT01224080|Experimental|Adiana Device|All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
3196385|NCT01224067|Active Comparator|Quetiapine|Quetiapine (dosage 50mg to 300mg + sertraline)Experimental
3196387|NCT01224054||Bypass gastric|The mixed surgery which combine the gastric reduction with some degree of disabsorption
3196388|NCT01224054||Biliopancreatic diversion|The mal-absorptive surgery which reduce the intestinal absorption of food
3196389|NCT01224054||Duodenal exclusion|This surgery provides disabsortion by duodenal derivation maintaining an intact stomach
3196390|NCT01224041|Experimental|Tacrolimus group|
3196391|NCT01224028|Experimental|Tacrolimus group|
3196392|NCT01224028|Placebo Comparator|Placebo|
3196393|NCT01224015|Other|onabotulinumtoxinA 24U|24 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
3196394|NCT01224015|Placebo Comparator|placebo (normal saline)|Normal Saline (placebo) injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
3196395|NCT01224015|Experimental|onabotulinumtoxinA 44U|44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
3196396|NCT01223989|Experimental|group bread|group who received an hypocaloric balanced diet including bread
3196397|NCT01223989|Active Comparator|group without bread|group who received a hypocaloric balanced diet with exclusion of bread
3196398|NCT01223963||Macrolane|Women that have had breast enhancement with Macrolane Volume Restoration Factor.
3196399|NCT01223937|Experimental|Desmopressin 25 μg|Participants took 1 orally disintegrating tablet of desmopressin 25 μg every night approximately 1 hour before bedtime for the entire duration of the 3-month treatment period.
3196400|NCT01223937|Placebo Comparator|Placebo|Participants took 1 orally disintegrating tablet of placebo every night approximately 1 hour before bedtime for the entire duration of the 3-month treatment period.
3196401|NCT01223924|Experimental|M2ES 7.5-90mg|M2ES dose escalating
3196402|NCT01223924|Placebo Comparator|Placebo|placebo contract
3196403|NCT01223911|Experimental|A|
3196404|NCT01223911|Placebo Comparator|B|
3196405|NCT01223898|Experimental|Nilotinib|
3196406|NCT01223885|Experimental|Camel's milk, Cow's milk allergy|
3196407|NCT01223872||Routine Patient Care|
3196408|NCT01223872||Previously-enrolled REACH Clinic Patients|
3196409|NCT01223872||New REACH Clinic Patients|
3196410|NCT01223859|Experimental|intervention|Interstitial soft palate RF surgery
3196411|NCT01223833||tamoxifen|100 postmenopausal women with early breast cancer treated with tamoxifen in the adjuvant setting
3196412|NCT01223833||aromatase inhibitors|200 postmenopausal women with early breast cancer treated with an aromatase inhibitor in the adjuvant setting
3196413|NCT01223820|Experimental|Capsaicin|
3196414|NCT01223807|No Intervention|Control Group|The control group will receive only usual care.
3196415|NCT01223807|Experimental|Diaphragmatic breathing training|The training group will be submitted to a diaphragmatic breathing training program of 4 weeks.
3196416|NCT01223794||Experimental Group|Fall in higher risk
3196417|NCT01223794||Control Group|Fall in lower risk
3196418|NCT01223781|Experimental|Feedforward stimulation|Prior to any gait condition likely to invoke freez, auditory stimulation is presented
3196419|NCT01223781|Experimental|Feedback stimulation|Once a device identifies freezing, a auditory stimulation is triggered
3196420|NCT01223768|Experimental|Acetyl-L-carnitine|
3196421|NCT01223768|Placebo Comparator|placebo|
3196422|NCT01223755|Experimental|Sirolimus|
3196423|NCT01223755|Active Comparator|conventional therapy|
3196424|NCT01223742|Experimental|ACETYL-L-CARNITINE|
3196425|NCT01223742|Placebo Comparator|placebo|
3196426|NCT01223729|Experimental|Acetyl-L-Carnitine|
3196427|NCT01223729|Placebo Comparator|placebo|
3196428|NCT01223716|Experimental|Perceptual learning|
3196429|NCT01223716|Experimental|Video Game|
3196430|NCT01223716|Experimental|Occlusion Therapy|
3196431|NCT01223703|Active Comparator|n-3 PUFAs|
3196432|NCT01223703|Placebo Comparator|Placebo|
3196433|NCT01223690|Placebo Comparator|Placebo|250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
3196434|NCT01223690|Active Comparator|Clarithromycin|1000 mg of clarithromycin diluted in 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
3196435|NCT01223677|Active Comparator|rumination focused CBT|RFCBT-group. This group training is based on research showing that dysfunctional forms of rumination are characterized by an abstract evaluative style of processing, whereas functional forms of of processing are more concrete and process-focused. The training uses psycho-education, functional analysis, group discussion, experiential exercises and behavioral experiments to facilitate the shift from dysfunctional ruminative thinking to a more helpful concrete thinking style.
3196436|NCT01223677|Active Comparator|rumination focused CBT (online)|The online training is based on research showing that dysfunctional forms of rumination are characterized by an abstract evaluative style of processing, whereas functional forms of of processing are more concrete and process-focused. The training uses psycho-education, functional analysis, experiential exercises and behavioral experiments to facilitate the shift from dysfunctional ruminative thinking to a more helpful concrete thinking style.
3196437|NCT01223677|No Intervention|No training control group|No training control group. Participants within this condition received no treatment, but only filled out the outcome measures at each measurement period.
3196438|NCT01223664|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
3196439|NCT01223664|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation
3196440|NCT01223651|Active Comparator|CGMS at sea level.|To assess reliability of continuous glucose monitoring system at sea level whilst subject undergo's a hyperinsulinaemic glucose clamp study.
3196441|NCT01223651|Active Comparator|CGMS reliability at simulated 8000 feet.|To assess reliability of continuous glucose monitoring system at a simulated altitude of 8,000 feet whilst the participant undergo's a hyperinsulinaemic glucose clamp study.
3196442|NCT01223638||Congenital hypothyroidism|Patient which were diagnosed with congenital hypothyroidism
3196443|NCT01223638||Controls|Patients without any endocrine or hearing problems
3196444|NCT01223625|Active Comparator|Rosuvastatin 5mg/day|Rosuvastatin 5mg/day
3196445|NCT01223625|Active Comparator|Rosuvastatin 40mg/day|Rosuvastatin 40mg/day
3196446|NCT01223612|Experimental|Ranibizumab|Intravitreal injection of ranibizumab
3196447|NCT01223612|Active Comparator|Laser|Modified ETDRS laser
3196448|NCT01223586||Regression|Patients with regression of plaque volume by statin
3196449|NCT01223586||Non regression|Patients without regression of plaque volume by statin
3196450|NCT01223547|No Intervention|Control group|Participants in this arm continues their usual insulin therapy
3196451|NCT01223547|Active Comparator|Carb counting|Participants in this arm are taught carb counting
3196452|NCT01223547|Active Comparator|Carb counting and bolus calculator|Participants in this arm are taught carb counting and are provided with an integrated glucose meter and bolus calculator.
3196453|NCT01223534|Active Comparator|Arm A, Standard practice, TST|Participants allocated to screening as stablished by current practice (TST)
3196454|NCT01223534|Experimental|Arm B, Experimental, TST plus QFT-IT|Participants allocated to screening with TST, and if positive, followed by QFT-IT to confirm tuberculosis infection.
3196455|NCT01223521|Experimental|Immediate intrauterine contraception|IUD (either Cu-IUD or LNG-IUS) inserted immediately after abortion.
3196456|NCT01223521|No Intervention|Control group|Post-abortal contraception is prescribed by the hospital but on the responsibility of the patient.
3196457|NCT01223482||Miscarriage with genetic testing|This is a study population of women that have had a miscarriage and had genetic testing performed. The investigators would like to know what their experiences were following their miscarriage and testing.
3196458|NCT01223482||Miscarriage without genetic testing|This cohort is considered the control group. These women have not had genetic testing done, but are asked questions regarding their miscarriage experience.
3196459|NCT01223469|Experimental|Atrial Fibrillation|
3196460|NCT01223469|Experimental|Right-sided Supraventricular Tachycardia|
3196461|NCT01223443|Experimental|PCI-stenting|Stenting the moderate SVG lesion with the paclitaxel stent
3196462|NCT01223443|No Intervention|Standard medical treatment|
3196463|NCT01223430|Experimental|Si-Ni-Tang|
3196464|NCT01223430|Placebo Comparator|Placebo|
3196465|NCT01223404|Experimental|Placebo, Nicotine, Mecamylamine|"Participants undergo 3 test sessions:~In the first session (placebo), a placebo patch and a placebo capsule is administered.~In the second session (nicotine), a nicotine patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (mecamylamine), a placebo patch and a mecamylamine capsule is administered."
3196466|NCT01223404|Experimental|Nicotine, Placebo, Mecamylamine|"Participants undergo 3 test sessions:~In the first session (nicotine), a nicotine patch and a placebo capsule is administered.~In the second session (placebo), a placebo patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (mecamylamine), a placebo patch and a mecamylamine capsule is administered."
3196467|NCT01223404|Experimental|Placebo, Mecamylamine, Nicotine|"Participants undergo 3 test sessions:~In the first session (placebo), a placebo patch and a placebo capsule is administered.~In the second session (mecamylamine), a placebo patch (7 mg/24 hrs) and a mecamylamine capsule is administered.~In the third session (nicotine), a nicotine patch and a placebo capsule is administered."
3196468|NCT01223404|Experimental|Nicotine, Mecamylamine, Placebo|"Participants undergo 3 test sessions:~In the first session (nicotine), a nicotine patch and a placebo capsule is administered.~In the second session (mecamylamine), a placebo patch (7 mg/24 hrs) and a mecamylamine capsule is administered.~In the third session (placebo), a placebo patch and a placebo capsule is administered."
3196469|NCT01223404|Experimental|Mecamylamine, Placebo, Nicotine|"Participants undergo 3 test sessions:~In the first session (mecamylamine), a placebo patch and a mecamylamine capsule is administered.~In the second session (placebo), a placebo patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (nicotine), a nicotine patch and a placebo capsule is administered."
3196470|NCT01223404|Experimental|Mecamylamine, Nicotine, Placebo|"Participants undergo 3 test sessions:~In the first session (mecamylamine), a placebo patch and a mecamylamine capsule is administered.~In the second session (nicotine), a nicotine patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (placebo), a placebo patch and a placebo capsule is administered."
3196471|NCT01223391|Experimental|Abdominal binder|Standing with abdominal compression using elastic vs. non-elastic abdominal binders.
3196472|NCT01223391|Placebo Comparator|No abdominal binder|Standing without abdominal compression
3196473|NCT01223378|Experimental|BOL-303259-X|ophthalmic solution
3196474|NCT01223378|Active Comparator|Latanoprost|ophthalmic solution
3196475|NCT01223365|Experimental|Hydrocodone ER|Participants were titrated (or re-titrated for roll-over participants) at escalating dosages of extended-release hydrocodone tablets at dosages of 15, 30, 45, 60, or 90 mg orally every 12 hours until deemed successful for managing their pain during the open-label titration period. Once a successful dose was identified, participants entered the 52 week open-label treatment period in which hydrocodone ER was administered at the successful dose (15, 30, 45, 60, or 90 mg) every 12 hours.
3196476|NCT01223352|Experimental|Bosentan 2 mg/Kg t.i.d.|2 mg/kg bosentan administered three times a day (morning, afternoon, evening) for a planned duration of 24 weeks
3196477|NCT01223352|Experimental|Bosentan 2 mg/Kg b.i.d.|2 mg/kg bosentan administered twice daily (morning and evening) for a planned duration of 24 weeks
3196478|NCT01223339|Experimental|Single Dose Japanese Cohort|This will be a single dose Cohort in which Japanese healthy participants will receive 3 ascending single doses (1 mg, 5 mg, and 25 mg) of ertugliflozin or placebo through 3 dosing periods. A minimum wash out period of 7-days will be set between each dose administration.
3196517|NCT01223027|Active Comparator|Sorafenib + BSC|Patients in the sorafenib control arm received400 mg of sorafenib (2 x 200 mg tablets) orally taken twice daily.
3196518|NCT01223014||1|Single cohort of 6 subjects
3196479|NCT01223339|Experimental|Single dose Western cohort|This will be a single dose Cohort in which Western healthy participants will receive 3 ascending single doses (1 mg, 5 mg, and 25 mg) of ertugliflozin through 3 dosing periods. A minimum wash out period of 7-days will be set between each dose administration.
3196480|NCT01223339|Experimental|Multiple Dose Japanese Cohort|This will be a multiple dose Cohort in which Japanese healthy participants will receive once-daily 25 mg ertugliflozin or placebo for 7 days.
3196481|NCT01223326|Experimental|N-acetylcysteine|Intravenous N-acetylcysteine
3196482|NCT01223326|Placebo Comparator|Placebo|Placebo
3196483|NCT01223313|Experimental|Woman's Condom|The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
3196484|NCT01223300||Osteoporosis|
3196485|NCT01223274|Experimental|CPAP/PEEP Intervention|Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
3196486|NCT01223274|Active Comparator|Control|Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
3196487|NCT01223248|Experimental|stereotactic IGIMRT using a single dose of 24 Gy|This is a phase III, multicenter, randomized, study comparing two dosing schedules for hypofractionated image-guided radiation therapy to bone, spine, soft tissue, and lymph nodes in patients with metastatic disease
3196488|NCT01223248|Experimental|stereotactic IGIMRT 27 Gy in 3 fractions|This is a phase III, multicenter, randomized, study comparing two dosing schedules for hypofractionated image-guided radiation therapy to bone, spine, soft tissue, and lymph nodes in patients with metastatic disease
3196489|NCT01223235|Experimental|bevacizumab & polyvalent vaccine-KLH conjugate + OPT-821|This is a single institution, open label, pilot study of bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
3196490|NCT01223222|Placebo Comparator|1% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
3196491|NCT01223222|Active Comparator|2% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
3196492|NCT01223222|Active Comparator|5% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
3196493|NCT01223209|Experimental|LTX-315|The dose range of 0,25-2.0 mg/ML LTX-315 will be used. In combination with a fixed dose of GV-1001.
3196494|NCT01223196|Placebo Comparator|Placebo|One arm of the study subjects will be treated with Placebo only, once a day, for 6 months
3196495|NCT01223196|Active Comparator|Pioglitazone|One arm of the study subjects will be treated with Pioglitazone, 15mg, once a day, for 6 months
3196496|NCT01223183|Active Comparator|isotonic saline then hypertonic saline|Subjects inhaled nebulized isotonic saline on study day 1, and then after a 5-24 day washout period, subjects inhaled nebulized 7% hypertonic saline on study day 2.
3196497|NCT01223183|Active Comparator|hypertonic saline then isotonic saline|Subjects inhaled nebulized 7% hypertonic saline on study day 1, and then after a 5-24 day washout period, subjects inhaled nebulized isotonic saline on study day 2.
3196498|NCT01223170|Experimental|Enhanced Internet-based intervention|Behavioral: Tailored content Behavioral: Generic Internet-based information Behavioral: Discussion forum Behavioral: Behavioral monitoring
3196499|NCT01223170|Placebo Comparator|Control|Behavioral: Generic Internet-based information Behavioral: Discussion forum
3196500|NCT01223157|Experimental|Obese patients|
3196501|NCT01223157|Experimental|Normal weight subjects|
3196502|NCT01223144|Experimental|Patients with essential tremor|Patients with essential tremor
3196503|NCT01223144|Active Comparator|age- and sex-matched control subjects|age- and sex-matched control subjects
3196504|NCT01223131|Experimental|Insulin glargine|injection once daily at bedtime
3196505|NCT01223131|Active Comparator|NPH insulin|injection once daily at bedtime or twice daily in the morning and at bedtime
3196506|NCT01223118|Experimental|Oocyte Vitrification|Each patient will have oocytes randomized into two groups immediately after retrieval. Half of oocytes will be vitrified, thawed and inseminated. The other half will be inseminated only. All embryos will be biopsied for PGD prior to transfer and one embryo from each group will be transferred (vitrification and control groups). Following delivery, buccal swabs will be collected on all infants.
3196507|NCT01223105|Experimental|Slow Freezing|oocytes will be frozen by slow freeze/ rapid thaw
3196508|NCT01223105|Experimental|Vitrification|oocytes will be frozen using rapid freezing/rapid thaw
3196509|NCT01223092||Patients undegoing infertility treatment|Male and female patients undergoing infertility treatment
3196510|NCT01223079|Other|r-hFSH (Gonal F)|Patients will be treated with r-hFSH throughout the stimulation phase of their first cycle until r-hCG administration.
3196511|NCT01223079|Other|r-hFSH (Gonal F) and r-hLH (Luveris)|Patients will be treated with r-hFSH only until they have 2 follicles greater than or equal to 14mm. Patients will then bring 300IU/day of r-hLH until r-hCG administration.
3196512|NCT01223066||Women treated with Macrolane in the breasts|
3196513|NCT01223053|Active Comparator|Active|Topical ketoprofen 10% Cream
3196514|NCT01223053|Placebo Comparator|Placebo Cream|Placebo Cream
3196515|NCT01223040|Experimental|SYSTANE® Balance Lubricant Eye Drops|SYSTANE Balance Lubricant Eye Drops dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
3196516|NCT01223027|Experimental|Dovitinib + best supportive care (BSC)|Patients randomized to the dovitinib treatment arm received 500 mg of dovitinib orally on 5 days on/2 days off dosing schedule.
3196519|NCT01223001|Active Comparator|Duloxetine|Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
3196520|NCT01223001|Placebo Comparator|Sugar pill|Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
3196521|NCT01222988|Other|very low calorie diet program|
3196522|NCT01222975|Experimental|1|Risperidone orally disintegrating tablets of Ranbaxy Laboratories, Ltd
3196523|NCT01222975|Active Comparator|2|Risperdal® M-Tab of Janssen Pharmaceutica Products L.P.
3196524|NCT01222962|Experimental|fed treatment|18 healthy volunteers administered with a single dose of Eurartesim
3196525|NCT01222962|Experimental|Fasted Treatment|18 healthy volunteers treated with a single dose of Eurartesim
3196526|NCT01222949|Experimental|Asian Healthy Volunteers|Asian males with a body weight ≤ 65 kg (12 subjects) Asian females with a body weight ≤ 65 kg (12 subjects)
3196527|NCT01222949|Experimental|Caucasian Healthy Volunteers|Caucasian males with a body weight ≤ 65 kg (12 subjects) Caucasian females with a body weight ≤ 65 kg (12 subjects) Caucasian males with a body weight > 65 kg (24 subjects)
3196528|NCT01222923|Active Comparator|2|Risperdal® M-Tab of Janssen Pharmaceutica Products L.P.
3196529|NCT01222923|Experimental|1|Risperidone 1 mg ODT tablets of Ranbaxy Laboratories, Ltd
3196530|NCT01222910|Experimental|Test|Valacyclovir hydrochloride tablets 1 gm of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
3196531|NCT01222910|Active Comparator|Reference|VALTREX® (valacyclovir HCl) caplets 1 gm of GlaxoSmithKline Research Triangle Park, NC 27709
3196532|NCT01222897|Experimental|Test|Valacyclovir hydrochloride tablets 1 gm of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
3196533|NCT01222897|Active Comparator|Reference|VALTREX® (valacyclovir HCl) caplets 1 gm of GlaxoSmithKline Research Triangle Park, NC 27709
3196534|NCT01222884|Active Comparator|Iron isomaltoside 1000|Iron isomaltoside 1000 (Monofer)administered as 500 mg intravenous single bolus injections OR administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
3196535|NCT01222884|Active Comparator|Iron sucrose|Iron sucrose administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
3196536|NCT01222871|Experimental|Triamcinolone|Triamcinolone soaked nasopore dressing
3196537|NCT01222871|Placebo Comparator|Control Group|Saline soaked sponge
3196538|NCT01222858|Active Comparator|Internet Education Program|Participants receive 12 weekly Internet-based weight loss lessons containing information for modification of diet and activity behaviors.
3196539|NCT01222858|Experimental|Innovative Technology Intervention|Participants receive a 12-week Internet-based eating and activity intervention including multimedia lessons and enhanced self-monitoring of weight loss behaviors with automated feedback.
3196540|NCT01222845|Experimental|Pinhead oat porridge|
3196541|NCT01222845|Experimental|Rolled oat porridge|
3196542|NCT01222832|Experimental|Bacitracin|Nasopore sponge soaked in Bacitracin, no oral antibiotics
3196543|NCT01222832|No Intervention|Saline|Nasopore sponge soaked in saline, routine oral antibiotics
3196544|NCT01222819|Experimental|IV filgrastim|as a single daily dose of 5 mcg/kg (rounded to 300 mcg or 480 mcg) in bolus IV injection, as per manufacturer's recommendations.
3196545|NCT01222819|Active Comparator|SC filgrastim|given as a single daily dose of 5 mcg/kg (rounded to 300 mcg or 480 mcg)
3196546|NCT01222780|Experimental|Marqibo|Marqibo® intravenously (IV) over 60 minutes (+ 10 minutes) every 7 days (+ 3 days) for 4 consecutive weeks (day 1, 8, 15, 22) for a 28-day treatment cycle
3196547|NCT01222767|Experimental|Arm 1|
3196548|NCT01222754|Experimental|1|Radiation with Lenalidomide
3196549|NCT01222715|Experimental|Arm I (vinorelbine tartrate, cyclophosphamide, bevacizumab)|Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1 and 8 and cyclophosphamide IV over 30-60 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1.
3196550|NCT01222715|Experimental|Arm II (vinorelbine tartrate, cyclophosphamide, temsirolimus)|Patients receive vinorelbine tartrate and cyclophosphamide as in arm I. Patients also receive temsirolimus IV over 30-60 minutes on days 1, 8, and 15.
3196551|NCT01222702|Experimental|Cadazolid 250 mg|Subjects received 250 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
3196552|NCT01222702|Experimental|Cadazolid 500 mg|Subjects received 500 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
3196553|NCT01222702|Experimental|Cadazolid 1000 mg|Subjects received 1000 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
3196554|NCT01222702|Active Comparator|Vancomycin 125 mg|Subjects received one vancomycin capsule (125 mg) four times daily and reconstituted placebo-matching cadazolid suspension twice daily for 10 days
3196555|NCT01222689|Experimental|Treatment (erlotinib hydrochloride, selumetinib)|Patients receive selumetinib PO QD and erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3196556|NCT01222663|Other|Standard therapy|Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate
3196557|NCT01222663|Experimental|Hemoperfusion|standard therapy + 2 sessions of hemoperfusion within the first 24 hours
3196558|NCT01222650|Experimental|KSO-0400 Low Dose|
3196559|NCT01222650|Experimental|KSO-0400 High Dose|
3196560|NCT01222650|Experimental|Silodosin|
3196561|NCT01222650|Placebo Comparator|Placebo|
3196562|NCT01222637|Experimental|CetuGEX™, 3-weekly|application q3w
3196563|NCT01222637|Experimental|CetuGEX™ 2-weekly|application q2w
3196564|NCT01222624|Experimental|PankoMab-GEX™, 3-weekly|application, q3w
3196565|NCT01222624|Experimental|Experimental: PankoMab-GEX™, 2-weekly|application q2w
3196566|NCT01222624|Experimental|PankoMab-GEX™, weekly|application q1w
3196567|NCT01222611|No Intervention|Standard HAART|ART with 3 drugs including 2 NRTIs plus a ritonavir boosted PI (different to FPV) or a NNRTI
3196568|NCT01222611|Experimental|HAART inlcuding Fos APV/r|ART with 3 drugs including 2 NRTIs plus ritonavir boosted fosamprenavir
3196569|NCT01222585|Experimental|Treatment|Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours
3196570|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 1)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 54 Gy; Stereotactic Boost to Primary: 10 Gy; Total Dose to Primary: 64 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
3196571|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 2)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 50 Gy; Stereotactic Boost to Primary: 15 Gy; Total Dose to Primary: 65 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
3196572|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 3)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 46 Gy; Stereotactic Boost to Primary: 20 Gy; Total Dose to Primary: 66 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
3196573|NCT01222559|Experimental|co.don chondrosphere®|co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
3196574|NCT01222559|Active Comparator|Micofracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
3196575|NCT01222546|Experimental|CH5132799|
3196576|NCT01222533|Experimental|Tiotropium low|Tiotropium inhalation solution low dose
3196577|NCT01222533|Experimental|Tiotropium medium|Tiotropium inhalation solution medium dose
3196578|NCT01222533|Experimental|Tiotropium high|Tiotropium inhalation solution high dose
3196579|NCT01222533|Active Comparator|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
3196580|NCT01222533|Placebo Comparator|Tiotropium placebo|Placebo inhalation solution
3196581|NCT01222520|Experimental|Telmisartan and amlodipine FDC|once a daily
3196582|NCT01222520|Active Comparator|Telmisartan monotherapy|once a daily
3196583|NCT01222507||Brain Speed Test|60 subjects who complete 60 Second Brain Game and Brain Speed Test
3196584|NCT01222494|Placebo Comparator|Antipsychotic Treated Educational Control|Antipsychotic treated participants randomized to this arm will receive diet and exercise education at monthly intervals with a study clinician or coordinator.
3196585|NCT01222494|Experimental|Antipsychotic Treated Weekly Behavioral Weight Loss|Antipsychotic treated participants randomized to this arm will engage in an evidence-based, 16 week manualized behavioral weight loss intervention that includes weekly meetings and phone check-ins with a trained study therapist.
3196586|NCT01222494|Active Comparator|Non-antipsychotic Treated Weekly Behavioral Weight Loss|Participants assigned to this arm will engage in an evidence-based, 16 week manualized behavioral weight loss intervention that includes weekly meetings and phone check-ins with a trained study therapist.
3196587|NCT01222481||Newly-diagnosed Head and Neck Cancer|
3196588|NCT01222468|Active Comparator|nabilone|nabilone 0.5 mg tablets dose-titrated over an 11-week period to a maximum of 3mg po daily. Subjects are allowed to drop back to the previous dose following a dose increase once if required
3196589|NCT01222468|Placebo Comparator|placebo|look-alike 0.5 mg placebo tablets titrated to a maximum daily dose of 3.0 mg daily over an 11-week phase. Subjects are allowed to drop back to the previous dose following a dose increase once during the 11-week phase if required
3196590|NCT01222455|Experimental|1|Mild hepatic impairment
3196591|NCT01222455|Experimental|2|Moderate hepatic impairment
3196592|NCT01222455|Experimental|3|Severe hepatic impairment
3196593|NCT01222455|Experimental|4|Matched healthy volunteers with normal hepatic function
3196594|NCT01222442|Experimental|1|400 µg AZD3199 + moxifloxacin placebo
3196595|NCT01222442|Experimental|2|1200 µg AZD3199 + moxifloxacin placebo
3196596|NCT01222442|Active Comparator|3|AZD3199 placebo + moxifloxacin 400 mg
3196597|NCT01222442|Placebo Comparator|4|AZD3199 placebo + moxifloxacin placebo
3196598|NCT01222429|Active Comparator|diet following American Diabetes Association guidelines|Participants will follow diets based on ADA guidelines. This group will also receive weekly nutrition classes.
3196599|NCT01222429|Experimental|vegan diet|Participants in the intervention group will follow a low-fat, vegan diet for 20 weeks, and will attend nutrition classes in the form of a weekly support group.
3196600|NCT01222416|Experimental|fluorodeoxyglucose PET/CT (FDG-PET/CT)|A PET/CT scan prior to the initiation of therapy, and then two additional scans following the initiation of therapy. Each patient will have up to three scans in a 6 month time frame.
3196826|NCT01220804||NPDR|Type 2 diabetic patients with nonproliferative diabetic retinopathy (NPDR)
3196601|NCT01222416|Experimental|fluorodeoxythymidine PET/CT (FLT-PET/CT)|A PET/CT scan prior to the initiation of therapy, and then two additional scans following the initiation of therapy. Each patient will have up to three scans in a 6 month time frame.
3196602|NCT01222403|Experimental|Fluad|Subjects aged >65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).
3196603|NCT01222403|Experimental|Vantaflu_aTIV|Subjects aged >65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).
3196604|NCT01222390|Experimental|Contour Profile Tissue Exander|Patients undergoing breast reconstruction using a Contour Profile Tissue Expander (CPX3).
3196605|NCT01222377|Experimental|Arm I|Patients undergo endoscopic breast surgery.
3196606|NCT01222364|Active Comparator|Standard Cord Clamping|
3196607|NCT01222364|Experimental|Delayed Cord Clamping|
3196608|NCT01222351|Experimental|BAY 94-9172|BAY 94-9172 PET/CT
3196609|NCT01222338|Active Comparator|Immunomodulator intervention|Two cohorts or arms of at least 60 subjects each (total 120) with pulmonary TB positive for sputum AFB smear will be randomized in a 1:1 ratio to receive once-daily, tablet of V-5 immunitor in combination with standard ATT for 2 months followed by ATT outside of trial for next 4 months or however long it needs to be.
3196610|NCT01222338|Placebo Comparator|placebo|Control Cohort 1 (60 subjects) will receive standard first-line ATT regimen: (daily Isoniazide (H) 150mg, Rifampicin (R) 300mg, Ethambutol (E) 400mg, and Pyrazinamide (Z) 400mg during first 2 months, followed by H/R three times per week for the next 4 months. Patients also will receive placebo preparation, appearing identical to V-5 immunitor, taken once daily 30 minutes prior or after meal for 2 months
3196611|NCT01222325|Active Comparator|swl 3000 impulses- 60 imp/min|patients in this group were submitted to extracorporeal shockwave lithotripsy (SWL) 3000 impulses at 60 impulses per minute under general anesthesia. Unique session
3196612|NCT01222325|Active Comparator|swl- 4000 impulses - 90 impulses /min|patients in this group were submitted extracorporeal shockwave lithotripsy (swl) to 4000 impulses at 90 impulses per minute under general anesthesia- unique session
3196613|NCT01222312|Active Comparator|Arm A cisplatin|Cisplatin 75 mg/m2, d1 Docetaxel 75 mg/m2, d1 every 3 weeks (d22) max. 6 cycles
3196614|NCT01222312|Experimental|Arm B oxaliplatin|Oxaliplatin 85 mg/m², d1 Docetaxel 50mg/m2, d1 every 2 weeks (d15) max. 8 cycles
3196615|NCT01222299|Experimental|Arm 1 - Low Dose|bepotastine besilate nasal product - low dose
3196616|NCT01222299|Experimental|Arm 2 - Medium Dose|bepotastine besilate nasal product - medium dose
3196617|NCT01222299|Experimental|Arm 3 - High Dose|bepotastine besilate nasal product - high dose
3196618|NCT01222299|Placebo Comparator|Arm 4 - Placebo|placebo comparator nasal product
3196619|NCT01222286|Experimental|IPH2101 0.2 mg/kg|0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
3196620|NCT01222286|Experimental|IPH2101 2 mg/kg|2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
3196621|NCT01222273|Other|Open label|open label Vitamin D
3196622|NCT01222260|Experimental|Treatment Arm|Subjects with AL will receive Bendamustine and Dexamethasone
3196623|NCT01222247|Active Comparator|Betamethasone 3MG/ML|A course of two 2 mL intramuscular (IM) injections containing 12 mg of betamethasone, 24 hours apart
3196624|NCT01222247|Placebo Comparator|Placebo|A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
3196625|NCT01222234|Experimental|Group 1: Cholecalciferol - CKD|Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.
3196626|NCT01222234|Experimental|Group 2: Calcitriol - CKD|Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). They will be administered calcitriol 0.25mcg daily for 8 weeks.
3196627|NCT01222234|Experimental|Group 3: Cholecalciferol - non-CKD|Patients in this arm have low vitamin D levels and normal kidney function. They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.
3196628|NCT01222208|Active Comparator|Oral Nutrition|Subjects will receive an oral nutrition regimen comprised of 50% of their Resting Energy Expenditure (REE) as dextrose and 20% of their REE as pressurized whey protein
3196629|NCT01222208|Placebo Comparator|Peripheral Parenteral Nutrition|Subjects will receive a peripheral parenteral nutrition (PPN) regimen comprised of 50% of their Resting Energy Expenditure (REE) as dextrose and 20% of their REE as amino acids.
3196630|NCT01222195|Experimental|Lenalidomide + Darbepoetin alfa|Lenalidomide 10 mg/day orally days 1-21 and Darbepoetin alfa 200 mcg subcutaneously every 2 weeks of 28 day cycle
3196631|NCT01222182||Eligible plan beneficiaries on atorvastatin|A group of 225 eligible patients would no longer have atorvastatin covered by their prescription plan and would need to be changed to another equivalent anti-hyperlipidemic agent.
3196632|NCT01222169|Experimental|larynx assessment under stimulation|
3196633|NCT01222169|Placebo Comparator|Larynx assessment under stimulation|
3196634|NCT01222156|Experimental|CGCI navigation|Subjects with CGCI navigation to specific target intracardiac anatomical sites
3196635|NCT01222143|Experimental|NOVE-HiDAC and Nilotinib|All patients will be receiving nilotinib combined with mitoxantrone, etoposide and high-dose cytarabine reinduction therapy. Patients achieving complete remission will receive consolidation therapy with nilotinib combined with high-dose cytarabine and mitoxantrone.
3196636|NCT01222117|Experimental|Plasmin Open-label Treatment Group A|Open-label 150 mg Plasmin administered without initial proximal pulse; 5-hour infusion using 10 mL/hour infusion rate.
3196637|NCT01222117|Experimental|Plasmin Open-label Treatment Group B|Open-label 150 mg Plasmin administered with initial proximal pulse; 5-hour infusion using 15 mL/hour infusion rate
3196638|NCT01222117|Experimental|Plasmin Open-label Treatment Group C|Open-label 150 mg Plasmin administered with proximal pulse; 5 hour infusion using 30 mL/hour infusion rate.
3196639|NCT01222117|Experimental|Plasmin Open-label Treatment Group D|Open-label 150 mg Plasmin administered with proximal pulse; 2-hour infusion using 35 mL/hour infusion rate
3196640|NCT01222117|Active Comparator|Plasminogen Activator Blinded Group E|PA administered for five hours at a dose and volume according to the Investigator's clinical judgement/standard practice
3196744|NCT01221415||Femoral Nerve Stimulator|Subjects having orthopedic surgery requiring an femoral peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
3196641|NCT01222117|Placebo Comparator|PA Placebo Blinded Treatment Arm F|PA placebo (normal saline for injection) administered for five hours at a dose and volume according to the Investigator's clinical judgement/standard practice for PA administration
3196642|NCT01222117|Experimental|Plasmin Open-label Treatment Group G|Open-label 150 mg Plasmin administered without pulsing; 5-hour infusion using 60 mL/hour infusion rate
3196643|NCT01222117|Experimental|Plasmin Open-label Treatment Group H|Open-label 150 mg Plasmin administered without pulsing; 2-hour infusion using 75 mL/hour infusion rate
3196644|NCT01222117|Experimental|Plasmin Open-label Treatment Group I|Open-label 150 mg Plasmin administered without pulsing; 5-hour infusion using 30 mL/hour infusion rate with balloon occlusion catheter
3196645|NCT01222117|Experimental|Plasmin Open-label Treatment Group J|Open-label 150 mg Plasmin administered without pulsing; 2-hour infusion using 35 mL/hour infusion rate with balloon occlusion catheter
3196646|NCT01222117|Experimental|Plasmin Open-label Treatment Group M|Open-label 250 mg Plasmin administered without pulsing; 5-hour infusion using 30 mL/hour infusion rate with balloon occlusion catheter
3196647|NCT01222104||Angio-Seal|Angio-Seal attempted and/or deployed
3196648|NCT01222104||Not deployed|Other method of closure
3196649|NCT01222091|Active Comparator|Propranolol, Then Placebo|Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
3196650|NCT01222091|Placebo Comparator|Placebo, Then Propranolol|Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
3196651|NCT01222078|Experimental|otelixizumab|otelixizumab
3196652|NCT01222065||Glaucoma/Normal|Two groups will be studies: patients with glaucomatous visual field loss and age and gender matched normal patients without visual field loss
3196653|NCT01222052|Experimental|Arm A Taxane-containing|3 courses FEC q3weeks followed by 3 courses Docetaxel q3weeks
3196654|NCT01222052|Active Comparator|Arm B standard anthracyclin|6 courses of FEC q3weeks
3196655|NCT01222052|No Intervention|Observation|
3196656|NCT01222039|Experimental|Conventional treatment plus high dose: 3x10e6 cells / Kg.|Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
3196657|NCT01222039|Experimental|Conventional treatment plus low dose: 1x10e6 cells / Kg|Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
3196658|NCT01222026|Active Comparator|Strontium Ranelate|Receiving Strontium Ranelate + Ca/Vitamin-D
3196659|NCT01222026|Placebo Comparator|Placebo|Receiving Placebo + Ca/Vitamin D
3196660|NCT01222013|Experimental|Imatinib Mesylate|
3196661|NCT01222000|Experimental|right controlled against moisturizing cream|
3196662|NCT01222000|Experimental|left controlled against moisturizing cream|
3196663|NCT01221987||Cohort A|Females > 21 years of age, diagnosed with invasive cervical cancer
3196664|NCT01221987||Cohort B|Females > 21 years of age, diagnosed with moderate or severe cervical intraepithelial neoplasia
3196665|NCT01221974|Experimental|Essure,Hydrosalpinx, Infertility|
3196666|NCT01221948|Experimental|Deep Brain Stimulation|Rechargeable Deep Brain Stimulation System
3196667|NCT01221935||Patients initiated on Pristiq as a first line treatment|
3196668|NCT01221935||Patients initiated on Pristiq as a 2nd-line treatment|
3196669|NCT01221935||Patients initiated on a SNRI or SSRI as a first-line treatment|
3196670|NCT01221935||Patients initiated on a SNRI or SSRI as a 2nd-line treatment|
3196671|NCT01221922|Experimental|Acne treatment|Treatment of acne scars
3196672|NCT01221909|Experimental|Tranexamic acid single dose of 500mg|
3196673|NCT01221909|Placebo Comparator|Saline|
3196674|NCT01221896||Hyperparathyroidism|Patients with hyperparathyroidism, prior to surgery.
3196675|NCT01221883|Placebo Comparator|Placebo|Placebo capsule in ER, identical follow up like those in the active arm.
3196676|NCT01221883|Experimental|Diazepam|10 mg of Diazepam mg orally at ER only (a single administration)
3196677|NCT01221870|Experimental|Tesetaxel once every 3 weeks|Tesetaxel 27 mg/m2 orally once every 21 days for up to 12 months
3196678|NCT01221870|Experimental|Tesetaxel once weekly|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks in a 28-day cycle for up to 12 months
3196679|NCT01221857|Experimental|NiCord|
3196680|NCT01221844|Experimental|Lactoferrin treatment in HT pregnacies|Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of one capsule of 100 mg of bLf (Lattoglobina, Grunenthal, Italy) twice a day before meals. In twin pregnancies or in severe anemia, HT pregnant women are treated until delivery with two capsules of 100 mg of bLf twice a day, before meals.
3196681|NCT01221844|Active Comparator|Ferrous sulfate in HT pregnancies|Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of 520 mg of ferrous sulfate (Ferro-Grad, Abbott Laboratories, USA), once a day during meal.
3196682|NCT01221831|Experimental|estetrol dose 1 / P1|
3196683|NCT01221831|Experimental|estetrol dose 1 / P2|
3196684|NCT01221831|Active Comparator|estradiol valerate/dienogest pill|
3196685|NCT01221831|Experimental|estetrol dose 2 / P1|
3196686|NCT01221831|Experimental|estetrol dose 2 / P2|
3196687|NCT01221818|Experimental|1|
3196688|NCT01221818|Experimental|2|
3196689|NCT01221818|Experimental|3|
3196690|NCT01221818|Experimental|4|
3196691|NCT01221818|Experimental|5|
3196692|NCT01221818|Experimental|6|
3196745|NCT01221402|Experimental|Extended-release niacin|
3196746|NCT01221402|Placebo Comparator|Placebo|
3196827|NCT01220804||Control Population|Healthy volunteers
3196878|NCT01220401|Experimental|ERRT-M|Exposure, Relaxation, and Rescripting Therapy for military populations. 4 sessions.
3196693|NCT01221792|Active Comparator|carvedilol|Patients randomized to carvedilol will be administered doses ranging from 6.25 to 15.625 mg/day using a flexible-dosing model. After a 1 week titration, investigators my increase daily dose by 6.25 mg/day at weeks 1 and 2 for a maximum dose of 15.625 mg/day. Weeks 3-4 will patients will remain on a stable, tolerable dose. At week 5 patients will have a 1 week taper.
3196694|NCT01221792|Placebo Comparator|Sugar Pill|Patients randomized to placebo will follow same dosing guidelines as if they were in the active comparator arm, carvedilol.
3196695|NCT01221779|Placebo Comparator|sham tDCS|
3196696|NCT01221779|Experimental|anodal tDCS|
3196697|NCT01221753|Experimental|TPF Induction Chemotherapy followed by Chemoradiotherapy|Patients received 3 cycles (21 days each) of TPF induction chemotherapy: docetaxel 75 mg/m2 IV day 1; cisplatin 100 mg/m2 IV day 1 (carboplatin substitute permitted); 5-FU 1000 mg/m2/day IV pump continuous days 1-4. Concurrent chemoradiotherapy followed 4-6 weeks after day 1 of cycle 3 TPF induction: cetuximab 400 mg/m2 IV loading dose 1 week prior and 250 mg/m2 IV weekly (panitumumab substitute permitted); carboplatin AUC 1.5 (Calvert formula) IV weekly; Intensity modulated radiation therapy (IMRT)-response based dosing for 6-7 weeks.
3196698|NCT01221740|Experimental|Milnacipran|"The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period.~12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8"
3196699|NCT01221727|Other|Midazolam|All 27 subjects will receive midazolam.
3196700|NCT01221727|Active Comparator|Denosumab|Eighteen (18) subjects will receive denosumab.
3196701|NCT01221714||Active/Placebo|ACTIVE VITAMIN; PLACEBO OMEGA MAX
3196702|NCT01221714||Active/Active|ACTIVE VITAMIN; ACTIVE OMEGA MAX
3196703|NCT01221714||Placebo/Active|PLACEBO VITAMIN; ACTIVE OMEGA MAX
3196704|NCT01221714||Placebo/Placebo|PLACEBO VITAMIN; PLACEBO OMEGA MAX
3196705|NCT01221701|Experimental|In-Home Cognitive Behavioral Therapy|Mothers will receive 15 weekly sessions of IH-CBT plus one booster session scheduled 1 month later.
3196706|NCT01221701|No Intervention|typical home visitation|Standard of care in home visitation in which mothers can receive treatment in the community if they choose.
3196707|NCT01221688|Other|group 2|patients without proven axillary involved nodes will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
3196708|NCT01221688|Experimental|group 1|group 1 : patients with proven involved axillary nodes will undergo SLNB and complete level I-II axillary lymphadenectomy.
3196709|NCT01221636|Other|Low Metal Abatacept|Reference
3196710|NCT01221636|Experimental|High Metal Abatacept|
3196711|NCT01221623|Experimental|AA4500|collagenase clostridium histolyticum
3196712|NCT01221623|Placebo Comparator|Placebo|Placebo
3196713|NCT01221610|Experimental|Drug Releasing Balloon|Passeo-18 Lux Drug Releasing Balloon catheter
3196714|NCT01221610|Active Comparator|Standard PT A (POBA)|Uncoated Passeo-18 PTA catheter
3196715|NCT01221597|Experimental|AA4500|collagenase clostridium histolyticum
3196716|NCT01221597|Placebo Comparator|Placebo|placebo
3196717|NCT01221584||1|Subject 18 years of age or older on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks..
3196718|NCT01221571|Experimental|AFM13|IV (intravenous) infusion, dose escalation
3196719|NCT01221558|Experimental|6mg lycopene|
3196720|NCT01221558|Experimental|15mg lycopene|
3196721|NCT01221558|Placebo Comparator|placebo|
3196722|NCT01221545|Experimental|A - AZD1656|AZD1656
3196723|NCT01221545|Placebo Comparator|B - Placebo|Placebo
3196724|NCT01221532|Experimental|SHHE Peridischarge intervention|Patients receive the Support from Hospital to Home (SHHE) Peridischarge Intervention plus usual care
3196725|NCT01221532|No Intervention|Usual Care|
3196726|NCT01221519|Experimental|1|AZD1656
3196727|NCT01221519|Experimental|2|AZD1656
3196728|NCT01221519|Experimental|3|AZD1656
3196729|NCT01221493|Experimental|Cryo biospy|
3196730|NCT01221480||Beta Blocker Use|
3196731|NCT01221480||No beta blocker use|
3196732|NCT01221467|Active Comparator|Overnight closed-loop combined with real-time CGM|
3196733|NCT01221467|Active Comparator|Real-time CGM alone|
3196734|NCT01221454|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
3196735|NCT01221454|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation
3196736|NCT01221441|Experimental|TissueGene-C|TissueGene-C at 3 x 10e7 cells per injection (intraarticular)
3196737|NCT01221441|Placebo Comparator|Placebo Control|Normal Saline injection
3196738|NCT01221428|Experimental|umbilical cord mesenchymal stem cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells,one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery.
3196739|NCT01221415||Interscalene Ultrasound|Subjects having orthopedic surgery requiring an interscalene peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
3196740|NCT01221415||Interscalene Nerve Stimulator|Subjects having orthopedic surgery requiring an interscalene peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
3196741|NCT01221415||Popliteal Ultrasound|Subjects having orthopedic surgery requiring an popliteal peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
3196742|NCT01221415||Popliteal Nerve Stimulator|Subjects having orthopedic surgery requiring an popliteal peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
3196743|NCT01221415||Femoral Ultrasound|Subjects having orthopedic surgery requiring an femoral peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
3196779|NCT01221129||Dietary Restriction|
3196962|NCT01219855|Placebo Comparator|Cohort 2: Sugar Capsule|
3196747|NCT01221389|Active Comparator|Colloid Control|Patients will receive 2 units of 250 ml of hydroxyethylated starch solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
3196748|NCT01221389|Active Comparator|Plasma|Patients will receive 2 units of AB+ plasma once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
3196749|NCT01221376|Experimental|Imatinib Mesylate|
3196750|NCT01221363|Active Comparator|Lifestyle counselling|Theory based individually tailored lifestyle counselling aimed at reduction of sitting time during leisure time and at work. Four individual sessions over a six months period.
3196751|NCT01221363|No Intervention|Control group|No intervention control group
3196752|NCT01221350|Experimental|Lipoic acid|Lipoic acid 600 mg oral dose (two 300 mg capsules) once daily in the morning during 60 days
3196753|NCT01221350|Placebo Comparator|Placebo|Placebo (two placebo capsules) orally once daily in the morning during 60 days
3196754|NCT01221337|Other|haemodialyzer EVODIAL-haemodialyzer VIE|"Equal number of patients will start either with the haemodialyzer VIE 2,1 or EVODIAL 2,2 followed by a wash out period, before starting the other haemodialyzer."
3196755|NCT01221337|Other|haemodialyzer VIE-haemodialyzer Evodial|"Equal number of patients will start either with the haemodialyzer VIE 2,1 or EVODIAL 2,2 followed by a wash out period, before starting the other haemodialyzer."
3196756|NCT01221324||Patients after open resection of colorectal cancer|
3196757|NCT01221311|Experimental|Fully Covered Metallic Stent|Among patients randomized to the covered, self-expandable metallic stent (cSEMS) group, the endoscopist will deploy a cSEMS of sufficient length to traverse the papilla. Dilation will not be performed unless the cSEMS deployment catheter cannot be advanced over a guidewire beyond the stricture. A biliary sphincterotomy may be performed at the discretion of the treating endoscopist.
3196758|NCT01221311|Active Comparator|Plastic Stent|Patients randomized to the plastic stent (PS) group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and multiple (as many as technically feasible) PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing endoscopic retrograde cholangiopancreatography (ERCP), until the stricture has been obliterated using clinical and fluoroscopic criteria (details below).
3196759|NCT01221298|Experimental|ABT-450/r and ABT-072, plus ribavirin (RBV)|ABT-450/r (150/100 mg) once daily (QD) and ABT-072 (400 mg) QD plus weight-based RBV divided twice daily (BID) for 12 weeks.
3196760|NCT01221285|Experimental|German cockroach allergenic extract|Participants will receive weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
3196761|NCT01221272|Experimental|Ranolazine/Placebo|Participants received ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.
3196762|NCT01221272|Experimental|Placebo/Ranolazine|Participants received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.
3196763|NCT01221259|Experimental|Drug E2212|
3196764|NCT01221259|Placebo Comparator|Placebo|
3196765|NCT01221246|Experimental|GM602|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
3196766|NCT01221246|Placebo Comparator|Placebo Comparator|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio; then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients receive Placebo.
3196767|NCT01221233|Experimental|1|Neuromuscular Electrical Stimulation plus Posterior Stabilization Exercises
3196768|NCT01221233|Active Comparator|2|Posterior Lumbar Stabilization Exercises
3196769|NCT01221220|Active Comparator|Behavioral Treatment|Six-month, family-based, group, behavioral weight control program
3196770|NCT01221220|Experimental|Behavioral Treatment plus Environmental Strategies|Six-month, family-based, group, behavioral weight control program plus home-based environmental intervention
3196771|NCT01221207|Active Comparator|Device - Total Contact Cast (TCC)|A total contact cast (TCC) is a special cast technique that is used to take the pressure and shear stress off the ulcer to assist in the healing.
3196772|NCT01221207|Active Comparator|Removable Cast Walker (RCW)|The removable cast walker (RCW) is a commercial product that is similar to a cast. It is secured with Velcro straps around the foot and leg and it is also effective at removing the pressure and shear stress on the foot.
3196773|NCT01221207|Active Comparator|Instant Total Contact Cast (ITCC)|The instant total contact cast (ITCC) is a technique that uses the removable cast walker, but secures it so it cannot be removed between clinic visits and evaluation by the subject or the physician.
3196774|NCT01221194|Active Comparator|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
3196775|NCT01221194|Active Comparator|PFC Stockings|The stocking therapy group will be given PFC shear reducing stockings to wear.
3196776|NCT01221181|Experimental|Eculizumab|Eculizumab 900 mg IV one a week for 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.
3196777|NCT01221168||Men with or without Prostate Cancer|"Men with a histological confirmed prostate cancer, and their family members in case of hereditary prostate cancer.~Men with no prostate cancer after a screening procedure for this disease, so that their biological samples can be compared to those of men with prostate cancer."
3196778|NCT01221142|Experimental|Hypothermia|Device: Cincinnati Sub-Zero Hyper-Hypothermia to core temperature of 34C for 24 hours, rewarming rate 0,5/2h until the patient reaches 36,5C
3196780|NCT01221116|No Intervention|1: Type of surgery|Two types of patients are compared (placebo vs levosimendan): CABG - coronary artery bypass grafting and AVR - aortic valve replacement (either with or without CABG - coronary artery bypass grafting)
3196781|NCT01221103|Experimental|DOT|Combination of dexamethasone, ofatumumab and bendamustine
3196782|NCT01221090|Experimental|Personal Digital Assistant|Individuals in this arm were taught to use a diabetes self-care software, Diabetes Pilot™ (Digital Altitudes, Arlington Heights, IL), developed for PalmOS® (Palm, Sunnyvale, CA) which was loaded on to compatible PDAs, the Tungsten™ E2 handheld device. The Diabetes Pilot allowed participants to monitor their blood glucose, blood pressure, medication usage, physical activity, and dietary intake by tracking these measures in an electronic diary.
3196783|NCT01221090|Active Comparator|CDSMP|6-week, classroom-based program for diabetes self-management. The CDSMP, developed by Stanford University, equipped participants with the education and skill sets needed to take a more proactive approach in managing their chronic condition(s) and related symptoms.
3196784|NCT01221090|Active Comparator|PDA/CDSMP|Combined intervention
3196785|NCT01221090|No Intervention|Control|Usual Care
3196786|NCT01221077|Experimental|Arm A: Erolitinib plus OSI-906|As of 01 March 2013, OSI-906 is no longer being administered
3196787|NCT01221077|Placebo Comparator|Arm B: Eroltinib plus Placebo|As of 01 March 2013, the matching placebo is no longer being administered
3196788|NCT01221064|Other|Early drainage removal|Patients randomised to early drainage removal arm will have the drain removed in postoperative day 1. Lymph will be punctured on a regular basis
3196789|NCT01221064|Other|Late drainage removal|Patients randomised to late drainage removal arm will have the drains kept until total daily drainage is 30ml and then removed
3196790|NCT01221051|Active Comparator|oxytocin|early cord clamping, administration of oxytocin 10 IU i.v, controlled cord traction, uterine massage after placenta expulsion
3196791|NCT01221051|Placebo Comparator|saline solution|early cord clamping, wait for signs of placenta detachment, encourage the woman to push out placenta by her own effort, uterine massage after placenta expulsion
3196792|NCT01221038||group 1|young women not using OC
3196793|NCT01221038||group 2|young women using OC
3196794|NCT01221038||group 3|young men (database)
3196795|NCT01221025|Experimental|parecoxib|Parecoxib, a water-soluble prodrug of valdecoxib, is a high-selective COX-2 inhibitor that is first available for intravenous administration.
3196796|NCT01221012||men wearing Semipermeable garment|
3196797|NCT01221012||air permeable garment type BP2|
3196798|NCT01221012||air permeable garment type BP3|
3196799|NCT01221012||air permeable garment type MO|
3196800|NCT01221012||air permeable garment type BP1|
3196801|NCT01220999|Experimental|111In-CS-1008, CS-1008|
3196802|NCT01220986||Right hepatectomy|Intervals from inflow division.
3196803|NCT01220973|Experimental|Atorvastatin and Celecoxib|
3196804|NCT01220960|Experimental|Art Therapy intervention group|For participants who will be part of the art therapy intervention, the art therapy group will be a closed group for eight women with breast cancer who are in treatment and recently have had surgery. The group will meet once a week for two hours over a period of 8 weeks, and will focus on exploring the expressive capabilities of art making in a supportive group. This group will be held in the conference room at the Cedars Breast Clinic. Each week will revolve around a theme that pertains to the experience of women living with breast cancer, and will be guided by the women's needs in the group. A broad range of art materials will be made available and various art techniques explored. No art experience is necessary. The intervention group will also need to fill out simple questionnaires before the art therapy groups starts and after the group finishes
3196805|NCT01220960|No Intervention|Control Group|The group not assigned to the intervention group will be asked to fill out questionnaires at two separate times (before and after the intervention group is run). The Control group will be offered the opportunity to join an open art therapy group upon completing the questionnaires.
3196806|NCT01220947|Experimental|Group A|Danoprevir 200 mg twice a day (BID) + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
3196807|NCT01220947|Experimental|Group B|Danoprevir 100 mg BID + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
3196808|NCT01220947|Experimental|Group C|Danoprevir 50 mg BID + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
3196809|NCT01220947|Experimental|Group D|Danoprevir 100 mg BID + ritonavir 100 mg + Pegasys 180 μg sc qw + Copegus 1000 mg or 1200 mg po daily for 12 weeks or 24 weeks
3196810|NCT01220947|Active Comparator|Group E|Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 48 weeks
3196811|NCT01220934||Cohort|
3196812|NCT01220921|Experimental|Lumbar Microdiscectomy|Patients aged 18-80 with symptomatic lumbar disc herniation resulting in single nerve root compression recalcitrant to non-invasive therapies for at least 6 weeks
3196813|NCT01220921|Experimental|Single-Level Lumbar Fusion|Patients aged 18-80 with symptomatic grade I degenerative or isthmic spondylolisthesis with mechanical back pain with or without radiculopathy recalcitrant to non-invasive therapies for at least 3 months
3196814|NCT01220908|Experimental|permanent Coil(s) implant, QOL measure|Coil implantation as treatment. Treatment is permanent implant.
3196815|NCT01220895|Experimental|ACT (mutlimer selection) plus standard therapy|Adoptive Cellular Therapy prepared using Multimer Selection in combination with standard best available antiviral drug therapy
3196816|NCT01220895|Active Comparator|Best available antiviral drug therapy|
3196817|NCT01220882|No Intervention|Radiographic skeletal age assessment|Participant group studied will include all pediatric patients presenting to our institution with a unilateral or bilateral SCFE. Patients with metabolic and endocrine conditions will be included.
3196818|NCT01220869|Experimental|Degarelix|
3196819|NCT01220856|Experimental|Reparixin|Reparixin + Immunosuppression
3196820|NCT01220856|No Intervention|No experimental intervention|Immunosuppression only
3196821|NCT01220843|Placebo Comparator|Placebo|DOuble blinded, same labels than the active drug same dosage (2 tablets 3 times per day) during the meal
3196822|NCT01220843|Experimental|Sevelamer carbonate|DOuble blinded, dosage 2 tablets 3 times per day corresponding to 4.8/d to taken during meals
3196828|NCT01220791|Active Comparator|Follicular Medrol|In an Antagonist protocol for IVF patients will also receive 4mg tabl. Methylprednisolone twice a day from the day 2 of ovarian stimulation and until the day of the pregnancy test on luteal day-14 post oocyte retrieval
3196829|NCT01220791|Placebo Comparator|No medrol group|Patients will receive only Antagonist protocol for IVF as usual
3196830|NCT01220778|Experimental|Exercise|
3196831|NCT01220778|No Intervention|Control|
3196832|NCT01220765|No Intervention|Standard care|Patients randomized to the standard care group receive standard of care using pulse oximetry
3196833|NCT01220765|Experimental|Capnography|In the intervention group capnography is measured using a cannula under the nose connected to the capnograph. The capnographic device displays respiratory rate, end-tidal carbon dioxide (ETCO2) levels, and continuous waveforms.
3196834|NCT01220752|Experimental|IMRT + carbon ion boost|(8 x 3 GyE) carbon ion therapy followed by 50 Gy IMRT (2 Gy/ Fx)corresponding to a total dose of approximately 74 GyE.
3196835|NCT01220739|Sham Comparator|IV tPA + Sham Transcranial Laser Therapy|Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by sham transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset.
3196836|NCT01220739|Active Comparator|IV tPA +Transcranial Laser Therapy|Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset.
3196837|NCT01220726|Active Comparator|Botox|Botox 200U
3196838|NCT01220726|Placebo Comparator|Placebo|
3196839|NCT01220713|Experimental|Treatment 1--1.5 atm abs|
3196840|NCT01220713|Experimental|Treatment 2--2.0 atm abs|
3196841|NCT01220713|Sham Comparator|Placebo--equivalent to breathing air|
3196842|NCT01220700|Experimental|Triclosane|triclosan coated suture material
3196843|NCT01220700|Active Comparator|Control|ordinary suture material
3196844|NCT01220687|Placebo Comparator|Placebo 20ppm|Nitrogen at 20 ppm at the beginning of study start with gradual taper at 10 minutes of the study and completely off by 17 minutes of the study
3196845|NCT01220687|Experimental|iNO 20 ppm|Nitric Oxide 20 ppm at the beginning of study start with gradual taper at 10 minutes of the study and completely off by 17 minutes of the study
3196846|NCT01220674||community dwelling older adults, normal controls|men and women 55 years of age or older who are cognitively intact.
3196847|NCT01220674||community dwelling older adults, mild cognitive impairment|men and women 55 years of age or older who have minimal cognitive decline (MMSE 20-24).
3196848|NCT01220661|Experimental|One dose|One dose prophylactic antibiotic
3196849|NCT01220648|Experimental|Nilotinib in conjunction with low dose interferon alfa|
3196850|NCT01220635|Experimental|Skill Group Program|Positive Thoughts and Actions Program
3196851|NCT01220635|Active Comparator|Individual Support Program|Measure of Adolescent Potential for Suicide (MAPS) - modified
3196852|NCT01220622|Active Comparator|Nimodipine|
3196853|NCT01220622|Placebo Comparator|Placebo|
3196854|NCT01220609|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3196855|NCT01220596|Experimental|Sequential therapy|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
3196856|NCT01220596|Active Comparator|Peginterferon alfa-2a monotherapy|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
3196857|NCT01220583|Experimental|Arm I|Patients undergo 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) 5 days a week for 6-6.5 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiotherapy.
3196858|NCT01220583|Experimental|Arm II|Patients undergo 3D-CRT or IMRT as in arm I.
3196859|NCT01220570|Experimental|Ridaforolimus + Dalotuzumab|Ridaforolimus (MK-8669) + Dalotuzumab (MK-0646)
3196860|NCT01220570|Experimental|Ridaforolimus|Ridaforolimus (MK-8669)
3196861|NCT01220570|Experimental|Dalotuzumab|Dalotuzumab (MK-0646)
3196862|NCT01220557|Experimental|PRIMAS group|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
3196863|NCT01220557|Active Comparator|Control group|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
3196864|NCT01220544|Experimental|HaploTransplant with NK cells|Haploidentical transplantation of mega-dose CD34+ hematopoetic stem cells with transfer of CD56+CD3-NK cells at day +2
3196865|NCT01220518|Active Comparator|CT-P13|infliximab
3196866|NCT01220518|Active Comparator|Remicade|infliximab
3196867|NCT01220492|Experimental|conventional plus MSC treatment|participants will receive conventional treatment plus a dose of MSC from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.
3196868|NCT01220492|Experimental|conventional plus placebo treatment|participants will receive conventional plus placebo treatment from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.
3196869|NCT01220479|No Intervention|Control Healthy|
3196870|NCT01220479|No Intervention|Control Diabetic|
3196871|NCT01220479|Experimental|Exercise Diabetic|
3196872|NCT01220479|Experimental|Exercise Healthy|
3196873|NCT01220466|Experimental|Refractive Error|
3196874|NCT01220440|Experimental|Methylphenidate, Dexamphetamine, Placebo|The 36 participants received each of the three medications for two weeks. Six different medication sequences are possible. The participants are randomly chosen for each of the six sequences in a way that allow six participants into each of the six sequences to balance the sequences.
3196875|NCT01220427||Clinical high-risk prostate cancer, radical prostatectomy|
3196876|NCT01220414|Active Comparator|Men|
3196877|NCT01220414|Active Comparator|Women|
3196879|NCT01220388|Experimental|L-lysine|11 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
3196880|NCT01220388|Placebo Comparator|placebo|11 days treatment with study drug, order of periods (L-lysine or placebo) being sorted out.
3196881|NCT01220375|Experimental|1|Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell release from bone marrow and HSC movement into the peripheral circulation.
3196882|NCT01220362|Other|Group 1|Bupivacaine 0.125%
3196883|NCT01220362|Other|Group 2|Bupivacaine 0.125%/Fentanyl 2mcg/ml
3196884|NCT01220349|Experimental|Echocardiographic 2D strain analysis|
3196885|NCT01220336|Experimental|Health Coaching|
3196886|NCT01220323|Active Comparator|direct current stimulation|The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm.
3196887|NCT01220323|Sham Comparator|sham stimulation|
3196888|NCT01220310|Experimental|Intervention|Online diabetes workshop observation and learning sessions
3196889|NCT01220297|Experimental|Carmustine Etoposide Cyclophosphamide|Carmustine + Etoposide + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.
3196890|NCT01220297|Experimental|FTBI + Cyclophosphamide|FTBI + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.
3196891|NCT01220284|Experimental|Satraplatin in combo with vinorelbine|"Escalating doses of satraplatin and oral vinorelbine in subsequent cohorts of 3-6 patients according to the type and severity grade of acute toxicities observed during cycle 1.~The dose escalation process will be discontinued once the MTD is achieved."
3196892|NCT01220271|Experimental|Phase 1: 160 mg LY2157299|"During Radiation therapy:~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~LY2157299: 80 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.~Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~LY2157299: 80 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
3196893|NCT01220271|Experimental|Phase 1: 300 mg LY2157299|"During Radiation therapy:~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~LY2157299: 150 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.~Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~LY2157299: 150 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
3196894|NCT01220271|Experimental|Phase 2: Established dose LY2157299|"During Radiation therapy:~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~LY2157299: Phase 1 established dose taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.~Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~LY2157299: Phase 1 established dose taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
3196895|NCT01220271|Experimental|Phase 2: no LY2157299 (control)|"During Radiation therapy:~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
3196896|NCT01220258|Experimental|Azithromycin ophthalmic solution, 1%|
3196897|NCT01220245|Experimental|Heparin-bonded endoluminal fempop bypass|Heparin-bonded ePTFE endoluminal femoro-popliteal bypass versus surgical femoro-popliteal bypass
3196898|NCT01220245|Active Comparator|Surgical femoro-popliteal bypass|Surgical femoro-popliteal bypass.
3196899|NCT01220232|Active Comparator|Abacavir/Lamivudine|
3196900|NCT01220232|Experimental|Lersivirine + Abacavir/Lamivudine|
3196901|NCT01220219|Experimental|Pregabalin controlled release, 82.5 mg|
3196902|NCT01220219|Experimental|Pregabalin controlled release, 165 mg|
3196903|NCT01220219|Other|Pregabalin immediate release, 75mg|Reference Treatment
3196904|NCT01220206|Placebo Comparator|Placebo|2 placebo capsules daily
3196905|NCT01220206|Experimental|one POMx capsule|One POMx capsule, one placebo capsule daily
3196906|NCT01220206|Experimental|2 POMx Capsules|2 POMx Capsules daily
3196907|NCT01220193||Normal cornea|
3196908|NCT01220193||Post laser refractive surgery|
3196909|NCT01220193||Cornea pathology|
3196910|NCT01220193||Cataract surgery|
3196911|NCT01220180||Epilepsy|
3196912|NCT01220180||Neuropathic Pain|
3196913|NCT01220180||Fibromyalgia|
3196914|NCT01220167|Experimental|Ondansetron Orally Dissolving Filmstrip|
3196915|NCT01220167|Active Comparator|Ondansetron Orally Disintegrating Tablet|
3196916|NCT01220154|Experimental|Carboplatin Paclitaxel & Bevacizumab|Intraperitoneal carboplatin with weekly intravenous paclitaxel and intravenous bevacizumab
3196917|NCT01220141||A|
3196918|NCT01220128|Experimental|Cohort A-WT1 Group|This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of WT1 ASCI according to the treatment schedule.
3196919|NCT01220128|Placebo Comparator|Cohort A-Placebo Group|This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
3196920|NCT01220128|Experimental|Cohort B-WT1 Group|This group included breast cancer patients who received WT1 ASCI, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
3196921|NCT01220128|Placebo Comparator|Cohort B-Placebo Group|This group included breast cancer patients who received placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
3196922|NCT01220128|Experimental|Cohort C-WT1 Group|This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of WT1 ASCI, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
3196923|NCT01220128|Placebo Comparator|Cohort C-Placebo Group|This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of placebo, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
3196924|NCT01220128|Experimental|Cohort D-WT1 Group|This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer, who received WT1 ASCI, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
3196925|NCT01220128|Experimental|Cohort E-WT1 Group|This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer who were to receive WT1 ASCI, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule. Enrolment in this group was to take place in case of absence of a safety signal and of an adequate induction of an immune response by WT1 ASCI in Cohort D.
3196926|NCT01220128|Placebo Comparator|Cohort E-Placebo Group|This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer who were to receive placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule. Enrolment in this group will take place in case of absence of a safety signal and of an adequate induction of an immune response by WT1 ASCI in Cohort D.
3196927|NCT01220115||No treatment|Patients aged 2 to less than 12
3196928|NCT01220115||No treatment patients aged 12 to less than 18|Patients aged 12 to less than 18
3196929|NCT01220115||No treatment Patients greater than 18 years|patients greater than 18 years
3196930|NCT01220089|Active Comparator|Standard maintenance|During months 7 to 18, individuals in the Standard Maintenance condition will receive informational handouts by mail (or e-mail) regarding weight maintenance.
3196931|NCT01220089|Active Comparator|Intensified Maintenance|"During months 7 to 18, individuals in the Intensified Maintenance condition will continue to have monthly in-person visits with the weight loss counselor (Weight Coach)."
3196932|NCT01220076|Experimental|Tamoxifene|
3196933|NCT01220050|Experimental|Paricalcitol|
3196934|NCT01220050|Active Comparator|Standard therapy|
3196935|NCT01220037|Experimental|Young regular diet|During the time of the study this group will adhere to a standardized regular diet.
3196936|NCT01220037|Experimental|Young low protein diet|During the time of the study this group will adhere to a standardized low protein diet.
3196937|NCT01220037|Experimental|Young high protein|During the time of the study this group will adhere to a standardized high protein diet.
3196938|NCT01220037|Experimental|Elderly|During the time of the study this group will adhere to a standardized high protein diet
3196939|NCT01220024|Experimental|2, 5x5cm bupivacaine collagen sponges|
3196940|NCT01220024|Placebo Comparator|2, Placebo collagen sponges|
3196941|NCT01220011|Experimental|NO INTERVENTION|
3196942|NCT01220011|Active Comparator|fetoscopic laser|
3196943|NCT01219998||NGAL Kinetics in neonates|to describe postoperative kinetics of urinary NGAL in neonates and to identify the threshold for accurate prediction of severe AKI requiring RRT in neonates and infants undergoing cardiac surgery with cardiopulmonary bypass
3196944|NCT01219985|Experimental|Investigation arm|"standard and respiratory-gated PET acquisitions  for patients included in the trial."
3196945|NCT01219972||Allografted patients|"All consecutive patients who underwent an allogeneic blood stem cells transplantation performed at saint Louis hospital during the study recruitment period~if alive at 100 days post-transplant~and who gave informed consent"
3196946|NCT01219959|Active Comparator|Non-glucose Sparing|Dianeal only
3196947|NCT01219959|Experimental|Glucose Sparing|Dianeal, Extraneal, Nutrineal
3196948|NCT01219946||1|Patients with Chronic Obstructive Pulmonary Disease
3196949|NCT01219933|Experimental|1|
3196950|NCT01219920|Active Comparator|FOLFIRI|Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
3196951|NCT01219920|Experimental|FOLFOXIRI|Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
3196952|NCT01219907|Experimental|Arm I|"VACCINE THERAPY: Patients receive HER2 peptide vaccine intradermally once weekly for 3 weeks.~CHEMOTHERAPY: Patients receive cyclophosphamide IV on day -1.~IMMUNOTHERAPY: Patients receive ex vivo-expanded HER2 specific T-cell IV over 30 minutes on days 1, 10, and 20."
3196953|NCT01219894||RUTTS Score <30%|Patients with evidence of complete healing of stent at 3 months
3196954|NCT01219894||RUTTS<30%|Group with evidence of incomplete healing of the stent
3196955|NCT01219881|Active Comparator|Desflurane|Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Desflurane.
3196956|NCT01219881|Active Comparator|Sevoflurane|Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Sevoflurane.
3196957|NCT01219868|Experimental|Physician-nurse team|
3196958|NCT01219855|Experimental|Cohort 1: CTAP101 Capsules 60µg|
3196959|NCT01219855|Experimental|Cohort 1: CTAP101 Capsules 90µg|
3196960|NCT01219855|Placebo Comparator|Cohort 1: Sugar Capsule|
3196961|NCT01219855|Experimental|Cohort 2: CTAP101 Capsules 30µg|
3196963|NCT01219842|Active Comparator|INVASIVE (INV) group|Modern endovascular and/or open revascularization according to the recommendations in the TASC II document.
3196964|NCT01219842|Active Comparator|NON-INVASIVE (NON) group|Patients receiving only best medical treatment (BMT).
3196965|NCT01219829||Family History patients|Patients with a strong family history of pancreatic cancer or with a genetic syndrome that puts them at risk for pancreas cancer.
3196966|NCT01219829||Recurrence patients|Patients who underwent surgery for pancreatic cancer and developed tumor recurrence after surgery
3196967|NCT01219816|Experimental|Patients under 60 years|Hyper CVAD regimen + Epratuzumab (Cyclophosphamide Vincristine Doxorubicin Dexamethasone)
3196968|NCT01219816|Experimental|Patients older than 60 years or < =60 years|Vincristine + Aracytine + Dexamethasone
3196969|NCT01219803|Experimental|High dose GGQL Decoction|
3196970|NCT01219803|Experimental|Mild dose GGQL Decoction|
3196971|NCT01219803|Experimental|Low dose GGQL Decoction|
3196972|NCT01219803|Placebo Comparator|Placebo|
3196973|NCT01219790|Experimental|irradiation + zometa|
3196974|NCT01219777|Experimental|Carboplatin|AUC 5.0 or 6.0
3196975|NCT01219777|Experimental|Bevacizumab|15 mg/kg
3196976|NCT01219777|Experimental|Paclitaxel|60-80 mg/m2
3196977|NCT01219764|Active Comparator|Full Dose|Full dose of Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.
3196978|NCT01219764|Experimental|Half dose|Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days.
3196979|NCT01219751|Experimental|Sunitinib|Sunitinib 50 mg D1-D28 every 6 weeks
3196980|NCT01219738|Experimental|budesonide 360ug|asthmatic subject received different doses of inhaled budesonide in random other
3196981|NCT01219738|Experimental|budesonide 720ug|asthmatic subject received different doses of inhaled budesonide in random other
3196982|NCT01219738|Experimental|budesonide 1440ug|asthmatic subject received different doses of inhaled budesonide in random other
3196983|NCT01219738|Placebo Comparator|placebo|asthmatic subject received inhaled placebo
3196984|NCT01219738|Experimental|Budesonide720ug 4 times|asthmatic subject received 720ug of inhaled budesonide 4 times separated by 30 minutes.
3196985|NCT01219712|Active Comparator|Preoperative Optimization|"Patients with proximal femur fracture who are > 65 yrs old and have an increased NT-proBNP would be randomized to either Standard Management or Optimized Management.~The main aim of optimization is to achieve a normal oxygen delivery to the tissues preoperatively.~Hb would be optimized to > 90 g/l~SaO2 > 96%~Stroke volume index (SVI) > 30~Heart rate should ideally be < 80~Stroke volume index (SVI) > 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is < 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal."
3196986|NCT01219712|No Intervention|Standard treatment|Patients who are randomized to this group would be managed according to existing routines within the hospital. Consequently, these patients would be transferred to the Orthopaedic ward after initial management in the Emergency Department, including fluid therapy, oxygen and pain management. Since these patients have a significantly high NT-proBNP, a Cardiologist would be consulted and a decision for optimization taken together with the attending Anaesthesiologist and Orthopaedic Surgeon prior to surgery.
3196987|NCT01219699|Experimental|BYL719|In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene, and in patients whose tumors are have wild-type PIK3CA gene
3196988|NCT01219699|Experimental|BYL719 + fulvestrant|In post-menopausal patients with estrogen receptor positive locally advanced or metastatic breast cancer whose tumors have an alteration of the PIK3CA gene, and in patients whose tumors are have wild-type PIK3CA gene
3196989|NCT01219686|Experimental|escitalopram 20mg + pindolol 15mg|Days 1-2: escitalopram 10 mg + placebo, days 3-42: escitalopram 20mg + placebo Days 1-14: pindolol 15 mg, days 15-17: pindolol 7.5 mg
3196990|NCT01219686|Active Comparator|Escitalopram 30 mg|Days 1-2: escitalopram 10 mg+ placebo, days 3-4 escitalopram 20 mg + placebo, days 5-42: escitalopram 30mg+ placebo
3196991|NCT01219686|Active Comparator|escitalopram 20 mg|days 1-2: escitalopram 10 mg+ placebo, days 3-42: escitalopram 20 mg + placebo
3196992|NCT01219673|Placebo Comparator|Placebo|Placebo by mouth 2 times every day.
3196993|NCT01219673|Experimental|Armodafinil|Armodafinil 150 mg by mouth once a day.
3196994|NCT01219673|Experimental|Minocycline|Minocycline 100 mg by muth two times a day.
3196995|NCT01219673|Experimental|Bupropion|Bupropion 100 mg by mouth two times a day.
3196996|NCT01219673|Experimental|Armodafinil + Minocycline|"Armodafinil 150 mg by mouth once a day.~Minocycline 100 mg by mouth two times a day."
3196997|NCT01219673|Experimental|Armodafinil + Bupropion|"Armodafinil 150 mg by mouth once a day.~Bupropion 100 mg by mouth two times a day."
3196998|NCT01219673|Experimental|Minocycline + Bupropion|"Minocycline 100 mg by muth two times a day.~Bupropion 100 mg by mouth two times a day."
3196999|NCT01219673|Experimental|Armodafinil + Minocycline + Bupropion|"Armodafinil 150 mg by mouth once a day.~Minocycline 100 mg by muth two times a day.~Bupropion 100 mg by mouth two times a day."
3197000|NCT01219647|Experimental|aerobic exercise|Subjects will train on a recumbent cross trainer 20-30 minutes/session for three times/week for six months under supervision of a fitness specialist
3197001|NCT01219647|Active Comparator|stretching|Subjects will particiate in supervised stretching at same frauency, duration and intensity of aerobic exericse arm
3197002|NCT01219621|Active Comparator|DDD Long AVD|
3197003|NCT01219621|Experimental|safeR|
3197004|NCT01219608|Active Comparator|Glutamine 0.5 g/kg/day|
3197005|NCT01219608|Active Comparator|Glutamine 1 g/kg/day|
3197006|NCT01219608|Placebo Comparator|Enteral Nutrition|
3197007|NCT01219595|Active Comparator|Part 1|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.
3197008|NCT01219595|Other|No treatment|20 non-UTI susceptible women will be enrolled to collect data on the types of E. coli flora present in non-UTI women.
3197009|NCT01219595|Active Comparator|Part 2A|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
3197010|NCT01219595|Placebo Comparator|Part 2B|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
3197011|NCT01219595|Active Comparator|Part 3A|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.
3197012|NCT01219595|Placebo Comparator|Part 3B|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for one 4-week period.
3197013|NCT01219582||Group 1|
3197014|NCT01219569||2. Sevoflurane|Subjects will receive sevoflurane at 1.5% and 2.5% end tidal after steady state maintenance has been achieved and have pupillometry readings taken and every 10 minutes for 30 minute at each drug dose.
3197015|NCT01219569||1.Propofol|1.Subjects will receive propofol infusion and have pupillometry readings taken in both eyes after induction, after steady state maintenance has been achieved and at 30 minutes
3197016|NCT01219556||Group 1|
3197017|NCT01219543|Experimental|Part A|Daily dosing of AZD1480 to the patients with solid tumours excluding HCC
3197018|NCT01219543|Experimental|Part B|BID dosing of AZD1480 to the patients with advanced HCC (Child-Pugh A to B7)
3197019|NCT01219543|Experimental|Part C|BID dosing of AZD1480 to the patients with solid tumours excluding HCC
3197020|NCT01219543|Experimental|Expansion|BID dosing of AZD1480 to the patients with EGFR or ROS mutant NSCLC and non-smokers with lung metastasis and gastric cancer and solid tumour with biopsy available.
3197021|NCT01219530||Gestational Carriers|
3197022|NCT01219530||Intended Parents|
3197023|NCT01219517|Experimental|Study Group|All patients in the study receive the same treatment. All will have 2 polar body biopsies and all embryos biopsied prior to transfer.
3197024|NCT01219491||Egg donor recipients|
3197025|NCT01219478||control|0 metabloil risk
3197026|NCT01219478||1|1 metabloil risk
3197027|NCT01219478||2|2 metabloil risk
3197028|NCT01219478||3|3 metabloil risk
3197029|NCT01219465|Experimental|umbilical cord mesenchymal stem cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells
3197030|NCT01219452|Experimental|umbilical cord mesenchymal stem cells|intramuscular injection of umbilical cord mesenchymal stem cell
3197031|NCT01219426||students from the University of Nantes|To be more than 18 years old (the legal age to gamble in France)
3197032|NCT01219426||pathological gamblers seeking treatment|To be more than 18 years old (the legal age to gamble in France)and pathological gambler
3197033|NCT01219413|Experimental|aliskiren, placebo, perindopril|
3197034|NCT01219413|Experimental|perindopril, placebo, aliskiren|
3197035|NCT01219400|Experimental|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
3197036|NCT01219374||egg donors|anonymous egg donors
3197037|NCT01219348|Experimental|Indeolamine 2,3 deoxygenase|To inhibit immune suppression and tolerance, by blocking the IDO enzyme with vaccination against IDO.
3197038|NCT01219322|Experimental|intravenous bicarbonate|Intravenous bicarbonate(05meq/cc ) 50 cc will be injected.
3197039|NCT01219322|Placebo Comparator|Intravenous injection of 50 cc normal saline|Injection of volume equivalent of normal saline to compare the establish the effect of same volume as the experimental drug
3197040|NCT01219309|Active Comparator|Omega 3/6 treatment|
3197041|NCT01219309|Placebo Comparator|Placebo|
3197042|NCT01219283||Control (no PGD)|Receive their planned IVF treatment without PGD. 2 morphologically best embryos are transferred.
3197043|NCT01219283||Case (PGD)|Receive PGD in addition to their planned IVF Cycle. 2 morphologically best PGD normal embryos are transferred.
3197044|NCT01219270||GFR >= 60|MDRD eGFR 60 or more
3197045|NCT01219270||GFR <60|Under MDRD eGFR 60
3197046|NCT01219257||SpA patients|The patients may be included when their rheumatologist has decided that the patient are going to start biological medication.
3197047|NCT01219244|Experimental|Caloric restriction|
3197048|NCT01219244|Experimental|omega-3 supplementation|
3197049|NCT01219244|Experimental|resveratrol supplementation|
3197050|NCT01219244|Placebo Comparator|placebo|
3197051|NCT01219244|Experimental|2nd step: intervention + physical /cognitive training|most effective dietary intervention plus physical and cognitive training
3197052|NCT01219244|Placebo Comparator|2nd step: most effective dietary intervention plus control|most effective dietary intervention plus control
3197053|NCT01219231|Experimental|Exercise|
3197054|NCT01219231|Placebo Comparator|Placebo|
3197055|NCT01219218|Experimental|A|Treatment group. Patients in this group receive actual shockwave therapy.
3197056|NCT01219205|Active Comparator|major branched retinal venous occlusion|
3197057|NCT01219205|Active Comparator|macular branched retinal venous occlusion|
3197058|NCT01219192|Experimental|M2ES 15mg|
3197059|NCT01219192|Experimental|M2ES 30mg|
3197060|NCT01219192|Experimental|M2ES 45mg|
3197061|NCT01219192|Experimental|M2ES 60mg|
3197062|NCT01219179|Experimental|sterile water|Intervention group received sterile water if their sodium value was greater or equal to 150 mEq/liter
3197063|NCT01219166||laparoscopic Roux-en-Y-gastric-bypass without cholecystectomy|
3197064|NCT01219166||laparoscopic Roux-en-Y-gastric baypass with cholecystectomy|
3197065|NCT01219153|Experimental|Extended high dose letrozole regimen /GnRH antagonist|
3197066|NCT01219153|Active Comparator|Short low dose letrozole regimen /GnRH antagonist|
3197067|NCT01219140|Experimental|2 POMx Capsules|2 POMx Capsules daily
3197068|NCT01219140|Placebo Comparator|2 placebo Capsules|2 placebo Capsules daily
3197069|NCT01219127|Experimental|Derma-PACE|Pre-treatment evaluations include complete history and physical examination, chemistry and coagulation profiles, detailed past surgical and medical treatments. The local findings of the ulcer are quantitatively assessed using the S(AD) SAD classification (6) including photo-documentation for the size, shape and configuration of the ulcer
3197070|NCT01219114||1|
3197071|NCT01219101|Experimental|clomiphene citrate and ethinyl estradiol|Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
3197249|NCT01218126|Experimental|losmapimod 15 mg|losmapimod 15 mg
3197072|NCT01219101|Active Comparator|clomiphene citrate and placebo|Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
3197073|NCT01219088|No Intervention|Controlled group|Spinal anesthesia with 0.5% bupivacaine alone
3197074|NCT01219088|Active Comparator|Femoral nerve block|Spinal anesthesia plus femoral nerve block with 20 mL of 0.25% bupivacaine
3197075|NCT01219088|Active Comparator|Intrathecal morphine|Spinal anesthesia plus 0.1 mg of intrathecal morphine
3197076|NCT01219088|Active Comparator|Periarticular bupivacaine infiltration|Spinal anesthesia plus periarticular infiltration with 20 mL of 0.25% bupivacaine
3197077|NCT01219075|Experimental|Arm I|Patients receive oral soy isoflavones supplement once daily for 12 months in the absence of disease progression.
3197078|NCT01219075|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 12 months in the absence of disease progression.
3197079|NCT01219062|Placebo Comparator|control|The patient will be performed spinal anesthesia alone, with postoperative PCA
3197080|NCT01219062|Active Comparator|Morphine|The patient will received intrathecal Morphine for 0.1 mg. in Isobaric bupivacaine in spinal anesthesia and postoperative PCA
3197081|NCT01219062|Active Comparator|bupivacaine|the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
3197082|NCT01219049|Experimental|Tyrosine 1000 mg / day|Patients receive 1000 mg tyrosine per day.
3197083|NCT01219049|Experimental|Tyrosine 2000 mg / day|Patients receive 2000 mg tyrosine per day.
3197084|NCT01219049|Placebo Comparator|Placebo|Patients receive placebo daily.
3197085|NCT01219036|Other|Non-adherent|
3197086|NCT01219036|Other|Adherent|
3197087|NCT01219010|Experimental|001|Siltuximab 15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
3197088|NCT01218997|Experimental|Medisorb naltrexone 380 mg (VIVITROL)|
3197089|NCT01218997|Active Comparator|Oral naltrexone 50 mg|
3197090|NCT01218984|Experimental|Medisorb naltrexone 75 mg|
3197091|NCT01218984|Experimental|Medisorb naltrexone 150 mg|
3197092|NCT01218984|Experimental|Medisorb naltrexone 300 mg|
3197093|NCT01218971|Experimental|Medisorb naltrexone 380 mg|Intramuscular (IM) injection administered once every 4 weeks for up to 48 weeks.
3197094|NCT01218971|Experimental|Medisorb naltrexone 190 mg|IM injection administered once every 4 weeks for up to 48 weeks.
3197095|NCT01218958|Experimental|Medisorb naltrexone 190 mg|
3197096|NCT01218958|Experimental|Medisorb naltrexone 380 mg|
3197097|NCT01218958|Placebo Comparator|Placebo for Medisorb naltrexone 190 mg|
3197098|NCT01218958|Placebo Comparator|Placebo for Medisorb naltrexone 380 mg|
3197099|NCT01218945||Fat Removal|Patients undergoing surgical fat removal
3197100|NCT01218932|Experimental|A|Primaquine only, followed by chloroquine/primaquine, followed by chloroquine only
3197101|NCT01218932|Active Comparator|B|Primaquine alone, followed by chloroquine, followed by chloroquine/primaquine
3197102|NCT01218919||Brio DBS System|Eligible subjects in this study will be screened to confirm that they meet the strict guidelines for advanced, levodopa-responsive Parkinson's disease that are not adequately controlled with medication followed by bilateral surgery to implant the Brio™ deep brain stimulation system
3197103|NCT01218906||Cohort Population (Case )|Participants will be examined for febrile illness to diagnose dengue and to identify common causes of fever.
3197104|NCT01218893|Active Comparator|15-15-15|This group will receive three times 15 infected mosquito bites under chloroquine prophylaxis, as we know that this dose is protective.
3197105|NCT01218893|Experimental|10-10-10|This group will receive three times 10 infected and 5 uninfected mosquito bites under chloroquine prophylaxis.
3197106|NCT01218893|Experimental|5-5-5|This group will receive three times 5 infected and 10 uninfected mosquitobites under chloroquine prophylaxis.
3197107|NCT01218893|Placebo Comparator|0-0-0|This group will receive three times 15 uninfected mosquitobites under prophylaxis.
3197108|NCT01218880|Experimental|M2ES-A|
3197109|NCT01218880|Experimental|M2ES-B|
3197110|NCT01218880|Experimental|M2ES-C|
3197111|NCT01218880|Experimental|M2ES-D|
3197112|NCT01218867|Experimental|Cohort 1 (1x10(6) cells (high dose IL-2)|Patients will receive (1x10(6) cells plus high dose aldesleukin
3197113|NCT01218867|Experimental|Cohort 2 (3x10(6) cells (high dose IL-2)|Patients will receive (3x10(6) cells plus high dose aldesleukin
3197114|NCT01218867|Experimental|Cohort 3 (1x10(7) cells (high dose IL-2)|Patients will receive (1x10(7) cells plus high dose aldesleukin
3197115|NCT01218867|Experimental|Cohort 4 (3x10(7) cells (high dose IL-2)|Patients will receive (3x10(7) cells plus high dose aldesleukin
3197116|NCT01218867|Experimental|Cohort 5 (1x10(8) cells (high dose IL-2)|Patients will receive (1x10(8) cells plus high dose aldesleukin
3197117|NCT01218867|Experimental|Cohort 6 (3x10(8) cells (high dose IL-2)|Patients will receive (3x10(8) cells plus high dose aldesleukin
3197118|NCT01218867|Experimental|Cohort 7 (1x10(9) cells (high dose IL-2)|Patients will receive (1x10(9) cells plus high dose aldesleukin
3197119|NCT01218867|Experimental|Cohort 8 (1x10(9) cells (low dose IL-2)|Patients will receive (1x10(9) cells plus low dose aldesleukin
3197120|NCT01218867|Experimental|Cohort 9 (3x10(9) cells (low dose IL-2)|Patients will receive (3x10(9) cells plus low dose aldesleukin
3197121|NCT01218867|Experimental|Cohort10(1x10(10) cells (low dose IL-2)|Patients will receive (1x10(10) cells plus low dose aldesleukin
3197122|NCT01218867|Experimental|Cohort11(3x10(10) cells (low dose IL-2)|Patients will receive (3x10(10) cells plus low dose aldesleukin
3197123|NCT01218854|Active Comparator|Standard|Clinician intuition method
3197124|NCT01218854|Experimental|L-NASS|Laser assisted needle angle selection system
3197125|NCT01218854|Experimental|B-NASS|Block assisted needle angle selection system
3197126|NCT01218854|Experimental|MD-NASS|mobile-device assisted needle angle selection system
3197127|NCT01218841|Experimental|Fish oil lipid emulsion|Parenteral lipid emulsion composed by fish oil which is rich in the omega-3 polyunsaturated fatty acids eicosapentanoic and docosahexanoic.
3197128|NCT01218841|Active Comparator|MCT/LCT lipid emulsion|Parenteral lipid emulsion containing 50% of medium-chain triglycerides and 50% of soybean oil
3197129|NCT01218828|Active Comparator|Standard therapy|Hydration with 0.9% saline per a standard protocol (control group)
3197130|NCT01218828|Experimental|LVEDP-based hydration strategy|LVEDP guided hydration with 0.9% saline (treatment group)
3197131|NCT01218815|Experimental|Culprit lesion IRA Revascularization|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
3197132|NCT01218815|Active Comparator|Complete IRA revascularization|Primary PCI of culprit lesion in IRA with DES stent
3197133|NCT01218802|Active Comparator|Rosuvastatin|Participants will take Rosuvastatin 10 mg. daily for 96 weeks
3197134|NCT01218802|Placebo Comparator|Sugar Pill placebo|Participants will take a placebo that appears on the exterior to be the same as active drug. They will take one capsule daily.
3197135|NCT01218789|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 1 year
3197136|NCT01218776||Male, Female, Kidney Disease, Elderly|Non-interventional patient registry
3197137|NCT01218763||ICD patients|Candidates may come from the investigator's general population, who require DR ICD or CRT-D therapy for primary or secondary ICD indication and meet all study eligibility criteria
3197138|NCT01218750|Experimental|edematous tractional epimacular membrane|Diabatic maculopathy comes to the edematous or tractional form. It is believed that epiretinal membranes are comprised from glial components. The processes of these cells may invade through the internal limiting membrane of the retina to the vitreous causing the vitreoretinal adhesion and anomalous posterior detachment of vitreous (APVD). In the macula, APVD causes vitreo-macular traction syndrome, which results in diffuse diabetic macular edema. If vitreoschisis is present, a place of dissection is crucial. If break occurs in front of the hyalocytes remaining on the retinal surface, the vitreous layer is thick and easily shrinks concentrically, which results in the formation of epimacular membrane.
3197139|NCT01218737|Experimental|Association|0.3% gatifloxacin and 1.0% prednisolone acetate association in eye drops plus placebo
3197140|NCT01218737|Active Comparator|Isolated ingredients|0.3% gatifloxacin and 1.0% prednisolone acetate isolated eye drops formulations
3197141|NCT01218685||Health adults|
3197142|NCT01218685||Health children|
3197143|NCT01218685||Pregnants|
3197144|NCT01218685||Elderly over 65 years old|
3197145|NCT01218685||HIV patients|
3197146|NCT01218685||Kidney transplant|
3197147|NCT01218685||Oncologic patients|
3197148|NCT01218685||Rheumatologic adult patients|
3197149|NCT01218685||Rheumatologic children patients|
3197150|NCT01218672|Active Comparator|GreenLight XPS|Photoselective vaporization of the prostate using GreenLight XPS laser system.
3197151|NCT01218672|Active Comparator|TURP|Monopolar and bipolar Transuretheral resection of the prostate (TURP)
3197152|NCT01218659|Active Comparator|Enzyme Replacement Therapy|
3197153|NCT01218659|Experimental|AT1001|
3197154|NCT01218646|Experimental|Group 1: Investigational Quadrivalent Influenza Vaccine|Participants will receive a dose of Investigational Quadrivalent Inactivated Influenza Vaccine
3197155|NCT01218646|Experimental|Group 2: Investigational Trivalent Influenza Vaccine|Participants will receive a dose of Investigational Trivalent Inactivated Influenza Vaccine
3197156|NCT01218646|Active Comparator|Group 3: Licensed 2010-2011 Trivalent Influenza Vaccine|Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
3197157|NCT01218646|Active Comparator|Group 4: Licensed 2010-2011 Trivalent Influenza Vaccine|Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
3197158|NCT01218633|Placebo Comparator|Saline|
3197159|NCT01218633|Active Comparator|GLP-1-(9,36)-amide|
3197160|NCT01218633|Active Comparator|Exendin-9,39 @30pmol/kg/min|
3197161|NCT01218633|Active Comparator|Exendin-9,39 @300pmol/kg/min|
3197162|NCT01218620|Experimental|Regimen I (Arm I)|"Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral ketoconazole once daily on days 1-10 for course 2 only."
3197163|NCT01218620|Experimental|Regimen I (Arm II)|"Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral rifampin once daily on days 1-10 for course 2 only."
3197164|NCT01218620|Experimental|Regimen II (Arm I)|"Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral ketoconazole once daily on days 1-10 for course 2 only."
3197165|NCT01218620|Experimental|Regimen II (Arm II)|"Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral rifampin once daily on days 1-10 for course 2 only."
3197166|NCT01218607|Placebo Comparator|Placebo|
3197167|NCT01218607|Active Comparator|Active|
3197168|NCT01218594|Experimental|Endostatin combine CCRT|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
3197169|NCT01218581|Active Comparator|group A|Group A received oral letrozole (2.5 mg/day, Femara, Novartis PharmaServices, Basel, Switzerland)
3197170|NCT01218581|Active Comparator|group B|group B received goserelin subcutaneosly (3.6 mg/month, Zoladex@, Zeneka Pharma International, UK)
3197171|NCT01218568|Experimental|Rifaximin plus lactulose|
3197172|NCT01218568|Active Comparator|lactulose|30-60ml/day
3197278|NCT01217931|Experimental|Group 2|Pazopanib + possible Everolimus
3197279|NCT01217931|Experimental|Group 3|Everolimus + possible Bevacizumab
3197173|NCT01218555|Experimental|Lenalidomide combination with everolimus|Non-randomized study of escalating doses of daily, orally administered lenalidomide in combination with standard doses of everolimus, an orally available mammalian target of rapamycin (mTOR) inhibitor.
3197174|NCT01218542|Experimental|Volumetric modulated arc therapy|Single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.
3197175|NCT01218529|Experimental|Whole Brain Radiation Therapy (WBRT) + lapatinib|Whole Brain Radiation Therapy (30Gy in 10 fractions) and lapatinib 1250mg once daily for 2 weeks followed by lapatinib treatment 1500mg once daily for 4 weeks.
3197176|NCT01218516|Active Comparator|Farletuzumab plus Chemotherapy|During Combination Therapy, farletuzumab will be given with a protocol-approved platinum doublet (either carboplatin/paclitaxel, carboplatin/pemetrexed, or cisplatin/pemetrexed) for at least 4, but not more than 6, cycles. Participants who experience clinical benefit from the Combination Therapy will enter the Monotherapy Phase and receive farletuzumab as monotherapy until disease progression.
3197177|NCT01218516|Placebo Comparator|Placebo plus Chemotherapy|During Combination Therapy, placebo will be given with a protocol-approved platinum doublet (either carboplatin/paclitaxel, carboplatin/pemetrexed, or cisplatin/pemetrexed) for at least 4, but not more than 6, cycles. Participants who experience clinical benefit from the Combination Therapy will enter the Monotherapy Phase and receive placebo as monotherapy until disease progression.
3197178|NCT01218503|Experimental|CHOICES - obese|behavioral weight loss treatment - overweight/obese females
3197179|NCT01218490|Experimental|lymphadenectomy|after surgery of the ovarian cancer, patient will have Pelvis and aortic-cava lymphadenectomy
3197180|NCT01218490|No Intervention|no lymphadectomy|after surgery, the patient will not have pelvic and aortic-cave lymphadenectomy
3197181|NCT01218477|Experimental|Dasatinib, 100/140 mg QD|Participants received dasatinib, 100/140 mg once daily (QD), depending on cohort (100 mg for those with chronic myeloid leukemia [CML]-chronic phase; 140 mg for those with CML-advanced phase)
3197182|NCT01218477|Experimental|Dasatinib, 100/140 mg QD + BMS-833923, 50 mg QD|Participants received dasatinib, 100/140 mg once daily (QD), depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase) plus BMS-833923, 50 mg, QD
3197183|NCT01218477|Experimental|Dasatinib, 100/140 mg QD + BMS-833923, 100 mg BID/QD|Participants received BMS-833923, 100 mg twice daily (BID) for 7 days then once daily (QD) + dasatinib, 100/140 mg QD, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
3197184|NCT01218477|Experimental|Dasatinib, 100 /140 mg QD+ BMS-833923, 200 mg BID/QD|Participants received BMS-833923, 200 mg twice daily (BID) for 7 days then 200 mg once daily (QD) plus dasatinib, 100 /140 mg QD), depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
3197185|NCT01218464|Experimental|Conventional plus MSC treatment|Participants will receive conventional treatment plus a dose of MSC from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit
3197186|NCT01218464|Experimental|Conventional plus pacebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit
3197187|NCT01218451|Experimental|Group 1|Single dose of NeisVac-C vaccine at 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
3197188|NCT01218451|Experimental|Group 2|Single dose of NeisVac-C vaccine at 6 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
3197189|NCT01218451|Active Comparator|Group 3|Two doses of NeisVac-C vaccine at 2 and 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
3197190|NCT01218438|Experimental|Study Epochs 1-4|"Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.~Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.~Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.~Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion."
3197191|NCT01218425|Experimental|Medication|In this study, a crossover design is applied. All participants receive all three treatments in randomized order on separate days.
3197192|NCT01218412|Experimental|Web-based, Mi=Based Intervention|4 session web-based, MI-based intervention.
3197193|NCT01218399|Active Comparator|Budesonide|"Combination of budesonide and formoterol. Medications are given according to the package insert and manufacturer's instructions.~Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Symbicort study arm."
3197194|NCT01218399|Placebo Comparator|Placebo Comparator: Budesonide|"Control of budesonide alone. Medication was given according to the package insert and manufacturer's instructions.~Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Budesonide study arm."
3197195|NCT01218386|Experimental|Study Group|"Start with estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~If day 25 is Monday: 6 days Tuesday: 10 days Wednesday: 9 days Thursday: 8 days Friday: 7 days Saturday: 6 days Sunday: 6 days of Progynova, 2x2 mg per day After this pretreatment: Standard GnRH antagonist treatment protocol with start rFSH (Puregon®) at a dose of 150 IU From day 2 of the cycle onwards; GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation"
3197196|NCT01218386|Active Comparator|Control group|Standard GnRH antagonist treatment protocol with start rFSH (Puregon®) at a dose of 150 IU From day 2 of the cycle onwards; GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation
3197197|NCT01218373|Active Comparator|Intervention Group: HOMESWEETHOME services|Monitoring and alarm handling services. eInclusion services. Domotica services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.
3197198|NCT01218373|Placebo Comparator|Control Group: No HOMESWEETHOME services|Normal care.
3197199|NCT01218360||Participants|All participants enrolled
3197200|NCT01218347|Experimental|Rosuvastatin|rosuvastatin treatment
3197201|NCT01218334||1|Cardiac Inpatient
3197202|NCT01218334||2|Cardiac Outpatient
3197203|NCT01218334||3|Cardiac Clinic Patient
3197204|NCT01218321||Antiepileptic treatment group|Group of patients treated by antiepileptic medications
3197205|NCT01218308|Experimental|FluLaval® Quadrivalent Group|Subjects between 3 and 8 years of age at the time of first vaccination received, if primed, 1 dose of FluLaval® Quadrivalent vaccine at Day 0 and, if unprimed, 2 doses of FluLaval® Quadrivalent vaccine at Days 0 and 28. The vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
3197206|NCT01218308|Active Comparator|Havrix Group|Subjects between 3 and 8 years of age at the time of first vaccination received, if primed, 1 dose of Havrix™ vaccine at Day 0 and, if unprimed, 2 doses of Havrix™ vaccine at Days 0 and 28. The vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
3197207|NCT01218295|Experimental|Respiratory muscle training|Patients assigned to this arm train the respiratory muscles by means of normocapnic hyperpnea.
3197208|NCT01218282|Experimental|Home Exercise Training Group A1|Patients assigned to this arm maintain the prescribed walking speed during the training with a metronome
3197209|NCT01218282|Experimental|Home Exercise Training Group A2|Patients assigned to this arm cover a fixed distance in a given period of time.
3197210|NCT01218282|No Intervention|Control|
3197211|NCT01218269|Other|no arms|all patients will receive the treatment - there is only one arms
3197212|NCT01218256|Active Comparator|Hypertrophy resistance training|Aerobic endurance training combined with hypertrophy resistance training in type 2 diabetes mellitus.
3197213|NCT01218256|Active Comparator|Endurance resistance training|Aerobic endurance training combined with hypertrophy resistance training in type 2 diabetes mellitus.
3197214|NCT01218243|Experimental|acupoint|Needle at bilateral BL33 60-80 mm with a 45°angle.A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd)is put on with Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. There are 5 sessions in the first two weeks and 3 sessions in the last two weeks, 30 min/session.
3197215|NCT01218243|Sham Comparator|non-acupoint|Take the place 2 cun far from BL33 on the outside horizontally as the non-point. Needle on the non-point for 60-80mm with a 45°angle. A feeling of soreness and distension will be felt .Needle with a 100-125mm long needle without lifting, thrusting or rotating.Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.
3197216|NCT01218230|Active Comparator|Intravitreal Pegaptanib|
3197217|NCT01218217|Experimental|SQ109 75 mg|75 mg SQ109 monotherapy daily
3197218|NCT01218217|Experimental|SQ109 150 mg|150 mg SQ109 daily
3197219|NCT01218217|Experimental|SQ109 300 mg|300 mg SQ109 daily
3197220|NCT01218217|Experimental|SQ109 150 mg + RIF|150 mg SQ109 + RIF standard dose daily
3197221|NCT01218217|Experimental|SQ109 300 mg + RIF|300 mg SQ109 + RIF standard dose daily
3197222|NCT01218217|Active Comparator|RIF Mono|Standard dose Rifampicin monotherapy daily
3197223|NCT01218204|Other|Part A Run-in|Subjects on stable 40mg atorvastatin > 4 weeks may raise their dose to 80mg for 2 weeks in order to qualify for Part A.
3197224|NCT01218204|Experimental|Part A Co-Dosing 800mg GSK1292263|Dosing for 14 days
3197225|NCT01218204|Other|Part B Washout|Washout for 4 weeks
3197226|NCT01218204|Active Comparator|Part B Run-in 10mg atorvastatin|Dosing for 4 weeks
3197227|NCT01218204|Active Comparator|Part B Run-in 80mg atorvastatin|Dosing for 4 weeks
3197228|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 100mg GSK1292263|Dosing for 14 days
3197229|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 300mg GSK1292263|Dosing for 14 days
3197230|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 800mg GSK1292263|Dosing for 14 days
3197231|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 10mg ezetimibe|Dosing for 14 days
3197232|NCT01218204|Experimental|Part B Dosing 100mg GSK1292263|Dosing for 14 days
3197233|NCT01218204|Experimental|Part B Dosing 300mg GSK1292263|Dosing for 14 days
3197234|NCT01218204|Experimental|Part B Dosing 800mg GSK1292263|Dosing for 14 days
3197235|NCT01218204|Experimental|Part B Dosing Placebo GSK1292263|Dosing for 14 days
3197236|NCT01218204|Experimental|Part B Co-Dosing 80mg atorvastatin + 800mg GSK1292263|Dosing for 14 days
3197237|NCT01218204|Experimental|Part B Co-dosing 80mg atorvastatin + Placebo (GSK1292263)|Dosing for 14 days
3197238|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + Placebo (GSK1292263)|Dosing for 14 days
3197239|NCT01218191||Subarachnoid hemorrhage|Patients presenting a SAH
3197240|NCT01218178||Sodium bicarbonate plus NAC|Sodium bicarbonate plus NAC
3197241|NCT01218178||Saline hydration plus NAC|Saline hydration plus NAC
3197242|NCT01218165|No Intervention|Control Group|without intervention
3197243|NCT01218165|Experimental|Intervention Group|This group receives a probiotic drink daily for 6 week.
3197244|NCT01218152||cancer patients|patients who are seen by oncologists and who are willing to donate an extra blood sample when blood is taken routinely
3197245|NCT01218152||NF1 patients|patients, who have neurofibromatosis type 1 and who have developped an MPNST,donating a blood sample
3197246|NCT01218126|Experimental|losmapimod 2.5 mg|losmapimod 2.5 mg
3197247|NCT01218126|Placebo Comparator|placebo|
3197248|NCT01218126|Experimental|losmapimod 7.5 mg|losmapimod 7.5 mg
3197250|NCT01218113|Experimental|3D_HIV Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 3 doses of the HIV Vaccine 732462 at Weeks 0, 4 and 28, administered intramuscularly in the deltoid of the non-dominant arm.
3197251|NCT01218113|Experimental|2D_HIV Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 2 doses of the HIV Vaccine 732462 at Weeks 0 and 4 and one dose of placebo (saline solution) at Week 28, administered intramuscularly in the deltoid of the non-dominant arm.
3197252|NCT01218113|Placebo Comparator|Control Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 3 doses of placebo (saline solution) at Weeks 0, 4 and 28, administered intramuscularly in the deltoid of the non-dominant arm.
3197253|NCT01218100|Experimental|1|Combination group - starting dose level nebivolol 5mg and lisinopril 10mg
3197254|NCT01218100|Active Comparator|2|Nebivolol monotherapy group - starting dose level nebivolol 5mg
3197255|NCT01218100|Active Comparator|3|Lisinopril monotherapy group - starting dose level lisinopril 10mg
3197256|NCT01218100|Placebo Comparator|4|Placebo group - starting dose is placebo
3197257|NCT01218087|Experimental|Cranial cup device and Moldable positioner device|The cranial cup for 12/24 hours and the moldable positioner device was used for positioning infants the remainder of the 24 hours
3197258|NCT01218087|Active Comparator|Moldable positioner device|Moldable positioner device was used for positioning infants for 24/24 hours
3197259|NCT01218074|Active Comparator|Thromboelastography alone|Patients undergo standard of care Thromboelastography to evaluate overall coagulation performances.
3197260|NCT01218074|Experimental|Aggregometry+Tromboelastography|Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
3197261|NCT01218048|Experimental|Neo-Adjuvant Cetuximab|"Neo-Adjuvant Cetuximab + Surgery + Post-Surgical Radiation + Cisplatin (or Carboplatin)~NOTE: Based the results of surgery if the treating physician feels patient is not a candidate for chemotherapy, radiation can be given alone or with cetuximab."
3197262|NCT01218009|Experimental|Albuterol Spiromax|Albuterol multi-dose dry powder inhaler (Spiromax) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for the 12 week double-blind period. Participants then continue into the 40 week open-label period in which they take albuterol multi-dose dry powder inhaler (Spiromax) inhalations of 90 mcg /inhalation as required (PRN).
3197263|NCT01218009|Placebo Comparator|Placebo Spiromax|Placebo delivered using a multi-dose dry powder inhaler (Spiromax) as 2 inhalations four times a day for the 12 week double-blind period. Participants then continue into the 40 week open-label period in which they administer albuterol multi-dose dry powder inhaler (Spiromax) inhalations of 90 mcg /inhalation as required (PRN).
3197264|NCT01217996|Other|Intervention Group|Children treated for a brain tumor (BT) or acute lymphoblastic leukemia (ALL) will complete the computerized working memory training program (intervention).
3197265|NCT01217996|Other|Control Group|Children treated for a brain tumor (BT) or acute lymphoblastic leukemia (ALL) will complete the computerized working memory training program (control).
3197266|NCT01217970|Active Comparator|Ibudilast 20mg BID|Ibudilast 20mg oral BID 7 days
3197267|NCT01217970|Active Comparator|Ibudilast 50mg BID|Ibudilast 50mg oral BID 7 days
3197268|NCT01217970|Placebo Comparator|Placebo|Placebo oral BID 7 days (0mg ibudilast)
3197269|NCT01217957|Experimental|Phase 1: Ixazomib 1.68 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 1.68 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 1.68 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
3197270|NCT01217957|Experimental|Phase 1: Ixazomib 2.23 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 2.23 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 2.23 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
3197271|NCT01217957|Experimental|Phase 1: Ixazomib 2.97 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 2.97 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 2.97 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
3197272|NCT01217957|Experimental|Phase 1: Ixazomib 3.95 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 3.95 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 3.95 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
3197273|NCT01217957|Experimental|Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone|In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 4.0 mg fixed dose, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
3197274|NCT01217944|Experimental|Ranibizumab driven by disease activity|Participants received active ranibizumab on day 1. Thereafter they received ranibizumab treatment based on disease activity criteria
3197275|NCT01217944|Experimental|Ranibizumab driven by stabilization criteria|Participants received ranibizumab on day 1 and month 1. Thereafter they received ranibizumab based on stabilization criteria for visual acuity
3197276|NCT01217944|Active Comparator|Verteporfin PDT|Participants received active vPDT on day 1. From month 3 onwards participants could receive ranibizumab, vPDT or a combination of the two if needed.
3197277|NCT01217931|Experimental|Group 1|Pazopanib + possible Bevacizumab
3197281|NCT01217931|Experimental|Group 5|Bevacizumab + possible Pazopanib
3197282|NCT01217931|Experimental|Group 6|Bevacizumab + possible Everolimus
3197283|NCT01217918|Experimental|Cohort 1|PH-797804
3197284|NCT01217918|Experimental|Cohort 2|PH-797804
3197285|NCT01217918|Experimental|Cohotr 3|PH-797804
3197286|NCT01217905|Experimental|1|
3197287|NCT01217892|Experimental|1|Dapagliflozin 2.5 mg twice-daily plus open-label metformin
3197288|NCT01217892|Experimental|2|Dapagliflozin 5.0 mg twice-daily plus open-label metformin
3197289|NCT01217892|Experimental|3|Dapagliflozin 10 mg once-daily plus open-label metformin
3197290|NCT01217892|Placebo Comparator|4|Placebo plus open-label metformin
3197291|NCT01217879||Group 1|
3197292|NCT01217866||LAVH, techniques|Women aged 35-75 who underwent laparoscopic assisted vaginal hysterectomy via either suture technique vaginally or Enseal coagulation cutting device vaginally
3197293|NCT01217853||SENSIMED Triggerfish|
3197294|NCT01217840|Experimental|vitamin D|"Subjects were assigned to receive two observed doses of vitamin D2 (150,000 IU ergocalciferol, Barr Laboratories and Winthrop (Sanofi-Aventis)), given at baseline and 12 weeks. Capsules were packaged by the hospital's clinical trial pharmacist and were administered by study staff blinded to group assignments.~Intervention: Height, weight, and BMI were obtained at baseline, 12 weeks and 24 weeks"
3197295|NCT01217840|Placebo Comparator|Placebo|Subjects were assigned to receive two observed doses of placebo, given at baseline and 12 weeks. Capsules were packaged by the hospital's clinical trial pharmacist and were administered by study staff blinded to group assignments. Height, weight, and BMI were obtained at baseline, 12 weeks and 24 weeks
3197296|NCT01217827|Experimental|Clinical Reminder|Reminder of potential candidacy for an implantable cardioverter defibrillator. The reminder is placed in the medical record with copy to the primary provider and any cardiologist managing the patient.
3197297|NCT01217827|No Intervention|Control|This group does not receive an intervention.
3197298|NCT01217814|Placebo Comparator|Placebo|Placebo 2 mL to match sarilumab once a week (qw) and 0.5 mL to match golimumab every 4 weeks (q4w) on top of MTX (15-25 mg) qw for 12 weeks.
3197299|NCT01217814|Active Comparator|Golimumab 50 mg|Golimumab 50 mg q4w and placebo (matched to sarilumab) qw on top of MTX (15-25 mg) qw for 12 weeks.
3197300|NCT01217814|Experimental|Sarilumab 150 mg|Sarilumab 150 mg qw and placebo (matched to golimumab) q4w on top of MTX (15-25 mg) qw for 12 weeks.
3197301|NCT01217801|Experimental|Ondansetron (ODFS)|single dose of Ondansetron Orally Dissolving Filmstrip 8 mg
3197302|NCT01217801|Active Comparator|Zofran (ODT)|Single dose of Zofran (Ondansetron) ODT Orally Disintegrating Tablets 8 mg
3197303|NCT01217788|Experimental|PH94B intranasal spray|
3197304|NCT01217788|Placebo Comparator|Placebo intranasal spray|
3197305|NCT01217775|Experimental|PH80 intranasal spray|Start using study medication on 14th of the cycle, or the day symptoms start to bother, or if no symptoms on day 21st of the cycle but no later than day 21st of the cycle, up to 6-times per day, and continuing until day 2-3 of the menses
3197306|NCT01217775|Placebo Comparator|Placebo intranasal spray|Start using study medication on 14th of the cycle, or the day symptoms start to bother, or if no symptoms on day 21st of the cycle but no later than day 21st of the cycle, up to 6-times per day, and continuing until day 2-3 of the menses
3197307|NCT01217762|Experimental|11 Gy IRay|Day 0 Lucentis followed by 11 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 2)
3197308|NCT01217762|Experimental|16 Gy IRay|Day 0 Lucentis followed by 16 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 27)
3197309|NCT01217762|Experimental|16 Gy IRay - Radiation First|16 Gy IRay and Lucentis PRN (N = 13)
3197310|NCT01217762|Experimental|24 Gy IRay|Day 0 Lucentis followed by 24 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 19)
3197311|NCT01217749|Experimental|Group 1|In Group 1, PCI-32765 420 mg PO was administered daily for 1 cycle (28 days) before the start of ofatumumab IV dosing
3197312|NCT01217749|Experimental|Group 2|In Group 2, PCI-32765 420 mg PO daily was initiated concomitantly with ofatumumab IV (PCI-32765 initiated on Day 2 of Cycle 1)
3197313|NCT01217749|Experimental|Group 3|In Group 3, two cycles of ofatumumab IV were administered prior to the start of PCI-32765 420 mg PO daily
3197314|NCT01217736|Experimental|VTP-27999|
3197315|NCT01217736|Active Comparator|aliskiren|
3197316|NCT01217736|Placebo Comparator|placebo|
3197317|NCT01217723|Experimental|Thymoglobulin|Thymoglobulin will be administered on Days -2, -1 prior to the transplant and on the day of transplant.
3197318|NCT01217723|Other|No Thymoglobulin|Patients will receive a standard preparative regimen. (i.e. one that does not normally contain Thymoglobulin.)
3197319|NCT01217671|Experimental|Alpha-1 Antitrypsin|
3197320|NCT01217671|Placebo Comparator|Placebo|
3197321|NCT01217658|Experimental|The Happiest Baby on The Block|"Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block."
3197322|NCT01217658|Active Comparator|AAP Education|Those receiving the control group allocation will be counseled in the American Academy of Pediatrics guidelines regarding Infant Colic (AAP Infant Colic counseling).
3197323|NCT01217645|Experimental|150 mg [14C] AZD6765|
3197324|NCT01217632|Placebo Comparator|FG-3019 Placebo|Placebo will be administered at 15-45 mg/kg every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
3197325|NCT01217632|Experimental|FG-3019|FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
3197326|NCT01217619|Experimental|Erlotinib|Single-arm
3197327|NCT01217606|Experimental|Triple Combination Therapy|Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
3197328|NCT01217606|Active Comparator|Combigan®|Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
3197329|NCT01217593|Experimental|ultrasound|Ultrasound guidance will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
3197572|NCT01215747|Experimental|Kiacta (eprodisate disodium)|
3197330|NCT01217593|Active Comparator|predetermined distance|The predetermined distance technique will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
3197331|NCT01217580|Experimental|20 ml per side of 0.5% ropivacaine|Ultrasound guided TAP blocks will be performed once patient is in the recovery area. Patients will be placed on their back with their hands resting comfortably above their head. Using an ultrasound guided technique, the ultrasound probe will be positioned on abdominal until the three lateral abdominal wall muscles and TAP are clearly imaged. A two or four inch, 20 gauge needle will be advanced using an in-plane technique. After visual confirmation that the needle tip is in the TAP, 1 ml of preservative free 0.9% sodium chloride will be injected to reconfirm correct placement in the TAP. Then 20 ml of 0.5% ropivacaine will be injected. The procedure will be repeated on the other side.
3197332|NCT01217580|Placebo Comparator|20 ml per side of 0.9% sodium chloride|Ultrasound guided TAP blocks will be performed once patient is in the recovery area. Patients will be placed on their back with their hands resting comfortably above their head. Using an ultrasound guided technique, the ultrasound probe will be positioned on abdominal until the three lateral abdominal wall muscles and TAP are clearly imaged. A two or four inch, 20 gauge needle will be advanced using an in-plane technique. After visual confirmation that the needle tip is in the TAP, 1 ml of preservative free 0.9% sodium chloride will be injected to reconfirm correct placement in the TAP. Then 20 ml of 0.9% preservative free sodium chloride will be injected. The procedure will be repeated on the other side.
3197333|NCT01217567|Experimental|1st c-section, no previous lower abdominal surgery - s.l.|
3197334|NCT01217567|Experimental|Woman with previous ceasarean section - staples left|
3197335|NCT01217567|Experimental|1st c-section, no previous lower abdominal surgery|
3197336|NCT01217567|Experimental|Woman with previous ceasarean section|
3197337|NCT01217554||age-matched healthy male participants|age-matched healthy male participants without LBP
3197338|NCT01217554||participants with non specific chronic LBP|male participants with non specific chronic LBP
3197339|NCT01217541|Other|Education and supervision|Personnel in nursing home units get intervention in form of education and supervision
3197340|NCT01217541|No Intervention|Control|Only registering of patient and personnel data in the beginning and the end of the study without any form of intervention.
3197341|NCT01217528|Active Comparator|Group A|"Group A:~VT zone: 350ms~VF zone: 280ms"
3197342|NCT01217528|Experimental|Group B|"Group B:~VT zone: 320ms~VF zone: 250ms"
3197343|NCT01217515|Experimental|Diltiazem hydrochloride 4% cream|2.5 cm Diltiazem hydrochloride 4% cream applied peri-anally three times daily for eight weeks.
3197344|NCT01217515|Experimental|Diltiazem hydrochloride 2% cream|2.5 cm of Diltiazem hydrochloride 2% cream applied peri-anally three times daily for eight weeks.
3197345|NCT01217515|Placebo Comparator|Placebo cream|2.5 cm placebo cream applied peri-anally three times daily for eight weeks.
3197346|NCT01217502|Experimental|Self management|
3197347|NCT01217489||Attendees to symptomatic breast clinic|
3197348|NCT01217476|Active Comparator|Trafermin 0.01% spray|
3197349|NCT01217476|Placebo Comparator|Matching placebo spray|
3197350|NCT01217463|Active Comparator|Trafermin 0.01% spray|
3197351|NCT01217463|Placebo Comparator|Matching placebo spray|
3197352|NCT01217450|Experimental|Treatment (selumetinib, cetuximab)|Patients receive oral MEK inhibitor AZD6244 once or twice daily on days 1-28 and cetuximab IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3197353|NCT01217437|Experimental|Arm I (temozolomide, irinotecan hydrochloride)|Patients receive temozolomide PO and irinotecan hydrochloride IV over 90 minutes on days 1-5.
3197354|NCT01217437|Experimental|Arm II (temozolomide, irinotecan hydrochloride, bevacizumab)|Patients receive temozolomide PO and irinotecan hydrochloride IV as in arm I and bevacizumab IV over 30-90 minutes on days 1 and 15.
3197355|NCT01217411|Active Comparator|Arm I (WBRT or SRS)|Patients with >= 4 brain lesions undergo WBRT as in phase I and patients with =< 3 brain lesions undergo SRS as in phase I.
3197356|NCT01217411|Experimental|Arm II (WBRT or SRS and RO4929097)|Patients with >= 4 brain lesions receive RO4929097 and undergo WBRT as in phase I and patients with =< 3 brain lesions receive RO4929097 and undergo SRS as in phase I.
3197357|NCT01217385|Experimental|DOSI Pre-Surgery|Participants undergo approximately four assessments of breast health using the DOSI technology during treatment and prior to surgery for breast cancer.
3197358|NCT01217372|Experimental|Lemon supplementation YES|60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
3197359|NCT01217372|No Intervention|Lemon supplementation NO|No lemon supplementation
3197360|NCT01217359|Experimental|Interferon Alfa-2b|Patients will receive a single dose of interferon
3197361|NCT01217346||cardiac syndrome X|subjects fulfilling the clinical triad of cardiac syndrome X
3197362|NCT01217333|Active Comparator|In-person|Participants in this arm have been randomized to receive Consultation Planning in-person
3197363|NCT01217333|Active Comparator|Telephone|Participants in this arm have been randomized to receive Consultation Planning by telephone.
3197364|NCT01217320|Experimental|creatine supplementation|will receive 5g/d of creatine monohydrate throughout the trial
3197365|NCT01217320|Placebo Comparator|placebo|will receive 5g/d of placebo (dextrose) throughout the trial
3197366|NCT01217307|Experimental|Metformin|metformin 500mg twice daily during 4 months
3197367|NCT01217307|Placebo Comparator|Placebo|Placebo twice daily during 4 months
3197368|NCT01217294|Sham Comparator|spinal morphine, sham block|"Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as specified by the anaesthetist performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham ultrasound guided fascia iliaca plane block with saline.~Post-operative analgesia with Paracetamol 1g four times daily, and patient controlled analgesia (PCA) with morphine (1mg bolus, 5 minute lockout period)"
3197369|NCT01217294|Active Comparator|ultrasound guided fascia iliaca block|"Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.~Post-operative analgesia with Paracetamol 1g four times daily, and patient controlled analgesia (PCA) with morphine (1mg bolus, 5 minute lockout period)"
3197370|NCT01217281|No Intervention|Control|"Full mouth supra-gingival debridement using hand instruments and ultrasonic scalers, in one session. Patient motivation and oral hygiene instructions Review and prophylaxis at 1 month, 3 months and 6 months after initial treatment session.~Full mouth periodontal therapy provided at the end of the 6month period (supra and sub- gingival full mouth scaling)"
3197371|NCT01217281|Active Comparator|Test/ Non-surgical Periodontal Therapy|"Full mouth periodontal therapy (sub and supra- gingival debridement) provided under local anaesthesia in two half-mouth sessions.~Review and prophylaxis 1 month, 3 months and 6 months after the end of the initial therapy."
3197372|NCT01217268|Experimental|Training and supervision of staff|Staff members get training in person centered care by supervision using video-conference kit
3197373|NCT01217255||Brazilian Subject's|Subject's will be recruited from the Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paolo (HCFMUSP); Universidade Estadual de Campinas (UNICAMP); Universidade Federal de São Paulo (UNIFESP)
3197374|NCT01217255||Canadian Subject's|Recruited from The Hospital for Sick Children
3197375|NCT01217242||Children with cerebral palsy (CP)|ages 2 to < 10 years who are able to walk with or without an assistive device
3197376|NCT01217229|Experimental|PLX3397|
3197377|NCT01217216|Active Comparator|Group-based Intervention|We randomly assigned 30 individuals to a group-based intervention to promote weight loss through dietary restriction and physical activity.
3197378|NCT01217216|Active Comparator|Telephone-based Intervention|We randomly assigned 22 individuals to the telephone-based intervention to promote weight loss through dietary restriction and physical activity.
3197379|NCT01217203|Experimental|IPH2101 and lenalinomide|
3197380|NCT01217190|Experimental|Ondansetron OSF|
3197381|NCT01217190|Active Comparator|Zofran ODT|
3197382|NCT01217177|Experimental|2.5 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (2.5mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
3197383|NCT01217177|Experimental|5.0 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (5.0mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
3197384|NCT01217177|Experimental|10 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (10mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
3197385|NCT01217164|No Intervention|higher protein|
3197386|NCT01217151|Sham Comparator|Usual treatment|The hemodynamic management will be performed according to the institution's standard of care, using fluids at the discretion of the anesthesiologist and the ICU specialist.
3197387|NCT01217151|Active Comparator|NICOM|"For volume replacement, crystalloids will be used following the standard procedure according to the anesthesiologist or ICU specialist. Mean arterial pressure and cardiac index will be assessed every 5 minutes, and a volume bolus (250 mL colloid in 10 minutes) will be used to achieve a:~Mean arterial pressure ≥ 65 mmHg (intra and postoperatively), AND~Cardiac index ≥ 2.5 L/min/m2 (intra and postoperatively).~If these cardiovascular parameters are not met after the first colloid infusion, a supplementary bolus will be added. In case of not achieving the target, additional colloid boluses and/or pharmacologic support (norepinephrine in case of persistent hypotension, dobutamine in case of low cardiac output) will be provided according to the protocol"
3197388|NCT01217138|Other|Original epinephrine autoinjector group|Participants were given original epinephrine autoinjector trainer wrapped by a gray sticky paper.
3197389|NCT01217138|Active Comparator|Modified epinephrine autoinjector group|Participants were given the same epinephrine autoinjector trainer wrapped by a gray sticky paper which was modified by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.
3197390|NCT01217112|Active Comparator|GWP42004 and placebo|Contains GWP42004 5 mg and placebo (excipients only)
3197391|NCT01217112|Active Comparator|1:1 GWP42003 : GWP42004|Contains 5 mg each of GWP42003 and GWP42004
3197392|NCT01217112|Active Comparator|20:1 GWP42003 : GWP42004|Contains 100 mg GWP42003 and 5 mg GWP42004
3197393|NCT01217112|Placebo Comparator|Placebo|Contains excipients only
3197394|NCT01217112|Active Comparator|GWP42003 and placebo|Contains 100 mg GWP42003 and placebo (excipients only)
3197395|NCT01217099|No Intervention|methylprednisolone|methylprednisolone pulse azithromycin
3197396|NCT01217099|No Intervention|azithromycin|azithromycin
3197397|NCT01217086|Active Comparator|CT-P13|
3197398|NCT01217086|Active Comparator|Remicade|
3197399|NCT01217073|Experimental|Omarigliptin 0.25 mg (Base)|Omarigliptin 0.25 mg administered once weekly for 12 weeks (Base)
3197400|NCT01217073|Experimental|Omarigliptin 1 mg (Base)|Omarigliptin 1 mg administered once weekly for 12 weeks (Base)
3197401|NCT01217073|Experimental|Omarigliptin 3 mg (Base)|Omarigliptin 3 mg administered once weekly for 12 weeks (Base)
3197402|NCT01217073|Experimental|Omarigliptin 10 mg (Base)|Omarigliptin 10 mg administered once weekly for 12 weeks (Base)
3197403|NCT01217073|Experimental|Omarigliptin 25 mg (Base)|Omarigliptin 25 mg administered once weekly for 12 weeks (Base)
3197404|NCT01217073|Placebo Comparator|Placebo (Base)|Matching placebo to omarigliptin administered once weekly for 12 weeks (Base)
3197405|NCT01217073|Experimental|Pooled omarigliptin (Extension)|Participants who received omarigliptin during the base study, received omarigliptin 25 mg once weekly and placebo to metformin once daily for 66 weeks (Extension).
3197406|NCT01217073|Active Comparator|Placebo/Metformin|Participants who received matching placebo to omarigliptin during the base period, received pioglitazone administered once daily and matching placebo to omarigliptin once weekly for 66 weeks (extension period). Note: A protocol amendment removed pioglitazone during the extension period. Participants discontinued pioglitazone and switched to blinded metformin. Participants who were previously rescued with open-label metformin during the base period continued in the extension period on open-label metformin.
3197407|NCT01217060|Experimental|Docetaxel + 5-FU + Radiation + Surgery|Docetaxel 20 mg/m2 given by vein (IV) once a week up to 5 1/2 weeks. Dexamethasone 10 mg IV 30 minutes prior to weekly Docetaxel. 5-FU 300 mg/m2 IV, continuously for 96 hours 5 days a week for about 5 1/2 weeks. Radiation 50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks. Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
3197408|NCT01217047|Experimental|Group A|For 3 weeks, you will need to come to the International Center for Spinal Cord Injury at Kennedy Krieger Institute (ICSCI) one (1) time per week during which you will perform FES cycling for 1 hour each.
3197409|NCT01217047|Experimental|Group B|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform FES cycling for 1 hour each.
3197410|NCT01217047|Experimental|Group C|For 3 weeks, you will need to come to the ICSCI five (5) times per week during which you will perform FES cycling for 1 hour each.
3197411|NCT01217047|Experimental|Group D|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform cycling without FES for 1 hour each.
3197412|NCT01217034|Experimental|TACE with sorafenib|TACE(on demand) with sorafenib till untreatable progression
3197413|NCT01217034|Active Comparator|TACE alone|TACE(on demand) till unreatable progression
3197414|NCT01217021|Experimental|Assess [18F] MNI-558 and PET imaging|
3197415|NCT01217008|Experimental|GRNOPC1|Subjects who receive an injection of GRNOPC1
3197416|NCT01216995|Active Comparator|Dose A|Dose A
3197417|NCT01216995|Placebo Comparator|Placebo|Placebo
3197418|NCT01216982|Active Comparator|Lovaza, omega-3 fatty acid ethyl ester|
3197419|NCT01216982|Placebo Comparator|Placebo|one gram corn oil in a soft gelatin capsule
3197420|NCT01216956|Experimental|Extended release nicotinic acid|
3197421|NCT01216956|Placebo Comparator|Placebo|
3197422|NCT01216943|Experimental|Triple Combination Therapy|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
3197423|NCT01216930||All colorectal cancer patients|
3197424|NCT01216917||Fitness|
3197425|NCT01216917||Whole-body vibration|
3197426|NCT01216917||Control|
3197427|NCT01216904|Placebo Comparator|Placebo patch|
3197428|NCT01216904|Active Comparator|Nicotine patch|
3197429|NCT01216891|Experimental|Team-based treatment|
3197430|NCT01216865|Experimental|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
3197431|NCT01216865|Active Comparator|Standard Therapy|Any therapy for diabetic foot which is routinely practiced and accepted in China
3197432|NCT01216839|Experimental|Everolimus|
3197433|NCT01216826|Experimental|Everolimus|
3197434|NCT01216787|Experimental|Treatment (gamma-secretase inhibitor RO4929097, surgery)|Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Within 35-56 days after completion of therapy, patients with stable or responsive disease undergo surgery. Patients may continue RO4929097 for 28 days after surgery in the absence of disease progression or unacceptable toxicity.
3197435|NCT01216774|Experimental|Low load + fatigue|
3197436|NCT01216774|Active Comparator|High load|
3197437|NCT01216774|Placebo Comparator|Low load|
3197438|NCT01216761|Active Comparator|CHG then PI then IT|"Skin antisepsis prior to any peripheral blood culture collection on Floor A was performed with CHG for 3 months, followed by PI for 3 months, followed by IT for 3 months. Each 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT"
3197439|NCT01216761|Active Comparator|IT then CHG then PI|"Skin antisepsis prior to any peripheral blood culture collection on Floor B was performed with iodine tincture for 3 months, followed by Chlorhexidine gluconate for 3 months, followed by povidone iodine for 3 months. Each 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI"
3197440|NCT01216761|Active Comparator|PI then IT then CHG|"Skin antisepsis prior to any peripheral blood culture collection on Floor C was performed with povidone iodine for 3 months, followed by iodine tincture for 3 months, followed by chlorhexidine gluconate for 3 months. Each 3 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG"
3197441|NCT01216748|Experimental|health life-time non smokers|health lifetime non-smokers will be challenged with 4 respiratory maneuvers:quiet breathing, hypocapnic hyperventilation, hypercapnic hyperventilation, and eucapnic hyperventilation
3197442|NCT01216735|Active Comparator|smokers, Fluticasone first, then Placebo|The current smokers will be given a 3-week treatment course of inhaled fluticasone (220 ug fluticasone twice a day administered as a MDI) . The subjects and the investigators will be blinded to the random choice of inhaler.
3197443|NCT01216735|Placebo Comparator|smokers Placebo first, then Fluticasone|The current smokers will be given a 3-week treatment course of inhaled placebo MDI. The subjects and the investigators will be blinded to the random choice of inhaler.
3197444|NCT01216735|No Intervention|health non-smokers|The healthy non-smokers will have only visit 1 and no intervention.
3197445|NCT01216722|Experimental|Resistance Strengthening|Body weight antigravity positioning and elastic resistance bands are used to provide resistance for strengthening in supine, sitting, and standing in subjects post liver transplant.
3197446|NCT01216722|No Intervention|Usual Care Control|Subjects perform the usual care of progressive ambulation and increased activity post liver transplant
3197447|NCT01216709|Experimental|iron drops|
3197448|NCT01216709|Experimental|iron-fortified formula (2.3 mg iron/L)|
3197449|NCT01216709|Experimental|iron-fortified formula (12.4 mg iron /L)|
3197573|NCT01215747|Placebo Comparator|Placebo|
3197450|NCT01216696|Experimental|Intervention|"Intervention Details:~Drug: ipilimumab~Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first."
3197451|NCT01216683|Experimental|Arm I|Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of induction therapy, patients receive rituximab IV on day 1. Treatment repeats every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
3197452|NCT01216683|Experimental|Arm II|Patients receive rituximab IV on day 1, bortezomib IV on days 1, 4, 8, and 11, and bendamustine hydrochloride IV over 1 hour on days 1 and 4. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of induction therapy, patients receive rituximab as in arm I.
3197453|NCT01216683|Experimental|Arm III|Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 1 hour on days 1 and 2. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Immediately after completing induction therapy, patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for 13 courses in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of induction therapy, patients receive rituximab IV on day 1. Treatment repeats every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
3197454|NCT01216657|Experimental|sunitinib|50 mg Sunitinib daily for 4 weeks, then 2 weeks without treatment
3197455|NCT01216644|Experimental|FLOT|Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP
3197456|NCT01216644|Active Comparator|ECF|Epirubicin 50 mg/m2, d1 Cisplatin 60 mg/m², d1 5-FU 200 mg/m², d1-d21 every 3 weeks (q3w) 3 cycles (9 weeks) pre-OP and 3 cycles (9 weeks) post-OP
3197457|NCT01216631|Active Comparator|IA steroid|Intra-articular injection of steroid (80mg depomedrone)
3197458|NCT01216631|Experimental|IA infliximab|intra-articular injection of 100mg infliximab
3197459|NCT01216631|Experimental|IV infliximab|intravenous infusions of infliximab given at 0, 2, 6 and 14 weeks at a dose of 5mg/kg (patient body weight)
3197460|NCT01216618|Experimental|Device|Subject starts with two clamps including device use follows by a clamp without device use
3197461|NCT01216618|No Intervention|Control|Subject starts with clamps without device
3197462|NCT01216605|Active Comparator|Oxytocin|
3197463|NCT01216605|Placebo Comparator|Placebo|
3197464|NCT01216592||COPD|
3197465|NCT01216579|Placebo Comparator|Reference arm|Asthmatic patients managed as per British Thoracic Society guidelines by symptoms and lung function.
3197466|NCT01216579|Active Comparator|Mannitol managed arm|Group of asthmatic patients managed according to their mannitol challenge.
3197467|NCT01216566|Experimental|I. Patients with chronic neck pain|
3197468|NCT01216553|Active Comparator|hypertonic inhalation + O2|oxygen for 30 minuets after inhalation of 3% saline 4 times daily
3197469|NCT01216553|Active Comparator|Epinephrine & bromhexine nebulized + O2|oxygen for 30 minuets after inhalation of racemic epinephrine with bromhexine 4 times daily
3197470|NCT01216540||Patients receiving vancomycin|
3197471|NCT01216527|Experimental|experimental group|Neo-adjuvant Chemoradiotherapy followed by Surgery
3197472|NCT01216527|Active Comparator|control group|only Surgery
3197473|NCT01216488|Active Comparator|40 ml of Xylocaine|
3197474|NCT01216488|Experimental|25 ml of Xylocaine|
3197475|NCT01216475|Active Comparator|Femtosecond LASIK|2 lasers refractive procedure
3197476|NCT01216475|Experimental|SMILE|Small incision lenticule extraction (SMILE)
3197477|NCT01216449|Experimental|Intravenous Citalopram|
3197478|NCT01216449|Placebo Comparator|Normal Saline|250mL of 0.9% Sodium Chloride Solution
3197479|NCT01216436|Experimental|Vaccine plus untransfected DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm A), each subject will be coinjected with additional mature autologous dendritic cells that are not transfected with RNA.
3197480|NCT01216436|Experimental|Vaccine plus GITRL RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm B), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding the immune modulator GITR-L.
3197481|NCT01216436|Experimental|Vaccine plus antiCTLA4 RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm C), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding immune modulator anti-CTLA4 mAb.
3197482|NCT01216436|Experimental|Vaccine plus GITRL/ antiCTLA4 RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm D), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding both GITR-L and anti-CTLA4 mAb immune modulators.
3197483|NCT01216423||Incidence of recent stroke in patients with PFO|
3197484|NCT01216423||Incidence of recent stroke in patients without PFO|
3197485|NCT01216410|Active Comparator|Metoclopramide|Prophylaxis with metoclopramide and phenylephrine infusion.
3197486|NCT01216410|Placebo Comparator|Phenylephrine infusion|Prophylactic phenylephrine infusion and placebo antiemetics
3197487|NCT01216410|Active Comparator|Combination Group|Metoclopramide and Ondansetron prophylaxis with phenylephrine infusion
3197488|NCT01216397|Experimental|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
3197489|NCT01216397|Experimental|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
3197490|NCT01216384|Experimental|BI 671800 active|SRD part: 3 dose groups each consisting of 12 subjects (9 active, 3 placebo), subjects receive single dose. MRD part: 3 dose groups each consisting of 12 subjects (9 active, 3 placebo), subjects receive single dose followed by multiple doses with a PK sampling interval in between.
3197491|NCT01216384|Placebo Comparator|Placebo|3 subjects will receive placebo in each of the 3 doses in the SRD part and 3 doses in the MRD part
3197492|NCT01216371|Active Comparator|Sunitinib|one year adjuvant treatment with sunitinib
3197493|NCT01216371|Placebo Comparator|Placebo|one year treatment with placebo
3197494|NCT01216358||Arm 1: Combined contraceptive|Initiating an estrogen/progesterone contraceptive
3197495|NCT01216358||Arm 2: Progesterone only contraceptive|Initiating a progesterone-only contraceptive
3197496|NCT01216358||Arm 3 (control): Non-hormonal contraceptive|Initiating or using non-hormonal contraception or not using contraception
3197497|NCT01216332|Experimental|High-Dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
3197498|NCT01216332|Active Comparator|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
3197499|NCT01216319|Experimental|Nipple Reconstruction Cylinder|
3197500|NCT01216306|Experimental|Television reduction curriculum|Students are taught the television reduction curriculum during the school day and parents are invited to attend after-school meetings to discuss reducing their children's television viewing.
3197501|NCT01216306|No Intervention|Control|Students will be taught the standard preschool curriculum.
3197502|NCT01216293|Experimental|Dexlansoprazole 60 mg QD|
3197503|NCT01216293|Active Comparator|Esomeprazole 40mg QD|
3197504|NCT01216293|Placebo Comparator|Placebo QD|
3197505|NCT01216280|Placebo Comparator|2 x 10 mg placebo capsule|2 x 10 mg placebo capsules, administered orally with water, b.i.d.
3197506|NCT01216280|Experimental|10mg Natura-alpha + 10 mg placebo|10 mg Natura-alpha capsule + 10 mg placebo capsule administered orally with water, b.i.d.
3197507|NCT01216280|Experimental|2 x 10 mg Natura-alpha capsules|2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
3197508|NCT01216267|Active Comparator|lansoprazole|lansoprazole for 7 days
3197509|NCT01216254|Active Comparator|Classic electrocoagulation|Arm of the study where the classic low-frequency electrocoagulation is used during the operation
3197510|NCT01216254|Experimental|High Frequency electrocoagulation|Arm of the study where the tested high-frequency electrocoagulation is used during the operation
3197511|NCT01216241|Active Comparator|Daptomycin|Daptomycin intravenous 8mg/kg once per day 5-10 days.
3197512|NCT01216241|Placebo Comparator|Saline Placebo|Saline solution
3197513|NCT01216215||Asthmatic sporadic and familial|
3197514|NCT01216215||Control subjects spradic and familial|
3197515|NCT01216176|Experimental|Phase 1 - Cohort A|Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer
3197516|NCT01216176|Active Comparator|Phase 2 - Cohort B [Anastrozole + AZD0530]|Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 175 mg orally once daily, or as specified per protocol, until disease progression or 4-6 months of treatment completed.
3197517|NCT01216176|Placebo Comparator|Phase 2 - Cohort B [Anastrozole + Placebo]|Dual treatment with 1 mg anastrozole orally once daily together with Placebo orally once daily, or as specified per protocol, until disease progression or4-6 months of treatment completed.
3197518|NCT01216163|Experimental|Treatment A|
3197519|NCT01216163|Active Comparator|Treatment B|
3197520|NCT01216163|Placebo Comparator|Treatment C|
3197521|NCT01216150||aspirin|group treated with aspirin alone
3197522|NCT01216150||aspirin clopidogrel|Goup treated with aspirin and clopidogrel
3197523|NCT01216137|Experimental|Exercise: Vestibular Rehabilitation|Balance and eye movement training
3197524|NCT01216137|Active Comparator|Exercise Control|Bicycle ergometry and stretching
3197525|NCT01216137|No Intervention|Wait-listed Control|Wait-listed Control
3197526|NCT01216098|Experimental|Experimental arm - D|Experimental arm - Women randomized to this arm will receive doula support alongside standard care.
3197527|NCT01216098|No Intervention|No intervention - ND|No intervention - Women randomized to this arm will receive standard care alone.
3197528|NCT01216085|Experimental|imatinib|Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
3197529|NCT01216072|Experimental|Fingolimod|Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period .
3197530|NCT01216072|Active Comparator|Multiple Sclerosis Disease Modifying Treatments (MS DMTs)|Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months. An open-label extension of up to 3 months of treatment with fingolimod was to be available for patients in the DMT arm who successfully completed all study visits.
3197531|NCT01216059|Experimental|Intervention group|Subjects will receive daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study.
3197532|NCT01216059|No Intervention|Control Group|Subjects will receive a weekly text message reminder about pop-culture, sports or weather.
3197533|NCT01216046|Experimental|Treatment Arm|Subjects randomized to study drug will take VX-809 for 14 days followed by a 14 day washout. Next subjects will take VX-770 for 14 days followed by a 14 day washout. Lastly, subjects will take both VX-809 and VX-770 for 14 days.
3197534|NCT01216046|Placebo Comparator|Placebo Arm|Subjects randomized to placebo will take VX-809 placebo for 14 days followed by a 14 day washout. Next subjects will take VX-770 placebo for 14 days followed by a 14 day washout. Lastly, subjects will take both VX-809 and VX-770 placebo for 14 days.
3197535|NCT01216020|Experimental|cetuximab plus radiotherapy|Cetuximab given one week before radiotherapy (loading dose, 400 mg/m2) plus weekly (250 mg/m2), concomitant with radiotherapy (7O Gy on clinically involved sites).
3197754|NCT01214486|Experimental|Raltegravir|
3197536|NCT01216020|Active Comparator|cisplatin plus radiotherapy|CDDP 40 mg/mq in a single weekly 1-hour infusion concomitant to radiotherapy: (70 Gy to clinically involved sites)
3197537|NCT01216007|Active Comparator|TIVA|TIVA
3197538|NCT01216007|Active Comparator|Inhalational|Inhalational/volatile general anesthetic
3197539|NCT01215981|Active Comparator|Participants Receiving 1 Dose of Vaccine|"Control group participants (healthy volunteers):~Age 18 to 50 years~No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome~No flu vaccine in previous 4 months~and/or HSCT recipients who are greater than 60 days post transplant."
3197540|NCT01215981|Active Comparator|Participants Receiving 2 Doses of Vaccine|Hematopoietic stem cell transplant (HSCT) recipients who are greater than 60 days post transplant.
3197541|NCT01215968|Placebo Comparator|Placebo|"Each participant will receive placebo on Week 1. Participants randomized to placebo will receive once-weekly doses of placebo on Weeks 2 to 5.~Placebo will be administered by single subcutaneous injection into the skin of the abdominal wall.~Participants regularly taking metformin will continue their normal dosing regimen throughout the study."
3197542|NCT01215968|Experimental|LY2189265|"Participants randomized to LY2189265 will receive once-weekly doses of LY2189265 on Weeks 2 to 5.~1.5 milligram (mg) LY2189265 will be administered by single subcutaneous injection into the skin of the abdominal wall.~Participants regularly taking metformin will continue their normal dosing regimen throughout the study."
3197543|NCT01215955|Experimental|3 Day Algorithm|"Basal insulin glargine plus mealtime bolus insulin lispro titrated based on blood glucose readings from the past three days.~(Sites were assigned to Study A and Study B according to an allocation plan that was pre-specified before initiation of Study A and Study B)"
3197544|NCT01215955|Experimental|Daily Algorithm|"Basal insulin glargine plus mealtime bolus insulin lispro titrated based on blood glucose readings from the previous day.~(Sites were assigned to Study A and Study B according to an allocation plan that was pre-specified before initiation of Study A and Study B)"
3197545|NCT01215942|Experimental|120 milligrams (mg) of LY2127399|"Given every 4 weeks for 240 weeks for those participants from Study BCDO or Study BCDV. Participants who had been receiving placebo immediately prior to enrollment will receive a 240 mg loading dose when initiating treatment.~Or~Given every 4 weeks for 168 weeks for those participants from Study BCDM."
3197546|NCT01215942|Experimental|90 mg LY2127399|"Given every 2 weeks for 240 weeks for those participants from Study BCDO or Study BCDV. Participants who had been receiving placebo immediately prior to enrollment will receive a 180 mg loading dose when initiating treatment.~Or~Given every 2 weeks for 168 weeks for those participants from Study BCDM."
3197547|NCT01215929|Active Comparator|Dextroamphetamine|
3197548|NCT01215929|Placebo Comparator|Placebo|
3197549|NCT01215916|Experimental|Pemetrexed followed by LY573636|Pemetrexed on Day 1 followed by LY573636 on Day 4
3197550|NCT01215916|Experimental|LY573636 followed by Pemetrexed|LY573636 on Day 1, Pemetrexed on Day 4
3197551|NCT01215903|Experimental|Fish gelatin and omega-3|
3197552|NCT01215903|Experimental|Omega-3|
3197553|NCT01215890|Active Comparator|risedronate plus calcium and viamin D|
3197554|NCT01215890|Placebo Comparator|placebo plus clacium and vitamin D|
3197555|NCT01215864|Experimental|TCD-717|
3197556|NCT01215851|Experimental|TMC207|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus pyrazinamide placebo administered once daily
3197557|NCT01215851|Experimental|TMC207 and pyrazinamide|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: < or = 55kg received 2 tablets/day; >55kg to 75kg received 3 tablets/day; >75kg received 4 tablets/day
3197558|NCT01215851|Experimental|PA-824 and pyrazinamide|PA-824 administered once daily as 200mg tablets and pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: < or = 55kg received 2 tablets/day; >55kg to 75kg received 3 tablets/day; >75kg received 4 tablets/day and moxifloxacin placebo (matched to moxifloxacin tablets) administered once daily
3197559|NCT01215851|Experimental|PA-824 and moxifloxacin and pyrazinamide|PA-824 administered once daily as 200mg tablets and pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: < or = 55kg received 2 tablets/day; >55kg to 75kg received 3 tablets/day; >75kg received 4 tablets/day and moxifloxacin administered once daily as 400mg tablets
3197560|NCT01215851|Active Comparator|Rifafour e-275 mg|Rifafour e-275 administered once daily with each tablet containing 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, and 275mg ethambutol and dose by weight as follows: 30kg-37kg received 2 tablets/day; 38kg-54kg received 3 tablets/days; 55kg-70kg received 4 tablets/day; > or = 71kg received 5 tablets/day
3197561|NCT01215851|Experimental|TMC207 and PA-824|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus PA-824 administered once daily as 200mg tablets
3197562|NCT01215825||HD, LD, NIL|HD: the highest daily dose of steroids receiving more than 60 mg/day LD: the highest daily dose of steroids receiving less or equal to 60 mg/day NIL: no steroid use
3197563|NCT01215799|Experimental|Bafetinib|
3197564|NCT01215786|Other|AGN-207281 ophthalmic solution|AGN-207281 0.1% ophthalmic solution on Days 1-7 and AGN-207281 0.3% ophthalmic solution on Days 8-14
3197565|NCT01215786|Active Comparator|Timolol ophthalmic solution 0.5%|timolol ophthalmic solution 0.5%
3197566|NCT01215786|Placebo Comparator|Placebo|AGN-207281 vehicle ophthalmic solution (Placebo)
3197567|NCT01215773|Experimental|BI 671800 HEA medium dose|Tablet, oral administration with 240 mL of water for each treatment
3197568|NCT01215773|Experimental|BI 671800 HEA high dose|2 Tablets, oral administration with 240 mL of water for each treatment
3197569|NCT01215773|Placebo Comparator|Placebo|Matching to HEA 200 mg tablets, oral administration
3197570|NCT01215760|Active Comparator|MIRROR|Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
3197571|NCT01215760|Active Comparator|Home program|The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
3197574|NCT01215734|Active Comparator|High-Dose Trivalent Inactivated Influenza Vaccine|Forty adult hematopoetic stem cell transplant recipients at least 6 months post transplant will receive high dose trivalent influenza vaccine
3197575|NCT01215734|Active Comparator|Standard dose Trivalent Inactivated Flu Vaccine|Twenty Adult stem cell transplant recipients at least 6 months post transplant will receive standard dose trivalent influenza vaccine.
3197576|NCT01215721|Experimental|Vesicare|Vesicare 5mg daily for 90 days was prescribed for men presenting with post-Robotic Assisted Radical Prostatectomy (RARP) severe incontinence.
3197577|NCT01215708|Active Comparator|Nifedipine|nifedipine retard 20mg daily
3197578|NCT01215708|Active Comparator|tamsulosin|tamsulosin 0,4mg
3197579|NCT01215708|Placebo Comparator|placebo|placebo capsule
3197580|NCT01215695|Active Comparator|Control|Patients will be randomly assigned to having their ETT placed with use of a pre-formed stylet provided by the manufacturer of the GVL (control group)
3197581|NCT01215695|Experimental|Intervention|Patients will be randomly assigned to either having their ETT placed with use of flexible, disposable tracheoscope (aScope, Ambu, Denmark) (intervention group).
3197582|NCT01215682|Active Comparator|vit D|
3197583|NCT01215682|Placebo Comparator|placebo|
3197584|NCT01215669|Experimental|Group 1: Adult Intradermal (ID) Vaccine|Participants aged 18 to 59 years will be vaccinated with IDflu™ influenza vaccine
3197585|NCT01215669|Active Comparator|Group 2: Adult Intramuscular (IM) Vaccine|Participants aged 18 to 59 years will be vaccinated with Vaxigrip® Influenza vaccine
3197586|NCT01215669|Experimental|Group 3: Elderly Intradermal (ID) Vaccine|Participants aged 60 years or older will be vaccinated with IDflu™ Influenza vaccine
3197587|NCT01215669|Active Comparator|Group 4: Elderly Intramuscular (IM) Vaccine|Participants aged 60 years or older will be vaccinated with Vaxigrip® Influenza vaccine
3197588|NCT01215656|Experimental|Probiotic|follow on formula with the probiotic Lactobacillus fermentum
3197589|NCT01215656|Active Comparator|Control|follow on formula without probiotics
3197590|NCT01215643|Experimental|ALV 1000 mg|Alisporivir (ALV) 600 mg twice daily (BID) for 1 week, followed by ALV 1000 mg once daily (QD) during Weeks 2 to 24.
3197591|NCT01215643|Experimental|ALV 600 mg+RBV|Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with ribavirin (RBV) during Weeks 2 to 24.
3197592|NCT01215643|Experimental|ALV 800 mg+RBV|Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
3197593|NCT01215643|Experimental|ALV 600 mg+PEG|Alisporivir (ALV) 600 mg BID with Peginterferon alfa-2a (PEG) for 1 week, followed by ALV 600 mg QD with PEG once weekly during Weeks 2 to 24.
3197594|NCT01215643|Active Comparator|PEG+RBV|Peginterferon alfa-2a (PEG) and RBV during Weeks 1 to 24.
3197595|NCT01215630||Healthy subjects|Men Women Age; 18-75
3197596|NCT01215617|Experimental|Aerobic Interval Training|Patients randomized to training will meet for supervised aerobic interval training three times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate
3197597|NCT01215617|Other|Control|Patients will receive standard medical treatment at the University Hospital lung department.
3197598|NCT01215591|Active Comparator|Gradual wean from Nasal CPAP|Nasal CPAP for gradual wean group it was cycled off for 3 hours alternating with 3 hours on for first 48 hours, if successful the cycle was extended to 6 hours off and 3 hours on for the next 48 hours. If the baby tolerated this regime the prongs were removed and CPAP was kept off.
3197599|NCT01215591|No Intervention|Sudden wean from Nasal CPAP|Usual practice to wean the preterm neonates from nasal CPAP
3197600|NCT01215578|Experimental|patient treated|patient who receive sunitinib (SUTENT)
3197601|NCT01215565|Experimental|patient treated|patient who receive sunitinib
3197602|NCT01215552|Experimental|HT-0712|
3197603|NCT01215539|Experimental|Panitumumab,capecitabine,oxaliplatin|"Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg.~Oxaliplatin 130 mg/m2 IV infusion over 2 hours on Day 1 Capecitabine 2000 mg/m2 divided in two doses, orally, on Days 1 - 14"
3197604|NCT01215513|Experimental|Degarelix|
3197605|NCT01215500|Experimental|Radiation therapy|
3197606|NCT01215487||1 - Chronic Myelogenous Leukemia Patients|Patients will be selected from patients referred to the primary hospital site for treatment and assessment. The patients will be approached by the physicians and or the study research nurse to consider participation in the study. Patients may be selected by participating off-site hospital centres and may be enrolled at those collaborating centres.
3197607|NCT01215474||NSCLC Stadium III-IV|
3197608|NCT01215448|No Intervention|Lifestyle changes|Lifestyle changes(booklet and audio cassette of recommended diet, physical activity and breathing exercises)
3197609|NCT01215448|Experimental|Wheatgrass juice & lifestyle changes|Wheatgrass juice & lifestyle changes
3197610|NCT01215435|Experimental|Pre-breakfast BIAsp 30|
3197611|NCT01215435|Experimental|Pre-dinner BIAsp 30|
3197612|NCT01215422||children intubated with Glidescope|children intubated with Glidescope
3197613|NCT01215422||children intubated with DCI|children intubated with DCI
3197614|NCT01215409||Group 1|
3197615|NCT01215396|Placebo Comparator|Carbohydrate Placebo|
3197616|NCT01215396|Active Comparator|Single Dose|"The Amino Vital Focus Zone is a dietary supplement of amino acid mixture, which also contains some minerals, vitamin C, flavour, and sweetener, and its appearance is clear to slightly opaque powder. The Amino Vital Focus Zone contains the five kind of amino acid (L-Leucine, L-Isoleucine, L-Valine, L-Arginine, and L-Glutamine), Citric acid, Vitamin C, some mineral, and sweetener.~Powdered treatments will be dissolved in water and administered orally. This treatment will contain 0.96 g of amino acids."
3197617|NCT01215396|Active Comparator|Double Dose|"The Amino Vital Focus Zone is a dietary supplement of amino acid mixture, which also contains some minerals, vitamin C, flavour, and sweetener, and its appearance is clear to slightly opaque powder. The Amino Vital Focus Zone contains the five kind of amino acid (L-Leucine, L-Isoleucine, L-Valine, L-Arginine, and L-Glutamine), Citric acid, Vitamin C, some mineral, and sweetener.~Powdered treatments will be dissolved in water and administered orally. This treatment will contain 1.92 g of amino acids."
3197801|NCT01214122|Experimental|Treatment A|AZD9668 - 2 x30mg tablets
3197618|NCT01215383||psychiatric patients|20 in patients and outpatients with schizophrenia, schizoaffective and bipolar disorder based on psychiatrist diagnostic evaluation using DSM-IV criteria, before and at least two months after antipsychotic therapy will be enrolled.
3197619|NCT01215383||healthy volunteers|"Ten healthy volunteers will be checked as controls:~Employee from the hospital staff with no metabolic disease (Diabetes mellitus, hypertension or dyslipidemia) and non-smokers."
3197620|NCT01215357|Experimental|Ecopipam|Ecopipam is a selective antagonist of one the classes of dopamine receptor.
3197621|NCT01215344|Experimental|VRD|VELCADE, Lenalidomide, Dexamethasone
3197622|NCT01215344|Experimental|VDD|VELCADE, liposomal doxorubicin, dexamethasone
3197623|NCT01215331|Active Comparator|Insulin|Rapid acting insulin and long acting insulin
3197624|NCT01215331|Experimental|Oral Hypoglycemic Agents|Metformin + glyburide + insulin if needed
3197625|NCT01215305||Visiting outpatient departments, if symtoms|patients with upper GI symptoms, visiting the outpatient departments of peripheral hospitals in Greece
3197626|NCT01215292|Placebo Comparator|Acyline & T Gel & Placebo Ketoconazole|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel (T gel) 5 gm daily Days 1-10, + placebo tab PO 1x daily, Day 3-10
3197627|NCT01215292|Experimental|Acyline & T Gel & Ketoconazole 400|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Days 1-10, + ketoconazole 400mg PO 1x daily, Days 3-10
3197628|NCT01215292|Experimental|Acyline & T gel & Ketoconazole 800|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + ketoconazole 800mg PO 1x daily, Days 3-10
3197629|NCT01215292|Experimental|Acyline & T gel & Dutasteride|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + dutasteride 2.5 mg PO 1x daily, Days 3-10
3197630|NCT01215292|Experimental|Group 5: anastrazole|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + anastrazole 1 mg PO 1x daily, Days 3-10
3197631|NCT01215279|Experimental|AZD2423|AZD2423 Oral Treatment for 28 days
3197632|NCT01215279|Placebo Comparator|Placebo|Oral treatment for 28 days
3197633|NCT01215266|Active Comparator|Sorafenib|
3197634|NCT01215266|Placebo Comparator|Placebo|
3197635|NCT01215253|Active Comparator|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at end of first week. For patients on anti-arrhythmic therapy at the time of randomization, their ECG will be checked at end of first week on 500 mg dose and again at end of second week on 1000 mg dose. For patients with CrCl <60ml/min prior to randomization, their CrCl will be checked again at 2 weeks and study drug discontinued if <30ml/min. For patients with CrCl <60ml/min at 2 weeks, their CrCl will be checked again at 4 weeks and study drug discontinued if <30ml/min.
3197636|NCT01215253|Placebo Comparator|Placebo|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at end of first week. For patients on anti-arrhythmic therapy at the time of randomization, their ECG will be checked at end of first week on 500 mg dose and again at end of second week on 1000 mg dose. For patients with CrCl <60ml/min prior to randomization, their CrCl will be checked again at 2 weeks and study drug discontinued if <30ml/min. For patients with CrCl <60ml/min at 2 weeks, their CrCl will be checked again at 4 weeks and study drug discontinued if <30ml/min.
3197637|NCT01215240|Experimental|Prophylactic peritoneal dialysis|Prophylactic peritoneal dialysis
3197638|NCT01215227|Experimental|Preladenant 2 mg|Participants who received preladenant 2 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 2 mg in this extension study. Participants will receive preladenant 2 mg taken orally twice daily (BID): one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
3197639|NCT01215227|Experimental|Preladenant 5 mg|Participants who received preladenant 5 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 5 mg in this extension study. Participants will receive preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
3197640|NCT01215227|Experimental|Preladenant 5 mg (on placebo in parent study)|Participants who received placebo to preladenant tablet in parent study NCT01155466 or NCT01227265 will receive preladenant 5 mg in this extension study. Participants will receive preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
3197641|NCT01215227|Experimental|Preladenant 10 mg|Participants who received preladenant 10 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 10 mg in this extension study. Participants will receive preladenant 10 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
3197642|NCT01215227|Active Comparator|Rasagiline 1 mg|Participants who received rasagiline 1 mg in parent study NCT01155466 or NCT01227265 will continue to receive rasagiline 1 mg in this extension study. Participants will receive rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.
3197643|NCT01215227|Active Comparator|Rasagiline 1 mg (on placebo in parent study)|Participants who received placebo to rasagiline capsule in parent study NCT01155466 or NCT01227265 will receive rasagiline 1 mg in this extension study. Participants will receive rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.
3197644|NCT01215214|Experimental|midazolam|period 1: midazolam administration alone period 2: ketoconazole 400 mg PO for 4 days administration, midazolam iv single administration period 3: rifampicin 600 mg PO for 9 days administration, midazolam iv single administration
3197645|NCT01215201|Other|Scaling and root planing|Control group
3197646|NCT01215188|Experimental|V114 Aluminum-adjuvanted|
3197647|NCT01215188|Experimental|V114 Non-adjuvanted|
3197648|NCT01215188|Active Comparator|Prevnar 13™|
3197649|NCT01215175|Experimental|Adults-Adjuvanted V114|V114, aluminum-adjuvanted single intramuscular (IM) 0.5 mL injection
3197650|NCT01215175|Active Comparator|Adults-Prevnar™|Prevnar™, single intramuscular (IM) 0.5 mL injection
3197651|NCT01215175|Experimental|Toddlers-Adjuvanted V114|V114, aluminum-adjuvanted single intramuscular (IM) 0.5 mL injection
3197802|NCT01214122|Experimental|Treatment B|Warfarin - 10 x2.5 mg tablets
3197652|NCT01215175|Experimental|Toddlers-Non-adjuvanted V114|V114, non-adjuvanted single intramuscular (IM) 0.5 mL injection
3197653|NCT01215175|Active Comparator|Toddlers-Prevnar™|Prevnar™, single intramuscular (IM) 0.5 mL injection
3197654|NCT01215162|Experimental|Single arm study|Patients with stage T1/T2No breast cancer receiving breast conserving treatment
3197655|NCT01215149|Experimental|Group A|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 6. Vaccine:Placebo=10:3
3197656|NCT01215149|Experimental|Group B|Ad35-ENVA at Month 0 followed by Ad26.ENVA.01 at Month 6. Vaccine:Placebo=10:3
3197657|NCT01215149|Experimental|Group C|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=10:3
3197658|NCT01215149|Experimental|Group D|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=10:3
3197659|NCT01215149|Experimental|Group E|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
3197660|NCT01215149|Experimental|Group F|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
3197661|NCT01215149|Experimental|Group G|Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
3197662|NCT01215149|Experimental|Group H|Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
3197663|NCT01215149|Experimental|Group I|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
3197664|NCT01215149|Experimental|Group J|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
3197665|NCT01215149|Experimental|Group K|Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
3197666|NCT01215149|Experimental|Group L|Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
3197667|NCT01215136|Active Comparator|Cohort 1|Single-agent everolimus (enrollment limited to patients with patients with creatinine clearance < 60 ml/min AND Karnofsky performance status of 60-70%)
3197668|NCT01215136|Active Comparator|Cohort 2|Everolimus plus paclitaxel (enrollment limited to patients with creatinine clearance < 60 ml/min OR Karnofsky performance status of 60-70%)
3197669|NCT01215123||Bevacizumab|Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
3197670|NCT01215110|Experimental|TMC207 700/500/400|TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14
3197671|NCT01215110|Experimental|TMC207 500/400/300|TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.
3197672|NCT01215110|Experimental|TMC207 400/300/200|TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14
3197673|NCT01215110|Experimental|TMC207 200/100|TMC207- 200 mg Day 1 and 100 mg Days 2-14
3197674|NCT01215110|Active Comparator|Rifafour e-275 mg|Rifafour e-275 mg
3197675|NCT01215097|Experimental|Linagliptin|once a day
3197676|NCT01215097|Placebo Comparator|placebo|once a day
3197677|NCT01215084|Experimental|Chinese Subpopulation: Fampridine-PR 10 mg|Chinese ethnic participants were administered a single dose of Fampridine-PR 10 mgs
3197678|NCT01215084|Experimental|Japanese Subpopulation: Fampridine-PR 10mg|Japanese ethnic participants were administered a single dose of Fampridine-PR 10 mgs
3197679|NCT01215084|Experimental|Caucasian Subpopulation: Fampridine-PR 10mg|Caucasian ethnic participants were administered a single dose of Fampridine-PR 10 mgs
3197680|NCT01215071|Experimental|limited lymphadenectomy|Fields 5, 7, 9, 11, 13, 14 are removed
3197681|NCT01215071|Experimental|extended lymphadenectomy|Fields 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 are removed
3197682|NCT01215058||1|
3197683|NCT01215045||ReSTOR +4|AcrySof ReSTOR Aspheric +4
3197684|NCT01215032|Experimental|Metformin|This is the only arm of this phase 2 open label study
3197685|NCT01215019|Active Comparator|Arm 1|20% Mannitol
3197686|NCT01215019|Active Comparator|Arm 2|3% sodium chloride
3197687|NCT01214993|Experimental|Treatment A|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive GSK1349572 50mg (two 25mg tablets) q24h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
3197688|NCT01214993|Experimental|Treatment B|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive GSK1349572 50mg (two 25mg tablets) q12h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
3197689|NCT01214993|Placebo Comparator|Treatment C|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive placebo q24h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
3197690|NCT01214980|Experimental|MIST Therapy in conjunction with SOC|Low-frequency, non-contact ultrasound administered in conjunction with standard of care treatment
3197691|NCT01214980|Active Comparator|Control arm|Standard of care treatment
3197692|NCT01214967|Experimental|1|Problem Solving Education, a psycho-educational intervention
3197693|NCT01214967|No Intervention|2|Usual care
3197694|NCT01214954|Active Comparator|Control group|Standard rehabilitation
3197695|NCT01214954|Experimental|Resistance training|10 weeks of supervised progressive resistance training initiated within the first week after total hip replacement.
3197696|NCT01214941|Placebo Comparator|Placebo|
3197697|NCT01214941|Active Comparator|Ticlopidine|
3197698|NCT01214941|Active Comparator|Ticlopidine and itraconazole|
3197699|NCT01214928|Active Comparator|Cholecalciferol|Cholecalciferol 50,000IU po once weekly for 12 continuous weeks.
3197700|NCT01214928|Placebo Comparator|Placebo|Matching placebo po once weekly for 12 continuous weeks
3197701|NCT01214915|Experimental|Anagrelide Hydrochloride|
3197702|NCT01214902|Experimental|Experimental CIMT|Two month home program that includes restricting the non hemiplegic hand an hour a day during play
3197703|NCT01214902|Active Comparator|Active Play|Two month home program that includes active use of hemiplegic hand during play one hour a day
3197889|NCT01213524|Active Comparator|usual brand smoking|positive control: usual brand smoking
3197704|NCT01214889|Experimental|Study Group A|Participants will receive a single dose of DTacP-IPV//PRP T combined vaccine (PENTAXIM™) at age 2, 4 and 6 months.
3197705|NCT01214889|Active Comparator|Study Group B|Participants will receive a dose of DTacP IPV combined vaccine (TETRAXIM™) and PRP-T vaccine (ActHIB™) at 2, 4, and 6 months of age.
3197706|NCT01214876||Children 1-5 years old|
3197707|NCT01214876||Children 6-10 years old|
3197708|NCT01214876||Adults 25 years and above|
3197709|NCT01214863||T3|Model SN60T3 assigned by AcrySof Toric calculator
3197710|NCT01214863||T4|Model SN60T4 assigned by AcrySof Toric calculator
3197711|NCT01214863||T5|Model SN60T5 assigned by AcrySof Toric calculator
3197712|NCT01214850|Experimental|rMenB+OMV|Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart
3197713|NCT01214850|Experimental|MenACWY|Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart
3197714|NCT01214850|Active Comparator|Control|Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart
3197715|NCT01214837|Experimental|MenACWY3|Subjects received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
3197716|NCT01214837|Experimental|MenACWY4|All the subjects received a 3-dose primary series at 2, 4 and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
3197717|NCT01214837|Placebo Comparator|Routine Vaccines|Subjects received routine vaccines only, including PCV-13, at 2, 4 and 6 months of age and a toddler dose at 12 months of age.
3197718|NCT01214811|Other|Mepilex Border Ag|Non comparative study with one active arm - Mepilex Border Ag
3197719|NCT01214785|Active Comparator|Sanitation intervention|
3197720|NCT01214785|No Intervention|Control|
3197721|NCT01214772|Experimental|heparin,pregnancy,IVF failure|Women in the heparin arm are administered 5000 IU twice a day on the day of embryo transfer
3197722|NCT01214759|Other|Truvada and Raltegravir|Single arm
3197723|NCT01214746|Placebo Comparator|Placebo|
3197724|NCT01214746|Active Comparator|Atorvastatin|
3197725|NCT01214733|Experimental|1|
3197726|NCT01214720|Experimental|1|
3197727|NCT01214707||Exercise protocol|No arms are required for this study as all subjects complete the entire protocol
3197728|NCT01214694|Experimental|Active Comparator: Internet Resources Comparison (IRC)|Participants will receive the Internet resource comparison group treatment
3197729|NCT01214694|Experimental|I-InTERACT|Participants will receive a 24 week, 27 session internet-based parenting skills program
3197730|NCT01214694|Experimental|I-InTERACT Express|Participants will receive an abbreviated 7 week, 14 session version of the I-InTERACT parenting skills program.
3197731|NCT01214681|Placebo Comparator|Placebo|
3197732|NCT01214681|Experimental|Hi-maize 260|
3197733|NCT01214681|Experimental|Polydextrose|
3197734|NCT01214681|Active Comparator|Hi-maize 260 and polydextrose|
3197735|NCT01214668|Experimental|LY573636 + Liposomal Doxorubicin|
3197736|NCT01214655|Experimental|LY2523355 1,2,3|Days 1,2 and 3. Starting dose is 2mg/m2.
3197737|NCT01214655|Experimental|LY2523355 1,5,9|Days 1, 5 and 9. Starting dose is 8mg/m2.
3197738|NCT01214642|Experimental|LY2523355 Days 1, 5, 9|LY2523355 administered intravenously on Days 1, 5 and 9, starting dose is 2 milligrams per meter squared (mg/m^2) for 2 planned 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
3197739|NCT01214642|Experimental|LY2523355 Days 1, 8|LY2523355 administered intravenously on Days 1 and 8, starting dose is 8 mg/m^2 for 2 planned 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
3197740|NCT01214642|Experimental|LY2523355 Days 1, 5 + pegfilgrastim|LY2523355 administered intravenously on Days 1 and 5, starting dose is 8 mg/m^2 for 2 planned 21-day cycles and 6 mg pegfilgrastim administered subcutaneously on Day 6 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
3197741|NCT01214642|Experimental|LY2523355 Days 1, 4 + pegfilgrastim|LY2523355 administered on Days 1 and 4, starting dose is 12 mg/m^2 for 2 planned 21-day cycles and 6 mg pegfilgrastim administered subcutaneously on Day 5 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
3197742|NCT01214629|Experimental|LY2523355|
3197743|NCT01214629|Experimental|LY2523355 + pegfilgrastim|
3197744|NCT01214616|Experimental|afatinib and vinorelbine IV|patient to receive 20mg or 40mg of po daily afatinib in combination with vinorelbine IV
3197745|NCT01214603|Experimental|LY2090314|"The dose to be evaluated is 40mg LY2090314 administered on days 1, 8 and 15 of a 28 day cycle for at least two (2) 28 day cycles. Patients experiencing clinical benefit may continue treatment until after the discontinuation criteria are met.~Due to amendment on September 2010, study added two additional treatment schedules. Schedule 1 is a 40 mg dose given on Days 1, 5, and 9 of a 21-day cycle. Schedule 2 is 40 mg dose given on Days 1, 5, 9, and 12 of a 21-day cycle. Participants experiencing clinical benefit may continue treatment until after the discontinuation criteria are met."
3197746|NCT01214590|Experimental|VascuActive Treatment|
3197747|NCT01214577|Experimental|1|Up to three days of treatment
3197748|NCT01214564|Experimental|1|Up to three days of treatment
3197749|NCT01214538||Control group - culture negative|50 children with pneumococcal culture-negative Acute Otitis Media
3197750|NCT01214538||study group- culture positive|50 children with pneumococcal culture-positive Acute Otitis Media
3197751|NCT01214525||Meatotomy|Toilet trained children scheduled for urethral meatotomy for the treatment of urethral meatal stenosis.
3197752|NCT01214499|Active Comparator|Treatment Control|Transmyocardial revascularization (TMR) with Holmium YAG (yttrium aluminium garnet) laser, according to habitual clinical practice in the Department of Cardiovascular Surgery.
3197753|NCT01214499|Experimental|Experimental Treatment|Transmyocardial revascularization (TMR) with Holmium YAG laser plus the patient's own stem cells extracted from bone marrow.
3197755|NCT01214473|Experimental|Probiotic group|Once daily oral administration of a probiotic preparation (1 billion cells of Lactobacillus plantarum and 150 mg of fructooligosaccharides) for one week to newborn infants
3197756|NCT01214473|Placebo Comparator|Placebo|Once daily oral administration of maltodextrin for one week to newborn infants
3197757|NCT01214460||All MET calls|We make an Utstein type analyze to all MET calls
3197758|NCT01214460||All EMS calls|We make an Utstein type analyze to all EMS calls during June 2015
3197759|NCT01214460||All patient in the emergency department|We make an Utstein type analyze to all Emergency visits during June 2015
3197760|NCT01214447||Low - OSND less than 22|
3197761|NCT01214447||Moderate - OSND score 23-27|
3197762|NCT01214447||Normal - OSND score 28-32|
3197763|NCT01214434|Experimental|Promiseb Topical Cream|
3197764|NCT01214434|Sham Comparator|Bland emollient|
3197765|NCT01214421|Experimental|251 Prior Tolvaptan|"Tolvaptan tablets (as multiples of 15 or 30 mg) will be given orally twice daily until the last subject originating from the 156-04-251 trial who is eligible for efficacy analysis has completed the Month 24 visit. Dosing should occur on waking and approximately 9 hours later, irrespective of meals. Exact timing of dosing may be adjusted based on wake/sleep habits (eg, standard 8 AM and 5 PM may be switched to 10 PM and 7 AM if working a night shift). However, dosing times should be consistent for each individual's daily dose to maximize receptor suppression.Subjects should be titrated to the highest dose tolerated unless an equivalent dose was not tolerated and was associated with a significant adverse event in a prior trial. For example, the following titration schedule could be followed:~Day 0 - 45/15 mg split-dose regimen assigned Week 1 - tolerated dose, up-titrate to 60/30 mg Week 2 - tolerated dose, up-titrate to 90/30 mg Week 3 - tolerated dose, 90/30 mg continued."
3197766|NCT01214421|Experimental|251 Prior Placebo|Subjects on Placebo from a previous open-label trial and not on tolvaptan at the baseline visit, initial dosing will commence with the lowest dose regimen and up-titrated to the last tolerated dosing regimen (as explained above).
3197767|NCT01214421|Experimental|Other Prior Study|For subjects enrolling from a previous open-label trial and are on tolvaptan at the baseline visit, initial dose assignment will remain consistent with the dose regimen the subject is currently on. Should a subject enroll from a previous open-label trial and not be on tolvaptan at the baseline visit, initial dosing will commence with the lowest dose regimen and up-titrated to the last tolerated dosing regimen (as explained above).
3197768|NCT01214408|Experimental|GRP-A|
3197769|NCT01214408|Experimental|GRP-B|
3197770|NCT01214382|Experimental|Sertraline|
3197771|NCT01214369|Active Comparator|X-tip intraosseous injection|
3197772|NCT01214369|Active Comparator|PDL injection|
3197773|NCT01214356|Placebo Comparator|Lower Dose Vitamin D|Vitamin D3 supplementation of 400 IU/D or 4000 IU/D with combined calcium carbonate supplementation of 1000 mg/day
3197774|NCT01214356|Active Comparator|Higher Dose Vitamin D|Vitamin D3 supplementation of 4000 IU/D or 4000 IU/D with combined calcium carbonate supplementation of 1000 mg/day
3197775|NCT01214343|Experimental|Sorafenib with Low-dose FP|
3197776|NCT01214343|Active Comparator|Sorafenib|
3197777|NCT01214330|Experimental|Patient-Collected Cervical Pap Smear|women will receive a self Papanicolaou Smear test (SoloPap) in addition to their physician-collected Papanicolaou Smear
3197778|NCT01214317|Active Comparator|mitoxantrone and plasmapheresis|
3197779|NCT01214317|No Intervention|mitoxantrone|
3197780|NCT01214304|Placebo Comparator|Lavender Scent|Patients will receive aromatherapy with a fake lavender scent (placebo) which will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure.
3197781|NCT01214304|Experimental|Essential Lavender Oil|Patients will receive essential Lavender Oil which will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure.
3197782|NCT01214278|Experimental|Supplement 1|EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil uncoated capsules
3197783|NCT01214278|Experimental|Supplement 2|EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG)
3197784|NCT01214278|Experimental|Supplement 3|EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules
3197785|NCT01214278|Experimental|Supplement 4|DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL)
3197786|NCT01214252||Permacol Patients|Patients who have undergone surgical repair of their abdominal wall defect with Permacol Surgical Implants with at least 12 months follow up.
3197787|NCT01214239|Experimental|Linagliptin|once a day
3197788|NCT01214239|Placebo Comparator|Placebo|once a day
3197789|NCT01214226|Active Comparator|Pentoxifylline + Prednisolone|"Pentoxifylline 400 mg prolonged-released tablets 3 time a day [1200 mg/day]~+ Prednisolone 2 ORODISPERSIBLE TABLETS OF 20 MG 1 TIME PER DAY [40 mg/day]"
3197790|NCT01214226|Placebo Comparator|Placebo + Prednisolone|"Placebo prolonged-release tabled 3 time a day~+ Prednisolone 2 ORODISPERSIBLE TABLETS OF 20 MG 1 TIME PER DAY [40 mg/day]"
3197791|NCT01214200|Experimental|High Intensity Non-invasive Pos.Pressure|The High Intensity Non-invasive Pos.Pressure trial is a single arm interventional study. All participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation (HINPPV). Participants will receive HINPPV via bilevel positive airway pressure (BiPAP) if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O; or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
3197792|NCT01214187|Experimental|carbon monoxide inhalation|The primary intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
3197793|NCT01214187|Placebo Comparator|Oxygen 21%|
3197794|NCT01214174|Experimental|Dose 1|513ug
3197795|NCT01214174|Experimental|Dose 2|776ug
3197796|NCT01214174|Experimental|Dose 3|1046ug
3197797|NCT01214161|Experimental|lidocaine gel|This group will be those randomized to receiving the intervention with 2% lidocaine gel.
3197798|NCT01214161|Placebo Comparator|placebo gel (surgilube)|This group will be randomized to having the intervention with the placebo surgilube gel.
3197799|NCT01214148|Other|ORSIRO|
3197800|NCT01214135||1|Patients with a diagnosis of schizophrenia who have been hospitalized and received at least one dose of Seroquel XR or Seroquel IR during the study period (1st of July 2009 - 30th of September 2010).
3197803|NCT01214109|Experimental|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
3197804|NCT01214109|Active Comparator|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
3197805|NCT01214096|Placebo Comparator|placebo|
3197806|NCT01214096|Experimental|rhNRG-1|recombinant human neuregulin-1
3197807|NCT01214083|Experimental|Arm 1|N-acetylcysteine + high-dose naltrexone (150 mg)
3197808|NCT01214083|Experimental|Arm 2|High-dose naltrexone (150 mg) alone
3197809|NCT01214083|Active Comparator|Arm 3|Low-dose naltrexone (50 mg) alone
3197810|NCT01214070|Active Comparator|Arm 1|Group 1 - Combination Treatment
3197811|NCT01214070|Active Comparator|Arm 2|Group 2 - Combination Treatment
3197812|NCT01214070|Active Comparator|Arm 3|Group 3 - Combination Treatment
3197813|NCT01214070|Active Comparator|Arm 4|Group 4 - Combination Treatment
3197814|NCT01214070|Active Comparator|Arm 5|Group 5 - Monotherapy Treatment
3197815|NCT01214070|Active Comparator|Arm 6|Group 6 - Monotherapy Treatment
3197816|NCT01214070|Active Comparator|Arm 7|Group 7 - Monotherapy Treatment
3197817|NCT01214057|Experimental|Total Intravenous Anesthesia|Total Intravenous Anesthesia (TIVA) with propofol and remifentanyl
3197818|NCT01214057|Active Comparator|Inhaled Anesthesia|Inhaled anesthesia with sevoflurane and remifentanyl.
3197819|NCT01214044|Experimental|Study Drug|Subjects will have a total of 12 visits to OCTRI at OHSU over the 14-16 weeks of study. Subjects will first undergo an initial screening visit to determine eligibility. Subjects who meet criteria and agree to participate will then stop taking their current antidepressant medication (if applicable), during which time the study doctor and staff will conduct weekly mood assessments to ensure safety. Subjects will then have a study initiation/materials visit followed by 9 visits during treatment with placebo or escitalopram. A final post-study follow-up safety visit will be scheduled at the end of treatment.
3197820|NCT01214031|Other|Confocal Laser Endomicroscopy Arm|Confocal laser endomicroscopy (CLE) is another novel imaging tool for enabling histopathologic diagnosis in vivo during endoscopy. Specially designed confocal endoscopes have the confocal laser microscope integrated to the distal tip of the conventional endoscope. This provide images at a cellular level that have been shown to have a high sensitivity, specificity and accuracy.
3197821|NCT01214018||Reference|Nearest relatives of brain-dead patients who donated organs
3197822|NCT01214018||Opposition|Nearest relatives of brain-dead patients opposed to organ donation
3197823|NCT01214018||Medical/Legal|Nearest relatives of brain-dead patients for whom organ donation was not an option because of medical or legal reasons
3197824|NCT01214005|Experimental|schizophrenia|Smokers with schizophrenia or schizoaffective disorder
3197825|NCT01214005|Other|non-psychiatric|smokers without psychiatric illness
3197826|NCT01213992|Active Comparator|Monofer® 500 mg|500 mg iron isomaltoside 1000
3197827|NCT01213992|Active Comparator|Monofer® 1000 mg|1000 mg iron isomaltoside 1000
3197828|NCT01213979|Active Comparator|1000 mg iron isomaltoside 1000 as intravenous infusion|
3197829|NCT01213979|Active Comparator|500 mg iron isomaltoside 1000 as bolus injection|
3197830|NCT01213966|Experimental|800 mg OZ439 po single dose|800 mg OZ439 po single dose
3197831|NCT01213966|Experimental|400 mg OZ439 p.o. single dose|400 mg OZ439 p.o. single dose
3197832|NCT01213966|Experimental|200mg OZ439 p.o. single dose|200mg OZ439 p.o. single dose
3197833|NCT01213966|Experimental|1200 mg OZ439 po single dose|1200 mg OZ439 po single dose
3197834|NCT01213940|Other|baratric surgery|surgery vs.weight loss program 6 months prior to bariatric surgery
3197835|NCT01213940|Other|pre-bariatric weight loss program|weight loss program prior to bariatric surgery
3197836|NCT01213914|Experimental|High-volume hemofiltration at 70ml/kg/hr|Paired randomization into four groups via central randomization center. Group 1: age 18-65 and <40%TBSA Group 2: age 18-65 and >40%TBSA Group 3: age >65 and <40%TBSA Group 4: age >65 and >40%TBSA
3197837|NCT01213914|Active Comparator|Control group|Contemporary care via consideration of the Burn-Specific Sepsis Bundle adapted form the most recent Surviving Sepsis campaign recommendations and specifically modified to our patient population.
3197838|NCT01213901|Experimental|1|"Each patient will receive 2 insulin injections in the abdomen: Once using a pinch method and once using a spread method.~Injections will be given in a random order and the technician will be blinded to the injection.~Each patient will evaluate the comfort of the injection by completing a visual analog scale."
3197839|NCT01213888|Experimental|Arm II|
3197840|NCT01213888|Placebo Comparator|Arm I. Placebo + Pan-Retinal Photocoagulation|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
3197841|NCT01213875|Experimental|Experimental: Intervention and control|"I: Experimental Routine monitoring by health team in the reference institution, four home visits and four telephone contacts with trained nurses.~II: Control Routine monitoring by health team in the reference institution."
3197842|NCT01213875|No Intervention|Control|
3197843|NCT01213862|Experimental|intervention and control|"Group I - Intervention: Routine follow-up in a reference health institution with four home visits and four telephone contacts with specialist nurses.~Group II - Control: Routine follow-up with the health team in the reference institution."
3197844|NCT01213849|Experimental|200/100 mcg fluticasone furoate/vilanterol|4 inhalations of 50/25 mcg fluticasone furoate/vilanterol
3197845|NCT01213849|Experimental|400/100 mcg fluticasone furoate/vilanterol|4 inhalations of 100/25 mcg fluticasone furoate/vilanterol
3197846|NCT01213849|Experimental|800/100 mcg fluticasone furoate/vilanterol|4 inhalations of 200/25 mcg fluticasone furoate/vilanterol
3197847|NCT01213836|Active Comparator|First Seroquel XR then Seroquel IR|Patients randomised to Seroquel XR will have treatment for 10-16 days and after that cross-over to treatment with Seroquel IR for 10-16 days
3197848|NCT01213836|Active Comparator|First Seroquel IR then Seroquel XR|Patients randomised to Seroquel IR will have treatment for 10-16 days and after that cross-over to treatment with Seroquel XR for 10-16 days
3197849|NCT01213823||Cases|Potential cases were defined as patients with a diagnosis of severe hepatic injury identified in the acute-care inpatient cohort using ICD-9 codes associated with the case definition of severe liver injury. Case status was validated by a Consultant Gastroenterologist blinded to study drug exposure via medical record review using an apriori algorithm. Only validated cases were included in the analysis (N=69)
3197850|NCT01213823||Controls|Controls were defined as patients without a diagnosis of severe hepatic injury (i.e. with no ICD-9 codes associated with the case definition of severe liver injury) selected at random from the same acute-care inpatient cohort as cases (N=467)
3197851|NCT01213797||Suicide attempter and its entourage|"Suicide attempter and its close relatives (who are living under the same roof)~Comparison of the population of the close relations of committing suicide with the data of the Research Institute and Documentation in Economy of Health (IRDES) on the French population (sample of 20.000 people, representative of 95% of the French households)."
3197852|NCT01213784|Experimental|optimized diabetic control|each participant will be assigned to be optimized in a dedicated diabetic clinic
3197853|NCT01213784|No Intervention|control|participants will be assigned to follow what ever control they were in before the study and not to change any antidiabetic treatment during the interventions period.
3197854|NCT01213771|No Intervention|Preoperative care 2009|Patients are receiving the usual care
3197855|NCT01213758||Liver tumors|Patients where stereotactic body radiation therapy is planned for primary or metastatic liver tumors.
3197856|NCT01213745|Experimental|Intervention|
3197857|NCT01213745|Experimental|Attention|
3197858|NCT01213745|Active Comparator|Control|
3197859|NCT01213732|Experimental|L19TNFα plus melphalan|Subjects will be sequentially assigned to one of 2 dose levels of L19TNFα: 325 µg or 650 µg. All subjects will receive a single dose of L19TNFα and Melfalan (10mg/ L Limb volume).
3197860|NCT01213719|Experimental|creatine|will receive creatine monohydrate (20g/d) throughout 10 days
3197861|NCT01213719|Experimental|betaine|will receive betaine (2g/d) throughout 10 days
3197862|NCT01213719|Placebo Comparator|placebo (dextrose)|will receive dextrose(20g/d)throughout 10 days.
3197863|NCT01213719|Active Comparator|creatine plus betaine|will receive creatine (20g/d) plus betaine (2g/d) throughout 10 days
3197864|NCT01213706|Experimental|Whole Body Periodic Acceleration (WBPA)|All subjects will be performing this procedure. WBPA in spinal axis (pGz) will be administered with a platform that resembles a bed. The platform moves in a repetitive head-to-foot direction at 140 times a minute, producing 0.22 g.
3197865|NCT01213706|Experimental|Sham WBPA|"Sham WBPA :~All subjects will be performing this procedure before the WBPA. The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge."
3197866|NCT01213693|Experimental|ICS/LABA group|Patients assigned to this arm will take bid 50/500 mcg fluticasone/salmeterol combination
3197867|NCT01213693|Active Comparator|LABA group|Patients assigned to this arm will take bid 50 mcg salmeterol
3197868|NCT01213680|Active Comparator|1000 mg iron isomaltoside as intravenous infusion|
3197869|NCT01213680|Active Comparator|500 mg iron isomaltoside 1000 as bolus injection|
3197870|NCT01213667|Other|ranibizumab as needed|
3197871|NCT01213628|Experimental|Standard heating|Standard intraoperative warming measures including heated sheets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
3197872|NCT01213615||all patients eligible for implantation of a Hancock II Ultra|
3197873|NCT01213602||Femoral block preoperative|In one group (T1) with performance of femoral block before general anesthesia and administration of bolus of local anesthetic through stimulating catheter (combined anesthesia)
3197874|NCT01213602||Femoral block postoperative|In second group (T2) with a administration of local anesthetic through stimulating femoral catheter until awareness of patient (balanced anesthesia).
3197875|NCT01213589||Descending thoracic aortic dissection|Patients diagnosed with a descending thoracic aortic dissection and who are amenable to stent-graft operation. The patient had an indication for treatment by either endovascular stent graft implantation for either an acute, sub-acute or chronic Type B dissection.
3197876|NCT01213576|Active Comparator|albendazole 400mg and ivermectin 200mcg/kg|Annual treatment
3197877|NCT01213576|Active Comparator|Albendazole 800mg and ivermectin 400mcg/kg|Annual treatment
3197878|NCT01213576|Active Comparator|Albendazole 400mg and ivermectin 200mcg/kg|albendazole 400mg and ivermectin 200mcg/kg given twice a year
3197879|NCT01213576|Active Comparator|Albendazole 800mg and ivermectin 400mcg /kg bi-annually|Albendazole 800mg and ivermectin 400mcg/kg given twice a year
3197880|NCT01213563|Experimental|Actrapid insulin|Intensive glycaemic control Intervention: Actrapid insulin
3197881|NCT01213563|Active Comparator|Actrapid insulin+Gloucose|conventional glycaemic control Intervention: Actrapid insulin+Glucose
3197882|NCT01213550|Experimental|Chlorhexidine|
3197883|NCT01213550|Placebo Comparator|Placebo mouthrinse|
3197884|NCT01213537||Patients undergoing clinically indicated CRT implantation|"Patients may be included in the study if they fulfil the following;~Age ≥18 years old~Fulfil the current guidance for the implantation of a CRT device; optimal medical treatment for heart failure, broad QRS complex on electrocardiogram with or without evidence of cardiac dyssynchrony as appropriate, LVEF <35%, functional impairment as defined by an NYHA class of III-IV~Clinically stable with no unplanned admission to hospital for preceding 4 weeks~No changes in medications for heart failure in preceding 4 weeks~Able to read and understand patient information sheet and give informed consent~Patients must be excluded from the study if they fulfil they the following;~On positive pressure treatment for known sleep disordered breathing at the time of inclusion~Other known condition (untreated) likely to significantly disturb sleep eg. Restless legs syndrome, pain from any cause etc.~Pregnancy"
3197885|NCT01213524|Active Comparator|Active NRT + denicotinized cigarettes|42 mg nicotine replacement plus sensorimotor replacement
3197886|NCT01213524|Active Comparator|Placebo NRT + denicotinized cigarettes|inactive transdermal patches plus sensorimotor replacement
3197887|NCT01213524|Active Comparator|Active NRT + no cigarettes|42 mg nicotine replacement with no sensorimotor replacement
3197888|NCT01213524|Placebo Comparator|Placebo NRT + No cigarettes|Double placebo: No nicotine or sensorimotor replacement
3198054|NCT01212250|Placebo Comparator|placebo|Placebo tablets 2 BD
3197890|NCT01213511|Active Comparator|MECC Group|Patients operated for elective coronary artery bypass grafting with the use of minimal extracorporeal circulation.
3197891|NCT01213511|Active Comparator|CECC Group|Group of patients undergoing elective coronary bypass grafting with the use of conventional extracorporeal circulation.
3197892|NCT01213498|Active Comparator|Atorvastatin|
3197893|NCT01213498|Placebo Comparator|Unikalk|
3197894|NCT01213485||Cohort|
3197895|NCT01213472|Experimental|NY-ESO 1 Group|Patients will receive up to 24 doses of GSK2241658A Cancer Immunotherapeutic
3197896|NCT01213459||Cohort A|Women ≥15 years of age attending out-patient departments for routine cervical screening in the Kingdom of Saudi Arabia.
3197897|NCT01213446|Experimental|Biostate|
3197898|NCT01213433|Experimental|Amodiaquine+Artesunate|
3197899|NCT01213420|Experimental|Aloë Vera FORMULA F-BC-096|
3197900|NCT01213420|Active Comparator|Aloë Vera FORMULA F-BC-096 with modified preservative|
3197901|NCT01213420|Active Comparator|Eucerin Calming cream|
3197902|NCT01213420|Active Comparator|Nivea Cream|
3197903|NCT01213407|Experimental|Standard therapy plus Trivax|Standard therapy with Surgery, Temozolomide, and Radiotherapy; plus Trivax, 5x10e6 autologous interleukine-12 secreting dendritic cells charged with autologous tumour lysate.
3197904|NCT01213407|Active Comparator|Standard therapy|Surgery, Temozolomide, Radiotherapy
3197905|NCT01213394|Experimental|CellCept optimization|
3197906|NCT01213394|Active Comparator|Control|
3197907|NCT01213381|Experimental|SAR240550|"single cohort: SAR240550~combination cohort: SAR240550 in combination with Gemcitabine and Carboplatin"
3197908|NCT01213368|Experimental|dronedarone 300 mg|Dronedarone, 100mg + 200mg tablets twice daily, administered with food.
3197909|NCT01213368|Experimental|dronedarone 400 mg|Dronedarone, 400mg tablets twice daily, administered with food.
3197910|NCT01213368|Experimental|dronedarone 600 mg|Dronedarone, 400mg + 200mg tablets twice daily, administered with food.
3197911|NCT01213368|Placebo Comparator|placebo|Matching placebo tablets twice daily, administered with food.
3197912|NCT01213355|No Intervention|Placebo|placebo, plus scopolamine 0.5 mg
3197913|NCT01213355|Experimental|PF-05212377 5 mg, plus scopolamine 0.5 mg;|
3197914|NCT01213355|Experimental|PF-05212377 20 mg, plus scopolamine 0.5 mg;|
3197915|NCT01213355|Experimental|PF-05212377 60 mg, plus scopolamine 0.5 mg;|
3197916|NCT01213355|Active Comparator|donepezil 10 mg, plus scopolamine 0.5 mg.|
3197917|NCT01213342|Experimental|Treatment Group|This group will receive Omega-3 EFA supplements for 8 weeks. They will take 4 capsules/day.
3197918|NCT01213342|Placebo Comparator|Placebo Group|This group will receive placebo supplements for 8 weeks. They will take 4 capsules a day.
3197919|NCT01213329|Experimental|Phase I: Alemtuzumab|During Phase I Portion: Each kidney transplant recipient received one 30mg dose (IV push)of Alemtuzmab in the operating room per Standard of Care.
3197920|NCT01213316||Overall Participants|HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks (Initial Cohort), 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.
3197921|NCT01213316||Aging Participants|"HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.~Includes newly enrolled participants ≥ 50 years of age (Amendment Cohort), plus participants from the Initial Cohort who were ≥ 50 years of age at time of recruitment and who completed 48 weeks of treatment (Prolonged Cohort)."
3197922|NCT01213303||Blood donors|Evaluation of cardiovascular risk factors, oxidative stress and fatty acid metabolism in a cohort of blood donors
3197923|NCT01213290|Active Comparator|EUS-FNA with stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
3197924|NCT01213290|Active Comparator|EUS-FNA without stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
3197925|NCT01213277|Active Comparator|Fast Glycator|The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators
3197926|NCT01213277|Active Comparator|Control|These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients
3197927|NCT01213264||Spontaneous NMB reversal|Participants whose reversal from NMB is spontaneous (no reversal agent used)
3197928|NCT01213264||NMB reversal with sugammadex|Participants who are administered sugammadex for NMB reversal in accordance with routine anesthesiology practice, and labeling guidelines
3197929|NCT01213264||NMB reversal with other agents|Participants who are administered any other agent (other than sugammadex) for NMB reversal in accordance with routine anesthesiology practice, and labeling guidelines
3197930|NCT01213251|Experimental|Single Site Pacing|
3197931|NCT01213251|Experimental|Dual Site Pacing|
3197932|NCT01213251|No Intervention|Control|
3197933|NCT01213238|Experimental|Oxaliplatin + Capecitabine + Bevacizumab|Oxaliplatin 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle. Capecitabine starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle. Bevacizumab 10 mg/kg by vein on day 1 of a 21 day cycle.
3197934|NCT01213238|Experimental|Oxaliplatin + Capecitabine|Oxaliplatin 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle. Capecitabine starting dose of 500 mg/m2 by mouth twice daily, on days 1 -14 of a 21 day cycle.
3197935|NCT01213212|Experimental|Caloric restriction|Caloric restriction
3197936|NCT01213212|Sham Comparator|"Diet ad libitum"|"Diet ad libitum"
3198100|NCT01211873|Experimental|Dotarem 2 (gadoterate meglumine )|Pediatric patients were assigned to Dotarem group only.
3197937|NCT01213199|Experimental|Differin 0.3%|"Differin® 0.3% Gel~Adapalene 0.3%~Topical to the face, once daily application in the evening for the first four weeks and twice daily application in the morning and in the evening for the following 20 weeks."
3197938|NCT01213186|Experimental|Drug: high dose of MSC treatment|Participants will receive high dose of MSC from Day 0 through the Week 48 study visit. Participants will then be followed until the Week 48 study visit.
3197939|NCT01213186|Experimental|low dose of MSC treatment|Participants will receive a low dose of MSC treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks.
3197940|NCT01213186|Placebo Comparator|low dose of MSC|Participants will receive a saline placebo treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks.
3197941|NCT01213173|Active Comparator|1|
3197942|NCT01213173|Experimental|2|
3197943|NCT01213160|Experimental|AZD4547|
3197944|NCT01213147|Experimental|clomiphene citrate,pregnancy,poor responders|Woman in clomiphene citrate arm are administered 100mg/day oral from day 3 of menstrual cycle until day 7 of cycle
3197945|NCT01213147|Active Comparator|buserelin,pregnancy,poor responder|women in control arm are administered Buserelin buserelin 50 µg SC twice a day from cycle day 2 of menstrual cycle
3197946|NCT01213121|Experimental|bipolar depression|unmedicated patients with bipolar depression receiving quetiapine treatment
3197947|NCT01213121|No Intervention|Control|healthy controls matched for age, gender, and body mass index
3197948|NCT01213108|Experimental|Örebro prevention program|
3197949|NCT01213108|Active Comparator|Control|Business as usual
3197950|NCT01213095|Experimental|Rituximab|rituximab 375mg/m2, every 8 weeks, 12 times
3197951|NCT01213082|Experimental|24GyE + anti-VEGF|
3197952|NCT01213082|Experimental|16GyE + anti-VEGF|
3197953|NCT01213082|Sham Comparator|Sham Irradiation + anti-VEGF|
3197954|NCT01213069||all 5000 subjects|this is a purely descriptive study with one group
3197955|NCT01213056|Active Comparator|Mindfulness Based Cognitive Therapy * (MBCT)|Mindfulness based cognitive therapy aimed to improve coping with, and managing chronic headache pain.
3197956|NCT01213056|No Intervention|Delayed Treatment Control * (DT)|
3197957|NCT01213043|Active Comparator|Prolastin-C, 60 mg/kg|60 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 60 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).
3197958|NCT01213043|Experimental|Prolastin-C, 120 mg/kg|120 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 120 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).
3197959|NCT01213030|Active Comparator|10 mCi HX4|Patient will be injected with [F-18] FMISO
3197960|NCT01213030|Active Comparator|10 mCi FMISO|Patient will be injected with [F-18] HX4
3197961|NCT01213017|Experimental|Certolizumab pegol|
3197962|NCT01213004|Experimental|thoracic (study group 1) malignancies|On the same day as the CBCT scans and treatment session, patients will receive a research-only respiration correlated CT (RCCT scan), for calculating motion-corrected CBCT. The localization accuracy of motion-corrected CBCT using same-day RCCT will be compared to that using the standard RCCT from simulation.
3197963|NCT01213004|Experimental|abdominal (study group 2) malignancies|On the same day as the CBCT scans and treatment session, patients will receive a research-only respiration correlated CT (RCCT scan), for calculating motion-corrected CBCT. The localization accuracy of motion-corrected CBCT using same-day RCCT will be compared to that using the standard RCCT from simulation.
3197964|NCT01212991|Experimental|Enzalutamide|
3197965|NCT01212991|Placebo Comparator|Placebo|
3197966|NCT01212978|No Intervention|Delayed Intervention|These subjects will neither receive a pedometer or access to the motivational software until completion of the study.
3197967|NCT01212978|Active Comparator|Pedometer only|Participants in the this arm will receive a pedometer with instructions to reach a goal of 10,000 steps/day but will not receive access to the motivational software.
3197968|NCT01212978|Experimental|Pedometer + Motivational Software|In this arm, subjects will receive access to both a pedometer and motivational software
3197969|NCT01212952|Experimental|Arm I|Patients receive oral pomalidomide on days 1-21; bortezomib IV on days 1, 8, 15, 22; and oral dexamethasone on days 1, 8, 15, 22. Treatment repeats every 28 days for 8 courses. Patients then receive maintenance therapy comprising oral pomalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3197970|NCT01212926|Experimental|analysis of myocardial deformation in 2D strain|
3197971|NCT01212913|Experimental|group 1: Basal plus|Insulin glargine with dosage adjustment determined according to the mean value of the last three days Fasting Blood Glucose (FBG) Insulin glulisine, at initial dosing of 4IU, then weekly adjusted according to the mean value of the last three days PostPrandial Blood Glucose (PPBG)
3197972|NCT01212913|Active Comparator|group 2: Biphasic insulin|Insulin aspart/insulin aspart protamine 30/70 (novomix 30) given twice daily and titrated weekly (before breakfast and dinner) according to the lowest of three previous days' pre-meal levels (both breakfast and dinner). Target is 70 mg/dL < Pre-meal blood glucose (dinner and breakfast).
3197973|NCT01212900|Experimental|1|Wall Volume
3197974|NCT01212900|Active Comparator|2|Stenosis ?
3197975|NCT01212874|Active Comparator|Nitroglycerin|nitroglycerin titrated to control hypertension between anesthesia induction and initiation of cardiopulmonary bypass
3197976|NCT01212874|Active Comparator|Esmolol|esmolol titrated to control hypertension between anesthesia induction and initiation of cardiopulmonary bypass
3197977|NCT01212861|Experimental|Suprachoroidal Dissection Instrument|
3197978|NCT01212848|Experimental|TMS|
3197979|NCT01212848|Sham Comparator|Sham|
3197980|NCT01212835|Sham Comparator|no ring|Patients at this group will have RING REMOVED AT THE END OF SURGERY.
3198101|NCT01211860|Experimental|DCCR Treatment|DCCR Treatment 290 mg diazoxide choline
3198102|NCT01211847|Experimental|DCCR|DCCR Treatment with 290 mg Diazoxide Choline
3197981|NCT01212835|Active Comparator|RYGBP-Ring|Open Roux-en-Y gastric bypass with a silastic ring which is performed with linear cut stapler 100 mm and a biliopancreatic limb of 60 cm long and a alimentary limb of 100 cm long. All patients will have a 6.5 cm silastic ring located at the middle of the pouch above of the gastroenteroanastomosis.
3197982|NCT01212822|Experimental|Treatment (bevacizumab, FOLFOX)|"NEOADJUVANT THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive FOLFOX chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46 hours on days 1-2. Treatment with bevacizumab repeats every 2 weeks for 4 courses and treatment with FOLFOX repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients then undergo planned surgical resection 4-6 weeks after 6 courses of chemotherapy and at least 8 weeks since the last dose of bevacizumab.~ADJUVANT THERAPY: Beginning 8-10 weeks after surgery, patients receive bevacizumab IV, oxaliplatin IV, leucovorin calcium IV, and fluorouracil IV as in neoadjuvant therapy. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity."
3197983|NCT01212809|Active Comparator|Juvéderm Ultra|Juvéderm Ultra injection
3197984|NCT01212809|Active Comparator|Cosmoderm 1|Cosmoderm 1 injection
3197985|NCT01212783|Active Comparator|Present-Centered Therapy|Mothers will receive 15 weekly sessions of PCT plus two monthly booster sessions following the 15th session.
3197986|NCT01212783|Experimental|In-Home Cognitive Behavioral Therapy|Mothers will receive 15 weekly sessions of IH-CBT plus two booster sessions scheduled monthly following the 15th session.
3197987|NCT01212770|Experimental|Apremilast 20 mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
3197988|NCT01212770|Experimental|Apremilast 30 mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
3197989|NCT01212770|Placebo Comparator|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
3197990|NCT01212770|Placebo Comparator|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
3197991|NCT01212757|Experimental|Apremilast 20mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
3197992|NCT01212757|Experimental|Apremilast 30mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
3197993|NCT01212757|Placebo Comparator|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
3197994|NCT01212757|Placebo Comparator|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
3197995|NCT01212744|Experimental|rAvPAL-PEG|rAvPAL-PEG in varying doses
3197996|NCT01212731||Cohort 1|Subjects with a histological diagnosis of malignancy of the base of skull necessitating irradiation to a minimum of 60 Gy, ECOG PS 0-1 with no evidence of metastatic disease and an estimate life expectancy of at least 1 year and who is able to provide informed consent. Subjects will undergo standard CT simulation and radiotherapy treatment planning.
3197997|NCT01212731||Cohort 2|Subjects with a histological diagnosis of low grade glioma requiring radiotherapy. ECOG PS 0-1 with no evidence of metastatic disease and an estimated life expectancy of at least 1 year and who is able to provide informed consent. Subjects will undergo standard CT simulation and radiotherapy treatment planning.
3197998|NCT01212718|Active Comparator|5-FU|FUFA 5-flurouracil and folinic acid control
3197999|NCT01212718|Active Comparator|Folfiri|5-fluouracil and folinic acid in combination with irinotecan (Folfiri) systemic chemotherapy intensified treatment arm
3198000|NCT01212705|Experimental|ASV|
3198001|NCT01212692|Experimental|Mentally stimulating activities|
3198002|NCT01212692|Active Comparator|Mentally stimulating activities- other|
3198003|NCT01212679|Experimental|nerve growth factor|Patients who underwent TBI will be chosen to receive NGF randomly.
3198004|NCT01212679|Placebo Comparator|Control|Patients who underwent TBI will be chosen to receive nomral saline randomly.
3198005|NCT01212666|Experimental|Adductor-Canal-Block, Ropivacain|25 patients. ACB. 30 mL Ropivacain 7,5 mg/mL. Ultrasound-guided application.
3198006|NCT01212666|Placebo Comparator|Adductor Canal Block, Placebo (saline)|25 patients. ACB. 30 mL Saline. Ultrasound-guided application.
3198007|NCT01212653|Active Comparator|Golimumab|"In this 52-week, randomized, placebo-controlled study, patients will be randomized to receive either golimumab 50 mg monthly or matching placebo for 12 months using a 1:1 randomization procedure.~The doctors and patients and the nurse who administer the study medication (Golimumab) will be blinded. There will be one unblinded nurse to prepare the study medication."
3198103|NCT01211847|Placebo Comparator|Placebo|Placebo matching DCCR
3198104|NCT01211834|Experimental|Tocilizumab 8mg/kg+DMARDs|
3198105|NCT01211834|Placebo Comparator|Placebo+DMARDs|
3198008|NCT01212653|Placebo Comparator|Pacebo-controlled|"In this 52-week, randomized, placebo-controlled study, patients will be randomized to receive either Golimumab 50 mg monthly or matching placebo for 12 months using a 1:1 randomization procedure.~The doctors and patients and the nurse who administer the study medication (Golimumab) will be blinded. There will be one unblinded nurse to prepare the study medication."
3198009|NCT01212627|Experimental|Ridaforolimus,|Ridaforolimus: 20mg Daily, 5 days each week, on a 28 day cycle until progression
3198010|NCT01212601||1|
3198011|NCT01212588|Experimental|Mifepristone|Mifepristone 600mg once daily x 7 days
3198012|NCT01212588|Placebo Comparator|Placebo|Matching placebo tablets one daily
3198013|NCT01212575||300 patients|Female or male aged 18-65 years with a diagnosis of schizophrenia having received at least one dose of Seroquel XR or Seroquel IR during January - March 2010
3198014|NCT01212562||Immunocryosurgery|2 weeks daily imiquimod application prior to a session of cryosurgery and subsequently 3 weeks continued daily imiquimod application
3198015|NCT01212549|Active Comparator|Immunocryosurgery|2 weeks imiquimod, cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 3 weeks imiquimod
3198016|NCT01212549|Active Comparator|Cryoimmunotherapy|Cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 5 weeks imiquimod
3198017|NCT01212536|No Intervention|Conventional|conventional laryngoscopy for intubation
3198018|NCT01212536|Experimental|Airtraq|laryngoscopy with Airtraq for intubation
3198019|NCT01212510|Other|Tumor markers|measurement of tumor markers ( blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA )
3198020|NCT01212497|Experimental|Mindfulness meditation coaching|Assess effectiveness of using a virtual computer coach to train mindfulness meditation
3198021|NCT01212484|Experimental|Placebo (first), Carbidopa (second)|Crossover design Placebo first followed by carbidopa
3198022|NCT01212484|Experimental|Carbidopa (first), Placebo (second)|Crossover design carbidopa first followed by placebo
3198023|NCT01212471|Experimental|Bromfenac Ophthalmic Solution A|Bromfenac ophthalmic solution A
3198024|NCT01212471|Experimental|Bromfenac Ophthalmic Solution B|Bromfenac ophthalmic solution B
3198025|NCT01212471|Placebo Comparator|Placebo Comparator|Placebo Comparator
3198026|NCT01212445|Experimental|PEG + E, 13.125 g|Single sachet of PEG+E (13.125 g) dissolved in 125 mL of non-carbonated water ingested orally with entire volume taken at one time
3198027|NCT01212445|Experimental|PEG + E, 26.25 g|Two sachets of PEG+E (26.25 g) dissolved in 250 mL of non-carbonated water ingested orally with entire volume taken at one time
3198028|NCT01212445|Experimental|PEG + E, 39.375 g|Three sachets of PEG+E (39.375 g) dissolved in 375 mL of non-carbonated water ingested orally with entire volume taken at one time
3198029|NCT01212406|Placebo Comparator|Placebo|Olive oil
3198030|NCT01212406|Experimental|Vitamin D|Addition of D-cure (100.000U) to standard care
3198031|NCT01212393||Intervention group|reminders
3198032|NCT01212393||current practice group|no intervention
3198033|NCT01212380|Experimental|Arm 1|Patients receive carfilzomib IV over 30 minutes once daily on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.Performance of pharmacology, pharmacodynamic and pharmacogenomic studies allow assessment of carfilzomib mechanism of action and also to understand how the variability of these different features correlate with clinical benefit/response and also toxicity.
3198034|NCT01212367|Experimental|Dose Level 1|
3198035|NCT01212367|Experimental|Dose Level 2|This is a dose de escalation.
3198036|NCT01212354|Experimental|A - experimental|7 weeks Radiotherapy Intervention with with 5x2.3 Gy per week up to a total dose of 80.5 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.
3198037|NCT01212354|Active Comparator|B - control|7 weeks Radiotherapy Intervention with 5x2.0 Gy per week up to a total dose of 70 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.
3198038|NCT01212341|Experimental|Singe-dose infusion|Cohort 1: 1x10^6 cells/kg Cohort 2: 1x10^7 cells/kg
3198039|NCT01212341|Experimental|Repeated dose infusion|Cohort 3: 1x10^6 cells/kg Cohort 4: 3x10^6 cells/kg Cohort 5: 1x10^7 cells/kg Cohort 6: 3x10^7 cells/kg
3198040|NCT01212328|Experimental|Care coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
3198041|NCT01212328|Active Comparator|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
3198042|NCT01212315|No Intervention|Control group|Ordinary sutures (Vicryl / Monocryl) is used for wound closure
3198043|NCT01212315|Active Comparator|Group A|Triclosan coated sutures (Vicryl Plus / Monocryl Plus) is used for wound closure
3198044|NCT01212302|Experimental|aspirin, clopidogrel|If the treatment with aspirin and/or clopidogrel is insufficient (platelet function testing) the dose was increased or the drug was changed (clopidogrel to ticlopidine or prasugrel)
3198045|NCT01212289||Primary cardiac surgery|Pediatric patients receiving primary cardiac surgery
3198046|NCT01212289||Reoperation|Pediatric patients receiving cardiac surgery reoperation
3198047|NCT01212276|Experimental|Cohort 1|MORAb-028 0.1 mg/kg intravenous
3198048|NCT01212276|Experimental|Cohort 2|MORAb-028 0.2 mg/kg intravenous
3198049|NCT01212276|Experimental|Cohort 3|MORAb-028 0.5 mg/kg intravenous
3198050|NCT01212276|Experimental|Cohort 4|MORAb-028 1.0 mg/kg intravenous
3198051|NCT01212263|Experimental|Clomiphene Citrate plus HP uFSH|Starting from the 2nd day of the cycle Clomiphene Citrate( CC)50 mg tablets are given in 100 mg daily dose for 5 days together with an low dose HP uFSH (half ampoule: 37.5 IU) given im daily for 8-10 days.
3198052|NCT01212263|Active Comparator|Step-up HP uFSH|HP uFSH started in doses of half ampole (37.5 )IU daily from the 2nd day of cycle for 7 days ,then dose is stepped-up to one ampoule ( 75 IU) for 7 days then the one and a half amps (112.5) IU /day until follicular diameter reaches 18 mm mean diameter
3198053|NCT01212250|Experimental|Carvedilol|Tablet 6.25 mg BD
3198055|NCT01212237||fMRI Evaluation|"All patients will undergo the following standard imaging and radiotherapy procedures will be performed for each patient:~Standard MRI for radiotherapy treatment planning which takes about 60 minutes.~Radiotherapy treatment simulation with CT.~Radiotherapy treatment planning~Radiotherapy treatment~Routine follow-up every 3 months after the radiotherapy.~Special Procedures.~The following special imaging and radiotherapy procedures will be performed for each patient:~fMRI (30 minutes)~The 3MS examination, administered every 3 months during routine follow-up for one year after the completion of the radiotherapy."
3198056|NCT01212211|Experimental|change in drug therapy|Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
3198057|NCT01212211|No Intervention|reference|drug treatment of ten patients will remain unchanged during the three months of inclusion
3198058|NCT01212198||Korean type 2 diabetic patients|
3198059|NCT01212198||Koreans at high risk for diabetes|
3198060|NCT01212198||Korean gestational diabetic patients|
3198061|NCT01212185|Placebo Comparator|intranasal spray without oxytocin|Twice daily intranasal spray without oxytocin.
3198062|NCT01212185|Experimental|intranasal oxytocin spray|Twice daily intranasal oxytocin spray
3198063|NCT01212172|Active Comparator|Soprano/SHR|Alma Soprano/SHR 810 nm Diode Laser
3198064|NCT01212172|Active Comparator|LightSheer|LightSheer Duet 810 nm diode laser
3198065|NCT01212159|No Intervention|No self monitoring device|Standard or usual care of high LDL including lab lipid profiles after treatment with statin therapy. No device or telemedicine education will be provided
3198066|NCT01212159|Experimental|Self Monitoring Lipid Analyzer|Self measured blood lipids using a home lipidometer, and telephone reporting of data to the clinical center.
3198067|NCT01212146|Experimental|Probiotic-enriched Artichokes|Artichokes containing approximately 1.20 x 10^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme
3198068|NCT01212146|Active Comparator|Ordinary artichokes|Ordinary artichokes (probiotic free) of identical shape, texture, and appearance of probiotic-enriched artichokes
3198069|NCT01212133||A|
3198070|NCT01212120||All patients|All patients
3198071|NCT01212107|Experimental|2 mg LY2874455|2 mg LY287445 administered orally once daily for a minimum of (1) 28 day cycle
3198072|NCT01212107|Experimental|4 mg LY2874455|4 mg LY2874455 administered orally once daily for a minimum of (1) 28 day cycle
3198073|NCT01212107|Experimental|10 mg LY287445|10 mg LY2874455 administered orally once daily for a minimum of (1) 28 day cycle
3198074|NCT01212107|Experimental|16 mg LY2874455|8 mg LY2874455 administered orally twice daily for a minimum of (1) 28 day cycle
3198075|NCT01212107|Experimental|20 to 24 mg LY2874455|10 to 12 mg of LY2874455 administered orally twice daily for a minimum of (1) 28 day cycle
3198076|NCT01212107|Experimental|24 to 36 mg LY2874455|12 to 18 mg LY2874455 administered orally twice daily for a minimum of (1) 28 day cycle
3198077|NCT01212107|Experimental|28 to 56 mg LY2874455|14 to 28 mg LY2874455 administered orally twice daily for a minimum of (1) 28 day cycle
3198078|NCT01212107|Experimental|36 to 94 mg LY2874455|18 to 42 mg LY2874455 administered orally twice daily for a minimum of (1) 28 day cycle
3198079|NCT01212107|Experimental|44 to 128 mg LY2874455|22 to 64 mg LY2874455 administered orally twice daily for a minimum of (1) 28 day cycle
3198080|NCT01212107|Experimental|56 to 192 mg LY2874455|28 to 96 mg LY2874455 administered orally, twice daily for a minimum of (1) 28 day cycle
3198081|NCT01212107|Experimental|72 to 200 mg LY2874455|36 to 100 mg LY2874455 administered orally twice daily for a minimum of (1) 28 day cycle
3198082|NCT01212094|Experimental|Rituximab|Patients received 25mg of rituximab into the CSF and 200mg of rituximab intravenously at Month 0, followed by additional 200mg of rituximab intravenously at Month 0.5 and another 25mg of rituximab into CSF at months 1.5 and 12.
3198083|NCT01212094|Placebo Comparator|Placebo|Patients received normal saline into the CSF and intravenously at Month 0, followed by additional normal saline intravenously at Month 0.5 and another dose of normal saline into CSF at months 1.5 and 12.
3198084|NCT01212094|No Intervention|Baseline|Patients in their first year baseline prior to study drug phase
3198085|NCT01211964|Experimental|LEO 22811 oral solution 1.5 mg (fasted state)|
3198086|NCT01211964|Experimental|LEO 22811 single tablet 1.5 mg (fasted state)|
3198087|NCT01211964|Experimental|LEO 22811 single tablet 1.5 (fed state)|
3198088|NCT01211951|Experimental|KCT-0809 ophthalmic solution, low dose|
3198089|NCT01211951|Experimental|KCT-0809 ophthalmic solution, medium dose|
3198090|NCT01211951|Experimental|KCT-0809 ophthalmic solution, high dose|
3198091|NCT01211951|Placebo Comparator|Placebo|
3198092|NCT01211938|Active Comparator|single-fraction radiotherapy with concomitant 5FU and Hydrea|six 5-day cycles with a 9-day rest period between each cycle (split course). Each cycle includes : a single-fraction at a dose of 2 Gy per session for 5 sessions, combined with 5FU (800 mg/m2/day) and Hydrea (500 mg x 3/day) over the 5 days of the cycle. The total dose of radiotherapy is therefore 60 Gy delivered over 11 weeks.
3198093|NCT01211938|Experimental|hyperfractionated radiotherapy with concomitant Cetuximab|Bifractionated radiotherapy at a dose of 1.2 Gy per session at a rate of 2 sessions per day, at least 6h apart, 5 days per week over 5 weeks, without a split course, combined with Cetuximab. The total dose of radiotherapy is 60 Gy delivered over 5 weeks. Cetuximab (ErbituxÒ) is to be administered in a 2-hour IV infusion at a dose of 400 mg/m2, 8 days before the start of radiotherapy, then in a 1-hour infusion at a dose of 250 mg/m2 on days 1, 8, 15, 22 and 29 of radiotherapy.
3198094|NCT01211925|Experimental|critical ischemia|
3198095|NCT01211925|No Intervention|Control|Best medical treatment
3198096|NCT01211912|Experimental|Arm 1 (20 patients)|Pregnant women will be given a single dose of 1000 mg of acetaminophen orally after a baseline ultrasound and 60 minutes before a repeat ultrasound.
3198097|NCT01211912|Experimental|Arm 2 (34 patients)|Pregnant women will be given a single dose of 1000 mg of acetaminophen orally 30 minutes to 24 hours before a scheduled cesarean section.
3198098|NCT01211873|Experimental|Dotarem (gadoterate meglumine )|Dotarem and Magnevist were randomised as 2:1 ratio for adult patients.
3198099|NCT01211873|Active Comparator|Magnevist (gadopentetate dimeglumine)|Dotarem and Magnevist were randomised as 2:1 ratio
3198106|NCT01211821|Other|metoprolol|Treatment A
3198107|NCT01211821|Experimental|BMS-914392 + metoprolol|Treatment B
3198108|NCT01211808|Experimental|Treatment A (BMS-914832)|
3198109|NCT01211808|Experimental|Treatment B (BMS-914832 + diltiazem)|
3198110|NCT01211795|Active Comparator|Topical Ketoprofen gel|
3198111|NCT01211795|Placebo Comparator|Placebo gel|
3198112|NCT01211782|Experimental|AC-1204|
3198113|NCT01211782|Placebo Comparator|Placebo|
3198114|NCT01211769|Experimental|PUFAs|Polyunsaturated fatty acids (PUFAs): borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram; along with 1 gram of fish oil - rich in omega 3 PUFA;
3198115|NCT01211769|Active Comparator|Naltrexone|Naltrexone chlorhydrate 50 mg
3198116|NCT01211769|Placebo Comparator|Placebo|"Naltrexone Placebo: pill with 50mg of talcum powder, identical to the pill of naltrexone;~Polyunsaturated fatty acids Placebo (PUFAs Placebo): yellow liquid paraffin identical to the pills of borage seed and fish oil."
3198117|NCT01211769|Other|Naltrexone + PUFAs|"Polyunsaturated fatty acids (PUFAs): borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram; along with 1 gram of fish oil - rich in omega 3 PUFA;~Naltrexone chlorhydrate 50 mg"
3198118|NCT01211756|Experimental|Oxytocin|20 IU of intranasal oxytocin twice per day for the first week, 40 IU of intranasal oxytocin twice per day for the following 3 weeks, one week wash out, 4 week placebo trial.
3198119|NCT01211756|Placebo Comparator|Placebo|Four week placebo trial, one week wash out, 20 IU of intranasal oxytocin twice per day for one week, 40 IU of intranasal oxytocin twice per day for 3 weeks.
3198120|NCT01211743|Active Comparator|Lap Group|Patients in this group are operated for uncomplicated cholelithiasis with standard 4 port laparoscopic cholecystectomy
3198121|NCT01211743|Active Comparator|SILS group|Patients in this group are operated for uncomplicated cholelithiasis with Single Incision Laparoscopic Cholecystectomy
3198122|NCT01211730|Active Comparator|140 Group|Insulin treatment to target blood glucose at 140 mg/dl
3198123|NCT01211730|Active Comparator|180 Group|Insulin treatment to target blood glucose at 180 mg/dl
3198124|NCT01211717|Experimental|Branched Chained Amino Acids|
3198125|NCT01211717|Placebo Comparator|Cellulose mix|
3198126|NCT01211704|Placebo Comparator|Placebo, Counceling|Placebo
3198127|NCT01211704|Experimental|Paliperidone Palmitate|Paliperidone Palmitate
3198128|NCT01211691|Experimental|Phase 1 dose levels: KB004|"IV infusion 1x Weekly for a 21 day dosing cycle~Subjects with heme malignancies will be assigned to one of 11 planned KB004 (dose levels (20mg, 40mg, 70mg, 100mg, 140mg, 190mg, 250mg, 330mg)"
3198129|NCT01211691|Experimental|Phase 2 dose levels: KB004|"IV infusion 1x Weekly for a 21 day dosing cycle~Subjects will be assigned to the recommended Phase 2 dose of 250 mg"
3198130|NCT01211665|Experimental|Pulsed IVMP|Intravenous methylprednisolone (IVMP) 1 g/day administered the first 3 days of each weekly cycle, and repeated for 3 additional cycles (totaling 4 cycles). If necessary, 2 additional weekly cycles of 1 g IVMP daily for 3 days can be administered at the discretion of the investigator.
3198131|NCT01211665|Experimental|IVMP with oral prednisolone taper|Intravenous methylprednisolone (IVMP) 1g/day for 6 days followed by an oral taper of prednisolone over 2 months (suggested dosages starting at 80 mg and tapering to 5 mg). If necessary, additional cycles of 1 g IVMP daily for 3 to 5 days can be administered at any time.
3198132|NCT01211652||1|
3198133|NCT01211626|Active Comparator|Part A, Group 1 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 200 mg of ANA773 (n=6) or placebo (n=2)
3198134|NCT01211626|Active Comparator|Part A, Group 2 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 400 mg of ANA773 (n=6) or placebo (n=2)
3198135|NCT01211626|Active Comparator|Part A, Group 3 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 800 mg of ANA773 (n=6) or placebo (n=2)
3198136|NCT01211626|Active Comparator|Part A, Group 4 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 1200 mg of ANA773 (n=6) or placebo (n=2)
3198137|NCT01211626|Active Comparator|Part A, Group 5 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 1600 mg of ANA773 (n=6) or placebo (n=2)
3198138|NCT01211626|Active Comparator|Part B, Group 6 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 2000 mg of ANA773 (n=6) or placebo (n=2)
3198139|NCT01211626|Active Comparator|Part B, Group 7 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 1200 mg of ANA773 (n=6) or placebo (n=2)
3198140|NCT01211626|Active Comparator|Part B, Group 8 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 1600 mg of ANA773 (n=6) or placebo (n=2)
3198141|NCT01211626|Active Comparator|Part B, Group 9 HCV Infected Patient|multiple oral doses(5 administrations) every other day of 2000 mg of ANA773 (n=8) or placebo (n=2)
3198142|NCT01211613|Experimental|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
3198143|NCT01211613|Experimental|Mechanical Manipulation|Doctor of chiropractic will apply a mechanically-assisted thrust to the lumbar spine of research participants using the Activator IV Instrument.
3198144|NCT01211613|Active Comparator|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
3198145|NCT01211600|Active Comparator|Staples|Interrupted Ethicon Staples
3198146|NCT01211600|Active Comparator|Suture|Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
3198147|NCT01211587|Experimental|100mg safinamide|Two 50mg tablets of safinamide once per day for 12 weeks (weeks 1-12) Open Label part: Two 50mg tablets of safinamide once per day for 12 weeks (week 13-24)
3198148|NCT01211587|Placebo Comparator|Placebo|Two 50mg tablets of placebo once per day for 12 weeks (weeks 1-12) Open Label part: Two 50mg tablets of safinamide once per day for 12 weeks (week 13-24)
3198304|NCT01210560|Experimental|120 mg IR|
3198149|NCT01211574|Experimental|peer coach|Participants will be coached by a peer between treatment visits.
3198150|NCT01211574|Experimental|mentor|Participants will be coached by a mentor between treatment visits
3198151|NCT01211574|Experimental|Professional|Participants will be coached by an interventionist between treatment visits
3198152|NCT01211561|Experimental|Selenium, selenomethionine|
3198153|NCT01211561|Active Comparator|placebo|
3198154|NCT01211548||contrast CTA of the CAP|All patients being considered for a complex aortic surgery and undergoing medically indicated contrast enhanced CT aortic angiography of the chest abdomen and pelvis will be includedRaw data from CT coronary angiography will be available from all patients.
3198155|NCT01211535|Experimental|OPTI-FREE RepleniSH|OPTI-FREE RepleniSH multipurpose solution used with study contact lenses on a daily wear basis for 14 days
3198156|NCT01211535|Active Comparator|ReNu Biotrue|ReNu Biotrue multipurpose solution used with study contact lenses on a daily wear basis for 14 days
3198157|NCT01211522|Experimental|Haloperidol|Haloperidol
3198158|NCT01211522|Experimental|Ziprasidone|Ziprasidone
3198159|NCT01211522|Placebo Comparator|Placebo|Placebo
3198160|NCT01211509|Experimental|montelukast sodium|Daily treatment with 10 mg montelukast after diagnosis of fibroproliferative BOS (fBOS) which is the low neutrophilic phenotype within BOS
3198161|NCT01211509|Placebo Comparator|placebo|Lactose monohydricum Ph.Eur.
3198162|NCT01211496|Active Comparator|High-speed power training|Volunteers randomized into High-speed power training (HSPT) will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength for leg press (LP) and seated knee extension (KE) exercises.
3198163|NCT01211496|Active Comparator|Slow-speed strength training|Volunteers randomized into Slow-speed strength training (SSST) will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength for LP and KE exercises.
3198164|NCT01211496|No Intervention|placebo exercise (control group)|Volunteers randomized into the control group (CON) will undergo a placebo exercise intervention consisting of lower extremity range of motion and flexibility exercises performed 2 times per week with the assistance of the research staff.
3198165|NCT01211483|Experimental|Part A: U3-1287 (high dose) + Erlotinib|U3-1287 (high dose) intravenously (IV) every three weeks (Q3W) + Erlotinib 150 mg/day orally (PO) until cancer gets worse, side effects become unacceptable or participant withdraws consent
3198166|NCT01211483|Experimental|Part B: U3-1287 (low dose) + Erlotinib|U3-1287 (low dose) IV Q3W + Erlotinib 150 mg/day PO until cancer gets worse, side effects become unacceptable or participant withdraws consent
3198167|NCT01211483|Placebo Comparator|Part B: Placebo + Erlotinib|Placebo matching U3-1287 IV Q3W + Erlotinib150 mg/day PO until cancer gets worse, side effects become unacceptable or participant withdraws consent
3198168|NCT01211470|Experimental|PMX-30063|3 arms of PMX-300063
3198169|NCT01211470|Active Comparator|Daptomycin.|Daptomycin will be administered according to the approved product monograph information for ABSSSI.
3198170|NCT01211457|Experimental|decitabine/sapacitabine|decitabine will be administered in alternating cycles with sapacitabine
3198171|NCT01211444|Experimental|HGNS System|
3198172|NCT01211431|Active Comparator|Reference|Intrathécale morphine is used for post-cesarean pain control
3198173|NCT01211431|Experimental|Experimental|A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
3198174|NCT01211418|Experimental|Integrative Meditation|
3198175|NCT01211418|Active Comparator|Nondirective Therapy|
3198176|NCT01211405|Active Comparator|Low dose MDMA|Participants will receive 30 mg MDMA during each of two blinded experimental sessions.
3198177|NCT01211405|Active Comparator|Medium dose MDMA|Participants will receive 75 mg MDMA on each of two blinded experimental sessions
3198178|NCT01211405|Experimental|Full dose MDMA|Participants will receive 125 mg MDMA during each of two blinded experimental sessions, followed by a third open label session.
3198179|NCT01211379|No Intervention|FLU-Only Arm|In this arm, primary care patients who got flu shots were only provided with FOBT if the doctor decided to order it.
3198180|NCT01211379|Experimental|FLU-FOBT Arm|In this arm, patients who came in for primary care got a flu shot and were assessed by nurses for eligibility for colorectal cancer screening. Eligible patients were provided with home FOBT.
3198181|NCT01211366|Active Comparator|Conventional Transfusion|Infants will receive PRBCs, crystalloid, and colloid for hemodynamic instability per the usual routine at the discretion of the attending intensive care physician
3198182|NCT01211366|Experimental|Cell Saver|Infants will receive washed cell-saver RBCs for hemodynamic instability in the first 24 hours post-operative period as long as Hgb is < 13 gm/dL and cell-saver is available.
3198183|NCT01211353|Experimental|Personalized Drinking Feedback|Personalized feedback on drinking behaviors
3198184|NCT01211353|Active Comparator|Education-Only|Educational information about alcohol
3198185|NCT01211340|No Intervention|Usual Care|Usual hospice care- there is no intervention in this arm
3198186|NCT01211340|Experimental|ACTIVE|Behavioral intervention using web conferencing
3198187|NCT01211327|Experimental|Cyclosporine A|Cyclosporine A (CsA) 2% eye drops
3198188|NCT01211327|Active Comparator|Dexamethasone|Dexamethasone 0,1% eye drops
3198189|NCT01211314|Experimental|lercanidipine-enalapril fixed combination|uncontrolled hypertensive patients will receive fixed combination therapy
3198190|NCT01211301|Active Comparator|Food-based, Reduced Energy Diet Plan|
3198191|NCT01211301|Experimental|Medifast 5 & 1 Plan|
3198192|NCT01211288||control group|Age 19 and older, Non- smoker (quite smoking at least 6 months) Controlled Type II diabetes Controlled hypertension Non bisphosphate user Non- bruxer
3198193|NCT01211288||HIV positive|"HIV (+) patients with the following requirements:~Age 19 and older, Hemoglobin >8g/dl , Absolute neutrophil count >750/mm3, Platelet count>75,000cells/mm3, AST< 5 times the upper limit of normal (ULN), Bilirubin< 2.5 times ULN, Alkaline phosphate < 5 times ULN, Creatinine< 2.5 mg/ml Non- smoker (quite smoking at least 6 months) Controlled Type II diabetes Controlled hypertension Non bisphosphate user Non- bruxer"
3198194|NCT01211275|Experimental|arm 2|axitinib + cisplatin + premetrexed
3198195|NCT01211275|Active Comparator|arm 1|cisplatin + premetrexed
3198196|NCT01211262|Experimental|IMCgp100 weekly dosing regimen|Weekly IV infusions of IMCgp100 at the weekly MTD/recommended phase II dose (RP2D) over treatment cycles of eight weeks each.
3198197|NCT01211262|Experimental|IMCgp100 daily dosing regimen|Daily IV infusions of IMCgp100 administered on days 1 to 4 and days 22 to 25 of a six week treatment cycle at the MTD/daily recommended phase II dose (RP2D).
3198198|NCT01211249|Experimental|GLPG0259 (Part A)|
3198199|NCT01211249|Placebo Comparator|Placebo (Part A)|
3198200|NCT01211249|Experimental|GLPG0259 (Part B)|
3198201|NCT01211249|Placebo Comparator|Placebo (Part B)|
3198202|NCT01211236|Experimental|Maggot Debridement Therapy|
3198203|NCT01211236|Active Comparator|control|
3198204|NCT01211223|Experimental|Scaling and root planning + placebo + antibiotics|"Scaling and root planning + placebo~Scaling and root planning + metronidazole plus amoxicillin~Metronidazole plus amoxicillin + scaling and root planning"
3198205|NCT01211210|Active Comparator|A: 5Fu with Radiation|Patients receive fluorouracil IV continuously and undergo radiotherapy once daily 5 days a week for 5-6 weeks.
3198206|NCT01211210|Experimental|B: FOLFOX with radiation|Patients receive FOLFOX for 5 cycles and undergo radiotherapy as in arm I from the second cycle of FOLFOX
3198207|NCT01211210|Experimental|C: FOLFOX alone|Patients receive FOLFOX for 4 cycles
3198208|NCT01211197|Experimental|A|3 treatments will be investigated in randomized order
3198209|NCT01211197|Experimental|B|3 treatments will be investigated in randomized order
3198210|NCT01211197|Experimental|C|3 treatments will be investigated in randomized order
3198211|NCT01211184|Placebo Comparator|Fasting|patients undergo surgery in the fasting state
3198212|NCT01211184|Active Comparator|Water administration|Patients undergo hip surgery after receiving 800 ml water by mouth the morning 2 hours before surgery
3198213|NCT01211184|Active Comparator|carbohydrate drink|Patients undergo hip surgery after receiving 800 ml carbohydrate drink by mouth
3198214|NCT01211171||Group 1|
3198215|NCT01211158|Active Comparator|Propofol alone|Patients receiving propofol alone.
3198216|NCT01211158|Active Comparator|Ketofol|0.375 mg/kg each of ketamine and propofol (mixed in the same syringe) as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
3198217|NCT01211145|Placebo Comparator|1|Placebo
3198218|NCT01211145|Experimental|2|ZOMIG 0.5 mg
3198219|NCT01211145|Experimental|3|ZOMIG 2.5 mg
3198220|NCT01211145|Experimental|4|ZOMIG 5.0 mg
3198221|NCT01211132|Active Comparator|Cap arm|
3198222|NCT01211132|Active Comparator|Standard arm|
3198223|NCT01211119|Experimental|platelet-rich fibrin, PRF|
3198224|NCT01211106|Experimental|Arm 1: Integrated Conditions|Motivational enhancement therapy for addiction is combined with Prolonged exposure therapy for PTSD from the beginning of treatment. Both are delivered by the same provider throughout treatment.
3198225|NCT01211106|Experimental|Arm 2 Sequential therapy|Motivational enhancement therapy for addiction is delivered in the first 4 weeks and only after the addiction is addressed is the Prolonged exposure therapy for PTSD started.
3198226|NCT01211093|Experimental|High frequency whole body vibration|This group will receive a single 10-minute session of WBV therapy. The frequency of the vibration signals will be set at 30Hz.
3198227|NCT01211093|Active Comparator|low frequency whole body vibration|This group will receive a single 10-minute session of WBV. The frequency of the vibration signals will be set at 20 Hz.
3198228|NCT01211093|Active Comparator|Control|This group will stand on the same vibration platform for 10 minutes, but no vibration will be given.
3198229|NCT01211080||Threatening hemangioma|The group with cosmetically threatening of functionally threatening hemangiomas warranting active treatment according to our usual criteria (location face, hands, feet with a strong growth tendency and below age of 8 months)
3198230|NCT01211067||Patients age: 15 - 40 years-old|Patients within the 15 to 40 years-old age-group
3198231|NCT01211067||Patients age: 41 to 60 years-old|Patients within the group-age from 41 to 60 years-old
3198232|NCT01211067||Patients age: older than 61 years-old|Patients within the group-age from 61 years-old and older
3198233|NCT01211028|Other|Autologous ASCs|Expanded autologous ASCs (Adipose Stroma/Stem Cells) Intramuscular dose of 100 million expanded cells.
3198234|NCT01211015||Control group|healthy control group
3198235|NCT01211015||Disease group|asthma, COPD, ILD, lung malignancy
3198236|NCT01211002|Active Comparator|radiotherapy combined with EP|the dose of radiotherapy is 60-66 Gy / 30-33f.The combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
3198237|NCT01211002|Experimental|adiotherapy / EP /recombinant human endostatin|recombinant human endostatin: The number of courses is 3 ~ 4 and each course last for 28 days.dose:15mg，d1-14, intravenous injection.
3198238|NCT01210989|Active Comparator|Hepaguard|
3198239|NCT01210989|Placebo Comparator|Placebo|
3198240|NCT01210976|Experimental|levosimendan|
3198241|NCT01210976|Placebo Comparator|placebo|
3198242|NCT01210963||SENSIMED Triggerfish|
3198243|NCT01210950|Experimental|cell and RPR recepients|mesenchymal cells and plasma reach protein are injected to the callus center of short limb
3198244|NCT01210937|Experimental|CEA and TCD monitoring|CEA involves a neck incision and physical removal of the plaque from the inside of the artery.During the surgery, the patient will be monitored by TCD.
3198245|NCT01210924||Pediatric ART patients|
3198246|NCT01210911|Experimental|Gemcitabine, erlotinib and metformin|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine. Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food. Metformin will be administered at a dose of 500 mg twice daily. If well tolerated the dose will be increased to 1000 mg twice daily in the second week.
3198305|NCT01210521|No Intervention|Prior to intervention with Vitamin D|Patients will be analyzed for clinical, serological and immunological parameters before starting the interventional drug, Vitamin D.
3198306|NCT01210521|Active Comparator|Vitamin D Intervention|Patients will be analyzed for clinical, serological and immunological parameters after one month taking Vitamin D.
3198247|NCT01210911|Placebo Comparator|Gemcitabine, erlotinib and placebo|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine. Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food. PLacebo will be administered at a dose of 500 mg twice daily. If well tolerated the dose will be increased to 1000 mg twice daily in the second week.
3198248|NCT01210898|Experimental|Group 1|
3198249|NCT01210898|Experimental|Group 2|
3198250|NCT01210898|Experimental|Group 3|
3198251|NCT01210898|Experimental|Group 4|
3198252|NCT01210898|Experimental|Group 5|
3198253|NCT01210898|Experimental|Group 6|
3198254|NCT01210898|Experimental|Group 7|
3198255|NCT01210898|Experimental|Group 8|
3198256|NCT01210898|Experimental|Group 9|
3198257|NCT01210898|Experimental|Group 10|
3198258|NCT01210898|Experimental|Group 11|
3198259|NCT01210898|Experimental|Group 12|
3198260|NCT01210898|Experimental|Group 13|
3198261|NCT01210885|Experimental|Group I: Investigational MenABCWY Formulation 1|
3198262|NCT01210885|Experimental|Group II: Investigational MenABCWY Formulation 2|
3198263|NCT01210885|Experimental|Group III: Investigational MenABCWY Formulation 3|
3198264|NCT01210885|Experimental|Group IV: Investigational MenABCWY Formulation 4|
3198265|NCT01210885|Active Comparator|Group V: Active comparator investigational MenB|
3198266|NCT01210885|Active Comparator|Group VI: Active comparator MenACWY|
3198267|NCT01210859||Ureteral stents Detrusitol treatment Lyfestyle outcome|Ureteral stents Detrusitol treatment Lyfestyle outcome
3198268|NCT01210846|Experimental|tivozanib|
3198269|NCT01210833|Active Comparator|Healthy participants|Healthy participants aged from 18 to 60 with no history of hand injuries recruited by convenience sampling.
3198270|NCT01210833|Experimental|Hand Injured participants|Participants with hand injuries aged from 18 to 60 recruited from the outpatients attending the occupational therapy clinic.
3198271|NCT01210820|Experimental|Natural Astigmatism|Subjects with refractive astigmatism and no prior history of ophthalmic surgery. May include subjects with cataracts.
3198272|NCT01210820|Experimental|Post cataract with residual astigmatism|Subjects who have had cataract removal surgery but have residual astigmatism.
3198273|NCT01210807|Experimental|Multifocal Intraocular Lens|ZMB00 multifocal intraocular lens
3198274|NCT01210807|Active Comparator|Monofocal Intraocular Lens|ZCB00 monofocal intraocular lens
3198275|NCT01210768|Active Comparator|EC|Cyclophosphamide,600 mg/m2 q3wk and Epirubicin,90 mg/m2 q3wk
3198276|NCT01210768|Experimental|LC|liposomal doxorubicin, 37.5 mg/m2 q3wk, and Cyclophosphamide,600 mg/m2 q3wk
3198277|NCT01210755|Experimental|Rivaroxaban then Dabigatran|Cross-over study with 15 days between administration of Rivaroxaban and Dabigatran
3198278|NCT01210755|Experimental|Dabigatran then Rivaroxaban|Cross-over study with 15 days between administration of Dabigatran and Rivaroxaban
3198279|NCT01210742|Experimental|Viscosupplementation with routine management|
3198280|NCT01210742|Active Comparator|Routine management|Routine management for knee OA (NICE guidelines)
3198281|NCT01210716|Experimental|AMICUS Therapeutic plasma exchange, TPE|Patients are randomized to either TPE on AMICUS or Spectra.
3198282|NCT01210716|Active Comparator|Spectra Therapeutic plasma exchange, TPE|Patients are randomized to either TPE on AMICUS or Spectra.
3198283|NCT01210690||Patients, 1 - 11 months old, prescribed Keppra® oral solution|Epileptic patients who have been prescribed Keppra® (Levetiracetam) oral solution and who are between 1 and 11 months old. The patients will be followed as per current clinical practices for their condition. The choice of medical treatment, including the concomitant use of other antiepileptic drugs, is made independently by the physician in the regular course of practice and is not influenced by the study protocol.
3198284|NCT01210677|Active Comparator|Prednisone|Prednisone 0.5 mg/Kg per day orally for 3 months
3198285|NCT01210677|Placebo Comparator|Placebo|Matching placebo tablets(s) taken orally per day
3198286|NCT01210664|Experimental|Polyclonal Regulatory T Cells|Patients with Type 1 Diabetes Mellitus will have their regulatory T cells (Tregs) isolated by researchers and receive Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells by infusion
3198287|NCT01210651|Experimental|Hatha Yoga Practice Group|Participants in this group practiced 90-minute sessions of hatha yoga exercises twice weekly for a total of 8 weeks.
3198288|NCT01210651|Active Comparator|Attention Control Education Group|Participants in this group attended 90-minute educational seminars on yoga history twice weekly for a total of 8 weeks.
3198289|NCT01210638|Active Comparator|Oxymorphone Hydrochloride|Tablet
3198290|NCT01210638|Active Comparator|Opana|Tablet
3198291|NCT01210625|Active Comparator|Psyllium|Subjects will take 4 capsules containing 1 gram psyllium fiber 3 times a day (12g total per day)
3198292|NCT01210625|Experimental|Nutrabiotix 9g|Subjects take a total of 9g of Nutrabiotix a day (3 capsules of 1g Nutrabiotix 3 times a day)
3198293|NCT01210625|Experimental|Nutrabiotix 12g|Subjects take a total of 12g of Nutrabiotix a day (4 capsules of 1g Nutrabiotix 3 times a day)
3198294|NCT01210612|Active Comparator|Without Unilateral CAI|
3198295|NCT01210612|Active Comparator|With Unilateral CAI|
3198296|NCT01210599|Experimental|IV infusion of pamidronate vs placebo|
3198297|NCT01210586|Active Comparator|Nicotine Patch|Nicotine Patch for Smoking Cessation
3198298|NCT01210586|Placebo Comparator|Placebo Patch|
3198299|NCT01210573||Device adjustment|Advanced or suspected advanced heart failure. Most are anticipated to have severely depressed ejection fraction (<30% and typically <20%), but patients with preserved ejection fraction and either hypertrophy or restrictive cardiomyopathy will also be eligible. Patients pulmonary hypertension, on any therapy (other than diuretics alone), are also felt to be at high risk of developing right heart failure and may also be included. Patients who have already undergone LVAD or cardiac transplant are also considered to have advanced heart failure and are eligible to participate, regardless of the severity of their symptoms at the time of enrollment.
3198300|NCT01210560|Experimental|20 mg MR|
3198301|NCT01210560|Experimental|40 mg MR|
3198302|NCT01210560|Experimental|60 mg MR|
3198303|NCT01210560|Experimental|120 mg MR|
3198307|NCT01210495|Experimental|A|Participants in this group received axitinib + best supportive care. Participants with Child-Pugh Class A disease (score 5 or 6) were enrolled into the randomized portion at a starting axitinib dose of 5 mg BID orally. Participants with Child-Pugh Class B disease (score 7) were to begin enrollment into the randomized portion of the study following determination of the recommended axitinib starting dose in the non-randomized portion. Study treatment was administered in cycles of 4 weeks in duration
3198308|NCT01210495|Placebo Comparator|B|Participants in this group received placebo + best supportive care. Treatment was administered in cycles of 4 weeks in duration. The starting dose of placebo for participants with Child Pugh Class A disease (score 5 or 6) was chosen as 5 mg BID. Participants with Child-Pugh Class B, score 7 received placebo that was determined from the non-randomized portion of the study until the recommended starting dose was determined, participants with Child-Pugh Class B, score 7, were not permitted to enter the randomized portion of the study
3198309|NCT01210482||Temsirolimus|Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma)
3198310|NCT01210469|Experimental|Strengthening Group|Performed balance training with lower limbs muscle strengthening.
3198311|NCT01210469|Experimental|Stretching Group|Performed balance training with stretching
3198312|NCT01210469|No Intervention|Control Group|
3198313|NCT01210456|Active Comparator|Physiological Saline and N-Acetylcysteine|
3198314|NCT01210456|Active Comparator|Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|
3198315|NCT01210443|Experimental|Sitaxentan treatment|
3198316|NCT01210430|Active Comparator|Losartan|
3198317|NCT01210430|Active Comparator|Ascorbic Acid (VItamin C)|
3198318|NCT01210430|Placebo Comparator|Normal Saline|
3198319|NCT01210417||Trauma victims|All prehospital traumatic patients enrolled by our Helicopter Emergency Medical System (HEMS)
3198320|NCT01210404|Experimental|1.0|
3198321|NCT01210391|Experimental|New hydrolyzed infant formula|New, extensively hydrolyzed infant formula
3198322|NCT01210391|Active Comparator|Commercially available infant formula|Commercially available, extensively hydrolyzed infant formula.
3198323|NCT01210378|Experimental|Nitroglycerin|
3198324|NCT01210365|Experimental|furosemide (40 mg) +amiloride (10 mg)|One group of patients will receive furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow the tablet in whole form on an empty stomach with some liquid.
3198325|NCT01210365|Active Comparator|Lasix ®|One group of patients will receive Lasix® (furosemide 40 mg). For treatment, the patient will swallow the tablet in whole form on an empty stomach with some liquid.
3198326|NCT01210352|Experimental|CII Drug|Open Label
3198327|NCT01210339|Experimental|1|Treatment A (Clopidogrel 9 days), at least 14 days wash-out, Treatment B (Clopidogrel 4 days followed by Clopidogrel + Esomeprazole/ASA 5 days)
3198328|NCT01210339|Experimental|2|Treatment B (Clopidogrel 4 days followed by Clopidogrel + Esomeprazole/ASA 5 days), at least 14 days wash-out, Treatment A (Clopidogrel 9 days)
3198329|NCT01210326|Experimental|aspiration|90 patients with non-obstructive azoospermi undergo testicular sperm aspiration
3198330|NCT01210326|Experimental|extraction|90 patients with non-obstructive azoospermi undergo testicular sperm extraction
3198331|NCT01210313||no treatment|
3198332|NCT01210287|No Intervention|Observation|Observation of the HBV reactivation in HBsAg negative/HBcAg positive patients receiving RCHOP without prophylactic anti-HBV treatment.
3198333|NCT01210261|Active Comparator|Autoset S8|Single night auto-titrating CPAP treatment using the reference device (Resmed Autoset S8) with polysomnographic monitoring
3198334|NCT01210261|Experimental|Somnilink SPAP|Single night auto-titrating CPAP treatment using the test device with polysomnographic monitoring
3198335|NCT01210235|Experimental|FLU-FIT Arm|In this arm, eligible patients aged 50-75 will be offered a FIT kit
3198336|NCT01210235|No Intervention|FLU-Only Arm|In this arm, patients will receive flu shots as usual, without the FLU-FIT intervention.
3198337|NCT01210222|Experimental|Treatment (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3198338|NCT01210196||mild affected Fabry patients|
3198339|NCT01210170|Experimental|mometasone 400 mcg - 30 min|randomly assigned intervention
3198340|NCT01210170|Experimental|mometasone 400 mcg simultaneous|randomly assigned intervention
3198341|NCT01210170|Placebo Comparator|placebo- 30 min|randomly assigned intervention
3198342|NCT01210170|Placebo Comparator|placebo simultaneous|randomly assigned intervention
3198343|NCT01210170|Experimental|mometasone 400 mcg - 60 min|randomly assigned intervention
3198344|NCT01210170|Placebo Comparator|placebo- 60 min|randomly assigned intervention
3198345|NCT01210170|Experimental|mometasone 200 mcg - 30 min|randomly assigned intervention
3198346|NCT01210170|Experimental|mometasone 200 mcg - 60 min|randomly assigned intervention
3198347|NCT01210170|Experimental|mometasone 200 mcg simultaneous|randomly assigned intervention
3198348|NCT01210157||I Ischemic CMP|Patients with impaired ventricular function caused by coronary artery disease.
3198349|NCT01210157||II CMP|Patients with impaired ventricular function which is not caused by coronary artery disease. Subgroups based on etiology (familial cardiomyopathy, toxic cardiomyopathy, etc.)
3198350|NCT01210144|Experimental|Gonal-f® + Ovitrelle® + Long Agonist Protocol|
3198351|NCT01210144|Experimental|Gonal-f® + Ovitrelle® + Multi-dose Antagonist Protocol|
3198352|NCT01210131|Experimental|[18F]HX4|
3198353|NCT01210118|Experimental|High intensity intervention|"Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the 5 Αs (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided."
3198419|NCT01209715|Active Comparator|Fluticasone/salmeterol|Participants will be assigned to inhaled fluticasone/salmeterol twice a day for 3 weeks.
3198487|NCT01209312|Experimental|1/2 bolus, T-20|Will only give half the insulin dose 20 minutes before meal
3198354|NCT01210118|Other|Low intensity intervention|Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
3198355|NCT01210105||Macintosh #3 Laryngoscope|
3198356|NCT01210105||Glidescope|
3198357|NCT01210105||Ambu Pentax AWS|
3198358|NCT01210105||McGrath|
3198359|NCT01210105||Airtraq|
3198360|NCT01210105||Storz C-MAC|
3198361|NCT01210092||Macintosh #3 Laryngoscope|
3198362|NCT01210092||Glidescope|
3198363|NCT01210092||Ambu Pentax AWS|
3198364|NCT01210092||McGrath|
3198365|NCT01210092||Airtraq|
3198366|NCT01210092||Storz C-MAC|
3198367|NCT01210079|Experimental|Gabapentin|
3198368|NCT01210079|Placebo Comparator|Placebo|
3198369|NCT01210066|Active Comparator|Pain Challenge|Cold pressor test
3198370|NCT01210066|Active Comparator|Pain + Opioid Challenge|IV fentanyl 1mcg/kg followed by cold pressor test
3198371|NCT01210066|Active Comparator|Opioid Challenge|Administration of fentanyl 1mcg/kg of subject weight
3198372|NCT01210053|Experimental|Single arm|Patients receive oral sunitinib malate 25 mg daily in the absence of disease progression or unacceptable toxicity.
3198373|NCT01210040|Active Comparator|Folic Acid|2.8mg of Folic Acid given weekly
3198374|NCT01210040|Experimental|Folic Acid and Iron|2.8mg Folic Acid and 60mg Iron given weekly
3198375|NCT01210014|Placebo Comparator|A|Patients with Recurrent aphthous stomatitis
3198376|NCT01210014|Active Comparator|B|Patients with Recurrent aphthous stomatitis
3198377|NCT01210001|Experimental|BI 10773 low dose|BI 10773 tablets once daily
3198378|NCT01210001|Experimental|BI 10773 high dose|BI 10773 tablets once daily
3198379|NCT01210001|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
3198380|NCT01209988|Experimental|Tamsulosin 0.4mg|Perioperative tamsulosin 0.4mg daily
3198381|NCT01209988|Placebo Comparator|Control|No medication
3198382|NCT01209975||untreated glaucoma patients|We will evaluate the blood flow before and after Selective Laser Trabeculoplasty in patients with primary open angel glaucoma.
3198383|NCT01209962||Cohort|"The majority of recruited patients will be treated on protocol HUM00004531 A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin with Radiation Therapy in Patients with Pancreatic Cancer."
3198384|NCT01209949|Other|Adapalene 0.1% and Benzoyl Peroxide 2.5% gel|
3198385|NCT01209936|Experimental|deuterium oxide and BC3|Testing of total body water on the BC3 compared to total body water measured by deuterium oxide.
3198386|NCT01209923|Experimental|Body composition testing|Body composition tested using bioelectrical impedance and the DEXA or hydrostatic weighing methods.
3198387|NCT01209910|Experimental|free water|The subjects in this arm will be able to drink water followings study rules.
3198388|NCT01209910|No Intervention|Control|These subjects will be observed during the study.
3198389|NCT01209897|Active Comparator|Stage of Change|
3198390|NCT01209897|Experimental|Common Sense Model|
3198391|NCT01209897|Active Comparator|Action Model|
3198392|NCT01209884||Healthy Elderly sub-group|Healthy males between the age of 80-85 years old who have not experienced chronic disease during their lifetime.
3198393|NCT01209871|Experimental|Cohort 1 - DNA Vaccine|"Series of 3 autologous lymphoma immunoglobulin derived scFV-chemokine DNA vaccinations.~Cohort 1 dose 500 μg intramuscularly at 4-week intervals (+/- 3 business days) according to the following schedule: 0, 4, and 8 weeks."
3198394|NCT01209871|Experimental|Cohort 2 - DNA Vaccine|"Series of 3 autologous lymphoma immunoglobulin derived scFV-chemokine DNA vaccinations.~Cohort 2 dose 2500 μg intramuscularly at 4-week intervals (+/- 3 business days) according to the following schedule: 0, 4, and 8 weeks."
3198395|NCT01209858|Experimental|Experimental 1|
3198396|NCT01209858|Experimental|Experimental 2|
3198397|NCT01209832|Experimental|Drug Interaction arm|
3198398|NCT01209806|Active Comparator|simethicone|
3198399|NCT01209806|No Intervention|no simethicone|
3198400|NCT01209793|Experimental|Dose 1|(3:1, active: placebo)
3198401|NCT01209793|Experimental|Dose 2|(3:1, active: placebo)
3198402|NCT01209793|Experimental|Dose 3|(3:1, active: placebo)
3198403|NCT01209793|Experimental|Dose 4|(3:1, active: placebo)
3198404|NCT01209793|Experimental|Dose 5|(3:1, active: placebo)
3198405|NCT01209780|Experimental|TIV (3-8 years)|Non-Naive subjects received one dose and naive subjects received two doses, administered 4 weeks apart, of investigational trivalent influenza vaccine (TIV)
3198406|NCT01209780|Active Comparator|Control TIV (3-8 years)|Non-Naive subjects received one dose and Naive subjects received two doses, administered 4 weeks apart, of control vaccine. Subjects aged 3 to <4 years and subjects aged 4 to 8 years received different control TIV.
3198407|NCT01209780|Experimental|TIV ( 9-17 years)|All subjects received one dose of investigational TIV. The subjects in this cohort were included only for safety analysis.
3198408|NCT01209780|Active Comparator|Control TIV ( (9-17 years)|All subjects received one dose of the control vaccine. The subjects from this cohort were included only for safety analysis.
3198409|NCT01209767|Experimental|cryolipolysis|
3198410|NCT01209767|Active Comparator|subcision|
3198411|NCT01209767|Active Comparator|Control|Areas with cellulite that had no treatment performed were considered the control arm.
3198412|NCT01209754||Pregnant Women|Pregnant women exposed to an HIV prevention study agent during pregnancy
3198413|NCT01209754||Infant|Infants resulting from pregnancies where there exists maternal HIV prevention agent exposure
3198414|NCT01209741|Active Comparator|1|MK-0974 12MoRT
3198415|NCT01209741|Active Comparator|2|MK-0974 5Mo5C
3198416|NCT01209741|Active Comparator|3|MK-0974 12Mo5C
3198417|NCT01209728|Experimental|Primary insomnia patients and healthy subjects|Elderly participants, including primary insomnia patients and healthy subjects
3198418|NCT01209715|Placebo Comparator|Matching Placebo|Participants will be treated with placebo twice a day for 3 weeks.
3198420|NCT01209702|Placebo Comparator|Part 1: Placebo|Participants received intravenous infusions of placebo once every 4 weeks until Week 12. Following the Week 12 visit, participants who completed Part 1 of the study received open-label 8 mg/kg tocilizumab through Week 208.
3198421|NCT01209702|Experimental|Part 1: Tocilizumab|Participants received intravenous infusions of 8 mg/kg tocilizumab once every 4 weeks until Week 12. Following the Week 12 visit, participants who completed Part 1 of the study received open-label 8 mg/kg tocilizumab through Week 208.
3198422|NCT01209702|Placebo Comparator|Part 2: Placebo|Participants received intravenous infusions of placebo once every 4 weeks until Week 24. Participants who did not attain an ASsessment in Ankylosing Spondylitis-20 (ASAS20) response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
3198423|NCT01209702|Experimental|Part 2: Tocilizumab 4 mg/kg|Participants received intravenous infusions of 4 mg/kg tocilizumab once every 4 weeks until Week 24. Participants who did not attain an ASAS20 response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
3198424|NCT01209702|Experimental|Part 2: Tocilizumab 8 mg/kg|Participants received intravenous infusions of 8 mg/kg tocilizumab once every 4 weeks until Week 24. Participants who did not attain an ASAS20 response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
3198425|NCT01209689|Experimental|Tocilizumab 4 mg/kg|Patients received tocilizumab 4 mg/kg intravenously every 4 weeks for 24 weeks.
3198426|NCT01209689|Experimental|Tocilizumab 8 mg/kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks for 24 weeks.
3198427|NCT01209689|Placebo Comparator|Placebo|Patients received placebo to tocilizumab intravenously every 4 weeks for 24 weeks.
3198428|NCT01209676|Experimental|IMCgp100|IMCgp100 will be injected cutaneously or subcutaneously into the metastasis, and peritumoral area if applicable
3198429|NCT01209663|Active Comparator|Ward Care|Protocol based discharge to the surgery ward. Observation and treatment is conducted by ward nurses and general surgeons (current treatment).
3198430|NCT01209663|Experimental|Intermediate Care|Observation and treatment in an intermediate care bed in a minimum of 48 hours after randomization. Daily rounds will be carried out by both general surgeons and intensive care physicians.
3198431|NCT01209637|No Intervention|control|standard care of coronary artery diseases incl. recommended home based exercise 3x/week
3198432|NCT01209637|Active Comparator|Exercise training|exercise training for 4 weeks at 70% of ischemia free individual threshold within a rehabilitation care center
3198433|NCT01209637|Active Comparator|intensive exercise training|intensive exercise training incl. interval training
3198434|NCT01209611|Experimental|Autologous bone marrow mononuclear cells|Patients received autologous MNC transplantation. Bone marrow aspirates are harvested from the anterior iliac crest of the patients under general or local anesthesia. MNCs are isolated by density gradient centrifugation. The cell suspension was adjusted to a final volume of 6-20 ml with saline. The cell suspension was injected into expanded skin intradermally via a 27-gauge needle (approximately 0.5-1×10^6 cells/cm2).
3198435|NCT01209611|Placebo Comparator|Saline|Patient has intradermally and subcutaneously injection of saline.
3198436|NCT01209598|Experimental|Palbociclib 200mg|This is a phase II study of Palbociclib in patients with advanced / metastatic liposarcoma. A one-stage design is used to determine whether patients treated with Palbociclib achieved a PFS rate of ≥ 40% at 12 weeks.
3198437|NCT01209598|Experimental|Palbociclib 125mg|This is a phase II study of Palbociclib in patients with advanced / metastatic liposarcoma. A one-stage design is used to determine whether patients treated with Palbociclib achieved a PFS rate of ≥ 40% at 12 weeks.
3198438|NCT01209585||Rheumatoid Arthritis|Subject must have RA with inflamed joint
3198439|NCT01209585||Osteoarthritis|Subjects must have OA of the knee
3198440|NCT01209585||Pseudo gout|Subjects must have peusdo-gout of knee
3198441|NCT01209572|Experimental|calorimetric chamber|
3198442|NCT01209572|Experimental|Free living conditions|
3198443|NCT01209559||air-Q Intubating Laryngeal Airway|
3198444|NCT01209559||LMA FastrachTM or ILMA|
3198445|NCT01209546|Active Comparator|Flutter group|In Flutter group the exercise used the Flutter ®VRP1 (VarioRaw SA, Switzerland).
3198446|NCT01209546|Active Comparator|PEP group|In PEP group the exercise used the Flutter ®VRP1 (VarioRaw SA, Switzerland) without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1.
3198447|NCT01209546|Placebo Comparator|control group|In placebo patients were assessed as pulmonary function, respiratory muscle strength and transport properties of respiratory secretions
3198448|NCT01209546|Sham Comparator|Group Sham|Exercise with Flutter®VRP1 without the ball inside
3198449|NCT01209520|Experimental|Adjuvant Chemotherapy + Vidaza|
3198450|NCT01209507||Chemotherapy every 3 weeks|One treatment of chemotherapy every 3 weeks. Chemotherapy will either be 2 doses of 20 mg orally (PO) (12 hrs prior and immediately before treatment) or 1 dose via IV. The total dose per cycle is 20-40 mg every 3 weeks for 18 weeks.
3198451|NCT01209507||Weekly chemotherapy|Chemotherapy will be given three times in a three week cycle. Chemotherapy will be given either Day 1, 8, and day 15 or Day 1,2 and day 8). Chemotherapy will either be 2 doses of 20 mg PO (12 hrs priors and immediately before treatment) or 1 dose via IV. The total dose per cycle will be 20-40 mg approximately for 18 weeks.
3198488|NCT01209312|Experimental|1/2 bolus T0|Will give half the amount of insulin at the time of the meal
3198452|NCT01209494||Invasive EP Study Group|200 patients are studied before clinically indicated (according to AHA/ACC/ESC guidelines) first ICD implantation or ICD exchange. Invasive EP study is performed to test inducibility of malignant arrhythmia. In addition MAP recordings are performed for measurements of restitution properties. Pacing is done for 12-lead ECG and MAP recordings for analysis of BVR and TWA, if applicable.
3198453|NCT01209494||Noninvasive EP Study Group|"The assignment of patients to the invasive and noninvasive EP groups does not occur by randomization or for intervention.~In the noninvasive EP study group, 500 patients with chronically implanted ICD (>3 month after implantation) are investigated using non-invasive EP study via ICD programmer. Programmed electrical stimulation is performed to test for inducibility of malignant arrhythmia. In addition pacing is done for measurements of BVR from the 12-lead ECG."
3198454|NCT01209481|Experimental|Nutritional education|
3198455|NCT01209481|No Intervention|control|
3198456|NCT01209468|Active Comparator|oral appliance 2|Patients in treatment arm/group B will have a customized twinblock OA constructed for them individually. They will undergo an appliance acclimatization period of 4-5 weeks. Three months after baseline assessments - T1 (6 weeks of 'active' treatment), physiological measurements will be evaluated, clinical oral examinations conducted, quality of life and compliance assessed. Following this, a customized monobloc OA will be constructed for subjects individually and they will acclimatize to it for 4-5 weeks (so that the mandible is protruded to the maximum position they feel comfortable with when the appliance is worn). Prior to the active treatment phase, patients will not wear the monobloc OA for 1 week (washout phase). Three months later - T2 (6 weeks of 'active' treatment), all the previous measurements will be conducted again.
3198457|NCT01209468|Experimental|oral appliance 1|Patients in treatment arm/group A will have a customized monobloc OA constructed for them individually. They will undergo an appliance acclimatization period of 4-5 weeks. Three months after baseline assessments - T1 (6 weeks of 'active' treatment), physiological measurements will be evaluated, clinical oral examinations conducted, quality of life and compliance assessed. Following this, a customized twin-bloc OA will be constructed for subjects individually and they will acclimatize to it for 4-5 weeks (so that the mandible is protruded to the maximum position they feel comfortable with when the appliance is worn). Prior to the active treatment phase, patients will not wear the twin-bloc OA for 1 week (washout phase). Three months later - T2 (6 weeks of 'active' treatment), all the previous measurements will be conducted again.
3198458|NCT01209455|No Intervention|Saline|Volunteers will receive an incremental rising dose infusion of IA NAC (6 doses) together with a co-infusion of normal saline to determine a dose response curve for arterial vasodilatation in the forearm.
3198459|NCT01209455|Active Comparator|Histamine antagonists|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of histamine antagonists (H1 and H2 antagonists) to determine vasodilatation in response to NAC in the presence of histamine antagonists.
3198460|NCT01209455|Active Comparator|Low dose paracetamol|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of low dose paracetamol to determine whether the vasodilatory response to NAC is inhibited.
3198461|NCT01209455|Active Comparator|High dose paracetamol|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of higher dose paracetamol to determine whether the vasodilatory response to NAC is inhibited.
3198462|NCT01209442|Experimental|RT with Temozolomide and Bevacizumab|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily TMZ at 75 mg/m2 qd concurrent with IMRT (including weekends and holidays). Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Day 1 and the 1st Fx of IMRT must start on the same day. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab therapy, patients will have a brain MRI and if there is no evidence of disease progression, patients will receive 6 cycles of Bevacizumab and TMZ. Beginning a minimum of 28 days after the last radiation treatment the bevacizumab will be dosed at 10 mg/kg on day 1 and day 15 of each cycle. TMZ will be given at 150-200 mg/m2 qd on days 1-5 of each cycle. Each cycle is 28 days.
3198463|NCT01209429|Experimental|42 hour fast/GH infusion|
3198464|NCT01209429|Experimental|42 hour fast/Placebo infusion|
3198465|NCT01209429|Experimental|12 hour fast/GH infusion|
3198466|NCT01209429|Placebo Comparator|12 hour fast/Placebo infusion|
3198467|NCT01209416|Active Comparator|Ghrelin / Acipimox|Ghrelin infusion and tablet acipimox
3198468|NCT01209416|Active Comparator|Ghrelin / placebo|Ghrelin infusion and placebo tablets
3198469|NCT01209416|Active Comparator|Placebo / Acipimox|saline infusion and tablet Acipimox
3198470|NCT01209416|Placebo Comparator|Placebo / placebo|saline infusion and placebo tablets
3198471|NCT01209403|No Intervention|No treatment|
3198472|NCT01209403|Active Comparator|Glukose-infusion|Glucose-infusion during hemodialysis
3198473|NCT01209403|Active Comparator|Glucose-insulin infusion|Glucose-insulin infusion during hemodialysis
3198474|NCT01209390||Osteochondral lesions|Patients with osteochondral lesions in the knee, the ankle, or other joint
3198475|NCT01209377|Experimental|standard|EMDR treatment with bilateral stimulation via eye movement
3198476|NCT01209377|Experimental|fixed|EMDR treatment with eyes fixed
3198477|NCT01209377|Experimental|no focus|trauma exposition without external stimulus
3198478|NCT01209364|Experimental|Durolane|intraarticular hyaluronic acid
3198479|NCT01209364|Active Comparator|methylprednisolone|intraarticular injection
3198480|NCT01209351|Placebo Comparator|Placebo|Placebo
3198481|NCT01209351|Experimental|teduglutide|
3198482|NCT01209338|Active Comparator|sensitized group|One arm will be a sensitized group which would have received cancer health awareness sessions and / or screening earlier at least once in the past.
3198483|NCT01209338|No Intervention|non-sensitized group|The second arm will belong to an area which has never been exposed to any form of cancer awareness or screening activities thus this group is a completely non-sensitized group.
3198484|NCT01209325|Experimental|Vaccination|Gardasil (quadrivalent HPV types 6, 11, 16, 18) vaccination at weeks 0, 8, 24.
3198485|NCT01209312|Experimental|full bolus -20|Will administer full insulin bolus 20 minutes prior to meal
3198486|NCT01209312|Experimental|Full bolus, T0|Will administer full meal bolus at the start of the meal
3198878|NCT01206413|Experimental|LGI|Low glycemic index
3198489|NCT01209286|Experimental|Blinatumomab 15 μg|Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.
3198490|NCT01209286|Experimental|Blinatumomab 5/15 μg|Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, followed by 15 μg/m²/day starting from Week 2 of treatment.
3198491|NCT01209286|Experimental|Blinatumomab 5/15/30 μg|Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, a dose of 15 μg/m²/day in the subsequent 7 days, followed by 30 μg/m²/day starting from Week 3 of treatment.
3198492|NCT01209273||APD group|which can be 3 to 5 exchanges daily, and up to 20 liters daily( including up to two daytime exchanges)
3198493|NCT01209273||CAPD group|which can be 1 to 4 exchanges daily and up to 16 liters daily(including up to two daytime exchanges)
3198494|NCT01209260|Experimental|Radiofrequency energy needle|Radiofrequency energy needle for transseptal access
3198495|NCT01209260|Active Comparator|Mechanical needle|Mechanical (Brockenbrough) needle for transseptal access
3198496|NCT01209247|Active Comparator|patient treated by fluoroquinolone|patient treated by fluoroquinolone. Nasal, rectal and pharyngeal swabs
3198497|NCT01209247|Placebo Comparator|patient not receiving FQ treatment|reference group of patients not receiving FQ treatment, but hospitalized in the same wards at the same time
3198498|NCT01209234|Active Comparator|MRSA Decolonization|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
3198499|NCT01209234|Active Comparator|Education Arm|Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home. In addition, educational material on hygiene practices to prevent MRSA infection will be provided.
3198500|NCT01209221|Experimental|1|
3198501|NCT01209221|Experimental|2|
3198502|NCT01209221|Placebo Comparator|3|
3198503|NCT01209221|Placebo Comparator|4|
3198504|NCT01209208|Experimental|A|Budesonide
3198505|NCT01209208|Experimental|B|Mesalazine
3198506|NCT01209208|Placebo Comparator|C|
3198507|NCT01209195|Experimental|MM-121 + Paclitaxel|Escalating doses of MM-121 given IV QW in combination with paclitaxel at standard dose of 80 mg/m2 IV QW
3198508|NCT01209156|Experimental|Assess [18F] PBR111 and PET imaging|Evaluation of PET imaging with [18F]PBR111 in HV and AD subjects (Proof of Mechanism)
3198509|NCT01209143|Experimental|Vismodegib + rosiglitazone|Participants received rosiglitazone 4 mg orally on Days 1 and 8 of the study. Participants also received vismodegib 150 mg orally once a day beginning on Day 2 until one of the following occurred; disease progression, intolerable toxicity, most probably attributable to vismodegib, or patient withdrawal of consent.
3198510|NCT01209143|Experimental|Vismodegib + oral contraceptive|Participants received the oral contraceptive norethindrone 1 mg/ethinyl estradiol 35 µg (Ortho-Novum 1/35®) orally on Days 1 and 8 of the study. Participants also received vismodegib 150 mg orally once a day beginning on Day 2 until one of the following occurred; disease progression, intolerable toxicity, most probably attributable to vismodegib, or patient withdrawal of consent.
3198511|NCT01209130|Experimental|A|
3198512|NCT01209130|Experimental|B|
3198513|NCT01209117|Experimental|Periods 1 - 4|Subjects will be randomized in a cross over fashion to receive the GSK2248761 WBM capsule formulation or one of three WBM tablet formulations in one of four sequences.
3198514|NCT01209117|Experimental|Period 5|Subjects in Part B will receive a formulation of GSK2248761 200mg WBM Tablet chosen from Periods 1 - 4 in part A in the fed state (moderate fat meal).
3198515|NCT01209104|Experimental|Cohort 1-PK and and safety of GSK1325756 in subjects 40-64y|This arm assesses the pharmacokinetics and safety of a single oral ose of 100mg of GSK1325756 administered to subjects in the age range 40y-64y when administered in the fasted state, in the presence of a high-fat meal and in the presence of a proton-pump inhibitor.
3198516|NCT01209104|Experimental|Cohort 2- PK and safety of GSK1325756 in subjects aged 65y-80y|This arm assesses the pharmacokinetics and safety of a single dose of 100mg of GSK1325756 administered to a group of subjects in the 64y-80y age range in the fasted state
3198517|NCT01209091||No treatment|
3198518|NCT01209078|Experimental|Regimen 1|GSK1322322 1500mg and Placebo Linezolid given twice a day (BID) for 10 days
3198519|NCT01209078|Active Comparator|Regimen 2|Linezolid 600mg and placebo GSK1322322 given BID for 10 days
3198520|NCT01209065|Experimental|Part A|Approximately 12 subjects will be enrolled. In the first treatment period, all subjects will receive GSK1349572 50 mg every 24 hours for 5 days. In Period 2, subjects will receive GSK1349572 50 mg every 24 hours in combination with fosamprenavir 700 mg plus ritonavir 100 mg every 12 hours for 10 days. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
3198521|NCT01209065|Experimental|Part B|Approximately 15 subjects will be enrolled and receive three single doses of GSK1349572 approximately one week apart. One will be the current tablet formulation containing micronized drug substance and 2 will be new tablet versions, one containing unmicronized drug substance and one containing an intermediate particle size drug substance. Subjects will have a screening visit within 30 days prior to the first dose of study drug, three treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
3198522|NCT01209052|Experimental|COHORT 1|Interlocking design with Cohort 2. Single dose; treatment period over 2 days such that two subjects will receive GSK1325756 and at least one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK1325756 from 10mg, to 50mg, and 200mg, will be administered over the 6 week long treatment period allowing adequate washout period between doses.
3198647|NCT01208207|Experimental|etoricoxib 60 mg/etoricoxib 60 mg|The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg in Part I and Part II
3198879|NCT01206413|Active Comparator|HGI|High glycemic index
3198523|NCT01209052|Experimental|COHORT 2|Interlocking design with Cohort 1. Single dose; treatment period over 2 days such that two subjects will receive GSK1325756 and at least one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK1325756 from 25mg, to 100mg, and 400mg, will be administered over the 6 week long treatment period allowing adequate washout period between doses.
3198524|NCT01209052|Experimental|COHORT 3|Placebo controlled, 14-day, once daily, repeat-dose evaluation with one selected dose of GSK1325756 in 14 subjects. Dose selection based on review of safety and tolerability data from cohorts 1 and 2.
3198525|NCT01209052|Experimental|COHORT 4|Placebo controlled, 14-day, once daily, repeat-dose evaluation with a higher selected dose of GSK1325756 in 14 subjects. Dose selection based on review of safety and tolerability data from cohort 3.
3198526|NCT01209039|Experimental|Part A, cohort 1 and 2|Part A, Cohorts 1 and 2, will investigate escalating multiple daily doses of GSK1144814 in 19 subjects
3198527|NCT01209039|Experimental|Part A, cohort 3|Cohort 3 will investigate safety, tolerability and PK of a dose of GSK1144814 over a repeat treatment period of 28 days in 18 subjects and a potential drug drug interaction between GSK1144814 and the CYP3A4 sensitive substrate midazolam (in 15 subjects).
3198528|NCT01209039|Experimental|Part B|Part B will assess NK1 receptor occupancy following repeated administration of GSK1144814 given once daily until steady state is obtained
3198529|NCT01209026|Experimental|FF/GW642444M (200/25mcg)|Inhaled fluticasone furoate (200mcg) /GW642444M (25mcg) combination Days 1- 7; placebo tablet taken orally single dose (po SD) on Day 7.
3198530|NCT01209026|Experimental|FF/GW642444M (800/100 mcg)|Inhaled fluticasone furoate (800mcg) /GW642444M (100mcg) combination Days 1- 7; placebo tablet (po SD) on Day 7.
3198531|NCT01209026|Active Comparator|Moxifloxacin|Inhaled placebo on Days 1-7; moxifloxacin (400mg po SD) on Day 7
3198532|NCT01209026|Placebo Comparator|Placebo|Inhaled placebo on Days 1-7; placebo tablet (po SD) on Day 7.
3198533|NCT01209013|Experimental|Medlight PDT Balloon|
3198534|NCT01209000||FSGS/MCD Cohort (Cohort A)|"Focal Segmental Glomerulosclerosis/Minimal Change Disease (FSGS/MCD) Cohort~Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for FSGS or MCD.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
3198535|NCT01209000||MN Cohort (Cohort A)|"Membranous Nephropathy (MN) Cohort~Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for MN.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
3198536|NCT01209000||Other glomerulopathies cohort|"Participants enrolled in NEPTUNE and determined to not have FSGS/MCD or MN will be followed in a third group.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
3198537|NCT01209000||cNEPTUNE (Cohort B)|Participants < 19 years of age, with < 30 days exposure to immunosuppression therapy who are not scheduled for renal biopsy.
3198538|NCT01208987|Experimental|Intervention (with Medication History)|these patient visits generated a medication history
3198539|NCT01208974|Experimental|Phase 1 MTD NAC RT|"Phase 1 dose-escalation/de-escalation Prophylactic Nipple-Areolar Complex (NAC) radiation therapy (RT) to determine the maximum tolerated dose (MTD).~Nipple-Sparing Mastectomy~Axillary surgery~Immediate Breast Reconstruction~Prophylactic Nipple-Areolar Complex RT at one of the following four possible dose levels:~Dose level I: 20 Gy total (2.0 Gy for 10 fractions)~Dose level II: 25 Gy total (2.5 Gy for 10 fractions) (Starting Dose)~Dose level III: 30 Gy total (3.0 Gy for 10 fractions)~Dose level IV: 35 Gy total (3.5 Gy for 10 fractions)~Chemotherapy, if indicated, at physician discretion"
3198540|NCT01208974|Experimental|Potential RP2D Expansion|"Potential recommended phase 2 dose (RP2D) expansion cohort:~Nipple-Sparing Mastectomy~Axillary surgery~Immediate Breast Reconstruction~Prophylactic Nipple-Areolar Complex RT at the potential RP2D~Chemotherapy, if indicated, at physician discretion"
3198541|NCT01208961|Active Comparator|Epanova-Lovaza-Epanova-Lovaza|
3198542|NCT01208961|Active Comparator|Lovaza-Epanova-Lovaza-Epanova|
3198543|NCT01208948|Active Comparator|Alpha lipoic acid 600 mg|
3198544|NCT01208948|Placebo Comparator|placebo pill|
3198545|NCT01208922|Experimental|A|
3198546|NCT01208922|Active Comparator|B|
3198547|NCT01208896|Experimental|Rituximab|
3198548|NCT01208883|Experimental|repetitive per-treatment [18F]FDG-PET for treatment adaptation|
3198549|NCT01208870|Experimental|Variety Group|Traditional family based weight control treatment program with components to reduce variety of high energy dense foods incorporated into the treatment. Families meet weekly for 12 weeks, then by-weekly for 1 month and 1 monthly session for a total of 15 behavioral intervention sessions.
3198550|NCT01208870|Experimental|Nutrition Education Control|Traditional family based weight control treatment program, without components from habituation theory incorporated into the treatment. Families meet weekly for 12 weeks, then by-weekly for 1 month and 1 monthly session for a total of 15 behavioral intervention sessions.
3198551|NCT01208844||Posttraumatic Stress|
3198552|NCT01208844||Depression|
3198553|NCT01208844||Healthy|
3198554|NCT01208831|Experimental|LDE225|
3198555|NCT01208818|Active Comparator|BD|
3198556|NCT01208818|Experimental|C-BD|
3198557|NCT01208818|Experimental|HCO|
3198558|NCT01208818|Active Comparator|Control HD|
3198559|NCT01208805||Candidates for dorsal column stimulation|
3198560|NCT01208792|Experimental|Disease group|Two hundred patients with PAH will be included: 50 patients with idiopathic PAH (iPAH), 20 with PAH associated with HIV infection, 20 with porto-pulmonary hypertension, 20 with PAH secondary to congenital heart disorders, 40 with SSc, 20 with SLE, 20 with MCTD and 10 with a PAH associated with a Sjögren's syndrome. Two hundred patients without PAH will also be included: 80 patients with SSc and 20 in each of the following groups: HIV infection, porto-pulmonary hypertension, SLE, congenital heart disorders, MCTD and with Sjögren's syndrome.
3198561|NCT01208792|Other|Control group 1|Two hundred healthy blood donors age and sex-matched with patients with PAH, will be included as controls.
3198562|NCT01208792|Other|Control group 2|Twenty patients with proximal chronic thromboembolic pulmonary hypertension (CTPH) will also be included in a control arm of the study.
3198563|NCT01208779||1|Women with estrogen receptor positive breast cancer already receiving treatment with an aromatase inhibitor (AI) will be enrolled in the study
3198564|NCT01208766|Active Comparator|R1: 4 cycles Bortezomib, Melphalan, Prednisone (VMP)|All patients randomized to VMP treatment, will be treated with Bortezomib, Melphalan, Prednisone(VMP, 4 cycles) and will start intensification with VMP between 4 and 6 weeks after stem cell collection.
3198565|NCT01208766|Experimental|R1: 1 (2) cycle(s) HDM|All patients randomized to intensification with High Dose Melphalan will start intensification with HDM (in hospitals with a policy of double intensification, patients will be randomized between VMP, 1 HDM and 2 HDM) between 4 and 6 weeks after stem cell collection.
3198566|NCT01208766|No Intervention|R2: none|No consolidation, patients will continue to Lenalidomide maintenance.
3198567|NCT01208766|Experimental|R2: 2 cycles of VRD|In patients randomized to consolidation treatment, 2 cycles of Bortezomib, Lenalidomide,Dexamethasone (VRD) will start at 8 weeks after the end of the last course of VMP or HDM.
3198568|NCT01208753|Experimental|Aqueous formulations for formulation selection|50 mg once daily for 3 days of two different aqueous suspensions, with four day wash-out between formulation
3198569|NCT01208753|Experimental|GLPG0555 ascending doses|multiple ascending doses for 13 days, ranging from 100 mg once daily upto a maximum to be determined during escalation (given as once or twice daily)
3198570|NCT01208753|Placebo Comparator|3|once or twice daily for 13 days, matching the scheme of the multiple ascending dose.
3198571|NCT01208740|Experimental|Metformin|Metformin pre-treatment and co-administration
3198572|NCT01208740|Placebo Comparator|Placebo|Placebo pre-treatment and co-administration
3198573|NCT01208727|No Intervention|Control|22 controls patients without post conditionment
3198574|NCT01208727|Experimental|Intervention|22 posconditioned patients
3198575|NCT01208714|Active Comparator|revascularization|The patients randomized to this treatment will undergo PTA with stenting of the renal artery.
3198576|NCT01208714|Active Comparator|medical therapy|The patients randomized to this treatment will undergo optimal medical therapy
3198577|NCT01208701|Active Comparator|Atorvastatin|
3198578|NCT01208701|Placebo Comparator|Placebo|
3198579|NCT01208688|Experimental|FES Therapy|FES Therapy
3198580|NCT01208688|Active Comparator|Conventional Occupational Therapy|The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
3198581|NCT01208675||Mild cognitive impairment|550 patients with mild cognitive impairment or subjective cognitive symptoms at baseline.
3198582|NCT01208675||Healthy elderly subjects|400 elderly subjects, who are cognitively healthy at baseline.
3198583|NCT01208662|Active Comparator|High Dose Treatment|Lenalidomide, bortezomib, dexamethasone. Stem cell collection. Maintenance Lenalidomide.
3198584|NCT01208662|Experimental|High Dose Treatment with SCT|Lenalidomide, bortezomib, dexamethasone. Stem cell collection. Autologous Stem Cell Transplant. Maintenance Lenalidomide.
3198585|NCT01208649|Active Comparator|Exenatide|Drug (including placebo)
3198586|NCT01208649|Placebo Comparator|Placebo|
3198587|NCT01208636||Sun exposed people|Sun exposure >3 hours daily for at least 5 days weekly for the last 3 months.
3198588|NCT01208623||2D|2D digital venography images alone
3198589|NCT01208623||3D|3D rotational venography
3198590|NCT01208623||Combine|combined MDCT angiography/venography
3198591|NCT01208584||Chronic posttraumatic paraplegia|Paraplegic patients (Thoracic level of lesion Th1-Th12), ASIA A, spinal cord injury (SCI) 12-24 months
3198592|NCT01208584||Acute posttraumatic paraplegia|Paraplegic patients (Thoracic level of lesion Th1-Th12), ASIA A,SCI 2-6 months,
3198593|NCT01208584||Myelomeningocele patients|Myelomeningocele patients (congenital paraplegia, thoracic level of lesion Th1-Th12) ASIA A
3198594|NCT01208584||Volunteers|Volunteers without any neurological deficits
3198595|NCT01208571|Experimental|Lifestyle counseling|
3198596|NCT01208571|No Intervention|Treatment as usual|
3198597|NCT01208558|Active Comparator|Diet A and physiotherapy|"Behavioral: Diet A Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people, i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid junk food and juice. In order to match carbohydrate intake between the arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Behavioral: Physiotherapy Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end."
3198598|NCT01208558|Active Comparator|Diet B and physiotherapy|"Behavioral: Diet B Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A.~Other Name: Whole grains Behavioral: Physiotherapy Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end.~Other Name: Exercise"
3198599|NCT01208558|Active Comparator|Diet A only|"Behavioral: Diet A Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains as much as possible. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. In order to match carbohydrate intake between the intervention arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Other Name: No grains"
3198694|NCT01207895|Experimental|[18F]-FLT PET scans|
3198600|NCT01208558|Active Comparator|Diet B only|"Behavioral: Diet B Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A. The goal is that carbohydrate intake, as a proportion of total energy intake, should not differ between the groups.~Other Name: Whole grains"
3198601|NCT01208558|No Intervention|Control|Only follow-up. No intervention.
3198602|NCT01208519||Case Control Study 1|To define the impact of antibiotics on new acquisition of MRSA and ESBL-producing gram negative bacteria, a matched case-control study will be done (ratio 1:4). The control group will be selected among patients not receiving antibiotics, admitted in the same ward on the day of the corresponding case, with negative cultures at hospital admission. Matching criteria will include: age (±5 years), sex, and total length of hospitalization.
3198603|NCT01208519||Case control study 2|To define individual level of risk related to specific antibiotics, patients acquiring MRSA and ESBL-producing gram negative bacteria will be compared with patients not acquiring antibiotic-resistant strains after starting antibiotic therapy (ratio 1:4). Previously known risk factors or clinically relevant significant variables from the univariate analysis will be considered for inclusion in multivariate logistic regression analysis.
3198604|NCT01208506|Experimental|Dose level 1|
3198605|NCT01208506|Experimental|Dose level 2|
3198606|NCT01208506|Experimental|Dose level 3|
3198607|NCT01208506|Experimental|Dose level 4|
3198608|NCT01208506|Experimental|Dose level 5|
3198609|NCT01208506|Experimental|Dose level 6|
3198610|NCT01208506|Experimental|Dose level 7|
3198611|NCT01208506|Experimental|Dose level 8|
3198612|NCT01208493|Experimental|high protein preterm infant formula|preterm infant formula with high protein levels
3198613|NCT01208493|Active Comparator|control preterm formula|
3198614|NCT01208467||Basic science (DNA analysis)|DNA extracted from previously collected tumor samples is analyzed to validate the clinicopathologic associations and prognostic significance of ATR mutation.
3198615|NCT01208454|Experimental|Treatment (isotretinoin and vorinostat)|"Patients receive isotretinoin PO BID on days 1-14, PO suspension* of vorinostat QD on days 1-4 of course 1, and capsules of vorinostat PO QD on days 1-4 and 8-11 of course 2 and subsequent courses. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~EXPANSION COHORT 1 (=< 21 years of age): Once the MTD has been determined, patients are treated at that dose level as above.~EXPANSION COHORT 2 (22-30 years of age): Patients receive isotretinoin as above and vorinostat at the MTD on days 1-3 and 8-10."
3198616|NCT01208441|Experimental|Arm I|"Patients receive oral letrozole once daily on days 1-21. Beginning in course 2, patients also receive oral RO4929097 on days 1-3, 8-10, and 15-18. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Beginning 1 week after completion of neoadjuvant therapy, patients undergo surgery or tumor biopsy. Patients continue to receive oral letrozole once daily during surgery and for an additional 4 weeks."
3198617|NCT01208428|Active Comparator|Conventional cognitive behavioral therapy|Subjects randomized to this arm will receive conventional cognitive behavioral therapy for the treatment of major depression
3198618|NCT01208428|Experimental|Religious cognitive behavioral therapy|Subjects randomized to this arm will receive conventional cognitive behavioral therapy, but their religious beliefs will be utilized as a resource in the therapy
3198619|NCT01208415|Experimental|Device Implant|
3198620|NCT01208402|Active Comparator|oral long acting beta blocker|oral administration of long acting beta blocker as standard of care on the day of surgery
3198621|NCT01208402|Experimental|Esmolol infusion|given 30 minutes prior to induction up to 12 hours post-op
3198622|NCT01208389|Experimental|voretigene neparvovec-rzyl (AAV2-hRPE65v2)|Administration of study agent (AAV2-hRPE65v2) to the previously, uninjected contralateral eye:
3198623|NCT01208376||unexplained chronic ALT elevation|Case patients: HIV-infected, unexplained chronic alanine aminotransferase (ALT) elevation
3198624|NCT01208376||always normal ALT|Control patients: HIV-infected, always normal ALT values
3198625|NCT01208363|No Intervention|Unfortified Toubani|Children in the school will receive, 3 times per week 66g of raw unfortified (no added Fe) cowpea in form of Toubani (a cowpea based snack).
3198626|NCT01208363|Active Comparator|Fortified Cowpea|Study subjects will receive 3 times per week, as part of the school feeding programme 66g of raw fortified cowpea (with added 10mg Fe as NaFeEDTA)in form of Toubani (a cowpea based snack).
3198627|NCT01208350|Experimental|1|
3198628|NCT01208350|Experimental|2|
3198629|NCT01208350|Active Comparator|3|
3198630|NCT01208337|Other|Alemtuzumab induction|Intestine transplant recipients who receive induction with alemtuzumab prior to transplantation.
3198631|NCT01208324|Active Comparator|Estrogen patch|Vivelle Dot® 0.10 - 0.15 mg/day for 8 weeks
3198632|NCT01208324|Active Comparator|Amino Acids|L-Isoleucine (4.2 g), L-Leucine (6.6 g), L-Lysine (4.8 g), L-Methionine (1.5 g), L-Phenylalanine (6.6 g), L-Threonine (3.0 g), L-Valine (4.8 g)
3198633|NCT01208324|Placebo Comparator|Placebo Patch|Placebo
3198634|NCT01208324|Placebo Comparator|Placebo pills|31.5 g of lactose or microcellulose
3198635|NCT01208311||Patients with Hepatitis C Cirrhosis|Patients with Hepatitis C Cirrhosis
3198636|NCT01208298|Experimental|# 1727|Cold sore Patch
3198637|NCT01208285|Experimental|Group A|approximately 12 male and female subjects with moderate hepatic impairment
3198638|NCT01208285|Experimental|Group B|approximately 12 healthy male and female subjects
3198639|NCT01208272|Experimental|Binge Eating Disorder/Therapy|
3198640|NCT01208259|Experimental|Binge Eating Disorder/Therapy|
3198641|NCT01208233|Experimental|1 mg PF-03049423|
3198642|NCT01208233|Experimental|3 mg of PF-03049423|
3198643|NCT01208233|Experimental|6 mg of PF-03049423|
3198644|NCT01208233|Placebo Comparator|Placebo|
3198645|NCT01208220|Active Comparator|Negative pressure wound therapy|NPWT changed TIW
3198646|NCT01208220|Experimental|NPWT plus Collagenase Ointment|Collagenase applied TIW with NPWT
3198880|NCT01206413|Experimental|HB|Home-based exercise
3198648|NCT01208207|Experimental|etoricoxib 60 mg/etoricoxib 90 mg|The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg in Part I and etoricoxib 90 mg in Part II
3198649|NCT01208207|Experimental|etoricoxib 90 mg/etoricoxib 90 mg|The etoricoxib 90 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg in Part I and Part II
3198650|NCT01208207|Active Comparator|naproxen 1000 mg/naproxen 1000 mg|The naproxen 1000 mg/naproxen 1000 mg treatment sequence will receive naproxen 1000 mg in Part I and Part II
3198651|NCT01208194|Experimental|MGN1703|Study medication
3198652|NCT01208194|Placebo Comparator|Placebo|
3198653|NCT01208181|Experimental|Etoricoxib 60 mg/Etoricoxib 60 mg|The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and Part 2 of the study.
3198654|NCT01208181|Experimental|Etoricoxib 60 mg/Etoricoxib 90 mg|The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 2 of the study.
3198655|NCT01208181|Experimental|Etoricoxib 90 mg|The etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.
3198656|NCT01208181|Placebo Comparator|Placebo|The placebo treatment sequence will receive matching placebo to etoricoxib tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.
3198657|NCT01208168|Experimental|Active drug|
3198658|NCT01208168|Placebo Comparator|Vehicle alone|
3198659|NCT01208155|Experimental|1|Fostamatinib 50 mg tablet x 2
3198660|NCT01208155|Experimental|2|Fostamatinib 100 mg tablet (batch 1)
3198661|NCT01208155|Experimental|3|Fostamatinib 100 mg tablet (batch 2)
3198662|NCT01208155|Experimental|4|Fostamatinib 100 mg tablet (batch 4)
3198663|NCT01208142|Active Comparator|Standard of care|25 Control subjects will only receive SOC (a weekly standardized physical therapy and daily wear of an AFO).
3198664|NCT01208142|Experimental|Dynasplint|25 Patients will receive the standard of care as well as an Ankle Flexion Dynasplint
3198665|NCT01208129|Experimental|Active drug|
3198666|NCT01208129|Placebo Comparator|Vehicle alone|
3198667|NCT01208116||Subgroups|According to the demographic features, subjects may be divided into some subgroups.
3198668|NCT01208103|Experimental|Bevacizumab, Capecitabine, Oxaliplatin|Bevacizumab 7.5 mg/kg by vein on day 1 over 90 minutes of 21 day cycle. Capecitabine 750 mg/m2 by mouth twice a day beginning on day 1-14 of 21 day cycle. Oxaliplatin 130 mg/m2 by vein on day 1 over 2 hours of 21 day cycle.
3198669|NCT01208090|Experimental|Investigational drug - Dose 1|
3198670|NCT01208090|Experimental|Investigational drug - Dose 2|
3198671|NCT01208090|Placebo Comparator|Matching placebo|
3198672|NCT01208077||Acute CHF|"Recurrent or worsening (within 3 days) shortness of breath as the primary presenting ED complaint~Initial treating ED physician impression that the worsening dyspnea is most likely caused by decompensated CHF~Known history of physician diagnosed CHF~Natriuretic peptide (BNP, MR-pro ANP, NT pro BNP) level will be ordered by the treating physician as part of the patient's work up"
3198673|NCT01208077||Acute Stroke Syndrome|"Onset of abnormal neurological symptoms consistent with possible stroke, within the prior 24 hours, as the primary ED complaint~Initial treating ED physician impression that the abnormal neurological symptoms/signs are most likely caused by an acute stroke syndrome~Non contrast head CT will be ordered by the treating physician as part of the patient's work up"
3198674|NCT01208077||Acute Systemic Infection|"Any combinations of acute (within 3 days) symptoms and signs that the treating ED physician, after initial history and physical examination, attributes to a systemic infection~Blood cultures and/or a blood lactate will be ordered by the treating physician as part of the patient's work up"
3198675|NCT01208064|Experimental|Pazopanib|2 weeks at 600mg and then maintenance at 800mg
3198676|NCT01208064|Placebo Comparator|Placebo|placebo match 2 weeks at 600mg and then maintenance at 800mg
3198677|NCT01208051|Experimental|Arm A (cediranib maleate)|Patients receive cediranib maleate PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3198678|NCT01208051|Experimental|Arm B (cediranib maleate)|Patients receive cediranib maleate PO and lenalidomide PO as in Phase I. NOTE: As of April 10, 2015, patients assigned to this arm are to discontinue lenalidomide and may continue on cediranib alone.
3198679|NCT01208025||symptomatic carotid stenosis 30-69%|Patients with neurological symptoms due to ischemia in the carotid artery territory and with a carotid stenosis between 30% and 69% according to the European Carotid Surgery Trial (ECST) criteria.
3198680|NCT01208012|No Intervention|Metformin|Patients taking Metformin at individual dose
3198681|NCT01208012|Experimental|Metformin and Liraglutide|Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks.
3198682|NCT01207999||Group A|Subjects diagnosed with invasive cervical cancer
3198683|NCT01207986|Other|CT screening|CT interpretations and lung biopsies are guided by a suggested workup algorithm, which is not imposed in each HIV-caring centre
3198684|NCT01207973|Experimental|BI 113823|5 dose-groups of multiple oral doses of BI 113823
3198685|NCT01207960|Active Comparator|EMDR|Eye Movement Desensitization and Reprocessing
3198686|NCT01207960|No Intervention|WLC|Wait-list control group. EMDR treatment takes place after 4 weeks of no treatment which represents the wait-list comparison interval.
3198687|NCT01207947||Group 1|
3198688|NCT01207934|Placebo Comparator|placebo|saline placebo for fourteen days
3198689|NCT01207934|Experimental|low-dose leptin|30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
3198690|NCT01207934|Experimental|high-dose leptin|80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
3198691|NCT01207921|Experimental|Arm 1|"Lenalidomide 15 mg/day Cycle 1 (28 days).~If no unacceptable side effects Cycle 2 (28 days) will be lenalidomide 20 mg/day.~If no unacceptable side effects Cycles 3 thru 18 (28 days for each cycle) will be lenalidomide 25 mg/day."
3198692|NCT01207908|Experimental|IGF-1|IGF-1 plus standard steroid treatment
3198693|NCT01207908|No Intervention|Standard steroid treatment alone|
3198695|NCT01207869|Experimental|Mesenchymal stem cells|the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
3198696|NCT01207869|Placebo Comparator|Control|Normal saline
3198697|NCT01207856|Active Comparator|group A|specific cognitive rehabilitation
3198698|NCT01207856|Active Comparator|Groupe B : non specific rehabilitation|
3198699|NCT01207856|Other|group C|group C for MRI, neuropsychological and ecological assessments
3198700|NCT01207830|Experimental|Endo Bypass|Subjects implanted with the investigational ValenTx Endo Bypass System
3198701|NCT01207817||no condition|no condition - healthy volunteers
3198702|NCT01207804|Experimental|Device|
3198703|NCT01207791|Other|Minimal screening only (MSO)|Minimal screening
3198704|NCT01207791|Active Comparator|Screening, assessment, and referral (SAR)|
3198705|NCT01207791|Experimental|Brief intervention plus telephone boosters (BI-B)|
3198706|NCT01207778||preterm ESA recipients|infants 500-1250 grams who received erythropoietin (400 units/kg 3x/week) or darbepoetin (10 micrograms/kg 1x/week), from the first week of life through 35 weeks corrected gestation
3198707|NCT01207778||preterm controls|preterm infants 500-1250 grams who received placebo (sham dosing), from first week of life through 35 weeks corrected gestation
3198708|NCT01207778||term controls|Term infants with normal delivery
3198709|NCT01207765|Experimental|Zevalin|1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging on study day +1. 90Y Zevalin will be administered seven to nine days after 111In Zevalin administration. The dose of 90Y Zevalin will be 0.4 mCi/kg, capped at a maximum dose of 32 mCi.
3198710|NCT01207752|Experimental|Systane Balance|Artificial tear emulsion
3198711|NCT01207752|Active Comparator|Optive Lubricant Eye Drops|Artificial tear
3198712|NCT01207739|Active Comparator|Doxycycline|
3198713|NCT01207739|Active Comparator|Clarithromycin and hydroxychloroquine|
3198714|NCT01207739|Placebo Comparator|Placebo|
3198715|NCT01207726|Experimental|Arm I (azacitidine, entinostat)|Patients receive azacitidine SC on days 1-5 and 8-10 and entinostat PO QD on days 3 and 10. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3198716|NCT01207726|No Intervention|Arm II (standard of care)|Patients receive standard of care.
3198717|NCT01207700|Experimental|CHW based intervention post ACS|CHW trained and supervised for intervening upon post ACS patients to improve adherence to evidence based care
3198718|NCT01207700|No Intervention|Standard Care|Patients will be followed upto 12 months without a community health worker intervention as per standard practices of the hospital
3198719|NCT01207687|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes once every 3 weeks. Courses repeat every 6 weeks for up to 48 weeks in the absence of disease progression or unacceptable toxicity.
3198720|NCT01207661|Experimental|Mesenchymal Injection|Intra Articular injection in Patients with osteoarthritis of knee joint
3198721|NCT01207648||Retrospective Cohort|Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events were observed in this retrospective cohort study. In this study, medical records of participants evaluated between 1997 to 2009 were reviewed. The observation period started with the first medical record available on site till last medical record available on site or the end of the observation period (31 December 2009), whichever occurred first.
3198722|NCT01207635||Breast Cancer Patients|
3198723|NCT01207622|Active Comparator|Atomoxetine|
3198724|NCT01207622|Placebo Comparator|Placebo|
3198725|NCT01207609|Experimental|Laparoscopic Gastric Plication|Collect data prospectively on the safety and efficacy of the Laparoscopic Gastric Plication operation for 50 patients with Severe or Morbid Obesity
3198726|NCT01207596|Active Comparator|Hydromorphone|
3198727|NCT01207583||healthy children after vaccination|healthy children after vaccination
3198728|NCT01207570|Experimental|Endermotherapy|The subjects in the experimental group will receive a single session (5 minutes) of endermotherapy) applied to the gastrocnemius/soleus muscle group in the more affected side. The treatment will b e carried out by a qualified physiotherapist.
3198729|NCT01207570|Active Comparator|Passive stretching|The subjects in this group will receive a single session of passive stretching of the gastrocnemius/soleus muscle for 5 minutes.
3198730|NCT01207557|Active Comparator|Standard education only|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
3198731|NCT01207557|Active Comparator|Standard Education plus OIDA|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials plus the Ottawa Influenza Decision Aid and tested on their confidence with their immunization decision
3198732|NCT01207544|Experimental|fitball program|This group will undergo the fitball program consisting of a supervised exercise session once per week for 8 weeks, supplemented by home exercises. The exercise session will be conducted by a qualified physiotherapist.
3198733|NCT01207544|Active Comparator|Task-oriented program|This group will undergo the task-oriented motor training program consisting of a supervised exercise session once per week for 8 weeks, supplemented by home exercises. The exercise session will be conducted by a qualified physiotherapist.
3198734|NCT01207531||Survival Group|
3198735|NCT01207531||Death group|
3198736|NCT01207518|Experimental|Intervention Group|For the intervention group, there will be a Guide facilitator provided by the project team, normally the Project Manager or their delegate. The role of the Guide facilitator will be to provide basic information about the Guide and to facilitate the use of the web-based tools.
3198737|NCT01207518|Active Comparator|Control Group|The Control Group will be asked to provide immunization rates for the base year and two years of the study, and will be asked about their influenza immunization campaign activities to use as a comparator. They will receive the Guide and web-based tools following completion of the study.
3198738|NCT01207505|Experimental|Enchancing Emotion Regulation|12 week group 3 week modules: 1) Mindfulness 2) Emotion Regulation 3) Distress Tolerance
3198739|NCT01207492|Experimental|Nilotinib|Nilotinib 200 mg taken as 400 mg twice daily, continuously
3198740|NCT01207479|Experimental|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
3198741|NCT01207466|Other|Nelfilcon A invest'l / nelfilconA comm'l|Nelfilcon A investigational toric contact lenses worn first, with nelfilcon A commercial toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week.
3198742|NCT01207466|Other|Nelfilcon A comm'l / nelfilconA invest'l|Nelfilcon A commercial toric contact lenses worn first, with nelfilcon A investigational toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week.
3198743|NCT01207453|Other|Milnacipran then placebo|This arm of the study will contain half the study population after randomization. The participants in this arm will receive milnacipran for 6 weeks. They will undergo a one-week taper and a two week washout period and then crossover to a placebo for 6 weeks.
3198744|NCT01207453|Other|Placebo then milnacipran|"This arm of the study will contain half the study population after randomization. The participants in this arm will receive placebo for 6 weeks. They will undergo a one-week taper and a two week washout period and then crossover to milnacipran for 6 weeks."
3198745|NCT01207440|Experimental|CP-CML R/I|Chronic Phase (CP) CML resistant or intolerant (R/I) to dasatinib or nilotinib
3198746|NCT01207440|Experimental|AP-CML R/I|Accelerated Phase (AP) CML resistant or intolerant (R/I) to dasatinib or nilotinib
3198747|NCT01207440|Experimental|Blast Phase (BP) CML / Ph+ ALL|Blast Phase (BP) CML or Ph+ ALL resistant or intolerant (R/I) to dasatinib or nilotinib or Ph+ ALL resistant or intolerant (R/I) to dasatinib or nilotinib
3198748|NCT01207440|Experimental|CP-CML with T315I mutation|CP-CML patients who have the T315I mutation of BCR-ABL
3198749|NCT01207440|Experimental|AP-CML with T315I mutation|AP-CML patients who have the T315I mutation of BCR-ABL
3198750|NCT01207440|Experimental|BP-CML / Ph+ ALL with T315I mutation|BP-CML or Ph+ ALL patients who have the T315I mutation of BCR-ABL
3198751|NCT01207427|Placebo Comparator|Placebo|Each participant received 1 placebo capsule orally twice daily (BID) during the Run-in Placebo Period (1 week), the Double-blind Treatment Period (4 weeks), and the Run-out Placebo Period (1 week).
3198752|NCT01207427|Experimental|ADL5945 0.1 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally BID for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.1-milligrams (mg) ADL5945 capsule orally BID for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally BID for 1 week.
3198753|NCT01207427|Experimental|ADL5945 0.25 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally BID for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.25-mg ADL5945 capsule orally BID for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally BID for 1 week.
3198754|NCT01207414|Experimental|iloperidone gradual switch|"Participants taking risperidone, olanzapine or aripiprazole gradually decreased the dose they were taking: 50% of original dose on Day 1, 25% of original dose after the first week and the total discontinuation of the drug after the second week.~On Day 1 participants began taking iloperidone orally twice a day (bid) in the morning and in the evening beginning at a dose of 1 mg and increasing to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg bid on consecutive days over a 7-day period to achieve a total dose of 12-24 mg/day for 12 weeks."
3198755|NCT01207414|Experimental|iloperidone immediate switch|"Participants taking risperidone, olanzapine or aripiprazole discontinued the drug immediately.~On Day 1 participants began taking iloperidone orally twice a day (bid) in the morning and in the evening beginning at a dose of 1 mg and increasing to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg bid on consecutive days over a 7-day period to achieve a total dose of 12-24 mg/day for 12 weeks."
3198756|NCT01207401|Experimental|Paracervical Block|
3198757|NCT01207401|No Intervention|No Paracervical Block|
3198758|NCT01207388|Experimental|Blinatumomab|Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.
3198759|NCT01207375|Experimental|experimental group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
3198760|NCT01207375|Placebo Comparator|Placebo control group|The placebo control group will receive placebo memory exercises administered on a laptop computer twice a week for five weeks (10 placebo control sessions).
3198761|NCT01207362||Young adult|
3198762|NCT01207362||Older adult|
3198763|NCT01207349||close follow-up by nurse|close follow-up by nurse : patients were visited each tree months
3198764|NCT01207349||standard follow up|stantdard follow up at one year
3198765|NCT01207323|Experimental|Dose Escalation (MEHD7945A)|Participants will receive intravenous (IV) infusion of MEHD7945A in escalating doses Q2W until MTD is reached or up to disease progression as determined by the investigator, intolerable toxicity, withdrawal of consent, or death, whichever occurs first. Approximately 5 dose levels between 1 and 30 mg/kg will be evaluated.
3198766|NCT01207323|Experimental|Dose Expansion (MEHD7945A)|Participants will receive IV infusion of MEHD7945A Q2W at or below the MTD (decided from dose escalation part) up to disease progression as determined by the investigator, intolerable toxicity, withdrawal of consent, or death, whichever occurs first.
3198767|NCT01207310|Experimental|Pager Arm|Participants in the Pager Arm will be provided with alphanumeric pagers and will receive therapeutic messages on these pagers for 3 months in addition to individual smoking cessation counseling and nicotine patches.
3198768|NCT01207310|Active Comparator|Control Arm|Participants in the Control Arm will receive individual smoking cessation counseling and nicotine patches.
3198769|NCT01207297|Active Comparator|TAC group|Oral tacrolimus (0.04-0.08 mg/kg/d) and prednisone for 12 months.
3198770|NCT01207297|Active Comparator|CYC group|Pulse cyclophosphamide (750mg/m2 per month for six months) and prednisone followed by azathioprine (50mg/day）for 6 months.
3198771|NCT01207284|Experimental|Physical Therapy|Foot and ankle passive and active stretching, muscle strengthening, proprioception training and gait training.
3198772|NCT01207284|No Intervention|Control|
3198773|NCT01207271|Experimental|Cognitive Therapy|
3198774|NCT01207271|Experimental|Dynamic Therapy|
3198832|NCT01206829|Active Comparator|Audiological rehabilitation|16 hours of psychosocial rehabilitation course
3198775|NCT01207258|Experimental|Brief Intervention Group|Participants randomly assigned to this group receive a brief motivational enhancement therapy intervention group and are assessed at baseline, weekly for 12 weeks, and at 3, 6 and 12 months.
3198776|NCT01207258|No Intervention|Assessed Control Group|This group does not receive the intervention and is assessed at baseline, weekly for 12 weeks, and at 3, 6 and 12 months.
3198777|NCT01207258|No Intervention|No Contact Control Group|This group does not receive the intervention and is assessed only at 3 months.
3198778|NCT01207245|Active Comparator|Morning dose of tobramycin|Administration of tobramycin once daily dose in the morning
3198779|NCT01207245|Active Comparator|Evening tobramycin|Evening dose of tobramycin once daily
3198780|NCT01207232|Experimental|Time Plan Condition|A basic reminder mailing prompted each subject to write down a planned date and time for getting their flu shot.
3198781|NCT01207232|Experimental|Date Plan Condition|A basic reminder mailing prompted each subject to write down a planned date for getting their flu shot.
3198782|NCT01207232|Active Comparator|Control Condition|A basic reminder mailing prompted each subject to receive a flu shot.
3198783|NCT01207219|Experimental|Yoga therapy|Hatha yoga including breathing control (10 minutes), body posture(40-45minutes), and relaxation (5 minutes).
3198784|NCT01207219|Experimental|Aerobic exercise|Aerobic exercise includes walking on the treadmill for 15-20 minutes and stationary cycling for 25-30 minutes.
3198785|NCT01207219|No Intervention|Waitlist group|Patients in waiting list will be treated as usual and acted as control group.
3198786|NCT01207193|Experimental|bone cyst|Patients with bone cyst defect are injected with mesenchymal cells.
3198787|NCT01207180|Experimental|Follow-up phone call from Nurse|Patients in this are will receive a phone call follow-up from a nurse 1-3 days after their discharge from the ED.
3198788|NCT01207180|Placebo Comparator|Satisfaction survey|This group of patients will receive a phone call from a student who will conduct a brief satisfaction survey of the patient's experience in the ED.
3198789|NCT01207180|Placebo Comparator|Control group|Patients in this group will receive no phone call at 1-3 days.
3198790|NCT01207154||BIS guidance|Sedation guided according to a predetermined BIS level
3198791|NCT01207154||Clinical sign guided|Sedation guided by clinical signs
3198792|NCT01207141||rATG induction|Liver transplant recipients who receive induction with rATG prior to transplantation.
3198793|NCT01207141||no rATG induction|Liver transplant recipients who do not receive rATG induction therapy prior to transplantation.
3198794|NCT01207128|Active Comparator|Voriconazole, Micafungin|Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV) Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
3198795|NCT01207128|No Intervention|Voriconazole+Micafungin or Voriconazole+Placebo|Voriconazole+Micafungin or Voriconazole+Placebo
3198796|NCT01207115|Experimental|ABT-652 high dose|ABT-652 capsules- twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm.
3198797|NCT01207115|Experimental|ABT-652 low dose|ABT-652 capsules - twice daily for 8 weeks. The dose ABT-652 will depend on the Arm
3198798|NCT01207115|Active Comparator|Naproxen|Naproxen capsules- twice daily for 8 weeks
3198799|NCT01207115|Placebo Comparator|Placebo|Placebo capsules- twice daily for 8 weeks
3198800|NCT01207102|Experimental|Abraxane, Carboplatin|Abraxane 100mg/m2 IV days 1, 8 and 15 of a 28 day cycle Carboplatin area under the concentration curve, (AUC)2 IV days 1,8, and 15 of a 28 day Cycle
3198801|NCT01207089|Placebo Comparator|1|
3198802|NCT01207089|Experimental|2|AZD8329
3198803|NCT01207076|Experimental|receiving AHN-12 and 90Y-AHN-12|Patients receiving nonradiolabeled cold AHN-12 (.20 mg/kg to 1.0 mg/kg) of at least one dose and up to a total of 3 dosimetry infusions (intervals no sooner than 8 days and up to 21 days).
3198804|NCT01207063|Experimental|Radiotherapy|
3198805|NCT01207050|Experimental|Rozerem (Ramelteon)|The primary drug of interest is a melatonin agonist for the treatment of insomnia.
3198806|NCT01207050|Placebo Comparator|Sugar pill|Control condition.
3198807|NCT01207037|Other|Intervention|
3198808|NCT01207024||knee MRI|knee MRI for all patients undergoing bariatric surgery as usual care
3198809|NCT01207011|Experimental|1 AMR|
3198810|NCT01207011|Active Comparator|2 DOC|
3198811|NCT01206998|Experimental|Vaginal progesterone gel|
3198812|NCT01206998|Placebo Comparator|Placebo vaginal gel|
3198813|NCT01206972|Experimental|Arm 1|
3198814|NCT01206972|Experimental|Arm 2|
3198815|NCT01206972|Experimental|Arm 3|
3198816|NCT01206972|Active Comparator|Arm 4|
3198817|NCT01206959||monitor method|"blood pressure monitor Cuff circumference:22cm-48cm~stethoscopy Cuff circumference: 22cm-48cm"
3198818|NCT01206946|Experimental|Antenatal steroids|
3198819|NCT01206946|Placebo Comparator|Normal saline|
3198820|NCT01206933||Detectable HIV RNA and HCV RNA|HIV and HCV co-infected with detectable HIV RNA and HCV RNA
3198821|NCT01206933||Undetectable HIV and Detectable HCV|HIV and HCV infected, HIV RNA Undetectable(treated) and Detectable HCV RNA.
3198822|NCT01206933||Undetectable HIV and HCV|HIV and HCV infected, Undetectable HIV RNA and HCV RNA
3198823|NCT01206933||Undetectable HCV|HCV(mono-infected,) HCV RNA undetectable
3198824|NCT01206933||Detectable HCV RNA|Monoinfected HCV, detectable RNA
3198825|NCT01206933||Detectable HIV RNA|Monoinfected HIV, Detectable RNA
3198826|NCT01206868|Active Comparator|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
3198827|NCT01206868|Sham Comparator|Control|Standard kidney transplantation
3198828|NCT01206855|Active Comparator|SOC Treated Side of Incision|One side of the incision will be treated with surgeon's standard postoperative care including cleansing, creams, dressings
3198829|NCT01206855|Active Comparator|MIST Treated Side of Incision|One half of the incision will receive MIST Therapy treatments 3 times per week for 2 weeks
3198830|NCT01206842|Experimental|social cognition training|
3198831|NCT01206842|No Intervention|treatment as usual|
3198833|NCT01206816|Experimental|two experimental arms|patients receive increasing doses of BI 6727 in combination with increasing doses of BIBW 2992
3198834|NCT01206790|Experimental|Narrative Exposure Therapy (NET)|
3198835|NCT01206790|No Intervention|Waitinglist Control Group|
3198836|NCT01206777|Experimental|Rituximab|
3198837|NCT01206764|Experimental|RAD001|
3198838|NCT01206738|Experimental|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
3198839|NCT01206738|Experimental|Alternative intervention|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
3198840|NCT01206738|Active Comparator|General information|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
3198841|NCT01206725|Other|. Moderate Intensity Exercise Group|Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.
3198842|NCT01206725|Other|Aerobic interval training|Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min.
3198843|NCT01206712||T2DM patients treated with LANTUS + MET|T2DM patients treated with LANTUS + Metformin(MET) in their routine antidiabetic therapy. These patients do not receive any study specific medication.
3198844|NCT01206712||T2DM patients treated with SU + MET|T2DM patients treated with Sulfonylurea (SU) + Metformin(MET)in their routine antidiabetic therapy. These patients do not receive any study specific medication.
3198845|NCT01206712||T2DM patients treated with DPP-4 + MET|T2DM patients treated with Dipeptidylpeptidase 4 inhibitors (DPP-4) + Metformin(MET) in their routine antidiabetic therapy. These patients do not receive any study specific medication.
3198846|NCT01206712||Healthy subjects|healthy volunteres who do not receive any antidiabetic medication in their routine therapie.
3198847|NCT01206699|Experimental|corticoid|Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
3198848|NCT01206699|Placebo Comparator|physiological solution|Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
3198849|NCT01206686|Experimental|1 Hour Planning Prompt|
3198850|NCT01206686|Experimental|2 Hour Planning Prompt|
3198851|NCT01206686|Experimental|1 Day Planning Prompt|
3198852|NCT01206686|Experimental|Default Planning Prompt|
3198853|NCT01206686|Active Comparator|Control|
3198854|NCT01206660|Experimental|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
3198855|NCT01206660|Placebo Comparator|placebo|Placebo administered to affected area twice a day for 28 days
3198856|NCT01206647|No Intervention|Control arm|The patients randomized to the control arm will continue their current therapy, as individually prescribed. Insulin will be administered via subcutaneous injection and OADs (if applicable) will be administered orally, as individually prescribed.
3198857|NCT01206647|Experimental|Saxagliptin & metformin|Saxagliptin and metformin tablets will be administered orally. Pioglitazione (Rescue medication) tablets will be administered orally. Insulin glargine (Rescue medication) will be administered via subcutaneous injection as individually prescribed.
3198858|NCT01206634|Experimental|Regenerative injection therapy|
3198859|NCT01206634|Active Comparator|Exercise|
3198860|NCT01206621||ED patients presenting with dyspnea|
3198861|NCT01206608|Active Comparator|Low-dose SKY0402 + bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
3198862|NCT01206608|Active Comparator|Mid-dose SKY0402 + bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
3198863|NCT01206595|Active Comparator|SKY0402|Low-dose, low-mid dose, and mid-dose
3198864|NCT01206595|Active Comparator|Bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
3198865|NCT01206582|Active Comparator|Hemin|Panhematin®, Ovation Pharmaceuticals, Deerfield, Illinois (IL). Hemin was diluted in 25% albumin to obtain a concentration of 2.4 mg/mL and administered at a dose of 1.25 mL/Kg and at a rate of 60 mL/hour. 10 iv infusions for 8 weeks
3198866|NCT01206582|Placebo Comparator|Albumin|10 iv infusions for 8 weeks
3198867|NCT01206569|Experimental|advagraf|Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
3198868|NCT01206543|Experimental|Intraoperative imaging|
3198869|NCT01206517|Experimental|Cohort 1|Participants 10 or 11 years of age
3198870|NCT01206517|Experimental|Cohort 2|Participants 10 or 11 years of age
3198871|NCT01206517|Experimental|Cohort 3a-d|"Cohort 3a: Participants 10 or 11 years of age~Cohort 3b: Participants 12 or 13 years of age~Cohort 3c: Participants 14 or 15 years of age~Cohort 3d: Participants 16 or 17 years of age"
3198872|NCT01206478|Experimental|Amitriptyline plus Megestrol|Amitriptyline once daily at bedtime plus megestrol starting at visit 2
3198873|NCT01206478|Active Comparator|Placebo plus Megestrol|Matching placebo once daily at bedtime plus megestrol starting at visit 2
3198874|NCT01206465|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive pralatrexate IV over 5 minutes on day 1 and fluorouracil IV continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3198875|NCT01206452|Experimental|Ablation plus prednisone|Participants undergo ablation procedure and receive predinisone at protocol determined times.
3198876|NCT01206452|Placebo Comparator|Ablation plus placebo|Participants undergo ablation procedure and receive placebo at protocol determined times.
3198877|NCT01206439|Experimental|Nebivolol 5 or 10 mg, oral, daily|Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.
3198881|NCT01206413|Active Comparator|CONTROL|Non-exercisers
3198882|NCT01206400||pioglitazone vs placebo|15 patients in pioglitazone group and 15 in placebo group
3198883|NCT01206387|Experimental|active product|Desoximetasone Spray 0.25%
3198884|NCT01206387|Placebo Comparator|placebo comparator|vehicle
3198885|NCT01206361||fixed dose prostaglandin combination|
3198886|NCT01206348|Experimental|Open Label Combination|Solodyn, Ziana, Triaz FC
3198887|NCT01206335|Experimental|OHR/AVR118|Experimental Drug
3198888|NCT01206322|Experimental|Insulin vs. placebo|Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.
3198889|NCT01206322|Other|Healthy vs. Diabetic|Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.
3198890|NCT01206309||Controls|Never develop an immune mediated disorder
3198891|NCT01206309||Immune Mediated Disorder|Develop an immune mediated disorder
3198892|NCT01206296|Experimental|Intraperitoneal Gemcitabine|Intraperitoneal Gemcitabine
3198893|NCT01206283|Active Comparator|Cerebral perfusion pressure-targeted|15 comatose operated patients after aneurysmal subarachnoid haemorrhage and severe traumatic brain injury respectively were managed postoperatively using cerebral perfusion pressure-targeted therapy according to the American Associations of Neurological Surgeons. Results were categorised into different Glasgow Outcome Scores.
3198894|NCT01206283|Active Comparator|Intracranial pressure-targeted therapy|
3198895|NCT01206270|Experimental|Testosterone|Testosterone undecanoate 1000mg injection at baseline (0-week), 6-week, 18-week, 30-week
3198896|NCT01206270|Placebo Comparator|Placebo|Injection 4 ml of castor oil at baseline (week-0), week-6, week-18, week-30
3198897|NCT01206257||Group 1|
3198898|NCT01206244||Normal|Normal subjects
3198899|NCT01206244||Dry eye|clinically diagnosed dry eye with aqueous tear deficiency
3198900|NCT01206231||1|Patients with hypercholesterolemia
3198901|NCT01206218|Active Comparator|Group A|FLOT Regimen
3198902|NCT01206218|Experimental|Group B|FLO Regimen or FLOT Regimen
3198903|NCT01206205|Experimental|Lenalidomide, Bortezomib|"3 induction cycles of bortezomib, lenalidomide and dexamethasone (VRD) followed by high dose melphalan and autologous stem cell transplantation.~Two months after haematological recovery, patients will receive 2 consolidation cycles of VRD and maintenance therapy for 1 year with lenalidomide."
3198904|NCT01206192||Abused Chinese women|
3198905|NCT01206179|Experimental|non union|Patients with nonunion fracture of long bones
3198906|NCT01206166|Experimental|Enteral Nutrition + Parenteral Nutrition|Enteral nutrition with the addition of parenteral supplementation (Olimel 5.7%E/N9E).
3198907|NCT01206166|No Intervention|Enteral Nutrition Only|Enteral nutrition only - no intervention
3198908|NCT01206153|Experimental|metformin|
3198909|NCT01206140|Experimental|Arm I (selumetinib and temsirolimus)|Patients receive selumetinib PO twice daily on days 1-28 and temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22.
3198910|NCT01206140|Experimental|Arm II (selumetinib)|Patients receive selumetinib as in arm I. Patients who experience disease progression may cross over to arm I.
3198911|NCT01206127|Other|Postoperative positioning: Bed rest|Patients in this group must be lying down facing up 2 hours postoperatively
3198912|NCT01206127|Other|Postoperative positioning: Sitting up|Patients in this group should be sitting up in a chair 2 hours postoperatively
3198913|NCT01206114||Vaccinated persons|The participants have taken one or more doses of 2009 H1N1 vaccine, either as a monovalent vaccine or as a part of a trivalent seasonal 2010-2011 influenza vaccine
3198914|NCT01206114||Not (yet) vaccinated persons|The participants do not want to take any 2009 H1N1 vaccine or have not received any yet
3198915|NCT01206101|Experimental|Liraglutide|
3198916|NCT01206101|Placebo Comparator|Liraglutide placebo|
3198917|NCT01206088|Experimental|nilotinib|
3198918|NCT01206075|Other|Mozobil + G-CSF - 001|Up to four patients (splenectomized and non-splenectomized) previously mobilized with G-CSF (previous study), who failed to yield by 2 leukaphereses sufficient CD34+ cells for a future gene therapy procedure, will receive the combination of G-CSF+Mozobil
3198919|NCT01206075|Other|Mozobil|Sixteen or more patients (non-splenectomized and splenectomized) who were not previously mobilized will receive Mozobil alone.
3198920|NCT01206075|Other|Mozobil + G-CSF - 002|Patients who, in this study, fail to mobilize sufficient yields of blood stem cells with Mozobil alone will be invited to be re-mobilized with the combination of Mozobil plus G-CSF.
3198921|NCT01206062|Experimental|Intensive Control of SBP|"Participants randomized into the Intensive BP arm will have a goal of SBP <120 mm Hg. 2-drug therapy initiated in most Intensive participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP <120 mm Hg; at periodic milepost visits: addition of another drug required if not at goal."
3198922|NCT01206062|Active Comparator|Standard Control of SBP|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP <130 mm Hg @ 1 visit; <135 mm Hg @ 2 consecutive visits
3198923|NCT01206049|Experimental|Combination chemotherapy + panitumumab|
3198924|NCT01206049|Experimental|Combination chemotherapy + bevacizumab|
3198925|NCT01206023||Multiple Sclerosis|Multiple Sclerosis patients
3198926|NCT01206023||Healthy controls|healthy individuals
3198927|NCT01206010|Experimental|Varenicline + Active Tailored Dose|
3198928|NCT01206010|Placebo Comparator|Varenicline + Placebo Tailored Dose|
3198929|NCT01205997|Active Comparator|fentanyl|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
3198965|NCT01205724|Experimental|A|
3198930|NCT01205997|Placebo Comparator|placebo|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
3198931|NCT01205997|Active Comparator|magnesium sulphate|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
3198932|NCT01205984|Active Comparator|oral methylprednisolone|
3198933|NCT01205984|Placebo Comparator|placebo|
3198934|NCT01205971|Experimental|Motivational Interviewing|Motivational Interviewing to reduce caregiver risk factors for early childhood caries in their children is delivered by Dental Health Advocates (trained public housing residents) in combination with fluoride varnish applications, oral health assessments and referrals for children.
3198935|NCT01205971|Active Comparator|Dental Preventive Services|Fluoride varnish applications, written oral health educational materials regarding early childhood caries prevention, oral health assessments and referrals.
3198936|NCT01205958|Active Comparator|medication(Zaltoprofen)|
3198937|NCT01205958|Active Comparator|Acupuncture|
3198938|NCT01205958|Active Comparator|Zalprofen plus Acupuncture|
3198939|NCT01205932|Experimental|Arm 1|
3198940|NCT01205932|Experimental|Arm 2|
3198941|NCT01205932|Experimental|Arm 3|
3198942|NCT01205932|Active Comparator|Arm 4|
3198943|NCT01205919|Experimental|Internet-based self-help|This self-help training is exclusively provided via Internet over a period of 10 weeks. The treatment is based on the cognitive-behavioral approach and consists of 18 modules with helpful strategies to cope with tinnitus (e.g., applied relaxation, positive imagery, attention shift exercises, cognitive restructuring, sleep management, concentration management,). All modules include an information text, detailed practice instructions, worksheets and homework assignments. At the end of each treatment week, there is an e-mail contact between the participants and their therapist. The participants report on their work with the modules and if they had encountered any problems. The therapist provides feedback, support and recommendations on how to proceed.
3198944|NCT01205919|Active Comparator|Discussion forum group|To the participants of the control group the internet-based self-help after waiting time of 10 weeks is offered. During the waiting period participants receive access to a tinnitus online discussion forum.
3198945|NCT01205906|Experimental|Internet-based guided self-help|This self-help training is exclusively provided via Internet over a period of 10 weeks. The treatment is based on the cognitive-behavioral approach and consists of 18 modules with helpful strategies to cope with tinnitus (e.g., applied relaxation, positive imagery, attention shift exercises, cognitive restructuring, sleep management, concentration management,). All modules include an information text, detailed practice instructions, worksheets and homework assignments. At the end of each treatment week, there is an e-mail contact between the participants and their therapist. The participants report on their work with the modules and if they had encountered any problems. The therapist provides feedback, support and recommendations on how to proceed.
3198946|NCT01205906|Experimental|Cognitive-behavior group therapy|This well-established, cognitive-behavior group therapy was developed by Hiller and Haerkötter (2005) and consists of 10 weekly group sessions of 90 minutes. The strictly manualized program includes the following components focusing on the special needs of chronic tinnitus patients: Education, relaxation techniques, cognitive restructuring, the role of attentional processes for tinnitus perception, analysis of avoidance behaviors, tinnitus and the health care system as well as relapse prevention. For each session participants receive written materials, exercises and homework assignments to enhance understanding and to transfer the new information into the daily routine.
3198947|NCT01205906|Active Comparator|Discussion forum group|To the participants of the control group the group therapy or the internet-based self-help after waiting time of 10 weeks is offered. During the waiting period participants receive access to a tinnitus online discussion forum.
3198948|NCT01205893|Experimental|Reducer|Implant Reducer
3198949|NCT01205893|Sham Comparator|Control|No treatment
3198950|NCT01205880|Active Comparator|vectical ointment and clobex spray|patients were assigned to apply vectical ointment first then clobex spray on one target lesion and also apply clobex spray first then vectical ointment on a different target lesion on the opposite side of the body.
3198951|NCT01205867|Experimental|1|AZD8848 given to BChE deficient subjects and age & gender matched control subjects
3198952|NCT01205854|No Intervention|Conventional clinical and laboratory assessment|
3198953|NCT01205854|Experimental|Conventional assessment plus ultrasonography|
3198954|NCT01205841|Experimental|Adults|Patients from 16 years of age onwards
3198955|NCT01205841|Experimental|Children|Patients aged 5 to 15 years
3198956|NCT01205828|Experimental|Temozolomide and ABT-888 in HCC patients|Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days ABT-888 40 mg BID PO Days 1-7 every 28 days
3198957|NCT01205802|Active Comparator|PTFE group|MHV reconstruction with ringed Goretex
3198958|NCT01205802|Placebo Comparator|Homograft group|MHV reconstruction with homograft
3198959|NCT01205789||Universal Registry|Subjects who are either not eligible for randomization or for other reasons are not randomized will be consented for the Universal Registry
3198960|NCT01205776|Active Comparator|Percutaneous Coronary Intervention|Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
3198961|NCT01205776|Active Comparator|Coronary Artery Bypass Graft|Those patients receiving CABG
3198962|NCT01205750|Experimental|Glucose clamp|
3198963|NCT01205737|Experimental|TL011|
3198964|NCT01205737|Active Comparator|MabThera®|
3198968|NCT01205698|Placebo Comparator|Group 1 - Control A|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
3198969|NCT01205698|Experimental|Group 2 - Experimental A|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
3198970|NCT01205698|Placebo Comparator|Group 3 - Control B|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
3198971|NCT01205698|Experimental|Group 4 - Experimental B|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
3198972|NCT01205685|Experimental|OSI-906 + Erlotinib + Letrozole + Goserelin|"OSI-906 in a pill form, by mouth, twice a day (12 hours a part)~Erlotinib in a pill form, by mouth, once a day~Letrozole in a pill form, by mouth, once a day~Goserelin, by injection once per month for women who are pre-menopausal"
3198973|NCT01205672|Experimental|Metformin|Metformin 850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
3198974|NCT01205646|Experimental|Zometa & PET Scans|Zoledronate therapy & PET scan ;2 scans [about 1-2 weeks apart] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility, Bone scan (within 4 weeks prior to registration), bone turnover markers, and PSA will be obtained pretherapy. After that, Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration.
3198975|NCT01205633||CNS draining vein abnormalities|
3198976|NCT01205620|Experimental|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
3198977|NCT01205620|No Intervention|No intervention|No intervention will be performed in this control group
3198978|NCT01205607|Experimental|ITPR -9 & then -5 mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
3198979|NCT01205607|Experimental|ITPR -5 & then _9 mm HG|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
3198980|NCT01205594|Experimental|ITPR device|the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
3198981|NCT01205581|Active Comparator|Leukemia-HD|Subjects with a diagnosis of leukemia will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
3198982|NCT01205581|Active Comparator|Leukemia-SD|Subjects with a diagnosis of leukemia will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
3198983|NCT01205581|Active Comparator|Solid Tumor-HD|Subjects with a diagnosis of solid tumor will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
3198984|NCT01205581|Active Comparator|Solid Tumor-SD|Subjects with a diagnosis of solid tumor will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
3198985|NCT01205581|Active Comparator|HIV-HD|Subjects with a diagnosis of human immunodeficiency virus (HIV) will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
3198986|NCT01205581|Active Comparator|HIV-SD|Subjects with a diagnosis of human immunodeficiency virus (HIV) will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
3198987|NCT01205568|Experimental|Patients with Resistant Pulmonary Artery Stenosis|Vessels with resistant PA stenosis were identified during catheterization and eligible vessels were randomized to Cutting Balloon or High Pressure Balloon Dilation
3198988|NCT01205555|No Intervention|ultrasound alone group|Patients in the control group will have a standard ultrasound monitoring with HCG administered when the leading follicle reaches 18 mm, and IUI 36 h afterward.
3198989|NCT01205555|Experimental|LH testing combined with ultrasound monitoring|
3198990|NCT01205542|Experimental|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
3198991|NCT01205542|Active Comparator|Reference|Health check and advice to continue ordinary physical activity
3198992|NCT01205529|Other|AF with ST changes on ECG|Those patients with ST segment or J Point elevation on electrocardiogram. Can be on initial screening electrocardiogram or on electrocardiograms during procainamide infusion. These subjects will harbor cardiac sodium channel gene variants.
3198993|NCT01205516|Experimental|Methadone|
3198994|NCT01205516|Active Comparator|Controlled Release Morphine|Controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
3198995|NCT01205503|Other|Cycle 1 Saline; Cycle 2 Mesna|Saline infused over 15 minutes administered prior to and 3 hours post doxorubicin infusion (over 15 minutes) with following Cyclophosphamide 6 hours post doxorubicin during 1st cycle, then Mesna administered (infused over 15 minutes, 360 mg/m2) prior to and 3 hours post doxorubicin infusion with following Cyclophosphamide 6 hours post doxorubicin during 2nd cycle
3198996|NCT01205503|Other|Cycle 1 Mesna; Cycle 2 Saline|Mesna administered (infused over 15 minutes, 360 mg/m2) prior to and 3 hours post doxorubicin infusion with following Cyclophosphamide 6 hours post doxorubicin during 1st cycle, then Saline administered prior to and 3 hours post doxorubicin infusion (over 15 minutes) with following Cyclophosphamide 6 hours post doxorubicin during 2nd cycle
3198997|NCT01205477|Experimental|Methylprednisolone|Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine
3198998|NCT01205477|Placebo Comparator|Placebo|Infiltration of 1 mL of xylocaine
3198999|NCT01205464|Active Comparator|Doxycycline|Treatment with Capsule Doxycycline 200 mg, once daily, for 21 days.
3199000|NCT01205464|Placebo Comparator|Sugar pill|Capsule Placebo, 200 mg, once daily, for 21 days.
3199001|NCT01205451|Experimental|BTX-A|Botulinum toxin type A
3199002|NCT01205438|Experimental|LY2127399 every 2 weeks|
3199003|NCT01205438|Experimental|LY2127399 every 4 weeks|During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
3199004|NCT01205438|Placebo Comparator|Placebo|
3199005|NCT01205425|Experimental|CT|Procedure of stent implantation will be planed on the basis of both angiography and computed tomography results.
3199006|NCT01205425|Active Comparator|Angio|Procedure of stent implantation will be planned only on the basis of diagnostic coronary angiography.
3199007|NCT01205412||Assessed Cohort|Subjects attending out-patient health services for routine cervical screening or presenting for post-natal check up
3199008|NCT01205399||AlloMax Surgical Graft Group|
3199009|NCT01205386||CROSSER|
3199010|NCT01205373|Experimental|BI 671800 high dose|Oral drinking solution
3199011|NCT01205360|Active Comparator|Bupivacaine-Fentanyl (3-15)|Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.
3199012|NCT01205360|Experimental|Bupivacaine-Fentanyl (4-20)|Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
3199013|NCT01205360|Experimental|Bupivacaine-Fentanyl (6-30)|Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
3199014|NCT01205347|Experimental|Simvastatin 80mg|Simvastatin 80mg once a day
3199015|NCT01205347|Active Comparator|Simvastatin 10mg|Simvastatin 10mg once a day
3199016|NCT01205334|Experimental|Autologous CMV-specific CTL|"The patient will receive one of the following doses:~1.5x10^7 cells/m2~4.5x10^7 cells/m2~1.5x10^8 cells/m2"
3199017|NCT01205321|Experimental|Arm 1|
3199018|NCT01205321|Experimental|Arm 2|
3199019|NCT01205308|Active Comparator|Stanol ester spread|Vegetable oil based margarine with stanol ester enrichment
3199020|NCT01205308|Placebo Comparator|control spread|Vegetable oil based margarine without stanol ester enrichment
3199021|NCT01205295||Mental disorders|Preoperative and postoperative screening of mental disorders and efficacy of treatment in hip and shoulder patient.
3199022|NCT01205282|Experimental|Pioglitazone|A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). There will be 14 weeks of active treatment.
3199023|NCT01205282|Placebo Comparator|Placebo|
3199024|NCT01205269|Experimental|First 50 mcg, then 200 mcg, then placebo|period 1: AZD8683 50 mcg, period 2: washout, period 3: AZD8683 200 mcg, period 4:washout, period5: placebo
3199025|NCT01205269|Experimental|First 50 mcg, then placebo, then 200 mcg|period 1: AZD8683 50 mcg, period 2: washout, period 3: placebo, period 4: washout, period5:AZD8683 200 mcg
3199026|NCT01205269|Experimental|First 200 mcg, then placebo, then 50 mcg|period 1: AZD8683 200 mcg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD8683 50 mcg
3199027|NCT01205269|Experimental|First 200 mcg, then 50 mcg, then placebo|period 1: AZD8683 200 mcg, period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period 5: placebo
3199028|NCT01205269|Experimental|First placebo, then 200 mcg, then 50 mcg|period 1: placebo , period 2: washout, period 3: AZD8683 200 mcg, period 4: washout, period5: AZD8683 50 mcg
3199029|NCT01205269|Experimental|First placebo, then 50 mcg, then 200 mcg|period 1: placebo , period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period5: AZD8683 200 mcg
3199030|NCT01205256|Experimental|Methadone|0.25mg/kg IV of racemic methadone at the induction of anesthesia.
3199031|NCT01205243||ZIAGEN®|Patients administrated ZIAGEN® at the site
3199032|NCT01205230|Experimental|Pazonib+ketoconazole|Administration of oral pazopanib 400mg (2 200-mg tablets) once-daily each morning for at least 7 consecutive doses during Period 1. Then administration of oral ketoconazole 400 mg (2 - 200 mg tablets) followed immediately by pazopanib 400 mg (2 -200 mg tablets) once-daily each morning for a total of 5 consecutive doses during Period 2.
3199033|NCT01205230|Experimental|Pazonib+esomeprazole|Subjects will receive orally administered pazopanib 800mg (4 - 200mg tablets) once-daily each morning for at least 7 consecutive doses in Period 1. In the evening on the last day of Period 1, subjects will take their initial dose of esomeprazole 40 mg (1 - 40 mg capsule) approximately 3 hours after the evening meal. Subjects will continue to receive pazopanib (each morning) and esomeprazole each evening once-daily for a total of 5 consecutive doses.
3199034|NCT01205217|Experimental|Arm A|"Lapatinib in combination with epirubicin and cyclophosphamide followed by paclitaxel and lapatinib.~Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days Lapatinib 1000 mg orally once daily continuously Loperamide as required for the proactive management of diarrhoea~Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week Lapatinib 1000 mg orally once daily continuously Loperamide as required for the proactive management of diarrhoea"
3199035|NCT01205217|Active Comparator|Arm B|"Epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab.~Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days~Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week"
3199036|NCT01205204|Active Comparator|BF25 (Control)|GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
3199037|NCT01205204|Experimental|BC15(Study 1)|GROUP BC15 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
3199038|NCT01205204|Experimental|BC30(Study 2)|GROUP BC30 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
3199039|NCT01205204|Experimental|BC60 (Study 3)|GROUP BC60 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
3199040|NCT01205191|Experimental|CBT-ubiquitous|
3199041|NCT01205191|Placebo Comparator|CBT-placebo|Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management
3199042|NCT01205191|Active Comparator|CBT-TAU|Cognitive behavioural Therapy provided 'As Usual'
3199043|NCT01205178|Active Comparator|Tafenoquine|Tafenoquine, TQ is an 8-aminoquinoline (8-AQ) antimalarial drug being developed for the radical cure of acute P. vivax malaria. Chloroquine will be given for the first 3 days in second and third part of this study to treat Malaria.
3199044|NCT01205178|Active Comparator|Chloroquine|Dose for first 3 days for Part B & C of the study
3199045|NCT01205178|Active Comparator|Primaquine|once daily for first 14 days
3199046|NCT01205165|Experimental|Adefovir Dipivoxil 10mg|All enrolled subject were enrolled to adefovir dipivoxil 10mg arm.
3199096|NCT01204879|Experimental|CM for exercise-related activities|Standard care plus individual contingency management session for physical activities
3199047|NCT01205152|Experimental|asfotase alfa|An initial single intravenous (IV) infusion of 2 mg/kg asfotase alfa, followed by subcutaneous (SC) injections of 1 mg/kg asfotase alfa 3 times per week
3199048|NCT01205139|Experimental|001|TMC435 150 mg capsule once daily for 11 days
3199049|NCT01205139|Experimental|002|TMC278 25 mg tablet once daily for 11 days
3199050|NCT01205139|Experimental|003|TMC435 + TMC278 150 mg TMC435 capsule + 25 mg TMC278 tablet once daily for 11 days
3199051|NCT01205139|Experimental|004|TMC435 150 mg capsule once daily for 7 days
3199052|NCT01205139|Experimental|005|TDF 300 mg tablet once daily for 7 days
3199053|NCT01205139|Experimental|006|TMC435 + TDF 150 mg TMC435 capsule + 300 mg TDF tablet once daily for 7 days
3199054|NCT01205126|Experimental|OROS Hydromorphone hydrochloride (HCl)|OROS Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of titrationphase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
3199055|NCT01205126|Active Comparator|Oxycodone HCl Controlled release (CR)|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titrationphase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
3199056|NCT01205100|Active Comparator|Biofeedback|Patients will be taught to control abdominal and diaphragmatic muscles by bio-feedback using EMG recordings.
3199057|NCT01205100|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patients will take a pill of placebo.
3199058|NCT01205087|Placebo Comparator|Placebo|
3199059|NCT01205087|Active Comparator|OKT3 - 0.2|
3199060|NCT01205087|Active Comparator|OKT3 - 1|
3199061|NCT01205087|Active Comparator|OKT3 - 5|
3199062|NCT01205074|Experimental|Repeatability|
3199063|NCT01205074|Experimental|COPD|
3199064|NCT01205074|Experimental|Smokers|
3199065|NCT01205074|Experimental|CYP450 1A2 Inhibitors|
3199066|NCT01205074|Experimental|Cirrhosis Beta Blockers|
3199067|NCT01205074|Experimental|Alcohol|
3199068|NCT01205061|Experimental|Emervel Deep Lidocaine|Emervel Deep Lidocaine injected into left nasolabial fold. Juvederm® Ultra Plus injected into right nasolabial fold.
3199069|NCT01205061|Active Comparator|Juvederm® Ultra Plus|Juvederm® Ultra Plus injected into left nasolabial fold. Emervel Deep Lidocaine injected into the right nasolabial fold.
3199070|NCT01205048|Experimental|Emervel Classic Lidocaine|Emervel Classic Lidocaine injected into left nasolabial fold. Juvederm® Ultra injected into right nasolabial fold.
3199071|NCT01205048|Active Comparator|Juvederm® Ultra|Juvederm® Ultra injected into left nasolabial fold. Emervel Classic Lidocaine injected into right nasolabial fold.
3199072|NCT01205035|No Intervention|Observation|Observation; No treatment given
3199073|NCT01205035|Experimental|Intravitreal ranibizumab 2.0mg|Initial dose 2.0mg switched to 1.0mg at near conclusion of study.
3199074|NCT01205022|Experimental|Arm I|Patients receive irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes once every 2 weeks. Patients also receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV over 25 minutes once in weeks 3 and 9.Treatment continues in the absence of disease progression or unacceptable toxicity.
3199075|NCT01205009|Active Comparator|Ovitrelle supplemantation|The women will be given 250 mcg of Ovitrelle prior to their IVF cycle
3199076|NCT01205009|No Intervention|no Ovitrelle supplementation|
3199077|NCT01204996|Experimental|1|CNTO888 + docetaxel 15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
3199078|NCT01204996|Experimental|2|CNTO888 + gemcitabine 15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
3199079|NCT01204996|Experimental|3|CNTO888 + Paclitaxel and carboplatin 15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
3199080|NCT01204996|Experimental|4|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection 10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
3199081|NCT01204983||Observational|"This is a quality improvement project to evaluate the current standard of care of nutritional management for very low birth weight infants receiving donor human milk products in the NICU at Texas Children's Hospital.~There is no randomization, there are no control subjects, and therefore there is no probability of group assignment."
3199082|NCT01204970||COPD|COPD Gold class 1-4
3199083|NCT01204970||Transplant|Lung transplant recipients
3199084|NCT01204970||Control|Patients with normal spirometric data
3199085|NCT01204957|Experimental|Arm 1 Seaweed and Soy Protein|Arm 1 5 g/d Seaweed for 6 wk, then 5 g/d Seaweed and Soy Protein for 1 wk
3199086|NCT01204957|Experimental|Arm 2 Placebo and soy protein|Arm 2 5 g/d Placebo for 6 wk, then 5 g/d Placebo and Soy Protein for 1 wk
3199087|NCT01204931||Gastroesophageal Reflux Disease (GERD) Cases|"Erosive disease - presence of esophageal mucosal injuries documented endoscopically.~Non-erosive disease - normal esophagogastroduodenoscopy with symptoms"
3199088|NCT01204931||Control Group|normal subjects without symptoms of gastroesophageal reflux disease (GERD)
3199089|NCT01204918|Experimental|Riluzole addition to SSRI antidepressant|Riluzole 100mg added to ongoing SSRI or SNRI antidepressant for 8 weeks
3199090|NCT01204918|Placebo Comparator|Placebo addition to standard SSRI antidepressant|Placebo will be added to ongoing SSRI or SNRI antidepressant treatment for 8 weeks
3199091|NCT01204918|Experimental|Riluzole/Placebo addition to SSRI antidepressant|Riluzole 100mg added to ongoing SSRI or SNRI antidepressant for 4 weeks and placebo will added to ongoing SSRI or SNRI antidepressant treatment for 4 weeks
3199092|NCT01204905|Other|Open Label|
3199093|NCT01204892|Active Comparator|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
3199094|NCT01204892|Active Comparator|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
3199095|NCT01204879|Active Comparator|CM for general activities|Standard care plus individual contingency management session for general activities
3199216|NCT01204060|Active Comparator|Nasal allergen challenge|
3199097|NCT01204866|Experimental|Stage I|Three (3) healthy male or female volunteers aged 18-59 years, not previously exposed to Valortim and who do not have pre-existing allergies
3199098|NCT01204866|Experimental|Stage II|Up to 4 healthy male or female volunteers aged 18-59 previously exposed to intravenous (IV) Valortim in PharmAthene Study #0036-08-05
3199099|NCT01204853|Experimental|Sitaxentan treatment|
3199100|NCT01204840|Active Comparator|Group A - Control group|"Group A (n=10; control group) will receive the patch protocol consisting of the 100ug estrogen patch (Estradot), a Gonadotropin Releasing Hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), and gonadotropin stimulation with 412 IU of recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris)."
3199101|NCT01204840|Experimental|Group B - treatment group|"Group B will consist of 30 subjects. In addition to the same hormone stimulation patch protocol as Group A, subjects will be treated with growth hormone 10 IU (3.33mg) per day by subcutaneous injection starting day 1 of the last menstrual period in the month prior to gonadotropin stimulation, and will continue daily until the day of human chorionic gonadotropin (hCG) injection."
3199102|NCT01204827|Experimental|CHBV Sebivo|
3199103|NCT01204801|Experimental|Thermochemotherapy|Preoperative Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy.
3199104|NCT01204801|Active Comparator|Chemotherapy (control)|Preoperative Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs
3199105|NCT01204788|Experimental|Arm 1 (Prophylactic Arm)|Prophylactic Treatment (standard of care prophylactic antibiotics) + Prophylactic White Cell Transfusion
3199106|NCT01204788|Experimental|Arm 2 (Therapeutic Arm)|Prophylactic Treatment (standard of care prophylactic antibiotics) + Therapeutic White Cell Transfusion
3199107|NCT01204775|Experimental|Saxagliptin|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
3199108|NCT01204775|Placebo Comparator|Placebo|Placebo matching saxagliptin tablet
3199109|NCT01204762|Experimental|Part A Arm 1: pegIFN (180 μg)|
3199110|NCT01204762|Active Comparator|Part A Arm 2: pegIFNα-2a|
3199111|NCT01204762|Experimental|Part B: pegIFN lambda + Entecavir|
3199112|NCT01204749|Experimental|AMG 386|Arm A: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 15mg/kg IV QW
3199113|NCT01204749|Placebo Comparator|AMG 386 Placebo|Arm B: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 Placebo IV QW
3199114|NCT01204736||Group 1|Subjects with posterior deltoid-to-triceps tendon transfers
3199115|NCT01204736||Group 2|Subjects with biceps-to-triceps tendon transfers
3199116|NCT01204736||Group 3|Subjects with cervical SCI who have not had tendon transfers
3199117|NCT01204736||Group 4|Unimpaired control subjects
3199118|NCT01204723|Experimental|Behavioral Condition 1|Nicotine patch (21 mg) plus placebo oral cannabis (0 mg; 3 times a day on days 2-4, given once on day 5)
3199119|NCT01204723|Experimental|Behavioral Condition 2|Placebo nicotine patch (0 mg) plus oral cannabis (10 mg, 3 times each day, days 2-4, day 5 given once)
3199120|NCT01204723|Experimental|Behavioral Condition 3|Placebo nicotine patch (0 mg) plus placebo oral cannabis (0 mg, 3 times each day days 2-4, day 5 given once)
3199121|NCT01204710|Experimental|IMC-3G3 + Mitoxantrone|1 cycle = 3 weeks (21 days)
3199122|NCT01204710|Active Comparator|Mitoxantrone|1 cycle = 3 weeks (21 days)
3199123|NCT01204697|Experimental|A|
3199124|NCT01204697|Experimental|B|
3199125|NCT01204684|Experimental|Tumor Lysate-pulsed DC vaccination|Cohort #1 will receive autologous tumor lysate-pulsed DC vaccination together with a placebo cream or intramuscular injection of saline.
3199126|NCT01204684|Experimental|Tumor lysate-pulsed DC vaccination+0.2% resiquimod.|Cohort #2 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant 0.2% resiquimod.
3199127|NCT01204684|Experimental|Tumor-lysate pulsed DC vaccination +adjuvant polyICLC.|Cohort #3 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant poly ICLC (TLR3 agonist).
3199128|NCT01204671|Experimental|GSK2321138A Lot 1 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
3199129|NCT01204671|Experimental|GSK2321138A Lot 2 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
3199130|NCT01204671|Experimental|GSK2321138A Lot 3 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
3199131|NCT01204671|Active Comparator|Fluarix Group|Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
3199132|NCT01204671|Active Comparator|GSK2604409A Group|Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
3199133|NCT01204658|Experimental|10PP-LD/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of the GSK 2189242A (or 10PP) vaccine combined with low doses (LD) of pneumococcal pneumolysin toxoid proteins (dPly) and pneumococcal histidine protein D (PhtD) co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of the 10PP and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for the 10PP vaccine and on the right side for Infanrix hexa™.
3199173|NCT01204307|Experimental|docetaxel/cisplatin|The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
3199217|NCT01204060|Placebo Comparator|Nasal placebo challenge|
3199218|NCT01204034|Other|Inuvair|
3199134|NCT01204658|Experimental|10PP-HD/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of the GSK 2189242A (or 10PP) vaccine combined with high doses (HD) of pneumococcal pneumolysin toxoid proteins (dPly) and pneumococcal histidine protein D (PhtD), co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of the 10PP and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for the 10PP vaccine and on the right side for Infanrix hexa™.
3199135|NCT01204658|Active Comparator|Synflorix/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of Synflorix™ vaccine, co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of Synflorix™ and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for Synflorix™ and on the right side for Infanrix hexa™.
3199136|NCT01204658|Active Comparator|Prevnar 13/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of Prevnar 13™ vaccine, co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of Prevnar 13™ and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for Prevnar 13™ and on the right side for Infanrix hexa™.
3199137|NCT01204645||Acute Coronary Syndrome (ACS)|Continuous inclusion at emergency hospitals of patients with acute coronary syndrome (according to ESC/AHA definitions)
3199138|NCT01204645||Follow up|Patients included at 6 or 12 months follow-up visit after an acute coronary event.
3199139|NCT01204645||Coronary|Patients included when undergoing an coronary angiography for suspected or confirmed coronary heart disease
3199140|NCT01204619|No Intervention|Conventional training group|in-center conventional training programs + two home visits
3199141|NCT01204619|Experimental|Intensive training group|in-center conventional training programs + an extra structured patient home visits repeatedly and regularly
3199142|NCT01204606|Experimental|MMA group|
3199143|NCT01204606|Placebo Comparator|Control group|
3199144|NCT01204593|Experimental|Insulin glargine + insulin glulisine|"Insulin glargine dosage will be individually titrated once a week to obtain FPG 80-120 mg/dL (4.5-6.7 mmol/L).~Insulin glulisine dosage will be individually titrated once a week to obtain a 2-hour postprandial plasma glucose (PPG) < 180 mg/dL (<10.0 mmol/L) and ideally around 140 mg/dL."
3199145|NCT01204580|Experimental|Amaryl-M (Glimepiride + Metformin)|"Glimepiride 1 mg and metformin 250 mg are the active ingredients of Amaryl-M 1/250 mg film coated tablets.~Starting dosage is 1 tablet per day, then dosage titration will be based on the result of patient FBG test."
3199146|NCT01204567|Active Comparator|Training follow-up after discharge|Aerobic training Home-program
3199147|NCT01204541||AMD|
3199148|NCT01204541||Young normals|
3199149|NCT01204541||Older normals|
3199150|NCT01204528|Active Comparator|Paricalcitol 2 microgram/d|
3199151|NCT01204528|Active Comparator|Paricalcitol 1 microgram/d|
3199152|NCT01204528|Placebo Comparator|Placebo|
3199153|NCT01204515||Girls with IBS|Girls ages 7-12 years who meet Rome III criteria for IBS
3199154|NCT01204515||Healthy Girls (controls)|Girls ages 7-12 years who are otherwise healthy and have no complaints of stomach pain
3199155|NCT01204502|Experimental|HSVTK retrovirally-transduced donor T lymphocytes|"HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~dose 1 5x104 cells/kg~dose 2 5x105 cells/kg"
3199156|NCT01204489|Experimental|Intensified dietary counseling|The dietary intervention consists of tailored dietary counseling, information leaflets and self-evaluation cards given to the families.
3199157|NCT01204489|Active Comparator|Normal dietary counseling|Public health nurses continue their usual dietary counseling.
3199158|NCT01204476|Experimental|Treatment (cixutumumab, octreotide acetate, everolimus)|Patients receive cixutumumab IV over 60-90 minutes and octreotide acetate IM on day 1 and everolimus PO QD on days 1-21. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
3199159|NCT01204450|Other|Single Arm Temsirolimus + Valproic Acid|"Drug: temsirolimus 60-230mg/m2 weekly during each 28 day course, for up to 12 courses~Drug: valproic acid (VPA) All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses"
3199160|NCT01204437|Active Comparator|EC standard chemotherapy 4 cycles|
3199161|NCT01204437|Active Comparator|CMF standard chemotherapy 6 cycles|
3199162|NCT01204437|Experimental|Nab-Paclitaxel + Capecitabine 6 cycles|6 cycles of weekly nab-Paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
3199163|NCT01204398|Experimental|eligible hypertension patient|Patients will be given placebo for 2 weeks for wash-out, then qualified patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
3199164|NCT01204385||Study Group|
3199165|NCT01204372|Experimental|Treatment|Gemcitabine - Trastuzumab - Erlotinib
3199166|NCT01204359|No Intervention|follow-up|
3199167|NCT01204346|Experimental|MBT group|mentalization based treatment program
3199168|NCT01204346|Active Comparator|Treatment as usual group|treatment as usual group
3199169|NCT01204333|Experimental|Endovascular thrombolysis|
3199170|NCT01204333|Active Comparator|Standard treatment|
3199171|NCT01204320|Experimental|Paclitaxel-coated Balloon|Paclitaxel-coated Balloon Angioplasty
3199172|NCT01204320|Active Comparator|Paclitaxel-eluting Stent|Paclitaxel-eluting Stent Implantation
3199213|NCT01204086|Experimental|venlafaxine|
3199214|NCT01204086|Experimental|fluoxetine|
3199215|NCT01204073|Experimental|TAK-441|
3199174|NCT01204307|Active Comparator|Pemetrexed/cisplatin|The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
3199175|NCT01204294|Experimental|Bigu+Lina|biguanide plus linagliptin
3199176|NCT01204294|Experimental|Glin+Lina|glinide plus linagliptin
3199177|NCT01204294|Experimental|Glit+Lina|glitazone plus linagliptin
3199178|NCT01204294|Experimental|SU+Lina|sulfonylurea plus linagliptin
3199179|NCT01204294|Experimental|A-GI+Lina|alpha-glucosidase inhibitor plus linagliptin
3199180|NCT01204294|Active Comparator|SU+Met|sulfonylurea plus metformin
3199181|NCT01204294|Active Comparator|A-GI+Met|alpha-glucosidase inhibitor plus metformin
3199182|NCT01204281|Experimental|High assistance PAV+|Ventilatory support performed by PAV at 80% assistance (PB 840-plus) FiO2 and PEEP according to routine practice
3199183|NCT01204281|Active Comparator|Assist-control ventilation|Tidal volume, FiO2 and PEEP set according to routine practice
3199184|NCT01204268|No Intervention|Propofol group|Patients will receive the total intravenous anesthesia with propofol infusion during the surgery.
3199185|NCT01204268|Active Comparator|Sevo-C group|Patients will receive the anesthesia with continuous inhalation of sevoflurane.
3199186|NCT01204268|Experimental|Sevo-I group|Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.
3199187|NCT01204255|Experimental|Arm I|Patients apply lorazepam, diphenhydramine hydrochloride, and haloperidol gel topically over 2 minutes.
3199188|NCT01204242|Placebo Comparator|Placebo|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
3199189|NCT01204242|Experimental|Lidocaine|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
3199190|NCT01204229|Experimental|MCID|
3199191|NCT01204229|Experimental|BMI|
3199192|NCT01204216|Active Comparator|Aim 1|Subjects in this arm will be 10 people without diabetes as well as 10 people with diabetes and stable glycemic control. Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
3199193|NCT01204216|Active Comparator|Aim 2|For Aim 2, 10 additional subjects with diabetes in poor glycemic control will be studied initially and then again in improved glycemic control after at least 8 months (with up to 5 additional subjects entered as needed to ensure 10 completed paired studies) to assess the potential role of MRBC variation in the discordances seen between HbA1c and blood glucose testing. Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
3199194|NCT01204203|Experimental|Zometa|Zometa (zoledronic acid) will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles. This will continue until progression of disease and/or intolerable toxicity.
3199195|NCT01204190|Experimental|Arm 1|
3199196|NCT01204190|Experimental|Arm 2|
3199197|NCT01204190|Experimental|Arm 3|
3199198|NCT01204177|Experimental|Arm 1|
3199199|NCT01204164|Experimental|TG02 in AL|Single agent TG02 citrate in acute leukemia patients
3199200|NCT01204164|Experimental|TG02 in MM|Single Agent TG02 citrate in multiple myeloma patients
3199201|NCT01204164|Experimental|TG02 + CFZ in MM|TG02 in combination with carfilzomib and dexamethasone in multiple myeloma patients
3199202|NCT01204164|Experimental|TG02 + CFZ + DEX in CFZ refractory MM|TG02 in combination with carfilzomib and dexamethasone in carfilzomib refractory multiple myeloma patients
3199203|NCT01204138|Placebo Comparator|placebo|Patient randomized to one of two arms, either placebo, or Apremilast
3199204|NCT01204138|Active Comparator|Apremilast|Patients randomized to either placebo or apremilast
3199205|NCT01204125|Experimental|SAR240550 twice weekly/ paclitaxel weekly|SAR240550 will be administered at the dose of 5.6mg/kg as a 60-min intravenous (IV) infusion. Patients will receive SAR240550 infusions twice weekly (day 1 and day 4; total dose of 11.2mg/kg per week) and paclitaxel weekly as a 60-min IV infusion (day 1; dose of 80mg/m2).
3199206|NCT01204125|Experimental|SAR240550 weekly/ paclitaxel weekly|SAR240550 will be administered at the dose of 11.2 mg/kg as a 60-min intravenous (IV) infusion. Patients will receive SAR240550 infusions once weekly (day 1; total dose of 11.2mg/kg per week) and paclitaxel weekly as a 60-min IV infusion (day 1; dose of 80mg/m2).
3199207|NCT01204125|Active Comparator|Paclitaxel alone|Paclitaxel will be administered at the dose of 80mg/m2 as a 60-min IV infusion. Patients will receive weekly (day 1) paclitaxel infusions.
3199208|NCT01204112|Experimental|Tasocitinib (CP-690,550) plus Rifampin|
3199209|NCT01204099|Active Comparator|Docetaxel (NSCLC)|IV docetaxel administered once every three weeks as per standard of care. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
3199210|NCT01204099|Experimental|PX-866 (NSCLC)|Oral PX-866 administered daily at the RD in combination with IV docetaxel administered once every three weeks on a 21 day cycle. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
3199211|NCT01204099|Active Comparator|Docetaxel (SCCHN)|IV docetaxel administered once every three weeks as per standard of care. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
3199212|NCT01204099|Experimental|PX-866 (SCCHN)|Oral PX-866, administered daily at the RD in combination with IV docetaxel administered once every three weeks on a 21 day cycle. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
3199219|NCT01204021|Experimental|Tai Chi Chih|12 weeks of physical exercise in the form of Tai Chi Chih
3199220|NCT01204021|Active Comparator|Stress Education Control|Stress management education
3199221|NCT01204008|Experimental|CS|conservative discectomy
3199222|NCT01204008|Active Comparator|AS|
3199223|NCT01203995|No Intervention|Usual Care|
3199224|NCT01203995|Experimental|brief nutrition education|
3199225|NCT01203995|Active Comparator|In Center training|
3199226|NCT01203995|Experimental|Video Conference training|
3199227|NCT01203982|Active Comparator|Rosuvastatin 5mg|Rosuvastatin 5mg/day
3199228|NCT01203982|Active Comparator|Rosuvastatin 40mg|Rosuvastatin 40mg/day
3199229|NCT01203969|Experimental|Single port laparoscopic surgery|
3199230|NCT01203969|Active Comparator|Conventional laparoscopic surgery|
3199231|NCT01203956|Experimental|SmartFlex|Use Continuous Airway Pressure device with SmartFlex engaged
3199232|NCT01203956|Active Comparator|Standard|Use Continuous Airway Pressure device without SmartFlex engaged
3199233|NCT01203943|Experimental|Cohort 1|• Cohort 1: CC-930 50 mg PO daily (two 25 mg capsules once per day PO) beginning on Day 1 in the AM.
3199234|NCT01203943|Experimental|Cohort 2|• Cohort 2: CC-930 100 mg PO daily (one 100 mg capsule once per day PO) beginning on Day 1 in the AM
3199235|NCT01203943|Experimental|Cohort 3|• Cohort 3: CC-930 100 mg twice daily approximately 12 hours apart (one 100 mg capsule twice per day PO) beginning on Day 1.
3199236|NCT01203943|Placebo Comparator|Placebo|Placebo
3199237|NCT01203930|Experimental|Idelalisib|This arm consists of 2 cohorts. Participants in Cohort 1 will receive idelalisib for up to twelve 28-day cycles (or development of unacceptable toxicity) plus rituximab (8 doses through the end of Cycle 2). Upon completion of twelve 28-cycles, participants are eligible to remain on idelalisib in a continuation protocol. Participants in Cohort 2 will receive idelalisib until disease progression or development of unacceptable toxicity.
3199238|NCT01203917|Other|1|gefitinib 250mg tablet
3199239|NCT01203904||Pulmicort|
3199240|NCT01203891||Healthy brain subjects|The study seeks to recruit 100 normal, healthy brain subjects between ages 10 and 90 for SPECT brain imaging.
3199241|NCT01203878|Experimental|Imiquimod & photodynamic therapy|Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by one session of photodynamic therapy of the entire face with aminolevulinic acid and blue light
3199242|NCT01203878|Active Comparator|Imiquimod|Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by observation
3199243|NCT01203852|Experimental|Metoprolol + Chlorthalidone|Study participants in this group had their current hypertension treatment withdrawn, baseline labs drawn and hypertension documented. Participants were initiated on metoprolol tartrate 50 mg twice daily for two weeks, followed by dose titration to 100 mg twice daily for six additional weeks if blood pressure (BP) > 120/70 mmHg. BP measures were again recorded. Participants entered a washout where metoprolol was titrated, then discontinued, and the patient's hypertension was re-established. After another set of identical baseline labs, study participants were initiated on chlorthalidone 25 mg four days per week (Monday, Wednesday, Thursday, Saturday) 15 mg daily for two weeks, followed by 25 mg daily for an additional six weeks.
3199244|NCT01203839|Experimental|Radiation treatment|This is a Phase II single-arm study of PBI with external-beam radiation therapy in which a group of select women with early-stage invasive and noninvasive breast cancer will be given radiation to the partial breast.
3199245|NCT01203826|Experimental|asfotase alfa|asfotase alfa starting dose 3 mg/kg/week SC injection, increased to 6 mg/kg/week SC injection
3199246|NCT01203813|Experimental|Physician Intervention|"Physicians randomized to the intervention will receive:~Electronic alerts during office visits for patients with chronic kidney disease~Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program"
3199247|NCT01203813|No Intervention|Physician Control|Physicians randomized to the control arm will continue to manage their patients with chronic kidney disease according to routine primary care standards.
3199248|NCT01203787|Active Comparator|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg (2 tablets of 200 mg) twice daily until end of treatment or week 24
3199249|NCT01203787|Experimental|Sorafenib Ramp-Up Regimen|200 mg daily from Day 0-Day 13 200 mg twice daily from Day 14-Day 20 600 mg daily from Day 21-Day 27 400 mg twice daily beginning Day 28 until end of treatment or Week 24
3199250|NCT01203774|Active Comparator|Pen-administered vs syringe-admnistered Glargine|SoloSTAR pen-administered Glargine insulin then syringe-administered Glargine insulin
3199251|NCT01203774|Active Comparator|Syringe-administered vs pen-administered Glargine|Syringe-administered Glargine insulin and then pen-administered Glargine insulin
3199252|NCT01203761||Preoperative patients|ENT surgical patients, approximately 1 day before their procedure undertaken
3199253|NCT01203761||Postoperative patients|ENT surgical patients during their postoperative hospitalization
3199254|NCT01203761||Family members|Family members of ENT surgical patients, during the perioperative period
3199255|NCT01203748|Experimental|PVI + Lines Ablation|
3199256|NCT01203748|Active Comparator|PVI Ablation|
3199257|NCT01203748|Experimental|PVI + CFE|
3199258|NCT01203735|Other|Valproic acid, Chemoradiotherapy|
3199259|NCT01203722|Active Comparator|REGIMEN B|Fludarabine, Cytoxan, TBI, Mycophenolate Mofetil (MMF), Sirolimus
3199260|NCT01203722|Active Comparator|REGIMEN C|Fludarabine, Cytoxan, TBI, Mycophenolate Mofetil (MMF), Tacrolimus
3199261|NCT01203709|Experimental|Combination treatment|treatment arm
3199262|NCT01203696|Active Comparator|non-amlodipine|For patient with suboptimal angina control: anti-anginal agent excluding calcium channel blocker
3199263|NCT01203696|Active Comparator|non - amlodipine|For patient with suboptimal BP control: anti-hypertensive agent excluding calcium channel blocker
3199264|NCT01203683|Experimental|Active Computer-Based Program|Putatively therapeutic computer program.
3199265|NCT01203683|Placebo Comparator|Placebo computer-based program|Inert computer program.
3199266|NCT01203670|Experimental|Soft capsules of Phytalgic|Phytalgic is a food supplement. Its galenic form is soft capsule.
3199267|NCT01203657|Experimental|Tai Chi|Tai Chi instruction, 2x week in a community senior center setting
3199268|NCT01203657|No Intervention|Wait List Control|This is a wait list control group. There is no active or placebo intervention.
3199269|NCT01203644|Active Comparator|Bupivacaine HCl|(e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
3199270|NCT01203644|Active Comparator|SKY0402|Low dose, low-mid dose, mid-dose, and high dose
3199271|NCT01203631|Experimental|NNC 0142-0000-0002|
3199272|NCT01203631|Placebo Comparator|Placebo|
3199273|NCT01203605||In-patient adult non-cardiac surgery|Consecutive patients admitted to participating centres undergoing elective and non-elective non-cardiac surgery commencing during the seven day study period with a planned overnight stay. All eligible patients undergoing surgery within the seven day study period will be recruited wherever possible.
3199274|NCT01203592|Experimental|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
3199275|NCT01203566|Active Comparator|Conventional 3-port laparoscopic appendectomy|Laparoscopic appendectomy will be performed with the standard 3-port technique. The laparoscope is introduced via a 10mm subumbilical port. Dissection will be performed with a 5mm LLQ port and a 5mm RLQ port. Exploratory laparoscopy was first carried out to locate the appendix and to rule out other pathologies. The mesoappendix will be divided with the ultrasonic dissector (Sonosurg, Olympus surgical, Tokyo, Japan). The appendix will be ligated between two polydioxanone suture loops. The specimen will be delivered within a plastic bag via the subumbilical port. Purulent fluid will be irrigated and suctioned from the subhepatic space, right lower quadrant and the pelvis if present. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O absorbable subcuticular sutures. A pelvic drain (12Fr) will be inserted in cases of abscesses or gangrene.
3199276|NCT01203566|Active Comparator|LESS appendectomy|Two 5 mm ports and a 10mm port will be inserted through a 13mm transumbilical incision. Exploratory laparoscopy was first carried out to locate the appendix and to rule out other pathologies. Retraction of the appendix would be performed with a flexible curved forceps. The mesoappendix will be divided with the ultrasonic dissector (Sonosurg, Olympus surgical, Tokyo, Japan). The appendix will be ligated between two polydioxanone suture loops. The specimen will be delivered within a plastic bag via the subumbilical port. Purulent fluid will be irrigated and suctioned from the subhepatic space, right lower quadrant and the pelvis if present. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O absorbable subcuticular sutures. A pelvic drain (12Fr) will be inserted in cases of abscesses or gangrene.
3199277|NCT01203553||Control Group|The main operation will be performed as planned. For the closure of the abdominal wall, a standard technique will be applied using a running suture of PDS 1 loop. The distance of the sutures to the fascial border is 1cm and the distance between two stitches is not more than 1cm. The total length of suture is at least 4 times the total length of the abdominal incision
3199278|NCT01203553||Treatment Group|The main operation will be performed as planned. Prior to the closure of the abdominal wall a mesh will be implanted in a standardized fashion: A Dynamesh IPOM mesh will be used for the present study. The mesh has a width of 15cm and is tailored to overlap lateral and cranial boarders at least 5cm. The mesh will be placed intra-abdominally and fixed using intra-abdominal stitches using Prolene 2/0 in all four corners. After the initial fixation of the mesh in all quadrants, the boarders of the mesh will be adapted using Prolene 2/0 running sutures. The fixation aims to prevent any intestinal structures to herniate onto the mesh. Afterwards, the abdominal wall is closed as described in the control group.
3199279|NCT01203540|Experimental|Naaga in ABAK system|
3199280|NCT01203540|Placebo Comparator|Saline solution|
3199281|NCT01203527||Tamiflu use during first trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the first trimester of their pregnancy.
3199282|NCT01203527||Tamiflu use during second trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the second trimester of their pregnancy.
3199283|NCT01203527||Tamiflu use during third trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the first trimester of their pregnancy.
3199284|NCT01203527||Tamiflu use in non-pregnant women|This group will consist of twenty-five non-pregnant healthy female volunteers who are being treated with Oseltamivir.
3199285|NCT01203514|Experimental|Trial 1 Experimental|Infants 401-1,000g birthweight
3199286|NCT01203514|Sham Comparator|Trial 1: Sham Comparator|Infants 401-1,000g birthweight
3199287|NCT01203514|Experimental|Trial 2: Experimental|Infants 1,001-1,250g birth weight
3199288|NCT01203514|Sham Comparator|Trial 2: Sham Comparator|Infants 1,001-1,250g birth weight
3199289|NCT01203488|Experimental|Experimental|Vitamin A group.
3199290|NCT01203488|Sham Comparator|Control|Sham procedure Control group.
3199291|NCT01203462|Experimental|Bifidobacterium supplemented yogurt|Bifidobacterium supplemented (minimum dosage of 1E+10cfu/serving) vanilla flavored yogurt containing starter cultures: Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus
3199292|NCT01203462|Placebo Comparator|Placebo Yogurt|Vanilla flavored yogurt containing starter cultures Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus
3199293|NCT01203436|Experimental|Supplemental Oxygen|Supplemental oxygen to achieve a pulse oximetry target range of 96% to 99%.
3199294|NCT01203436|Active Comparator|Conventional Oxygen|Conventional oxygenation at a pulse oximetry target of 89% to 94%.
3199295|NCT01203410||Cohort 1|Term infants >2500g birthweight.
3199296|NCT01203397|Active Comparator|GROUP 2|
3199297|NCT01203397|Experimental|GROUP 1|
3199298|NCT01203384|Experimental|CHF5074 1x|oral tablet, multidose
3199299|NCT01203384|Experimental|CHF5074 2x|oral tablet, multidose
3199300|NCT01203384|Experimental|CHF5074 3x|oral tablet, multidose
3199301|NCT01203384|Placebo Comparator|Placebo|placebo, oral tablet, multidose
3199302|NCT01203371|Experimental|Naftopidil|0,25 mg (2 weeks) and 0,50 mg (10 weeks)
3199303|NCT01203371|Active Comparator|Tamsusolin|0,4 mg/day
3199304|NCT01203358|Active Comparator|Surfactant 1|Exosurf Neonatal (Burroughs Wellcome Co.)
3199305|NCT01203358|Active Comparator|Surfactant 2|Survanta (Ross Laboratories)
3199306|NCT01203345|Active Comparator|Immune globulin|Lyophilized human immune globulin product
3199307|NCT01203345|Placebo Comparator|Albumin solution|
3199308|NCT01203332||Alternative Venue Testing (AVT)|Participants recruited for testing through the AVT recruitment method.
3199309|NCT01203332||SSNIT - Index Recruiter|Participants recruited for HIV testing and to bring members of their social and sexual network to the study.
3199310|NCT01203332||SSNIT - Network Member|Participants recruited by someone in their social or sexual network to participate in the study, including HIV testing.
3199311|NCT01203319|Experimental|60mcg/1.0ml recombinant hepatitis B vaccine|600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 60mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
3199312|NCT01203319|Experimental|30mcg/1.0ml recombinant hepatitis B vaccine|600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
3199313|NCT01203319|Placebo Comparator|10mcg/1.0ml recombinant hepatitis B vaccine|300 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
3199314|NCT01203306|Experimental|Drugs: bevacizumab + octreotide LAR + capecitabine|bevacizumab + octreotide + metronomic capecitabine
3199315|NCT01203293|Experimental|Cognitive Behavior Therapy|
3199316|NCT01203293|Active Comparator|Treatment as usual|
3199317|NCT01203280|Experimental|balance, neck isometric strength and range of motion|
3199318|NCT01203267|Experimental|paclitaxel plus carboplatin (PCb) Arm|4 cycles of neoadjuvant paclitaxel plus carboplatin
3199319|NCT01203254|Placebo Comparator|Placebo|
3199320|NCT01203254|Active Comparator|Cholestagel|
3199321|NCT01203241|Active Comparator|Conventional ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum
3199322|NCT01203241|Active Comparator|Conventional ablation plus left atrial roof ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum plus creation of a radiofrequency line joining contralateral superior pulmonary veins throughout the left atrial roof.
3199323|NCT01203228|Active Comparator|A|Myeloablative conditioning
3199324|NCT01203228|Experimental|B|Reduced Intensity Conditioning
3199325|NCT01203215|Experimental|JumpStart|
3199326|NCT01203215|Experimental|Choose to Move|
3199327|NCT01203215|Active Comparator|Wellness|
3199328|NCT01203202|Placebo Comparator|PED 0|placebo
3199329|NCT01203202|Experimental|PED 1|PED-1 (clomipramine 15mg)
3199330|NCT01203202|Experimental|PED-2|PED-2 (Clomipramine 30mg)
3199331|NCT01203189|Active Comparator|Shampoo Group|Subjects in the S group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.
3199332|NCT01203189|Active Comparator|Foam group|Subjects in the F group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.
3199333|NCT01203189|Active Comparator|Cross Over Group|apply ketoconazole 2% foam to scalp twice daily for four weeks. Subjects in the Shampoo group will be able to cross over into the Foam group if the TDSS score does not improve by 60% at the end of the four week treatment period using shampoo.
3199334|NCT01203176|Active Comparator|Post-menopausal symptomatic women|
3199335|NCT01203176|Experimental|Post-menopausal asymptomatic women|
3199336|NCT01203163||PDT with porfimer sodium|
3199337|NCT01203150|Experimental|Supplement|Participants randomized to the 'supplement' arm will consume a blended drink containing 48g of ionexchange, hydrolyzed vanilla-flavored whey protein (Whey to Go, Solgar Vitamin and Herb, Leonia, NJ; 3g CH2O, < 3g Total Fat). The drink will be given in split doses immediately before and after each training session, which represents a timing schedule that best stimulates muscle anabolism in persons undergoing exercise training.
3199338|NCT01203150|Placebo Comparator|Placebo|As ingestion of the protein supplement is critically influenced by time of administration, participants assigned to the 'placebo' study arm will consume the identical supplement and dose on days during which training is not performed. This strategy will allow the groups to be isocaloric and equal in protein supplementation.
3199339|NCT01203137||tricuspid regurgitation, severe|To be included in the present study, the following 3 criteria for severe TR should be met based on the preoperative echocardiography: (1) TR jet > 30% of right atrial area, (2) inadequate cusp coaptation, and (3) systolic flow reversal in the hepatic vein.
3199340|NCT01203124|Placebo Comparator|1|Placebo given once daily on 7 days
3199341|NCT01203124|Experimental|2|Active treatment at Day 1 and Day 7. Placebo on Day 2, 3, 4, 5 and 6
3199342|NCT01203124|Experimental|3|Active treatment at Day 1, 4 and 7. Placebo on Day 2, 3, 5 and 6.
3199343|NCT01203124|Experimental|4|Active treatment at Day 1, 3, 5 and 7. Placebo on Day 2, 4 and 6.
3199344|NCT01203124|Experimental|5|Active treatment once daily on 7 days
3199345|NCT01203111|Experimental|Intensive insulin regimen|Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: + insulin glulisine if HbA1c ≥7% at week 12 (end of treatment period 1)
3199346|NCT01203111|Experimental|insulin regimen|Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: no change, if HbA1c <7% at week 12 (end of treatment period 1)
3199347|NCT01203098|Experimental|DU-176b 30mg once daily|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery
3199348|NCT01203098|Active Comparator|Enoxaparin sodium twice daily|Enoxaparin sodium 20mg (=2000IU) / 0.2mL twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery
3199349|NCT01203098|Experimental|DU-176b 15mg once daily|DU-176b 15mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery
3199350|NCT01203085||Pediatric patients|All patients 21 years of age and under who are enrolled in the 6601 study and have undergone the pediatric scale tests.
3199351|NCT01203072|Experimental|DU-176b 5 mg|
3199352|NCT01203072|Experimental|DU-176b 15 mg|
3199353|NCT01203072|Experimental|DU-176b 30 mg|
3199354|NCT01203072|Experimental|DU-176b 60 mg|
3199355|NCT01203072|Placebo Comparator|Placebo|
3199356|NCT01203046|Active Comparator|GROUP A: 7 DAYS ANTIBIOTIC THERAPY|Ertapenem will be administrated within the first 2 hours of Hospital´s admission and the during the next 7 days after surgery.
3199357|NCT01203046|Experimental|GROUP B - 3 DAYS ANTIBIOTIC THERAPY|Ertapenem will be administrated within the first 2 hours of Hospital´s admission and during the next 3 days after surgery.
3199358|NCT01203033||AML patients|newly diagnosed or relapsed AML patients
3199359|NCT01203020|Experimental|Allogeneic hematopoietic progenitor cell transplant|Intravenous busulfex 130mg/m2 on days -6 to -3 before transplant
3199360|NCT01203007|Experimental|Tailored diet|Tailored diet according to demonstrated food sensitivity
3199361|NCT01203007|Experimental|Low-antigen content (LAC) diet|Low-antigen content diet
3199362|NCT01202994|Experimental|Flute|Flutemetamol PET scan.
3199363|NCT01202981||Group 1|Patients who had cataract surgery by the Investigators between July 1, 2007 and June 30, 2008.
3199364|NCT01202981||Group 2|Patients who had cataract surgery by the Investigators between July 1, 2008 and July 1, 2009.
3199365|NCT01202955|Active Comparator|Tolcapone|Tolcapone
3199366|NCT01202955|Placebo Comparator|Placebo|Placebo
3199367|NCT01202942|Experimental|Quest|Participants smoke Quest cigarettes level 1 for 10 days, followed by level 2 for 10 days, and finally by level 3 for 10 days.
3199368|NCT01202942|No Intervention|Preferred brand|Participants smoke their preferred brand of cigarettes for the duration of the study.
3199369|NCT01202929||Type I achalasia|classic achalasia: complete esophageal motor failure
3199370|NCT01202929||Type II achalasia|compression achalasia: simultaneous panesophageal pressurization with aperistalsis
3199371|NCT01202929||Type III achalasia|spastic achalasia with aperistalsis: 100% spasm
3199372|NCT01202916||Congenital Heart Disease|
3199373|NCT01202916||Healthy children|
3199374|NCT01202903|Experimental|Omalizumab|Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 mL vial that was designed to deliver 150 mg of omalizumab for subcutaneous administration upon reconstitution with 1.4 mL sterile water for injection. The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
3199375|NCT01202903|Placebo Comparator|Placebo|The placebo was the same mixture of inactive excipients, in quality and quantity, as those used for the drug product. The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
3199376|NCT01202890|Experimental|Arm 1|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
3199377|NCT01202877|Experimental|5-azacytidine + PKC412|5-azacytidine 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
3199378|NCT01202864||Cases|3000 Cases
3199379|NCT01202864||Controls|3000 Controls
3199380|NCT01202851|Experimental|Relaxation Group 1|Simple stretching exercises, specific breathing skills, and guided relaxation for 3 sessions, 3 times a week for 6 weeks. Each session should last about 60 minutes. Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
3199381|NCT01202851|Experimental|Relaxation Group 2|Simple stretching exercises, specific breathing skills, and guided relaxation for 3 sessions, 3 times a week for 6 weeks. Each session should last about 60 minutes. Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
3199382|NCT01202851|Other|Waitlist Control Group (WLC)|Participants in this group given the option to take part in one of the two forms of relaxation (off study) after they finish their last questionnaire packet. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
3199383|NCT01202838||Composite Implant|Subject receiving composite implant
3199384|NCT01202825|Experimental|001|
3199385|NCT01202825|Placebo Comparator|008|
3199386|NCT01202825|Placebo Comparator|002|
3199387|NCT01202825|Experimental|009|
3199388|NCT01202825|Experimental|003|
3199389|NCT01202825|Placebo Comparator|004|
3199390|NCT01202825|Experimental|005|
3199391|NCT01202825|Experimental|010|
3199392|NCT01202825|Placebo Comparator|006|
3199393|NCT01202825|Experimental|007|
3199394|NCT01202812|Experimental|LOVAZA|
3199395|NCT01202812|Placebo Comparator|Placebo capsule|
3199396|NCT01202799|Experimental|Treatment A|2% w/w diclofenac sodium topical gel
3199397|NCT01202799|Active Comparator|Treatment B|
3199398|NCT01202799|Active Comparator|Treatment C|
3199399|NCT01202786||miRview mets Disclosed|Patients of group 1 will be submitted to the standard conventional work-up (see below) as well as miRview™ mets assay. Their physician will treat the patient based upon both results
3199400|NCT01202786||Control|Patients of group 2 will be submitted to the standard conventional work-up. miRview™ mets assay will be performed but will remain blinded for both the patient and referring physician. Treatment will be decided based on standard work-up results
3199443|NCT01202422|Other|Pregabalin immediate release, 150 mg|Reference Treatment
3199444|NCT01202409|Experimental|Panitumumab|Starting Dose of Panitumumab: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
3199543|NCT01201746|Placebo Comparator|Delayed treatment|Scaling Root planing and oral hygiene instructions
3199401|NCT01202773|Experimental|120 milligrams (mg) LY2127399|"Given every 4 weeks (Q4W) for 24 weeks. Participants receive a 240-mg loading dose when initiating treatment.~During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks (Q2W).~At Week 16, responders will receive 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period.~At Week 16, non-responders (NR) will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
3199402|NCT01202773|Experimental|90 mg LY2127399|"Given Q2W for 24 weeks. Participants receive a 180-mg loading dose when initiating treatment.~At Week 16, both responders and NR will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
3199403|NCT01202773|Placebo Comparator|Placebo|"Given Q2W for 24 weeks. Participants receive 2 injections of placebo when initiating treatment.~At Week 16, responders will receive 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.~At Week 16, NR will receive a 180-mg loading dose of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
3199404|NCT01202760|Experimental|120 mg LY2127399|"LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240-mg (2 SC injections of 120 mg each) loading dose of LY2127399 when initiating treatment.~During the Treatment Period, for blinding purposes, participants alternated injections of LY2127399 and injections of Placebo every 2 weeks.~After 16 weeks, non-responders received 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
3199405|NCT01202760|Experimental|90 mg LY2127399|"LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180-mg (2 SC injections of 90 mg each) loading dose of LY2127399 when initiating treatment.~After 16 weeks, non-responders continued to receive 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
3199406|NCT01202760|Placebo Comparator|Placebo|"Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections of Placebo when initiating treatment.~After 16 weeks, non-responders received 90 milligrams (mg) of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
3199407|NCT01202747|Experimental|LipiFlow Treatment|Treatment with LipiFlow device
3199408|NCT01202734|Experimental|001|Methylphenidate HCl Period 1: One tablet oral 36 mg once daily single-dose on Day 1 Period 2: Three tablets oral 18 mg once daily single-dose on Day 1 Period 3: Two tablets oral 36 mg once daily single-dose on Day 1. (Each treatment period will be separated by 3-7 days)
3199409|NCT01202721|Experimental|Atenolol|Atenolol or matching placebo 25 mg up-titrated to 100 mg.
3199410|NCT01202721|Experimental|Telmisartan|Telmisartan or matching placebo 40 mg up-titrated to 80mg
3199411|NCT01202695|Experimental|AVP-21D9|
3199412|NCT01202695|Placebo Comparator|Placebo|
3199413|NCT01202669||Epilepsy patients, EMU stay|
3199414|NCT01202656|Experimental|G-CSF then Saline|G-CSF (Granulocyte colony stimulating factor)
3199415|NCT01202656|Placebo Comparator|Saline then G-CSF|Normal Saline
3199416|NCT01202643|Experimental|G-CSF|G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation
3199417|NCT01202643|Placebo Comparator|Saline|Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation
3199418|NCT01202630|Experimental|Probiotic|BIO-K+ CL1285
3199419|NCT01202630|Placebo Comparator|Placebo|Placebo
3199420|NCT01202617||Schizophrenic outpatients between 18 & 70 years of age|
3199421|NCT01202604||Outpatients with bipolar disorder I or II (as per DSM-IV)|The percentage of patients who experience a relapse episode during the first 9 months after a mood event (manic or depressive).
3199422|NCT01202591|Experimental|AZD4547 + exemestane|Safety run-in: AZD4547 plus exemestane
3199423|NCT01202591|Experimental|AZD4547 + fulvestrant|A Randomised phase IIa: AZD4547 plus fulvestrant
3199424|NCT01202591|Placebo Comparator|Placebo + fulvestrant|Randomised phase IIa: Matching placebo plus fulvestrant
3199425|NCT01202578|Experimental|tympanostomy tube|performance and safety of tympanostomy tube delivery system
3199426|NCT01202565||Adalimumab|Participants with moderate to severe plaque psoriasis received adalimumab (Humira®) therapy according to the local product label and prescription/reimbursement guidelines.
3199427|NCT01202552|Experimental|group 1|receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain
3199428|NCT01202552|Experimental|group 2|receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site
3199429|NCT01202552|Experimental|group 3|receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
3199430|NCT01202526||RYGB patients with type 2 diabetes|Morbid obese patients with type 2 diabetes undergoing gastric bypass surgery
3199431|NCT01202526||RYGB patients without type 2 diabetes|Morbid obese patients with normal glucose tolerance undergoing gastric bypass surgery
3199432|NCT01202513|Experimental|Bimatoprost application|
3199433|NCT01202500|Other|12 months|
3199434|NCT01202500|Experimental|3 months|
3199435|NCT01202487|Experimental|Pre-treatment with LET|Pre-treatment with Lidocaine Epinephrine Tetracaine solution at least 45 minutes prior to laceration repair with tissue adhesive
3199436|NCT01202487|Placebo Comparator|Pre-treatment with Placebo|Pre-treatment with Placebo solution at least 45 minutes prior to laceration repair with tissue adhesive
3199437|NCT01202474|Experimental|insulin glulisine and insulin glargine|insulin glulisine and insulin glargine basal/bolus regimen in accordance with the summary of product characteristics and titrated to Plasma glucose target as defined by American Diabetes Association (ADA) recommendations age-specific goals (12)
3199438|NCT01202448|Active Comparator|DLBCL with risk factor|Patients have any of risk factors for secondary CNS involvement
3199439|NCT01202435|Experimental|Pregabalin controlled release, 82.5 mg|
3199440|NCT01202435|Other|Pregabalin immediate release, 25 mg|Reference Treatment
3199441|NCT01202422|Experimental|Pregabalin controlled release, 165 mg|
3199442|NCT01202422|Experimental|Pregabalin controlled release, 330 mg|
3199445|NCT01202396||ulcerative colitis patients with a pouch|"ulcerative colitis patients undergoing proctocolectomy with an ileal pouch anal anastomosis~comparing patients with versus those without pouchitis~no intervention"
3199446|NCT01202383|Active Comparator|NADCC tablets|
3199447|NCT01202383|Placebo Comparator|Placebo tablets|
3199448|NCT01202370|Experimental|AR-67|Phase 1 study
3199449|NCT01202357|Experimental|Case Management (1 year)|
3199450|NCT01202357|No Intervention|Standard Care (1 year)|
3199451|NCT01202344|Other|Restenosis|Patients who have restinosis immediately following angioplasty.
3199452|NCT01202344|Other|No Restenosis|Patients who do not have restinosis immediately following angioplasty.
3199453|NCT01202331|No Intervention|J|Stop Annual Treatment
3199454|NCT01202331|No Intervention|K|Stop Biannual Treatment
3199455|NCT01202331|Other|L|Continue Annual Treatment
3199456|NCT01202331|Other|M|Continue Biannual Treatment
3199457|NCT01202331|Experimental|N|Targeted Treatment by Age
3199458|NCT01202331|Experimental|O|Targeted Treatment by Clinical Exam
3199459|NCT01202305||HIV negative|
3199460|NCT01202305||HIV positive|
3199461|NCT01202292|Experimental|Lifestyle counseling|
3199462|NCT01202279|Active Comparator|Mucinex D|Mucinex D (1200 mg guaifenesin and 120 mg pseudoephedrine HCl) extended release bilayer tablet twice a day (bid) with a full glass of water for 7 days
3199463|NCT01202279|Placebo Comparator|Placebo|Placebo given bid with a full glass of water for 7 days
3199464|NCT01202266|Experimental|5 mg PF-05161704 or Placebo|
3199465|NCT01202266|Experimental|15 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
3199466|NCT01202266|Experimental|50 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
3199467|NCT01202266|Experimental|150 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
3199468|NCT01202266|Experimental|xx mg PF-05161704 or Placebo|Planned dose and dosing regimen will be determined based on emerging PK and safety data.
3199469|NCT01202266|Experimental|xxx mg PF-05161704 or Placebo|Dose will be determined based on data from previous 5 arms.
3199470|NCT01202266|Experimental|yy mg PF-05161704 or Placebo|Dose will be determined based on data from previous 6 arms
3199471|NCT01202266|Experimental|yyy mg PF-05161704 or Placebo|Dose will be determined based on data from previous 7 arms.
3199472|NCT01202253||Anidulafungin|
3199473|NCT01202240|Experimental|Tasocitinib (CP-690,550) plus Ketoconazole|
3199474|NCT01202227|Experimental|Pregabalin|Flexible dosing in 4 weeks followed by 48 weeks maintenance and one week taper period
3199475|NCT01202214|Experimental|Active drug|
3199476|NCT01202214|Placebo Comparator|Placebo|
3199477|NCT01202201||Study Cohort|Subjects hospitalized with acute gastroenteritis or rotavirus gastroenteritis
3199478|NCT01202188|Experimental|indacaterol and glycopyrronium (QVA149)|QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
3199479|NCT01202188|Active Comparator|glycopyrronium (NVA237)|NVA237 50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
3199480|NCT01202188|Active Comparator|indacaterol (QAB149)|QAB149 150 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
3199481|NCT01202188|Active Comparator|tiotropium|Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
3199482|NCT01202188|Placebo Comparator|Placebo|Matching placebo capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
3199483|NCT01202175|Experimental|Nebivolol|
3199484|NCT01202175|Placebo Comparator|Sugar pill|
3199485|NCT01202162|Active Comparator|Desflurane|Administration of Desflurane
3199486|NCT01202162|Active Comparator|Sevoflurane|Administration of Sevoflurane
3199487|NCT01202149|Active Comparator|Elidel Right Side, Hylatopic Plus Left Side|Elidel applied topically on Right Side of body twice a day and Hylatopic plus emollient foam applied topically on Left Side of body three times a day
3199488|NCT01202149|Active Comparator|Elidel Left Side Hylatopic Plus Right Side|Elidel applied topically on Left Side of body twice a day and Hylatopic plus emollient foam applied topically on Right Side of body three times a day
3199489|NCT01202136||Pancreatic cysts|patients referred to Johns Hopkins Hospital for evaluation and or treatment for 1 or more pancreatic cysts
3199490|NCT01202110|Experimental|Propranolol|Propranolol 1mg iv
3199491|NCT01202110|No Intervention|Control|Routine care
3199492|NCT01202097|Experimental|Salmeterol/Fluticasone|
3199493|NCT01202097|Active Comparator|Seretide|
3199494|NCT01202084|Experimental|Formoterol/Fluticasone Eurofarma|formoterol + fluticasone (12/250 mcg) twice a day per 12 weeks
3199495|NCT01202084|Active Comparator|Foraseq®|formoterol + budedonide (12/400 mcg) twice a day per 12 weeks
3199496|NCT01202084|Active Comparator|Fluticasone|fluticasone (500 mcg) twice a day per 12 weeks
3199497|NCT01202071|Experimental|Rabeprazole sodium Tablets, 5 mg|
3199498|NCT01202071|Experimental|Rabeprazole sodium Tablets, 10 mg|
3199499|NCT01202071|Experimental|Rabeprazole sodium Tablets, 20 mg|
3199500|NCT01202071|Experimental|Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets)|
3199541|NCT01201759|Experimental|Salsalate 2gr BID to placebo|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days.
3199584|NCT01201447||Questionable occlusal lesions|
3199501|NCT01202058|Experimental|NEVO™ SES|"Design Protocol Am3.0 - safety follow-up:~The study population consists of 103 subjects with atherosclerotic coronary artery disease treated with the NEVO™ SES. Candidates for the initial NEVO II Study must have met ALL inclusion criteria and NO exclusion criteria.~Design Original Protocol~Subjects randomized to treatment with the NEVO™ Sirolimus-eluting Coronary Stent System."
3199502|NCT01202058|Active Comparator|XIENCE V®/XIENCE PRIME™/PROMUS®|Subjects randomized to treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System
3199503|NCT01202045||systemic sclerosis patients|Every patient will have a rest echocardiography, a stress echocardiography, a right heart catheterization, a blood specimen, and a pulmonary function test.
3199504|NCT01202019|Experimental|Supplement|Participants randomized to the 'supplement' arm will consume a blended drink containing 48g of ionexchange, hydrolyzed vanilla-flavored whey protein (Whey to Go, Solgar Vitamin and Herb, Leonia, NJ; 3g CH2O, < 3g Total Fat). The drink will be given in split doses immediately before and after each training session, which represents a timing schedule that best stimulates muscle anabolism in persons undergoing exercise training.
3199505|NCT01202019|Placebo Comparator|Placebo|As ingestion of the protein supplement is critically influenced by time of administration, participants assigned to the 'placebo' study arm will consume the identical supplement and dose on days during which training is not performed. This strategy will allow the groups to be isocaloric and equal in protein supplementation.
3199506|NCT01202006|Experimental|Intervention|General practitioners of patients in the intervention group will receive detailed instructions on uptitration of ACE-inhibitors and beta-blockers before the inclusion of participants.
3199507|NCT01202006|No Intervention|Control|Patients in the control group receive care-as-usual. Their general practitioner will not be trained in applying the uptitration protocol.
3199508|NCT01201980||1|Subject population with essential arterial hypertension currently receiving treatment with a calcium antagonist
3199509|NCT01201967|Experimental|Collaborative care|Study care manager provides education and coordinates treatment between study psychiatrist, patient, and primary medical physician. This occurs in the hospital and by phone after discharge. Care manager may also provide phone-based therapy.
3199510|NCT01201967|Placebo Comparator|Usual care|Patient's physicians are informed of diagnosis of depression/anxiety disorder
3199511|NCT01201954|Active Comparator|sucrose|0,5 ml/kg of sucrose administered 2 minutes prior the procedure
3199512|NCT01201954|Placebo Comparator|sterile water|0,5 ml/kg of sterile water administered 2 minutes prior the procedure
3199513|NCT01201941||Intervention group|"During the first part of the study, the intervention group will not have access to the e-Chasqui system.~During the second part of the study, the intervention group will have access to the e-Chasqui system."
3199514|NCT01201941||Simultaneous/historical control group|"During the first part of the study, the intervention group will not have access to the e-Chasqui system.~During the second part of the study, the intervention group will not have access to the e-Chasqui system."
3199515|NCT01201928||Technosphere Insulin Inhalation Powder|
3199516|NCT01201928||Comparator|Based on parent trial
3199517|NCT01201915|Experimental|Cohort 1: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 12 weeks.
3199518|NCT01201915|Experimental|Cohort 2: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 12 weeks.
3199519|NCT01201915|Experimental|Cohort 3: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 8 weeks, followed by 4 weeks with no treatment, followed by a second 8-week vismodegib treatment period.
3199520|NCT01201902|Experimental|Group 1 : Low dose with adjuvant|Group 1: 18 ~ 64 years old subjects
3199521|NCT01201902|Experimental|Group 1: High dose with adjuvant|Group 1: 18 ~ 64 years old subjects
3199522|NCT01201902|Active Comparator|Group1 : Plain vaccine|Group 1: 18 ~ 64 years old subjects
3199523|NCT01201902|Experimental|Group 2 : Low dose with adjuvant|Group 2: greater than or equal to 65 years of age
3199524|NCT01201902|Experimental|Group 2 : high dose with adjuvant|Group 2: greater than or equal to 65 years of age
3199525|NCT01201863|Experimental|Intervention - Treatment|Men with TBI meeting study criteria with Low Testosterone levels will be randomly assigned to either a treatment or placebo group. They will participate in blood assays at baseline and every other week for 12 weeks during inpatient rehabilitation hospitalization. They will also be scored on the FIM (primary outcome measure) and the NIH Toolbox (Secondary Outcome Measure.
3199526|NCT01201863|Placebo Comparator|Intervention Placebo|Men with TBI meeting study criteria with Low Testosterone levels will be randomly assigned to either a treatment or placebo group. They will participate in blood assays at baseline and every other week for 12 weeks during inpatient rehabilitation hospitalization. They will also be scored on the FIM (primary outcome measure) and the NIH Toolbox (Secondary Outcome Measure.
3199527|NCT01201850|Experimental|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses.
3199528|NCT01201837|Placebo Comparator|Placebo|
3199529|NCT01201837|Experimental|Low Dose|CER-001 Low Dose
3199530|NCT01201837|Experimental|Mid Dose|CER-001 Mid Dose
3199531|NCT01201837|Experimental|High Dose|CER-001 High Dose
3199532|NCT01201824|Other|1|
3199533|NCT01201811|Experimental|Single-Arm|Azacitidine 75 mg/m^2/day Subcutaneous for 7 days Day every 28 days for up to 6 cycles
3199534|NCT01201798|Experimental|Durezol|Difluprednate 0.05% ophthalmic emulsion, 1 drop in study eye, 4 times a day for 14 days, followed by a 14-day tapering period
3199535|NCT01201798|Active Comparator|Pred Forte|Prednisolone acetate 1.0% ophthalmic suspension, 1 drop in study eye, 8 times a day for 14 days, followed by a 14-day tapering period
3199536|NCT01201785|Experimental|Aspirin dose range|
3199537|NCT01201772|Active Comparator|Prasugrel 60mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
3199538|NCT01201772|Active Comparator|Prasugrel 30mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
3199539|NCT01201772|No Intervention|Prasugrel 10mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
3199540|NCT01201759|Experimental|Placebo to Salsalate 2gr BID|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.
3199542|NCT01201746|Experimental|Periodontal Therapy|Scaling Root planing and oral hygiene instructions
3199544|NCT01201733|Experimental|Traditional Thai massage|The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region
3199545|NCT01201733|Active Comparator|Ultrasound therapy and hot pack|The participants will receive a thirty minutes session of Ultrasound therapy and hot pack
3199546|NCT01201720|Other|Albumin|Albumin solution for infusion 5%. dosage: 43,5 millimole intravenouse use , 6 plasma exchange with albumin in 11 days and administration of polyclonal gamma globulin.6 sessions
3199547|NCT01201707|Experimental|Treatment of CCSVI with Angioplasty|At the time of venography, these patients will have had a significant lesion (blockage) in the internal jugular and/or the azygos vein that will be treated with angioplasty.
3199548|NCT01201707|Sham Comparator|Observation of CCSVI|At the time of venography, these patients will have had a significant lesion (blockage) in the internal jugular and/or the azygos vein that will not be treated with angioplasty. These patients will be observed after treatment and compared to those patients who received treatment.
3199549|NCT01201694|Experimental|Surface-Controlled Water Soluble Curcumin Group|Starting dose 100 mg by mouth two times a day of a 28 day cycle.
3199550|NCT01201694|Experimental|Surface-Controlled Water Soluble Curcumin Expansion|Following finding of MTD surface-controlled water soluble curcumin, escalating dose levels
3199551|NCT01201681||Post-operativeTooth Pain|
3199552|NCT01201668||Persistent Tooth Pain|
3199553|NCT01201642|Experimental|Prednisolone|Prednisolone as 5 mg tablets will be given within 72 h after onset of Bell's palsy as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
3199554|NCT01201642|Experimental|Acute stage acupuncture|Accept acupuncture therapy within 10days after onset of Bell`s palsy, do not accept prednisolone therapy. The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints within 72 h after onset of Bell's palsy. Yifeng (TE17), Hegu (LI4) are punctured 0.5-1.0 cun, the others are punctured 0.1-0.3 cun. and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
3199555|NCT01201642|Experimental|Prednisolone + acute stage acupuncture|Accept prednisolone and acupuncture therapy within 10days after onset of Bwll`s palsy. Prednisolone used as same as the Arm of Prednisolone. The acupuncture points used as same as the Arm of Acute stage acupuncture.
3199556|NCT01201642|Experimental|Resting stage acupuncture|Accepted acupuncture therapy after 10 days of the onset of Bell`s palsy. The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. Penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints 7 d after enrolment. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
3199557|NCT01201642|Experimental|Prednisolone + resting stage acupuncture|Accept prednisolone and acupuncture therapy more than 10days after onset of Bwll`s palsy. Prednisolone used as same as the Arm of Prednisolone. The acupuncture points used as same as the Arm of Resting stage acupuncture.
3199558|NCT01201642|Other|Other treatment|Do not accept neither prednisolone nor acupuncture therapy. The therapy accepted is different from the five Arms Previously.
3199559|NCT01201629|Sham Comparator|t DC stimulation|Sham transcranial direct current stimulation tDCS induces slight short-lasting tingling with onset of the stimulation. These sensations usually fade away in seconds. Sham interventions are essential to blind the subject and the assessor in order to obtain unbiased assessment of intervention effects
3199560|NCT01201629|Experimental|tDC stimulation|Actual DC stimulation
3199561|NCT01201616|Experimental|High fat, low carbohydrate diet|Fats intake 55% , Protein 17% and carbohydrate 28% of total energy
3199562|NCT01201616|Active Comparator|Low fat, high carbohydrate diet|Fat intake 20%, Protein 17% and carbohydrate 63% of total energy intake
3199563|NCT01201603|Experimental|Orange Juice|Orange Juice reconstituted from frozen concerntrate
3199564|NCT01201603|Placebo Comparator|Orange drink|Sugars matched orange drink
3199565|NCT01201590|Experimental|High Flavanol Cocoa|609mg cocoa flavanols per 24g serving
3199566|NCT01201590|Placebo Comparator|Low flavanol cocoa|13mg cocoa flavanols per 24g serving
3199567|NCT01201577|Active Comparator|Placebo/Probiotic|
3199568|NCT01201577|Active Comparator|Placebo/Prebiotic|
3199569|NCT01201577|Active Comparator|Prebiotic/Probiotic|
3199570|NCT01201577|Placebo Comparator|Placebo/Placebo|
3199571|NCT01201564|Active Comparator|intraperitoneal onlay mesh repair|
3199572|NCT01201564|Active Comparator|sublay mesh repair|
3199573|NCT01201551|Active Comparator|healthy subjects without PVD|healthy subjects without primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo
3199574|NCT01201551|Active Comparator|healthy subjects with PVD|healthy subjects with primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo
3199575|NCT01201538|Experimental|Single arm|
3199576|NCT01201525|Experimental|Surgical scar - part 1|Surgical scar - part 1
3199577|NCT01201525|Placebo Comparator|Surgical scar - part 2|Surgical scar - part 2
3199578|NCT01201512||Temporomandibular disorders|
3199579|NCT01201499|Active Comparator|Intrathecal morphine|A single shot of intrathecal morphine given before the induction of general anesthesia. Followed by postoperative IV patient-controlled morphine analgesia.
3199580|NCT01201499|Active Comparator|Continuous IV remifentanil|Continuous administration of IV remifentanil during surgery, supported by a single bolus of IV morphine at the end of surgery. Followed by postoperative IV patient-controlled morphine analgesia.
3199581|NCT01201486||Pregnant women|Pregnant females in the 2nd trimester.
3199582|NCT01201473||Measure impact of research participation|
3199583|NCT01201460||Glucose testing|Patients participating in this study may be alerted to possible presence of (DM) or pre-(DM) or to inadequate glycemic control. In such a case, they were advised to follow-up with their physician for definitive diagnosis and treatment. Early diagnosis and improved glycemic control may be of significant benefit to the patients' health.
3199585|NCT01201434|Experimental|Probiotics, Treatment, Food Additive|
3199586|NCT01201408||Dental Caries assessment|
3199587|NCT01201395||Dental caries assessment|
3199588|NCT01201382|Experimental|IPT-AST|Interpersonal Psychotherapy-Adolescent Skills Training
3199589|NCT01201382|Active Comparator|Group Counseling|Group Counseling
3199590|NCT01201369|Active Comparator|Cypher™ Stent|Participants in the Cypher arm will be randomised to receive a Cypher™ (Cordis, Miami Lake, USA) coronary stent
3199591|NCT01201369|Active Comparator|Xience™ Stent|Patients in the Xience™ arm will receive a Xience™ Stent(Abbott Vascular, Santa Clara, USA.
3199592|NCT01201356|Experimental|Fingolimod 0.5 mg/day|
3199593|NCT01201330||ONJ sufferers|history of jaw osteonecrosis
3199594|NCT01201330||Bisphosphonate exposure|patients with exposure to bisphosphonates
3199595|NCT01201317|Experimental|AZD2423, 150 mg|Tablets, 150 mg once daily in the morning.
3199596|NCT01201317|Experimental|AZD2423, 20 mg|Tablets, 20 mg once daily in the morning.
3199597|NCT01201317|Placebo Comparator|Placebo|Tablets, placebo, once daily in the morning.
3199598|NCT01201304|Experimental|Interoceptive exposure|Repeated trials of voluntary hyperventilation intended to reduce fears of arousal-related body sensations.
3199599|NCT01201304|Placebo Comparator|Expressive writing|Expectancy control intervention.
3199600|NCT01201291|Active Comparator|Fraction of inspired oxygen of 0.4|Fraction of inspired normobaric oxygen of 0.4 (low oxygen group)
3199601|NCT01201291|Active Comparator|Fraction of inspired oxygen of 0.7|Fraction of inspired normobaric oxygen of 0.7 (high oxygen group)
3199602|NCT01201278|Experimental|Nasal insulin 8 IU|Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
3199603|NCT01201278|Experimental|Nasal insulin 16 IU|Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
3199604|NCT01201278|Active Comparator|Subcutaneous insulin lispro 8 U|Subcutaneous insulin lispro (Humalog®) 8 U
3199605|NCT01201265|Experimental|Overall Participants|Participants received a combination therapy of bevacizumab with gemcitabine plus carboplatin.
3199606|NCT01201252||Acute gastroenteritis Group|Suspected/confirmed cases of rotavirus gastroenteritis in children < 5 years of age
3199607|NCT01201239|Experimental|raltegravir|HIV-infected patients aged over 18 who have failed previous antiretroviral treatment with multi-drug resistant or with multi-drug intolerance are to accept Ral plus OBT.
3199608|NCT01201226|No Intervention|Patients|Perimenopausal women, who will undergo oelvic organ surgery, and will allow harvest of about half an oary for the study purpose
3199609|NCT01201213|Active Comparator|Extradural bupivacaine|Local anesthetic
3199610|NCT01201213|Active Comparator|Extradural levobupivacaine|local anaesthetic
3199611|NCT01201213|Active Comparator|Extradural ropivacaine|local anaesthetic
3199612|NCT01201213|Active Comparator|Intrathecal bupivacaine|local anaesthetic
3199613|NCT01201213|Active Comparator|Intrathecal levobupivacaine|local anaesthetic
3199614|NCT01201213|Active Comparator|Intrathecal ropivacaine|local anesthetic
3199615|NCT01201200||Group 1 - Obstructive Sleep Apnea (OSA)|Fifty-six patients with Obstructive Sleep Apnea
3199616|NCT01201200||Group 2 - Non-OSA Controls|Fifty individuals without OSA with similar age, gender and body mass index (BMI)
3199617|NCT01201200||Group 3 - Treatment|Fifteen patients with moderate and severe sleep apnea from group 1 underwent treatment with continuous positive airway pressure
3199618|NCT01201200||Group 4 - Placebo|Fifteen patients with moderate/severe sleep apnea underwent to placebo
3199619|NCT01201187|Experimental|YY-162|YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
3199620|NCT01201187|Placebo Comparator|Placebo|Placebo 1T/twice a day(bid) for 8weeks, po medication
3199621|NCT01201174|No Intervention|Patients with Hereditary Spherocytosis|All patients should have clinical and laboratory findings, consistent with mild to severe HS, diagnosed on the basis of spherocyte morphology, elevated MCHC (33-38 g/dl), with a mean value of (35.47 g/dl), increased osmotic fragility , splenomegaly and non-immune mediated hemolysis.
3199622|NCT01201161|Experimental|RANI/PPV|Preoperative intravitreal ranibizumab and pars plana vitrectomy
3199623|NCT01201161|Placebo Comparator|PPV|Sham injection and pars plana vitrectomy
3199624|NCT01201148|Experimental|Oscillating or intermittent tDCS|
3199625|NCT01201135||Sickle cell disease|
3199626|NCT01201135||hereditary spherocytosis.|
3199627|NCT01201122|Experimental|Weight based Mesalamine: Once daily|
3199628|NCT01201122|Experimental|Weight based Mesalamine: Twice daily|
3199629|NCT01201109||Diabetics|Diabetic patients operated for carpal tunnel syndrome
3199630|NCT01201109||Non-diabetics|Non-diabetic patients operated for carpal tunnel syndrome
3199631|NCT01201096||peptide radioreceptor therapy and liver transplantation|
3199632|NCT01201070|No Intervention|control group|
3199633|NCT01201070|No Intervention|no treatment|
3199634|NCT01201070|Active Comparator|TREATMENT WITH ANTITHROMBIN|3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
3199635|NCT01201057|Experimental|0.5% SPL7013 Gel|
3199636|NCT01201057|Experimental|1.0% SPL7013 Gel|
3199637|NCT01201057|Experimental|3.0% SPL7013 Gel|
3199638|NCT01201057|Placebo Comparator|Placebo Gel|
3199639|NCT01201044|Experimental|Gemcitabine, Nedaplatin,BAI plus 3DCRT|"Gemcitabine(1000mg/m2)，Nedaplatin(60mg/m2),BAI, Day 1/4weeks. 4weeks per cycle. Tumor assessment will be perforemd after 2 cycles. if no PD, patient will be treated with 3DCRTfor 1 month. for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin.~then patient will be followed for 1 year.."
3199640|NCT01201044|Other|Gemcitabine, Nedaplatin, IV Plus 3DCRT|"Gemcitabine 100mg/m2, D1 & D8 every 4 weeks Nedaplatin 75mg/m2, D1 every 4 weeks. every 4 weeks per cycle. Tumor assessment will be performed after 2 cycles. if no PD, patient will be treated with 3DCRT for 1 month.~for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin.~then patient will be followed for 1 year."
3199641|NCT01201018|Experimental|Oshadi DR|
3199831|NCT01199666|Experimental|Text message reminders|
3199642|NCT01201005|Active Comparator|Hydroxycobalamin|"Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma) is given as a singel intramuscular injection.~The syringe is covered so it is impossible to see whether it contains any substance"
3199643|NCT01201005|Sham Comparator|needle injection|"The controls receive an intramuscular injection: which is merely an introduction of the needle into the muscle whithout any injection. The syringe is covered so it is not possible to see whether the syringe contains any substance"
3199644|NCT01200992|Experimental|EN3348|8 mg mixed with sterile water for injection for a total volume of 50mL
3199645|NCT01200992|Active Comparator|Mitomycin C|40 mg powder will be reconstituted with sterile water for injection to a total volume of 40 mL
3199646|NCT01200914|Active Comparator|'PTA without use of the GORE VIABAHN'|Subjects randomized to 'PTA alone without use of the GORE VIABAHN' will receive the standard of care treatment which is Percutaneous Transluminal Angioplasty without the use of the 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
3199647|NCT01200914|Experimental|PTA with covered stent|Subjects randomized to PTA with covered stent will receive Percutaneous Transluminal Angioplasty followed by the delivery of a 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' .
3199648|NCT01200901|Experimental|Melancolic depression patients|Patients with major depression will be recruited for the 8-week clinical trial of quetiapine XR 100 - 300 mg (flexible dosing).
3199649|NCT01200862|Experimental|BGS649|
3199650|NCT01200862|Placebo Comparator|Placebo to BGS649|
3199651|NCT01200849|Experimental|Enhanced Label|Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
3199652|NCT01200849|No Intervention|Standard Label|Subjects in this arm will receive their prescriptions labeled with a standard label.
3199653|NCT01200810|Placebo Comparator|Arm I|"Patients receive oral placebo once daily on days 1-3, 8-10, and 15-17. Treatment repeats every 21 days for 18 courses in the absence of PSA progression.~COMBINATION PHASE: All patients then receive oral bicalutamide once daily on days 1-21 and oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity."
3199654|NCT01200810|Experimental|Arm II|"Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Treatment repeats every 21 days for 18 courses in the absence of PSA progression.~COMBINATION PHASE: All patients then receive oral bicalutamide once daily on days 1-21 and oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity."
3199655|NCT01200797|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3199656|NCT01200784|Experimental|250 mg/d modified release Nicotinamide|
3199657|NCT01200784|Experimental|500 mg/d modified release Nicotinamide|
3199658|NCT01200784|Experimental|750 mg/d modified release Nicotinamide|
3199659|NCT01200784|Experimental|1000 mg/d modified release Nicotinamide|
3199660|NCT01200784|Active Comparator|1000 mg/d immidiate release Nicotinamide|
3199661|NCT01200758|Active Comparator|Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)|Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) in combination with up to 8 cycles of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) or cyclophosphamide, vincristine, prednisolone (CVP) chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.
3199662|NCT01200758|Experimental|Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)|First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
3199663|NCT01200745|Active Comparator|capsaicin patch|
3199664|NCT01200745|Placebo Comparator|Hydrogel patch|
3199665|NCT01200732|Active Comparator|Tadalafil|
3199666|NCT01200732|Placebo Comparator|placebo|
3199667|NCT01200719|Experimental|tACS group|
3199668|NCT01200719|No Intervention|Control group|Patients in the control group followed exactly the same protocol but without receiving the transcranial alternating current stimulation .
3199669|NCT01200706|Active Comparator|Amoxicillin given twice a day|
3199670|NCT01200706|Active Comparator|Amoxicillin given three times a day|
3199671|NCT01200693|Active Comparator|ZES|Patients with coronary bifurcation lesions treated by Zotarolimus eluting stent
3199672|NCT01200693|Active Comparator|SES|Patients with coronary bifurcation lesions treated by Sirolimus eluting stent
3199673|NCT01200693|Active Comparator|EES|Patients with coronary bifurcation lesions treated by Everolimus eluting stent
3199674|NCT01200654|Experimental|MRSA Infections|Methicillin-Resistant Staphylococcus aureus Infections
3199675|NCT01200641|Active Comparator|melatonin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
3199676|NCT01200641|Active Comparator|gabapentin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
3199677|NCT01200641|Placebo Comparator|placebo|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
3199678|NCT01200628||Road traffic accident victims|Cohort of patients hospitalized in surgical department after a motor vehicle accident less than 2 weeks
3199679|NCT01200615|Other|Explanation about common side effects|50 patients started on SSRI's will be updated about its common side effects
3199680|NCT01200615|Other|Explaning side effects and the nocebo effect|subjects started on SSRI's will be updated about its common side effects and the nocebo effect
3200108|NCT01197534|Placebo Comparator|Dosing Regimen C|Oral Treatment
3199681|NCT01200615|Other|explanation about the nocebo effect|3. 50 patients started on SSRI's will receive an explenation on the nocebo effect, but will not be updated about common side-effects. Nonetheless, they will be informed of severe side-effects.
3199682|NCT01200602|Experimental|Arm A|Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.
3199683|NCT01200602|Active Comparator|Arm B|Patients have clinical observation for weight loss and gain for 4 weeks.
3199684|NCT01200589|Experimental|Arm A: Ofatumumab|Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.
3199685|NCT01200589|Active Comparator|Arm B: Rituximab|Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.
3199686|NCT01200576||1|healthy volunteers
3199687|NCT01200563|Active Comparator|Group 1|Subjects assigned to receive MIST Therapy will be treated 3 times per week. The duration of each MIST treatment will be dependent on the wound's area measured at baseline and at each weekly assessment.
3199688|NCT01200563|Active Comparator|Group 2|Subjects assigned to receive Negative Pressure Wound Therapy will be treated with the Vacuum Assisted Closure system. For administration of this study treatment, e.g., treatment cycle, target pressure and dressing changes, the manufacturer's recommended guidelines will be followed.
3199689|NCT01200563|Active Comparator|Group 3|Subjects assigned to this group will receive MIST Therapy treatments and Negative Pressure Wound Therapy.
3199690|NCT01200550||1|
3199691|NCT01200537|Active Comparator|Estradiol Patch|This group of patients will receive estradiol patches prior to the IVF cycle.
3199692|NCT01200537|Active Comparator|Oral Contraceptive Pills (OCP)|This group of patients will receive OCP's prior to the IVF cycle.
3199693|NCT01200524|Experimental|AZD2423, 20mg|
3199694|NCT01200524|Experimental|AZD2423, 150 mg|
3199695|NCT01200524|Placebo Comparator|Placebo|Tablet to match the 20 mg and 50 mg AZD2423 active tablet
3199696|NCT01200511|Experimental|ReSTOR +3.0|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
3199697|NCT01200498|Experimental|SB939|SB939 starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
3199698|NCT01200485|Experimental|Rasburicase Alone|Cycle 1 - All receive 3 mg/kg IV Day 1.
3199699|NCT01200485|Experimental|Arm A (Rasburicase)|Randomized Cycle 2, Rasburicase 0.15 mg/kg IV Day 1.
3199700|NCT01200485|Experimental|Arm B (Allopurinol)|Randomized Cycle 2, Allopurinol 300 mg/day IV Days 1-5 + Rasburicase 0.15 mg/kg IV Day 1 if uric acid blood levels dictate single dose or more.
3199701|NCT01200472|Experimental|Apremilast capsules|Apremilast in 10 mg capsules
3199702|NCT01200472|Placebo Comparator|Placebo|
3199703|NCT01200459|Experimental|Social/Mobile Intervention|Theory-based intervention to promote weight loss utilizing web, mobile phone and social media.
3199704|NCT01200459|No Intervention|Control|"Participants randomized to this group will have access to usual care health information via the SMART study website. This arm will be compared to our intervention group."
3199705|NCT01200446|Placebo Comparator|Placebo Docosahexaenoic Acid (DHA)|Eight subjects will take 8 placebo DHA capsules per day for 3 weeks.
3199706|NCT01200446|Experimental|Active Docosahexaenoic Acid (DHA)|Eight subjects will take 8 active DHA capsules per day for 3 weeks.
3199707|NCT01200433|Active Comparator|propofol|Subjects will be sedated with propofol.
3199708|NCT01200433|Active Comparator|dexmedetomidine|Subjects will be sedated with dexmedetomidine.
3199709|NCT01200420|Experimental|miravirsen|Dose escalation study with review of safety data following each cohort.
3199710|NCT01200420|Placebo Comparator|saline|Dose escalation study with review of safety data following each cohort.
3199711|NCT01200407||Filipino Hypertensive patients|Male and Female, 18 to 65 year old Filipino hypertensive patients prescribed by their doctors with Normetec
3199712|NCT01200394|Experimental|PF-00489791|
3199713|NCT01200394|Placebo Comparator|Placebo|
3199714|NCT01200381|Active Comparator|Group A|Automatic anonymous ICD/CRTD follow up (quarterly remote follow ups)
3199715|NCT01200381|Active Comparator|Group B1|Personal ICD/CRTD follow up (phone calls + quarterly remote follow ups)
3199716|NCT01200381|Active Comparator|Group B2|Personal ICD/CRTD follow up (Quarterly visits)
3199717|NCT01200368|Experimental|1|Experimental
3199718|NCT01200368|Active Comparator|2|Active comparator
3199719|NCT01200368|Active Comparator|3|Active comparator
3199720|NCT01200355|Experimental|micafungin|This is a single institution (MSKCC), randomized, open-label comparative trial of micafungin and posaconazole administered as prophylaxis against fungal infections during neutropenia following induction chemotherapy for myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS).
3199721|NCT01200355|Experimental|posaconazole|This is a single institution (MSKCC), randomized, open-label comparative trial of micafungin and posaconazole administered as prophylaxis against fungal infections during neutropenia following induction chemotherapy for myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS).
3199722|NCT01200342|Experimental|Genasense + Paclitaxel + Carboplatin|Genasense 900 mg intravenous (IV) on a fixed-dose as a 1-hour infusion on Days 1, 3, and 5 of a 21 day cycle; Paclitaxel 175 mg/m^2 IV over 3 hours Day 3 after Genasense; Carboplatin dose in mg (target area under the concentration [AUC)]=6) administered over 30 minutes IV Piggyback (IVPB) on Day 3 after Paclitaxel.
3199723|NCT01200329|Experimental|Gemcitabine + Busulfan + Melphalan|Gemcitabine 2775 mg/m2 by vein over about 3 hours on days -8 and -3. Busulfan 32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient. AUC 4,000 by vein over about 3 hours on days -8 to -5. Melphalan 60 mg/m2 by vein over about 30 minutes on days -3 and -2. Palifermin 60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2. Infusion of stem cells on Day 0.
3199724|NCT01200316|Experimental|Standard of Care Group|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
3199725|NCT01200316|Experimental|Rocking Motion Group|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
3200109|NCT01197521|Experimental|Dosing Regimen A|Oral Treatment
3199726|NCT01200303|Active Comparator|non-cathartic CTC and OC|This is a single arm, open label, prospective test comparison of non-cathartic, CAD-assisted CTC to segmentally unblinded optical colonoscopy (OC). All study subjects receive both tests, starting with CTC, followed by OC within 5 weeks. CTC results are recorded and revealed to endoscopist on a segment-by-segment basis after initial (blinded) OC evaluation; endoscopist can double check / confirm lesion presence after unblinding and this second read serves as reference standard.
3199727|NCT01200290|Experimental|LY2127399|
3199728|NCT01200277|Experimental|vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
3199729|NCT01200277|Sham Comparator|sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the bone cement is prepared to simulate the odor associated with mixing of polymethacrylate , but the needle is not placed and cement is not injected.
3199730|NCT01200264|Experimental|apremilast for all subjects|
3199731|NCT01200251|Experimental|Bimatoprost treated eyelid|one eyelid of the patient was randomized to the treatment arm and given the gel to use
3199732|NCT01200251|No Intervention|control arm - no gel|the other fellow eyelid of the patient did not receive any treatment until month 4 and the patient crossed over to treating both eyelids
3199733|NCT01200238|Experimental|STA-9090: Cohort A|"Cohort A participants received STA-9090 200 mg/m2 given intravenously (IV) over 1 hour once weekly (d1, 8, 15 of a 28 day cycle).~Participants were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal."
3199734|NCT01200238|Experimental|STA-9090: Cohort B|"Cohort B participants received STA-9090 150 mg/m2 given intravenously over 1 hour (IV) twice weekly (d1, 4, 8, 11, 15, 18 of a 28 day cycle).~Participants were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal."
3199735|NCT01200225||Cohort|
3199736|NCT01200212|Experimental|A|A Taxane (80mg/m2 Paclitaxel weekly or 75mg/m2 Docetaxel day1 q22) + 15mg/kg Bevacizumab day1 q22 + 1800 mg/m2 Capecitabine day 1-14 q22
3199737|NCT01200212|Active Comparator|B|A Taxane (80mg/m2 Paclitaxel weekly or 75mg/m2 Docetaxel day1 q22) + 15mg/kg Bevacizumab day1 q22
3199738|NCT01200199||Varicose veins|
3199739|NCT01200186||Group 1|
3199740|NCT01200186||Group 2|
3199741|NCT01200173|Active Comparator|1 = Tested product|
3199742|NCT01200173|Sham Comparator|2 = Control product|
3199743|NCT01200160||Lipid abnormalities|Niacin
3199744|NCT01200147|Active Comparator|Biopsy Arm|
3199745|NCT01200147|Active Comparator|Dilation Arm|
3199746|NCT01200134|Experimental|18F-FMISO PET-scanning|Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
3199747|NCT01200121|Experimental|Arm A Bevacizumab|48 patients randomized into arm A will receive repeated intra¬peritoneal application of Bevacizumab
3199748|NCT01200121|Placebo Comparator|Arm B Placebo|26 patients randomized into arm B will receive repeated intra¬peritoneal application of Placebo
3199749|NCT01200108|Experimental|Budesonide high dose via AKITA (1mg/2ml)|
3199750|NCT01200108|Experimental|Budesonide low dose via AKITA (0.5mg/2ml)|
3199751|NCT01200108|Active Comparator|Budesonide high dose via conventional nebulizer (1mg/2ml)|
3199752|NCT01200108|No Intervention|Placebo via AKITA|
3199753|NCT01200082||Healthy Controls|Male or female, age 19-65, no apparent signs of hepatobiliary diseases
3199754|NCT01200082||Patients with hepatobiliary diseases|Male or female, age 19-65, visiting the UNMC hepatology clinic for treatment from hepatobiliary diseases
3199755|NCT01200069|Placebo Comparator|Sugar water|500 milliliters of intravenous ringers lactate administered over 30 minutes prior to ECT for treatments 1,2 and 3
3199756|NCT01200069|Active Comparator|Ibuprofen|300mg/8milliliters of intravenous ibuprofen/caldolor over 30 min in 500mL of ringers lactate to be administered prior to ECT for treatments # 1, 2 and 3
3199757|NCT01200056|Active Comparator|Atorvastatin 10mg low dose|Atorvastatin 10mg daily for 6 months and compared to atorvastatin 40mg daily in the other arm. The primary endpoint of 6 months VH-IVUS findings and clinical outcomes would be monitored and compared.
3199758|NCT01200056|Active Comparator|Atorvastatin 40mg moderate dose|Atorvastatin 40mg daily for 6 months and compared to atorvastatin 10mg daily in the other arm. The primary endpoint of 6 months VH-IVUS findings and clinical outcomes would be monitored and compared.
3199759|NCT01200043|Experimental|fructose restriction|Isocaloric fructose restricted diet for 10 days
3199760|NCT01200030|Experimental|electrical stimulation with exercises|
3199761|NCT01200030|Placebo Comparator|placebo stimulation with exercises|
3199762|NCT01200030|No Intervention|Control|
3199763|NCT01200004|Experimental|Azacitidine + Lenalidomide|Azacitidine 75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle. Lenalidomide starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
3199764|NCT01200004|Experimental|Azacitidine + Lenalidomide + Grifola Frondosa|Once Lenalidomide MTD identified in combination with azacitidine, Grifola frondosa added. Cycle 1, azacitidine on day 1, lenalidomide on day 2 and Grifola frondosa on day 3. Azacitidine daily for 5 days every 28 days while lenalidomide and Grifola frondosa on days 1-21 of subsequent cycles.
3199765|NCT01200004|Experimental|Expansion Group A|Azacitidine + Lenalidomide MTD, then 2 weeks later Grifola frondosa
3199766|NCT01200004|Experimental|Expansion Group B|Azacitidine + Grifola Frondosa, then 2 weeks later Lenalidomide
3199767|NCT01199991||Normative database|
3199768|NCT01199978|Other|Fractionated Proton Radiation|Single arm study, delivering fractionated radiation with a technique (proton therapy) that may be associated with reduced side effects
3199769|NCT01199965|Other|IV DHE then MAP0004|Smokers and non-smokers received Intravenous Dihydroergotamine Mesylate (IV DHE) at Visit 2 followed by MAP0004 7-11 days later at Visit 3.
3199770|NCT01199965|Other|MAP0004 then IV DHE|Smokers and non-smokers received MAP0004 at Visit 2 followed by Intravenous Dihydroergotamine Mesylate (IV DHE) 7-11 days later at Visit 3.
3199771|NCT01199952|No Intervention|Control|The control group will not receive a counseling phone call one month after enrollment.
3199772|NCT01199952|Experimental|Intervention|Intervention arm receives a counseling phone call 3 to 4 weeks after enrollment. The call is from a health educator intended to assist with contraception.
3199773|NCT01199939|Experimental|ETR + DRV/rtv|Darunavir 800mg once daily orally for 48 weeks,Etravirine 400mg once daily orally for 48 weeks,Ritonavir 100mg once daily orally for 48 weeks
3199774|NCT01199926|Experimental|Vitamin D|Participants in this arm consumed a 4000 IU vitamin D supplement daily for 12 weeks while participating in a resistance exercise training program.
3199775|NCT01199926|Placebo Comparator|Placebo|Participants in this arm consumed a placebo (microcrystalline cellulose) daily for 12 weeks while participating in a resistance exercise training program.
3199776|NCT01199913||desflurane and sevoflurane|Subjects will be randomized to either desflurane or sevoflurane. They will be given the Mini Mental State exam at 1, 6 and 24 hours after the end of anesthesia.
3199777|NCT01199900|Experimental|(Part 1) 25 mg PF-04171327 predosed at -8 hours prior to OGTT|
3199778|NCT01199900|Experimental|(Part 1) 25 mg PF-04171327 predosed at -12 hours prior to OGTT|
3199779|NCT01199900|Active Comparator|(Part 1) 5 mg Prednisone|5 mg prednisone tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
3199780|NCT01199900|Experimental|(Part 2) 3 mg PF-04171327|
3199781|NCT01199900|Experimental|(Part 2) 10 mg PF-04171327|
3199782|NCT01199900|Active Comparator|(Part 2) 5 mg Prednisone|
3199783|NCT01199900|Active Comparator|(Part 2) 20 mg Prednisone|
3199784|NCT01199887|Experimental|IW001|Three dose cohorts, 0.1 mg, 0.5 mg, 1.0 mg
3199785|NCT01199874|Active Comparator|Primary 1: Rotavirus vaccine 6 and 10 weeks|EPI vaccines + rotavirus vaccine at 6 and 10 weeks
3199786|NCT01199874|Experimental|Primary 1: Rotavirus vaccine 6, 10 and 14 weeks|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks
3199787|NCT01199874|Experimental|Primary 1: Rotavirus vaccine 10 and 14 weeks|EPI vaccines + rotavirus vaccine at 10 and 14 weeks
3199788|NCT01199874|Experimental|Primary 2: Rotavirus vaccine withholding breast feeding|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks withholding breastfeeding
3199789|NCT01199874|Experimental|Primary 2: Rotavirus vaccine with immediate breast feeding|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks with immediate breastfeeding
3199790|NCT01199874|No Intervention|Baseline seroconversion for rotavirus|EPI vaccines
3199791|NCT01199861|Experimental|Fingolimod|Participants received Fingolimod 0.5 mg capsules orally once daily for 12 weeks. At Week 6 of study treatment participants received a seasonal influenza vaccination and a tetanus booster vaccination.
3199792|NCT01199861|Placebo Comparator|Placebo|Participants received placebo tablets orally once daily for 12 weeks. At Week 6 of study treatment participants received a seasonal influenza vaccination and a tetanus booster vaccination.
3199793|NCT01199848|Placebo Comparator|Placebo|Pbo
3199794|NCT01199848|Experimental|10G STRB powder|Dose 1
3199795|NCT01199848|Experimental|20G STRB powder|Dose 2
3199796|NCT01199848|Experimental|40G STRB powder|Dose 3
3199797|NCT01199848|Placebo Comparator|PlacebonoFiber|Placebo without fiber
3199798|NCT01199835|Experimental|high calcium|Dietary intake of calcium ~ 1500 mg/ d, including ~1200 mg/d from dairy products
3199799|NCT01199835|Active Comparator|Low calcium|Low dietary intake of calcium, i.e. ~ <600 mg/d, including 0-1 portion of dairy products
3199800|NCT01199822|Experimental|Olaratumab|
3199801|NCT01199809|Experimental|1|
3199802|NCT01199809|Placebo Comparator|2|
3199803|NCT01199783|Experimental|Daptomycin|Infusion of Daptomycin (6 mg/kg bodyweight) once daily
3199804|NCT01199783|Active Comparator|Vancomycin|Vancomycin once daily (effective blood-plasma concentration of 15 mg/l)
3199805|NCT01199770|Experimental|experimental pasta B, small|small portion experimental pasta B
3199806|NCT01199770|Experimental|experimental pasta C, small portion|small portion experimental pasta C
3199807|NCT01199770|Placebo Comparator|Control pasta, small|small portion Control pasta
3199808|NCT01199770|Other|No Load|Only water
3199809|NCT01199770|Active Comparator|Control pasta, medium|medium portion Control pasta
3199810|NCT01199770|Experimental|experimental pasta B, medium portion|medium portion experimental pasta B
3199811|NCT01199770|Experimental|experimental pasta C, medium portion|medium portion experimental pasta B
3199812|NCT01199757||FF|Cohort of patients receiving fluticasome furoate
3199813|NCT01199757||MF|cohort of patients on mometasone furoate
3199814|NCT01199757||FP|cohort of patients receiving fluticasone propionate
3199815|NCT01199744||Influenza virus infection patients exposed to zanamivir|Safety of Influenza virus infection patients exposed to zanamivir
3199816|NCT01199731|Experimental|GSK2248761 100mg OAD|In combination with darunavir/ritonavir BID and raltegravir BID
3199817|NCT01199731|Experimental|GSK2248761 200mg OAD|In combination with darunavir/ritonavir BID and raltegravir BID
3199818|NCT01199731|Active Comparator|Etravirine|In combination with darunavir/ritonavir BID and raltegravir BID
3199819|NCT01199718|Experimental|CX-4945|CX-4945 oral formulation
3199820|NCT01199705|Experimental|IgPro20|
3199821|NCT01199692||Age|
3199822|NCT01199692||Gender|
3199823|NCT01199692||Ethnicity|
3199824|NCT01199692||Body Mass Distribution|
3199825|NCT01199692||Dietary Habits|
3199826|NCT01199692||Exercise Habits|
3199827|NCT01199692||Medication Requirements|
3199828|NCT01199692||Disease State Burden|
3199829|NCT01199679|Experimental|Endoscopic Mucosal Resection (EMR) Group|
3199830|NCT01199679|Experimental|Banding Group|
3199832|NCT01199666|Active Comparator|standard of care for MMR, letter reminder for Hep A|MMR: automated phone call appointment reminder Hep A: recall letter, automated phone call appointment reminder
3199833|NCT01199653|Active Comparator|Non-operative treatment|Non-operative (conservative) treatment of the clavicle fracture
3199834|NCT01199653|Active Comparator|Operative treatment|Operative stabilization (i.e. ORIF) of the fracture with a plate and screws.
3199835|NCT01199640|Experimental|MLN1202|
3199836|NCT01199627|Experimental|A|"Group A: 1st dose 15mg/kg of TXA (tranexamic acid) in 100ml saline 0.9% after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
3199837|NCT01199627|Experimental|B|"Group B: 1st dose: 10mg/kg of TXA (tranexamic acid) in 100ml 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes of 10mg/kg of TXA in 100ml saline 0.9% at three hours after the first administration."
3199838|NCT01199627|Placebo Comparator|C|Placebo
3199839|NCT01199614|Experimental|open-label PTH(1-84)|open-label PTH(1-84) / variable dosing: 25mcg every other day, 25mcg every day, 50mcg every day, 75mcg every day, 100mcg every day
3199840|NCT01199601|Experimental|Concentrated postpartum counseling|Women randomized to receiving concentrated postpartum counseling from the retrained provider.
3199841|NCT01199601|No Intervention|Routine postpartum counseling|Women receiving intra-partum testing and post-partum counseling from existing cadres of hospital providers at standard of care.
3199842|NCT01199588|Experimental|Nexagon® High Dose|Weekly applications of Nexagon® high dose in addition to compression dressings.
3199843|NCT01199588|Placebo Comparator|Nexagon® Vehicle|Weekly applications of Nexagon® Vehicle in addition to compression dressings.
3199844|NCT01199588|No Intervention|No Investigational Product|Weekly application of compression dressings.
3199845|NCT01199588|Experimental|Nexagon® Low Dose|Weekly applications of Nexagon® low dose in addition to compression dressings.
3199846|NCT01199575|Experimental|A: Subjects younger than 65 years old.|"A: Lenalidomide starting at a low dose 2.5 or 5 mg, 21 days/cycle escalated based on patient tolerability. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles (3-7). Each patient may receive up to 7 cycles of treatment with the combination lenalidomide/rituximab if no progressive disease or significant toxicity. Patients with residual disease can elect to receive 6 additional cycles of single agent Revlimid as consolidation.~Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity."
3199847|NCT01199575|Experimental|B: Subjects age 65 years and older|"B: Lenalidomide starting at a low dose 2.5 or 5 mg, 21 days/cycle and escalated based on patient tolerability. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles (3-7). Each patient may receive up to 7 cycles of treatment with the combination lenalidomide/rituximab if no progressive disease or significant toxicity. Patients with residual disease can elect to receive 6 additional cycles of single agent Revlimid as consolidation.~Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity."
3199848|NCT01199562|Experimental|Arm I|Patients receive standard antiviral infection prophylaxis and management comprising ganciclovir, valganciclovir, or foscarnet sodium for 2 weeks or until the plasma CMV DNA Q-PCR is negative. Patients may receive additional courses based on subsequent CMV reactivations.
3199849|NCT01199549||Lycopene group|Mixed age and gender group of healthy volunteers for testing bio-availability of Lycopene containing supplement
3199850|NCT01199549||Resveratrol group|Mixed age and gender group of healthy volunteers for testing bio-availability of Resveratrol containing supplement
3199851|NCT01199549||Laflavon group|Mixed age and gender group of healthy volunteers for testing bio-availability of Soy Isoflavones containing supplement
3199852|NCT01199536||1|patients with Helicobacter-positive duodenal ulcer
3199853|NCT01199523|Placebo Comparator|Placebo|
3199854|NCT01199523|Experimental|mirabegron high dose|
3199855|NCT01199523|Experimental|mirabegron medium dose|
3199856|NCT01199523|Experimental|mirabegron low dose|
3199857|NCT01199523|Active Comparator|moxifloxacin|
3199858|NCT01199510|Experimental|Standard of Care plus FID 112903|SYSTANE® ULTRA Lubricant Eye Drops dosed 4 times daily
3199859|NCT01199510|Active Comparator|Standard of Care only|Post Cataract Standard of Care Regimen
3199860|NCT01199497|Experimental|Group 1|Fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
3199861|NCT01199497|Placebo Comparator|Group 2|Placebo
3199862|NCT01199471||Chinese Patients Requiring Surgery with Anesthesia|Chinese patients 18 to 70 years of age, meeting the American Society of Anesthesiologists (ASA) Physical Status Class 1 (normal healthy), Class 2 (mild systemic disease), or Class 3 (severe systemic disease), who underwent surgery requiring general anesthesia (sevoflurane) administered per local Prescribing Information and endotracheal intubation or laryngeal mask airway (LMA).
3199863|NCT01199458|Active Comparator|opioid|Preoxygenation for 5 min. Injection of opioid (alfentanil 20 mikrogr/kg iv) after 2 min:Injection of induction drug(propofol 2-2.5mg/kg) after anesthesia induction: Application of cricoid pressure for 15 sec.
3199864|NCT01199458|Placebo Comparator|placebo|Preoxygenation for 5 min. Injection of saline iv. after 2 min:Injection of induction drug(propofol 2-2.5mg/kg) after anesthesia induction: Application of cricoid pressure for 15 sec.
3199865|NCT01199445|Experimental|triple fortified extruded rice|
3199866|NCT01199445|Other|regular meal|regular vitamin A meal
3199867|NCT01199432|Experimental|Group B(CEF)|
3199868|NCT01199432|Experimental|Group A(CEFci)|
3199869|NCT01199432|Active Comparator|Group C(EC)|
3199870|NCT01199419||PCI|
3199871|NCT01199419||CABG|
3199872|NCT01199406|Placebo Comparator|normal saline|80 mL 0.9% NaCl
3199873|NCT01199406|Experimental|Levobupivacaine|80mL 0.125% levobupivacaine
3199932|NCT01198977|Active Comparator|Brief telephone-based counseling|Telephone based counseling and instructional video
3199933|NCT01198977|Placebo Comparator|Education Counseling|Mailed Physical Activity information and instructional video only
3199874|NCT01199380|Active Comparator|Standard Treatment (ST)|Participants will receive a standard, group smoking cessation treatment equated for contact time, based on the most recent clinical practice guideline for treating tobacco. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will complete between group exercises and will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events.
3199875|NCT01199380|Experimental|Behavioral Activation Treatment for Smoking|BATS includes standard smoking cessation strategies and identifying life areas, values, and daily activities to help manage mood. Participants will complete between group exercises and will also monitor and plan daily activities in line with their values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period.
3199876|NCT01199367|Experimental|Dose escallation|
3199877|NCT01199341|Experimental|Treatment A|AZD1981, low dose, + Warfarin
3199878|NCT01199341|Experimental|Treatment B|AZD1981, high dose, + Warfarin
3199879|NCT01199328|Active Comparator|1|Aspirin 81 mg
3199880|NCT01199328|Active Comparator|2|Esomeprazole 20mg/aspirin 81mg
3199881|NCT01199315|Experimental|1|Oral capsule. Dose single and followed by 5-day repeated dosing. Specific doses depend on panel.
3199882|NCT01199315|Placebo Comparator|2|Oral capsule. Dose single and followed by 5-day repeated dosing.
3199883|NCT01199302|Experimental|350 mg|
3199884|NCT01199289|Experimental|AMG 827 280 mg|280 mg AMG 827
3199885|NCT01199289|Placebo Comparator|Placebo|Placebo
3199886|NCT01199289|Experimental|AMG 827 140 mg|140 mg AMG 827
3199887|NCT01199289|Experimental|AMG 827 210 mg|210 mg AMG 827
3199888|NCT01199276|Experimental|Xenon|60%(1MAC)in oxygen (FiO2 = 0.35-0.45)
3199889|NCT01199276|Active Comparator|Sevoflurane|1.1-1.4% (1 MAC) in oxygen (FiO2 = 0.35-0.45) and medical air
3199890|NCT01199263|Experimental|Arm I (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
3199891|NCT01199263|Experimental|Arm II (paclitaxel and wild-type reovirus)|Patients receive paclitaxel as in arm I and wild-type reovirus IV over 1 hour on days 1-5.
3199892|NCT01199250||Basic science (biomarker analysis)|Previously collected samples are analyzed for biomarker and other laboratory analyses.
3199893|NCT01199237|Active Comparator|Sevoflurane|Patients receive sevoflurane, rocuronium with neostigmine + glycopyrrolate reversal (70 and 14 ug/kg)
3199894|NCT01199237|Active Comparator|Desflurane|Patients receive Desflurane, rocuronium with neostigmine + glycopyrrolate reversal (70 and 14 ug/kg)
3199895|NCT01199224|Experimental|Arm A|
3199896|NCT01199224|Experimental|Arm B|
3199897|NCT01199224|Experimental|Arm C|
3199898|NCT01199224|Experimental|Arm D|
3199899|NCT01199211||Exercise training, women, marathon.|Other: prospective study with no intervention
3199900|NCT01199198|Experimental|Tolvaptan Group|Tolvaptan Group: Starting dose 15 mg by mouth once a day for 14 days.
3199901|NCT01199198|Placebo Comparator|Placebo Group|Placebo Group: Placebo by mouth once a day for 14 days.
3199902|NCT01199185|Active Comparator|Tobacco Quitline Group|
3199903|NCT01199185|Experimental|Tobacco Quitline plus Interactive Technology Group|
3199904|NCT01199172|No Intervention|Control|
3199905|NCT01199172|Experimental|voice hygiene|Subjects will receive training in voice hygiene
3199906|NCT01199172|Experimental|VH + VP|
3199907|NCT01199159|Active Comparator|preoperative misoprostol|400mcg misoprostol given preoperatively
3199908|NCT01199159|Placebo Comparator|Placebo|
3199909|NCT01199146|Experimental|Abiraterone acetate|
3199910|NCT01199133|Active Comparator|Dpte and Dfar Allergen Extract|
3199911|NCT01199133|Placebo Comparator|Placebo tablets|
3199912|NCT01199120|Experimental|Omega 3|
3199913|NCT01199107|Experimental|Prolonged Exposure + Exercise|
3199914|NCT01199107|Active Comparator|Prolonged Exposure + Wellness Intervention|
3199915|NCT01199094||Patients with mutation in the Lrp5 gene|Patients known to have a mutation in Lrp5 known to be causing a high bone mass phenotype
3199916|NCT01199081|Experimental|Group A|"Dronedarone 400 mg twice daily for 8 weeks starting from randomization.~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
3199917|NCT01199081|Experimental|Group B|"Dronedarone 400 mg twice daily for 6 weeks starting 2 weeks after randomization.~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
3199918|NCT01199081|Experimental|Group C|"Dronedarone 400 mg twice daily for 4 weeks starting 4 weeks after randomization.~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
3199919|NCT01199068|Experimental|CS-7017+Erlotinib|Drug: CS-7017 from 0.25 mg to 0.50 mg twice a daily Drug: Erlotinib 150 mg once daily
3199920|NCT01199055|Experimental|CS-7017+Carboplatin/Paclitaxel|Drug: CS-7017 from 0.25 mg bid to 0.50 mg bid for up to 4~6 cycles (1 cycle: 3 weeks) Drug: Carboplatin IV, AUC of 6, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks) Drug: Paclitaxel IV, 200mg/m2, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)
3199921|NCT01199042|Other|BiPAP autoSV Advanced Device|Positive airway pressure device
3199922|NCT01199029|Experimental|(Part 1) 10 mg PF-04308515 (8hrs)|
3199923|NCT01199029|Experimental|(Part 1) 10 mg PF-04308515 (12hrs)|
3199924|NCT01199029|Active Comparator|(Part 1) 5 mg Prednisone|
3199925|NCT01199029|Experimental|(Part 2) X mg PF-04308515|
3199926|NCT01199029|Experimental|(Part 2) Y mg PF-04308515|
3199927|NCT01199029|Active Comparator|(Part 2) 5 mg Prednisone|
3199928|NCT01199029|Active Comparator|(Part 2) 20 mg Prednisone|
3199929|NCT01199016||1|
3199930|NCT01198990|Experimental|Group 1|"Subjects in will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.~eating/physical activity/positive affect/self-affirmation group."
3199931|NCT01198990|Experimental|Group 2|"Subjects will be randomized to the small change eating strategy and a physical activity goal.~eating/physical activity group. No intervention, just the eating strategy and physical activity components."
3200110|NCT01197521|Experimental|Dosing Regimen B|Oral Treatment
3199934|NCT01198964||Epileptic Patients|The population of patients with medically refractory epilepsy will already have been recommended clinically for electrode grid placement on the brain and high-level stimulation to map brain function.
3199935|NCT01198938|Active Comparator|Melatonin|
3199936|NCT01198925|Active Comparator|extended infusion|
3199937|NCT01198925|Experimental|continuous infusion|
3199938|NCT01198912|Placebo Comparator|placebo|
3199939|NCT01198912|Experimental|doxycycline 100 mg|
3199940|NCT01198899||left ventricular hypertrophy|Patients with left ventricular hypertrophy will be used.
3199941|NCT01198886|Placebo Comparator|Successful Aging Program|
3199942|NCT01198886|Experimental|Exercise-Nutrition Program|
3199943|NCT01198873|Experimental|Dronedarone|Dronedarone 400 mg twice a day
3199944|NCT01198873|Placebo Comparator|Placebo|Placebo (for Dronedarone) twice a day
3199945|NCT01198834|Placebo Comparator|Placebo Patch|Treatment with Placebo Patch
3199946|NCT01198834|Experimental|MRX-7EAT Patch|Treatment with MRX-7EAT Patch
3199947|NCT01198834|Experimental|Lidocaine Patch|Treatment with Lidocaine Patch
3199948|NCT01198834|Experimental|Etodolac Patch|Treatment with Etodolac Patch
3199949|NCT01198821|Experimental|Oral sodium bicarbonate and Gemcitabine|
3199950|NCT01198795|Experimental|1|Flexible-dose 10mg-20mg once-daily oral (10mg tablets) dose of escitalopram
3199951|NCT01198782|Experimental|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|SYSTANE® ULTRA Lubricant Eye Drops dosed 4 times daily
3199952|NCT01198769|Experimental|Rotarix Group|subjects received 2 oral doses of Rotarix™ vaccine at 2 and 4 months of age.
3199953|NCT01198756|Experimental|GSK2282512A 1 Group|Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3199954|NCT01198756|Active Comparator|Victoria strain Fluarix Group|Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3199955|NCT01198756|Active Comparator|Yamagata strain Fluarix Group|Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3199956|NCT01198756|Experimental|GSK2282512A 2 Group|Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants <12 months of age.
3199957|NCT01198730|Other|Acarbose|Acarbose for DM patient with HbA1c > 6.5%. Add on sitagliptin if HbA1c > 7.0% after 26 weeks.
3199958|NCT01198704||HCC patients|Patients notified on the national waiting list for hepatic transplant
3199959|NCT01198691|Placebo Comparator|Control Group|This group will receive the standard metallic staples to close their incision.
3199960|NCT01198691|Experimental|Case Group|This group will receive the Insorb absorbable staples to close their incision.
3199961|NCT01198665|Experimental|RAD001-CHOP|Prospective multicenter open-label phase I/II study Phase I: RAD001 2.5 - 10 mg PO daily D1-14 + CHOP every 3 weeks Phase II: Determined dosage of RAD001 + CHOP every 3 weeks Treatment will be continued until planned 6 cycles or disease progression
3199962|NCT01198652||Belfort-Dildy Obstetric Tamponade Tx|Patients treated with Belfort-Dildy Obstetric Tamponade System are eligible for inclusion in the cohort.
3199963|NCT01198639|Active Comparator|manual administration of iv anesthetics|
3199964|NCT01198639|Experimental|closed-loop administration of iv anesthetics|
3199965|NCT01198626|Experimental|JNJ-32729463|
3199966|NCT01198626|Active Comparator|moxifloxacin|
3199967|NCT01198626|Experimental|JNJ-32729463 Open-Label|subjects with suspected or confirmed S. aureus CABP may be entered into an open-label JNJ 32729463 treatment group at selected study sites
3199968|NCT01198613|Placebo Comparator|Placebo|
3199969|NCT01198613|Experimental|ToleroMune Ragweed Regimen 1|
3199970|NCT01198613|Experimental|ToleroMune Ragweed Regimen 2|
3199971|NCT01198613|Experimental|ToleroMune Ragweed Regimen 3|
3199972|NCT01198613|Experimental|ToleroMune Ragweed Regimen 4|
3199973|NCT01198600|Other|Phase 1: Habitual no Replacement, then Habitual Replacement|Contact lenses per participant's habitual prescription worn for 30 days with no replacement, followed by contact lenses per habitual prescription worn for 30 days with a replacement pair dispensed at Day 28.
3199974|NCT01198600|Other|Phase 1: Habitual Replacement, then Habitual no Replacement|Contact lenses per participant's habitual prescription worn for 30 days with replacement pair dispensed at Day 28, followed by contact lenses per habitual prescription worn for 30 days with no replacement.
3199975|NCT01198600|Other|Phase 2: Lotrafilcon B Replacement|Contact lenses worn for 56 days with replacement pair dispensed at Day 28.
3199976|NCT01198600|Other|Phase 3: Lotrafilcon B Replacement Replacement|Contact lenses worn for 43 days with replacement pair dispensed at Day 1 and Day 28.
3199977|NCT01198587|Experimental|Outpatient Zinc Sulfate|Zinc Sulfate
3199978|NCT01198587|Experimental|Inpatient Zinc Sulfate|Zinc Sulfate
3199979|NCT01198587|Placebo Comparator|Outpatient Placebo|Placebo oral capsule
3199980|NCT01198587|Placebo Comparator|Inpatient Placebo|Placebo oral capsule
3199981|NCT01198574|Experimental|Iron group|
3199982|NCT01198574|Experimental|Vitamin A group|Vitamin A group
3199983|NCT01198574|Experimental|Iron and Vitamin A group|Iron and Vitamin A group
3199984|NCT01198574|Experimental|Placebo group|Placebo group with folic acid
3199985|NCT01198561||repetitive Transcranial Magnetic Stimulation|repetitive Transcranial Magnetic Stimulation is a depressive patient group treated with rTMS
3200101|NCT01197573|Active Comparator|Standard DCD kidney transplant|Standard method of kidney transplant utilizing a DCD organ
3200102|NCT01197573|Active Comparator|rTPA Treatment Kidney Transplant|Ex-vivo treatment of kidney donated after cardiac death (DCD) with rTPA
3199986|NCT01198548|Experimental|Treatment (FOLXFOX, bevacizumab, cholecalciferol)|Patients receive high-dose cholecalciferol once daily. Patients also receive bevacizumab IV over 10 minutes, leucovorin calcium IV over 2 hours, oxaliplatin* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *Treatment with oxaliplatin is discontinued after course 8
3199987|NCT01198535|Experimental|Arm A (RO4929097, cetuximab)|Patients in Arm A will receive cetuximab at the standard dose: 400 mg/m2 IV loading dose on Day 1 followed by cetuximab 250 mg/m2 IV weekly. The RO4929097 will be dose escalated starting at 20 mg given daily 3 days on, 4 days off, weekly. The dose levels of RO4929097 to be explored will be 20 mg, 30 mg, 45 mg, 90 mg, 140 mg given days 1-3 weekly. No intrapatient dose escalation will be allowed.
3199988|NCT01198535|Experimental|Arm B (RO4929097, cetuximab)|Patients in Arm B will receive cetuximab 200 mg/m2 IV weekly without a loading dose. The RO4929097 will be dose escalated starting at 20 mg given daily 3 days on, 4 days off, weekly. The dose levels of RO4929097 to be explored will be 20 mg, 30 mg, 45 mg, 90 mg, 140 mg given days 1-3 weekly. No intrapatient dose escalation will be allowed.
3199989|NCT01198522|Other|Therapy of L19IL2 and Gemcitabine|Dose escalation study. Part A) Gemcitabine dose escalation. Part B) L19IL2 dose escalation.
3199990|NCT01198509|Active Comparator|Rheumatoid Arthritis (RA) - doxycycline|Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive doxycycline, 100 mg twice a day, for 2 months.
3199991|NCT01198509|Active Comparator|Rheumatoid Arthritis (RA) - vancomycin|Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive vancomycin, 250 mg four times a day, for 2 weeks
3199992|NCT01198509|No Intervention|RA, PsA, healthy|"Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive no antibiotic treatment for comparison with Doxycycline- and Vancomycin-treated patients.~Patients with psoriatic arthritis (PsA), to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.~Healthy individuals with no history of arthritis, to provide baseline samples of oral and intestinal microbiota for comparison with RA patients."
3199993|NCT01198496|Experimental|Blood pressure|"The incidence of recurrent stroke will be lower in a strict BP control group having lower BP target: less than 120/80 mmHg* than in a standard BP control group having BP target less than 140/90 mmHg or less than 130/80 mmHg for current DM/CKD/old MI in patients with hypertension.~This study uses BP target: less than 120/80 mmHg that is sat up for this study rather than the BP target recommended in the Guidelines for the management of hypertension, Japanese Society of Hypertension 2009.~BP management is strongly recommended in patients with hypertension, DM, and/or CKD for prevention of recurrent stroke in the Japanese guidelines for the management of stroke 2009."
3199994|NCT01198483|Active Comparator|Micro|Microincision cataract surgery
3199995|NCT01198483|Active Comparator|Small|Smallincision cataract surgery
3199996|NCT01198470|Experimental|TRIUMPH® Artificial Disc|Treatment of degenerative disc disease with the TRIUMPH Lumbar Artificial Disc. This is a non-randomized pilot study with only one arm (no control).
3199997|NCT01198457||Group 1|
3199998|NCT01198444||Group 1|
3199999|NCT01198431|Experimental|Sleep restriction|Each participant will be engaged in three consecutive nights of 4 hours of sleep per night (from 3.00 a.m. to 7.00 a.m.)
3200000|NCT01198431|Placebo Comparator|Normal sleep duration|Each participant will be engaged in three consecutive nights of 9 hours of sleep per night (from 10.00 p.m. to 7.00 a.m.)
3200001|NCT01198418|Experimental|Internet-based counseling|
3200002|NCT01198418|No Intervention|Survey Alone|
3200003|NCT01198405|Experimental|Enhanced External Counterpulsation|Treatment of Enhanced External Counterpulsation (EECP) with a prespecified protocol on top of guideline-driven standard medical therapy.
3200004|NCT01198405|Active Comparator|Control|Guideline-driven standard medical therapy.
3200005|NCT01198392|Experimental|S-1 plus cisplatin|S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks.Number of Cycles: until progression or unacceptable toxicity develops.
3200006|NCT01198392|Active Comparator|5-Fu plus cisplatin|5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.Number of Cycles: until progression or unacceptable toxicity develops.
3200007|NCT01198379|Experimental|Aspirin|
3200008|NCT01198379|Placebo Comparator|Sugar pills|Hemodialysis (HD) patients receive placebo not containing aspirin in this study.
3200009|NCT01198366|Placebo Comparator|Dose Finding Gr 1 placebo x 2|Subjects received two doses (x2) of placebo (sterile buffer) on study days 0 and 28.
3200010|NCT01198366|Experimental|Dose Finding Gr 2 AERAS-402 (1.5 x 10^10 vp) x2|Subjects received two doses (x2) of AERAS-402 (1.5 x 10^10 vp) on study days 0 and 28.
3200011|NCT01198366|Experimental|Dose Finding Gr 3 AERAS-402 (3.0 x 10^10 vp) x 2|Subjects received two doses (x2) of AERAS-402 (3.0 x 10^10 vp) on study days 0 and 28.
3200012|NCT01198366|Experimental|Dose Finding Gr 4 AERAS-402 (1.0 x 10^11 vp) x 2|Subjects received two doses (x2) of AERAS-402 (1.0 x 10^11 vp) on study days 0 and 28.
3200013|NCT01198366|Experimental|Expanded Safety Phase Gr 5 AERAS-402 (1.0 X 10^11 vp) x 3|Subjects received 3 doses (x3) of AERAS-402 (1.0 X 10^11 vp) on days 0, 28 and 280.
3200014|NCT01198366|Placebo Comparator|Expanded Safety Phase Gr 5 Placebo x3|Subjects received 3 doses (x3) of placebo (sterile buffer) on days 0, 28 and 280.
3200015|NCT01198353|Experimental|Ziprasidone|During the 12-week study period, patients were prescribed ziprasidone at 20 to 160 mg/day flexibly based on their effectiveness and tolerability. Fifty to one hundred percent of the past antipsychotic dose was maintained in the first week; during next 3 weeks, flexible dosing of 0-100% was used; then, ziprasidone was discontinued. This study included four visits: baseline, week 4, week 8, and week 12. Concomitant benzodiazepines (oral formula or injection) were allowed up to a dose of 4 mg of lorazepam-equivalents per day for anxiety and agitation.
3200016|NCT01198340|Active Comparator|With basal local anesthetics|
3200017|NCT01198340|Experimental|Without basal local anesthetics|
3200018|NCT01198327|Experimental|Ranibizumab as needed|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart; with optional peripheral laser to areas of non-perfusion.
3200019|NCT01198314|Experimental|LT, withdrawal of immunosuppression|
3200020|NCT01198314|Active Comparator|LT, maintenance of immunosuppression|
3200103|NCT01197560|Experimental|Lenalidomide|
3200021|NCT01198288|Active Comparator|Standard Care|"Drugs for COPD (as prescribed), oxygen therapy if needed*, check-up by the general practitioner and/or respirologist as usual.~Educational leaflet regarding optimization of oxygen therapy and drugs; Benefits of physical activity and proposal of a programme of exercise training; Energy conservation techniques; Nutritional counselling; Activity of daily Living (ADL) diary; Prevention and management of acute exacerbation~Monthly phone call with the aim of verifying:~the patients' clinical conditions;~the patient's adherence to the pharmacological treatments prescribed~the patient's compliance in filling out the clinical diary and the ADL diary"
3200022|NCT01198288|Experimental|domiciliary rehabilitation|"Same as the standard care group plus 10 (ten) home-based visits supervised by a specifically trained respiratory therapist (education+exercise training) Autonomous home-based programme: The patients will be given instructions and training in order to continue the exercise training programme on the days the respiratory therapist is not visiting them.~Counselling addressed at the outdoor activities."
3200023|NCT01198275|Active Comparator|n-3 PUFAs|
3200024|NCT01198275|Placebo Comparator|placebo|
3200025|NCT01198249|Experimental|amlodipine monotherapy|
3200026|NCT01198249|Experimental|losartan monotherapy|
3200027|NCT01198249|Experimental|HCTZ|
3200028|NCT01198249|Experimental|mlodipine and Losartan and HCTZ|
3200029|NCT01198223|Other|drug: garlic extract, nystatin|Drug: garlic extract 40mg/dl or nystatin suspension 100000 iu/ml tid for one month Patients had been clinically with denture stomatitis and confirmed by oral medicine specialist were selected for the study. Gender, age, medical history, erythema types, size, and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received garlic extract and second group used nystatin suspension for 1 month. Each patients was examined at the beginning of the therapy ,and then every 1 weeks up to 1 months .
3200030|NCT01198210|Placebo Comparator|saline|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
3200031|NCT01198210|Active Comparator|ketamine|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
3200032|NCT01198210|Active Comparator|dexamethasone|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
3200033|NCT01198210|Active Comparator|dexamethasone-ketamine|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
3200034|NCT01198184|Experimental|Treatment (temsirolimus and RO4929097)|Patients receive temsirolimus IV over 30 minutes on day -6 (course 1 only). Patients then receive temsirolimus IV or PO on days 1, 8, and 15 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3200035|NCT01198171||Basic science (DNA analysis)|DNA from archived frozen normal tissue samples is genotyped for the ancestry informative markers. Clinicopathological and demographic characteristics associated with each sample are also collected.
3200036|NCT01198158|Active Comparator|Arm I (everolimus)|Patients receive everolimus PO QD on days 1-28.
3200037|NCT01198158|Experimental|Arm II (everolimus with bevacizumab)|Patients receive everolimus PO QD on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 15.
3200038|NCT01198145|Experimental|Arm I: Sulfasalazine|Patients receive oral sulfasalazine twice daily during radiotherapy and for 4 weeks after completion of radiotherapy.
3200039|NCT01198145|Placebo Comparator|Arm II: Placebo|Patients receive oral placebo twice daily during radiotherapy and for 4 weeks after completion of radiotherapy.
3200040|NCT01198132|Experimental|Cholecalciferol|Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 3 times a week.
3200041|NCT01198132|Placebo Comparator|Placebo|Subjects receive matching placebo to Cholecalciferol once every two weeks along with subcutaneous injection of Rebif 3 times weekly.
3200042|NCT01198119|Experimental|Patient with oral cavity cancer|Patient treated by surgery for the oral cavity cancer
3200043|NCT01198080|Experimental|femoral osteonecrosis patients|patientswith femoral head osteonecrosis
3200044|NCT01198067|Experimental|Pomalidomide Schedule A|Starting dose 1 mg orally for 28 days
3200045|NCT01198067|Experimental|Pomalidomide Schedule B|Starting dose level 1 mg orally for 21 days then 7 days rest
3200046|NCT01198054|Experimental|Lenalidomine|Post-induction lenalidomide in patients with de novo AML with deletion 5q cytogenetic abnormality (del (5q)) or monosomy 5 (-5)
3200047|NCT01198028|Experimental|Erlotinib|Erlotinib 150 mg by mouth for 8 weeks.
3200048|NCT01198015||Rett syndrome girls|The study population (identical to the population in the preliminary research project) consists of a well-defined group of thirteen Dutch RTT girls with complete clinical, molecular, neurophysiological and metabolic work-up.
3200104|NCT01197560|Active Comparator|Investigators Choice|"One of the following:~Lenalidomide, Gemcitabine, Oxaliplatin, Rituximab, or Etoposide"
3200105|NCT01197547|Other|Genesys HTA|Genesys HTA Endometrial Ablation
3200106|NCT01197534|Experimental|Dosing Regimen A|Oral Treatment
3200107|NCT01197534|Experimental|Dosing Regimen B|Oral Treatment
3200049|NCT01198002|Experimental|120 milligrams (mg) LY2127399|"Given every 4 weeks (Q4W) for 100 weeks. Participants receive a 240 mg loading dose when initiating treatment. During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks (Q2W).~At Weeks 16 and 52, responders will receive 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 100-week treatment period.~At Week 16, non-responders (NR) will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
3200050|NCT01198002|Experimental|90 mg LY2127399|"Given Q2W for 100 weeks. Participants receive a 180 mg loading dose when initiating treatment.~At Weeks 16 and 52, responders will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q4W for the rest of the 100-week treatment period.~At Week 16, NR will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
3200051|NCT01198002|Placebo Comparator|Placebo|"Given Q2W for 52 weeks. At Week 16, responders will receive 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 52 weeks.~At Week 52, responders are randomized to receive 1 of the 2 doses of LY2127399, with loading dose of 240 mg or 180 mg of LY2127399, followed by 120 mg of LY2127399 Q4W or 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.~At Week 16, NR will receive a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
3200052|NCT01197989|Experimental|TEPSO socks|This arm include all patients sides (left or right) treated with TEPSO socks.
3200053|NCT01197989|Placebo Comparator|Standard socks|This arm include all patients sides (left or right) treated with standard cotton socks.
3200054|NCT01197976|Experimental|TEPSO socks|This arm include all patients sides (left or right) treated with TEPSO socks.
3200055|NCT01197976|Placebo Comparator|Standard socks|This arm include all patients sides (left or right) treated with standard cotton socks.
3200056|NCT01197963|Other|Surgical treatment|Surgical treatment of one arm of the patient population.
3200057|NCT01197963|Other|Medically controlled group|Managed by endocrinologists using current medical therapy such as pills, injections and life style medication.
3200058|NCT01197950|Active Comparator|Manual Acupuncture|Manual stimulation
3200059|NCT01197950|Experimental|Electro Acupuncture|Electrical and manual stimulation
3200060|NCT01197950|No Intervention|Standard care|No acupunture
3200061|NCT01197924||healthy volonteer children|paired for the sex and the age
3200062|NCT01197924||older children followed for a médulloblastome cérébelleux|children followed for a médulloblastome treaty by surgery, radiotherapy and chemotherapy
3200063|NCT01197911|Experimental|Mild impairment|
3200064|NCT01197911|Experimental|Moderate impairment|
3200065|NCT01197911|Experimental|Normal HF|
3200066|NCT01197898|Experimental|Collagenase Santyl|Ointment applied once daily
3200067|NCT01197898|Placebo Comparator|Vehicle Base|Applied once daily
3200068|NCT01197885|Experimental|IMAB362|Two different doses (antibody / body surface area) of IMAB362 will be administered sequentially.
3200069|NCT01197846|Experimental|Quetiapine|Quetiapine 300 mg or 600 mg
3200070|NCT01197846|Placebo Comparator|Placebo|
3200071|NCT01197833|Experimental|Endovenous ablation+polidocanol injectable microfoam 0.125%|Endovenous ablation followed by an injection of polidocanol injectable microfoam 0.125% to target vein
3200072|NCT01197833|Experimental|Endovenous ablation+polidocanol injectable micrfoam, 1.0%|Endovenous ablation followed by injection of polidocanol injectable microfoam, 1.0% to the target vein
3200073|NCT01197833|Active Comparator|endovenous ablation+vehicle (placebo)|endovenous ablation followed by injection of vehicle (placebo) to target vein
3200074|NCT01197820|Experimental|Arm 1|30 patients with liver tumour and 15 patients with kidney tumour will be enrolled.
3200075|NCT01197807|Active Comparator|Bulb suctioning|Bulb suctioning of mouth and nose immediately after delivery
3200076|NCT01197807|Active Comparator|Wiping|Gentle wiping of mouth then nose with soft cloth
3200077|NCT01197794|Experimental|AZD1981 10 mg|AZD1981 10 mg
3200078|NCT01197794|Experimental|AZD1981 40 mg|AZD1981 40 mg
3200079|NCT01197794|Experimental|AZD1981 100 mg|AZD1981 100 mg
3200080|NCT01197794|Experimental|AZD1981 400 mg|AZD1981 400 mg
3200081|NCT01197794|Experimental|AZD1981 80 mg|AZD1981 80 mg
3200082|NCT01197794|Experimental|AZD1981 200 mg|AZD1981 200 mg
3200083|NCT01197794|Placebo Comparator|Placebo|
3200084|NCT01197781|Experimental|Period 1|
3200085|NCT01197781|Experimental|Period 2|
3200086|NCT01197768|Experimental|Nutrition Intervention|The intervention group will receive a full nutrition assessment and a nutrition intervention.
3200087|NCT01197768|No Intervention|Control|This group will receive the nutrition assessment but no intervention from a Registered Dietician. If participant appears to be in danger due to BMI or Caloric intake status, their primary care physician will be notified.
3200088|NCT01197755|Experimental|Dosing Regimen A|Oral Treatment
3200089|NCT01197755|Experimental|Dosing Regimen B|Oral Treatment
3200090|NCT01197755|Placebo Comparator|Dosing Regimen C|Oral Treatment
3200091|NCT01197729||STEMI|(ST-Elevation myocardial infarction)
3200092|NCT01197729||NSTEMI|Non-ST-Elevation myocardial infarction
3200093|NCT01197664|Experimental|Arm I (paricalcitol and chemoradiotherapy)|Patients receive paricalcitol PO daily. Patients also receive standard care chemoradiotherapy with fluorouracil PO.
3200094|NCT01197664|Active Comparator|Arm II (chemoradiotherapy)|Patients receive standard care chemoradiotherapy as in Arm I.
3200095|NCT01197625|Experimental|DC-vaccine|
3200096|NCT01197612|Other|Single Arm; nostrils as experimental and comparator|each subject serves as their own control with one nostril being treated with pulmicort and one not
3200097|NCT01197599||Spinal Cord Injury|
3200098|NCT01197599||Able-Bodied Control|
3200099|NCT01197573|Active Comparator|Standard DCD liver transplant|Standard method of liver transplant utilizing a DCD organ
3200100|NCT01197573|Active Comparator|rTPA Treatment Liver Transplant|Ex-vivo treatment of liver donated after cardiac death (DCD) with rTPA
3200111|NCT01197521|Placebo Comparator|Dosing Regimen C|Oral Treatment
3200112|NCT01197508|Experimental|0.1 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 0.1 mg BID
3200113|NCT01197508|Experimental|1 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1 mg BID
3200114|NCT01197508|Experimental|4 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 4 mg BID
3200115|NCT01197508|Placebo Comparator|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
3200116|NCT01197495|Experimental|Treatment|Juvederm(R) Ultra XC Injectable Gel
3200117|NCT01197495|Experimental|Control|No treatment for 3 months followed by Juvederm(R) Ultra XC Injectable Gel at Month 3.
3200118|NCT01197469|Placebo Comparator|Placebo|Placebo
3200119|NCT01197469|Active Comparator|Tadalafil|
3200120|NCT01197456||Exposed/chemotherapy|Breast cancer patients who will undergo chemotherapy
3200121|NCT01197456||Unexposed|Breast cancer patients who will not undergo chemotherapy
3200122|NCT01197443|Experimental|Parent-only Group|Treatment will be administered to parents of the overweight child. Parent-only group treatment will include all of the same skills and techniques to promote weight loss, but the information will be delivered only to the parent. Participation of the children assigned to the parent-only treatment arm will be limited to the baseline and follow-up assessments.
3200123|NCT01197443|Active Comparator|Parent + child Group|The treatment for participants in the parent + child arm will be administered in two separate groups, one for the parents and one for the child.
3200124|NCT01197417|Experimental|Magnesium group|Intravenous Magnesium Sulfate
3200125|NCT01197417|Placebo Comparator|Placebo group|Normal Saline placebo
3200126|NCT01197404|Active Comparator|General Health Promotion|
3200127|NCT01197404|Experimental|Affect Management|
3200128|NCT01197391|Experimental|Cohort 1|Dose 1 versus placebo
3200129|NCT01197391|Experimental|Cohort 2|Dose 2 versus placebo
3200130|NCT01197378|Experimental|Cysteamine Bitartrate|Cysteamine bitartrate delayed-release capsules were administered twice daily for up to 96 months.
3200131|NCT01197365|Experimental|STUDY GROUP|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae"
3200132|NCT01197365|Other|CONTROL GROUP|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients
3200133|NCT01197352|Experimental|Text message queries with feedback|Weekly prompted queries about drinking behavior with personalized feedback.
3200134|NCT01197352|Active Comparator|Text message queries|Weekly prompted queries about drinking behavior
3200135|NCT01197352|No Intervention|Control|Weekly text reminders to complete final (12 week) instruments
3200136|NCT01197339|Experimental|treatment|
3200137|NCT01197339|Sham Comparator|Controls|
3200138|NCT01197326||Group 1|Patients who triggered MET/RRT calls prior to the use of the MP5 EWS patient monitor.
3200139|NCT01197326||Group 2|Patients who triggered MET/RRT calls after the use of the MP5 EWS patient monitor.
3200140|NCT01197313|Experimental|Exercise|
3200141|NCT01197300|Experimental|zoledronic acid|zoledronic acid
3200142|NCT01197287|Experimental|QAK423A Arm A|
3200143|NCT01197287|Experimental|QAK423A Arm B|
3200144|NCT01197287|Experimental|QAK423A Arm C|
3200145|NCT01197274||Mite-sensitized person|
3200146|NCT01197261|Active Comparator|OXN PR|Oxycodone Naloxone tablets
3200147|NCT01197261|Placebo Comparator|PLA|
3200148|NCT01197248|Active Comparator|Cystocele Plication|Placement of sutures over the pubocervical fascia during cystocele repair.
3200149|NCT01197248|Experimental|No Plication|Avoid sutures over pubocervical fascia during cystocele repair
3200150|NCT01197235|Experimental|darbepoetin-α|Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
3200151|NCT01197235|Placebo Comparator|isotonic saline|Infusion of isotonic saline will be performed 1 hour before angiography
3200152|NCT01197222|Active Comparator|EndoClear used|The EndoClear device is used during a laparoscopic abdominal surgery.
3200153|NCT01197222|No Intervention|Control|EndoClear Lens Cleaning Device not used during a laparoscopic abdominal surgery.
3200154|NCT01197209|Experimental|Ad-REIC/Dkk-3 Arm|Active arm on Ad-REIC/Dkk-3
3200155|NCT01197196|Experimental|Behavioral weight loss|
3200156|NCT01197196|Active Comparator|Migraine Education|
3200157|NCT01197170|Experimental|Anastrozole|1 mg PO (by mouth) daily for 28 days.
3200158|NCT01197170|Experimental|Anastrozole + Bevacizumab|Anastrozole 1 mg PO daily and Bevacizumab starting dose 10 mg IV Day 1 of 21 day cycle. Expansion group added when MTD dose of Anastrozole + Bevacizumab found.
3200159|NCT01197170|Experimental|Anastrozole + Everolimus|Anastrozole 1 mg PO daily and Everolimus starting dose 5 mg PO daily for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Everolimus found.
3200160|NCT01197170|Experimental|Anastrozole + Sorafenib|Anastrozole 1 mg PO daily and Sorafenib starting dose 200 mg PO twice a day for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Sorafenib found.
3200161|NCT01197170|Experimental|Anastrozole + Erlotinib|Anastrozole 1 mg PO daily and Erlotinib starting dose 75 mg PO daily for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Erlotinib found.
3200162|NCT01197157|Placebo Comparator|placebo|"• Group A: comprises 100 chronic hepatitis patients who will receive placebo twice daily orally with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.~All patients in this group will have an HCV RNA within 3 months before initiation of therapy, in addition to ALT levels, CBC and other routine liver function tests."
3200204|NCT01196910|Active Comparator|Stimulation over the left dorsolateral prefrontal cortex|Group A (fifteen subjects) - treatment by HLPFC coil high-frequency stimulation over the left dorsolateral prefrontal cortex (DLPFC).
3200163|NCT01197157|Experimental|Nitazoxanide|"• Group B: comprises 100 CHC patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.~All patients in this group will have an HCV RNA within 3 months before initiation of therapy, in addition to ALT levels, CBC and other routine liver function tests."
3200164|NCT01197144|Active Comparator|Adalimumab|Treatment with adalimumab 40 mg sc eow for 4 weeks
3200165|NCT01197144|Placebo Comparator|Placebo|Treatment with placebo s c eow for 4 weeks
3200166|NCT01197144|No Intervention|Healthy Controls|"Healthy volunteers, age ≥18. Will perform all the same pain assessments, blood sampling and baseline fMRI as RA patients~Exclusion criteria:~For fMRI - left handedness and all forms of metallic implants.~Fulfilling ACR criteria for fibromyalgia.~Severe ischemic heart disease.~Concurrent treatment for depression/anxiety with antidepressant drugs.~Concurrent neurological disease.~Other reason as evaluated by the P.I."
3200167|NCT01197131||autistic boys|Boys with autism spectrum disorder, age 5-15 years, diagnosis meets DSM-IV criteria ascertained by ADI-R or ADOS schedule or specialised paediatrician
3200168|NCT01197131||autistic girls|Girls with autism spectrum disorder, age 5-15 years, diagnosis meets DSM-IV criteria ascertained by ADI-R or ADOS schedule or specialised paediatrician.
3200169|NCT01197131||control boys|"Healthy boys, age 5-15 years, mental status assessed by Marburger Beurteilungsskala zum Asperger-Syndrome (MBAS)."
3200170|NCT01197131||control girls|"Healthy girls, age 5-15 years, mental status assessed by Marburger Beurteilungsskala zum Asperger Syndrome (MBAS)."
3200171|NCT01197118|Active Comparator|2|chemotherapy alone following radical resection
3200172|NCT01197118|Experimental|1|sequence chemoradiotherapy following radical resection
3200173|NCT01197105|Experimental|Aroeira|
3200174|NCT01197092|Active Comparator|Verum|
3200175|NCT01197092|Experimental|Control|
3200176|NCT01197079||MSM|Young men (under 26 years of age) who have sex with men
3200177|NCT01197079||Parents|Parents of Boys aged 9 to 18 years
3200178|NCT01197066|Other|Certolizumab Pegol|Single Arm
3200179|NCT01197053|Experimental|100 mcg DBV712 (active)|100 mcg DBV712 administered epicutaneously every 24 hours.
3200180|NCT01197053|Placebo Comparator|Placebo|Placebo will be administered epicutaneously every 24 hours
3200181|NCT01197040|Experimental|B-Experimental|Experimental
3200182|NCT01197040|Active Comparator|A-Active Comparator|Active Comparator
3200183|NCT01197027|Experimental|Enhanced counseling|5 intensive counseling sessions following acute HIV infection
3200184|NCT01197027|Active Comparator|Standard counseling|Standard HIV counseling following acute HIV infection
3200185|NCT01197014|Experimental|Amlodipine plus Losartan|
3200186|NCT01197014|Active Comparator|Amlodipine, Losartan|
3200187|NCT01197001|Experimental|Amlodipine plus Losartan|
3200188|NCT01197001|Active Comparator|Amlodipine, Losartan|
3200189|NCT01196988|Experimental|GSK2321138A 1 Group|Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
3200190|NCT01196988|Active Comparator|Fluarix Group|Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
3200191|NCT01196988|Active Comparator|GSK2604409A Group|Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
3200192|NCT01196988|Experimental|GSK2321138A 2 Group|Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
3200193|NCT01196975|Experimental|GSK2282512A 1 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3200194|NCT01196975|Experimental|GSK2282512A 2 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3200195|NCT01196975|Experimental|GSK2282512A 3 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3200196|NCT01196975|Active Comparator|Victoria Strain FluLaval Group|Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3200197|NCT01196975|Active Comparator|Yamagata Strain FluLaval Group|Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3200198|NCT01196962|Experimental|Internal jugular vein|
3200199|NCT01196949|Active Comparator|Manipulative and Rehabilitative Therapy|
3200200|NCT01196949|Active Comparator|Rehabilitative Therapy|
3200201|NCT01196936|Experimental|Arm I (tamoxifen citrate)|Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
3200202|NCT01196936|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
3200203|NCT01196923|Experimental|HeartLight Ablation|
3200205|NCT01196910|Active Comparator|stimulation over the right DLPFC|Group B (fifteen subjects) - Treatment by HLPFC coil high-frequency stimulation over the right DLPFC.
3200206|NCT01196910|Placebo Comparator|Treatment with HLPFC coil simulator mode|Group C (fifteen subjects) - Treatment with HLPFC coil simulator mode (sham).
3200207|NCT01196897|Experimental|Implantable device|WATCHMAN LAA Closure Technology (Gen 4.0)
3200208|NCT01196884||Asymptomatic ITP patients|
3200209|NCT01196884||ITP patients treated with Rituximab|
3200210|NCT01196884||ITP patients treated with steroids|
3200211|NCT01196871|Experimental|Low dose A|Lower dose of AT1001 with Fabrazyme.
3200212|NCT01196871|Experimental|High dose A|Higher dose of AT1001 with Fabrazyme.
3200213|NCT01196871|Experimental|Low dose B|Low dose AT1001 with Replagal
3200214|NCT01196871|Experimental|High dose B|Higher dose of AT1001 with Replagal.
3200215|NCT01196845|Other|obese + cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
3200216|NCT01196845|Other|obese + Sham cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
3200217|NCT01196845|Other|non-obese + cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
3200218|NCT01196845|Other|non-obese + Sham cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
3200219|NCT01196832||Chronic obstructive pulmonary disease patients|"COPD patients with exacerbation will be recruited during hospitalization in Intensive care unit or as outpatients in the clinical investigation centre of the CHU de Bordeaux.~Inclusion visit: blood sample for fibrocytes analysis. Second visit 2 months ± 7 days after the exacerbation: clinical and functional evaluation (plethysmography, TLCO, arterial gaz), blood sample for fibrocytes analysis."
3200220|NCT01196832||Control group|Subjects without any history of lung disease and with normal lung function testing
3200221|NCT01196819|Active Comparator|Xience V|Implantation of Xience V drug eluting stent
3200222|NCT01196819|Experimental|Firehawk|Implantation of Firehawk drug eluting stent
3200223|NCT01196793||febrile children, age 3 m to 5 y|
3200224|NCT01196780||Cohort|
3200225|NCT01196767|Experimental|ropivacaine|
3200226|NCT01196767|Other|normal saline|
3200227|NCT01196754|Other|sevoflurane|
3200228|NCT01196741|Active Comparator|Saracatinib plus weekly paclitaxel|
3200229|NCT01196741|Placebo Comparator|Placebo plus weekly paclitaxel|
3200230|NCT01196728|Experimental|CM3.1-AC100 dose A|Compound CM3.1-AC100 s.c.
3200231|NCT01196728|Experimental|CM3.1-AC100 dose B|Compound CM3.1-AC100 s.c.
3200232|NCT01196728|Experimental|CM3.1-AC100 dose C|Compound CM3.1-AC100 s.c.
3200233|NCT01196728|Placebo Comparator|Placebo|Placebo for compound CM3.1-AC100 s.c.
3200234|NCT01196715|Active Comparator|Darbepoetin Alfa|
3200235|NCT01196715|Active Comparator|G-CSF|
3200236|NCT01196715|Active Comparator|Best Supportive Care|Red cell transfusion support to achieve a predicted post-transfusion haemoglobin of 11.0 to 12.0 g/dl at a quantity and frequency such that the minimum haemoglobin is never below 8.0 g/dl
3200237|NCT01196702||CVID|Patients with common variable immunodeficiency
3200238|NCT01196702||CVID and granulomatous disease|Patients with CVID complicated with granulomatous inflammation
3200239|NCT01196702||CVID and bronchiectasis|Patients with CVID complicated by bronchiectasis
3200240|NCT01196702||Control on Immunoglobulin|Patients on immunoglobulin long-term who do not have an immunodeficiency
3200241|NCT01196702||Control bronchiectasis|Controls with bronchiectasis not caused by a known immunodeficiency
3200242|NCT01196702||Control with granulomatous disease|Control patients with Crohn's Disease as this is a disease that causes granulomatous inflammation.
3200243|NCT01196702||Healthy Controls|
3200244|NCT01196689|Experimental|1|AZD1981 100 mg twice daily for 6 ½ days
3200245|NCT01196676|Experimental|1|AZD4451
3200246|NCT01196676|Placebo Comparator|2|Placebo
3200247|NCT01196650|Active Comparator|1|IN 10 003 formulation A
3200248|NCT01196650|Active Comparator|2|IN 10 003 formulation B
3200249|NCT01196650|Placebo Comparator|3|Placebo capsules
3200250|NCT01196637||Thoracic outlet syndrome|These patients have documented thoracic outlet syndrome
3200251|NCT01196637||Normal Subjects|These patients have no thoracic outlet syndrome
3200252|NCT01196624|Active Comparator|TMS TO RT DLPF WITH EXPOSURE|TMS TO RIGHT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE
3200253|NCT01196624|Active Comparator|TMS TO RIGHT DLPF BRAIN AREA WITHOUT EXPOSURE|TMS TO RIGHT DLPF BRAIN AREA WITHOUT EXPOSURE
3200254|NCT01196624|Active Comparator|TMS TO LEFT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE|TMS TO LEFT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE
3200255|NCT01196624|Active Comparator|TMS TO LEFT DLPF BRAIN AREA WITHOUT EXPOSURE|TMS TO LEFT DLPF BRAIN AREA WITHOUT EXPOSURE
3200256|NCT01196611|Experimental|Function Voice Exercises|Behavioral: Function Voice Exercises Patients will receive 6 sessions of therapy over a course of 6 weeks, with one session per week.
3200257|NCT01196611|Experimental|Voice amplification|Behavioral: Voice amplification Patients will use VA over a course of 6 weeks.
3200258|NCT01196598|Active Comparator|PFMT group|Women who undergo to three months of a pelvic floor muscle training program.
3200259|NCT01196598|Active Comparator|HE + PFM group|Women who undergo to three months of a hypopressive exercises plus pelvic floor muscle contraction program.
3200260|NCT01196598|Active Comparator|HE group|Women who undergo to three months of a hypopressive exercises program.
3200261|NCT01196598|Active Comparator|Control|Women who undergo to a session for lifestyle advice.
3200262|NCT01196585|Experimental|Patients under CT- guided pleural biopsy|Arm A: Patients who go under CT-guided pleural needle biopsy for pleural diseases
3200410|NCT01195493|Active Comparator|control group|
3200263|NCT01196585|Experimental|Patients under ultrasonography guided needle biopsy|Arm B: Patients who go under ultrasonography guided cutting needle pleural biopsy for pleural diseases
3200264|NCT01196572|Experimental|Laser IU|Urethral stricture incised by Holmium laser
3200265|NCT01196572|Active Comparator|Cold knife IU|Urethral stricture incised by knife
3200266|NCT01196559|Experimental|Vinorelbine and Gemcitabine|Vinorelbine 25 ㎎/㎡ and Gemcibine1000㎎/㎡ D1, D8 every 3weeks
3200267|NCT01196546|Experimental|Vildagliptin/metformin|
3200268|NCT01196533|Experimental|Non Invasive Monitoring|Single group of hospitalized cardiovascular patients.
3200269|NCT01196507|Experimental|Carvedilol|Tablet Carvedilol 12.5 mg BD or maximum tolerated dose
3200270|NCT01196507|Placebo Comparator|Placebo|Placebo tablets 2 to 4 BD
3200271|NCT01196494|Experimental|intraoperative colon lavage|
3200272|NCT01196494|Active Comparator|stent and deferred surgery|
3200273|NCT01196481|Experimental|Carvedilol+VSL#3|Tablet Carvedilol 6.25 mg BD + VSL#3
3200274|NCT01196481|Active Comparator|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3-4 weeks till variceal ligation
3200275|NCT01196468||Anal/cervical dyplasia|Any patient presenting for care with any degree of anal or cervical dysplasia
3200276|NCT01196468||STI|Any patient presenting for care with any non-HIV sexually transmitted infection
3200277|NCT01196468||Lymphoma|Any patient presenting for care with malignant lymphoma of any histological type
3200278|NCT01196468||Seborrhoeic dermatitis/exanthema|Any patient presenting for care with seborrhoeic dermatitis/exanthema
3200279|NCT01196468||Thromobocytopaenia/Leucopaenia, or hypergammaglobulinaemia|Any patient presenting for care with unexplained thromobocytopaenia/leucopaenia of more than four weeks duration, or with hypergammaglobulinaemia
3200280|NCT01196442|Experimental|Arm I electric stimulation pain therapy|Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
3200281|NCT01196429|Experimental|Treatment (paclitaxel, carboplatin, temsirolimus, docetaxel)|"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus IV on days 1 and 8. Treatment repeats every 3 weeks for 6 courses. Patients then receive consolidation therapy comprising temsirolimus IV on days 1, 8, and 15. Treatment repeats every 3 weeks for 11 courses in the absence of disease progression or unacceptable toxicity.~NOTE: * For circumstances in which docetaxel should be substituted for paclitaxel, docetaxel is given IV over 1 hour."
3200282|NCT01196416|Experimental|Treatment (RO4929097, cisplatin, vinblastine, temozolomide)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21, cisplatin IV over 30 minutes and vinblastine IV over 30 minutes on days 1-3, and temozolomide PO QD on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without progressive disease continue to receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 and temozolomide as above in the absence of disease progression or unacceptable toxicity.
3200283|NCT01196390|Experimental|Arm I (radiotherapy, chemotherapy, trastuzumab)|Patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Patients also receive trastuzumab IV over 30-90 minutes on days 1, 8, 15, 22, 29, 36, and 57 and paclitaxel intravenously IV over 60 minutes and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Beginning 21-56 days after surgery, patients receive trastuzumab IV over 30-90 minutes. Treatment repeats every 21 days for 13 courses in the absence of disease progression or unacceptable toxicity.
3200284|NCT01196390|Experimental|Arm II (radiotherapy and chemotherapy)|Patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Patients also receive paclitaxel IV over 60 minutes and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
3200285|NCT01196377|Active Comparator|Nebulized albuterol 10mg/hr continuous|Active control arm, 10mg/hr continuous.
3200286|NCT01196377|Experimental|10mg/hr pulsed|Experimental 10mg/hr pulsed albuterol regimen.
3200287|NCT01196377|Experimental|25mg/hr continuous|Experimental 25mg/hr continuous albuterol.
3200288|NCT01196377|Experimental|25mg/hr pulsed|Experimental 25mg/hr pulsed albuterol
3200289|NCT01196364|Experimental|Sedentary activity, noncaloric beverage|
3200290|NCT01196364|Experimental|Sedentary activity, glucose beverage|
3200291|NCT01196364|Experimental|Exercise activity, noncaloric beverage|
3200292|NCT01196364|Experimental|Exercise activity, glucose beverage|
3200293|NCT01196351|Experimental|Sedentary activity, noncaloric beverage|
3200294|NCT01196351|Experimental|Sedentary activity, glucose beverage|
3200295|NCT01196351|Experimental|Exercise activity, noncaloric beverage|
3200296|NCT01196351|Experimental|Exercise activity, glucose beverage|
3200297|NCT01196338|Active Comparator|Non-weightbearing no ROM|"Patients will be placed in a back slab post-op and will remain non-weight bearing with crutches with no range of motion for a total of 6 weeks.~After 6 weeks post-op, they will be placed in a boot orthosis and permitted to weight-bear as tolerated."
3200298|NCT01196338|Experimental|Early weight-bearing and ROM|"Patients will be placed in a back slab post-operatively. At 2 weeks post op they will have the back slab removed and placed in a boot orthosis. At this time they will be permitted to weight-bear as tolerated and perform limited ankle range of motion exercises.~After 6 weeks post op they will start to wean from the boot orthosis."
3200299|NCT01196325||Laser Group|Patients who are clinically indicated for the laser treatment
3200300|NCT01196325||Anti-VEGF Group (Bevacizumab)|Patients who are clinically indicated for the intravitreal injection of Bevacizumab
3200301|NCT01196325||Anti-VEGF Group (Ranibizumab)|Patients who are clinically indicated for intravitreal injection of Ranibizumab
3200302|NCT01196325||Age-matched controls|Group of non-diabetic participants who will be age and gender matched
3200303|NCT01196299||Severe Traumatic Brain Injury Group|The severe traumatic brain injury group are patients admitted to the study with an admission GCS between 3 and 8.
3200304|NCT01196299||Moderate Head Injury Group|The moderate head injury group are patients admitted to the study with an admission GCS from 9 to 12.
3200305|NCT01196299||Mild Head Injury Group|The mild head injury group are patients admitted to the study with an admission GCS from 13 to 15.
3200306|NCT01196299||Healthy Volunteer Group|Healthy volunteers will be selected to match the age distribution of the TBI groups. They must be absent of any abnormal radiological findings.
3200307|NCT01196286|Experimental|MFG and CR|Subjects provided with both multifamily psychoeducation (MFG) and cognitive remediation (CR)
3200308|NCT01196286|Active Comparator|MFG|Subjects provided with only multifamily group psychoeducation (MFG)
3200309|NCT01196273||Regional Ruhrgebiets Cohort|
3200310|NCT01196260|Experimental|5-fluorouracil plus oxaliplatin|patients will be randomized assigned to receive 5-fluorouracil plus oxaliplatin
3200311|NCT01196234|Experimental|Paclitaxel/Carboplatin/Gefitinib|Paclitaxel/Carboplatin/Gefitinib
3200312|NCT01196234|Active Comparator|Paclitaxel/Carboplatin|Paclitaxel/Carboplatin
3200313|NCT01196221||Patients with 30 to 70% carotid artery stenosis|
3200314|NCT01196195|Experimental|QD kaletra|Once daily kaletra
3200315|NCT01196195|Active Comparator|BID kaletra|twice daily dose of kaletra
3200316|NCT01196169|Experimental|Daptomycin|Half of patients anticipated to be enrolled will receive daptomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.
3200317|NCT01196169|Active Comparator|Vancomycin|Half of patients anticipated to be enrolled will receive vancomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.
3200318|NCT01196130||Biomarker Assessment|Leftover sample of tumor tissue from a previous procedure used for biomarker testing. Blood drawn for biomarker testing, to check for levels of cytokines, and to check the circulating tumor cells (CTCs). Cancer Symptom Questionnaire completion about cancer symptoms.
3200319|NCT01196117|Active Comparator|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
3200320|NCT01196117|Placebo Comparator|14 days of Placebo therapy|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
3200321|NCT01196104|Experimental|Technosphere® Insulin Inhalation Powder (TI)|Insulin Glargine and Technosphere® Insulin Inhalation Powder
3200322|NCT01196104|Active Comparator|Comparator|Insulin Glargine and Insulin Aspart
3200323|NCT01196091|Experimental|LY2127399 every 2 weeks|Administered SC
3200324|NCT01196091|Experimental|LY2127399 every 4 wks|During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
3200325|NCT01196091|Placebo Comparator|Placebo|Administered SC
3200326|NCT01196078|Experimental|1|
3200327|NCT01196078|Active Comparator|2|
3200328|NCT01196065|Experimental|Single Arm|
3200329|NCT01196052|Experimental|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg was administered intravenously on Day 1 of each 3-week treatment cycle up to a maximum of 17 cycles.
3200330|NCT01196039|Experimental|A|
3200331|NCT01196039|Placebo Comparator|B|
3200332|NCT01196026|Experimental|Fluarix 6-11 months Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
3200333|NCT01196026|Experimental|Fluarix 12-35 months Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
3200334|NCT01196026|Experimental|Fluarix 3-9 years Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
3200335|NCT01196026|Active Comparator|Havrix Junior 6-11 months Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
3200336|NCT01196026|Active Comparator|Havrix Junior 12-35 months Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
3200337|NCT01196026|Active Comparator|Havrix Junior 3-9 years Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
3200338|NCT01196013|Experimental|Clofarabine|
3200339|NCT01196000|Active Comparator|Arm I|Patients undergo standard conventional laparoscopic resection.
3200340|NCT01196000|Experimental|Arm II|Patients undergo robotic-assisted laparoscopic resection.
3200341|NCT01195987||Hepatitis C with Arthritis|
3200342|NCT01195987||Hepatitis C without Arthritis|
3200343|NCT01195974|Experimental|Period 1|YASMIN + 200 mg GSK2248761 or Placebo
3200344|NCT01195974|Experimental|Period 2|YASMIN + 200 mg GSK2248761 or Placebo
3200345|NCT01195974|Other|Run In Period|YASMIN
3200346|NCT01195948|Experimental|B27PD 1 mg|Participants randomly assigned to the B27PD 1 mg arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
3200347|NCT01195948|Experimental|B27PD 4 mg|Participants randomly assigned to the B27PD 4 mg arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
3200348|NCT01195948|Placebo Comparator|Placebo|Participants randomly assigned to the placebo arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
3200349|NCT01195922|Experimental|Sirolimus|Subjects will be treated with sirolimus 21 days
3200350|NCT01195883|Active Comparator|Crystalloid|Lactated Ringers solution will be used for fluid replacement.
3200351|NCT01195883|Active Comparator|Colloid|Low-molecular weight colloid HES 130/0.4 (Voluven) will be used for fluid replacement
3200352|NCT01195844||Brazilian Children With Rotavirus Gastroenteritis|Brazilian children under 5 years of age who have diarrhea attributed to rotavirus located in 4 hospitals from 4 different Brazilian regions
3200353|NCT01195831|Experimental|Xamiol® gel|Calcipotriol (as hydrate) 50mcg/g plus betamethasone 0.5mg/g (dipropionate)
3200354|NCT01195831|Active Comparator|Calcipotriol scalp solution|Calcipotriol (as hydrate) 50 mcg/ml
3200355|NCT01195818|Experimental|RAS Inhibitors|RAS Inhibitors
3200356|NCT01195805|Active Comparator|Amiloride|
3200357|NCT01195805|Active Comparator|Spironolactone|
3200358|NCT01195805|Placebo Comparator|Placebo|1 tablet twice a day for 28 days
3200359|NCT01195792|Experimental|2 mg GSK1521498|Approximately 20 subjects will be randomised to receive 2 mg GSK1521498. The drug is being developed for the treatment of obesity due to excessive consumption of high calorie foods
3200360|NCT01195792|Experimental|5 mg GSK1521498|Approximately 20 subjects will be randomised to receive 5 mg GSK1521498. The drug is being developed for the treatment of obesity due to excessive consumption of high calorie foods
3200361|NCT01195792|Placebo Comparator|Placebo|Approximately 20 subjects will be randomised to receive matching placebo.
3200362|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A1 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.
3200363|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A1 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.
3200364|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A2 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.
3200365|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A2 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.
3200366|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A3 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.
3200367|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A3 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.
3200368|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B1 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.
3200369|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B1 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.
3200370|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B2 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.
3200371|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B2 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.
3200372|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B3 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.
3200373|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B3 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.
3200374|NCT01195779|Experimental|GSK2321138A vaccine Group|Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).
3200375|NCT01195779|Active Comparator|Fluarix Group|Subjects received 2 doses of Fluarix Vaccine.
3200376|NCT01195766|Experimental|Ofatumumab|Ofatumumab in addition to ESHAP therapy
3200377|NCT01195753|Experimental|Liver Cell Infusion|
3200378|NCT01195740|Experimental|Attachment Based Family Therapy|
3200379|NCT01195740|Active Comparator|Enhanced Usual Care|
3200380|NCT01195727|Experimental|Group 5A - Apixaban (Low Dose)|"Group 5: 12 years to <18 years;~0.66 mg/m² Oral solution, Oral, Twice A Day (BID), 10 days"
3200381|NCT01195727|Experimental|Group 5B - Apixaban (High Dose)|"Group 5: 12 years to <18 years;~1.32 mg/m² Oral solution, Oral, Twice A Day (BID), 10 days"
3200382|NCT01195714|Experimental|Ofatumumab|
3200383|NCT01195701||Anorgasmia (cases)|Women with difficulty or inability to reach sexual climax will be the cases in this study.
3200384|NCT01195701||Normal orgasmic function|Women who report that they usually or always achieve sexual climax will be the controls in this study.
3200385|NCT01195688|Experimental|BI 638683|1 single dose per subject as oral solution
3200386|NCT01195688|Placebo Comparator|Placebo solution|1 single dose per subject as oral solution
3200387|NCT01195675|Experimental|BI 10773|single oral (high and low) dose per subject
3200388|NCT01195675|Placebo Comparator|Placebo|2 single oral doses per subject
3200389|NCT01195675|Active Comparator|Moxifloxacin|single oral dose per subject
3200390|NCT01195662|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg tablets
3200391|NCT01195662|Placebo Comparator|Placebo matching Dapagliflozin|Placebo tablets matching dapagliflozin tablets
3200392|NCT01195649||Group 1|
3200393|NCT01195636|Experimental|XPF-002|
3200394|NCT01195636|Placebo Comparator|Placebo|
3200395|NCT01195623|Active Comparator|varicose vein surgery with preop duplex|The surgeon has planned surgery for varicose veins from a clinical examination and has then the extra information available from a preoperative duplex examination to plan surgery more in detail
3200396|NCT01195623|No Intervention|varicose vein surgery no preop duplex|The surgeon has planned surgery for varicose veins from a clinical examination only
3200397|NCT01195610|Experimental|New Nordic Diet|New Nordic Diet
3200398|NCT01195610|Experimental|Average Danish Diet|Average Danish Diet
3200399|NCT01195597|Experimental|E-Cigarette 7.2 mg nicotine|Well characterized group of 40 regular smokers not intending to quit experimenting the E-Cigarette with 7.2 mg nicotine cartridges.
3200400|NCT01195584||BMI < 25|Body Mass Index (WHO) established by WHO. BMI < 25 has been defined as 'normal weight'.
3200401|NCT01195584||25 >= BMI < 30|Body Mass Index (WHO) established by WHO. BMI >= 25 and < 30 has been defined as 'overweight'.
3200402|NCT01195584||BMI >= 30|Body Mass Index (WHO) established by WHO. BMI > 30 has been defined as 'obese'.
3200403|NCT01195571|No Intervention|vaccine administration|Each subject will receive on of four chimera CMV vaccines
3200404|NCT01195558||Blind with sleep problems|Blind individuals with no light perception and with sleep-related problems who may suffer from Non-24
3200405|NCT01195545|Experimental|Veritas Mesh in Hernia Repair|Subjects undergoing laparoscopic paraesophageal hiatal hernia repair using a bovine pericardium mesh (BP) (Veritas® Collagen Matrix, Synovis ®, St. Paul MN) as a reinforcing material during repair.
3200406|NCT01195532||Gliclazide/2|60 mg*1 for T 30 mg*2 For R
3200407|NCT01195532||Reference and test drug|Reference: 30 mg *2 Test: 60 mg *1
3200408|NCT01195519||peritoneal dialysis and hemodialysis patients|peritoneal dialysis and hemodialysis patients
3200409|NCT01195493|Experimental|test mouthrinse|
3200411|NCT01195480|Experimental|Prophylaxis arm|Patients who have relapsed in the bone marrow after previous myeloablative HSCT and achieve remission after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells after a second HSCT with reduced intensity conditioning.
3200412|NCT01195480|Experimental|Pre-emptive arm|In this arm, patients identified at high (> 50%) risk of relapse will be eligible for generation of donor-derived EBV CTL immediately prior to HSCT. These patients will be monitored for evidence of MRD in regular bone marrow aspirates for the first year post-HSCT. MRD positivity post-HSCT is highly predictive of subsequent relapse. In those patients who become MRD+ in the marrow at a level of minimum 5 x 10-4, cryopreserved CTL that have been transduced with a retroviral vector carrying the CD19-zeta transgene will be thawed and administered to the patient pre-emptively.
3200413|NCT01195467|Experimental|All Subjects Truvada/Raltegravir|All Subjects will receive the same intervention, Truvada/Raltegravir
3200414|NCT01195454|Experimental|Insulin glargine / New insulin glargine formulation|"Period 1: Insulin glargine~Period 2: New insulin glargine formulation~Period 3: New insulin glargine formulation~Period 4: New insulin glargine formulation~Duration of treatment: 1 day at each period"
3200415|NCT01195428|Active Comparator|Simvastatin|Simvastatin 40 mg daily.
3200416|NCT01195428|Placebo Comparator|Placebo|Placebo
3200417|NCT01195415|Experimental|Treatment (vismodegib, gemcitabine hydrochloride)|Patients receive vismodegib PO QD on days 1-28 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 (beginning in course 2). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3200418|NCT01195402|No Intervention|Control|Subjects do not receive any kind of active intervention.
3200419|NCT01195402|Active Comparator|pulmonary outpatient rehabilitation|Subjects participate in an outpatient pulmonary rehabilitation program
3200420|NCT01195389|Active Comparator|Resonator|Treatment with active Resonator device using low level magnetic fields
3200421|NCT01195389|Placebo Comparator|Placebo treatment|
3200422|NCT01195376|Experimental|BEZ235 Dose Escalation once daily|oral BEZ235 once daily (q.d.)
3200423|NCT01195376|Experimental|BEZ Dose escalation twice daily|oral BEZ235 twice daily (b.i.d.)
3200424|NCT01195363|Active Comparator|quetiapine SR|quetiapine SR, 200-600mg, po, qd
3200425|NCT01195363|Placebo Comparator|quetiapine sr Placebo|quetiapine SR placebo, 200-600mg, po qd
3200426|NCT01195350||stroke|
3200427|NCT01195337||Study Group|Newsletters, Physical Activity (PA) Prescription Plan, Pedometer
3200428|NCT01195324|Experimental|001|Canagliflozin/Warfarin Treatment A: Tablets oral canagliflozin 300 mg once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg single dose on Day 6 followed 14 days later by Treatment B: Tablets oral warfarin 30 mg single dose on Day 1
3200429|NCT01195324|Experimental|002|Canagliflozin/Warfarin Treatment B: Tablets oral warfarin 30 mg single dose on Day 1 followed 14 days later by Treatment A: Tablets oral canagliflozin 300 mg once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg single dose on Day 6
3200430|NCT01195311|Experimental|INCB024360|
3200431|NCT01195285|Active Comparator|Single-Incision Laparoscopic Cholecsytectomy (SILS)|
3200432|NCT01195285|Active Comparator|Traditional Laparoscopic Cholecystectomy (TLC)|
3200433|NCT01195272|Experimental|Single Arm|
3200434|NCT01195259||metformin|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
3200435|NCT01195259||rosiglitazone|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
3200436|NCT01195246|Experimental|HEPLISAV|0.5 mL HEPLISAV
3200437|NCT01195246|Active Comparator|Engerix-B|2.0 mL Engerix-B
3200438|NCT01195246|Active Comparator|Fendrix|0.5 mL Fendrix
3200439|NCT01195233|Other|bioxtra spray and mouth rinse|Drug: BioXtra spray or mouth rinse Patients had been xerostomia due to radiation of head and neck were selected for the study. Gender, age, medical history, VAS, dichotomous questionnaire of xerostomia , and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received BioXtra spray and second group used BioXtra mouth rinse for 2 weeks and then 1 weeks wash -out period and for other 2 weeks drugs is switched . Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and 35 days after first visit.
3200440|NCT01195220|Active Comparator|HIV-T|"Group 1, the control, will be the current standard of care, consenting video and testing for HIV alone (HIV-T).~This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test"
3200441|NCT01195220|Experimental|STI/HIV-T|"Group 2 will add routine STI testing for CT and GC, (STI/HIV-T).~This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED."
3200442|NCT01195220|Experimental|STI/HIV-Plus|"Group 3, in addition to combined STI/HIV testing, will add a behavioral video encouraging safer sex, which is chosen for participants based on their answers to a brief measure on stage of change (STI/HIV-PLUS).~This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes"
3200443|NCT01195207|Experimental|001|CNTO 3157 or placebo 0.003 mg/kg CNTO 3157 or placebo infusion
3200517|NCT01194765|Experimental|Cognitive Behavioural Therapy|
3200444|NCT01195207|Experimental|002|CNTO 3157 or placebo 0.01 mg/kg CNTO 3157 or placebo infusion
3200445|NCT01195207|Experimental|003|CNTO 3157 or placebo 0.03 mg/kg CNTO 3157 or placebo infusion
3200446|NCT01195207|Experimental|004|CNTO 3157 or placebo 0.1 mg/kg CNTO 3157 or placebo infusion
3200447|NCT01195207|Experimental|005|CNTO 3157 or placebo 0.3 mg/kg CNTO 3157 or placebo infusion
3200448|NCT01195207|Experimental|006|CNTO 3157 or placebo 1 mg/kg CNTO 3157 or placebo infusion
3200449|NCT01195207|Experimental|007|CNTO 3157 or placebo 3 mg/kg CNTO 3157 or placebo infusion
3200450|NCT01195207|Experimental|008|CNTO 3157 or placebo 10 mg/kg CNTO 3157 or placebo infusion
3200451|NCT01195194|Experimental|A- negative pre-transplant ELISPOT|Sirolimus: Start at 5 mg/day as soon as treatment allocation arrives to obtain targeting levels to 8 -15 ng/ml (immunoassay) in the first 3 months, followed by trough levels of 5-10 ng/ml.
3200452|NCT01195194|Experimental|B- Positive pre-transplant ELISPOT|Tacrolimus 0.1 mg/kg/12h starting as soon as treatment allocation arrives to obtain targeting troughs levels of 8-15 ng/ml the first 3 months, followed by trough levels of 5-10 ng/ml until the end of the study.
3200453|NCT01195181|Active Comparator|peginterferon alfa-2a plus ribavirin|patients will receive a fixed dose of 180ug/week of peginterferon alfa-2a plus ribavirin at 15mg/kg/daily.
3200454|NCT01195181|Active Comparator|peginterferon alfa-2b plus ribavirin|patients will receive a weight adjusted dose (1,5ug/kg) from 50 to 150ug/week of peginterferon alfa-2b (standard dose) or a lower dose (1,0ug/kg) at physician discretion (randomization list available only for 100 cases) plus ribavirin at 15mg/kg/daily.
3200455|NCT01195168||PCOS cohort|Women with PCOS as diagnosed by the NIH criteria
3200456|NCT01195168||Control cohort|Women without PCOS
3200457|NCT01195155|Active Comparator|LC n-3 PUFA|Supplementation with 4 x 1g fish oil capsules (Seven Seas, Ireland) containing 1.9g combined EPA and DHA daily for 6 weeks.
3200458|NCT01195155|Placebo Comparator|Placebo (olive oil) supplement|4 x 1g olive oil capsules (Millas Inc) were given daily for 6 weeks.
3200459|NCT01195155|No Intervention|Wash out period|A 6 week wash out period separated the LC n-3 PUFA and the Placebo (olive oil) arms. During this period the subjects took no supplements. This arm was designed to minimise a cross-over effect.
3200460|NCT01195142||PCOS-CSAT|Women with PCOS
3200461|NCT01195142||Control-CSAT|Control population consisting of women without PCOS, matched for age and BMI with the PCOS cohort
3200462|NCT01195129|Other|MicroVention Hydrogel Coils|FDA approved and in common use for cerebral aneurysm treatment.
3200463|NCT01195129|Active Comparator|Non-hydrogel coils|Cerecyte or bare platinum coils (FDA approved and in common use for treatment of cerebral aneurysm).
3200464|NCT01195116|Active Comparator|Dexmedetomidine|Dexmedetomidine is a FDA-approved medication that is a highly selective, short acting, alpha-2 adrenoreceptor agonist. To date, its safety and efficacy is well studied and established.It produces sedative, anxiolytic, and analgesic effects when used while patients undergo procedures and surgical operations.Interstitial Cystitis, as a chronic visceral pain syndrome, has the potential to have a neuropathic component for which an alpha-2 adrenergic agonist may be more effective than other classes, including opioids or NSAIDs.
3200465|NCT01195116|Placebo Comparator|Normal Saline|
3200466|NCT01195103|Experimental|10 mg/kg Lusedra|10 mg/kg Lusedra initial bolus.
3200467|NCT01195103|Active Comparator|6.5 mg/kg Lusedra|6.5 mg/kg Lusedra initial bolus.
3200468|NCT01195103|Active Comparator|Placebo + Midazolam|Placebo initial bolus with dose of midazolam based on patient's weight
3200469|NCT01195090|Active Comparator|sitagliptin|add sitagliptin100mg/d to pre-study OADs
3200470|NCT01195090|Active Comparator|pioglitazone|add pioglitazone 30mg/d to pre-study OADs
3200471|NCT01195077|Experimental|Seaweed, Spirulina, Seaweed + Spirulina|"Randomized to:~Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day."
3200472|NCT01195064||COPD+ OSAS- patients|Patients with chronic obstructive pulmonary disease (COPD) and without obstructive sleep apnea syndrome (OSAS), before planned cardiovascular surgery
3200473|NCT01195064||COPD- OSAS+ patients|Patients with obstructive sleep apnea syndrome (OSAS) and without chronic obstructive pulmonary disease (COPD), before planned cardiovascular surgery
3200474|NCT01195064||COPD+ OSAS+ patients|Patients with chronic obstructive pulmonary disease (COPD) and with obstructive sleep apnea syndrome (OSAS), with planned cardiovascular surgery
3200475|NCT01195064||COPD- OSAS- patients|Patients without chronic obstructive pulmonary disease (COPD) and without obstructive sleep apnea syndrome (OSAS), before planned cardiovascular surgery
3200476|NCT01195051|Experimental|Electronic medication reconciliation|Providers have access to a new, computer-based application to facilitate documentation and prescribing of outpatient medications in the inpatient setting.
3200477|NCT01195051|No Intervention|Control|
3200478|NCT01195025|Other|A.acetatedRingers, B.colloid & C.colloid+acetatedRingers|"First intervention: A. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by 150 minutes of equilibration, when blood samples were collected.~Washout >7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples."
3200479|NCT01195025|Other|A.colloid, B.colloid+acetatedRinger & C.acetatedRingers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout >7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected."
3200518|NCT01194765|No Intervention|Waiting List|
3200519|NCT01194713|Active Comparator|Sleep deprivation|"13 subjects will undergo full sleep deprivation~these subjects are blind to allocation ntil they enter the study center"
3200480|NCT01195025|Other|A.acetatedRingers, B.acetatedRingers+colloid & C.colloid|"First intervention: A. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout >7 days~Second intervention: B.Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples."
3200481|NCT01195025|Other|A.colloid, B.acetatedRingers & C.colloid+acetatedRingers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout >7 days~Second intervention: B. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout > 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples."
3200482|NCT01195025|Other|A.colloid+acetatedRingers, B.colloid & C.acetated Ringers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout >7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected."
3200483|NCT01195012|Other|wait-list control arm|Participants wait-listed to start the behavioral obesity treatment program (Helping HAND) after time two data collection (7 months after baseline).
3200484|NCT01195012|Experimental|Intervention arm|see intervention description
3200485|NCT01194999|Experimental|Pubovaginal sling procedure|Patients undergoing pubovaginal slings for stress urinary incontinence.
3200486|NCT01194986|Experimental|Pilot panel|[11C]AZ12807110 distribution and kinetics
3200487|NCT01194986|Experimental|Main panel|Histamine receptor occupancy reached by AZD5213
3200488|NCT01194973|Experimental|Eculizumab|
3200489|NCT01194960|Active Comparator|Docetaxel Alone|Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
3200490|NCT01194960|Experimental|TroVax plus Docetaxel|Subjects will receive both TroVax plus 10 cycles of Docetaxel.
3200491|NCT01194947||Study participants|patients 18 or older presenting to the Sheba Medical Center pigmented lesion clinic for skin cancer surveillance. Patients routinely undergo total skin examination that includes clinical and dermoscopic evaluation of skin lesions. Patients also routinely undergo annual total body digital photography that allows identification of new or changing lesions.
3200492|NCT01194934|Experimental|Group A|Group A: 2.0 mg/kg NOX-A12 IV every day for 5 days
3200493|NCT01194934|Experimental|Group B|Group B: 4.0 mg/kg NOX-A12 IV every day for 5 days
3200494|NCT01194934|Active Comparator|Group C|"The treatment groups will enter the study sequentially. The decision on starting groups C and D will be made after groups A and B have been completed and data are available.~Group C: 5 µg/kg filgrastim SC every day for 5 days"
3200495|NCT01194934|Experimental|Group D|"The treatment groups will enter the study sequentially. The decision on starting groups C and D will be made after groups A and B have been completed and data are available.~Group D: Safe and efficacious dose of NOX-A12 IV in combination with filgrastim SC for 5 days"
3200496|NCT01194908|Experimental|Arm A|Patients treated with decitabine and LBH589
3200497|NCT01194895|Experimental|protective ventilation|
3200498|NCT01194895|Active Comparator|conventional ventilation|
3200499|NCT01194882|Experimental|Insuman Implantable|Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.
3200500|NCT01194882|Active Comparator|Insuplant|Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.
3200501|NCT01194869|Experimental|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
3200502|NCT01194856|Active Comparator|Efavirenz 600 mg|Serving as the Control Arm - patients will maintain EFV-containing antiretroviral regimen
3200503|NCT01194856|Experimental|Arm B - Atazanavir/Ritonavir|Atazanavir 300 mg orally with Ritonavir 100 mg orally once daily for 96 wks
3200504|NCT01194843|Experimental|Ropivacaine|Ropivacaine administration by local per and post surgery infiltration
3200505|NCT01194843|Active Comparator|Physiological serum|Administration of physiological serum by local per and post surgery infiltration
3200506|NCT01194830|Active Comparator|Linagliptin|1 Tablet PO QD
3200507|NCT01194830|Placebo Comparator|Placebo|1 Tablet PO QD
3200508|NCT01194817|Other|Cemented fixation|Nexgen High-Flexion Knee Replacement System using Cemented Fixation
3200509|NCT01194817|Other|Cementless fixation|Nexgen High-Flexion Knee Replacement System using Cementless Fixation
3200510|NCT01194804|Experimental|Eculizumab|Treatment with eculizumab for patients with PNH who have successfully completed the C07-001 protocol
3200511|NCT01194791|Experimental|Lenalidomide, Cyclophosphamide and Dexamenthasone|
3200512|NCT01194778|Placebo Comparator|placebo|The participants of the placebo group will receive daily 1 placebo sachet containing only sucrose
3200513|NCT01194778|Active Comparator|vitamin K1|The participants of this group will receive daily 1 sachet containing 15 µg vitamin K1.
3200514|NCT01194778|Active Comparator|vitamin K2 - 15 µg|The participants of this group will receive daily 1 sachet containing 15 µg vitamin K2
3200515|NCT01194778|Active Comparator|vitamin K2 - 30 µg|The participants of this group will receive daily 1 sachet containing 30 µg vitamin K2
3200516|NCT01194778|Active Comparator|vitamin K2 - 45 µg|The participants of this group will receive daily 1 sachet containing 45 µg vitamin K2.
3200520|NCT01194713|No Intervention|Control night|control night of unrestricted sleep in 13 other subjects
3200521|NCT01194700|Experimental|Evohaler|
3200522|NCT01194700|Experimental|Volumatic spacer|
3200523|NCT01194700|Experimental|Aerochamber Plus|
3200524|NCT01194700|Experimental|Synchro-Breathe|
3200525|NCT01194674|Experimental|Microplasmin|
3200526|NCT01194648|Other|High Intensity Focused Ultrasound|HIFU, the Intervention
3200527|NCT01194622|Experimental|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
3200528|NCT01194622|Active Comparator|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
3200529|NCT01194622|Active Comparator|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
3200530|NCT01194609|Experimental|Low dose radiation, Immune cell therapy|Combination treatment of low-dose radiation 20cGy every 3 weeks three times and autologous immune cell therapy 2 consecutive weeks 3 times every 3 weeks
3200531|NCT01194596|Experimental|Spirometry and lifestyle counseling|Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
3200532|NCT01194596|No Intervention|Lifestyle counseling|No intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
3200533|NCT01194583||NO NICOTINE|Well characterized group of 100 regular smokers experimenting the E-Cigarette without nicotine cartridges (NO nicotine group).
3200534|NCT01194570|Experimental|Placebo|Participants with primary progressive multiple sclerosis (PPMS) received placebo matched to ocrelizumab at a schedule interval of 24 weeks up to at least 120 weeks.
3200535|NCT01194570|Placebo Comparator|Ocrelizumab 600 mg|Participants with PPMS received ocrelizumab as two IV infusions of 300 mg separated by 14 days at a scheduled interval of every 24 weeks up to at least 120 weeks.
3200536|NCT01194557|Active Comparator|rapid diagnostic test|Treatment and diagnosis of malaria in drugs hops using rapid diagnostic tests
3200537|NCT01194557|No Intervention|Presumptive malaria treatment|Presumptive treatment for malaria in drug shops
3200538|NCT01194544||population undergoing EGD in health examination.|
3200539|NCT01194531|No Intervention|CONTROL arm|Subjects assigned to this arm of the study will receive no PGS testing.
3200540|NCT01194531|Other|TEST arm|Subjects assigned to this arm of the study will receive PGS testing.
3200541|NCT01194518|Experimental|Lifestyle Intervention Program|
3200542|NCT01194505|Active Comparator|ACL, sciatic, femoral, obturator|ACL reconstruction surgery under ultrasound guided sciatic nerve block plus femoral nerve block plus obturator nerve block
3200543|NCT01194505|Active Comparator|ACL, sciatic nerve block, posterior lumbar plexus block|ACL reconstruction surgery under ultrasound guided sciatic nerve block plus posterior lumbar plexus block
3200544|NCT01194492|Other|Albumin kinetics|
3200545|NCT01194479|Active Comparator|Type 1 Diabetics|The active group were participants with type 1 diabetes.
3200546|NCT01194479|Other|Healthy Volunteers|The control group were participants without diabetes, matched by sex, age and BMI to the active comparator group.
3200547|NCT01194466|Active Comparator|Active TENS|Active high frequency TENS will be use for Active TENS.
3200548|NCT01194466|Experimental|Low Intensity TENS|Low Intensity TENS will be applied for one arm of the study
3200549|NCT01194466|Sham Comparator|No Treatment|TENS unit in place but not turned on
3200550|NCT01194453|Experimental|Group A|
3200551|NCT01194453|Active Comparator|Group B|
3200552|NCT01194440|Experimental|Arm I - IV Zoledronic Acid Prophylaxis|Patients receive zoledronic acid IV at months 1 and 6. Beginning 14 days after first zoledronic acid infusion, patients receive oral letrozole once daily for 12 months in the absence of disease progression or unacceptable toxicity.
3200553|NCT01194427|Experimental|Vorinostat and Tamoxifen|Vorinostat and tamoxifen are taken for about 14 days prior to definitive surgery.
3200554|NCT01194414|Experimental|Tocilizumab SC|"Participants received tocilizumab 162 mg subcutaneous (SC) injection weekly plus placebo to tocilizumab intravenous (IV) infusion every 4 weeks for a total of 24 weeks in the double-blind period. Participants continued to receive tocilizumab 162 mg SC injection weekly for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
3200555|NCT01194414|Experimental|Tocilizumab IV|"Participants received tocilizumab 8 mg/kg infusion (IV) every 4 weeks plus placebo to tocilizumab SC injection weekly for a total of 24 weeks in the double-blind period. Participants continued to receive tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
3200556|NCT01194414|Experimental|Tocilizumab SC Then Tocilizumab IV|"Participants who received tocilizumab 162 mg subcutaneous (SC) injection weekly plus placebo to tocilizumab IV infusion every 4 weeks for 24 weeks in double blind treatment period switched to tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
3200557|NCT01194414|Experimental|Tocilizumab IV Then Tocilizumab SC|"Participants who received tocilizumab 8 mg/kg infusion (IV) every 4 weeks plus placebo to tocilizumab SC injection weekly in double blind treatment period switched to tocilizumab 162 mg SC injection weekly for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose will be continued throughout the study."
3200558|NCT01194401||Cohort|
3200559|NCT01194388||MicroFx™ PGLA Treated Subjects|
3200560|NCT01194375|Experimental|Low Strength IDP-107|
3200561|NCT01194375|Experimental|High Strength IDP-107|
3200562|NCT01194375|Placebo Comparator|Placebo|
3200563|NCT01194362||45 specimens collected from BAV patients|
3200564|NCT01194362||45 specimens collected from TAV patients|
3200565|NCT01194362||15 specimens collected from CABG pts|
3200573|NCT01194323||Controls|No complaints or history of heartburn or acid regurgitation; no erosion at EGD; and normal pH monitoring
3200574|NCT01194323||GERD Cases|Patients with esophageal erosion at EGD and abnormal pH monitoring.
3200575|NCT01194310||phaco alone|patients w/ diagnosis of open angle glaucoma underwent phaco alone
3200576|NCT01194310||phaco-ELT|patients w/ diagnosis of open angle glaucoma underwent combined phaco plus ELT
3200577|NCT01194310||phaco-Trabectome|patients w/ diagnosis of open angle glaucoma underwent combined phaco plus Trabectome
3200578|NCT01194297|Experimental|Live attenuated influenza vaccine|One dose of live attenuated influenza vaccine, according to routine immunization recommendations
3200579|NCT01194297|Active Comparator|Inactivated influenza vaccine|One dose of inactivated influenza vaccine, according to routine immunization recommendations
3200580|NCT01194284||High-grade osteosarcoma patients|
3200581|NCT01194271|Experimental|Neoadjuvant Ipilimumab|Leuprolide Acetate 22.5 mg administered as a single intramuscular 3 month depot + Ipilimumab 10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy + Radical Prostatectomy Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
3200582|NCT01194258|Experimental|Lispro-PH20/Insulin lispro|"All enrolled participants underwent a titration period of 4 to 6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.~Next, participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.~Lispro-PH20 (Treatment A): 100 U/mL insulin lispro with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (combined: Lispro-PH20), injected SC, pre-meals, with doses titrated to each participant individually.~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually.~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
3200583|NCT01194258|Experimental|Aspart-PH20/Insulin Lispro|"All enrolled participants underwent a titration period of 4 to 6 weeks in which they received 100 U/mL insulin glulisine, injected SC, pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.~Aspart-PH20 (Treatment A): 100 U/mL insulin aspart with 5.0 µg/mL rHuPH20 (combined: Aspart-PH20), injected SC, pre-meals, with doses titrated to each participant individually.~Insulin lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually.~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
3200584|NCT01194245|Experimental|Lispro-PH20 / Insulin Lispro|"All enrolled participants underwent a titration period of 4-6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle with no washout period.~Lispro-PH20 (Treatment A): 100 U/mL insulin lispro with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, with doses titrated to each participant individually~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
3200585|NCT01194245|Experimental|Aspart-PH20 / Insulin Lispro|"All enrolled participants underwent a titration period of 4-6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle with no washout period.~Aspart-PH20 (Treatment A): 100 U/mL insulin aspart with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, with doses titrated to each participant individually~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
3200586|NCT01194232|Experimental|Sildenafil|15 subjects will receive 8 week course of Sildenafil administered at a dose of 20 mg per dose three times per day.
3200587|NCT01194219|Active Comparator|Apremilast|Subjects initially randomized to apremilast 30 mg twice a day, and who demonstrate a PASI 75 response at Week 32 will be randomized (1 to 1) to either continue to receive apremilast 30 mg ) BID or to receive placebo (until effect is lost). At the time effect is lost, subjects will be treated with apremilast 30 mg twice a day for the duration of their participation in the study.
3200588|NCT01194219|Placebo Comparator|Placebo|Subjects initially randomized to placebo, are assigned to apremilast 30 mg twice a day beginning at Week 16 for the duration of the subject's participation in the study.
3200589|NCT01194219|Active Comparator|Apremilast 30 mg|Apremilast 30 mg by mouth (PO) twice a day (BID). Participants initially randomized to apremilast 30 mg BID, and who were able to demonstrate a Psoriasis Area Severity Index (PASI) -75 response at week 32 were randomized (1 to 1) to either apremilast 30 mg BID or oral placebo (until effect is lost). At relapse/loss of response to therapy prior to Week 52 (the time at which 75% improvement in PASI score compared to baseline was lost) or at Week 52, participants were re-treated with apremilast 30 mg BID for the duration of their participation in the study. Non-responders or partial responders (PASI response <75) received additional topical therapies or phototherapy beginning at Week 32.
3200590|NCT01194206|Experimental|Arm I|Patients undergo 3 fractions of stereotactic body radiation therapy in 3 fractions delivered within 14 days in the absence of disease progression or unacceptable toxicity.
3200591|NCT01194193|Experimental|1|
3200592|NCT01194180|Experimental|Group A|"BCG-naive subjects receiving intradermal challenge injection of BCG and challenge site punch biopsy"
3200593|NCT01194180|Experimental|Group B|"BCG-naïve subjects receiving intradermal injection of MVA85A followed by intradermal challenge injection of BCG and challenge site punch biopsy"
3200594|NCT01194180|Experimental|Group C|"BCG-experienced subjects receiving intradermal challenge injection of BCG and challenge site punch biopsy"
3200595|NCT01194180|Experimental|Group D|"BCG-experienced subjects receiving intradermal injection of MVA85A followed by intradermal challenge injection of BCG and challenge site punch biopsy"
3200596|NCT01194167|Experimental|Eltrombopag|Eltrombopag 75 mg per day. Possible escalation to 150 mg per day after day 15 lab results. Possible escalation to 300 mg per day after day 29 lab results.
3200597|NCT01194154|Experimental|Mircera|
3200598|NCT01194154|Placebo Comparator|Placebo|
3200599|NCT01194141|Experimental|Exercise training|Aerobic exercise training 45-60 min/3x/week/12 weeks
3200600|NCT01194128|Experimental|Psychoeducatioinal Support|The intervention is comprised of three modules (see Table 6), each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.
3200601|NCT01194128|Active Comparator|INformation only control group|"Participants in the control group will receive a portion of the standardized packet of written information that is also provided to the treatment group. This packet will contain several fact sheets from a nationally-recognized expert source in caregiving (the Family Caregiver Alliance's National Center on Caregiving) and a national information and advocacy group (the National Citizens' Coalition for Nursing Home Reform). The fact sheets are relevant to the placement of a family member into a nursing home and are linked to the content areas covered in the intervention. Documents in this packet include Caregiving and Depression, End of Life Decision Making, and Taking Care of You: Self-Care for Family Caregivers from the Family Caregiver Alliance; and Family Involvement in Nursing Home Care, Problem Solving, and Residents' Rights from the National Citizen's Coalition."
3200602|NCT01194115|Experimental|Cephalexin and metronidazole|500 mg cephalexin per oral every 8 hours for total of 6 doses; 500 mg metronidazole per oral every 8 hours for total of 6 doses
3200603|NCT01194115|Placebo Comparator|Placebo/standard of care|Placebo pills per oral every 8 hours for total of 6 doses
3200604|NCT01194102|Experimental|Stroke Community Wellness Program|"Participants with stroke will attend a 12 week Community Wellness Program. The program consists of a Community Based Exercise Program at the YMCA (2x 1 hour exercise sessions per week with specially trained fitness instructors). They will also attend a 1 hour long Living with Stroke education session one time per week and an independent exercise session in the fitness centre one time per week."
3200605|NCT01194102|Active Comparator|Regular YMCA membership|"The control group will have access to YMCA facilities to use at their discretion but will not attend the Community Based Exercise Program for stroke survivors or the Living with Stroke education program. YMCA staff working with the control group will not receive specialized training in exercise and education for stroke survivors but will be trained on important safety precautions and contraindications to exercise after stroke."
3200606|NCT01194089|Active Comparator|Nasal Nicotine Spray|3 mg of nasal nicotine will be administered postoperatively.
3200607|NCT01194089|Placebo Comparator|Nasal Normal Saline Spray|1 ml of nasal normal saline spray will be administered postoperatively.
3200608|NCT01194076|Experimental|5day intensive treatment|
3200609|NCT01194063|Experimental|Omegaven|Administration of intravenous Omega-3 fish oil lipid emulsion 1 g/kg continuous infusion over 12-24 hrs
3200610|NCT01194050||Cohort|
3200611|NCT01194037|Experimental|Hanferon (low dose) sc weekly + RBV oral daily|
3200612|NCT01194037|Experimental|Hanferon (high dose) sc weekly + RBV oral daily|
3200613|NCT01194037|Active Comparator|Pegasys 180 ug sc weekly + RBV oral daily|
3200614|NCT01194024||Intubated within 24hrs of admission|All patients that are admitted to a participating burn center and intubated within 24 hours
3200615|NCT01193998|Active Comparator|Clinician exposed to Model result|
3200616|NCT01193998|Experimental|Clinician blinded to Model result|
3200617|NCT01193985|Experimental|Intervention|
3200618|NCT01193946||Single-arm design|There is currently considerable debate regarding the accuracy of the estimated average requirement (EAR) and the recommended dietary allowance (RDA) for older people. Very limited data obtained from older individuals are available to support the assumption that age does not affect protein requirement. Existing method like nitrogen balance has inherent limitations that diminish it from being considered a reference method. Indicator amino acid oxidation technique is emerging as an alternative method to measure dietary protein requirement. It is more accurate and less demanding. The current study will be the first time this technique is used with elderly adults and will provide an important foundation for geriatric nutrition research
3200619|NCT01193920|Experimental|1: GBS Trivalent Vaccine with aluminium - 20/20/20 μg|Non-pregnant women who received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
3200620|NCT01193920|Placebo Comparator|2: Placebo - Sterile saline|Non-Pregnant Women who received two injection of saline solution.
3200621|NCT01193920|Experimental|3: GBS Trivalent Vaccine - 0.5/0.5/0.5 µg|Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
3200622|NCT01193920|Experimental|4: GBS Trivalent Vaccine - 2.5/2.5/2.5 µg|Pregnant Women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
3200623|NCT01193920|Experimental|5: GBS Trivalent Vaccine - 5/5/5 µg|Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
3200624|NCT01193920|Placebo Comparator|6: Placebo - Sterile saline|Pregnant Women who received one injection of saline solution.
3200625|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 12.5 mcg|1 dose of 0.5 mL containing 12.5 mcg of Vi-CRM
3200626|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 5 mcg|1 dose of 0.5 mL containing 5 mcg of Vi-CRM
3200627|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 1.25 mcg|1 dose of 0.5 mL containing 1.25 mcg of Vi-CRM
3200628|NCT01193907|Active Comparator|Typherix|1 dose of 0.5 mL containing 25 mcg of Vi-polysaccharide
3200629|NCT01193894|Experimental|Profermin|
3200630|NCT01193894|Active Comparator|Fresubin|
3200631|NCT01193881|Experimental|Treatment (erlotinib, RO4929097)|Patients receive erlotinib hydrochloride PO QD on days 1-21 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3200632|NCT01193868|Experimental|RO4929097|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected for pharmacogenetic, pharmacodynamic, and biomarker studies by IHC, FISH, and TUNEL assay."
3200633|NCT01193842|Experimental|Arm A (VR-DA-EPOCH)|Patients receive vorinostat PO QD on days 1-5; rituximab IV on day 1; etoposide IV over 24 hours, doxorubicin hydrochloride IV over 24 hours, and vincristine sulfate IV over 24 hours on days 1-4; prednisone PO daily on days 1-5; and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3200634|NCT01193842|Experimental|ARM B (DA-R-EPOCH)|Patients receive rituximab, etoposide, doxorubicin hydrochloride, vincristine sulfate, prednisone, and cyclophosphamide as in Arm A. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3200635|NCT01193842|Experimental|ARM C (VR-CHOP)|Low-risk arm that closed after 2 participants were enrolled due to low accrual: Patients receive vorinostat PO QD on days 1-5; rituximab IV on day 1; doxorubicin hydrochloride IV over 24 hours, and vincristine sulfate IV over 24 hours on day 1; prednisone PO daily on days 1-5; and cyclophosphamide IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3200636|NCT01193829||NSCLC patients|
3200637|NCT01193816|Experimental|loxapine|loxapine
3200638|NCT01193816|Placebo Comparator|Placebo|Placebo
3200639|NCT01193803||Spondylodiscitis control group|Patients needing vertebral biopsy looking for tumoral etiology
3200640|NCT01193803||Prosthetic Joint Infection control group|Patients with primary prosthetic arthrosis surgery
3200641|NCT01193803||Septic arthritis control group|Arthrosic patients needing evacuating articular punction with leucocytes infiltration less than 1000 /mm3
3200642|NCT01193803||Spondylodiscitis case group|Patients suspected of Discitis and/or Vertebral Osteomyelitis is defined by the need of spinal biopsy in infectious context.
3200643|NCT01193803||Prosthetic Joint Infection case group|Patients suspected of Prosthetic Joint Infection defined by the need of surgical revision for diagnostic or therapeutic aiming in infectious context.
3200644|NCT01193803||Septic arthritis case group|Patients suspected of Septic arthritis without prosthesis were defined by the need of synovial punction and/or biopsy
3200645|NCT01193790|Experimental|Coblation|
3200646|NCT01193777|Placebo Comparator|Saline|
3200647|NCT01193777|Experimental|L-Carnitine|
3200648|NCT01193764|Experimental|cocoa|unsweetened 100% cocoa (Ghirardelli)
3200649|NCT01193764|Placebo Comparator|placebo|hydrolyzed gelatin powder (Gelita)
3200650|NCT01193751||asphyxiated newborns > 37 weeks of gestation|
3200651|NCT01193738|Active Comparator|active osteopathic compression|osteopathic compression of Pterygopalatine node
3200652|NCT01193738|Placebo Comparator|placebo osteopathic compression|placebo osteopathic compression
3200653|NCT01193725|Active Comparator|Prolonged Exposure Therapy (PE)|The PE protocol is based on manualized procedures, which are derived from the theory that effective treatment for PTSD requires that the underlying pathological fear structure be activated and paired with new information that is incompatible with the fear structure. PE involves imaginal exposure and in vivo exposure as the two primary strategies to elicit repeated confrontation of feared but objectively safe thoughts, feelings, situations and events.
3200654|NCT01193725|Experimental|Virtual Reality Exposure Therapy (VRET)|The VRET protocol follows the same procedures as the PE protocol with the primary exception being that all instances of imaginal exposure will be augmented by immersion into Virtual Iraq environments, thus creating a situation known as immersive exposure.
3200655|NCT01193725|Placebo Comparator|Waitlist|The waitlist (WL) participants will be asked to refrain from psychotherapy during the 5 weeks of study participation.
3200656|NCT01193712|Other|on-table non-responder|patients who do not show an improvement of more than or equal to 15% in LV dP/dtmax measured immediately after implantation of a cardiac resynchronization therapy device
3200657|NCT01193712|No Intervention|on-table responders|patients who do show an improvement of more than or equal to 15% in LV dP/dtmax measured immediately after implantation of a cardiac resynchronization therapy device
3200658|NCT01193699|Experimental|P1101|
3200659|NCT01193686|Experimental|Peer Visitation Training (Peer Mentor)|Veteran Peer Visitors participated in a 2-day training program and then provide at 1-5 visits to at least 2 recipients.
3200660|NCT01193686|Experimental|Peer Visitation|Veterans who received at least one visit from a Veteran Peer Visitor.
3200661|NCT01193660|Experimental|Umbilical Cord Blood & Erythropoietin & Rehabilitation|Allogenic umbilical cord blood infusion, erythropoietin injection & active rehabilitation
3200662|NCT01193660|Active Comparator|Erythropoietin & Rehabilitation|Erythropoietin injection, active rehabilitation
3200663|NCT01193660|Placebo Comparator|Only Rehabilitation|Active rehabilitation
3200664|NCT01193634|Experimental|Paradym RF ICD|Active implantable defibrillators range
3200665|NCT01193621|Active Comparator|haloperidol|"0.5, 1, 3 mg of haloperidol will be administered orally every 24 hours for 7 days to 4 healthy subjects in each dose level (a total of 12 subjects).~Dose groups are as follows; D2-receptor occupancy study Group Single Oral Dose No. of subjects~0.5 mg 4~1 mg 4~5 mg 4"
3200666|NCT01193608|Experimental|0.5 mg/kg AAB-003|
3200667|NCT01193608|Experimental|1 mg/kg AAB-003|
3200668|NCT01193608|Experimental|2 mg/kg AAB-003|
3200669|NCT01193608|Experimental|4 mg/kg AAB-003|
3200670|NCT01193608|Experimental|8 mg/kg AAB-003|
3200671|NCT01193608|Placebo Comparator|Placebo|
3200672|NCT01193595|Experimental|AVE8062/ bevacizumab|The combination of ombrabulin and bevacizumab will be administered every 3 weeks according to the following schedule: One day 1, ombrabulin will be administered as a 30 minutes intravenous (i.v) infusion. Bevacizumab will be administered as a 30-90 minutes i.v. infusion 24 hours after the end of ombrabulin infusion on day 2.
3200673|NCT01193582|Experimental|Group 1|
3200677|NCT01193569||Standard of Care|Standard of Care for stroke except mechanical therapy
3200678|NCT01193556|Active Comparator|Standard of Care|Traditional electrosurgery will be used for the tonsillectomy.
3200679|NCT01193556|Experimental|PlasmaBlade|The PEAK PlasmaBlade will be used for the tonsillectomy.
3200680|NCT01193543|Experimental|calanus oil|calanus oil 1 gram twice daily
3200681|NCT01193543|Placebo Comparator|olive oil|olive oil 1 gram twice daily
3200682|NCT01193530|Experimental|Bright Light Therapy|
3200683|NCT01193530|Placebo Comparator|Dim Red Light Therapy|After 14 days, Placebo Red Light group will begin receiving light therapy for another 14 days.
3200684|NCT01193517|Experimental|Phase I|Dose Escalation of Azacitidine + CAPOX (Capecitabine, Oxaliplatin)
3200685|NCT01193517|Experimental|Phase II|MTD of Azacitidine + CAPOX
3200686|NCT01193504|Active Comparator|Pred Forte|Patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Pred Forte BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
3200687|NCT01193504|Active Comparator|Lotemax|patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Lotemax BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
3200688|NCT01193491|Experimental|IPI-493|
3200689|NCT01193478|Active Comparator|Cohort 1|GS-5885 (3 mg), once daily or matching placebo, once daily
3200690|NCT01193478|Active Comparator|Cohort 2|GS-5885 (10 mg), once daily or matching placebo, once daily
3200691|NCT01193478|Active Comparator|Cohort 3|GS-5885 (30 mg), once daily or matching placebo, once daily
3200692|NCT01193478|Active Comparator|Cohort 4|GS-5885 ( up to 90 mg), once daily or matching placebo, once daily
3200693|NCT01193478|Active Comparator|Cohort 5|GS-5885 (up to 90 mg), once daily or matching placebo, once daily
3200694|NCT01193478|Active Comparator|Cohort 6 (optional)|GS-5885 (up to 90 mg), once daily or matching placebo, once daily
3200695|NCT01193465|Experimental|humidity|
3200696|NCT01193452|Experimental|S-1/LV|S-1 combined with Leucovorin
3200697|NCT01193452|Active Comparator|sLV5FU2|5-FU/LV infusion
3200698|NCT01193439||Patients with high risk|
3200699|NCT01193439||Patients in normal conditions|
3200700|NCT01193426||Cirrhosis patient|All consecutive patients with cirrhosis admitted to the five participating center Patients were hospitalized or treated in an ambulatory setting for treatment of ascites or complications of cirrhosis. Ascitic fluid was obtained by paracentesis according to the usual clinical management for these patients.
3200701|NCT01193413||Non-infected necrosis group|There is no necrosis infection in severe acute pancreatitis.
3200702|NCT01193413||Single drainage group|The patients with necrosis infection in severe acue pancreatitis were cured by single drainage.
3200703|NCT01193413||Combined surgery group|If there was no clinical improvement after single drainage about 7 days, an open necrosectomy was performed in the patients with necrosis infection.
3200704|NCT01193400|Experimental|Clofarabine-Cytarabine|Induction therapy with a combination of clofarabine and low-dose cytarabine followed by consolidation therapy with clofarabine and low-dose cytarabine
3200705|NCT01193387|Experimental|IDeg (M) IM1|
3200706|NCT01193387|Experimental|IDeg (M) IM2|
3200707|NCT01193374|Experimental|Parent/child tailored mailed materials|Family provided newsletters tailored to issues and readiness to change. Family receives educational nutrition DVD, pedometers for family activities and child nutrition/physical activity games
3200708|NCT01193374|Active Comparator|Basic information at single time|Family provided with high quality booklet from American Dietetic Association providing the same information that intervention arm received but not tailored.
3200709|NCT01193361|Experimental|Arm 1 - BMS-791325 plus peg-interferon alfa-2a and ribavirin|
3200710|NCT01193361|Experimental|Arm 2 - BMS-791325 plus peg-interferon alfa-2a and ribavirin|
3200711|NCT01193361|Placebo Comparator|Arm 3 - Placebo plus peg-interferon alfa-2a and ribavirin|
3200712|NCT01193348|Experimental|Eculizumab|
3200713|NCT01193335|Active Comparator|Group 1: Preterm infants|Infant born at < 37 weeks of gestation.
3200714|NCT01193335|Active Comparator|Group 2: Term infants|Infants born at ≥ 37 weeks of gestation
3200715|NCT01193296|Experimental|Vildagliptin|
3200716|NCT01193296|Active Comparator|Sitagliptin|
3200717|NCT01193283|Experimental|SAA hematologic response|Treatment-naive severe aplastic anemia patients will receive a low dose of cyclophosphamide (120mg/kg) and low dose cyclosporine ( target therapeutic level of 100-200 micrograms per liter). Cyclophosphamide will be given once daily for 4 doses. Cyclosporine will be started after cyclophosphamide completion, cyclosporine will be given twice daily. The dosing will be modified to attain the therapeutic level.
3200718|NCT01193270|Experimental|Vitamin E|A single intragastric dose of dl-α-tocopheryl acetate (Aquasol E®) 50 IU/kg.
3200719|NCT01193270|Placebo Comparator|Placebo|Sterile water in volume equal to that of the comparator drug.
3200720|NCT01193257|Experimental|Orteronel + prednisone|
3200721|NCT01193257|Placebo Comparator|Placebo + prednisone|
3200722|NCT01193244|Experimental|Orteronel + prednisone|
3200723|NCT01193244|Placebo Comparator|Placebo + prednisone|
3200724|NCT01193231||Acuvail 0.45%|Each subject will be randomized to the eye that they will use Acuvail in for 3 days after PRK
3200725|NCT01193231||Systane Ultra Preservative Free Tears|Each subject's contralateral eye (other eye) will use Sytane for 3 days after PRK surgery.
3200726|NCT01193218|Experimental|BI 10773 low dose QD|BI 10773 tablets low dose once a day
3200727|NCT01193218|Experimental|BI 10773 mid-low dose QD|BI 10773 tablets mid-low dose once a day
3200728|NCT01193218|Experimental|BI 10773 mid-high dose QD|BI 10773 tablets mid-high dose once a day
3200729|NCT01193218|Experimental|BI 10773 high dose QD|BI 10773 tablets high dose once a day
3200730|NCT01193218|Placebo Comparator|Placebo|Placebo tablets once a day
3200731|NCT01193205|Experimental|20 weeks skills group|Participants receive 20 weeks of Dialectical Behaviour Therapy Skills training, covering 5 modules: mindfulness, interpersonal effectiveness, emotional regulation, distress tolerance, dialectics.
3201333|NCT01188941|No Intervention|Standard of Care|
3200732|NCT01193205|No Intervention|Waitlist|Participants on the waitlist condition will be assessed at baseline and symptoms monitored at 10 weeks, 20 weeks and 8 months following baseline assessment. They will then be offered the active treatment.
3200733|NCT01193192||Arm #1 (Test Group)|100 subject administered Neevo® or NeevoDHA® daily
3200734|NCT01193192||Arm #2 (Control group)|100 subject administered a prenatal vitamin daily
3200735|NCT01193179|Experimental|OPC-262|
3200736|NCT01193166|Experimental|001|paliperidone palmitate 78 117 156 or 234 mg monthly injection for 12 months
3200737|NCT01193166|Active Comparator|002|olanzapine flexible dosing as prescribed by the study doctor for 12 months
3200738|NCT01193166|Active Comparator|003|paliperidone flexible dosing as prescribed by the study doctor for 12 months
3200739|NCT01193166|Active Comparator|004|aripiprazole flexible dosing as prescribed by the study doctor for 12 months
3200740|NCT01193166|Active Comparator|005|haloperidole flexible dosing as prescribed by the study doctor for 12 months
3200741|NCT01193166|Active Comparator|006|perphenazine flexible dosing as prescribed by the study doctor for 12 months
3200742|NCT01193166|Active Comparator|007|quetiapine flexible dosing as prescribed by the study doctor for 12 months
3200743|NCT01193166|Active Comparator|008|risperidone flexible dosing as prescribed by the study doctor for 12 months
3200744|NCT01193153|Experimental|001|paliperidone palmitate 78 117 156 234 mg (50 75 100 or 150 mg eq.) monthly by i.m. injection for 15 months
3200745|NCT01193153|Placebo Comparator|002|Placebo monthly by i.m. injection for 15 months
3200746|NCT01193140|Experimental|Arm A|
3200747|NCT01193127|Experimental|OMS302 Solution|OMS302 Solution
3200748|NCT01193127|Experimental|OMS302 Mydriatic Solution|OMS302 Mydriatic Solution
3200749|NCT01193127|Experimental|OMS302 Anti-inflammatory Solution|OMS302 Anti-inflammatory Solution
3200750|NCT01193127|Placebo Comparator|Balanced Salt Solution (BSS) Solution|Balanced Salt Solution (BSS) Solution
3200751|NCT01193114|Experimental|Ecologically-Based Behavioral Treatment|Ecologically-Based Treatment was provided over a period of 6 months. The treatment integrated independent housing, case management services and substance abuse counseling. Specifically, the mothers were housed in an apartment of their choice and received three months of utility and rental assistance of up to $600 per month.
3200752|NCT01193114|Active Comparator|Treatment as Usual|The Mothers were offered services provided through the family shelter.
3200753|NCT01193101|Experimental|LCZ696 100 mg|LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.
3200754|NCT01193101|Experimental|LCZ696 200 mg|LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.
3200755|NCT01193101|Experimental|LCZ696 400 mg|LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.
3200756|NCT01193101|Placebo Comparator|Placebo|Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.
3200757|NCT01193088||CMT1A|
3200758|NCT01193088||Genetically undefined CMT|Families/people with genetically undefined CMT with common causes ruled out.
3200759|NCT01193075||CMT1B|
3200760|NCT01193075||CMT2A|
3200761|NCT01193075||CMT4A|
3200762|NCT01193075||CMT4C|
3200763|NCT01193075||All other CMT|
3200764|NCT01193062|Experimental|Cohort 1|Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
3200765|NCT01193062|Experimental|Cohort 2|Subjects will be receive single oral doses of PF-04995274 not exceeding 15mg or a placebo
3200766|NCT01193049|Experimental|Prednisone, then Placebo|Prednisone in the first crossover treatment period and placebo in the second crossover treatment period
3200767|NCT01193049|Experimental|Placebo, then Prednisone|Placebo in the first crossover treatment period and prednisone in the second crossover treatment period
3200768|NCT01193036||Interview|
3200769|NCT01193036||Symptom Inventory Assessment|
3200770|NCT01193023|Active Comparator|Pressure support|"in this arm, pressure support will be recorded under 3 conditions:~with the initial Expiratory Trigger Setting (ETS)~with ETS +10%~with ETS -10%"
3200771|NCT01193023|Experimental|NAVA|Neurally Adjusted ventilatory Assist is a ventilation mode where the ventilator is piloted by the electrical activity of the diaphragm Ventilation is triggered and cycled off by the electrical activity of the diaphragm, the pressure delivered being proportional to this activity.
3200772|NCT01193010|Active Comparator|Control|Surgery without computer-assisted planning.
3200773|NCT01193010|Experimental|Computer-Assisted Surgical Planning|
3200774|NCT01192997|Active Comparator|Menveo-Meningitec|Subjects who were primed with Meningitec who will receive Novartis Menveo
3200775|NCT01192997|Active Comparator|MenACWY-TT-Meningitec|Subjects who were primed with Meningitec who will receive GSK MenACWY-TT
3200776|NCT01192997|Active Comparator|Menveo-Menjugate|Subjects who were primed with Menjugate who will receive Novartis Menveo
3200777|NCT01192997|Active Comparator|MenACWY-TT-Menjugate|Subjects who were primed with Menjugate who will receive GSK MenACWY-TT vaccine.
3200778|NCT01192997|Active Comparator|Menveo-NeisVac-C|Subjects who were primed with NeisVac-C who will receive Novartis Menveo
3200779|NCT01192997|Active Comparator|MenACWY-TT-NeisVac-C|Subjects who were primed with NeisVac-C who will receive GSK MenACWY-TT vaccine
3200780|NCT01192984|Experimental|KW-0761|
3200781|NCT01192971|Experimental|A 850|Arm 850: Experimental apatinib 850 mg qd, and it should be continued until disease progression or intolerable toxicity or patient withdrawal of consent
3200782|NCT01192971|Experimental|B750|B750: apatinib 750 qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3200783|NCT01192932||COPD|COPD patients aged 40 or more, with a smoking history of > 10 pack-years, a post-bronchodilator FEV1/VC < 0.7 and an optimal treatment according to GOLD guidelines will be included. Exclusion criteria are: COPD exacerbation or respiratory infection in the 4 weeks before the begin of the study, concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active malignancy or malignancy of any organ system within the past 5 years.
3200784|NCT01192919||Patients with lung cancer|Patients with lung cancer requiring therapy
3200785|NCT01192906|Experimental|1|
3200786|NCT01192906|Experimental|2|
3200787|NCT01192906|Placebo Comparator|3|
3200788|NCT01192893||OPUS|OPUS is a prospective study of postmenopausal women recruited in the general population between April 1999 and April 2001 from five European centers (Aberdeen (UK), Berlin (Germany), Kiel (Germany), Paris (Hospital Cochin, France), and Sheffield (UK)). Investigations were approved at each institution according to the Declaration of Helsinki. Written consent was obtained from all subjects. Each center recruited approximately 500 postmenopausal women comprising 100 individuals in each 5-yr age band between 55 and 79. Ninety-nine percent of subjects were of white ethnicity.
3200789|NCT01192880|Experimental|Bitopertin 10 mg + Antipsychotics|Treatment Period 1: Participants will receive bitopertin 10 milligrams (mg) tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin 10 mg tablet orally once daily for 28 weeks (up to Study Week 52). After Week 52 there will be a 4-week washout period for at least 50 percent (%) of participants (up to Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and continue to receive bitopertin 10 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
3200790|NCT01192880|Experimental|Bitopertin 20 mg + Antipsychotics|Treatment Period 1: Participants will receive bitopertin 20 mg tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin 20 mg tablet orally once daily for 28 weeks (up to Study Week 52). After Week 52 there will be a 4-week washout period for at least 50% of participants (up to Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and continue to receive bitopertin 20 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
3200791|NCT01192880|Placebo Comparator|Placebo|Treatment Period 1: Participants will receive bitopertin matching placebo tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin matching placebo tablet orally once daily for 32 weeks (up to Study Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and will be switched to (in blinded manner) bitopertin 10 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
3200792|NCT01192867|Experimental|RO4917838 20 milligrams (mg)|Participants, on stable antipsychotics, will receive RO4917838 orally at 20 mg once daily (QD) up to 56 weeks followed by an optional treatment extension for up to 3 years.
3200793|NCT01192867|Experimental|RO4917838 10 mg|Participants, on stable antipsychotics, will receive RO4917838 orally at 10 mg QD up to 56 weeks followed by an optional treatment extension for up to 3 years.
3200794|NCT01192867|Placebo Comparator|Placebo|Participants, on stable antipsychotics, will receive RO4917838 matching placebo orally QD up to 56 weeks.
3200795|NCT01192854|Experimental|1|
3200796|NCT01192854|Active Comparator|2|
3200797|NCT01192841|No Intervention|White coat group|Participants continued their regular practice of wearing their physician white coat.
3200798|NCT01192841|Experimental|Uniform group|Participants were given a clean uniform (scrubs) at the beginning of the day.
3200799|NCT01192828|Experimental|Taurine|Treatment with Taurine
3200800|NCT01192815|Experimental|Arm I|Patients receive erlotinib hydrochloride orally or via gastrostomy tube once daily in weeks 1-9 and then for 2 years following completion of radiation therapy. Beginning on day 1 of week 2, patients undergo radiation therapy once daily, 5 times a week, for 5-7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3200801|NCT01192802|Active Comparator|1 dose, Albendazole , tablet|
3200802|NCT01192802|Active Comparator|2 doses, albendazole, tablet|1 tablet of 400 mg of albendazole per day for two consecutive days
3200803|NCT01192802|Active Comparator|3 doses albendazole, 400mg, tablet|
3200804|NCT01192789|Other|Intervention|Severe Pneumonia Treatment by LHWs with Amoxicillin at 90mg/kg/day for severe pneumonia
3200805|NCT01192789|Other|Control|LHWs refer the severe pneumonia case to local health facility or private practitioner.
3200806|NCT01192776|Active Comparator|33.5°C for 72 hours|Target Temp: 33.5°C Duration: 72 hrs
3200807|NCT01192776|Experimental|33.5°C for 120 hours|Target Temp: 33.5°C Duration: 120 hrs
3200808|NCT01192776|Experimental|32.0°C for 72 hours|Target Temp: 32.0°C Duration: 72 hrs
3200809|NCT01192776|Experimental|32.0°C for 120 hours|Target Temp: 32.0°C Duration:120 hrs
3200810|NCT01192763|Experimental|Arm I|Patients receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10 in the absence of disease progression or unacceptable toxicity. Beginning 7 days after completion of gamma-secretase inhibitor RO4929097, patients undergo complete resection comprising pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy based on the anatomic location of the cancer. Tumor tissue from biopsy and surgery and blood samples are collected periodically for pharmacodynamic studies.
3200811|NCT01192724|Active Comparator|Triple antiplatelet therapy (TAPT) group|3-month use of cilostazol in addition to dual antiplatelet agent
3200812|NCT01192724|Active Comparator|Dual antiplatelet therapy (DAPT) group|Aspirin and clopidogrel (dual antiplatelet therapy, DAPT) for 1 year
3200813|NCT01192711|Experimental|insulin + DID|Three prandial (before or at the end of meal administration, based on doctor counselling and patient decision) injections per day of insulin glulisine associated with basal insulin glargine; the DID will be used to estimate the CHO content of the food intended to eat. Insulin doses in this group will be adjusted based on DID calculations and pre-meal BG values.
3200814|NCT01192711|No Intervention|insulin + usual care|Three prandial (before or at the end of meal administration, based on doctor counselling and patient decision) injections of insulin glulisine associated with basal insulin glargine. Insulin doses in group B will be adjusted based on SMBG values reviewed during the doctor office visit.
3200815|NCT01192698|Experimental|IV interferon|IV interferon oral ribavirin
3200816|NCT01192698|No Intervention|Standard of care|standard of care
3200907|NCT01191957|Active Comparator|I. V. Busulphan plus Cyclophosphamide|Conventional conditioning regimen with intravenous (i.v.) Busulphan (Busilvex), 12.8 mg/kg followed by Cyclophosphamide, 120 mg/kg iv.
3200817|NCT01192685|Other|Depressed outpatients treated with TMS|This a 12- week study (1-4 week screening, 6 weeks treatment, 2 weeks follow-up) outpatient open label clinical trial. Twenty-five subjects diagnosed with depression with a Montgomery Asberg Depression Rating Scale (MADRAS) score of 26 or higher, will be enrolled into this trial, up to fifty subjects will be consented. Transcranial Magnetic Stimulation (TMS) will be administered to subjects 5 days a week for 6 weeks. Near infrared spectroscopy (NIRS), a spectroscopic method that uses the near infrared region of the electromagnetic spectrum (from about 700 nm to 2500 nm), will be used to assess blood flow in the brain.
3200818|NCT01192672|Experimental|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
3200819|NCT01192672|Active Comparator|Control Writing|The participants were instructed to write for 30-minute intervals for 4 consecutive days about all of the actions they performed that day for a 24 hour period. The subjects were asked not to write about their feelings or thoughts related to these actions.
3200820|NCT01192672|No Intervention|Usual Care|Subjects in this group did not receive an intervention. They filled out measures at baseline, 1 month, and 3 month follow-up time periods.
3200821|NCT01192659||Patients treated with saxagliptin or placebo|Patients will be treated with saxagliptin or placebo, on top of whatever baseline treatment for diabetes the patient is already receiving.
3200822|NCT01192659||Patients currently or previously on treatment|Patients currently or previously on (within 6 months) treatment with DPP4 inhibitors and/or GLP-1 mimetics are excluded.
3200823|NCT01192646|Active Comparator|Home based life saving skills training|Home based life saving skills will done in one the study group and in the control group no training will be done
3200824|NCT01192646|No Intervention|NO HBLSS|No intervention will be given to the control clusters
3200825|NCT01192594|Experimental|MAPP Trained Case Managers|Consumers assigned to case managers who receive training in the Milestones of Adjustment Post-Psychosis Recovery Model
3200826|NCT01192594|Active Comparator|Non-MAPP trained case managers|Consumers of case managers not trained in the Milestones of Adjustment Post-Psychosis Recovery Model
3200827|NCT01192581|No Intervention|control|routine treatment for brain hypoperfusion
3200828|NCT01192581|Experimental|Vuloven1|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
3200829|NCT01192581|Experimental|Vuloven2|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
3200830|NCT01192581|Experimental|Vuloven3|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
3200831|NCT01192568|Experimental|Oxybutynin Chloride|
3200832|NCT01192555|Experimental|Treatment Plan|Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells) and Cytoxan (Cyclophosphamide)
3200833|NCT01192542|Other|galyfilcon A prototype lens/enfilcon A lens|galyfilcon A prototype contact lens worn daily for 6-8 days first then enfilcon A contact lens worn daily for 6-8 days second.
3200834|NCT01192542|Other|enfilcon A lens/galyfilcon A prototype lens|enfilcon A contact lens worn daily for 6-8 days first then galyfilcon A prototype contact lens worn daily for 6-8 days second.
3200835|NCT01192529|Experimental|Experimental Group|"In addition to their daily diet, patients of this group will receive 400 ml per day of Supressi nutritional supplement"
3200836|NCT01192529|Active Comparator|Control Group|"In addition to their daily diet, patients of this group will receive 400 ml per day of T-Diet plus High Protein product"
3200837|NCT01192516|Experimental|Arm 1|Tailored activity pacing
3200838|NCT01192516|Experimental|Arm 2|General activity pacing and symptom management (Occupational therapy)
3200839|NCT01192516|No Intervention|Arm 3|Usual care group
3200840|NCT01192503|Active Comparator|rasagiline|
3200841|NCT01192503|Placebo Comparator|placebo (sugar pill)|
3200842|NCT01192490|Experimental|Lidocaine Arm|This arm will receive intracervical and cervical lidocaine prior to placement of a Mirena.
3200843|NCT01192490|Placebo Comparator|Lubricant|Subjects in this arm will receive KY gel intracervically and on the cervix prior to placement of a Mirena.
3200844|NCT01192477|Experimental|Ozone 0.1 ppm|
3200845|NCT01192477|Experimental|Ozone 0.2 ppm|
3200846|NCT01192477|Sham Comparator|Filtered air|
3200847|NCT01192464|Experimental|autologous CAR.CD30 EBV specific-CTLs|"Group One Dose (CTLs CAR.CD30) at Day 0: 2x10^7 cells/m2~Group Two Dose (CTLs CAR.CD30) at Day 0: 5x10^7 cells/m2~Group Three Dose (CTLs CAR.CD30) at Day 0: 1x10^8 cells/m2"
3200848|NCT01192438|Experimental|Procedure/surgery|
3200849|NCT01192412|Active Comparator|'Less tight' control.|The diastolic blood pressure (dBP) treatment goal is 100 mmHg.
3200850|NCT01192412|Active Comparator|'Tight' control.|The diastolic blood pressure (dBP) treatment goal is 85 mmHg.
3200851|NCT01192399|Experimental|Eculizumab|Eculizumab intravenous infusions every week x 4 doses, then 900 mg 1 week later for 1 dose, then 900 mg every 2 weeks for 4 doses
3200852|NCT01192373|Experimental|High circulating free fatty acids|using Heparin af intralipid infusion for 8 hours
3200853|NCT01192373|Active Comparator|Low circulation free fatty acids|using hyperinsulinaemic euglycemic clamp for 8 hours
3200854|NCT01192360|Experimental|Cardiac Patients|
3200855|NCT01192360|Experimental|Pulmonary Patients|
3200856|NCT01192321|Experimental|Toric T3 - T9|Bilateral implantation of a Toric intraocular lens (IOL) models T3, T4, T5, T6, T7, T8 or T9
3200857|NCT01192321|Active Comparator|Monofocal|Bilateral implantation of a monofocal intraocular lens (IOL) model with no toric component.
3200858|NCT01192308|Experimental|40mg QD dose intervention|40mg QD dose intervention during 4 weeks in patients with CYP2D6 variant allele or using CYP2D6 inhibitor.
3200859|NCT01192295|Experimental|Oxycodone HCl controlled-release|Oxycodone hydrochloride (HCl) controlled-release (CR)
3200860|NCT01192282||Genital Warts|All female patients with Genital Warts presenting to Groote Schuur Hospital
3200908|NCT01191957|Experimental|I. V. Busulphan plus Fludarabine|Reduced toxicity conditioning regimen with intravenous (i.v.)Busulphan (Busilvex), 12.8 mg/kg plus Fludarabine, 4 x 40 mg/m².
3200909|NCT01191944|Experimental|pramipexole Extended release|subjects will receive 0.375mg once a day to 4.5mg once a day depending on investigator's judgement
3200861|NCT01192269|Experimental|Docosahexaenoic Acid Supplement|"DHA supplement: Experimental~1 x 950 mg capsules per day orally, each capsule providing ~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric)."
3200862|NCT01192217|Active Comparator|VATS group|
3200863|NCT01192217|Active Comparator|Mini-thoracotomy group|
3200864|NCT01192204|Active Comparator|10% FBR containing bioadhesive gel|Drug consisting of 10% FBR containing bioadhesive gel. Participants instructed to apply 0.5 gm of 10% FBR containing bioadhesive gel four times a day to lesional site
3200865|NCT01192204|Placebo Comparator|Placebo Gel|Color/consistency matched placebo (no black raspberry) gel
3200866|NCT01192191|Experimental|Fluticasone Furoate/GW642444 100/25mcg|Combination inhaled corticosteroid and long-acting beta2-agonist
3200867|NCT01192191|Experimental|Fluticasone Furoate/GW642444 200/25mcg|Combination inhaled corticosteroid and long-acting beta2-agonist
3200868|NCT01192178|Active Comparator|FLOVENT™ DISKUS™ 100 mcg|FLOVENT™ DISKUS™ 100 mcg is an inhaled corticosteroid indicated in the US for maintenance treatment of asthma as prophylactic therapy in patients 4 years and older.
3200869|NCT01192178|Experimental|ADVAIR™ DISKUS™ 100/50 mcg|ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a corticosteroid and a long acting beta2 adrenergic agonist indicated for; maintenance treatment of asthma in patients 4 years of age and older.
3200870|NCT01192165|Experimental|Treatment Group 1|Trametinib plus Docetaxel
3200871|NCT01192165|Experimental|Treatment Group 2|Trametinib plus Erlotinib
3200872|NCT01192165|Experimental|Treatment Group 3|Trametinib plus Pemetrexed
3200873|NCT01192165|Experimental|Treatment Group 4|Trametinib plus Pemetrexed and Carboplatin
3200874|NCT01192165|Experimental|Treatment Group 5|Trametinib plus nab-Paclitaxel
3200875|NCT01192165|Experimental|Treatment Group 6|Trametinib plus Pemetrexed and Cisplatin
3200876|NCT01192152|Experimental|5 mg saxagliptin + 2 Glucophage XR 500 mg tablet|
3200877|NCT01192152|Experimental|FDC tablet (5 mg saxa + 1000 mg metformin XR) (single dose)|under fed state, single dose
3200878|NCT01192152|Experimental|FDC tablet (5 mg saxa + 1000 mg metformin XR) (4 days)|under fed state, 4 days
3200879|NCT01192139|Experimental|5 mg saxagliptin + a single 500 mg metformin XR tablet|
3200880|NCT01192139|Experimental|FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fed)|under fed state
3200881|NCT01192139|Experimental|FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fasting)|under fasted state
3200882|NCT01192126|Experimental|Bausch & Lomb new daily disposable|New daily disposable contact lenses
3200883|NCT01192126|Active Comparator|Johnson & Johnson Acuvue Moist|Contact lenses
3200884|NCT01192113|Experimental|Group A: Diabetic Peripheral Neuropathy (IV)|
3200885|NCT01192113|Experimental|Group B: Diabetic Peripheral Neuropathy (IM)|
3200886|NCT01192113|Experimental|Group C: Idiopathic Peripheral Neuropathy|
3200887|NCT01192113|Experimental|Group D: Nutritional & Metabolic Peripheral Neuropathy|
3200888|NCT01192113|Experimental|Group E: Compression Peripheral Neuropathy|
3200889|NCT01192100|Experimental|Breakfast Skipping|Breakfast skipping serves as the baseline/control arm since the participants habitually skip breakfast (i.e., skip breakfast at least 5 times/week). Thus, during the week prior to and including the testing day, the participants will continue to skip breakfast each morning.
3200890|NCT01192100|Experimental|Normal Protein Breakfast Meals|For 7 days, the participants will consume normal protein breakfast meals each morning. These meals will consist of cereal-based foods and will be 350 kcal, which is approximately 18% of daily energy intake for overweight and obese adolescents ages 9-18 y. The macronutrient composition of these meals will contain 15% protein (13 g of dietary protein), 65% CHO, and 20% fat.
3200891|NCT01192100|Experimental|Protein-rich Breakfast Meals|For 7 days, the participants will consume protein-rich breakfast meals each morning. These meals will consist of home-cooked foods and will be 350 kcal, which is approximately 18% of daily energy intake for overweight and obese adolescents ages 9-18 y. The macronutrient composition of these meals will contain 40% protein (35 g of protein), 40% CHO, and 20% fat.
3200892|NCT01192087|Experimental|Cetuximab arm|patients receive weekly cetuximab in combination with IMRT and carbon ion boost
3200893|NCT01192074||Ultrasound of the spine|Pregnant women receiving labor epidural analgesia or spinal anesthesia for cesarean delivery
3200894|NCT01192061||Normal tension glaucoma group|
3200895|NCT01192061||Control group|
3200896|NCT01192048||Study Subjects|Individuals with Congenital Heart Disease and family members with or without Congenital Heart Disease. A blood sample collection will be required for all study participants.
3200897|NCT01192035|Active Comparator|NNRTI|
3200898|NCT01192035|Active Comparator|Protease inhibitor|
3200899|NCT01192022|Active Comparator|TachoSil®|TachoSil® absorbable patches, applied topically, once, intraoperatively to stop bleeding. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
3200900|NCT01192022|Active Comparator|Surgicel® Original|Surgicel® Original absorbable patches, applied topically, once, intraoperatively to stop bleeding. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
3200901|NCT01192009|Experimental|Immobilization and Leucine|
3200902|NCT01192009|Placebo Comparator|Immobilization and Placebo|
3200903|NCT01191996|Experimental|MIS416|MIS416, immunomodulating microparticle, given intravenously weekly
3200904|NCT01191983|Experimental|Methoxy polyethylene glycol-epoetin beta|Participants will receive 1.2 mcg/kg methoxy polyethylene glycol-epoetin beta given in monthly doses at each visit. Dose will be measured on the basis of the participants Hb level during the study period. The dose administration will be the nearest possible dose using the prefilled syringes containing 50, 75 and 100 mcg/kg Q4W.
3200905|NCT01191970||Epidural recipients|Subjects who received epidural analgesia during labor
3200906|NCT01191970||Non-epidural recipients|Subjects who did not receive epidural analgesia during labor
3201037|NCT01191112|Experimental|Peptide Based enteral formula|
3200910|NCT01191944|Active Comparator|pramipexole Immediate release|subjects will receive 0.125mg three times a day to 1.0mg three times a day depending on investigator's judgement
3200911|NCT01191931||prostate cancer|Patients with histologically proven prostate cancer (positive biopsy) and who are planned to undergo radical prostatectomy.
3200912|NCT01191918|Experimental|donepezil|donepezil plus Lithium
3200913|NCT01191918|Placebo Comparator|Control|Placebo plus Lithium
3200914|NCT01191905|Experimental|High dose CRRT|Clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
3200915|NCT01191905|Active Comparator|Conventional dose CRRT|clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
3200916|NCT01191892|Placebo Comparator|Placebo|Carboplatin, Gemcitabine and Placebo
3200917|NCT01191892|Experimental|vandetanib|Carboplatin, Gemcitabine and vandetanib
3200918|NCT01191879||acute MI group|Patients presenting with acute ST elevation myocardial infarction, admitted to the intensive cardiac care unit and that are planned for emergency primary PCI
3200919|NCT01191879||Controls|Patients undergoing a non-invasive evaluation of possible myocardial ischemia.
3200920|NCT01191866||Diabetes mellitus|All children and adolescents with type 1 diabetes mellitus attending Assaf Harofeh Pediatric Diabetes Clinic
3200921|NCT01191840|Experimental|Algorithm-determined therapy|
3200922|NCT01191840|Active Comparator|Standard of Care|
3200923|NCT01191827||risperidone|
3200924|NCT01191827||clozapine|Patients with schizophrenia treated with clozapine
3200925|NCT01191814|Active Comparator|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
3200926|NCT01191814|Active Comparator|Plastic Stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a plastic stent
3200927|NCT01191801|Experimental|Group A: vosaroxin + cytarabine|vosaroxin (short IV infusion within 10 minutes) on days 1 and 4: cytarabine on days 1 through 5; a maximum of 2 cycles of Induction and 2 cycles for Consolidation
3200928|NCT01191801|Placebo Comparator|Group B: placebo + cytarabine|placebo (short IV infusion within 10 minutes and volume matched to vosaroxin) on days 1 and 4: cytarabine on days 1 through 5; a maximum of 2 cycles of Induction and 2 cycles for Consolidation
3200929|NCT01191788|Experimental|Group CBT|Clients received up to 16 sessions of group CBT for depression
3200930|NCT01191788|Active Comparator|Comparison|Treatment as Usual comparison condition
3200931|NCT01191775|Experimental|PNT2258|PNT2258 is composed of PNT100, a 24-mer oligonucleotide, the active drug substance encapsulated in a liposome.
3200932|NCT01191762|Active Comparator|sevelamer carbonate|2400 mg (3 pills) with each meal
3200933|NCT01191762|Placebo Comparator|placebo control|3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.
3200934|NCT01191749|Experimental|Alemtuzumab|Alemtuzumab 10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
3200935|NCT01191736|Experimental|No training, assessed within 60 mins|Subjects receive no training
3200936|NCT01191736|Experimental|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
3200937|NCT01191736|Experimental|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
3200938|NCT01191736|Experimental|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
3200939|NCT01191736|Experimental|Ultra-brief video; assessed at 2 months|
3200940|NCT01191736|Experimental|Brief video; assessed 2 months later|
3200941|NCT01191736|Experimental|Brief video + hands-on; ass'd 2 ms later|
3200942|NCT01191723|Other|Treatment A, then Treatment B, then Treatment C|"There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.~Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
3200943|NCT01191723|Other|Treatment A, then Treatment C, then Treatment B|"There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.~Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
3200944|NCT01191723|Other|Treatment B, then Treatment A, then Treatment C|"There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.~Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
3200945|NCT01191723|Other|Treatment B, then Treatment C, then Treatment A|"There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.~Tablets were orally administered after oral inhalation dosing."
3200946|NCT01191723|Other|Treatment C, then Treatment A, then Treatment B|"There was 48 hour wash-out between treatment visits. Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.~Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
3200947|NCT01191723|Other|Treatment C, then Treatment B, then Treatment A|"There was 48 hour wash-out between treatment visits.~Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.~Tablets were orally administered after oral inhalation dosing."
3200948|NCT01191710|Experimental|Antagonist group|Antagonist protocol for IVF
3200949|NCT01191710|Active Comparator|Agonist group|Long Agonist protocol for IVF
3200950|NCT01191684|Experimental|Treatment (vaccine therapy)|Patients receive MVAp53 subcutaneously on days 0, 21, and 42 in the absence of unacceptable toxicity.
3200951|NCT01191645|Experimental|Primperan|
3200952|NCT01191645|Active Comparator|Naloxon|
3200953|NCT01191645|Placebo Comparator|Natriumklorid|
3200954|NCT01191645|Experimental|Ultiva|
3200955|NCT01191632|Active Comparator|Radiation 0,5Gy|"Radiation: one time Radiation with an intensity of 0.5 Gy Group A~Beginning on a weekday 48 hours before surgery"
3200956|NCT01191632|Active Comparator|No radiation|Control group with 0Gy radiation
3200957|NCT01191632|Active Comparator|Radiation 2Gy|"Radiation: one time Radiation with an intensity of~2.0 Gy Group B~Beginning on a weekday 48 hours before surgery"
3200958|NCT01191632|Active Comparator|Radiation 5Gy|"Radiation: one time Radiation with an intensity of~5 Gy Group C Beginning on a weekday 48 hours before surgery"
3200959|NCT01191619|Experimental|McIvor group|groups in which proseal laryngeal mask airway is inserted with McIvor retractor.
3200960|NCT01191606|Active Comparator|Group A|the exchange of ventilatory mode from volume controlled ventilation to pressure controlled ventilation
3200961|NCT01191606|Active Comparator|Group B|the exchange of ventilatory mode from pressure controlled ventilation to volume controlled ventilation
3200962|NCT01191593|Experimental|Adductor-Canal-Blockade with ropivacaine|
3200963|NCT01191593|Placebo Comparator|Adductor-Canal-blockade with saline|
3200964|NCT01191580|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy is a brief, manualized therapy that has shown efficacy in treating major depression in several controlled trials including a large trial for depressed HIV-infected individuals and other randomized trials in depressed individuals with other comorbid medical illnesses. Research shows that Interpersonal Psychotherapy improves social skills and functioning. Interpersonal Psychotherapy has shown remarkable flexibility and efficacy across age ranges, cultures, formats, and modes of delivery. We recently obtained promising pilot data in a small open trial on the acceptability and efficacy of individual IPT for depressed breast cancer patients of diverse ethnic background, socioeconomic status, and cancer progression stage.
3200965|NCT01191580|Experimental|Problem-Solving Therapy|Problem-Solving Therapy is a brief, manualized form of cognitive-behavioral therapy (CBT) that has been adapted to treat depression in cancer patients, and has shown highly promising results.
3200966|NCT01191580|Active Comparator|Brief Supportive Psychotherapy|Brief Supportive Psychotherapy, a relatively unstructured psychotherapy commonly used in clinical practice, focuses on the patient's affect. It builds a strong therapeutic alliance through careful, empathic listening and validating and encouraging toleration of the patient's emotions. It has shown promising results in depressed individuals with cancer and other medical illnesses.
3200967|NCT01191567|Active Comparator|Conventional treatment|
3200968|NCT01191567|Experimental|VAC treatment|
3200969|NCT01191554|Experimental|High dosage|A loading dose of 30 mg/kg and a maintenance infusion of 16 mg/kg through out the operation, and 2 mg/kg into the cardiopulmonary bypass (CPB) prime volume.
3200970|NCT01191554|Experimental|Low dosage|A loading dose of 10 mg/kg and a maintenance infusion of 1 mg/kg through out the operation, and 1 mg/kg into the cardiopulmonary bypass (CPB) prime volume.
3200971|NCT01191541|Other|DNR+Ara-c,DNR|one group treated with DNR+Ara-C one group treated with DNR
3200972|NCT01191515||Near visual outcomes with Monofocal IOL|Evaluation of intermediate visual outcomes of patients undergoing routine cataract surgery with phacoemulsification and monofocal IOl placement in the capsular bag in at least one eye.
3200973|NCT01191515||Intermediate Visual outcomes|Evaluation of intermediate visual outcomes of patients undergoing routine cataract surgery with phacoemulsification and monofocal IOl placement in the capsular bag in at least one eye.
3200974|NCT01191502||TECNIS MULTIFOCAL (TMF) INTRAOCULAR LENS|
3200975|NCT01191502||CRYSTALENS HD (CHD) INTRAOCULAR LENS|
3200976|NCT01191489|Experimental|High Flow Conditioned Oxygen Therapy in high risk patients|
3200977|NCT01191489|Active Comparator|Non-invasive mechanical ventilation in High Risk Patients|
3200978|NCT01191489|Experimental|High Flow Conditioned Oxygen Therapy in Low Risk Patients|
3200979|NCT01191489|Active Comparator|Conventional Oxygen Therapy in Low Risk Patients|
3200980|NCT01191476|Active Comparator|Sevoflurane|Subjects received sevoflurane, a inhalational (volatile) anesthetic, which was administered for induction and maintenance of general anesthesia. Inhalational induction was induced via vital capacity induction at 8% and maintained at 0.8-1.5 minimum alveolar concentration (MAC).
3200981|NCT01191476|Active Comparator|Propofol|Subjects received propofol, an intravenous (IV) anesthetic, which was administered for induction and maintenance of general anesthesia.
3200982|NCT01191476|Active Comparator|Propofol Induction and Sevoflurane Maintenance|Subjects received a bolus dose of propofol of 1.5 mg/kg administered for IV induction followed by sevoflurane at 0.8-1.5 MAC for maintenance anesthesia.
3200983|NCT01191463|Experimental|Mung Bean Meals and Guava fruit|Subject in this group will receive, a lunch meal based on 50g of Mung beans together with a local, Vitamin C rich fruit (Guava)
3200984|NCT01191463|Active Comparator|Mung Bean|Subjects in this group will receive a lunch meal based on 50g mung beans but without any vitamin C source.
3200985|NCT01191463|No Intervention|School feeding program|Subjects in this arm, will receive the regular school feeding program as provided by the school authorities
3200986|NCT01191450|Active Comparator|Higroton®|Chlorthalidone 25mg - one oral tablet a day in the morning
3200987|NCT01191450|Experimental|Diupress®|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning
3200988|NCT01191424|Experimental|CHF1535 NEXT DPI|Male and female adolescents and adult patients (≥ 12 years old) treated with CHF1535 NEXT DPI
3200989|NCT01191424|Active Comparator|Free combination BDP and FF|Male and female adolescents and adult patients (≥ 12 years old) treated with a free combination of licenced BDP and FF
3200990|NCT01191411|Active Comparator|Mailed invitations for FIT test kits|"Fecal Immunochemical Tests (FIT) kits from Polymedco Incorporated are mailed to patients' homes for free colorectal cancer screening.~Intervention: Screening for colorectal cancer using a Polymedco home FIT kit. Mailed invitation to complete a free one sample home FIT kit. Automated and live phone call reminders to promote screening completion, plus usual medical care.~Patients with abnormal FIT results are navigated to complete a diagnostic colonoscopy."
3201038|NCT01191086|Experimental|Open-label USL255|Topiramate extended-release capsules (USL255) up to a maximum of 400 mg per day
3201039|NCT01191073|Experimental|CAD/CAM fabricated dentures|group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)
3201334|NCT01188941|Experimental|Assigned a Health System Navigator|
3200991|NCT01191411|Active Comparator|Mailed invitations for a colonoscopy|"Invitation to schedule a colonoscopy are mailed to patients' homes for free colorectal cancer screening.~Intervention: Screening for colorectal cancer with colonoscopy. Mailed invitation to complete one free colonoscopy. Automated and live phone reminders to promote screening completion, plus usual medical care.~Patients with abnormal polyps or adenomas will follow standard clinical protocol after their procedure."
3200992|NCT01191411|Active Comparator|Visit Based Care|"No invitation to complete colorectal cancer screening.~Intervention: Usual medical care. Patients will continue to see their regular physician, and follow their physician's regular standard of care."
3200993|NCT01191398|Placebo Comparator|Placebo and Ketamine|Normal Saline 0.9% will act as a placebo. Two ml of normal saline 0.9% will be administered intravenously 30 minutes prior to the administration of the ketamine.
3200994|NCT01191398|Active Comparator|Atropine and Ketamine|Atropine will be administered as a single dose of 0.01 mg/kg, with a minimum of dosage of 0.1 mg and a maximum dosage of 0.4 mg, intravenously 30 minutes before the administration of the ketamine.
3200995|NCT01191398|Active Comparator|Glycopyrrolate and Ketamine|Glycopyrrolate will be administered as a single dose of 0.01 mg/kg, with no minimum dosage and a maximum dose of 0.4 mg, intravenously 30 minutes before the administration of the ketamine.
3200996|NCT01191385||Group 1|
3200997|NCT01191372|Placebo Comparator|saline for injection|
3200998|NCT01191372|Experimental|ARC19499 Low Dose|
3200999|NCT01191372|Experimental|ARC19499 Mid Dose|
3201000|NCT01191372|Experimental|ARC19499 High Dose|
3201001|NCT01191359|Active Comparator|sublingual administration|oral immunotherapy with drops applied once daily by single dose containers (200 STU per dose)
3201002|NCT01191359|Active Comparator|vestibular administration|oral immunotherapy with drops applied by single dose containers (200 STU per dose)
3201003|NCT01191346||3T MRI|Patients receiving 3T MRI
3201004|NCT01191333|Experimental|Active rTMS|Those receiving experimental treatment will receive 20 to 30 sessions of rTMS in blocks of 5 sessions. The treatment will be delivered by trained medical personnel.
3201005|NCT01191333|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 to 30 sessions of sham rTMS in blocks of 5 sessions. The treatment will be delivered by trained medical personnel.
3201006|NCT01191320|Placebo Comparator|Placebo|Placebo
3201007|NCT01191320|Experimental|Androxal 12.5 mg|12.5 mg/day
3201008|NCT01191320|Experimental|Androxal 25 mg|25 mg/day
3201009|NCT01191307||Shunt Implant|hydropcephalus cohort
3201010|NCT01191307||Cochlear Implant|hearing impaired cohort
3201011|NCT01191307||Spinal Cord Stiumulation|spinal cord injury cohort
3201012|NCT01191307||Vagus Nerve Stimulation|epilepsy cohort
3201013|NCT01191307||Deep Brain Stimulation|dystonia cohort
3201014|NCT01191294|Experimental|Medical Students|3rd year medical students during their primary care clerkship
3201015|NCT01191281|Experimental|Diet/nutrition counsel+food aid|Intervention. Patients enrolled in the intervention group will receive a multi-component intervention that includes dietary and nutritional counseling and food assistance (food aid basket)
3201016|NCT01191281|Active Comparator|dietary/nutritional counseling|Patients enrolled in the comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
3201017|NCT01191268|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
3201018|NCT01191268|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
3201019|NCT01191268|Active Comparator|Insulin Glargine|"Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
3201020|NCT01191255|Active Comparator|Active Control|PhosLo (calcium acetate) Renvela (sevelamer carbonate)
3201021|NCT01191255|Placebo Comparator|Placebo|Placebo
3201022|NCT01191255|Experimental|KRX-0502 (Ferric Citrate)|ferric citrate
3201023|NCT01191229|No Intervention|Tecnis One-Piece MF IOL|It is planned that about 25 people who are at least 18 years old who are scheduled to have the Tecnis One-Piece Multifocal Intraocular Lenses placed into their eyes after cataract surgery
3201024|NCT01191229|No Intervention|Crystalens AO|It is planned that about 25 people who are at least 18 years old and have been implanted with Crystalens AO
3201025|NCT01191216|Experimental|Arm I|Patients receive oral 1-methyl-d-tryptophan twice daily on days 1-21 and docetaxel IV over 1 hour on day 1 (in course one patients receive 1-methyl-d-tryptophan once daily on days 1 and 3-21).
3201026|NCT01191203|Active Comparator|Depo Medroxyprogesterone Acetate|
3201027|NCT01191203|Active Comparator|Copper IUD (CuT360)|
3201028|NCT01191190|Experimental|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered.~Each patient may receive 3 cycles of treatment in the absence of progressive disease or significant toxicity."
3201029|NCT01191177|Experimental|Lovaza group|Patients randomized to this group will receive Lovaza 1gram per kilogram of body weight, not exceeding 4grams a day
3201030|NCT01191177|Placebo Comparator|Placebo group|Patients randomized to this group will receive corn oil supplement 1gram per kilogram of body weight, not exceeding 4grams per day
3201031|NCT01191164|Experimental|Study Arm|
3201032|NCT01191151||Orthopedic injury, osteoarthritis|All eligible patients receiving orthopedic, sports medicine, arthroscopy and related surgery or nonoperative treatment
3201033|NCT01191138|Other|Infracolic Anastamosis|The gastrojejunal anastamosis is done in the infracolic compartment
3201034|NCT01191138|Other|Supracolic Anastamosis|The gastrojejunal anastamosis is done in the supracolic compartment
3201035|NCT01191125|Experimental|medical food with AN777|
3201036|NCT01191125|Active Comparator|oral nutritional formula|
3201040|NCT01191073|Active Comparator|traditional fabricated dentures|group receiving traditional fabricated dentures (double blind)
3201041|NCT01191060|Experimental|lenalidomide, bortezomib with ASCT|"RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent)~Autologous stem cell transplant:~Melphalan: infused over two days (day -2 and day -1) or as a single infusion (day-2) according to institutional practice Re-infusion of PBSCs RVD q 21 days (2 cycles) Maintenance Lenalidomide q28 days (12 months)"
3201042|NCT01191060|Experimental|lenalidomide, bortezomib without ASCT|RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent) RVD q 21 days (5 cycles) Maintenance Lenalidomide q28 days (12 months)
3201043|NCT01191021|Other|Propofol|Volunteers will receive propofol anesthesia on the study day.
3201044|NCT01191008||Latan-timolol maleate fixed comb ophthalmic solution|
3201045|NCT01190995|Experimental|Sucrose|The enrolled neonates will be administered a sterile solution of 24 % sucrose orally for a period of 7 days from enrollment The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure.
3201046|NCT01190995|Placebo Comparator|Placebo|The enrolled neonates will be administered double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
3201047|NCT01190982|Experimental|LEP-ETU|All patient will have baseline to confirm disease status. The disease progression/response is assessed inaccordance to the RECIST guidelines
3201048|NCT01190943||Ancillary-Correlative (biomarker sampling and analysis)|Archived tumor tissue and peripheral blood DNA specimens are analyzed for DNA copy number profiling, gene expression profiling, DNA methylation profiling, microRNA profiling, and genomic resequencing. Clinical data including demographics; date of diagnosis, surgery, chemotherapy, recurrence, progression, and death; imaging; toxicity; and pathologic data elements associated with the specimens are also collected and analyzed.
3201049|NCT01190930|Experimental|Arm A (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; dexamethasone PO BID on days 1-5, 29-33, and 57-61; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
3201050|NCT01190930|Experimental|Arm B (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; dexamethasone PO BID on days 1-5, 29-33, and 57-61; higher-dose methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
3201051|NCT01190930|Experimental|Arm C (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on day 1; dexamethasone PO BID on days 1-5; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
3201052|NCT01190930|Experimental|Arm D (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on day 1; dexamethasone PO BID on days 1-5; higher-dose methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
3201053|NCT01190930|Experimental|Arm LR-C (risk-adapted chemotherapy)|Patients receive consolidation, interim maintenance I, delayed intensification, interim maintenance II, and maintenance therapy. See detailed description.
3201054|NCT01190930|Experimental|Arm LR-M (risk-adapted chemotherapy)|Patients receive consolidation and maintenance therapy. See detailed description.
3201055|NCT01190917|Active Comparator|Cognitive Behavioral Therapy Group|
3201056|NCT01190917|Active Comparator|Social Play Group|
3201057|NCT01190904||Coronary Artery Disease (≥50%) with or without PCI|We propose to investigate four specific aims using 1,143 diabetic men who have CAD (≥50%) lesion in at least one major epicardial vessel with or without PCI.
3201058|NCT01190891|Active Comparator|Manual Physical Therapy|The orthopaedic manual physical therapy (OMPT) intervention approach used in this study will be based on an impairment model. The physical therapist providing the intervention will address the impairments found in the shoulder joints to include the acromioclavicular joint, glenohumeral joint, and scapular-thoracic joints, and cervical/thoracic spine. Patients will receive procedures tailored to their specific impairments. Procedures will include mobilizations and manipulations of the joint and soft-tissues.
3201059|NCT01190891|Active Comparator|Corticosteroid Injection (Subacromial)|Location: Subacromial space; Syringe: 10mL; Needle: 25 gauge, 1.5 inch; Anesthetic: 6 mL of 1% lidocaine or marcaine; Corticosteroid: 1.0 mL Triamcinolone Acetonide (Kenalog), 40 mg/mL
3201060|NCT01190878|Experimental|ISV-303 BID|
3201061|NCT01190878|Experimental|ISV-303 QD|
3201062|NCT01190878|Active Comparator|Xibrom BID|
3201063|NCT01190878|Placebo Comparator|DuraSite Vehicle BID|
3201064|NCT01190865|Other|HP802-247|Assessment Duration = 8 days Assessment Duration = 15 days Assessment Duration = 22 days Assessment Duration = 29 days Assessment Duration = 31 days Assessment Duration = 43 days Assessment Duration = 50 days Assessment Duration = 57 days
3201065|NCT01190852|Experimental|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
3201066|NCT01190852|Active Comparator|Azelastine mono|REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)
3201067|NCT01190852|Active Comparator|Azelastine|COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
3201068|NCT01190839|Experimental|Infliximab|Infliximab Type=equal unit=mg number=5 form=intravenous infusion route=intravenous use once every 8 weeks
3201069|NCT01190839|Placebo Comparator|Placebo|Placebo Type=equal unit=mg number=5 form=intravenous infusion route=intravenous use once every 8 weeks
3201115|NCT01190475|Placebo Comparator|Placebo|
3201070|NCT01190826|Experimental|ASM-024 10 mg|ASM-024 administered once by inhalation at a target dose of 10 mg
3201071|NCT01190826|Experimental|ASM-024 100 mg|ASM-024 administered once at a target dose of 100 mg
3201072|NCT01190826|Placebo Comparator|Placebo|Placebo administered once by inhalation
3201073|NCT01190813|Active Comparator|Levodopa/Carbidopa|Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
3201074|NCT01190813|Placebo Comparator|Placebo|Oral placebo tid
3201075|NCT01190787|Experimental|VMP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
3201076|NCT01190787|Experimental|VCP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
3201077|NCT01190787|Experimental|VP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
3201078|NCT01190774|Experimental|Dentist behaviour|Patient completes the MDAS which is handed to receptionist who then gives the information to the dentist with patient knowledge
3201079|NCT01190774|Experimental|Dentist behaviour and patient expectancy|Patient completes the MDAS and hands to the dentist
3201080|NCT01190761|Experimental|A|Galantamine 4 mg Tablet, single dose
3201081|NCT01190761|Active Comparator|B|Reminyl 4 mg Tablet, single dose
3201082|NCT01190748|Experimental|A|Galantamine 4 mg Tablet, single dose
3201083|NCT01190748|Active Comparator|B|Reminyl 4 mg Tablet, single dose
3201084|NCT01190735|Experimental|Caffeine|Each patient will take pills twice per day containing 100-200 mg of caffeine (as synthetic caffeine alkaloid). Patients will be instructed to take whatever caffeine-containing beverages they are accustomed to taking, without changing their habitual schedule (note that all will be taking <200 mg per day). Caffeine intake will be assessed at each visit. Patients will continue their usual PD medications, without change in dose or timing for the entire duration of the study. Medication will be provided in pre-packaged dosettes.
3201085|NCT01190722|Experimental|etoricoxib|active study drug, coxib
3201086|NCT01190722|Active Comparator|diclofenac|active traditional NSAID control
3201087|NCT01190709|Other|unreamed Intramedullary Nailing|tibial fracture fixed with unreamed Intramedullary Nailing
3201088|NCT01190709|Other|Dynamic Compression Plate|tibial fracture fixed with Dynamic Compression Plate
3201089|NCT01190696|Other|hip spica casting|Patients in the spica cast group treated with skeletal traction and spica cast applied for them
3201090|NCT01190696|Other|titanium elasting nailing|For patients in the Titanium Elasting Nailing group, the nail applied retrogradely in femoral shaft fracture
3201091|NCT01190683|Active Comparator|cholecalciferol|cholecalciferol 60,000IU/week for first eight weeks followed by 60,000 IU every 15 days for four months along with calcium placebo
3201092|NCT01190683|Active Comparator|Calcium carbonate|two tablets of calcium carbonate daily equivalent to 1 gm of elemental calcium for six months along with vitamin D placebo
3201093|NCT01190683|Active Comparator|oral calcium and cholecalciferol|60,000 IU of cholecalciferol every week for ist eight week and then 60,000IU every 15 days for next four months along with 1 gm of elemental calcium ever day for six months
3201094|NCT01190683|Placebo Comparator|lactose|identical placebos
3201095|NCT01190670|Experimental|Part 1, Group 1|ASP015K, low dose followed by high dose, with oral tacrolimus
3201096|NCT01190670|Experimental|Part 1, Group 2|ASP015K, high dose followed by low dose, with oral tacrolimus
3201097|NCT01190670|Experimental|Part 2|ASP015K high dose with intravenous tacrolimus
3201098|NCT01190657|Experimental|Selbex 50mg (14 days)|
3201099|NCT01190657|Experimental|Selbex 50mg (56 days)|
3201100|NCT01190644|Experimental|ACE 011 (Sotatercept)|35mg dose of ACE 011 will be given by subcutaneous injection on Day 1. Up to two additional doses of ACE 011 will be given every 42 days during the treatment period (Day 43 and Day 85)
3201101|NCT01190631|Experimental|Acrysof IQ (SN60WF) IOL|AcrySof IQ SN60WF intraocular lens (IOL) implanted in one eye only during cataract surgery.
3201102|NCT01190592|Experimental|Milk|
3201103|NCT01190592|Experimental|Juice|
3201104|NCT01190592|Placebo Comparator|Water|
3201105|NCT01190553|Experimental|Treatment|IV amantadine treatment
3201106|NCT01190540|Active Comparator|OSS Phase 1|Thirty-six sites will receive the On Site Support service (OSS) activities for nine to 15 months; 18 will be randomly assigned to receive the OSS in phase 1
3201107|NCT01190540|Active Comparator|OSS Phase 2|Thirty-six sites will receive the OSS activities for nine to 15 months; 18 will be randomly assigned to receive the OSS in phase 2 that will serve as a control group in phase 1 and receive OSS nine months later.
3201108|NCT01190527|Other|FDG-PET|All subjects will have the same course of treatment, the study treatment.
3201109|NCT01190514|Experimental|Bioequivalence and Food effect|
3201110|NCT01190501|Experimental|complier device|
3201111|NCT01190488|Experimental|Intervention - Decision Aid|In addition to usual care, patients assigned to the intervention group will also be asked to view and/or read the EOL-PtDA during their hospitalization. The EOL-PtDA can be utilized anytime in the course of their hospitalization (all hospital rooms at UCH have a DVD player). This could be before, during, or after the palliative care team consultation.
3201112|NCT01190488|Active Comparator|Active comparison|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
3201113|NCT01190475|Experimental|BGS649 high dose|
3201114|NCT01190475|Experimental|BGS649 low dose|
3201116|NCT01190449|Experimental|Arm I|Patients receive high-dose ofatumumab IV over 2-8 hours on days 1, 8, 15, and 22 and then once monthly in months 3-9.
3201117|NCT01190449|Experimental|Arm II|Patients receive a lower dose of ofatumumab IV over 2-8 hours on days 1, 8, 15, and 22 and then once monthly in months 3-9.
3201118|NCT01190436|Experimental|Bisoprolol|
3201119|NCT01190423|Experimental|Family Based therapy for young adults|
3201120|NCT01190410|Experimental|Certolizumab pegol: high-dose group|400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
3201121|NCT01190410|Experimental|Certolizumab pegol: low-dose group (weight adjusted)|200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
3201122|NCT01190397|Experimental|Blephasteam Arm|
3201123|NCT01190397|Active Comparator|warm and moist compresses arm|
3201124|NCT01190384|Experimental|Bean Soup|Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
3201125|NCT01190384|Active Comparator|Couscous plus Fiber|Soup with added fiber; has a low ORAC value. Subject serving is isocaloric to the experimental Bean soup.
3201126|NCT01190384|Active Comparator|Couscous plus Grape Seed Extract|Control for ORAC value of the Bean soup; for examining the effect of fiber in the bean soup.
3201127|NCT01190371|Other|Artesunate|Confirmation of artemisinin tolerance
3201128|NCT01190358|Placebo Comparator|Placebo|Sugar pill
3201129|NCT01190358|Active Comparator|Grape seed extract|300mg of grape seed extract.
3201130|NCT01190345|Experimental|WITH bevacizumab|"bevacizumab 15 mg/kg on day 1 of each cycle : 4 cycles of 5-fluorouracil 500 mg/m² IV + epirubicin 100 mg/m² IV + cyclophosphamide 500 mg/m² IV (FEC100) every 21 days and 4 cycles of docetaxel 100 mg/m² IV every 21 days.~Patients with HER2+ disease will receive trastuzumab (8 mg/kg (IV then 6 mg/kg, every 21 days), which will be started with docetaxel and administered for a total duration of 54 weeks, 18 injections."
3201131|NCT01190345|Active Comparator|without bevacizumab|"4 cycles 5-fluorouracil 500 mg/m² IV + epirubicin 100 mg/m² IV + cyclophosphamide 500 mg/m² IV of (FEC100) every 21 days and 4 cycles of docetaxel 100 mg/m² IV every 21 days.~Patients with HER2+ disease will receive trastuzumab (8 mg/kg (IV then 6 mg/kg, every 21 days), which will be started with docetaxel and administered for a total duration of 54 weeks, 18 injections."
3201132|NCT01190332|Placebo Comparator|conventional technique of ERCP|
3201133|NCT01190332|Active Comparator|Rendezvous technique|
3201134|NCT01190319|Placebo Comparator|Placebo Beverage|The placebo beverage is matched in energy, macronutrient composition and sensory properties to the active beverage, but is devoid of strawberry polyphenols.
3201135|NCT01190319|Experimental|Strawberry Beverage|The strawberry beverage is matched in energy, macronutrient composition and sensory properties to the placebo beverage, but contains strawberry polyphenols.
3201136|NCT01190306|Experimental|CXL Treatment|Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light.
3201137|NCT01190306|Active Comparator|Sham Control|Eyes in the control group will be treated with riboflavin only.
3201138|NCT01190293|Experimental|All subjects|All Subjects will receive the same intervention.
3201139|NCT01190280||AC - operation|Patients admitted with acute cholecystitis randomized to operation
3201140|NCT01190280||AC - observation|Patients admitted with acute cholecystitis randomized to observation
3201141|NCT01190280||SGBS - operation|Patients admitted with uncomplicated gallstone disease randomized to operation
3201142|NCT01190280||SGBS - observation|Patients admitted with uncomplicated gallstone disease randomized to observation
3201143|NCT01190280||1983 - stones|Patients that in 1983 were diagnosed with gallstones in a population screening
3201144|NCT01190280||1983 - operation|Patients that were operated for gallstone disease at Haukeland University Hospital, Bergen, Norway, in 1983
3201145|NCT01190280||1983 - controls|Patients that were shown not to have gallstones in a 1983 population screening
3201146|NCT01190280||Gallstone patients|Patients with symptoms from gallstone disease
3201147|NCT01190267|Experimental|Asenapine|All enrolled participants receive open-label asenapine 2.5 mg twice daily (BID) on Day 1-3, which is increased to 5.0 mg BID on Day 4 (dose can be increased earlier at the investigator's discretion). Asenapine dosing is flexible for the remainder of the 26-week open-label drug administration period, and can be adjusted to either 2.5 mg or 5.0 mg BID at the investigator's discretion, based on tolerability and/or symptomatology.
3201148|NCT01190254|Experimental|Asenapine 2.5 mg BID|Participants receive active asenapine 2.5 mg tablets sublingually BID for 8 weeks.
3201149|NCT01190254|Experimental|Asenapine 5.0 mg BID|Participants receive active asenapine 2.5 mg tablets sublingually BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive active asenapine 5.0 mg tablets sublingually BID for the remainder of the 8-week treatment period.
3201150|NCT01190254|Placebo Comparator|Placebo|Participants receive placebo asenapine tablets sublingually BID for 8 weeks.
3201151|NCT01190241|Experimental|Targeted treatment|Targeted treatment with desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib
3201152|NCT01190228|Experimental|Group 1: JE-CV Vaccine Booster|Participants previously vaccinated with JE-CV vaccine will receive a booster dose of JE-CV vaccine on Day 0.
3201153|NCT01190228|Experimental|Group 2: JE-CV Vaccine First Dose|JE-CV vaccine naïve participants will receive a single dose of JE-CV vaccine on Day 0.
3201154|NCT01190228|Active Comparator|Group 3: Varicella Vaccine|JE-CV vaccine naïve participants will receive one dose of Varicella vaccine on Day 0.
3201155|NCT01190215|Experimental|Fluarix Group|Subjects previously vaccinated with Pandemrix vaccine received 1 dose of Fluarix vaccine. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.
3201156|NCT01190215|Active Comparator|Havrix Group|Subjects previously vaccinated with Pandemrix vaccine received 1 first dose of Havrix vaccine (subjects aged above 15 years) or Havrix-Junior vaccine (subjects aged 15 years and below). A second dose was given outside the study setting, at Month 6. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.
3201157|NCT01190202||Subjects|Subjects at least 6 months of age, enrolled in catchment areas of study 110021 (NCT00866619).
3201158|NCT01190189|Experimental|Group A|Subjects received control vaccine in the primary study NCT00294047
3201159|NCT01190176|Experimental|Single Group|NCT00294047 study subjects who had normal cervical cytology but tested positive for oncogenic HPV at their concluding NCT00294047 study visit or were pregnant at their concluding NCT00294047 study visit
3201160|NCT01190163|Experimental|A|
3201161|NCT01190163|Active Comparator|B|
3201162|NCT01190150|Experimental|0.65 g / 1.3 g tranexamic acid|Participants received a single dose of 0.65 g tranexamic acid on Day 1 and a single dose of 1.3 g tranexamic acid on Day 8.
3201163|NCT01190150|Experimental|1.3 g / 0.65 g tranexamic acid|Participants received a single dose of 1.3 g tranexamic acid on Day 1 and a single dose of 0.65 g tranexamic acid on Day 8.
3201164|NCT01190137|Active Comparator|400 IU Vitamin D3|
3201165|NCT01190137|Experimental|400 IU Vitamin D2|
3201166|NCT01190124||CohortHIV|Adult multiple-experienced HIV infected patients who needed to change their antiretroviral therapy and initiated raltegravir + optimized background therapy under the Early Access Program.
3201167|NCT01190111|Experimental|CYT107 (r-hIL-7)|
3201168|NCT01190098|Experimental|Lacosamide|
3201169|NCT01190098|Placebo Comparator|Sugar pill|
3201170|NCT01190085|Active Comparator|Ghrelin (1 microg/kg)|A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
3201171|NCT01190085|Active Comparator|Ghrelin (3 microg/kg)|A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
3201172|NCT01190085|Placebo Comparator|Saline Solution|Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
3201173|NCT01190059|Experimental|EVLP Group|EVLP Group are those recipient lung transplant patients that received donor lungs that had been placed on the ex vivo lung perfusion system with Steen Solution™ .
3201174|NCT01190046|Other|Resistance exercise training|Exercise is being used as an experimental tool to determine if remediation of muscle disuse counteracts cellular/molecular defects in muscle structure/function.
3201175|NCT01190033|Active Comparator|Neurolysis|In this intervention the neurotome will be connected
3201176|NCT01190033|Placebo Comparator|Neurotome OFF|neurotome not raised
3201177|NCT01190020|Active Comparator|Lubiprostone|
3201178|NCT01190020|Placebo Comparator|Placebo|
3201179|NCT01190007|Experimental|Caduet|
3201180|NCT01189994|Experimental|Acupuncture|Patients will receive acupuncture treatment in addition to standard care, coming to twelve weekly acupuncture sessions
3201181|NCT01189994|Active Comparator|Orientation|Patients will receive standard care only, coming to three monthly orientation sessions
3201182|NCT01189981|Experimental|eHealth intervention|Standard lifestyle counseling. Short Message Service (SMS) encouragements for physical activity,
3201183|NCT01189981|Active Comparator|Lifestyle counseling|Standard lifestyle counseling. No Short Message Service (SMS) encouragements for physical activity.
3201184|NCT01189968|Experimental|Carboplatin and Pemetrexed plus demcizumab|Carboplatin and Pemetrexed plus demcizumab
3201185|NCT01189968|Experimental|Pemetrexed plus demcizumab|Pemetrexed plus demcizumab
3201186|NCT01189955|Active Comparator|HS total thyroidectomy|In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.
3201187|NCT01189955|Active Comparator|conventional total thyroidectomy|A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
3201188|NCT01189929|Experimental|Gemcitabine and demcizumab With or Without Abraxane®|Gemcitabine and demcizumab With or Without Abraxane®
3201189|NCT01189916|Experimental|Transrectal NOTES appendectomy|These patients will undergo an experimental surgical procedure that uses flexible endoscopic instruments (i.e., inserted through the rectum).
3201190|NCT01189890|Experimental|Sitagliptin|Sitagliptin phosphate 100 mg or 50 mg once daily (QD)
3201191|NCT01189890|Active Comparator|Glimepiride|Glimepiride 1-6 mg QD
3201192|NCT01189877|Experimental|pO2 measurements|In patients meeting eligibility requirements outlined below, comparisons will be made between direct pO2 measurements using a tissue hypoximeter and IHC-assessed expression of hypoxia related proteins (HIF-1α, VEGF, CA IX and GLUT-1) in both normal and tumor tissue.
3201193|NCT01189864||Ciprofloxicin or Vigamox or other.|
3201194|NCT01189864||Nonsteroidal (Acular, Voltaren Xibrom, etc)|
3201195|NCT01189864||Steroid (FML, Pred Forte, Flarex, etc.)|
3201196|NCT01189851|Other|IORT|Treated with Intraoperative Radiation Therapy
3201197|NCT01189838||Low Cyr61|Low Cyr61 immunohistochemical stain in patients' TCC tumor
3201198|NCT01189838||High Cyr61|High Cyr61 immunohistochemical stain in patients' TCC tumor
3201199|NCT01189825|Experimental|Exercise|
3201200|NCT01189812|Placebo Comparator|sugar pill|
3201201|NCT01189812|Active Comparator|Lithium|
3201202|NCT01189799|Experimental|Motivational Therapy Aftercare|
3201203|NCT01189799|Other|Dual Recovery Anonymous|Aftercare Treatment as Usual
3201204|NCT01189786|Experimental|Cohort 2: CD34+ cells as a top off|"Cohort 2 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD34 Reagent system' as a topoff without the need for additional conditioning prior to the infusion. These patients who have already received SCT and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse."
3201250|NCT01189448|Active Comparator|Spiramycine|Spiramycin group : spiramycin 1g tid orally
3201515|NCT01187654|Active Comparator|control|injection of autologous serum
3201205|NCT01189786|Experimental|Cohort 1: CD34+ Cells for transplant|Cohort 1 consists of patients receiving CD34+ selected peripheral blood stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The stem cells will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory.
3201206|NCT01189773|Experimental|1|Ibuprofen given orally (10 mg/kg, max = 600 mg) and codeine given orally (1 mg/kg, max = 60 mg).
3201207|NCT01189773|Placebo Comparator|2|Ibuprofen given orally (10 mg/kg, max = 600 mg) and placebo given orally ( identical in taste color to codeine preparation).
3201208|NCT01189760|Experimental|onabotulinumtoxinA 44U|44 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
3201209|NCT01189760|Other|onabotulinumtoxinA 24U|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo (normal saline) injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
3201210|NCT01189760|Placebo Comparator|placebo (normal saline)|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
3201211|NCT01189747|Experimental|onabotulinumtoxinA|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1.
3201212|NCT01189747|Placebo Comparator|placebo (normal saline)|normal saline injected into bilateral Crow's Feet Line areas on Day 1.
3201213|NCT01189734|Placebo Comparator|laparoscopic common bile duct exploration|
3201214|NCT01189734|Active Comparator|laparoscopic cholecystectomy with intraoperative ES|
3201215|NCT01189721|Active Comparator|sevoflurane|Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min. patients who are in this group will be infused propofol intraoperatively.
3201216|NCT01189721|Experimental|propofol|Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min. patients included this group will be inhaled sevoflurane intraoperatively.
3201217|NCT01189708|Experimental|Mesh implantation|Ultrapro® Mesh implantation
3201218|NCT01189708|Active Comparator|Standard wound closure without a mesh|Standard wound closure
3201219|NCT01189695|Experimental|Boosted lopinavir monotherapy|
3201220|NCT01189695|Active Comparator|boosted lopinavir + optimized background regimens (OBRs)|
3201221|NCT01189682|Active Comparator|Tegaderm HP|
3201222|NCT01189682|Placebo Comparator|Tegaderm|
3201223|NCT01189682|Active Comparator|Tegaderm CHG|
3201224|NCT01189669|Active Comparator|LC n-3 PUFA|Supplementation with 4 x 1g fish oil capsules (Seven Seas, Ireland) containing 1.9g combined EPA and DHA daily for 6 weeks.
3201225|NCT01189669|Placebo Comparator|Placebo (olive oil) supplement|4 x 1g olive oil capsules (Millas Inc) were given daily for 6 weeks.
3201226|NCT01189669|No Intervention|Wash out period|A 6 week wash out period separated the LC n-3 PUFA and the Placebo (olive oil) arms. During this period the subjects took no supplements. This arm was designed to minimise a cross-over effect.
3201227|NCT01189656|Experimental|Vaccine+Lamivudine group|Subjects assigned into the experimental and the controlled groups with randomization and double-blindness by a ratio of 2:1
3201228|NCT01189656|Placebo Comparator|Placebo+Lamivudine group|
3201229|NCT01189643|Experimental|Chemotherapy|This is a pilot study to evaluate the acute toxicities and activity of irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator based therapy in newly diagnosed patients with DSRCT.
3201230|NCT01189617|Experimental|Formula PD-F-7619|At least twice per week for one week, massage about a dime-sized amount of the PD-F-7619 personal lubricant product to the application site as directed.
3201231|NCT01189604|Placebo Comparator|Arm1 - Placebo|
3201232|NCT01189604|Active Comparator|Arm 2 - ICI35,868 (propofol)|
3201233|NCT01189604|Active Comparator|Arm 3 - ICI35,868 (propofol)|
3201234|NCT01189604|Active Comparator|Arm 4 - ICI35,868 (propofol)|
3201235|NCT01189604|Active Comparator|Arm 5 - ICI35,868 (propofol)|
3201236|NCT01189604|Active Comparator|Arm 6 - ICI35,868 (propofol)|
3201237|NCT01189604|Active Comparator|Arm 7 - ICI35,868 (propofol)|
3201238|NCT01189591|Experimental|Sleep deprivation|Slow-wave sleep deprivation for one night as an experimental treatment for major depressive disorder
3201239|NCT01189578||Recreational cocaine users|Individuals who have used cocaine in the past 3 months, but do not meet DSM-IV-TR diagnostic criteria for Cocaine Dependence.
3201240|NCT01189565||Joint Replacement Patients|
3201241|NCT01189552|Active Comparator|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001). LETS ACT is based on the belief that the best way to improve mood, remain sober, and to make long-term life changes is by changing and increasing one's activity level. It has been modified to accommodate the needs of a substance using population currently receiving inpatient substance use treatment. Treatment is provided over a 4-week period and is provided in small group format, with each group consisting of 3-5 patients.
3201242|NCT01189552|Placebo Comparator|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Treatment is provided over a 4-week period and is provided in small group format, with each group consisting of 3-5 patients.
3201243|NCT01189526|Experimental|IVRI|IVRI : intravitreal ranibizumab (0.5mg) injection
3201244|NCT01189526|Active Comparator|Laser|Laser : macular laser photocoagulation
3201245|NCT01189513|Experimental|SCH 900105|10 mg/kg intravenous Days 1, 8 and 15 of 30 day cycle.
3201246|NCT01189500|Experimental|Tamoxifen and Desvenlafaxine SR|
3201247|NCT01189487|Experimental|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium 12g/day (3 g four times a day) IV
3201248|NCT01189461|Experimental|pegaptanib sodium arm|all patients will receive pegaptanib sodium
3201249|NCT01189448|Active Comparator|Pyrimethamine/Sulfadiazine|Women who are enrolled and randomised in Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.
3201251|NCT01189435|Experimental|erlotinib|This will be a single institution, single-arm, two-stage, open-label study of erlotinib in the treatment of patients with recurrent EGFR-mutant lung cancer following completion of adjuvant erlotinib or gefitinib therapy.
3201252|NCT01189422|Experimental|Segment 1: 3 Arms|
3201253|NCT01189422|Experimental|Segment 2: 4 Arms|
3201254|NCT01189409|Experimental|PEG then Senna|PEG in stepped bowel protocol
3201255|NCT01189409|Experimental|Senna then PEG|Stepped bowel protocol with Senna then PEG
3201256|NCT01189396|Experimental|T|Four doses of A006 taken in 30 minute intervals. Doses will have an escalating number of inhalations (1, 1, 2, and 4 inhalations). Total cumulative Albuterol dose at 90 minutes is 1440 mcg.
3201257|NCT01189396|Active Comparator|R|Four doses of Proventil-HFA taken in 30 minute intervals. Doses will have an escalating number of inhalations (2, 2, 4, and 8 inhalations). Total cumulative Albuterol dose at 90 minutes is 1440 mcg.
3201258|NCT01189396|Placebo Comparator|P|Four doses of Placebo DPI taken in 30 minute intervals. Doses will have an escalating number of inhalations (1, 1, 2, and 4 inhalations). Total cumulative Albuterol dose at 90 minutes is 0 mcg.
3201259|NCT01189383|Experimental|IL15-DC Vaccine|Approximately 9 x 10^6 DCs will be injected (subcutaneously)total per vaccination visit. Patients will receive four vaccinations at weeks 0, 4, 8 and 12.At each scheduled vaccination the patient will receive a total of 3 injections, i.e., 3 mL injections at each of 3 anatomical locations.Injection sites are in upper and lower extremities. Subsequent DC injections will be rotated to different locations on the upper and lower extremities.
3201260|NCT01189370|Experimental|Intra-Patient Dose Escalation: Sorafenib|All patients will receive a starting dose of sorafenib 400 mg by mouth twice daily. At four weeks, all patients who have not experienced Grade 3 or 4 toxicity will undergo dose escalation using a treatment schedule of days 1-5 days of each week. Doses will continue to be escalated every 4 weeks depending on tolerability and tumor response.
3201261|NCT01189357||failed meniscal transplantation|
3201262|NCT01189344|Experimental|Not surgical group|The Nos surgical (NS) group includes 15 patients for whom bariatric surgery is planned. Body mass index (BMI) of this group of patients is ≥40 Kg/m2.
3201263|NCT01189344|Experimental|Surgical group|The Surgical (S) group includes 15 patients who had undergone Roux-en-Y bariatric surgery 2 to 3 months before inclusion in the study
3201264|NCT01189331|No Intervention|CT and FFR|
3201265|NCT01189318|Experimental|Seroquel XR|Patients with MDD receives Seroquel XR.
3201266|NCT01189318|No Intervention|healthy control|
3201267|NCT01189305|Experimental|Behavioral Couples Therapy|
3201268|NCT01189305|Experimental|Individual Drug Counseling|
3201269|NCT01189292|Active Comparator|Dexamethasone injection|Administration of 8mg(2ml) intravenous Dexamethasone (Mephameson®)
3201270|NCT01189292|Placebo Comparator|Placebo (NaCl 0.9%)|
3201271|NCT01189279|Experimental|Part 1: bimatoprost Formulation A|bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
3201272|NCT01189279|Experimental|Part 1: bimatoprost Formulation B|bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
3201273|NCT01189279|Experimental|Part 2: bimatoprost Formulation C|bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
3201274|NCT01189266|Experimental|Arm 1 Phase I Vorinostat 180 mg/m^2|"Patients in phase I receive vorinostat PO on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Patients undergo 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. Patients then receive maintenance therapy comprising vorinostat PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~Interventions:"
3201275|NCT01189266|Experimental|Arm 2 Phase 1 Virinostat 230 mg/m^2|"Patients receive a higher dose of vorinostat PO on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Patients undergo 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. Patients then receive maintenance therapy comprising vorinostat PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~Interventions:"
3201276|NCT01189266|Experimental|Arm 3 Phase II Evaluation Virinostat 230 mg/m^2|Patients in phase II receive vorinostat PO on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Patients undergo 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. Patients then receive maintenance therapy comprising vorinostat PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3201277|NCT01189253|Active Comparator|Doxorubicin 75 mg/m² every 3 weeks|Doxorubicin administered on day 1 every 3 weeks for a maximum of 6 cycles
3201278|NCT01189253|Experimental|Trabectedin IV 3 hours|Trabectedin administered on day 1 every 3 weeks at the dose of 1.3 mg/m² until progression
3201279|NCT01189253|Experimental|Trabectedin IV 24 hours every 3 weeks|Trabectedin administered on day 1 every 3 weeks at the dose of 1.5 mg/m² over 24 hours until progression
3201280|NCT01189240|Experimental|Phase I Dose Finding|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
3201281|NCT01189240|Experimental|Phase II Stage I|"Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15.Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
3201282|NCT01189240|Experimental|Phase II Stage II Arm 1|"Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
3201283|NCT01189240|Active Comparator|Phase II Stage II Arm 2|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
3201284|NCT01189240|Experimental|Phase I Dose Finding - Level 1 5mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 5mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
3201285|NCT01189240|Experimental|Phase I Dose Finding - Level 2 10mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 10mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
3201286|NCT01189240|Experimental|Phase I Dose Finding - Level 3 20mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 20mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
3201287|NCT01189227|Experimental|Arm 1: Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
3201288|NCT01189227|Experimental|Arm 2: Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
3201289|NCT01189214|Experimental|Memantine|
3201290|NCT01189201|Experimental|BI 10773/linagliptin FDC SID|medium single dose ofBI 10773/linagliptin FDC (Formulation A1)
3201291|NCT01189201|Experimental|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
3201292|NCT01189201|Experimental|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
3201293|NCT01189201|Experimental|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
3201294|NCT01189188|Experimental|With ultrasound guidance|In this group of patients, ultrasound guidance will be used when drawing blood from the radial artery.
3201295|NCT01189188|Active Comparator|Without ultrasound guidance|In this group of patients, no ultrasound guidance will be used when drawing blood from the radial artery.
3201296|NCT01189175|Experimental|BI 113823|single oral dose per subject
3201297|NCT01189175|Experimental|BI 113823 + Ketokonazole|after wash-out 5 days ketokonazole with BI 113823 on day 3
3201298|NCT01189162|Experimental|NIMV- nasal respiratory support|Infants with RDS will be treateg with nasal intermittent mandatory ventilation
3201299|NCT01189162|Experimental|HFNC- nasal respiratory support with HFNC|Infants with RDS will be treated with nasal respiratory support with high flow nasal canulla
3201300|NCT01189149|Experimental|IV fluids|Infants will get IV fluids whem indicated until able to tolerate full oral feedings
3201301|NCT01189149|Experimental|Oro/naso gastric tube feeding|Infants will get oro/naso gastric tube feeding whem indicated until able to tolerate full oral feedings
3201302|NCT01189136|Sham Comparator|Sham treatment|34 gauge needle inserted 3cm above the medial ankle, but nonconductive cables are connected, so that no electrical stimulation is applied, over a 30-minute treatment period
3201303|NCT01189136|Experimental|PTNS Active Treatment|34 gauge needle inserted 3cm above the medial ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
3201304|NCT01189123|Active Comparator|Standard dose influenza vaccine|Fluzone (Sanofi Pasteur)
3201305|NCT01189123|Active Comparator|High Dose Vaccine|High Dose Fluzone by sanofi pasteur
3201306|NCT01189110|Active Comparator|Arm 1|Stimulation of auriculotherapy points on both ears with functioning Stim Flex 400A TENS unit once a week for 5 weeks.
3201307|NCT01189110|Placebo Comparator|Arm 2|Stimulation of auriculotherapy points on both ears with disabled Stim Flex 400A TENS unit once a week for 5 weeks.
3201308|NCT01189097|Experimental|dextromethorphan|
3201309|NCT01189084||Observational immunotherapy follow-up|
3201310|NCT01189071|Active Comparator|Darifenacin|3 days of preoperative darifenacin anticholinergic medication
3201311|NCT01189071|No Intervention|no pill|The control group will have the standard of care which is no preoperative anticholinegic medication.
3201312|NCT01189058|Experimental|rTMS and CIMT|This group will receive both rTMS and CIMT.
3201313|NCT01189058|Experimental|rTMS and no CIMT|This group will receive rTMS only.
3201314|NCT01189058|Experimental|Sham and CIMT|This group will receive CIMT and sham rTMS.
3201315|NCT01189058|No Intervention|Sham and no CIMT|This group will receive sham rTMS and no CIMT.
3201316|NCT01189045|Experimental|Aerobic Program|The Aerobic Program will be the Experimental arm of this trial, where a structured, progressive aerobic exercise will be conducted in a class format
3201317|NCT01189045|Active Comparator|Balance and Flexibility Program|The Balance and Flexibility Program will be a non-aerobic intervention that will act as an Active Comparator. Stretching, balance exercises, yoga- or Tai Chi-style classes will be conducted.
3201318|NCT01189032|Experimental|High concentration|
3201319|NCT01189032|Experimental|Low concentration|
3201320|NCT01189032|Placebo Comparator|Placebo|
3201321|NCT01189019|Experimental|Group 1 - 2mg ranibizumab monthly|2mg ranibizumab monthly
3201322|NCT01189019|Active Comparator|Group 2 - 2mg x 3 then PRN|
3201323|NCT01189006|Experimental|dextromethorphan|Research clinical trial of double-blind, stratified randomized, parallel group, double-centre study
3201324|NCT01188993|Active Comparator|septic shock TPT then TEE|Group 1: Each patient will be assessed by both the transpulmonary thermodilution technique and transesophageal echocardiography (TEE)..
3201325|NCT01188993|Active Comparator|septic shock TEE then TPT|Goup 2: Each patient will be assessed by both transesophageal echocardiography (TEE) and the transpulmonary thermodilution technique.
3201326|NCT01188980||NoBE (control)|
3201327|NCT01188980||BE without dysplasia|
3201328|NCT01188980||BE with dysplasia|
3201329|NCT01188967|Experimental|GSK598809|Active medication
3201330|NCT01188967|Placebo Comparator|Placebo|Placebo
3201331|NCT01188954|Active Comparator|Doxycycline|Doxycyline, family of tetracycline antibiotics, used to scleroses the lymphatic vessels that may have transected during dissection.
3201332|NCT01188954|Placebo Comparator|Normal Saline/Water|The standard care is wetting and suctioning fluids followed with suturing of the groin.
3201335|NCT01188928|Experimental|LEO 80185|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension
3201336|NCT01188928|Active Comparator|Betamethasone|Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle
3201337|NCT01188928|Active Comparator|Calcipotriol|Calcipotriol 50 mcg/g in the topical suspension vehicle
3201338|NCT01188928|Placebo Comparator|Topical suspension vehicle|The topical suspension vehicle alone
3201339|NCT01188915|Experimental|intensive screening|annual breast cancer detection based on mammography, echography and RMI.
3201340|NCT01188902|Experimental|walnut|western type diet with 48 g walnut per day
3201341|NCT01188902|No Intervention|control|
3201342|NCT01188876|Experimental|Carboplatin/Pralatrexate|
3201343|NCT01188863|Experimental|Solid Oral Dose - 150 mg tablets|
3201344|NCT01188863|Experimental|Solid Oral Dose - 50 mg tablets|
3201345|NCT01188863|Experimental|Liquid Oral Dose|
3201346|NCT01188850|Experimental|6mg of DNA/dose|Subjects who have previously received a 3 dose series of VGX-3100 containing either 0.6, 2 or 6mg DNA/dose will receive a fourth dose of VGX-3100 containing 6mg of DNA/dose administered via IM injection + electroporation at Day 0
3201347|NCT01188837|Active Comparator|Full Kinetic Chain Manipulative Therapy|
3201348|NCT01188837|Active Comparator|Full Kinetic Chain Rehabilitation|
3201349|NCT01188837|Active Comparator|Full Kinetic Chain Manipulative Therapy with Rehabilitation|
3201350|NCT01188824|Active Comparator|Cilostazol|Pletaal® (Cilostazol) 100 mg, bid p.o.
3201351|NCT01188824|Placebo Comparator|placebo|"Placebo~1 tablet, bid p.o."
3201352|NCT01188811|Experimental|Arm 1: lipoic acid|28 subjects receive oral lipoic acid 1200mg daily
3201353|NCT01188811|Placebo Comparator|Arm 2: placebo|28 subjects receive placebo daily
3201354|NCT01188798|Experimental|Transplant recipients receiving Methotrexate|Participants will be biologically stratified according to disease, donor, and KIR match. In addition to a standard backbone of 2 GVHD prophylactics, a computer generated randomization procedure will assign participants to a third GVHD prophylactic medication (MTX or pentostatin)
3201355|NCT01188798|Experimental|Transplant recipients receiving Pentostatin|Participants will be biologically stratified according to disease, donor, and KIR match.between donor and host.In addition to a standard backbone of 2 GVHD prophylactics, a computer generated randomization procedure will assign participants to a third GVHD prophylactic medication (MTX or pentostatin)
3201356|NCT01188772|Experimental|Sofosbuvir 200 mg (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive sofosbuvir 200 mg (2 x 100 mg tablets)+placebo to match sofosbuvir (2 tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
3201357|NCT01188772|Experimental|Sofosbuvir 400 mg (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive sofosbuvir 400 mg (4 x 100 mg tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
3201358|NCT01188772|Active Comparator|Placebo (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive placebo to match sofosbuvir (4 tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
3201359|NCT01188772|Experimental|Sofosbuvir 400 mg (Genotype 2/3)|Participants with genotype 2 or 3 HCV infection received sofosbuvir 400 mg (4 x 100 mg tablets)+PEG+RBV for 12 weeks.
3201360|NCT01188759|Experimental|Voriconazole and Anidulafungin Combination|Subjects in the combination arm will receive voriconazole and anidulafungin in combination for 2-4 weeks followed by voriconazole monotherapy to complete 6-12 weeks of therapy.
3201361|NCT01188759|Active Comparator|Voriconazole Monotherapy|Subjects in the monotherapy arm will receive voriconazole monotherapy for 6-12 weeks of therapy.
3201362|NCT01188746|Experimental|Questionnaire or interview|A pre-experimental design was chosen to examine changes in QoL following a palliative intervention.
3201363|NCT01188733|Experimental|Sandostatin LAR 10mg|Sandostatin LAR ( long-acting octreotide) administered every 28 days in a dose of 10mg
3201364|NCT01188733|Experimental|Sandostatin LAR 30mg|Comparison of drug doses
3201365|NCT01188733|Placebo Comparator|Saline|Saline control
3201366|NCT01188720|No Intervention|Baseline|Assessment only baseline
3201367|NCT01188720|Experimental|Acute exercise|Exercise immediately before sexual activity, three times per week.
3201368|NCT01188720|Active Comparator|General exercise|Exercise not immediately before sexual activity, three times per week.
3201369|NCT01188707|Experimental|Belinostat, Erlotinib, NSCLC|
3201370|NCT01188694|Experimental|Psychotherapy plus Methylene Blue, USP|
3201371|NCT01188694|Placebo Comparator|Psychotherapy Plus Placebo|
3201372|NCT01188694|Other|Delayed Psychotherapy|
3201373|NCT01188681|Experimental|Phase 1: 15 mg/kg TRU-016 + Bendamustine|TRU-016 (15 mg/kg) and bendamustine (70 mg/m2), n = 6 patients
3201374|NCT01188681|Experimental|Phase 1: 20 mg/kg TRU-016 + Bendamustine|TRU-016 (20 mg/kg) and bendamustine (70 mg/m2), n = 6 patients
3201375|NCT01188681|Experimental|Phase 2: TRU-016 and bendamustine|TRU-016 (20 mg/kg) and bendamustine (70 mg/m2), n = 32 patients
3201376|NCT01188681|Active Comparator|Phase 2: Bendamustine|Bendamustine (70 mg/m2), n = 33 patients
3201377|NCT01188668|Experimental|Aripiprazole + Desvenlafaxine SR|
3201378|NCT01188655||Treatment Group Enbrel|
3201379|NCT01188629|Placebo Comparator|Safety Training|
3201380|NCT01188629|Experimental|Personal Health Partner and Counseling (PHP+C)|
3201381|NCT01188603|Experimental|flibanserin|flibanserin 100 mg dose every evening
3201382|NCT01188590||Patients undergoing heart surgery|
3201383|NCT01188577|Experimental|Epinephrine Inhalation Aerosol, HFA|Experimental treatment of 10 inhalations of 125 mcg epinephrine base propelled by HFA 134a
3201384|NCT01188577|Active Comparator|Epinephrine Inhalation Aerosol, CFC|Epinephrine Inhalation Aerosol, CFC propelled, 220 mcg/inhalation , 10 inhalations
3201385|NCT01188564|Experimental|rhC1INH|
3201386|NCT01188564|Placebo Comparator|Placebo (Saline)|
3201387|NCT01188551|Experimental|dexmedetomidine w/ midazolam|Midazolam 0.5 mg/kg given orally pre-op and 1 dose of dexmedetomidine 1mcg/kg given intranasally in OR.
3201388|NCT01188551|Active Comparator|fentanyl w/ midazolam|Midazolam 0.5 mg/kg given orally pre-op and 1 dose of fentanyl 2mcg/kg given intranasally in OR.
3201389|NCT01188551|Experimental|dexmedetomidine w/o midazolam|1 dose of dexmedetomidine 1mcg/kg given intranasally in OR without any pre-medication.
3201390|NCT01188551|Active Comparator|fentanyl w/o midazolam|1 dose of fentanyl 2mcg/kg given intranasally in the OR without any pre-medication.
3201391|NCT01188538|Experimental|Epiduo gel|"Dose or Concentration:Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel.~Mode and Frequency of Administration:Topical to the face, once daily application in the evening.~Duration of Treatment:12 weeks"
3201392|NCT01188538|Active Comparator|BPO gel|"Dose or Concentration:Adapalene 0% / Benzoyl Peroxide 2.5% Gel.~Mode and Frequency of Administration:Topical to the face, once daily application in the evening.~Duration of Treatment:12 weeks"
3201393|NCT01188512|Experimental|BPZE1 - Low dose|1,000 colony forming units (cfu) of BPZE1
3201394|NCT01188512|Experimental|BPZE1- middle dose|100,000 colony forming units (cfu) of BPZE1
3201395|NCT01188512|Experimental|BPZE1 - High dose|10,000,000 colony forming units (cfu) of BPZE1
3201396|NCT01188512|Placebo Comparator|Placebo|Formulation buffer
3201397|NCT01188499|Experimental|Carboplatin/Paclitaxel + Birinapant|Carboplatin (AUC 6/Paclitaxel (175 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
3201398|NCT01188499|Experimental|Irinotecan + Birinapant|Irinotecan (350 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
3201399|NCT01188499|Experimental|Docetaxel + Birinapant|Docetaxel (75 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
3201400|NCT01188499|Experimental|Gemcitabine + Birinapant|Gemcitabine (1000 mg/m2/IV) once weekly (7 days +/- 2 days) for 3 consecutive weeks followed by 1 week off + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 2 week off for each cycle (4 weeks per cycle).
3201401|NCT01188499|Experimental|Liposomal Doxorubicin + Birinapant|Liposomal doxorubicin (40 mg/m2/IV) every 4 weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 2 weeks off for each cycle (4 weeks per cycle).
3201402|NCT01188486|Experimental|pulmonary interstitial lymphography|stereotactic body radiation therapy & pulmonary interstitial lymphography
3201403|NCT01188473|Experimental|NPPV plus standard of care|NPPV initiated early and for a prolonged period of time in addition to standard of care in the management of children admitted to the hospital with status asthmaticus
3201404|NCT01188473|No Intervention|Control: standard of care alone|standard of care in the management of children admitted to the hospital with status asthmaticus
3201405|NCT01188460|Placebo Comparator|Control Group|Receive one weekly telephone follow-up call per week to monitor sleep progress, complete 7 weeks of sleep diaries only (sleep diary measures Total Sleep Time in hours, Time to Fall Asleep in minutes, Number of Nocturnal Awakenings, Sleep Efficiency as a percentage, and Sleep Quality as units on a scale), complete questionnaires at three study timepoints
3201406|NCT01188460|Experimental|Experimental Group|Receive one weekly telephone call to monitor sleep progress, complete 7 weeks of sleep diaries (sleep diary measures Total Sleep Time in hours, Time to Fall Asleep in minutes, Number of Nocturnal Awakenings, Sleep Efficiency as a percentage, and Sleep Quality as units on a scale), implement one chapter per week of self-help manual for insomnia over 7 weeks at home, complete questionnaires at three study timepoints
3201407|NCT01188447|Experimental|Eligible low-risk trauma patients|Paramedics will use the Canadian C-Spine Rule to evaluate low-risk trauma patients meeting the study inclusion criteria in order to determine the need for spinal immobilization for transport to the hospital.
3201408|NCT01188434|Experimental|Integrated Behavioral Treatment|Combined substance abuse, parenting skills, and basic needs intervention
3201409|NCT01188434|Active Comparator|casework treatment as usual|services as usual as referred by child welfare
3201410|NCT01188421|Active Comparator|buprenorphine|Sublingual buprenorphine/naloxone tablets (or placebo)
3201411|NCT01188421|Active Comparator|clonidine|Oral clonidine tablets (or placebo)
3201412|NCT01188421|Experimental|tramadol ER|Oral tramadol tablets (or placebo)
3201413|NCT01188408|Experimental|Liposome Entrapped Docetaxel (LE-DT)|Disease status and tumor responses/progression is assessed in accordance to the RECIST guideline
3201414|NCT01188395||subtypes of bipolar disorders|Bipolar I Disorder with alcoholism Bipolar I Disorder without alcoholism Bipolar II Disorder with alcoholism Bipolar II Disorder without alcoholism
3201415|NCT01188382||Healthy elderly|Healthy elderly 60-82 years; Normal MRI; No psychiatric or neurological disorder and without signs of advanced atherosclerotic disease
3201416|NCT01188369|Experimental|levosimendan|infusion 0,1ug/kg/min for duration of ca. 4 hours prior to operation and until the end of operation
3201417|NCT01188369|Placebo Comparator|Placebo|Identical placebo
3201418|NCT01188343|Experimental|Group 1|Participants will receive the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 0 and Measles, mumps, and rubella live attenuated virus vaccine (MMR) on Day 42
3201419|NCT01188343|Experimental|Group 2|Participants will receive Measles, mumps, and rubella live attenuated virus vaccine (MMR) on Day 0, and the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 42.
3201420|NCT01188343|Experimental|Group 3|Participants will receive the Measles, mumps, and rubella live attenuated virus vaccine (MMR) and the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 0
3201421|NCT01188330|Experimental|WITH Comprehensive Geriatric assessment|Conventional haematological management of patients and Comprehensive Geriatric assessment (CGA) at diagnosis followed by interventions according to disabilities detected and planned monthly follow up by a nurse practitioner during 6 months.
3201422|NCT01188330|Active Comparator|Conventional|Conventional haematological management of patients
3201423|NCT01188317|Experimental|1|
3201424|NCT01188317|Placebo Comparator|2|
3201425|NCT01188304|Experimental|1|
3201426|NCT01188304|Placebo Comparator|2|
3201427|NCT01188291||Sleep Apnea / Hypopnea syndrome|Study group composed of patients with Obstructive Sleep Apnea / Hypopnea syndrome
3201428|NCT01188278||Patients in CP-CML treated with 2G TKI|Patients in CP-CML treated with 2G TKI (nilotinib or dasatinib) post imatinib failure
3201516|NCT01187641||colon cancer|patients undergoing treatment for colon cancer
3201429|NCT01188265|Experimental|Valproate & dextromethorphan 30 mg|Valproate and dextromethorphan 30 mg per day
3201430|NCT01188265|Experimental|VPA & dextromethorphan 60 mg|VPA & dextromethorphan 60 mg per day
3201431|NCT01188265|Active Comparator|VPA & Placebo|VPA & placebo
3201432|NCT01188252|Experimental|Roniciclib|
3201433|NCT01188239||HIGH 6wks LOW 6wks NICOTINE|"Well characterized group of 100 regular smokers experimenting the E-Cigarette loaded with ORIGINAL 7.4 mg nicotine cartridges for 6 weeks followed by CATEGORIA 5.2 mg nicotine cartridges for a further 6 weeks (high and low nicotine group)."
3201434|NCT01188226|Experimental|Nano Hybrid Composite Denture teeth|Denture teeth are made of nano hybrid composite material
3201435|NCT01188213|Experimental|Purified MSM|
3201436|NCT01188200|Experimental|Nutritional Formula #M979|nutritional formula
3201437|NCT01188200|Active Comparator|Regular standard meal|standard meal
3201438|NCT01188187|Experimental|Custirsen, Docetaxel, Prednisone|"Three doses of 640 mg custirsen administered intravenously (IV) as a loading dose between Days -9 to -1. Custirsen, 640 mg, given IV weekly on Days 1, 8, and 15 of each 21-day cycle. Docetaxel (75 mg/M^2 via intravenous injection) on Day 1 of every 21 days plus prednisone (5 mg tablets taken by mouth) twice each day and dexamethasone (8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration).~Treatment continues for 10 cycles or until unacceptable toxicity or disease progression."
3201439|NCT01188187|Active Comparator|Docetaxel, Prednisone|"Docetaxel (75 mg/M^2 via intravenous injection) on Day 1 of every 21 days plus prednisone (5 mg tablets taken by mouth) twice each day and dexamethasone (8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration).~Treatment continues for 10 cycles or until unacceptable toxicity or disease progression."
3201440|NCT01188174|Experimental|Clofarabine|
3201441|NCT01188161||Normal subjects|Volunteers without a history of dizzyness or vertigo
3201442|NCT01188148|Active Comparator|VPA & Placebo|VPA & Placebo
3201443|NCT01188148|Experimental|VPA & memantine|
3201444|NCT01188135|Experimental|Interactive Voice messaging|"Participants will receive three kinds of interventions calls from the IVR phone system. (1) The first call is to orient the participant to the IVR system, ask permission to leave detailed messages in the future, and to encourage adherence in this initial period of great risk for premature discontinuation. (2) The Refill Reminder Call is to remind patients that a refill their antidepressant medications and occurs approximately 6 days before the prior dispense of medication is due to run out. (3) The Tardy Refill Call is made to participants for whom EMR records indicate that a scheduled refill was missed"
3201445|NCT01188135|No Intervention|Usual care arm|usual care treatment with no interactive phone reminder calls phone
3201446|NCT01188135|Experimental|IVR messaging w/ Psycho-ed. materials|"Participants will receive three kinds of interventions calls from the IVR phone system. (1) The first call is to orient the participant to the IVR system, ask permission to leave detailed messages in the future, and to encourage adherence in this initial period of great risk for premature discontinuation. (2) The Refill Reminder Call is to remind patients that a refill their antidepressant medications and occurs approximately 6 days before the prior dispense of medication is due to run out. (3) The Tardy Refill Call is made to participants for whom EMR records indicate that a scheduled refill was missed. In addition, participants will receive educational material about antidepressant medication."
3201447|NCT01188122|Experimental|AnapnoGuard|
3201448|NCT01188109|Experimental|Gemcitabine / Cisplatin|Single arm study. All patients will receive gemcitabine and cisplatin as adjuvant therapy.
3201449|NCT01188096|Experimental|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
3201450|NCT01188083|Experimental|Fructose Drink|Subject will drink 3-8oz drinks per day for 4 weeks
3201451|NCT01188083|Experimental|Glucose Drink|Subject will drink 3-8oz drinks per day for 4 weeks
3201452|NCT01188070|Sham Comparator|Usual Care Attention Control|Provision of printed educational material and attendance at one group session. This session will focus on nutrition education and flexibility and stretching.
3201453|NCT01188070|Experimental|Psychoeducation plus exercise|Psychoeducation intervention plus an individualized exercise program which will include monitored, individually-prescribed aerobic and resistance exercise.
3201454|NCT01188070|Active Comparator|Psychoeducation|Psychoeducational program to involve group sessions over consecutive weeks. The sessions will use the principles of adult learning, emphasizing active learning, group exercises and discussion, and coaching as well as brief talks to provide content. The curriculum will focus on the strengthening of caregiver self-efficacy through enhancement of knowledge and understanding, the acquisition, strengthening, and practice of caregiving skills, and the development of a more clinical or strategic outlook on the caregiving role.
3201455|NCT01188057|Experimental|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, single dose
3201456|NCT01188057|Active Comparator|NIRAVAM TM|NIRAVAM TM 2 mg orally disintegrating tablets, single dose
3201457|NCT01188044||Study group|Healthy children
3201458|NCT01188031|Experimental|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, single dose
3201459|NCT01188031|Active Comparator|NIRAVAM TM|NIRAVAM TM 2 mg orally disintegrating tablets, single dose
3201460|NCT01188018|Active Comparator|Brief Advice|
3201461|NCT01188018|Experimental|Motivational Interviewing|
3201462|NCT01188018|Active Comparator|Health Education|
3201463|NCT01188005|Experimental|OSAS patients|This arm includes the OSAS diagnosed cohort that has been planned to undergo four polysomnographic studies. One standard, one with oxygen supplementation, one with n-CPAP device and one post antioxidants administration
3201464|NCT01188005|No Intervention|Control Group|This group is scheduled to undergo a plain polysomnographic study, whilst plasma cytokine levels will be measured. It will comprise of healthy, non-OSAS volunteers.
3201465|NCT01187992|Experimental|Full-dose atorovastatin (80 mg/d)|For patients randomised to this arm, atorvastatin in the fixed dose of 80 mg/ day was started immediately after randomisation.
3201517|NCT01187628|Experimental|Arm 1|
3201518|NCT01187615|Experimental|Arm 1|
3201519|NCT01187615|Experimental|Arm 2|
3201552|NCT01187355|Active Comparator|renu fresh MPS|MPS used for 30 days as indicated for contact lens care.
3201466|NCT01187992|No Intervention|Conventional medical treatment|For patients randomised to this arm, adherence to the National Cholesterol Education Program, Adult Treatment Panel III guidelines was required. In particular, in these patients,atorvastatin was started at the initial dosage of 20 mg/day immediately after randomisation. Subsequently, atorvastatin dosage was titrated in order to attain low-density lipoprotein cholesterol (LDL-C) levels <100 mg/dL (2.5 mmol/L).
3201467|NCT01187979|Active Comparator|Control|All eligibly enrolled learners in the intervention schools will receive a prevention program delivered by MIET Africa and the KwaZulu-Natal Department of Education. No cash incentives will be paid for meeting milestones
3201468|NCT01187979|Experimental|Cash incentive|All eligibly enrolled learners in the intervention schools will receive a cash incentivised prevention program delivered by MIET Africa and the KwaZulu-Natal Department of Education
3201469|NCT01187966|Placebo Comparator|Placebo|Drug: Placebo
3201470|NCT01187966|Experimental|High Dose (100mg/day)|
3201471|NCT01187966|Experimental|Low dose (50mg/day)|
3201472|NCT01187953|Experimental|LCP-Tacro|The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
3201473|NCT01187953|Experimental|Prograf (tacrolimus)|Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Doses will be adjusted according to whole blood tacrolimus trough levels. In the initial post-transplant period, plasma trough levels will be measured at 24 and 48 hours. Study drugs will be adjusted to maintain the whole blood pre-dose (trough) concentration of tacrolimus in the target range of 6 - 11 ng/mL for the first 30 days, then 4 - 11 ng/mL for the remainder of the study.
3201474|NCT01187940|Experimental|PEGASUS|PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
3201475|NCT01187940|No Intervention|Placebo|Will receive managment as usual from their local educational and NHS services
3201476|NCT01187927||Female subjects|Subjects received Cervarix® as per routine practice
3201477|NCT01187914||Open Irrigation|Those individuals who had an ablation using open irrigation cooled-tip RF ablation.
3201478|NCT01187901|Active Comparator|Erlotinib and Sulindac|Erlotinib 75 mg per day in combination with sulindac 150 mg twice daily for 6 months.
3201479|NCT01187901|Placebo Comparator|Placebo A and Placebo B|Placebo capsules matching erlotinib active comparator (Placebo A) once daily and placebo capsules matching sulindac active comparator (Placebo B) twice daily for 6 months
3201480|NCT01187888|Active Comparator|Rasagiline|
3201481|NCT01187888|Placebo Comparator|Sugar pill|
3201482|NCT01187875|Placebo Comparator|Control|Dextrin Control
3201483|NCT01187875|Experimental|Hi-maize resistant starch 9g|Hi-maize resistant starch 9g
3201484|NCT01187875|Experimental|Novalose 330 resistant starch 9g|Novalose 330 resistant starch 9g
3201485|NCT01187875|Experimental|4.5g Hi-maize and 4.5g Novalose 330|4.5g Hi-maize and 4.5g Novalose 330
3201486|NCT01187862|Other|Basel cocktail|
3201487|NCT01187849|Active Comparator|Metformin|
3201488|NCT01187849|Placebo Comparator|Placebo|
3201489|NCT01187836|Experimental|TRV120027|
3201490|NCT01187836|Placebo Comparator|Placebo|
3201491|NCT01187823|Active Comparator|Nocturnal oxygen therapy|
3201492|NCT01187823|Active Comparator|Adaptive servo ventilation|Bipap® auto SV Advanced
3201493|NCT01187810|Experimental|Combination of Fenretinide, Cytarabine, and Methotrexate|IV for 7 days for each 21 day cycle
3201494|NCT01187797|Experimental|Intervention|
3201495|NCT01187784|Active Comparator|CBT|Coping Cat cognitive-behavioral therapy protocol
3201496|NCT01187784|No Intervention|Waitlist Control|Treatment as usual
3201497|NCT01187771|Active Comparator|Laparoscopic Gastric Banding|
3201498|NCT01187771|Active Comparator|Continuous Positive Airway Pressure|
3201499|NCT01187758|Experimental|Educational intervention|Multifacet educational intervention that includes workshops, seminars and focus group meetings
3201500|NCT01187758|No Intervention|Control - no intervention|This group did not have any intervention, but their population was screened for carriage of antibiotic resistant bacteria
3201501|NCT01187745||suspect kidney stones|Patients presenting with flank abdominal pain
3201502|NCT01187732|Experimental|Washing without water|The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
3201503|NCT01187732|Active Comparator|Traditional soap and water bath|The control intervention is the traditional bathing assistance as performed in care dependent patients by using tap water, a bowl, towels, washcloths and soap.
3201504|NCT01187719|No Intervention|Control|ARV prophylaxis for PMTCT follows national guidelines.
3201505|NCT01187719|Experimental|phenytoin interaction|ARV prophylaxis for PMTCT follows national guidelines + start phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
3201506|NCT01187706||gynecological cancer survivors|"Criteria for including: (1)Been diagnosed as cervical cancer, ovarian cancer or endometrial cancer, and has completed six months after the relevant treatment. (2)Age from 20 - 70 years old. (3) Agreed to participate in this study.~Criteria for exclusion: Combined with other non-gynecologic cancer (cervical cancer, ovarian cancer or endometrial cancer) patients."
3201507|NCT01187706||healthy controls|Criteria for including: (1)Not those who suffer from cancer.(2)20-70 years old.(3)Agreed to participate in this study.Criteria for exclusion:Had undergone gynecologic surgical removal of ovaries or uterus were.
3201508|NCT01187693|Other|Shoe lift|
3201509|NCT01187680|Experimental|Spraygel|
3201510|NCT01187680|Active Comparator|Control|
3201511|NCT01187667||Haloperidol prevention group|ICU patients with a high risk for delirium who are treated with haloperidol for preventive reason.
3201512|NCT01187667||Control group|Historical cohort group of patients (2008-2009)with a determined risk of 50% or more for delirium who were not treated with haloperidol for preventive reason.
3201513|NCT01187654|Experimental|AC133 recipients|intra coronary injection of bone marrow derived AC133+ cells
3201514|NCT01187654|Experimental|MNC recipients|intra coronary injection of bone marrow derived MNC
3201520|NCT01187602||Women at average risk for ovarian cancer|Women at average risk for ovarian cancer (no first degree relatives with breast or ovarian cancer) undergoing gynecologic evaluation at UVA for non-malignant or routine indications.
3201521|NCT01187602||Women with ovarian cancer|Women with known or suspected ovarian cancer who are undergoing evaluation and/or treatment at UVA Cancer Center
3201522|NCT01187602||Increased risk for ovarian cancer|Women at increased risk of ovarian cancer based on family history, personal history, or genetic factors defined as either BRCA1 or BRCA2 mutations who still retain both fallopian tubes and both ovaries.
3201523|NCT01187589|Experimental|Pulsehaler|Fully operational Pulsehaler, with protocol enabled
3201524|NCT01187589|Active Comparator|Nebulizer|Deactivated Pulsehaler (protocol disabled), so only the nebulizer is active
3201525|NCT01187576|Experimental|Intervention|Multi-professional team intervention with PAR, lifestyle brochure
3201526|NCT01187576|Active Comparator|Conventional treatment|Ordinary recommendations on health behaviours, lifestyle brochure
3201527|NCT01187576|No Intervention|retrospective med history comparison|Treatment as usual (retrospective data collection)
3201528|NCT01187537|Experimental|Continuous Femoral Nerve Block|
3201529|NCT01187537|Active Comparator|Single-Inj Nerve Block with IV PCA|
3201530|NCT01187537|Active Comparator|IV PCA|
3201531|NCT01187511|Active Comparator|GSK561679|GSK561679 was given orally, once a day in the evening, for 21 days, at a dose of 350mg, administered as four tablets consisting of 3 x 100mg tablets plus 1 x 50mg tablet.
3201532|NCT01187511|Placebo Comparator|Placebo|Placebo was given orally, once a day in the evening, for 21 days, in the form of four tablets that matched those of GSK561679
3201533|NCT01187498|Experimental|Behavioral Training|Behavioral training using delayed voiding, urge suppression techniques, and pelvic floor muscle training
3201534|NCT01187498|Active Comparator|Drug Therapy|Oxybutynin chloride, extended-release, individually-titrated, 5-30 mg
3201535|NCT01187485|Experimental|Androderm® 2.5mg|Study subjects will be randomized to one of the study arms: 2.5 mg of Androderm®.
3201536|NCT01187485|Experimental|Androderm® 5.0 mg|Study subjects will be randomized to one of the study arms: 5.0 mg of Androderm®.
3201537|NCT01187485|Experimental|Androderm® 7.5mg|Study subjects will be randomized to one of the study arms: 7.5 mg of Androderm®.
3201538|NCT01187472||Treated subjects|Subjects treated on a previous study of locally advanced head and neck cancer
3201539|NCT01187459|Experimental|10 ug/day|
3201540|NCT01187459|Experimental|50 ug/day|
3201541|NCT01187446|Experimental|TSEBT & Vorinostat|"Total skin electron beam therapy (TSEBT) will be performed per institution guidelines.~Vorinostat will be administered at a dose of 400 mg/day, starting one day prior to the initiation of TSEBT. During TSEBT, vorinostat should be taken in the morning and preferably prior to TSEBT."
3201542|NCT01187446|Active Comparator|TSEBT only|"Total skin electron beam therapy (TSEBT) will be administered according to the Stanford 6-field technique or equivalent technique per institutional standards. Patients will receive a planned total skin dose of 12 grey (Gy) fractionated at 2 Gy/cycle (each cycle requiring 2 days of treatment); 4 days each week; for a total of 3 weeks. Supplements will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions (1-2 Gy fractions to a total dose of 12 Gy). Discrete tumors may receive additional boost treatment not to exceed 12 Gy."
3201543|NCT01187433|Experimental|Dengue Vaccine Group|Participants will receive Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus vaccine
3201544|NCT01187433|Placebo Comparator|Control Group|Participants will receive a placebo, NaCl 0.9%.
3201545|NCT01187420||EEG and Cerebral Vasospasm|Cerebral Vasospasm and role of BIS vista monitor in Subarachnoid Hemorrhage (SAH) patients
3201546|NCT01187407|Experimental|12 or 18 mg flexible dose LY2216684 + SSRI|"LY2216684: flexible dose of 12 or 18 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to a 12 or 18 mg flexible dose of LY2216684.~During the AT Phase, participants first received 6 mg LY2216684 QD for 3 days, followed by 12 mg QD for the next 11 days. Then, based on efficacy and tolerability, dosage could be increased to 18 mg QD over the next 6 weeks. Participants on 18 mg QD could have had their dose decreased back to 12 mg QD. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
3201547|NCT01187407|Experimental|6 mg fixed dose LY2216684 + SSRI|"LY2216684: fixed dose of 6 mg, administered orally, QD for 8 weeks, adjunctive to an SSRI~Prior to entering the AT Phase, participants completed a 3-week CF Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to 6 mg fixed dose of LY2216684.~During the AT Phase, participants received a 6 mg fixed dose of LY2216684 adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the DC Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
3201548|NCT01187407|Placebo Comparator|Placebo + SSRI|"Placebo: administered orally, QD for 8 weeks, adjunctive to an SSRI~Prior to entering the AT Phase, participants completed a 3-week CF Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to placebo.~During the AT Phase, participants received placebo (administered orally, QD) adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the DC Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
3201549|NCT01187381||Participants with Breast Cancer|Participants with early or metastatic HER2-positive breast cancer who were receiving treatment with trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines, will be observed. Dosing and treatment duration of the trastuzumab will be at the discretion of the treating physician.
3201550|NCT01187368|Other|Bridge to Transplant|Bridge to Transplant
3201551|NCT01187355|Experimental|Alcon MPDS|MPDS used for 30 days as specified in protocol for contact lens care.
3201599|NCT01187043|Experimental|ARM 4|9 mg Proellex
3201553|NCT01187342||Non-striatal lesion group|acute ischemic Stroke in MCA territory of 10-100 cm³ with sparing of striatocapsular structures
3201554|NCT01187342||Striatal lesion group|acute ischemic stroke in MCA/AchA territory with involvement of at least 125 mm³ of striatocapsular structures
3201555|NCT01187329|Experimental|hyperinsulinemic normoglycemic clamp (HNC)|Patients will be randomized to receive treatment with HNC during cardiac surgery.
3201556|NCT01187329|Placebo Comparator|standard glucose management|Patients will be randomized to receive treatment with standard glucose management during cardiac surgery.
3201557|NCT01187316|Experimental|TENS|
3201558|NCT01187316|Active Comparator|Massage therapy and muscle stretching|
3201559|NCT01187290|No Intervention|neoadjuvant chemotherapy|Chemotherapy Docetaxel 75 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
3201560|NCT01187290|Experimental|neoadjuvant chemoradiotherapy|Docetaxel 75 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
3201561|NCT01187277|Experimental|Group A|Group A = conventional therapy means: 50 min individual physiotherapy and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
3201562|NCT01187277|Active Comparator|Group B|Group B = conventional therapy plus robot-assisted means: 30 min individual physiotherapy plus 20 min robot-assisted gait training and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
3201563|NCT01187264|Active Comparator|methotrexate 10 mg|oral methotrexate 10 mg once weekly
3201564|NCT01187264|Active Comparator|methotrexate 25mg|oral methotrexate 25 mg once weekly
3201565|NCT01187251||Group 1 - mp3 users|Subjects who have been using mp3 players for at least 1 hour per day for at least 1 year
3201566|NCT01187251||Group 2 - mp3 non-users|Subjects who does not listen regularly to mp3 music
3201567|NCT01187238|No Intervention|Arm1-radical radiotherapy alone group|Arm1-radical radiotherapy alone group, the eligibility patients will received radical intensity-modulated radiotherapy alone
3201568|NCT01187238|Experimental|Arm2-concurrent chemoradiotherapy group|Arm2-concurrent chemoradiotherapy group, the eligibility patients will received radiotherapy the same as radical radiotherapy arm,and also will received the concurrent chemotherapy wiht the regimen consist of cisplatin 40mg/m2, weekly for 7weeks.
3201569|NCT01187225|Active Comparator|Fibrinogen concentrate|
3201570|NCT01187225|Active Comparator|Cryoprecipitate|
3201571|NCT01187212|Active Comparator|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day (D) 1
3201572|NCT01187212|Experimental|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
3201573|NCT01187199|Experimental|Carboplatin Group|Carboplatin: Starting dose AUC 2 by vein on day 1 of a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
3201574|NCT01187199|Experimental|Paclitaxel Group|Paclitaxel: Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
3201575|NCT01187199|Experimental|Sorafenib Group|Sorafenib: Starting dose 200 mg by mouth daily for a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
3201576|NCT01187186|Experimental|Moderate Hepatic Impairment|Subjects with Moderate Hepatic Impairment
3201577|NCT01187186|Experimental|Normal Hepatic Function|Subjects with Normal Hepatic Function
3201578|NCT01187160|Experimental|Transoral robotic surgery (TORS)|da Vinci® Robotic Surgical System
3201579|NCT01187147|Experimental|Green Tea|Recruited subjects will be asked to take green tea capsules for 3 months and then stopped for another 3 months.
3201580|NCT01187134|Active Comparator|Intervention group|
3201581|NCT01187134|No Intervention|Conventional CME|Hospitals receive conventional continuing medical education in lecture style twice a year. They receive current publications and recommendations for national and international meetings regarding diagnosis and therapy of sepsis.
3201582|NCT01187121||Experimental|Those persons randomized to the Decide Your Time program.
3201583|NCT01187121||Standard Pracitice|Those persons randomized to the standard probationary practice condition.
3201584|NCT01187108|Placebo Comparator|Placebo pills|
3201585|NCT01187108|Active Comparator|Acetazolamide alone|
3201586|NCT01187108|Active Comparator|N-acetylcysteine alone|
3201587|NCT01187108|Active Comparator|Combination of N-acetylcysteine and acetazolamide|
3201588|NCT01187095|Experimental|counselling|Does couples in IVF treatment benefit from emotional disclosure
3201589|NCT01187095|Active Comparator|Control|Neutral writing exercise
3201590|NCT01187082|Experimental|bladdertraining group|Cognitive training in groups at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
3201591|NCT01187082|Active Comparator|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
3201592|NCT01187069|Experimental|Training course for practice nurses in autonomy support|
3201593|NCT01187069|No Intervention|Control|Control practices were randomly drawn from among intervention practice applicants and were informed by mail about their status as control practice.
3201594|NCT01187056|Experimental|Training, decision making|General practitioners receive training in shared decision-making and risk communication, and use their newly acquired skills in real-life consultations with 7 patients with high cholesterol.
3201595|NCT01187056|Active Comparator|Training, usual practice|The control group GPs will receive 2 hours of training in the primary care guideline for prevention of cardiovascular disease
3201596|NCT01187043|Experimental|ARM 1|1 mg Proellex
3201597|NCT01187043|Experimental|ARM 2|3 mg Proellex
3201598|NCT01187043|Experimental|ARM 3|6 mg Proellex
3201600|NCT01187043|Experimental|ARM 5|12 mg proellex
3201601|NCT01187017|Experimental|Flu/Cy Response at 6 months|The primary objective is to assess Fludarabine/ Cyclophosphamide (Flu/Cy) hematological response in SAA.The primary endpoint will be response at six months.
3201602|NCT01187004||Acute Lung Injury (ALI)|patients who might develop acute lung injury (ALI) after cardiac surgery with cardiopulmonary by pass
3201603|NCT01186991|Experimental|Onartuzumab + Bevacizumab + Paclitaxel|Participants will receive treatment with onartuzumab, bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable drug-related toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
3201604|NCT01186991|Experimental|Onartuzumab + Placebo + Paclitaxel|Participants will receive treatment with onartuzumab, placebo matching to bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
3201605|NCT01186991|Active Comparator|Placebo + Bevacizumab + Paclitaxel|Participants will receive treatment with placebo matching to onartuzumab, bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
3201606|NCT01186978|Other|Single arm|This phase II study will evaluate whether a reduction in the RT dose, concomitant with a decrease in the RT field size, in patients that achieve CR and have a negative post-chemotherapy PET scan following 4 to 6 cycles of rituximab containing chemotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity.
3201607|NCT01186952|No Intervention|Optimized usual care|participants will attend one visit with the dietician (30mn) and the physical activity specialist (30mn) when they will be given Canadian guidelines pamphlets for physical activity and food consumption. They will also receive a phone call once a month to discuss about issues in guidelines following.
3201608|NCT01186952|Active Comparator|Diet intervention alone|Participants will attend one visit with the physical activity specialist (30mn) when they will receive the physical activity guidelines. Monthly phone call will be make to discuss about issues in physical activity guidelines following.These individuals will also be enrolled in a supervised caloric restriction program. They will have to visit the dietician once a week for the first months and then twice a month for 3 months. The diet intervention will focus on a low fat diet. At each session participants will be weighed and taken the blood pressure.
3201609|NCT01186952|Active Comparator|diet intervention and exercise program|"Participants will attend diet intervention as described for group 2. They will also follow a supervised exercise program three days per week for 4 months. The exercise training is an interval high intensity aerobic (85-90% heart rate reserve) program with resistance exercises (15RM, 2-3 repetitions). Each session will last one hour. At the end of month 1, 2, and 3, all participants will receive the SWA armband for 7 days to record physical activity and estimate energy expenditure.~At the end of Month 4, all participants will attend a study visit for repeat baseline testing."
3201610|NCT01186939|Experimental|Azacitidine|Azacitidine (study drug) plus best supportive care.
3201611|NCT01186926|Experimental|HGNS Treatment|
3201612|NCT01186913||Classic SCID (Stratum A)|Patients with classic SCID after allogeneic hematopoietic stem cell transplantation
3201613|NCT01186913||Leaky SCID, Omenn syndrome, or RS (Stratum B)|Patients with leaky SCID, Omenn syndrome, or Reticular Dysgenesis (RS) after allogeneic hematopoietic stem cell transplantation
3201614|NCT01186913||ADA Deficiency or XSCID treated with PEG-ADA (Stratum C)|Patients with ADA Deficiency or XSCID who are treated with PEG-ADA (patients with ADA Deficiency) or patients who are treated with gene therapy (ADA Deficiency or XSCID)
3201615|NCT01186900|Experimental|Ultrasound-guided needle aspiration|One arm is ultrasound-guided needle aspiration, the other active comparison is traditional open incision and drainage of skin abscess
3201616|NCT01186900|Active Comparator|open incision and drainage|
3201617|NCT01186887|Placebo Comparator|Celecoxib|
3201618|NCT01186887|Placebo Comparator|Placebo|
3201619|NCT01186861|Experimental|Arm A: OSI-906 plus erlotinib|OSI-906 150 mg twice daily (BID) starting on Day 1; erlotinib 150 mg once daily (QD) starting on Day 1
3201620|NCT01186861|Placebo Comparator|Arm B: placebo plus erlotinib|placebo BID starting on Day 1: erlotinib 150 mg QD starting on Day 1
3201621|NCT01186848|Active Comparator|1550-nm erbium-doped fractionated laser|
3201622|NCT01186848|Active Comparator|Combination treatment|"micro-focused ultrasound and 1550nm-fractionated laser"
3201623|NCT01186835|Experimental|Combination Botulinum Toxin A and Hyaluronic Acid|One side of face treated with the combination of Botulinum Toxin A and Hyaluronic Acid injections.
3201624|NCT01186835|Active Comparator|Botulinum Toxin A alone|Other side of face treated with =Botulinum Toxin A injection alone.
3201625|NCT01186822|Experimental|Lung Flute for BHT|The Lung Flute arm participants were instructed to blow twice in to the Lung Flute device vigorously enough to make the reed oscillate, followed by 5 normal breaths. This was repeated 10 times, followed by 3 huff coughs to complete 1 cycle. Two such cycles were recommended twice a day. One of these cycles was performed under supervision of the study personnel at the time of enrollment and at each subsequent study visit. Baseline COPD medication regimen was continued in all participants, although the primary physicians of the participants could make medically necessary changes. Chest physical therapy, additional breathing exercises and formal pulmonary rehabilitation programs were not prescribed to any of the participants during the study.
3201626|NCT01186822|No Intervention|No intervenstion|No intervention. Same population.
3201627|NCT01186809|Experimental|Cytokine Induced Killer|Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)
3201628|NCT01186796|Experimental|Fulvestrant|
3201629|NCT01186783|No Intervention|standard treatment|All patients receive established medical therapy according to current guidelines and therapeutic standards.
3201630|NCT01186783|Active Comparator|ivabradine (add-on)|Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.
3201631|NCT01186770|Experimental|Arm 1|Active Treatment
3201632|NCT01186770|Experimental|Arm 2|Active Treatment
3201633|NCT01186770|Experimental|Arm 3|Active Treatment
3201634|NCT01186770|Placebo Comparator|Arm 4|Oral Placebo
3201635|NCT01186757|Active Comparator|PF-03715455 1.6mg BID|
3201636|NCT01186757|Active Comparator|PF-03715455 4 mg BID|
3201637|NCT01186757|Active Comparator|PF-03715455 10 mg BID|
3201638|NCT01186757|Placebo Comparator|Placebo|
3201639|NCT01186744|Experimental|Active Treatment (10 mg) BID / Placebo BID|Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
3201640|NCT01186744|Experimental|Active Treatment (10 mg) BID|Continuous active treatment (CP-690,550) for 56 weeks
3201641|NCT01186744|Experimental|Active Treatment (5 mg) BID / Placebo BID|Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
3201642|NCT01186744|Experimental|Active Treatment (5 mg) BID|Continuous active treatment (CP-690,550) for 56 weeks
3201643|NCT01186731|Experimental|Liposome Entrapped Docetaxel (LE-DT)|
3201644|NCT01186718||Control Group|Control group = functional symmetric cervical motion.
3201645|NCT01186718||Experimental subject group|Experimental subject group = asymmetric cervical motion
3201646|NCT01186705|Experimental|MK-2206|This will be a single-arm, phase II study of the AKT inhibitor MK-2206 in patients with KRAS-wild-type, PIK3CA-mutated, colorectal cancer whose tumors have progressed through standard chemotherapy regimens.
3201647|NCT01186692|Experimental|Melody TPV Implant|Melody® Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.
3201648|NCT01186679|Experimental|Intralesional|"Surgical transplantation into the lesion site in chronic patients~Direct intrathecal implantation in acute and subacute patients"
3201649|NCT01186679|Experimental|intrathecal|direct into the CSF through lumbar puncture
3201650|NCT01186666|Experimental|Non ST-elevation acute coronary syndrome|"Coronary intervention using IVUS-VH & FDG PET-MDCT:~All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers."
3201651|NCT01186666|Experimental|Stable coronary artery disease|"Coronary intervention using IVUS-VH & FDG PET-MDCT:~All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers."
3201652|NCT01186653|Experimental|Symbicort|Symbicort® (budesonide / formoterol, 400 micrograms/9 micrograms one puff bd, dose as per NICE guidelines
3201653|NCT01186653|Active Comparator|Seretide|fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
3201654|NCT01186640|Experimental|FCM-A followed by A-maintenance|First treatment phase: Chemoimmunotherapy A-FMC maximum 4 cycles. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c.
3201655|NCT01186614|Experimental|Novel treatment paradigm|treatment protocol including - mechanical CPR, therapeutic hypothermia, ECMO, coronary intervention
3201656|NCT01186601|Experimental|Arm 1|
3201657|NCT01186588|Experimental|001|Canagliflozin One 300-mg dose of canagliflozin on Day 1
3201658|NCT01186575|Experimental|Text Message|Context-sensitive text messages are sent to men after undergoing circumcision
3201659|NCT01186575|No Intervention|Usual Care|Usual care after adult male circumcision (no text messages)
3201660|NCT01186562|Active Comparator|Sitagliptin|
3201661|NCT01186562|Placebo Comparator|Placebo|
3201662|NCT01186549|Active Comparator|ephedrine 30 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
3201663|NCT01186549|Active Comparator|ephedrine 70 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
3201664|NCT01186549|Active Comparator|lidocaine0.5mg/kg -ephedrine30 micrograms/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
3201665|NCT01186549|Active Comparator|lidocaine 0.5mg/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
3201666|NCT01186549|Placebo Comparator|normal saline 2ml|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
3201667|NCT01186536|Experimental|Whey protein supplementation|Daily whey protein supplementation
3201668|NCT01186536|Experimental|Soy Protein supplementation|Daily soy protein supplementation
3201669|NCT01186536|Experimental|Placebo|Daily carbohydrate placebo supplementation
3203381|NCT01174420|Experimental|ologen Collagen Matrix|
3201670|NCT01186523|Experimental|400 kcal of exercise/session|400 kcal of exercise/session
3201671|NCT01186523|Experimental|600 Kcal of exercise/session|600 Kcal of exercise/session
3201672|NCT01186523|Experimental|Control, no exercise|No exercise control group
3201673|NCT01186510|Experimental|Lung perfusion|
3201674|NCT01186510|Active Comparator|no lung perfusion|
3201675|NCT01186497|Experimental|Treatment sequence AEBDC|
3201676|NCT01186497|Experimental|Treatment sequence BACED|
3201677|NCT01186497|Experimental|Treatment sequence CBDAE|
3201678|NCT01186497|Experimental|Treatment sequence DCEBA|
3201679|NCT01186497|Experimental|Treatment sequence EDACB|
3201680|NCT01186484|Experimental|001|JNJ-212082 250 mg 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
3201681|NCT01186471|Experimental|001|A643 (nicotine) 1mg oromucosal nicotine spray- three times daily during each treatment period
3201682|NCT01186471|Experimental|002|A643 (nicotine) 2mg oromucosal nicotine spray- three times daily during each treatment period
3201683|NCT01186471|Placebo Comparator|003|placebo placebo - three times daily during each treatment period
3201684|NCT01186458|Experimental|Fludarabine, Velcade and Rituximab|Fludarabine, Velcade and Rituximab
3201685|NCT01186445|Experimental|Morphine chlorhydrate|Intracoronary injection of morphine chlorhydrate during reperfusion
3201686|NCT01186445|Placebo Comparator|Saline solution|Intracoronary injection of saline solution during reperfusion
3201687|NCT01186432|Experimental|Active|ranibizumab sustained delivery implant
3201688|NCT01186419|Experimental|SPD602 (16mg)|
3201689|NCT01186419|Experimental|SPD602 (32mg)|
3201690|NCT01186406|Experimental|Gliadel, Radiation Therapy, Avastin, Temodar|Single arm study where patients with newly diagnosed Grade IV malignant glioma will receive Gliadel at the time of resection, followed by radiation therapy (XRT), Avastin, and Temodar for approximately 6 1/2 weeks, followed by Avastin and Temodar post-radiation
3201691|NCT01186393|Experimental|Control|Arm includes dietary manipulation in the free-living setting to include potatoes/potato products frequently in the diet (5-7 days / week). Control diet will be prescribed for weight maintenance.
3201692|NCT01186393|Experimental|Low Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
3201693|NCT01186393|Experimental|High Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on High Glycemic Index foods.
3201694|NCT01186380||TEE Procedure|patients requiring TEE procedure by their physician
3201695|NCT01186367|Experimental|Linear Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training, at 60% to 75 % of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at baseline.
3201696|NCT01186367|Experimental|Nonlinear Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at Baseline and and as well as the CPET performed at Week 8.
3201697|NCT01186367|Experimental|Progressive Stretching Group (Attention control)|The ultimate goal for the progressive stretching program is 3 to 4 individual stretching sessions/week for 10 to 50 minutes per session (+/- 10 minutes).
3201698|NCT01186354|Experimental|Receiving results via web-based program|participants will receive genetic risk results for Type 2 diabetes via a web-based program that they access on their own
3201699|NCT01186341||Chronic Pain|New or existing patients of the center who are seeking their initial treatment at the Integrative Medicine center for chronic pain (chronic > 3 months) who report their average pain level over the past month to be at least a 4 of 10 on the Visual Analog Scale.
3201700|NCT01186315|Active Comparator|Prolonged Exposure therapy|These treatments include repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories.
3201701|NCT01186315|Experimental|Exposure therapy + VR/ER|prolonged exposure therapy plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
3201702|NCT01186302|Other|Midlevel provider|Patients were assigned to a midlevel provider (arm 1) or to a physician (arm 2) for their abortion.
3201703|NCT01186302|Other|Physician arm|Patients were assigned to a midlevel provider (arm 1) or to a physician (arm 2) for their abortion.
3201704|NCT01186289|Experimental|atorvastatin|high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
3201705|NCT01186289|Placebo Comparator|placebo|
3201706|NCT01186276|Placebo Comparator|Corn Starch|Corn starch will serve as the control arm.
3201707|NCT01186276|Experimental|Fiber|Fiber will serve as the intervention.
3201708|NCT01186263|Experimental|99mTc- labeled albumin macroaggregates (MAA)|Diagnostic MAA- SPECT- imaging.
3201709|NCT01186263|Experimental|99mTc- labeled albumin microspheres (B20)|Diagnostic B20- SPECT- imaging.
3201710|NCT01186250|Active Comparator|Pioglitazone|Pioglitazone
3201711|NCT01186250|Placebo Comparator|Placebo|Placebo
3201712|NCT01186211||Patients presenting for elective TKA|Patients will be advised preoperatively about an accelerated path while in hospital that will share many attributes of the standard TOH care map but with several additions, chosen to help reduce pain and hemarthrosis, both felt to be the major impediments to faster recuperation.
3201713|NCT01186198||MINI TREK RX 1.20 mm Coronary Dilatation Catheter|
3201714|NCT01186185|Experimental|Fludrocortisone|
3201715|NCT01186172|Experimental|Ethanol-lock|Treatment with a combination of ethanol-lock and parenteral therapy
3201716|NCT01186172|Active Comparator|Antibiotic lock|Treatment with a combination of antibiotic-lock and parenteral therapy
3201717|NCT01186159|Experimental|Normal Saline|
3201718|NCT01186146|Active Comparator|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
3201719|NCT01186146|Experimental|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
3201720|NCT01186133||DESSIAN|consecutive patients receiving CYPHER stent
3201721|NCT01186133||K-XIENCE|consecutive patients receiving Xience stent
3201722|NCT01186133||GENOUS|consecutive patients receiving GENOUS stent
3201723|NCT01186133||ELEMENT|consecutive patients receiving PROMUS-ELEMENT stent
3201724|NCT01186133||PRIME|consecutive patients receiving XIENCE-PRIME stent
3201725|NCT01186133||NOBORI|consecutive patients receiving NOBORI stent
3201726|NCT01186133||INTEGRITY|consecutive patients receiving RESOLUTE-INTEGRITY stent
3201727|NCT01186133||XPEDITION|consecutive patients receiving XIENCE-XPEDITION stent
3201728|NCT01186133||BIOMATRIX|consecutive patients receiving BIOMATRIX stent
3201729|NCT01186133||CILOTAX|consecutive patients receiving CILOTAX stent
3201730|NCT01186133||DEB|consecutive patients receiving Drug eluting balloon
3201731|NCT01186133||DESYNE|consecutive patients receiving DESYNE stent
3201732|NCT01186133||PREMIER|consecutive patients receiving PROMUS-PREMIER stent
3201733|NCT01186133||ORSIRO|consecutive patients receiving ORSIRO stent
3201734|NCT01186133||ONYX|consecutive patients receiving ONYX stent
3201735|NCT01186133||BVS|consecutive patients receiving Bioresorbable Vascular Scaffold
3201736|NCT01186133||BVS AMI|consecutive acute myocardial infarction patients receiving Bioresorbable Vascular Scaffold
3201737|NCT01186133||Ultimaster|consecutive patients receiving Ultimaster stent
3201738|NCT01186133||Synergy|consecutive patients receiving Synergy stent
3201739|NCT01186133||Biofreedom|consecutive patients receiving Biofreedom stent
3201740|NCT01186133||Firehawk|consecutive patients receiving Firehawk stent
3201741|NCT01186120|Experimental|Biolimus A9-eluting stent|NOBORI stent
3201742|NCT01186120|Active Comparator|Everolimus-eluting stent|PROMUS ELEMENTE stent
3201743|NCT01186107|Experimental|Endeavor Resolute stent|zotarolimus-eluting stent
3201744|NCT01186107|Active Comparator|Cypher stent|sirolimus-eluting stent
3201745|NCT01186094|Active Comparator|Cypher|Sirolimus-eluting stent
3201746|NCT01186094|Active Comparator|Endeavor Resolute|Zotarolimus-eluting Stent
3201747|NCT01186081|Experimental|Preoperative chemoradiotherapy|Preoperative chemoradiotherapy with conventional radiation schedule and oral fluoropyrimidine (capecitabine)
3201748|NCT01186081|Active Comparator|Postoperative chemoradiotherapy|Postoperative chemoradiotherapy with conventional radiation schedule and oral fluoropyrimidine (capecitabine)
3201749|NCT01186068|Experimental|V-101 Cream 0.01% Concentration|Low dose
3201750|NCT01186068|Experimental|V-101 Cream 0.06% Concentration|Mid-dose
3201751|NCT01186068|Experimental|V-101 Cream 0.1% Concentration|Mid-dose
3201752|NCT01186068|Experimental|V-101 Cream 0.15% Concentration|High dose
3201753|NCT01186068|Placebo Comparator|Vehicle|Cream without an active ingredient
3201754|NCT01186055||Smoking Cessation Counseling|Individuals will receive individual and group counseling for 8 weeks (6 visits) while they quit smoking.
3201755|NCT01186042||Aging in HIV|20-40 years of age or older than 50
3201756|NCT01186016|Experimental|Genetic Education Session (GES)|The objectives are to: discuss the impact of the human genome project; define basic genetic concepts and terminology; distinguish between single-gene and multifactorial genetic diseases/conditions; describe genetic counseling/testing; identify uses of pharmacogenetics; discuss psychological and legal/ethical implications of genetic discoveries; smoking as a multifactorial behavior; findings of epidemiological studies about smoking heritability; research about candidate genotypes DRD2 and CYP2A6; and potential use of genotyping to tailor smoking cessation treatment.
3201757|NCT01186016|Active Comparator|Nutrition Education Session (NES)|
3201758|NCT01186003|No Intervention|Standard insulin drip therapy|
3201759|NCT01186003|Active Comparator|Insulin drip and Detemir|Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
3201760|NCT01185990||Tinnitus subjects|Subjects with chronic, moderate to severe unilateral tinnitus.
3201761|NCT01185990||Healthy control subjects|
3201762|NCT01185977|Active Comparator|Fluoxetine|1 week single-blinded placebo lead-in and double-blinded FLX treatment for 8 weeks
3201763|NCT01185977|Placebo Comparator|Placebo (PBO)|Placebo treatment for 9 weeks of study
3201764|NCT01185964|Experimental|Phase 1b: Olaratumab + doxorubicin|"All cycles are 21 days.~Cycles 1-8: Olaratumab 15 mg/kg on days 1+8, and doxorubicin 75 mg/m2 on day 1~All subsequent cycles until progression: Olaratumab 15 mg/kg on days 1+8"
3201765|NCT01185964|Experimental|Phase 2: Olaratumab and doxorubicin|"All cycles are 21 days.~Cycles 1-8: Olaratumab 15 mg/kg on days 1+8, and doxorubicin 75 mg/m2 on day 1~All subsequent cycles until progression: Olaratumab 15 mg/kg on days 1+8"
3201766|NCT01185964|Active Comparator|Phase 2: Doxorubicin: Optional Olaratumab After Progression|"All cycles are 21 days.~Cycles 1-8: doxorubicin 75 mg/m2 on day 1 until disease progression.~At disease progression: optional Olaratumab 15 mg/kg on days 1+8 until further progression."
3201767|NCT01185951|Active Comparator|Achilles tendinopathy|Patients suffering both, insertional and midportion Achilles tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
3201768|NCT01185951|Active Comparator|Patella tendinopathy|Patients suffering patella tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
3201769|NCT01185951|Active Comparator|Epikondylitis|Patients suffering both, lateral (tennis elbow) or medial (golfers' elbow) elbow tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
3201770|NCT01185938|Active Comparator|Rosuvastatin|
3201771|NCT01185938|No Intervention|Control|
3201772|NCT01185925|Placebo Comparator|Placebo|Control Group
3201773|NCT01185925|Active Comparator|sildenafil, pde5 inhibitor|treatment group; sildenafil 50 mg three times a day for 1 year
3201774|NCT01185912||Cardiomyocyte apoptosis|Elective aortic valve replacement patience
3201775|NCT01185899||Suspected ACS patients|Patients presenting with chest pain to the Emergency Department, who are suspected of having ACS, will be asked to participate in the study.
3201776|NCT01185873|Experimental|1|
3201777|NCT01185860|Active Comparator|A|
3201778|NCT01185860|Experimental|B|
3201779|NCT01185860|Placebo Comparator|C|
3201780|NCT01185847|Experimental|A non-squamous|
3201781|NCT01185847|Experimental|A squamous|
3201782|NCT01185847|Active Comparator|B non-squamous|
3201783|NCT01185847|Active Comparator|B squamous|
3201784|NCT01185821|Experimental|BAF312 10 mg/2 mg|10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
3201785|NCT01185821|Experimental|BAF312 2 mg/2 mg|2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
3201786|NCT01185821|Experimental|BAF312 1.25 mg/2 mg|1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
3201787|NCT01185821|Experimental|BAF312 .5 mg/2 mg|.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
3201788|NCT01185821|Experimental|BAF312 .25 mg/2 mg|.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
3201789|NCT01185808|Active Comparator|Vitamin D|Vitamin D 5,000IU/day for 6 weeks
3201790|NCT01185808|Placebo Comparator|Placebo|Placebo for 6 weeks.
3201791|NCT01185795|Experimental|Cardioviva™ yogurt|
3201792|NCT01185795|Placebo Comparator|Placebo yogurt|
3201793|NCT01185782|Experimental|SJ-0021 group|
3201794|NCT01185782|Active Comparator|Purified pituitary gonadotropin group|
3201795|NCT01185769|Experimental|High fat|500 mg of tocotrienol will be administered at single dose after consumption of high fat diet
3201796|NCT01185769|Experimental|Low fat|500 mg of tocotrienol will be administered at single dose after consumption of low fat diet
3201797|NCT01185756|Experimental|ICD implantation|"MIBG for diagnostic purpose:~MIBG scintigraphy for diagnostic purpose"
3201798|NCT01185743|Active Comparator|olanzapine|olanzapine
3201799|NCT01185743|Active Comparator|ziprasidone|ziprasidone
3201800|NCT01185743|Placebo Comparator|Sugar pill|Sugar pill
3201801|NCT01185730|Experimental|pulmonary hypertension|cohort of patients with pulmonary hypertension
3201802|NCT01185704|Experimental|Day 1 protocol|
3201803|NCT01185704|Experimental|Day 7 protocol|
3201804|NCT01185678||Group1|
3201805|NCT01185665|Active Comparator|TENS|FBSS patients treated with TENS
3201806|NCT01185665|Placebo Comparator|Sham-TENS|patients treated with Sham-Tens
3201807|NCT01185639|Experimental|SBRT for metastatic NSCLC|SBRT for lung lesions, liver lesions, adrenal lesions, spinal lesions
3201808|NCT01185626|No Intervention|Usual care|The gynaecological oncologist (GO) provides care as usual. Currently, hospitals provide follow-up following the Dutch guidelines, meaning that they see their patients on given time points based on the number of years after diagnosis. Most hospitals give their patients leaflets regarding the diagnosis and treatment they receive, however none of them provide personalized information. All information is given during the initial treatment phase, but none of the GOs give additional information during follow-up. None of the GOs is actively screening on psychosocial needs. As this might change in time, we will ask the providers and patients about the type of information they provide, respectively, receive.
3201809|NCT01185626|Experimental|SCP care|After initial treatment, the GO provides the patient with a paper SCP and takes time to discuss all items in the SCP. Each time during follow-up meetings between patient and GO, the patient will receive an updated SCP if applicable. The paper SCP is extracted from the online registration system 'ROGY' (Registrationsystem Oncological GYnaecology) and combines personal patient and disease data with tailored information that is related to the specific situation of this patient. Recurrences, toxicities or additionally involved specialists will be registered in ROGY and automatically updated in the personal SCP.
3201810|NCT01185613|Experimental|Therapy™ Cool Flex Ablation Catheter|
3201811|NCT01185600|Active Comparator|Transfusion with washed RBC|Subject assigned to this arm will be transfused with washed RBC
3201812|NCT01185600|Active Comparator|Transfusion with unwashed RBC|Subjects assigned to this arm will be transfused with unwashed RBC
3201813|NCT01185587||healthy patients with a normal heart|
3201814|NCT01185587||patients with HF without an lCD|
3201815|NCT01185587||patients with HF and an ICD without shock|
3201816|NCT01185587||patients with HF and an ICD with shock|
3201817|NCT01185574|Experimental|Vitamin D supplementation|The study medication (a capsule of 50,000 IU of vitamin D2) will be administered once a week for six months.
3201818|NCT01185561|No Intervention|Usual medical care|Participants assigned to this arm represent the control group and will receive usual medical care only.
3201819|NCT01185561|Experimental|Psychoeducational intervention|Participants assigned to this arm represent the experimental group and will receive group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes
3201820|NCT01185548|Experimental|Tasisulam and Tolbutamide|"Three periods and continued access to study drug (tasisulam) every 28 days until disease progression:~Period 1: 500 mg tolbutamide administered once on Day 1~Period 2: 500 mg of tolbutamide and patient specific dose of tasisulam administered once on Day 1~Period 3: patient specific dose of tasisulam administered once on Day 1 and 500 mg tolbutamide administered once on day 4 (administration day in period 3 may be adjusted based on interim PK analyses)"
3201821|NCT01185535|Active Comparator|2 times topical anesthesia for glottis|
3201822|NCT01185535|Active Comparator|3 times topical anesthesia for glottis|
3201823|NCT01185535|Active Comparator|4 times topical anesthesia for glottis|
3201824|NCT01185522||Tocilizumab|Eligible participants receiving tocilizumab according to summary of product characteristics in a real life setting will be observed for 4 months
3201890|NCT01185067|Placebo Comparator|maltodextrin capsule|Maltodextrin capsules (matched for appearance and taste to grape seed extract capsules) twice daily for six weeks
3201891|NCT01185054|Experimental|Fluids as Tolerated (FAT) Group|The FAT group will receive ½ strength apple juice and will form the experimental group in this study.
3201892|NCT01185054|Active Comparator|Electrolyte Maintenance Solution (EMS)|The EMS group will form the control group as solutions such as Pediatric Electrolyte® are routinely recommended for use in children with gastroenteritis.
3201825|NCT01185509|Experimental|Trastuzumab and Vinorelbine - Cohort A|Cycle 1: Patients received trastuzumab 8 mg/kg intravenously (IV) on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Cycles 2+: Patients received trastuzumab 6 mg/kg IV on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Patients were treated until disease progression or unacceptable toxicity. Eligibility required patients to have HER2 amplification by FISH (mean ratio > 2.0). The CTC tests of the first 11 patients were done at DFCI. The study team then decided to proceed with a different CTC test performed outside of DFCI. Because the method of CTC isolation was different from that performed by DFCI, the first 11 patients were placed into a separate cohort (Cohort A) and the remaining 20 patients represented the main cohort.
3201826|NCT01185509|Experimental|Trastuzumab and Vinorelbine - Main Cohort|Cycle 1: Patients received trastuzumab 8 mg/kg intravenously (IV) on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Cycles 2+: Patients received trastuzumab 6 mg/kg IV on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Patients were treated until disease progression or unacceptable toxicity. Eligibility required patients to have HER2 amplification by FISH (mean ratio > 2.0). The CTC tests of the first 11 patients were done at DFCI. The study team then decided to proceed with a different CTC test performed outside of DFCI. Because the method of CTC isolation was different from that performed by DFCI, the first 11 patients were placed into a separate cohort (Cohort A) and the remaining 20 patients represented the main cohort.
3201827|NCT01185496||CGM|Blinded/Unblinded CGM wear in adjunct with SMBG meter diabetes management
3201828|NCT01185470|Experimental|Subjects with Implantable pump|Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo study device implantation .
3201829|NCT01185457||Left interscalene block|Left shoulder surgery under left interscalene block and HRV
3201830|NCT01185457||Right interscalene block|Right shoulder surgery under right interscalene block and HRV
3201831|NCT01185444|Experimental|Hya-Joint|The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.
3201832|NCT01185444|Active Comparator|Hyalgan|the control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.
3201833|NCT01185431|Experimental|Ficus carica (Fig paste)|
3201834|NCT01185431|Placebo Comparator|Control (Placebo paste)|
3201835|NCT01185418||risperidone|
3201836|NCT01185418||aripiprazole|
3201837|NCT01185418||haloperidol|
3201838|NCT01185418||amisulpride|
3201839|NCT01185418||lactose|
3201840|NCT01185405|Experimental|EA group|Voriconazole dosage adjustment according to the each measurements of voriconazole levels from day 1, using NONMEM program
3201841|NCT01185405|Active Comparator|CA group|Voriconazole dosage adjustment according to the levels from day 5, using predefined protocol
3201842|NCT01185379|Active Comparator|Efalex Active 50+|
3201843|NCT01185379|Active Comparator|DHA-rich fish oil|
3201844|NCT01185379|Placebo Comparator|Placebo|
3201845|NCT01185366|Experimental|Everolimus Group 1|Everolimus 10 mg by mouth once a day.
3201846|NCT01185366|Active Comparator|Sunitinib Group 2|Sunitinib 50 mg by mouth daily for 4 weeks on / 2 weeks off.
3201847|NCT01185353|Experimental|1 mg LY3009104 once daily|Administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
3201848|NCT01185353|Experimental|2 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
3201849|NCT01185353|Experimental|4 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
3201850|NCT01185353|Experimental|8 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
3201851|NCT01185353|Placebo Comparator|Placebo once daily|Placebo administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
3201852|NCT01185353|Experimental|2 mg LY3009104 twice daily|(Not utilized in Part A) After 12 weeks treatment with 1 mg LY3009104 once daily or Placebo once daily in Part A, administered orally twice daily for 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
3201893|NCT01185041|Placebo Comparator|Maltodextrin|6g/day of placebo (maltodextrin)
3203382|NCT01174420|Active Comparator|Mitomycin-C (MMC)|
3201853|NCT01185340|Experimental|LY2216684 + SSRI|"LY2216684: flexible dose of 12 or 18 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to the LY2216684 treatment arm.~For the first 2 weeks of the AT Phase, participants received a starting dose of 12 mg QD. Then, based on efficacy and tolerability, the dose could be increased to 18 mg QD over the next 6 weeks. Participants who had their dose increased to 18 mg QD could have had their dose decreased to 12 mg QD. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
3201854|NCT01185340|Placebo Comparator|Placebo + SSRI|"Placebo: Administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to the placebo treatment arm.~During the AT Phase, participants received placebo (administered orally, QD) adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
3201855|NCT01185327||Study|Infants to Israeli Ethiopian-origin Mothers
3201856|NCT01185327||Control|Infants to Israeli non-Ethiopian-origin mothers
3201857|NCT01185314|Other|1|EGFR mutation testing
3201858|NCT01185301|Active Comparator|ADA + 2.5 mg MTX|2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks
3201859|NCT01185301|Active Comparator|ADA + 5 mg MTX|5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
3201860|NCT01185301|Active Comparator|ADA + 10 mg MTX|10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
3201861|NCT01185301|Active Comparator|ADA + 20 mg MTX|MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks
3201862|NCT01185288|Experimental|Adalimumab + Low Dose Methotrexate|Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, low dose methotrexate (7.5 mg orally once weekly).
3201863|NCT01185288|Active Comparator|Adalimumab + High Dose Methotrexate|Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, high dose methotrexate (20 mg orally once weekly).
3201864|NCT01185275||Severe Asthma Patients|Severe asthma patients symptomatic despite high dose inhaled corticosteroid and long acting beta-agonist
3201865|NCT01185262|Experimental|Lenalidomida, Rituximab|Phase I: Lenalidomide will be administered from day 1 to 21 of 28 days cycles, escalating doses (from 2,5mg to 25 mg).Rituximab dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).
3201866|NCT01185249|Experimental|Body weight taken in a standing position|Subjects will be weighed in the early morning, as standard of care dictates. They will also be weighed after evening medications are given, around 9pm. The evening weight is not standard, therefore considered the study intervention.
3201867|NCT01185236|Experimental|simvastatin/ezetimibe (vytorin) group|vytorin 10/20mg po once daily for 12weeks
3201868|NCT01185236|Active Comparator|atorvastatin group|atorvastatin 20mg po once daily for 12weeks
3201869|NCT01185223|Other|Valganciclovir|
3201870|NCT01185223|Active Comparator|Ganciclovir|
3201871|NCT01185210|Placebo Comparator|Placebo|Subjects will receive placebo (mix of sugar and salt).
3201872|NCT01185210|Experimental|Alanine - 12.5|Subjects will receive 12.5 grams of alanine
3201873|NCT01185210|Experimental|Alanine - 25|Subjects will receive 25 grams of alanine.
3201874|NCT01185197|Experimental|Myfortic plus low-dose steroid|Not necessary
3201875|NCT01185197|Active Comparator|Standard-dose steroid|Not necessary
3201876|NCT01185184|Experimental|1|Subjects will receive in random order, the immediate release tablet containing 10 mg of CP-690,550 and two different controlled-release capsules containing 20 mg of CP-690,550.
3201877|NCT01185171|Experimental|ZD1839 500mg by mouth (po) daily|Single arm, two-stage, phase II trial of induction therapy with carboplatin and paclitaxel, followed by ZD1839, 5-FU, hydroxyurea, and hyperfractionated radiotherapy, followed by adjuvant ZD1839 alone.
3201878|NCT01185158|Experimental|ZD1839 (IRESSA) 250mg|ZD1839(IRESSA) 250mg orally (po) daily
3201879|NCT01185145|Experimental|Mammosite|Accelerated Partial Breast Irradiation using Mammosite RTS
3201880|NCT01185145|Experimental|IMRT|Accelerated partial breast irradiation using IMRT planning technique of external beam radiotherapy
3201881|NCT01185132|Experimental|IMRT|Intensity modulated radiotherapy, 38.5 Gy, 10 fractions over 5 days
3201882|NCT01185132|Active Comparator|3D-CRT|Three dimensional conformal external radiotherapy, 38.5 Gy, 10 fractions over 5 days
3201883|NCT01185119|Active Comparator|GLP-1|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
3201884|NCT01185119|Placebo Comparator|placebo|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
3201885|NCT01185093||Fourth grade students|Each participant will attend two presentations and six hands-on activities led by St. Jude faculty and research staff on topics within their expertise, such as cells and cancer, and healthy living. The pre-test will take place within 7±1 days before the program presentations and before students receive copies of the printed material. Two post-tests will take place. The first post-test will be administered within 7±1 days after the final scheduled program presentation and will be a measure of knowledge acquisition. The second post-test will take place 90±7 days post-intervention and will be a measure of knowledge retention.
3201886|NCT01185080|Experimental|1. AZD8848|20 μg AZD8848 three times weekly
3201887|NCT01185080|Placebo Comparator|2. Placebo|Placebo three times weekly
3201888|NCT01185080|Experimental|3. AZD8848 and placebo|60 μg AZD8848 once weekly and placebo twice weekly
3201889|NCT01185067|Active Comparator|grape seed extract capsule|Grape seed extract (MegaNatural BP, Polyphenolics, Inc.) 300 milligram capsules twice daily for six weeks
3201894|NCT01185041|Experimental|Watermelon|(6g per day)containing L-citrulline/L-arginine (4/2 g)
3201895|NCT01185028|Experimental|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
3201896|NCT01185002|Experimental|MgC boosts|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered MgC boosts."
3201897|NCT01185002|Experimental|Suprep boosts|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered Suprep boosts"
3201898|NCT01185002|Experimental|Suprep boosts - Reduced dose|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered a reduced dose of Suprep boosts"
3201899|NCT01184989|Other|Dabigatran etexilate|open label, once daily dose approved by EMEA and Health Canada
3201900|NCT01184976|Experimental|0.6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 0.6mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
3201901|NCT01184976|Experimental|2mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 2mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
3201902|NCT01184976|Experimental|6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
3201903|NCT01184963|Other|Controls|Women in reproductive age regular ovulatory cycles
3201904|NCT01184963|Other|PCOS patients|Patients with anovulatory cycles, hyperandrogenism with or without polycystic ovarian appearance
3201905|NCT01184950|Experimental|Trainer Curriculum|
3201906|NCT01184950|No Intervention|No Curriculum|
3201907|NCT01184937|Experimental|Patient education program|
3201908|NCT01184937|No Intervention|Standard care|
3201909|NCT01184924|No Intervention|Control|Usual Care only. Usual care is defined as the care these subjects would like to seek from any health care practitioner or other program they may seek for healthy living. The subjects in this arm will be offered the AF Tai Chi intervention after an 8 week followup data collection
3201910|NCT01184924|Experimental|Tai Chi|Usual care plus Tai Chi. These subjects will be allowed to seek care from any health practitioner or any other programs and will receive the AF Tai Chi program for 8 weeks.
3201911|NCT01184911|Experimental|SP|Asymptomatic parasitemic pregnant women who receive the standard dose of sulfadoxine-pyrimethamine for prevention of placental malaria
3201912|NCT01184898|Experimental|Sirolimus and MEC|Sirolimus and MEC (Mitoxantrone, Etoposide, and Cytarabine)
3201913|NCT01184885|Experimental|Hyper-CVAD and Sirolimus|Hyper-CVAD and Sirolimus
3201914|NCT01184872|Experimental|Daptomycin|"Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days."
3201915|NCT01184872|Active Comparator|Vancomycin or Semi-Synthetic Penicillins (SSPs)|"Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days."
3201916|NCT01184859|Experimental|Desmopressin 10µg|Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.
3201917|NCT01184859|Experimental|Desmopressin 25µg|Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.
3201918|NCT01184859|Experimental|Desmopressin 50µg|Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.
3201919|NCT01184859|Experimental|Desmopressin 100µg|Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.
3201920|NCT01184859|Placebo Comparator|Placebo|Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.
3201921|NCT01184846|Experimental|IgPro10|10% liquid formulation of human immunoglobulin (IgPro10). IgPro10 will be administered by IV infusion as one induction dose of 2 g/kg body weight (bw), followed by seven 3-weekly maintenance doses of 1 g/kg bw.
3201922|NCT01184833||Group 1|
3201923|NCT01184820|Experimental|Arm 1|
3201924|NCT01184820|Experimental|Arm 2|
3201925|NCT01184807|Other|OPB-51602|
3201926|NCT01184794|Placebo Comparator|Saline|Placebo solution
3201927|NCT01184794|Experimental|levobupivacaine, analgesia|Active drug
3201928|NCT01184781|Other|A|On the same patient, we compare both methods (video-colonoscopy vs capsule endoscopy)
3201929|NCT01184768||participants in the 6th tromsø study|
3201930|NCT01184755|Experimental|Resperate device used for 8 weeks|Participants to use Resperate device to guide breathing for 8 weeks. After the primary 8-week trial, this group is divided into two subgroups to examine 16-week data: one subgroup that stops using the device after 8 weeks, and one asked to continue to use the device for the full 16 weeks.
3201931|NCT01184755|Active Comparator|Relaxation control device|Participants use modified device to pace breathing in the 13/minute range for daily practice for 8 weeks and no device thereafter
3201932|NCT01184755|No Intervention|Usual Care|Participants continue their usual medication and other management for their hypertension. All participants (including UC) are given a home BP monitor and asked to take their BP in morning and evening 3 days/week.
3201933|NCT01184729||Spinal Cord Injury|
3201934|NCT01184716|Active Comparator|Vitamin D fortified bread and milk|
3201935|NCT01184716|No Intervention|Non-fortified bread and milk|
3201936|NCT01184690|Active Comparator|Single-operator DBE|Single-operator double-balloon endoscopy
3201937|NCT01184690|Active Comparator|Dual-operator DBE|Dual-operator double-balloon endoscopy
3201938|NCT01184677|Placebo Comparator|Group size 4|
3201939|NCT01184677|Experimental|Group size 3|ProSeal LMA size 3 is inserted to the patients of Group size 3.
3201986|NCT01184352||PCI patients treated with Glider Device|
3201940|NCT01184664|Experimental|Varenicline + Active Patch|Participants will use varenicline (1mg BD) + an active, 15mg/16hr Nicotine Patch
3201941|NCT01184664|Placebo Comparator|Varenicline + Placebo Patch|Participants will use varenicline (1mg BD) + a Placebo Nicotine Patch
3201942|NCT01184651||Girls|Girls with 21-hydroxylase deficiency (21-OHD) congenital adrenal hyperplasia (CAH) ages 10-13
3201943|NCT01184651||Parents|Parent, guardian, or significant caretaker of girls with CAH
3201944|NCT01184638|No Intervention|Local anesthesia|Patients received local anesthesia without any intervention of general anesthetics
3201945|NCT01184638|Active Comparator|Inhalational anesthesia|Patients received sevoflurane anesthesia during general anesthesia
3201946|NCT01184638|Active Comparator|Intravenous anesthesia|Patients received intravenous anesthetic (Propofol) during general anesthesia
3201947|NCT01184625|Experimental|Exercise|
3201948|NCT01184625|No Intervention|No intervention|12 weeks of stable physical exercise level.
3201949|NCT01184612|Active Comparator|(BSF) MI sessions|5 semi-structured manualised MI sessions was conducted by existing prison staff having undergone 3 days of Motivational Interviewing workshop training and 2 days of training with the BSF manual.
3201950|NCT01184612|Active Comparator|(BSF+) MI sessions with supervision|5 semi-structured manualised MI sessions was conducted by ordinary prison staff having undergone 3 days of Motivational Interviewing workshop training and 2 days of training with the BSF manual, followed by ongoing Motivational Interviewing training with feedback based on audio taped sessions in peer supervision groups.
3201951|NCT01184612|Active Comparator|(UPI) Usual Planning Interview|5 sessions was conducted by prison staff according to usual working practices, with the exception that content was structured into 5 sessions and audio recorded. The provision of a government decree served as a basis for the intervention, covering planning of prison activities and post release arrangements including strategies for drug use cessation.
3201952|NCT01184586|Active Comparator|Intervention arm - ESWT Storz Duolith high energy|Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (STORZ DUOLITH, 1000 impulses, 0.55-0,8mJ/mm2)
3201953|NCT01184586|Sham Comparator|Control - SHAM ESWT STORZ DUOLITH [0.01mJ/mm2]|Three weekly sessions of sham extracorporeal shock wave with modified probe without shockwave transduction (1000 impulses)
3201954|NCT01184573||Mild to Moderate CP|Subjects must have a history compatible with chronic pancreatitis.
3201955|NCT01184573||Healthy Controls|Subjects must be in good health of greater than 18 years of age.
3201956|NCT01184560|Experimental|Sibutramine + Orlistat|"A lipase inhibitor used for weight loss. Lipase is an enzyme found in the bowel that assists in lipid absorption by the body. Orlistat blocks this enzyme, reducing the amount of fat the body absorbs by about 30%. It is known as a fat blocker. Because more oily fat is left in the bowel to be excreted, Orlistat can cause an oily anal leakage and fecal incontinence"
3201957|NCT01184560|Placebo Comparator|Sibutramine + Orlistat(Placebo)|"Sibutramine : one of components included into Diet Pills. This reduces appetite, normalizes amount of cholesterol in blood, and reduces abdominal fat.~Orlistat : A lipase inhibitor used for weight loss. Lipase is an enzyme found in the bowel that assists in lipid absorption by the body. Orlistat blocks this enzyme, reducing the amount of fat the body absorbs by about 30%. It is known as a fat blocker. Because more oily fat is left in the bowel to be excreted, Orlistat can cause an oily anal leakage and fecal incontinence."
3201958|NCT01184547|Experimental|COMBEX|Community Based Exercise Program or exercise group and quality of life Intervention- The community-based exercise program consisted of 12 weeks of exercise with a community-based trainer after hospital discharge.
3201959|NCT01184547|Active Comparator|Standard Of Care|Standard of Care group, group with no exercise and quality of life. Intervention- No exercise training received.
3201960|NCT01184534||Questionnaires + Video|
3201961|NCT01184534||Questionnaires|
3201962|NCT01184521||pulse CO-oximeter|
3201963|NCT01184508|Experimental|LY2300559|
3201964|NCT01184508|Placebo Comparator|Placebo|
3201965|NCT01184495|Experimental|Epoetin Bio-Manguinhos|
3201966|NCT01184495|Active Comparator|EPO-BioSimilar|Subcutaneous administration of EPO-BioSimilar
3201967|NCT01184482|Experimental|Cetuximab and lapatinib|All patients will receive cetuximab by IB weekly and daily doses of lapatinib orally in 3 week cycles with response assessed every 2 cycles.
3201968|NCT01184469||Fresh embryo transfers|Patients who received fresh blastocyst transfer
3201969|NCT01184469||Thawed embryo transfers|Patients who received transfers of frozen/thawed embryos
3201970|NCT01184456|Experimental|GanedenBC30, GBI-30, PTA-6086|
3201971|NCT01184456|Placebo Comparator|Placebo|
3201972|NCT01184443|Experimental|Olanzapine|Those who choose to take olanzapine as part of their treatment (standard practice plus medication).
3201973|NCT01184443|No Intervention|Comparison|Those who choose not to take olanzapine as part of their treatment (standard practice).
3201974|NCT01184430|Active Comparator|advanced hemodynamic monitoring|advanced hemodynamic monitoring with pulse contour analysis ( LiDCO rapid) and goal-directed therapy
3201975|NCT01184430|No Intervention|standard monitoring|hemodynamic monitoring based on the standard operating procedures of our clinic
3201976|NCT01184417|Active Comparator|Phenobarbital group|10 mg/kg IV phenobarbital in 100 ml saline
3201977|NCT01184417|Placebo Comparator|Placebo group|100 ml saline
3201978|NCT01184404|Experimental|Treatment|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
3201979|NCT01184404|No Intervention|Control|
3201980|NCT01184391|Experimental|Test: Divalproex Sodium|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
3201981|NCT01184391|Active Comparator|Reference: Depakote Tablets|DEPAKOTE® Tablets, 500 MG Abbott Laboratories
3201982|NCT01184378|Placebo Comparator|control formula|formula containing only vegetable fats
3201983|NCT01184378|Experimental|new formula|new formula with dairy lipids and soluble milk proteins
3201984|NCT01184365|Experimental|EnMP-1|The goal of the EnMP-1 is to enable participants, through a behavioural, psycho-educational intervention, to better manage and understand their fatigue. This program is provided in four, two-hour sessions held weekly.
3201985|NCT01184365|Active Comparator|EnMP-2|The goal of the EnMP-2 is to control for group effects
3201987|NCT01184339||Standard of Care|Current practice methods for the determination of bacteremia, specific to site practice.
3201988|NCT01184339||Gold Standard ID/AST|"Identification of S. aureus: coagulase positive, catalase positive, Staphaurex positive, and PYR negative, if performed).~Determination of MRSA:S. aureus gold standard and </=11mm OXA DD or </=21mm CFX DD.~Determination of MSSA: S. aureus gold standard and >/=13mm OXA DD or >/=22mm CFX DD."
3201989|NCT01184326|Experimental|Pazopanib and Everolimus|Pazopabib 400 mg PO QD, Everolimus 5 mg PO QD
3201990|NCT01184313||aortic valve surgery|
3201991|NCT01184300|Experimental|Rapid Genotyping|Patients randomized to the Rapid Genotyping arm will have their CYP2C19*2 carrier status determined at the time of percutaneous coronary intervention with subsequent alteration in anti-platelet therapy for *2 carriers.
3201992|NCT01184300|No Intervention|Standard Therapy|Patients randomized to the Standard Therapy arm will not undergo genotyping at the time of percutaneous coronary intervention. All patients will receive clopidogrel 75 mg daily for 1 week. At the end of the 1 week period, their CYP2C19*2 carrier status will be verified.
3201993|NCT01184287|Experimental|ranpirnase|All patients who do not progress after two cycles of pemetrexed—carboplatin will receive the study drug, ranpirnase
3201994|NCT01184274|Experimental|SB939|
3201995|NCT01184261|Experimental|Arm I|Patients attend behavioral sessions for smoking and binge drinking cessation over 30 minutes once weekly in weeks 1-6.
3201996|NCT01184261|Experimental|Arm II|Patients attend behavioral sessions for smoking cessation over 30 minutes once weekly in weeks 1-6.
3201997|NCT01184235||Autism Spectrum Disorders|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is Autism Spectrum Disorder
3201998|NCT01184235||Attention Deficit Hyperactivity Disorder|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is Attention Deficit Hyperactivity Disorder.
3201999|NCT01184235||Unaffected 1st Degree Relatives|This group will include unaffected, non treated first degree relatives of this study's subjects receiving or anticipating receiving pharmacological intervention.
3202000|NCT01184235||Mood Disorders|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is mood disorder.
3202001|NCT01184222|Active Comparator|Arm Active SENGO|The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.
3202002|NCT01184222|Placebo Comparator|Arm sham SENGO|The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted.
3202003|NCT01184196|Active Comparator|Arm 1|Subjects randomized to Arm 1 will receive Betadine surgical scrub at the time of primary total knee arthroplasty.
3202004|NCT01184196|Active Comparator|Arm 2|Subjects in Arm 2 will receive ChloraPrep surgical scrub prior to elective primary total knee arthroplasty.
3202005|NCT01184183||Accuseal patch|
3202006|NCT01184183||Bovine Pericardial patch|
3202007|NCT01184170|Experimental|Metabolically Normal|"Subjects in this group are metabolically normal. They have low liver fat defined as less than five percent as determined by magnetic resonance spectroscopy.~Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits."
3202008|NCT01184170|Experimental|Metabolically Abnormal|"Subjects in this group are metabolically abnormal. They have high liver fat defined as at least ten percent as determined by magnetic resonance spectroscopy.~Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits."
3202009|NCT01184157|Experimental|Home|Home-based STI screening using self-obtained vaginal swabs and postal return of samples.
3202010|NCT01184157|Active Comparator|Clinic|Receive STI screening in a clinical setting such as a private physician or clinic.
3202011|NCT01184144|Experimental|pioglitazone|Pioglitazone study drug
3202012|NCT01184144|No Intervention|No drug|"Placebo like comparitor"
3202013|NCT01184131|Experimental|Mentor Training|The group that is randomized into the intervention group to attend Mentor Training Sessions.
3202014|NCT01184131|No Intervention|No Mentor Training|
3202015|NCT01184118|No Intervention|FP Discontinued|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
3202016|NCT01184118|Active Comparator|FP 220 mcg 2 puffs BID|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
3202017|NCT01184105|Experimental|Cohort 1 (pre)|Active treatment or placebo
3202018|NCT01184105|Experimental|Cohort 2 (post)|Active treatment or placebo
3202019|NCT01184092|Experimental|Sequence 1|
3202020|NCT01184092|Experimental|Sequence 2|
3202021|NCT01184092|Experimental|Sequence 3|
3202022|NCT01184092|Experimental|Sequence 4|
3202023|NCT01184092|Experimental|Sequence 5|
3202024|NCT01184092|Experimental|Sequence 6|
3202025|NCT01184079|Experimental|12 months|Administration of 3rd dose at 12 months quadrivalent human papillomavirus vaccine
3202026|NCT01184079|Active Comparator|6 month|Administration of 3rd dose at 6 months quadrivalent human papillomavirus vaccine
3203383|NCT01174407||cd35|
3202027|NCT01184066|Experimental|ACTS Intervention|The intervention arm are the women who received the ACTS Intervention. It is a 45 minute intervention provided by a breast cancer survivor. The intervention includes a discussion of the patient's attitudes towards chemotherapy, communication strategies with providers, the recommended treatment in accordance with tumor size and tumor characteristics
3202028|NCT01184066|Active Comparator|Usual Care|This group receives care as usual.
3202029|NCT01184053|Experimental|Trisenox treatment|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
3202030|NCT01184040|No Intervention|(A) Non-contingent control|Participants assigned to the control condition will be told to wear the pedometer daily and select a twice-weekly meeting schedule with research staff for 12 weeks (study weeks 4-15). On days randomly selected as meeting days, participants will be asked to bring in their pedometers. Participants who attend their scheduled meetings will receive a $5 gift card just for attending and bringing the pedometer, so long as it has registered steps walked in at least the past 4 days. They will be congratulated if they walked 10,000 steps or more on the prior 4 days, and encouraged to walk 10,000 steps or more per day on subsequent days.
3202031|NCT01184040|Experimental|VIP CM|Participants assigned to Increasing Variable Interval Prize (VIP) Reinforcement group will be scheduled for the same study visits as those in the Control group, but will also earn chances to win prizes if they have walked more than 10,000 steps in the past 4 days.
3202032|NCT01184027||G-tube/swallowing intervention|patients will receive G-tube/nutritional and swallowing intervention. As per patient needs
3202033|NCT01184027||G-tube/swallowing counseling|G-tube/ad lib dietary and swallowing counseling. Current standard of care.
3202034|NCT01184027||nutrition/swallowing intervention|Patients will receive active nutrition and swallowing intervention based on patients caloric and swallowing needs.
3202035|NCT01184027||nutrition/swallowing counseling|Patients will have ad lib dietary intake with general nutrition and swallowing counseling.
3202036|NCT01184014|Experimental|Experimental group|a study-specific steroid (NPH) dosing algorithm plus standard recommended care. The intervention is Neutral Protamine Hagedorn (NPH) insulin plus complete insulin orders (CIO).
3202037|NCT01184014|Active Comparator|Control group|the standard recommended care (Methodist Hospital Complete Insulin Orders)
3202038|NCT01184001|Experimental|Sequence 1|
3202039|NCT01184001|Experimental|Sequence 2|
3202040|NCT01183975||Patients treated with SAGB by solicited teams|Patients treated with SAGB by solicited teams. No selection criteria at cohort inclusion applied to the 500 (+50) first patients treated in order to ensure consecutive and exhaustive recruitment in the concerned centers over the inclusion period.
3202041|NCT01183962|Other|Vitamin D|Subject receives daily dose of Vitamin D
3202042|NCT01183962|Other|No medicine|Subject does not receive medication
3202043|NCT01183949|Experimental|Treatment|Patients will be enrolled into 3 groups which will run sequentially. Groups A and B will receive AT7519M only, whereas Group C will receive AT7519M in combination with Bortezomib.
3202044|NCT01183936|Active Comparator|2 cm margin of excision|Patients with CMM >2 mm treated with an excision of 2-cm.
3202045|NCT01183936|Active Comparator|4 cm margin of excision|Patients with CMM >2 mm treated with an excision of 4-cm.
3202046|NCT01183923|Other|Broccoli Sprouts, then Alfalfa Sprouts|
3202047|NCT01183923|Other|Alfalfa Sprouts, then Broccoli Sprouts|
3202048|NCT01183910|Placebo Comparator|Calcium carbonate placebo pill|Placebo medication to treat the appearance of the skin in patients with senile purpura
3202049|NCT01183910|Active Comparator|Nutraceutical|Patients take a novel, natural nutraceutical product to improve the appearance of the skin of patients with senile purpura
3202050|NCT01183897|Experimental|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|This phase II study of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response in of primary refractory neuroblastoma in bone marrow (i.e., incomplete response to standard treatment).
3202051|NCT01183884|Experimental|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles.
3202052|NCT01183871|Active Comparator|good pulmonary functions (group 1)|FVC and/or FEV1 of 80% of predicted or more
3202053|NCT01183871|Active Comparator|mild pulmonary dysfunction (group 2)|FVC and/or FEV1 of 70%-79% of predicted
3202054|NCT01183871|Active Comparator|moderate pulmonary dysfunction (group 3)|FVC and/or FEV1 of 60%-69% of predicted
3202055|NCT01183871|Active Comparator|severe pulmonary dysfunction (group 4)|FVC and/or FEV1 of 50%-59% of predicted
3202056|NCT01183858|Experimental|Erlotinib 150 mg|Erlotinib 150 mg single daily oral dose until disease progression.
3202057|NCT01183858|Experimental|Erlotinib 300 mg|Erlotinib 300 mg single daily oral dose until disease progression.
3202058|NCT01183845|Experimental|Exam with colon capsule|Colon Capsule Endoscopy
3202059|NCT01183832||Concomitant|In this group, anastrazole is concomitant to the radiotherapy
3202060|NCT01183832||Sequential|In this group, anastrazole is sequential to the radiotherapy (start after the end of radiotherapy)
3202061|NCT01183819|Experimental|Space Fortress and Exercise|Participants engage in aerobic exercise 4 times week and Space Fortress sessions 3 times a week for a total of 12 weeks.
3202062|NCT01183819|Active Comparator|Control Games and Exercise|Participants engage in aerobic exercise 4 times a week and control game sessions 3 times a week for a total of 12 weeks.
3202063|NCT01183819|Active Comparator|Control Games and Stretching|Participants engage in stretching/toning exercises 4 times a week and control game sessions 3 times a week for a total of 12 weeks.
3202064|NCT01183806|Experimental|Rivastigmine and exercise program|Experimental group: Rivastigmine and exercise program: All patients will monthly receive Rivastigmine (Exelon patch). The exercise training program consists of two 40-minute sessions per week for six months and includes aerobic, strength, flexibility and balance training
3202065|NCT01183806|Active Comparator|Rivastigmine|Control group : Rivastigmine All patients will monthly receive Rivastigmine (Exelon patch)
3202066|NCT01183793|Other|Bras pair|MR-enterography then barium follow through
3202067|NCT01183793|Other|Bras impair|Barium follow-through then MR-enterography
3202068|NCT01183780|Experimental|FOLFIRI + Ramucirumab|
3202069|NCT01183780|Placebo Comparator|FOLFIRI + Placebo|
3202070|NCT01183767|Active Comparator|EGCG|Epigallocatechin-Gallate (EGCG)
3202071|NCT01183767|Placebo Comparator|Placebo|
3202072|NCT01183754||patients receiving drug-eluting stents|
3202073|NCT01183728|Experimental|MSV autologous transplantation|Bone marrow collected from patient will be used for mesenchymal stem cells isolation and expansion under GMP conditions at IBGM-Valladolid (MSV). Autologous MSV implanted in knee by articular injection
3202074|NCT01183715|Experimental|Cohort 1|Subjects in Cohort 1 will receive 2 single doses of PF-05161704 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-05161704 will be administered in Period 4 in the fasted state.
3202075|NCT01183715|Experimental|Cohort 2|Subjects in Cohort 2 will receive 2 single doses of PF-05161704 and 1 placebo dose in random order in Periods 1-3
3202076|NCT01183702|Active Comparator|non-LASIK|These participants have NOT had LASIK surgery.
3202077|NCT01183702|Active Comparator|LASIK|These participants have had LASIK surgery.
3202078|NCT01183689|No Intervention|Control Group|"Self-Guided Behavior Changes. This group will be used to determine average rate of weight gain over 3 years with little intervention. Participants randomized to this group will receive one face-to-face session that will provide general education of self-weighing and information about both the small and large changes approach. Participants will also be provided with quarterly newsletters describing study events and very limited information on health eating."
3202079|NCT01183689|Experimental|Small behavior changes|Participants randomized to this group will be taught to self-weigh daily and report weights regularly. They will be reinforced for maintaining weight below randomization weight and taught that if weight exceeds randomization weight, they should reinstate small changes (e.g., modify diet by approximately 100 kcal, decrease portion sizes or change types of food, increase activity by 2000 steps/day).
3202080|NCT01183689|Experimental|Large behavior changes|Participants randomized to this group will be taught to self-weigh daily and report weights regularly. They will be reinforced for maintaining weight below randomization weight and taught that if weight exceeds randomization weight, they should reinstate large changes (e.g., modify diet to 1200-1500 or 1500-1800 kcal/day with < 30% fat, increase exercise to 250 minutes/week of moderate intensity activity).
3202081|NCT01183676|Experimental|Divalproex Sodium|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG - Mylan Pharmaceuticals Inc
3202082|NCT01183676|Active Comparator|Depakote Tablets|DEPAKOTE® Tablets, 500 MG Abbott Laboratories
3202083|NCT01183663|Experimental|Lenalidomide + Bevacizumab|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Bevacizumab starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
3202084|NCT01183663|Experimental|Lenalidomide + Sorafenib|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Sorafenib starting dose: 200 mg by mouth daily for 28 a day cycle.
3202085|NCT01183663|Experimental|Lenalidomide + Temsirolimus|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Temsirolimus starting dose: 15 mg by vein every week for a 28 day cycle.
3202086|NCT01183663|Experimental|Lenalidomide + Oxaliplatin + Leucovorin + 5-fluorouracil|Lenalidomide starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle. Oxaliplatin starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle. Leucovorin 400 mg/m2 by vein on day 1 of a 21 day cycle. 5-fluorouracil 400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.
3202087|NCT01183650|Experimental|Tadalafil|5 mg, administered orally, daily for 10 days
3202088|NCT01183637|Experimental|Treatment|Patients assigned to the treatment arm will receive treatment with the Kensey Nash Corp. Cartilage Repair Device.
3202089|NCT01183637|Active Comparator|Control|Patients assigned to the Control Arm will receive treatment with the standard surgical technique known as microfracture.
3202090|NCT01183624|Experimental|Experimental Patch|Herbal Patch
3202091|NCT01183624|Placebo Comparator|Control Patch|Placebo Patch
3202092|NCT01183611|Experimental|A1|health neonates born to mother with positive for both HBsAg and e antigen
3202093|NCT01183611|Active Comparator|A2|health neonates born to mother with positive for both HBsAg and e antigen
3202094|NCT01183611|Experimental|B1|health neonates born to a mother positive for HBsAg, negative for the hepatitis B e antigen
3202095|NCT01183611|Active Comparator|B2|health neonates born to a mother positive for HBsAg, negative for the hepatitis B e antigen
3202096|NCT01183611|Experimental|C1|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
3202097|NCT01183611|Active Comparator|C2|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
3202098|NCT01183611|Placebo Comparator|C3|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
3202099|NCT01183598|Experimental|Single Arm|
3202100|NCT01183585|Experimental|1|
3202101|NCT01183572|Active Comparator|Folic Acid and Iron|0.4mg of folic acid and 30 mg elemental iron taken daily for 6 months
3202102|NCT01183572|Placebo Comparator|Folic Acid|0.4mg of folic acid taken daily for 6 months
3202103|NCT01183572|Active Comparator|Multivitamins, Folic Acid, and Iron|A multivitamin and micronutrient supplement that constitutes 1 RDA of Vitamins A (2500 IU), B1 (1.4 mg), B2 (1.4 mg), B6 (1.9 mg), B12 (2.6 ug), niacin (18 mg), C (70 mg), E (10 mg), and folic acid (0.4 mg)along with 30 mg of elemental iron taken daily for 6 months.
3202104|NCT01183546||Wheelchair Users with Spinal Cord Injury|wheelchair users with spinal cord injury
3202105|NCT01183533|Experimental|off label rt-PA used|off label rt-PA used on all subject enrolled within 3 hours of waking with stroke symptoms at the standard of care dose.
3202106|NCT01183520|Active Comparator|90 grams of Salmon|Subjects will consume 90 grams of salmon twice a week for 4 weeks
3202107|NCT01183520|Active Comparator|180 grams of salmon|Subjects will consume 180 grams of salmon twice a week for 4 weeks
3202108|NCT01183520|Active Comparator|270 Grams of Salmon|Subjects will consume 270 grams of salmon twice a week for 4 weeks
3202109|NCT01183507|Active Comparator|NIA intervention|
3202110|NCT01183507|Experimental|TSE intervention|
3202111|NCT01183494|Experimental|UGT1A1*1/*1|Participants with UGT1A1*/*1 genotype will receive escalating doses of FOLFIRI (folinic acid+fluorouracil+irinotecan) and bevacizumab. The initial dose of irinotecan will be 260 mg/m2 administered as a 120 min intravenous infusion every two weeks. The dosage of irinotecan will be increased to 310, 370, and 420 mg/m2, and further irinotecan doses will be increased by 14%. 5-FU will be administered as a 400 mg/m2 bolus right after the end of the irinotecan infusion, followed by 2,400 mg/m2 over a 46 h continuous infusion plus LV 200 mg/m2 every two weeks. Bevacizumab will be administered at a dose of 5 mg/kg over 15-30 min IV (after an initial 90 min infusion without a reaction) every two weeks. The first dose will be administrated on day 2 (48 hours after the first irinotecan administration), while the second dose on day 14 (the same day as the second irinotecan administration). No dose escalation will be performed for 5-FU, LV or bevacizumab.
3202112|NCT01183494|Experimental|UGT1A1*1/*28|Participants with UGT1A1*1/*28 genotype will receive escalating doses of FOLFIRI (folinic acid+fluorouracil+irinotecan) and bevacizumab. The initial dose of irinotecan will be 260 mg/m2 administered as a 120 min intravenous infusion every two weeks. The dosage of irinotecan will be increased to 310, 370, and 420 mg/m2, and further irinotecan doses will be increased by 14%. 5-FU will be administered as a 400 mg/m2 bolus right after the end of the irinotecan infusion, followed by 2,400 mg/m2 over a 46 h continuous infusion plus LV 200 mg/m2 every two weeks. Bevacizumab will be administered at a dose of 5 mg/kg over 15-30 min IV (after an initial 90 min infusion without a reaction) every two weeks. The first dose will be administrated on day 2 (48 hours after the first irinotecan administration), while the second dose on day 14 (the same day as the second irinotecan administration). No dose escalation will be performed for 5-FU, LV or bevacizumab.
3202113|NCT01183481|Experimental|Aprepitant and Granisetron|Patients will be given a single dose of Granisetron 2 mg orally and Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the Palliative radiation therapy.
3202114|NCT01183468|Experimental|Part 1a(Aralast NP)-Subjects Aged 16-35 Yrs|Subjects aged 16-35 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by intravenous (IV) infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
3202115|NCT01183468|Experimental|Part 1a (Aralast NP)-Subjects 8-15 Yrs|Subjects aged 8-15 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
3202116|NCT01183468|Experimental|Part 1b (Aralast NP)--Subjects Aged 18-35 Yrs|Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.
3202117|NCT01183468|Experimental|Part 1b (Aralast NP)-Subjects 8-17 Yrs|Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.
3202118|NCT01183455|Experimental|Aralast NP|Participants will receive Aralast NP (90mg/kg) intravenously once a week for 12 weeks.
3202119|NCT01183455|Placebo Comparator|Placebo|Participants will receive placebo intravenously once a week for 12 weeks.
3202120|NCT01183442|Active Comparator|vitamin D (Oleovit®)|vitamin D drops
3202121|NCT01183442|Placebo Comparator|Placebo|placebo drops
3202122|NCT01183429|Experimental|3F8 and 13-cis-retinoic acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(8), patients no longer receive high dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles.
3202123|NCT01183416|Experimental|3F8 monoclonal antibody and 13-cis-Retinoic Acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. The patients are post-transplant and in 1st complete/very good partial remission (CR/VGPR),89 with no evidence of NB by standard studies, but are at high risk for relapse.
3202124|NCT01183390|Experimental|Investigational Test Product|Anastrozole 1 mg Tablets
3202125|NCT01183390|Active Comparator|Reference Listed Drug|Arimidex® 1 mg Tablets
3202126|NCT01183377||1|Female athlete Triad syndrom was based on menstrual disorder,Eating Disorder and bone loss
3202127|NCT01183364|Experimental|STA-9090 and Docetaxel|STA-9090 (ganetespib) and Docetaxel
3202128|NCT01183351|Experimental|Psychosocial intervention|This is a single-group pilot-study
3202129|NCT01183325|Experimental|Proceed Ventral Patch placement|Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
3202130|NCT01183312|Experimental|Placebo, then Flumazenil|Subjects in this arm will first receive a day of placebo, then a day of sublingual flumazenil
3202131|NCT01183312|Experimental|Flumazenil, then Placebo|Subjects in this group will first receive a day of sublingual flumazenil, then a day of placebo.
3202132|NCT01183299|Active Comparator|High salt intake|
3202133|NCT01183299|Placebo Comparator|Low salt intake|
3202134|NCT01183286|Active Comparator|CFFONE|
3202135|NCT01183286|Placebo Comparator|CF website|
3202136|NCT01183273|Active Comparator|Micro-laparoscopic bypass|
3202137|NCT01183273|Active Comparator|Laparoscopic gastric bypass|
3202138|NCT01183260|Experimental|Trabecular Metal Revision Cup|Patients randomized to this arm will receive a trabecular metal revision component which does not have a titanium inner surface and requires a cemented highly crosslinked polyethylene liner.
3202139|NCT01183260|Active Comparator|Trabecular Metal Modular Cup|Patients randomized to this arm will receive a trabecular metal modular component which has a titanium inner surface and requires a non-cemented highly crosslinked polyethylene liner.
3202140|NCT01183247|Active Comparator|Rapamycin|Rapamycin-MMF-tacrolimus
3202141|NCT01183247|Active Comparator|Everolimus|Everolimus - tacrolimus - MMF
3202142|NCT01183247|Active Comparator|Prednisone|tacrolimus - MMF -prednisone
3202143|NCT01183234|Experimental|SPD544 (Equasym XL)|
3202144|NCT01183234|Experimental|Methylphenidate hydrochloride (Metadate CD )|
3202145|NCT01183221|Experimental|placebo spray|
3202146|NCT01183208|Experimental|Cohort 1 active treatment and placebo|Active treatment and placebo
3202147|NCT01183208|Experimental|Cohort 2 - Active treatment and placebo|Active treatment and placebo
3202148|NCT01183208|Experimental|Cohort 3 Active Treatment and placebo|Active treatment and placebo
3202149|NCT01183182|Experimental|Needle Guidance|Lung biopsies performed with the needle guidance system.
3202150|NCT01183169|Experimental|Treatment A: ALV 600 mg QD|Alisporivir (ALV) 600 mg once daily (QD) with Peginterferon alfa-2a (PEG) and Ribavirin (RBV) for up to 48 weeks
3202151|NCT01183169|Experimental|Treatment B: ALV 800 mg QD|Alisporivir (ALV) 800 mg QD with PEG and RBV for up to 48 weeks
3202152|NCT01183169|Experimental|Treatment C1: ALV Placebo - 600 mg QD|ALV Placebo with PEG and RBV for up to 48 weeks; participants not achieving complete early virologic response (cEVR) after 12 weeks of treatment may switch to active ALV 600 mg QD with PEG and RBV.
3202153|NCT01183169|Experimental|Treatment C2: ALV Placebo - 400 mg BID|ALV Placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR after 12 weeks of treatment may switch to active ALV 400 mg twice daily (BID) with PEG and RBV.
3202154|NCT01183169|Experimental|Treatment D: ALV 400 mg BID|Alisporivir (ALV) 400 mg twice daily BID with PEG and RBV for up to 48 weeks
3202155|NCT01183156|Active Comparator|Re-invitation letter|
3202156|NCT01183156|Active Comparator|Educational Meeting|
3202157|NCT01183143|Experimental|GONAL-f®|
3202158|NCT01183130|Experimental|Compliance monitoring in real time|Patients get their opioid substitution medications in electronic compliance monitoring devices and send information of their medication intakes with mobile phone to the clinic every day during the two month study period.
3202159|NCT01183130|Active Comparator|Compliance monitoring|Patients get their opioid substitution medications in electronic compliance monitoring devices. Information of their medication intakes will be reviewed during the weekly visits to the clinic.
3202160|NCT01183117|Experimental|SM-01|
3202161|NCT01183117|Active Comparator|PTA|
3202162|NCT01183104|Experimental|Sitagliptin|
3202163|NCT01183104|Active Comparator|Glimepiride|
3202164|NCT01183091||First AF ablation|Description of the patients experiencing an AF ablation
3202165|NCT01183078|Other|Free-hand technique|Free-hand technique utilized to find screw holes.
3202166|NCT01183078|Other|Wand technique|Wand technique is utilized to find screw holes.
3202167|NCT01183065|Experimental|pralatrexate and vitamin supplementation|This will be an open-label, single arm, Simon optimal two-stage design phase II study.
3202168|NCT01183052|Other|Training|20 sessions of training
3202169|NCT01183039|Active Comparator|Ventilatory threshold|Training at the ventilatory threshold
3202170|NCT01183039|Active Comparator|Metabolic threshold|Training at the metabolic threshold
3202171|NCT01183013|Active Comparator|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily
3202172|NCT01183013|Active Comparator|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily
3202173|NCT01183013|Active Comparator|Pioglitazone 45 mg|Pioglitazone Capsules 45 mg once daily
3202174|NCT01183013|Active Comparator|Linagliptin 5mg|Linagliptin 5mg Tablets once daily
3202175|NCT01183013|Experimental|Linagliptin 5mg / Pioglitazone 15 mg|Linagliptin 5mg / Pioglitazone 15 mg Tablets once daily
3202176|NCT01183013|Experimental|Linagliptin 5mg / Pioglitazone 30 mg|Linagliptin 5mg / Pioglitazone 30 mg Tablets once daily
3202177|NCT01183013|Experimental|Linagliptin 5mg / Pioglitazone 45 mg|Linagliptin 5mg / Pioglitazone 45 mg Tablets once daily
3202178|NCT01183000|Active Comparator|peritoneal closure|
3202179|NCT01183000|No Intervention|Non closure of the peritoneum|
3202180|NCT01182987|Active Comparator|Dementia care management|Patients and family caregivers will be offered dementia care management, which includes detailed comprehensive assessment, education, counseling, referrals to community agencies, collaboration with medical providers and frequent telephone follow-up
3202181|NCT01182987|No Intervention|Usual care|Patients and care family care givers will receive usual support and medical care offered by the health plan.
3202182|NCT01182974|Active Comparator|paracetamol treatment|
3202183|NCT01182974|Active Comparator|control- dypirone treatment|
3202184|NCT01182961|Experimental|Treadmill +virtual reality training|
3202185|NCT01182961|Active Comparator|Treadmill alone|
3202186|NCT01182961|Active Comparator|standard of care exercise group|
3202187|NCT01182948|Experimental|Aerobic Exercise|The aerobic training group will use cardiovascular training devices.
3202188|NCT01182948|Experimental|Resistance Exercise|The resistance training group will perform exercises on weight machines and free weights.
3202189|NCT01182935||participants in the 4th Tromsø study|
3202190|NCT01182922|Active Comparator|Doctor's Information Invitation|Standard invitation with additional leaflet containing information concerning particular doctor performing the examination, that is: his personal data (name, surname, academic title, workplace, picture) and data concerning experience and achievements of the center where he is employed.
3202191|NCT01182922|Active Comparator|Gender Preference Invitation|Standard invitation with additional information about possibility of choosing doctor's gender, mentioned below proposed date of examination
3202192|NCT01182922|Active Comparator|Standard Invitation|Standard invitation without additional information about a doctor or possibility of choosing doctor's gender.
3202193|NCT01182870|Experimental|cholecalciferol|cholecalciferol in doses 800-6000 IU per day
3202194|NCT01182870|Placebo Comparator|placebo|placebo identical looking as cholecalciferol capsules
3202195|NCT01182844|No Intervention|Control|Usual care
3202196|NCT01182844|Experimental|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
3202197|NCT01182831|Active Comparator|percutaneous fluoro guided celiac plexus neurolysis|
3202198|NCT01182831|Active Comparator|EUS guided neurolysis|
3202199|NCT01182818||Observation|all adult patients (18 - 60 years of age) with an acute cerebrovascular event of any etiology
3202200|NCT01182805|Other|Single arm study.|
3202201|NCT01182792|Experimental|Antioxidant|
3202202|NCT01182792|Placebo Comparator|Control|
3202203|NCT01182779|Experimental|A|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E."
3202204|NCT01182779|Active Comparator|B|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E."
3202205|NCT01182766|Experimental|topiramate|topiramate with brief behavioral enhancement therapy
3202206|NCT01182766|Placebo Comparator|Placebo|Placebo with brief behavioral enhancement therapy
3202207|NCT01182753|Experimental|A|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E."
3202208|NCT01182753|Active Comparator|B|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E."
3202209|NCT01182740||glidescope|
3202210|NCT01182740||storz c-mac|
3202211|NCT01182740||mcgrath vl|
3202212|NCT01182740||ambu pentax aws|
3202213|NCT01182740||macintosh laryngoscope|
3202214|NCT01182740||others|
3202215|NCT01182727|Experimental|salsalate|Salsalate will be administered in two divided doses of 2grams in the morning and 2 grams in the evening. Salsalate will be administered for 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until a tolerated dose or a minimum dose of 2 grams per day is reached.
3202216|NCT01182714|Other|removal of catheter|
3202217|NCT01182701|Active Comparator|Behavioral intervention|
3202218|NCT01182701|No Intervention|Education support|
3202219|NCT01182675|Experimental|T-cell Graft Permissive SCID|"Patients with SCID with:~i. NK- phenotype; ii. NK+ phenotype with 10/10 HLA-matched relative or unrelated donor; or iii. NK+ phenotype with maternal engraftment by STR analysis and undergoing haplocompatible HSCT from maternal donor Intervention: Transplant Conditioning with Mobilization Only"
3202220|NCT01182675|Experimental|T-cell Graft Resistant SCID|Patients with SCID with NK+ phenotype with HLA-mismatched donor Intervention: Transplant Conditioning with Mobilization and Alemtuzumab
3202221|NCT01182662|Experimental|Human umbilical cord-derived MSCs and cyclosporin|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated to apply in trimonthly for 2 cycle and CsA 5mg/kg po for 12 months
3202222|NCT01182662|Active Comparator|cyclosporine A|cyclosporine A at a dose of 5 mg CsA/kg
3202223|NCT01182649|Experimental|EES Group|Patients who received an everolimus eluting stent
3202224|NCT01182649|Active Comparator|SES Gruop|Patients who received a sirolimus eluting stent
3202225|NCT01182636|Experimental|Investigational Test Product|Adapalene Topical Gel, 0.1%
3202226|NCT01182636|Active Comparator|Reference Listed Drug|Differin® (adapalene 0.1%) Topical Gel
3202227|NCT01182636|Placebo Comparator|Placebo|Gel base only
3202228|NCT01182623||In vivo diagnosis|Patients undergoing colonoscopy where one or more polyps up to 10mm in size are found.
3202229|NCT01182610|Experimental|Treatment group|"Panitumumab 9mg/kg on Days 1, 22, and 43~Paclitaxel 200mg/m2 on Days 1 and 22~Carboplatin AUC=6 on Days 1 and 22~5FU 225mg/m2/day on Days 1-15 and 22-36"
3202230|NCT01182597|Active Comparator|IV PPI|Pantoprazole 3.3mg/hr for 72hrs
3202231|NCT01182597|Experimental|Oral PPI|Lansoprazole (Takepron OD) 30mg PO q12h
3202232|NCT01182584||Graves' disease|
3202233|NCT01182584||Healthy volunteers|
3202234|NCT01182571||heart transplantation|
3202235|NCT01182558|Other|Activation of Hypothenar Eminence|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
3202236|NCT01182558|Other|Activation of Thenar Eminence|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
3202237|NCT01182558|Other|Activation of Extensor Digitorum Brevis|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
3202238|NCT01182558|Placebo Comparator|Maintain Relaxation of the Opposite Side|While the muscle of the right side is activated periodically and the compound muscle action potential is tested frequently, the muscle on the left side is maintained at rest and the compound muscle action potential is tested infrequently.
3202239|NCT01182545|Placebo Comparator|The normoventilation group|15 minutes prior to CO2 insufflation, the patients' lungs were ventilated with a tidal volume (TV) of about 8 mL.kg-1 and respiratory rate (R.R) owas adjusted to maintain an end-tidal CO2 (ETCO2) of 4.6-6 kPa throughout the procedure.
3202240|NCT01182545|Active Comparator|The hyperventilation group|15 minutes prior to CO2 insufflation, the patients' lungs were ventilated with a TV of 8 mL.kg-1 with the adjustment of the R.R to maintain an ETCO2 of 4-4.6 kPa, until the end of anaesthesia.
3202241|NCT01182532|Active Comparator|Western therapy|
3202242|NCT01182532|Experimental|TCM treatment|
3202243|NCT01182532|Experimental|Western therapy plus TCM treatment|The combination of both western therapy and TCM treatment.
3202244|NCT01182519||Diagnosed with metastatic breast cancer|"The primary objective of this study is to examine the association between urinary PGE-M and the presence or absence of lung metastases in patients with breast cancer. These patients will be subdivided into a set with lung metastases (group 1A; clinically assessed as per guidelines below) versus those with no evidence of lung metastases (group 1B; no known lung metastases). Group #2 (control) will have been treated for early stage breast cancer and will have no known metastases."
3202245|NCT01182519||History of early breast cancer|History of early breast cancer and currently no evidence of disease
3202246|NCT01182506|Experimental|Breast cancer survivors|Participants from both groups will be asked to complete two follow up neurocognitive assessments face to face at MSKCC. The first will be completed within 1-4 weeks after completing the memory training and the second will take place 3-4 months after completing the memory training. Collateral sources will be contacted at these same points to complete their brief assessments as well to test for maintenance of the treatment effect.
3202247|NCT01182506|Experimental|Collateral source|Participants from both groups will be asked to complete two follow up neurocognitive assessments face to face at MSKCC. The first will be completed within 1-4 weeks after completing the memory training and the second will take place 3-4 months after completing the memory training. Collateral sources will be contacted at these same points to complete their brief assessments as well to test for maintenance of the treatment effect.
3202248|NCT01182493|Experimental|Insulin Pump Treatment|Patients will get an insulin pump
3202249|NCT01182493|No Intervention|Insulin treatment with MDI|patients treated with Multiple Daily Injections (MDI); basal/bolus therapy with rapid- and long-acting analogs with at least 3 injections per day
3202250|NCT01182467||Crohn's disease|Patients will receieve Radiation: PET-CT scan
3202251|NCT01182441|Experimental|WATCHMAN|Subjects assigned to receive the WATCHMAN device.
3202252|NCT01182441|Active Comparator|Warfarin|Subjects assigned to warfarin therapy.
3202253|NCT01182428|Experimental|XIENCE V® / XIENCE PRIME™|
3202254|NCT01182428|Active Comparator|CYPHER SELECT|
3202255|NCT01182415|Experimental|High-dose chemotherapy with autologous stem cell transplant|
3202256|NCT01182402|Experimental|Electronic compliance monitoring|Suboxone treated patients in Kuopio city area get their unsupervised Suboxone doses in electronic compliance monitoring devices during the 4 month study.
3202257|NCT01182389|Active Comparator|robotic VT Ablation|Robotic VT ablation by substrate elimination
3202258|NCT01182389|Active Comparator|Conventional therapy|review of ICD programming to ensure that detection and therapy will occur appropriately.
3202259|NCT01182376|Placebo Comparator|Placebo|Half of the patients will be assigned placebo.
3202260|NCT01182376|Experimental|Multaq® (dronedarone)|Half of the patients will be prescribed dronedarone.
3202261|NCT01182363|No Intervention|Control|Usual early intervention services
3202262|NCT01182363|Experimental|Problem Solving Education|
3202263|NCT01182350|Experimental|Bevacizumab +irradiation+ erlotinib|"Radiation therapy to consist of 59.4Gy delivered using conventional conformal treatment planning.~Bevacizumab,and erlotinib will be given according to dosage, time frame listed."
3202264|NCT01182350|Experimental|Bevacizumab + Irradiation|"(promoter methylation negative, no EGFR over-expression): Bevacizumab plus irradiation:~Radiation therapy to consist of 59.4Gy delivered using conventional conformal treatment planning.~Bevacizumab, 10 mg/kg IV, will be given at least three weeks from the biopsy and at least two weeks after start of the radiation therapy and then every 14 +/- 3 days concurrently with radiation therapy, during the interim period, and for up to 10 maintenance cycles."
3202265|NCT01182350|Experimental|Bevacizumab+irradiation+temozolomide|"Bevacizumab plus irradiation plus temozolomide (promoter methylation positive, no EGFR over-expression)~Radiation therapy to consist of 59.4Gy delivered using conventional conformal treatment planning.~Bevacizumab and radiation will be given according to dosage and time frame listed."
3202266|NCT01182350|Experimental|Bevacizumab+ irradiation+erlotinib+temozol|"Bevacizumab plus irradiation plus erlotinib plus temozolomide (promoter methylation positive, EGFR over-expressed)~• Radiation therapy to consist of 59.4Gy delivered using conventional conformal treatment planning.~Bevacizumab, erlotinib and temozolomide will be given according to dosage, time frame listed."
3202267|NCT01182337|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
3202268|NCT01182337|Placebo Comparator|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
3202269|NCT01182298||Hepatitis C|latino participants with Hepatitis C
3202270|NCT01182285|Experimental|A - Phase I Radioiodine-Resistant|Drug: Valproic Acid Week 1 - 10 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening
3202271|NCT01182285|Active Comparator|B1 - Phase 2 Schedule 1|Drug: Valproic Acid Week 11 - 17 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening Drug: Cytomel (25 micrograms) Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Liothyronine Sodium (Cytomel) for 4 weeks (25 micrograms twice a day)
3202272|NCT01182285|Active Comparator|B2 - Phase 2 Schedule 2|Drug: Valproic Acid Week 11 - 52 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening Weeks 17-52: Patients who show a response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria or have a decreased thyroglobulin level from Day 1 of the treatment (registered as a partial response to the treatment) will continue on valproic acid at their current dose for a total of 52 weeks.
3202273|NCT01182246|Experimental|AXP107-11|
3202274|NCT01182233|Experimental|Total Skeletal Irradiation|Three subjects determined to be eligible for study and agree to participate are assigned to receive 200 cGy of TSI-HT for 5 days. If this dose level is well tolerated in the first 3 subjects, the dose will be increased and given over 5 days. The dose will continue to be increased until the maximum toelrated dose is reached.
3202275|NCT01182220||Ultrasound L5/S1 catheter placement|Pt will have back scanned with Ultrasound and L5/S1 interspace localized for epidural placement.
3202814|NCT01178528|Experimental|"Drug:Carvedilol and Drug:Ivabradine"|up to 12.5/5 mg bd
3202276|NCT01182220||Control Group|Patients will have catheter placed after clinically evaluating the back as is done routinely resulting in mid lumbar catheter placement in general.
3202277|NCT01182207|Experimental|Investigational Test Product|Drospirenone/Ethinyl Estradiol Tablets, 3 mg/0.02 mg
3202278|NCT01182207|Active Comparator|Reference Listed Drug|YAZ® Tablets, 3 mg/0.02 mg
3202279|NCT01182194|Experimental|Investigational Test Product|Drospirenone/Ethinyl Estradiol Tablets, 3 mg/0.02 mg
3202280|NCT01182194|Active Comparator|Reference Listed Drug|YAZ® Tablets, 3 mg/0.02 mg
3202281|NCT01182181|Experimental|Investigational Test Product|Anastrozole Tablets, 1 mg
3202282|NCT01182181|Active Comparator|Reference Listed Drug|Arimidex® Tablets, 1 mg
3202283|NCT01182168|Experimental|gemcitabine and cisplatin plus Everolimus|This is a single-institution phase I study of gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001) in patients with advanced urothelial cancer.
3202284|NCT01182142|Experimental|Capecitabine|All patients will receive capecitabine.
3202285|NCT01182129|Active Comparator|Swedish Snus Type 1|The subject keeps one pouch of snus still between the upper lip and the gum for 30 minutes. Amount of nicotine extracted, plasma nicotine concentration at 30 minutes (C30), Tmax, Cmax, AUCinf and heart rate for each treatment.
3202286|NCT01182129|Active Comparator|Swedish Snus Type 2|The subject keeps one pouch of snus still between the upper lip and the gum for 30 minutes. Amount of nicotine extracted, plasma nicotine concentration at 30 minutes (C30), Tmax, Cmax, AUCinf and heart rate for each treatment.
3202287|NCT01182129|Active Comparator|4 mg Nicorette chewing gum|Nicorette is chewed according to instructions in package insert over 30 minutes.
3202288|NCT01182116|Experimental|J Pouch side to end|Colorectal surgery Function Quality of Life
3202289|NCT01182103||Major depressive patients|
3202290|NCT01182103||Healthy subjects|
3202291|NCT01182090|Active Comparator|Prolapse repair by open approach|Correction of urogenital prolapse by open surgery approach
3202292|NCT01182090|Active Comparator|Prolapse repair by laparoscopic approach|Correction of urogenital prolapse by laparoscopic approach
3202293|NCT01182077|Experimental|Group 1|ASP015K low dose and midazolam followed by ASP015K high dose and midazolam
3202294|NCT01182077|Experimental|Group 2|ASP015K high dose and midazolam followed by ASP015K low dose and midazolam
3202295|NCT01182064||Non infarct|
3202296|NCT01182064||Posttraumatic acute myocardial infarct without coronary injury|
3202297|NCT01182064||Posttraumatic acute myocardial infarct with coronary injury|
3202298|NCT01182051|Experimental|Cognitive behavioral therapy|Key treatment ingredients in CBT include psychoeducation, trigger identification, progressive muscle relaxation training, cognitive restructuring, problem solving, in vivo exposure, and relapse prevention (see Appendix I for an outline of the treatment manual).
3202299|NCT01182051|Active Comparator|Relaxation Training|RT will consist of progressive muscle relaxation training, diaphragmatic breathing, and thermal biofeedback.
3202300|NCT01182038|Experimental|Birth seat group|Randomized to birth on a midwife designed birth seat
3202301|NCT01182038|No Intervention|Non-birth seat group|Randomized to birth in any other position except on the midwife designed birth seat.
3202302|NCT01182025|Active Comparator|Western therapy|
3202303|NCT01182025|Experimental|Xiyanping Injection|
3202304|NCT01182025|Experimental|Xiyanping Injection with western medicine|
3202305|NCT01182012|Experimental|Lifestyle counseling|Adjust drug treatment to control cardiovascular factor risks. A nurse will implement a lifestyle counseling in order to improve compliance of treatment and a healthy lifestyle.
3202306|NCT01181999|Experimental|rituximab|
3202307|NCT01181986|Experimental|Exenatide SC (Sub-study 1)|Study groups will be individuals with recent onset (<3 years) or established (>5 years) T2D. The plan is to achieve 40 complete studies of subcutaneous injection of exenatide BID (Byetta®, 5 or 10 µg) or identically looking Placebo SC for 10 days, separated by 14-day washout period. On the next day after each treatment phase, a single dose of the assigned medication will be injected just before a fat-enriched breakfast meal. A lunch meal of similar caloric and nutrient content will be administered 4 hours following the breakfast meal. Endothelial function will be measured just prior to the injection and every 2 hours during 8-hour post-breakfast period.
3202308|NCT01181986|Experimental|Exenatide IV (Sub-study 2)|Study group will be individuals with recent onset (<1 year) T2D on diet and impaired glucose tolerance. The plan is to achieve 35 complete studies. The intervention will include 3 randomly ordered visits with intravenous infusion of exenatide in the presence (v1) or absence (v2) of GLP-1 receptor inhibitor exendin-9, and a control test with Placebo IV without exendin-9 (v3). Endothelial function will be measured at baseline and 2 hours later during the final 15 minutes of the infusion cocktails. Study participants will remain fasting during the test visit (3 hours total).
3202309|NCT01181973|Active Comparator|Treatment sequence #1|One 1-mL subcutaneous injection at 30 mg/mL in Period 1 and two 1-mL subcutaneous injections at 15 mg/mL each in Period 2
3202310|NCT01181973|Active Comparator|Treatment sequence #2|Two 1-mL subcutaneous injections at 15 mg/mL each in Period 1 and one 1-mL SC injection at 30 mg/mL in Period 2
3202311|NCT01181960||001|Risperidone long acting injectable - New Starts Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
3202312|NCT01181960||002|Risperidone long acting injectable - Continuous Users Patients who have been on Risperidone long acting injectable for at least 6 months before baseline with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
3202313|NCT01181960||003|Paliperidone Palmitate -New and Continuous Users Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
3202314|NCT01181960||004|Other Antipsychotics - New Starts Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
3202315|NCT01181947||patients undergoing TEVAR|Those with a thoracic aortic aneurysm/dissection
3202316|NCT01181934|Experimental|001|A643 (nicotine) 1mg oromucosal nicotine spray- three times daily during each treatment period
3202892|NCT01177930||Feeding with milk without DHA and ARA|
3202317|NCT01181934|Experimental|002|A643 (nicotine) 2mg oromucosal nicotine spray- three times daily during each treatment period
3202318|NCT01181934|Placebo Comparator|003|placebo placebo - three times daily during each treatment period
3202319|NCT01181921|Experimental|Galantamine|
3202320|NCT01181908|Experimental|GSK1144814|Subjects will receive either GSK1144814 or placebo at each treatment arm.
3202321|NCT01181908|Placebo Comparator|placebo|Subjects will receive either GSK1144814 or placebo at each treatment arm.
3202322|NCT01181895|Experimental|Vilanterol|Vilanterol inhalation powder once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
3202323|NCT01181895|Active Comparator|Salmeterol|Placebo inhalation powder via NDPI once daily + Salmeterol inhalation powder twice daily for 12 weeks
3202324|NCT01181895|Placebo Comparator|Placebo|Placebo inhalation powder via NDPI once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
3202325|NCT01181882|Experimental|Fish Oil and Aspirin|
3202326|NCT01181869||Oxygen therapy|Database of patients on oxygen
3202327|NCT01181869||ventilation|database of patients on ventilatory support
3202328|NCT01181869||Continuous positive airway pressure|Sleep apnoea patients on CPAP
3202329|NCT01181856|Experimental|Group A|Intramuscular immunisation
3202330|NCT01181856|Experimental|Group B|Intradermal immunisation
3202331|NCT01181843||Cesearean sections receiving duramorph|
3202332|NCT01181830|Active Comparator|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate for 8 weeks
3202333|NCT01181830|Placebo Comparator|placebo|administration of 8.1 mmol bid of placebo for 8 weeks
3202334|NCT01181817|Other|SCS|patients with Failed back Surgery syndrome treated with SCS
3202335|NCT01181804|Experimental|Boceprevir Tablets then Capsules (fed)|Participants will start therapy with a single dose of boceprevir tablets, orally, in fed condition, and then 4 days later will take a single dose of boceprevir capsules, orally, in fed condition.
3202336|NCT01181804|Experimental|Boceprevir Capsules then tablets (fed)|Participants will start therapy with a single dose of boceprevir capsules, orally, in fed condition, and then 4 days later will take a single dose of boceprevir tablets, orally, in fed condition.
3202337|NCT01181804|Experimental|Boceprevir Tablets then Capsules (fasted)|Participants will start therapy with a single dose of boceprevir tablets, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir capsules, orally, following an overnight fast.
3202338|NCT01181804|Experimental|Boceprevir Capsules then Tablets (fasted)|Participants on this study arm will start therapy with a single dose of boceprevir capsules, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir tablets, orally, following an overnight fast.
3202339|NCT01181791|Experimental|probiotic group|Lactobacillus reuteri will be given at a dose of 1x108 colony forming units (CFU)/day
3202340|NCT01181791|Placebo Comparator|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present.
3202341|NCT01181778||All Qualified Participants|All healthy women who consulted their physician for information on contraceptive choices and were eligible for primary and secondary outcome measure analysis, based on the physician's assessment
3202342|NCT01181765|Experimental|Infliximab infusions (5 mg/kg) at weeks 0, 2, 6, 14 and 22|
3202343|NCT01181752||Group A|Baseline/control subjects who are only tested on postoperative day 30
3202344|NCT01181752||Group B|Subjects who will be tested on postoperative day 1 and day 30
3202345|NCT01181752||Group C|"Subjects who cannot proficiently administer the medication on postoperative day 1 will be re-classified as Group C subjects"
3202346|NCT01181726|Experimental|Investigational Test Product|Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg
3202347|NCT01181726|Active Comparator|Reference Listed Drug|Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets
3202348|NCT01181713||No Antibiotic|No prophylactic antibiotic post intravitreal injection
3202349|NCT01181713||Prophylactic Antibiotic|Group treated with 3 day course of prophylactic topic antibiotic, fourth generation fluoroquinolones, after each intravitreal injection
3202350|NCT01181700|Experimental|Treatment A|
3202351|NCT01181700|Experimental|Treatment B|
3202352|NCT01181700|Experimental|Treatment C|
3202353|NCT01181700|Active Comparator|Treatment D|
3202354|NCT01181700|Active Comparator|Treatment E|
3202355|NCT01181700|Active Comparator|Treatment F|
3202356|NCT01181700|Active Comparator|Treatment G|
3202357|NCT01181674|Experimental|Group 1 (short)|
3202358|NCT01181674|Experimental|Group 2 (long)|
3202359|NCT01181674|Other|Standard care|
3202360|NCT01181661|Experimental|Full Group Contingency|This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
3202361|NCT01181661|Experimental|Mixed Group Contingency|This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
3202362|NCT01181648||oropharynx cancer survivors|This study has two components. First, we will conduct a cross-sectional survey of 200 oropharynx cancer survivors, diagnosed with HPV+ tumors, who are at least 12 months from their last treatment. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis.
3202363|NCT01181635|Experimental|Psychotherapy|Short-term pychotherapy and/or psychoeduchative courses.
3202364|NCT01181622|Experimental|denufosol tetrasodium Inhalation Solution|
3202365|NCT01181622|Placebo Comparator|Placebo|
3202366|NCT01181609|Experimental|1|
3202367|NCT01181583|Experimental|Tailored Internet-delivered CBT|
3202368|NCT01181583|Experimental|Non-tailored Internet-delivered CBT|
3202369|NCT01181583|Active Comparator|Online discussion group|
3202370|NCT01181570|Experimental|Adalimumab|
3202371|NCT01181570|Placebo Comparator|Placebo|
3202414|NCT01181310|Experimental|D, E, B, C, A|Participants received treatment D, E, B, C, A for Periods 1, 2, 3, 4, and 5, respectively.
3202372|NCT01181557||rectal cancer with stoma|rectal cancer submitted to rectal anterior resection with stomia (RARS). Differences in QoL between the two groups were analyzed during three time: first preoperative, second postoperative and latter six month after stoma reconversion
3202373|NCT01181557||rectal cancer without stoma|rectal cancer submitted to rectal anterior resection (RAR) Differences in QoL between the two groups were analyzed during three time: first preoperative, second postoperative and latter six month later
3202374|NCT01181557||anterior resection of rectum|patients with rectal cancer submitted to RAR and patients with rectal cancer submitted to RARS
3202375|NCT01181544|Experimental|Heparin dose titration|
3202376|NCT01181531|Active Comparator|Traditional Vitamin D Therapy|
3202377|NCT01181531|Experimental|Cinacalcet|
3202378|NCT01181505|Experimental|Tolterodine|
3202379|NCT01181492||*1/*1|Grouped by CYP3A4*1G polymorphism, wild-type homozygote
3202380|NCT01181492||*1/*1G|Grouped by CYP3A4*1G polymorphism,*1/*1G: mutant heterozygote
3202381|NCT01181492||*1G/*1G|Grouped by CYP3A4*1G polymorphism,*1G/*1G: mutant homozygote
3202382|NCT01181479|Experimental|AG200-15 (cycles 1-13)|AG200-15 containing ethinyl estradiol and levonorgestrel. Type of intervention is drug.
3202383|NCT01181479|Active Comparator|Lessina crossover to AG200-15|Lessina containing ethinyl estradiol and levonorgestrel for 6 cycles followed by AG200-15 for 6 cycles. Type of intervention is drug.
3202384|NCT01181453|Experimental|Dermagraft(R)|Weekly application of Dermagraft(R) with standard care
3202385|NCT01181453|Other|Standard care only|Weekly application of standard care
3202386|NCT01181440|Experimental|Dermagraft(R) and conventional care|
3202387|NCT01181440|Other|Conventional care only|
3202388|NCT01181427|Placebo Comparator|Single Ascending Dose (SAD)|Healthy volunteers, receiving single ascending doses of ABT-267 or placebo.
3202389|NCT01181427|Placebo Comparator|Multiple Ascending Dose (MAD)|Healthy volunteers, receiving multiple ascending doses of ABT-267 or placebo, OR, multiple doses of ABT-267 + single dose of a Cytochrome P450 inhibitor or placebo + single dose of a Cytochrome P450 inhibitor.
3202390|NCT01181427|Active Comparator|Food Effect (FE)|Healthy volunteers, receiving ABT-267, multi-dose, food effect.
3202391|NCT01181427|Placebo Comparator|Antiviral Activity|HCV genotype 1-infected treatment naïve subjects receiving multiple ascending doses of ABT-267 or placebo monotherapy for 3 days.
3202392|NCT01181427|No Intervention|Resistance Monitoring|"HCV genotype 1-infected treatment naïve subjects, receiving at least one dose of ABT-267 or placebo in the Antiviral Activity arm, follow-up to monitor resistance developed to ABT-267, no treatment and only blood samples will be collected"
3202393|NCT01181414|Experimental|Atrioventricular junction ablation|Atrioventricular junction ablation by using radiofrequency energy.
3202394|NCT01181414|Active Comparator|Drug control of ventricular rate|Drug control of ventricular rate.
3202395|NCT01181401|Active Comparator|TPF standard|"TPF version 1 (standard)~Induction chemotherapy:~Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 every 21 days for 3 cycles~Antibody therapy with:~cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX~RTX: HART (72 Gy), IMRT or 3D-conformal techniques"
3202396|NCT01181401|Experimental|TPF experimental|"TPF version 2 (experimental)~Induction chemotherapy:~Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles~Antibody therapy with:~cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX~RTX: HART (72 Gy), IMRT or 3D-conformal techniques"
3202397|NCT01181401|Active Comparator|Standard RCT|"Standard RCT:~HART (72 Gy), IMRT or 3D-conformal techniques~with concurrent chemotherapy: Cis-platinum 30 mg/m2 once weekly d 1, 8, 15, 22, 29, 36 5-FU 600mg/m² /24h c.i. d 1-5"
3202398|NCT01181388|Active Comparator|intra-guide-catheter infusion of tirofiban|
3202399|NCT01181388|Experimental|intra-thrombus-aspiration-catheter infusion of tirofiban|
3202400|NCT01181375|Experimental|Assays on cervical cancer tissue|
3202401|NCT01181362|Other|Endoscopy|
3202402|NCT01181349||P07535 study participants with a TOF ratio <0.9|Participants enrolled in the P07535 study who are included in the primary outcome measurement, which is defined as the incidence of postoperative residual neuromuscular blockade, who had a TOF ratio <0.9 at PACU arrival.
3202403|NCT01181349||P07535 study participants with a TOF ratio ≥0.9|Participants enrolled in the P07535 study who are included in the primary outcome measurement, which is defined as the incidence of postoperative residual neuromuscular blockade, who had a TOF ratio ≥0.9 at PACU arrival.
3202404|NCT01181336|Experimental|Group 2|"FLU-v Low Dose with adjuvant. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.~10 subjects."
3202405|NCT01181336|Experimental|Group 3|"FLU-v High Dose with water for injection. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.~10 subjects."
3202406|NCT01181336|Experimental|Group 4|High Dose FLU-v with adjuvant FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection. 10 subjects
3202407|NCT01181336|Experimental|Group 1|FLU-v Low Dose with water for injection FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection 10 subjects
3202408|NCT01181336|Placebo Comparator|Control Group|Placebo with adjuvant (4 subjects) or Placebo without adjuvant (4 subjects)
3202409|NCT01181323|Experimental|Group 1: LAIV|0.2 ml of Live attenuated influenza vaccine (LAIV), Flumist® given intranasally (IN) and 0.5 ml of placebo given intramuscularly (IM) injection administered to 120 maternal subjects.
3202410|NCT01181323|Experimental|Group 2: TIV|0.5 ml of Inactivated Trivalent Influenza Vaccine (TIV), Fluzone® given intramuscularly (IM) and 0.2 ml of placebo given intranasally (IN) administered to 120 maternal subjects.
3202411|NCT01181310|Experimental|A, B, D, E, C|Participants received treatment A, B, D, E, C for Periods 1, 2, 3, 4, and 5, respectively.
3202412|NCT01181310|Experimental|B, C, E, A, D|Participants received treatment B, C, E, A, D for Periods 1, 2, 3, 4, and 5, respectively.
3202413|NCT01181310|Experimental|C, D, A, B, E|Participants received treatment C, D, A, B, E for Periods 1, 2, 3, 4, and 5, respectively.
3202647|NCT01179776|Placebo Comparator|Placebo|
3202415|NCT01181310|Experimental|E, A, C, D, B|Participants received treatment E, A, C, D, B for Periods 1, 2, 3, 4, and 5, respectively.
3202416|NCT01181310|Experimental|A, C, B, E, D|Participants received treatment A, C, B, E, D for Periods 1, 2, 3, 4, and 5, respectively.
3202417|NCT01181310|Experimental|B, D, C, A, E|Participants received treatment B, D, C, A, E for Periods 1, 2, 3, 4, and 5, respectively.
3202418|NCT01181310|Experimental|C, E, D, B, A|Participants received treatment C, E, D, B, A for Periods 1, 2, 3, 4, and 5, respectively.
3202419|NCT01181310|Experimental|D, A, E, C, B|Participants received treatment D, A, E, C, B for Periods 1, 2, 3, 4, and 5, respectively.
3202420|NCT01181310|Experimental|E, B, A, D, C|Participants received treatment E, B, A, D, C for Periods 1, 2, 3, 4, and 5, respectively.
3202421|NCT01181297|Experimental|Extensively Hydrolyzed Formula with a Probiotic|Extensively Hydrolyzed Formula with a Probiotic
3202422|NCT01181297|Placebo Comparator|Extensively Hydrolyzed Formula without a Probiotic|
3202423|NCT01181284||Lisinopril|Participants will be randomized 2 to 1 to receive drug versus placebo.
3202424|NCT01181271|Experimental|Autologous then Allogeneic transplant|"All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.~Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.~Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD)."
3202425|NCT01181258|Experimental|Patients Receiving NK Cell Infusion|Non-Myeloablative Conditioning Using Rituximab, Fludarabine, Cyclophosphamide and Methylprednisolone followed by Interleukin 2-activated Allogeneic Natural Killer Cells infusion for Patients with Refractory NHL and CLL
3202426|NCT01181245|Experimental|FG-3019|All subjects are treated with FG-3019
3202427|NCT01181232|Experimental|MR low-dose group|
3202428|NCT01181232|Experimental|MR high-dose group|
3202429|NCT01181232|Active Comparator|IR group|
3202430|NCT01181219|Experimental|CXL without epithelial removal|Application of Riboflavin and the consequent UV-irradiation with intact corneal epithelium
3202431|NCT01181219|Active Comparator|CXL with epithelial removal|Corneal epithelial removal prior to Riboflavin and the consequent UV-irradiation
3202432|NCT01181206|Active Comparator|Arm 1|
3202433|NCT01181206|Active Comparator|Arm 2|
3202434|NCT01181180|Experimental|balance treatment|
3202435|NCT01181167|Experimental|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery.
3202436|NCT01181167|Active Comparator|enoxaparin sodium|enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery.
3202437|NCT01181154|Placebo Comparator|equivalent volume total (=1000 ml)|Placebo : equivalent volume total (=1000 ml)
3202438|NCT01181154|Experimental|rituximab (Mabthera®)|rituximab (Mabthera®), 1000 mg at day 1 and day 15
3202439|NCT01181141|Experimental|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery
3202440|NCT01181141|Active Comparator|Enoxaparin sodium|Enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery
3202441|NCT01181128|Experimental|Individualized (Tailored) Prophylaxis|"On rFVIIIFc Day 0, all participants underwent pharmacokinetic (PK) analysis with 50 IU/kg rFVIIIFc to estimate their PK parameters and guide the appropriate dose or interval of dosing. A subset of participants (Sequential PK subgroup) also had PK analyses performed with a single dose of 50 IU/kg Advate (Advate Day 0) within 8 weeks prior to rFVIIIFc Day 0. A >= 96 hour washout was performed before the PK dose of Advate or rFVIIIFc was administered. Repeat PK profiling with a single dose of 50 IU/kg rFVIIIFc was conducted at Week 14 or after 12 to 24 weeks of prophylaxis with rFVIIIFc.~After PK assessments, all participants started twice weekly treatment with 25 IU/kg of rFVIIIFc via intravenous (IV) injection on Day 1 and 50 IU/kg on Day 4, followed by individualized dose and interval modification within the range of 25 to 65 IU/kg every 3 to 5 days, as determined by rFVIIIFc PK analysis, to maintain a trough level of 1% to 3% (or higher, as clinically indicated) FVIII activity."
3202442|NCT01181128|Experimental|Weekly Prophylaxis|65 IU/kg of rFVIIIFc via IV injection every 7 days
3202443|NCT01181128|Experimental|Episodic (On-Demand) Dosing|10 to 50 IU/kg rFVIIIFc via IV injection, as required to treat a bleeding episode
3202444|NCT01181115|Experimental|Active treatment|Interferon treatment for MS
3202445|NCT01181102|Experimental|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery.
3202446|NCT01181102|Active Comparator|enoxaparin sodium|enoxaparin sodium 20mg (=2000IU) 0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery.
3202447|NCT01181076|Experimental|Individualized Nutrition|
3202448|NCT01181076|No Intervention|Control group|The patients in the control group will be nourished after established routine, first by the oral route, later by the PN route. Naso-jejunal tube will not be inserted and enteral nutrition will not be given.
3202449|NCT01181063|Experimental|400/12 μg D94-2BF (60/40) inhaler|
3202450|NCT01181063|Experimental|320/9 μg D94-2BF (20/80) inhaler|
3202451|NCT01181063|Active Comparator|Symbicort 320/9 μg inhaler|
3202452|NCT01181063|Experimental|320/9 μg D94-2F (60/40) inhaler|
3202453|NCT01181063|Experimental|320/9 μg D94-2BF (60/40) inhaler|
3202454|NCT01181050|Experimental|4.0 mg/kg|Subjects received a single dose of 4 mg/kg NNC0142-0002
3202455|NCT01181050|Placebo Comparator|Placebo|Subjects received a single dose of placebo
3202456|NCT01181037||100 patients, displaced subcapital fracture, T.A.N nail.|100 patients sustained a displaced femoral subcapital fracture, that were operated on with closed reduction and internal fixation with TAN nail.
3202457|NCT01181037||100 patients, displaced subcapital fracture, Bipolar H.A..|
3202458|NCT01181024|Experimental|A: HV ascending dose|
3202459|NCT01181024|Experimental|B: HV food effect|
3202460|NCT01181024|Experimental|C: Hepatitis C|
3202696|NCT01179425|Active Comparator|non-marijuana dependent controls|
3202461|NCT01181011|Experimental|amlodipine/telmisartan/combination|all patients will be assigned to 6 treatment sequences. cross-over design was adopted to ensure each patient would take amlodipine/telmisartan/combination single dose in randomized order
3202462|NCT01180998|Other|Spherical contact lens users|Habitual spherical contact lens (non-toric lens) users tried one of two toric lenses in a daily wear modality.
3202463|NCT01180998|Other|Contact lens drop-outs|Habitual spectacle users (for vision correction) who have failed contact lens fit and wear, tried one of two toric lenses in a daily wear modality.
3202464|NCT01180998|Other|Habitual Correction with Spectacles (Neophytes)|Habitual spectacle lens wearers (for vision correction) who have never used or been fitted with contact lenses tried one of two toric lenses in a daily wear modality.
3202465|NCT01180985|Other|galyfilcon A prototype/comfilcon A|The galyfilcon A prototype lenses are worn during first period and comfilcon A lenses worn during second period. Each period consists of daily lens wear for one week.
3202466|NCT01180985|Other|comfilcon A/galyfilcon A prototype|The comfilcon A lenses are worn during first period and galyfilcon A prototype lenses worn during second period. Each period consists of daily lens wear for one week.
3202467|NCT01180959|Experimental|Erlotinib + Bevacizumab|Erlotinib 150 mg by mouth once a day. Bevacizumab 10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes.
3202468|NCT01180946|Active Comparator|Ergocalciferol|Weekly ergocalciferol for 16 weeks
3202469|NCT01180946|Placebo Comparator|Placebo|Placebo pill. Note that all subjects in this arm will receive vitamin D repletion at the conclusion of the study.
3202470|NCT01180933|Experimental|fish oil|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 500 mg DHA and 150 eicosapentaenoic acid per day from gestational week 22 until delivery
3202471|NCT01180933|Experimental|folate|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 400 µg folate (methyltetrahydrofolate)per day from gestational week 22 until delivery
3202472|NCT01180933|Experimental|fish oil + folate|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 500 mg DHA, 150 mg eicosapentaenoic acid and 400 µg MTHF per day from gestational week 22 until delivery
3202473|NCT01180933|Placebo Comparator|placebo|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women from gestational week 22 until delivery
3202474|NCT01180920||Periodontal disease|11 patients with periodontal disease, specifically generalized chronic or aggressive periodontitis will be selected. In general, the disease group will be comprised of subjects that need an open flap procedure.
3202475|NCT01180920||Healthy periodontium|11 patients without periodontal disease will be selected. In general, the healthy group will be comprised of subjects that are requiring a gingivectomy or crown lengthening procedure.
3202476|NCT01180907||patients with cancer|
3202477|NCT01180907||patients with autoimmune diseases|
3202478|NCT01180907||healthy subjects|
3202479|NCT01180894|Active Comparator|Iron sucrose|100 mg IV TIW
3202480|NCT01180894|Placebo Comparator|Placebo|Pacebo - Normal Saline
3202481|NCT01180881||Proton Radiation Patients at MGH|Pediatric brain and central nervous system (CNS) tumor patients treated with proton beam radiation therapy
3202482|NCT01180868||patients with cancer|patients with hematological malignancies and solid tumors
3202483|NCT01180868||patients with autoimmune dosorders|patients with Rheumatoid arthritis, Crohns's disease, systemic lupus erythematosus.
3202484|NCT01180868||healthy subjects|
3202485|NCT01180855|Placebo Comparator|Placebo|Placebo pills prepared by Takeda Pharmaceutical.
3202486|NCT01180855|Active Comparator|Rozerem|Rozerem 8mg
3202487|NCT01180855|Active Comparator|Rozerem + Multi Component Behavior Therapy|Rozerem 8mg in combination with 4 small group sessions and 2 phone calls of Multi Component Behavior Therapy.
3202488|NCT01180842|Other|Alternative Treatment|The CF Patient Population receiving the specific yoga study treatment
3202489|NCT01180829|No Intervention|Control condition|No interventions text messages sent
3202490|NCT01180829|Experimental|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking
3202491|NCT01180829|Experimental|Consciousness raising text message|A series of 12 text messages, each of which contains text designed to get the person to think about his or her drinking
3202492|NCT01180816|Experimental|Temozolomide (Temodar)|
3202493|NCT01180803|Experimental|oxygen-saving valves|
3202494|NCT01180803|Active Comparator|continuous oxygen supplementation|
3202495|NCT01180790|Experimental|Segment 1: 200 mg ACH-0141625|200 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a and ribavirin for 48 weeks
3202496|NCT01180790|Experimental|Segment 1: 400 mg ACH-0141625|400 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a plus ribavirin for 48 weeks
3202497|NCT01180790|Experimental|Segment 1: 800 mg ACH-0141625|800 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a plus ribavirin for 48 weeks
3202498|NCT01180790|Placebo Comparator|Segment 1: Placebo|Placebo for 28 days plus Peg-IFN alpha-2a plus ribavirin for 48 weeks
3202499|NCT01180790|Experimental|Segment 2: 200 mg ACH-0141625|200 mg ACH-0141625 for 12 weeks plus Peg-IFN and ribavirin for up to a total of 24 or 48 weeks
3202500|NCT01180790|Experimental|Segment 2 : 400 mg ACH-0141625|400 mg ACH-0141625 for 12 weeks plus Peg-IFN and ribavirin for up to a total of 24 or 48 weeks
3202501|NCT01180790|Experimental|Segment 2 : 800 mg ACH-0141625|800 mg ACH-0141625 for 12 weeks plus Peg-IFN and ribavirin for up to a total of 24 or 48 weeks
3202502|NCT01180777|Other|etafilcon A (A)/etafilcon A (B)/etafilcon A (C)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (B) worn second, then printed etafilcon A Lens with PVP (C) worn the last. Each period consisted of approximately one week of daily lens wear.
3202503|NCT01180777|Other|etafilcon A (A)/etafilcon A (C)/etafilcon A (B)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (C) worn second, then printed etafilcon A Lens with PVP (B) worn the last. Each period consisted of approximately one week of daily lens wear.
3202697|NCT01179425|Experimental|Marijuana-dependent subjects|
3202504|NCT01180777|Other|etafilcon A (C)/etafilcon A (A)/etafilcon A (B)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (A) worn second, then printed etafilcon A Lens with PVP (B) worn the last. Each period consisted of approximately one week of daily lens wear.
3202505|NCT01180777|Other|etafilcon A (B)/etafilcon A (C)/etafilcon A (A)|Printed etafilcon A Lens with PVP (B) worn first, then printed etafilcon A Lens with PVP (C) worn second, then printed etafilcon A Lens with PVP (A) worn the last. Each period consisted of approximately one week of daily lens wear.
3202506|NCT01180777|Other|etafilcon A (C)/etafilcon A (B)/etafilcon A (A)|Printed etafilcon A Lens with PVP (C) worn first, then printed etafilcon A Lens with PVP (B) worn second, then printed etafilcon A Lens with PVP (A) worn the last. Each period consisted of approximately one week of daily lens wear.
3202507|NCT01180777|Other|etafilcon A (B)/etafilcon A (A)/etafilcon A (C)|Printed etafilcon A Lens with PVP (C) worn first, then printed etafilcon A Lens with PVP (A) worn second, then printed etafilcon A Lens with PVP (C) worn the last. Each period consisted of approximately one week of daily lens wear.
3202508|NCT01180764|Experimental|Lovaza|Lovaza 4g po qd
3202509|NCT01180764|Placebo Comparator|Placebo|Matching placebo
3202510|NCT01180751|Other|[18F]-Fluorodeoxyglucose|Scanning Procedure: Non-diagnostic Computed Tomography (CT) scan followed by a Diagnostic Positron Emission Tomography (PET) scan.
3202511|NCT01180738|Active Comparator|Body weight supported treadmill training|
3202512|NCT01180738|Active Comparator|Overground walking training|
3202513|NCT01180712|Active Comparator|Blaeberry concentrated caspule|"30 obese male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given a total daily dose of 1.4 grams of mirtoselect (a concentrated blaeberry extract) a day formulated in hard gelatin capsules (0.47 gram per capsule) administered thrice a day for 21 days.~Mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/)"
3202514|NCT01180712|Placebo Comparator|Placebo capsules containing lactose|"30 obese male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given a placebo consisting of lactose formulated in hard gelatin capsules administered thrice a day for 21 days."
3202515|NCT01180699|Experimental|influenza vaccine - intradermal|intradermal versus intramuscular
3202516|NCT01180699|Active Comparator|influenza vaccine - intramuscular|
3202517|NCT01180686|Active Comparator|Multiple thrust Impulse instrument|This instrument automatically delivers 12 thrusts at the same intensity over the joint involved.
3202518|NCT01180686|Active Comparator|Single impulse Activator IV instrument|This is a manual spring loaded device that delivers one thrust to the joint involved
3202519|NCT01180673|Experimental|MINT-TLC|
3202520|NCT01180673|Active Comparator|Control Condition|
3202521|NCT01180660|Active Comparator|Lidocaine|Lidocaine infusion
3202522|NCT01180660|Placebo Comparator|Placebo|Placebo Normal Saline Infusion
3202523|NCT01180647|Active Comparator|Extended-release naltrexone (XR-NTX)|A single 380mg IM depot injection of XR-NTX in the week prior to release from jail. A second 380mg IM injection is offered to persons in the XR-NTX arm post-release and 4 weeks after the initial injection.
3202524|NCT01180647|Placebo Comparator|Motivational Enhancement Counseling Only|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
3202525|NCT01180634|Experimental|1|Inhaled MP-376 (Aeroquin)
3202526|NCT01180634|Placebo Comparator|2|Placebo
3202527|NCT01180621|Experimental|Fluviral|0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
3202528|NCT01180608|Active Comparator|Pregabalin|
3202529|NCT01180608|Placebo Comparator|placebo + pregabalin|
3202530|NCT01180595|Other|Modular|Trabecular Metal Modular Tibial Total Knee Component
3202531|NCT01180595|Other|Monoblock|Trabecular Metal Monoblock Tibial Total Knee Component
3202532|NCT01180569|Experimental|lenalidomide|Eligible patients for this clinical trial will be treated for 6 cycles with lenalidomide at 15 mg daily by mouth on Days1-21 of 28 day cycle, preceded by an escalating schema for safety (5mg daily for 2 weeks; 10 mg daily for 2 weeks; and 15 mg daily for 2 weeks) and then a one week rest).
3202533|NCT01180556|Experimental|Probiotics supplementation|Supplementation by probiotics for 4 weeks
3202534|NCT01180556|Placebo Comparator|Placebo|Supplementation of placebo for 4 weeks
3202535|NCT01180543|Active Comparator|Active Comparator: Oplon Active Patch|
3202536|NCT01180543|Placebo Comparator|Placebo Comparator: Placebo patch|
3202537|NCT01180530||A|
3202538|NCT01180517|Active Comparator|Drug Eluting Balloon|
3202539|NCT01180517|Active Comparator|Plain Old Balloon Angioplasty (POBA)|
3202540|NCT01180478|Other|Narrow Band Imaging|Narrow Band Imaging (NBI)
3202541|NCT01180478|Other|White Light Trans Urethral Resection|White Light Trans Urethral Resection
3202542|NCT01180465|Experimental|LIPO-102 High|
3202543|NCT01180465|Experimental|LIPO-102, Low|
3202544|NCT01180465|Placebo Comparator|LIPO-102; Placebo|
3202545|NCT01180452|Other|Single group open label|Prospective Cohort
3202546|NCT01180426|Experimental|Tosedostat|
3202547|NCT01180413|Experimental|Vasodilatory|Patients in this arm will receive intensive vasodilatory treatment
3202548|NCT01180400|Experimental|TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1-4 mg BID
3202549|NCT01180400|Placebo Comparator|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
3202550|NCT01180374|Experimental|Active Canabidiol and Active Delta-9-THC|
3202551|NCT01180374|Placebo Comparator|Placebo and Active Delta-9-THC|
3202552|NCT01180374|Experimental|Active Cannabidiol and Placebo|
3202553|NCT01180374|Placebo Comparator|Placebo and Placebo|
3202554|NCT01180361||Active SLE patients|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Fulfill 1982 ACR revised criteria for SLE. SLE activity status designated using the SLEDAI disease activity index. Patients excluded if previous documentation of a connective tissue disorder other than SLE.
3202555|NCT01180361||Psoriatic arthritis|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Diagnosed according to criteria described by McGonagle et al (McGonagle, D., Conaghan, P.G., and Emery, P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 1999; 42: 1080-1086.)
3202556|NCT01180361||Normal controls|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Healthy volunteers. Not on corticosteroids.
3202557|NCT01180361||Active RA patients|Age 18-65, male and female, no methotrexate or statin therapy in prior 3 months. Not on biological therapies. satisfy at least 4 of the 7 revised criteria (1987) for the classification of RA
3202558|NCT01180348|Experimental|Botulift|Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
3202559|NCT01180348|Active Comparator|Botox|Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
3202560|NCT01180335|Active Comparator|Chemotherapy|4 cycles FEC followed by 4 cycles docetaxel
3202561|NCT01180335|Experimental|Genomic driven chemotherapy|High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
3202562|NCT01180322|Active Comparator|Arm A|Standard Therapy
3202563|NCT01180322|Experimental|Arm B|"Investigational Therapy Azacitidine Prior"
3202564|NCT01180322|Experimental|Arm C|"Investigational Therapy Azacitidine Concurrent"
3202565|NCT01180322|Experimental|Arm D|"Investigational Therapy Azacitidine After"
3202566|NCT01180309||lingual frenum alterations|individuals each one with their phonological system complete
3202567|NCT01180296|Experimental|Progesterone Group|
3202568|NCT01180296|Placebo Comparator|Placebo|
3202569|NCT01180283|Experimental|lodenafil carbonate (Helleva®)|
3202570|NCT01180270||Cervical dystonia|"patients suffering from cervical dystonia~under routine botulinum toxin treatment"
3202571|NCT01180270||healthy volunteers|control group
3202572|NCT01180244|Active Comparator|Active treatment|Subjects in this group will receive the noninvasive cortical stimulation signal from the treatment device
3202573|NCT01180244|Placebo Comparator|Placebo group|Subjects in this group will be provided the same experience as those in the active treatment arm, but will not receive the noninvasive cortical stimulation signal from the treatment device
3202574|NCT01180231|Active Comparator|Moxonidine|
3202575|NCT01180231|Active Comparator|Diet|
3202576|NCT01180231|Active Comparator|Moxonidine and diet|Subjects will be asked to take moxonidine and follow dietary plan designed by a qualified nutritionist for 6 months.
3202577|NCT01180231|No Intervention|Control|Subjects will not be asked to take any interventions.
3202578|NCT01180205|Active Comparator|T/A|Telmisartan + Amlopidpine
3202579|NCT01180205|Active Comparator|O/HCT|Olmesartan + Hydrochlorothiazide
3202580|NCT01180192|Experimental|oxygen|
3202581|NCT01180179|Active Comparator|Lansoprazole 30mg once daily|Lansoprazole 30mg once daily
3202582|NCT01180179|Active Comparator|Famotidine 40mg once daily|Famotidine 40mg once daily
3202583|NCT01180166|Experimental|nimotuzumab|Combination of nimotuzumab and capecitabine concurrent chemoradiotherapy is received by patients.
3202584|NCT01180153|Experimental|SOX: advanced BTC or ampullary carcinoma|unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma receive SOX regimen
3202585|NCT01180140|No Intervention|1|without seamguard
3202586|NCT01180140|Experimental|2|with seamguard
3202587|NCT01180127|Active Comparator|exercise, dietary intervention|aerobic training and flavanol containing food product for 12 weeks
3202588|NCT01180127|Active Comparator|no exercise, dietary intervention|wait list control plus flavanol containing food product for 12 weeks
3202589|NCT01180127|Active Comparator|exercise, food product lacking flavanol|aerobic training plus food product without flavanol for 12 weeks
3202590|NCT01180127|Placebo Comparator|wait list control food additive without flavanol|wait list control plus food product without flavanol for 12 weeks
3202591|NCT01180114|Experimental|SUUBI-MAKA|Involves creating and broadening asset ownership opportunities and life options for children (ages 12 to 15 years) orphaned due to AIDS in Uganda.
3202592|NCT01180114|Other|Usual Care|No intervention for asset ownership, development of future planning skills, enhancement of mental health and reduction of risk taking behaviors for children orphaned due to AIDS in Uganda.
3202593|NCT01180101|Active Comparator|Lifestyle modification group|This group will undergo supervised exercise training 5 days per week and follow hypocaloric diet for 12 weeks. All exercise training sessions will be supervised by an Exercise Physiologist or Research Nurse, and will be conducted in the Exercise Physiology Laboratory at the CCF CRU. Exercise training will consist of walking, running on a treadmill, and stationary cycling on a cycle ergometer. Each exercise session will include a brief standardized warm-up and cool-down that include a series of stretching exercises.
3202594|NCT01180101|Active Comparator|Bariatric Surgery Group|This group will include CKD patients who undergo bariatric surgery.
3202595|NCT01180101|No Intervention|CKD Group (control)|This group will not undergo any form of weight loss intervention
3202596|NCT01180088|Experimental|ANTERIOR APPROACH|SURGICAL TECHNIQUE
3202597|NCT01180075||TDF/FTC/EFV Intensive Sampling-Group A|Patients receiving TDF/FTC/EFV who undergo intensive pharmacokinetic sampling over 24 hours
3202598|NCT01180075||TDF/FTC/ATV/r Intensive Sampling Group A|Patients receiving TDF/FTC/ATV/r who undergo intensive pharmacokinetic sampling over 24 hours
3202599|NCT01180075||TDF/FTC/EFV Sparse Sampling Group B|Patients receiving TDF/FTC/EFV who undergo sparse pharmacokinetic sampling on 1 or 2 visits depending on subject's availability
3202600|NCT01180075||TDF/FTC/ATV/r Sparse Sampling Group B|Patients receiving TDF/FTC/ATV/r who undergo sparse pharmacokinetic sampling on 1 or 2 visits depending on subject's availability
3202601|NCT01180062|Active Comparator|Arm 1|Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.
3202698|NCT01179412|Experimental|2% povidone-iodine|
3202699|NCT01179399|Experimental|TAK-960|
3202602|NCT01180062|Active Comparator|Active Comparator - Arm 2|Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
3202603|NCT01180062|Active Comparator|Active Comparator - Arm 3|Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
3202604|NCT01180049|Active Comparator|temsirolimus (Torisel) 175mg weekly x 3, then 75mg weekly|
3202605|NCT01180049|Active Comparator|temsirolimus (Torisel) 75mg weekly|
3202606|NCT01180036|Active Comparator|Rituximab Treatment Arm|Patients randomized to the RTX arm will receive 1000 mg IV on Days 1 and 15. Patients who achieve complete remission at 6 months will not be retreated. A second course of RTX 1000 mg IV will be administered at study month 6 for individuals who have not achieved a complete remission, but have achieved a minimum of >25% reduction in Time 0 proteinuria. Dosing at study month 6 will be independent of CD19+ B cell count.
3202607|NCT01180036|Active Comparator|Cyclosporine Treatment Arm|Patients randomized to the Cyclosporine arm will be started at a dose of CsA = 3.5 mg/kg/day p.o. divided into 2 equal doses given at 12 hour intervals. Target trough CsA blood levels are 125 to 175 ng/ml. Patients will have their doses adjusted according to their blood levels of CSA as monitored every 2 weeks until the target trough level is reached. If a complete remission is achieved by 6 months, CSA will be tapered and discontinued over a three-month period. If after 6 months there has not been a reduction in proteinuria of at least 25% of baseline values, the drug will also be discontinued. If there has been a >25% reduction in baseline proteinuria (but not complete remission) the CSA will be continued for an additional 6 months.
3202608|NCT01180023|Experimental|Sweeping|
3202609|NCT01180023|No Intervention|No sweeping|
3202610|NCT01179997|Active Comparator|Tissue Doppler Imaging (TDI) optimization|Interventricular pacing delay optimized according to Tissue-Doppler echocardiography
3202611|NCT01179997|Active Comparator|Electrocardiographic optimization|Interventricular pacing delay optimized according to QRS width observation in the 12-lead surface electrocardiogram
3202612|NCT01179984|Experimental|PTA and study stent|Bard® LifeStent® Vascular Stent System
3202613|NCT01179971|Experimental|Fish oil|3g/d
3202614|NCT01179971|Experimental|Gamma-linolenic Acid|3g/d gamma-linolenic acid
3202615|NCT01179971|Experimental|Fish oil plus GLA|1.5 g/d DHA + EPA plus 1.5g/d gamma-linolenic acid
3202616|NCT01179971|Sham Comparator|Olive oil|3 g/d olive oil
3202617|NCT01179958|Experimental|aerobic training|24 weeks of aerobic training, 4 times/week
3202618|NCT01179958|Placebo Comparator|stretching/toning|stretching/toning condition, 24 weeks to parallel the active intervention group
3202619|NCT01179945|Experimental|sodium benzoate containing|
3202620|NCT01179945|Active Comparator|non sodium benzoate containing|
3202621|NCT01179932||Anesthesia Record|The nursing and anesthesia records will be examined for accuracy and completeness
3202622|NCT01179919|Experimental|Oseltamivir Dosed Group|Oseltamivir 75 mg by mouth every 12 hours for 9 doses
3202623|NCT01179906|Experimental|Lifestyle intervention-exercise & diet|Subjects trained for 48 weeks with a personal trainer
3202624|NCT01179893|Active Comparator|IVIG|Intravenous Immunoglobulin, 2G/Kg, infused over 2 days in the Medical Day Unit of the University Health Network
3202625|NCT01179893|Experimental|PLEX|Patients received one plasma volume plasma exchanges with 5% albumin replacement fluid. Five plasma exchange procedures occurred every second day with breaks over the weekend allowed. Patients treated in the apheresis units at the University Health Network.
3202626|NCT01179880|Experimental|1|
3202627|NCT01179880|Placebo Comparator|2|
3202628|NCT01179867|Experimental|Electronic Medication Reconciliation|"Electronic medication reconciliation includes:~Electronic retrieval of the community drug list at admission~Generation of discharge prescription using the discharge reconciliation module at discharge~Transfer of information on discontinued and changed medication to respective dispensing pharmacies and prescribing physicians"
3202629|NCT01179867|No Intervention|Usual practice medication reconciliation|Usual practice in dealing with medication reconciliation. This includes viewing the hospital medications through the hospital electronic pharmacy system, and viewing the community drugs in the patient's chart, if it was collected at admission (not always the case). However not all physicians view the community drugs before writing the discharge prescription. The physician will write a paper discharge prescription to be given to the patient, but communications are generally not made directly to the community pharmacist or previous prescribing physicians.
3202630|NCT01179854|Experimental|500 mg|Group of active treatment of Remegal 500 mg
3202631|NCT01179854|Experimental|Remegal 750 mg|Group of active treatment of Remegal 750 mg
3202632|NCT01179854|Experimental|Remegal 1000 mg|Group of active treatment of Remegal 1000 mg
3202633|NCT01179854|Placebo Comparator|Placebo|Placebo
3202634|NCT01179841|Experimental|Playgroup and Parent Training|"One to two-hour individual therapeutic sessions with parent training in the home or clinic, 1x every week over six months;~parent training/enrichment once a week in our clinic for 20 sessions at 1-2 hours;~a playgroup session for 1-2 hours 2x week for 6 months in our clinic and~Community treatment as usual."
3202635|NCT01179841|Active Comparator|Parent Training|"Parent enrichment sessions once a week for 20 sessions (for 1-2 hours)~Community treatment as usual."
3202636|NCT01179828|Active Comparator|1|Oxycodone 15mg
3202637|NCT01179828|Active Comparator|2|Clobazam 20mg
3202638|NCT01179828|Active Comparator|3|Imipramine 75mg
3202639|NCT01179828|Placebo Comparator|4|Tolterodine 1mg
3202640|NCT01179815||1|Patients with type 1 or type 2 diabetes mellitus, monogenetic diabetes, pancreatogenic diabetes, drug-induced diabetes, other forms
3202641|NCT01179802|Experimental|1|single event of a prolonged strenuous endurance exercise (mountain marathon)
3202642|NCT01179789|Active Comparator|Optimal Diet|Diet advices will receive the Optimal Diet for Elderly
3202643|NCT01179789|Experimental|VSL#3|Diet advices + VSL-3: will receive the Optimal Diet for Elderly + VSL#3® probiotic blend
3202644|NCT01179789|Experimental|AISA-5203-L|Diet advices + 5203-L: will receive the Optimal Diet for Elderly + AISA-5203-L fruit extracted terpene
3202645|NCT01179789|Experimental|Argan oil|Diet advices + Argan oil: will receive the Optimal Diet for Elderly + Argan
3202646|NCT01179776|Experimental|Ilomedin and standard low dose treatment|
3202648|NCT01179763||Retinal layer thickness analysis|Optical coherence tomography will be conducted to analyze retinal layer thickness (safe examination)
3202649|NCT01179750|No Intervention|No Ultrasonic Coagulating Shears group|the one arm: operated group without using Ultrasonic coagulation shears during gastrectomy;
3202650|NCT01179750|Experimental|ultrasonic coagulation shears group|the other arm: operated group using ultrasonic coagulation shears during gastrectomy
3202651|NCT01179737|Experimental|Nilotinib|Participants in cohort 1 were assigned to receive nilotinib 50 mg during 14 days, followed by 150 mg during 14 days, followed by 300 mg during 140 days. Participants in cohort 2 were assigned to receive nilotinib 300 mg during 168 days
3202652|NCT01179737|Placebo Comparator|Placebo|Participants were assigned to receive placebo to nilotinib to match 50 mg and 150 mg capsules during 168 days.
3202653|NCT01179724|Experimental|high dose proton pump inhibitor|
3202654|NCT01179724|Active Comparator|H2 receptor antagonist|
3202655|NCT01179711|Other|glasses prescription|At initial visit(of study), the physician will reduce the diopter of hyperopic glasses as much as the patient can maintain their eye alignment (maximum amount 1.5D).
3202656|NCT01179698|Other|Stryker navigation system|
3202657|NCT01179672|Experimental|Duloxetine|
3202658|NCT01179672|Placebo Comparator|Placebo|
3202659|NCT01179659|Active Comparator|Protonix|Protonix 40 mg DR Tablet (Wyeth Pharmaceuticals)
3202660|NCT01179659|Experimental|Pantoprazole 40 mg DR Tablet|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
3202661|NCT01179646|Active Comparator|Protonix|Protonix 40 mg DR Tablet
3202662|NCT01179646|Experimental|Pantoprazole|Pantoprazole 40 mg DR Tablet
3202663|NCT01179633|Active Comparator|Oplon Active Patch|
3202664|NCT01179633|Placebo Comparator|Placebo patch|
3202665|NCT01179620|Experimental|Certoparin|
3202666|NCT01179607|Active Comparator|M0002|"Started at 0.3 mg/day and increased every 3 days (to 1, 3 and 6 mg/day)~for hyponatraemic subjects: dose was increased until the evening serum level was between 132 mmol/l and 145 mmol/l;~for normonatraemic subjects the dose was increased until a 500 ml increase in the 24-h urine volume compared with Day-1 was reached.~Once the required response or max dose was achieved, subjects entered a maintenance phase where they remained on the same dose of M0002 or placebo until 15 days."
3202667|NCT01179607|Placebo Comparator|Placebo|
3202668|NCT01179594|Placebo Comparator|A|
3202669|NCT01179594|Experimental|B|
3202670|NCT01179594|Placebo Comparator|C|
3202671|NCT01179594|Experimental|D|
3202672|NCT01179581|Experimental|1|single ascending doses
3202673|NCT01179581|Placebo Comparator|2|single dose placebo
3202674|NCT01179581|Experimental|3|multiple dose, 10 days, capsules (dosing depends on outcome of single-dose part; can be once or twice daily).
3202675|NCT01179581|Placebo Comparator|4|multiple dose, capsules, 10 days; scheme to match that of Study Arm 3.
3202676|NCT01179568|Active Comparator|CGT with Citalopram|Targeted psychotherapy for complicated grief will be combined with SSRI medication.
3202677|NCT01179568|Active Comparator|Citalopram|Citalopram is an Selective Serotonin Reuptake Inhibitor (SSRI) medication. It will be combined with grief-focused clinical management.
3202678|NCT01179568|Placebo Comparator|Placebo (Sugar pill)|Inactive medication. It will be combined with grief-focused clinical management.
3202679|NCT01179568|Active Comparator|CGT with Placebo|The targeted psychotherapy for complicated grief will be combined with inactive medication.
3202680|NCT01179555|Experimental|Pt. 1 Behavioral Activation|"Behavioral Activation (BA) is a behavioral technique to help people overcome avoidant tendencies through goal setting, activity scheduling, and graded task assignment. The key component of BA involves developing an Action Plan, and having the subject document each step of the plan as he or she implements it, reinforcing the steps towards goal attainment. Action Plans are easily applied to diabetes self-care tasks because the latter lend themselves to documentation of simple, step-by-step plans. In this study, a Community Health Educator (CHE) - interventionist will schedule and deliver four 45-60 minute in-home BA sessions within 3 months of randomization (i.e., one session every 2-3 weeks)."
3202681|NCT01179555|Placebo Comparator|Pt. 1 Supportive Therapy|The purpose of Supportive Therapy (ST) is to explore the impact of aging and diabetes on the subject's life. In contrast to the BA intervention, the interventionist does not discuss the importance of dilated eye exams. In subsequent sessions, ST facilitates and deepens knowledge about the subject's life situation in relation to his or her health and other life difficulties. The ST therapist encourages this process and creates an accepting, nondirective, and supportive opportunity for discussion.
3202682|NCT01179542||first trimester|first trimester
3202683|NCT01179542||third trimester|third trimester
3202684|NCT01179542||prgnancies complicated with IUGR|prgnancies complicated with IUGR
3202685|NCT01179542||preeclampsia|preeclampsia
3202686|NCT01179529|Experimental|Omalizumab|
3202687|NCT01179516|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
3202688|NCT01179516|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
3202689|NCT01179516|Experimental|Vortioxetine 15 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 15 mg, encapsulated tablets, orally, once daily for up to 7 weeks.
3202690|NCT01179503|Active Comparator|Calcium only|1200 mg Calcium per day
3202691|NCT01179503|Experimental|Vitamin D plus calcium|2000 IU vitamin D plus 1200 mg calcium per day
3202692|NCT01179490|Experimental|SyB L-0501 + prednisolone|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible. Prednisolone (60 mg/m2/day) will be administered orally for 4 consecutive days and the course will be observed for the next 24 days.
3202693|NCT01179464|Active Comparator|Aminobiphosphonates|Aminobiphosphonates
3202694|NCT01179464|Experimental|Aminobiphosphonates and Statin|Aminobiphosphonates and Statin
3202695|NCT01179451||Post streptococcal reactive arthritis (PSRA)|children who were diagnosed with psra at least one year before the study
3202700|NCT01179386||methylphenidate|30 adolescents who are treated with Methylphenidate will perform the driving simulator and seat pressure mapping tests, in 2 different days : 1. with their regular methylphenidate medication and 2: without the methylphenidate medication after a 4 days washout period. Results will be recorded and statistical test will be performed.
3202701|NCT01179386||no medication|30 adolescents : control group , not suffering from ADHD and without methylphenidate medication will perform the driving simulator and seat pressure mapping tests. Results will be recorded and statistical test will be performed.
3202702|NCT01179373|Active Comparator|TMS, High Frequency|High Frequency TMS with H coil to prefrontal cortex
3202703|NCT01179373|Active Comparator|TMS, Low Frequency|Low Frequency TMS to Prefrontal cortex
3202704|NCT01179373|Placebo Comparator|Sham Stimulation|Sham TMS with H Coil on Prefrontal Cortex
3202705|NCT01179360||Imaging group|
3202706|NCT01179347|Experimental|tiotropium|2 inhalations once daily delivered with Respimat® inhaler
3202707|NCT01179347|Placebo Comparator|placebo|2 inhalations once daily delivered with Respimat® inhaler
3202708|NCT01179334|Experimental|Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks. Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
3202709|NCT01179334|Placebo Comparator|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 12 weeks. Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
3202710|NCT01179321|No Intervention|Control|
3202711|NCT01179321|Experimental|Early nutrition intervention|
3202712|NCT01179308|Active Comparator|General-epidural anesthesia|Epidural and general anesthesia
3202713|NCT01179308|Active Comparator|General anesthesia|General anesthesia alone
3202714|NCT01179295|Experimental|Arm 1|
3202715|NCT01179295|Experimental|Arm 2|
3202716|NCT01179295|Experimental|Arm 3|
3202717|NCT01179295|Experimental|Arm 4|
3202718|NCT01179282|Placebo Comparator|PLACEBO|PLACEBO NASAL SPRAY
3202719|NCT01179282|Active Comparator|DUST MITE ALLERGEN|Subjects will use dust mite Dermatophagoides pteronyssinus (Dp) extract or placebo nasal spray at home for 2 weeks, with a 1 month washout period followed by 2 weeks of the other nasal spray.
3202720|NCT01179269|Experimental|Pazopanib plus Paclitaxel|Pazopanib daily and weekly Paclitaxel IV.
3202721|NCT01179256|Experimental|CURCUMIN|oral supplementation of curcumin 2000mg
3202722|NCT01179256|Placebo Comparator|PLACEBO|oral PLACEBO TABLET
3202723|NCT01179243||intensive care patients|no interventions
3202724|NCT01179230||PET SPECT|Subjects will have both types of imaging performed, PET and SPECT
3202725|NCT01179217|Experimental|L-glutamine|Patients will be randomized to receive investigational product, L-Glutamine.
3202726|NCT01179217|Placebo Comparator|100% maltodextrin|Patients will be randomized to receive Placebo.
3202727|NCT01179204||Patiens operated with TKA|
3202728|NCT01179191|Experimental|morphine sulfate and naltrexone hydrochloride (EMBEDA)|
3202729|NCT01179178||COPD-patients|
3202730|NCT01179178||Older adults (65-81 y)|
3202731|NCT01179165||Type 2 diabetes age 40-75|Only one diagnostic/observational group
3202732|NCT01179152|Active Comparator|Budicort|75 children will receive treatment with Budicort 200 mcg
3202733|NCT01179152|Active Comparator|Symbicort|75 children will receive treatment with Symbicort 160 mcg
3202734|NCT01179152|No Intervention|counselling|75 children who will not treated as their request but will be folowedup
3202735|NCT01179139|Active Comparator|Healthy Control|
3202736|NCT01179139|Experimental|CRS|
3202737|NCT01179126|Experimental|complete multivessel revascularization|
3202738|NCT01179126|Active Comparator|stress echo guided revascularization|
3202739|NCT01179113|Placebo Comparator|Placebo|Placebo: Will receive a normal saline bolus during induction, and an infusion of normal saline intraoperatively
3202740|NCT01179113|Active Comparator|Esmolol|Will receive Esmolol Loading: 0.5 mg/kg bolus during induction Infusion: 15 mcg /kg/min, infusion intraoperatively
3202741|NCT01179100|Placebo Comparator|Normal Saline|Normal Saline: Calculated and adjusted to match loading dose and infusion rate of lidocaine equivalent adjusted for weight.
3202742|NCT01179100|Active Comparator|Lidocaine|
3202743|NCT01179074|Active Comparator|Oesophageal stent alone|Patients of inoperable oesophageal cancer in this arm underwent oesophageal stenting with self expandable metal stents
3202744|NCT01179074|Active Comparator|Oesophageal stent followed by EBRT|Patients in this arm underwent oesophageal stenting with self expandable metal stents followed by external beam radiotherapy (30Gy/10#/2weeks)
3202745|NCT01179061|Experimental|Apelin infusion|6 hour infusion of apelin peptide into circulation
3202746|NCT01179061|Placebo Comparator|Placebo|Infusion of saline into systemic circulation
3202747|NCT01179048|Experimental|Liraglutide|
3202748|NCT01179048|Placebo Comparator|Placebo|
3202749|NCT01179035|Active Comparator|Expedited Primary Care|Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
3202750|NCT01179035|Experimental|Transitions Clinic - Parolee Targeted Care|Following randomization, subjects in this arm receive ongoing primary care in a parolee-targeted clinic. Parolee-targeted care includes care from clinicians with a knowledge of the impacts of incarceration on health and experience caring for formerly incarcerated patients, a community health worker that works in medical and social services coordination and chronic disease education, and linkages with community-based organizations serving formerly incarcerated individuals.
3202751|NCT01179009|Experimental|ketamine 100-hour infusion|100-hour infusion of ketamine plus a safener (clonidine)
3202752|NCT01179009|Experimental|ketamine 40-minute infusion|40-minute ketamine infusion following a 100-hours +/- placebo (saline) infusion. Participants will also receive a safener (clonidine)
3202812|NCT01178528|Experimental|Ivabradine|7.5 mg bd
3202813|NCT01178528|Active Comparator|Carvedilol|up to 25 mg bd
3202753|NCT01178996|Experimental|Thymosin alpha 1|Patients affected by chronic hepatitis C not responding to a course with approved doses of PEGinterferon alpha plus ribavirin therapy (i.e. at least 1.0 mcg/kg PEGinterferon alpha2b, 180 mcg PEGinterferon alfa2a, 800 mg ribavirin).
3202754|NCT01178996|Placebo Comparator|Placebo|Patients affected by chronic hepatitis C not responding to a course with approved doses of PEGinterferon alpha plus ribavirin therapy (i.e. at least 1.0 mcg/kg PEGinterferon alpha2b, 180 mcg PEGinterferon alfa2a, 800 mg ribavirin).
3202755|NCT01178983|Experimental|telebiofeedback|
3202756|NCT01178983|Active Comparator|biofeedback|
3202757|NCT01178957||Type 1 diabetes|
3202758|NCT01178944|Experimental|Treatment (pralatrexate, oxaliplatin)|Patients receive pralatrexate IV over 3-5 minutes and oxaliplatin IV over 2 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Oxaliplatin will be discontinued after 12 courses.
3202759|NCT01178931|Active Comparator|Oral dydrogesterone|Study group receiving 2x10mg of oral dydrogesterone until a pregnancy test or in the case of pregnancy until 10 week.
3202760|NCT01178931|Active Comparator|Crinone 8% vaginal gel|Control group is receiving vaginal gel, 1x90mg, until a pregnancy test or in the case of pregnancy until 10 week.
3202761|NCT01178918||Healthy volunteers from recipients of H1N1 vaccine|
3202762|NCT01178905|Other|Mother CMV positive|
3202763|NCT01178892|Placebo Comparator|Placebo|
3202764|NCT01178892|Experimental|Omega-3|
3202765|NCT01178892|Experimental|Yoga|
3202766|NCT01178892|Experimental|Exercise|
3202767|NCT01178892|Other|Usual Activity 1|Usual Activity 1 and Usual Activity 2 arms will be compared to the Yoga and Exercise arms.
3202768|NCT01178892|Other|Usual Activity 2|Usual Activity 1 and Usual Activity 2 arms will be compared to the Yoga and Exercise arms.
3202769|NCT01178879|Experimental|Telehealth consultation|Telehealth nurse consultation plus treatment as usual
3202770|NCT01178879|No Intervention|Conventional|Treatment as usual
3202771|NCT01178866||Clinical course|complicated course group (death within 30 days after surgery or ICU stay > 4 days) and uncomplicated course group (ICU stay ≤ 4 days).
3202772|NCT01178853|Experimental|Pitavastatin/Rosuvastatin|
3202773|NCT01178853|Experimental|Rosuvastatin/Pitavastatin|
3202774|NCT01178840|Other|WC then FC2|The couples will use 4 PATH Woman's Condom then 4 FC2 female condom.
3202775|NCT01178840|Other|FC2 then WC|The couples will use 4 FC2 female condom then 4 PATH Woman's Condom.
3202776|NCT01178827|Experimental|Sanctura XR®|Sanctura XR® (trospium chloride), 60mg once daily for 10 days
3202777|NCT01178827|Active Comparator|Oxybutynin IR|Oxybutynin IR (oxybutynin immediate release), 5 mg three times daily for 2 days
3202778|NCT01178827|Placebo Comparator|Oxybutynin IR placebo|Oxybutynin IR placebo three times daily for 2 days
3202779|NCT01178814|Experimental|Revlimid|Revlimid (Lenalidomide) capsule taken orally once a day
3202780|NCT01178801||liver cancer|Clinical data of patients with liver cancer
3202781|NCT01178788|Active Comparator|17 alfa hydroxy Progesterone caproate|Women treated with i.m. 17P injection/weekly (Lentogest, IBSA, Italy)
3202782|NCT01178788|Active Comparator|Micronized Progesterone|micronized P 200 mg per vagina /day (Utrogestan, Besins Healthcare, Belgium)
3202783|NCT01178788|Active Comparator|Control|Routine clinical controls
3202784|NCT01178775|No Intervention|1|control design
3202785|NCT01178775|No Intervention|2|education only group
3202786|NCT01178775|Experimental|3|education and education and walking program design
3202787|NCT01178762|Experimental|Observation|
3202788|NCT01178749||Chronic Hepatitis C Infection|patients Receiving 24-week Interferon-α with Ribavirin Treatments
3202789|NCT01178736||Cancer Screening and Diagnosis|Screening of asymptomatic women for Breast and Cervical cancer in the age group of 35-64 years. Diagnostic assessment of symptomatic women for Ovarian and Endometrial cancer in the age group of 50-64 years.
3202790|NCT01178710|Experimental|treatment|
3202791|NCT01178710|No Intervention|untreated|control
3202792|NCT01178697|Active Comparator|Intravitreal triamcinolone|
3202793|NCT01178697|Active Comparator|Intravitreal bevasizumab|
3202794|NCT01178684||1: HIV-pos on d4T with neuropathy|
3202795|NCT01178684||2: HIV-pos on d4T without neuropathy|
3202796|NCT01178684||3: HIV-neg without peripheral neuropathy|
3202797|NCT01178684||4 HIV-pos on d4T with asymtomatic neuropathy|
3202798|NCT01178671|Experimental|Sertraline and Mirtazapine|Flexible dose of both medications for up to 24 weeks
3202799|NCT01178671|Active Comparator|Sertraline and Sugar pill|Sertraline and Sugar pill for up to 24 weeks
3202800|NCT01178658|Experimental|BuEAM|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
3202801|NCT01178645|Experimental|BuEAM|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
3202802|NCT01178632|Experimental|Passiflora, Anxiety Disorders|1 tablet Passiflora;Crataegus;Salix; PO;BID
3202803|NCT01178632|Active Comparator|Valeriane, Anxiety Disorder|1 tablet Valeriana officinalis, PO, BID
3202804|NCT01178619||AGA|
3202805|NCT01178619||symmetrical IUGR|
3202806|NCT01178619||asymmetrical IUGR|
3202807|NCT01178593|No Intervention|Standard Medical Therapy (SMT)|standard medical treatment (care as usual) with supportive talks
3202808|NCT01178593|Active Comparator|Gut focused hypnotherapy|weekly sessions of gut focused hypnotherapy in groups (10 sessions within 12 weeks)
3202809|NCT01178554|Active Comparator|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
3202810|NCT01178554|Experimental|Standard Manual Treatment (SMT)|Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
3202811|NCT01178554|Experimental|Modular Maual Treatment (MMT)|Therapists used a modular manual (Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems; Chorpita & Weisz, 2004) to help children with primary problems of anxiety, depression, and conduct.
3202815|NCT01178515|Sham Comparator|Full fat milk|Full fat milk contain 3% fat
3202816|NCT01178515|Experimental|Partially defatted milk|Partially defatted milk contains 2% of fat
3202817|NCT01178515|Experimental|Defatted milk|Defatted milk contains 1% fat
3202818|NCT01178489||Patients undergoing arthroplasty|Patients undergoing primary, unilateral, total hip or knee arthroplasty under spinal anaesthesia
3202819|NCT01178476|Experimental|Hyposafe Hypoglycemia alarm device|EEG based hypoglycemia detection
3202820|NCT01178476|Active Comparator|Regular glucose control|Regular glucose control group
3202821|NCT01178463||I. Obstructive Azoospermia|
3202822|NCT01178463||II. Non-Obstructive Azoospermia Patients|
3202823|NCT01178450|Active Comparator|Subtotal parathyroidectomy|The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland
3202824|NCT01178450|Experimental|Cinacalcet|Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
3202825|NCT01178424|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of mindfulness skills taught in the program.
3202826|NCT01178424|Active Comparator|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
3202827|NCT01178411|Experimental|ARQ 197 as monotherapy or in combination with other drug (s)|ARQ 197 will be administered twice daily, orally, with meals
3202828|NCT01178385|Experimental|Cognitive-behavioral therapy|Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
3202829|NCT01178385|Active Comparator|Treatment as Usual|Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
3202830|NCT01178372|Active Comparator|lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
3202831|NCT01178372|Active Comparator|probiotics|
3202832|NCT01178346|Experimental|NicVAX|Experimental vaccine
3202833|NCT01178346|Placebo Comparator|Placebo|Placebo vaccine
3202834|NCT01178320||Simvastatin|Participants in the main AIM-HIGH study who are receiving simvastatin.
3202835|NCT01178320||Simvastatin and Extended-Release Niacin|Participants in the main AIM-HIGH study who are receiving simvastatin and extended-release niacin.
3202836|NCT01178307||Part 1|Patient interview and developmental questionnaires
3202837|NCT01178307||Part 2|Content Expert Panel (doctors, nurses) + Patients and Caregivers Questionnaire Development
3202838|NCT01178307||Part 3|Patient MDASI-GIST Questionnaire
3202839|NCT01178294|Experimental|OBI-1|Initial dose: 200 U/kg - additional doses at the discretion of the investigator based on FVIII activity level and clinical assessment of response to treatment (upper limit: 400 U/kg every 2 hours)
3202840|NCT01178281|Experimental|Pomalidomide 0.5 mg|Pomalidomide 0.5 mg capsule taken by mouth once daily. Participants may take capsules for at least 168 days unless there are unacceptable side effects, progression of MPN-associated myelofibrosis or recurrence of RBC-transfusion-dependence.
3202841|NCT01178281|Placebo Comparator|Placebo|One placebo capsule taken by mouth once daily. Participants may take capsules for at least 168 days unless there are unacceptable side effects, progression of MPN-associated myelofibrosis or recurrence of RBC-transfusion-dependence.
3202842|NCT01178268|Active Comparator|XIENCE V EECSS|Patients who will receive this stent.
3202843|NCT01178268|Active Comparator|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
3202844|NCT01178255|Experimental|Group 1|
3202845|NCT01178255|Experimental|Group 2|
3202846|NCT01178255|Experimental|Group 3|
3202847|NCT01178255|Experimental|Group 4|
3202848|NCT01178242|Experimental|Salivary Gland and Labial Mucous Membrane Transplantation|
3202849|NCT01178229|Experimental|Physiotherapy|group of bruxist children that received physiotherapy to change the head posture
3202850|NCT01178229|No Intervention|Control|Group of bruxist children that did not receive treatment
3202851|NCT01178216|Experimental|Rituxan|All study patients will receive Rituxan 1g on day 15 from start of desensitization and either 3M or 6M post transplant depending on the presence of DSA.
3202852|NCT01178190||lung cancer|
3202853|NCT01178177||SOT recipients|solid organ transplant recipients with invasive pulmonary aspergillosis
3202854|NCT01178177||Hematologic disease|Hematologic disease patients with invasive pulmonary aspergillosis
3202855|NCT01178164|Experimental|Diagnosis of Fabry disease|
3202856|NCT01178151|Experimental|afinitor|10mg afinitor daily orally
3202857|NCT01178138|Other|Prazosin effects on methamphetamine|Randomized placebo controlled trial of prazosin effects on methamphetamine
3202858|NCT01178125|Experimental|DR-102|desogestrel/ethinyl estradiol 0.15/0.02 mg for 21 days then ethinyl estradiol 0.01 mg for 7 days
3202893|NCT01177917|Experimental|Cow milk-based infant formula with prebiotic blend|
3202859|NCT01178112|Experimental|Trientine + Carboplatin MTD Group|Trientine starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group.
3202860|NCT01178112|Experimental|MTD Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group
3202861|NCT01178112|Experimental|Carboplatin PK Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group. PK testing blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
3202862|NCT01178112|Experimental|Trientine PK Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group. PK testing blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
3202863|NCT01178099|Experimental|Prasugrel|Participants received a single 10 milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants<60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).
3202864|NCT01178086||Cohort|
3202865|NCT01178073|Active Comparator|Combination ambrisentan + tadalafil|ambrisentan + tadalafil
3202866|NCT01178073|Active Comparator|Monotherapy ambrisentan|ambrisentan
3202867|NCT01178073|Active Comparator|Monotherapy tadalafil|tadalafil
3202868|NCT01178060|Active Comparator|Personalized Risk Information|Patients received personalized stroke and heart attack risk assessment information.
3202869|NCT01178060|Other|Standard Education|Patients received general risk information on heart attack and stroke.
3202870|NCT01178047|Active Comparator|Rasagiline|
3202871|NCT01178047|Placebo Comparator|Placebo|
3202872|NCT01178034|Experimental|pharmacogenetic warfarin dose|Warfarin maintenance dose on the basis of demographic/pharmacogenetic data
3202873|NCT01178021|Active Comparator|Chloroquine|Standard arm
3202874|NCT01178021|Experimental|Chloroquine/Primaquine|Chloroquine combined with primaquine
3202875|NCT01178008|Experimental|Active acupuncture group|Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints.
3202876|NCT01178008|Placebo Comparator|Placebo acupuncture group|Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
3202877|NCT01177995|Experimental|Social Network|Leaders of labor migrant social networks will be trained to disseminate HIV prevention messages to the members of their social networks. The training will sequentially target ways to increase network members' HIV-related knowledge and norms, attitudes, intentions, and confidence in how to avoid risk. Leaders will be encouraged to have these discussions with network members between and after training sessions.
3202878|NCT01177982|Active Comparator|Usual RBT (t-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club
3202879|NCT01177982|Experimental|Reduced RBT (r-RBT)|Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social Club Job Club
3202880|NCT01177982|Experimental|Abbreviated RBT (a-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation
3202881|NCT01177982|Active Comparator|Enhanced RBT (e-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club Recovery housing CAP short term housing admission Recovery sponsor
3202882|NCT01177982|Active Comparator|Early compliant t-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social club Job club
3202883|NCT01177982|Active Comparator|Early non-compliant t-RBT|t-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club e-RBT: Recovery housing CAP short term housing admission Recovery sponsor
3202884|NCT01177982|Experimental|Early compliant r-RBT|a-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation r-RBT: Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
3202885|NCT01177982|Experimental|Early non-compliant r-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social Club Job Club
3202886|NCT01177969|Experimental|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
3202887|NCT01177969|Placebo Comparator|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
3202888|NCT01177956|Experimental|Cetuximab + Cisplatin + 5-Fluorouracil (5-FU)|
3202889|NCT01177943|Experimental|Atomoxetine Oral Solution|
3202890|NCT01177943|Active Comparator|Atomoxetine Capsule Formulation|
3202891|NCT01177930||Feeding with milk with DHA and ARA|
3202980|NCT01177241||CLBP OU|
3202894|NCT01177917|Placebo Comparator|Marketed Cow milk-based infant formula|
3202895|NCT01177904|Active Comparator|Progesterone 5 Weeks|The study group stop receiving P4 on the day of their first US at 5 weeks pregnancy
3202896|NCT01177904|Other|Control Group : P4 8 weeks|Progesterone will be given until 8 weeks of pregnancy
3202897|NCT01177891||Subject index|Population of familial cases of POF : 20 families with at least two subjects with POF nonsyndromic
3202898|NCT01177891||Population Index Related topics|Women, healthy women, men are potential carriers
3202899|NCT01177891||Population control|100 Caucasian women with normal cycles until at least the age of 40 years and a proven fertility
3202900|NCT01177852|Experimental|Notuss® syrup|Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
3202901|NCT01177852|Active Comparator|Dropropizine + Pseudoephedrine and brompheniramine|Group 2: combined use of dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate.
3202902|NCT01177839||Intussusception cohort|Subjects with Intussusception
3202903|NCT01177826||Group 1|Cases
3202904|NCT01177826||Group 2|Controls
3202905|NCT01177813|Experimental|BI 10773 low dose|Patients receive BI 10773 low dose tablets once daily
3202906|NCT01177813|Experimental|BI 10773 high dose|Patients receive BI 10773 high dose tablets once daily
3202907|NCT01177813|Placebo Comparator|Placebo|Patients receive tablets identical to those containing BI 10773 low dose and high dose and to Sitagliptin
3202908|NCT01177813|Active Comparator|Sitagliptin 100 mg|Patients receive Sitagliptin 100 mg tablets once daily
3202909|NCT01177813|Experimental|BI 10773 high dose open label|Patients receive BI 10773 high dose tablets open label once daily
3202910|NCT01177800|Experimental|Infliximab|5 milligram per kilogram (mg/kg) infusion (a fluid or a medicine delivered into a vein by way of a needle) of infliximab administered intravenously (into a vein) at Week 0, 2 and 6 followed by maintenance regimen of 5 mg/kg infliximab at Week 14 and 22. Placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial infusion), matched to infliximab will be given at Week 10, 12 and 16. Total duration of treatment will be 26 weeks.
3202911|NCT01177800|Experimental|Placebo|Placebo infusion, matched to infliximab will be given intravenously at Week 0, 2 and 6. At Week 10, 12 and 16, participants will receive 5 mg/kg infliximab intravenously. Placebo infusion will be again given at Week 14 and 22. Total duration of treatment will be 26 weeks.
3202912|NCT01177787|Active Comparator|zeltiq|Cryolipolysis had been done for 1 hour on ipsilateral thigh fat through Zeltiq machine.
3202913|NCT01177787|Sham Comparator|electrical stimulation|Lipolysis had been done for 30 minutes on controlateral thigh fat through amplitude modulated frequency.
3202914|NCT01177774||Recent-onset tics that will persist|Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who, when reassessed at 1 year after the first tic began (i.e. 6-12 months after study enrollment) will turn out to meet criteria for a chronic tic disorder (including Tourette syndrome). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).
3202915|NCT01177774||Recent-onset tics that will remit|Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who will no longer have tics when reassessed 1 year after the first tic began (6 to 12 months after study enrollment). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).
3202916|NCT01177774||Tic-free control subjects|Children with no current or past tic disorder of similar age, sex and handedness as the children in the recent-onset tics groups.
3202917|NCT01177774||Existing TS/CTD|Children with current tics whose first tics were more than 12 months ago (DSM-5 Tourette's Disorder or Persistent [Chronic] Motor or Phonic Tic Disorder), of similar age, sex and handedness as the children in the recent-onset tics groups.
3202918|NCT01177761|Active Comparator|exercise|endurance,balance, power, resistance type exercise
3202919|NCT01177761|No Intervention|sedentary control|Subjects were instructed to do not relevantly change their lifestyle
3202920|NCT01177748||Patients on the Stroke Unit|
3202921|NCT01177735|Experimental|Pomalidomide|
3202922|NCT01177722|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T (Lot A)|
3202923|NCT01177722|Experimental|Group 2: DTaP-IPV-Hep B-PRP-T (Lot B)|
3202924|NCT01177722|Experimental|Group 3: DTaP-IPV-Hep B-PRP-T (Lot C)|
3202925|NCT01177722|Active Comparator|Group 4: Active Control|
3202926|NCT01177709|Experimental|Metformin|
3202927|NCT01177696|Experimental|psychotherapy|"The study aims to evaluate the effectiveness of an intervention of psychotherapy in improving the mental health of caregivers.~This intervention is based on theoretical approaches to care adjusted to cognitive theory, in order to be applied in primary health care centres."
3202928|NCT01177696|No Intervention|Control|
3202929|NCT01177683|Experimental|Arm 1|Bendamustine in combination with bortezomib and pegylated liposomal doxorubicin.
3202930|NCT01177657||Gastroenteritis cohort|Children born after 6 March 2006, at least 12 weeks of age and hospitalized for rotavirus severe gastroenteritis
3202931|NCT01177657||Hospital control cohort|Children hospitalized for non gastroenteritis causes
3202932|NCT01177657||Neighbourhood control cohort|Children without any symptoms of gastroenteritis or severe gastroenteritis
3202933|NCT01177644|Experimental|Active|
3202934|NCT01177618||Probands|Severe, early-onset COPD subjects that bring the family into the study
3202935|NCT01177618||Relatives|Relatives of early-onset COPD probands, including first-degree relatives (parents, siblings, and children), second-degree relatives (aunts, uncles, grandparents, half-siblings), spouses, and other affected individuals.
3202936|NCT01177605|Placebo Comparator|Vanilla flavored milk-based beverage containing no prebiotics|Vanilla flavored milk-based beverage containing no prebiotics
3202937|NCT01177605|Experimental|Vanilla flavored milk-based beverage containing prebiotics|Vanilla flavored milk-based beverage containing prebiotics
3202981|NCT01177228|Placebo Comparator|Placebo|Vedolizumab-matching placebo, intravenous (IV), infusion on Days 1, 15, 29 and 85.
3202982|NCT01177228|Experimental|Vedolizumab 2 mg/kg|Vedolizumab, 2 mg/kg, IV infusion on Days 1, 15, 29 and 85.
3202983|NCT01177228|Experimental|Vedolizumab 6 mg/kg|Vedolizumab 6 mg/kg, IV infusion on Days 1, 15, 29 and 85.
3202938|NCT01177592|Experimental|Guided Therapy|Subjects on chronic clopidogrel therapy (≥ 5 days maintenance or loading within 4 hours of PCI) will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing
3202939|NCT01177592|No Intervention|Standard Therapy|Patients randomized to the control arm will remain on 75mg clopidogrel arm throughout the study.
3202940|NCT01177579|No Intervention|Aim 1; Biomarkers|Blood concentrations of copper coenzymes will be monitored for 1 year
3202941|NCT01177579|Experimental|Copper supplement Arm|4 mg or 8 mg copper will be compared in a randomized controlled study
3202942|NCT01177579|No Intervention|Normal Controls|Normal subjects will be used to generate reference measures.
3202943|NCT01177566|Active Comparator|pimecrolimus (Elidel)|pimecrolimus twice daily to a chosen target lesion on one side of body
3202944|NCT01177566|Active Comparator|topical medical device cream (Eletone)|topical medical device cream three times daily to a chosen target lesion on one side of the body
3202945|NCT01177553|Active Comparator|Surgery Group|"Patients randomized to surgery will have hospital arrangements (laboratory tests and anesthesia assessment) finalized for a surgery the next day. Patients will sign the informed consent form.~Patients undergoing surgery will be admitted to Tampa General Hospital and will complete usual hospital admission procedures."
3202946|NCT01177553|Active Comparator|Expectant Management Group|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
3202947|NCT01177540|Experimental|Arm A|
3202948|NCT01177540|Experimental|Arm B|
3202949|NCT01177514|Experimental|GABAPENTIN|Group of patients treated with oral gabapentin
3202950|NCT01177514|Placebo Comparator|PLACEBO|Group given the placebo capsules
3202951|NCT01177501|Experimental|Topotecan|
3202952|NCT01177488|Experimental|BATE-T|Behavioral Activation Therapeutic Exposure done while the patient is at home via videoconferencing technology
3202953|NCT01177488|Active Comparator|BATE-IP|Behavioral Activation Therapeutic Exposure done in the therapist's office
3202954|NCT01177475|Active Comparator|natural milk|
3202955|NCT01177475|Experimental|pasteurized milk|
3202956|NCT01177462||hemineglect stroke patients|Stroke patients with hemineglect
3202957|NCT01177462||Control stroke patients|Stroke patients without hemineglect
3202958|NCT01177462||Normal control|Normal subjects
3202959|NCT01177436|Experimental|Patients treated for prostatic pathology|Patients treated for prostatic pathology (benign or malign)in the hospital department.
3202960|NCT01177423|Active Comparator|Quicksleeper intraosseous anesthesia|Pulpal and periapical molar and premolar sedation is managed by Quicksleeper intraosseous anesthesia.
3202961|NCT01177423|Active Comparator|Inferior alveolar nerve block|Pulpal and periapical molar and premolar sedation is managed by inferior alveolar nerve block.
3202962|NCT01177410|Placebo Comparator|Placebo|
3202963|NCT01177410|Experimental|Mesalamine Granules 750 mg|
3202964|NCT01177410|Experimental|Mesalamine Granules 1500 mg|
3202965|NCT01177397|Experimental|CC-223|All patients will receive CC-223, but serial patient groups will receive different dose levels in Phase 1. The number of groups will be determined by the number of dose levels required to establish dose-limiting toxicity.
3202966|NCT01177384|Experimental|Sitagliptin|Sitagliptin 100 mg daily (q.d.) + acarbose (continuing the current stable dose of at least 50 mg three times daily [t.i.d.])
3202967|NCT01177384|Placebo Comparator|Placebo|Placebo q.d. + acarbose (continuing the current stable dose of at least 50 mg t.i.d.)
3202968|NCT01177371|Experimental|Arm I|"HIGH-DOSE CHEMOTHERAPY: Patients receive oral busulfan every 6 hours on days -8 to -5 and cyclophosphamide IV over 2 hours on days -4 and -3, or -4 to -2.~TRANSPLANTATION: Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine IV over 6 hours on day -1, over 10 hours twice daily on days 0-20, and then orally every 12 hours beginning on day 21 and continuing for 12 months with taper at 9 months. Patients also receive methylprednisolone IV or orally beginning on day 8 and continuing for 7 months with taper at 4 months. Some patients may also receive methotrexate IV on days 1, 3 and 6."
3202969|NCT01177358|Experimental|Botulinum Toxin A injection|"A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.~5 Units (0.1 mL) of Botulinum Toxin A will be injected at three sites along the incision (midline and 1.5 cm lateral to midline) following a thyroidectomy or parathyroidectomy."
3202970|NCT01177358|Placebo Comparator|Saline|0.1 mL of normal saline in a placebo vial containing 2 mL of normal saline will be injected along the incision (midline and 1.5 cm lateral to midline) following a thyroidectomy or parathyroidectomy.
3202971|NCT01177345||Terminal Disease|Terminal cervical cancer- not treatable
3202972|NCT01177345||Early Disease|Early cervical cancer = meaning treatable with hysterectomy.
3202973|NCT01177345||Advanced Disease|Advanced cervical cancer- treatable with chemotherapy and/or radiation.
3202974|NCT01177332|Experimental|Fasted|Two-hour cycling test, fasted condition
3202975|NCT01177332|Other|Glucose-fed|Two-hour cycling test, glucose-fed condition
3202976|NCT01177306|Experimental|Extended Release Guanfacine|pre and post testing of working memory in subjects whose ADHD has responded to extended release guanfacine. Subjects will be tested before starting study drug and after 6-8 weeks on a stable dose of the study drug.
3202977|NCT01177293|Active Comparator|treatment A - reference w/ water|
3202978|NCT01177293|Experimental|Treatment B - ODT (test) w/o water|
3202979|NCT01177241||CLBP|
3202984|NCT01177228|Experimental|Vedolizumab 10 mg/kg|Vedolizumab 10 mg/kg, IV infusion on Days 1, 15, 29 and 85.
3202985|NCT01177215||Digital chest tube|All patients will be treated with the digital chest tube device
3202986|NCT01177202|Experimental|Group A|HAC1 Dose = 15ug; Alum Dose = 0
3202987|NCT01177202|Experimental|Group B|HAC1 Dose = 15ug; Alum Dose = 0.75mg
3202988|NCT01177202|Experimental|Group C|HAC1 Dose = 45ug; Alum Dose = 0
3202989|NCT01177202|Experimental|Group D|HAC1 Dose = 45ug; Alum Dose = 0.75mg
3202990|NCT01177202|Experimental|Group E|HAC1 Dose = 90ug; Alum Dose = 0
3202991|NCT01177202|Experimental|Group F|HAC1 Dose = 90ug; Alum Dose = 0.75mg
3202992|NCT01177202|Placebo Comparator|Group G|Saline
3202993|NCT01177202|Active Comparator|Group H|H1N1
3202994|NCT01177189|Other|Arm 1|Young healthy men and women aged 18-30
3202995|NCT01177189|Other|Arm 2|Older healthy men and women aged >70.
3202996|NCT01177176|Other|Standard Care|Standard tobacco counseling provided to hospital inpatients as part of routine, clinical-guideline compliant care in the study hospital. No post-discharge treatment is offered in this arm.
3202997|NCT01177176|Experimental|Extended Care Management|In addition to Standard Care, subjects in this arm receive Extended Care Management intervention to facilitate the continued use of smoking cessation treatment (counseling and medication use) after hospital discharge. This consists of 3 months of telephone-based contact after discharge.
3202998|NCT01177163|Other|001|Placebo one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
3202999|NCT01177163|Experimental|002|JNJ 28431754 100 mg/placebo one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
3203000|NCT01177163|Experimental|003|JNJ 28431754 300 mg/placebo one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
3203001|NCT01177150|Experimental|001|JNJ-28431754/ Placebo Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses the evening dose will be administered at 10 hours after the morning dose.
3203002|NCT01177150|Experimental|002|JNJ-28431754 Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
3203003|NCT01177137|Experimental|TRT|TRT includes treatment with a conventional sound generator (SG) and directive counseling (DC)
3203004|NCT01177137|Other|Partial TRT|Partial TRT includes treatment with a placebo sound generator (placebo SG) and directive counseling (DC).
3203005|NCT01177137|Other|Standard of Care (SC)|The standard of care arm includes care as typically delivered in US military medical centers
3203006|NCT01177124|Experimental|MBSR 6 Weeks Program|
3203007|NCT01177124|No Intervention|Usual Care (UC)|
3203008|NCT01177111|Experimental|Sunflower seed Oil|
3203009|NCT01177111|Active Comparator|Mustard seed oil|
3203010|NCT01177098|Experimental|bimatoprost/timolol formulation A|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
3203011|NCT01177098|Active Comparator|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
3203012|NCT01177085|Experimental|Mushroom|Mushroom enriched weight loss diet. Participants will be given a personalized diet plan, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
3203013|NCT01177085|Active Comparator|No mushroom diet|Participants will be given a personalized diet plan, without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
3203014|NCT01177072|Experimental|Components-Based Interventions (CBI)|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
3203015|NCT01177072|Experimental|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
3203016|NCT01177072|No Intervention|Wait List Control|Eligible clients will not be provided therapy at enrollment. After the study period has completed, control clients will be re-interviewed. Those that remain eligible due to symptom cutoff scores will be offered therapy. In the interim, controls will receive a phone call once a month; those with indications of possible harm to self or others will be referred to a psychiatrist.
3203017|NCT01177059|Other|Anti-HIV-1 Ribozyme (OZ1) transduced cells|OZ1 transduced cells Long term follow up of previously infused OZ1 transduced cells
3203018|NCT01177033||Best endovascular treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
3203019|NCT01177033||Best surgical treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
3203020|NCT01177020||Placentas after delivery or abortion|
3203021|NCT01177007|Experimental|TheraSphere|
3203022|NCT01176994|Experimental|Skin lesions|Individuals with skin lesions whose lesions are not sent for histology by dermatologists
3203023|NCT01176981|Experimental|HDMTX|This is a single arm study. All subjects enrolled in the study will be in this arm.
3203024|NCT01176968|Experimental|Eplerenone plus standard of care|
3203025|NCT01176968|Placebo Comparator|Placebo plus standard of care|Matching placebo for eplerenone 25mg film coated tablets.
3203283|NCT01175135|Experimental|PF-02545920 5 mg|
3203284|NCT01175135|Experimental|PF-02545920 15 mg|
3203026|NCT01176955|Experimental|Internet survey|Subjects will receive a weekly email link to complete an internet survey about their acne and use of the study medication.
3203027|NCT01176955|Placebo Comparator|Control|Subjects will receive standard-of-care treatment with the study medication, without internet surveys.
3203028|NCT01176942|Experimental|Probiotic|
3203029|NCT01176942|Placebo Comparator|Placebo|
3203030|NCT01176929|Experimental|Interventional group|Usual treatment + prevention program of recurrent suicidal acts
3203031|NCT01176929|Active Comparator|Control group|Usual treatment
3203032|NCT01176916|Other|A|This is a single arm NIS.
3203033|NCT01176903|Experimental|Glyco SD1|Single administration of Glyco pMDI dose level 1
3203034|NCT01176903|Experimental|Glyco SD2|Single administration of Glyco pMDI dose level 2
3203035|NCT01176903|Experimental|Glyco SD3|Single administration of Glyco pMDI dose level 3
3203036|NCT01176903|Experimental|Glyco SD4|Single administration of Glyco pMDI dose level 4
3203037|NCT01176903|Experimental|Glyco SD5|Single administration of Glyco pMDI dose level 5
3203038|NCT01176903|Placebo Comparator|Placebo SP|Single administration of Placebo pMDI
3203039|NCT01176903|Experimental|Glyco MD1|Multiple administration of Glyco pMDI dose level 1
3203040|NCT01176903|Experimental|Glyco MD2|Multiple administration of Glyco pMDI dose level 2
3203041|NCT01176903|Experimental|Glyco MD3|Multiple administration of Glyco pMDI dose level 3
3203042|NCT01176903|Placebo Comparator|Placebo MP|Multiple administration of placebo pMDI
3203043|NCT01176903|Active Comparator|Tiotropium|Multiple administration of tiotropium
3203044|NCT01176890|Experimental|Vago|Truncally vagotomized subjects (due to duodenal ulcer operation)
3203045|NCT01176890|Experimental|Cardia|truncally vagotomized subjects (due to esophagus resection)
3203046|NCT01176890|Experimental|Healthy controls|Healthy control subjects
3203047|NCT01176877|Other|keloid scar|Those with a diagnosis of keloid scar.
3203048|NCT01176864|Active Comparator|Double-balloon enteroscopy|DBE for suspected or known small-bowel bleeding
3203049|NCT01176864|Active Comparator|Single-balloon enteroscopy|SBE for suspected or known small-bowel bleeding
3203050|NCT01176851|Experimental|Glyco pMDI|Glyco pMDI 100 µg
3203051|NCT01176851|Experimental|Glyco pMDI Charcoal|Glyco pMDI 100 µg + charcoal block
3203052|NCT01176851|Active Comparator|Glyco IV injection|Glyco solution for injection 100 µg
3203053|NCT01176825|Experimental|CBT|14-week individual cognitive-behavior therapy
3203054|NCT01176825|No Intervention|Treatment As Usual|14-week waitlist control
3203055|NCT01176812||Dermal Fillers|Facial Wasting
3203056|NCT01176799|Active Comparator|Arm A: Control Arm|"Doxorubicin - 60mg/m2 day 1~Cyclophosphamide~-600mg/m2 day1, every 3 weeks x 4 cycles"
3203057|NCT01176799|Experimental|Arm B: Experimental|Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
3203058|NCT01176773|Experimental|Juvéderm® Ultra Lip Injectable Gel|
3203059|NCT01176760|Experimental|Vago|Truncally vagotomized subjects (due to duodenal ulcer operation)
3203060|NCT01176760|Experimental|Cardia|Truncally vagotomized subjects (due to cardia resection)
3203061|NCT01176760|Experimental|Ctrl|Healthy matched control subjects
3203062|NCT01176747|Experimental|BDP/formoterol NEXT DPI|Radiolabelled BDP/formoterol 100/6 µg dry powder administered via the NEXT inhaler
3203063|NCT01176734|Experimental|active t-VNS|active t-VNS
3203064|NCT01176721|Active Comparator|t-VNS verum|Active stimulation of the left auricle by t-VNS
3203065|NCT01176721|Placebo Comparator|Sham|Sham-simulation of the left auricle by the t-VNS device.
3203066|NCT01176708|Experimental|Liver transplanted|10 Liver transplanted patients
3203067|NCT01176708|Experimental|Kidney transplanted|10 kidney transplanted individuals
3203068|NCT01176708|Experimental|Healthy controls|10 healthy controls
3203069|NCT01176695|Experimental|1|fish oil containing lipid emulsion
3203070|NCT01176695|Active Comparator|2|MCT/LCT containing lipid emulsion
3203071|NCT01176682||1|Adult patients treated with NSAID therapy for diagnosed OA, RA or AS, and with GI risk factors
3203072|NCT01176669|Experimental|Apatinib|
3203073|NCT01176656||SU|T2DM patients with a prescription for a sulfonylurea but no insulin
3203074|NCT01176656||Antidiabetic without SU|T2DM patients with an oral antidiabetic drug other than an SU, and no insulin
3203075|NCT01176656||Insulin|T2DM patients using insulin, with or without other oral antidiabetics
3203076|NCT01176643|Active Comparator|standard care plus yoga|Participants will be asked to complete two yoga classes weekly over a period of eight weeks.
3203077|NCT01176643|No Intervention|Standard care|
3203078|NCT01176617|No Intervention|Conventional Monitoring Strategy|Subjects will be monitored for 12 months using the conventional strategy which includes wearing a monitor over 3 separate 30-day periods over the first year post-ablation and daily pulse checks.
3203079|NCT01176617|Other|Reveal XT|Subjects will be monitored using the conventional monitoring strategy for the first 6 months post-ablation. During the next 6 months, subjects will be monitored using the data from the Reveal device, transmitted from home every 30 days.
3203080|NCT01176604|Other|TheraSphere Treatment|Injection via arterial catheter of TheraSphere microspheres containing yttrium-90 (Y-90) to whole liver, lobar or segmental treatment delivered as a sequence of treatments using approximately 30 - 90 days apart.
3203081|NCT01176591|Active Comparator|Physiological Stressor + Aprepitant|
3203082|NCT01176591|Active Comparator|Psychological Stressor + Aprepitant|
3203083|NCT01176591|Placebo Comparator|Physiological Stressor + Placebo|
3203084|NCT01176591|Placebo Comparator|Psychological Stressor + Placebo|
3203085|NCT01176578|Experimental|T2DM|Type 2 Diabetes Mellitus
3203086|NCT01176578|Experimental|IGT|Impaired Glucose Tolerance
3203087|NCT01176578|Active Comparator|NGT|Normal Glucose Tolerance
3203285|NCT01175135|Placebo Comparator|Placebo|
3203088|NCT01176565|Active Comparator|Standard SBP Reduction Arm|"Intravenous nicardipine hydrochloride will be used as necessary (pro re nata or PRN) as the primary agent in lowering SBP.~The goal for the standard BP reduction group will be to reduce and maintain SBP < 180 mmHg for 24 hours from randomization. 160 mmHg is the target SBP for this arm.~For the standard group, SBP below the assigned treatment range is not artificially elevated to stay within the range if lower SBP occurs with nicardipine turned off (no fluid bolus given unless SBP falls below 110 mmHg with nicardipine off and there is risk for hypotension). Euvolemic fluid maintenance is encouraged for all patients according to their medical needs, which may differ."
3203089|NCT01176565|Active Comparator|Intensive SBP Reduction Arm|"Intravenous nicardipine hydrochloride will be used as necessary (pro re nata or PRN) as the primary agent in lowering SBP.~The goal for the intensive BP reduction group will be to reduce and maintain SBP < 140 mmHg for 24 hours from randomization. 125 mmHg is the target SBP for this arm.~For the intensive group, SBP falling below 110 mmHg (lower limit of the assigned treatment range) with nicardipine off is treated with normal saline fluid bolus to prevent or remedy hypotension. Euvolemic fluid maintenance is encouraged for all patients according to their medical needs, which may differ."
3203090|NCT01176552|Experimental|Study group: GM-CSF, IFN, IL-2|
3203091|NCT01176539||Sleep Clinic|
3203092|NCT01176513|Experimental|GE 148-002|
3203093|NCT01176487|Experimental|A|A clinical trial using 3-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer
3203094|NCT01176474|Experimental|Nivolumab and Peptide Vaccine|"Cohorts 1 through 3: Participants will receive nivolumab with the peptide vaccine within 8 days after their first apheresis procedure.~Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG with Escalating Doses of Anti-PD-1 Antibody Nivolumab (BMS-936558). Level 1: 1 mg/kg Nivolumab + peptide vaccine. Level 2: 3 mg/kg Nivolumab + peptide vaccine. Level 3: 10 mg/kg Nivolumab + peptide vaccine."
3203095|NCT01176474|Experimental|Nivolumab and Ipilimumab|Cohorts 4 and 5. Participants will receive their first dose of nivolumab with ipilimumab within 28 days after screening blood draws. Both drugs will be given. Cohort 4: nivolumab 1mg/kg plus ipilimumab 3mg/kg. Cohort 5: nivolumab 3mg/kg plus ipilimumab 1mg/kg.
3203096|NCT01176461|Experimental|A1 - Phase I Dose Escalation|Cohorts 1 through 5. Each treatment cycle is comprised of 6 doses of BMS-936558 and 6 peptide vaccines administered every 2 weeks for 12 weeks (cohort 6 has no peptides) (Cycle 1: Weeks 1, 3, 5, 7, 9, and 11; Cycle 2: Weeks 13, 15, 17, 19, 21, and 23) with tumor response assessments at the end of each cycle (during Weeks 12 and 24).
3203097|NCT01176461|Active Comparator|A2 - BMS-936558 Without Peptide Vaccine|Cohort 6. Each treatment cycle is comprised of 6 doses of BMS-936558 administered every 2 weeks for 12 weeks (cohort 6 has no peptides) (Cycle 1: Weeks 1, 3, 5, 7, 9, and 11; Cycle 2: Weeks 13, 15, 17, 19, 21, and 23) with tumor response assessments at the end of each cycle (during Weeks 12 and 24).
3203098|NCT01176448|Experimental|Fractionated laser|This Arm is the section of scar that will be treated with Fractionated Laser
3203099|NCT01176448|Active Comparator|Dermabrasion|Dermabrasion is the gold standard for scar resurfacing and will be used as the control against which Fractionated Laser is compared.
3203100|NCT01176435|Active Comparator|0.76 mg/kg L-DOPA|Solution taken orally three times a day.
3203101|NCT01176435|Active Comparator|0.51 mg/kg L-DOPA|Solution taken orally three times a day.
3203102|NCT01176435|Placebo Comparator|Placebo|Solution taken orally three times a day.
3203103|NCT01176422||advanced Myelodysplastic Syndrome or acute myeloid leukemia|advanced MDS and AML with/without associated cytogenetic abnormality
3203104|NCT01176409|Experimental|High dose valacyclovir|Valacyclovir 1g po BID
3203105|NCT01176409|Active Comparator|Low dose valacyclovir|Valacyclovir 500mg po BID
3203106|NCT01176409|Placebo Comparator|Placebo|Inert placebo
3203107|NCT01176396|Active Comparator|Caries prevention active intervention|Patients receive CAMBRA related products like CHX, 5000ppm F-toothpaste etc according to their risk level
3203108|NCT01176396|Placebo Comparator|control treatment|Patients receive treatment according to standard of care
3203109|NCT01176383|No Intervention|Control group|The control group will have a standard NHS cessation clinic experience
3203110|NCT01176383|Experimental|Respiragene test and risk score|Subjects will have a buccal swab taken at first attendance for a 12 gene test of SNP variants associated with risk of lung cancer. From the genetic data and clinical data (any history of COPD, family history of lung cancer in a first degree relative and age) a risk score is calculated from which a lifetime risk of lung cancer if the subject continues to smoke can be calculated. This is expected to be a powerful motivator to encourage smoking cessation.
3203111|NCT01176370|Experimental|Implantable Counterpulsation Therapy|The study is a single arm study with up to 20 patients enrolled and implanted with implantable counterpulsation. Patients that meet eligibility will be enrolled and implanted into the treatment arm of the study. There is not a control arm in this feasibility study.
3203112|NCT01176357||1|CABG
3203113|NCT01176357||2|Valve surgery
3203114|NCT01176344|Experimental|Vitamin D supplementation|Participants in the intervention arm will receive 50,000 IU (1.25 mg) cholecalciferol capsules given once monthly
3203115|NCT01176344|Placebo Comparator|Placebo|The control arm will receive identical inert placebo capsules given once monthly.
3203116|NCT01176331||vitrectomy|
3203117|NCT01176318|Experimental|erdosteine|standard care plus erdosteine for 10 days
3203118|NCT01176318|Placebo Comparator|placebo|Standard care for exacerbation of COPD plus placebo
3203119|NCT01176305||Danish Women 15 to 49 years old.|Free of previous VTE and current use of oral contraceptives.
3203120|NCT01176292|Other|Rotating Platform High-Flex Cruciate Substituting TKA|
3203121|NCT01176292|Other|Rotating Platform Cruciate Substituting TKA|
3203122|NCT01176279|Active Comparator|Manual and automated washing of the line|Place in the radial artery the system of invasive monitoring of the blood pressure (BD DTXPlus ™). Insert in line a second 3-way stopcock above the one that has the BD DTXPlus ™; this second 3-way stopcock will be called proximal key. On the distal 3-way stopcock key (the one of TM BD DTXPlus ™), put the needless connector included in the kit to make the extractions of blood. Connect an arterial blood sampling syringe on the proximal 3-way stopcock key. With the assembled system, it is necessary to print a curve of invasive determination of the blood pressure.
3203286|NCT01175135|Active Comparator|Risperidone 3 mg|
3203123|NCT01176279|Experimental|Automated washing of the line|Place in the radial artery the system of invasive monitoring of the blood pressure (BD DTXPlus ™). Insert in line a second 3-way stopcock above the one that has the BD DTXPlus ™; this second 3-way stopcock will be called proximal key. On the distal 3-way stopcock key (the one of BD DTXPlus™), put the needless connector included in the kit to make the extractions of blood. On the proximal 3-way stopcock key put a second identical needless connector: in the intervention group the two 3-way stopcock keys have, each one, a needless connector. With the assembled system, it is necessary to print a curve of invasive determination of the blood pressure.
3203124|NCT01176266|Experimental|Asfotase alfa|A total of 6 mg/kg/week of asfotase alfa administered by SC injection (either 1 mg/kg asfotase alfa 6 times per week, or 2 mg/kg asfotase alfa 3 times per week)
3203125|NCT01176253||25 newly diagnosed Type 1 diabetics|25 newly diagnosed Type 1 diabetics within onset of symptoms
3203126|NCT01176253||25 healthy volunteers|25 healthy volunteers (age & sex matched)
3203127|NCT01176240|Experimental|Droxidopa|droxidopa active drug
3203128|NCT01176240|Placebo Comparator|Placebo|Placebo matched control
3203129|NCT01176227|Placebo Comparator|Kyodophilus matching placebo capsules|
3203130|NCT01176227|Active Comparator|Kyodophilus multi strain probiotic capsules|
3203131|NCT01176214|Experimental|early tracheostomy|see study description
3203132|NCT01176214|Active Comparator|late tracheostomy|"Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails"
3203133|NCT01176201|Experimental|A|400 mg suspension
3203134|NCT01176201|Active Comparator|B|5 x 200 mg immediate release capsule
3203135|NCT01176188|Experimental|Comfort Care|Parental soothing, including tactile and auditory strategies, followed by a quiet period with the application of earmuffs to block auditory stimulation
3203136|NCT01176188|Active Comparator|Usual Care|
3203137|NCT01176175|Experimental|50 mg|Progesterone microspheres injectable suspension 50 mg
3203138|NCT01176175|Experimental|100 mg|Progesterone microspheres injectable suspension 100 mg
3203139|NCT01176175|Experimental|200 mg|Progesterone microspheres injectable suspension 200 mg
3203140|NCT01176175|Experimental|300 mg|Progesterone microspheres injectable suspension 300 mg
3203141|NCT01176162||"Group < 28"|• Gestational Age < 28 weeks
3203142|NCT01176162||"Group 28 - < 33"|• Gestational Age : 28 - < 33 weeks
3203143|NCT01176162||"Group 33- < 37"|Gestational Age : 33- < 37 weeks
3203144|NCT01176162||"Group > 37"|Gestational Age > 37 weeks
3203145|NCT01176149|Experimental|SMBG + intensive education|Patients will receive specific educational interventions to teach them how to perform Self monitoring Blood Glucose (SMBG), how to modify diet and level of physical activity according to blood glucose levels, and the actions to be undertaken in case of abnormal values (hypoglycemia, particularly elevated glucose levels). Patients will be instructed to modify their lifestyle habits (diet, physical activity) in order to reach specific goals (weight reduction, reduction in fat consumption intake, reduction in saturated fat intake, increase in fiber intake, regular physical activity.
3203146|NCT01176149|No Intervention|Usual Care|Usual Care
3203147|NCT01176136|Experimental|HOPS Intervention|Middle school age children who receive the Homework, Organization, and Planning Skills (HOPS) intervention.
3203148|NCT01176136|No Intervention|Treatment As Usual|Middle school age children randomly assigned to receive treatment-as-usual services available through the school and community.
3203149|NCT01176123|Active Comparator|CBT-I in person|Cognitive behavioral therapy for insomnia delivered in person
3203150|NCT01176123|Experimental|CBT-I via telephone therapy|Cognitive behavioral therapy for insomnia delivered by telephone
3203151|NCT01176110|Experimental|thermal management with LMA PerfecTemp™|
3203152|NCT01176110|Active Comparator|no specific thermal management|
3203153|NCT01176097|Experimental|6 - 8 cohorts|6 patients in each cohort will receive AZD5658
3203154|NCT01176097|Placebo Comparator|6 - 8 cohorts|2 patients in each cohort will receive placebo
3203155|NCT01176084|Experimental|low carbohydrate diet|
3203156|NCT01176084|Experimental|diet & exercise|
3203157|NCT01176058|Active Comparator|open label|
3203158|NCT01176045||Pre-surgical treatment|Patients who are pre & post-surgical treated with ocular lubricants.
3203159|NCT01176045||Non-presurgical treatment|Patients who are only post-surgical treated with ocular lubricants
3203160|NCT01176032|Experimental|Aliskiren|"Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks. In addition to the study medication, amlodipine 5mg was given to patients who did not achieve the required blood pressure (<140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication. At week 18 the dose of amlodipine was increased to 10mg if the required level (<140/90 mmHg) was still not achieved.~HCTZ 12.5mg was prescribed at week 26 if the required values (<140/90 mmHg) had not been reached."
3203161|NCT01176032|Active Comparator|Lostaran|"Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks. In addition to the study medication, amlodipine 5mg was given to patients who did not achieve the required blood pressure (<140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication. At week 18 the dose of amlodipine was increased to 10mg if the required level (<140/90 mmHg) was still not achieved.~HCTZ 12.5mg was prescribed at week 26 if the required values (<140/90 mmHg) had not been reached."
3203162|NCT01176019|Experimental|Interactive Video|In addition to standard care, the experimental arm will receive an interactive video designed to inform and educate patients about the choices that exist concerning prenatal screening and diagnosis.
3203163|NCT01176019|No Intervention|Control|A control arm will receive standard care, which is the opportunity to meet with a genetic counselor.
3203164|NCT01176006|Active Comparator|Group A|10/10 HLA Matched Related Donor or Unrelated Donor Transplant.
3203165|NCT01176006|Active Comparator|Group B|9/10 HLA Matched Related Donor or Unrelated Donor Transplant.
3203166|NCT01176006|Other|Group C|Donor
3203167|NCT01175993|Experimental|Intervention 1|Elliptical Training
3203168|NCT01175993|Active Comparator|Intervention 2|Bright Light Therapy
3203287|NCT01175122|Experimental|H2N3 MO 2003/AA ca Vaccine|Participants will receive a nasal spray administration of the H2N3 MO 2003/AA ca vaccine on Day 0 and Day 28.
3203169|NCT01175980|Experimental|Treatment (vorinostat)|Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3203170|NCT01175954|Experimental|Lacosamide Open-Label|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
3203171|NCT01175941|Experimental|NRL001|10 mg NRL001 in a 2 g suppository
3203172|NCT01175941|Placebo Comparator|Placebo|Matched placebo control
3203173|NCT01175928|Experimental|Peristaltic Pulse PCD|Peristaltic Pulse Pneumatic Compression Device (NormaTec PCD)
3203174|NCT01175928|Sham Comparator|Sham Device|Sham Pneumatic Compression Device (looks and sounds like real device, but applies no compression)
3203175|NCT01175915|Active Comparator|Western therapy|
3203176|NCT01175915|Experimental|Reduning Injection|
3203177|NCT01175915|Experimental|Reduning Injection plus western therapy|
3203178|NCT01175902|Active Comparator|Arm 1|Latanoprost first, then Dorzolamide/Timolol Patients first on Latanoprost eyedrops once a day, then on Dorzolamide/Timolol twice a day
3203179|NCT01175902|Active Comparator|Arm 2|Dorzolamide/Timolol first, then Latanoprost Patients first on Dorzolamide/Timolol eyedrops twice a day, then on Latanoprost eyedrops once a day
3203180|NCT01175889|Experimental|one side ACE blade|
3203181|NCT01175889|Active Comparator|one side scalpel|
3203182|NCT01175876|Experimental|1|Device: RIPC RIPC consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins Procedure: Carotid Artery Stenting
3203183|NCT01175876|Sham Comparator|2|Procedure: Carotid Artery Stenting
3203184|NCT01175863|Active Comparator|Intravascular ultrasound|
3203185|NCT01175863|Active Comparator|Fractional flow reserve|
3203186|NCT01175850|Experimental|Drug-Coated Balloon (DCB)|IN.PACT Admiral: Balloon Angioplasty
3203187|NCT01175850|Active Comparator|Standard PTA|Standard Percutaneous Transluminal Angioplasty (PTA) Balloon: Balloon Angioplasty
3203188|NCT01175837|Experimental|Short-term fasting prior to systemic chemotherapy|"COHORT I: Patients fast 24 hours before day 1 of course 2 of chemotherapy. If fast is well tolerated, patients may escalate fasting by 12 hours for each subsequent course of chemotherapy for up to 3 courses in the absence of unacceptable toxicity.~COHORT II: Patients fast at the longest fasting regimen found to be safe and tolerable in cohort I before day 1 of each course of course of chemotherapy for up to 4 courses in the absence of unacceptable toxicity."
3203189|NCT01175824|Experimental|Insulin lispro low mixture (LM)|Two daily injections (breakfast and dinner) of insulin lispro mix 75/25
3203190|NCT01175824|Active Comparator|Insulin glargine+insulin lispro|Once-daily (bedtime) basal insulin glargine and once-daily (before the main meal with the highest average 2-hour postprandial blood glucose concentration) prandial insulin lispro
3203191|NCT01175811|Experimental|Premixed Insulin|Twice daily (before breakfast and lunch) insulin lispro mix 50 (50% insulin lispro, 50% insulin lispro protamine suspension [LM50]) and once daily (before dinner) insulin lispro mix 25 (25% insulin lispro, 75% insulin lispro protamine suspension [LM25])
3203192|NCT01175811|Active Comparator|Basal-Bolus|Once daily (bedtime) insulin glargine and three pre-meal insulin lispro
3203193|NCT01175798|No Intervention|No treatment (standard of care)|Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
3203194|NCT01175798|Experimental|Vitamin D repletion|Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
3203195|NCT01175785|Experimental|Treatment (chemo, radiation, transplant, GVHD prophylaxis)|Patients receive fludarabine phosphate IV over 1 hour on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI twice daily on days -4 to -1. Patients undergo unmanipulated single- or double-unit umbilical cord blood transplantation on day 0 and receive ex vivo-expanded cord blood progenitor cells IV over 4 hours following the last unmanipulated cord blood infusion. Patients initially receive CSP IV over 1 hour beginning on day -3. CSP may be given PO when the patient can tolerate oral medications and has a normal gastrointestinal transit time. CSP is given until day 100, and may taper on day 101 if there is no graft versus host disease. Patients also receive MMF IV every 8 hours on days 0 to 7 and then may receive MMF PO beginning day 8 to 30. MMF is continued for a minimum of 30 days or until 7 days after blood counts recover whichever is later. If there is no evidence of acute GVHD and donor CD3 engraftment is at least 50% from one donor MMF may be tapered.
3203196|NCT01175772|Experimental|Metronomic Chemoterapy|Maintenance Treatment for Ovary Carcinoma by Metronomic Chemotherapy
3203197|NCT01175759|Experimental|Healthy control group|
3203198|NCT01175759|Experimental|UPRL|
3203199|NCT01175746|Experimental|nicardipine|
3203200|NCT01175746|Active Comparator|remifentanil|
3203201|NCT01175733|Experimental|Panitumumab|
3203202|NCT01175720|Experimental|test and control|The test and control technique will be tested in a split-mouth design.
3203203|NCT01175707|Experimental|Daptomycin|500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted
3203204|NCT01175707|Active Comparator|Vancomycin|Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician
3203205|NCT01175694|Active Comparator|Brachytherapy|Interstitial multicatheter brachytherapy
3203206|NCT01175681|Experimental|treatment|remote ischaemic preconditioning
3203207|NCT01175681|No Intervention|untreated|control
3203208|NCT01175668|Experimental|NMS/Clonidine|
3203209|NCT01175668|Active Comparator|NMS/Phenobarbital|
3203210|NCT01175655|Experimental|MSC|
3203211|NCT01175642|Experimental|Cognitive remediation|Cognitive remediation
3203212|NCT01175642|Active Comparator|Functional Adaptive Skills Training|Functional and social skills group treatment
3203213|NCT01175642|Active Comparator|Combined Treatment|Combined cognitive remediation and functional adaptive skills training
3203214|NCT01175629||Group 1|The Vietnam Era Twin (VET) Registry is a closed cohort composed of 7,369 middle-aged male-male twin pairs both of whom served in the military during the time of the Vietnam conflict (1965-1975). The Registry is a United States Department of Veterans Affairs resource that was originally constructed from military records; the Registry has been in existence for more than 15 years. It is one of the largest national twin registries in the US and currently has subjects living in all 50 states. Initially formed to address questions about the long-term health effects of service in Vietnam the Registry has evolved into a resource for genetic epidemiological studies of mental and physical health conditions. Several waves of mail and telephone surveys have collected a wealth of health-related information on Registry twins. Other data collection efforts have focused on specific sets of twin pairs and conducted detailed clinical or laboratory testing.
3203215|NCT01175616|Experimental|Creatine|Open-Label Active Treatment with Creatine 5 grams daily for 8 weeks.
3203216|NCT01175603|Experimental|Cognitive behavioral intervention|Women in the intervention condition will receive 6 two-hour intervention sessions delivered weekly in a group format by the Study Clinician. Each session contains didactic instruction on core content, as well as activities and group discussion. One of the strengths of embedding the MB Course within home visiting is our ability to have home visitors reinforce the material presented by the Study Clinician. The 6-week curriculum is divided into three modules: (a) pleasant activities, (b) thoughts, and (c) relationships with others. Each module has two sessions. These sessions map onto core cognitive-behavioral concepts.
3203217|NCT01175603|No Intervention|Usual home visiting|Women in the control group will receive usual home visiting services and information on postpartum depression.
3203218|NCT01175590|Experimental|Besivance|besifloxacin ophthalmic suspension 0.6%
3203219|NCT01175590|Placebo Comparator|Vehicle|Vehicle of Besivance
3203220|NCT01175577|Active Comparator|Supplement 1|
3203221|NCT01175577|Active Comparator|Supplement 2|
3203222|NCT01175577|Active Comparator|Food-based Intervention|
3203223|NCT01175577|Placebo Comparator|Placebo|
3203224|NCT01175564|Experimental|Active|Each cohort will have 9 volunteers that will receive TC-5214
3203225|NCT01175564|Placebo Comparator|Placebo|Each cohort will have 3 volunteers that will receive placebo
3203226|NCT01175551||Group 1|women screened at Penn OB/GYN Associates or Helen O. Dickens Center with a documented singleton pregnancy less than 18 weeks gestational age
3203227|NCT01175551||Group 2|Nulliparous pregnant women (no previous pregnancy greater than 15 weeks) screened at Penn OB/GYN Associates or Helen O. Dickens Center less than 18 weeks gestational age
3203228|NCT01175538|Experimental|Lactulose|
3203229|NCT01175525|Placebo Comparator|sugar pill|sugar pill dissolved in water to be given 4 times a day 30 minutes prior to meals
3203230|NCT01175525|Active Comparator|Cromolyn|Cromolyn dose of 200mg(dissolved in water) will be given 4 times a day(30 minutes before a meal)
3203231|NCT01175512|Placebo Comparator|Placebo|
3203232|NCT01175512|Active Comparator|Naltrexone|
3203233|NCT01175486|Experimental|Actos|Actos 30 mg for 6 months
3203234|NCT01175486|Active Comparator|Acarbose|Acarbose 50mg tid for 6 months
3203235|NCT01175473|Experimental|Lixisenatide|1-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 2 weeks, followed by 20 mcg QD for up to Week 4.
3203236|NCT01175473|Active Comparator|Liraglutide|2-step initiation regimen of liraglutide: 0.6 milligram (mg) QD subcutaneously for 1 week, followed by 1.2 mg QD for 1 week, then 1.8 mg QD up to Week 4.
3203237|NCT01175460|Experimental|Chemoradiotherapy|Thoracic radiation 60Gy over 30 fractions.Concurrently, nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 was given on Days 1-14,repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
3203238|NCT01175447|Experimental|Chemoradiotherapy with S-1|radiation 54Gy over 30 fractions,and concurrent with s-1 on days 1-14 and 29-42
3203239|NCT01175434|Experimental|School-Based Medication Group|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse will begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
3203240|NCT01175434|No Intervention|Usual Care Group|Children in the Usual Care group will not receive preventive medications delivered at school. These children will continue to receive all of their asthma care from their parents and primary care physicians.
3203241|NCT01175421||Patients undergoing sleep study|
3203242|NCT01175408|Active Comparator|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
3203243|NCT01175408|Active Comparator|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will send the data to their endocrinologist and receive feedback based on the uploaded glucose data.
3203244|NCT01175408|Active Comparator|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
3203245|NCT01175408|Active Comparator|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
3203246|NCT01175395|Experimental|IBI-20089/Lucentis|Alternate treatment of either 6.9 mg IBI-20089/Lucentis or 13.8 mg IBI-20089/Lucentis
3203288|NCT01175109|Experimental|Escalating doses of imatinib and LBH589|"Study will incorporate a 3+3 dose escalation design."
3203549|NCT01173250|Placebo Comparator|stapled ileoanal pouch with diverting ileostomy|
3203247|NCT01175382|Active Comparator|Behavioral Treatment alone|Behavioral treatment is implemented in 4 clinic visits over a period of 6 weeks, followed by 6 weeks of combined behavioral + drug therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and daily bladder diaries, supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
3203248|NCT01175382|Active Comparator|Drug Therapy (Tolterodine + tamsulosin)|Drug therapy for 6 weeks implemented in a clinic visit with telephone follow-up at 3 weeks, followed by 6 weeks of combined drug + behavioral therapy. Participants in the drug group will receive an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
3203249|NCT01175382|Experimental|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
3203250|NCT01175369|No Intervention|Usual Care|Usual asthma care
3203251|NCT01175369|Experimental|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
3203252|NCT01175356|Experimental|Treatment (131I-MIBG, chemotherapy)|See Detailed Description.
3203253|NCT01175343|Experimental|Treatment (RO4929097)|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected for correlative studies. Ascitic fluid may also be collected."
3203254|NCT01175330|Placebo Comparator|CABG and intralipid infusion|Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Intralipid Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
3203255|NCT01175330|Active Comparator|CABG and omega-3 fatty acid infusion|Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Omegaven Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
3203256|NCT01175317|Experimental|Goal-directed fluid optimization|Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
3203257|NCT01175317|Other|Regimen based on expertise anaesthesist|Fluid regimen based on expertise anaesthesist
3203258|NCT01175304||Workers in a Barcelona tertiary hospital|Workers attending annual medical checkups
3203259|NCT01175291|Active Comparator|Arm A - FOLFOX 7 + MK-0646|
3203260|NCT01175291|Placebo Comparator|Arm B - FOLFOX 7 + Placebo|
3203261|NCT01175278|No Intervention|Observation Arm|Patients who are asymptomatic (no symptoms) will participate in the observational portion of the study.
3203262|NCT01175278|Experimental|Balloon Kypholasty|
3203263|NCT01175278|Active Comparator|Control Arm|Non-surgical Management Treatment Group
3203264|NCT01175265|No Intervention|pulmonary rehabilitation, no breathing retraining|Forty COPD patients (23 females) with a mean (SD) age of 66.0 (6.3) years and a FEV1 of 47.1 (18.9) % predicted were randomized to conventional pulmonary rehabilitation (n=20) and conventional pulmonary rehabilitation plus breathing retraining (n=20).
3203265|NCT01175265|No Intervention|breathing retraining|Forty COPD patients (23 females) with a mean (SD) age of 66.0 (6.3) years and a FEV1 of 47.1 (18.9) % predicted were randomized to conventional pulmonary rehabilitation (n=20) and conventional pulmonary rehabilitation plus breathing retraining (n=20).
3203266|NCT01175252||Gastroenteritis Cohort|All children suffering with gastroenteritis
3203267|NCT01175239|Experimental|Single infusion of autologous CD34+ cells|
3203268|NCT01175226|Experimental|BTA798|
3203269|NCT01175226|Placebo Comparator|Placebo|
3203270|NCT01175213|Experimental|IGSC - rHuPH20 then IGSC or IGIV|"Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20). Participants then went into a safety follow-up with either SC administration of IGSC, 10% or intravenous (IV) administration of Immune Globulin Intravenous (Human) (IGIV), 10%, only. The IV or SC administration route was at the discretion of the participant and the investigator.~Note: IGIV, 10% is the same product as IGSC, 10%."
3203271|NCT01175213|Experimental|IGIV, 10% only|"Participants were treated with Immune Globulin Intravenous (Human) (IGIV), 10% only, via the intravenous (IV) route throughout the study.~Note: IGIV, 10% is the same product as IGSC, 10%."
3203272|NCT01175200|Active Comparator|Prasugrel|
3203273|NCT01175200|Active Comparator|Clopidogrel|
3203274|NCT01175200|Active Comparator|Lansoprazole|proton pump inhibitor
3203275|NCT01175200|Placebo Comparator|Placebo|
3203276|NCT01175187||EPIDURAL FEVER|
3203277|NCT01175187||EPIDURAL WITHOUT FEVER|
3203278|NCT01175187||GROUP 1: EPIDURAL FEVER . GROUP 2 EPIDURAL WITHOUT FEVER|
3203279|NCT01175161|Experimental|Immediate postpartum IUD insertion|Women assigned to have the IUD placed 10 minutes to 48 hours postpartum
3203280|NCT01175161|Experimental|6 week postpartum IUD insertion|Women who receive the IUD at the traditional time frame.
3203281|NCT01175148|Experimental|Recipient - Atorvastatin to prevent GVHD|Atorvastatin calcium (Lipitor) will be administered at dose of 40mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning. Patients will receive atorvastatin until +180 days or development of grade 2 GVHD. This is the experimental arm for outcome measures.
3203282|NCT01175148|Other|Donor - Atorvastatin conditioning for donors|Sibling donors will start taking Atorvastatin calcium (Lipitor) orally at 40mg once daily between 14-28 days before the anticipated first day of apheresis or bone marrow harvest.
3203289|NCT01175096|Active Comparator|RAD001|2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day Dose level modifications/interruptions must follow guidelines. One treatment cycle consists of 28 days.
3203290|NCT01175083|Experimental|<6S|Children below 6 months of age with sickle cell disease
3203291|NCT01175083|Active Comparator|<6NS|Healthy children below 6 months of age
3203292|NCT01175083|Experimental|7-11S|Children between 7-11 months of age with sickle cell disease
3203293|NCT01175083|Active Comparator|7-11NS|Healthy children between 7-11 months of age
3203294|NCT01175083|Experimental|12-23S|Children between 12-23 months of age with sickle cell disease
3203295|NCT01175083|Active Comparator|12-23NS|Healthy children between 12-23 months of age
3203296|NCT01175070|Experimental|Pegaptanib|Participants receiving 6-weekly treatment with pegaptanib sodium (Macugen [TM]) for ischaemic diabetic macular oedema over a 30 week period.
3203297|NCT01175057||Group A|10 patients who undergo home monitoring with the MeDiNa Homebox for 4 weeks and then 4 weeks without the MeDina Homebox
3203298|NCT01175057||Group B|Group B starts without the MeDiNa Homebox for 4 weeks and then undergo Homemonitoring with the MeDiNa Homebox for 4 weeks.
3203299|NCT01175044|Active Comparator|Betadine Lavage|dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000ml of sterile saline irrigation
3203300|NCT01175044|Placebo Comparator|Saline Lavage|2000 ml sterile saline lavage alone
3203301|NCT01175031|Experimental|REMstar Auto with A-Flex|Manipulation of positive airway pressure (PAP) will occur throughout the night to induce breaking events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced, and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night. Events will be measured with REMstar Auto with A-Flex.
3203302|NCT01175031|Other|Manually Scored Polysomnography (PSG)|Manipulation of positive airway pressure (PAP) will occur throughout the night to induce breaking events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced, and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night. Events will be Manually Scored Polysomnography (PSG).
3203303|NCT01175018|Experimental|Anakinra|Anakinra 100 mg injectable subcutaneously daily
3203304|NCT01175018|Placebo Comparator|Placebo|0.67 ml of sodium chloride (NaCl) 0.9% solution
3203305|NCT01175005||Fever and a central venous catheter|
3203306|NCT01174992|Experimental|Evicel|
3203307|NCT01174992|Other|Sutures only|
3203308|NCT01174979|Experimental|Caroverin|
3203309|NCT01174979|Placebo Comparator|Placebo|
3203310|NCT01174966||Survivor Nonsurvivor|
3203311|NCT01174953|Other|Finasteride plus soy|Finasteride and soy
3203312|NCT01174940|Experimental|Extracorporeal Photopheresis|Patients will receive 2 ECP treatments on day -10 and day -8 and then for two consecutive days every two weeks starting from post engraftment (ANC > 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.
3203313|NCT01174927|Active Comparator|Heroin-dependent patients_1|daily dose of diacetylmorphine (30 mg to 500 mg) in 5 ml
3203314|NCT01174927|Placebo Comparator|Heroin-dependent patients_2|5 ml saline
3203315|NCT01174914|Experimental|Naltrexone Low-dose 3mg capsule|Each person in this arm 1 of the study had never received any ARV drugs and in this study received only one Low-Dose Naltrexone 3mg capsule nightly for 9 months (no placebo).
3203316|NCT01174914|Active Comparator|Naltrexone Low Dose + ARVs|In this Arm 3, Patients were on ARV's plus being given Naltrexone Low-Dose (3mg) once daily at bedtime for 9 months.
3203317|NCT01174914|Placebo Comparator|ARV's (continued,standard) plus Placebo|In this arm 2, patients were started or continued on their standard ARV drugs plus placebo capsule once daily at bedtime; in the 2nd and 3rd arms patients did not know whether they were taking Low-Dose Naltrexone or a placebo.
3203318|NCT01174888|Experimental|GROUP I (Dose levels 1-2):|Patients receive midostaurin orally (PO) twice daily on days 1-14 and bortezomib intravenously (IV) on days 1, 4, 8, and 11. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3203319|NCT01174888|Experimental|GROUP II (Dose levels 3-6)|Patients receive mitoxantrone hydrochloride IV over 10 minutes, etoposide IV over 1 hour, and cytarabine IV over 6 hours on days 1-6. Patients also receive midostaurin PO twice daily on days 8-21 and bortezomib IV on days 8, 11, 15, and 18. Treatment continues in the absence of disease progression or unacceptable toxicity.
3203320|NCT01174875||Pregnant mothers, infants and children|Women in their early pregnancy who are attending the first trimester antenatal ultrasound scan at the public maternity units at KK Women's and Children's Hospital (KKH) and National University Hospital (NUH). Only women age 18 years and above who are Singapore Citizens or Singapore Permanent Residents. Participants have to intend to eventually deliver in NUH or KKH and to reside in Singapore for the next 5 years. Willingness to donate cord, cord blood and placenta. The fetus should be racially homogenous with both sets of grandparents of the same ethnicity. Babies born from these mothers will be followed up until the child is at least 9 years of age.
3203321|NCT01174862||Aspirin responder|Normal aspirin responsiveness in ASPI test (Multiplate)
3203322|NCT01174862||Aspirin non-responder|Reduced aspirin responsiveness in ASPI test (Multiplate)
3203323|NCT01174849|Active Comparator|Synflorix|
3203324|NCT01174849|Active Comparator|Prevenar13|
3203325|NCT01174849|Experimental|COMBO|COMBINATION SCHEDULE of comparator vaccine 1 and comparator vaccine 2 Synflorix at 1,2,4 months then Prevenar13 at 6 months.
3203326|NCT01174823|Experimental|Bepotastine Besilate Ophthalmic Solution|
3203327|NCT01174823|Placebo Comparator|Placebo|
3203328|NCT01174810|No Intervention|Control|
3203329|NCT01174810|Experimental|Exenatide|
3203330|NCT01174797||Patients being evaluated for active ischemia|Subjects with known or suspected CAD who are scheduled to undergo routine exercise MPI or stress echocardiography for the detection of active ischemia are eligible for enrollment.
3203331|NCT01174771||PSP patients|People that have been clinically diagnosed with atypical parkinsonism, i.e., PSP
3203332|NCT01174771||CBD patients|People that have been clinically diagnosed with atypical parkinsonism, i.e., CBD
3203333|NCT01174771||Age-matched healthy controls|People that have not been diagnosed with any kind of neurologic movement disorder.
3203380|NCT01174433|Experimental|Tryton bifurcation stent system|
3203334|NCT01174758||Parkinson's disease|Individuals participating in the study have been diagnosed with idiopathic Parkinson's disease.
3203335|NCT01174732|Experimental|T1|A006 albuterol inhalation powder, 120 mcg/inhalation, 1 inhalation
3203336|NCT01174732|Experimental|T2|A006 albuterol inhalation powder 180 mcg/ inhalation, 1 inhalation
3203337|NCT01174732|Experimental|T3|A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations
3203338|NCT01174732|Experimental|T4|A006 albuterol inhalation powder 180 mcg/inhalation, 2 inhalations
3203339|NCT01174732|Placebo Comparator|P|Placebo, 2 inhalations
3203340|NCT01174732|Active Comparator|R1|Proventil 90 mcg/inhalation, 2 inhalations
3203341|NCT01174732|Active Comparator|R2|Proventil 90 mcg/inhalation, 4 inhalations
3203342|NCT01174719|Active Comparator|Hydroxyethylstarch|
3203343|NCT01174719|Active Comparator|Humanalbumin|
3203344|NCT01174719|Active Comparator|Ringer lactate|
3203345|NCT01174706|Experimental|Usual care arm|Patients randomized to this group will receive usual care. Usual care at the three study sites varies but will be defined as whatever information is usually given to patients regarding the prescription medication or over the counter medicine they were prescribed at emergency department discharge.
3203346|NCT01174706|Experimental|Information prescription|Patients randomized to this arm will receive written information from Medline Plus regarding the prescription or over the counter medicine they have been prescribed at ED discharge plus information on their health condition.
3203347|NCT01174706|Experimental|Informationist|Patients in this arm will receive the same information as patients in group 2 but will also be given contact information for a clinical informationist if they have further questions about their prescription medicine or over the counter medicine prescribed at ED discharge.
3203348|NCT01174706|Experimental|practical assistance|Subjects will be offered practical assistance with obtaining prescription such as location of most convenient pharmacy and hours of operation, programs that offer drugs more cheaply, fax prescription from ED to pharmacy
3203349|NCT01174693|Active Comparator|Clopidogrel|Plavix® 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014
3203350|NCT01174693|Experimental|Triflusal|Disgre® 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014
3203351|NCT01174680|Experimental|patients with stable angina pectoris|stable patients, who have been admitted to one of the participating centres for an elective coronary angiography
3203352|NCT01174667|Experimental|Fascial massage|A specific type of fascial massage to release restricted lumbodorsal fascia.
3203353|NCT01174667|No Intervention|No treatment control|Patient will rest quietly without receiving any instruction.
3203354|NCT01174654|No Intervention|Referral to community resources|
3203355|NCT01174654|Experimental|Contingency Management|
3203356|NCT01174641|Experimental|TMS intervention|Trans-cranial magnetic stimulation will be applied at a 1Hz rate for 20min over the ipsilesional posterior parietal cortex of patients showing left neglect after a right hemisphere stroke
3203357|NCT01174641|Placebo Comparator|Placebo TMS|1 Hz trans-cranial magnetic stimulation will be applied over the vertex
3203358|NCT01174602|Experimental|Exposure Therapy for AN (AN-EX/RP)|Exposure Therapy and Ritual Prevention (AN-EX/RP) includes 12 sessions of confronting feared eating situations without the use of anxiety reducing behaviors.
3203359|NCT01174602|Active Comparator|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT)
3203360|NCT01174589|Other|6 weeks of physical training|The 6 weeks of physical training consists of muscle strength training of both legs, balance and coordination exercises 2 times a week.
3203361|NCT01174589|Other|12 weeks of physical exercise|The 12 weeks of physical training consists of muscle strength training of both legs, balance and coordination exercises 2 times a week.
3203362|NCT01174576|Experimental|caffeinated coffee|200 mL caffeinated coffee with 3 mg caffeine per kg body weight
3203363|NCT01174576|Experimental|decaffeinated coffee|200 mL decaffeinated coffee, same amount as caffeinated coffee
3203364|NCT01174576|Experimental|Water|200 mL, control intervention
3203365|NCT01174563|Experimental|Single Arm|
3203366|NCT01174550|Active Comparator|Functional diagnostic tests|Stress Echocardiogram Nuclear Stress Test Exercise Electrocardiogram
3203367|NCT01174550|Active Comparator|Anatomic diagnostic test|Coronary Angiography
3203368|NCT01174524|Experimental|gestoden and ethinylestradiol|"Gestoden 60 mcg plus ethinylestradiol 15 mcg, once a day, administered in 24∕4 regimen, for three months.~The use of gestoden and ethinylestradiol can do an improvement of the quality of life before and after the use of the drug.Numerous large clinical trials have shown that this combination is as effective in preventing pregnancies as other oral contraceptives presently on the market. Irregular bleeding and spotting rates appear to be at least as good as older formulations. In general, the incidence of side effects associated with the progestin and estrogen components tends to be low, with very little impact on lipid and carbohydrate metabolism. . For this, the regimen can ameliorate the quality of life of the patients."
3203369|NCT01174511|Experimental|A-1 COOL cream|"A research product - A-1 COOL cream contain herbal medicine plants basically :~WATER PETROLATUM~WILD YAM (DIOSCOREA VILLOSA) EXTRACT~SORBITAN SESQUIOLEATE~CALENDULA OFFICINALIS EXTRACT~MINERAL OIL~ARNICA MONTANA EXTRACT~MICROCRYSTALLINE WAX~LICORICE (GLYCYRRHIZA GLABRA) EXTRACT~DECYL OLEATE~DICOCOYL PENTAERYTHRITYL DISTEARYL CITRATE~BEESWAX~ALUMINUM STEARATES"
3203370|NCT01174511|Placebo Comparator|Vaselin ointment|Using the study as placebo.
3203371|NCT01174498|Active Comparator|t-VNS sytem Vagus stimulation|Subjects experience a transcutaneous vagal stimulation by the t-VNS device
3203372|NCT01174498|Sham Comparator|Sham transcutaneous stimulation|Sham stimulation with an attached t-VNS device
3203373|NCT01174485|Experimental|exercise|exercise plus liposuction
3203374|NCT01174485|No Intervention|sedentary|physical inactivity plus liposuction
3203375|NCT01174472|Active Comparator|Conventional Balloon Angioplasty (COBA)|Patients with lesions treated with conventional balloon angioplasty
3203376|NCT01174472|Experimental|Drug Eluting Balloon Angioplasty (DEB)|Patients with lesions treated with Drug Balloon Angioplasty
3203377|NCT01174459||Patient with Restless Legs Syndrome|
3203378|NCT01174446|Experimental|BAX 326|Recombinant factor IX (rFIX)
3203379|NCT01174446|Active Comparator|BeneFIX|Recombinant Factor IX (rFIX)
3203384|NCT01174394|Experimental|DCEAS|"Body electroacupuncture plus dense cranial electroacupuncture stimulation (DCEAS)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
3203385|NCT01174394|Placebo Comparator|n-CEA|"Body electroacupuncture plus non-invasive cranial electroacupuncture (n-CEA)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
3203386|NCT01174381|Experimental|Lifestyle modification|Lifestyle modification for behavior change related to NCD prevention
3203387|NCT01174368|Experimental|Cancer macrobeads|Cancer Macrobead placement in abdominal cavity
3203388|NCT01174355|Experimental|ND0801|
3203389|NCT01174342||Pregnant women|Healthy pregnant women
3203390|NCT01174329|Experimental|"Patient-regulated neuro-electrostimulation by Saliwell Crown"|"Patient regulated (by a remote control) neuro-electrostimulation by Saliwell Crown"
3203391|NCT01174329|Active Comparator|"Automatic neuro-electrostimulation by Saliwell Crown"|No remote control used
3203392|NCT01174316|Experimental|autotitrating NIV|approximately 24 hours using autotitrating non-invasive ventilation for as many hours as possible whilst an inpatient in hospital
3203393|NCT01174316|Active Comparator|Standard non-invasive ventilation|approximately 24 hours using standard non-invasive ventilation for as many hours as possible whilst an inpatient in hospital.
3203394|NCT01174303|Experimental|IDegAsp - BIAsp|
3203395|NCT01174303|Experimental|BIAsp - IDegAsp|
3203396|NCT01174290|Experimental|Haloperidol 1mg IV q6h|
3203397|NCT01174290|Placebo Comparator|D5W 0.2mL IV q6h|
3203398|NCT01174277||Collection of blood sample|Blood draw
3203399|NCT01174264|Experimental|Arm I (vismodegib on empty stomach)|Patients receive a single dose of vismodegib PO on an empty stomach. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28.
3203400|NCT01174264|Experimental|Arm II (vismodegib after high fat meal)|Patients receive a single dose of vismodegib PO after eating a high fat meal. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28.
3203401|NCT01174264|Experimental|Arm III (vismodegib after low fat meal)|Patients receive a single dose of vismodegib PO after eating a low fat meal. Beginning 7 days later, patients receive vismodegib PO after eating a meal daily on days 1-28.
3203402|NCT01174238|Experimental|Arm A|Patients enrolled in Arm A and Arm B will receive the same treatment with study drugs axitinib, carboplatin, and paclitaxel. Patients enrolled in Arm A and Arm B will have tumor imaging assessments: PET-CT, CT Scan, and/or MRI. In addition patients enrolled in Arm A will also have FLT-PET scans.
3203403|NCT01174238|Experimental|Arm B|Patients enrolled in Arm A and Arm B will receive the same treatment with study drugs axitinib, carboplatin, and paclitaxel. Patients enrolled in Arm A and Arm B will have tumor imaging assessments: PET-CT, CT Scan, and/or MRI. Patients enrolled in Arm B will not have FLT-PET scans.
3203404|NCT01174225|Active Comparator|I|Participants who elect to have an IUD inserted at the time of abortion will be randomized to either Arm I or Arm II. In this arm participants will receive the Flexi T 380(+) IUD. The participant is counseled that she may leave the device in for up to five years. She will be followed for up to five years to determine expulsion rate, discontinuation rate, pregnancy rate, and overall satisfaction with form of contraception.
3203405|NCT01174225|Active Comparator|II|Participants who elect to have an IUD inserted at the time of abortion will be randomized to either Arm I or Arm II. In this arm participants will receive the Nova T IUD. The participant is counseled that she may leave the device in for up to five years. She will be followed for up to five years to determine expulsion rate, discontinuation rate, pregnancy rate, and overall satisfaction with form of contraception.
3203406|NCT01174225|No Intervention|III|"Participants who elect for forms of contraception other than a copper IUD will chose which form of contraception they would like to use and be put into one of the groups specified below based on her contraceptive choice. These participants will be observed throughout the study for overall satisfaction and repeat pregnancy rate.~Groups - Participants will be in one of the five following groups Group A - Oral contraceptive pill 28day supply provided after abortion Group B - Medroxyprogesterone acetate (Depo-provera)150mg IM provided after abortion, lasts for 3 months Group C - Ethinyl estradiol and etonogestrel (Nuva ring) provided at time of abortion, lasts for 28 days Group D - Condoms provided at time of abortion Group E - Other"
3203407|NCT01174212|Experimental|Experimental|Patients receiving antibiotics approximately 1 hour prior to incision are considered to be in the experimental group of this study.
3203408|NCT01174212|Other|Control|Control group is to receive no antibiotics until the intraoperative cultures have been obtained.
3203409|NCT01174199|Experimental|Arm I|Patients receive oral vorinostat once daily on days 1-14 and temsirolimus IV on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3203410|NCT01174186|Active Comparator|Spondyloarthritis and calprotectin elevated|Spondylitis patients with elevated levels of fecal calprotectin. Patients are treated with adalimumab
3203411|NCT01174186|Active Comparator|Spondyloarthritis and calprotectin normal|Spondylitis patients with normal levels of fecal calprotectin. Patients are treated with adalimumab.
3203412|NCT01174173|Experimental|Ranolazine|1000 mg PO BID
3203413|NCT01174160|Experimental|vernakalant HCl|vernakalant hydrochloride
3203414|NCT01174160|Placebo Comparator|placebo|placebo
3203415|NCT01174147||Hospital Candida Cases|People who developed a positive blood culture for Candida while hospitalized
3203416|NCT01174134|Placebo Comparator|Milk-based beverage w/out DHA|
3203417|NCT01174134|Experimental|Milk-based beverage with DHA|
3203418|NCT01174134|Experimental|Milk-based beverage containing DHA at a higher level|
3203419|NCT01174121|Experimental|Arm 2|Young unselected TIL (CLOSED)
3203420|NCT01174121|Experimental|Arm 4|Young unselected TIL + pembrolizumab at time of progression for a total of 4 doses.
3203636|NCT01172600|Active Comparator|Entonox|Patients will receive inhaled Entonox along with the interventional block they are scheduled.
3203421|NCT01174121|Experimental|Arm 3|Young unselectedTIL + pembrolizumab prior to cell administration and continuing for a total of 4 doses (CLOSED)
3203422|NCT01174121|Experimental|Arm 1|Young CD8+ enriched TIL (CLOSED)
3203423|NCT01174108|Experimental|1|Target doses: CD34+ cells 8 x 106/kg; CD3+ cells 2 x 107/kg
3203424|NCT01174095||Follow-up Group|"Subjects who received AdGVVEGF121cDNA in either IRB protocol #0794-894 entitled Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Diffuse Coronary Artery Disease or IRB protocol #0297-693 entitled Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Diffuse Coronary Artery Disease Via Minimally Invasive Surgery."
3203425|NCT01174082|Experimental|KLH Vaccine (Patient)|After DLI on same day, patients receive vaccine according to donor randomization (the same type of vaccine that their donors received).
3203426|NCT01174082|Experimental|KLH-id Vaccine (Patient)|After DLI on same day, patients receive vaccine according to donor randomization (the same type of vaccine that their donors received).
3203427|NCT01174082|Experimental|KLH Vaccine (Donor)|Donor Group 1: (non-specific vaccination) vaccinated with KLH only vaccine 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.
3203428|NCT01174082|Experimental|Vaccine KLH-id (Donor)|Donor Group 2: (myeloma specific vaccination) vaccinated with KLH-id vaccine 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collections.
3203429|NCT01174069|Experimental|NOTES cholecystectomy|
3203430|NCT01174056|Experimental|Pioglitazone+zileuton placebo|Pioglitazone 45 mg qD for 2 weeks plus Sugar pill q6hr for 5 days
3203431|NCT01174056|Experimental|Zileuton+pioglitazone placebo|Sugar pill qD for 2 weeks plus Zileuton 600 mg q6hr for 5 days
3203432|NCT01174056|Sham Comparator|Pioglitazone placebo+zileuton placebo|Sugar pill qD for 2 weeks plus Sugar pill q6hr for 5 days
3203433|NCT01174043|Experimental|Erlotinib|
3203434|NCT01174030|Experimental|CD07805/47 Gel 0.5% QD|
3203435|NCT01174030|Experimental|CD07805/47 Gel 0.18% QD|
3203436|NCT01174030|Experimental|CD07805/47 Gel 0.18% BID|
3203437|NCT01174030|Placebo Comparator|Vehicle Gel QD|
3203438|NCT01174030|Placebo Comparator|Vehicle Gel BID|
3203439|NCT01174017|Active Comparator|Standard loose Iodine 125 seeds|Prostate brachytherapy implant to be performed with standard format loose Iodine 125 seeds
3203440|NCT01174017|Experimental|AnchorSeed Iodine 125 implant|Prostate brachytherapy implant to be performed with a new design of Iodine 125 seed that has a coating to increase adherence to tissue
3203441|NCT01174004|Experimental|1|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
3203442|NCT01174004|Placebo Comparator|2|placebo, tablet, once daily by mouth for 6 weeks
3203443|NCT01173991|Experimental|Carbohydrate counting|This group received carbohydrate counting training
3203444|NCT01173991|No Intervention|Controls|This group received standard education
3203445|NCT01173978|Experimental|No intervention|Each participant is examined during a normal, active lifestyle, without any intervention: The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl
3203446|NCT01173978|Experimental|Intervention|Each participant is examined during a 12 days intervention.The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl
3203447|NCT01173965|Active Comparator|Endometrial ablation with microwaves|Endometrial ablation with the use of MEA(microwaves endometrial ablation device)
3203448|NCT01173965|Active Comparator|Endometrial ablation with bipolar diathermy|Endometrial ablation with Novasure(bipolar impedence control system)
3203449|NCT01173939|Active Comparator|Active comparator: Standard Pravastatin Group|
3203450|NCT01173939|Active Comparator|Intensive Rosuvastatin Group|
3203451|NCT01173926|Experimental|IAsp|
3203452|NCT01173926|Experimental|IDeg|
3203453|NCT01173926|Experimental|IDegAsp|
3203454|NCT01173913|Experimental|ModraDoc001 10 mg capsules|The optimal dose weekly bi-daily oral docetaxel - ModraDoc001 10 mg in combination with ritonavir will be determined with a classical dose escalation design. Approximately 24 patients will be enrolled depending on required number of dose levels before MTD is reached.
3203455|NCT01173913|Experimental|ModraDoc003 10mg tablets and ModraDoc004 10/50 mg|Both new oral dosage forms, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets will be investigated to see whether these new formulations have comparable pharmacokinetic characteristics, in terms of systemic exposure to docetaxel, as ModraDoc001 10 mg capsule.
3203456|NCT01173913|Experimental|ModraDoc006 10 mg tablet|The optimal dose weekly bi-daily oral docetaxel - ModraDoc006 10 mg in combination with ritonavir will be determined with a classical dose escalation design. Approximately 24 patients will be enrolled depending on required number of dose levels before MTD is reached.
3203457|NCT01173900|Other|Class-based delivery|All girls attending standard 6 in schools selected for class-based vaccine delivery
3203458|NCT01173900|Other|Age-based delivery|All girls born in 1998 attending schools selected for age-based delivery
3203459|NCT01173887|Active Comparator|mLSG15|
3203460|NCT01173887|Experimental|mLSG15 + KW-0761|
3203461|NCT01173874|Experimental|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
3203462|NCT01173874|No Intervention|Cognitive activity control group|This is a non-specific mental activity control condition, conducted two times per week for a total of 30 sessions.
3203463|NCT01173861|Experimental|Physical activity counseling|Group receives face-to-face physical activity counseling.
3203464|NCT01173861|Active Comparator|Manual|Group receives physical activity manual.
3203465|NCT01173848|Active Comparator|Vitamin D2|Patients randomized to take vitamin D2
3203466|NCT01173848|Active Comparator|Vitamin D3|Patient's randomized to take Vitamin D3
3203467|NCT01173822|Experimental|Treatment group|Ultra filtration of residual blood.
3203468|NCT01173822|No Intervention|Control|The current practice in our institution was to displace all the remaining volume in the CPB circuit into a transfer pack by displacing the remaining blood in the CPB circuit with additional Lactated Ringers solution. This transfer pack is then given to the anesthetist for reinfusion into the patient.
3203469|NCT01173809|Active Comparator|Control|Patient will continue taking Amiodarone before, during and after catheter ablation (8 weeks post-ablation).
3203470|NCT01173809|Active Comparator|Study|Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
3203471|NCT01173796|Experimental|PMFL ablation|Radio-frequency catheter ablation of the mitral isthmus only
3203472|NCT01173796|Experimental|Repeat PVAI and triggers ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
3203473|NCT01173770|Experimental|Cohort 1: ADC3680B vs. Placebo|
3203474|NCT01173770|Experimental|Cohort 2: ADC3680B vs. Placebo|
3203475|NCT01173770|Experimental|Cohort 3: ADC3680B vs Placebo|
3203476|NCT01173770|Experimental|Cohort 4: ADC3680B vs. Placebo|
3203477|NCT01173770|Experimental|Cohort 5: ADC3680B vs. Placebo|
3203478|NCT01173770|Experimental|Cohort 6: ADC3680B|
3203479|NCT01173757|Experimental|PF-04995274|
3203480|NCT01173744|Experimental|Gamma-3 Nail|
3203481|NCT01173744|Active Comparator|DHS|
3203482|NCT01173731|Experimental|AFQ056|
3203483|NCT01173718|Experimental|GORE® ACUSEAL Vascular Graft|
3203484|NCT01173705||Normal weight: abdominal surgery|Lean individuals undergoing elective abdominal surgery
3203485|NCT01173705||Obese: abdominal or bariatic surgery|Obese subjects undergoing elective abdominal or bariatric surgery
3203486|NCT01173692|Placebo Comparator|Placebo|Twice Daily Orally
3203487|NCT01173692|Experimental|Minocycline|100 mg Twice Daily Orally
3203488|NCT01173679|Other|dasatinib, rituximab, fludarabine|Single-arm, open-label
3203489|NCT01173666|Placebo Comparator|Drug therapy|Patients will be treated by standard medical therapy.
3203490|NCT01173666|Experimental|Drug therapy + stenting angioplasty|Patients will be treated by standard medical therapy + stenting angioplasty of renal artery.
3203491|NCT01173653|Placebo Comparator|Standard EM Smoking Cessation Info|Patients discharged from ER receive pamphlet re: smoking cessation
3203492|NCT01173653|Active Comparator|Patients contact 1-800-QUIT-NOW before leaving ED|Prior the patient leaving the ED, the PI will assist the patient with contacting 1-800-QUIT-NOW, who will help patient to quit smoking.
3203493|NCT01173640|Experimental|Midazolam Alone|Baseline pharmacokinetics. On Study Visit Day 1, subjects will receive a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
3203494|NCT01173640|Experimental|Single dose resveratrol|On Study Visit Day 8, subjects will receive a 1 g oral dose of resveratrol followed 2 hours later by a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
3203495|NCT01173640|Experimental|Multiple dose resveratrol|Between Study Visit Days 8 and 15, subjects will take a 1 g dose of resveratrol daily. On Study Visit Day 15, subjects will receive a 1 g oral dose of resveratrol followed 2 hours later by a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
3203496|NCT01173627|Experimental|A - Test fentanyl citrate 400 mcg troche|Test fentanyl citrate 400 mcg troche
3203497|NCT01173627|Active Comparator|B - Actiq 400 mcg|Actiq 400 mcg
3203498|NCT01173614||Normal subjects|Subjects with two normal eyes.
3203499|NCT01173601|Experimental|12 milligrams (mg) LY2216684 + SSRI|"LY2216684: 12 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the LY2216684 12-mg treatment arm (AT Phase).~Participants who completed the AT Phase or discontinued early entered a 2-week Discontinuation (DC) Phase. Participants were randomly assigned to either abrupt DC or tapered DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
3203500|NCT01173601|Experimental|18 milligrams (mg) LY2216684 + SSRI|"LY2216684: 12 milligrams (mg), administered orally, once daily (QD) for 1 week, followed by 18 mg, administered orally, once daily for 7 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the LY2216684 18-mg treatment arm (AT Phase).~Participants who completed the AT Phase or discontinued early entered a 2-week Discontinuation (DC) Phase. Participants were randomly assigned to either abrupt DC or tapered DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
3203501|NCT01173601|Placebo Comparator|Placebo + SSRI|"Placebo: Tablet equivalent to LY2216684, administered orally, once daily (QD) for 11 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the placebo treatment arm (AT Phase).~Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase. Participants who had received placebo were assigned to the abrupt DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
3203502|NCT01173588|Experimental|Yogurt+fiber+probiotic|Yogurt YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
3203503|NCT01173588|Placebo Comparator|regular yogurt|yogurt YR had no additional fiber or bifidobacterium
3203504|NCT01173575||Bacterial Infection|All Patients with bacterial infection receiving fosfomycin may be included
3203505|NCT01173562|Experimental|Mebendazole|
3203637|NCT01172600|Placebo Comparator|Oxygen|Patients will receive inhaled oxygen along with the interventional block they are scheduled.
3203506|NCT01173549|Experimental|001|no intervention Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
3203507|NCT01173549|Experimental|002|Canagliflozin/Placebo Placebo/Canagliflozin Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).
3203508|NCT01173536|Active Comparator|A|
3203509|NCT01173536|Active Comparator|B|
3203510|NCT01173536|Experimental|C|
3203511|NCT01173523|Experimental|Cohort A: STA-9090|Once weekly IV dosing of STA-9090 200mg/m2 was given weeks 1, 2, and 3 of a 4-week cycle. Participants received treatment until evidence of progressive disease or unacceptable toxicity. Participants were stratified at baseline into 2 distinct prognostic groups. Cohort A participants had relapsed > 60 days following initial chemotherapy completion.
3203512|NCT01173523|Experimental|Cohort B: STA-9090|Once weekly IV dosing of STA-9090 200mg/m2 was given weeks 1, 2, and 3 of a 4-week cycle. Participants received treatment until evidence of progressive disease or unacceptable toxicity. Participants were stratified at baseline into 2 distinct prognostic groups. Cohort B participants had not responded or had relapsed </= 60 days from the completion of initial chemotherapy.
3203513|NCT01173510|Experimental|Raltegravir plus tenofovir/emtricitabine|
3203514|NCT01173510|Active Comparator|Efavirenz/Emtricitabine/Tenofovir|
3203515|NCT01173497|Experimental|INIPARIB, irinotecan|
3203516|NCT01173484||Vomiting-predominant idiopathic gastroparesis|Vomiting with retching and nausea are the most bothersome symptoms
3203517|NCT01173484||Dyspepsia-predominant idiopathic gastroparesis|Unpleasant or troublesome sensation (discomfort or pain) centered in the upper abdomen is the most bothersome symptom; this sensation may be characterized by or associated with upper abdominal fullness, fullness after small meals, bloating, or nausea
3203518|NCT01173484||Regurgitation-predominant idiopathic gastroparesis|Effortless regurgitation of acid or undigested food or heartburn is the most bothersome symptom
3203519|NCT01173471|Experimental|1) AZD4017|Europe: 200 mg AZD4017
3203520|NCT01173471|Placebo Comparator|2) Placebo|Europe: placebo
3203521|NCT01173471|Experimental|3) AZD4017|USA: 800 mg AZD4017
3203522|NCT01173471|Placebo Comparator|4) Placebo|USA: placebo
3203523|NCT01173458||Blood Draw|"Approximately 1 and one-half teaspoons of blood will be drawn at times specified.~one sample prior to treatment initiation~one sample after completion of treatment~one sample every 6 to 8 weeks during follow up visits~one sample at the time of Relapse"
3203524|NCT01173432|Active Comparator|continuous positive airway pressure|using continuous positive airway pressure (CPAP) device during sleep, for the study period (4 weeks)
3203525|NCT01173432|No Intervention|control|observation for the study period (4 weeks, no CPAP)
3203526|NCT01173419|Active Comparator|VenaCure EVLT NeverTouch|
3203527|NCT01173419|Active Comparator|RF ClosureFAST|
3203528|NCT01173406|Sham Comparator|Standard care (SC)|Standard care
3203529|NCT01173406|Active Comparator|Extended education (ME+SC)|Motivational enhancement education + Standard care
3203530|NCT01173393|No Intervention|Standard Treatment|"For patients randomised to hospital cooling:~LMA/ Intubation and ventilation with 100% oxygen~Measure temperature using tympanic probe and record~Insert IV line and administer drugs as per protocol~Fluid challenge with standard temperature saline only as per current guideline (suspected hypovolemia)~Post resuscitation: midazolam 1-5 mg only to maintain LMA/ intubation as needed.~Pancuronium 8 mg only if intubation unable to be maintained with midazolam.~After arrival at the Emergency Department, all patients receive standard care."
3203531|NCT01173380|Sham Comparator|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
3203532|NCT01173380|Active Comparator|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
3203533|NCT01173367|Active Comparator|Aggressive Fever Treatment|
3203534|NCT01173367|Active Comparator|Permissive Fever Treatment|
3203535|NCT01173354|Experimental|COPD patients only|Free balanced amino acid mixture or free essential amino acid mixture
3203536|NCT01173341||Subroup 2|Subgroup2 represents will undergo trastuzumab therapy only
3203537|NCT01173341||Subgroup 1|Subgroup 1 are anthracycline only treated patients.
3203538|NCT01173341||Subgroup 3|Subgroup 3 are patients that will undergo trastuzumab therapy with anthracyclines.
3203539|NCT01173328|Experimental|Pursed-lip Breathing|
3203540|NCT01173315|Experimental|Group MV|Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg
3203541|NCT01173315|Experimental|Group MVB|Group MVB: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg)plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg)
3203542|NCT01173315|Placebo Comparator|Group P|Group P: starch (placebo
3203543|NCT01173302|Experimental|Post vaccination|All the subjects had been vaccinated with antirabies vaccine.
3203544|NCT01173289|Experimental|External Beam Radiotherapy|"Definition of target volume:~Gross tumor volume (GTV) = gross tumor defined with intravenous bolus contrast administration given CT scan~Clinical target volume (CTV) = GTV + included volumes of clinical and suspected subclinical involvement (draining lymph nodes)~Planning target volume (PTV) = CTV + 5-10 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning :~Total dose 65 Gy for gross tumor, 62.4 Gy for microscopic involved area, 58.5 Gy for high risk lymph node area and 52 Gy for elective lymph node area in 26 fractions during 6 weeks~Dose prescription: 90% isodose volume of prescribed dose encompassed PTV~The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the esophagus, lung, contralateral normal thyroid, arytenoids, vocal cord and spinal cord, etc., was calculated."
3203545|NCT01173263|Active Comparator|BIS 70|BIS levels of 70, will be targeted (Anxiolysis/high-frequency EEG activity, beta-augmentation);
3203546|NCT01173263|Active Comparator|BIS 50|BIS levels of 50 will be targeted, (Low frequency EEG activity, theta-delta activity)
3203547|NCT01173263|Active Comparator|BIS 35|BIS levels of 35 will be targeted (low frequency EEG activity)
3203548|NCT01173250|Active Comparator|stapled ileoanal pouch without diverting ileostomy|
3203550|NCT01173237|Active Comparator|Tracheal intubation|Endotracheal tube is a airway device used for ventilation or surfactant administration, in preterm babies with SDR surfactant deficiency.
3203551|NCT01173237|Experimental|Proseal laryngeal mask airway|Laryngeal mask airway is a airway device used for ventilation with self-inflating bag or flow-inflating bag. In this study it will be used for surfactant administration, in preterm babies with SDR surfactant deficiency.
3203552|NCT01173224|Experimental|Cohort 2: 20 mg 10 days|Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg).
3203553|NCT01173224|Experimental|Cohort 3: 30 mg 1 day|Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
3203554|NCT01173224|Experimental|Cohort 1: 20 mg, 1 day|Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg).
3203555|NCT01173211|Experimental|Arm 1: Fluarix®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Fluarix®.
3203556|NCT01173211|Experimental|Arm 3: Fluzone®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Fluzone®.
3203557|NCT01173211|Experimental|Arm 2: Agriflu®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Agriflu®.
3203558|NCT01173198|Active Comparator|WAVEFRONT GUIDED LASIK|
3203559|NCT01173198|Active Comparator|WAVEFRONT OPTIMIZED|
3203560|NCT01173172|Experimental|BNCT, recurrent head and neck cancer|Single arm treated by BNCT only
3203561|NCT01173159|Experimental|Omegaven|Subjects will receive Omegaven at a dose of up to 1 g/kg body weight/day until they no longer require TPN or until their conjugated/direct bilirubin has normalized and their enteral lipid intake is sufficient to discontinue intravenous lipids.
3203562|NCT01173120|Experimental|Abatacept Combination Product (ACP)|Participants from the long-term period of study NCT00559585 who enrolled in the ACP substudy switched to administration of subcutaneous (SC) abatacept via the ACP for the duration of the substudy. Abatacept was administered SC using the ACP by the participant or caregiver on Substudy Day 1 and at weekly intervals thereafter. The ACP was a pre-filled liquid product device delivering 125 mg abatacept/device (125 mg/mL).
3203563|NCT01173107|Experimental|MDRD eGFR 10~50 ml/min/1.73m2|
3203564|NCT01173094|Experimental|PTA|The patients with short-obstruction in the below-knee artery will be included in this group.
3203565|NCT01173094|Experimental|bypass|The patients with long-obstruction in the below-knee artery will be included in this group.
3203566|NCT01173081|Experimental|Teriparatide|Patients randomized into this group will inject 20mcg of teriparatide once daily for 16 weeks or until the study endpoint is achieved. Additionally, patients will take oral calcium (1,000mg) and vitamin D3 (1,000 IU) supplements daily.
3203567|NCT01173081|Placebo Comparator|Placebo Control|Patients randomized into this group will inject a matching dose of placebo once daily for 16 weeks or until the study endpoint is achieved. Additionally, patients will take oral calcium (1,000mg) and vitamin D3 (1,000 IU) supplements daily.
3203568|NCT01173055|Experimental|Milnacipran|Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
3203569|NCT01173055|Experimental|Placebo|Placebo will be given orally twice daily in tablet form at different times during the course of the study.
3203570|NCT01173042|Placebo Comparator|Control|Shake containing heavy whipping cream, glucose and chocolate syrup
3203571|NCT01173042|Experimental|Peanut|Shake containing control (whipping cream, glucose and chocolate syrup) + 3oz of peanuts
3203572|NCT01173042|Experimental|Oil blend|Shake containing control (heavy whipping cream, glucose and chocolate syrup) + oil blend (equivalent to fatty acids provided in 3oz peanuts)
3203573|NCT01173029||Resistant Arterial Hypertension|Subjects with systemic arterial hypertension in whom arterial pressure control was not achieved (24hr ambulatory pressure monitoring: mean 24hr systolic pressure >/=130 mmHg or mean 24hr diastolic pressure >/=80mmHg) by non-investigation specialized hypertensive unit care, in spite of appropriate drug treatment regimen with three or more anti-hypertensive drugs including a diuretic. Anti-hypertensive drug treatment was non-investigational and was prescribed at discretion of the physician who performed primary evaluation.
3203574|NCT01173029||Pseudo-resistant Arterial Hypertension|Subjects with systemic arterial hypertension in whom arterial pressure control was achieved (24hr ambulatory pressure monitoring: mean 24hr systolic pressure <130 mmHg and mean 24hr diastolic pressure <80mmHg) by non-investigation specialized hypertensive unit care, with appropriate drug treatment regimen with three or more anti-hypertensive drugs including a diuretic. Anti-hypertensive drug treatment was non-investigational and was prescribed at discretion of the physician who performed primary evaluation.
3203575|NCT01173016|Experimental|Laronidase After Transplantation|Patients with Mucopolysaccharidosis type IH (MPS I, Hurler syndrome) treated with a prior allogeneic transplant >2 years previously and treated with Laronidase weekly for 2 years after transplant.
3203576|NCT01172990|Experimental|Conventional Group|Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- Percutaneous Coronary Intervention PCI between 24 to 48 hours from randomisation according to local policy and guidelines
3203577|NCT01172990|Active Comparator|Immediate Invasive Group|Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting Percutaneous Coronary Intervention(PCI) will be performed according to local policy and guidelines
3203578|NCT01172977||HbA1c ≤ 7|Stroke patients with mild diabetes mellitus HbA1c ≤ 7
3203579|NCT01172977||HbA1c ≥ 7,5|Stroke patients with severe diabetes mellitus HbA1c ≥ 7,5
3203580|NCT01172964|Experimental|Arm I|Patients undergo debulking craniotomy and receive injections of HB1.F3.CD neural stem cells directly into brain tissue on day 0. Patients then receive oral 5-fluorocytosine every 6 hours on days 4-10 in the absence of disease progression or unacceptable toxicity.
3203581|NCT01172951|Active Comparator|OGTT-OGTT-Physical tests|2 successive Oral Glucose Tolerance Tests followed by a physical tests session
3203582|NCT01172951|Active Comparator|OLTT-OLTT-Physical tests|2 successive Oral Lipid Tolerance Tests followed by a physical test session
3203583|NCT01172951|Active Comparator|OGTT-OLTT-Physical tests|Oral glucose tolerance test followed by an oral lipid tolerance test (or vice-versa) followed by a physical tests session
3203792|NCT01171430|Experimental|MRI WHOLE BODY|
3203584|NCT01172938|Experimental|Apremilast 20 mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
3203585|NCT01172938|Experimental|Apremilast 30mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
3203586|NCT01172938|Placebo Comparator|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
3203587|NCT01172938|Placebo Comparator|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
3203588|NCT01172925|Experimental|Tiotropium|Inhaler
3203589|NCT01172925|Placebo Comparator|Placebo|Inhaler
3203590|NCT01172899|Experimental|Laparoscopic adjustable gastric band|
3203591|NCT01172899|Active Comparator|Control group|
3203592|NCT01172873|Active Comparator|DCS + Exposure and Response Prevention|Participants in this arm receive 10 twice-weekly 60-minute sessions of Exposure and Response Prevention (E/RP) therapy and 50mg of D-Cycloserine immediately after each therapy session. D-Cycloserine is only administered on days in which therapy sessions are held.
3203593|NCT01172873|Active Comparator|E/RP alone (no DCS administration)|Participants in this arm received twice-weekly 60 minute sessions of E/RP alone for a total of 10 sessions.
3203594|NCT01172860|Experimental|EndoVe treatment|Use of the EndoVe device to safely and effectively ablate rectal tumor tissue
3203595|NCT01172847|Active Comparator|A|
3203596|NCT01172847|Active Comparator|B|
3203597|NCT01172847|Experimental|C|
3203598|NCT01172834|Experimental|Lifestyle counseling|
3203599|NCT01172821|Experimental|tiotropium low dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
3203600|NCT01172821|Experimental|tiotropium high dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
3203601|NCT01172821|Active Comparator|50 mcg salmeterol|Twice daily, delivered with HFA MDI (+ inhalation of placebo Respimat® inhaler once daily)
3203602|NCT01172821|Placebo Comparator|placebo|Once daily, delivered with Respimat® inhaler + twice daily delivered with HFA MDI
3203603|NCT01172808|Experimental|tiotropium low dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
3203604|NCT01172808|Experimental|tiotropium high dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
3203605|NCT01172808|Active Comparator|50 mcg salmeterol|Twice daily, delivered with HFA MDI (+ inhalation of placebo Respimat® inhaler once daily)
3203606|NCT01172808|Placebo Comparator|placebo|Once daily, delivered with Respimat® inhaler + twice daily delivered with HFA MDI
3203607|NCT01172795||healthy controls|
3203608|NCT01172795||chronic whiplash patients|
3203609|NCT01172795||Fibromyalgia patients|
3203610|NCT01172782|Placebo Comparator|control group|control group (CG) received 6 mg of hyperbaric bupivacaine and 0.05 mL of saline.
3203611|NCT01172782|Active Comparator|2.5 ug hydromorphone recieved group|the 2.5 μg hydromorphone group (2.5HG) received 1.2 (6 mg) mL of 0.5% hyperbaric bupivacaine and 2.5 μg of hydromorphone in 0.05 mL of saline
3203612|NCT01172782|Active Comparator|5 μg hydromorphone group|5 μg hydromorphone group received 1.2 mL of 0.5% hyperbaric bupivacaine and 5 μg of hydromorphone in 0.05 mL of saline
3203613|NCT01172782|Active Comparator|the 10 μg hydromorpnone group|the 10 μg hydromorphone group received 1.2 mL of 0.5% hyperbaric bupivacaine and 10 μg of hydromorphone in 0.05 mL of saline.
3203614|NCT01172769|Experimental|Temsirolimus|
3203615|NCT01172756|Experimental|Arm 1|
3203616|NCT01172756|Experimental|Arm 2|
3203617|NCT01172756|Experimental|Arm 3|
3203618|NCT01172756|Placebo Comparator|Arm 4|
3203619|NCT01172743||Diabetes|Individuals with diabetes that fit eligibility criteria.
3203620|NCT01172743||Normal Control|Individuals without history of diabetes.
3203621|NCT01172730||Ultrasound scanning|
3203622|NCT01172717|Experimental|Panitumumab|Single arm study
3203623|NCT01172704|Active Comparator|Care as Usual|Participants randomized to CAU receive the standard care given to patients of the Boston Medical Center who are interested in learning more about HIV/AIDS. Included in this care would be referrals for HIV counseling and testing.
3203624|NCT01172704|Experimental|Skills Building - Motivational Interviewing|Participants randomized to SB-MI will receive three individual sessions and a booster. Content of the sessions are as follows; Session 1: Risk Behavior Feedback & Building Motivation; Session 2: Building Motivation & Skill Selection and Practice; Session 3: Developing Change Plan & Skill Practice and Booster Session(s): Review Change Plan Implementation, Maintaining Motivation & Skill Practice.
3203625|NCT01172691|Experimental|Placebo and Study|
3203626|NCT01172652|Experimental|ziprasidone|
3203627|NCT01172652|Placebo Comparator|Placebo|
3203628|NCT01172639|Other|CoBRA classic high risk group|"Methotrexate (MTX)~Sulphasalazine~Step down steroid full dose"
3203629|NCT01172639|Other|CoBRA slim high risk group|"MTX~Step down steroid half dose"
3203630|NCT01172639|Other|CoBRA avant-garde high risk group|"MTX~Leflunomide~Step down steroid half dose"
3203631|NCT01172639|Other|CoBRA slim low risk group|"MTX~Step down steroid half dose"
3203632|NCT01172639|Other|Tight Step Up low risk group|"MTX~No additional oral steroids allowed"
3203633|NCT01172626||epileptic patients|epileptic patients receiving treatment with continuous Sodium Valproate
3203634|NCT01172613||healthy subjects no symptoms|
3203635|NCT01172613||allergic rhinitis patient|
3203638|NCT01172587|Experimental|Lifestyle Counseling|Couples receive behavioral couples therapy for parental drug use.
3203639|NCT01172574|Experimental|Motor control exercise|Subjects of the exercise group underwent a 3-month (13-week) treatment program directed on 3-weekly 1-hr one-to-one sessions by the researcher who had experience in the specific exercise treatment of the spinal region. During the next 3 months, the subjects were urged to perform the exercises alone at home at least once a day, and compliance was monitored by the activity quota chart given to them at the beginning of each study-month.
3203640|NCT01172574|No Intervention|Control group|The control group underwent treatment throughout a 6-month period, directed by each patient's medical practitioner. This consisted of the patients carrying out regular weekly general exercises (walking and swimming). Three of them regularly attended other treatment providers involving group general exercise programs. Two patients received the application of local pain-relieving methods such as heat, massage, laser and ultrasound and one did nothing except for receiving osteoporotic medication.
3203641|NCT01172561|Active Comparator|Usual Care Group|All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
3203642|NCT01172561|Experimental|Lay Health Advisor Intervention|The Lay Health Advisor education intervention - The intervention consisted of an intensive, reinforced, one on one, interactive ed. program (an initial meeting, then 2 calls and a series of 4 postcards mailed at regular intervals and a 2nd visit. Woman were enrolled for about 12 to 14 months.
3203643|NCT01172548|Experimental|imatinib mesylate|
3203644|NCT01172535|Experimental|Lopinavir/ritonavir|Participants will receive lopinavir/ritonavir in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.
3203645|NCT01172522|Experimental|Fexofenadine left; placebo right|"Topical treatment active versus placebo.~Double blind randomized placebo controlled split face intrasubject comparison."
3203646|NCT01172522|Experimental|Fexofenadine right; placebo left|Split face double blind
3203647|NCT01172509|Placebo Comparator|sugar pill|placebo administered under double blind conditions
3203648|NCT01172509|Experimental|3 mg of R-baclofen|3 mg of R-Baclofen administered double blind
3203649|NCT01172509|Experimental|10 mg of R-baclofen|10 mg of R-baclofen administered double-blind
3203650|NCT01172509|Experimental|25 mg of R-baclofen|25 mg of R-baclofen administered double blind
3203651|NCT01172509|Placebo Comparator|second sugar pill|the second placebo administered double blind
3203652|NCT01172496|Experimental|1 mg tablet; 1mg solution|
3203653|NCT01172496|Experimental|1mg solution; 1mg tablet|
3203654|NCT01172483|Experimental|multimodal community program|multimodal community program of exercise and education
3203655|NCT01172483|Active Comparator|active control|general practice in primary care and education of chronic disorders
3203656|NCT01172457|Active Comparator|Epiduroscopy with ozone therapy|Patients in this group will receive 30 mL of ozone at a concentration of 30 mcg / ml by epiduroscopy.
3203657|NCT01172457|Placebo Comparator|Epiduroscopy with oxygen therapy|Patients in this group will receive 30 mL of oxygen by epiduroscopy.
3203658|NCT01172444|Experimental|Test|Sandoz Mesalamine 1 g Suppository
3203659|NCT01172444|Active Comparator|Reference|Canasa 1 g Suppository
3203660|NCT01172444|Placebo Comparator|Placebo|Sandoz 1 g Placebo Suppository
3203661|NCT01172431|Experimental|Indapamide|Indapamide SR 1.5mg qd
3203662|NCT01172431|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide 25mg qd
3203663|NCT01172418|Active Comparator|Thymoglobulin and Daclizumab|Group I: Our standard steroid avoidance protocol, i.e., 3 daily doses of 1 mg/kg of Thymoglobulin®, the first to be infused at surgery, accompanied by 2 doses of anti-CD25 humanized monoclonal antibody, the first also to be given at surgery, and the second 2 weeks later. (controls)
3203664|NCT01172418|Experimental|Thymoglobulin and Alemtuzumab|Group II: A new steroid avoidance protocol in which 1 dose of 1 mg/kg of Thymoglobulin® is to be infused at surgery followed by 1 dose of alemtuzumab (Campath-1H) at 0.3 mg/kg within 24 hours. No further antibody therapy will be used.
3203665|NCT01172405|Experimental|Ibuprofen + Caffeine|72 patients treated with one or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
3203666|NCT01172405|Active Comparator|Ibuprofen|72 patients treated with one or two tablets of ibuprofen 400 mg when presenting headache.
3203667|NCT01172392|Experimental|PegIFN + Nucleosidic or Nucleotidic Analog|
3203668|NCT01172392|Active Comparator|Nucleosidic or Nucleotidic Analog|
3203669|NCT01172379|Experimental|Experimental 1|
3203670|NCT01172379|Experimental|Experimental 2|
3203671|NCT01172379|Experimental|Experimental 3|
3203672|NCT01172379|Placebo Comparator|Placebo Comparator|
3203673|NCT01172353|Experimental|sodium bicarbonate|hydration with sodium bicarbonate
3203674|NCT01172353|Active Comparator|saline|hydration with saline 1ml/Kg/h for 6 hours
3203675|NCT01172340|Experimental|Behavioral and support intervention|one individual counseling session with diet and exercise recommendations plus 16 weeks of group sessions, plus 8 weeks of phone followup
3203676|NCT01172340|Placebo Comparator|wait-listed control group|Controls receive individual counseling session and recommendations, mailed health information, and after post-test measures are offered an abbreviated group-based intervention
3203677|NCT01172327|Experimental|Multicomponent exercise|This arm is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks.
3203678|NCT01172327|Active Comparator|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks.
3203679|NCT01172314|Experimental|EAA+LEU vs total AA|
3203680|NCT01172314|Experimental|Total AA vs EAA+LEU|
3203681|NCT01172301|Experimental|Oral EAA vs total AA supplement|
3203682|NCT01172288|Experimental|N-Acetylcysteine|NAC was titrated up to a maximum dose of 2400 mg over the course of 2 weeks. Subjects were assigned 600 mg twice a day for weeks 1-2, and then were assigned 1200 mg twice a day for the remainder of the 12 week study.
3203683|NCT01172288|Placebo Comparator|Placebo|Placebo: Subjects were assigned to take two capsules twice a day for weeks 1-2, and then were assigned 4 capsules twice a day for the remainder of the 12 week study.
3203684|NCT01172275|Experimental|N-Acetylcysteine|N-Acetylcysteine effervescent tablets. 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
3203685|NCT01172275|Placebo Comparator|Placebo|Placebo effervescent tablets. 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
3203686|NCT01172262||Bothered Tinnitus|Either responds with a Global Tinnitus Scale of Moderately or Severely Bothered. Score >30 on the Tinnitus Handicap Index (THI).
3203687|NCT01172249|Experimental|Glucosamine-Chondroitin Mantecorp|1 capsule three times daily before meals (drug test - glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg - Mantecorp)
3203688|NCT01172249|Active Comparator|Condroflex|1 capsule three times daily before meals (reference medication - glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg - Condroflex ®).
3203689|NCT01172236|Experimental|Lactoferrin|
3203690|NCT01172223|Experimental|LAPADO|Non-pegylated liposomal doxorubicin (NPLD; Myocet, 60 mg/m2 i.v. day 1 q3 weeks), Paclitaxel (175 mg/m2 i.v. day 1 q3 weeks), and Lapatinib (GW572016, Tykerb, 750-1500 mg/d orally daily until the day of the definitive surgery)
3203691|NCT01172210||Bulimia Nervosa|
3203692|NCT01172210||Bulimia Nervosa w/ Alcohol Use Disorder|
3203693|NCT01172210||Healthy Controls|
3203694|NCT01172197|Active Comparator|Ropivacaine|Local anaesthetic bolus and infusion
3203695|NCT01172197|Active Comparator|Levobupivacaine|Local anaesthetic bolus and infusion
3203696|NCT01172184||Severe mitral regurgitation|Patients with severe mitral regurgitation are admitted for pre-operation cardiac catheterization and are willing to participate in this study.
3203697|NCT01172171|Active Comparator|Melatonin|The randomized patients will receive 10 ml 0,1 mg/ml melatonin intracoronarily and 49 mg intravenously.
3203698|NCT01172171|Placebo Comparator|Isotonic saline|The randomized patients will receive 10 ml isotonic saline (NaCl)and 490 ml intravenously.
3203699|NCT01172158||Forgotten ureteral stents|
3203700|NCT01172145|Placebo Comparator|Cholinesterase inhibitor only|
3203701|NCT01172145|Experimental|Cholinesterase Plus Modafinil|
3203702|NCT01172119|Experimental|BioFreedom Standard Dose|
3203703|NCT01172119|Experimental|BioFreedom Low Dose|
3203704|NCT01172119|Active Comparator|Taxus Liberte drug eluting stents|
3203705|NCT01172106|Placebo Comparator|Encouragement on drug compliance|The intervention for the placebo comparator will be encouragement on drug compliance
3203706|NCT01172106|Experimental|Family psychoeducation|The experimental group will receive weekly sessions of psychoeducation for 12 weeks in addition to receiving drug compliance encouragement
3203707|NCT01172080|No Intervention|control|Participants in this group are monitored for adherence to colonoscopy recommendations.
3203708|NCT01172080|Experimental|intervention|Participants to receive a protocol of reminder letters and a phone call regarding due follow up colonoscopy
3203709|NCT01172067|Experimental|Quickopt Group|the QuickOpt Group patients will be optimized by QuickOpt(IEGM);
3203710|NCT01172067|Active Comparator|Echocardiography group|the Echo Group patients will be optimized by Echo.
3203711|NCT01172054|Experimental|VAX128|Novel H1N1 Influenza vaccine
3203712|NCT01172054|Placebo Comparator|Placebo|one IM injection
3203713|NCT01172028|Experimental|Alimta and Taxotere|Alimta and Taxotere given in combination with dose modifications.
3203714|NCT01172015|Experimental|PTI patients|Study NK cells functions, phenotypic changes and transcripts from ITP patients
3203715|NCT01172015|Other|healthy volunteers|Study NK cells functions, phenotypic changes and transcripts from healthy volunteers
3203716|NCT01172002|Experimental|leflunomide group|
3203717|NCT01172002|Active Comparator|Azathioprine group|
3203718|NCT01171989|Experimental|GSK2202083A + SYNFLORIX GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of GSK2202083A and Synflorix™ vaccines in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of GSK2202083A vaccine at Day 0 and of Synflorix™ vaccine at Month 1. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
3203719|NCT01171989|Active Comparator|INFANRIX HEXA/MENJUGATE GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of Infanrix hexa™ vaccine and 2 doses of Menjugate® vaccine in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of Infanrix hexa™ vaccine co-administered with Menjugate® vaccine at Day 0. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
3203720|NCT01171989|Active Comparator|INFANRIX HEXA/NEISVAC-C + SYNFLORIX GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of Infanrix hexa™ vaccine and Synflorix™ vaccines in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of Infanrix hexa™ vaccine co-administered with NeisVac-C® vaccine at Day 0 and 1 dose of Synflorix™ vaccine at Month 1. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
3203721|NCT01171976|Experimental|TE Ranibizumab 0.5 mg and Laser|On Day 1, all patients received an intravitreal injection with 0.5 mg ranibizumab and subsequently entered Phase A which comprised of monthly injections. Laser therapy was applied at Day 1. It could then be re-administered according to ETDRS criteria at any visit with 0.5 mg ranibizumab treatment if deemed necessary by the Treating Investigator with a minimal treatment interval between laser treatments of 3 months. Laser therapy was administered ≥ 30 minutes prior to the ranibizumab injection.
3203722|NCT01171976|Experimental|TE Ranibizumab 0.5 mg alone|Patients received ranibizumab intravitreal injection therapy only.
3203723|NCT01171976|Active Comparator|PRN Ranibizumab 0.5 mg|Patients received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.
3203724|NCT01171963|Experimental|Rotarix Group|Subjects aged between and including 6 and 16 weeks at the time of first vaccination received 2 doses of Rotarix™ vaccine, liquid formulation, at Day 0 and at Month 1. As part of the routine childhood vaccination according to the Expanded Program of Immunization (EPI) recommendations in China, subjects in this group also received 3 doses of Infanrix™ vaccine and 3 doses of the oral poliovirus vaccine manufactured by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (OPV). The Infanrix™ and the OPV vaccines were administered independently of (Sub-cohort 1) or concomitantly with (Sub-cohort 2) the Rotarix™ vaccine. When administered concomitantly, subjects received the 3 doses of Infanrix™ vaccine at Months 1, 2 and 3, and the 3 doses of the OPV vaccine at Day 0, Month 1 and Month 2. The Rotarix™ and OPV vaccines were administered orally; the Infanrix™ vaccine was administered intramuscularly in the left anterolateral thigh.
3203725|NCT01171963|Placebo Comparator|Placebo Group|Subjects aged between and including 6 and 16 weeks at the time of first vaccination received 2 doses of Placebo at Day 0 and at Month 1. As part of the routine childhood vaccination according to the Expanded Program of Immunization (EPI) recommendations in China, subjects in this group also received 3 doses of Infanrix™ vaccine and 3 doses of the oral poliovirus vaccine manufactured by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (OPV). The Infanrix™ and the OPV vaccine were administered independently of (Sub-cohort 1) or concomitantly with (Sub-cohort 2) the Placebo. When administered concomitantly, subjects received the 3 doses of Infanrix™ vaccine at Months 1, 2 and 3, and the 3 doses of the OPV vaccine at Day 0, Month 1 and Month 2. The Placebo and the OPV vaccine were administered orally; the Infanrix™ vaccine was administered intramuscularly in the left anterolateral thigh.
3203726|NCT01171950|Other|All Patients|All patients meeting the patient selection criteria will be treated with the CentriMag device.
3203727|NCT01171937|Active Comparator|Open-Label Risperidone|Risperidone oral solution (1mg/mL) qd for 8 weeks.
3203728|NCT01171937|Placebo Comparator|Placebo|Placebo
3203729|NCT01171924|Experimental|Arm A: 5 days/week schedule|
3203730|NCT01171924|Experimental|Arm B: 3 days/week schedule|
3203731|NCT01171898|Experimental|Dose Escalation Cohort (Phase 1)|ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily. Once Recommended Phase 2 Dose (RP2D) has been selected, Phase 1 participants being treated at the lower dose levels will be allowed to escalate to the RP2D level at the discretion of the primary investigator.
3203732|NCT01171898|Experimental|Non-metastatic CRPC (Phase 2)|Participants with non-metastatic, treatment-naive Castration-Resistant Prostate Cancer (CRPC) with rapidly rising Prostate Specific Antigen (PSA) will be enrolled. ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
3203733|NCT01171898|Experimental|Treatment-naive metastatic CRPC (Phase 2)|Participants with treatment-naive metastatic CRPC will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.
3203734|NCT01171898|Experimental|Post-abiraterone metastatic CRPC (Phase 2)|Participants with metastatic CRPC that are chemotherapy-naive, but have been previously treated with abiraterone will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.
3203735|NCT01171885|Placebo Comparator|Placebo|Bilateral superficial cervical block.
3203736|NCT01171885|Experimental|Ropivacaine 0.25%|Bilateral superficial cervical block
3203737|NCT01171885|Experimental|Ropivacaine 0.5%|Bilateral superficial cervical block.
3203738|NCT01171872||Unaffected|Individuals who do not have IBD
3203739|NCT01171872||Affected|Individuals who have IBD
3203740|NCT01171859|Experimental|Doxycycline + Tauroursodeoxycholic acid|
3203741|NCT01171846|Active Comparator|Physiotherapy|
3203742|NCT01171846|No Intervention|Control|Women allocated to the Control group will only receive, by post, the same Lifestyle Advice Sheet as the intervention group.
3203743|NCT01171833|Experimental|Group A(Sevoflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.~Each subgroup has 4 patients.~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
3203744|NCT01171833|Experimental|Group B(Desflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.~Each subgroup has 4 patients.~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
3203745|NCT01171833|Experimental|Group C(Isoflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.~Each subgroup has 4 patients.~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
3203746|NCT01171820|Active Comparator|TAXUS® Liberté™|
3203747|NCT01171820|Active Comparator|XIENCE V® EECSS|
3203748|NCT01171807|Active Comparator|Dexamethasone 21-phosphate encapsulated into red cells|
3203749|NCT01171807|Sham Comparator|Placebo|
3203750|NCT01171794|Active Comparator|ibuprofen|600mg ibu TID
3203751|NCT01171794|Placebo Comparator|placebo|visually identical
3203752|NCT01171781|Active Comparator|3 weekly CDDP based CCRT|radiation (conventioal or IMRT) with 3 cycles of 3-weekly cisplatin
3203753|NCT01171781|Experimental|weekly cisplatin based CCRT|radiation (conventional or IMRT) with 7 cycles of weekly cisplatin therapy
3203754|NCT01171768||patients with hemoptysis within 2 weeks|
3203755|NCT01171768||patients without hemoptysis within 2 years|
3203756|NCT01171755|Experimental|Gemcitabine, Ts-1|Gemcitabine : 1000/m2 will be administered on days 1 and 8 at every 3 weeks . TS-1 will be administered orally according to body surface area (BSA) as follows : BSA<1.25 M2, 80 mg/day; 1.25 M2≤BSA<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
3203789|NCT01171469|Experimental|Dose Level 1|5 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
3203790|NCT01171456|Placebo Comparator|Metformin Placebo|
3203757|NCT01171742|Experimental|IHIO|Intermittent hepatic inflow occlusion (IHIO) by clamping of the portal triad, minimizes blood loss and operation time during liver resection. In addition, ischemic preconditioning with IHIO has been reported to have protective effects in patients undergoing liver resection. IHIO'll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
3203758|NCT01171742|Sham Comparator|Control|The donor liver parenchyma'll be transected without IHIO.
3203759|NCT01171716|Other|Dietary Protein Intake|LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
3203760|NCT01171703|Experimental|bypass|femoral-popliteal bypass
3203761|NCT01171703|Experimental|stent|
3203762|NCT01171690|Experimental|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
3203763|NCT01171677|Experimental|IntenSati|"IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem."
3203764|NCT01171677|No Intervention|Treatment as Usual|
3203765|NCT01171664|Placebo Comparator|Placebo|Placebo containing no active pharmaceutical ingredients
3203766|NCT01171664|Experimental|STAHIST|STAHIST tablet for the symptomatic treatment of Seasonal Allergic Rhinitis
3203767|NCT01171651|Experimental|JX-594 followed by sorafenib|1e9 pfu (plaque-forming units) total JX-594 dose on each of up to four (4) JX-594 treatment days. Sorafenib is initiated after 3 JX-594 treatments and briefly interrupted if an optional 4th JX-594 treatment is given.
3203768|NCT01171638||Critical Controls|"Critically injured patients with NO severe traumatic lower extremity injuries to provide normative data for the critically injured physiological status upon arrival at study site"
3203769|NCT01171638||Investigational cohort|"Soldiers with severe traumatic lower extremity injuries in stable or critical physiological status presenting to a participating study site within 12 hours of their injury, to provide data on the acute post-injury phase. This cohort will be made up of:~Patients meeting inclusion criteria for investigational cohort, who have UNILATERAL severe lower extremity injuries~Patients meeting inclusion criteria for investigational cohort, who have BILATERAL severe lower extremity injuries.~Patients meeting inclusion criteria for investigational cohort, who have been clinically diagnosed by the treating provider using that treating providers standards for diagnosing ACS and the patient in addition to be diagnosed with ACS undergoes four-compartment leg fasciotomy."
3203770|NCT01171625|Other|CEP Aortic Bioprothesis, model 3300TFX|
3203771|NCT01171612||Coronary Stent|Patients with coronary Bare Metal Stent (BMS) or Drug Eluting Stent (DES) undergoing noncardiac surgery
3203772|NCT01171586|Experimental|SMS Only|"The SMS only group will receive hints, tips, strategies, and questions related to weight loss behaviors, physical activity, nutrition, and motivation. The messages will be pushed to participants (i.e. no response needed) and pulled from participants (i.e. response is needed). The SMS only group will also receive a brief printed or web based outline on weight loss resources and information."
3203773|NCT01171586|Experimental|SMS + Phone Counseling|"This group will receive hints, tips, strategies, and questions related to weight loss behaviors, physical activity, nutrition, and motivation. The messages will be pushed to participants (i.e. no response needed) and pulled from participants (i.e. response is needed). The group will also receive monthly counseling calls from a Health Coach to discuss barriers and solutions and will receive a brief printed or web based outline on weight loss resources and information."
3203774|NCT01171586|No Intervention|Control|The Control group will receive a binder with an attractive set of Standard Print Materials related to weight loss that is comparable to what one would receive from community resources such as libraries, magazines and national non-profit or governmental organizations such as 5-A Day, American Heart Association and the like.
3203775|NCT01171573||Myositis Patients|Cases with myositis PM DM IBM Venepuncture
3203776|NCT01171573||Healthy controls|Control
3203777|NCT01171560|Active Comparator|EZ Blocker|Patients assigned to the EZ group will be intubated using a conventional tube in an adequate size as it is standard of care and single lung ventilation will be provided using the EZ-Blocker.
3203778|NCT01171560|Active Comparator|Double lumen tube|"The patients assigned to the double lume tube group will be intubated using the double lume tube in an adequate size as it is standard of care."
3203779|NCT01171534|Active Comparator|Vessel Loop fasciotomy closure|Fasciotomy closure using vessel loops and staples.
3203780|NCT01171534|Experimental|DermaClose fasciotomy closure|Fasciotomy closure via DermaClose device
3203781|NCT01171521|Experimental|DermaClose Group|DermaClose device applied to complex soft-tissue wound, with or without negative pressure wound therapy, and prospectively followed for primary and secondary outcomes for one year.
3203782|NCT01171508||Breast cancer patients|12 breast cancer patients aged 30-70 years undergoing a lumpectomy at Herlev Hospital. ASA score I-III.
3203783|NCT01171495|Experimental|Ensure Plus + Multivitamin/Counselling|
3203784|NCT01171495|Active Comparator|Multivitamin/Counselling|
3203785|NCT01171482|Experimental|The FM group|Patients in the FM group will be administered 5-FU plus mitomycin
3203786|NCT01171482|Active Comparator|The sorafenib group|Patients in the sorafenib group will be administered sorafenib
3203787|NCT01171469|Experimental|Dose Level 3|15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
3203788|NCT01171469|Experimental|Dose Level 2|10 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
3203791|NCT01171456|Active Comparator|Metformin|
3203793|NCT01171417||Cohort 1|1st-line Faslodex 500 mg
3203794|NCT01171417||Cohort 2|2nd-line Faslodex 500 mg
3203795|NCT01171417||Cohort 3|3rd- line Faslodex 500 mg
3203796|NCT01171417||Cohort 4|patients on exemestane
3203797|NCT01171404||1|Patients, older than 18, hospitalized within 24 hours of onset of symptoms and diagnosed with UA, STEMI or NSTEMI
3203798|NCT01171391|Experimental|VA106483 1mg|
3203799|NCT01171391|Experimental|VA106483 2mg|
3203800|NCT01171391|Experimental|VA106483 4mg|
3203801|NCT01171391|Placebo Comparator|Sugar pill|
3203802|NCT01171378|Other|Ofatumumab|Single arm study
3203803|NCT01171365|Active Comparator|Ciclesonide|Ciclesonide 320 microgrammes twice daily
3203804|NCT01171365|Placebo Comparator|Placebo|Placebo 2 inhalations twice daily
3203805|NCT01171352||ICU Dialysis Patients|Any patient 18 years and older who is admitted to the OHSU Hospitals ICUs with ARF, or End Stage Renal Disease (ESRD) for a diagnosis other than hyperkalemia, as the sole determinant for that level of care, will be invited to participate. The patient must have acute or chronic needs for dialytic support during their ICU stay.
3203806|NCT01171339|No Intervention|Control|"Usual care in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
3203807|NCT01171339|Experimental|Intervention arm|"Intervention: Healthcare assistant (HCA) and computer assisted optimization of multi-medication (complex intervention) in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
3203808|NCT01171326|Experimental|Topical Minocycline Foam FXFM244 - 4%|Minocycline Foam FXFM244 - 4%
3203809|NCT01171326|Experimental|Topical Minocycline Foam FXFM244 - 1%|Minocycline Foam FXFM244 - 1%
3203810|NCT01171313|Experimental|Treatment sequence 1|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
3203811|NCT01171313|Experimental|Treatment sequence 2|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
3203812|NCT01171313|Experimental|Treatment sequence 3|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
3203813|NCT01171313|Experimental|Treatment sequence 4|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
3203814|NCT01171287|Experimental|Aircast Walker|Automobile driving with an Aircast Walker applied to each participant's right lower extremity
3203815|NCT01171287|Experimental|Walking cast|Automobile driving with a walking cast applied to each participant's right lower extremity
3203816|NCT01171287|Active Comparator|Running shoe|Automobile driving with a running shoe applied to each participant's right lower extremity
3203817|NCT01171274|Active Comparator|Hatha Yoga|"9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.~One class of 90 minutes per week, 10 minutes training at home each day."
3203818|NCT01171274|Active Comparator|Exercise information|"9 weeks of exercises practiced at home.~Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients."
3203819|NCT01171261|Experimental|Jackie Chan Studio Fitness|The Jackie Chan Studio Fitness (J-MAT) cartridge includes four types of activities that use a four panel floor mat made of flexible material that functions as the wireless interface game controller. The celebrity actor and choreographer Jackie Chan is the avatar character in the game that demonstrates and guides users in four types of aerobic and anaerobic game modes.
3203820|NCT01171261|Experimental|XaviX Tennis|XaviX Tennis simulates tennis using a tennis racket controller and an infrared sensor to detect speed and timing of the player's swing of the racquet. The Tennis cartridge includes three playing modes. In Tournament Tour players select from eight different characters with different skills and play opponents in a bracketed tournament. In Exhibition mode players choose a computer opponent or play a tennis match with a friend. The Training Games mode includes a) Serving, b) Target Challenge, c) Serve & Finish, and d) Rally Time.
3203821|NCT01171261|Experimental|XaviX Bowling|XaviX Bowling uses a wireless bowling ball game controller to simulate bowling. The cartridge includes three modes. In Regular Game up to four people can select from 8 preset bowlers with different characteristics. In Tournament Mode up to eight people can play. Challenge Games consists of three games called Against the Clock, Moving Pins, and Panel Crusher.
3203822|NCT01171261|Experimental|XaviX Boxing|XaviX Boxing uses boxing gloves as the game controller and allows players to box against five different computer opponents in Championship and Exhibition modes and to practice boxing skills in Exercise mode. Exercise mode includes Punch Fast, Panel Toucher, Punch the Red Ball, and Combination Training.
3203823|NCT01171248||type 1 diabetes|
3203824|NCT01171248||non-diabetics|
3203825|NCT01171222||veteran soccer players from Saarland County, Germany|
3203826|NCT01171209|Experimental|IFN-alfa|One single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c.
3203827|NCT01171209|Experimental|Interferon-beta|One single injection of IFN-beta followed by blood test for MxA9.12 hours after injection
3203828|NCT01171183|Placebo Comparator|Placebo|
3203829|NCT01171183|Active Comparator|Carvedilol controlled release|controlled release carvedilol (Coreg CR) at 80 mg/day in once daily dosing
3203830|NCT01171170|Active Comparator|carboplatin-paclitaxel-bevacizumab|paclitaxel 200 mg/m2 d1 - carboplatin area under the curve (AUC) 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
3203831|NCT01171170|Experimental|standard treatment plus nitroglycerin|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
3203832|NCT01171157||Group 1|Subjects with influenza like illness
3203833|NCT01171144||Gastroenteritis Group|All children suffering with gastroenteritis
3203915|NCT01170546|Experimental|KLC (Kneeling Leg Curl)|plate-loaded kneeling leg curl
3203916|NCT01170533|Active Comparator|Omeprazole|prospective, open-label, two-sequence, three-period, randomized crossover study
3203834|NCT01171131||Chronic TBI Patients - Non-penetrating|"Chronic TBI patients should have a history of head trauma manifesting in one or more of the following:~Loss of consciousness~Post-traumatic amnesia~Focal neurologic deficits, seizure~Persistent symptoms of increased arousal (e.g. difficulty falling or staying asleep, anger and hypervigilance)~Impairment in social, occupational, or other important areas of functioning (e.g. problems with work and relationships.) Patients will be excluded from the study if we are unable to obtain informed consent and if they are non-communicative (i.e. in a vegetative state)."
3203835|NCT01171131||Chronic TBI Patients - Blast|"Chronic TBI Blast injury patients should have a history of head trauma manifesting in one or more of the following:~Loss of consciousness~Post-traumatic amnesia~Focal neurologic deficits, seizure~Persistent symptoms of increased arousal (e.g. difficulty falling or staying asleep, anger and hypervigilance)~Impairment in social, occupational, or other important areas of functioning (e.g. problems with work and relationships.) Patients will be excluded from the study if we are unable to obtain informed consent and if they are non-communicative (i.e. in a vegetative state)."
3203836|NCT01171131||Healthy Volunteers|"Healthy volunteers include gender, age and race matched volunteers able to provide informed consent who have,~No significant medical history~Take no medications (other than birth control pills)~Fever free~No history of head trauma or recent injury/infection~No history of neurological or psychiatric disorders or alcohol or drug dependency."
3203837|NCT01171118|Experimental|Sedation & Physostigmine & Room Air|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
3203838|NCT01171118|Placebo Comparator|Sedation & Placebo & Room Air|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
3203839|NCT01171118|Experimental|Sedation & Physostigmine & Oxygen|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
3203840|NCT01171118|Placebo Comparator|Sedation & Placebo & Oxygen|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
3203841|NCT01171105|Experimental|1|AZD5213 (dose escalating)
3203842|NCT01171105|Placebo Comparator|2|Placebo
3203843|NCT01171092|Experimental|bortezomib and G-CSF|
3203844|NCT01171079|Experimental|Interceed|
3203845|NCT01171053|Placebo Comparator|Attention control|Weekly support from therapist without CBT-interventions
3203846|NCT01171053|Experimental|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support
3203847|NCT01171040||Consecutive patients received echocardiographic examinations|Consecutive patients received echocardiography are willing to participate in this study.
3203848|NCT01171027|Experimental|NOTES(R) Cholecystectomy|Natural Orifice Translumenal Endoscopic Surgery techniques
3203849|NCT01171027|Active Comparator|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
3203850|NCT01171014|Experimental|High dose probiotic|Bifidobacterium lactis HN019, 10 billion cfu/day
3203851|NCT01171014|Experimental|Low dose probiotic|Bifidobacterium lactis HN019, 1 billion cfu/day
3203852|NCT01171014|Placebo Comparator|Placebo|Placebo
3203853|NCT01170988|Other|surgical procedure|T-graft bypass or conventional bypass
3203854|NCT01170975|Other|Treatment sequence 1|Treatment Period 1: Tesetaxel 10 mg in the fed state; Treatment Period 2: Tesetaxel 10 mg in the fasted state
3203855|NCT01170975|Other|Treatment sequence 2|Treatment Period 1: Tesetaxel 10 mg in the fasted state; Treatment Period 2: Tesetaxel 10 mg in the fed state
3203856|NCT01170962|Experimental|Arm 1: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior null responders)
3203857|NCT01170962|Experimental|Arm 2: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior null responders)
3203858|NCT01170962|Experimental|Arm 3: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior partial responders)
3203859|NCT01170962|Experimental|Arm 4: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior partial responders)
3203860|NCT01170962|Experimental|Arm 5: Placebo plus peginterferon alfa-2a and ribavirin|(prior partial responders only)
3203861|NCT01170949|Experimental|Miltefosine|
3203862|NCT01170949|Placebo Comparator|Placebo|
3203863|NCT01170936|Experimental|Canakinumab|
3203864|NCT01170923|Experimental|FDG-PET guided|Chemotherapy regimen will be changed depending on metabolic response.
3203865|NCT01170923|Active Comparator|CT guided|Chemotherapy regimen will be changed depending on CT findings (RECIST).
3203917|NCT01170533|Active Comparator|Pantoprazole|prospective, open-label, two-sequence, three-period, randomized crossover study
3203866|NCT01170910|Other|Static incubation|If conservation in static incubation (group 1) is chosen by random selection, the transplant should be carried out while keeping the cold ischemic time (CIT) as short as possible (preferably less than 18 hours). Keep in mind that for reasons of homogeneity for result analysis and for conservation quality, it is recommended that kidneys in group 1 be conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution.
3203867|NCT01170910|Experimental|Pulsatile perfusion|If conservation in a pulsatile perfusion machine (group 2) is chosen by random selection, the kidney will be placed in the perfusion machine within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
3203868|NCT01170897|Other|Maximally Tolerated Dose|To identify the maximally tolerated dose (MTD) of PEGPH20.
3203869|NCT01170884|Active Comparator|Combigan® + Lumigan®|COMBIGAN® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution) adjunctive to LUMIGAN® (bimatoprost 0.03% ophthalmic solution)
3203870|NCT01170884|Active Comparator|Lumigan®|LUMIGAN® (bimatoprost 0.03% ophthalmic solution) plus Gen Teal® Mild (hypromellose 0.2% eye drops) used for masking purposes
3203871|NCT01170871|Experimental|Experimental|Escalating doses of Ixabepilone and Pemetrexed
3203872|NCT01170858|Experimental|Icodextrin group|7.5% icodextrin dialysis solution
3203873|NCT01170858|Active Comparator|glucose solution group|2.5% or 4.25% glucose dialysis solution
3203874|NCT01170845|Placebo Comparator|Control group|Patients in the control group received saline for 7 days starting at the beginning of surgery
3203875|NCT01170845|Active Comparator|S group|Patients in the S group received sivelestat sodium hydrate at a dosage 4.8mg/kg/day for 7 days starting at the beginning of surgery
3203876|NCT01170819|Active Comparator|Dinoprostone Vaginal Insert|
3203877|NCT01170819|Experimental|Double Balloon Catheter|
3203878|NCT01170806|Active Comparator|Orlistat (Lipiblock) treatment|Lipiblock is a new Orlistat formulation, produce by Germed Pharma, Brazil. Capsule 120mg
3203879|NCT01170806|Active Comparator|Orlistat (Xenical) treatment|Xenical is a innovator Orlistat formulation, produced by Roche
3203880|NCT01170793|No Intervention|2|no educative telephone coaching (ETC)
3203881|NCT01170793|Experimental|1|with educative telephone coaching (ETC)
3203882|NCT01170780|Placebo Comparator|Placebo|Saline
3203883|NCT01170780|Active Comparator|Dexamethasone|Corticosteroid (Fortecontin 8 mg)
3203884|NCT01170767|Experimental|Avastin|intravitreal injection of bevacizumab
3203885|NCT01170767|Active Comparator|Lucentis|intravitreal injection of ranibizumab
3203886|NCT01170754|Experimental|PEG-3350 and Gatorade|255 miralax with 64 oz gatorade.
3203887|NCT01170754|Active Comparator|Golytely 4 Liters|Golytely 4 Liters
3203888|NCT01170741|No Intervention|Delayed Control Condition|Participants assigned to the delayed treatment control condition will be offered biological testing and the tailored cue-card intervention upon completion of their 3- month follow-up interview. Use of a delayed treatment control group design will permit us to separate intervention effects on HIV risk behaviors from the general effects of participating in the study and completing a detailed HIV risk assessment.
3203889|NCT01170728||Virtue® Male Sling|Device: Coloplast Virtue® Male Sling
3203890|NCT01170715|Experimental|Experimental Group|Enbrel (etanercept): started with self-injection of 50 mg subcutaneous twice weekly for 12 weeks, followed by self-injection of 50 mg subcutaneous weekly for 40 weeks.
3203891|NCT01170702|Placebo Comparator|Group 1|TAP Block utilizing 15mL of 0.9% normal saline per side
3203892|NCT01170702|Experimental|Group 2|TAP Block utilizing 15ml of 0.2% ropivacaine per side
3203893|NCT01170702|Experimental|Group 3|TAP Block utilizing 15ml of 0.5% ropivacaine per side
3203894|NCT01170702|Experimental|Group 4|TAP Block utilizing 15ml of 0.75% ropivacaine per side
3203895|NCT01170689||Inpatient schizophrenia or schizoaffective disorder|
3203896|NCT01170676|Experimental|Puff City GA|Puff City is an NHLBI-funded (C. Joseph, PI; Henry Ford Health System, Detroit, MI), web-based intervention that targets three key asthma management issues in youth: 1) smoking reduction or cessation in those who are smokers, 2) improving adherence to asthma controller medication use, and 3) improving compliance of carrying a rescue inhaler at all times for use at the first sign of asthma symptoms. Puff City Ga. is a replication study in the rural southeastern United States that adds biological assessments in addition to self-report data.
3203897|NCT01170676|Active Comparator|General Asthma Education|Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
3203898|NCT01170663|Experimental|Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel|Ramucirumab (IMC-1211B) DP and Paclitaxel
3203899|NCT01170663|Placebo Comparator|Placebo and Paclitaxel|Placebo and Paclitaxel
3203900|NCT01170650|Experimental|Arm A|EC145 + Pegylated Liposomal Doxorubicin (PLD)
3203901|NCT01170650|Active Comparator|Arm B|placebo + Pegylated Liposomal Doxorubicin (PLD)
3203902|NCT01170637|Active Comparator|Ibuprofen 200 mg|Oral administration as a fixed dose combination tablet (RhinAdvil(R))
3203903|NCT01170637|Active Comparator|Pseudoephedrine-HCl 30 mg|Oral administration as a fixed dose combination tablet (RhinAdvil(R))
3203904|NCT01170637|Active Comparator|Ibuprofen 200 mg BI|Oral administration as a fixed dose combination tablet (BI product)
3203905|NCT01170637|Active Comparator|Pseudoephedrine-HCl 30 mg BI|Oral administration as a fixed dose combination tablet (BI product)
3203906|NCT01170611|Experimental|AAISAFER alone - AAISAFER+PREVENTIVE ALGORITHM - DDD|
3203907|NCT01170598|Experimental|Exercise|
3203908|NCT01170585|Placebo Comparator|Placebo|randomised to placebo.
3203909|NCT01170585|Active Comparator|Active|randomised to rosuvastatin.
3203910|NCT01170572||Long bone fracture|Patients presenting to accident and emergency during the study period with long bone or clavicle fracture
3203911|NCT01170559|Experimental|Group 1: ILR Group|Group allocated to receiving an ILR in the A&E department.
3203912|NCT01170559|No Intervention|Group 2: Conventional|Group randomised to conventional lines of investigation
3203913|NCT01170546|Experimental|KLCIR|plate-loaded kneeling leg curl with internal rotation
3203914|NCT01170546|Experimental|SP (Squat Press)|plate-loaded squat press
3203919|NCT01170507|Active Comparator|vitamin D3 1000 IU|
3203920|NCT01170507|Active Comparator|Vitamin D3 3000 IU|
3203921|NCT01170507|Active Comparator|Vitamin D3 5000 IU|
3203922|NCT01170507|Placebo Comparator|Placebo|
3203923|NCT01170494|Active Comparator|D2 2000 IU daily|
3203924|NCT01170494|Active Comparator|D3 2000 IU daily|
3203925|NCT01170494|Active Comparator|D2 1000 IU + D3 1000 IU daily|
3203926|NCT01170494|Active Comparator|D2 25000 IU Q2wk|
3203927|NCT01170494|Active Comparator|D3 25000 IU Q2wk|
3203928|NCT01170494|Active Comparator|D2 50000 IU Q4wk|
3203929|NCT01170494|Active Comparator|D3 50000 IU Q4wk|
3203930|NCT01170494|Placebo Comparator|placebo daily|
3203931|NCT01170481||papilloedema without glaucoma|
3203932|NCT01170481||papilloedema with glaucoma|
3203933|NCT01170481||glaucoma without papilloedema|
3203934|NCT01170468|Experimental|Vitamin D3|Vitamin D3 5000 IU daily
3203935|NCT01170468|Placebo Comparator|Placebo|Placebo daily
3203936|NCT01170455|Experimental|Blind Intubation Device|
3203937|NCT01170455|Active Comparator|Direct laryngoscope|
3203938|NCT01170442|Experimental|vitamin D3 2000 IU|
3203939|NCT01170442|Experimental|vitamin D3 5000 IU|
3203940|NCT01170442|Placebo Comparator|Placebo|
3203941|NCT01170429|Experimental|I. Procaterol Hydrochloride|Meptin (Procaterol hydrochloride) Tablets, 25µg twice daily orally plus inhaled budesonide 200µg twice daily for eight weeks;
3203942|NCT01170429|Placebo Comparator|II. Procaterol hydrochloride placebo|Meptin placebo (Procaterol hydrochloride) Tablets, 25µg twice daily orally plus inhaled budesonide 200µg twice daily for eight weeks;
3203943|NCT01170416||12-Lead Body Surface Mapping - Focal VT .|Body surface mapping (BSM) will be completed in patients with a defined focal VT site during the EP study.
3203944|NCT01170416||12-Lead BSPM - Scar related VT, exit not identified|Body surface mapping will be competed on patients with scar related VT where the exit cannot be identified
3203945|NCT01170416||12-Lead BSPM - Scar related VT exit identified|Body surface mapping will be competed on patients with scar related VT where the exit is identified
3203946|NCT01170416||12-Lead BSPM - Supraventricular tachycardia|Body surface mapping will be completed on patients requiring an EP study for the treatment of symptoms related to supraventricular tachycardia
3203947|NCT01170403||NGT/IFG/DM, MeS/no-MeS|NGT: normal glucose tolerance IFG: impaired glucose tolerance DM : diabetes mellitus MeS: metabolic syndrome no-MeS: no metabolic syndrome
3203948|NCT01170390|Other|All participants|A low dose oral contraceptive given cyclically (21 days of active pills/cycle with a 7 day hormonal-free interval) for 2 cycles (56 days).
3203949|NCT01170390|Active Comparator|Aviane and Portia|A low dose oral contraceptive given cyclically (30mcg EE component, 21 days of active pills/cycle with a 7 day hormonal-free interval) for two cycles
3203950|NCT01170390|Active Comparator|Aviane & Aviane|A very-low dose oral contraceptive given continuously for 56 days (20mcg EE component, 28 days of active pills/cycle with no hormone free interval)
3203951|NCT01170377||Mental Retardation|Patients receiving valproate or not
3203952|NCT01170364|Experimental|Sibutramine|Participants in this arm receive sibutramine 15mg for one week followed by two weeks of placebo.
3203953|NCT01170364|Experimental|Placebo|Participants are prescribed two weeks of placebo, followed by one week of 15mg sibutramine.
3203954|NCT01170351|Active Comparator|Group-A|Treatment-naive AIH patients consenting to participate
3203955|NCT01170351|Experimental|Group-B|Treatment-naive AIH patients consenting to participate. This group will receive Cyclosporine-A according to a set protocol.
3203956|NCT01170338|Experimental|active Chantix|active drug to help smoking cessation
3203957|NCT01170338|Placebo Comparator|sugar pill|
3203958|NCT01170325|Experimental|Group A|
3203959|NCT01170325|Placebo Comparator|Group B|
3203960|NCT01170312|Active Comparator|Autologous conditioned plasma|
3203961|NCT01170312|Placebo Comparator|Normal saline|
3203962|NCT01170286|Experimental|DBV712 Viaskin|The experimental arm is composed of subjects treated with whole peanut extract on an epicutaneous delivery system (Viaskin patch)
3203963|NCT01170286|Placebo Comparator|Placebo Viaskin|The placebo arm is composed of subjects treated with a placebo formulation on an epicutaneous delivery system (Viaskin patch)
3203964|NCT01170273|Placebo Comparator|Placebo Arm|placebo capsule
3203965|NCT01170273|Experimental|Cholecalciferol 4000 IU|cholecalciferol 4000 IU daily
3203966|NCT01170260|Active Comparator|Info-only sexual risk reduction|Corresponding intervention gives information only on STDs/HIV
3203967|NCT01170260|Experimental|Sex plus alcohol risk reduction|Corresponding intervention gives info focusing on sex and alcohol risk reduction only
3203968|NCT01170260|Experimental|Sex + alcohol + marijuana risk reduction|Corresponding intervention gives info on sex, alcohol, and marijuana risk reduction
3203969|NCT01170247|Experimental|Intranasal Ketamine|
3203970|NCT01170247|Active Comparator|Intramuscular Ketamine|
3203971|NCT01170234||Eosinophilic esophagitis (EoE)|Treatment-naïve EoE patients, age 7 -65
3203972|NCT01170221|Experimental|TR-701 FA|TR0-701 FA 200 mg tablets once a day for six days followed by 4 days of placebo
3203973|NCT01170221|Active Comparator|Linezolid|Linezolid 600 mg tablets oral twice a day for 10 days
3203974|NCT01170208|Other|Group I|Type 1 diabetes treated with basal-bolus insulin therapy, incorporating carbohydrate-counting
3203975|NCT01170208|Other|Group II|Type 2 diabetes treated with basal-bolustherapy
3203976|NCT01170208|Other|Group III|Type 2 diabetes treated with biphasic insulin
3203977|NCT01170182|Experimental|Omeprazole|Omeprazole Delayed Release Capsules of Dr. Reddy's Laboratories Limited
3203978|NCT01170182|Active Comparator|Prilosec|Prilosec® 40 mg Merck & Co. Inc
3203979|NCT01170169|Experimental|Omeprazole|Omeprazole Delayed Release Capsules of Dr. Reddy's laboratories limited
3203980|NCT01170169|Active Comparator|Prilosec|Prilosec® 40 mg of Merck & Co.Inc.
3203981|NCT01170143|Active Comparator|Trastuzumab QW|Arm A: Trastuzumab 2mg/kg, d1; qw (loading dose 4mg/kg wk1) Paclitaxel 80mg/m2,. d1; qw Carboplatin AUC 2 d1, qw
3203982|NCT01170143|Active Comparator|Trastuzumab Q3W|Arm B: Trastuzumab 6mg/kg, d1(loading dose 8mg/kg wk1) Paclitaxel 175mg/m2,. d1, q3w; Carboplatin AUC 6 ,. d1,q3w
3203983|NCT01170130|Experimental|Lidmyd|The same group is used for the first and the second part of the experiment. Initially the patients will be given topical cyclopentolate 1% and Phenylephrine 10% and the pupil diameter will be recorded. In the second part of the experiment lidocaine 1% will be introduced intracamerally and the pupil size will be recorded again. The 2 measurements will be statistically compared/evaluated.
3203984|NCT01170117|Placebo Comparator|Placebo|Control group receiving placebo
3203985|NCT01170117|Experimental|Olanzapine|Group receiving olanzapine
3203986|NCT01170091||Pramipexole|
3203987|NCT01170078|Experimental|Arm A: Epoetin Hospira administered IV for three doses|
3203988|NCT01170078|Active Comparator|Arm B: Epogen administered IV for three doses|
3203989|NCT01170065|Experimental|BIBF 1120 low qd|Low dose BIBF 1120 once daily
3203990|NCT01170065|Experimental|BIBF 1120 low bid|Low dose BIBF 1120 twice daily
3203991|NCT01170065|Experimental|BIBF 1120 medium bid|Intermediate dose BIBF 1120 twice daily
3203992|NCT01170065|Experimental|BIBF 1120 high bid|High dose BIBF 1120 twice daily
3203993|NCT01170039|Active Comparator|Lubiprostone|
3203994|NCT01170039|Placebo Comparator|Placebo|
3203995|NCT01170026|Experimental|Family Check-up/Individual MI|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use plus 2 session Individual Motivational Intervention for the adolescent
3203996|NCT01170026|Active Comparator|Psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors especially substance use
3203997|NCT01170013|Experimental|Family Check-up|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use
3203998|NCT01170013|Active Comparator|Psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors especially substance use
3203999|NCT01169987||Participants Treated with Adalimumab|Participants with chronic plaque psoriasis in whom adalimumab (Humira) treatment is initiated. All medications will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.
3204000|NCT01169974||healthy volunteers|
3204001|NCT01169948||Patients awaiting cardiac surgery|
3204002|NCT01169935|Experimental|Administration of Intra-dermal SPIO|MRI scanning before and after intra-dermal injection of SPIO.
3204003|NCT01169935|Experimental|Mantoux, Venesection, Labelled cells|Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by venesection.
3204004|NCT01169935|Experimental|Mantoux, Apheresis, Labelled cells|Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by apheresis.
3204005|NCT01169935|Experimental|Mantoux, Administration of Endorem|Mantoux test then MRI scanning before and after administration of Endorem.
3204006|NCT01169935|Experimental|Mantoux only|Mantoux test then serial MRI scanning.
3204007|NCT01169922|Experimental|SEXUAL PLUS ALCOHOL RISK REDUCTION|Intervention contains information geared toward sexual risk reduction as well as alcohol risk reduction.
3204008|NCT01169922|Active Comparator|INFORMATION-ONLY SEXUAL RISK REDUCTION|Intervention contains information geared toward sexual risk reduction only.
3204009|NCT01169909|Experimental|Ranibizumab treatment|Patients will receive a sub-tenons injection of Ranibizumab 0.5mg, to be repeated twice with 30 day intervals between each dose.
3204010|NCT01169883|Active Comparator|Attention Control Group|1) Doctor Asthma Messages delivered over a 10 week time period; 2) Asthma Supervision; and 3) Music Tracks.
3204011|NCT01169883|Experimental|Intervention Group|1) Coping Peer Support delivered over a 10 week time period; 2) Coping Peer Asthma Messages delivered over a 10 week time period; 3) Asthma Supervision; and 4) Music Tracks.
3204012|NCT01169870|Experimental|Genexol-PM|Genexol-PM 300mg/m2, diluted with 500ml of 5% dextrose or normal saline, intravenous infusion over 1 hour on day 1, every 3 week cycle.
3204013|NCT01169870|Active Comparator|Paclitaxel|Paclitaxel 175mg/m2, diluted with 500ml of 5% dextrose or normal saline, intravenous infusion over 3 hour on day 1, every 3 week cycle.
3204014|NCT01169857|Experimental|Velcade Therapy|
3204015|NCT01169844|Experimental|AIN457|
3204016|NCT01169831|Experimental|Sedentary Older Adults|
3204017|NCT01169831|Experimental|Older Endurance Athletes|
3204018|NCT01169818|Experimental|Intervention group|Initiation on a fixed dose of insulin glargine, then subjects will self-adjusted their basal insulin dose every 3 days
3204019|NCT01169818|Active Comparator|Usual standard of care group|Initiation on a fixed dose of insulin glargine, then basal insulin dose is adjusted at each visit by a physician
3204020|NCT01169805|Experimental|ONSERAN|
3204021|NCT01169805|Experimental|NASEA|
3204022|NCT01169805|Experimental|ALOXI|
3204023|NCT01169805|Placebo Comparator|normal saline|
3204024|NCT01169792||Breast cancer patients|Breast cancer patients who underwent surgery with or without chemotherapy, endocrine therapy and/or radiation therapy. The patients are categorized according to the genetic polymorphisms or the activity score of the cytochrome P450 metabolism.
3204025|NCT01169779|Experimental|Lixisenatide|1-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 2 weeks, followed by 20 mcg QD up to Week 24.
3204026|NCT01169779|Placebo Comparator|Placebo|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, followed by 20 mcg QD up to Week 24.
3204027|NCT01169753|Placebo Comparator|Placebo|Patients randomized to nonintervention will take a placebo every morning for 2 weeks.
3204028|NCT01169753|Experimental|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
3204029|NCT01169740||Neonatal jaundice|Infants born between July 1st 2010 and July 31st 2010 and admitted to normal newborn nursery
3204030|NCT01169714|Experimental|Dosing Healthy Adult|Ascending Doses in Healthy Adult Volunteers
3204031|NCT01169714|Experimental|Dosing Healthy Elderly|Dosing in Healthy Elderly volunteers
3204134|NCT01168986|Active Comparator|Exercise|Participants perform an exercise to strengthen the deep neck flexors
3204415|NCT01166620||Patients with rheumatoid arthritis new to infliximab|
3204032|NCT01169701|Active Comparator|Tacrolimus|Participants continued with the same tacrolimus+Mycophenolic acid (MPA) (Myfortic® or Cell-Cept®) doses that were taken before study initiation (tacrolimus levels 4-7 ng/ml).
3204033|NCT01169701|Experimental|Everolimus|Participants received an initial dose (day 1) of Everolimus (EVL) 2mg at night and tacrolimus (if taking Prograf®, a full dose of Prograf® in the morning and a 50% dose of Prograf® at night; if taking Advagraf®, a 75% dose in the morning. On days 2 and 3, participants took EVL 2 mg twice daily (bid) without tacrolimus. On days 4 and 5, the EVL dose was adjusted and levels maintained between 5-8 ng/mL. Participants also continued with their MPA doses that were taken prior to study initiation.
3204034|NCT01169675|Experimental|BIBW 2992 low dose|patient receives low dose tablet BIBW 2992 po daily plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
3204035|NCT01169675|Experimental|BIBW 2992 medium dose|patient receives medium dose BIBW 2992 po daily plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
3204036|NCT01169675|Experimental|BIBW 2992 high dose|patient receives high dose BIBW 2992 po daily plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
3204037|NCT01169675|Experimental|BIBW 2992 low dose 6 day|patient receives low dose BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
3204038|NCT01169675|Experimental|BIBW 2992 medium dose 6 day|patient receives medium BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
3204039|NCT01169675|Experimental|BIBW 2992 high dose 6 day|patient receives high dose BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
3204040|NCT01169662|Active Comparator|Vegetable/ Fruit juice|450ml active product, 45 ml no added sugar squash (for flavour)
3204041|NCT01169662|Placebo Comparator|Placebo juice|
3204042|NCT01169649|Experimental|islet cell carcinomas and carcinoid tumors|This is an open label phase II study of MK-2206 administered to patients with metastatic neuroendocrine tumors.
3204043|NCT01169636|Experimental|Panobinostat MTD + ICE|Phase 1: Escalating Panobinostat dose with routine ICE Chemotherapy
3204044|NCT01169636|Experimental|ICE Chemotherapy|Phase 2: Routine ICE Chemotherapy (Ifosfamide, Carboplatin, + Etoposide)
3204045|NCT01169636|Experimental|Panobinostat + ICE|Phase 2: Panobinostat with ICE Chemotherapy
3204046|NCT01169623|Experimental|Educational Intervention|55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
3204047|NCT01169623|Placebo Comparator|CONTROL|55 of head nurses who will not participate in educational intervention will be considered as a control arm
3204048|NCT01169610|Experimental|Open Label|
3204049|NCT01169584|Experimental|Single Arm - JX-594|Intratumoral injection of JX-594
3204050|NCT01169571||Group I - No loading dose|No loading dose to be administered during the loading-dose paradigms
3204051|NCT01169571||Group II - Loading dose over 10 minutes|Loading dose dexmedetomidine 1 mcg/kg administered over 10 minutes during the loading-dose paradigms
3204052|NCT01169571||Group III - Loading dose over 20 minutes|Loading dose dexmedetomidine 1 mcg/kg administered over 20 minutes during the loading-dose paradigms
3204053|NCT01169558|Experimental|Bevacizumab|Bevacizumab will be administered in combination with fluoropyrimidine-based chemotherapy as first line treatment in participants with metastatic cancer of the colon or rectum until disease progression or study completion.
3204054|NCT01169545||Cancer patients over the age of 18|Cancer patients over the age of 18 who are receiving active treatment.
3204055|NCT01169532|Experimental|Treatment (ridaforolimus and vorinostat)|Patients receive ridaforolimus PO once daily on days 1-5 and vorinostat PO twice daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3204056|NCT01169519|Active Comparator|Sildenafil|Pharmacokinetic and hemodynamic evaluation following sildenafil administration
3204057|NCT01169506|Experimental|COPD patients and healthy individuals|
3204058|NCT01169493|Experimental|VVI-40 to RV DDD-40 to Bi-V DDD-40|Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
3204059|NCT01169493|Experimental|VVI-40 to Bi-V DDD-40 to RV DDD-40|Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
3204060|NCT01169493|Experimental|Bi-V DDD-40 to VVI-40 to RV DDD-40|Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
3204061|NCT01169493|Experimental|Bi-V DDD-40 to RV DDD-40 to VVI-40|Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
3204062|NCT01169493|Experimental|RV DDD-40 to VVI-40 to Bi-V DDD-40|Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
3204063|NCT01169493|Experimental|RV DDD-40 to Bi-V DDD-40 to VVI-40|Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
3204064|NCT01169480|Experimental|Massage Giver|Participants in the experimental group will be asked to give one 50-minute Swedish massage to another volunteer.
3204065|NCT01169480|No Intervention|Passive Controls|Participants in this arm will wait in a classroom (as usual) and do nothing out of their ordinary routines.
3204066|NCT01169467|Active Comparator|Standard-of-Care plus Precedex|Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment.
3204067|NCT01169467|Placebo Comparator|Standard-of-Care|Subjects who are treated with the standard of care sedation regiment only.
3204068|NCT01169454||Monitor then drain|Subjects who are treated with intermittent CSF drainage
3204069|NCT01169454||Drain then monitor|Subjects who are treated with continuous CSF drainage at set pressure thresholds
3204135|NCT01168986|No Intervention|No intervention|Participants receive/perform no intervention
3204136|NCT01168973|Experimental|Ramucirumab + Docetaxel|
3204504|NCT01165918||Donated embryos|
3204070|NCT01169428|Active Comparator|Standard Behavioral Weight-Loss Maintenence|"Attention/Education/Support Control~Group designed to control for educational content as well as multiple nonspecific treatment factors (e.g., support, time invested, leader attention, positive expectancy)"
3204071|NCT01169428|Active Comparator|Behavioral: Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss.
3204072|NCT01169415|Experimental|Protracted (30 days), Dexamethasone|Participants will receive a protracted course (30 days) of dexamethasone after surgery.
3204073|NCT01169415|Experimental|Abbreviated (14 days), dexamethasone|Participants will receive an abbreviated (14 days) course of dexamethasone after surgery.
3204074|NCT01169402|Experimental|Fluconazole|
3204075|NCT01169389|Active Comparator|Durolane|
3204076|NCT01169389|Placebo Comparator|Bupivacaine|
3204077|NCT01169350|Experimental|Diagnostic (18F FDG and 18F FMISO PET/CT)|Patients undergo 18F FDG and 18F FMISO PET/CT scans before starting neoadjuvant chemotherapy (without or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy.
3204078|NCT01169337|Experimental|Arm A (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3204079|NCT01169337|Active Comparator|Arm B (observation)|Patients undergo observation until progression to symptomatic myeloma.
3204080|NCT01169324|Experimental|DBS on|baseline settings
3204081|NCT01169324|No Intervention|DBS off|DBS off
3204082|NCT01169311|Experimental|HEEA Stapler|hemorrhoidopexy using Covidien EEA Hemorrhoid and Prolapse Stapling Set
3204083|NCT01169298|Experimental|Lenalidomide|Lenalidomide: 25mg daily on day1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort) or 35 mg daily of each 28 days (3rd cohort)
3204084|NCT01169272|Experimental|CRT-SonR 9770|Active implantable defibrillator with ability to cardiac resynchronization therapy
3204085|NCT01169259|Active Comparator|Vitamin D + fish oil|
3204086|NCT01169259|Active Comparator|Vitamin D + fish oil placebo|
3204087|NCT01169259|Active Comparator|Vitamin D placebo + fish oil|
3204088|NCT01169259|Placebo Comparator|Vitamin D placebo + fish oil placebo|
3204089|NCT01169246||Paradym VR, DR and CRT models|
3204090|NCT01169233|Other|Shorter Wavelength (green)|
3204091|NCT01169233|Other|Intermediate Wavelength (white w/ green filter)|
3204092|NCT01169233|Other|Longer Wavelength (red)|Placebo
3204093|NCT01169220|Experimental|Split prep|
3204094|NCT01169220|Active Comparator|Whole prep|
3204095|NCT01169207||Unaffected|Individuals who do not have IBD
3204096|NCT01169207||Affected|Individuals with IBD
3204097|NCT01169194||Affected|Patients with IBD
3204098|NCT01169194||Unaffected|Individuals who do not have IBD
3204099|NCT01169181|Active Comparator|AMES therapy with rTMS|Each subject will participate in 30 therapy sessions over a 10- to 15-week period. A session will last 90 to 120 minutes, which includes 20 minutes of AMES+rTMS, followed by an EMG test. During the hand-opening phase of the AMES therapy, the subjects assigned to the AMES+rTMS treatment group will be subjected to trains of TMS pulses.
3204100|NCT01169181|Active Comparator|AMES therapy with tDCS|Each subject will participate in 30 therapy sessions over a 10- to 15-week period. A session will last 90 to 120 minutes, which includes 20 minutes of AMES+tDCS, followed by an EMG test. A constant current will be applied throughout the entire 20-minute therapy session with the AMES device.
3204101|NCT01169155|Active Comparator|Study 3. Adults 20-49 Years of Age|"Using a randomized, non-blinded, repeated measures, clinical intervention design, our two working hypotheses as stated in Specific Aims 1 and 2 will be tested in a linked study, Study 3, with adult participants 20-49 years of age to ensure that the alarms tested will also work for adults in this age group.~This arm will use the alarm signal identified in Study 2 that is significantly associated with Electroencephalography (EEG)-defined awakening and successful completion of simulated escape behaviors by children after awakening from slow wave sleep. A lower frequency tone smoke alarm will evaluate the influence of alarm signal frequency on awakening. A conventional residential tone smoke alarm will be used as a reference stimulus. Both a male and a female voice will be used as alarm stimuli. Note that these will be strangers' voices, and not a mother's voice."
3204102|NCT01169155|Active Comparator|Study 4. Older Adults 60-84 Years of Age|Study 4 of this project will take the voice alarm script in Study 2 and compare it with a low-frequency 520 Hz square wave tone smoke alarm in awakening older adults 60-84 years of age from slow wave sleep and prompting their performance of a simulated escape procedure. Note that this will necessarily be a female stranger's voice, and not a mother's voice, in this older age group. As in Studies 1 and 2, a conventional residential tone smoke alarm will be used as a reference stimulus in Study 4. In order to maintain the same experimental design across these studies, a fourth alarm type will be introduced. This fourth alarm will be a hybrid of the low-frequency 520 Hz square wave tone smoke alarm and the voice alarm, i.e., the stimulus will begin with the 520 Hz square wave tone in a T-3 pattern followed by the voice script, with this stimulus being repeated until the subject completes the escape procedure.
3204103|NCT01169155|Active Comparator|Study 1. Maternal Voice Smoke Alarm Characteristics|"Study 1. Identification of Specific Maternal Voice Smoke Alarm Characteristics Associated With Awakening and Escaping.~Using a randomized, non-blinded, repeated measures, clinical intervention design, Study 1 will identify the critical elements (i.e., use of child's first name and/or behavior commands in message content) in the maternal voice signal that are significantly associated with EEG-defined awakening (and completion of simulated escape behaviors by children after awakening from S4). A conventional residential tone smoke alarm meeting current NFPA 72 National Fire Alarm Code will be used as a reference stimulus to allow comparison of responses to the voice alarm stimuli with responses to a conventional residential tone alarm stimulus."
3204137|NCT01168973|Placebo Comparator|Placebo + Docetaxel|
3204138|NCT01168960|Other|Cognitive Behavioral Treatment|A single intervention study
3204139|NCT01168947|Experimental|5% dextrose|5% dextrose rinsing fluid
3204140|NCT01168934|Experimental|1|Each subject will receive single oral and IV doses of crizotinib separated by at least 14 days.
3204141|NCT01168921|Experimental|Eltrombopag|Starting dose 75 mg by mouth (PO) daily for 28 day cycle.
3204104|NCT01169155|Active Comparator|Study 2. Mother's Versus Stranger's Voice Alarms & Alarm Freq.|"Study 2. Comparison of Mother's Versus Stranger's Voice Smoke Alarms and Alarm Frequency.~Study 2 will take the voice alarm script that was the most successful in Study 1 in awakening and prompting children to perform the simulated escape behaviors, and will compare mother's voice to a female stranger's voice using this script. This will determine whether mother's voice is a critical factor for success of the voice smoke alarm. In addition, a Temporal-Three (T-3) pattern smoke alarm with dominant tones in lower frequency ranges similar to the human voice range will be included as a stimulus in Study 2 to evaluate the influence of alarm signal frequency on EEG-defined awakening (as well as completion of simulated escape behaviors by children after awakening from S4). As in Study 1, a conventional residential tone smoke alarm will be used as a reference stimulus in Study 2. This conventional residential tone alarm has a higher frequency signal than the other T-3 tone alarm."
3204105|NCT01169155|Active Comparator|Study 5. Male Voice and Hybrid Tone/Voice Alarm for Children|Study 5. Children 5-12 Years of Age (Testing Male Voice and Hybrid Tone/Voice Alarm) Using a randomized, non-blinded, repeated measures, clinical intervention design, our two working hypotheses as stated in Specific Aims 1 and 2 will be tested in Study 5 among children 5-12 years of age using the following 4 alarm stimuli: female stranger's voice, male stranger's voice, hybrid of the low-frequency 520 Hz square wave tone smoke alarm and the voice alarm (from Study 4), and conventional high frequency tone residential alarm. This study arm will allow comparison of a male versus female voice and also evaluate the hybrid low frequency tone/voice alarm among children 5-12 years of age. The same protocol will be used for children in this study arm as was used in Studies 1 and 2.
3204106|NCT01169142|Active Comparator|Immediate Vitamin D3|Will start Vitamin D3 immediately
3204107|NCT01169142|Active Comparator|Three month delay|Half the subjects will be delayed three months (but evaluated) before getting Vitamin D3. (If the level is very low they will start immediately)
3204108|NCT01169129|Active Comparator|surgery+whole-brain irradiation|brain metastases is resected and the patient is submitted to whole-brain irradiation
3204109|NCT01169129|Active Comparator|whole-brain irradiation+radiosurgery|patients will be submitted to whole-brain irradiation and after, they will be submitted to radiosurgery.
3204110|NCT01169103|Experimental|recombinant human growth hormone|Forty subjects will be randomized to receive either recombinant human growth hormone or placebo.
3204111|NCT01169103|Placebo Comparator|Placebo|Forty subjects will be randomized to receive either recombinant human growth hormone or placebo.
3204112|NCT01169090|Experimental|SK-0403 100 mg QD|
3204113|NCT01169090|Experimental|SK-0403 200 mg QD|
3204114|NCT01169090|Experimental|SK-0403 400 mg QD|
3204115|NCT01169090|Experimental|SK-0403 200 mg BID|
3204116|NCT01169090|Sham Comparator|Placebo|
3204117|NCT01169090|Active Comparator|Sitagliptin 100 mg QD|
3204118|NCT01169077|Experimental|Group I: 0.25 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 0.25 mg, on Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
3204119|NCT01169077|Experimental|Group II: 1.0 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 1.0 mg, on Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
3204120|NCT01169077|Experimental|Group III: 4.0 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 4.0 mg, Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
3204121|NCT01169064|Active Comparator|Silver-containing surgical dressing|Self adhesive 4 x 10 dressing impregnated with nanocrystalline silver
3204122|NCT01169064|Active Comparator|Cloth adhesive dressing|Soft cloth adhesive wound dressing
3204123|NCT01169051||Thoracic sugery statins|
3204124|NCT01169051||Thoracic surgery non-statins|
3204125|NCT01169038|Active Comparator|Antibiotics|"Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~**Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. **We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway."
3204126|NCT01169025|Experimental|Ketamine|Subjects receive 0.3 mg/kg IV ketamine over 5 minutes and are evaluated every 10 minutes. Residual or recurring pain will be treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, subjects are asked if they need additional pain medication every 10 minutes, unless an earlier, spontaneous request is made by the subject or the provider determines that more is needed. For the potential of rare ketamine side effects (dysphoria, anxiety, or agitation), 2 mg IV midazolam is given every 5 minutes as needed for any of these symptoms. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
3204127|NCT01169025|Active Comparator|Fentanyl|Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
3204128|NCT01169012|Other|Single Arm Trial|Single Arm Trial
3204129|NCT01168999|Active Comparator|spinal manipulation|a spinal manipulation known to be effective in the treatment of low back pain for some individuals
3204130|NCT01168999|Placebo Comparator|sham spinal manipulation|a sham spinal manipulation intended to mimic the studied spinal manipulation
3204131|NCT01168999|No Intervention|natural history|No intervention is provided to participants in this arm of the study
3204132|NCT01168999|Placebo Comparator|Enhanced sham spinal manipulation|"a sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
3204133|NCT01168986|Active Comparator|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
3204142|NCT01168908|Experimental|Revatio (sildenafil)|This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
3204143|NCT01168908|Other|Placebo|This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
3204144|NCT01168895|Experimental|Arm 1|
3204145|NCT01168895|Experimental|Arm 2|
3204146|NCT01168869||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
3204147|NCT01168856||Cohort|
3204148|NCT01168843||normal pregnant|
3204149|NCT01168830|Experimental|Investigational device|
3204150|NCT01168817|Experimental|Arm 1|
3204151|NCT01168817|Active Comparator|Arm 2|
3204152|NCT01168817|Placebo Comparator|Arm 3|
3204153|NCT01168804|Experimental|single arm bendamustine bortezomib dexamethasone|single arm combination regimen: bendamustine - bortezomib- dexamethasone
3204154|NCT01168791|Experimental|doxorubicin plus palifosfamide-tris|
3204155|NCT01168791|Active Comparator|doxorubicin plus placebo|
3204156|NCT01168778|No Intervention|Control|
3204157|NCT01168778|Experimental|Intervention|
3204158|NCT01168765|Experimental|Intervention group|This is the promotora plus group that will receive the TSSC newsletter and exposure to the media campaign but will also receive monthly visits by promotoras/lay health workers who will review the monthly newsletter with participants, emphasize role model stories, and discuss physical activity and healthful food choices using motivational interviewing strategies.
3204159|NCT01168765|Other|Control group|TSSC Media Campaign only participants who will receive a newsletter and the same exposure to the media campaign intervention as other community members not enrolled in the behavioral intervention.
3204160|NCT01168752|Experimental|schedule A|"Debio 0932 will be administered orally to sequential escalating dose cohorts, as an every-other-day schedule.~Each dose level (DL) for each schedule will be determined according to the maximum grade of treatment-related AEs observed during the first 30 days treatment period (DLT period) in the previous DL.~Dose-escalation could be undertaken only after a minimum of 3 (or 6 in case of DLT) patients have been followed up and evaluated for at least 1 DLT period."
3204161|NCT01168752|Experimental|schedule B|"Debio 0932 will be administered orally to sequential escalating dose cohorts, as a daily schedule.~Each dose level (DL) for each schedule will be determined according to the maximum grade of treatment-related AEs observed during the first 30 days treatment period (DLT period) in the previous DL.~Dose-escalation could be undertaken only after a minimum of 3 (or 6 in case of DLT) patients have been followed up and evaluated for at least 1 DLT period."
3204162|NCT01168739|Experimental|Quercetin|not necessary, contained in protocol
3204163|NCT01168739|Placebo Comparator|Placebo|not necessary, contained in protocol
3204164|NCT01168726|Experimental|Protective Behavioral Strategies|Personalized feedback on use of protective behavioral strategies.
3204165|NCT01168726|Experimental|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
3204166|NCT01168726|Active Comparator|Alcohol Education|Educational information about harms associated with heavy drinking.
3204167|NCT01168713|Active Comparator|Levofloxacin|
3204168|NCT01168713|Experimental|CEM-101|
3204169|NCT01168700|Placebo Comparator|Placebo|Placebo 1.2 g per day for 12 weeks, followed by a second treatment period with aged garlic extract during 12 more weeks.
3204170|NCT01168700|Experimental|Aged garlic extract (Kyolic ®)|Aged garlic extract, 1.2 g per day for 12 weeks, followed by a second treatment period with placebo during 12 more weeks.
3204171|NCT01168687|Experimental|Group A|Twenty moderate to heavy social alcohol users (women 7-20 drinks/week --moderate 7-14 and heavy 15-20 and men 15-25 drinks/week --moderate 7-14 and heavy 15-25 drinks/week) will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.
3204172|NCT01168687|Experimental|Group B|Twenty moderate to heavy social alcohol users as described above will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days.
3204173|NCT01168674|Placebo Comparator|Sugar pill|Patients are randomized to a sugar pill (placebo), added to their current medications.
3204174|NCT01168674|Active Comparator|Ziprasidone|Patients are randomized to ziprasidone, added to their current medications.
3204175|NCT01168661|No Intervention|Control arm|Participants in this arm will be recruited from the group who applied to participate in the study and fulfilled the inclusion criteria but for various reasons (such as time constraints) could not participate.
3204176|NCT01168661|Active Comparator|Cognitive psychotherapy arm|In this arm, participants will attend a group meeting to practice cognitive psychotherapy once a week. They will also practice on their own >= 4 times a week.
3204177|NCT01168661|Active Comparator|Mindfulness based cog psychotherapy arm|In this arm, participants will attend a group meeting to practice mindfulness based cognitive psychotherapy once a week. They will also practice on their own >= 4 times a week.
3204178|NCT01168661|Active Comparator|Yoga treatment group|Persons in this arm will practice yoga >= 5 time each week (2 times in a supervised group and the other times on their own).
3204179|NCT01168648|Experimental|Yoga as stress management|The intervention consists of following a program of yoga at least three times a week for three months. The yoga program has been designed to reduce stress.
3204180|NCT01168648|Active Comparator|Control group|The group rests without using any specific program for relaxation at least three times a week for three months.
3204181|NCT01168648|Other|Yoga as stress management fewer tests|Eight persons participated in the same intervention as the experimental arm but did not undergo the full range of tests because they did not meet all the inclusion criteria for the study, most commonly because of medication use or body mass index.
3204182|NCT01168635|Experimental|Intervention|Virtually-delivered spirometry quality improvement program
3204183|NCT01168635|No Intervention|Standard of Care|
3204320|NCT01167413||FIbromyalgia Patients|Patients diagnosed as suffering from Fibromyalgia according to the ACR criteria
3204184|NCT01168609||patients with acute myocardial infarction|Acute myocardial infarction (AMI) was defined using the European Society of Cardiology / American College of Cardiology guidelines. Myocardial infarction was detected by the presence of at least two of the following criteria: chest pain lasting more than 30 minutes, typical electrocardiographic changes, and elevated creatinine kinase-MB fraction. Consecutive patients 18 years of age or older who presented within 12 hours after the onset of symptoms were considered for enrollment. Patients who had ST-segment elevation of 1 mm or more in two or more contiguous leads were classified as ST-segment elevation MI.
3204185|NCT01168596|Placebo Comparator|sugar pill|Placebo tablet, 1 per day, duration is approximately 12 weeks.
3204186|NCT01168596|Active Comparator|rasagiline|Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks.
3204187|NCT01168583||Positive Fluid Balance of 2000ml|
3204188|NCT01168583||Negative Fluid Balance of 2000ml|
3204189|NCT01168570||SAA monitored group|FMF-Amyloidosis patients receiving colchicine with a purpose to normalize SAA levels
3204190|NCT01168570||Historical control group|FMF-Amyloidosis patients receiving colchicine at a dose determined to stop FMF attacks. obtained from the Fibrillex study
3204191|NCT01168557|Experimental|Stress-Echo and EIT|Patients who routinely undergo stress-echocardiography will additionally be measured by EIT using a rubber belt, which will be placed around their chest
3204192|NCT01168544|Experimental|loading dose and 50.000 IU vit D3/month|Loading dose based on body weight and baseline serum 25 (OH)D level + 50.000 IU vit D3/month consolidation
3204193|NCT01168544|Experimental|Loading dose and 25.000 IU vit D3/month|Loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
3204194|NCT01168544|Active Comparator|800 IU vit D3/dag|800 IU vit D3/dag
3204195|NCT01168531|Placebo Comparator|placebo arm|
3204196|NCT01168531|Active Comparator|pregabalin arm|
3204197|NCT01168531|Experimental|dexamethasone with pregabalin arm|
3204198|NCT01168505|No Intervention|no iron supplentation|
3204199|NCT01168505|Experimental|iron supplement|
3204200|NCT01168492|Experimental|ketamine|group with triple sedation (ketamine, midazolam, meperidine)
3204201|NCT01168492|Placebo Comparator|placebo|group with conventional sedation and placebo ( midazolam, meperidine and placebo)
3204202|NCT01168479|Active Comparator|standard arm|The standard arm receives the current gold standard, namely 77Gy to the prostate in 35 fractions of 2.2 Gy, 5 times per week.
3204203|NCT01168479|Experimental|FLAME boost|In the experimental arm patients receive in addition to the current gold standard of 77 Gy to the prostate an integrated boost to the macroscopically visible tumour to reach a total dose of 95 Gy in 35 fractions of 2.7 Gy, 5 times per week.
3204204|NCT01168466|No Intervention|Neurofeedback|Waitlist control group.
3204205|NCT01168466|Experimental|QEEG-based Neurofeedback Training|A randomly selected half of participants waits 15 weeks for the other half to complete treatment, and are then reassessed, serving as controls. They then receive the same treatment as the experimental group.
3204206|NCT01168453||neutral head position|supine with neutral head position
3204207|NCT01168453||head rotation|supine with 30° head rotation
3204208|NCT01168414|Active Comparator|Ganfort|Fixed combination of Bimatoprost and Timolol
3204209|NCT01168414|Active Comparator|Duotrav|Fixed combination of Travoprost and Timolol
3204210|NCT01168401|Experimental|Norovirus Bivalent (GI.1 and GII.4) VLP Vaccine|
3204211|NCT01168401|Placebo Comparator|Saline|
3204212|NCT01168388||Movement disorder|
3204213|NCT01168375|Active Comparator|conventional therapy|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
3204214|NCT01168375|Active Comparator|conventional therapy plus umbilical cord serum eye drop|
3204215|NCT01168362||High risk group|positive cardiovascular risk group
3204216|NCT01168362||Low risk group|negative cardiovascular risk group
3204217|NCT01168349||Cohort|
3204218|NCT01168336|Experimental|betahistine|Betahistine 24 mg tablets
3204219|NCT01168336|Experimental|betahistine XR|betahistine 32 mg tablets
3204220|NCT01168336|Placebo Comparator|placebo|
3204221|NCT01168323|Experimental|Spaced education clinicians - cohort 1|Spaced education clinicians receive four isomorphic cycles of 9 spaced education emails over 36-weeks (0-2 emails per week). Each email contained one question-explanation.
3204222|NCT01168323|No Intervention|Control clinicians - cohort 2|Control clinicians received no intervention
3204223|NCT01168310|Experimental|1|
3204224|NCT01168310|Experimental|2|
3204225|NCT01168310|Experimental|3|
3204226|NCT01168310|Experimental|4|
3204227|NCT01168310|Experimental|5|
3204228|NCT01168310|Active Comparator|6|
3204229|NCT01168310|Placebo Comparator|7|
3204230|NCT01168245|Experimental|NICE-System NeuroAD|Treatment Group
3204231|NCT01168245|Sham Comparator|Sham-TMS|Control Group
3204232|NCT01168232|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3204233|NCT01168219|Experimental|Treatment (chemotherapy and transplant)|"REDUCED-INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3, busulfan IV over 45 minutes on days -6 to -3, and anti-thymocyte globulin IV over 4-10 hours on days -6 to -5 (matched sibling donor [MSD]) or -6 to -4 (matched unrelated donor [MUD]).~TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0 or on days 0-1.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus PO or IV on days -2 to 90 with taper on days 150-180. Patients also receive methotrexate IV on days 1, 3, 6 (MSD), and 11 (MUD).~CONSOLIDATION: Beginning on day 42, patients receive azacitidine SC or IV on days 1."
3204234|NCT01168206|Placebo Comparator|Placebo|
3204235|NCT01168206|Experimental|TK3|1 capsule, 3 times per day.
3204236|NCT01168193|Other|Patients that underwent surgery|Single arm
3204237|NCT01168180|Experimental|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
3204321|NCT01167400|Experimental|Cybercycling|cybercycling for 3 months
3204238|NCT01168180|Active Comparator|Ultrasound therapy and hot pack|The participants will receive thirty minutes session of Ultrasound therapy and hot pack for 9 sessions over a period of 3 weeks
3204239|NCT01168167||raltegravir-based cART|Patients who begin cART in regular clinical routine with 2N(t)RTI plus raltegravir (n=10 patients) will be offered to participate in this observation arm, but only if no other antiretroviral drugs and no concomitant drugs with relevant impact on antiretroviral's pharmacokinetics are administered. At time of study inclusion, patients should be characterised by a HIV-1 RNA load of >5,000 copies/mL and CD4-cell count of >200/µL within 12 weeks before cART initiation.
3204240|NCT01168167||standard of care-cART|Patients who begin cART in regular clinical routine with 2N(t)RTI plus either a boosted protease inhibitor or efavirenz (n=10 patients) at standard doses will be offered to participate in this observation arm. They will be offered to participate in this trial only if no other antiretroviral drugs and no concomitant drugs with relevant impact on antiretroviral's pharmacokinetics are administered. At time of study inclusion, patients should be characterised by a HIV-1 RNA load of >5,000 copies/mL and CD4-cell count of >200/µL within 12 weeks before cART initiation.
3204241|NCT01168154|Active Comparator|Lactobacillus Reuterii|
3204242|NCT01168154|Placebo Comparator|Placebo|
3204243|NCT01168128|Experimental|Tailored Action Plan|A Tailored Action Plan is an intervention selected to overcome barriers identified before the design and delivery of the intervention.
3204244|NCT01168063|Experimental|Helicobacter pilory triple treatment|Triple treatment on this arm is based on results of molecular detection of resistance to antibiotics
3204245|NCT01168063|Active Comparator|Helicobacter pilori standard recommended treatment|H.Pylori Eradication rate with empirical treatment
3204246|NCT01168050|Experimental|Nilotinib|
3204247|NCT01168037||Open repair|Open Surgical Repair (aortic replacement with revascularization of visceral arteries)
3204248|NCT01168037||Endovascular (Windows 1)|Endovascular therapy branched or fenestrated stent-graft
3204249|NCT01168037||Endovascular (Windows 3)|Endovascular therapy branched or fenestrated stent-graft (vascutek anaconda)
3204250|NCT01168024|Experimental|CINCOR™ System Treatment|Use of the CINCOR™ System and CCS-1 device during the pericutanous coronary intervention (PCI) procedure plus Standard of Care peri-procedural hydration for the prevention of contrast induced nephropathy (CIN).
3204251|NCT01168024|Other|Standard of Care|The control group will receive a peri and post-procedural hydration rate.
3204252|NCT01168011|Experimental|rigosertib|Doses of rigosertib up to 700 mg twice a day or three times a day every day of 21-day cycles.
3204253|NCT01167985|Experimental|Root canal sealer group+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
3204254|NCT01167985|Experimental|Provisional restoration material+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
3204255|NCT01167985|Experimental|Experimental- Different root canal sealer+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
3204256|NCT01167972||1|
3204257|NCT01167959||obesity diabetes, surgical and dietary|
3204258|NCT01167946|Experimental|Group A|will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks
3204259|NCT01167946|Active Comparator|Group B|will receive 2 consecutive daily pulses every 3 weeks for 24 weeks
3204260|NCT01167946|Active Comparator|Group C|will receive 3 consecutive daily pulses every 3 weeks for 24 weeks.
3204261|NCT01167933|Experimental|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd.
3204262|NCT01167933|Active Comparator|Zocor|Zocor® 80 mg tablets of Merck & Co. Inc., USA
3204263|NCT01167920|Active Comparator|Virtual Hypertension Clinic Group|In the VHC group, patients will be ask to regularly measure blood pressure with the Stabil-o-Graph so that these readings are transmitted to Virtual Hypertension Clinic. The data will be reviewed weekly and the patient will receive feedback and intervention if needed at every 2 week interval to achieve blood pressure goal. Once they reach goal, the feedback will be less intense and given at four week intervals till the end of the study.
3204264|NCT01167920|No Intervention|Usual Care Group|The Usual Care Group (UCG) patients will be told their BP is not in control and encouraged to work with their physician to improve it. There will be no further structured intervention during the rest of the study.
3204265|NCT01167907|Experimental|0.2% ropivacaine|Patients with evidence of sciatic and saphenous nerve block will be randomized to receive a postoperative continuous infusion of either saline (control) or 0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement.
3204266|NCT01167907|Placebo Comparator|Saline|Patients with evidence of sciatic and saphenous nerve block will be randomized to receive a postoperative continuous infusion of either saline (control) or 0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement.
3204267|NCT01167894|Experimental|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd.
3204268|NCT01167894|Active Comparator|Zocor|Zocor® 80 mg tablets of Merck & Co. Inc., USA
3204269|NCT01167881|Experimental|BI 10773 dose plus metformin|Patients receive one BI10773 tablet and one placebo Glimepiride capsule once daily
3204270|NCT01167881|Active Comparator|Glimepiride 1-4 mg plus metformin|Patients receive one glimepiride capsule and one placebo tablet Bi 10773 once daily.
3204271|NCT01167868|Experimental|FosD|Four sequential cohorts of Japanese subjects are planned with doses ranging from 50mg once daily to a maximum of 200mg twice daily. One cohort of White subjects is also planned to receive the same dose regimen as the third dose level in Japanese subjects
3204272|NCT01167868|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
3204273|NCT01167855|Experimental|Intervention|"Telemedicine asthma education sessions~Asthma health assessment via telemonitoring~Provider treatment prompts~School absenteeism~Prescription filling profile"
3204274|NCT01167829|Experimental|Acyline and oral testosterone|
3204275|NCT01167816|Experimental|azacitabine|
3204276|NCT01167803|Active Comparator|Reference - desflurane|The patients in this group will undergo anesthesia using remifentanil associated with desflurane.
3204277|NCT01167803|Experimental|Experimental - xenon|The patients in this group will undergo anesthesia using remifentanil associated with xenon
3204322|NCT01167400|Active Comparator|Traditional Stationary Biking|Traditional exercise on a stationary bike for 3 months.
3204278|NCT01167777||male/female|Symtomatic and asymptomatic males and females attending STD, family planning, public health and women's health clinics, or other applicable centers, who are being screened for CT or GC.
3204279|NCT01167764|Active Comparator|tranexamic acid|tranexamic acid 250mg po 3 times/day for 1 months
3204280|NCT01167764|Placebo Comparator|placebo|placebo po 3 times/day for 1 months
3204281|NCT01167751|Experimental|MNC implantation|Implantation of BM derived MNC
3204282|NCT01167751|Experimental|AC 133 implantation|Implantation of BM derived AC 133
3204283|NCT01167751|Placebo Comparator|Control|Injection of cell carrier
3204284|NCT01167738|Experimental|PEXG regimen + metformin|cisplatin and epirubicin at 30 mg/mq on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15, Metformin at 2 g days 1-28
3204285|NCT01167738|Active Comparator|PEXG regimen|cisplatin and epirubicin at 30 mg/mQ on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15
3204286|NCT01167725|Active Comparator|Arm I|Patients receive standard systemic therapy, at the discretion of patients' oncologist, comprising combinations of fluorouracil, leucovorin calcium, irinotecan hydrochloride, oxaliplatin, and/or capecitabine (including FOLFOX4, mFOLFOX6, CapeOx, or FOLFIRI), bevacizumab, or cetuximab. Treatment repeats in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may crossover to arm II.
3204287|NCT01167725|Experimental|Arm II|Patients undergo cytoreduction surgery and hyperthermic intraperitoneal mitomycin C over 45-90 minutes. Beginning 8 weeks after surgery, patients receive standard systemic therapy as in arm I. Treatment with systemic therapy repeats for 6 courses in the absence of disease progression or unacceptable toxicity.
3204288|NCT01167712|Experimental|Arm I (adjuvant chemotherapy suboptimally debulked)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.
3204289|NCT01167712|Experimental|Arm II (neoadjuvant chemotherapy)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive surgery between courses 3 and 4.
3204290|NCT01167686|Experimental|Food supplement|Half of the subjects participating in the trial (91) will recieve four tablets of the food supplement (Gardemont Goldrain Plus) three times a day for seven consecutive days from inclusion.
3204291|NCT01167673|Active Comparator|treatment with study drug|patients receiving study drug for 4 weeks. 3 capsules a day of coltect
3204292|NCT01167673|Placebo Comparator|placebo|patients receiving similar capsules but no active ingredients
3204293|NCT01167660||Healthy newborn babies|Healthy newborn babies immediately after birth.
3204294|NCT01167660||Sick newborn babies|Sick newborn babies whose medical condition indicates performing coagulation tests.
3204295|NCT01167647||bronchoscopy patients|
3204296|NCT01167634|No Intervention|1|
3204297|NCT01167634|Experimental|2|Deposit contract with a 1:1 match
3204298|NCT01167634|Experimental|3|Deposit contract with a 2:1 match
3204299|NCT01167634|Experimental|Experimental 4|Deposit contract with no match
3204300|NCT01167608||People with Parkinson's disease|Individuals diagnosed with Parkinson's disease
3204301|NCT01167595|Experimental|PEP uP Protocol|PEP-uP protocol and treatment algorithm implemented for all patients in ICU.
3204302|NCT01167595|No Intervention|Standard Feeding Protocol|Enteral feeds are guided by a standard feeding protocol specified by pre-printed ICU admission orders. The admitting physician has the option of initiating the enteral feeding protocol or keeping the patient nil per os (NPO).
3204303|NCT01167582|Experimental|Liberal Transfusion Strategy|Patients randomly allocated to the liberal transfusion strategy receive one unit of packed red cells following randomization and receive enough blood to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days. Any transfusion following the initial unit of packed red cells must be preceded by blood test documenting a hemoglobin concentration below 10 g/dL.
3204304|NCT01167582|Experimental|Restrictive transfusion strategy|"Receive a transfusion if they develop symptoms related to anemia. Transfusion is also permitted, but not required, in the absence of symptoms only if the hemoglobin concentration falls below 8 g/dL. Blood is administered one unit at a time and the presence of symptoms is reassessed. Only enough blood is given to relieve symptoms. If the transfusion is given because the hemoglobin concentration falls below 8 g/dL, then only enough blood is given to increase the hemoglobin concentration above 8 g/dL.~Symptoms of anemia that will be indications for transfusion are: 1) Definite angina requiring treatment with sublingual nitroglycerin or equivalent therapy. 2) Unexplained tachycardia or hypotension."
3204305|NCT01167569|Active Comparator|A|Ascorbic Acid
3204306|NCT01167569|Placebo Comparator|B|5% Dextrose Water or Normal Saline (placebo)
3204307|NCT01167556|Experimental|Family Motivational Intervention|An intervention provided to parents consisting of 6 sessions of training in Interactions Skills and 6 sessions training in Motivational Interviewing.
3204308|NCT01167556|Active Comparator|Routine care for parents|Routine care for parents consisting of 2 sessions psycho-education and individual support
3204309|NCT01167543||Pediatric patients with symptoms or diagnosis of GER|
3204310|NCT01167543||Control group of pediatric subjects with no symptoms of GER.|
3204311|NCT01167517|Experimental|Instructional digital video disc (DVD)|Breast milk expression instructions provided by digital video disc at the time of hospital discharge.
3204312|NCT01167517|Placebo Comparator|Instructions in print format|Breast milk expression instructions provided in print format at the time of hospital discharge.
3204313|NCT01167504||Saliva Sample Collection|Saliva collection
3204314|NCT01167491|Other|Disease group|Physiopathology
3204315|NCT01167478|Experimental|Caffeine|
3204316|NCT01167452|Experimental|Sulfamethoxazole/trimethoprim|2 DS tablets of sulfamehtoxazole/trimethoprim (1600 mg/320 mg)
3204317|NCT01167439|No Intervention|Mild dysphagia|
3204318|NCT01167439|Active Comparator|Severe dysphagia|
3204319|NCT01167426|Active Comparator|20 mg/0.5 mL Glatiramer Acetate|Participants received once daily subcutaneous administration of 20 mg glatiramer acetate as 20 mg/1.0 mL utilizing autoject 2 for glass syringe for two weeks (Period 1), followed by 20 mg/0.5 mL utilizing the autoject 2 device for four weeks (Period 2).
3204323|NCT01167387|Experimental|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrine; 240 mOsm/L) in dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
3204324|NCT01167387|Placebo Comparator|water|The control group will receive plain water with the same volume and timing of treatment.
3204325|NCT01167374|Experimental|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
3204326|NCT01167361||Children with upper or lower respiratory infections|Respiratory Virus infections in children who are symptomatic with either an Upper Respiratory Tract Infections and/or Lower Respiratory Tract Infections is determined by using a novel highly sensitive and rapid assay for RV detection. An aliquot from the leftover sample remaining after clinical diagnostic testing will be used for FilmArrayTM analysis. Specimens collected will include nasopharyngeal washes, nasopharyngeal swabs, tracheal aspirates and bronchoalveolar lavage as ordered by the treating physician. Diagnostic studies on this specimen will be performed as ordered and the results will be available to the treating physicians after reporting.
3204327|NCT01167335|Experimental|BGG492|
3204328|NCT01167335|Placebo Comparator|Placebo|
3204329|NCT01167322|Experimental|NPC-07|Single administration of NPC-07 at a dose of 20mg/kg body weight
3204330|NCT01167296|Active Comparator|Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.removed uterine stent was sent for bacterial culture too.
3204331|NCT01167296|Experimental|without Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
3204332|NCT01167283|Active Comparator|Electrostimulation|Neuromuscular electrical stimulation
3204333|NCT01167283|Sham Comparator|Sham stimulation|Sham stimulation
3204334|NCT01167270|Active Comparator|Parenting Insight|Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
3204335|NCT01167270|Placebo Comparator|Child Safety Insights|A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the AAP guidelines and the Academy's guide for health supervision, Bright Futures
3204336|NCT01167257|Experimental|Experimental arm|"Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation~Liposome encapsulated botulinum toxin A'"
3204337|NCT01167257|Placebo Comparator|Control arm|"Normal saline 50 mL in single intravesical instillation~Normal saline instillation'"
3204338|NCT01167244|Experimental|BMS-690514|
3204339|NCT01167231||Group 1|
3204340|NCT01167218||verify now assay|subjects who have Myelodysplastic syndrome, immune thrombocytopenia, and myeloproliferative disorders with platelet disorders
3204341|NCT01167192|Experimental|Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation|"Cisplatin 75 mg/m^2 IV every 21 days for 4 cycles or Carboplatin AUC 6 IV every 21 days for 4 cycles.~Radiation beginning cycle 2 day 1 daily for 5-6 weeks 45-50 Gy.~Recommended mastectomy~Recommended adjuvant chemotherapy~-doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 for 14 days for 4 cycles followed by paclitaxel 175 mg/m2 for 14 days for 4 cycles)"
3204342|NCT01167179|No Intervention|comparison group|Usual care Participants in the comparison group receive the usual care which consists of a 5 year medical routine control schedule based on the national guidelines, and - if appropriate - involvement of the dietician and the speech language therapist.During years one to five the routine control appointments are planned at a minimum of every 2, 3, 4, 6 and 12 months respectively. Most patients who undergo a total laryngectomy have additional contact with an oncology nurse during their 6-8 weekly medical control visits at the outpatient clinic for approximately the first year of follow-up. All other head and neck cancer patients have no structured follow-up contact with an oncology nurse.
3204343|NCT01167179|Experimental|nurse-led consultation|"Interventional care Year 1 follow-up: 2-monthly medical control visit + 30 minute nursing consultation, to a minimum of 6 in year 1. No restrictions with regard to cancer stage, site or treatment modality.~Intervention consist of standardised nursing consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. Goals: helping patients (and their partners) cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship."
3204344|NCT01167166|Experimental|rigosertib|Patients will receive 2400 mg dose of rigosertib as a intravenous continuous infusion over 24 hours for 72 to 120 consecutive hours every 2 weeks for the first 4 weeks then will receive oral rigosertib at a 560 mg twice-daily dose as capsules taken continuously.
3204345|NCT01167153|Experimental|Valsartan/amlodipine|Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.
3204346|NCT01167153|Active Comparator|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.
3204347|NCT01167140|Experimental|Cryo-Touch II|
3204348|NCT01167127|No Intervention|Tablet|OXN tablet, oral BID, flexible dose design
3204349|NCT01167114|Experimental|STA-9090|All subjects receive STA-9090
3204350|NCT01167101|Other|Pantoprazole|controls Pantoprazole 40mg qd for 28days
3204351|NCT01167101|Active Comparator|Pantoprazole + Rebamipde|Pantoprazole 40mg qd + Rebamipide 100mg Tid for 28days
3204352|NCT01167088|Experimental|Mitoquinone mesylate tablets (MitoQ)|
3204353|NCT01167088|Placebo Comparator|Matching placebo tablet|
3204354|NCT01167075|Active Comparator|Fresubin Original|
3204355|NCT01167075|Experimental|Intestamin plus Fresubin Original|
3204356|NCT01167062|Placebo Comparator|Placebo|
3204357|NCT01167062|Experimental|Tamsulosin Hydrochloride OCAS 0.4 mg|
3204358|NCT01167049|Experimental|CAPECITABINE|"Single arm:~Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; repeat three cycles (approximately 3- months);"
3204414|NCT01166620||Patients with rheumatoid arthritis new to adalimumab|
3204359|NCT01167036|Experimental|FascialEdge tool|A massage tool used to loosen adhesions in the superficial fascia
3204360|NCT01167036|Placebo Comparator|Placebo|Detuned electric point stimulation over the upper trapezius trigger point
3204361|NCT01167023|Experimental|7.5 mg Prasugrel|Participants were to receive 7.5 milligrams (mg) of prasugrel orally, once daily if they weighed ≥60 kilograms (kg) and if pharmacodynamic (PD) measures indicated that the 5-mg prasugrel dose did not produce a steady-state PD response equivalent to inhibition of platelet activation (IPA) ≥25%. Because these criteria were not met, no participants received 7.5 mg of prasugrel.
3204362|NCT01167023|Placebo Comparator|Placebo|
3204363|NCT01167023|Experimental|5 mg Prasugrel|
3204364|NCT01167010|Experimental|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a day for 12 weeks.
3204365|NCT01167010|Active Comparator|Foraseq|Foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
3204366|NCT01167010|Active Comparator|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
3204367|NCT01166997|Experimental|Ultrasound accelerated thrombolysis|Patients in this arm will receive anti-coagulation (intravenous unfractionated heparin) plus the EkoSonic Endovascular System will be used to deliver a low dose <20mg rt-PA (Actilyse) directly into the occlusive pulmonary thrombus.
3204368|NCT01166997|Active Comparator|Intravenous unfractionated heparin|Patients in this arm will receive the standard of care: intravenous unfractionated heparin used as anti-coagulation treatment.
3204369|NCT01166984|Experimental|AB103 Peptide Antagonist|AB103 Peptide Antagonist given intravenously
3204370|NCT01166984|Placebo Comparator|Placebo|Saline
3204371|NCT01166971|Experimental|ReSTOR +3|Bilateral Implantation of ReSTOR +3 Intraocular lenses after cataract extraction
3204372|NCT01166971|Active Comparator|Tecnis MF|Bilateral Implantation of Tecnis Multifocal Intraocular lenses after cataract extraction
3204373|NCT01166958|Active Comparator|Daily teriparatide (Forteo)|
3204374|NCT01166958|Active Comparator|Monthly cycles of teriparatide followed by raloxifene|
3204375|NCT01166945|Placebo Comparator|Short Course|Short course (5 days) of antimicrobial therapy and placebo for next 9 days.
3204376|NCT01166945|Active Comparator|Long Course|Long course (14 days) of antimicrobial therapy.
3204377|NCT01166932|Active Comparator|amoxicillin/clavulanic acid|patients who received amoxicillin/clavulanic acid
3204378|NCT01166932|Active Comparator|ceftriaxone/oxacillin|
3204379|NCT01166919|Experimental|Medical Tool|Matrix Radiofrequency Treatment of Port Wine Stain Birthmarks
3204380|NCT01166893||Burn wound|Modulated Imaging and Laser Speckle Imaging
3204381|NCT01166880||Laser Speckle Imaging|Laser Speckle Imaging Infant Head Blood flow
3204382|NCT01166867||Infant Development|Photo-plethysmography monitoring
3204383|NCT01166854||Muscle weakness|Diffuse Optical Spectroscopy
3204384|NCT01166841|Experimental|PSVC line clamped|Clamping of the percutaneously placed superior vena cava line placed for minimally invasive mitral valve repair/replacement.
3204385|NCT01166841|No Intervention|Unclamped PSVC|Unclamped percutaneously placed superior vena cava line placed for minimally invasive mitral valve repair/replacement.
3204386|NCT01166828|Experimental|1|The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
3204387|NCT01166828|Active Comparator|2|TAC participants will have six phone contacts every other week for three months.
3204388|NCT01166815|Active Comparator|Zinc supplemented|"Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. Bulk boxes will identify the products as A and B."
3204389|NCT01166815|Placebo Comparator|Placebo|"Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. Bulk boxes will identify the products as A and B."
3204390|NCT01166789|Active Comparator|Lubiprostone|Lubiprostone 48ug taken daily for 14 days.
3204391|NCT01166789|Placebo Comparator|Placebo|2 capsules containing a substance with no active ingredient taken daily for 14 days.
3204392|NCT01166776||Umbilical cord|To isolate Umbilical cord Wharton's jelly matrix to be used as a scaffold for tissue regenerative applications, including avascular necrosis.
3204393|NCT01166763|Experimental|high dose vitamin D3 (10,000 IU weekly)|Group/Cohort Label vitamin D3
3204394|NCT01166750|Experimental|CD-ROM-treatment|
3204395|NCT01166750|Active Comparator|Wait-list Control Group|
3204396|NCT01166737|No Intervention|Control Arm - Chemotherapy only|Chemotherapy for platinum-sensitive Ovarian Cancer can be selected on investigators choice
3204397|NCT01166737|Experimental|Procedure/Surgery|Maximum effort cytoreductive surgery
3204398|NCT01166724|Active Comparator|Sirolimus|patients will be switched from Tacrolimus to Sirolimus
3204399|NCT01166724|No Intervention|Tacrolimus|Patient will stay on Tacrolimus
3204400|NCT01166711|Experimental|Bare Metal Stent (BMS) followed by Drug Eluting Balloon (DEB)|
3204401|NCT01166711|Active Comparator|Drug Eluting Stent (DES)|
3204402|NCT01166698|Experimental|AZD9819|Inhaled suspension
3204403|NCT01166698|Placebo Comparator|Placebo|Inhaled suspension
3204404|NCT01166685|Active Comparator|Everolimus-eluting stent|A Xience Prime stent (Everolimus-eluting stent) is implanted in significant coronary lesions.
3204405|NCT01166685|Active Comparator|Bare-metal stent|Implantation of a bare-metal stent
3204406|NCT01166685|Experimental|Biodegradable Polymer-DES|Implantation of a Biodegradable Polymer-DES
3204407|NCT01166659|Experimental|CyPass Micro-Stent|Subjects receive the CyPass Micro-Stent
3204408|NCT01166646|Experimental|Halobetasol Proprionate Lotion 0.05%|Subjects randomized to receive lotion
3204409|NCT01166646|Active Comparator|Halobetasol Proprionate Cream 0.05%|Subjects randomized to receive cream
3204410|NCT01166633|Experimental|Pitavastatin 2 mg|
3204411|NCT01166633|Active Comparator|Atorvastatin 10mg|
3204412|NCT01166620||Patients with rheumatoid arthritis new to abatacept.|
3204413|NCT01166620||Patients with rheumatoid arthritis new to etanercept|
3204416|NCT01166594|Experimental|Bevacizumab|Tested Drug
3204417|NCT01166594|Placebo Comparator|Control|Control - BSS
3204418|NCT01166568|Experimental|PresVIEW Implantation|Subjects have PresView Scleral Implants surgical placed in the eye
3204419|NCT01166555|Experimental|1|
3204420|NCT01166542|Active Comparator|REOLYSIN, paclitaxel, carboplatin|
3204421|NCT01166542|Placebo Comparator|placebo, paclitaxel, carboplatin|
3204422|NCT01166529|Experimental|EUS-CPN|
3204423|NCT01166516|Other|Treatment with HUD IBV Valve System|Treatment with HUD IBV Valve System in Post-Approval Study
3204424|NCT01166503||Early Surgery|This group will be made up of subjects whose parents choose to have them undergo corrective surgery at or before age 11 months.
3204425|NCT01166503||Standard Surgery|This group will be made up of subjects who present after age 11 months or whose parents choose to have them undergo corrective surgery between 11-18 months.
3204426|NCT01166490|Experimental|1|ASG-5ME
3204427|NCT01166477|Active Comparator|Triple therapy|The patients who would be allocated to this arm will continue with their triple therapy treatment, based on any protease inhibitor boosted with ritonavir
3204428|NCT01166477|Experimental|Monotherapy|Those patients allocated to this arm will start to take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
3204429|NCT01166464|Experimental|Text Messaging|A text message-based intervention for smoking cessation
3204430|NCT01166464|Placebo Comparator|Control|Individuals in this group will receive generic (non-smoking related) text messages on the same schedule as the intervention arm. This provides a control for staff/program contact time and participant burden.
3204431|NCT01166451|Experimental|Low-iron|Infants randomly assigned at 6 months of age to receive low-iron formula (average 2.3 mg/L, range 1.6 - 2.4 mg/L) until 12 months of age.
3204432|NCT01166451|Experimental|High-iron|Infants randomly assigned at 6 months of age to receive high-iron formula (average 12.7 mg/L) until 12 months of age.
3204433|NCT01166438|Experimental|Botox A|A single intradetrusor injection of 100U botulinum toxin A (Botox A®) plus daily oral placebo tablets
3204434|NCT01166438|Active Comparator|Standardized Anticholinergic Regimen|A standardized 3-step anticholinergic regimen of daily oral solifenacin 5mg, solifenacin 10mg, and/or trospium chloride XR 60mg, as well as a single intradetrusor injection of saline (placebo). All subjects will begin on solifenacin 5 mg for 2 mo. If a subject's symptoms are not adequately controlled at 2 mo, she will be escalated to solifenacin 10mg, and similarly at 4 mo to trospium XR 60mg. If a subject's symptoms are adequately controlled on solifenacin 5 mg, she may continue that study medication for the entirety of the study (6 mo). Additionally, if a subject is dose-escalated to solifenacin 10mg at study mo 2 or 4, and her symptoms are adequately controlled, she may continue the solifenacin 10mg dose for the remainder of the study.
3204435|NCT01166425|Active Comparator|Lithium Carbonate|Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID (three times a day) at visit 1 (total dose 900 mg). Participants weighing < 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID (two times a day) the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose.
3204436|NCT01166425|Placebo Comparator|placebo|Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
3204437|NCT01166412|Active Comparator|Dose level AG1000-6.5|
3204438|NCT01166412|Active Comparator|Dose level AG1000-12.5|
3204439|NCT01166399||Primiparous women with an obstetric anal sphincter tear|Subjects in this trial will be primiparous women who underwent anal sphincter repair at the time of a singleton vaginal delivery. Sphincter tears will be clinically characterized at the time of delivery as <50% tear through the anal sphincter (modified WHO 3a), >50% (modified WHO 3b), or complete tear through the anal sphincter (4th degree). Subjects in this study will not have receive study interventions.
3204440|NCT01166386|Experimental|1|Treatment intervention using a 10-session behavioral program
3204441|NCT01166386|Placebo Comparator|2|Patients will spend time with a therapist viewing video discs and standard rehabilitation care
3204442|NCT01166373|Experimental|Enrollment video arm|Arm of subjects that will be shown a standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process.
3204443|NCT01166373|No Intervention|No video intervention arm|This group of subjects will not view a standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process.
3204444|NCT01166373|Experimental|ULS|Uterosacral Ligament Suspension was one of the randomized surgical treatments in the OPTIMAL study
3204445|NCT01166373|Experimental|SSLF|Sacrospinous Ligament Fixation was one of the randomized surgical treatments in the OPTIMAL study.
3204446|NCT01166373|Experimental|PMT|Perioperative Behavioral Therapy/Pelvic Muscle Training was one of the randomized non-surgical (behavioral) interventions in the OPTIMAL study.
3204447|NCT01166373|Other|Usual Care|No Perioperative Behavioral Therapy/Pelvic Muscle Training (i.e., usual care) was one of the randomized non-surgical (behavioral) interventions in the OPTIMAL study.
3204448|NCT01166360||Patients 2009|Patients undergoing cardiac surgery in 2009
3204449|NCT01166360||Patients 2008|Patients undergoing cardiac surgery in 2008
3204450|NCT01166347|Experimental|HeartWare® VAS|Implant of HeartWare® Ventricular Assist System
3204451|NCT01166347|Active Comparator|Control LVAD|Implant of FDA-approved LVADs approved for destination therapy
3204452|NCT01166334|Active Comparator|WebQuit study group|Intervention arm 1 (identity and description withheld to protect integrity of study)
3204453|NCT01166334|Active Comparator|WebQuit control group|Intervention arm 2 (identity and description withheld to protect integrity of study)
3204454|NCT01166321|Experimental|Carbon Ion Radiotherapy Boost|Carbon Ion Boost to the Macroscopic Tumor visible on contrast-enhanced MR-Imaging
3204455|NCT01166308|Experimental|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I Part of the Trial
3204456|NCT01166308|Active Comparator|Standard Treatment: Fractionated Stereotacitc Radiotherapy|Standard Precision Radiotherapy performed as Fractionated Stereotactic Radiotherapy (FSRT) up to 36 Gy in single dosis of 2 Gy
3204457|NCT01166282|Placebo Comparator|Double-blind Placebo EOW|Placebo for adalimumab every other week (eow) for 12 weeks.
3204458|NCT01166282|Experimental|Double-blind Adalimumab EOW|Adalimumab (body surface area dosing 24 mg/m^2 up to a maximum of 40 mg) every other week (eow) for 12 weeks.
3204459|NCT01166282|Experimental|Open-label Adalimumab EOW|Adalimumab (body surface area dosing 24 mg/m^2 up to a maximum of 40 mg) every other week (eow) for up to 192 weeks.
3204460|NCT01166269|Experimental|Grass-Allergen x 6|This arm will receive 6 injections of allergen.
3204461|NCT01166269|Active Comparator|grass-allergen x 3 and placebo x 3|this arm will receive 3 injections of allergen, and 3 injections of placebo.
3204462|NCT01166269|Placebo Comparator|placebo x 6|this arm will receive 6 injections of placebo.
3204463|NCT01166256|Experimental|High-flow nasal cannula|In this arm,patients with acute hypoxemic respiratory failure were treated with high-flow nasal cannula system(Optiflow, Fisher & Paykel, Auckland, New Zealand) to achieve SpO2 >92% or PaO2 >65 mmHg.
3204464|NCT01166256|Active Comparator|Non-invasive ventilation|In this arm, patients with acute hypoxemic respiratory failure is treated with the bi-level positive airways pressure mode (BiPAP Vision, Respironics Inc., Murrysville, PA) S/T mode to achieve SpO2 >92% or PaO2 >65 mmHg.
3204465|NCT01166243|Experimental|Fibrin Pad|Biologic
3204466|NCT01166243|Other|Standard of Care|Procedure
3204467|NCT01166230||Patients with Ta/T1, randomized to white light cystoscopy|Patients with non-invasive papillary bladder cancer (Ta/T1), enrolled in the previously completed pivotal phase III study PC B305/04 who were followed for recurrence.
3204468|NCT01166230||Patients with Ta/T1 randomized to Hexvix cystoscopy|Patients with non-invasive papillary bladder cancer (Ta/T1), enrolled in the previously completed pivotal phase III study PC B305/04 who were followed for recurrence.
3204469|NCT01166217|Experimental|ABCE, ACBD, BACD, BCAE, CABE and CBAD|
3204470|NCT01166204|Experimental|Single group|
3204471|NCT01166191|Experimental|SCLC|
3204472|NCT01166178|Experimental|Zoledronic Acid|Participants received zoledronic acid infusion in addition to calcium and vitamin D
3204473|NCT01166178|Placebo Comparator|Placebo|Participants received placebo to zoledronic acid infusion in addition to calcium and vitamin D
3204474|NCT01166165|Active Comparator|Cholecalciferol|
3204475|NCT01166165|Placebo Comparator|Placebo|
3204476|NCT01166139|Experimental|Nilotinib 400 mg twice daily|
3204477|NCT01166126|Experimental|Treatment (temsirolimus and selumetinib)|"Treatment Phase: This period begins with the first intravenous (through the vein) infusion of TEMSIROLIMUS and the first AZD6244 administration by mouth (visit 2, Week 1) and will continue until Week 8 (Visit 4).~As many as 38 patients will receive the same dosage of TEMSIROLIMUS injected in the veins once a week for 8 weeks, and the AZD6244 will be given as capsules by mouth twice a day for 8 weeks. That is one cycle. The TEMSIROLIMUS and AZD6244 will be given to participants as an outpatient, unless admission to the hospital was needed for treatment of related side effects or underlying disease. The subsequent cycles of TEMSIROLIMUS and AZD6244 will be given every 8 weeks. The TEMSIROLIMUS will be injected in a vein over 30 minutes.~The continuation phase begins with visits at weeks 12 in patients who receive at least two cycles of treatments."
3204478|NCT01166113|Experimental|PCP|
3204479|NCT01166100|Experimental|Fluoxetine Hydrochloride|Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited
3204480|NCT01166100|Active Comparator|Prozac ® weekly TM|Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company
3204481|NCT01166087|Experimental|Fluoxetine Hydrochloride|Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited
3204482|NCT01166087|Active Comparator|Prozac ® weekly|Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company
3204483|NCT01166074||SCIG|
3204484|NCT01166061|Experimental|Cohort 1|Subjects to receive either active or placebo
3204485|NCT01166061|Experimental|Cohort 2|Subjects to receive either active or placebo comparator
3204486|NCT01166061|Experimental|Cohort 3|Subjects to receive either active or placebo comparator
3204487|NCT01166061|Experimental|Cohort 4|Subjects to receive either active or placebo comparator
3204488|NCT01166061|Experimental|Cohort 5|Subjects to receive either active or placebo comparator
3204489|NCT01166048|Placebo Comparator|Milk powder pill|Patients will receive 2 placebo pills per day for a period of 4 weeks.
3204490|NCT01166048|Experimental|Duloxetine|In the experimental arm of the study patients will receive duloxetine, which will be titrated up to a dosage of 120mg over a period of two weeks and continued at this dosage for two weeks.
3204491|NCT01166022|Experimental|Exercise|Muscle strengthening program using weights and resistance bands in combination with a home based cycle ergometry program. The home-based exercise program will be performed up to 5 times weekly.
3204492|NCT01166022|No Intervention|Typical Activity|Subjects in this group will be asked to maintain their typical daily activity. Those assigned to this arm will be given the opportunity to join the intervention arm seven months after their screening visit.
3204493|NCT01165996|Experimental|Arm I: decitabine|INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts &lt; 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
3204494|NCT01165983|Placebo Comparator|Placebo|
3204495|NCT01165983|Experimental|Aliskiren|
3204496|NCT01165970|Active Comparator|Glandosane|After in situ exposition the enamel and dentin samples will demineralize with Glandosane.
3204497|NCT01165970|Experimental|Saliva natura|After in situ exposition the enamel and dentin samples will remineralize with Saliva natura
3204498|NCT01165957||Mobile bearings|Tibial polyethylene inserts retrieved from total knee replacements where the insert is designed to slide or rotate on the metal baseplate.
3204499|NCT01165957||Fixed bearings|Tibial polyethylene inserts retrieved from total knee replacements where the insert is locked to the metal baseplate.
3204500|NCT01165944|No Intervention|Standard diabetes therapy|Standard diabetes therapy with either oral agents or insulin injections
3204501|NCT01165944|Active Comparator|Oral diabetic agents and pramlintide|
3204502|NCT01165944|Active Comparator|Insulin injection with pramlintide|
3204503|NCT01165931|Experimental|Arm 1|
3204505|NCT01165866|Active Comparator|Treatment 1.|Metoclopramide 0.3 mg/kg max 10 mg in burette and mixed with normal saline to make up 50 cc of medication and normal saline as a single intravenous dose. Complete blood count,serum electrolytes,renal function,HCO3 level will be requested.Oral fluid will be started thereafter and increased gradually until patient discharge.
3204506|NCT01165866|Other|Treatment2.|Ondansetron 0.15 mg/kg max 4 mg in burette and mixed with normal saline to make up 50 cc of medication and normal saline to be given over 10 minutes,then patient will be kept NPO for one hour after completion of the anti emetic infusion and last episode of vomiting . Oral fluid will be started thereafter and increased gradually until fully tolerated and the patient is ready for discharge
3204507|NCT01165853|Other|Glucose|
3204508|NCT01165853|Other|Fructose|
3204509|NCT01165840|Experimental|Dapsone|Dapsone 100 mg PO x 1 dose
3204510|NCT01165827||Patients with aortic valve procedures|"All consecutive patients from participating hospitals with aortic valve defects who have received one of the following therapies:~surgical aortic valve replacement,~aortic valve surgery (Ross procedure, David procedure)~percutaneous transvascular (retrograde) aortic valve implantation~percutaneous transapical aortic valve implantation~aortic valve valvuloplasty as principal indication. If the aortic valve insufficiency is concurrent with combination procedures (e.g. coronary artery bypass graft, mitral valve surgery) the aortic valve stenosis must fulfil only the criteria for indication according to the German National guidelines (see: detailed study description)."
3204511|NCT01165814|Active Comparator|Tramadol at fixed intervals|
3204512|NCT01165814|Active Comparator|Tramadol on request|
3204513|NCT01165814|Active Comparator|Naproxen at fixed intervals|
3204514|NCT01165814|Active Comparator|Naproxen on request|
3204515|NCT01165801|No Intervention|Control Group (CO)|Fifty-four patients with cataract and non-exudative age-related macular degeneration (AMD) were randomized into an early surgery group (ES=28) with immediate cataract surgery and a control group (CO=26) where surgery was performed after six months.
3204516|NCT01165788||autologous BMT recipients|Lymphoma patients who received an autologous BMT as adults
3204517|NCT01165775||Threatened pre term labor patients|Patients receiving betamethasone to minimize the complications of prematurity will monitor blood glucose levels using the Dexcom Seven Plus Continuous Glucose Monitoring System.
3204518|NCT01165762|Experimental|Immune Tolerance, Kidney transplantation|Induction of immune tolerance in Haplotype matched living donor kidney transplantation.
3204519|NCT01165736|Active Comparator|Intravenous: PF-05186462|
3204520|NCT01165736|Active Comparator|Oral: PF-05186462|
3204521|NCT01165736|Active Comparator|Intravenous: PF-05089771|
3204522|NCT01165736|Active Comparator|Oral: PF-05089771|
3204523|NCT01165736|Active Comparator|Intravenous: PF-05150122|
3204524|NCT01165736|Active Comparator|Oral: PF-05150122|
3204525|NCT01165736|Active Comparator|Intravenous: PF-05241328|
3204526|NCT01165736|Active Comparator|Oral: PF-05241328|
3204527|NCT01165723|Experimental|IV Dose 1: experimental|
3204528|NCT01165723|Experimental|IV Dose 2: experimental|
3204529|NCT01165710||001|Patients with Atrial Fibrillation (AF) Treatment patterns of AF according to patient demographics clinical factors risk stratification and geographic regions.
3204530|NCT01165697||Fabry disease biomarker|Neuro-retinal fluorescein angiography (NRFA) exam will be administered once every 6 months for up to 3 years.
3204531|NCT01165684|Experimental|Step-wise|
3204532|NCT01165684|Active Comparator|Basal-bolus|
3204533|NCT01165671|Experimental|Experimental Arm|Carbon Ion Radiotherapy to the Macroscopic Tumor 6 x 3 Gy E up to 18 Gy E
3204534|NCT01165671|Active Comparator|Standard Arm|Proton Radiotherapy to the Macroscopic Tumor 5 x 2 Gy E up to 10 Gy E (Standard dose) applied after 48-52 Gy photon radiotherapy
3204535|NCT01165658|Experimental|Proton Therapy|The radiation prescription dose ranges from 45 Gy in 3 Gy fractions to 60 Gy in 4 Gy fractions. Patients will be assigned to receive 1 of 3 doses of radiation therapy, based on when they joined the study. The first group of at least 3 participants will receive the lowest total radiation dose. If the first dose is tolerated well by the first group of participants in this study, then the next group of participants will receive the second, higher dose of radiation. If this dose is tolerated, then a third group will be treated at the highest dose.
3204536|NCT01165645|Experimental|Arm I|Patients receive oral lopinavir and ritonavir twice daily for 28 days in the absence of disease progression or unacceptable toxicity.
3204537|NCT01165645|No Intervention|Arm II|Patients receive no therapy.
3204538|NCT01165632|Experimental|Arm I|Beginning at no more than 1 week before biopsy or resection, patients undergo fluorine F 18 fluorodopa-labeled PET/CT scan and pre-operative MRI. Patients then undergo stereotactic craniotomy. Some patients may also undergo radiation therapy.
3204539|NCT01165619||Hypothalamic Amenorrhea|This group is for pre-menopausal women between the aged 18-40 who have been previously diagnosed with Hypothalamic Amenorrhea. They can be currently diagnosed or may have recovered.
3204540|NCT01165619||Healthy Adult Men|This group is men over the age of 18 who do not have any history of reproductive disorders or chronic disease.
3204541|NCT01165619||Healthy Adult Women|This group is pre-menopausal, regularly menstruating women ages 18-40 who do not have a history of reproductive disorders or chronic disease.
3204542|NCT01165619||Idiopathic Hypogonadotropic Hypogonadism|This group is for adult men and women over the age of 18 who have been diagnosed with Idiopathic Hypogonadotropic Hypogonadism with or without anosmia.
3204543|NCT01165606|Experimental|Physiotherpy|
3204544|NCT01165593||Patients with atrial fibrillation|Patients with atrial fibrillation who have received a cardiac CT scan as part of normal care prior to catheter-based treatment of atrial fibrillation.
3204545|NCT01165580|Experimental|Single Arm|
3204546|NCT01165567|Experimental|sarpogrelate 300 mg per day|Patients in the sarpogrelate group receive sarpogrelate 300 mg per day for 24 hours before exposure to contrast agent.
3204547|NCT01165567|No Intervention|No sarpogrelate medication|
3204548|NCT01165554|Experimental|[18F] Flutemetamol|
3204549|NCT01165541|Active Comparator|Quetiapine fumarate extended release (Quetiapine XR)|Quetiapine XR 50-400mg
3204550|NCT01165541|Experimental|Quetiapine XR and Mirtazapine|Quetiapine XR 50-400mg + Mirtazapine 7.5-45mg
3205237|NCT01160653|No Intervention|2|Able Bodied
3204551|NCT01165528|Active Comparator|Adaptive support ventilation in ARDS|patients of ARDS will be randomized to this arm to receive mechanical ventilation as per ASV protocol
3204552|NCT01165528|Active Comparator|conventional ventilation strategy in ARDS|
3204553|NCT01165515||Healthy young females|20 healthy females, aged between 18 and 35 years
3204554|NCT01165515||Healthy young males|20 healthy males, aged between 18 and 35 years
3204555|NCT01165515||Healthy elderly smokers|20 healthy smokers, aged between 45 and 75 years
3204556|NCT01165515||Healthy elderly non-smokers|20 healthy non-smokers, aged between 45 and 75 years
3204557|NCT01165515||Healthy young female smokers|20 healthy female smokers, aged between 18 and 35 years
3204558|NCT01165515||Healthy young male smokers|20 healthy male smokers, aged between 18 and 35 years
3204559|NCT01165515||Healthy postmenopausal women|20 healthy postmenopausal women
3204560|NCT01165515||Female CMP Patients|20 female patients suffering from cardiomyopathy (ischemic or dilating)
3204561|NCT01165515||Male CMP Patients|20 male patients suffering from cardiomyopathy (ischemic or dilating)
3204562|NCT01165515||Female CHD patients|30 female patients suffering from cardiac heart disease, before aorto-coronary bypass surgery (and after)
3204563|NCT01165515||Male CHD Patients|30 male patients suffering from cardiac heart disease, before aorto-coronary bypass surgery (and after)
3204564|NCT01165515||male athlets|20 male athlets
3204565|NCT01165515||female athlets|20 female athlets
3204566|NCT01165502|Experimental|CM3.1-AC100|Compound CM3.1-AC100 s.c.
3204567|NCT01165502|Placebo Comparator|Placebo|Placebo for compound CM3.1-AC100 s.c.
3204568|NCT01165489||Laryngomalacia|Patients with Laryngomalacia
3204569|NCT01165489||Control Group|Patients without Laryngomalacia
3204570|NCT01165476|Active Comparator|manufacturer #1|treprostinil diethanolamine from manufacturer #1
3204571|NCT01165476|Experimental|manufacturer #2|treprostinil diethanolamine from manufacturer #2
3204572|NCT01165463|Experimental|Clinic-based SOPT basic training|Clinic-based SOPT basic training for 10 hours.
3204573|NCT01165463|Experimental|Home-based SOPT basic training|Home-based SOPT basic training for 10 hours.
3204574|NCT01165463|Active Comparator|Crossword Puzzles Training|Crossword puzzles training for 10 hours in our lab.
3204575|NCT01165463|Experimental|SOPT basic and SOPT booster-training|Clinic-based SOPT basic training and SOPT booster training.
3204576|NCT01165450|Active Comparator|Nexagon|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
3204577|NCT01165450|Placebo Comparator|Vehicle only|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
3204578|NCT01165437||Suspected Arterial Disease|Patients with known or suspected arterial disease and patients screened using AHA/ACC criteria for P.A.D.
3204579|NCT01165424|Experimental|MFNS 50 μg device|"MFNS 50 μg spray device. The dose will be as follows:~3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.~12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning."
3204580|NCT01165411||Patients with CVCs and PICC lines placed|This group will have either Standard of Care (control) or Process Improvement infection control changes administered.
3204581|NCT01165398||Residents, PAs, mid level providers|Lehigh Valley Health Network residents, physician assistants, and mid level providers who place central lines and attend the central lines simulation course
3204582|NCT01165385|Experimental|Pazopanib and Cisplatin|"Steady state period:Pazopanib will be given 8 days prior to cisplatin~Then pazopanib will be given 400 mg, 600 mg or 800 mg/day, daily and cisplatin 60, 75 or 100 mg/m2 , day 1 - 3 weekly, depending of the dose level"
3204583|NCT01165372|Experimental|Artesunate 2mg|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with artesunate 2mg/kg/day for 3 days and followed by DHA-PPQ treatment at doses according to National guidelines for 3 days.
3204584|NCT01165372|Experimental|Artesunate 4mg|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with artesunate 4mg/kg/day for 3 days and followed by DHA-PPQ treatment at doses according to National guidelines for 3 days.
3204585|NCT01165372|Experimental|DHA-piperaquine|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with dihydroartemisinin-piperaquine once daily according to weight for 3 days.
3204586|NCT01165359|Experimental|Part A: ITX 5061|Participants will receive ITX 5061 once a day for 3 days.
3204587|NCT01165359|Placebo Comparator|Part A: Placebo|Participants will receive placebo once a day for 3 days.
3204588|NCT01165359|Experimental|Part B: ITX 5061|Participants will receive ITX 5061 once a day for 14 days.
3204589|NCT01165359|Placebo Comparator|Part B: Placebo|Participants will receive placebo once a day for 14 days.
3204590|NCT01165359|Experimental|Part C: ITX 5061|Participants will receive ITX 5061 once a day for 28 days.
3204591|NCT01165359|Placebo Comparator|Part C: Placebo|Participants will receive placebo once a day for 28 days.
3204592|NCT01165346|Experimental|Stereotaxic radiation by CyberKnife|Implantation of fiducials Stereotaxic radiation by CyberKnife : 3 X 15 Gy over 8 to 10 days
3204593|NCT01165333|Experimental|Dose escalation|In the first part of the trial, a dose-ranging study in ca. 18-21 patients will be done. A standard dose escalation strategy will be used including 3 to 6 patients at each dose level, the first cohort of patients being treated at dose level one Interventions : Cilengitide dose escalation ; Concomitant radiotherapy ; Pharmacokinetic ; Pharmacogenetic
3204594|NCT01165333|Experimental|Cohort extension|An additional 20 patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations Interventions : Cilengitide ; Concomitant radiotherapy ; Pharmacokinetic ; Pharmacogenetic
3204625|NCT01165125|Other|FF/GW642444 and keto|Ketoconazole (400mcg) administered on Days 1-11, with co-administration of fFF / GW642444 (200mcg/25mcg) on Days 5-11
3204663|NCT01164787|Experimental|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
3204595|NCT01165320|Experimental|Participants with Esophageal Candidiasis|Candida infection is strongly suspected based on clinical symptoms and the participant's clinical course, white moss (plaque) is observed on the esophageal mucosa, and therapy via intravenous infusion is judged to be suitable for the present episode of esophageal candidiasis. MK-0991 therapy as a single loading dose of 70 mg/m^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 7 and 28 days, respectively.
3204596|NCT01165320|Experimental|Participants with Invasive Candidiasis|Candida infection is strongly suspected based on the presence of refractory fever not responding to an antibiotic agent, or clinical symptoms at the site of disease, or the participant's clinical course. In addition, at least 1 of the following criteria must be met: 1) Candida infection is strongly suspected based on radiographic imaging findings and positive serological test for fungus, 2) yeast is observed by direct microscopy or histopathological test of tissue biopsied from the site of disease, or 3) Candida species are observed by culture test of specimens sampled from the site of disease. MK-0991 therapy as a single loading dose of 70 mg/m^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 14 and 56 days, respectively.
3204597|NCT01165320|Experimental|Participants with Aspergillosis|Aspergillus infection is strongly suspected based on clinical symptoms and the participant's clinical course, and characteristic radiographic imaging findings are observed. In addition, at least 1 of the following criteria must be met: 1) risk factors predisposing to an Aspergillus infection, 2) positive serological test for Aspergillus, 3) acute-branching mold with separated hyphae are observed by direct microscopy or histopathological test, or 4) Aspergillus species are observed by culture test. MK-0991 therapy as a single loading dose of 70 mg/m^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 14 and 84 days, respectively.
3204598|NCT01165307|Active Comparator|Medical Therapy|Subjects will be prescribed monthly packets of Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills. Subjects who are unable to tolerate oral contraceptive pills or are unwilling to take oral contraceptive pills will be prescribed naproxen sodium pills. The latter will be administered as follows; 500mg with onset of menses, then 250mg three times daily for the duration of the menses (or maximum of five days).
3204599|NCT01165307|Active Comparator|Radiofrequency Endometrial Ablation|Subjects will undergo NovaSure® radiofrequency endometrial ablation within 4 weeks of randomization. The procedure will occur at any time during the menstrual cycle, without endometrial pre-treatment. Endometrial thinning will be carried out using suction curettage in 50% of the cases included in the ablation group. Random assignment for this treatment will be included in the overall randomization plan.
3204600|NCT01165294|Experimental|001|ketamine An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
3204601|NCT01165294|Experimental|002|Placebo An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
3204602|NCT01165281|Experimental|001|R331333 (referred to as JNS024 ER or CG5503) One 25 mg to 200 mg capsule twice daily for 4 weeks.
3204603|NCT01165281|Active Comparator|002|Oxycodone CR One 5 mg to 40 mg capsule twice daily for 4 weeks.
3204604|NCT01165268|Active Comparator|Dapagliflozin (T2DM)|
3204605|NCT01165268|Active Comparator|Dapagliflozin (Healthy Subjects)|
3204606|NCT01165255||Infants born to women who were exposed to antidepressants|Women ages 12 through 49 (as of delivery date) who were dispensed an antidepressant between 01 January 1995 and 30 September 2004 from the original Bupropion study.
3204607|NCT01165242|Experimental|Group A|Subjects were vaccinated with vaccine GSK134612 Lot A
3204608|NCT01165242|Experimental|Group B|Subjects were vaccinated with vaccine GSK134612 Lot B
3204609|NCT01165242|Active Comparator|Group C|Subjects were vaccinated with Menactra®
3204610|NCT01165229|Experimental|Zoster vaccine group|Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
3204611|NCT01165229|Placebo Comparator|Placebo group|Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
3204612|NCT01165216|Experimental|Dose Level 1: Ipilimumab, 3 mg/kg + Paclitaxel + Carboplatin|Participants received ipilimumab, 3 mg/kg, administered as a single dose intravenously (IV) over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, area under the curve (AUC)=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
3204613|NCT01165216|Experimental|Dose Level 2: Ipilimumab, 10 mg/kg + Paclitaxel + Carboplatin|Participants received ipilimumab, 10 mg/kg, administered as a single dose IV over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, AUC=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
3204614|NCT01165203|Experimental|GSK1437173A Group|Subjects who received three doses of GSK1437173A vaccine (Months 0, 2 and 6), administered intramuscularly, in the deltoid muscle of the non-dominant arm.
3204615|NCT01165203|Placebo Comparator|Placebo Group|Subjects who received three doses of placebo (Months 0, 2 and 6), administered intramuscularly, in the deltoid muscle of the non-dominant arm.
3204616|NCT01165190||Pioglitazone group|
3204617|NCT01165177|Experimental|Zoster vaccine group|Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
3204618|NCT01165177|Placebo Comparator|Placebo group|Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
3204619|NCT01165164|Experimental|FID 115958D|Lubricant eye drop
3204620|NCT01165151|Experimental|Small group|10-member groups
3204621|NCT01165151|Active Comparator|Large group|30-member groups
3204622|NCT01165138|Experimental|Fluticasone furoate/Vilanterol (GW642444)|Fluticasone furoate/Vilanterol inhalation powder once daily for 12 weeks
3204623|NCT01165138|Experimental|Fluticasone Furoate|Fluticasone furoate inhalation powder once daily for 12 weeks
3204624|NCT01165138|Placebo Comparator|Placebo|Placebo inhalation powder once daily for 12 weeks
3204662|NCT01164800|Active Comparator|Mavik®|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
3204626|NCT01165125|Other|Ketoconazole Placebo to match & FF/GW642444|ketoconazole placebo to match administered on days 1-11. FF/GW642444 (200mcg/25mcg) co-administered on Days 5-11
3204627|NCT01165112|Experimental|Treatment (chemotherapy and monoclonal antibody therapy)|Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60 minutes on days 1-3, and carboplatin IV over 60 minutes on day 1. Patients with CD20+ T-cell lymphoma disease also receive rituximab IV on day 2 or 3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
3204628|NCT01165099|Experimental|manual acupuncture|Sterile needles were inserted intramuscularly to a depth of 15-20mm until an unusual (De-Qi) sensation developed and remained inserted for 30-60 minutes and were manually manipulated during this time. The following bilateral acupoints on the hands and feet at Hegu (LI 4), Sanyinjiao (Sp 6) Kunlun (BL 60) and Zhiyin (BL 67)were used.
3204629|NCT01165099|Experimental|electro acupuncture|Sterile needles were inserted intramuscularly to a depth of 15-20mm until an unusual (De-Qi) sensation developed and remained inserted for 30-60 minutes and were either electronically simulated withm2 Hz pulses of 0.5 msec duration for 30 minutes sufficient to cause non-painful muscle contractions. The following bilateral acupoints on the hands and feet at Hegu (LI 4), Sanyinjiao (Sp 6) Kunlun (BL 60) and Zhiyin (BL 67)were used.
3204630|NCT01165099|Sham Comparator|Sham manual or electro acupuncture|Sterile needles were inserted adjacent to the specific acupuncture sites identified for the manual and electro groups to a depth of 1-1.5mm only and insufficient to provoke an unusual sensation and left in position for a 30-60 minutes. Those randomised to 'sham-manual' received no stimulation and those randomised to 'sham-electro' were connected to the electrical stimulator but the current not activated.
3204631|NCT01165099|No Intervention|control group|Following randomisation to be control group, no specific treatment was organised at this time.
3204632|NCT01165073|Experimental|Naso-gastric tube feeding|
3204633|NCT01165073|Active Comparator|Oral feeding|
3204634|NCT01165060|Experimental|Bezafibrate|All patients in the trial will use bezafibrate 400 mg once daily until week 12, and subsequently use 800 mg onde daily until week 24.
3204635|NCT01165047|Experimental|Nitric Oxide|80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM
3204636|NCT01165034|No Intervention|Usual care|Best usual practice including general respiratory specialist and primary care
3204637|NCT01165034|Experimental|Breathlessness Support Service|Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
3204638|NCT01165021|Experimental|Pemetrexed + Cisplatin|
3204639|NCT01164995|Experimental|MK-1775 and carboplatin|MK-1775: oral capsules. Carboplatin: intravenous infusion in 30 minutes
3204640|NCT01164969||H. pylori eradication failure|People who are not able to eradicate H. pylori although the appropriate antibiotic therapy taken.
3204641|NCT01164956|Other|arm 1|"no compano comparison arm, participants serve as their own controls; methylphenidate and placebo are administered in blocks, with one then the other administered in one block. There are 4 blocks, Order of the two treatments within a block is random. There are therefore theoretically 16 potential armsrison arm, participants serve as their own controls"
3204642|NCT01164956|Other|arm 2|"no comparison arm, participants serve as their own controls; methylphenidate and placebo are administered in blocks, with one then the other administered in one block. There are 4 blocks, Order of the two treatments within a block is random. There are therefore theoretically 16 potential arms"
3204643|NCT01164943|Active Comparator|Human FSH|
3204644|NCT01164943|Active Comparator|Recombinant FSH|
3204645|NCT01164930|Experimental|Acceptance and Commitment Therapy group|8-week ACT group
3204646|NCT01164930|No Intervention|Wait-list control group|Participants will be offered treatment following wait-list data collection
3204647|NCT01164917|Active Comparator|AMG811|All will receive AMG 811, either on Day 1 or Day 85
3204648|NCT01164917|Placebo Comparator|AMG811 Placebo|All will receive placebo, either on Day 1 or Day 85
3204649|NCT01164904|Experimental|Experimental|Ten escalating dose levels of AMG 181 administered as a single dose SC or IV in healthy volunteers and SC in subjects with mild-to-moderate ulcerative colitis.
3204650|NCT01164891|Experimental|Single Arm|
3204651|NCT01164878||Before|ELBW infants before change of feeding policy
3204652|NCT01164878||After|ELBW infants after change of feeding policy
3204653|NCT01164865|Experimental|OPTI-FREE RepleniSH|OPTI-FREE RepleniSH multipurpose disinfecting solution used with study contact lenses on a daily basis for 2 weeks.
3204654|NCT01164865|Active Comparator|Clear Care|Clear Care contact lens care system used with study contact lenses on a daily basis for 2 weeks.
3204655|NCT01164852|No Intervention|Expectant management|Expectant management: refers to pregnancy prolongation during which time women and fetuses are carefully monitored for indications for delivery.
3204656|NCT01164852|Active Comparator|Interventionist management|Interventionist management: in which blood pressure is stabilized, corticosteroids are given for acceleration of fetal maturity and delivery is planned within 48-72 hours.
3204657|NCT01164826|Experimental|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
3204658|NCT01164826|Active Comparator|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
3204659|NCT01164813|Experimental|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
3204660|NCT01164813|Active Comparator|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
3204661|NCT01164800|Experimental|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
3205813|NCT01156337||low sodium diet 80 mmol/day|
3204664|NCT01164787|Active Comparator|Mavik®|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
3204665|NCT01164774|Experimental|Ramipril|Ramipril 10 mg capsules of Dr. Reddy's Laboratories Limited
3204666|NCT01164774|Active Comparator|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
3204667|NCT01164761|Experimental|Ramipril|Ramipril 10 mg capsules of Dr. Reddy's Laboratories Limited
3204668|NCT01164761|Active Comparator|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
3204669|NCT01164748||Sentinel Node Biopsy|All women who has Sentinel Node Biopsy as their primary treatment of the axilla
3204670|NCT01164748||Axillary Lymph Node Dissection|All women who had Axillary Lymph Node Dissection as primary axillary treatment
3204671|NCT01164735||Correlative studies|Archived tumor tissue samples are analyzed for topoisomerase 2-alpha gene alteration and expression and chromosome 17 polysomy by FISH and IHC. Clinical information associated with each endometrial carcinoma sample (e.g., age, race/ethnicity, cell type, histologic grade, disease stage, and regimen type) is also collected.
3204672|NCT01164722|Experimental|Arm I: Infrared coagulator treatment|Infrared photocoagulation therapy. The infrared coagulator (IRC) contact tip is placed in direct contact with lesion under high-resolution anoscopy (HRA) guidance. Patients then undergo IRC ablation for 1.5 second pulses. IRC ablation is reapplied until the level of submucosal vessels are reached.
3204673|NCT01164722|Active Comparator|Arm II: Expectant management|Patients receive standard of care and undergo clinical observation. After 12 months, patients may receive IRC ablation to all anal intraepithelial neoplasia lesions despite of their size.
3204674|NCT01164709|Experimental|bortezomib + nelfinavir|escalation 3 by 3 cohorts
3204675|NCT01164696||Group 1|
3204676|NCT01164683|Experimental|Arm 1|Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
3204677|NCT01164683|Active Comparator|Arm 2|Usual care
3204678|NCT01164670||Men|Men over 70 years old.
3204679|NCT01164670||Women|Women over 70 years old.
3204680|NCT01164657|Experimental|study group|Randomized to give birth on a birthing seat
3204681|NCT01164657|No Intervention|control group|Randomized to birth in any other position except the birthing seat
3204682|NCT01164644|Active Comparator|Arnica Montana|The subject will take twelve pills by mouth three times a day over four days.
3204683|NCT01164644|Placebo Comparator|Placebo|The subject will take twelve pills by mouth three times a day over four days.
3204684|NCT01164631|Experimental|Orthodontic treatment|Snoring patients enrolling for tonsil surgery with maxillary constriction, and/or jaw retrognathism
3204685|NCT01164631|No Intervention|Control Group|Patients enrolled for tonsils surgery
3204686|NCT01164618|Experimental|Group 1|The subjects in this arm will begin on the daily remote ischemic preconditioning (RIPC) protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily exercise.
3204687|NCT01164618|Experimental|Group 2|The subjects in this arm will begin on the exercise protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily remote ischemic preconditioning (RIPC).
3204688|NCT01164592|Active Comparator|Therapy with adaptive servo ventilation|optimal medical therapy + adaptive servoventilation
3204689|NCT01164592|No Intervention|Optimal medical therapy according to guidelines|optimal medical therapy
3204690|NCT01164579|Experimental|Tofacitinib (CP 690,550) 10 mg BID plus MTX|
3204691|NCT01164579|Experimental|Tofacitinib (CP-690,550) 10 mg BID, tablet plus placebo MTX|
3204692|NCT01164579|Active Comparator|Placebo tofacitinib (CP-690,55) plus MTX 10 mg/wk to 20 mg/wk|
3204693|NCT01164566|Experimental|Arm I|Patients undergo transnasal esophagoscopy at baseline and 3 months following completion of radiation therapy and/or chemotherapy.
3204694|NCT01164553|Experimental|Group 2, 0.5 mL TIV|Naive cohort participants (n=180) receive 0.25 mLTrivalent Inactivated Vaccine (TIV) in two intramuscular doses 28-42 days apart. Fully Primed cohort participants (previously vaccinated) (n=40) will receive 0.5 mL Trivalent Inactivated Influenza Vaccine (TIV) in one intramuscular dose.
3204695|NCT01164553|Active Comparator|Group 1, 0.25 mL TIV|Naive cohort participants (n=90) receive 0.25 mLTrivalent Inactivated Vaccine (TIV) in two intramuscular doses 28-42 days apart. Fully Primed cohort participants (previously vaccinated) (n=20) will receive 0.25 mL Trivalent Inactivated Influenza Vaccine (TIV) in one intramuscular dose
3204696|NCT01164540|Experimental|1|Oral Treatment
3204697|NCT01164540|Placebo Comparator|2|Oral treatment
3204698|NCT01164514|Active Comparator|Group 1 - vaccine alone|8 subjects to receive vaccine (10 mcg) alone on Days 0, 29 and 59.
3204699|NCT01164514|Experimental|Group 3 - vaccine + CPG 7909 (250 mcg)|8 subjects to receive vaccine (10 mcg) with 250 mcg of adjuvant on Days 0, 29 and 59.
3204700|NCT01164514|Experimental|Group 2 - vaccine + CPG 7909 (500 mcg)|8 subjects to receive vaccine (10 mcg) with 500 mcg of adjuvant on Days 0, 29 and 59.
3204701|NCT01164514|Placebo Comparator|Group 4 - Placebo|4 subjects to receive normal saline (placebo) on Days 0, 29 and 59.
3204702|NCT01164501|Experimental|BI 10773 low dose|BI 10773 tablets once daily
3204703|NCT01164501|Experimental|BI 10773 high dose|BI 10773 tablets once daily
3204704|NCT01164501|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
3204705|NCT01164488|Experimental|1|
3204742|NCT01164150|Other|Arm A Control|Radiation: 45 Gy/25 fraction external beam pelvic radiotherapy delivered using a 3-dimensional planned technique followed by 11 Gy / 2 fractions vaginal vault brachytherapy
3204743|NCT01164137|Experimental|Medication Reconciliation Intervention|Participants receiving a pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at identifying and correcting medication discrepancies.
3204744|NCT01164137|No Intervention|Medication Reconciliation Non-Interven.|Participants not receiving a pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at identifying and correcting medication discrepancies.
3204706|NCT01164475|Experimental|Fixed Dose Plerixafor|10 microgram per kilogram (mcg/kg) granulocyte-colony stimulating factor (G-CSF) subcutaneous (SC) injection once daily in morning from Day 1 through Day 4 (G-CSF mobilization period), followed by 20 milligram (mg) plerixafor SC injection (fixed dose) in evening of Day 4 (10 to 11 hours prior to first apheresis), and then 10 mcg/kg G-CSF SC injection in morning of Day 5 (1 hour prior to first apheresis). Apheresis process and treatment with plerixafor (10 to 11 hours prior to apheresis) and G-CSF (1 hour prior to apheresis) was continued until the target number of cluster of differentiation 34 (CD34+) stem cells (greater than or equal to [>=] 5*10^6 cells/kg) was collected or until a maximum 4 apheresis sessions occurred.
3204707|NCT01164475|Active Comparator|Weight-Based Plerixafor|G-CSF 10 mcg/kg SC injection once daily in morning from Day 1 through Day 4 (G-CSF mobilization period), followed by plerixafor 0.24 milligram per kilogram (mg/kg) SC injection (weight-based dose) in evening of Day 4 (10 to 11 hours before first apheresis), and then G-CSF 10 mcg/kg SC injection in morning of Day 5 (1 hour prior to first apheresis). Apheresis process and treatment with plerixafor (10 to 11 hours prior to apheresis) and G-CSF (1 hour prior to apheresis) was continued until the target number of CD34+ stem cells (>=5*10^6 cells/kg) was collected or until a maximum 4 apheresis sessions occurred.
3204708|NCT01164462|Other|A 2|During the normal opening hours of five testing centers, clients with a rapid finger-stick blood specimen test
3204709|NCT01164462|Other|B group|During evenings and week-ends (i.e. when the centers are closed) only community based with rapid HIV testing
3204710|NCT01164462|Other|A1 group|During the normal opening hours of five testing centers, clients with a conventional test.
3204711|NCT01164449|Experimental|1|Space TGC system with incorporated eMPC advised insulin titration to establish glycaemic control
3204712|NCT01164423|Experimental|1|Space TGC system with incorporated eMPC advised insulin infusion to establish glycaemic control
3204713|NCT01164410||Pediatric Colonoscopy|Patients undergoing colonoscopy in the Department of Pediatric Gastroenterology at the Cleveland Clinic Children's Hospital in Cleveland, Ohio.
3204714|NCT01164397||Dislipidemic Population|People with high levels of total cholesterol, LDL, C-HDL and triglycerides
3204715|NCT01164371||Initial presentation of coronary disease - Stable angina|Patients whose initial symptomatic presentation of coronary disease is stable angina (either diagnosis or symptoms)
3204716|NCT01164371||Initial presentation of coronary disease - ACS|Patients whose initial symptomatic presentation of coronary disease is acute coronary syndrome (ST-elevation myocardial infarction [STEMI], non-STEMI [nSTEMI] or unstable angina) without prior stable angina or symptoms of stable angina
3204717|NCT01164371||Initial presentation of coronary disease - Coronary death|Patients whose initial symptomatic manifestation of coronary disease is coronary death with no prior diagnosis of stable angina (or symptoms of stable angina) or diagnosis of acute coronary syndrome
3204718|NCT01164371||Initial presentation of coronary disease - None|Patients without symptomatic presentation of coronary disease, either alive or dead from non-coronary cause
3204719|NCT01164358||study arm I|"patients who have been enrolled in the previous study Intrastromal Correction of Ametropia by Femtosecond Laser (study ISCAF), study arm 1, Presbyopia sub-group: treatment pattern 5-Rings"
3204720|NCT01164358||study arm II|"patients who have been enrolled in the previous study Intrastromal Presbyopia Correction by Means of Femtosecond Laser (study # 0905)"
3204721|NCT01164345|Experimental|MOZOBIL|treatment with mozobil for autologous stem cell collection
3204722|NCT01164332|Other|Method A|First experimental detection method
3204723|NCT01164332|Other|Method B|Second experimental detection method
3204724|NCT01164319|Active Comparator|Group 1 (no early recurrence)|Patients without atrial fibrillation recurrences through the implantable cardiac monitors during the 3 months post-ablation period.
3204725|NCT01164319|Active Comparator|Group 2 (early AF recurrence)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period.
3204726|NCT01164319|Active Comparator|Group 3 (early recurrence-no reablation)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period from Group 2 would not receive reablation.
3204727|NCT01164319|Active Comparator|Group 4 (early recurrence-early reablation)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period from Group 2 will receive early reablation based on data stored by implanted monitor.
3204728|NCT01164306|Experimental|LifeSkills training|
3204729|NCT01164306|Active Comparator|Healthy Lifestyle Behaviors|
3204730|NCT01164293|Experimental|Atopy patch test|Atopy patches were applied on food allergy patient's back for 48 hrs then the patches were removed. Reaction was evaluated at 48 and 72 hrs after applying atopy patch test
3204731|NCT01164280|Experimental|Pulse Rate Change|Patients are subjected to different pulse rate settings of their neurostimulator. The effect of pulse rate changes on clinical outcome is measured.
3204732|NCT01164228|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 22, and 29 and oral sunitinib malate once daily on days 1-14 and 22-35.
3204733|NCT01164228|Active Comparator|Arm II|Patients receive oral sunitinib malate once daily on days 1-14 and 22-35.
3204734|NCT01164215|Experimental|mFOLFOX6|"Patients will receive cycle 1 of standard dose mFOLFOX6, with the same dose of mFOLFOX6 continued in subsequent cycles, once patient achieves the target AUC.~mFOLFOX 6 is a regimen comprised of Oxaliplatin + Leucovorin +5-Fluorouracil (FU)"
3204735|NCT01164202|Placebo Comparator|Placebo|placebo 3cps/days 4 weeks over 6 during 1 year
3204736|NCT01164202|Experimental|Sunitinib|sunitinib (SUTENT®) 37,5 mg/d (3 cps of 12,5 mg) orally 4 weeks over 6 (4 weeks of treatment followed by 2 weeks without treatment) during 1 year
3204737|NCT01164189|Other|Temozolomide|Administered orally on day 1-5, 150-200 mg/m(2), repeated every 4 weeks, up to 12 cycles
3204738|NCT01164189|Experimental|Temozolomide + Bevacizumab|"TMZ: Administered orally on day 1-5, 150-200 mg/m(2), repeated every 4 weeks, up to 12 cycles~Beva: 10 mg/kg bw IV in 90 minutes on day 1 and 14, 4 week cycles."
3204739|NCT01164176|Experimental|RAD001 group|
3204740|NCT01164163|Experimental|Treatment (Ruxolitinib)|
3204741|NCT01164150|Experimental|Arm B|Radiation: 45 Gy / 25 fractions pelvic radiotherapy using intensity modulated radiotherapy (IMRT) followed by 11 Gy / 2 fractions vaginal vault brachytherapy
3205047|NCT01162122|Experimental|Licensed TIV|Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).
3204745|NCT01164124|Experimental|Probiotic supplementation|500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter & Gamble.Inc)
3204746|NCT01164124|Placebo Comparator|Routine feedings|
3204747|NCT01164111|Experimental|Preoperative resistance training|preoperative resistance training: Duration 8 weeks. Intensity: 3 sets of 80 % of 1 repetition max (1 RM) in each exercise. Frequency: 2 times/week
3204748|NCT01164111|No Intervention|Control|Standard preoperative track.: No training intervention. Standard preoperative information.
3204749|NCT01164098|Active Comparator|Rituximab|Participants will receive Rituximab post within 24 of Kidney Transplant
3204750|NCT01164098|No Intervention|No rituximab|Participants will not receive Rituximab within 24 hours of Kidney Transplant
3204751|NCT01164085|Experimental|Ketorolac|4mg intravitreal injection of ketorolac
3204752|NCT01164072||HIGH NICOTINE|Well characterized group of 100 regular smokers experimenting the E-Cigarette loaded with 7.2 mg nicotine cartridges (high nicotine group).
3204753|NCT01164059|Experimental|atypical antipsychotics|Olanzapine, Quetiapine, or Aripiprazole
3204754|NCT01164059|Active Comparator|typical antipsychotics|Haloperidol or Flupentixol
3204755|NCT01164046|Active Comparator|vitamin K antagonists|
3204756|NCT01164046|Active Comparator|Low molecular weight heparin|
3204757|NCT01164033|Active Comparator|A|
3204758|NCT01164033|Experimental|B|
3204759|NCT01164033|Experimental|C|
3204760|NCT01164033|Experimental|D|
3204761|NCT01164020|Placebo Comparator|placebo control|this only receives placebo (dextrose)
3204762|NCT01164020|Experimental|placebo and exercise|this is trained and receives placebo
3204763|NCT01164020|Experimental|creatine supplementation|this is non-exercise trained and receives creatine supplementation
3204764|NCT01164020|Experimental|Creatine and Exercise|this is exercised trained and receives creatine supplementation
3204765|NCT01164007|Experimental|Dacarbazine + Bevacizumab|Participants with unresectable/metastatic melanoma not previously treated with chemotherapy for metastatic disease will receive dacarbazine and bevacizumab until disease progression, unacceptable toxicity, participant withdrawal, or physician decision to discontinue.
3204766|NCT01163994|Active Comparator|MEM-ceftriaxone|
3204767|NCT01163994|Active Comparator|MEM-doxycycline|
3204768|NCT01163994|No Intervention|controls|
3204769|NCT01163994|Active Comparator|EM-doxycycline|
3204770|NCT01163981|No Intervention|Blind cannulation|Cannulation without guidance
3204771|NCT01163981|Experimental|Ultrasound guided cannulation|Ultrasound guided cannulation
3204772|NCT01163968|Experimental|Weight reduction program|MOMENTUM intervention
3204773|NCT01163955|Other|Sitting in a chair|Sitting in a chair with back support and feet flat on the ground
3204774|NCT01163955|Other|Sitting on the Floor|Sitting on the floor without back support, crossed leg style
3204775|NCT01163942|Active Comparator|No G-CSF, No 2nd ATG|Patients randomised not to receive G-CSF (alongside ATG and CSA) and to not receive early retreatment in case of no response.
3204776|NCT01163942|Active Comparator|No G-CSF, yes 2nd ATG|Patients randomised not to receive G-CSF (alongside ATG and CSA) but they do receive early retreatment in case of no response.
3204777|NCT01163942|Active Comparator|Yes G-CSF, No 2nd ATG|Patients randomised to receive G-CSF (alongside ATG and CSA) and to not receive early retreatment in case of no response.
3204778|NCT01163942|Active Comparator|Yes G-CSF, Yes 2nd ATG|Patients randomised to receive G-CSF (alongside ATG and CSA) and to receive early retreatment in case of no response.
3204779|NCT01163929|Experimental|paclitaxel, trastuzumab and everolimus|
3204780|NCT01163916||Patients with RA, PsA and AS|Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) prescribed adalimumab as part of Routine Clinical Care in Russia.
3204781|NCT01163903|Experimental|Pantoprazole and doxorubicin|
3204782|NCT01163890|Experimental|WHI|
3204783|NCT01163890|Active Comparator|Usual Care|
3204784|NCT01163877|Other|Symptomatic malaria infection|
3204785|NCT01163877|Other|Asymptomatic malaria infection|
3204786|NCT01163877|Other|Hookworm infection|
3204787|NCT01163877|Other|Schistosoma haematobium infection|
3204788|NCT01163864|Experimental|affect regulation training|
3204789|NCT01163864|Active Comparator|health and lifestyle|
3204790|NCT01163851|Experimental|PF-04950615 (RN316)|
3204791|NCT01163838|Placebo Comparator|Placebo|
3204792|NCT01163838|Experimental|RN316: 1 mg/kg every 2 weeks|
3204793|NCT01163838|Experimental|RN316: 2 mg/kg every 4 weeks|
3204794|NCT01163838|Experimental|RN316: 4 mg/kg every 4 weeks|
3204795|NCT01163838|Experimental|RN316: 4 mg/kg every 8 weeks|
3204796|NCT01163838|Experimental|RN316: 8 mg/kg every 8 weeks|
3204797|NCT01163838|Experimental|RN316: 12 mg/kg every 8 weeks|
3204798|NCT01163825|Experimental|Nerve Growth Factor|Dose 1
3204799|NCT01163825|Experimental|Nerve Growth Factor 2|Dose 2
3204800|NCT01163812|Experimental|Laparoscopic D2 gastrectomy|
3204801|NCT01163799|Experimental|Alefacept (ASP0485)|Safety and efficacy of alefacept in combination with alemtuzumab induction and calcineurin inhibitor (CNI) and corticosteroid withdrawal.
3204802|NCT01163786|Experimental|Bortezomib|Patients will Receive 2 4week cycles of Bortezomib. Each cycle will consist of weekly bortezomib with a 2 week interval between cycles.
3204803|NCT01163760|Other|etafilcon A / ocufilcon D|etafilcon A contact lens worn first daily disposable , ocufilcon D contact lens worn second daily disposable
3204804|NCT01163760|Other|oculfilcon D / etafilcon A|ocufilcon D contact lens worn first, etafilcon A contact lens worn second
3204805|NCT01163760|Other|ocufilcon D / ocufilcon D|ocufilcon D contact lens worn first and second
3204806|NCT01163760|Other|etafilcon A / etafilcon A|etafilcon A contact lens worn first and second
3204807|NCT01163747|Active Comparator|Methotrexate|Participants continued to receive their standard dose of methotrexate up to Week 8. From Week 8 participants also received 8 mg/kg tocilizumab intravenously every 4 weeks until Week 20. At Week 3 participants received both pneumococcal and tetanus toxoid vaccinations.
3204808|NCT01163747|Experimental|Tocilizumab + Methotrexate|Participants received 8 mg/kg tocilizumab intravenously at Baseline (Day 1) and every 4 weeks up to Week 20, in addition to their standard dose of methotrexate. At Week 3 participants received both pneumococcal and tetanus toxoid vaccinations.
3204809|NCT01163734|Experimental|Ranolazine|
3204810|NCT01163734|Placebo Comparator|Saline 0.9%|Saline 0.9% and placebo tablet
3204811|NCT01163721|Experimental|Ranolazine|Participants were randomized to receive ranolazine for 12 weeks.
3204812|NCT01163721|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match ranolazine for 12 weeks.
3204813|NCT01163708|Active Comparator|Navigation alone|Navigation system alone vs Prophecy technique with Navigation system validation
3204814|NCT01163708|Experimental|Prophecy and Navigation validation|
3204815|NCT01163682|Active Comparator|Electro-acupuncture|45 minute sessions scheduled once a week for 12 weeks.
3204816|NCT01163682|Sham Comparator|Sham acupuncture|45 minute sessions scheduled once a week for 12 weeks
3204817|NCT01163669||kidney transplant recipients|
3204818|NCT01163656|Active Comparator|Direct Laryngoscopy|Laryngoscopy will be performed with the randomized device, which will be the Miller Laryngoscope.
3204819|NCT01163656|Active Comparator|Glidescope Cobalt Video Laryngoscopy|Laryngoscopy will be performed with the randomized device, which will be the Glidescope Cobalt Video Laryngoscope.
3204820|NCT01163643|Experimental|0.3% BOL-303242-X ophthalmic suspension|0.3% BOL-303242-X ophthalmic suspension
3204821|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension|2% BOL-303242-X ophthalmic suspension
3204822|NCT01163643|Placebo Comparator|Vehicle|Vehicle twice daily (BID)
3204823|NCT01163643|Experimental|1% BOL-303242-X ophthalmic suspension|1% BOL-303242-X ophthalmic suspension
3204824|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension in the morning|2% BOL-303242-X ophthalmic suspension in the morning (AM) and vehicle in the afternoon (PM)
3204825|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension PM|Vehicle in the AM and 2% BOL-303242-X ophthalmic suspension in the PM.
3204826|NCT01163630|Experimental|1|esomeprazole 20mg/ASA 81 mg FDC after a 10-hour fast
3204827|NCT01163630|Experimental|2|esomeprazole 20mg/ASA 81 mg FDC 30 minutes after start of a high-fat, high-calorie breakfast
3204828|NCT01163617|Experimental|Current/Physiolis Syringe|Self-injection using current syringe at Week 0 (Visit 1), self-injection using Physiolis syringe at Week 2 (Visit 2) (Phase A)
3204829|NCT01163617|Experimental|Physiolis/Current Syringe|Self-injection using Physiolis syringe at Week 0 (Visit 1), self-injection using current syringe at Week 2 (Visit 2) (Phase A)
3204830|NCT01163617|Experimental|Current/Physiolis Autoinjector|Self-injection using current autoinjector at Week 0 (Visit 1), self-injection using Physiolis autoinjector at Week 2 (Visit 2) (Phase A)
3204831|NCT01163617|Experimental|Physiolis/Current Autoinjector|Self-injection using Physiolis autoinjector at Week 0 (Visit 1), self-injection using current autoinjector at Week 2 (Visit 2) (Phase A)
3204832|NCT01163617|Experimental|Physiolis Autoinjector at 2° to 8°C|Injection performed by health care provider at Week 4 (Visit 3) using Physiolis autoinjector at storage temperature (2° to 8°C) (Phase B)
3204833|NCT01163617|Experimental|Current Autoinjector 2° to 8°C|Injection performed by health care provider at Week 4 (Visit 3) using current autoinjector at storage temperature (2° to 8°C) (Phase B)
3204834|NCT01163617|Experimental|Physiolis Autoinjector 20° to 27°C|Injection performed by health care provider at Week 4 (Visit 3) using Physiolis autoinjector at room temperature (20° to 27°C) (Phase B)
3204835|NCT01163617|Experimental|Current Autoinjector 20° to 27°C|Injection performed by health care provider at Week 4 (Visit 3) using current autoinjector at room temperature (20° to 27°C) (Phase B)
3204836|NCT01163604|Experimental|Argatroban group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive continuous infusions of argatroban for 2 days before and 3 days after stenting, with accompanied aspirin and clopidogrel treatment.
3204837|NCT01163604|Experimental|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
3204838|NCT01163591||Case|Patients with overt diabetic nephropathy as evidenced by ACR greater than or equal to 30mg/mmol on urinalysis and eGFR greater than or equal to 15ml/min/1.73m2 and less than 60ml/min/1.73m2
3204839|NCT01163591||Control|Patients without diabetic nephropathy as defined by the absence of albuminuria (defined by a random spot urinary ACR <2.5 mg/mmol in women or ACR<3.5 mg/mmol in men)and eGFR greater or equal to 90 ml/min/1.73m2
3204840|NCT01163565|Active Comparator|Ligasure device|
3204841|NCT01163565|No Intervention|Hand ties|
3204842|NCT01163552|Experimental|Surgical Debulking and Intrathoracic Hyperthermic Chemotherapy|Patients in this trial will undergo surgical debulking followed by intrathoracic hyperthermic chemotherapy perfusion.
3204843|NCT01163526||neuroendocrine metastases|15 patients with neuroendocrine metastases
3204844|NCT01163526||colon cancer metastases|15 patients with colon cancer metastases
3204845|NCT01163526||HCC treated with cyberknife radiation and chemotherapy|15 patients with HCC treated with cyberknife radiation and chemotherapy
3204846|NCT01163526||HCC treated with Sirsphere embolization and chemotherapy|15 patients with HCC treated with Sirsphere embolization and chemotherapy
3204847|NCT01163513||White population|
3204848|NCT01163513||Indian|
3204849|NCT01163513||Pakistani|
3204850|NCT01163513||Bangladeshi|
3204851|NCT01163513||Other|other South Asian
3204852|NCT01163500|Placebo Comparator|Pill|
3204853|NCT01163500|Experimental|Coenzyme Q10|
3204854|NCT01163487|Experimental|Dichloroacetate (DCA)|25 mg/kg/day, 37.5 mg/kg, or 50 mg/kg/day oral DCA.
3204855|NCT01163474|Experimental|Arm 1 - All study participants|Evaluate video clinic visit prior to Face-to-Face usual care visit
3204856|NCT01163461|Experimental|Immediate Treatment|individuals will receive 60 hours of speech therapy
3204857|NCT01163461|Experimental|Delayed Treatment|individuals will receive 60 hours of speech therapy after 6 week delay period
3204958|NCT01162772||Female Diabetics|female, 25-75 years old, no pregnancy, with/out Hormone replacement therapy T2DM, HbA1c > 7% with metformin mono-therapy
3204858|NCT01163448|Experimental|High-Dose Single-Fraction Image-Guided Radiotherapy|This will assess the feasibility and safety of this approach in men at high-risk for extraprostatic prostate cancer undergoing RP. This initial trial has been designed in a manner intended to emphasize patient comfort and safety.
3204859|NCT01163435|Experimental|high dose dual therapy|group A1 and A2 - high dose dual therapy (rabeprazole 20 mg qid, amoxicillin 750 mg qid for 14 days)
3204860|NCT01163435|Experimental|sequential therapy|group B1 and B2 - sequential therapy (rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days)
3204861|NCT01163435|Active Comparator|clarithromycin-based triple therapy|group C1 - clarithromycin-based triple therapy (rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days)
3204862|NCT01163435|Active Comparator|levofloxacin-based triple therapy|group C2 - levofloxacin-based triple therapy (rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days)
3204863|NCT01163422|Active Comparator|Immediate RVRT|RVRT switched on immediately after pacemaker implant
3204864|NCT01163422|Placebo Comparator|Delayed RVRT|RVRT switched on 4 weeks after pacemaker implant
3204865|NCT01163409|Experimental|acupuncture|will be made with classic acupuncture needling in traditional points, surpassing the skin
3204866|NCT01163409|Experimental|sham acupuncture|sham acupuncture will be done through a needle and a plastic device attached to skin in traditional acupuncture points.
3204867|NCT01163409|Experimental|exercise training resistance and aerobic|Aerobic exercise for 1 hour and resistance exercises for major muscle groups.
3204868|NCT01163409|No Intervention|healthy lifestyle|Group 4 - will be the control group who receive follow-up and recommendation for physical activity, but without any intervention supervised.
3204869|NCT01163396|Experimental|FOLFOXIRI plus bevacizumab|BEVACIZUMAB 5 mg/Kg i.v. followed by IRINOTECAN 165 mg/sqm i.v. over 1 hr followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hr concomitantly with l-LV 200 mg/sqm over 2 hrs followed by 5FU 3.200 mg/sqm c.i. over 48 hrs starting on day 1. Cycles repeated every 2 weeks
3204870|NCT01163370|Placebo Comparator|control and exercise|this is trained and receives placebo
3204871|NCT01163370|Experimental|creatine|this is non-exercise trained and receives creatine supplementation
3204872|NCT01163370|Experimental|exercise and creatine|this is exercised trained and receives creatine supplementation
3204873|NCT01163370|Placebo Comparator|placebo|this only receives placebo (dextrose)
3204874|NCT01163357|Experimental|Group I (bortezomib, fludarabine phosphate, TMI, melphalan)|Patients receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. Patients also undergo TMI BID on days -9 to -7. If no DLT is observed in the first cohort, bortezomib IV will be added on days -6 and -3 for subsequent cohorts.
3204875|NCT01163357|Experimental|Group II (bortezomib, fludarabine phosphate, melphalan|Patients receive fludarabine phosphate IV and melphalan IV as in Stratum I. Patients also receive bortezomib IV on days -6, -3, 1, and 4.
3204876|NCT01163344||Dance Therapy Group|This will group will undergo dance therapy once a week for a series of 8 weeks.
3204877|NCT01163344||Physical Therapy Group|This group will undergo physical therapy sessions once a week for a series of 8 weeks
3204878|NCT01163331|Experimental|Singing Therapy Group|Singing Therapy Group
3204879|NCT01163318||Adalimumab 40 mg/0.8 mL syringe for subcutaneous injection|Participants with rheumatoid arthritis who received adalimumab, per approved label
3204880|NCT01163305||metastatic colorectal cancer|
3204881|NCT01163292||Adalimumab|Participants who continued adalimumab treatment after completion of Study NCT00870467 (M06-859)
3204882|NCT01163292||Non-Adalimumab|Participants who discontinued adalimumab treatment after completion of Study NCT00870467(M06-859)
3204883|NCT01163279|Experimental|Cognitive Training|
3204884|NCT01163279|Active Comparator|Psychosocial Education|
3204885|NCT01163266|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 8 weeks.
3204886|NCT01163266|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
3204887|NCT01163266|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week then vortioxetine 20 mg, encapsulated tablets, orally, once daily for up to 7 weeks.
3204888|NCT01163253|Experimental|Active Treatment|"The study is anticipated to continue for up to at least 2 years post First Market Approval (FMA) in a global, major market.~All subjects will receive 10 mg BID of CP-690,550 for first 3 months of trial. Study has the option for variable dosing with 5 mg or 10 mg BID after first 3-months of treatment based on PI discretion"
3204889|NCT01163240||pediatric|
3204890|NCT01163227|Placebo Comparator|Placebo|
3204891|NCT01163227|Experimental|AQW051 Dose 1|
3204892|NCT01163227|Experimental|AQW051 Dose 2|
3204893|NCT01163227|Experimental|AQW051 Dose 3|
3204894|NCT01163214|Experimental|Nerve Block|Preoperative femoral block with indwelling femoral catheter and a single shot sciatic block.
3204895|NCT01163214|Active Comparator|Periarticular Injection|Injection combination prior to skin closure.
3204896|NCT01163201|Experimental|Treg Plus CD3+Teff Treatment|Includes dose adjustment of T regulatory (Treg) and CD3+ T effector (CD3+ Teff) cells in recipients of double UCB transplantation
3204897|NCT01163188||Proband|Very low birth weight children (< 32 weeks of gestation) and/ or Very preterm children (< 1500 g birthweight) of the Bavarian Longitudinal Study
3204898|NCT01163188||Controls|Term born children of the Bavarian Longitudinal Study
3204899|NCT01163162|Experimental|Paricalcitol|After baseline measurements are complete, pt will receive 2 mcg Paricalcitol (Zemplar) for 7 consecutive days. After this, Kidney function will again be measured. The pt will then be washed off the paricalcitol for 7 days then kidney function will be measured for the last time.
3204900|NCT01163149|Experimental|Cohort 1|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (2.1 mg/kg/week total)
3204901|NCT01163149|Experimental|Cohort 2|Cohort 2: Daily SC injections of 0.5 mg/kg asfotase alfa (3.5 mg/kg/week total)
3204959|NCT01162772||Male diabetics|25-75 years, T2DM, HbA1c > 7% with metformin mono-therapy
3204960|NCT01162759|No Intervention|Usual Care|The control group receiving usual care
3204961|NCT01162759|Experimental|Home Blood Pressure Monitoring Group|Intervention group
3204902|NCT01163149|No Intervention|Concurrent Control|Following completion of the Week 24 visit, all patients (including those randomized to the concurrent control cohort) may be eligible to participate in an open-label extension treatment period. In this extension period, all patients will be treated with daily SC injections of 0.5 mg/kg/day asfotase alfa (a total of 3.5 mg/kg/week) for approximately 24 weeks, then subjects will receive 1 mg/kg/day 6 days/week for an additional 48 weeks or until regulatory approval of the drug.
3204903|NCT01163097|Experimental|Palifermin 40 µg/kg and heparin IV infusion|Treatment A: palifermin 40 µg/kg/day for three consecutive days as IV bolus injections and continuous heparin IV infusion
3204904|NCT01163097|Experimental|Palifermin 40 µg/kg|Treatment B: palifermin 40 µg/kg/day for three consecutive days as IV bolus injections
3204905|NCT01163097|No Intervention|Control group without any treatment|Treatment C: control group without any treatment administered.
3204906|NCT01163084|Experimental|Arm I (leuprolide acetate, goserelin acetate, vismodegib)|Patients receive LHRH analogue comprising leuprolide acetate IM or goserelin acetate SC on day 1 and vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.
3204907|NCT01163084|Active Comparator|Arm II (leuprolide acetate, goserelin acetate)|Patients receive LHRH analogue comprising leuprolide acetate or goserelin acetate as in Arm I. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.
3204908|NCT01163071|Experimental|ABI-011|
3204909|NCT01163045|Experimental|neuromonitoring and neurostimulation|
3204910|NCT01163045|Experimental|neurostimulation of recurrent laryngeal nerve|
3204911|NCT01163032|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
3204912|NCT01163032|Placebo Comparator|placebo|Placebo capsules, PO daily for 6 months
3204913|NCT01163019||Chest pain|Patients who present to the emergency department with a chief complaint of chest pain and have a moderate pre-test probability for an acute coronary syndrome
3204914|NCT01163006|Experimental|polydextrose|
3204915|NCT01163006|Experimental|soluble glucofibre|
3204916|NCT01163006|Placebo Comparator|isocaloric dietary control|
3204917|NCT01163006|Placebo Comparator|full caloric control|
3204918|NCT01162993|Experimental|Spinal Cord Stimulation|Spinal cord stimulation
3204919|NCT01162993|No Intervention|Treatment as usual|Treatment as usual
3204920|NCT01162967|Active Comparator|Benznidazole|
3204921|NCT01162967|Experimental|Posaconazole, low dose|
3204922|NCT01162967|Experimental|Posaconazole, high dose|
3204923|NCT01162954|Experimental|DA-6034|
3204924|NCT01162954|Placebo Comparator|Placebo|
3204925|NCT01162941|Experimental|Steroid dependant ITP|more than 10 mg of prednisolone per day is required to maintain a platelet count above 20X109/L (minimum follow up duration: 3 months after diagnosis)
3204926|NCT01162928|Experimental|1|3-chamber-bag combined with Oxepa
3204927|NCT01162928|Active Comparator|2|3-chamber-bag combined with Pulmocare
3204928|NCT01162915|Experimental|Safety|Infusion of autologous bone marrow-derived mesenchymal stem cells.
3204929|NCT01162902|Experimental|Diltiazem treated group|Diltiazem 180mg treated group
3204930|NCT01162902|Active Comparator|Bisoprolol treated group|Bisoprolol 5mg treated group
3204931|NCT01162902|Active Comparator|Candesartan treated group|Candesartan 32mg treated group
3204932|NCT01162889|Placebo Comparator|Placebo - SC injection|
3204933|NCT01162889|Experimental|Drug dose level 1 - SC injection|
3204934|NCT01162889|Experimental|Drug dose level 2 - SC injection|
3204935|NCT01162889|Experimental|Drug dose level 3- SC injection|
3204936|NCT01162889|Experimental|Drug dose level 4 - SC injection|
3204937|NCT01162889|Experimental|Drug dose level 5 - SC injection|
3204938|NCT01162889|Experimental|Drug dose level 6 - IV Infusion|
3204939|NCT01162889|Experimental|Drug dose level 7 - IV Infusion|
3204940|NCT01162889|Experimental|Drug dose level 8 - IV infusion|
3204941|NCT01162889|Placebo Comparator|Placebo - IV infusion|
3204942|NCT01162889|Experimental|Drug dose level 9 - IV infusion|
3204943|NCT01162876|Experimental|saxagliptin|5 mg daily for 14days
3204944|NCT01162863|Active Comparator|Lubiprostone 8 mcg BID|
3204945|NCT01162863|Active Comparator|Lubiprostone 24 mcg QD|
3204946|NCT01162863|Placebo Comparator|Placebo|
3204947|NCT01162850|Active Comparator|Polypodium Leucotomos|Oral Polypodium Leucotomos twice daily plus sunscreen SPF 45 for 12 weeks.
3204948|NCT01162850|Placebo Comparator|Placebo|Oral Placebo twice daily plus sunscreen SPF 45 for 12 weeks.
3204949|NCT01162837|Other|All subjects|All subjects are enrolled in this arm and will use the BEAM device on one side of the face and the other side of the face will be the control
3204950|NCT01162824|Other|No endothelial dysfunction|
3204951|NCT01162824|Other|Endothelial Dysfunction|Definition of abnormal epicardial and microvascular vasoreactivity Abnormal epicardial vasoreactivity is defined as a reduction of the baseline coronary diameter ≥75% after glyceryltrinitrate i.c. together with a reproduction of the angina symptoms reported by the patient and/or ischemic ECG-changes. Abnormal microvascular vasoreactivity is defined as the reproduction of the angina symptoms together with ischaemic ECG-changes, but without changes in epicardial vasomotion.
3204952|NCT01162811|No Intervention|Control group|The control group receives conventional care and treatment
3204953|NCT01162811|Experimental|Intervention group|the intervention group receives visualization and relaxation exercises together with structured behavioural attention
3204954|NCT01162798|Active Comparator|Control|commercially available formula
3204955|NCT01162798|Experimental|Test|test formula
3204956|NCT01162785|Experimental|First Dose SCH 721015|Part1: 2 Instillations of intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume
3204957|NCT01162785|Experimental|Second Dose SCH 721015|Part 2: Subjects who have a complete response to treatment at Week 12 in Part 1 receive second regimen of intravesical administration of SCH 721015 with Syn3 on same Day 1 and Day 4 regimen at same dose level.
3205039|NCT01162161||toxic pulmonary edema|patients with a pulmonary edema preceded by pneumonia
3204962|NCT01162746|Experimental|Intravitreal dexamethasone and intravitreal ranibizumab|"Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT."
3204963|NCT01162746|Active Comparator|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
3204964|NCT01162733|Active Comparator|Study Drug 1|Vancomycin 15mg/kg
3204965|NCT01162733|Active Comparator|Study Drug 2|Vancomycin 30mg/kg
3204966|NCT01162720|Experimental|Short duration tourniquet|Patients allocated to this group will have the pneumatic tourniquet applied to the index limb for approximately 20-30 minutes during cement fixation of the prosthesis.
3204967|NCT01162720|Active Comparator|Long duration tourniquet|Patients randomised to this arm will have the tourniquet applied from commencement of surgery and removed just prior to skin closure.
3204968|NCT01162707|Experimental|Pressure Measurement System|CardioMEMS HF Pressure Measurement System
3204969|NCT01162694|Active Comparator|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
3204970|NCT01162694|Active Comparator|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will send the uploaded data and receive feedback from their endocrinologist every 2 weeks.
3204971|NCT01162681|Experimental|A-623 high dose weekly|
3204972|NCT01162681|Experimental|A-623 low dose weekly|
3204973|NCT01162681|Experimental|A-623 high dose every 4 weeks|
3204974|NCT01162681|Placebo Comparator|Placebo|
3204975|NCT01162655|Experimental|Telehealth|Complete CBT group via telehealth
3204976|NCT01162655|Experimental|Internet|Complete Internet-based CBT program
3204977|NCT01162642|Experimental|Green Tea|4 cups daily of green tea for 6 weeks
3204978|NCT01162642|Placebo Comparator|No Green Tea|4 cups daily of placebo tea for 6 weeks
3204979|NCT01162629||Osteon|Patients requiring dental implants with deficient alveolar bone height
3204980|NCT01162616|Other|Iron absorption|
3204981|NCT01162603|Experimental|TAFLUPROST 0.0015% EYEDROPS|Tafluprost 0.0015% preservative-free ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means of Goldmann and Perkins applanation tonometry.
3204982|NCT01162603|Active Comparator|LATANOPROST 0.005% EYEDROPS|Latanoprost 0.005% preservative-added ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means Goldmann and Perkins applanation tonometry.
3204983|NCT01162590|Experimental|Rotarix Group|Subjects will receive Rotarix™.
3204984|NCT01162590|Placebo Comparator|Placebo Group|Subjects will receive placebo.
3204985|NCT01162577|Experimental|Intervetion|The intervention group received the 5 standard tobacco calls plus 3 weight calls with a weight coach to address weight concerns related to quitting smoking
3204986|NCT01162577|No Intervention|Control|Participants in this arm received only the 5 standard tobacco calls
3204987|NCT01162564||NG-TSM|Patients receiving NG-TSM to repair an abdominal incisional/ventral hernia
3204988|NCT01162551|Experimental|Sirolimus and Methotrexate|"Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.~One cycle is 28 days"
3204989|NCT01162525|Experimental|pTNS treatment|
3204990|NCT01162512|Experimental|Physical Activity|Participants will receive 7 weeks of weekly news letters and phone calls. The news letters and phone calls will include information about physical activity and ways to increase physical activity levels. This is in addition the standard medical care.
3204991|NCT01162512|No Intervention|Standard Medical Care|Participants will receive standard medical care
3204992|NCT01162499|Experimental|Exendin-(9-39) first, then Vehicle|"After an overnight fast, an intravenous (IV) infusion of Exendin-(9-39) will be started 1 hour prior to the meal challenge and continued for 5 hours. After the first hour of the infusion, subjects will undergo a mixed meal tolerance test in which Pediasure (10cc/kg) will be consumed by mouth or gastrostomy/nasogastric tube over a period of 15 minutes (for infants under 12 months, Pediasure will be replaced by the infant's formula). Blood samples will be drawn at different time points during the infusion to measure blood glucose, plasma insulin, glucagon and plasma glucagon-like-peptide-1 (GLP-1). The Exendin-(9-39) dose for the first 3 subjects will be 300pmol/kg/min and, if tolerated, the dose will be increased to 500pmol/kg/min for subsequent subjects.~The next day, all procedures will be repeated except subjects will receive an IV infusion of normal saline (vehicle) over 6 hours."
3205040|NCT01162161||control group|not ventilated patients without any pulmonary edema receiving a bronchoscopy due to another pulmonary problem (no pneumonia, no heart failure)
3205041|NCT01162148|Experimental|1|conventional
3205042|NCT01162148|Experimental|2|sham IMT
3205043|NCT01162148|Experimental|3|Conventional plus threshold IMT
3205044|NCT01162148|Experimental|4|threshold IMT alone
3205045|NCT01162135|Experimental|Open Label Pilot Study|
3205046|NCT01162122|Experimental|aTIV|Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).
3204993|NCT01162499|Active Comparator|Vehicle first, then Exendin-(9-39)|"After an overnight fast, an intravenous (IV) infusion of normal saline (vehicle) will be started 1 hour prior to the meal challenge and continued for 5 hours. After the first hour of the infusion, subjects will undergo a mixed meal tolerance test in which Pediasure (10cc/kg) will be consumed by mouth or gastrostomy/nasogastric tube over a period of 15 minutes (for infants under 12 months, Pediasure will be replaced by the infant's formula). Blood samples will be drawn at different time points during the infusion to measure blood glucose, plasma insulin, glucagon and plasma glucagon-like-peptide-1 (GLP-1).~The next day, all procedures will be repeated except subjects will receive an IV infusion of Exendin-(9-39) which will be started 1 hour prior to the meal challenge and continue for 5 hours. The dose for the first 3 subjects will be 300pmol/kg/min and, if tolerated, the dose will be increased to 500pmol/kg/min for subsequent subjects."
3204994|NCT01162486|Active Comparator|Rifampin control|Rifampin + midazolam
3204995|NCT01162486|Experimental|RPT 1|RPT Cohort 1 - 5 mg/kg
3204996|NCT01162486|Experimental|RPT 2|RPT Cohort 2 - 10 mg/kg
3204997|NCT01162486|Experimental|RPT 3|RPT Cohort 3 - 15 mg/kg
3204998|NCT01162486|Experimental|RPT 4|RPT Cohort 4 - 20 mg/kg
3204999|NCT01162486|Experimental|RPT 5|RPT Cohort 5 - Maximal tolerated dose, if dose limiting toxicities are observed
3205000|NCT01162473|Active Comparator|Delayed Sensitivity|All subjects will undergo a food challenge (week 2). Subjects undergoing delayed desensitization via milk oral immunotherapy with milk protein powder will begin build-up of desensitization during Week 16 and continue thru Week 50. Total active participation will last 51 weeks.
3205001|NCT01162473|Active Comparator|Immediate Sensitivity|All subjects will undergo a food challenge (week 2). Subjects undergoing immediate desensitization via milk oral immunotherapy with milk protein powder will begin build-up of desensitization during Week 3 and continue thru Week 35. Total active participation will last 38 weeks.
3205002|NCT01162460|Active Comparator|Carbamazepine controlled release|
3205003|NCT01162460|Experimental|Eslicarbazepine acetate|
3205004|NCT01162447||PCO|Healthy control subjects and patients with polycystic ovarian syndrome will be recruited for the study.
3205005|NCT01162434||Patients|Up to 8 patients who have received Deep Brain Stimulation for Treatment Resistant Depression at Frenchay Hospital (UK) will be recruited.
3205006|NCT01162434||Healthy volunteers|Up to 16 healthy volunteers, matched to the DBS patients on age, sex, handedness, and education, will be recruited.
3205007|NCT01162421|Experimental|Early Adalimumab|Participants in the Early Adalimumab arm will receive adalimumab and methotrexate at Baseline and every other week for study duration.
3205008|NCT01162421|Active Comparator|Standard of Care|Participants in the Standard of Care arm will receive methotrexate and other disease modifying antirheumatic drugs as per local treatment guidelines and study doctor's judgement. Adalimumab may be initiated after a minimum of 6 months.
3205009|NCT01162395|Experimental|A|Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD)
3205010|NCT01162382|Experimental|Transcranial Magnetic Stimulation|Open-label transcranial magnetic stimulation
3205011|NCT01162369||Group 1 - Non-Delirius Patients|
3205012|NCT01162369||Group 2 - Delirious Patients|
3205013|NCT01162343||Older Emergency Department Patients|Patients who were 65 years or older from the emergency department were enrolled.
3205014|NCT01162330||Babies referred for further hearing tests|Babies referred for further hearing tests after their neonatal hearing screening tests
3205015|NCT01162317|Active Comparator|Arm 1: sham acupuncture|sham acupuncture
3205016|NCT01162317|Experimental|Arm 2: acupuncture|acupuncture
3205017|NCT01162304|Active Comparator|ER Oxycodone vs IR Oxycodone|"Extended release Oxycodone to assess pain relief adverse effects, treatment satisfaction and impact of treatment on health related quality of life.~IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every four hours"
3205018|NCT01162291||movement|healthy subjects, randomised to do flexion and extension movements with their left and right elbow joint after intramuscular application of NaCl 2ml in the right musculus biceps brachii, and 1ml in the left musculus biceps brachii
3205019|NCT01162291||rest|healthy subjects are randomised to rest after intramuscular application of NaCl 1ml in the left and 2ml in the right musculus biceps brachii
3205020|NCT01162278|Other|single fraction|Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 35Gy in one fraction. Subsequent cohorts of patients will receive an additional 5Gy per treatment to a maximum planned dose of 50Gy in one fraction.
3205021|NCT01162265||Contacts|Contacts of active cases of tuberculosis
3205022|NCT01162265||new entrants|new entrants from high incidence (>40/100000) countries.
3205023|NCT01162252|Active Comparator|Mindfulness-Based Stress Reduction|
3205024|NCT01162252|Active Comparator|Living Well|
3205025|NCT01162239|Experimental|Extended Brief Contact|Following standard brief treatment, participants have monthly meetings with medical staff.
3205026|NCT01162239|Experimental|Extended Health Education|Following standard treatment, participants receive monthly counseling with content based on a health education model.
3205027|NCT01162239|Experimental|Extended Relapse Prevention plus varenicline|Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model plus access to ongoing medication treatment with varenicline.
3205028|NCT01162239|Experimental|Extended Relapse Prevention|Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model.
3205029|NCT01162226|Experimental|training program|
3205030|NCT01162213|Experimental|100 mg of Lychee fruit extract|
3205031|NCT01162213|Experimental|200 mg of Lychee fruit extract|
3205032|NCT01162213|Experimental|600 mg of Lychee fruit extract|
3205033|NCT01162213|Experimental|2000 mg of Lychee fruit extract|
3205034|NCT01162200|Other|Stereotactic Body Radiation Therapy|SBRT dose per fraction
3205035|NCT01162174|Experimental|100 mg of Oligonol|
3205036|NCT01162174|Experimental|200 mg of Oligonol|
3205037|NCT01162174|Placebo Comparator|0 mg of Oligonol|
3205038|NCT01162161||hydrostatic pulmonary edema|patients with a pulmonary edema caused by chronic heart failure
3205048|NCT01162109|Placebo Comparator|Severe sepsis without zinc|Mechanically ventilated patients with severe sepsis will be randomized to receive IV zinc or placebo
3205049|NCT01162109|Experimental|Zinc in severe sepsis|Mechanically ventilated patients with severe sepsis will be randomized to receive IV zinc or placebo
3205050|NCT01162109|Experimental|Healthy Volunteers receiving zinc|Cohort of healthy volunteers will receive a single dose of 500 mcg/kg IBW IV zinc and pharmacokinetics will be measured for 8 hours. PK in sepsis patients and healthy volunteers will be compared.
3205051|NCT01162096|Experimental|Transplantation|
3205052|NCT01162083||Mitral Valve disease|Patients with mitral valve disease, deemed suitable and ready for elective valve repair or replacement. No significant arrhythmias, other valvular disease or LV dysfunction present. We shall also be recruiting patients undergoing a Mitraclip procedure.
3205053|NCT01162083||COPD|Patients with isolated chronic obstructive pulmonary disease and no cardiac disease.
3205054|NCT01162083||Mixed Lesions|Patients with proven limitation from both cardiac and respiratory disease.
3205055|NCT01162083||CRT|Patients with symptomatic heart failure who have responded to cardiac resynchronisation therapy (biventricular pacemaker).
3205056|NCT01162083||Cardiomyopathy|Heart Failure of primarily myopathic origin, without rhythm disturbance, ongoing ischaemia or significant valvular disease.
3205057|NCT01162070|Active Comparator|Free strategy|Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
3205058|NCT01162070|Experimental|Experimental strategy|Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
3205059|NCT01162044|No Intervention|No intervention|Subjects will be assessed, but no active intervention given
3205060|NCT01162044|Experimental|Computer game|Subjects will play with computer game while in the Emergency Room
3205061|NCT01162018|Experimental|Acupuncture Arm|
3205062|NCT01162018|Sham Comparator|Sham Acupuncture|
3205063|NCT01162005|Experimental|Tacrolimus|Tacrobell
3205064|NCT01161979|Experimental|Zonisamide|Zonisamide Capsules 100 mg of Dr.Reddy's laboratories Limited
3205065|NCT01161979|Active Comparator|Zonegran|Zonegran Capsules 100 mg of EISAI INC
3205066|NCT01161966|Experimental|Zonisamide|Zonisamide Capsules 100 mg of Dr.Reddy's laboratories Limited
3205067|NCT01161966|Active Comparator|Zonegran|Zonegran Capsules 100 mg of EISAI INC
3205068|NCT01161940|Experimental|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited
3205069|NCT01161940|Active Comparator|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
3205070|NCT01161927|Experimental|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited
3205071|NCT01161927|Active Comparator|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
3205072|NCT01161914|Active Comparator|Cerezyme®|60 U/kg infusion (every 2 weeks for 24 weeks)
3205073|NCT01161914|Experimental|ISU302|60 U/kg infusion (every 2 weeks for 24 weeks)
3205074|NCT01161901||blood sample|
3205075|NCT01161862|Experimental|Bi-hormonal with meal-priming bolus|The first meal-priming bolus was solely based on weight (0.05 U/kg), after which meal-priming boluses were automatically adapted by the control system online targeting 75% of the anticipated insulin needed in the first four hours after the start of the meal
3205076|NCT01161862|Experimental|Bi-hormonal without meal-priming bolus|The insulin controller was entirely reactive to CGMG; there were no meal priming boluses and no meal announcements
3205077|NCT01161836|Experimental|iniparib|"Segment 1: 400 mg [14C]-iniparib single administration~Segment 2: Iniparib, 5.6mg/kg, extension treatment with or without additional chemotherapy"
3205078|NCT01161823||Nebivolol|2,5mg or maximum 5mg per day
3205079|NCT01161823||Menoflavon|2 times 1 pill at 40mg Isoflavone per day
3205080|NCT01161810||Post-Burn Rehabilitation|Patients with an acute burn injury who are admitted to the hospital with anticipated length of stay of 5 days or greater
3205081|NCT01161784|Placebo Comparator|Nutrient drink|
3205082|NCT01161784|Experimental|Probiotics|
3205083|NCT01161771||Patients with cataract and corneal astigmatism|Patients with cataract(s) and corneal astigmatism who received surgical treatment (cataract extraction and limbal-relaxing incisions)
3205084|NCT01161758|Active Comparator|Passive cervical mobilisation|Grade III cervical mobilization technique as described by Maitland. Applied to left C5/6 Segment.
3205085|NCT01161758|Placebo Comparator|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique.
3205086|NCT01161758|No Intervention|Non-contact control|Non-contact control, which involved the subject resting in the treatment position without any physical contact between the researcher and the subject.
3205087|NCT01161732|No Intervention|Conventional treatment|In the conventional treatment group, indications for aortic valve replacement surgery are development of symptoms, reduced left ventricular systolic function and an increase in aortic jet velocity > 0.5 m/sec during follow-up.
3205088|NCT01161732|Active Comparator|Early Surgery|Early surgery is performed within 2 months of randomization.
3205089|NCT01161719|Experimental|Videoconference|Parent training through videoconference
3205090|NCT01161719|Active Comparator|Control|Parent training through face to face conference
3205091|NCT01161706|No Intervention|Control|0 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
3205092|NCT01161706|Experimental|8 fluid ounces vegetable juice|8 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
3205093|NCT01161706|Experimental|16 fluid ounces vegetable juice|16 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
3205094|NCT01161693|No Intervention|Standard pillow under head|Control (C) - Standard pillow under head (figure 1) as is the usual practice at BC Women's Hospital
3205136|NCT01161394|Experimental|pioglitazone 30mg|8 patients will get this drug
3205137|NCT01161394|Placebo Comparator|Placebo|8 patient will get this drug
3205814|NCT01156337||moderate sodium intake 120 mmol/day|
3205095|NCT01161693|Active Comparator|Troop Elevation Pillow in horizontal position-HERP|TROOP® elevation pillow (designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table)
3205096|NCT01161693|Active Comparator|Troop Elevation Pillow in horizontal position-HERP-H|Operating table tilted in Trendelenberg position so angle of Troop pillow is parallel to floor (figure 3) until establishment of adequate block and then the bed levelled to horizontal i.e. to the same position as group (HERP) (figure 2)
3205097|NCT01161641|Experimental|ODSH at 0.125 mg/kg/h|First cohort of 3 subjects to be administered the lowest dose of ODSH.
3205098|NCT01161641|Experimental|ODSH at 0.250 mg/kg/h|Second cohort of 3 subjects to receive the medium dose of ODSH
3205099|NCT01161641|Experimental|ODSH at 0.375 mg/kg/h|Third and last cohort of subject to receive the high dose of ODSH.
3205100|NCT01161628|Experimental|Rituxan|All patients receive Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
3205101|NCT01161615|Placebo Comparator|Placebo|Therapy with placebo
3205102|NCT01161615|Experimental|MRX-7EAT|Therapy with experimental drug
3205103|NCT01161602|Experimental|0.2mg Pumosetrag|
3205104|NCT01161602|Experimental|0.5mg Pumosetrag|
3205105|NCT01161602|Experimental|0.8mg Pumosetrag|
3205106|NCT01161602|Placebo Comparator|Placebo|
3205107|NCT01161576|Experimental|Group A|The first dose cohort consists of 6 subjects who received AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies (gc) total dose. This is equal to 900,000,000,000 molecules of the drug.
3205108|NCT01161576|Experimental|Group B|The second dose cohort consists of 10 subjects, who will receive AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies (gc) total dose. This is equal to 285,000,000,000 molecules of the drug.
3205109|NCT01161563|Active Comparator|Leuprolide acetate|Polymeric matrix formulation of leuprolide acetate (Eligard 45 mg) injected subcutaneously in upper or mid-abdominal area. Injection occurred either 6 months before or 6 months after injection of triptorelin pamoate suspension (Trelstar 22.5 mg) intramuscularly in the buttock.
3205110|NCT01161563|Active Comparator|Triptorelin pamoate|Triptorelin pamoate suspension (Trelstar 22.5 mg) injected intramuscularly in the buttock. Injection occurred either 6 months before or 6 months after injection of polymeric matrix formulation of leuprolide acetate (Eligard 45 mg) subcutaneously in upper or mid-abdominal area.
3205111|NCT01161550|Experimental|Arm 1|"GCSF 300 mcg SC Days 1-6~Cladribine 5 mg/m2 IV Days 2-6~Cytarabine 2 mg/m2 IV Days 2-6~ATRA 15 mg/m2 PO QD Days 7-20~Midostaurin 25 mg PO BID Days 7-20"
3205112|NCT01161550|Experimental|Arm 2|"GCSF 300 mcg SC Days 1-6~Cladribine 5 mg/m2 IV Days 2-6~Cytarabine 2 mg/m2 IV Days 2-6~ATRA 15 mg/m2 PO QD Days 7-20~Midostaurin 50 mg PO BID Days 7-20"
3205113|NCT01161537|Experimental|VX-770|"Part A: Subjects received placebo tablets matched to VX-770 150 milligram (mg) orally twice daily from Day 1 to 14 (Placebo run-in period), followed by VX-770 150 mg tablets orally twice daily from Day 15 to 42 (VX-770 treatment period), and then placebo tablets matched to VX-770 150 mg orally twice daily from Day 43 to 57 (Placebo washout period) during Part A of the study.~Part B: Subjects received VX-770 150 mg tablets orally twice daily for 48 weeks during Part B of the study. Part B included subjects from Part A and newly enrolled subjects."
3205114|NCT01161524|Experimental|1|
3205115|NCT01161524|Placebo Comparator|2|
3205116|NCT01161511|Experimental|1|XmAb5574
3205117|NCT01161498|Active Comparator|Radiation/Cisplatin|Participants received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42. Radiation was administered concurrently with cisplatin in 35 fractions over a 7-week period.
3205118|NCT01161498|Experimental|Talimogene Laherparepvec + Radiation/Cisplatin|The first dose of talimogene laherparepvec was up to 8 mL total volume (up to 4 mL per lesion) at 10⁶ plaque-forming units (PFU)/mL, administered into all injectable affected nodes on Day 0. Subsequent doses were up to 8 mL total volume (up to 4 mL per lesion) at 10⁸ PFU/mL on Days 21, 42, and 63. Participants also received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42 and radiation administered concurrently in 35 fractions over a 7-week period.
3205119|NCT01161485|Active Comparator|HIV Testing and Counseling|HIV Testing and Counseling
3205120|NCT01161485|Active Comparator|Contingency Management (CM)|Contingency management is based on Skinner's principles of operant conditioning in behavioral psychology, dating back to the 1930s (Skinner 1938). The basis of this model is that behavior is learned and reinforced by environmental contingencies that reward or punish.
3205121|NCT01161485|Experimental|CM with Strengths-based case management|Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community.
3205122|NCT01161472|Experimental|4mg fesoterodine|
3205123|NCT01161472|Experimental|fesoterodine 8mg|
3205124|NCT01161472|Active Comparator|1mg alprazolam|
3205125|NCT01161472|Placebo Comparator|Placebo|
3205126|NCT01161459|Experimental|Tripterygium wilfordii|120mg/d for 6 months,then decrease to 60mg/d by 30mg/d every month for 12 months
3205127|NCT01161459|Active Comparator|FK506|
3205128|NCT01161446|Experimental|Home Testing|
3205129|NCT01161446|No Intervention|Standard Testing|
3205130|NCT01161433|Experimental|Intervention|Virtually delivered spirometry quality improvement program
3205131|NCT01161433|No Intervention|Standard of Care|
3205132|NCT01161420|Experimental|Inspire Therapy|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
3205133|NCT01161407|Placebo Comparator|Placebo|Placebo control for calcium carbonate, given in same capsule form as the calcium carbonate, 3 times per day with meals.
3205134|NCT01161407|Active Comparator|Calcium Carbonate (Phosphate Binder)|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium.
3205135|NCT01161394|Experimental|Pioglitazone 15mg|8 patient will receive this drug
3205138|NCT01161381||Normal|Subjects that underwent night polysomnography with an observed Apnea-Hypopnea Index (AHI) < 5.
3205139|NCT01161381||OSAHS patients|Subjects that underwent night polysomnography with an observed Apnea-Hypopnea Index (AHI) > 5.
3205140|NCT01161368|Experimental|lapatinib, vinorelbine|"Drug: Lapatinib, Vinorelbine Lapatinib 1250mg orally once daily continuously~plus~Vinorelbine 20 mg/m2 intravenously (IV) once weekly [Days 1 and 8] for 2 weeks, followed by a rest week in a 3-week cycle."
3205141|NCT01161355|Experimental|AZD9668|Tablets and intravenous (IV) dose
3205142|NCT01161329|No Intervention|Control group|Participants in the control group are instructed to live their ordinary life.
3205143|NCT01161329|Experimental|Intervention group|Exercising two times/week according to the High-Intensity Functional Exercise Program (HIFE) in groups of 5-7 patients in combination with motivational discussions.
3205144|NCT01161316|Active Comparator|Control|mFOLFOX-6 + cetuximab until disease progression or early withdrawal.
3205145|NCT01161316|Experimental|Experimental|8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.
3205146|NCT01161277|Active Comparator|aripiprazole|
3205147|NCT01161277|Active Comparator|haloperidol|
3205148|NCT01161277|Placebo Comparator|suger pill|
3205149|NCT01161264|Experimental|18-60 YOA|
3205150|NCT01161264|Experimental|≥ 60 YOA|
3205151|NCT01161251||Atrial fibrillation patients|Non-valvular atrial fibrillation (paroxysmal, persistent or permanent)
3205152|NCT01161238||Lower-limb amputee|Subjects with at least one lower limb amputated at the trans-tibial level
3205153|NCT01161225|Experimental|peer-led asthma self-managment program|
3205154|NCT01161225|Active Comparator|Adult-led asthma self-management program|
3205155|NCT01161212|Other|Control group|
3205156|NCT01161212|Other|Intervention group|
3205157|NCT01161199||Untreated non-controllers|
3205158|NCT01161199||Elite controllers|
3205159|NCT01161199||HAART-suppressed|
3205160|NCT01161186|Experimental|Nab-paclitaxel,Gemcitabine, and Capecitabine|
3205161|NCT01161173||Erlotinib|Participants received erlotinib (Tarceva) at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics. The recommended daily dose of erlotinib is 150 mg orally once daily.
3205162|NCT01161160|Experimental|AREPANRIX 1/2 GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 half (1/2) pediatric dose of Arepanrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
3205163|NCT01161160|Experimental|PANDEMRIX 1/2 GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 half (1/2) pediatric dose of Pandemrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
3205164|NCT01161160|Experimental|AREPANRIX GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 pediatric dose of Arepanrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
3205165|NCT01161147|Experimental|Meloxicam|Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited
3205166|NCT01161147|Active Comparator|Mobic|Mobic Tablets 15 mg of Boehringer Ingelheim Pharmaceuticals Inc
3205167|NCT01161134|Experimental|Meloxicam|Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited
3205168|NCT01161134|Active Comparator|Mobic|Mobic Tablets 15 mg of Boehringer Ingelheim Pharmaceuticals Inc
3205169|NCT01161121|Experimental|Adenosine then Regadenoson|Adenosine infusion will be compared to Regadenoson for efficacy and safety/side effects. Arterial blood pressure, coronary pressure, heart rate, oxygen saturation and coronary flow, FFR, and coronary flow velocity will be assessed. Safety will be assessed by monitoring for any side effects such as chest pain, headache, flushing, nausea, or arrhythmias. Adenosine infusion will be administered at 140 mcg/kg for 2 minutes and once mean coronary flow velocity returns to within 15% of pre-dose value, Regadenoson IV bolus 0.4 mg/5 ml will be administered followed by a 5 cc normal saline flush.
3205170|NCT01161108|Active Comparator|Group A: Fast Release Melatonin|"Subjects will be randomized to one of the two treatment arms and to the order of study medication v.s. placebo.~The subject will undergo the assigned treatment for 7 weeks (3 weeks of study drug, a one week wash-out and 3 weeks of placebo, or vice versa)."
3205171|NCT01161108|Active Comparator|Group B: Timed Release Melatonin|"Subjects will be randomized to one of the two treatment arms and to the order of study medication v.s. placebo.~The subject will undergo the assigned treatment for 7 weeks (3 weeks of study drug, a one week wash-out and 3 weeks of placebo, or vice versa)."
3205172|NCT01161095|Experimental|Immediate|LNG-IUS insertion within the timeframe of delivery of the placenta to 72 hours postpartum
3205173|NCT01161095|Active Comparator|Interval|LNG-IUS insertion after 6 weeks postpartum
3205174|NCT01161082|Experimental|Group 1 with atorvastatin|Dose 1 versus placebo
3205175|NCT01161082|Experimental|Group 2 with atorvastatin|Dose 1 versus placebo
3205176|NCT01161082|Experimental|Group 3 with atorvastatin|Dose 2 versus placebo
3205177|NCT01161082|Experimental|Group 4 with atorvastatin|Dose 2 versus placebo
3205178|NCT01161082|Experimental|Group 5 with atorvastatin|Dose 3 versus placebo
3205179|NCT01161082|Experimental|Group 6 with atorvastatin|Dose 3 versus placebo
3205180|NCT01161082|Experimental|Group 7 without atorvastatin|Dose 3 versus placebo
3205181|NCT01161082|Experimental|Group 8 with atorvastatin|Dose4 versus placebo
3205182|NCT01161069|Active Comparator|PF-03049423|Cohorts 1 through 3 were healthy young adult volunteers; cohorts 4 and 5 were healthy elderly adult volunteers
3205183|NCT01161069|Placebo Comparator|Drug|Placebo in oral solution, given once daily for 14 days
3205184|NCT01161056||Healthy Control Group|
3205185|NCT01161030|Experimental|almonds|
3205186|NCT01161017|Active Comparator|1 Amitriptyline.|Amitriptyline
3205187|NCT01161017|Active Comparator|2 Topiramate|Topiramate
3205232|NCT01160718|Placebo Comparator|Arm B: Fulvestrant / Placebo|Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Placebo 3 caps p.o. bid (same appearance as AZD6244)
3205233|NCT01160692|Experimental|Arm 1|
3205234|NCT01160692|Placebo Comparator|Arm 2|
3205235|NCT01160666|Experimental|1: Belilumab|
3205188|NCT01161004|Experimental|Sugammadex - Nacl 9/00|"Sugammadex - Nacl 9/00:~Patients will first receive sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~In case of complete reversal of myorelaxation, total intravenous anesthesia is stopped and patients are allowed to awake.~In the adverse case, patients wil receive Nacl 9/00 5 minutes after the first bolus of sugammadex.~The study is finished 5 minutes after this second injection and care is let to the choice of the anesthesiologist in charge."
3205189|NCT01161004|Experimental|Nacl 9/00 - sugammadex|"Nacl 9/00 - Sugammadex :~Patients wil first receive Nacl 9/00. In case of complete reversal of myorelaxation, total intravenous anesthesia is stopped and patients are allowed to awake.~In the adverse case, patients wil receive sugammadex 5 minutes after the first bolus of Nacl 9/00.~Sugammadex is given as: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~The study is finished 5 minutes after the injection of sugammadex and care is let to the choice of the anesthesiologist in charge."
3205190|NCT01160991|Active Comparator|Amisulpride|Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.
3205191|NCT01160991|Experimental|Olanzapine|Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.
3205192|NCT01160991|Placebo Comparator|Placebo|Placebo capsules are given at 8:00 a.m. Procedures are performed as described above.
3205193|NCT01160978|Active Comparator|Simvastatin 80 mg group|The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
3205194|NCT01160978|Experimental|Control Rx|The transplant recipients who have received an organ from non-treated donors.
3205195|NCT01160965|Active Comparator|0.5% levobupivacaine|Participants given 15mls of 0.5% levobupivacaine as the solution for their epidural top-up
3205196|NCT01160965|Active Comparator|0.75% Rpoivacaine|Participants given 15mls of 0.75% ropivacaine as the solution for their epidural top-up.
3205197|NCT01160952|Other|long-term group|long-term group refers to prophylaxis by using itraconazole for up to 90 days
3205198|NCT01160952|Other|short term group|short term group refers to prophylaxis by itraconazole for 30 days
3205199|NCT01160926|Experimental|AZD6244 + capecitabine + radiotherapy|10 days single-agent dosing AZD6244 Then 35 days dosing of AZD6244 in combination with standard chemoradiotherapy
3205200|NCT01160926|Experimental|Cediranib + capecitabine + radiotherapy|10 days single agent dosing with Cediranib (AZD2171) then 35 days dosing of AZD2171 in combination with standard chemoradiotherapy
3205201|NCT01160913|Active Comparator|Continuous wound infusion above the fascia|
3205202|NCT01160913|Active Comparator|Continuous wound infusion below the fascia|
3205203|NCT01160900|Experimental|multivessel revascularization|Complete Revascularization : the Infarcted related artery was opened followed by dilatation of other significantly narrowed arteries during the same procedure
3205204|NCT01160887||Patients with diabetic peripheral neuropathy|
3205205|NCT01160887||Healthy matched controls|
3205206|NCT01160874|Experimental|TDA/H|
3205207|NCT01160874|Other|Sleep apnea patient|
3205208|NCT01160874|Other|Healthy volunteer|
3205209|NCT01160861|Experimental|A|
3205210|NCT01160861|Experimental|B|
3205211|NCT01160861|Experimental|C|
3205212|NCT01160848|Other|Part 1|Three areas will be randomized to either a pre-treatment cleaning using a wipe containing an ethyl alcohol solution(one area) or a cleansing wipe containing saline water (two areas), before application of the Visonac cream. One of the areas cleaned with saline wipe will also be occluded with a transparent dressing (Tegaderm) during the incubation time. In vivo fluorescence spectroscopy will be performed in the three areas before cream application, and at 1h, 1.5h, 2h, 2.5h and 3 h after cream application
3205213|NCT01160848|Other|Part 2|For each patient, 3 areas were randomized to treatment with Visonac for 24 hours (2 areas) or Visonac for 1 hour (1 area)
3205214|NCT01160835|Experimental|Quadriceps-sparing total knee arthroplasty|Quadriceps-sparing arthrotomy with side-cutting instruments
3205215|NCT01160835|Active Comparator|Medial parapatellar total knee arthroplasty|Medial parapatellar arthrotomy with front-cutting instruments
3205216|NCT01160822|Experimental|Part A: Canakinumab|In this ascending dose part, participants received a single intra-articular injection of canakinumab. The beginning dose was 150 mg, escalating to the 300 mg dose and then to 600 mg.
3205217|NCT01160822|Placebo Comparator|Part A: Placebo|Participants received a single intra-articular injection of canakinumab-matching placebo.
3205218|NCT01160822|Experimental|Part B: Canakinumab|Participants received a single intra-articular injection of canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.
3205219|NCT01160822|Placebo Comparator|Part B: Placebo|Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.
3205220|NCT01160822|Active Comparator|Part B: Naproxen|Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.
3205221|NCT01160809|Experimental|Mosquito repellent and LLINs group vs. LLINs group only|This study is based on two population groups: 1) a group of households that use LLINs alone (control) and 2) a group of households that use both mosquito repellent and LLINs (repellent group).
3205222|NCT01160796|Experimental|Lcr35®|
3205223|NCT01160796|Placebo Comparator|placebo|
3205224|NCT01160770|Experimental|Clobazam|
3205225|NCT01160757|Other|ultrasound|
3205226|NCT01160744|Experimental|IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin|IMC-1121B + Pemetrexed + Carboplatin [Area Under the Concentration Time Curve 6 (AUC 6)] or Cisplatin
3205227|NCT01160744|Active Comparator|Pemetrexed + Carboplatin (AUC 6) or Cisplatin|Pemetrexed + Carboplatin (AUC 6) or Cisplatin
3205228|NCT01160744|Experimental|IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin|IMC-1121B + Gemcitabine + Carboplatin [Area Under the Concentration Time Curve 5 (AUC 5)] or Cisplatin
3205229|NCT01160744|Active Comparator|Gemcitabine + Carboplatin (AUC 5) or Cisplatin|Gemcitabine + Carboplatin (AUC 5) or Cisplatin
3205230|NCT01160731|Experimental|Cisplatin, Etoposide & Panobinostat|
3205231|NCT01160718|Active Comparator|Arm A: Fulvestrant / AZD6244|Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days AZD6244 75 mg p.o. bid
3205236|NCT01160653|Experimental|1|Gait training and Cognitive Training
3205238|NCT01160640|Placebo Comparator|Ceftriaxone/Doxycycline/Placebo Oral Cap|ceftrixone 250mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus placebo oral capsule PO bid x 14 days
3205239|NCT01160640|Active Comparator|Ceftriaxone, Doxycycline, Metronidazole|ceftriaxone 250 mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus metronidazole 500 mg PO bid x 14 days
3205240|NCT01160627|Active Comparator|Standard treatment|Hydration
3205241|NCT01160627|Active Comparator|Combined Acetylcystein and Sodium Bicarbonat|
3205242|NCT01160627|Active Comparator|Sodium Bicarbonate|
3205243|NCT01160627|Active Comparator|Acetylcystein for 2 days|Standard treatment + acetylcystein for 2 days
3205244|NCT01160614|Experimental|ORF Tablets|ORF Tablets
3205245|NCT01160601|Experimental|paclitaxel/carboplatin plus bavituximab|Patients will receive paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve [AUC] 6) on Day 1 of each 21 day cycle for up to 6 cycles, in combination with 3 mg/kg bavituximab administered weekly.
3205246|NCT01160601|Active Comparator|paclitaxel/carboplatin|Patients will receive paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve [AUC] 6) on Day 1 of each 21 day cycle for up to 6 cycles.
3205247|NCT01160588||Sertraline treatment|Participants with Generalized Anxiety Disorder, and/or Social Anxiety Disorder, and/or Separation Anxiety Disorder will undergo MRI scanning, EEG's, and sertraline treatment.
3205248|NCT01160588||Healthy Controls|Healthy control participants will undergo MRI scanning and EEG's.
3205249|NCT01160588||Cognitive Behavioral Therapy|Participants with Generalized Anxiety Disorder, and/or Social Anxiety Disorder, and/or Separation Anxiety Disorder will undergo MRI scanning, EEG's, and talk therapy (CBT).
3205250|NCT01160484|Experimental|DVD-R single arm|"Dose schematic of Dexamethasone + Bortezomib + Pegylated Liposomal Doxorubicin + Lenalidomide (DVD-R) Therapy:~Dexamethasone*- 40 mg IV Bortezomib**- 1.0 mg/m2 IV Push Pegylated Liposomal Doxorubicin*- 4.0 mg/m2 IV Lenalidomide***- 10 mg PO~Per 28 Day Cycle~Intravenous infusion (IV) Days 1, 4, 8 and 11 ** Intravenous push (IVP) Days 1, 4, 8 and 11 *** Per Orem (PO) Days 1-14"
3205251|NCT01160458|Experimental|IMC-A12 Monotherapy in Patients|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
3205252|NCT01160445|Experimental|HD IL-2 + Zanolimumab - Melanoma|"Patients with metastatic melanoma Zanolimumab 14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.~Aldesleukin (IL-2) 720,000 IU/kg every 8 hours for a maximum of 15 doses."
3205253|NCT01160445|Experimental|HD IL-2 + Zanolimumab - Renal Cell|"Patients with metastatic renal cancer Zanolimumab 14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.~Aldesleukin (IL-2) 720,000 IU/kg every 8 hours for a maximum of 15 doses."
3205254|NCT01160432|Experimental|Methadone naloxone combination product 2/0,04 mg/ml|Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml
3205255|NCT01160432|Active Comparator|Methadone 2 mg/ml|Normal treatment except the dilution of methadone solution (5 mg/ml → 2 mg/ml).
3205256|NCT01160419|Other|FLOT|Docetaxel, Oxaliplatin, Folinic acid, 5-FU, q 2 weeks, application of 6 cycles
3205257|NCT01160406||ischemic stroke, no atrial fibrillation|Patients who have suffered ischemic stroke or transient ischemic attack without known atrial fibrillation
3205258|NCT01160393|Other|Miniaturized bypass system|Miniaturized bypass system and the incidence of atrial fibrillation after cardiac surgery
3205259|NCT01160380|Experimental|Armodafinil|The patients receive armodafinil for all 56 days of the study.
3205260|NCT01160380|Placebo Comparator|Placebo-First|These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
3205261|NCT01160367|Active Comparator|standard of care health decision making|Patient-family dyads will receive the standard of care for support of patient and family members health care decision making during a clinic appointment.
3205262|NCT01160367|Experimental|TAILORED intervention|Patients and family members who receive the TAILORED Decision Making Intervention
3205263|NCT01160354|Experimental|Plerixafor + Clofarabine|"Phase I: Plerixafor starting at 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before a 1 hour (+/- 30 minutes) IV administration of Clofarabine.~Phase II: Plerixafor at the highest dose tolerated in Phase I.~Phase I and II: Clofarabine fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles)."
3205264|NCT01160341|Experimental|Testosteron, secondary hypogonadism|
3205265|NCT01160328|No Intervention|Control Group|Participants in this group will not receive any treatment.
3205266|NCT01160328|Experimental|Lupron Group|Participants in this group will receive leuprolide acetate (Lupron) treatment for 7 weeks resulting in temporary decreases in testosterone levels.
3205267|NCT01160328|Other|Lupron & Testosterone Group|Participants in this group will receive 7 weeks of leuprolide acetate (Lupron) treatment with testosterone gel (Androgel).
3205268|NCT01160315|Experimental|Arm A (GnRha arm)|IM injection of Triptorelin -Decapeptyl PR 11.25mg- (every 3 months) and Norethisterone acetate- Primolut-Nor 5 mg- per os continuously until the end of the chemotherapy
3205269|NCT01160315|Active Comparator|Arm B (control Arm)|Norethisterone acetate alone, 5mg par day, (ARM B) until the end of the chemotherapy.
3205270|NCT01160302|Experimental|Microgranular Curcumin|Consume 4g microgranular curcumin (Curcumin C3 Complex) twice per day
3205271|NCT01160289|Experimental|1 mg LY2452473 + 5 mg tadalafil|
3205272|NCT01160289|Experimental|5 mg LY2452473 + 5 mg tadalafil|
3205273|NCT01160289|Experimental|5 mg LY2452473 + placebo|
3205274|NCT01160289|Active Comparator|10 mg tadalafil + placebo|
3205275|NCT01160289|Active Comparator|5 mg tadalafil + placebo|
3205276|NCT01160276|Active Comparator|Cyclosporine|The first group is composed of 14 renal graft recipients under cyclosporine
3205277|NCT01160276|Active Comparator|Tacrolimus|The second group is composed of 14 renal graft recipients under tacrolimus
3205278|NCT01160263|Other|patients without stiffness|
3205279|NCT01160263|Other|patients with pyramidal stiffness|
3205280|NCT01160263|Other|patients with mixed stiffness|
3205281|NCT01160237|Experimental|Group A|Subjects previously vaccinated with a vaccine against the pandemic H1N1 strain
3205282|NCT01160237|Experimental|Group B|Subjects previously vaccinated with a vaccine against the pandemic H1N1 strain
3205283|NCT01160237|Active Comparator|Group C|Subjects not previously vaccinated with a vaccine against the pandemic H1N1 strain
3205284|NCT01160224|Active Comparator|GW766944|This is the active drug (GW766944)
3205285|NCT01160224|Placebo Comparator|Placebo|Placebo Arm.
3205286|NCT01160211|Experimental|Lapatinib plus trastuzumab plus aromatase inhibitor|Experimental
3205287|NCT01160211|Active Comparator|trastuzmab plus aromatase inhibitor|Active Comparator
3205288|NCT01160211|Active Comparator|lapatinib plus aromatase inhibitor|Active Comparator
3205289|NCT01160198|Experimental|ferrous bisglycinate chelate 1 OD|ferrous bisglycinate chelate 1 tablet daily
3205290|NCT01160198|Active Comparator|ferrous ascorbate|ferrous ascorbate, 1 tablet daily
3205291|NCT01160198|Experimental|ferrous bisglycinate chelate 2 OD|ferrous bisglycinate chelate 2 tablets daily
3205292|NCT01160185||cisplatin|
3205293|NCT01160185||cisplatin + topotecan|
3205294|NCT01160185||cisplatin + paclitaxel|
3205295|NCT01160172|Experimental|Group A|
3205296|NCT01160172|Experimental|Group B|
3205297|NCT01160172|Experimental|Group C|
3205298|NCT01160172|Experimental|Group D|
3205299|NCT01160172|Placebo Comparator|Group E|
3205300|NCT01160172|Placebo Comparator|Group F|
3205301|NCT01160159||Thrombophilia|
3205302|NCT01160159||Healthy volunteers|
3205303|NCT01160146||Lifestyle counseling|"Clinicians provide lifestyle management counseling regarding healthful lifestyle behaviors and daily physical activity.~Logging foods for accountability and counting calories~Close attention to portion control and appropriate serving sizes of foods consumed~Consumption of appropriate calorie and sugar free beverages~Good meal distribution and avoidance of meal skipping~Balance of food groups using the MyPlate concept (USDA Choose My Plate)-inclusion of all food groups with emphasis on fruits, vegetables, whole grains, low-fat dairy products and lean meat/fish/poultry~Increasing physical activity with reasonable, sustainable exercise or activity. Working toward a goal of at least 30 minutes, 5 days per week"
3205304|NCT01160133|Experimental|Systane|Systane Lubricant Eye Drops
3205305|NCT01160133|Experimental|Refresh Tears|Refresh Tears Lubricant Eye Drops
3205306|NCT01160120|Other|1|Patients can be either treatment-naïve or treatment-experienced when entering this clinical trial. After meeting the inclusion and exclusion criteria, patients will start with generic FDC of TDF/3TC/EFV 1 pill a day at night time. Only patient who are on individual TDF 3TC and EFV will undergo TDM sampling ( 11-13 hours after dosing) at baseline.
3205307|NCT01160107|Experimental|RP followed MPR|
3205308|NCT01160094||Patients|ErbB2+ metastatic breast cancer patients
3205309|NCT01160081||National Health and Nutrition Survey 2006 (ENSANUT 2006)|
3205310|NCT01160068|Experimental|Metformin|Metformin Hydrochloride 1000 mg tablets of Dr. Reddy's Laboratories Limited
3205311|NCT01160068|Active Comparator|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
3205312|NCT01160055||Cohort A|Subjects with a new episode of Acute Otitis Media (<3 days of onset) who have not yet received antibiotic therapy for the episode.
3205313|NCT01160055||Cohort B|Subjects who have had a diagnosis of Acute Otitis Media within 2-3 days prior to study enrolment and received antibiotic therapy, but remain symptomatic.
3205314|NCT01160042|Experimental|Metformin|Metformin Hydrochloride 1000 mg tablets of Dr. Reddy's Laboratories Limited
3205315|NCT01160042|Active Comparator|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
3205316|NCT01160029|Experimental|Nateglinide|Nateglinide Tablets 120 mg of Dr. Reddys Laboratories Limited
3205317|NCT01160029|Active Comparator|Starlix|Starlix Tablets 120 mg of Novartis
3205318|NCT01160003|Experimental|Treatment Period 1|5mg of GW870086X or placebo will be given once daily for 14 days.
3205319|NCT01160003|Experimental|Treatment Period 2|GW870086X (5mg or 8.75mg) or placebo will be given once daily for 14 days. In a randomised dose escalating manor following on from treatment period 1.
3205320|NCT01160003|Experimental|Treatment Period 3|8.75mg of GW870086X or placebo will be given once daily for 14 days.
3205321|NCT01159990|Experimental|Recombinant adenovirus serotype 5 (rAd5) Gag/Pol Env A/B/C|Participants will receive one intramuscular injection of rAd5 Gag/Pol Env A/B/C.
3205322|NCT01159990|Active Comparator|rAd5 gag/pol|Participants will receive one intramuscular injection of rAd5 gag/pol.
3205323|NCT01159977|Experimental|Facilitated small group|Facilitated small groups.
3205324|NCT01159977|Active Comparator|Unstructured protected time|Same time provided as for facilitated small groups, but without structure.
3205325|NCT01159977|Placebo Comparator|Usual practice|No protected time.
3205326|NCT01159964|Experimental|Cohort 1|Subjects will receive investigational dose-level A (different from dose-levels B and C). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
3205327|NCT01159964|Experimental|Cohort 2|Subjects will receive investigational dose-level B (different from dose-levels A and C). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
3205328|NCT01159964|Experimental|Cohort 3|Subjects will receive investigational dose-level C (different from dose-levels A and B). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
3205329|NCT01159951||Hepatitis Cohort|Subjects suffering with hepatitis
3205330|NCT01159938|Experimental|T2DM, albuminuria but normal kidney function|
3205331|NCT01159938|No Intervention|Healthy participants|
3205332|NCT01159938|Experimental|T2DM, normal urinary albumin excretion rate (UAER)|
3205333|NCT01159925||Possible hepatitis A Cohort|Children with an acute disease characterized by discrete onset of symptoms and jaundice
3205334|NCT01159925||Probable hepatitis A Cohort|Children with an increase in serum levels of transaminase 2.5 times higher than the maximum limit of the normal interval
3205335|NCT01159925||Confirmed hepatitis A Cohort|Children presenting a positive result for Immunoglobulin M for hepatitis A virus
3205336|NCT01159912|Experimental|Fluticasone Furoate OD and Placebo BID|Fluticasone furoate inhalation powder once daily and placebo inhalation powder twice daily for 24 weeks
3205337|NCT01159912|Active Comparator|Fluticasone Propionate BID and Placebo OD|Fluticasone propionate inhalation powder twice daily and placebo inhalation powder once daily for 24 weeks
3205863|NCT01155986|Placebo Comparator|Placebo Plaster|Active Comparator
3205338|NCT01159912|Placebo Comparator|Placebo only BID|Placebo inhalation powder twice daily for 24 weeks
3205339|NCT01159886|Active Comparator|left lateral|After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus position. Then terminal ileal intubation will be attempted.
3205340|NCT01159886|Active Comparator|supine|After confirmation of cecal intubation, patient will undergo randomization to the supine position. Then terminal ileal intubation will be attempted.
3205341|NCT01159873|Experimental|CEP-37251|
3205342|NCT01159873|Placebo Comparator|Placebo|
3205343|NCT01159860|Active Comparator|Cryosurgery|One lesion on the patients' trunk or proximal extremities will be treated with cryosurgery.
3205344|NCT01159860|Active Comparator|Curettage|One lesion on one side of the patients' trunk or proximal extremities will be treated by curettage.
3205345|NCT01159847|Experimental|Sitagliptin|Patients will receive insulin therapy with sitagliptin.
3205346|NCT01159847|Active Comparator|Insulin|Patients will receive insulin therapy without sitagliptin.
3205347|NCT01159834||Gardasil, HPV infection|
3205348|NCT01159821|Experimental|001|31001074/paroxetine 1 tablet of 31001074 will be administered on Day 1 and Day 13. One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
3205349|NCT01159808|Experimental|INX-08189|
3205350|NCT01159808|Placebo Comparator|Placebo|
3205351|NCT01159782|Other|Asthma, Healthy|Asthmatics or Healthy Volunteers
3205352|NCT01159769|Experimental|Olopatadine 0.2%|1 drop self-administered in each eye once daily in the morning for 7 days
3205353|NCT01159756|Experimental|Travacom|Travacom ophthalmic solution
3205354|NCT01159743||Efavirenz|HIV-infected patients on initial antiretroviral therapy for at least two years with efavirenz (Sustiva®; EFV) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
3205355|NCT01159743||Lopinavir / Ritonavir|HIV-infected patients on initial antiretroviral therapy for at least two years with lopinavir/ritonavir (Kaletra®; LPV/r) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
3205356|NCT01159730|Experimental|Multiple doses of VB-201|
3205357|NCT01159730|Placebo Comparator|Placebo|
3205358|NCT01159704|Experimental|Network plus HIV Counseling&Education|"Social network peer education model plus HIV testing and counseling; the C & E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
3205359|NCT01159704|Active Comparator|HIV Counseling and Education (C&E) only|"HIV testing and counseling C&E; the C & E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
3205360|NCT01159691||Neupro|Routine treatment as per approved label in Europe/ in accordance with the terms of the local marketing authorization for Neupro® transdermal patch.
3205361|NCT01159678|Experimental|online psychoeducation|
3205362|NCT01159665|Experimental|PPV 5-30 minutes after injection|Primary Pars Plana Vitrectomy 5 to 30 minutes after 125µg of ocriplasmin intravitreal injection
3205363|NCT01159665|Experimental|PPV 31-60 minutes after injection|Primary Pars Plana Vitrectomy 31 to 60 minutes after 125µg of ocriplasmin intravitreal injection
3205364|NCT01159665|Experimental|PPV 2-4 hours after injection|Primary Pars Plana Vitrectomy 2 to 4 hours after 125µg of ocriplasmin intravitreal injection
3205365|NCT01159665|Experimental|PPV 24 hours (+2 hours) after injection|Primary Pars Plana Vitrectomy 24 hours (+2 hours)after 125µg of ocriplasmin intravitreal injection
3205366|NCT01159665|Experimental|PPV 7 days (+1 day) after injection|Primary Pars Plana Vitrectomy 7 days (+1 day)after 125µg of ocriplasmin intravitreal injection
3205367|NCT01159665|No Intervention|PPV without injection|Control Arm, no ocriplasmin intravitreal injection
3205368|NCT01159652|Placebo Comparator|Bedtime Placebo|
3205369|NCT01159652|Placebo Comparator|Middle of the Night Placebo|
3205370|NCT01159652|Experimental|Zolpidem|
3205371|NCT01159652|Experimental|Zaleplon|
3205372|NCT01159639|No Intervention|aspirin low responders monotherapy|patients with inappropriate response to aspirin assessed by multiple electrode aggregometry
3205373|NCT01159639|Active Comparator|aspirin low responders dual antiplatelet therapy|patients with inappropriate response to aspirin 300 mg therapy after CABG, randomized to receive clopidogrel 75 mg in addition to aspirin
3205374|NCT01159626|Experimental|Single dose|
3205375|NCT01159626|Experimental|Multiple dose|
3205376|NCT01159613||Non Responders|Non Responders
3205377|NCT01159613||RESPONDERS|
3205378|NCT01159600|Experimental|BI 10773 Arm 2|BI 10773 once daily high dose
3205379|NCT01159600|Placebo Comparator|Placebo|Placebo matching BI 10773
3205380|NCT01159600|Experimental|BI 10773 open-label|BI 10773 once daily high dose open label
3205381|NCT01159600|Experimental|BI 10773 Arm 1|BI 10773 once daily low dose
3205382|NCT01159587||Group 1|
3205383|NCT01159587||Group 2|
3205384|NCT01159574|Experimental|all patients|"ClaPd therapy:~Dexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.~Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day."
3205385|NCT01159561|Experimental|Vaccinated|Western Equine Encephalitis Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, administered in 0.5 mL doses subcutaneously in the upper outer aspect of the triceps in a 3-dose primary series (Days 0, 7, and 28) with a mandatory boost (Day 180)
3205386|NCT01159548|No Intervention|Saline|
3205387|NCT01159548|Other|Promethazine 6.25 mg|
3205388|NCT01159548|Other|Promethazine 3 mg|
3205389|NCT01159535|Active Comparator|MBRP|The Mindfulness Based Relapse Prevention (MBRP) intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants). Individual sessions will be team-taught by two therapists and will include mindfulness practices targeting craving, Negative affect, and reactivity, as well as discussion about how to implement practice into high-risk situations and in daily life.
3205642|NCT01157442|Experimental|cell phone sms messages|The experimental arm will receive the cell phone SMS text messaging intervention.
3205390|NCT01159535|Active Comparator|Relapse Prevention (RP)|The RP intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants). Individual sessions will be team-taught by two therapists and will include discussions of personal high-risk situations, coping skills assessment, and exercises to evaluate expectancies, self-efficacy, and craving.
3205391|NCT01159535|Active Comparator|Treatment as Usual|All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
3205392|NCT01159522|Experimental|SCB01A|This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
3205393|NCT01159509||Infants ages -13 years that had HPS in infancy|
3205394|NCT01159496|Experimental|Active|
3205395|NCT01159496|Placebo Comparator|Placebo|
3205396|NCT01159483|Experimental|Cohort 1|
3205397|NCT01159483|Experimental|Cohort 2|
3205398|NCT01159470||bacterial infection|children with fever due to bacterial infection
3205399|NCT01159470||viral infection|children with fever due to viral infection
3205400|NCT01159457|Active Comparator|1|celiac patients who did not respond to initial hepatitis B vaccine series , will receive Sci-B-Vac vaccination series
3205401|NCT01159457|Active Comparator|2|celiac patients who did not respond to initial hepatitis B vaccine series , will receive Engerix 3-dose vaccination series
3205402|NCT01159431|Experimental|Active|
3205403|NCT01159431|Other|Control|
3205404|NCT01159418|Experimental|Panobinostat (LBH589), Carboplatin and Paclitaxel|
3205405|NCT01159405|Experimental|99mTc-GP|99mTc-GP with SPECT/CT imaging & whole body scan.
3205406|NCT01159392||Brain injury plus acute lung injury|Patients with severe brain injury (Glasgow coma score<13) with acute lung injury (PaO2/FiO2 <300 mmHg)
3205407|NCT01159379|Experimental|ertapenem, tolerance tests|Patients with IgE-mediated allergy to beta-lactams
3205408|NCT01159366|Active Comparator|occluded culprit artery|An occluded lesion was defined as a lesion with 100% stenosis or TIMI-flow grade 0 or 1.
3205409|NCT01159366|Active Comparator|non-occluded culprit artery|A non-occluded lesion was defined as a lesion without 100% stenosis or TIMI-flow grade 0 or 1.
3205410|NCT01159353|Experimental|insulin glulisine + insulin aspart|insulin glulisine (1 day) + wash-out (7 days) + insulin aspart (1 day)
3205411|NCT01159353|Experimental|insulin aspart + insulin glulisine|insulin glulisine (1 day) + wash-out (7 days) + insulin aspart (1 day)
3205412|NCT01159327|Experimental|Arm A|Sorafenib maintenance arm
3205413|NCT01159327|No Intervention|Arm B|observation arm
3205414|NCT01159314|Experimental|Arm A - Baerveldt 250 mm2|Patients receiving Baerveldt 250 mm2
3205415|NCT01159314|Experimental|Arm B - Baerveldt 350 mm2|Patients receiving Baerveldt 350 mm2
3205416|NCT01159301|Experimental|Treatment (entinostat, sorafenib tosylate)|Patients receive oral entinostat once daily on days 1 and 15 and oral sorafenib tosylate twice daily on days 1-28 (days 15-28 only of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3205417|NCT01159275|Other|1|First Generic LPV/r 200/50 mg BID, then cross over to Pediatric Aluvia 200/50 mg BID
3205418|NCT01159275|Other|2|First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
3205419|NCT01159262|Experimental|Dexmedetomidine 0.05 mcg/kg|Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
3205420|NCT01159262|Experimental|Dexmedetomidine 0.1 mcg/kg|Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
3205421|NCT01159262|Experimental|Dexmedetomidine 0.2 mcg/kg|Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
3205422|NCT01159249|Other|Open Met add-on vildagliptin|
3205423|NCT01159249|Other|Open TZD add-on vildagliptin|
3205424|NCT01159249|Other|Open α-GI add-on vildagliptin|
3205425|NCT01159249|Other|Glinides add-on vildagliptin|
3205426|NCT01159236|Experimental|Group 1: ER-Positive|"Participants with Estrogen Receptor (ER)-Positive breast cancers receive Standard T/FAC or T/FEC chemotherapy before surgery.~T/FAC or T/FEC: Combination chemotherapy with sequential paclitaxel (80 mg/m2) weekly x 12 weeks followed by 5-fluorouracil (500 mg/m2), cyclophosphamide (500 mg/m2) and doxorubicin (50 mg/m2) or epirubicin (100 mg/m2) (FAC or FEC) once every 3 weeks for 4 treatments."
3205427|NCT01159236|Experimental|Group 2: ER-Negative|Participants with ER-negative cancers (randomized between Group 2 & Group 3), Standard T/FAC or T/FEC chemotherapy before surgery.
3205428|NCT01159236|Experimental|Group 3: ER-Negative + Bevacizumab|Participants with ER-negative cancers (randomized between Group 2 & Group 3), T/FEC chemotherapy combined with 10 mg Bevacizumab every 2 weeks during first 3 treatments before surgery.
3205429|NCT01159223|Experimental|1|ATV/r 200 mg/100 mg OD
3205430|NCT01159223|Experimental|2|ATV/r 300 mg/100 mg OD
3205431|NCT01159197|Experimental|cognitive behaviorial therapy|
3205432|NCT01159171|Experimental|1|
3205433|NCT01159158|Experimental|Nateglinide|Nateglinide Tablets 120 mg of Dr. Reddys Laboratories Limited
3205434|NCT01159158|Active Comparator|Starlix|Starlix Tablets 120 mg of Novartis
3205435|NCT01159145|Experimental|D961H 10 mg capsule|2 way crossover
3205436|NCT01159145|Experimental|Omeprazole 10 mg tablet|2 way crossover
3205437|NCT01159132|Active Comparator|1|RAL 400 mg OD
3205438|NCT01159132|Active Comparator|2|RAL 800 mg OD
3205439|NCT01159119|Experimental|EUR-1066-A|Treatment with Eur-1006-A.
3205440|NCT01159119|Experimental|EUR-1066-B|Treatment with Eur-1066-B
3205441|NCT01159119|Active Comparator|Zenpep|Control Group: Consist of treatment with Zenpep
3205442|NCT01159093|Experimental|Family Decision Support|Families will receive informational vaccine reminder telephone calls.
3205443|NCT01159093|Experimental|Clinical Decision Support|In this treatment arm, clinicians receive the decision support at the point of care within an electronic health record.
3205444|NCT01159093|Experimental|Family DS+ Clinician DS|Families will receive informational vaccine reminder calls and their clinicians will receive electronic health record-based decision support for immunizations.
3205445|NCT01159093|Other|Control|This group will receive regular primary care with no decision support.
3205446|NCT01159080|Active Comparator|routine dose tacrolimus and less myfortic|
3205447|NCT01159080|Experimental|reduced dose tacrolimus and conventional myfortic|
3205448|NCT01159067|Experimental|Arm I|Patients receive oral deferasirox once daily for up to 6 months in the absence of unacceptable toxicity.
3205449|NCT01159054|Experimental|This study has only one arm.|Blood sample and scan results to be compared before and after intervention in each subject.
3205450|NCT01159041|Experimental|Family Focused Treatment (FFT)|15 session family-based treatment emphasizing improving relationship skills to combat depression symptoms and support recovery.
3205451|NCT01159041|Active Comparator|Individual Treatment (IP)|15 session individually-based treatment to assist children in understanding the causes of their symptoms.
3205452|NCT01159028|Experimental|BP1001|Subjects are treated with open-label study drug (BP1001) in a dose-escalation model.
3205453|NCT01159028|Experimental|BP1001 in combination with LDAC|AML subjects are treated with open-label escalating study drug (BP1001) in combination with low dose ara-C (LDAC)
3205454|NCT01159015|Experimental|KetoNaph|KetoNaph Ophthalmic Solution
3205455|NCT01159015|Placebo Comparator|Vehicle|Vehicle of KetoNaph Ophthalmic Solution
3205456|NCT01159002||Critically ill ICU patients|ICU patients with brain injuries who will be receiving a feeding tube.
3205457|NCT01158989||Critically ill|Critically ill subjects were intubated, mechanically ventilated and sedated
3205458|NCT01158989||Ambulatory Group|Subjects were scheduled for an outpatient procedure but were otherwise healthy
3205459|NCT01158976|Experimental|DHA supplementation|
3205460|NCT01158976|Placebo Comparator|Soybean Oil|
3205461|NCT01158950|Experimental|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
3205462|NCT01158950|Placebo Comparator|Placebo|Drug: Placebo for tolcapone administered at study visit
3205463|NCT01158950|Experimental|Entacapone|Drug: Entacapone 200mg (single dose) administered at study visit
3205464|NCT01158937|Experimental|Extended Meropenem Infusion|Meropenem Infusion over 3 hours
3205465|NCT01158937|Experimental|Bolus Meropenem Infusion|Meropenem infusion over 30 minutes
3205466|NCT01158924|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
3205467|NCT01158911||non-diabetic Chronic Kidney disease|
3205468|NCT01158898|Active Comparator|TPI ASM8 low dose|
3205469|NCT01158898|Active Comparator|TPI ASM8 high dose|
3205470|NCT01158898|Placebo Comparator|Placebo|
3205471|NCT01158859|Experimental|Pregabalin|
3205472|NCT01158859|Placebo Comparator|Placebo|
3205473|NCT01158846|Active Comparator|prasugrel/bivalirudin|60 mg loading dose of prasugrel will be followed by maintenance dose of 10mg (or 5mg according to body weight and age). During primary PCI, Bivalirudin will be used as anticoagulant (bolus plus infusion), on a weight-adjusted dose.
3205474|NCT01158846|Active Comparator|clopidogrel/abciximab|600mg loading dose of clopidogrel will be followed by 75mg maintenance dose. During primary PCI abciximab (bolus plus infusion) will be used as anticoagulant.
3205475|NCT01158833||spastic diplegia due to Cerebral Palsy|
3205476|NCT01158820|Placebo Comparator|Placebo + Standard of Care of midazolam and fentanyl|"Nebulized lidocaine 2% (maximum dose 200 mg) will be administered for 20 minutes.~Following nebulization, syringe A (placebo) will be given at a rate of 1 µg/kg (based on a concentration of 4 µg/ml) for 10 minutes. Supplemental topical anesthesia will be administered by the pulmonologist during this time.~After step 2, syringe B (midazolam 2 mg and fentanyl 50 µg) will be administered by the anesthesiologist. The infusion rate of syringe A (placebo) will be decreased to 0.7 µg/kg/hr. Syringe C (placebo) will be infused at 4 µg/kg/min (based on 10 mg/ml concentration)~Boluses of 0.5 mg midazolam and 12.5 µg fentanyl will be administered by the pulmonologist from syringe D as needed for patient comfort. Syringe E (benadryl 25 mg) will be administered in entirety by the anesthesiologist after the 6th and 16th bolus of midazolam/fentanyl."
3205477|NCT01158820|Active Comparator|dexmedetomidine and ketamine + Standard of Care|"Nebulized lidocaine 2% (maximum dose 200 mg) will be administered for 20 minutes.~Following nebulization, syringe A (dexmedetomidine) will be given at a rate of 1 µg/kg (based on a concentration of 4 µg/ml) for 10 minutes. Supplemental topical anesthesia will be administered by the pulmonologist during this time.~After step 2, syringe B (ketamine 30 mg) will be administered by the anesthesiologist. The infusion rate of syringe A (dexmedetomidine) will be decreased to 0.7 µg/kg/hr. Syringe C (ketamine) will be infused at 4 µg/kg/min (based on 10 mg/ml concentration)~Boluses of 0.5 mg midazolam and 12.5 µg fentanyl will be administered by the pulmonologist from syringe D as needed for patient comfort. Syringe E (benadryl 25 mg) will be administered in entirety by the anesthesiologist after the 6th and 16th bolus of midazolam/fentanyl."
3205478|NCT01158807||HHT- Brain Arteriovenous Malformation|"Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT and~Presence of Brain Arteriovenous Malformation"
3205479|NCT01158807||HHT -NO BAVM|1. Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT
3205480|NCT01158794||Study participants|Participants with sickle cell disease and transfusional iron-overload, and non-sickle cell disease (thalassemia major, cancer patients, etc.) and iron overload. Participants with iron overload, defined as too much iron in the body as a consequence of too many blood transfusions.
3205481|NCT01158781|No Intervention|TBI standard care|This group will receive no study related interventions.
3205482|NCT01158781|Experimental|gait, balance, arm function, cognition|12 weeks of training for balance, gait, upper limb function, and cognition
3205483|NCT01158768||Violence, Comorbidity|
3205484|NCT01158755|Active Comparator|Standard dose rifampisin|"Subjects in this arm receive 450 mg rifampicin orally.~In accordance with national TB treatment standard that encourages the use of 4 drugs, all subjects -both in active comparator and experimental arm- will also receive isoniazide 300 mg p.o. and pyrazinamide 1500 mg p.o.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
3205485|NCT01158755|Experimental|High dose rifampisin|"Subjects in this arm receive 600 mg Rifampisin i.v. for 14 days, and the dosage will be switched to 450 mg Rifampisin p.o afterwards until completion of TB medication (in accordance with National TB Program)~In accordance with national TB treatment standard that encourages the use of 4 drugs, all subjects -both in active comparator and experimental arm- will also receive isoniazide 300 mg p.o. and pyrazinamide 1500 mg p.o.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
3205486|NCT01158742||1|Caucasians who donated a kidney at Mayo Clinic in Rochester, Minnesota (MN)
3205487|NCT01158742||2|Caucasians who donated a kidney at the University of Minnesota
3205488|NCT01158742||3|African-Americans who donated a kidney at the University of Alabama
3205489|NCT01158729|Experimental|ATIII experimental group|30 neonates (4-30 days of age) undergoing surgery requiring cardiopulmonary bypass will receive Antithrombin (Recombinant) prior to initiation of bypass
3205490|NCT01158729|Placebo Comparator|Placebo Controls|30 neonates (4-30 days of age) undergoing surgery requiring cardiopulmonary bypass will receive placebo prior to initiation of bypass
3205491|NCT01158716|Active Comparator|Remote Ischemic Preconditioning|
3205492|NCT01158716|No Intervention|Control|
3205493|NCT01158703|Active Comparator|clopidogrel|aspirin and clopidogrel
3205494|NCT01158703|Placebo Comparator|sugar pill|aspirin and placebo
3205495|NCT01158690|Experimental|resource card group|The intervention group will receive an envelope with a gift voucher and a resource card (wallet size card with on the one side safety measures and on the other side contact details of resources for violence).
3205496|NCT01158690|Active Comparator|control group|The control group will receive the same envelop with a gift voucher and a letter of thanks.
3205497|NCT01158664|Experimental|0.6 mm tread pitch implant|
3205498|NCT01158664|Experimental|0.1 mm tread pitch implant|
3205499|NCT01158651|Experimental|active therapy|"If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment course lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).~You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection."
3205500|NCT01158638|No Intervention|Usual Care|Usual Care
3205501|NCT01158638|Active Comparator|10,000 Steps Group|Each participant randomized to this study arm will receive a pedometer and a generic recommendation to accumulate 10,000 Steps per Day.
3205502|NCT01158638|Experimental|Web Mediated Step Group|Participants randomized to this study arm receive an introduction to the study website. Each person utilizes the website to track their daily physical activity steps. Goals are given on a weekly basis to increase steps by 10% per day per week over baseline values. The website channels each participant through a series of motivational messages designed to increase compliance with recommended physical activity targets
3205503|NCT01158625|No Intervention|Morning dosing of antihypertensive drugs|
3205504|NCT01158625|Active Comparator|Nighttime dosing of antihypertensive drugs|
3205505|NCT01158612|Experimental|Growth hormone|The effect of Growth hormone on the collagen synthesis rate
3205506|NCT01158612|Placebo Comparator|Saline|
3205507|NCT01158599|Other|IXIARO 0,5 ml|IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28
3205508|NCT01158586|Experimental|Levobupivacaine|patient control epidural analgeisa using 0.2% levobupivacaine with 2ug/ml fentanyl
3205509|NCT01158586|Active Comparator|Ropivacaine|patient controlled epidural analgesia using 0.2% ropivacaine with 2ug/ml fentanyl
3205510|NCT01158573||Healthy non-asthmatic obese adults|Healthy non-asthmatic obese adults
3205511|NCT01158573||Healthy non-asthmatic non-obese adults|Healthy non-asthmatic non-obese adults
3205512|NCT01158573||Asthmatic obese adults|Asthmatic obese adults
3205513|NCT01158573||Asthmatic non-obese adults|Asthmatic non-obese adults
3205514|NCT01158560|Experimental|Vitamin D and gargling|Participants will be given a weekly dose of 10,000 IU of vitamin D3 (oral capsule) and asked to gargle with tap water twice daily
3205515|NCT01158560|Experimental|Vitamin D and general health advice|Participants will be given a weekly dose of 10,000 IU of vitamin D3 (oral capsule) and will receive general health advice in place of gargling advice
3205516|NCT01158560|Placebo Comparator|Placebo and general health advice|Participants will be given an aesthetically matched placebo capsule to take once weekly and will be given general health advice in place of gargling advice.
3205517|NCT01158560|Placebo Comparator|Placebo and gargling|Participants will be given an aesthetically matched placebo capsule to take once weekly and will be asked to gargle with tap water twice daily
3205518|NCT01158534|Experimental|Arm I|Patients receive oral celecoxib twice daily and recombinant interferon alpha-2b subcutaneously, once daily, 5 times a week. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3205519|NCT01158521|Experimental|Arm I|Patients receive oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
3205520|NCT01158508|Experimental|Remote Ischemic Preconditioning|Patients with aneurysmal subarachnoid hemorrhage, after aneurysm treatment, will be given prophylactic remote ischemic preconditioning by transient lower limb ischemia.
3205521|NCT01158482||IVC Filter Placement or Removal|Patients undergoing IVC filter placement and/or IVC filter removal at Stanford Medical Center.
3205522|NCT01158456||African Americans|Subjects will be classified as African American if they report themselves, biological parents and both sets of biological grandparents as African American or African descent.
3205643|NCT01157442|No Intervention|Control|The control group will receive the standard of care but no SMS text messages.
3205523|NCT01158456||European American|Subjects will be classified as European American if they report themselves, biological parents and both sets of biological grandparents as European American or European descent.
3205524|NCT01158443|Experimental|Behavioral activation therapy|The Behavioral Activation Program for Energy and Productivity (BA-PEP) is a manualized, 8-session intervention, scheduled to coincide with maintenance armodafinil treatment. It is a structured counseling program with homework, short-term activities and goals, and includes problem-solving, identification of barriers and strategies for their resolution, with an ongoing focus on achieving employment or training.
3205525|NCT01158443|Placebo Comparator|supportive counseling (SC)|Supportive counseling is designed to create an empathic, accepting environment, to direct attention to the patient's feelings and to facilitate acceptance of affective experience using supportive statements, reflective listening and empathic communications.
3205526|NCT01158430|Experimental|ACT group therapy|"Third generation cognitive behavioral therapy~Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions & 1 booster session 1 month after 9th session, a total of 35.5 hours"
3205527|NCT01158430|No Intervention|Control|Control group assigned to wait list (treatment as usual). After 9 months they are offered ACT group therapy, but not as part of the research project.
3205528|NCT01158417|Placebo Comparator|Placebo|Placebo tablets
3205529|NCT01158417|Experimental|Resveratrol 40 mg oral three times a day|Resveratrol
3205530|NCT01158417|Experimental|resveratrol 500 mg oral once daily.|Resveratrol
3205531|NCT01158404|Experimental|Notch Inhibitor|
3205532|NCT01158391|Experimental|NTrainer® Intervention|NTrainer® Intervention - Infants in the experimental group will receive the NTrainer System patterned synthetic orocutaneous stimulation during the first 30 minutes of a tube (gavage) feeding session. The intervention may be provided up to 4 times daily to achieve an average of 30 sessions distributed over a two week period.
3205533|NCT01158391|Sham Comparator|Control Intervention|Control Intervention - Infants in the Control group will be provided orocutaneous stimulation with a 'quiet pacifier' during the first 30 minutes of a tube (gavage) feeding session. The intervention may be provided up to 4 times daily to achieve an average of 30 sessions distributed over a two week period.
3205534|NCT01158378|Active Comparator|DuraSeal Dural Sealant System|
3205535|NCT01158378|Experimental|Adherus Dural Sealant System|
3205536|NCT01158365|Experimental|Dermacyd (different fragrances)|Day 1 until 30: Investigational Product (Dermacyd) Day 31 until 37: wash-out Day 38 until 67: Glycerine Vegetal Soap Granado Traditional
3205537|NCT01158365|Active Comparator|Glycerine Vegetal Soap Granado Traditional|Day 1 until 30: Glycerine Vegetal Soap Granado Traditional Day 31 until 37: wash-out Day 38 until 67: Investigational Product (Dermacyd)
3205538|NCT01158352|Experimental|Nutritional supplemntation formula|Nutritional supplementation standardized formula (powder added to liquids or food) containing 25% of recommended DRI for calories, high protein (20% of calories) and multi vitamins and mineral(25%-100% of DRI for recommended daily allowance or adequate intake)
3205539|NCT01158352|Placebo Comparator|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
3205540|NCT01158339|Active Comparator|Arm 1: CBGT|Cognitive Behavioural Group Therapy (CBGT)
3205541|NCT01158339|Experimental|Arm 2: CBGT-ISE|Cognitive Behavioural Group Therapy, with in-Session Exposure (CBGT-ISE).
3205542|NCT01158326|Active Comparator|Resfenol Solution oral|Acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride active drug
3205543|NCT01158326|Placebo Comparator|Placebo|Placebo oral solution
3205544|NCT01158313||Thickener|"Patients with history of swallowing difficulties associated with aging and/or neurological diseases including patients with:~neurodegenerative diseases.~non-progressive neurological diseases including stroke.~older patients including nursing home patients."
3205545|NCT01158287|Experimental|Sorafenib 400mg bd, p.o, continuously|
3205546|NCT01158274|Experimental|Treatment|Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3205547|NCT01158261||Vascular Surgery Subjects Treated with EVICEL|
3205548|NCT01158235|Experimental|LTX-109 (Lytixar)|Ascending dose study. Start enrollment to group 1: 1% LTX-109/placebo, then group 2: 2%LTX-109/placebo and finally group 3: 5%LTX-109/placebo dosed in each nostril TID for 3 consecutive days.
3205549|NCT01158222|Experimental|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 42 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
3205550|NCT01158209||Assessed cohort|Subjects attending out-patient health services for gynaecological examination.
3205551|NCT01158196|Experimental|infra-red diode laser|one session, one dose
3205552|NCT01158183||Group 1|No intervention
3205553|NCT01158170|Experimental|prophylactic cranial irradiation|Patients receive Erlotinib or gefitinib until disease progression or intolerable toxicity, and prophylactic cranial irradiation 25GY over 10 fractions.
3205554|NCT01158170|Active Comparator|Conctrol|Patients received Erlotinib or gefitinib until disease progression,or intolerable toxicity
3205555|NCT01158144|Experimental|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
3205556|NCT01158144|Active Comparator|Conctrol|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
3205557|NCT01158131|Experimental|Lifestyle Intervention group|Participants in this group will take part in the lifestyle intervention.
3205558|NCT01158131|No Intervention|Post-gestational diabetes mellitus (GDM) Follow-up Group|Participants in this group will not take part in the intervention.
3205645|NCT01157429|Placebo Comparator|Placebo pill|Individuals receive 12 sessions of trauma-focused cognitive behavioral therapy plus seven doses of placebo pill.
3205559|NCT01158118|Experimental|Arm 1 - Donor|"Days 1-5: Mobilization with 5 mcg/kg/day GM-CSF (first 4 donors were mobilized with 10 mcg/kg GM-CSF then changed to 5 mcg/kg for remaining donors)~Day 5: Mobilization with 320 mcg/kg plerixafor IV~Day 5: Leukopheresis~If PBSC collected are not adequate, then donor will be mobilized with GM-CSF and plerixafor IV on day 6 and have leukopheresis collection on day 6."
3205560|NCT01158118|No Intervention|Arm 2 - Recipient|"Conditioning Regimens~fludarabine and busulfan +/- thymoglobulin~fractionated total body irradiation and cyclophosphamide~busulfan and cyclophosphamide~single dose total body irradiation and cyclophosphamide~Day -2 = GvHD prophylaxis~Day 0 or +1 = PBSC transplant~Day +7 until neutrophil engraftment = G-CSF 5 ug/kg/day"
3205561|NCT01158105|Experimental|Bortezomib|1.6 mg/m2 intravenous infusion will be administered on days 1, 8, 15, 22 of each 35 day cycle, for up to 6 cycles. Patients who continue to respond during the initial treatment phase with no ongoing significant adverse events will be eligible to receive up to 6 additional cycles. This maintenance dose will be administered on days 1 and 15.
3205562|NCT01158092|Active Comparator|Treatment with SInergy™ System|Lateral branch denervation using the SInergy™ System
3205563|NCT01158092|Active Comparator|Conservative Treatment|Treatment with physical therapy, chiropractic care, and medication
3205564|NCT01158066|No Intervention|CT cardiac|the patient will undergo cardiac CT
3205565|NCT01158040||Insulin pump|Women suffering from pregestational diabetes mellitus and being treated with insulin pump during pregnancy and delivery
3205566|NCT01158040||IV insulin|Women suffering from pregestational diabetes mellitus and being treated with insulin sub-cutan (SC) during pregnancy and IV insulin during delivery
3205567|NCT01158040||Healthy|Healthy women accepted for delivery in our institute
3205568|NCT01158027||children|
3205569|NCT01158014|Experimental|Fibrin Glue, surgery|Conjunctival autograft will be glued using fibrin glue to pterygia bed after removal
3205570|NCT01158014|Active Comparator|Control|Conjunctival autograft will be sutured using 10/0 vicryl sutures to pterygia bed after removal
3205571|NCT01158001|Experimental|Psychotherapy via telemedicine|In this arm, veterans received standard psychotherapy (prolonged exposure therapy) in a novel format - interacting with a therapist via videoconferencing.
3205572|NCT01158001|Active Comparator|Face-to-face (in person) psychotherapy|In this arm, veterans received standard psychotherapy (prolonged exposure therapy) in the traditional format - in person with a therapist.
3205573|NCT01157988|Experimental|ibritumomab tuixetan, response, toxicity|
3205574|NCT01157975|Experimental|Pioglitazone|
3205575|NCT01157975|Experimental|Prednisone|
3205576|NCT01157962|Experimental|Group A Sentinel lymphadenectomy|In group A exclusively sentinel lymphadenectomy is performed
3205577|NCT01157962|Active Comparator|Group B radical pelvine lymphadenectomy|in group B radical systematic pelvic lymphadenectomy is done. In patients with tumor free lymph nodes either radical hysterectomy or, in women seeking parenthood, radical trachelectomy is performed. If lymph nodes are tumor-involved systematic pelvic and paraaortic lymphadenectomy followed by primary chemoradiation is recommended.
3205578|NCT01157949|Active Comparator|Study withdrawn|Study withdrawn
3205579|NCT01157949|Placebo Comparator|Withdrawn|Study withdrawn
3205580|NCT01157936|Active Comparator|Allopurinol treatment|
3205581|NCT01157936|Placebo Comparator|Placebo|
3205582|NCT01157923|Experimental|intervantion group|Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor.
3205583|NCT01157923|No Intervention|control group|Regular treatment, No change will be made in the insulin pump setting during the study(unless there is a medical need or any safety concern).
3205584|NCT01157897|Experimental|Cohort 1|15ug VMP001 per vaccination Immunization Days: -1 or 0, 28, 84
3205585|NCT01157897|Experimental|Cohort 2|30ug VMP001 per vaccination Immunization Days: 14, 42, 84
3205586|NCT01157897|Experimental|Cohort 3|60ug VMP001 per vaccination Immunization Days: 28, 56, 84
3205587|NCT01157897|No Intervention|Control|No Vaccinations given for controls
3205588|NCT01157884||Kidney Transplantation|
3205589|NCT01157871|Experimental|placebo|4 administrations at 2-week interval of placebo solution
3205590|NCT01157871|Experimental|NV1FGF 16 mg|4 administrations at 2-week interval of 4mg at each administration
3205591|NCT01157871|Experimental|NV1FGF 32 mg|4 administrations at 2-week interval of 8mg at each administration
3205592|NCT01157858|Active Comparator|Everolimus + octreotide LAR|Octreotide LAR combined with everolimus
3205593|NCT01157858|Active Comparator|Octreotide LAR|Octreotide LAR monotherapy
3205594|NCT01157845|Experimental|Laboratory assay|
3205595|NCT01157819|Active Comparator|Ciloxan Ear Drops|Ciloxan (Alcon, Inc.) Sterile Ophthalmic and Ear Drops
3205596|NCT01157819|Experimental|Foam Otic Cipro|Patients randomized to this study arm will receive the experimental product
3205597|NCT01157806|Experimental|radiochemotherapy instead of surgery|
3205598|NCT01157793|Experimental|Group 1|
3205599|NCT01157793|Experimental|Group 2|
3205600|NCT01157780|Experimental|fish oil|When a subject develops PNALD (three consecutive direct bilirubin concentrations > 2 mg/dL), and is able to tolerate at least trophic feeds (1 mL Q12h), the subject will be randomized to either the control group (our current hospital practice including advancement of enteral feeding, ursodiol, and cyclic PN, but not ω3PUFA) or the active treatment group (current hospital practice plus the addition of enteral ω3PUFA supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period). All patients will be started at 1 g/kg/day with a maximum dose of 4 g/day.
3205601|NCT01157780|No Intervention|standard of care|When a subject develops PNALD (three consecutive direct bilirubin concentrations > 2 mg/dL), and is able to tolerate at least trophic feeds (1 mL Q12h), the subject will be randomized to either the control group (our current hospital practice including advancement of enteral feeding, ursodiol, and cyclic PN, but not ω3PUFA) or the active treatment group (current hospital practice plus the addition of enteral ω3PUFA supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period). All patients will be started at 1 g/kg/day with a maximum dose of 4 g/day.
3205644|NCT01157429|Active Comparator|D-cycloserine plus CBT|Individuals receive 12 sessions of manualized trauma-focused cognitive behavioral therapy plus seven doses of D-cycloserine.
3205602|NCT01157767||breast pts who have undergone surgery|This will be a feasibility study designed to evaluate the compliance of an at-home, directed exercise program and its influence on physical measures during post-operative adjuvant chemotherapy and radiation (if applicable).
3205603|NCT01157754|Experimental|OCP+GnRH antagonist|Microgynon 14 to 21 tablets starting COH on day 5 post pill, rFSH + GnRH antagonist
3205604|NCT01157754|Active Comparator|long GnRH agonist|daily triptorelin starting day 21st of previous cycle
3205605|NCT01157741|No Intervention|Standard Practice (H-C)|1) Hospital control group (Group H-C): children assigned to this group received the standard hospital-based, outpatient treatment package, which consisted of fortnightly follow-up for growth monitoring, health and nutrition education, and micronutrient supplementation.
3205606|NCT01157741|Experimental|C-C|Community-based follow-up (Group C-C): the standard community-based follow-up package was identical to the one provided to the hospital-based control group, except that the follow-up visits took place at the nearest CNFU rather than the HNFU.
3205607|NCT01157741|Experimental|C-SF|Community-based follow-up plus supplementary food (Group C-SF): children assigned to this group received the same treatment package as those in Group C-C, except that supplementary food (SF) packets and preparation instructions were also provided at the time of each follow-up clinic visit for consumption at home in addition to the children's usual meals.
3205608|NCT01157741|Experimental|C-PS|Community-based follow-up plus psychosocial stimulation (Group C-PS): children assigned to this group received the same treatment package as those in Group C-C, except that they were also provided with psychosocial stimulation (PS).
3205609|NCT01157741|Experimental|C-SF+PS|Community-based follow-up plus SF and PS (Group C-SF+PS): children assigned to this group received the same treatment package as those in the Group C-C, except that they were also provided with both SF and PS, as described above.
3205610|NCT01157728||Relapsing Multiple Sclerosis patients|
3205611|NCT01157728||healthy volunteer|
3205612|NCT01157715|Experimental|0.5 mg cohort|patients will receive monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii. prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .
3205613|NCT01157715|Experimental|2.0 mg cohort|patients will receive monthly intravitreal injections of 2.0 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii. prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .
3205614|NCT01157702|Experimental|Vaccine|Vaccination with one dose (0.5 mL) of inactivated influenza vaccine
3205615|NCT01157689||Coartem, chloroquine, quinine|All children with a positive malaria test will included. Results will be subanalysed acording to treatment given by routine health staff.
3205616|NCT01157676|Active Comparator|Open cystectomy|Standard of care treatment
3205617|NCT01157676|Active Comparator|Robotic assisted radical cystectomy|Standard of care treatment
3205618|NCT01157663|Experimental|Adapted Balance Training group|
3205619|NCT01157663|Active Comparator|Standard Balance training group|Balance training with unipedal standing during 8 weeks
3205620|NCT01157650|Experimental|Autologous mesenchymal stem cells|Fistulizing Crohn's disease
3205621|NCT01157624|Active Comparator|oxygen|
3205622|NCT01157624|Placebo Comparator|air supplement|
3205623|NCT01157611|Active Comparator|Mentoring program group|type 1 diabetes patients participating in online base mentoring program
3205624|NCT01157611|No Intervention|Control group|type 1 diabetes patients receiving regular clinic visits
3205625|NCT01157598|Active Comparator|BIS group|
3205626|NCT01157598|Placebo Comparator|non BIS group|
3205627|NCT01157585|Other|drug|
3205628|NCT01157572|Active Comparator|Metoprolol|
3205629|NCT01157572|Placebo Comparator|Placebo|
3205630|NCT01157546|Placebo Comparator|Control|group A (control) will receive a bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side) via both TAP catheters.The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
3205631|NCT01157546|Experimental|TAP|group B (TAP) will receive a bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side) via TAP catheters. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
3205632|NCT01157533|Experimental|Vancomycin Loading|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
3205633|NCT01157520||Cesarean|Women scheduled for elective Cesarean section under spinal anesthesia
3205634|NCT01157507|Active Comparator|Botulinum A toxin|Botulinum A toxin intravesical injection.
3205635|NCT01157507|Sham Comparator|Bladder overdistension|Standard treatment: bladder overdistension
3205636|NCT01157507|Placebo Comparator|Placebo|
3205637|NCT01157494||children with hemiplegia|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
3205638|NCT01157481|Experimental|Conventional therapy plus nifedipine|
3205639|NCT01157481|Active Comparator|Conventional therapy|
3205640|NCT01157468||Cases|"The Case group is constituted with patients with Systemic Lupus Erythematosus from Martinique, divided en 2:~30 patients with a quiescent lupus~30 patients with an active lupus"
3205641|NCT01157468||Controles|"The Control group is constituted by people coming to give blood to the French Blood Establishment of Martinique."
3205864|NCT01155986|Active Comparator|Lidocaine Plaster|
3205646|NCT01157416|Active Comparator|D-cycloserine plus CBT|Individuals receive 12 sessions of manualized trauma-focused cognitive behavioral therapy plus seven doses of D-cycloserine.
3205647|NCT01157416|Placebo Comparator|Placebo plus CBT|Individuals receive 12 sessions of trauma-focused cognitive behavioral therapy plus seven doses of placebo pill.
3205648|NCT01157403|Experimental|mesenchymal stem cells|To study the safety and efficacy of autologous transplantation of bone marrow mesenchymal stem cells in treatment of newly diagnosed patients with T1DM.
3205649|NCT01157390|Experimental|Infant formula|The infants will be fed with Wondersun infant formula with high proportion of palmitic acid at the sn-2 position
3205650|NCT01157390|Active Comparator|Breast feeding|Complete breast feed within the first 3 month
3205651|NCT01157377|Experimental|AGN-214868 total dose 500 ng|AGN-214868 injected into the bladder for total dose of 500 ng on Day 1.
3205652|NCT01157377|Experimental|AGN-214868 total dose 1000 ng|AGN-214868 injected into the bladder for total dose of 1000 ng on Day 1.
3205653|NCT01157377|Experimental|AGN-214868 total dose 2000 ng|AGN-214868 injected into the bladder for total dose of 2000 ng on Day 1.
3205654|NCT01157377|Experimental|AGN-214868 total dose 6000 ng|AGN-214868 injected into the bladder for total dose of 6000 ng on Day 1.
3205655|NCT01157377|Experimental|AGN-214868 total dose 18000 ng|AGN-214868 injected into the bladder for total dose of 18000 ng on Day 1.
3205656|NCT01157377|Experimental|AGN-214868 total dose 60000 ng|AGN-214868 injected into the bladder for total dose of 60000 ng on Day 1.
3205657|NCT01157377|Placebo Comparator|Placebo to AGN-214868|Placebo to AGN-214868 injected into the bladder on Day 1.
3205658|NCT01157364|Other|bimatoprost 20 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 20 µg generation 2 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
3205659|NCT01157364|Other|bimatoprost 15 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 15 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
3205660|NCT01157364|Other|bimatoprost 10 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
3205661|NCT01157364|Other|bimatoprost 6 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
3205662|NCT01157364|Other|bimatoprost 15 µg generation 1, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
3205663|NCT01157364|Other|bimatoprost 10 µg generation 1, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
3205664|NCT01157351|Experimental|001|paliperidone palmitate 78 117 156 or 234 mg monthly injection for 15 months
3205665|NCT01157351|Active Comparator|002|aripiprazole flexible dosing as prescribed by the study doctor for 15 months
3205666|NCT01157351|Active Comparator|003|haloperidole flexible dosing as prescribed by the study doctor for 15 months
3205667|NCT01157351|Active Comparator|004|olanzapine flexible dosing as prescribed by the study doctor for 15 months
3205668|NCT01157351|Active Comparator|005|paliperidone flexible dosing as prescribed by the study doctor for 15 months
3205669|NCT01157351|Active Comparator|006|perphenazine flexible dosing as prescribed by the study doctor for 15 months
3205670|NCT01157351|Active Comparator|007|quetiapine flexible dosing as prescribed by the study doctor for 15 months
3205671|NCT01157351|Active Comparator|008|risperidone flexible dosing as prescribed by the study doctor for 15 months
3205672|NCT01157338|Active Comparator|diagnostic cardiac catheterization|patients with diagnostic cardiac catheterization
3205673|NCT01157338|Active Comparator|therapeutic cardiac catheterization|patient with angioplasty
3205674|NCT01157325|Active Comparator|Non-neuraxial analgesia|Parturients will not receive neuraxial analgesia
3205675|NCT01157325|Active Comparator|Neuraxial analgesia|Parturients will receive neuraxial analgesia
3205676|NCT01157312|Experimental|minimal stimulation protocol|5 days of CC (100mg/day) from day 3 followed by 150 IU of highly purified uFSH on cycle day 9 for three treatment cycles
3205677|NCT01157312|Active Comparator|clomiphene citrate(CC)|5 days of CC (100mg/day) from cycle day 3 for three treatment cycles.
3205678|NCT01157299||Hemodynamic instability|Hypotension and/or evidence of end-organ hypoperfusion
3205679|NCT01157299||Hemodynamic stability|"Normotension and end-organ normoperfusion along with~Vasopressor, vasodilator or inotropic therapy~Edema and/or evidence of hypervolemia"
3205680|NCT01157299||"Hemodinamically normal"|"Normotension and end-organ normoperfusion along with~Non vasopressor, vasodilator or inotropic therapy~Normohydration state~Non Systemic Inflammatory Response Syndrome~Spontaneous breathing and PEEP, or CPAP, equal or less than 5 cm H2O"
3205681|NCT01157286||level of apnea|patients will be separated depending on the iah(apnea hypopnea index) in mild, moderate and severe
3205682|NCT01157273||High Anxiety (HA) group|13 participants of both genders, 19-42 years old, with no history of psychiatric disorders and scores above 41 in STAI-Trait
3205683|NCT01157273||Low Anxiety (LA) group|11 participants of both genders, 19-42 years old, with no history of psychiatric disorders and scores below 41 in STAI-Trait
3205684|NCT01157260|Experimental|AST-120|AST-120 administration 2g three times a day
3205685|NCT01157260|No Intervention|Control|Control Chronic Kidney disease stage 3,4
3205686|NCT01157247|Other|Group SNI|Insertion of spinal needle with introducer
3206395|NCT01152632|No Intervention|waiting list|
3205687|NCT01157247|Other|Group SNI+LA|Local infiltration of lidocaine was applied three minutes after insertion of spinal needle with introducer
3205688|NCT01157247|Other|Group SNI+F|Intravenous fentanyl was applied 3 min before insertion of spinal needle with introducer
3205689|NCT01157247|Other|Group SN|Spinal puncture was performed only with spinal needle without introducer, local anesthetic infiltration or intravenous fentanyl before spinal puncture.
3205690|NCT01157234|Active Comparator|Nebivolol|Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of <140/90 and continued until month-12 of the study.
3205691|NCT01157234|Active Comparator|Metoprolol|Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of <140/90 and continued until month-12 of the study.
3205692|NCT01157221|Experimental|intervention group|intervention group: end-range mobilization/scapular mobilization treatment approach group
3205693|NCT01157221|Active Comparator|control|
3205694|NCT01157221|Sham Comparator|control-criteria group|
3205695|NCT01157208|Experimental|Diet A|This diet is high in omega-3 fatty acids, low in trans fatty acids, and low in omega-6 fatty acids. Subjects are encouraged to eat fatty fish daily (e.g., salmon), to limit vegetable oil intake, and to eat fruits, vegetables and whole grains. Specifically formulated and other provided foods for this group will include salmon-salad sandwiches, hummus with olive oil, other bean dips and bean dishes, frozen and canned fish, and blueberry-flax muffins.
3205696|NCT01157208|Experimental|Diet B|This diet is low in trans fatty acids and low in omega-6 fatty acids. Subjects are encouraged to to limit vegetable oil intake, to replace meats and eggs with beans and lean fish/shellfish, and to eat fruits, vegetables and whole grains. Specifically formulated and other provided foods for this group will include hummus with olive oil, other bean dips and bean dishes, lean fish and shellfish,and blueberry muffins.
3205697|NCT01157195|Active Comparator|CI therapy|
3205698|NCT01157195|Experimental|Tele-AutoCITE|AutoCITE stands for Automated Constraint Induced Therapy Extender.
3205699|NCT01157182|Experimental|Investigational Test Product|Estradiol/Norethindrone acetate 1/0.5 mg Tablets
3205700|NCT01157182|Active Comparator|Reference Listed Drug|Activella® 1/0.5 mg Tablets
3205701|NCT01157169|Experimental|Investigational Test Product|Buprenorphine 8 mg Sublingual Tablets
3205702|NCT01157169|Active Comparator|Reference Listed Drug|Subutex® 8 mg Sublingual Tablets
3205703|NCT01157143|Experimental|NV1FGF 500 μg|8 intramuscular injections for a total of 500 μg administered in one single administration 3 to 8 days before major amputation
3205704|NCT01157143|Experimental|NV1FGF 2000 μg|8 intramuscular injections for a total of 2000 μg administered in one single administration 3 to 8 days before major amputation
3205705|NCT01157143|Experimental|NV1FGF 4000 μg|8 intramuscular injections for a total of 4000 μg administered in one single administration 3 to 8 days before major amputation
3205706|NCT01157130|Experimental|Intervention Group|Each patient will have a weekly goal of 2000 calories burned and 18 MET-hours of exercise which can be achieved in 4 to 7 hours of physical activity per week. Resistance training, using weight machines and aerobic training using treadmills, elliptical trainers and stationary bicycles, will be utilized in the intervention group.
3205707|NCT01157130|No Intervention|Control Group|The control group will receive basic information on physical activity but not be instructed.
3205708|NCT01157117|Experimental|Omalizumab/milk OIT|Participants receive blinded omalizumab injections every 2 to 4 weeks through Month 16 and unblinded omalizumab injections thereafter until the Month 28 desensitization oral food challenge (OFC). Participants ingest milk powder daily starting at Month 4 with a dose of 0.07 mg milk protein and escalate for 22 to 40 weeks until reaching the maintenance dose of 3.84 g milk protein (minimum required maintenance dose is 520 mg milk protein). At Month 28, participants complete a 10g milk OFC and discontinue omalizumab injections. If they fail the OFC they permanently discontinue ingestion of the milk powder; if they pass the OFC they continue ingestion of the maintenance dose of milk powder through Month 30 and then discontinue it.
3205709|NCT01157117|Placebo Comparator|Placebo for omalizumab/milk OIT|Participants receive blinded placebo for omalizumab injections every 2 to 4 weeks through Month 16; after unblinding the injections are discontinued. Participants ingest milk powder daily starting at Month 4 with a dose of 0.07 mg milk protein and escalate for 22 to 40 weeks until reaching the maintenance dose of 3.84 g milk protein (minimum required maintenance dose is 520 mg milk protein). At Month 28, participants complete a 10g milk oral food challenge (OFC); if they fail the OFC they permanently discontinue ingestion of the milk powder; if they pass the OFC they continue ingestion of the maintenance dose of milk powder through Month 30 and then discontinue it.
3205710|NCT01157117|No Intervention|Untreated control|Participants did not receive any study intervention but provided regular blood draws at specific study time points to allow mechanistic comparisons with the participants in the other two groups who did receive study intervention.
3205711|NCT01157104|Experimental|IDX320 + PBO → IDX320 + IDX184|400 mg IDX320 and IDX184 matching placebo (PBO) once daily for 7 days; followed by 400 mg IDX320 and 100 mg IDX184 once daily for 7 days
3205712|NCT01157104|Experimental|IDX184 + PBO → IDX184 + IDX320|100 mg IDX184 and IDX320 matching PBO for 7 days; followed by 100 mg IDX184 and 400 mg IDX320 for 7 days
3205713|NCT01157104|Placebo Comparator|IDX320 PBO + IDX184 PBO|IDX320 matching PBO + IDX184 matching PBO for 14 days
3205714|NCT01157091|Experimental|Arm I|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3205715|NCT01157078|Experimental|TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1-4 mg BID
3205716|NCT01157078|Placebo Comparator|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
3205717|NCT01157065|Experimental|AL-78898A|Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up
3205718|NCT01157065|Active Comparator|Lucentis|Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up
3205719|NCT01157052|Active Comparator|Ca2+/Mg2+ pre & post cycle 1|Arm A:Ca2+/Mg2+: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 1
3205720|NCT01157052|Active Comparator|Ca2+/Mg2+pre & post cycle 2|Arm B:Ca2+/Mg2+: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 2
3205721|NCT01157039|Experimental|Dietary Supplement|Arm A: At cycle 2, patients will be randomized to receive for 6 days- Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3
3205722|NCT01157039|Experimental|Dietary supplement|Arm B: At cycle 2, patients will be randomized to receive for 6 days: Glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3.
3205723|NCT01157026|Experimental|Tocotrienol Rich Fraction plus Tamoxifen|
3205724|NCT01157026|Active Comparator|Placebo plus tamoxifen|
3205725|NCT01157013|Experimental|Advanced Hepatocellular Carcinoma|Hepatocellular carcinoma patients not candidates to local and/or curative treatment and an expected overall survival of at least three months and who are susceptible of receiving sorafenib therapy.
3205726|NCT01157000|Experimental|001|Canagliflozin On Day 1 all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
3205727|NCT01156987|Experimental|Healthy Volunteers|Five healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition.
3205728|NCT01156987|Experimental|Breast Cancer Patients|40 breast cancer patients who have suspected breast lesion that will be biopsied will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection and SWIFT acquisition.
3205729|NCT01156974|Experimental|care guide|patients receive education about care goals and work with a care guide to achieve goals
3205730|NCT01156974|Active Comparator|no care guide|patients receive education about care goals and usual care to achieve goals
3205731|NCT01156961|Experimental|Single Arm|
3205732|NCT01156948|Active Comparator|vaginal misoprostol|vaginal misoprostol was administered to this group of nulliparous women
3205733|NCT01156948|Experimental|oral misoprostol|oral misoprostol
3205734|NCT01156935|Experimental|Laugh yoga|experimental laugh yoga
3205735|NCT01156922|Experimental|Rituximab|Rituximab induction two infusions (500 mg/m2, max 1000 mg) two weeks apart, followed by maintenance Rituximab infusions (500 mg/m2, max 1000 mg) after 3, 6, 10 and 15 months.
3205736|NCT01156909|Experimental|Rituximab|Rituximab induction using two infusions (500mg/m2, max 1000 mg) two weeks apart, followed by maintenance Rituximab infusions (500 mg/m2, max 1000 mg) after 3, 6, 10 and 15 months.
3205737|NCT01156896|Experimental|Iron intervention|"All study subjects with malaria and all control subjects will receive an iron intervention (supplement or fortification dose of iron).~Control subjects will be studied on only one occasion.~Study subjects with malaria will receive the same iron intervention two weeks later, after the malarial episode has been successfully treated."
3205738|NCT01156870|Experimental|SAR566658|SAR566658 will be administered by intravenous (IV) infusion according to three different schedules
3205739|NCT01156857|Experimental|A|Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
3205740|NCT01156857|Experimental|B|Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of progestin (oral tablets).
3205741|NCT01156844|Experimental|Indacaterol 37.5 µg (twice a day)|"Indacaterol 37.5 µg twice a day (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3205742|NCT01156844|Experimental|Indacaterol 75 µg (once a day)|"Indacaterol 75 µg once a day (qd) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and Placebo to Indacaterol inhaled once daily via Concept1 in the evening for 16 days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3205743|NCT01156844|Experimental|Indacaterol 150 µg (every other day)|"Indacaterol 150 µg every other day (qod) inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for a total of 16 days. Indacaterol 150 µg inhaled via Concept1, a SDDPI, in the morning and Placebo to Indacaterol inhaled via Concept1 in the evening on odd days; and Placebo to Indacaterol inhaled via Concept1 in the morning and in the evening on even days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3205744|NCT01156844|Placebo Comparator|Placebo|"Placebo to Indacaterol twice daily (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3205745|NCT01156818||Children|Age 8-21 years
3205746|NCT01156818||Adult|Age 21-80 years
3205747|NCT01156805|Experimental|Educational intervention, Control|Experimental, intervention group has received educational training to improve food habits and physical activity
3205748|NCT01156792|Experimental|FP 100mcg BID plus GSK2190915 100mg QD (AM)|FP 100mcg BID plus GSK2190915 100mg QD (AM)
3205749|NCT01156792|Experimental|FP 100mcg BID plus GSK2190915 300mg QD (AM)|FP 100mcg BID plus GSK2190915 300mg QD (AM)
3205750|NCT01156792|Active Comparator|FP 100mcg BID plus montelukast 10mg QD (PM)|FP 100mcg BID plus montelukast 10mg QD (PM)
3205751|NCT01156792|Active Comparator|FP 100mcg BID plus placebo BID|FP 100mcg BID plus placebo BID
3205752|NCT01156792|Active Comparator|FP/SAL 100/50mcg BID plus placebo BID|FP/SAL 100/50mcg BID plus placebo BID
3205753|NCT01156779|Experimental|DA-3091|SR-exenatide
3205754|NCT01156779|Placebo Comparator|Placebo of DA-3091|Placebo
3205755|NCT01156753|Experimental|CDX-011|
3205756|NCT01156753|Active Comparator|"Investigator's Choice chemotherapy"|
3205757|NCT01156740|Active Comparator|Intramuscular benzathine Penicillin G|A single dose of intramuscularly administered intramuscular benzathine penicillin G (IM BPG). The dosing was as follows: IM BPG; 600,000 U > 27kg or 1,200,000 U <27 kg
3205758|NCT01156740|Active Comparator|Amoxicillin|A 10-day once daily dose of Amoxicillin was given in an oral form. The first dose was given at the time of randomization, and parents were instructed on giving the remaining doses. Dosing was as follows: 750 mg/QD
3205759|NCT01156727||SURVEY: 6 months post-deployment|Michigan Army National Guard soldiers 6 months post deployment between August 2011 and December 2013
3205760|NCT01156727||SURVEY: 12 months post-deployment|Michigan Army National Guard soldiers 12 months post deployment between August 2011 and December 2013.
3205761|NCT01156727||INTERVIEWS|Michigan Army National Guard soldiers 12-24 months post deployment between October 2011-April 2014. Also key stakeholders from the B2B program.
3205762|NCT01156714|Other|Arm 1|Treadmill training with aerobic exercise
3205763|NCT01156714|Other|Arm 2|Memory training with computerized memory program
3205764|NCT01156714|Other|Arm 3|Combination of treadmill training and computerized memory program
3205765|NCT01156701||Cohort1: Prophylaxis with untreated index|"Individuals are eligible to be included in the prophylaxis with untreated index cohort if they are at least 5 years old and have at least 6 months of continuous enrollment, and~Received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034), and~Have no diagnosis of influenza (ICD-9 487.xx) on the day of Relenza dispensing or in the 3 preceding days, and~A household member (index case) with the same family identifier code has had a medical visit (outpatient, inpatient or emergency room (ER) visit) in the 3 days preceding or the day of the Relenza dispensing with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has not received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
3205766|NCT01156701||Cohort2: Prophylaxis with treated index|"Individuals are eligible to be included in the prophylaxis with treated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~Received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034), and~Have no diagnosis of influenza (ICD-9 487.xx) on the day of Relenza dispensing or in the 3 preceding days, and~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) in the 3 days preceding or the day of the Relenza dispensing with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
3205767|NCT01156701||Cohort3: No prophylaxis with untreated index|"Individuals are eligible to be included in the no prophylaxis with untreated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~Have not received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034) within 3 days following the date on which~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has not received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
3205768|NCT01156701||Cohort4: No prophylaxis with treated index|"Individuals are eligible to be included in the no prophylaxis with treated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~Have not received a dispensing of Relenza(HICL=020398 or HCPCS = G9018 or G9034) within 3 days following the date on which~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has received zanamivir (Relenza) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza"
3205769|NCT01156688|Active Comparator|Sublingual Misoprostol|
3205770|NCT01156688|Active Comparator|Buccal misoprostol|
3205771|NCT01156675|Experimental|FLEXUS™ Interspinous Spacer|
3205772|NCT01156675|Active Comparator|XSTOP® Interspinous Spacer|
3205773|NCT01156662|Active Comparator|No aspiration|
3205774|NCT01156662|Active Comparator|Thrombus aspiration|
3205775|NCT01156649|Sham Comparator|Sham PAP therapy|Sham PAP will be used with 30 children, and consists of continuous sub-therapeutic levels of air pressure (approximately 1 cm of water) that are delivered through the nasal interface device.
3205776|NCT01156649|Active Comparator|Treatment group|30 children will receive active treatment PAP, which consists of automatically adjusted air pressures that are delivered through the nasal interface device at levels which effectively treats the obstructive events.
3205777|NCT01156636|Active Comparator|Sildenafil|
3205778|NCT01156636|Placebo Comparator|Placebo|
3205779|NCT01156623|Experimental|With EBUS-TBNA group|The patients enrolled in present study are those with non-small lung cancer and receive contrast-enhanced computed tomography (CT) and Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) examination. In this group, further EBUS-TBNA will be arranged if patients agreed it.
3205780|NCT01156623|No Intervention|Without EBUS-TBNA group|The patients enrolled in present study are those with non-small lung cancer and receive contrast-enhanced computed tomography (CT) and Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) examination. In this group, no EBUS-TBNA will be arranged if patients refused it despite we advised it.
3205781|NCT01156610|Experimental|Integrated Cessation Counseling|"IVR System: IVR will be used for two purposes: (1) to facilitate access to treatment for low-SES and minority smokers and (2) perform six-month outcome assessment.~Tobacco Treatment Specialist Calls: A tobacco treatment specialist will make four attempts to contact the patient by phone within 14 days. On contacting the patient, the specialist will screen the patient for readiness to quit, provide brief (10 to 15 minutes) counseling tailored to the patient's readiness to quit, and provide information and support for use of medications that could be or were prescribed and about relevant community resources.~NRT: Patients who do not have a contraindication and smoke > 10 cigarettes per day, will be offered a free 6-week kit of generic nicotine patches (2 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches). Individuals who smoke 5-10 cigarettes/day will be offered a 6-week course, starting with the 14 mg patch. Those with a contraindication will not get NRT."
3205808|NCT01156389|Active Comparator|Pyramax arm|Subjects in arm B will take a three day treatment course of Pyramax, followed by a follow up period of 40 days since last Pyramax dosing and a study completion evaluation.
3205809|NCT01156376|Experimental|PO-019|Formula 12027-019 Mouthwash
3205782|NCT01156610|Active Comparator|Usual Care|"IVR Call: Similar to the initial IVR call for the intervention arms, the initial control arm call will confirm the participant's identify and provide a brief description of the study (obtaining information about health behaviors), with the opportunity for the individual to accept or decline participation. Following this introduction, the IVR script will confirm smoking status. The phone script will collect specific information about current smoking (cigarettes/day), prior quit attempts, and motivation to quit during the next month. No further contact will be made with patients in the control clinics until the outcome assessment call. In the control practices, the IVR machine will also generate a text note documenting the information obtained for the patients' EHR for use by the patient's health care providers as part of their visit-based best practices."
3205783|NCT01156597|Active Comparator|Pioglitazone Group|This is a baseline versus treatment study comparing subjects on pioglitazone to a matched group of subjects treated with either metformin or sulfonylurea with the intent of controlling blood sugar to a comparable level
3205784|NCT01156597|No Intervention|Comparator Group|This group of subjects will be maintained on standard treatment with either metformin or sulfonylurea with the intent of controlling blood sugar to a comparable level as group treated with pioglitazone.
3205785|NCT01156584|Experimental|Single arm|Toca 511 vector/ Toca FC prodrug
3205786|NCT01156571|Experimental|cangrelor|"Cangrelor was administered as a 30 µg/kg bolus followed by a 4.0 µg/kg/min cangrelor IV infusion for a minimum of 2 hours or until conclusion of the index procedure, whichever is longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours.~Following the discontinuation of the cangrelor infusion, 600mg of clopidogrel was administered."
3205787|NCT01156571|Active Comparator|clopidogrel|"Clopidogrel 300 mg or 600 mg administered pre or post PCI. Selection of dose and timing of dose were per investigator discretion.~During the PCI a placebo infusion was given to maintain the blinding of the trial. In addition, placebo capsules were administered at the end of the infusion mimic the 600mg post infusion dose provided in the cangrelor arm."
3205788|NCT01156545|Experimental|Treatment arm|BIBW 2992 plus simvastatin arm
3205789|NCT01156545|Active Comparator|control arm|BIBW 2992 arm
3205790|NCT01156532||Adalimumab Treatment in Participants with Psoriasis|Participants with moderate to severe chronic plaque psoriasis defined as Psoriasis Area and Severity Index (PASI) ≥ 10 and body surface area ≥ 10% with or without psoriatic arthritis, who have an adalimumab therapy indication because they are candidates for systemic therapy or phototherapy and other systemic therapies are medically less appropriate.
3205791|NCT01156519|Other|Salivary cortisol|
3205792|NCT01156493|Experimental|Protein Hydrolyzed Formula|Infants assigned to this group will receive HP formula when breast milk not available or indicated to receive formula by the attending physician
3205793|NCT01156493|No Intervention|Control|Infants in this group will receive standard prematrue formula when no breast milk available or indicated by the attending physician
3205794|NCT01156480|Experimental|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via intravenous (IV) route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. Subjects in placebo group will receive equal volume of placebo on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
3205795|NCT01156480|Placebo Comparator|Placebo|Subjects in placebo group will receive equal volume of placebo (as compared to hydrocortisone arm) on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
3205796|NCT01156467|Active Comparator|Control|Infants randomised to this arm will receive a regular nasogastric tube, and the ventilatory care is given as routinely is done.
3205797|NCT01156467|Active Comparator|NAVA|Infants randomised to this arm will receive and Edi-catheter as an oro-/nasogastric tube and the Edi-signal will be monitored and when possible NAVA-ventilation used.
3205798|NCT01156454||Surgery followed by x-ray assessment|After nodes are removed they are taken to radiology to be x-rayed
3205799|NCT01156441|Experimental|surgical mitral valve repair|Non-invasive transesophageal echocardiography will be performed on all study volunteers to determine if the individual has mitral regurgitation and, if so, to what degree. Mitral valve repair will be performed with mitral valve annuloplasty via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia.
3205800|NCT01156441|No Intervention|control: medical management|Clinical observation will be continued without surgery. Non-invasive transesophageal echocardiography will be performed on all study volunteers to determine if the individual has mitral regurgitation and, if so, to what degree.
3205801|NCT01156428||Control Subjects (normal volunteers)|"Control kidney specimens will be obtained from donor transplant kidneys or nephrectomy specimens performed on patients undergoing nephrectomy for the clinical indication of an identified renal mass.~In the case of donor transplant kidneys, the renal biopsy will be conducted during the act of living donor nephrectomy and transplantation.~In the case of renal mass nephrectomies, representative normal tissue will be obtained from the nephrectomized kidney at a site distant from the renal mass."
3205802|NCT01156428||Renal Disease Subjects|Patients who require a renal biopsy based upon clinical indications such as proteinuria, hematuria, acute renal failure (ARF) of unclear etiology, chronic kidney disease of unclear etiology, nephrotic syndrome, nephritic syndrome, suspected lupus nephritis or any other medically warranted indication for a biopsy.
3205803|NCT01156415|Experimental|Agomelatine (AGO178) 0.5 mg|
3205804|NCT01156415|Experimental|Agomelatine (AGO178) 1 mg|
3205805|NCT01156402|Experimental|Active Intervention: Obesity Prevention|
3205806|NCT01156402|Experimental|Alternative Intervention/control: Oral Health|
3205807|NCT01156389|Active Comparator|Ritonavir plus Pyramax arm|Subjects in arm A will take 7 days of ritonavir followed by 3 days of ritonavir plus Pyramax followed by 7 days of ritonavir followed by 33 days follow-up period (40 days since last Pyramax dosing) and a study completion evaluation.
3205810|NCT01156376|Experimental|PO-020|Formula 12027-020 Mouthwash
3205811|NCT01156376|Active Comparator|PO-116-A|Cool Mint Listerine
3205815|NCT01156324|Placebo Comparator|Control|Participants of the routine care control group will each receive a $50 gift certificate at the end of each IVF cycle for which they completed the questionnaires.
3205816|NCT01156324|Experimental|Online Stress Management Group (Upliv)|Personalized online stress management program consisting of weekly sessions which each include relaxation exercises, stress management strategies, and lifestyle modification advice. Participants in Upliv will also be given a set of personal care products as part of the program.
3205817|NCT01156311|Experimental|Glatiramer acetate (GA) and dimethyl fumarate|Participants taking a stable dose of GA for at least 12 months prior to the study remain on that dose throughout the study. Dimethyl fumarate is administered at 120 mg three times a day (TID) on Days 1-7, and 240 mg TID on Day 8 until the end of treatment (approximately 6 months).
3205818|NCT01156311|Experimental|Interferon beta (IFNβ) and dimethyl fumarate|Participants taking a stable dose of one of the IFNβ products for at least 12 months prior to the study remain on that product and dose throughout the study. Dimethyl fumarate is administered at 120 mg three times a day (TID) on Days 1-7, and 240 mg TID on Day 8 until the end of treatment (approximately 6 months).
3205819|NCT01156298||Cohort 1|Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS. Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not. Cohort 1 patients will have annual EDSS, self-report EDSS, medication review and relapse recalculation. SF-36 and SDMT assessments will be performed at years 1 and 5 during routine office visits. A MRI will be performed each patient's 15 year anniversary date.
3205820|NCT01156298||Cohort 2|Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS. Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not. Patients will be waiving written informed consent and asked to provide concomitant medication, self-reported EDSS, and SF-36 only.
3205821|NCT01156285||AAU|patient with acute attack of anterior uveitis
3205822|NCT01156272||Replacement aortic heart valve|ATS 3f® Aortic Bioprosthesis, Model 1000, Size 19mm
3205823|NCT01156259|Experimental|30 Gy|
3205824|NCT01156259|Active Comparator|40 Gy|
3205825|NCT01156246|Experimental|1|Dapagliflozin/metformin tablet, high fat, high calorie breakfast day 1, visit 2, 7-14 days wash-out, Dapagliflozin/metformin tablet, fasting conditions day 1, visit 3.
3205826|NCT01156246|Experimental|2|Dapagliflozin/metformin tablet, fasting conditions day 1, visit 2, 7-14 days wash-out, Dapagliflozin/metformin tablet, high fat, high calorie breakfast day 1, visit 3.
3205827|NCT01156233|Experimental|Cuff palpation technique|Cuff palpation by the investigator's finger.
3205828|NCT01156233|Experimental|Withdrawing tube technique|Identification of the tube by withdrawing until good quality breath sounds
3205829|NCT01156220|Experimental|female|"The healthy female volunteers receive furosemide and aminohippurate sodium PAH as single dose randomised on day 1 or day 2."
3205830|NCT01156220|Experimental|male|"The healthy male volunteers receive furosemide and aminohippurate sodium PAH as single dose randomised on day 1 or day 2"
3205831|NCT01156207|Experimental|Aliskiren|
3205832|NCT01156207|Placebo Comparator|placebo|
3205833|NCT01156194|Active Comparator|Homeopathy 1|Arnica montana C6 and Bellis perennis C6
3205834|NCT01156194|Active Comparator|Homeopathy 2|Arnica montana C30 and Bellis perennis C30
3205835|NCT01156194|Placebo Comparator|Placebo|globules identical to true comparators
3205836|NCT01156181|Experimental|Cervical discharge removal|Cervical discharge will be removed using a cotton swab before embryo transfer during ICSI cycles
3205837|NCT01156181|Active Comparator|Control|Embryo transfer without any intervention
3205838|NCT01156155||Participants with Rheumatoid Arthritis|Rheumatoid arthritis patients Digital xray of jaw and teeth Blood draw questionnaires Periodontal Examination Bilateral digital xray of hands
3205839|NCT01156155||Osteoarthritis|Osteoarthritis patients Digital xray of jaw and teeth Blood draw questionnaires Periodontal Examination
3205840|NCT01156142|Experimental|Arm I|Patients receive doxepin hydrochloride oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm II on day 2.
3205841|NCT01156142|Placebo Comparator|Arm II|Patients receive placebo oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm I on day 2.
3205842|NCT01156129|Active Comparator|Arm A: Standard therapy (use of medications)|stool softener
3205843|NCT01156129|Experimental|Arm B: Acupressure bracelets|device - Biobands
3205844|NCT01156129|Experimental|Arm C|Sugar free gum
3205845|NCT01156116|Active Comparator|Continuous positive airway pressure|2 weeks of continuous positive airway pressure (CPAP) treatment which includes wearing the CPAP mask for 8 hours each night
3205846|NCT01156116|Placebo Comparator|Placebo|2 weeks of oral administration of a placebo tablet 30min before bedtime
3205847|NCT01156103|Experimental|SCORES|America SCORES, Bay Area, after-school program
3205848|NCT01156103|No Intervention|Usual care|Standard after-school programming
3205849|NCT01156090||Vectibix|patients who received at least one treatment of Vectibix
3205850|NCT01156077|Experimental|oral TR-701 FA|Single oral dose of 200 mg TR-701
3205851|NCT01156077|Experimental|IV TR-701 FA|Single IV infusion of 200 mg TR-701 FA
3205852|NCT01156064||Case (subjects with digestive diseases)|The investigators cases are subjects with confirmed digestive diseases.
3205853|NCT01156064||Control|Healthy individuals aged between 18 and 90 years who are asymptomatic for digestive diseases.
3205854|NCT01156051|Experimental|Guanfacine Extended-Release Tablets|Guanfacine Extended-Release Tablets 1mg, 2mg, 3mg, and 4mg
3205855|NCT01156051|Placebo Comparator|Placebo comparator|Placebo control
3205856|NCT01156038|Experimental|Atopy patch test|Atopy patches were applied on healthy volunteer's back for 48 hrs then the patches were removed. Reaction was evaluated 48 and 72 hrs after applying atopy patch test
3205857|NCT01156025|Experimental|GV550|(Ganciclovir 1.5 mg/g ophtalmic gel)
3205858|NCT01156025|Placebo Comparator|Placebo|Placebo ophtalmic gel
3205859|NCT01156012|Experimental|T2345|One drop of T2345
3205860|NCT01156012|Active Comparator|Prostaglandin|One drop
3205861|NCT01155999|Experimental|T1225|
3205862|NCT01155999|Active Comparator|Tobramycin|
3205865|NCT01155973|Experimental|EDUCORE intervention|Use of low risk SCORE table. Use of visual impact images. Handing the patient a pamphlet (advice on how to maintain cardiovascular health plus the low risk SCORE table with the patient's current score marked).
3205866|NCT01155973|Active Comparator|control group|Use of low risk SCORE table; verbally informing the patient of his/her CVR. Giving advice/verbal information on risk factors.
3205867|NCT01155960|Active Comparator|Arimidex|Arimidex® Tablets 1 mg
3205868|NCT01155960|Experimental|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
3205869|NCT01155947|Active Comparator|Arimidex|Arimidex® Tablets 1 mg
3205870|NCT01155947|Experimental|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
3205871|NCT01155934|Experimental|Risperidone Orally Disintegrating|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
3205872|NCT01155934|Active Comparator|Risperdal M-TAB|(Risperdal M-TAB) 1 mg risperidone orally disintegrating tablets Janssen Pharmaceutica Products
3205873|NCT01155921|Experimental|Risperidone Orally Disintegrating|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
3205874|NCT01155921|Active Comparator|Risperdal M-TAB|(Risperdal M-TAB) 1 mg risperidone orally disintegrating tablets Janssen Pharmaceutica Products
3205875|NCT01155908|Experimental|Amlodipine Besylate/Benazepril Hydrochloride|10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules of Dr.Reddy's Laboratories Limited
3205876|NCT01155908|Active Comparator|Lotrel|Lotrel® (10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules) of Novartis
3205877|NCT01155895|Experimental|Amlodipine Besylate/Benazepril Hydrochloride|10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules of Dr.Reddy's Laboratories Limited
3205878|NCT01155895|Active Comparator|Lotrel|Lotrel® (10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules) of Novartis
3205879|NCT01155882||Whipple Surgery at the Splenic Artery|Whipple at the Splenic Artery (WATSA) is at resecting tumors with negative microscopic margins (R0) at the resection line on the pancreas and at the tangential posterior, uncinate, and venous margins.
3205880|NCT01155869|Experimental|XR-NTX|Depot naltrexone (Vivitrol) 380 mg. IM monthly
3205881|NCT01155869|Active Comparator|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
3205882|NCT01155856|Experimental|telemedicine|Within 24 hours after admission for exacerbation of COPD, patients in the intervention group are sent home for further treatment (telemedicine based) instead of the conventional treatment at the hospital. Patients in the intervention group will receive the same treatment as the control group and have daily contact with the physician/nurse at the hospital through a videoconference system.
3205883|NCT01155856|No Intervention|control|The control group will receive usual care and treatment at the hospital until discharge(typically between 5-7 days).
3205884|NCT01155843||Asthmatic, chronic stress|
3205885|NCT01155843||Asthmatic, non-stress|
3205886|NCT01155830||Infants with CHD|Infants with Congenital Diaphragmatic Hernia (CHD)
3205887|NCT01155830||Infants with sepsis|Infants who are culture positive for sepsis and require vasopressor support
3205888|NCT01155830||Infants treated with ECMO|Infants suffering cardiopulmonary failure significant enough to require heart/lung bypass treatment with extracorporeal membrane oxygenation (ECMO)
3205889|NCT01155817|Experimental|Nilotinib|
3205890|NCT01155804|Other|Exercice|
3205891|NCT01155804|Other|non-exercice|
3205892|NCT01155791|Experimental|combination sodium selenite and docetaxel|
3205893|NCT01155778|Experimental|Recombinant human heparan N-sulfatase|rhHNS, HGT-1410
3205894|NCT01155765|Experimental|Prasugrel|Prasugrel per os 10 mg/day
3205895|NCT01155765|Active Comparator|Clopidogrel|Clopidogrel per os 150 mg/day
3205896|NCT01155752|Experimental|PULMOZYME|active drug
3205897|NCT01155752|Placebo Comparator|placebo|cross over to placebo
3205898|NCT01155739||procalcitonine monitoring|PCT group: antibiotic use is tailored by serum procalcitonin values, determined every 48houres.
3205899|NCT01155739||control group|control group: antibiotic use and length of treatment as defined by guidelines
3205900|NCT01155726|Active Comparator|Nelfilcon A, Masked, Unmasked|Nelfilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (unmasked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
3205901|NCT01155726|Active Comparator|Nelfilcon A, Masked, Partially Masked|Nelfilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (partially masked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
3205902|NCT01155726|Active Comparator|Etafilcon A, Masked, Unmasked|Etafilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (unmasked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
3205903|NCT01155726|Active Comparator|Etafilcon A, Masked, Partially Masked|Etafilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (partially masked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
3205904|NCT01155713|Experimental|Arm 1 - TKI258 - bioavailability|
3205905|NCT01155713|Experimental|TKI258 - food effect|
3205906|NCT01155700|Experimental|Omalizumab|Omalizumab treatment
3205907|NCT01155687||Psychosocial counseling|the group received annualized treatment of psychosocial counseling
3205908|NCT01155687||Medication|this group received medical treatment by the local medical doctor
3205909|NCT01155674||Sepsis patients|Patients presenting sepsis
3205910|NCT01155674||SIRS patients|Patients presenting with the systemic inflammatory response syndrome
3205911|NCT01155674||Healthy subjects|Healthy blood donors
3205912|NCT01155661|Experimental|LY2216684 (edivoxetine) + SSRI|
3205913|NCT01155648|Experimental|PSV group.|Chest wall compression plus increase of 10 cmH2O of PSV.
3205914|NCT01155648|Active Comparator|chest wall compression group|Chest wall compression
3205915|NCT01155635|Active Comparator|Beta-blocker|Use of Carvedilol with any dose
3205916|NCT01155635|Active Comparator|Non Beta-blocker|No use of Carvedilol
3205917|NCT01155622|Active Comparator|32º Celsius|Endovascular Cooling was set at a target temperature of 32°C
3205918|NCT01155622|Active Comparator|34º Celsius|Endovascular Cooling was set at a target temperature of 32°C
3205919|NCT01155609|Experimental|Supportive care (oral complications management)|Patients receive L-Lysine PO QD until completion of radiotherapy and resolution of mucositis in the absence of disease progression or unacceptable toxicity.
3205920|NCT01155596|No Intervention|Control group|Base on positive pressure ventilation with intubation and mechanical ventilator, weaning processes will undergo by Pulmonologists.
3205921|NCT01155596|Experimental|Experimental group|Experimental group is weaning with the support of negative pressure ventilator.
3205922|NCT01155583|Experimental|Arm I|Patients receive azacitidine subcutaneously once or twice weekly and oral dexamethasone once weekly starting on day 1. Patients also receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
3205923|NCT01155570||Humira|Humira 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 80 mg.
3205924|NCT01155557|Active Comparator|Specific Strength Training|10 weeks of specific strength training of neck and shoulder muscles using elastic resistance.
3205925|NCT01155557|Active Comparator|Lifestyle Counseling|10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
3205926|NCT01155544|Active Comparator|Aripiprazole|
3205927|NCT01155544|Placebo Comparator|Placebo|
3205928|NCT01155531|Experimental|Telenzepine - Group A|Group A: No Sertraline; 0, 1, 2, 3 mg/day Telenzepine
3205929|NCT01155531|Experimental|Sertraline plus Telenzepine - Group B|Sertraline 50 mg/day; 0, 1, 2, 3 mg/day Telenzepine
3205930|NCT01155531|Experimental|Sertraline plus Telenzepine - Group C|Sertraline 50, 100 mg/day; 0, 1, 2, 3 mg/day Telenzepine
3205931|NCT01155531|Experimental|Sertraline plus Telenzepine - Group D|Sertraline 50, 100, 150 mg/day; 0, 1, 2, 3 mg/day Telenzepine
3205932|NCT01155518|Experimental|testosterone|intramuscular injections every 2 weeks
3205933|NCT01155518|Experimental|clomiphene|oral drug thrice a week
3205934|NCT01155518|Placebo Comparator|placebo for testosterone|placebo for testosterone arm
3205935|NCT01155518|Placebo Comparator|placebo for clomiphene|oral placebo for clomiphene arm
3205936|NCT01155505|Experimental|CC-5013 in combination with Paclitaxel|"Cohorts of 3 evaluable patients will initially be entered within each dose level, sequentially. In each dose level the second and third patient will enter 2 weeks after the first one. The second and third patient may be treated simultaneously, except if a DLT is reported in the first patient, in which case the second and third patient should be treated sequentially, at least one week apart.~Dose escalation will be done when all the patients included in each DL will finish the first treatment cycle. Three additional patients will be sequentially entered (separated by one week each other) if one DLT is observed in cycle 1 among the first 3 patients entered within a dose level. If a DLT is observed in a second patient at this dose level, no further dose escalation will be allowed and the dose level will be considered the MTD.~Once the RD (one level below the MTD) has been defined, additional patients (up to 12) will be treated in order to confirm the safety profile of the combination."
3205937|NCT01155492||Subjects with Parkinson's disease|Male and female subjects with clinically diagnosed Parkinson's disease, Stage I-IV.
3205938|NCT01155492||Control subjects|Age- and gender-matched subjects who do not have Parkinson's disease
3205939|NCT01155492||Multiple system atrophy.|Men and women with clinically diagnosed multiple system atrophy.
3205940|NCT01155479|Experimental|Preladenant 2 mg|Preladenant 2 mg oral tablet and placebo for rasagiline taken in the morning (AM) followed by preladenant 2 mg oral tablet taken in the evening (PM) for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
3205941|NCT01155479|Experimental|Preladenant 5 mg|Preladenant 5 mg oral tablet and placebo for rasagiline taken in the AM followed by preladenant 5 mg taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
3205942|NCT01155479|Experimental|Preladenant 10 mg|Preladenant 10 mg oral tablet and placebo for rasagiline taken in the AM followed by preladenant 10 mg taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
3205943|NCT01155479|Placebo Comparator|Placebo|Placebo for preladenant and placebo for rasagiline taken in the AM followed by placebo for preladenant taken in the PM for 26 weeks (Part 1); preladenant 5 mg was taken twice daily for 26 weeks (Part 2).
3205944|NCT01155479|Active Comparator|Rasagiline|Rasagiline 1 mg oral capsule and placebo for preladenant taken in the AM followed by placebo for preladenant taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
3205945|NCT01155466|Experimental|Preladenant 2 mg|Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks
3205946|NCT01155466|Experimental|Preladenant 5 mg|Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks
3205947|NCT01155466|Experimental|Preladenant 10 mg|Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks
3205948|NCT01155466|Placebo Comparator|Placebo|Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks
3205949|NCT01155466|Active Comparator|Rasagiline 1 mg|Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks
3205950|NCT01155453|Experimental|BKM120 + GSK1120212 DE|Dose Escalation
3205951|NCT01155453|Experimental|BKM120 + GSK1120212 NSCLC patients|Advanced RAS or BRAF mutant NSCLC patients
3205952|NCT01155453|Experimental|BKM120 + GSK1120212 ovarian cancer patients|Advanced RAS or BRAF mutant ovarian cancer patients
3205953|NCT01155453|Experimental|BKM120 + GSK1120212 pancreatic cancer patients|Advanced RAS or BRAF mutant pancreatic cancer patients
3205954|NCT01155440|Experimental|LIDOCAINE group|Beside general anesthesia, patients will receive intravenous lidocaine bolus 1.5 mg/kg just prior induction and an infusion of lidocaine 2mg/kg/h will be started and maintained during the whole surgical procedure. Entering the recovery room, this infusion will be decreased at the rate of 1mg/kg/hour for the 48 first hours
3205955|NCT01155440|Active Comparator|Epidural group|Beside general anesthesia, patient will receive epidural freezing medication for 48 hours.
3205956|NCT01155427||entecavir|Patients initiating special antiviral treatments for CHB
3205957|NCT01155427||tenofovir|Patients initiating special antiviral treatments for CHB
3205958|NCT01155427||lamivudine|Patients initiating special antiviral treatments for CHB
3205959|NCT01155427||telbivudine|Patients initiating special antiviral treatments for CHB
3205960|NCT01155427||adefovir|Patients initiating special antiviral treatments for CHB
3205961|NCT01155414|Experimental|Investigational infant formula A|Investigational Protein Hydrolysate formula
3205962|NCT01155414|Active Comparator|Hydrolysate based Infant Formula|
3205963|NCT01155414|Experimental|Investigational Infant Formula B|Investigational Protein Hydrolysate Formula
3205964|NCT01155401||1|Patients with acute upper gastrointestinal bleeding
3205965|NCT01155388|Experimental|Ferumoxytol|"Participants will receive 1 of the following 2 ferumoxytol dose regimens:~Four IV injections of ferumoxytol 3.5 mg Fe/kg (maximum of 255 mg/dose) administered on nonconsecutive days within a 14-day period as follows: Day 1 (dose 1), Days 3* through 10 (dose 2), Days 5 through 12 (dose 3), and Days 7 through 14 (dose 4). *Participants participating in PK sampling received the second dose on Day 4 after the 72-hour PK sample was collected.~Two IV injections of ferumoxytol 7.0 mg Fe/kg (maximum of 510 mg/dose), the first administered on Day 1 and the second on Days 3 through 9."
3205966|NCT01155388|Active Comparator|Oral Iron|Participants will receive oral iron: 2.5 mg Fe/kg twice daily (maximum of 100 mg/dose) on Days 1 through 35.
3205967|NCT01155375|Experimental|Ferumoxytol|"Participants will receive 1 of the following 2 ferumoxytol dose regimens:~Four IV injections of ferumoxytol 3.5 mg Fe/kg (maximum of 255 mg/dose) administered on nonconsecutive days within a 14-day period as follows: Day 1 (dose 1), Days 3* through 10 (dose 2), Days 5 through 12 (dose 3), and Days 7 through 14 (dose 4). *Participants participating in PK sampling received the second dose on Day 4 after the 72-hour PK sample was collected.~Two IV injections of ferumoxytol 7.0 mg Fe/kg (maximum of 510 mg/dose), the first administered on Day 1 and the second on Days 3 through 9."
3205968|NCT01155375|Active Comparator|Oral Iron|Participants will receive oral iron 2.5 mg Fe/kg twice daily (maximum of 100 mg/dose) on Days 1 through 35.
3205969|NCT01155362|Experimental|1 unit Human Placenta-Derived Cells PDA001|1 unit PDA001 in 240 millilters (mL) infused intravenously in one arm on Day 0 and Day 7.
3205970|NCT01155362|Experimental|4 units Human Placenta-Derived Cells PDA001|4 units PDA001 in 240 mL infused intravenously in one arm on Day 0 and Day 7.
3205971|NCT01155362|Placebo Comparator|vehicle control|4 units placebo in 240 mL infused intravenously in one arm on Day 0 and Day 7.
3205972|NCT01155349|Experimental|InSight Brain Fitness|
3205973|NCT01155349|Placebo Comparator|No contact-control|
3205974|NCT01155336|Experimental|Lovaza®|Lovaza® is a prescription grade EPA+DHA fish oil supplement. Four capsules (each containing 1 gram of fish oil) were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
3205975|NCT01155336|Placebo Comparator|Corn Oil|The placebo contained 1 gram of corn oil in each capsule. Four capsules were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
3205976|NCT01155323|Active Comparator|etafilcon A/omafilcon A|etafilcon A contact lenses will be worn during the first week and omafilcon A contact lenses will be worn during the second. Lenses were replaced daily
3205977|NCT01155323|Active Comparator|omafilcon A/etafilcon A|omafilcon A contact lenses will be worn during the first week and etafilcon A contact lenses will be worn during the second. Lenses were replaced daily.
3205978|NCT01155310|Experimental|Helium/Oxygen|Helium/Oxygen 78%/22% will be administered for a maximum of 72 hours.
3205979|NCT01155310|Active Comparator|Air/Oxygen|Air/Oxygen will be administered for a maximum of 72 hours.
3205980|NCT01155297|Sham Comparator|Control Group|At the control group, with 34 subjects, will be performed stretching and metabolic exercises. This group will make the assessments before and the reassessments after the end of the program.
3205981|NCT01155297|Active Comparator|Training group|At the training group, with 34 subjects, will be performed stretching, physical training and resistance. This group will make the assessments before and the reassessments after the end of the program.
3205982|NCT01155284|Experimental|Sitagliptin and Lansoprazole|Sitagliptin 50mg co-administered with Lansoprazole 30mg. Subjects age 11-17 years at Visit 2 will take 1 capsule of each once daily Subjects age 18-45 years at Visit 2 will take 2 capsules of each once daily
3205983|NCT01155284|Placebo Comparator|Placebo|Sitagliptin Placebo and Lansoprazole placebo capsules will be administered. Subjects age 11-17 years at Visit 2 will take 1 placebo capsule of each once daily Subjects age 18-45 years at Visit 2 will take 2 placebo capsules of each once daily
3205984|NCT01155271|Active Comparator|ERGO|General endurance training on cycloergometer
3205985|NCT01155271|Active Comparator|ERGONIV/ ERGOSPIRO|General endurance training on cycloergometer using ventilatory assistance (ERGONIV) or additional respiratory muscle training (ERGOSPIRO)
3205986|NCT01155258|Experimental|Arm I|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and vinorelbine ditartrate IV over 5-10 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3205987|NCT01155245||Forteo (teriparatide)|postmenopausal women with osteoporosis
3205988|NCT01155245||Forteo (teriparatide) with AFF|Women with atypical femur fractures
3205989|NCT01155232||Forteo (teriparatide)|postmenopausal women and men with osteoporosis Teriparatide is marketed as Forteo by Eli Lilly Teriparatide is not supplied (observational study)
3205990|NCT01155232||Forteo (teriparatide) in AFF|women who have experienced an atypical femur fracture (AFF) Teriparatide is not supplied (observational study)
3205991|NCT01155219|Experimental|Geltim LP®|Geltim LP® 1 mg/g (0.1 % timolol maleate, without preservative) packaged in single-dose containers (unidoses); one drop in the conjunctival sac of each eye in the morning (84 days).
3205992|NCT01155219|Active Comparator|Xalatan®|Xalatan® (Latanaprost) aqueous eye drop (one drop in the conjunctival sac of each eye in the evening during 84 days.
3206150|NCT01154270|Experimental|IMRT + C12-boost|(8 x 3 GyE) carbon ion therapy followed by 50 Gy IMRT (2 Gy/ Fx)corresponding to a total dose of approximately 74 GyE.
3205993|NCT01155206|Experimental|high glucagon|For one of the two studies to be performed in random order, the subject will receive an infusion of glucagon at a dose that has been shown to achieve high physiological plasma levels. The IV glucagon will be administered at a rate of 3ng/kg/min.
3205994|NCT01155206|Experimental|low glucagon|For one of the two studies to be performed in random order, the subject will receive an infusion of glucagon at a low rate that is designed to mimic basal plasma glucagon concentration. The IV glucagon will be administered at a rate of 0.65ng/kg/min.
3205995|NCT01155193||Children with risk for Respiratory Syncytial Virus Infection|The study population will consist of preterm infants and children born with hemodynamically significant congenital heart disease
3205996|NCT01155180|Experimental|Leptin|We will start the leptin at a dose of 0.08mg/kg fat mass in men and 0.14mg/kg fat mass in women
3205997|NCT01155180|Placebo Comparator|Placebo|We will start the placebo at a dose of 0.08mg/kg fat mass in men and 0.14mg/kg fat mass in women
3205998|NCT01155167|Placebo Comparator|Placebo|
3205999|NCT01155167|Experimental|Topical dilator|
3206000|NCT01155154|Active Comparator|clindamycin|clindamycin 300 mg (two 150 mg capsules) every 6 hours for 7 days
3206001|NCT01155154|Active Comparator|cepahlexin|
3206002|NCT01155154|Placebo Comparator|Placebo|
3206003|NCT01155141|Experimental|No arms|There are no arms to this study. All patients receive drug (H.P. Acthar Gel)
3206004|NCT01155128|Experimental|Lifestyle interventions|After recruitment of the participants and consented to participate those deemed eligible for inclusion completed baseline surveys will be randomly assigned to an intervention group and another control group that will receive the usual care
3206005|NCT01155128|Placebo Comparator|lifestyle interventions|After recruitment of the participants and consented to participate those deemed eligible for inclusion completed baseline surveys will be randomly assigned to an intervention group and another control group that will receive the usual care
3206006|NCT01155115|Experimental|Primary Ciliary Dyskinesia (PCD) Patients|
3206007|NCT01155115|Experimental|Cystic Fibrosis (CF) Patients|
3206008|NCT01155076|Experimental|Vitality product|Proprietary blend of ginseng, cordyceps, and pomegranate
3206009|NCT01155076|Placebo Comparator|Placebo|Placebo
3206010|NCT01155063||Main Group|Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer Who Are Disease-Free After 2-3 Years Of Initial Adjuvant Tamoxifen Therapy
3206011|NCT01155050|Active Comparator|Tele-health Home Monitoring|Participants will use the tele-health monitoring equipment to measure daily weight.
3206012|NCT01155050|No Intervention|Self-Directed Group|Participants will receive information on physical activity recommendations and guidelines on nutrition aimed at promoting weight loss.
3206013|NCT01155050|Active Comparator|TrestleTree Telephone Coaching|Participants will speak to Trestletree health coaches for 15 to 60 minutes each session. During these sessions, the coaches will identify the participant's stage of change and intervene accordingly. The telephone calls will be centered on weight loss.
3206014|NCT01155050|Active Comparator|Home monitoring + telephone coach|System to track stage of change in weight loss.
3206015|NCT01155037|Experimental|3.75 µg of the vaccine on days 0 and 21|Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
3206016|NCT01155037|Experimental|7.5 µg of the vaccine on days 0 and 21|Patients infected with HIV will receive 7.5µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
3206017|NCT01155037|Active Comparator|3.75 µg of the vaccine on day 0|The volunteers in the control group will receive a single application of 3.75 µg dose of the vaccine.
3206018|NCT01155024|Other|Traditional Socket First, then DM Socket|Initial fitting of a traditional diagnostic prosthetic socket in first intervention period and initial fitting of a direct manufactured prosthetic socket in the second intervention period
3206019|NCT01155024|Other|DM Socket First, then Traditional Socket|Initial fitting of a direct manufactured prosthetic socket in first intervention period and initial fitting of a traditional diagnostic prosthetic socket in the second intervention period
3206020|NCT01155011|Experimental|MIPARC intervention|"Eleven Continuing Care Retirement Communities were randomized to either the MIPARC intervention or an attention-control condition. The intervention focused on increasing light to moderate PA.~The MIPARC study intervenes on four levels: individual (pedometer self monitoring, educational materials and monthly counseling calls, support), interpersonal (monthly group educational sessions and peer mentoring), environment (walking signage prompts, tailored environmental resources, step counts)and policies (review of on-site activity opportunities and walkability, recommendations for policy change and peer led advocacy)to increase the activity levels of residents.~For the first 3 months, intervention participants will engage in either a group educational session, phone counseling call, or a peer led session, on a rotating basis."
3206021|NCT01155011|Active Comparator|Health Education Control|The control group received an active health education intervention. The education curriculum will involve both lectures and mailed materials. The lectures were delivered to match the MIPARC intervention schedule. Sessions included information on general health and healthy aging. Physical activity was not discussed in these sessions but participants received information on the benefits of PA. Control participants also received health check phone calls to match the individual attention paid to participants in the MIPARC intervention sites.
3206022|NCT01154998||Cases|
3206023|NCT01154998||Controls|
3206024|NCT01154985|Placebo Comparator|Placebo|3x placebo capsules TID
3206025|NCT01154985|Experimental|EPA-E 1800 mg/day|2x EPA-E 300 mg capsules + 1placebo capsule TID
3206026|NCT01154985|Experimental|EPA-E 2700 mg/day|3x EPA-E 300 mg capsules TID
3206027|NCT01154972|Experimental|Single arm study - Sentinel Node Localisation|
3206028|NCT01154959|Experimental|Regimen 1|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 3 months (3RHZEM)
3206029|NCT01154959|Experimental|Regimen 2|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, and moxifloxacin daily for 2 months (2 RHZEM daily / 2 RHM daily)
3206030|NCT01154959|Experimental|Regimen 3|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, and moxifloxacin thrice weekly for 2 months (2 RHZEM daily / 2RHM thrice weekly)
3206396|NCT01152619|Experimental|1|
3206397|NCT01152619|Experimental|2|
3206031|NCT01154959|Experimental|Regimen 4|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, ethambutol and moxifloxacin thrice weekly for 2 months (2 RHZEM daily / 2 RHEM thrice weekly)
3206032|NCT01154959|Active Comparator|Control Regimen|Rifampicin, isoniazid, pyrazinamide and ethambutol thrice weekly for 2 months followed by rifampicin and isoniazid thrice weekly for 4 months (2 RHZE thrice weekly / 4 RH thrice weekly)
3206033|NCT01154946||DAC group|patients who show detrusor after-contraction during voiding cystometrography (CMG)
3206034|NCT01154933|Experimental|exenatide 5 mcg|exenatide 5 mcg
3206035|NCT01154933|Experimental|exenatide 10 mcg|exenatide 10 mcg
3206036|NCT01154933|Placebo Comparator|placebo|placebo
3206037|NCT01154920|Experimental|PCC Group + RT|Group A: Paclitaxel, Carboplatin and Cetuximab (PCC) Induction + Radiation (RT)
3206038|NCT01154920|Experimental|PCC Group + RT + Chemotherapy|Group A: Paclitaxel, Carboplatin and Cetuximab (PCC) Induction + Radiation (RT) + Chemotherapy
3206039|NCT01154920|Experimental|C-TPF Group + RT|Group B: Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) Induction + Radiation (RT)
3206040|NCT01154920|Experimental|C-TPF Group + RT + Chemotherapy|Group B: Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) Induction + Radiation (RT) + Chemotherapy
3206041|NCT01154907||Girls ages 10-12|"In 18 rural schools in Ugu District, South Africa. Undergoing mass-treatment provided by the Department of Health.~Praziquantel was administered at 40mg/kg in annual mass-treatment"
3206042|NCT01154907||Young adult women|"In rural schools in three districts, South Africa. Undergoing mass-treatment provided by the Departments of Health.~Praziquantel was administered at 40mg/kg in annual mass-treatment"
3206043|NCT01154894|Experimental|Placebo-controlled trial|
3206044|NCT01154881|Experimental|IDeg 100U/mL 0.4U/kg|
3206045|NCT01154881|Experimental|IDeg 100U/mL 0.6U/kg|
3206046|NCT01154881|Experimental|IDeg 100U/mL 0.8U/kg|
3206047|NCT01154881|Experimental|IDeg 200U/mL 0.6U/kg|
3206048|NCT01154868|Other|Healos|
3206049|NCT01154855||Periodontitis|"Patients with severe periodontal disease Intervention (Procedure/surgery): Prophylaxis; Gross debridement for diseased patients~Other Names:~Teeth cleaning~1 per patient at 2nd visit lasting approximately 1 hour."
3206050|NCT01154855||Healthy patients|"Patients without periodontal (gum) disease Intervention (Procedure/surgery): Prophylaxis; Gross debridement for diseased patients~Other Names:~Teeth cleaning"
3206051|NCT01154842||Hemodialysis|Adult hemodialysis patients (age>18 years)
3206052|NCT01154829|Active Comparator|first choice treatment|Treatment with amisulpride
3206053|NCT01154829|Active Comparator|second choice treatment|treatment with aripiprazole
3206054|NCT01154816|Experimental|Arm I (neuroblastoma- measurable)|Patients with measurable neuroblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3206055|NCT01154816|Experimental|Arm II (Neuroblastoma- MIBG evaluable)|Patients MIBG evaluable neuroblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3206056|NCT01154816|Experimental|Arm III (rhabdomyosarcoma)|Patients with rhabdomyosarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3206057|NCT01154816|Experimental|Arm IV (osteosarcoma)|Patients with osteosarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3206058|NCT01154816|Experimental|Arm V (Ewing sarcoma/peripheral PNET)|Patients with Ewing sarcoma/peripheral PNET receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3206059|NCT01154816|Experimental|Arm VI (non-RMS soft tissue sarcoma)|Patients with non-RMS soft tissue sarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3206060|NCT01154816|Experimental|Arm VII (hepatoblastoma)|Patients hepatoblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3206061|NCT01154816|Experimental|Arm VIII (malignant germ cell tumor)|Patients with malignant germ cell tumor receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3206062|NCT01154816|Experimental|Arm IX (Wilms tumor)|Patients with Wilms tumor receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3206063|NCT01154816|Experimental|Arm X (acute lymphoblastic leukemia)|Patients with acute lymphoblastic leukemia receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3206064|NCT01154816|Experimental|Arm XI (acute myelogenous leukemia)|Patients acute myelogenous leukemia receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3206065|NCT01154816|Experimental|Arm XII (rhabdoid malignancy)|Patients with rhabdoid malignancy receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3206066|NCT01154803|Experimental|Ready to Use Therapeutic Food (RUTF)|500 kcal /day for 2 weeks
3206067|NCT01154803|Experimental|Micronutrient Powder (MNP)|2 x 1 g sachets micronutrients /day for 2 weeks
3206068|NCT01154803|No Intervention|no supplement|no supplementation
3206069|NCT01154790|Experimental|CG100649|By the amount of doses, the groups are classified
3206070|NCT01154790|Active Comparator|Naproxen|By the amount of doses, the groups are classified
3206071|NCT01154790|Placebo Comparator|Placebo|By the amount of doses, the groups are classified
3206072|NCT01154764|Experimental|CG100649|study drug CG100649 (1 mg x 6 capsules) will be administered alone on Day 1, or the combination of CG100649 (1 mg x 6 capsules) and Dongkwang ketoconazole tablets (200 mg x 2 tablets) will be administered together on Day 1, followed by additional Dongkwang ketoconazole tablets (200 mg x 2 tablets) which will be administered once a day for 4 days (Days 2-5), for a total of 5 days.
3206073|NCT01154764|Experimental|CG100649 and ketoconazole|study drug CG100649 (1 mg x 6 capsules) will be administered alone on Day 1, or the combination of CG100649 (1 mg x 6 capsules) and Dongkwang ketoconazole tablets (200 mg x 2 tablets) will be administered together on Day 1, followed by additional Dongkwang ketoconazole tablets (200 mg x 2 tablets) which will be administered once a day for 4 days (Days 2-5), for a total of 5 days.
3206074|NCT01154751|Other|Device SUPERA Stent|SUPERA Interwoven Self-Expanding Nitinol Stent System
3206075|NCT01154738|Experimental|Lidocaine|Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Lidocaine
3206076|NCT01154738|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
3206077|NCT01154725|Other|Habitual stoma care|habitual patient education
3206078|NCT01154725|Experimental|Patient education and rehabilitation|patient education and rehabilitation
3206079|NCT01154712|Active Comparator|Real Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
3206080|NCT01154712|Sham Comparator|Sham Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
3206081|NCT01154699|Experimental|Usual Care first, then Bilevel PAP|"Subjects will begin the study by continuing their usual care for 4 weeks. They will complete questionnaires and breathing tests at the start and end of this 4 week period. After a Washout Period of an additional 4 weeks of usual care, they will then start Bilevel PAP therapy for 4 weeks. Just before and after the Bilevel PAP they will complete questionnaires and breathing tests."
3206082|NCT01154699|Experimental|Bilevel PAP first, then Usual Care|"Subjects will begin the study by starting on Bilevel PAP for 4 weeks. Just before and after the Bilevel PAP they will complete questionnaires and breathing tests. After a 4 week Washout Period of usual care, they will start a Usual Care period for 4 weeks. They will complete questionnaires and breathing tests at the start and end of this 4 week period."
3206083|NCT01154673|Experimental|Intensive HAART|"Patients in this arm will receive the following HAART regimen:~Raltegravir 400 mg BID + Maraviroc 150mg BID + emtricitabine 200mg /tenofovir 300mg QD + lopinavir 400 mg/ritonavir 100mg BID for 96 weeks"
3206084|NCT01154673|Placebo Comparator|Placebo Arm|Placebo (in place of raltegravir and maraviroc) will be added to standard HAART (Emtricitabine 200mg /tenofovir 300mg QD + Lopinavir 400 mg/ritonavir 100mg BID) for 48 weeks and then offered open label Raltegravir and Maraviroc after 48 weeks
3206085|NCT01154660|Experimental|Neutral|
3206086|NCT01154660|Active Comparator|Trendelenberg|
3206087|NCT01154647|Experimental|selective serotonin reuptake inhibitor|intravenous, acute, 20mg/ml
3206088|NCT01154647|Placebo Comparator|1 ml 0.9 % NaCl|
3206089|NCT01154634|Experimental|First 5 mg, then placebo, then 16 mg, then 40 mg|period 1: AZD2516 5 mg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD2516 16 mg, period 6: washout, period 7: AZD2516 40 mg.
3206090|NCT01154634|Experimental|First 40 mg, then 16 mg, then placebo, then 5 mg|period 1: AZD2516 40 mg, period 2: washout, period 3: AZD2516 16 mg, period 4: washout, period 5: placebo, period 6: washout, period 7: AZD2516 5 mg.
3206091|NCT01154634|Experimental|First 16 mg, then 5 mg, then 40 mg, then placebo|period 1: AZD2516 16 mg, period 2: washout, period 3: AZD2516 5 mg, period 4: washout, period 5: AZD2516 40 mg, period 6: washout, period 7: placebo.
3206092|NCT01154634|Experimental|First placebo, then 40 mg, then 5 mg, then 16 mg|period 1: placebo, period 2: washout, period 3: AZD2516 40 mg, period 4: washout, period 5: AZD2516 5 mg, period 6: washout, period 7: AZD2516 16 mg
3206093|NCT01154621|Experimental|1|Single dose of 750mg of intravenous AZD9742 in healthy elderly volunteers
3206094|NCT01154621|Placebo Comparator|2|Sterile 5% dextrose solution
3206095|NCT01154608|Experimental|pancreatic enzymes|
3206096|NCT01154608|Placebo Comparator|control|
3206097|NCT01154595|Active Comparator|Food-for-Training component|Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
3206098|NCT01154595|Experimental|Food-for-Training + RUF (Plumpy Doz(r))|"Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.~In addition, a blanket supplementation with 47g RUF (Plumpy Doz(r)) per day per child is provided."
3206099|NCT01154582|Experimental|Egg|
3206100|NCT01154582|Experimental|Cottage cheese|
3206101|NCT01154569|Active Comparator|Post Roux-en-Y gastric bypass|Post-bypass receiving a single dose of azithromycin
3206102|NCT01154569|Active Comparator|Controls|BMI and sex matched. Have not undergone surgery
3206103|NCT01154556||HIV1 positive, NNRTI exposure and failure|
3206104|NCT01154543||HIV positive, gential HSV,Famvir™ 500mg bd, suppressive|
3206105|NCT01154530|Active Comparator|Chlorhexidine mouthwash|Participants randomized to chlorhexidine mouthwash prior to gastroscopy
3206106|NCT01154530|No Intervention|No mouthwash|Mouthwash is not performed prior to gastroscopy as is the standard today.
3206107|NCT01154504|Other|clinical treatment|"Patients with previous diagnosis of decompensated III and IV Heart Failure will be included. The clinical treatment will be optimized.~Clinical assessment, Adrenomedullin, Angiotensin II, Brain Natriuretic Peptide, oxydative stress, sympathetic nervous system activity will be evaluated at the beginning, at discharge and 90 days after randomization(plus or minus3)."
3206108|NCT01154504|Experimental|ultrafiltration|"ultrafiltration will be done on decompensated patients III and IV acute heart failure on Intensive Care Unit. This patients will have biochemical analysis, adrenomedullin, angiotensin II,Brain Natriuretic Peptide, oxydative stress measurements,sympathetic nervous system activity evaluated and clinical outcome analyzed at the beginning,at discharge and 90 days after randomization(plus or minus 3).~Diuretic will be withdrawn during ultrafiltration."
3206151|NCT01154257|Experimental|Cleaning teeth with toothbrush|Following randomisation one side of the mouth (split mouth study) will be assigned to cleaning teeth with a toothbrush
3206225|NCT01153828||(2) 9 months to 6 years|Age at time of prescription was 9 months to 6 years
3206109|NCT01154504|Experimental|isovolumetric hemofiltration|Patients randomized to this group will have isovolumetric hemofiltration on Intensive Care Unit. They will have biochemical analysis, Adrenomedullin plasmatic level, Brain Natriuretic Peptide Level, Angiotensin II level, Oxydative stress measurement,sympathetic nervous system, and clinical outcome evaluated at the study beginning,at discharge and 90 days after randomization(plus or minus 3).
3206110|NCT01154491|Placebo Comparator|Placebo|Two placebos: placebo for ferric carboxymaltose and placebo for erythropoietin
3206111|NCT01154491|Experimental|FE|Ferric carboxymaltose and placebo for erythropoietin
3206112|NCT01154491|Experimental|EPOFE|Ferric carboxymaltose and erythropoietin
3206113|NCT01154478|Experimental|B group|Diet rich in omega-3 fatty acids
3206114|NCT01154478|Experimental|C group|Diet rich in polyphenols
3206115|NCT01154478|Experimental|D group|Diet rich in polyphenols and in omega-3 fatty acids
3206116|NCT01154478|Placebo Comparator|A group (control group)|diet with low content of omega-3 fatty acids and polyphenols
3206117|NCT01154465|Active Comparator|Anatomical guidance puncture|"The patient is placed supine (with a slight neck extension for jugular punctures).~The preparation of the CVC installation will follow the procedures for disinfection, for skin preparation of the operator, for installation of sterile fields and for local anaesthesia.~The veins will be tracked by simple palpation of the carotid pulse.~The puncture will be made following:~The anterior Boulanger's incision for the internal jugular vein;~When venous aspiration is obtained, the catheter is assembled according to the Seldinger method."
3206118|NCT01154465|Experimental|US-guided puncture|"The patient is placed supine (with a slight neck extension for jugular punctures).~The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed. A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:~- The anterior Boulanger's incision for the internal jugular vein pathway;"
3206119|NCT01154452|Experimental|Arm I (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.
3206120|NCT01154452|Experimental|Arm II (vismodegib and gamma-secretase inhibitor RO4929097)|Patients receive vismodegib PO and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.
3206121|NCT01154439|Experimental|Everolimus|Everolimus mice-regimen
3206122|NCT01154426|Experimental|Treatment (gemcitabine hydrochloride and ABT-888)|Patients receive oral ABT-888 twice daily on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 21* days in the absence of disease progression or unacceptable toxicity.
3206123|NCT01154413|Experimental|Intensive education of the doctor/nursing team on the protocol|
3206124|NCT01154413|No Intervention|Without intervention in the team|
3206125|NCT01154400|Experimental|Casein protein hydrolysates|15 g casein protein hydrolysates and 15 g maltodextrin
3206126|NCT01154400|Experimental|Whey protein hydrolysates|15 g whey protein hydrolysates and 15 g maltodextrin
3206127|NCT01154400|Experimental|Casein protein hydrolysates + LEU|15 g casein protein hydrolysates + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
3206128|NCT01154400|Experimental|Whey protein hydrolysates + LEU|15 g whey protein hydrolysates + 1.5 g LEU (40% of EAA content) + 15 g maltodextrin
3206129|NCT01154387|Active Comparator|Anti-Thymocyte Globulin|Anti-Thymocyte Globulin induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
3206130|NCT01154387|Experimental|TOL101 (Dose A)|TOL101 induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
3206131|NCT01154387|Experimental|TOL101 (Dose B)|TOL101 induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
3206132|NCT01154374|Experimental|MEBO Wound Ointment|Topical application twice daily
3206133|NCT01154374|Active Comparator|Standard of Care (sterile saline moistened gauze)|Topical application twice daily
3206134|NCT01154361|Experimental|Arm A|
3206135|NCT01154361|Active Comparator|Arm B|
3206136|NCT01154348|Experimental|Washout period, S-707106 tablet|14-day washout of metformin, followed by S-707106 once daily for 14 days under fed conditions
3206137|NCT01154348|Placebo Comparator|Washout, placebo|14-day washout of metformin followed by placebo for S-707106 once daily for 14 days under fed conditions
3206138|NCT01154348|Experimental|Maintenance, S-707106 tablet plus metformin|14-day maintenance of metformin, followed by S-707106 once daily plus open-label metformin twice daily for 14 days under fed conditions
3206139|NCT01154348|Placebo Comparator|Maintenance, placebo plus metformin|14-day maintenance of metformin, followed by placebo for S-707106 once daily plus open-label metformin twice daily for 14 days under fed conditions
3206140|NCT01154335|Experimental|Dose Level 1|"combination of OSI-906 and everolimus~OSI-906: 50 mg Twice a Day, cycle-28 days~Everolimus: 5mg Daily, cycle-28 days"
3206141|NCT01154335|Experimental|Dose Level 2|"combination of OSI-906 and everolimus~OSI-906: 100 mg Twice a Day, cycle-28 days~Everolimus: 10mg Daily, cycle-28 days"
3206142|NCT01154335|Experimental|Dose Level 2a|"combination of OSI-906 and everolimus~OSI-906: 100 mg Twice a Day, cycle-28 days~Everolimus: 5mg Daily, cycle-28 days"
3206143|NCT01154322|Experimental|Pediatric mask|
3206144|NCT01154309|Experimental|1|Clients are invited to attend 18 group CBT sessions
3206145|NCT01154309|No Intervention|2|Clients receive usual care
3206146|NCT01154296|Experimental|Rapid HIV Testing w/ Counseling (Group 1)|Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.
3206147|NCT01154296|No Intervention|Rapid HIV Testing & Information Only (Group 2)|Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.
3206148|NCT01154283|Active Comparator|Bi-level, standard, NIPPV|Standard NIPPV with both an inspiratory and expiratory positive airway pressure.
3206149|NCT01154283|Experimental|IPAP-only, NIPPV|NIPPV with only inspiratory positive airway pressure, no expiratory positive airway pressure
3206152|NCT01154257|Experimental|Cleaning teeth with foam swab|Following randomisation one side of the mouth (split mouth study) will be assigned to cleaning teeth with a faom swab
3206153|NCT01154244||Drug naive type II DM|Newly diagnosed type II Diabetes Mellitus
3206154|NCT01154231||Nonacog Alfa (Genetical Recombination)|
3206155|NCT01154218|Experimental|1|"All subjects will receive four treatments in one of the indicated orders:~A-B-C-D, B-D-A-C, C-A-D-B, D-C-B-A"
3206156|NCT01154205||Patients post implantation of ICD or CRTD|
3206157|NCT01154192|Experimental|PCOS group|Intervention: Each subject in the PCOS group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
3206158|NCT01154192|Experimental|Normal group|Intervention: Each subject in the Normal group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
3206159|NCT01154192|Experimental|Oligomenorrhea group|Intervention: Each subject in the Oligomenorrhea group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
3206160|NCT01154179|No Intervention|Normocaloric feeding|This control group will receive energy and protein intakes as recommended by the use of Schofield equations, as is current practice (100% of requirements)
3206161|NCT01154166|Experimental|ReQuip PR|Ropinirole PR tablets of 2.0 mg, 4.0mg and 8.0 mg
3206162|NCT01154166|Placebo Comparator|Placebo|Placebo
3206163|NCT01154153|Placebo Comparator|Placebo|"placebo during the screening phase and~placebo during the treatment phase.~All children had the option to take rescue medication, (Claritin®) as needed to relieve symptoms of AR."
3206164|NCT01154153|Experimental|TAA-AQ|"placebo during the screening phase and~TAA-AQ (Nasacort AQ) during the treatment phase.~All children had the option to take rescue medication, (Claritin®) as needed to relieve symptoms of AR."
3206165|NCT01154140|Experimental|A|
3206166|NCT01154140|Active Comparator|B|
3206167|NCT01154127|Experimental|NVA237 followed by Placebo|"Period 1: 50 μg NVA237 via NEOHALER inhaler device for 21 days~Period 2: Matching placebo via NEOHALER inhaler device for 21 days~The washout period ran for 14 to 28 days between treatment periods. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study.~Salbutamol (albuterol) was used as rescue medication throughout the study."
3206168|NCT01154127|Experimental|Placebo followed by NVA237|"Period 1: Matching placebo of NVA237 via NEOHALER inhaler device for 21 days~Period 2: 50 μg NVA237 via NEOHALER inhaler device for 21 days~The washout period ran for 14 to 28 days between treatment periods. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study.~Salbutamol (albuterol) was used as rescue medication throughout the study."
3206169|NCT01154114|Experimental|moderate hepatic impaired subjects|Male and female subjects with moderate hepatic impairment defined by a Child-Pugh score of 7-9 will be included. The subjects will be administered 40 mg oral doses of darapladib (SB-480848) enteric-coated tablets daily for 10 consecutive days.
3206170|NCT01154114|Experimental|normal healthy volunteers|Healthy male and female subjects will be included and will be matched as closely as possible to the group of moderate hepatic impairment subjects for gender, age and body mass index. Each subject will receive daily 40 mg oral doses of darapladib (SB-480848) enteric-coated tablets for 10 consecutive days.
3206171|NCT01154101|Active Comparator|Cohort 2 - 500mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 2 will commence after Cohort 1 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee.~Cohort 2 will be administered at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff."
3206172|NCT01154101|Active Comparator|Cohort 3 - 1000mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 3 will commence after Cohort 2 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee.~Cohort 3 will be administered four SRT2104 capsules at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff."
3206173|NCT01154101|Active Comparator|Cohort 1 - 250mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 1 will be administered at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff.~Dosing for Cohort 2 will not commence until Cohort 1 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee."
3206174|NCT01154088|Experimental|Group A|
3206175|NCT01154088|Experimental|Group B|
3206176|NCT01154088|Active Comparator|Group C|
3206177|NCT01154062|Experimental|low dose|Pazopanib tablet
3206178|NCT01154049|Experimental|single arm|3 doses of the vaccine, on days 0, 30 and 60.
3206179|NCT01154036|Experimental|Phase I: ezetimibe (EZ) 10 mg + atorvastatin (Atorva) 10 mg|Co-administration of EZ 10 mg tablet + Atorva 10 mg tablet; once daily for 6 weeks
3206180|NCT01154036|Active Comparator|Phase I: Atorvastatin 20 mg|Atorvastatin 20 mg tablet once daily for 6 weeks
3206181|NCT01154036|Active Comparator|Phase I: Rosuvastatin 10 mg|Rosuvastatin 10 mg tablet once daily for 6 weeks
3206182|NCT01154036|Experimental|Phase II: EZ 10mg+Atorva 10mg|Participants who had previously received EZ 10 mg + Atorva 10 mg in Phase I and continued on EZ 10 mg + Atorva 10 mg once daily for 6 weeks during Phase II regardless of whether or not LDL-C goals were achieved in Phase I
3206183|NCT01154036|Experimental|Phase II: EZ 10mg + Atorva 20mg [A]|Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched to EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II
3206184|NCT01154036|Active Comparator|Phase II: Atorva 40mg|Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched Atorva 40 mg once daily for 6 weeks in Phase II
3206185|NCT01154036|Experimental|Phase II: EZ 10mg + Atorva 20mg [R]|Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and received EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II
3206186|NCT01154036|Active Comparator|Phase II: Rosuvastatin 20mg|Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and were switched to Rosuvastatin 20 mg once daily for 6 weeks in Phase
3206187|NCT01154023|Experimental|stimulus control therapy|Focuses on strengthening the bed and bedroom as cues for sleepiness and sleep, weaken them as cues for arousal, and developing a consistent sleep-wake pattern
3206188|NCT01154023|Experimental|sleep restriction therapy|Sleep restriction therapy consolidates sleep by restricting the amount of time spent in bed and limiting sleep to a specific time period .
3206189|NCT01154023|Experimental|multi-component intervention|Combines stimulus control and sleep restriction: strengthen the bed and bedroom as cues for sleepiness and sleep, weaken them as cues for arousal, develop a consistent sleep-wake pattern, consolidate sleep by restricting the amount of time spent in bed and limit sleep to a specific time period
3206190|NCT01154010|Active Comparator|Active Device|"ActiPatch, a device that emits a low frequency energy called pulsed electromagnetic field (PEMF), will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids."
3206191|NCT01154010|Placebo Comparator|Placebo Device|Patients wear the PEMF placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.
3206192|NCT01153997|Experimental|A|
3206193|NCT01153997|Experimental|B|
3206194|NCT01153997|Placebo Comparator|C|
3206195|NCT01153997|Placebo Comparator|D|
3206196|NCT01153984|Experimental|Erlotinib|Participants will receive 150 milligrams (mg) erlotinib orally daily until disease progression, unacceptable toxicity, withdrawal due to any reason or death.
3206197|NCT01153971|Experimental|1|
3206198|NCT01153958|Experimental|Colposeptine (A)|
3206199|NCT01153958|Active Comparator|Metronidazole (B)|
3206200|NCT01153945||Hypothyroid|
3206201|NCT01153945||Non hypothyroid|
3206202|NCT01153945||Healthy subjects|
3206203|NCT01153932|Experimental|Continuous regimen; 6mg/kg once weekly|Once Weekly
3206204|NCT01153932|Experimental|Intermittent regimen; 6mg/kg twice weekly|Twice weekly on 1st, 3rd and 5th weeks, once weekly on 2nd, 4th and 6th weeks, and no active drug on 7th to 10th week of each 10 week cycle
3206205|NCT01153919|Active Comparator|Arm I|Patients receive romiplostim subcutaneously once weekly for 8 weeks in the absence of disease progression or unacceptable toxicity.
3206206|NCT01153919|Placebo Comparator|Arm II|Patients receive placebo subcutaneously once weekly for 8 weeks. Patients failing to achieve a platelet count of &gt; 100,000/L cross over to arm I.
3206207|NCT01153906||Exposed cohort|Females 9-25 years of age, who received at least one dose of Cervarix® as part of their routine health care.
3206208|NCT01153906||Unexposed cohort|Females 9-25 years of age, who did not receive Cervarix®
3206209|NCT01153893|Experimental|Synflorix/Infanrix primed Group|Subjects previously primed with the Synflorix™ vaccine in the primary study 110521 (NCT00678301) received a booster dose of the Synflorix™ vaccine co-administered with a booster dose of the Infanrix™ vaccine at 15-21 months of age. Synflorix™ vaccine was administered intramuscularly in the right thigh or deltoid muscle of the arm. Infanrix™ vaccine was administered intramuscularly in the left thigh or deltoid muscle of the arm.
3206210|NCT01153893|Experimental|Synflorix/Infanrix unprimed Group|Unprimed subjects from the primary study 110521 (NCT00678301), not previously vaccinated with any pneumococcal vaccine, received a 2-dose catch-up vaccination of Synflorix™ vaccine at 15-21 and 17-23 months of age and a booster dose of Infanrix™ vaccine co-administered with the first dose of Synflorix™ vaccine at 15-21 months of age. Synflorix™ vaccine was administered intramuscularly in the right thigh or deltoid muscle of the arm. Infanrix™ vaccine was administered intramuscularly in the left thigh or deltoid muscle of the arm.
3206211|NCT01153880||Age <9 months definitive|Age at time of prescription was <9 months
3206212|NCT01153880||Age <9 months uncertain|Age at time of prescription was uncertain for <9 months
3206213|NCT01153880||9 months to 6 years|Age at time of prescription was 9 months to 6 years
3206214|NCT01153880||7 to 18 years|Age at time of prescription was 7 to 18 years
3206215|NCT01153880||19 to 65 years|Age at time of prescription was 19 to 65 years
3206216|NCT01153880||66 years and older|Age at time of prescription was 66 years and older
3206217|NCT01153867|Experimental|Schema Focused Therapy|Participants will receive Schema Focused Therapy
3206218|NCT01153854|Experimental|ORS-Raceca In hospital Group|This group included 135 dehydrated patients which need an oral rehydration therapy in hospital and were assigned to received oral rehydration solution and racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.
3206219|NCT01153854|Placebo Comparator|ORS-Placebo in hospital group|This group included 135 dehydrated patients which need an oral rehydration therapy in hospital and were assigned to received oral rehydration solution and placebo in double blind assigned.
3206220|NCT01153854|Placebo Comparator|ORS-Placebo ambulatory group|This group included 92 non dehydrated patients which were assigned to received oral rehydration solution and placebo in double blind assigned and ambulatory (in home) bases.
3206221|NCT01153854|Experimental|ORS-Raceca ambulatory group|This group included 92 non dehydrated patients which were assigned to received oral rehydration solution and racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned and ambulatory (in home) bases.
3206222|NCT01153841|Experimental|Synflorix Group|Subjects receiving Synflorix™(GSK 1024850A) co-administered along with Infanrix hexa™.
3206223|NCT01153841|Active Comparator|Control Group|Subjects receiving Infanrix hexa™ vaccine alone.
3206224|NCT01153828||(1) Age <9 months|Age at time of prescription was <9 months
3206398|NCT01152619|Placebo Comparator|3|
3206226|NCT01153828||(3) 7 years to 18 years|Age at time of prescription was 7 years to 18 years
3206227|NCT01153828||(4) 19 to 65 years|Age at time of prescription was 19 to 65 years
3206228|NCT01153828||(5) 66 years and older|Age at time of prescription was 66 years and older
3206229|NCT01153815|Placebo Comparator|placebo|Sodium chloride
3206230|NCT01153815|Experimental|GSK1358820(Botulinum Toxin Type A)|"GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)"
3206231|NCT01153802|Experimental|Healthy Male Volunteers|All the 12 subjects enrolled in the study were exposed to at least one dose of GSK1360707 15 mg, 30 mg, 60 mg, 90 mg, 120 mg and 150 mg. All the subjects completed the study. The initial dose, given in the study as a single-dose was 15 mg GSK1360707. The remaining subjects were dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose did not exceed 150 mg per day, the maximum total dose given in the FTIH study.
3206232|NCT01153789|Experimental|Patients orthoptic rehabilitation|Children with vertigo-headache and vergence disorders
3206233|NCT01153789|Other|Control Orthoptic diagnostic|Healthy controls
3206234|NCT01153776|Experimental|64-slice CT angiography|64-slice CT angiography
3206235|NCT01153763|Other|All patients|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
3206236|NCT01153750|Experimental|Glivec and 5-Fluorouracil/Leucovorin|"All patients will receive Glivec® 600 mg once daily without dose escalation. Glivec® will be given on day -4, -3, -2, -1, 1, 2, 3 and 4. There will be no day 0. Patients will also receive 5-FU (2000mg/qm 24hc.i. d1 + d2) and leucovorin (200mg/qm 2h-infusion) qd15."
3206237|NCT01153737|Experimental|manual therapy|
3206238|NCT01153737|Active Comparator|TENS|Electric Nerve Stimulation (TENS)
3206239|NCT01153724|Experimental|Olodaterol|
3206240|NCT01153724|Experimental|Olodaterol + Fluconazole|
3206241|NCT01153711|Experimental|BI 1744 10 mcg|solution for oral inhalation
3206242|NCT01153711|Experimental|Ketoconazole 400 mg|tablet
3206243|NCT01153698||patients after hip or knee replacement|
3206244|NCT01153685|Experimental|Fluviral A Group|Subjects aged between 18 and 60 years who received one dose of Fluviral vaccine at Day 0, administered intramuscularly in the deltoid region of the non-dominant arm.
3206245|NCT01153685|Experimental|Fluviral B Group|Subjects over 60 years of age who received one dose of Fluviral vaccine at Day 0, administered intramuscularly in the deltoid region of the non-dominant arm.
3206246|NCT01153672|Experimental|Treatment (enzyme inhibitor therapy, AI sensitization therapy)|Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD, letrozole PO QD, OR exemestane PO QD for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
3206247|NCT01153659|Experimental|1|
3206248|NCT01153659|Active Comparator|2|
3206249|NCT01153659|Active Comparator|3|
3206250|NCT01153646|Experimental|Cohort 1: 1x10e9 and Cohort 2: 1x10e10 T cells per infusion|Group of patients receiving genetically modified T-cells
3206251|NCT01153633|Active Comparator|Prontosan Wound Solution and Gel|Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel. Secondary dressing to be a semi occlusive dressing. Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)
3206252|NCT01153633|Placebo Comparator|Normal Saline and Placebo Gel|Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel. Secondary dressing to be a semi occlusive dressing. Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)
3206253|NCT01153620|Placebo Comparator|Ringer's Solution|
3206254|NCT01153620|Active Comparator|Lavasept 0.04%|
3206255|NCT01153607|Experimental|Arm 1|
3206256|NCT01153607|Experimental|Arm 2|
3206257|NCT01153607|Experimental|Arm 3|
3206258|NCT01153594|Experimental|Recovery Management Checkups (RMC)|Participants in the RMC group are interviewed quarterly. When they were found to be in need of treatment, the participant was transferred from the interviewer to a linkage manager to receive the intervention (described next). They were also able to re-enter treatment on their own and naturally cycle through multiple periods of substance use, treatment, incarceration and recovery.
3206259|NCT01153594|No Intervention|Control Group|Participants in the control group are interviewed quarterly. While they do not receive any active intervention from the research team, they are able to re-enter treatment on their own and naturally cycle through multiple periods of substance use, treatment, incarceration and recovery.
3206260|NCT01153581|Experimental|Ganirelix acetate|Subjects were given 250 μg in 0.5ml normal saline for 16 days. (Organon, Roseland, NJ, USA)
3206261|NCT01153581|Experimental|17β-Oestradiol, E2|The same women added 17β-Oestradiol, E2; 0.2 mg day−1 patch (Vivelle; CIBA Pharmaceuticals, Summit, NJ) for days 4-16.
3206262|NCT01153581|Experimental|Progesterone|The same women added progesterone (P4, 200 mg day−1 Prometrium, oral, Solvay Pharmaceuticals, Marietta, GA, USA) on days 13-16.
3206263|NCT01153568|Placebo Comparator|Placebo|placebo
3206264|NCT01153568|Experimental|Vitamin D 3|Vitamin D3 will be available in doses of 60, 90, 120, and 150 µg
3206265|NCT01153555||Intermediate coronary lesions|"Diagnostic device: FFR~Diagnostic device: IVUS RF~At participating centers, FFR and IVUS are standard of care diagnostic procedures for patients with intermediate (40-80% angiographic stenosis by visual estimate). Both modalities were used regularly for such patients whether or not they are participants in this clinical study. In FIRST, the decision to perform percutaneous coronary intervention (PCI) was left to the discretion of the investigator, and was not dictated by the clinical protocol."
3206266|NCT01153542|Experimental|VX-770|
3206267|NCT01153542|Experimental|desipramine|
3206268|NCT01153529||Group 1|OEF/OIF Veterans
3206311|NCT01153217|Experimental|Abacavir|Switch from tenofovir to abacavir
3206312|NCT01153217|No Intervention|tenofovir|Follow same ART regimen
3206269|NCT01153503|Active Comparator|Ketorolac 30 mg, IV + TAP block|"Ketorolac 30 mg, IV + Bilateral ultrasound-guided TAP blocks at the end of the surgery~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
3206270|NCT01153503|Active Comparator|TAP block|"Intraoperative (at the end of surgery): Bilateral ultrasound-guided TAP block at the end of the surgery~First 24-h Postoperative: IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
3206271|NCT01153503|No Intervention|Ketorolac 30 mg|"Intraoperative (at the end of surgery): Ketorolac 30 mg, IV at the end of the surgery.~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h +IV-PCA morphine.~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
3206272|NCT01153490|Placebo Comparator|Placebo|
3206273|NCT01153490|Active Comparator|Quetiapine ER|
3206274|NCT01153477|No Intervention|TAU|This group is the control group by which we are comparing our intervention. This group will not receive an intervention from us but will continue to be treated at the Intensive Outpatient facility from which we recruited them.
3206275|NCT01153477|Experimental|Counseling (TMAC-E)|This telephone based intervention includes six factors to improve our extended treatment model: Incentive component; Patient choice; Provision of cell phones to those who need them; Social support and community resources; Positive recovery factors; and Outreach following dropout.
3206276|NCT01153464|No Intervention|Treatment As Usual|In this arm, participants are not provided any intervention through the study, they are just followed for research purposes at 3m, 6m, 9m, and 12m post baseline as the comparison group.
3206277|NCT01153464|Experimental|Recovery Support Counseling|This group is eligible to receive the telephone based recovery support counseling from paraprofessionals based out of the City of Philadelphia's Department of Behavioral Health.
3206278|NCT01153451|No Intervention|Usual Care|Responsible inpatient and ambulatory physicians assigned to usual care will not receive any email(s) of patients' test results generated from the notification system.
3206279|NCT01153451|Other|Email Notification|Responsible inpatient and ambulatory physicians will receive automated email(s) of patients' tests results finalized post-discharge generated from the notification system. Finalized results will be batched such that no provider will receive more than one email per day.
3206280|NCT01153438||Gastric bypass, Gastric banding|
3206281|NCT01153425|Active Comparator|Teriparatide (Forteo)|20 µg of Teriparatide will be self-injected subcutaneously once a day for 12 months and an MRI at 3T ('Virtual Bone Biopsy') will be performed at 0 and 12 months.
3206282|NCT01153425|Active Comparator|Zoledronic Acid (Reclast)|5 mg of zoledronic Acid will be administered intravenously at baseline and 12 months and an MRI at 3T ('Virtual Bone Biopsy) will be performed at 0 and 12 months.
3206283|NCT01153412|No Intervention|Control Group|Control group no intervention
3206284|NCT01153412|Experimental|Osteopathic Manipulative Treatment|Osteopathic Manipulative medicine group
3206285|NCT01153399||1|Patients with Non Small Cell Lung Cancer, visiting hospital oncology clinics
3206286|NCT01153386|Experimental|0.5 mg treprostinil diethanolamine|0.5 mg treprostinil diethanolamine
3206287|NCT01153386|Experimental|2.5 mg treprostinil diethanolamine|2.5 mg treprostinil diethanolamine
3206288|NCT01153386|Experimental|1 mg treprostinil diethanolamine|1 mg treprostinil diethanolamine
3206289|NCT01153373|Placebo Comparator|Minimal Intervention Control|"All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only. The reports will not be printed or dynamic referrals generated, and all patients will receive treatment-as-usual by their ED providers."
3206290|NCT01153373|Active Comparator|DARSSA Intervention|All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
3206291|NCT01153360|Experimental|T3|triiodothyronine
3206292|NCT01153360|Active Comparator|cyanocobalamin|vitamin B12
3206293|NCT01153347|Experimental|SSRI/Serotonin/SNRI+ TC-5214 0.5 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 0.5 mg BID
3206294|NCT01153347|Experimental|SSRI/Serotonin/SNRI + TC-5214 2 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 2 mg BID
3206295|NCT01153347|Experimental|SSRI/Serotonin/SNRI + TC-5214 4 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 4 mg BID
3206296|NCT01153347|Placebo Comparator|SSRI/Serotonin/SNRI + Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
3206297|NCT01153334|Experimental|Early intensive rosuvastatin therapy|
3206298|NCT01153334|Placebo Comparator|Conventional statin therapy|
3206299|NCT01153321|Experimental|1|Oral treatment
3206300|NCT01153321|Placebo Comparator|2|Oral treatment
3206301|NCT01153308||Bariatric Surgery Patients|Bariatric Surgery patients at UMass Memorial Medical Center
3206302|NCT01153295|Experimental|Positive diagnosis|The diagnosis of IBS is based on the international ROME III criteria, few blod tests, and abscence of danger signals
3206303|NCT01153295|Active Comparator|Diagnosis of exclusion|The diagnosis of IBS is based on normal extended blood tests, screening for celiac sprue and lactose intolerance, stool for ova and parasites and endoscopy with biopsy
3206304|NCT01153269||HIV-infected patients with hepatitis co-infection|HIV-infected patients with co-infections of Hepatitis B or Hepatitis C
3206305|NCT01153256|Experimental|group M|
3206306|NCT01153256|Placebo Comparator|Group R-0.6|
3206307|NCT01153256|Placebo Comparator|Group R-0.9|
3206308|NCT01153243|Active Comparator|Ergocalciferol|The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)
3206309|NCT01153243|Placebo Comparator|Placebo pill|The investigators will give intervention group 12 weeks of placebo pill (in pill every week)
3206310|NCT01153230||poisoned patient|after patients died the pathological findings evaluated with autopsy
3206313|NCT01153204|Experimental|Group Psychotherapy (GP)|Time-limited group psychotherapy is a technique based on psychodrama, an in-depth method of group psychotherapy. Active methods are used to enable past, present, and future life events to be explored. Sexual issues and their possible solutions are enacted rather than simply discussed. Time-limited group psychotherapy focuses on a central or core issue or a circumscribed area of conflict (psychogenic erectile dysfunction) as the only or major object of intervention efforts.
3206314|NCT01153204|Active Comparator|Sildenafil|Participants took sildenafil citrate 50 mg as needed for sexual activity (on demand), no more than once daily, according to psychiatric prescription. Sildenafil citrate was taken with a glass of water on an empty stomach (at least 2 hours after eating). Participants met with a psychiatrist every month for 30-minutes to report adverse effects and to obtain the following month's dosage of four pills.
3206315|NCT01153204|Active Comparator|Group Psychotherapy (GP) plus Sildenafil|The same as above.
3206316|NCT01153191|Experimental|Pressurized irrigation|first group-After closure of patients abdominal wall fascia, Hydrostatic irrigation with 3 liters of normal saline with Simpulse Solo irrigation system (Davol) at less than 15PSI will be applied to subcutaneous tissues prior to closure
3206317|NCT01153191|Experimental|Sub Q Antibiotic|second group of patients will receive 2mg/lg of gentamicin in 20 ml of sterile saline injected into the superficial tissues above the ABD wall fascia prior to initial incision
3206318|NCT01153165|Experimental|Citalopram|Participants will be commenced on Citalopram 20mgs daily
3206319|NCT01153165|Placebo Comparator|Control|Control group - will receive a matched placebo
3206320|NCT01153139|Experimental|bilateral theta burst stimulation to the DLPFC|intermittent TBS (iTBS) to the left DLPFC continuous TBS (cTBS) to the right DLPFC
3206321|NCT01153139|Placebo Comparator|Sham stimulation|Sham stimulation with a 45° tilted coil
3206322|NCT01153126|No Intervention|No Intervention: Usual Care|A group receiving usual care plus 5 reliable websites
3206323|NCT01153126|Experimental|Intervention|A group using the Comprehensive Health Enhancement Support System (CHESS.)
3206324|NCT01153113|Experimental|Treatment Arm A|• 5x106 cells per infusion administered ID
3206325|NCT01153113|Experimental|Treatment Arm B|• 1x107 cells per infusion administered ID (Treatment arm B).
3206326|NCT01153100|No Intervention|Standard insulin drip therapy|Standard insulin drip therapy
3206327|NCT01153100|Active Comparator|Insulin drip and glargine|Insulin drip and glargine 0.25 units per kg body weight
3206328|NCT01153074|Experimental|Occluder|The patients with bronchopleural fistulas treated with bronchoscopic deployment of the cardiac septal defects occluder.
3206329|NCT01153061|Experimental|Fistula closure with occluder|Patients with benign tracheoesophageal fistulas will be submitted to the correction with the occluder.
3206330|NCT01153048|Experimental|Specific education intervention with peer educators|
3206331|NCT01153048|No Intervention|General education session in the health structure|
3206332|NCT01153035|Other|Surgery followed by RFA|
3206333|NCT01153009|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
3206334|NCT01153009|Experimental|Vortioxetine 15 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 15 mg, encapsulated tablets, orally, once daily for 7 weeks, then placebo-matching capsules, orally, once daily for one week.
3206335|NCT01153009|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 20 mg, encapsulated tablets, orally, once daily for 7 weeks, then placebo-matching capsules, orally, once daily for one week.
3206336|NCT01153009|Active Comparator|Duloxetine 60 mg|Duloxetine 30 mg capsules, orally, once daily for one week then duloxetine 60 mg, capsules, orally, once daily for 7 weeks, then duloxetine 30 mg capsules, once daily, for one week.
3206337|NCT01152996|Experimental|Vortioxetine|Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks.
3206338|NCT01152970||drug-using youth with violent injury|Youth(ages 14-24) who report illicit drug use and who present to an urban ED for an acute violent injury
3206339|NCT01152970||drug-using youth with non-violent injury|Youth(ages 14-24) who report illicit drug use and who present to an urban ED for non-violence related care
3206340|NCT01152957|Experimental|Community Health Worker Model|Care, Attention, Resources, Information, Nutrition and Optimism Project (CARIÑO Project) will provide outreach support services to patients with poorly controlled diabetes, such as health education, lifestyle changes, home visits, follow-up phone calls, support groups, one on one counseling and coaching, and assistance with resource referrals.
3206341|NCT01152931|Active Comparator|COHORT A= Amodiaquine + Artesunate|Amodiaquine will be administered orally at 10mg/kg daily for 3days. Artesunate 50mg will be administered orally daily for 3days.For subjects >6months< 1 years 4mg/kg daily for 3 days
3206342|NCT01152931|Active Comparator|cohort B= Lumefantrine +Artemether|Artemether 20mg/Lumefantrine 120mg fixed combination administered daily for 3 days
3206343|NCT01152931|Experimental|cohort C = Artesunate + vitamin A|Artesunate 50mg daily for 4days. if >6 months< 1 year 4mg/kg daily for 4days + Vitamin A 5000IU daily for 4days if < 1 year and 10,000IU daily for 4days if > 1 year respectively
3206344|NCT01152931|Experimental|Artesunate, vitamin E oral administration|Artesunate 50mg daily for 4 days.if >6 months< 1 year 4mg/kg daily for 4 days + vitamin E 100mg daily administered orally to the experimental group 4 days.
3206345|NCT01152931|Experimental|cohort E will be given Artesunate and Zinc orally|cohort E will be given Artesunate 50mg daily for 4 days. if > 6 months< 1 year 4mg/kg daily for 4 days + zinc gluconate 50mg orally daily for 4 days. if < 1 year 25 mg daily for 4 days
3206346|NCT01152931|Experimental|cohort F= Artesunate and selenium will be given orally|Artesunate 50mg daily for 4 days. if > 6 months< 1 year 4mg/kg daily for 4 days + selenium 100ug daily for 4 days. if < 1 year 50ug daily for 4 days.
3206347|NCT01152931|Experimental|cohort G = Amodiaqiune and Vitamin A will be given orally|Amodiaquine 10mg/kg daily for 3 days + vitamin A 5000iu daily for 4 days if < 1 year. 10,000 IU daily for 4 days if > 1 year.
3206348|NCT01152931|Experimental|cohort H = amodiaquine and vitamin E administerd orally|Amodiaquine 10mg/kg daily for 4 days + vitamin E 100 mg daily for 4 days
3206394|NCT01152632|Placebo Comparator|non-acupoints|Three non-acupoints were chosen,two of which were located on the arm and one one the leg.
3206349|NCT01152931|Experimental|cohort I = Amodiaquine and Zinc will be given orally|Amodiaquine 10mg/kg daily for 4 days + zinc 50mg daily 4 days. if < 1 year 25 mg daily for 4 days.
3206350|NCT01152931|Experimental|Cohort J = amodiaquine and selenium will be given orally|Amodiaquine 10mg/kg daily for 4 days + selenium 100ug daily for 4 days if > 1 year. 50ug daily for 4 days if < 1 year.
3206351|NCT01152931|Experimental|K= Artesunate+ vitamin A + vitamin E|Tab Artesunate 50mg orally dly x 4 days + Vitamin A, 5000IU orally, dly x 4 days if ≤ 1yr. 10,000IU orally dly x 4days if > 1 yr + vitamin E 100 mg orally dly for 4 days
3206352|NCT01152931|Experimental|L = Artesunate+ Vitamin A + Zinc|Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if < 1 year. 10,000IU daily for 4 days if > 1 year. All administered orally.
3206353|NCT01152931|Experimental|M = Artesunate+ Vitamin A + selenium|Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if < 1 year. 10,000IU orally daily for 4 days if > 1 year.
3206354|NCT01152931|Experimental|N = Artesunate + Vitamin E + Zinc|Artesunate 50mg daily for 4 days. vitamin E 100mg daily for 4 days. Zinc 50 mg daily for 4 days if > 1 year. 25 mg daily for 4 days if < 1 year.
3206355|NCT01152931|Experimental|O = Artesunate+ Vitamin E + Selenium|Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if > 1 year. 50 ug orally daily for 4 days if < 1 year.
3206356|NCT01152918|Experimental|Linkage-to-Care Component: Financial Incentive (FI)|HIV test sites will provide financial incentives to encourage linkage to HIV care.
3206357|NCT01152918|Active Comparator|Linkage-to-Care Component: Standard of Care (SOC)|HIV test sites will provide the standard-of-care to their patients for linkage to HIV care.
3206358|NCT01152918|Experimental|Viral Suppression Component: FI|HIV care sites will provide financial incentives to encourage viral load suppression.
3206359|NCT01152918|Active Comparator|Viral Suppression Component: SOC|HIV care sites will provide the standard-of-care to their patients for viral load suppression.
3206360|NCT01152918|Experimental|Prevention for Positives Component: Counseling and SOC|Participants will take part in a computerized HIV risk reduction counseling program and receive SOC for HIV infection.
3206361|NCT01152918|Active Comparator|Prevention for Positives Component: SOC|Participants will receive SOC for HIV infection.
3206362|NCT01152905||Air/TIVA group|The patients received during the anesthesia a mixture of air with 30% oxygen All patients received total intravenous anesthesia (TIVA) using target controlled infusion of propofol and remifentanil.
3206363|NCT01152905||Nitrous oxide/TIVA group|The patients received nitrous oxide with 30% oxygen.All patients received total intravenous anesthesia (TIVA) using target controlled infusion of propofol and remifentanil.
3206364|NCT01152879||Home Parenteral Nutrition|Patients receiving home parenteral nutrition
3206365|NCT01152853|Experimental|single arm|PF00299804 treatment arm
3206366|NCT01152840|Experimental|RAD001|RAD001 daily po medication
3206367|NCT01152827|Experimental|RAD001|RAD001 10 mg daily po medication
3206368|NCT01152814|Experimental|Arm 1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
3206369|NCT01152801|Experimental|RAD001|
3206370|NCT01152788|Active Comparator|rIL-21|
3206371|NCT01152788|Active Comparator|Dacarbazine|
3206372|NCT01152775|Placebo Comparator|No Media|Sixty participants will be randomized into one of two cohorts: 1. No media 2. Yes media
3206373|NCT01152775|Experimental|Yes Media Newly Diagnosed Breast Cancer Pts|Sixty participants will be randomized into one of two cohorts: 1. No media 2. Yes media
3206374|NCT01152762|Experimental|Standardized Respiratory Physiotherapy|Standardized Respiratory Physiotherapy is the intervention in all selected patients
3206375|NCT01152749|Experimental|UNG-GC-2|2 mg experimental NRT product
3206376|NCT01152749|Experimental|UNG-GC-4|4 mg experimental NRT product
3206377|NCT01152749|Active Comparator|Nicorette® Gum-2|2 mg Nicorette® Gum
3206378|NCT01152749|Active Comparator|Nicorette® Gum-4|4 mg Nicorette® Gum
3206379|NCT01152736|Experimental|NSC018|Nicotine
3206380|NCT01152736|Active Comparator|Nicotine Gum|Nicorette® Gum
3206381|NCT01152723|Experimental|UNG-GA|New NRT product
3206382|NCT01152723|Experimental|UNG-GB|New NRT product
3206383|NCT01152723|Active Comparator|Nicorette® Gum|Nicorette® Gum
3206384|NCT01152697|Experimental|Patient Noncompliance|There was only one arm for this study.
3206385|NCT01152684||HIV-Positive Latinos living in San Diego or Tijuana|This is an exploratory study of Latinos living with HIV in the San Diego-Tijuana US-Mexico border region.
3206386|NCT01152671|Experimental|Arm 1|
3206387|NCT01152671|Placebo Comparator|Arm 2|
3206388|NCT01152658|Placebo Comparator|Nacl Injection|"Blood samples (4 test tubes) will be extracted from control groups and 8 test tubes for the trial group. The blood of the trial group will be centrifuged and the platelet fraction extracted and counted (only 4 test tubes).~NACL0.9% solution will be then injected to the control group in sterile conditions under ultrasound control~double blind procedure"
3206389|NCT01152658|Experimental|PRGF|1. Blood samples (4 test tubes) will be extracted from control groups and 8 test tubes for the trial group. The blood of the trial group will be centrifuged and the platelet fraction extracted and counted (only 4 test tubes).2. The enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control.
3206390|NCT01152645|Experimental|ARQ 197|
3206391|NCT01152632|Experimental|specific points of Bladder meridian and Shanjiao meridian|In traditional Chinese acupuncture theory, Bladder meridian and Shanjiao meridian have been considered as the main pathological meridian location of migraine. Meanwhile, specific points on both meridians have been used widely in its treatment for a long time.
3206392|NCT01152632|Experimental|non-specific points of Bladder meridian and Shanjiao meridian|Non-specific points of Shaoyang meridians are also used in cure of migraine. It is conventionally thought to be less effective using non-specific points than specific ones.
3206393|NCT01152632|Active Comparator|specific points of Stomach meridian|Specific points of Stomache meridian for migraine were searched in Chinese ancient data. And this group is set to compare with specific points of Shaoyang meridians for their possible different brain networks.
3206399|NCT01152619|Placebo Comparator|4|
3206401|NCT01152593|Experimental|Intranasal Mupirocin|
3206402|NCT01152580|Placebo Comparator|Sugar pill|
3206403|NCT01152580|Active Comparator|melatonin|
3206404|NCT01152567||ACE|Patients treated for hypertension with ACEs without CVD
3206405|NCT01152567||Candesartan|Patients treated for hypertension with candesartan without CVD
3206406|NCT01152554|Experimental|SSRI/Serotonin/SNRI + TC-5214 1-4 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214 1-4 mg BID
3206407|NCT01152554|Placebo Comparator|SSRI/Serotonin/SNRI + placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + placebo BID
3206408|NCT01152541|Active Comparator|Hypotonic Riboflavin|Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
3206409|NCT01152541|Active Comparator|Riboflavin/dextran|Administration of Riboflavin/dextran every 2 minutes for the duration of UV exposure.
3206410|NCT01152515|No Intervention|Control|stopping of propofol and remifentanil infusion
3206411|NCT01152515|Active Comparator|Remifentanil|stopping of propofol and maintenance of remifentanil infusion
3206412|NCT01152489|No Intervention|Standard Care|Immunizations are given with standard care of no pain control
3206413|NCT01152489|Active Comparator|Experimental|Vibrating device with cold pack held to arm proximal to injections within the same dermatome; caretakers offered and instructed in use of distraction cards.
3206414|NCT01152489|Sham Comparator|Sham Device|The device without batteries or cold pack held to arm proximal to injections. No formal distraction.
3206415|NCT01152476|Active Comparator|group SR|
3206416|NCT01152476|Active Comparator|group S|
3206417|NCT01152450|Experimental|Tiotropium daily dose q.d.|two actuations delivered via Respimat® inhaler
3206418|NCT01152450|Experimental|Tiotropium half daily dose b.i.d.|two actuations delivered via Respimat® inhaler
3206419|NCT01152450|Placebo Comparator|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
3206420|NCT01152437|Experimental|BIBW 2992|Patients receive BIBW 2992 tablets once daily
3206421|NCT01152437|Active Comparator|Cetuximab|Patients receive cetuximab intravenously once a week, every week
3206422|NCT01152424||Acute eosinophilic pneumonia|
3206423|NCT01152424||Community acquired pneumonia|
3206424|NCT01152411|Experimental|Autologous bone marrow stem cells|
3206425|NCT01152398|Experimental|MVA-BN-HER2|
3206426|NCT01152385|Experimental|high|AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)
3206427|NCT01152385|Experimental|Middle|AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)
3206428|NCT01152385|Experimental|low|AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)
3206429|NCT01152385|Placebo Comparator|4|
3206430|NCT01152372|Other|Arm 1|Beta cell function by frequently sampled intravenous glucose tolerance test
3206431|NCT01152372|Other|Arm 2|Modified glucose disposal test assessment of insulin sensitivity, endogenous glucose production and insulin secretion
3206432|NCT01152372|Other|Arm 3|Endogenous glucose production and insulin sensitivity by isotope dilution and isoglycemic, heperinsulinemic clamp
3206433|NCT01152359|Experimental|Arm 1|Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.
3206434|NCT01152359|Active Comparator|Arm 2|Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
3206435|NCT01152346|Other|ARM 1|Sequence- Azacitidine followed by Vidaza®
3206436|NCT01152346|Other|ARM 2|Sequence-Vidaza® followed by Azacitidine
3206437|NCT01152333|Active Comparator|Exendin (9-39) Acetate|Exendin (9-39) is a synthetic peptide that acts as an antagonist to the GLP-1 receptor. Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length at 600-750 pM/kg/min.
3206438|NCT01152333|Placebo Comparator|Saline|Saline 0.9% will be used as the control infusion.
3206439|NCT01152320|No Intervention|Standard of Care|
3206440|NCT01152320|Experimental|Intervention|Spirometry Fundamentals™ CD training program
3206441|NCT01152307|Experimental|Decision Aid|Group receiving the decision aid (DVD/booklet)
3206442|NCT01152307|No Intervention|Control|Group not receiving the decision aid (DVD/booklet)
3206443|NCT01152294|No Intervention|Control|Group not receiving the decision aid (DVD and booklet)
3206444|NCT01152294|Experimental|Decision Aid|Group receiving the decision aid (DVD/booklet)
3206445|NCT01152281|Active Comparator|Maximal Control|Basic awareness messages with stories of people living with AIDS
3206446|NCT01152281|Experimental|Instrumental|Instrumental messages with stories of people living with HIV
3206447|NCT01152281|Experimental|Empowering|Empowering messages with stories of people living with HIV
3206448|NCT01152281|Experimental|Instrumental and Empowering|Instrumental and empowering messages with stories of people living with HIV
3206449|NCT01152281|Active Comparator|Minimal Control|Basic awareness messages with stories of people who are not infected with HIV
3206522|NCT01151735|Placebo Comparator|placebo injection|placebo injection given for prodromal symptoms as double blinded therapy
3206523|NCT01151722|No Intervention|no injection|no bevacizumab
3206450|NCT01152268||Adolescent Male Participants|"Self-report questionnaire data will be collected one time, between Days 1-7 post initiation of cancer therapy(e.g. Days 2-8 of being on-treatment for cancer) among eligible participants and their families who enroll on the study. Patients who agree to participate will be asked to complete a battery of paper and pencil questionnaires (which will also be available on-line if preferred) that assess risk/protective factors for sperm banking. When the banking recommendation is Yes or further assessment required, the profiling and referral tool will be given to the family and instructions for completion will be provided. The tool will include a list of key items which will be based on the most influential barriers to banking sperm."
3206451|NCT01152255|Experimental|Panel A - MK6186 40 mg|MK6186 40 mg
3206452|NCT01152255|Placebo Comparator|Panel A - Placebo|placebo
3206453|NCT01152255|Experimental|Panel B - MK6186 150 mg|MK6186 150 mg
3206454|NCT01152255|Placebo Comparator|Panel B - Placebo|placebo
3206455|NCT01152255|Experimental|Panel C - MK6186 <=150 mg|MK6186 <=150 mg
3206456|NCT01152255|Placebo Comparator|Panel C - Placebo|placebo
3206457|NCT01152255|Experimental|Panel D - MK6186 <=150 mg|MK6186 <=150 mg
3206458|NCT01152255|Placebo Comparator|Panel D - Placebo|placebo
3206459|NCT01152242|Active Comparator|Part 1|Part I of the trial
3206460|NCT01152242|Active Comparator|Part 2|Part II of the trial
3206461|NCT01152229||nuisance bleeding|
3206462|NCT01152229||alarming bleeding|
3206463|NCT01152229||maintenance therapy|
3206464|NCT01152216|Experimental|Dimebon|
3206465|NCT01152203|Experimental|Bendamustine + Bevacizumab|Bendamustine starting dose of 70 mg/m^2 by vein on Days 1 and 2 of a 28 day cycle. Bevacizumab 10 mg/kg by vein on Days 1 & 15 of every 28 day cycle.
3206466|NCT01152190|Experimental|5 milligrams (mg) Tadalafil|
3206467|NCT01152190|Placebo Comparator|Placebo|
3206468|NCT01152177|Active Comparator|Electronic reminders|Electronic reminders
3206469|NCT01152177|No Intervention|Usual care|usual care
3206470|NCT01152164||rectal cancer patients|
3206471|NCT01152151|Active Comparator|Postal reminders|Postal reminders
3206472|NCT01152151|Active Comparator|Electronic reminders|Electronic reminders
3206473|NCT01152138|Active Comparator|Open Cell Stent|Open cell stent (Driver™ or Integrity™,Medtronic), routinely employed during percutaneous coronary interventions for ST elevation acute myocardial infarction
3206474|NCT01152138|Active Comparator|Closed Cell Stent|Closed cell stent (Presillion Plus™, Cordis), routinely employed during percutaneous coronary interventions for ST elevation acute myocardial infarction
3206475|NCT01152125|Experimental|Autologous bone marrow stem cells|
3206476|NCT01152112|Experimental|Treatment, Office Setting, myomectomy|Myomectomy for uterine polyps and/or fibroids occurring in an office setting
3206477|NCT01152112|Experimental|Treatment, Hospital Setting, myomectomy|Myomectomy for uterine polyps and/or fibroids occurring in a hospital setting
3206478|NCT01152099|Active Comparator|GroupA|"Ambulatory treatment is performed during one month. Specific exercises and prevention measures are taught. Multilayer bandage is applied daily during the first four weeks.~The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month,and this time the treatment corresponding to the group B or experimental will be applied."
3206479|NCT01152099|Experimental|GroupB|"Ambulatory treatment is carried out during one month. Specific exercises measures of prevention are taught. MLD is carried out followed by a daily multilayer bandage during the first four weeks. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month, and this time the treatment corresponding to the group A or Control will be applied."
3206480|NCT01152086|Active Comparator|Hiking first|This group first starts with mountain hiking over 9 weeks followed by a 9 weeks control period.
3206481|NCT01152086|Active Comparator|Control first|This group first starts with the control period (9 weeks) followed by the 9 weeks mountain hiking intervention.
3206482|NCT01152073|Placebo Comparator|Placebo|Study participants whose drink formulation contains no active ingredients but will appear and taste similar to the two other formulations. This will form the control formulation
3206483|NCT01152073|Active Comparator|Second Formulation|Study participants' drink formulation will include Red Yeast Rice 600mg, Niacin 12.5mg, Phytosterol esters 650mg, L-Carnitine 150mg, vitamin C 500mg, and Co-Q-10 25mg.
3206484|NCT01152073|Active Comparator|Third Formulation|The third formulation will be identical to the second, but without the Red Yeast Rice.
3206485|NCT01152060||prednisone|
3206486|NCT01152060||prednisone and anti-virus|
3206487|NCT01152047|Experimental|oxytocin, satiety|Oxytocin is given as infusion to examine if this decreases satiety compared to saline during a drinking test
3206488|NCT01152034|Experimental|Psychoeducation group therapy|The structured group program comprised of an initial block of 12 weekly sessions with three additional monthly booster sessions, designed to support participants in the application of knowledge and skills to everyday life situations. All participants also received standard psychiatric care as well.
3206489|NCT01152034|Placebo Comparator|Treat as Usual|Patients who were assigned to the control group received standard psychiatric care and standard pharmacological treatment without group-based psychosocial intervention. Weekly phone calls to the control group over the initial 12 weeks were controlled for any extra contact time with researchers outside of the structured intervention group.
3206524|NCT01151722|Experimental|experimental 2|bevacizumab before vitrectomy
3206525|NCT01151722|Experimental|experimental 3|bevacizumab after vitrectomy
3206490|NCT01152021|Active Comparator|Dexmedetomidine Group|Dexmedetomidine given as 2mcg/kg bolus over 10 minutes followed by 1.5mcg/kg/hr infusion for duration of scan. The bolus may be repeated up to 2 times at any time during the sedation in the event that adequate sedation conditions (minimum Ramsay Sedation Score of 4) are not achieved. In the event that dexmedetomidine is unable to achieve motionless conditions, after a total of 3 boluses, 0.5 mg/kg IV pentobarbital may be administered at q1 minute intervals up to a maximum of 2 mg/kg, per established protocol.
3206491|NCT01152021|Active Comparator|Propofol Group|Propofol bolus at an initial dose of 1 mg/kg over 1 minute then up to two additional 1 mg/kg boluses may be administered (total 3 mg/kg) - each over a one (1) minute interval, waiting 30 seconds after completion of each bolus to reassess sedation level. Once a minimum Ramsey Sedation Score 4 is achieved, an infusion at 125 mcg/kg/min is initiated. It may be titrated to 300 mcg/kg/min. If there is movement or awakening the patient may be rebolused with no more than 2 doses of Propofol at 1 mg/kg over 1 minute, in the same dosing manner as described above, waiting 30 seconds between doses. If adequate sedation is not achieved, 0.5 mg/kg IV pentobarbital may be administered at q1 minute intervals up to a maximum of 2 mg/kg.
3206492|NCT01152008||healthy volunteers|
3206493|NCT01151995||Remote plus on-site|Subjects will have remote source document verification performed 2-4 weeks prior to study monitors scheduled visit and any variables that were not able to be verified remotely will be verified on-site.
3206494|NCT01151995||On-site monitoring|Traditional source document verification will be performed when study monitor is on site
3206495|NCT01151982|Experimental|Psychosocial Intervention|"The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.~We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.~The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.~The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources."
3206496|NCT01151982|No Intervention|Usual Care|The kind of care that general practitioners usually provide when not knowing the level and risk profile of depression of the patients
3206497|NCT01151969|Experimental|New multicomponent intervention|
3206498|NCT01151969|No Intervention|Usual Care|
3206499|NCT01151956||actinic keratosis patients|patients who see their non-hospital based dermatologist, because of multiple actinic keratoses and who are then routinely treated with topical 5% Imiquimod
3206500|NCT01151943|Experimental|Transversus Abdominis Plane (TAP) Block|Patients will receive a bilateral transversus abdominis plane block
3206501|NCT01151943|Active Comparator|Incisional Infiltration of Local Anesthetic|Patients will receive an incisional infiltration with local anesthetic (continuous administration of levobupivacaïne during 48 hours)
3206502|NCT01151917||Bilio-pancreatic diversion|Each subject is own control
3206503|NCT01151904|Experimental|COMBIGAN® with Latanoprost|Patients on current latanoprost monotherapy that qualify for study entry will have COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) added to the latanoprost for 12 additional weeks.
3206504|NCT01151891||Diabetics|Diabetics in the parish of St. James, Jamaica
3206505|NCT01151878|Experimental|Glucomannan|glucomannan preparation in sachets: 1 saschet of 1.26g 2 times per day (daily dosage 2,52g); duration of intervention: 4 weeks
3206506|NCT01151878|Placebo Comparator|Placebo|maltodextrin prepared in sachets (1,3 g per sachet); 2 sachets per day; duration of intervention: 4 weeks
3206507|NCT01151865|Active Comparator|Dexmedetomidine|"Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4."
3206508|NCT01151865|Placebo Comparator|Saline placebo|An identical syringe to that in the intervention arm, but which does not contain dexmedetomidine, will be provided. The initial rate of infusion and subsequent adjustments will be the same as in the dexmedetomidine group.
3206509|NCT01151852|Experimental|Imatinib|Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
3206510|NCT01151852|Placebo Comparator|Placebo|Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
3206511|NCT01151839|Active Comparator|Surgery Alone|
3206512|NCT01151839|Active Comparator|Neoadjuvant chemoradiation followed by surgery|
3206513|NCT01151813|Active Comparator|Varenicline|
3206514|NCT01151813|Placebo Comparator|Placebo|
3206515|NCT01151800|Experimental|IVR group|
3206516|NCT01151800|No Intervention|Usual care|
3206517|NCT01151787|Active Comparator|cyclobenzaprine hydrochloride|
3206518|NCT01151787|Placebo Comparator|placebo|
3206519|NCT01151761|Experimental|SBRT, Chemo and Liver Transplantation|The patients received Stereotactic Body Radiotherapy and Chemotherapy followed by a liver transplantation. The chemo could be any combination of the following: Gemcitabine, Cisplatin, Carboplatin, Capecitabine and 5FU
3206520|NCT01151735|Active Comparator|C-1-esterase inhibitor 1000 units|1000 units of C-1-esterase inhibitor given at time of prodromal symptoms
3206521|NCT01151735|Active Comparator|1500 units of C-1-esterase inhibitor|treatment with 1500 units of C-1-esterase inhibitor IV at the time of prodromal symptoms to decrease risk of exacerbation of HAE
3206617|NCT01151072|Experimental|IDeg s.c. deltoid|
3206526|NCT01151709||physicians|primary care practitioners, both family practice and internal medicine physicians from a random sample of providers nationwide
3206527|NCT01151696|Experimental|hydroxyzine|Patients will receive intravenous hydroxyzine 1mg/kg at the beginning of the morphine titration protocol, and intravenous morphine 0.15 mg/kg then 0.05 mg/kg if necessary, every 5 minutes.
3206528|NCT01151696|Placebo Comparator|Placebo|Patients will receive intravenous placebo at the beginning of the morphine titration protocol, and intravenous morphine 0.15 mg/kg then 0.05 mg/kg if necessary, every 5 minutes.
3206529|NCT01151683|Active Comparator|Magnesium|Magnesium chelate 600 mg per day
3206530|NCT01151683|Placebo Comparator|Placebo|Placebo 4 capsules per day
3206531|NCT01151670|Experimental|Arm I|Pioglitazone 22.5 mg once daily by mouth
3206532|NCT01151670|Experimental|Arm 2|Pioglitazone 45 mg once daily by mouth
3206533|NCT01151657|Placebo Comparator|Placebo|Capsules containing maltodextrin.
3206534|NCT01151657|Experimental|Probiotics|Probiotics containing the 3 strains: Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12 in the dose of 2 x 109 - 10 x 109 CFU/capsule. The patients are to take 2x2 capsules a day.
3206535|NCT01151644|Active Comparator|VACCINATION OF PATIENTS|
3206536|NCT01151644|Active Comparator|VACCINATION OF HEALTHY CONTROLS|
3206537|NCT01151631|Active Comparator|100% occipital nerve stimulation|Stimulation frequency and pulse width will be uniformly held constant at 60 Hz and pulse width at 450 ms. The perception and discomfort amplitude will be defined by increasing the stimulation amplitude in steps of 0.1 V. The amplitude at which the patient starts feeling paraesthesis is called the perception threshold. The threshold at which the patient does not want the voltage to be increased any further because of painful sensations is designated the discomfort threshold. 100% stimulation is defined as stimulation at 90% of the range between perception and discomfort thresholds.
3206538|NCT01151631|Sham Comparator|30% occipital nerve stimulation|30% stimulation means a stimulation level at 30% of the range between perception threshold and 100% stimulation level
3206539|NCT01151605|Experimental|obese|20 obese subjects
3206540|NCT01151605|Active Comparator|lean|20 lean subjects
3206541|NCT01151605|Experimental|type 2 diabetes|20 type 2 diabetes
3206542|NCT01151579|Active Comparator|Levalbuterol 0.63|Patients received an initial dose of levalbuterol 0.63 mg alternating with albuterol 2.5 mg.
3206543|NCT01151579|Active Comparator|Levalbuterol 1.25|Patients received an initial dose of levalbuterol 1.25 mg alternating with albuterol 2.5 mg.
3206544|NCT01151566||Renal Compromise|Those referred for CT scan with identified renal compromise necessitating use of no contrast agent
3206545|NCT01151566||Sensitivity to CT Contrast Agents|Those referred for CT scan with prior demonstration of contrast sensitivity requiring use of no contrast
3206546|NCT01151553|Other|Patients with CHF with CRT Therapy|Patients with CHF with CRT Therapy
3206547|NCT01151540|Experimental|1|
3206548|NCT01151527||Sporadic (idiopathic) or familial interstitial pneumonia|We are recruiting patients with Idiopathic Pulmonary Fibrosis and other types of Idiopathic Interstitial Pneumonias that occur sporadically or familial (2 or more affected individuals in a family). Participation can be done by mail or visiting Duke University Medical Center (Durham, NC)or National Jewish Health (Denver, CO).
3206549|NCT01151514||nrHA-AKI patients|Patients with hospital-acquired acute kidney injury not referred to the nephrologists
3206550|NCT01151514||lrHA-AKI patients|Patients with hospital-acquired acute kidney injury whao are late referred to the nephrologists
3206551|NCT01151501|Experimental|noninvasive positive pressure ventilation|
3206552|NCT01151488|Experimental|Resistance Training|16 weeks of moderate intensity resistance training, 3x/week
3206553|NCT01151449|Experimental|Treatment (gamma-secretase/Notch signalling pathway inhibitor)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3206554|NCT01151436|Experimental|hyaluronic acid|
3206555|NCT01151423|Experimental|anti-vWF Nanobody|
3206556|NCT01151423|Placebo Comparator|Placebo|
3206557|NCT01151410|Experimental|Aliskiren|Patients will receive one of the following doses based on the their weight: Low weight (≥20 to <50 kg) patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg Mid weight (≥50 to <80 kg) patients: Starting dose 75 mg with optional titration to 150 and then 300 mg High weight (≥80 to ≤150 kg) patients: Starting dose 150 mg with optional titration to 300 and then 600 mg
3206558|NCT01151410|Active Comparator|Enalapril|Patients will receive one of the following doses based on their weight: Low weight (≥20 to <50 kg) patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg Mid weight (≥50 to <80 kg) patients: Starting dose 5 mg with optional titration to 10 and then 20 mg High weight (≥80 to ≤150 kg) patients: Starting dose 10 mg with optional titration to 20 and then 40 mg
3206559|NCT01151397|Active Comparator|Peg + Vitamin D + Ribavirin|Peg + Vitamin D + Ribavirin for 3 months
3206560|NCT01151397|Active Comparator|Peg + Ribavirin|Peg + Ribavirin for 6 months
3206561|NCT01151384|Experimental|LE-DT|
3206562|NCT01151371|Experimental|narafilcon B daily disposable 4 weeks|narafilcon B soft contact lenses worn daily on a daily disposable/replacement schedule, for 4 weeks
3206563|NCT01151371|Active Comparator|nelfilcon A daily disponsable 1 week|nelfilcon A soft contact lenses worn daily on a daily disposable/replacement schedule, for 1 week
3206564|NCT01151371|Active Comparator|lotrafilcon B daily wear, monthly replacement, 4-weeks|lotrafilcon B soft contact lenses worn daily on a 1-month replacement schedule, for 4 weeks
3206565|NCT01151345|Experimental|diltiazem|
3206566|NCT01151319|Experimental|Stage 1.|The first stage will start from a low and well tolerated, but likely less immunogenic dose of ChAdV63.HIVconsv (n=2).
3206567|NCT01151319|Experimental|Stage 2|The highest dose of ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0 and 8, respectively (n=8). Followed up at 6,12 and 24 months after last vaccination.
3206568|NCT01151319|Experimental|Stage 3|Three doses of pSG2.HIVconsv DNA followed by boost with high dose ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0,4,8,12 and 20, respectively (n=8). Followed up at 6, 12 and 24 months after last vaccination.
3206618|NCT01151072|Experimental|IDeg s.c. thigh|
3206569|NCT01151319|Experimental|Stage 4|Three doses of pSG2.HIVconsv DNA followed by boost with MVA.HIVconsv followed by boost with high dose ChAdV63.HIVconsv at weeks at week 0,4,8,12 and 16, respectively (n=8).
3206570|NCT01151319|Placebo Comparator|Stage 2 Placebo|Time-course matched to vaccinations (n=2)
3206571|NCT01151319|Placebo Comparator|Stage 3 placebo|Time-course matched to vaccinations (n=2)
3206572|NCT01151319|Placebo Comparator|Stage 4 placebo|Time-course matched to vaccinations (n=2)
3206573|NCT01151306|Placebo Comparator|Lactose tablet|
3206574|NCT01151306|Active Comparator|Simvastatin 20mg|
3206575|NCT01151280|Experimental|WallFlex Biliary Fully Covered Stent|All eligible patients entered into the study will be treated with a WallFlex Biliary Fully Covered Stent
3206576|NCT01151267|Other|Control Arm|The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation >97% and end tidal CO2 at 35-45mmHg.
3206577|NCT01151267|Active Comparator|HSH Group|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
3206578|NCT01151254|Active Comparator|PA-Intravenous Sedation|Propofol based total intravenous anesthesia and postoperative sedation
3206579|NCT01151254|Active Comparator|Volatile sedation|Total inhalational anesthesia and postoperative sedation with the AnaConda device
3206580|NCT01151241|Experimental|Early discharge|Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.
3206581|NCT01151241|Active Comparator|Normal Discharge|Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
3206582|NCT01151228|Placebo Comparator|Zero volume|Patients will not ingest any apple juice prior to the second ultrasound.
3206583|NCT01151228|Experimental|50 mL|Patients will ingest 50 mL apple juice prior to the second ultrasound.
3206584|NCT01151228|Experimental|100 mL|Patients will ingest 100 mL apple juice prior to the second ultrasound.
3206585|NCT01151228|Experimental|200 mL|Patients will ingest 100 mL apple juice prior to the second ultrasound.
3206586|NCT01151228|Experimental|300 mL|Patients will ingest 300 mL apple juice prior to the second ultrasound.
3206587|NCT01151228|Experimental|400 mL|Patients will ingest 400 mL apple juice prior to the second ultrasound.
3206588|NCT01151215|Experimental|1|AZD8931 40mg (bd) plus anastrozole 1mg (od)
3206589|NCT01151215|Experimental|2|AZD8931 20mg (bd) plus anastrozole 1mg (od)
3206590|NCT01151215|Placebo Comparator|3|Placebo (bd) plus anastrozole 1mg (od)
3206591|NCT01151202|Experimental|AG NPP709 syrup|AG NPP709 contains Ivy leaf extract and coptis rhizoma extract
3206592|NCT01151202|Active Comparator|Ivy leaf extract syrup|
3206593|NCT01151189|Placebo Comparator|Placebo|The placebo is a licensed product manufactured by Allermed, Inc. and is used for evaluation of delayed-type of hypersensitivity reactions in adults.
3206594|NCT01151189|Experimental|MVA85A/AERAS-485|MVA85A/AERAS-485 is a recombinant modified vaccinia virus Ankara expressing the M. tuberculosis antigen, Ag85A. Dosage of the study vaccine to be administered will be 1x10^8 pfu.
3206595|NCT01151176|Active Comparator|Insulin|Intensive Insulin Therapy
3206596|NCT01151176|Other|Regular Insulin|Sub Cutaneous Regular Insulin
3206597|NCT01150916|Active Comparator|Heart failure|Patients must fulfill Framingham and/or Boston criteria for heart failure and have systolic or diastolic disfunction in rest echocardiography.
3206598|NCT01150916|Active Comparator|Liver Cirrhosis|Patients must have a biopsy proven diagnosis of liver cirrhosis or the diagnosis established on clinical basis in cases of known etiology of liver disease, peripheral signs of chronic liver disease, esophageal varices at endoscopy and an imaging method with evidence of cirrhosis.
3206599|NCT01150916|Active Comparator|Other causes of ascites|Patients must fulfill stringent diagnostic criteria for the cause of ascites, by clinical criteria, laboratory and imaging tests and histology when appropriate.
3206600|NCT01150916|Active Comparator|Concurrent heart failure and cirrhosis|Patients must fulfill the aforementioned criteria for both conditions.
3206601|NCT01150851|Active Comparator|caloric restriction|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration
3206602|NCT01150851|Active Comparator|aerobic exercise|supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
3206603|NCT01150851|Active Comparator|caloric restriction and aerobic exercise|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration, and supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
3206604|NCT01150851|No Intervention|usual diet and usual activity|usual diet and usual activity
3206605|NCT01150838|Experimental|Propofol administration|"Propofol 2 mg/kg administered to first subject. Dose will be increased by 0.3 mg/kg for the next subject if intubation score is not excellent. Dose will be decreased by 0.3 mg/kg if intubation score is excellent. This dosing scheme will be continued."
3206606|NCT01150747||Risk of positive chlamydia|"current, untreated endocervical C. trachomatis infection~mucopurulent cervicitis on pelvic examination~Sexual contact with a male partner recently diagnosed with C. trachomatis, and/or non-gonococcal urethritis"
3206607|NCT01149226|Placebo Comparator|placebo control|
3206608|NCT01149226|Experimental|oral medication chloral hydrate|
3206609|NCT01151137|Experimental|Dronedarone|Dronedarone 400 mg twice a day until the CSED
3206610|NCT01151137|Placebo Comparator|placebo|Placebo (for Dronedarone) twice a day until the CSED
3206611|NCT01151124|Experimental|CTX0E03 DP|human neural stem cell product, once only injection, increasing doses
3206612|NCT01151098|Experimental|BTDS 5, 10 or 20|Buprenorphine transdermal patch
3206613|NCT01151085||Voriconazole|Subjects who are treated with voriconazole
3206614|NCT01151072|Experimental|IDeg i.m. thigh|
3206615|NCT01151072|Experimental|IDeg i.v.|
3206616|NCT01151072|Experimental|IDeg s.c. abdomen|
3206619|NCT01151059|Other|Group 1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
3206620|NCT01151046|Experimental|MM-121 (SAR256212) + exemestane|
3206621|NCT01151046|Placebo Comparator|Placebo + exemestane|
3206622|NCT01151033|Experimental|stent implantation|ProNOVA XR Polymer Free Drug Eluting Stent implantation - single arm
3206623|NCT01151020|Experimental|Arm 1|Zenith® TX2® Low Profile TAA Endovascular Graft (Thoracic Aortic Aneurysm)
3206624|NCT01151007||Patients with colorectal carcinoma|Patient with colorectal carcinoma operated in Martinique between January 1st, 2007 and December 31st, 2009
3206625|NCT01150994|No Intervention|Treatment as Usual|
3206626|NCT01150994|No Intervention|Screening Alone|Enhanced screening among ED patients
3206627|NCT01150994|Experimental|Safety Assessment and Follow-up Telephone Intervention|SAFTI: Safety Assessment in the ED combine with a Follow-up Telephone Intervention.
3206628|NCT01150981|Experimental|Rosiglitazone|One 8mg capsule daily for 6 weeks.
3206629|NCT01150981|Placebo Comparator|Placebo|One capsule daily for 6 weeks.
3206630|NCT01150968|Experimental|Internal Medicine Residents|All UCSf Internal Medicine residents for 2009-2010
3206631|NCT01150955|Active Comparator|Resveratrol|Dietary supplement of resveratrol 500 mg three times a day over five weeks.
3206632|NCT01150955|Placebo Comparator|Placebo|
3206633|NCT01150942|Experimental|vero cell-derived JE vaccine|vero cell-derived vaccine group
3206634|NCT01150942|Active Comparator|Mouse brain-derived JE vaccine|Mouse brain-derived JE vaccine group
3206635|NCT01150929|Active Comparator|Fixed bearing|One of the 2 used implants.
3206636|NCT01150929|Active Comparator|Rotating platform|One of the 2 used implants.
3206637|NCT01150903||PDE5 inhibitor prescription|
3206638|NCT01150903||Age-matched Control|
3206639|NCT01150890|Experimental|AMG 827 IV 350 MG|350 mg AMG 827
3206640|NCT01150890|Experimental|AMG 827 IV 700 MG|700 mg AMG 827
3206641|NCT01150890|Placebo Comparator|PLACEBO|Placebo
3206642|NCT01150890|Experimental|AMG 827 IV 210 MG|210 mg AMG 827
3206643|NCT01150877|Experimental|Experimental Dietary Supplement (e.g., vitamins, minerals)|Experimental arm is supplemented with high-dose of vitamin D.
3206644|NCT01150877|No Intervention|No Intervention|
3206645|NCT01150864|Active Comparator|Passive Humidifier|The Passive Humidifier (HME)will changed every 24 hours
3206646|NCT01150864|Active Comparator|Active-Passive humidifier|The Active-Passive Humidifier will be changed every 24 hours
3206647|NCT01150864|Active Comparator|Hot Water Humidifier|Hot water humidifier will be set at 36-37 °C
3206648|NCT01150825||STEMI|Patients with ST segment elevation myocardial infarction, verified by elevated troponin levels
3206649|NCT01150825||NSTEMI|Patients with non-ST segment elevation myocardial infarction, verified by elevated levels of troponin
3206650|NCT01150812|Experimental|1|
3206651|NCT01150786|Experimental|selenium|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
3206652|NCT01150786|Placebo Comparator|placebo capsule|The patients in this arm took one placebo capsule daily for 12 weeks.
3206653|NCT01150760||Alvimopan Users|
3206654|NCT01150760||Matched controls|
3206655|NCT01150695|Experimental|Group A (DVC-LVS)|Single dose of the Dynport Vaccine Company Live Vaccine Strain (DVC-LVS) product in one arm and normal saline (NS) control in the other arm on Day 0.
3206656|NCT01150695|Experimental|Group B (USAMRIID-LVS)|Single dose of the United States Army Medical Research Institute of Infectious Diseases Live Vaccine Strain (USAMRIID-LVS) product in one arm and normal saline (NS) control in the other arm on Day 0.
3206657|NCT01150669||Observational|Cryopreserved specimens are studied in vitro with lestaurtinib with or without chemotherapy agents. Samples are analyzed for FLT3 protein expression and/or activation; sensitivity to lestaurtinib with or without chemotherapy agents; and activation of STAT, AKT, and RAS-MAPK and other pathways by western blot. The most effective treatment from this study is then validated in vivo in a NOD/SCID xenograft model.
3206658|NCT01150630|Experimental|adjuvant PEXG|cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 6 months
3206659|NCT01150630|Experimental|perioperative PEXG|cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 3 months before surgery and 3 months after surgery
3206660|NCT01150630|Active Comparator|Adjuvant Gemcitabine|Adjuvant Gemcitabine at 1000 mg/mq for 3 weeks every 4 weeks for 6 months
3206661|NCT01150617|Active Comparator|long-acting insulin plus analogues|three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening.
3206662|NCT01150617|Active Comparator|long-acting insulin and oral agents|treatment will be once-daily long-acting insulin and oral antidiabetic agents
3206663|NCT01150604|Experimental|Self-help course|
3206664|NCT01150578||Lexi-Echo pilot|Appropriate patients at University of Arizona Medical Center stress imaging laboratory who have a routine regadenoson SPECT nuclear scan will have simultaneous cardiac echo images obtained.
3206665|NCT01150565|Experimental|LiRIS low dose|The first dose group of approximately 10 patients receive low dose LiRIS on Day 1 to Day 14.
3206666|NCT01150565|Experimental|LiRIS high dose|The second dose group of approximately 10 patients receive high dose LiRIS on Day 1 to Day 14.
3206667|NCT01150552||Poultry exposed individuals|Any individual who had an occupational contact with poultry in the previous five years will be considered exposed. Individuals working on poultry farms, poultry wet markets, or keeping limited numbers of poultry in their backyard, are considered exposed.
3206668|NCT01150552||Non-poultry exposed adult controls|Unexposed individuals must have no occupational exposure to poultry in their lifetime and must also not be exposed to poultry purchased from live bird markets.
3206669|NCT01150539|Experimental|Overweight/obese women with PCOS|10 overweight/obese women with polycystic ovary syndrome
3206670|NCT01150526|Placebo Comparator|Placebo|Oral Placebo capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
3206671|NCT01150526|Experimental|CaHMB Pre|Oral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
3206672|NCT01150526|Experimental|CaHMB Pre and Post|Oral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A CaHMB capsule and placebo gel dosage are are then administered 3 times daily during the remainder of the study.
3206673|NCT01150526|Experimental|HMB Free Acid Gel Pre|Oral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
3206674|NCT01150526|Experimental|HMB Free Acid Gel Pre and Post|Oral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and HMB free acid gel dosage are then administered 3 times daily during the remainder of the study.
3206675|NCT01150513|Active Comparator|EC-T|
3206676|NCT01150513|Experimental|TP|
3206677|NCT01150500|Experimental|Drug Eluting Stent|Up to two lesions in two separate target vessels may be treated under this protocol. The lesions should be amenable to treatment with at least one 2.25 mm stent, a second lesion could be treated with any stent from 2.25 to 3.5 mm.
3206678|NCT01150487|Experimental|Sensitized Renal Allograft Recipients|Patients who have antibodies against their donors in their blood.
3206679|NCT01150474|Experimental|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
3206680|NCT01150474|Placebo Comparator|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
3206681|NCT01150461|Experimental|losartan|Losartan 50 mg b.i.d.
3206682|NCT01150461|Placebo Comparator|placebo|Placebo b.i.d.
3206683|NCT01150448|Experimental|001|Paliperidone palmitate Treatment A All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
3206684|NCT01150448|Experimental|002|Paliperidone palmitate Treatment B Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq patients who do not wish to have multiple blood samples collected will also be assigned to Treatment B
3206685|NCT01150435||Maintenance Medication D, S- Methadon|
3206686|NCT01150435||Maintenance Medication S- Methadon|
3206687|NCT01150435||Buprenorphine|
3206688|NCT01150435||Buprenorphine+ Naloxone|
3206689|NCT01150422|No Intervention|Standard of care for post medical abortion follow-up|Standard of care includes a routine hospital visit two weeks after mifepristone administration. At the hospital visit, the woman will undergo a bimanual and vaginal ultrasound examination. In the event the woman fails to return for the follow-up visit, each hospital will follow their standard procedure for contacting women who fail to attend their follow-up visit, i.e. three efforts to contact the woman. Form 2a will document the results of any clinical examinations, any additional medical abortion-related care given and the abortion outcome. At the follow-up visit, women will also be asked about the acceptability of current medical abortion follow-up procedures and their future preferences.
3206690|NCT01150422|Active Comparator|Alternative follow-up|"At their first clinic visit, women will be asked to provide their phone number for contact purposes. Women will also be asked to complete a semi-quantitative pregnancy test in the clinic and the results of the test will be noted on a study form. After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist.~Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned date two weeks after mifepristone administration. The checklist will indicate that if the woman answers yes to any of the questions, then she should return to the clinic for a follow-up visit. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests."
3206691|NCT01150409|Experimental|hydrocortisone|Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
3206692|NCT01150409|Placebo Comparator|Normal Saline (placebo)|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
3206693|NCT01150383|Active Comparator|group RO (Room air / Oxygen)|RO (Room air / Oxygen): First 6 weeks of exercise training under normoxic conditions (Room air), followed by 6 weeks of exercise training with oxygen supplementation.
3206694|NCT01150383|Active Comparator|group OR (Oxygen / Room air)|OR (Oxygen / Room air): First 6 weeks of exercise training with oxygen supplementation, followed by 6 weeks of exercise training under normoxic conditions (room air).
3206695|NCT01150370|Experimental|Males undergoing circumcision|
3206696|NCT01150357|Experimental|Low Dose Aliskiren|Participants received body-weight stratified dose of aliskiren capsules (6.25/12.5/25 mg) once daily. Participants whose body weight ≥ 20 kilogram (kg) to less than < 50 kg received 6.25 mg; ≥50 kg and < 80 kg received 12.5 mg and ≥ 80 kg and ≤ 150 kg received 25 mg of aliskiren.
3206697|NCT01150357|Experimental|Mid dose|Participants received body-weight stratified dose of aliskiren capsules (37.5/75/150 mg) once daily. Participants whose body weight ≥ 20 kg to < 50 kg received 37.5 mg; ≥50 kg and < 80 kg received 75 mg and ≥ 80 kg and ≤ 150 kg received 150 mg of aliskiren.
3206698|NCT01150357|Experimental|High dose|Participants received body-weight stratified dose of aliskiren capsules (150/300/600 mg) once daily. Participants whose body weight ≥ 20 kg to < 50 kg received 150 mg; ≥50 kg and < 80 kg received 300 mg and ≥ 80 kg and ≤ 150 kg received 600 mg of aliskiren.
3206699|NCT01150344|Active Comparator|Malarone|"Malarone (atovaquone + proguanil combination):~patients treated with Malarone®"
3206700|NCT01150344|Active Comparator|Riamet|"RIAMET (artemether + LUMEFANTRIN combination):~patients treated with Riamet®"
3206701|NCT01150331|Experimental|Clonazepam + levetiracetam|Clonazepam IV 1 mg+ levetiracetam IV 2500 mg
3206702|NCT01150331|Active Comparator|Clonazepam + placebo|Clonazepam IV 1 mg + placebo levetiracetam IV
3206703|NCT01150318|Experimental|1|Patients treated by 131 iodine for thyroid cancer
3206704|NCT01150305||1|Patient presenting familial dominant non syndromic hearing loss starting between 4 and 40 years old, over 2 generations
3206705|NCT01150305||2|Healthy volunteer from the same families
3206706|NCT01150292|Experimental|DHA - Sunflower oil|400 mg DHA supplementation by day for 2 weeks then placebo for 2 weeks after a wash out period of 6 to 9 weeks
3206707|NCT01150292|Experimental|Sunflower oil - DHA|Placebo during 2 weeks then 400 mg DHA supplementation by day for 2 weeks after a wash out period for 6 to 9 weeks
3206708|NCT01150266|Experimental|Alteplase|Alteplase 0.9mg/kg (maximum 90mg), 10% IV bolus over 1 minute and the remainder over one hour infusion in patients with ischemic stroke after awaking.
3206709|NCT01150253|Experimental|probiotic fermented milk|
3206710|NCT01150253|Placebo Comparator|placebo|
3206711|NCT01150240||Primary Immunodeficiency Disease|Patients with primary Immunodeficiency disease (PID)
3206712|NCT01150214||DE-MRI|All patients will undergo Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI)to quantify the degree of atrial structural remodeling or fibrosis pre-ablation and DE-MRI will be obtained at 3, 6, and 12 months follow-up to detect and quantify ablation-related scar formation.
3206713|NCT01150201|Experimental|Aliskiren|Aliskiren
3206714|NCT01150201|Active Comparator|Losartan|ARB
3206715|NCT01150188|Active Comparator|Amino acids|Amino acid supplementation between meals for eight weeks
3206716|NCT01150188|Placebo Comparator|Placebo|Supplementation of placebo (inert components) between meals for eight weeks
3206717|NCT01150175|Experimental|Autologous bone marrow cells|
3206718|NCT01150175|Placebo Comparator|Plasma|
3206719|NCT01150162|Experimental|Mucosta and Omeprazole|
3206720|NCT01150162|Active Comparator|Omeperazole|
3206721|NCT01150149|No Intervention|1|
3206722|NCT01150149|Experimental|2|No face touch
3206723|NCT01150149|Experimental|3|Surgical face mask
3206724|NCT01150149|Experimental|4|Surgical face mask + no face touch
3206725|NCT01150136||1|Children with proven CF and known genotype, age 0-17 yr
3206726|NCT01150123|Experimental|5 µg_No Adj|Subjects received either 1 or 2 doses of active vaccine (5 µg) without any adjuvant
3206727|NCT01150123|Experimental|20 µg_No Adj|Subjects received either 1 or 2 doses of active vaccine (20 µg) without any adjuvant.
3206728|NCT01150123|Experimental|5 µg_Alum|Subjects received either 1 or 2 doses of active vaccine (5 µg) with Alum adjuvant.
3206729|NCT01150123|Experimental|20 µg_Alum|Subjects received either 1 or 2 doses of active vaccine (5 µg) with Alum adjuvant.
3206730|NCT01150123|Experimental|5 µg_MF59-H|Subjects received either 1 or 2 doses of active vaccine (5 µg) adjuvanted with 4.87 mg of MF59
3206731|NCT01150123|Experimental|20 µg_MF59-H|Subjects received either 1 or 2 doses of active vaccine (20 µg) adjuvanted with 4.87 mg of MF59
3206732|NCT01150123|Experimental|5 µg_MF59-F|Subjects received either 1 or 2 doses of active vaccine (5 µg) adjuvanted with 9.75 mg of MF59
3206733|NCT01150123|Experimental|20 µg_MF59-F|Subjects received either 1 or 2 doses of active vaccine (20 µg) adjuvanted with 9.75 mg of MF59
3206734|NCT01150123|Placebo Comparator|Placebo|Subjects received 2 injections of placebo administered 1 month apart
3206735|NCT01150097|Experimental|Everolimus + reduced tacrolimus|Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.
3206736|NCT01150097|Experimental|Tacrolimus elimination|Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.
3206737|NCT01150097|Active Comparator|Tacrolimus control|Participants were maintained on a whole blood trough level of 6 - 10 ng/mL tacrolimus.
3206738|NCT01150084|Experimental|lunchtime walking|
3206739|NCT01150084|Other|waiting-list control|
3206740|NCT01150071||Children born extremely preterm|national cohort of children born before 28 weeks' gestational age or with a birthweight less than 1000 g. 365 eligible survivors
3206741|NCT01150045|Active Comparator|Arm A - FOLFOX and placebo (12 treatments)|Patients receive FOLFOX every 2 weeks plus placebo every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
3206742|NCT01150045|Experimental|Arm B - FOLFOX and celecoxib (12 treatments)|Patients receive FOLFOX every 2 weeks plus celecoxib every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
3206743|NCT01150045|Active Comparator|Arm C - FOLFOX and placebo (6 treatments)|Patients receive FOLFOX every 2 weeks plus placebo every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
3206744|NCT01150045|Experimental|Arm D - FOLFOX and celecoxib (6 treatments)|Patients receive FOLFOX every 2 weeks plus celecoxib every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
3206745|NCT01150032||Osteopenic women|Women with osteopenia: Bone Mineral Density T-score between -1.0 and -2.5 (for whom with clinical factor risk) or -3.0 (for whom without clinical factor risk)
3206746|NCT01150019||Obese Group|
3206747|NCT01150019||Non Obese Group|
3206748|NCT01150006||Healthy male participants|
3206749|NCT01149993|Experimental|pre-transplant immunosuppression|subjects in this arm will receive Myfortic 720mg twice daily for 7 days prior to transplantation. Intra-operatively, the donor kidney will receive an infusion of Thymoglobulin, prior to the transplantation.
3206750|NCT01149993|Experimental|pre-transplant induction|subjects in this arm will not receive any pre-transplant immunosuppression. However, the donor kidney will receive an infusion of Thymoglobulin prior to transplantation.
3206751|NCT01149993|Active Comparator|standard of care|subjects in this arm will not receive any pre-transplant immunosuppression, and the donor kidney will not receive an additional dose of Thymoglobulin prior to transplantation. This is the standard of care protocol for Georgetown University Hospital
3206752|NCT01149980|Experimental|Citalopram|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's
3206753|NCT01149980|Active Comparator|Celexa|Celexa 40 mg Tablets of Forest Labs
3206754|NCT01149967|Experimental|Citalopram|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's
3206755|NCT01149967|Active Comparator|Celexa|Celexa 40 mg Tablets of Forest Labs
3206756|NCT01149954|Experimental|Ibuprofen|Ibuprofen 200 mg gel Capsules of Dr. Reddy's laboratories Limited
3206757|NCT01149954|Active Comparator|Advil|Advil liquigels 200 mg gel capsules of Wyeth Consumer Healthcare
3206758|NCT01149941|Experimental|Ibuprofen|Ibuprofen 200 mg gel Capsules of Dr. Reddy's laboratories Limited
3206759|NCT01149941|Active Comparator|Advil|Advil liquigels 200 mg gel capsules of Wyeth Consumer Healthcare
3206760|NCT01149928||C/S delivered, wet lung|
3206761|NCT01149928||C/S delivered, healthy infants|
3206762|NCT01149889|Experimental|active stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
3206763|NCT01149876|Experimental|Nu Skin Product|
3206764|NCT01149876|Experimental|Nu Skin product with galvanic spa system|
3206765|NCT01149876|Active Comparator|Tretinoin cream 0.05|
3206766|NCT01149876|Placebo Comparator|over the counter moisturizer|
3206767|NCT01149863|Experimental|Plerixafor 17 hours prior to apheresis|Dosing of plerixafor will occur at 3PM (1500 hours).
3206768|NCT01149850|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks and oral temozolomide on days 1-5. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
3206769|NCT01149837||residual blood donor samples|Protocol describes testing an HTLV-I/II antibody reactive population from this cohort using the InnoLIA HTLV I/II Score line immunoassay
3206770|NCT01149824|Other|Dose Escalating|
3206771|NCT01149811||Fipamezole ODT Cohort 1|
3206772|NCT01149811||Fipamezole ODT Cohort 2|
3206773|NCT01149798|Experimental|Abraxane and Cisplatin combination|Abraxane and Cisplatin combination
3206774|NCT01149785|Experimental|1|There should be at least 14-day washout period between treatment A and B.
3206775|NCT01149772|Experimental|ACCESS|Medically ill patients received six-sessions of cognitive behavioral therapy tailored to their unique needs. Patients received 2 core modules and 3 elective modules. Elective modules focused on physical health, cognitive restructuring, behavioral activation, and relaxation. The six session was a wrap up that everyone received. Patients also had the option to receive 2 follow-up booster sessions to aid in maintenance of skills learned.
3206776|NCT01149772|No Intervention|Enhanced Usual Care|Patients in this arm received feedback about their physical and emotional health functioning and were still able to receive usual primary care services.
3206777|NCT01149759|Experimental|Cyclosporine A|5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks.
3206778|NCT01149746|Experimental|Tamsulosin|0.4 mg Capsule
3206779|NCT01149746|Active Comparator|Flomax®|0.4 mg Capsule
3206780|NCT01149733|Experimental|Tamsulosin|0.4 mg Capsule
3206781|NCT01149733|Active Comparator|Flomax®|0.4 mg Capsule
3206782|NCT01149720|Experimental|ARQ 197 Capsule, oral|Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
3206783|NCT01149720|Experimental|ARQ 197 Tablet, oral|Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
3206784|NCT01149720|Experimental|ARQ 197 Capsule D, oral|Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
3206785|NCT01149707|Experimental|PUR 0110 Rectal Enema 250 mg|Active treatment
3206786|NCT01149707|Experimental|PUR 0110 Rectal Enema 500 mg|Active treatment
3206787|NCT01149707|Experimental|PUR 0110 Rectal Enema 1000 mg|Active treatment
3206788|NCT01149707|Placebo Comparator|Placebo Enema|Placebo comparator
3206789|NCT01149694|Other|Cohort 1|
3206790|NCT01149694|Other|Cohort 2|
3206791|NCT01149694|Other|Cohort 3|
3206792|NCT01149694|Other|Cohort 4|
3206793|NCT01149681|Experimental|Group A|
3206794|NCT01149668|Experimental|PCI-24781|
3206795|NCT01149655|Experimental|Phase 1|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
3206796|NCT01149655|Experimental|Phase 2|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
3206797|NCT01149655|Placebo Comparator|Phase 3|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg) or placebo
3206798|NCT01149642|Experimental|Oral immunomodulatory solution|The oral supplement is a 74g sachet containing 302 kcal and 16.7g proteins as well as immunonutrients such as L-Arginine, ARN and omega-3.
3206799|NCT01149642|Placebo Comparator|Placebo|The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
3206800|NCT01149629|Active Comparator|Fed Dosing|Subjects fed a high calorie, high fat meal prior to receiving 3 x 100mg capsules
3206801|NCT01149629|Active Comparator|Fasted Dosing|Subjects fasted prior to receiving 3 x 100mg capsules
3206802|NCT01149629|Active Comparator|Bioequivalence|Subjects fasted prior to receiving 1x 300mg capsule
3206803|NCT01149629|Active Comparator|TID Dosing|Droxidopa 300 mg given TID
3206804|NCT01149616|Active Comparator|Intervention|Dexamethasone 8mg iv x 1
3206805|NCT01149616|Placebo Comparator|Placebo|placebo
3206806|NCT01149603|Experimental|Implantation of the HeartMate II VAD|Consenting patients who meet the study inclusion and exclusion criteria will be implanted with a HeartMate II ventricular assist device.
3206807|NCT01149590|Experimental|CT Calcium Score & Coronary Angiography|CT Scan
3206808|NCT01149590|No Intervention|No CT Scan|No CT Scan
3206809|NCT01149577|Experimental|Schizophrenia patients|The study population of 25 schizophrenia patients constituted the active arm of the study.
3206894|NCT01148849|Experimental|MGAH22|Anti-HER2 monoclonal antibody (margetuximab)
3206895|NCT01148836|Experimental|Coenzyme Q 10 and Pulmonary Hypertension|PAH subjects to take Co-Q daily for three months
3206901|NCT01148797|Experimental|Canakinumab|
3206810|NCT01149564|Placebo Comparator|IV ibuprofen|The first dose of either oral or IV ibuprofen will be given at the time the patient is randomized.The subsequent doses of indometacin or ibuprofen are also determined according to the echocardiographic PDA flow patterns at intervals of once every 24 hours from the last dose. The dosage of both oral ibuprofen (Ibuprofen suspension, 20 mg/ml, Yung Shing Co., Taiwan) and IV ibuprofen (PedeaR 20 mg/ml, developed by Orphan Europe and approved by the EMEA) are an initial dose of 10 mg/kg and then 5 mg/kg at 24-hour intervals as indicated by PDA flow pattern.
3206811|NCT01149564|Active Comparator|Oral ibuprofen|
3206812|NCT01149551||Group 1|
3206813|NCT01149538|Experimental|Choline Bitartrate|Choline Bitartrate supplementation
3206814|NCT01149538|Placebo Comparator|Placebo|Placebo for choline bitartrate supplementation
3206815|NCT01149525|Experimental|1|oral solution of L-Carnitine, 4g per day
3206816|NCT01149525|Placebo Comparator|2|Similar oral solution without L-Carnitine
3206817|NCT01149512||LAGB patients in Weight Wise Program|All patients seen within the Weight Wise program and selected for surgical management, who have undergone LAGB will be included in this analysis.
3206818|NCT01149499|Experimental|Valacyclovir|Test 1000 mg Valacyclovir Tablet
3206819|NCT01149499|Active Comparator|Valtrex|Reference Listed 1000 mg Valtrex Tablet
3206820|NCT01149486|Experimental|Generic Test Product|Losartan potassium/Hydrochlorothiazide 100/25 mg Tablets
3206821|NCT01149486|Active Comparator|Reference Listed Drug|Hyzaar® 100/25 mg Tablets
3206822|NCT01149473|Experimental|Generic Test Product|Losartan potassium/Hydrochlorothiazide 100/25 mg Tablets
3206823|NCT01149473|Active Comparator|Reference Listed Drug|Hyzaar® 100/25 mg Tablets
3206824|NCT01149460|Experimental|Valacyclovir|Test 1000 mg Tablet
3206825|NCT01149460|Active Comparator|Valtrex|Reference Listed Valacyclovir 1000 mg Tablet
3206826|NCT01149434|Experimental|Pharmacokinetic Arm|Patients going on Pharmacokinetic arm will receive JI-101 & Everolimus (4 patients only)
3206827|NCT01149434|Experimental|Pharmacodynamic arm|Patients going on the Pharmacodynamic study will receive JI-101 only.
3206828|NCT01149421|Experimental|1.5 milligram (mg) LY2189265|LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
3206829|NCT01149421|Experimental|0.75 milligram (mg) LY2189265|LY2189265: 0.75 milligram (mg), subcutaneous (SC), once weekly (QW)
3206830|NCT01149421|Placebo Comparator|Placebo|Placebo: subcutaneous (SC), once weekly (QW)
3206831|NCT01149408|Experimental|All patients|All participants enrolled.
3206832|NCT01149395|Experimental|Dexlansoprazole|
3206833|NCT01149382||islet cell transplant recipients|
3206834|NCT01149369|Active Comparator|Aprepitant|Aprepitant 125 mg per day
3206835|NCT01149369|Placebo Comparator|Aprepitant-placebo|Placebo aprepitant 125mg per day
3206836|NCT01149356|Experimental|Arm I|Patients receive oral exemestane once daily on days 1-21 and oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3206837|NCT01149356|Active Comparator|Arm II|Patients receive exemestane as in arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3206838|NCT01149343|Experimental|GSK2302025A Cohort 1|Male or female patients with histologically proven cutaneous melanoma received the investigational Low-Dose (LD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
3206839|NCT01149343|Experimental|GSK2302025A Cohort 2|Male or female patients with histologically proven cutaneous melanoma received the investigational Middle-Dose (MD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
3206840|NCT01149343|Experimental|GSK2302025A Cohort 3|Male or female patients with histologically proven cutaneous melanoma received the investigational High-Dose (HD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
3206841|NCT01149343|Experimental|GSK2302025A Cohort 4|In Phase 2 of the study subjects received the optimal investigational dose-level identified in Phase 1. Patients received a treatment consisting of 24 injections of the experimental GSK2302025A immunotherapeutic.
3206842|NCT01149330|Experimental|Adapalene-BPO Gel|
3206843|NCT01149317|Experimental|Acupuncture|Weekly acupuncture treatment for up to 14 weeks
3206844|NCT01149304|Experimental|Group A|Medication group with patients receiving the study medication according to the study protocol for 8 weeks after HDR brachytherapy.
3206845|NCT01149304|No Intervention|Group B|Comparison group with patients receiving the standard therapy of HDR brachytherapy without the study specific medication.
3206846|NCT01149291||End stage renal disease patients|
3206847|NCT01149278|Active Comparator|high pressure|
3206848|NCT01149278|Placebo Comparator|normal pressure|
3206849|NCT01149265|Experimental|Online support group|
3206850|NCT01149265|Active Comparator|Expressive writing|
3206851|NCT01149252|Placebo Comparator|Psoralait|
3206896|NCT01148836|Experimental|Coenzyme Q 10 and Normal Controls|Normal controls to take Co-Q daily for three months
3206897|NCT01148823|Experimental|Postoperative day 1|Dressing was removed on the first postoperative day
3206898|NCT01148823|Experimental|Postoperative day 6|Dressing was removed on the 6th postoperative day
3206899|NCT01148810|Placebo Comparator|Placebo|
3206900|NCT01148810|Experimental|BAF312|
3206852|NCT01149213|Experimental|Transcranial Direct Current Stimulation|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~The patient will receive tDCS every other week during the first three months, then once a month during the next three months."
3206853|NCT01149200|Experimental|TC-6499|
3206854|NCT01149200|Placebo Comparator|Placebo|
3206855|NCT01149187||IGRA in solitary pulmonary nodules|Inpatients who undergo percutaneous needle biopsy for diagnosis of pulmonary nodules in Seoul National University hospital for six months are going to be included. Patients who are not tolerable for PCNB or do not agree the enrollment of study will be excluded.
3206856|NCT01149174|No Intervention|transurethral resection alone|Patients with non-muscle invasive bladder cancer who underwent transurethral resection alone;
3206857|NCT01149174|Active Comparator|intravesical mitomycin-C|Patients with non-muscle invasive bladder cancer who underwent one intravesical instillation of mitomycin-C immediately after transurethral resection
3206858|NCT01149174|Experimental|electromotive mitomycin-C|Patients with non-muscle invasive bladder cancer who underwent single immediate intravesical instillation of electromotive mitomycin-C immediately before transurethral resection
3206859|NCT01149161|Active Comparator|C group|Routine central neck dissection
3206860|NCT01149161|No Intervention|N group|No central neck node dissection
3206861|NCT01149148|Active Comparator|Intervention INVOS Cerebral Oximetry Monitoring|Intervention will be initiated if rSO2 drops > 20% from baseline or rSO2 declines below 50%.
3206862|NCT01149148|Active Comparator|Standard of Care|Blinded cerebral oximetry monitoring with no intervention in surgical procedures and anesthesia without deviation from standard of care.
3206863|NCT01149135|Active Comparator|Standard light treatment|standard light treatment 5000K; 10 000 lux
3206864|NCT01149135|Experimental|blue enriched light|Blue enriched light with a low intensity (750 lux)
3206865|NCT01149122|Active Comparator|Gemcitabine/Oxaliplatin with Erlotinib|
3206866|NCT01149122|Active Comparator|Gemcitabine/Oxaliplatin without Erlotinib|
3206867|NCT01149109|Experimental|lomustine (CCNU) + temozolomide (TMZ) and radiotherapy|60 Gy standard radiotherapy (RT, 30 x 2 Gy) Six 42-day courses of oral CCNU 100 mg/m2 (day 1) and oral TMZ 100 mg/m2 (day 2-6), first CCNU application during the first week of RT CCNU/TMZ and radiotherapy start 2-5 weeks after diagnosis (day of surgery for glioblastoma (GBM)). In courses 2-6, TMZ dose are adjusted according to the hematotoxicity observed in the previous course and can be increased stepwise up to 200 mg/m2/day
3206868|NCT01149109|Active Comparator|temozolomide and radiotherapy|60 Gy standard radiotherapy (RT, 30 x 2 Gy) and concomitant TMZ therapy (daily TMZ 75 mg/m2) starting with the first day of radiotherapy Six 28-day courses of TMZ (day 1-5) starting 4 weeks after completion of radiotherapy. In the first course TMZ is given at a dose of 150 mg/m2/day, in case no toxicity is observed, the 2nd course is applied at a daily dose of 200 mg/m2
3206869|NCT01149096||Arm I (conventional bone marrow harvest)|Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
3206870|NCT01149096||Arm II (filgrastim, bone marrow harvest)|Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
3206871|NCT01149083|Experimental|Arm I (veliparib)|Patients receive veliparib PO BID on days 1-21.
3206872|NCT01149083|Experimental|Arm II (veliparib, carboplatin)|Patients receive carboplatin IV over 30 minutes on day 1 and veliparib as in Arm I.
3206873|NCT01149057|Experimental|Single Arm|
3206874|NCT01149044|Active Comparator|Upfront Thrombectomy followed by PCI|Upfront manual aspiration thrombectomy followed by PCI
3206875|NCT01149044|Active Comparator|PCI Alone|PCI without upfront manual aspiration thrombectomy
3206876|NCT01149031|Active Comparator|low level laser therapy, using a probe|"The treatment will be done by using a LLL-probe touching several areas of the vulvar vestibule, according to the selected protocol.~Every patient will be treated twice weekly for 6 weeks."
3206877|NCT01149031|Placebo Comparator|Placebo|The patients will be treated with placebo-probe, according to the same protocol
3206878|NCT01149018|Experimental|Tetrahydrocannabinol|
3206879|NCT01149018|Placebo Comparator|Placebo|
3206880|NCT01149005|Experimental|insulin|patients who will get insulin with main meals during Intravenous (IV) antibiotic therapy due to pulmonary exacerbation
3206881|NCT01148992|Active Comparator|Lofexidine|
3206882|NCT01148992|Placebo Comparator|Placebo|
3206883|NCT01148979|Experimental|Adjunct Lisdexamfetamine (Vyvanse)|Participants receive Lisdexamfetamine Dimesylate 20-50 mg capsule each morning for 4 weeks. After a washout period of 2 weeks, they receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) capsule) each morning for 4 weeks.
3206884|NCT01148979|Placebo Comparator|Adjunct Placebo|Participants receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) 20-50 mg capsule) each morning for 4 weeks. After a washout period of 2 weeks, they receive Lisdexamfetamine Dimesylate capsule each morning for 4 weeks.
3206885|NCT01148966|Experimental|Treatment (photodynamic therapy)|Patients receive aminolevulinic acid PO 4 hours before undergoing surgery.
3206886|NCT01148953|Active Comparator|ALN-TTR01|
3206887|NCT01148953|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3206888|NCT01148927||Adult acute lymphoblastic leukemia patients|
3206889|NCT01148914||Baseline level of biomarkers|
3206890|NCT01148901|Experimental|Remicade|Infliximab 5 mg/kg was administered as specified in the Summary of Product Characteristics for patients with ankylosing spondylitis
3206891|NCT01148888|Experimental|Magnesium Sulfate|The study will be conducted in the 45 minute interval between the completion of spinal instrumentation and the completion of skin closure. Once the spinal instrumentation is complete and the integrity of the spinal cord pathways is confirmed using SEPs and MEPs, magnesium will be administered for the remainder of surgery.
3206892|NCT01148862|Other|Group A|Group A will wear the MiniMed Paradigm® X54 System with the Low Glucose Suspend (LGS) feature activated
3206893|NCT01148862|Other|Group B|Group B will wear the MiniMed Paradigm® X54 System with the Low Glucose Suspend (LGS) feature deactivated
3206902|NCT01148784|Active Comparator|Quadrupled Hamstring Allograft|
3206903|NCT01148784|Active Comparator|Doubled Tibialis Anterior Allograft|
3206904|NCT01148771|Experimental|Ertapenem 1 gram intravenous (IV) 5 minute bolus|Participants received ertapenem 1 gram every 24 hours for 3 doses with each dose infused as a 5 minute IV bolus.
3206905|NCT01148771|Active Comparator|Ertapenem 1 gram IV 30 minute infusion|Participants received ertapenem 1 gram every 24 hours for 3 doses with each dose infused as a 30 minute infusion (i.e., the standard dose).
3206906|NCT01148758|Experimental|Single Arm|
3206907|NCT01148745|Other|ferumoxytol|FDA approved drug
3206908|NCT01148732||Patient needed intubation in emergency department|
3206909|NCT01148719|Active Comparator|Index group|Patients in the index group receive the diagnostic triage instrument. This includes echocardiographic, electrocardiographic and spirometric measurements and blood testing.
3206910|NCT01148719|No Intervention|Control|Participants receive care as usual.
3206911|NCT01148706|Experimental|ActiSight Needle Guidance System|
3206912|NCT01148693|Active Comparator|gentamicin|adding 10mg gentamicin to every 10 ml of contrast media
3206913|NCT01148693|Placebo Comparator|Placebo|Identical placebo
3206914|NCT01148680|Experimental|immediate registration on islet graft list|"group 1 'immediate registration on infusion waiting list' : patients who will be immediately registrated on islet cell infusion waiting list after randomization.~Intervention : Procedure/surgery (islet graft)"
3206915|NCT01148680|Active Comparator|delayed registration on islet graft list|"group 2 'delayed registration on infusion waiting list' : patients who will be registrated 6 months later on islet cell infusion waiting list after randomization.~Intervention : Procedure/surgery (islet graft)"
3206916|NCT01148667|Active Comparator|Infants drink formula added with LGG|Infants have been randomized (1:1) to get casein hydrolysate with or without LGG
3206917|NCT01148667|Placebo Comparator|Infants drink casein hydrolysate without LGG|Infants get extensively hydrolysed casein formula
3206918|NCT01148654||1- Preterm Labor 22.0-33.6 weeks gestational age|Pregnant women between 22.0 and 33.6 weeks gestational age presenting to the Hospital of the University of Pennsylvania (HUP) complaining of Preterm labor (PTL), preterm premature rupture of membranes (PPROM), or cervical insufficiency (CI).
3206919|NCT01148654||2- Preterm birth 34-36.6 weeks gestational age|Pregnant women delivering at the University of Pennsylvania between 34.0 and 36.6 weeks gestational age
3206920|NCT01148641||LNS-regular|Lipid-based nutrient supplement, regular (peanut) flavor
3206921|NCT01148641||LNS-cinnamon|Lipid-based nutrient supplement, cinnamon flavor
3206922|NCT01148628|Experimental|RAD 001 in combination with CaelyxTM|"RAD001 will be given p.o. at increasing doses (no intra-patient)and CaelyxTM will be administered i.v. at a fixed dose.~At each dose level 3 to 6 patients will be entered, according to toxicities observed; the first 3 patients can be treated simultaneously; subsequent patients can be treated after the first 3 have been observed for at least one cycle (4 weeks).~The dose escalation process will be discontinued once the MTD has been achieved and the RD will be evaluated in a subsequent expansion part of the study."
3206923|NCT01148615|Experimental|Aflibercept/ docetaxel|"Patients with advanced cancer will receive different doses of aflibercept in combination with approved dose of docetaxel.~Aflibercept 4 or 6mg/kg over 1 hour IV immediately followed by Docetaxel 75mg/m2 IV over 1 hour on Day 1, every 3 weeks"
3206924|NCT01148602|No Intervention|'Off Clock'|"Stopwatch timers will NOT be used for off clock weeks, so patients presenting with hyperacute stroke will be managed normally without the visual timer."
3206925|NCT01148602|Active Comparator|"'On Clock"|"LED stopwatch-clock timers will be posted for all patients presenting during ON clock weeks. All patients presenting with hyperacute stroke will be managed normally with the addition of a visual stopwatch timer."
3206926|NCT01148576|Other|control group|patients only with chronic hepatitis B
3206927|NCT01148576|Active Comparator|model group|patients with chronic hepatitis B and hepatic steatosis
3206928|NCT01148576|Experimental|Essentiale group|patients with chronic hepatitis B and hepatic steatosis
3206929|NCT01148576|Experimental|treatment group 2|patients with chronic hepatitis B and hepatic steatosis
3206930|NCT01148563|No Intervention|Standard Care|The Standard Care group will continue regular LSU HCSD disease management care for heart failure patients with no additional intervention.
3206931|NCT01148563|Active Comparator|Tele-health Monitoring Group|The tele-monitoring intervention group will have the continual standard care from their physician plus the tele-health monitoring. The tele-health monitor will collect the following data: weight, blood pressure, pulse oximetry, pulse rate, & patient responses to disease-specific questions regarding changes in state of health for 6 months.
3206932|NCT01148550||Group 1|Mitochondrial Hepatopathy Disease Group
3206933|NCT01148550||Group 2|Subjects with Suspected Mitochondrial Hepatopathy who do not meet the enrollment criteria for Group 1 Subjects with Suspected Mitochondrial Hepatopathy who do not meet the enrollment criteria for Group 1
3206934|NCT01148537|Experimental|BTDS|Buprenorphine transdermal patches 5, 10, 20, and 2 * 20 mcg/h.
3206935|NCT01148537|Placebo Comparator|Placebo TDS|Matching placebo transdermal patches 5, 10, 20 and 2 * 20.
3206936|NCT01148537|Active Comparator|Moxifloxacin|Moxifloxacin hydrochloride 400 mg tablets
3206937|NCT01148524|Other|rMenB06|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 6 months) and placebo (at 1 and 2 months) in V72P10 study had a blood draw.
3206938|NCT01148524|Other|rMenB0|Subjects who had received 1 dose of rMenB+OMV-NZ (at 0 month) and 3 doses of placebo (at 1, 2 and 6 months) in V72P10 study had a blood draw.
3206939|NCT01148524|Other|rMenB016|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 1 and 6 months) and 1 dose of placebo (at 2 months) in V72P10 study had a blood draw.
3206940|NCT01148524|Other|rMenB01|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 1 month) and placebo (at 2 and 6 months) in V72P10 study had a blood draw.
3206941|NCT01148524|Other|rMenB026|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 2 and 6 months) and 1 dose of placebo (at 1 month) in V72P10 study had a blood draw.
3206942|NCT01148524|Other|rMenB02|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 2 months) and placebo (at 1 and 6 months) in V72P10 study had a blood draw.
3207068|NCT01147627|Active Comparator|pioglitazone|
3206943|NCT01148524|Other|rMenB012|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 1 and 2 months) and 1 dose of placebo (at 6 months) in V72P10 study had a blood draw.
3206944|NCT01148524|Other|rMenB6|Subjects who had received 1 dose of rMenB+OMV-NZ (at 6 months) and 3 doses of placebo (at 0, 1 and 2 months) in V72P10 study had a blood draw.
3206945|NCT01148524|Other|Naive|An additional study group of naïve subjects that served as a baseline comparator for assessing antibody persistence in the vaccine groups and had blood draw for serological analyses at the time of enrollment.
3206946|NCT01148511|Experimental|Treat and Extend|Patients received ranibizumab 0.5 mg intravitreally (ivt) once a month for 3 months. If the disease was inactive 4 weeks later, the next visit was postponed 2 weeks to 6 weeks later. If the disease was inactive during subsequent visits, the next visit was postponed an additional 2 weeks to 8 weeks later, the maximum interval between visits. If the disease became active at any visit, the patient received ranibizumab 0.5 mg ivt and the follow-up schedule started over.
3206947|NCT01148511|Active Comparator|Treat and Observe|Patients received ranibizumab 0.5 mg intravitreally (ivt) once a month for 3 months. All subsequent visits occurred monthly. If the disease was active, the patient received ranibizumab 0.5 mg ivt. If the disease was inactive, no treatment was administered and the patient was instructed to return 1 month later.
3206948|NCT01148498|Experimental|Group 1|Older adults with mild Dementia Alzheimer's Type (DAT)
3206949|NCT01148498|Experimental|Group 2|Older adult controls with possible Alzheimer's Disease Pathology
3206950|NCT01148498|Experimental|Group 3|Older adult controls with no evidence of Alzheimer's Disease
3206951|NCT01148498|Experimental|Group 4|Younger subjects who are assumed to have no cognitive impairment
3206952|NCT01148472|Experimental|Escitalopram|
3206953|NCT01148472|Active Comparator|Duloxetine|
3206954|NCT01148459|Experimental|Group A|Infants enrolled to this group will receive 3 doses of the experimental vaccine.
3206955|NCT01148459|Active Comparator|Group B|Infants enrolled to this group will receive 3 doses of the rabies comparator vaccine.
3206956|NCT01148446|Experimental|R-CHOP|R-CHOP (every 21 days) for six courses Cyclophosphamide: 750 mg/m2, IV, day 1 Doxorubicin: 50 mg/m2, IV, day 1 Vincristine: 1.4 (max 2) mg/m2, IV, day 1 Prednisone: 75 mg/m2, IV, days 1-5 Rituximab: 375 mg/m2, IV, day 1 G-CSF: 300 µg tota, SC; days 7-11
3206957|NCT01148446|Experimental|R-mini-CEOP|R-miniCEOP (every 21 days)for six courses Cyclophosphamide: 50 mg/m2, IV, day 1 Epirubicin: 50 mg/m2, IV, day 1 Vinblastine: 5 mg/m2, IV, day 1 Prednisone: 60 mg/m2, IV/PO, days 1-5 Rituximab: 375 mg/m2, IV, day 1 G-CSF: 300 µg tota, SC; days 7-11
3206958|NCT01148433||TESTIM® - drug given by prescription|Male patients with Hypogonadism
3206959|NCT01148420|Experimental|DMPA & MPA|150 mg intramuscularly received DMPA and two 10 mg tablets of MPA every 8 hours for 3 days
3206960|NCT01148394|No Intervention|Traditional|Involves traditional management of patients with preoperative mechanical bowel preparation, no preoperative education, nasogastric tube, delayed feeding and mobilisation, use of drains
3206961|NCT01148394|Active Comparator|Multimodal rehabilitation|Involves preoperative patient education, no preoperative mechanical bowel preparation, no nasogastric tube, early oral feeding and mobilisation, physiotherapy
3206962|NCT01148368|Experimental|renal impairment patients|renal impairment patients who eGFR is lower than 30 ml/min/1.73m^2 without hemodialysis
3206963|NCT01148368|Active Comparator|healthy volunteers|healthy volunteers group
3206964|NCT01148329||Single arm observational study|To evaluate real world clinical outcomes data for the PROMUS™ Element™ Coronary Stent System in unselected patients in routine clinical practice
3206965|NCT01148316|Active Comparator|Fluoxetine|drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
3206966|NCT01148316|Active Comparator|Group cognitive-behavioral therapy|weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
3206967|NCT01148303|Experimental|Etoricoxib First|This arm will receive etoricoxib for six days, followed by placebo for eight days.
3206968|NCT01148303|Experimental|Etoricoxib Second|This arm will get placebo for eight days before beginning their fast, followed by etoricoxib for six days.
3206969|NCT01148290|Active Comparator|Tension free vaginal tape|
3206970|NCT01148290|Experimental|Bulking agent injection|
3206971|NCT01148277|Active Comparator|Propofol and Remifentanyl|Propofol, colonoscopies, liver diseases, cirrhosis
3206972|NCT01148277|Active Comparator|midazolam and fentanyl|midazolam and fentanyl, colonoscopies, liver diseases
3206973|NCT01148277|Experimental|control midazolam anf fentanyl|midazolam anf fentanyl
3206974|NCT01148264|Experimental|olanzapine|
3206975|NCT01148264|Active Comparator|metoclopramide|
3206976|NCT01148238||Diabetes type 1 older than 10 years|Blood samples will be taken from 10 patients with diabetes type 1 older than 10 years and 10 healthy age-and sexmatched controls.
3206977|NCT01148238||Newly diagnosed type 1 diabetes|Blood samples will be taken from 10 patients with newly diagnosed type 1 diabetes and 10 healthy age-and sexmatched controls.
3206978|NCT01148238||LADA|Blood samples will be taken from 10 patients with LADA and 10 healthy age-and sexmatched controls.
3206979|NCT01148225|Other|adalimumab|"This study is a Phase 3, open-label multicenter study designed to evaluate long-term safety and efficacy of adalimumab in adult subjects with non-infectious intermediate-, posterior-, or pan-uveitis who have either discontinued from study M10-877 or M10-880 for having met Treatment Failure criteria or have successfully completed study M10-877 or M10-880.~Starting at Baseline, all subjects will receive open label adalimumab 40 mg eow SC regardless of treatment assignment in the randomized, double-masked studies M10-877 or M10-880."
3206980|NCT01148199|Active Comparator|Multiple plastic stents|Multiple plastic stents placement after sphincterotomy and stricutre dilation. ERCP repeated every 3 - 4 months during 1-year
3206981|NCT01148199|Experimental|Self-expandable metalic stent|Self-expandable metalic stent after sphincterotomy. Stent removal scheduled for 6 months
3207021|NCT01147861|Other|5mg BID|Subjects will receive 1 x 5mg tablet and 1 placebo tablet in the morning, and 1 x 5mg tablet and 1 placebo tablet in the evening on Day 1 and Day 2.
3207022|NCT01147861|Other|10mg QD|Subjects will receive 2 x 5mg tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
3206982|NCT01148186|Experimental|Educational intervention|Administration of an educational intervention to inform patients of the risks and safe alternatives to their current potentially inappropriate medication. The textual content of this knowledge transfer tool will be divided into three parts: a) presentation of the evidence-based risks associated with the targeted potentially inappropriate medication (e.g. benzodiazepines); b) presentation of evidence-based equally or more effective therapeutic substitutes for the medical condition (e.g. insomnia and anxiety); and c) presentation of evidence based tapering recommendations where applicable.
3206983|NCT01148186|No Intervention|Wait-list group|
3206984|NCT01148173|Experimental|Systemic and intrathecal chemotherapy|
3206985|NCT01148160||1|Patients with hematologic malignancies who were given voriconazole to treat invasive (pulmonary) aspergillosis at Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
3206986|NCT01148147|Placebo Comparator|Placebo|Intracoronary Placebo administration
3206987|NCT01148147|Active Comparator|Adenosine|Intracoronary adenosine administration
3206988|NCT01148134||Bcr-Abl positive ALL|
3206989|NCT01148134||Bcr-Abl negative ALL|
3206990|NCT01148108|Experimental|Mantle Cell Lymphoma|Patients with relapsed or refractory mantle cell lymphoma
3206991|NCT01148108|Experimental|Diffuse Large B Cell Lymphoma|Patients with relapsed or refractory diffuse large B cell lymphoma
3206992|NCT01148108|Experimental|Multiple Myeloma|Patients with relapsed or refractory multiple myeloma
3206993|NCT01148095|Experimental|1|AZD2516 (dose escalating)
3206994|NCT01148095|Placebo Comparator|2|Placebo
3206995|NCT01148069|Experimental|Surgery combined with IMRT-IGRT|
3206996|NCT01148056|Experimental|Short course IMRT|Patients will receive short course IMRT (Intensity Modulated Radiation Therapy) prior to surgery. Dose will be 5 Gy x 5, followed by surgery the week after
3206997|NCT01148043|Placebo Comparator|Placebo|
3206998|NCT01148043|Experimental|Hydroxychloroquine|
3206999|NCT01148030||Single|3M Skin and Nasal Antiseptic
3207000|NCT01148017|Experimental|ACWY - 4|Subjects who had previously received 4 doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in the parent study during their first year of life are administered one booster dose of the same vaccine at 60 months of age.
3207001|NCT01148017|Experimental|ACWY - 2|Subjects who had previously received 1 or 2 doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in the parent study during their second year of life, are administered one booster dose of the same vaccine at 60 months of age.
3207002|NCT01148017|Other|Naïve - 40|Control subjects, age-matched with the intervention groups subjects (40 months of age), to receive 1 optional dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
3207003|NCT01148017|Active Comparator|Naïve - 60|Control subjects, age-matched with the intervention groups subjects (60 months of age), are administered one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
3207004|NCT01147978|Experimental|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
3207005|NCT01147978|No Intervention|Usual Procedure|Usual discharge procedure from the ICU
3207006|NCT01147965|Experimental|Ad5 CEA Vaccine|Single arm dose escalation study
3207007|NCT01147952|Experimental|12 week exercise training|
3207008|NCT01147952|No Intervention|Conventional Care|
3207009|NCT01147939|Experimental|Elacytarabine|
3207010|NCT01147939|Active Comparator|Investigator's Choice|
3207011|NCT01147926|Placebo Comparator|Placebo|Placebo
3207012|NCT01147926|Active Comparator|Prucalopride|1 milligram (mg) or 2 mg
3207013|NCT01147913|Experimental|Positive Interpretation Training|Four sessions of positive information-processing training for interpretation of ambiguous scenarios relevant to themes of depression.
3207014|NCT01147913|Sham Comparator|Attention Control Training|"Four sessions of interpretation training for filler or neutral scenarios, unrelated to themes associated with depression."
3207015|NCT01147900|Experimental|Boostrix-REF Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, reference formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
3207016|NCT01147900|Experimental|Boostrix-US Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, United States(US)-marketed formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, US-marketed formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
3207017|NCT01147900|Experimental|Boostrix-INV Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, investigational formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
3207018|NCT01147887|Experimental|001|Drug combination/ 26489112 On Day 1 and on Day 19 a single oral dose of a drug combination consisting of midazolam (2 mg/mL liquid) tolbutamide (a 500 mg tablet) and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21 a single oral dose of two 26489112 tablets will be taken.
3207019|NCT01147874|No Intervention|psoriatic arthritis (PsA) questionnaire|
3207020|NCT01147861|Placebo Comparator|Placebo|Subjects will receive 2 placebo tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
3207023|NCT01147861|Other|25mg BID|Subjects will receive 1 x 25mg tablet and 1 placebo tablet in the morning, and 1 x 25mg tablet and 1 placebo tablet in the evening on Day 1 and Day 2.
3207024|NCT01147861|Other|50mg QD|Subjects will receive 2 x 25mg tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
3207025|NCT01147848|Experimental|Fluticasone furoate/Vilanterol (GW642444)|Fluticasone furoate/vilanterol inhalation powder once daily + placebo inhalation powder twice daily for 24 weeks
3207026|NCT01147848|Active Comparator|Fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol inhalation powder twice daily + placebo inhalation powder once daily for 24 weeks
3207027|NCT01147835|Placebo Comparator|Placebo Lollipop|The placebo group will ingest the same herbal lollipop formula without the active ingredient.
3207028|NCT01147835|Experimental|Chinese Licorice Root|The experimental group will ingest the herbal lollipop formula with the active ingredient.
3207029|NCT01147822|Experimental|Pazopanib|800 mg administered once daily orally continuous dosing
3207030|NCT01147822|Active Comparator|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment
3207031|NCT01147809|Active Comparator|Eltrombopag|Drug: eltrombopag olamine thrombopoietin receptor agonist
3207032|NCT01147809|Placebo Comparator|Placebo|Other: Placebo Placebo tablets with no active pharmaceutical ingredient
3207033|NCT01147796|Active Comparator|Thrombus|patients with positive TEE (thrombus)
3207034|NCT01147796|Placebo Comparator|No thrombus|patients with negative TEE (no thrombus)
3207035|NCT01147783||SimBaby|
3207036|NCT01147783||Infants (1-12 mo)|
3207037|NCT01147770|Experimental|stop progesterone|
3207038|NCT01147757|Placebo Comparator|saline|Group S (n = 15): saline
3207039|NCT01147757|Experimental|remifentanil 0.3 mcg/kg/min|Group 0.3 (n = 15): remifentanil 0.3 mcg/kg/min
3207040|NCT01147757|Experimental|remifentanil 0.6 mcg/kg/min|Group 0.6 (n = 15): remifentanil 0.6 mcg/kg/min
3207041|NCT01147757|Experimental|remifentanil 0.9 mcg/kg/min|Group 0.9 (n = 15): remifentanil 0.9 mcg/kg/min
3207042|NCT01147744|Experimental|GSK2190915 10mg and placebo|GSK2190915 10mg (1 x 10mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
3207043|NCT01147744|Experimental|GSK2190915 30mg and placebo|GSK2190915 30mg (1 x 30mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
3207044|NCT01147744|Experimental|GSK2190915 100mg QD and placebo|GSK2190915 100mg (1 x 100mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
3207045|NCT01147744|Experimental|GSK2190915 300mg QD and placebo|GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
3207046|NCT01147744|Active Comparator|Fluticasone propionate 100mcg and placebo|Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS and two placebo tablets in the morning and one placebo capsule in the evening
3207047|NCT01147744|Active Comparator|Montelukast 10mg and placebo|Montelukast 10mg (1 x 10mg capsule) once daily in the evening and two placebo tablets in the morning and inhaled placebo twice daily via ACCUHALER/DISKUS
3207048|NCT01147744|Placebo Comparator|Placebo Comparator|Two GSK2190915 placebo tablets once daily in the morning, montelukast placebo capsule once daily in the evening and fluticasone propionate placebo twice daily via ACCUHALER/DISKUS
3207049|NCT01147731|Experimental|warfarin plus albiglutide|A single dose of 25mg warfarin on day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 25mg warfarin on day 45.
3207050|NCT01147718|Experimental|digoxin plus albiglutide|A single dose of 0.5mg digoxin administered on Day 1 followed by 5 weekly subcutaneous injections of albiglutide, followed by a further single dose of 0.5mg digoxin on Day 38.
3207051|NCT01147705|Active Comparator|Allopurinol|Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks.
3207052|NCT01147705|Placebo Comparator|Placebo|Same number of tablets and appearance as active drug.
3207053|NCT01147692|Experimental|simvastatin plus albiglutide|A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
3207054|NCT01147679||bvFTD|This group will include 33 patients who have been diagnosed with behavioral variant frontotemporal dementia by Dr. Mario Mendez. Patients diagnosed elsewhere must have a secondary evaluation at the UCLA FTD Clinic to confirm their diagnosis before study enrollment.
3207055|NCT01147679||Alzheimer's disease|This group will include 33 patients who have been diagnosed with clinically probable Alzheimer's disease by Dr. Mario Mendez. Patients diagnosed elsewhere must have a secondary evaluation at the UCLA FTD Clinic to confirm their diagnosis before study enrollment.
3207056|NCT01147679||Controls|33 health individuals without clinically significant cognitive impairments will be enrolled in this study.
3207057|NCT01147666|Experimental|Population A; Experimental Drug|Patients responding normally to current treatment
3207058|NCT01147666|Active Comparator|Population A; Active Comparator|Patients responding normally to current treatment
3207059|NCT01147666|Experimental|Population B; Experimental Drug|Patients not responding well to current treatment
3207060|NCT01147666|Active Comparator|Population B; Active Comparator|Patients not responding well to current treatment
3207061|NCT01147666|Placebo Comparator|Population B; Placebo Comparator|Patients not responding well to current treatment
3207062|NCT01147653|Active Comparator|Autologous UCB Reinfusion First,Then Placebo|Subjects receive their autologous umbilical cord blood cells at Baseline, than placebo at Year 1.
3207063|NCT01147653|Placebo Comparator|Placebo First, Then Autologous UCB Reinfusion|Subjects receive placebo at Baseline, then autologous umbilical cord blood cell reinfusion at Year 1.
3207064|NCT01147640|Experimental|CXA 101/tazobactam and metronidazole|
3207065|NCT01147640|Active Comparator|meropenem with matching saline placebo|
3207066|NCT01147627|Active Comparator|Exenatide|
3207067|NCT01147627|Active Comparator|Premixed insulin analog|
3207069|NCT01147614|Active Comparator|specialty mental health care referral|
3207070|NCT01147614|Experimental|Brief Cognitive Behavioral Therapy|
3207071|NCT01147601|Active Comparator|Topical 0.5% Timolol|Half of the enrolled subjects (intervention group) will receive topical 0.5% Timolol.
3207072|NCT01147601|Placebo Comparator|Placebo|Aqueous placebo, 2-3 drops to cover the hemangioma, twice daily
3207073|NCT01147588|Experimental|1|lansoprazole 60 mg + clopidogrel 300 mg/ 75 mg
3207074|NCT01147588|Experimental|2|omeprazole 80 mg + clopidogrel 300/75 mg
3207075|NCT01147588|Experimental|3|esomeprazole 40 mg + clopidogrel 300/75 mg
3207076|NCT01147588|Experimental|4|clopidogrel 300/75 mg alone
3207077|NCT01147575|Active Comparator|Creatine monohydrate|The patients received orally 200 mg CMH per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH respectively the groups were switched for another 6 months (period 2).
3207078|NCT01147575|Placebo Comparator|Placebo|The patients received orally 200 mg Placebo per kg body weight divided in three doses per day in identically prepared capsules. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without Placebo respectively the groups were switched for another 6 months (period 2).
3207079|NCT01147562|Other|Lung Cancer Patients|Patients with a suspected or confirmed diagnosis of lung cancer, whether or not scheduled for lesion biopsy, thoracentesis or surgical resection of their tumor
3207080|NCT01147549|Experimental|1|[C14]AZD9668
3207081|NCT01147536|Experimental|HSPPC-96 treatment|
3207082|NCT01147523|Experimental|Vitamin E|Vitamin E, capsules 400 mg daily, for 52 weeks
3207083|NCT01147510|Active Comparator|Monotherapy of medium dose ICS|
3207084|NCT01147510|Experimental|Combination of low ICS and montelukast|
3207085|NCT01147497|Experimental|misoprostol|Misoprostol 400mcg taken buccally 2 hours prior to IUD insertion visit
3207086|NCT01147497|Placebo Comparator|placebo|Pill that is identical to the study drug in appearance, taste, and smell, taken buccally 2 hours prior to IUD insertion visit
3207087|NCT01147484|Experimental|Foretinib|
3207088|NCT01147471|Active Comparator|Operative rib fixation|"Randomized subjects will be operated upon within 72 hours of ventilation (early fixation) to stabilize the stove-in segment. Where all fractured ribs are accessible and the number of fractured ribs is few, stabilization of all fractured ribs would be the goal. However, where fractured ribs are in areas difficult to access, enough ribs, based on surgeon judgment, would be fixed to stabilize the stove-in segment. Post-operatively, the patients would receive the standard of care, similar to what is outlined for the non-operative arm.~Operative fixation will be accomplished utilizing the MatrixRIB Fixation System (Synthes CMF, West Chester, PA, USA) according to the device's instructions for use. Sites will obtain the product based on their medical center's normal purchasing practices."
3207089|NCT01147471|No Intervention|Non-operative arm|"Randomized subjects to receive standard of care therapy for blunt thoracic trauma (as per each participating institution's own protocols):~a. Ventilatory support b.Timing of extubation (removal from ventilator): c.Analgesia: institution should provide adequate analgesia utilizing available resources including oral, parenteral, epidural, local nerve blocks etc., d.Chest physical therapy, e.Postural drainage, f.Incentive spirometry - after extubation."
3207090|NCT01147458|Experimental|PF-04191834 followed by placebo|PF-04191834 600 mg BID dose followed by matched placebo plus naproxen placebo.
3207091|NCT01147458|Experimental|Placebo followed by PF-04191834|Placebo followed by 600 mg BID dose of PF-04191834 plus naproxen placebo.
3207092|NCT01147458|Experimental|PF-04191834+Naproxen followed by Naproxen|PF-04191834 600 mg BID + Naproxen 500 mg BID followed by Naproxen 500 mg BID plus PF-04191834 placebo
3207093|NCT01147458|Experimental|Naproxen followed by PF-04191834+Naproxen|Naproxen 500 mg BID followed by PF-04191834 600 mg BID + Naproxen 500 mg BID
3207094|NCT01147445|Experimental|Cohort 1: 5 mcg dmLT|6 subjects to receive 5 micrograms (mcg) of dmLT vaccine.
3207095|NCT01147445|Experimental|Cohort 4: 100 mcg dmLT|6 subjects to receive 100 mcg of dmLT vaccine.
3207096|NCT01147445|Experimental|Cohort 2: 25 mcg dmLT|6 subjects to receive 25 mcg of dmLT vaccine.
3207097|NCT01147445|Experimental|Cohort 3: 50 mcg dmLT|6 subjects to receive 50 mcg of dmLT vaccine.
3207098|NCT01147445|Experimental|Cohort 5: 50 mcg or 100 mcg dmLT|12 subjects randomized, double-blinded, to receive either 50 mcg or 100 mcg of dmLT vaccine.
3207099|NCT01147432|Experimental|PF-04427429|
3207100|NCT01147432|Placebo Comparator|Placebo|
3207101|NCT01147432|Active Comparator|EMLA|
3207102|NCT01147419|Experimental|bypass|Patients presenting with long occlusion of the superficial femoral artery enrolled in bypass arm will undergo suprageniculate femoropopliteal bypass surgery to bypass the occluded superficial femoral artery. And the graft will be artificial blood vessel.
3207103|NCT01147419|Experimental|stent|
3207104|NCT01147406|Experimental|Active|N6022
3207105|NCT01147406|Placebo Comparator|Placebo|Placebo
3207106|NCT01147393|Experimental|All subjects|two weekly infusions of 90Y-epratuzumab tetraxetan in combination with four weekly infusions of 200 mg/m2 veltuzumab.
3207107|NCT01147380|Experimental|Small dose|From the donor liver perfusate, mononuclear cell will be extracted and cultured. Then, the cells will be stimulated with IL-2. The number of inoculation cells( mainly NK cells) is between 10 and 100 million cells. The cells will be given to the liver transplant recipient who had the same donor for liver and liver perfusate. Patient of this arm receive small dose of liver NK cell inoculation as described.
3207108|NCT01147380|Experimental|Large dose|From the donor liver perfusate, mononuclear cell will be extracted and cultured. Then, the cells will be stimulated with IL-2. The number of inoculation cells(mainly NK cells) is between 100 and 1000 million cells. The cells will be given to the liver transplant recipient who had the same donor for liver and liver perfusate.Patient of this arm receive large dose of liver NK cell inoculation as described.
3207109|NCT01147367|No Intervention|Control|no physical activity intervention
3207110|NCT01147367|Experimental|Exercise intervention|3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
3207111|NCT01147354|Experimental|experimental group|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
3207112|NCT01147354|Placebo Comparator|control group|The patients in this arm took one placebo capsule daily for 12 weeks.
3207113|NCT01147341|Placebo Comparator|placebo|Placebo (0.9% sodium chloride) given as 2 subcutaneous (sc) injections at weeks 0, 2, and 4, followed y 1 sc injection given an weeks 6, 8, and 10. At week 12 subjects entered the open label phase. Subjects received 400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 12,14 and 16, followed by 1 sc injection at weeks 18, 20, and 22.
3207114|NCT01147341|Active Comparator|active treatment with Cimzia|400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 0, 2, and 4, followed by 1 sc injection at weeks 6, 8, and 10. At week 12 subjects entered the open label phase. Subjects received 400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 12,14 and 16, followed by 1 sc injection at weeks 18, 20, and 22.
3207115|NCT01147328||1|Patients who did not have their data accessed in the VHR by a provider within 6 months after they consented will be part of the control group
3207116|NCT01147328||2|Patients who had their data accessed in the VHR by a provider within 6 months after they consented will be part of the intervention group
3207117|NCT01147315|Experimental|Hybrid bone substitution|Hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow
3207118|NCT01147302|Experimental|C1 Esterase Inhibitor (Human)|Subjects were to receive C1 esterase inhibitor intravenously at a rate of approximately 1 mL per minute as tolerated. Subjects were to receive a total of 7 doses over a 2-week period: an initial IV infusion of 5000 U (not to exceed 100 U/kg) on Day 1, followed by 2500 U (not to exceed 50 U/kg) IV on Days 3, 5, 7, 9, 11, and 13
3207119|NCT01147302|Placebo Comparator|Normal Saline|placebo infused as above
3207120|NCT01147289|Experimental|dexalgen|Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose for 3 days, at least
3207121|NCT01147289|Active Comparator|Meloxicam|Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose for at least 3 days.
3207122|NCT01147276|Experimental|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
3207123|NCT01147263||Patients diagnosed with Fibromyalgia|
3207124|NCT01147250|Placebo Comparator|Placebo|Placebo matched to lixisenatide once daily (QD) up to end of treatment.
3207125|NCT01147250|Experimental|Lixisenatide|Lixisenatide 10 mcg QD for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to end of treatment.
3207126|NCT01147237|Experimental|Single arm study|
3207127|NCT01147224||ATEM|A prospective one-arm non-interventional study with asthma patients treated with Alvesco.
3207128|NCT01147211|Experimental|MK2206 in combination with Gefitinib|MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
3207129|NCT01147198|Active Comparator|Ready to Use Supplementary Food|Ready to Use Supplementary Food treatment
3207130|NCT01147198|Active Comparator|Premix|Premix Corn Soy Blend-oil treatment
3207131|NCT01147185|Other|Intensive training|Locomotor training using a robotic device of at least 50 minutes
3207132|NCT01147185|Active Comparator|Standard training|Locomotor training using a robotic device of maximally 25 minutes
3207133|NCT01147172|Experimental|Elevess|Gel implant (dermal filler) composed of hyaluronan produced by Streptococcus equi (bacterial fermentation) that is cross-linked and suspended in phosphate buffered saline with 0.3% lidocaine HCl and 0.1% sodium metabisulfite
3207134|NCT01147159|Other|Skin Prick Test|
3207135|NCT01147133|Experimental|Original|Treatment phase with the original formulation of clopidogrel
3207136|NCT01147133|Active Comparator|Generic|Treatment phase with the generic clopidogrel
3207137|NCT01147120|Active Comparator|Progressive Muscle Relaxation|
3207138|NCT01147120|Active Comparator|Clinical Massage Therapy|
3207139|NCT01147107|Experimental|Raltegravir based therapy|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
3207140|NCT01147107|Active Comparator|Efavirenz based therapy|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
3207141|NCT01147081|Experimental|Arm 1|
3207142|NCT01147068|Experimental|PanBlok 135µg No Adjuvant|135µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
3207143|NCT01147068|Experimental|PanBlok 45µg No Adjuvant|45µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
3207144|NCT01147068|Experimental|PanBlok 45µg and GLA 1.0µg, SE 2%|45µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
3207145|NCT01147068|Experimental|PanBlok 15µg and GLA 1.0µg, SE 2%|15µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
3207146|NCT01147068|Experimental|PanBlok 7.5µg and GLA 1.0µg, SE 2%|7.5µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
3207147|NCT01147068|Experimental|PanBlok 3.8µg and GLA 1.0µg, SE 2%|3.8µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
3207148|NCT01147068|Placebo Comparator|Placebo|0.9% Sodium Chloride; Two 0.5 mL IM injections 21 days apart
3207149|NCT01147055|Experimental|1|There should be at least 14-day washout period between treatment A and B.
3207150|NCT01147042|Active Comparator|gp91 CGD with relatively high baseline superoxide|"Patients with X-linked Chronic Granulomatous Disease (CGD) with a missense gp91phox mutation and relatively high baseline superoxide production.~IFN-gamma was the administered intervention."
3207151|NCT01147042|Active Comparator|Autosomal Recessive CGD with p47|Patients with Autosomal Recessive Chronic Granulomatous Disease (CGD) with p47 phox mutation. IFN-gamma was the administered intervention.
3207152|NCT01147016|Experimental|HER2Bi-armed activated T cells + Neoadjuvant Chemotherapy|"HER2Bi-armed activated T cells - Total of 4 of the T cell infusions IV over a period of 1 month~Cyclophosphamide, doxorubicin hydrochloride, paclitaxel -As prescribed by physician, standard of care."
3207153|NCT01147003|Experimental|BGG492 low dose|
3207154|NCT01147003|Placebo Comparator|Placebo|
3207155|NCT01147003|Experimental|BGG492 high dose|
3207434|NCT01145014|Experimental|BI 660848 400 mg|oral drinking solution
3207156|NCT01146990||Infants Born to Mothers in the 17P-ES-003 Study|Infants Born to Mothers Who Participated in the 17P-ES-003 Study and whose mothers consented for them to be followed for this study.
3207157|NCT01146977|Experimental|Autologous HCT|"5.1.3. After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.~5.1.3.1. If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue."
3207158|NCT01146977|Active Comparator|HDAC chemotherapy|If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.
3207159|NCT01146964|Experimental|Phacoemulsification, Safety, Efficacy|
3207160|NCT01146964|Experimental|MSSICS, Safety, Efficacy|
3207161|NCT01146951|Experimental|Rufinamide (E2080)|
3207162|NCT01146951|Placebo Comparator|Placebo|
3207163|NCT01146938|Experimental|hepatic impairment patients|Hepatic impairment patients group Child-Pugh score A or Child-Pugh score B (not Child-Pugh score C)
3207164|NCT01146938|Active Comparator|Healthy volunteers|healthy volunteers group
3207165|NCT01146925|Experimental|CRMD-001-Deferiprone|
3207166|NCT01146925|Placebo Comparator|Placebo|
3207167|NCT01146912|Experimental|Text message vaccine reminders|Receipt of text message vaccine reminders
3207168|NCT01146912|Active Comparator|automated phone call from clinic|Receipt of automated phone call from clinic
3207169|NCT01146899|Experimental|Provider Alert|Provider receives alert for patient visit
3207170|NCT01146899|No Intervention|No Alert|No alert provided
3207171|NCT01146886|Experimental|BI 135585|1 single dose per subject as oral solution in Part 1, or 3 single doses per subject as oral solution and 2 different tablet formulations in Part 2
3207172|NCT01146886|Placebo Comparator|Placebo to BI 135585|1 single dose per subject as oral solution in Part 1
3207173|NCT01146873|Active Comparator|Group 1: Lopinavir/ritonavir (LPV/r)|Participants are assigned to remain on their current LPV/r-based antiretroviral regimen. Ritonavir-boosted lopinavir syrup was given twice per day at 230 mg/m^2 per dose. Children able to swallow tablets were given 1 tablet twice per day (200 mg lopinavir/50 mg ritonavir) if body surface area was less than 0.9m^2 or 2 tablets twice per day if body surface area was 0.9m^2 or higher.
3207174|NCT01146873|Experimental|Group 2: Efavirenz (EFV)|Participants are assigned to switch to an EFV-based antiretroviral regimen. Efavirenz was prescribed once daily in the evening at 200 mg for weights of 10 kg to 13.9 kg (22-30 lb) and 300mg for weights of 14 kg to 24.9 kg (31-55 lb). Efavirenz was available in 50-mg and 200-mg capsules. If children were unable to swallow capsules, caregivers were shown how to open the capsules and dissolve the contents in water.
3207175|NCT01146873|Active Comparator|Group D: Stavudine (D4T)|Children are assigned to remain on their current antiretroviral regimen, which includes D4T. D4T was given at 1 mg/kg twice daily
3207176|NCT01146873|Experimental|Group A: Abacavir (ABC)|Children stop taking D4T and switch to ABC. ABC was given at 8 mg/kg twice daily.
3207177|NCT01146860|Experimental|BNO 1016|sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
3207178|NCT01146860|Placebo Comparator|Placebo|sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration: 15 days
3207179|NCT01146847|Experimental|1|Space TGC system with incorporated eMPC advised insulin titration to establish tight glycaemic control
3207180|NCT01146834|Experimental|Arm A|VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11 in combination with high-dose cyclophosphamide at 2.0 g/m2 on day 4. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.
3207181|NCT01146834|Experimental|Arm B|VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Day 12 start pheresis collection
3207182|NCT01146834|Experimental|Arm C|High-dose cyclophosphamide at 2.0 g/m2 on day 1. G-CSF is given for ten (+/- two) consecutive days starting on day 2 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.
3207183|NCT01146821|No Intervention|Standard care|Standard care
3207184|NCT01146821|Active Comparator|standard care + 0.20gm/kg fish oil|standard care + 0.20gm/kg fish oil
3207185|NCT01146821|Active Comparator|standard care + 0.50 gm/kg fish oil|standard care + 0.50 gm/kg fish oil
3207186|NCT01146808|Experimental|ADV plus hepatitis B vaccination|Adefovir dipivoxil and hepatitis B vaccination: All subjects will receive adefovir 10mg po daily, or adjusted for renal function and an option for Hepatitis B vaccination, double dose.
3207187|NCT01146795|Experimental|Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab|Three 21 day cycles of carboplatin, paclitaxel, and bevacizumab
3207188|NCT01146782|Experimental|Treatment|Treatment with the Attune Sleep Apnea System
3207189|NCT01146769|Experimental|Pelvic floor exercise|
3207190|NCT01146769|No Intervention|Control|
3207191|NCT01146756|Experimental|AZD6244 & Thoracic Radiotherapy|AZD6244 in combination with thoracic radiotherapy (RT)- the aim is to determine the recommended phase II dose (RP2D).
3207192|NCT01146743|Active Comparator|EUS-guided|EUS-guided gallbladder drainage in acute cholecystitis with high risk patients
3207193|NCT01146743|Active Comparator|percutaneous transhepatic|percutaneous transhepatic gallbladder drainage in acute cholecystitis with high risk patients
3207194|NCT01146730|Experimental|Workcoping and IPS|CBT based counseling and supported employment
3207195|NCT01146730|Active Comparator|Ordinary care by GP or NAV|Ordinary care by GP or The Norwegian Labour and Welfare Administration (NAV)
3207196|NCT01146717|Experimental|Exercise|
3207197|NCT01146717|Placebo Comparator|Control group|
3207198|NCT01146704|Active Comparator|Arm 1|Standard protein diet group as control based on 0.5 gram protein per pound of lean body mass with same calories: 15% protein and 55% carbohydrate.
3207199|NCT01146704|Active Comparator|Arm 2|High protein diet group based on 1 gram of protein per pound of lean body mass: 30% protein and 40% carbohydrate.
3207200|NCT01146691||Standard staffing model|All patients in participating ICUs during the blocks of time when a single intensivist staffs a participating ICU for a 7 day period. The intensivist will be present during daytime hours, and takes call from home afterwards.
3207201|NCT01146691||24-7 shiftwork staffing model|All patients in participating ICUs during the blocks of time when the 24-7 in-hospital intensivist coverage model is in place. This model is enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am. Call rooms will be provided to allow the night shift intensivist to sleep, if the workload permits.
3207202|NCT01146678|Experimental|Lantus(insulin glargine)/lixisenatide on-site mix|Single dose injection of an on site mix of Lantus U100 and lixisenatide (800µg/mL in Lantus U100) at one peri-umbilical site under fasting conditions
3207203|NCT01146678|Active Comparator|lixisenatide + Lantus (insulin glargine)|Single dose, separate injection simultaneous injections of Lantus U100 and lixisenatide (100µg/mL) at opposite peri-umbilical sites within 1 minute under fasting conditions
3207204|NCT01146665|Experimental|medical care plus computer-based PAF|
3207205|NCT01146665|Sham Comparator|medical care plus computer-based sham|
3207206|NCT01146652|Experimental|Extension study|Sarilumab (SAR153191), Disease Modifying Anti-Rheumatic Drug (DMARD) therapy as required in the initial protocol.
3207207|NCT01146639|Experimental|MDCT and additional DynaCT|
3207208|NCT01146626|Active Comparator|Peg+ Vitamin D+ Ribavirine|Peg+ Vitamin D+ Ribavirine
3207209|NCT01146626|Experimental|Peg+ Ribavirine|Peg+ Ribavirine
3207210|NCT01146613|Active Comparator|Varenicline|Varenicline Tartrate
3207211|NCT01146613|Placebo Comparator|Sugar Pill|
3207212|NCT01146600|Experimental|Random Group A|Subjects will be randomized to group A or group B. The order of presentation of placebo and clarithromycin will be opposite in these two groups, but investigators and subjects will remain blinded to group allocation and order of treatment presentation within the groups.
3207213|NCT01146600|Experimental|Random Group B|Subjects will be randomized to group A or group B. The order of presentation of placebo and clarithromycin will be opposite in these two groups, but investigators and subjects will remain blinded to group allocation and order of treatment presentation within the groups.
3207214|NCT01146587|Experimental|GangTrainer GT1|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo robotic treatment with the Gangtrainer GT1 for 30 minutes of gross therapy time every workday for a 8 weeks period
3207215|NCT01146587|Experimental|Lokomat|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo robotic treatment with the Lokomat for 30 minutes of gross therapy time every workday for a 8 weeks period
3207216|NCT01146587|Active Comparator|Conventional Physiotherapy|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo a conventional physiokinetherapeutic treatment session for 30 minutes of gross therapy time every workday for a 8 weeks period
3207217|NCT01146574|Experimental|0.1mg/kg Sotatercept|Approximately 8 subjects will be randomized to receive either a single 0.1 mg/kg subcutaneous dose of sotatercept or matching placebo in a 3:1 ratio
3207218|NCT01146574|Experimental|0.3mg/kg Sotatercept|Dose Group 1: 0.3 mg/kg sotatercept subcutaneous every 28 days
3207219|NCT01146574|Experimental|0.5mg/kg Sotatercept|Dose Group 2: 0.5 mg/kg sotatercept subcutaneous every 28 days
3207220|NCT01146574|Experimental|0.7mg/kg Sotatercept|Dose Group 3: 0.7 mg/kg sotatercept subcutaneous every 28 days
3207221|NCT01146574|Placebo Comparator|Placebo|The Placebo to Sotatercept ratio is 1:3 meaning for every 1 patient that receives Placebo, 3 patients will receive Sotatercept.
3207222|NCT01146561|Experimental|Tanezumab 20 mg|
3207223|NCT01146561|Placebo Comparator|Placebo|
3207224|NCT01146548|Experimental|the fluoxetine group|Multiple System Atrophy's patients with fluoxétine
3207225|NCT01146548|Placebo Comparator|the placebo group|Multiple System Atrophy's patients with placebo
3207226|NCT01146535|Experimental|Interferon-alpha|"Interferon-alpha~150 IU lozenges bid for 5 days"
3207227|NCT01146535|Placebo Comparator|maltose|"maltose~200 mg maltose lozenges bid for 5 days"
3207228|NCT01146522|Experimental|LCQ908|
3207229|NCT01146522|Placebo Comparator|Placebo|
3207230|NCT01146509|Experimental|1|
3207231|NCT01146496|Active Comparator|Storage container|Ultraviolet light resistant plastic in-ground pesticide storage container
3207232|NCT01146496|No Intervention|Control|
3207233|NCT01146483|Active Comparator|Pantoprazole|two-arm study: 2-period, 2-sequence, cross-over study.Volunteers will be administered either sequence 1 or sequence 2 randomly.
3207234|NCT01146483|Placebo Comparator|Placebo|
3207235|NCT01146470|Experimental|RGC 200 mg|
3207236|NCT01146470|Experimental|RGC 400 mg|
3207237|NCT01146470|Placebo Comparator|Placebo|
3207238|NCT01146457|Placebo Comparator|Placebo|
3207239|NCT01146457|Active Comparator|Morphine 25|
3207240|NCT01146457|Active Comparator|Morphine 50|
3207241|NCT01146457|Active Comparator|Morphine 75|
3207242|NCT01146457|Active Comparator|Morphine 100|
3207243|NCT01146444|Experimental|sunscreens with a low, medium, high SPF|sunscreens with a low, medium, and high SPF. UVA and UVB irradiation
3207244|NCT01146444|Experimental|vehicle|Intra-individual application of vehicle in random order; UVA and UVB irradiation
3207245|NCT01146431||Hemodynamic parameters|Hemodynamic parameters will be used as a guide for anesthesia.
3207246|NCT01146431||BIS|Bispectral Index (BIS) will be used as a guide for anesthesia.
3207247|NCT01146418|Experimental|Corifollitropin alfa 150 μg|Participants in Base Study P06029 received a single injection of 150 ug corifollitropin alfa on Stimulation Day 1 and daily injections of placebo-recFSH from Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.
3207248|NCT01146418|Active Comparator|recFSH 300 IU|Participants in the reference group in Base Study P06029 received a single injection of placebo for corifollitropin alfa on Stimulation Day 1 and daily injections of 300 IU recFSH on Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.
3207249|NCT01146392||1|Primary care patients with COPD diagnosis
3207250|NCT01146379|Experimental|Low Movement Dose, 3200 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
3207251|NCT01146379|Experimental|Medium Movement Dose, 6400 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
3207252|NCT01146379|Experimental|High Movement Dose, 9600 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
3207253|NCT01146379|Experimental|Individual Maximum High Movement Dose|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
3207254|NCT01146353||CRRT Patients receiving Peramivir|"Eligible patients are male or female patients ≥18 years of age who are hospitalized, undergoing CVVH or CVVHD, and receiving peramivir.~Eligible patients will additionally have the following: blood flow rate will be required to be ≥100 mL/ min with an ultrafiltrate +/- dialysis flow rate greater than or equal to 3000mL/hr, and the continuous renal replacement therapy must be scheduled to run for the full duration of the dosing interval (full 24 hours).~Written informed consent in a form approved by the Northwestern University and the Midwestern University Institutional Review Boards will be granted by the patient."
3207255|NCT01146340|Experimental|SBRT|SBRT 40 Gy in 5 fractions over 29 days delivered using step and shoot IGRT
3207256|NCT01146327|Experimental|PF-04620110|
3207257|NCT01146327|Placebo Comparator|Placebo Comparator|
3207258|NCT01146314|Experimental|Lifestyle intervention|A 6-month 14 session lifestyle intervention led by a psychologist and a dietitian for 90 minutes group sessions. Intervention sessions were help weekly, biweekly, and monthly over the course of 6 months.
3207259|NCT01146301|Active Comparator|300 mg Loading dose clopidogrel|
3207260|NCT01146301|Experimental|600 mg Loading dose of clopidogrel|
3207261|NCT01146288|Experimental|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.
3207262|NCT01146288|Experimental|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.
3207263|NCT01146275|Other|Participants in the Pilot study 31GB0601|"This is an additional safety follow up 7-years post treatment, for subjects enrolled in a pilot study using a previous formulation of Macrolane for breast augmentation.~Radiological breast examinations - MRI of breast, mammography and ultrasound of breast"
3207264|NCT01146249||1: healthy subject|
3207265|NCT01146249||3: post stroke patients|
3207266|NCT01146249||2: vestibular patients|Vestibular patients with a unique history of peripheric vestibular disorder
3207267|NCT01146249||4: ataxic patients|Patient with proprioception disorder related to peripheral neuropathy
3207268|NCT01146249||5: Old fallers|Old subjects with a history of falls (one or more during the last year)
3207269|NCT01146236|Active Comparator|Sutures|Orthopedic surgical wound closed with sutures
3207270|NCT01146236|Active Comparator|Staples|Orthopedic surgical wound closed with metallic staples
3207271|NCT01146223||Basic science (correlative studies)|Patient mRNA samples from diagnosis are analyzed via quantitative PCR to measure WT1 and VEGF-1 expression.
3207272|NCT01146210||Ancillary-correlative|Previously collected cryopreserved cells are analyzed via western blot to identify patients with Fanconi anemia.
3207273|NCT01146197|Experimental|Amiloride, Indometacin, Eplerenone|Amiloride, indometacin(+Omeprazole), Eplerenone
3207274|NCT01146197|Experimental|Amiloride, Eplerenone, indometacin|Amiloride, Eplerenone, indometacin (+Omeprazole)
3207275|NCT01146197|Experimental|Eplerenone, Amiloride, indometacin|Eplerenone, Amiloride, indometacin (+Omeprazole)
3207276|NCT01146197|Experimental|Eplerenone, Indometacin, Amiloride|Eplerenone, Indometacin, Amiloride
3207277|NCT01146197|Experimental|Indometacin, Eplerenone, Amiloride|Indometacin, Eplerenone, Amiloride
3207278|NCT01146197|Experimental|Indometacin, Amiloride, Eplerenone|Indometacin, Amiloride, Eplerenone
3207279|NCT01146184|Experimental|Single-Incision Cholecystectomy|Extracting the gallbladder laparoscopically is made difficult through a single incision.
3207280|NCT01146171|Experimental|BMS-844203 (CT-322)|
3207281|NCT01146158|Experimental|surgery Axillary dissection|surgery Axillary dissection
3207282|NCT01146145|Experimental|treatment|intravenous morphine titration combined to ketamine
3207283|NCT01146145|Placebo Comparator|placebo|morphine titration alone
3207284|NCT01146132|Other|Luxembourg diet + wine|Luxembourg variant of the mediterranean Diet, physical activity with wine consumption
3207285|NCT01146132|Other|conventional + wine|conventional Diet with red wine
3207286|NCT01146132|Other|conventional|conventional diet without wine
3207287|NCT01146132|Other|Luxembourg diet|Luxembourg variant of the mediterranean Diet, physical activity with wine consumption
3207288|NCT01146119|Experimental|Multimeric-001, Adjuvanted|64 subjects received 2 injections of Adjuvanted Multimeric-001, 500 mcg with an interval of 21 days and then 60 days later were further immunized with a 15% dose of commercial seasonal trivalent vaccine (season 2011).
3207289|NCT01146119|Active Comparator|PBS and TIV 15%|32 subjects received 2 injections of PBS (Phosphate Buffered Saline) with an interval of 21 days and then were further immunized 60 days later with a 15% dose of commercial seasonal trivalent vaccine (season 2011).
3207290|NCT01146119|Placebo Comparator|Placebo, Adjuvanted|32 subjects received Adjuvanted PBS (Placebo) with an interval of 21 days.
3207291|NCT01146119|Experimental|Co-administration M-001 and TIV 15%|24 subjects received 2 injections on the same day, one injection containing Adjuvanted Multimeric-001 500 mcg and the other containing TIV 15%.
3207292|NCT01146119|Experimental|Co administration of M-001 and TIV 50%|24 subjects received 2 injections on the same day, one injection containing Adjuvanted Multimeric-001 500 mcg and the other containing TIV 50%.
3207293|NCT01146119|Active Comparator|Co administration of PBS and TIV 50%|24 subjects received 2 injections on the same day, one injection containing PBS and the other containing TIV 50%.
3207294|NCT01146106|Experimental|Pravastatin Sodium Tablets 80 mg|Dr.Reddy's Laboratories Limited
3207295|NCT01146106|Active Comparator|Pravachol 80 mg Tablets|Bristol Myers Squibb
3207296|NCT01146093|Experimental|Pravastatin Sodium Tablets 80 mg|Dr.Reddy's Laboratories Limited
3207297|NCT01146093|Active Comparator|Pravachol 80 mg Tablets|Bristol Myers Squibb
3207298|NCT01146080|Experimental|Promus Element|21 consecutive patients with Promus Element implanted to treat coronary artery lesion
3207299|NCT01146080|Active Comparator|Promus|21 consecutive patients with Promus stent implanted to treat coronary artery lesions
3207300|NCT01146067|Experimental|Rivastigmine|Rivastigmine capsules 1.5 mg of Dr.Reddy's Laboratories Limited
3207301|NCT01146067|Active Comparator|Exelon|Exelon 1.5 mg capsules of Novartis
3207302|NCT01146054|Experimental|SBRT and Gemzar|Before stereotactic Body Radiotherapy (SBRT) 3-5 gold fiducials are placed by endoscopic ultrasound or CT guidance. A simulation FDG-PET/CT (Fludeoxyglucose (18F) - Positron emission tomography/Computerized tomography) scan will be used for treatment planning purposes (standard free-breathing CT and respiratory-correlated 4-D (4 dimensional) pancreatic protocol CT). Patients are treated by either respiratory gated (Trilogy, Elekta, Novalis) or by respiratory tracking (CyberKnife). SBRT is delivered in 5 fractions of 6.6 Gy by LINAC-based or CyberKnife based radiotherapy over a five-day period. Gemcitabine, cycles should resume/start up to 4 weeks following SBRT on a 3-week on, 1-week off schedule. Initial follow up is at 4, 6, 9 and 12 months and then for years 2-5 is every 3-6 months.
3207303|NCT01146041|Experimental|Rivastigmine|Rivastigmine capsules 1.5 mg of Dr.Reddy's Laboratories Limited
3207304|NCT01146041|Active Comparator|exelon|Exelon 1.5 mg capsules of Novartis
3207305|NCT01146028|Experimental|Tizanidine HCl 4 mg|Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited
3207306|NCT01146028|Active Comparator|Zanaflex|Zanaflex 4 mg Tablets
3207307|NCT01146015|Experimental|1|
3207308|NCT01146002|Other|Guanfacine treated.|Single arm - all patients treated with study drug. Comparison is against pre-treatment performance.
3207309|NCT01145989|Experimental|AT9283|Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
3207310|NCT01145976|Active Comparator|CY-ATG(Arm1)|"Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2"
3207311|NCT01145976|Experimental|Flu-ATG(Arm2)|Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
3207312|NCT01145963|Experimental|experimental pasta B|Past B
3207313|NCT01145963|Experimental|experimental pasta C|Pasta C
3207314|NCT01145963|Placebo Comparator|Control pasta|Control
3207315|NCT01145950|Experimental|Group 1|
3207316|NCT01145950|Experimental|Group 2|
3207317|NCT01145937|Experimental|PET|"Partial endothelial trepanation in addition to anterior lamellar keratoplasty.~The endothelium en Descemet are paracentrally and circular loosened, but some tissue bridges are left in place. This 'island' is able to mould to the healthy donor curvature."
3207318|NCT01145937|Active Comparator|DALK|Conventional DALK grafting procedure where the Big Bubble technique is used according to Anwar et al.
3207319|NCT01145924|Active Comparator|EBUS TBNF|single arm trial, patients with enlarged mediastinal nodes will be examine
3207320|NCT01145911||Glaucoma patients|Glaucoma patients
3207321|NCT01145898||Glaucoma patients|Patients with Glaucoma
3207322|NCT01145885|Experimental|BI 6727|BI 6727 cycles in every 21 days
3207323|NCT01145872|Experimental|Mindfulness Based Cognitive Therapy|
3207324|NCT01145872|Active Comparator|Health Enhancement Program|
3207325|NCT01145859|Experimental|Arm 1|
3207326|NCT01145846|Experimental|Arm I (AI regimen)|Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Idarubicin 12 mg/m2/day iv daily for 3 days (D 1-3)
3207327|NCT01145833|Active Comparator|Immediate treatment group|The immediate treatment group begins the 5-month treatment immediately after baseline assessment.
3207328|NCT01145833|Other|Delayed Treatment Group|The delayed treatment group serves as the control group. This group starts treatment 5 months after the baseline assessment. No intervention is involved during this 5-month waiting period. After 5 months, the delayed group is assessed for the second time and then begins the 5-month treatment.
3207329|NCT01145820|Experimental|Juice Plus|
3207330|NCT01145820|Placebo Comparator|Placebo|
3207331|NCT01145807|Placebo Comparator|Placebo|non Transfersome® placebo
3207332|NCT01145807|Sham Comparator|Transfersome® vehicle|Transfersome® vehicle
3207333|NCT01145807|Experimental|TDT 067|TDT 067
3207334|NCT01145781|Active Comparator|Single-freeze cryotherapy|Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw.
3207335|NCT01145781|Active Comparator|Double-freeze cryotherapy|Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.
3207336|NCT01145768|Experimental|1|Each cohort will have 9 volunteers that will receive TC-5214
3207337|NCT01145768|Placebo Comparator|2|Each cohort will have 3 volunteers that will receive placebo
3207338|NCT01145755|Experimental|AZD2066|
3207339|NCT01145755|Placebo Comparator|Placebo|
3207340|NCT01145755|Active Comparator|Duloxetine|Duloxetine
3207341|NCT01145742|Experimental|self-management support and BP telemonitoring|collaborative intervention involving home BP monitoring, home behavior change counseling to enhance self management, and intensification of treatment by primary care doctors
3207342|NCT01145742|No Intervention|usual care|usual primary care management of BP. lipids, and glucose
3207343|NCT01145729|Active Comparator|Biomarker feedback|Biomarkers of tobacco exposure (laboratory values) delivered to health care provider
3207344|NCT01145729|Placebo Comparator|Usual care (general counseling)|Brochure about pesticides, lead, SHS
3207345|NCT01145716|Other|Surgical exploration|Descriptive
3207346|NCT01145703|Active Comparator|RDA Vitamin D|
3207347|NCT01145703|Experimental|Vit D repletion + 6M Supplementation|
3207348|NCT01145703|Experimental|Vit D repletion + 6M Supplementation +AEX|
3207349|NCT01145703|Experimental|Vit D repletion + 6M Supplementation +RT|
3207350|NCT01145690||Internet-based CBT|All participants in this cohort received Internet-based CBT for social anxiety disorder in 2005. All participants were Swedish adults with a DSM-IV diagnosis of social anxiety disorder.
3207351|NCT01145677|Experimental|Topiramate|
3207352|NCT01145664|Active Comparator|Western therapy|
3207353|NCT01145664|Experimental|Herbal concentrate-granules plus western therapy|
3207354|NCT01145664|Experimental|Reduning Injection plus western therapy|
3207355|NCT01145638|Experimental|iron isomaltoside 1000|Iron isomaltoside intravenously as bolus or infusion
3207356|NCT01145638|Active Comparator|iron sulphate|oral iron sulphate twice a day
3207357|NCT01145625|Experimental|5% MTF|5% Minoxidil Topical Foam
3207358|NCT01145625|Active Comparator|2% MTS|2% Minoxidil Topical Solution
3207359|NCT01145612|Experimental|Losartan|Losartán dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
3207360|NCT01145612|Experimental|Atenolol|Atenolol dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
3207361|NCT01145599||Type-2 diabetes, NPDR|Type-2 diabetic patients with NPDR.
3207362|NCT01145586|Experimental|Lactase EUF|1 oral tablet of the test drug before breakfast, lunch and dinner for 42 consecutive days
3207363|NCT01145586|Active Comparator|Lactase Ref|1 oral tablet of the comparative drug before breakfast, lunch and dinner for 42 consecutive days
3207364|NCT01145573|Placebo Comparator|Placebo|Inactive pill taken daily
3207365|NCT01145573|Active Comparator|Calcium|1000mg of calcium taken daily
3207366|NCT01145560|Experimental|1|AZD9773 250/50 units/kg
3207367|NCT01145560|Experimental|2|AZD9773 500/100 units/kg
3207368|NCT01145560|Placebo Comparator|3|
3207369|NCT01145547|Active Comparator|low glycemic index effect on post-prandial peak|Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a low Glycemic Index.
3207370|NCT01145547|Active Comparator|high glycemic index effect on post-prandial peak|Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a high Glycemic Index.
3207371|NCT01145534|Active Comparator|Glibenclamide|Patients used 5 mg glibenclamide daily for 60 days
3207372|NCT01145534|Experimental|Experimental|Patients ingested the infusion of Cissus verticillata L. prepared as 1 g in 150 mL of hot water for 10 min. This was done daily for 60 days
3207373|NCT01145508|Experimental|Arm A (vaccine therapy and chemotherapy)|Patients receive rilimogene-galvacirepvec SC on day 1 of course 1 and fowlpox-PSA-TRICOM vaccine SC on days 15, 29, 43, and 57 of course 1. Beginning on day 85 (day 1 of course 2), patients receive docetaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment with docetaxel and prednisone repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3207374|NCT01145508|Active Comparator|Arm B (docetaxel, prednisone)|Patients receive docetaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3207375|NCT01145495|Experimental|Treatment (lenalidomide, rituximab)|Patients receive lenalidomide PO QD on days 1-21. Treatment with lenalidomide repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, 15, and 22 and in weeks 13, 21, 29, and 37 in the absence of disease progression or unacceptable toxicity.
3207376|NCT01145482|Experimental|insulin|20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
3207377|NCT01145482|Placebo Comparator|Saline|200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
3207378|NCT01145456|Experimental|Treatment (RO4929097 and gemcitabine hydrochloride)|Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3207379|NCT01145443||Continuous intensivist staffing model|These are the patients admitted to participating Intensive Care Units during the 3 month phases of the study when a single intensivist was the sole attending physician of record for intervals of 2 weeks (or 1/2 month).
3207435|NCT01145014|Experimental|BI 660848 600 mg|oral drinking solution
3207436|NCT01145014|Experimental|BI 660848 10,0 mg|immediate release tablet
3207437|NCT01145014|Experimental|BI 660848 50,0 mg|immediate release tablet
3207380|NCT01145443||Discontinuous intensivist staffing model|These are the patients admitted to participating Intensive Care Units during the 3 month phases of the study when, for intervals of 2 weeks (or 1/2 month), there was a single intensivist who was the primary attending of record during Mondays-Fridays, but cross-covering colleagues took over that role during the weekends.
3207381|NCT01145430|Experimental|Treatment (veliparib and liposomal doxorubicin hydrochloride)|Patients receive veliparib PO BID on days 1-14 and pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3207382|NCT01145417|Experimental|Pregabalin (Lyrica)|
3207383|NCT01145404|Experimental|Arm A: Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
3207384|NCT01145404|Experimental|Arm B|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
3207385|NCT01145391|No Intervention|Control|Patients receive usual care.
3207386|NCT01145391|Active Comparator|Intervention|An outreach coordinator raised patient and provider awareness of unmet Blood Pressure goals, arranged Blood Pressure-focused clinic visits, and furnished providers with treatment decision support.
3207387|NCT01145365|Active Comparator|Combination Therapy Group|Patients in this arm will have surgically established drainage of their Crohns perianal fistulas and/or abscesses (exam under anesthesia (EUA)) done BEFORE beginning medical therapy with Cimzia.
3207388|NCT01145365|No Intervention|Control Group|Patients in this group will begin medical therapy with Cimzia regardless of status of surgically established drainage.
3207389|NCT01145352||Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis during registered period (2.5 year).
3207390|NCT01145339|Experimental|Lactase EUF|1 chewable tablet of the test drug 30 minutes before the standard lactose dose (25 g).
3207391|NCT01145339|Active Comparator|Lactase Ref|1 chewable tablet of the comparative drug 30 minutes before the standard lactose dose (25 g).
3207392|NCT01145326|Sham Comparator|Control|Sham-Functional microneedles (no actual microneedles) application, prior to 4% lidocaine gel (LG4) placement.
3207393|NCT01145326|Experimental|Microneedle|Functional microarray (FMA) (microneedles) application, prior to 4% lidocaine gel (LG4) placement.
3207394|NCT01145313||Patients diagnosed with Major Depressive Disorder|Patients diagnosed with MDD who are treated with antidepressants and subsequently augment with atypical antipsychotic therapy.
3207395|NCT01145261||Anxiety|Children with anxiety disorders
3207396|NCT01145261||healthy controls|children without anxiety disorders
3207397|NCT01145248|Experimental|Malignant biliary disease|
3207398|NCT01145248|Experimental|Benign biliary disease|
3207399|NCT01145235||Females previously treated with Macrolane in their breasts.|
3207400|NCT01145222|Experimental|A. CNS 7056|Initial low dose plus supplemental doses as necessary.
3207401|NCT01145222|Experimental|B. CNS 7056|Initial intermediate dose plus supplemental doses as necessary.
3207402|NCT01145222|Experimental|C. CNS 7056|Initial high dose plus supplemental doses as necessary.
3207403|NCT01145222|Active Comparator|D. Midazolam|Initial standard dose plus supplemental doses as necessary.
3207404|NCT01145183|Experimental|Doxazosin|Doxazosin is a long-acting and selective alpha 1-NE blocker, which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system.
3207405|NCT01145183|Placebo Comparator|Placebo|Matched placebo daily dosing.
3207406|NCT01145170|Experimental|Nimotuzumab|The study consists of a single treatment group, which will receive the first-line therapy for the disease. The therapy is the standard radiotherapy and a dose of the investigational product (nimotuzumab) at 150 mg/m2.
3207407|NCT01145157|Experimental|Signature Knee Guide|Total Knee Arthroplasty using the Signature Knee Guide with the Vanguard Knee System
3207408|NCT01145157|Active Comparator|Conventional Instrumentation|Total Knee Arthroplasty will be performed using Conventional Instrumentation with the Vanguard Knee System
3207409|NCT01145157|Active Comparator|Computer Assisted Navigation|Total Knee Arthroplasty will be performed using Computer Assisted Navigation with the Vanguard Knee System
3207410|NCT01145144|Experimental|DHEA supplementation|DHEA was added to induction of ovulation by recombinant FSH and recombinant LH, in IVF long protocol
3207411|NCT01145144|No Intervention|only induction of ovulation by same long protocol without DHEA|
3207412|NCT01145131|Experimental|Beef steak|
3207413|NCT01145131|Experimental|Minced beef|
3207414|NCT01145079|Experimental|Endeavor arm|
3207415|NCT01145079|Active Comparator|Endeavor resolute arm|
3207416|NCT01145079|Active Comparator|Xience arm|
3207417|NCT01145079|Active Comparator|Cypher arm|
3207418|NCT01145066|Experimental|borage and echium oil combination|borage/echium oil combination containing 0.85g/day SDA and 1.7 g/day GLA
3207419|NCT01145066|Active Comparator|fish oil|Croda 18:12 fish oil
3207420|NCT01145066|Placebo Comparator|corn oil|
3207421|NCT01145053||Treatment|
3207422|NCT01145040||Partition 1|Overt primary hypothyroidism
3207423|NCT01145040||Partition 2|"Hypothyroidism with full dose levothyroxine substitution therapy (more than 1.75 µg per kg of body mass)"
3207424|NCT01145040||Partition 3|Overt primary hyperthyroidism
3207425|NCT01145027|No Intervention|Control group|
3207426|NCT01145027|Experimental|Sensorial Stimulus|The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste, in order to trigger the cephalic phase of insulin secretion
3207427|NCT01145014|Experimental|BI 660848 2 mg|oral drinking solution
3207428|NCT01145014|Experimental|BI 660848 10 mg|oral drinking solution
3207429|NCT01145014|Experimental|BI 660848 20 mg|oral drinking solution
3207430|NCT01145014|Experimental|BI 660848 50 mg|oral drinking solution
3207431|NCT01145014|Experimental|BI 660848 100 mg|oral drinking solution
3207432|NCT01145014|Experimental|BI 660848 150 mg|oral drinking solution
3207433|NCT01145014|Experimental|BI 660848 200 mg|oral drinking solution
3207438|NCT01145014|Experimental|Placebo|matching placebo (oral drinking solution and IR tablets)
3207439|NCT01145001|Active Comparator|Active Nicotine Patch and Contingency Management|Subjects in this group will receive Contingency Management and active nicotine patch
3207440|NCT01145001|Active Comparator|Nicotine Patch with no Contingency Management|Subjects in this group will receive active nicotine patch without contingency management for abstinence
3207441|NCT01145001|Placebo Comparator|Placebo patch and Contingency Management|Subjects in this group will receive a placebo transdermal patch and contingency management
3207442|NCT01145001|Placebo Comparator|Placebo Patch and no Contingency Management|Subjects in this group will receive a placebo patch and will not receive contingency management
3207443|NCT01144975|Active Comparator|XOMA 052|
3207444|NCT01144975|Placebo Comparator|Placebo|
3207445|NCT01144962|Sham Comparator|Control group|Patients in the control group will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.
3207446|NCT01144962|Active Comparator|Cohort 1|10x10^6 MSC
3207447|NCT01144962|Active Comparator|Cohort 2|30x10^6 MSC
3207448|NCT01144962|Active Comparator|Cohort 3|90x10^6 MSC
3207449|NCT01144949|Active Comparator|silodsosin|
3207450|NCT01144949|Placebo Comparator|placebo|
3207451|NCT01144936|Experimental|Panel 1: VX-985 Dose 1|
3207452|NCT01144936|Experimental|Panel 2: VX-985 Dose 2|
3207453|NCT01144936|Experimental|Panel 3: VX-985 Dose 3|
3207454|NCT01144923|Active Comparator|Conservative treatment|Pharmacotherapy with nortriptyline and/ or gabapentin, physical therapy (e.g. range of motion, therapeutic massage, strengthening exercises), and possibly others (e.g. acupuncture)
3207455|NCT01144923|Experimental|Epidural Steroids|A series of up to 3 epidural steroid injections (ESI)with depo-methylprednisolone
3207456|NCT01144923|Experimental|Combination Treatment|These patients will receive both treatments. They can have up to 3 epidural steroid injections (ESI) with depo-methylprednisolone, and conservative treatment (i.e. pharmacotherapy with nortriptyline and/ or gabapentin, and physical therapy)
3207457|NCT01144910||BHR non-atopy|Patients from the outpatient Department of Allergy, Pneumology and Cystic fibrosis, children's hospital, Goethe-University, Frankfurt, Germany. Over a time-span of 5 years the investigators will explore the lung function and the bronchial hyperresponsiveness. Bronchial methacholine challenges will be performed at baseline and after 1, 3 and 5 years.
3207458|NCT01144910||BHR atopy|Patients from the outpatient Department of Allergy, Pneumology and Cystic fibrosis, children's hospital, Goethe-University, Frankfurt, Germany. Over a time-span of 5 years the investigators will explore the lung function and the bronchial hyperresponsiveness. Bronchial methacholine challenges will be performed at baseline and after 1, 3 and 5 years.
3207459|NCT01144897|Experimental|PET Acetate Imaging with Docetaxel|"PET-acetate as an intermediate endpoint in the assessment of response of patients undergoing docetaxel for hormone refractory prostate cancer (HRPC).~Subjects will be treated with docetaxel, 75 mg/m2 every 21 days until disease progression or unacceptable toxicity occurs. Subjects will have two PET acetate scans - one prior to beginning chemotherapy and one approximately 8-9 weeks after chemotherapy has begun."
3207460|NCT01144884|Other|Single arm trial|"Education:To standardize, treatment education will consist of counsel to stay active. Details will be given to subjects verbally & reinforced in the home booklet.~Posture:Facilitation of proper posture has been show to increase recruitment of the lumbar multifidus & deep neck flexors. Instruction will be given verbally & in writing.~Stretching:Stretching exercises will be targeted to address these common impairments. Patients will be introduced to proper stretching procedures. Each stretch will be held for 30s & repeated two times,each side as applicable. The following stretches will be performed:~Upper trap Anterior/medial Scalene Suboccipital Pectoralis~Muscular Performance: Muscle performance will be trained incorporating components of strength, endurance and motor control. Each of the exercises listed below are outlined based on progressions.~Isometric Cervical Extension Craniocervical flexion Seated Row Seated T Palms Up Seated Side Arm Raises"
3207461|NCT01144871||Male Parent/Guardians|Male Parent/Guardian of Adolescent 12-17 yo. Health care members of either San Francisco General Hospital or Kaiser Permanente Northern California.
3207462|NCT01144871||Female Parent/Guardian|Female Parent/Guardian of Adolescent 12-17 yo. Health care members of either San Francisco General Hospital or Kaiser Permanente Northern California.
3207463|NCT01144858||patients with persistent atrial fibrillation ablation|
3207464|NCT01144845||Thoracic surgical patients|Patients with pulmonary malignancies
3207465|NCT01144832|Placebo Comparator|placebo capsule|
3207466|NCT01144832|Active Comparator|ebastine|
3207467|NCT01144819||STEMI|Patients with STEMI according to ESC STEMI guidelines: Age above 18 years and able to give written, informed consent to participation in the project.
3207468|NCT01144806|Active Comparator|Group 1|Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
3207469|NCT01144806|Active Comparator|Group 2|Ready to use therapeutic food (RUTF / PlumpyNut)will be provided to parent/care givers of children with severe malnutrition in enrolled in this group
3207470|NCT01144767|Experimental|Computer-generated advisor|Participants receive sessions with a computer-generated adviser who will provide tailored advice and encouragement to engage in physical activity.
3207471|NCT01144767|Active Comparator|Comparison control condition|Participants will receive live, group sessions on health topics unrelated to physical activity.
3207472|NCT01144741||Freeman-Sheldon syndrome Classic Type|"Patients who have all features required by the Stevenson criteria, including: very small mouth (microstomia); whistling-face appearance (pursed lips); H or V shaped chin dimple; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping."
3207473|NCT01144741||Freeman-Sheldon syndrome Craniofacial Type|"Patients who have only the face and skull physical findings required by the Stevenson criteria, including: very small mouth (microstomia), whistling-face appearance (pursed lips), H or V shaped chin dimple, very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases)."
3207564|NCT01144169|Experimental|Hydroxychloroquine (HC)|HC orally for 14 days prior to nephrectomy
3207474|NCT01144741||Freeman-Sheldon syndrome Mixed Type|Patients who have the face and skull physical findings required by the Stevenson criteria and some but not all required joint problems.
3207475|NCT01144741||Sheldon-Hall syndrome|Patients who have all features required by the Stevenson criteria, including: small mouth (not microstomia); neck webbing (pterygium colli); small but prominent chin; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
3207476|NCT01144741||Distal Arthrogryposis Type 1|Patients with features consistent with this diagnosis, including restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
3207477|NCT01144741||Distal Arthrogryposis Type 3|Patients with features consistent with this diagnosis, including: gap in the roof of the mouth (cleft palate); drooping eyelid (blepharoptosis); and backbones curve problems; and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
3207478|NCT01144728|Experimental|Single arm Glimepiride+metformin|Start and titration based on FBG and tolerance. Titration should be achieved within maximum 4 weeks.
3207479|NCT01144715|Experimental|Hand Mentor Therapy|Use of the Hand Mentor (TM) Stroke Therapy Device at home for 8 weeks
3207480|NCT01144715|Active Comparator|Control|Self administered home therapy program
3207481|NCT01144702|Experimental|artesunate & mefloquine combination|ASMQ will be administered to individuals with uncomplicated malaria by P. falciparum according to the dose regimen for age and weight, standardized (Farmanguinhos, Ministry of Health). For patients in the range of 5 to <18kg (6 months to 5 years old), will be offered treatment in the pediatric presentation of Artesunate+Mefloquine 25 +50 mg (5 to <9 kg = 1 tablet once daily for 3 days, 9 to <18 kg = 2 tablets once daily for 3 days). To study subject aged 18 or more kilos (six years or more years old) will be given the combination of Artesunate + Mefloquine presentation ASMQ 100 +200 mg (18 to 29 kg = 1 tablet once daily for 3 days, 30 kg or more = 2 tablets once daily for 3 days). Clinically and biochemically monitoring will be done for 42 days.
3207482|NCT01144689|Experimental|Mindfulness Training|
3207483|NCT01144689|Active Comparator|Smoking Cessation Therapy|
3207484|NCT01144676|Experimental|Group A1: Dapivirine Vaginal Ring|
3207485|NCT01144676|Placebo Comparator|Group A2: Placebo Vaginal Ring|
3207486|NCT01144676|Experimental|Group B1: Dapivirine Vaginal Ring|
3207487|NCT01144676|Placebo Comparator|Group B2: Placebo Vaginal Ring|
3207488|NCT01144663|Experimental|Group A|3 primary doses of meningococcal vaccine GSK 134612 at 2, 3 and 4 months of age with a booster dose of meningococcal vaccine GSK 134612 at 12 months of age.
3207489|NCT01144663|Experimental|Group B|2 primary doses of meningococcal vaccine GSK 134612 at 2 and 4 months of age with a booster dose of meningococcal GSK 134612 at 12 months of age.
3207490|NCT01144663|Active Comparator|Group C|2 primary doses of MenC-CRM197 at 2 and 4 months of age with a booster dose of MenC-CRM197 at 12 months of age.
3207491|NCT01144663|Active Comparator|Group D|2 primary doses of MenC-TT at 2 and 4 months of age with a booster dose of MenC-TT at 12 months of age.
3207492|NCT01144650|Placebo Comparator|Placebo|Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
3207493|NCT01144650|Experimental|Dapsone|Patients will receive either a single total dose of 250 mg IV and oral dosage
3207494|NCT01144637|Experimental|Group 1|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
3207495|NCT01144637|Experimental|Group 2|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
3207496|NCT01144637|Experimental|Group 3|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
3207497|NCT01144637|Placebo Comparator|Group 4|Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
3207498|NCT01144624|Experimental|1|"AZD9773 250 units/kg (1 infusion) + 50 units/kg (9 infusions) (Dose Cohort 1):~AZD9773 500 units/kg (1 infusion) + 100 units/kg (9 infusions) (Dose Cohort 2)"
3207499|NCT01144624|Placebo Comparator|2|
3207500|NCT01144611|Active Comparator|bIAP|intravenous as a bolus of bIAP (alkaline phosphatase, 1000 IU) just prior to surgery followed by a 40 IU/kg bIAP infusion during the first 8 hours post surgery.
3207501|NCT01144611|Placebo Comparator|placebo|intravenous as a bolus just prior to surgery followed by an infusion during the first 8 hours post surgery.
3207502|NCT01144598||Turkish patients with rheumatoid arthritis|
3207503|NCT01144585|Experimental|RIPC|those who receive RIPC and RIPoC before and after CPB
3207504|NCT01144585|Placebo Comparator|Control|this group have same pneumatic cuff around their arm, but it is not inflated.
3207505|NCT01144572||1|Chinese postmenopausal HR(+) EBC patients during adjuvant Aromatase Inhibitors(AIs) treatment
3207506|NCT01144559|Active Comparator|Continuous Infusion|Each subject will have one lower extremity (Right or Left) randomized to receive a perineural catheter with a continuous infusion of local anesthetic and then the outcomes will be measured.
3207507|NCT01144559|Active Comparator|Bolus Administration|The opposite lower extremity (right or left) will be randomized to receive a perineural catheter with the local anesthetic being delivered via a bolus as opposed to continuous as is the case with their other extremity. The outcome measures will then be assessed as described.
3207508|NCT01144546|Experimental|Passive Leg Raising|elevation of both legs to a 45 degrees for about 1-2 minute before anesthesia induction
3207509|NCT01144533|Placebo Comparator|Isotonic saline|
3207510|NCT01144533|Experimental|Steroid|
3207511|NCT01144533|Experimental|Hyaluronate|
3207512|NCT01144533|Experimental|Steroid + Hyaluronate|
3207513|NCT01144520||Normoglycemic|Healthy subjects that do not have diabetes
3207514|NCT01144520||Type II Diabetes (HbA1c <7 or 7%)|Subject that have Type II Diabetes with good glucose control with glycated hemoglobin (HbA1c <7 or 7%)
3207515|NCT01144520||Type II Diabetes (HbA1c between 7.1-9)|Subjects with Type II Diabetes with moderate glucose control (HbA1c between 7.1-9)
3207516|NCT01144520||Type II Diabetes (HbA1c >9%)|Subjects with Type II Diabetes with poor glucose control (HbA1c >9%)
3207517|NCT01144507||Group A|Approximately 60 subjects with a heterogeneous echo pattern of the liver on abdominal ultrasound (HTG US).
3207518|NCT01144507||Group B|Approximately 680 subjects with a normal echo pattern on abdominal ultrasound (NL US). Of these subjects, approximately 110 will be matched 1:1 with Group A participants and followed for the duration of the study. The remaining unmatched subjects will not be followed beyond their initial visit.
3207519|NCT01144507||Group C|An estimated 30 subjects with cirrhosis pattern on abdominal ultrasound. These subjects will be followed in the study.
3207520|NCT01144507||Group D|An estimated 30 subjects with diffusely homogeneous echogenic pattern at screening ultrasound will be followed in the study.
3207521|NCT01144494|Active Comparator|Intraocular pressure lowering drug|Eyedrops for lowering intraocular pressure
3207522|NCT01144494|Placebo Comparator|Artificial Tears|Lubricated eye drops
3207523|NCT01144481||breast cancer with metastasis|female breast cancer patients with metastases to any site
3207524|NCT01144468||MAP3 Participants|study participants in the MAP.3 study are randomly assigned to either placebo or 25 mg exemestane daily for 5 years. Allocation is blinded. We are following 354 of these study participants and are blinded to treatment allocation.
3207525|NCT01144455|Active Comparator|Gemcitabine|Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle
3207526|NCT01144455|Experimental|240 mg/m2 TH-302 + Gemcitabine|"TH-302: 240 mg/m2 administered IV over 30 minutes Day 1, 8, and 15 of each 28-day cycle~Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle"
3207527|NCT01144455|Experimental|340 mg/m2 TH-302 + Gemcitabine|"TH-302: 340 mg/m2 of TH-302 be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.~Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle"
3207528|NCT01144442|Experimental|HIPC Treatment|Patients treated with hyperthermic intraperitoneal chemotherapy at first recurrence of disease.
3207529|NCT01144429|Active Comparator|100 DPP/mL|Concentration of solution fo s.c. injection: 100 DPP/mL
3207530|NCT01144429|Active Comparator|1000 DPP/mL|Concentration of solution fo s.c. injection: 1000 DPP/mL
3207531|NCT01144429|Active Comparator|5000 DPP/mL|Concentration of solution fo s.c. injection: 5000 DPP/mL
3207532|NCT01144429|Active Comparator|10000 DPP/mL|Concentration of solution fo s.c. injection: 10000 DPP/mL
3207533|NCT01144416|Experimental|Single injection of 150 µg SCH 900962 (MK-8962)|Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7
3207534|NCT01144416|Active Comparator|Daily 300 IU recFSH|Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of recFSH from Stimulation Days 1-7
3207535|NCT01144403|Experimental|Rituximab|Rituximab, 375 milligram per meter square (mg/m^2) was given intravenously on Day 1 and then every 28 days (+/-7 days) for 6 cycles, followed by 2 consolidated infusions in responders as rituximab induction therapy. Rituximab infusions were administered concomitantly with prescribed chemotherapy i.e., fludarabine, cyclophosphamide and mitoxantrone (maximum 6 cycles).
3207536|NCT01144390|Experimental|CBT plus MMT|cognitive behavioral therapy for heroin addicts with methadone maintenance treatment
3207537|NCT01144390|Active Comparator|methadone maintenance treatment|methadone maintenance treatment for heroin addicts
3207538|NCT01144377|Experimental|180 mg LY2541546 Q4W + Placebo|"LY2541546: 180 milligrams (mg) administered subcutaneously every 4 weeks (Q4W) for 52 weeks.~Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks."
3207539|NCT01144377|Experimental|180 mg LY2541546 Q2W|LY2541546: 180 milligrams (mg) administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
3207540|NCT01144377|Experimental|270 mg LY2541546 Q2W|LY2541546: 270 milligrams (mg) LY2541546 administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
3207541|NCT01144377|Experimental|270 mg LY2541546 Q12W + Placebo|"LY2541546: 270 milligrams (mg) administered subcutaneously every 12 weeks (Q12W) for 52 weeks.~Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks."
3207542|NCT01144377|Placebo Comparator|Placebo Comparator Q2W|Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
3207543|NCT01144364|Experimental|1|
3207544|NCT01144351|Experimental|ELND002|ELND002 sc injection
3207545|NCT01144351|Placebo Comparator|Placebo|placebo injection
3207546|NCT01144338|Experimental|Exenatide Once Weekly|
3207547|NCT01144338|Placebo Comparator|Placebo|
3207548|NCT01144312|Experimental|pharmacokinetics of fentanyl|
3207549|NCT01144299|Experimental|Fluarix Adult Group|Subjects aged 18 to 60 years received one dose of Fluarix™.
3207550|NCT01144299|Experimental|Fluarix Elderly Group|Subjects aged > 60 years received one dose of Fluarix™.
3207551|NCT01144286|Placebo Comparator|placebo|placebo pessary, single dose
3207552|NCT01144286|Experimental|Arasertaconazole nitrate 150 mg|Arasertaconazole nitrate 150 mg pessary, single dose
3207553|NCT01144286|Experimental|arasertaconazole nitrate 300 mg|Arasertaconazole nitrate 300 mg pessary, single dose
3207554|NCT01144286|Experimental|arasertaconazole 600 mg|Arasertaconazole nitrate 600 mg pessary, single dose
3207555|NCT01144273|Active Comparator|0.5% Ropivacaine|group receiving TAP block (0.5% ropivacaine at TAP plane)
3207556|NCT01144273|Placebo Comparator|normal saline|group receiving placebo (saline) at TAP plane
3207557|NCT01144260|Experimental|Bafetinib|
3207558|NCT01144247|Experimental|alloreactive CTL arm|
3207559|NCT01144234|Experimental|Invitation letter to male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
3207560|NCT01144234|Placebo Comparator|Information letter|In this arm the pregnant women got an information letter about antenatal care.
3207561|NCT01144221|Experimental|Stem cell treatment|Patients treated via stem cell injection
3207562|NCT01144182|No Intervention|Current Best Practice (CBP)|CBP received no intervention and only current best practices for inpatient HF care.
3207563|NCT01144182|Active Comparator|Quality improvement program (QIP)|Comprehensive quality improvement program (QIP) intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
3207566|NCT01144143|Placebo Comparator|Salt Water|
3207567|NCT01144143|Active Comparator|Methylprednisolone acetate|
3207568|NCT01144117|Experimental|Erythropoietin|Erythropoietin treated patients contra placebo.
3207569|NCT01144104|Experimental|Public Service Announcements|Demographically targeted public service announcement
3207570|NCT01144104|Experimental|Interactive Multi-Media Computer Program|Personally tailored information about seeking care for depression based on respondent characteristics
3207571|NCT01144104|Active Comparator|Attention Control Video|Two-minute video focusing on common sleep disorders.
3207572|NCT01144091|Experimental|pentoxyphylline cardio|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo coronary angiography
3207573|NCT01144091|Placebo Comparator|placebo cardio|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo coronary angiography
3207574|NCT01144091|Experimental|radiology pentoxyphylline|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo computed tomography with contrast
3207575|NCT01144091|Placebo Comparator|radiology placebo|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo computed tomography with contrast
3207576|NCT01144078|Experimental|High Intensity Interval Exercise|This arms receives the High Intensity Interval Exercise intervention
3207577|NCT01144078|Experimental|Traditional Intensity Exercise|This arms receives the Traditional Intensity Exercise intervention
3207578|NCT01144065||Patient with acute MI|Patients with acute MI ( elevated cardiac enzymes + chest pain or typical ECG changes)admitted to the cardiology department at Meir Medical Center
3207579|NCT01144065||Patient with prior cardiovascular disease and/or diabetes|These patients do not have acute coronary syndrome or stroke. Prior cardiovascular disease (CVD) is defined as a history of hospital admission due to acute coronary artery occlusion, percutaneous coronary interventions (PCI), coronary artery bypass grafting, any aortic or peripheral vascular disease that was either symptomatic or required intervention, ischemic or hemorrhagic stroke or transient ischemic attack.
3207580|NCT01144065||Patients without prior cardiovascular disease or diabetes|These patients do not have acute coronary syndrome or stroke Prior cardiovascular disease (CVD) or diabetes
3207581|NCT01144052|Active Comparator|Natalizumab|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.
3207582|NCT01144052|Experimental|Interferon-beta-1b|250 mcg (8 MIU) subcutaneous injections every other day
3207583|NCT01144026|Experimental|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
3207584|NCT01144026|Experimental|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
3207585|NCT01144000|Experimental|Daptomycin|High dose Daptomycin in hip, knee and shoulder prosthesis infections
3207586|NCT01143987|Experimental|Cinacalcet|Oral cinacalcet
3207587|NCT01143974|Experimental|PC Regimen|
3207588|NCT01143961|Experimental|NBL with one-way valve|NBL performed with one-way valve in ventilator circuit during procedure
3207589|NCT01143961|No Intervention|Standard NBL|Performance of standard NBL with recording of changes in regional ventilation by electrical impedance tomography
3207590|NCT01143948|Active Comparator|15 patient sliding scale regular insulin|
3207591|NCT01143948|Active Comparator|15 patient BBI NPH plus regular insulin|
3207592|NCT01143948|Active Comparator|15 patients BBI Glargine plus Glulisine|
3207593|NCT01143935||Live patients|All patients undergoing CT scans of the abdomen for non hepatobiliary conditions
3207594|NCT01143935||Autopsy cases|All autopsy cases with no liver disease or trauma.
3207595|NCT01143922||Patients with gastrointestinal tract malignancies|All patients with GI tract malignancies undergoing surgery will be subjected to intraoperative ultrasound
3207596|NCT01143909|Experimental|No FFP transfusion prior to intervention|Patients with a coagulopathy (INR 1,5-3,0), who are randomized to omitting transfusion of fresh frozen plasma before they undergo an intervention.
3207597|NCT01143909|No Intervention|FFP transfusion prior to intervention|Patients with a coagulopathy (INR 1,5-3,0), who are randomized to transfusion of fresh frozen plasma before they undergo an intervention. This is considered standard care.
3207598|NCT01143896|Experimental|Arm 1: Depression Collaborative Care|Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
3207599|NCT01143896|No Intervention|Arm 2: Usual Care|Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.
3207600|NCT01143883|Experimental|Silverlon Dressing|The Silverlon(Cura Surgical, Geneva, IL) dressing is applied to the surgical wound postoperatively. This dressing is coated with silver nylon.
3207601|NCT01143883|Active Comparator|Standard of Care Dressing|The standard plain gauze is used to dress the wound postoperatively
3207602|NCT01143870|Other|Hemoglobin A1C|Diabetes control related to patients using standard hemoglobin A1C
3207603|NCT01143870|Experimental|Face|Face expressing emotion used to depict diabetes control
3207604|NCT01143870|Experimental|Letter grade|Letter grade used to express diabetes control
3207605|NCT01143857|Active Comparator|Varenicline|
3207606|NCT01143857|Placebo Comparator|Placebo|
3207722|NCT01142986|Experimental|Low Threshold Stepped Care (LTSC)|Subjects in this condition will receive low intensity care during the first 3-months (13 weeks) of study participation, and usual counseling care during the final 3-months (13 weeks) of participation.
3207607|NCT01143844||Exposed females, ages 11-40|"Prior exposure to alkylating agent chemotherapy and/or radiation therapy~At least 1 year from completion of chemotherapy and/or radiation therapy~Uterus and at least one ovary are present~Not pregnant or breastfeeding in the past 3 months~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~No medical condition (other than cancer) known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
3207608|NCT01143844||Unexposed females, ages 40-50|"Never exposed to chemotherapy or radiation therapy~Regular menstrual cycle (every 21-35 days)~Uterus and at least one ovary are present~Not pregnant or breastfeeding in the past 3 months~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~No medical condition known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
3207609|NCT01143844||Unexposed females, ages 11-35|"Never exposed to chemotherapy or radiation therapy~Regular menstrual cycle (every 21-35 days)~Uterus and at least one ovary are present~Not pregnant or breastfeeding in the past 3 months~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~No medical condition known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
3207610|NCT01143831|Experimental|All study participants|Three blood collections, one at baseline, one two weeks later, and the final blood collection 4 weeks from baseline, after taking Vitamin K orally for 14 days.
3207611|NCT01143818||AndroGel (testosterone gel )1%|AndroGel is topical testosterone gel 1% (1 sachet of 5 g contains 50 mg of testosterone), 1 daily dose.
3207612|NCT01143805|Experimental|Treatment A: Tasocitinib 10 mg oral tablet|
3207613|NCT01143805|Experimental|Treatment B: Tasocitinib 10 mg IV Infusion|
3207614|NCT01143792|Experimental|CRA + HIV prevention|
3207615|NCT01143792|Active Comparator|Case Management + HIV prevention|
3207616|NCT01143792|Active Comparator|MET + HIV prevention|
3207617|NCT01143779|Experimental|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
3207618|NCT01143766|Active Comparator|Standard sedation|Patients will receive combination opiate and benzodiazepine for sedation, the current standard of care.
3207619|NCT01143766|Active Comparator|Gapabentin|Patients will receive gabapentin 900mg PO x 1 dose, one hour prior to the procedure. At the time of ERCP, patients will be sedated in a standard fashion.
3207620|NCT01143753|Experimental|RO5212054: Continuous Dosing Cohort|Participants will receive RO5212054 in escalating dose levels.
3207621|NCT01143753|Experimental|RO5212054: New Formulation (F05) Bridging Cohort|Participants will receive RO5212054 as a single dose of new formulation (F05-150 mg film-coated tablet with different ratios of ingredients than F03 to increase bioavailability) and a single dose of current clinical Formulation (F03-150 mg film-coated tablet) in a cross-over manner. Participants will be alternately assigned to receive either F05 or F03 as their first dose, followed by the opposite Formulation as their second dose. Dose of RO5212054 will be decided based on the results of continuous dosing cohort.
3207622|NCT01143740|Experimental|Single Arm|
3207623|NCT01143727|Active Comparator|A|Santyl
3207624|NCT01143727|Active Comparator|B|Tegaderm Hydrogel
3207625|NCT01143714|Active Comparator|A|
3207626|NCT01143714|Placebo Comparator|B|
3207627|NCT01143701|Experimental|ADHD Collaborative Intervention|The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the American Academy of Pediatrics consensus recommendation for evidence-based ADHD care.
3207628|NCT01143701|No Intervention|Typical ADHD care|Physicians in this group will provide typical ADHD care.
3207629|NCT01143688|Active Comparator|albuterol inhaler|albuterol
3207630|NCT01143688|Placebo Comparator|placebo inhaler|placebo
3207631|NCT01143688|Placebo Comparator|placebo acupuncture|placebo
3207632|NCT01143662|Experimental|Group 1|Ypeginterferon alfa-2b 90mcg per week
3207633|NCT01143662|Experimental|Group 2|Ypeginterferon alfa-2b 135mcg per week
3207634|NCT01143662|Experimental|Group 3|Ypeginterferon alfa-2b 180mcg per week
3207635|NCT01143662|Active Comparator|Group 4|Pegasys 180mcg per week
3207636|NCT01143649|Experimental|active tDCS + CIMT - stroke patients|Participants will receive 5 sessions of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT - 10 consecutive sessions Monday- Friday).
3207637|NCT01143649|Experimental|active tDCS + CIMT - Healthy|Participants will receive one session of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT)
3207638|NCT01143649|Experimental|tACS - Healthy Subjects|The investigators will have 40 healthy subjects who will undergo one session of treatment with active tACS (in which the order in which they receive either sham or active transcranial alternating current stimulation (tACS) stimulation will be randomized).
3207639|NCT01143649|Sham Comparator|sham tDCS + CIMT - stroke patients|Participants will receive 5 sessions of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT - 10 consecutive sessions Monday- Friday). For the sham session, tDCS is turned off after 30seconds.
3207640|NCT01143649|Sham Comparator|sham tDCS + CIMT - Healthy|Participants will receive one session of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT). The sham stimulation consists of 30 seconds of stimulation at the beginning of the 40 min of treatment.
3207641|NCT01143649|Sham Comparator|sham tACS - Healthy Subjects|The investigators will have 40 healthy subjects who will undergo one day of treatment with sham tACS. All participants received active and sham stimulation in a randomized order.
3207765|NCT01142661|Experimental|Eribulin mesylate|
3207642|NCT01143636|Sham Comparator|Active tDCS - pelvic pain patients|ACTIVE tDCS: Subjects will receive a total of 10 consecutive sessions of active tDCS over a two-week period (administered Monday - Friday). During each session, the anode electrode will be placed over the primary motor cortex of the predominantly painful side.
3207643|NCT01143636|Experimental|Sham tDCS - pelvic pain patients|SHAM tDCS: Subjects will receive a total of 10 consecutive sessions of sham tDCS over a two-week period (administered Mon-Fri). During each session, the anode will be placed over the primary motor cortex of the predominantly painful side.
3207644|NCT01143636|Experimental|Active tDCS - healthy|The healthy controls will undergo one day of treatment with active tDCS. All participants will receive both active and sham stimulation in a randomized order.
3207645|NCT01143636|Experimental|Sham tDCS - healthy|The healthy controls will undergo one day of treatment with sham tDCS. All participants will receive both active and sham stimulation in a randomized order.
3207646|NCT01143623|Active Comparator|Probiotic|
3207647|NCT01143623|Active Comparator|Probiotic-2|
3207648|NCT01143623|Placebo Comparator|Placebo|
3207649|NCT01143610|Experimental|Newly forming bone|Miller class I or II deep recessions treated by the newly forming bone technique.
3207650|NCT01143610|Active Comparator|Subepithelial connective tissue graft|Miller class I or II deep recessions treated by subepithelial connective tissue graft.
3207651|NCT01143597|Active Comparator|Somatosensory stimulation (SS)|Participants in the SS group receive median nerve electrical stimulation applied to the skin of the wrists.
3207652|NCT01143597|Active Comparator|Massed practice + somatosensory stimulation (MP+SS)|Participants in the MP+SS group receive a combined intervention consisting of SS and a skill-based exercise protocol
3207653|NCT01143597|Active Comparator|Conventional resistance training (CRT)|Participants in the CRT group will participate in a weight-based exercise program
3207654|NCT01143584|Experimental|Rapid escalation|Weekly escalation of cabergoline dose in macroprolactinomas Start with 1 mg/week. increase by 1mg/wk every week till 4 weeks. after 4 weeks Cabergoline dose would be increased @1mg/wk every 4 weekly till normalization of prolactin and >50% decrease in tumor volume from baseline.
3207655|NCT01143584|Active Comparator|Conventional escalation|"Conventional escalation of cabergoline~In the Conventional escalation group schedule of cabergoline dosing will be 0.5 mg once a week for 4 weeks. Cabergoline will be incrementally dose adjusted on the basis of individual Prolactin values till amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or till primary endpoint."
3207656|NCT01143545|Experimental|1|Allogeneic tumor cell vaccine + chemotherapy
3207657|NCT01143441|Experimental|Cohort A|Long-Term daclizumab cohort
3207658|NCT01143441|Experimental|Cohort B|New Treatment Cohort
3207659|NCT01143441|No Intervention|Cohort C|MS Controls
3207660|NCT01143402|Experimental|Arm I (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who are unable to be treated with temozolomide may be treated with dacarbazine IV every 3 weeks (with approval from the Principal Investigator). Patients who experience disease progression may crossover to arm II.
3207661|NCT01143402|Experimental|Arm II (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3207662|NCT01143389|Active Comparator|Riboflavin 0.1% eyedrops every 5 minutes|The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 5 minutes for this arm).
3207663|NCT01143389|Active Comparator|Riboflavin 0.1% eyedrops every 2 minutes|The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 2 minutes for this arm).
3207664|NCT01143376|Active Comparator|Moderate intensity exercise|Moderate intensity exercise
3207665|NCT01143376|Experimental|High Intensity training|High Intensity intermittent training
3207666|NCT01143376|Experimental|Short springs|short springs training
3207667|NCT01143363|Placebo Comparator|Resting - control|No exercise
3207668|NCT01143363|Experimental|Moderate intensity exercise|Moderate intensity exercise (continuous) 1h after breakfast
3207669|NCT01143363|Experimental|High intensity intermittent training|High intensity intermittent training 1h after breakfast
3207670|NCT01143363|Experimental|Short sprint|Short sprint 1h after breakfast
3207671|NCT01143350|Experimental|EHPAD Training and Stimulation|"EHPAD of the group of Training / Stimulation will benefit:~after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.~of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD."
3207672|NCT01143350|Placebo Comparator|2- EHPAD control|EHPAD of the reference group, will have their habitual functioning
3207673|NCT01143337|Experimental|1|dose1
3207674|NCT01143337|Placebo Comparator|2|Placebo
3207675|NCT01143324||MAST™ procedure|
3207676|NCT01143311|Other|ARM A|"4 distinct biopsies will be taken~in a non UV-exposed area (inner arm)~in a UV-exposed area (external surface of the forearm)~in a pretumoral region (actinic keratosis)~inside the tumor"
3207677|NCT01143298|Experimental|LEO 27847 oral solution 0.1 mg|LEO 27847 oral solution 0.1 mg
3207678|NCT01143298|Experimental|LEO 27847 tablet 0.10 mg|LEO 27847 tablet 0.10 mg
3207679|NCT01143298|Experimental|LEO 27847 tablet 0.01 mg|LEO 27847 tablet 0.01 mg
3207723|NCT01142986|Experimental|Voucher-Based Stepped Care (VBSC)|Subjects in this condition will receive usual counseling care during the entire 6 months of study participation. They will receive voucher reinforcement, and will have the opportunity to earn voucher incentives during the first 3-months of care (13 weeks).
3207724|NCT01142986|No Intervention|Routine Stepped-Care (RSC)|Subjects in this condition will receive usual counseling care during the entire 6-month study (26 weeks).
3207725|NCT01142960|Active Comparator|Placebo|Starch
3207726|NCT01142960|Experimental|Lycium Barbarum|Lycium Barbarum supplement
3207766|NCT01142622|Experimental|Ropivacaine nebulization|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
3208104|NCT01140165|Active Comparator|butter|Danish butter
3207680|NCT01143285|Experimental|I - Early and active nutritional support.|During the initial consultation, the dietician will answer the questions of the patient and their family. Patients will be seen regularly in follow-up for weight measurement, serum albumin assay, a 1 or 3 day food record and an evaluation of appetite level. Nutritional counselling is then adjusted accordingly and:Balanced meals are continued if weight is stable and appetite is undiminished.Protein and energy fortification is recommended if weight loss is observed or if food intake decreases between 2 consultations leading to total food intake of less than 50% of required food intake. When a patient presents with signs of malnutrition according to the criteria set out by the Authority for Health, oral nutritional support (ONS) is set up, in agreement with the department head. Two 200ml bottles of Fortimel Extra are to be taken every day. If this ONS strategy is insufficient to improve the patient's nutritional status, artificial nutrition should be discussed.
3207681|NCT01143285|No Intervention|II - No nutritional support|Should malnutrition develop in a group II patient, ONS will be ordered. It will consist of two 200ml Fortimel Extra* bottles per day in addition to regular meals. Ideally, the ONS should be taken as a snack outside of meal times so as to not spoil the appetite. If this ONS is insufficient to improve the nutritional status of the patient, artificial nutrition (either enteral or parenteral) will be discussed.
3207682|NCT01143272|Active Comparator|Saccharomyces boulardii|Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
3207683|NCT01143272|Placebo Comparator|Microcristallin cellulose|Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
3207684|NCT01143259|Placebo Comparator|300 mg Polyethylene|
3207685|NCT01143259|Active Comparator|Alvimopan|
3207686|NCT01143246|Experimental|Terlipressin|intravenous terlipressin (1 mg) every 6 hours with concomitant albumin
3207687|NCT01143246|Placebo Comparator|Placebo|lyophilized mannitol
3207688|NCT01143233|Active Comparator|control formula group|infants are fed a commercial, hydrolysed formula during the first 4 month of life, according to protocol
3207689|NCT01143233|Experimental|intervention formula 1 group|infants are fed hydrolyzed infant formula with different protein content during the first 4 month of life, according to protocol
3207690|NCT01143233|Experimental|intervention formula 2 group|infants are fed hydrolyzed infant formula with different protein content with pro- and prebiotics during the first 4 month of life, according to protocol
3207691|NCT01143233|Experimental|intervention formula 3 group|infants are fed hydrolyzed instant formula with different protein content with pro- and prebiotics during the first 4 months of life, according to protocol
3207692|NCT01143233|No Intervention|Reference group|infants are breast fed
3207693|NCT01143220||ICD / CRT-D patient|Patients implanted with a single or dual chamber ICD or CRT-D device approved in Japan capable of using the IBP feature.
3207694|NCT01143207|Experimental|Medroxyprogesterone acetate|Single injection of Medroxyprogesterone acetate (hormonal contraceptive)
3207695|NCT01143194|Experimental|oréVida™ 60mg/day|
3207696|NCT01143194|Experimental|oréVida™ 120mg/day (1)|
3207697|NCT01143194|Experimental|oréVida™ 120mg/day (2)|
3207698|NCT01143194|Placebo Comparator|Placebo|
3207699|NCT01143142|Experimental|Tailoring|Individuals assigned to the experimental group will receive a two-page brochure tailored based on their responses to the survey.
3207700|NCT01143142|Active Comparator|Untailored information|Individuals assigned to the control group will receive the CDC vaccine information sheet that is standardly provided.
3207701|NCT01143129|Experimental|dexamethasone|Single dose of dexamethasone (1 mg/kg) at the start of the cardiac surgical procedure
3207702|NCT01143129|Placebo Comparator|Placebo|
3207703|NCT01143103|Experimental|Respiratory therapy with cough assist|
3207704|NCT01143103|Active Comparator|Usual respiratory therapy|
3207705|NCT01143090|Experimental|Open Label|Subjects will continue on treatment with the same dose of lurasidone flexible dosing - 40 mg to 12 mg once daily taken orallay at endpoint of the D1050289 ( NCT01143077) core study.
3207706|NCT01143077|Experimental|Lurasidone Open-Label Arm A|
3207707|NCT01143077|Experimental|Lurasidone Open-Label Arm B|
3207708|NCT01143077|Experimental|Lurasidone Open-Label Arm C|
3207709|NCT01143064|Active Comparator|Progesterone|
3207710|NCT01143064|Placebo Comparator|Lipid emulsion without progestrone|
3207711|NCT01143051|Active Comparator|Treatment C|Active comparator arm utilizing marketed Primatene Mist with CFC propellant at the labeled dose.
3207712|NCT01143051|Experimental|Treatment 1|T1 is HFA propelled epinephrine inhalation aerosol 125 mcg/inhalation
3207713|NCT01143051|Experimental|Treatment 2|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation
3207714|NCT01143038|Experimental|Romiplostim|Participants received romiplostim administered weekly by subcutaneous injection during the 12-month treatment period. The starting dose was 1 μg/kg with weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L.
3207715|NCT01143025|Active Comparator|Ropivacaine 50 mg|Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity
3207716|NCT01143025|Experimental|Ropivacaine 100 mg|Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity
3207717|NCT01143025|Experimental|Ropivacaine 150 mg|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
3207718|NCT01143012|Active Comparator|Group eczema education session|One group will attend a group eczema education session. All subjects will answer quality of life questions two times.
3207719|NCT01143012|Active Comparator|Control group|The other group will not attend the group eczema education session. Both groups will be asked quality of life questions two times.
3207720|NCT01142999|Active Comparator|Intervention (moisturizer group)|One group will be instructed to use a choice of 3 FDA-approved moisturizers and soap substitutes on their newborn infants.
3207721|NCT01142999|Active Comparator|Control group (no moisturizers)|This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.
3207764|NCT01142687|Placebo Comparator|Placebo capsule|• Group 3: 3 placebo capsules three times per day within 30 minutes before breakfast, lunch and dinner
3207727|NCT01142947|Other|beclomethasone dipropionate (BD)|Patients who meet eligibility criteria will be treated with 6 weeks of beclomethasone dipropionate to assess change in pulmonary function and asthma control. These change will be used as phenotypes in a genetic association study. There is no placebo group.
3207728|NCT01142934|Other|TegaDerm CHG|TegaDerm CHG is the interventional arm to be compared with the control group in which the dressing is TegaDerm (without CHG).
3207729|NCT01142921|Active Comparator|Ordinary Tannenbaum biliary stent|Ordinary Tannenbaum biliary stent
3207730|NCT01142921|Experimental|Anti-reflux Tannenbaum biliary stent|Anti-reflux Tannenbaum biliary stent
3207731|NCT01142908|Experimental|Arm 1|The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
3207732|NCT01142908|No Intervention|Arm 2|The education control group - these participants will receive educational material about CVD reduction.
3207733|NCT01142882|Active Comparator|Traditional Prevention|educator-delivered, small-group HIV & disease prevention education
3207734|NCT01142882|Experimental|Web-based Prevention|self-directed, interactive & customized web-based HIV & disease prevention education
3207735|NCT01142817||HIV Postive Women|Women living with HIV who meet study eligibility criteria
3207736|NCT01142817||Healthy Control Subjects|Women without HIV who meet study eligibility criteria
3207737|NCT01142804|Experimental|Enhanced Usual Care Group|Participants received weekly emailed tips of the week to provide support for walking.
3207738|NCT01142804|Experimental|WalkLink Group|Participants received weekly emailed tips of the week, plus evidence-based online fitness walking program.
3207739|NCT01142804|Experimental|WalkLink+ Group|Participants received weekly emailed tips, plus evidence-based online fitness walking program, plus online/in-person social network intervention.
3207740|NCT01142791|Other|ExAblate treatment|
3207741|NCT01142778|Experimental|Trastuzumab, Docetaxel, and Bevacizumab|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of <70% will receive trastuzumab and docetaxel along with bevacizumab in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the bevacizumab infusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
3207742|NCT01142778|Active Comparator|Trastuzumab and Docetaxel|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of <70% will receive trastuzumab and docetaxel in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the study treatment perfusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
3207743|NCT01142778|Active Comparator|Trastuzumab and Docetaxel (Standard Regimen)|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of >/=70% will receive trastuzumab and docetaxel in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the study treatment perfusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
3207744|NCT01142765|Experimental|Group 1|1 dose of AdCh63 MSP1 and 1 dose MVA MSP1 followed by sporozoite challenge
3207745|NCT01142765|Experimental|Group 2|1 dose of AdCh63 AMA1 and 1 dose MVA AMA1 followed by sporozoite challenge
3207746|NCT01142765|Experimental|Group 3|1 dose of AdCh63 AMA1 and 1 dose AdCh63 MSP1 co-administered into separate arms followed by 1 dose of MVA AMA1 and 1 dose MVA MSP1 co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge
3207747|NCT01142765|Experimental|Group 4|1 dose of AdCh63 MSP1 and 1 dose AdCh63 ME-TRAP co-administered into separate arms followed by 1 dose of MVA MSP1 and 1 dose MVA ME-TRAP co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge
3207748|NCT01142765|Other|Group 5|Non-vaccinated controls for sporozoite challenge
3207749|NCT01142752||Control|Control group of women with uneventful pregnancy
3207750|NCT01142752||Population at risk with preterm birth|Women medically considered at risk for PTB and actually delivering preterm
3207751|NCT01142752||Population at risk without preterm birth|Women medically considered at risk for PTB but with uneventful pregnancy
3207752|NCT01142739||Parkinson's Disease patient|levodopa-treated parkinson's disease (PD) patients
3207753|NCT01142739||Non Parkinson's disease controls|Non Parkinson's disease controls
3207754|NCT01142726|Active Comparator|Abatacept, 125 mg, plus methotrexate, 2.5 mg|Participants received abatacept, 125 mg subcutaneously, plus methotrexate, 2.5 mg orally as tablets, once weekly, during the 12-month Treatment Period
3207755|NCT01142726|Active Comparator|Methotrexate, 2.5 mg, plus abatacept placebo|Participants received methotrexate, 2.5 mg, orally as tablets, plus abatacept placebo subcutaneously, once weekly during the 12-month Treatment Period
3207756|NCT01142726|Active Comparator|Abatacept, 125 mg, plus methotrexate placebo|Participants received abatacept, 125 mg subcutaneously, plus methotrexate placebo tablets orally, once weekly during the 12-month Treatment Period
3207757|NCT01142700|Experimental|BMS-824393 (10mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
3207758|NCT01142700|Experimental|BMS-824393 (30 mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
3207759|NCT01142700|Experimental|BMS-824393 (100 mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
3207760|NCT01142700|Placebo Comparator|Placebo|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
3207761|NCT01142700|Other|Peginterferon alfa-2a plus Ribavirin|Weeks 13 - 48
3207762|NCT01142687|Active Comparator|dihydrocapsiate 3 mg|• Group 1: 1 Dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner
3207763|NCT01142687|Active Comparator|dihydrocapsiate 9 mg|• Group 2: 3 Dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner
3207767|NCT01142622|Active Comparator|Ropivacaine instillation|Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity before surgery
3207768|NCT01142609|Experimental|Internet (eGetgoing)|Subjects will assigned to use an accredited web-based platform (eGetgoingTM, CRC Health Group, Inc.) to deliver routine substance abuse counseling.
3207769|NCT01142609|No Intervention|Routine on-site|Subjects will attend routine face-to-face individual counseling sessions.
3207770|NCT01142596|Experimental|Asenapine 5 mg BID|Participants continue in the same arm they were on in core trial P06124 (except placebo arm starts 5 mg BID at Week 2) and will be re-randomized after Week 6 to asenapine 5 mg BID or asenapine 10 mg BID, administered open-label for 46 weeks. Open label dose can be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
3207771|NCT01142596|Experimental|Asenapine 10 mg BID|Participants continue in the same arm they were on in core trial P06124 (except placebo arm starts 5 mg bid at Week 2) and will be re-randomized after Week 6 to asenapine 5 mg BID or asenapine 10 mg BID, administered open-label for 46 weeks. Open label dose can be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
3207772|NCT01142570|Active Comparator|Group 1|Patients will be receive caloric support as dictated by Hariss-Benedict Formula (Group 1)
3207773|NCT01142570|Active Comparator|Group 2|Patients will be receive caloric support as dictated by Indirect Calorimetry (Group 2)
3207774|NCT01142570|Active Comparator|Group 1A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the first(Group 1A)group will receive caloric support calculated by the HARISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight."
3207775|NCT01142570|Active Comparator|Group 2A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight."
3207776|NCT01142570|Active Comparator|Group 3A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the third group will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight."
3207777|NCT01142544||Pediatric ALIEN|All children from 1 month to 18 years old meeting the American-European Consensus Conference definition of acute lung injury
3207778|NCT01142531||COPD|COPD patients aged 40 or more, with a smoking history of > 10 PY and a post-bronchodilator FEV1/VC < 0.7 will be included. Exclusion criteria are: COPD exacerbation or respiratory infection in the 4 weeks before the begin of the study, concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active malignancy or malignancy of any organ system within the past 5y.
3207779|NCT01142505|Placebo Comparator|Placebo|Patients in the placebo arm will be given an inactive version of the investigational medical product formed of the excipient mannitol (which is coated with the active drug montelukast in the active comparator arm)
3207780|NCT01142505|Active Comparator|Montelukast|Patients in the active arm will be given an active version of the investigational medical product formed of the inactive excipient mannitol with a coating of active drug montelukast.
3207781|NCT01142479|Placebo Comparator|herbal A|dilute of (TPE-1) decoction.
3207782|NCT01142479|Experimental|herbal B|TPE-1 decoction (100 ml)
3207783|NCT01142466|Experimental|Rebif (3x44 mcg) Group|
3207784|NCT01142466|No Intervention|No treatment Group|
3207785|NCT01142440|Experimental|behavioral intervention|
3207786|NCT01142440|No Intervention|convention dental treatment|
3207787|NCT01142427||Ancillary-Correlative (classification)|Patients undergo blood sample collection and bone marrow biopsies at baseline and during and after induction therapy for immunophenotyping for ALL confirmation and classification, DNA ploidy, genomic variation, and cytogenetic (BCR-ABL, trisomies 4+10, and molecular testing for translocations) analysis by flow cytometry and FISH. Immunophenotype results obtained on this study are used to determine patient's assignment to specific clinical-trial treatments. Some samples (leukemic and germline) may be banked for current and/or future analyses.
3207788|NCT01142401|Experimental|Arm A (fulvestrant)|Patients receive fulvestrant IM on day 1 (days -14, 1, and 15 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may crossover to arm C.
3207789|NCT01142401|Experimental|Arm B (fulvestrant, bortezomib)|Patients receive fulvestrant as in arm A and bortezomib IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3207790|NCT01142401|Experimental|Arm C (fulvestrant, bortezomib)|Patients receive fulvestrant IV on day 1 and bortezomib IM on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3207791|NCT01142388|Experimental|Arm I (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
3207792|NCT01142388|Experimental|Arm II (cixutumumab, paclitaxel)|Patients receive cixutumumab IV over 1 hour on days 1 and 15, and paclitaxel as in Arm I.
3207793|NCT01142362|Experimental|0.6mg of DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 0.6 mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
3207794|NCT01142362|Experimental|2mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 2mg of DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
3207795|NCT01142362|Experimental|6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 6 mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
3207796|NCT01142349|Experimental|Lifestyles A|Cognitive Behavioral Therapy for Pain and Insomnia
3207797|NCT01142349|Experimental|Lifestyle B|Cognitive Behavioral Therapy for Pain
3207798|NCT01142349|Active Comparator|Lifestyles C|Osteoarthritis Education
3207799|NCT01142336|Experimental|Simvastatin|Simvastatin 40mg qHS for 1 year
3207800|NCT01142336|Placebo Comparator|Placebo|Placebo 1 tablet qHS for 1 year
3207801|NCT01142323|Experimental|Fenofibrate|fenofibrate 160 mg po daily
3207886|NCT01141608|Experimental|Health Education Intervention|Health Education Intervention
3207887|NCT01141595|Experimental|Kuvan®|Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
3207802|NCT01142310|Active Comparator|Lamotrigine|Dose titration: begin at Baseline at 25mg PO QD for two weeks. Increase to 50mg PO QD at Week 2 for two weeks. Increase to 100mg PO QD at Week 4. Increase to 150mg PO QD at Week 5. Increase to 200mg PO QD at Week 6. Increase to 250mg PO QD at Week 7. Increase to 300mg PO QD at Week 8. Increase to 350mg PO QD at Week 9. Increase to 400mg PO QD at Week 10. Stay at 400mg PO QD from Week 10 to Week 48.
3207803|NCT01142310|Placebo Comparator|Placebo|Placebo administered the same as the Lamotrigine just described.
3207804|NCT01142297|Other|dental implant|standard SLA surface and chemically modified surface
3207805|NCT01142284|Placebo Comparator|Placebo|Placebo
3207806|NCT01142284|Experimental|Cilostazol|cilostazol
3207807|NCT01142284|Experimental|Probucol|probucol
3207808|NCT01142284|Experimental|Cilostazol + Probucol|cilostazol and probucol
3207809|NCT01142271|Experimental|Billroth-I|Patients in this group should be underwent gastroduodenostomy as reconstruction procedure after standard distal subtotal gastrectomy with lymph node dissection.
3207810|NCT01142271|Experimental|Roux en Y|Patients in this group should be underwent jejunojejunostomy and gastrojejunostomy as reconstruction procedure after standard distal gastrectomy.
3207811|NCT01142258|Experimental|Trazodone|Study group will receive trazodone 50mg
3207812|NCT01142258|Placebo Comparator|Placebo|Inert pill
3207813|NCT01142245|Active Comparator|oral esomeprazole|"Esomeprazole placebo IV loading bolus~Esomeprazole placebo intravenous infusion for 72 hours~Oral Esomeprazole: 80 mg/Day on Day 1, 2 and Day 3, and the drug will be given as 40 mg q12h."
3207814|NCT01142245|Active Comparator|Intravenous Esomeprazole|"Esomeprazole IV loading bolus 80mg~• Esomeprazole intravenous infusion 8mg/hr for 72 hours"
3207815|NCT01142232|Experimental|Melphalan with lenalidomide|Melphalan will be given on Day -2 and Day -1. Lenalidomide will be given from Day -7 to Day +2.
3207816|NCT01142219|Experimental|L-arginine|0.1g/kg/day for 6 months
3207817|NCT01142206|Active Comparator|Physical Activity|A standard behavioral weight loss intervention with a physical activity prescription of 200 minutes of moderate intensity physical activity per week.
3207818|NCT01142206|Experimental|Physical Activity & TV Watching|A standard behavioral weight loss intervention with a physical activity prescription of 200 minutes of moderate intensity physical activity per week and an additional prescription of reducing TV watching to 10 hours per week or less.
3207819|NCT01142193|Experimental|USL255|
3207820|NCT01142193|Placebo Comparator|Placebo|
3207821|NCT01142180|Active Comparator|TAE group|Patients will be undergone TAE after endoscopic hemostasis.
3207822|NCT01142180|Active Comparator|No TAE group|No TAE procedure will be performed after endoscopic treatment.
3207823|NCT01142167|Active Comparator|Standard Colonoscopy|Colonoscopy with standard instrument
3207824|NCT01142167|Experimental|Ultra-thin colonoscopy|New prototype scope
3207825|NCT01142154|Experimental|oral, liquid solution|
3207826|NCT01142141|Other|Manual therapy, kinesiotherapy|
3207827|NCT01142128|Active Comparator|Nexium alone|Nexium alone is given for one month to be compared to a placebo to Nexium, Viokase 16 plus Nexium and Viokase 16 plus a placebo to Nexium
3207828|NCT01142128|Placebo Comparator|Placebo to Nexium, alone|Placebo to Nexium is given instead of Nexium for one month. This will be compared to the Nexium alone, Viokase 16 plus Nexium and Viokase 16 plus placebo to Nexium
3207829|NCT01142128|Active Comparator|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month.
3207830|NCT01142128|Placebo Comparator|Viokase 16 + placebo to Nexium|Viokase 16 is given with a placebo to Nexium for one month to be compared against Viokase 16 plus Nexium, Nexium alone and Placebo to Nexium alone
3207831|NCT01142115|Experimental|Monza|nonCE marked intermittent catheter
3207832|NCT01142115|Active Comparator|control|SpeediCath coated catheter
3207833|NCT01142102|Experimental|Arm 1|Radiation Therapy
3207834|NCT01142089|Placebo Comparator|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours)
3207835|NCT01142089|Experimental|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
3207836|NCT01142076|Placebo Comparator|placebo|Dose treatment group, 10%
3207837|NCT01142076|Active Comparator|Xinju Xiaogao Prescription|treatment group
3207838|NCT01142063||Treatment A (Reference fasted)|Treatment A (Reference fasted): A 40 mg tablet strength neratinib administered as a single dose of 6 x 40 mg under fasted condition.
3207839|NCT01142063||Treatment B (Test fasted)|Treatment B (Test fasted): A 240 mg tablet strength neratinib administered as a single dose of 1 x 240 mg under fasted condition.
3207840|NCT01142063||Treatment C (Reference fed)|Treatment C (Reference fed): A 40 mg tablet strength neratinib administered as a single dose of 6 x 40 mg under fed condition.
3207841|NCT01142063||Treatment D (Test fed)|Treatment D (Test fed): A 240 mg tablet strength neratinib administered as a single dose of 1 x 240 mg under fed condition.
3207842|NCT01142037|Experimental|Furanocoumarin|Includes participants first refraining from eating foods with furanocoumarins for one week, followed by 2 weeks of increasing furanocoumarin consumption. Participants will be asked to consume cooked parsnips and parsley.
3207843|NCT01142024|Placebo Comparator|saline|saline hydration
3207844|NCT01142024|Experimental|Glutathione|
3207845|NCT01142011|Experimental|Belimumab|"The first cycle of Belimumab is a loading cycle of 3 doses over 28 days (days 1, 15, 29).~After the first cycle, additional cycles of belimumab will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles)."
3207846|NCT01141998|Placebo Comparator|Placebo|
3207847|NCT01141998|Active Comparator|Vitamin D administered orally|
3207848|NCT01141998|Experimental|Vitamin D administered via UVB|
3207849|NCT01141985|Other|Treated|This is a single arm study.
3207888|NCT01141569|Experimental|Treatment (RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3207889|NCT01141556|Placebo Comparator|Placebo|Placebo (NaCl) i.v. intraoperatively, followed by an daily bolus of Placebo (NaCl) i.v. until discharge from ICU (no longer than 13 days)
3207850|NCT01141972|Active Comparator|Supplement|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml [≥75 nmol/L]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency
3207851|NCT01141972|Placebo Comparator|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
3207852|NCT01141933|Other|Usual care|Subjects in this group receive the usual treatment only.
3207853|NCT01141933|Experimental|Individual intervention|Consisting in a 12 weekly sessions with a therapist. Each session lasts 1 hour.
3207854|NCT01141933|Experimental|Group intervention|Consisting in a 12 weekly sessions with two therapists. Number of subjects in each group is from 5 to 10. Each session lasts 2 hours.
3207855|NCT01141920|Active Comparator|3-month counseling induction: routine care|Participants assigned to this condition will receive routine stepped-care treatment at ATS. Participants will begin in Step 2 (one counseling session per week), and be advanced to higher intensity care based on missed counseling sessions and drug-positive urine samples. Participants advanced to Step 3 will be scheduled to attend 2 group counseling sessions per week (in addition to individual counseling), and those advanced to Step 4 will be scheduled to attend 8 group counseling sessions per week (in addition to individual counseling). Time of methadone dosing will be based on step of care.
3207856|NCT01141920|Experimental|3-month counseling induction: low threshold|Participants assigned to this treatment arm will receive low threshold counseling. These participants will be scheduled to attend one counseling session per month with their individual counselor for the first 3-months. Participants can attend more counseling sessions if they desire, and they can meet with program supervisors to address crisis situations. They can receive methadone dosing any time during the clinic hours (7:30 am-1:15 pm and 4:00 pm - 6:00 pm)
3207857|NCT01141907|Experimental|Heart Failure Self Care Support|
3207858|NCT01141907|Active Comparator|Usual Heart Failure Care|
3207859|NCT01141894|Active Comparator|Routine fluid treatment|Buffered Glucose 25 mg/ml 1ml/kg/h Ringer`s Acetate 2 ml/kg/h and additionally as needed Voluven at the attending anaesthetist's discretion Phenylephrine 50 μg for correction of hypotension
3207860|NCT01141894|Experimental|Goal directed haemodynamic treatment|Goal directed haemodynamic treatment Dobutamine 0.2-10 μg/kg/min Buffered Glucose 25 mg/ml 1ml/kg/h Ringer`s Acetate 2 ml/kg/h Voluven 3 ml/kg as fluid challenge at the attending anaesthetist's discretion Phenylephrine 50 μg for correction of hypotension
3207861|NCT01141881|Experimental|TPA,IVB,F/U|
3207862|NCT01141868|Experimental|Internet Intervention|
3207863|NCT01141868|Experimental|Delayed Intervention|Receive access to the online Internet intervention after completing post-assessments.
3207864|NCT01141855|Experimental|Champix plus counselling|varenicline tartrate will be initiated whilst subjects are inpatients with the standard MIMS dosing schedule (including period of titration). In combination with Quit SA (5A) telephone counselling service
3207865|NCT01141855|Active Comparator|counselling alone|5A counselling via Quit SA (quitline) telephone counselling service. (maximum 8 phone calls per subject within a 3 month period).
3207866|NCT01141842|Experimental|lung cancer|breath samples of patients with confirmed lung cancer
3207867|NCT01141842|Active Comparator|underlying lung disease|patients with underlying lung disease and impairment in lung function
3207868|NCT01141842|Sham Comparator|healthy individual|healthy individual with no lung disease and no history of cancer including lung cancer
3207869|NCT01141816|Experimental|Contrast-Enhanced Ultrasound|
3207870|NCT01141803|No Intervention|control|
3207871|NCT01141803|Active Comparator|Apples|
3207872|NCT01141803|Active Comparator|Apple pomace|
3207873|NCT01141790|Placebo Comparator|Silence|"The control group listened silence and was evaluated the same things."
3207874|NCT01141777|Active Comparator|Spirulina platensis|
3207875|NCT01141777|Placebo Comparator|Soya bean|
3207876|NCT01141764|Experimental|Study Group|"In our study, patients will be scanned with their DBS electrodes turned on and off.~Participation involves undergoing 2 separate PET scans on 2 separate days. The MRI and neuropsychological tests will either be performed on the same day as one of the PET scans or on a separate day.~Procedures performed in this study are not part of the standard management of epilepsy."
3207877|NCT01141738|Experimental|Caregiver Problem-Solving Intervention|The experimental treatment will provide structured information, guided problem-solving, and training in skills for coping with stress and emotional responses (e.g., relaxation, cognitive reframing, changing negative problem orientation, PS skills).
3207878|NCT01141738|Other|Wait List Control|WLC subjects will be offered an intervention after the 6 month assessment. Both groups will receive standard services provided by the rehabilitation team to CGs of stroke survivors.
3207879|NCT01141725|Experimental|Treatment (combination chemotherapy)|Patients receive bendamustine hydrochloride IV on days 1-5 and idarubicin IV on days 1 and 2. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3207880|NCT01141712|Other|Autologous transplant|Patients will receive BCNU 300 mg/m^2 Day -6, Etoposide 100 mg/m^2 BID Days -5 to -2, Cytarabine 100 mg/m^2 BID Days -5 to -2, and Melphalan 140 mg/m^2 Day -1 followed by autologous HCT.
3207881|NCT01141699||female|Women who live in the Shuang Ho Region of Taipei City. Women can read and write chinese language.
3207882|NCT01141660|Experimental|Endotracheal Tube|Children undergoing adenotonsillectomy are randomized to endotracheal tube or laryngeal mask airway.
3207883|NCT01141660|Experimental|Laryngeal Mask Airway|Children undergoing adenotonsillectomy are randomized to endotracheal tube or laryngeal mask airway.
3207884|NCT01141647|Experimental|24-Month Supported Employment|Evidence-Based Supported Employment Vocational Rehabilitation or Other Vocational Services
3207885|NCT01141608|Experimental|Vigorous Intensity High Dose Exercise|Usual Care Augmented with Vigorous Intensity High Dose Exercise
3207890|NCT01141556|Active Comparator|Selenase|Selenase Bolus 4000 microgram i.v. intraoperatively, followed by an daily bolus of Selenase 1000 microgram i.v. until discharge from ICU (no longer than 13 days)
3207891|NCT01141543||cohort 1|Patients in Cohort 1 will be followed with daily Flowcytometric studies to quantify CXCR4 positive cells.The samples will be obtained before the following doses of FLUDARABINE and BUSULFAN. Eighteen hrs (range 18 -20 hrs) after start of the last dose of FUDARABINE andBUSULFAN and before the first dose of TBI a PB sample as well as bone marrow aspirate and biopsy will be obtained to repeat the studies as conducted prior to the first dose of PLERIXAFOR
3207892|NCT01141543||Cohort 2|Patients in Cohort 2 will receive the second dose of PLERIXAFOR 24 hrs after the first dose. A PB sample for a CBS and Flowcytometry will be drawn prior to the dose. Nine hrs later a further study sample for Flowcytometry will be obtained prior to administration of the second dose of FLUARABINE and BUSULFAN. Flowcytometric studies will be repeated on day 3 and 4. Eighteen hrs (range 18 - 20 hrs) after start of the last dose of FLUDARABINE and BUSULFAN and before the first dose of TBI a PB sample as well as bone marrow aspirate and biopsy will be obtained to repeat the studies as conducted prior to the first dose of PLERIXAFOR.
3207893|NCT01141543||cohort 3|Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN
3207894|NCT01141543||Cohort 4|Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN
3207895|NCT01141530||Tissue Bank Samples|Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study. All samples studied will be obtained through the UAMS Tissue Bank.
3207896|NCT01141504|Placebo Comparator|Placebo|Oral placebo capsules similar in color and size to the intervention
3207897|NCT01141504|Active Comparator|PeakATP 250|Oral supplement capsules containing 250 mg/day of PeakATP
3207898|NCT01141504|Active Comparator|PeakATP 400|Oral supplement capsules containing 400 mg/day of PeakATP
3207899|NCT01141504|Active Comparator|PeakATP 400 plus proprietary blend|Oral supplement capsules containing 400 mg/day of PeakATP plus a proprietary blend
3207900|NCT01141491|Experimental|Arm A|Vaccine plus OPT-821
3207901|NCT01141491|Active Comparator|Arm B - OPT-821 immunologic adjuvant|Patients will be given 10 injections of OPT-821 alone as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
3207902|NCT01141478|Active Comparator|Proton Beam Radiotherapy plus Sorafenib|A combination of radiation therapy (proton) to kill tumor cells as well as Sorafenib which is a study drug administered to patients to stop tumor growth.
3207903|NCT01141478|Active Comparator|Sorafenib|Sorafenib is an oral pill taken daily to inhibit tumor growth at the cellular level.
3207904|NCT01141465||IPDA FP/SAL DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL DPI at ≥twice the equivalent BDP-equivalent dose
3207905|NCT01141465||IPDA FP/SAL MDI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL MDI at ≥twice the equivalent BDP-equivalent dose
3207906|NCT01141465||IPDI FP/SAL DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL DPI at equivalent BDP-equivalent dose
3207907|NCT01141465||IPDI BUD/FOR DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as BUD/FOR DPI at equivalent BDP-equivalent dose
3207908|NCT01141465||IPDI FP/SAL MDI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL MDI at equivalent BDP-equivalent dose
3207909|NCT01141465||IPDA BUD/FOR DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as BUD/FOR DPI at ≥twice the equivalent BDP-equivalent dose
3207910|NCT01141452||IPDA FP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as fluticasone via metered dose inhaler
3207911|NCT01141452||IPDA HFA-BDP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as extra-fine hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
3207912|NCT01141452||IPDA CFC-BDP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as chlorofluorocarbon beclomethasone dipropionate via metered dose inhaler
3207913|NCT01141452||IPDI CFC-BDP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as chlorofluorocarbon beclomethasone dipropionate via metered dose inhaler
3207914|NCT01141452||IPDI HFA-BDP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
3207915|NCT01141452||IPDI FP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as fluticasone propionate via metered dose inhaler
3207916|NCT01141439||IPDI HFA-BDP MDI|Patients who commenced inhaled corticosteroid therapy as HFA-BDP via MDI
3207917|NCT01141439||IPDI FP MDI|Patients who commenced inhaled corticosteroid therapy as FP via MDI
3207918|NCT01141439||IPDA FP MDI|Patients who had a step up in inhaled corticosteroid therapy as FP via MDI
3207919|NCT01141439||IPDA HFA-BDP MDI|Patients who had a step up in inhaled corticosteroid therapy as HFA-BDP via MDI
3207920|NCT01141439||IPDI CFC-BDP MDI|Patients who commenced inhaled corticosteroid therapy as CFC-BDP via MDI
3207921|NCT01141439||IPDA CFC-BDP MDI|Patients who had a step up in inhaled corticosteroid therapy as CFC-BDP via MDI
3207962|NCT01141140|Other|M-O-R|Men (M) overweight or obese (O) and restrained (R).
3207963|NCT01141140|Other|W-NO-NR|Women (W) non-obese (NO) and non-restrained (NR).
3207964|NCT01141140|Other|W-NO-R|Women (W) non-obese (NO) and restrained (R).
3207965|NCT01141140|Other|W-O-NR|Women (W) overweight or obese (O) and non-restrained (NR).
3207922|NCT01141426|Active Comparator|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
3207923|NCT01141426|Experimental|Intensive Short-Term Dynamic Psychotherapy (ISTDP) Group|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
3207924|NCT01141413||RA patients using Remicade®|
3207925|NCT01141413||RA patients using Orencia®|
3207926|NCT01141400||depression & initial prescription for an antidepressant|A sample of adults with a diagnosis of depression and an initial prescription fill for an antidepressant
3207927|NCT01141387||Patients at the intervention sites|The intervention sites will receive the results of the patient-reported depression severity collected during the phone interviews on a monthly basis. The patients in the intervention arm will be interviewed by phone once per month for 6 months.
3207928|NCT01141387||Patients at the usual care sites|The usual care sites will receive the results of the patient-reported depression severity at the end of the study. Patients in the usual care arm will be interviewed at 3 months and 6 months post study enrollment.
3207929|NCT01141374|No Intervention|control group without treatment|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
3207930|NCT01141374|Experimental|Auriculotherapy by needles|The investigators used 3 points, Shenmen, Kidney, and Brain Stem with semi-permanent needles of 1.8 mm, 1 time per week for 8 sessions.
3207931|NCT01141374|Experimental|Auriculotherapy by seeds|The investigators used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.
3207932|NCT01141361||Peripheral arterial disease patients|Patients with a peripheral arterial disease, defined by an ankle to brachial index below 0.90
3207933|NCT01141348|Experimental|Special Intervention|
3207934|NCT01141348|Experimental|Delayed Intervention|
3207935|NCT01141335|Experimental|PTFE mesh|A Lichtenstein tension-free hernioplasty is performed using PTFE mesh
3207936|NCT01141335|Active Comparator|polypropylene mesh|A Lichtenstein tension-free hernioplasty is performed using polypropylene mesh
3207937|NCT01141322|Experimental|UDCA treatment|Patients with drug-induced liver injury will be randomly allocated to UDCA treatment group: oral intake ursodeoxycholic acid (UDCA) 13-15 mg/kg BW/day into 3 divided doses after meal till the endpoint or the 8th week. UDCA is 100 mg per tab.
3207938|NCT01141322|Placebo Comparator|Placebo|Patients with drug-induced liver injury will be randomly allocated to placebo group. The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
3207939|NCT01141309|Experimental|sorafenib with everolimus|This is a two-stage phase II study combining sorafenib with everolimus in patients with thyroid cancer.
3207940|NCT01141296|Active Comparator|Fenofibrate|
3207941|NCT01141296|Placebo Comparator|sugar pill|
3207942|NCT01141283|Experimental|BTDS|Buprenorphine transdermal patch
3207943|NCT01141270|Experimental|AFOLIA|225 IU sc
3207944|NCT01141270|Active Comparator|Gonal-f|225 IU sc
3207945|NCT01141257|Experimental|Angiocal®|Angiocal®
3207946|NCT01141244|Experimental|Treatment (temsirolimus, irinotecan, temozolomide)|Patients receive temsirolimus IV over 30 minutes on days 1 and 8 or on days 1, 8, and 15 and temozolomide PO and irinotecan hydrochloride PO on days 1-5. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
3207947|NCT01141231|No Intervention|Standard Care|Standard oral hygiene care for 8 weeks, including instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice.
3207948|NCT01141231|Active Comparator|Acupuncture Group 1|Acupuncture at 3 sites on each ear, on the chin, on each forearm, and on each leg twice a week for 4 weeks; and standard oral hygiene as in standard of care arm.
3207949|NCT01141231|Active Comparator|Acupuncture Group 2|Acupuncture twice a week for 4 weeks and standard oral hygiene as in standard of care arm.
3207950|NCT01141218||Never-smokers with lung cancer|
3207951|NCT01141205|Experimental|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
3207952|NCT01141205|Placebo Comparator|Saline|Saline
3207953|NCT01141192|Active Comparator|Vitamin D3 supplement|60,000 IU vitamin D3 oral supplement provided every four weeks at weeks 0, 4, 8, and 12 in the form of one 50,000 and two 5,000 IU vitamin D3 supplements in gelcap form.
3207954|NCT01141192|Placebo Comparator|Sugar Pill|Inactive placebo tablets identical in appearance to the active comparator provided every four weeks at weeks 0,4,8,and 12.
3207955|NCT01141179|Experimental|LEO 27847|
3207956|NCT01141166|Experimental|nutritional and physical rehabilitation plan|
3207957|NCT01141153|Experimental|Oral anticoagulation plus dual antiplatelet therapy|
3207958|NCT01141153|Active Comparator|Dual antiplatelet therapy|
3207959|NCT01141140|Other|M-NO-NR|Men (M) non-obese (NO) and non-restrained (NR).
3207960|NCT01141140|Other|M-NO-R|Men (M) non-obese (NO) and restrained (R).
3207961|NCT01141140|Other|M-O-NR|Men (M) overweight or obese (O) and non-restrained (NR).
3208105|NCT01140165|Experimental|cheese|
3207966|NCT01141140|Other|W-O-R|Women (W) overweight or obese (O) and restrained (R).
3207967|NCT01141127|Active Comparator|INTERMITENT ADMINISTRATION|Administration of 10 mg/kg of Tranexamic Acid at the beginning ,the middle and at the end of the intervention
3207968|NCT01141127|Experimental|continuous administration of Tranexamic Acid|Administration of 10 mg /Kg of Tranexamic Acid at the beginning in the priming pump and continuous infusion of 1 mg/KG of Tranexamic Acid until the end of the intervention
3207969|NCT01141114|Experimental|Use of a Patient Navigator|
3207970|NCT01141114|Other|Usual Care|No Intervention - usual care
3207971|NCT01141101||MRSA-exposed|The MRSA-exposed group will include 100 MRSA-colonized mothers and their babies
3207972|NCT01141101||MRSA-unexposed|The MRSA-unexposed group will include 100 MRSA-negative mothers and their babies.
3207973|NCT01141088|Experimental|Bilateral stent-in-stent insertion|The passage of the bilateral metal stent across the stricture, stent-in-stent method.
3207974|NCT01141088|Active Comparator|Bilateral side-by-side insertion|The passage of the bilateral metal stent across the stricture, side-by-side method.
3207975|NCT01141075|Experimental|Ataluren (PTC124)|
3207976|NCT01141062|Experimental|Treated leiomyomas|Philips MR-guided HIFU
3207977|NCT01141049|Active Comparator|Gabapentin|Gabapentin will be titrated over a 7-day period to the dose target or the maximum tolerated dose. The maximum dose will be 1200mg TID. Participants must be able to tolerate and comply with at least 400 mg daily.
3207978|NCT01141049|Placebo Comparator|Placebo|Placebo capsules will be administered TID.
3207979|NCT01141036|Active Comparator|propofol|propofol
3207980|NCT01141036|Active Comparator|Midazolam|Midazolam
3207981|NCT01141023|Experimental|Datscan and AV-133|
3207982|NCT01141010|Sham Comparator|Plain language|Conventional plain language will be given without any psychological intervention
3207983|NCT01141010|Active Comparator|Pre-psycho-language|Prior surgery psychological linguistic intervention
3207984|NCT01141010|Active Comparator|Intra-psycho-language|Intraoperative psychological linguistic intervention
3207985|NCT01141010|Active Comparator|Post-psycho-language|Postoperative psychological linguistic intervention
3207986|NCT01141010|Active Comparator|Combined language|Psychological linguistic intervention will be given in a combination of pre-, intra- and post-operatively
3207987|NCT01140997|Experimental|Group 1|Ypeginterferon alfa-2b 90mcg per Week, with Ribavirin 1000-1200mg/d
3207988|NCT01140997|Experimental|Group 2|Ypeginterferon alfa-2b 135mcg per Week, with Ribavirin 1000-1200mg/d
3207989|NCT01140997|Experimental|Group 3|Ypeginterferon alfa-2b 180mcg per Week, with Ribavirin 1000-1200mg/d
3207990|NCT01140997|Active Comparator|Group 4|Pegasys 180mcg per Week, with Ribavirin 1000-1200mg/d
3207991|NCT01140984|Experimental|treatment|
3207992|NCT01140971|Active Comparator|Misoprostol|Use 25 micrograms vaginal every 6 hours (max dosis 200 micrograms in 48 hours)
3207993|NCT01140971|Active Comparator|Foley|Foley catheter number 14 or 16 was installed intracervical for no more than 48 hours.
3207994|NCT01140945||Males attending in vitro fertilization clinic|
3207995|NCT01140932|Experimental|Intervention|Medical and behavioural intervention
3207996|NCT01140906|Placebo Comparator|Placebo|
3207997|NCT01140906|Experimental|Vortioxetine: 15 mg|
3207998|NCT01140906|Experimental|Vortioxetine: 20 mg|
3207999|NCT01140906|Other|Duloxetine: 60 mg|Active Reference
3208000|NCT01140893|Experimental|exenatide|55 subjects
3208001|NCT01140893|Placebo Comparator|Placebo|55 subjects
3208002|NCT01140880|Experimental|Contingency Management|"Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for stimulant metabolites. Increasingly valuable incentives will be provided for urine samples that lack metabolites of stimulant drugs.~Participants reporting recent (i.e., < 48 hours) exposure to HIV viral inoculum will have the opportunity to initiate Truvada (1 pill daily for 28 days)."
3208003|NCT01140880|Sham Comparator|Yoked Contingency Management|"Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for stimulant metabolites. Incentives will be provided to participants independent of stimulant drug use and determined in the same rate and timing as a randomly selected participant in the active CM condition.~Participants reporting recent (i.e., < 48 hours) exposure to HIV viral inoculum will have the opportunity to initiate Truvada (1 pill daily for 28 days)."
3208004|NCT01140867|Experimental|1|
3208005|NCT01140854||Hypertension (case)|Elderly patients 60 years old or older undergoing simple lumbar spine surgery under general anesthesia will receive neurologic/neuropsychometric examinations.
3208006|NCT01140854||Normotension (control)|Middle-aged patients (40-60 years) undergoing simple lumbar spine surgery under general anesthesia as controls to compare their performance to those patients >60 years - will also receive neurologic/neuropsychometric examinations.
3208007|NCT01140841||Fipamezole ODT|
3208008|NCT01140841||Placebo|
3208009|NCT01140828|Active Comparator|Rabeprazole|Rabeprazole
3208010|NCT01140828|Placebo Comparator|Rabeprazole Placebo|Rabeprazole Placebo
3208011|NCT01140815|Active Comparator|Total|The Smith and Nephew Total Knee System
3208012|NCT01140815|Experimental|Deuce|The Journey Deuce Bicompartmental Knee System
3208013|NCT01140802||IBD patients|Crohn's disease or ulcerative colitis patients
3208014|NCT01140802||Healthy controls (non-IBD)|Patients comprise ethnicity - matched patients undergoing colonoscopy for polyp or colorectal cancer screening, or rectal bleeding
3208015|NCT01140802||Relatives of IBD patients|They will be a first degree relative of a IBD patient.
3208016|NCT01140789||Crohn's disease patients|Diagnosis of Crohn's disease by endoscopy, radiology and histology
3208017|NCT01140789||Ulcerative colitis patients|Diagnosis of ulcerative colitis defined by endoscopy, radiology and histology
3208018|NCT01140789||Non-IBD patients|Ethically, sex and aged-matched controls attending clinics or endoscopy for functional upper gastrointestinal diseases or screening colonoscopy.
3208102|NCT01140191|Experimental|WR 279,396|All subjects in this one-arm study will receive topical WR 279,396
3208106|NCT01140152||No rejection|Intestinal transplant recipients with no evidence of biopsy proven rejection
3208019|NCT01140776||OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required."
3208020|NCT01140763||Sysmex's 5-blade cutter.|
3208021|NCT01140737|Experimental|Axitinib|Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily.
3208022|NCT01140711|Experimental|Gastric bypass|Patients submitted to gastric bypass for treatment of morbid obesity
3208023|NCT01140711|Experimental|Sleeve gastrectomy|Patients submitted to sleeve gastrectomy for treatment of morbid obesity
3208024|NCT01140698||Term and preterm newborn infants|5 infants of each gestational age of 24-42 weeks
3208025|NCT01140672|Experimental|Cohort 1 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 3 mg per day for 14 days. (2 placebo: 8 active)
3208026|NCT01140672|Experimental|Cohort 2 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 3 mg per day for 14 days. (2 placebo: 8 active)
3208027|NCT01140672|Experimental|Cohort 3 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 30 mg per day for 14 days. (2 placebo: 8 active)
3208028|NCT01140672|Experimental|Cohort 4 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 100 mg per day for 14 days. (2 placebo: 8 active)
3208029|NCT01140672|Experimental|Cohort 5 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 300 mg per day for 14 days. (2 placebo: 8 active)
3208030|NCT01140672|Experimental|Cohort 6 (N=10) Optional cohort|Placebo-controlled, multiple doses of PF-04634817 up to 300 mg per day for 14 days. (2 placebo: 8 active)
3208031|NCT01140659|Other|Objective measurement of sweat|"We selected 40 patients from February 2007 to May 2009. All participants were randomized into two groups of 20 patients (G3 and G4) and underwent the sympathectomy, being followed for 12 months. We used an objective method for measuring sweat, checking the TEWL (transepidermal water loss) measured by the VapoMeter, and evaluated the quality of life before and after the operation. Also studied were: incidence and intensity of the compensatory hyperhidrosis."
3208032|NCT01140646|Experimental|Arm I|The first week of the study is a baseline week where data are being collected but study agent is not being taken. Patients then receive oral s-adenosyl-L-methionine, 400 mg, once daily on days 8-14 and twice daily on days 15-49 in the absence of unacceptable toxicity.
3208033|NCT01140620|Experimental|ketamine and risperidone|Oral risperidone pretreatment and intravenous ketamine infusion
3208034|NCT01140620|Active Comparator|ketamine and placebo|Oral placebo risperidone pretreatment and intravenous ketamine infusion
3208035|NCT01140620|Active Comparator|saline and risperidone|Oral risperidone pretreatment and intravenous saline infusion
3208036|NCT01140620|Placebo Comparator|saline and placebo|Oral placebo risperidone pretreatment and intravenous saline infusion
3208037|NCT01140620|No Intervention|Patients with Schizophrenia|Patients with schizophrenia will not receive study drug and will not undergo randomisation.
3208038|NCT01140607|Experimental|Cohort 1: normal hepatic function: cabazitaxel|"cabazitaxel 25mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
3208039|NCT01140607|Experimental|Cohort 2: mild hepatic impairment : cabazitaxel|"cabazitaxel 20mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
3208040|NCT01140607|Experimental|Cohort 3: moderate hepatic impairment: cabazitaxel|"cabazitaxel 10mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
3208041|NCT01140607|Experimental|Cohort 4: severe hepatic impairment: cabazitaxel|"cabazitaxel 5 mg/m^2 or 10mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
3208042|NCT01140607|Experimental|Cohort 5: normal hepatic function: cabazitaxel and midazolam|"cabazitaxel 25mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks).~Midazolam is given orally in single dosing on day -1 and day 1 (crossover)"
3208043|NCT01140594|Active Comparator|Wavefront-guided PRK|Wavefront-guided PRK
3208044|NCT01140594|Active Comparator|Wavefront-guided LASIK|Wavefront-guided LASIK
3208045|NCT01140581|Experimental|Group A|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks followed by dronedarone 400 mg twice daily for 8 weeks
3208046|NCT01140581|Experimental|Group B|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks. Two weeks wash-out followed by dronedarone 400 mg twice daily for 6 weeks
3208047|NCT01140581|Experimental|Group C|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks. Four weeks wash-out followed by dronedarone 400 mg twice daily for 4 weeks
3208048|NCT01140568|Experimental|nilotinib|
3208049|NCT01140555|Experimental|GYNECARE GYNOCCLUDE™|GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device
3208050|NCT01140542|Active Comparator|Roflumilast|500µg, once daily
3208051|NCT01140542|Placebo Comparator|Placebo|
3208052|NCT01140529|Experimental|Dexmedetomidine|
3208053|NCT01140529|Active Comparator|Haloperidol|
3208054|NCT01140529|Placebo Comparator|Placebo|
3208055|NCT01140516|Active Comparator|Trimethoprim|Prophylactic Antibiotics
3208056|NCT01140516|Placebo Comparator|Simple syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
3208057|NCT01140503|Experimental|apremilast|apremilast 20mg bid
3208058|NCT01140490|No Intervention|Sub-total Parathyroidectomy|
3208059|NCT01140477|Experimental|Crystalens toric IOL|Toric Accommodating Lens Crystalens toric silicone multi-piece accommodating IOL (Models AT-50T/AT-52T)
3208060|NCT01140477|Active Comparator|Crystalens IOL|Accommodating Lens Crystalens silicone multi-piece accommodating IOL (Models AT-50SE/AT-52SE)
3208103|NCT01140178|Experimental|HPPH|a fixed HPPH dose of 4 mg/m2 infused over 1 hour, and 24 hours later light doses escalating from 100 J/cm2 to 125 and 140 J/cm2, respectively.
3208061|NCT01140464|Active Comparator|Enhanced Usual Care|Usual care treatment of depression in primary care settings. Usual care considered enhanced as patients and their parents were given screening results and encouraged to seek care from their primary care doctor and behavioral health services.
3208062|NCT01140464|Active Comparator|Collaborative Care|Collaborative care intervention for depression. Involves care management, evidence based treatments in primary care setting, symptom monitoring and stepped care design
3208063|NCT01140451|Experimental|Ataluren (PTC124)|Ataluren (PTC124)
3208064|NCT01140438|Active Comparator|Metformin + NPH Insulin|Patients are treated with metformin during the run-in period (3 months) and also after randomization. By randomization insulin treatment will be added in the form of injections of NPH insulin in the evenings.
3208065|NCT01140438|Active Comparator|Metformin + sitagliptin +/-repaglinid|Patients are treated with metformin during the run-in period (3 months) and also after randomization. By randomization sitagliptin tablets will be added.If HbA1c after 6 months of treatment is > 10 % above the upper limit of normal,then treatment with repaglinide tablets tree times daily at mealtimes will be added.
3208066|NCT01140425|Experimental|PF-00232798 supratherapeutic dose|PF-00232798 supratherapeutic dose
3208067|NCT01140425|Experimental|PF-00232798 therapeutic dose|PF-00232798 therapeutic dose
3208068|NCT01140425|Placebo Comparator|Placebo for PF-00232798|Placebo for PF-00232798
3208069|NCT01140425|Active Comparator|Moxifloxacin|Moxifloxacin
3208070|NCT01140412|Experimental|Cohort 1|Twice daily regimen
3208071|NCT01140412|Experimental|Cohort 2|Once daily regimen
3208072|NCT01140399|Active Comparator|Infusional drug treatment|Diuretics or diuretics plus fixed low dose dopamine infusion
3208073|NCT01140399|Experimental|Ultrafiltration|Device: Ultrafiltration appliance Sessions of 8 h UF are conducted on 2 subsequent days in the first 48 hours after randomization; a third session is performed on day 3 in case of persistent congestion
3208074|NCT01140386||hospital pediatric patients 1/1/2000-12/31/2008 documented VTE|Age <18 Hospitalized for greater than or equal to 24 hours VTE documented during hospital admission
3208075|NCT01140373|Experimental|autologous T cells & cyclophosphamide.|This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of engineered autologous T cells targeted to Prostate-Specific Membrane Antigen (PSMA) administered one day after pretreatment with cyclophosphamide.
3208076|NCT01140360|Experimental|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA > 1.8 m2 or 55 mg/m2 twice daily for patients with BSA < 1.8 m2. For patients with a BSA > 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA < 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
3208077|NCT01140347|Experimental|Ramucirumab DP and BSC|
3208078|NCT01140347|Placebo Comparator|Placebo and BSC|
3208079|NCT01140334|Experimental|Reinforced On-Site Integrated Care (ROIC)|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. In addition, they will be able to earn a voucher incentive for each week of psychiatric compliance.
3208080|NCT01140334|Active Comparator|Standard On-Site Integrated Care (SOIC).|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week.
3208081|NCT01140321|Experimental|Neridronato|Thalassemia Major or Severe Thalassemia Intermedia
3208082|NCT01140321|No Intervention|Placebo|Thalassemia Major or Severe Thalassemia Intermedia
3208083|NCT01140308|Placebo Comparator|Sugar Pill|Simvastatin 20mg + Placebo
3208084|NCT01140308|Active Comparator|Co Q10|Simvastatin 20mg + CoQ10
3208085|NCT01140295|Active Comparator|1, Miralax|Miralax colonoscopy preparation
3208086|NCT01140295|Active Comparator|2, senna|Senna colonoscopy preparation
3208087|NCT01140282|Active Comparator|Arm I (Control)|Patients refrain from increasing physical activity levels for 16 weeks.
3208088|NCT01140282|Experimental|Arm II (Exercise)|Patients participate in supervised exercise sessions over 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30-45 minutes once weekly for 16 weeks.
3208089|NCT01140269|No Intervention|No PCR testing|Control patients will not have PCR testing. This group will have routine testing and treatment as defined by the standard of care.
3208090|NCT01140269|Experimental|PCR testing|PCR will be used in parallel with routine laboratory tests such as culture. Treatment for PCR results will be based on the standard of care. Treatment of the patient will be dependent on the physician's clinical judgment based on existing clinical information including PCR, microbiology, patient physical presentation, and other laboratory results.
3208091|NCT01140256||SGA infants|SGA infants were recruited at birth and zinc stable isotope was administered at birth and at 6 months of age .This was a longitudinal study whereby the growth trajectory and zinc pools were measured.
3208092|NCT01140256||AGA|AGA infants were recruited at birth and zinc stable isotope was administered at birth and at 6 months of age .This was a longitudinal study whereby the growth trajectory and zinc pools were measured.
3208093|NCT01140256||SGA infant|Infants who were born small for gestational age were recruited and zinc stable isotopes were administered at birth and at 6 months.
3208094|NCT01140243|Experimental|test product|Dietary supplement
3208095|NCT01140243|Active Comparator|standart|Dietary supplement
3208096|NCT01140217|Experimental|Active treatment|Norethindrone Acetate Transdermal Delivery System
3208097|NCT01140204|Placebo Comparator|Placebo control|Contrast medium without Paclitaxel
3208098|NCT01140204|Active Comparator|Iopromide Paclitaxel 0.85 mg|Iopromide Paclitaxel 0.85 mg
3208099|NCT01140204|Active Comparator|Iopromide Paclitaxel 4.27 mg|Iopromide Paclitaxel 4.27 mg
3208100|NCT01140204|Active Comparator|Iopromide Paclitaxel 8.54 mg|Iopromide Paclitaxel 8.54 mg
3208101|NCT01140204|Active Comparator|Iopromide Paclitaxel 17.08 mg|Iopromide Paclitaxel 17.08 mg
3208107|NCT01140152||Rejection|Intestinal transplant recipients who had evidence of biopsy proven rejection
3208108|NCT01140139|Experimental|HIV DNA + Hydroxyurea|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption. The patients also received 500 mg of hydroxyurea daily.
3208109|NCT01140139|Experimental|HIV DNA|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
3208110|NCT01140139|Placebo Comparator|Placebo|PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
3208111|NCT01140126|Experimental|Antibody (UB-421)|
3208112|NCT01140113|No Intervention|Placebo|this group had undergone to routine coronary artery bypass graft surgery
3208113|NCT01140113|Experimental|Modified Ultrafiltration|patients after weaning from bypass were submitted to ultrafiltration
3208114|NCT01140100|Active Comparator|propofol-propofol|
3208115|NCT01140100|Experimental|thiopental-propofol|
3208116|NCT01140087|Experimental|Interventional|Face Transplantation
3208117|NCT01140074|Experimental|Zinc sulfate|Children in active treatment group will be given zinc sulfate 10-20 mg per day orally plus probiotics
3208118|NCT01140074|Placebo Comparator|Placebo|Children will be given placebo plus probiotics
3208119|NCT01140061|Experimental|Panel A - MK-0873 5.1 mg|In Part I, healthy participants received skin patches containing nothing (plain patch), placebo, and various potencies of MK-0873 cream (0.05%, 0.5%, or 2%; yielding a dose of 5.1 mg of MK- 0873) once daily for 21 days.
3208120|NCT01140061|Placebo Comparator|Panel A - Placebo|In Part I, healthy participants received skin patches containing nothing (plain patch) or placebo once daily for 10 days.
3208121|NCT01140061|Experimental|Panel B - MK-0873 25 mg|In Part II, healthy participants received skin application of 0.5% MK-0873 cream (yielding a dose of 25 mg of MK- 0873) twice daily for 10 days.
3208122|NCT01140061|Placebo Comparator|Panel B - Placebo|In Part II, healthy participants received skin application of placebo cream twice daily for 10 days.
3208123|NCT01140061|Experimental|Panel C - MK-0873 100 mg|In Part II, healthy participants received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) once daily for 10 days.
3208124|NCT01140061|Placebo Comparator|Panel C - Placebo|In Part II, healthy participants received skin application of placebo cream once daily for 10 days.
3208125|NCT01140061|Experimental|Panel D - MK-0873 200 mg|In Part II, healthy participants received skin application of 2% MK-0873 (yielding a dose of 100 mg of MK-0873) twice daily for 10 days.
3208126|NCT01140061|Placebo Comparator|Panel D - Placebo|In Part II, healthy participants received skin application of placebo cream twice daily for 10 days.
3208127|NCT01140061|Experimental|Panel E and Extension - MK-0873 200 mg|In Part III, participants with mild psoriasis received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) twice daily for up to 28 days.
3208128|NCT01140061|Placebo Comparator|Panel E and Extension - Placebo|In Part III, participants with mild psoriasis received skin application of placebo cream twice daily for up to 28 days.
3208129|NCT01140048||All Enrolled Participants|All participants who completed Protocol 272 and were enrolled in Protocol 374
3208130|NCT01140035|Experimental|Intensive insulin therapy|"Intensive insulin therapy with goal of glucose < 150 mg/dl~Control group with standard insulin therapy with goal of glucose 180 mg/dl"
3208131|NCT01140022||Female Patients 18-25 yo|Female patients aged 18-25 who have come to one of the ED or urgent care sites for care, regardless of the presence of CT symptoms.
3208132|NCT01140009|Placebo Comparator|Group 1|FLuviral 2010/11Tri-valent Seasonal Influenza Vaccine (TIV)1st; saline placebo 10 days later
3208133|NCT01140009|Placebo Comparator|Group 2|Saline placebo 1st; Fluviral 2010/11 Tri-valent Seasonal Influenza Vaccine (TIV)10 days later
3208134|NCT01139996|Experimental|Transdermal Clonidine/Oral Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of a Clonidine Transdermal system at a dose of 0.3 mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3 mg after 12 hours
3208135|NCT01139996|Placebo Comparator|Comparator|Placebo group will receive a placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final placebo tablet
3208136|NCT01139970|Experimental|Treatment (temozolomide and veliparib)|"Patients receive veliparib PO QD on day 1 and twice daily on days 4-12 and temozolomide PO QD on days 3-9 of course 1.~Beginning at least 30 days after the start of treatment, patients receive veliparib PO BID on days 1-8 and temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients achieving complete remission receive 5 more courses in the absence of disease progression or unacceptable toxicity."
3208137|NCT01139957||Ancillary-correlative|Patients complete the Health Update Questionnaire annually for up to 5 years. The questionnaire focuses specifically on cancer risk, incidence, and mortality. Patients also receive ongoing communication (e.g., periodic newsletters, copies of study-related publications, etc.) to keep them informed regarding study-related research results, new research findings, new research opportunities for which patients may be eligible, and evolving clinical recommendations regarding hereditary breast/ovarian cancer.
3208138|NCT01139944||Group 1|Archived tumor and intrathoracic lymph node tissue samples are analyzed for aberrant DNA methylation (p16/CDKN2A, DAP kinase, H-cadherin, APC, and RASSF1A) by methylation-specific PCR. Analyses are then compared with the preliminary data from the Johns Hopkins institutional study.
3208139|NCT01139918||Cohort A|40 patients with moderate psoriatic arthritis and moderate psoriasis
3208140|NCT01139918||Cohort B|40 patients with mild psoriatic arthritis and moderate psoriasis
3208141|NCT01139918||Cohort C|40 patients with moderate psoriatic arthritis and mild psoriasis
3208142|NCT01139905|Other|1|standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour
3208185|NCT01139528|Active Comparator|Operative treatment|Closed reduction of the fracture and osteosynthesis with 2-3 intramedullary K-wires (Bouquet method), cast treatment for 7-10 days followed by 5 weeks of buddy-strapping before removal of the K-pins
3208143|NCT01139892||Surgical management|Surgical clipping will be performed within 6 weeks of randomization, according to standards of practice, and under general anaesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, bypasses, and other flow-redirecting treatments that do not directly clip the aneurysm will not be included.
3208144|NCT01139892||Endovascular management|Endovascular treatment will be performed within 6 weeks of randomization, according to standards of practice, and under general anaesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling or stents, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
3208145|NCT01139879|Experimental|P400 support surface|All patients will receive the P400 mattress
3208146|NCT01139866||Group 1: SABER™-Bupivacaine|Received 5.0 mL SABER™-Bupivacaine in previous C803-017 trial
3208147|NCT01139866||Group 2: SABER™-Placebo|Received 5.0 mL SABER™-Placebo in previous C803-017 trial
3208148|NCT01139853|Active Comparator|Nasogastric Tube|10 French Nasogastric Tube inserted before surgery
3208149|NCT01139853|No Intervention|No Nasogastric Tube|
3208150|NCT01139840|Active Comparator|vitamin D2|
3208151|NCT01139840|Active Comparator|vitamin D3|
3208152|NCT01139827||normal|normal group has no diabetes.
3208153|NCT01139827||IGT|IGT group has impaired fasting glucose or impaired glucose tolerance.
3208154|NCT01139814|Experimental|Catheter Robot|device
3208155|NCT01139801|Active Comparator|Oxytocin|Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.
3208156|NCT01139801|Experimental|Misoprostol|Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
3208157|NCT01139788|Experimental|LY2624587|
3208158|NCT01139775|Experimental|Phase 1: LY2603618 130 to 275 mg|"Cycle 1-2 (21-day cycle):~Day 1: pemetrexed 500 milligrams per meter square (mg/m^2) + cisplatin 75 mg/m^2~Day 2: LY2603618 at 130-275 milligrams (mg)~After 2 cycles, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
3208159|NCT01139775|Experimental|Phase 2: Pemetrexed + Cisplatin + LY2603618|"Cycles 1-4 (21-day cycle):~Before 25 Oct 2012:~Day 1: pemetrexed 500 mg/m^2 + cisplatin 75 mg/m^2~Day 2: LY2603618 dose from phase 1 portion of trial~After 25 Oct 2012:~Day 1: pemetrexed 500 mg/m^2 + cisplatin 75 mg/m^2~After 4 cycles, participants may continue on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion is met.~Maintenance Therapy Experimental Arm (every 21 days):~Before 25 Oct 2012:~Day 1: pemetrexed 500 mg/m^2~Day 2: LY2603618 dose determined from phase 1~After 25 Oct 2012:~Day 1: pemetrexed 500 mg/m^2~If, as of 25 Oct 2012, participant was in maintenance therapy and randomized to the experimental arm, the participant is eligible to continue with pemetrexed (Day 1)/LY2603618 (Day 2) therapy if the investigator deems it is in the best interest of the participant and the participant consents."
3208160|NCT01139775|Active Comparator|Phase 2: Pemetrexed + Cisplatin|"Cycle 1-4 (21-day cycle):~Day 1: pemetrexed 500 mg/m^2 + cisplatin 75 mg/m^2~After 4 cycles, participants may continue on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion is met.~Maintenance Therapy Comparator Arm: Phase 2 (every 21 days):~Day 1: pemetrexed 500 mg/m^2"
3208161|NCT01139762|Experimental|Tadalafil|
3208162|NCT01139762|Placebo Comparator|Placebo|
3208163|NCT01139749|Active Comparator|Oral isotretinoin|Subjects from treatment arm will be treated with low-dose oral isotretinoin - 20 mg a day, every other day, for six months
3208164|NCT01139749|Active Comparator|salicylic acid and ciclopirox olamine|Subjects from comparison arm will be treated with topical salicylic acid and ciclopirox olamine shampoo
3208165|NCT01139736|Experimental|Probiotics|IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks. VSL#3 was selected for use in this study because (a) it contains three different Bifidobacteria strains (in addition to lactobacilli and streptococci) and the limited evidence available Bifidobacteria as the most effective probiotics in IBS .
3208166|NCT01139723|Experimental|A|
3208167|NCT01139723|Experimental|B|
3208168|NCT01139697||Patients with systolic heart failure|Patients with systolic heart failure defined as ejection fraction <45%
3208169|NCT01139684|Experimental|Exercise|
3208170|NCT01139658||All comers|
3208171|NCT01139645|Experimental|Proton Pump Inhibitors|patients were started on Proton Pump inhibitors for 3 months (the whole duration of the study)
3208172|NCT01139645|No Intervention|No Proton Pump Inhibitors|patients are not taking any Proton Pump Inhibitor, and they are matched by age to patients in the experimental group.
3208173|NCT01139619||1|Inoperable non small cell lung cancer patients. Diagnosed between 2010-05-31 and 2009-06-01.
3208174|NCT01139606|Experimental|Vibration trainig|
3208175|NCT01139593||morning dose|women undergoing IVF/ICSi taking their gonadotropin dose in the am
3208176|NCT01139593||evening dose|Women undergoing IVF/ICSI taking their gonadotropin in the evening
3208177|NCT01139580|Experimental|Calcipotriene Foam|Calcipotriene Foam 0.005%,
3208178|NCT01139580|Placebo Comparator|Vehicle Foam|Vehicle Foam
3208179|NCT01139567||Standard Care Group|Subjects who will undergo only standard wound care management.
3208180|NCT01139567||Hyperbaric Oxygen Therapy Group|Subjects who are selected for adjunctive hyperbaric oxygen therapy in addition to standard wound care intervention.
3208181|NCT01139541|No Intervention|Control|Participants in the control condition will be asked to refrain from using the WalkStations during the study period.
3208182|NCT01139541|Experimental|Individual|In the individual condition, participants will not be part of a team. They will receive weekly email feedback on their Walkstation performance (e.g. number of time slots they signed up for, and number of times they showed up for the time slot.)
3208183|NCT01139541|Experimental|Pairs|In the pair condition, participants will be randomly assigned to a partner. They will receive the same feedback as those in the individual condition, for both themselves AND their partner.
3208184|NCT01139541|Experimental|Groups|In the group condition, participants will be randomly assigned to a group of 5 people. They will receive the same feedback as those in the individual condition, for both themselves AND each member of their group.
3208186|NCT01139528|No Intervention|Conservative treatment|No attempt of reduction of the fracture, 7-10 days of cast treatment followed by 5 weeks of buddy-strapping
3208187|NCT01139515|Experimental|Treatment A|1 X 20 mg eletriptan
3208188|NCT01139515|Experimental|Treatment B|1 X 40 mg eletriptan
3208189|NCT01139515|Experimental|Treatment C|2 X 40 mg eletriptan
3208190|NCT01139515|Experimental|Treatment D|1 X 40 mg tablet given 2 hr after initial 1 X 40 mg tablet dose
3208191|NCT01139502|Active Comparator|Work rehab with cognitive therapy|Work rehabilitation based on the cognitive therapeutical model
3208192|NCT01139502|Active Comparator|Work rehab with cognitive training|Work rehabilitation with the addition of weekly training of concentration, memory, and executive function
3208193|NCT01139489|Active Comparator|procalcitonin-guidance|A daily advise to continue or stop antibiotics based on the measurement of the biomarker procalcitonin
3208194|NCT01139489|No Intervention|standard-of-care|standard-of-care treatment of ICU infections based upon consensus guidelines and expert opinion
3208195|NCT01139476||AHS BEEA participants|A subset of 1990 AHS cohort members who are male private pesticide applicators, living and over 50 years of age at the time contact, cancer free, and who completed AHS Phases IIII.
3208196|NCT01139476||Non-AHS BEEA participants|A group of 225 age-, race-, and countymatched, non-AHS controls, who have not lived or worked on a farm as an adult, or held a job applying pesticides.
3208197|NCT01139463||Antipsychotic treatment|Patients were not taking any medications - apart from the prescribed antipsychotic - for a period of 1 month prior to the study with psychotic relapse or newly diagnosed psychotic disorder were recruited from psychiatric inpatient and outpatient clinics of the Split Clinical Hospital.
3208198|NCT01139450|Experimental|Test|Test product that contains the active pharmaceutical ingredient
3208199|NCT01139450|Active Comparator|Reference|Reference product that contains the active pharmaceutical ingredient
3208200|NCT01139450|Placebo Comparator|Vehicle|Placebo that contains no active pharmaceutical ingredient
3208201|NCT01139437|Experimental|Adults|Adults ages 18 to 49 years of age. Open label.
3208202|NCT01139437|Experimental|Seropositive children - vaccine|Children ages 15 to 59 months of age who already have HPIV2 antibodies receiving the HPIV2 vaccine.
3208203|NCT01139437|Experimental|Seronegative infants and children - low dose vaccine|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a low dose of the HPIV2 vaccine.
3208204|NCT01139437|Experimental|Seronegative infants and children - standard dose vaccine|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a standard dose of the HPIV2 vaccine.
3208205|NCT01139437|Placebo Comparator|Seropositive children - placebo|Children ages 15 to 59 months of age who already have HPIV2 antibodies receiving a placebo.
3208206|NCT01139437|Placebo Comparator|Seronegative infants and children - low dose placebo|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a low dose of placebo.
3208207|NCT01139437|Placebo Comparator|Seronegative infants and children - standard dose placebo|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a standard dose of placebo.
3208208|NCT01139424|Experimental|open label treatment arm|endoscopic suturing
3208209|NCT01139411|Experimental|Behavioral Weight Control with Enhanced Parent Involvement|This treatment arm included periodic dyadic sessions with adolescents and their parents, focusing on weight-related communication combined with standard behavioral weight control.
3208210|NCT01139411|Placebo Comparator|Behavioral Weight Control with Minimal Parent Involvement|This treatment arm included standard behavioral weight control delivered to the adolescent with minimal parent involvement.
3208211|NCT01139385||clipless|laparoscopic cholecystectomy performed by harmonic scalpel with closure and division of the cystic duct only by the device
3208212|NCT01139385||traditional|laparoscopic cholecystectomy performed by harmonic scalpel with closure of the cystic duct only by titanium clip
3208213|NCT01139372|Experimental|FID 115958D|Lubricant eye drop
3208214|NCT01139359|Experimental|Single Arm, darinaparsin and CHOP|open label, single arm, unblinded
3208215|NCT01139346|Experimental|oral darinaparsin|open label, single arm, dose escalation
3208216|NCT01139294|No Intervention|standard IV therapy|control arm of the study
3208217|NCT01139294|Experimental|Hylenex|1ml subcutaneous with initiation of intravenous fluids then every 24 hours with a maximum dose of 3 injections in 72 hours
3208218|NCT01139281|Active Comparator|Study Group|The Study Group(SG) received Ginkgo biloba extract(GBE761)(240mg/day)plus cisplatin(CDDP)
3208219|NCT01139281|Placebo Comparator|Control Group(CG)|The Control Group received Placebo plus CDDP
3208220|NCT01139255|Experimental|Podcasting + mobile media|
3208221|NCT01139255|Active Comparator|Podcasting|
3208222|NCT01139242|Other|Body & Soul nutritional intervention|This is a standardized intervention to increase fruit and vegetable consumption among church members through pastoral and peer counseling and church activities/menus.
3208223|NCT01139242|Experimental|Newsletters/peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening among church members out-of-date according to screening guidelines. For those up-to-date, promotion is of increased physical activity.
3208224|NCT01139229|Other|HE group|
3208225|NCT01139229|Other|HS group|
3208226|NCT01139229|Other|SA group|
3208227|NCT01139216|Experimental|Daikenchuto (TU-100) 7.5g/day|Daikenchuto (TU-100) 2.5g TID (7.5g/day)
3208228|NCT01139216|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID (15g/day)
3208229|NCT01139216|Placebo Comparator|Placebo|Placebo TID
3208230|NCT01139203|Active Comparator|lamivudine|
3208231|NCT01139203|Active Comparator|lamivudine and adefovir|
3208232|NCT01139203|Active Comparator|entecavir|
3208233|NCT01139190|Experimental|PL3100|
3208234|NCT01139190|Active Comparator|Naproxen|
3208235|NCT01139177|Experimental|Stent placement|
3208236|NCT01139164|Experimental|Single Arm, non-randomized study|
3208237|NCT01139151|Experimental|Group 1 - 3 Day Thiarabine|Thiarabine 3 days in a row in each cycle.
3208238|NCT01139151|Experimental|Group 2 - 5 Day Thiarabine|Thiarabine 5 days a row in each cycle.
3208239|NCT01139138|Experimental|Panitumumab + Irinotecan + Everolimus|
3208283|NCT01138826|Active Comparator|treatment A - reference w/ water|
3208240|NCT01139125|Experimental|Cystagon, Cysteamine Bitartrate|We are examining the safety and efficacy of this medication on the treatment of schizophrenia patients.
3208241|NCT01139099|Other|Arm|There is no arm in this study.
3208242|NCT01139086||Cardiovascular disease|Diagnosis of cardiomyopathy or ischemic heart disease without heart failure
3208243|NCT01139086||Chronic heart failure|Diagnosis of cardiomyopathy or ischemic heart disease LVEF <40%
3208244|NCT01139086||Control|Age and body built matched with chronic heart failure group
3208245|NCT01139060|Experimental|Intervention Group|18-month organized treatment program focused on outreach and engagement for chronic or recurrent depression
3208246|NCT01139060|No Intervention|Usual Care|
3208247|NCT01139047|Active Comparator|metronidazole 1% gel|
3208248|NCT01139047|Active Comparator|azelaic acid 15% gel|
3208249|NCT01139034|Experimental|shoulder FES treatment|
3208250|NCT01139021|Experimental|B246_12_M12|Subjects assessed one year post administration of rMenB+OMV NZ and MMRV at 12th month after primary vaccination at 2nd ,4th and 6th months of age.
3208251|NCT01139021|Experimental|B246_12M13|Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 13th month after primary vaccination at 2nd ,4th and 6th months of age.
3208252|NCT01139021|Experimental|B13_15_27|Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at 13th and 15th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27 months of age.
3208253|NCT01139021|Experimental|B12_14_26|Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 26 months of age.
3208254|NCT01139021|Experimental|B_24_26|Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.
3208255|NCT01139021|Experimental|B12M13|Subject was randomized in group B13_15_27 but treated as group B12_M13.
3208256|NCT01139008|Active Comparator|metronidazole 1% gel|
3208257|NCT01139008|Active Comparator|azelaic acid 15% gel|
3208258|NCT01138995|Active Comparator|Ankle-foot orthosis (AFO) Control Group|"The Control Group will walk with the a usual ankle-foot orthosis (AFO) for 30 weeks."
3208259|NCT01138995|Experimental|Ness L300 Treatment Group|The Original Treatment Group will walk with the Ness L300 for 30 weeks.
3208260|NCT01138982|Experimental|Mentoring program|Mentor and mentee meet at least every second week, for 2-4 h on every occasion, during 1 year (i.e., for a minimum of two school semesters). Meetings take place outside school and work hours, and the pairs choose activities of their own preferences. No monetary incentives exist, and the mentors are laymen volunteers. The program objective is to establish a safe and supportive relationship, by which the youth is assumed to benefit in social, emotional, and academic development, and as a consequence, be less prone to use alcohol and drugs.
3208261|NCT01138982|No Intervention|Control group|No intervention provided, only brief phone calls to control for attention bias
3208262|NCT01138969|Active Comparator|Esomeprazole plus clopidogrel group|esomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months
3208263|NCT01138969|No Intervention|Clopidogrel group|clopidogrel 75 mg qd for 6 months
3208264|NCT01138956|Experimental|Group 1|Pentavalent antimonial, 20mg/kg/day, 28 days, IV, plus N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po.
3208265|NCT01138956|Active Comparator|Group 2|Pentavalent antimonial, 20mg/kg/day, 28 days
3208266|NCT01138943|Active Comparator|Chlorhexidine alcohol-base mouthrinse|
3208267|NCT01138943|Experimental|non alcohol chlorhexidine mouthrinse|
3208268|NCT01138930|Experimental|Berberine|
3208269|NCT01138930|Placebo Comparator|Placebo|
3208270|NCT01138904|Active Comparator|IROX arm: FOLFIRI -> FOLFOX|"IROX arm: FOLFIRI -> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr"
3208271|NCT01138904|Active Comparator|OXIR arm: FOLFIRI -> FOLFOX|"OXIR arm: FOLFIRI -> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr"
3208272|NCT01138891||Removed breast implants for any reason|
3208273|NCT01138878||Patient pre-study group|A set of all 16-65 yr olds (not know already to be HIV-positive) accessing the healthcare setting prior to the introduction of the HIV testing pilot programme
3208274|NCT01138878||Staff pre-study group|A set of staff working within the healthcare setting prior to the introduction of the HIV screening programme
3208275|NCT01138878||Patient intra-study group|A set of patients, aged 16-65 and known not to be HIV-positive, who access the healthcare setting during the HIV testing pilot programme
3208276|NCT01138878||Post-study staff group|A set of staff who worked within the healthcare setting for the duration of the HIV testing pilot programme
3208277|NCT01138865|Other|1|Device: AutoSet Spirit--Wash--Modified-AutoSet Spirit 3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
3208278|NCT01138865|Other|2|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
3208279|NCT01138852|Experimental|ampicillin-sulbactam|This is the drug used to prevent post-cesarean infection
3208280|NCT01138852|Active Comparator|cefuroxime|This drug was compared to ampicillin sulbactam for prevention of infection
3208281|NCT01138839|Placebo Comparator|sterile water|Pregnant women will receive 2.5 cc of sterile water every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 doses after delivery.
3208282|NCT01138839|Experimental|Dexamethasone|Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.
3208284|NCT01138826|Experimental|Treatment B - ODT (test) w/ water|
3208285|NCT01138826|Experimental|Treatment C - ODT (test) w/o water|
3208286|NCT01138813||1|Male and female patients aged 18-70 years old with newly diagnosed operable glioma of grade II or higher
3208287|NCT01138787|Active Comparator|Reference spread|"2250 mg PS (as PSE) in spread (30 g)~50 mg labeled D7-cholesterol,~30 mg 3,4-13C-cholesterol, iv dosed at same time."
3208288|NCT01138787|Placebo Comparator|Placebo spread|"regular light margarine (30 g)~50 mg labeled D7-cholesterol,~30 mg 3,4-13C-cholesterol, iv dosed at same time."
3208289|NCT01138787|Experimental|Test spread|"2250 mg PS in innovatively processed spread (30 g)~50 mg labeled D7-cholesterol,~30 mg 3,4-13C-cholesterol, iv dosed at same time."
3208290|NCT01138774|Placebo Comparator|Control group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + placebos supplements
3208291|NCT01138774|Experimental|EPA group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA (1.3 g/day, 3 capsules of 433 mg/day) supplement (EPA Group).
3208292|NCT01138774|Experimental|Lipoic acid group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + LA (300 mg/day, 3 capsules of 100 mg/day) supplement (LA Group)
3208293|NCT01138774|Experimental|EPA+LA group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA/LA (1.3 g /day and 300 mg/day respectively).
3208294|NCT01138761|No Intervention|Physician/resident instruction|This arm is standard of care instruction given to parents/caregivers of children with atopic dermatitis by the dermatologist and/or dermatology resident during a patient visit.
3208295|NCT01138761|Active Comparator|Nurse instruction|Following the usual standard of care instruction by physician/resident (which both the treatment group and the non-treatment group will receive); the dermatology nurse will give enhanced instruction about skin care and medications to the caregivers/parents who were randomized to the treatment group.
3208296|NCT01138748|Experimental|Radiation therapy|
3208297|NCT01138735|Active Comparator|adapalene/benzoyl peroxide|Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks
3208298|NCT01138735|Placebo Comparator|Topical Gel Vehicle|Topical Gel Vehicle applied topically once daily for 12 weeks
3208299|NCT01138709|Experimental|Convexity/Vitala|For all enrolled Subjects, STAGE 1 (Days 1 - 14 equals Convex Product Wear Period followed by, for those who successfully complete Stage I, weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 15 to 21), followed by 8 hours of daily wear time per week (Day 22 to 28), followed by 12 hours of daily wear time (Days 29 to 43).
3208300|NCT01138696||Stryker Dacron synthetic graft|
3208301|NCT01138696||Trevira synthetic graft|
3208302|NCT01138683|Active Comparator|ultrafiltration group|
3208303|NCT01138683|Active Comparator|diuretics group|
3208304|NCT01138670||Cardiac device group|
3208305|NCT01138657|Experimental|Adalimumab|Participants received adalimumab 80 mg subcutaneous loading dose at Baseline followed by 40 mg doses every other week (eow) starting at Week 1 for a maximum of 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper until Week 15.
3208306|NCT01138657|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection at Baseline followed by eow dosing starting at Week 1 for up to 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper until Week 15.
3208307|NCT01138631|Active Comparator|Embryoscope|
3208308|NCT01138631|No Intervention|Conventional incubator|
3208309|NCT01138618||CHEMPAQ-venous-CHEMPAQ-venous|The two arms only differ in order of kind of blood samples.
3208310|NCT01138618||Venous-CHEMPAQ-Venous-CHEMPAQ|The two arms only differ in order of kind of blood samples.
3208311|NCT01138605|Experimental|005|Darunavir 400 mg tablet intake of 2 tablets once daily in combination with ritonavir
3208312|NCT01138605|Experimental|006|Ritonavir Liquid formulation 80 mg/ml taken in combination with Darunavir
3208313|NCT01138605|Experimental|007|Ritonavir 100 mg capsule to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
3208314|NCT01138605|Experimental|008|Ritonavir 100 mg tablet to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
3208315|NCT01138605|Experimental|001|Darunavir Oral suspension 100 mg/ml 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
3208316|NCT01138605|Experimental|002|Darunavir 375 mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight between 20 and 30 kg
3208317|NCT01138605|Experimental|003|Darunavir 450 mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight between 30 and 40 kg
3208318|NCT01138605|Experimental|004|Darunavir 600mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight as of 40 kg
3208319|NCT01138605|Experimental|009|Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.
3208320|NCT01138592||Primary Care Patients|Any patient undergoing a telemedicine evaluation involving auscultation of the heart and lungs.
3208321|NCT01138579|Experimental|1|
3208322|NCT01138566||ESBL- and/or AmpC-(+) or (-)|
3208323|NCT01138553|Experimental|Mifepristone|
3208324|NCT01138540|Active Comparator|Semirecumbent position|Semirecumbent position of patients on mechanical ventilation in the bed of the ICU
3208325|NCT01138540|Experimental|lateral-Trendelenburg position|lateral-Trendelenburg position of patients on mechanical ventilation in the bed of the ICU
3208326|NCT01138527||Biopsy-proven prostate cancer|Patients with biopsy-proven prostate cancer, planned for radical prostatectomy
3208327|NCT01138514|Active Comparator|Clindamycin 1%/Benzoyl Peroxide 5%|
3208328|NCT01138514|Active Comparator|Reference Product|
3208329|NCT01138514|Placebo Comparator|Vehicle|
3208330|NCT01138501|Experimental|rFVIII|
3208331|NCT01138488|Experimental|NN5401|
3208401|NCT01137981||Pregnant, HIV Positive Women|Any pregnant, HIV positive woman exposed to antiretroviral drugs during pregnancy.
3208332|NCT01138475|Active Comparator|Paricalcitol|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules,cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
3208333|NCT01138475|Active Comparator|cholecalciferol|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules, cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
3208334|NCT01138475|Placebo Comparator|placebo|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules, cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
3208335|NCT01138462|No Intervention|Standard Precautions|control arm, standards precautions for all residents living in the nursing home of control arm, including MRSA carriers
3208336|NCT01138462|Other|Intervention|Intervention arm, standards precautions for all residents living in nursing homes of intervention arm, and topical decolonization for MRSA carriers, including environmental disinfection
3208337|NCT01138449|Experimental|Vitamin A|Vitamin A capsules have retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil
3208338|NCT01138449|Placebo Comparator|Placebo|Placebo capsules contain minute amounts of vitamin E in soybean oil
3208339|NCT01138436|Experimental|MEBO Wound Ointment (MEBO)|Topical application once a day
3208340|NCT01138436|Active Comparator|Standard of Care|Application of Profore multilayer compression bandage system
3208341|NCT01138423|Experimental|Aliskiren|
3208342|NCT01138423|Experimental|Moxonidine|
3208343|NCT01138423|Experimental|Hydrochlorothiazide|
3208344|NCT01138423|Placebo Comparator|Placebo|
3208345|NCT01138410|Experimental|SCIB1|
3208346|NCT01138397|Experimental|Group 1|Participants at 18 to 59 years of age
3208347|NCT01138397|Experimental|Group 2|Participants at 60 years of age or older
3208348|NCT01138384|Experimental|Foretinib and Lapatinib|Patients will receive foretinib as a continuous oral dose, and lapatinib as a continuous oral dose. Lapatinib will commence on Day1, Cycle 1 and foretinib will commence on Day 3, Cycle 1.
3208349|NCT01138371||Familial hypercholesterolemia|"Heterozygous FH with documented CAD and LDL-C ≥ 200 mg/dL (Documented CAD may be represented as: Lesion(s) on coronary angiography, history of myocardial infarction, CABG, PTCA, progressive angina demonstrated by stress testing, history of other revascularization procedure)~Homozygous FH and LDL-C > 500 mg/dL~Heterozygous FH and LDL-C ≥ 300 mg/dL~On stable LDL apheresis therapy for at least 6 months"
3208350|NCT01138345||Treatment w/Surgery|Breast Cancer survivors treated with surgery with or without radiation.
3208351|NCT01138345||Treatment w/endocrine therapy|Breast Cancer survivors treated with surgery with or without radiation plus endocrine therapy.
3208352|NCT01138345||Treatment w/ chemotherapy|Breast Cancer survivors treated with surgery with or without radiation and chemotherapy with or without endocrine therapy.
3208353|NCT01138293|Experimental|motion sensor integrated in a mobile phone|A motion sensor integrated in a mobile phone. The system analyses kind, intensity and duration of physical activity and eating habits.
3208354|NCT01138280|Experimental|Heat disinfection|Experimental arm: Heat disinfection link to RO water treatment system and piping system to dialysis machine
3208355|NCT01138280|No Intervention|Conventional RO water treatment|Placebo arm: conventional chemical disinfection link to RO water treatment system.
3208356|NCT01138254|No Intervention|control group|ESRD patients will not receive FIR therapy in this study.
3208357|NCT01138254|Experimental|Far infrared therapy|Patients will receive far infrared therapy 40 minutes three times weekly (TIW) for 6 months.
3208358|NCT01138241||1|ARV experience (TDF based HAART)
3208359|NCT01138241||2|ARV experience (non TDF based ART)
3208360|NCT01138241||3|ARV Naive
3208361|NCT01138228||Normal vision|This within-subjects design is counter balanced for order. Each operator sees the subject's arm either initially with the normal eye or with the device, then repeats with the second condition (i.e., device or normal vision).
3208362|NCT01138228||Vein Imaging Device|This within-subjects design is counter balanced for order. Each operator sees the subject's arm either initially with the normal eye or with the device, then repeats with the second condition (i.e., device or normal vision).
3208363|NCT01138215|Experimental|1|Receive 1 course of VZV vaccine : 2 doses of vaccines with 3 months apart.
3208364|NCT01138202|Experimental|1|boosted LPV/r 400/100 mg BID + 2 NRTI
3208365|NCT01138202|Experimental|2|boosted LPV/r 600/150 mg BID + 2 NRTI
3208366|NCT01138176|No Intervention|Standard care|
3208367|NCT01138176|Experimental|Cooling|Reduction of rectal temperature to 33.5 C for 72 hours
3208368|NCT01138163|Experimental|Docetaxel plus bavituximab 1 mg/kg|
3208369|NCT01138163|Experimental|Docetaxel plus bavituximab 3 mg/kg|
3208370|NCT01138163|Placebo Comparator|Docetaxel plus placebo|
3208371|NCT01138150|Active Comparator|Treximet|"Fourteen participants randomized to receive Treximet (sumatriptan & naproxen) during an acute migraine attack. Blood drawn for immune & inflammatory markers (adipocytokines,cytokines, sex hormones) at different time points - on presentation with moderate to severe migraine pain; then 30 minutes, 1 hour and 2 hours after administration of study drug (Treximet).~Participants will be offered a traditional headache rescue medicine at 2 hours after administration of Treximet if participant still reports moderate to severe pain and desires further treatment. Rescue medicine may include the following: prochlorperazine 10 mg IV preceded by diphenhydramine 25 mg IV/PO or metoclopramide 10 mg IV preceded by diphenhydramine 25 mg IV/PO or Toradol 30 mg IV to be determined by the physician."
3208402|NCT01137968|Experimental|imetelstat plus standard of care|imetelstat plus standard of care (bevacizumab or observation)
3208403|NCT01137968|Other|Standard of care|Bevacizumab or observation
3208404|NCT01137955|Experimental|Rifaximin|Antibiotic
3208405|NCT01137955|Placebo Comparator|Placebo|
3208372|NCT01138150|Placebo Comparator|Sugar Pill|"Fourteen participants randomized to receive placebo during an acute migraine attack. Blood is drawn for immune & inflammatory markers (adipocytokines,cytokines), sex hormones at different time points - on presentation with moderate to severe migraine pain, then 30 minutes, 1 hour and 2 hours after administration of placebo.~Participants will be offered a traditional headache rescue medicine at 2 hours after administration of placebo if participant still reports moderate to severe pain and desires further treatment. Rescue medicine may include the following: prochlorperazine 10 mg IV preceded by diphenhydramine 25 mg IV/PO or metoclopramide 10 mg IV preceded by diphenhydramine 25 mg IV/PO or Toradol 30 mg IV to be determined by the physician."
3208373|NCT01138137|Experimental|All subjects|
3208374|NCT01138124||UK GPRD 1993-2008|The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993.
3208375|NCT01138111|Experimental|Arm 1|
3208376|NCT01138098|Experimental|Infanrix-hexa/Engerix-B Group|Subjects aged 11-12 year old received 3 doses of Infanrix-hexa vaccine in the primary study (217744/031 (NCT01457495)) and a challenge dose of Engerix-B vaccine in this study. Engerix-B was administered as a single dose intramuscularly into the deltoid region of the non-dominant arm.
3208377|NCT01138098|Active Comparator|Infanrix-IPV+Hib/Engerix-B Group|Subjects aged 11-12 year old received 3 doses of Infanrix-IPV+Hib and Engerix-B vaccines in the primary study (217744/031 (NCT01457495)) and a challenge dose of Engerix-B vaccine in this study. Engerix-B was administered as a single dose intramuscularly into the deltoid region of the non-dominant arm.
3208378|NCT01138085|Experimental|Dose Escalation|Dose escalation will proceed until unacceptable toxicity is observed. Dose escalation decisions will take into account all available data, including PK data and the safety profile of prior cohorts and will occur following review of these data by the investigator(s), GSK medical monitor, pharmacokineticist, and statistician.
3208379|NCT01138085|Experimental|Expansion Cohorts|"Enrollment into expansion cohort(s) in Part 2A may begin once a recommended dosing regimen(s) is identified in Part 1A utilizing a once daily continuous dosing schedule for both GSK1120212 and GSK2141795. Enrolment to cohorts utilizing this daily dosing schedule may proceed in parallel with enrolment in Part 1B. Expansion cohort(s) will preferentially enroll subjects with treatment-refractory, measurable and biopsiable triple negative breast cancer or BRAF- wild type melanoma. Subjects selected for enrollment into Part 2A or Part 2B will be tested for PTEN deficiency and must agree to provide paired tumor biopsies (at baseline and once while on- treatment). An additional tumor biopsy at the time of disease progression should also be collected if feasible.~In Part 2A and Part 2B, up to 35 additional subjects per tumor type and schedule (i.e., a total of up to 70 subjects per schedule tested) may be enrolled in a two-stage design to better characterize safety, PK and PD."
3208380|NCT01138072|Experimental|Treatment A|Simvastatin 20mg (single dose) Day 1
3208381|NCT01138072|Experimental|Treatment B|Atorvastain 20 mg (single dose) Day 3
3208382|NCT01138072|Experimental|Treatment C|Rosuvastatin 10mg (single dose) Day 7
3208383|NCT01138072|Experimental|Treatment X|GSK2248761 200mg single dose Day 10-14, Day 16-17, Day 19-21, Day 23-24
3208384|NCT01138072|Experimental|Treatment D|GSK2248761 200mg + simvastatin 20 mg Day 15
3208385|NCT01138072|Experimental|Treatment E|GSK2248761 200mg + atorvastatin 20 mg Day 18
3208386|NCT01138072|Experimental|Treatment F|GSK2248761 200mg + rosuvastatin 20 mg Day 22
3208387|NCT01138059||Acute ischemic stroke patients with unclear onset|
3208388|NCT01138046|Experimental|Lap+weekly Pacli|These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib. Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent.
3208389|NCT01138033|Experimental|Part 1|Part 1 - dose escalation; starting dose 80 mg BID
3208390|NCT01138033|Experimental|Part 2|Part 2 - Dose expansion phase of the study at the maximum tolerated dose and schedule identified in Part 1 in patients with tumors known to over express FAK
3208391|NCT01138033|Experimental|Part 3|Part 3 - Characterize the biologically active dose range by analysis of PD markers in skin, hair and in tumor tissue in subjects with solid tumors amendable to biopsy and know to over express FAK
3208392|NCT01138033|Experimental|Part 4|Part 4 - Explore further the safety, PK, tolerability and anti-tumor activity of GSK2256098 in subjects with relapsed glioblastoma multiforme (GBM).
3208393|NCT01138033|Experimental|Part 5|Part 5 will investigate the time course, the extent of an apparent change in the PK of GSK2256098 following repeated dosing, and screen for potential CYP3A induction as a possible mechanism of reduced systemic exposure of GSK2256098 at Day 15 and later time points.
3208394|NCT01138020|Experimental|Arm 1|Cognitive intervention
3208395|NCT01138020|Active Comparator|Arm 2|Educational intervention
3208396|NCT01138007|Experimental|323U66 SR 150 mg cohort|323U66 SR 150 mg tablet is orally administered once in the morning and 323U66 SR 150 mg placebo tablet is orally administered once in the evening throughout the treatment phase.
3208397|NCT01138007|Experimental|323U66 SR 300 mg cohort|323U66 SR 150 mg tablet is orally administered once in the morning and 323U66 SR 150 mg placebo tablet is orally administered once in the evening during the first week of the treatment phase. At the second week, 323U66 SR 300mg cohort is up-titrated to a daily dose of 323U66 SR 300 mg, administered as 323U66 SR 150 mg tablet twice daily in the morning and in the evening, and the same daily dose is maintained to administer until the end of the treatment phase.
3208398|NCT01138007|Placebo Comparator|Placebo cohort|323U66 SR placebo tablet is orally administered twice daily throughout the treatment phase.
3208399|NCT01137994|Experimental|Lapatinib plus Chemotherapy|Lapatinib (1250mg once daily) in combination with chemotherapy (docetaxel, paclitaxel or vinorelbine) selected at the discretion of the investigator
3208400|NCT01137994|Experimental|Trastuzumab plus Chemotherapy|Trastuzumab (either 6mg/kg q3-weekly or 2mg/kg weekly) in combination with chemotherapy (docetaxel, paclitaxel or vinorelbine) selected at the discretion of the investigator
3208493|NCT01137435|Experimental|Study Group|
3208406|NCT01137942||H. pylori eradication failure|Those who eradicated Helicobacter pylori with appropriate antibiotic therapy and those who did not.
3208407|NCT01137929||With APN, With VUR, With Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will also have VUR by VCUG and a renal scar on follow-up DMSA renal scan.
3208408|NCT01137929||With APN, With VUR, Without Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will also have VUR by VCUG and NO renal scar on follow-up DMSA renal scan.
3208409|NCT01137929||With APN, without VUR, with Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan but who will NOT have VUR by VCUG; however they will have a renal scar on follow-up DMSA renal scan.
3208410|NCT01137929||With APN, Without VUR, Without Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will NOT have VUR by VCUG, NOR will they have a renal scar on follow-up DMSA renal scan.
3208411|NCT01137929||Without APN, With VUR|This group of children who present with a febrile UTI will be found NOT to have APN on DMSA renal scan and will also have VUR by VCUG. They will not undergo a second DMSA scan since the first one is normal.
3208412|NCT01137929||Without APN, Without VUR|This group of children who present with a febrile UTI will be found NOT to have APN on DMSA renal scan and will also NOT have VUR by VCUG, NOR a renal scar on follow-up DMSA renal scan.
3208413|NCT01137916|Experimental|drug|Imatinib 800 mg
3208414|NCT01137903|Other|Patients undergoing medical treatment|"Antibiotic treatment within 90 days with:~Ciprofloxacin Amoxicillin /Clavulanic acid. Trimethoprim /Sulfamethoxazole."
3208415|NCT01137903|Other|Patients undergoing surgical treatment|Conservative surgical Minor amputation 7 days antibiotic after surgical
3208416|NCT01137890|Experimental|Zonisamide|Participants administered blind capsules containing either placebo or zonisamide.
3208417|NCT01137890|Placebo Comparator|Placebo|Participants administered only placebo capsules containing lactose.
3208418|NCT01137877|Active Comparator|Infant Formula #1|Milk-based Infant Formula Powder
3208419|NCT01137877|Experimental|Investigational Infant Formula #1|Investigational Milk-based Infant Formula Powder
3208420|NCT01137877|Experimental|Investigational Infant Formula #2|Investigational Milk based infant formula powder
3208421|NCT01137877|Active Comparator|Human Milk|Reference group
3208422|NCT01137864|Experimental|Infectious disease specialist advice|Patients receiving the intervention (infectious disease specialist advice)
3208423|NCT01137864|No Intervention|Control|Patients not receiving infectious disease specialist advice
3208424|NCT01137851||New to bDMARD|New to bDMARD RA patients with high and low cost share who continue or discontinue treatment
3208425|NCT01137838||Patients with RA and new to abatacept|
3208426|NCT01137838||Patients with RA and new to infliximab|
3208427|NCT01137838||Patients with RA and new to etanercept|
3208428|NCT01137838||Patients with RA and new to adalimumab|
3208429|NCT01137812|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
3208430|NCT01137812|Active Comparator|Sitagliptin 100 mg|Each patient will receive 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
3208431|NCT01137799|Experimental|001|JNJ-39393406 10mg nanosuspension (sort of liquid formulation) once daily (single dose)
3208432|NCT01137799|Experimental|002|JNJ-39393406 30mg nanosuspension (sort of liquid formulation) once daily (single dose)
3208433|NCT01137799|Experimental|003|JNJ-39393406 50mg nanosuspension (sort of liquid formulation) once daily (single dose)
3208434|NCT01137799|Experimental|004|JNJ-39393406 100mg nanosuspension (sort of liquid formulation) once daily (single dose)
3208435|NCT01137799|Experimental|005|JNJ-39393406 200mg nanosuspension (sort of liquid formulation) once daily (single dose)
3208436|NCT01137799|Placebo Comparator|006|placebo Once daily (single dose)
3208437|NCT01137786|Active Comparator|IOPAMIDOL 370|
3208438|NCT01137786|Active Comparator|IODIXANOL 320|
3208439|NCT01137773|Experimental|Intensive IV Insulin|Patients will receive IV insulin to maintain target glucose levels of 80-110 mg/dl
3208440|NCT01137773|Active Comparator|Conventional Insulin Treatment|Patents will receive conventional IV insulin treatment with target glucose levels of 150-170 mg/dl
3208441|NCT01137760|Placebo Comparator|Sugar pill|
3208442|NCT01137760|Experimental|Galactooligosaccharide 2.5 g|
3208443|NCT01137760|Experimental|Galactooligosaccharide 5.0 g|
3208444|NCT01137747|Experimental|Dose Level 0 (starting dose)|"Carfilzomib - 20 mg/m2 days 1 and 2, 27 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 36 mg/m2 for all subsequent doses. If DLT occurs while receiving 36 mg/m2, the dose may be reduced to 27 mg/m2.~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
3208445|NCT01137747|Experimental|Dose Level +1|"Carfilzomib - 20 mg/m2 days 1 and 2, 36 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 45 mg/m2 for all subsequent doses. If DLT occurs while receiving 45 mg/m2, the dose may be reduced to 36 mg/m2.~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
3208446|NCT01137747|Experimental|Dose Level +2|"Carfilzomib - 20 mg/m2 days 1 and 2, 45 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 56 mg/m2 for all subsequent doses. If DLT occurs while receiving 56 mg/m2, the dose may be reduced to 45 mg/m2.~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
3208447|NCT01137721||Pre-Hydroxyurea - subjects with SCD|Patients with a diagnosis of HbSS (sickle cell anemia) or HbS/ß0-thalassemia (beta thalassemia) who will be treated with hydroxyurea therapy.
3208448|NCT01137721||Sibling control|Sibling control with no diagnosis of HbSS or HbS/ß0-thalassemia.
3208449|NCT01137721||Observational - subjects with SCD|Patients with a diagnosis of HbSS or HbS/ß0-thalassemia.
3208450|NCT01137721||Pre-transfusion - subjects with SCD|Patients with a diagnosis of HbSS or HbS/ß0-thalassemia who will be treated with transfusion therapy.
3208451|NCT01137708|Experimental|Treatment Sequence 1|
3208452|NCT01137708|Experimental|Treatment Sequence 2|
3208453|NCT01137695|Active Comparator|Symlin Naive, Usual Dose|Symlin 120 mcg three times daily in patients not previously treated with pramlintide before the study.
3208454|NCT01137695|Experimental|Symlin Naive, Dose Escalation|Escalation of pramlintide dose to 360 mcg three times daily in patients not taking pramlintide prior to study.
3208455|NCT01137695|Active Comparator|Symlin treated, Usual Dose|pramlintide 120 mcg three times daily in patients who have been treated with pramlintide 120 mcg prior to the trial.
3208456|NCT01137695|Experimental|Symlin Treated, Dose Escalation|pramlintide 360 mcg three times daily in patients previously treated with 120 mcg prior to the study.
3208457|NCT01137682|Experimental|Pasireotide LAR 40 mg|Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution)
3208458|NCT01137682|Experimental|Pasireotide LAR 60 mg|Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution)
3208459|NCT01137682|Active Comparator|Control arm (octreotide or lanreotide)|"If a patient is randomized to the open label arm the investigator will either:~be instructed to contact a Novartis delegate to initiate shipment of either octreotide LAR 30 mg or lanreotide ATG 120 mg from a Novartis or designee depot to the site, or~continue to dispense either octreotide LAR 30 mg or lanreotide ATG 120 mg available at the institution to the patient if permitted by local regulations."
3208460|NCT01137669|Placebo Comparator|Placebo|10 subjects to receive placebo subcutaneously.
3208461|NCT01137669|Experimental|ZOSTAVAX®|30 subjects to receive 0.65 mL ZOSTAVAX® subcutaneously.
3208462|NCT01137656|Other|Acetylcholine and Blood|This is single arm study. Acetylcholine and blood is infused in brachial artery of non-dominant arm. Blood flow
3208463|NCT01137630|Experimental|K40a|K40a is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
3208464|NCT01137630|Experimental|K40b|K40b is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
3208465|NCT01137630|Placebo Comparator|Placebo|Placebo is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
3208466|NCT01137604|Experimental|Cohort 1|"Cohort 1 assessed participants with recurrent Grade 4 malignant glioma (ie, glioblastoma [GBM]) who were bevacizumab-naive. Participants were planned to be accrued in Cohort 1 and randomized in a 1:1 ratio to receive lenvatinib (experimental) or bevacizumab (active comparator).~Cohort 1 - Bevacizumab~Cohort 1 - Lenvatinib"
3208467|NCT01137604|Experimental|Cohort 2|Cohort 2 assessed participants with recurrent Grade 3 malignant glioma who were bevacizumab-naive. Participants in Cohort 2 were planned to be treated with lenvatinib.
3208468|NCT01137604|Experimental|Cohort 3|Cohort 3 assessed participants with recurrent GBM who had disease progression following prior bevacizumab treatment. Participants in Cohort 3 were planned to be treated with lenvatinib.
3208469|NCT01137591|Experimental|APAP and NAC combination|N-acetyl-p-aminophenol and placebo (APAP-NAC) combination pill
3208470|NCT01137591|Placebo Comparator|APAP and Placebo combination|N-acetyl-p-aminophenol and placebo (APAP-placebo) combination pill
3208471|NCT01137578|Other|Cohort A: US, MRI with contrast, MRI without contrast|Subjects with a central venous catheter (CVC) in place and asymptomatic for a CVC-related DVT to have an Ultrasound (US), Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
3208472|NCT01137578|Other|Cohort B: US, MRI with contrast, MRI without contrast|Subjects with a CVC in place either symptomatic for a CVC-related DVT or having an incidental diagnosis of CVC-related DVT by radiographic imaging performed for other clinical reasons to have an Ultrasound, Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
3208473|NCT01137578|Other|Cohort C: US, MRI with contrast, MRI without contrast|Subjects with a CVC in place having an MRI for clinical reasons to have an Ultrasound, Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
3208474|NCT01137565|Experimental|AMG 853|
3208475|NCT01137565|Placebo Comparator|Placebo|
3208476|NCT01137552|Experimental|A|Dose Escalation
3208477|NCT01137552|Experimental|B|Dose Expansion
3208478|NCT01137539|Experimental|Gynecare TVT-SECUR system|All patients enrolled into the study will receive the TVT-SECUR system to treat stress urinary incontinence
3208479|NCT01137526|Experimental|ABT-384 Dose 1|
3208480|NCT01137526|Experimental|ABT-384 Dose 2|
3208481|NCT01137526|Active Comparator|donepezil|
3208482|NCT01137526|Placebo Comparator|placebo|
3208483|NCT01137513||Chest Pain|Acute Myocardial ischemia
3208484|NCT01137487|Other|residual gastric volume|
3208485|NCT01137487|Other|residual gastric volume not monitored|
3208486|NCT01137474|Experimental|Dapagliflozin, 10 mg|Oral tablets administered as 10 mg once daily for up to 12 weeks
3208487|NCT01137474|Placebo Comparator|Placebo-matching dapagliflozin|Oral tablets administered once daily in the morning
3208488|NCT01137474|Experimental|Dapagliflozin, 2. 5 mg|Oral tablets administered as 2.5 mg once daily for up to 12 weeks (Arm discontinued as of Protocol Amendment 8)
3208489|NCT01137474|Experimental|Dapagliflozin, 5 mg|Oral tablets administered as 5 mg once daily for up to 12 weeks (Arm discontinued as of Protocol Amendment 8)
3208490|NCT01137461|Other|abdominal ultrasound|traditional technique
3208491|NCT01137461|Other|transvaginal ultrasound|new technique
3208492|NCT01137448|Experimental|Weight Loss|Subjects will be enrolled in a weight loss program and will receive weight loss and nutritional counseling.
3208494|NCT01137409||Suspected or Diagnosed with Coronary artery disease|All patients with suspected or previously diagnosed coronary artery disease
3208495|NCT01137396|Experimental|Modafinil|
3208496|NCT01137396|Placebo Comparator|Placebo|
3208497|NCT01137383|Experimental|Treatment group|
3208498|NCT01137370||Patients with TB|
3208499|NCT01137370||People without TB|
3208500|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L.plantarum WCFS1)|
3208501|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L.plantarum NIZO3400)|
3208502|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L. plantarum NIZO2877)|
3208503|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L.plantarum CBS125632)|
3208504|NCT01137357|Active Comparator|Yoghurt with Lactobacillus casei Shirota|
3208505|NCT01137357|Placebo Comparator|Placebo Yoghurt|
3208506|NCT01137331|Experimental|K301|K301 applied topically to the affected area of the scalp once daily during the 4 weeks. Treatment is to be applied before bedtime and can be washed out with the patient's normal shampoo in the morning.
3208507|NCT01137331|Placebo Comparator|Placebo|Placebo applied topically to the affected area of the scalp once daily during the 4 weeks. Treatment is to be applied before bedtime and can be washed out with the patient's normal shampoo in the morning.
3208508|NCT01137318|Experimental|Cognitive remediation and Behavioral Intervention|
3208509|NCT01137318|Placebo Comparator|Low Level Cognitive Remediation and Behavioral Parent Traning|
3208510|NCT01137292||Active Treatment|Patients who are eligible for voriconazole treatment according to their physician decision.
3208511|NCT01137266|Active Comparator|skin resistence|1) the location with the lowest resistance
3208512|NCT01137266|Active Comparator|irradiation|2) the site that causes an irradiation sensation
3208513|NCT01137266|Active Comparator|random|3) a random stimulation site.
3208514|NCT01137253|Experimental|Trimethaphan|Response to intrabrachial vasodilators during autonomic withdrawal
3208515|NCT01137253|Placebo Comparator|Placebo|Response to intrabrachial vasodilators during saline intravenous (IV) infusion
3208516|NCT01137240||Children with mitochondrial disorders|suffering from gastrointestinal dysfunction
3208517|NCT01137227||Description|"2137 studies retrieved in 8 databases (Biomed Central, CINAHL, EMBASE, ERIC, PsycInfo, PUBMED, SCOPUS, SPORTDiscus and uploaded in EndNote Web®.~332 studies were excluded as duplicates by EndNote Web®.~1805 titles and abstracts were assessed independently by two researchers (PG/AM): 1541 studies excluded.~264 studies referred for full-text assessment by two independent investigators (PG/AM)~225 studies were excluded according to the eligibility criteria (in case of discrepancies in the assessment of the researchers, studies were reviewed in duplicate)~39 Studies assessed for quality using STROBE~13 Studies were included in the descriptive synthesis"
3208518|NCT01137214|Active Comparator|CPAP|Continuous Positive Airway Pressure
3208519|NCT01137214|Active Comparator|Adaptive Servo-Ventilator|Non-invasive positive pressure ventilator that applies a constant expiratory pressure, as well as a variable inspiratory pressure.
3208520|NCT01137201|Experimental|Mesenteric defects sutured|Closure of the mesenteric defects using running, non-absorbable suture
3208521|NCT01137201|No Intervention|Mesenteric defects not sutured|Non-closure of the mesenteric defects
3208522|NCT01137188|Experimental|Intervention group|Intensive weight loss program and regular group sessions with clinical dietician. Complete dietary substitution with a low calorie diet containing 800-1000 kcal/day for 8 weeks
3208523|NCT01137188|No Intervention|No intervention|Study subjects will receive routine dietary counseling for 8 weeks and will cross over to intervention upon completion
3208524|NCT01137149|Active Comparator|Treatment as Usual- Psychotherapy|The TAU condition will be implemented consistent with usual and customary clinical practices within the Child Psychiatry Clinic at Seattle Children's Hospital (SCH. Within the SCH system, TAU for a depressed adolescent will typically consist of an individual therapy approach with adjunct family sessions and pharmacotherapy as deemed necessary by the primary therapist. The therapeutic approach typically used is cognitive behavioral but is administered in an eclectic, non-manualized fashion. Therapists for the TAU arm of the study will be care providers currently working within the SCH system. For this phase of the study, we will draw on clinicians whose level of experience is comparable to that of the Behavioral Activation therapists.
3208525|NCT01137149|Experimental|Behavioral Acitivation Therapy|Behavioral activation is a 12 week psychotherapeutic intervention utilizing a semi-structured format. Initial sessions focus on specific areas (Assessment and orientation, Activation, Problem Solving, Goal Setting, Overcoming Barriers, Avoidance) interspersed as needed by sessions that focus on individual issues and applications. In these sessions the therapists maintains the session structure, but can use techniques presented in earlier sessions based on their functional analysis of the particular case. Parents participate in at least two of the ATA sessions but more active parental participation can be included as needed.
3208526|NCT01137136||SMAC (SMc AI user Cohort)|All patients who took the AI (Aromatase inhibitor)will be enrolled
3208527|NCT01137123|Active Comparator|standard two field +follow-up|
3208528|NCT01137123|Experimental|standard two field +adjuvant chemotherapy|
3208529|NCT01137123|Experimental|total two field+follow-up|
3208530|NCT01137123|Experimental|total two field+adjuvant chemotherapy|
3208531|NCT01137123|Experimental|three field+follow-up|
3208532|NCT01137123|Experimental|three field+adjuvant chemotherapy|
3208533|NCT01137110|Active Comparator|Levetiracetam 1000mg BID for 3 days|
3208534|NCT01137110|Active Comparator|Levetiracetam 1000mg BID x hospital stay|
3208535|NCT01137097|Active Comparator|Lateral sentinel group|Lateral sentinel lymph node biopsy with radioisotope
3208536|NCT01137097|No Intervention|No intervention for lateral neck|No lateral sentinel lymph node biopsy with radioisotope
3208537|NCT01137084|Active Comparator|a steroid immunosuppression protocol|
3208538|NCT01137084|Active Comparator|a steroid-free immunosuppression protocol|without steroid
3208539|NCT01137071|Experimental|Monoclonal antibody hu3S193|Monoclonal antibody hu3S193 will be administered to 51 patients at the dose of 30mg/m2 every other week (total of 12 infusions) for a total of 23 weeks.
3208540|NCT01137058|Experimental|U-healthcare|glucose meter and U-healthcare
3208589|NCT01136733|Active Comparator|Everolimus|
3208541|NCT01137058|Active Comparator|SMBG group|Diabetic patients who do self monitoring of blood glucose only were categorized into self monitoring of blood glucose (SMBG) group.
3208542|NCT01137058|No Intervention|control|conventional treatment
3208543|NCT01137045|Active Comparator|SPEEDA with modified TRC-ID regimen|35 healthy volunteers
3208544|NCT01137045|Active Comparator|VERORAB with modified TRC-ID regimen|35 healthy volunteers
3208545|NCT01137045|Active Comparator|SPEEDA with modified TRC-ID regimen plus ERIG|35 healthy volunteers
3208546|NCT01137045|Active Comparator|VERORAB with modified TRC-ID regimen plus ERIG|35 WHO category III patients
3208547|NCT01137045|Active Comparator|SPEEDA with ESSEN IM regimen plus ERIG|35 healthy volunteers
3208548|NCT01137045|Active Comparator|TRCS SPEEDA with modified TRC-ID regimen plus ERIG|35 healthy volunteers
3208549|NCT01137032|Experimental|Pandel Cream 0.1%|Pandel Cream 0.1%
3208550|NCT01137019|Active Comparator|Biolimus-eluting stent|
3208551|NCT01137019|Active Comparator|Everolimus-eluting stent|
3208552|NCT01137006|Experimental|IMC-20D7S (A)|
3208553|NCT01137006|Experimental|IMC-20D7S (B)|
3208554|NCT01136993||All bi-directional telestroke consultations|
3208555|NCT01136980|Placebo Comparator|Sham placebo procedure|"Sham Procedure:~An upper GI Endoscopy is performed with a standard endoscope, during 30-45 minutes. The patient is under general anesthesia. EGD explores the esophagus, the stomach and the GEJ."
3208556|NCT01136980|Active Comparator|TIF Transoral Fundoplication|"Intervention:~TIF. Transoral Incisionless Fundoplication. the EsophyX device is introduced over a standard endoscope, through the mouth, into the stomach."
3208557|NCT01136967|Experimental|Cohort 1 (V600E BRAF negative)|Cohort 1 (V600E BRAF negative) enrolled participants not harboring the V600E BRAF mutation with disease progression following up to 2 prior systemic anticancer regimens (excluding anti-VEGF) for unresectable Stage III or Stage IV melanoma.
3208558|NCT01136967|Experimental|Cohort 2 (V600E BRAF positive)|Cohort 2 (V600E BRAF positive) enrolled participants harboring the activating BRAF mutations (mainly the V600E mutation) with disease progression following BRAF V600E-targeted therapy.
3208559|NCT01136954|Experimental|1|
3208560|NCT01136941|Experimental|Treatment|Research participants will be administered Zileuton according to the dose escalation/de-escalation schema provided in the protocol.
3208561|NCT01136928|Experimental|American ginseng and efavirenz|This is a sequential study. Healthy volunteers will receive efavirenz alone for 14 days followed by efavirenz plus American ginseng for an additional 14 days.
3208562|NCT01136915|Active Comparator|IOPAMIDOL injection 370|
3208563|NCT01136915|Active Comparator|Iodixanol 320|
3208564|NCT01136902||Type 2 DM|This group includes subjects diagnosed with type 2 diabetes mellitus with none or minimal diabetic retinopathy.
3208565|NCT01136889|Active Comparator|PFMT plus routine pessary management|"Women allocated to the intervention group will be invited to attend 5 out-patient appointments over a 16 week period with a trained specialist women's health physiotherapist at the study centre. Women will be taught how to contract the muscles, and also how to contract and hold prior to an event that increases intra-abdominal pressure (the Knack). Tailored advice will be given on ways of reducing intra-abdominal pressure, e.g. advice on weight loss, chronic cough, heavy lifting and general exercise. A prolapse specific Lifestyle Advice sheet will also be given to the women by the physiotherapist."
3208566|NCT01136889|Active Comparator|Lifestyle|Women allocated to the control group will be sent a Lifestyle Advice Leaflet only. They will have no planned intervention after their pessary is fitted, other than routine pessary management according to local protocols. The Lifestyle Advice Leaflet gives instructions on seeking advice, where appropriate, about weight loss, constipation, and avoidance of heavy lifting, coughing and high impact exercise, with a view to minimising increases in intra-abdominal pressure which may cause the prolapse to worsen.
3208567|NCT01136876|Active Comparator|Non-ionic iodinated contrast agent|
3208568|NCT01136876|Active Comparator|Non-ionic contrast media comparator|
3208569|NCT01136863|Active Comparator|felodipine group, active, pill|felodipine and HCTZ treatment group
3208570|NCT01136863|Placebo Comparator|placebo, no treatment, pill|placebo and HCTZ group
3208571|NCT01136850|Active Comparator|SP, chloroquine treatment; bed net|Treatment course of sulphadoxine pyrimethamine and chloroquine on enrolment. Long lasting insecticide treated bed net
3208572|NCT01136850|Experimental|3 x SP plus azithromycin; bed nets|Three x monthly courses of azithromycin and sulphadoxine pyrimethamine plus long lasting insecticide treated bed net.
3208573|NCT01136837||fragmented QRS positive|fQRS at 48 hours after Primary PCI
3208574|NCT01136824||Sarcoma Subjects|Soft tissue sarcoma patients treated with the adjuvant and neoadjuvant chemotherapy protocol of doxorubicin plus ifosfamide (AI)
3208575|NCT01136811|Experimental|Computer assisted surgery|
3208576|NCT01136798|Placebo Comparator|Usual T2 DM med regimen|Subjects will continue on Type 2 DM therapy but will add placebo injected subcutaneously twice daily to their regimen for a total of 6 weeks.
3208577|NCT01136798|Experimental|Usual T2 DM med regimen plus Exenatide|Subjects will continue on Type 2 DM therapy but will add injectable exenatide to their regimen There will be twice daily treatment with subcutaneous injections of 5 µg of Exenatide for 2 weeks followed by 4 weeks of treatment with twice daily subcutaneous injections of 10 µg of Exenatide.
3208578|NCT01136785|Active Comparator|Active CPAP therapy|7 days of treatment in the laboratory with active CPAP therapy.
3208579|NCT01136785|Sham Comparator|Sham CPAP therapy|7 days of sham CPAP therapy in the laboratory.
3208580|NCT01136772|Experimental|Paliperidone palmitate|Intramuscular injections of paliperidone palmitate 39-234 mg every month
3208581|NCT01136772|Active Comparator|Haloperidol decanoate|Intramuscular injections of haloperidol decanoate 25-200 mg every month
3208582|NCT01136759|Placebo Comparator|Pregnancy cohort, placebo|Pregnant women will receive placebo gel.
3208583|NCT01136759|Experimental|Lactation cohort, tenofovir gel|Lactating mothers will receive tenofovir gel.
3208584|NCT01136759|Experimental|Pregnancy cohort, tenofovir gel|Pregnant women will receive tenofovir gel.
3208585|NCT01136746|Active Comparator|Sliding scale regular insulin|
3208586|NCT01136746|Experimental|Basal-bolus therapy|
3208587|NCT01136733|Experimental|Lenvatinib|
3208588|NCT01136733|Experimental|Lenvatinib plus Everolimus|
3208590|NCT01136720||patients injected with the Halifax produced 18-FDG|
3208591|NCT01136707||Patients with rheumatoid arthritis new to Orencia|
3208592|NCT01136694||RA patients who are new bDMARD users|
3208593|NCT01136694||RA patients who are existing DMARD users|
3208594|NCT01136668|Experimental|Treatment group|
3208595|NCT01136668|Active Comparator|Control Group|
3208596|NCT01136655|Experimental|BUD 160/FM 2.25|2.25 μg formoterol (as 80/2.25 μg Symbicort pMDI × 1 inhalation) + 40 μg budesonide HFA pMDI × 2 inhalations
3208597|NCT01136655|Experimental|BUD 160/FM 4.5|placebo HFA pMDI × 1 inhalation + 4.5 μg formoterol (as 80/2.25 μg Symbicort pMDI × 2 inhalations)
3208598|NCT01136655|Experimental|BUD 160/FM 9.0|placebo HFA pMDI × 1 inhalation + 9 μg formoterol (as 80/4.5 μg Symbicort pMDI × 2 inhalations)
3208599|NCT01136655|Placebo Comparator|BUD 160|placebo HFA pMDI × 1 inhalation + 80 μg budesonide HFA pMDI × 2 inhalations
3208600|NCT01136655|Active Comparator|BUD 160/Foradil 12.0|Foradil Aerolizer 12 μg × 1 inhalation + 80 μg budesonide HFA pMDI × 2 inhalations
3208601|NCT01136629||Subjects with hyper-pigmented spots|Subjects age 21 to 80 year old, who have elected to undergo a plastic surgery will be enrolled. Subjects will be from Chinese, Malay, Indian or Caucasian ancestry. Subjects will be female or male with a hyper-pigmented spots.
3208602|NCT01136616||Nasal Fracture|"67 patients admitted for facial fractures and who undergo routine CT scans of the face are to be studied. CT scans are evaluated to assess the position, comminution and displacement of the 5 said buttresses.~The buttresses are graded Grade 1 Simple fracture without displacement Grade 2 Simple fracture with displacement Grade 3 Comminuted fracture without displacement Grade 4 Comminuted fracture with minimal displacement Grade 5 Comminuted fractured with displacement~The septum is graded from Grade 0 Septum is straight Grade 1 Septum is deviated by less than 1 half the distance from the midline to the nasal turbinate Grade 2 Septum is deviated by more than 1 half the distance from the midline to the nasal turbinate Grade 3 Septum is almost touching the nasal turbinate"
3208603|NCT01136603|Experimental|TIGR Mesh|Experimental - TIGR Mesh
3208604|NCT01136603|Active Comparator|Control|Control group - Non absorbable Polypropylene mesh
3208605|NCT01136590|Experimental|tranexamic acid|tranexamic acid will be administered as a bolus (10-mg/kg dose ) or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery
3208606|NCT01136590|Placebo Comparator|placebo|The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
3208607|NCT01136577|Experimental|LEDDYBLOO®|LEDDYBLOO® phototherapy device equipped with 20 at 30 blue and white LEDs
3208608|NCT01136577|Experimental|Double BILITRON®|Double BILITRON® phototherapy corresponding to two small ramps associated together each one equipped of 5 blue LEDS
3208609|NCT01136577|Experimental|Futura®|Future phototherapy device equipped with 8 fluorescent tubes
3208610|NCT01136564|Active Comparator|Paricalcitol|
3208611|NCT01136564|Placebo Comparator|Placebo|
3208612|NCT01136551|Active Comparator|IR formulation|Healthy volunteers will receive imediate release formulation of Huperzine A (0.4mg)
3208613|NCT01136551|Experimental|CR 1|"CR formulation~Healthy volunteers will receive controlled release formulation 1 of Huperzine A (0.4mg)"
3208614|NCT01136551|Experimental|CR 2|"CR formulation~Same volunteers will receive controlled release formulation 2 of Huperzine A (0.4mg)"
3208615|NCT01136538|Experimental|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
3208616|NCT01136538|Active Comparator|Valtrex (R)|Valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline
3208617|NCT01136525|Experimental|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
3208618|NCT01136525|Active Comparator|Valtrex (R)|Valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline
3208619|NCT01136512||metformin use|Patients with type 2 diabetes treated with metformin
3208620|NCT01136512||no metformin use|Patients with type 2 diabetes who are not being treated with metformin
3208621|NCT01136499|Experimental|LBH PANOBINOSTAT|40 mg 3 days per week
3208622|NCT01136473||congenital cataract or aphakic glaucoma|children with congenital cataract or aphakic glaucoma
3208623|NCT01136460||Primary congenital glaucoma|Primary congenital glaucoma patients and their immediate relatives
3208624|NCT01136447|Placebo Comparator|Neurostimulation|Block catheter will be introduced using neurostimulation
3208625|NCT01136447|Active Comparator|Ultrasound|Block catheter will be introduced using ultrasound
3208626|NCT01136421|Active Comparator|Ipratropium bromide|Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.
3208627|NCT01136421|Experimental|Magnesium sulfate|Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.
3208628|NCT01136408|Experimental|Dabigatran etexilate 220 mg daily|Dabigatran etexilate 110 mg capsule, twice a day, oral administration
3208629|NCT01136408|Experimental|Dabigatran etexilate 300 mg daily|Dabigatran etexilate 150 mg capsule, twice a day, oral administration
3208630|NCT01136408|Active Comparator|Warfarin|Dose-adjusted warfarin based on target INR values
3208631|NCT01136395|Active Comparator|LD kidney transplantation, ABOi|Living donor (LD) kidney transplantation, ABO incompatible (ABOi); Immunosuppressive treatment: Tacrolimus (Tacr)/ Mycophenolate sodium (MPS), Basiliximab induction, Rtx induction
3208632|NCT01136395|Active Comparator|LD kidney transplantation, ABOc|Living donor (LD) kidney transplantation, ABO compatible (ABOc); Immunosuppressive treatment: Tacr/MPS, Basiliximab induction
3208684|NCT01136031|Experimental|Paclitaxel and irinotecan|
3208685|NCT01136018||intentional lateral caudal approach|
3208633|NCT01136395|Active Comparator|DD kidney transplantation|Deceased donor (DD) kidney transplantation, ABO compatible; Immunosuppressive treatment: Tacr/MPS, Basiliximab induction
3208634|NCT01136382|Experimental|1|Budesonide pMDI 160 ug bid (80 ug x 2 inhalations bid)
3208635|NCT01136382|Placebo Comparator|2|Placebo pMDI 2 inhalations bid
3208636|NCT01136369||OSNA Breast Cancer System|
3208637|NCT01136356|Experimental|Morphine, then Buprenorphine|Healthy, out of treatment opioid-dependent residential volunteers (N=7) were randomized to receive morphine (120 mg/day i.m.) administered in four divided doses each day for 9 days (30 mg of morphine four times per day). Participants then underwent an 18-day period of spontaneous opioid withdrawal, during which four double blind i.m. placebo injections were administered daily. After the period of spontaneous withdrawal, participants received buprenorphine (32 mg/day i.m.) administered in four divided doses each day for 9 days (8 mg of buprenorphine four times per day) followed by a second 18-day period of spontaneous withdrawal identical to the withdrawal period described above.
3208638|NCT01136356|Experimental|Buprenorphine, then Morphine|Healthy, out of treatment opioid-dependent residential volunteers (N=7) were randomized to receive buprenorphine (32 mg/day i.m.) administered in four divided doses each day for 9 days (8 mg of buprenorphine four times per day). Participants then underwent an 18-day period of spontaneous withdrawal, during which four double blind i.m. placebo injections were administered daily. After the period of spontaneous withdrawal, participants received morphine (120 mg/day i.m.) administered in four divided doses each day for 9 days (30 mg of morphine four times per day) followed by a second 18-day period of spontaneous withdrawal identical to the withdrawal period described above.
3208639|NCT01136343|Experimental|lifestyle modified project|education, counseling
3208640|NCT01136343|No Intervention|control|waiting list control
3208641|NCT01136317|Experimental|Omeprazole|
3208642|NCT01136317|Experimental|Rabeprazole|
3208643|NCT01136317|Placebo Comparator|Placebo|
3208644|NCT01136304||Adults with Type 1 Gaucher disease (GD1)|Adults with GD1 who are cared for at one of the participating research sites whether treatment naive or treated in past or currently with imiglucerase enzyme replacement treatment.
3208645|NCT01136291|Other|physical exercise|exercise on obese and overweight pregnant women, routine prenatal care and nutritional counseling
3208646|NCT01136291|No Intervention|no exercise|Routine prenatal care and nutritional counseling. No exercise
3208647|NCT01136278|Experimental|clonidine, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
3208648|NCT01136252|Experimental|Adalimumab|
3208649|NCT01136239|Placebo Comparator|Placebo|Placebo (600mg twice daily)
3208650|NCT01136239|Active Comparator|N-acetylcysteine|N-acetylcysteine (600mg twice daily)
3208651|NCT01136226|Other|Eligard (TM)|Eligard (TM) administered 22.5mg
3208652|NCT01136213||Multiple system atrophy|
3208653|NCT01136213||Idiopathic Parkinson Disease|
3208654|NCT01136213||Volunteers without neuropsychiatric disorder (Control)|
3208655|NCT01136200|Experimental|Infectious disease specialist advice|Patients receiving the intervention (infectious disease specialist advice)
3208656|NCT01136200|No Intervention|Control|Patients not receiving infectious disease specialist advice
3208657|NCT01136187|Experimental|Radial approach|Primary percutaneous coronary intervention from the radial approach
3208658|NCT01136187|Active Comparator|Femoral approach|Primary percutaneous coronary intervention from the femoral approach
3208659|NCT01136174|Experimental|BIBF 1120 50 mg|Low dose for cohort 1
3208660|NCT01136174|Experimental|BIBF 1120 100 mg|Middle dose for cohort 2
3208661|NCT01136174|Experimental|BIBF 1120 150 mg|High dose for cohort 3
3208662|NCT01136174|Placebo Comparator|Placebo|Placebo for cohort 1,2,3
3208663|NCT01136161|Experimental|RUTI 5 micrograms of FCMtb in HIV -|n=12
3208664|NCT01136161|Experimental|RUTI 25 micrograms of FCMtb in HIV -|n=12
3208665|NCT01136161|Experimental|RUTI 50 micrograms of FCMtb in HIV -|n=12
3208666|NCT01136161|Placebo Comparator|RUTI Matching Placebo in HIV -|n=12
3208667|NCT01136161|Experimental|RUTI 5 micrograms of FCMtb in HIV +|n=12
3208668|NCT01136161|Experimental|RUTI 25 micrograms of FCMtb in HIV +|n=12
3208669|NCT01136161|Experimental|RUTI 50 micrograms of FCMtb in HIV +|n=12
3208670|NCT01136161|Placebo Comparator|RUTI Matching Placebo in HIV +|n=12
3208671|NCT01136148|Experimental|A Medical and Mental Health Unit|A specialist unit for cognitively impaired older patients admitted as a medical emergency to the acute hospital.
3208672|NCT01136148|Active Comparator|Standard care wards|The standard care provided by the acute hospital for cognitively impaired older patients admitted as a medical emergency.
3208673|NCT01136135||CARDIAC MRI|
3208674|NCT01136122|Active Comparator|CPAP Arm|Receive effective CPAP treatment for one month
3208675|NCT01136122|No Intervention|Control Arm|Receive no treatment for one month
3208676|NCT01136109||Bedside ultrasound only|Bedside ultrasound to determine the dimensions of the inferior vena cava
3208677|NCT01136109||Ultrasound with ventilator changes|Bedside ultrasound to determine the dimensions of the inferior vena cava pre and post ventilator changes.
3208678|NCT01136096|Experimental|Lifestyle counseling|To promote participants' exercise behaviors with individualized home-based exercise program was designed based on the Health Belief Model and Transtheoretical Model
3208679|NCT01136096|Other|Control|Received oral instruction and written general education information without individualized exercise program
3208680|NCT01136083|Experimental|Exercise training|Subjects in exercise group will undergo individualized high aerobic interval training on treadmill for 30 minutes under the supervision of an experienced physical therapist 3 times a week and home exercise twice a week with accelerometer.
3208681|NCT01136083|Active Comparator|Control group|Subjects in control group will not undergo individualized high aerobic interval training on treadmill. They will receive usual care as normally does in hospital.
3208682|NCT01136070||Burn Trauma Patients|
3208683|NCT01136057||Influenza A Exposure|Participants will include people who have recovered from influenza, received a seasonal influenza vaccine, or have both recovered from influenza and received a seasonal influenza vaccine.
3208686|NCT01136005|Experimental|dexpanthenol 5% cream|dexpanthenol 5% cream
3208687|NCT01136005|Active Comparator|cetomacrogol cream|a vehicle
3208688|NCT01135992|Experimental|IGlar/IDeg|
3208689|NCT01135992|Experimental|IDeg 3TW|
3208690|NCT01135979||Arterio-venous fistulae creation|
3208691|NCT01135966|Active Comparator|Conventional training|
3208692|NCT01135966|Experimental|Whole body vibration training|
3208693|NCT01135953|Experimental|ARM 1 - CONTROL|Subject given tDCS every day of the week (5 sessions) at 2 mA.
3208694|NCT01135953|Experimental|Arm 2 - INCREASING|Subjects given increasing intensity during tDCS across the week (Monday 1mA, Tuesday 1.5mA, Wednesday 1.5 mA, Thursday 2 mA, Friday 2mA).
3208695|NCT01135953|Experimental|ARM 3 - CYCLOSERINE|D-cycloserine (100 mg) given on the Monday and Thursday sessions, administering tDCS at 2 mA.
3208696|NCT01135940|Experimental|1|2-octylcyanoacrylate (Dermabond) closure
3208697|NCT01135940|Active Comparator|2|Standard staple closure
3208698|NCT01135927|Experimental|A|
3208699|NCT01135927|Active Comparator|B|
3208700|NCT01135914|Experimental|Combination Therapy|Participants received ranibizumab intravitreal injection and laser photocoagulation treatments
3208701|NCT01135914|Experimental|Ranibizumab Monotherapy|Participants received ranibizumab intravitreal injection therapy only
3208702|NCT01135914|Active Comparator|Laser Monotherapy|Participants received Laser photocoagulation therapy only
3208703|NCT01135901|Experimental|group programme|Group based behaviour change programme
3208704|NCT01135888||HED children|
3208705|NCT01135888||HED adolescents|
3208706|NCT01135888||Control children|
3208707|NCT01135888||Control adolescents|
3208708|NCT01135875||GBM Patients|GBM Patients with a histologically confirmed or suspected diagnosis of glioblastoma multiforme.
3208709|NCT01135875||Normal Controls|Normal Controls will be adult volunteers who identify themselves as not having been diagnosed with a glioblastoma multiforme.
3208710|NCT01135862|Experimental|platelet administered|patients will receive 6 packs of platelets
3208711|NCT01135862|No Intervention|no platelets administered|patients will not receive platelets
3208712|NCT01135836|Experimental|pulmonary recruitment maneuver|a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anestheiologist held the fifth positive pressure inflation for approximately 5 seconds.
3208713|NCT01135836|Experimental|intraperitoneal normal saline|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity
3208714|NCT01135836|Placebo Comparator|Control group|CO2 was removed by passive exsufflation through the port site.
3208715|NCT01135797||Patients from phase I-II studies|
3208716|NCT01135784|Active Comparator|MIGRA-ZEN RELIEF PLUS|Active treatment
3208717|NCT01135784|Placebo Comparator|Placebo for Migra zen plus|Placebo
3208718|NCT01135758|Experimental|ketamine 0.5 mg/kg i.v.|Single administration of ketamine 0.5 mg/kg i.v.
3208719|NCT01135745|Experimental|Deep Brain Stimulation Therapy for OCD|Reclaim® DBS Therapy uses thin wires to deliver electric current (stimulation) to a very specific target in the brain. These wires are implanted surgically. They are attached to internal neurostimulators implanted under the skin of the chest below the collarbone, similar to cardiac pacemakers, or in the abdominal wall. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
3208720|NCT01135732||study group-previous sphincterotomy|
3208721|NCT01135732||control group-not previous sphincterotomy|
3208722|NCT01135719|Active Comparator|Wavefront guided LASIK/PRK|Wavefront-guided LASIK/PRK
3208723|NCT01135719|Active Comparator|Wavefront optimized LASIK/PRK|Wavefornt optimized LASIK/PRK
3208724|NCT01135706||Pulmonary Hypertension|Patients having a right heart catheterization and CT pulmonary angiogram with a diagnosis of Pulmonary Hypertension
3208725|NCT01135706||Non Pulmonary Hypertension|Patients having a right heart catheterization and CT pulmonary angiogram without a diagnosis of Pulmonary Hypertension.
3208726|NCT01135680|Placebo Comparator|Arm 1|"Cohort A: 9 mL HPN-100 or placebo~Cohort B: 12 mL HPN-100 placebo"
3208727|NCT01135680|Placebo Comparator|Arm 2|"This study requires 4 periods. In each of the periods you will receive one of the dose groups listed below. At the completion of the study you will have participated in all 4 dose groups. The order in which you participate in each dose group will be randomly assigned.~Dose Group A: 9 mL placebo via oral syringe 3 times daily for 3 days~Dose Group B: single oral dose of 400 mg moxifloxacin on study Day 3~Dose Group C: 6 mL HPN-100 and 3 mL placebo via oral syringe 3 times daily for 3 days~Dose Group D: 9 mL HPN-100 via oral syringe 3 times daily for 3 days"
3208728|NCT01135667|Active Comparator|clopidogrel|clopidogrel 150 mg once daily for 30 days (and then 75 mg for additional 11 months - not study related)
3208729|NCT01135667|Active Comparator|Prasugrel|Prasugrel 10 mg once daily for 30 days (and then clopidogrel 75 mg once daily for additional 11 months - not study related)
3208730|NCT01135654|Experimental|Non-Physician Provider|
3208731|NCT01135654|No Intervention|Control|
3208732|NCT01135654|Active Comparator|Primary Care Provider|In clinics randomized to this arm, we will train (and provide technical assistance to) Primary Care providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment.
3208733|NCT01135641|Experimental|Rituximab, ciclosporine and corticosteroids|As soon as the diagnosis of chronic GVHD requiring systemic immunosuppressive therapy is confirmed, patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.Rituximab should be administered within 14 days of starting prednisone. Follow-up dates for response assessment and laboratory tests relate to the date of Rituximab infusion.Patients having a partial response after the 1st cycle of Rituximab will be eligible to receive a second cycle of 4 infusions during 4 weeks. A delay of 8 weeks (from the first infusion of Rituximab) will be observed between the two cycles of Rituximab therapy.Patients who relapse after an initial treatment with one cycle of 4 infusions of Rituximab will be eligible to receive a second cycle of Rituximab therapy.
3208847|NCT01134848|Active Comparator|Secretin|
3208894|NCT01134471|Active Comparator|Bonewax|Patients treated with the hemostatic bonewax
3208734|NCT01135628|Active Comparator|MHE and diet plus lactobacillus reuteri|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods and lactobacillus reuteri.
3208735|NCT01135628|Active Comparator|MHE and diet|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods.
3208736|NCT01135628|Active Comparator|MHE and diet plus nitazoxanide|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods and nitazoxanide.
3208737|NCT01135615|Other|Sevelamer|
3208738|NCT01135615|Other|calcium acetate|
3208739|NCT01135602|Experimental|Topiramate|1 group
3208740|NCT01135589|Experimental|HSCT|
3208741|NCT01135576|Placebo Comparator|Placebo juices|Consumption of non-iron fortified fruit juices as part of the usual diet
3208742|NCT01135576|Experimental|Iron fortified fruit juices|Consumption of iron fortified fruit juices as part of the usual diet
3208743|NCT01135563|Experimental|Vinblastine and Sirolimus|The standard 3+3 Phase 1 trial design will be used for the conduct of this study. Three to six patients can be concurrently enrolled onto a dose level. Accrual is suspended when a cohort of three has been enrolled until toxicity data for that cohort have been reported, or when the study endpoints have been met.
3208744|NCT01135550|Active Comparator|Standard Arm|"Subjects scheduled to undergo radiation therapy are enrolled before the therapy is started. Once radiation therapy begins they will complete a daily diary about any headaches or nausea/vomiting they experience.~If they experience increased headache or vomiting they will be randomized to receive either a high or a low dose of dexamethasone, to control these symptoms."
3208745|NCT01135550|Active Comparator|Control Arm|"Subjects scheduled to undergo radiation therapy are enrolled before the therapy is started. Once radiation therapy begins they will complete a daily diary about any headaches or nausea/vomiting they experience.~If they experience increased headache or vomiting they will be randomized to receive either a high or a low dose of dexamethasone, to control these symptoms."
3208746|NCT01135537|Experimental|Thymoglobulin|Thymoglobulin 7.5 mg/kg/course prior to HSCT
3208747|NCT01135524|Experimental|BTDS|Buprenorphine transdermal patch
3208748|NCT01135511|Experimental|Treatment 1|
3208749|NCT01135511|Experimental|Treatment 2|
3208750|NCT01135511|Experimental|Treatment 3|
3208751|NCT01135511|Placebo Comparator|Treatment 4|
3208752|NCT01135511|Active Comparator|Treatment 5|
3208753|NCT01135498|Experimental|1|
3208754|NCT01135485||Study group I|Study group I will include children who have undergone stage I palliation employing allograft material for left ventricular outflow tract reconstruction at CHOP during infancy (<1 year of age). Stage I palliation is defined as an operation in which augmentation of the native ascending aorta and aortic arch is performed to bypass atresia or critical obstruction of the left heart structures.
3208755|NCT01135485||Study Group II|Study group II who have undergone stage II palliation in which allograft material is used, but have not undergone antecedent stage I palliation. Stage II palliation is defined as a superior cavopulmonary anastomosis in which the superior vena cava is anastomosed to the ipsilateral pulmonary artery via either the bidirectional Glenn or hemi-Fontan procedures.
3208756|NCT01135485||Control Group|The control group who have undergone palliative or corrective surgery for congenital heart disease during infancy (<1 year of age) not requiring allograft material.
3208757|NCT01135472|Experimental|Nexium|ARM 1: NEXIUM 40MG ONCE DAILY, ARM 2: NEXIUM 40MG TWICE DAILY, ARM 3: NEXIUM 80MG TWICE DAILY
3208758|NCT01135459|Experimental|CEP-33457|200 mcg of CEP-33457
3208759|NCT01135459|Placebo Comparator|Placebo|
3208760|NCT01135446|Experimental|dapagliflozin (0.001 mg)|Cohort 1
3208761|NCT01135446|Experimental|dapagliflozin (0.01 mg)|Cohort 2
3208762|NCT01135446|Experimental|dapagliflozin (0.1 mg)|Cohort 3
3208763|NCT01135446|Experimental|dapagliflozin (0.3 mg)|Cohort 4
3208764|NCT01135446|Experimental|dapagliflozin (1 mg)|Cohort 5
3208765|NCT01135446|Experimental|dapagliflozin (2.5 mg)|Cohort 6
3208766|NCT01135433|Experimental|ASP group|ASP1941 and metformin
3208767|NCT01135433|Placebo Comparator|Placebo group|placebo and metformin
3208768|NCT01135420|Active Comparator|Usual Care|Psychiatry inpatient usual care
3208769|NCT01135420|Experimental|Telephone Monitoring|Patients in the TM condition will receive an in-person session while in treatment, followed by monitoring over the telephone for three months after discharge. The intervention will incorporate motivational interviewing to monitor patients' substance use, facilitate entry into outpatient treatment, and encourage 12-step self-help group participation.
3208770|NCT01135407||group #1|Parkinson's disease patients at a disease's stage characterized by motor complications
3208771|NCT01135407||group #2|Parkinson's disease patients treated by subthalamic nucleus deep brain stimulation.
3208772|NCT01135407||group #3|healthy controls
3208773|NCT01135394|Experimental|Pioglitazone (Actos)|Participants will have metabolism studies to consist of outpatient X-ray and MR measurements of bone density and body composition, metabolic testing (intravenous glucose tolerance test), and muscle and adipose tissue biopsies. Blood will also be drawn for genetic testing and for microarray studies of leukocytes. Upon completion of the above studies, the participant will begin pioglitazone therapy. Every 4 weeks throughout the drug intervention, glycemic control, lipoprotein profile, and weight will be monitored. After 12 weeks of pioglitazone therapy, the X-ray and MR measurements of body composition, the biopsies, microarray studies for leukocytes and the metabolic tests will be repeated.
3208774|NCT01135381|Experimental|CHF patients, IVR-Enhanced Care|Patients with congestive heart failure (CHF) who receive the interactive voice response (IVR) intervention.
3208775|NCT01135381|Experimental|COPD patients, IVR-Enhanced Care|Patients with chronic obstructive pulmonary disease (COPD) who receive the interactive voice response (IVR) intervention.
3208776|NCT01135381|No Intervention|CHF patients, Usual Discharge Care|Patients with congestive heart failure (CHF) who receive usual discharge care (no intervention).
3208777|NCT01135381|No Intervention|COPD patients, Usual Discharge Care|Patients with chronic obstructive pulmonary disease (COPD) who receive usual discharge care (no intervention).
3208848|NCT01134835|Experimental|IMP Pioglitazone|Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
3208778|NCT01135368|Experimental|Lansoprazole|"Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.~Depending on response, dosage could then be decreased to 15 mg, once daily, or increased to 30 mg, twice daily for up to 4 years and 10 months."
3208779|NCT01135342|Experimental|Diet & Exercise plus Sleep Intervention|Diet and exercise instruction to promote weight loss plus cognitive behavioral therapy for insomnia.
3208780|NCT01135342|Sham Comparator|Diet & Exercise plus Passion and Balance|Diet and exercise instruction to promote weight loss plus sessions that are of general interest, but unrelated to diet, exercise, or sleep.
3208781|NCT01135329|Experimental|Transplant|Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.
3208782|NCT01135303|Experimental|VistaO2 device|This device combines the transcutaneous oxyhemoglobin saturation (allowing to compute the oxyhemoglobin desaturation index), the slow variations in heart rate and an index of nocturnal respiratory events calculated by analyzing the movements of the chest performed by chest impedance variations.
3208783|NCT01135290|Other|B|
3208784|NCT01135290|Active Comparator|A|
3208785|NCT01135277||Sepsis|Patients who have been diagnosed with Sepsis within 24 hours of admission
3208786|NCT01135277||Non-Septic|Patients who have not been diagnosed with sepsis within 24 hours of admission
3208787|NCT01135264|Active Comparator|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur & Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
3208788|NCT01135264|Experimental|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
3208789|NCT01135251|Experimental|dimiracetam|Capsules containing 400 mg of dimiracetam will be administered orally, twice a day for 8 weeks in ascending schedule, contingent on tolerability of the previous dose, as follows: 1 capsule for two weeks (800mg/day), two capsules for the next two weeks (1600mg/day)and 4 capsules for the final 4 weeks (3200mg/day).
3208790|NCT01135251|Placebo Comparator|sugar pill|capsules containing 400 mg of inert material will be orally administered twice a day with the same modalities used for the dimiracetam arm: one capsule for 2 weeks, 2 capsules for another 2 weeks and 4 capsules for 4 weeks
3208791|NCT01135225|Active Comparator|PROMUS(TM) Element(TM) Coronary Stent|PROMUS(TM) Element(TM) Everolimus-Eluting Coronary Stent System
3208792|NCT01135225|Experimental|Evolution Coronary Stent A|Evolution Everolimus-Eluting Monorail Coronary Stent System
3208793|NCT01135225|Experimental|Evolution Coronary Stent B|Evolution Everolimus-Eluting Monorail Coronary Stent System
3208794|NCT01135212|Active Comparator|Fimasartan 60mg|Take one tablet of Fimasartan 60mg once a day in the morning
3208795|NCT01135212|Active Comparator|Fimasartan 120mg|Take one tablet of Fimasartan 120mg once a day in the morning
3208796|NCT01135212|Active Comparator|Candesartan 8mg|Take one tablet of Candesartan 8mg once a day in the morning
3208797|NCT01135186|Other|Sapropterin|open label study of sapropterin dihydrochloride
3208798|NCT01135173|Active Comparator|Arm A|Motivational and educational intervention, delivered by a trained physician from the SCTS plus written self-help materials.
3208799|NCT01135173|Experimental|Arm B|"Behavioral counseling intervention conducted by a trained physician at the SCTS cessation clinic. Subjects complete homework before the session to facilitate this process. Subjects are asked to identify high-risk situations and difficulties in previous cessation attempts and are walked through a series of suggestions in the event of a slip. Three brief (approximately 10 minute) phone calls are provided to subjects during the 90 day follow-up period. These calls are used to identify early relapse, encourage participants, and provide support. In addition, they are used to review materials and information provided during the sessions."
3208800|NCT01135160||TKA/THA|All patients receiving TKA/THA meeting inclusion but not exclusion criteria
3208801|NCT01135147|Experimental|Diet|Patients treated with diet and physical therapy for the entire 6 months of the study
3208802|NCT01135147|Active Comparator|Surgery|Patients undergoing adenotonsillectomy at some point of the study period
3208803|NCT01135134|Experimental|Mometasone furoate nasal spray (MFNS) (50 μg spray device)|"The dose will be as follows:~5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks"
3208804|NCT01135134|Placebo Comparator|MF placebo nasal spray|"Administration will be as follows:~5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks"
3208805|NCT01135121||Weaning failure|
3208806|NCT01135121||Weaning succes|
3208807|NCT01135108|Placebo Comparator|A1: Placebo|Placebo
3208808|NCT01135108|Experimental|A2: KAI-1678|Experimental
3208809|NCT01135095|Experimental|low-dose imaging|low dose versus standard dose imaging
3208810|NCT01135082|Other|1|Receive valent pneumococcal conjugated vaccine in HIV - infected children
3208811|NCT01135082|Other|2|Receive valent pneumococcal conjugated vaccine in HIV negative children
3208812|NCT01135069|Active Comparator|Generic|treatment of acne for 12 weeks
3208813|NCT01135069|Active Comparator|Brand|Treatment of acne for 12 weeks
3208814|NCT01135069|Placebo Comparator|Placebo|Treatment if acne for 12 weeks as placebo
3208844|NCT01134861|Experimental|Arm 2: Concurrent STD RT|Vinblastine 5 mg/m2 i.v. bolus weekly first 5 weeks Cisplatin 100 mg/m2 i.v. over 30-60 minutes, days 1 & 29 RT: 63 GY/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1
3208845|NCT01134861|Experimental|Arm 3: Concurrent HFX RT|Oral VP-16 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40 (76 mg/day if BSA < 1.7m2) Cisplatin 50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36 RT: 69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1
3208846|NCT01134848|Active Comparator|Morphine-neostigmine|
3208815|NCT01135056|Active Comparator|Sorafenib, Multikinase Inhibitor, Tablet|"Sorafenib tosylate:~Sorafenib is a multikinase inhibitor that decreases tumor cell proliferation.~Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, RET, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR- ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of the human hepatocellular carcinoma and renal cell carcinoma, and several other human tumor xenografts in immunocompromised mice. A reduction in tumor angiogenesis and increases in tumor apoptosis was seen in models of human hepatocellular and renal cell carcinoma. Additionally a reduction in tumor cell signaling was seen in a model of human hepatocellular carcinoma."
3208816|NCT01135056|Active Comparator|SIR-Spheres, Microspheres, Device|"SIR-Spheres:~SIR-Spheres consist of biocompatible resin microspheres containing yttrium-90, with a size between 20 and 60 microns in diameter. Yttrium-90 is a high-energy pure beta-emitting isotope with no primary gamma emission. The half life of yttrium-90 is 64.1 hours. In clinical use which requires the isotope to decay to infinity, 94% of the radiation is delivered in 11 days leaving only background radiation with no therapeutic value.~SIR-Spheres is implanted into hepatic tumours by delivery via either the common hepatic artery or the right or left hepatic artery using a catheter or implanted port . Once SIR-Spheres is implanted into the liver, it is not metabolised or excreted and it stays permanently in the liver."
3208817|NCT01135043|Experimental|education|educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.
3208818|NCT01135043|Placebo Comparator|control|patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure.
3208819|NCT01135030|Active Comparator|Posterior referencing|
3208820|NCT01135030|Active Comparator|Anterior referencing|
3208821|NCT01135017|Experimental|Dronedarone|Dronedarone 400 mg twice a day for 12 weeks
3208822|NCT01135017|Placebo Comparator|Placebo|Placebo (for Dronedarone) twice a day for 12 weeks
3208823|NCT01135004||Pneumothorax patients|Primary spontaneous pneumothorax patients undergoing thoracoscopic bullectomy
3208824|NCT01134991|Placebo Comparator|Topical Minocycline Foam FXFM244 Placebo|Minocycline Foam FXFM244 Placebo
3208825|NCT01134991|Experimental|Topical Minocycline Foam FXFM244, 1%|Minocycline Foam FXFM244, 1%
3208826|NCT01134991|Experimental|Topical Minocycline Foam FXFM244, 4%|Minocycline Foam FXFM244, 4%
3208827|NCT01134978|Experimental|Practice Schedules|Subjects are randomly assigned to either a blocked or random practice schedule when learning three 3-D computer mazes. A blocked practice schedule is created when the tasks to be learned are presented in a predictable order, while a random practice schedule has tasks presented in a nonsequential, unpredictable order. Neural activity and behavioral measures will differ for the two practice schedules. For memory and transfer, it is predicted that random practice will be better than blocked practice.
3208828|NCT01134965|Experimental|Digoxin plus Flibanserin|Flibanserin 100 mg tablets once daily for 7 days plus Digoxin 0.5 mg (2 tables of 0.25 mg) as single dose
3208829|NCT01134965|Experimental|Digoxin|Digoxin 0.5 mg as single dose
3208830|NCT01134952|Experimental|Mycophenolate to sirolimus switch|Liver transplant recipients with Hepatitis C virus switched from mycophenolate mofetil (MMF) to sirolimus (SRL) for 3 months and then switched back to MMF
3208831|NCT01134939||HIV-infected women and men|
3208832|NCT01134926|No Intervention|intra-uterine residua. expectant management|The patients in this arm will not get any treatment and be followed up by US examinations
3208833|NCT01134926|Experimental|Intra-uterine residua. misoprostol|The patients in this arm will be treated with misoprostol at the recruitment day. If there will be sonographic evidence of intra-uterine residua the day after, they'll gat another dose.
3208834|NCT01134900|Experimental|Dashboard|Patients appear on dashboard and are eligible for pharmacy intervention in addition to existing clinical decision support interventions.
3208835|NCT01134900|No Intervention|Control|Patients do not appear on dashboard for pharmacy intervention, but only receive existing clinical decision support interventions.
3208836|NCT01134887|Experimental|Arm 1: Intervention-Veterans|"Veterans enrolled in the Intervention-Veterans arm received a copy of the NIA guide for Talking with Your Doctor [Informational Guide for Patients]. Just prior to their next scheduled visit an educator met with each Veteran in the intervention arm individually for 20-30 minutes to review the material in the pamphlet and develop a plan for enhancing communication about self-management of hypertension with their doctor [Educational Coaching]. To facilitate communication change, the educator assisted the patient in setting a goal to achieve during their visit. The educator also provided telephone follow-up within 24 hours to review satisfaction and effectiveness of the visit and assess barriers and facilitators to communicating about self-management."
3208837|NCT01134887|Active Comparator|Arm 2: Control-Veterans|"Veterans enrolled in the Control-Veterans arm received a copy of the NIA guide for Talking with Your Doctor [Informational Guide for Patients]. This pamphlet was specifically developed for this purpose (updated in 2002). It has pictorials and is written at an 8th grade level."
3208838|NCT01134887|Experimental|Arm 3: Intervention-Physicians|"Primary care providers randomly assigned to the Intervention-Physicians arm of this study received a copy of the Four Habits of Highly Effective Physicians [Monograph for Physicians]. The Four Habits provided practical evidence-based advice for improving patient-physician communication. Second, physicians participated in an audiotaped intensive 30 minute, one-on-one educational intervention with PI Frankel after their first set of visits from their three participating patients [Video-Assisted Coaching], but before seeing them for follow-ups. The main goal of this meeting was to review and discuss the analysis of the physician's videotaped visits using the Four Habits framework, with a particular focus on improving communication about self-management."
3208839|NCT01134887|Active Comparator|Arm 4: Control-Physicians|"Primary care providers randomly assigned to the Control-Physicians arm of the study did not receive coaching or additional resources, and conducted their primary care practice as usual [Control]."
3208840|NCT01134874|Experimental|Standard weight loss intervention|
3208841|NCT01134874|Experimental|Standard weight loss intervention plus technology|
3208842|NCT01134874|Experimental|Technology only|
3208843|NCT01134861|Active Comparator|Arm 1: Sequential ChemoRT|Vinblastine 6 mg/m2 i.v. bolus weekly first 5 weeks Cisplatin 100 mg/m2 i.v. over 30-60 minutes, days 1 & 29 RT: 63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 50
3208849|NCT01134835|Placebo Comparator|Placebo|Placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
3208850|NCT01134822||Idiopathic pulmonary fibrosis (IPF)|
3208851|NCT01134809||Major abdominal surgery|Patients having major abdominal surgery
3208852|NCT01134783|Experimental|Intervention Group|The CHOICES intervention included a 1-credit, academic college course focusing on healthy weight behaviors and participation in a social networking and social support website
3208853|NCT01134783|No Intervention|Control Group|Control group (serving as a comparison group)
3208854|NCT01134770||Prenatal Cocaine|Use of cocaine at anytime during pregnancy. Subjects may also have used other drugs in combination with Cocaine
3208855|NCT01134770||Prenatal Nicotine-Alcohol-Marijuana|Subjects may have used any of these drugs during pregnancy, alone or in combination. This group has not used cocaine during pregnancy.
3208856|NCT01134770||Drug-Free Pregnancy|"Subjects did not use any of the following drugs during pregnancy:~cocaine, nicotine, alcohol, marijuana."
3208857|NCT01134757|Other|house dust mite and alternaria allergy|As the intervention patients with house dust mite or alternaria allergy will undergo a bronchial allergen challenge with mite or alternaria extract. The early asthmatic response (EAR) and the late asthmatic response (LAR) will be measured before and after one year of allergen specific immunotherapy. Except of the challenge no further interventions are planned.
3208858|NCT01134744||Chest trauma|chest x-ray applied for patients with chest trauma and the manifestations compared with clinical examination
3208859|NCT01134731|Experimental|paliperidone|dose escalation , levels 1-5 daily dosing ranged from 1-5mg
3208860|NCT01134731|Active Comparator|lithium|dose escalation, level 1-5 daily dosing 300-1500mg
3208861|NCT01134731|Placebo Comparator|placebo|1-5 placebo capsules
3208862|NCT01134718|Experimental|001|TMC435 (F021) one morning dose of 150 mg
3208863|NCT01134718|Experimental|002|TMC435 (G006) one morning dose of 150 mg
3208864|NCT01134718|Experimental|003|TMC435 (G007) one morning dose of 150 mg
3208865|NCT01134705|Experimental|BDP HFA 320 µg/day|During the 6-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.
3208866|NCT01134705|Placebo Comparator|Placebo|During the 6-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.
3208867|NCT01134692|Placebo Comparator|Propranolol + Placebo|
3208868|NCT01134692|Active Comparator|Propranolol + Norfloxacin|drug
3208869|NCT01134692|Experimental|Propranolol + Probiotic|VSL#3
3208870|NCT01134679|Experimental|Phone calls|Disease management with close patient follow-up, using phone calls.
3208871|NCT01134653|Experimental|Jump stretch|Distraction with early mobilization
3208872|NCT01134653|Active Comparator|RICE|Subject receive standard ankle sprain treatment of Rest Ice compression and elevation for one week. This is followed by traditional strength and range of motion therapy. The subject does not receive distraction treatments.
3208873|NCT01134627|Experimental|Minocycline group|
3208874|NCT01134627|Placebo Comparator|Placebo Group|
3208875|NCT01134614|Experimental|Arm A (ipilimumab and sargramostim)|Patients receive induction therapy comprising ipilimumab IV over 90 minutes on day 1 and sargramostim SC once daily on days 1-14. Treatment repeats every 21 days for 4 courses. After 12 weeks of induction treatment, anti-tumor response is assessed and patients then receive maintenance therapy comprising ipilimumab IV over 90 minutes on day 1 and sargramostim SC once daily on days 1-14. Treatment with ipilimumab repeats every 12 weeks and treatment with sargramostim repeats every 21 days. After 12 weeks of maintenance therapy, anti-tumor response is reassessed and patients with responsive or stable disease then continue maintenance therapy until disease progression or unacceptable toxicity.
3208876|NCT01134614|Active Comparator|Arm B (ipilimumab)|Patients receive induction therapy comprising ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 courses. After 12 weeks of induction treatment, anti-tumor response is assessed and patients then receive maintenance therapy of ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 12 weeks. After 12 weeks of maintenance therapy, anti-tumor response is reassessed and courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity
3208877|NCT01134588|Active Comparator|Reference group|This group will fill out paper questionnaires.
3208878|NCT01134588|Experimental|Experimental group|This group will fill out touch-screen questionnaires.
3208879|NCT01134575|Experimental|CMC-544 (Inotuzumab Ozogamycin)|First patients > 16 years and < 16 years receive CMC-544 at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle. With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
3208880|NCT01134562|Placebo Comparator|Placebo|Participants received a single dose of placebo intravenous (IV) injection after hemodialysis.
3208881|NCT01134562|Experimental|Etelcalcetide|Participants received a single dose of etelcalcetide by intravenous (IV) injection after hemodialysis.
3208882|NCT01134549|Placebo Comparator|Placebo|Participants received a single dose of placebo intravenous injection.
3208883|NCT01134549|Experimental|Etelcalcetide|Participants received a single dose of etelcalcetide intravenous injection; the starting dose was 0.5 mg.
3208884|NCT01134536|Experimental|Tapentadol Oral Solution (OS)|
3208885|NCT01134523|Active Comparator|Group A: EC-T regimen|
3208886|NCT01134523|Experimental|Group B: ET regimen|
3208887|NCT01134510|Experimental|C1 esterase inhibitor|10 subjects will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
3208888|NCT01134510|Placebo Comparator|Placebo|10 subjects placebo [normal saline] in addition to standard of care immunosuppressive therapy.
3208889|NCT01134497|Active Comparator|Arm A (control): carboplatin + placebo|The control arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus placebo by mouth on days 1-21 of a 21 day cycle.
3208890|NCT01134497|Experimental|Arm B: carboplatin + ZD4054|The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
3208895|NCT01134471|Active Comparator|Ostene|Patients treated with the hemostatic Ostene
3208896|NCT01134458|No Intervention|Control|Receive primary care and management of CVD according to the discretion of their primary care provider. They will also receive generic educational information concerning CVD at baseline and at study end (at their request). We will collect outcomes at baseline and 3-months.
3208897|NCT01134458|Experimental|Web-based Intervention|Given current risk assessment for CVD based on Health Dialog Cardiac Risk Calculator, recommendations for behavior change, and Health Dialog's Living with Coronary Heart Disease. Can change initial patient risk information provided by the Risk Calculator during the initial visit, noting what they are will work on during the study. Sent monthly email reminders to log onto the system to choose that months' behavioral modules. Given a choice of at least 2 health behavior modules per month (smoking cessation, exercise, diet, and weight) to improve their CVD risk. Information on risk, CVD knowledge, medication management and side effects will be provided to all participants. It will also provide tailored information to help the individual initiate and maintain these behaviors.
3208898|NCT01134445|Other|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
3208899|NCT01134432|Experimental|Prednisolone + Rituximab|
3208900|NCT01134432|Active Comparator|Prednisolone|
3208901|NCT01134419|Experimental|Computerized Handoff Tool plus training|Computerized handoff tool implemented together with team training for residents
3208902|NCT01134419|Active Comparator|Team training only|No computerized tool
3208903|NCT01134406|Experimental|Hydros Joint Therapy|Experimental viscosupplement.
3208904|NCT01134406|Experimental|Hydros-TA Joint Therapy|Experimental viscosupplement.
3208905|NCT01134406|Active Comparator|Synvisc-One|Commercial control.
3208906|NCT01134393|Experimental|telmisartan/amlodipine|start low dose and uptitrate to high dose on the basis of blood pressure goal
3208907|NCT01134380||[*1] Genotype - Good responders to Clopidogrel|This group of patients is defined thanks to the DNA extracted from their saliva: [*1] genotype patients are good responders to clopidogrel
3208908|NCT01134380||[*2] genotype with adapted thienopyridine treatment|This group of patients is defined thanks to the DNA extracted from their saliva: [*2] genotype patients are bad responders to clopidogrel and their thienopyridine treatment has been adapted
3208909|NCT01134367||1|Patients with GERD
3208910|NCT01134354||TEFTOM|Patient outcome measure
3208911|NCT01134341|Experimental|Pralatrexate & Bexarotene|
3208912|NCT01134328|Experimental|AC-150 Combo|
3208913|NCT01134328|Active Comparator|AC-150A 0.1%|
3208914|NCT01134328|Active Comparator|AC-150B 0.005%|
3208915|NCT01134328|Other|Vehicle|
3208916|NCT01134315||Paricalcitol|Pediatric participants who received paricalcitol capsules to treat secondary hyperparathyroidism (SHPT). Paricalcitol was prescribed by each physician under the usual and customary practice of that physician.
3208917|NCT01134315||Calcitriol|Pediatric participants who received calcitriol to treat secondary hyperparathyroidism (SHPT). Calcitriol was prescribed by each physician under the usual and customary practice of that physician.
3208918|NCT01134302|Active Comparator|Arm 1|Hybrid Management
3208919|NCT01134302|Active Comparator|Arm 2|Norwood Management
3208920|NCT01134289|Active Comparator|lumbar sympathetic block|Unilateral lumbar sympathetic blockade using chirocaine
3208921|NCT01134289|No Intervention|contralateral side|
3208922|NCT01134276|Active Comparator|PTBD|biliary drainage : PTBD procedure for obstructive jaundice in patients with periampullary cancer
3208923|NCT01134276|Active Comparator|ERBD|biliary drainage : ERBD/ENBD procedure for obstructive jaundice in patients with periampullary cancer
3208924|NCT01134263|Experimental|Group 1|CYD Dengue vaccine - Phase III Lot 1
3208925|NCT01134263|Experimental|Group 2|CYD Dengue vaccine - Phase III Lot 2
3208926|NCT01134263|Experimental|Group 3|CYD Dengue vaccine - Phase III Lot 3
3208927|NCT01134263|Experimental|Group 4|CYD Dengue vaccine - Phase II Lot
3208928|NCT01134263|Placebo Comparator|Group 5|NaCl 0.9%
3208929|NCT01134250|Experimental|F16IL2 in combination with paclitaxel|
3208930|NCT01134237|Active Comparator|Urokinase|arm of interest
3208931|NCT01134237|Placebo Comparator|Control|Normal saline as a placebo for control arm
3208932|NCT01134224|Experimental|NN5401 - low dose|
3208933|NCT01134224|Experimental|NN5401 - medium dose|
3208934|NCT01134224|Experimental|NN5401 - high dose|
3208935|NCT01134224|Active Comparator|biphasic insulin aspart 30 - low dose|
3208936|NCT01134224|Active Comparator|biphasic insulin aspart 30 - medium dose|
3208937|NCT01134224|Active Comparator|biphasic insulin aspart 30 - high dose|
3208938|NCT01134211|Other|nelfilcon A / filcon II 3|Nelfilcon A contact lenses worn first, with filcon II 3 contact lenses worn second. Both products worn in both eyes on a daily wear, daily disposable basis for one week each.
3208939|NCT01134211|Other|filcon II 3 / nelfilcon A|Filcon II 3 contact lenses worn first, with nelfilcon A contact lenses worn second. Both products worn in both eyes on a daily wear, daily disposable basis for one week each.
3208940|NCT01134198|Active Comparator|Mifepristone|Mifepristone 600mg
3208941|NCT01134198|Placebo Comparator|placebo|Placebo
3208942|NCT01134185|Active Comparator|Group I|Moderate hepatic impairment (grade B)
3208943|NCT01134185|Active Comparator|Group II|Severe hepatic impairment (grade C)
3208944|NCT01134185|Active Comparator|Group III|healthy subjects
3208945|NCT01134172||Breast cancer survivors|Women being treated for stage I-III breast cancer who were employed prior to this diagnosis will be recruited in their physicians' offices.
3208946|NCT01134172||Comparison group|Peer controls will be nominated by participants in the breast cancer survivor group or recruited by community outreach and matched for age, language, and ethnicity. This cohort is no longer recruiting.
3208947|NCT01134159||Xience V|Those who have only received a Xience V stent
3208948|NCT01134159||Taxus Liberte|Those who have received only a Taxus Liberte stent
3209036|NCT01133574|Experimental|A3|Part A, Parallel design Arm 3
3209037|NCT01133574|Experimental|A4|Part A, Parallel design Arm 4
3209038|NCT01133574|Experimental|A5|Part A, Parallel design Arm 5
3208949|NCT01134146|Experimental|Intensity Modulated Radiation Therapy (IMRT)|Intensity Modulated Radiation Therapy (IMRT) Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
3208950|NCT01134120|Experimental|LY2784544|
3208951|NCT01134107|Experimental|Insulin Lispro 6 Day (6D)|
3208952|NCT01134107|Active Comparator|Insulin Aspart 6 Day (6D)|
3208953|NCT01134094|Active Comparator|Non-Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
3208954|NCT01134094|Active Comparator|Operative|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
3208955|NCT01134081|Experimental|CelTx™|Living bilayered cell therapy product
3208956|NCT01134081|Active Comparator|Free Gingival Grafts|Harvested tissue from palate
3208957|NCT01134055|Experimental|investigational arm 1|5 mg/mL pazopanib eye drops TID with allowance for as-needed ranibizumab injection
3208958|NCT01134055|Experimental|investigational arm 2|5 mg/mL pazopanib eye drops QID with allowance for as-needed ranibizumab injection
3208959|NCT01134055|Experimental|investigational arm 3|10 mg/mL pazopanib eye drops BID with allowance for as-needed ranibizumab injection
3208960|NCT01134055|Experimental|investigational arm 4|10 mg/mL pazopanib eye drops TID with allowance for as-needed ranibizumab injection
3208961|NCT01134055|Experimental|investigational arm 5|10 mg/mL pazopanib eye drops QID with allowance for as-needed ranibizumab injection
3208962|NCT01134055|Placebo Comparator|placebo control arm|Placebo eye drops QID with allowance for as-needed ranibizumab injection
3208963|NCT01134055|Active Comparator|active open-label control arm|Ranibizumab intravitreal injection every 4 weeks
3208964|NCT01134042|Experimental|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks
3208965|NCT01134042|Active Comparator|Fluticasone Furoate|Fluticasone furoate inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks
3208966|NCT01134042|Active Comparator|Fluticasone Propionate|Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 24 weeks
3208967|NCT01134029|No Intervention|Enhanced Usual Care|Control Group
3208968|NCT01134029|Experimental|Stepped Care|Intervention
3208969|NCT01134016|Experimental|Antroquinonol|"6 dose levels, Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~A maximum of 36 patients were planned based on a criteria of a maximum of 6 patients per cohort: 1 to 6 patients were planned for each dose group in the accelerated phase; 3 to 6 patients for each dose group in the standard phase .~The method of dose escalation in the accelerated titration phase continued to the next higher dose level until a patient experienced MT or a DLT. Standard titration phase start with 3+3 patients. Dose escalation proceeded sequentially between cohorts."
3208970|NCT01133990|Active Comparator|FOLIRI|
3208971|NCT01133990|Experimental|E7820|FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820
3208972|NCT01133990|Experimental|FOLFIRI plus Bevacizumab|
3208973|NCT01133977|Experimental|Lenvatinib + Dacarbazine (Phase 1b)|Participants received 16 mg, 20 mg or 22 mg lenvatinib once daily in combination with dacarbazine
3208974|NCT01133977|Experimental|Lenvatinib + Dacarbazine (Phase 2)|Participants received lenvatinib per the maximum tolerated dose (MTD) as determined in the Phase Ib of the study in combination with dacarbazine
3208975|NCT01133977|Active Comparator|Dacarbazine (Phase 2)|Participants received dacarbazine
3208976|NCT01133964|Experimental|milk|skim milk
3208977|NCT01133964|Experimental|casein drink|
3208978|NCT01133964|Experimental|whey drink|
3208979|NCT01133964|Sham Comparator|water|
3208980|NCT01133951|Experimental|OAC triple therapy|
3208981|NCT01133951|Placebo Comparator|Placebo|
3208982|NCT01133938||Closed reduction < 12 months of age|
3208983|NCT01133938||Open reduction < 12 months of age|
3208984|NCT01133938||Open reduction with concomitant osteotomies > 12 months fo age|
3208985|NCT01133925|Active Comparator|ODESSA|ODESSA trial (NCT 00693030)Patients were randomized (2:2:2:1) to receive multiple TAXUS Libertè™ vs Cypher Select™ vs Endeavor™ vs Libertè BM stents, in overlap. At 6-months follow-up coronary angiography (QCA), IVUS and Optical Coherence Tomography assessments were made. Data reported in J. Am. Coll. Cardiol. Intv. 2010;3;531-539. DOI 10.1016/j.jcin.2010.02.008.
3208986|NCT01133925|Experimental|Resolute Sprint arm|Zotarolimus Eluting stents (Resolute Sprint) implanted in overlap to treat long coronary lesions
3208987|NCT01133912|Experimental|paclitaxel, gemcitabine, lapatinib|paclitaxel 80mg/m2 D1, D8 gemcitabine 1000mg/m2 D1, D8, every 3 weeks, 6 cycle lapatinib(Tykerb®)1000mg every day
3208988|NCT01133899|Experimental|GAA-2|2.4 grams of guanidinoacetic acid
3208989|NCT01133899|Experimental|GAA-1|1.2 grams of guanidinoacetic acid
3208990|NCT01133899|Experimental|GAA-4|4.8 grams of guanidinoacetic acid
3208991|NCT01133899|Placebo Comparator|PLACEBO|cellulose
3208992|NCT01133886|Experimental|Decitabine|
3208993|NCT01133873|Experimental|1|
3208994|NCT01133873|Placebo Comparator|2|
3208995|NCT01133860|Experimental|eltrombopag|
3209039|NCT01133574|Experimental|A6|Part A, Parallel design Arm 6
3208996|NCT01133847|Experimental|Intensive Reading Instruction|Specialized phonologically-based reading instruction provided by well-trained tutors either individually (one-on-one) or to groups of two students for 45 minutes, four days per week, for 16 weeks. The instructional approach includes an individualized combination of published programs targeting word reading and decoding; reading fluency; and reading comprehension.
3208997|NCT01133847|Experimental|ADHD Intervention|Carefully-managed medication and behavioral parent training. Medication treatment begins with a four-week titration period, beginning with a trial of methylphenidate. If benefit is insufficient or side effects are intolerable, the physician may initiate a trial of mixed salt amphetamine, followed by either Atomoxetine or Guanfacine. When the optimum medication and dosage is determined the child returns for monthly medication maintenance visits until the end of the 16-week intervention period. Parent training consists of nine group sessions provided by a psychologist addressing ADHD and its treatment, principals of behavior modification, and evidence-supported practices for managing behavior.
3208998|NCT01133847|Experimental|Combined ADHD and Reading Instruction|"All interventions described in Reading Instruction and ADHD treatment arms:~Phonologically-based reading instruction provided for 45 minutes, four days per week, for 16 weeks. Carefully-managed medication and behavioral parent training. Medication treatment begins with a trial of methylphenidate. If benefit is insufficient or side effects are intolerable, the physician may initiate a trial of mixed salt amphetamine, followed by either Atomoxetine or Guanfacine. When the optimum medication and dosage is determined the child returns for monthly medication maintenance visits until the end of the 16-week intervention period. Parent training consists of nine group sessions on parenting a child with ADHD."
3208999|NCT01133834||patients with meningococcemia|Patients with meningococcemia admitted at the Intensive Care Unit
3209000|NCT01133821|Placebo Comparator|Placebo|Subjects will receive 20 weeks of an experimental psychotherapy called interpersonal and social rhythm therapy (IPSRT) plus placebo (sugar pill). This condition will be called IPSRT-PLA.
3209001|NCT01133821|Experimental|IPSRT plus quetiapine|Subjects will receive 20 weeks of an experimental psychotherapy called interpersonal and social rhythm therapy (IPSRT) plus the FDA approved medication quetiapine (Seroquel). This condition will be called IPSRT-QUE.
3209002|NCT01133795|Experimental|Midodrine, Albumin|Midodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
3209003|NCT01133782|Experimental|Rapid result|Result of diagnostic PCR panel provided the following day
3209004|NCT01133782|No Intervention|Delayed result|Result of dagnostic PCR panel provided within 10+/-2 days at follow-up visit.
3209005|NCT01133769||Surgical vs Non surgical|This is an open, prospective, randomized, dual arm, parallel group clinical study of open reduction and internal fixation (ORIF) or intramedullary nail (IMN) versus non operative treatment for clavicle fracture in polytrauma patients with associated chest injury, with or without additional injuries to the head, abdomen, pelvis and extremities.
3209006|NCT01133756|Experimental|Lenvatinib plus carboplatin + gemcitabine|Phase IB and Phase II
3209007|NCT01133756|Active Comparator|Carboplatin + gemcitabine|Phase II
3209008|NCT01133743|Experimental|Lenalidomide and Dexamethasone|Lenalidomide target dose of 25 mg PO OD continuously (28-day cycle) using an initial dose escalation period. Oral dexamethasone 12 mg daily on days 1-7, 14 and 21 of each cycle.
3209009|NCT01133730|Experimental|Active treatment group|Ultrasound-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine
3209010|NCT01133730|Placebo Comparator|Placebo arm|Ultrasound-guided TFP block with 20ml of 5% dextrose solution
3209011|NCT01133717||Control without Sleep Apnea|
3209012|NCT01133717||Subjects with Sleep Apnea|
3209013|NCT01133704|Active Comparator|sipuleucel-T (APC8015)|
3209014|NCT01133704|Placebo Comparator|Placebo|
3209015|NCT01133691||healthy children aged 6 - 12 years|
3209016|NCT01133678|Experimental|Everolimus escalating dose|Find the highest safe dose of Everolimus when combined with induction chemotherapy.
3209017|NCT01133678|Experimental|Everolimus or Placebo|Subject will receive Everolimus or Placebo (dose determined in Phase 1 portion)
3209018|NCT01133665|Experimental|Sub Group 1|All Subjects Enrolled in the Trial
3209019|NCT01133652|Active Comparator|VeinViewer|The Veinviewer machine will be used to guide intravenous access.
3209020|NCT01133652|Active Comparator|Ultrasound|The Ultrasound will be used to guide intravenous access.
3209021|NCT01133652|Active Comparator|Conventional IV placement|IV will be placed using conventional technique
3209022|NCT01133639|Placebo Comparator|Placebo|Placebo plus standard of care
3209023|NCT01133639|Experimental|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
3209024|NCT01133626|Placebo Comparator|Placebo|Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
3209025|NCT01133626|Experimental|BDP HFA 320 µg/day|Participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning for 6 weeks (42 days). During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
3209026|NCT01133626|Active Comparator|Prednisone|Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a 10/mg a day prednisone capsule.
3209027|NCT01133613|Experimental|Cohort 1|0.03 mg/ml BMP-7 or placebo via intraarticular knee injection
3209028|NCT01133613|Experimental|Cohort 2|0.1 mg/ml BMP-7 or placebo via intraarticular knee injection
3209029|NCT01133613|Experimental|Cohort 3|0.3 mg/ml BMP-7 or placebo via intraarticular knee injection
3209030|NCT01133600|Active Comparator|daptomycin|Dosed at 6mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if creatinine clearance (CrCl)is <30ml/min.
3209031|NCT01133600|Active Comparator|vancomycin|Dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
3209032|NCT01133587|Experimental|admissions contract|"contract regarding patient-guided admissions"
3209033|NCT01133587|Active Comparator|wait list control|1 year on waiting list
3209034|NCT01133574|Experimental|A1|Part A, Parallel design Arm 1
3209035|NCT01133574|Experimental|A2|Part A, Parallel design Arm 2
3209040|NCT01133574|Experimental|A7|Part A, Parallel design Arm 7
3209041|NCT01133574|Experimental|A8|Part A, Parallel design Arm 8
3209042|NCT01133574|Placebo Comparator|A9|Part A, Parallel design Arm 9
3209043|NCT01133574|Experimental|B1-1|Part B, Cross-over design, Arm 1
3209044|NCT01133574|Experimental|B1-2|Part B, Cross-over design, Arm 2
3209045|NCT01133574|Experimental|B2-1|Part B, Cross-over design, Arm 3
3209046|NCT01133574|Experimental|B2-2|Part B, Cross-over design, Arm 4
3209047|NCT01133574|Placebo Comparator|B3|Part B, Cross-over design, Arm 5
3209048|NCT01133561|Active Comparator|actozone A|Pioglitazone 30 mg tablets daily
3209049|NCT01133561|Placebo Comparator|actozone B|placebo
3209050|NCT01133548|Experimental|1|Testosterone Gel 1.62%
3209051|NCT01133535||Pancreatitis, acute, recurrent|Patients with acute recurrent pancreatitis where the cause is unknown
3209052|NCT01133522|Experimental|Evolocumab|Participants received one of 5 dose levels of evolocumab administered as multiple subcutaneous doses.
3209053|NCT01133522|Placebo Comparator|Placebo|Participants received matching placebo dose regimens by subcutaneous injection.
3209054|NCT01133509|Other|gardisil|gardisil
3209055|NCT01133496|Experimental|Alendronate Sodium|Alendronate Sodium Tablets, 70 mg of Dr. Reddy's
3209056|NCT01133496|Active Comparator|Fosamax|Fosamax Tablets 70 mg of Merck & Company. Inc., USA.
3209057|NCT01133483|Experimental|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories
3209058|NCT01133483|Active Comparator|Allegra-D 24 hour ER Tablets|Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.
3209059|NCT01133470|Experimental|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories
3209060|NCT01133470|Active Comparator|Allegra-D 24 hour ER Tablets|Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.
3209061|NCT01133457|Experimental|Finasteride|Finasteride tablets 1 mg of Dr. Reddy's
3209062|NCT01133457|Active Comparator|Propecia|Propecia 1 mgTablets of Merck & Co.,
3209063|NCT01133444|Experimental|Finasteride|Finasteride tablets 1 mg of Dr. Reddy's
3209064|NCT01133444|Active Comparator|Propecia|Propecia 1 mgTablets of Merck & Co.,
3209065|NCT01133431|Experimental|CKD-501 + Glimepiride -> CKD-501 placebo + Glimepiride|This study is randomized, single-blinded, two-period, 2 treatments, crossover design to assess the pharmacokinetics interaction between CKD-501 and sulfonylurea.
3209066|NCT01133431|Experimental|CKD-501 placebo + Glimepiride -> CKD-501 + Glimepiride|This study is randomized, single-blinded, two-period, 2 treatments, crossover design to assess the pharmacokinetics interaction between CKD-501 and sulfonylurea.
3209067|NCT01133418|Experimental|Cognitive Training|Computerized Progressive Attention Training
3209068|NCT01133418|Sham Comparator|Non-progressive cognitive training|Children in the control condition will participate in the same tasks as children in the Intervention arm. They will experience the same number of blocks and trials of training as the intervention group. Further, their training will be conducted by the same set of trainers and for the same amount of time as the intervention group. However, children in the control group will remain at the lowest level for each CT task throughout training irrespective of performance.
3209069|NCT01133405|Experimental|LY2886721 Part 1|Up to 3 single doses will be administered over 3 periods (each period is 8 days) in a crossover fashion either LY:LY:LY or LY:LY:Placebo in random order with variable doses ranging from 1 mg up to 200 mg
3209070|NCT01133405|Placebo Comparator|Placebo Part 1|Single dose in up to 1 period (the period is 8 days)
3209071|NCT01133405|Experimental|LY2886721 Part 2 low dose|Single dose of LY2886721, dose determined by Part 1
3209072|NCT01133405|Experimental|LY2886721 Part 2 high dose|Single dose of LY2886721, dose determined by Part 1
3209073|NCT01133405|Placebo Comparator|Placebo Part 2|Single dose
3209074|NCT01133392|Experimental|Insulin Lispro A|20 units (U) subcutaneously (SC)
3209075|NCT01133392|Active Comparator|Insulin lispro B|20 units (U) subcutaneously (SC)
3209076|NCT01133379|Experimental|PO-019|1.40% Potassium Oxalate Sensitive Mouthwash without fluoride (12027-019)
3209077|NCT01133379|Experimental|PO-020|1.40% Potassium Oxalate Sensitive Mouthwash with fluoride (12027-020)
3209078|NCT01133379|Sham Comparator|PO-021|Vehicle Control Mouthrinse (without potassium oxalate and without fluoride) (12027-021)
3209079|NCT01133366|Active Comparator|warfarin alone|
3209080|NCT01133366|Experimental|warfarin with mipomersen|
3209081|NCT01133353|Experimental|Tetrabenazine MR|
3209082|NCT01133353|Placebo Comparator|Placebo|
3209083|NCT01133327|Experimental|Adapt Carotid Stent System|Intervention with Adapt Carotid Stent System with the FilterWire EZ System
3209084|NCT01133301|Active Comparator|Naltrexone-Placebo|In the first three weeks of the study, 50 mg Naltrexone will be administrated, the following three three weeks placebo will be administrated.
3209085|NCT01133301|Placebo Comparator|Placebo-Naltrexone|The first three weeks, placebo will be administrated, the following three weeks 50 mg Naltrexone will be administrated.
3209086|NCT01133275|Experimental|Lenalidomide and Prednisone Therapy|All participants received lenalidomide and prednisone therapy for 6 cycles (24 weeks). Each cycle is 28 days (4 weeks).
3209087|NCT01133249||Total hip|all consented patients receiving total hip arthroplasty
3209088|NCT01133236|Experimental|Salt and Fluid|Intervention: Fluid 800 Ml and Salt 2 g per day Control: FLuid and Salt Free
3209089|NCT01133223|Active Comparator|Thrombectomy|
3209090|NCT01133223|Active Comparator|Usual Care|
3209091|NCT01133210|Experimental|Maraviroc|Subjects will receive 12 weeks of treatment with maraviroc (300 mg po bid).
3209092|NCT01133210|Placebo Comparator|Placebo|Subjects will receive 12 weeks of treatment with placebo
3209093|NCT01133197||controls|No hand arthritis
3209094|NCT01133197||CMC Arthritis|Patients with arthritis
3209095|NCT01133171|Experimental|Dashboard Plus Nurse|Patients randomized to this intervention arm were seen twice over six months by a research nurse to collect data on risk factors and received counseling plus a computerized dashboard intervention.
3209289|NCT01131650||diabetica retinopathy prevalence|
3209096|NCT01133171|Experimental|Nurse Alone|Patients randomized to this intervention arm were seen twice over six months by a research nurse to collect data on risk factors and received counseling.
3209097|NCT01133171|No Intervention|Control|Patients randomized to this group were followed retrospectively to collect data on their primary care visits and laboratory results and past medical history over the 12 month study period. They had no contact with study personnel and did not receive any type of intervention.
3209098|NCT01133158|Experimental|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone|
3209099|NCT01133145|Experimental|vascularized transplantation|allogeneic vascularized knee transplantation
3209100|NCT01133132|Placebo Comparator|Control|This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
3209101|NCT01133132|Experimental|Intervention|For those subjects randomized to the Survivorship CHESS condition they will receive a smartphone and access to a web based information system that provides access to clinical information about colon cancer treatment, survivorship, exercise planning and tracking functions to allow these subjects to monitor their self defined exercise goals and objectives.
3209102|NCT01133119|Active Comparator|Treatment Group 1|
3209103|NCT01133119|Experimental|Treatment Group 2|
3209104|NCT01133106|Experimental|In-person behavioral intervention|behavioral counseling plus antidepressant treatment prescribed by participant's own provider; consisted of orientation session plus 6 counseling sessions in person with a psychosocial nurse practitioner
3209105|NCT01133106|Experimental|Telephone behavioral intervention|This arm is identical to the in-person Arm except that the intervention is delivered by telephone instead of in-person.
3209106|NCT01133106|Active Comparator|Standard care|participants have orientation to the study with the same written materials given those in the experimental arms. Keep a medication log and keep appointments with their own post-stroke provider
3209107|NCT01133080|Experimental|Minocycline|
3209108|NCT01133080|Placebo Comparator|Placebo|
3209109|NCT01133054|Experimental|low FFR|FFR<0.75
3209110|NCT01133054|No Intervention|high FFR|FFR > 0.75
3209111|NCT01133041|Experimental|NBI observation|
3209112|NCT01133041|Experimental|i-Scan observation|
3209113|NCT01133028|Experimental|Combined|This represents a combination of the tolerance training and behavioral management interventions together.
3209114|NCT01133028|Active Comparator|Behavioral management|This represents the behavioral contingency management intervention only.
3209115|NCT01133015|Experimental|Intermediate lesion|Intermediate lesion will be evaluated by both IVUS and FFR
3209116|NCT01133002||VTE management registry|Patients receiving enoxaparin, with or without oral anticoagulation, within Day 0-10 after diagnosis of VTE
3209117|NCT01132976|Active Comparator|Goal-based motivational interview|Participants randomised to this group will receive the goal based motivational interview - Personal Concerns Inventory (PCI) in addition to treatment as usual.
3209118|NCT01132976|Other|Treatment as usual|Participants randomly allocated to this group will receive treatment as usual only, ie no specific motivational intervention.
3209119|NCT01132963|Experimental|Outdoor Shoes|Patient will be asked to do balance tests while wearing outdoor shoes.
3209120|NCT01132963|Active Comparator|Pillow Paws Slippers|Patient will be asked to complete balance tests while wearing standard hospital issue 'Pillow Paw' slippers on their feet
3209121|NCT01132950|Active Comparator|Didactic Educational Counseling|
3209122|NCT01132950|Experimental|Motivation Interviewing|Participant will receive two sessions of personalized motivational interviewing.
3209123|NCT01132846|Active Comparator|Low dose Dopamine|"Drug: Dopamine~Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study"
3209124|NCT01132846|Placebo Comparator|Placebo|Drug: Placebo Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
3209125|NCT01132846|Active Comparator|Low Dose Nesiritide|Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
3209126|NCT01132820|Experimental|Treatment (cediranib maleate)|Patients receive cediranib maleate PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3209127|NCT01132807|Experimental|Treatment (chemotherapy and F-18 PET/CT)|See Detailed Description
3209128|NCT01132794|Placebo Comparator|Placebo|Intranasal nasal saline
3209129|NCT01132794|Active Comparator|Dexmedetomidine|Intranasal dexmedetomidine
3209130|NCT01132781|Placebo Comparator|Placebo|200mg twice daily of placebo drug
3209131|NCT01132781|Active Comparator|200mg theophylline|200mg twice daily of slow release theophylline
3209132|NCT01132768|Active Comparator|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily.
3209133|NCT01132768|Experimental|Olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily.
3209134|NCT01132755|Experimental|Patients who require diagnostic laparoscopy|Diagnostic peritoneal lavage will be performed at the time of laparoscopy utilizing a Veress needle/Seldinger technique to insert a peritoneal dialysis catheter. This is not a new technique. The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon.
3209135|NCT01132742||hospitalised children|
3209136|NCT01132703|Experimental|RP-1127 (Glyburide for Injection)|
3209137|NCT01132703|Placebo Comparator|Placebo|Placebo (RP-1127 excipients without active)
3209138|NCT01132690|Experimental|30 units/kg|
3209139|NCT01132690|Experimental|60 units/kg|
3209140|NCT01132677|Active Comparator|Hyaluronic Acid (HA) Injection|Patients allocated to the HA group will receive a single IA injection Hylan G-F 20 Synvisc One™ (1 injection of 6cc's). All injections will be administered as outlined on the company label. Aspiration of the knee will not be performed.
3209141|NCT01132677|Active Comparator|Corticosteroid Injection|Patients allocated to the corticosteroid injection will receive a single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label. Aspiration of the knee will not be performed.
3209232|NCT01132092||Hearing loss (experimental 3)|15 hearing loss subjects, male and female, adults, evaluated by new device
3209142|NCT01132664|Experimental|HER2+ metastatic breast cancer|Patients with HER2-overexpressing metastatic breast cancer, with or without PIK3 signaling pathway alteration, who have previously failed trastuzumab
3209143|NCT01132664|Experimental|HER2+ metastatic breast cancer with BM|Patients with HER2-overexpressing metastatic breast cancer and brain metastases, with or without PIK3 signaling pathway alteration, who have previously failed trastuzumab
3209144|NCT01132651|Experimental|Chillow cooling pillow|This group of subjects will follow their current eczema regimen with the addition of using the cooling pillow at night to sleep on.
3209145|NCT01132651|Placebo Comparator|Standard of care (regular pillow at night)|This group of subjects will serve as the control group following a their current eczema care regimen, including sleeping on their normal pillow.
3209146|NCT01132638|Active Comparator|Magnesium Pantoprazole|
3209147|NCT01132638|Active Comparator|Magnesium Esomeprazole|
3209148|NCT01132625|Experimental|AUY922|
3209149|NCT01132612|Experimental|Fixed-time interval regimen|Secukinumab 150 mg subcutaneous (sc) administered at Week 1 (baseline) of the extension study and every 12 weeks thereafter
3209150|NCT01132612|Experimental|Treatment at start of relapse regimen|Placebo administered at Week 1 (baseline) of the extension study and every 12 weeks thereafter. If relapse, then switch to secukinumab 150 mg sc administered every 4 weeks
3209151|NCT01132612|Experimental|Open-label|Secukinumab 150 mg sc administered every 4 weeks
3209152|NCT01132586|Experimental|Treatment (lenalidomide, cytarabine, idarubicin)|"INDUCTION:~COHORT I: Patients receive lenalidomide PO QD on days 1-21, cytarabine IV continuously over 96 hours on days 5-8, and idarubicin IV over 1 hour on days 5-7.~COHORT II: Patients receive lenalidomide PO QD on days 1-21, cytarabine IV continuously over 24 hours on days 5-11, and idarubicin as above.~Patients with residual disease on day 18 undergo a second course of induction therapy.~CONSOLIDATION:~COHORT I: Patients receive lenalidomide PO QD on days 1-14, idarubicin IV over 1 hour on days 5-6, cytarabine IV continuously on days 5-7. Treatment continues for 1 course in the absence of disease progression or unacceptable toxicity.~COHORT II: Patients 2 receive 4 courses of consolidation therapy comprising lenalidomide PO QD on days 1-14 and cytarabine IV every 12 hours on days 5, 7, and 9. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3209153|NCT01132573|Experimental|Treatment (entinostat and clofarabine)|"Patients receive entinostat PO on days 1 and 8 and clofarabine IV over 2 hours on days 3-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity (only for patients >= 60 years of age with newly diagnosed ALL or ABL who are unable or unwilling to tolerate standard multi-agent chemotherapy and patients with relapsed or refractory ALL or ABL).~Patients 40-59 years of age with newly diagnosed ALL receive standard multi-agent induction chemotherapy beginning on day 11. Patients >= 21 years of age in their first relapse with sensitive disease begin initiation of allogeneic transplant after one course of entinostat and clofarabine."
3209154|NCT01132547|Experimental|Arm I cyproheptadine hydrochloride|Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.
3209155|NCT01132547|Placebo Comparator|Arm II placebo|Patients receive an oral placebo twice daily for 8 weeks.
3209156|NCT01132534||SE then AFI/NBI|Patients will be randomised to be examined by standard videoendoscopy (SE) then combined AFI/NBI during the esophagogastroduodenoscopy (EGD) examination at same setting.
3209157|NCT01132534||AFI/NBI then SE|Patients will be randomised to be examined by combined AFI/NBI then standard videoendoscopy (SE) during the EGD examination at same setting.
3209158|NCT01132521|Experimental|ulinastatin group|Regular treatments plus ulinastatin. Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
3209159|NCT01132521|Placebo Comparator|placebo group|Regular treatment plus placebo. Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
3209160|NCT01132508||Treatment|
3209161|NCT01132495|Other|Cohort A: PCI plus OMT|PCI plus optimal medical treatment
3209162|NCT01132495|Other|Cohort A: OMT alone|Optimal medical treatment alone
3209163|NCT01132495|Other|Cohort B|FFR > 0.80; treatment according to local practice
3209164|NCT01132482|Experimental|Sildenafil|Subjects will receive escalating doses of sildenafil
3209165|NCT01132482|Placebo Comparator|Placebo|During the placebo arm, subjects receiving placebo will have sham dose escalation to maintain blinding.
3209166|NCT01132469|Experimental|Endoscopic Submucosal Dissection|Single-arm for ESD procedure and retrospective surgical procedure(Laparoscopy, Open surgery)data collection
3209167|NCT01132456|Experimental|Different patient subset|Patients with dual vessel treatment where each vessel has a lesion with length ≤ 27 mm and reference vessel diameters between 2.25 mm and 4.0 mm.
3209168|NCT01132456|Experimental|38 mm Cohort|Patients with at least one lesion amenable to treatment with a 38 mm length Endeavor Resolute stent. Patients may have one or two lesions, if the two lesions are located in separate target vessels.
3209169|NCT01132443|Experimental|Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,|Apply topically once daily; clindamycin (CLN); benzoyl peroxide (BPO); methylparaben-free (MPF)
3209170|NCT01132443|Active Comparator|Duac/ formulation 1|Apply topically once daily, Topical Gel (CLN 1%-BPO 5%), methylparaben-preserved
3209171|NCT01132443|Active Comparator|Duac/ formulation 2|Apply topically once daily, Duac Once Daily Gel (CLN 1%-BPO 5%), MPF
3209172|NCT01132430|Placebo Comparator|Usual care|Standard medical care within 4-6 week period
3209173|NCT01132430|Experimental|Motivational interviewing|Brief MI sessions within 4-6 week period
3209174|NCT01132417||Multidrug resistant (MDR)bacterial strains|
3209175|NCT01132404|Experimental|TAK-448 Dose 1|
3209176|NCT01132404|Experimental|TAK-448 Dose 2|
3209177|NCT01132404|Active Comparator|Leuprorelin|
3209178|NCT01132391|Experimental|1|Endoanal application
3209179|NCT01132391|Experimental|2|Perianal application
3209180|NCT01132378|Active Comparator|Mini-midvastus approach|Mini Midvastus approach with skin incision less than 13 cm long and vastus medialis obliquus dissection not more than 3 cm from the patellar margin was used to perform total knee arthroplasty in 40 patients.
3209233|NCT01132092||Gold standard 1|15 Normal hearing subjects, male and female, adults, evaluated by gold standard device
3209290|NCT01131637|Experimental|rhNRG-1|recombinant human neuregulin-1
3209181|NCT01132378|Active Comparator|Medial Parapatellar Approach|Mini Medial Parapatellar approach with skin incision less than 13 cm. The extension into quadriceps tendon did not exceed 3 cm.Mini medial parapatellar approach was used to perform total knee arthroplasty.
3209182|NCT01132365||knee arthroplasty|
3209183|NCT01132352|Experimental|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
3209184|NCT01132352|Active Comparator|Keppra®|Keppra® 750 mg Tablets of UCB Pharma Inc.,
3209185|NCT01132339||Enhanced MR (case group)|those with an exposure to gadolinium-based contrast agent
3209186|NCT01132339||Unenhanced MR (control group)|those without an exposure to gadolinium-based contrast agent
3209187|NCT01132339||Unenhanced CT (control group)|those without an exposure to iodine-containing contrast agent
3209188|NCT01132339||Enhanced CT (case group)|those with an exposure to iodine-containing contrast agent
3209189|NCT01132326|Experimental|Droxidopa|Open-Label Droxidopa
3209190|NCT01132313|Experimental|2|4 weeks of high dose TID BI 207127 and QD BI 201335 in combination with RBV, Part 1
3209191|NCT01132313|Experimental|1|4 weeks of low dose three times per day (TID) BI 207127 and once daily (QD) BI 201335 in combination with RBV, Part 1
3209192|NCT01132313|Experimental|3|16 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
3209193|NCT01132313|Experimental|4|28 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
3209194|NCT01132313|Experimental|5|40 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
3209195|NCT01132313|Experimental|6|28 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 2
3209196|NCT01132313|Experimental|7|28 weeks of TID BI 207127 and QD BI 201335 without RBV, Part 2
3209197|NCT01132313|Experimental|8|16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
3209198|NCT01132313|Experimental|9|24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
3209199|NCT01132313|Experimental|10|24 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 3
3209200|NCT01132313|Experimental|11|16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
3209201|NCT01132313|Experimental|12|24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
3209202|NCT01132300|Experimental|Treatment|
3209203|NCT01132287|Experimental|1 FID 112903|FID 112903
3209204|NCT01132287|No Intervention|No Intervention|
3209205|NCT01132274|Active Comparator|Conventional catheter ablation|Radiofrequency catheter ablation through fluoroscopic guidance
3209206|NCT01132274|Experimental|Non-fluoroscopic catheter ablation|Radiofrequency catheter ablation guided by the EnSite NavX (St.Jude Medical, St Paul, MN, USA) mapping-system
3209207|NCT01132261|Active Comparator|1|brain preservation diet
3209208|NCT01132261|No Intervention|2|
3209209|NCT01132248|Experimental|Mefloquine|15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
3209210|NCT01132248|Placebo Comparator|S/P|sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
3209211|NCT01132222|Experimental|Ibuprofen + Psuedoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets
3209212|NCT01132222|Active Comparator|Advil® Cold and Sinus|Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare
3209213|NCT01132209|Active Comparator|Large tissue bites|As control the conventional large bites technique (mass closure) will be applied in with bites widths of 1 cm and inter-suture spacing of 1 cm with the use of PDS plus ll 1-0 double loop suture material with a 48 mm needle.
3209214|NCT01132209|Experimental|small tissue bites|In the other group of 288 patients the small bites technique will be applied with bite widths of 0,5 cm and inter suture spacing of 0,5 cm with the use of PDS plus ll 2-0 single suture material with a 31 mm needle placed in the linea alba. In the small bites technique, twice as many stitches will be placed per sutured cm, with a smaller needle and thinner suture material.
3209215|NCT01132196|Experimental|Divalproex Sodium DR Tablets 500 mg|Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Laboratories Limited
3209216|NCT01132196|Active Comparator|Depakote DR 500 mg Tablets|Depakote DR 500 mg Tablets of Abbott Laboratories PR Ltd.,
3209217|NCT01132183|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
3209218|NCT01132183|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
3209219|NCT01132170|Experimental|Divalproex Sodium DR Tablets 500 mg|Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Laboratories Limited
3209220|NCT01132170|Active Comparator|Depakote DR 500 mg Tablets|Depakote DR 500 mg Tablets of Abbott Laboratories PR Ltd.,
3209221|NCT01132157|Experimental|Propofol group|
3209222|NCT01132157|Active Comparator|Desflurane group|
3209223|NCT01132144|Experimental|Endometrial injury group|Endometrial biopsy was performed once with a pipelle de Cornier® in the month before initiating controlled ovarian stimulation.
3209224|NCT01132144|Sham Comparator|Control group|Introduction of the speculum and wiping of the cervix with gaze for 30 seconds.
3209225|NCT01132131|Active Comparator|Delegation form|
3209226|NCT01132131|Active Comparator|Regular doctor's consultation|
3209227|NCT01132118|Other|Placebo then HCQ|This arm of the study will contain half the study population after randomization. The participants in this arm will receive hydroxychloroquine for 8 weeks and then crossover to a placebo for 8 weeks. Study staff will be blinded to which order they are taking the hydroxychloroquine and placebo in.
3209228|NCT01132118|Other|HCQ then Placebo|This arm of the study will contain half the study population after randomization. The participants in this arm will receive hydroxychloroquine for 8 weeks and then crossover to a placebo for 8 weeks. Study staff will be blinded to which order they are taking the hydroxychloroquine and placebo in.
3209229|NCT01132105||Normal subjects|Adults normal hearing and vestibular function subjects
3209230|NCT01132092||Normal hearing (experimental 1)|76 Normal hearing subjects, male and female, adults, , evaluated by new device
3209231|NCT01132092||Normal hearing (experimental 2)|15 Normal hearing subjects, male and female, adults, , evaluated by new device
3209288|NCT01131650||diabetic retinopathy|
3209234|NCT01132092||Gold Standard 2|15 hearing loss subjects, male and female, adults, evaluated by gold standard device
3209235|NCT01132079|Experimental|Pimecrolimus cream treatment|
3209236|NCT01132079|Active Comparator|Betamethasone valerate cream treatment|
3209237|NCT01132066|Experimental|tDCS|tDCS will provide an increase in cortical excitability. Patients will be randomized to receive tDCS or sham stimulation.
3209238|NCT01132066|Placebo Comparator|sham|Sham stimulation will provide identical subjective sensation as anodal tDCS.
3209239|NCT01132053||PML|These are subjects who have confirmed PML.
3209240|NCT01132053||Control|These are subjects who do not have PML. They may be healthy or immune compromised due to Cancer, Transplant, or HIV.
3209241|NCT01132040|Experimental|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories
3209242|NCT01132040|Active Comparator|Mysoline|Mysoline Tablets of Yamanouchi Pharma Technologies Inc,
3209243|NCT01132027|Experimental|Tacrolimus|Tacrolimus Capsules, 5 mg of Dr.Reddy's Laboratories Limited
3209244|NCT01132027|Active Comparator|Prograf Capsules|Prograf Capsules of Astellas Pharma US, Inc.,
3209245|NCT01131988|Experimental|Tacrolimus|Tacrolimus Capsules, 5 mg of Dr.Reddy's Laboratories Limited
3209246|NCT01131988|Active Comparator|Prograf Capsules|Prograf Capsules of Astellas Pharma US, Inc.,
3209247|NCT01131975|Experimental|Lamotrigine (chewable, dispersible)|Lamotrigine Tablets (chewable, dispersible),25 mg of Dr. Reddy's Laboratories Limited
3209248|NCT01131975|Active Comparator|Lamictal|Lamictal Tablets 25 mg of Glaxo SmithKline
3209249|NCT01131962|Active Comparator|band ligation group|this group will have immediate control of the hematemesis by endoscopic band ligation.
3209250|NCT01131962|Active Comparator|sclerotherapy group|This group will have immediate control of hematemesis by endoscopic sclerotherapy
3209251|NCT01131949|Experimental|Lamotrigine (chewable, dispersible)|Lamotrigine Tablets (chewable, dispersible),25 mg of Dr. Reddy's Laboratories Limited
3209252|NCT01131949|Active Comparator|Lamictal|Lamictal Tablets 25 mg of Glaxo SmithKline
3209253|NCT01131936|Experimental|Amlodipine Tablets, 10 mg|Amlodipine Tablets, 10 mg of Dr. Reddy's Laboratories Limited
3209254|NCT01131936|Active Comparator|Norvasc Tablets, 10 mg|
3209255|NCT01131923|Experimental|Amlodipine Tablets, 10 mg|Amlodipine Tablets, 10 mg of Dr. Reddy's Laboratories Limited
3209256|NCT01131923|Active Comparator|Norvasc Tablets, 10 mg|
3209257|NCT01131910|Experimental|Vaccination against TBE|"Less than 60 years old: Two doses of TBE- vaccine separated by a month and a third dose 12 months after the first dose~60 years and above: Three doses, given at 0+1+3 months and a 4 th dose 12 months after the first dose"
3209258|NCT01131897|Experimental|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
3209259|NCT01131897|Active Comparator|Keppra®|Keppra® 750 mg Tablets of UCB Pharma Inc.,
3209260|NCT01131884|Active Comparator|Fosamax|Fosamax at 70 mgs q weekly by mouth for the duration of the study.
3209261|NCT01131884|Placebo Comparator|Placebo Sugar Pill|Double blind study using Fosamax versus placebo. Placebo is an inactive drug.
3209262|NCT01131871|Active Comparator|Standard Behavioral Weight Loss Intervention|
3209263|NCT01131871|Experimental|Enhanced Weight Loss Intervention|
3209264|NCT01131858|Placebo Comparator|Placebo|Placebo
3209265|NCT01131858|Active Comparator|Vitamin D|Vigantol (cholecalciferol) 4000 IE/day
3209266|NCT01131845|Experimental|Treprostinil diethanolamine|
3209267|NCT01131832|Experimental|Plant sterol|Plant sterol supplementation, 2 grams per day of plant sterols in a margarine
3209268|NCT01131819|Other|1|The novel intervention we propose to use, the Wii Fit, will be introduced for a period of at least 20 minutes but not greater than 30 minutes per day to all the subjects in the study.
3209269|NCT01131806|Active Comparator|MD Flu/Sal|fluticasone125 mcg/ salmeterol 25 mcg 2puffs (medium dose group) inhaled twice daily; salbutamol evohaler allowed from 100 to 400 mcg for inhalation as needed basis.
3209270|NCT01131806|Experimental|HD Flu/Sal|fluticasone 250 mcg/salmeterol 25 mcg 2puffs (high dose group) inhaled twice daily; salbutamol evohaler allowed from 100 to 400 mcg for inhalation as needed basis.
3209271|NCT01131793|Experimental|RF Guidewire|
3209272|NCT01131780|Experimental|Ibuprofen + Psuedoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets
3209273|NCT01131780|Active Comparator|Advil® Cold and Sinus|Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare
3209274|NCT01131767|Experimental|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.
3209275|NCT01131767|Active Comparator|Aleve Cold and Sinus|Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).
3209276|NCT01131754|Experimental|Heparin sol 100U/L|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
3209277|NCT01131754|Active Comparator|saline|peripheral venous catheter flushing with 3 mL of normal saline from mono-use vials (prepared by the hospital pharmacy) at the end of each drug infusion. Independently of the number of drug infusions, all patients will receive at least two catheter flushes every day.
3209278|NCT01131741|Experimental|Epinephrine|
3209279|NCT01131741|Placebo Comparator|Control|
3209280|NCT01131728|Experimental|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.
3209281|NCT01131728|Active Comparator|Aleve Cold and Sinus|Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).
3209282|NCT01131715||Study group|Patients who are included in the pharmacist follow-up procedure
3209283|NCT01131702|Experimental|Ranitidine Tablets, 300 mg|Ranitidine Tablets, 300 mg of Dr. Reddy's Laboratories Limited
3209284|NCT01131702|Active Comparator|Zantac Tablets, 300 mg|
3209285|NCT01131676|Experimental|BI 10773 low dose|BI 10773 tablets once daily
3209286|NCT01131676|Experimental|BI 10773 high dose|BI 10773 tablets once daily
3209287|NCT01131676|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
3209291|NCT01131637|Placebo Comparator|placebo|placebo
3209292|NCT01131624|Active Comparator|Ferric carboxymaltose|"Subjects with bw ≥66 kg will receive an infusion of 1,000 mg iron as FCM and after 1 week a further 500 mg iron as FCM, depending on Hb at screening.~subjects with bw <66 kg, 2-3 infusions of 500 mg iron as FCM will be administered within 2 weeks from baseline, depending on Hb at screening"
3209293|NCT01131624|Active Comparator|Oral Iron|Oral Iron oral iron preparation will be provided at 200 mg iron per day in a convenient dosage schedule.
3209294|NCT01131611|Experimental|CBPT intervention|Standard PT treatment + CBPT
3209295|NCT01131611|Placebo Comparator|Control-Attention|Standard PT treatment + weekly phone calls
3209296|NCT01131585|Experimental|Active laser photocoagulation and ranibizumab|"Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.~Ranibizumab intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment."
3209297|NCT01131585|Active Comparator|Active laser photocoagulation and sham injection|"Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.~Sham intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment."
3209298|NCT01131572|Other|N-acetylcysteine|open label treatment. Each subject receives N-acetylcysteine.
3209299|NCT01131559|Active Comparator|Lisdexamfetamine|Drug
3209300|NCT01131559|Placebo Comparator|Placebo|Drug
3209301|NCT01131546|Experimental|Levamlodipine besylate (2.5mg)|
3209302|NCT01131546|Experimental|Levamlodipine besylate (5mg)|
3209303|NCT01131546|Active Comparator|Amlodipine maleate (5mg)|
3209304|NCT01131533|Experimental|Erythropoietin|patients with chronic macular edema associated with diabetic retinopathy
3209305|NCT01131520|Experimental|Computerized Brief Intervention|Computerized one-session brief intervention for drug use
3209306|NCT01131520|Active Comparator|Counselor delivered brief intervention|This is a brief intervention focused on drug use delivered by a behavioral health counselor and based on motivational interviewing
3209307|NCT01131507|Experimental|EUR-1008 (APT-1008)|
3209308|NCT01131494|Experimental|Swallowing exercises|
3209309|NCT01131481|Other|AcrySof MA50BM,AVS Model X-60|AcrySof MA50BM, AVS Model X-60
3209310|NCT01131468|Experimental|N-acetylcysteine|N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin
3209311|NCT01131468|No Intervention|Controls|Vancomycine and/or amikacin alone
3209312|NCT01131455|Active Comparator|Fusion+ACP+Autograft|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus, external rotation and neutral foot dorsiflexion). The arthrodesis undertaken for all groups will be the standard arthroscopic ankle arthrodesis with portals to the ankle (anterior medial / anterior lateral), skin incision only technique with dissection through the capsule and penetration to the joint. Standard debridement of the gutters, tibia osteophyte, tibia-talor joint resection and autograft preparation will be performed in the joint. Depending on randomization of the subject, (Autologous concentrated Plasma)ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and reduced.
3209313|NCT01131455|Active Comparator|Fusion + ACP +DBM|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus and external rotation and neutral foot dorsiflexion). Depending on the randomization of the subject, (Autologous Concentrated Plasma)ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and then reduced.
3209314|NCT01131455|No Intervention|Standard-Fusion +Autograft only|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus and external rotation and neutral foot dorsiflexion). The arthrodesis undertaken for all groups will be the standard arthroscopic ankle arthrodesis with portals to the ankle (anterior medial / anterior lateral), skin incision only technique with blunt dissection through the capsule and penetration to the joint. Depending on the randomization of the subject, ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and then reduced.
3209315|NCT01131442||The patient group|
3209316|NCT01131442||healthy control group|
3209317|NCT01131429|Experimental|first-line erlotinib|erlotinib in first-line treatment and docetaxel/cisplatin in second-line treatment
3209318|NCT01131429|Active Comparator|second-line erlotinib|docetaxel/cisplatin in first-line treatment and erlotinib in second-line treatment
3209319|NCT01131416|Experimental|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
3209320|NCT01131416|No Intervention|Conventional|Conventional postoperative feeding schedule
3209321|NCT01131403||BW= using baby wipes and CW= using cotton wool|
3209322|NCT01131403||wet wipe, cotton wool|Group 1 (BW),(n= 01-19):Using of wet wipe during the diaper changes Group 2 (CW),(n=20-40):Using a cotton wool cloth, moistened with clear water during the diaper changes.
3209323|NCT01131377|Experimental|Acetazolamide|"If ABGA is pH ≥ 7.43 & HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV.~If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip."
3209324|NCT01131377|Placebo Comparator|Placebo|This group will be managed with general metabolic alkalosis treatment such as electrolyte correction, hydration except acetazolamide.
3209325|NCT01131364|Experimental|F16IL2 in combination with doxorubicin|
3209326|NCT01131351|Experimental|OPC-67683|Dose Escalation
3209327|NCT01131325|Experimental|Nilotinib|
3209328|NCT01131312|Experimental|Cytology|Referred to colposcopy if cytology is high grade
3209329|NCT01131312|Experimental|HPV|Referred to colposcopy if cytology is high grade orHPV +
3209330|NCT01131312|Experimental|Colposcopy|All refer to colposcopy
3209331|NCT01131299|Active Comparator|Alpha cyclodextrin first then placebo|Randomized subjects will receive alpha cyclodextrin 2g orally three times a day for 12-14 weeks. After the one week washout, the subjects will receive 2 tablets orally of placebo (three times a day for 12-14 weeks).
3209332|NCT01131299|Placebo Comparator|Placebo first then Alpha cyclodextrin|Participants will receive 2 tablets orally of placebo (three times a day for 12-14 weeks). The subjects will have a one-week washout. After the washout, the participants will receive alpha cyclodextrin 2g orally three times a day for 12-14 weeks.
3209333|NCT01131273|Active Comparator|Methadone maintenance for 12 weeks|Methadone maintenance for 12 weeks as compared to 12 weeks maintenance on Suboxone.
3209334|NCT01131273|Active Comparator|buprenorphine-naloxone (Suboxone)|12 weeks of maintenance on buprenorphine-naloxone (Suboxone) at daily doses ranging from 8 to 32 mg with counseling
3209335|NCT01131260|Experimental|Open Group|
3209336|NCT01131260|Other|Masked Group|Usual fetal heart rate monitoring
3209337|NCT01131247|Experimental|ofatumumab + bendamustine|
3209338|NCT01131234|Experimental|Treatment (cediranib maleate and RO4929097)|Patients receive gamma-secretase inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17 (days 1-3, 8-10, 15-17 22-24, 29-31, and 36-38 of course 1 only) and cediranib maleate PO QD on days 1-21 (days 22-42 course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
3209339|NCT01131195|Active Comparator|Arm A: bevacizumab and paclitaxel|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Paclitaxel (90 mg/m2) i.v. is given on days 1, 8, and 15 of a 4 week cycle. Both medications are given until PD, unacceptable adverse event, or consent withdrawal. If an unacceptable adverse event to any of the drugs in this treatment arm occurs the remaining tolerated drug is given until PD, consent withdrawal, or unacceptable adverse event according to local investigators opinion.
3209340|NCT01131195|Active Comparator|Arm B: bevacizumab, cyclophosphamide and capecitabine|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Cyclophosphamide (50 mg) and capecitabine (3x 500 mg) p.o. are given daily. All three medications are given until PD, unacceptable adverse event, or consent withdrawal. If an unacceptable adverse event to any of the drugs in this treatment arm occurs the remaining tolerated drug(s) is (are) given until PD, consent withdrawal, or unacceptable adverse event according to local investigators opinion
3209341|NCT01131182|Experimental|Sitagliptin|Sitagliptin 100 mg administered orally daily as monotherapy or in combination with metformin over the Ramadan period.
3209342|NCT01131182|Active Comparator|Sulfonylurea|Sulfonylurea administered orally daily as monotherapy or in combination with metformin over the Ramadan period.
3209343|NCT01131169|Experimental|relapsed multiple myeloma|This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma.
3209344|NCT01131169|Experimental|high-risk multiple myeloma|This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma.
3209345|NCT01131143|Experimental|Treatment Group 1|Patients will receive a pre-visit, post-referral and post-contact phone call using providers voice
3209346|NCT01131143|Experimental|Treatment Group 2|Patients will receive a previsit, post-referral and post-contact call using a generic voice
3209347|NCT01131143|No Intervention|Treatment Group 3|Patients will be provided usual care with no additional phone calls.
3209348|NCT01131130|Experimental|Investigational contact lens|Bausch & Lomb
3209349|NCT01131130|Active Comparator|Acuvue Oasys Contact Lens|Johnson & Johnson Lens
3209350|NCT01131130|Active Comparator|Air Optix Aqua|Ciba Vision
3209351|NCT01131117||Pregnant women|
3209352|NCT01131104||Cohort 1|Participants with NAION who have used PDE5 inhibitors
3209353|NCT01131091|Other|Group A|Subjects with end stage renal disease (ESRD) who are receiving hemodialysis treatment
3209354|NCT01131091|Other|Group B|Subjects with severe renal impairment
3209355|NCT01131091|Other|Group C|Subjects with moderate renal impairment
3209356|NCT01131091|Other|Group D|Subjects with mild renal impairment
3209357|NCT01131091|Other|Group E|Healthy subjects
3209358|NCT01131078|Experimental|Bevacizumab + Irinotecan + Capecitabine (1000 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle. Irinotecan was administered as a 240 mg/m^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice daily (Day 2 to 15). Cycle length was 3 weeks consisting of 2 weeks of capecitabine treatment followed by 1 week without treatment up to 6 cycles. After 6 cycles, participants with objective response or SD were treated with bevacizumab alone until unacceptable toxicity, PD, or participant withdrawal.
3209359|NCT01131078|Experimental|Bevacizumab + Capecitabine (1250 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle in combination with capecitabine administered orally at 1250 mg/m^2 twice daily (Day 1 to 14). Cycle length was 3 weeks with 2 weeks of capecitabine treatment followed by 1 week without treatment up to 6 cycles. After 6 cycles, participants with objective response or SD were treated with bevacizumab alone until unacceptable toxicity, PD, or participant withdrawal.
3209360|NCT01131078|Experimental|Bevacizumab + Capecitabine (650 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 Week cycle in combination with capecitabine administered orally at 650 mg/m^2 twice daily (Day 1 to 21). Cycle length was 3 weeks with 3 weeks of capecitabine treatment without interruptions. Participants received the same regimen until unacceptable toxicity, PD, or participant withdrawal.
3209361|NCT01131065|Experimental|Hepatitis B immune globulin|Treatment group (newly liver transplanted subjects due to HBV induced liver disease)
3209362|NCT01131052|Active Comparator|BASAL PLUS|Diabetic subjects receive insulin glargine once daily plus corrective doses of insulin glulisine before meals and bedtime as needed
3209363|NCT01131052|Active Comparator|sliding scale regular insulin (SSRI)|Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed
3209364|NCT01131039|Experimental|Single|
3209365|NCT01131013|Experimental|Three-way crossover|2 oral dose levels of CK-2017357 and placebo
3209366|NCT01131000|Experimental|Ibuprofen|
3209367|NCT01131000|Placebo Comparator|Saline|Normal Saline
3209368|NCT01130987|Experimental|Comprehensive Handoff Program|Introduction of Computerized tool plus team training
3209369|NCT01130974|Experimental|Bausch & Lomb contact lens|Bausch & Lomb daily disposable cosmetic tint contact lens
3209370|NCT01130974|Active Comparator|Marketed daily disposable contact lens|Marketed daily disposable cosmetic tint contact lens
3209371|NCT01130935||1|
3209372|NCT01130922|Experimental|Moxifloxacin IV|
3209373|NCT01130922|Active Comparator|Moxifloxacin oral|
3209374|NCT01130909|Experimental|AZD6765 75 mg|
3209375|NCT01130909|Experimental|AZD6765 150 mg|
3209376|NCT01130909|Active Comparator|Ketamine 0.5 mg/kg|
3209377|NCT01130909|Placebo Comparator|125 mL sterile NaCl 0.9%|
3209378|NCT01130896||MRI and Cardiac Devices|Clinically indicated MRI (all types) in patients with implanted pacemakers and ICD
3209379|NCT01130883||Respiratory Infections|Czech patients with acute tracheitis, acute tracheobronchitis or acute bronchitis; or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid®SR treatment 6 weeks prior to the next Klacid®SR dose or in intervals: 7-week - 3- month, 4- month - 12- month, 13- month - 24- month prior to the next Klacid®SR dose (next Klacid®SR dose = dose administered within this PMOS).
3209380|NCT01130870|Active Comparator|Sensory threshold - Amplitude|Stimulation amplitude set at sensory threshold.
3209381|NCT01130870|Experimental|25% below sensory threshold - Amplitude|Stimulation amplitude 75% of sensory threshold.
3209382|NCT01130870|Experimental|50% below sensory threshold - Amplitude|Stimulation with amplitude set 50% below sensory threshold
3209383|NCT01130844|Experimental|MMX Mesalamine (30mg/kg)|
3209384|NCT01130844|Experimental|MMX Mesalamine (60 mg/kg)|
3209385|NCT01130844|Experimental|MMX Mesalamine (100 mg/kg)|
3209386|NCT01130818|Experimental|1|single ascending doses
3209387|NCT01130818|Placebo Comparator|2|single dose placebo
3209388|NCT01130818|Experimental|3|single dose, oral solution, 50 mg
3209389|NCT01130818|Experimental|4|single dose, capsules (fasting)
3209390|NCT01130818|Experimental|5|single dose, capsules (fed)
3209391|NCT01130805|Experimental|Pazopanib in combination with capecitabine and oxaliplatin|Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks
3209392|NCT01130792|Experimental|Lactobacillus GG|LGG once daily for 4 weeks
3209393|NCT01130792|Placebo Comparator|Inulin|
3209394|NCT01130779|Experimental|tarceva|continuation of tarceva
3209395|NCT01130766|Experimental|stereotactic radiosurgery (SRS)|
3209396|NCT01130766|No Intervention|observation|
3209397|NCT01130740|No Intervention|Arm 1|usual care
3209398|NCT01130740|Experimental|Arm 2|Osteoarthritis Intervention - Primary care providers receive patient-specific osteoarthritis information and treatment recommendations approximately one week prior to the patient's first post-enrollment routine appointment with PCP; patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
3209399|NCT01130727|Active Comparator|green tea extract|
3209400|NCT01130727|Active Comparator|Cocoa extract rich in polyphenols|
3209401|NCT01130727|Placebo Comparator|placebo|
3209402|NCT01130727|Placebo Comparator|cocoa extract with low polyphenol|
3209403|NCT01130714|Experimental|Resistance training|Group assigned to complete resistance training during duration of chemotherapy.
3209404|NCT01130714|No Intervention|Control|Usual care.
3209405|NCT01130688|Experimental|single arm of experimental drug combination|
3209406|NCT01130675|Active Comparator|eight ounces of caffeinated coffee for breakfast and lunch|
3209407|NCT01130675|No Intervention|standard care|
3209408|NCT01130662|Experimental|Decitabine Midostaurin combination|
3209409|NCT01130649||Epilepsy patients, electronic diary|Cohort of epilepsy patient using an electronic diary system to record all seizures, side effects, and medication compliance
3209410|NCT01130649||Epilpesy patient, no electronic diary|Group of epilepsy patients who are followed using the standard of care, which is a paper diary and routine outpatient follow up visits
3209411|NCT01130636|Experimental|Tamiflu|Lactating women (up to 20 subjects) who present with clinical symptoms indicative of influenza will be recruited (a maximum of 6 months period of recruitment) to receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules, provided free of charges for the study) at a standard dose of 75 mg twice daily. These subjects will have a 12 hour pharmacokinetic plasma, urine and breast milk study undertaken after the steady state in oseltamivir concentrations (both active and inactive metabolites will be measured) is reached in blood, i.e. after three days after treatment.
3209412|NCT01130597|Experimental|patiromer|spironolactone + patiromer
3209413|NCT01130584||Cancer patient|
3209414|NCT01130571||Non-Small Cell Lung Cancer|
3209415|NCT01130558|Active Comparator|Ordering template and education|Internal medical residents who were asked to use the insulin order template and received education about basal-bolus insulin ordering.
3209416|NCT01130558|Active Comparator|Education|Internal medical residents who received education about basal-bolus insulin ordering.
3209417|NCT01130532|Active Comparator|2.5 milligram (mg) titrated to 5 mg Tadalafil|2.5 mg for 4 weeks, followed by 5 mg for 8 weeks with option to continue treatment at 5 mg for an additional 4 weeks
3209418|NCT01130532|Active Comparator|5 mg Tadalafil|5.0 mg for 12 weeks with option to continue treatment for additional 4 weeks
3209419|NCT01130532|Placebo Comparator|Placebo|for 12 weeks
3209420|NCT01130519|Experimental|1|All patient will be receiving fixed starting dose of bevacizumab (10 mg /kg IV every 2 weeks) and erlotinib (150 mg/day PO)
3209421|NCT01130506|Experimental|Treatment (decitabine, vorinostat, cytarabine)|"INDUCTION THERAPY: Patients receive decitabine IV over 1 hour on days 1-10; vorinostat PO on days 5-10; and high-dose cytarabine IV over 2 hours on days 12, 14, and 16 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR proceed to maintenance therapy. Patients who achieve CR with incomplete blood count recovery undergo bone marrow aspiration and biopsy at count recovery or day 42 before proceeding to maintenance therapy.~MAINTENANCE THERAPY: Patients receive decitabine IV over 1 hour on days 1-5 and vorinostat PO on days 5-10. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity."
3209422|NCT01130493|Other|IPX066-CLE-OLE|Dose conversion from CLE to IPX066, IPX066 (Part 1 Period 1), Open-label IPX066, CLE (Part 1 Period 2), OLE (Part 2)
3209423|NCT01130493|Other|CLE-IPX066-OLE|Dose conversion from CLE to IPX066, CLE (Part 1 Period 1), Open-label IPX066, IPX066 (Part 1 Period 2), OLE (Part 2)
3209424|NCT01130480|Experimental|A|
3209425|NCT01130467||Normal control|
3209426|NCT01130467||pure ADHD|
3209427|NCT01130467||ADHD with comorbidity|
3209428|NCT01130454|Active Comparator|SCIO Test Group|
3209429|NCT01130454|Placebo Comparator|SCIO Placebo Group|
3209430|NCT01130441||self-harming group|
3209431|NCT01130441||non-self-harming group -control group|
3209432|NCT01130428|Experimental|Intervention group|As a mechanical intervention, we will use a vibration platform to administer mechanical stimulation to the forearm of subjects (see Figure 1). All subjects will participate in a single experiment during which they will receive the mechanical intervention a fixed dose of; the duration of an experiment is approximately three hours.
3209433|NCT01130415||Patients treated with sacral neuromodulation|
3209434|NCT01130402||Neck masses|Patients with previously untreated neck masses
3209435|NCT01130376|Experimental|Vaccine and cytokines|"Day 0: Patients receive GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injection.~Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC.~Further vaccine boosters are given on day 42 and day 84. GTU-MultiHIV B clade vaccine 1mg/ml being administered as 10 intradermal injections of 100 µl/injection."
3209436|NCT01130376|Active Comparator|Vaccine alone|"Day 0: Patients are given GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injections.~Day 42: GTU-MultiHIV B clade vaccine as day 0.~Day 84: GTU-MultiHIV B clade vaccine as day 0."
3209437|NCT01130376|Active Comparator|Cytokines alone|"Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC."
3209438|NCT01130363||Fundic Gland Polyps on PPI|Patients found to have fundic gland polyps on endoscopic evaluation that have also been prescribed and regularly take a proton pump inhibitor.
3209439|NCT01130363||Fundic Gland Polyp not on PPI|Patients found to have fundic gland polyps on endoscopic evaluation that have not been prescribed a proton pump inhibitor.
3209440|NCT01130363||Group 3 (Control Group)|Individuals who are prescribed proton pump inhibitor but are not found to have fundic gland polyps on endoscopic evaluation.
3209441|NCT01130337|Experimental|1|
3209442|NCT01130324||VIBATIV treated pregnant women|Women treated with telavancin (any dose or duration) during pregnancy.
3209443|NCT01130311|Experimental|Cholecalciferol (Vitamin D)|Intramuscular injection of VITAMIN D, 600,000 UNITS WILL BE GIVEN TO THE TEST SUBJECTS AT WEEK 0 and at week 4 OF the TRIAL
3209444|NCT01130311|Placebo Comparator|SALINE, INTRAMUSCULAR INJECTION|NORMAL SALINE INJECTION WILL BE GIVEN TO THE CONTROL SUBJECTS at week 0 and week 4 of the trial
3209445|NCT01130298|Experimental|1|
3209446|NCT01130285||Non-Lung Cancer, Heavy Smoker|Subjects will be ≥ 50 years of age and have a ≥ 20 pack year smoking history and will be either healthy volunteers or individuals undergoing diagnostic bronchoscopy, with absence of lung cancer documented at the time of enrollment.
3209447|NCT01130272|Experimental|JNJ-27018966 5 mg twice daily|
3209448|NCT01130272|Experimental|JNJ-27018966 25 mg twice daily|
3209449|NCT01130272|Experimental|JNJ-27018966 100 mg twice daily|
3209450|NCT01130272|Experimental|JNJ-27018966 200 mg twice daily|
3209451|NCT01130272|Placebo Comparator|Placebo|Matching placebo oral tablets twice daily
3209452|NCT01130246|Experimental|A-002 500 mg|Once daily oral administration
3209453|NCT01130246|Placebo Comparator|Matched Placebo|Once daily oral administration
3209454|NCT01130233|Experimental|robotic|robotic assisted rectal resection
3209455|NCT01130233|Active Comparator|laparoscopic|laparoscopic rectal resection
3209456|NCT01130220||Brain Tumor Patient|"A one-time focus group will be held in a quiet room for approximately 30-60 minutes until a saturation of themes has been identified."
3209457|NCT01130220||Health Care Provider|"A one-time focus group will be held in a quiet room for approximately 30-60 minutes until a saturation of themes has been identified."
3209458|NCT01130194|Experimental|Experimental|C-MOPP-R chemotherapy, 6 cycles Peripheral blood stem cell mobilization Radioimmunotherapy Autologous Hematopoietic Stem Cell Transplantation
3209459|NCT01130181|Experimental|Cholecalciferol|
3209460|NCT01130181|Placebo Comparator|Placebo|
3209461|NCT01130168|Experimental|Placebo/ISMN ER/Amlodipine (Sequence 1)|Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.
3209462|NCT01130168|Experimental|ISMN ER/Amlodipine/Placebo (Sequence 2)|Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
3209463|NCT01130168|Experimental|Amlodipine/Placebo/ISMN ER (Sequence 3)|Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
3209464|NCT01130168|Experimental|ISMN ER/Placebo/Amlodipine (Sequence 4)|Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.
3209514|NCT01129778|Experimental|Received Zegerid (Ome-NaBic)|Administered Ome-NaBic 40 mg orally 1 h before breakfast and bedtime
3209628|NCT01129102|Active Comparator|IKH-01|Norethisterone 1mg, Ethinyl estradiol 0.035mg
3209465|NCT01130168|Experimental|Placebo/Amlodipine/ISMN ER (Sequence 5)|Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
3209466|NCT01130168|Experimental|Amlodipine/ISMN ER/Placebo (Sequence 6)|Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule for 4 weeks during Period, with a 2-week washout between each period.
3209467|NCT01130155||Mwanza Region|Households, and patients presenting at public health facilities in Mwanza Region
3209468|NCT01130155||Mbeya Region|Households, and patients presenting at public health facilities in Mbeya Region
3209469|NCT01130155||Mtwara Region|Households, and patients presenting at public health facilities in Mtwara Region
3209470|NCT01130142|Active Comparator|Arm 1 (Phase 2)|IPI-926 in combination with gemcitabine
3209471|NCT01130142|Placebo Comparator|Arm 2 (Phase 2)|Placebo in combination with gemcitabine
3209472|NCT01130129|Experimental|Ex-vivo treatment of platelets|Ex-vivo treatment of platelets
3209473|NCT01130103|Experimental|Paroxetine|Paroxetine and Prolonged Exposure Therapy
3209474|NCT01130103|Placebo Comparator|Placebo pill|Placebo pill plus Prolonged Exposure Therapy
3209475|NCT01130077|Experimental|HLA Restristed glioma antigen peptides plus Poly ICLC|All subjects will receive vaccine plus Poly ICLC will receive 9 injections ( once every 3 weeks)
3209476|NCT01130064|Experimental|QAX576|QAX576
3209477|NCT01130064|Placebo Comparator|Placebo|Placebo
3209478|NCT01130051|Experimental|Colcrys® 0.6 mg intact tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
3209479|NCT01130051|Experimental|Colcrys® 0.6 mg tablet on applesauce|One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
3209480|NCT01130038||Children with DCD and Typical Development|
3209481|NCT01130038||Children with DCD|2 groups Children with DCD and Typical Development
3209482|NCT01130025|Experimental|Innohep®|Long-term treatment with Innohep® only.
3209483|NCT01130025|Active Comparator|Warfarin|Oral treatment with warfarin in combination with overlapping initial (5 to 10 days) treatment with Innohep®.
3209484|NCT01130012|Other|Lifestyle, follow-up, early care, standard care high/low risk|Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.
3209485|NCT01130012|Other|Close follow-up|Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
3209486|NCT01129999|Experimental|Cognitive-Behavioral Therapy|
3209487|NCT01129999|Experimental|Hypnotherapy|
3209488|NCT01129986|Experimental|Dermastream|
3209489|NCT01129960|Experimental|Eslicarbazepine acetate 800 mg once daily (QD)|
3209490|NCT01129960|Experimental|Eslicarbazepine acetate 1200 mg QD|
3209491|NCT01129960|Experimental|Eslicarbazepine acetate 1600 mg QD|
3209492|NCT01129960|Placebo Comparator|Placebo|
3209493|NCT01129947|Experimental|DHEA|
3209494|NCT01129934|Experimental|Morphine-Promethazine|Pain relief by administration of morphine-promethazine combination
3209495|NCT01129934|Active Comparator|morphine|pain relief by administration of morphine
3209496|NCT01129921|Active Comparator|Decompression with mild® Device Kit|Fluoroscopically guided percutaneous lumbar decompression using the Vertos mild® Device Kit for bone and tissue removal to decompress the targeted stenosed level(s).
3209497|NCT01129921|Sham Comparator|Sham lumbar decompression|Sham procedure of fluoroscopically guided percutaneous placement of mild® Device Kit instrumentation with no removal of bone or tissue.
3209498|NCT01129895|Experimental|Health promotion|5 workshops on the initiation of health prevention projects in each clinic will be organized by the intervention team and than the clinic will be followed by the intervention team for 6 months.
3209499|NCT01129895|No Intervention|Promoting Health|No intervention follow-up only
3209500|NCT01129882|Experimental|Aripiprazole IM depot|Active treatment of aripiprazole IM depot (300mg or 400mg)
3209501|NCT01129856|Active Comparator|Ocular Iontophoresis EGP-437, Low Dose|Ocular Iontophoresis with EGP-437 4.0 mA-min at 1.5 mA
3209502|NCT01129856|Active Comparator|Ocular Iontophoresis EGP-437, High Dose|Ocular Iontophoresis with EGP-437 6.5 mA-min at 2.5 mA
3209503|NCT01129856|Placebo Comparator|Ocular Iontophoresis Placebo|Ocular Iontophoresis with Placebo 6.5 mA-min at 2.5 mA
3209504|NCT01129843|Experimental|Directly observed home based daily iron therapy|Village volunteers will provide directly observed home based daily iron supplementation( ferrous sulphate) to enrolled anemic women in the experimental arm
3209505|NCT01129843|Active Comparator|Clinic driven unsupervised daily iron therapy|In the control group of villages, clinic driven unsupervised iron ( ferrous sulphate) supplementation will be offered on monthly basis to anemic women for 3 months
3209506|NCT01129830|Other|Dehydroepiandrosterone|infertile women with low anti mullerian hormone levels
3209507|NCT01129817|Experimental|Cognitive Functional Therapy|
3209508|NCT01129817|Active Comparator|Manual Therapy and Exercise|
3209509|NCT01129804|Experimental|Network Support|Network Support treatment is aimed at helping patients change their social support network so that it supports abstinence. In this treatment patients will be encouraged to attend AA meetings and engage in other activities that would involve non-drinkers. These activities would be determined by the patient, with help from the therapist. Patients would learn about methods of avoiding drinking, making new friends, and getting enjoyment from activities other than drinking. In addition patients will learn specific skills intended to help them make new acquaintances and change their circle of friends.
3209510|NCT01129804|Active Comparator|Packaged Cognitive-Behavioral Treatment|The purpose of Packaged Cognitive-Behavioral Treatment (PCBT) is to train patients in a variety of skills that they can use to keep themselves from drinking.
3209511|NCT01129791|Experimental|Raw Milk first|Organic raw cow's milk
3209512|NCT01129791|Placebo Comparator|Pasteurized milk first|Organic pasteurized cow's milk
3209513|NCT01129791|Placebo Comparator|Non-Dairy Milk first|Unflavored soy milk
3209725|NCT01128426||1|
3209515|NCT01129765||Parents of congested children|Parents of children less than six years of age with nasal congestion for which nasal suctioning and salt water irrigation is traditionally recommended.
3209516|NCT01129752||children at risk for depression|children at familial risk for depression
3209517|NCT01129739|Experimental|Human umbilical cord-derived MSCs|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated to apply in trimonthly for 2 cycle
3209518|NCT01129739|Active Comparator|cyclosporine A (CsA)|CsA at a dose of 5 mg CsA/kg
3209519|NCT01129726|Experimental|Intubation|Transillumination-guided Fiberoptic Intubation
3209520|NCT01129713|Active Comparator|Nexium|Comparing 40 mg.once daily in healing erosive esophagitis.
3209521|NCT01129713|Active Comparator|Secretol|Comparing the efficacy of 80/80 Secretol once daily in healing erosive esophagitis.
3209522|NCT01129700|Experimental|short-course CRT-5FU|
3209523|NCT01129687||ANSRS group|Patients qualifying for the study.
3209524|NCT01129674|Active Comparator|Standard of Care|
3209525|NCT01129674|Experimental|LY2140023|"20mg, 40mg or 80mg~After 104 weeks, patients have the option to continue on treatment until the end of the study"
3209526|NCT01129661|Placebo Comparator|normal saline (0.9%)|
3209527|NCT01129661|Experimental|CSL112|
3209528|NCT01129648|Placebo Comparator|BCX4208 placebo + Allopurinol placebo|Administered daily for 21 days.
3209529|NCT01129648|Active Comparator|BCX4208 placebo + Allopurinol 100mg|Administered daily for 21 days.
3209530|NCT01129648|Active Comparator|BCX4208 placebo + Allopurinol 200 mg|Administered daily for 21 days.
3209531|NCT01129648|Active Comparator|BCX4208 Placebo + Allopurinol 300 mg|Administered daily for 21 days.
3209532|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol Placebo|Administered daily for 21 days.
3209533|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol 100 mg|Administered daily for 21 days.
3209534|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol 200 mg|Administered daily for 21 days.
3209535|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol 300 mg|Administered daily for 21 days.
3209536|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol placebo|Administered daily for 21 days.
3209537|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol 100 mg|Administered daily for 21 days.
3209538|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol 200 mg|Administered daily for 21 days.
3209539|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol 300 mg|Administered daily for 21 days.
3209540|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol Placebo|Administered daily for 21 days.
3209541|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol 100 mg|Administered daily for 21 days.
3209542|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol 200 mg|Administered daily for 21 days.
3209543|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol 300 mg|Administered daily for 21 days.
3209544|NCT01129635|Experimental|CRT Candidate|"Patients with NYHA Class III or IV heart failure; EF ≤ 30% and QRS duration ≥ 120 ms, who are scheduled for CRT surgery.~Intervention: Cardiac Resynchronization Therapy (CRT) implantation"
3209545|NCT01129622|Experimental|Letrozole, Breast enhancement, Safety|Single arm of healthy postmenopausal women who received baseline diagnostic MRI will receive letrozole of 12.5 mg/day orally for three successive days. A second post treatment breast MRI is done right after receiving the three days of letrozole treatment and within one month after the first MRI .
3209546|NCT01129609||All Enrolled Subjects|
3209547|NCT01129596||1|
3209548|NCT01129583|Experimental|Botulinum Toxin|100 U injected into biceps, 100 U into brachialis
3209549|NCT01129583|Placebo Comparator|Saline|100 U injected into biceps, 100 U into brachialis
3209550|NCT01129570|Experimental|Siliphos - dose escalation|
3209551|NCT01129557|Active Comparator|Tekturna|Tekturna (Aliskiren), a direct renin inhibitor (DRI) 300 mg by mouth once daily for 9 months
3209552|NCT01129557|Active Comparator|Diovan|Diovan (Valsartan), an angiotensin receptor blocker (ARB) 320 mg by mouth once daily for 9 months
3209553|NCT01129557|Active Comparator|Tekturna & Diovan|Tekturna (Aliskiren), a direct renin inhibitor (DRI) 150 mg by mouth once daily & Diovan (Valsartan), an angiotensin receptor (ARB) 160 mg by mouth once daily for 9 months
3209554|NCT01129544|Experimental|Gene Transfer|open label single arm study
3209555|NCT01129531|Experimental|AGN-214868 3.25 μg|AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 3.25 μg per treatment.
3209556|NCT01129531|Experimental|AGN-214868 16.25 μg|AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 16.25 μg per treatment.
3209557|NCT01129531|Placebo Comparator|Placebo|Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
3209558|NCT01129518|Experimental|Two Dose MenC Group|Two doses of MenC-CRM197 priming at 3 and 4 months of age.
3209559|NCT01129518|Experimental|Single Dose MenC-CRM197 Group|One dose of MenC-CRM197 priming at 3 months of age.
3209560|NCT01129518|Experimental|Single Dose MenC-TT Group|Single dose MenC-TT priming at 3 months of age
3209561|NCT01129518|Experimental|Control Group|Zero dose MenC priming
3209562|NCT01129492|Placebo Comparator|Sham Laser|Ten applications of placebo were performed (twice a week) with the same method and Laser equipment, which has a placebo function available with a red ordinary light indistinguishable of the Laser light.
3209563|NCT01129492|Active Comparator|Active Laser|Ten applications of low-level Laser therapy (twice a week) were performed with a continuous wave diode laser device (830nm, beam area of 0.2827cm2), using the punctual method, continuous emission mode, output power of de 50 mW and fluence of 70J/cm2.
3209564|NCT01129479|Active Comparator|Galantamine|
3209565|NCT01129479|Placebo Comparator|Placebo|
3209566|NCT01129466|Active Comparator|Supplement A followed by supplement B|
3209567|NCT01129466|Active Comparator|Supplement B followed by Supplement A|
3209568|NCT01129453|Experimental|Vaccine-recipients|
3209569|NCT01129453|Placebo Comparator|Placebo|
3209570|NCT01129440|Active Comparator|Fluoride Varnish|Topical fluoride varnish (FV) applications every 6 months
3209571|NCT01129440|Experimental|FV + Glass Ionomer Sealants|Topical fluoride varnish (FV) applications every 6 months, and fluoride-releasing glass ionomer sealants (GIS) placed on primary molars at baseline and annually, as needed
3209572|NCT01129427|Experimental|Group clopidogrel - clopidogrel + pantoprazole|"Period 1:~Day 1: clopidogrel 300 mg loading dose~Day 2 to Day 5: clopidogrel 75 mg, once daily~Period 2:~Day -7 to Day -1: pantoprazole 80 mg, once daily~Day 1: clopidogrel 300 mg loading dose + pantoprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 75 mg + pantoprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions."
3209573|NCT01129427|Placebo Comparator|Group placebo - placebo + pantoprazole|"Period 1:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Period 2:~Day -7 to Day -1: pantoprazole 80 mg, once daily~Day 1: placebo loading dose + pantoprazole 80 mg concomitantly~Day 2 to Day 5: placebo + pantoprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions."
3209574|NCT01129427|Experimental|Group clopidogrel + pantoprazole - clopidogrel|"Period 1:~Day -7 to Day -1: pantoprazole 80 mg, once daily~Day 1: clopidogrel 300 mg loading dose + pantoprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 75 mg + pantoprazole 80 mg concomitantly, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose~Day 2 to Day 5: clopidogrel 75 mg, once daily~Each intake is under fasted conditions."
3209575|NCT01129427|Placebo Comparator|Group placebo + pantoprazole placebo|"Period 1:~Day -7 to Day -1: pantoprazole 80 mg, once daily~Day 1: placebo loading dose + pantoprazole 80 mg concomitantly~Day 2 to Day 5: placebo + pantoprazole 80 mg concomitantly, once daily~Period 2:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Each intake is under fasted conditions."
3209576|NCT01129414|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~Day 1: clopidogrel 600 mg loading dose~Day 2 to Day 5: clopidogrel 150 mg, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 600 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 150 mg + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
3209577|NCT01129414|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
3209578|NCT01129414|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 600 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 150 mg + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: clopidogrel 600 mg loading dose~Day 2 to Day 5: clopidogrel 150 mg, once daily~Each intake is under fasted conditions"
3209579|NCT01129414|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Each intake is under fasted conditions"
3209580|NCT01129401|Other|Stonewall Project Participants|
3209581|NCT01129388|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily"
3209582|NCT01129388|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:~Day 1: placebo loading dose in the morning under fasted conditions~Day 2 to Day 5: placebo in the morning under fasted conditions, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily~Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily"
3209583|NCT01129388|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~Day -5 to Day -1: omeprazole 80 mgin the evening 2 hours after dinner, once daily~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily"
3209584|NCT01129388|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily in the evening 2 hours after dinner~Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily~Period 2:~Day 1: placebo loading dose in the morning under fasted conditions~Day 2 to Day 5: placebo in the morning under fasted conditions, once daily"
3209585|NCT01129375|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~Day 1: clopidogrel 300 mg loading dose~Day 2 to Day 5: clopidogrel 75 mg, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 300 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 75 mg + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
3209586|NCT01129375|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
3209587|NCT01129375|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 300 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 75 mg + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose~Day 2 to Day 5: clopidogrel 75 mg, once daily~Each intake is under fasted conditions"
3209588|NCT01129375|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Each intake is under fasted conditions"
3209589|NCT01129362||Group 1|Participants that only received Pentacel® vaccine.
3209590|NCT01129362||Group 2|Participants that only received a single brand of pertussis vaccine other than Pentacel® vaccine.
3209627|NCT01129102|Experimental|NPC-01|Norethisterone 1mg, Ethinyl estradiol 0.02mg
3209591|NCT01129362||Group 3|Participants that received more than one brand of Pertussis vaccine or one or more doses of an unknown brand.
3209592|NCT01129349|Experimental|Oprozomib|Phase I, Dose Escalation, Single Arm, Open Label
3209593|NCT01129336|Experimental|Patients without bone metastases|Patients with no bone metastasis were randomized into a 1:1 ratio to standard therapy plus zoledronic acid 4mg IV Zoledronic acid administration monthly during Months 1-18.
3209594|NCT01129336|Experimental|Patients with bone metastases|Patients with bone metastasis received standard therapy + zoledronic acid for 18 months (discontinued upon disease progression/secondary malignancy)
3209595|NCT01129323|Experimental|Reduced-Intensity Preparative Regimen for Allogeneic SCT|Patient in this arm will receive maximally tolerated (reduced) doses of cytotoxic therapy with the goals of suppressing the immune system, and ablate host hematopoiesis to ensure engraftment of the donor's hematopoietic system.
3209596|NCT01129297||BMI ≥ 35 kg/m2 and diabetes|BMI (Body Mass Index) ≥ 35 kg/m2 and diabetes defined by a fasting blood glucose ≥ 7 mmol/l and/or ≥ to 11.1 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
3209597|NCT01129297||BMI ≥ 35 kg/m2 with intolerance glucose|BMI (Body Mass Index) ≥ 35 kg/m2 with intolerance glucose defined by a fasting blood glucose> 6 mmol/L and <7 mmol/l and / or> 7.8 mmol/l and <11.1 mmol/l , 120 minutes after ingestion of glucose (oral glucose tolerance test)
3209598|NCT01129297||BMI ≥ 35 kg/m2 without diabetes|BMI (Body Mass Index)≥ 35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
3209599|NCT01129297||BMI <27 kg/m2 without diabetes|BMI (Body Mass Index) <27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
3209600|NCT01129297||27 < BMI < 35 kg/m2 without diabetes|BMI (Body Mass Index) <27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
3209601|NCT01129284|Experimental|Acthar gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
3209602|NCT01129271|Experimental|Group clopidogrel fed - fasting|"Period 1:~Day 1: clopidogrel 300 mg loading dose with high fat breakfast~Day 2 to Day 5: clopidogrel 75 mg/day with standard breakfast, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg/day under fasted conditions, once daily"
3209603|NCT01129271|Placebo Comparator|Group placebo fed - fasting|"Period 1:~Day 1: placebo loading dose with high fat breakfast~Day 2 to Day 5: placebo with standard breakfast, once daily~Period 2:~Day 1: placebo loading dose under fasted conditions~Day 2 to Day 5: placebo under fasted conditions, once daily"
3209604|NCT01129271|Experimental|Group clopidogrel fasting - fed|"Period 1:~Day 1: clopidogrel 300 mg loading dose under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg/day under fasted conditions, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose with high fat breakfast~Day 2 to Day 5: clopidogrel 75 mg/day with standard breakfast, once daily"
3209605|NCT01129271|Placebo Comparator|group placebo fasting -fed|"Period 1:~Day 1: placebo loading dose under fasted conditions~Day 2 to Day 5: placebo in fasted conditions, once daily~Period 2:~Day 1: placebo loading dose with high fat breakfast~Day 2 to Day 5: placebo with standard breakfast, once daily"
3209606|NCT01129258|Experimental|PF-04991532|
3209607|NCT01129258|Placebo Comparator|Placebo|
3209608|NCT01129245|Experimental|Placebo first, then celecoxib|control menstrual cycle, placebo menstrual cycle, celecoxib cycle
3209609|NCT01129245|Experimental|Celecoxib first, then placebo|control menstrual cycle, celecoxib menstrual cycle, placebo menstrual cycle
3209610|NCT01129232|Experimental|GAD-alum|GAD-alum administered at 0 and 1 months after inclusion
3209611|NCT01129232|Placebo Comparator|Placebo|
3209612|NCT01129219|Experimental|Usual care|Subjects in the control group were asked to maintain their current lifestyle. No restrictions were placed on their exercise activities.
3209613|NCT01129206|Experimental|Arm I|Patients receive pralatrexate IV over 3-5 minutes and docetaxel IV on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3209614|NCT01129193|Experimental|Arm I (Hematologic Malignancies)|Patients will receive orally administered AR-42 three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
3209615|NCT01129193|Experimental|Arm II (Solid Tumors)|Patients will receive orally administered AR-42 three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
3209616|NCT01129180|Experimental|Arm I|Patients receive bortezomib IV on days 4, 8, 11, and 15 and azacitidine SC on days 1-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Attempt to collect Correlative studies will be made.
3209617|NCT01129154|Experimental|panitumumab|Patients will receive six infusions of panitumumab every 2 weeks for the first cycle.
3209618|NCT01129141|Experimental|Tele-PTM|Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
3209619|NCT01129141|Other|Wait List Control|Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
3209620|NCT01129128|Active Comparator|Echinacea preparation 1|Commercially available Echinacea purpurea product
3209621|NCT01129128|Active Comparator|Echinacea preparation 2|Commercially available Echinacea purpurea product
3209622|NCT01129128|Placebo Comparator|Placebo|Inert liquid that is similar in appearance and taste to the active Echinacea products
3209623|NCT01129115|Active Comparator|Nonexercise control group|
3209624|NCT01129115|Experimental|Aerobic Exercise Group 1|
3209625|NCT01129115|Experimental|Aerobic Exercise Group 2|
3209626|NCT01129115|Experimental|Aerobic Exercise Group 3|
3209629|NCT01129102|Placebo Comparator|Placebo|Placebo for NPC-01
3209630|NCT01129089|Experimental|LNS-PLW|There will be 48 pregnant or lactating women (PLW) in this arm. They will be randomized to receive cumin flavored LNS-PLW or LNS-PLW with no added flavor on day 2. On day 3, the PLW getting a test-dose of cumin flavored LNS-PLW on day 2 will receive LNS-PLW with no added flavor and the PLW getting a test-dose of LNS-PLW with no added flavor on day 2 will receive cumin flavored LNS-PLW.
3209631|NCT01129089|Experimental|LNS-Child|There will be 48 infant and young children(IYC) in this arm. They will be randomized to receive cardamom flavored LNS-Child or LNS-Child with no added flavor on day 2. On day 3, the IYC getting a test-dose of LNS-Child with no added flavor on day 2 will receive cardamom flavored LNS-Child and the IYC getting a test-dose of cardamom flavored LNS-Child on day 2 will receive LNS-Child with no added flavor.
3209632|NCT01129089|Experimental|MNP-Child|There will be 48 infant and young children(IYC) in this arm. They will receive MNP on day 2 and day 3.
3209633|NCT01129063|Experimental|Sequence clopidogrel 75 / 75 / 300 mg|"Period 1: clopidogrel 75 mg single dose~Period 2: clopidogrel 75 mg single dose~Period 3: clopidogrel 300 mg single dose~Each intake is at around 8:00 AM under fasted conditions."
3209634|NCT01129050|Experimental|Low-dose Flaxseed Oil|2.2 g ALA (alpha-linolenic acid) per day
3209635|NCT01129050|Experimental|High-dose Flaxseed Oil|6.6 g ALA (alpha-linolenic acid) per day
3209636|NCT01129050|Experimental|Low-dose Fish Oil|1.2 g EPA+DHA (700 mg EPA and 500 mg DHA) per day
3209637|NCT01129050|Experimental|High-dose Fish Oil|3.6 g EPA+DHA (2.1 g EPA and 1.5 g DHA) per day
3209638|NCT01129050|Placebo Comparator|Placebo|4 g or 6 g soybean oil per day
3209639|NCT01129037|Other|Goal directed fluid management|
3209640|NCT01129024|Experimental|S-888711 0.5 mg tablet|S-888711 0.5 mg tablet q.d.
3209641|NCT01129011|Experimental|PN400|Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily
3209642|NCT01129011|Active Comparator|Naproxen|Naproxen 500 mg dosed twice daily
3209643|NCT01128998|Experimental|S-1 and Sorafenib|
3209644|NCT01128985|Experimental|001|Canagliflozin 50 mg 50 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
3209645|NCT01128985|Experimental|002|Canagliflozin 100 mg 100 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
3209646|NCT01128985|Experimental|003|Canagliflozin 300 mg 300 mg capsule once daily for 7 consecutive days from Day 1 to Day 7.
3209647|NCT01128985|Placebo Comparator|004|Placebo matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
3209648|NCT01128972|Experimental|Test Dentifrice + Test Mouth Rinse (MR)|Test fluoride dentifrice and test fluoride MR
3209649|NCT01128972|Experimental|Test Dentifrice + Sterile Water Rinse|Test fluoride dentifrice and sterile water rinse
3209650|NCT01128972|Experimental|Placebo Dentifrice + Test MR|Placebo dentifrice and test fluoride rinse
3209651|NCT01128972|Active Comparator|Reference Dentifrice + Sterile Water Rinse|Marketed fluoride dentifrice with sterile water rinse
3209652|NCT01128972|Placebo Comparator|Placebo Dentifrice + Sterile Water Rinse|Placebo dentifrice and sterile water rinse
3209653|NCT01128959|Experimental|Intravenous Carbamazepine (IV CBZ)|
3209654|NCT01128946|Experimental|Fluoride Toothpaste 1|Fluoride toothpaste containing sodium fluoride (NaF)
3209655|NCT01128946|Experimental|Fluoride Toothpaste 2|Fluoride toothpaste containing stannous fluoride (SnF) and NaF.
3209656|NCT01128946|Experimental|Fluoride Toothpaste 3|Fluoride toothpaste containing sodium monofluorophosphate (NaMFP) and NaF.
3209657|NCT01128946|Active Comparator|Reference Dentifrice|Low fluoride toothpaste containing NaF
3209658|NCT01128933|Experimental|Hypertensive patients|Hypertensive patients with at least moderate renal artery stenosis
3209659|NCT01128920|Experimental|Skin and Needle Hygiene Intervention|
3209660|NCT01128920|Experimental|Assessment-Only Condition|
3209661|NCT01128907||1|Hematological neutropenic patients at high risk of Invasive Aspergillosis with persistent fever and an opportunist infection suspicion.
3209662|NCT01128907||2|Patients without hematological illness and without Invasive Aspergillosis suspicion.
3209663|NCT01128894|Experimental|albiglutide|weekly albiglutide subcutaneous injection
3209664|NCT01128894|Active Comparator|liraglutide|liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
3209665|NCT01128881|Experimental|IMMUNINE|
3209666|NCT01128868|Active Comparator|Proximal femur locking plate|Treatment of reverse oblique intertrochanteric or subtrochanteric fractures with a Proximal Femur Locking Compression Plate (PF-LCP, PF-LCP Hook Plate, PeriLoc)
3209667|NCT01128868|Other|Trochanteric nail|Treatment of reverse oblique intertrochanteric or subtrochanteric fractures with Trochanteric Nails (PFNA, TFN, GN)
3209668|NCT01128855|Experimental|Cohort 1|3 mg/kg GSK2402968 / placebo
3209669|NCT01128855|Experimental|Cohort 2|6 mg/kg GSK2402968 / placebo
3209670|NCT01128855|Experimental|Cohort 3|9 mg/kg GSK2402968 / placebo
3209671|NCT01128855|Experimental|Cohort 4|12 mg/kg GSK2402968 / placebo
3209672|NCT01128842|Experimental|Neratinib + Capecitabine|Neratinib + Capecitabine
3209673|NCT01128829|Experimental|water-sucralose|"Subjects in this group drank water 10 min before drinking a glucose load on their first oral glucose tolerance test (OGTT) and drank sucralose 10 min before drinking a glucose load on their second OGTT. The two OGTT were separated on average by 1 week (i.e. washout was approximately 1 week)."
3209674|NCT01128829|Experimental|sucralose-water|"Subjects in this group drank sucralose 10 min before drinking a glucose load on their first OGTT and drank water 10 min before drinking a glucose load on their second OGTT. The two OGTT were separated on average by 1 week (i.e. washout was approximately 1 week)."
3209675|NCT01128816|No Intervention|Standard HF therapy|Subjects will receive optimal standard therapy for heart failure conforming to national guidelines as determined by the referring cardiologist
3209676|NCT01128816|Active Comparator|Standard therapy for HF + ASV|Subjects will receive treatment with Adaptive Servo Ventilation in addition to optimal standard therapy for heart failure conforming to national guidelines, as determined by the referring cardiologist
3209677|NCT01128790|Experimental|remote ischemic preconditioning|4 cycles of 5 mins upper limb ischemia induced by blood pressure cuff inflation 20mmHg above systolic blood pressure
3209678|NCT01128790|Sham Comparator|Sham control|4 x 5 mins of upper limb blood pressure cuff inflation to 10mmHg (non-occlusive)
3209679|NCT01128777|Experimental|Cognitive behavioral group therapy|Cognitive behavioral group therapy for adolescents and a parallel group for parents
3209680|NCT01128777|Active Comparator|Nondirective supportive group therapy|Nondirective supportive group therapy for adolescents and a parallel group for parents
3209681|NCT01128764|Experimental|CBT for depression and healthy lifestyle plus exercise|CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
3209682|NCT01128764|Active Comparator|CBT for depression|CBT for depression only
3209683|NCT01128751|Active Comparator|Embol-X|Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
3209684|NCT01128751|Active Comparator|DBT dynamic bubble trap|Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
3209685|NCT01128751|No Intervention|Control group|In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
3209686|NCT01128738|Active Comparator|GSK1358820|Onabotulinum toxin type A
3209687|NCT01128738|Placebo Comparator|Placebo|Placebo
3209688|NCT01128725|Other|Group Alzhamyd|"The patients coming in consultation for a mnésique complaint will see each other offering the study. During a consultation, the following balance sheet will be accomplished :clinical Maintenance, collection of records and used treatments~psycho-behaviour Valuation through Neuropsychiatric Inventory (NPI) and through Inventory Apathy~Valuation of self-government in the activities of daily life (IADL). Further to this balance sheet, it is habitually offered on the subjects of advice (principally centered on the proposals of use of external helps for instance book memo, agenda and internal assistants medium notes-techniques and associations to keep information) and a new consultation 1 year afterwards including the same balance sheet.~In a supplementary way in this clinical valuation, a blood sample will be accomplished at the time of inclusion and 12 months afterwards."
3209689|NCT01128712|Other|Group 1|Pregabalin (150mg/day)
3209690|NCT01128712|Other|Group 2|Pregabalin (450mg/day)
3209691|NCT01128699|Experimental|ISA+AVI|injection of intraoperative subconjunctival Avastin as an adjunct to Ahmed valve implant
3209692|NCT01128699|Active Comparator|AVI|Ahmed valve implant
3209693|NCT01128686||CHB patients who started LAM as an initial antiviral treatment|CHB patients who started LAM as an initial antiviral treatment at least 5 years prior to this investigation
3209694|NCT01128673||Body Cooled|Infants undergoing total body cooling for HIE
3209695|NCT01128673||HIE,Selective Head Cooled|Infants undergoing head cooling for HIE
3209696|NCT01128660||RSD-citizens|Residents of Southern Denmark, who filed more than 9 prescriptions during 2009.
3209697|NCT01128634|Other|GSK573719|GSK573719
3209698|NCT01128634|Other|GSK573719/GW642444|GSK573719/GW642444
3209699|NCT01128621|Other|Part A|Part A is open label, in T2DM subjects on established metformin monotherapy. Subjects will receive a single dose of GSK1292263 with food. This will permit a comparison of GSK1292263 exposures in this cohort with those observed in study GPR111598 in which T2DM subjects were drug naïve or washed off prior anti-diabetic medications.
3209700|NCT01128621|Placebo Comparator|Part B - PLA|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
3209701|NCT01128621|Active Comparator|Part B - Active|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
3209702|NCT01128621|Active Comparator|Part B - Sitagliptin|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
3209703|NCT01128608|Active Comparator|Control Group - Healthy Subjects|Healthy volunteers with normal EGD.
3209704|NCT01128608|Active Comparator|NERD Group|Subjects with NERD. Heartburn symp x2 wk for 3 months. Normal EGD and abnormal 24 hour pH.
3209705|NCT01128595|Active Comparator|ICS|
3209706|NCT01128595|Active Comparator|ICS/LABA|
3209707|NCT01128595|Active Comparator|LABA|
3209708|NCT01128595|Placebo Comparator|Placebo|
3209709|NCT01128582|Active Comparator|Rozerem|Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
3209710|NCT01128582|Placebo Comparator|placebo|Comparing the effect of Rozerem vs. placebo on GERD symptomatology
3209711|NCT01128569|Placebo Comparator|Placebo|Placebo Inhaler
3209712|NCT01128569|Active Comparator|inhaled corticosteroid(ICS)/long acting bronchodilator (LABA)|ICS/LABA inhaler
3209713|NCT01128569|Active Comparator|ICS|ICS inhaler
3209714|NCT01128556|Experimental|Bepreve|topical ocular treatment as indicated
3209715|NCT01128543|Active Comparator|lapatinib 1250mg|Patients will receive 1250mg lapatinib once a day for 24 weeks.
3209716|NCT01128543|Active Comparator|Vinorelbine 25mg/sqm|Patients will receive vinorelbine 25mg/sqm IV Day 1 and Day 8, every 3 week for 24 weeks.
3209717|NCT01128530|Experimental|JNJ-32729463|JNJ-32729463 250 mg tablet and matching linezolid placebo twice daily
3209718|NCT01128530|Active Comparator|linezolid|linezolid 600 mg tablet and matching JNJ-32729463 placebo twice daily
3209719|NCT01128517|Experimental|Bahavioral|Education about complementary food given to mothers
3209720|NCT01128478|Other|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
3209721|NCT01128478|No Intervention|Nil-per-mouth regimen|Conventional management
3209722|NCT01128452|Placebo Comparator|Placebo|Placebo
3209723|NCT01128452|Experimental|EVT 101|EVT 101
3209724|NCT01128439||1|
3209726|NCT01128413|Experimental|Fluid Optimization (FO)|"Cheetah NICOM® (non-invasive cardiac output monitoring) Passive Leg Raise Testing (PLRT) that demonstrates a >/= 15% change in stroke volume index (SVI) or cardiac index (CI) will receive a 500ml normal saline bolus. NICOM® PLRT with SVI or CI <15% will receive a saline lock. If bolused, NICOM® PLRT will be performed within 10 minutes after the bolus with the decision to re-bolus or saline lock according to repeated NICOM® PLRT measurements. If saline locked, NICOM® PLRT will be performed every 30 minutes with the decision to re-bolus or saline lock according to repeated NICOM® PLRT measurements.~Additionally, USCOM®, IVC Ultrasound collapsibility, CURVES Questionnaire, and repeat lactate measurements will be performed."
3209727|NCT01128413|Active Comparator|Routine Care (RC)|Patients randomized to receive routine ED care will receive IV fluid administration per the treating clinicians discretion. The Cheetah NICOM®PLRT, USCOM®, IVC Ultrasound collapsibility, and CURVES Questionnaire will be performed and repeat lactate measurements will only be revealed to the routine care arm if they are used as part of the provider's routine care.
3209728|NCT01128400||rs1761667- AA genotype|subjects carrying the CD36 genotype rs1761667, i.e. a Single Nucleotide Polymorphism that significantly reduces CD36 level and has a minor allele frequency of 38-48%.
3209729|NCT01128400||rs1761667-GG genotype|subjects who are homozygous of CD36 genotype rs1761667-G allele.
3209730|NCT01128400||rs1761667-AG genotype|Heterozygous of CD36 gene rs1761667-A genotype.
3209731|NCT01128387|Experimental|Dose Level -1|Panitumumab/Cisplatin/Fluorouracil and Radiation therapy 1.5mg/kg Panitumumab, 60mg/m2 cisplatin, 750mg/m2 5FU (Fluorouracil)
3209732|NCT01128387|Experimental|Dose Level 1|Panitumumab/Cisplatin/Fluorouracil and Radiation therapy 1.5mg/kg Panitumumab, 80mg/m2 cisplatin, 1000mg/m2 5FU (Fluorouracil)
3209733|NCT01128374|Experimental|intervention|Therapy
3209734|NCT01128361|Experimental|Aerobic Exercise|
3209735|NCT01128361|Active Comparator|Stretching|
3209736|NCT01128348|Experimental|patient advocate|"Patient advocate works with patient before, during, and after a visit to asthma doctor.~Patient receives video of asthma education materials"
3209737|NCT01128348|Active Comparator|asthma education|Patient receives video of asthma education materials
3209738|NCT01128335|Active Comparator|Arm 1|MMF(1000mg bid) + tacrolimus + standard of care medications
3209739|NCT01128335|Experimental|Arm 2|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
3209740|NCT01128335|Experimental|Arm 3|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
3209741|NCT01128335|Experimental|Arm 4|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
3209742|NCT01128322|Experimental|S-Amlodipine 2.5mg + Telmisartan 40mg|
3209743|NCT01128322|Experimental|S-Amlodipine 2.5mg + Telmisartan 80mg|
3209744|NCT01128322|Experimental|S-Amlodipine 5mg + Telmisartan 40mg|
3209745|NCT01128322|Experimental|S-Amlodipine 5mg + Telmisartan 80mg|
3209746|NCT01128322|Active Comparator|S-Amlodipine 2.5mg|
3209747|NCT01128322|Active Comparator|S-Amlodipine 5mg|
3209748|NCT01128322|Active Comparator|Telmisartan 40mg|
3209749|NCT01128322|Active Comparator|Telmisartan 80mg|
3209750|NCT01128322|Placebo Comparator|Placebo|
3209751|NCT01128309|Experimental|Stress Reduction Intervention|Stress Reduction Intervention
3209752|NCT01128309|Active Comparator|Active Control Condition|
3209753|NCT01128296|Experimental|Hydroxychloroquine + Gemcitabine (HcGc)|Hydroxychloroquine orally twice daily in combination with gemcitabine for 31 days prior to surgical resection
3209754|NCT01128283||Sepsis|Patients with severe sepsis
3209755|NCT01128283||Non-infected|ICU patients without evidence of infection
3209756|NCT01128270|Experimental|1A: Chloral Hydrate and DCA: Env|Subjects consume Chloral Hydrate 1.5ug/kg by mouth for 5 nights. On the 6th day they consume DCA 2.5ug/kg by mouth and have blood samples drawn. (Period 1)
3209757|NCT01128270|Experimental|1B: Chloral Hydrate Env dose|Drug Study Subjects are admitted to the clinical research unit and receive 1.5 ug/kg (environmental dose) of Chloral Hydrate for 5 nights. Pharmacokinetics are done on days 1 and day 5. (Period 2)
3209758|NCT01128270|Experimental|2A: Chloral Hydrate and DCA therapeutic|Drug Study Subjects are admitted to the clinical research center and receive a clinical dose of Chloral Hydrate for 5 nights (25mg/kg). On day 6 they are given a clinical dose (25mg/kg)of Dichloroacetate. (Period 3)
3209759|NCT01128270|Experimental|2B: Chloral Hydrate Therapeutic|Subjects are given 25 mg/kg of Chloral Hydrate for five nights. Pharmacokinetics are done on days 1 and 5. (Period 4)
3209760|NCT01128257||1|
3209761|NCT01128257||2|
3209762|NCT01128244|Experimental|Vitamin B6 Effects in OC Users|"All subjects will be given an infusion of labeled serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.~The results from analysis of vitamin B6 and these amino acids in blood will provide us with specific measurements of the rates of two aspects of metabolism (Primary Outcomes 1 and 2) and specific measurements of vitamin B6 nutritional status (Primary Outcomes 3 and 4)."
3209763|NCT01128218|Experimental|Tumor fluorescence|A single arm in this open-label study where all patients are treated with the study drug - 5-aminolevulinic acid. Areas of the brain that are fluorescent and areas that are not fluorescent are evaluated for presence of tumor cells
3209764|NCT01128205||Diagnosed for 6 months or more|
3209765|NCT01128192|Experimental|Pasireotide 600 µg sc bid|n=19. Pasireotide 600 µg sc bid
3209766|NCT01128192|Experimental|Pasireotide 900 µg sc bid|n=19. Pasireotide 900 µg sc bid
3209767|NCT01128192|Experimental|Pasireotide 1200 µg sc bid|n=7. Due to increased severity of gastro-intestinal side effects, this arm was discontinued. These participants were only included in the safety analysis.
3209768|NCT01128179|Experimental|Lanthanum carbonate|
3209769|NCT01128179|Placebo Comparator|Placebo|
3209770|NCT01128166||Patients implanted with a CRT-D (Cardiac Resynch. Therapy)|
3209771|NCT01128153|Experimental|Saxagliptin 5 mg once daily|
3209772|NCT01128153|Placebo Comparator|Placebo once daily|
3209773|NCT01128140|Experimental|Motivational Enhancement Therapy|
3209774|NCT01128140|Active Comparator|Education|
3210053|NCT01126073|Placebo Comparator|placebo|
3209775|NCT01128127|Experimental|Multifaceted intervention 1|psycho-educational workshop + audit-feedback + computer-based clinical decision support system (CCDSS) + usual intervention
3209776|NCT01128127|Experimental|Multifaceted intervention 2|audit-feedback + computer-based clinical decision support system (CCDSS) + usual intervention
3209777|NCT01128127|Active Comparator|Control|usual intervention
3209778|NCT01128114|Experimental|Quetiapine XR|Quetiapine fumarate (Seroquel XR)
3209779|NCT01128101|Experimental|Spironolactone|The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
3209780|NCT01128088||PCA and Volulyte|
3209781|NCT01128088||PCA and Hartmann's|
3209782|NCT01128088||Spinal and Volulyte|
3209783|NCT01128088||Spinal and Hartmann's|
3209784|NCT01128075||naïve subjects|Cohort of RMS patients who initiate disease modifying treatment with Rebif®
3209785|NCT01128075||non-naïve subjects|Cohort of RMS patients who initiate treatment with Rebif® after having failed therapy with other disease modifying drugs on the basis of lack of efficacy, compliance, safety, tolerability or convenience, as per clinical judgment of study investigator
3209786|NCT01128049|Active Comparator|Normal Patient Population|Non-Dry Eye patient population (intervention remains the same across all arms)
3209787|NCT01128049|Active Comparator|MGD Patient Population|Meibomium Gland Dysfunction population(intervention remains the same across all arms)
3209788|NCT01128049|Active Comparator|ADDE Population|Aqueous Deficient Dry Eye population(intervention remains the same across all arms)
3209789|NCT01128036||CHF, cardomyopathy|Patients with signs of poor peripheral perfusion due to cardiomyopathy or congestive heart failure
3209790|NCT01128023||PET Rb-82 perfusion imaging|Patients diagnosed with or suspected coronary artery disease requiring evaluation and/or risk stratification will undergo PET Rb-82 perfusion imaging.
3209791|NCT01128023||SPECT perfusion imaging|Patients diagnosed with or suspected coronary artery disease who have undergone SPECT myocardial perfusion imaging.
3209792|NCT01128010||alcoholic liver disease|alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution
3209793|NCT01128010||controls|Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination
3209794|NCT01127997||study A|post-breakfast meal tolerance test + post-lunch meal tolerance test
3209795|NCT01127997||study B|fasting + post-lunch meal tolerance test
3209796|NCT01127984|Experimental|treatment with tissucol|patients treated with tissucol, local application in the pocket of PM / ICD
3209797|NCT01127984|Active Comparator|vacuum drainage system|patients treated with application of vacuum drainage system.
3209798|NCT01127958|Active Comparator|SeQuent Please|PCI with drug-eluting balloon
3209799|NCT01127958|Active Comparator|Xience Prime|PCI with a drug-eluting stent
3209800|NCT01127945|Experimental|atorvastatin 80mg|
3209801|NCT01127945|Active Comparator|conventional therapy (for heart failure)|
3209802|NCT01127932|Experimental|CBT for suicide|
3209803|NCT01127932|Active Comparator|Enhanced care control group|This group is designed to be an active control which provides detailed information about substance use, suicide risk, and depression without providing any CBT or other specific therapy.
3209804|NCT01127919||Low Commitment|Group 1 participants will take a 1-credit hour course that involves exercise training only.
3209805|NCT01127919||High Commitment|Group 2 participants will take a 3-credit hour course that involves exercise training plus an online cognitive component that provides information on fitness and health topics and includes quizzes and other written course work
3209806|NCT01127919||Non-Exercise|Group 3 participants will take the cognitive component of the formal course but will not partake in the formalized exercise program for a period of 35 weeks.
3209807|NCT01127906|Other|Randomized cross-over sequence|Randomized unbalanced sequence of incomplete block design with replicates within sequence
3209808|NCT01127893|Experimental|Tanezumab 10 mg|
3209809|NCT01127893|Experimental|Tanezumab 5 mg|
3209810|NCT01127893|Experimental|Tanezumab 2.5 mg|
3209811|NCT01127880|Active Comparator|Ancef 1 gm or Clindamycin 300 mg|Group A will receive Ancef 1gm or Clindamycin 300mg if penicillin or bet-lactam allergy exists
3209812|NCT01127880|Placebo Comparator|Placebo|Group B will receive .9% Normal Saline as a placebo.
3209813|NCT01127854||Cases|
3209814|NCT01127854||Controls|
3209815|NCT01127841|Experimental|Rituximab and Bendamustine|
3209816|NCT01127828|Active Comparator|Probiotic yoghurt (Cultura)|Cultura yoghurt containing: L bulgaricus, S thermophilus
3209817|NCT01127828|Placebo Comparator|Yoghurt with no probiotic|
3209818|NCT01127789|Experimental|non-invasive brain stimulation|
3209819|NCT01127776|Experimental|Apos System|
3209820|NCT01127776|Placebo Comparator|CONTROL|
3209821|NCT01127763|Experimental|RAD001+carboplatin|Carboplatin (starting dose was initially AUC 6, later decreased to AUC 5, then AUC 4) every 3 weeks as IV infusion and RAD001 as 5 mg pill each day until disease progression or unacceptable toxicity.
3209822|NCT01127750|Experimental|FTY720|
3209823|NCT01127737|Placebo Comparator|Control|
3209824|NCT01127737|Active Comparator|Intervention|Educational intervention consisting of a mnemonic and a workbook used by kidney transplant recipients (KTRs) to assist with early detection of SCCs.
3209825|NCT01127724|Experimental|group 1- 1000 mcg|Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months
3209826|NCT01127724|Experimental|Group 2- 100 mcg|Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months
3209827|NCT01127724|Experimental|group 3- 2000 mcg|Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
3209828|NCT01127672|Active Comparator|control|corticosteroid injection into the origin of the plantar fascia
3209829|NCT01127672|Active Comparator|experimental|platelet rich plasma injection into the origin of the plantar fascia
3209830|NCT01127659|Active Comparator|diabetes with HH-active|Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.
3209831|NCT01127659|No Intervention|diabetes with normal testosterone|Eugonadal subjects with diabetes. They will not be treated
3209832|NCT01127659|Active Comparator|obese with HH-active|Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.
3209833|NCT01127659|No Intervention|obese with normal testosterone|Eugonadal non-diabetic obese subjects. They will not be treated
3209834|NCT01127659|Placebo Comparator|Diabetes with HH-placebo|Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to placebo.
3209835|NCT01127659|Placebo Comparator|Obese with HH-placebo|Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to placebo.
3209836|NCT01127646|Experimental|Atomoxetine|Participants received 25-80 milligrams (mg) of atomoxetine orally, once daily during the run-in period for up to 7 days. The run-in period was followed by the 4-week on/off period in which participants received 25-80 mg of atomoxetine orally, once daily for 4 weeks, except for the off-days, where participants received 1 or 2 oral once daily placebo doses per week, with 6 nonconsecutive, double-blinded placebo doses in total over the 4-week on/off period. The on/off period was followed by a run-out period in which participants received 25-80 mg of atomoxetine orally, once daily for 1-5 days.
3209837|NCT01127646|Active Comparator|Osmotic-release oral system methylphenidate|Participants received 18-54 mg of osmotic-release oral system (OROS) methylphenidate orally, once daily during the run-in period for up to 7 days. The run-in period was followed by the 4-week on/off period in which participants received 18-54 mg of OROS methylphenidate orally, once daily for 4 weeks, except for the off-days, where participants received 1 or 2 oral once daily placebo doses per week, with 6 nonconsecutive, double-blinded placebo doses in total over the 4-week on/off period. The on/off period was followed by a run-out period in which participants received 18-54 mg of OROS methylphenidate orally, once daily for 1-5 days.
3209838|NCT01127633|Experimental|Solanezumab|
3209839|NCT01127633|Placebo Comparator|Placebo|
3209840|NCT01127620|Experimental|Bilastine|20 mg encapsulated tablets
3209841|NCT01127620|Active Comparator|Cetirizine|10 mg encapsulated tablets
3209842|NCT01127620|Placebo Comparator|Placebo|Encapsulated tablets
3209843|NCT01127607|Experimental|stimulant medication|blinded lisdexamfetamine at the optimal dose for the individual participant as previously determined during the med optimization portion of the study
3209844|NCT01127607|Placebo Comparator|placebo pill|placebo medication identical in appearance to active med
3209845|NCT01127581|Experimental|MVI 200|MVI 200 mcg vaginal insert
3209846|NCT01127581|Active Comparator|Dinoprostone Vaginal Insert (DVI)|10 mg Dinoprostone vaginal insert
3209847|NCT01127568|Experimental|Propranolol|Propranolol is a beta-blocker (blocking beta- adrenergic receptors) that reduces sympathetic activity. It is a well-known drug typically prescribed to individuals suffering from hypertension, tachycardia, cardiac arrhythmia, tremors, thyroid disease, or migraine.
3209848|NCT01127568|Placebo Comparator|Placebo|The placebo is an inactive capsule that will have no medication effect, but looks exactly like the medication.
3209849|NCT01127542|Experimental|Lenalidomide for early stage poor prognosis CLL|
3209850|NCT01127529||Subjects with severe congenital protein C deficiency|Registry subjects will be identified by working with Hemophilia Treatment Centers and Thrombosis Centers known to have subjects with severe congenital protein C deficiency, as well as by working with centers that use Ceprotin in emergency care situations.
3209851|NCT01127503|Experimental|Metyrosine|
3209852|NCT01127503|Placebo Comparator|Placebo|
3209853|NCT01127477|Experimental|1|
3209854|NCT01127464|Experimental|.3 dose level of DCVax -001|.3 dose level of DCVax plus fixed dose of 1.6 ml Poly ICLC
3209855|NCT01127464|Experimental|1 mg dose level of DCVax -001|1 mg dose level of DCVax -001 plus 1.6 ml of poly ICLC
3209856|NCT01127464|Experimental|3 mg dose level of DCVax-001|3 mg dose level of DCVax-001 plus poly ICLC
3209857|NCT01127464|Placebo Comparator|Placebo|sterile saline
3209858|NCT01127464|Experimental|poly-ICLC alone|1.6 mg of poly-ICLC alone
3209859|NCT01127451|Experimental|Denileukin diftitox|12 mcg/kg/day on Days 1 through 4 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks)
3209860|NCT01127438|Active Comparator|fospropofol disodium Subgroup 1 Lower Dose|
3209861|NCT01127438|Active Comparator|: fospropofol disodium Subgroup 1 Approved Dose|
3209862|NCT01127438|Active Comparator|fospropofol disodium Subgroup 2 Lower Dose|
3209863|NCT01127438|Active Comparator|fospropofol disodium Subgroup 2 Approved Dose|
3209864|NCT01127438|Active Comparator|fospropofol disodium Subgroup 3 Lower Dose|
3209865|NCT01127438|Active Comparator|fospropofol disodium Subgroup 3 Approved Dose|
3209866|NCT01127425|Active Comparator|1|Intervention: Surgery: laparoscopic sigmoid resection without fast track postoperative care
3209867|NCT01127425|Active Comparator|2|Intervention: Surgery: conventional (open) sigmoid resection without fast track postoperative care
3209868|NCT01127412|Active Comparator|Physical activity stimulating program|Advices to stimulate motor activity and motor development at the age of two weeks, two months, four months, eight months and eleven months
3209869|NCT01127412|No Intervention|Control|
3209870|NCT01127399||Bariatric, nonasthma|Participants that will have had a bariatric surgery but do not have asthma.
3209871|NCT01127399||Bariatric, asthma|Participants that will have had a bariatric surgery and have been physician diagnosed with asthma prior to the surgery.
3209872|NCT01127399||Control, nonasthma|Healthy participants that who will not be getting a bariatric surgery and who do not have asthma.
3209873|NCT01127399||Control, asthma|Healthy participants that will not be having a bariatric surgery but do have asthma.
3209874|NCT01127386|Experimental|fix dose lenalidomide 25mg, basic cachexia management|dose reduction according to toxicity possible
3209875|NCT01127386|Experimental|CRP-response guided lenalidomide, basic cachexia management|start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
3209876|NCT01127386|Experimental|placebo|to generate data about basic cachexia management, no direct comparator for treatment arms efficacy
3209877|NCT01127373|Experimental|radiation therapy via multi-beam IMRT|This is a single-arm feasibility study of multi-beam IMRT with daily set-up verification in the treatment of women with node-positive breast cancer who will receive radiation to the breast/chest wall and regional lymph nodes, including the internal mammary lymph nodes.
3210241|NCT01124786|Experimental|CO-1.01|
3209878|NCT01127360|Experimental|Bevacizumab|Bevacizumab 1,25 mg, intravitreal injections every 4th to 12th week
3209879|NCT01127360|Active Comparator|Ranibizumab|Ranibizumab 0,5 mg, intravitreal injection, every 4th to 12th week
3209880|NCT01127334||Systolic Heart Failure, Dyssynchrony, CRT-D|Patients with systolic heart failure and dyssynchrony that have a CRT-D that have not been optimized in the past 3 months.
3209881|NCT01127321|Placebo Comparator|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
3209882|NCT01127321|Experimental|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
3209883|NCT01127321|Experimental|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
3209884|NCT01127321|Experimental|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
3209885|NCT01127321|Experimental|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
3209886|NCT01127308|Experimental|[14C]Ertugliflozin|Single dose - oral dosing suspension
3209887|NCT01127295|Other|Tamoxifen, Anastrozole, letrozole, Exemestane|Current hormonotherapy treatment in hormono dependent breast cancer
3209888|NCT01127282|Experimental|Vitamin|Vitamin(vitamin A 15mg,C 500mg,E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics
3209889|NCT01127282|Placebo Comparator|Control|Placebo(digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
3209890|NCT01127269|Experimental|Insulin Glargine|"Patients will receive insulin glargine titrated based on standard of care as recommended by the ADA/EASD Consensus Algorithm. Step 1: insulin glargine initiation regimen for insulin naive patients/ Switch to insulin glargine for patient already treated with basal insulin.~Step 2: the insulin dosage of patients will be titrated according to the ADA/EASD Consensus Algorithm."
3209891|NCT01127256|Experimental|1|
3209892|NCT01127256|Active Comparator|2|
3209893|NCT01127243|Active Comparator|inpatient LSH|LSH means laparoscopic supracervical hysterectomy
3209894|NCT01127243|Experimental|Day-case LSH|LSH means laparoscopic supracervical hysterectomy
3209895|NCT01127230||Liposuction patients|Patients who already opted and are scheduled for liposuction.
3209896|NCT01127217|Experimental|amlodipine/losartan|
3209897|NCT01127217|Active Comparator|amlodipine|
3209898|NCT01127204|Active Comparator|arm 1 (reference strategy)|AZT-3TC-LPV/r twice a day
3209899|NCT01127204|Experimental|arm 2 (simplification strategy)|ABC-3TC-EFV once a day
3209900|NCT01127191||Military|
3209901|NCT01127178|Experimental|E7016 + TMZ|
3209902|NCT01127165|Experimental|Zonisamide Low Dose Group|
3209903|NCT01127165|Experimental|Zonisamide High Dose group|
3209904|NCT01127152|Active Comparator|Automatic relays|Automatic relays of noradrenalin using intensive basis.
3209905|NCT01127152|Active Comparator|Manual relays|Relays of noradrenalin using manual method
3209906|NCT01127139||Czech patients with essential hypertension|Czech hypertensive patients (women and men) with systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg who can be treated with fixed-combination Tarka®.
3209907|NCT01127126|Active Comparator|Bryophyllum|muscle relaxing substance
3209908|NCT01127126|Placebo Comparator|Placebo|control group postmenopausal women suffering from overactive bladder
3209909|NCT01127113|Active Comparator|SPIO-labelled mononuclear cells|
3209910|NCT01127113|Placebo Comparator|Unlabelled mononuclear cells|
3209911|NCT01127113|Active Comparator|SPIO alone|
3209912|NCT01127100|Experimental|Transdermal fentany matrix|Transdermal fentanyl matrix is second-line medication on the neuropathic pain but gabapentin is the first-line medication. So, transdermal fentanyl matrix is experimental arm and gabapentin is active comparator arm.
3209913|NCT01127100|Active Comparator|gabapentin|Gabapentin is the first-line medication in neuropathic pain. So, gabapentin is active comparator in this study and transdermal fentanyl matrix is experimental.
3209914|NCT01127087|Experimental|RYGB CaOx Stone Formers|"Subjects with enteric hyperoxaluria after Roux-en-Y Gastric Bypass (RYGB).~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
3209915|NCT01127087|Experimental|Idiopathic Hyperoxaluria CaOx Stone Formers|"Subjects with idiopathic hyperoxaluria.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
3209916|NCT01127074|Experimental|KS24.22-vaccination|"The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).~Immediately before administration, KS24.22 cells were thawed and lethally irradiated. KS24.22 cells were adjusted to 10E7/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites."
3209917|NCT01127061|Experimental|Exercise Training|Participants in the exercise group will undergo 4 months of training, 4-7 days per week with a minimum of 20 minutes per day. The protocol will be custom designed in consultation with an exercise physiologist based on data from the initial cardiopulmonary stress test. Exercise regimen will begin at a low level of intensity then increase in duration and training intensity to a goal of 60 minutes a day and 80% of the heart rate reserve during the 1st month of the study protocol with maintenance of the program thereafter. There is no need to come to a participating site for actually doing the exercise regimen. No strength training or burst activity will be prescribed and all activities will fall well within the recommended national guidelines for recreational exercise.
3209918|NCT01127061|No Intervention|Usual Activity|Participants in this group are not restricted in their activities. They simply are not guided in their physical activities by the study team. At the end of the 4 month study period, they will also receive an individualized exercise prescription for personal use.
3209919|NCT01127048|Experimental|Prospan Hustenzäpfchen|
3209920|NCT01127048|Placebo Comparator|Placebo|
3209921|NCT01127035|Experimental|SLIT|sublingual immunotherapy biologically standardized
3209922|NCT01127035|Placebo Comparator|placebo|same preparation of SLIT without the allergen
3209923|NCT01127022|Active Comparator|480 mg/d choline intake|480 mg/d choline derived from the diet [380 mg choline/d] plus supplemental choline chloride [100 mg choline/d]
3209924|NCT01127022|Experimental|930 mg/d choline intake|930 mg/d choline derived from the diet [380 mg choline/d] plus supplemental choline chloride [550 mg choline/d]
3209925|NCT01127009|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11; and mitoxantrone IV, etoposide IV over 1 hour, and intermediate-dose cytarabine IV over 6 hours on days 1-6. Treatment continues in the absence of disease progression or unacceptable toxicity.
3209926|NCT01126996||MenC vaccinated healthy children|Children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.
3209927|NCT01126983|Experimental|Non-Suture|No suture will be used to secure the leads. Benzoin and Steri-Strips will be used like in the other two arms.
3209928|NCT01126970|Placebo Comparator|Placebos.|Velneperit Placebo q.d.+ Orlistat Placebo t.i.d.
3209929|NCT01126970|Experimental|Velneperit 400 mg|Velneperit 400 mg q.d.
3209930|NCT01126970|Active Comparator|Orlistat 120 mg|Orlistat 120 mg t.i.d.
3209931|NCT01126970|Experimental|Velneperit 400 mg + Orlistat 120 mg|Velneperit 400 mg q.d.and Orlistat 120 mg t.i.d
3209932|NCT01126957|Experimental|Ketamine|Participants received 0.5-1.5 micrograms/kg Fentanyl, followed 0.5 mg/kg Ketamine infusion, followed by propofol to maintain sedation.
3209933|NCT01126957|Placebo Comparator|Placebo|Participants received 0.5-1.5 micrograms/kg Fentanyl, followed by placebo infusion, followed by propofol to maintain sedation.
3209934|NCT01126944|Experimental|system heart mate II|left ventricular assist device
3209935|NCT01126944|No Intervention|normal medical care|Optimal medical treatment for heart failure according to international guidelines
3209936|NCT01126918|Active Comparator|Brochure Condition|Participants in this condition receive an educational brochure about healthy body image via post-mail.
3209937|NCT01126918|Experimental|Group Condition|Participants in this condition attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
3209938|NCT01126892|Experimental|Nilotinib|
3209939|NCT01126879|Experimental|Arm I|Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
3209940|NCT01126879|Placebo Comparator|Arm II|Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
3209941|NCT01126866|Experimental|preoperative chemotherapy|
3209942|NCT01126853|Experimental|Vaccination|Receipt of up to 3 series of double dose combination hepatitis A/B vaccine (Twinrix)
3209943|NCT01126840||Questionnaire + Telephone Interview|Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete. The phone interview should take 30-45 minutes to complete.
3209944|NCT01126827|Active Comparator|Supportive Psychotherapy|
3209945|NCT01126827|Active Comparator|Mindfulness-Based Cognitive Behavioral Therapy|
3209946|NCT01126814|Experimental|one|
3209947|NCT01126801|Experimental|Estradiol|
3209948|NCT01126801|Placebo Comparator|Placebo control|
3209949|NCT01126788||PADnet + testing|
3209950|NCT01126788||Parks Flo-lab Test|
3209951|NCT01126775||group non-high-risk|
3209952|NCT01126775||group high risk|
3209953|NCT01126762|Experimental|Dietary advice and grocery store card|Dietary advice to consume low mercury, high DHA fish plus a grocery store gift card to support the purchase of fish
3209954|NCT01126762|Experimental|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
3209955|NCT01126762|Placebo Comparator|Control|General dietary advice not focused on fish intake
3209956|NCT01126749|Experimental|E7389 in combination with gemcitabine plus cisplatin|
3209957|NCT01126749|Experimental|gemcitabine plus cisplatin|
3209958|NCT01126736|Experimental|Low Dose E7389 in Combination with Pemetrexed|
3209959|NCT01126736|Active Comparator|Pemetrexed|
3209960|NCT01126736|Experimental|High Dose E7389 in Cominbation with Pemetrexed|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
3209961|NCT01126723|Experimental|Tai Chi group|
3209962|NCT01126723|Active Comparator|Educational Control group|
3209963|NCT01126697|No Intervention|Enhanced standard of care|
3209964|NCT01126697|Active Comparator|Lisinopril|
3209965|NCT01126697|Active Comparator|Coenzyme Q10|
3209966|NCT01126697|Active Comparator|Coenzyme Q10 and Lisinopril|
3209967|NCT01126684|Active Comparator|Atorvastatin|
3209968|NCT01126684|Placebo Comparator|Placebo|
3209969|NCT01126671|Active Comparator|Low Dose Vitamin D|Subjects are randomized to take 200 IU vitamin D3 daily in this arm.
3209970|NCT01126671|Active Comparator|High Dose Vitamin D|Subjects are randomized to take 1000 IU vitamin D3 daily in this arm.
3209971|NCT01126658||All subjects act as their own contral|
3209972|NCT01126645|Other|local ablation group|Local ablation group: Potentially curative treatment of early HCC includes surgical resection and local ablation (RFA, PEI, BT). Recurrence rates after such approaches are reported to amount to 50% at 3 years and 70% at 5 years. Tumor recurrence may be either due to de novo development of new primary tumors or due to intrahepatic (unrecognized) metastases. Prevention of recurrence after local ablation is an important strategy to improve overall survival. So far, adjuvant chemoembolization and chemotherapy have not proven to be effective in preventing recurrences. There is, however, a strong rationale to assume that sorafenib will be of value in the adjuvant treatment of HCC as sorafenib has a dual mechanism of action (inhibition of tumor proliferation and antiangiogenesis) and has proven efficacy in HCC.
3210049|NCT01126099|Placebo Comparator|Placebo|In the double blind phase (12 weeks), study participants will take either prazosin for placebo. For the open label phase (12 weeks), all study participants will take prazosin.
3209973|NCT01126645|Active Comparator|palliative treatment group|"Radioembolization has been reported to be effective in patients with unresectable HCC with preserved liver function from a number of trials. Successful downstaging of disease rendering patients eligible for potentially curative therapies, and even histologically confirmed complete responses of unresectable HCC, have repeatedly been reported providing the rationale to evaluate SIRT+sorafenib in comparison to sorafenib alone.~The impact of cirrhosis as a concomitant disease in most patients with HCC is that it limits the ability of many patients to tolerate chemotherapy and is an independent cause of death in HCC patients. Thus, the historical difficulty in demonstrating an effect of therapy on survival in patients with advanced-stage, unresectable HCC (the majority). A new therapy that is effective in controlling hepatic disease, is less toxic than traditional chemotherapy, and improves the quality of life for patients in the advanced stages of HCC could represent an alternative."
3209974|NCT01126632||Cap Assisted Colonoscopy|Patients receiving colonoscopies where scope is fitted with cap
3209975|NCT01126632||Standard Colonoscopy|Patients receiving standard colonoscopy without the cap on the scope
3209976|NCT01126619||Anti-TNF|Participants with moderate to severe psoriasis who were prescribed an Anti Tumor Necrosis Factor (anti-TNF) agent prior to enrollment according to national approved indications and reimbursement guidelines.
3209977|NCT01126606|Experimental|Group 1|Dermacyd Silver Frutal followed by Dermacyd Silver Frutal+PH_DESYLSTY_FR followed by wash out followed by Glycerine Vegetal Soap Granado Traditional
3209978|NCT01126606|Experimental|Group 2|Glycerine Vegetal Soap Granado Traditional followed by wash out followed by Dermacyd Silver Floral followed by Dermacyd Silver Floral + PH_DESYLSTY_FR
3209979|NCT01126593|Placebo Comparator|Placebo group|The placebo group will receive the same subacromial infusion catheter as the study group.However, the reservoir will be filled with 200cc of 0.9% normal saline.
3209980|NCT01126593|No Intervention|Control group|The control group patients will receive no continuous infusion catheter.
3209981|NCT01126593|Experimental|Study Group|Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The infusion rate will be 4cc per hour.
3209982|NCT01126580|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks~Placebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52"
3209983|NCT01126580|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks~Placebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52"
3209984|NCT01126580|Active Comparator|Metformin|"Metformin: 500 milligrams per day (mg/day), orally, for Week 1; 1000 mg/day, orally, for Week 2; 1500 mg/day, orally, for Week 3; 2000 or at least 1500 mg/day, orally, for Weeks 4 through Week 52~Placebo: subcutaneously (SC), once weekly for 52 weeks"
3209985|NCT01126567||High Sampling Rate|Samples will be obtained at a high rate
3209986|NCT01126567||Low Sampling Rate|Samples will be obtained at a low rate
3209987|NCT01126554||Critically ill patients|
3209988|NCT01126541|Experimental|A|1000 mg IV rituximab
3209989|NCT01126541|Experimental|B|2 x 1000 mg IV rituximab
3209990|NCT01126528|Experimental|Vitamin D3|Vitamin D3 (cholecalciferol)
3209991|NCT01126528|Placebo Comparator|Control|Placebo control group
3209992|NCT01126515||Hyperbaric oxygen|In this open-label feasibility study, all subjects will receive 60 hyperbaric oxygen sessions (100% oxygen, 1.5 atmospheres absolute (atm abs), for 60 minutes), delivered daily, five days per week.
3209993|NCT01126502|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive alvespimycin hydrochloride IV over 60 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3209994|NCT01126476|Active Comparator|small volume strata|12 in small volume strata
3209995|NCT01126476|Active Comparator|large volume strata|12 in large volume strata
3209996|NCT01126463|Experimental|Rhenium Lipiodol|Hepatic Intra-Arterial Administration of radio-active lipiodol.
3209997|NCT01126450|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-28 and cetuximab IV once weekly over 1-2 hours on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3209998|NCT01126437|Experimental|tiotropium 2.5 mcg and placebo|Patients receive one of the active tiotropium arms daily
3209999|NCT01126437|Active Comparator|tiotropium 18 mcg and placebo|Patients receive one of the active tiotropium arms daily
3210000|NCT01126437|Experimental|tiotropium 5 mcg and placebo|Patients receive one of the active tiotropium arms daily
3210001|NCT01126424|Experimental|Solifenacin|Participants received 21 days of treatment with 5 mg solifenacin, in tablet form once a day.
3210002|NCT01126424|Active Comparator|Oxybutynin|Participants received 21 days of treatment with 10 mg oxybutynin (1 x 5 mg twice daily) in capsule form.
3210003|NCT01126424|Placebo Comparator|Placebo|Participants received 21 days of treatment with placebo.
3210004|NCT01126411|No Intervention|control|control group / no immunoadsorption
3210005|NCT01126411|Active Comparator|immunoadsorption|immunoadsorption
3210006|NCT01126398||Ankle / dist. tibia fracture fixation|
3210007|NCT01126385||Transpedicular stabilization|Patients undergoing transpedicular stabilization of the spine
3210008|NCT01126359|Placebo Comparator|Lidocaine then Placebo-Saline|
3210009|NCT01126359|Active Comparator|Placebo-Saline then Lidocaine|
3210010|NCT01126346|Experimental|Arm I|Patients and their caregiver(s) receive a hyperthermic intraperitoneal chemotherapy (HIPEC) orientation with a Survivorship Navigator (SN) over 90 minutes following their initial surgical consult. Patients then receive telephone calls over 20-30 minutes from the SN once weekly for 3 weeks prior to HIPEC. After HIPEC, patients meet with the SN for 20-30 minutes to discuss adjustments and adaptation to the surgery and hospitalization 3-4 days post-HIPEC, biweekly for two weeks and weekly thereafter until hospital discharge. After hospital discharge, patients receive telephone calls from the SN twice monthly for 1 month.
3210050|NCT01126086|Experimental|Mild impairment|Patients with mild hepatic impairment
3210051|NCT01126086|Experimental|Moderate impairment|Patients with moderate impairment
3210011|NCT01126333||Long term Sirolimus or Tacrolimus|"Ths study cohort will consist of participants who successfully completed two years of the original Spare the Nephron (STN) study, a two year prospective multi-center study where participants were assigned to receive either center-specific CNI regimen (assigned at the time of transplantation) or were switched to replace the CNI with Sirolimus therapy.~In this current long-term follow-up study, we will approach patients who previously enrolled in the STN study and offer them the opportunity to enroll to be followed-up for another 3 years. There will be no change in immunosuppression unless clinically indicated. The majority of effort is standard care with every 6 month follow-up appointments.Participants will be required to consent to participate in the three year extension study."
3210012|NCT01126320|Experimental|AnapnoGuard 100|Respiratory guard system during mechanical ventilation
3210013|NCT01126320|Active Comparator|Control|routine mechanical ventilator
3210014|NCT01126307|Active Comparator|verapamil|verapamil 80mg tid
3210015|NCT01126307|Placebo Comparator|placebo sugar pill|placebo tid
3210016|NCT01126294|Experimental|Melatonin 5 mg|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
3210017|NCT01126294|Experimental|Melatonin 10 mg|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
3210018|NCT01126294|Placebo Comparator|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
3210019|NCT01126281|Experimental|Floseal use|
3210020|NCT01126268|Experimental|Retapamulin ointment 1%|
3210021|NCT01126255|Active Comparator|1|Clobetasol propionate 0.05%, topical application, once daily about 2 g, during 12 weeks
3210022|NCT01126255|Experimental|2|Progesterone 8%, topical application, once daily about 2 g, during 12 weeks
3210023|NCT01126242|Experimental|tape|Group I will be treated with non-elastic adhesive tape around the affected ankle, applied by the 'van Unen-technique'. This technique is an alternative for the 'Coumans- technique'. The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity. Taping is a treatment that involves no loss of time, requires no crutches and is not attended with any ultimate impairment of function.
3210024|NCT01126242|Active Comparator|Lace-up brace|The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
3210025|NCT01126242|Active Comparator|Semi rigid brace|A semi-rigid brace, the M-step® from Medi®, will be applied. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
3210026|NCT01126229|Placebo Comparator|Placebo|Dietary Supplement: placebo
3210027|NCT01126229|Experimental|300 mg/d Resveratrol|Dietary Supplement: 300 mg/d Resveratrol
3210028|NCT01126229|Experimental|1000 mg/d Resveratrol|Dietary Supplement: 1000 mg/d Resveratrol
3210029|NCT01126216|Experimental|Reduced RT + Pacitaxel/Cisplatin|63,6 Gy accelerated hyperfractionated radiotherapy with Paclitaxel (20mg/m^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m^2/d) on days 1-4 and 29-32, followed by a salvage operation or neck dissection if there is persisting tumor
3210030|NCT01126216|Active Comparator|Standard RT + 5-Fluorouracil/Cisplatin|70,6 Gy accelerated hyperfractionated radiotherapy with 5-Fluorouracil(600mg/m^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m^2/d) on days 1-5 and 29-33, followed by a salvage operation or neck dissection if there is persisting tumor
3210031|NCT01126203|Experimental|selective laser trabeculoplasty (SLT)|
3210032|NCT01126203|Experimental|Argon laser trabeculoplasty (ALT)|
3210033|NCT01126190|Experimental|Neugranin|
3210034|NCT01126190|Active Comparator|Pegfilgrastim|
3210035|NCT01126177|Placebo Comparator|Placebo|Placebo once daily for 14 days
3210036|NCT01126177|Experimental|SNG001|
3210037|NCT01126164|Experimental|parent handbook|parent handbook
3210038|NCT01126164|Experimental|peer basics|peer delivered basics
3210039|NCT01126164|Experimental|parent handbook and peer basics|parent handbook and peer basics
3210040|NCT01126151|Experimental|parent handbook|parent handbook to increase the quantity and quality of communications about alcohol
3210041|NCT01126151|Experimental|parent handbook with boosters|boosters are given to parents at three times (move in, visit weekend; student visits home)
3210042|NCT01126151|Experimental|parent handbook delay|parent handbook is delayed and given after semester has begun
3210043|NCT01126138|Other|Arm A|Vinorelbine plus Capecitabine
3210044|NCT01126138|Other|Arm B|Docetaxel plus Capecitabine
3210045|NCT01126125|Experimental|Iodized oil to mother|400 mg iodine as iodized oil to breastfeeding mother
3210046|NCT01126125|Active Comparator|Iodized oil to infant|100 mg of iodine as iodized oil to infant
3210047|NCT01126112|Experimental|Panitumumab|Panitumumab: 6 mg/Kg Q2W Treatment cycles repeated every 14 days. Subjects will be evaluated for tumour response every 3 cycles (6 wks ± 1 wk) the first 24 weeks and every 8 weeks ± 2 weeks thereafter (per the revised-RECIST 1.1 guideline) until PD or withdrawal from the trial.
3210048|NCT01126099|Experimental|Prazosin|In the double blind phase (12 weeks), study participants will take either prazosin for placebo. For the open label phase (12 weeks), all study participants will take prazosin.
3210052|NCT01126086|Experimental|Healthy subjects|Matched healthy subjects
3210054|NCT01126073|Active Comparator|Niacin/Laropiprant 2000mg/40 mg|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will be randomized in the ratio 1:1 to either receive ER niacin/laropiprant or placebo in addition to the statin therapy. Patients in the ER niacin/laropiprant group will receive 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.
3210055|NCT01126060|Active Comparator|Fibrin sealant|usage of fibrin sealant after surgery
3210056|NCT01126060|No Intervention|Control|No usage of fibrin sealant
3210057|NCT01126047|Other|PFT's, eCO, and pulse oximetry|All subjects in the study will undergo complete pulmonary function testing (spirometry, blood collection for carboxyhemoglobin, diffusing capacity); exhaled carbon-monoxide testing, and pulse oximetry.
3210058|NCT01126034|Experimental|intervention|"Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:~The name and medical record # of the patients involved~Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy~A reminder of the adverse effect of long-term metoclopramide therapy~A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients~A request that the physician document the discontinuation trial in the electronic medical record"
3210059|NCT01126034|No Intervention|non-intervention|No intervention letters were sent to subjects in this arm
3210060|NCT01126021|Active Comparator|Control|Given access to mental exercises but receives no rewards for use.
3210061|NCT01126021|Experimental|Atomistic|Each individual is awarded for his or her individual participation
3210062|NCT01126021|Experimental|Altruistic|Participants are paired and rewarded according to the other individual's participation.
3210063|NCT01126021|Experimental|Team-based|Teams compete against each other and receive rewards according to relative participation.
3210064|NCT01126008|Experimental|weekly docetaxel and cisplatin|
3210065|NCT01125995|Active Comparator|late CCRT|radiotherapy start on day one of the third cycle of chemotherapy
3210066|NCT01125995|Experimental|Early CCRT|Radiotherapy start on day 1 of 1st cycle of chemotherapy
3210067|NCT01125982|Active Comparator|Desflurane|Patients will receive Desflurane to provide sleep during anaesthesia for laparoscopic cholecystectomy. Analgesia will be provided by remifentanil.
3210068|NCT01125982|Active Comparator|Propofol|Patients will receive Propofol to provide sleep during anaesthesia for laparoscopic cholecystectomy. Analgesia will be provided by remifentanil.
3210069|NCT01125969|Active Comparator|Control|
3210070|NCT01125969|Experimental|Incentive|
3210071|NCT01125969|Experimental|Peer Mentoring|
3210072|NCT01125969|Experimental|Incentives and Peer Mentoring|
3210073|NCT01125956|No Intervention|Control|This group will receive usual diabetes care through their primary care clinicians.
3210074|NCT01125956|Experimental|Peer counseling|A peer counselor will be assigned to each participant who currently has good diabetes control but had poor control in the past 3 years.
3210075|NCT01125956|Experimental|Financial incentives|Patient participants in the financial incentive arm will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
3210076|NCT01125943|Experimental|Acetylcholine|Intra-arterial infusion of acetylcholine in two increasing dosages during 5 minutes each during the intra-arterial infusion of bevacizumab
3210077|NCT01125943|Experimental|Nitroprusside|Infusion of two increasing dosages of nitroprusside during 5 minutes each during the continuous infusion of bevacizumab
3210078|NCT01125930|Placebo Comparator|Vehicle gel|Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
3210079|NCT01125930|Active Comparator|Atralin gel|Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
3210080|NCT01125917|Experimental|BTDS|Buprenorphine transdermal patch
3210081|NCT01125904|Experimental|crizotinib|
3210082|NCT01125891|Experimental|gemcitabine and ON 01910.Na|
3210083|NCT01125878|Active Comparator|Starch Composite B|
3210084|NCT01125878|Active Comparator|Starch Composite C|
3210085|NCT01125878|Active Comparator|Starch Composite D|
3210086|NCT01125878|Placebo Comparator|Placebo|
3210087|NCT01125865|Active Comparator|SEMS|Self-expandable metallic stent will be inserted for the malignant hilar obstruction.
3210088|NCT01125865|Active Comparator|DLS|DoubleLayer plastic stent (Olympus) will be inserted for malignant hilar obstruction.
3210089|NCT01125852|Active Comparator|Intervention group|Patients in this group are treated with usual therapeutic endoscopy including endoscopic combination therapy and 72 hours intravenous proton pump inhibitor. Within 24 hours from the therapeutic endoscopy they receive supplementary angiographic embolization.
3210090|NCT01125852|Active Comparator|Control group|Patients in this arm receive standard treatment including therapeutic endoscopy with endoscopic combination therapy followed by 72 hours intravenous proton pump inhibitor.
3210091|NCT01125839||Spondylitis|Patients who checked spine MRI for back pain
3210092|NCT01125813|Experimental|human cl-rhFVIII|
3210093|NCT01125800|Experimental|LDE225 233mg/m2 daily dose|Pediatric dose.
3210094|NCT01125800|Experimental|LDE225 372mg/m2 daily dose|Pediatric dose.
3210095|NCT01125800|Experimental|LDE225 425 mg/m2 daily dose|Pediatric dose.
3210096|NCT01125800|Experimental|LDE225 680 mg/m2 daily dose|Pediatric dose.
3210097|NCT01125800|Experimental|LDE225 800 mg/m2 daily dose|Adult dose
3210098|NCT01125787|Experimental|ofatumumab + bendamustine|
3210099|NCT01125774|Experimental|Telcagepant|Telcagepant 140 mg was administered once daily at bedtime for 7 consecutive days each month, beginning at the onset of menses, for up to 6 months. Dosing could begin up to 3 days prior to menses onset if prodromal symptoms reliably predicted onset of menses.
3210100|NCT01125774|Placebo Comparator|Placebo|Placebo was administered once daily at bedtime for 7 consecutive days each month, beginning at the onset of menses, for up to 6 months. Dosing could begin up to 3 days prior to menses onset if prodromal symptoms reliably predicted onset of menses.
3210101|NCT01125761|Experimental|dexamethasone 0.5 mg and 1.0 mg clemastine cream|
3210102|NCT01125761|Active Comparator|dexamethasone 0,5 mg cream|
3210103|NCT01125748|Experimental|Omalizumab|Participants received omalizumab subcutaneously at the same dose and dosing interval as administered prior to enrollment in this study. The dose of omalizumab was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.
3210104|NCT01125748|Placebo Comparator|Placebo|Participants received placebo subcutaneously at the same dosing interval as omalizumab was administered prior to enrollment in this study.
3210105|NCT01125735|Experimental|MIST Therapy|MIST Therapy is a low energy, low intensity ultrasound delivered through a saline mist to the wound bed.
3210106|NCT01125735|Other|Standard of Care|Standard of Care with saline rinse using a sham device which is a nebulizer compressor designed to deliver a continuous saline mist to a skin treatment site. The saline mist generated has been designed to be comparable to that delivered by the MIST Therapy System, but without the ultrasound waves.
3210107|NCT01125722|Active Comparator|Investigator Placement Group|
3210108|NCT01125722|Active Comparator|Subject Placement Group|
3210109|NCT01125696|Active Comparator|Standard of Care|
3210110|NCT01125696|Experimental|Tenofovir|
3210111|NCT01125683|Experimental|1|2,5 mg once daily
3210112|NCT01125683|Active Comparator|2|single dose of 5 mg
3210113|NCT01125683|Placebo Comparator|3|
3210114|NCT01125683|Experimental|4|60 mg once daily
3210115|NCT01125683|Experimental|5|60 mg three times daily
3210116|NCT01125670|Experimental|fast-fed sequence group|
3210117|NCT01125670|Experimental|fed-fast sequence group|
3210118|NCT01125657|Experimental|formualation-A to -B sequence group|
3210119|NCT01125657|Experimental|formulation-B to -A sequence group|
3210120|NCT01125644|Experimental|Single Arm|"Patients are males and females between 18 and 75 years of age with proven fungal etiology confirmed by mycological culture test and by hystopathological exam (patients with definite diagnosis), or patients with fungal infection of which is difficult to determine the etiological agent but with diagnosis of deep mycosis based on blood testing for fungal infection and/or clinical radiological examination, and/or endoscopic clinical examination, clinical symptomatology (patients with clinical diagnosis)."
3210121|NCT01125631|Experimental|PF-04360365 8.5 mg/kg|
3210122|NCT01125631|Placebo Comparator|Placebo|
3210123|NCT01125618|Experimental|MVP village|Wealth stratified and randomly selected households residing in a village exposed to the Millennium Villages Project intervention (or health and development intervention package)
3210124|NCT01125618|Active Comparator|Comparison village|Villages receiving routine services through established programs
3210125|NCT01125605||Adults > 12 years|adult patients and patients older than 12 years
3210126|NCT01125605||Children 6-12 years|children between 6 and 12 years
3210127|NCT01125605||Children 1-6 years|children between 1 and 6 years
3210128|NCT01125592|Experimental|Footbath|Participants in this arm of the study will receive 4 30 minutes ionic footbath sessions, one each week for 4 weeks.
3210129|NCT01125579||Children aged 6-12|"Children suffering from nervous restlessness, e.g. in agitated depression (ICD 10, F3 and DSM IV affective disorders), aged 6-12 years"
3210130|NCT01125566|Active Comparator|Arm B: trastuzumab with vinorelbine|patients receive weekly intravenous infusion of trastuzumab and vinorelbine
3210131|NCT01125566|Experimental|Arm A: BIBW 2992 with vinorelbine|patients receive BIBW 2992 tablets once daily combined with weekly intravenous infusion of vinorelbine
3210132|NCT01125553|Experimental|IDegAsp B|
3210133|NCT01125553|Experimental|IDegAsp F|
3210134|NCT01125527|Active Comparator|Arm 1|
3210135|NCT01125527|Active Comparator|Arm 2|
3210136|NCT01125514|Experimental|Furosemide 60 mg|Treatment period 1 (Day 1 to Day 7): All eligible patients received 60 mg furosemide, 150 mg placebo of aliskiren, and 300 mg placebo aliskiren once daily.
3210137|NCT01125514|Experimental|Furosemide 60 mg + Aliskiren 150 mg|Treatment Period 2 (Day 8 to day 17): Patients received 60 mg furosemide, 150 mg aliskiren and 300 mg placebo once daily.
3210138|NCT01125514|Experimental|Furosemide 60 mg + Aliskiren 300 mg|Treatment Period 3 (Day 18 to day 27): Patients received 60 mg furosemide, 300 mg aliskiren and 150 mg placebo of aliskiren once daily.
3210139|NCT01125501|Active Comparator|Protandim|one capsule a day for 30 days of protandim given, followed by a wash out period.
3210140|NCT01125501|Placebo Comparator|Placebo|one capsule a day for 30 days will be given followed by a washout period.
3210141|NCT01125488|Experimental|LNG-IUS|LNG-IUS insertion during conservative surgery and GnRH agonist 6 doses.
3210142|NCT01125488|Active Comparator|GnRH agonist|The second group of patients receive GnRH agonist (triptorelin 3.75 mg, sc q28day) alone for 24 weeks.
3210143|NCT01125462||Subjects previously treated with Gonal-f|Subjects who had undergone at least one treatment cycle with Gonal-f powder and solvent for solution for injection within the past 12 months (equivalent to 75 IU/ml, 450 IU/0.75ml or 1050 IU/1.75 ml)
3210144|NCT01125462||Subjects previously treated with urine-derived FSH|Subjects which had undergone at least one treatment cycle with urine-derived FSH therapy with vials within the past 12 months
3210145|NCT01125449|Other|Intravenous IVC Intervention|Intravenous ascorbic acid, 1.5g/kg at an infusion rate not to exceed 250mg/min.
3210146|NCT01125436|Experimental|Cholecalciferol|Nutritional supplement
3210147|NCT01125436|Placebo Comparator|placebo|
3210148|NCT01125410|Experimental|Dequalinium chloride 10mg|
3210149|NCT01125410|Active Comparator|clindamycin vaginal cream 2%|
3210150|NCT01125397|Experimental|Behavioral Intervention|
3210242|NCT01124786|Active Comparator|gemcitabine|
3210151|NCT01125397|No Intervention|Control|These participants will be randomized to receive no behavioral intervention prior to bariatric surgery.
3210152|NCT01125384|No Intervention|nurse swabbing|
3210153|NCT01125384|Experimental|"accurate swabbing by a physician"|
3210154|NCT01125371|Experimental|Computerized Brief Alcohol Intervention + IVR|Computer-delivered brief alcohol intervention (CBI) with booster phone calls delivered by IVR+ text messages (TM)
3210155|NCT01125371|Active Comparator|Computerized Brief Alcohol Intervention|Computerized Brief Alcohol Intervention only (CBI)
3210156|NCT01125371|Placebo Comparator|Attention Control|Attention control
3210157|NCT01125358|Experimental|10 mg LY2140023|
3210158|NCT01125358|Experimental|80 mg LY2140023|
3210159|NCT01125358|Experimental|160 mg LY2140023|
3210160|NCT01125358|Placebo Comparator|Placebo|
3210161|NCT01125345|Experimental|Hydrophobic IOL|The single piece Acrysof hydrophobic IOL model- SN60WF
3210162|NCT01125345|Active Comparator|Hydrophilic IOL|Rayner Intraocular Lenses Ltd., England, Model C-flex 570C
3210163|NCT01125345|Active Comparator|Hydrophillic IOL|Bausch and Lomb ltd, model Akreos Adapt
3210164|NCT01125332|Placebo Comparator|group gel KY|
3210165|NCT01125332|Experimental|group gel lidocaine|
3210166|NCT01125319|Other|patients Hemophagocytic lymphohisticytosis group|
3210167|NCT01125319|Other|group control patient|
3210168|NCT01125319|Other|healthy control group|
3210169|NCT01125293|Experimental|single arm|Combination of everolimus & rituximab with bortezomib in patients with relapsed or refractory WM
3210170|NCT01125280|Experimental|SBO score application|Acute strangulated SBO patients will receive a severity score at emergency admission. According to the score, they will be managed either conservatively or surgically. During surgery, the need of small bowel resection will be evaluated. The endpoint will be to correlate the type and success of treatment with the score in order to validate this new tool in SBO assessment.
3210171|NCT01125267|Experimental|multifamily group-adherence|multifamily group treatment with a focus on improving adherence to antipsychotic medication
3210172|NCT01125267|Active Comparator|multifamily group-standard|multifamily group focused on problems identified by group participants
3210173|NCT01125267|No Intervention|treatment as usual|
3210174|NCT01125254|Experimental|Amlodipine|amlodipine 5mg qd
3210175|NCT01125254|Placebo Comparator|Controls|placebo
3210176|NCT01125241|Experimental|Wuling capsule|
3210177|NCT01125241|Placebo Comparator|Placebo|
3210178|NCT01125215|Placebo Comparator|Placebo|Matched gel base of capsaicin nanoparticle
3210179|NCT01125215|Experimental|Capsaicin|0.075% capsaicin nanoparticle gel
3210180|NCT01125202|Experimental|SCT-based behavioral intervention|Intervention participants continue to receive routine dialysis care, as well as a 16 week dietary counseling intervention based on Social Cognitive Theory. Dietary counseling is paired with Personal Digital Assistant-based dietary self-monitoring.
3210181|NCT01125202|Active Comparator|Attention control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
3210182|NCT01125189|Experimental|Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg)|
3210183|NCT01125189|Experimental|Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg)|
3210184|NCT01125189|Placebo Comparator|Placebo plus peg-interferon alfa-2a and ribavirin|
3210185|NCT01125176|Experimental|All subjects|In Cycle -1, even numbered patients will receive oral lenalidomide daily on days 1-14 and then no treatment on days 15-28. In Cycle -1, odd numbered patients will receive oral thalidomide daily days 1-14 followed by no treatment on days 15-28. Starting with cycle 1, all patients will alternate daily thalidomide (every odd day) with daily lenalidomide (every even day) for days 1-28. Rituximab will be given on days 1, 8, 15, and 22 starting with Cycle 1, and then again every 6th cycle thereafter (cycles 7, 13, 19, etc.)
3210186|NCT01125163|Active Comparator|multivitamin with iron|daily oral multivitamin providing 2mg/kg of iron
3210187|NCT01125163|Placebo Comparator|multivitamin without iron|daily oral multivitamin without iron
3210188|NCT01125137|Experimental|Biopsy|
3210189|NCT01125124|Active Comparator|Silver Nitrate 1|Patients submitted to pleurodesis via pleural catheter using 30ml of 0.5% silver nitrate solution.
3210190|NCT01125124|Experimental|Silver Nitrate 2|Patients submitted to instilation of 30ml 0.3% silver nitrate solution via pleural catheter.
3210191|NCT01125124|Experimental|Silver Nitrate 3|Patients submitted to instilation of 60ml 0.3% silver nitrate solution via pleural catheter.
3210192|NCT01125111||robotic surgery group|
3210193|NCT01125111||laparoscopic surgery group|
3210194|NCT01125098||PRO-CT group: Experimental|COPD patients in the PRO-CT group will continue or discontinue antibiotic therapy depending on PRO-CT values.
3210195|NCT01125098||Standard group: No intervention|COPD patients in the Standard group will continue antibiotic therapy for 10 days according to guidelines recommended treatment plan in case of COPD exacerbations.
3210196|NCT01125085|Other|131I-L19SIP RIT in Combination with WBRT|131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)
3210197|NCT01125072||entire cohort|patients presenting to the emergency department with chest pain and being admitted to rule out acute coronary syndrome
3210198|NCT01125059|Active Comparator|Methadone Group|0.2 mg/kg IV methadone
3210199|NCT01125059|Placebo Comparator|Placebo Group|5 mL saline bolus
3210200|NCT01125046|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months. Patients may then receive bevacizumab IV every 3 weeks for up to 12 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
3210201|NCT01125033|Experimental|Vitamin C & Vitamin E.|The patients in this arm received one tablet of vitamin C (200 mg) and one capsule of vitamin E (400 mg) daily for 8 weeks
3210202|NCT01125033|Experimental|Vitamin C & Placebo|The patients in this arm received one tablet of vitamin C (200 mg) and one placebo capsule daily for 8 weeks.
3210203|NCT01125033|Experimental|Vitamin E & Placebo|The patients in this arm received one capsule of vitamin E (400 mg) and one placebo tablet daily for 8 weeks.
3210204|NCT01125033|Placebo Comparator|Double Placebo|The patients in this arm received one placebo capsule and one placebo tablet daily for 8 weeks.
3210205|NCT01125020|Active Comparator|gemcitabine and oxaliplatin|
3210206|NCT01125020|Active Comparator|doxorubicin, 5-Fu and cisplatin|
3210207|NCT01125007|Active Comparator|toothbrush|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
3210208|NCT01125007|Experimental|medium toothbrush|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
3210209|NCT01124994|Active Comparator|Mucosectomy|Patients in this arm are undergoing mucosctomy after previous confocal laser endomicroscopy.
3210210|NCT01124981|Placebo Comparator|Albumin|
3210211|NCT01124981|Experimental|Haemocomplettan® P|
3210212|NCT01124968|Experimental|eConsulta|Those patients who are offered to use the eConsulta, a web where they can virtually consult with their primary care doctor or nurse.
3210213|NCT01124955|Active Comparator|Intervention Group|Patients receive 5 sessions of real acupuncture. The technique of acupuncture used in this study is Yamamoto New Scalp Acupuncture called YNSA.
3210214|NCT01124955|Placebo Comparator|Non-penetrating acupuncture|The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
3210215|NCT01124942|Experimental|MGuard|MGuard net protective stent, investigational device
3210216|NCT01124942|Active Comparator|BMS plus thrombectomy|Bare-metal stent plus manual thrombectomy device
3210217|NCT01124929|Active Comparator|Arm 1: Category I treatment for 6 months|Anti-tuberculosis drugs
3210218|NCT01124929|Active Comparator|Arm 2: Category I treatment for 9 months|Anti-tuberculosis drugs,
3210219|NCT01124916|Active Comparator|Laparoscopic Abdominal Sacrocolpopexy (LASC)|Women assigned to this cohort will receive standard laparoscopic abdominal sacrocolpopexy (LASC)
3210220|NCT01124916|Experimental|Robotic Assisted Laparoscopic (RASC)|Women assigned to this cohort will receive robotic assisted laparoscopic abdominal sacrocolpopexy (RASC)
3210221|NCT01124903|Experimental|Dehydration|Multiple measures of hydration status were made when subjects were normally hydrated (euhydrated) and when dehydrated. The diagnostic usefulness of the measures was determined.
3210222|NCT01124890|Placebo Comparator|Conservative|no transfer for early percutaneous coronary intervention after thrombolysis
3210223|NCT01124890|Active Comparator|early PCI|transfer for early percutaneous coronary intervention after thrombolysis
3210224|NCT01124877|Other|Open|
3210225|NCT01124864|Experimental|EGFR mutant patients|Patients with EGFR activating mutation tumors (Note: These patients must have progressed on one prior EGFR TKI containing regimen unless they have documented T790M activating mutation). Patients received AUY922 at 70 mg/m^2 weekly infusions.
3210226|NCT01124864|Experimental|Kras mutant patients|Patients with KRAS mutant tumors. Patients received AUY922 at 70 mg/m^2 weekly infusions.
3210227|NCT01124864|Experimental|EGFR and Kras wild type patients|Patients exhibiting both mutations were stratified to the KRAS mutation stratum. Patients received AUY922 at 70 mg/m^2 weekly infusions.
3210228|NCT01124864|Experimental|Patients with EML4-ALK translocation|Patients with NSCLC who have tumors with an inversion in the short arm of chromosome 2 that results in the fusion of the echinoderm microtubule-associated protein-like 4 (EML4) gene with the ALK gene leading to the production of an EML4-ALK fusion tyrosine kinase. ALK is a transmembrane protein, which has a kinase domain and is not usually expressed in the lung. EML4 mediate ligand-independent dimerization, and therefore constitutive activity of the ALK tyrosine kinase domain. Patients received AUY922 at 70 mg/m^2 weekly infusions.
3210229|NCT01124864|Experimental|Modified EGFR mutant patients|The modified EGFR stratum was defined as patients less heavily pretreated who had received one or two lines of prior therapy, with a documented response to a EGFR tyrosine kinase inhibitor (TKI) (complete response (CR), partial response (PR) or stable disease (SD) for ≥ 6 months), unless the patient had de novo resistance to EGFR TKI. Patients received AUY922 at 70 mg/m^2 weekly infusions.
3210230|NCT01124851|Experimental|Arm 1|ABT-652 Dose 1 vs placebo capsules administered orally once daily for 7 days
3210231|NCT01124851|Experimental|Arm 2|ABT-652 Dose 2 vs placebo capsules administered orally once daily for 7 days
3210232|NCT01124851|Experimental|Arm 3|ABT-652 Dose 3 vs placebo capsules administered orally once daily for 7 days
3210233|NCT01124838|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection at Baseline followed by every other week (eow) dosing starting at Week 1 for up to 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 10 to 35 mg/day at study entry followed by a protocol-defined mandatory taper until Week 19.
3210234|NCT01124838|Experimental|Adalimumab|Participants received adalimumab 80 mg subcutaneous loading dose at Baseline followed by 40 mg doses eow starting at Week 1 for a maximum of 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper until Week 19.
3210235|NCT01124825|Active Comparator|IGel|Subjects will receive an IGel(TM) airway induction and maintenance of positive pressure ventilation
3210236|NCT01124825|Active Comparator|King Airway|Subject will receive a KING-LTS-D(TM) for induction and maintenance of positive pressure ventilation
3210237|NCT01124812|Experimental|131I-L19SIP|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy: Treatment dose of 131I-L19SIP RIT is titrated in cohorts of 3 patients.
3210238|NCT01124799|Experimental|001|TMC435 one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening for 9 days
3210239|NCT01124799|Placebo Comparator|002|Placebo placebo dose in the morning at noon and in the evening for 9 days
3210240|NCT01124799|Active Comparator|003|Ciprofloxacin one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg for 9 days
3210243|NCT01124773||Previous HT use and cognition|Women who were aged 50-54 at the time of randomization into the WHI hormone trials.
3210244|NCT01124760|Experimental|1|AZD9742
3210245|NCT01124747|Experimental|ASP1585 and 14C-Labeled ASP1585|
3210246|NCT01124734|Experimental|Course 1 of HD IL-2|Patients will be given cycle 1 HD IL-2 600,000 IU/kg. On the day after discharge, patients will be given oral temozolomide at 75 mg/m2 daily for 7 days. Cycle 2 - patients will HD IL-2 600,000 IU/kg. Patient will receive temozolomide at 75 mg/m2 for 21 days after discharge.
3210247|NCT01124734|Experimental|Course 2|The response determined from Course 1 will determine the patient's next step.
3210248|NCT01124721|Experimental|Cogmed cognitive training|Computerized working memory, attention and cognitive tasks
3210249|NCT01124721|Active Comparator|Active placebo|Cognitive training, however the training does not increase in difficulty, or does so to a minimal degree.
3210250|NCT01124708|Placebo Comparator|Placebo|Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
3210251|NCT01124708|Active Comparator|TC-5619|TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, one capsule once daily p.o.
3210252|NCT01124656|Experimental|Pioglitazone-Azilsartan QD|(Dependent on glycosylated hemoglobin level at screening)
3210253|NCT01124643|Experimental|Replagal 0.2 mg/kg EOW|Intravenous, 0.2mg/kg EOW
3210254|NCT01124630|Experimental|CS-1008 with FOLFIRI|Experimental drug CS-1008 in combination with FOLFIRI
3210255|NCT01124617|Experimental|Tapentadol|Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
3210256|NCT01124617|Placebo Comparator|Placebo|Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
3210257|NCT01124604|Experimental|Tapentadol Hydrochloride|
3210258|NCT01124604|Placebo Comparator|Placebo|
3210259|NCT01124591|Experimental|Treatment|Assessment and brief intervention
3210260|NCT01124578||Control|Existing used daily change-out device
3210261|NCT01124578||Egret|Extended Use Catheter w/BIOSAFE
3210262|NCT01124565|Experimental|RT001|RT001 (Botulinum Toxin Type A) Topical Gel
3210263|NCT01124552|Experimental|RT001 Botulinum toxin Type A (Dose A)|RT001 (Botulinum toxin Type A)
3210264|NCT01124552|Experimental|RT001 Botulinum toxin type A (Dose B)|RT001 (Botulinum Toxin Type A)
3210265|NCT01124552|Other|Dose C|Vehicle Control
3210266|NCT01124552|Placebo Comparator|Dose D|Placebo
3210267|NCT01124539|Experimental|AR-67|
3210268|NCT01124526|Experimental|Rituximab, Fludarabine, ciclophosphamide|"Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:~RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2)"
3210269|NCT01124513|Active Comparator|Digital Camera|Digital camera images will be taken of a a 2cm^2 area of sun protected skin.
3210270|NCT01124513|Active Comparator|Spectrophotometer|The probe of the protable reflectance spectrophotometer is lightly applied to the sufance of the skin and a reading is taken.
3210271|NCT01124513|Active Comparator|Videodermoscopy|The instrument is put in contact with sun protected skin and an image is taken of a 2 cm^2 area.
3210272|NCT01124500|Experimental|methylphenidate via transdermal patch compared to placebo|The proposed study is a within-subject, cross-over, randomized and double-blinded pilot trial, designed to evaluate the efficacy and feasibility of sustained-release, long-acting methylphenidate via transdermal patch compared to placebo in fatigued patients with Head and Neck malignancies
3210273|NCT01124487|Experimental|palm olein|
3210274|NCT01124487|Experimental|olive oil|
3210275|NCT01124487|Experimental|lard|
3210276|NCT01124474|No Intervention|Standard fluid management|Standard intraoperative fluid management as determined by usual monitoring and decision making applied by anesthesiology team
3210277|NCT01124474|Other|Vigileo model number MHM1|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV>12%.
3210278|NCT01124461||Brain Tumor|Brain neoplasms, malignant
3210279|NCT01124448|Experimental|Lactobacillus salivarius PS2|Women with mastitis (n=25) receiving Lactobacillus salivarius PS2 (9.5 log per day, 21 days)
3210280|NCT01124448|Active Comparator|Lactobacillus salivarius PS2B|Lactating women without mastitis (n=15)
3210281|NCT01124422|Experimental|fluticasone propionate/salmeterol DISKUS 250/50 + tiotropium|This is the active DISKUS (that is, containing fluticasone propionate/salmeterol combination) + open-label tiotropium
3210282|NCT01124422|Placebo Comparator|placebo DISKUS + tiotropium|This is the DISKUS and excipient minus the active ingredient (which is fluticasone propionate/salmeterol combination) + open-label tiotropium
3210283|NCT01124409|Active Comparator|3DCRT with EPID|this patients randomised to this arm will be planned by 3DCRT and during treatment setup error will be identified and corrected by weekly EPID if error >3mm.Weekly CBCT will be done for this arm to note the setup error but will not be corrected.
3210284|NCT01124409|Active Comparator|IGRT with CBCT|The patients randomised to this arm will be planned by 3DCRT and set up error during RT will be verified by CBCT and error corrected if >3mm.Weekly EPID will be done for setup error documentation but no correction based on EPID in this arm.
3210285|NCT01124396||30 ug|30 ug
3210286|NCT01124396||60 ug|60 ug
3210287|NCT01124396||Placebo|Placebo
3210288|NCT01124383|Active Comparator|General anesthesia|
3210289|NCT01124383|Active Comparator|Local anesthesia with sedation|
3210290|NCT01124370|Experimental|Treatment|All enrolled subjects will undergo attempted system implantation and therapeutic assessment. Subjects' baseline assessment values will serve as control parameters for the therapy evaluation.
3210291|NCT01124357|Active Comparator|novasure|Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
3210292|NCT01124357|Other|thermachoice|ThermachoiceTM III thermal balloon ablation
3210293|NCT01124344|Active Comparator|Placebo or BMS-866949 (3 mg)|Panel 1: Healthy Male Subjects
3210294|NCT01124344|Active Comparator|Placebo or BMS-866949 (10 mg)|Panel 2: Healthy Male Subjects
3210295|NCT01124344|Active Comparator|Placebo or BMS-866949 (30 mg)|Panel 3: Healthy Male Subjects
3210296|NCT01124344|Active Comparator|Placebo or BMS-866949 (45 mg)|Panel 4: Healthy Male Subjects
3210297|NCT01124344|Active Comparator|Placebo or BMS-866949 (60 mg)|Panel 5: Healthy Male Subjects
3210298|NCT01124344|Active Comparator|Placebo or BMS-866949 (90 mg)|Panel 6: Healthy Male Subjects
3210299|NCT01124344|Active Comparator|Placebo or BMS-866949 (3 - 60 mg)|Panel 7: Females
3210300|NCT01124331|Experimental|High Oxygen saturation|Higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter, for durations as specified in each trial protocol.
3210301|NCT01124331|Active Comparator|Lower oxygen saturation|Lower (SpO2 85-89%) functional oxygen saturation target range from birth, or soon thereafter, for durations as specified in each trial protocol.
3210302|NCT01124318|Active Comparator|Lactofiltrum|
3210303|NCT01124318|Placebo Comparator|Placebo|
3210304|NCT01124305|Active Comparator|Traditional Instrumentation|Control group: Cases performed with traditional surgical instruments
3210305|NCT01124305|Experimental|Customized Patient Instrumentation|Experimental group: Cases performed with custom instruments specifically made for each patient using pre-op CT scans.
3210306|NCT01124292|Experimental|Able-bodied subject with piercing|Able-bodied subjects who already have tongue piercing.
3210307|NCT01124292|Experimental|Able-bodied subject without piercing|Able-bodied subjects who willing to receive a tongue piercing for this study.
3210308|NCT01124292|Experimental|Subjects with spinal cord injury|Persons with mobility limitations requiring power wheel chair, able to move tongue, able to follow simple commands, and have some experience with computers. All participants willingly received a mid-line tongue piercing.
3210309|NCT01124279|Experimental|AMG 853|
3210310|NCT01124266|Experimental|endoscopist only|
3210311|NCT01124266|Experimental|nurse participation|
3210312|NCT01124253|Experimental|NP plus recombinant human endostatin|
3210313|NCT01124253|No Intervention|vinorelbine plus cisplatin|
3210314|NCT01124227|Sham Comparator|Standard Care|
3210315|NCT01124227|Active Comparator|2 Icodextrin PD changes / day|
3210316|NCT01124227|Active Comparator|1 Icodextrin PD change/day|
3210317|NCT01124214|No Intervention|High Resolution endoscopy (HRE)|Standard of care, high resolution endoscopy surveillance/ evaluation of BE and or IEN
3210318|NCT01124214|Active Comparator|Endomicroscopy (EM)|Standard of care, high resolution endoscopy surveillance/ evaluation of BE and or IEN and endomicroscopy esophageal evaluation
3210319|NCT01124201|Experimental|Stabilization group|In the Segmental Stabilization group exercises focused on the transversus abdominis and lumbar multifidus muscles.
3210320|NCT01124201|Experimental|Strengthening group|In the Superficial Strengthening group, exercises focused on the rectus abdominis, abdominus obliquus internus, abdominus obliquus externus and erector spinae muscles.
3210321|NCT01124201|Experimental|Stretching group|Stretching group: erector spinae, posterior connective tissues and ischiotibials muscles
3210322|NCT01124188|Experimental|Study Intervention Arm|Higher-dose venlafaxine and Problem Solving Therapy for Depression and Pain (PST-DP)
3210323|NCT01124188|Active Comparator|Active Control|Higher-dose venlafaxine and supportive management (SM)
3210324|NCT01124175|Experimental|Generic Test Product|Losartan 100 mg Tablets
3210325|NCT01124175|Active Comparator|Reference Listed Drug|Cozaar® 100 mg Tablets
3210326|NCT01124162|Experimental|Generic Test Product|Losartan 100mg Tablets
3210327|NCT01124162|Active Comparator|Reference Listed Drug|Cozaar® 100 mg Tablets
3210328|NCT01124149|Experimental|MMX mesalamine/ mesalazine|
3210329|NCT01124136|Experimental|Neurostimulation + Medication management|Investigational nerve stimulator device implanted to heart plus standard medication therapy.
3210330|NCT01124136|Other|Standard of Care (Control)|Standard of Care treatment is medication management only. Heart failure medications control symptoms and comorbidities, i.e. blood thinners, lipid lowering, and diuretics, and manage heart function, i.e. heart rhythm, rate, and pumping strength.
3210331|NCT01124123|Experimental|Bilastine 20 mg|Single dose 20 mg bilastine oral tablet. Test drug
3210332|NCT01124123|Active Comparator|Bilastine 10 mg|Single dose 10 mg Bilastine endovenous. Control drug
3210333|NCT01124110|Other|1-800-QUIT-NOW Telephone Hotline|The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
3210334|NCT01124110|Experimental|Tobacco Tactics Intervention|This intervention contains a website, medications, and nurse counseling.
3210335|NCT01124097|Experimental|Eslicarbazepine acetate 800 mg once daily (QD)|
3210336|NCT01124097|Experimental|Eslicarbazepine acetate 1200 mg QD|
3210337|NCT01124097|Experimental|Eslicarbazepine acetate 1600 mg QD|
3210338|NCT01124097|Placebo Comparator|Placebo|
3210339|NCT01124084||Health Care Providers|
3210340|NCT01124071|Active Comparator|Korean Diet|Provision of 2 Korean meals per day, 6 days per week
3210341|NCT01124071|Active Comparator|Western Diet|Lifestyle counseling, dietary advice, grocery vouchers
3210342|NCT01124058|Experimental|Loading|1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose
3210343|NCT01124058|Active Comparator|Maintenance|Re-start same dose as previously stable on
3210344|NCT01124045|Experimental|DUREZOL|Difluprednate ophthalmic emulsion, 0.05%, 1 drop in the study eye at the end of surgery (Day 0) and 4 times a day beginning on the day after surgery (Day 1) for 14 days, followed by a tapering period of 14 days, dependent upon the Investigator's determination of adequate response to treatment
3210380|NCT01123785|Placebo Comparator|Control|Matched vehicle-control
3210381|NCT01123785|Experimental|INO-8875|Adenosine agonist eye drop
3210382|NCT01123772|Placebo Comparator|Control|Vehicle control
3210345|NCT01124045|Active Comparator|PRED FORTE|Prednisolone acetate ophthalmic suspension, 1.0%, 1 drop in the study eye at the end of surgery (Day 0) and 4 times a day beginning on the day after surgery (Day 1) for 14 days, followed by a tapering period of 14 days, dependent upon the Investigator's determination of adequate response to treatment
3210346|NCT01124032|Experimental|ADHD adults|
3210347|NCT01124032|Experimental|healthy adults|
3210348|NCT01124019||Random Sample|A random sample of 600 women undergoing screening mammography
3210349|NCT01124019||BIRADS score of 4|An additional 600 women determined to have a Breast Imaging Reporting and Data System (BIRADS) score of 4 as determined by final mammogram results.
3210350|NCT01124006|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
3210351|NCT01124006|Placebo Comparator|Water for injection|Sterile water for injection
3210352|NCT01123993|No Intervention|Lifestyle counselling|
3210353|NCT01123980|Experimental|BIAsp 30|0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride
3210354|NCT01123980|Active Comparator|Insulin glargine|0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride
3210355|NCT01123967|Experimental|PRO+NRT+TC|Proactive outreach (mailed invitation letter followed by telephone outreach) combined with free nicotine replacement therapy (NRT) and telephone counseling (PRO+NRT+TC)to usual care (UC)
3210356|NCT01123967|Active Comparator|Usual Care (UC)|Usual (standard) care - Smoking cessation products: patch, gum, lozenge, inhaler and nasal spray
3210357|NCT01123954|Other|Arm 1|
3210358|NCT01123941|Experimental|NVGH Vi-CRM197 conjugate vaccine|
3210359|NCT01123941|Active Comparator|Vi-polysaccharide vaccine|
3210360|NCT01123928|Experimental|Counseling|Subjects will be asked to watch a 5-10 min video and participate in a 10-15 min pre-operative counseling session with a trained nurse. Subjects will also participate in a 5 min post-operative counseling session.
3210361|NCT01123928|No Intervention|Non-counseling|
3210362|NCT01123915|Experimental|Opal-HIV-Gag(c)|Opal-HIV-Gag(c) administered ex vivo to separated white blood cells on 4 occasions at 4 weekly intervals.
3210363|NCT01123915|Placebo Comparator|Diluent|Administered ex vivo to separated white blood cells on 4 occasions at 4 weekly intervals.
3210364|NCT01123902|Experimental|hand-held fan|
3210365|NCT01123902|Placebo Comparator|wristband|
3210366|NCT01123889|Active Comparator|control|corticosteroid injection into subacromial space
3210367|NCT01123889|Experimental|experimental|patients will receive an injection of platelet rich plasma into the subacromial space
3210368|NCT01123876|Experimental|Veliparib and FOLFIRI|Veliparib in combination with FOLFIRI regimen.
3210369|NCT01123863||Patient Group|"This study will administer Brigance Preschool Screen -II to 3 year old children with SCD followed at St. Jude Children's Research Hospital~Intervention: Brigance Preschool Screen -II"
3210370|NCT01123863||control group|"The control group will consist of 3-year-old children attending day care in the Memphis area and serve as a population that come from a similar socioeconomic background as the SCD patient population.~Intervention: Brigance Preschool Screen -II"
3210371|NCT01123850|Active Comparator|Single ARM - Copios Bone Filler|All subjects will undergo an instrumented, pedicle screw PLF procedure. Autograft or other interbody devices identified by the surgeon to be in the best interest of the patient may be used. Enrolled patients will receive CopiOs BVF sponge soaked with bone marrow aspirate on one side and autologous bone on the other side. All patients will receive both CopiOs BVF and autologous bone. Patients will serve as self-controls in this counter-balanced study.
3210372|NCT01123837|Active Comparator|D5LR|In the treatment group, a 250cc bolus over 2 hrs of D5LR will be initiated prior to the end of surgery and continued in PACU.Blood glucose will be measured at 3 different timepoints using a point of care testing device (Accu-Chek). We will be measuring changes in blood glucose levels associated with PONV and the type and number of rescue medicines given at 30, 60, and 120 minutes after anesthesia and the first postoperative morning
3210373|NCT01123837|Active Comparator|lactated ringers|In the control group, a 250cc bolus over 2 hrs of LR will be initiated prior to the end of surgery and continued in PACU. Blood glucose will be measured at 3 different timepoints using a point of care testing device (Accu-Chek). We will be measuring changes in blood glucose levels associated with PONV and the type and number of rescue medicines given at 30, 60, and 120 minutes after anesthesia and the first postoperative morning.
3210374|NCT01123824|Experimental|Sequence clopidogrel 300/75 mg - 600/150 mg|"Period 1:~Day 1: clopidogrel, 300 mg loading dose + placebo~Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily~Period 2:~Day 1: clopidogrel, 600 mg loading dose~Day 2 to Day 5: clopidogrel, 150 mg, once daily~Each intake is at around 8:00 AM fasted for at least 10 hours"
3210375|NCT01123824|Experimental|Sequence clopidogrel 600/150 mg - 300/75 mg|"Period 1:~Day 1: clopidogrel, 600 mg loading dose~Day 2 to Day 5: clopidogrel, 150 mg, once daily~Period 2:~Day 1: clopidogrel, 300 mg loading dose + placebo~Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily~Each intake is at around 8:00 AM fasted for at least 10 hours"
3210376|NCT01123811|Experimental|Cetuximab IF|Treatment with combination of Cetuximab and Irinotecan 5-FU
3210377|NCT01123798||Stable controls|Uninjured soldiers to provide normative data for stable physiological status
3210378|NCT01123798||Critical controls|"Critically injured soldiers with no lower extremity traumatic injuries (excepting skin abrasions and small/superficial fragmentation wounds) to provide normative data for the shock physiological status."
3210379|NCT01123798||Lower extremity trauma|Soldiers with severe traumatic lower extremity injuries in stable and shock physiologic status. This is the investigational cohort.
3210383|NCT01123772|Experimental|INO-8875|Active drug
3210384|NCT01123759|Active Comparator|Tilapia|Subjects are fed 6 oz tilapia once a week for 3 months
3210385|NCT01123759|Active Comparator|Salmon|Subjects fed 6 oz salmon once a week for 3 months
3210386|NCT01123707|Experimental|Aripiprazole/Escitalopram combination therapy|
3210387|NCT01123694||Xeroderma Pigmentosum patients|Xeroderma Pigmentosum patients who attend Camp Sundown, a camp for children with this condition.
3210388|NCT01123681||Ventilator associated pneumonia|
3210389|NCT01123681||No pneumonia|
3210390|NCT01123668||ADHD and non-ADHD Smokers|Those that are defined as regular smokers (10 cigarettes/day or Carbon Monoxide reading of 10 ppm). The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
3210391|NCT01123655|Other|Arm 1|"The study will have 3 treatment arms each with 10-12 patients who have demonstrated T cell immunity to CII and have an in vitro response to APL A12 at the screening visit. Patients will be randomized to one of the 3 treatment arms. Each of the 3 treatments will be given for 16 weeks.~In keeping with a sequential dose escalation strategy, the originally proposed randomization scheme will be modified so that subjects will be randomized to receive:~either the lowest dose (30 micrograms) or placebo (Block 1). We will begin with the lowest dose (30 micrograms/day) and enroll 6 to receive 30 micrograms/day APL A12 and 2 to receive placebo for 16 weeks. Results will be reported to the DMC for a decision to proceed to the next block based on indications of safety"
3210392|NCT01123655|Experimental|Arm 2|followed by the next higher dose (50 micrograms) or placebo (Block 2).
3210393|NCT01123655|Experimental|Arm 3|Block 3 (Arm 3) will include placebo and both doses of APL/A12 to ensure 10-12 patients are enrolled in each arm ( total of approximately 32 subjects) so we will have 24 subjects who complete the 16 weeks of study treatment. Arms 2 and 3 will run simultaneously.
3210394|NCT01123642||Group 1|Operation Enduring Freedom and Operation Iraqi Freedom Veterans
3210395|NCT01123616|Active Comparator|non-triclosan-coated|Two arms are separeted by computer randomization at abdomial wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
3210396|NCT01123616|Active Comparator|triclosan coated suture|Two arms are separeted by computer randomization at abdomial wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
3210397|NCT01123590||Thymoma|Patients with thymoma
3210398|NCT01123590||Control|Normal controls
3210399|NCT01123577|Experimental|Intervention|
3210400|NCT01123577|No Intervention|Control|Participants receive usual care by providers.
3210401|NCT01123564|Experimental|Lucentis (ranibizumab)|
3210402|NCT01123564|Active Comparator|Laser|
3210403|NCT01123551|Experimental|Nebulized Morphine|After randomization, patients will receive 10 mg of morphine (1ml) diluted in 4 ml normal saline and nebulized with 6 l/mn during 10 min. Nebulization will be repeated systematically 3 times every twenty minutes unless the patient pain was resolved (VAPS 30%). In addition, patients receive a bolus of IV placebo(5 ml normal saline . IV placebo (2 ml) will be repeated every 10 minutes if the objective of analgesia was not reached .
3210404|NCT01123551|Active Comparator|Intravenous morphine|After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS >30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS >30%).
3210405|NCT01123538|Other|Natural progesterone|Combined menopausal treatment containing natural progesterone
3210406|NCT01123538|Active Comparator|Chlormadinone acetate|Combined menopausal treatment containing chlormadinone acetate
3210407|NCT01123525|Experimental|Adenosine cardioplegia|Adenosine cardioplegia
3210408|NCT01123525|Active Comparator|Control|Standard hyperkalemic cardioplegia
3210409|NCT01123512|Experimental|Kiva VCF Treatment System|
3210410|NCT01123512|Active Comparator|Balloon Kyphoplasty|
3210411|NCT01123486|Experimental|hydromorphone|open label single arm pharmacokinetic-pharmacodynamic study
3210412|NCT01123473|Experimental|Lapatinib|Chemotherapy + lapatinib
3210413|NCT01123473|Placebo Comparator|Placebo|Chemotherapy + placebo
3210414|NCT01123447|Active Comparator|Surgery|Isolated ulnar shaft fractures will be treated with open reduction and internal fixation using a limited contact dynamic compression (LC-DC) plate with screws. These will remain at the fracture site for the lifetime of the patient.
3210415|NCT01123447|Active Comparator|Short arm cast|Those individuals randomized to the non-operative treatment group will be treated with a closed reduction and short-arm (below-elbow) cast.
3210416|NCT01123434||1|Localised with one of any high recurrence risk factors, or locally advanced Chinese prostate cancer patients confirmed histologically through radical prostatectomy either with laparoscopy or laparotomy within 1 month after surgery. Before the patient recruitment, the investigator has decided to prescribe immediate postoperative adjuvant hormonal treatment to the patient according to the Chinese routine practice.
3210417|NCT01123421||With osteoporotic fracture|Approximately 100 postmenopausal women that have been enrolled in a population-based case-control study that have experienced a clinically-diagnosed fracture of thoracolumbar spine or distal forearm due to minimal or moderate trauma based on review on their inpatient and outpatient medical records will be enrolled.
3210418|NCT01123421||Without osteoporotic fracture|Approximately 100 control women will have no history of a prior spine, hip, or wrist fracture.
3210419|NCT01123408|Experimental|clozapine|During the first 6 weeks clozapine was gradually increased to 500 mg/day and then continued. For the next period, it could vary from 200-800 mg/day;
3210420|NCT01123408|Experimental|Olanzapine|During the first 6 weeks olanzapine was increased to 20 mg and remained fixed for until the end of six week. During the last 6 weeks olanzapine could vary from 10 to 30 mg/day
3210421|NCT01123408|Active Comparator|Haloperidol|During the first 6 weeks haloperidol was increased to 20 mg and remained fixed for until the end of six week. During the last 6 weeks the dose could vary from 10 to 30 mg/day
3210422|NCT01123395|Experimental|Colcrys® (colchicine USP) 0.6 mg intact tablet|One Colcrys® (colchicine USP) 0.6 mg intact tablet taken by mouth
3210423|NCT01123395|Experimental|Colcrys® 0.6 mg tab in apple juice|One Colcrys® 0.6 mg tablet crushed and dissolved in apple juice
3210568|NCT01122355|Active Comparator|niacin arm|
3210424|NCT01123382|Experimental|IM Electrical Stimulation (IM ES)|The IM ES Group will receive electrical stimulation treatment for three weeks (6 hrs daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
3210425|NCT01123382|Active Comparator|Usual Care (UC)|The Usual Care Group will receive outpatient therapy for four weeks, coupled with prescribed daily home exercises.
3210426|NCT01123356|Experimental|Oratumumab and Lenalidomide|"Single arm, non randomized study~Ofatumumab, Lenalidomide: -Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1.~Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28.~Treatment to be administered for up to 6 cycles"
3210427|NCT01123343|Active Comparator|LRI Templates|To evaluate the ability of the TRUEVISION 3D VISUALIZATION AND GUIDANCE SYSTEM FOR MICROSURGERY to provide the ophthalmic surgeon appropriate alignment, orientation and sizing information during cataract or refractive lens exchange surgery compared to the current standard of care (manual markings or heuristic techniques) for LRI.
3210428|NCT01123343|Active Comparator|Capsulorhexis Templates|To evaluate the ability of the TRUEVISION 3D VISUALIZATION AND GUIDANCE SYSTEM FOR MICROSURGERY to provide the ophthalmic surgeon appropriate alignment, orientation and sizing information during cataract or refractive lens exchange surgery compared to the current standard of care (manual markings or heuristic techniques) for Capsulorhexis.
3210429|NCT01123330|Experimental|Motivational Interviewing plus DVD|Caregivers watched a 15-minute educational video designed for the project emphasizing the importance of good oral health in children, and how the caregiver can keep children free from tooth decay. The MI interviewer engaged the parent in a discussion of their thoughts and concerns regarding their child's oral health and what changes they wished to make regarding monitoring their child's oral health. Feedback from the child's dental exam was also reviewed. MI+DVD caregivers received a brochure displaying a photo of their child and for those who chose to set specific goals for their child's oral health, those goals were listed on the brochure. Caregivers choosing not to set specific goals were offered a list of 10 project recommendations regarding dietary intake, oral hygiene, and dental check-ups. The session ended with a dialogue regarding possible barriers to implementing the personal plan and how the caregiver planned to overcome those barriers.
3210430|NCT01123330|Active Comparator|DVD only|Caregivers watched the same educational video. At the end of the video, caregivers were given a glossy-printed brochure displaying the project developed recommendations as well as the child's photograph. The brochure was not re-mailed, as it was for the MI+DVD group and caregivers in this condition did not receive any feedback from the dental examination regarding their child's oral health status.
3210431|NCT01123317|Experimental|Oxytocin|Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2
3210432|NCT01123304|Experimental|MORAb 028|
3210433|NCT01123291|Active Comparator|routine follow-up coronary angiography|routine follow-up coronary angiography at 8-12 after discharge for percutaneous coronary intervention
3210434|NCT01123291|Active Comparator|clinical follow-up|no routine follow-up coronary angiography at 8-12 after discharge for percutaneous coronary intervention
3210435|NCT01123278|Experimental|Testosterone gel|Testosterone transdermal gel 50 mg/day
3210436|NCT01123278|Placebo Comparator|Placebo gel|Placebo gel
3210437|NCT01123265||Anti-TNF|
3210438|NCT01123265||Methotrexate|
3210439|NCT01123252|Active Comparator|Seasonal Affective Rhinitis Group 1|Active Comparator Group
3210440|NCT01123252|Placebo Comparator|Seasonal Affective Rhinitis Group 2|Placebo Group
3210441|NCT01123239|Experimental|Coached Care|"Coached Care pairs patients with linguistically and ethnically matched peer coaches who have been trained to promote patient participation in the medical visit. The coaches, who themselves have diabetes, meet with patients immediately before each of their regularly scheduled medical visits to encourage active involvement in information seeking and decision-making."
3210442|NCT01123239|Active Comparator|Standard Diabetes Education|Patients receive one-on-one diabetes education sessions before each medical visit. These sessions are purely informational, and do not include the specific patient activation components of the coached care intervention.
3210443|NCT01123226|Experimental|Diversified HVLA spinal manipulation|
3210444|NCT01123226|Active Comparator|Trigger point pressure release|
3210445|NCT01123200|Other|Brain Computer Interface In-Home Use|
3210446|NCT01123187|Experimental|islet transplantation|Islet transplantation
3210447|NCT01123174|Experimental|ALGOS group|Algorithm of case management over the 6 months following the suicidal gesture (systematic telephone contact, postcards and crisis card)
3210448|NCT01123174|No Intervention|Control group|Treatment as usual (referral back to the general practitioner)
3210449|NCT01123161|Active Comparator|Group1: IV t-PA and normothermia|IV tpa and normothermia
3210450|NCT01123161|Active Comparator|Group 2 : IV t-PA and hypothermia and anti-shivering treatment|IV tpa and hypothermia and anti-shivering treatment
3210451|NCT01123148|Other|Tilt testing|
3210452|NCT01123135|Active Comparator|Vaginal ERT|1gm of estrogen vaginal cream [EVC] at bed time 3 times a week
3210453|NCT01123135|Placebo Comparator|Placebo|1gm of placebo at bed time 3 times a week
3210454|NCT01123122|Active Comparator|Strict glucose control|
3210455|NCT01123122|No Intervention|Standard glucose control|
3210456|NCT01123109|Other|nulliparous females|nulliparous women over the age of 18
3210457|NCT01123096||Stress Urinary Incontinence|Patients with the primary complaint of stress incontinence with minimal or no urge incontinence symptoms. They must be able to read English as the study involves use of validated questionnaires which have only been validated in English.
3210458|NCT01123083|Experimental|otelixizumab|otelixizumab
3210459|NCT01123083|Placebo Comparator|placebo|placebo
3210460|NCT01123070|Experimental|TL011|TL011 infusions
3210461|NCT01123070|Active Comparator|MabThera|MabThera infusions
3210462|NCT01123044|Experimental|corneal stem cell transplant|
3210463|NCT01123044|No Intervention|conservative medical therapy|
3210464|NCT01123031|Active Comparator|lansoprazole|lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
3210465|NCT01123031|Active Comparator|esomeprazole|esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
3210466|NCT01123018||Older Adults|Persons over age 60 Participants will complete the Memtrax memory screening test
3210467|NCT01123005|Experimental|Carbogen arm|
3210468|NCT01123005|Experimental|DCA arm|
3210469|NCT01122979|Experimental|group 1: insulin glargine + insulin glulisine|insulin glargine once daily + glulisine at meal times
3210470|NCT01122979|Active Comparator|group 2 NPH insulin + regular insulin|NPH insulin (isophane insulin) (2 or more divided doses) + regular insulin at meal times
3210471|NCT01122966|Other|trabeculectomy|Subjects who have trabeculectomies with intraocular bevacizumab injection
3210472|NCT01122953|Experimental|Phenytoin|
3210473|NCT01122953|Active Comparator|Epamin|
3210474|NCT01122940|Active Comparator|Epamin: McNeil LA LLC|
3210475|NCT01122940|Experimental|Phenytoin: Laboratorios Pfizer SA DE CV|
3210476|NCT01122927|Experimental|Phase 1 and Phase 2|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
3210477|NCT01122901|Experimental|Group A (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, 15-17, and 22-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3210478|NCT01122901|Experimental|Group B (gamma-secretase inhibitor RO4929097, surgery)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days -6 to -1. Patients undergo surgical resection on day 0. Within 30 days after surgical resection, patients receive gamma-secretase inhibitor RO4929097 as in group A.
3210479|NCT01122888|Experimental|Arm I (course 1)|Patients receive cilengitide IV over 1 hour twice weekly for 2 weeks.
3210480|NCT01122888|Other|Arm II (course 1)|Patients do not receive treatment and undergo a 2-week rest period.
3210481|NCT01122875|Experimental|A|
3210482|NCT01122862|Active Comparator|0.12% Chlorhexidine Mouthrinse|Commercially available 0.12% Chlorhexidine mouthrinse
3210483|NCT01122862|Active Comparator|Cosmetic mouthrinse|Commercially available cosmetic mouthrinse
3210484|NCT01122862|Placebo Comparator|Sterile Water|Sterile Water
3210485|NCT01122849|Experimental|Prototype Nasal Dilator|Prototype Nasal Dilator
3210486|NCT01122849|Active Comparator|Marketed Nasal Strip|Marketed Nasal Strip
3210487|NCT01122849|Placebo Comparator|Placebo Nasal Strip|Placebo
3210488|NCT01122836|Experimental|Massage Dose 1|This arm receives weekly 60-minute massage for 4 weeks after a 4-week period of no treatment.
3210489|NCT01122836|Experimental|Massage - Dose 2|This arm receives weekly 60-minute massage for 4 weeks.
3210490|NCT01122836|Experimental|Massage - Dose 3|This arm receives 2 weekly 30-minute massage for 4 weeks.
3210491|NCT01122836|Experimental|Massage - Dose 4|This arm receives 2 weekly 60-minute massages for 4 weeks.
3210492|NCT01122836|Experimental|Massage - Dose 5|This arm receives 3 weekly 30-minute massages for 4 weeks.
3210493|NCT01122836|Experimental|Massage - Dose 6|This arm receives 3 weekly 60-minute massages for 4 weeks.
3210494|NCT01122823|Experimental|On-line workshop|The online CDSMP is an internet-based program for people with 1 or more chronic conditions. It's built on self-efficacy theory, facilitated by lay leaders, and uses a curriculum emphasizing problem solving, decision making, and confidence building in weekly sessions over six weeks. It addresses generic topics and skills relevant to managing any chronic condition, including: action plans; problem solving; nutrition; exercise; fatigue; breathing; managing medications; managing stress and emotions; working with health care providers. The structure includes: 1) password-protected, interactive web-based instruction; 2) web-based bulletin board discussion groups to enable participatory learning and support; 3) and a reference book that contains the program content and supplemental information.
3210495|NCT01122797||Alcoholic liver disease|Alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution
3210496|NCT01122797||Controls|Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination.
3210497|NCT01122784|Active Comparator|Group 1|160 Volunteers will be vaccinated with 80 mcg rF1V vaccine with adjuvant at Study Days 0, 56 and 182
3210498|NCT01122784|Active Comparator|Group 2|40 Volunteers will be vaccinated with 80 mcg rF1V vaccine without adjuvant at Study Days 0, 56 and 182
3210499|NCT01122784|Active Comparator|Group 3|160 Volunteers will be vaccinated with 80 mcg rF1V vaccine with adjuvant at Study Days 0, 56 and 121
3210500|NCT01122784|Active Comparator|Group 4|40 Volunteers will be vaccinated with 80 mcg rF1V vaccine without adjuvant at Study Days 0, 56 and 121
3210501|NCT01122771|Active Comparator|Ambisome|15mg Ambisome on days 1,3 and 5
3210502|NCT01122771|Experimental|Ambisome + Miltefosine|Ambisome 5mg + miltefosine 10 days
3210503|NCT01122771|Experimental|Ambisome +paromomycin|AmBisome IV infusion (single dose, day 1) + Paromomycin base 11mg/kg/day IM (Gland Pharma, India) for 10 days (days 2-11)
3210504|NCT01122771|Experimental|Miltefosine + paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
3210505|NCT01122758||COPD cohort|"Inclusion criteria:~Patients ≥ 35 years.~Diagnosis of COPD (GOLD PBD FEV1/FVC ratio <0.70).~Being in a stable phase of disease (8 weeks without exacerbation).~Cummulative smoking ≥ 10 pack-years.~Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);~Absence of malignancy or very serious comorbidities that would prevent study completion.~Exclusion criteria:~Patients <35 years.~Recent exacerbation (<8 weeks).~Not giving written informed consent.~Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,~Diffuse bronchiectasis not associated with COPD.~Presence of malignancy or very serious comorbidities that would prevent study completion.~Difficulty to perform appropriate follow-up."
3210506|NCT01122758||Control cohort|"Inclusion criteria:~Patients ≥ 35 years.~Absence of diagnosis of COPD (GOLD PBD FEV1/FVC ratio >=0.70).~Cummulative smoking ≥ 10 pack-years.~Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);~Absence of malignancy or very serious comorbidities that would prevent study completion.~Exclusion criteria:~Patients <35 years.~Not giving written informed consent.~Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,~Diffuse bronchiectasis not associated with COPD.~Presence of malignancy or very serious comorbidities that would prevent study completion.~Difficulty to perform appropriate follow-up."
3210507|NCT01122745||Catheter Group|Patient will have continuous interscalene block for pain relief placed preoperatively. They will go home with the portable pump. Pain score will be tracked via phone and compared with the control or single short group.
3210508|NCT01122745||Single shot group|Patient will have single shot interscalene block and will go home. Pain will be tracked using phone. Pain will be compared with the catheter group.
3210509|NCT01122732||US Group|Interscalene catheter will be placed with US guidance without any nerve stimulation guidance.
3210510|NCT01122732||NS Group|Catheter will be placed using nerve stimulation guidance
3210511|NCT01122706|Experimental|Taiji|35 healthy participants will regularly during 12 weeks attend Taiji training classes twice a week for one hour. (Sept. 6th till Nov. 25th 2010).
3210512|NCT01122706|No Intervention|waiting list control group|35 healthy participants are not allowed to attend any Taiji training during the intervention period (Sept. 6th till Nov. 25th 2010).
3210513|NCT01122693|Active Comparator|standard 2D ultrasound images|
3210514|NCT01122693|Experimental|high-quality 2D ultrasound images|
3210515|NCT01122693|Active Comparator|nerve stimulation techniques|
3210516|NCT01122680|Experimental|Treatment A|patients inhale 2 puffs (dose of 1.25 mcg) once daily in the evening via Respimat inhaler
3210517|NCT01122680|Experimental|Treatment C|patients inhale 2 puffs (dose of 5 mcg) once daily in the evening via Respimat inhaler
3210518|NCT01122680|Placebo Comparator|Placebo|patients inhale 2 puffs of placebo matching tiotropium once daily in the evening via Respimat inhaler
3210519|NCT01122680|Experimental|Treatment B|patients inhale 2 puffs (dose of 2.5 mcg) once daily in the evening via Respimat inhaler
3210520|NCT01122667|Experimental|Part 1 - Panel A|Subjects with severe renal impairment
3210521|NCT01122667|Experimental|Part 1 - Panel B|Healthy matched control subjects
3210522|NCT01122667|Experimental|Part 2 - Panel C|Subjects with moderate renal impairment
3210523|NCT01122667|Experimental|Part 2 - Panel D|Healthy matched control subjects
3210524|NCT01122667|Experimental|Part 2 - Panel E|Subjects with mild renal impairment
3210525|NCT01122667|Experimental|Part 2 - Panel F|Healthy matched control subjects
3210526|NCT01122654||Control|
3210527|NCT01122654||Experimental 1|
3210528|NCT01122654||Experimental 2|
3210529|NCT01122641|Placebo Comparator|Placebo|
3210530|NCT01122641|Experimental|Vildagliptin|Vildagliptin 50mg bid
3210531|NCT01122628||DVR-A|Patients with a distal radial fracture treated with a DVR-A locking plate
3210532|NCT01122615|Experimental|Sunitinib + Temsirolimus|Sunitinib 12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle. Temsirolimus 6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.
3210533|NCT01122602|Experimental|Arm 1|
3210534|NCT01122602|Active Comparator|Arm 2|
3210535|NCT01122602|Placebo Comparator|Arm 3|
3210536|NCT01122589|Experimental|Motivation Interviewing/CBT|
3210537|NCT01122589|Active Comparator|Control|Receive a smoking cessation pamphlet and watch a series of six weekly 30-45 minutes general wellness videos.
3210538|NCT01122576|Experimental|Crystalens AO|Eligible subjects to undergo small incision cataract surgery and were implanted with the Crystalens AO bilaterally.
3210539|NCT01122576|Active Comparator|ReSTOR|Eligible subjects to undergo small incision cataract surgery and were implanted with the ReSTOR IOL bilaterally.
3210540|NCT01122576|Active Comparator|Tecnis Multifocal IOL|Eligible subjects to undergo small incision cataract surgery and were implanted with the Tecnis Multifocal IOL bilaterally.
3210541|NCT01122524||Chromosomal Abnormality|Fetus affected by chromosomal abnormality
3210542|NCT01122524||No Chromosomal Abnormality|Fetus not affected by chromosomal abnormality
3210543|NCT01122511|Experimental|700 ug dexamethasone and ranibizumab|Intravitreal injection of 700 ug dexamethasone and ranibizumab into study eye
3210544|NCT01122511|Active Comparator|ranibizumab and sham|Intravitreal injection of ranibizumab and Sham into study eye
3210545|NCT01122498|Experimental|1|
3210546|NCT01122498|Experimental|2|
3210547|NCT01122498|Experimental|3|
3210548|NCT01122485|Experimental|Low dose group|two tablets per dose (one tablet of investigational drug and one tablet of placebo)
3210549|NCT01122485|Experimental|High dose group|two tablets per dose (two tablets of investigational drug)
3210550|NCT01122485|Placebo Comparator|Control group|two tablets per dose (two tablets of placebo)
3210551|NCT01122472|Experimental|Lenalidomide|Lenalidomide daily for 3 weeks every 4 weeks for 24 months
3210552|NCT01122472|Placebo Comparator|Placebo|Placebo daily for 3 weeks every 4 weeks for 24 months
3210553|NCT01122459|Active Comparator|Hartmanns|These patients will receive Hartmanns during anaesthesia
3210554|NCT01122459|Active Comparator|Voluven 6%|
3210555|NCT01122446|Placebo Comparator|Placebo comparator|Two doses of placebo day 1 and 30
3210556|NCT01122446|Active Comparator|Alum-GAD (Diamyd)|20 microgram Diamyd day 1 and 30
3210557|NCT01122433|Experimental|C-MAC|After a maximum of three failed intubation attempts using direct laryngoscope the C-MAC video laryngoscope is used as an emergency airway device.
3210558|NCT01122420|Experimental|Goal-Setting Tool|
3210559|NCT01122420|Active Comparator|Health Web Sites|
3210560|NCT01122407|Experimental|trimethaphan|Trimethaphan infusion doses of 4 mg/min
3210561|NCT01122407|Experimental|Trimethaphan plus L-NMMA|Trimethaphan infusion 4 mg/min L-NMMA (L-NG-monomethyl Arginine citrate) infusion 250 mpg/kg/min A small group of arm 1 will receive both drugs.
3210562|NCT01122394|Experimental|Tailored Intervention (TI)|Tailored intervention based on the transtheoretical model
3210563|NCT01122394|Placebo Comparator|Attention Placebo (AP)|Attention Placebo
3210564|NCT01122381|Experimental|Arm 1-ethosuximide|"ethosuximide blinded capsules of 250mg ESX; titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed 30mg/kg/d) vs maximum tolerability"
3210565|NCT01122381|Placebo Comparator|Arm 2-placebo comparator|"placebo same size blinded capsules as the 250mg ESX; similar titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed 30mg/kg/d) vs maximum tolerability"
3210566|NCT01122368|Experimental|1 Micafungin|IV
3210567|NCT01122368|Placebo Comparator|2 Placebo|IV
3210569|NCT01122355|Active Comparator|fenofibrate arm|
3210570|NCT01122342|Experimental|Vaginal Testosterone|Daily application of vaginal testosterone for 28 days.
3210571|NCT01122329|Placebo Comparator|inactive food packet|
3210572|NCT01122329|Active Comparator|Axona®|
3210573|NCT01122316|Experimental|Metformin|
3210574|NCT01122303||SJS|Stevens-Johnson syndrome patients with dry eye
3210575|NCT01122303||Control|Non-autoimmune dry eye patients
3210576|NCT01122290||negative emotion|Children experienced induction of mild negative emotion through a jigsaw with a missing piece (negative emotion group)
3210577|NCT01122290||neutral emotion|Vs. Same task with No missing piece (neutral emotion).
3210578|NCT01122264|Experimental|Tadalafil on demand|10 milligrams (mg) or 20 mg on demand
3210579|NCT01122264|Experimental|Tadalafil once a day|5 mg or 2.5 mg once a day
3210580|NCT01122264|Active Comparator|Sildenafil Citrate|50 mg, 100 mg, or 25 mg on demand
3210581|NCT01122251|Experimental|Lercanidpine + Valsartan|L10/V80, L20/V80, L10/V160, L20/V160
3210582|NCT01122251|Active Comparator|Lercanidipine or Valsartan|L10, L20, V80, V160
3210583|NCT01122251|Placebo Comparator|Placebo|Placebo comparators of Lercanidipine and Valsartan
3210584|NCT01122238|Experimental|1, Nicotine Patch, Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
3210585|NCT01122238|Experimental|2, Nicotine Patch, Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
3210586|NCT01122238|Experimental|3, Nicotine Patch, Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
3210587|NCT01122238|Experimental|4, Nicotine Patch, Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
3210588|NCT01122238|Experimental|5, Nicotine Patch, No Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
3210589|NCT01122238|Experimental|6, Nicotine Patch, No Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
3210590|NCT01122238|Experimental|7, Nicotine Patch, No Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
3210591|NCT01122238|Experimental|8, Nicotine Patch, No Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
3210592|NCT01122238|Experimental|9, No Nicotine Patch, Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
3210593|NCT01122238|Experimental|10, No Nicotine Patch, Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
3210594|NCT01122238|Experimental|11, No Nicotine Patch, Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
3210595|NCT01122238|Experimental|12, No Nicotine Patch, Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
3210596|NCT01122238|Experimental|13, No Nicotine Patch, No Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
3210597|NCT01122238|Experimental|14, No Nicotine Patch, No Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
3210598|NCT01122238|Experimental|15, No Nicotine Patch, No Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
3210599|NCT01122238|Experimental|16, No Nicotine Patch, No Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
3210600|NCT01122225||Septic shock|
3210601|NCT01122199|Experimental|Open Label|RAD001+ AMG479
3210602|NCT01122186|Experimental|Intervention Condition|Eight sessions of Motivational Interviewing and Cognitive Behavioral Skills Training, adapted to target both MA use and medication adherence, as well as sexual risk behaviors and polydrug use.
3210603|NCT01122186|Active Comparator|Education Condition|Eight sessions of education with content designed to mirror the information covered in the intervention condition. The content will be as follows: 3 sessions focusing on medication adherence; 3 sessions focusing on the dangers of methamphetamine use; 1 session addressing sexual risk; and 1 session addressing poly-substance use.
3210604|NCT01122173|Experimental|Robotic catheter manipulation, Ablation|To evaluate the safety and effectiveness of the family of Artisan guide catheters when used to remotely introduce and position commercially available cardiac RF ablation catheters to treat subjects with paroxysmal atrial fibrillation.
3210605|NCT01122160|Placebo Comparator|placebo|Placebo with berries (blackberries + strawberries)
3210606|NCT01122160|Experimental|omeprazole|Prilosec (omeprazole) 20.6 mg tablet with berries (blackberries + strawberries)
3210607|NCT01122147|Active Comparator|chamomilla tincture mouthwash|Chamomile comprises bisaboloids, matricine and chamazulene, flavonoids, and cumarins having therapeutical anti-inflammatory, analgesic, musculotropic, and spasmolytic action
3210608|NCT01122147|Placebo Comparator|placebo mouth wash|placebo mouthwash is produced with the same taste and smell for using in placebo/ control group.
3210609|NCT01122134||20 adults with severe malaria|20 adult patients admitted with severe malaria
3210610|NCT01122121|Experimental|Combined Radiotherapy and Hormone Therapy|Leuprorelin 11.25 milligram (mg) sustained release (SR), injection, subcutaneously, once every 3 months up to 3 years and flutamide 250 mg, tablet, orally, thrice daily for 30 days from the first dose of leuprorelin. Radiotherapy 70 +/- 4 Gray (Gy) in 35 fractions at a rate of 5 fractions of 2 Gy per week up to 3 years. An interval of a maximum of 2 weeks is authorized between radiation of the pelvis with 50 Gy (±4) (5 weeks) and radiation of the prostate with an additional 20 Gy.
3210611|NCT01122121|Active Comparator|Hormone Therapy alone|Leuprorelin 11.25 mg SR, injection, subcutaneously, once every 3 months up to 3 years and flutamide 250 mg, tablet, orally, thrice daily for 30 days from the first dose of leuprorelin.
3210612|NCT01122108|Active Comparator|Cholestyramine 12 grams|Cholestyramine 12 grams
3210613|NCT01122108|Active Comparator|Colesevelam HCl|Colesevelam HCl, 4 grams
3210614|NCT01122095||Psoriasis|Children with psoriasis Age matched controls without psoriasis or other significant inflammatory disease
3210615|NCT01122095||Control patient|Age matched, without psoriasis or significant inflammatory disease
3210616|NCT01122069||Contrast echocardiography|110 patients with acute non-ST elevation myocardial infarct were examined with contrast echocardiography prior to coronary angiography.
3210617|NCT01122056|Active Comparator|A = Active group|Patients will receive interactive exercise training session from an experienced multiple sclerosis
3210618|NCT01122056|No Intervention|B = Control group (Placebo Comparator)|Patients will receive general advice about benefits/side effects of physical activity in multiple sclerosis.
3210619|NCT01122043||Endoglide|Patients with moderate degrees of corneal decompensation from a variety of disorders which require DSAEK corneal transplantation surgery, with or without concurrent cataract surgery, to restore visual acuity.
3210620|NCT01122030|Experimental|Cohort 1|In this cohort 9 participants received one 0.1 mg naldemedine tablet and 3 participants received matching placebo administered on Day 15 under fasted conditions.
3210621|NCT01122030|Experimental|Cohort 2|In this cohort 9 participants received a single dose of 0.3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
3210622|NCT01122030|Experimental|Cohort 3|In this cohort 9 participants received a single dose of 1 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
3210623|NCT01122030|Experimental|Cohort 4|In this cohort 9 participants received a single dose of 3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
3210624|NCT01122030|Experimental|Cohort 5|In this cohort 9 participants received a single dose of 0.03 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.
3210625|NCT01122030|Experimental|Cohort 6|In this cohort 9 participants received a single dose of 0.01 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.
3210626|NCT01122017|Experimental|Medial Opening-Wedge Osteotomy|Medial Opening-Wedge Osteotomy (MOWO) is an approach for the correction of malalignment of the knee
3210627|NCT01122004|Active Comparator|Gabapentin|
3210628|NCT01122004|Active Comparator|Pregabalin|
3210629|NCT01121978|No Intervention|Conservative treatment group|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole or vision deterioration occurs
3210630|NCT01121978|Experimental|Early vitrectomy|Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine green dye assisted internal limiting membrane peeling
3210631|NCT01121965|No Intervention|Conservative treatment group|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole occurs
3210632|NCT01121965|Experimental|Early vitrectomy|Pars plana vitrectomy with ILM peeling would be employed when visual symptoms occur.
3210633|NCT01121952|Placebo Comparator|Placebo|Single high-velocity, low-amplitude (HVLA) thrust manipulation towards Tibia, not affecting the dysfunctional talo-crural joint
3210634|NCT01121952|Experimental|Treatment|Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation on dysfunctional talo-crural joint
3210635|NCT01121939|Experimental|1|combination of bevacizumab, pertuzumab, and sandostatin for patients with advanced neuroendocrine cancers
3210636|NCT01121926|Experimental|Trazodone HCl OAD|OAD: Once A Day
3210637|NCT01121926|Active Comparator|Trazodone HCl (Apotex Corp.)|
3210638|NCT01121913|Experimental|Trazodone Contramid® OAD (test product 1)|Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)
3210639|NCT01121913|Experimental|Trazodone Contramid® OAD(test product 2)|Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)
3210640|NCT01121913|Active Comparator|Triticco®|
3210641|NCT01121913|Active Comparator|Desyrel®|
3210642|NCT01121900|Experimental|Trazodone HCl OAD|OAD: Once A Day
3210643|NCT01121900|Active Comparator|Trazodone HCl (Apotex Corp.)|
3210644|NCT01121887|Active Comparator|Standard treatment|
3210645|NCT01121887|Experimental|Motivational Interviewing|
3210646|NCT01121874|Active Comparator|LRTI|These patients will undergo ligament reconstruction with tendon interposition (LRTI) surgery. They will serve as a control group, against which to compare the investigational surgical technique.
3210647|NCT01121874|Experimental|Suture fixation system|CMC arthroplasty which reconstructs palmar oblique ligament using a suture fixation system.
3210749|NCT01121198|Experimental|ASP1941 single arm|
3210750|NCT01121198|Experimental|ASP1941 repeated arm|
3210751|NCT01121198|Placebo Comparator|placebo single arm|
3210648|NCT01121874|Experimental|Suture fixation system + 2 week immobilization|CMC arthroplasty which reconstructs palmar oblique ligament using a suture fixation system, and with a decreased immobilization time from 6 to 2 weeks post-surgery.
3210649|NCT01121848|Active Comparator|5-FU & LV|"Day 1: LV 400 mg/m2 (given as a 2-hour infusion)~Day 1 and 2: 5-FU given as a bolus IV 400 mg/m2 dose on Day 1 followed by 2400 mg/m2 continuous infusion over 46 hours.~This chemotherapy regimen will be administered each two weeks."
3210650|NCT01121848|Experimental|XELOX or modified FOLFOX-6|"XELOX:~Day 1: Oxaliplatin 130 mg/m2 (2 hours infusion)~This chemotherapy regimen will be administered each two weeks.~OR modified FOLFOX-6:~Day 1: Oxaliplatin 85 mg/m2 (given as a 2-hour infusion)~Day 1: LV 400 mg/m2 (given as a 2-hour infusion simultaneous to oxaliplatin)~Day 1 and 2: 5-FU given as a bolus IV 400 mg/m2 dose on Day 1 followed by 2400 mg/m2 continuous infusion over 46 hours (Day 1 and 2)~This chemotherapy regimen will be administered each two weeks."
3210651|NCT01121835|Experimental|Insulin glargine|"Administered once a day in the evening, at the same time every day. The starting daily dose is 0.2 U/Kg of body weight or 12 U, at the investigator's decision.~Insulin glulisine is administered for patients of the insulin glargine group requiring insulin glulisine at week 12 (visit 11).~Insulin glulisine is administered prior (10-15 min) to the main meal of the day, which is the meal with highest Post-Prandial Plasma Glucose (PPPG) on the 3 profiles performed before week 12.~Starting dose is of 4 units per day."
3210652|NCT01121835|Experimental|Premixed insulin|administered once a day (in the evening at dinner) or twice a day (in the morning before breakfast and in the evening at dinner). Starting daily dose will be 6 U at breakfast and 6 U at dinner, if administered twice a day or 12 U at dinner if administered once a day
3210653|NCT01121822|Experimental|Group 1|Participants at age 18 to 59 years
3210654|NCT01121822|Experimental|Group 2|Participants at age 60 years or older
3210655|NCT01121809|Other|Raltegravir|Raltegravir 400 mg bid
3210656|NCT01121809|Other|Etravirine|Etravirine 200 mg bid
3210657|NCT01121796|Active Comparator|Vitamin D|
3210658|NCT01121796|Placebo Comparator|Placebo|
3210659|NCT01121796|Active Comparator|Unique vehicle for Vitamin D supplementation|
3210660|NCT01121783|Active Comparator|Lactisole-Glucose|
3210661|NCT01121783|Active Comparator|Lactisole-water|
3210662|NCT01121783|Placebo Comparator|Water-Glcuose|
3210663|NCT01121783|Placebo Comparator|Water-Water|
3210664|NCT01121770|Experimental|Arixtra|
3210665|NCT01121757|Experimental|Azacitidine followed by Lenalidomide|"Azacitidine 75 mg/m2 subcutaneously (SC) or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.~Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1."
3210666|NCT01121757|Experimental|Lenalidomide followed by Azacitidine|"Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.~Azacitidine 75 mg/m2 subcutaneously (SC) or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a."
3210667|NCT01121731|Experimental|Interferon α-5|
3210668|NCT01121731|Experimental|Interferon α-5 plus Interferon α-2b|
3210669|NCT01121731|Active Comparator|Interferon α-2b (INTRON® A)|
3210670|NCT01121718|Experimental|ICG Intervention|Intraoperative NIR fluorescence imaging was performed after injection of 1.0 ml of 100 µM, 250 µM or 500 µM of ICG:HSA in four quadrants around the primary lesion. (The intervention to be administered is the ICG.)
3210671|NCT01121705|No Intervention|A1. standard duration|Patients were randomly assigned in a 1:1 ratio to two treatment arms. In the standard treatment group (A1), patients were treated for 24 weeks irrespective of the HCV RNA status at week 4 with Peg-interferon alfa-2b at a dose of 1.5 mcg per kilogram of body weight weekly in combination with oral ribavirin administered at a dose of 1000 mg/day for patients with a weight <75 kg or 1200 mg/day for those with a weight of ≥75 kg. Patients enrolled in Arm A1 will be treated for standard 24 weeks duration of treatment with standard dosages of PegInterferon alpha 2b and weight-based dosages of ribavirin.
3210672|NCT01121705|Experimental|B 1 I or II|In the variable treatment group, patients with a virologic response at week 4 will receive treatment for 12 weeks and those without a virologic response at 4 weeks treatment for 36 weeks. Patients without RVR will be treated for 24 or 36 weeks and labelled (B1I) or (B1II, respectively Intervention: different durations of treatment for patients without RVR
3210673|NCT01121692|Experimental|VCT/Women's CoOp|
3210674|NCT01121692|Experimental|Women's CoOp/Men's CoOp|
3210675|NCT01121692|Experimental|Couples CoOp|
3210676|NCT01121679||Patients aged 80 years and older|Patients aged 80 years and older and hospitalized in a cardiology department
3210677|NCT01121666|Active Comparator|Gonal-f® (Follitropin alfa)|
3210678|NCT01121666|Experimental|AFOLIA-150 (Follitropin alfa)|
3210679|NCT01121640|Other|CA125 every screen, HE4 at confirmatory screen.|CA125 will be used at every screen. Women with a parametric empirical Bayes (PEB) longitudinal algorithm score above the 90th percentile will be asked to return for early recall screening. Women with a PEB score above the 95th percentile will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
3210680|NCT01121640|Other|CA125 and HE4 at every screen.|CA125 and HE4 will both be used at every screen. Women with a PEB score above the 95th percentile on either CA125 or HE4 will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
3210681|NCT01121627|Experimental|Computerized cognitive training|A 12 week computerized cognitive training
3210682|NCT01121614|Experimental|LOTUS|LOTUS ultrasonic instrument
3210683|NCT01121614|Experimental|Ethicon Harmonic Scalpel|Ultrasonic instrument
3210684|NCT01121614|Experimental|LigaSure|Bipolar feedback vessel sealing device
3210685|NCT01121601|Experimental|Group COSEAL|
3210686|NCT01121601|Active Comparator|Reference group|
3210687|NCT01121588|Experimental|Crizotinib|
3210688|NCT01121575|Experimental|Arm 1|PF-02341066 AND PF-00299804: Patients will be treated with combined cMET inhibitor (PF-02341066) and panHER inhibitor (PF-00299804).
3210752|NCT01121198|Placebo Comparator|placebo repeated arm|
3210753|NCT01121185|Experimental|MBL-HCV1|
3210689|NCT01121575|Experimental|Arm 2|PF-00299804 FOLLOWED BY COMBINED PF-02341066 AND PF-00299804: Patients will be treated with single agent panHER inhibitor (PF-00299804) until disease progression and then with the maximum tolerated combined dose of cMET inhibitor (PF-02341066) and panHER inhibitor (PF-00299804).
3210690|NCT01121562|Experimental|Sunitinib arm|
3210691|NCT01121549||Aromasin|All patients included in the study
3210692|NCT01121536|Experimental|Armodafinil 150-200 mg/day|Participants began taking armodafinil at a dosage of 50 mg/day; the dosage was increased by 50 mg/day on days 2 and 4, up to a dosage of 150 mg/day. At the discretion of the investigator, the dosage of armodafinil may be increased to 200 mg/day on day 6 or thereafter, and reduced to 150mg/day if the higher dose is not well tolerated. Treatment was administered for six months.
3210693|NCT01121523|Experimental|Cue-directed tactile stimulation|
3210694|NCT01121523|Active Comparator|Control group|
3210695|NCT01121497|Experimental|Physostigmine|Colonoscopy sedation with or without physostigmine
3210696|NCT01121484|Experimental|desvenlafaxine succinate sustained-release|
3210697|NCT01121484|Placebo Comparator|Placebo|
3210698|NCT01121471|Placebo Comparator|Safflower Oil|8.0 g/day safflower oil
3210699|NCT01121471|Experimental|CLA 6.4g/day|Conjugated linoleic acid at a dose of 6.4g/day in a supplement with a total of 8.0g oil
3210700|NCT01121445|No Intervention|CPAP with heated humidification|Standard of care
3210701|NCT01121432||Mediastinal lymphadenopathy|
3210702|NCT01121419||Neuroblastoma|
3210703|NCT01121406|Experimental|BI 6727|Patients receive BI 6727 infusion every 3 weeks
3210704|NCT01121406|Active Comparator|Cytotoxic|At the investigator discretion, patient will receive one of the following cytotoxics: topotecan, paclitaxel, gemcitabine or liposomal doxorubicin
3210705|NCT01121393|Experimental|Arm A BIBW 2992|Patients receive a tablet of BIBW 2992 daily until progression or unacceptable toxicity
3210706|NCT01121393|Active Comparator|Arm B Chemotherapy|Patients receive Gemcitabine and Cisplatin, maximum is 6 courses
3210707|NCT01121380|Experimental|Cohort A - 10 mg|
3210708|NCT01121380|Experimental|Cohort B - 20 mg|
3210709|NCT01121380|Experimental|Cohort C - 40 mg|
3210710|NCT01121380|Experimental|Cohort D - 80 mg|
3210711|NCT01121380|Experimental|Cohort E - X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
3210712|NCT01121380|Experimental|Cohort F - 2X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
3210713|NCT01121380|Experimental|Cohort G - 4X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
3210714|NCT01121380|Placebo Comparator|Placebo|In each cohort there is a placebo arm
3210715|NCT01121367||Emphysema-alone|
3210716|NCT01121367||CPFE group|
3210717|NCT01121367||IPF-alone|
3210718|NCT01121367||smokers|
3210719|NCT01121367||nonsmokers|
3210720|NCT01121354|Experimental|Cefazolin 2g (Test)|
3210721|NCT01121354|Active Comparator|Cefazolin 1.5g (Control)|
3210722|NCT01121341|Experimental|EVOH|Procedure: Endoscopic vein with an open CO2 system harvesting
3210723|NCT01121341|Active Comparator|OVH|Procedure: Conventional vein harvesting
3210724|NCT01121328|Experimental|Autologous cord blood transfusion|Collected cord blood at birth will be transfused for the preterm neonate
3210725|NCT01121315||1|Diabetes type II patients, according to medical records, prescriptions or lab results, followed for >6 months after diagnosis.
3210726|NCT01121302|Experimental|1|dose escalating
3210727|NCT01121302|Placebo Comparator|2|placebo
3210728|NCT01121289|Experimental|NN1218, formulation A|
3210729|NCT01121289|Experimental|NN1218, formulation B|
3210730|NCT01121289|Experimental|NN1218, formulation B (high)|
3210731|NCT01121289|Experimental|NN1218, formulation C|
3210732|NCT01121289|Experimental|NN1218, formulation D|
3210733|NCT01121289|Active Comparator|insulin aspart|
3210734|NCT01121276|Experimental|NN1218, formulation A|
3210735|NCT01121276|Experimental|NN1218, formulation B|
3210736|NCT01121276|Experimental|NN1218, formulation C|
3210737|NCT01121276|Experimental|NN1218, formulation D|
3210738|NCT01121276|Active Comparator|insulin aspart|
3210739|NCT01121263||Angiogram Review Group|All consecutive and consenting patients undergoing diagnostic cardiac catheterization in a 3 month period
3210740|NCT01121263||Therapeutic Intervention Group|"Cohort 2 Therapeutic Intervention Group - HCR Patients (including those from the angiogram review group) who undergo Hybrid coronary revascularization (HCR) with minimally invasive LIMA-LAD CABG, OR~Cohort 2 Therapeutic Intervention Group - PCI Patients (including those from the angiogram review group) who meet the proposed anatomic and clinical eligibility criteria and undergo multivessel Percutaneous Coronary Intervention with Drug Eluting Stents"
3210741|NCT01121250|Experimental|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
3210742|NCT01121250|Active Comparator|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
3210743|NCT01121250|No Intervention|Usual Care|Participants do not receive any services.
3210744|NCT01121237||CKD5, renal anaemia, haemodialysis|CKD5, renal anaemia, haemodialysis receiving recombinant human erythropoietin alfa (biosimilar)
3210745|NCT01121224|Active Comparator|BMS Group|Patients who receive a bare metal stent in the saphenous vein graft target lesion(s).
3210746|NCT01121224|Experimental|DES Group|Patients who receive a drug-eluting stent in the saphenous vein graft target lesion(s).
3210747|NCT01121211|Active Comparator|Testosterone|Testosterone x 24 weeks
3210748|NCT01121211|Placebo Comparator|Placebo|Placebo x 24 weeks
3210754|NCT01121185|Placebo Comparator|0.9% sodium chloride|
3210755|NCT01121172||obese|obese subjects according to International Obesity Task Force criteria
3210756|NCT01121172||lean|
3210757|NCT01121159||Preoperatively preformed orbital plates|Reconstruction with MatrixMIDFACE Preformed Orbital Plate (Synthes) or Custom-made orbital implant
3210758|NCT01121159||Non-preformed orbital plates|Reconstruction with Orbital Floor Mesh Plate or SynPOR Titanium Reinforced Fan Sheet (both Synthes)
3210759|NCT01121146|Active Comparator|Crosslinked Marathon polyethylene|
3210760|NCT01121146|Active Comparator|Standard Enduron polyethylene|
3210761|NCT01121133|Experimental|Arm A (navitoclax and rifampin)|
3210762|NCT01121120|Experimental|TXA127|300mcg/kg/day administered subcutaneously up to 28 days
3210763|NCT01121120|Placebo Comparator|Placebo|300mcg/kg/day administered subcutaneously up to 28 days
3210764|NCT01121107|Experimental|Left Atrial Pressure Monitoring System|Left Atrial Pressure (LAP) Monitoring System
3210765|NCT01121107|Active Comparator|Patient Advisor Module|Patient Advisory Module
3210766|NCT01121081|Placebo Comparator|Placebo|sugar pills
3210767|NCT01121081|Experimental|Dunaliella|drug
3210768|NCT01121068||Health care workers|
3210769|NCT01121055|Placebo Comparator|Control|Placebo 1T by mouth (po) at night one day before FB and placebo 1T po 30min before the FB
3210770|NCT01121055|Experimental|Lorazepam|Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB
3210771|NCT01121042|Active Comparator|Ondansetron|Ondansetron oral capsule 8mg daily
3210772|NCT01121042|Placebo Comparator|Placebo|Placebo (100% lactose) matched oral capsule
3210773|NCT01121029|Experimental|Hematopoietic stem cells|
3210774|NCT01121016|Active Comparator|combination therapy|combination therapy with inhaled budesonide and oral montelukast
3210775|NCT01121016|Placebo Comparator|monotherapy|monotherapy with inhaled budesonide and placebo of montelukast
3210776|NCT01121003|Other|Low fructose diet/no exercise|
3210777|NCT01121003|Experimental|high fructose diet/no exercise|
3210778|NCT01121003|Experimental|high fructose diet+exercise|
3210779|NCT01120990|Other|All patients|All eligible patients in the study consist a single group and the same intervention is assigned to all of them.
3210780|NCT01120977||Male|
3210781|NCT01120977||Female|
3210782|NCT01120964|Experimental|Intravenous L-Citrulline|
3210783|NCT01120964|Placebo Comparator|Placebo of Intravenous L-Citrulline|
3210784|NCT01120925|Experimental|MNC|Bone marrow derived MNC
3210785|NCT01120925|Experimental|CD133|CD133 derived from Bone marrow
3210786|NCT01120925|Placebo Comparator|Control|Normal saline with 5% Human Serum Albumin
3210787|NCT01120912|Experimental|Oral insulin and placebo|
3210788|NCT01120899|Experimental|Minocycline|
3210789|NCT01120873|Experimental|Metamin 3D|A randomized, double-blinded and placebo-controlled study
3210790|NCT01120847||Veterans with PTSD|No intervention; this is an observational study.
3210791|NCT01120847||Control group w/out PTSD|No intervention; this is an observational study.
3210792|NCT01120834|Experimental|all subjects|
3210793|NCT01120821|Experimental|Study drug|Gleevec treatment
3210794|NCT01120808|Experimental|All Participants|Participants were registered competitors in RacingThePlanet 6 stage 7 day 155mile (250km) ultramarathon.
3210795|NCT01120795|Experimental|pegylated interferon and ribavirin|Anti hepatitis C agents
3210796|NCT01120782|Active Comparator|etafilcon A toric new lens/etafilcon A toric lens|The lens worn first is a new etafilcon A toric contact lens and the lens worn second is a marketed etafilcon A toric contact lens. Each lens worn for a maximum of 15 minutes bilaterally.
3210797|NCT01120782|Active Comparator|etafilcon A toric lens/etafilcon A toric new lens|The lens worn first is a marketed etafilcon A toric contact lens and the lens worn second is a new etafilcon A toric contact lens. Each lens worn for a maximum of 15 minutes bilaterally.
3210798|NCT01120769|Active Comparator|Acetaminophen|
3210799|NCT01120769|Placebo Comparator|Placebo|
3210800|NCT01120756|Experimental|Goal-oriented attentional self-regulation training|Goal-oriented attentional self-regulation training (GOALS).
3210801|NCT01120756|Experimental|Pathfinder Attention Regulation Training|Pathfinder Attention Regulation Training.
3210802|NCT01120756|Active Comparator|Brain Health Education|Brain Health Education (EDU)
3210803|NCT01120756|Experimental|Tonic and Phasic Alertness Training|Tonic and Phasic Alertness Training (TAPAT)
3210804|NCT01120730|Active Comparator|HES|Fluid resuscitation with HES
3210805|NCT01120730|Placebo Comparator|ringers lactat|Standard treatment
3210806|NCT01120717|Experimental|QVA149|110µg/50µg capsule for oral inhalation, once daily, delivered by a single dose dry powder inhaler (SDDPI)
3210807|NCT01120717|Placebo Comparator|Placebo|Placebo to match QVA149, capsules for inhalation once daily, delivered by an SDDPI
3210808|NCT01120704|Experimental|1, 26Wks, Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3210809|NCT01120704|Experimental|2, 26Wks, Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3210810|NCT01120704|Experimental|3, 26Wks, Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3210811|NCT01120704|Experimental|4, 26Wks, Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3210812|NCT01120704|Experimental|5, 26Wks, Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3210813|NCT01120704|Experimental|6, 26Wks, Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3210814|NCT01120704|Experimental|7, 26Wks, Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3210815|NCT01120704|Experimental|8, 26Wks, Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3210816|NCT01120704|Experimental|9, 26Wks, No Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3210817|NCT01120704|Experimental|10, 26Wks, No Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3210818|NCT01120704|Experimental|11, 26Wks, No Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3210819|NCT01120704|Experimental|12, 26Wks, No Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3210820|NCT01120704|Experimental|13, 26Wks, No Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3210821|NCT01120704|Experimental|14, 26Wks, No Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3210822|NCT01120704|Experimental|15, 26Wks, No Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3210823|NCT01120704|Experimental|16, 26Wks, No Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3210824|NCT01120704|Experimental|17, 8Wks, Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3210825|NCT01120704|Experimental|18, 8Wks, Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3210826|NCT01120704|Experimental|19, 8Wks, Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3210827|NCT01120704|Experimental|20, 8Wks, Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3210828|NCT01120704|Experimental|21, 8Wks, Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3210829|NCT01120704|Experimental|22, 8Wks, Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3210830|NCT01120704|Experimental|23, 8Wks, Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3210831|NCT01120704|Experimental|24, 8Wks, Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3210832|NCT01120704|Experimental|25, 8Wks, No Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3210833|NCT01120704|Experimental|26, 8Wks, No Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3210834|NCT01120704|Experimental|27, 8Wks, No Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3210835|NCT01120704|Experimental|28, 8Wks, No Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3210836|NCT01120704|Experimental|29, 8Wks, No Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3210837|NCT01120704|Experimental|30, 8Wks, No Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3210838|NCT01120704|Experimental|31, 8Wks, No Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3210839|NCT01120704|Experimental|32, 8Wks, No Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3210840|NCT01120691|Experimental|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
3210841|NCT01120691|Active Comparator|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
3210842|NCT01120691|Active Comparator|open-label tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
3210843|NCT01120678||Neonates assessed for sepsis.|
3210844|NCT01120665|Experimental|PLACEBO-CONTROL|PLACEBO + CONTROL TO EXERCISE
3210845|NCT01120665|Experimental|ESTROGEN THERAPY + CONTROL|ESTROGEN THERAPY (estradiol valerate 1 mg/dia orally) + CONTROL TO EXERCISE
3210846|NCT01120665|Experimental|PLACEBO+AEROBIC TRAINING|PLACEBO + AEROBIC TRAINING (cicle-ergometer, 50 minutes, 3x week)
3210847|NCT01120665|Experimental|ESTROGEN THERAPY + AEROBIC TRAINING|ESTROGEN THERAPY (estradiol valerate 1 mg/dia orally) + AEROBIC TRAINING (cicle-ergometer, 50 minutes, 3x week)
3210848|NCT01120652|Experimental|Mind-Body Skills Training|This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices.
3210849|NCT01120652|Active Comparator|Supportive Counseling|This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice.
3210850|NCT01120639|Experimental|PTV (Planning Target Volume) < 60 cm3|"Hypofractionated stereotactic radiosurgery with concurrent temozolomide~Dose Levels:~25 Gy in 5 fractions~30 Gy in 5 fractions~35 Gy in 5 fractions~40 Gy in 5 fractions"
3210851|NCT01120639|Experimental|Planning Target Volume of 60 to 150 cm3|"Hypofractionated stereotactic radiosurgery with concurrent temozolomide~Dose Levels:~25 Gy in 5 fractions~30 Gy in 5 fractions~35 Gy in 5 fractions~40 Gy in 5 fractions"
3210852|NCT01120626|Active Comparator|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
3210853|NCT01120626|Placebo Comparator|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
3210854|NCT01120613|Experimental|chronotherapy|Patients identified with Nocturnal Hypertension, will have one of the blood pressure medications switched from daytime dosing to nighttime dosing
3210855|NCT01120600|Experimental|Odanacatib 50 mg once weekly|Participants will receive one Odanacatib 50 mg tablet once weekly. In addition, they will receive a weekly dose 5600 IU of open-label Vitamin D3 as well as a sufficient supply of open-label calcium carbonate so that their total daily calcium intake from both dietary and supplemental sources is approximately 1200 mg.
3210856|NCT01120600|Placebo Comparator|Placebo once weekly|Participants will receive one Placebo tablet once weekly. In addition, they will receive a weekly dose 5600 IU of open-label Vitamin D3 as well as a sufficient supply of open-label calcium carbonate so that their total daily calcium intake from both dietary and supplemental sources is approximately 1200 mg.
3210857|NCT01120574|No Intervention|1|Oxygen therapy group.
3211047|NCT01119339|Experimental|LAS 41004 dosage 4|
3210858|NCT01120574|Active Comparator|2|Home mechanical ventilation plus oxygen therapy group.
3210859|NCT01120548|Experimental|Rehabilitation + Ventilation Group|Patient Heart Failure with sleep disordered breathing who follows ventilation therapy and physical training.
3210860|NCT01120548|No Intervention|Rehabilitation Only Group|
3210861|NCT01120535|Experimental|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
3210862|NCT01120522|Experimental|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
3210863|NCT01120509|Experimental|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
3210864|NCT01120496|Experimental|hypertonic saline|hypertonic saline (HS)
3210865|NCT01120496|Placebo Comparator|normal saline (NS)|normal saline (NS)
3210866|NCT01120470|Experimental|OGX-427 and Prednisone|OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427
3210867|NCT01120470|Active Comparator|Prednisone|"Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization"
3210868|NCT01120457|Experimental|Arm 1: Dose Escalation and Expansion cohort (AML Patients)|"Dose Escalation: BMS-936564 0.3-10 mg/kg solution, Intravenous, Single 60 minute infusion as monotherapy 7 days/cycle 1 and with chemotherapy for subsequent cycles (28 days/cycle)~Dose Expansion: BMS-936564 maximum tolerated dose (MTD) based on dose escalation, solution, Intravenous, Single 60 minute infusion as monotherapy 7 days/cycle 1 and with chemotherapy for subsequent cycles (28 days/cycle)"
3210869|NCT01120457|Experimental|Arm 2: Dose Expansion cohort (DLBCL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
3210870|NCT01120457|Experimental|Arm 3: Dose Expansion cohort (CLL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
3210871|NCT01120457|Experimental|Arm 4: Dose Expansion cohort (FL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
3210872|NCT01120444|Active Comparator|Subcutaneous delivery of insulin|A bolus dose of insulin will be given subcutaneously just prior to a standardized meal.
3210873|NCT01120444|Experimental|Intradermal delivery of insulin|A bolus dose of insulin will be given intradermally just prior to a standardized meal
3210874|NCT01120431|Active Comparator|Oral rehydration therapy|
3210875|NCT01120431|Experimental|hylenex-facilitated SC hydration|
3210876|NCT01120418|Experimental|Besifloxacin Ophthalmic Suspension 0.6%|Topical ocular administration three times daily (TID) for 5 days
3210877|NCT01120405|Experimental|Xenon|0.8-1.1 minimum alveolar concentration (MAC) Xenon in 30 % oxygen (Group A)
3210878|NCT01120405|Active Comparator|sevoflurane|0.8-1.1 Minimum Alveolar Concentration (MAC) Sevoflurane in 30 % oxygen (Group B)
3210879|NCT01120392|Experimental|Treatment group - Nintendo wii.|
3210880|NCT01120392|Active Comparator|conventional - Physical Therapy|
3210881|NCT01120379||XV-LTF cohort|
3210882|NCT01120366|Active Comparator|SWITCH|Tocilizumab monotherapy
3210883|NCT01120366|Active Comparator|ADD-ON|Tocilizumab plus methotrexate combination
3210884|NCT01120353||Cancer survivors|Survivors of cancer, diagnosed under 21 years of age, between 1970 and 1999 This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, for an increased risk of late-occurring events associated with excess mortality and morbidity.
3210885|NCT01120353||Sibling Controls|A group of sibling controls will be identified to provide: (1) the ability to make direct comparisons with the survivors, (2) data on outcomes in a non-cancer population, and (3) additional comparison group to determine consistency of findings between data sources.
3210886|NCT01120340|Active Comparator|mesalamine|Posology: mesalamine: 1,6 g/die for ten days every month for 24 months
3210887|NCT01120340|Placebo Comparator|placebo|
3210888|NCT01120327|Experimental|Amlodipine|Amlodipine
3210889|NCT01120327|Placebo Comparator|Placebo|Placebo
3210890|NCT01120314|Experimental|Severe renal impairment population|
3210891|NCT01120314|Experimental|Moderate renal impairment population|
3210892|NCT01120314|Experimental|Mild renal impairment population|
3210893|NCT01120314|Experimental|Healthy population|Healthy matched subjects
3210894|NCT01120301|Experimental|Transcranial Laser Therapy|
3210895|NCT01120301|Sham Comparator|Sham control procedure|
3210896|NCT01120275|Experimental|Treatment (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3210897|NCT01120249|Experimental|Arm I|Patients receive oral everolimus once daily on days 1-42. Treatment repeats every 6 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
3210898|NCT01120249|Placebo Comparator|Arm II|Patients receive oral placebo once daily on days 1-42. Treatment repeats every 6 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
3210899|NCT01120236|Experimental|Arm I (androgen deprivation and cixutumumab)|Patients receive androgen deprivation therapy comprising bicalutamide PO QD on days 1-28 and either goserelin acetate SC or leuprolide acetate IM every 1, 3, 4, 6, or 12 months. Patients also receive cixutumumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for 7 courses in the absence of disease progression or unacceptable toxicity.
3210900|NCT01120236|Active Comparator|Arm II (androgen deprivation therapy)|Patients receive androgen deprivation therapy comprising bicalutamide and either goserelin acetate or leuprolide acetate as in arm I.
3210901|NCT01120223|Experimental|LEO 80185 gel once daily application|
3210902|NCT01120210|Experimental|Part 1 (Main Study)|3 consecutive 1-hour infusions of JNJ-39588146 5, 15, or 30 ng/kg/min or matching placebo
3210903|NCT01120210|Experimental|Part 2 (Extended Infusion Sub-Study)|1 18-hr infusion of JNJ-39588146 of the highest tolerated dose from Part 1 of the study or matching placebo
3210952|NCT01119950|Experimental|NVA237 25.0 µg q.d.|NVA237 25.0 µg once daily
3210904|NCT01120197|Experimental|Exercise group|"Exercise group with intervention~Subjects in the intervention group must participate in a training course consisted of 24 sessions over 3 months. The exercises include aerobic, stretching, balance and functional training, i.e. circuit exercises focus been on: the prevention of falls and fractures, improving balance and coordination, improving posture, and informing subjects about risk factors for falls and for osteoporosis and fractures. A 3-hour session of information and supervision will be hold for the intervention group by the same physiotherapist who leads the training sessions. The focus is on body awareness and ergonomic advice in specific, daily-life situations (e.g. lifting/carrying, resting positions)."
3210905|NCT01120197|Other|Control Group|"Control group with no intervention~Subjects in the control group are asked to maintain their current lifestyle. No restrictions are placed on their exercise activities. The control group is followed for the same duration as the intervention group."
3210906|NCT01120184|Experimental|Trastuzumab + Taxane (docetaxel or paclitaxel)|
3210907|NCT01120184|Experimental|Trastuzumab emtansine + pertuzumab|
3210908|NCT01120184|Experimental|Trastuzumab emtansine + pertuzumab placebo|
3210909|NCT01120171|Experimental|1|Cyclofosfamide/Liposomal-encapsulated doxorubicin
3210910|NCT01120158|Experimental|1|Paclitaxel/Bevacizumab
3210911|NCT01120145||Therapeutic efficacy study|Asymptomatic parasitemic pregnant women at 16-26 weeks of gestation will be enrolled into the study and followed weekly for 42 days after the receipt of sulphadoxine-pyrimethamine intermittent preventive treatment in pregnancy to assess the clearance of parasitemia.
3210912|NCT01120145||Birth outcomes study|Women presenting for delivery will be enrolled and assessed for a history of sulphadoxine-pyrimethamine intermittent preventive treatment in pregnancy and evidence of malaria infection by placental histology, maternal peripheral parasitemia, maternal anemia and infant cord blood parasitemia.
3210913|NCT01120145||Characterizing molecular markers of SP resistance|Parasitemic outpatients attending the health facility will be tested for parasite molecular markers of sulphadoxine-pyrimethamine resistance.
3210914|NCT01120132|Experimental|Cyclosporine low dose , Prednisolone Acetate|Administration of a solution of Cyclosporine (low dose) and a suspension of Prednisolone Acetate
3210915|NCT01120132|Experimental|Cyclosporine high dose, Prednisolone Acetate|Administration of a solution of Cyclosporine (high dose) and a suspension of Prednisolone Acetate
3210916|NCT01120132|Experimental|Cyclosporine high dose|Administration of a solution of Cyclosporine (high dose) and Placebo
3210917|NCT01120132|Experimental|Cyclosporine low dose|Administration of a solution of Cyclosporine (low dose) and Placebo
3210918|NCT01120132|Active Comparator|Prednisolone Acetate|Administration of a suspension of Prednisolone Acetate and Placebo
3210919|NCT01120132|Placebo Comparator|Placebo|Administration of Placebo
3210920|NCT01120119|Experimental|Calcitriol|
3210921|NCT01120119|Placebo Comparator|placebo|
3210922|NCT01120106|Active Comparator|levosimendan|levosimendan continuous infusion at a rate of 0.1 mcg/kg<min
3210923|NCT01120106|Placebo Comparator|placebo|saline infusion
3210924|NCT01120093|Experimental|Aclidinium bromide 100 μg bid|Aclidininum bromide 100 μg twice daily by inhalation
3210925|NCT01120093|Experimental|Aclidininum bromide 200 μg bid|Aclidininum bromide 200 μg twice daily by inhalation
3210926|NCT01120093|Experimental|Aclidininum bromide 400 μg bid|Aclidininum bromide 400 μg twice daily by inhalation
3210927|NCT01120093|Placebo Comparator|Placebo|Placebo twice-daily by inhalation
3210928|NCT01120093|Active Comparator|Formoterol 12 μg bid|Formoterol 12 μg twice daily by inhalation
3210929|NCT01120080|Placebo Comparator|Practical Counseling|
3210930|NCT01120080|Active Comparator|Alcohol Intervention Counseling|
3210931|NCT01120067|Experimental|Intensive Treatment|Intensive 3 week treatment for pain and PTSD. This includes elements of Cognitive Processing Therapy and CBT for Chronic Pain
3210932|NCT01120067|Experimental|Treatment as Usual|Treatment as Usual. Participants are eligible for all treatment services as needed except for treatment of pain or PTSD
3210933|NCT01120041|Experimental|Prenatal MI - Postpartum MI|Motivational interviewing counseling given during the prenatal and postpartum phases
3210934|NCT01120041|Experimental|Prenatal MI - Postpartum Health Ed|Motivational interviewing counseling given during the prenatal phase with traditional health education given during the postpartum phase
3210935|NCT01120041|Experimental|Prenatal Health Ed - Postpartum MI|Traditional health education given during the prenatal phase with motivational interviewing counseling given during the postpartum phase
3210936|NCT01120041|Placebo Comparator|Prenatal Health Ed/Postpartum Health Ed|Traditional health education given during the prenatal phase and the postpartum phase
3210937|NCT01120028|Experimental|Campath-1H/Sirolimus|Induction therapy allocation: Campath-1H Maintenance therapy allocation (at 6 months post-transplant): Sirolimus
3210938|NCT01120028|Experimental|Campath-1H/Tacrolimus|Induction therapy allocation: Campath-1H Maintenance therapy allocation (at 6 months post-transplant): Tacrolimus
3210939|NCT01120028|Active Comparator|Basliximab/Tacrolimus|Induction therapy allocation: Basiliximab Maintenance therapy allocation (at 6 months post-transplant): Tacrolimus
3210940|NCT01120028|Active Comparator|Basliximab/Sirolimus|Induction therapy allocation: Basiliximab Maintenance therapy allocation (at 6 months post-transplant): Sirolimus
3210941|NCT01120015|Experimental|Diacerein|diacerein 50mg oD first month, 50 mg BD next 2 months
3210942|NCT01120002|Placebo Comparator|Placebo pill|
3210943|NCT01120002|Active Comparator|Tamibarotene|
3210944|NCT01119989|No Intervention|weight maintenance diet|
3210945|NCT01119989|Placebo Comparator|weight maintenance + fructose|
3210946|NCT01119989|Experimental|weight maintenance diet + fructose and amino-acid|
3210947|NCT01119976|Experimental|Group A|Reduced calorie diet and exercise plan that changes with phases of the menstrual cycle
3210948|NCT01119976|Active Comparator|Group B|Different reduced calorie diet and exercise plan based on MyPyramid.gov website
3210949|NCT01119963|Active Comparator|17-alpha hydroxyprogesterone caproate, Makena®|250 mg of 17P, Makena® intramuscular (IM) weekly.
3210950|NCT01119963|Placebo Comparator|Placebo|Castor Oil (Placebo)intramuscular (IM) weekly
3210951|NCT01119950|Experimental|NVA237 12.5 µg q.d.|NVA237 12.5 µg once daily
3210953|NCT01119950|Experimental|NVA237 12.5 µg b.i.d.|NVA237 12.5 µg twice daily
3210954|NCT01119950|Experimental|NVA237 50.0 µg q.d.|NVA237 50.0 µg once daily
3210955|NCT01119950|Experimental|NVA237 25.0 µg b.i.d.|NVA237 25.0 µg twice daily
3210956|NCT01119950|Experimental|NVA237 100.0 µg q.d.|NVA237 100.0 µg once daily
3210957|NCT01119950|Experimental|NVA237 50.0 µg b.i.d.|NVA237 50.0 µg twice daily
3210958|NCT01119950|Placebo Comparator|Placebo|Placebo to NVA237 once daily
3210959|NCT01119937|Experimental|NVA237|50µg once daily
3210960|NCT01119937|Experimental|Tiotropium|18µg once daily
3210961|NCT01119924|Active Comparator|Mirtazapine|Mirtazapine 15mg/day or placebo once a day on the fist week, then 30 mg/day or placebo once a day, and then for 7 consecutive weeks
3210962|NCT01119924|Placebo Comparator|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
3210963|NCT01119898|Experimental|PENNSAID Gel|Diclofenac sodium 2.0% w/w
3210964|NCT01119898|Placebo Comparator|Vehicle|The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
3210965|NCT01119885||001|fentanyl matrix Knee osteoarthritis starting with 12mcg/h (flexible dose)
3210966|NCT01119885||002|fentanyl matrix Hip osteoarthritis starting with 12mcg/h (flexible dose)
3210967|NCT01119872|Other|Compliance-guided PEEP group|Positive End-Expiratory Pressure(PEEP) level was set daily, according to the method described by Suter in 1978. Static compliance (Cst) was calculated at different levels of PEEP at a constant tidal ventilation of 6-8 ml/kg of predicted body weight. Cst was determined by dividing tidal volume by the difference between the pressure at the end of inflation hold and the PEEP. The maximum value of Cst in individual patients was considered as the best PEEP.
3210968|NCT01119872|Other|FiO2-driven-PEEP group|"PEEP was set based on the patient fraction of inspired oxygen (FiO2) according to the Positive End-Expiratory Pressure(PEEP) strategy reported in 2000:Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network."
3210969|NCT01119859|Experimental|Tocilizumab 8 mg/kg|Patients received 6 infusions of tocilizumab 8 mg/kg intravenously every 4 weeks and 12 injections of placebo to adalimumab subcutaneously every 2 weeks.
3210970|NCT01119859|Active Comparator|Adalimumab 40 mg|Patients received 12 injections of adalimumab 40 mg subcutaneously every 2 weeks and 6 infusions of placebo to tocilizumab intravenously every 4 weeks.
3210971|NCT01119846|Experimental|Part A|Part A (Cohort 1) is a single-blind, randomized, placebo-controlled, 5-period crossover in which drug naïve T2DM subjects will receive escalating doses of GSK1292263 in each of 3 periods and placebo and open-label sitagliptin in the other 2 periods. The sequence will be randomized, but will maintain the low, medium and high dose order for GSK1292263.
3210972|NCT01119846|Experimental|Part B|Part B (Cohort 2) is a single-blind, randomized, 2-period study in which T2DM subjects will receive a single dose of GSK1292263, fasted or fed.
3210973|NCT01119846|Experimental|Part C|Part C (Cohort 3, optional Cohort 4) is a single-blind, randomized, placebo-controlled, 5-arm study of 14 days of dosing with GSK1292263, placebo or open-label sitagliptin. An optional Cohort 4 may be enrolled to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1292263 when dosed in a BID regimen.
3210974|NCT01119833|Experimental|GMI-1070|
3210975|NCT01119833|Placebo Comparator|Placebo|
3210976|NCT01119820|Experimental|Tissue Donation|This study will involve females over 18 who are scheduled to undergo elective surgery. These patients will be screened for participation in this study, which will only involve the collection of discarded tissue.
3210977|NCT01119807|Experimental|IV|
3210978|NCT01119807|Experimental|Humeral IO|
3210979|NCT01119807|Active Comparator|Tibial IO|
3210980|NCT01119794|Experimental|ofatumumab and bortezomib|Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
3210981|NCT01119781|Experimental|peginterferon beta-1a|Single dose of peginterferon beta-1a at either 63 or 125 mcg in renal impaired Participants and healthy volunteers
3210982|NCT01119768|Active Comparator|Esomeprazole 8 weeks treatment|20 mg q.d. (quaque die) once a day dosing for 8 weeks
3210983|NCT01119768|Active Comparator|Esomeprazole 2 Weeks Treatment|20 mg q.d. (quaque die) once a day dosing for 2 weeks
3210984|NCT01119742|Experimental|Butenafine Hydrochloride 1% A|1
3210985|NCT01119742|Experimental|Butenafine Hydrochloride 1% B|2
3210986|NCT01119742|Active Comparator|Butenafine Hydrochloride 1%|3
3210987|NCT01119742|Placebo Comparator|Vehicle A|4
3210988|NCT01119742|Placebo Comparator|Vehicle B|5
3210989|NCT01119729||HIV-infected Outpatients|
3210990|NCT01119716||All Enrolled Participants|Participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options
3210991|NCT01119703||Arm 1: Healthy, elderly participants|Healthy participants 65 years old and older.
3210992|NCT01119703||Arm 2: Healthy, young, participants|Healthy participants 25 to 40 years old.
3210993|NCT01119690|Active Comparator|Rapeseed oil|
3210994|NCT01119690|Active Comparator|Milk fat|
3210995|NCT01119677|Experimental|Group 1|No dose titration
3210996|NCT01119677|Experimental|Group 2|Fast dose titration
3210997|NCT01119677|Experimental|Group 3|Slow dose titration
3210998|NCT01119664|Experimental|No prior chemotherapy|Intrapleural SCH 721015 (Ad.hIFN-α2b) instilled over 2-5 minutes on Days 1 and 4. Chemotherapy administered for 4 to 6 cycles Subjects with malignant pleural mesothelioma who have been previously untreated with chemotherapy
3210999|NCT01119664|Experimental|Patients with prior Pemetrexed-based chemotherapy|Intrapleural SCH 721015 (Ad.hIFN-α2b) instilled over 2-5 minutes on Days 1 and 4. Chemotherapy administered for 4 to 6 cycles Subjects with malignant pleural mesothelioma who have been previously treated with chemotherapy
3211000|NCT01119651|Experimental|Tazarotene Foam without irradiation|Subjects will be exposed to Tazarotene Foam Patch without irradiation
3211001|NCT01119651|Experimental|Tazarotene Foam with UVA and UVB irradiation|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB irradiation
3211046|NCT01119339|Experimental|LAS 41004 dosage 3|
3211002|NCT01119651|Experimental|Tazarotene Foam & UVA/UVB/visible light|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB and visible light irradiation
3211003|NCT01119651|Placebo Comparator|Vehicle Foam without irradiation,|Subjects will be exposed to Vehicle Foam Patch without irradiation
3211004|NCT01119651|Placebo Comparator|Vehicle Foam with UVA and UVB irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB irradiation
3211005|NCT01119651|Placebo Comparator|Vehicle Foam with UVA & UVB visible light irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB and visible light irradiation
3211006|NCT01119651|Sham Comparator|Blank patch without irradiation|Subjects will be exposed to blank patch without irradiation,
3211007|NCT01119651|Sham Comparator|Blank patch with UVA and UVB irradiation|Subjects will be exposed to blank patch with UVA and UVB irradiation
3211008|NCT01119651|Sham Comparator|Blank Patch with UVA & UVB visible light irradiation|Subjects will be exposed to Blank Patch with UVA and UVB and visible light irradiation
3211009|NCT01119638|Active Comparator|Escitalopram Drug|"Drug:~Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion."
3211010|NCT01119638|Active Comparator|Risperidone Drug|Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
3211011|NCT01119625|Experimental|Synflorix™ Commercial-Commercial + Infanrix™-IPV/Hib Group|children primed with 3 doses of commercial lot of Synflorix™ co-administered with Rotarix™ and Infanrix™-hexa in the primary phase of the study (NCT00808444) and boosted with commercial lot of Synflorix™ co-administered with Infanrix™-IPV/Hib. The Synflorix™ vaccine (commercial lots) was administered intramuscularly in the right deltoid or anterolateral thigh and the Infanrix™-IPV/Hib vaccine was administered intramuscularly in the left deltoid or anterolateral thigh.
3211012|NCT01119625|Active Comparator|Synflorix™ Clinical-Commercial + Infanrix™-IPV/Hib Group|children primed with 3 doses of clinical lot of Synflorix™ + Rotarix™ co-administered with Infanrix™-hexa in the primary phase of the study (NCT00808444) and boosted with commercial lot of Synflorix™ co-administered with Infanrix™-IPV/Hib. The Synflorix™ vaccine (clinical and commercial lots) was administered intramuscularly in the right deltoid or anterolateral thigh and the Infanrix™-IPV/Hib vaccine was administered intramuscularly in the left deltoid or anterolateral thigh.
3211013|NCT01119612|Active Comparator|Iron|
3211014|NCT01119612|Placebo Comparator|Placebo|
3211015|NCT01119599|Experimental|Treatment (RO4929097, surgery, radiation therapy)|See Detailed Description.
3211016|NCT01119560||Ancillary-Correlative (Questionnaire, saliva & tissue sample)|The biologic mother of the patient is asked to complete a Diet History Questionnaire about diet during pregnancy, and information on demographics, lifestyle factors, medication used during pregnancy, history of breast feeding, and family history of cancer or birth defects. Parents are given ORAgene saliva collection kits for self-collection. Saliva bio-specimen samples are collected from both biologic parents and the patient. Tissue samples previously stored in a tissue bank are obtained for deceased patients, if available. DNA is extracted from samples, amplified and analyzed using real-time PCR quantitation assay, and genotyped using single nucleotide polymorphisms.
3211017|NCT01119547|Experimental|Home exercise|The patients is training at home during 6 v. with an individual exercise program.
3211018|NCT01119547|Experimental|Exercise in group|The patients is doing their individual exercise program in a group.
3211019|NCT01119534|Experimental|Transpulmin|Suppository composed by guaiacol, eucalyptol, menthol and camphor
3211020|NCT01119534|Active Comparator|Comparator 1|Suppository composed by guaiacol
3211021|NCT01119534|Active Comparator|Comparator 2|Syrup composed by guaifenesin
3211022|NCT01119521|Experimental|Group A: INH; BCG|6 months of Isoniazid (INH) treatment for latent tuberculosis infection (LTBI) (completed within no more than 7 months) followed by intradermal Bacillus Calmette-Guérin (BCG) revaccination.
3211023|NCT01119521|Experimental|Group B: observation; BCG; observation; INH|7 months of observation (run in period) followed by intradermal Bacillus Calmette-Guérin (BCG) revaccination followed after 6 months of observation by 6 months of Isoniazid (INH) treatment for latent tuberculosis infection (LTBI).
3211024|NCT01119508|Experimental|Ipilimumab + Temozolomide|Induction: Ipilimumab 10 mg/kg IV over 90 minutes Day 1 + Temozolomide 200 mg/m2 PO on Days 1 - 4, every 3 weeks for 4 courses over 3 months.
3211025|NCT01119482|Other|Vaccination|Healthy volunteers before and after vaccination
3211026|NCT01119469|Experimental|Cognitive Therapy (CT)|There will be 12 50-minute individual sessions conducted at weekly intervals. Booster sessions will be conducted one, three and six months after treatment. Sessions include psychoeducation, attention training, cognitive restructuring, behavioral experiments, imagery rescripting and relapse prevention.
3211027|NCT01119469|Experimental|Exposure Therapy (ET)|There will be 12 50-minute individual sessions conducted at weekly intervals. Booster sessions will be conducted one, three and six months after treatment. Sessions include change of safety behavior, exposition (in sensu and in vivo), and response prevention.
3211028|NCT01119469|No Intervention|Waiting List (WL)|12 weeks waiting time
3211029|NCT01119456|Experimental|IMC-RON8|
3211030|NCT01119443|Other|Treatment sequence A|V4: PPX ER 1.5mg x 1 fed, V5: PPX ER 0.375mg x 4 fed, V6:: PPX ER 1.5mg x 1 fasted, V5: PPX ER 0.375mg x 4 fasted
3211031|NCT01119443|Other|Treatment sequence B|V4: PPX ER 0.375mg x 4 fed, V5: PPX ER 1.5mg x 1 fed, V6:: PPX ER 0.375mg x 4 fasted, V5: PPX ER 1.5mg x 1 fasted
3211032|NCT01119430|Placebo Comparator|Fluoxetine plus placebo|
3211033|NCT01119430|Active Comparator|Fluoxetine plus DU125530|
3211034|NCT01119417|Experimental|BQ123|endothelin blocker
3211035|NCT01119417|Placebo Comparator|Saline|IV saline
3211036|NCT01119404||Metabolic Syndrome|120 men with metabolic syndrome
3211037|NCT01119404||Coronary Heart Disease (CHD)|120 men with angiographically verified CHD
3211038|NCT01119404||Control|80 physically active men
3211039|NCT01119391||Patients undergoing IVF|Women undergoing an in vitro fertilization cycle
3211040|NCT01119378|Experimental|Post Menopausal|post menopausal women between the ages 50-70 yrs.
3211041|NCT01119365|Experimental|Light|Bright light
3211042|NCT01119352|Experimental|1|
3211043|NCT01119352|Placebo Comparator|2|
3211044|NCT01119339|Experimental|LAS 41004 dosage 1|
3211045|NCT01119339|Experimental|LAS 41004 dosage 2|
3211048|NCT01119339|Experimental|LAS 41004 dosage 5|
3211049|NCT01119339|Experimental|LAS 41004 dosage 6|
3211050|NCT01119339|Placebo Comparator|Placebo|
3211051|NCT01119339|Active Comparator|Reference|
3211052|NCT01119326|Placebo Comparator|Placebo|Placebo procedure
3211053|NCT01119326|Experimental|Autologous Fat Transfer (AFT) group|Subjects will be registered in the context of either the Early AFT subgroup, or the Delayed AFT subgroup based on the timing of their wound closure: early AFT subgroup will contain subjects who are medically stable such that study sites are amenable to AFT within 2-4 weeks of definitive closure (STSG) or healing (secondary closure) and the delayed AFT subgroup will contain subjects who are medically stable such that study sites are amenable to AFT within 6 months or more of definitive closure (STSG) or healing (secondary closure
3211054|NCT01119313|Experimental|LAS 41002|
3211055|NCT01119313|Active Comparator|Active|
3211056|NCT01119300|Active Comparator|Standard care|Standard care
3211057|NCT01119300|Experimental|Genotype-guided dosing algorithm|Genotyping for CYP2C9*2, CYP2C9*3, and VKORC1 (-1639G→A) was performed with the use of a point-of-care test. For patients assigned to the genotype-guided group, warfarin doses were prescribed according to pharmacogenetic-based algorithms for the first 5 days.
3211058|NCT01119287|Experimental|Maxidex|Dexamethasone 0.1% ophthalmic suspension, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days [Visit 4 through Visit 6 morning only]
3211059|NCT01119287|Experimental|Patanol|Olopatadine hydrochloride 0.1% ophthalmic solution, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days [Visit 4 through Visit 6 morning only]
3211060|NCT01119287|Placebo Comparator|Tears Naturale II|Inactive ingredients, used as placebo, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days [Visit 4 through Visit 6 morning only]
3211061|NCT01119274|Active Comparator|Non-genotype-guided dosing algorithm|
3211062|NCT01119274|Experimental|Genotype-guided dosing algorithm|
3211063|NCT01119261|Active Comparator|Non-genotype-guided dosing algorithm|
3211064|NCT01119261|Experimental|Genotype-guided dosing algorithm|
3211065|NCT01119248||Children undergoing MRI|120 children ages of 6 months and 8 years for MRI and axillary temperature before MRI and after the MRI with MRI compatible device
3211066|NCT01119235|Active Comparator|Cohort 1: PF-04531083|
3211067|NCT01119235|Active Comparator|Cohort 2: PF-04531083|
3211068|NCT01119222|Active Comparator|Gabapentin 1200mg|
3211069|NCT01119222|Active Comparator|Diphenhydramine 50 mg|
3211070|NCT01119222|Active Comparator|Morphine 10 mg|
3211071|NCT01119222|Placebo Comparator|Placebo formulations|
3211072|NCT01119209|Active Comparator|Ropivacaine|
3211073|NCT01119209|Placebo Comparator|Saline|
3211074|NCT01119196|No Intervention|glucose-based dialysate|most frequently used Standard of Care (SOC) dialysate
3211075|NCT01119196|Other|Icodextrin dialysate|alternate SOC dialysate
3211076|NCT01119183|No Intervention|1|
3211077|NCT01119183|Active Comparator|2|
3211078|NCT01119183|Experimental|3|
3211079|NCT01119170|Placebo Comparator|control starter formula|
3211080|NCT01119170|Experimental|D-lactate probiotics|
3211081|NCT01119157|Experimental|humoral and cellular immune response|
3211082|NCT01119157|Experimental|reactogenicity|
3211083|NCT01119144|Experimental|Polycaprolactone / Tricalcium Phosphate|Polycaprolactone / Tricalcium Phosphate group to assess efficacy of new implant
3211084|NCT01119144|Active Comparator|Control|Control group with titanium mesh
3211085|NCT01119131|Active Comparator|Arm 1|Will be on high dose vitamin D3 (10,000 IU daily) and 1000 mg of calcium
3211086|NCT01119131|Placebo Comparator|Arm 2|Will be on placebo and 1000mg of calcium.
3211087|NCT01119118|Experimental|1|ZD4054 + multimodal PET/MRI imaging
3211088|NCT01119105|Experimental|BC-3781 dose 100mg|
3211089|NCT01119105|Experimental|BC-3781 dose 150mg|
3211090|NCT01119105|Active Comparator|Vancomycin|
3211091|NCT01119092|Sham Comparator|Sham intervention plus standard treatment|"This group will receive a laying of hands treatment in addition to standard treatment. The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between."
3211092|NCT01119092|No Intervention|Control Group|This group will be individuals who suffer from the same injury but will be instructed to stretch at home 5 days a week for 2 weeks.
3211093|NCT01119092|Experimental|Grade IV AP joint mobilization plus standard treatment|This group will receive 3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
3211094|NCT01119079|Placebo Comparator|Standard labor epidural protocol|Standard labor epidural protocol
3211095|NCT01119079|Experimental|10ml Normal Saline prior to lidocaine|
3211096|NCT01119066|Experimental|Total Body Irradiation, Thiotepa and Cyclophosphamide|Hyperfractionated total body irradiation to a dose of 1375-1500 cGy (depending on age, stage of disease and requirement of general anesthesia) with lung shielding) Thiotepa (5 mg/kg/day x 2 or 10 mg/kg/day x 1) Cyclophosphamide (60 mg/kg/day x 2) (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)
3211097|NCT01119066|Experimental|Busulfan, Melphalan and Fludarabine|Busulfan (0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified according to pharmacokinetics Melphalan (70mg/m2/day x 2 ) Fludarabine (25mg/m2/ day x 5)
3211098|NCT01119066|Experimental|Clofarabine, Melphalan and Thiotepa|Clofarabine (20mg/m2/ day x 5) (or, for children <18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval), Melphalan (70 mg/m2/day x 2) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)
3211099|NCT01119066|Experimental|Melphalan, Fludarabine and Thiotepa|Melphalan (70 mg/m2/day x 2) Fludarabine (25mg/m2/ day x 5 ) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)
3211100|NCT01119053|Sham Comparator|Arm I|In this branch of study, study participants obtain the VNS therapy after a defined space of time of 12 weeks.
3211101|NCT01119053|Experimental|Arm II|Within this space of time, study participants obtain the VNS therapy at once.
3211151|NCT01118637|No Intervention|Wait list|Assigned to wait list for 10 weeks before receiving step 1 treatment.
3211102|NCT01119040|Experimental|NOTES PEG Rescue|A new way of performing surgery is called Natural Orifice Translumenal Endoscopic Surgery, or NOTES, for short. NOTES may allow surgeons to perform abdominal surgery without any skin incisions. By using natural openings in the body, like the mouth, surgeons can enter the stomach with a tube instead of the traditional method of making an incision in the skin of the abdomen.
3211103|NCT01119027||Surgeons|Surgeons and trainee surgeons attending laparoscopic colorectal training courses will be recruited to study using different training models to compare each model and correlate outcomes with each model to pre-course experience. .
3211104|NCT01119027||Trainee Surgeons|Surgeon and trainee surgeons attending laparoscopic colorectal training courses will be recruited to study using different training models to compare each model and correlate outcomes with each model to pre-course experience.
3211105|NCT01119014|Experimental|Aripirazole|
3211106|NCT01119014|Experimental|Quetiapine prolong|
3211107|NCT01119001|Experimental|P300 Brain Computer Interface for people with ALS|
3211108|NCT01118988|Experimental|Mentorship|"Subjects randomly assigned to this arm received the specified Mentorship Intervention"
3211109|NCT01118988|No Intervention|Control|Subjects randomly assigned to this control group receive treatment as usual (TAU).
3211110|NCT01118988|No Intervention|Mentors|"Subjects recruited to the Mentor arm of the study are UCLA Pediatric Pain Program patients between the ages of 14 and 18. These mentors are identified by the Principal Investigator as children who have not necessarily eliminated pain, but have learned how to cope with pain and maintain appropriate functioning in daily life. Mentors undergo an in depth training from doctoral level psychologists who are members of the research team. Mentors present pain coping information developed by the research team, provide support, and encourage mentees to attend pain management therapies. They are also monitored by doctoral level psychologists throughout the duration of the study to ensure safety and appropriate contact with mentees via telephone."
3211111|NCT01118975|Experimental|Pilot Phase - Vornistat 200 to 400mg + Lapatinib|lapatinib 1,250 mg continuous daily and escalating doses of vorinistat (200mg run-up, 300mg, and 400mg 4 days on 3 days off)
3211112|NCT01118975|Experimental|Phase II - Vorinistat 400mg + Lapatinib|lapatinib 1,250 mg continuous daily and vorinostat 400 mg 4 days on 3 days
3211113|NCT01118962|Experimental|Lacosamide|"Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949).~Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses."
3211114|NCT01118949|Experimental|Lacosamide|
3211115|NCT01118936|No Intervention|Washout|
3211116|NCT01118936|Active Comparator|Mablet|
3211117|NCT01118936|Placebo Comparator|Placebo|
3211118|NCT01118923|No Intervention|Washout|
3211119|NCT01118923|Active Comparator|Mablet|
3211120|NCT01118923|Placebo Comparator|Placebo|
3211121|NCT01118910|Experimental|Vusion ointment|
3211122|NCT01118897|Experimental|Neoadjuvant chemoradiation|All patients will receive concurrent chemoradiation. Chemotherapy will consist of Inj. Gemcitabine 300mg/mt2 weekly throughout the course of Radiotherapy. Radiotherapy will be delivered using Tomotherapy to a dose of 57Gy/25# over 5 weeks
3211123|NCT01118884|Experimental|sedation|20 healthy uncooperative children aged 36-96 months were examined in a cross-over study design , each patient served as his/her own control. Each patient was assigned randomly to received 1 of 2 drug regimens for initial sedation session and the other regimen administered at second session which was one week later.
3211124|NCT01118871|Active Comparator|Standard of care|
3211125|NCT01118871|Experimental|NRTI sparing arm|
3211126|NCT01118858||Case|Pediatric patients who have a primary diagnosis of ADHD, combined type, hyperactive impulsive, or inattentive type (ADD).
3211127|NCT01118858||Control|Healthy subjects: Age and gender matched subjects who do not meet any of the exclusion criteria
3211128|NCT01118845|Experimental|SyB L-0501|
3211129|NCT01118819|Experimental|Clostridium novyi-NT spores|
3211130|NCT01118806||medical residents, vit d|vitamin
3211131|NCT01118806||levels of vitamin d|resident
3211132|NCT01118793||double dosing of Clopidogrel|
3211133|NCT01118780|Experimental|Duloxetine 30 milligrams (mg) -120 mg|
3211134|NCT01118780|Placebo Comparator|Placebo|
3211135|NCT01118767|Experimental|Cell phone intervention|Participant receives short text messages
3211136|NCT01118767|No Intervention|Standard of care|Participant receives standard of care support but not short text messages
3211137|NCT01118754|Experimental|DE-101 ophthalmic suspension high dose|
3211138|NCT01118754|Experimental|DE-101 ophthalmic suspension low dose|
3211139|NCT01118754|Placebo Comparator|DE-101 ophthalmic suspension vehicle|
3211140|NCT01118728|Experimental|Sarilumab|Sarilumab 150 mg subcutaneous (SC) injection every week (or every other week in case of safety issue) for 260 weeks, or until commercially available, or until discontinuation of the project, whichever came first.
3211141|NCT01118715|Experimental|Compression glove|Patients in this group have a compression glove incorporated into their splint for 2 weeks post-op, and wear a glove underneath their cast for 3 weeks. The patient then wears the glove at night after cast removal.
3211142|NCT01118715|No Intervention|Control|Patients in this group undergo standard recovery procedures. This includes a splint worn for 2 weeks post-op, followed by a short arm cast worn for the next 3 weeks.
3211143|NCT01118702|Active Comparator|001|Concerta one 54mg tablet once
3211144|NCT01118702|Active Comparator|002|Ritalin-SR 3-20mg tablets once
3211145|NCT01118702|Active Comparator|003|Novo-Methylphenidate ER-C one 54mg tablet once
3211146|NCT01118689|Experimental|MLN0128|
3211147|NCT01118676|Experimental|Cilengitide with standard radiochemotherapy|Cilengitide (4 dose levels are defined :12, 18, 27 et 40 mg /hour) concomitant with radiotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction) and cisplatin and vinorelbine based chemotherapy.
3211148|NCT01118663|Experimental|Acetadote without EDTA|Acetadote EF [Ethylenediaminetetraacetic Acid (EDTA) - Free]
3211149|NCT01118663|Active Comparator|Acetadote|Acetadote [Old formulation containing EDTA]
3211150|NCT01118637|Experimental|Immediate|Assigned immediately after baseline assessment to receive step 1 treatment (web-based self-help)
3211152|NCT01118598|Placebo Comparator|placebo arm|this group will receive placebo as per protocol
3211153|NCT01118598|Active Comparator|tredaptive|tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks
3211154|NCT01118585|Other|TIF Procedure|Transoral incisionless fundoplication procedure using the EsophyX device.
3211155|NCT01118572|Experimental|YM177 group|
3211156|NCT01118572|Active Comparator|etodolac group|
3211157|NCT01118572|Placebo Comparator|placebo group|
3211158|NCT01118559|Experimental|fast-fed sequence group|drug is administered in a fasted condition first, and fed-condition study follows
3211159|NCT01118559|Experimental|fed-fast sequence group|drug is administered in a fed condition first, and fasted-condition study follows
3211160|NCT01118546||controls 2|patient without CAD, not on aspirin and without history of hypersensitivity
3211161|NCT01118546||case of hypersensitivity|patient with CAD on aspirin, with a history of hypersensitivity
3211162|NCT01118546||controls 1|patient with CAD on aspirin, without history of hypersensitivity
3211163|NCT01118533|Experimental|metallic blades|laryngoscope blade material
3211164|NCT01118533|Active Comparator|plastic laryngoscope blades|Laryngoscope Blade Material
3211165|NCT01118520|Active Comparator|perindopril|ACE inhibitor blood pressure lowering agent
3211166|NCT01118520|Active Comparator|amlodipine|calcium channel blocker blood pressure lowering agent
3211167|NCT01118520|Placebo Comparator|placebo|inactive substance identical in appearance to the othe two comparators
3211168|NCT01118507||TRISOMY|mothers of a trisomic fetus 21
3211169|NCT01118507||NORMAL KARYOTYPE|mothers of DISOMIQUE foetus 21
3211170|NCT01118494||CKD patients|People who have been diagnosed with CKD，and been in the stage of 3 or 4.
3211171|NCT01118481||Pressure and flow velocity|
3211172|NCT01118481||Pressure only|
3211173|NCT01118455|Experimental|Vagus Nerve Stimulation (VNS) Therapy|Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
3211174|NCT01118455|Experimental|Anti-Epileptic Drug (AED)|This arm will supply a comparison between VNS and new AEDs which is necessary to determine an overall treatment regimen for the 30% to 40% of patients who fail to respond to 2 AEDs.
3211175|NCT01118429|Experimental|Oxybutynin|Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
3211176|NCT01118429|Placebo Comparator|Placebo|Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
3211177|NCT01118416|Experimental|intervention condition|Participants randomized to the intervention condition will undergo 4 one-hour sessions of motivational interviewing (MI), during which their sexual risk taking and substance use patterns will be discussed with a trained counselor with the goal of reducing instances of unprotected anal sex and substance use.
3211178|NCT01118416|Active Comparator|Education condition|Participants randomized to the education condition will undergo 4 one-hour sessions during which they will view video segments and discuss sexual risk taking and substance use with a health educator, with the goal of reducing instances of unprotected anal sex and substance use by making informed decisions.
3211179|NCT01118403|Experimental|Sultamicillin, Antibiotic Prophylaxis|Sultamicillin, Antibiotic Prophylaxis
3211180|NCT01118403|Placebo Comparator|Placebo|Physiologic Sodium Chloride Solution
3211181|NCT01118390|Experimental|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
3211182|NCT01118390|Active Comparator|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
3211183|NCT01118377|Experimental|Capecitabine + radiation therapy|Participants received 9 weeks of capecitabine 650 mg/m^2 orally (po) twice daily (bid) plus radiation therapy (180 cGy/day 5 days a week, total target dose of 56 Gy) followed by a 2-week rest period. Participants then received 3 cycles of capecitabine 1250 mg/m^2 po bid for 14 days followed by a 7-day rest period without radiation therapy.
3211184|NCT01118364|Experimental|cigarette with cannabis|"a cigarette tobacco trade mark Drum with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)"
3211185|NCT01118364|Other|cigarette without cannabis|"a cigarette tobacco trade mark Drum"
3211186|NCT01118351|Experimental|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
3211187|NCT01118325|Experimental|AZD6140 45 mg bd|
3211188|NCT01118325|Experimental|AZD6140 90 mg bd|
3211189|NCT01118325|Active Comparator|Clopidogrel 75 mg od|
3211190|NCT01118312|Active Comparator|Nasal Steroid|Intranasal mometasone, 1 spray (age < 12 yr) or 2 sprays (age >= 12 yrs) each nostril once a day
3211191|NCT01118312|Placebo Comparator|Placebo|Intranasal placebo, 1 spray (age < 12 yr) or 2 sprays (age >= 12 yrs) each nostril once a day
3211192|NCT01118299|Experimental|Device|AMPLATZER Cardiac Plug
3211193|NCT01118299|Active Comparator|Optimal Medical Therapy (control)|Warfarin Dabigatran
3211194|NCT01118286||Group 1|
3211195|NCT01118273|Experimental|Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|
3211196|NCT01118273|Active Comparator|Naproxen Sodium 440 mg (BAYH6689)|
3211197|NCT01118273|Experimental|Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|
3211198|NCT01118273|Active Comparator|Naproxen Sodium 220 mg (BAYH6689)|
3211199|NCT01118273|Active Comparator|DPH 50mg|
3211200|NCT01118273|Active Comparator|Ibuprofen 400 mg / Diphenhydramine citrate 76 mg|
3211201|NCT01118260|Active Comparator|TIVA|Total intravenous anaesthesia (TIVA) with propofol and remifentanil
3211202|NCT01118260|Active Comparator|Spinal|Spinal anaesthesia with bupivacaine and fentanyl
3211203|NCT01118247|Experimental|pure Ti|Cup and stem partly coated with pure titanium
3211204|NCT01118247|Active Comparator|pure Ti and HA|Cup and stem partly coated with pure titanium, and fully coated with HA.
3211205|NCT01118234|Experimental|Rituximab|Treatment with Rituximab 375 mg/m² every 3 months for 24 months
3211206|NCT01118234|No Intervention|Observation|Observation for 24 months
3211207|NCT01118221|Experimental|Arm 1|enroll in pulmonary rehabilitation program
3211208|NCT01118221|No Intervention|Arm 2|no structured exercise
3211209|NCT01118208|Experimental|Blister Packaging|Patients will receive all prescription medications on blister pack cards.
3211210|NCT01118208|Active Comparator|Dispense as Usual|Patients will receive all prescription medications in standard pill bottles.
3211211|NCT01118195||TBI and Suicidal Behavior|
3211212|NCT01118195||TBI and No Suicidal Behavior|
3211213|NCT01118182||Traumatic Brain Injury (TBI)|Veterans with a positive history of TBI
3211214|NCT01118182||No Traumatic Brain Injury (TBI)|Veterans with a negative history of TBI
3211215|NCT01118169||Veterans|
3211216|NCT01118156||Mental Health Clinicians|MH Clinicians at the Denver and Grand Junction VA Medical Centers
3211217|NCT01118143|Experimental|intervention group|Tailored oral health literacy instruction
3211218|NCT01118143|No Intervention|control group|Oral health instruction not tailored to oral health literacy level
3211219|NCT01118130||Case|MS patients experiencing an adverse drug reaction to an MS immunomodulatory therapy
3211220|NCT01118130||Control|MS patients not experiencing an adverse drug reaction to an MS immunomodulatory therapy
3211221|NCT01118117|Experimental|Misago™ Self-Expanding Stent System|
3211222|NCT01118104|Other|Pulmonary vocational rehabilitation|
3211223|NCT01118091|Active Comparator|Arm 1-Aldesleukin|Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.
3211224|NCT01118091|Experimental|Arm 2 - Adoptive cell therapy|Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10^9 to 2x10^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x10^8) and the administration of high-dose aldesleukin.
3211225|NCT01118078||Biomarker (DNA methylation, gene expression, RT-PCR)|Archived tumor tissue samples are analyzed for DNA copy number determination, gene expression analysis, DNA methylation, and genomic re-sequencing by microarray analysis-based methods, including PCR analysis, DNA methylation analysis-specific RT-PCR, and quantitative RT-PCR (reverse transcriptase-polymerase chain reaction)
3211226|NCT01118052|Experimental|Treatment (EGEN-001)|Patients receive intraperitoneal EGEN-001 on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3211227|NCT01118026|Experimental|ABVD +/- BEACOPP + radiation|"Patients receive ABVD administered by intravenous (IV) infusion on days 1 and 15 of each cycle. A cycle is considered 28 days. Patients receive a total of two cycles.~Patients undergo a PET scan following two cycles of ABVD. If the PET scan is negative, then the patient will receive four more cycles of ABVD (a total of 6 cycles of ABVD). If the PET scan is positive, then the patient receives four cycles of escalated BEACOPP for 21 days (a total of 4 cycles).~3-6 weeks after BEACOPP therapy, patients receive radiation therapy for 5 days per week (a total of 3.5 weeks).~All patients will be followed for a maximum of ten years."
3211228|NCT01118013|Experimental|Treatment|"Matched-unrelated donor: Patients receive antithymocyte globulin, tacrolimus, and methotrexate as in HLA-identical donor regimen. Patients also receive oral mycophenolate mofetil twice daily on days 0 to 60.~Allogeneic Stem Cell Transplantation: Patients undergo allogeneic peripheral blood stem cell transplantation on days 0 and 1. Patients then receive filgrastim subcutaneously daily beginning on day 7 and continuing until blood counts recover.~Donor Lymphocyte Infusion (DLI): After day 180 (or day 210 for patients without an HLA-identical donor), patients with stable or progressive disease and no active GVHD may receive up to 3 DLIs every 8 weeks.~Blood samples are collected at baseline and then periodically during study therapy for pharmacokinetic studies.~After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for up to 5½ years."
3211229|NCT01118000|Experimental|limb ischemia preconditioning|limb ischemic preconditioning consists of three 5-min cycles of left upper limb ischemia induced by a blood pressure cuff placed on the left upper arm and inflated to 200 mmHg,with an intervention 5-min of reperfusion during which the cuff was deflated.
3211230|NCT01117987|Experimental|Core imatinib|Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.
3211231|NCT01117987|Experimental|Core placebo|Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.
3211232|NCT01117974|Experimental|Liposuction|
3211233|NCT01117961|No Intervention|control|
3211234|NCT01117961|Experimental|Intervention|Lifestyle intervention delivered during pregnancy
3211235|NCT01117948|Experimental|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
3211236|NCT01117948|Placebo Comparator|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
3211237|NCT01117935|Experimental|Arm I|Patients undergo hypofractionated intensity modulated radiotherapy once daily, 5 days a week, for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with intermediate- and high-risk disease may also receive concurrent and adjuvant or long-term androgen deprivation therapy for up to 36 months.
3211238|NCT01117922|Experimental|Intervention|After consent, subjects will be assigned to either a usual care group (no intervention) or an intervention group (targeted interconceptional interventions).
3211239|NCT01117922|Other|Usual Care Group|This group will receive usual care.
3211240|NCT01117909|Sham Comparator|"Laying of hands plus standard therapy"|Subjects will lie on their back as if they were receiving the joint mobilization treatment and the therapist will place their hands in a position as if to perform the mobilization but no movement will occur. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression
3211241|NCT01117909|Experimental|Standard therapy with joint mobilization|This group will receive three 60-second bouts of posterior joint mobilizations applied to the ankle joint during each treatment session, in addition to standard therapy. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression
3211242|NCT01117896|Experimental|Adult vs Pedi manikin CC quality|"The primary objective is to determine whether chest compression deterioration occurs at the same rate in pediatric and adult manikins. The primary endpoint will be the difference in mean number of effective compressions per minute in each manikin at times 1, 2, 5 and 10 minutes.~Another objective is to identify the correlation between the anaerobic threshold and the deterioration of compressions in each manikin. The endpoint will be the difference between mean time to ineffective compressions (defined as 10 consecutive compressions that fail to meet AHA guidelines for depth and rate) and mean time to anaerobic threshold in each manikin."
3211243|NCT01117896|Experimental|Stepstool use|A third main objective is to determine the effect of the stepstool use on the quality of chest compressions and metabolic demand. The endpoint will be the difference between mean time to ineffective compressions (defined as 10 consecutive compressions that fail to meet AHA guidelines for depth and rate) and mean time to anaerobic threshold in each experimental group.
3211244|NCT01117870|Placebo Comparator|Placebo|The needle will be continuously stimulated at a low voltage to give a sensation of PRF treatment.
3211245|NCT01117870|Experimental|Pulsed Radiofrequency|PRF will be applied for 120 seconds at 42 degrees celsius.
3211246|NCT01117857|Experimental|Duloxetine|After a one-week placebo lead-in, all eligible subjects will receive Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg Duloxetine per day for 7 weeks.
3211247|NCT01117844|Experimental|Feasibility|
3211248|NCT01117844|Experimental|Phase 2|
3211249|NCT01117818|Active Comparator|A: AFFITOPE AD02|
3211250|NCT01117818|Active Comparator|B: AFFITOPE AD02|
3211251|NCT01117818|Active Comparator|C: AFFITOPE AD02|
3211252|NCT01117818|Active Comparator|D: Placebo control|
3211253|NCT01117805|Active Comparator|Intervention|Subjects will be randomized to the program intervention which is a female-specific, culturally relevant, self-regulation based telephone counseling intervention designed for African American women with asthma.
3211254|NCT01117805|No Intervention|usual care|Usual care at the University of Michigan Health System is based on the guidelines as recommended by the National Asthma Education and Prevention Program Expert Panel Report 3 (NAEPP-EPR3): Diagnosis and Treatment of Asthma and is coordinated so that all patients receive the same action plan, educational materials and instructions in use of devices.
3211255|NCT01117792|Experimental|S-ICD System|
3211256|NCT01117779||Kidney lesions amenable to cryoablation|Kidney lesions treated with cryoablation.
3211257|NCT01117766|Active Comparator|Active drug|
3211258|NCT01117766|Placebo Comparator|Placebo|
3211259|NCT01117753|Experimental|OPT-A|OPT-A is an outpatient family-based treatment for co-occurring substance use and internalizing disorders
3211260|NCT01117753|Active Comparator|Treatment as Usual|Treatment as usual in a community based mental health center
3211261|NCT01117740||Thoracoscopy Group|
3211262|NCT01117740||Indwelling Pleural Catheters|
3211263|NCT01117727|Experimental|Pilot Testing|
3211264|NCT01117714|Active Comparator|EUS/EBUS with FNA|EUS/EBUS staging will be performed to evaluate for the presence of mediastinal adenopathy. Each lymph node will be characterized according to published criteria. Staging will follow the TNM system of the AJCC. If present and accessible, at least one lymph node from each accessible station will be aspirated with a separate fine needle using routine FNA and cytological techniques. If multiple lymph nodes are present in a single station, the largest lymph node from that location will be sampled. Patients with cytologically proven mediastinal lymph node metastases (N2 or 3), or those with mediastinal invasion of tumor (T4), will be treated according to standard clinical practice (typically chemotherapy and/or radiotherapy). All complications, morbidity, length of stay attributed to the staging procedures will be recorded at 30 days, or at the time of surgery, whichever is first. All patients will will subsequently undergo surgical resection and complete mediastinal lymph node dissection.
3211265|NCT01117714|Active Comparator|Surgical Mediastinoscopy|Within two months following CT scan, surgical mediastinoscopy will be performed to evaluate for the presence of mediastinal adenopathy. Each lymph node will be characterized according to published criteria. Staging will follow the TNM system of the AJCC. Patients with cytologically proven mediastinal lymph node metastases (N2 or 3), or those with mediastinal invasion of tumor (T4), will be treated according to standard clinical practice (typically chemotherapy and/or radiotherapy). All complications, morbidity, length of stay attributed to the diagnostic method (medical or surgical) used for staging will be recorded at 30 days, or at the time of surgery, whichever is first. All patients will will subsequently undergo surgical resection and complete mediastinal lymph node dissection.
3211266|NCT01117701|Experimental|A - with SGW|Measurement of the forces needed to passage the ureteroscope in the ureter with a SGW in place.
3211267|NCT01117701|Experimental|B - without SGW|Measurement of the forces needed to passage the ureteroscope in the ureter without a SGW in place.
3211268|NCT01117688|Active Comparator|B - without SGW|Ureteroscopy without SGW in place.
3211269|NCT01117688|Active Comparator|A - with SGW|Ureteroscopy with SGW in place.
3211270|NCT01117675|Other|Arm I|Arm I: HIV-infected patients controlled through Virtual Hospital
3211271|NCT01117675|Other|Arm II|Arm II: HIV-infected patients controlled through Standard Care
3211272|NCT01117662|Experimental|Rituximab|Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
3211273|NCT01117662|Placebo Comparator|Control|Intravenous application of placebo (NaCl 0,9 %) matching active treatment
3211274|NCT01117649|Experimental|1|hyper-oncotic colloid
3211275|NCT01117649|Active Comparator|2|iso-oncotic colloid
3211276|NCT01117649|Active Comparator|3|crystalloid
3211279|NCT01117636|Placebo Comparator|Arm 3|
3211280|NCT01117623|Experimental|Arm 1|
3211281|NCT01117623|Experimental|Arm 2|
3211282|NCT01117623|Experimental|Arm 3|
3211283|NCT01117623|Experimental|Arm 4|
3211284|NCT01117623|Experimental|Arm 5|
3211285|NCT01117623|Experimental|Arm 6|
3211286|NCT01117623|Experimental|Arm 7|
3211287|NCT01117623|Experimental|Arm 8|
3211288|NCT01117610|Active Comparator|epidural injection (group I)|patients in Group I will receive epidural injection of 0.1% ropivacaine 10 ml before skin incision.
3211289|NCT01117610|Placebo Comparator|epidural injection group (group C)|control group will receive no medication preoperatively and during operation
3211290|NCT01117597|Active Comparator|low RF exposure level|Intervention with low RF exposure level SAR 1.5 W/kg
3211291|NCT01117597|Sham Comparator|sham RF exposure|Intervention with sham RF exposure
3211292|NCT01117597|Active Comparator|high RF exposure level|intervention with high RF exposure level SAR 6W/kg
3211293|NCT01117584|Experimental|ASP1941 lowest dose|oral tablet
3211294|NCT01117584|Experimental|ASP1941 low dose|oral tablet
3211295|NCT01117584|Experimental|ASP1941 high dose|oral tablet
3211296|NCT01117584|Experimental|ASP1941 highest dose|oral tablet
3211297|NCT01117584|Placebo Comparator|Placebo|oral tablet
3211298|NCT01117571||open label|iUni® Unicompartmental Knee Resurfacing Device
3211299|NCT01117545|Experimental|EFT|Six sessions of EFT (Emotional Freedom Techniques)
3211300|NCT01117545|No Intervention|Wait List|One month wait period
3211301|NCT01117532|Experimental|EFT|Four 90 minute group EFT classes
3211302|NCT01117532|No Intervention|No Treatment|
3211303|NCT01117519|Active Comparator|unbalanced infusion solution|
3211304|NCT01117519|Active Comparator|balanced infusion solution compound|
3211305|NCT01117493|Other|Usual care|Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.
3211306|NCT01117493|Experimental|Expert Patient Programme|Receives a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
3211307|NCT01117480||Moderate-to-severe rheumatoid arthritis|Participants with moderate-to-severe rheumatoid arthritis treated with adalimumab in routine clinical practice
3211308|NCT01117467|Experimental|Solo|Students will perform their simulation scenario solo and receive feedback within the group
3211309|NCT01117467|Experimental|Paired|Students will be paired with one of their peers for this simulation scenario
3211310|NCT01117454|Other|Flecainide then placebo|In this crossover study, half of the subjects will be randomized to flecainide plus standard therapy with beta-blockers first, then crossover to placebo plus standard therapy with beta-blockers.
3211311|NCT01117454|Other|Placebo then flecainide|In this crossover study, half of the subjects will be randomized to placebo plus standard therapy with beta-blockers first, then crossover to flecainide plus standard therapy with beta-blockers.
3211312|NCT01117441|Active Comparator|R1 control arm|see detailed protocol description
3211313|NCT01117441|Experimental|R1 experimental arm|see detailed protocol description
3211314|NCT01117441|Active Comparator|R2 control arm|see detailed protocol description
3211315|NCT01117441|Experimental|R2 experimental arm|see detailed protocol description
3211316|NCT01117441|Active Comparator|R-HR control arm|see detailed protocol description
3211317|NCT01117441|Experimental|R-HR experimental arm|see detailed protocol description
3211318|NCT01117428|Experimental|Sym004|
3211319|NCT01117415||Gall Bladder Surgery|Who have symptomatic cholelithiasis and wish to undergo laparoscopic cholecystectomy for treatment.
3211320|NCT01117389||Mothers of Childhood cancer survivors|Mothers or female primary caregivers of active patients (aged 9-17) and young adult female patients aged 18-26 in the After Completion of Therapy (ACT) clinic at SJCRH. Mothers or female primary caregivers of active patients (aged 9-17) and young adult female patients aged 18-26 in the ACT clinic surviving childhood cancer will be asked to complete a questionnaire which queries sociodemographic, medical, and psychological variables which may relate to HPV vaccination.
3211321|NCT01117389||Acquaintance control Group|"Mothers or female primary caregivers ( with daughters aged 9-17) and young adult females aged 18-26 referred for study participation by participants from the ACT clinic. Participants have daughters aged 9-17 years or young adult females aged 18-26 at the time of study enrollment For those acquaintance controls electing to complete the paper-and-pencil questionnaire, the study team will send it to them in the mail along with a pre-addressed, stamped, return envelope. For those electing to complete the on-line questionnaire, the participant's email address will be collected and a secured link to our on-line questionnaire will be sent to them in an email.~A supplemental community control sample (meeting the inclusion and exclusion criteria outlined above) will also be utilized via the subject pool in the Department of Psychology at The University of Memphis."
3211322|NCT01117376|Active Comparator|Erythromycin|21 patients admitted in ICU with intolerance to enteral feeding defined as more than 250 ml of gastric residual volume (GRV) found by aspiration technique.
3211323|NCT01117376|Active Comparator|Methylnaltrexone|21 patients admitted in ICU with intolerance to enteral feeding defined as more than 250 ml of gastric residual volume (GRV) found by aspiration technique.
3211324|NCT01117363|Experimental|Rye porrige breakfast|
3211325|NCT01117363|Active Comparator|Refined wheat reference bread breakfast|
3211370|NCT01116986|Experimental|6, Patch, Gum, No Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3211422|NCT01116856|Experimental|Nutrition + mixed training|In this group the nutrition will be combined with 50% of resistance training plus 50% of aerobic training.
3211326|NCT01117350|Experimental|Insulin Glargine|"Insulin glargine administered once a day, in the morning or in the evening, at the most convenient time. The time of injection, once chosen was to remain unchanged during the whole duration of the study.~The starting dose was 0.2 Unit per kilogram of body weight or 10 Units. Patients were empowered to adjust their insulin doses, under strict investigator's supervision. Insulin titration (by 2 or 4 Units) was done every 3 days according to the median value of Fasting Plasma Glucose (FPG) of the last 3 days. The goal was to achieve 70 < FPG ≤ 100 mg/dL (3.9 < FPG ≤ 5.5 mmol/L). Minor deviations from the titration scheme could be allowed, based on Investigator's judgment and patient's situation."
3211327|NCT01117350|Active Comparator|Liraglutide|"Liraglutide administered once a day, in the morning or in the evening, at the most convenient time. The time of injection , once chosen was to remain unchanged during the whole duration of the study.~The dose was 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24. The dose might be decreased to 1.2 mg for safety reasons (e.g. gastro-intestinal tolerability), based on Investigator's judgment."
3211328|NCT01117337|No Intervention|Mesh Non Fixation Group|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed by ant means
3211329|NCT01117311|Experimental|VNB off first, then VNB on|Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB off first for the first intervention (Mixed Meal 2), then VNB on for the second intervention (Mixed Meal 3).
3211330|NCT01117311|Experimental|VNB on first, then VNB off|Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB on first for the first intervention (Mixed Meal 2), then VNB off for the second intervention (Mixed Meal 3).
3211331|NCT01117298|Experimental|Tadalafil|
3211332|NCT01117298|Placebo Comparator|Placebo|
3211333|NCT01117285|Active Comparator|3-day post-graduate course|3-day post-graduate course on the use of the COTiD program in clinical practice
3211334|NCT01117285|Experimental|Combined implementation strategy|The combined implementation strategy
3211335|NCT01117272||PCOS group|Who met the 2003 Rotterdam criteria.
3211336|NCT01117272||Mild hyperprolactinaemia group|Who were diagnosed with prolactin levels above the upper limit of normal (24.29 ng/ml) and under 100 ng/ml.
3211337|NCT01117272||Control group|Without PCOS and with normal prolactin levels.
3211338|NCT01117246|Experimental|Treated bone metastasis|Patients with bone metastasis causing pain.
3211339|NCT01117233|Experimental|Single IV Dose 1|
3211340|NCT01117233|Experimental|Single IV Dose 2|
3211341|NCT01117233|Experimental|Single IV Dose 3|
3211342|NCT01117233|Experimental|Single IV Dose 4|
3211343|NCT01117233|Experimental|Single IV Dose 5|
3211344|NCT01117220|Placebo Comparator|2|
3211345|NCT01117220|Active Comparator|1|
3211346|NCT01117194|Experimental|shoulder training, rehabilitation robot|
3211347|NCT01117194|No Intervention|control group|
3211348|NCT01117181|Experimental|Methylphenidate|Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention
3211349|NCT01117181|Placebo Comparator|Placebo|matching placebo and psychosocial intervention
3211350|NCT01117129|Experimental|A|
3211351|NCT01117129|Placebo Comparator|B|
3211352|NCT01117116|Active Comparator|fluticasone propionate and salmeterol|
3211353|NCT01117116|Active Comparator|budesonide and formoterol|
3211354|NCT01117064|Active Comparator|NMTD adjustment testing|We will determine effective NMTD device settings for reducing AHI.
3211355|NCT01117064|Active Comparator|CPAP vs NMTD device|We will randomly assign previously titrated CPAP vs. NMTD to each subject then compare the resultant AHI between the two devices.
3211356|NCT01117064|Active Comparator|NMTD efficacy and tolerability|Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
3211357|NCT01117051|Placebo Comparator|placebo|placebo
3211358|NCT01117051|Active Comparator|Resolor|prucalopride
3211359|NCT01117038|Experimental|enalapril and avanafil|
3211360|NCT01117038|Experimental|amlodipine and avanafil|
3211361|NCT01117025|Active Comparator|Circumferential PVI|
3211362|NCT01117025|Active Comparator|Circumferential PVI+renal denervation|
3211363|NCT01117012|Experimental|VX-770|VX-770 (ivacaftor) 150 milligram (mg) tablet orally twice daily (q12h).
3211364|NCT01116999|Experimental|Tracheal intubation|
3211365|NCT01116986|Experimental|1, Patch, Gum, Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3211366|NCT01116986|Experimental|2, Patch, Gum, Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3211367|NCT01116986|Experimental|3, Patch, Gum, Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3211368|NCT01116986|Experimental|4, Patch, Gum, Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3211369|NCT01116986|Experimental|5, Patch, Gum, No Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3211717|NCT01114893|Experimental|Travoprost Group B|Travoprost Group B
3211371|NCT01116986|Experimental|7, Patch, Gum, No Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3211372|NCT01116986|Experimental|8, Patch, Gum, No Prequit, Int In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3211373|NCT01116986|Experimental|9, Patch, No Gum, Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3211374|NCT01116986|Experimental|10, Patch, No Gum, Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3211375|NCT01116986|Experimental|11, Patch, No Gum, Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3211376|NCT01116986|Experimental|12, Patch, No Gum, Prequit, Int In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3211377|NCT01116986|Experimental|13, Patch, No Gum, No Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3211378|NCT01116986|Experimental|14, Patch, No Gum, No Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3211379|NCT01116986|Experimental|15, Patch, No Gum, No Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3211380|NCT01116986|Experimental|16, Patch, No Gum, No Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3211381|NCT01116986|Experimental|17, No Patch, Gum, Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3211382|NCT01116986|Experimental|18, No Patch, Gum, Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3211383|NCT01116986|Experimental|19, No Patch, Gum, Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3211384|NCT01116986|Experimental|20, No Patch, Gum, Prequit, Int In-Person, Int Phone, 16Wk|How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt
3211385|NCT01116986|Experimental|21, No Patch, Gum, No Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3211386|NCT01116986|Experimental|22, No Patch, Gum, No Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3211387|NCT01116986|Experimental|23, No Patch, Gum, No Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3211388|NCT01116986|Experimental|24, No Patch, Gum, No Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3211389|NCT01116986|Experimental|25, No Patch, No Gum, Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3211390|NCT01116986|Experimental|26, No Patch, No Gum, Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3211391|NCT01116986|Experimental|27, No Patch, No Gum, Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3211392|NCT01116986|Experimental|28, No Patch, No Gum, Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3211393|NCT01116986|Experimental|29, No Patch, No Gum, No Prequit, Min In-Person, Min Phone, 16|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3211394|NCT01116986|Experimental|30, No Patch, No Gum, No Prequit, Min In-Person, Int Phone, 8W|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3211395|NCT01116986|Experimental|31, No Patch, No Gum, No Prequit, Int In-Person, Min Phone, 8W|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3211396|NCT01116986|Experimental|32, No Patch, No Gum, No Prequit, Int In-Person, Int Phone, 16|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3211397|NCT01116973|Other|CICC comparison with PICC|All patients will be having CVP reading taken from the CICC
3211398|NCT01116973|Other|PICC group|The transition to the PICC, a 5.0-French, 18-gauge double lumen PICC (BARD, Power PICC Solo Catheter with Tip Location Stylet; Salt Lake City, UT) will be inserted
3211399|NCT01116960||Faculty; MD|Full time Faculty members working with the Department
3211400|NCT01116960||CRNAs|Full time CRNAs working within the department
3211401|NCT01116960||Residents|Residents working within the department
3211402|NCT01116947|Active Comparator|Intervention Arm|1. Treatment Arm (CASES) will receive high protein meals during thrice weekly hemodialysis in-center (each meal includes ~50 g of protein, ~850 Cal, and phos/protein ratio <10 mg/g) PLUS dietary counseling to continue similar high protein intake with low phosphorus to protein ratio and to avoid foods with high preservative content. Fosrenol 1.0 to 1.5 g per meal will be prescribed (use of pill crusher will be recommended) and will be titrated based on bi-weekly phosphorus levels.
3211403|NCT01116947|Active Comparator|Control Arm (CONTROLS)|2. Control Arm (CONTROLS) will receive salad boxes in-center (no protein, low calorie) and routine dietary counseling and will continue pre-existing phosphorus binder regimen.
3211404|NCT01116934||PLS patients|Eight PLS patients (one female) from 6 families.
3211405|NCT01116934||Healthy controls|Healthy donors had abstained from taking drugs for two weeks prior to the study. Due to wide spread use of oral contraceptives only male probands were chosen.
3211406|NCT01116921|Active Comparator|nCPAP Control Group|Infants in the Control Group were maintained continuously on nasal CPAP 6 cm H2O with no surfactant administered.
3211407|NCT01116921|Experimental|LMA Group|Once proper placement of the LMA was achieved, surfactant (Curosurf®, 2.5 ml/kg, Chiesi USA, Inc., Cary, NC) was administered. The LMA cuff was then deflated, LMA removed and the infant placed back on nasal CPAP 6 cm H2O.
3211408|NCT01116908|No Intervention|Control|
3211409|NCT01116908|Active Comparator|LifeStraw Family|
3211410|NCT01116895|Active Comparator|1 Active comparator LEO 22811|
3211411|NCT01116895|Active Comparator|2 Active comparator LEO 22811|
3211412|NCT01116895|Active Comparator|3 Active comparator LEO 22811|
3211413|NCT01116895|Placebo Comparator|4 Placebo comparator|
3211414|NCT01116882|Active Comparator|SOS|Patients randomized to the SOS arm are transferred to tertiary hospitals for their PCI procedure.
3211415|NCT01116882|Experimental|Non-SOS|Patients in the non-SOS arm are randomized to stay at the community hospitals for their PCI procedure.
3211416|NCT01116869||MBC patients|300 MBC patients, each of whom will provide a series of at least 3 blood draws (baseline, 3-4 weeks and 6-8 weeks after the initiation of the systemic therapy) for CTC analysis, will be enrolled. All MBC patients will be followed for a maximum of 36 months for disease progression and survival.
3211417|NCT01116869||Benign disease volunteers|100 Benign disease volunteers whom will donate blood 1 time for CTC analysis, will be enrolled as controls.
3211418|NCT01116869||Healthy volunteers|100 Healthy volunteers whom will donate blood 1 time for CTC analysis, will be enrolled as controls.
3211419|NCT01116856|Experimental|Nutrition|This groups will follow a diet.
3211420|NCT01116856|Experimental|Nutrition + resistance training|In this group, nutrition and resistance training will be combined.
3211421|NCT01116856|Experimental|Nutrition + aerobic training|In this group nutrition and aerobic training will be combined.
3211718|NCT01114893|Experimental|Travoprost Group C|Travoprost Group C
3211423|NCT01116843|Experimental|PF-00299804|Patient will receive PF-00299804 pre-operatively at a dose of 45 mg once daily orally for 7-11 days depending on surgery schedule.
3211424|NCT01116843|Placebo Comparator|Placebo arm|Patient will receive matching Placebo for 7-11 days depending on surgery schedule.
3211425|NCT01116830|Placebo Comparator|Placebo|
3211426|NCT01116830|Experimental|RO4917838|
3211427|NCT01116817|Experimental|LPV/r monotherapy 400/100 mg twice daily, orally administered|LPV/r monotherapy 400/100 mg twice daily, orally administered
3211428|NCT01116817|Active Comparator|Lumbar puncture|LPV/r 400/100 mg twice daily + 2 NRTI, orally administered.
3211429|NCT01116804|Other|inoperable liver cancer patients|
3211430|NCT01116791|Experimental|CRS+HIPC|Patients with biliary, gastric, or pancreatic carcinoma and metastatic or recurrent disease confined to the abdominal compartment
3211431|NCT01116778|Experimental|eN-Lac® Capsules|
3211432|NCT01116778|Other|Placebo Capsules|
3211433|NCT01116765|Experimental|experimental group|Infants in the experimental group receive an oral stimulation program consisting of stimulation of the oral structures during 10 consecutive days
3211434|NCT01116765|Other|control group|Infant in the control group receive no stimulation only non nutritive sucking during feeding
3211435|NCT01116752|Active Comparator|Strict control|Children requiring intensive care and mechanical ventilation and/or vasopressor/inotropic support who develop critical illness hyperglycemia (persistent BG values if >140 mg/dL) will be randomized to have their glucose levels managed with insulin infusions and receive strict glycemic control (80-140 mg/dL)
3211436|NCT01116752|Active Comparator|Conservative control|Children requiring intensive care and mechanical ventilation and/or vasopressor/inotropic support who develop critical illness hyperglycemia (persistent BG values if >140 mg/dL) will be randomized to have their glucose levels managed with insulin infusions and receive conservative control (190-220 mg/dL).
3211437|NCT01116739|Experimental|COHS administered fluoride varnish and oral health education|Paraprofessionals, called community oral health specialists (COHS), will be trained to administer fluoride varnish and oral health education to head start children quarterly for 2 years.
3211438|NCT01116739|Active Comparator|Usual care|Usual care will include regular dental services provided by the Indian Health Service.
3211439|NCT01116726|Experimental|Motivational interviewing and enhanced community services|Motivational interviewing sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries, provided shortly after childbirth, and at 6, 12, and 18 months. Enhanced community services will involve development of culturally appropriate messages related to the mitigation of risk factors for ECC through public service announcements and brochures.
3211440|NCT01116726|Active Comparator|Enhanced community services|Enhanced community services will involve development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
3211441|NCT01116713|Active Comparator|Dexamethasone group|This group of patients received intravenous dexamethasone (8 mg) 60 minutes before skin incision.
3211442|NCT01116713|Placebo Comparator|Placebo group|Patients of these group received homologated placebo 60 minutes before skin incision.
3211443|NCT01116687|Experimental|Treatment (RO4929097)|See detailed description.
3211444|NCT01116674||Glycemic Control|Critically ill children at participating centers who require select vital organ support measure (i.e. mechanical ventilation, vasopressor, or continuous renal replacement therapy) will have routine blood glucose (BG) screening initiated (i.e. at least q 12 hours). If a patient has a BG reading of > 140 mg/dL, a repeat BG will be obtained in 1-2 hours. If this second BG is > 140 mg/dL the patient will be diagnosed with critical illness hyperglycemia and an insulin infusion will be started and BG will be maintained between 80-140 using a pediatric specific developed and tested algorithm.
3211445|NCT01116661|Experimental|ALA|
3211446|NCT01116648|Experimental|Arm I (cediranib maleate and olaparib)|Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3211447|NCT01116648|Active Comparator|Arm II (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3211448|NCT01116635|Experimental|50mg dose loading per vial of doxorubicin|
3211449|NCT01116635|Experimental|75mg dose loading per vial of doxorubicin|
3211450|NCT01116622|Experimental|Daily oral erlotinib and bexarotene capusles|Open label dose-ranging trial
3211451|NCT01116583|Active Comparator|Gabapentin|Gabapentin group
3211452|NCT01116583|Placebo Comparator|Placebo|Placebo group
3211453|NCT01116570|Experimental|Physical training|The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. As a result, lower limb muscles will be mainly solicited. These muscles are heterogeneous in terms of deficiency, but this latter is compatible with cycling. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. Over a 2 to 4 weeks initial period, the program will be conducted in the laboratory or at home under the supervision of a coach. Then a systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
3211454|NCT01116570|Other|control|None intervention
3211455|NCT01116557|Other|THERMOCOOL® group|Radiofrequency ablation to achieve PVI using the CARTO® 3 System, the THERMOCOOL® Catheter and the LASSO® Circular Mapping Catheter.
3211456|NCT01116557|Active Comparator|PVAC® group|Radiofrequency ablation to achieve PVI using fluoroscopy and the PVAC®
3211457|NCT01116544|Experimental|AMES therapy with EMG biofeedback|The AMES device provides a 30 minute treatment period of alternating passive flexion and then extension of the hand while vibrators vibrate the muscles of the hand. The subjects job is to attempt to assist the device in the movement. A computer screen will provide visual feedback of the amount of EMG activity the subject is able to generate in the hand. This study will examine whether AMES therapy combined with EMG biofeedback can restore hand opening to plegic stroke subjects.
3211780|NCT01114542|Active Comparator|IGlar 0.8 U/kg|
3211458|NCT01116544|Experimental|AMES therapy with Torque biofeedback|The AMES device provides a 30 minute treatment period of alternating passive flexion and then extension of the hand while vibrators vibrate the muscles of the hand. The subjects job is to attempt to assist the device in the movement. A computer screen will provide visual feedback of the amount of torque (force) the subject is able to generate in the hand during the movement. This study will examine whether AMES therapy combined with Torque biofeedback can restore hand opening to plegic stroke subjects.
3211459|NCT01116531|Active Comparator|Duloxetine and tramadol|To ascertain the double-blinding of subjects and investigators, duloxetine and pregabalin will be administered as 2 similar capsules twice a day. Each of these capsules will contain either 30mg of duloxetine, 75 mg of pregabalin or placebo. Capsules will be prepared at the hospital pharmacy.
3211460|NCT01116531|Active Comparator|Pregabalin and tramadol|To ascertain the double-blinding of subjects and investigators, duloxetine and pregabalin will be administered as 2 similar capsules twice a day. Each of these capsules will contain either 30mg of duloxetine, 75 mg of pregabalin or placebo. Capsules will be prepared at the hospital pharmacy.
3211461|NCT01116518|Active Comparator|physiotherapy|
3211462|NCT01116518|Active Comparator|acromioplasty|
3211463|NCT01116518|Active Comparator|acromioplasty and rotator cuff reconstruction|
3211464|NCT01116505|No Intervention|gluten-containing diet|
3211465|NCT01116505|Active Comparator|Active comparator, gluten-free diet|
3211466|NCT01116492|Active Comparator|Lap Group|Patients in this group are operated for uncomplicated cholelithiasis with standard 4 port laparoscopic cholecystectomy
3211467|NCT01116492|Active Comparator|SILS group|Patients in this group are operated for uncomplicated cholelithiasis with Single Incision Laparoscopic Cholecystectomy
3211468|NCT01116479|Active Comparator|Haemoglobin (<6.0 mmol/l)|Blood transfusion thresholds:Haemoglobin < 6.0 mmol/l (9.9 g/dL)
3211469|NCT01116479|Experimental|Haemoglobin (< normal range)|Blood transfusion threshold: Haemoglobin < 7.1 mmol/l (11.7 g/dL) for female and 8.1 mmol/l (13.4 g/dL) for males
3211470|NCT01116466|Experimental|ActiGait|Receiving ActiGait - implantable drop foot stimulator
3211471|NCT01116453|Experimental|Acupuncture|
3211472|NCT01116453|Active Comparator|Usual Care|usual care followed by delayed acupuncture
3211473|NCT01116440|Experimental|BGS649 co-administered with Levora 28™|
3211474|NCT01116440|Placebo Comparator|Placebo co-administered with Levora 28™|
3211475|NCT01116427|Experimental|Abatacept|Receives abatacept during first course of treatment, switching to placebo during extension phase.
3211476|NCT01116427|Placebo Comparator|Placebo, followed by abatacept|Receives a placebo for first course of treatment, switching to abatacept in the extension phase.
3211477|NCT01116401|Experimental|GnRH Agonist Injection|We will be administering an injection of leuprolide acetate (a GnRH agonist) to all participants.
3211478|NCT01116388|Other|test product|product free of gluten and casein
3211479|NCT01116388|Other|control product|product containing gluten and milk protein
3211480|NCT01116375||Obese children with OSA|To determine whether, in obese children with moderate-severe OSA who are prescribed PAP therapy, increased hours of PAP usage per night over a one-year period is associated with a greater improvement in HOMA-IR
3211481|NCT01116362|Other|secondary repair|secondary closure beyond the first week.the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
3211482|NCT01116362|Other|primary repair|during first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
3211483|NCT01116349|Active Comparator|Surgical treatment|Patients included in the surgical group will have surgery to treat the fracture.
3211484|NCT01116349|Active Comparator|Conservative treatment group|Patients included in the conservative group will be taken to a plaster room where a Hanging Support System(HSS) brace will be installed by a qualified technician.
3211485|NCT01116336|Experimental|Erlotinib and Green Tea Polyphenon E|Patients will receive erlotinib, at pre-defined dose level, with polyphenon E.
3211486|NCT01116310|Experimental|Fitogyn|4 weeks with placebo followed by 16 weeks with Fitogyn, both taking two capsules per day during the breakfast.
3211487|NCT01116310|Placebo Comparator|Placebo|20 weeks with placebo, taking two capsules per day during the breakfast.
3211488|NCT01116297|Experimental|Imaging with S-FLARE imaging system|3 patients to be imaged by S-FLARE imaging system.
3211489|NCT01116284|Experimental|Revision of gastric bypass|A laparoscopic plication of the gastrojejunostomy will be performed after three 5-mm trocars are placed in the upper abdomen. Then using Ethibond suture, laparoscopic plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period with an expected discharge from the hospital within 24 hours.
3211490|NCT01116271|Experimental|1|Selumetinib (AZD6244) in combination with irinotecan
3211491|NCT01116258|Experimental|1|
3211492|NCT01116258|Placebo Comparator|2|
3211493|NCT01116245|Experimental|Low Dose|5x10^7 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
3211494|NCT01116245|Experimental|Middle Dose|3.3x10^8 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
3211495|NCT01116245|Experimental|High Dose|1x10^9 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
3211496|NCT01116245|Placebo Comparator|Placebo|normal saline x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
3211532|NCT01116037|Other|ATS 3f Aortic Bioprosthesis|ATS 3f Aortic Bioprosthesis, Model 1000 (equine pericardial bioprosthesis)
3211533|NCT01116024|Experimental|3f Enable Aortic Bioprosthesis Model 6000|Single arm study
3211534|NCT01116011|Experimental|AZD7268|
3211535|NCT01116011|Placebo Comparator|Placebo|
3211536|NCT01115998|Experimental|Power wheelchair|
3211497|NCT01116232|Experimental|anti-thymocyte globulin, rituximab, sirolimus, tacrolimus,|"anti-thymocyte globulin: Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter~Rituximab: The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour;~For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).~Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose."
3211498|NCT01116219|Active Comparator|Stratum mut EGFR|"Bevacizumab 7.5 mg/kg i.v. every 3 weeks and~Erlotinib 150 mg p.o. daily until progression."
3211499|NCT01116219|Active Comparator|Stratum wtEGFR|"Cohort 1:~Induction chemotherapy with~Bevacizumab 7.5 mg/kg i.v. and~Pemetrexed 500 mg/m2 i.v. and~Cisplatin* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression.~Followed by maintenance therapy in patients without disease progression with~Bevacizumab 7.5 mg/kg i.v. and~Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression.~Cohort 2:~Induction chemotherapy with~Pemetrexed 500 mg/m2 i.v. and~Cisplatin* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression.~Followed by maintenance therapy in patients without disease progression with~o Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression."
3211500|NCT01116206|Experimental|Prucalopride|prucalopride 2- milligram (mg), orally once daily for 12 weeks
3211501|NCT01116206|Placebo Comparator|Placebo|Matching placebo, orally once daily for 12 weeks
3211502|NCT01116180|Active Comparator|Candesartan|
3211503|NCT01116180|Placebo Comparator|Placebo|
3211504|NCT01116167|Experimental|Letrozole -Berberine|
3211505|NCT01116167|Active Comparator|Letrozole|
3211506|NCT01116167|Active Comparator|Berberine|
3211507|NCT01116154|Experimental|Arm I|Patients receive oral vorinostat twice daily on days 1-14 and oral lenalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3211508|NCT01116141|Active Comparator|Methotrexate (MTX) + Folic Acid|20 mg MTX weekly + 1 mg folic acid daily
3211509|NCT01116141|Experimental|0.3 mg CH-4051|0.3 mg CH-4051 daily
3211510|NCT01116141|Experimental|1.0 mg CH-4051|1.0 mg CH-4051 daily
3211511|NCT01116141|Experimental|3.0 mg CH-4051|3.0 mg CH-4051 daily
3211512|NCT01116141|Experimental|3.0 mg CH-4051 + folic acid|3.0 mg CH-4051 + 1.0 mg folic acid daily
3211513|NCT01116128|Experimental|D-MP|
3211514|NCT01116115|Active Comparator|Standard vegetable oil based formula|
3211515|NCT01116115|Active Comparator|InFat™ based infant formula|
3211516|NCT01116115|No Intervention|Breast-fed|
3211517|NCT01116102|Experimental|24 ga catheter, dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
3211518|NCT01116102|Experimental|24 ga catheter, no dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
3211519|NCT01116102|Experimental|24 ga catheter, dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
3211520|NCT01116102|Experimental|24 ga catheter, no dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
3211521|NCT01116102|Experimental|25 ga needle, dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
3211522|NCT01116102|Experimental|25 ga needle, no dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
3211523|NCT01116102|Experimental|25 ga needle, dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
3211524|NCT01116102|Experimental|25 ga needle, no dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
3211525|NCT01116089|Active Comparator|PARI LC® PLUS nebulizer|
3211526|NCT01116089|Active Comparator|PARI eFlow® rapid electronic nebulizer|
3211527|NCT01116076|Experimental|DECISION+ Program|Exposure to the Decision+ Program
3211528|NCT01116076|No Intervention|Control|Usual Care
3211529|NCT01116063|Experimental|Single arm open label|All patients will receive the study drugs and will be evaluated
3211530|NCT01116050|Placebo Comparator|Placebo|
3211531|NCT01116050|Experimental|MISOPROSTOL|
3211537|NCT01115998|Other|Control group|
3211538|NCT01115985|Experimental|single-add first group|single administration first, then concomitant administration
3211539|NCT01115985|Experimental|combi-add first group|concomitant administration first, then single administration
3211540|NCT01115972|Experimental|single-add first group|single administration first, then concomitant administration
3211541|NCT01115972|Experimental|combi-add first group|concomitant administration first, then single administration
3211542|NCT01115959|Active Comparator|valproic acid|Valproic acid given orally 400mg twice daily
3211543|NCT01115959|Placebo Comparator|placebo|Placebo twice daily for one month
3211544|NCT01115946|Experimental|single-add first group|single administration first, then concomitant administration
3211545|NCT01115946|Experimental|combi-add first group|concomitant administration first, then single administration
3211546|NCT01115933|Experimental|XIENCE PRIME SV EECSS|XIENCE PRIME SV EECSS: Small Vessel Everolimus Eluting Coronary Stent System
3211547|NCT01115920|Experimental|Arm 1|Cohort 1, Dose 0.010 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
3211548|NCT01115920|Experimental|Arm 2|Cohort 2, Dose 0.025 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
3211549|NCT01115920|Experimental|Arm 3|Cohort 3, Dose 0.050 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
3211550|NCT01115920|Experimental|Arm 4|Cohort 4, Dose 0.100 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
3211551|NCT01115920|Experimental|Arm 5|Cohort 5, Dose 0.250 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
3211552|NCT01115907|Experimental|Freedom SOLO stentless valve implant|Appropriate subjects will receive the Freedom SOLO stentless valve implant as a replacement for a diseased or damaged native or prosthetic aortic valve.
3211553|NCT01115894|Experimental|active medication + psychotherapy|
3211554|NCT01115894|Experimental|placebo + psychotherapy|
3211555|NCT01115894|Experimental|active medication+brief supportive counseling|
3211556|NCT01115894|Experimental|placebo + brief supportive counseling|
3211557|NCT01115868|Experimental|Group 2 - 2 doses of Prevascar and placebo|
3211558|NCT01115868|Experimental|Group 1 - 2 doses of Prevascar and placebo|
3211559|NCT01115868|Experimental|Group 3 - 2 doses of Prevascar and placebo|
3211560|NCT01115868|Experimental|Group 4 - 2 doses of Prevascar and placebo|
3211561|NCT01115855|Experimental|Eplerenone arm|Add on standard heart failure therapy
3211562|NCT01115855|Placebo Comparator|Placebo arm|Add on standard heart failure therapy
3211563|NCT01115842|Experimental|Vitamin D|The patients will be given Vitamin D - 4000IU per day for 5 days (Day 1 through 5)
3211564|NCT01115842|No Intervention|control|
3211565|NCT01115803|Experimental|Arm A: LY2584702 + Erlotinib|
3211566|NCT01115803|Experimental|Arm B: LY2584702 + Everolimus|
3211567|NCT01115790|Experimental|Prexasertib|
3211568|NCT01115777||Pediatric patients treated with radiotherapy|
3211569|NCT01115751|Experimental|LY2780301|"Part A: daily dosing~Part B (if determined as needed by pharmacokinetic, pharmacodynamic, and safety data): twice daily dosing~Part C: Dose and frequency as determined by Parts A and B of the study."
3211570|NCT01115738|Placebo Comparator|Placebo and 60 milligram (mg) Prasugrel|Placebo loading dose administered once orally before percutaneous coronary intervention (PCI) and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
3211571|NCT01115738|Experimental|600 mg Clopidogrel and 60 mg Prasugrel|600-mg clopidogrel loading dose administered once orally before PCI and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
3211572|NCT01115738|Experimental|600 mg Clopidogrel and 30 mg Prasugrel|600-mg clopidogrel loading dose administered once orally before PCI and 30-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
3211573|NCT01115725||Gonal-f® prefilled pen|
3211574|NCT01115712|Active Comparator|Pioglitazone 30 mg|Pioglitazone 30 mg
3211575|NCT01115712|Placebo Comparator|Placebo|Placebo
3211576|NCT01115699|Experimental|Repetitive Transcranial Magnetic Stimulation|All subjects will receive 10 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for a fixed-flexible period of 5 treatments per week for up to 6 weeks.
3211577|NCT01115686|Active Comparator|Branched-chain aminoacids|Branched-chain aminoacids are natural constituents of the food. Branched-chain aminoacids will be orally administered in the form of capsules.
3211578|NCT01115686|Placebo Comparator|placebo|The placebo will be orally administered in the form of capsules
3211579|NCT01115673|Experimental|ACE-1000|1000 mg Acetaminophen Caplet
3211580|NCT01115673|Active Comparator|ACE-650|650 mg Acetaminophen Caplet
3211581|NCT01115673|Placebo Comparator|ACE-0|0 mg Acetaminophen Caplet
3211582|NCT01115660|Experimental|stroke education|Patients in this arm receive a telephone call by a medication coach who reviews their condition and importance of adherence to medication regimen.
3211583|NCT01115660|No Intervention|control arm|Subjects in this arm received instruction at hospital discharge and a 3-month follow-up call to collect study data.
3211584|NCT01115647|Experimental|Ready-to-Use Therapeutic Foood (RUSF)|"Caretakers will receive weekly RUSF, 350g, and will be advised to feed it(50 g d-1 or 3 tablespoons/day) in one meal or on demand. These are pre-defined quantities. However, minimum quantities required for a timely (≤15 days) recovery from moderate malnutrition will be determined during the pilot phase.~Besides supplementary food, parents will be provided with the usual nutrition counsels prevailing currently in the health services.Children will be home-visited once a week by assessors for anthropometry, 24-hours recall of dietary and breastfeeding intake, and morbidity signs. Feeding practices will be assessed, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members."
3211623|NCT01115374|Active Comparator|manual lymphatic drainage|Application of manual lymphatic drainage
3211624|NCT01115374|Experimental|low frequency sound waves|Application of low frequency sound waves
3211719|NCT01114880|Placebo Comparator|Placebo|Blinded placebo from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.
3211585|NCT01115647|Active Comparator|CSB++|"Caretakers will receive weekly CSB++ (450g) rations. Parents will be advised to feed the CSB++ (65g d-1 diluted in 370 g water) in one meal or on demand. These are pre-defined quantities. However, minimum quantities of CSB++ required for a timely (≤15 days) recovery from moderate malnutrition in the area will be determined during the pilot phase. Besides supplementary foods, parents will be provided with the usual nutrition counsels prevailing currently in the health services, i.e. to keep on breastfeeding, to increase diet diversity and to feed frequent snacks.~Feeding practices will be also assessed, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members."
3211586|NCT01115647|Active Comparator|Children Centered Counseling (CCC)|"The counsellor will spend 1 hour daily (during the 3 first days and then weekly) within the household for identifying enhancing and blocking factors and adapt consequently the treatment strategies in agreement with the caretakers.~As in the other study arms, children will be home-visited once a week by assessors for anthropometry, 24-hours recall of dietary and breastfeeding intake, and morbidity signs. Feeding practices will be also assessed in each arm, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members.There will be no dietary supplements intervention, outside normal practices in Burkina."
3211587|NCT01115634|Experimental|Fibroblast|Injection of autologous cultured fibroblast
3211588|NCT01115621|Active Comparator|Glutenfree diet|Glutenfree diet during the first year of life
3211589|NCT01115621|No Intervention|Control - normal diet|
3211590|NCT01115608|Experimental|Pharmacist follow-up|"The patients will receive pharmaceutical follow-up during one year after discharge from the hospital. Three meetings are arranged, one at discharge, one after three months and the last after one year. Patients will be called up for arrangement of consultation. Written information concerning drugs used will be supplied."
3211591|NCT01115608|No Intervention|Control group|The control group receives no follow-up from the pharmacist, but will after one year, when they are out of the study, receive one follow-up visit and drug review.
3211592|NCT01115595|No Intervention|Placebo injection|Placebo injection with standard medication (oral antihistamine and/or topical nasal steroid)
3211593|NCT01115582|Experimental|Cholic Acid Capsule|Manufactured cholic acid capsules
3211594|NCT01115569|Experimental|Hydrocodone Bitartrate|Open-label, all patients fulfilling the protocol Inclusion/Exclusion criteria will receive HC-CR in a flexible dosing regimen.
3211595|NCT01115556|Experimental|Lucentis 2.0 mg|Lucentis 2.0 mg
3211596|NCT01115556|Active Comparator|LUCENTIS 0.5 mg|
3211597|NCT01115543|Active Comparator|calcitriol|The subjects were randomized to receive calcitriol in a dose-escalating fashion for up to 24 weeks.
3211598|NCT01115543|Experimental|alfacalcidol|
3211599|NCT01115530|No Intervention|1|Control inpatient GEM rehabilitation and continue twice weekly low level walking/stretching to control for time/interaction with intervention/exercise groups
3211600|NCT01115530|Experimental|2|Resistance exercise (2x/week)
3211601|NCT01115530|Experimental|3|Nutritional (amino acid metabolite) supplement twice daily
3211602|NCT01115530|Experimental|4|Resistance exercise (2x/week) and nutritional (amino acid metabolite) supplement twice daily
3211603|NCT01115517|Experimental|Bevacizumab|
3211604|NCT01115517|Active Comparator|Mitomycin C|
3211605|NCT01115504|Experimental|Thiamine|Thiamine tablets of 300mg are prescribed for 1 months
3211606|NCT01115504|Placebo Comparator|Plascebo|Tablets of 300mg placebo are prescribed for 1 months
3211607|NCT01115491|Experimental|A|
3211608|NCT01115478|Active Comparator|Vitamin A|
3211609|NCT01115478|Active Comparator|Zinc|
3211610|NCT01115478|Active Comparator|Vitamin A + Zinc|
3211611|NCT01115478|Placebo Comparator|Placebo|
3211612|NCT01115465|Other|Macroplastique|Macroplastique will be used for the treatment in an open-label, five year, post-market study
3211613|NCT01115452|Experimental|5% KNO3 solution|Participants to apply 5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period.
3211614|NCT01115452|Experimental|2.5% KNO3 solution|Participants to apply 2.5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period.
3211615|NCT01115452|Placebo Comparator|Sterile Water|Participants to apply sterile water to a single sensitive tooth for two minutes, in each of the five day treatment period.
3211616|NCT01115439||falciparum malaria|Febrile children (above six months of age) and non-pregnant adults with confirmed uncomplicated P. falciparum infection
3211617|NCT01115426|Other|anti-angiotensin II drugs|Never treated patients with non-nephrotic proteinuria (1-3 g/day), microhematuria, no-evidence of renal failure or other relevant diseases and with diagnosis of I-II stage IgA- or pauciimmune-MsPGN were considered eligible.
3211618|NCT01115413||young maternal age|maternal age of < 18 years
3211619|NCT01115413||adult maternal age|maternal age >/= 18 years
3211620|NCT01115387||ARM at risk individuals|"A group of 1,500 participants (from 49 to 65 years old) who have at least one parent with age related maculopathy.~These individuals with ARM-affected parents and relatives have a substantially higher risk (6-12 fold) of developing ARM than the general population. They will be followed prospectively with fundus photography every two years and questionnaires (distributed over six month intervals) to assess external risks for ARM development in order to investigate genotype-phenotype correlations of early onset clinical features of ARM."
3211621|NCT01115387||Partners/Spouses of ARM at risk individuals|"A group of 1,500 participants (from 49 to 65 years old) who are the spouses/partners of individuals with ARM affected parents.~We will invite the partners or spouses to participate in order to compare their risk of developing ARM with those individuals with an increased risk of ARM based on a positive family history."
3211622|NCT01115387||ARM affected individuals and relatives.|"Individuals who have experienced vision loss from ARM and have at least one brother or sister who also has experienced vision loss from ARM can participate in the study. They also need to have at least one adult child (from 49 to 65 years old) who wishes to participate in this study.~We will allow for additional recruitment to compensate for additional family members (such as parents, aunts and uncles) who wish to participate as well as to address potential drop out and those who may be deemed ineligible based on review of their medical and/or eye records. As many as 4000 individuals in this group will be allowed to enroll."
3211625|NCT01115361|Experimental|PPFP in child immunization|Women attending immunization services for their infant will receive educational brochures, group education and individual counseling on the benefits of the health timing and spacing of births,, pregnancy risk and return to fertility during the extended postpartum period (12 months), and referral to family planning services for those who are interested.
3211626|NCT01115361|No Intervention|Control - Standard of care|The control arm will receive standard of care infant immunization services.
3211627|NCT01115335|Active Comparator|Gomco|NMC performed using a Gomco clamp
3211628|NCT01115335|Active Comparator|Mogen clamp|NMC performed using a Mogen clamp
3211629|NCT01115335|Active Comparator|Plastibell|NMC performed using a Plastibell device
3211630|NCT01115322|Experimental|Tazarotene Foam without irradiation|Subjects will be exposed to Tazarotene Foam Patch without irradiation
3211631|NCT01115322|Experimental|Tazarotene Foam with UVA and UVB irradiation|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB irradiation
3211632|NCT01115322|Experimental|Tazarotene Foam with UVA , UVB, and visible light irradiation|Subjects will be exposed to Tazarotene Foam with UVA and UVB and visible light irradiation
3211633|NCT01115322|Placebo Comparator|Vehicle Foam without irradiation|Subjects will be exposed to Vehicle Foam Patch without irradiation
3211634|NCT01115322|Placebo Comparator|Vehicle Foam with UVA and UVB irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB irradiation
3211635|NCT01115322|Placebo Comparator|Vehicle Foam with UVA and UVB and visible light irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB and visible light irradiation
3211636|NCT01115322|Sham Comparator|No Treatment without irradiation|Subjects will be exposed to a Blank Patch without irradiation
3211637|NCT01115322|Sham Comparator|No Treatment with UVA and UVB irradiation|Subjects will be exposed to a Blank Patch with UVA and UVB irradiation
3211638|NCT01115322|Sham Comparator|No Treatment with UVA and UVB and visible light irradiation|Subjects will be exposed to a Blank Patch with UVA and UVB and visible light irradiation
3211639|NCT01115309|Other|XprESS Balloon Device|
3211640|NCT01115296|Active Comparator|'L. reuteri DSM 17938 and ATCC PTA 6475|L. reuteri will be delivered at a dose of 1x108 CFU of each strain of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day.
3211641|NCT01115296|Placebo Comparator|Placebo|Placebo
3211642|NCT01115283|Experimental|Perceptual learning|Patients will be asked to practice a range of visual discrimination tasks for a period of time (each therapy session:1-2 hrs, 4-5 sessions/wk for ~1-6 months).
3211643|NCT01115283|Experimental|Occlusion therapy|The fellow sound will be covered with a standard eye patch for a period of time (1-2 hrs/day, 4-5 days/wk for ~1-3 months). The idea is to push the brain to use the weaker amblyopic eye.
3211644|NCT01115283|Experimental|Video game|Patients will be asked to play videogames for a period of time (each therapy session:1-2 hrs, 4-5 sessions/wk for ~1-6 months).
3211645|NCT01115270||Hydrocephalus Patients|Those patients diagnosed with Normal Pressure Hydrocephalus.
3211646|NCT01115270||Normal Participants|Individuals who are not diagnosed with Normal Pressure Hydrocephalus.
3211647|NCT01115257|Other|group 1|90 eyes of 90 patients, with severe PDR, some with tractional retinal detachment (TRD) not involving the macula were included in the study and treated with vitrectomy
3211648|NCT01115257|Other|panretinalphotocoagulation (group 2)|90 eyes of 90 patients, with severe PDR, some with tractional retinal detachment (TRD) not involving the macula were included in the study and treated with panretinalphotocoagulation
3211649|NCT01115244|Experimental|Dapsone gel, 5%|ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
3211650|NCT01115244|No Intervention|Not treated|One arm of the patient will be left untreated.
3211651|NCT01115231||Group 1|Case control subjects will be recruited (150 persons). Controls are subjects without AMD diagnosis
3211652|NCT01115231||Group 2|Case (i.e., within 5 years) subjects will be recruited (150 persons). Cases are defined as subjects with diagnosed AMD.
3211653|NCT01115218||Glaucoma patients|
3211654|NCT01115205|Experimental|Supervised walking groups|Patients included in walking groups, under the supervision of a qualified personal trainer.
3211655|NCT01115205|Active Comparator|Controls|Patients receiving the standard counselling procedures of the Verona Diabetic Clinic.
3211656|NCT01115192|Experimental|Group A|Patients with chronic blepharitis, that will be treated with blephacura
3211657|NCT01115192|Experimental|Group B|Patients with chronic blepharitis that will be treated with diluted baby shampoo
3211658|NCT01115179|Active Comparator|Propofol|Propofol anesthesia
3211659|NCT01115179|Active Comparator|Control|Anesthesia with isoflurane alone
3211660|NCT01115179|Active Comparator|Solvent|Anesthesia with isoflurane together with the solvent of propofol (intralipid)
3211661|NCT01115166||Cardiac surgery|Patients subjected to open cardiac surgery with the help of extracorporal circulation.
3211662|NCT01115153|Experimental|Antibiotic prophylaxis|Rate of Wound infection in patients with gangrenous appendicitis with single doses of antibiotic (before surgery)
3211663|NCT01115153|Active Comparator|Antibiotic treatment, wound infection|Rate of Wound infection in patients with gangrenous appendicitis with five days antibiotic therapy (after surgery)
3211664|NCT01115140|Active Comparator|Group A1|metformin plus placebo
3211665|NCT01115140|Experimental|Group A2|metformin plus folic acid
3211666|NCT01115140|Active Comparator|Group A3|placebo plus folic acid
3211667|NCT01115140|Placebo Comparator|Group A4|placebo cp, 2 cps daily
3211668|NCT01115140|No Intervention|Group B|observation
3211669|NCT01115127|Active Comparator|myo-inositol|30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.
3211670|NCT01115127|Active Comparator|melatonin|30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months
3211671|NCT01115127|Active Comparator|melatonin plus myo-inositol|30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months
3211716|NCT01114893|Experimental|Travoprost Group A|Travoprost Group A
3211672|NCT01115114|Placebo Comparator|Treatment as Usual (TAU)|Study Intervention 1 Treatment as usual (TAU) will be psychiatry follow-up at local Community Mental Health Clinic at least every 3 months.
3211673|NCT01115114|Active Comparator|IMBED|Study Intervention 2 A Primary Care Provider (PCP) will be located within the community mental health clinic one day weekly to specifically run a Metabolic Syndrome Clinic.
3211674|NCT01115114|Active Comparator|Liaison|Study Intervention 3 A Medical Case Manager(MCM) will be assigned to a patient who is identified on the basis of routine screening to need medical follow-up for metabolic syndrome.
3211675|NCT01115101|Experimental|Oxycodon|
3211676|NCT01115101|Active Comparator|Patient controlled analgesia (PCA) device with Pritramid|
3211677|NCT01115088|Experimental|Aspartame|Food or beverages containing Aspartame in comparison to Stevia or Sucrose
3211678|NCT01115088|Experimental|Sucrose|Food or beverages containing Sucrose in comparison to Aspartame or Stevia
3211679|NCT01115088|Experimental|Stevia|Food or beverages containing Stevia in comparison to Aspartame or Sucrose
3211680|NCT01115075|Experimental|Dietitian|Recruitment of dietitians and senior level or graduate level dietetics students who are not restrained eaters. This group is skilled in identifying and accurately recording food than individuals not trained in dietetics.
3211681|NCT01115062|Experimental|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg)
3211682|NCT01115062|Experimental|LMX-4 Cream|LMX-4 (liposomal lidocaine 4%) cream
3211683|NCT01115062|Placebo Comparator|Placebo Patch|Placebo Patch
3211684|NCT01115049|Experimental|Experimental mouthwash|The experimental mouthwash (Buccagel®, Curaden Healthcare, Saronno, Italy) was made up of: purified water, dicaprylyl-ether, coco-caprylate caprate, xylitol, glyceryl-stearate, ceteareth-20, ceteareth-12, cetyl-palmitate, cetearyl-alcohol, chlorobutanol, aroma, hexetidine, methylparaben, propylparaben, sodium saccharin, citric acid and colorant C.I. 16255.
3211685|NCT01115049|Active Comparator|Chlorexidine-based mouthwash|A conventional commercial mouthwash (Curasept® ADS 0.20%, Curaden Healthcare, Saronno, Italy) made up of: water, xylitol, propylenglycol, Peg-40 of hydrogenated ricin oil, ascorbic acid, chlorhexidine digluconate, aroma, poloxamer 407, sodium metabisulfite, sodium citrate and colorant C.I. 42090.
3211686|NCT01115036|Experimental|panobinostat|
3211687|NCT01115023|Experimental|iron group|This group received an iron cooking pot for daily household cooking as an intervention
3211688|NCT01115023|No Intervention|Aluminium group|the subjects in this group were asked to continue cooking in the aluminium pot and not to cook in the iron pot if they possessed one.
3211689|NCT01115010|Experimental|Stiffening wire only if difficulty|Colonoscopy is performed with the unassisted colonoscope. The stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying.
3211690|NCT01115010|Experimental|Stiffening wire #1 transverse colon|Colonoscopy is started with the unassisted colonoscope. Stiffening wire #1 is introduced on entry of the tip of the colonoscope into the transverse colon.
3211691|NCT01115010|Experimental|Stiffening wire #2 transverse colon|Colonoscopy is started with the unassisted colonoscope. Stiffening wire #2 is introduced on entry of the tip of the colonoscope into the transverse colon.
3211692|NCT01114997|Active Comparator|Lidocaine|Pre-Induction: Lidocaine Loading: 1 mg/kg Post- Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
3211693|NCT01114997|Active Comparator|Esmolol|Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Post-Induction: Infusion dose 7.5 - 15 mcg /kg/min
3211694|NCT01114997|Experimental|Lidocaine + Esmolol (Combo)|"Performed with the administration of both drugs.~Pre-induction:~Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)~Post-induction:~Infusion rate: Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)"
3211695|NCT01114984||10% after breast biopsy|Incidence Post-operative pain after breast surgery.
3211696|NCT01114984||20% after lumpectomy|Incidence Post-operative pain after breast surgery
3211697|NCT01114984||30% after simple mastectomy|Incidence Post-operative pain after breast surgery
3211698|NCT01114984||50% after mastectomy with reconstruction|Incidence Post-operative pain after breast surgery
3211699|NCT01114984||50% after radical mastectomy|Incidence Post-operative pain after breast surgery
3211700|NCT01114984||50% after radi mastectomy+reconstruction|Incidence Post-operative pain after breast surgery after radical mastectomy with reconstruction
3211701|NCT01114984||40% after cosmetic augmentation|Incidence Post-operative pain after breast surgery
3211702|NCT01114984||40% after breast reduction|Incidence Post-operative pain after breast surgery
3211703|NCT01114971|Active Comparator|Fentanyl|"Fentanyl 50 micrograms/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or Heart Rate (HR) > 80 bpm)"
3211704|NCT01114971|Experimental|Labetalol|"Labetalol 5 mg/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
3211705|NCT01114971|Experimental|Esmolol|"Esmolol 10 mg/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
3211706|NCT01114958|Experimental|IA Cisplatin / IV Thiosulfate|Single-arm study
3211707|NCT01114945|Experimental|Video-Mac|Video-Mac device used during intubation procedure
3211708|NCT01114945|Experimental|GlideScope|GlideScope device used during intubation procedure
3211709|NCT01114945|Experimental|McGrath|McGrath device used during intubation procedure
3211710|NCT01114945|Active Comparator|Direct Macintosh Laryngoscopy|Direct Macintosh Laryngoscopy (DL) used during intubation procedure
3211711|NCT01114932||BMI-I|Patients with BMI values between 18.5-24.9
3211712|NCT01114932||BMI-II|Patients with BMI values between 25-29.9
3211713|NCT01114932||BMI-III|Patients with BMI values between 30-49.9
3211714|NCT01114893|Active Comparator|TRAVATAN|TRAVATAN 0.004% once daily
3211715|NCT01114893|Placebo Comparator|Travoprost Vehicle|Travoprost Vehicle
3211720|NCT01114880|Experimental|Adalimumab|Blinded adalimumab from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.
3211721|NCT01114854|Other|Topiramate IR followed by Topiramate ER|Dosing with IR followed by dosing with ER
3211722|NCT01114841|Experimental|Tazarotene Foam|Subjects will be exposed to patches containing Tazarotene foam 0.1%
3211723|NCT01114841|Placebo Comparator|Vehicle Foam|Subjects will be exposed to patches containing Vehicle Foam
3211724|NCT01114828|Experimental|3.75 mg|Once-daily oral administration of OPC-41061
3211725|NCT01114828|Experimental|7.5 mg|Once-daily oral administration of OPC-41061
3211726|NCT01114802|Experimental|Project Onward website + social network|This arm has the website which includes 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
3211727|NCT01114802|Active Comparator|Project Onward website|This arm has the website which includes 8 weeks of Internet-based cognitive behavioral therapy.
3211728|NCT01114776||Sickle Cell Disease (SCD)|Patients with sickle cell diseases, 16 years or older with 10-20 years of transfusion (defined as 0.2-0.6mg Fe/kg/day exposure with annual ferritin levels greater than 2500 in at least 60% of years of chronic transfusion); 0 to 9 years old at the initiation of chronic transfusions; no exchange transfusions in the previous 6 months; and iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months or ferritin level greater than 1500mg/dl.
3211729|NCT01114776||Thalassemia Major (TM)|Patients with β-thalassemia major and transfusion-dependent E-beta THAL. 16 years or older with 10-20 years of chronic transfusion (defined above), 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
3211730|NCT01114776||Diamond Blackfan Anemia (DBA)|Patients with DBA, 16 years or older with 10-20 years of transfusion, 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
3211731|NCT01114776||Controls|
3211732|NCT01114763||Metabolic syndrome|40 men with metabolic syndrome
3211733|NCT01114763||Control|40 physically active men
3211734|NCT01114750|Active Comparator|Oral Insulin in Dextran Matrix|A group consisting of male healthy volunteers will be given placebo and one single dose of insulin in dextran matrix, for estimation of post-dose relative bioavailability.
3211735|NCT01114750|Placebo Comparator|Placebo|A group consisting of male healthy volunteers will be given placebo and one single dose of insulin in dextran matrix, for estimation of post-dose relative bioavailability.
3211736|NCT01114737|Experimental|Sapropterin dihydrochloride|
3211737|NCT01114737|Placebo Comparator|Tablet without active ingredient|
3211738|NCT01114724|Experimental|Valiant Thoracic Stent Graft with the Captivia Delivery System|
3211739|NCT01114711||Frovatriptan|All subjects will be taking Frovatriptan tablets within 48 hours prior to the scan session (Visit 2).
3211740|NCT01114698|Experimental|JNJ26489112|
3211741|NCT01114698|Active Comparator|Venlafaxine XR|
3211742|NCT01114698|Placebo Comparator|Placebo|
3211743|NCT01114685|Active Comparator|Effects of taking AlgaeCal-1|Following a bone health plan with Algae-cal-1 supplement
3211744|NCT01114685|Active Comparator|Effects of taking AlgaeCal-2|Following a bone-health plan while consuming AlgaeCal 2
3211745|NCT01114672|Active Comparator|Ergocalciferol|
3211746|NCT01114672|Placebo Comparator|oral placebo|
3211747|NCT01114659||Women with PCOS|
3211748|NCT01114659||Normal Control|
3211749|NCT01114646|Other|Cemented Hip Hemiarthroplasty|This arm received a hemiarthroplasty with a cemented femoral prosthesis (VerSys LD/Fx, Zimmer, Warsaw, IN).
3211750|NCT01114646|Experimental|Press-Fit Hip Hemiarthroplasty|This arm received a press-fit hemiarthroplasty (VerSys Beaded FullCoat, Zimmer, Warsaw, IN),
3211751|NCT01114620|Experimental|Arepanrix Group|Healthy Japanese male and female adults, 65 years of age or older, who received one dose of the study vaccine Arepanrix™, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
3211752|NCT01114607|Experimental|Treatment sequence ABCDE|Eligible subjects will be randomized in sequence ABCDE and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
3211753|NCT01114607|Experimental|Treatment sequence ABDEC|Eligible subjects will be randomized in sequence ABDEC and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
3211754|NCT01114607|Experimental|Treatment sequence ABECD|Eligible subjects will be randomized in sequence ABECD and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
3211755|NCT01114607|Experimental|Treatment sequence ABCED|Eligible subjects will be randomized in sequence ABCED and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, E= a film coated tablet of GSK1605786 GSK formulation 500 mg once daily and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
3211774|NCT01114555|Experimental|Bevacizumab, Irinotecan and Temozolomide|This is a phase II study of the combination of irinotecan, temozolomide and bevacizumab in patients with resistant NB.
3211775|NCT01114542|Experimental|IDeg 0.4 U/kg|
3211776|NCT01114542|Experimental|IDeg 0.6 U/kg|
3211777|NCT01114542|Experimental|IDeg 0.8 U/kg|
3211756|NCT01114607|Experimental|Treatment sequence ABDCE|Eligible subjects will be randomized in sequence ABDCE and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
3211757|NCT01114607|Experimental|Treatment sequence ABEDC|Eligible subjects will be randomized in sequence ABEDC and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
3211758|NCT01114607|Experimental|Treatment sequence BACDE|Eligible subjects will be randomized in sequence BACDE and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
3211759|NCT01114607|Experimental|Treatment sequence BADEC|Eligible subjects will be randomized in sequence BADEC and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
3211760|NCT01114607|Experimental|Treatment sequence BAECD|Eligible subjects will be randomized in sequence BAECD and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
3211761|NCT01114607|Experimental|Treatment sequence BACED|Eligible subjects will be randomized in sequence BACED and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
3211762|NCT01114607|Experimental|Treatment sequence BADCE|Eligible subjects will be randomized in sequence BADCE and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
3211763|NCT01114607|Experimental|Treatment sequence BAEDC|Eligible subjects will be randomized in sequence BAEDC and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
3211764|NCT01114594||PKD|Patients with Autosomal Dominant Polycystic Kidney Disease
3211765|NCT01114594||non-PKD CKD|Patients with non-Polycystic Chronic Kidney Disease
3211766|NCT01114581|Active Comparator|Guaifenesin|Mucinex 1200mg (Guaifenesin)given as 2, 600mg tablets
3211767|NCT01114581|Placebo Comparator|Placebo|Given as 2 tablets
3211768|NCT01114568|Experimental|Ertugliflozin 10 mg: tablet→osmotic capsule (OC) fast→OC slow|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 6 hours (EP-Osmotic Capsule-Fast) and C) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 14 hours (EP-Osmotic Capsule-Slow). Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
3211769|NCT01114568|Experimental|Ertugliflozin 10 mg: tablet→OC slow→OC fast|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
3211770|NCT01114568|Experimental|Ertugliflozin 10 mg: OC fast→tablet→OC slow|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
3211771|NCT01114568|Experimental|Ertugliflozin 10 mg: OC fast→OC slow→tablet|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
3211772|NCT01114568|Experimental|Ertugliflozin 10 mg: OC slow→tablet→OC fast|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
3211773|NCT01114568|Experimental|Ertugliflozin 10 mg: OC slow→OC fast→tablet|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
3211778|NCT01114542|Active Comparator|IGlar 0.4 U/kg|
3211779|NCT01114542|Active Comparator|IGlar 0.6 U/kg|
3211781|NCT01114529|Experimental|Everolimus|Conversion from CNI to everolimus in combination with Myfortic and steroids
3211782|NCT01114529|Active Comparator|Calcineurin inhibitor, Prograf or Neoral|Control arm: CNI continuation, either Prograf or Neoral in combination with Myfortic and steroids
3211783|NCT01114516|No Intervention|control|emergent cerclage with no peri-operative antibiotics or indomethacin
3211784|NCT01114516|Experimental|indomethacin and antibiotics|perioperative antibiotics and indomethacin
3211785|NCT01114503|Experimental|Part A|Up to 4 cohorts of 5 patients receive dose rising treatments of otelixizumab
3211786|NCT01114503|Experimental|Part B - Otelixizumab|Parallel dosing group in Part B receive otelixizumab over 8 days at a dose decided upon results from Part A
3211787|NCT01114503|Active Comparator|Part B - Methylprednisolone|Parallel dosing group in Part B of weekly doses of methylprednisolone for 12 weeks
3211788|NCT01114490|Experimental|Part 1 - Group 1|Moderate Hepatic Patients
3211789|NCT01114490|Experimental|Part 1 - Group 2|Healthy Subjects
3211790|NCT01114490|Experimental|Part 2 - Group 1|Mild Hepatic Patients
3211791|NCT01114490|Experimental|Part 2 - Group 2|Healthy Subjects
3211792|NCT01114464||young women with breast cancer|
3211793|NCT01114451|Experimental|Early Staple Removal|Skin staple removal on post-operative day #3
3211794|NCT01114451|Experimental|Delayed Staple Removal|Skin staple removal on post-operative day 7-10
3211795|NCT01114438|Experimental|Device|
3211796|NCT01114412||Patients|Patients with overactive bladder syndrome
3211797|NCT01114412||Healthy volunteers|Healthy volunteers
3211798|NCT01114399|Experimental|Standard Broccoli|Standard Broccoli
3211799|NCT01114399|Experimental|High Glucosinolate Broccoli|High Glucosinolate Broccoli
3211800|NCT01114399|Experimental|Peas|Peas
3211801|NCT01114386||COPD patients, CHF patients|COPD and CHF patients with smoking history (> 10 pack/years), male and female, older than 50 years, referred to Hospital for dyspnea and chronic cough.
3211802|NCT01114373|Active Comparator|Melatonin|Subjects with mild to moderate essential hypertension will be given 24mg time release melatonin for 4 weeks either before or after exposure to 4 week of placebo with no washout period.
3211803|NCT01114373|Placebo Comparator|Placebo|Subjects with mild to moderate essential hypertension will be given placebo for 4 weeks either before or after exposure to 4 weeks of 24mg daily dose of time release melatonin with no washout period.
3211804|NCT01114360|Active Comparator|Melatonin|African-American subjects with mild to moderate essential hypertension will be given 8mg time release melatonin for 4 weeks. (either before or after placebo exposure).
3211805|NCT01114360|Placebo Comparator|Placebo|African-American subjects with mild to moderate essential hypertension will be given placebo for 4 weeks (either before or after exposure to melatonin)
3211806|NCT01114347|Experimental|Cranberry|Patients randomized to this arm will recieve one gel capsule containing cranberry PAC (36 mg of type A pro anthocyandines: Urell, Pharmatoka) per day starting at the day of the pelvic surgery (j0) until day 10 postop (j10). The gel capsule in taken orally in the morning with a large glass of water.
3211807|NCT01114347|Placebo Comparator|Placebo|The patients randomized to this arm will recieve one placebo gel capsule per day starting on the day of the pelvic surgery (j0) until the 10th day post-op (j10). The gel capsule is taken orally in the morning with a large glass of water. The placebo contains lactose and is conditioned in a manner to be identical in caliber and color with the experimental treatment gel capsules.
3211808|NCT01114334|Active Comparator|Guideline-based Medical Management|"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.~The evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications"
3211809|NCT01114334|Experimental|Motivational Interview with GBMM|Motivational Interviewing for Depression combined with guideline-based medical management for depression
3211810|NCT01114308|Experimental|Probuphine|Patients are first inducted on SL BPN then switched to 4 buprenorphine implants
3211811|NCT01114308|Placebo Comparator|placebo implant|patients are first inducted on SL BPN then switched to 4 placebo implants
3211812|NCT01114308|Active Comparator|sublingual buprenorphine|patients are inducted on SL BPN, then continue on SL BPN
3211813|NCT01114295|Experimental|Overt Obscure Gastrointestinal Bleeders|The only cohort in this study are those patients identified as having overt, obscure gastrointestinal bleeding who will then undergo CE or CTE.
3211814|NCT01114282|Experimental|VELCADE with pralatrexate|Pralatrexate,10 mg/m2, IV bolus on days 1, 8, and 15 VELCADE,1.3 mg/m2, IV bolus on days 1, 8, and 15
3211815|NCT01114256||Fine needle aspiration (FNA) biopsies|Fine needle aspiration biopsies (FNA) will be performed prior to and 0 to 336 hours after the therapeutic monoclonal antibody infusion.
3211816|NCT01114230|Experimental|Dose Level 1|
3211817|NCT01114230|Experimental|Dose Level 2|
3211818|NCT01114230|Experimental|Dose Level 3|
3211819|NCT01114230|Experimental|Dose Level 4|
3211820|NCT01114230|Experimental|Dose Level 5|
3211821|NCT01114230|Experimental|Dose Level 6|
3211822|NCT01114230|Experimental|Dose Level 7|
3211823|NCT01114230|Experimental|Dose Level 8|
3211824|NCT01114230|Experimental|Dose Level 9|
3211873|NCT01113918||Obsity PCOS Women|"Polycystic ovary syndrome (PCOS) was diagnosed according to the European Society for Human Reproduction (ESHRE)/American Society of Reproductive Medicine (ASRM) case definition which requires presentation of signs and/or symptoms of a minimum of 2 of the following 3 criteria: polycystic ovary morphology (PCOM), oligomenorrhea or amenorrhea (Oligo-An), androgen excess (HA).~Body mass index (BMI) was defined as body weight in kilograms divided by body height in meters squared (kg/m2). Obesity was defined as BMI≥25 kg/m2, according to the Asia-Pacific definition."
3211874|NCT01113918||Non-obesity PCOS Women|The subjects BMI were less than ≥25 kg/m2 and out of criteria of PCOS by European Society for Human Reproduction (ESHRE)/American Society of Reproductive Medicine (ASRM).
3211875|NCT01113905||Radiation Only|
3211825|NCT01114217|Experimental|Ferumoxytol|Participants received ferumoxytol or placebo during AMAG-FER-IDA-301 [NCT01114139]. Participants enrolled in AMAG-FER-IDA-303, a 6-month Extension Study, were evaluated monthly and could receive treatment with ferumoxytol only if they met criteria defined as persistent or recurrent IDA, hemoglobin <11.0 grams per deciliter (g/dL) and transferrin saturation (TSAT) <20% at any evaluation visit, (except study termination visit). Participants who met criteria began a 5-week treatment period (TP) and received 2 doses of ferumoxytol 510 mg intravenously (IV). The first IV 510-mg dose was administered on TP Day 1 (Baseline); the second 2-8 (5±3) days after Dose 1. The first treatment course with ferumoxytol for participants who previously received placebo in AMAG-FER-IDA-301 was considered Course 1; Course 2 included participants who previously received ferumoxytol in AMAG-FER-IDA-301; subsequent treatment courses were serially numbered.
3211826|NCT01114204|Experimental|Ferumoxytol|Participants received a total of 2 doses of IV ferumoxytol 510 milligrams (mg) (17 milliliters [mL]). The first IV 510 mg dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose, for a total cumulative dose of 1.02 grams (g).
3211827|NCT01114204|Active Comparator|Iron Sucrose|Participants received an IV injection or infusion of iron sucrose 200 mg (10 mL) on Day 1 (Baseline) and on 4 other non-consecutive days over a 14-day period, for a total cumulative dose of 1.0 g. Participants receiving their first ever exposure to IV iron sucrose, received a test dose on Day 1 prior to receiving the remainder of the first dose, as prescribed in the package insert for some countries.
3211828|NCT01114191|Experimental|Arm 1|
3211829|NCT01114178||claudicants|patients referred for a treadmill test
3211830|NCT01114165|Experimental|SeptiFast Test|Pathogen detection by SeptiFast Test as an adjunct to traditional microbiological assessments including blood culture
3211831|NCT01114165|Active Comparator|Only Conventional Diagnostics|Pathogen detection only by conventional microbiological assessments, e.g. blood culture
3211832|NCT01114152|Experimental|1|Dose level A, B, C and optional Dose level D and E: single administration and one to three times daily for 6 days (Japanese n=8)
3211833|NCT01114152|Placebo Comparator|2|placebo given (2 subjects in each dose group)
3211834|NCT01114139|Experimental|Ferumoxytol|Participants received a total of 2 doses of IV ferumoxytol 510 milligrams (mg) (17 milliliters [mL]). The first IV 510 mg dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose, for a total cumulative dose of 1.02 grams (g).
3211835|NCT01114139|Placebo Comparator|Placebo|Participants received a total of 2 doses of IV saline (17 mL). The first IV dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose.
3211836|NCT01114126|Experimental|Neu-P11 2mg|
3211837|NCT01114126|Experimental|Neu-P11 5 mg|
3211838|NCT01114126|Experimental|Neu-p11 20 mg|
3211839|NCT01114126|Experimental|Neu-P11 50 mg|
3211840|NCT01114126|Placebo Comparator|Placebo|
3211841|NCT01114113|Active Comparator|non-trigger meal|"Measurement of intestinal transport eating a non-trigger meal."
3211842|NCT01114113|Active Comparator|"trigger meal baseline"|"Measurement of intestinal transport after eating a trigger meal."
3211843|NCT01114113|Placebo Comparator|"trigger meal with placebo"|Measurement of intestinal transport with blinded placebo
3211844|NCT01114113|Active Comparator|"trigger meal with enzymes (blinded)"|Measurement of intestinal transport with blinded active enzyme capsule
3211845|NCT01114100|Active Comparator|sertraline, panic education|treatment with sertraline after panic education
3211846|NCT01114100|Placebo Comparator|placebo after panic education|treatment with placebo after panic education
3211847|NCT01114100|No Intervention|care as usual|patient received no diagnosis an no panic education, they had a 24 weeks follow up with a visit at 12 weeks and 24 weeks to evaluate their complaints
3211848|NCT01114087|Experimental|1|Patients presenting with chronic myeloid leukaemia or malignant GIST and receiving for the first time a treatment by imatinib, a tyrosin-kinase inhibitor, preceded or not by hydroxyurea therapy for less than one month.
3211849|NCT01114074||Factor XII deficiency|Patients deficient in coagulation factor XII
3211850|NCT01114074||Factor XI Deficiency|Patients deficient in coagulation factor XI
3211851|NCT01114074||Prekallikrein deficiency|Patients deficient in prekallikrein
3211852|NCT01114074||HMWK deficiency|Patients deficient in high molecular weight kininogen (HMWK)
3211853|NCT01114074||Control group|Healthy controls
3211854|NCT01114061|Experimental|InsuPatch|The arm with the treatment: using the insupatch device to heat the insulin infusion site.
3211855|NCT01114035|Experimental|Patients|intestinal epithelial dysplasia
3211856|NCT01114035|Other|Control|Children without intestinal epithelial dysplasia
3211857|NCT01114022|Active Comparator|Active comparator|cylindrical PVC cuff
3211858|NCT01114022|Experimental|Experimental 1|cylindrical polyurethane cuff
3211859|NCT01114022|Experimental|Experimental 2|conic PVC cuff
3211860|NCT01114022|Experimental|Experimental 3|conic polyurethane cuff
3211861|NCT01114009|Experimental|Lung recruitment maneuver|The maneuver briefly increases the alveolar pressure to open recruitable lung (50 cmH2O), sustained with adequate positive end-expiratory pressure(PEEP) after lung recruitment, to avoid derecruitment.
3211862|NCT01114009|Active Comparator|Lung protective strategy|Lung protective strategy group received lung protective strategy without recruitment maneuver
3211863|NCT01113996|No Intervention|Standard treatment - usual care|
3211864|NCT01113996|Experimental|Protein supplementation|
3211865|NCT01113996|Experimental|Protein supplementation and strength training|
3211866|NCT01113970|Experimental|Single Arm|open label, single arm, unblinded
3211867|NCT01113957|Experimental|Arm A|ABT-888 in combination with temozolomide
3211868|NCT01113957|Active Comparator|Arm B|pegylated liposomal doxorubicin alone
3211869|NCT01113944|Active Comparator|Program 1|Program 1
3211870|NCT01113944|Active Comparator|Program 2|Program 2
3211871|NCT01113931|Experimental|Doxycycline Hyclate 200 mg tablet|Once daily
3211872|NCT01113931|Active Comparator|Vibramycin 100 mg capsule|Twice daily
3211876|NCT01113905||Radiation and Chemotherapy|
3211877|NCT01113892|Active Comparator|EXXCEL Soft|
3211878|NCT01113892|Experimental|FUSION Bioline|
3211879|NCT01113879|Active Comparator|Arm 1|Aphasia therapy with no exercise adjuvant
3211880|NCT01113879|Experimental|Arm 2|Aphasia therapy with an exercise adjuvant
3211881|NCT01113879|Sham Comparator|Arm 3|Aphasia therapy with a stretching adjuvant
3211882|NCT01113866||heart failure|
3211883|NCT01113840|Placebo Comparator|Control|Control group continues with their daily activity as they were prior to randomization. Receive bi-weekly follow-up phone calls to assess health status and encourage adherence with protocol.
3211884|NCT01113840|Active Comparator|Exercise|Exercise classes three times per week in a controlled, supervised environment.
3211885|NCT01113827|Active Comparator|150mg olive extract|
3211886|NCT01113827|Active Comparator|50mg olive extract|
3211887|NCT01113827|Placebo Comparator|Placebo control|
3211888|NCT01113801|Placebo Comparator|Placebo|
3211889|NCT01113801|Experimental|2 mg LY2382770|
3211890|NCT01113801|Experimental|10 mg LY2382770|
3211891|NCT01113801|Experimental|50 mg LY2382770|
3211892|NCT01113788||imaging|imaging with usual catheter/fluoroscopy, no cartosound
3211893|NCT01113775||presence of right ventricle dysfunction|
3211894|NCT01113775||absence of right ventricle dysfunction|
3211895|NCT01113762|Experimental|resurfacing|a hip replacement that leaves most of the underlying bone intact and mimics the natural biomechanical features of the hip joint
3211896|NCT01113762|Experimental|large head THA|a standard stemmed THA but with a large metal head, and a metal-metal articulation
3211897|NCT01113762|Active Comparator|28 mm ceramics-polyethylene|a standard 28 mm head uncemented THA
3211898|NCT01113762|Active Comparator|28 mm metal-polyethylene THA|a standard stemmed uncemented THA
3211899|NCT01113749|Experimental|Decision support|Structured decision aid with prompting to share information in discussion with primary treating health care providers.
3211900|NCT01113749|No Intervention|Control|Usual care
3211901|NCT01113736|Experimental|Human Peritoneal Membrane: AlloMEM™|For use as a homologous tissue where native peritoneum is absent or traumatized. By decreasing adhesions and providing a peritoneal remodeling capacity, both the time needed for ileostomy closure and the risk of enterotomy or seromyotomy would be reduced. The combination could lead to decreased complication rates and therefore decreased morbidity for the surgical patients requiring an ileostomy.
3211902|NCT01113723|Other|CMAC Device|CMAC Intubating device time to achieve successful tracheal intubation.
3211903|NCT01113723|Active Comparator|Fiberoptic bronchoscope|Fiberoptic bronchoscope Intubating device time to achieve successful tracheal intubation.
3211904|NCT01113710||Neupro®|Routine treatment in accordance with the local marketing authorization for Neupro® in RLS
3211905|NCT01113697||Clinical Investigator Collaborative (CIC) Asthma study cohort|Participants will be healthy volunteer research subjects with allergic asthma who will have an allergen inhalation challenge at CIC sites across Canada.
3211906|NCT01113697||Western Red Cedar Asthma study cohort|Participants will be volunteer research subjects with Western Red Cedar asthma, who will have a plicatic acid inhalation challenge at The Lung Centre at Vancouver General Hospital.
3211907|NCT01113697||Environmental Exposure Unit (EEU), Kingston General Hospital|Subjects will be over 19 years of age so that they qualify for studies involving allergen challenge.
3211908|NCT01113671|Placebo Comparator|Placebo|
3211909|NCT01113671|Experimental|d-alpha-tocopheryl acetate|
3211910|NCT01113645||Cerebral perfusion evaluation|All patients are evaluated by GOS (Glasgow Outcome Score) and neurocognitive tests by FAB (frontal assessment battery) and MMSE (mini mental state examination) scores. Hemodynamic monitoring by CT perfusion scan, as well as by trans-cranial Doppler.
3211911|NCT01113632|Experimental|Ofatumumab 1000mg|Ofatumumab 300mg IV Day 1 followed by ofatumumab 1000mg weekly for a total of 8 weeks
3211912|NCT01113632|Experimental|Ofatumumab 2000mg|Ofatumumab 300mg IV Day 1 followed by ofatumumab 2000mg weekly for a total of 8 weeks
3211913|NCT01113619|Experimental|RP-G28|Study Drug RP-G28
3211914|NCT01113619|Placebo Comparator|Placebo|Study Drug Placebo
3211915|NCT01113606|Active Comparator|Obagi Nu-Derm System (ONDS)|
3211916|NCT01113606|Active Comparator|Standard of Care|
3211917|NCT01113593|Experimental|1|
3211918|NCT01113593|Experimental|2|
3211919|NCT01113593|Experimental|3|
3211920|NCT01113593|Experimental|4|
3211921|NCT01113593|Experimental|5|
3211922|NCT01113580|Experimental|Adults|Healthy volunteers aged 18 to 59 years
3211923|NCT01113580|Experimental|Older Adults|Healthy volunteers aged 60 years or older
3211924|NCT01113567|Placebo Comparator|Diet and lactose-free milk|Lactose-free milk
3211925|NCT01113567|Active Comparator|Diet and whole milk|Whole milk with lactose
3211926|NCT01113554|Experimental|Arm I|Patients attend exercise therapy sessions over 1 hour 3 times a week for 6 months. Exercise therapy sessions are comprised of a 10 minute warm-up of light stretching and aerobic type exercise (walking, cycling), 30 minutes of endurance type exercise (cycle, walking), and 20 minutes of resistance training exercise.
3211927|NCT01113541|Experimental|Active treatment (switch to oral Ziprasidone)|
3211928|NCT01113528|Experimental|Regenerative therapy|
3211929|NCT01113528|Placebo Comparator|Sugar pill|
3211930|NCT01113515|Placebo Comparator|Placebo|Placebo gel
3211931|NCT01113515|Experimental|Galnobax 20% QD|Esmolol Hydrochloride (Galnobax) 20% gel once daily
3211932|NCT01113515|Experimental|Galnobax 20% BID|Esmolol Hydrochloride (Galnobax) 20% gel twice daily
3211933|NCT01113515|Experimental|Galnobax 14% BID|Esmolol Hydrochloride (Galnobax) 14% gel twice daily
3211934|NCT01113489|Experimental|beclomethasone dipropionate suspension for nebulization|
3211935|NCT01113489|Placebo Comparator|placebo|
3211936|NCT01113476|Experimental|Nab-paclitaxel, Gemcitabine + Bevacizumab|Starting doses of Nab-paclitaxel 50 mg/m^2, Bevacizumab 5 mg/kg + fixed dose of Gemcitabine 1000 mg/m^2
3211937|NCT01113463|Experimental|TPI 287|TPI 287 Starting dose 160 mg/m^2 intravenous (IV) every 3 weeks
3211938|NCT01113437|Experimental|Omalizumab|There are 2 arms of the study; patients in one arm receiving omalizumab and in the other arm receiving placebo.
3212083|NCT01112371|No Intervention|Non treatment|
3211939|NCT01113437|Placebo Comparator|Placebo|There are 2 arms of the study; patients in one arm receiving omalizumab and in the other arm receiving placebo.
3211940|NCT01113424|Experimental|NRT-2|2 mg single-dose of a new NRT product
3211941|NCT01113424|Active Comparator|GUM-2|2 mg single-dose of a marketed nicotine gum
3211942|NCT01113424|Experimental|NRT-4|4 mg single-dose of a new NRT product
3211943|NCT01113424|Active Comparator|GUM-4|4 mg single-dose of marketed nicotine gum
3211944|NCT01113411|Active Comparator|Intensive Rehabilitation|
3211945|NCT01113411|Active Comparator|Standard Rehabilitation|
3211946|NCT01113398|Experimental|AMG 102 with Avastin|Avastin will be administered as a continuous intravenous infusion at 10 mg/kg prior to AMG 102, which will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg. Subjects will receive infusions every 2 weeks.
3211947|NCT01113385|Experimental|Galactose|Oral galactose will be given at a dose of 0.2gm/kg/dose twice a day (BID) to a maximum of 15 gm BID for a period of 16 weeks.
3211948|NCT01113372|Experimental|Clopidogrel 3 months|Regime of dual antiplatelet therapy (DAPT) including aspirin+clopidogrel for 3 months.
3211949|NCT01113372|Active Comparator|Clopidogrel 12 months|Regime of dual antiplatelet therapy (DAPT) including aspirin+clopidogrel for 12 months.
3211950|NCT01113359||study group|hypertensive patients
3211951|NCT01113359||control group|healthy volunteer
3211952|NCT01113346|Experimental|Filtrum-STI|
3211953|NCT01113346|Placebo Comparator|Placebo|
3211954|NCT01113333|Experimental|SAR113945|SAR113945, single dose according to dose escalation design
3211955|NCT01113333|Placebo Comparator|Placebo|0.9% saline solution, single dose
3211956|NCT01113320|Placebo Comparator|Placebo|
3211957|NCT01113320|Active Comparator|Safinamide|
3211958|NCT01113307||Hard to heal wounds|
3211959|NCT01113294|Experimental|ablation|
3211960|NCT01113281|Experimental|VPM1002 in three dosages|
3211961|NCT01113281|Active Comparator|BCG|
3211962|NCT01113268|Other|1:cohort|Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
3211963|NCT01113255|Active Comparator|CHRONIC REPIRATORY FAILURE|
3211964|NCT01113255|Active Comparator|ACUTE RESPIRATORY FAILURE|
3211965|NCT01113242||A:|Patients with idiopathic PD and with MMSE < à 26
3211966|NCT01113242||B:|Patients with idiopathic PD and with MMSE ≥ à 26
3211967|NCT01113229|Experimental|Misoprostol|10 UI of oxytocin IV during delivery of the anterior shoulder of the newborn and two misoprostol tablets taken orally (400µg) following cord clamp
3211968|NCT01113229|Placebo Comparator|PLACEBO|10 UI of oxytocin IV during delivery of the anterior shoulder of the newborn and two placebo tablets taken orally following cord clamp.
3211969|NCT01113203|Experimental|Resistance training|Progressive high intensity resistance training performed twice a week for 16 weeks, and achieving in 7 exercises for the main muscles, the protocol of 4 sets of 6RM and 2 of 4RM.
3211970|NCT01113190|Active Comparator|CBI in ED with AMET at 3 months|computer-delivered brief intervention (CBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
3211971|NCT01113190|Active Comparator|CBI in ED with EUC at 3 months|computer-delivered brief intervention (CBI) at baseline with enhanced usual care-EUC at 3 months
3211972|NCT01113190|Active Comparator|IBI in ED with AMET at 3 months|intervener-delivered brief intervention (IBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
3211973|NCT01113190|Active Comparator|IBI in ED with EUC at 3 months|intervener-delivered brief intervention (IBI) at baseline with enhanced usual care-EUC at 3 months
3211974|NCT01113190|Active Comparator|EUC in ED with AMET at 3 months|enhanced usual care (EUC) at baseline with adapted motivational enhancement therapy-AMET at 3 months
3211975|NCT01113190|Active Comparator|EUC in ED with EUC at 3 months|enhanced usual care (EUC) at baseline with EUC at 3 months
3211976|NCT01113177||Distraction splint therapy|All JIA patients with asymmetric mandibular growth due to unilateral TMJ arthritis are offered non-surgical functional orthodontic splint therapy with a distraction splint. Mandibular growth is thereafter evaluated in the affected side compared with the mandibular growth in the healthy side of the same individual.
3211977|NCT01113164|Experimental|Ondansetron, Placebo, Sertraline|LL-carriers receiving ondansetron compared to either placebo or sertraline, will result in a significant reduction in alcohol consumption.
3211978|NCT01113164|Experimental|Sertraline, Placebo, Ondansetron|SL and SS-carriers receiving sertraline compared to either placebo or ondansetron, will result in a significant reduction in alcohol consumption.
3211979|NCT01113151|No Intervention|Washout|
3211980|NCT01113151|Active Comparator|Mablet|
3211981|NCT01113151|Placebo Comparator|Placebo|
3211982|NCT01113138|No Intervention|Baseline|
3211983|NCT01113138|Active Comparator|Mablet|
3211984|NCT01113138|Active Comparator|Magnesium sulfate|
3211985|NCT01113125|Experimental|Fucicort|
3211986|NCT01113125|Placebo Comparator|Fucidin|
3211987|NCT01113112||Biobehavioral factors|Those with biobehavioral factors that contribute to a permissive local environment for macrophage-tumor interactions that enhance tumor growth in ovarian cancer
3211988|NCT01113099|Experimental|Academic detailing of physicians|
3211989|NCT01113099|No Intervention|Usual care|
3211990|NCT01113086|Experimental|Left active anodal DLPFC|We will place the anodal electrode on the left dorsolateral prefrontal cortex. Stimulation will be given at 2 mA for a total of 20 mins for 10 consecutive sessions (Monday through Friday).
3211991|NCT01113086|Experimental|Right active anodal DLPFC|We will place the anodal electrode on the right dorsolateral prefrontal cortex. Stimulation will be given at 2 mA for a total of 20 mins for 10 consecutive sessions (Monday through Friday).
3211992|NCT01113086|Placebo Comparator|Sham tDCS|Sham tDCS: For sham-controlled tDCS subjects, the same montage will be used; however current will be applied for only 30 seconds.
3212121|NCT01112020|Experimental|CHG Catheter Dressing Patch|
3212122|NCT01112020|Active Comparator|Biopatch|Biopatch Protective Disk with CHG
3211993|NCT01113086|Other|Open-Label Arm|In addition to this study we will have an open label arm in which subjects who received sham stimulation through the course of the study will have the opportunity to receive active stimulation free of charge. The same parameters and identical procedures as is done in the original study will be used. Data will be collected as an open label, which will therefore provide additional information. Data obtained from this open label portion of the study will be kept separate.
3211994|NCT01113073|Experimental|Elective open heart surgery|Patients who had undergone elective open heart surgery
3211995|NCT01113060||CAD patients|Representative sample of coronary artery disease patients receiving aspirin therapy for secondary prevention
3211996|NCT01113047|Experimental|Non responder Olmesartan/Amlodipine|Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
3211997|NCT01113034|Active Comparator|DAS181 Dry Powder 10 mg qd x 3 days|
3211998|NCT01113034|Placebo Comparator|Lactose Placebo|
3211999|NCT01113021|Experimental|LLLT and Physical Strength training in Humans|
3212000|NCT01113008|Experimental|Remote postcondtioning|Patients assigned to remote ischemic postconditioning (randomized controlled trial)
3212001|NCT01113008|Placebo Comparator|Control group|
3212002|NCT01112995|Experimental|Probiotic|subjects will be given a pill formulation of a probiotic Lactobacillus rhamnosus to be taken once a day.
3212003|NCT01112995|Placebo Comparator|Sugar pill|placebo identical to the active product will be given
3212004|NCT01112982|Other|MRI Arm|"All study participants: Standard demographics will be obtained including a baseline serum urate, creatinine, and hs-CRP. Study subjects will have their index joint determined (the joint that is most often involved with acute attacks of gout in each particular patient). A plain radiograph of the index joint will be obtained, as well as an MRI with and without gadolinium enhancement to assess for presence and degree synovial pannus."
3212005|NCT01112982|Other|Febuxostat Sub-Study Arm|"To analyze the effect of urate-lowering therapy (specifically with febuxostat [Uloric]) on the synovial pannus in the index joint of a subgroup of patients. Subjects not currently on any urate-lowering therapy, or on a serum urate lowering drug other than febuxostat (Uloric) and who have a serum urate level of > or = to 9.0, will be treated with febuxostat (Uloric) and their serum urate level will be followed at months 1, 3, 6, and 9. MRI (with and without gadolinium) of the same index joint will be repeated at month 9 to assess for the presence and degree of synovial pannus. Because initiation of urate-lowering therapy can induce acute attacks of gout, these subjects will also be started on colchicine as a prophylactic (and remain on colchicine for 6 months)."
3212006|NCT01112969|Experimental|Internet-based supportive coaching OSCAR|Arm 1: Internet-based supportive coaching OSCAR
3212007|NCT01112969|Other|Waiting list control group (treatment as usual, TAU)|
3212008|NCT01112956||STD clinic patients|Patients attending sexually transmitted Disease clinics. If the initial testing result reported to the patient is confirmed by the Western Blot test, no follow-up specimens will be collected. If the initial testing result reported to the patient is different from the result by the Western Blot test, patients will be asked to provide a follow-up specimen 3-4 months after initial testing.
3212009|NCT01112956||Pregnant women|Women recruited from prenatal clinic. A follow-up visit may or may not needed depending on results from the initial test and Western blot test.
3212010|NCT01112956||Men who have Sex with men (MSM)|Men recruited from a clinic for MSM with high risk for HIV infection. A follow-up visit may or may not needed depending on results from the initial test and Western blot test.
3212011|NCT01112943|Experimental|Acupuncture|Acupuncture on predefined points once a week for 20 minutes over the seven week pulmonary rehabilitation course
3212012|NCT01112943|Active Comparator|Pulmonary Rehabilitation|A seven week exercise and educational class run twice a week using international guidelines.
3212013|NCT01112943|No Intervention|Control|Three assessments over the same time frame of three months but without intervention
3212014|NCT01112917|Experimental|VenaTech Convertible Vena Cava Filter|Implantation of the VenaTech Convertible Filter. The filter is pre-loaded in a cartridge (syringe) and provided as a system with introducer accessories and instructions to accommodate delivery and implantation either using the femoral or jugular approach.
3212015|NCT01112891|Experimental|1|
3212016|NCT01112891|Experimental|2|
3212017|NCT01112891|Experimental|3|
3212018|NCT01112878|Placebo Comparator|Sugar Pill|"Frequency and Dosage:~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
3212019|NCT01112878|Active Comparator|Clonidine|"Dosage: 0.2 mg~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
3212020|NCT01112878|Active Comparator|Gabapentin|"Dosage: 600 mg~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
3212021|NCT01112865|Other|Mark VII/Current pen|Subject will use Mark VII pen for 2 months followed by Current pen for 2 months
3212022|NCT01112865|Other|Current pen/Mark VII|Subject will use current Genotropin pen for 2 months followed by Mark VII pen for 2 months
3212023|NCT01112852|Active Comparator|EVL + vasoconstrictor|Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
3212024|NCT01112852|Experimental|EVL + PPI|Pantoloc 40 mg intravenously per day was instituted on enrollment and continued for 5
3212025|NCT01112839|Active Comparator|Less Intensive Group|Participants in this group would receive print materials on diet and exercise and two individual counseling sessions; one at the beginning of the study and another 6 months later.
3212026|NCT01112839|Experimental|Intensive Group|Participants in this group would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
3212027|NCT01112826|Experimental|Capecitabine|Capecitabine 650 mg/m2 bid
3212028|NCT01112826|No Intervention|Standard treatment|Treatment according to National Comprehensive Cancer Network (NCCN) guideline.
3212029|NCT01112813|Experimental|Lithium|Lithium Carbonate, 0.4-0.8 mmol/L for 2 months
3212030|NCT01112800||Participants|Previously untreated patients referred to St. Jude Children's Research Hospital (SJCRH) between the ages of 0 and 21 years with a diagnosis of osteosarcoma, ESFT, rhabdomyosarcoma and intermediate and high-risk non-rhabdomyosarcoma soft tissue sarcomas whose planned treatment includes administration of a cumulative anthracycline dose ≥ 375 mg/m2.
3212031|NCT01112787|Experimental|Tazarotene Foam|Subjects will be exposed to patches containing Tazarotene Foam 0.1%,
3212032|NCT01112787|Placebo Comparator|Vehicle Foam|Subjects will be exposed to patches containing Vehicle Foam.
3212033|NCT01112787|Active Comparator|Sodium Laural Sulfate|Subjects will be exposed to patches containing Sodium Laural Sulfate.
3212034|NCT01112787|Placebo Comparator|Distilled Water|Subjects will be exposed to patches containing Distilled Water.
3212035|NCT01112774|Experimental|tDCS/Spinal cord injury|Subjects will be randomized to receive 10 sessions of either active or sham tDCS. Stimulation will be given on consecutive days (Monday- Friday) at 2 mA over the primary motor cortex area.
3212036|NCT01112774|Experimental|tDCS/Healthy subjects|Subjects will receive 2 sessions of stimulation: one active and one sham tDCS on two separate visits. The order in which they receive the stimulation will be randomized. Stimulation parameters will be at 2 mA for a total of 20 minutes.
3212037|NCT01112761|Experimental|Healthy Subjects|Each subject will undergo each of the three conditions (active anodal tDCS, cathodal tDCS and sham tDCS), but the order in which they do so will be randomized.
3212038|NCT01112761|Experimental|Athletes with history of concussion|Each subject will undergo each of the three conditions (active anodal tDCS, cathodal tDCS and sham tDCS), but the order in which they do so will be randomized.
3212039|NCT01112735|Experimental|ARTISS|ARTISS will be used as an adjuvant to standard of care.
3212040|NCT01112735|Other|Standard of care|Standard of care
3212041|NCT01112722|Active Comparator|Apitox, purified honeybee toxin, injections|active treatment drug 'Apitox, purified honeybee toxin, lyophilized in saline'
3212042|NCT01112722|Placebo Comparator|histamine injection|the histamine injection produces a similar local effect of pain and erythema as the active drug
3212043|NCT01112709|Experimental|SCT|This arm is a long-term, Social Cognitive Theory (SCT)-based intervention, emphasizing self-regulation and other SCT strategies to optimize training, with faded contact.
3212044|NCT01112709|Active Comparator|Control|"This arm will be the control condition; a Standard intervention with minimal contact."
3212045|NCT01112696|Other|Sensor|All subjects that wear sensors (all subjects)
3212046|NCT01112683|Experimental|Memantine|The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 & 10 mg/d divided dose week three, 10mg/BID week four).
3212047|NCT01112683|Placebo Comparator|Placebo|These are identically-looking pills to the ones in the Memantine Arm
3212048|NCT01112670|Experimental|ABCB1 Group 1|ABCB1 CGC/CGC genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
3212049|NCT01112670|Experimental|ABCB1 Group 2|ABCB1 CGC/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
3212050|NCT01112670|Experimental|ABCB1 Group 3|ABCB1 TTT/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
3212051|NCT01112644|Experimental|OXN PR|Different daily doses; intake every 12 hours
3212052|NCT01112644|Placebo Comparator|PLA|Different daily doses; intake every 12 hours
3212053|NCT01112631||Stage II patients post surgery|Stage II patients treated with surgery alone
3212054|NCT01112631||Stage III patients post surgery|Stage III patients treated with surgery and PORT
3212055|NCT01112605||otherwise healthy persons|healthy persons, no major trauma or surgery of ankle or calves, no bone or muscle disease, age 18-60
3212056|NCT01112579|Experimental|Treatment|
3212057|NCT01112579|Other|Control|
3212058|NCT01112553||Treximet|All migraine subjects will receive Treximet during a migraine episode at Visit 2.
3212059|NCT01112540|Placebo Comparator|Placebo Group|
3212060|NCT01112540|Experimental|Morphine|
3212061|NCT01112527|Experimental|Arm A|Patients with Glioblastoma that has returned or grown after chemotherapy or radiation treatment and who will be having a standard operation to remove the tumor.
3212062|NCT01112527|Experimental|Arm B|Participants with glioblastoma at first recurrence who are not surgical candidates and who have not had prior anti-VEGF therapy.
3212063|NCT01112527|Experimental|Arm C|Participants with glioblastoma who are not surgical candidates and who are at first recurrence from a therapeutic regimen containing bevacizumab.
3212064|NCT01112514|Experimental|ICG Injection|These participants underwent a colonoscopy after having an ICG injection.
3212065|NCT01112488|No Intervention|Control|usual care
3212066|NCT01112488|Experimental|multidisciplinary intervention|Patient engagement Programme
3212067|NCT01112462|Experimental|Tablet|Paracetamol 500 mg/Phenylephrine 5 mg tablet
3212068|NCT01112462|Active Comparator|Sachet|Paracetamol 1000 mg/Phenylephrine 10 mg sachet
3212069|NCT01112449|Experimental|Low dose selenized-yeast|200 µg/day of selenized-yeast (SY)
3212070|NCT01112449|Experimental|selenomethionine|The second group will receive 200 µg/day of selenomethionine (SM)
3212071|NCT01112449|Placebo Comparator|Placebo|no active medication.
3212072|NCT01112449|Experimental|High dose selenized-yeast|The fourth group will receive 285 µg/day of selenized-yeast (SY).
3212073|NCT01112436|Placebo Comparator|control group (group C)|control group will receive no medication preoperatively and during operation
3212074|NCT01112436|Active Comparator|periarticular injecion group (group I)|patients in Group I will receive oral oxycodone SR 10 mg and celecoxib 200 mg 1 hour preoperatively with sips of water, and receive periarticular injection of combination of ropivacaine 15 mg, morphine 10 mg, ketorolac 30 mg epinephrine 0.3 mg and cefmetazole 1000mg during operation.
3212075|NCT01112423|Experimental|BMS-823778 (2 mg)|
3212076|NCT01112423|Experimental|BMS-823778 (10 mg)|
3212077|NCT01112423|Experimental|BMS-823778 (20 mg)|
3212078|NCT01112423|Placebo Comparator|Placebo|
3212079|NCT01112397|Experimental|1|AZD1480 until Maximum Tolerated Dose (MTD) is reached
3212080|NCT01112397|Experimental|2|AZD1480 dose expansion of MTD
3212081|NCT01112384|Experimental|SB939|
3212082|NCT01112371|Experimental|Contractubex|
3212084|NCT01112358|Experimental|r-FSH + r-hLH|Lutropin alfa (r-hLH) will be administered at a daily dose of 150 International Units (IU) from the presence of at least one follicle greater than (>) 14 millimeter (mm) to complete ovarian stimulation. Follitropin alfa (r-FSH) will be administered at an initial dose of 225-450 IU per day (according to standard center practice); the dose will then be adjusted to ovarian response as assessed by ovarian ultrasound and/or serum estradiol. Participants will also receive analogous GnRH antagonist and natural progesterone, as per standard center practice. To complete follicular maturation and trigger ovulation, a single dose of 250 milligrams (mg) of recombinant Human Chorionic Gonadotropin (r-hCG) will be administered subcutaneously at 12 hours after the last injection of lutropin alfa and/or follitropin alfa and analogous GnRH antagonist.
3212085|NCT01112358|Active Comparator|r-FSH|Follitropin alfa (r-FSH) will be administered at an initial dose of 225-450 IU per day (according to standard center practice); the dose will then be adjusted to ovarian response as assessed by ovarian ultrasound and/or serum estradiol. Participants will also receive analogous GnRH antagonist and natural progesterone, as per standard center practice. To complete follicular maturation and trigger ovulation, a single dose of 250 mg of r-hCG will be administered subcutaneously at 12 hours after the last injection of follitropin alfa and analogous GnRH antagonist.
3212086|NCT01112319|Experimental|Elf_care|The trial group will receive with Elf_Care unit (Hot-Cold & Electrotherapy) during physiotherapy treatment ( 28 minutes twice a week)
3212087|NCT01112319|Active Comparator|control group|The control group will receive before physiotherapy COLD HOT or Electrotherapy treatment depends on the patient and physiotherapy prefer.
3212088|NCT01112306|Experimental|1|ACT-293987, twice daily
3212089|NCT01112280|Experimental|cap-assisted chromoendoscopy|To the tip of the colonoscope, transparent cap is fitted and applied. In addition, panchromoendoscopy using indigocarmine solution is preformed in this group.
3212090|NCT01112280|No Intervention|Conventional colonoscopy|Neither transparent cap nor chromoendoscopy is applied in this group and conventional colonoscopy is performed.
3212091|NCT01112267|Experimental|Tramadol Hydrochloride (HCl)/acetaminophen|Participants will receive 1 tablet containing fixed dose of combination of tramadol hydrochloride (HCl) 75 milligram (mg) /acetaminophen Extended Release (ER) 650 mg orally once daily on Days 1 to 3, 1 tablet twice daily (tramadol HCl 150 mg/acetaminophen 1300 mg) on Days 4 to 7, then 1 or 2 tablets twice daily on Days 8 to 28.
3212092|NCT01112267|Placebo Comparator|Placebo|Prticipants will receive 1 tablet matching placebo once daily orally on Days 1 to 3, 1 tablet twice daily on Days 4 to 7, then 1 or 2 tablets twice daily on Days 8 to 28.
3212093|NCT01112254|Experimental|MRI±biopsy|a MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm from the initial lesion), not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI ± biopsy results.
3212094|NCT01112254|No Intervention|Standard care|The patients will be operated without additional exams
3212095|NCT01112241|Experimental|albuterol-tiotropium|At visit 1, lung function measurements will be performed in triplicate before and 90 min after inhaling four separate doses of 100 μg of albuterol (Ventolin®) and soon after 18 μg of tiotropium bromide [Spiriva®] to ensure maximal or near-maximal bronchodilation. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber (Volumatic®) and tiotropium by a dry-powder device (Handihaler®).
3212096|NCT01112228||Obese patients|
3212097|NCT01112215|Active Comparator|azathioprine|
3212098|NCT01112215|Active Comparator|Enteric-coated Mycophenolate Sodium|
3212099|NCT01112189|Experimental|Patients with stem cells|Patients that receive the stem cells treatment
3212100|NCT01112189|Active Comparator|Compressed sleeve treatment|Patients that will receive the compressed sleeve treatment
3212101|NCT01112163|Experimental|Enhanced external counter pulsation|One session of enhanced external counter pulsation (60 minutes)
3212102|NCT01112150|Active Comparator|Pumping group|Patients in this arm will get a pumping session 2-3 times a day .
3212103|NCT01112150|Active Comparator|No pumping|These patients will not receive pumping but only classical treatment clinically indicated (diuretics, oxygen, Digoxin, Nitrates, ACE inhibitors etc, as necessary)
3212104|NCT01112137|Experimental|Hypertensive individuals: clopidogrel (600 mg, bolus)|
3212105|NCT01112137|Experimental|Hypertensive individuals: clopidogrel (75 mg daily)|
3212106|NCT01112137|Active Comparator|Normotensive individuals: clopidogrel (600 mg, bolus)|
3212107|NCT01112137|Active Comparator|Normotensive individuals: clopidogrel (75 mg, daily)|
3212108|NCT01112111||75 PCOS Patients - step up regime|Group A will be comprised of 75 patients and these will receive a low dose step stimulation regime
3212109|NCT01112111||75 PCOS patients -step down regime|Group B will be comprised of 75 patients who will receive a step down regime of stimulation
3212110|NCT01112111||75 PCOS patients - sequential regime|Group C will be comprised of 75 patients who will be treated using a sequential stimulation regime
3212111|NCT01112098|Experimental|Educational Pamphlet and letter|Letter invites patient to self-schedule a DXA; educational pamphlet includes information about DXA scans
3212112|NCT01112085|Experimental|Ranibizumab 0.05mg|Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
3212113|NCT01112085|Experimental|Ranibizumab 0.5mg|Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
3212114|NCT01112072|Active Comparator|Intacs combined with CXL|Intacs placement followed by collagen crosslinking with UV light and riboflavin
3212115|NCT01112072|Active Comparator|Intacs followed by CXL|Intacs placement, to be followed by corneal collagen crosslinking with UV light and riboflavin 3 months later
3212116|NCT01112059|Placebo Comparator|Placebo|Patients given placebo twice a day for 8 days at beginning of inpatient CF exacerbation
3212117|NCT01112059|Active Comparator|doxycycline|Patients given doxycycline 100 mg tablet twice a day for 8 days at the beginning of inpatient CF exacerbation
3212118|NCT01112046|Experimental|Endoscopic submucosal dissection|
3212119|NCT01112046|Active Comparator|Laparoscopic resection|
3212120|NCT01112033||chronic HCV infection|The study was performed on therapeutically naïve patients with chronic HCV infection. Patients with positivity of anti-HCV antibodies, and detectable HCV RNA in serum for at least 6 months, were included in the study.
3212123|NCT01112020|Active Comparator|Tegaderm CHG|Tegaderm CHG IV Securement Dressing
3212124|NCT01112007||prehypertension|Subjects with prehypertension, that is, individuals with systolic blood pressure in the range of 120-139 mmHg or diastolic BP between 80-89 mmHg.
3212125|NCT01111968|Experimental|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
3212126|NCT01111968|Experimental|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
3212127|NCT01111968|Experimental|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
3212128|NCT01111968|Experimental|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
3212129|NCT01111968|Experimental|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
3212130|NCT01111968|Experimental|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
3212131|NCT01111968|Experimental|pandemic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
3212132|NCT01111968|Experimental|pandemic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
3212133|NCT01111968|Experimental|pandemic vaccine 13|15µg of A/H1N1 with no adjuvant
3212134|NCT01111968|Placebo Comparator|placebo group 14|placebo
3212135|NCT01111955|Active Comparator|BMS-823778 (2 mg)|+ metformin
3212136|NCT01111955|Active Comparator|BMS-823778 (10 mg)|+ metformin
3212137|NCT01111955|Active Comparator|BMS-823778 (20 mg)|+ metformin
3212138|NCT01111955|Placebo Comparator|Placebo|+ metformin
3212139|NCT01111942|Active Comparator|radiation and weekly carboplatin|
3212140|NCT01111942|Other|conservation surgery|
3212141|NCT01111929|Active Comparator|Counseling for LAM|"Will receive proper postpartum counseling for LAM by trained research nurse. This is in addition to, adequate contraceptive counseling including information about LAM and its prerequisites.~Women that choose to use LAM will be advised to return to our contraception outpatient clinic to have a long term method of contraception as soon as any of the requirements of LAM expires."
3212142|NCT01111929|Experimental|Counseling for LAM+ LNG-EC|LAM counseling and contraceptive counseling +two 0.75 mg Levonorgestrel EC pills
3212143|NCT01111903|Experimental|lenalidomide|Phase II: lenalidomide 20 mg/day in continuous regimen. Phase I: lenalidomide 25 mg/day 21 days/28 + carboplatin AUC 5 + caelyx 30 mg/m2
3212144|NCT01111890|Experimental|Azarga|Azarga (brinzolamide 1% / timolol 0.5%)
3212145|NCT01111890|Active Comparator|Cosopt|Cosopt (dorzolamide 2% / timolol 0.5%)
3212146|NCT01111864|Experimental|MixMe powder (iron & micronutrients)|
3212147|NCT01111864|Placebo Comparator|MixMe powder (micronutrients, no iron)|
3212148|NCT01111864|Experimental|Sprinkles (iron and micronutrients)|Vitamin A 300 µg; Vitamin C 30 mg; Folic Acid 160 µg; Iron 12.5 mg; Zinc 5 mg
3212149|NCT01111864|Placebo Comparator|Sprinkles (micronutrients, no iron)|Vitamin A 300 µg; Vitamin C 30 mg; Folic Acid 160 µg; Zinc 5 mg
3212150|NCT01111851|Experimental|Fosaprepitant 150 mg|Fosaprepitant 150 mg
3212151|NCT01111851|Experimental|Aprepitant 165 mg|Aprepitant 165 mg
3212152|NCT01111851|Experimental|Aprepitant 250 mg|Aprepitant 250 mg
3212153|NCT01111838|Experimental|STA-9090|This is an open-label Phase 2 clinical study in patients with advanced colorectal cancer (CRC). Patients will be treated with 200mg/m2 of STA-9090 during a 1-hour intravenous infusion 1 time per week for three consecutive weeks followed by a 1 week dose-free interval. Patients tolerating STA-9090 will be permitted to continue treatment until disease progression.
3212154|NCT01111825|Experimental|Temsirolimus plus Neratinib|This is an open-label, single arm, dose-escalation phase I-II study to determine the maximum tolerated dose (MTD) of temsirolimus with daily neratinib, and to determine the safety and efficacy of this combination when given to patients with advanced breast carcinoma. Patients with trastuzumab-refractory HER2-amplified disease or triple negative disease will be enrolled in both phases of this clinical trial.
3212155|NCT01111812||weight measurements|This study include 1000 weight measurements of children and adolescence, boys and girls, ages 5-18, that taking pat in a multi-disciplinary intervention program for treatment of the overweight and obese in Meir medical center.
3212156|NCT01111799|Experimental|Clomiphene citrate + IUI + endometrial biopsy|Clomiphene citrate + IUI + endometrial biopsy
3212157|NCT01111799|No Intervention|Clomiphene citrate + IUI|
3212158|NCT01111799|Experimental|gonadotrophines + IUI + endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
3212159|NCT01111799|No Intervention|gonadotrophines + IUI|
3212160|NCT01111799|Experimental|natural cycle + IUI + endometrail biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
3212161|NCT01111799|No Intervention|natural cycle + IUI|
3212162|NCT01111773|Experimental|Heated Lidocaine and Tetracaine Patch|
3212163|NCT01111747|Experimental|PRP|In this group PRP will be used in the patellar tendon donor site.
3212164|NCT01111747|Sham Comparator|Control|In this group PRP will not be aded to the patellar tendon donor site
3212165|NCT01111734|Experimental|Treatment Group|The study consists of eight weeks of open label N-Acetylcysteine. All eligible study subjects will be treated with 600mg of N-Acetylcysteine twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks. weeks. Subjects will be seen every two weeks during the 8-week study. Efficacy and safety assessments will be performed at each visit.
3212166|NCT01111734|Experimental|Control|40 healthy age-matched peers with undergo the same baseline testing as the NAC subjects as well as baseline fMRI. They will not engage in any follow up visits.
3212218|NCT01111344|Experimental|Glizigen + Viusid|
3212219|NCT01111344|Placebo Comparator|Placebo|
3212220|NCT01111331|Experimental|BI 10773 25 mg|1 tablet 25 mg BI 10773 qd for 5 days
3212221|NCT01111331|Experimental|BI 10773 25 mg + Warfarin 25 mg|1 tablet 25 mg BI 10773 qd for 7 days plus 5 tablets 5 mg warfarin single dose
3212222|NCT01111331|Active Comparator|Warfarin 25 mg|5 tablets 5 mg warfarin single dose
3212223|NCT01111318|Experimental|BI 10773|50 mg single dose
3212661|NCT01108081|Active Comparator|Arm 3|Health education
3212167|NCT01111721|Experimental|Project POWER Intervention Group|Intervention group participants will attend the Project POWER intervention sessions, complete a pre-intervention assessment and participate in 3, 6, and 12 month follow-up interviews when they will be asked to provide urine specimens for STI testing. The intervention consists of eight bi-weekly, 1.5 hour sessions. Intervention group participants will also attend one booster group session four weeks after the intervention before being released. Intervention participants will receive booster phone calls from a nurse-interventionist at 2, 6, and 10 weeks after release from prison. Booster phone calls will reinforce intervention content and support participant efforts to reduce risky sex behaviors and make healthy choices.
3212168|NCT01111721|Active Comparator|NC DOC Standard of Care for STIs|Control group participants will receive the North Carolina Department of Correction standard of care for Sexually Transmitted Infections, complete one interview in prison and participate in 3, 6, and 12 month follow up interviews when they will be asked to provide urine specimens for STI testing.
3212169|NCT01111708|Experimental|Close Rectal-Ileo Pouch Anal Anastomosis|
3212170|NCT01111708|Active Comparator|Conventional Ileo Pouch Anal Anastomosis|
3212171|NCT01111708|Active Comparator|Ileo Neo Rectal Anastomosis|
3212172|NCT01111695|Experimental|Honey and ionic silver dressing|
3212173|NCT01111682|Active Comparator|Mannitol|0.9% normal saline infusion and boluses of mannitol
3212174|NCT01111682|Active Comparator|Hypertonic Saline|3% hypertonic saline continuous infusion, with intermittent boluses as needed
3212175|NCT01111669|Experimental|Tranexamic Acid|Patients in the tranexamic acid (TA) group will receive a bolus of TA, prepared according to patient weight (15mg / kg loading dose). The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation for the duration of the operation.
3212176|NCT01111669|Placebo Comparator|Normal Saline|The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution as the intervention group. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of normal saline for the duration of the operation.
3212177|NCT01111656|Active Comparator|1|Interferon beta-1b 250ug subcutaneously every other day
3212178|NCT01111656|Experimental|2|Interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
3212179|NCT01111643||I|
3212180|NCT01111630|Experimental|once weekly|
3212181|NCT01111630|Active Comparator|three times weekly|
3212182|NCT01111617|Experimental|Real-Time fMRI|Real-Time fMRI
3212183|NCT01111604|Active Comparator|mFOLFOX-6|mFOLFOX-6
3212184|NCT01111604|Experimental|mFOLFOX-6 + IMC-1121B|mFOLFOX-6 + IMC-1121B
3212185|NCT01111604|Experimental|mFOLFOX-6 + IMC-18F1|mFOLFOX-6 + IMC-18F1
3212186|NCT01111591|No Intervention|2. Bile duct cancer - control|Bile duct cancer patients do not administration of COX inhibitor
3212187|NCT01111591|Experimental|3. Pancreas cancer - experimental|Pancreas cancer patients take a COX2 inhibitor 200mg every 12hours for 6 months
3212188|NCT01111591|No Intervention|4. Pancreas cancer - control|Pancreas cancer patients do not administration of COX inhibitor
3212189|NCT01111591|Experimental|Bile duct cancer - experimental|Bile duct cancer patients take a COX2 inhibitor 200mg every 12hours for 6 months
3212190|NCT01111578||New enteral feeding tube|
3212191|NCT01111565|Active Comparator|Escitalopram monotherapy|
3212192|NCT01111565|Active Comparator|Aripiprazole monotherapy|
3212193|NCT01111565|Active Comparator|Aripiprazole/Escitalopram combination therapy|
3212194|NCT01111552|Active Comparator|Escitalopram monotherapy|
3212195|NCT01111552|Active Comparator|Aripiprazole monotherapy|
3212196|NCT01111552|Active Comparator|Aripiprazole/Escitalopram combination therapy|
3212197|NCT01111539|Active Comparator|Escitalopram monotherapy|
3212198|NCT01111539|Active Comparator|Aripiprazole monotherapy|
3212199|NCT01111539|Active Comparator|Aripiprazole/Escitalopram combination therapy|
3212200|NCT01111526|Experimental|LBH589, in Addition to Glucocorticoids|Phase I Dose Escalation, Followed by Phase II Treatment at Maximum Tolerated Dose (MTD) of LBH589, in Addition to Glucocorticoids.
3212201|NCT01111513|Active Comparator|Continuous femoral block|Patients receive a continuous femoral block for 48 hours and they have patient controlled analgesics.
3212202|NCT01111513|Active Comparator|Single dose femoral block|Patients receive a single dose femoral block and have patient controlled analgesics.
3212203|NCT01111513|Active Comparator|Patient controlled analgesics|Patients do not receive a femoral block. They only have patient controlled analgesics.
3212204|NCT01111500|Active Comparator|external rotation immobilization|Patient will wear an external rotation brace to immobilize the injured arm.
3212205|NCT01111500|Active Comparator|internal rotation immobilization|Patient will wear an internal rotation brace to immobilize the injured arm.
3212206|NCT01111487|Active Comparator|Group I|This group will use a pressure level of 10 cmH2O.
3212207|NCT01111487|Active Comparator|Group II|This group will use a pressure level of 15 cmH2O.
3212208|NCT01111474|Active Comparator|Cyanoacrylate|3 applications of cyanoacrylate (48 hours interval)at the cervical region of the sensitive tooth
3212209|NCT01111474|Active Comparator|Laser|3 Low intensity laser application (48 hour interval). The application of 1J/cm2 was performed for eight seconds at three points along the dental neck, using the infrared wavelength (660nm)
3212210|NCT01111461|Experimental|Lenvatinib 24 mg|Participants with advanced endometrial cancer and disease progression following platinum-based, first line chemotherapy.
3212211|NCT01111448|Experimental|Temsirolimus|25 mg/day 1; 8; 15; 22 of each 28-day cycle
3212212|NCT01111435||Individuals with Multiple Sclerosis|
3212213|NCT01111422|No Intervention|Control|Age and sex matched peritoneal dialysis patients
3212214|NCT01111422|Experimental|N-acetylcysteine|N-acetylcysteine in stable peritoneal dialysis patients
3212215|NCT01111409|Experimental|VFIX|
3212216|NCT01111396||Patient with ALL under chemotherapy|This group consists of patients with initial diagnosis of acute lymphatic leukemia (ALL), who are enrolled into the GMALL 2003 chemotherapy study. There is no change of the initial GMALL 2003 treatment protocol for the present study.
3212217|NCT01111370|Experimental|CGM|continuous glucose monitoring system
3212224|NCT01111305|Active Comparator|Reslizumab + DEC|Reslizumab 1 mg/kg iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
3212225|NCT01111305|Placebo Comparator|Placebo + DEC|Placebo iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
3212226|NCT01111292|Experimental|Arm I (inositol)|Beginning within 14 days after colonoscopy, patients receive inositol PO QD on days 1-14 and BID on days 15-90.
3212227|NCT01111292|Placebo Comparator|Arm II (placebo)|Beginning within 14 days after colonoscopy, patients receive placebo PO QD on days 1-14 and BID on days 15-90.
3212228|NCT01111279|Placebo Comparator|Placebo|
3212229|NCT01111279|Experimental|gpASIT+TM|
3212230|NCT01111279|Experimental|gpASIT+TM/adjuvant|
3212231|NCT01111253|Active Comparator|Conservative strategy with antibiotics|"Hospital admission~Intravenous fluids and at least 48 hours of intravenous antibiotics and subsequently switch to oral antibiotics if tolerated (otherwise continuation i.v.) to complete a full 10-day treatment duration~Adequate pain relief~Oral intake as tolerated~Daily monitoring"
3212232|NCT01111253|No Intervention|Liberal strategy without antibiotics|"Admission only if discharge criteria are not met~No initial antibiotics~Intravenous fluids only for those not tolerating oral liquids~Adequate pain relief~Oral intake as tolerated~Daily monitoring when admitted to the hospital~Self-monitoring at home (Patient diary with temperature and VAS pain score until full recovery)"
3212233|NCT01111240||Psoriatic Arthritis|Participants with Psoriatic Arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 24 months.
3212234|NCT01111214||group 1|Hospitalized children ≤14 years of age with invasive pneumococcal disease
3212235|NCT01111201||questionnaires|There will be four versions of the questionnaire, each slightly modified to be more specific toward the treatment paradigms in the respective target patient population (Breast Cancer/ Lymphoma/Autologous Bone Marrow Transplant/ Allogeneic Bone Marrow Transplant). All questionnaire versions will consist of seven sections.
3212236|NCT01111188|Experimental|all subjects|Subjects will receive PD 0332991 plus bortezomib. The dose of each agent will be dependent on the time point the subject enters the trial.
3212237|NCT01111162|Experimental|Vaccine|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
3212238|NCT01111149|Placebo Comparator|Sugar Pill|Sugar pill will be given to patients as a comparison group to the active varenicline group. In the fist week, one placebo pill will be given per patient, followed by 2 pills per day for the remaining 12 weeks of the study.
3212239|NCT01111149|Experimental|Varenicline|Varenicline has not previously been examined for its efficacy and safety in subjects with schizophrenia. Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study. This is an experimental group to be compared against both placebo and bupropion HCl.
3212240|NCT01111149|Active Comparator|Bupropion HCl|Bupropion HCl is an established smoking cessation agent and will be used to compare its efficacy and safety against varenicline. Subjects in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study.
3212241|NCT01111136|Experimental|stress intervention|Stress intervention.
3212242|NCT01111123|Active Comparator|1|Lac-Hydrin lotion twice daily everyday + Ultravate ointment twice daily on weekends only
3212243|NCT01111123|Placebo Comparator|2|Lac-Hydrin lotion twice daily everyday + placebo ointment twice daily on weekends only
3212244|NCT01111110|Experimental|Anti-static then Static for Albuterol|albuterol anti-static first then static chamber second.
3212245|NCT01111110|Experimental|Static then Anti-static for Albuterol|static then antistatic albuterol
3212246|NCT01111097|Active Comparator|Cohort 1|Subjects are given a dose of Dichloroacetate 4mg/kg twice a day for 30 days
3212247|NCT01111097|Active Comparator|Cohort 2|Subjects are given a dose of Dichloroacetate 12.5mg/kg twice a day for 30 days
3212248|NCT01111071||STEMI|patients with discharge diagnosis of ST elevation myocardial infarction
3212249|NCT01111071||nSTEMI|patients with discharge diagnosis of non ST elevation myocardial infarction
3212250|NCT01111071||unstable angina|patients with discharge diagnosis of unstable angina
3212251|NCT01111058|Experimental|Everolimus (RAD001)|Subjects will receive Everolimus
3212252|NCT01111058|Experimental|Placebo|Subjects will receive placebo
3212253|NCT01111045|Active Comparator|Arm 1|0.03 mg/ml BMP-7, single intraarticular knee injection
3212254|NCT01111045|Active Comparator|Arm 2|0.1 mg/ml BMP-7, single intraarticular knee injection
3212255|NCT01111045|Active Comparator|Arm 3|0.3 mg/ml BMP-7, single intraarticular knee injection
3212256|NCT01111045|Placebo Comparator|Arm 4|1 ml placebo, single intraarticular knee injection (control)
3212257|NCT01111032||Treadmill test|
3212258|NCT01111019|Experimental|Treated subjects|Subjects will be treated with 0.057 milligram per kilogram per day (mg/kg/day) r-hGH. Subjects still under treatment after 31 January 2011 will be treated with a dose reduced to 0.035 mg/kg/day until the end of the study.
3212259|NCT01111019|No Intervention|Historic cohort of non-treated subjects|
3212260|NCT01110980|Experimental|Swallowing therapy|Swallowing therapy in combination with individual dietary counselling
3212261|NCT01110980|Active Comparator|Individual dietary counselling|Swallowing therapy only on indication. (usual care)
3212262|NCT01110954|Active Comparator|PD L 506 2nd dose|Different dosage
3212263|NCT01110954|Experimental|PD L 506|
3212264|NCT01110941|Experimental|SOL|single arm
3212265|NCT01110928||Norditropin®|
3212266|NCT01110915|Experimental|MRI group|Subjects randomized to the MRI group will undergo a one-hour MRI scan, including 16 individual sequences in the chest and head region, at 9-12 weeks post-implant.
3212267|NCT01110915|Active Comparator|Control group|Subjects randomized to the Control group will wait for one hour without having any MRI scan at 9-12 weeks post-implant.
3212268|NCT01110902|Experimental|AGO178C 0.5 mg /day|
3212269|NCT01110902|Experimental|AGO178C 1 mg / day|
3212270|NCT01110902|Placebo Comparator|Placebo|
3212271|NCT01110889|Experimental|AGO178C 0.5 mg /day|
3212272|NCT01110889|Experimental|AGO178C 1 mg / day|
3212273|NCT01110889|Placebo Comparator|Placebo|
3212274|NCT01110876|Experimental|Phase I Group 1: Vorinostat + Erlotinib + Temozolomide|"Phase I 3-Drug Combination Vorinostat with Erlotinib + Temozolomide~Starting doses Vorinostat 200 mg orally twice daily on Days 1-7 and 15-21 of every cycle; Erlotinib 200 mg orally once daily on Days 1-21; Temozolomide 125 mg/m^2 orally once daily on Days 1-7 and 15-21."
3212275|NCT01110876|Experimental|Phase I Group 2: Vorinostat + Erlotinib|"This Phase I arm to be activated only after completion of Part A of the Phase II trial of the 3-Drug combination. If part A of the Phase II trial shows lack of efficacy, trial will be terminated.~Vorinostat orally twice daily, Days 1-14; and Erlotinib orally once daily Days 1-21 of every cycle."
3212276|NCT01110876|Experimental|Phase II Part A 3-Drug Combination|"Vorinostat+Erlotinib+Temozolomide where drug dosing based on the MTD identified in the Phase I portion of the study.~Vorinostat 200 mg orally twice daily on Days 1-7 and 15-21 of every cycle; Erlotinib 200 mg orally once daily on Days 1-21; Temozolomide 100 mg/m^2 orally once daily on Days 1-7 and 15-21."
3212277|NCT01110876|Experimental|Phase II Part B 2-Drug Combination|"This Phase II Part B arm to be activated only after completion of Part A of the Phase I and II Part A trial of the 3-Drug combination. If part A of the Phase II trial shows lack of efficacy, trial will be terminated.~Vorinostat orally twice daily, Days 1-14; and Erlotinib orally once daily Days 1-21 of every cycle."
3212278|NCT01110863||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
3212279|NCT01110850||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
3212280|NCT01110837|Active Comparator|Allergen|
3212281|NCT01110837|Placebo Comparator|Placebo|
3212282|NCT01110824|Experimental|Enalapril and carvedilol|Enalapril 2.5 to 10 mg BID plus Carvedilol 6.25 to 25 mg BID
3212283|NCT01110824|No Intervention|Control|Control arm without intervention
3212284|NCT01110811|Active Comparator|TIF procedure|Transoral Incisionless Fundoplication (TIF)
3212285|NCT01110811|Sham Comparator|Sham procedure|Sham procedure consisting of upper GI endoscopy
3212286|NCT01110772|Experimental|2-octyl cyanoacrylate|As recommended, povidone iodine is used for skin antisepsis. After drying, a layer of cyanoacrylate is applied on the skin surface with the purpose of immobilizing skin bacteria.
3212287|NCT01110772|Active Comparator|iodine povacrylex in isopropyl alcohol|Iodine povacrylex in isopropyl alcohol (Duraprep 3M) This is considered a standard of care in our hospital as many other institutions. It's efficacy and safety have been demonstrated.
3212288|NCT01110759||Under Local Infiltration|
3212289|NCT01110759||Under Peripheral Nerve Block|
3212290|NCT01110746|Experimental|Formulation A|Single Injection
3212291|NCT01110746|Experimental|Formulation B|Single Injection
3212292|NCT01110720|Experimental|Davunetide 30 mg BID|
3212293|NCT01110720|Placebo Comparator|Placebo|
3212294|NCT01110707|Experimental|r-hFSH + r-hLH|
3212295|NCT01110707|Active Comparator|r-hFSH alone|
3212296|NCT01110681|Other|Solesta|Open label.
3212297|NCT01110668|Experimental|Nilotinib|
3212298|NCT01110655|Experimental|Intravenous hypertonic saline|
3212299|NCT01110655|Experimental|Oral hypertonic saline|
3212300|NCT01110642|Experimental|Lovastatin solution|All patients will receive lovastatin solution
3212301|NCT01110629|Experimental|Arm 1|
3212302|NCT01110629|Placebo Comparator|Arm 2|
3212303|NCT01110616|Experimental|Sequence 1|MK3134-Lorazepam-Placebo-MK3134-Lorazepam
3212304|NCT01110616|Experimental|Sequence 2|MK3134-Lorazepam-Placebo-Lorazepam-MK3134
3212305|NCT01110616|Experimental|Sequence 3|MK3134-Placebo-Lorazepam-MK3134-Lorazepam
3212306|NCT01110616|Experimental|Sequence 4|MK3134-Placebo-Lorazepam-Lorazepam-MK3134
3212307|NCT01110616|Experimental|Sequence 5|Lorazepam-Placebo-MK3134-MK3134-Lorazepam
3212308|NCT01110616|Experimental|Sequence 6|Lorazepam-Placebo-MK3134-Lorazepam-MK3134
3212309|NCT01110616|Experimental|Sequence 7|Lorazepam-MK3134-Placebo-MK3134-Lorazepam
3212310|NCT01110616|Experimental|Sequence 8|Lorazepam-MK3134-Placebo-Lorazepam-MK3134
3212311|NCT01110616|Experimental|Sequence 9|Placebo-MK3134-Lorazepam-MK3134-Lorazepam
3212312|NCT01110616|Experimental|Sequence 10|Placebo-MK3134-Lorazepam-Lorazepam-MK3134
3212313|NCT01110616|Experimental|Sequence 11|Placebo-Lorazepam-MK3134-MK3134-Lorazepam
3212314|NCT01110616|Experimental|Sequence 12|Placebo-Lorazepam-MK3134-Lorazepam-MK3134
3212315|NCT01110603|Experimental|MK-4827 + carboplatin|
3212316|NCT01110603|Experimental|MK-4827 + carboplatin/paclitaxel|
3212317|NCT01110603|Experimental|MK-4827 + carboplatin/liposomal doxorubicin|
3212318|NCT01110590|Experimental|Arm 1|
3212319|NCT01110590|Experimental|Arm 2|
3212320|NCT01110590|Experimental|Arm 3|
3212321|NCT01110590|Placebo Comparator|Arm 4|
3212322|NCT01110577||Traveling cohort|Overweight patients with or without type 2 diabetes or pre-diabetes
3212323|NCT01110564||1|COPD patients
3212324|NCT01110551|Experimental|Group 2: low dose ; ID|D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, D4: 2 x 10^5 or placebo intradermally on Days 0 and 90.
3212325|NCT01110551|Experimental|Group 1: low dose; SC|D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, D4: 2 x 10^5 or placebo subcutaneously on Days 0 and 90.
3212326|NCT01110551|Experimental|Group 4: high dose; ID|D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, D4: 3 x 10^5 or placebo intradermally on Days 0 and 90.
3212327|NCT01110551|Experimental|Group 3: high dose; SC|D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, D4: 3 x 10^5 or placebo subcutaneously on Days 0 and 90.
3212328|NCT01110525|Experimental|1|AZD1981 + Oral contraceptive
3212329|NCT01110525|Placebo Comparator|2|Placebo + Oral contraceptive
3212330|NCT01110512|Experimental|Flavonid|
3212331|NCT01110512|Active Comparator|Daflon|
3212332|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 1|AGN-210961 Formulation 1 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
3212333|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 2|AGN-210961 Formulation 2 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
3212334|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 3|AGN-210961 Formulation 3 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
3212335|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 4|AGN-210961 Formulation 4 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
3212336|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 5|AGN-210961 Formulation 5 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
3212337|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 6|AGN-210961 Formulation 6 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
3212338|NCT01110499|Experimental|Part 2, AGN-210961 Formulation 7|AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
3212339|NCT01110499|Active Comparator|Part 2, bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% in both eyes once daily for 4 weeks.
3212340|NCT01110486|Experimental|Monotherapy, once daily|
3212341|NCT01110486|Experimental|Combination with carboplatin|
3212342|NCT01110486|Experimental|Combination with docetaxel|
3212343|NCT01110486|Experimental|Monotherapy, twice daily|
3212344|NCT01110486|Experimental|IV Monotherapy, once daily|
3212345|NCT01110473|Experimental|Monotherapy, once daily|
3212346|NCT01110473|Experimental|Monotherapy, twice daily|
3212347|NCT01110473|Experimental|Combination with Azacitidine|
3212348|NCT01110473|Experimental|IV monotherapy, once daily|
3212349|NCT01110447|Experimental|VSL#3|VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus.
3212350|NCT01110447|Placebo Comparator|Placebo|Placebo sachets contain corn starch
3212351|NCT01110434|Experimental|Topiramate|Topiramate (200 mg daily)
3212352|NCT01110434|Placebo Comparator|Sugar pill|
3212353|NCT01110421|Experimental|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose) will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
3212354|NCT01110421|Experimental|Cefepime|Cefepime 50 mg/kg per dose (up to 2 g/dose) will be administered every 8 hours as 30-minutes IV (at least 3 days of IV cefepime only or IV cefipime followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
3212355|NCT01110408|Experimental|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose) will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
3212356|NCT01110408|Experimental|Cefepime|Cefepime 50 mg/kg per dose (up to 2 g/dose) will be dministered every 8 hours as 30-minutes IV (at least 3 days of IV cefepime only or IV cefepime followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
3212357|NCT01110395||Heart Failure|Magnetic Resonance Spectroscopy
3212358|NCT01110382|Experimental|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose)will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium). Total duration of treatment 5 to 14 days.
3212359|NCT01110382|Experimental|Meropenem|Meropenem 20 mg/kg per dose (up to 1 g/dose) will be administered every 8 hours as 30-minutes IV (at least 3 days of IV meropenem only or IV meropenem followed by oral amoxicillin/clavulanate potassium). Total duration of treatment 5 to 14 days.
3212360|NCT01110369|Experimental|Resistance exercise training and protein drink|
3212361|NCT01110369|Placebo Comparator|Resistance exercise training and placebo drink|
3212362|NCT01110356|Experimental|Ferinject|
3212363|NCT01110356|Placebo Comparator|Saline|
3212364|NCT01110343|Active Comparator|mindfulness intervention group|Mindfulness intervention is a formatted curriculum based on Mindfulness based stress reduction techniques which have proven effective in reducing stress related to pain, everyday living and medical and psychiatric disorders.
3212365|NCT01110343|Active Comparator|conventional parent support group|a 6 week behavioral program, with weekly 1.5 hour sessions with a trained parent mentor, 3 monthly booster sessions and follow-up.
3212366|NCT01110330|Experimental|Ketoconazole 2% cream (formulation F126)|ketoconazole 2% cream (formulation F126) A topical white homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
3212367|NCT01110330|Experimental|Ketoconazole 2% cream (formulation F012) (Nizoral)|ketoconazole 2% cream (formulation F012) (Nizoral) A topical white homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
3212368|NCT01110330|Placebo Comparator|Placebo cream|Placebo cream A topical white homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
3212369|NCT01110317|Experimental|001|paliperidone palmitate 100 mg Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1 8 36 and 64.
3212370|NCT01110304|Active Comparator|Conservative treatment|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed.
3212371|NCT01110304|Active Comparator|Surgical treatment|Patients will undergo surgery to treat their AC joint dislocation.
3212372|NCT01110291||Breast cancer|Twenty patients with verified high risk breast cancer will be included in the study.
3212373|NCT01110278||Urge Incontinent Women|Women with documented urge/urgency incontinence with established care at the Oregon Health and Science University.
3212374|NCT01110278||Control Women|Women with no urge/urgency incontinence with established care at the Oregon Health and Science University.
3212375|NCT01110265|Placebo Comparator|placebo training|
3212376|NCT01110265|Experimental|attention training|
3212377|NCT01110252|Active Comparator|pre-procedure|emphysema patients evaluated prior to the stem cells infusion
3212378|NCT01110252|Experimental|post-procedure|emphysema patients evaluated 30 days after the stem cells infusion
3212514|NCT01109212|Placebo Comparator|Placebo|patients treated with placebo 2 tablets bid plus irbesartan 2x150 mg once a day for 12 weeks
3212379|NCT01110239|Experimental|remote limb preconditioning|Subjects with subarachnoid hemorrhage will undergo escalating times of limb ischemia to determine tolerability and safety. The leg will be made transiently ischemic with application of a blood pressure cuff for up to 3 cycles of 10 minutes.
3212380|NCT01110226|Experimental|KML001 plus Cisplatin|
3212381|NCT01110213|Experimental|Physical activity|Participants received individual tailored telephone counseling and group-tailored newsletters encouraging leisure time physical activity. Content was based on goal setting theory and decisional balance.
3212382|NCT01110213|Experimental|Fruit and vegetable|Participants received individual tailored telephone counseling and group-tailored newsletters encouraging fruit and vegetable intake. Content was based on goal setting theory and decisional balance.
3212383|NCT01110200|Active Comparator|ADVAIR DISKUS 250/50 mcg BID|Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
3212384|NCT01110200|Active Comparator|Serevent 50 mcg BID|Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
3212385|NCT01110187|Experimental|IV LCM (lacosamide)|Patients with severe traumatic brain injury (TBI) or subarachanoid hemorrhage (SAH) randomized to seizure prophylaxis with either lacosamide.
3212386|NCT01110187|Active Comparator|IV fPHT (fos-phenytoin)|Patients with TBI or SAH randomized to seizure prophylaxis with fos-phenytoin
3212387|NCT01110174|Experimental|HD PET/CT|utilization of PET/CT for diagnostic of breast cancer progression.
3212388|NCT01110161||Visceral fat mass|The study population will include Chinese adult men and women, over the age of 18 years. All subjects will be recruited at Fudan University. Subjects will represent a wide range of BMI values (18.5 - 40 kg/m2).
3212389|NCT01110148|Experimental|Video-based informed consent|patients receiving informed consent through video format
3212390|NCT01110148|Active Comparator|traditional informed consent|patients receiving traditional informed consent from the physicians.
3212391|NCT01110135|Experimental|Treatment (chemotherapy and colony-stimulating factor)|Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60-240 minutes on days 1-3, dexamethasone PO on days 1-4, and filgrastim SC beginning on day 5 and continuing until peripheral blood stem cell collection is complete. Patients undergo leukapheresis daily for a minimum of 3 days or until > 5 x 10^6 CD34+/kg has been collected.
3212392|NCT01110109||Continuous Suctioning|Anesthesia staff will suction secretions continuously at 20 mmHg with a safety stop of 5 seconds every 30 minutes.
3212393|NCT01110109||Intermittent Suctioning|Anesthesia staff will suction secretions intermittently using an intermittent suction regulator. The regulator will be set to suction at 100-150 mmHg. The regulator has a preset cycle of intermittent suctioning for 15 seconds with an 8 second pause.
3212394|NCT01110096|Experimental|Group A - family camp|Obese families participate in a two week camp with two years follow-up.
3212395|NCT01110096|Other|Group B - family lifestyle school|Families participate in a four day practical course about lifestyle.
3212396|NCT01110083|Experimental|Arm 1|
3212397|NCT01110070|Experimental|ChonDux plus microfracture|
3212398|NCT01110070|Active Comparator|Microfracture|
3212399|NCT01110057|Experimental|Active|GW856553
3212400|NCT01110057|Placebo Comparator|Placebo|Placebo
3212401|NCT01110044|Experimental|Group A|Subjects will be administered 251154 vaccine at birth, Infanrix hexa™ at 2, 4, 6 and 12-18 months of age, Synflorix™ at 2, 4, 6 and 12-18 months of age, Rotarix™ at 2 and 4 months of age.
3212402|NCT01110044|Active Comparator|Group B|Subjects will be administered no vaccine at birth, Infanrix hexa™ at 2, 4, 6 and 12-18 months of age, Synflorix™ at 2, 4, 6 and 12-18 months of age, Rotarix™ at 2 and 4 months of age.
3212403|NCT01110031|Experimental|Treatment|Six months treatmet with ofatumumab will be given to subjects with chronic lymphocytic leukemia.
3212404|NCT01110018|Active Comparator|Period 1|20μg intravenous infusion administered over 30 minutes
3212405|NCT01110018|Active Comparator|Period 2|1000μg Oral dose
3212406|NCT01110018|Active Comparator|Period 3|50μg Intravenous infusion administered over 30 minutes
3212407|NCT01110018|Active Comparator|Period 4|1000μg Inhaled dose
3212408|NCT01110018|Active Comparator|Period 5|100μg Intravenous infusion administered over 30 minutes
3212409|NCT01110005|Active Comparator|D5 Lactated Ringer's solution (D5LR)|IV fluid containing glucose administered throughout labor at an average infusion rate of 125 ml/hr.
3212410|NCT01110005|Active Comparator|Lactated Ringer's solution (LR)|Non-glucose IV fluid administered throughout labor at an average infusion rate of 125 ml/hr.
3212411|NCT01109992|Active Comparator|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
3212412|NCT01109992|Experimental|Exercise + Regadenoson (Lexiscan)|Exercise plus Regadenoson (Lexiscan) Rubidium-82 Positron Emission Tomography
3212413|NCT01109979|Active Comparator|Estradiol+MPA|
3212414|NCT01109979|Active Comparator|Estradiol+DRSP|
3212415|NCT01109966|Active Comparator|Amino acid based formula|"Patients will be randomised to one of two arms:~Group I: receiving a new amino-acid based formula Group II: receiving a standard AAF formula"
3212416|NCT01109966|Active Comparator|New amino acid based formula|"Patients will be randomised to one of two arms:~Group I: receiving a new amino-acid based formula Group II: receiving a standard AAF formula"
3212417|NCT01109953||Breath-Hold PET/CT image|In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both.
3212418|NCT01109940|Experimental|AIN457|
3212419|NCT01109927|Experimental|Insulin treatment|Insulin given as soon as possible after diagnosis
3212420|NCT01109927|No Intervention|Conventional treatment|Diet, oral hypoglycemic agents and insulin first when clinically needed
3212421|NCT01109914|Experimental|Renal transplant recipients (MMF)|"Renal transplant recipients using prednisolone and mycophenolate mofetil (MMF) but no other immunosuppressive drug.~Intervention: vaccination with Dukoral"
3212515|NCT01109199|Experimental|PolyGlycopleX (PGX)|
3212422|NCT01109914|Experimental|Renal transplant recipients (CNI)|"Renal transplant recipients using prednisolone and a calcineurin inhibitor (cyclosporine or tacrolimus) but no other immunosuppressive drug.~Intervention: vaccination with Dukoral"
3212423|NCT01109914|Experimental|Healthy volunteers|"Healthy volunteers (partners, brothers or sisters of the renal transplant recipients).~Intervention: vaccination with Dukoral"
3212424|NCT01109901|Other|anterior submuscular transposition|it is kind of surgical method
3212425|NCT01109901|Other|Anterior subcutaneous transposition|it is kind of surgical method
3212426|NCT01109888|Active Comparator|Cetrotide|
3212427|NCT01109862|Experimental|THA|Total hip arthroplasty
3212428|NCT01109862|Active Comparator|HAP|Bipolar Hemiarthroplasty
3212429|NCT01109849|Active Comparator|weight recovery treatment- monitoring|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the monitoring arm , participants will continue on their ER stimulant 7 days a week and have their weight, height and BMI checked monthly.
3212430|NCT01109849|Active Comparator|behavior therapy|10 week basic parent training, advanced 8 week parent training course. monthly boosters, option for individual parent training sessions, school consultant assigned to each subject
3212431|NCT01109849|Experimental|ER stimulant|daily use of 12 hour extended release methylphenidate product
3212432|NCT01109849|Experimental|weight recovery treatment- caloric supplement|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the caloric supplement arm, participants will continue on their ER stimulant 7 days a week, have their weight, height and BMI checked monthly and be prescribed a 150 kcal caloric supplement to be consumed every evening.
3212433|NCT01109849|Experimental|weight recovery treatment- drug holiday|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the drug holiday arm, participants will only take their ER stimulant on school days a week and have their weight, height and BMI checked monthly.
3212434|NCT01109836|Experimental|Motivation and lifestyle intervention|Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
3212435|NCT01109836|No Intervention|Control|Standard stroke care
3212436|NCT01109823|Active Comparator|patients with normal renal function|Patients with normal renal function hospitalized at the Department Intensive Care Unit who are being treated with levofloxacin I.V. (500mg, twice daily) for an infection.
3212437|NCT01109823|Active Comparator|patients with hyperfiltration|Patients with hyperfiltration hospitalized at the Department Intensive Care Unit who are being treated with levofloxacin I.V. (500mg, twice daily) for an infection.
3212438|NCT01109810||IVIg and SCIg therapy|
3212439|NCT01109797|Experimental|Transition Social Behavioral Intervention|
3212440|NCT01109797|Experimental|Diabetes Transition Clinic|
3212441|NCT01109784|Experimental|prasugrel|prasugrel per os 10mg/day
3212442|NCT01109784|Active Comparator|clopidogrel|clopidogrel per os 150mg/day
3212443|NCT01109771|Active Comparator|absorbable fixation left side|
3212444|NCT01109771|Active Comparator|absorbable fixation right side|
3212445|NCT01109758|Experimental|1|
3212446|NCT01109745|No Intervention|usual primary care|Number of participating children: 85
3212447|NCT01109745|Experimental|PELICAN Primary care|Intervention arm: the integration of the output of the Pelican instrument (i.e., individualised HRQL information) in daily care to guide disease management for children with asthma treated in primary care. Number of participants: 85 children
3212448|NCT01109745|No Intervention|usual secondary care|number of participating children: 50
3212449|NCT01109745|Experimental|PELICAN Secondary Care|Intervention arm: the integration of the output of the Pelican instrument (i.e., individualised HRQL information) in daily care to guide disease management for children with asthma treated in primary care. Number of participants: 50 children
3212450|NCT01109732|Experimental|Systematic physical training|Hospital-based SET two days per week for 12 weeks and one home-based exercise session every week. The group-based SET was based on The Norwegian Ullevaal Model, a modified cardiac rehabilitation program, and was slightly adjusted to be applicable to this patient group. Each SET session lasted for 60 minutes and consisted of warm-up exercises, three high-intensity, two moderate-intensity and cool-down exercises, including stretching. The exercises were generally simple aerobic dance movements and walking and involved the use of both upper and lower extremities. The warm-up exercises included large muscle movements that were repeated later in the higher-intensity intervals, but with greater force and a larger range of movement.
3212451|NCT01109732|No Intervention|Treatment as of today|The control group did not receive any additional follow-up regarding exercise at discharge beyond the general advice about the importance of exercise that is routinely provided at the hospital.
3212452|NCT01109706||patient treated by statines|
3212453|NCT01109706||patient without normolipidemic treatment|
3212454|NCT01109693|Active Comparator|Continue sertraline|Continue sertraline at the dosage at 3 weeks
3212455|NCT01109693|Active Comparator|Augment with mirtazapine|Add mirtazapine to sertraline
3212456|NCT01109693|Active Comparator|Switch to mirtazapine|Stop sertraline and switch to mirtazapine
3212457|NCT01109680|Experimental|14 C labelled Neramexane, capsule|
3212458|NCT01109667||oral anticoagulant|Patients receiving and not receiving oral anticoagulant therapy.
3212459|NCT01109667||INR Level|Group I: Patients not receiving OAT, Group II: Patients under OAT and INR values in good therapeutic range and Group III: Patients under OAT and INR values over the therapeutic range.
3212460|NCT01109628|Experimental|Protein drink|
3212461|NCT01109628|Placebo Comparator|Placebo drink|
3212462|NCT01109615|Experimental|Chemotherapy|
3212463|NCT01109602|Experimental|Arm 1: Yoga Group|"Yoga Group, 8 week bi-weekly in-person yoga training focused on strength, flexibility, and balance~Yoga focused on strength, flexibility, and balance"
3212516|NCT01109199|Placebo Comparator|Rice Flour|
3212517|NCT01109186||kidney-transplanted patients|
3212569|NCT01108744|Active Comparator|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
3212570|NCT01108744|Active Comparator|Mannitol|20% mannitol, dosed by patient's ideal body weight
3212464|NCT01109602|Experimental|Arm 2: Yoga Group Plus|"Yoga Group Plus: 8 week, bi-weekly in-person yoga training focused on strength, flexibility, and balance paired with almost daily at home yoga focused on breathing and relaxation.~Yoga focused on strength, flexibility, and balance~Data for both yoga groups were combined for analyses as there were not any differences between these two groups."
3212465|NCT01109602|No Intervention|Arm 3: Wait list control group|wait-list control: will be assessed before and after 8 weeks. Will then be offered the 8 week yoga intervention.
3212466|NCT01109589||Children aged 0-2 yrs|
3212467|NCT01109589||Women aged 15-60 yrs|
3212468|NCT01109576|Experimental|DSL workshop participants|Three to five Veterans with DSL.
3212469|NCT01109563|Active Comparator|Computer Check-In Control|The Computer Check-In gives the participant contact with the research therapist, an assessment of marijuana use and the current impact of use, and a reminder about optional support sessions.
3212470|NCT01109563|Experimental|Marijuana Check-Ins|The MCI, a MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.
3212471|NCT01109550||with biliary candidiasis|Patients with positive fungal cultures of bile samples.
3212472|NCT01109550||without biliary candidiasis|Patients with negative fungal cultures of bile samples.
3212473|NCT01109537||RLS Diagnosis|
3212474|NCT01109537||Healthy Controls|
3212475|NCT01109524|Experimental|Cetuximab + Cisplatin + Vinorelbine|
3212476|NCT01109511|Active Comparator|oxycodone+naloxone|
3212477|NCT01109511|Active Comparator|Control|Oxycodone alone without naloxone
3212478|NCT01109498|Experimental|Dose cohort 3 x 10^11gc/kg|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
3212479|NCT01109498|Experimental|Alipogene Tiparvovec, Human LPL [S447X]|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections with immunosuppressants
3212480|NCT01109498|Experimental|Alipogene Tiparvovec, Human LPL [S447X], 1xE12 gc/kg|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections with immunosuppressants
3212481|NCT01109485|Experimental|Olopatadine|Olopatadine hydrochloride ophthalmic solution 0.1%
3212482|NCT01109472|Experimental|Patient Tailored Magazine|Patient responses from computer assisted telephone interviews will be used to develop a patient tailored educational magazine.
3212483|NCT01109459|Experimental|Pediatric vision screening|intervention
3212484|NCT01109459|Active Comparator|Pediatric blood pressure screening|control
3212485|NCT01109459|No Intervention|Primary care providers observation only|Observational
3212486|NCT01109446|Experimental|Platelet Rich Plasma|
3212487|NCT01109446|Sham Comparator|Isotonoic Saline Solution|
3212488|NCT01109446|Active Comparator|Steroid (Triamcinolonacetonid)|
3212489|NCT01109420||1/ Cohort 1|Affected and non-affected members of families with non-medullary thyroid cancer
3212490|NCT01109394||1/Cohort 1|Adult or Pediatric subjects, with any malignancy, pre-malignancy, suspected malignancy, family history of malignancy, or without malignancy undergoing surgery or well visit.
3212491|NCT01109394||2/Cohort 2|Human samples, specimens and data collected on IRB approved protocols that are now closed
3212492|NCT01109394||3/Cohort 3|Parent/caregiver of a participating pediatric or adult subject who is being treated for, or who has previously been treated for any form of pediatric cancer.
3212493|NCT01109381|Experimental|Treatment with GT08|Initial phase - omeprazole, N-acetyl cysteine (NAC), lauric acid dose and duration titration from 1 up to 14 days of treatment. Secondary phase - 14 days treatment with omeprazole, NAC, lauric acid
3212494|NCT01109342||Vaccine Recipients|Participants received HIV preventive vaccine VRC-HIV ADV014-00-VP in previous trials RV 156A/WRAIR 1078A or RV 172/WRAIR 1218.
3212495|NCT01109342||Placebo Recipients|Participants received a placebo vaccine in previous trials RV 156A/WRAIR 1078A or RV 172/WRAIR 1218.
3212496|NCT01109329|Experimental|HMPV challenge virus|Participants will receive the HMPV challenge virus.
3212497|NCT01109316|Active Comparator|Insulin Lispro 2 Day|
3212498|NCT01109316|Experimental|Insulin Lispro 6 Day|
3212499|NCT01109316|Active Comparator|Insulin Aspart 6 Day|
3212500|NCT01109303|Active Comparator|TightRope System|Patients are operated on using the TightRope implant by Arthrex.
3212501|NCT01109303|Active Comparator|Screw fixation implant|Patients are operated on using the rigid four-cortices 3,5 mm screw fixation by Synthes.
3212502|NCT01109290||HED children|
3212503|NCT01109290||HED adults|
3212504|NCT01109290||Control children|
3212505|NCT01109290||Control adults|
3212506|NCT01109277||Healthy term and late-preterm neonates|
3212507|NCT01109264|Experimental|Bendamustine Hydrochloride|
3212508|NCT01109264|Active Comparator|Chlorambucil|
3212509|NCT01109251|Other|Intervention group|Group of patients presenting a non controlled AHT or a masked AHT, benefiting from an optimised caring at visit 0.
3212510|NCT01109251|Other|Control group|Patients presenting a non controlled AHT(persistent AHT, AHT necessiting an adaptation of the treatment by the generalist) with information of the generalist on the necessity of obtaining the tensional control according the HAS recommendations
3212511|NCT01109238||Process Feasibility|
3212512|NCT01109225|Experimental|Myocardial infarction|"All patients. Patients hospitalized for a first myocardial infarction with known shift of the segment ST revascularized in acute phase by primary angioplasty and dated less than 4 days.~Intervention:~blood sample~MRI~echocardiography~urine sample~pulmonary echography~vascular check~renal echography"
3212513|NCT01109212|Experimental|Bindarit|Patients treated with bindarit 2x300 mg bid plus irbesartan 2x150 mg once a day for 12 weeks
3212518|NCT01109173|Experimental|Nepafenac 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional dose was administered between 30-120 minutes prior to surgery.
3212519|NCT01109173|Active Comparator|NEVANAC|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery.
3212520|NCT01109173|Placebo Comparator|Nepafenac Vehicle 0.3%|Nepafenac Ophthalmic Suspension 0.3% Vehicle, one drop in affected eye once daily for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional dose was administered between 30-120 minutes prior to surgery.
3212521|NCT01109173|Placebo Comparator|NEVANAC Vehicle|Nepafenac 0.1% vehicle, one drop in affected eye three times daily, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery.
3212522|NCT01109160|Experimental|Azithromycin|Add-on of study-drug (azithromycin) to 'standard of care': 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment).
3212523|NCT01109147|Active Comparator|aripiprazole|"Imagery: A fMRI session is conducted on schizophrenic patients under aripiprazole (medication taken and stabilized for at least six weeks before inclusion, no intervention on the medication is scheduled during the study).~Genetic: pharmacogenetic sampling. One sample was collected for each subject."
3212524|NCT01109147|Active Comparator|risperidone|"Imagery: A fMRI session is conducted on schizophrenic patients under rsiperidone (medication taken and stabilized for at least six weeks before inclusion, no intervention on the medication is scheduled during the study).~Genetic: pharmacogenetic sampling. One sample was collected for each subject."
3212525|NCT01109147|Other|control|Imagery: A fMRI session is conducted on healthy volunteers. Genetic: pharmacogenetic sampling. One sample was collected for each subject.
3212526|NCT01109134|Experimental|Tirofiban intracoronary bolus-only|Tirofiban bolus administered via intracoronary route at the time of primary PCI with no additional peri/postprocedural maintenance infusion
3212527|NCT01109134|Active Comparator|Tirofiban intravenous bolus+infusion|Tirofiban bolus administered intravenously before PCI, followed by periprocedural maintenance infusion
3212528|NCT01109121|Active Comparator|Allopurinol|Allopurinol
3212529|NCT01109121|Experimental|Combination 400|Tranilast and Allopurinol
3212530|NCT01109121|Experimental|Combination 600|Tranilast and Allopurinol
3212531|NCT01109108||Children <2 years of age|Children <2 years of age with and without respiratory tract infection
3212532|NCT01109108||Children 2<5 years of age|Children 2<5 years of age with and without respiratory tract infection
3212533|NCT01109095|Experimental|HER.CAR CMV-specific CTLs|Subject will be assigned a dose level at study entry.
3212534|NCT01109082||Adolescents with idiopathic scoliosis|Adolescents with idiopathic scoliosis
3212535|NCT01109069|Experimental|PCI-32765|
3212536|NCT01109056|Experimental|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
3212537|NCT01109056|Placebo Comparator|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
3212538|NCT01109030|Active Comparator|Pioglitazone+Citalopram+Chlordiazepoxide|Pioglitazone 15 mg Q12h will be given to the patients in active comparator group for 6 weeks. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.Chlordiazepoxide 10 mg/day for first three weeks
3212539|NCT01109030|Placebo Comparator|Placebo+ Citalopram+ Chlordiazepoxide|"Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks."
3212540|NCT01109017||Norditropin®|
3212541|NCT01109004|Active Comparator|Tandem auto transplant|Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance
3212542|NCT01109004|Active Comparator|RVD consolidation|Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance
3212543|NCT01109004|Active Comparator|Lenalidomide maintenance|Initial autologous transplant followed by lenalidomide maintenance
3212544|NCT01108991|Active Comparator|COPD education + Usual care|Six weeks of COPD self-management education plus usual care
3212545|NCT01108991|Experimental|Physical activity self-management|Cognitive behavioral counseling to increase lifestyle physical activity delivered over five months plus six weeks of COPD self-management education and usual care
3212546|NCT01108978|Placebo Comparator|Placebo|
3212547|NCT01108978|Active Comparator|Dehypotin|
3212548|NCT01108965||Extraventricular Drainage|Includes hydrocephalus patients that are in recovery from shunt explanation.
3212549|NCT01108939|Experimental|Antimalarial treatment|
3212550|NCT01108939|Sham Comparator|Observation|
3212551|NCT01108926|Experimental|All Subjects|All Subjects will receive the same intervention
3212552|NCT01108913|Active Comparator|Bimosiamose|
3212553|NCT01108913|Placebo Comparator|Placebo|
3212554|NCT01108900||Patients with erectile dysfunction (ED)|100 ED patients in the study that were switched to sildenafil after a previous treatment with udenafil proved ineffective and/or was poorly tolerated
3212555|NCT01108861|Experimental|Endoprosthesis|GORE VIABAHN® Endoprosthesis
3212556|NCT01108861|Active Comparator|Plain old balloon angioplasty|Plain old balloon angioplasty
3212557|NCT01108848||Berinert|Patients requiring treatment with Berinert®
3212558|NCT01108835|Active Comparator|comprehensive care programme|Comprehensive care involving multidisciplinary input.
3212559|NCT01108835|No Intervention|Control group|Control arm with usual care
3212560|NCT01108809||Patients with arterial hypertension|
3212561|NCT01108796||Patients at cardiovascular risk|
3212562|NCT01108783|Experimental|Bilastine|
3212563|NCT01108783|Active Comparator|Desloratadine|
3212564|NCT01108783|Placebo Comparator|Placebo|
3212565|NCT01108770||HED affected males|
3212566|NCT01108770||Unaffected male controls|
3212567|NCT01108757|Experimental|Drug|
3212568|NCT01108757|Placebo Comparator|Placebo|
3212662|NCT01108081|Experimental|Arm 4|Combined physical activity and diet
3212571|NCT01108731|Active Comparator|Patients taking the drug Milnacipran|Randomize patients signing informed consent and give 50% of them Milnacipran -- blinded to the investigators.
3212572|NCT01108731|Placebo Comparator|Patients taking the placebo|Randomize patients signing informed consent and give 50% of them the placebo -- blinded to the investigators.
3212573|NCT01108718|Experimental|Participants: Tempur Pedic first.|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder who receive the Tempur-Pedic mattress first, then the Control Mattress.
3212574|NCT01108718|Placebo Comparator|Participants: Control Mattress first.|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic mattress.
3212575|NCT01108705|Experimental|Brivanib|
3212576|NCT01108705|Placebo Comparator|Placebo|
3212577|NCT01108692|Experimental|Active|Patients will be followed by telecardiology.
3212578|NCT01108692|Active Comparator|Control|Patients will be followed in the conventional manner. They will be equipped with telecardiology but data will not be used for patient surveillance.
3212579|NCT01108679||Buprenorphine|Opioid-dependent drug users who are initiating buprenorphine treatment at the Albert Einstein College of Medicine Division of Substance Abuse (DoSA) or at Montefiore's Comprehensive Health Care Center (CHCC).
3212580|NCT01108653|Other|Group 1: Usual care sick-leave management|
3212581|NCT01108653|Other|Group 2: Structuralised sick-leave program|
3212582|NCT01108640||Elective surgical patients|
3212583|NCT01108640||Massive resuscitation patients|
3212584|NCT01108640||surgical patients on pressors|
3212585|NCT01108627|Active Comparator|corticosteroid + long acting beta agonist; steroids|
3212586|NCT01108627|Placebo Comparator|placebo + corticosteroid + long acting beta agonist; steroids|
3212587|NCT01108614|Experimental|Intervention|Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
3212588|NCT01108614|No Intervention|Usual|Routine HIV prevention, including health education, counseling and testing, condom promotion.
3212589|NCT01108601|Other|Ringer's Lactate|Each patient will act as their own control with one ear receiving treatment, and the contralateral ear acting as control.
3212590|NCT01108588|Experimental|Sequence 1|Aspirin - Clopidogrel - Placebo
3212591|NCT01108588|Experimental|Sequence 2|Clopidogrel - Placebo - Aspirin
3212592|NCT01108588|Experimental|Sequence 3|Placebo - Aspirin - Clopidogrel
3212593|NCT01108588|Experimental|Sequence 4|Aspirin - Placebo - Clopidogrel
3212594|NCT01108588|Experimental|Sequence 5|Clopidogrel - Aspirin - Placebo
3212595|NCT01108588|Experimental|Sequence 6|Placebo - Clopidogrel - Aspirin
3212596|NCT01108575|Experimental|Inspiratory muscle strength training|
3212597|NCT01108575|Sham Comparator|Sham Inspiratory muscle strength training|
3212598|NCT01108562|Placebo Comparator|Control Group|Patients will receive a Dilaudid PCA in combination with a placebo infusion of normal saline.
3212599|NCT01108562|Experimental|Lidocaine Group|Patients will be receive a Dilaudid PCA in combination with a continuous Lidocaine infusion.
3212600|NCT01108536|Experimental|adaptive trans-tibial socket|subjects are fitted with experimental sockets.
3212601|NCT01108523|Experimental|HP828-101|HP828-101 Experimental Formulation
3212602|NCT01108510|Experimental|ATV+COBI+FTC/TDF|COBI + RTV placebo + ATV + FTC/TDF once daily
3212603|NCT01108510|Active Comparator|ATV+RTV+FTC/TDF|RTV + COBI placebo + ATV + FTC/TDF once daily
3212604|NCT01108484|Experimental|Supervised exercise|Cardiorespiratory and resistance training
3212605|NCT01108484|Experimental|Exercise + diet counseling|Cardiorespiratory and resistance training + Diet counseling to improve food intake(more fruit and vegetable and less fat food)
3212606|NCT01108484|Experimental|Exercise + diet counseling + psycho support|Cardiorespiratory and resistance training + Diet counseling to improve food intake(more fruit and vegetable and less fat food) + Weekly sessions to modify the behaviour
3212607|NCT01108484|No Intervention|Control|They will keep their usual way of life
3212608|NCT01108458|Experimental|Pertuzumab plus Erlotinib Hydrochloride|"Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks~Erlotinib hydrochloride 150 mg/day by mouth"
3212609|NCT01108445|Active Comparator|RAD001|Subjects in this treatment arm will receive everolimus/RAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
3212610|NCT01108445|Active Comparator|Sunitinib|Subjects in this treatment arm will take sunitinib 50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
3212611|NCT01108432|Experimental|Electronic Referrals|Dental practices randomized to the experimental group will have options on how to refer patients to the tobacco cessation website.
3212612|NCT01108432|No Intervention|Routine Referral|Dental practices in this arm will refer patients to the Decide2Quit website by using an information prescription.
3212613|NCT01108419|Active Comparator|1 = Test Product normal dose|Fermented dairy product containing probiotics - normal dose
3212614|NCT01108419|Active Comparator|2 = Test Product high dose|Fermented dairy product containing probiotics - high dose
3212615|NCT01108419|Sham Comparator|3 = Control Product normal dose|Non-fermented dairy product - normal dose
3212616|NCT01108419|Sham Comparator|4 = Control Product high dose|Non-fermented dairy product - high dose
3212617|NCT01108406|Experimental|SoundBite Hearing System|"The objective of this study was to assess the long-term safety and quality of life impact of the SoundBite™ Hearing System.~Safety was measured in terms of dental, audiological and medical adverse events related to device or procedure.~Quality of Life was measured in terms of changes in Abbreviated Profile of Hearing Aid Benefit (APHAB) and as reported in a quality of life survey (SSD Questionnaire).~The duration of the study was 6 months with measures taken at Day 1, 3 months and 6 months."
3212618|NCT01108393|Experimental|Agomelatine A|
3212619|NCT01108393|Placebo Comparator|Placebo|
3212658|NCT01108094|Experimental|Itraconazole 200 mg twice daily|200 mg twice daily; oral
3212659|NCT01108081|Experimental|Arm 1|Physical activity
3212660|NCT01108081|Experimental|Arm 2|Diet
3212620|NCT01108380|Experimental|1. CD34|"4 days injection of G-CSF (10μg/kg, Subcutaneous infusion)~On 5th day, plasmapheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells)~CD 34 cells will be selected by CliniMACS (Miltenyi Biotec, Bergisch- Gladbach, Germany) (at least 1x10(7) of CD 34 cell)~In same day, right portal vein embolization with infusion of CD 34 cells into left portal vein will be performed."
3212621|NCT01108380|Active Comparator|2. Mononucelar cell|"4 days injection of G-CSF (10μg/kg, Subcutaneous infusion)~On 5th day, plasma pheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells)~In same day, right portal vein embolization with infusion of mononuclear cells into left portal vein will be performed."
3212622|NCT01108380|Other|3. Control|Without infusion of G-CSF, patients will be performed just right portal vein embolization
3212623|NCT01108354||ADHD patients|10 male adult ADHD patients and 10 female adult ADHD patients
3212624|NCT01108354||healthy controls|20 age- and sex-matched healthy volunteers
3212625|NCT01108341|Experimental|Bendamustine and Ofatumumab|There are 6 planned and 2 optional 28-day cycles in which participants are administered both bendamustine and ofatumumab in the following doses: Bendamustine administered at 90 mg/m^2 intravenously (iv) on study days 1 and 2. Ofatumumab administered at 300 mg iv on day 1 and 1000 mg iv on day 8 of cycle 1. Ofatumumab administered at 1000 mg iv on day 1 of all additional cycles.
3212626|NCT01108328|Experimental|PolyGlycopleX (PGX)|5 grams of PGX 3 times per day with each main meal (breakfast, lunch and dinner)
3212627|NCT01108328|Placebo Comparator|Rice flour|5 grams of rice flour 3 times per day at each main meal (breakfast, lunch and dinner)
3212628|NCT01108315|Experimental|Intervention|The participant used the web and/or phone-based PRO reporting symptoms to enter symptoms twice a week at minimum.
3212629|NCT01108315|No Intervention|Usual Care|The participants on this arm do not record their symptoms. They report symptoms as they would under usual care.
3212630|NCT01108302|No Intervention|PPH Treatment only|Auxilliary nurse midwives will be able to treat for PPH only, not provide Oxytocin in Uniject
3212631|NCT01108302|Experimental|Oxytocin in Uniject|Auxilliary Nurse Midwives will provide 10IU Oxytocin in Uniject device IM immediately after delivery
3212632|NCT01108289|Experimental|Oxytocin in Uniject|Community Health Officers will provide 10 IU Oxytocin in Uniject device IM immediately after delivery of baby
3212633|NCT01108289|No Intervention|PPH Treatment Only|Community Health Officers will be able to treat for PPH only, not provide Oxytocin in Uniject
3212634|NCT01108263|Active Comparator|Integra Flowable on wound bed|INTEGRA™ Flowable is a wound Matrix made of bovine (cow) collagen. It provides a scaffold for cellular and capillary growth. Dosage is dependent on the size of the wound. It will be applied once.
3212635|NCT01108263|Active Comparator|INTEGRA Flowable on wound & injected subcutaneously|INTEGRA™ Flowable is a wound Matrix made of bovine (cow) collagen. It provides a scaffold for cellular and capillary growth. Dosage is dependent on the size of the wound. It will be applied once.
3212636|NCT01108250|Experimental|polypoidal choroidal vasculopathy|patients with polypoidal choroidal vasculopathy
3212637|NCT01108250|Active Comparator|control|control group with no polypoidal choroidal vasculopathy
3212638|NCT01108237|Other|TruMatch™ Personalized Solutions|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using TruMatch™ Personalized Solutions
3212639|NCT01108237|Other|Historical Control|Total Knee Arthroplasty (PFC Sigma System) implanted using conventional and CAS surgical techniques without TruMatch™ instrumentation.
3212640|NCT01108224|Experimental|Psychosocial support|
3212641|NCT01108224|No Intervention|Control group|
3212642|NCT01108211|Experimental|Treatment Group|This group will receive Vibration Therapy.
3212643|NCT01108211|No Intervention|Observation Group|This group does not receive Vibration Therapy
3212644|NCT01108198|Active Comparator|mometasone furoate cream|The study patient consecutive patients who were referred to outpatient clinic of Pediatric surgery for surgical treatment of non-retractable foreskin. The study patients were randomized to have either mometasone cream or placebo
3212645|NCT01108198|Placebo Comparator|moisturizer|
3212646|NCT01108185||Acute Respiratory Infections|Slovak patients with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP).
3212647|NCT01108172|Active Comparator|Usual Care|
3212648|NCT01108172|Experimental|Virtual Ward|
3212649|NCT01108146|Experimental|Arm 1|"Drug: Hydrocortisone 10 mg~Group 1: Administration of Hydrocortisone and/or Placebo in the following order:~1 week placebo-1 week hydrocortisone 10 mg/d -1 week placebo - 1 week hydrocortisone 30 mg/d"
3212650|NCT01108146|Experimental|Arm 2|"Drug: Hydrocortisone 30 mg~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo"
3212651|NCT01108133|Experimental|Hydrocortisone, fMRI, Intrusions|10 mg Hydrocortisone are administered one hour before the fMRI experiment. We use the script-driven imagery paradigm to induce intrusive memories during fMRI scanning.
3212652|NCT01108133|Experimental|Dexamethasone, fMRI, Intrusions|2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment. (DEX-Test). We use the script-driven imaging paradigm to induce intrusive memories during fMRI-scanning.
3212653|NCT01108133|Experimental|Placebo, fMRI, Intrusions|Placebo is administered one hour before the fMRI experiment. We use the script-driven imaging paradigm to induce intrusive memories during fMRI-scanning in patients with posttraumatic stress disorder.
3212654|NCT01108120|Experimental|continuous intra-femoral thrombolysis group|Continuous intra-femoral injection urokinase was taken by a mini-pump in 100 diabetic foot ulcers (Wegnar 2 ~ 4 stage) for 7 - 9 days.Then they receive conventional therapy. The healing rate of foot ulcers is observed during hospitalization period. At 1, 4 and 8 year during follow up, the recurrence rate of diabetic foot ulcers are observed.
3212655|NCT01108120|Experimental|conventional therapy group|Conventional therapy group receives an intravenous injection of prostaglandin E1 20 ug per day. The follow up was taken for 8 years.
3212656|NCT01108107|Other|Chemotherapy only|Chemotherapy only, if mutations in KRAS, BRAF or PIK3CA gene
3212657|NCT01108107|Other|Chemotherapy + biological treatment|Addition of biological treatment, if no mutations in KRAS, BRAF, and PIK3CA genes.
3212663|NCT01108068|Experimental|Lithium|patients with OPPG will be treated with lithium for 6 months
3212664|NCT01108068|No Intervention|Unaffected controls|Family members of patients with OPPG will have DXA and pQCT to compare to OPPG patients. These unaffected participants will not receive lithium.
3212665|NCT01108055|Experimental|pazopanib + paclitaxel|"Cycle of 28 days. Pazopanib: 800mg daily~Cycle of 28 days Paclitaxel: 80mg/m2 on days 1,8 and 15"
3212666|NCT01108042|Experimental|Taxotere, Cisplatin, 5-Fluorouracil (5-FU)|Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out.
3212667|NCT01108029|Active Comparator|memantine|memantine 20 mg/day (2 tablets 1 time a day in the morning)
3212668|NCT01108029|Placebo Comparator|placebo|2 tablets (1 time a day in the morning) during 3 months
3212669|NCT01108003|Experimental|Arm I|Patients receive oral broccoli sprout extract once daily on days 1-14 in the absence of disease progression or unacceptable toxicity.
3212670|NCT01108003|Placebo Comparator|Arm 2|Patients receive mango juice alone.
3212671|NCT01107990||Single right ventricles|
3212672|NCT01107990||Single left ventricles|
3212673|NCT01107977|Experimental|Iyengar yoga|
3212674|NCT01107977|No Intervention|Waitlist control|
3212675|NCT01107964|Active Comparator|Omega-3-acid ethyl esters|
3212676|NCT01107964|Placebo Comparator|Corn oil capsule|
3212677|NCT01107951|Other|Rituximab -dexamethasone|only one arm receive four doses weekly rituximab and four dosis daily dexamethasona
3212678|NCT01107938|Experimental|10 mg ilaprazole|
3212679|NCT01107938|Experimental|15 mg ilaprazole|
3212680|NCT01107938|Active Comparator|40 mg esomeprazole|
3212681|NCT01107925|Experimental|5 mg prasugrel|
3212682|NCT01107925|Active Comparator|10 mg prasugrel|
3212683|NCT01107925|Active Comparator|75 mg clopidogrel|
3212684|NCT01107912|Experimental|5 milligrams (mg) prasugrel|
3212685|NCT01107912|Active Comparator|10 mg prasugrel|
3212686|NCT01107912|Active Comparator|75 mg clopidogrel|
3212687|NCT01107899|Active Comparator|clopidogrel 600 mg|
3212688|NCT01107899|Active Comparator|prasugrel 60 mg|
3212689|NCT01107899|Experimental|prasugrel 30 mg|
3212690|NCT01107886|Experimental|Saxagliptin|
3212691|NCT01107886|Placebo Comparator|Placebo|Placebo
3212692|NCT01107873||duplex ultrasonography|conduct duplex ultrasonography after caudal block with sevoflurane anaesthesia in children
3212693|NCT01107860||Group I|
3212694|NCT01107860||Group II|
3212695|NCT01107834||Healthy Control|HIV-negative children born to healthy, HIV-negative women
3212696|NCT01107834||Exposed to HIV/HAART|HIV-negative children exposed to HIV and HAART in utero
3212697|NCT01107821|Experimental|Engenex™-pump|Negative Pressure Wound Therapy with the Engenex™-pump and Bio-Dome™ Dressing
3212698|NCT01107808|No Intervention|Control|The adolescents randomized to Standard of care group will receive the medical and behavioral counseling regarding their obesity as a patient of the Children's Center for Weight Management (CCWM). They will not receive any pharmacological treatment for their vitamin D deficiency or insulin resistance. Calcium and vitamin D dietary intake will be determined using a specific food frequency questionnaire at each study visit for all groups. This will be used to determine effect of nutrition counseling.
3212699|NCT01107808|Experimental|Calcium and Vit D|The participants in the vitamin D/calcium group will receive standard of care through the CCWM along with the addition of treatment with ergocalciferol (vitamin D2) and calcium carbonate for their vitamin D deficiency. The vitamin D treatment will be 50,000 IU orally weekly for 8 weeks. This treatment regimen for vitamin D deficiency has been found to be safe to children and adolescents. 32 33The dose of calcium supplementation will be calcium carbonate orally 1200mg daily. This is the daily recommended intake of calcium for adolescents
3212700|NCT01107808|Experimental|Metformin/ Vit D|The participants randomized into the vitamin D/calcium/Metformin treatment group will receive standard of care through the CCWM in addition to treatment for their Vitamin D deficiency with the same doses of ergocalciferol (vitamin D2) and calcium carbonate as previously outlined. Additionally, these participants will receive Metformin ER to treat insulin resistance. The Metformin ER will be started at 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks).
3212701|NCT01107782|Experimental|sildenafil|
3212702|NCT01107782|Placebo Comparator|Placebo control|
3212703|NCT01107769||VISIONAIRE™|Total knee arthroplasty with VISIONAIRE™ patient-matched cutting blocks
3212704|NCT01107769||Standard Instrumentation|Total knee arthroplasty with standard instrumentation
3212705|NCT01107756|Experimental|TAXOTERE (Docetaxel) + GRANOGYTE 34 (Lenograstim)|Taxotere (Docetaxel) is given as background treatment and should be administered by the treating physician in accordance with the prescribing information outlined in the package insert + Granocyte 34 (lenograstim)
3212706|NCT01107743||Amlodipine and Atorvastatin Combination Tablet|Subjects taking Amlodipine and Atorvastatin Combination Tablets
3212707|NCT01107730|Active Comparator|L-Carnitine|L-Carnitine intravenously (2 gr/day [1grX2] for 2 days prior to surgery, and postoperatively for 4 days
3212708|NCT01107730|Active Comparator|Vitamin C|VitC intravenously (2g/day [500mgX4] for 2 days prior to surgery, and postoperatively for 4 days
3212709|NCT01107730|Active Comparator|Placebo|
3212710|NCT01107717|Experimental|Triple Therapy|initiation a combination of metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) at the time diabetes is diagnosed
3212711|NCT01107717|Active Comparator|conventional therapy|sequential addition of metformin, glyburide and basal insulin
3212712|NCT01107704|Experimental|Family Support Intervention|
3212713|NCT01107704|No Intervention|Control Group|
3212714|NCT01107691|Experimental|Resistance training|1 set of progressive resistance training per session
3212715|NCT01107691|Experimental|3 sets per session|3 sets of progressive resistance training per session
3212716|NCT01107691|No Intervention|Control|Non exercise control group
3212802|NCT01107158||Group 2|These patients have uterine dystocia
3212717|NCT01107678|Experimental|YMCA PAN|YMCA PAN (Physical activity and nutrition)- Consists of organized physical activity and controlled serving sizes of healthy low fat snacks
3212718|NCT01107678|Experimental|YMCA Standard CAre|YMCA standard care - Follow the standard care of the YMCA after school Y-Care program for physical activity and nutrition
3212719|NCT01107665|Experimental|Pazopanib and Paclitaxel|Treatment on study will be administered in 4-week cycles. Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
3212720|NCT01107639|Experimental|Additional immunotherapy (cetuximab)|All patients in the experimental arm will be given additional immunotherapy (cetuximab) during cycles 1 and 2, during RT and after surgery.
3212721|NCT01107639|Active Comparator|Without additional immunotherapy|Standard therapy without immunotherapy (cetuximab).
3212722|NCT01107626|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 1
3212723|NCT01107626|Experimental|Arm II|Patients receive pemetrexed IV over 10 minutes on days 1.
3212724|NCT01107626|Experimental|Arm III|Patients receive bevacizumab as in arm I and pemetrexed as in arm II.
3212725|NCT01107613|Experimental|Intervention Arm|All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader letter sent to the primary care provider outlining the needs of this patient.
3212726|NCT01107613|No Intervention|Control/Standard Care|All patients will receive prednisone X 10 days and antibiotics X 5 days. This group will receive educational handouts on AECOPD.
3212727|NCT01107600|Experimental|Nobel Active®|Immediate implant and socket preservation
3212728|NCT01107587|Experimental|HRV group|Subjects will receive GSK Biologicals' human rotavirus vaccine 444563.
3212729|NCT01107587|Placebo Comparator|Placebo Group|Subjects will receive placebo.
3212730|NCT01107574|Experimental|Gabapentin and Osteopathic Manipulative Medicine|6 weeks of both Gabapentin 900 mg HS given orally was accompanied with Osteopathic Manipulative Medicine treatment 30 minutes weekly to the tender points of the musculoskeletal system of each patient for 6 weeks.
3212731|NCT01107574|Experimental|Gabapentin|Gabapentin was given orally at 900 mg at HS weekly for 6 weeks.
3212732|NCT01107574|Experimental|Osteopathic Manipulative Medicine|6 weeks of Osteopathic Manipulative Medicine Treatment was applied to the patients tender points in the musculoskeletal system weekly by a 30 minute treatment.
3212733|NCT01107561|Experimental|Seldinger technique|Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire.
3212734|NCT01107561|Active Comparator|Surgical airway approach|The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
3212735|NCT01107548|Experimental|Evidence-based treatment, lifestyle counseling|
3212736|NCT01107535||Infants receiving Synagis (palivizumab) immunoprophylaxis|Infants born <= 32 weeks of gestation and are younger than 6 months of age, children with bronchopulmonary dysplasia who have received medical treatment in the last 6 months until the first year of life, and children 12 months or younger with hemodynamically significant acyanotic congenital heart disease (pulmonary hypertension or heart failure in treatment) prescribed Synagis (palivizumab) immunoprophylaxis according to the usual clinical practice.
3212737|NCT01107522|Experimental|Arm A|Single Agent CTO
3212738|NCT01107522|Experimental|Arm B|Combination CTO and Temodar®
3212739|NCT01107522|Experimental|Arm C|Combination CTO, Temodar®, Radiation therapy
3212740|NCT01107509|Experimental|Neo-adjuvant everolimus|
3212741|NCT01107496|Experimental|SPN-812|viloxazine, oral, 300mg, tid, 6 weeks
3212742|NCT01107496|Placebo Comparator|Placebo|placebo, oral, tid, 6weeks
3212743|NCT01107483||AC group|asymptomatic carriers
3212744|NCT01107483||CH group|patients with chronic hepatitis
3212745|NCT01107483||HC group|patients with hepatic cirrhosis
3212746|NCT01107483||ACLF group|patients with acute on chronic liver failure
3212747|NCT01107483||healthy control|healthy volunteers
3212748|NCT01107470||Group A1|Age 18-34y (with short protocol)
3212749|NCT01107470||Group A2|age 35-42y ( with short protocol)
3212750|NCT01107470||Group B1|age 18-34y ( with long protocol)
3212751|NCT01107470||Group B2|age 35-42y ( with long protocol)
3212752|NCT01107457|Experimental|10 mg Ixekizumab|"Part A:~10 milligrams (mg) ixekizumab given subcutaneous (SC) on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
3212753|NCT01107457|Experimental|25 mg Ixekizumab|"Part A:~25 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC (Q4W). Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
3212754|NCT01107457|Experimental|75 mg Ixekizumab|"Part A:~75 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
3212755|NCT01107457|Experimental|150 mg Ixekizumab|"Part A:~150 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~Administered 120 mg ixekizumab SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344."
3212756|NCT01107457|Placebo Comparator|Placebo|"Part A:~Placebo given on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional) 120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
3212803|NCT01107145|Experimental|Mefloquine- Artesunate|Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
3213063|NCT01105429|Active Comparator|BMS-820132 (1.0 mg) or Placebo|
3212757|NCT01107457|Experimental|120 mg Ixekizumab|"Part B: (optional)~120 mg ixekizumab given SC every 4 weeks. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236.~Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344."
3212758|NCT01107457|Experimental|80 mg Ixekizumab|"Part B: (optional)~Subsequent to an amendment on May 2012, administration changed to 80 mg ixekizumab Q4W through Week 236.~Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344."
3212759|NCT01107444|Experimental|LY2181308 + Docetaxel|"Lead in Phase:~Day -2 and Day -1 of a 2 day lead-in period: LY2181308 750 mg~Cycle 1 (cycle = 21 days)~Day 1, Day 6, Day 14: LY2181308 750 mg, Day 1: docetaxel 75mg/m2~Cycles 2-6 (cycle = 21 days):~Day 1 through 21: LY2181308 750 mg once weekly, Day 1: Docetaxel 75mg/m2~After 6 cycles, it may be possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met."
3212760|NCT01107444|Active Comparator|Docetaxel|"Cycles 1-6 (Cycle = 21 days):~Day 1: Docetaxel 75 mg/m2~After 6 cycles, it may be possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met."
3212761|NCT01107431|Active Comparator|Sucrose with Dietary Supplement|Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
3212762|NCT01107431|Active Comparator|Sucrose without Dietary Supplement|Consumed 70 grams of sucrose without simultaneously taking the dietary supplement
3212763|NCT01107418|Experimental|1|
3212764|NCT01107418|Experimental|2|
3212765|NCT01107418|Experimental|3|
3212766|NCT01107418|Experimental|4|
3212767|NCT01107405|Active Comparator|Loteprednol etabonate base (QD)|Loteprednol etabonate ophthalmic base dosed once/day.
3212768|NCT01107405|Active Comparator|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base dosed two times/day
3212769|NCT01107405|Active Comparator|Loteprednol etabonate base (QID)|Loteprednol etabonate ophthalmic base dosed four times/day.
3212770|NCT01107405|Active Comparator|Loteprednol etabonate suspension (QID)|Loteprednol etabonate ophthalmic suspension dosed four times/day
3212771|NCT01107405|Placebo Comparator|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate, dosed either QD, BID, or QID
3212772|NCT01107392|Experimental|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
3212773|NCT01107392|Placebo Comparator|Placebo (Normal saline)|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
3212774|NCT01107379||Balloon catheter device|Dilation of sinuses using Relieva Balloon Sinuplasty System
3212775|NCT01107353|Active Comparator|First Imipramine Pamoate, then Tofranil-PM|First 75 mg imipramine pamoate capsule, then 75 mg Tofranil-PM capsule (after washout period)
3212776|NCT01107353|Active Comparator|First Tofranil PM, then imipramine pamoate|First 75 mg Tofranil-PM capsule, then 75 mg imipramine pamoate capsule (after washout period)
3212777|NCT01107340|Other|AMIStem Hip System|Patients who comply with the protocol and received an AMIStem femoral component.
3212778|NCT01107314||trauma patient|SBP less than 90mmHg
3212779|NCT01107288|Experimental|Intervention group|Randomized to receive the intervention first
3212780|NCT01107288|Other|Delayed intervention control group|Randomized to wait-list control first
3212781|NCT01107275|Experimental|2 primary ID doses|two doses of rabies vaccines given intradermally on days 0 and 28
3212782|NCT01107275|Experimental|3 primary ID doses|three doses of rabies vaccines given intradermally on days 0, 7, and 28
3212783|NCT01107262||Poultry exposed adults|This seroepidemiological study proposes to compare adults with occupational exposure to poultry with non-poultry exposed adult controls for evidence of previous infections with AI viruses.In this study, any person with occupational exposure to poultry i.e. works in poultry production facility or raises a smaller number of poultry on his/her farm will be considered exposed. The questionnaire used in this study will capture poultry exposure data through a group of variables assessing type of occupational setting, length of time of exposure, flock size, type of work performed, and personal protective equipment (PPE) used.
3212784|NCT01107262||Poultry Non-exposed Adult Controls|Controls, adults who were never exposed to poultry, will be enrolled from urban areas such as the capital Beirut. Controls will be invited to volunteer by word of mouth at public/community sites.
3212785|NCT01107249|Other|BS Ultraflex or Wallstent stents|All subjects receive a stent of surgeons choice from selected stents.
3212786|NCT01107236|Experimental|IW-6118|
3212787|NCT01107236|Placebo Comparator|Placebo|
3212788|NCT01107236|Active Comparator|Naproxen Sodium|
3212789|NCT01107223|Experimental|Training to antibiotic prescription|Physicians randomized in the education group attended a two days seminar focussed on evidence-based guidelines on antibiotic use in respiratory tract infections.
3212790|NCT01107223|Placebo Comparator|control|
3212791|NCT01107210||stroke patients|50 patients recruited in the stroke rehabilitation unit in the University Hospital, Leuven, Belgium will be included
3212792|NCT01107197|Active Comparator|Isonitrogenous isocaloric formula|Patients were given standard diet plus 2 bottles of an hypercaloric oral formula isonitrogenous isocaloric to the experimental one
3212793|NCT01107197|Experimental|Enriched nutrition formula|Patients were given standard diet plus 2 bottles of an hypercaloric oral formula enriched in arginine, zinc and antioxidant oligoelements
3212794|NCT01107184|Experimental|Preconditioning|The remote ischemic stimulus will be applied after induction of anaesthesia, but before cardiopulmonary bypass.
3212795|NCT01107184|Experimental|Postconditioning|The remote ischemic stimulus during cardiopulmonary bypass.
3212796|NCT01107184|Experimental|Pre and postconditioning|The remote ischemic stimulus will be applied twice, after induction of anaesthesia and during cardiopulmonary bypass.
3212797|NCT01107184|Sham Comparator|Control|
3212798|NCT01107171|Placebo Comparator|placebo|Tang-min Lin pills analogue
3212799|NCT01107171|Experimental|Tang-min-ling pills high dosage|Tang-min-ling pills, high dosage, 12g, tid po
3212800|NCT01107171|Experimental|Tang-min-ling pills low dosage|low dosage group:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
3212801|NCT01107158||Group 1|Control group: these patients have mechanical dystocia; cholesterol metabolism factors are a priori not involved.
3212804|NCT01107145|Experimental|Artemether-Lumefantrine|Artemether-Lumefantrine, Lumet, Cipla 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
3212805|NCT01107145|Active Comparator|Chloroquine|Chloroquine (Farmaguinhos, Brazil): Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)
3212806|NCT01107132||Diabetic Retinopathy|T2DM Patient suffering from Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema (DME)
3212807|NCT01107119|Experimental|Integrated care pathway|"program for~communication and information flow aimed at collaboration between hospitals, general practitioners and home care services~systematic patient follow-up in home care services by using checklists"
3212808|NCT01107119|Active Comparator|usual care|usual care
3212809|NCT01107106||Adolescents|250 postmenarcheal adolescent girls
3212810|NCT01107106||Adults|250 adult women
3212811|NCT01107093|Placebo Comparator|Placebo|
3212812|NCT01107093|Active Comparator|CDB-2914|
3212813|NCT01107080||Degradation|30 mastectomy, partial mastectomy, and mammoplasty samples will be analyzed to define the effective post-excision time window in which the device must be used before the results can no longer be evaluated. The mammoplasty specimens are necessary to assess normal tissue outcomes.
3212814|NCT01107080||Reproducibility|25 Partial Mastectomy cases will be analyzed to distinguish between different implementation methods of the technology.
3212815|NCT01107067|Experimental|testosterone replacement therapy|
3212816|NCT01107054|Experimental|PF-00610355 450 µg|An orally inhaled dose of PF-00610355 450 µg
3212817|NCT01107054|Experimental|PF-00610355 1200 µg|An orally inhaled dose of PF-00610355 1200 µg
3212818|NCT01107054|Active Comparator|moxifloxacin 400 mg|A single oral dose of moxifloxacin 400 mg on Day 4.
3212819|NCT01107054|Placebo Comparator|placebo|A single oral dose of non-matched placebo on Day 4.
3212820|NCT01107041|Experimental|Mobilyze!|
3212821|NCT01107028||Rehab|Subjects randomized to the Rehab group will have data collected at baseline and then within one week enroll in a pulmonary rehabilitation program. Data will again be collected within one week of completing pulmonary rehabilitation and again six months later.
3212822|NCT01107028||Wait|Subjects randomized to the Wait group will have data collected at baseline and wait eight weeks before enrolling in a pulmonary rehabilitation program. Data will again be collected within one week of completing pulmonary rehabilitation and again six months later.
3212823|NCT01107015|No Intervention|Group 1: Usual Care|Provider-driven care, based in office, no special diabetes management; Patient self-monitoring of blood glucose (SMBG)
3212824|NCT01107015|Active Comparator|Group 2: patient intervention|Home diabetes monitoring by patient using mobile phone to communicate information and receive feedback
3212825|NCT01107015|Active Comparator|Group 3: patient-physician intervention|Home diabetes monitoring by patient using mobile phone to communicate and receive feedback; Physician can access unanalyzed information from the patient's electronic logbook
3212826|NCT01107015|Active Comparator|Group 4: data analyzed intervention|Home diabetes monitoring by patient using mobile phone to communicate information and receive feedback; Physician can access raw and analyzed patient data; Physician receives report summary and treatment recommendations
3212827|NCT01107002|Experimental|Day 5 embryo transfer group|Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
3212828|NCT01106989|Experimental|Heated lidocaine/tetracaine patch|Active
3212829|NCT01106976||Group 1 Parkinson disease subjects|Subjects with Parkinson disease who previously participate in a motor and brain PET (brain positron emission tomography) imaging study who were invited for a longitudinal observational study.
3212830|NCT01106963||Tibial shaft fractures|Patients had tibial shaft fractures in the last 3 years. All were treated with intramedullary (IM) reamed nails with 2 or 3 interlocking screws.
3212831|NCT01106950|Experimental|Treated Patients|Patients are treated with donor natural killer cells, fludarabine, cyclophosphamide, Denileukin diftitox, Donor lymphapheresis and IL-2.
3212832|NCT01106937||Patients with low Factor XIII|Postoperative occurence of pulmonary embolism in patients scheduled to undergo a neurosurgical procedure with laboratory-confirmed low levels of Factor XIII
3212833|NCT01106924|Experimental|Probiotic|daily probiotic consumption
3212834|NCT01106924|Placebo Comparator|Placebo|daily placebo consumption
3212835|NCT01106898|Experimental|Treatment (chemotherapy with or without maintenance therapy)|"SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity."
3212836|NCT01106885|No Intervention|Enhanced Usual Care|"Adult patients with diabetes and depression.~Report screening results~Notify PCP of screening results (optional per patient)~PCP referrals~Educational materials regarding diabetes, physical activity, and depression"
3212837|NCT01106885|Experimental|Staged Care Management|Adult patients with diabetes and depression
3212838|NCT01106872|Experimental|Treatment|Bevacizumab Combined with Gemcitabine, Docetaxel and Valproic Acid in Advanced Sarcoma
3212839|NCT01106859|Active Comparator|zopiclone|Zopiclone is taken at bedtime 9 hours before driving. The middle-of-the-night medication is a placebo matching zolpidem tartrate sublingual tablet.
3212840|NCT01106859|Experimental|zolpidem 3 hours prior|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is zolpidem tartrate sublingual tablet taken 3 hours prior to driving.
3212841|NCT01106859|Experimental|zolpidem 4 hours prior|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is zolpidem tartrate sublingual tablet taken 4 hours prior to driving.
3212842|NCT01106859|Placebo Comparator|Placebo|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is a placebo matching zolpidem tartrate sublingual tablet.
3212843|NCT01106846|Placebo Comparator|Group A: Saline group|Group A: Saline group , infusion of saline intravenously
3212844|NCT01106846|Active Comparator|Group B: 1% Ketamine group|Group B: Infusion of ketamine 1% intravenously
3212845|NCT01106833|Active Comparator|calcineurin inhibitor|Sirolimus + calcineurin inhibitor + prednisone
3212846|NCT01106833|Experimental|Sirolimus and prednisone|Sirolimus + prednisone
3212847|NCT01106820|Active Comparator|Resistance training|
3212848|NCT01106820|Active Comparator|Relaxation training|
3212849|NCT01106807|Experimental|CD07223 1.5% gel|500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks and Epiduo vehicle gel on the other half-face
3212850|NCT01106807|Experimental|CD07223 0.5% gel|500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks and Epiduo vehicle gel on the other half-face
3212851|NCT01106807|Active Comparator|Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel|500 microliters of Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel on one half-face and 500 microliters of the Epiduo vehicle gel on the other half-face in the morning and in the afternoon, 500 microliters of Epiduo vehicle gel on both half-faces
3212852|NCT01106794||Patient samples|Fresh-frozen and fixed tumor samples, correspondent normal brain tissue samples, cerebrospinal fluid, urine, and serum samples from patients affected with diffuse intrinsic pontine glioma or brainstem glioma
3212853|NCT01106781||1|Patients in this group should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation.
3212854|NCT01106768||test cohort|Evaluation of oral health needs of children with attention deficit disorder with or without hyperactivity
3212855|NCT01106768||not disorder cohort|children without attention deficit disorder
3212856|NCT01106755|Experimental|hemiparetic gait|gait training on ground level
3212857|NCT01106742|Experimental|AndoSan, UC|AndoSan as a supplement to 10 UC patents
3212858|NCT01106742|Experimental|AndoSan, CD|AndoSan as a supplement to 10 CD patients.
3212859|NCT01106729|Other|Cyanidin 3 glucoside|
3212860|NCT01106716|Placebo Comparator|A1: Placebo|Placebo
3212861|NCT01106716|Experimental|A2: KAI-1678|Experimental
3212862|NCT01106716|Active Comparator|A3: Lidocaine|Lidocaine
3212863|NCT01106703|Experimental|PG102 group|
3212864|NCT01106703|Placebo Comparator|placebo group|
3212865|NCT01106690|Other|Placebo/Sitagliptin|Each patient will receive matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients will be switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.
3212866|NCT01106690|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.
3212867|NCT01106690|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.
3212868|NCT01106677|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
3212869|NCT01106677|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
3212870|NCT01106677|Active Comparator|Sitagliptin 100 mg|Each patient will receive 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
3212871|NCT01106677|Other|Placebo/Sitagliptin|Each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52. Placebo and sitagliptin will be given with protocol-specified doses of metformin immediate release.
3212872|NCT01106664|Placebo Comparator|P|
3212873|NCT01106664|Experimental|E|
3212874|NCT01106651|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
3212875|NCT01106651|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
3212876|NCT01106651|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
3212877|NCT01106638|Experimental|Intensive behavioral intervention|Eight session, behavioral intervention targeting HIV-infected smokers
3212878|NCT01106638|Active Comparator|Standard care|Advice to quit, smoking cessation brochure, offer of nicotine patch
3212879|NCT01106625|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
3212880|NCT01106625|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
3212881|NCT01106625|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
3212882|NCT01106612|Experimental|Initial coronary CT angiography|EKG-gated, computed tomography angiography of the coronary arteries during heart rate control
3212883|NCT01106612|Active Comparator|Initial nuclear stress test|Stress radionuclide myocardial perfusion imaging
3212884|NCT01106599|Experimental|A|
3212885|NCT01106586|Experimental|Stribild|
3212886|NCT01106586|Active Comparator|ATV/r + FTC/TDF|
3212887|NCT01106560|Active Comparator|Anterior Approach Group|(AMIS)
3212888|NCT01106560|Active Comparator|Posterior Approach Group|(Posterior)
3212889|NCT01106547|Experimental|Methylprednisolone|
3212890|NCT01106547|Placebo Comparator|placebo/sodium chloride|
3212891|NCT01106534|Placebo Comparator|12 month DAPT arm|placebo + aspirin
3212892|NCT01106534|Active Comparator|30 month DAPT arm|clopidogrel + aspirin OR prasugrel + aspirin
3212893|NCT01106521|Experimental|PBSI|PBSI is a form of accelerated partial breast irradiation involving the insertion of 103-palladium stranded seeds under ultra-sound guidance and light sedation after CT planning in lieu of whole breast adjuvant radiotherapy.
3212894|NCT01106508|Experimental|LEQ506|
3212983|NCT01105936|Experimental|Paracetamol caplets|Two 665 mg sustained release paracetamol caplets administered orally with water.
3212895|NCT01106495|Experimental|Enhanced External Counterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. Patients with subclinical atherosclerosis whose serum LDL high than 160mg/ml receive EECP 1- hour session every working day over a 7 week period. Simvastatin is used to decrease cholesterol level for 7 weeks.
3212896|NCT01106495|Active Comparator|Control|Subjects whose LDL higher than 160 mg/dl with subclinical atherosclerosis. Simvastatin is used to decrease cholesterol level for 7 weeks.
3212897|NCT01106482|Active Comparator|Arm 1|
3212898|NCT01106482|Active Comparator|Arm 2|
3212899|NCT01106482|Active Comparator|Arm 3|
3212900|NCT01106482|Active Comparator|Arm 4|
3212901|NCT01106469|Experimental|001|JNJ-41443532 25mg tablet once daily
3212902|NCT01106469|Experimental|002|JNJ-41443532 100mg tablet once daily
3212903|NCT01106469|Experimental|003|JNJ-41443532 250mg tablet once daily
3212904|NCT01106469|Experimental|004|JNJ-41443532 500mg once daily (with 250mg tablets)
3212905|NCT01106469|Experimental|005|JNJ-41443532 1000mg once daily (with 250mg tablets)
3212906|NCT01106469|Experimental|006|JNJ-41443532 1500mg once daily (with 250mg tablets)
3212907|NCT01106469|Placebo Comparator|007|Placebo Matching placebo
3212908|NCT01106456|Experimental|All Nations Breath of Life (ANBL)|"All participants in the proposed study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT) then randomized into either the culturally-tailored All Nations Breath of Life program (ANBL) or Nontailored program (NT)."
3212909|NCT01106456|Experimental|Nontailored (NT)|"All participants in the proposed study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT) then randomized into either the culturally-tailored All Nations Breath of Life program (ANBL) or Nontailored program (NT)."
3212910|NCT01106443|Active Comparator|Total Thyroidectomy - CLND|Total thyroidectomy without central lymph node dissection.
3212911|NCT01106443|Experimental|Total Thyroidectomy +CLND|Total thyroidectomy with central lymph node dissection.
3212912|NCT01106443|Experimental|Hemi-thyroidectomy + CLND|Hemi-thyroidectomy with central lymph node dissection.
3212913|NCT01106443|Active Comparator|Hemi-thyroidectomy - CLND|Hemi-thyroidectomy without central lymph node dissection.
3212914|NCT01106430|Experimental|Lisdexamfetamine Dimesylate|
3212915|NCT01106430|Active Comparator|Atomoxetine Hydrochloride|
3212916|NCT01106417|Experimental|NeoFuse|Anterior Cervical Discectomy and Fusion with NeoFuse
3212917|NCT01106417|Active Comparator|MasterGraft Granules|Anterior Cervical Discectomy and Fusion with MasterGraft Granules
3212918|NCT01106404|Other|6-week AdaptiveStim followed by 6-week manual programming|
3212919|NCT01106404|Other|6-week manual followed by 6-week AdaptiveStim programming|
3212920|NCT01106391|Experimental|AAA stent graft system|Abdominal aortic aneurysm stent graft system
3212921|NCT01106378||NEVO™ Sirolimus-eluting Coronary Stent System.|Subjects treated during routine clinical practice with the NEVO™ Sirolimus-eluting Coronary Stent System and diagnosed with acute STEMI for primary intervention and/or diabetes mellitus and/or multi vessel disease.
3212922|NCT01106378||CYPHER Select® Plus Coronary Stent|Subjects treated during routine clinical practice with the CYPHER Select® Plus Coronary Stent System and diagnosed with acute STEMI for primary intervention and/or diabetes mellitus and/or multi vessel disease
3212923|NCT01106365|Experimental|prefrontal cortex (PFC)|rTMS with the H-coil to the prefrontal cortex (PFC)
3212924|NCT01106365|Active Comparator|motor cortex|rTMS with the H-coil to the motor cortex
3212925|NCT01106365|Sham Comparator|sham treatment|sham treatment
3212926|NCT01106352|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) + docetaxel|Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection. In the randomized phase IIa part of the protocol, the dose established in the dose-escalation part of the protocol (Phase I) will be used, i.e. 5 doses of 50 kBq/kg b.w. every 6 weeks in combination with the approved step-down dose of docetaxel (60 mg/m^2) administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone.
3212927|NCT01106352|Active Comparator|Docetaxel|Docetaxel (75 mg/m2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m^2 is allowed as per the approved docetaxel label.
3212928|NCT01106339||A|Patients with somatoform disorders due to DSM-IV
3212929|NCT01106326|Experimental|Intervention|"Teens participating in this study will have:~directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study~three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications)."
3212930|NCT01106300||Multi-organ failure|Sedated ventilated patients in multi-organ failure
3212931|NCT01106300||Single-organ failure|Sedated ventilated patients in single organ failure
3212932|NCT01106287|Experimental|Treatment Sequence 1|Period 1: Placebo - Period 2: 80 mg - Period 3: 100 mg - Period 4: Placebo - Period 5: 140 mg
3212933|NCT01106287|Experimental|Treatment Sequence 2|Period 1: 60 mg - Period 2: 80 mg - Period 3: 100 mg - Period 4: 120 mg - Period 5: Placebo
3212934|NCT01106287|Experimental|Treatment Sequence 3|Period 1: 60 mg - Period 2: Placebo - Period 3: 100 mg - Period 4: 120 mg - Period 5: 140 mg
3212935|NCT01106287|Experimental|Treatment Sequence 4|Period 1: 60 mg - Period 2: 80 mg - Period 3: Placebo - Period 4: 120 mg - Period 5: 140 mg
3212936|NCT01106261|Experimental|Pulmonary metastasectomy|Pulmonary metastasectomy
3212937|NCT01106261|Active Comparator|Active monitoring|Active monitoring
3212938|NCT01106248|Other|Eribulin Mesylate|
3212939|NCT01106235|Experimental|Treatment (immunostimulant, autologous lymphocytes, and chemo)|Patients receive cyclophosphamide IV on days -3 and -2 followed by an infusion of IL-21 modulated, MART-1 specific CD8+ cytotoxic T lymphocytes over 30-60 minutes on day 0. Beginning within 24 hours of T cell infusion, patients receive low-dose aldesleukin SC BID for 14 days in the absence of disease progression or unacceptable toxicity.
3213064|NCT01105429|Active Comparator|BMS-820132 (3 mg) or Placebo|
3212940|NCT01106209||Prematurely born infants in the NICU|Preterm infant patients delivered at UUMC and hospitalized in the NICU who are ≤1500 grams or <30 weeks gestational age at birth
3212941|NCT01106209||Healthy term infants|Term infants delivered at UUMC without complication, either via cesarean section or vaginal delivery
3212942|NCT01106209||Infants having surgery at <1 year old|Infants admitted to the PCMC same-day surgery unit in preparation for elective surgery within the first year of life
3212943|NCT01106196||MI plus respiratory illness|Patients with an incident myocardial infarction who also have a record of a visit to primary care with a respiratory tract infection
3212944|NCT01106183|Active Comparator|Transfer Factor|Transfer factor supplement; 2 capsules per day
3212945|NCT01106183|Placebo Comparator|Sugar pill|
3212946|NCT01106170|Experimental|Arm 1|Participants will consume 330 mg of Provex CV supplement, by mouth, per day, for 4 weeks followed by 4 weeks of 330 mg of placebo (cornstarch)
3212947|NCT01106170|Experimental|Arm 2|Participants will consume 330 mg placebo (cornstarch), by mouth, per day for 4 weeks followed by 4 weeks of 330 mg of ProvexCV for 4 weeks.
3212948|NCT01106157|Experimental|Anti-Thymocyte Globin plus pegylated GCSF|Subjects will receive an infusion of Anti-Thymocyte Globin (ATG) followed by 6 doses of pegylated GCSF every 2 weeks for 10 weeks.
3212949|NCT01106157|Placebo Comparator|Placebo|Saline infusion will be given on both Day 1 and Day 2 followed by placebo injection given in identical volumes in identical syringes in the identical subcutaneous manner
3212950|NCT01106144||Acute myeloid leukemia|
3212951|NCT01106131|Experimental|CKD-501 0.5mg|
3212952|NCT01106131|Active Comparator|Pioglitazone 15mg|
3212953|NCT01106118||Group 1|
3212954|NCT01106105||control (Body Mass Index < 25)|
3212955|NCT01106105||Obese (Body Mass Index > 35)|
3212956|NCT01106092|Experimental|GSK2036874A GROUP 1|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 1) intramuscularly into the anterolateral region of the left thigh, at Day 0.
3212957|NCT01106092|Experimental|GSK2036874A GROUP 2|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 2) intramuscularly into the anterolateral region of the left thigh, at Day 0.
3212958|NCT01106092|Experimental|GSK2036874A GROUP 3|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 3) intramuscularly into the anterolateral region of the left thigh, at Day 0.
3212959|NCT01106092|Active Comparator|ZILBRIX/HIB/POLIORIX GROUP|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of Zilbrix/Hib™ and Poliorix™ vaccines at Day 0, administered intramuscularly into the anterolateral regions of the left and right thighs, respectively.
3212960|NCT01106079|Experimental|Intensive management|
3212961|NCT01106079|Active Comparator|Standard management|
3212962|NCT01106066|Experimental|S-1/oxaliplatin/RT|Radiotherapy + 4 dose levels of oxaliplatin/S-1
3212963|NCT01106053|Experimental|Pramipexole|Open-label trial of pramipexole.
3212964|NCT01106040|Experimental|Lymphoseek, Lymphatic mapping, Injection|
3212965|NCT01106027|Experimental|Eculizumab|"Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery. Patients will be given 900 mg of eculizumab on Day 1 post-transplant. Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant.~At week 4, patients will be assessed for donor specific anti-donor human leukocyte antigen (HLA) antibody (DSA). Patients with total DSA normalized values <5000 will stop eculizumab treatment. Patients with total DSA normalized values >5000 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly."
3212966|NCT01106014|Experimental|1|Selexipag is up-titrated from Day 1 to Week 12 to each patient's maximum tolerated dose in the range of 200-1600 µg twice a day (b.i.d.) in 200 µg steps starting with one 200 µg oral tablet on Day 1. From Day 2 onwards, a b.i.d. dose regimen with an interval of approximately 12 hours is followed. If this dose (selexipag 200 μg b.i.d.) is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg. Up-titration is followed by a stable maintenance treatment period from Week 12 onwards, up to Week 26, at the maximum tolerated dose
3212967|NCT01106014|Placebo Comparator|2|Matching placebo is administered orally with a dosing interval of approximately12 h. A (mock) up-titration scheme is followed
3212968|NCT01106001|Active Comparator|Levobupivacaine|Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children
3212969|NCT01106001|Placebo Comparator|Saline|Saline (also saline solution) is a general term referring to a sterile solution of sodium chloride (NaCl, more commonly known as salt) in water but is only sterile when it is placed intravenously, otherwise, a saline solution is a salt water solution.
3212970|NCT01105975|Experimental|30 milligram (mg) LY2484595 monotherapy|
3212971|NCT01105975|Experimental|100 mg LY2484595 monotherapy|
3212972|NCT01105975|Experimental|500 mg LY2484595 monotherapy|
3212973|NCT01105975|Placebo Comparator|Placebo|
3212974|NCT01105975|Active Comparator|20 mg Atorvastatin monotherapy|
3212975|NCT01105975|Experimental|100 mg LY2484595 + 20 mg Atorvastatin|
3212976|NCT01105975|Active Comparator|40 mg Simvastatin monotherapy|
3212977|NCT01105975|Experimental|100 mg LY2484595 + 40 mg Simvastatin|
3212978|NCT01105975|Active Comparator|10 mg Rosuvastatin monotherapy|
3212979|NCT01105975|Experimental|100 mg LY2484595 + 10 mg Rosuvastatin|
3212980|NCT01105949|Other|Marketed nasal strip|Marketed nasal strip
3212981|NCT01105949|Experimental|NexGen JB Organic PET/PE|NexGen JB Organic PET/PE, prototype nasal dilator strip
3212982|NCT01105949|Experimental|NexGen AB 2R11|NexGen AB 2R11
3213065|NCT01105429|Active Comparator|BMS-820132 (10 mg) or Placebo|
3212984|NCT01105936|Placebo Comparator|Placebo caplets|Two placebo caplets administered orally with water.
3212985|NCT01105923|Experimental|Receive CDS intervention|Providers in clinics that will receive the CDS alert, as their clinic was randomized into our study.
3212986|NCT01105923|No Intervention|No CDS intervention|
3212987|NCT01105910|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
3212988|NCT01105910|Active Comparator|Sensitive Eyes|Sensitive Eyes Eye Drops (Bausch & Lomb)
3212989|NCT01105897||Surgically treated endometriosis patients|Women scheduled for operation on suspected endometriosis in two study hospitals specialized in the surgical treatment of endometriosis between January 2005 - December 2007 (Päijät-Häme Central Hospital) and January 2008 - December 2008 (Helsinki University Hospital).
3212990|NCT01105884|Active Comparator|Group 1|
3212991|NCT01105884|Active Comparator|Group 2|
3212992|NCT01105884|Active Comparator|Group 3|
3212993|NCT01105884|Active Comparator|Group 4|
3212994|NCT01105884|Active Comparator|Group 5|
3212995|NCT01105871|Active Comparator|naloxone|4 mg in 10 ml saline iv bolus
3212996|NCT01105871|Placebo Comparator|saline placebo|10 ml of normal saline iv bolus
3212997|NCT01105832|Experimental|Proximal humeral fracture - intervention|20 patients will be randomized to 20 micrograms daily of Teriparatide (Forsteo)
3212998|NCT01105832|No Intervention|Proximal humeral fracture|20 patients will receive standard treatment (physiotherapy)
3212999|NCT01105819|Other|Standard oral care with chlorhexidine|The control group will receive a standard oral care. This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed
3213000|NCT01105819|Active Comparator|Lactobacillus plantarum 299|The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
3213001|NCT01105806||cardiopulmonary resuscitation (CPR) video|This pilot study involves a two-arm parallel design comparing the effectiveness of a CPR video versus a CPR narrative script in advance directive (AD) completion over a 1 month time frame post intervention.
3213002|NCT01105806||cardiopulmonary resuscitation (CPR) narrative script|This pilot study involves a two-arm parallel design comparing the effectiveness of a CPR video versus a CPR narrative in advance directive (AD) completion over a 1 month timeframe post intervention.
3213003|NCT01105780|Experimental|001|JNJ-41443532 250mg tablet once daily for 1 day
3213004|NCT01105780|Placebo Comparator|002|Placebo Matching placebo
3213005|NCT01105767|No Intervention|Group 1 Standard|Trainees received a preventive medicine briefing augmented with SSTI and MRSA SSTI prevention information and personal hygiene instructions. Trainees seeking medical care for an SSTI received standardized SSTI care (e.g., antimicrobial therapy, wound management, patient education) at the Troop Medical Clinic. High-touch common surfaces within the battalion areas were cleaned with standard Environmental Protection Agency-registered disinfectants.
3213006|NCT01105767|Active Comparator|Group 2 Enhanced Standard|Trainees received the components of the Standard group as well as supplemental training, education and hygiene. They were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit. Supplemental SSTI education for trainees and drill sergeants was also provided (e.g., pocket cards, posters). Drill sergeants received briefings on SSTI and skin inspection/minor wound care.
3213007|NCT01105767|Active Comparator|Group 3 Chlorhexidine|Trainees received the components of the Standard and Enhanced Standard groups and were offered chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) to use with a wash cloth after using their personal soap for the additional once-weekly shower. Trainees were provided with verbal and written/graphic instructions for use.
3213008|NCT01105754|No Intervention|Standard Care|Parents of children in the standard care group will complete the baseline assessment, but no asthma prompt will be created for either the caregiver or provider, and no information regarding the interview will be shared with the provider. After the baseline assessment, the office visit will proceed according to usual care.
3213009|NCT01105754|Experimental|Multifaceted Prompting Intervention|Multifaceted Prompting Intervention
3213010|NCT01105741||Active Crohn's disease - single arm|Active Crohn's disease, a decision is made to start treatment with adalimumab.
3213011|NCT01105728|Experimental|Study arm|Endoscopic resection
3213012|NCT01105715||Rheumatoid Arthritis (RA) Case Subjects|"Fulfill the American College of Rheumatology (ACR) 1987 Classification Criteria for RA~Have currently active disease as assessed by Clinical Disease Activity Index (CDAI) score of >10~Have > or = 3 swollen joints"
3213013|NCT01105715||Control Subjects|"Age, sex, and 5-year age categories matched to cases~No historical diagnosis of RA and other primary autoimmune or inflammatory disorders"
3213014|NCT01105702|Experimental|TBL/RT|"Cycle 1(One 42-day cycle)~Temozolomide 75 mg/m^2 orally (42 consecutive days), beginning the night prior to the first radiation treatment~Radiation within 3-5 weeks of surgery~Bevacizumab 10mg/kg, IV, starting 29 (+3) days post surgery and every 2 weeks~Treatment Cycles 2-7 (28 days per cycle)~Temozolomide at a dose of 150 mg/m^2 on Days 1-7~Bevacizumab 10 mg/kg on Day 8 and Day 22~Initiate Lithium carbonate treatment at 300 mg, orally, twice a day; dose increased every 7 days up to 600mg, orally, twice a day, to a serum lithium level of 0.8-1.2 mEq/L."
3213015|NCT01105676|Experimental|single group single arm study|Open no masking is used. All involved know the identity of the intervention assignment
3213016|NCT01105663||Sedated, Intubated, Morphine|Subjects will receive morphine/midazolam as part of clinical care. Pharmacokinetic and pharmacogenetic sampling and pharmacodynamic monitoring will occur as indicated. Pharmacokinetic samples will be assayed in the laboratory of the Division of Clinical Pharmacology and Therapeutics. Pharmacogenetic samples will be assayed in the laboratory of the Center for Applied Genomics at CHOP.
3213061|NCT01105442||Levobupivacaine|Patients who received levobupivacaine and morphine on demand
3213062|NCT01105429|Active Comparator|BMS-820132 (0.3 mg) or Placebo|
3213017|NCT01105663||Sedated, Intubated, Midazolam|Subjects will receive morphine/midazolam as part of clinical care. Pharmacokinetic and pharmacogenetic sampling and pharmacodynamic monitoring will occur as indicated. Pharmacokinetic samples will be assayed in the laboratory of the Division of Clinical Pharmacology and Therapeutics. Pharmacogenetic samples will be assayed in the laboratory of the Center for Applied Genomics at CHOP.
3213018|NCT01105650|Experimental|Arm 1: CsA|Patients receiving Cyclosporine (CsA) and Natural Killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
3213019|NCT01105650|Experimental|Arm 2: CsA plus Methylprednisolone (10mg)|Patients receiving Cyclosporine (CsA), methylprednisolone and natural killer cells (NK) infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
3213020|NCT01105650|Experimental|Arm 3: CsA plus Methylprednisolone (1 mg)|Patients receiving Cyclosporine (CsA), methylprednisolone and natural killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
3213021|NCT01105650|Experimental|Arm 4: CsA minus Methylprednisolone|Patients receiving Cyclosporine (CsA), no methylprednisolone, eliminating IL-2 doses 4-6 and receiving Natural Killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 3 doses given post NK cell infusion.
3213022|NCT01105637|Other|Exercise|
3213023|NCT01105624|Experimental|azithromycin ophthalmic solution, 1%|
3213024|NCT01105624|Experimental|rewetting drops|
3213025|NCT01105611|Experimental|Raltegravir|Raltegravir in combination with Tenofovir/Emtricitabine
3213026|NCT01105611|Active Comparator|Atazanavir/Ritonavir|Atazanavir 300mg orally once daily with Ritonavir 100mg orally once daily; together with combination of Tenofovir/Emtricitabine
3213027|NCT01105598|Experimental|Cohort 1|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
3213028|NCT01105598|Experimental|Cohort 2|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
3213029|NCT01105598|Experimental|Cohort 3|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
3213030|NCT01105598|Experimental|Cohort 4|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
3213031|NCT01105598|Experimental|Cohort 5|Free-living subjects (18 active/6 placebo) with mild dyslipidemia
3213032|NCT01105585|Experimental|ZCB00 IOL|Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens (IOL) randomly assigned to one eye, with AcrySof Natural IQ (SN60WF) IOL in the fellow eye for contralateral implantation
3213033|NCT01105585|Active Comparator|SN60WF IOL|AcrySof Natural IQ (SN60WF) intraocular lens (IOL) randomly assigned to one eye, with Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens in the fellow eye for contralateral implantation
3213034|NCT01105572|Experimental|Intel Home Health Guide|Participants in the intervention group will receive the use of the Intel Healthguide, an Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback when transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager. Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care. Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes.
3213035|NCT01105572|No Intervention|Case Management Only|All participants in the comparison group, are identified for outreach and assistance by a nurse case manager. Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care. Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes.
3213036|NCT01105559||Group 1|Participants previously received 3 doses and a booster dose of the investigational vaccine DTaP IPV Hep B PRP-T.
3213037|NCT01105559||Group 2|Participants previously received 3 doses CombAct-Hib™ + Engerix™ B + OPV and a booster dose of CombAct-Hib™ + Oral poliovirus vaccine (OPV) vaccine.
3213038|NCT01105559||Group 3|Participants previously received 3 doses DTaP IPV Hep B PRP-T; a dose of Engerix™ B at birth, and a booster dose of DTaP IPV Hep B PRP-T vaccine.
3213039|NCT01105546|Experimental|prophylaxis|prophylaxis with recombinant activated FVII 90 µg/kg/day i.v.
3213040|NCT01105546|Active Comparator|on demand treatment|treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
3213041|NCT01105533|Experimental|Cohort 1|
3213042|NCT01105533|Experimental|Cohort 2|
3213043|NCT01105533|Experimental|Cohort 3|
3213044|NCT01105533|Experimental|Cohort 4|
3213045|NCT01105533|Experimental|Cohort 5|
3213046|NCT01105533|Experimental|Cohort 6|
3213047|NCT01105533|Experimental|Cohort 7|
3213048|NCT01105533|Experimental|Cohort 8|
3213049|NCT01105533|Experimental|Cohort 9|
3213050|NCT01105533|Experimental|Cohort 10|
3213051|NCT01105520||intralspinal processes|Patients with intralspinal processes
3213052|NCT01105507|Experimental|canakinumab arm|
3213053|NCT01105481|Experimental|amisulpride add-on|
3213054|NCT01105481|Placebo Comparator|placebo add-on|
3213055|NCT01105468||Mamma Carcinoma, no treatment|
3213056|NCT01105468||Mamma Carcinoma, treatment|
3213057|NCT01105468||No Mamma Carcinoma diagnosed by X-ray|
3213058|NCT01105455|Placebo Comparator|High fiber|High fiber carbohydrate foods with a high / medium glycemic index. Whole wheat bread and/or brown rice are provided to subjects if they wish. Subjects are provided with a list of other recommended carbohydrate foods.
3213059|NCT01105455|Active Comparator|Low GI|Carbohydrate foods with a low glycemic index. Low GI rice and whole grain bread provided to subjects if they wish. Subjects are provided with a list of recommended foods.
3213060|NCT01105442||Bupivacaine|Patients who received bupivacaine + sufentanil
3213066|NCT01105429|Active Comparator|BMS-820132 (30 mg) or Placebo|
3213067|NCT01105429|Active Comparator|BMS-820132 (75 mg) or Placebo|
3213068|NCT01105429|Active Comparator|BMS-820132 (150 mg) or Placebo|
3213069|NCT01105429|Active Comparator|BMS-820132 (300 mg) or Placebo|
3213070|NCT01105429|Active Comparator|BMS-820132 (TBD) or Placebo|
3213071|NCT01105416|Placebo Comparator|Enhanced Standard Care (ESC)|Standard emergency department care plus informational brochures
3213072|NCT01105416|Experimental|Brief Prevention Intervention (BPI)|Brief Prevention Intervention in the Pediatric ED
3213073|NCT01105403|Experimental|CD34+ mobilisation for transplantation|
3213074|NCT01105390|Experimental|Treatment (rilotumumab, cisplatin, pemetrexed disodium)|Patients receive anti-HGF monoclonal antibody AMG 102 (AMG 102) IV over 1 hour, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without disease progression may continue AMG 102 IV over 1 hour on day 1, every 3 weeks, as maintenance therapy in the absence of disease progression.
3213075|NCT01105377|Experimental|Treatment (entinostat, azacitidine)|Patients receive azacitidine subcutaneously on days 1-5 and 8-10 and oral entinostat on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3213076|NCT01105351|Active Comparator|folic acid plus B6 and B12|folic 400 µg plus vitamin B12 plus B6
3213077|NCT01105351|Placebo Comparator|Folic acid|folic acid alone
3213078|NCT01105338|Active Comparator|Green tea drink|Green tea drink
3213079|NCT01105338|Active Comparator|Green tea capsules|Green tea capsules
3213080|NCT01105338|Placebo Comparator|Green tea placebo capsules|Green tea placebo capsules
3213081|NCT01105338|Active Comparator|Lycopene capsules|Lycopene capsules
3213082|NCT01105338|Placebo Comparator|Lycopene placebo capsules|Lycopene placebo capsules
3213083|NCT01105338|Active Comparator|Tomato rich diet|Tomato rich diet
3213084|NCT01105312|Experimental|panobinostat (LBH589) and letrozole|Each patient will receive panobinostat (LBH589) and letrozole. Patients will be administered LBH589 PO, 3 days per week for a total of 4 weeks. Patients will also be administered letrozole 2.5 mg PO Days 1-28 every 4 weeks. There are two phases of the study. The first phase determines the maximum tolerated dose for LBH589 in combination with letrozole. The second phase is to assess and confirm the response rate and safety profile of LBH589 in combination with letrozole.
3213085|NCT01105286|Experimental|Calcipotriol ointment|
3213086|NCT01105273|Experimental|HAPLO|
3213087|NCT01105260||control|group with classical rehabilitation program
3213088|NCT01105260||training|group with an 8 weeks interval training program on wheelchair independence
3213089|NCT01105247|Experimental|PCI-32765|
3213090|NCT01105234|Experimental|Calcipotriol ointment|
3213091|NCT01105221|Experimental|Acupuncture|
3213092|NCT01105221|Active Comparator|Artificial tear drop|
3213093|NCT01105208|Experimental|Arm 1|
3213094|NCT01105208|Active Comparator|Arm 2|
3213095|NCT01105195|Active Comparator|DuraPrep|
3213096|NCT01105195|Active Comparator|ChloraPrep|
3213097|NCT01105182||Radiofrequency Ablation|
3213098|NCT01105169|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate.
3213099|NCT01105169|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
3213100|NCT01105169|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
3213101|NCT01105169|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
3213102|NCT01105156||Gastric Band Patients|
3213103|NCT01105143|Active Comparator|lifestyle intervention|Multimodal lifestyle intervention to reduce body weight
3213104|NCT01105143|Placebo Comparator|placebo|placebo
3213105|NCT01105130|Placebo Comparator|Arm I - Placebo|Patients receive oral placebo twice daily (total of 6 capsules per day).
3213106|NCT01105130|Experimental|Arm II - low dose|Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).
3213107|NCT01105130|Experimental|Arm III - high dose|Oral L-arginine twice daily = 6 capsules per day.
3213108|NCT01105117|Active Comparator|1|ACT-385781A (Actelion Epoprostenol)
3213109|NCT01105117|Active Comparator|2|Flolan®
3213110|NCT01105104|Other|MedMinder System|
3213111|NCT01105104|Other|MedMinder System - deactivated|
3213112|NCT01105091|Active Comparator|1|ACT-385781A (Actelion Epoprostenol)
3213113|NCT01105091|Active Comparator|2|Flolan®
3213114|NCT01105078|Other|Flow rate|Comparison between a flow rate of 2.5/l/min/m2 versus 3.0/l/min/m2
3213115|NCT01105065|Experimental|Patients with RVD|Patients who exhibited retinal vascular dysregulation at the initial visit. Intervention: brimonidine 0.15% three times per day for 8 weeks.
3213116|NCT01105052|Active Comparator|Bibliotherapy|A group receiving a self-help book to work on for six weeks with no therapist support.
3213117|NCT01105052|Experimental|Bibliotherapy with support|A group receiving a self-help book to work on for six weeks, together with brief weekly telephone calls (<15 minutes) from a therapist.
3213118|NCT01105052|No Intervention|Wait-list control group|This group receives no intervention until about five months after the two treatment groups, when participants in this group receive the self-help book without therapist support.
3213119|NCT01105039||lap. hernia repair|undergoing laparoscopic groin hernia repair
3213120|NCT01105026|Experimental|bioactive glass|
3213121|NCT01105013|Experimental|tonaftato|Apply the product in sufficient quantity to cover the affected area 2 times daily (every 12 hours) for 60 days.
3213122|NCT01104987||alendronate|A cross sectional study assessing the prevalence of osteoporosis and vertebral fractures in AS has been conducted during the spring in 2009. Patients with osteoporosis that fulfilled the inclusion criteria and did not have any exclusion criteria for the present trial were asked to join this study.
3213123|NCT01104961|Experimental|Contact Lens Packaging Solution #1|Test solution - contact lens packaging solution
3213124|NCT01104961|Experimental|Contact lens packaging solution #2|Test solution - contact lens packaging solution
3213125|NCT01104961|Placebo Comparator|Balanced salt solution|Control solution
3213126|NCT01104948|Experimental|DA-8031|
3213127|NCT01104948|Placebo Comparator|Placebo|
3213128|NCT01104935|Experimental|trastuzumab monotherapy|"H group (trastuzumab monotherapy group)~Trastuzumab: 1-year treatment~Loading dose, 8 mg/kg; from 2nd dose, 6 mg/kg; iv inj, qw, 18 times"
3213129|NCT01104935|Active Comparator|trastuzumab and chemotherapy|"H+CT group (combination therapy of trastuzumab and chemotherapy)~Chemotherapy: 12 to 24 weeks~Select chemotherapy from certain regimens (PTX, DTX, TC, AC, EC, FEC, CMF and TCb (CBDCA)) based on decision of a physician or a patient. Initiate administration of trastuzumab after completion of chemotherapy as a sequential combination. However, concomitant administration is allowed when combining trastuzumab with PTX, DTX and CMF. In cases of TCb (CBDCA), trastuzumab is used concomitant administration."
3213130|NCT01104909|Active Comparator|Clinical dry weight|Group which the dry weight will be assessed based on clinical examination.
3213131|NCT01104909|Active Comparator|Bioimpedance|Group which the dry weight will be assessed by bioimpedance data.
3213132|NCT01104896|Active Comparator|Nicotine|One or two 15mg nicotine patch(es) applied from 6am to 10pm according to the patients tobacco dependence measured by the Fagerström scale.
3213133|NCT01104896|Placebo Comparator|Placebo|One or two patch(es) with placebo
3213134|NCT01104883|Experimental|Adductor-Canal-Blockade|Adductor-Canal-Blockade with ropivacaine
3213135|NCT01104883|Placebo Comparator|Adductor-Canal-blockade with saline|Adductor-Canal-blockade with isotonic saline
3213136|NCT01104870|Active Comparator|Dose Group 1|UT-15C 0.25 mg twice daily
3213137|NCT01104870|Active Comparator|Dose Group 2|UT-15C 1.25 mg twice daily
3213138|NCT01104870|Active Comparator|Dose Group 3|UT-15C individual Maximum Tolerated Dose
3213139|NCT01104857|Experimental|Diaphragm muscle biopsy|Patients admitted to the ICU meeting severe sepsis / septic shock criteria
3213140|NCT01104857|Active Comparator|Elective laparotomy|
3213141|NCT01104844|Active Comparator|Half dose strength|Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg), i.e 2 tablets equating to ½ the dose in the standard investigational drug
3213142|NCT01104844|Active Comparator|Quarter dose strength|Investigational drug quarter dose strength (acetaminophen125mg + Ibuprofen 37.5mg) i.e. 2 tablets equating to ¼ the dose in the standard investigational drug.
3213143|NCT01104844|Active Comparator|Acetaminophen standard dose|Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
3213144|NCT01104844|Active Comparator|ibuprofen low dose|Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
3213145|NCT01104844|Active Comparator|Ibuprofen high dose|Ibuprofen High dose 300mg i.e. 2 tablets equating to twice the ibuprofen dose as in the standard investigational drug
3213146|NCT01104844|Placebo Comparator|placebo|2 Placebo tablets
3213147|NCT01104844|Experimental|Full Dose Strength|Investigational drug full dose strength (acetaminophen 500mg + ibuprofen 150mg) i.e. 2 tablets
3213148|NCT01104831|Placebo Comparator|21 degree Cooling|Room temperature water circulated through cryotherapy sleeve.
3213149|NCT01104831|Active Comparator|10 degree cooling|Cooled water circulated through a cryotherapy sleeve.
3213150|NCT01104805|Experimental|Therapeutic Education System (TES)|Participants randomized to this arm will replace approximately 2 hours of Standard Treatment with the Therapeutic Education System (TES) (comprised of a web-based version of the Community Reinforcement Approach and contingency management).
3213151|NCT01104805|Other|Treatment-as-Usual (TAU)|Participants randomized to TAU will receive standard treatment offered and prescribed, as usual, in the outpatient substance abuse treatment program.
3213152|NCT01104792|Experimental|1|Cariprazine flexible dose, oral administration once daily for 48 weeks
3213153|NCT01104779|Experimental|1|Cariprazine once daily fixed-flexible low dose
3213154|NCT01104779|Experimental|2|Cariprazine once daily fixed-flexible high dose
3213155|NCT01104779|Placebo Comparator|3|Placebo
3213156|NCT01104766|Experimental|1|Cariprazine low dose
3213157|NCT01104766|Experimental|2|Cariprazine high dose
3213158|NCT01104766|Active Comparator|3|Aripiprazole
3213159|NCT01104766|Placebo Comparator|4|Placebo
3213160|NCT01104753||Non-interventional post-authorisation safety study|
3213161|NCT01104727|Active Comparator|Multi port|4-Ports Cholecystectomy (4PC): a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.
3213162|NCT01104727|Active Comparator|Single port|"Single-Port Cholecystectomy (SPC): a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.~In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones."
3213163|NCT01104714||All patients|As the trial progresses, patients will be classified as either chemotherapy responders or non-responders.
3213164|NCT01104701|Active Comparator|Group A|2 mg exenatide once weekly subcutaneous (SC). This arm is used as a reference arm in the study.
3213165|NCT01104701|Experimental|Group B|Low dose 5 mg exenatide once monthly suspension SC.
3213166|NCT01104701|Experimental|Group C|Medium dose 8 mg exenatide once monthly suspension SC.
3213167|NCT01104701|Experimental|Group D|High dose 11 mg exenatide once monthly suspension SC.
3213168|NCT01104675|Experimental|ENMD-2076 treatment|
3213169|NCT01104662|Experimental|Daptomycin, Bacteremia, Severe Renal Impairment|Cohort 1. Daptomycin was given intravenously 6 milligrams per kilogram (mg/kg) per administration. For bacteremia participants with Creatinine Clearance (CLcr) below 30 milliliters per minute (mL/min) and currently receiving hemodialysis, daptomycin was administered immediately following each hemodialysis session (3 per week) for 14 to 42 days based on disease resolution or Investigator discretion. For participants not receiving dialysis, daptomycin was administered every 48 hours for 14 to 42 days based on disease resolution or Investigator discretion.
3213170|NCT01104662|Active Comparator|Vancomycin or SSP, Bacteremia, Severe Renal Impairment|Cohort 1. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by Methicillin-Susceptible Staphylococcus Aureus (MSSA) could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered intravenously (IV) until end of antibiotic therapy for bacteremia or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
3213171|NCT01104662|Experimental|Daptomycin, Bacteremia, Moderate Renal Impairment|Cohort 2. Daptomycin was given intravenously 6 milligrams per kilogram (mg/kg) per administration. For bacteremia participants with CLcr values between 30 and 50 mL/min not receiving dialysis, daptomycin was administered every 24 hours for 14 to 42 days based on disease resolution or Investigator discretion.
3213172|NCT01104662|Active Comparator|Vancomycin or SSP , Bacteremia, Moderate Renal Impairment|Cohort 2. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for bacteremia or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
3213173|NCT01104662|Experimental|Daptomycin, cSSSI, Severe Renal Impairment|Cohort 3. Daptomycin was given intravenously 4 milligrams per kilogram (mg/kg) per administration. For cSSSI participants with CLcr below 30 mL/min and currently receiving hemodialysis, daptomycin was administered immediately following each hemodialysis session (3 per week) for 7 to 14 days based on disease resolution or Investigator discretion. For participants not receiving dialysis, daptomycin was administered every 48 hours for 7 to 14 days based on disease resolution or Investigator discretion.
3213174|NCT01104662|Active Comparator|Vancomycin or SSP , cSSSI, Severe Renal Impairment|Cohort 3. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
3213175|NCT01104662|Experimental|Daptomycin, cSSSI, Moderate Renal Impairment|Cohort 4. Daptomycin was given intravenously 4 milligrams per kilogram (mg/kg) per administration. For cSSSI participants with CLcr values between 30 and 50 mL/min not receiving dialysis, daptomycin was administered every 24 hours for 7 to 14 days based on disease resolution or Investigator discretion.
3213176|NCT01104662|Active Comparator|Vancomycin or SSP , cSSSI, Moderate Renal Impairment|Cohort 4. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
3213177|NCT01104649|Experimental|Riluzole|Riluzole 50 mg is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)
3213178|NCT01104649|Placebo Comparator|Placebo comparator|Placebo is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)
3213179|NCT01104636||Single group prospective treatment cohort (varenicline)|
3213180|NCT01104623||ADHD - Patients|Adults (18-50 years old). All eligible subjects will experience the voice recording procedure followed by the assessment of adult ADHD diagnostics. The diagnostic guidelines for ADHD in adulthood will be accomplished as outlined by expert consensus of the German Society for Psychiatry, Psychotherapy and Neurology, with a semi-structured clinical interview following the DSM-IV-TR criteria and the ADHD-Checklist (ADHD-CL) for DSM-IV (Hesslinger et al., 2002) to assess the severity of ADHD-Symptoms. Childhood ADHD symptoms will be rated retrospectively amongst others by using the short version (WURS-k) of the Wender Utah Rating Scale (Ward et al., 1993), German version (Retz-Junginger et al., 2002). To strengthen the validity of the ADHD diagnosis the reported symptoms were corroborated by second party reports.
3213181|NCT01104623||Healthy Controls|Adults(18-50 years old). All eligible subjects will experience the voice recording procedure followed by the ADHD-Checklist (ADHD-CL) for DSM-IV (Hesslinger et al., 2002. To assess the severity of Non-ADHD, the absence of childhood ADHD symptoms will be rated retrospectively amongst others by using the short version (WURS-k) of the Wender Utah Rating Scale (Ward et al., 1993), German version (Retz-Junginger et al., 2002).
3213182|NCT01104610|Active Comparator|NIV-PSV without Target Volume|Pressure Support Non Invasive Ventilation without Target Volume
3213183|NCT01104610|Active Comparator|NIV-PSV with Target Volume|Non Invasive Pressure Support Ventilation with Target Volume set
3213184|NCT01104610|Active Comparator|NIV-CPAP|Pressure Support Ventilation in CPAP mode
3213185|NCT01104584|Experimental|Gadobutrol (Gadavist, BAY86-4875)|Patients first received an unenhanced magnetic resonance mammography (MRM), followed by a gadobutrol-enhanced MRM. Gadobutrol was administered at the standard dose of 0.1 mmol/kg body weight (bw) [0.1 ml/kg bw] as an intravenous injection (i.v.) at a rate of 2 ml/sec. Unenhanced MRM (UMRM) and combined unenhanced and contrast (gadobutrol)-enhanced MRM (CMRM) image sets were evaluated in a randomized fashion. After the evaluation of the UMRM or CMRM the respective X-ray mammography (XRM) was added and evaluated together with the UMRM images.
3213186|NCT01104571|Other|Part 1: Control|No peri-operative therapy given
3213187|NCT01104571|Experimental|Part 1: Trastuzumab|Trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery.
3213188|NCT01104571|Experimental|Part 1: lapatinib|Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery
3213189|NCT01104571|Other|Part 2: Control|No peri-operative therapy
3213190|NCT01104571|Experimental|Part 2: Trastuzumab|Trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery.
3213191|NCT01104571|Experimental|Part 2: lapatinib- trastuzumab combination|Lapatinib 1000mg/day p.o. continuously for 28 days, in combination with trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery. Both drugs should start 11 days (+2 or -1 day) before the scheduled surgery.
3213192|NCT01104545|Experimental|Panel A - Sequence 1|.25 mg - 1.25 mg - Pbo - 20 mg
3213193|NCT01104545|Experimental|Panel A - Sequence 2|.25 mg - 1.25 mg - 5 mg - Pbo
3213194|NCT01104545|Experimental|Panel A - Sequence 3|.25 mg - Pbo - 5 mg - 20 mg
3213195|NCT01104545|Experimental|Panel A - Sequence 4|Pbo - 1.25 mg - 5 mg - 20 mg
3213196|NCT01104545|Experimental|Panel B - Sequence 1|.5 mg - 2.5 mg - Pbo - 40 mg
3213197|NCT01104545|Experimental|Panel B - Sequence 2|.5 mg - 2.5 mg - 10 mg - Pbo
3213198|NCT01104545|Experimental|Panel B - Sequence 3|.5 mg - Pbo - 10 mg - 40 mg
3213199|NCT01104545|Experimental|Panel B - Sequence 4|Pbo - 2.5 mg - 10 mg - 40 mg
3213200|NCT01104532|Experimental|Dosing Regimen 1|
3213201|NCT01104532|Experimental|Dosing Regimen 2|
3213202|NCT01104532|Experimental|Dosing Regimen 3|
3213203|NCT01104532|Experimental|Dosing Regimen 4|
3213204|NCT01104519|Experimental|1|Niaspan - Placebo
3213205|NCT01104519|Experimental|2|Placebo - Niaspan
3213206|NCT01104506|Active Comparator|Painless plexus|Patient with a painless avulsion of brachial plexus
3213207|NCT01104506|Active Comparator|Healthy|Healthy volunteers
3213208|NCT01104506|Experimental|Painful plexus|Patient with a painful avulsion of brachial plexus
3213209|NCT01104493|Experimental|1|Single dose of monovalent vaccine
3213210|NCT01104493|Placebo Comparator|2|Placebo
3213211|NCT01104467|Experimental|Desmoteplase 70 µg/kg|
3213212|NCT01104467|Experimental|Desmoteplase 90 µg/kg|
3213213|NCT01104467|Placebo Comparator|Placebo|
3213214|NCT01104428|Placebo Comparator|placebo|
3213215|NCT01104428|Experimental|"Drug:ziying"|
3213216|NCT01104415|Experimental|LX1606 Open Label Dose Escalation|
3213217|NCT01104402|No Intervention|Standard Care|Subjects will receive education about signs and symptoms indicative of worsening CF.
3213218|NCT01104402|Active Comparator|Home monitoring|Subjects will be randomized to monitor home spirometry and symptoms using a handheld device.
3213219|NCT01104376|Experimental|CYP2B6|"Healthy volunteers will receive Efavirenz and Vericonazole as follow:~In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered. In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
3213220|NCT01104363|Experimental|Snow white Plaster 2|Test
3213221|NCT01104363|Active Comparator|Primopattern LC gel + PVS|Control
3213222|NCT01104350|Experimental|Radiotherapy and Concurrent Gemcitabine Chemotherapy|This is a Phase I dose-escalation study examining the safety and tolerability of intensity modulated external radiation therapy using image-guidance in combination with gemcitabine chemotherapy as an alternative to radical cystectomy.
3213223|NCT01104337|Experimental|Paracetamol 2g/d|18 patients on stable warfarin therapy received a 10-day regimen of paracetamol 2g/d
3213224|NCT01104337|Experimental|Paracetamol 3g/d|18 patients on stable warfarin therapy received a 10-day regimen of paracetamol 3g/d
3213225|NCT01104337|Placebo Comparator|Placebo|9 patients on stable warfarin therapy received a 10-day regimen of placebo
3213226|NCT01104311|Experimental|Aggressive BP lowering|Lowering of systolic blood pressure between 110mmHg and 120mmHg during study period
3213227|NCT01104311|Active Comparator|Modest BP lowering|Lowering of systolic blood pressure between 130mmHg and 140mmHg
3213228|NCT01104298|Active Comparator|Arm A|"Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.~Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous"
3213229|NCT01104298|Experimental|Arm B|"Trabectedin Presentation: vials with trabectedin 1 mg and sucrose 400 mg. Pharmaceutical form: A white or whitish lyophilized powder as concentrate for solution for injection.~Route of administration: for intravenous use after reconstitution and further dilution.~Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.~Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous"
3213230|NCT01104285||Standard care|Treatment of pleural effusion with diuresis
3213231|NCT01104285||Chest tube|Treatment of pleural effusion with diuresis and chest tube
3213232|NCT01104272|Experimental|Energy Level 1|Subcutaneous Adipose Tissue Treated With Energy Level 1.
3213274|NCT01103934|Active Comparator|Fluticasone Propionate plus Vitamin D3|Subjects will be treated with fluticasone propionate and Vitamin D once daily for 2 weeks during allergy season
3213496|NCT01102309|Active Comparator|Control Group (CG)|Group assigned to conventional therapy only
3213233|NCT01104259|Experimental|Treatment (veliparib with cisplatin and vinorelbine tartrate)|Patients receive veliparib PO BID on days 1-14 (days 0-13 of course 1 only). Patients also receive cisplatin IV over 1 hour on day 1 and vinorelbine ditartrate IV over 10-20 minutes on days 1 and 8. Treatment repeats every 21 days for 6-10 courses in the absence of disease progression or unacceptable toxicity. Treatment with veliparib alone may continue in the absence of disease progression or unacceptable toxicity.
3213234|NCT01104246|Experimental|Testosterone Transdermal Systems|Testosterone
3213235|NCT01104233||The soft spreading|Patients with lung cancer underwent Video-assisted Thoracoscopic Surgery (VATS) with soft spreading (using LAP Protector).
3213236|NCT01104233||The rigid spreading|Patients with lung cancer underwent Video-assisted Thoracoscopic Surgery (VATS) with rigid spreading.
3213237|NCT01104220||Lean, metabolically normal|Subjects with body mass index 18.5 - 24.9 kg/m² and normal liver fat (IHTG content ≤5%)
3213238|NCT01104220||Obese, metabolically normal|Subjects with body mass index ≥30.0 kg/m² and normal liver fat (IHTG content ≤5%)
3213239|NCT01104220||Obese, metabolically abnormal|Subjects with body mass index ≥30.0 kg/m² and increased liver fat (IHTG content ≥10%)
3213240|NCT01104220||Obese, scheduled for bariatric surgery|Subjects with a body mass index 35.0 - 55.0 kg/m² undergoing bariatric surgery, who are either metabolically normal or metabolically abnormal
3213241|NCT01104207|Experimental|Arm 1|Half of the study participants will receive 2000 pulses of 1 Hz active rTMS daily on 10 consecutive work days.
3213242|NCT01104207|Sham Comparator|Arm 2|Half of the study participants will receive 2000 pulses of 1 Hz placebo rTMS daily on 10 consecutive work days.
3213243|NCT01104194|Experimental|Fish-oil|
3213244|NCT01104194|Placebo Comparator|Placebo|Olive oil capsules, identical in appearance to fish oil capsules
3213245|NCT01104181|Experimental|swab and brush or swab and swab|we will determine which collection method is superior
3213246|NCT01104168||Nursing home residents with diabetes|
3213247|NCT01104155|Active Comparator|eribulin mesylate, 21 day cycle|
3213248|NCT01104155|Active Comparator|eribulin mesylate, 28 day cycle|
3213249|NCT01104142||MDI|Subject on multiple Daily Injections
3213250|NCT01104142||CSII|Subjects on Continuous Subcutaneous Insulin Infusion
3213251|NCT01104129||Control Group|Individual who has not had pancreatic cancer/IPMN; surgical resection for lesion of pancreas; history of colorectal, gastric cancer, esophageal, or head-and-neck cancer; administration of chemotherapy less than 1 week prior to enrollment; or an endoscopic procedure conducted less than 1 week prior to enrollment.
3213252|NCT01104129||Diagnosis of Pancreatic Cancer/IPMN|Patients diagnosed with Pancreatic Cancer/Intraductal Papillary Mucinous Neoplasm who are scheduled for surgical resection.
3213253|NCT01104116|Experimental|PET/CT imaging|Surgical patients will undergo [18F]-FDG PET/CT imaging
3213254|NCT01104103|Experimental|BOA(R)|Nurse or paramedic uses the BOA(R)-Constricting IV Band to attempt placement of an upper extremity IV in an adult
3213255|NCT01104103|Active Comparator|Standard care|Nurse or paramedic uses standard IV starting technique in the upper extremity of adults
3213256|NCT01104090|Active Comparator|C-MAC direct laryngoscopy|The laryngoscopy is performed with the CMAC used as Macintosh blade
3213257|NCT01104090|Experimental|C-MAC Indirect laryngoscopy|The CMAC is used as videolaryngoscope
3213258|NCT01104064|Experimental|Real rTMS combined with CIT|
3213259|NCT01104064|Sham Comparator|Sham rTMS combined with CIT|
3213260|NCT01104051||Radiofrequency Ablation|The treatment to be used in this trial is radiofrequency nerve ablation of lateral branches from S1 - S4 using radiofrequency treatments; Simplicity lll Electrode, a single RF electrode with a single percutaneous entry point.
3213261|NCT01104051||Sham|subjects to be blinded,to receive sham procedure; The treatment to be used in this trial is radiofrequency nerve ablation of lateral branches from S1 - S4 using radiofrequency treatments; Simplicity lll Electrode, a single RF electrode with a single percutaneous entry point.
3213262|NCT01104038|Active Comparator|Nutrition Education/Lifestyle Counseling|Children in this group will receive weekly group nutrition sessions , 30 minutes per week for 12 weeks, identical to those provided for the EXCEL intervention group and delivered by a registered dietician.
3213263|NCT01104038|Experimental|EXCEL|The EXCEL arm is the experimental arm of the study. Participants in this arm will receive supervised physical activity in the form of novel gaming (technology-mediated physical activity, 60 minutes per session, three times per week , for 12 weeks and 12 weeks of group nutrition education sessions.
3213264|NCT01104025|Experimental|Induction Therapy|ATG, rabbit: intravenous, 5 mg/kg/dose, 5 consecutive days Dexamethasone: intravenous, 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days Etoposide: intravenous, 150 mg/m2 weekly, starting 7 days after first dose of Thymoglobulin Methotrexate and hydrocortisone: intrathecal to patients with central nervous system involvement, age< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg, on day 7, 14, 21 and 42
3213265|NCT01104012||All patients|Allergy patients, asthma and rhinitis
3213266|NCT01103986|No Intervention|Control Group|
3213267|NCT01103986|Experimental|motivational/ health literacy education|
3213268|NCT01103973|Placebo Comparator|Control (Spa Certificate)|For every three months in the study control subjects received $50 spa gift certificates.
3213269|NCT01103973|Experimental|Mind/Body Program|Ten week group mind/body program. Skills include relaxation training, cognitive strategies, and lifestyle modifications.
3213270|NCT01103960|Experimental|Telmisartan80mg+Amlodipine5mg|combination therapy
3213271|NCT01103960|Active Comparator|amlodipine 5 mg|Monotherapy
3213272|NCT01103947|Active Comparator|EcoAnesthesia Mask first|"Both the standard adult facemask (Portex Adult, USA) and the new facemask (EcoAnesthesia Mask, Intersurgical, Inc., Liverpool, NY, USA) will be tested in each patient for three minutes. The order of usage of each mask will be randomly assigned to each patient. This group will receive the EcoAnesthesia Mask first."
3213273|NCT01103947|Active Comparator|Standard mask first|"Both the standard adult facemask (Portex Adult, USA) and the new facemask (EcoAnesthesia Mask, Intersurgical, Inc., Liverpool, NY, USA) will be tested in each patient for three minutes. The order of usage of each mask will be randomly assigned to each patient. Patients in this arm will receive the standard mask first."
3213492|NCT01102335|Experimental|Telbivudine|
3213275|NCT01103934|Placebo Comparator|Fluticasone Propionate plus Placebo|Subjects will be treated with fluticasone propionate and placebo for Vitamin D once daily for 2 weeks during allergy season
3213276|NCT01103921|Other|Glucose|
3213277|NCT01103921|Other|Fructose|
3213278|NCT01103921|Other|High-Fructose Corn Syrup|
3213279|NCT01103921|Other|Aspartame|No sugar
3213280|NCT01103908||Pediatric cardiac output (CO) after CPB|Cardiac output measurements made in pediatric patients after cardiopulmonary bypass.
3213281|NCT01103856|Experimental|Patient Mentor Intervention|The patient mentor intervention from TSHC has been adapted to the inpatient setting. Participants randomized to that arm will receive 2 sessions with a patient mentor during their hospitalization, as well as 5 phone call sessions over the 10 weeks after discharge and a brief meeting between the subject and the mentor when the subject attends their first outpatient visit at TSHC after discharge.
3213282|NCT01103856|Placebo Comparator|HIV transmission risk reduction|Participants randomized to the control arm will receive an attention control intervention delivered by a patient educator who is not an HIV patient mentor. We will use a modified version of the RESPECT intervention for our attention control group. Similar to the active intervention, these patients will receive 2 sessions in the hospital and 5 phone calls over 10 weeks after discharge.
3213283|NCT01103843|Active Comparator|Maintenance Dose Arm|Open label clopidogrel 75 mg daily or prasugrel 10 mg daily
3213284|NCT01103843|Active Comparator|Loading Dose Arm|Clopidogrel 600 mg or Prasugrel 60 mg at time of PCI.
3213285|NCT01103830|Experimental|Group 1|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fed condition following a high-fat/low-Kcal meal."
3213286|NCT01103830|Active Comparator|Group 2|"4 tablets of Riamet® on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.~Administration of Riamet® will be in fed condition following a high-fat/low-Kcal meal."
3213287|NCT01103830|Other|Group 3|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~Administration will be in the morning, in fed condition, following a high-fat/low-Kcal meal~1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning."
3213288|NCT01103830|Experimental|Group 4|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fed condition following a high-fat/high-Kcal meal."
3213289|NCT01103830|Experimental|Group 5|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fasting condition."
3213290|NCT01103830|Other|Group 6|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~Administration will be in the morning, in fasting condition.~1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning."
3213291|NCT01103817|No Intervention|Vitamin D Sufficient|"Sufficient is defined as a 25 OH vitamin D level >50 nmol/l measured at baseline. No clinical intervention will be assigned to this group.~Subjects will have fasting bloodwork done. Other study measurements to be taken include: height and weight, stage of puberty, blood pressure, vitamin D and calcium intake information, diabetes risk information, demographic information and spot urine sample.~We will also do a non-invasive test called a PAT or 'peripheral arterial tonometry' to look at the health of your blood vessels."
3213292|NCT01103817|Experimental|Vitamin D Deficient|"Deficient is defined as a 25 OH vitamin D level ≤ 37.5 nmol/l. This group will receive Vitamin D.~Subjects will have fasting bloodwork done. Other study measurements to be taken include: height and weight, stage of puberty, blood pressure, vitamin D and calcium intake information, diabetes risk information, demographic information and spot urine sample.~We will also do a non-invasive test called a PAT or 'peripheral arterial tonometry' to look at the health of your blood vessels."
3213293|NCT01103791|Experimental|Cohort 1|Docetaxel-PNP 20mg/m2
3213294|NCT01103791|Experimental|Cohort 2|Docetaxel-PNP 35mg/m2
3213295|NCT01103791|Experimental|Cohort 3|Docetaxel-PNP 45mg/m2
3213296|NCT01103791|Experimental|Cohort 4|Docetaxel-PNP 60mg/m2
3213297|NCT01103791|Experimental|Cohort 5|Docetaxel-PNP 75mg/m2
3213298|NCT01103791|Experimental|Cohort 6|Docetaxel-PNP 90mg/m2
3213299|NCT01103778|Experimental|Velcade® therapy|Patients with greater than 1gm of proteinuria per day will receive Velcade®.
3213300|NCT01103765|Placebo Comparator|classic strategy|after drug-eluting stent(DES) deployment perform of Intravascular ultrasound analysis without post-dilatation
3213301|NCT01103765|Active Comparator|post-dilatation strategy|After drug-eluting stent (DES) deployment IVUS analysis and systematic post-dilatation with noncompliant balloon 0.25mm larger than stent balloon. After post dilatation new IVUS analysis.
3213302|NCT01103752||Surgery|This group (n=220) consist of patients undergoing hip or knee replacement in a fast-track setup and they are tested 3 times for postoperative cognitive dysfunction.
3213303|NCT01103739|Experimental|cohort 1|
3213304|NCT01103739|Experimental|cohort 2|
3213305|NCT01103726|Experimental|Stage 1|
3213306|NCT01103726|Experimental|Stage 2|
3213307|NCT01103713|Experimental|AZCQ|Azithromycin/Chloroquine
3213308|NCT01103687|Experimental|Ad26.ENVA.01 (rAd26)|Participants will receive the Ad26.ENVA.01 (rAd26) vaccine at baseline.
3213309|NCT01103687|Placebo Comparator|Placebo Vaccine|Participants will receive the placebo vaccine at baseline.
3213310|NCT01103674|Other|Numeris-AF Guided Coagulation System|
3213311|NCT01103661|Other|Numeris-AF Guided Coagulation System|
3213312|NCT01103648|Active Comparator|Simvastatin arm|A subset of individuals started the study period taking monotherapy with simvastatin. After a 12-week period, ezetimibe was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
3213493|NCT01102335|Active Comparator|TACE only|
3213494|NCT01102322||1|
3213313|NCT01103648|Active Comparator|Ezetimibe arm|A subset of individuals started the study period taking monotherapy with ezetimibe. After a 12-week period, simvastin was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
3213314|NCT01103648|Experimental|Simvastatin-Ezetimibe arm|To each subset of individuals which started the study period taking monotherapy with simvastatin or ezetimibe (active comparators), the other drug (ezetimibe or simvastatin, respectively) was combined for more 12 weeks (combination period = experimental arm).
3213315|NCT01103635|Experimental|Arm I|Patients receive tremelimumab over 1 hour on day 1 and CD40 agonist monoclonal antibody CP-870,893 IV over 30 minutes on days 2, 22, 43, and 64. Treatment repeats every 12 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3213316|NCT01103622|Experimental|1|twice daily Day 1 to Day 7; digoxin on day 4
3213317|NCT01103622|Placebo Comparator|2|twice daily Day 1 to Day 7; digoxin on day 4.
3213318|NCT01103609|Experimental|1|twice daily on Day 1 to Day 10, with Warfarin on Day 4
3213319|NCT01103609|Placebo Comparator|2|twice daily on Day 1 to Day 10, with Warfarin on Day 4
3213320|NCT01103596||HIV-infected patients, 1st wave|HIV-infected ARV-experienced patients treated by a combination including Kaletra
3213321|NCT01103596||HIV-infected patients, 2nd wave|HIV-infected ARV-experienced patients treated by a combination including Kaletra
3213322|NCT01103583|Experimental|Hydroxyurea|
3213323|NCT01103583|Placebo Comparator|Placebo|
3213324|NCT01103570|Experimental|group 1 cholecystocholangiography|cholangiography via gall bladder
3213325|NCT01103570|Experimental|group2 cystic duct cholangiography|cystic duct cholangiography
3213326|NCT01103544||Patients with advanced / metastatic TCCU after CDDP-failure|
3213327|NCT01103531|Experimental|Exercise Group|Participants in this group will be scheduled for 24 exercise training sessions over an 8-week period (three times weekly) and will be supervised by a certified exercise physiologist.
3213328|NCT01103531|Active Comparator|Education Group|Participants in this group will meet with a counselor who will present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
3213329|NCT01103518|Experimental|Combination 1|Ethinyl Estradiol + Cyproterone acetate
3213330|NCT01103518|Active Comparator|Combination 2|Ethinyl Estradiol + Cyproterone acetate
3213331|NCT01103505|Experimental|Device monitoring arm|participants in the device monitoring arm will receive a packed device at home, with instructions to install and connect the device to a modem as well as instructions for daily use of the device.
3213332|NCT01103505|No Intervention|Standard care (control) arm|Standard care instruction per clinic routine for home vision monitoring to detect progression of AMD.
3213333|NCT01103492|Experimental|Ablation catheter|Procedure using the HALO90 Ablation catheter to heat a thin layer of rectal tissue using radiofrequency to reduce inflammation and bleeding in subjects with radiation proctitis.
3213334|NCT01103479|No Intervention|Control|Participants will complete interviewer-administered pre- and post-test
3213335|NCT01103479|Experimental|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer screening guidelines, communication skills, and health literacy training
3213336|NCT01103479|Experimental|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational digital video disc (DVD) on CRC and CRC screening
3213337|NCT01103466|Active Comparator|New ostomy appliance (Atlas)|Atlas= new base plate. Due to company confidentiality the product is just called Atlas and this is not short for any other names
3213338|NCT01103466|Active Comparator|SenSura|Commercially available ostomy appliance
3213339|NCT01103466|Active Comparator|Conform 2|Commercially available ostomy appliance
3213340|NCT01103453|Experimental|Intervention Group|Study group are persons diagnosed as suffering from Mild Cognitive Impairment will undergo a series of 9 sessions on a computer program of a virtual supermarket to improve their Executive and IADL functions.
3213341|NCT01103440|Other|Conventional Strategy|Patient receive 325 mg ASA orally and loading does of 600mg Clopidogrel at time of procedure
3213342|NCT01103440|Active Comparator|Aggressive Strategy|Patient receive 325mg ASA orally and loading does of 600mg Clopidogrel at time of procedure with addition of IV GP IIb/IIIa inhibitor bolus intra procedurally
3213343|NCT01103427|Active Comparator|Internet-based coaching .|"Arm 1. Those in the active comparator arm will benefit from automated internet-based coaching. The subjects will be recruited from the general population reporting not to be associated with the University Hospital of North Norway and randomized to arm 1 or 2."
3213344|NCT01103427|Experimental|SMS based coaching|"Arm 2. The subjects will receive automated coachingby SMS.The subjects will be recruited from the general population reporting not to be associated with the University Hospital of North Norway and randomized to arm 1 or 2."
3213345|NCT01103427|Experimental|SMS coaching UNN recruited|Arm 3.The subjects will be recruited from those reporting to be associated with the University Hospital of North Norway and randomized to arm 3 or 4.
3213346|NCT01103427|Experimental|Craving/Panic function. UNN recruited|"Arm 4. The subjects will in addition to the automated coachingby SMS get a SMS panic/craving function. The subjects will be recruited from subjects reporting to be associated with the University Hospital of North Norway and randomized to arm 3 or 4."
3213347|NCT01103414|Experimental|Mitoglitazone 50 mg capsules|Mitoglitazone 50 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
3213348|NCT01103414|Experimental|Mitoglitazone 100 mg capsules|Mitoglitazone 100 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
3213349|NCT01103414|Experimental|Mitoglitazone 150 mg capsules|Mitoglitazone 150 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
3213350|NCT01103414|Active Comparator|Pioglitazone 45 mg capsules|Pioglitazone 45 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
3213351|NCT01103414|Placebo Comparator|Matching placebo|Placebo capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
3213352|NCT01103401|Active Comparator|Tobramycin/Dexamethasone|
3213353|NCT01103401|Active Comparator|Tobramycin/Dexamethasone plus Ketorolac tromethamine|
3213354|NCT01103388|Experimental|Rituximab|
3213355|NCT01103388|No Intervention|No Rituximbab|
3213356|NCT01103375|Experimental|Treatment (enzyme inhibitor, immunotherapy)|Patients receive isotretinoin PO QD on days 1-21 and erlotinib hydrochloride PO QD on days 1-28.
3213357|NCT01103362|Experimental|flibanserin 100mg|flibanserin 100mg po qd
3213358|NCT01103349|Experimental|BI671800|Patients receive BI671800 capsules twice daily
3213359|NCT01103349|Active Comparator|Montelukast|Patients receive Montelukast encapsulated tablets once daily
3213360|NCT01103349|Placebo Comparator|Placebo|Patients receive placebo capsules and/or encapsulated placebo tablets
3213361|NCT01103336|Experimental|Nicorandil in saline|
3213362|NCT01103336|Placebo Comparator|saline|
3213363|NCT01103323|Experimental|Regorafenib (Stivarga, BAY73-4506)+BSC|Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care(BSC).
3213364|NCT01103323|Placebo Comparator|Placebo+BSC|Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care (BSC).
3213365|NCT01103310|Experimental|Arm 1|Cancer patients, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, PET/CT
3213366|NCT01103310|Experimental|Arm 2|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY94-9392 in blood
3213367|NCT01103297|Other|Variable Angle Distal Radius Plate|
3213368|NCT01103284|Experimental|DiaPep277|Administration of 1 mg DiaPep277®, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.
3213369|NCT01103284|Placebo Comparator|Placebo|Administration of placebo, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.
3213370|NCT01103271|Experimental|Open-label Placebo Immediate Treatment|Participants will begin taking placebo pills for four weeks immediately after enrolling in the study.
3213371|NCT01103271|Placebo Comparator|Open-label Placebo Waitlist Treatment|Participants will wait two weeks after enrolling in the study to begin taking placebo pills for four weeks.
3213372|NCT01103258|Active Comparator|high ligation and stripping|surgery consisting of high ligation in combination with long saphenous stripping
3213373|NCT01103258|Active Comparator|duplex guided foam sclerotherapy|duplex guided foam sclerotherapy
3213374|NCT01103245|Placebo Comparator|Renin-Angiotensin Aldosterone Activation|Renin-Angiotensin-Aldosterone System (RAAS) Activation
3213375|NCT01103245|Active Comparator|Aliskiren, Spironolactone, or Placebo|Determination of effects of MR antagonism or renin inhibition.
3213376|NCT01103245|Active Comparator|Increased Dose, Combination, or Placebo|Determination of effects of MR antagonism and/or renin inhibition.
3213377|NCT01103232|Experimental|Electrical Muscle Stimulation|Electrical muscle stimulation of the right wrist flexor muscles was applied
3213378|NCT01103232|Sham Comparator|Control|Transcutaneous electrical nerve stimulation was applied
3213379|NCT01103219|Placebo Comparator|Control|Participants in this group will receive nutrition from birth and during the hospital stay until discharge according to the routines of the participating institutions.
3213380|NCT01103219|Active Comparator|Intervention|The participants in this group will receive increased supply of energy, protein, vitamin A, docosahexaenoic acid, and arachidonic acid from birth and during the hospital stay until discharge.
3213381|NCT01103206|Experimental|Control group|Parathyroid hormone suppression tests using successively (each test will be separate for a two week period) an intravenous calcium loading or cinacalcet will be performed in a group of 12 healthy volunteers.
3213382|NCT01103206|Experimental|Primary hyperparathyroidism dose I|Parathyroid hormone suppression test using the first dose of cinacalcet in patients with primary hyperparathyroidism.
3213383|NCT01103206|Experimental|Primary hyperparathyroidism dose II|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
3213384|NCT01103193|Active Comparator|remifentanil injected|a mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
3213385|NCT01103193|Active Comparator|sevoflurane in step up concentration|a mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
3213386|NCT01103180|Experimental|Escitalopram|10-20 mg of escitalopram for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
3213387|NCT01103180|Placebo Comparator|Placebo|Inert placebo (sugar pill) taken daily for eight weeks
3213388|NCT01103154|Active Comparator|Carvedilol|carvedilol 6.25mg per day
3213389|NCT01103154|Active Comparator|N+I|nadolol 40mg per day, ISMN 10 mg per day
3213390|NCT01103141|Active Comparator|Micropuncture|
3213391|NCT01103141|Active Comparator|Standard|
3213392|NCT01103115|Placebo Comparator|Placebo|Subjects in this group will take the placebo tablets
3213393|NCT01103115|Active Comparator|Ca600mg+VitD400IU|subjects receive a daily dose of 600 mg elemental calcium and 400 IU vitamin D3
3213394|NCT01103115|Active Comparator|Ca600mg+VitD800IU|subjects receive a daily dose of 600 mg elemental calcium and 800 IU vitamin D3
3213395|NCT01103102|Active Comparator|Lowest Dose|
3213396|NCT01103102|Active Comparator|Intermediate Dose|
3213397|NCT01103102|Active Comparator|Highest Dose|
3213398|NCT01103102|Placebo Comparator|Placebo Control|
3213399|NCT01103076|Active Comparator|Polyamide 210 H|Chronic HD patients will be treated in random order with either polyamide or HCO membranes (Polyflux 210 H or HCO 1100) for one month (12 HD sessions) before the crossover.
3213495|NCT01102309|Experimental|Experimental Group (EG)|Group assigned to robot plus conventional therapy
3213400|NCT01103076|Experimental|HCO 1100|Chronic HD patients will be treated in random order with either polyamide or HCO membranes (Polyflux 210 H or HCO 1100) for one month (12 HD sessions) before the crossover.
3213401|NCT01103063|Experimental|AZCQ|Azithromycin/chloroquine
3213402|NCT01103063|Active Comparator|SP|sulfadoxine-pyrimethamine (Fansidar)
3213403|NCT01103050|Active Comparator|QAV680 + Cetirizine Placebo|
3213404|NCT01103050|Experimental|QAV680 + Cetirizine|
3213405|NCT01103050|Active Comparator|Cetirizine + QAV680 Placebo|
3213406|NCT01103050|Placebo Comparator|QAV680 Placebo + Cetirizine Placebo|
3213407|NCT01103037|Experimental|QAV680|
3213408|NCT01103037|Placebo Comparator|QAV680 Placebo|
3213409|NCT01103024|Experimental|AIN457 300mg s.c every 2 weeks|
3213410|NCT01103024|Experimental|AIN457 300mg s.c every 4 weeks|
3213411|NCT01103024|Experimental|AIN457 150mg s.c every 4 weeks|
3213412|NCT01103024|Placebo Comparator|Placebo s.c every 2 weeks|
3213413|NCT01103011|Experimental|ND0611 dose 1, ND0611 dose 2, placebo|
3213414|NCT01102998||Brain Tumor Survivors|Brain tumor survivors ages 8 to 18 years who are at least 5 years post diagnosis and at least 2 years post active therapy or observation and their parents/guardians will be approached to participate during clinic visits.
3213415|NCT01102985|Experimental|aerobic resistance|12 month aerobic resistance exercise at a fitness center
3213416|NCT01102985|Active Comparator|home based physical activity|national recommendations for physical activity for adults
3213417|NCT01102972|Experimental|ATV + ABC/3TC|Subjects will change to ATV 400mg administered as two 200mg capsules orally, once daily and to the fixed-dose combination tablet of ABC 600mg/3TC 300mg (EPZICOM) administered as one tablet orally, once daily for 48 weeks. The subject's pre-study RTV will be discontinued.
3213418|NCT01102972|Active Comparator|ATV + RTV + TDF/FTC|Subjects will continue their pre-study therapy, un-modified, of ATV 300mg administered as one capsule orally, once daily plus RTV 100mg administered orally, once daily plus fixed dose combination tablet tenofovir 300mg/emtricitabine 200mg administered as one tablet orally, once daily for 48 weeks.
3213419|NCT01102959|Experimental|Photographic Material|Photographic Educational Material on Carbohydrate Counting
3213420|NCT01102946|Experimental|PRP plus ranibizumab|Patients will be submitted to panretinal photocoagulation plus intravitreal injections of ranibizumab
3213421|NCT01102946|Active Comparator|PRP|Patients will only be submitted to panretinal photocoagulation
3213422|NCT01102933||Unselected post-myocard infarct patients|Patients diagnosed with MI at Uppsala University Hospital
3213423|NCT01102920|Experimental|Tailored behavioural treatment and CPAP|Tailored behavioural treatment targeting physical activity and eating habits.
3213424|NCT01102920|Active Comparator|CPAP-treatment|CPAP-treatment as usual. Advice about benefits of physical activity and weight loss.
3213425|NCT01102907||Liquid Meal|
3213426|NCT01102907||Solid Meal|
3213427|NCT01102894|Experimental|Low fiber and High Fiber|Subjects consume a low fiber cereal and swallow the SmartPill device that measures gastrointestinal transit time Subjects consume a high fiber cereal along with swallowing the SmartPill device that measures gastrointestinal transit time
3213428|NCT01102881|Placebo Comparator|No fiber|No fiber added to muffins or cereal
3213429|NCT01102881|Experimental|Fiber made from corn starch|Muffins and cereal made with novel corn fiber
3213430|NCT01102881|Experimental|Glucose polymer fiber|Muffins and cereal made from glucose polymer fiber
3213431|NCT01102868|Sham Comparator|Needle in acupuncture point Li11|Acupuncture needle in the acupuncture point Li11
3213432|NCT01102868|Experimental|IMS of musculus pronator teres|Acupuncture needle in musculus pronator teres
3213433|NCT01102816|Experimental|Individualized acupuncture|
3213434|NCT01102816|No Intervention|Routine care|
3213435|NCT01102803|Placebo Comparator|Sugar Pill|Participants will receive placebo augmented cognitive behavioral therapy
3213436|NCT01102803|Experimental|D-Cycloserine|Participants will receive D-Cycloserine augmented cognitive behavioral therapy
3213437|NCT01102777|Other|Usual Care|Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
3213438|NCT01102777|Other|Internet-mediated Walking Program|"participants in the intervention arm are asked to participate in a walking program~automated internet-mediated walking program: intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress"
3213439|NCT01102764|Experimental|Arm 1: PE via telemedicine|PE via telemedicine
3213440|NCT01102764|Active Comparator|Arm 2: PE in person|PE in person
3213441|NCT01102751||Vitamin D deficient females|(n =18, mean age 29.1±9.9 yrs)
3213442|NCT01102751||vitamin D sufficient healthy females|(control group; n = 19, mean age 28.5±5.2 yrs)
3213443|NCT01102751||genetically-determined hypophosphatemic rahitis|(n=13, mean age 26.5±15.1 yrs)
3213444|NCT01102738||Premature babies (<32 weeks)|All premature babies born at less than 32 completed weeks gestation who are admitted to an Imperial College NHS Healthcare Trust Neonatal Intensive Care Unit (St. Mary's Hospital or Queen Charlotte's & Chelsea Hospital), and whose parents/guardians have given their consent will be eligible to enter the study.
3213445|NCT01102725||Colorectal Surgery|Subject who are undergoing a colon or rectal resection
3213446|NCT01102712|Experimental|BTVA|
3213447|NCT01102699|Experimental|Filgrastim, G-CSF|Single s.c. dose of G-CSF (300 microg)
3213448|NCT01102686|Experimental|Pyrimethamine|
3213449|NCT01102673|Experimental|PF-04991532|This will be a crossover study with 2 cohorts and an interleaving design with placebo substitution. The study will be conducted over 4 treatment periods in Cohort 1 (n=9) and over 3 treatment periods in Cohort 2 (n=9). Six subjects will be allocated to receive PF-04991532 and three subjects will be allocated to receive placebo treatment during each dosing period, except for the 4th period of Cohort 1. The 4th period of Cohort 1 will be dedicated to assess the effect of food on PF-04991532 PK parameters at one of the doses previously tested in Cohort 1; hence all 9 subjects will be dosed with PF-04991532 in an open-label fashion. A washout period of at least 7 days will occur between each dose.
3213450|NCT01102673|Placebo Comparator|Placebo|This will be a crossover study with 2 cohorts and an interleaving design with placebo substitution. The study will be conducted over 4 treatment periods in Cohort 1 (n=9) and over 3 treatment periods in Cohort 2 (n=9). Six subjects will be allocated to receive PF-04991532 and three subjects will be allocated to receive placebo treatment during each dosing period, except for the 4th period of Cohort 1. The 4th period of Cohort 1 will be dedicated to assess the effect of food on PF-04991532 PK parameters at one of the doses previously tested in Cohort 1; hence all 9 subjects will be dosed with PF-04991532 in an open-label fashion. A washout period of at least 7 days will occur between each dose.
3213451|NCT01102660|Other|Treatment Sequence 1|
3213452|NCT01102660|Other|Treatment Sequence 2|
3213453|NCT01102660|Other|Treatment Sequence 3|
3213454|NCT01102660|Other|Treatment Sequence 4|
3213455|NCT01102647|Experimental|Phytosterol ester|Plant sterol compared with placebo
3213456|NCT01102634|Experimental|Acu-TENS|Application of TENS over acupuncture points
3213457|NCT01102634|Placebo Comparator|Placebo-TENS|Application of Acu-TENS but with no electricity
3213458|NCT01102621||case-control, head and neck cancer with radiotherapy|The group of exposed individuals had to be patients with disease-free survival interval of at least two years subsequent to treatment for head and neck cancer by means of radiotherapy alone or in combination, in which the auditory system was included in the field of irradiation.
3213459|NCT01102621||case-control, head an neck cancer without radiotherapy|The group of non-exposed individuals (control group) had to be patients who had not undergone oncological treatment that put their hearing at risk and who were age-matched (2 years). This group was formed by individuals who had had pelvic tumors or skin tumors and who had only undergone local surgery to remove their tumors, and by female volunteers from the hospital. All of these individuals were asked whether they would be willing to participate in a study, without knowing in advance whether they had any previous hearing problems or complaints.
3213460|NCT01102608|Experimental|1|
3213461|NCT01102595|Experimental|1: Temozolomide plus Radiation|"Group 1:~Neoadjuvant phase: Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.~Adjuvant phase: Temozolomide 75 mg/m2/d x 42-49 days with standard radiation therapy (60 Gy).~Maintenance phase: Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
3213462|NCT01102595|Experimental|2: Temozolomide plus Radiation plus Bevacizumab|"Neoadjuvant phase: Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles + bevacizumab 10 mg/kg every 15 days.~Adjuvant phase: Temozolomide 75 mg/m2/d x 42-49 days with standard radiation therapy (60 Gy) + bevacizumab 10 mg/kg every 15 days.~Maintenance phase: Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
3213463|NCT01102569||Pancreatic cancer and Ashkenazi decent|Patients with pancreatic cancer will be asked to join the study if they identify themselves as being of Ashkenazi descent, as well as patients at a high-risk of pancreas cancer based on family history, and will be followed from the time of diagnosis.
3213464|NCT01102556||Surgery Patients/High-risk Patients|Patients who have undergone surgery for pancreatic cancer or pre-neoplastic lesions of the pancreas will be accrued to the study. In addition, patients who are determined to be at high-risk for pancreatic cancer (with a significant family history) will also be recruited for study enrollment.
3213465|NCT01102543||Premature babies < 28 GA|
3213466|NCT01102543||Premature babies > 28 & < 32 weeks GA|
3213467|NCT01102517|Experimental|VATS group|video-assisted thoracoscopic surgery
3213468|NCT01102517|Other|axillary thoracotomy|Control group
3213469|NCT01102504|Experimental|Tomato extract (Ateronon)|Supplementation of tomato extract containing 28 mg/day for 12 months in addition to routine treatment.
3213470|NCT01102504|Placebo Comparator|Placebo|Placebo
3213471|NCT01102491|Experimental|Ramosetron prophylaxis|ramosetron prophylaxis at the end of surgery with starting PCA and 1 day after surgery
3213472|NCT01102491|No Intervention|Control|no antiemetic prophylaxis
3213473|NCT01102452|Placebo Comparator|Commercially Available Wet Noodle|Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
3213474|NCT01102452|Experimental|PPB-R-203-02 Noodle|PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
3213475|NCT01102439|Active Comparator|Standard dose clopidogrel|300 mg Loading x 1 day, 75 mg/d x 13 days
3213476|NCT01102439|Experimental|Double dose clopidogrel|600 mg Loading x 1 day, 150 mg/d x 6 days, 75 mg/d x 7 days
3213477|NCT01102439|Active Comparator|Standard dose aspirin|Aspirin 81mg/d x 14 days
3213478|NCT01102439|Experimental|High dose aspirin|Aspirin 325 mg/d x 14 days
3213479|NCT01102426|Experimental|Arm A|plitidepsin + dexamethasone combination
3213480|NCT01102426|Active Comparator|Arm B|dexamethasone single agent
3213481|NCT01102413|Experimental|Monofer|Injections or infusions
3213482|NCT01102413|Active Comparator|Iron Sulphate|Oral intake
3213483|NCT01102400|Experimental|1|
3213484|NCT01102387|Experimental|LAS41003|
3213485|NCT01102387|Active Comparator|LAS189962|
3213486|NCT01102387|Active Comparator|LAS189961|
3213487|NCT01102374|Experimental|High Dose Vitamin D|100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
3213488|NCT01102374|Active Comparator|Standard Dose Vitamin D|12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
3213489|NCT01102361|Experimental|Transperineal Biopsy|Biopsy of the prostate using transperineal approach
3213490|NCT01102348|Experimental|PEP-uP Protocol (after)|PEP-uP protocol and treatment algorithm implemented for all patients in ICU.
3213491|NCT01102348|No Intervention|Standard feeding protocol (before)|Enteral feeds are guided by a standard feeding protocol specified by pre-printed ICU admission orders. The admitting physician has the option of initiating the enteral feeding protocol or keeping the patient nil per os (NPO).
3213497|NCT01102296|Active Comparator|male homosexuals|HIV-uninfected male homosexuals will be provided 2 doses of HAV vaccine, which will be administered at baseline and 6th month of follow-up.
3213498|NCT01102296|Active Comparator|HIV-infected male homosexuals, group1|HIV-infected male homosexuals will be provided 3 doses of HAV vaccine, which will be administered at baseline, 1st, and 6th month of follow-up.
3213499|NCT01102296|Active Comparator|HIV-infected male homosexuals, group 2|HIV-infected male homosexuals will be provided 2 doses of hepatitis A vaccine, which will be administered at baseline and 6th month of follow-up.
3213500|NCT01102283||Stent Group|
3213501|NCT01102270|Active Comparator|Eszopiclone|Eszopiclone 3mg prior to sleep (1 night)
3213502|NCT01102270|Placebo Comparator|Sugar Pill|Sugar Pill (placebo) prior to sleep (1 night)
3213503|NCT01102257|Experimental|Omega-3 EFA Supplement|"The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 esssential fatty acid i.e Omega-3 EFA supplement comprised of:~2000 mg EPA 1000 mg DHA"
3213504|NCT01102257|Placebo Comparator|Olive Oil|Gel Capsule
3213505|NCT01102244|Experimental|Tobradex ST|tobramycin 0.3%, dexamethasone 0.05%
3213506|NCT01102244|Active Comparator|Azasite|azithromycin 1%
3213507|NCT01102231|Experimental|A|Chemoradiotherapy
3213508|NCT01102218|Experimental|erythropoietin plus pentoxifylline|
3213509|NCT01102218|Active Comparator|erythropoietin alone|
3213510|NCT01102205||healthy|
3213511|NCT01102205||euthyroid hashimoto|
3213512|NCT01102205||hypothyroid hashimoto|
3213513|NCT01102192||Myasthenia gravis with thymoma|Myasthenia gravis with thymoma
3213514|NCT01102192||Myasthenia gravis without thymoma|Myasthenia gravis without thymoma
3213515|NCT01102192||Thymoma without Myasthenia gravis|Thymoma without Myasthenia gravis
3213516|NCT01102192||cardiac, or thyroid surgery|cardiac, or thyroid surgery
3213517|NCT01102179||Chronic kidney disease|"All patients with stage 2-5 (pre-dialysis) chronic kidney disease~One-time blood draw (10 ml)"
3213518|NCT01102153||Coolgard|invasive cooling
3213519|NCT01102153||ArcticSun|non-invasive (surface) cooling
3213520|NCT01102140|Active Comparator|POMx|15 subjects will received 1000 mg of oral POMx for 12 weeks.
3213521|NCT01102140|Placebo Comparator|Control- sugar Pill|15 subjects will receive a matching sugar pill for 12 weeks.
3213522|NCT01102127||Goiter|Patients with nodular goiter
3213523|NCT01102114|Placebo Comparator|Placebo Vaccine|
3213524|NCT01102114|Experimental|NicVAX Vaccine|
3213525|NCT01102088|Experimental|Radiation + Chemotherapy|"Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.~For the phase II part of the study once the MTD has been achieved proton therapy will be allowed. Treatment dose will be identical to that of the photon treatment where the PTV is treated to 50.4 Gy(RBE) (RBE=1.1) while the CTV is boosted to 63 Gy(RBE) in 28 fractions.~Chemotherapy Administration: Schedule of chemotherapy, and modifications of chemotherapy drugs during chemoradiation treatment will be at the discretion of the treating medical oncologist per their standard of practice and with consideration to standard chemotherapy drugs in the treatment of esophageal cancer."
3213526|NCT01102075|Experimental|Electroacupuncture|The Electroacupuncture therapy protocol included a total of 12 acupuncture points at the CV12,CV6, bilateral ST25, SP15, SP14,LI4, LI11, ST36, ST44. All acupuncture points were prepared with 70% alcohol pads, and disposable stainless steel needles were used. Abdominal acupuncture points were inserted horizontally 6~6.5cm in depth and the others were inserted vertically 2~2.5cm in depth until patient can feel De-Qi. All acupuncture points were stimulated electrically with a frequency of 24 Hz an intensity of 0.27-1.3mA(tolerable strength) with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks by practitioner who had had 6 years of acupuncture training and 3 more years of clinical experience.
3213527|NCT01102075|Sham Comparator|Sham electroacupuncture procedure|The Sham electroacupuncture therapy protocol(Non-acupoint, No electrical stimulation)included the same number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment, but superficially at non acupuncture points 15 mm to the lateral of each acupuncture point was treated. The points were not stimulated electrically, but the sound of the pulse generator was heard by the participants. (Lee SH, LeeBC 2009) Those receiving EA or SEA therapy were treated on alternate days to prevent crosstalk among groups, which could have compromised the blinded study design.
3213528|NCT01102075|No Intervention|Waiting list|No treatment was done for waiting group, but could receive same treatments as Electroacupuncture group after the end of trial.
3213529|NCT01102062|Experimental|Orange Juice|1 glass (=200mL) of orange juice
3213530|NCT01102049|Experimental|self-administered food intake|self-administered food intake according to dietary protocol
3213531|NCT01102036|Placebo Comparator|Yoghurt without probiotics|Yoghurt without probiotic bacteria
3213532|NCT01102036|Active Comparator|Cultura yoghurt|Cultura yoghurt with L casei F19, acidophilus La5 adn B lactis Bb 12
3213533|NCT01102023|Experimental|solar salt based-diet|
3213534|NCT01102010|Experimental|Blood transfusion|"Restrictive strategy: Blood transfusion when hemoglobin is less than 6 mmol/l (9.7 g/dl)~Liberal strategy: Blood transfusion when hemoglobin is less than 7 mmol/l (11.3 g/dl)"
3213535|NCT01101984|Experimental|DE-089|DE-089 ophthalmic solution
3213536|NCT01101984|Active Comparator|HA|0.1% sodium hyaluronate ophthalmic solution
3213537|NCT01101971|Experimental|first year medical students|
3213538|NCT01101958|Other|Chartis System-EBV Treatment|Subjects with heterogeneous emphysema, had their collateral ventilation status in the target treatment lobe assessed using the Chartis System (CV- or CV+) and underwent endobronchial lung volume reduction (ELVR) with endobronchial valves (EBV).
3213539|NCT01101932|Experimental|(Part 1) PF-04308515|
3213540|NCT01101932|Placebo Comparator|(Part 1) Solution Placebo|
3213541|NCT01101932|Experimental|(Part 2) PF-04308515 Tablet|
3213542|NCT01101919|Experimental|CP-690,550 Dose Group|
3213543|NCT01101906|Experimental|Arm A: OSI-906|150 mg BID
3213544|NCT01101906|Placebo Comparator|Arm B: Placebo|Placebo BID
3213545|NCT01101893|Experimental|Period 1|In period 1 all subjects will receive Raltegravir 400mg q12h from Day 1 to Day 5
3213546|NCT01101893|Experimental|Period 2|In period 2 all subjects will receive GSK2248761 200mg q24h from Day 1 to Day 5.
3213547|NCT01101893|Experimental|Period 3|Day 1 of Period 3 will be the day after Day 5 of Period 2. Subjects will receive GSK2248761 200mg q24h + raltegravir 400mg q12h from Day 1 to Day 5.
3213548|NCT01101880|Experimental|Treatment (chemotherapy and colony stimulating factor)|"INDUCTION THERAPY: Patients receive filgrastim SC daily beginning the day prior to chemotherapy and continuing until blood counts recover. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 5 days.~CONSOLIDATION THERAPY: Patients receive filgrastim SC daily for 5 days beginning the day prior to chemotherapy. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 4 days.~Treatment with induction therapy may continue for up to 2 courses and treatment with consolidation therapy may continue for up to 3 courses in the absence of disease progression or unacceptable toxicity."
3213549|NCT01101867|Experimental|Aspart flexible dose|aspart dose determined based upon carbohydrate intake.
3213550|NCT01101867|Active Comparator|Aspart fixed dose|fixed meal dose of aspart (based upon weight or total daily insulin dose)
3213551|NCT01101854||Biopsy Arm|A single subject (current OSU Comprehensive Wound Center patient) will provide 2 tissue samples (3 mm punch biopsies performed by a wound care physician) from a single wound over a 4-week time period.
3213552|NCT01101854||Debridement Arm|A single subject (current OSU Comprehensive Wound Center patient) will provide 1 debrided tissue sample as part of their standard wound care treatment (no new wounds will be created). The subject's wound care physician will perform the debridement during an office visit or in the operating room (OR) during surgical debridement.
3213553|NCT01101841|Experimental|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate)
3213554|NCT01101841|Placebo Comparator|Placebo capsules|Sugar pill
3213555|NCT01101815|Active Comparator|Oral Naltrexone (ON)|Oral naltrexone for 48 weeks versus implantable naltrexone for 48 weeks
3213556|NCT01101815|Active Comparator|Implantable Naltrexone (IN)|48 Weeks of implantable naltrexone as compared with 48 weeks of oral naltrexone
3213557|NCT01101802|Active Comparator|Mycophenolate mofetil|Patients were given 1gm bd mycophenolate mofetil for 8 weeks
3213558|NCT01101802|Placebo Comparator|Sugar pill|
3213559|NCT01101789|Active Comparator|triclosan|triclosan-coated sutures
3213560|NCT01101789|Placebo Comparator|control|sutures without triclosan-coating
3213561|NCT01101763||All Subjects|Healthy males
3213562|NCT01101737|No Intervention|Usual care|Patients not invited to the nurse-led clinic will continue with usual GP care
3213563|NCT01101737|Experimental|Nurse-led blood pressure clinic|Patients randomly allocated to the intervention will be invited to a specialist nurse-led blood pressure clinic.
3213564|NCT01101724|No Intervention|Standard of Care|In this group, the treating attending physician will be free to make rest recommendations as they see fit. An internal survey of physician practice found that the vast majority of physicians instruct patients rest for 1-2 days, then to return to school and physical activity after the patient's symptoms have resolved. The amount of rest will vary from patients to patient based on variation in symptom resolution and patient compliance. This advice is consistent with best practices outlined by the CDC.
3213565|NCT01101724|Experimental|Intervention|Mandated Rest.
3213566|NCT01101711||Patients with subarachnoid hemorrhage|
3213567|NCT01101698|Active Comparator|Vitamin K2, calcification score changes, vitamin D|90 μg vitamin K2+10μg cholecalciferol
3213568|NCT01101698|Active Comparator|Vitamin D, calcium score changes|10μg cholecalciferol (vitamin D)
3213569|NCT01101685|Active Comparator|Escitalopram|7 days dosing at 10mg per day
3213570|NCT01101685|Placebo Comparator|Placebo|7 days dosing at 10mg daily
3213571|NCT01101672|Experimental|Single-port laparoscopic colectomy|
3213572|NCT01101672|Active Comparator|Conventinal laparoscopic colectomy|
3213573|NCT01101659|Experimental|001|JNJ-40411813 500 mg as 20 mL of oral suspension single dose
3213574|NCT01101659|Placebo Comparator|002|Placebo 20 mL of oral suspension single dose
3213575|NCT01101659|Other|003|ketamine Ketanest S. vials of 20 ml with 5 mg/ml diluted with saline to 0.02 mg Ketamine per mL and per kg bodyweight of the volunteer
3213576|NCT01101659|Other|004|normal saline infusion 0.5 mL /min over 90 minutes
3213577|NCT01101646|Experimental|001|rabeprazole sodium four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
3213578|NCT01101646|Experimental|002|rabeprazole sodium two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
3213579|NCT01101646|Experimental|003|rabeprazole sodium four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
3213580|NCT01101633|Active Comparator|1|500 ml beverage containing alginate (3%)
3213581|NCT01101633|Active Comparator|2|330 ml beverage containing alginate (3%)
3213582|NCT01101633|Placebo Comparator|3|500 ml beverage without alginate (placebo)
3213583|NCT01101633|Placebo Comparator|4|330 ml beverage without alginate (placebo)
3213584|NCT01101620|Active Comparator|Levosimendan|
3213585|NCT01101620|Placebo Comparator|Placebo|
3213586|NCT01101607|Active Comparator|Pediatric Emergency Physician|Patients randomized to Pediatric Emergency Physician Group will have their fracture reduced by a Pediatric Emergency Physician
3213587|NCT01101607|Active Comparator|Orthopaedic physician|Patients to be randomized to Orthopaedic physician Group will have their fracture reduced by an Orthopaedic Physician
3213588|NCT01101594|Experimental|hLL1-DOX|4 Different dose levels of hLL1-DOX will be studied in groups of 3-6 patients. Once an optimal dose has been found, up to additional 30 patients will be studied at that dose level.
3213589|NCT01101581|Experimental|Veltuzumab and 90Y-Epratuzumab Tetraxetan|Veltuzumab and 90Y-Epratuzumab Tetraxetan target different b-cells. Veltuzumab will be administered in all 4 weekly study drug treatments. 90Y-Epratuzumab Tetraxetan will be administered only on days 8 & 15. The dose of veltuzumab remains the same for all patients.
3213590|NCT01101581|Experimental|90Y-epratuzumab tetraxetan|90Y-epratuzumab tetraxetan will be administered 6 mCi/m2 on days 8 and 15.
3213772|NCT01100281||FTD (Frontotemporal lobar degenerative)|
3213591|NCT01101568|Experimental|Single Sequence|Simvastatin will be administered on Day 1 and Day 10. Rosuvastatin will be administered on Day 3 and Day 12. GSK1292263 will be administered on Days 6 to 14.
3213592|NCT01101555|Experimental|COHORT 1: CUMULATIVE DOSE 1.5MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 3 days, dose 0.3, 0.5, 0.7, four patients in cohort, one of which is on placebo, escalation increment N/A
3213593|NCT01101555|Experimental|COHORT 2: CUMULATIVE DOSE 3.5MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 0.3, 0.5, 0.7, 1.0, 1.0 four patients in cohort, one of which is on placebo, escalation increment 2.3 fold.
3213594|NCT01101555|Experimental|COHORT 3: CUMULATIVE DOSE 6.0MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 7 days, dose 0.3, 0.7, 5 x 1.0 four patients in cohort, one of which is on placebo, escalation increment 1.7 fold.
3213595|NCT01101555|Experimental|COHORT 4: CUMULATIVE DOSE 8.0MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 0.3, 0.7, 1.0, 2 x 3.0 four patients in cohort, one of which is on placebo, escalation increment 1.33 fold.
3213596|NCT01101555|Experimental|COHORT 5: CUMULATIVE DOSE 10MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 10 days, dose 10 x 1.0 four patients in cohort, one of which is on placebo, escalation increment 1.25 fold.
3213597|NCT01101555|Experimental|COHORT 6: CUMULATIVE DOSE 15MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 15 days, dose 15 x 1.0 six patients in cohort, one of which is on placebo, escalation increment 1.5 fold.
3213598|NCT01101555|Experimental|COHORT 7: CUMULATIVE DOSE 15MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 5 x 3.0 six patients in cohort, one of which is on placebo, escalation increment N/A
3213599|NCT01101542||Cervarix Group|Subjects received 3 doses of the Cervarix vaccine. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0,1, 6 month vaccination schedule. According to the prescribing information, if flexibility in the vaccination schedule is necessary, the second dose can be administered between 1 month and 2.5 months after the first dose.
3213600|NCT01101529|Placebo Comparator|Standard antiemetic therapy plus placebo|Standard anti-emetic prophylaxis consisting of 1/dexamethasone 6 mg daily during the chemotherapy days and 2/tropisetron (Navoban)5 mg daily during chemotherapy and 2 days after
3213601|NCT01101529|Experimental|aprepitant (Emend)|Aprepitant given orally 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after as an addition to standard antiemetic therapy as in the placebo arm.
3213602|NCT01101503|Experimental|Intensive multifactorial group|Intensive multifactorial therapy group receive intensive blood glucose, blood pressure and blood lipids control.
3213603|NCT01101503|Experimental|conventional multifactorial therapy group|Conventional multifactorial therapy group receive conventional blood glucose, blood lipids and blood lipids control to the local targets.
3213604|NCT01101477|Active Comparator|Titration by target effect site concentration (Cet) 0.5μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
3213605|NCT01101477|Active Comparator|Titration by Cet 0.2μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
3213606|NCT01101477|Active Comparator|Titration by Cet 0.1μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
3213607|NCT01101464|Experimental|Asenapine Sequence 1|
3213608|NCT01101464|Experimental|Asenapine Sequence 2|
3213609|NCT01101451|Active Comparator|Arm I (EBRT, IMRT)|Patients undergo pelvic EBRT or IMRT once daily, 5 days a week, for 5.5 weeks.
3213610|NCT01101451|Experimental|Arm II (cisplatin, EBRT, IMRT)|Patients receive cisplatin IV over 1-2 hours on day 1 and undergo radiotherapy as in Arm I. Treatment with cisplatin repeats every 7 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3213611|NCT01101438|Experimental|Arm I|Patients receive oral metformin hydrochloride twice daily (once daily in weeks 1-4). Treatment continues for up to 5 years in receptor positive (ER and/or PgR positive) subjects in the absence of disease progression or unacceptable toxicity.
3213612|NCT01101438|Placebo Comparator|Arm II|Patients receive oral placebo twice daily (once daily in weeks 1-4). Treatment continues for up to 5 years in receptor positive (ER and/or PgR positive) subjects in the absence of disease progression or unacceptable toxicity.
3213613|NCT01101412|Experimental|Arm I: Antimicrobial Solution|Antimicrobial solution into central or peripheral venous catheter (CVC or PVC) once daily for 90 days. Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug infusion or blood aspiration.
3213614|NCT01101412|Active Comparator|Arm II: Saline Solution|Saline solution into CVC or PVC once daily for 90 days. Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug infusion or blood aspiration.
3213615|NCT01101399|Active Comparator|Ferric carboxymaltose|Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the next scheduled chemotherapy cycle after randomisation or continuous chemotherapy. In subjects with weight ≤66 kg, the first dose iron will be 500 mg; the second dose (500 mg) will be administered on the visit 4 (week 2).
3213616|NCT01101399|No Intervention|Local standard of care.|Subjects will be treated according to the local institutional practice.
3213617|NCT01101386||Voriconazole|Pharmacokinetic Monitoring
3213618|NCT01101373||1|All subjects who received BAC for treatment resistant depression between 2000 and 2009
3213619|NCT01101360|Active Comparator|Matrix RF followed by Pulse Dye Laser|
3213620|NCT01101347|Experimental|Aneurysm-Embolization System|
3213621|NCT01101334|Experimental|CS-7017 plus erlotinib|
3213622|NCT01101334|Active Comparator|erlotinib|
3213623|NCT01101321|Experimental|Reformulated OXY 80 mg (Totowa)|Reformulated OXY 80 mg (Totowa) x 1 dose
3213624|NCT01101321|Active Comparator|Reformulated OXY 80 mg (Wilson)|Reformulated OXY 80 mg (Wilson) x 1 dose
3213625|NCT01101308|Experimental|Reformulated OXY 10 mg (Totowa)|Reformulated OXY 10 mg (Totowa) x 1 dose
3213626|NCT01101308|Active Comparator|Reformulated OXY 10 mg (Wilson)|Reformulated OXY 10 mg (Wilson) x 1 dose
3213678|NCT01101035|Experimental|Febuxostat|Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.
3213627|NCT01101282|No Intervention|'Usual care'|"Participants will receive 'usual medical care' consisting of the following:~Medical management: Bronchodilators, corticosteroids, antibiotics and supplemental oxygen will be provided (where appropriate) in accordance with Australian and New Zealand COPD management guidelines (COPDX guidelines).~Non-invasive ventilation: if clinically indicated and prescribed in accordance with standardised hospital guidelines.~Physical rehabilitation: Participants will be assessed by a physiotherapist and prescribed appropriate exercises to facilitate a safe and timely discharge. Participants will perform physical rehabilitation according to a standardised protocol with an aim of maximising physical function at discharge.~Other allied health (e.g. occupational therapy, speech pathology, dietician) assessments and interventions, as required."
3213628|NCT01101282|Experimental|'Usual care' plus PEP mask therapy|"This will comprise:~'Usual care'~PEP mask therapy"
3213629|NCT01101269|Experimental|Subjects with diabetic nephropathy|Renal blood flow (RBF) will be measured using contrast enhanced ultrasound (CEU) and urine protein will be measured both on and off angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).
3213630|NCT01101269|Active Comparator|Healthy volunteers|Renal blood flow (RBF) will be measured using contrast enhanced ultrasound (CEU) and urine protein will be measured both on and off angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).
3213631|NCT01101256||Fondaparinux Prophylaxis group|
3213632|NCT01101256||Fondaparinux Therapy group|
3213633|NCT01101243|Active Comparator|Group 1|Body surface area: 88 %
3213634|NCT01101243|Active Comparator|Group 2|Body surface area: 22 %
3213635|NCT01101243|Active Comparator|Group 3|Body surface area: 88 %
3213636|NCT01101243|Active Comparator|Group 4|Body surface area: 88 %
3213637|NCT01101243|No Intervention|Group 5|Body surface area: 0 %
3213638|NCT01101230|Experimental|Almond|
3213639|NCT01101230|Placebo Comparator|Muffin|
3213640|NCT01101217|Placebo Comparator|placebo|placebo for 6 weeks
3213641|NCT01101217|Active Comparator|zinc|zinc sulfate 220 mg per day orally for 6 weeks
3213642|NCT01101204|Active Comparator|M1000 S10 F100|metformin 1000mg, fenofibrate 100mg and simvastatin 10mg
3213643|NCT01101204|Active Comparator|M1000 S10 F267|metformin 1000mg, fenofibrate 267mg and simvastatin 10mg
3213644|NCT01101204|Active Comparator|M1000 S40 F100|metformin 1000mg, fenofibrate 100mg and simvastatin 40mg
3213645|NCT01101204|Active Comparator|M1000 S40 F267|metformin 1000mg, fenofibrate 267mg and simvastatin 40mg
3213646|NCT01101204|Active Comparator|M2500 S10 F100|metformin 2500mg, fenofibrate 100mg and simvastatin 10mg
3213647|NCT01101204|Active Comparator|M2500 S10 F267|metformin 2500mg, fenofibrate 267mg and simvastatin 10mg
3213648|NCT01101204|Active Comparator|M2500 S40 F267|metformin 2500mg, fenofibrate 267mg and simvastatin 40mg
3213649|NCT01101204|Active Comparator|M2500 S40 F100|metformin 2500mg, fenofibrate 100mg and simvastatin 40mg
3213650|NCT01101204|Placebo Comparator|Therapeutic Lifestyle Change|Only therapeutic lifestyle change
3213651|NCT01101191|Experimental|Reformulated OXY 80 mg|Reformulated OXY 80 mg x 1 dose
3213652|NCT01101191|Active Comparator|Original OxyContin® (OXY) 80 mg|Original OxyContin® (OXY) 80 mg x 1 dose
3213653|NCT01101178|Experimental|Reformulated OXY 80 mg|Reformulated OXY 80 mg x 1 dose
3213654|NCT01101178|Active Comparator|Original OxyContin® (OXY) 80 mg|Original OxyContin® (OXY) 80 mg x 1 dose
3213655|NCT01101165|Experimental|Reformulated OXY 40 mg|Reformulated OXY 40 mg x 1 dose
3213656|NCT01101165|Active Comparator|Original OxyContin® (OXY) 40 mg|Original OxyContin® (OXY) 40 mg x 1 dose
3213657|NCT01101152|Experimental|Female|
3213658|NCT01101152|Experimental|Male|
3213659|NCT01101139|Experimental|Experimental|Single injection of Sugammadex 0.25 mg/kg
3213660|NCT01101139|Placebo Comparator|Placebo comparator|Single injection of Saline 0.9%
3213661|NCT01101126|Experimental|Disease Management|Comprehensive care delivered by designated nurses and pulmonologists, in collaboration with the primary practitioners and other healthcare professionals in the community
3213662|NCT01101126|Active Comparator|Unual care|Care delivered by the primary practitioner with the advice of a consultant pulmonologist
3213663|NCT01101113|Experimental|Cinacalcet|stepwise dose of cinacalcet + regular medical medication including vit D
3213664|NCT01101113|Active Comparator|Control|conventional treatment for secondary HPT including vit D and phosphate binder
3213665|NCT01101100|Experimental|1|
3213666|NCT01101087|Experimental|Taurolock|
3213667|NCT01101087|Placebo Comparator|Placebo|
3213668|NCT01101074||6-23 months|
3213669|NCT01101074||2-8 years|
3213670|NCT01101074||9-17 years|
3213671|NCT01101074||18-44 years|
3213672|NCT01101074||45-60 years|
3213673|NCT01101074||>60 years|
3213674|NCT01101061|Active Comparator|AMG 785|Six (6) Japanese women in cohorts 1, 2, and 4 will receive a single weight-based dose of AMG 785. Four (4) non-Japanese women in cohort 3 will receive a single weight-based dose of AMG 785.
3213675|NCT01101061|Placebo Comparator|PLACEBO|Two (2) women in each of cohorts 1, 2, 3, and 4 will receive a single dose of placebo.
3213676|NCT01101048|Placebo Comparator|A|Two (2) women in each of cohorts 1 and 4, and two (2) men in cohort 2 will receive placebo every 2 weeks for a total of 6 doses. Two (2) women in each of cohorts 3 and 5, and two (2) men in cohort 6 will receive placebo every 4 weeks for a total of 3 doses. Six (6) women in cohort 7 will receive placebo every 2 weeks for a total of 12 doses. In addition, subjects in cohorts 4 have the option to receive an additional 6 doses of placebo; subjects in cohorts 5 and 6 have the option to receive an additional 3 doses. Subjects in cohort 7 have the option to transition to 6 months of alendronate treatment.
3213677|NCT01101048|Active Comparator|B|Six (6) women in each of cohorts 1 and 4, and six (6) men in cohort 2 will receive AMG 167 every 2 weeks for a total of 6 doses. Six (6) women in each of cohorts 3 and 5, and six (6) men in cohort 6 will receive AMG 167 every 4 weeks for a total of 3 doses. Eighteen (18) women in cohort 7 will receive AMG 167 every 2 weeks for a total of 12 doses. In addition, subjects in cohorts 4 have the option to receive an additional 6 doses of AMG 167; subjects in cohorts 5 and 6 have the option to receive an additional 3 doses. Subjects in cohort 7 have the option to transition to 6 months of alendronate treatment.
3213679|NCT01101035|Active Comparator|Allopurinol|Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was <6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance [eCLcr] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was <6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but <60 mL/min).
3213680|NCT01101022|Active Comparator|SPD489|
3213681|NCT01101022|Placebo Comparator|Placebo|
3213682|NCT01101009|Active Comparator|Perindopril+amlodipine|
3213683|NCT01101009|Active Comparator|Olmesartan/amlodipine|
3213684|NCT01100996|No Intervention|fasted control|Volunteers are fasted for 10 hours and subjected to experimental endotoxemia
3213685|NCT01100996|Placebo Comparator|control feeding|Volunteers are fed a control nutrition starting 1 hour prior to LPS administration until 6 hours after LPS
3213686|NCT01100996|Active Comparator|enriched feeding|volunteers receive the investigational feeding starting 1 hour prior to LPS administration until 6 hours after LPS
3213687|NCT01100970||Unipolar electric needle|
3213688|NCT01100970||Bipolar electric needle|
3213689|NCT01100970||Control|Infants who were born in a vaginal birth
3213690|NCT01100957|Active Comparator|Conventional flexible videoscope for intubation|
3213691|NCT01100957|Experimental|Single-patient flexible endoscope|Single-patient flexible video-endoscope used for tracheal intubation in this intervention-arm
3213692|NCT01100944|Experimental|Therapy in Thymic Malignancies|PXD101 (Belinostat) will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression. A conventional 3+3 dose escalation design was used with up to 3 additional patients added if one patient exhibited a dose limiting toxicity (DLT). Dose escalation was halted if at least 2 out of a maximum of 6 patients within a cohort exhibited a DLT.
3213693|NCT01100931|Experimental|YM155 in Solid Tumors|"Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m^2, dose level 2:5 mg/m^2 , dose level 3:6 mg/m^2, dose level 4:8 mg/m^2, dose level 5:10 mg/m^2 (MTD), dose level 6:12 mg/m^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).~Phase II: 10 mg/m^2 (MTD)intravenous infusion over 72 hours every 21 days."
3213694|NCT01100918|Active Comparator|1: Dyssynchrony positive|
3213695|NCT01100918|Active Comparator|2a: Dyssynchrony negative|
3213696|NCT01100918|Active Comparator|2b: Dyssynchrony negative|
3213697|NCT01100892|No Intervention|Control group|Observation only. Does not receive once-daily insulin detemir.
3213698|NCT01100892|Experimental|Once-daily insulin detemir|Once-daily insulin detemir
3213699|NCT01100879|Active Comparator|Ferric carboxymaltose|Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the next scheduled chemotherapy cycle after randomisation or continuous chemotherapy. In subjects with weight ≤66 kg, the first dose iron will be 500 mg; the second dose (500 mg) will be administered on the visit 3 (week 2).
3213700|NCT01100879|No Intervention|Local standard of care.|Subjects will be treated according to the local institutional practice.
3213701|NCT01100866|Active Comparator|Group 1|POMELLA™ 2 x 500mg capsule once daily
3213702|NCT01100866|Placebo Comparator|Group 2|POMELLA™ placebo
3213703|NCT01100853|Active Comparator|Extended release VIVITROL injection 380 mg, 24 weeks|Efficacy of 24 week course of Extended Release VIVITROL 380 mg with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
3213704|NCT01100853|Placebo Comparator|VIVITROL placebo injection, 24 weeks|Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
3213705|NCT01100827||EGFR mutation status in patients|
3213706|NCT01100801|Experimental|TS-1 with cisplatin|"Chemotherapy injection (60mg/m2 cisplatin) will be given on day 1.~14 days of Oral TS-1 (40mg/m²) will be prescribed. Subjects will take it after breakfast and evening meal on Day 1-14 of a 3-weekly treatment cycle. Each cycle is about 21 days."
3213707|NCT01100801|Experimental|TS-1 with oxaliplatin|"Chemotherapy injection (100mg/m2 oxaliplatin) will be given on day 1.~14 days of Oral TS-1 (40mg/m²) will be prescribed. Subjects will take it after breakfast and evening meal on Day 1-14 of a 3-weekly treatment cycle. Each cycle is about 21 days."
3213708|NCT01100788|Placebo Comparator|Placebo|No treatment
3213709|NCT01100788|Experimental|scFOS 5 g|5 g scFOS
3213710|NCT01100788|Experimental|scFOS 8 g|8 g scFOS
3213711|NCT01100775|Experimental|Galantamine, then Placebo|Participants took lead-in 3 days of 4mg/ twice a day of galantamine followed by 8 mg on the 4th day, the day of testing. Then, after a period of at least one month, participants took lead-in 3 days of 4mg/ twice a day of placebo followed by 8 mg on the 4th day, the day of testing.
3213712|NCT01100775|Experimental|Placebo, then Galantamine|Participants took lead-in 3 days of 4mg/ twice a day of placebo followed by 8 mg on the 4th day, the day of testing. Then, after a period of at least one month, participants took lead-in 3 days of 4mg/ twice a day of galantamine followed by 8 mg on the 4th day, the day of testing.
3213713|NCT01100762|Experimental|Single Group|
3213714|NCT01100736|Experimental|Bosentan|Bosentan 125mg twice daily will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of bosentan therapy
3213715|NCT01100736|Experimental|Sitaxsentan|Sitaxsentan 100mg once daily + placebo tablet will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of sitaxsentan therapy
3213716|NCT01100736|Placebo Comparator|Placebo|Placebo tablet twice daily will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of placebo therapy
3213771|NCT01100281||PSP (Progressive supranuclear palsy)|
3213717|NCT01100723|Experimental|Computer directed dosing decisions|This study will be an open-label, non-randomized, single arm design. Patients will have their mineral and bone disorders managed by the computer directed algorithm. The computer algorithm will make recommendations for dosing active vitamin D and cinacalcet. The doses of these medications recommended by the algorithm will then be prescribed to the subjects participating in the study unless overridden by the patients primary attending nephrology for other clinical or safety concerns. At any time in the study, subjects may be on neither, one, or both of these medication depending on their laboratory results and the output recommendations of the algorithm.
3213718|NCT01100710||healthy volunteers|
3213719|NCT01100697||thoracal lesion|spinal lesion at thoracal level detected at prenatal ultrasound exam
3213720|NCT01100697||lumbar lesion|spinal lesion at lumbar level detected at prenatal ultrasound exam
3213721|NCT01100697||sacral lesion|spinal lesion at sacral level detected at prenatal ultrasound exam
3213722|NCT01100684|Experimental|Treatment|0.5 mg asimadoline bid
3213723|NCT01100684|Placebo Comparator|Placebo|Placebo
3213724|NCT01100671||Healthy patients|
3213725|NCT01100658|Active Comparator|Methylphenidate|Administered 1 capsule each day for 1 week, .3 mg/kg dose.
3213726|NCT01100658|Placebo Comparator|Placebo|Administered 1 capsule each day for 1 week.
3213727|NCT01100645|Experimental|Test|Sominex ® (Passiflora incarnata L. 50 mg, Valeriana officinalis L. 40 mg and Crataegus oxyacantha L. 30 mg)
3213728|NCT01100645|Placebo Comparator|Placebo|Excipient
3213729|NCT01100632|Experimental|Treatment|Treatment with the combination of Panax ginseng, vitamins and minerals
3213730|NCT01100632|Placebo Comparator|Placebo|Placebo.
3213731|NCT01100619|Experimental|All subjects|All subjects will receive daily XL184, and two single doses of rosiglitazone, 3 weeks apart
3213732|NCT01100606|Experimental|EUR-1008 (APT-1008) in Apple Juice|
3213733|NCT01100606|Experimental|EUR-1008 (APT-1008) in Apple Sauce|
3213734|NCT01100593|Active Comparator|1.75 inch catheter length|Length of catheter to be used
3213735|NCT01100593|Active Comparator|2.5 inch catheter length|length of catheter to be used
3213736|NCT01100580|Active Comparator|water therapy|"The term water therapy refers to an abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer)."
3213737|NCT01100580|Experimental|low salt diet + water therapy|low salt diet refers to a salt intake of 4 g/day
3213738|NCT01100567|Placebo Comparator|Placebo platform|Randomized to stand on placebo platform for 10 minutes/day
3213739|NCT01100567|Active Comparator|Low-magnitude mechanical stimulation|Randomized to stand on LMMS platform 10 minutes/daily
3213740|NCT01100554|Experimental|all patients|
3213741|NCT01100541|Experimental|Polymeric plate characteristics|Evaluation, in the volunteers viewpoint, of the polymeric plate characteristics.
3213742|NCT01100528|Experimental|Arm I|Patients receive dacarbazine IV on days 1 and 29. Beginning 4 weeks after the second dose of dacarbazine, patients receive recombinant interferon alfa-2b subcutaneously 3 times a week for 24 weeks in the absence of disease progression or unacceptable toxicity.
3213743|NCT01100515|Experimental|Experimental arm|Hyperbaric oxygen therapy at 2 absolute atmosphere (1-hour plateau) followed by 4 hours of normobaric oxygen therapy
3213744|NCT01100515|Active Comparator|Control|6 hours course of normobaric oxygen therapy via a face full mask
3213745|NCT01100502|Experimental|Brentuximab vedotin|brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
3213746|NCT01100502|Placebo Comparator|Placebo|placebo every 3 weeks by IV infusion
3213747|NCT01100489|Experimental|Arm I|Patients undergo breast-conserving surgery consisting of partial mastectomies followed by external beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
3213748|NCT01100463|Placebo Comparator|Placebo Lotion|
3213749|NCT01100463|Experimental|0.1% Uracil|
3213750|NCT01100450|Experimental|Resistance Training|
3213751|NCT01100437|Experimental|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|EMBEDA (morphine sulfate plus naltrexone hydrochloride ER) capsules crushed and mixed in solution and administered orally at each patient's stable dose, given either once daily or twice daily.
3213752|NCT01100437|Experimental|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole|EMBEDA (morphine sulfate plus naltrexone hydrochloride ER) capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily
3213753|NCT01100424|Experimental|Contact lens wearers|Contact lens wearers experienced three currently available contact lens/contact lens care combinations in randomized order: balafilcon A + Optifree RepleniSH, balafilcon A + ReNu MultiPlus, and balafilcon A + Unisol 4 saline.
3213754|NCT01100424|No Intervention|Non-lens wearers|Non-lens wearers completed one study visit and served as the control group.
3213755|NCT01100411|Active Comparator|Air Optix Aqua|Contact lens material: Lotrafilcon A
3213756|NCT01100411|Active Comparator|Biofinity|Contact lens material: Comfilcon A
3213757|NCT01100411|Active Comparator|Proclear|Contact lens material: Omafilcon A
3213758|NCT01100411|Active Comparator|Acuvue Oasys|Contact lens material: Senofilcon A
3213759|NCT01100411|Active Comparator|Acuvue 2|Contact lens material: Etafilcon A
3213760|NCT01100411|Active Comparator|Purevision|Contact lens material: Balafilcon A
3213761|NCT01100398||NAFLD/NASH prevalence|Any subject between the ages of 18-70 without known fatty liver disease who meet inclusion criteria
3213762|NCT01100385|Placebo Comparator|Healthy (placebo)|
3213763|NCT01100385|Active Comparator|Healthy (Ateronon)|
3213764|NCT01100385|Placebo Comparator|Cardiovascular Group (placebo)|
3213765|NCT01100385|Active Comparator|Cardiovascular Group (Ateronon)|
3213766|NCT01100320|Experimental|Reformulated OXY 40 mg|Reformulated OXY 40 mg x 1 dose
3213767|NCT01100320|Active Comparator|Original OxyContin® (OXY) 40 mg|Original OxyContin® (OXY) 40 mg x 1 dose
3213768|NCT01100307|Experimental|pegaptanib sodium|
3213769|NCT01100307|Sham Comparator|sham injection|
3213770|NCT01100294|Experimental|Vaccination with Fluval P|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant. Dose: 0.25 ml (total 3 μg HA), single dose.
3213774|NCT01100268|Experimental|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
3213775|NCT01100255|Active Comparator|Group A|0.5mg/kg IV ketamine infusion over 40 minutes then IV saline infusion over 40 minutes
3213776|NCT01100255|Active Comparator|Group B|IV saline infusion over 40 minutes then 0.5mg/kg IV ketamine infusion over 40 minutes
3213777|NCT01100242|Experimental|Arm 1: VELCADE and Sorafenib|Patients will be given VELCADE® (bortezomib) 1mg/m2 intravenously on days 1,4,8 & 11 and sorafenib at a dosage of 200 mg orally twice per day. One full course is comprised of 21 days.
3213778|NCT01100216|Active Comparator|Nicotine Lozenge|4 mg nicotine lozenge (LOZ
3213779|NCT01100216|Active Comparator|Camel Snus Frost|
3213780|NCT01100216|Active Comparator|Stonewall Spearment Tablet|
3213781|NCT01100216|Active Comparator|Skoal Wintergreen|
3213782|NCT01100203|Active Comparator|Treatment|
3213783|NCT01100203|No Intervention|Control|
3213784|NCT01100190|Experimental|NUVANCE Facial Rejuvenation System|
3213785|NCT01100177|Experimental|Sunitinib plus radiothery|"Sunitinib at doses of 37.5mg/m2/daily in a continuous dosing during 8 weeks.~After evaluation of efficacy, they will receive Sunitinib 37.5 mg/d and treatment with Radiation therapy (total dose 60 Gy).~After radiation therapy, Sunitinib al 37.5 mg/d will be continued until progression."
3213786|NCT01100164|Experimental|eszopiclone 3 mg|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
3213787|NCT01100164|Active Comparator|zopiclone 7,5mg|Zopiclone once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
3213788|NCT01100151|Experimental|RDC-1036 (ALKS 37)|Capsules for oral administration
3213789|NCT01100151|Placebo Comparator|Placebo|Capsules for oral administration
3213790|NCT01100125|Experimental|sitagliptin|
3213791|NCT01100125|Active Comparator|insulin dose increase|
3213792|NCT01100112|Experimental|Budesonide|Budesonide-MMX 9 mg tablet
3213793|NCT01100099|Experimental|Gluten challenge.|Diagnosis of celiac disease. Before and after a gluten challenge small bowel biopsies will be taken, and blood samples will be drawn for tetramer staining of gluten specific T cells.
3213794|NCT01100086|Experimental|Reformulated OXY 10 mg|Reformulated OXY 10 mg x 1 dose
3213795|NCT01100086|Active Comparator|Original OxyContin® (OXY)10 mg|Original OxyContin® (OXY)10 mg x 1 dose
3213796|NCT01100073||Patients with Parkinson's disease|Early and advanced Parkinson's disease patients
3213797|NCT01100060|Experimental|Group 1|Co-administer the test chloroquine (CQ) formulation (620 mg CQ base) plus microsphere azithromycin (AZ) (2000 mg) on Day 1.
3213798|NCT01100060|Active Comparator|Group 2|Co-administer the individual tablets of CQ 2 x 500 mg (600 mg CQ base) tablets plus AZ IR 4 x 500 mg tablets on Day 1.
3213799|NCT01100047|Experimental|1|
3213800|NCT01100047|Placebo Comparator|2|
3213801|NCT01100034||1|pediatric patients with plaque psoriasis on etanercept
3213802|NCT01100021|Experimental|tamsulosin + avanafil|
3213803|NCT01100021|Experimental|Doxazosin + avanafil|
3213804|NCT01100008|Experimental|Magnetic resonance imaging|
3213805|NCT01099995|Active Comparator|One HBO session|hyperbaric oxygen therapy one dive at 2 absolute atmosphere (1-hour plateau) - oxygen was delivered via a full face mask - followed by 4 hours of normobaric oxygen therapy
3213806|NCT01099995|Experimental|2 HBO sessions|Two sessions of hyperbaric oxygen therapy at 2 absolute atmosphere (1-hour plateau) with oxygen delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
3213807|NCT01099982||Advanced Heart Failure Therapy Group|Patients diagnosed with end stage heart failure undergoing either VAD implantation or heart transplantation.
3213808|NCT01099982||Normal Hearts Group|Control samples will be obtained from individuals undergoing other types of cardiac surgery during which it is routine to discard some tissue intraoperatively.
3213809|NCT01099969|Experimental|Glidescope with non-styletted Endotrol ETT|The patients in this arm will be intubated using a Glidescope videolaryngoscope with non-styletted Endotrol endotracheal tube (ETT).
3213810|NCT01099969|Active Comparator|Glidescope with styletted regular ETT|The patientsin this arm will be intubated using the glidescope videolaryngoscope and regular endotracheal tube (ETT) with gliderite stylet.
3213811|NCT01099969|Experimental|McGrath with non-styletted Endotrol ETT|The patients in this arm will be intubated using McGrath videolaryngoscope and non-styletted Endotrol endotracheal tube (ETT).
3213812|NCT01099969|Active Comparator|McGrath with with styletted regular ETT|The patients receiving this arm will be intubation using McGrath videolaryngoscope and regular endotracheal tube (ETT) with Gliderite stylet.
3213813|NCT01099956||diabetes group|
3213814|NCT01099956||control group|
3213815|NCT01099943|Experimental|Intervention: Education, Decision Support Tools|Clinic sites randomized to the intervention group will participate in an educational intervention comprised of lectures on antimicrobial resistance and implement decision support tools to guide primary care providers in appropriate antibiotic prescribing for common infectious conditions.
3213816|NCT01099943|No Intervention|No education, no implemented decision support tools|Clinics randomized to the control will not participate in the education intervention and implementation of decision support tools.
3213817|NCT01099930|Active Comparator|Non-randomized control group|Patients meeting inclusion/exclusion criteria not consenting to treatment will be requested to consent to control group and followed while receiving standard of care.
3213818|NCT01099930|Experimental|Stem Cell Transplantation|Patients will undergo stem cell transplantation for the treatment of Multiple Sclerosis
3213819|NCT01099917|Experimental|Maitake|This is a phase II trial examining hematopoietic response in MDS patients.
3213820|NCT01099904|Experimental|1|Normal Renal Function
3213821|NCT01099904|Experimental|2|Mild Renal Impairment
3213822|NCT01099904|Experimental|3|Moderate Renal Impairment
3213823|NCT01099891|Experimental|EGF|
3213824|NCT01099891|Placebo Comparator|Placebo|
3213825|NCT01099878|Active Comparator|Cycling Exercise with Functional Electrical Stimulation|Cycling Exercise with Functional Electrical Stimulation
3213826|NCT01099878|Placebo Comparator|Cycling Exercise|Cycling Exercise
3213827|NCT01099839|Experimental|one group|"Subjects will receive ASP1941 alone, Miglitol alone and ASP1941 + Miglitol in different order."
3213828|NCT01099826|Experimental|lifestyle counseling tailored|
3213829|NCT01099826|Experimental|lifestyle counseling motivational|
3213830|NCT01099826|No Intervention|control|
3213831|NCT01099813||Inpatients assessed for critical care|Patients admitted to Critical Care Units participating in the ICNARC CMP programme who have been assessed at any time on a ward prior to ICU admission by a critical care decision maker (e.g. the CCOT or any member of the medical staff on duty for the unit)
3213832|NCT01099800||Mexican/Mexican American families|Parents and children who self-identify as being of Mexican heritage whether US-born or Mexican-born
3213833|NCT01099800||Puerto Rican families|Parents and children who self-identify as Puerto Rican whether US-born or island-born.
3213834|NCT01099787||FAP IBS|
3213835|NCT01099774|Experimental|Bimatoprost 0.03% Formulation B Ophthalmic Solution|Bimatoprost 0.03% Formulation B Ophthalmic Solution
3213836|NCT01099774|Active Comparator|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% Ophthalmic Solution
3213837|NCT01099761|Experimental|ACE-031 0.5 mg/kg q4wk|
3213838|NCT01099761|Experimental|ACE-031 1.0 mg/kg q2wk|
3213839|NCT01099761|Placebo Comparator|Placebo|
3213840|NCT01099748|Active Comparator|Methadone|Dose of methadone must not change from 1 week prior to study start and through the duration of the study.
3213841|NCT01099748|Experimental|Lersivirine + Methadone|
3213842|NCT01099735||CPAP, Manometry|Patients undergoing Manometry before weight loss surgery
3213843|NCT01099722|Active Comparator|Inhaler|
3213844|NCT01099722|Active Comparator|inhaler|Symbicort
3213845|NCT01099709|Experimental|Reformulated OXY 10 mg|Reformulated OXY 10 mg x 1 dose
3213846|NCT01099709|Active Comparator|Original OxyContin® (OXY) 10 mg|Original OxyContin® (OXY) 10 mg x 1 dose
3213847|NCT01099696|Experimental|B. infantis 35624|B. infantis 35624 in white capsules
3213848|NCT01099696|Placebo Comparator|placebo|white placebo capsules (inert)
3213849|NCT01099683|Experimental|NRL001|All subjects will receive 10 mg NRL001 in a 2 g rectal suppository
3213850|NCT01099683|Placebo Comparator|Placebo|All subjects will receive placebo
3213851|NCT01099670|Experimental|7.5 mg NRL001|Nine subjects will receive 7.5 mg NRL001 in a 2 g suppository; three will receive matching placebo.
3213852|NCT01099670|Experimental|10 mg NRL001|Nine subjects will receive 10 mg NRL001 in a 2 g suppository; three will receive matching placebo.
3213853|NCT01099670|Experimental|12.5 mg NRL001|Nine subjects will receive 12.5 mg NRL001 in a 2 g suppository; three will receive matching placebo.
3213854|NCT01099670|Experimental|15 mg NRL001|Nine subjects will receive 15 mg NRL001 in a 2 g suppository; three will receive matching placebo.
3213855|NCT01099657|Experimental|Virtual Reality Hypnosis|Virtual Reality Hypnosis for chronic pain
3213856|NCT01099657|Experimental|Virtual Reality Distraction|Virtual Reality Distraction for Chronic Pain
3213857|NCT01099644|Experimental|131 I-8H9|This is a phase I study of 131I-8H9 for patients with DSRCT and other 8H9-reactive solid tumors metastatic to the peritoneum.
3213858|NCT01099631|Experimental|Treatment with Salmonella typhimurium|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
3213859|NCT01099618|Active Comparator|Metformin|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg (n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
3213860|NCT01099618|Active Comparator|Sitagliptin|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000 mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg (n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
3213861|NCT01099618|Placebo Comparator|Placebo|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000 mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg(n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
3213862|NCT01099605|Placebo Comparator|Pump device|One arm will have continuous subcutaneous infusion of normal saline.
3213863|NCT01099605|Active Comparator|Bupivacaine|will receive continuous infusion of bupivacaine
3213864|NCT01099579|Experimental|Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg|Patients weighing 5 to <10 kg received atazanavir (ATV), 150-mg powder dosed in 50-mg packets, and ritonavir (RTV) oral solution, 80 mg. Stage 1: Initial dose was determined by patient's weight on the day of first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage. All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from the powder to the capsule formulation of ATV. Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
3213924|NCT01099150|Experimental|42 healthy volunteers - crossover|"Acute consumption of three interventions (60 g dark chocolate enriched in flavan-3-ols, 60 g standard dark chocolate, or 60 g white chocolate) on three separate days (at least 2 weeks apart) in random order.~Post-prandial measurements at t = 0 h, t = 2 h and t = 6 h."
3213925|NCT01099137|Experimental|Vildagliptin|Vildagliptin will be added to uncontrolled diabetic patients with sulphonylurea and metformin
3213865|NCT01099579|Experimental|Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg|Patients weighing 10 to <15 kg received ATV powder, 200 mg, dosed in 50-mg sachet packets and RTV oral solution, 80 mg. Stage 1: Initial dose was determined by the patient's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from the powder to the capsule formulation of ATV. Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
3213866|NCT01099579|Experimental|Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg|Patients weighing 15 to <25 kg received 250 mg of ATV powder dosed in 50-mg sachet packets, with 80 mg of RTV solution. Stage 1: Initial dose was determined by the patient's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from powder to the capsule formulation of ATV. Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
3213867|NCT01099566|Experimental|Prasugrel|
3213868|NCT01099566|Placebo Comparator|pills consisting of lactose-starch|
3213869|NCT01099553|Other|Standard preparation instructions|The control arm will receive written instructions on preparing for a colonoscopy per standard of care at Boston Medical Center
3213870|NCT01099553|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus instructions asking them to watch an educational video on the Center for Digestive Disorders website
3213871|NCT01099540|Experimental|Pazopanib|
3213872|NCT01099527|Experimental|Everolimus|"Everolimus (RAD001) dose escalation of capecitabine, everolimus~Capecitabine dose escalation of capecitabine, everolimus"
3213873|NCT01099514|Experimental|Nilotinib|Nilotinib 400 mg (2 capsules) PO BID q 28 days
3213874|NCT01099501|Active Comparator|Oxepa|Oxepa (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
3213875|NCT01099501|Active Comparator|Control group|Pulmocare or Jevity (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
3213876|NCT01099488|Other|All subjects|Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received a GSK2231392A vaccine, were enrolled for blood withdrawal to support the development of CD8+ T cell immunological detection assays.
3213877|NCT01099475|Experimental|Pringle manoeuvre 15 minutes|When intermittent pedicle occlusion during parenchymal transection is necessary, 2 cycles of 15 minutes of hepatic inflow occlusion will be applied each followed by 5 minutes of reperfusion. During inflow occlusion, the complete portal triad was clamped using a rubber sling.
3213878|NCT01099475|Experimental|Pringle manoeuvre 30 minutes|When intermittent pedicle occlusion during parenchymal transection is necessary, 1 cycle of 30 minutes of hepatic inflow occlusion will be applied followed by 5 minutes of reperfusion. During inflow occlusion, the complete portal triad was clamped using a rubber sling.
3213879|NCT01099462||Children with fever|
3213880|NCT01099449|Experimental|Arm I|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and after oxaliplatin administration (part of FOLFOX chemotherapy comprising leucovorin calcium, fluorouracil, and oxaliplatin).
3213881|NCT01099449|Placebo Comparator|Arm II|Patients receive placebo IV over 30 minutes immediately before and after oxaliplatin administration (part of FOLFOX chemotherapy).
3213882|NCT01099449|Experimental|Arm III|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and placebo IV over 30 minutes immediately after oxaliplatin administration (part of FOLFOX chemotherapy).
3213883|NCT01099436|Experimental|TAC + Zoledronic acid|six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC) and zoledronic acid (Zometa)
3213884|NCT01099436|Active Comparator|TAC|six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC)
3213885|NCT01099423|Active Comparator|Immediate nephrectomy|Surgery followed by Sunitinib
3213886|NCT01099423|Experimental|Deferred nephrectomy|Sunitinib (3 cycles) followed by surgery followed by Sunitinib
3213887|NCT01099410||Group 1|volunteer subjects
3213888|NCT01099397||PEAR Participants|All participants eligible for PEAR study. Each participant will be have fasting and oral glucose tolerance test data collected.
3213889|NCT01099384|Active Comparator|Behavioral: written self-help materials|Behavioral: written self-help materials
3213890|NCT01099384|Experimental|Group behavioral counseling|Group behavioral counseling, weekend program
3213891|NCT01099371|Experimental|exercise|
3213892|NCT01099358|Experimental|Cetuximab and Cisplatin (D)|"Cycle 1 (1 week, combination therapy):~400 milligrams per square meter (mg/m²) cetuximab administered (admin) intravenously (I.V) on week 1, day 1.~100 mg/m² cisplatin administered I.V on week 1, day 1. Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/m²/day (d) administered starting on week 1, day 1.~After 1 cycle, participants may continue treatment as determined by the physician until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
3213926|NCT01099137|Active Comparator|Sulphonylurea dose-up|Sulphonylurea dose will be increased to uncontrolled diabetic patients with sulphonylurea and metformin
3213927|NCT01099124|Experimental|M2ES combined with chemotherapy|
3213928|NCT01099111||Irritable Bowel Syndrome|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
3213893|NCT01099358|Experimental|Cetuximab and Cisplatin (C)|"Cycle 1 (4 weeks, combination therapy):~100 mg/m² Cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3 and 4, day 1.~Cycle 2-6 (3 weeks combination therapy):~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 1, 2, and 3, day 1.~After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
3213894|NCT01099358|Experimental|Cetuximab on Cisplatin (B)|"Cycle 1:~400 mg/m² cetuximab admin I.V on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 2 and 3, day 1.~Cycle 2:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1- 4.~250 mg/m² cetuximab admin I.V on week 1-3, day 1.~Cycle 3 + :~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~250 mg/m² cetuximab admin I.V on week 1-3, day 1.~After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
3213895|NCT01099358|Experimental|Cisplatin on Cetuximab (A)|"Cycle 1:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3, day 1.~Cycle 2 +:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~250 mg/m² cetuximab admin I.V on weeks 1-3, day 1.~After 7 cycles, participants may then receive weekly Cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
3213896|NCT01099345||Group 1 - OAB with DO+|Subjects that DO+ nocturia
3213897|NCT01099345||Group 2- OAB with DO-|Subjects that DO- nocturia
3213898|NCT01099332|Active Comparator|Gastro-retentive zinc cysteine tablet|Once daily administration by mouth of a gastro-retentive, sustained-release preparation of zinc cysteine with excipients, all G.R.A.S., with adequate water.
3213899|NCT01099332|Placebo Comparator|Identical appearance of placebo with active comparator|Once daily administration of placebo of identical physical appearance to that of active comparator with similar amount of water.
3213900|NCT01099319|Experimental|Renalof|
3213901|NCT01099319|Placebo Comparator|Placebo|
3213902|NCT01099306|Active Comparator|intervention|pharmacist-physician collaborative approach to manage Metabolic syndrome
3213903|NCT01099306|No Intervention|control|physician only team to manage Metabolic syndrome
3213904|NCT01099293||Cirrhosis, w/o hepatic encephalopathy|Patients with liver cirrhosis without hepatic encephalopathy by clinical (West-Haven), neurophysiological tests (PHES) nor Critical Flicker Frequency evidence.
3213905|NCT01099293||Cirrhosis-minimal hepatic encephalopathy|Patients with cirrhosis, without clinical evidence of hepatic encephalopathy (West Haven 0) and with positive tests for both, PHES and CFF.
3213906|NCT01099293||Cirrhosis, Hepatic encephalopathy I|Patients with cirrhosis and clinical evidence of hepatic encephalopathy with a West Haven score of I.
3213907|NCT01099293||Control|Healthy subjects willing to participate in the study
3213908|NCT01099280|Experimental|oxytocin group|2 milliunits/min and doubled every 30 minutes to a maximum of 32 milliunits/min or until four contractions in 10 minutes was achieved
3213909|NCT01099280|Experimental|dinoprostone and oxytocin|a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
3213910|NCT01099267||Lenalidomide|No intervention was given during this extension study which gathered survival information on participants of study NCT00065156 (Celgene study CC-5013-MDS-003). During the CC-5013-MDS-003 study, participants initially took a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle. The study was amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.
3213911|NCT01099228|Active Comparator|131-I MIBG and 111I-n pentetreotide|131-I MIBG and 111I-n pentetreotide
3213912|NCT01099228|Active Comparator|131-I MIBG and In-111 DOTATATE|131-I MIBG and In-111 DOTATATE
3213913|NCT01099215|Other|PVS-10200|Each subject will receive one treatment of PVS-10200 delivered by ultrasound guided injection perivascular to the region of the target lesion within 24 hours of the completed angioplasty and stent placement.
3213914|NCT01099202|Experimental|Procrit|Starting dose 40,000 units subcutaneously once a week with chemotherapy.
3213915|NCT01099202|No Intervention|No Procrit|No intervention.
3213916|NCT01099189||Observed cohort|All patients recruited. Observed for clinical outcomes
3213917|NCT01099176|Experimental|Atorvastatin|10mg of Atorvastatin
3213918|NCT01099176|Experimental|Fenofibrate|267mg of Fenofibrate
3213919|NCT01099176|Experimental|Fenofibrate and atorvastatin|10mg of Atorvastatin and 267mg of fenofibrate
3213920|NCT01099176|Placebo Comparator|Therapeutic Lifestyle Change|Placebo and Therapeutic Lifestyle Change
3213921|NCT01099163|Experimental|3g CLA|3 g CLA (50:50%) AND other diabetes medication currently prescribed to participant, 100 IU vitamin E
3213922|NCT01099163|Active Comparator|3 g CLA|3 g CLA (50:50%) AND other diabetes medication currently prescribed to participant, vitamin E placebo
3213923|NCT01099163|No Intervention|3 g MCT + vit E placebo|3 g MCT AND other diabetes medication currently prescribed to participant, 100 IU vitamin E placebo
3213929|NCT01099111||Ulcerative Colitis|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
3213930|NCT01099111||Crohn's Disease|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
3213931|NCT01099111||Colo Rectal Cancer|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
3213932|NCT01099111||Control: Normal Subjects|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
3213933|NCT01099098||Patients with TB sequelae|
3213934|NCT01099098||People without TB sequelae|
3213935|NCT01099085|Active Comparator|XP/simvastatin|Capecitabine/cisplatin + simvastatin
3213936|NCT01099085|Placebo Comparator|XP/placebo|Capecitabine/cisplatin + placebo
3213937|NCT01099072|Active Comparator|Methylphenidate+placebo|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Placebo
3213938|NCT01099072|Experimental|methylphenidate+carnitine|
3213939|NCT01099059|Active Comparator|Ritalin|receive ritalin depending on weight
3213940|NCT01099059|Experimental|Amantadine|100-150 mg depending on weight (100 mg/day for <30 Kg and 150 mg/day for >30 Kg)
3213941|NCT01099046|No Intervention|medication only|medication = anti-diuretics
3213942|NCT01099046|Active Comparator|medication + water intake|anti-diuretics + water intake (at least 2.0 litters per day)
3213943|NCT01099046|Active Comparator|medication + tympanic tubing|anti-diuretics + tympanic tubing (under local anesthesia)
3213944|NCT01099046|Active Comparator|medication + regular sleep|anti-diuretics + regular sleep (regular sleep program under dark everynight)
3213945|NCT01099033||Hiatal/Paraesophageal hernia patients|patients with hiatal or paraesophageal hernias
3213946|NCT01099033||control group|patients without hiatal or paraesophageal hernias who are undergoing crural dissection for heller myotomy, or who are undergoing gastric bypass surgery
3213947|NCT01099007|Active Comparator|At Home|Participants in the At Home group receive a workbook from the research staff at their baseline visit that outlines an accepted nutrition and physical activity program to complete on their own.
3213948|NCT01099007|Experimental|In Person|Participants in the In Person group have weekly visits for the 12 weeks to the research office. The first visit can last up to one and a half hours and each subsequent visit can last approximately one hour. Group meetings provide appropriate nutrition and physical activity information as well as behavioral change strategies. Sessions also include some light physical activity (equal to brisk walking).
3213949|NCT01098994|Other|Haptoglobin 1/1|Individuals with type 1 diabetes and the Haptoglobin 1/1 phenotype
3213950|NCT01098994|Other|Haptoglobin 2/1|Individuals with type 1 diabetes and the Haptoglobin 2/1 phenotype
3213951|NCT01098994|Other|Haptoglobin 2/2|Individuals with type 1 diabetes and the Haptoglobin 2/2 phenotype
3213952|NCT01098981|Experimental|Target group|A combined treatment with transcranial US and systemic tPA
3213953|NCT01098981|Active Comparator|Control group|Systemic tPA alone
3213954|NCT01098968|No Intervention|Normal PE|2 Physical Education sessions / week
3213955|NCT01098968|Experimental|PE Volume|4 Physical Education sessions/week (increased volume)
3213956|NCT01098968|Experimental|PE Volume + Intensity|4 Physical Education sessions/week of high intensity (increased volume and intensity)
3213957|NCT01098955|Experimental|ACT Group 1|Acceptance and Commitment Therapy (ACT). Varenicline 2 mg daily for 12 weeks.
3213958|NCT01098955|Experimental|MBC Group 2|Motivational and Behavioral Counseling (MBC). Varenicline 2 mg daily for 12 weeks.
3213959|NCT01098942||Surgical|Roux-en-Y gastric bypass surgery
3213960|NCT01098942||Non-surgical|Non-surgical lifestyle weight management
3213961|NCT01098929||Congenital Diaphragmatic Hernia (CDH)|Individuals affected with congenital diaphragmatic hernia (CDH)
3213962|NCT01098929||Unaffected|Healthy family members of individuals affected with congenital diaphragmatic hernia (CDH)
3213963|NCT01098916|Experimental|X-rays at home|Home hospitalized elderly patients undergo X-rays at home
3213964|NCT01098916|Active Comparator|Hospital X-rays|Home hospitalized elderly patients undergo X-rays examinations in hospital
3213965|NCT01098903||Sunitinib|Patients with a malignancy treated with sunitinib
3213966|NCT01098890|Placebo Comparator|Placebo|Placebo will be administered every 12 hours for a total five doses. Patients will be followed for a total of 6 months.
3213967|NCT01098890|Active Comparator|tPA (tissue plaminogen activator)|Intraventricular TPA will be administered every 12 hours for a total five doses. Patients will be followed for a total of 6 months.
3213968|NCT01098877|Placebo Comparator|Placebo|
3213969|NCT01098877|Experimental|Cohort 1, 1mg|
3213970|NCT01098877|Experimental|Cohort 1, 3mg|
3213971|NCT01098877|Experimental|Cohort 1, 10mg|
3213972|NCT01098877|Experimental|Cohort 2, 30mg|
3213973|NCT01098877|Experimental|Cohort 2, 100mg|
3213974|NCT01098877|Experimental|Cohort 2, 300mg|
3213975|NCT01098877|Experimental|Cohort 3, 600mg|
3213976|NCT01098877|Experimental|Cohort 3, 900mg|
3213977|NCT01098877|Experimental|Cohort 3, up to 900mg (fed)|
3213978|NCT01098877|Placebo Comparator|Cohort 3, placebo (fed)|
3213979|NCT01098851||Obstructive Sleep Apnea|Surgery patients at high risk for Obstructive Sleep Apnea
3213980|NCT01098851||Surgery Patients|Surgery patients at low risk for Obstructive Sleep Apnea
3213981|NCT01098838|Experimental|Weekly dosing of LCL161|by mouth (oral)
3213982|NCT01098838|Experimental|Comparison of LCL161|tablet versus liquid
3213983|NCT01098838|Experimental|Twice daily dosing of LCL161|by mouth for 4 days followed by a 3-day rest period every week
3213984|NCT01098825||District VI AAP clinicians|
3213985|NCT01098812|Active Comparator|Control IOL|Approved Intraocular control lens
3213986|NCT01098812|Experimental|Toric IOL|Investigational Toric IOL
3213987|NCT01098812|Experimental|Higher Cylinder Toric IOL|Investigational Toric IOLs with higher cylinder powers.
3213988|NCT01098799||Control|Healthy controls
3213989|NCT01098799||Chronic kidney disease-1|Chronic kidney disease not taking dialysis treatment
3213990|NCT01098799||Kidney Transplant|Kidney transplants
3213991|NCT01098786||Healthy|
3213992|NCT01098773||patients requiring ventilation|
3213993|NCT01098773||patients who weaned permanently|
3213994|NCT01098760|Experimental|Arm 1|
3213995|NCT01098747|Experimental|Treatment A|
3213996|NCT01098747|Active Comparator|Treatment B|
3213997|NCT01098747|Active Comparator|Treatment C|
3213998|NCT01098747|Placebo Comparator|Treatment D|
3213999|NCT01098734|Placebo Comparator|Group 1|0%; vehicle cream
3214000|NCT01098734|Active Comparator|Group 2|0.5% WBI-1001 cream
3214001|NCT01098734|Active Comparator|Group 3|1.0% WBI-1001 cream
3214002|NCT01098721|Placebo Comparator|Group 1|A placebo cream applied topically twice daily (BID)by each of 20 patients, once in the morning and once in the evening for 12 weeks.
3214003|NCT01098721|Active Comparator|Group 2|A 1.0% WBI-1001 cream applied topically twice daily (BID) by each of 40 patients, once in the morning and once in the evening for 12 weeks.
3214004|NCT01098695|Experimental|EcoFIT offered|
3214005|NCT01098695|No Intervention|No Feedback or services offered|
3214006|NCT01098656|Experimental|lenalidomide|
3214007|NCT01098656|No Intervention|Observation|
3214008|NCT01098630||Group I (limited participation)|Patients do not complete any questionnaires at baseline. At baseline, patients' medical record information is collected; sites complete the Functional Comorbidity Index; and physicians, nurses, and study coordinators complete the follow-up questionnaire. Staff complete the treatment review form after treatment or 7 months after study registration.
3214009|NCT01098630||Group II (full participation)|Patients complete the Patient Registration Survey and Patient Questionnaire at baseline. At baseline, patients' medical record information is collected; sites complete the Functional Comorbidity Index; and physicians, nurses, and study coordinators complete the follow-up questionnaire. Staff complete the treatment review form after treatment or 7 months after study registration.
3214010|NCT01098617||hemorrhage|The patients who had bleeding induced by endoscopic sphincterotomy
3214011|NCT01098604|Active Comparator|32mm ceramic head group|patients performed with THA using 32mm ceramic head
3214012|NCT01098604|Active Comparator|28mm ceramic head group|patients performed with THA using 28mm ceramic head
3214013|NCT01098591||Myocardial infarction|Patients with post-myocardial infarction receiving cell therapy either intracoronarily or intramyocardial
3214014|NCT01098591||Ischemic cardiomyopathy|Patients with ischemic cardiomyopathy treated with cell therapy either intracoronarily or intramyocardial
3214015|NCT01098578|Experimental|Floseal|Received 1 syringe of Floseal for treatment of posterior epistaxis.
3214016|NCT01098565|Experimental|Study device arm|
3214017|NCT01098552||High-risk radical prostatectomy patients|
3214018|NCT01098552||Primary external beam radiotherapy patients|
3214019|NCT01098552||Primary prostate brachytherapy patients|
3214020|NCT01098552||Hormone refractory prostate cancer patients|
3214021|NCT01098552||Active Surveillance|
3214022|NCT01098552||Prostate biopsy patients|
3214023|NCT01098539|Active Comparator|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
3214024|NCT01098539|Active Comparator|sitagliptin|albiglutide matching placebo + sitagliptin
3214025|NCT01098526|Experimental|Cohort 1|Subjects will receive a single dose of GSK1349572 100 mg in Period 1 followed by a washout of at least 6 days. Subjects will then receive GSK1349572 50 mg once a day for 5 days in Period 2. Period 3 will begin immediately after Period 2. In Period 3 subjects will receive GSK1349572 50 mg once a day in the morning and Efavirenz 600 mg once a day at bedtime for 14 days. There will be a screening visit up to 30 days before Period 1 and a follow up visit 7-14 days after the end of Period 3.
3214026|NCT01098513|Experimental|Part A|Subjects will be randomized in a three-way crossover design to receive a single dose of each of three different tablet formulations of GSK1349572 50 mg (2 tablets). Formulation AP, AW and AX.
3214027|NCT01098513|Experimental|Part B|A total of 18 subjects who complete Part A will return for Part B. Subjects from Part A will be asked to participate on a first come first served basis until there are 18 subjects, at which time enrolment to Part B will be closed. Part B will be a three way crossover design using either formulation AW or AX depending upon the results from Part A. Subjects will receive a single dose of 50 mg GSK1349572 with either a low fat, moderate fat or high fat meal in each period.
3214028|NCT01098500||Cancer patients|Adults (age ≥18 years) with at least two ICD-9 codes for a particular cancer within a 6 month timeframe and at least one code for a TKI drug that occurs on or after the first cancer diagnosis code
3214029|NCT01098487|Experimental|Open Label|Oral eltrombopag once daily, starting dose 50 mg (or 25 mg for subjects of East Asian ancestry).
3214030|NCT01098474|Experimental|Group A|Subjects will receive 1 dose of GSK's investigational vaccine 692342.
3214031|NCT01098474|Experimental|Group B|Subjects will receive 2 doses of GSK's investigational vaccine 692342.
3214032|NCT01098474|Active Comparator|Group C|Subjects will receive 3 doses of a Menjugate™.
3214033|NCT01098474|Experimental|Group D|Subjects will receive 1 dose of GSK's investigational vaccine 692342 concomitantly with the last dose of their primary Expanded Programme on Immunisation vaccines regimen.
3214034|NCT01098474|Experimental|Group E|Subjects will receive 2 doses of GSK's investigational vaccine 692342, one month apart, concomitantly with the last two doses of their primary Expanded Programme on Immunisation vaccines regimen.
3214035|NCT01098474|Active Comparator|Group F|Subjects will receive the primary Expanded Programme on Immunisation vaccines regimen.
3214036|NCT01098461|Active Comparator|albiglutide 15mg weekly|once weekly subcutaneous injection of albiglutide 15mg
3214037|NCT01098461|Active Comparator|albiglutide 30mg weekly|once weekly subcutaneous injection of albiglutide 30mg
3214038|NCT01098461|Active Comparator|albiglutide 30mg every other week|subcutaneous injection of 30mg albiglutide every other week
3214039|NCT01098461|Placebo Comparator|placebo|once weekly subcutaneous injection of placebo to match albiglutide
3214040|NCT01098448|Active Comparator|Scaling and root planing|scaling and root planing as a solo therapy
3214041|NCT01098448|Experimental|Periodontal surgery|
3214042|NCT01098448|Experimental|systemic antibiotics|
3214043|NCT01098448|Experimental|Local delivery of tetracycline|
3214044|NCT01098448|Experimental|local antibiotic and systemic antibiotics|
3214045|NCT01098448|Experimental|local antibiotics and surgery|
3214046|NCT01098448|Experimental|systemic antibiotics and surgery|
3214047|NCT01098448|Experimental|local and systemic antibiotics and surgery|
3214048|NCT01098435|Experimental|RDC-0313 (ALKS 33)|2-capsules taken orally
3214049|NCT01098435|Placebo Comparator|Placebo|2-capsules taken orally
3214050|NCT01098422|Experimental|Yttrium-90 Radioactive Resin Microspheres|
3214051|NCT01098409|Experimental|sodium nitrite 24 hours before|
3214052|NCT01098409|Experimental|sodium nitrite during surgery|
3214053|NCT01098409|Placebo Comparator|0.9% sodium chloride|
3214054|NCT01098383|Placebo Comparator|Placebo for AChEI and Choline|
3214055|NCT01098383|Experimental|AChEI and Choline|Acetyl-choline Esterase Inhibitor and Choline supplements
3214056|NCT01098357|Experimental|Biochaperone PDGF-BB low dose|BioChaperone PDGF-BB is a new formulation of the B isoform dimer of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) containing the new excipient Biochaperone, a dextran modified polymer. The finished product is a sterile multi-dose spray vial.
3214057|NCT01098357|Experimental|Biochaperone PDGF-BB High dose|BioChaperone PDGF-BB is a new formulation of the B isoform dimer of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) containing the new excipient Biochaperone, a dextran modified polymer. The finished product is a sterile multi-dose spray vial.
3214058|NCT01098357|Active Comparator|Regranex|Becaplermin gel (Regranex® Gel 0.01%, Systagenix, formerly and Johnson & Johnson) is a topical gel of rhPDGF-BB conditioned in a gel tube.
3214059|NCT01098357|Experimental|Very Low Dose BioChaperone PDGF-BB|BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
3214060|NCT01098318|Experimental|Rhodiola rosea|Herbal extract
3214061|NCT01098318|Active Comparator|Sertraline|Conventional anti-depressant
3214062|NCT01098318|Placebo Comparator|Sugar pill|Lactose monohydrate
3214063|NCT01098305|Active Comparator|Varenicline|
3214064|NCT01098305|Placebo Comparator|Placebo|
3214065|NCT01098292||Healthy Control|"Healthy Control participants do not suffer from any Urological Chronic Pelvic Pain Syndromes or from the following conditions:~Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome"
3214066|NCT01098292||Positive Control|"Positive Control participants do not suffer from any Urological Pelvic Pain Syndromes like Interstitial Cystitis and/or Chronic Prostatitis. However Positive Controls have a history of one of the following conditions:~Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome"
3214067|NCT01098266|Experimental|A: NGR-hTNF + BIC|NGR-hTNF plus Best Investigator's Choice
3214068|NCT01098266|Placebo Comparator|B: Placebo+BIC|Placebo plus Best Investigator's Choice
3214069|NCT01098253|Experimental|Adherence Intervention|Factors affecting adherence to oral hypoglycemic agents and antidepressants were addressed using a problem solving process.
3214070|NCT01098253|No Intervention|Usual Care|
3214071|NCT01098240|Experimental|Active Treatment|CP-601,927
3214072|NCT01098240|Placebo Comparator|Placebo|Placebo
3214073|NCT01098227||RSV positive subjects|Subjects admitted to Winthrop University Hospital with lower viral respiratory infection and RSV positive status by DFA and/or Viral culture
3214074|NCT01098227||RSV negative subjects|Subjects admitted to Winthrop University Hospital with a lower viral respiratory infection and RSV status negative by DFA and viral culture. these subjects may be positive for other viruses detected by DFA or viral culture (Adenovirus, Influenza A or B, Metapneumovirus or parainfluenza) or not
3214075|NCT01098227||Control group|Children in the same age range without respiratory conditions and who are well enough to perform the test from the out patient setting
3214076|NCT01098175||Control group|open surgery with exposure of the surgical wound to the air.
3214077|NCT01098175||Full peritoneal conditioning|Full peritoneum cavity conditioning will be performed as follows. A continuous flow of less than 0.5 l/min of gas will be instilled in the lowest part of the operating wound. As gas premixed bottles with CO2+ 4% of oxygen and 10% of N2O will be used. This gas will be humidified and at 31-32 °C to be achieved by a commercial humidifier (Fisher and Paykel) programmed in order to maintain 100% relative humidity at 31-32°C upon entrance of the peritoneal cavity.
3214078|NCT01098162||Vimpat®|Routine treatment in accordance with the local marketing authorization for Vimpat® added to one Baseline antiepileptic drug.
3214079|NCT01098149|Active Comparator|AFB stand alone|Patients are switched in AFB treatment, without blood volume control.
3214080|NCT01098149|Active Comparator|BD and BVC|Patients are switched into bicarbonate dialysis with Blood Volume Control
3214081|NCT01098136|Active Comparator|Chiropractic treatment|Management for one-sided pelvic pain, as decided by the chiropractor
3214082|NCT01098136|Active Comparator|Conventional health care|Conventional health care for one-sided pelvic pain
3214083|NCT01098136|Active Comparator|Conventional and alternative treatment|Treament of pregnant women with other pelvic pain syndromes.
3214084|NCT01098123||Diet counseling, nutritional index|Lightweight as athletes with weight limit
3214085|NCT01098123||nutritional index|Heavyweight athletes without weight limit
3214086|NCT01098110|Experimental|Asenapine 5 mg BID|Participants received a 5 mg asenapine fast dissolving tablet twice daily (BID) for 6 weeks.
3214087|NCT01098110|Experimental|Asenapine 10 mg BID|Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.
3214088|NCT01098110|Placebo Comparator|Placebo BID|Participants received matching placebo BID for 6 weeks.
3214089|NCT01098097||Peginterferon alpha and ribavirin|Peginterferon alpha and ribavirin will be administered at the discretion of the treating physician, in accordance per label according to local guidelines for all participating countries.
3214090|NCT01098084|Experimental|Decitabine|
3214091|NCT01098071|Experimental|mometasone furoate nasal spray|
3214092|NCT01098058|Experimental|CBT plus treatment as usual|
3214093|NCT01098058|Active Comparator|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
3214094|NCT01098045||HIV-infection with fat redistribution (lipoatrophy)|"Evidence of HIV infection~Age ≥ 20 and ≤ 60 years of age~BMI measurement between 18-24 kg/m2~HIV positive, on a stable HAART treatment regimen (including an NRTI) for > 12 months~No evidence of fat redistribution rated by the investigator."
3214095|NCT01098045||Healthy controls|"No history of HIV infection~Age ≥ 20 and ≤ 60 years of age~BMI measurement between 18-29.9 kg/m2"
3214096|NCT01098045||HIV-infected with fat redistribution (lipohypertrophy)|"Evidence of HIV infection~Age ≥ 20 and ≤ 60 years of age~BMI measurement between 25-29.9 kg/m2~HIV positive, on a stable HAART treatment regimen (including an NRTI) for > 12 months~Evidence of significant fat redistribution rated by the investigator, including 1) significant fat atrophy of the face, arms or legs, and 2) significant increase in fat accumulation of the neck."
3214097|NCT01098045||Dicer Cohort|30 men [HV-infected with fat redistribution (n = 10), HIV-infected without fat redistribution (n=10), and healthy controls (n= 10)] will be recruited for this group.
3214098|NCT01098032|Active Comparator|Systemic alone therapy group|Systemic alone therapy group will be treated by intravenous sodium bicarbonate plus NAC administration. Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. (9) The initial i.v. bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days. Additional NAC dose (1.2 g) will be administered i.v. during the procedure.
3214099|NCT01098032|Experimental|RenalGuard System group|Prophylactic controlled hydration with saline (0.9%) plus N-acetylcystein (NAC; 6 g in total). In the RenalGuard group, an initial bolus (priming) of 250 ml will be administered. In case of left ventricular dysfunction (ejection fraction ≤30%) and/or unstable hemodynamic conditions the bolus will be reduced to 150 ml. Following the initial bolus, furosemide (0.25 mg/kg) will be administered in order to achieve the optimal urine flow (≥300 ml/h). The hydration will be continued throughout the duration of the procedure and will last 4 hours following the procedure. Additional doses of furosemide are allowed in case of decrease of urine flow <300 ml/h.
3214100|NCT01098019|Experimental|Xeomin|Each bottle of Xeomin will be reconstituted with 2 mL of NaCl 0.9 which will give a final concentration of 5 U of botulinum toxin A per 0.1 mL. The area affected will be injected with 0.1 mL at each 1-2 square cm for a maximum total dose of 200 units (4mL).
3214101|NCT01098019|Placebo Comparator|Placebo|Patients will receive 0.9% mL NaCl alone. The area affected will be injected with 0.1 mL at each 1-2 square cm for a maximum volume of 4 mL.
3214102|NCT01098006|Other|Group 1|Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B viruss (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.
3214103|NCT01098006|Other|Group 2|HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with activee inflammation and varying degrees of liver fibbrosis.
3214104|NCT01098006|Other|Group 3|Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.
3214105|NCT01098006|Other|Group 4|HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.
3214106|NCT01097993|Experimental|1 = Tested product|
3214107|NCT01097993|Active Comparator|2 = Control product|
3214108|NCT01097980|Experimental|Trazodone|Trazodone versus placebo in a randomized, double-blind manner
3214109|NCT01097980|Placebo Comparator|Placebo|Patients received placebo
3214110|NCT01097967|Active Comparator|CPAP in sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
3214111|NCT01097967|No Intervention|no CPAP in non sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
3214112|NCT01097967|Active Comparator|CPAP in non sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
3214113|NCT01097941|Active Comparator|LAIV/LAIV|
3214114|NCT01097941|Active Comparator|IIV/IIV|
3214115|NCT01097941|Active Comparator|IIV/LAIV|
3214116|NCT01097928||Patients undergoing Pulmonary Embolectomy|
3214117|NCT01097915||PROP taste sensitivity|"PROP Sensitive and non sensitive individuals are defined as Tasters and Non-tasters, respectively. Taster are further divided in Super-taster who perceived PROP as extremely bitter and Medium tasters who perceived PROP as moderately bitter."
3214118|NCT01097902|Active Comparator|Ibuprophen 800 mg|Oral ibuprofen 800 mg, administered 24 hours after exposure to UV radiation for the creation of an inflamed lesion, and 2 hours prior to site evaluation.
3214119|NCT01097902|Placebo Comparator|Placebo|Oral placebo administered 24 hours after exposure to UV radiation for the creation of an inflamed lesion, and 2 hours prior to site evaluation.
3214120|NCT01097889|Active Comparator|Treatment Group 1|
3214121|NCT01097889|Experimental|Treatment Group 2|
3214122|NCT01097876|Experimental|Active PF-04447943|
3214123|NCT01097876|Placebo Comparator|Placebo PF-04447943|
3214124|NCT01097863|Experimental|nelfilcon A, modified inversion indicator|Nelfilcon A investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for one week
3214125|NCT01097863|Experimental|nelfilcon A, no inversion indicator|Nelfilcon A investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for one week
3214126|NCT01097863|Active Comparator|nelfilcon A, inversion indicator|Nelfilcon A commercially marketed contact lenses worn in both eyes on a daily wear, daily disposable basis for one week.
3214127|NCT01097850|Other|Right|Application of henna paste to right hand/foot plus CeraVe moisturizer
3214128|NCT01097850|Other|Left|Application of henna paste to the left hand/foot plus CeraVe moisturizer
3214129|NCT01097837||Epilepsy|Cohort is comprised of women with epilepsy between 18 and 47.
3214130|NCT01097811|Active Comparator|Erythromycin|
3214131|NCT01097811|Active Comparator|Neomycin|
3214132|NCT01097798|Experimental|Aliviador|
3214133|NCT01097798|Active Comparator|Gelol|
3214134|NCT01097785|Active Comparator|Simvastatin|40 mg Simvastatin 1 pill every day for 30 days
3214135|NCT01097785|Placebo Comparator|Placebo|Placebo cap 1 pill every day for 30 days
3214136|NCT01097772|Other|Ovation Abdominal Stent Graft System|Implant of Ovation Abdominal Stent Graft System
3214137|NCT01097759||LigaSure|LigaSure is a vascular sealing device that can seal the hemorrhoidal plexus during hemorrhoidectomy (surgery)
3214138|NCT01097759||Stapler|Circular stapler that removes excess loose tissue above the anus and interrupts the blood supply during hemorrhoidal surgery
3214139|NCT01097746|Experimental|Bevacizumab + Carboplatin + Paclitaxel|"Carboplatin AUC 5 by vein Day 1 of Cycles 1-6. Paclitaxel 80 mg/m2 by vein (IV) over about 3 hours on Day 1 followed by Carboplatin, then on Days 8 and 15 of Cycle 1 Paclitaxel alone. On Day 1 of Cycles 2-6 Paclitaxel is followed by Carboplatin and Bevacizumab, then on Days 8 and 15 only Paclitaxel.~Bevacizumab 15 mg/kg IV over about 1 ½ hours on Day 1 of Cycles 2-6."
3214140|NCT01097733||Pre-procedural cardiac CT|CRT patients will undergo pre-procedural cardiac CT to assess for dyssynchrony, scar, and coronary venous anatomy. The CT venogram will be randomize to pre-knowledge to implanting physician or blinded. The CT dyssynchrony and scar assessment will remain blinded to caregivers and patients.
3214141|NCT01097720||LTG-exposed|Children exposed to LTG during pregnancy.
3214142|NCT01097720||VPA-exposed|Children exposed to VPA during pregnancy.
3214143|NCT01097720||CBZ-exposed|Children exposed to CBZ during pregnancy.
3214144|NCT01097707|Experimental|1mg LY500307|
3214145|NCT01097707|Experimental|3mg LY500307|
3214146|NCT01097707|Experimental|10mg LY500307|
3214147|NCT01097707|Experimental|25mg LY500307|
3214148|NCT01097707|Placebo Comparator|Placebo|
3214149|NCT01097694|Active Comparator|Imatinib mesylate|Group on active imatinib treatment
3214150|NCT01097694|Placebo Comparator|Placebo|Group on Placebo treatment
3214151|NCT01097681|Experimental|Normal renal function group|
3214152|NCT01097681|Experimental|Mild renal impairment group|
3214153|NCT01097681|Experimental|Moderate renal impairment group|
3214154|NCT01097668|Experimental|Intradermal injection|Injections will be given by the intradermal route
3214155|NCT01097668|Experimental|Subcutaneous injection|Injections will be given by the subcutaneous route
3214156|NCT01097655||HIV-infected Participants|"HIV-infected participants starting with Kaletra tablets.~Participants included 3 subgroups:~antiretroviral therapy (ART) treatment-naïve participants starting with Kaletra tablets~participants receiving their first protease inhibitor (PI)-containing regimen (apart from Kaletra) pretreated with any non nucleoside reverse transcriptase inhibitor (NNRTI)-containing or nucleoside reverse transcriptase inhibitor (NRTI)-containing regimen~participants pretreated with a PI-containing regimen (apart from Kaletra)."
3214157|NCT01097642|Active Comparator|Ixabepilone|Brand name is Ixempra ®; it is an epothilone B analog used in combination with other chemotherapeutics against cancer.
3214158|NCT01097642|Experimental|Ixabepilone plus Cetuximab|Cetuximab, brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor and monoclonal antibody used with Ixabepilone against cancer.
3214159|NCT01097629|Experimental|Suvorexant HD|Drug
3214160|NCT01097629|Experimental|Suvorexant LD|Drug
3214161|NCT01097629|Placebo Comparator|Placebo|Placebo Comparator
3214162|NCT01097616|Experimental|Suvorexant HD|Drug
3214163|NCT01097616|Experimental|Suvorexant LD|Drug
3214164|NCT01097616|Placebo Comparator|Placebo|Placebo Comparator
3214165|NCT01097590|Experimental|Active TLA Gut™ column|The active column contain an engineered protein with the ability to specifically bind the inflammatory cells.
3214166|NCT01097590|Placebo Comparator|Placebo TLA Gut™column|The placebo column is identical to the active column except it does not contain the engineered protein that specifically bind the inflammatory cells.
3214167|NCT01097577|Experimental|pregabalin|
3214168|NCT01097577|Placebo Comparator|lactose capsule|
3214169|NCT01097564||COL4A1 genetic testing|COL4A1 genetic testing
3214170|NCT01097551||Patients with type 1 diabetes|Diabetes duration >= 5 years, age >= 18 and <= 60 years old, patients with no visible diabetic retinopathy, and no arterial hypertension
3214171|NCT01097551||Healthy subjects|Sex and age-matched control healthy subjects
3214172|NCT01097538|Active Comparator|Body-weight supported treadmill training|Supported treadmill walking
3214173|NCT01097538|Experimental|Total body recumbent stepper training|Recumbent stepper exercise training
3214174|NCT01097525|Active Comparator|Wavefront guided (WFG) PRK|
3214175|NCT01097525|Active Comparator|WFG LASIK|
3214176|NCT01097525|Active Comparator|Wavefront optimized (WFO) PRK|
3214177|NCT01097525|Active Comparator|WFO LASIK|
3214178|NCT01097512|Experimental|Regimen 1: AS703569/gemcitabine|Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle
3214179|NCT01097512|Experimental|Regimen 2: AS703569/gemcitabine|AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle
3214180|NCT01097499|Active Comparator|LED application|Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.
3214181|NCT01097499|No Intervention|No LED application|These patients will receive conventional dental implant treatment without the application of the LED therapy.
3214182|NCT01097486|Active Comparator|Allograft|Cervical Spinal Fusion with Allograft
3214183|NCT01097486|Experimental|NeoFuse|Cervical Spinal Fusion with NeoFuse
3214184|NCT01097473|Active Comparator|Exercise training|Subjects participate in a once weekly supervised exercise training group, duration of 60 min.
3214185|NCT01097473|No Intervention|Control|Control group receives no intervention
3214186|NCT01097460|Experimental|MM-111 + Herceptin|MM-111 will be combined with Herceptin
3214187|NCT01097447||Ciprofloxicine or Vigamox or other|up to qid till epithelialized.
3214188|NCT01097447||Topical Nonsteroidal (Acular, Acuvail, Voltaren Xibrom|up to qid for up to 5-10 days postop
3214189|NCT01097447||Topical steroid (FML, Pred Forte, Flarex|qid for up to 8 weeks
3214190|NCT01097434|Active Comparator|Arm 1|Biodegradable polymer limus-eluting stents
3214191|NCT01097434|Active Comparator|Arm 2|Permanent polymer limus-eluting stent
3214192|NCT01097421||Patient with parkinsons disease|
3214193|NCT01097408|Experimental|AZD7295|
3214194|NCT01097408|Placebo Comparator|Matched placebo|
3214195|NCT01097395|Active Comparator|Standard Weight-Based Ribavirin Dosing|1000 mg daily in patients weighing <75 kg and 1200 mg daily in patients weighing ≥ 75 kg
3214196|NCT01097395|Experimental|Concentration-Controlled Ribavirin Dosing|Dose adjusted based on first dose AUC0-12
3214197|NCT01097382|Experimental|AMBIEN CR|AMBIEN CR 12.5 mg once daily immediately before bedtime or in elderly/hepatically impaired patients: 6.25 mg once daily immediately before bedtime
3214198|NCT01097369||Anti-rasburicase antibodies|
3214199|NCT01097356|No Intervention|common care|HPV+ patients with LSIL on their PAP smear, waiting for 6 months to receive a new PAP smear
3214200|NCT01097356|Experimental|probiotic drinkers|HPV+, LSIL patients who will drink the study drink for 6 months
3214201|NCT01097343|Active Comparator|75 mg clopidogrel|
3214202|NCT01097343|Active Comparator|150 mg clopidogrel|
3214203|NCT01097330|Active Comparator|Ablation|Catheter based radiofrequency ablation for ischemic ventricular tachycardia
3214204|NCT01097330|Active Comparator|Amiodarone|amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study.
3214205|NCT01097304|Experimental|Treatment (ursodiol)|Patients receive ursodiol PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
3214206|NCT01097278|Experimental|Arm I|Participants receive oral cholecalciferol once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
3214207|NCT01097278|Active Comparator|Arm II|Participants receive oral placebo once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
3214208|NCT01097252|Active Comparator|weekly cisplatin|Weekly cisplatin 40mg/m2 during radiation therapy
3214209|NCT01097252|Experimental|tri-weekly cisplatin|cisplatin 75mg/m2 three cycles, every 3 weeks
3214210|NCT01097239|Experimental|High Intensity Focused Ultrasound|Transrectal High Intensity Focused Ultrasound (HIFU) treatment of the PelvicTumour
3214211|NCT01097226|Experimental|Apple flavanols|
3214212|NCT01097200|Other|Elevate meshes|The use of Elevate (American Systems trade mark) meshes for the treatment of pelvic prolapse.
3214213|NCT01097200|Other|Sacrocolpopexy|Sacrocolpopexy for the correction of the prolapse
3214214|NCT01097174||CyPass Micro-stent|Patients in whom CyPass Micro-stent implantation was attempted.
3214215|NCT01097161|Experimental|Speech treatment on prosodic basis|Patients receive 20 therapy sessions over a course of 3 months, with one double session per week.
3214216|NCT01097148|Active Comparator|Atracurium, TBW|Dose of atracurium 0.5 mg/kg based on total body weight
3214217|NCT01097148|Active Comparator|Atracurium IBW|dose 0.5 mg/kg based on ideal body weight
3214218|NCT01097135|No Intervention|Standard surgical skin preparation|
3214219|NCT01097135|Active Comparator|Standard Surgical Skin Preparation with Duraprep|standard surgical skin prep
3214220|NCT01097122|Experimental|Healthy young adult subjects|Forearm vibration will be applied in healthy young adult subjects
3214221|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 1 at middle dose|
3214222|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 1 at low dose|
3214223|NCT01097096|Placebo Comparator|Placebo + Adjuvant 1 at middle dose|
3214224|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 2 at middle dose|
3214225|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 2 at low dose|
3214226|NCT01097096|Placebo Comparator|Placebo + Adjuvant 2 at middle dose|
3214227|NCT01097096|Active Comparator|CAD106 450μg + either Adjuvant 1 or 2 at middle dose|
3214228|NCT01097096|Active Comparator|CAD106 450μg + either Adjuvant 1 or 2 at low dose|
3214229|NCT01097096|Placebo Comparator|Placebo + either Adjuvant 1 or 2 at middle dose|
3214230|NCT01097070|Experimental|Bevirimat 200 mg twice daily, 15 days|
3214231|NCT01097070|Experimental|Bevirimat 300 mg once daily, 15 days|
3214232|NCT01097070|Experimental|Bevirimat 400 mg once daily, 15 days|
3214233|NCT01097057|Experimental|Treatment (rituximab, etoposide, carboplatin, ifosfamide)|Patients receive rituximab IV on day 1, etoposide IV on days 2-4, carboplatin IV on day 3, and ifosfamide IV on day 3 over 24 hours. Patients also receive G-CSF SC once daily beginning on day 6 and continuing until apheresis is completed and plerixafor SC once daily for up to 4 days beginning 24 hours after recovery from nadir and continuing until apheresis is completed. Patients may undergo up to 4 apheresis procedures until the optimal number of CD34+ cells are collected.
3214234|NCT01097044|Experimental|Afamelanotide|
3214235|NCT01097044|Placebo Comparator|Placebo|
3214236|NCT01097031||Continuous Infusion|
3214237|NCT01097031||Intermittent Infusion|
3214238|NCT01097031||Infusion Continuous|
3214239|NCT01097018|Active Comparator|Perifosine + Capecitabine|Perifosine 1 tablet daily + Capecitabine BID days 1 - 14 every 21 days
3214240|NCT01097018|Placebo Comparator|Placebo + Capecitabine|Placebo 1 tablet daily + Capecitabine BID days 1 - 14 every 21 days
3214241|NCT01097005||Klaricid|Those with an exposure
3214242|NCT01096992|Experimental|Phase 1|Bendamustine, Fludarabine + Rituximab
3214243|NCT01096992|Experimental|Phase 2|Bendamustine 30 mg/m2 by vein (fixed), Days 1,2,3 + Fludarabine + Rituximab
3214244|NCT01096979|Experimental|LIPO-102, High|LIPO-102, High
3214245|NCT01096979|Experimental|LIPO-102, Low|LIPO-102, Low
3214246|NCT01096979|Experimental|Placebo|Pbo
3214247|NCT01096966|Experimental|Bupivacaine TTS|
3214248|NCT01096966|Placebo Comparator|Placebo patch|
3214249|NCT01096953|Active Comparator|Telepsychiatry|Psychiatry provided over telehealth network
3214250|NCT01096953|Active Comparator|Face-to-face care|Psychiatry provided in person
3214251|NCT01096940|Experimental|1|AZD1656
3214252|NCT01096940|Experimental|2|Simvastatin
3214253|NCT01096940|Experimental|3|AZD1656 + simvastatin
3214254|NCT01096927|Experimental|Non operative Treatment group|Patients with Lower Abdominal and suspected Acute Appendicitis, treated non-operatively with 7 days antibiotic therapy (Amoxicillin and Clavulanic Acid)
3214255|NCT01096914|Active Comparator|Radiofrequency|patients treated with percutaneous radiofrequency ablation
3214256|NCT01096914|Active Comparator|laser|Patients treated with percutaneous laser ablation
3214257|NCT01096901|Active Comparator|Comprehensive behavioral weight loss|The group will be implemented to induce a 6% weight loss over 3 months. The lessons will follow protocols from the Look AHEAD trial and Diabetes Prevention Program. This behavioral program has been shown to promote long-term weight loss and a reduction in diabetes and cardiovascular risk factors, and is based on the social cognitive theory.
3214258|NCT01096901|No Intervention|Education and Support Control group|Participants in this group will receive support and education about healthy eating and activity with lessons based on the Look AHEAD support and education control condition. Participants will attend monthly closed group meetings and meetings will be designed to promote retention but not weight loss.
3214259|NCT01096888|No Intervention|Standard WIC care|Patients randomized to this group will receive standard WIC care and an information packet surround healthy eating and activity topics.
3214260|NCT01096888|Active Comparator|Enhanced WIC weight loss program|Participants randomized into this condition will receive standard WIC care, but will also receive weight loss classes provided through the internet. Topics will cover behavioral weight loss topics, based off the protocols of the Look AHEAD program.
3214261|NCT01096875|Active Comparator|Atorvastatin|Hydroxymethylglutaryl-CoA Reductase Inhibitors
3214262|NCT01096875|Placebo Comparator|Placebo|Atorvastatin like pill
3214263|NCT01096862|Experimental|Group 1|lowest dose
3214264|NCT01096862|Experimental|Group 2|low dose
3214265|NCT01096862|Experimental|Group 3|high dose
3214266|NCT01096862|Experimental|Group 4|highest dose
3214267|NCT01096862|Experimental|Group 5|medium dose
3214268|NCT01096862|Placebo Comparator|Placebo|
3214269|NCT01096849|Experimental|plazomicin (10 mg/kg)|Patients received two intravenous (IV) infusions daily for 5 consecutive days: 10 milligrams per kilogram (mg/kg) plazomicin followed by placebo.
3214270|NCT01096849|Experimental|plazomicin (15 mg/kg)|Patients received two IV infusions daily for 5 consecutive days: 15 mg/kg plazomicin followed by placebo.
3214271|NCT01096849|Active Comparator|levofloxacin|Patients received two IV infusions daily for 5 consecutive days: placebo followed by 750 milligrams (mg) levofloxacin.
3214272|NCT01096836|Experimental|Diet counseling|Outcomes of the study may enhance diet counseling
3214273|NCT01096836|Experimental|exercise training|
3214274|NCT01096823|Experimental|Iyengar Yoga|
3214275|NCT01096823|No Intervention|Waitlist Control|
3214276|NCT01096810|Experimental|TBL 12|TBL 12, sea cucumber, will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression
3214277|NCT01096797|Experimental|Children undergoing adenotonsillectomy|Children between 2-6 years old undergoing elective adenoidectomy with or without tonsillectomy from the ENT Service of the San Gerardo Hospital.
3214278|NCT01096784|Active Comparator|rhIGF-I/rhIGFBP-3|Continuous IV Infusion
3214279|NCT01096784|No Intervention|Control|The comparator group will receive no treatment with rhIGF-1/rhIGFBP-3
3214280|NCT01096771|Experimental|ClinOleic 20%|96 hour continuous infusion.
3214281|NCT01096771|Active Comparator|Intralipid 20%|96 hour continuous infusion.
3214282|NCT01096758||PKU patients|
3214283|NCT01096758||healthy controls|
3214284|NCT01096745|Experimental|Gemcitabine/Cisplatin|
3214285|NCT01096745|Experimental|S-1/Cisplatin|D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
3214286|NCT01096732|Experimental|GDC-0449|Study drug.
3214287|NCT01096719|Experimental|Energy Density|
3214288|NCT01096719|Active Comparator|Lifestyle Treatment|
3214289|NCT01096719|Experimental|Energy Density + Lifestyle Treatment|
3214290|NCT01096706|Experimental|Nitric Oxide Clamp|Forearm blood flow response to Urocortins 2, 3 and Substance P in the presence of Nitric Oxide clamp
3214291|NCT01096706|Placebo Comparator|Saline Placebo|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of saline placebo.
3214292|NCT01096706|Experimental|Fluconazole|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of intra-arterial Fluconazole.
3214293|NCT01096706|Experimental|Aspirin|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of cyclooxygenase inhibition with Aspirin.
3214294|NCT01096706|Experimental|Combined|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of inhibition of cycloxygenase, EDHF and NO pathways with Aspirin, Fluconazole and NO clamp.
3214295|NCT01096693|Placebo Comparator|Saline Placebo|In this arm, the response in forearm blood flow to incremental doses of Urocortins 2, 3 and Substance P will be studied co infused with saline placebo.
3214296|NCT01096693|Active Comparator|Response to Urocortin infusion in presence of Astressin 2B|This arm studies the response to intra arterial infusion of incremental doses of Urocortins 2, 3 and Substance P in the presence or absence of a selective antagonist - Astressin 2B.
3214297|NCT01096680|Experimental|SPD489 20 mg|
3214298|NCT01096680|Experimental|SPD489 50 mg|
3214299|NCT01096680|Experimental|SPD489 70 mg|
3214300|NCT01096680|Active Comparator|Armodafinil|
3214301|NCT01096680|Placebo Comparator|Placebo|
3214302|NCT01096667|Placebo Comparator|Placebo|Placebo to ertugliflozin (resembling either 1 mg or 5 mg), placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days.
3214303|NCT01096667|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
3214749|NCT01093742|Experimental|cohort 1|HM10560A 0.089 mg/kg or Placebo
3214304|NCT01096667|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
3214305|NCT01096667|Experimental|Ertugliflozin 25 mg|Ertugliflozin 25 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to HCTZ once daily for 28 days
3214306|NCT01096667|Active Comparator|HCTZ 12.5mg|HCTZ 12.5 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to ertugliflozin (resembling 25 mg) once daily for 28 days
3214307|NCT01096654|Active Comparator|CT-scan|In this group treatment will be based on the outcome of the CT-scan only. Patients will be treated by adrenalectomy (Adx) if an unilateral lesion is visible on the CT-scan and the contralateral gland is normal. If bilateral lesions, bilateral enlargement or symmetric normal adrenal glands are present patients will be treated by the mineralocorticoid receptor antagonist (MRA)
3214308|NCT01096654|Active Comparator|Adrenal Vein Sampling|"This group will be treated according to the results of the adrenal vein sampling only. Adrenal vein sampling will be performed under the continuous infusion of ACTH (adrenocorticotropic hormone). A cortisol ratio ≥ 3 between the adrenal vein and the inferior vena cava is set as the criterium for successful cannulation. The criterium for lateralization is a aldosterone/cortisol ratio ≥ 4 between the adrenal veins and a lower aldosterone/cortisol ratio in the contralateral adrenal vein than in the inferior vena cava.~If AVS fails patients will be treated according to the CT-findings as described in the group with CT-scan only. Patients with a successful AVS will be treated by Adrenalectomy if unilateral production of aldosterone is shown. If no unilateral aldosterone production is present, i.e. the aldosterone/cortisol ratio is less than 4, patients will be treated by MRA."
3214309|NCT01096641|Other|Fatigued patients: Immediate start CBT|After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients. At the end of the therapy, after 6 months, a second assessment will take place.This assessment will include the same measurements as at baseline.
3214310|NCT01096641|Other|fatigues patients: delayed CBT (after 6 months)|The fatigued patients on the waiting list will start with CBT after 6 months
3214311|NCT01096641|No Intervention|non-fatiqued controls|Non-fatigued control group. This group is not included in the randomization.
3214312|NCT01096628|Experimental|Chiropractic + Exercise|
3214313|NCT01096628|Active Comparator|Exercise|
3214314|NCT01096615|Active Comparator|Tested product: Lactobacillus paracasei LP-33|Each patient will be randomly assigned to either tested product or comparative product (placebo) in accordance with a randomisation table
3214315|NCT01096615|Placebo Comparator|Comparative product : placebo|Each patient will be randomly assigned to either tested product or comparative product (placebo) in accordance with a randomisation table .
3214316|NCT01096602|Experimental|Group 1|DC AML Fusion Vaccine
3214317|NCT01096589|Experimental|Arm 1 - 3M Coban 2|3M Coban 2 - 2 apps/wk
3214318|NCT01096589|Experimental|Arm 2 - 3M Coban 2|3M Coban 2 - 3 apps/wk
3214319|NCT01096589|Experimental|Arm 3 - 3M Coban 2|Arm 3 - 3M Coban 2 - 5 apps/wk
3214320|NCT01096589|Active Comparator|Arm 4 - Comprilan|Comprilan short-stretch bandage 5 apps/wk
3214321|NCT01096576|Experimental|A|
3214322|NCT01096576|Placebo Comparator|B|
3214323|NCT01096563|Experimental|1|AZD9164
3214324|NCT01096563|Placebo Comparator|2|
3214325|NCT01096550|Experimental|Intensive Outpatient|Buprenorphine patients receiving 9 or more hours of outpatient counseling.
3214326|NCT01096550|Active Comparator|Outpatient|Buprenorphine patients receiving between 2 and 8 hours of outpatient counseling.
3214327|NCT01096537||Young workers|"Exposed young workers graduated in sectors at risk of occupational asthma (bakery, pastry-making or hairdressing)~Non-exposed young workers graduated in sectors without specific occupational exposure as the sale or the food sectors."
3214328|NCT01096524|Other|Control group standard physiotherapy|Standard pathway of care pre-and post-TKA without using NMES.
3214329|NCT01096524|Experimental|Kneehab|Kneehab on the quadriceps of the affected leg, 20 minutes, twice per day, 5 days per week over 12-week intervention (6 weeks pre-op, 6 weeks post op).
3214330|NCT01096511||Group 1|
3214331|NCT01096498|Experimental|Arm 1|
3214332|NCT01096498|Active Comparator|Arm 2|
3214333|NCT01096485|Experimental|Arm 1|
3214334|NCT01096485|Active Comparator|Arm 2|
3214335|NCT01096472|Experimental|LAS41003|Once daily
3214336|NCT01096472|Active Comparator|LAS189962|Once daily
3214337|NCT01096472|Active Comparator|LAS189961|Once daily
3214338|NCT01096446|Experimental|Higher Infusion|Infants randomized into the experimental group will receive 2 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
3214339|NCT01096446|Other|Standard Infusion|Infants randomized into the control group will receive 0.5 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
3214340|NCT01096433|Experimental|CPAP|The subjects introduced with CPAP treatment
3214341|NCT01096420|Experimental|acupuncture|
3214342|NCT01096420|Active Comparator|topiramate|
3214343|NCT01096407||Paclitaxel-Induced Myalgias/Arthralgias|
3214344|NCT01096394||Ovarian cancer|Patients with presumed Stage III-IV ovarian, primary fallopian tube, or primary peritoneal papillary serous carcinoma.
3214345|NCT01096381||Will receive bevacizumab|
3214346|NCT01096381||Will not receive bevacizumab|
3214347|NCT01096368|Experimental|Arm I (radiotherapy, chemotherapy)|Patients undergo 3-dimensional conformal radiation therapy over 6-7 weeks. Patients then receive liposomal vincristine sulfate IV on days 1, 8, and 15 (courses 1-3 only); etoposide IV over 1-2 hours on days 1-3; carboplatin on day 1, cisplatin IV over 1-8 hours on day 1; cyclophosphamide IV over 30-60 minutes on days 1-2 and filgrastim. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3214348|NCT01096368|Active Comparator|Arm II (radiotherapy)|Patients undergo 3-dimensional conformal radiation therapy over 6-7 weeks.
3214385|NCT01096108|Experimental|Standard Contest plus MAPS|Smoking abstinence, 1 prize award (month 1) plus motivational and problem-solving counseling (MAPS - Counseling phone calls); 20 weeks.
3214349|NCT01096355|Experimental|Group A|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3 and 8-10.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
3214350|NCT01096355|Experimental|Group B|"Patients receive oral RO4929097 once daily on days 1-7.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
3214351|NCT01096355|Experimental|Group C|"Patients receive oral RO4929097 once daily on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
3214352|NCT01096355|Experimental|Group D|"Patients receive oral RO4929097 once daily on days 1, 8, and 15.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
3214353|NCT01096355|Experimental|Group E|"Patients receive oral RO4929097 once daily on days 1, 4, 8, 11, 15, and 18.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
3214354|NCT01096355|Experimental|Group F|"Patients receive oral RO4929097 once daily days 1-5, 8-12, and 15-19.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
3214355|NCT01096342|Experimental|Treatment|Patients receive dinaciclib IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3214356|NCT01096329|Active Comparator|Cohort 2|Testosterone Spray (5%) vs Intrinsa® Patch
3214357|NCT01096329|Active Comparator|Cohort 3|Testosterone Spray (1%) vs Intrinsa® Patch
3214358|NCT01096329|Active Comparator|Cohort 1|Testosterone Spray (5%) vs Testosterone Spray (1%)
3214359|NCT01096316|Experimental|Intervention|"The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:~enhanced education of patients and providers~engagement of patients~depression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation."
3214360|NCT01096316|No Intervention|Usual Care|Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.
3214361|NCT01096303||COPD tobacco and/or marihuana users|COPD patients with history of tobacco and/or marihuana smoking.
3214362|NCT01096290|Experimental|Lubiprostone 24mcg BID for 30 days|Active medication
3214363|NCT01096290|Placebo Comparator|Placebo|Placebo, matched, blinded
3214364|NCT01096277|Active Comparator|Sitagliptin|100 mg sitagliptin per day for 2 weeks
3214365|NCT01096277|Placebo Comparator|Placebo|1 placebo tablet per day for 2 weeks
3214366|NCT01096277|No Intervention|Healthy Control|Healthy control subjects
3214367|NCT01096264|Other|Healthy volunteer|"Healthy volunteer undergoing two imagery evaluation :~SSI technique for local PWV and arterial stiffness evaluation~SphygmoCor® for aortic PWV."
3214368|NCT01096264|Other|vEDS patients|"vEDS patients undergoing two imagery evaluations:~SSI technique for local PWV and arterial stiffness evaluation~SphygmoCor® for aortic PWV."
3214369|NCT01096251|Experimental|CBT|CBT group: in-hospital treatment (diet, physical activity, dietitian counseling, 8 sessions of CBT) plus 8 outpatient telephone-based sessions of CBT-oriented psychological support and monitoring with the same CBT inpatient psychotherapists.
3214370|NCT01096251|Experimental|BST|BST group: in-hospital treatment (diet, physical activity, dietitian counseling, 8 sessions of BST) plus 8 outpatient telephone-based sessions of BST-oriented psychological support and monitoring with the same BST inpatient psychotherapists.
3214371|NCT01096225||vaccinated group|
3214372|NCT01096212|Experimental|generic sevoflurane|
3214373|NCT01096212|Active Comparator|origianl sevoflurane|
3214374|NCT01096186|Other|Open Label IPX066|Subjects received IPX066 95 mg, IPX066 145 mg, IPX066 195 mg, or IPX066 245 mg for approximately 9 months. The dose and dosing frequency was determined by the investigator.
3214375|NCT01096160|Experimental|Panel A - 1 mg QD|MK8266 1 mg once daily or placebo
3214376|NCT01096160|Experimental|Panel B - 2 mg QD|MK8266 2mg once daily or placebo
3214377|NCT01096160|Experimental|Panel C - 4 mg QD|MK8266 4 mg once daily or placebo
3214378|NCT01096160|Experimental|Panel D - 4 mg BID|MK8266 4 mg twice daily or placebo
3214379|NCT01096160|Experimental|Panel E - 4 mg TID|MK8266 4 mg three times daily or placebo
3214380|NCT01096147|Active Comparator|SCS|patients receiving SCS for chronic leg and/or back pain.
3214381|NCT01096134|Experimental|HPV Vaccine|Eligible girls were offered 3 doses of the HPV vaccine
3214382|NCT01096121|Placebo Comparator|2|
3214383|NCT01096121|Experimental|1|Enalapril
3214384|NCT01096108|Experimental|Standard Contest|Smoking abstinence, 1 prize award (month 1)
3214889|NCT01092754|Other|A: Other|
3214386|NCT01096108|Experimental|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
3214387|NCT01096108|Experimental|Extended Contests plus MAPS|Extended quit and win contests (3 successive monthly contests) plus motivational and problem-solving counseling (MAPS). {Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3) plus Counseling phone calls.
3214388|NCT01096095|Placebo Comparator|Placebo|Placebo
3214389|NCT01096095|Experimental|Sodium phenylbutyrate|Active drug
3214390|NCT01096082|Placebo Comparator|Placebo|
3214391|NCT01096082|Experimental|Lithium Carbonate|
3214392|NCT01096069||Rituximab|Rheumatoid arthritis patients undergoing treatment with rituximab.
3214393|NCT01096056|Experimental|Influenza vaccine GSK2186877A formulation 1 Group|Subjects received 2 doses of influenza vaccine GSK2186877A formulation 1 at Day 0 and Day 21 and 1 dose of Fluarix vaccine at Month 6.
3214394|NCT01096056|Experimental|Influenza vaccine GSK2186877A formulation 2 Group|Subjects received 1 dose of influenza vaccine GSK2186877A formulation 2 at Day 0 and 1 dose of Fluarix vaccine at Month 6.
3214395|NCT01096043|Placebo Comparator|Placebo|Each Strata of the study will have a placebo control. In strata A, the chance of getting active drug is 4 out of 5, in Strata B the chance of getting active drug is 3 ot of 4, and in Strata C, the chance of getting active Drug is 4 out of 5. In the event that a patient is allocated to receive placebo, the treatment may be stopped if the patient's condition fails to improve or worsens during the placebo infusion.
3214396|NCT01096043|Experimental|Strata 1 CXL-1020|Patients assigned to CXL-1020 in strata one will have their dose increased from the initial dose 2 times during the study period. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
3214397|NCT01096043|Experimental|Strata 2 CXL-1020|In strata 2, patients who are assigned to active treatment will receive one of up to 3 possible fixed dose levels of CXL-1020 for a period of 6 hours. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
3214398|NCT01096043|Experimental|Strata 3 CXL-1020|In strata 3, patients assigned to receive CXL-1020 will receive a fixed dose of CXL-1020 for 6 hours, and then the dose may be increased or decreased, based on the investigators assessment of the patient. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
3214399|NCT01096030|Experimental|Regorafenib|
3214400|NCT01096017|Experimental|1|Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI ⇒salbutamol pMDI 200 μg +placebo Turbuhaler®
3214401|NCT01096017|Experimental|2|salbutamol pMDI 200 μg +placebo Turbuhaler® ⇒Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI
3214402|NCT01096004|Experimental|1|
3214403|NCT01096004|Placebo Comparator|2|
3214404|NCT01095991|Experimental|1|AZD1656, day 1-5, AZD1656 + Sitagliptin day 6-10, Sitagliptin day 11-15.
3214405|NCT01095991|Experimental|2|Sitagliptin day 1-5, AZD1656 + Sitagliptin day 6-10, AZD1656 day 11-15.
3214406|NCT01095978||Acute upper respiratory tract diseases, bronchitis, pneumonia|
3214407|NCT01095965|Experimental|Lifestyle education|Nutrition education comprised of 4 components: Curriculum (8 weeks), follow-up meetings (4 monthly plus 2-bimonthly), education materials for use at home and vegetable gardening demonstrations.
3214408|NCT01095952|Experimental|AVNS ON|Consulta downloaded with AVNS to provide high frequency bursting during fastly conducted AF. AVNS will be programmed on for five months. The feasibility and safety of the AVNS algorithm to reduce inappropriate shocks will be monitored.
3214409|NCT01095939|Placebo Comparator|Control Arm|
3214410|NCT01095939|Experimental|Benazepril|
3214411|NCT01095926|Experimental|Doxorubicin|
3214412|NCT01095913|Experimental|IC-Green Injections|ICG Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
3214413|NCT01095900||LIS group)|
3214414|NCT01095900||BT group|
3214415|NCT01095887|Experimental|eculizumab|Eculizumab was given on Day 0, day 1, and weekly for the first four weeks after transplant.
3214416|NCT01095861|Experimental|FlexTip ETT|FlexTip ETT
3214417|NCT01095861|Placebo Comparator|Control|Standard Flexible ETT Mallinckrodt Hi-Lo cuffed tracheal tube Catalog # 86114 Mallinckrodt, ST. Louis, MO, 63134
3214418|NCT01095848|Experimental|0.25ml dose DPX-0907|On each vaccination day the lyophilized antigen/adjuvant/liposome complex is re-suspended in the oil (Montanide 1SA51 VG) before injection. The vaccine is not an emulsion.
3214419|NCT01095848|Experimental|1ml dose DPX-0907|On each vaccination day the lyophilized antigen/adjuvant/liposome complex is re-suspended in the oil (Montanide 1SA51 VG) before injection. The vaccine is not an emulsion.
3214420|NCT01095835|Experimental|PEG-IFN48|Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks.
3214421|NCT01095835|Experimental|PEG-IFN96|Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by another 48 weeks of PEG-IFN treatment (total 96 weeks of treatment).
3214422|NCT01095835|Experimental|PEG-IFN+LAM96|Treatment with PEG-IFN and lamivudine in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by 48 weeks of only PEG-IFN treatment (total 96 weeks of treatment).
3214423|NCT01095822|Active Comparator|Aliskiren|25 patients with recently diagnosed hypertension and mild to moderate type 2 diabetes will constitute the proposed study population. The diagnosis of diabetes will be made based on the American Diabetes Association criteria, such as random plasma glucose >200 mg/dL with or without symptoms of hyperglycemia (polydipsia, polyuria, polyphagia) and weight loss, or fasting plasma glucose > 126 mg/dL, to be determined at least twice. Patients will qualify if they are insulin-free, treated with an oral antiglycemic agent,(metformin only) and/or managed on diet alone for no less than 30 days and have adequate glucose control at the time of their Screening Visit.
3214477|NCT01095549|Placebo Comparator|Control group|HD patients who will not receive far infrared therapy in this study.
3214522|NCT01095224|Experimental|rAd35 Env A and rAd5 Env A|Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env A vaccine at Month 3.
3214523|NCT01095224|Experimental|rAd35 Env A and rAd5 Env B|Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
3214524|NCT01095224|Experimental|rAd35 Env A and rAd35 Env A|Participants will receive the rAd35 Env A vaccine at baseline and at Month 3.
3214424|NCT01095822|Experimental|Aliskiren + Valsartan|25 patients with recently diagnosed hypertension, and mild to moderate type 2 diabetes will constitute the proposed study population. The diagnosis of diabetes will be made based on the American Diabetes Association criteria, such as random plasma glucose >200 mg/dL with or without symptoms of hyperglycemia (polydipsia, polyuria, polyphagia) and weight loss, or fasting plasma glucose > 126 mg/dL, to be determined at least twice. Patients will qualify if they are insulin-free, treated with an oral antiglycemic agent,(metformin only) and/or managed on diet alone for no less than 30 days and have adequate glucose control at the time of their Screening Visit.
3214425|NCT01095809|Experimental|bevacizumab|intravitreous bevacizumab 2,5 mg at baseline, week 4 and 8. reinjection is required.
3214426|NCT01095809|Experimental|triamcinolone acetonide|intravitreous triamcinolone 2 mg, frequency: 3 months
3214427|NCT01095796|Experimental|Stribild|Stribild plus placebo to match Atripla
3214428|NCT01095796|Active Comparator|Atripla|Atripla plus placebo to match Stribild
3214429|NCT01095783|Experimental|Physiotherapeutic intervention|
3214430|NCT01095783|Other|control|The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
3214431|NCT01095770|Active Comparator|Ablation Frontiers Ablation|This group will undergo AF ablation using Ablation Frontiers Technology.
3214432|NCT01095770|Active Comparator|LASSO ablation|This group will undergo atrial fibrillation ablation with traditional LASSO technology
3214433|NCT01095770|Active Comparator|Reveal XT monitoring|This group will be monitored pre and post ablation using a Reveal XT implantable loop recorder.
3214434|NCT01095770|Active Comparator|Permanent Pacemaker - dual chamber|This group will be monitored pre and post ablation with a dual chamber permanent pacemaker
3214435|NCT01095757|Other|Plerixafor + Chemo and G-CSF|Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.
3214436|NCT01095744||EOAD typical AD|this cohort is constituted with early onset typical AD.
3214437|NCT01095744||LOAD typical|this group is constituted with late onset typical AD
3214438|NCT01095744||atypical AD|this group is constituted with atypical form of focal cortical atrophy, like posterior cortical atrophy and logopenic progressive aphasia.
3214439|NCT01095744||young controls|under 65
3214440|NCT01095744||old controls|over 65
3214441|NCT01095731|Placebo Comparator|Sugar Pill, Hunt Hess Grade I-III|Good Grade (Hunt Hess I-III), n=15
3214442|NCT01095731|Experimental|Tiopronin, Hunt Hess Grade I-III|Good Grade (Hunt Hess I-III), n=15
3214443|NCT01095731|Experimental|Tiopronin, Hunt Hess Grade IV-V|Poor Grade (Hunt Hess IV-V), n=15
3214444|NCT01095731|Placebo Comparator|Sugar Pill, Hunt Hess Grade IV-V|Poor Grade (Hunt Hess IV-V), n=15
3214445|NCT01095718|Experimental|Errorless Learning|"Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them.~The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.~The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.~During cueing the patient will mostly receive verbal and visual cues and if necessary physical help."
3214446|NCT01095718|Active Comparator|Modeling|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step.Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance. Then the therapist asks immediately to the patient to do the steps."
3214447|NCT01095718|Active Comparator|Trial and Error|"Trial and Error refers to the regular unstructured learning and is considered as control condition.~Here the patient is encouraged to complete the task. When there is mistake, the therapist corrects it. Verbal cues will only be provided if the patient is unable to find and complete the correct next step or commit mistakes. The therapist use general instruction: Here is task, I will ask you to actions, followed by specific instruction, and I will help you after you have tried."
3214448|NCT01095705|Active Comparator|Conventional procedure|Local anaesthesia (Lidocaïne)
3214449|NCT01095705|Experimental|Conventional procedure + Hypnosis|Local anaesthesia (Lidocaïne) and Hypnosis
3214450|NCT01095692|Active Comparator|only surgery|
3214451|NCT01095692|Experimental|surgery + TOT|
3214452|NCT01095679|Experimental|Baclofen|
3214453|NCT01095679|Placebo Comparator|Placebo|Placebo
3214454|NCT01095666|Experimental|Group 1|
3214455|NCT01095666|Experimental|Group 2|
3214456|NCT01095666|Experimental|Group 3|
3214457|NCT01095653|Experimental|Group 1|
3214458|NCT01095653|Experimental|Group 2|
3214459|NCT01095653|Experimental|Group 3|
3214460|NCT01095640|Experimental|adapalene 0.3% topical gel (Actavis Mid-Atlaqntic LLC)|
3214461|NCT01095640|Active Comparator|Differin® (adapalene 0.3% topical gel)|
3214462|NCT01095640|Placebo Comparator|Vehicle Control|
3214463|NCT01095627|Other|Metacholine Challenge|Exhaled breath analysis following metacholine challenge
3214464|NCT01095614||12 women with oral contraception|
3214465|NCT01095614||12 women without any contraception|
3214466|NCT01095601|Other|Treatment A|2x100 mg Formulation II avanafil tablet, fasted
3214467|NCT01095601|Other|Treatment B|2x100 mg Formulation II avanafil tablet, fed
3214468|NCT01095601|Other|Treatment C|2x100 mg Formulation I avanafil tablet, fasted
3214469|NCT01095601|Other|Treatment D|1x50 mg Formulation II avanafil tablet, fasted
3214470|NCT01095588|Experimental|Avanafil|
3214471|NCT01095588|Placebo Comparator|Placebo|
3214472|NCT01095575|Active Comparator|group 1|NS preoperatively and MO postoperatively
3214473|NCT01095575|Active Comparator|group 2|MO preoperatively and NS postoperatively
3214474|NCT01095562|Experimental|ABT-126 Dose 1|
3214475|NCT01095562|Experimental|ABT-126 Dose 2|
3214476|NCT01095562|Placebo Comparator|Sugar Pill|
3214478|NCT01095549|Experimental|Far infrared therapy|In this study, a WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt〈mw〉/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on maintenance HD.
3214479|NCT01095510|Experimental|500 U CINRYZE (10-25 kg body weight)|Single IV dose of 500 U CINRYZE
3214480|NCT01095510|Experimental|1000 U CINRYZE (10-25 kg body weight)|Single IV dose of 1000 U CINRYZE
3214481|NCT01095510|Experimental|1000 U CINRYZE (>25 kg body weight)|Single IV dose of 1000 U CINRYZE
3214482|NCT01095510|Experimental|1500 U CINRYZE (>25 kg body weight)|Single IV dose of 1500 U CINRYZE
3214483|NCT01095497|Experimental|IV CINRYZE First, Then SC CINRYZE Dose 1|
3214484|NCT01095497|Experimental|IV CINRYZE First, Then SC CINRYZE Dose 2|
3214485|NCT01095484||Rotigotine|Patients who have a documented medical necessity to receive treatment with rotigotine treatment in accordance with standard medical practice.
3214486|NCT01095471|Experimental|PCV13|Initial vaccination with PCV13
3214487|NCT01095471|Experimental|PCV7|Initial intervention with PCV7
3214488|NCT01095458|Experimental|Phone based weight management group|Group based weight management program delivered via conference calls
3214489|NCT01095458|Experimental|Clinic based weight management group|Traditional clinical based group weight management program
3214490|NCT01095445|No Intervention|Standard of care treatment|Participants will be randomized to receive only the standard 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin).
3214491|NCT01095445|Active Comparator|Extended therapy|Participants will be randomized to receive 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin) in addition to their standard of care therapy.
3214492|NCT01095432||Main Study Group|All subjects who are undergoing a standard of care colonoscopy for flexible sigmoidoscopy and have a history of UC and agree to participate will be in the main study group.
3214493|NCT01095419|No Intervention|Control|Patients were seated in a chair for the same period then those from MT group, but did not receive intervention
3214494|NCT01095419|Experimental|Massage Therapy|Patients in the postoperative period of coronary artery bypass graft surgery, which receive intervention for 3 consecutive days
3214495|NCT01095406|Active Comparator|S1 ventilation|Mechanical ventilation with S1 the thrid hour of ventilation
3214496|NCT01095406|No Intervention|Servo i ventilation|1 hour ventilation in pressure support mode with Servo i
3214497|NCT01095393||Certolizumab pegol (CZP)|Patients with RA receiving treatment with certolizumab pegol (CZP; Cimzia®)
3214498|NCT01095393||Non-biologic DMARD|Subjects with RA receiving treatment with non-biologic DMARD
3214499|NCT01095380|Active Comparator|Treadmill training - manual assist (TM)|Participants in the TM group received partial body weight support unilateral or bilateral manual assistance from a trainer for stepping
3214500|NCT01095380|Active Comparator|Treadmill training - electrical stimulation (TS)|Participants in the TS group received partial body weight support and bilateral functional electrical stimulation to assist stepping
3214501|NCT01095380|Active Comparator|Overground Training (OG)|Training over ground with body weight support and electrical stimulation for dorsiflex assistance
3214502|NCT01095380|Active Comparator|Treadmill training - locomat robot (LR)|Treadmill training with partical body weight support and assistance of a robotic gait orthosis for stepping
3214503|NCT01095367|Active Comparator|Seprafilm™|Subject will have 3 sheets of Seprafilm™ placed in her abdominal cavity (in the pelvis, upper abdomen and below the incision) at the end of debulking surgery. At 7-21 days after surgery the subject will receive a contrast dye, Iohexol (Omnipaque™), into her intraperitoneal port. The subject will then undergo 3 abdominal X-rays, to assess the extent of abdominal adhesions.
3214504|NCT01095367|No Intervention|No Seprafilm™|Subject will undergo debulking surgery without Seprafilm™ placement (standard care). At 7-21 days after surgery the subject will receive a contrast dye, Iohexol (Omnipaque™), into her intraperitoneal port. The subject will then undergo 3 abdominal X-rays, to assess the extent of abdominal adhesions.
3214505|NCT01095354||Asthma Patients|Spirometry. Bronchodilator with Salbutamol. Induced sputum in > 10 years of age using Sodium Chloride Inhalation. Multiple Breath Washout (MBW).
3214506|NCT01095341||THP|THP: patients undergoing parathyroidectomy according to tertiary hyperparathyroidism
3214507|NCT01095341||Other causes|patients with hyperthyroidism not caused by parathyroidectomy
3214508|NCT01095328|Experimental|intervention|Screening for Q-fever during pregnancy
3214509|NCT01095328|No Intervention|control|No screening for Q-fever during pregnancy
3214510|NCT01095315|No Intervention|standard|parturients were placed back to the supine position immediately after spinal injection following standard protocol of spinal anesthesia
3214511|NCT01095315|Experimental|lateral|the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
3214512|NCT01095302|Experimental|Ombrabulin/ docetaxel/cisplatin|AVE8062 combined with docetaxel and cisplatin will be administered once in every 3 weeks, with 30-minute intravenous infusion
3214513|NCT01095289||Total Laryngectomized|
3214514|NCT01095276|Placebo Comparator|Nebulized saline|patients on mechanical ventilation who were randomized to receive a placebo comparator (vehicle solution for dornase alpha)
3214515|NCT01095276|Active Comparator|dornase alpha|patients on mechanical ventilation who were randomly assigned to receive dornase alpha by in-line nebulization
3214516|NCT01095263|Experimental|Sham then Stimulation|
3214517|NCT01095263|Experimental|Stimulation then Sham|
3214518|NCT01095250|Experimental|AIN457 300mg s.c every 2 weeks|AIN457 300 mg s.c. at baseline, Week 1 and Week 2, then every 2 weeks.
3214519|NCT01095250|Experimental|AIN457 300mg s.c. every 4 weeks|AIN457 300 mg s.c. at baseline and Week 2, then every 4 weeks.
3214520|NCT01095250|Experimental|AIN457 150mg s.c every 4 weeks|AIN457 150 mg s.c. at baseline and Week 2, then every 4 weeks
3214521|NCT01095250|Placebo Comparator|Placebo s.c every 2 weeks|Placebo s.c at baseline, Week 1 and Week 2, then every 2 weeks
3214525|NCT01095224|Experimental|rAd5 Env A and rAd5 Env A|Participants will receive the rAd5 Env A vaccine at baseline and at Month 3.
3214526|NCT01095224|Experimental|rAd5 Env A and rAd5 Env B|Participants will receive the rAd5 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
3214527|NCT01095211|Active Comparator|B-Vitamins|folic acid, cobalamin, vitamin B6
3214528|NCT01095211|Placebo Comparator|placebo|none of the vitamins (99.5% mannitol)
3214529|NCT01095198|Active Comparator|2nd Reminder Letter|50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be be mailed a standard second reminder letter
3214530|NCT01095198|Experimental|Offer of Vaginal Self Collection|50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be selected to be mailed a second reminder letter and offer of vaginal self collection
3214531|NCT01095185|Experimental|Standard therapy + Simvastatin|"Standard therapy: Endoscopic variceal ligation (EVL)+ B Blockers (Propanolol titrated until achieve maximum tolerated dose)~Simvastatin (20 mg for 15 days and after 40 mg/day until the end of the study)"
3214532|NCT01095185|Placebo Comparator|Standard therapy + placebo|"Standard therapy: Endoscopic variceal ligation (EVL)+ B Blockers (Propanolol titrated maximum tolerated dose).~Placebo"
3214533|NCT01095172|Experimental|Rituximab|"Rituximab 375mg/m2~Low dose tacrolimus with mycophenylate mofetil, hydrocortisone and 1 week prednisolone"
3214534|NCT01095172|Active Comparator|Control group|Low dose tacrolimus with mycophenylate mofetil and continued prednisolone
3214535|NCT01095159|Active Comparator|TVT-O|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).
3214536|NCT01095159|Active Comparator|TVT-S|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
3214537|NCT01095133|Experimental|Amiloride|
3214538|NCT01095133|Placebo Comparator|Placebo|
3214539|NCT01095107|Other|Control Arm = Decreased Energy Density|Decreased energy density = 35-50 grams of fat per day between meals and snacks
3214540|NCT01095107|Other|Treatment Arm = Increased Energy Density|increased increased energy density : Intake > 50 grams of fat per day between meals and snacks
3214541|NCT01095094|Experimental|Arm I|Patients receive oral ritonavir and lopinavir twice daily in the absence of disease progression or unacceptable toxicity.
3214542|NCT01095081||Group 1|
3214543|NCT01095068|Experimental|physical exercise|Physical exercise
3214544|NCT01095055|Experimental|Group 1|AdCh63 AMA1
3214545|NCT01095055|Experimental|Group 2|AdCh63 AMA1 followed by MVA AMA1
3214546|NCT01095042|Experimental|Control group|30 Asymptomatic Healthy Volunteers Intervention : Observation of emotional behavior in asymptomatic healthy volunteers subjected to stress.
3214547|NCT01095042|Experimental|Experimental group|"Persons reached by digestive pathologies (SII or IBD). Group SII : 30 patients Group IBD: 60 patients (30 patients RCH and 30 patients CD)~Intervention : Observation of emotional behavior in person affected by digestive pathologies subjected to stress."
3214548|NCT01095029|Experimental|Off/Off|Pacemaker status: Bilateral Off for four weeks before first PET scann.
3214549|NCT01095029|Experimental|On/On|Pacemaker status: Bilateral On. PET scan one hour after activation and after four weeks continuous stimulation.
3214550|NCT01095029|Experimental|On/Off|Pacemaker status: Unilateral On. PET scan one hour after activation and after four weeks continuous stimulation.
3214551|NCT01095016|Experimental|Meptin swinghaler|
3214552|NCT01095016|Active Comparator|Berotec|
3214553|NCT01095003|Experimental|Vinflunine plus Capecitabine|
3214554|NCT01095003|Active Comparator|Capecitabine single-agent|
3214555|NCT01094977|Experimental|Low Dose|TXA 10mg/kg bolus before incision and 5 mg/kg infusion until skin closure
3214556|NCT01094977|Experimental|High Dose|TXA 100 mg/kg bolus before incision and 10 mg/kg infusion until skin closure
3214557|NCT01094977|Placebo Comparator|Placebo|Normal saline 10 ml before skin incision and infusion according to weight until skin closure
3214558|NCT01094951|Other|ENGAGE|"In stage 1, study investigators will train Neighborhood House caseworkers to screen their clients for depressive symptoms.~In stage 2, study investigators will train Neighborhood House caseworkers to use the ENGAGE intervention in referring their clients to mental health services"
3214559|NCT01094938||Repair|
3214560|NCT01094925|Placebo Comparator|Placebo|
3214561|NCT01094925|Active Comparator|Gabapentin 300mg|
3214562|NCT01094925|Active Comparator|Gabapentin 600mg|
3214563|NCT01094899|Experimental|Type 1 Diabetics without Neuropathy|Adult male with type 1 diabetes and without peripherical neuropathy
3214564|NCT01094899|Experimental|Type 2 Diabetics without Neuropathy|Adult male with type 2 diabetes and without peripherical neuropathy
3214565|NCT01094899|Experimental|Type 1 Diabetics with Neuropathy|Adult male with type 1 diabetes and with peripherical neuropathy
3214566|NCT01094899|Experimental|Type 2 Diabetics with Neuropathy|Adult male with type 1 diabetes and with peripherical neuropathy
3214567|NCT01094886|Experimental|001|Rivaroxaban 10mg tablet daily receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
3214568|NCT01094873|Experimental|Arm A, group 1|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^8vp at week 14 and 1 dose Ad6NSmut 5 x 10^8vp at week 24, after starting PEG-IFN and ribavirin therapy.~Patients: 2"
3214569|NCT01094873|Experimental|Arm A, group 2|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^9vp at week 14 and 1 dose Ad6NSmut 5 x 10^9vp at week 24, after starting PEG-IFN and ribavirin therapy.~Patients: 2"
3214570|NCT01094873|Experimental|Arm A, group 3|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 14 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24, after starting PEG-IFN and ribavirin therapy.~Patients: 6"
3214571|NCT01094873|Experimental|Arm A, group 4|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 2 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 12, after starting PEG-IFN and ribavirin therapy.~Patients: 6"
3214890|NCT01092754|Other|B: Other|
3214572|NCT01094873|Experimental|Arm A, group 5|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at weeks 14 and 18, and 1 dose Ad6NSmut 2.5 x 10^10vp at week 28, after starting PEG-IFN and ribavirin therapy.~Patients: 4"
3214573|NCT01094873|Experimental|Arm A, group 6|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at weeks 2 and 6, and 1 dose Ad6NSmut 2.5 x 10^10vp at week 16, after starting PEG-IFN and ribavirin therapy.~Patients: 4"
3214574|NCT01094873|Experimental|Arm B, group 1|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^8vp at week 4 and 1 dose Ad6NSmut 5 x 10^8vp at week 14.~Patients: 2"
3214575|NCT01094873|Experimental|Arm B, group 2|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^9vp at week 4 and 1 dose Ad6NSmut 5 x 10^9vp at week 14.~Patients: 2"
3214576|NCT01094873|Experimental|Arm B, group 3|"Interventions: AdCh3NSmut; Ad6NSmut.~1 dose AdCh3NSmut 2.5 x 10^10vp at week 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 14.~Patients: 4"
3214577|NCT01094860|Experimental|Continuous Infusion Nelarabine|Starting dose 200 mg/m2 x 5 days
3214578|NCT01094847|Experimental|Treatment A|DWJ1252 given by oral administration under fasting conditions
3214579|NCT01094847|Active Comparator|Treatment B|DWJ1252 given by oral administration, 30 minutes after a meal
3214580|NCT01094847|No Intervention|Treatment C|mosapride by oral administration 30 minutes before meals
3214581|NCT01094834|Experimental|DWP05195|
3214582|NCT01094821|Experimental|3 mg ATI-7505|3 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
3214583|NCT01094821|Placebo Comparator|Placebo|Placebo capsule three times daily for 9 days followed by transit scintigraphy
3214584|NCT01094821|Experimental|10 mg ATI-7505|10 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
3214585|NCT01094821|Experimental|20 mg ATI-7505|20 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
3214586|NCT01094808|Experimental|Pregabalin 75 mg|Subjects randomized to this arm received a single dose of pregabalin 75 mg orally
3214587|NCT01094808|Experimental|Pregabalin 200 mg|Subjects randomized to this arm received a single dose of pregabalin 200 mg orally
3214588|NCT01094808|Placebo Comparator|Placebo|Subjects randomized to this arm received a single dose of placebo medication orally
3214589|NCT01094795||Patients initiating abatacept|
3214590|NCT01094795||Patients receiving other biologic disease-modifying drugs|
3214591|NCT01094795||Patients with early rheumatoid arthritis (RA)|
3214592|NCT01094795||Patients with prevalent RA identified by hospitalization|
3214593|NCT01094795||General population|
3214594|NCT01094782|Active Comparator|Healthy - True Acupuncture|Healthy volunteers with no neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7.This group received true acupuncture treatment (the needles punctured the skin).
3214595|NCT01094782|Sham Comparator|Healthy - Sham Acupuncture|Healthy with no neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received sham acupuncture treatment (the needles did not puncture the skin).
3214596|NCT01094782|No Intervention|Healthy - No Treatment|Healthy volunteers with no neck or back pain who attended 3 visits over 4 weeks and received no sham or true acupuncture treatment.
3214597|NCT01094782|Active Comparator|Pain - True Acupuncture|Volunteers with radiating neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received true acupuncture treatment (the needles punctured the skin).
3214598|NCT01094782|Sham Comparator|Pain - Sham Acupuncture|Volunteers with radiating neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received sham acupuncture treatment (the needles did not puncture the skin).
3214599|NCT01094782|No Intervention|Pain - No Treatment|Volunteers with radiating neck or back pain who attended 3 visits over 4 weeks and received no sham or true acupuncture treatment.
3214600|NCT01094769|Experimental|Moxonidine|
3214601|NCT01094769|Placebo Comparator|Placebo|
3214602|NCT01094756|Active Comparator|Obese group - Group 1|If you have a BMI between 33kg - 45kg and weight under 350 lbs you could be in group 1.
3214603|NCT01094756|No Intervention|Lean group - Group 2|If you have a BMI between 18.5 kg - 24.9 kg you could be in group 2.
3214604|NCT01094743|Other|galyfilcon A prototype lens / lotrafilcon B lens|The galyfilcon A prototype lenses will be worn during the first period and lotrafilcon B lenses will be worn during the second period. Each period consists of daily lens wear for one week.
3214605|NCT01094743|Other|lotrafilcon B lens / galyfilcon A prototype lens|The lotrafilcon B lenses will be worn during the first period and galyfilcon A prototype lenses will be worn during the second period. Each period consists of daily lens wear for one week.
3214606|NCT01094730|Other|galyfilcon A prototype/marketed galyfilcon A|The galyfilcon A prototype lens worn daily for 12-16 days during the first period then the marketed galyfilcon A lens worn daily for 12-16 days during the second period.
3214607|NCT01094730|Other|marketed galyfilcon A/galyfilcon A prototype|The marketed galyfilcon A lens worn daily for 12-16 days during the first period then the galyfilcon A prototype lens worn daily for 12-16 days during the second period; during each period.
3214608|NCT01094717|Experimental|acitretin and excimer|
3214609|NCT01094717|Experimental|tazarotene and excimer|
3214610|NCT01094704|Experimental|Hypertonic Saline - 1 hour|sodium chloride (7%); mucociliary clearance measured 1 hour post dose
3214611|NCT01094704|Experimental|Hypertonic Saline - 4 hours|sodium chloride (7%); mucociliary clearance measured four hours post-dose.
3214612|NCT01094691|Experimental|Renal Allograft Biopsy|Urine left over from clinic visits is analyzed for 'Haufen' by negative staining electron microscopy as a marker of intra-renal polyomavirus nephropathy. Correlate Haufen, urine, and plasma data with the clinical presentation and with renal biopsy findings. Patients with PVN will be approached for study participation in which their routine samples will be monitored until urine is negative for 'Haufen', and a study protocol biopsy will be obtained for confirmation.
3214613|NCT01094678|Experimental|Stent|
3214614|NCT01094665|Experimental|Focal Laser Thermal Therapy|Thermal therapy delivered to lesion visible on MRI.
3214708|NCT01094041|Experimental|Gluten rich diet|
3214615|NCT01094652|Experimental|Whole grain diet|Participants in this group will be given whole grain snacks on school days and food packages consisting of whole grain breads, breakfast cereals, rice, snack foods, and pasta to replace their typical grains consumed at home.
3214616|NCT01094652|Active Comparator|Refined grain diet|Participants in this group will be given refined grain snacks on school days and food packages consisting of refined grain breads, breakfast cereals, rice, snack foods, and pasta to replace their typical grains consumed at home.
3214617|NCT01094639|Placebo Comparator|Supragingival prophylaxis|Plaque removal
3214618|NCT01094639|Active Comparator|Scaling root planing|SRP+oral hygiene
3214619|NCT01094626|Experimental|Experimental|Fifteen subjects will be randomly selected to undergo S-MRI prior to surgery. These subjects would receive Secretin, administered by IV bolus injection over 1 minute followed by a 30 second saline flush.
3214620|NCT01094626|No Intervention|Controls|Fifteen subjects will be selected as controls, undergoing MRI without secretin-enhancement and matched for age, sex, race and tumor-type.
3214621|NCT01094613|Experimental|Delayed Release 6MP|"6 Mercaptopurine delayed release oral tablet for targeted ileal delivery, to be administered once nightly before bedtime, for 12 weeks.~The dose is 2 x 40 mg DR-6MP (total dose, 80 mg DR-6MP)."
3214622|NCT01094613|Active Comparator|Purinethol|6 Mercaptopurine Tablet (50 mg) administered orally, at doses of 1-1.5 mg/kg body weight, daily for 12 weeks. Individual patient doses range from 50 mg to 150 mg, including 75, 100 and 125 mg daily, as per patient weight at baseline, and then are up-titrated to clinical efficacy at two week intervals, as needed. Doses may be down-titrated as well if occurrences of AE's warrant dose reduction.
3214623|NCT01094600|Experimental|Secretin|Single arm (open label).
3214624|NCT01094587|Active Comparator|Sutured closure|
3214625|NCT01094587|Active Comparator|Sutureless closure|
3214626|NCT01094574|Active Comparator|Alfentanil|Experimental inflammation, and tissue injury sites were created, an infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
3214627|NCT01094574|Active Comparator|Propranolol|Experimental inflammation and tissue injury sites were created, an infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
3214628|NCT01094574|Placebo Comparator|Placebo|Experimental inflammation and tissue injury sites were created, an infusion of normal saline was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
3214629|NCT01094561|Experimental|Synthetic Human Secretin|Single arm (open label).
3214630|NCT01094548|Experimental|Tecemotide (L-BLP25) plus single low dose cyclophosphamide|
3214631|NCT01094548|Experimental|Tecemotide (L-BLP25) plus multiple low dose cyclophosphamide|
3214632|NCT01094535|Experimental|Secretin|One-arm (open label): Synthetic Human Secretin. Patients will undergo four Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) evaluations.
3214633|NCT01094522|Experimental|Methadone|One half the Study patients will be randomized to receive a loading dose of IV methadone, followed by IV doses (given by the ICU nurse), on a PRN basis, for pain control for up to 24 hours during their postoperative course while they are intubated.
3214634|NCT01094522|Active Comparator|Morphine|One half the Study patients will be randomized to receive a loading dose of IV morphine, followed by IV doses (given by the ICU nurse), on a PRN basis, for pain control for up to 24 hours during their postoperative course while they are intubated.
3214635|NCT01094509|Experimental|Tai Chi|Tai Chi exercises
3214636|NCT01094509|Experimental|Guided autobiography|Autobiographical writing during class sessions and at home
3214637|NCT01094509|Experimental|Qigong|Qigong exercises (exploratory, not part of the original protocol, added to gain experience with this intervention)
3214638|NCT01094509|Active Comparator|Successful aging|Seminars on the theme of successful aging
3214639|NCT01094509|Experimental|Combination|Combination of Tai Chi exercises and autobiographical writing
3214640|NCT01094509|Placebo Comparator|Comparison|No assigned experimental activity (exploratory, not part of the original protocol, added to gain experience with a placebo comparator)
3214641|NCT01094496|Experimental|CDX-1307 Vaccine Regimen|Chemotherapy with CDX-1307 vaccine regimen (neoadjuvant phase), followed by bladder removal surgery (cystectomy). CDX-1307 vaccine regimen will continue to be given for up-to 1 year post-surgery (adjuvant/long-term follow-up phase).
3214642|NCT01094483|Experimental|1|PN400 + ASA
3214643|NCT01094483|Placebo Comparator|2|Placebo + ASA
3214644|NCT01094457|Active Comparator|standard group|patients in this group received standard dual antiplatelet therapy, i.e. aspirin 300mg/d and clopidogrel 75mg/d
3214645|NCT01094457|Experimental|intensive group|patients in this group received intensive antiplatelet therapy and the regimen can be adjusted according to results of platelet aggregation function test by LTA
3214646|NCT01094444|Experimental|Vitamin K3-lotion|A lotion containing 1.5 mM Vitamin K3.
3214647|NCT01094444|No Intervention|B|Standard lotion without Vitamin K3
3214648|NCT01094418||IGT group|IGT diagnosed by endocrinologist
3214649|NCT01094418||DM group|DM diagnosed by endocrinologist and whose primary NCS screening shows SNAP amplitudes of sural and superficial peroneal nerves greater than 10mA DM patients with no previous diagnosis of peripheral polyneuropathy
3214650|NCT01094418||Normal healthy participants|Normal health participants with no previous history of DM, IGT, thyroid disorder, hypercholesterolemia, or other condition associated with peripheral polyneuropathy
3214651|NCT01094405|Experimental|EBV Vaccine|
3214652|NCT01094392||treatment every 6th week during 6 months|
3214653|NCT01094392||treatment every 2nd week during 6 months|
3214654|NCT01094379|Active Comparator|Standard lap chole|Laparoscopic cholecystectomy using four entry sites to the abdominal cavity
3214655|NCT01094379|Active Comparator|Single incision lap chole|Laparoscopic cholecystectomy using one entry site to the abdominal cavity
3214656|NCT01094366|Sham Comparator|No Paracervical Block for Pain Control|Subject will not receive a paracervical block during the procedure
3214657|NCT01094366|Active Comparator|Paracervical Block for Pain Control|Subject will receive a paracervical block during the procedure.
3214658|NCT01094353|Active Comparator|Mini-sling|The minisling Ophira™ is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
3214659|NCT01094353|Active Comparator|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
3214660|NCT01094340|Other|Thalidoide|CSF
3214661|NCT01094314|Active Comparator|sequential medium|
3214662|NCT01094314|Active Comparator|single medium|
3214663|NCT01094301|Experimental|The SPR System|The SPR System is an investigational two-staged device which delivers stimulation to the muscles in the shoulder. Subjects with chronic post-stroke shoulder pain who meet eligibility criteria for the first stage (SPR Trial Stage) will receive a temporary Lead and External Stimulator. Subjects who qualify and who agreed to proceed will advance to the second stage (SPR Implant Stage) which uses an Implantable Pulse Generator (IPG) and Implantable Lead. Subjects will be followed until 36-months after IPG stimulation has been started.
3214664|NCT01094288|Experimental|MLN8237 + docetaxel|
3214665|NCT01094275||wild / normal type allele of CYP2C gene|clopidogrel 75 mg alone.
3214666|NCT01094275||wild / normal type allele of CYP2C|clopidogrel 75 mg + omeprazole 20 mg.
3214667|NCT01094275||Loss of Haplotype CYP2C19|clopidogrel 75mg alone
3214668|NCT01094275||Loss of function haplotype of CYP2C|clopidogrel 75mg + omerprazole 20mg.
3214669|NCT01094262|Experimental|JNJ-42160443 (lower dose)|
3214670|NCT01094262|Experimental|JNJ-42160443 (higher dose)|
3214671|NCT01094262|Active Comparator|Oxycodone CR (standard pain medication)|
3214672|NCT01094262|Placebo Comparator|Placebo|
3214673|NCT01094249|Experimental|001|divalproex sodium ER/paliperidone ER Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
3214674|NCT01094236|Experimental|Supervisor Treatment Group|Supervisors watched the CD intervention
3214675|NCT01094236|Experimental|Administrators - Treatment|School administrators got access to the intervention binder with CD's, workbook and worksheets
3214676|NCT01094236|Experimental|Students|3rd grade students at participating study schools
3214677|NCT01094236|Experimental|Supervisor Control Group|Supervisors watched a video on playground equipment safety
3214678|NCT01094236|Experimental|Administrators - Control|Administrators did not have access to any treatment materials.
3214679|NCT01094236|Experimental|School Staff|School staff surveyed at staff meetings
3214680|NCT01094223|Experimental|Mindfulness|
3214681|NCT01094223|Active Comparator|Health Education|
3214682|NCT01094210||G1|500 ppm F Test Toothpaste
3214683|NCT01094210||G2|1100 ppm F Control Toothpaste
3214684|NCT01094197||Transfused microchimeric subject|Former trauma patient who underwent blood transfusion and has recent evidence of long-term transfusion-associated microchimerism
3214685|NCT01094184|Experimental|Bevacizumab 10 mg/kg Q2W|Participants will receive bevacizumab at a dose of 10 milligrams per kilogram (mg/kg) every 2 weeks (Q2W) as intravenous infusion along with paclitaxel every week (Q1W) or docetaxel every 3 weeks (Q3W) as per discretion of the treating physician until disease progression, unacceptable toxicity or withdrawal of consent.
3214686|NCT01094184|Experimental|Bevacizumab 15 mg/kg Q3W|Participants will receive bevacizumab at a dose of 15 mg/kg Q3W as intravenous infusion along with paclitaxel Q1W or docetaxel Q3W as per discretion of the treating physician until disease progression, unacceptable toxicity or withdrawal of consent.
3214687|NCT01094171|Experimental|Poliorix Group|Subjects received 3 primary doses of PoliorixTM and InfanrixTM vaccines at 3, 4.5 and 6 months of age. All vaccines were administered intramuscularly in the anterolateral side of the left thigh (Poliorix) and the right thigh (Infanrix).
3214688|NCT01094158|Experimental|high dose|Aramchol 300 mg daily (high dose)
3214689|NCT01094158|Experimental|low dose|100 mg daily (low dose)
3214690|NCT01094158|Placebo Comparator|Placebo|Placebo and two doses will be compared. The Aramchol: placebo ratio is of 2:1.
3214691|NCT01094145|Sham Comparator|Placebo|Stimulator setting is OFF
3214692|NCT01094145|Active Comparator|Deep Brain Stimulation|Stimulator setting is ON
3214693|NCT01094132|Other|Review by colposcopy + multispectral digital colposcopy|All patients belong under this arm, as all will be reviewed by both conventional colposcopy and by Multispectral Digital Colposcopy (MDC). The nature of these techniques are explained below.
3214694|NCT01094119|Active Comparator|Bair Hugger heated blanket|Patients will be warmed during surgery with the Bair Hugger heated blanket.
3214695|NCT01094119|Active Comparator|LMA PerfecTemp system|Patients will be warmed during surgery with the PerfecTemp heated pad .
3214696|NCT01094106|Active Comparator|Ropivacaine 0,75%|Postoperative wound infusion 15 mg /h / 48h
3214697|NCT01094106|Placebo Comparator|NaCl 0,9%|Postoperative wound infusion with NaCl 0,9% 2 ml /h /48h
3214698|NCT01094093|Experimental|Part B|Four dose levels of AMG 139 administered as a single dose SC or IV in subjects with moderate-severe psoriasis (Part B).
3214699|NCT01094093|Experimental|Part A|Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers.
3214700|NCT01094080|Active Comparator|standard infant formula|infants are fed a commercial formula during the first 4 month of life, according to protocol
3214701|NCT01094080|Experimental|modified infant formula|infants are fed a modified infant formula (modified protein content and fatty acid pattern) during the first 4 month of life, according to protocol
3214702|NCT01094080|Other|breast milk|infants are breast fed
3214703|NCT01094067|Experimental|1|Placebo at visit 1, tezosentan at visit 2
3214704|NCT01094067|Experimental|2|Tezosentan at visit 1, placebo at visit 2
3214705|NCT01094054|Active Comparator|Dietary and lifestyle modification|Patients in this arm will eat meals that are identical in size and caloric composition to those consumed by participants in the other arm who undergo adjustable gastric banding
3214706|NCT01094054|Experimental|Adjustable gastric banding|Subjects will undergo gastric banding as per clinical practice
3214707|NCT01094041|Experimental|Gluten free diet|
3214709|NCT01094028|Experimental|Saline group|Only 30 mL of saline was injected directly in the umbilical vein after clamping. The injection was performed with a 30-mL syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute and at the end of the injection, the solution was milked toward the cord insertion.
3214710|NCT01094015|Active Comparator|Lidocaine-Prilocaine cream|
3214711|NCT01094015|Placebo Comparator|placebo|
3214712|NCT01094002|Experimental|Occupational therapy intervention (OTI)|198 subjects. The OTI schedule consisted of a daily 45-minute session, Monday through Friday, for the duration of hospitalisation. Activities were carried out in a structured manner and varied according to need and day of admission. On the first day, the patient's needs were analysed, including the need for iatrogenic prevention, retraining in basic and instrumental activities of daily living, technical aids, instruct the primary caregiver in patient mobilisation techniques, and social and occupational motivation. All OTI participants received an average of 5 sessions during hospitalisation.
3214713|NCT01094002|No Intervention|Conventional treatment model group|202 subjects. All subjects received medical treatment, nursing care, physical therapy, and social assistance in accordance with the usual practice of the geriatrics unit.
3214714|NCT01093989|Placebo Comparator|Immediate iron|Iron-deficient children will be randomized to receive iron concurrently with anti-malarial treatment or one month later (delayed iron group).
3214715|NCT01093989|Active Comparator|Delayed iron|
3214716|NCT01093976|Experimental|Dronabinol|Dronabinol (Marinol) - 2.5mg-15mg by mouth once a day for twelve-weeks
3214717|NCT01093963|Active Comparator|Lisdexamfetamine|Drug
3214718|NCT01093963|Placebo Comparator|Placebo|Drug
3214719|NCT01093950||PROSPECTIVE BODY CONTOURING SUBJECTS|"It is anticipated that the participants will undergo body contouring procedures including lipoplasty [internal fat suction removal], abdominoplasty [surgical removal of lower abdominal skin and fat], breast reduction [surgical removal of breast skin, fat, and breast tissue to reduce breast size], breast augmentation [surgical breast enlargement], thigh lift [surgical removal of upper thigh tissue], and brachioplasty [surgical removal of upper arm tissue].~These procedures will be evaluated by pre- and post-operative digital scans, analog measurements, and clinical examinations and photographs."
3214720|NCT01093924|No Intervention|self-guided weight loss maintenance|15-month self-guided weight loss maintenance group will receive monthly reminders to maintain their weight loss and newsletters that contain health information.
3214721|NCT01093924|Experimental|DVD group|15-month weight loss maintenance intervention deliver via DVD.
3214722|NCT01093924|Experimental|face-to-face group|15-month weight loss/weight loss maintenance intervention delivered in a group setting
3214723|NCT01093911|Experimental|CDP7657|CDP7657 in dose escalating cohorts
3214724|NCT01093911|Placebo Comparator|Placebo|
3214725|NCT01093898||No intervention|
3214726|NCT01093885|Other|open label: medication Ambrisentan|"Open label study of Ambrisentan.~Ambrisentan will begin at 5mg daily for the first month.~Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week. Subjects will continue their present dose and schedule of disease modifying/antifibrotic medication for the duration of the study."
3214727|NCT01093859|Experimental|PRX-105 Infusion|
3214728|NCT01093846|Experimental|AIN457 300 mg every 2 weeks|
3214729|NCT01093846|Experimental|AIN457 300 mg monthly|
3214730|NCT01093846|Placebo Comparator|Placebo|
3214731|NCT01093833|Experimental|Continuous Glucose Monitoring|Each subject will participate in one experimental intervention. Blood glucose will be measured with the BD continuous glucose monitor (BD CGM), with the Medtronic Guardian CGM and the YSI Glucose Analyzer as controls for 12-14 hours.
3214732|NCT01093820|Experimental|Epopoetinum beta|Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
3214733|NCT01093807|Placebo Comparator|Placebo|
3214734|NCT01093807|Experimental|Lercanidipine 10 mg|
3214735|NCT01093807|Experimental|Lercanidipine 20 mg|
3214736|NCT01093807|Experimental|Enalapril 10 mg|
3214737|NCT01093807|Experimental|Enalapril 20 mg|
3214738|NCT01093807|Experimental|Lercanidipine 10 mg/Enalapril 10 mg|
3214739|NCT01093807|Experimental|Lercanidipine 10mg/Enalapril 20 mg|
3214740|NCT01093807|Experimental|Lercanidipine 20mg/Enalapril 10 mg|
3214741|NCT01093807|Experimental|Lercanidipine 20mg/Enalapril20mg|
3214742|NCT01093794|Experimental|1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~Co-administration of 50 mg sitagliptin and 500 mg metformin~sitagliptin/metformin 50 mg/500 mg FDC tablet~sitagliptin/metformin 50 mg/850 mg FDC tablet~Co-administration of 50 mg sitagliptin and 850 mg metformin"
3214743|NCT01093794|Experimental|2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~sitagliptin/metformin 50 mg/500 mg FDC tablet~Co-administration of 50 mg sitagliptin and 850 mg metformin~Co-administration of 50 mg sitagliptin and 500mg metformin~sitagliptin/metformin 50 mg/850 mg FDC tablet"
3214744|NCT01093794|Experimental|3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~Co-administration of 50 mg sitagliptin and 850 mg metformin~sitagliptin/metformin 50 mg/850 mg FDC tablet~sitagliptin/metformin 50 mg/500 mg FDC tablet~Co-administration of 50 mg sitagliptin and 500mg metformin"
3214745|NCT01093794|Experimental|4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~sitagliptin/metformin 50 mg/850 mg FDC tablet~Co-administration of 50 mg sitagliptin and 500 mg metformin~Co-administration of 50 mg sitagliptin and 850 mg metformin~sitagliptin/metformin 50 mg/500 mg FDC tablet"
3214746|NCT01093781|Experimental|Aliskiren|Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
3214747|NCT01093755|Active Comparator|dexlansoprazole|Participants will be treated with dexlansoprazole 60-90 mg/day for 6 months
3214748|NCT01093755|Active Comparator|omeprazole|Participants will be treated with omeprazole 20mg/day for a minimum of 6 weeks. If symptomatic can increase dose by 20mg twice.
3214750|NCT01093742|Experimental|cohort 2|HM10560A 0.179 mg/kg or Placebo
3214751|NCT01093742|Experimental|cohort 3|HM10560A 0.357 mg/kg or Placebo
3214752|NCT01093742|Experimental|cohort 4|HM10560A 0.714 mg/kg or Placebo
3214753|NCT01093729|Experimental|Cohort1|HM11260C 0.5mcg/kg or Placebo
3214754|NCT01093729|Experimental|Cohort2|HM11260C 2mcg/kg or Placebo
3214755|NCT01093729|Experimental|Cohort3|HM11260C 4mcg/kg or Placebo
3214756|NCT01093729|Experimental|Cohort4|HM11260C 8mcg/kg or Placebo
3214757|NCT01093729|Experimental|Cohort5|HM11260C 14mcg/kg or Placebo
3214758|NCT01093716|Experimental|rTMS|Compare the change in craving parameters following high frequency rTMS stimulation of right and left DLPFC in patients with alcohol dependence
3214759|NCT01093703|No Intervention|Conventional Therapy|In the conventional therapy group, no medication changes other than the ones needed to achieve target awake average SBP will be undertaken. Time at which patients are taking their BP medications will be recorded.
3214760|NCT01093703|Active Comparator|Intensive Therapy|In the intensive therapy group, BP medications will be adjusted to both control awake average systolic BP to target and to cover the overnight period in an attempt to control nocturnal hypertension.
3214761|NCT01093690|Experimental|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg orally four times a day on day 2-5
3214762|NCT01093690|Placebo Comparator|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
3214763|NCT01093677|Experimental|A|750 mg of LIM-0705 BID for 14 days. Up to 20 subjects.
3214764|NCT01093677|Placebo Comparator|B|Placebo BID for 14 days. Up to 10 subjects.
3214765|NCT01093664|Experimental|AFFITOPE AD02|
3214766|NCT01093651|Experimental|DPPIV inhibition|Four to six months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count >350 cells/µL) and virologic (plasma HIV RNA <50 copies/mL) status.
3214767|NCT01093651|Placebo Comparator|Placebo|Four to six months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count >350 cells/µL) and virologic (plasma HIV RNA <50 copies/mL) status.
3214768|NCT01093638|Experimental|Oral Formulation of Insulin|Oral formulation of insulin fed concomitantly with premature infant formula
3214769|NCT01093638|Placebo Comparator|Oral Formulation of Placebo|Oral formulation of placebo fed concomitantly with premature infant formula
3214770|NCT01093625|Experimental|Narafilcon B Contact Lens|Investigational Silicone Hydrogel Contact Lens
3214771|NCT01093625|Active Comparator|Spectacles|
3214772|NCT01093612|Experimental|Arm I|PART ONE: Patients are randomized to 1 of 3 dose levels. Patients undergo a PET scan 24-48 hours after injection of copper Cu 64-DOTA-trastuzumab. PART TWO: Patients undergo a PET scan 24-48 hours after injection of copper Cu 64-DOTA-trastuzumab.
3214773|NCT01093599|Active Comparator|Quit Line Only|Control Participants will call the Wisconsin Tobacco Quit Line intervention including phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
3214774|NCT01093599|Active Comparator|Quit Line plus MTS|Participants in the study group will receive the Quit Line intervention (talk to a Quit Line Counselor, receive quit smoking materials and get 4 weeks of nicotine patches) and also receive 4 weeks of training in mindfulness meditation through the mindfulness for smokers intervention.
3214775|NCT01093586|Experimental|Arm I|PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
3214776|NCT01093573|Experimental|Arm I|Patients receive azacitidine IV over 10-20 minutes on days 1-7 and oral midostaurin twice daily on days 8-21.
3214777|NCT01093560|Experimental|young women with MetS|"Saturated fat (control)~n-3 Polyunsaturated fat (experimental)~monounsaturated fat"
3214778|NCT01093547|Active Comparator|Dianeal only|Patients in Dianeal during the daily exchanges and randomised to Dianeal during the long-dwell exchange
3214779|NCT01093547|Active Comparator|Dianeal; Extraneal long-dwell exchange|Patients in Dianeal during the daily exchanges and randomised to Extraneal during the long-dwell exchange
3214780|NCT01093534|Placebo Comparator|Placebo|Participants received 2 placebo tablets once daily for 12 weeks.
3214781|NCT01093534|Experimental|Solifenacin 5 mg|Participants received one 5 mg solifenacin tablet and one placebo tablet, once daily for 12 weeks.
3214782|NCT01093534|Experimental|Solifenacin 10 mg|Participants received two 5 mg solifenacin tablets once daily for 12 weeks.
3214783|NCT01093521|Experimental|100 mg/m2 dose|Five day continuous IV Gallium Nitrate (Ganite®) infusion at 100 mg/m2
3214784|NCT01093521|Experimental|200 mg/m2 dose|Five day continuous IV Gallium Nitrate (Ganite®) infusion at 200 mg/m2
3214785|NCT01093495|Experimental|CPAP group|Subjects in this group will continue receiving CPAP until no oxygen requirement for 24 hours, then will be weaned off CPAP completely as long as they tolerate. CPAP will be re-instituted if subjects meet failing criteria. Another trial off CPAP will start 24 hours after failure and/or after being on 21% for 24 hours. CPAP will be weaned off directly to room air at all times.
3214786|NCT01093495|Experimental|Nasal Cannula Group|Subjects will be weaned from CPAP (when FiO2 <0.30) to Nasal cannula (2 L/min) with whatever FiO2 they need until they are off oxygen and NC completely. However, if these infants fail on NC they will be put back to nCPAP. Infants will then be maintained on CPAP until stable on CPAP-30% for 24 hours. Infants will be tried for another weaning using NC. So, infants assigned to NC will be weaned only through NC. CPAP will be used only for stabilization in between trials if needed.
3214787|NCT01093482||mechanically ventilated patients|"Patients who are admitted to the participating intensive care units and require invasive mechanical ventilation (endotracheal tube or tracheostomy) for more than 12 hours.~Patients who are admitted to the participating intensive care units and require non-invasive mechanical ventilation (Bilevel positive airway pressure (BIPAP) or continuous positive airway pressure (CPAP) with nasal or facial mask) for more than 1 hour."
3214788|NCT01093469|Experimental|Aquaphor Healing Ointment|Aquaphor Healing Ointment three times daily to atopic dermatitis
3214789|NCT01093469|Active Comparator|Atopiclair Nonsteroidal Cream|Atopiclair Nonsteroidal Cream three times daily to atopic dermatitis
3214790|NCT01093469|Active Comparator|EpiCream Skin Barrier Emulsion|EpiCream Skin Barrier Emulsion three times daily to atopic dermatitis
3214791|NCT01093456||chronic kidney disease|ESKD patients treated with peritoneal dialysis
3214792|NCT01093456||Healthy volunteers|healthy volunteers, aged 18 years and above
3214793|NCT01093443|Placebo Comparator|A|Patients undergo a standard treatment with a classical GnRH antagonist protocol.
3214794|NCT01093443|Active Comparator|B|Before undergoing a standard protocol for ovarian stimulation, patients in this group receive a pretreatment with GnRH antagonists during 3 consecutive days
3214795|NCT01093430|Experimental|Anterior superior iliac spine|The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
3214796|NCT01093430|Active Comparator|Control|The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
3214797|NCT01093417|Placebo Comparator|Placebo|Participants that have been randomized into this arm will receive placebo pills.
3214798|NCT01093417|Active Comparator|Vitamin D 4000 IU|Participants that have been randomized into this arm will receive Vitamin D 4000 IU (International Units) daily.
3214799|NCT01093404|Experimental|Thrombus aspiration|Thrombus aspiration is then followed by standard balloon angioplasty (PCI).
3214800|NCT01093404|Active Comparator|Standard balloon angioplasty (PCI)|
3214801|NCT01093391|Placebo Comparator|BARE METAL STENT|BARE METAL STENT - STENT CRONUS
3214802|NCT01093391|Experimental|DRUG ELUTING STENT|STENT INSPIRON WITH SIROLIMUS
3214803|NCT01093378||Fertile group|fertile group
3214804|NCT01093378||Infertility group|Fertility troubles
3214805|NCT01093365|Experimental|Schizophrenia|To measure the effects of varenicline on cognition of smokers with schizophrenia.
3214806|NCT01093352|No Intervention|Standard|Standard expose and bond.
3214807|NCT01093352|Experimental|Alveolar-decortication|Following surgical exposure of the impacted canine, additional perforations will be made in the surrounding cortical bone prior to wound closure.
3214808|NCT01093339||No treatment|Subjects w/ condition and subjects w/o condition of GERD (gastroesophageal reflux disease)
3214809|NCT01093326|Experimental|Ponesimod 10 mg|Ponesimod 10 mg oral use
3214810|NCT01093326|Experimental|Ponesimod 20 mg|Ponesimod 20 mg oral use
3214811|NCT01093326|Experimental|Ponesimod 40 mg|Ponesimod 40 mg oral use
3214812|NCT01093313|Experimental|Attention training|
3214813|NCT01093313|Active Comparator|Cognitive therapy|
3214814|NCT01093300|Experimental|Paclitaxel-eluting balloon catheter|Paclitaxel-eluting balloon catheter use for treatment of ISR lesion
3214815|NCT01093300|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent use for treatment of ISR lesion
3214816|NCT01093274|Active Comparator|Polyethylene glycol|Preparation with Polyethylene Glycol and bisacodyl
3214817|NCT01093274|Experimental|Picolax|Preparation with Sodium Picosulphate and Bisacodyl.
3214818|NCT01093261|Experimental|Hydrocortisone and fludrocortisone|Patients with glucocorticoid insufficiency
3214819|NCT01093261|Placebo Comparator|Placebo|Patients with glucocorticoid insufficiency
3214820|NCT01093261|No Intervention|Controlled|Adapted glucocorticoid function
3214821|NCT01093248||Heroin-addicted Patients|Heroin-addicted outpatient department (OPD) patients who seek help for methadone maintenance treatment
3214822|NCT01093222|Experimental|Treatment (sorafenib tosylate and erlotinib hydrochloride)|Patients receive sorafenib tosylate PO twice daily and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3214823|NCT01093209|Sham Comparator|Conventional Laser Therapy|
3214824|NCT01093209|Active Comparator|Interferential Laser Therapy|
3214825|NCT01093196|Active Comparator|Rd|Induction treatment with oral Lenalidomide and low dose dexamethasone followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone
3214826|NCT01093196|Experimental|MPR|Induction treatment with oral Lenalidomide, Prednisone and Melphalan followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone
3214827|NCT01093196|Experimental|CPR|Induction treatment with oral Lenalidomide, Cyclophosphamide and Prednisone for followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone.
3214828|NCT01093183|Experimental|Treatment (lenalidomide and cyclophosphamide)|Patients receive lenalidomide PO QD on days 1-21 and cyclophosphamide PO QD on days 1-28. Treatment repeats every 28 days for at least 4 courses in the absence of disease progression or unacceptable toxicity. Treatment modifications may apply according to response.
3214829|NCT01093170|Experimental|RNA-144101|
3214830|NCT01093157|Active Comparator|ACTH (HP Acthar gel) 40 units|
3214831|NCT01093157|Active Comparator|ACTH (HP Acthar gel) 80 units|
3214832|NCT01093131|Active Comparator|Intravenous Hydration|Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.
3214833|NCT01093131|Active Comparator|Intravenous hydration and sodium bicarbonate|Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
3214834|NCT01093131|Active Comparator|Oral hydration|Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure
3214835|NCT01093131|Active Comparator|Oral hydration and oral sodium bicarbonate|Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
3214836|NCT01093118|Experimental|TMI-358|Active treatment
3214837|NCT01093118|Placebo Comparator|MMI-467|
3214891|NCT01092741|Experimental|Gleevec|Gleevec 400 mg by mouth (P.O.) twice daily = 800 mg total daily dose
3214838|NCT01093092|Experimental|Treatment (calcitriol, cisplatin, gemcitabine hydrochloride)|Patients receive calcitriol PO on days 1, 2, 8, 9, 15 and 16; cisplatin IV over 2 hours on day 2; and gemcitabine hydrochloride IV over 30 minutes on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3214839|NCT01093079||Laparoscopic partial nephrectomy|
3214840|NCT01093079||Open Partial nephrectomy|
3214841|NCT01093066|Experimental|surgical resection and chemotherapy|"Maximal and optimal TURB using a standardized procedure. The TURB will always try to be optically complete.~Neoadjuvant chemotherapy for 3 months with the intensified MVAC (6 cycles administered every 2 weeks): METHOREXATE: 30 mg/m2 D1 - VINBLASTINE: 3 mg/m2 D2 - ADRIAMYCINE 30 mg/m2 D2 - CISPLATINE 70 mg/m2 D2. + G-CSF: 5 µg/kg from D4 to D10 New maximal standardized TURB at the end of the chemotherapy. In case of a lesion localized at the bladder dome, and if a maximal TURB appears to be unsafe, a partial cystectomy without lymph node dissection will be performed."
3214842|NCT01093053|Experimental|Mind-Body Skills Groups|
3214843|NCT01093053|Active Comparator|Standard Treatment|
3214844|NCT01093040|Experimental|Cohort 1|CAT-354 will be administered by SC injection
3214845|NCT01093040|Experimental|Cohort 2|CAT-354 will be administered by SC injection
3214846|NCT01093040|Experimental|Cohort 3|CAT-354 will be administered by SC injection
3214847|NCT01093027|Other|15 - 30|The upper limb with tremor will be cooled with 15 degrees Celsius water for 10 minutes at Visit 1 and with 30 degrees Celsius water for 10 minutes at Visit 2.
3214848|NCT01093027|Other|30 - 15|The upper limb with tremor will be cooled with 30 degrees Celsius water for 10 minutes at Visit 1 and with 15 degrees Celsius water for 10 minutes at Visit 2.
3214849|NCT01093014|Experimental|Arm 1: High-force muscle stimulation|High-force muscle stimulation
3214850|NCT01093014|Experimental|Arm 2: Low-force muscle stimulation|Low-force muscle stimulation
3214851|NCT01093014|Experimental|Arm 3: Sequential low-force and high-force muscle stimulation|Sequential low-force and high-force muscle stimulation
3214852|NCT01093001|Active Comparator|Lead size|The pacemaker lead will be < or = to 7Fr. The ICD lead will be 9 Fr.
3214853|NCT01093001|Active Comparator|RV Lead position|50 patients will be randomized to RV apex lead placement.
3214854|NCT01093001|Active Comparator|Mid-Septum Lead position|50 patients will be randomized to RV mid-septum lead placement.
3214855|NCT01093001|Active Comparator|CS lead position|50 patients will have lead placed in the CS
3214856|NCT01092988|Experimental|Exablate 2100|MR Guided Focused Ultrasound treatment
3214857|NCT01092975|Experimental|1.25 mg phenylephrine|
3214858|NCT01092975|Experimental|2.5 mg phenylephrine|
3214859|NCT01092975|Experimental|5.0 mg phenylephrine|
3214860|NCT01092975|Experimental|10.0 mg phenylephrine|
3214861|NCT01092975|Experimental|20.0 mg phenylephrine|
3214862|NCT01092975|Experimental|40.0 mg phenylephrine|
3214863|NCT01092975|Experimental|60.0 mg phenylephrine|
3214864|NCT01092975|Experimental|80.0 mg phenylephrine|
3214865|NCT01092962|Experimental|Mycophenolate mofetil|Mycophenolate mofetil
3214866|NCT01092962|Active Comparator|Cyclophosphamide|Cumulative dose of 148mg/kg of cyclophosphamide in 84 days (2mg/kg/day during 12 weeks)
3214867|NCT01092923|Experimental|Air/Oxygen|Sevoflurane with Air/Oxygen Mix
3214868|NCT01092923|Experimental|sevoflurane in N2O/O2|
3214869|NCT01092910|Experimental|Esteem Implant|Subjects are implanted with the Esteem Totally Implantable Hearing System
3214870|NCT01092897||Subjects with PAH treated with Imatinib|
3214871|NCT01092884|Active Comparator|Polypodium leucotomos|Subjects randomized to this arm will receive oral supplementation with Polypodium leucotomos extract
3214872|NCT01092884|Placebo Comparator|Sugar pill|Subjects randomized to this arm will receive oral supplementation with placebo
3214873|NCT01092858|Experimental|Arm 1|
3214874|NCT01092858|Placebo Comparator|Arm 2|
3214875|NCT01092845|Experimental|PF-04457845 followed by placebo|
3214876|NCT01092845|Experimental|Placebo followed by PF-04457845|
3214877|NCT01092832|Experimental|Active voriconazole|All subjects in this study will receive active voriconazole in an open-label fashion; there is no comparator in this study.
3214878|NCT01092819||acute ischemic stroke|Patients presenting with symptoms of acute ischemic stroke within 8 hours from symptom onset and with an imaging-defined large cerebral vessel occlusion.
3214879|NCT01092806|Active Comparator|Prograf|Patients are treated until steady-state conditions with Prograf and then investigated with clamp
3214880|NCT01092806|Experimental|Advagraf|The patients are treated with Advagraf until steady-state conditions and then investigated with clamp
3214881|NCT01092793|Active Comparator|Krill|
3214882|NCT01092793|Active Comparator|Fish oil|
3214883|NCT01092793|No Intervention|Control|
3214884|NCT01092780|Experimental|MK-7288 10mg/Pbo/MK-7288 20mg/Modafinil|Participants received single doses of study drug in the following order: MK-7288 10 mg in Treatment Period 1, Placebo (Pbo) in Treatment Period 2, MK-7288 20 mg in Treatment Period 3 and Modafinil 200 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
3214885|NCT01092780|Experimental|MK-7288 20mg/MK-7288 10mg/Modafinil/Pbo|Participants received single doses of study drug in the following order: MK-7288 20 mg in Treatment Period 1, MK-7288 10 mg in Treatment Period 2, Modafinil 200 mg in Treatment Period 3 and Placebo in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
3214886|NCT01092780|Experimental|Modafinil/MK-7288 20mg/Pbo/MK-7288 10mg|Participants received single doses of study drug in the following order: Modafinil 200 mg in Treatment Period 1, MK-7288 20 mg in Treatment Period 2, Placebo in Treatment Period 3 and MK-7288 10 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
3214887|NCT01092780|Experimental|Pbo/Modafinil/MK-7288 10 mg/MK-7288 20mg|Participants received single doses of study drug in the following order: Placebo in Treatment Period 1, Modafinil 200 mg in Treatment Period 2, MK-7288 10 mg in Treatment Period 3 and MK-7288 20 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
3214888|NCT01092767|Experimental|Valiant Thoracic Stent Graft with the Captivia Delivery System|Valiant Thoracic Stent Graft with the Captivia Delivery System
3214892|NCT01092728|Active Comparator|Group 1: Completely Resectable|Dasatinib 100 mg daily for 7 days and then surgical resection on Day 8. Afterwards, Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).
3214893|NCT01092728|Active Comparator|Group 2: Unresectable|100 mg Dasatinib daily continued up to 12 months/12 cycles (1 cycle = 4 weeks of treatment).
3214894|NCT01092715|Experimental|Mobilization|Spinal mobilization and exercises
3214895|NCT01092715|Active Comparator|Massage|Neck massage and exercises
3214896|NCT01092702|Other|Varenicline|Everyone on study will receive Varenicline daily for 12 weeks
3214897|NCT01092689|Experimental|PhIP|Prior to surgery, consented subjects will ingest a capsule containing [14C]PhIP. This amount of [14C]PhIP (84 micrograms PhIP; 15.6 micro-curies) is equivalent to that in 2 very well done grilled/barbecued chicken breasts (Sinha 1995); the amount of radioactivity is equivalent to the dose received in a commercial airline flying at 30,000 ft. for 5 h (HPS 2007) or to the amount received during a typical chest x-ray.
3214898|NCT01092676|Active Comparator|Regular Ibuprofen Dosing|Regular Ibuprofen Dosing throughout 4 days of study
3214899|NCT01092676|Active Comparator|PRN Ibuprofen dosing|As needed Ibuprofen dosing
3214900|NCT01092663|Active Comparator|Colesevelam HCl: 3 tablets, 2x/day|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
3214901|NCT01092663|Active Comparator|Colesevelam plus Sitagliptin|"Colesevelam: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.~Sitagliptin: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks."
3214902|NCT01092650|Active Comparator|Smoked|Deuterated Phenanthrene spiked in a study cigarette
3214903|NCT01092650|Experimental|Oral|Deuterated phenanthrene in an oral dose
3214904|NCT01092637||Cooled|Child was allocated standard intensive care plus moderate whole body hypothermia treatment within 6 hours of birth
3214905|NCT01092637||Non-cooled|Child was allocated standard intensive care only within 6 hours of birth
3214906|NCT01092624|Experimental|Pessary and solifenacin|
3214907|NCT01092624|Placebo Comparator|Pessary and placebo|
3214908|NCT01092611|Other|Group A|Subjects who were administered the GSK HIV vaccine 732462 in primary studies and who accepted to participate in this study
3214909|NCT01092611|Other|Group B|Subjects who were administered placebo in primary studies and who accepted to participate in this study
3214910|NCT01092572|Experimental|Simvastatin 40 mg/d|simvastatin 40 mg per day taken orally
3214911|NCT01092572|Placebo Comparator|Sugar pill|
3214912|NCT01092559|Experimental|nitric oxide via GeNO Nitrosyl system|Nitric Oxide via GeNO Nitrosyl system
3214913|NCT01092546|Experimental|Arm 1|
3214914|NCT01092533|Experimental|Mycophenolate sodium + Prednisolone|Mycophenolate sodium 1440 mg/day Prednisolone: initial dose 1 mg/kg/day, maintenance dose 5 mg/day
3214915|NCT01092533|Active Comparator|Prednisolone|Prednisolone: initial dose 1 mg/kg/day, maintenance dose 5 mg/day
3214916|NCT01092520|Experimental|Gabapentin|
3214917|NCT01092507|Experimental|JE-CV Group|Participants will receive one dose of Japanese encephalitis chimeric virus vaccine (JE-CV)
3214918|NCT01092507|Active Comparator|SA14-14-2 vaccine Group|Participants will receive one dose of Japanese encephalitis live vaccine, SA14-14-2 vaccine. (CD.JEVAX®)
3214919|NCT01092494||OC use|OC use after postoperative gonadotropin-releasing hormone agonist treatment
3214920|NCT01092494||OC non-use|Only postoperative gonadotropin-releasing hormone agonist treatment
3214921|NCT01092481|Active Comparator|FOLFOX_12 or CAPOX_8|6 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX
3214922|NCT01092481|Experimental|FOLFOX_6 or CAPOX_4|3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX
3214923|NCT01092468|Placebo Comparator|Diathermy|Perforator flap elevation using conventional diathermy technique
3214924|NCT01092468|Active Comparator|Harmonic Scalpel|Perforator flap elevation using Harmonic Scalpel
3214925|NCT01092455||Citrasate and heparin reduction|Sequential hemodialysis treatment study in which all enrollees move through four (4) separate treatment phases. Results from the separate phases will be compared to standard bicarbonate dialysis with standard does of heparin.
3214926|NCT01092442||Retrospective Patients|Retrospective Patients: The patient group who had the CryoValve SG Pulmonary Human Heart Valve implanted prior to the February 2008 clearance of the valve.
3214927|NCT01092442||Prospective Patients|Prospective Patients: The patient group that had the CryoValve SG Pulmonary Human Heart Valve implanted after the February 2008 clearance of the valve.
3214928|NCT01092429||one,two,and three vessels disease; mortality|
3214929|NCT01092403|Experimental|ASM-024|ASM-024 once daily by inhalation
3214930|NCT01092403|Placebo Comparator|Placebo|Placebo once daily by inhalation
3214931|NCT01092390|Experimental|Lovaza|4 grams per day
3214932|NCT01092377|Experimental|DHA/EPA capsules and iron tablet|
3214933|NCT01092377|Experimental|DHA/EPA and placebo tablet|
3214934|NCT01092377|Placebo Comparator|placebo capsules & placebo tablet|
3214935|NCT01092377|Experimental|iron tablet and placebo capsules|
3214936|NCT01092364|Experimental|Cell phone intervention|Behavioral lifestyle intervention for weight loss, delivered by cell phone.
3214937|NCT01092364|Experimental|Personal counseling intervention|Behavioral lifestyle intervention for weight loss, delivered by personal counseling.
3214938|NCT01092364|No Intervention|Advice only|Advice only control group.
3214939|NCT01092351|Experimental|Nitrofurantoin|Adult patients with a microbiologically confirmed uncomplicated urinary tract infection
3214940|NCT01092338|Active Comparator|4000IU|Subjects in this arm take a daily dose of 4000IU of Vitamin D3
3214941|NCT01092338|Active Comparator|7000IU|Subjects in this arm of the study take a daily dose of 7000IU of Vitamin D3
3214942|NCT01092325|Experimental|Cohort 1 CXL-1020|An intravenous infusion of CXL-1020 administered for a total of 4 hours over a total of 3 occasions separated by at least one week. Each of the 3 doses of CXL-1020 are different, starting with the lowest dose and increasing to the highest dose.
3215000|NCT01091974|Experimental|1 - CBT-I + placebo|CBT-I and placebo
3214943|NCT01092325|Placebo Comparator|Cohort 1 Placebo|A 4 hour infusion of Placebo administered one time randomly among the 3 active doses of CXL-1020 in cohort 1
3214944|NCT01092325|Experimental|Cohort 2 CXL-1020|An intravenous infusion of CXL-1020 administered for a total of 4 hours over a total of 3 occasions separated by at least one week. Each of the 3 doses of CXL-1020 are different, starting with the lowest dose and increasing to the highest dose.
3214945|NCT01092325|Placebo Comparator|Cohort 2 Placebo|A 4 hour infusion of Placebo administered one time randomly among the 3 active doses of CXL-1020 in cohort 1
3214946|NCT01092325|Active Comparator|Echo Cohort A CXL-1020|A 4 hour infusion of a fixed dose of CXL-1020 which was studied in Cohort 1 or Cohort 2 which is expected to be well tolerated and have hemodynamic effect
3214947|NCT01092325|Active Comparator|Echo Cohort B CXL-1020|CXL-1020 administered at a fixed rate for the initial 2 hours and at a higher fixed rate for the last 2 hours of a 4 hour infusion at doses which were studied in Cohort 1 or Cohort 2 and expected to be well tolerated and have hemodynamic effects
3214948|NCT01092312|Experimental|Signature Knee Guide|Vanguard Knee System with Signature Knee Guide
3214949|NCT01092312|Active Comparator|Conventional Approach|Vanguard Complete Knee System with Conventional Approach
3214950|NCT01092299|Experimental|Cohort 1 (2 arms)|Period 1: randomized to either fasting IR or ER1. Period 2: Cross-over to either IR or ER1. Period 3: ER1 in fed conditions.
3214951|NCT01092299|Experimental|Cohort 2 (2 arms)|Period 1: randomized to either fasting IR or ER2. Period 2: Cross-over to either IR or ER2. Period 3: ER2 in fed conditions.
3214952|NCT01092299|Experimental|Cohort 3( 2 arms)|Period 1: randomized to either fasting IR or ER3. Period 2: Cross-over to either IR or ER3. Period 3: ER3 in fed conditions.
3214953|NCT01092299|Experimental|Cohort 4 (2 arms)|Period 1: randomized to either fasting IR or MR4. Period 2: Cross-over to either IR or MR4. Period 3: MR4 in fed conditions.
3214954|NCT01092299|Experimental|Part 2: Extended/Modified release|Extended/Modified release capsule to be determined
3214955|NCT01092299|Placebo Comparator|Part 2: Placebo|
3214956|NCT01092286|Experimental|neuromuscular warm-up|coaches in this arm use the prescribed warm-up before team practices
3214957|NCT01092286|No Intervention|no warm-up|coaches use their usual warm-up before team practices
3214958|NCT01092273||Bimatoprost versus Travoprost|
3214959|NCT01092247|Placebo Comparator|Standard diet: Nutritional support|
3214960|NCT01092247|Experimental|Nutritional intervention: Ketogenic diet.|
3214961|NCT01092234|Active Comparator|Traditional ward|
3214962|NCT01092234|Experimental|Observational unit|Organizational change. Innovative organization of in-hospital care
3214963|NCT01092221|Experimental|Allopurinol|
3214964|NCT01092221|Placebo Comparator|Placebo|
3214965|NCT01092182|Experimental|A|Burkitt lymphoma Low Risk Arm
3214966|NCT01092182|Experimental|B|Burkitt lymphoma High Risk Arm
3214967|NCT01092182|Experimental|C|DLBCL high risk arm
3214968|NCT01092169||Sickle cell beta|
3214969|NCT01092156|Active Comparator|Education on Infant-led latching|
3214970|NCT01092156|No Intervention|Standard education|
3214971|NCT01092143|Experimental|BI671800 (low dose)|Patients receive BI671800 (low dose) capsules twice daily
3214972|NCT01092143|Active Comparator|Fluticasone|Patients inhale from Fluticasone MDI twice daily
3214973|NCT01092143|Placebo Comparator|placebo|Patients receive placebo capsules twice daily
3214974|NCT01092143|Experimental|BI671800 (medium dose)|Patients receive BI671800 (medium dose) capsules twice daily
3214975|NCT01092143|Experimental|BI671800 (high dose)|Patients receive BI671800 (high dose) capsules twice daily
3214976|NCT01092130|Experimental|Vitamin D|Patients were randomized by an automated computer system to 2000 IU oral cholecalciferol once daily or control (i.e. no extra medication), in a 1:1 ratio for a period of six weeks. Blood was collected in a sitting position on visits 2-4 and patients were asked to collect 24h urine samples prior to visits 2 and 4. Heart failure medication was maintained unchanged throughout the trial. Changes in diuretic dose were permitted if necessary to treat decompensation or renal dysfunction.
3214977|NCT01092117|Other|Ovation™ Abdominal Stent Graft System|Implant of Ovation™ Abdominal Stent Graft System
3214978|NCT01092104|Experimental|TBR-652 25 mg QD|TBR 25 mg QD for 10 days
3214979|NCT01092104|Placebo Comparator|Placebo|Matching Placebo QD for 10 days
3214980|NCT01092104|Experimental|TBR-652 50 mg QD|TBR-652 50 mg QD for 10 days
3214981|NCT01092104|Experimental|TBR-652 75 mg QD|TBR-652 75 mg QD for 10 days
3214982|NCT01092104|Experimental|TBR-652 100 mg QD|TBR-652 100 mg QD for 10 days
3214983|NCT01092104|Experimental|TBR-652 150 mg|TBR-652 150 mg QD for 10 days
3214984|NCT01092091|Experimental|PEG-BCT-100|Pegylated Recombinant Human Arginase I
3214985|NCT01092078|Experimental|Motivational Interviewing|Individuals in the motivational interviewing (MINT) arm of the study will receive telephone-based lifestyle interviewing for 6-months. Counseling will be aimed at modifying diet and/or physical activity behaviors associated with decreasing blood pressure.
3214986|NCT01092078|Experimental|Patient Navigation|Participants in the patient navigation arm will receive patient navigation for colonoscopy.
3214987|NCT01092078|Experimental|PLUS|Both patient navigation for colorectal cancer screening and motivational interviewing for blood pressure control
3214988|NCT01092065|Experimental|AFQ056 100 mg (Bid)|
3214989|NCT01092065|Placebo Comparator|Placebo|
3214990|NCT01092052|Experimental|1|
3214991|NCT01092039|Experimental|XIGO pill|Oral Xigo tablet
3214992|NCT01092039|Placebo Comparator|Placebo|Oral placebo tablet
3214993|NCT01092026|Experimental|cord blood transplant|Eiligible patients receive cord blood transplantation with coinfusion of mesenchymal stem cells
3214994|NCT01092013|Active Comparator|Operating room training|
3214995|NCT01092013|Active Comparator|Skills lab training|
3214996|NCT01092000||Faculty/Staff|
3214997|NCT01092000||Graduate Students|
3214998|NCT01092000||Undergraduate Students|
3214999|NCT01091987|Experimental|Non-pharmacological approach of insomnia|Non-pharmacological approach of insomnia based on cognitive-behavioural techniques (education on sleep, sleep hygiene, stimulus control, cognitive techniques)
3215001|NCT01091974|Experimental|2 - CBT-I + Armodafinil|CBT-I + Armodafinil
3215002|NCT01091974|Placebo Comparator|3 - Placebo only|Placebo only
3215003|NCT01091974|Experimental|4 - Armodafinil only|Armodafinil only
3215004|NCT01091961|Active Comparator|Continuing ACEi/ARB|Patients in this group will continue to take their chronic ACEi/ARB medications up to and including the day of surgery.
3215005|NCT01091961|Active Comparator|Holding ACEi/ARB|Patients in this arm will hold their chronic ACEi/ARB medication at least 24 hours prior to surgery.
3215006|NCT01091948|Active Comparator|Fiberoptic Intubation|Subjects will be intubated with the Fiberoptic laryngoscope.
3215007|NCT01091948|Active Comparator|GlideScope® Video Laryngoscope|Subjects will be intubated with the GlideScope® Video Laryngoscope.
3215008|NCT01091935||Lidocaine|"Adults >18 yrs , attending St Joseph's Health Care Pain Clinic with a diagnosis of chronic neuropathic pain who are being treated with an lidocaine infusion of 5 mg/kg over 45 minutes~Consecutive patients from two time periods:~June 15 to August 21, 2009~October 15-Dec 22,2009"
3215009|NCT01091922|Placebo Comparator|Low Flavanol|Low flavanol drink containing 23 mg of total flavanols. Macro- and micro-nutrient matched with active comparator
3215010|NCT01091922|Active Comparator|High Flavanols|High Flavanol drink containing 495 mg of total flavanols
3215011|NCT01091909|Experimental|post-extraction wound healing|53 individuals with diabetes and 29 controls, without diabetes, were followed for 60 days after dental extractions, and were examined after 3, 7, 21, and 60 postoperative days.
3215012|NCT01091896|No Intervention|1 - no bevacizumab|Patients will not receive bevacizumab before nor during vitrectomy
3215013|NCT01091896|Experimental|2- bevacizumab before vitrectomy|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
3215014|NCT01091896|Experimental|3- bevacizumab after vitrectomy|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
3215015|NCT01091883|Experimental|Exablate treatment|Exablate 2000
3215016|NCT01091883|Active Comparator|Radiation|External Beam Radiation
3215017|NCT01091870|Placebo Comparator|Placebo: soluble blue pigment|Soluble blue pigment for placebo controlling.
3215018|NCT01091870|Experimental|Sildenafil, 75mg daily|Sildenafil citrate, 75 mg daily divided in 3 doses. From third to 14th day after subarachnoid hemorrhage.
3215019|NCT01091870|Experimental|Sildenafil, 150 mg daily|Sildenafil citrate, 150 mg daily divided in 3 doses from third to 14th day after subarachnoid hemorrhage.
3215020|NCT01091857|Experimental|Exercise intervention (STRIDE)|
3215021|NCT01091857|Active Comparator|Health and Wellness Control|
3215022|NCT01091844|Active Comparator|Spontaneous Fill Technique|"We allow the bladder to spontaneously fill, then allow the patient to void and afterward catheterize the patient to check a postvoid residual (spontaneous fill technique)."
3215023|NCT01091844|Active Comparator|Retrograde Fill Technique|"We assess bladder emptying by filling the bladder retrograde through the catheter already in place with 300 mL of saline and then removing the catheter and allowing the patient to void (retrograde-fill technique). We will determine postvoid residual indirectly by subtracting voided volume from the 300 mL infused volume. No catheterization will be performed with this technique unless they void less than 200 mL."
3215024|NCT01091831|Active Comparator|CRD|Oral therapy with Cyclophosphamide, Lenalidomide and Dexamethasone.
3215025|NCT01091831|Active Comparator|MEL200|High dose Melphalan therapy (200 mg/m2) followed by stem cell support for 2 cycles every 4 months (for 1 cycle if at least VGPR was achieved after the 1st MEL200)
3215026|NCT01091818|Active Comparator|midazolam|
3215027|NCT01091818|Experimental|dexmedetomidin|
3215028|NCT01091792|Experimental|Bevacizumab|Bevacizumab + temozolomide + radiotherapy followed by adjuvant bevacizumab + temozolomide
3215029|NCT01091779||Hypertensive and normotensive|
3215030|NCT01091766|Active Comparator|bupivacaine|test solution consists of bupivacaine 0.125%
3215031|NCT01091766|Active Comparator|bupivacaine+epinephrine|test solution consists of bupivacaine 0.125% with epinephrine 1:200000
3215032|NCT01091766|Active Comparator|epinephrine|test solution consists of epinephrine 1:200000
3215033|NCT01091753|Placebo Comparator|morning administration group|
3215034|NCT01091753|Experimental|nocturnal administration group|
3215035|NCT01091740|Experimental|ZES resolute (Endeavor Resolute)|
3215036|NCT01091740|Active Comparator|EES (Xience)|
3215037|NCT01091727|Experimental|Botulinum toxin A|Botulinum toxin A 300U diluted with sterile saline (1 ml per injection site) and injected into 30 sites of the bladder, sparing the trigone.
3215038|NCT01091727|Placebo Comparator|Placebo|Sterile saline 30 cc injected into 30 sites in the bladder, sparing the trigone.
3215039|NCT01091714|Active Comparator|PRN Dry Eye Omega Benefits|4 capsules per day = 2240 mg Omega-3s
3215040|NCT01091714|Active Comparator|Nature's Made|2 capsules per day = 2400mg Omega-3s
3215041|NCT01091714|Active Comparator|Thera Tears|4 capsules per day = 2332mg Omega-3s
3215042|NCT01091701|Experimental|Ex vivo cultured adult allogenic MSCs|
3215043|NCT01091701|Placebo Comparator|Plasmalyte-A|
3215044|NCT01091688|Experimental|Just-in-Time intervention|"The infants and physicians in the experimental group will receive the Just-in-Time intervention sheets at the time of discharge."
3215045|NCT01091688|No Intervention|Routine discharge care|The infants and physicians in the routine discharge care arm will receive the same information and details as is per normal routine in the nursery.
3215046|NCT01091675|Experimental|etoricoxib|All the patients who fulfil the eligibility criteria will start a 4-week open label treatment period to evaluate the response to treatment with etoricoxib 90 mg.
3215047|NCT01091662|Experimental|eslicarbazepine acetate 1600 mg|Subjects randomized to 1600 mg QD of eslicarbazepine acetate will titrate from 600 mg QD(Day 0) to 1200 mg once a day(Week 2) to 1600 mg QD (Weeks 3-18) and may taper down from 1600 mg to 800 mg QD 3 days after the Week 18 visit.
3215048|NCT01091662|Experimental|eslicarbazepine acetate 1200 mg|"Subjects randomized to 1200 mg QD eslicarbazepine acetate will titrate from 400 mg QD (Day0) to 800 mg QDweek2) to 1200 mg QD(weeks 3-18) and may taper down from 1200 mg to 600 mg QD 3 days after the Week 18 visit.~Subjects may continue in an open-label extension study with a starting dose of 1200 mg QD, or taper off their previous antiepileptic drugs during weeks 2-8."
3215049|NCT01091649|Active Comparator|A|Low dose ABT-450 capsule and ritonavir capsules (reference).
3215050|NCT01091649|Active Comparator|B|Low dose ABT-450 SDD Tablet Form 1 and ritonavir capsules (test 1)
3215051|NCT01091649|Active Comparator|C|Low dose ABT-450 SDD Tablet Form 2 and ritonavir capsules (test 2).
3215052|NCT01091649|Active Comparator|D|High dose ABT-450 capsule and ritonavir capsules (reference).
3215053|NCT01091649|Active Comparator|E|High dose ABT-450 SDD Tablet Form 1 or 2 and ritonavir capsule (test)
3215054|NCT01091636|Experimental|HIPEC|Intraoperative Hyperthermic Intraperitoneal Chemotherapy in Patients with Ovarian Cancer
3215055|NCT01091623|Active Comparator|strength training|
3215056|NCT01091623|Active Comparator|endurance training|
3215057|NCT01091623|Active Comparator|combined training|
3215058|NCT01091610||1|all emergency medical staff having suffered an accident during work
3215059|NCT01091610||2|non emergency medical personnel having suffered an injury due to a medical mission, e.g. transported patient having suffered additional injury due to an ambulance accident or collision of an ambulance with another vehicle.
3215060|NCT01091597|Active Comparator|usual ablation|Wide-area circumferential ablation of the pulmonary veins
3215061|NCT01091597|Experimental|Box isolation of the pulmonary veins|Single Box lesion set encompassing all four pulmonary veins and the posterior wall of the left atrium.
3215062|NCT01091584|Active Comparator|intervention group|The intervention is to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse.
3215063|NCT01091584|No Intervention|control group|usual care
3215064|NCT01091571|Placebo Comparator|Endotoxemia placebo|Endotoxin combined with placebo
3215065|NCT01091571|Experimental|Endotoxemia Dipyridamole|Endotoxin combined with Dipyridamol treatment
3215066|NCT01091558||Colonoscopy|Healthy volunteer who is having a screening colonoscopy
3215067|NCT01091558||Ulcerative Colitis|Patients with confirmed ulcerative colitis who are scheduled for endoscopy for medical reasons.
3215068|NCT01091545|Other|FFDM+DBT|Single-armed study. Women are their own controls with paired images of digital mammography and breast tomosynthesis.
3215069|NCT01091532|Experimental|Cohort 1|Subjects will be assigned to receive either UK-396,082 or placebo
3215070|NCT01091532|Experimental|Cohort 2|Subjects will be assigned to receive either UK-396,082 or placebo
3215071|NCT01091532|Experimental|Cohort 3|Subjects will be assigned to receive either UK-396,082 or placebo
3215072|NCT01091532|Experimental|Cohort 4|Subjects will be assigned to receive either UK-396,082 or placebo
3215073|NCT01091519||Toviaz(fesoterodine) plus educational materials|
3215074|NCT01091519||Toviaz(fesoterodine) alone|Toviaz(fesoterodine) without additional educational materials
3215075|NCT01091506|Experimental|L-methylfolate|L-methylfolate 15mg (a medical food)
3215076|NCT01091506|Placebo Comparator|Placebo|Placebo
3215077|NCT01091493|No Intervention|Non-Antibiotic|Patients will not receive antibiotics, although the study is double-blind.
3215078|NCT01091493|Active Comparator|Antibiotic|Patients will receive in a masked way, moxifloxacin.
3215079|NCT01091480||Patients with HCM|Patients ≥ 15 years with HCM(sarcomere of origin or not) defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic
3215080|NCT01091467||Patients with HF|Each patient seen in hospital emergency or for congestive heart failure and with an ejection fraction above 45%
3215081|NCT01091454|Experimental|Treatment (cisplatin and brostallicin)|Patients receive cisplatin IV over 2 hours on day 1 and brostallicin IV over 10 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3215082|NCT01091441||Patients with heart failure|Patients hospitalized for acute heart failure
3215083|NCT01091428|Experimental|Alisertib (Phase 1 - Ovarian cancer)|Participants with ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).
3215084|NCT01091428|Experimental|Alisertib (Phase 1 - Breast cancer)|Participants with breast cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).
3215085|NCT01091428|Experimental|Alisertib 40 mg BID+Paclitaxel 60 mg/m^2 (Phase 2)|Alisertib 40 mg, orally, BID on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).
3215086|NCT01091428|Experimental|Paclitaxel 80 mg/m^2 (Phase 2)|Paclitaxel 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).
3215087|NCT01091415|Experimental|calcium phosphate bone cement|one arm; volar locking plate alone the other arm; calcium phosphate bone cement as well as volar locking plate
3215088|NCT01091402||chronic urticaria|
3215089|NCT01091402||asthma|
3215090|NCT01091402||seasonal allergic rhinitis|
3215091|NCT01091402||normal controls|
3215092|NCT01091389|Experimental|GP ablation|Thoracoscopic PV isolation with GP ablation
3215093|NCT01091389|Experimental|No GP ablation|Thoracoscopic PV isolation with no GP ablation
3215094|NCT01091376|Experimental|Concomitant Erlotinib and radiotherapy|Patients received Erlotinib and radiation therapy.
3215095|NCT01091363|Experimental|cultural tailoring|eight weekly 40-minute individualized counseling sessions of cognitive behavioral therapy and cultural tailoring intervention (CBCT) plus 8-week NRT
3215096|NCT01091363|Active Comparator|brief cessation counseling|This arm receives eight, weekly 10-minute brief cessation counseling sessions that are not tailored to Korean culture.
3215097|NCT01091350|Active Comparator|Diprifusor group|Propofol was infused via Diprifusor TCI (Target-controlled infusion)
3215098|NCT01091350|Experimental|Orchestra group|Propofol was infused via Orchestra TCI
3215099|NCT01091337|Experimental|Procaterol|"Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes~+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment"
3215100|NCT01091337|Active Comparator|Salbutamol|Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
3215101|NCT01091324|Active Comparator|Dextromethorphan|
3215102|NCT01091324|Active Comparator|Silymarin|
3215103|NCT01091324|Placebo Comparator|sugar pill|
3215104|NCT01091298|Experimental|Group 1|
3215105|NCT01091298|Placebo Comparator|Group 2|
3215106|NCT01091285|Active Comparator|Single Balloon Catheter|Cervix Ripening is achieved by a single balloon catheter. Further induction by cytotec or/amniotomy and pitocin
3215107|NCT01091285|Active Comparator|Double balloon catheter|Cervix Ripening is achieved by a double balloon catheter. Further induction by cytotec or/amniotomy and pitocin
3215108|NCT01091272|Experimental|Cohort 1|Single dose 3 period interleaved cross-over with placebo substitution
3215109|NCT01091272|Experimental|Cohort 2|Single dose 4 period interleaved cross-over, placebo substitution, with food effect
3215110|NCT01091272|Experimental|Cohort 3|Single dose 4 period cross-over, placebo insertion, with food effect
3215111|NCT01091272|Experimental|Optional Cohort 4|Single dose 3 period cross-over with placebo substitution
3215112|NCT01091259|Experimental|Irinotecan with Bevacizumab|Irinotecan is administered every 3 weeks at a dose of 175 mg/m^2, bevacizumab is administered at 15 mg/kg every 3 weeks. Irinotecan is administered before bevacizumab. Patients will continue on therapy until evidence of disease progression, or until development of adverse events that prevent further treatment, or if the patients wishes to discontinue therapy.
3215113|NCT01091246|Experimental|Q/LAIV (MEDI3250)|Q/LAIV (quadrivalent live attenuated influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 temperature sensitive, cold-adapted, attenuated, 6:2 resassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], B/Victoria [B/Malaysia/2506/2004], and B/Yamagata [B/Florida/4/2006]).
3215114|NCT01091246|Experimental|FluMist/B/Yamagata|FluMist/B/Yamagata (trivalent live attenuated influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Yamagata [B/Florida/4/2006])
3215115|NCT01091246|Experimental|FluMist/B/Victoria|FluMist/B/Victoria (trivalent live attenuated influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature sensitive, cold-adapted, attenuated, 6:2 reassortant influenza stains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Victoria [B/Malaysia/2506/2004]).
3215116|NCT01091233||Paracentesis|Paracentesis as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
3215117|NCT01091220|Placebo Comparator|Placebo|0.9% saline
3215118|NCT01091220|Experimental|Certolizumab pegol|Certolizumab pegol 400 mg
3215119|NCT01091207|Experimental|Sorafenib|The patients will receive daily oral administration of sorafenib 400 mg twice daily.
3215120|NCT01091194|Other|Exercise|Interval-based aerobic exercise
3215121|NCT01091194|No Intervention|Control|No intervention other than regular follow up hospital visits
3215122|NCT01091181|Active Comparator|high incision group|hysterotomy at cesarean performed 2 cm above plica vesicouterina
3215123|NCT01091181|Active Comparator|low incision group|hysterotomy at cesarean performed 2 cm below plica vesicouterina
3215124|NCT01091168|Experimental|arm A: Vinflunine|Drug:vinflunine
3215125|NCT01091168|Active Comparator|arm B: Alkylating agent of physician choice|
3215126|NCT01091155|Experimental|ColonRing TM|
3215127|NCT01091142|Experimental|NP001|
3215128|NCT01091142|Placebo Comparator|Placebo|
3215129|NCT01091129|Experimental|Treatment|Treatment with the miraDry System in both axilla
3215130|NCT01091116|Experimental|Double dose MEN16132 0.125 mg|Intra-articular administration of two 0.125 mg doses of MEN16132 at 2-week interval.
3215131|NCT01091116|Experimental|Double dose MEN16132 0.25 mg|Intra-articular administration of two 0.25 mg doses of MEN16132 at 2-week interval.
3215132|NCT01091116|Experimental|Double dose MEN16132 0.5 mg|Intra-articular administration of two 0.5 mg doses of MEN16132 at 2-week interval.
3215133|NCT01091116|Experimental|Single dose MEN16132 0.5 mg|Intra-articular administration of one 0.5 mg dose of MEN16132 followed by one intra-articular injection of placebo at 2-week interval.
3215134|NCT01091116|Placebo Comparator|Placebo|Intra-articular administration of two doses of Placebo at 2-week interval.
3215135|NCT01091103|Experimental|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression, unacceptable toxicity, or withdrawal.
3215136|NCT01091090|Experimental|Cognitive behavioral|Subjects with receive a cognitive behavioral intervention for smoking cessation
3215137|NCT01091090|Active Comparator|Control|Treatment as usual
3215138|NCT01091077|Placebo Comparator|Naringenin|Single dose of naringenin, compared to placebo in the same individual.
3215139|NCT01091064|Experimental|Early depart|Patients who will be liberated at triage with mild acute viral bronchiolitis
3215140|NCT01091064|No Intervention|Medical visit group|Patients with acute viral bronchiolitis who will wait to be seen by the physician
3215141|NCT01091051|Active Comparator|Ustekinumab|Ustekinumab S/C 45mg or 90mg depending on patient's weight or placebo injection. 10 with PPPP and 10 with PPP will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20
3215142|NCT01091051|Placebo Comparator|Placebo|Placebo S/C (Sodium Chloride). 10 with PPPP and 10 with PPP will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
3215143|NCT01091038|Placebo Comparator|Routine Care|Usual care of patients in the ambulatory setting
3215144|NCT01091038|Experimental|Basic Clinical Decision Support|Providers use basic clinical decision support
3215291|NCT01090011|Experimental|sequential arm|patients to receive BIBW 2992 once daily, upon progression add biweekly cetuximab
3215145|NCT01091025|Other|CF patients without known diagnose of CFRD|There is only one arm. All patients in the study had the same procedures (ie. an OGTT). Investigators used the screening criteria in parallel to this.
3215146|NCT01091012|Other|Sildenafil 20mg oral|
3215147|NCT01091012|Other|Sildenafil 10mg intravenous|
3215148|NCT01090999|No Intervention|1|"All patients will receive an initial in-hospital rehabilitation program which includes: Education, Physiotherapy, lower and upper extremities training and respiratory muscles training. Following completion of this program, patients will undergo concealed randomization to one of two maintenance strategies.~The No Intervention group will undergo a standard, minimal monitoring program."
3215149|NCT01090999|Active Comparator|2|"All patients will receive an initial in-hospital rehabilitation program which includes: Education, Physiotherapy, lower and upper extremities training and respiratory muscles training. Following completion of this program, patients will undergo concealed randomization to one of two maintenance strategies.~The active comparator group will undergo an intensive maintenance program after the initial in-hospital rehabilitation program."
3215150|NCT01090986||1|Patients with a restrictive pulmonary disease and hypercapnic chronic respiratory failure with standard criteria for NIV. Also COPD patients who need NIV because of another reason (obesity, nocturnal hyperventilation or nocturnal hypercapnic response to oxygen).
3215151|NCT01090973|Experimental|Oral drug treatment|LBH589 will be given orally (by mouth), 40 mg once-a-day, 3 times weekly every week on days 1, 3 & 5, then 8, 10 &12, then 15, 17 & 19, then 22, 24 & 26.
3215152|NCT01090960|Experimental|A|
3215153|NCT01090947||Patients referred to CAG.|Sequential design with ProtoCAD and CAG
3215154|NCT01090934|Experimental|high resolution EEG|
3215155|NCT01090934|Active Comparator|Stereo Electroencephalography|
3215156|NCT01090921|Experimental|Single-Arm|Bortezomib is administered at a dose of 1.6mg/m2 IV push over 3 to 5 seconds. Treatment is administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle. Dexamethasone is also administered at a dose of 40mg daily on day of and day after each dose of Bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone. The study duration for a given subject will be approximately 30 weeks.
3215157|NCT01090908||Ages 6-11 years|
3215158|NCT01090908||Ages 12-17 years|
3215159|NCT01090895|Active Comparator|Vitamin C|Vitamin C infusion
3215160|NCT01090895|Placebo Comparator|Placebo|Saline solution
3215161|NCT01090882|Sham Comparator|Control|Sham wash, sham injection
3215162|NCT01090882|Experimental|Subperitoneal injection|Local anaesthetic injection to diaphragm with sham wash over liver and gall bladder
3215163|NCT01090882|Active Comparator|Topical LA|Local anaesthetic washed over gall bladder and liver. Sham injection of diaphragm
3215164|NCT01090869|Active Comparator|Physical training, unchanged diet|Daily endurance training equivalent to 600 kcal/day and unchanged habitual diet
3215165|NCT01090869|Active Comparator|Physical training, increased diet|Daily endurance training equivalent to 600 kcal/day, and increased diet by 600 kcal/day.
3215166|NCT01090869|Active Comparator|Diet, unchanged physical activity|Energy-reduced diet by 600 kcal/day, and unchanged sedentary lifestyle
3215167|NCT01090869|No Intervention|Control|Unchanged sedentary lifestyle and diet
3215168|NCT01090856|No Intervention|No pre-dilation side branch|
3215169|NCT01090856|Active Comparator|Pre-dilation side branch|
3215170|NCT01090830|Experimental|Belinostat|This is a one arm, open label study of the investigational medication Belinostat.
3215171|NCT01090817|Experimental|Mesenchymal stromal cells|Mesenchymal stromal cells administered weekly for 4 weeks
3215172|NCT01090804|Experimental|breathing exercise|BreatheMAX breathing device is Water pressure Threshold Bottle. The level of water in the cylinder determines the load for treatment. In the treatment using 20% PNIP (Peak negative inspiratory pressure) was performed with 6-10 breaths/set; 10 set/day
3215173|NCT01090778|Other|Norditropin SimpleXx sc bolus injection|Single sc bolus injection of 3 mg growth hormone without interval exercise
3215174|NCT01090778|Other|Norditropin SimpleXx single sc injection|Single sc bolus injection of 3 mg growth hormone with interval exercise
3215175|NCT01090778|Other|Norditropin SimpleXx contin. sc infusion|Continuous sc infusion of 3 mg growth hormone without interval exercise
3215176|NCT01090778|Other|Norditropin SimpleXx cont. sc infusion|Continuous sc infusion of 3 mg growth hormone with interval exercise
3215177|NCT01090765|Experimental|TRC105 1 mg/kg every 2 weeks|Intravenous infusion at 1 mg/kg every 2 weeks
3215178|NCT01090765|Experimental|TRC105 3 mg/kg every 2 weeks|Intravenous infusion at 3 mg/kg every 2 weeks
3215179|NCT01090765|Experimental|TRC105 10 mg/kg every 2 weeks|Intravenous infusion at 10 mg/kg every 2 weeks
3215180|NCT01090765|Experimental|TRC105 10 mg/kg weekly|Intravenous infusion at 10 mg/kg weekly
3215181|NCT01090765|Experimental|TRC105 15 mg/kg every 2 weeks|Intravenous infusion at 15 mg/kg every 2 weeks
3215182|NCT01090765|Experimental|TRC105 20 mg/kg every 2 weeks|Intravenous infusion at 20 mg/kg every 2 weeks
3215183|NCT01090752|Placebo Comparator|Pioglitazone|placebo-controlled, randomized, cross-over study
3215184|NCT01090752|Placebo Comparator|Metformine|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
3215185|NCT01090739|Experimental|TOPAS|TOPAS Treatment for Fecal Incontinence
3215186|NCT01090726|Experimental|Storz videolaryngoscope|Macintosh overview followed by Airtraq overview followed by Storz videolaryngoscope overview and intubation.
3215187|NCT01090726|Active Comparator|Airtraq|Macintosh overview followed by Storz videolaryngoscope overview followed by Airtraq overview and intubation.
3215188|NCT01090713|Active Comparator|Lisdexamfetamine|drug
3215189|NCT01090713|Placebo Comparator|Placebo|Placebo comparator
3215190|NCT01090700|Experimental|001|TMC435 TMC435 150 mg daily for 7 days
3215191|NCT01090700|Other|002|Escitalopram Escitalopram 10 mg daily for 7 days
3215192|NCT01090700|Experimental|003|TMC435 + Escitalopram TMC435 150 mg + escitalopram 10 mg daily for 7 days
3215292|NCT01089998|Experimental|Arm 1|
3215293|NCT01089998|Experimental|Arm 2|
3215193|NCT01090687||Group I Microcalcifications|After classification as BI-RADS 4/5, approximately 75 to 100 subjects with primary findings based on microcalcifications will be recruited to have a breast CT scan.
3215194|NCT01090687||Group II Soft tissue findings|After classification as BI-RADS 4/5, approximately 75 to 100 subjects with primary soft tissue findings, with or without associated microcalcifications, will be recruited to have a breast CT scan.
3215195|NCT01090674||1|Patients with amyotrophic lateral sclerosis.
3215196|NCT01090661|Experimental|mipomersen IV (supra-therapeutic dose)|200 mg of mipomersen IV / placebo SC
3215197|NCT01090661|Experimental|mipomersen SC (therapeutic dose)|200 mg of mipomersen SC / placebo IV
3215198|NCT01090661|Active Comparator|moxifloxacin IV|400 mg of moxifloxacin IV / placebo SC
3215199|NCT01090661|Placebo Comparator|placebo|Placebo IV / placebo SC
3215200|NCT01090648|Experimental|001|etravirine One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
3215201|NCT01090622|Placebo Comparator|Matching Placebo|
3215202|NCT01090622|Experimental|XPF-001|
3215203|NCT01090609|Experimental|Stent implantation|Cronus Stent implantation
3215204|NCT01090596|Active Comparator|Naproxen-Treated|
3215205|NCT01090596|Placebo Comparator|placebo|
3215206|NCT01090583||Cesarean Delivery Patients|
3215207|NCT01090570|Experimental|PLX3397 25 mg|
3215208|NCT01090570|Experimental|PLX3397 50 mg|
3215209|NCT01090570|Experimental|PLX3397 100 mg|
3215210|NCT01090570|Experimental|PLX3397 200 mg|
3215211|NCT01090570|Experimental|PLX3397 300 mg|
3215212|NCT01090570|Placebo Comparator|Placebo|
3215213|NCT01090557||RSV positive subjects|Subjects admitted to the hospital with Lower respiratory tract Viral infection symptoms from which nasopharyngeal mucous samples are positive for RSV by Direct Fluorescent Antibody technique and/or viral culture
3215214|NCT01090557||RSV negative subjects|Subjects admitted to the hospital with Lower respiratory tract Viral infection symptoms from which nasopharyngeal mucous samples are negative for RSV by Direct Fluorescent Antibody technique and/or viral culture (usually positive for influenza A & B, parainfluenza, human metapneumovirus or adenovirus)
3215215|NCT01090557||Control group|Children with same age range, ethnic background, and gender distribution as the study group coming for evaluation in the outpatient setting without evidence of viral infection
3215216|NCT01090518|Active Comparator|Prolonged Exposure therapy with Hydrocortisone|
3215217|NCT01090518|Placebo Comparator|Prolonged Exposure therapy with placebo|
3215218|NCT01090505|Experimental|Drug:S-1:80mg/m2;oxaliplatin 130mg/m2|Drug: Neoadjuvant chemotherapy(S-1+Oxaliplatin) followed by D2 gastrectomy
3215219|NCT01090505|No Intervention|surgery|Procedure/Surgery: Gastrectomy with D2 dissection
3215220|NCT01090492|Experimental|Secondary Raynaud 4 mg dose (period 1)|
3215221|NCT01090492|Experimental|Secondary Raynaud 4 mg dose (period 2)|
3215222|NCT01090492|Experimental|Secondary Raynaud 20 mg dose (period 1)|
3215223|NCT01090492|Experimental|Secondary Raynaud 20 mg dose (period 2)|
3215224|NCT01090492|Experimental|Primary Raynaud 4 mg dose (period 1)|
3215225|NCT01090492|Experimental|Primary Raynaud 4 mg dose (period 2)|
3215226|NCT01090492|Experimental|Primary Raynaud 20 mg dose (period 1)|
3215227|NCT01090492|Experimental|Primary Raynaud 20 mg dose (period 2)|
3215228|NCT01090479|No Intervention|Control|This group will perform an ordinary shower the night prior and the morning of their scheduled surgery date.
3215229|NCT01090479|Experimental|2% Chlorhexidine cloth|This group will use the 2% chlorhexidine wipes the night prior as well as the morning of their surgery date.
3215230|NCT01090453|Experimental|GSK2202083A Group|Subjects aged between and including 8 and 12 weeks of age at the time of first vaccination received 3 doses of GSK2202083A vaccine, co-administered with Prevenar 13® at 2, 4 and 12 months of age. The GSK2202083A and Prevenar 13® vaccines were administered intramuscularly into the right and left sides of the thigh, respectively. An optional 2-dose vaccination with Rotarix™ was offered to the study participants at 2 and 4 months of age.
3215231|NCT01090453|Active Comparator|Infanrix hexa Group|Subjects aged between and including 8 and 12 weeks of age at the time of first vaccination received 3 doses of Infanrix hexa™ vaccine, co-administered with Prevenar 13® and Menjugate® at 2, 4 and 12 months of age. The Infanrix hexa™ and Prevenar 13® vaccines were administered intramuscularly into the right and upper left sides of the thigh, respectively and the Menjugate® vaccine was administered intramuscularly in the lower left thigh. An optional 2-dose vaccination with Rotarix™ was offered to the study participants at 2 and 4 months of age.
3215232|NCT01090440|Experimental|Three-way cross- over|Three regimens will be administered in this study: A: GSK1144814 Tablet (100mg) Fasted State; B: GSK1144814 Tablet (200mg) Fasted State and C: GSK 1144814 Tablet (100mg) Fed State (FDA high fat breakfast).
3215233|NCT01090427|Experimental|Ustekinumab Half-standard Dosage|Participants will receive ustekinumab at half the standard dosage at Weeks 0, 4, 16, 28, and 40. In addition, all participants will receive a single SC dose of placebo at Week 12.
3215234|NCT01090427|Experimental|Ustekinumab Standard Dosage|Participants will receive ustekinumab at the standard dosage at Weeks 0, 4, 16, 28, and 40. In addition, all participants will receive a single SC dose of placebo at Week 12.
3215235|NCT01090427|Experimental|Placebo|Participants will receive matching placebo at Week 0 and 4, followed by ustekinumab at half-standard or standard dosage at Weeks 12, 16, 28, and 40.
3215236|NCT01090414|Experimental|Idelalisib|Participants will receive up to 300 mg of idelalisib once or twice daily until disease progression or unacceptable toxicity.
3215237|NCT01090401|Experimental|Patients with Linox smart S DX lead|
3215238|NCT01090388||1|Participants voluntarily completed a telephone interview using a questionnaire compiled using validated, patient-centered measures of cancer outcomes and psychosocial status.
3215239|NCT01090375|Experimental|Exercise|
3215240|NCT01090375|Placebo Comparator|Non Exercise|
3215241|NCT01090362||Cohort 1|Cohort complete with 5,088 retrospective patients and 5,499 prospective patients recruited from 19 countries.
3215242|NCT01090362||Cohort 2|Cohort completed with 11,351 patients enrolled from 30 countries
3215243|NCT01090362||Cohort 3|Cohort 3 completed with 11,139 patients enrolled globally from 32 countries
3215244|NCT01090362||Cohort 4|Cohort 4 ongoing (commenced Aug 2014) with 2600 patients recruited to date and a target of 11,000 patients enrolled from 35 countries.
3215245|NCT01090362||Cohort 5|Final cohort to commence August 2015 with a target of 11,000 patients enrolled. Last patient enrolled to complete 2 years of follow-up.
3215246|NCT01090349|Experimental|Direct Alerts ON|Direct Alerts in implantable device were turned on
3215247|NCT01090349|Active Comparator|Direct Alerts OFF|Direct Alerts in implantable device were turned off
3215248|NCT01090336||Clopidogrel group|At the discretion of the attending cardiologist patients are treated with clopidogrel (600mg loading and 75mg daily dose)
3215249|NCT01090336||Prasugrel group|At the discretion of the attending cardiologist patients are treated with prasugrel (60mg loading and 10mg daily dose)
3215250|NCT01090323|Experimental|ICL670|
3215251|NCT01090310|Experimental|AIN457 300mg every 2 weeks|AIN457 300 mg subcutaneous (s.c.) weekly for 3 weeks followed by AIN457 300 mg s.c. every 2 weeks
3215252|NCT01090310|Experimental|AIN457 300 mg every 4 weeks|AIN457 300 mg s.c. at baseline for Week 2 followed by AIN457 300 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly
3215253|NCT01090310|Experimental|AIN457 150 mg every 4 weeks|AIN457 150 mg s.c. and placebo s.c. at Baseline and Week 2 followed by AIN457 150 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly
3215254|NCT01090310|Placebo Comparator|Placebo|Placebo s.c. every 2 weeks
3215255|NCT01090297|Active Comparator|Fixed pressure|
3215256|NCT01090297|Active Comparator|Auto-adjusting pressure|
3215257|NCT01090284||Heavy weight mesh|This cohort includes patients undergoing inguinal hernioplasty with polypropylene heavy weight mesh.
3215258|NCT01090284||Light weight mesh|This cohort includes patients undergoing inguinal hernioplasty with polypropylene light weight mesh.
3215259|NCT01090271|Experimental|Eccentric training|
3215260|NCT01090258|Experimental|Automated settings|Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
3215261|NCT01090258|Active Comparator|protocolized settings|Ventilator settings performed by the local respiratory therapists according to the local protocols
3215262|NCT01090245|Active Comparator|Attendance Information Group|Participants in the Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing. In addition, they will receive the standard treatment offered by the Walden House Los Angeles program.
3215263|NCT01090245|Experimental|Attendance Incentive Group|Participants in the Attendance Incentive Group could receive up to $841.50 in incentives for their treatment attendance and the standard treatment offered by the Walden House Los Angeles program.
3215264|NCT01090232|Experimental|chronic HEV infection|in kidney-transplant recipients with chronic HEV infection
3215265|NCT01090232|Active Comparator|control|the host responses in kidney-transplant recipients without viral infection (controls)
3215266|NCT01090219|Experimental|two differents meshes|Heavy-weight versus low-weight polypropylene meshes
3215267|NCT01090206|Other|Hemophilia, Vitamin D deficiency|"Hemophilia, Rickets - Vitamin D per endocrine consult~Hemophilia, Vitamin D deficient - Vitamin D 2000 units daily plus calcium~Hemophilia, Normal Vitamin D - no intervention - observation only"
3215268|NCT01090193|Other|obstructive jaundice|
3215269|NCT01090180|Experimental|Arm 1: Dexamethasone|Dexamethasone (oral)
3215270|NCT01090180|Placebo Comparator|Arm 2: Placebo|Placebo (inactive)
3215271|NCT01090167|Experimental|Clofarabine|
3215272|NCT01090154|Experimental|Cimzia|Treatment with open label Cimzia (certolizumab pegol)
3215273|NCT01090141|Active Comparator|Subjects recieving 100 mg of Micafungin|
3215274|NCT01090141|Active Comparator|Subjects recieving 300 mg of Micafungin|
3215275|NCT01090128|Experimental|All patients|All participants enrolled.
3215276|NCT01090102|Experimental|Mesalamine|
3215277|NCT01090102|Placebo Comparator|Placebo|
3215278|NCT01090089|Experimental|Lenalidomid, PBSCT|A1 Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
3215279|NCT01090089|Active Comparator|Lenalidomid|A2 Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
3215280|NCT01090076|Experimental|Abound|Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)
3215281|NCT01090076|Placebo Comparator|Placebo|Placebo comparator that contains none of the active ingredients
3215282|NCT01090050|Active Comparator|Sumatriptan/Naproxen Sodium|In Treatment Period Month 1: Subjects randomized to Sumatriptan/Naproxen Sodium will treat daily with 1 tablet Sumatriptan 85mg / Naproxen Sodium 500mg per day x 30 days. Subjects will be provided with 30 tablets of Sumatriptan/Naproxen Sodium for rescue. In Treatment Period Months 2 and 3: Subjects randomized to Sumatriptan/Naproxen Sodium will be provided with 14 tablets of Sumatriptan/Naproxen Sodium to treat on 14 or fewer days per month. Subjects will be provided with 14 tablets of Sumatriptan/Naproxen Sodium per month for rescue.
3215283|NCT01090050|Active Comparator|Naproxen Sodium|In Treatment Period Month 1: Subjects randomized to Naproxen Sodium will treat daily with 1 tablet Naproxen Sodium 500mg per day x 30 days. Subjects will be provided with 30 tablets of Naproxen Sodium for rescue. In Treatment Period Months 2 and 3: Subjects randomized to Naproxen Sodium will be provided with 14 tablets of Naproxen Sodium to treat on 14 or fewer days per month. Subjects will be provided with 14 tablets of Naproxen Sodium per month for rescue.
3215284|NCT01090037|Experimental|TRK-100STP|
3215285|NCT01090037|Placebo Comparator|Placebo|
3215286|NCT01090024|Experimental|BI 671800 AM and PM|Patients receiving two capsules twice daily
3215287|NCT01090024|Experimental|BI 671800 AM|Patients receiving four capsules in the morning
3215288|NCT01090024|Experimental|BI 671800 PM|Patients receiving four capsules in the evening
3215289|NCT01090024|Placebo Comparator|Placebo|Patients receiving four capsules twice a day
3215290|NCT01090011|Experimental|combination arm|patients to receive medium BIBW 2992 once daily plus biweekly cetuximab infusion at low, median and high dose level
3215296|NCT01089985|Experimental|Serum eye drops|Patient's autologous serum is diluted in saline solution
3215297|NCT01089972||20 gauge group|
3215298|NCT01089972||22 gauge group|
3215299|NCT01089959|Other|Esomeprazole|Effect of PPI esomeprazole on acid reflux & related arousals during sleep in patients with GERD.
3215300|NCT01089933|Experimental|Thoracic PVB + multimodal anesthesia|Thoracic PVB + multimodal anesthesia
3215301|NCT01089933|Active Comparator|Local anesthetic + multi-modal analgesia|Local anesthetic + multi-modal analgesia
3215302|NCT01089920|Experimental|High dose coffee|High dose of polyphenols from soluble coffee
3215303|NCT01089920|Experimental|Medium dose coffee|Medium dose of polyphenols from soluble coffee
3215304|NCT01089920|Experimental|Low dose coffee|Low dose of polyphenols from soluble coffee
3215305|NCT01089920|Experimental|High dose green tea|High dose of green tea polyphenols from infusion
3215306|NCT01089920|Experimental|Medium dose green tea infusion|Medium dose of green polyphenols from infusion
3215307|NCT01089920|Experimental|Low dose green tea infusion|low dose of polyphenols from an infusion of green tea
3215308|NCT01089894||18F-FLT 1|18F-FLT in differentiating benign from malignant pulmonary nodules
3215309|NCT01089894||18F-FLT 2|18F-FLT in evaluating therapeutic response of platinum-based chemotherapy (The chemotherapeutic drugs used in the study are all approved by the Department of Health, Taiwan.)
3215310|NCT01089894||18F-FLT 3|18F-FLT in evaluating therapeutic response of EGFR tyrosin kinase inhibitors (The target therapeutic drugs used in the study are all approved by the Department of Health, Taiwan.)
3215311|NCT01089881||Group 1|patients with BPH
3215312|NCT01089881||Group 2|patients with newly diagnosed prostate cancer
3215313|NCT01089881||Group 3|patients who have received curative treatment for prostate cancer and are suspicious of recurrence/metastases because of a persistent increase in their serum PSA.
3215314|NCT01089868||Group A|Patients who suffer from a suspected GBM and will undergo a microsurgical procedure for diagnosis verification. MRI and Positron Emission Tomography (PET) scans are scheduled prior to microsurgery, post microsurgery and after having completed radiochemotherapy and an additional scan after TMZ chemotherapy.
3215315|NCT01089868||Group B|Patients enrolled in Group B suffer from a suspected GBM which cannot be accessed microsurgically either due to a an eloquent location of the tumor, or patient's refusal to undergo surgery. In these patients, diagnosis will be obtained by means of stereotactic surgery. After an initial PET and MRI scan prior to biopsy, patients will be monitored by post radiochemotherapy as well as post 3-months chemotherapy MRI/PET scans.
3215316|NCT01089855|Experimental|Carbamazepine|
3215317|NCT01089842|Experimental|Health coaching|
3215318|NCT01089842|No Intervention|Control|
3215319|NCT01089829||CKD Stage 4|eGFR <30
3215320|NCT01089829||CKD Stage 5|Receiving Haemodialysis or Peritoneal dialysis therapy
3215321|NCT01089816||All|Anyone presenting with influenza-like-illness
3215322|NCT01089803||Patients Treated with Laryngectomy|Patients initially treated with laryngectomy and followed for 12 months after receiving this treatment.
3215323|NCT01089803||Patients Treated with Chemoradiation|Patients treated initially with chemoradiation and followed for 12 months after receiving treatment.
3215324|NCT01089790|Experimental|1|
3215325|NCT01089790|Active Comparator|2|
3215326|NCT01089764|Experimental|Couplelinks.ca Intervention|Intervention arm - Couple participates in the Couplelinks.ca program.
3215327|NCT01089764|No Intervention|No Intervention|Couple is waitlisted for participation in the Couplelinks.ca program.
3215328|NCT01089751|Experimental|Sanctura XR®|Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks.
3215329|NCT01089751|Placebo Comparator|Placebo|Placebo once daily on an empty stomach for 14 weeks.
3215330|NCT01089738|Experimental|Dosing|Ascending Doses
3215331|NCT01089725|Placebo Comparator|Placebo|
3215332|NCT01089725|Experimental|2.5 mg tanezumab SC and placebo IV|
3215333|NCT01089725|Experimental|5 mg tanezumab SC and placebo IV|
3215334|NCT01089725|Experimental|10 mg tanezumab SC and placebo IV|
3215335|NCT01089725|Experimental|10 mg tanezumab IV|
3215336|NCT01089712||Patients undergoing cardiac surgery|The patient population for this study consists of all patients undergoing cardiac surgical interventions. All patients who meet the eligibility criteria may be included in the study regardless of gender, race or ethnicity.
3215337|NCT01089699|Active Comparator|Professionally-led online support|Members assigned to 10-week online support group with a professional counsellor.
3215338|NCT01089699|Active Comparator|Peer-led online support|
3215339|NCT01089699|Active Comparator|self-study materials|
3215340|NCT01089686|Active Comparator|Venoplasty (treatment)|Patients will be randomized to treatment or non-treatment arm with a 2:1 ratio. Patients who meet the inclusion/exclusion criteria and who are randomized to the treatment arm of the study will receive venoplasty at the time of the diagnostic venogram.
3215341|NCT01089686|Sham Comparator|Sham procedure (non-treatment)|Patients will be randomized to treatment or non-treatment with a 2:1 ratio. Patients who meet the inclusion/exclusion criteria and who are randomized to the non-treatment arm of the study will receive the diagnostic venogram only.
3215342|NCT01089673||no treatment|retrospective data analysis
3215343|NCT01089660|Experimental|Study Group 1|Swine-origin A/H1N1 Vaccine Low-dose
3215344|NCT01089660|Experimental|Study Group 2|Swine-origin A/H1N1 Vaccine High-dose
3215345|NCT01089647|Active Comparator|budesonide nasal spray and a montelukast pill|treatment arm
3215346|NCT01089647|Placebo Comparator|sugar pill, salt water nasal spray|placebo
3215347|NCT01089621|Experimental|Duloxetine|
3215348|NCT01089608|Placebo Comparator|Unifluid|Eye drops in Single Dose Unit
3215349|NCT01089608|Experimental|Azithromycin|Eye drops Single dose unit
3215350|NCT01089595|Active Comparator|Nilotinib|Nilotinib 400 mg po bid
3215351|NCT01089595|Active Comparator|Nilotinib + Imatinib|Nilotinib 400 mg BID with Imatinib 400 mg daily
3215352|NCT01089582||AD patients|
3215353|NCT01089569|Active Comparator|Exenatide|5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
3215713|NCT01087203|Placebo Comparator|Placebo|
3215354|NCT01089569|Active Comparator|Insulin Glargine|.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
3215355|NCT01089569|Active Comparator|Exenatide + Insulin Glargine|"Exenatide: 5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study~+ Insulin Glargine: 0.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results"
3215356|NCT01089556|Experimental|Duloxetine|"Initial Treatment:~Duloxetine 30 milligram (mg) daily for 1 week~Duloxetine 60 mg daily for 7 weeks~Intensive Treatment:~Duloxetine 90 mg (60 mg in the morning, 30 mg in the evening) daily for 1 week~Duloxetine 120 mg (60 mg twice daily) daily for 7 weeks"
3215357|NCT01089556|Experimental|Pregabalin+Duloxetine|"Initial Treatment:~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks~Intensive Treatment:~Pregabalin 300 mg (150 mg twice daily) daily for 8 weeks~Duloxetine 30 mg daily for 1 week~Duloxetine 60 mg daily for 7 weeks"
3215358|NCT01089556|Experimental|Pregabalin|"Initial Treatment:~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks~Intensive Treatment:~Pregabalin 450 mg (300 mg in the morning, 150 mg in the evening) daily for 1 week~Pregabalin 600 mg (300 mg twice daily) daily for 7 weeks"
3215359|NCT01089556|Experimental|Duloxetine + Pregabalin|"Initial Treatment:~Duloxetine 30 mg daily for 1 week~Duloxetine 60 mg daily for 7 weeks~Intensive Treatment:~Duloxetine 60 mg daily for 8 weeks~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks"
3215360|NCT01089543|Experimental|Rabeprazole 10 mg|
3215361|NCT01089543|Experimental|Rabeprazole 20 mg|
3215362|NCT01089543|Experimental|Rabeprazole 40 mg|
3215363|NCT01089543|Placebo Comparator|Placebo|
3215364|NCT01089530|No Intervention|Standard care|
3215365|NCT01089517|Active Comparator|Lucentis|
3215366|NCT01089517|Experimental|E10030 low dose plus Lucentis|
3215367|NCT01089517|Experimental|E10030 high dose plus Lucentis|
3215368|NCT01089504|Active Comparator|Phenobarbital|Phenobarbital, 4-5 mg/kg/day, for 4 months
3215369|NCT01089504|Placebo Comparator|Placebo|Placebo in a volume equivalent to active drug for 4 months
3215370|NCT01089452|Active Comparator|Perindopril monotherapy|Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks
3215371|NCT01089452|Active Comparator|Perindopril/amlodipine|Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.
3215372|NCT01089452|Experimental|Olmesartan/amlodipine FDC|Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
3215373|NCT01089439|Active Comparator|1: INOMAX|"Nitric oxide by inhalation INOMAX:~active arm treated with nitric oxide"
3215374|NCT01089439|Placebo Comparator|2: Placebo|placebo arm treated with placebo at the same conditions
3215375|NCT01089426|Other|Historical controls|A subset of patients previously seen, who have had at least 2 consecutive direct bilirubin levels > 2 mg/dL, who depended on parenteral nutrition for at least 90 days after surgical therapy for congenital or acquired intestinal diseases
3215376|NCT01089426|Experimental|Omegaven™|
3215377|NCT01089413||Cohort|
3215378|NCT01089400||Influenza A/H1N1 patients|
3215379|NCT01089400||Non influenza A/H1N1 patients|
3215380|NCT01089387|Experimental|injection of bone marrow cells|
3215381|NCT01089374|Other|Partial breast radiation after lumpectomy|Radiation per NSABP B-39/R0413 protocol.
3215382|NCT01089361|Placebo Comparator|Normal saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
3215383|NCT01089361|Experimental|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
3215384|NCT01089348|Experimental|Lactofiltrum|
3215385|NCT01089348|Active Comparator|Control|
3215386|NCT01089335||Papillary thyroid cancer|Patients with preoperatively diagnosed highly differentiated papillary thyroid cancer
3215387|NCT01089335||Tumour of uncertain malignant potential|Thyroid tumours with preoperative cytology indicating follicular neoplasia, or on cytology suspected but not proven malignancy
3215388|NCT01089322|Experimental|Stantardized treament|oral and inhaled corticosteroid plus LABA
3215389|NCT01089309|Experimental|Aldosteron blokade, Arterial stiffness, Glucose homeostasis|
3215390|NCT01089296|Other|Individually customized physiotherapy|The intervention involves handling the infant and changing its position. It focuses on improving symmetry, muscle balance and movement in infants. The parent who is with the infant during the admission period will carry out the daily intervention after being taught by the physiotherapist.
3215391|NCT01089296|No Intervention|Control|Ordinary follow up in the Neonatal Intensive Care Unit (NICU).
3215392|NCT01089283||LRRK2 mutation|Parkinson patients that carry mutation on LRRK2 gene
3215393|NCT01089283||GBA mutation|Parkinson patients that carry mutation on GBA gene
3215394|NCT01089283||no mutation|Parkinson patients that don't carry mutation on LRRK2 or GBA genes
3215395|NCT01089283||healthy|Healthy volunteers
3215396|NCT01089244||Group A|"Patients with a suspected WHO II low grade glioma, disease progression within~1 year"
3215397|NCT01089244||Group B|Patients with a suspected WHO II low grade glioma, progression free within 1 year
3215398|NCT01089231|Placebo Comparator|Placebo - healthy subjects|Dietary Supplement: corn oil capsules (6 per day) about 3 months
3215399|NCT01089231|Placebo Comparator|Placebo - hyperlipedemic subjects|Dietary Supplement: corn oil capsules (6 per day) about 3 months
3215400|NCT01089231|Experimental|Fish oil - hyperlipidemic subjects|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months
3215401|NCT01089231|Experimental|Fish oil - healthy subjects|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months.
3215402|NCT01089218|No Intervention|control|control without intervention
3215403|NCT01089218|Active Comparator|Amoxicillin/clavulanate|
3215404|NCT01089205|Experimental|Torrent's Metformin tablets 750 mg|
3215405|NCT01089205|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA|
3215406|NCT01089192|Experimental|Torrent's Metformin tablets 750 mg|
3215407|NCT01089192|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
3215408|NCT01089179|Experimental|Torrent's Metformin tablets 500 mg|
3215409|NCT01089179|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
3215410|NCT01089166|Experimental|Torrent's Metformin tablets 500 mg|
3215411|NCT01089166|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
3215412|NCT01089140|Experimental|. Tranexamic acid low dose 10 mg/kg|
3215413|NCT01089140|Experimental|Tranexamic acid 100mg/kg|
3215414|NCT01089140|Placebo Comparator|Saline Placebo|
3215415|NCT01089127|Experimental|Indacaterol 18.75 μg|Patients inhaled indacaterol 18.75 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
3215416|NCT01089127|Experimental|Indacaterol 37.5 μg|Patients inhaled indacaterol 37.5 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
3215417|NCT01089127|Experimental|Indacaterol 75 μg|Patients inhaled indacaterol 75 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
3215418|NCT01089127|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
3215419|NCT01089127|Active Comparator|Salmeterol 50 μg|Patients inhaled salmeterol 50 μg twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. In addition, patients inhaled placebo to indacaterol once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
3215420|NCT01089127|Placebo Comparator|Placebo|Patients inhaled placebo to indacaterol once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
3215421|NCT01089101|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Courses repeat every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. Patients who experience a sustained objective response from selumetinib on the phase I or phase II portions of the trial, and who have completed 2 years of treatment and stopped study drug may be enrolled on the re-treatment study after progression/recurrence. Patients in the re-treatment study may continue treatment indefinitely in the absence of disease progression or unacceptable toxicities.
3215422|NCT01089075|Placebo Comparator|placebo/20 mg hydrocortisone|Order of study treatment: 7 days placebo followed by 7 days 20 mg hydrocortisone
3215423|NCT01089075|Active Comparator|20 mg hydrocortisone/placebo|Order of study treatment: 7 days 20 mg hydrocortisone followed by 7 days placebo
3215424|NCT01089062|Other|Treatment A, then Treatment B, then Treatment C|"The second dose in each treatment group (A,B,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4."
3215425|NCT01089062|Other|Treatment A, then Treatment C, then Treatment B|"The second dose in each treatment group (A,C,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4."
3215426|NCT01089062|Other|Treatment B, then Treatment A, then Treatment C|"The second dose in each treatment group (B,A,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4."
3215427|NCT01089062|Other|Treatment B, then Treatment C, then Treatment A|"The second dose in each treatment group (B,C,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4."
3215476|NCT01088711|Experimental|Healthy Omarigliptin|Obese healthy participants receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel A).
3215477|NCT01088711|Placebo Comparator|Healthy Placebo|Obese healthy participants receive once-weekly placebo by mouth for 4 weeks (Panel A).
3215944|NCT01085682|Active Comparator|Lifestyle counseling|
3215428|NCT01089062|Other|Treatment C, then Treatment A, then Treatment B|"The second dose in each treatment group (C,A,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4."
3215429|NCT01089062|Other|Treatment C, then Treatment B, then Treatment A|"The second dose in each treatment group (C,B,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4."
3215430|NCT01089049|Experimental|Pre-Menopausal|
3215431|NCT01089049|Experimental|Post-Menopausal|
3215432|NCT01089036||survival|ECMO survival patients
3215433|NCT01089036||ECMO non-survival|ECMO non-survivals
3215434|NCT01089023|Experimental|1|
3215435|NCT01089010|Experimental|Three-way crossover|2 oral dose levels of CK-2017357 and placebo
3215436|NCT01088997|Experimental|High Dose Milrinone|Subjects will receive a bolus intravenous (IV) infusion of 50 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.5 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
3215437|NCT01088997|Experimental|Low Dose Milrinone|Subjects will receive a bolus intravenous (IV) infusion of 20 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.2 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
3215438|NCT01088984|Experimental|Bendamustine|Bendamustine 90 or 120 mg/m^2 administered as an intravenous (IV) infusion over 60 minutes on Days 1 and 2 of each 21-day cycle (maximum of 12 total cycles), with delays up to 2 weeks for neutrophil and platelet count recovery, for up to a 35-day cycle.
3215439|NCT01088971|Active Comparator|Duolac 7S|
3215440|NCT01088971|Placebo Comparator|starch capsule|
3215441|NCT01088958|Experimental|Micronutrient Sprinkles|Sales of Sprinkles in these groups of villages by community vendors
3215442|NCT01088945|Experimental|Enhanced Discharge Process|Caregivers of these infants will receive individual coaching in order to enhance their understanding of their infant's problems and enhance their knowledge and skills to care for their fragile infants.
3215443|NCT01088945|Active Comparator|Standard Discharge Process|These infants will receive the hospital's current standard of care for the discharge of fragile infants from the NICU.
3215444|NCT01088932|Experimental|SRX246|SRX246
3215445|NCT01088932|Placebo Comparator|Placebo|placebo
3215446|NCT01088919|Experimental|Dosing Regimen 1|
3215447|NCT01088919|Experimental|Dosing Regimen 2|
3215448|NCT01088919|Experimental|Dosing Regimen 3|
3215449|NCT01088919|Experimental|Dosing Regimen 4|
3215450|NCT01088906|Experimental|1 ARM|pemetrexed 500 mg/m2 IV + cisplatin 75 mg/m2 every 21 days
3215451|NCT01088893|No Intervention|observation|
3215452|NCT01088893|Experimental|Everolimus|
3215453|NCT01088880|Experimental|Canakinumab|
3215454|NCT01088867|Other|Acupuncture|14 weeks of electroacupuncture therapy.
3215455|NCT01088854|Experimental|positive airway pressure|
3215456|NCT01088841|Active Comparator|75 g glucose + 150 ppm lactisole|
3215457|NCT01088841|Active Comparator|75 g glucose + 300 ppm lactisole|
3215458|NCT01088841|Active Comparator|75 g glucose + 450 ppm lactisole|
3215459|NCT01088841|Placebo Comparator|75 g glucose|
3215460|NCT01088828||Group A|"Foetuses with clubfoot identified in utero (n=15). Of these:~around 10 will be born with clubfoot and will form most of Group B,~around 5 will be born without clubfoot and will form part of group C."
3215461|NCT01088828||Group B|Neonates affected by clubfoot (n=10)
3215462|NCT01088828||Group C|Control group of unaffected neonates (n=10)
3215463|NCT01088828||Group D|Young adults having completed treatment (n=5)
3215464|NCT01088828||Group E|Control group of young unaffected adults (n=5)
3215465|NCT01088815|Experimental|Gemcitabine, nab-paclitaxel, GDC-0449|Gemcitabine and nab-Paclitaxel in combination with GDC-0449 (Vismodegib)
3215466|NCT01088802|Experimental|Dose de-escalating radiation therapy with chemotherapy|This protocol combines selective radiation therapy dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks) in patients with HPV-associated cancers of the oropharynx
3215467|NCT01088789|Other|Arm A|Vaccine only.
3215468|NCT01088789|Other|Arm B|Arm B receives vaccine as well as a single dose of intravenous cyclophosphamide.
3215469|NCT01088789|Other|Arm C|In addition to Vaccine Arm C receives a daily dose of metronomic cyclophosphamide orally.
3215470|NCT01088776|Experimental|Supplement|
3215471|NCT01088776|Placebo Comparator|Control|
3215472|NCT01088763|Experimental|Arm I|"GROUP A: Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~GROUP B: Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-5, 8-12, 15-19, and 22-26. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients may also receive concurrent oral dexamethasone twice daily on the days of gamma-secretase inhibitor RO4929097 administration.~Once the MTD or recommended phase II dose of RO4929097 plus dexamethasone in children with solid tumors, including CNS tumors, or lymphoma has been identified, this dose is used for patients with relapsed-refractory T-ALL (phase 2 portion of the study) to evaluate RO4929097 in combination with dexamethasone using one of the studied schedules."
3215473|NCT01088750|Other|surgery alone|watch and wait strategy after complete resection of localised (e.g. Stage IA) nodular lymphocyte-predominant HL
3215474|NCT01088750|Experimental|CVP|3 cycles of intensity-reduced, anthracycline-free chemotherapy (Cyclophosphamide, vinblastine and prednisone)
3215475|NCT01088724|Experimental|chemotherapy|
3215796|NCT01086657|Experimental|Group 6|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 24
3215478|NCT01088711|Experimental|T2D Omarigliptin|Obese participants with T2D receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel B).
3215479|NCT01088711|Placebo Comparator|T2D Placebo|Obese participants with T2D receive once-weekly placebo by mouth for 4 weeks (Panel B).
3215480|NCT01088685|Experimental|Experimental Blister Patch|Experimental Hydrogel Blister patch
3215481|NCT01088685|Active Comparator|Marketed Pflaster|Scholls Blasen Pflaster
3215482|NCT01088672|Other|Acute Ischemic Stroke|Single arm post market surveillance study for CE marked mechanical thrombectomy device, Trevo retriever for treatment of eligible patients experiencing acute ischemic stroke Mechanical thrombectomy intervention for all subjects in Acute Ischemic Stroke
3215483|NCT01088659|Experimental|1|
3215484|NCT01088659|Experimental|2|
3215485|NCT01088633|Other|Exhaled particle analysis|
3215486|NCT01088620|Experimental|Panitumumab plus pemetrexed and cisplatin (PemCisP)|
3215487|NCT01088620|Active Comparator|Pemetrexed and cisplatin (PemCis)|
3215488|NCT01088607|Experimental|UDCA Withdrawal and Reinstitution|Each study subject will undergo serial UDCA withdrawal and reinstitution.
3215489|NCT01088594|Experimental|1|pioglitazone 45 mg
3215490|NCT01088594|Experimental|2|Rosiglitazone 8 mg
3215491|NCT01088594|Placebo Comparator|3|Placebo
3215492|NCT01088581|No Intervention|Observation group|No adjuvant chemotherapy after resection
3215493|NCT01088581|Active Comparator|Adjuvant group|Adjuvant chemotherapy after resection
3215494|NCT01088568|Experimental|TICL group|
3215495|NCT01088568|Active Comparator|LASIK group|
3215496|NCT01088555|Active Comparator|Control group|Healthy subjects with no history of kidney stones, heart liver or kidney disease, not pregnant /lactating.
3215497|NCT01088555|Active Comparator|Stone formers|History of calcium containing kidney stones, hypercalciuria on previous urine tests, no heart /liver / kidney disease, not pregnant/lactating
3215498|NCT01088542|No Intervention|No intervention|Communities in the no intervention arm received no intervention from the project and continued to implement prevention services as usual.
3215499|NCT01088542|Experimental|Communities That Care Intervention|Communities randomly assigned to the experimental condition received 5 years of training and technical assistance (from 2003 to 2008) to implement the Communities That Care (CTC) prevention system in their communities. They also received 5 years of funding to support a full-time community coordinator and 4 years of seed money to implement tested and effective prevention programs selected as a result of their CTC process.
3215500|NCT01088529|Experimental|AA+LHRHa|Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) and 1,000 mg abiraterone acetate (AA) plus 5 mg of prednisone daily for 3 months prior to radical prostatectomy.
3215501|NCT01088529|Experimental|LHRHa|Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) prior to radical prostatectomy.
3215502|NCT01088516|Experimental|Aluvia-based HAART|Study regimen: ZDV/3TC (combivir) + 2 Aluvia Tabs all PO BID to start at 14-30 weeks gestational age (GA) and continue through labor and as long as the mother breastfeeds
3215503|NCT01088503||ADP receptor inhibitor treatment|Participants admitted for non ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) and treated with an ADP receptor inhibitor during the index hospitalization.
3215504|NCT01088490||critically ill|Critically ill patients admitted to ICU
3215505|NCT01088477||Breast cancer patients with acquired anti-hormonal resistance|
3215506|NCT01088464|Experimental|Cohort 1|
3215507|NCT01088464|Experimental|Cohort 2|
3215508|NCT01088464|Experimental|Cohort 3|
3215509|NCT01088438|Experimental|Contextualization workshop|A four-hour course on contextualization.
3215510|NCT01088438|No Intervention|Control|No intervention
3215511|NCT01088425||Spontaneous|Mothers with children conceived after spontaneous cycle
3215512|NCT01088425||Vitrificatíon|Mothers with children conceived after vitrification cycle
3215513|NCT01088425||slow- rate freezing|Mothers with children conceived after slow- rate freezing cycle
3215514|NCT01088412||Treated|Patients treated with somatropin for improvement of growth
3215515|NCT01088412||Untreated|Untreated patients with presence or history of neoplastic disease evaluated for endocrine or growth disorder or with any SHOX deficiency related disorder
3215516|NCT01088399||Somatropin replacement treatment|Adult participants with growth hormone deficiency receiving somatropin replacement treatment.
3215517|NCT01088399||No treatment|Adult participants with growth hormone deficiency receiving no somatropin replacement treatment.
3215518|NCT01088386||Patients|All patients who will be receiving Zyprexa Relprevv must be enrolled into the Zyprexa Relprevv Patient Care Program
3215519|NCT01088373|Experimental|Azacitidine, Lenalidomide|
3215520|NCT01088360||Patients with rheumatoid arthritis initiating abatacept|
3215521|NCT01088360||Pts with RA initiating other biologic disease-modifying drugs|
3215522|NCT01088360||Pts w/ RA non-biologic disease-modifying anti-rheumatic drugs|
3215523|NCT01088347|Experimental|Advanced cervical cancer patients|
3215524|NCT01088334||IVTE, follow-up|no malignancy at basal screening, no extensive screening
3215525|NCT01088334||IVTE, screening|No malignancy at basal screening, screening by means of CT-Chest/abdomen and mammography in women
3215526|NCT01088321||Patients initiating abatacept|
3215527|NCT01088321||Patients initiating other biologic disease-modifying drugs|
3215528|NCT01088321||Pts initiate non-biologic disease-modify anti-rheumatic drugs|
3215529|NCT01088308|Experimental|Single Arm|All Patients underwent Intervention.
3215530|NCT01088295|Experimental|Telmisartan|Telmisartan 40mg po daily for 24 weeks
3215531|NCT01088282|Active Comparator|Implantation of difractive multifocal IOL|
3215532|NCT01088282|Sham Comparator|Implantation of monofocal IOL|
3215533|NCT01088269||AF|Hypertensive patients in AF
3215534|NCT01088269||Non-AF|Hypertensive Patients
3215535|NCT01088256|Active Comparator|etoricoxib, peripheral hyperalgesia|14 patient with neuropathic pain and peripheral hyperalgesia get etoricoxib 90mg for 8 days
3215536|NCT01088256|Active Comparator|etoricoxib, no peripheral hyperalgesia|14 patients with neuropathic pain without peripheral hyperalgesia get etoricoxib 90mg for 8 days
3215537|NCT01088256|Placebo Comparator|placebo, peripheral hyperalgesia|14 patients with neuropathic pain with peripheral hyperalgesia get placebo for 8 days
3215538|NCT01088256|Placebo Comparator|placebo, no peripheral hyperalgesia|14 patients with neuropathic pain without peripheral hyperalgesia get placebo for 8 days
3215539|NCT01088243|Experimental|Mesalamine|Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
3215540|NCT01088243|Placebo Comparator|Placebo|Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
3215541|NCT01088230|Experimental|Botox®|this group will receive an injection of botox in the wrist flexors and forearm pronators
3215542|NCT01088230|Placebo Comparator|Saline|This group will receive an injection of saline solution in the same muscle groups as the treatment group (wrist flexors and pronators).
3215543|NCT01088204|Active Comparator|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
3215544|NCT01088204|Experimental|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
3215545|NCT01088191|Active Comparator|Hyaluronan Alone|Hyaluronan Alone
3215546|NCT01088191|Experimental|MSB-CAR001|Single Dose of MSB-CAR001 Combined With Hyaluronan
3215547|NCT01088178|Experimental|Immediate Postplacental|Within 10 minutes from delivery of placenta
3215548|NCT01088178|Experimental|Early Postpartum|After 10 minutes from delivery of placenta but within 48hrs from delivery
3215549|NCT01088178|Experimental|Interval|After 6 weeks postpartum
3215550|NCT01088165|Experimental|Adalimumab treatment group|
3215551|NCT01088165|Active Comparator|Fumaric acid esters treatment group|
3215552|NCT01088152|Active Comparator|Usual care of celiac disease women|Written information corresponding to that offered when seeking medical advice for celiac disease in primary care
3215553|NCT01088152|Experimental|Celiac School|Structured education using problem-based learning at 10 sessions
3215554|NCT01088139|No Intervention|Control|
3215555|NCT01088139|Experimental|Nutritional Supplementation|
3215556|NCT01088126|Active Comparator|Focal ablation|PV isolation + CFAE-targeted focal ablation
3215557|NCT01088126|Active Comparator|Linear ablation|PV isolation + CFAE-guided linear ablation
3215558|NCT01088113||Tai Chi|Healthy subjects with Tai Chi practice
3215559|NCT01088113||Qigong|Healthy subjects with Qigong practice
3215560|NCT01088100||Patients with POCD - cases|Out of the 976 patients included in the ISPOCD2 study (Abildstrom H, Christiansen M et al. Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery. Anesthesiology 2004;101:855-61) the 93 patients with POCD whose blood samples are stored will be included together with 2x93 controls (without POCD), who will be matched by type of surgery, age, education, ASA-score and sex.
3215561|NCT01088100||Patients without POCD - controls|Out of the 976 patients included in the ISPOCD2 study (Abildstrom H, Christiansen M et al. Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery. Anesthesiology 2004;101:855-61) the 93 patients with POCD whose blood samples are stored will be included together with 2x93 controls (without POCD), who will be matched by type of surgery, age, education, ASA-score and sex.
3215562|NCT01088087|Placebo Comparator|Colostrum|
3215563|NCT01088087|No Intervention|Sugar pill|
3215564|NCT01088074|Active Comparator|Histoacryl Tissue Adhesive|Histoacryl Blue (HAB) Tissue Adhesive (n-butyl-2 cyanoacrylate; B. Braun Corp., Melsungen, Germany). Histocryl is a FDA-approved sterile liquid skin adhesive that has been utilized as a substitute for sutures for wound closure for approximately 40 years.
3215565|NCT01088074|Active Comparator|Dermabond|Dermabond High Viscosity Tissue Adhesive (2-ocytl cyanoacrylate; Ethicon, Somerville, NJ). Dermabond is also a FDA-approved liquid bonding agent that has been utilized for wound closure for approximately 10 years and proven as effective as sutures.
3215566|NCT01088074|Active Comparator|Staples|Visistat 35W Stapler (Teleflex Corp, Limerick, PA). The FDA-approved Weck staple system with stainless steel staples has been proven over years of use and remains the standard accepted closure approach due to speed of insertion as well as removal.
3215567|NCT01088074|Active Comparator|Running Subcuticular with Monocryl|Monocryl 4-0 Suture (Ethicon, Somerville, NJ). Monocryl is an FDA-approved absorbable, synthetic, suture indicated for soft tissue approximation.
3215568|NCT01088061||lean women with PCOS|
3215569|NCT01088061||Obese women with PCOS|
3215570|NCT01088061||lean control women|
3215571|NCT01088061||Obese control women|
3215572|NCT01088048|Experimental|Idelalisib + Rituximab|Idelalisib 100 mg or 150 mg twice daily + rituximab 375 mg/m^2 for 8 weekly doses
3215573|NCT01088048|Experimental|Idelalisib + Rituximab + Bendamustine|Idelalisib 150 mg twice daily + rituximab 375 mg/m^2 on Day 1 + bendamustine 90 mg/m^2 on Days 1 & 2 of Cycles 1-6 for participants with iNHL or MCL. Bendamustine 70 mg/m^2 for for participants with CLL only.
3215574|NCT01088048|Experimental|Idelalisib + Bendamustine|Idelalisib 100 mg or 150 mg twice daily + bendamustine 90 mg/m^2 or 70 mg/m^2 on Days 1 & 2 of Cycles 1-6.
3215575|NCT01088048|Experimental|Idelalisib + Ofatumumab|Idelalisib 150 mg twice daily + 12 doses of ofatumumab over the course of 6 months. For participants with CLL only.
3215576|NCT01088048|Experimental|Idelalisib + Fludarabine|Idelalisib 150 mg twice daily + oral fludarabine 40 mg/m^2 on Days 1-5 of Cycles 1-6. For participants with CLL only.
3215577|NCT01088048|Experimental|Idelalisib + Everolimus|Idelalisib 150 mg twice daily + oral everolimus 10 mg once daily. For participants with MCL only.
3215578|NCT01088048|Experimental|Idelalisib + Bortezomib|Idelalisib 150 mg twice daily + bortezomib 1.3 mg/m^2 once weekly for 3 weeks (Days 1, 8, and 15) followed by a 13-day rest period. For participants with MCL only.
3215579|NCT01088048|Experimental|Idelalisib + Chlorambucil|Idelalisib 150 mg twice daily + chlorambucil 10 mg/m^2 on Days 1-7 every 28 days. For participants with CLL only.
3215580|NCT01088048|Experimental|Idelalisib + Rituximab + Chlorambucil|Idelalisib 150 mg twice daily + rituximab 375 mg/m^2 + chlorambucil 10 mg/m^2 for participants with CLL only.
3215934|NCT01085721|Experimental|Dexchlorpheniramine pseudoephedrine guaifenesin|
3215581|NCT01088048|Experimental|Idelalisib + Rituximab + Lenalidomide|Idelalisib 150 mg twice daily + rituximab 375 mg/m^2 + lenalidomide 5, 10 or 20 mg (M.D. Anderson Cancer Center only)
3215582|NCT01088035|Experimental|Carboplatin|
3215583|NCT01088022|Experimental|Aprepitant, Palonosetron, dexametasone|
3215584|NCT01088022|Placebo Comparator|Placebo, Palonosetron, Dexamethasone|
3215585|NCT01088009|Experimental|early add-on|
3215586|NCT01088009|Active Comparator|SOC|Patients will receive oral lamivudine 100mg,daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
3215587|NCT01088009|Other|De-novo combination|patients in this arm will receive oral lamivudine 100mg and adefovir 10mg for 104 weeks
3215588|NCT01087996|Experimental|Auto-hMSCs|Participants will receive an injection of 20 million, 100 million or 200 million autologous human mesenchymal stem cells.
3215589|NCT01087996|Experimental|Allo-hMSCs|Participants will receive an injection of 20 million, 100 million or 200 million allogeneic human mesenchymal stem cells.
3215590|NCT01087983|Experimental|Lapatinib + Sirolimus|Lapatinib starting oral dose of 500 mg daily for 21 day cycle. Sirolimus starting oral dose 1 mg daily.
3215591|NCT01087983|Experimental|Lapatinib + Metformin|Lapatinib starting oral dose of 500 mg daily for 21 day cycle. Metformin Starting oral dose 1000 mg daily.
3215592|NCT01087970|Experimental|Triplet Combination Therapy|"Cycle 1:~Week 1 - Cetuximab 400 milligrams/square meter (mg/m²) on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin area under curve (AUC) 5 on Day 1 or Cisplatin 75 mg/m² on Day 1~Week 2 - Cetuximab 250 mg/m² on Day 1~Week 3 - Cetuximab 250 mg/m² on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m² on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin AUC 5 on Day 1 or Cisplatin 75 mg/m² on Day 1~Week 2 - Cetuximab 250 mg/m² on Day 1~Week 3 - Cetuximab 250 mg/m² on Day 1~Following Cycle 6, Cetuximab Monotherapy: 250 mg/m² intravenously weekly on Day 1"
3215593|NCT01087957|Active Comparator|Ankle-Foot Orthosis (AFO)|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
3215594|NCT01087957|Active Comparator|WalkAide|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
3215595|NCT01087944|Experimental|1|"Peginterferon via auto-injector device.~All participants will receive Peginterferon in a cross-over design."
3215596|NCT01087944|Active Comparator|2|"Peginterferon via pre-filled syringe.~All participants will receive Peginterferon in a cross-over design."
3215597|NCT01087931|Active Comparator|Bupivacaine|This group will receive bupivacaine (10ml of 0.5%) administered directly into the surgical wound at the iliac crest bone harvest site.
3215598|NCT01087931|Placebo Comparator|Saline|This group will receive normal saline (10ml) administered directly into the surgical wound at the iliac crest bone harvest site.
3215599|NCT01087918|Experimental|First RAGT, then strength training|16 sessions of 45 minutes of robot-assisted gait training 4 times a week in first intervention period and 16 sessions of 45 minutes of strength training 4 times a week in second intervention period.
3215600|NCT01087918|Experimental|First strength training, then RAGT|16 sessions of 45 minutes of strength training 4 times a week in first intervention period and 16 sessions of 45 minutes of robot-assisted gait training 4 times a week in second intervention period.
3215601|NCT01087905|Active Comparator|2 Weeks of Nicotine Patch Only, No CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~2 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks"
3215602|NCT01087905|Active Comparator|2 Weeks of Nicotine Patch Only plus CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling~2 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks"
3215603|NCT01087905|Active Comparator|2 Wks Nicotine Patch+Nic Gum, No CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~2 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks~2 Weeks of Nicotine gum dosed as follows:~If < 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
3215604|NCT01087905|Active Comparator|2 Wks Nicotine Patch+Nic Gum plus CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling~2 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks~2 Weeks of Nicotine gum dosed as follows:~If < 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
3215605|NCT01087905|Active Comparator|6 Weeks of Nicotine Patch Only, No CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~6 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks"
3215606|NCT01087905|Active Comparator|6 Weeks of Nicotine Patch Only plus CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling~6 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks"
3215635|NCT01087762|Placebo Comparator|Placebo|"Matching Placebo to CZP injections from Week 0 to Week 24. Placebo subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16.~After 24 weeks, all subjects were randomized to active treatment with CZP 200 mg Q2W or CZP 400 mg Q4W."
3215714|NCT01087190|Experimental|INH treatment group|"randomly allocated to INH treatment group in renal transplant recipients with ELISPOT (+)~INH 300 mg po qd for 9 months"
3215607|NCT01087905|Active Comparator|6 Wks Nicotine Patch+Nic Gum, No CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~6 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks~6 Weeks of Nicotine gum dosed as follows:~If < 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
3215608|NCT01087905|Active Comparator|6 Wks Nicotine Patch+Nic Gum plus CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling~6 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks~6 Weeks of Nicotine gum dosed as follows:~If < 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
3215609|NCT01087892|Active Comparator|Dietary supplement Probiotic drink|"Double blind~Probiotic containing the live strain 100g/day orally, twice daily for the duration of the course of antibiotics plus seven days"
3215610|NCT01087892|Placebo Comparator|Dietary supplement probiotic placebo drink|"Double blind~'placebo' is actually a control product~Placebo drink contains no strain 100gs orally, twice daily for the duration of the course of antibiotics plus seven days"
3215611|NCT01087879|Active Comparator|Oral contraceptive pill|9 weeks treatment with contraceptive pill.
3215612|NCT01087879|Active Comparator|Contraception vaginal ring|9 weeks treatment with vaginal ring.
3215613|NCT01087879|Active Comparator|Transdermal contraceptive patch|9 weeks treatment with a transdermal contraceptive patch.
3215614|NCT01087866|Experimental|Metformin|
3215615|NCT01087866|Active Comparator|Insulin|
3215616|NCT01087853|Active Comparator|Phase A1: Plasmalyte|Plasmalyte
3215617|NCT01087853|Active Comparator|Phase A2: 0.9% Saline|0.9% Saline
3215618|NCT01087853|Active Comparator|Phase B1: PlasmaVolume|PlasmaVolume
3215619|NCT01087853|Active Comparator|Phase B2: Voluven|Voluven
3215620|NCT01087840|Experimental|Raltegravir, NPEP|"Drug: Raltegravir Tablet 400mg taken orally, twice daily with or without food for 28 days along with Truvada 1 tablet taken orally daily for 28 days.~Arms: Raltegravir/Truvada"
3215621|NCT01087814|Active Comparator|efavirenz|
3215622|NCT01087814|Experimental|over-encapsulated efavirenz|
3215623|NCT01087801|Active Comparator|ChiRhoStim|Human Secretin for Injection
3215624|NCT01087801|Placebo Comparator|Placebo|Saline for Injection
3215625|NCT01087788|Experimental|CZP 200 mg Q2W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.~At every visit, subjects received one injection of 200 mg CZP and one injection of Placebo to maintain the study blind."
3215626|NCT01087788|Experimental|CZP 400 mg Q4W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 8 onwards.~Subjects received 2 injections of Placebo every 4 weeks in between the 2 injections of 200 mg CZP to maintain the study blind."
3215627|NCT01087788|Placebo Comparator|Placebo|"Matching Placebo to Certolizumab Pegol (CZP) injections from Week 0 to Week 24. Placebo subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group and were re-randomized to either CZP 200 mg Q2W or CZP 400 mg Q4W arm on Week 16.~After 24 weeks, all subjects were re-randomized to active treatment with CZP 200 mg every two weeks (Q2W) or CZP 400 mg every four weeks (Q4W)."
3215628|NCT01087788|Other|Placebo to CZP 200 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 22 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
3215629|NCT01087788|Other|Placebo to CZP 400 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 24 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
3215630|NCT01087788|Other|Placebo to CZP 200 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 30 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
3215631|NCT01087788|Other|Placebo to CZP 400 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 32 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
3215632|NCT01087775|Experimental|Cognitive Training|Plasticity Based Adaptive Cognitive Remediation (PACR)
3215633|NCT01087762|Experimental|CZP 200 mg Q2W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.~At every visit, subjects received one injection of 200 mg CZP and one injection of Placebo to maintain the study blind."
3215634|NCT01087762|Experimental|CZP 400 mg Q4W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 8 onwards.~Subjects received 2 injections of Placebo every 4 weeks in between the 2 injections of 200 mg CZP to maintain the study blind."
3215708|NCT01087229|Experimental|equimolar oxygen-nitrous oxide mixture|"equimolar oxygen-nitrous oxide mixture~Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture."
3215636|NCT01087762|Other|Placebo to CZP 200 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 22 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
3215637|NCT01087762|Other|Placebo to CZP 400 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 24 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
3215638|NCT01087762|Other|Placebo to CZP 200 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 30 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
3215639|NCT01087762|Other|Placebo to CZP 400 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 32 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
3215640|NCT01087749|Experimental|Chronic Kidney Disease|Propranolol, Losartan, and Eprosartan will be administered to patients who have been diagnosed with Chronic Kidney disease and have a glomerular filtration rate (GFR) below 40ml/min.
3215641|NCT01087749|Experimental|Healthy Volunteers|Propranolol, Losartan, and Eprosartan will be administered to healthy volunteers without chronic kidney disease.
3215642|NCT01087736|Experimental|Topiramate|Participants will be randomly assigned to either the topiramate arm or placebo arm. Neither the participant nor the researchers will know which arm the participant is in. Participants in the topiramate arm will be ingesting daily doses of topiramate that will gradually increase to a maximum, and then taper off.
3215643|NCT01087736|Placebo Comparator|Placebo|The Drug Product Services Laboratory at UCSF will purchase and supply our lab with USP or NF grade topiramate study capsules and matching placebo capsules. Randomization will be done by a consulting biostatistician, who will be the only one to know which participants are assigned to placebo. Dosing will follow the same procedures as with topiramate in that arm of the study. If adverse events occur, there will be a procedure in place for unblinding only that participant.
3215644|NCT01087723|Experimental|Bivalirudin|Given immediately upon enrollment as an intravenous (IV) bolus of 0.75 mg/kilogram (mg/kg), followed immediately by an infusion of 1.75 mg/kg/hour (mg/kg/h). This infusion was to be run continuously until completion of PCI, at which time the infusion was reduced to 0.25 mg/kg/h for at least 4 hours. An optional PCI-dose infusion of 1.75 mg/kg/h was also permitted for up to 4 hours at the discretion of the operator.
3215645|NCT01087723|Active Comparator|Standard of Care: Heparins with Optional GPI|"Standard-of-care anti-thrombotic therapy as outlined in the European Society of Cardiology Dosing Guidelines for Management of STE-ACS, not including bivalirudin: UFH (100 international units/kg [IU/kg] without GPI and 60 IU/kg with GPI). Any of the following approved GPIs were used either as a routine strategy or as a bail out: eptifibatide (two 180-micrograms/kilogram [μg/kg] IV boluses with a 10-minute [min] interval followed by an infusion of 2.0 μg/kg/min for 72-96 hours); tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18-24 hours); or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours [maximum dose of 10 μg/min]).~For this study, the control consisted of treatment with UFH or low molecular weight heparin (LMWH) with or without GPI and is referred to as heparins with optional GPI."
3215646|NCT01087710|Experimental|novel nutritional formula|
3215647|NCT01087710|Active Comparator|Control nutritional product|1 8oz serving per day for 12 weeks
3215648|NCT01087697|Experimental|Implanted with NUC|Patients who have been implanted with the Neo-Urinary Conduit
3215649|NCT01087684|Active Comparator|Argon laser trabeculoplasty|Patients received standard argon laser treatment
3215650|NCT01087684|Active Comparator|Selective laser trabeculoplasty|Patients received a standard selective laser treatment
3215651|NCT01087671|Other|Open-lable study with one arm|
3215652|NCT01087658|Experimental|Glutamine and calcium magnesium|"Glutamine 10g p.o. 3-times a day beginning at day -2 for 7 consecutive days during each chemotherapy cycle. 1g of calcium and 1g of magnesium i.v. over 30 minutes just before the chemotherapy and repeated at the same dose after the completion of the oxaliplatine infusion.~All patients will receive an oxaliplatin based chemotherapy with XELOX, FOLFOX-4 or mFOLFOX-6."
3215653|NCT01087658|Active Comparator|Calcium magnesium|"1g of calcium and 1g of magnesium i.v. over 30 minutes just before the chemotherapy and repeated at the same dose after the completion of the oxaliplatine infusion.~All patients will receive an oxaliplatin based chemotherapy with XELOX, FOLFOX-4 or mFOLFOX-6."
3215654|NCT01087645|Experimental|Trial part 1|
3215655|NCT01087645|Experimental|Trial part 2|
3215656|NCT01087632|Experimental|Armolipid Plus|Armolipid Plus is an association of berberine 500 mg, red yeast rice titled in 3 mg monacolin K,- policosanol 10 mg,coenzyme Q10 2 mg,astaxanthin 0,5 mg,folic acid 0,2 mg
3215657|NCT01087632|Placebo Comparator|Placebo|Placebo matching Armolipid plus
3215658|NCT01087619|No Intervention|Follow-up|Patients diagnosed biochemically and clinically with primary hyperparathyroidism who are followed only
3215659|NCT01087619|Experimental|Surgery|Patients diagnosed biochemically and clinically with primary hyperparathyroidism who are treated with parathyroid surgery
3215660|NCT01087593|Experimental|Treatment with transdermal 17β-estradiol|
3215661|NCT01087593|Placebo Comparator|Control|
3215662|NCT01087580|Experimental|Chemotherapy alone, no radiation therapy|"A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days~B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel"
3215709|NCT01087229|Placebo Comparator|Placebo|Patients randomized to this arm will have the placebo.
3215710|NCT01087216|Active Comparator|Group Laser = Arm As A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
3215711|NCT01087216|Placebo Comparator|Bras B : the control group|patient to accept habitual treatment of corticoid
3215712|NCT01087203|Experimental|Tanezumab|
3215663|NCT01087580|Experimental|Chemotherapy with Radiation Therapy|"A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel~GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index < 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week."
3215664|NCT01087567|Experimental|Intensive insulin regimen|A weight based, basal bolus will be given for 12 weeks.
3215665|NCT01087567|Active Comparator|Routine Care|Routine Care patients receive oral medications based upon the 2009 ADA treatment recommendations: Metformin, Glimepiride, Pioglitazone.
3215666|NCT01087554|Experimental|Arm A: Vorinostat + Sirolimus|"Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase."
3215667|NCT01087554|Experimental|Arm B: Vorinostat + Everolimus|"Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.~Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase."
3215668|NCT01087554|Experimental|Arm C: Vorinostat + Temsirolimus|"Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.~Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase."
3215669|NCT01087541|No Intervention|Control|Usual clinical health care
3215670|NCT01087541|Experimental|Intervention|Behavioural program of education for health professionals. Standardized program of 6 hours for health professionals ( doctors and nurses )
3215671|NCT01087528|Experimental|1|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
3215672|NCT01087515|Other|Blood donation|
3215673|NCT01087502|Experimental|Linagliptin|52 weeks treatment
3215674|NCT01087502|Placebo Comparator|Placebo|First 12 weeks of treatment
3215675|NCT01087502|Active Comparator|Glimepiride|Placebo patients switch to glimepiride after 12 weeks (40 weeks treatment)
3215676|NCT01087489|Experimental|4% lidocaine|Eyes were anesthetized with 0.5% proparacaine and then with three cotton swabs soaked in 4% liquid lidocaine applied with moderate pressure to the site of the injection inferotemporally to the limbus. Each participant was assigned to have this prep during one of the consecutive study visits if unilateral or in one eye if patient requires bilateral injections given the same day
3215677|NCT01087489|Experimental|3.5% ophthalmic lidocaine gel|Eye was anesthetized with 0.5% proparacaine and then with 3.5% ophthalmic lidocaine gel applied to the surface of the eye. Each participant was randomly assigned to receive this preparation during one of two consecutive intravitreal injection (if unilateral disease) or in one eye if requiring bilateral injections given on the same day.
3215678|NCT01087476|Experimental|doxycycline hyclate|Patients will be randomly assigned to receive either a sub-microbial dose of doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
3215679|NCT01087463|Experimental|single arm|In this single arm study, the Quantum nailing system will be used in all patients.
3215680|NCT01087450||Stage1|1. Prospective dose response group. 3 subjects per dose at 200U/kg, 400U/kg and 600U/kg rHuEPO
3215681|NCT01087450||Stage 2 Randomized, blinded trial|Control group: Randomized to placebo treatment Treatment Group: Randomized to rHuEPO treatment
3215682|NCT01087437|Experimental|gastrolith calcium treatment|
3215683|NCT01087424|Experimental|R mini CHOP|Induction : 3 cycles every 3 weeks Consolidation :3 cycles every 3 weeks
3215684|NCT01087411|Experimental|Motivational Interviewing and omega 3|This arm is the group that receives the intervention program and eats fish liver oil capsules. Represents 25 % of all participants.
3215685|NCT01087411|Experimental|Motivational intervewing and placebo|This arm is the group that receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.
3215686|NCT01087411|Experimental|Controll and omega 3|This arm is the group that does not receives the intervention program and eats fish liver oil capsules. Represents 25 % of all participants.
3215687|NCT01087411|Placebo Comparator|Controll and placebo|This arm is the group that does not receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.
3215688|NCT01087398|Experimental|Intervention|
3215689|NCT01087385||Troponin T elevation|
3215690|NCT01087385||No troponin T elevation|
3215691|NCT01087359|Active Comparator|LPS + melatonin night|
3215692|NCT01087359|Placebo Comparator|LPS + placebo night|
3215693|NCT01087359|Active Comparator|LPS + melatonin day|
3215694|NCT01087359|Placebo Comparator|LPS + placebo day|
3215695|NCT01087359|Experimental|LPS night|
3215696|NCT01087359|Experimental|LPS day|
3215697|NCT01087346|Experimental|Genetic Information|Information about genetic factors in child obesity risk
3215698|NCT01087346|Active Comparator|Control|Information about child health
3215699|NCT01087346|Experimental|Family Environment Information|Information about family environment factors in children's obesity risk
3215700|NCT01087346|Experimental|Gene times Family Environment Information|Information about interactions between genetic and family environment factors in children's obesity risk
3215701|NCT01087294|Experimental|1A/T cell arm (closed)|Dose escalation of CAR+ T cells based on the patients actual body weight
3215702|NCT01087294|No Intervention|2/Donor arm|
3215703|NCT01087294|Experimental|1B/T memory stem celll arm|Dose escalation with 6 dose levels of CAR+ T memory cells based on the patients actual body weight
3215704|NCT01087255|No Intervention|Usual Care|Usual care patients will have outpatient care and monitoring procedures, as determined by them and their health care providers.
3215705|NCT01087255|Experimental|Electronic Pillbox Monitoring System|Usual care plus receive use of the wireless electronic pillbox and medication monitoring system
3215706|NCT01087242|Placebo Comparator|controlled group|Tang-min Lin analogue 6g,tid,po
3215707|NCT01087242|Experimental|Tang-min Lin pill|Tang-min Lin pills 6g,tid,po
3215715|NCT01087190|No Intervention|Control group|"randomly allocated to control group in renal transplant recipients with ELISPOT (+)~no treatment"
3215716|NCT01087190|No Intervention|Observation group|"allocated to observation group in renal transplant recipients with ELISPOT (-)~no treatment"
3215717|NCT01087177|Experimental|Exposure to Pedialink CEASE Trained Site|Parents at a practice where the clinicians were trained to address tobacco use through the Pedialink CEASE module.
3215718|NCT01087164|Experimental|Compliance|Parents will be randomized to receive high or no compliance condition where those in the experimental group will be asked about whether or not they will protect their daughter from cervical cancer or for males, their son from genital warts.
3215719|NCT01087164|Experimental|Message sidedness|Parents will be given either a one-sided verbal message or a two-sided verbal message about the HPV vaccine.
3215720|NCT01087151|Active Comparator|A|
3215721|NCT01087151|Experimental|B|
3215722|NCT01087151|Experimental|C|
3215723|NCT01087138|Experimental|Exercise|exercise class 3x's/week
3215724|NCT01087138|Experimental|exercise and calcium intake|exercise class 3x's/week and 1500mg calcium/day
3215725|NCT01087138|No Intervention|usual exercise and calcium|usual exercise and calcium intake
3215726|NCT01087125||Pregnant RA patients with abatacept exposure during pregnancy|
3215727|NCT01087112|Active Comparator|Child Health Centre care|TAU involved scheduled health visitor calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The health visitor is encouraged to promote attachment and to detect postnatal depressions. Mothers may be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Additional treatment was initiated in 1/3 of the cases. This was registered at the end-point interview.
3215728|NCT01087112|Experimental|Mother-Infant Psychoanalytic tmt|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. The analyst strives to recruit the baby for an emotional interchange, though this does not imply any belief that the infant understands verbal communication. The analyst addresses the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst takes great care in enrolling the participant mother. This is to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her all space needed to vent her own frustration, depression and anxiety.
3215729|NCT01087099|Experimental|Albendazole|Treatment with albendazole
3215730|NCT01087086|Experimental|Crononutrition|"Dietary pattern:~Personalized diet~Caloric restriction (-30% Total energy intake)~High adherence to the Mediterranean Diet~Macronutrient distribution (30% Protein, 40% Carbohydrates and 30% Fat)~Low glycemic index/load~Increased antioxidant capacity of the diet"
3215731|NCT01087086|Placebo Comparator|American Heart Association|"Dietary pattern:~Personalized diet~Caloric diet (-30% Total energy intake)~Macronutrients distribution according to the American Heart Association (AHA) guidelines"
3215732|NCT01087073|Experimental|Patient Activation|Patient knowledge in diabetes self-management behaviors and clinical measures (HbA1c, LDL, HDL, BMI, BP) are tracked at baseline, 10-weeks (post-program), 3 months (post-program) and 6 months (post-program).
3215733|NCT01087073|Experimental|Provider Training Evaluation|Pre-post surveys are conducted at each training session to assess overall satisfaction with the curriculum, knowledge of SDM, and understanding of techniques to promote its use in the healthcare setting.
3215734|NCT01087073|Experimental|Quality Improvement Evaluation|We measure quality improvement efforts through biannual staff experience surveys and one-on-one provider and clinic staff interviews.
3215735|NCT01087073|Experimental|Community Outreach Evaluation|"Pre-post surveys will be disseminated at nutrition tours (Save-A-Lot, Walgreens, 61st Street Farmers Market) to assess change in knowledge of healthy eating behaviors and proper nutrition. Surveys will also assess participant satisfaction of the tours.~Interviews will also be performed with community stakeholders to assess the costs/benefits of the collaboration and overall feedback on involvement."
3215736|NCT01087073|No Intervention|Global Evaluation of the Intervention|A chart review will be performed in order to evaluate our intervention to improve diabetes processes of care and clinical outcomes among our target population. Chart abstractions will be performed on medical records obtained from our six intervention clinics. In addition, chart abstractions from two University of Illinois at Chicago clinics and three FQHCs located on the West Side of Chicago will serve as control data.100 charts will be randomly selected from each clinic per year of the intervention. The chart review will contain charts from adult diabetes patients over a seven year period that matches the duration of the Improving Diabetes project.
3215737|NCT01087060||cysts surgically removed|
3215738|NCT01087060||cysts under surveillance|
3215739|NCT01087047||Physiological modifications|Pregnant women who attend the routine ultrasound control in our institution before 14 weeks of pregnancy
3215740|NCT01087047||MRI and acoustic|Women undergoing an MRI for obstetrical purpose
3215741|NCT01087034||Milwaukee brace|Children with an infantile scoliosis requiring Milwaukee bracing
3215742|NCT01087034||Cheneaux brace|Children with an infantile scoliosis requiring Cheaneaux bracing
3215743|NCT01087021|Experimental|cabazitaxel|"At every cycle (every 3 weeks), on Day 1, patients will receive cabazitaxel, administered by intravenous (IV) infusion over 1 hour, at 25 mg/m2.~An IV premedication regimen composed of up to 4 treatments (antihistamine, corticosteroids, H2 antagonist other than cimetidine at all cycles, plus palonosetron at cycle 1) will be administered before cabazitaxel infusion."
3215744|NCT01087008|Experimental|Zoledronate acid|
3215745|NCT01087008|Other|No treatment control|
3215746|NCT01086982|Experimental|Octreotide acetate LAR 30 MG|Test
3215747|NCT01086982|Active Comparator|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|
3215748|NCT01086969|Experimental|Study Group|Participants in three age cohorts - Children: 2 - 11 years of age; Adolescents: 12 - 17 years of age, and Adults: 18 - 55 years of age will be enrolled.
3215749|NCT01086943|Experimental|device arm|
3215793|NCT01086657|Experimental|Group 3|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 8
3215794|NCT01086657|Experimental|Group 4|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 12
3215795|NCT01086657|Experimental|Group 5|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 16
3215750|NCT01086930|Experimental|Intervention Group|"In addition to standard care participants in Group A will receive:~• One hour of extra hand training five times per week for 8 weeks~The training will be supervised by a therapist and provided to the target hand. It will consist of FES-assisted hand exercises on an instrumented exercise workstation (ReJoyce). The hand exercises will be incorporated into computer games and will involve the following tasks using different manipulanda:~reaching~grasping~manipulating~pulling~rotating~releasing"
3215751|NCT01086930|Other|Standard Care Group|Participants in the control group will not receive any training on the instrumented workstation or electrical stimulation to the hand or upper limb. They will however continue to receive standard care as well as three 15-minute specific hand activity sessions per week specifically devoted to the practice of hand activities in a one-to-one format with a therapist (as per the treatment received by the experimental group).
3215752|NCT01086917|Experimental|Group 1|to receive a dose of 2,500 PfSPZ Challenge
3215753|NCT01086917|Experimental|Group 2|to receive a dose of 10,000 PfSPZ Challenge
3215754|NCT01086917|Experimental|Group 3|to receive a dose of 25,000 PfSPZ Challenge
3215755|NCT01086891|Experimental|1|Patients with chronic obstructive pulmonary disease who show arterial oxygen desaturation to effort.
3215756|NCT01086891|Experimental|2|Patients with interstitial lung disease who show arterial oxygen desaturation to effort
3215757|NCT01086878|Experimental|Cotrimoxazole|
3215758|NCT01086865|Active Comparator|Petivit BC|
3215759|NCT01086865|Experimental|Apetiviton BC|
3215760|NCT01086852|Experimental|FACTOR X|Human Coagulation Factor X
3215761|NCT01086839|Experimental|sodium chloride 6%|"Cross-Over! experimental (days 1 - 28), then Wash-Out (28 days),then placebo comparator (days 57 - 85)."
3215762|NCT01086839|Placebo Comparator|sodium chloride 0,9%|"Cross-Over! placebo comparator (days 1 - 28), then Wash-Out (28 days),then experimental (days 57 - 85)."
3215763|NCT01086826|Active Comparator|RT+CDDP/5-FU|"RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU 800 mg/m2/day for 4 will be administered as continuos iv infusion Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy."
3215764|NCT01086826|Experimental|RT+CETUXIMAB|"RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CETUXIMAB:~Cetuximab 400 mg/m2 as first dose, 7 days before the beginning of radiotherapy as 120 minutes IV infusion. Subsequent doses of 250 mg/ m2 will be administered as 60 minutes IV infusion, weekly, for 7 times."
3215765|NCT01086826|Active Comparator|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|"INDUCTION CTx(TPF):~DOCETAXEL:~75 mg/m², 1 hour IV infusion, Day and every 3 weeks~CISPLATIN:~80mg/m², intravenous infusion over 30-minute to 3 hours,Day 1 immediately after docetaxel administration and then every 3 weeks 5-FU 800 mg/m²/day, 24 hour continous infusion over 4 days, Day 1 after the end of cisplatin infusion, and every 3 weeks.~RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU 800 mg/m2/day for 4 will be administered as continuos iv infusion"
3215766|NCT01086826|Experimental|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|"DOCETAXEL:~75 mg/m², 1 hour IV infusion, Day and every 3 weeks~CISPLATIN:~80mg/m², intravenous infusion over 30-minute to 3 hours,Day 1 immediately after docetaxel administration and then every 3 weeks 5-FU 800 mg/m²/day, 24 hour continous infusion over 4 days, Day 1 after the end of cisplatin infusion, and every 3 weeks.~RADIOTHRAPY:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CETUXIMAB:~Cetuximab 400 mg/m2 as first dose, 7 days before the beginning of radiotherapy as 120 minutes IV infusion. Subsequent doses of 250 mg/ m2 will be administered as 60 minutes IV infusion, weekly, for 7 times."
3215767|NCT01086813|Experimental|1|
3215768|NCT01086800|Other|HLSE plus PAP|
3215769|NCT01086800|Other|HLSE plus Oxygen|
3215770|NCT01086800|Other|Healthy Lifestyles and Sleep Education|
3215771|NCT01086787||Non heart failure patients|Patients without heart failure undergoing open chest surgery
3215772|NCT01086787||Orthopedic patients|Patients without heart failure undergoing orthopedic surgery
3215773|NCT01086787||Heart failure patients|Patients with heart failure undergoing open chest surgery.
3215774|NCT01086774|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
3215775|NCT01086761|Experimental|MP0112 (0.04 mg)|Single 0.04 mg intravitreal injection of MP0112 in the study eye.
3215776|NCT01086761|Experimental|MP0112 (0.15 mg)|Single 0.15 mg intravitreal injection of MP0112 in the study eye.
3215777|NCT01086761|Experimental|MP0112 (0.4 mg)|Single 0.4 mg intravitreal injection of MP0112 in the study eye.
3215778|NCT01086761|Experimental|MP0112 (1.0 mg)|Single 1.0 mg intravitreal injection of MP0112 in the study eye.
3215779|NCT01086761|Experimental|MP0112 (2.0 mg)|Single 2.0 mg intravitreal injection of MP0112 in the study eye.
3215780|NCT01086761|Experimental|MP0112 (3.6 mg)|Single 3.6 mg intravitreal injection of MP0112 in the study eye.
3215781|NCT01086748|Experimental|160 mg LY2140023|80 mg LY2140023 administered orally, twice daily (BID) for up to 7 weeks.
3215782|NCT01086748|Active Comparator|4 mg Risperidone|2 mg risperidone administered orally, BID for up to 7 weeks.
3215783|NCT01086748|Placebo Comparator|Placebo|Placebo administered orally, BID for up to 7 weeks.
3215784|NCT01086748|Experimental|80 mg LY2140023|40 mg LY2140023 administered orally, BID for up to 7 weeks.
3215785|NCT01086735|Experimental|donor lymphocyte infusion|Donor T-cell transduction
3215786|NCT01086722|Experimental|"karolinska cocktail"|The karolinska cocktail contains dextromethorphan, caffeine, losartan and omeprazol
3215787|NCT01086696|Experimental|1|subjects with tumor types typically treatedwith taxanes
3215788|NCT01086696|Experimental|2|subjects with tumor types typically treatedwith taxanes
3215789|NCT01086683|Experimental|Intervention group|
3215790|NCT01086683|No Intervention|Control group|Wait list control group: The control group received usual care including clinical control visits but no systematic rehabilitation activities.
3215791|NCT01086657|Experimental|Group 1|Inactivated H5N1 Vaccine at Enrollment and inactivated H5N1 Vaccine at Week 24
3215792|NCT01086657|Experimental|Group 2|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 4
3215797|NCT01086605|Experimental|Arm I|Patients receive pixantrone dimaleate IV over 1 hour on day 1. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3215798|NCT01086605|Experimental|Arm II|Patients receive pixantrone dimaleate IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3215799|NCT01086592|Active Comparator|Control|
3215800|NCT01086592|Experimental|Strengthening exercise|Strong progressive strengthening exercises of lower limbs.
3215801|NCT01086592|Experimental|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
3215802|NCT01086592|Experimental|Electrotherapy+weights|
3215803|NCT01086579|Experimental|Treatment Arm (IN.PACT Falcon Drug Eluting Balloon)|IN.PACT Falcon™ paclitaxel drug-eluting balloon (DEB) dilatation and provisional spot bare metal stenting (Bare Metal Stent).
3215804|NCT01086579|Active Comparator|Control Arm PES|Control Arm: paclitaxel-eluting stent (PES) implantation as per standard practice.
3215805|NCT01086566|Experimental|Multiple Boost Group-15 mcg|25 healthy adults who have previously received both Clade 1 and Clade 3 vaccines as a participant in study DMID 05-0043 will receive a single dose of 15 mcg of A/Indonesia/5/05.
3215806|NCT01086566|Experimental|Primed Group-15 mcg|30 healthy adults who have previously received H5N1 vaccine at any dose will receive a single dose of 15 mcg of A/Indonesia/5/05.
3215807|NCT01086566|Experimental|Unprimed Group-90 mcg|15 healthy adults with no previous receipt of H5N1 vaccine at any dose will receive 2 doses of 90 mcg of A/Indonesia/5/05 vaccine separated by 28 days.
3215808|NCT01086566|Experimental|Unprimed Group-15 mcg|15 healthy adults with no previous receipt of H5N1 vaccine at any dose will receive 2 doses of 15 mcg of A/Indonesia/5/05 vaccine separated by 28 days.
3215809|NCT01086566|Experimental|Primed Group-90 mcg|30 healthy adults who have previously received H5N1 vaccine at any dose will receive a single dose of 90 mcg of A/Indonesia/5/05.
3215810|NCT01086553|Experimental|A|9mg budesonide OD
3215811|NCT01086553|Active Comparator|B|3mg budesonide TID
3215812|NCT01086540|Experimental|Rituximab|
3215813|NCT01086540|Placebo Comparator|Control|
3215814|NCT01086527|Experimental|SLCO2B1{NM_007256.2}:c.[935G>A] + [=]|Individuals in this group will be homozygous for SLCO2B1{NM_007256.2}:c.[935G>A].
3215815|NCT01086514|Experimental|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|In this study we will perform Dual Energy Contrast Enhanced Digital Mammography (DE CEDM) on patients with newly diagnosed breast cancer using a dedicated research system, derived from a standard digital mammography unit and review workstation (Senographe DS and SenoAdvantage) modified to deliver the required dual energy paired exposures and visualization of combined images.
3215816|NCT01086488|Experimental|Nasopharyngeal Carcinoma|A: Experimental B: Active Comparator
3215817|NCT01086475|Experimental|D-cycloserine|Subjects randomized to D-cycloserine will be administered 50 mg 30 minutes prior to each of ten Social Skills Training Sessions
3215818|NCT01086475|Placebo Comparator|Placebo|Subjects randomized to placebo arm will receive placebo pill 30 minutes prior to each of ten Social Skills Training Sessions
3215819|NCT01086462|Experimental|GSK2239633|Single dose infusion of study drug over 15 minutes
3215820|NCT01086449|Experimental|Group A|
3215821|NCT01086436|Experimental|Rotavirus Group|Subjects will receive Rotarix™
3215822|NCT01086436|Placebo Comparator|Placebo Group|Subjects will receive placebo.
3215823|NCT01086423|Experimental|INFANRIX-IPV+HIB 1 GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.
3215824|NCT01086423|Experimental|INFANRIX-IPV+HIB 2 GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.
3215825|NCT01086423|Active Comparator|INFANRIX-HIB+POLIORIX GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.
3215826|NCT01086410|Active Comparator|FF/444 Dose B|Fluticasone furoate/GW642444 Dose B inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
3215827|NCT01086410|Active Comparator|FF/444 Dose A|Fluticasone furoate/GW642444 Dose A inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
3215828|NCT01086410|Placebo Comparator|Placebo|Placebo inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
3215829|NCT01086410|Active Comparator|Prednisolone|Placebo inhalation powder once daily for 6 weeks' treatment + 1 oral prednisolone 10mg capsule each day on the last 7 days of the study
3215830|NCT01086397||1|
3215831|NCT01086384|Experimental|Fluticasone furoate/GW642444|
3215832|NCT01086384|Experimental|fluticasone furoate|
3215833|NCT01086371|Experimental|RAS walking|Subjects will walk while listening to music 20 minutes per day every day during the study period.
3215834|NCT01086371|Active Comparator|RAS no walking|Subjects will be listening to music but not performing walking exercise, for 20 minutes per day every day during the study period.
3215835|NCT01086371|Active Comparator|Walking no RAS|Subjects will be walking without listening to music for 20 minutes per day every day during the study period
3215836|NCT01086358|Active Comparator|Triptan|Arm 1 subjects began with their prescribed triptan
3215837|NCT01086358|Active Comparator|Treximet 85Mg-500Mg Tablet|Arm 2 subjects began with Treximet (sumatriptan 85 mg/naproxen sodium 500 mg)
3215838|NCT01086345|Experimental|Arm I|Patients receive bevacizumab IV over 30 minutes on days 1 and 15. Patients also receive irinotecan hydrochloride IV on days 1 and 15 beginning in course 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
3215935|NCT01085721|Active Comparator|Dexchlorpheniramine|
3215936|NCT01085708|Experimental|1|
3215937|NCT01085708|Experimental|2|
3215839|NCT01086332|Experimental|phase 1/2|An escalating study of gemcitabine when combined with 1250 mg of nelfinavir twice daily. Dose of gemcitabine is increased for new subjects based on the experiences and tolerance of prior subjects. When the maximum tolerated dose is identified, a recommended phase 2 dose will be assigned and further subjects will receive that dose.
3215840|NCT01086319||Patients exposed to saxagliptin|
3215841|NCT01086319||Patients exposed to oral antidiabetic drugs (not saxagliptin)|
3215842|NCT01086306||Patients exposed to Saxagliptin|
3215843|NCT01086306||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
3215844|NCT01086293||Patients exposed to Saxagliptin|
3215845|NCT01086293||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
3215846|NCT01086280||Patients exposed to Saxagliptin|
3215847|NCT01086280||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
3215848|NCT01086267|Experimental|BMS-908662 (A1)|Phase 1
3215849|NCT01086267|Experimental|Cetuximab (A1)|Phase 1
3215850|NCT01086267|Experimental|BMS-908662 (B1)|Phase 2
3215851|NCT01086267|Experimental|BMS-908662 + Cetuximab (B2)|Phase 2
3215852|NCT01086254|Experimental|Iniparib/ Gemcitabine/ Cisplatin|"Iniparib, 5.6 mg/kg, 60-min IV infusion twice weekly (days 1, 4, 8, and 11). Infusion starts after completion of GC regimen administration.~Gemcitabine, 1250 mg/m2, 30-min IV infusion on day 1 and day 8 and cisplatin 75mg/m², 3- to 4-hour IV infusion on day 1 of each 3-week cycle after the end of gemcitabine infusion."
3215853|NCT01086254|Active Comparator|Gemcitabine/ Cisplatin|Gemcitabine, 1250 mg/m2, 30-min IV infusion on day 1 and day 8 and cisplatin 75mg/m², 3- to 4-hour IV infusion on day 1 of each 3-week cycle after the end of gemcitabine infusion.
3215854|NCT01086241|Active Comparator|A: routine 2D mammogram|Subject receives regular 2D mammogram.
3215855|NCT01086241|Active Comparator|B: Routine Mammogram + tomosynthesis|Routine Mammogram and tomosynthesis
3215856|NCT01086228||XIENCE V / PROMUS stent|Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
3215857|NCT01086215||Limb Ischemia|Patients presenting with limb ischemia for treatment
3215858|NCT01086215||Deep Vein Thrombosis|Patients presenting with deep vein thrombosis for treatment
3215859|NCT01086215||Hemodialysis Access|Patients presenting with thrombosed hemodialysis access for treatment
3215860|NCT01086215||Other Thrombotic Conditions|Patients presenting with a thrombotic condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment
3215861|NCT01086202||Tornier Reversed Shoulder Arthroplasty Medial Offset|
3215862|NCT01086202||Lateral offset arthroplasty|
3215863|NCT01086176||Patient-control|
3215864|NCT01086163||Omacor dose titration|"Stable documented coronary artery disease proven by angiography treated with statin and aspirin. In order to achieve homogeneity within this population, the following additional inclusion criteria will apply:~survived first-time AMI more than 12 months ago~stable medical treatment during the last 3 months (except removal of Plavix)~Ethnicity: Caucasians~Males, 50 - 60 yrs~non-diabetics~excluded are those who eat more than one meal of fish / week~excluded are those who take omega-3 supplements of any sorts"
3215865|NCT01086150|Other|Healthy control patients|Subjects 18 to 70 years of age, non-diabetic with no nervous system disease
3215866|NCT01086150|Other|Type I or Type II diabetes with painful diabetic neuropathy|18 to 70 years old with significantly painful diabetic neuropathy
3215867|NCT01086150|Other|Subjects with Type I or Type II diabetes|18 to 70 years of age with Type I or Type II diabetes with significantly painful diabetic neuropathy.
3215868|NCT01086124||Echocardiography 1 month|Patients will all have an echocardiography 1 month post myocardial infarction and 3 months post myocardial infarction
3215869|NCT01086111||PMSF|type 2 diabetes patient receiving a protein sparing diet
3215870|NCT01086111||sleeve gastrectomy|type 2 diabetes patient receiving a gastric bypass
3215871|NCT01086111||RYGBP|type 2 diabetes patient receiving a gastric bypass
3215872|NCT01086098||All paced patients|
3215873|NCT01086085|Experimental|A|
3215874|NCT01086085|Experimental|B|
3215875|NCT01086085|Experimental|C|
3215876|NCT01086085|Experimental|D|
3215877|NCT01086072||Myocardial Infarction - STEMI|
3215878|NCT01086072||Myocardial Infarction - NSTEMI|
3215879|NCT01086059||Cohort 1 - Exposure cohort|Pregnant women with a current diagnosis of RA, JRA, or Crohn's disease who have used adalimumab in the first trimester of pregnancy for any length of time from the date of conception.
3215880|NCT01086059||Cohort 2 - Matched Diseased Comparison Cohort|Pregnant women with a current diagnosis of RA, JRA, or Crohn's disease who have not used adalimumab or any TNF antagonist in pregnancy.
3215881|NCT01086059||Cohort 3-Non-Diseased Comparison Cohort|Pregnant women without a current diagnosis of an autoimmune disease and who have not used adalimumab or any TNF antagonist at any time in pregnancy nor have they been exposed to any known human teratogen during pregnancy.
3215882|NCT01086059||Cohort 4 - Registry Group|Pregnant women who have used adalimumab for any length of time following the first day of the last menstrual period until the end of pregnancy who do not meet Cohort 1 inclusionary criteria.
3215883|NCT01086046|Active Comparator|Heparin|Heparin injection 10 IU/kg/hr within 24h
3215884|NCT01086046|Experimental|Low molecular weight heparin|"Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days"
3215885|NCT01086033||Humira|Participants with rheumatoid arthritis treated with Humira (adalimumab) as prescribed by the rheumatologist in the setting of routine clinical care.
3215886|NCT01086020|Active Comparator|atorvastatin|patients will be treated with atorvastatin 10mg/d after randomization, and continued for two years
3215887|NCT01086020|Experimental|atorvastatin and ezetimibe|patients will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d after randomization, and continued for two years
3215888|NCT01086007||Pain patients|Patients with pain related sexual dysfunction after laparoscopic inguinal hernia repair
3215889|NCT01086007||Non-pain patients|Patients with no pain related sexual dysfunction after laparoscopic inguinal hernia repair
3215890|NCT01085994||Procalcitonin-guided group|
3215891|NCT01085994||Routine practice group|
3215938|NCT01085708|Experimental|3|
3215892|NCT01085981|Active Comparator|GRAS ingredients cream|"The study will be placebo controlled double blind study which will require two office visits after informed consent and sensitivity testing done with the study cream on the day of recruitment.~On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit Then placebo or active cream will be applied and the pt restudied. the same process is repeated another day with the second arm cream."
3215893|NCT01085981|Placebo Comparator|placebo cream then doppler study|
3215894|NCT01085968|Experimental|PD Subjects|PD subjects who undergo to PC-based neurorehabilitation intervention. This intervention will train research subjects to improve movement initiation in response to visual stimuli.
3215895|NCT01085968|Active Comparator|Control Subjects|Age matched controls who undergo to PC-based neurorehabilitation intervention. This intervention will train research subjects to improve movement initiation in response to visual stimuli.
3215896|NCT01085955||Acute Peripartum|pregnant women who have recently given birth and diagnosed with peripartum cardiomyopathy
3215897|NCT01085955||Healthy Peripartum|Healthy pregnant women who have recently given birth, used as controls
3215898|NCT01085955||Healthy, non-pregnant women|Healthy non-pregnant women without cardiac disease, used as controls
3215899|NCT01085955||New Non-ischemic CMP|Women 18-60 years old who have been diagnosed with non-ishemic cardiomyopathy within the last 6 months and have an ejection fraction less than OR equal to 45% by echocardiogram.
3215900|NCT01085942||Asymptomatic rotator cuff tear|Subjects identified with an asymptomatic rotator cuff tear
3215901|NCT01085929|Active Comparator|Incision and Drainage|Abscess underwent incision and drainage
3215902|NCT01085929|Active Comparator|Ultrasound guided needle aspiration|Ultrasound was used to identify the abscess location. A needle was introduced into the abscess cavity and aspiration of the contents were attempted.
3215903|NCT01085903|Active Comparator|normal subjects|Normal subjects are persons without stroke who receive baseline, CPS, Post CPS and Follow up interventions.
3215904|NCT01085903|Active Comparator|stroke subjects|Stroke subjects are persons who have had a stroke affecting the right hemisphere and are subject to neglect or dysphagia who receive modafinil, placebo, baseline, CPS, Post CPS and Follow up interventions.
3215905|NCT01085890|Experimental|Motivational interviewing group|The participants in this arm had 2 group seminars with information on hypertension and related lifestyle factors. They participated in 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
3215906|NCT01085890|No Intervention|Treatment as usual|Participants in this group received treatment as usual for their high blood pressure, but no informational seminars and no extra visits with motivational interviewing and blood pressure measurement.
3215907|NCT01085877|Active Comparator|Trial part 1|
3215908|NCT01085877|Experimental|Trial part 2|
3215909|NCT01085864||Patients with lung nodules on CT scan.|Patients with lung nodules on CT scan.
3215910|NCT01085851|Experimental|Dexchlorpheniramine 1% lotion|
3215911|NCT01085851|Active Comparator|Dexchlorpheniramine 1% cream|
3215912|NCT01085838|Experimental|Cohort 1|The first cohort of 5 patients will start with a dosage of 100 mg erlotinib daily
3215913|NCT01085838|Experimental|Cohort 2|The second cohort of patients will receive 150 mg of erlotinib daily
3215914|NCT01085838|Experimental|Cohort 3|The third cohort of five patients will be enrolled to receive 300 mg of erlotinib daily
3215915|NCT01085825|Active Comparator|Manual Vacuum Aspiration|
3215916|NCT01085825|Active Comparator|Electric Vacuum Aspiration|
3215917|NCT01085812|Experimental|2|40, 80 or 120 mg/day F2695 SR capsules, oral administration, once daily dosing.
3215918|NCT01085812|Placebo Comparator|1|Matching placebo capsules, oral administration, once daily dosing.
3215919|NCT01085799|Experimental|Health Education Intervention|Groups of schools receiving the health education intervention
3215920|NCT01085799|No Intervention|Control Schools - Regular curriculum|Groups of schools not receiving the health education intervention
3215921|NCT01085786|Active Comparator|14-day sequential treatment|One in which the first component consists of a proton pump inhibitor and amoxicillin given for 7 days followed by the PPI, clarithromycin and metronidazole for 7 days.
3215922|NCT01085786|Experimental|14-day hybrid treatment|esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
3215923|NCT01085773|No Intervention|Standard written information on exercise|The Control group got the diabetes outpatients clinics standard written information on exercise as a part of the treatment for Type 2 Diabetes and were, like other Type 2 Diabetes patients in the clinic, advised at inclusion to be physically active.
3215924|NCT01085773|Experimental|Exercise on Prescription|In Denmark, Exercise on Prescription have focused on individual behavioral change and an exercise program for 16 weeks. The physical training consisted of both aerobic and strength training and took place in supervised groups
3215925|NCT01085773|Experimental|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
3215926|NCT01085760|Experimental|Vancomycin 125 mg orally 4 times a day|The patients will be randomized into four groups of ten patients: one group will receive low dose vancomycin, one group will receive high dose vancomycin, one group will receive low dose metronidazole and one group will receive high dose metronidazole.
3215927|NCT01085760|Experimental|Vancomycin 250 mg orally 4 times a day|
3215928|NCT01085760|Experimental|Metronidazole 250 mg orally 3 times a day|
3215929|NCT01085760|Experimental|Metronidazole 500 mg orally 3 times a day|
3215930|NCT01085747||Plastic stent|
3215931|NCT01085747||Covered SEMS|
3215932|NCT01085734|Active Comparator|Group 1|Group 1 receives Avastin at baseline followed by sham Osurdex at week 1. Additional Avastin based on macular edema
3215933|NCT01085734|Active Comparator|Group 2|Group 2 receives Avastin at baseline followed by Osurdex at week 1. Retreatment with Avastin based on macular edema
3215939|NCT01085708|Active Comparator|4|
3215945|NCT01085682|Active Comparator|Standard care|
3215946|NCT01085669||VEPTR patients|Children treated with VEPTR Implants for severe spinal or thoracic deformities
3215947|NCT01085656|Experimental|OXi4503|Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.
3215948|NCT01085643|Active Comparator|Lubiprostone|Same patients are included in both the Lubiprostone arm and the Placebo arm. The reason why the same patients are assigned to two arms is because an effect comparison is done after taking the placebo and later after taking the lubiprostone.
3215949|NCT01085643|Placebo Comparator|Placebo|Same patients are included in both the Lubiprostone arm and the Placebo arm. The reason why the same patients are assigned to two arms is because an effect comparison is done after taking the placebo and later after taking the lubiprostone.
3215950|NCT01085630|Experimental|Arm I|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3215951|NCT01085630|Active Comparator|Arm II|Patients undergo observation until disease progression.
3215952|NCT01085604||Low back pain|Individuals with current low back pain attributed to poor trunk neuromuscular control (clinical instability).
3215953|NCT01085591|Experimental|CB-183,315, 125 mg|125 milligrams (mg) CB 183,315 administered orally twice daily, alternating with twice daily oral administration of placebo tablets, for 10 days.
3215954|NCT01085591|Experimental|CB-183,315, 250 mg|250 mg CB 183,315 administered orally twice daily, alternating with twice daily oral administration of placebo tablets, for 10 days.
3215955|NCT01085591|Active Comparator|Vancomycin, 125 mg|125 mg vancomycin administered orally four times a day for 10 days.
3215956|NCT01085578|Placebo Comparator|Cohort1|CG400549/placebo
3215957|NCT01085578|Placebo Comparator|Cohort2|CG400549/placebo
3215958|NCT01085578|Other|Cohort3|CG400549
3215959|NCT01085565|Experimental|Exablate treatment|
3215960|NCT01085552|Other|1|Group A consists of 11 Caucasian male subjects Group B consists of 12 Japanese male subjects
3215961|NCT01085526|Active Comparator|alutard phl prat. treatment group|18 subjects receiving active treatment: basophil activity, plasma cells and immunoglobulins measured
3215962|NCT01085526|No Intervention|control group|control
3215963|NCT01085526|Active Comparator|alutard phl.prat., treatment group2|basophil activity, basophil biology measured
3215964|NCT01085513|Active Comparator|Patients|Patients previously indicated for manometry
3215965|NCT01085513|Active Comparator|Healthy volunteers|Healthy volunteers
3215966|NCT01085500|Experimental|Simulation Curriculum|General surgery residents will undergo a simulation-based educational curriculum (Mastery Learning TEP Curriculum) on TEP hernia repair
3215967|NCT01085500|Other|Current Practice|General surgery residents will undergo current practice of learning how to perform the TEP repair in the operating room under direct supervision of the staff surgeon without any simulation pre-training.
3215968|NCT01085487||Group 1|
3215969|NCT01085487||Group 2|
3215970|NCT01085487||Group 3|
3215971|NCT01085474||1|1. Pilot Study: 60 patients (all in the intervention group) 30 patients with intervention A and 30 patients with B intervention)
3215972|NCT01085474||2|Main Study: 600 patients (30 pharmacies control group and 30 pharmacies intervention group, 10 patients per pharmacy)
3215973|NCT01085448|Other|Low back pain|Individuals with current low back pain.
3215974|NCT01085435||S-ICD System Commercial Patients|Patients implanted with a CE marked S-ICD System, not participating in Cameron Health's Investigational Device Exemption (IDE) Clinical Study.
3215975|NCT01085422|Experimental|Arm A|
3215976|NCT01085409||Tinnitus|Patients with tinnitus
3215977|NCT01085409||Artery disease|Subjects with mobility constraints as a results of severe artery disease which in some cases led to leg amputation.
3215978|NCT01085409||Anxiety|Subjects with anxiety complaints
3215979|NCT01085409||Controls|Healthy controls
3215980|NCT01085370|No Intervention|Control Group|standard medical care only
3215981|NCT01085370|Experimental|Intervention group|2 sessions with early psychological interventions
3215982|NCT01085357|Experimental|CyPass Micro-Stent + Cataract Surgery|Subjects receive the CyPass Micro-Stent at the conclusion of their cataract surgery
3215983|NCT01085357|Active Comparator|Cataract Surgery Only|Subjects do not receive the CyPass Micro-Stent at the conclusion of their cataract surgery
3215984|NCT01085344|Experimental|Factor VIII|escalating dose Factor VIII
3215985|NCT01085331|Experimental|Part 1 or Safety Run-in Part: Pimasertib+FOLFIRI|
3215986|NCT01085331|Experimental|Part 2 or Phase 2 Randomized part: Pimasertib+FOLFIRI|Planned, not performed
3215987|NCT01085331|Experimental|Part 2 or Phase 2 Randomized part: Placebo+FOLFIRI|Planned, not performed
3215988|NCT01085318|Active Comparator|Arm 1 MS Patients|Rebif 44 tiw
3215989|NCT01085318|No Intervention|Arm 2 Healthy Control|
3215990|NCT01085305|Experimental|PCIT|Provision of Parent-Child Interaction Therapy
3215991|NCT01085305|Active Comparator|TAU|Treatment as usual from other therapists in the same clinics
3215992|NCT01085292|Experimental|Group A|
3215993|NCT01085292|Experimental|Group B - D|
3215994|NCT01085279|Experimental|Non-ablative fractional laser|"In each patient, one side of the face was treated with non-ablative fractional laser in four-five sessions.~Note: this study had a split-face design. In each patient, each side of the face was randomized to receive either non-ablative fractional laser therapy or triple topical therapy."
3215995|NCT01085279|Active Comparator|Triple topical therapy|"In each patient, one side of the face was treated with triple topical therapy (Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1%) during 15 weeks.~Note: this study had a split-face design. In each patient, each side of the face was randomized to receive either non-ablative fractional laser therapy or triple topical therapy."
3215996|NCT01085266|Experimental|Dimebon (latrepirdine)|Patients receive dimebon 10mg orally 3 times per day for 1 week and 20 mg orally 3 times per day thereafter.
3215997|NCT01085253||Parkinson|"without gait impairment~with gait and/or balance impairment~with sleep disorders (RBD)~abnormalities of the brainstem and basal ganglia will be studied in relation with parkinsonism, gait and presence of RBD"
3216101|NCT01084564||1|moderate to severe uncontrolled asthma
3215998|NCT01085253||PSP|supranuclear palsy patients study the abnormalities with the brainstem and basal ganglia and relation with the observed neurological signs (eye movements, balance, neuropsychological assessment and parkinsonism)
3215999|NCT01085253||controls|age matched controls
3216000|NCT01085240|Other|Start Later|The participants receive the Mission Possible intervention but it is delayed by 3 months.
3216001|NCT01085240|Experimental|Start Now|The participants start the Mission Possible program right away.
3216002|NCT01085227||Patients carrier of a LRRK2 mutation|
3216003|NCT01085227||Asymptomatic relatives of LRRK2 patients|
3216004|NCT01085214|Experimental|AZD6244 (Selumetinib) Treatment|Participants receive AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3216005|NCT01085201|Experimental|Stage 1|12-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
3216006|NCT01085201|Experimental|Stage 2|24-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
3216007|NCT01085201|Experimental|Stage 3|24-hour infusion to adults with SCD who are having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
3216008|NCT01085201|Experimental|Stage 4|24-hour infusion to children with SCD who are having a pain crisis. THIS STAGE IS COMPLETE AFTER STUDYING 3 PATIENTS BY AGREEMENT FROM THE FDA, IRB, AND DSMB. THIS STAGE IS CLOSED TO ACCRUAL.
3216009|NCT01085201|Experimental|Stage 2B|48-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AFTER STUDYING 3 PATIENTS BY AGREEMENT FROM THE FDA, IRB, AND DSMB. THIS STAGE IS CLOSED TO ACCRUAL.
3216010|NCT01085188|Experimental|Assertive Continuing Care (ACC)|Behavioral intervention comprised of the community reinforcement approach plus case management delivered in home and other community settings to youth and their caregivers.
3216011|NCT01085188|Experimental|Contingency Management (CM)|Using a prize drawing system (no, low, medium and large value prizes) with adolescents could earn escalating prize drawing opportunities by completing verifiable pro-social activities and providing negative urine test and breath alcohol test results.
3216012|NCT01085188|Experimental|ACC + CM|This arm is the combination of arms 1 and 2.
3216013|NCT01085188|Active Comparator|Usual Continuing Care (UCC)|UCC consists of a discharge recommendation to seek aftercare services at nearest treatment provider to where the patient lived. This service primarily consisted of outpatient group counseling.
3216014|NCT01085175|Experimental|Cohort 1|Low risk Heart Failure patients
3216015|NCT01085175|Experimental|Cohort 2|High risk Heart Failure patients with history of Implantable Cardioverter-Defibrillator firing
3216016|NCT01085149|Experimental|study group|simvastatin will be inserted to sockets
3216017|NCT01085149|No Intervention|control|sockets will be left to healing without material in socket
3216018|NCT01085136|Active Comparator|Investigator`s choice of chemotherapy|Patients will be treated with investigator`s choice of chemotherapy
3216019|NCT01085136|Experimental|BIBW 2992 and Paclitaxel|Patients will be treated with BIBW 2992daily with a medium dose and weekly administration of Paclitaxel at a dose of 80 mg/m2
3216020|NCT01085123|Experimental|1|PET 1: baseline, PET 2: 10 mg Zomig® Rapimelt, PET 3: 5 mg ZOMIG® Rapimelt, PET 4 2.5 mg ZOMIG® Rapimelt
3216021|NCT01085110||Persistent Pain patients|Patients with persistent postherniotomy pain after laparoscopic operation and pain related impaired daily function
3216022|NCT01085097|Experimental|laquinimod 0.5 mg + prednisolone/prednisone|laquinimod 0.5 mg + Mycophenolate Mofetil (MMF) + prednisolone/prednisone
3216023|NCT01085097|Experimental|laquinimod 1 mg + prednisolone/prednisone|laquinimod 1 mg + Mycophenolate Mofetil (MMF) + prednisolone/prednisone
3216024|NCT01085097|Placebo Comparator|placebo + prednisolone/prednisone|Mycophenolate Mofetil (MMF) + prednisolone/prednisone+ placebo
3216025|NCT01085084|Experimental|Laquinimod 0.5 mg arm|laquinimod 0.5 mg + placebo
3216026|NCT01085084|Experimental|Laquinimod 1 mg|laquinimod 1 mg
3216027|NCT01085084|Placebo Comparator|Placebo|placebo
3216028|NCT01085071|Active Comparator|Normal-high potassium (NHP)|A potassium target of 4.5 mmol/L.
3216029|NCT01085071|Active Comparator|Normal-low potassium (NLP)|A potassium target of 4.0 mmol/L.
3216030|NCT01085058|Experimental|A: lenograstim|total group
3216031|NCT01085045|Experimental|Inhaled PT003 (Dose 1)|PT003 MDI Dose 1
3216032|NCT01085045|Experimental|Inhaled PT003 (Dose 2)|PT003 MDI Dose 2
3216033|NCT01085045|Experimental|Inhaled PT005 (Dose 1)|PT005 MDI Dose 1
3216034|NCT01085045|Experimental|Inhaled PT005 (Dose 2)|PT005 MDI Dose 2
3216035|NCT01085045|Placebo Comparator|Inhaled Placebo|Placebo MDI
3216036|NCT01085045|Active Comparator|Tiotropium bromide 18 μg (Spiriva Handihaler®)|Tiotropium Bromide inhalation powder
3216037|NCT01085045|Active Comparator|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 12 μg
3216038|NCT01085045|Experimental|Inhaled PT001 (Dose 1)|PT001 MDI Dose 1
3216039|NCT01085032|Experimental|Arm A|Behavioral Counseling and Nicotine Patch
3216040|NCT01085032|Placebo Comparator|Arm B|Behavioral counseling and placebo patch
3216041|NCT01085019|Experimental|Dietary supplement: Cinnamon|
3216042|NCT01085019|Experimental|Dietary supplement: Oregano|
3216043|NCT01085019|Experimental|Dietary supplement: Ginger|
3216044|NCT01085019|Experimental|Dietary supplement: Rosemary|
3216045|NCT01085019|Experimental|Dietary supplement: Black pepper|
3216046|NCT01085019|Placebo Comparator|Dietary supplement: Placebo|
3216047|NCT01085006|Experimental|Tranexamic acid|
3216048|NCT01085006|Placebo Comparator|normal saline infusion|
3216049|NCT01084993|Active Comparator|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
3216050|NCT01084993|Active Comparator|Heparin|70 U/kg or standard practice
3216051|NCT01084980|Experimental|Tacrolimus|
3216052|NCT01084967||Healthy lean control group|BMI:18.5-22.9kg/m2. Age:14-30 years old. To be proved normal by the examinations of liver and kidney function,blood lipids profile,fasting and postprandial plasma glucose, fasting insulin and HbA1c.
3216053|NCT01084967||obesity group with BMI ≥30|obesity group 1500, lean healthy control group 1500
3216054|NCT01084941|Experimental|Lifestyle intervention|Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
3216055|NCT01084941|Active Comparator|Standard of care group|Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
3216056|NCT01084928|Experimental|Intervention Arm (Diet and Exercise)|The lifestyle intervention will include a 16-week intervention period, followed by an 8 week, less intensive maintenance period.
3216057|NCT01084915||SAGB VC group|Retrospectively patients with a SAGB-VC gastric band are inventorized. They will also be interviewed and BAROS scores will be taken.
3216058|NCT01084902|Experimental|latnoprost|once daily
3216059|NCT01084902|Active Comparator|Brinzolamide|two times daily
3216060|NCT01084889||symptomatic genital descensus|"Women with a symptomatic genital descensus : at least stage II (ICS-classification according pelvic organ prolapse quanification (POP-Q) system), or stage I with a symptomatic requiring intervention.~Standard method to implant the TiLOOP® Total 6 surgical mesh transvaginally."
3216061|NCT01084876|Active Comparator|CT-P6 & Paclitaxel|CT-P6 + Paclitaxel
3216062|NCT01084876|Active Comparator|Herceptin & Paclitaxel|Trastuzumab + Paclitaxel
3216063|NCT01084863|Active Comparator|CT-P6 & Paclitaxel|CT-P6 + Paclitaxel
3216064|NCT01084863|Active Comparator|Herceptin & Paclitaxel|Trastuzumab + Paclitaxel
3216065|NCT01084850||Diabetes Type II|Patients with type 2 Diabetes Mellitus
3216066|NCT01084850||Control|Patients with no diabetes
3216067|NCT01084824|Active Comparator|Liquid nitrogen and canthardin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterwards.
3216068|NCT01084824|Placebo Comparator|Liquid nitrogen and placebo|Liquid nitrogen applied to wart(s) then placebo vehicle afterwards.
3216069|NCT01084811||chronic rhinosinusitis with nasal polyps|
3216070|NCT01084811||chronic rhinosinusitis without nasal polyps|
3216071|NCT01084811||Control group|
3216072|NCT01084772|Other|VISIONAIRE Instrumentation|TKA with VISIONAIRE instrumentation
3216073|NCT01084772|Other|Standard Instrumentation|TKA with standard instrumentation
3216074|NCT01084759|Experimental|Etoposide and Testosterone|Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy).On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days.
3216075|NCT01084746|Active Comparator|PC-based tailored intervention|
3216076|NCT01084746|Active Comparator|Printed educational materials|
3216077|NCT01084746|No Intervention|No patient intervention|Patients will not receive a patient-directed intervention.
3216078|NCT01084707|Experimental|Oral Nicotine 24-SA|2 Self-administrations of Experimental Nicotine once every hour
3216079|NCT01084707|Experimental|Oral Nicotine 24|2 administrations of Experimental Nicotine by study personnel once every hour
3216080|NCT01084707|Experimental|Oral Nicotine 48|2 administrations of Experimental Nicotine by study personnel once every 30 minutes
3216081|NCT01084707|Active Comparator|NiQuitin™ Lozenge 4 mg|1 NiQuitin™ lozenge, administered by study personnel once every hour
3216082|NCT01084707|Active Comparator|Nicorette® Gum 4 mg|1 piece Nicorette® gum, chewed for 30 minutes once every hour
3216083|NCT01084681|Active Comparator|SILK Artery Reconstruction Device|One arm will receive only the commercially available SILK Artery Reconstruction Device [flow diverter] (no intracranial coils are to be used in association with the SILK device).
3216084|NCT01084681|Active Comparator|Coils|The other arm will be treated with commercially available intracranial coils: the coils can be used with eventual balloon remodeling and/or stents when necessary.
3216085|NCT01084668||Adalimumab|Participants with moderate to severe chronic plaque psoriasis treated with adalimumab after biologic disease modifying anti-rheumatic drug (BDMARD) failure
3216086|NCT01084655|Experimental|TAK-700 with docetaxel and prednisone|
3216087|NCT01084642||survey|Participants will be asked to complete a survey as a one time assessment.
3216088|NCT01084629||Surveillance Barrett's esophagus|Patients scheduled for endoscopic surveillance of Barrett's esophagus
3216089|NCT01084629||Barrett's esophagus post ablation|Patients scheduled for surveillance endoscopy who have undergone ablative therapies (PDT, RF ablation) for their Barrett's esophagus
3216090|NCT01084616||Vaginal Dryness|
3216091|NCT01084616||Non-vaginal dryness|
3216092|NCT01084603|Experimental|Oral Nicotine 1|One oral administration of 1 mg nicotine
3216093|NCT01084603|Experimental|Oral Nicotine 2|Two oral administrations of 1 mg nicotine
3216094|NCT01084603|Experimental|Oral Nicotine 4|Four oral administrations of 1 mg nicotine
3216095|NCT01084603|Active Comparator|NiQuitinTM Nicotine Lozenge 4 mg|One 4 mg marketed nicotine lozenge
3216096|NCT01084603|Active Comparator|Nicorette® Gum 4 mg|One marketed Nicorette® nicotine gum 4 mg chewed for 30 minutes
3216097|NCT01084590|Experimental|Healthy Eating/Physical Activity|This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
3216098|NCT01084590|Active Comparator|Safety/Injury Prevention|This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
3216099|NCT01084577|Active Comparator|Urgotul® Silver|Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
3216100|NCT01084577|Active Comparator|AQUACEL® Ag|AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
3216102|NCT01084551|Experimental|SPM 962 4.5|started at 2.25 mg/day to 4.5 mg/day for 13 weeks
3216103|NCT01084551|Experimental|SPM 962 6.75|started at 2.25 mg/day to 6.75 mg/day for 13 weeks
3216104|NCT01084551|Placebo Comparator|placebo|for 13 weeks
3216105|NCT01084538||End stage chronic kidney disease|Secondary hyperparathyroidism defined as intact PTH > 300 pg/mL
3216106|NCT01084525|Experimental|OTO-104 (steroid) 3 mg|
3216107|NCT01084525|Placebo Comparator|Placebo|
3216108|NCT01084525|Experimental|OTO-104 (steroid) 12 mg|The start of 12 mg dose cohort is contingent on safety data from 3 mg dose cohort.
3216109|NCT01084512||Healthy group|control subjects
3216110|NCT01084512||Paraplegic group|Paraplegic subjects
3216111|NCT01084512||Tetraplegic group|tetraplegic subjects
3216112|NCT01084499|Experimental|RT Group|"1st period: Reference drug~2nd period: Test drug"
3216113|NCT01084499|Experimental|TR Group|"1st period: Test drug~2nd period: Reference drug"
3216114|NCT01084486|Experimental|Metformin, Adiponectine, Arterial Compliance|
3216115|NCT01084473|Experimental|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
3216116|NCT01084473|Active Comparator|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
3216117|NCT01084473|Placebo Comparator|Placebo|The study subjects will be given a saline infusion.
3216118|NCT01084460||EUS-suspected gastric GISTs|In this retrospective study, 50 patients with EUS-suspected gastric GISTs, less than 3 cm were enrolled and had EUS follow-up at least two times over a period of more than 24 months.
3216119|NCT01084447|Placebo Comparator|control group|In placebo muscular training group the respiratory exercise was used a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA) no load.
3216120|NCT01084447|Active Comparator|trained group|In trained group the respiratory exercise used a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)the load was initially set at 40% of the maximal inspiratory pressure.
3216121|NCT01084434|Experimental|Probiotic group|Group of 25 volunteers consuming probiotic product once a day for 7 weeks
3216122|NCT01084434|Experimental|Prebiotic group|Group of 25 volunteers consuming prebiotic product once a day for 7 weeks
3216123|NCT01084434|Experimental|Synbiotic group|Group of 25 volunteers consuming synbiotic product once a day for 7 weeks.
3216124|NCT01084434|Placebo Comparator|Placebo group|Group of 25 volunteers consuming placebo product once a day for 7 weeks
3216125|NCT01084421|Experimental|Computer based intervention|Participants receive content about adolescent sexual risk and HIV prevention, strategies to support sexual specific communication and parent-adolescent communication in general.
3216126|NCT01084421|No Intervention|Wait list control group|Participants will receive the computer based intervention at 3 months follow-up
3216127|NCT01084408|Active Comparator|Sequent®Please|
3216128|NCT01084408|Active Comparator|Taxus™Liberté™|
3216129|NCT01084395|Experimental|Adolescent Safer Sex Intervention|
3216130|NCT01084395|Experimental|Parent Safer Sex Intervention|
3216131|NCT01084395|Other|Adolescent Health Promotion Control|
3216132|NCT01084395|Other|Parent Health Promotion Control|
3216133|NCT01084382|Active Comparator|Arthrospira platensis supplement|
3216134|NCT01084382|Placebo Comparator|Protein/Dextran supplemented|
3216135|NCT01084369|Experimental|Testosterone, Vardenafil|All patients will receive Testosterone (n=40) of these (10 patients) will also receive Vardenafil
3216136|NCT01084356||hand|patients admitted for Tc MDP for evaluation of carpal/metacarpal and finger bone lesions
3216137|NCT01084356||thyroid|patients admitted for Tc thyroid scan
3216138|NCT01084356||parathyroid|patients investigated for parathyroid adenoma
3216139|NCT01084356||sentinel node|patients who are due to sentinel node biopsy
3216140|NCT01084343|Active Comparator|Panel 1|Subjects in this panel receive the low dose of vaccine (10 microgram of peptides). Twelve subjects are included in this panel, 8 of them receive the active vaccine and 4 receive the carrier only (placebo).
3216141|NCT01084343|Active Comparator|Panel 2|Subjects in this panel receive the high dose of vaccine (50 microgram of peptides). Twelve subjects are included in this panel, 8 of them receive the active vaccine and 4 receive the carrier only (placebo).
3216142|NCT01084330|Experimental|AUY922|
3216143|NCT01084330|Active Comparator|Docetaxel or Irinotecan|
3216144|NCT01084317||asthmatic children|patients under 18 age, with newly diagnosed asthma
3216145|NCT01084304||Active|Use of ovulation tests to aid conception
3216146|NCT01084304||Control|No ovulation tests to aid conception
3216147|NCT01084291|Experimental|DEN1 Vaccine|Participants will receive a single dose of investigational vaccine for dengue virus subtype 1.
3216148|NCT01084291|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine.
3216149|NCT01084278|Experimental|Healthy|Healthy participants with normal renal function (Creatinine Clearance [CrCl] ≥90 mL/min) received one colchicine 0.6 mg tablet on study day 1.
3216150|NCT01084278|Experimental|Mild renal impairment|Participants with mild renal impairment (estimated Glomerular Filtration Rate [eGFR] 60 to 89 mL/min) received one colchicine 0.6 mg tablet on study day 1.
3216151|NCT01084278|Experimental|Moderate renal impairment|Participants with moderate renal impairment (CrCl/eGFR 30 to 59 mL/min) received one colchicine 0.6 mg tablet on study day 1.
3216152|NCT01084278|Experimental|Severe renal impairment|Participants with severe renal impairment (eGFR 15 to 29 mL/min) received one colchicine 0.6 mg tablet on study day 1.
3216153|NCT01084278|Experimental|End stage renal disease (ESRD)|Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on study day 1 immediately following dialysis. After a 14-day washout, participants received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.
3216154|NCT01084252|Experimental|ISA Arm|"Phase 1: Accelerated dose escalation phase (1 patient/cohort), two administrations every two weeks (Q2W) per dose cohort. Followed by basic dose escalation phase evaluating Isatuximab administration weekly (QW) and Q2W with 3-6 patients/cohort treated until disease progression or unsatisfactory safety. Cohort 1-10 will enroll patients with CD38+ hematological malignancies and cohort 11 onwards will enroll patients with multiple myeloma only. Two expansion cohorts will evaluate the recommended Phase 2 dose (RP2D) in standard risk and high risk multiple myeloma patients.~Phase 2: Stage 1 will further evaluate four randomized arms. Arm 1: Dose 1 Q2W, Arm 2: Dose 2 Q2W, Arm 3: Dose 2 Q2W for 2 cycles then every 4 weeks (Q4W), Arm 4: Dose 3 QW for 1 cycle then Q2W. Stage 2 will use the dose and schedule determined from stage 1 ie Isatuximab Dose 3 every week for 4 infusions followed by Dose 3 every 2 weeks."
3216155|NCT01084252|Experimental|ISAdex arm|Phase 2 (stage 2) : Isatuximab Dose 3 every week for 4 infusions followed by Dose 3 every 2 weeks and dexamethasone Dose 4 IV or per os (Dose 5 for ≥75y.o patients) on days 1, 8, 15, 22 of each cycle.
3216156|NCT01084239|No Intervention|Standard of care|Subjects in this arm (50% of the total cohort) continued to receive standard non-invasive evaluation of acute chest pain symptoms in the emergency department - mostly comprising of, but not limited to - exercise treadmill test, stress test with imaging and stress echocardiography.
3216157|NCT01084239|Experimental|Cardiac CT|Subjects in this arm (50% of the total cohort) were randomized to receive a cardiac computed tomography scan as part of the initial evaluation of acute chest pain symptoms, upon presentation to the emergency department.
3216158|NCT01084226|Active Comparator|Sterol|Additional plant sterols incorporated in the rye bread
3216159|NCT01084226|Placebo Comparator|control|No added plant sterol in the identical-looking rye bread
3216160|NCT01084213|Active Comparator|IPTp with SP|Study women will receive at least two doses of SP during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
3216161|NCT01084213|Experimental|IST using RDTs|Scheduled intermittent screening using rapid diagnostic tests and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester.
3216162|NCT01084200|Experimental|Propofol|anesthesia maintenance with propofol and remifentanil
3216163|NCT01084200|Experimental|Sevoflurane|Sevoflurane and Remifentanil for anesthesia maintenance
3216164|NCT01084200|Experimental|Sevoflurane+Propofol|Sevoflurane+Propofol for anesthesia maintenance
3216165|NCT01084187|Active Comparator|vardenafil on demand|four sexual attempts with 20 mg vardenafil during next four weeks
3216166|NCT01084187|Placebo Comparator|placebo|placebo of vardenafil during four weeks
3216167|NCT01084187|Active Comparator|daily vardenafil|10 mg of vardenafil each day during four weeks
3216168|NCT01084174|Experimental|Active SLIT/Placebo OIT|These subjects will receive peanut powder given orally and placebo extract given sublingually.
3216169|NCT01084174|Experimental|Active OIT/Placebo SLIT|These subjects will receive peanut extract given sublingually and placebo powder given orally.
3216170|NCT01084161|Experimental|N1539 5 mg|
3216171|NCT01084161|Experimental|N1539 7.5 mg|
3216172|NCT01084161|Experimental|N1539 15 mg|
3216173|NCT01084161|Experimental|N1539 30 mg|
3216174|NCT01084161|Experimental|N1539 60 mg|
3216175|NCT01084161|Placebo Comparator|Placebo|
3216176|NCT01084161|Active Comparator|morphine|
3216177|NCT01084148|Experimental|V0034CR01B|cream
3216178|NCT01084148|Placebo Comparator|V0034 CR 01B vehicle|cream
3216179|NCT01084135|Experimental|Rivastigmine- Liquid form|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
3216180|NCT01084135|Placebo Comparator|Liquid placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
3216181|NCT01084109|Active Comparator|1|Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
3216182|NCT01084109|Active Comparator|2|Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
3216183|NCT01084096|Active Comparator|Intervention|Eligible women at high risk for preterm birth will be identified and four 6 mg doses of dexamethasone will be administered before delivery.
3216184|NCT01084096|No Intervention|Control|Control arm will not receive a specific intervention for comparison.
3216185|NCT01084083|Experimental|Group 1|After induction therapy with Paclitaxel and Cisplatin, patients undergo low-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 5 weeks (27 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 6 weeks.
3216186|NCT01084083|Experimental|Group 2|After induction therapy with Paclitaxel and Cisplatin, patients undergo standard-dose IMRT 5 days per week for approximately 6 weeks (33 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 7 weeks.
3216187|NCT01084070|Experimental|Early oral feeding|
3216188|NCT01084070|Active Comparator|Traditional Care|
3216189|NCT01084057|Experimental|Arm I (Cohort A)|Patients receive oral vorinostat once daily on days 1-14 and ixabepilone IV over 3 hours on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3216190|NCT01084057|Experimental|Arm II (Cohort B)|Patients receive oral vorinostat once daily on days 1-7 and 15-21. Patients also receive ixabepilone IV over 3 hours on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3216191|NCT01084044|Experimental|ulinastatin|
3216192|NCT01084044|Active Comparator|saline solution|
3216193|NCT01084044|Placebo Comparator|Sugar pill|
3216194|NCT01084031|Experimental|propofol|
3216195|NCT01084005|Experimental|linagliptin|patients receive linagliptin 5 mg tablets once daily
3216196|NCT01084005|Placebo Comparator|placebo|patients receive placebo tablets matching linagliptin 5 mg once daily
3216197|NCT01083992|Other|Galvus + vitamin D|Galvus in combination with vitamin D
3216198|NCT01083992|Other|Galvus|vitagliptin as monotherapy
3216199|NCT01083979|Experimental|Liposomes|Intravesical instillation of Liposomes in sterile water totally 40 cc at four weekly treatments.
3216200|NCT01083966|Experimental|Avastin|IA Avastin
3216201|NCT01083953|Experimental|Sevoflurane|1 arm will receive sevoflurane at varying concentrations at which extubation is attempted according to the Dixon up and down method
3216202|NCT01083953|Experimental|Desflurane|1 arm will receive desflurane at varying end tidal concentration at which extubation will be attempted according to Dixon up and down method
3216203|NCT01083940|Experimental|Reminders to providers|
3216204|NCT01083940|No Intervention|usual care|
3216205|NCT01083927|Active Comparator|Rotational Narrow Strip Graft|Technique of surgery
3216206|NCT01083927|Active Comparator|Full Graft|Surgical technique
3216207|NCT01083914||OPCAB|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
3216208|NCT01083914||CPB|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
3216209|NCT01083914||MECC|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
3216210|NCT01083901|Experimental|Resistance training with Acetaminophen|Acetaminophen
3216211|NCT01083901|Experimental|Resistance Training with ibuprofen|Ibuprofen
3216212|NCT01083901|Placebo Comparator|placebo|Placebo
3216213|NCT01083888|Experimental|1 group|
3216214|NCT01083875|Experimental|0.5% amlexanox oral rinse|Patients treated with an oral rinse containing the active 0.5% amlexanox
3216215|NCT01083875|Placebo Comparator|Vehicle|Patients treated with an oral rinse containing no active
3216216|NCT01083862|Experimental|Educational Intervention - Video & Text|"Educational Intervention - Video & Text describing Living with Coronary Artery Disease."
3216217|NCT01083862|Active Comparator|Educational Intervention - Text Only|"Educational Intervention - Text Only describing Living with Coronary Artery Disease."
3216218|NCT01083849||Paricalcitol|Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.
3216219|NCT01083823|Active Comparator|Self-reported mood swings|Participants who self-identify as experiencing severe mood swings that interfere with life.
3216220|NCT01083823|Active Comparator|Healthy|Participants who self-identify as not experiencing mood swings in the past or at present and who deny past / present problems with substance use.
3216221|NCT01083810||therapy-naive|Patients who had not received prior antiretroviral drug therapy
3216222|NCT01083810||pre-treated|Patients that had previously received antiretroviral therapy, but are protease inhibitor naive
3216223|NCT01083810||non-B|Patients infected with non-B subtypes of HIV-1
3216224|NCT01083797|Other|dexmedetomidine, chloral hydrate|sedation with dexmedetomidine or chloral hydrate on separate occasions in the same patients
3216225|NCT01083784|Experimental|Prophylactic group|the group that used prophylactic anticonvulsants (valproate, clonazepam)
3216226|NCT01083784|No Intervention|Control group|control group
3216227|NCT01083771|Experimental|Olive Oil|At least 3 tablespoons of olive oil each day
3216228|NCT01083758|Other|LEO 80185 (Taclonex® Scalp topical suspension/ Xamiol® gel)|
3216229|NCT01083745||IVF patients - 1|Poor responders
3216230|NCT01083745||IVF patients - 2|Good responders
3216231|NCT01083732|Experimental|dabigatran etexilate|treatment with dabigatran oral solution as a single dose
3216232|NCT01083719|Experimental|FDG-PET|A comparison of FDG-PET versus MRI based target volume delineation in glioblastoma and the role of FDG-PET/CT in the alteration of MRI based target volumes.
3216233|NCT01083706|Experimental|Treatment (chemotherapy)|Patients receive azacitidine SC or IV on days 1-7. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3216234|NCT01083693||Rheumatoid, Psoriatic Arthritis, Ankylosing Spondylitis|Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, patients with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.
3216235|NCT01083680||Participants with Crohn's Disease (CD)|Participants with Crohn's Disease treated with adalimumab (HUMIRA®) in routine clinical practice.
3216236|NCT01083667|Experimental|Pyrimethamine|Open label. Only one arm will receive the intervention.
3216237|NCT01083654|Active Comparator|Standard Treatment Counseling|Standard Treatment (ST) will consist of 12 weeks of open-label varenicline and smoking cessation counseling consisting of four sessions: one in-person pre-quit counseling session during Study Visit 2, counseling during a phone call on the day after the quit day, and two additional in-person counseling sessions at Study Visits 3 and 4 (one week and three weeks after the quit day, respectively).
3216238|NCT01083654|Experimental|Culturally-Tailored Treatment|The Culturally-Tailored Treatment will consist of 12 weeks of open-label varenicline and culturally-tailored (for American Indians) smoking cessation counseling consisting of four sessions: one in-person pre-quit counseling session during Study Visit 2, counseling during a phone call on the day after the quit day, and two additional in-person counseling sessions at Study Visits 3 and 4 (one week and three weeks after the quit day, respectively).
3216239|NCT01083641|Experimental|Estrogen Therapy|Estrogen therapy
3216240|NCT01083628|Experimental|Text Messaging Adjunct|
3216241|NCT01083615|Experimental|Custirsen|"Study treatment starts with a Loading Dose Period (1 week) during which 3 infusions of custirsen will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel (75 mg/m2 total dose) or cabazitaxel (25 mg/m2 total dose) on a 21-day cycle with weekly custirsen infusions (640 mg total dose) on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.~Participants will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol."
3216324|NCT01083017||standardized anti-hypertensive treatment|
3216242|NCT01083615|Placebo Comparator|Placebo|"Study treatment starts with a Loading Dose Period (1 week) during which 3 infusions of placebo (isotonic, 0.9% sodium chloride) will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel (75 mg/m2 total dose) or cabazitaxel (25 mg/m2 total dose) on a 21-day cycle with weekly placebo infusions on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.~Participants will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol."
3216243|NCT01083602|Experimental|panobinostat + bortezomib & dexamethasone|panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma
3216244|NCT01083589|Experimental|Imatinib Mesylate + Docetaxel|Imatinib Mesylate (Gleevec) Oral 400 mg daily + Docetaxel (Taxotere) 60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
3216245|NCT01083576|Active Comparator|Paromomycin Alone Treatment|Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated cutaneous leishmaniasis (CL) lesions once daily for 20 days
3216246|NCT01083576|Active Comparator|WR 279,396|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days
3216247|NCT01083563||RA inadequate response to methotrexate|Individuals with rheumatoid arthritis who have had an inadequate response to methotrexate and will be starting on an anti-TNF agent.
3216248|NCT01083563||RA inadequate response to anti-TNF.|Individuals with rheumatoid arthritis who have had an inadequate response to an anti-TNF and will be be given a rituximab infusion.
3216249|NCT01083550|Experimental|DA intervention|Decision aid exposure + usual care
3216250|NCT01083550|No Intervention|Control|Usual care
3216251|NCT01083537|Experimental|Cisplatin|"Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour"
3216252|NCT01083537|Experimental|Paclitaxel|"Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~Hydration: Infuse Paclitaxel in 250cc NS over 1 hour"
3216253|NCT01083524|Experimental|Group 1|Dichloroacetate Sodium 3.0 mg/kg, BID
3216254|NCT01083524|Experimental|Group 2|Dichloroacetate Sodium 6.25 mg/kg, BID
3216255|NCT01083524|Experimental|Group 3|Dichloroacetate Sodium 12.5 mg po bid
3216256|NCT01083511||Symptomatic|Individuals with signs and symptoms of a respiratory tract infection where it is suspected that such signs and symptoms are caused by a respiratory virus infection.
3216257|NCT01083498|Experimental|Ablative fractional laser|"In each patient, a square test region of 5-10 cm2 was treated with ablative fractional laser in three sessions in combination with intermittent topical bleaching with triple topical therapy (hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream) to prevent laser-induced postinflammatory hyperpigmentation.~Note: this study had a split-lesion design. In each patient, two test regions were randomized to receive either ablative fractional laser therapy or no treatment."
3216258|NCT01083498|No Intervention|Control|"In each patient, a square test region of 5-10 cm2 was treated with topical bleaching with triple topical therapy (hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream)alone (to allow comparison of the regions).~Note: this study had a split-lesion design. In each patient, two test regions were randomized to receive either ablative fractional laser therapy or no treatment."
3216259|NCT01083485|Experimental|Tablets Oxycodone Naloxone (OXN)|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)
3216260|NCT01083485|Active Comparator|Oxycodone|Oxycodone PR 20mg or 10mg (twice a day) BID for 2.5 days (total 5 dosages)
3216261|NCT01083472|Active Comparator|Strattice(TM) TM repair|Strattice(TM) TM will be placed in the intraperitoneal or retrorectus position to support the repair of abdominal wall defect
3216262|NCT01083472|Active Comparator|Standard of Care repair|Abdominal wall defect will be repaired using current standard of care techniques of either suture alone or suture with absorbable surgical mesh
3216263|NCT01083459||PCV13 immunized|Children who receive the 13-valent pneumococcal conjugate vaccine
3216264|NCT01083459||PCV13 unimmunized|PCV13 unimmunized Household members of PCV13 immunized children
3216265|NCT01083446|Active Comparator|A|Nutritional intervention, standard Israeli breakfast
3216266|NCT01083446|Active Comparator|B|Nutritional Intervention, fast
3216267|NCT01083433|No Intervention|Standard Diabetes Care|Patients will attend diabetes clinic as usual, once every 3 months.
3216268|NCT01083433|Experimental|Intensive Diabetes Clinic|Patients will attend diabetes clinic on a monthly basis for 4 months in a row. Each patient will have a 30 minute visit with a physician, 30 minutes dedicated to diabetes education, and 45 minutes with a child psychologist.
3216269|NCT01083433|Experimental|Intensive Diabetes Clinic plus CGM|Patients in this group will include all procedures as listed for group 2 (intensive diabetes clinic) in addition to wearing a continuous glucose monitor for 3-5 days each month. Patients will also have an additional 30 minutes with a psychology graduate student dedicated to adherence with the CGM.
3216270|NCT01083420|Active Comparator|Dexamethasone|Dexamethasone 0.01% mouthwash
3216271|NCT01083420|Experimental|Minocycline|Minocycline 0.2% mouthwash
3216272|NCT01083407|Experimental|0.12% Chlorhexidie Digluconate|Oral care included use of an oral gel containing chlorhexidine digluconate 0.12% as an active ingredient (chlorhexidine digluconate 0.12%; methylcellulose gel 2.12%, 25 g; gooseberry syrup, 4 drops; menthol solution 50%,3 drops; and distilled water, to 30 g).The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular,lingual, occlusal, and incisal). After each quadrant was cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto- anterior movements.
3216273|NCT01083407|Placebo Comparator|Toothbrushing|This group received the same oral care that experimental group with the use of a similarly formulated gel without the antiseptic agent.The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
3216274|NCT01083394|Active Comparator|conventional PTA|In stent restenosis is treated with PTA using a conventional balloon.
3216275|NCT01083394|Experimental|PTA with PEB|In stent restenosis is treated with PTA using a paclitaxel eluting balloon.
3216276|NCT01083381|Active Comparator|treatment group|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months. MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months.
3216277|NCT01083381|Placebo Comparator|Control group|Receives the same dosage of Risperidone. Placebo is given to this group in same form and appearance as MS14 in the other arm of the study.
3216278|NCT01083368|Experimental|Arm I|Patients receive temsirolimus IV over 30-60 minutes once weekly and bevacizumab IV over 30-90 minutes once every two weeks . Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
3216279|NCT01083355||Mechanical ventilation|Critical care patients
3216280|NCT01083329|Placebo Comparator|placebo|for 16 weeks
3216281|NCT01083329|Active Comparator|nicotinic acid|"for 16 weeks :~week 1 = 375 mg per day,~week 2 = 500 mg per day,~week 3 = 750 mg per day,~week 4 = 1000 mg per day,~week 5 = 1500 mg per day,~weeks 6 to 16 = 2000 mg per day."
3216282|NCT01083316|Experimental|Single Arm - Investigational|"Induction:~Bortezomib (Velcade) 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4~Melphalan 70-100 mg/m2/day IV on days -2 and -1"
3216283|NCT01083303|Experimental|weaning at 1500 g|weaning infants from an incubator at 1500 g
3216284|NCT01083303|Active Comparator|weaning at 1600 g|weaning infants from an incubator at 1600 g
3216285|NCT01083290|Experimental|Order of strenghts; 25 mg, 50 mg, 100 mg|
3216286|NCT01083290|Experimental|Order of strenghts; 50 mg, 100 mg, 25 mg|
3216287|NCT01083290|Experimental|Order of strenghts; 100 mg, 25 mg, 50 mg|
3216288|NCT01083277|Experimental|variable ventilation|A novel means of conducting mechanical ventilation that involves an approximately 40% variation in tidal volume around a set mean tidal volume
3216289|NCT01083277|Other|conventional ventilation|This is the control arm of the study, in which tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
3216290|NCT01083264|Experimental|Arm 1|
3216291|NCT01083264|Experimental|Arm 2|
3216292|NCT01083264|Experimental|Arm 3|
3216293|NCT01083251|Experimental|Peg + Vitamin D|Treatment arm with vitamin D will be treated first with vitamin D supplement for 3 months before the initiation of antiviral therapy. Vitamin D levels will be measures at baseline and three months after. The serum vitamin D-25-OH levels should be > 32 ng/ml before the initiation of antiviral treatment). HBV DNA levels will be also measure at baseline and after 3 months of mono therapy with vitamin D
3216294|NCT01083251|Active Comparator|Peginterferon|
3216295|NCT01083251|Active Comparator|Sebivo|Nucleotide Analog Telbivudine 600 mg daily
3216296|NCT01083251|Active Comparator|entecavir + vitamin d|baraclude 1 mg x1/ day + vitamin d
3216297|NCT01083238|Experimental|1|AZD5069 following a 10-hour fast
3216298|NCT01083238|Experimental|2|AZD5069 30 minutes after the start of a high fat meal
3216299|NCT01083225|Experimental|Client feedback|
3216300|NCT01083225|Active Comparator|Treatment as usual|
3216301|NCT01083212|Experimental|1|Gemfibrozil day 1-5 + AZD1656 day 4, 1 week without, Placebo day 1-5 + AZD1656 day 4
3216302|NCT01083212|Experimental|2|Placebo day 1-5 + AZD1656 day 4, 1 week without, Gemfibrozil day 1-5 + AZD1656 day 4
3216303|NCT01083199|Experimental|CONTINUUMTM|
3216304|NCT01083186||Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism|Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)
3216305|NCT01083173||Participants with HIV-1 infection|Participants treated with Kaletra (lopinavir/ritonavir 200 mg/50 mg and 100 mg/25 mg) tablet
3216306|NCT01083160||Non responders to other anti-TNF|Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.
3216307|NCT01083147||Dry AMD|subjects diagnosed as intermediate AMD in at least one eye
3216308|NCT01083134||percentage of stenosis|
3216309|NCT01083121||Adalimumab|Participants who were prescribed with adalimumab per approved prescribing information of adalimumab in Korea.
3216310|NCT01083108|Experimental|Surgical Arm|Roux-en-Y Gastric Bypass
3216311|NCT01083108|Active Comparator|Non-surgical Arm|Low-calorie Diet
3216312|NCT01083095|Active Comparator|3 +/- 1 bite|Volunteers were exposed to mosquito biting for 10 min
3216313|NCT01083095|Active Comparator|6 +/- 1 bite|Volunteers were exposed to mosquito biting for 10 min
3216314|NCT01083095|Active Comparator|9 +/- 1 bite|Volunteers were exposed to mosquito biting for 15 min
3216315|NCT01083069||COOL|Patients after therapy with mild hypothermia
3216316|NCT01083069||UnCool|Patients without therapy with mild hypothermia due to non-operational cooling-devices
3216317|NCT01083056||Epimacular Gliosis Without Macular Hole|
3216318|NCT01083056||Epimacular Gliosis With Macular Hole|
3216319|NCT01083043||Type 2 Diabetes Mellitus|
3216320|NCT01083030|Placebo Comparator|Conventional PTA|Angioplasty of SFA with uncoated balloon catheters
3216321|NCT01083030|Active Comparator|Drug coated balloon|Angioplasty of SFA with paclitaxel-coated balloon catheters
3216322|NCT01083017||chlorthalidone|
3216323|NCT01083017||motivational invervention|motivational interview(s) vs. repeated calls vs. no particular intervention
3216325|NCT01083004|Active Comparator|Indocyanine green arm|
3216326|NCT01083004|Active Comparator|Brilliant blue|
3216327|NCT01082991|Other|prevention|
3216328|NCT01082978|Experimental|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
3216329|NCT01082978|Experimental|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
3216330|NCT01082978|No Intervention|Usual standard of care|Patients randomized to this arm of the trial will not be given a Portable Health File. This arm is the concurrent control comparator arm.
3216331|NCT01082965|Experimental|Treatment|
3216332|NCT01082965|Placebo Comparator|Placebo|
3216333|NCT01082952||Asthmatic patients|
3216334|NCT01082952||Non asthmatic patients|
3216335|NCT01082939|Experimental|CFAR|CFAR: Cyclophosphamide 250 mg/m^2/day intravenous (IV) Days 3-5, Fludarabine 25 mg/m^2/day IV Days 3-5, Alemtuzumab 30 mg IV Days 1, 3 and 5 over 2-4 hours, repeated every four weeks for a total of 6 planned cycles, and Rituximab Cycle 1 (Week 1): 375 mg/m^2/day IV Day 2 over 4- 6 hours, Cycle 2 - 6 (Week 1): 500 mg/m^2/day IV Day 2 over 4- 6 hours.
3216336|NCT01082926|Experimental|Arm I|Patients receive intratumoral GRm13Z40-2 therapeutic allogeneic lymphocytes over 10 minutes on days 1 and 3 and intratumoral aldesleukin over 3 hours on days 2-5 (days 1-5 in week 2). Treatment repeats every week for 2 courses in the absence of disease progression or unacceptable toxicity.
3216337|NCT01082913|Experimental|Sacral Surface Electrical (SSE)|
3216338|NCT01082913|No Intervention|control|
3216339|NCT01082900|Experimental|Prophylactic CPAP intervention|Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the DR via T piece (Neopuff)
3216340|NCT01082900|Active Comparator|No Intervention|Provision of standard care in the Delivery Room
3216341|NCT01082887|Experimental|TIL-Ad-INFg|
3216342|NCT01082874|Experimental|Active Clonidine and Active ASA|
3216343|NCT01082874|Experimental|Active Clonidine and Placebo ASA|
3216344|NCT01082874|Experimental|Placebo Clonidine and Active ASA|
3216345|NCT01082874|Placebo Comparator|Placebo Clonidine and Placebo ASA|
3216346|NCT01082861|Experimental|HPV&HBV vaccin|HPV&HBV vaccin
3216347|NCT01082861|Experimental|HPV vaccination|HPV vaccination
3216348|NCT01082861|Experimental|HBV vaccination|HBV vaccination
3216349|NCT01082848|Experimental|aripiprazole|
3216350|NCT01082848|Placebo Comparator|placebo|
3216351|NCT01082835||the group of Jiangzhuo Qinggan prescription|
3216352|NCT01082835||the group of irbesartan|
3216353|NCT01082822|Sham Comparator|standard of care|In the first step, the patient was periodontally treated until the inflammation was eliminated through control of bacterial biofilm and oral hygiene for about 6 months. Then the rigid fixed appliances were placed on the diseased teeth, reverse beveled open-flap surgery was performed in the buccal and palatal maxillary sides of the periodontitis-caught teeth to allow granulation tissue debridement and proper root preparation. The roots were completely scaled, and 17%EDTA was applied for 2 minutes to demineralize the root surfaces and bone wall defects, the flap was sutured.
3216354|NCT01082822|Experimental|PDLSC cell sheet transplantion|Periodontal ligament stem cell derived cell sheet or pellet with carrier such as Bioss was implanted into periodontal defect area at post surgical treatment.
3216355|NCT01082822|Experimental|the bio-ss implantation|implantation of Bioss at post surgical treatment
3216356|NCT01082809|No Intervention|Sunitinib|Sunitinib, 37.5 mg orally once daily continuously, comprising a 4-week cycle
3216357|NCT01082796|Other|CYP2C19 EMs group|cyp2c19*1/*1 carriers
3216358|NCT01082796|Other|CYP2C19 PMs group|cyp2c19*2/*2 or *2/*3
3216359|NCT01082783||patients with acute media infarct|
3216360|NCT01082783||controls with cardiovascular risks|
3216361|NCT01082770|Active Comparator|TEGO|TEGO needle free access devices will be used in patients randomised to this arm
3216362|NCT01082770|Placebo Comparator|Control|Patients will continue to receive current standard of practice, ie a 'bung' cap at the end of the hemodialysis line
3216363|NCT01082744|Active Comparator|Continuous paravertebral block with ropivacaine|
3216364|NCT01082744|Experimental|Continuous paravertebral block with ropivacaine and sufentanil|
3216365|NCT01082731|Experimental|Mefloquine- Artesunate|Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
3216366|NCT01082731|Active Comparator|Artemether- Lumefantrine|Artemether-Lumefantrine: 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
3216367|NCT01082718|Experimental|Pregnant women|Pregnant women with P. falciparum malaria
3216368|NCT01082718|Active Comparator|Non pregnant women|Non pregnant women with P. falciparum malaria
3216369|NCT01082705|Active Comparator|Artemether-lumefantrine|Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
3216370|NCT01082705|Experimental|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine administered once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
3216371|NCT01082692|Experimental|3mg DNA/dose|Subjects will receive a 4 dose series of PENNVAX-B containing 3mg of DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8 and Week 16.
3216372|NCT01082679|Other|methadone via specialty care|
3216373|NCT01082679|Other|Suboxone via specialty care|
3216374|NCT01082679|Other|Suboxone via primary care|
3216375|NCT01082666|Experimental|Continuous control|Continuous control of cuff pressure using a pneumatic device
3216376|NCT01082666|Active Comparator|Manual control|Manual control of cuff pressure is a routine practice in ICU patients
3216377|NCT01082653|Experimental|Safety|infusion of autologous bone marrow-derived stem cells
3216378|NCT01082640|Placebo Comparator|Placebo|Placebo-matching capsules, orally, twice daily for up to 12 months.
3216379|NCT01082640|Experimental|Febuxostat 30 mg BID|Febuxostat 30 mg, capsules, orally, twice daily (BID) for up to 12 months.
3216380|NCT01082640|Experimental|Febuxostat 40/80 mg QD|Participants initially received febuxostat 40 mg, capsules, once daily (QD) and one placebo-matching capsule QD and remained on this dose for up to 12 months if their serum urate (sUA) was <6.0 mg/dL at the Day 14 visit. Participants whose sUA was ≥6.0 mg/dL at the Day 14 visit received febuxostat 80 mg, capsule, QD, and one placebo-matching capsule QD at the Month 1 visit, and for the remainder of the study.
3216381|NCT01082627|Experimental|Somatostatin+common daily practice|
3216382|NCT01082627|Placebo Comparator|common daily practice|
3216383|NCT01082614|No Intervention|Standard fluid management|standard intraoperative fluid management as determined by usual monitoring and decision making applied by anesthesiology team
3216384|NCT01082614|Experimental|Goal directed therapy|Intraoperative fluid management guided by stroke volume variation determined by arterial pressure pulse wave contour analysis
3216385|NCT01082601||Optimal Medical therapy|Subjects with Class I,IIor III congestive heart failure on optimal medical therapy. Planned catheter ablation for paroxysmal or persistent atrial fibrillation. Paroxysmal AF defined as recurrent AF(2 or more episodes in one month) that terminate within seven days. Persistent AF defined as sustained beyond seven days, or lasting less than seven days but requiring pharmacologic or electrical cardioversion.
3216386|NCT01082588|Active Comparator|pravastatin|pravastatin 40mg, once a day, shortly after baseline for 12 consecutive weeks
3216387|NCT01082588|Placebo Comparator|Placebo|placebo, once a day, shortly after baseline for 12 consecutive weeks
3216388|NCT01082575||Major Surgery|Oxygen Monitoring
3216389|NCT01082562|Experimental|Arm 1 - BMS-844421|
3216390|NCT01082562|Placebo Comparator|Arm 2 - 0.9% sodium chloride injection solution|
3216391|NCT01082562|Experimental|Arm 3 - BMS-844421|
3216392|NCT01082562|Placebo Comparator|Arm 4 - 0.9% sodium chloride injection solution|
3216393|NCT01082562|Experimental|Arm 5 - BMS-844421|
3216394|NCT01082562|Placebo Comparator|Arm 6 - 0.9% sodium chloride injection solution|
3216395|NCT01082562|Experimental|Arm 7 - BMS-844421|
3216396|NCT01082562|Placebo Comparator|Arm 8 - 0.9% sodium chloride injection solution|
3216397|NCT01082562|Experimental|Arm 9 - BMS-844421|
3216398|NCT01082562|Placebo Comparator|Arm 10 - 0.9% sodium chloride injection solution|
3216399|NCT01082562|Experimental|Arm 11 - BMS-844421|
3216400|NCT01082562|Placebo Comparator|Arm 12 - 0.9% sodium chloride injection solution|
3216401|NCT01082562|Experimental|Arm 13 - BMS-844421|
3216402|NCT01082562|Placebo Comparator|Arm 14 - 0.9% sodium chloride injection solution|
3216403|NCT01082562|Experimental|Arm 15 - BMS-844421|
3216404|NCT01082562|Placebo Comparator|Arm 16 - 0.9% sodium chloride injection solution|
3216405|NCT01082549|Active Comparator|gemcitabine/carboplatin|
3216406|NCT01082549|Experimental|gemcitabine/carboplatin plus Iniparib|
3216407|NCT01082536||One ventricle pts, bypass, perfusion|1. Single ventricle patients who undergo cardiopulmonary bypass and selective cerebral perfusion.
3216408|NCT01082536||One ventricle pts, bypass only|Single ventricle patients who undergo cardiopulmonary bypass but not selective cerebral perfusion
3216409|NCT01082536||One ventricle pts, no bypass/perfusion|Single ventricle patients who undergo surgery, but do not undergo cardiopulmonary bypass or selective cerebral perfusion.
3216410|NCT01082536||Two ventricle pts, bypass, perfusion|Two ventricle patients who undergo cardiopulmonary bypass and selective cerebral perfusion.
3216411|NCT01082536||Two ventricle pts, bypass only|Two ventricle patients who undergo cardiopulmonary bypass but not selective cerebral perfusion.
3216412|NCT01082536||Two ventricle pts, no bypass/perfusion|Two ventricle patients who do not undergo cardiopulmonary bypass or selective cerebral perfusion.
3216413|NCT01082523|Active Comparator|Text message reminders|
3216414|NCT01082523|No Intervention|Control|
3216415|NCT01082510|Active Comparator|BCG maintenance therapy|
3216416|NCT01082510|Experimental|UFT maintenance therapy|
3216417|NCT01082497|Experimental|Mindfulness|
3216418|NCT01082497|Active Comparator|Education|8 - weekly workshops on affect consciousness for all staff
3216419|NCT01082484|Experimental|Treprostinil|Treprostinil iontophoresis (250, 25 and 2.5 microM)
3216420|NCT01082484|Experimental|Iloprost|Iloprost iontophoresis (200, 20 and 2 microM)
3216421|NCT01082484|Placebo Comparator|NaCl 0.9%|
3216422|NCT01082471|Experimental|M6G|An initial slow bolus injection up to 60 min prior to end of surgery. If required, two additional slow bolus injections to achieve baseline pain relief. Continuing on PCA for a minimum of 24 hours.
3216423|NCT01082471|Active Comparator|Morphine|An initial slow bolus injection up to 60 min prior to end of surgery. If required, two additional slow bolus injections to achieve baseline pain relief. Continuing on PCA for a minimum of 24 hours.
3216424|NCT01082445|Experimental|N-acetylcysteine|50 patients that receive 600 mg of acetylcysteine for 3 times a day.
3216425|NCT01082445|Placebo Comparator|Placebo|50 subjects taking placebo pills 3 times a day
3216426|NCT01082419|Other|Group A|healthy volunteers
3216427|NCT01082419|Other|Group B|patients with supposed disease free liver (normal hepatic and pancreatic biochemistry)
3216428|NCT01082419|Other|Group D|patients with cirrhosis
3216429|NCT01082419|Other|Group E|patients with liver tumour and surgery indication
3216430|NCT01082419|Other|Group F|patients with reversible liver diseases and with acute left cardiac insufficiency
3216431|NCT01082419|Other|Group C|patients with non cirrhotic hepatopathy
3216432|NCT01082419|Other|Group G|patients with reversible liver diseases and with biliary cholestasis
3216433|NCT01082406|Experimental|Trial part 1|
3216434|NCT01082406|Experimental|Trial part 2|
3216435|NCT01082393|Active Comparator|topical tacrolimus|
3216436|NCT01082393|Active Comparator|topical pimecrolimus|
3216437|NCT01082393|Active Comparator|local steroids|
3216438|NCT01082393|Placebo Comparator|cold cream|
3216439|NCT01082380|Experimental|1|
3216440|NCT01082367|Experimental|TOBI (tobramycin inhaled solution)/Placebo|Participants randomized to TOBI received the investigational treatment for 28 days twice daily (bi)d in the first treatment cycle. At the end of first treatment cycle, participants who were positive for P. aeruginosa entered the open label (OL) phase of the study and received TOBI for 28 days bid. Participants who were negative for P. aeruginosa at the end of first treatment cycle and agreed to participate in the cross-over treatment period received placebo for 28 days bid (second treatment cycle).
3216441|NCT01082367|Placebo Comparator|Placebo/TOBI|Participants randomized to placebo group received 0.9 % saline (NaCl) for 28 days bid in the first treatment cycle. At the end of first treatment cycle, participants who were positive for P. aeruginosa entered the OL phase of the study and received TOBI for 28 days bid. Participants who were negative for P. aeruginosa at the end of first treatment cycle and agreed to participate in the cross-over treatment period received TOBI for 28 days bid (second treatment cycle).
3216442|NCT01082341|Experimental|Fy(+)|14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites
3216443|NCT01082341|Active Comparator|Fy(+) control|Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites.
3216444|NCT01082341|Active Comparator|Fy(-)|Six Fy(-) volunteers will be exposed to infective mosquito bites.
3216445|NCT01082328|Experimental|Kuvan®|
3216446|NCT01082302|Active Comparator|oral intake of green tea beverage|Healthy volunteers are asked to drink a defined amount of green tea beverage over 7 days
3216447|NCT01082302|Experimental|Polyphenon E 15% ointment|3 times daily application of Polyphenon E 15% ointment on genital and perianal warts over 7 days
3216448|NCT01082276|Other|Rifampin/Lurasidone|Healthy Normal Subject
3216449|NCT01082263|Other|Midazolam/Lurasidone|Schizophrenia patient
3216450|NCT01082250|Other|Reference Formulation|Dosed 12.5% drugload 3X40mg
3216451|NCT01082250|Other|Test Formulation|25% Drugload 1X120mg
3216452|NCT01082237|Active Comparator|escitalopram|All subjects will receive escitalopram (ESC), brand name Lexapro (Forest Laboratories, Inc., New York) throughout the study. Dosing will start at 5 mg/d, be titrated to 10 mg after 4 days, and continue at 10 mg/d thereafter; an additional dose titration to 20 mg will be pursued at week 8 for those not significantly better (<50% improvement on IDS-30 at week 8 visit) and as tolerated.
3216453|NCT01082224|Experimental|Waitlisted with HCC-Exception Points|Participants undergo CT and MRI every 90 days for the trial with iodinated contrast dye and motexafin gadolinium, during liver transplant wait listing. Possible Eovist-enhanced MRI substudy participation
3216454|NCT01082211|Experimental|Partial Breast Re-Irradiation|Partial Breast Re-Irradiation (PBrI) 3D-Conformal External Beam 1.5 Gy x 15 (BID) to 45 Gy Total
3216455|NCT01082185|Other|Ovation Abdominal Stent Graft System|Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
3216456|NCT01082159|Other|lumbar decompression|Percutaneous lumbar decompression with mild® Device Kit.
3216457|NCT01082146|Experimental|Lurasidone|LURASIDONE 40mg
3216458|NCT01082133|Experimental|Chemotherapy and Miltenyi, CliniMACS|Busulfan 0.6-1.0 mg/Kg/dose IV Q 12 hours X4 Doses Fludarabine 35 mg/m2/dose IV once daily X4 Doses Cyclophosphamide 10 mg/Kg/dose IV once daily X4 Doses Anti-thymocyte globulin - Thymoglobulin 2.5 mg/Kg/dose IV daily X4 Doses Miltenyi CliniMACS
3216459|NCT01082120|Experimental|1|AZD1656 day 1-5, AZD1656 + Pioglitazone day 6-10, Pioglitazone day 11-15
3216460|NCT01082120|Experimental|2|Pioglitazone day 1-5, AZD1656 + Pioglitazone day 6-10, AZD1656 day 11-15
3216461|NCT01082107|Other|Solar disinfection of drinking water|
3216462|NCT01082094|Experimental|ACRX-100|"Cohort 1 = Low dose~Cohort 2 = Middle dose~Cohort 3 = High Dose"
3216463|NCT01082081|Experimental|Paracetamol 1000 mg|Paracetamol 1000 mg
3216464|NCT01082081|Experimental|Paracetamol 500 mg|Paracetamol 500 mg
3216465|NCT01082081|Placebo Comparator|Placebo|Placebo
3216466|NCT01082068|Experimental|Arm 1|XL147 (SAR245408) + letrozole
3216467|NCT01082068|Experimental|Arm 2|XL765 + letrozole
3216468|NCT01082055||Currently receiving antiarrythmic drugs|
3216469|NCT01082042||Standard Care|Individuals who attended the local falls group
3216470|NCT01082042||Intervention group|Individuals who undertook the 12 week exercise (Nintendo WiiFit) intervention
3216471|NCT01082029|Experimental|Lansoprazole|
3216472|NCT01082029|Placebo Comparator|Placebo|
3216473|NCT01082016|No Intervention|Control|Monitor sleep in ICU without attempts at promotion
3216474|NCT01082016|Experimental|Sleep promotion|Measure sleep in ICU with sleep promotion program in effect
3216475|NCT01082003|Other|Permanent Implant|Trental and Vitamin E for 6 months
3216476|NCT01082003|Other|Tissue Expander|Trental and Vitamin E for 6 months
3216477|NCT01081990|Placebo Comparator|Placebo Pill|
3216478|NCT01081990|Experimental|Flexeril|
3216479|NCT01081977|Active Comparator|Early Cord Clamping Group|Early Cord Clamping Group (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate).
3216480|NCT01081977|Experimental|Delayed Cord Clapming Group|Delayed Umbilical Cord Clamping Group (Clamping of Umbilical Cord within 2 minutes of shoulder delivery of neonate).
3216481|NCT01081964|Active Comparator|Levofloxacin 500mg|Levofloxacin 500mg once daily for 7 days
3216482|NCT01081964|Experimental|Zabofloxacin 5 days|Zabofloxacin 400mg for 5 days
3216483|NCT01081964|Experimental|Zabofloxacin 3 days|Zabofloxacin 400mg for 3 days
3216484|NCT01081951|Experimental|1|200mg, 400mg BID - CAPSULES Olaparib paclitaxel iv and carboplatin iv
3216485|NCT01081951|Active Comparator|2|paclitaxel iv and carboplatin iv
3216486|NCT01081938|Experimental|1|Insulin Glargine + Insulin Glulisine
3216487|NCT01081938|Active Comparator|2|Insulin Glulisine
3216488|NCT01081925||Congestive heart failure|Patients suffering from sudden worsening of congestive heart failure
3216489|NCT01081912|Active Comparator|Hydrocodone Bitartrate Capsules|Hydrocodone Bitartrate Controlled-Release Capsules
3216490|NCT01081912|Placebo Comparator|Placebo comparator|
3216491|NCT01081899|Experimental|The LCP-I Program.|The Italian version of the Liverpool Care Pathways version 11 for hospital) Programme.
3216492|NCT01081899|No Intervention|standard healthcare practices|No specific interventions are planned in the control wards.
3216493|NCT01081886|Experimental|PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
3216494|NCT01081886|Active Comparator|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
3216495|NCT01081873||Advanced prostate cancer participants|Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment within local reimbursement guidelines.
3216496|NCT01081860||Carpal tunnel syndrome|Patients with carpal tunnel syndrome
3216497|NCT01081860||Trigger finger|Patients with trigger fingers
3216498|NCT01081860||Dupuytren Contracture|Patients with Dupuytren
3216499|NCT01081860||Trauma to the hand|Patients with an acute trauma to the hand
3216500|NCT01081847|Active Comparator|Group A|Montanide ISA 720 Dose by peptide 50ug
3216501|NCT01081847|Active Comparator|Group B|Montanide ISA 51 Dose by peptide 50ug
3216502|NCT01081847|Active Comparator|Group C|Montanide ISA 720 Dose by peptide 100ug
3216503|NCT01081847|Active Comparator|Group D|Montanide ISA 51 Dose by peptide 100ug
3216504|NCT01081847|Placebo Comparator|Group E|Control Group. no peptide. Isotonic saline solution
3216505|NCT01081834|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
3216506|NCT01081834|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
3216507|NCT01081834|Experimental|Placebo/Sitagliptin|In the Main Study, each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52.
3216508|NCT01081821|Experimental|001|single dose NJ-39758979/ matching placebo Single oral dose of JNJ-39758979 (either 50 100 300 600mg) or Placebo
3216509|NCT01081821|Experimental|002|multi-dose JNJ-39758979 /matching placebo JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
3216510|NCT01081808|Other|Armed Activated T Cells|Activated T Cells (ATC) armed with the bispecific antibody OKT3 x Cetuximab (EGFRBi). ATC will be expanded for 14 days from a leukapheresis product, armed with EGFRBi, cryopreserved and infused in 8 divided doses. Patients will also receive low dose subcutaneous IL-2(3000,000 IU/m2/day) and GM-CSF (250ug/m2 twice per week)
3216511|NCT01081795|Experimental|Topiramate (JNS019) 50 mg|In titration period, topiramate 25 milligram (mg) tablet will be given once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and will be continued further for 18 weeks in the fixed dose period.
3216512|NCT01081795|Experimental|Topiramate 100 mg|In titration period, topiramate 25 mg tablet will be given once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and will be continued further for 18 weeks in the fixed dose period.
3216513|NCT01081795|Placebo Comparator|Placebo|In titration period, matching placebo tablet will be given once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice orally from Day 22 to Day 28 and will becontinued further for 18 weeks in the fixed dose period.
3216514|NCT01081782|Experimental|E1|
3216515|NCT01081782|Experimental|E2|
3216516|NCT01081782|Experimental|E3|
3216517|NCT01081782|Placebo Comparator|P|
3216518|NCT01081769|Experimental|Paliperidone Palmitate|paliperidone palmitate injection with 150 mg equivalent on Day 1 100 mg equivalent on Day 8 75 mg equivalent on Day 38 and flexible dosing with 25 50 75 100 or 150 mg equivalent once monthly thereafter
3216519|NCT01081769|Active Comparator|Oral Antipsychotics|oral antipsychotics daily treatment according to local label for maximally 24 months
3216520|NCT01081756|Experimental|Subjects treated with r-hCG|Subjects treated with r-hCG
3216521|NCT01081756|Active Comparator|Subjects treated with urinary hCG|Subjects treated with urinary hCG
3216522|NCT01081743|Experimental|Social worker|
3216523|NCT01081743|No Intervention|Control|Control group is followed-up as usually (usual care)
3216524|NCT01081730||001|ustekinumab as prescribed
3216525|NCT01081730||002|anti-TNF biologics as prescribed
3216526|NCT01081730||003|non-anti-TNF biologics as prescribed
3216527|NCT01081730||004|systemic non-biological treatments as prescribed
3216528|NCT01081730||005|general population non-treated cohort
3216529|NCT01081717||001|golimumab as prescribed
3216530|NCT01081717||002|anti-TNF biologics as prescribed
3216531|NCT01081717||003|non-anti-TNF biologics as prescribed
3216532|NCT01081717||004|systemic non-biological treatments as prescribed
3216533|NCT01081717||005|general population non-treated cohort
3216534|NCT01081704|Experimental|001|ustekinumab Single dose of 45 mg subcutaneous injection
3216535|NCT01081704|Experimental|002|ustekinumab Single dose of 90 mg subcutaneous injection
3216536|NCT01081691|Experimental|001|CNTO 5825 0.1 mg/kg single dose Intravenously (IV) or matching placebo
3216537|NCT01081691|Experimental|002|CNTO 5825 0.3 mg/kg single dose IV or matching placebo
3216538|NCT01081691|Experimental|003|CNTO 5825 1 mg/kg single dose IV or matching placebo
3216539|NCT01081691|Experimental|004|CNTO 5825 3 mg/kg single dose IV or matching placebo
3216540|NCT01081691|Experimental|005|CNTO 5825 10 mg/kg single dose IV or matching placebo
3216541|NCT01081691|Experimental|006|CNTO 5825 For atopic patient:10 mg/kg single IV dose or matching placebo
3216542|NCT01081691|Experimental|007|CNTO 5825 For atopic patient: 3 mg/kg single dose SC or matching placebo
3216543|NCT01081678|Experimental|AMG 785 dose group 2|Four doses of 140mg AMG 785
3216544|NCT01081678|Experimental|AMG 785 dose group 3|Four doses of 210mg AMG 785
3216545|NCT01081678|Experimental|AMG 785 dose group 1|Four doses of 70mg AMG 785
3216546|NCT01081678|Placebo Comparator|Placebo arm|Four doses of placebo
3216547|NCT01081665||Chronic Kidney Disease|All eligible patients treated with IV Paricalcitol (Zemplar)
3216548|NCT01081652|Experimental|Crinone 8% group|Female subjects undergoing IVF/ET treated with Crinone 8% intravaginally
3216549|NCT01081652|Active Comparator|Intramuscular progesterone group|Female subjects undergoing IVF/ET treated with 60 mg progesterone intramuscularly once daily
3216550|NCT01081639|Experimental|Gonal-f|
3216551|NCT01081639|Active Comparator|Puregon|
3216552|NCT01081626|Experimental|Group I: Chronic Low dose Protocol|Gonal-f will be injected on the second or third day of a spontaneous or progestogen-induced menstrual cycle (Day 0), with a daily dose of 75 International Units (IU) for 7 days. Ovarian response will be assessed on Day 7 of stimulation by ultrasound scan. If no follicle has reached at least 10 to 12 millimeter (mm) diameter, stimulation will be continued with the same dose for further 7 days. On Day 14 of stimulation, if no ovarian response is seen, the dose will be increased by 37.5 IU (total 112.5 IU) and administered for the next 7 days. Subsequent increments of 37.5 IU, at intervals of 7 days up to Day 35 of stimulation would be made, depending on ovarian response.
3216553|NCT01081626|Experimental|Group II: Low dose Protocol|Gonal-f will be administered on the second or third day of a spontaneous or progestogen-induced menstrual cycle (Day 0), with a daily dose of 75 IU for 7 days. Ovarian response will be assessed on Day 7 of stimulation by ultrasound scan. If no follicle has reached at least 10 to 12 mm diameter, the dose will be increased by 37.5 IU (total 112.5 IU) and administered for the next 7 days. Subsequent increments of 37.5 IU, at intervals of 7 days up to Day 35 of stimulation will be made, depending on ovarian response.
3216554|NCT01081613||AUY922|Patients with estrogen receptor (ER) positive, hormone therapy refractory breast cancer.
3216555|NCT01081600||AUY922|Patients with HER2 positive breast cancer which has become trastuzumab resistent.
3216556|NCT01081587|Experimental|Nutritional Support Team|
3216557|NCT01081587|Active Comparator|Usual care|
3216558|NCT01081574|Experimental|10 mg Bilastine once daily for 7 days|10 mg Bilastine dispersible oral tablet
3216559|NCT01081561|Active Comparator|Cross-linking|Corneal collagen cross-linking with riboflavin and UVA light
3216560|NCT01081561|Active Comparator|Cross-linking plus INTACS|Corneal collagen cross-linking with riboflavin and UVA light plus INTACS
3216561|NCT01081548|Experimental|Generic|
3216562|NCT01081548|Active Comparator|Lipitor|
3216563|NCT01081535|Experimental|ketorolac|
3216564|NCT01081535|Experimental|fentanyl|
3216565|NCT01081483|Active Comparator|ABT-072 Tablet|ABT-072 50 mg Tablet, every day (QD), single ascending doses, groups 1-3
3216566|NCT01081483|Placebo Comparator|Placebo|Placebo Tablet, QD, single doses, groups 1-3
3216567|NCT01081457|Active Comparator|ON|Stimulator switched ON
3216568|NCT01081457|Sham Comparator|OFF|Stimulator switched OFF
3216569|NCT01081444|Active Comparator|1|Active rTMS
3216570|NCT01081444|Placebo Comparator|2|sham rTMS
3216571|NCT01081431|Experimental|Lenalidomide|
3216572|NCT01081418|Experimental|Standard care|Standard care comprised a treatment network consisting of open and closed inpatient wards, day-clinics, an outpatient centre, and eight private psychiatrists. Each patient was treated by a private psychiatrist or by a psychiatrist in the outpatient centre. Home visits were possible, but office visits were the general rule. Patients were allowed to use all treatment offers in the outpatient centre. Outside office hours, patients could refer themselves to the psychiatric hospital. Psychosocial treatments as supportive therapy, psychoeducation, psychotherapy, and family intervention were provided infrequently and in a less intensive and unsystematic way, and only in the minority of cases. This 'standard of care' definition is in accordance with other studies.
3216573|NCT01081405|Experimental|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
3216574|NCT01081392|Experimental|LPS sequence 1|Nebulizers A then B then C
3216575|NCT01081392|Experimental|LPS sequence 2|Nebulizers B then C then A
3216576|NCT01081392|Experimental|LPS sequence 3|Nebulizers C then A then B
3216577|NCT01081392|Experimental|LPS sequence 4|Nebulizers A then C then B
3216578|NCT01081392|Experimental|LPS sequence 5|Nebulizers C then B then A
3216579|NCT01081392|Experimental|LPS sequence 6|Nebulizers B then A then C
3216580|NCT01081379||pre-conception immunity|pre-conception immunity- pregnant women with CMV seropositive
3216581|NCT01081379||primary CMV infection|primary CMV infection- pregnant women with primary CMV infection (defined as CMV IgG sero-conversion, the presence of low avidity IgG antibodies or the presence of IgM with no previous IgG antibodies).
3216582|NCT01081353|Experimental|Arm 1|
3216583|NCT01081353|Active Comparator|Arm 2|
3216584|NCT01081353|Active Comparator|Arm 3|
3216585|NCT01081353|Active Comparator|Arm 4|
3216586|NCT01081340|Experimental|Social network building intervention|Healthy lifestyle intervention focused on building reciprocal social ties between the intervention group members
3216587|NCT01081340|Active Comparator|Home visit|Home visits focused on preventable infant injuries
3216588|NCT01081327||Patients receiving Warfarin|
3216589|NCT01081314|Experimental|Standard DBT + PTSD Protocol|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team) plus a modified version of Prolonged Exposure therapy for PTSD.
3216590|NCT01081314|Active Comparator|Standard DBT|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
3216591|NCT01081301|Experimental|Living with Hope Program|Receive Living with Hope Program
3216592|NCT01081288|Active Comparator|Women aged 47-49 invited for breast screening|
3216593|NCT01081288|Active Comparator|Women aged 71-73 invited for breast screening|
3216594|NCT01081275|Active Comparator|CI Therapy|CI therapy involves repetitive practice with the more-affected hand on typical daily living activities (such as stacking objects, pouring, moving objects) for 3.5 hours per day, along with physical restraint of the better hand to keep it from assisting, and home practice exercises.
3216595|NCT01081275|Active Comparator|CAM treatments|CAM treatments are holistic physical treatments designed to work on the entire body to improve quality of life and overall health. This study will use yoga, relaxation exercises, aquatherapy (pool therapy), and massage.
3216596|NCT01081262|Experimental|Arm I (carboplatin and paclitaxel)|Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
3216597|NCT01081262|Experimental|Arm II (oxaliplatin and capecitabine)|Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
3216598|NCT01081262|Experimental|Arm III (carboplatin, paclitaxel, bevacizumab)|Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
3216599|NCT01081262|Experimental|Arm IV (oxaliplatin, capecitabine, bevacizumab)|Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III.
3216600|NCT01081249|Experimental|Placebo then Oxytocin|Participant was randomized to receive placebo before the first psychotherapy session, and then received the active drug at the second visit.
3216601|NCT01081249|Experimental|Oxytocin then placebo|Participant was randomized to receive placebo before the first psychotherapy session, and then received the active drug at the second visit.
3216602|NCT01081236||Compensated liver cirrhosis|
3216603|NCT01081236||Decompensated liver cirrhosis|
3216604|NCT01081223|Experimental|TVI-Brain-1|Biological/Vaccine: Cancer vaccine plus immune adjuvant, plus activated white blood cells
3216605|NCT01081210||Ultrasound screening|Patients admitted to Department of medicine at local hospital. Randomized inclusion, informed consent obtained.
3216606|NCT01081197||Out-day patients' clinic|Alcohol abusers referred to out-day patients' clinic which consent to participate in the study
3216607|NCT01081197||Control|Control group for the cardiac arm of the study will be matched controls from the Nord-Trøndelag Health Study (HUNT)
3216608|NCT01081184||primary Sjögren syndrome|
3216609|NCT01081184||Healthy volunteers|
3216610|NCT01081158|Experimental|Treatment-naïve 800 mg TID|"Period 1: SCH 900518 (800 mg TID) or placebo for 7 days~Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 µg/kg QW) or placebo + PegIntron for 14 days."
3216611|NCT01081158|Experimental|Treatment-experienced: 800 mg TID|"Period 1: SCH 900518 (800 mg TID) or placebo for 7 days~Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 ug/kg QW) or placebo + PegIntron for 14 days"
3216612|NCT01081158|Experimental|Treatment-naïve: 400 mg + RTV BID|"Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.~Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days."
3216613|NCT01081158|Experimental|Treatment-experienced: 400 mg + RTV BID|"Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.~Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days."
3216614|NCT01081145|Experimental|Extended-release Guanfacine HCl|
3216615|NCT01081145|Placebo Comparator|Placebo|
3216616|NCT01081132|Experimental|Extended-release Guanfacine HCl|
3216617|NCT01081132|Placebo Comparator|Placebo|
3216618|NCT01081119|Experimental|Project CHOICE|Middle school receives Project CHOICE
3216619|NCT01081119|No Intervention|No Project CHOICE|Middle school does not receive Project CHOICE
3216620|NCT01081106|Other|Low-Level Laser Therapy|
3216621|NCT01081093|Experimental|Biventricular pacing|
3216622|NCT01081067||Control|Routine cow milk-based infant formula
3216623|NCT01081067||Investigational|Cow milk-based infant formula containing probiotics
3216624|NCT01081054|Other|Ambulatory Treatment|Patients are treated ambulatory with oral antibiotic for 10 days; for the first five days these patients are contacted by telephone daily to progress oral intake.
3216625|NCT01081054|Active Comparator|Hospital treatment|Patients are hospitalized and treated with antibiotic, for the first days by endovenous antibiotic and with diet progression orally.
3216626|NCT01081041|Experimental|Safety Lead-In (cetuximab manufactured by ImClone)|"Cycle 1:~Week 1 - Cetuximab 400 milligrams per square meter (mg/m^2) on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin area under the curve (AUC) 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
3216627|NCT01081041|Experimental|Cetuximab manufactured by ImClone|"Cycle 1:~Week 1 - Cetuximab 400 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
3216675|NCT01080664|Experimental|Regimen 1|Regimen 1: AS703569 administered on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
3216676|NCT01080664|Experimental|Regimen 2|Regimen 2: AS703569 administered on Days 1, 2, 3, 4, 5, 6 of a 21-day cycle
3216677|NCT01080651|Active Comparator|CYP2C19 extensive metabolizer|
3216678|NCT01080651|Active Comparator|CYP2C19 poor metabolizer|
3216786|NCT01079923|Active Comparator|Single High Dose Supplementation|Age 18 to 40 years, non-pregnant, non-lactating, female subjects .
3216628|NCT01081041|Experimental|Cetuximab manufactured by Boehringer Ingelheim|"Cycle 1:~Week 1 - Cetuximab 400 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
3216629|NCT01081028||Group One: Patients enrolled between Sep2009 and Nov2011|Newly diagnosed multiple myeloma patients enrolled between Sep 2009 and Nov 2011.
3216630|NCT01081028||Group Two: Patients enrolled between Dec2012 and mid-2016|Newly diagnosed multiple myeloma patients enrolled between Dec 2012 and mid-2016
3216631|NCT01081002|Active Comparator|Anesthesia (=A) with lidocaine 10%|3 min before sedation 4 puffs of terbutaline diluted lidocaine solution (Xylocaine ® 10% spray, Astra Zeneca, London, UK) will be sprayed on the pharynx
3216632|NCT01081002|Placebo Comparator|A with diluted gentian root solution|3 min before sedation 4 puffs of highly diluted gentian solution will be sprayed on the pharynx
3216633|NCT01080989|Other|health screening and clinical diagnosis and treatment for p|The study project can be divided into two parts: (1) health screening for the community and (2) clinical diagnosis and treatment for patients at National Referral Hospital (NRH) in Solomon islands.
3216634|NCT01080976||Primary Care Physicians|
3216635|NCT01080976||Diabetologists|
3216636|NCT01080963|Active Comparator|Daptomycin|
3216637|NCT01080963|Active Comparator|Cefuroxime|
3216638|NCT01080950||fever zinc vit. d|patients with fever but without sepsis
3216639|NCT01080950||sepsis zinc vit. d|patients with sepsis
3216640|NCT01080937||Patient with acute heart failure|Hospitalized patient, whatever the mode of initial admission with acute heart failure
3216641|NCT01080924|Experimental|Low frequency ultrasound spectroscopy|Low frequency ultrasound spectroscopy after broncholysis
3216642|NCT01080911|Experimental|spinal morphine 0.05 mg|spinal morphine 0.05 mg plus 0.5% heavy marcaine 3.5 ml
3216643|NCT01080911|Active Comparator|spinal morphine 0.1 mg|spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
3216644|NCT01080898||DMLA patients|patients > 50 years with suspicion of choroidal neo-vessels complicating age related macular degeneration (DMLA)
3216645|NCT01080885|Experimental|Busy Bodies/Better Bites|Healthy Eating/Physical Activity Intervention
3216646|NCT01080885|Active Comparator|Healthy Spots/Safe Tots|Injury Prevention and Safety Intervention
3216647|NCT01080872||Titanium-NO coated stent|Patients receiving titanium-nitride-oxide coated stents during the intervention.
3216648|NCT01080872||Everolimus eluting stent|Patients receiving everolimus eluting stents during the intervention.
3216649|NCT01080859||BAS|Patient's receiving BAS
3216650|NCT01080859||EES|Patients receiving EES
3216651|NCT01080846|Experimental|600 mcg of sublingual misoprostol|
3216652|NCT01080833|Active Comparator|ERCP mechanical simulator practice|Trainees who are offered ERCP Mechanical Simulator (EMS) training in addition to routine training (study group)
3216653|NCT01080833|No Intervention|No ERCP mechanical simulator practice|Trainees undergoing routine ERCP training only (control group).
3216654|NCT01080820|Placebo Comparator|Placebo + Viread|
3216655|NCT01080820|Active Comparator|Viread|
3216656|NCT01080820|Experimental|CMX157 + Viread|
3216657|NCT01080807|Experimental|150 mg/day armodafinil|
3216658|NCT01080807|Placebo Comparator|Matching placebo|
3216659|NCT01080794|Active Comparator|Double rTMS|High frequency rTMS stimulation of the bilateral primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC).
3216660|NCT01080794|Active Comparator|M1 Active rTMS + DLPFC Sham rTMS|High frequency stimulation of the primary motor cortex (M1) and sham stimulation of the dorsolateral prefrontal cortex (DLPFC).
3216661|NCT01080794|Active Comparator|DLPFC Active rTMS + M1 Sham rTMS|High frequency stimulation of the dorsolateral prefrontal cortex (DLPFC) and sham stimulation of the primary motor cortex (M1).
3216662|NCT01080794|Sham Comparator|Double Sham rTMS|Sham rTMS stimulation of the bilateral primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC).
3216663|NCT01080781||Group 1|normal pressures in right auricle (<10 mmHg) /and or pulmonary artery (<35 mmHg)
3216664|NCT01080781||Group 2|high pressures in right auricle (> 10 mmHg) /and or pulmonary artery (>35 mmHg)
3216665|NCT01080768|Experimental|Aliskiren/amlodipine + Placebo to amlodipine|"During the first week of active treatment, patients were instructed to take one tablet of aliskiren/amlodipine 150/5 mg and one capsule of placebo to amlodipine daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 2 tablets of aliskiren/amlodipine 150/5 mg/day and 1 capsule of placebo to amlodipine.~The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."
3216666|NCT01080768|Active Comparator|Amlodipine + Placebo to aliskiren/amlodipine|"During the first week of active treatment, patients were instructed to take one capsule of amlodipine 5 mg and one tablet of placebo to aliskiren/amlodipine 150/5 mg daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 1 capsule of amlodipine 10 mg/day and 2 tablets of placebo to aliskiren/amlodipine 150/5 mg/day.~The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."
3216667|NCT01080716|Experimental|WRSS1 vaccine|WRSS1 is a live attenuated S. sonnei vaccine candidate derived from the Mosely strain of S.sonnei
3216668|NCT01080716|Placebo Comparator|Placebo vaccine|Placebo
3216669|NCT01080703|Experimental|Lower extremity strengthening|
3216670|NCT01080690|Active Comparator|EGD|In this arm EGD will be performed before EUS
3216671|NCT01080690|Active Comparator|EUS|In this arm, EUS will be performed before EGD.
3216672|NCT01080677|Placebo Comparator|Placebo|Participants will receive placebo to match caffeine/propranolol (single dose)
3216673|NCT01080677|Experimental|Low dose|Participants will receive caffeine/propranolol 400/40 mg combination tablet (single dose)
3216674|NCT01080677|Experimental|High dose|Participants will receive caffeine/propranolol 1000/40 mg combination tablet (single dose)
3217372|NCT01075230|Active Comparator|Standard TKA|
3216679|NCT01080638|Experimental|Abciximab IC bolus|After CAG, For patients with undergoing percutaneous coronary intervention, intracoronary only or intravenous bolus abciximab(0.25mg/kg body weight) administration with intravenous bolus group has subsequent 12-hours continuous infusion at a dose 0.125ug/kg per minute (maximum: 10ug/min)
3216680|NCT01080638|Active Comparator|Abciximab IV bolus and 12hr continuous|
3216681|NCT01080625|Experimental|phenylephrine|100 mcg of phenylephrine is administered at the time of reperfusion
3216682|NCT01080625|Experimental|epinephrine|10 mcg of epinephrine is administered iv at the time of reperfusion
3216683|NCT01080625|Placebo Comparator|control|10 ml of normal saline is administered at the time of reperfusion
3216684|NCT01080612|Experimental|330 mg pregabalin controlled release: 400 to 500 calories|
3216685|NCT01080612|Experimental|330 mg pregabalin controlled release: 600 to 750 calories|
3216686|NCT01080612|Experimental|330 mg pregabalin controlled release: 800 to 1000 calories|
3216687|NCT01080612|Other|300 mg pregabalin immediate release|
3216688|NCT01080599|Experimental|conventional pubic approach|
3216689|NCT01080599|Experimental|inguinal approach|
3216690|NCT01080586|Active Comparator|NEORAL® Capsule 100 mg|
3216691|NCT01080586|Experimental|Cyclosporine 100 mg Capsule|
3216692|NCT01080560|Active Comparator|NEORAL® Capsule 100 mg|
3216693|NCT01080560|Experimental|Cyclosporine 100 mg Capsule|
3216694|NCT01080547|Active Comparator|Conventional Treatment （Laparoscopic）|Randomized group of patients receiving laparoscopic colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.
3216695|NCT01080547|Active Comparator|FTMD Treatment （Laparoscopic）|Randomized group of patients receiving laparoscopic colectomy with Fast Track Multi-Displine（FTMD）treatment and XELOX chemotherapy.
3216696|NCT01080547|Active Comparator|Conventional Treatment（Open Surgery）|Randomized group of patients receiving open colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.
3216697|NCT01080547|Active Comparator|FTMD Treatment（Open Surgery）|Randomized group of patients receiving open colectomy with Fast Track Multi-Displine（FTMD） treatment and XELOX chemotherapy.
3216698|NCT01080534|Active Comparator|Prograf® Capsule 5 mg|
3216699|NCT01080534|Experimental|Tacrolimus Capsule 5 mg|
3216700|NCT01080521||Observational (cognitive function during chemotherapy)|Patients receive standard chemotherapy. Treatment repeats for 6 courses. Patients complete neurocognitive evaluations (Patient Assessment and Own Functioning scale and HeadMinder Custom Research Tool) and quality-of-life assessments (Hospital Anxiety and Depression Scale, FACT-O, and FACT/GOG-Ntx subscale) at baseline, before the fourth course of chemotherapy, at 3 weeks after the sixth course of chemotherapy, and at 6 months after the sixth course of chemotherapy.
3216701|NCT01080508||10 Asa I & II patients|
3216702|NCT01080495|Other|TEE (transesophageal echcardiography)|all patients get TEE and all parameters (radial strain, fractional shortening and fractional area change) are evaluated
3216703|NCT01080482|Active Comparator|Prograf® Capsule 5 mg|
3216704|NCT01080482|Experimental|Tacrolimus Capsule 5 mg|
3216705|NCT01080469|Active Comparator|Prograf® Capsule 1 mg|
3216706|NCT01080469|Experimental|Tacrolimus Capsule 1 mg|
3216707|NCT01080456|Active Comparator|Prograf® Capsule 1 mg|
3216708|NCT01080456|Experimental|Tacrolimus Capsule 1 mg|
3216709|NCT01080443|Active Comparator|Cellcept® 250 mg Capsule|
3216710|NCT01080443|Experimental|Mycophenolate Mofetil Capsule 250 mg|
3216711|NCT01080417|Active Comparator|Cellcept® 250 mg Capsule|
3216712|NCT01080417|Experimental|Mycophenolate Mofetil Capsule 250 mg|
3216713|NCT01080404|Experimental|Bariatric surgery (overall study)|A prospective follow-up study is to estimate the prevalence of OSA and associated metabolic abnormalities in Finnish morbidly obese subjects and to evaluate the effects of bariatric surgery on OSA and associated metabolic abnormalities. The study is conducted in seven hospitals in Finland and 300 patients are planned to be recruited in the study.
3216714|NCT01080404|Experimental|Bariatric surgery (randomised substudy)|As a substudy of a larger trial, a randomized study on the effects of bariatric surgery compared to CPAP treatment will be performed in obese (BMI 35-45) patients with OSA. The included 100 (15/center) patients are randomised to two groups: surgical intervention group (50) and CPAP group (50). Patients in the surgical intervention group undergo standardised surgical treatment (laparoscopic gastric bypass), including general health information, such as avoidance of smoking, alcohol drinking, and importance of healthy nutrition and regular exercise. The CPAP group will be assigned to CPAP treatment and they also receive the general health information.
3216715|NCT01080404|Active Comparator|CPAP (randomised substudy)|As a substudy of a larger trial, a randomized study on the effects of bariatric surgery compared to CPAP treatment will be performed in obese (BMI 35-45) patients with OSA. The included 100 patients are randomised to two groups: surgical intervention group (50) and CPAP group (50). Patients in the surgical intervention group undergo standardised surgical treatment (laparoscopic gastric bypass), including general health information, such as avoidance of smoking, alcohol drinking, and importance of healthy nutrition and regular exercise. The CPAP group will be assigned to CPAP treatment and they also receive the general health information.
3216716|NCT01080391|Active Comparator|Lenalidomide and Dexamethasone (Rd)|Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on Days 1 to 21 and Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22.
3216717|NCT01080391|Experimental|Carfilzomib, Lenalidomide, and Dexamethasone (CRd)|Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m2 was administered intravenously (IV) on Days 1 and 2 of Cycle 1, escalating to 27 mg/m2 on Days 8, 9, 15, and 16 of Cycle 1 and continuing on Days 1, 2, 8, 9, 15, and 16 of Cycle 2 through Cycle 12 and then from Cycle 13 through Cycle 18, 27 mg/m2 on Days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on Days 1 to 21 from Cycle 1 through Cycle 18 and from Cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22 from Cycle 1 through Cycle 18 and from Cycle 19 and higher.
3216718|NCT01080378|Other|Higher Birth Weight|3447g to 3879g
3216719|NCT01080378|Other|Lower Birth Weight|2624g to 2964g
3216720|NCT01080378|Other|Normal Birth Weight|2965g to 3446g
3216721|NCT01080365|Experimental|1|Commercial Tablet
3216722|NCT01080365|Experimental|2|Clinical Tablet
3216723|NCT01080352|Experimental|Vitamin C treatment|"Each subjects receive 12 weeks of 1 weekly treatment with intravenous vitamin c.~5grams are given at week 1, 30 grams at week 2 and 60 grams at week 3-12. If eligibility criteria are met the subject may continue with 1 weekly vitamin c treatment of 60 grams at week 13-20."
3216724|NCT01080339||Physical Activity and Nutrition|Supervised physical activity in the form of novel gaming and exercise equipment several times per week for 12 weeks will be provided in addition to weekly nutrition education sessions.
3216725|NCT01080339||Nutrition Education Only|Children in this group will receive weekly group nutrition sessions, identical to those provided for the Physical Activity + Nutrition group
3216726|NCT01080326|Experimental|Endoscopic Translumenal Omental Patch|Patients with the clinical diagnosis of a perforated viscus who are scheduled to undergo surgical exploration will be recruited. The endoscope will be gently advanced through the ulcer. Irrigation with saline will proceed. Then a viable mobile piece of omentum will be identified and pulled into the ulcer. After the omentum is located in the stomach, clips will be used to fix the Endoscopic Translumenal Omental Patch in place.
3216727|NCT01080313||Patients with head and neck cancer|
3216728|NCT01080300|Experimental|Gabapentin Extended Release|Active treatment
3216729|NCT01080300|Other|Placebo|Placebo
3216730|NCT01080287||Migraineurs with & w/out auras having orthostatic intolerance|Subjects between ages 18 and 65, having ICHD-II classification of migraine with or without aura, having symptoms of orthostatic intolerance
3216731|NCT01080287||Migraineurs with or without auras|Subjects between ages 18 and 65 having ICHD-II classification of migraine with or without auras
3216732|NCT01080274||positive ergometry|positive ergometry as specified by a cardiologist on site.
3216733|NCT01080274||negative ergometry.|negative ergometry as specified by cardiologist on site.
3216734|NCT01080274||patients with positive stress test|100 patients with positive ergometry test as specified by the cardiologist in charge. All patients are ambulatory patients referred for routine check up.
3216735|NCT01080261|Experimental|PROMUS Element|everolimus-eluting coronary stent
3216736|NCT01080248|Experimental|Arm 1 (gemcitabine & pazopanib)|"Gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle.~Pazopanib 800 mg PO daily of each 28 day cycle."
3216737|NCT01080235|Active Comparator|1|Control. Forty-two residency programs randomly assigned and stratified according to size, affiliation, geographic location, and presence of geriatrics fellowship. Twenty-one in the control arm. This group will use PIM as a data collection tool during baseline and follow-up time (i.e. audit of 50-75 charts, survey from 50-75 patients, and one system survey). They will not see the summary results of the data collected; they will not be required to complete a quality improvement plan based on the summary data. Local researchers will collect the data. Individual trainees will not do data collection or audits. At both baseline and follow-up, trainees will complete pre and post test surveys of 1) geriatric and 2) quality improvement knowledge, skills, and attitudes.
3216738|NCT01080235|Other|2|There are 21 residency programs in intervention arm who will 1) use PIM as a data collection tool (local researchers will audit 50-75 charts, survey 50-75 patients, and complete one system survey); 2) Each trainee will audit of up to five patient charts; collect 5 patient surveys; and complete the system survey as a group; 3) Summary data from these data streams will be reviewed by group; then they will design and implement a quality improvement plan; 4) At follow-up, local researchers will re-audit same 50-75 charts, collect surveys from same 50-75 patients, and complete one system survey. At baseline and follow-up, trainees and faculty will complete surveys of geriatric and quality improvement knowledge, skills, and attitudes.
3216739|NCT01080222|Experimental|Treatment Arm A|Treatment Arm A was discontinued as a result of patients meeting a pre-defined stopping rule related to viral breakthrough during the first four weeks of dosing.
3216740|NCT01080222|Experimental|Treatment Arm B|Treatment Arm B was discontinued as a result of patients meeting a pre-defined stopping rule relating to viral breakthrough.
3216741|NCT01080222|Experimental|Treatment Arm C|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 12 weeks for a total treatment duration of 24 weeks.~Enrollment for this arm is complete. No additional subjects will be recruited."
3216742|NCT01080222|Experimental|Treatment Arm D|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 12 weeks for a total treatment duration of 24 weeks.~Enrollment for this arm is complete. No additional subjects will be recruited."
3216743|NCT01080222|Experimental|Treatment Arm E|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 24 weeks for a total treatment duration of 36 weeks."
3216744|NCT01080222|Experimental|Treatment Arm F|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 24 weeks for a total treatment duration of 36 weeks."
3216745|NCT01080209|Experimental|Brimo PS DDS® 400 μg (2 implants)|Patients who received Brimo PS DDS® 400 μg (2 implants) in a previous study.
3216746|NCT01080209|Experimental|Brimo PS DDS® 400 μg (1 implant)|Patients who received Brimo PS DDS® 400 μg (1 implant) in a previous study.
3216747|NCT01080209|Experimental|Brimo PS DDS® 200 μg (2 implants)|Patients who received Brimo PS DDS® 200 μg (2 implants) in a previous study.
3216748|NCT01080209|Experimental|Brimo PS DDS® 200 μg (1 implant)|Patients who received Brimo PS DDS® 200 μg (1 implant) in a previous study.
3216749|NCT01080209|Experimental|Brimo PS DDS® 100 μg (1 implant)|Patients who received Brimo PS DDS® 100 μg (1 implant) in a previous study.
3216750|NCT01080209|Experimental|Brimo PS DDS® 50 μg (1 implant)|Patients who received Brimo PS DDS® 50 μg (1 implant) in a previous study.
3216751|NCT01080209|Sham Comparator|Sham|Patients who received sham in a previous study.
3216785|NCT01079936|Experimental|Lenalidomide + High-Dose Melphalan|Lenalidomide beginning dose level 25 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.
3217373|NCT01075230|Active Comparator|Standard TKA with PRP|
3216752|NCT01080196|Experimental|RENEW|"RENEW will occur on a recumbent ergometer that appears like a normal stepper ergometer. While resisting the foot pedal movement the participant experiences eccentric muscle contractions about the knee and hip while performing negative work. The progression of the 3 x/week (every other day), 12 week RENEW program will be determined as a function of the rating of perceived exertion (RPE) using a target workload on the monitor. RENEW will be increased very slowly over the first 3 weeks and, subsequently, to maintain an 11-13 perceived exertion. During the formal RENEW training regimen the participants become fully acclimated to the device (week 3-4) the total RENEW load will increase weekly with no increase in their RPE."
3216753|NCT01080196|No Intervention|TRADITIONAL|"The TRAD group will perform their lower extremity resistance exercise for 15 minutes per session with isotonic weight machines and cuff weights as part of their multicomponent exercise fall reduction program (MCERFP). The progression of the 3 x/week, 12 week TRAD program will be determined as a relative function of their 1 repetition maximum (1RM) weight that can be lifted in a safe and successful manner. The 1RM will be measured before the 12 week training program and every 2 weeks thereafter. A target resistance workload (i.e., weight level) commensurate with 60-70% of the 1RM of the knee and hip extensors will be calculated bi-monthly and 3 sets of 15 repetitions of 3-4 different knee and hip exercises will be used over a 15 minute time period."
3216754|NCT01080183|Experimental|Feedback form|patients receive feedback regarding their prms in addition to doctor receiving report
3216755|NCT01080183|No Intervention|usual care|patients do not receive feedback form prior to the encounter, clinicians continue to receive patient reported measures prior to the appointment
3216756|NCT01080170||Anastrazole|Newly diagnosed, non-metastatic, hormone-receptor positive breast cancer patients, who have undergone lumpectomy, have been advised to not require chemotherapy, but will need to undergo radiation therapy and will be initiating therapy with anastrazole.
3216757|NCT01080170||Control group - 2|Healthy controls.
3216758|NCT01080157||Volunteers 18+, at risk for diabetes|
3216759|NCT01080144|Experimental|Critical Flicker Frequency|Critical Flicker Frequency Procedure
3216760|NCT01080131|Experimental|Canakinumab 150 mg|"Participants received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Participants completing the 12 week core study could continue to be treated in a 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.~In the second extension study participants were to receive open-label on demand treatment with canakinumab 150 mg sc upon new flare for 1 year, for a total duration of 18 months."
3216761|NCT01080131|Active Comparator|Triamcinolone acetonide 40 mg|"Participants received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Participants completing the 12 week core study could continue to be treated in a 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.~In the second extension study participants were to switch to open-label on demand treatment with canakinumab 150 mg sc upon new flare for 1 year. Triamcinolone acetonide was not to be administered in the second extension study."
3216762|NCT01080118|Other|control group|Control group, taught with a standard Macintosh laryngoscope
3216763|NCT01080118|Experimental|Study group|Study group taught with the Airtraq video laryngoscope
3216764|NCT01080105|Experimental|AIM + surveillance|Participants will receive access to the AIM website and calls from a motivational coach for 12 weeks plus an additional year of surveillance and optional coach support.
3216765|NCT01080105|Experimental|AIM intervention|Participants will receive access to the AIM web based intervention and calls from a motivational coach for 12 weeks
3216766|NCT01080105|Active Comparator|Educational website|Participants will be given access to a static website with depression prevention related materials and handouts.
3216767|NCT01080092|Experimental|breathing technique group|technique as a stress management technique, reinforced by biofeedback
3216768|NCT01080092|Placebo Comparator|no breathing technique|the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
3216769|NCT01080079|Active Comparator|Group A -Terbinafine HCl|Terbinafine HCl
3216770|NCT01080079|Active Comparator|Group B - Terbinafine HCl|Terbinafine HCl
3216771|NCT01080079|Active Comparator|Group C - Terbinafine HCl|Terbinafine HCl
3216772|NCT01080079|Active Comparator|Group D Terbinafine HCl|Terbinafine HCl
3216773|NCT01080079|Active Comparator|Group E|Terbinafine HCl
3216774|NCT01080079|Placebo Comparator|Group F - Placebo|Placebo application
3216775|NCT01080066||Non-Interventional Study|
3216776|NCT01079988|Experimental|Cyclosporin|Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
3216777|NCT01079988|Experimental|Retinoids|Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
3216778|NCT01079988|Experimental|Systemic corticosteroids|Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
3216779|NCT01079988|Experimental|Methotrexate|Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
3216780|NCT01079988|Experimental|Systemic corticosteroids/methotrexate|"Corticosteroid starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%.~Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks."
3216781|NCT01079962|Experimental|Bisoprolol|
3216782|NCT01079962|Active Comparator|Atenolol|
3216783|NCT01079949|Experimental|r-hLH + r-hFSH|
3216784|NCT01079949|Active Comparator|r-hFSH|
3217374|NCT01075217|Experimental|Isovue 250 (iopamidol)|
3216787|NCT01079923|Active Comparator|Daily Dose Supplementation|Age 18 to 40 years, non-pregnant, non-lactating, female subjects.
3216788|NCT01079910|Experimental|Experimental toothpaste|0.1% isopropylmethylphenol and 1150ppm fluoride
3216789|NCT01079910|Other|Marketed toothpaste|NaF/Silica toothpaste containing 1150ppm fluoride
3216790|NCT01079897|Active Comparator|Atopiclair|
3216791|NCT01079897|Experimental|EHK02-01|Ectoine containing cream
3216792|NCT01079871|Experimental|FID 114657 (ORB Preserved Ocular Emulsion)|ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
3216793|NCT01079858|Experimental|FID 114657 (ORB Preserved Ocular Emulsion)|ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
3216794|NCT01079845|Experimental|Low-glycemic Load Diet|
3216795|NCT01079845|Active Comparator|Low-fat Diet|
3216796|NCT01079832|Experimental|Arm I: CyberKnife Radiosurgery|Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.
3216797|NCT01079819|Active Comparator|A1 (BMS-708163)|
3216798|NCT01079819|Placebo Comparator|A2 (Placebo)|
3216799|NCT01079819|Active Comparator|B1 (BMS-708163)|
3216800|NCT01079819|Placebo Comparator|B2 (Placebo)|
3216801|NCT01079806|Active Comparator|Entecavir|Participants received entecavir, 0.015 mg/kg up to 0.5 mg, once daily, for 96 to 144 weeks, depending on response
3216802|NCT01079806|Placebo Comparator|Placebo|Participants received placebo, 0 mg, once daily, for 48 to 96 weeks, depending on response
3216803|NCT01079780|Experimental|Arm I|Patients receive cetuximab IV over 60-120 minutes and irinotecan hydrochloride over 60-90 minutes on day 1.
3216804|NCT01079780|Experimental|Arm II|Patients receive ramucirumab IV over 60 minutes on day 1 and cetuximab and irinotecan hydrochloride as in arm I.
3216805|NCT01079767|Other|Temsirolimus|Temsirolimus
3216806|NCT01079754|Experimental|Spinal morphine 0.05 mg|Patient received spinal morphine 0.05 mg
3216807|NCT01079754|Active Comparator|Spinal morphine 0.1 mg|Patient received spinal morphine 0.1 mg
3216808|NCT01079741|Experimental|Dose-escalation component|Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen and Montanide will be held constant.
3216809|NCT01079741|Active Comparator|Phase II is the randomized component.|The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B).
3216810|NCT01079728||ischemic stroke patients|patients with an ischemic stroke in the anterior (ACA, MCA) and posterior flow area (PCA, BA) of any severity in the last 36h
3216811|NCT01079715|Experimental|Propranolol|Oral Propranolol administration is the experimental arm of this study
3216812|NCT01079715|No Intervention|Control|Control arm is treated following the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group
3216813|NCT01079676|Experimental|Filgrastim|
3216814|NCT01079676|Active Comparator|Granulokine|
3216815|NCT01079663|Experimental|Chlorhexidine chip (Periochip®)|
3216816|NCT01079663|Placebo Comparator|Placebo chip|
3216817|NCT01079650||children suffering from abdominal or testicle pain|
3216818|NCT01079637|Experimental|Midfoot Fusion Bolt|
3216819|NCT01079637|Experimental|Cast treatment|
3216820|NCT01079624|Experimental|GIP two doses and GLP-1 one dose|Intervention with infusion of GIP or GLP-1 intravenously
3216821|NCT01079624|Placebo Comparator|Saline infusion|Control
3216822|NCT01079598|Other|Treatment|RF ablation with ClosureRFS Stylet
3216823|NCT01079572|Experimental|web-based|The patient will undergo xrays at the closest PACs enabled imaging centre and will login and answer questions online. The surgeon will review the images and patient responses and determine whether the patient needs to be seen more urgently or a per routine.
3216824|NCT01079572|Active Comparator|in-person|Patients will attend their follow-up appointments in-person as per usual
3216825|NCT01079559|Active Comparator|Simplex™ P|All patients will receive preoperative antibiotics administered within the hour prior to surgery. All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
3216826|NCT01079559|Experimental|Simplex™ P with Tobramycin|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
3216827|NCT01079546||Sq.CC of head and neck TASMC|
3216828|NCT01079546||hadassa Jerusalem|
3216829|NCT01079546||sheba hospital|
3216830|NCT01079546||rambam Haifa|
3216831|NCT01079546||belinson Petah Tikva|
3216832|NCT01079546||Nazeret|
3216833|NCT01079546||soroka beer sheva|
3216834|NCT01079533|Active Comparator|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
3216933|NCT01078792||COPD exacerbation|Patients admitted to hospital with COPD exacerbation
3216934|NCT01078779|Experimental|Chloroquine|
3216935|NCT01078779|Placebo Comparator|Placebo|
3216835|NCT01079533|Experimental|Minimal Cue and TLC|Participants randomized to the experimental arm will receive a minimal cue after completing the baseline survey. A follow up survey will be sent 9 months after completion of the minimal cue to assess whether the participant received CRCS. If the participant has not had CRCS they will receive a more intensive telephone linked communication intervention. A second follow up will be sent 9 months after the TLC is delivered to assess final screening status.
3216836|NCT01079507||adult acute lymphoblastic leukemia|Patients were diagnosed as adult acute lymphoblastic leukemia.
3216837|NCT01079494|Active Comparator|intervention group|physician-pharmacist teamwork
3216838|NCT01079494|No Intervention|control|physician only team
3216839|NCT01079481|Experimental|taxol plus everolimus|
3216840|NCT01079468||Total Hip Arthroplasty|
3216841|NCT01079468||Total Hip Resurfacing Arthroplasty|
3216842|NCT01079455|Active Comparator|HA|Coxarthrosis
3216843|NCT01079455|Active Comparator|Corticosterone|Coxarthrosis
3216844|NCT01079455|Placebo Comparator|Bupivacaine|Coxarthrosis
3216845|NCT01079442|Active Comparator|Treatment arm: coffee|coffee administration
3216846|NCT01079442|Placebo Comparator|Water arm|The control drink consists of 100 ml warm water
3216847|NCT01079429||MGUS or SMM|Patients with Monoclonal gammopathy of undetermined significance or smoldering myeloma
3216848|NCT01079416||Capsule endoscopy|Study device
3216849|NCT01079416||Esophagogastroduodenoscopy|Gold standard
3216850|NCT01079390|Experimental|High dose acupuncture|six needle applied during acupuncture
3216851|NCT01079390|Experimental|Low dose acupuncture|two needles will be applied.
3216852|NCT01079390|Placebo Comparator|placebo acupuncture|sham acupuncture treatment will be applied
3216853|NCT01079377||Adolescent Surgical Candidates|Adolescents at the Center for Adolescent Bariatric Surgery, Columbia University Medical Center
3216854|NCT01079377||Obese Treatment-Seeking Adolescents|Obese Treatment-Seeking Adolescents, Maxcor Program for Overweight Education and Reduction (POWER) Program
3216855|NCT01079377||Normal-Weight Adolescents|Normal-Weight Adolescents
3216856|NCT01079364|Experimental|Insulin glargine + Insulin glulisine|Daily injection of insulin glargine plus one injection of mealtime insulin glulisine at the main meal
3216857|NCT01079364|Active Comparator|Premixed insulin|twice daily premixed insulin (before breakfast and evening meal).
3216858|NCT01079338|Experimental|caffeine|
3216859|NCT01079325|Experimental|SB-509|
3216860|NCT01079325|Placebo Comparator|Placebo|Saline
3216861|NCT01079312|Active Comparator|Propofol infusion|Anaesthesiologist`s managed intravenous infusion of propofol 10mg/ml
3216862|NCT01079312|Active Comparator|Patient-controlled sedation|self-administration of propofol and remifentanil mixture during ERCP
3216863|NCT01079299|Experimental|IPC plus standard compression|
3216864|NCT01079299|Active Comparator|Standard compression alone|
3216865|NCT01079286|Experimental|nelfinavir and temsirolimus|dose escalation
3216866|NCT01079273|Active Comparator|Vaccine|All Subjects enrolled in this study will receive the study vaccine (single-arm)
3216867|NCT01079260|Active Comparator|Standard ONS|
3216868|NCT01079260|Experimental|High Energy, Low volume ONS|High energy, low volume ONS
3216869|NCT01079247|Active Comparator|Liberal|Maintain hemoglobin at 10-11 g/dL
3216870|NCT01079247|Active Comparator|Restrictive|Maintain hemoglobin at 7-8 g/dL
3216871|NCT01079234|Experimental|Flex + insulin aspart|
3216872|NCT01079234|Experimental|Fixed + insulin aspart|
3216873|NCT01079234|Active Comparator|IGlar + insulin aspart|
3216874|NCT01079221|Experimental|Knee extensor exercise training|High intensity aerobic knee-extensor exercise training
3216875|NCT01079208|Placebo Comparator|standard starter infant formula|standard starter infant formula
3216876|NCT01079208|Experimental|test starter formula|test infant formula
3216877|NCT01079208|Experimental|test starter formula with synbiotics|starter formula with synbiotics and adapted protein levels
3216878|NCT01079195||Single Patient group with Hypertension|Single Patient group with Hypertension
3216879|NCT01079182||Ankylosing spondylitis|Participants with ankylosing spondylitis
3216880|NCT01079169|Experimental|Cranberry capsule|
3216881|NCT01079169|Placebo Comparator|Placebo capsule|
3216882|NCT01079143|Experimental|Certican EMT+|Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®.
3216883|NCT01079143|Experimental|Certican EMT-|Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®.
3216884|NCT01079143|Active Comparator|Neoral EMT+|Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®.
3216885|NCT01079143|Active Comparator|Neoral EMT-|Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®.
3216886|NCT01079130|Experimental|Indacaterol 18.75 µg|"Indacaterol 18.75 µg once daily in the morning via Concept1, a single-dose dry powder inhaler (SDDPI) and Placebo to Salmeterol in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI) for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
3216887|NCT01079130|Experimental|Indacaterol 37.5 µg|"Indacaterol 37.5 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
3216936|NCT01078766|Experimental|CIMT+HABIT|"Form of summer camp, for six hours per day for 10 consecutive work days."
3217375|NCT01075217|Active Comparator|Visipaque 270 (iodixanol)|
3216888|NCT01079130|Experimental|Indacaterol 75 µg|"Indacaterol 75 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
3216889|NCT01079130|Experimental|Indacaterol 150 µg|"Indacaterol 150 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
3216890|NCT01079130|Active Comparator|Salmeterol|"Salmeterol 50 µg twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI) and Placebo to Indacaterol once daily in the morning via Concept1, a SDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
3216891|NCT01079130|Placebo Comparator|Placebo|"Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
3216892|NCT01079117|Active Comparator|Sevre-Long™|slow release oral morphine
3216893|NCT01079117|Active Comparator|Methadone|Methodone
3216894|NCT01079104|Active Comparator|Control|Standard Medical Therapy
3216895|NCT01079104|Experimental|Hepa Wash|"Treatment with the liver support system Hepa Wash"
3216896|NCT01079091|Active Comparator|Control|Standard Medical Therapy
3216897|NCT01079091|Experimental|Hepa Wash|"Treatment with the liver support system Hepa Wash"
3216898|NCT01079078|Experimental|Test|Acetaminophen extended release gelcaps 650 mg of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
3216899|NCT01079078|Active Comparator|Reference|Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)of McNeil Consumer & Specialty Pharmaceuticals, Division of MCNEIL-PPC, Inc. Fort Washington, PA 19034 USA
3216900|NCT01079065|Experimental|Test|Famotidine Tablets, USP 20 mg of OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
3216901|NCT01079065|Active Comparator|Reference|Pepcid® AC Acid reducer famotidine tablets 20 mg of Johnson & Johnson. Merck Consumer Pharmaceutical Co. Fort Washington, PA 19034 USA
3216902|NCT01079052|Experimental|Test|Famotidine Tablets, USP 20 mg of OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
3216903|NCT01079052|Active Comparator|Reference|Pepcid® AC Acid reducer famotidine tablets 20 mg of Johnson & Johnson. Merck Consumer Pharmaceutical Co. Fort Washington, PA 19034 USA
3216904|NCT01079013|Experimental|treosulfan|
3216905|NCT01079000|Active Comparator|Control - usual care (UC)|Usual care after an ED visit for asthma will include the provision of discharge instructions/plan, and action plan, and verbal instructions for follow-up with their PCP, and a faxed copy of the ED chart to the patient's PCP.
3216906|NCT01079000|Experimental|Opinion leader (OL) guidance to patients' PCPs|In addition to UC, OL guidance will be provided to the patients' PCP. A letter signed by an influential, respected, and local clinical leader (Respirologist) will encourage follow-up within two weeks and provide management suggestions.
3216907|NCT01079000|Experimental|Care manager education to patients|In addition to UC and OL guidance provided to the patients' PCP, care manager self-management education will be provided to patients. A care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged.
3216908|NCT01078987|Active Comparator|Group 1|One to three 5-day course of plasma exchange (plasmapheresis)
3216909|NCT01078987|Active Comparator|Group 2|One to three 5-day course of plasma exchange (plasmapheresis)
3216910|NCT01078987|No Intervention|Group 3|No intervention taken
3216911|NCT01078987|Active Comparator|Group 4|One to three 5-day course of plasma exchange (plasmapheresis)
3216912|NCT01078974|Experimental|pomalidomide, dexamethasone, rituximab|"Drug: pomalidomide Taken orally once a day~Drug: dexamethasone Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15~Drug: rituximab Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15"
3216913|NCT01078961|Experimental|Dose Escalation|
3216914|NCT01078948|Experimental|Active 2mA tDCS|The stimulator will be used to deliver anodal stimulation to the left prefrontal cortex and cathodal stimulation to the right prefrontal cortex. The placement of the anode is proposed to enhance activity in the left frontal cortex; the cathode aims to reduce activity in the right prefrontal cortex.
3216915|NCT01078948|Sham Comparator|Sham tDCS|The system setup is identical to that of active tDCS; however, the stimulator will be turned off after 30 seconds.
3216916|NCT01078922|Experimental|Ofatumumab|The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
3216917|NCT01078909|Experimental|300mg Fish Oil (EPA + DHA) Supplement|
3216918|NCT01078909|Experimental|600mg Fish Oil (EPA+DHA) Supplement|
3216919|NCT01078909|Experimental|900mg Fish Oil (EPA + DHA) Supplement|
3216920|NCT01078909|Experimental|1800mg Fish Oil (EPA + DHA) Supplement|
3216921|NCT01078909|Placebo Comparator|Placebo|
3216922|NCT01078883||Lung cancer|Patients with primary stage IIIb and IV lung cancer
3216923|NCT01078870|Experimental|A|
3216924|NCT01078870|Experimental|B|
3216925|NCT01078870|Experimental|C|
3216926|NCT01078844|Placebo Comparator|Placebo|Treatment as usual plus placebo
3216927|NCT01078844|Active Comparator|memantine|Treatment as usual plus memantine
3216928|NCT01078831||ARDS / ALI patients|
3216929|NCT01078818|Experimental|IV trivalent saccharose hydroxide ferrous|
3216930|NCT01078818|Active Comparator|Oral ferrous fumarate|
3216931|NCT01078818|Placebo Comparator|Oral and intravenous Placebo|
3216932|NCT01078805||FORTEO (teriparatide)-treated|FORTEO-treated
3216937|NCT01078753|Experimental|Desmopressin|During treatment period I participants received 120 μg per day desmopressin oral lyophilisate tablet for 14 days. Participants for whom treatment was effective (a reduction of ≥ 75% from Baseline in the number of wet nights), and who showed no problems with tolerability, continued to receive the same treatment for a further 14 days in treatment period II. Participants for whom efficacy was inadequate (a reduction of <75% from Baseline in the number of wet nights), but who showed no tolerability problems, received an increased dose of desmopressin oral lyophilisate tablet 240 µg for 14 days in treatment period II.
3216938|NCT01078753|Placebo Comparator|Placebo|Participants received matching placebo tablets during treatment periods I and II according to the same efficacy criteria as participants in the Desmopressin treatment group.
3216939|NCT01078740||Non-CF subjects|Rectal tissue obtained from study subjects without cystic fibrosis (CF) as part of scheduled colonoscopy/biopsies performed for clinical care
3216940|NCT01078740||CF subjects|"Rectal tissue obtained from study subjects with cystic fibrosis (CF) in one of three ways:~Rectal biopsy as part of scheduled colonoscopy/biopsies performed for clinical care~Sigmoidoscopy/biopsy added onto a scheduled, unrelated procedure or surgery performed under general anesthesia~Sigmoidoscopy/biopsy performed for the sole purpose of obtaining rectal tissue for the current study"
3216941|NCT01078714|Experimental|Bumetanide|
3216942|NCT01078714|Placebo Comparator|Control|
3216943|NCT01078701|Experimental|GHB11L1|Dose levels: 6.0 log10 TCID50/volunteer, 6.5 log10 TCID50/volunteer and 7.0 log10 TCID50/volunteer
3216944|NCT01078701|Placebo Comparator|SPGN buffer|SPGN buffer administration by liquid nasal spray
3216945|NCT01078675|Experimental|1|
3216946|NCT01078662|Experimental|1|olaparib 400mg BD
3216947|NCT01078649|Experimental|Debio 1143 (AT-406)|Open label study. All patients participating in the study will receive Debio 1143 (AT-406).
3216948|NCT01078636||EMCI (only cohort recruiting in this study)|Newly recruited early amnestic Mild Cognitive Impairment patients; estimated enrollment 200
3216949|NCT01078636||LMCI (not recruiting in this study)|Late Mild Cognitive Impairment patients; approximately 400 LMCI participants anticipated to follow from the original ADNI study
3216950|NCT01078636||CN (not recruiting in this study)|Cognitively Normal patients; approximately 200 CN participants anticipated to follow from the original ADNI study
3216951|NCT01078623|Active Comparator|Formoterol 12 μg|Formoterol fumarate 12 μg twice daily
3216952|NCT01078623|Placebo Comparator|Placebo|Placebo twice daily
3216953|NCT01078623|Experimental|Aclidinium 200 μg / formoterol 12 μg|Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
3216954|NCT01078623|Experimental|Aclidinium 200 μg / formoterol 6 μg|Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
3216955|NCT01078623|Experimental|Aclidinium 200 μg|Aclidinium bromide 200 μg twice daily
3216956|NCT01078610||Psoriatic arthritis patients|
3216957|NCT01078597||Patients with early Rheumatoid Arthritis|Patients , aged 18 years or over, diagnosed with Rheumatoid Arthritis, with evidence of disease activity within the last year.
3216958|NCT01078584||Hypertensive Participants|Hypertensive diabetics and non-diabetics, with or without isolated systemic hypertension and/or renal dysfunction, who were naïve to trandolapril or on trandolapril within past 30 days.
3216959|NCT01078571||RA patients in treatment with adalimumab (Humira)|RA patients in treatment with adalimumab (Humira) at 40mg alternate weeks
3216960|NCT01078558||Patients with rheumatic disease|Patients suffering from rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
3216961|NCT01078545||Adv. PCa patients with LUTS treated with GnRH analogue|Patients with advanced prostate cancer and lower urinary tract symptoms treated with GnRH analogue Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine)
3216962|NCT01078532|Experimental|SMART PHR|Patients receive the active PHR
3216963|NCT01078532|Other|Passive PHR|Usual PHR Care
3216964|NCT01078519|No Intervention|Massages baths|doulas, massages and baths
3216965|NCT01078519|Active Comparator|Combined spinal-epidural anesthesia|local anesthetics in low doses with opioids
3216966|NCT01078506||Hong Kong Chinese|Without a history of known intracranial pathologies.
3216967|NCT01078480|Experimental|Arm sling treatment|Displaced midshaft fracture of the collar bone treated with an arm sling
3216968|NCT01078480|Experimental|Operation|Displaced midshaft fracture of the collar bone treated with operation using a pre contoured titanium plate and screws.
3216969|NCT01078454|Experimental|ARM A (Mel-Dex)|Patients receive melphalan 0.22 mg/kg orally (PO) and dexamethasone 40 mg PO on days 1-4 every 4 weeks. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
3216970|NCT01078454|Experimental|ARM B (B-Mel-Dex)|Patients receive melphalan 0.22 mg/kg PO and dexamethasone 40 mg PO on days 1-4 and bortezomib 1.3 mg/m^2 intravenously (IV) on days 1, 4, 8, and 11 every 4 weeks. Treatment repeats every 4 weeks for 2 cycles. Patients then receive melphalan PO and dexamethasone PO on days 1-4 and bortezomib IV on days 1, 8, 15, and 22 every 5 weeks. Treatment repeats every 5 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3216971|NCT01078441|Experimental|Treatment (combination chemotherapy)|Patients receive bortezomib 1.3 mg/m2 subcutaneously on days 1, 8, and 15; liposomal doxorubicin 30 mg/m2 intravenously (IV) over 1 hour on day 4; oral dexamethasone 20mg on days 1, 2, 8, 9, 15 and 16; and cyclophosphamide 750 mg/m2 IV over 2 hours on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
3216972|NCT01078428|Active Comparator|Silicone gel|Gel containing silicone gel
3216973|NCT01078428|Placebo Comparator|Vaseline|Gel containing petrolatum gel
3216974|NCT01078402||Single patients group: RA, PsA and AS|Single patients group with: Active Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS)
3216975|NCT01078389|Experimental|Febuxostat 40 mg or 80 mg|Febuxostat 40 mg or 80 mg (based on serum urate levels at Day 14), capsules, orally, once daily for up to 24 Months.
3216976|NCT01078389|Placebo Comparator|Placebo|Febuxostat placebo-matching capsules, orally, once daily for up to 24 Months.
3216977|NCT01078376|Experimental|Cohort 1: Healthy Adults (18 years to 45 years old)|Azilsartan medoxomil 80 mg, tablets, orally, one day only
3217060|NCT01077752|Experimental|1|Patients with continuous ropivacaine preperitoneal infusion
3216978|NCT01078376|Experimental|Cohort 1: Adolescents (≥12 to <17 years old)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
3216979|NCT01078376|Experimental|Cohort 2: Children (≥6 to <12 years old)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
3216980|NCT01078376|Experimental|Cohort 3: Children (≥1 to <6 years old)|Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
3216981|NCT01078363|Active Comparator|ramipril|ramipril, 5mg starting dose to maximum dose of 20mg daily dose for one year.
3216982|NCT01078363|Placebo Comparator|Placebo|Sugar pill manufactured to mimic ramipril 5mg starting dose , increasing to 20mg daily for one year.
3216983|NCT01078324||Ischemic colitis|Ischemic colitis, Diverticulosis
3216984|NCT01078311||HCC patients on Sorafenib|
3216985|NCT01078298|Experimental|varenicline|
3216986|NCT01078298|Placebo Comparator|placebo|placebo
3216987|NCT01078285||Control|
3216988|NCT01078285||Intervention Arm|
3216989|NCT01078272|Experimental|Remote Ischemic Preconditioning (RIPC)|Randomized subjects who are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
3216990|NCT01078272|Placebo Comparator|Sham Remote Ischemic Preconditioning|Patients who prior to stenting have the RIPC blood pressure cuff placed but not inflated for 3 5 minute episodes with 5 minute rest periods.
3216991|NCT01078246||Raltegravir Cohort Only|Participants with HIV-1 infection who received raltegravir (RAL) on or after 12 October 2007 (the market authorization date in the United States) (Raltegravir Cohort). These participants contributed data to the Raltegravir Cohort only.
3216992|NCT01078246||Historical and Raltegravir Cohorts Only|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), and 2) received RAL on or after 12 October 2007 (Raltegravir Cohort). These participants contributed data to the Historical and Raltegravir Cohorts only.
3216993|NCT01078246||Historical Cohort Only|Participants with HIV-1 infection who received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort). These participants contributed data to the Historical Cohort only.
3216994|NCT01078246||Historical and Concurrent Cohorts Only|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), and 2) received therapy with a new non-RAL antiretroviral therapy after 12 October 2007 (Concurrent Cohort). These participants contributed data to the Historical and Concurrent Cohorts only.
3216995|NCT01078246||Concurrent Cohort Only|Participants with HIV-1 infection who received therapy with a new non-RAL antiretroviral therapy after 12 October 2007 (Concurrent Cohort). These participants contributed data to the Concurrent Cohort only.
3216996|NCT01078246||Concurrent and Raltegravir Cohorts Only|Participants with HIV-1 infection who 1) received therapy with a new non-RAL antiretroviral therapy on or after 12 October 2007 (Concurrent Cohort), and 2) received RAL after 12 October 2007 (Raltegravir Cohort). These participants contributed data to the Concurrent and Raltegravir Cohorts only.
3216997|NCT01078246||Historical, Concurrent and Raltegravir Cohorts|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), 2) received therapy with a new non-RAL antiretroviral therapy on or after 12 October 2007 (Concurrent Cohort), and 3) received RAL after 12 October 2007 (Raltegravir Cohort). These participants contributed data to all three cohorts.
3216998|NCT01078233||Raltegravir Cohort|Participants with HIV-1 infection who started raltegravir on or after 21 December 2007 (the authorization date in the European Union) and had at least 1 month prospective follow-up in the Raltegravir Cohort. Participants from the Historical Cohort and Concurrent Cohort were eligible for inclusion in the Raltegravir Cohort.
3216999|NCT01078233||Historical Cohort|Participants with HIV-1 infection who started a new antiretroviral drug as part of a combination antiretroviral therapy (cART) regimen on or after 1 January 2006 and before 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Historical Cohort.
3217000|NCT01078233||Concurrent Cohort|Participants with HIV-1 infection who started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. Participants from the Historical Cohort were eligible for inclusion in the Concurrent Cohort.
3217001|NCT01078220||3-Dose Safety Population (Primary)|Females between ages 9 to 26 at receipt of the first dose of GARDASIL who are members of the participating MCOs and have completed the 3-dose regimen of GARDSIL vaccination with 12 months.
3217002|NCT01078220||Pregnancy Safety Population|Females who received at least one dose of GARDASIL during pregnancy.
3217003|NCT01078220||Autoimmune Safety Population|Females who have received at least one dose of GARDASIL and have been members in the same MCO for at least 12 months prior to receiving their first dose of GARDASIL.
3217004|NCT01078220||Any Dose Safety Population (Secondary)|Females who have received at least one dose of GARDASIL and have been members in the same MCO for at least 12 months prior to receiving their first dose of GARDASIL.
3217005|NCT01078194||Weight regain / weight loss failure|Weight regain of more than 10 kg from or weight loss of less than 50% EWL 18 months after lap. gastric bypass
3217006|NCT01078181|Active Comparator|banded gastric bypass|Banded gastric bypass (circular anastomosis 21mm) using the A.M.I. B-Band (Soft Gastric Bypass Band)
3217007|NCT01078181|Active Comparator|non-banded gastric bypass|non-banded gastric bypass (circular anastomosis 21mm)
3217008|NCT01078168|Active Comparator|Acitretin|oral, 30 mg per day, day 1-28
3217009|NCT01078168|Placebo Comparator|Placebo|oral, day 1-28
3217010|NCT01078155||Participants with Active Rheumatoid Arthritis (RA)|Participants (women and men) with active early and long-standing RA according to American College of Rheumatology revised criteria from 1987 were prescribed adalimumab in the usual manner in accordance with the terms of the local market authorization with regards to dose, population and indication as well as local guidelines. The decision to prescribe or not to prescribe an anti-TNF was taken prior to a participant's enrollment in the study.
3217011|NCT01078142|Experimental|Single arm|Bendamustin, Rituximab, Temsirolimus
3217203|NCT01076582|Active Comparator|Arm 2|
3217012|NCT01078129|Active Comparator|behavior therapy - CRT|behavior program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions) by means REHACOM® software
3217013|NCT01078129|Sham Comparator|non-CRT|no intervention
3217014|NCT01078116||Patients with Rheumatoid Arthritis|Eligible rheumatoid arthritis patients treated with adalimumab according to the approved Summary of Product Characteristics (SmPC) in European Union
3217015|NCT01078090||Rheumatoid arthritis|Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 5 years.
3217016|NCT01078064||Study group|Patients with symptoms suggesting gastroesophageal reflux and referred to perform an impedance study.
3217017|NCT01078051|Active Comparator|Optimal medical therapy|optimal medical therapy
3217018|NCT01078051|Active Comparator|drug-eluting stent|Cypher, xience, Endeavor, Taxus
3217019|NCT01078038|Active Comparator|Cypher|Sirolimus-eluting stent
3217020|NCT01078038|Active Comparator|Xience V|Everolimus-eluting stent
3217021|NCT01078025||transvaginal hybrid cholecystectomy|
3217022|NCT01078025||laparoscopic cholecystectomy|
3217023|NCT01078012|Active Comparator|Trained counselling|Comparison of outcomes before intervention vs. 2 months after
3217024|NCT01077999|Active Comparator|Carboplatin + paclitaxel + radiotherapy|Carboplatin AUC = 2, Paclitaxel 50 mg/m2 (both weekly) , a total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
3217025|NCT01077999|Experimental|Carboplatin+ paclitaxel+ panitumumab+ radiotherapy|Carboplatin AUC = 2, Paclitaxel 50 mg/m2 (both weekly) , a total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy. Panitumumab panitumumab: 6mg/kg in weeks 1-3-5.
3217026|NCT01077973|Experimental|Treatment A|
3217027|NCT01077973|Active Comparator|Treatment B|
3217028|NCT01077973|Placebo Comparator|Treatment C|
3217029|NCT01077960|Experimental|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
3217030|NCT01077947|Active Comparator|Functional anesthetic discography|"The patients disc levels for surgical treatment will be based exclusively on their Functional anesthetic discography results. The discography will be performed at a maximum of two disc levels. Discs showing the following MRI findings will be considered for discography:~Loss of disc signal intensity on T-2 weighted sagittal MR images.~Loss of disc height on sagittal MR images.~Patients will be followed-up at 3 weeks, 3 months, 6 months and 1 year after the surgery by research personnel. Patients will be asked to complete questionnaires before their discography and at every follow-up visit."
3217031|NCT01077947|Active Comparator|Provocative Discography|"The patients disc levels for surgical treatment will be based exclusively on their Provocative Discography results. The discography will be performed at a maximum of two disc levels. Discs showing the following MRI findings will be considered for discography:~Loss of disc signal intensity on T-2 weighted sagittal MR images.~Loss of disc height on sagittal MR images.~The control disc, in the case provocative discography group must appear normal on the MRI - must have preserved disc height and central disc signal intensity on T-2 weighted images. The provocative discography will be performed using the standard IASP criteria. The patients will be followed-up at 3 weeks, 3 months, 6 months and 1 year after the surgery."
3217032|NCT01077934||Injured Extremity without compartment syndrome|
3217033|NCT01077934||Injured extremity with compartment syndrome|
3217034|NCT01077921|Experimental|Propranolol|Drug arm
3217035|NCT01077921|Placebo Comparator|Sugar pill|Placebo arm
3217036|NCT01077908|Experimental|ACT plus standard therapy|Adoptive Cellular Therapy (ACT) prepared using Multimer or Gamma Catch Selection in combination with standard best available antiviral drug therapy
3217037|NCT01077908|Active Comparator|Best available antiviral drug therapy|
3217038|NCT01077895|Experimental|CVVH with fluid removal|
3217039|NCT01077895|Active Comparator|CVVH without fluid removal|
3217040|NCT01077882|Placebo Comparator|current therapy|
3217041|NCT01077882|Experimental|current therapy with educational program|
3217042|NCT01077856||Pre-Vaccine|Registry, survey, and HPV status data from 2004-2006
3217043|NCT01077856||Post-Vaccine|Registry, survey, and HPV status data from 2011-2012
3217044|NCT01077843||Exposure|Ankylosing spondylitis patients currently exposed to anti-inflammatory treatments
3217045|NCT01077843||Non-exposure|Ankylosing spondylitis patients not currently exposed to anti-inflammatory treatments
3217046|NCT01077830||Ezetimibe/Simvastatin 10/40 mg|Participants who received Ezetimibe/Simvastatin 10/40 mg in the base study
3217047|NCT01077830||Placebo|Participants who received placebo in the base study
3217048|NCT01077817||Esophageal Cancer Cases|Participants with any United Kingdom General Practice Research Database (GPRD) Medical code for esophageal cancer (cases). Cases were confirmed and case onset dates determined by electronic algorithm (based on electronic medical record data) or by medical record review.
3217049|NCT01077817||Comparison Sample (Case-Cohort)|Participants who were matched to cases by age and membership in the GPRD on the case's onset date, and had not experienced any form of esophageal cancer or Paget's Disease and had not received oral or intravenous steroids or chemotherapy or radiotherapy, as indicated by GPRD codes.
3217050|NCT01077817||Non-treated Comparators|Participants who did not initiate treatment of osteoporosis with a study drug
3217051|NCT01077817||Alendronate|Participants initiating treatment for osteoporosis with alendronate
3217052|NCT01077817||Etidronate|Participants initiating treatment for osteoporosis with etidronate
3217053|NCT01077817||Ibandronate|Participants initiating treatment for osteoporosis with ibandronate
3217054|NCT01077817||Risedronate|Participants initiating treatment for osteoporosis with risedronate
3217055|NCT01077817||Raloxifene|Participants initiating treatment for osteoporosis with raloxifene
3217056|NCT01077804||Varivax vaccinated children|Children who are members of Kaiser Permanente Medical Care Program (KPMCP) and who received a first dose of the varicella vaccine, Varivax, in 1995 between the ages of 12 and 23 months.
3217057|NCT01077791|Experimental|original cognitive therapy|
3217058|NCT01077791|No Intervention|no intervention|
3217059|NCT01077765|Experimental|treatment|treatment
3217061|NCT01077752|Active Comparator|2|Patients with intravenous lidocaine infusion
3217062|NCT01077752|Placebo Comparator|3|Patients without local anesthetics
3217063|NCT01077739|Experimental|Avastin (bevacizumab) + standard of care|
3217064|NCT01077726|Experimental|1|
3217065|NCT01077713|Experimental|1|
3217066|NCT01077713|Experimental|2|
3217067|NCT01077700|Experimental|ABT-288 Dose 1|low dose of ABT-288
3217068|NCT01077700|Experimental|ABT-288 Dose 2|high dose of ABT-288
3217069|NCT01077700|Placebo Comparator|Sugar Pill|inactive substance
3217070|NCT01077674||Entropy - BIS|Patients undergoing surgery in sevoflurane anaesthesia.
3217071|NCT01077661||Patients administrated Nebivolol|There is only one group. This group includes patients administrated Nebivolol
3217072|NCT01077648||Women diagnosed with advanced breast cancer|Women diagnosed with advanced breast cancer during January 1, 1995-December 31, 2007 and treated as part of the Henry Ford Health System
3217073|NCT01077635||HIV-1 infected children aged 6 ≤ 18 years|HIV-1 infected children aged 6 ≤ 18 years currently or having ever been exposed to FPV/RTV; this is the indicated group for the licensed dose in the paediatric population.
3217074|NCT01077622|Experimental|2000 mg dose|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
3217075|NCT01077609||Allergic rhinitis (AR) & Flixonase|Patients initiating treatment for allergic rhinitis on intranasal fluticasone propionate
3217076|NCT01077609||AR & prescription for intranasal steroid other than Flixonase|Random sample of patients initiating treatment for allergic rhinitis with an intranasal steroid other than Flixonase
3217077|NCT01077596||New users of antidepressants Jan. 1, 1996 to Dec. 31, 2006|All new users of antidepressants January 1, 1996 through December 31, 2006. Individuals 18 years of age or older with medical and pharmacy benefits and at least 6 months of health plan enrollment before the first antidepressant prescription.
3217078|NCT01077570||Repaglinide|
3217079|NCT01077557||No HIV infection|Subjects without HIV infection (Group 1) are adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. A 3:1 match of subjects without HIV infection to a subject with HIV infection will occur. Each member of the comparator group without HIV infection will be matched on gender, month/year of IHCIS enrolment, and duration of enrollment to the respective study subject with HIV infection.
3217080|NCT01077557||HIV infection with no antiretroviral (ARV) drug exposure|HIV infection with no ARV drug exposure (Group 2) represents adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. HIV exposure will be identified by ICD-9-CM code 042 or v08 in one or more diagnostic fields. This group will have no pharmacy dispensing for ARV drugs.
3217081|NCT01077557||HIV infection with ARV drug exposure|HIV infection with ARV drug exposure (Group 3) represents adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. HIV exposure will be identified by ICD-9-CM code 042 or v08 in one or more diagnostic fields. This group will have at least one pharmacy dispensing for an HIV antiretroviral drug.
3217082|NCT01077544|Experimental|Group 1|1 year to < 10 years pediatric patients with newly diagnosed CP-Ph+ CML, or CP or AP-Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or relapsed/refractory Ph+ ALL (acute lymphoblastic leukemia) treated at the proposed dose of 230 mg/m2 bid.
3217083|NCT01077544|Experimental|Group 2|>= 10 years to <18 years pediatric patients with newly diagnosed CP-Ph+ CML, or CP or AP-Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or relapsed/refractory Ph+ ALL (acute lymphoblastic leukemia) treated at the proposed dose of 230 mg/m2 bid.
3217084|NCT01077531|Active Comparator|Otelixizumab|Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
3217085|NCT01077531|Placebo Comparator|Placebo|Matching placebo for intravenous infusion
3217086|NCT01077518|Experimental|Ofatumumab and Bendamustine (Arm A)|Up to 8 cycles of bendamustine (90 mg/m2) on Days 1,2 every 21 days with12 doses of ofatumumab (1000 mg, Day 1 q21 days when with bendamustine and q28 days when given as monotherapy)
3217087|NCT01077518|Active Comparator|Bendamustine (Arm B)|Up o 8 cycles of bendamustine (120 mg/m2) on Days 1,2 every 21 days
3217088|NCT01077505|Experimental|albiglutide|albiglutide 50mg weekly
3217089|NCT01077492||Suspected mediastianl lymph nodes|Patients with (suspected) lung cancer requiring MLN staging after CT-PET during routine work-up according to existing staging guidelines.
3217090|NCT01077479|Experimental|Metformin|
3217091|NCT01077466|Experimental|Natalizumab|24 patients: 12 with secondary progressive multiple sclerosis 12 with primary progressive multiple sclerosis
3217092|NCT01077453|Experimental|Arm I (2.5 mg letrozole)|Patients receive 2.5 mg of letrozole PO thrice weekly for 6 months.
3217093|NCT01077453|Experimental|Arm II (1.0 mg letrozole)|Patients receive 1.0 mg of letrozole PO thrice weekly for 6 months.
3217094|NCT01077453|Experimental|Arm III (0.25 mg letrozole)|Patients receive 0.25 mg of letrozole PO thrice weekly for 6 months.
3217095|NCT01077453|Experimental|Arm IV (2.5 mg letrozole)|Patients receive 2.5 mg of letrozole PO once daily for 6 months.
3217096|NCT01077440||Men - age 18+|
3217097|NCT01077427|Active Comparator|Gemcitabine + Capecitabine|
3217098|NCT01077427|Experimental|Gemcitabine + Cisplatin + regional hyperthermia|
3217099|NCT01077401|Experimental|Ranibizumab 0.5mg|Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
3217100|NCT01077401|Experimental|Ranibizumab 2.0 mg|Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
3217285|NCT01075906|Experimental|Colchicine|Colchicine Sprinkle Capsules, 0.3 mg - dose administered according to age range on Day 1
3217101|NCT01077388|Experimental|Dietician electronic counseling|This arm will receive care and supportive emails and phone calls from a study dietician for about 6 months. We will also provide a blood pressure monitor, a pedometer, and a scale with instructions for using them at home.
3217102|NCT01077388|No Intervention|Self Care|This arm will continue to get care as usual from their regular doctor. They will also get a blood pressure monitor and a scale at the end of the study.
3217103|NCT01077375|Placebo Comparator|Placebo|Placebo tablets, twice a day, oral administration
3217104|NCT01077375|Experimental|Milnacipran|Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses.
3217105|NCT01077362|Experimental|Placebo|Participants will receive subcutaneous (SC) injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants will cross over to receive SC injections of ustekinumab 45 mg at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 40. If early escape, SC injections of 45 mg ustekinumab will be given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 40. For participants entering early escape, a SC placebo injection will be given at Week 24 to maintain the blind.
3217106|NCT01077362|Experimental|Ustekinumab 45 mg|Participants will receive SC injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 40. If early escape, SC injections of 90 mg ustekinumab will be given at Week 16 and every 12 weeks thereafter with the last dose at Week 40. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
3217107|NCT01077362|Experimental|Ustekinumab 90 mg|Participants will receive SC injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 40. If early escape, the same dosage schedule will continue. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
3217108|NCT01077349|Experimental|high volume hemofiltration|
3217109|NCT01077349|Active Comparator|standard care|
3217110|NCT01077336||Hospitalized patients with candidemia|
3217111|NCT01077323||Exenatide Initiators|
3217112|NCT01077323||Other Antidiabetic Drug Initiators|
3217113|NCT01077323||Non-Diabetes Cohort|
3217114|NCT01077310|Active Comparator|Intramuscular naltrexone|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
3217115|NCT01077310|Placebo Comparator|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail.
3217116|NCT01077297|Experimental|Tezosentan|
3217117|NCT01077284|Experimental|Febuxostat|Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
3217118|NCT01077284|Active Comparator|Allopurinol|Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.
3217119|NCT01077284|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 6 months.
3217120|NCT01077271||Premature infants 33 - 35 wGA prophylaxed with palivizumab|Premature infants 33 - 35 weeks gestational age (wGA) prophylaxed with Synagis (palivizumab)
3217121|NCT01077258||Rheumatoid arthritis|Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 24 months.
3217122|NCT01077245|Experimental|MIYA-BM|MIYA-BM Fine Granules (CBM588)
3217123|NCT01077245|Placebo Comparator|Placebo|Placebo Fine Granules (without CBM588)
3217124|NCT01077232||Psoriasis Patients|Patients with moderate to severe plaque psoriasis
3217125|NCT01077206|Active Comparator|Simvastatin 80mg|
3217126|NCT01077206|Active Comparator|Simvastatin 40mg|
3217127|NCT01077193|Other|Gastric Plication Surgery|
3217128|NCT01077180|Experimental|Rheos Device|
3217129|NCT01077180|Active Comparator|Medical Management|
3217130|NCT01077167|Experimental|1|
3217131|NCT01077154|Experimental|Denosumab|Patients will receive denosumab as a subcutaneous injection (under the skin), and will take daily calcium and vitamin D supplementation, for up to 5 years.
3217132|NCT01077154|Placebo Comparator|Placebo|Patients will receive placebo as a subcutaneous injection (under the skin), and will take daily calcium and vitamin D supplementation, for up to 5 years.
3217133|NCT01077128||Patients with psoriasis|All eligible patients with psoriasis treated with Adalimumab
3217134|NCT01077115|Experimental|Laparoscopic cholecystectomy|
3217135|NCT01077115|Active Comparator|Open cholecystectomy|
3217136|NCT01077102|Experimental|Eccentric exercise training|
3217137|NCT01077102|Active Comparator|Concentric exercise training|
3217138|NCT01077089||Transported TBI patients|Traumatically brain injured patients undergoing in-hospital transport.
3217139|NCT01077076|Experimental|Zegerid OTC Capsules|20 mg omeprazole and 1100 mg sodium bicarbonate
3217140|NCT01077076|Active Comparator|Prilosec OTC™ tablets containing 20 mg-equivalent omeprazole|20.6 mg omeprazole-magnesium complex.
3217141|NCT01077076|Placebo Comparator|Placebo|Inert substance
3217142|NCT01077063|Active Comparator|paracentesis|cutting and draining procedure for malignant ascites
3217143|NCT01077063|Active Comparator|Pleurx catheter|a catheter drainage system the subject uses himself/herself.
3217144|NCT01077050|Other|SciBase III|Subjects with suspected malignant melanoma or lesions designated for total excision were included into the study. To ensure no selection bias, all eligible lesions from a subject were included into the study. All study eligible skin lesion(s) were examined with the investigational device, photographed and removed by an excisional biopsy.
3217145|NCT01077037|Experimental|Decision Aid|Receives Decision Aid
3217146|NCT01077037|No Intervention|Control|Patient receives usual care.
3217147|NCT01077024|Experimental|Smoking-cessation treatment + substance treatment as usual|
3217148|NCT01077024|No Intervention|Substance-treatment as usual|Treatment as usual is outpatient stimulant-dependence treatment as typically provided by the participating site.
3217149|NCT01077011|Experimental|Lubricant eye drop|Lubricant eye drop
3217150|NCT01077011|Active Comparator|GenTeal Gel|GenTeal Gel
3217151|NCT01076998|Experimental|Lubricant eye drop|Lubricant eye drop
3217152|NCT01076998|Active Comparator|Refresh PM Ointment|Refresh PM Ointment
3217153|NCT01076985||Lopinavir/ritonavir group|All pregnant women in this noninterventional, post-marketing observational study, who were prescribed lopinavir/ritonavir (Kaletra) in accordance with the local Prescribing Information for the treatment of HIV infection.
3217154|NCT01076972||Lopinavir/ritonavir group|All patients in this non-interventional, post-marketing observational study, who were prescribed lopinavir/ritonavir (Kaletra) in accordance with the local Prescribing Information for the treatment of HIV infection.
3217155|NCT01076959||Humira|The sponsor was required to include all patients diagnosed with rheumatoid arthritis and who were treated Humira in routine medical practice during the review period by the PMDA. The safety analysis set included all patients who met all eligibility criteria and received at least one dose of Humira. The full analysis set included all patients who were treated with Humira for at least 2 weeks and had complete DAS 28 assessments at baseline and at least one other time point.
3217156|NCT01076946||TLVBS|patients with transient left ventricular ballooning
3217157|NCT01076933|Experimental|rTMS|rTMS sessions
3217158|NCT01076933|Sham Comparator|control|sham rTMS (control)
3217159|NCT01076920|Experimental|Intervention arm|
3217160|NCT01076907|Experimental|Warm water loading of sigmoid colon|Warm water loading of sigmoid colon and irrigation when spasms occur.
3217161|NCT01076907|Placebo Comparator|Control|No water loading, only air and waiting for spasms to subside.
3217162|NCT01076894|Active Comparator|epidural anesthesia|
3217163|NCT01076894|Active Comparator|intercostal anesthesia|
3217164|NCT01076881|Experimental|combined aerobic and resistance training|
3217165|NCT01076881|Active Comparator|resistance training alone|
3217166|NCT01076868|Experimental|Primaquine|Primaquine 14 days
3217167|NCT01076855||Elderly with mild dementia|>70 years old and presence of a carer
3217168|NCT01076842|Active Comparator|A Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
3217169|NCT01076842|Active Comparator|B Exenatide|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
3217170|NCT01076842|Active Comparator|C Levemir+Exenatide|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
3217171|NCT01076829|Active Comparator|Spice patty|hamburger meat cooked with spice mixture
3217172|NCT01076829|Placebo Comparator|salt patty|Subjects consume salt containing hamburger meat
3217173|NCT01076803|Experimental|Lanreotide (acetate)|
3217174|NCT01076790|Active Comparator|Dexmedetomidine|Analgo-sedative, adjuvant of propofol anesthesia
3217175|NCT01076777|Experimental|Physical exercise|Manualised Exercise performed in groups (5-8 participants per group). 3 sessions (á 60 minutes) per week for 12 consecutive weeks
3217176|NCT01076777|Active Comparator|Cognitive-behavioral therapy|Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
3217177|NCT01076764|Experimental|Otamixaban - 0.080 mg/kg bolus + 0.100 mg/kg/h infusion|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:~Drug A: Otamixaban (0.080 mg/kg bolus followed by 0.100 mg/kg/h infusion)~Drug B: Placebo (for UFH)~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:~Drug C: Placebo (for Eptifibatide)"
3217178|NCT01076764|Experimental|Otamixaban - 0.080 mg/kg bolus + 0.140 mg/kg/h infusion|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:~Drug A: Otamixaban 0.080 mg/kg bolus followed by 0.140 mg/kg/h infusion)~Drug B: Placebo (for UFH)~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:~Drug C: Placebo (for Eptifibatide)"
3217179|NCT01076764|Active Comparator|UFH + Eptifibatide|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:~Drug A: Placebo (for Otamixaban)~Drug B: UFH (60 IU/kg bolus followed by 12 IU/kg/h infusion)~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:~Drug C: Eptifibatide (180 mcg/kg bolus followed by 2 mcg/kg/min infusion)"
3217180|NCT01076751||CRPC patients|
3217181|NCT01076738||single group study|
3217182|NCT01076725|Active Comparator|Standard technique group|In the standard technique group(n = 63), the PLMA was inserted by index finger insertion technique.
3217183|NCT01076725|Experimental|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
3217184|NCT01076712|Experimental|Physiotherapy Interventions|Physiotherapy Interventions including strengthening exercise, balance training, gait training with visual cue, gait training with treadmill.
3217185|NCT01076712|Other|Education|Education
3217186|NCT01076699|Active Comparator|Group taking 0.075 mg RVX-100|This group is taking 0.075 mg RVX-100
3217187|NCT01076699|Active Comparator|Group taking 0.125 mg RVX-100|This group is taking 0.125 mg RVX-100
3217188|NCT01076699|Active Comparator|0.250 mg RVX-100|This group is taking 0.250 mg RVX-100
3217189|NCT01076699|Placebo Comparator|placebo|This group is taking a placebo
3217190|NCT01076686||Bupivacaine and low dose SKY0402|
3217191|NCT01076686||Bupivacaine and high dose SKY0402|
3217192|NCT01076686||Bupivacaine|
3217193|NCT01076686||High dose SKY0402|
3217194|NCT01076673|Experimental|PBSC and Hyaluronic Acid|Peripheral blood stem cells and hyaluronic acid injections
3217195|NCT01076673|Active Comparator|Hyaluronic Acid|Hyaluronic Acid
3217196|NCT01076647|Experimental|IDeg 3TW|
3217197|NCT01076647|Active Comparator|IGlar OD|
3217198|NCT01076634|Experimental|IDeg 100 U/mL|
3217199|NCT01076634|Experimental|IDeg 200 U/mL|
3217200|NCT01076621||A|
3217201|NCT01076595||Group 1|
3217202|NCT01076582|Experimental|Arm 1|
3217204|NCT01076569||Ancillary-Correlative (molecular analysis)|Banked bone marrow samples from diagnosis and remission are used to develop a detailed molecular map of pediatric high-risk acute myeloid leukemia. Analysis includes genome SNP genotyping, expression, and methylation profiling.
3217205|NCT01076556|Experimental|Treatment (rituximab, cyclophosphamide, alvocidib)|Patients receive rituximab IV over 4 hours on days 1 (days 1-3 in course 1), cyclophosphamide IV over 30-60 minutes on days 1-3, and alvocidib IV over 4.5 hours on days 1 and 8 (day 8 only in course 1).
3217206|NCT01076543|Experimental|Treatment (lenalidomide, temsirolimus)|Patients receive lenalidomide PO on days 1-21 and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 2 courses may continue therapy for up to 52 weeks.
3217207|NCT01076530|Experimental|Arm I|Patients receive oral vorinostat and oral temozolomide once daily on days 1-5. Courses repeat every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
3217208|NCT01076504|Experimental|Amrubicin/Carboplatin with Pegfilgrastim|Systemic therapy
3217209|NCT01076478|Placebo Comparator|Arm 1|2 tablets BID
3217210|NCT01076478|Experimental|Arm 2|100 mg Cilostazol (2 tablets BID)
3217211|NCT01076478|Experimental|Arm 3|200 mg Cilostazol (2 Tablets BID)
3217212|NCT01076465|Experimental|Lifestyle counselling|Educational intervention, monitoring of clinical status, monitoring of treatment adherence
3217213|NCT01076465|Active Comparator|Comparator|Usual care
3217214|NCT01076452|Active Comparator|STN|Participants were randomized to receive deep brain stimulation on STN (Subthalamic Nucleus) target.
3217215|NCT01076452|Active Comparator|GPi|Participants were randomized to receive deep brain stimulation on GPi (Globus Pallidus) target.
3217216|NCT01076439|Active Comparator|Olopatadine Nasal Spray (Patanase)|
3217217|NCT01076439|Active Comparator|Fluticasone Furoate Nasal Spray (Veramyst)|
3217218|NCT01076439|Placebo Comparator|Saline Nasal Spray (Placebo)|
3217219|NCT01076426|Experimental|Probiotics|probiotics treatment
3217220|NCT01076426|Placebo Comparator|Placebo|
3217221|NCT01076413|Experimental|skill-based exercise|2 times per week for 12 weeks. warm-up, stretching, strengthening, and skill-based exercises. Pre-gait and gait activities including stepping patterns and walking patterns and treadmill training at various walking speeds
3217222|NCT01076413|Active Comparator|aerobic exercise training|warm-up, strengthening and aerobic conditioning (treadmill walking)
3217223|NCT01076400|Experimental|Part 1: MK-1775 + topotecan/cisplatin|Part 1: Dose escalation study. MK-1775 capsules will be administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3 . Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
3217224|NCT01076400|Experimental|Part 2: MK-1775 + topotecan/cisplatin|Part 2: MK-1775 capsules will be administered at the dose determined in Part 1 twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3. Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
3217225|NCT01076400|Placebo Comparator|Part 2: Placebo to MK-1775 + topotecan/cisplatin|Part 2: Placebo to MK-1775 capsules will be administered twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3. Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
3217226|NCT01076387|Active Comparator|open radical cystectomy|This is a prospective, randomized study designed to compare two techniques of radical cystectomy with PLND (open and robotic) for bladder cancer.
3217227|NCT01076387|Active Comparator|robotic-assisted radical cystectomy|This is a prospective, randomized study designed to compare two techniques of radical cystectomy with PLND (open and robotic) for bladder cancer.
3217228|NCT01076335|Experimental|Neoadjuvant Hormones + Docetaxel|Neoadjuvant Hormonal Therapy plus Docetaxel followed by Radical Prostatectomy
3217229|NCT01076322|Experimental|Treatment-A sequence|Meptin® Swinghaler / Ventolin® MDI
3217230|NCT01076322|Experimental|Treatment-B sequence|Ventolin® MDI / Meptin® Swinghaler
3217231|NCT01076309||Tamsulosin|Patients taking tamsulosin
3217232|NCT01076309||Non-tamsulosin|Patients not taking tamsulosin.
3217233|NCT01076283|Active Comparator|Baclofen|Baclofen 10 mg three times a day (t.i.d.) for 8-10 days
3217234|NCT01076283|Placebo Comparator|Cyproheptadine|Cyproheptadine 2 mg t.i.d. for 8-10 days
3217235|NCT01076270|Experimental|Filgrastim and plerixafor for PBSC mobilization|"Donors receive filgrastim subcutaneously (SC) and plerixafor SC on day -14 and undergo leukapheresis to collect peripheral blood stem cells (PBSC) on day -13. These cells are frozen to preserve them. Treatment modifications may apply according to sufficient collection of PBSC. Patients receive standard high-dose conditioning and undergo allogeneic PBSC transplantation on day 0 using the previously frozen cells.~After completion of study treatment, donors are followed up 1 day after the last stem cell donation."
3217236|NCT01076257|Experimental|Constraint-induced Movement Therapy|
3217237|NCT01076257|Other|Transditional rehabilitation|
3217238|NCT01076244|Other|Minimally invasive lumbar decompression|
3217239|NCT01076231|Experimental|Arm I|"Patients undergo proton beam radiotherapy over 5.5-7.5 weeks. Patients receive concurrent chemotherapy comprising cisplatin IV on days 1, 8, 29, and 36 and etoposide IV on days 1-5 and days 29-33.Treatment continues in the absence of disease progression or unacceptable toxicity.~Beginning 4-6 weeks after completion of chemoradiotherapy, patients may undergo surgical resection or additional chemoradiotherapy."
3217240|NCT01076218||Diabetes|Patients with type 1 diabetes requiring multiple daily insulin injections or using insulin pumps
3217241|NCT01076205||Patients with rheumatoid arthritis|Patients with moderate to severe active rheumatoid arthritis.
3217242|NCT01076192||Moderate-to-severe chronic plaque psoriasis|Participants with moderate-to-severe chronic plaque psoriasis treated with adalimumab in routine clinical practice
3217243|NCT01076179||Human Immunodeficiency Virus (HIV)-Infected Participants|HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists
3217370|NCT01075243|Experimental|Paracetamol 650 mg|Paracetamol 650 mg
3217244|NCT01076166||Children with lower respiratory tract infection|Thai children with lower respiratory tract infections on Klacid Granules for Oral Suspension
3217245|NCT01076153||Patients with respiratory tract infection|Thai patients with upper or lower respiratory tract infections on Klacid MR.
3217246|NCT01076140|Active Comparator|Nebivolol|Nebivolol 5 mg daily for 2 weeks, then 5 or 10 mg daily for 2 weeks
3217247|NCT01076140|Active Comparator|Lisinopril|20 mg once daily for 2 weeks, then 20 or 40 mg once daily for 2 weeks
3217248|NCT01076127|Experimental|Ketllebell group|Basic ketllebell training 3 x 20 min a week for 8 weeks
3217249|NCT01076127|Sham Comparator|Control group|Control group. Receives a health examination before and after the intervention period, and are advised to stay active.
3217250|NCT01076114||Control|Patients with no evidence of glaucoma or as a suspect with normal intraocular pressure, normal cup to disc ratio with no other ocular pathology and a normal ophthalmic exam.
3217251|NCT01076114||Glaucoma Suspect|Patients with abnormal cup to disc ratio or increased intraocular pressure (>21mm/Hg) with an otherwise normal ophthalmic exam.
3217252|NCT01076101||Sisters who have a diagnosis of SLE|Sisters who have a diagnosis of SLE
3217253|NCT01076101||Unaffected Sisters|Sisters of SLE patients who do not have a diagnosis of SLE
3217254|NCT01076088|Experimental|Sitagliptin 50 mg + metformin 500 mg|Sitagliptin 50 mg and metformin 500 mg twice a day for 24 weeks.
3217255|NCT01076088|Experimental|Sitagliptin 50 mg + metformin 850 mg|Sitagliptin 50 mg and metformin 850 mg twice a day for 24 weeks.
3217256|NCT01076088|Active Comparator|Metformin 500 mg|Metformin 500 mg twice daily for 24 weeks.
3217257|NCT01076088|Active Comparator|Metformin 850 mg|Metformin 850 mg twice daily for 24 weeks.
3217258|NCT01076088|Experimental|Sitagliptin 100 mg|Sitagliptin 100 mg once daily for 24 weeks.
3217259|NCT01076088|Placebo Comparator|Placebo|Matching placebo tablets for 24 weeks.
3217260|NCT01076075|Active Comparator|placebo/pioglitazone|Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg; Phase B (Weeks 24-54): placebo to Sitagliptin 100 mg + pioglitazone 30 mg
3217261|NCT01076075|Experimental|Sitagliptin|Phase A (Weeks 0-24): Sitagliptin 100 mg; Phase B (Weeks 24-54): Sitagliptin 100 mg + placebo to pioglitazone
3217262|NCT01076062|No Intervention|Expectant management (EM) arm|Standard of care: routine clinic appointments until they deliver, fetal heart rate and contraction monitoring during their 41st week if not delivered. Also if they have not gone into labor the subjects will be scheduled for an induction by 42 weeks.
3217263|NCT01076062|Experimental|Induction of Labor (IOL) arm|Elective induction of labor at 39 weeks.
3217264|NCT01076049|Experimental|Standard Care|purely observes standard operation of ER doctor
3217265|NCT01076049|Experimental|Irrisept Arm|
3217266|NCT01076036|Experimental|CorPath 200 System|Robotic-assisted PCI with the CorPath 200
3217267|NCT01076010|Experimental|Tivozanib|
3217268|NCT01076010|Active Comparator|Sorafenib|
3217269|NCT01075997|Experimental|A cell phone tips|This group will receive a cell phone and cell phone service for 1 year. This group will receive a daily video reminders and tips for the first 6 months of the study. For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent. The group will be instructed on how to use the cell phone. The group will be asked to check blood sugar on a schedule determined by their providers. The group will have blood sugars downloaded from from the glucometer by their providers at every visit and reviewed. The group will have the A1c measured. Also it will have this test repeated about every 3 months. They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
3217270|NCT01075997|Active Comparator|B no cell phone tips|This group will receive a cell phone and cell phone service for 1 year. For the second 6 months this group will be seen by their providers at least every 3 months. The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by their provider. The groups will have blood sugars downloaded from from the glucometer by their provider at every visit and reviewed. The group will have A1c measured. Also it will have this test repeated about every 3 months. They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
3217271|NCT01075984|Active Comparator|POS IV 200 mg single dose (Cohort 0)|POS 200 mg IV single dose infused over 1.5 hours on Day 1 followed 12 hours later by POS oral 400 mg, then by POS oral 400 mg BID on Days 2 through 6 and a single morning dose on Day 7 (Cohort 0)
3217272|NCT01075984|Placebo Comparator|Dextrose 5% in water (Cohort 0)|Placebo IV single dose infused over 1.5 hours on Day 1 followed 12 hours later by POS oral 400 mg, then by POS oral 400 mg BID on Days 2 through 6 and a single morning dose on Day 7 (Cohort 0)
3217273|NCT01075984|Experimental|POS IV 200 mg BID (Cohort 1)|POS 200 mg IV infused over 1.5 hours BID on Day 1, followed by POS 200 mg IV once daily on Days 2 through 14, then by POS 400 mg oral BID through Day 28 (Cohort 1)
3217274|NCT01075984|Experimental|POS IV 300 mg BID (Cohort 2)|POS 300 mg IV infused over 1.5 hours BID on Day 1, followed by POS 300 mg IV once daily on Days 2 through 14, then by POS 400 mg oral BID through Day 28 (Cohort 2). After Day 5, POS IV was administered continuously or intermittently, depending on oral tolerability.
3217275|NCT01075984|Experimental|POS IV 300 mg BID (Cohort 3)|POS 300 mg IV infused over 1.5 hours BID on Day 1, followed by POS 300 mg IV once daily on Days 2 through 5, then by POS 200 mg oral TID or POS 400 mg oral BID through Day 28, or POS 200-300 mg IV once daily as required (Cohort 3). After Day 5, POS IV was administered continuously or intermittently, depending on oral tolerability.
3217276|NCT01075971|Experimental|Buprenorphine hydrochloride|
3217277|NCT01075945|Experimental|Dihydroartemisinin- piperaquine|orally tablets
3217278|NCT01075945|Active Comparator|artemether- lumefantrine|oral tablets
3217279|NCT01075932|Active Comparator|1 g DHA-rich fish oil|1 g DHA-rich fish oil containing 450 mg DHA + 90 mg EPA plus 1 g olive oil
3217280|NCT01075932|Active Comparator|2 g DHA-rich fish oil|2 g DHA-rich fish oil containing 900 mg DHA + 180 mg EPA
3217281|NCT01075932|Placebo Comparator|Placebo|2 g olive oil
3217282|NCT01075919|Active Comparator|DHA-rich fish oil|1 g DHA-rich fish oil containing 450 mg DHA + 90 mg EPA
3217283|NCT01075919|Active Comparator|EPA-rich fish oil|1 g EPA-rich fish oil containing 300 mg EPA + 200 mg DHA
3217284|NCT01075919|Placebo Comparator|Placebo|1 g Olive oil
3217371|NCT01075243|Placebo Comparator|Placebo|Placebo
3217286|NCT01075906|Experimental|colchicine at steady state|colchicine sprinkle capsules 0.3 mg - dose administered according to age range on Day 15 following once daily dosing of colchicine on Days 2 - 14
3217287|NCT01075893||Adenomatous polyp|Patients who have begun the polyp-cancer sequence (ie. are in polyp surveillance after excision of a prior adenomatous polyp) will be used to test those patients at higher risk of colorectal.
3217288|NCT01075893||Patients at normal risk of cancer|Patients found to have endoscopically and histological normal mucosa.
3217289|NCT01075893||Ulcerative colitis|Patients who are under surveillance for known ulcerative colitis will be used to test those patients at higher risk of colorectal.
3217290|NCT01075867||Control group|Before ELIPS implementation 12 months follow-up
3217291|NCT01075867||Treatment group|After ELIPS implementation 12 months follow-up
3217292|NCT01075815|Experimental|rFSH + rhLH|Recombinant human luteinizing hormone (rhLH,Luveris®) injection 150 IU subcutaneously daily along with rFSH 300 IU subcutaneously daily from S1 to S4 and then rFSH dose can be adjusted depending on the ovarian response till r-hCG administration day.
3217293|NCT01075815|Active Comparator|rFSH|rFSH injection 300 IU subcutaneously daily from S1 to S4 and then dose can be adjusted depending on the ovarian response till r-hCG administration day.
3217294|NCT01075802|Experimental|Tamoxifen|Dose escalation of tamoxifen in patients with low endoxifen levels
3217295|NCT01075789|Placebo Comparator|Placebo|This arm will include children aged 6 years of age and older seen at the Royal Children's Hospital who are having an NGT inserted for a clinical indication and who have never experienced an NGT insertion before. These children will be randomised to be in this placebo arm or the treatment arm in a 1:1 ratio. The placebo for swallowing is a viscous, coloured, sucrose-flavoured gel designed to match the appearance of the treatment lignocaine gel to be swallowed by the treatment arm, and normal saline will be delivered to the nasal turbinates and nasopharynx in a similar way to atomised xylocaine in the treatment arm.
3217296|NCT01075789|Active Comparator|Lignocaine|This arm will include children aged 6 years of age and older seen at the Royal Children's Hospital who are having an NGT inserted for a clinical indication and who have never experienced an NGT insertion before. These children will be randomised to be in this treatment placebo arm or the treatment arm in a 1:1 ratio. The children in the treatment arm will receive xylocaine viscous 2% to swallow, and atomised 10% xylocaine to the nasal turbinates and nasopharynx.
3217297|NCT01075789|Active Comparator|Pre/post intervention evaluation group|This is a contemporaneous arm of children aged 6 years of age and older requiring nasogastric intubation for a clinical reason, who have previously had a nasogastric tube inserted. These children will be ask to rate by recall their previous NGT intubation on a VAS pain scale, and then will perform a post-procedure VAS pain assessment.
3217298|NCT01075776|Experimental|CNP|Infusion of CNP prior to IR injury
3217299|NCT01075776|Placebo Comparator|Saline|Effect of saline infusion prior to IR injury
3217300|NCT01075763|Experimental|Treatment arm - Rebif®|Subjets in this arm received interferon beta-1a (Rebif® 22 mcg tiw)
3217301|NCT01075763|Placebo Comparator|Placebo arm|Subjects in this arm received placebo
3217302|NCT01075750||Normal Saline|Patients receiving Normal Saline during and after the renal transplantation.
3217303|NCT01075750||Elomel Isoton|Patients receiving Elomel Isoton during and after renal transplantation
3217304|NCT01075737||Subjects with Multiple Sclerosis|Subjects with diagnosed MS according to the revised Mc Donald criteria 2005; aged >21 years.
3217305|NCT01075737||Caregivers|Caregivers (aged >21 years) for MS subjects.
3217306|NCT01075724|Active Comparator|Forced air|Forced Air Warming
3217307|NCT01075724|Experimental|Resistive HotDog Warming|Warming by resistive Warming
3217308|NCT01075711||NIS in-house doctors|This group will be assigned to general physicians, practicing doctors and interns (in-house doctors) with an observation period of 3 months. Three subjects are expected per in-house doctor therefore altogether, 1000 in-house doctors will be obtained or appointed for the observation study.
3217309|NCT01075711||NIS specialists|This group will be assigned to specialists (rheumatologist) with an observation period of 9 months. Ten subjects per rheumatologist are expected therefore altogether, 500 rheumatologists will be obtained or appointed for the observation study.
3217310|NCT01075698|Active Comparator|Non-ARB group|
3217311|NCT01075698|Active Comparator|ARB group|
3217312|NCT01075685|Experimental|Web-based alcohol programme|"Participants could log on to their account and access the programme whenever they wanted to.~They received automated email reminders inviting them to use follow-up tools, especially the diary in order to register their alcohol intake on the previous week:~4 weeks after starting the programme, so that they would take advantage of the monitoring stage in case they had not spontaneously done so.~2 weeks later for 6-week follow-up."
3217313|NCT01075685|Placebo Comparator|Minimum information|Participants could log on to their account and access the programme whenever they wanted to. At 6 week follow-up they received an automated email reminder inviting them to use the diary in order to register their alcohol intake on the previous week.
3217314|NCT01075672|Experimental|Cognitive Behavioral Therapy|
3217315|NCT01075672|Experimental|Behavioral Medicine with Cognitive Behavioral Therapy|Participants enrolled in this arm of this study will be treated by the behavioral medicine interns with cognitive behavioral therapy focused on both their general health concerns and mental health concerns.
3217316|NCT01075659|Experimental|LHN1548|Two single doses of an experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
3217317|NCT01075659|Active Comparator|2019706|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
3217318|NCT01075659|Active Comparator|2020005|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
3217319|NCT01075646|Experimental|Ropivacaine|After a bolus administration of Ropivacaine a perfusion ot the same anesthetic is initiated through an elastomeric wound during 48 hours
3217320|NCT01075646|Placebo Comparator|saline solution|After a bolus administration of saline solution a perfusion ot saline solution is initiated through an elastomeric wound during 48 hours
3217321|NCT01075633|Experimental|Fecal occult blood testing|Immunochemical fecal occult blood test Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
3217322|NCT01075633|Active Comparator|Colonoscopy|Colonoscopy with sedation.
3217323|NCT01075620|Experimental|PFC sigma RP|Posterior stabilized rotating platform knee (press Fit Condylar Sigma rotating-platform, Depuy, Warsaw, Indiana)
3217324|NCT01075620|Active Comparator|LCS RP|non posterior stabilized Low Contact Stress Rotating-Platform; Depuy, Warsaw, Indiana
3217325|NCT01075594||1|Patients with dyslipidemia on lipid lowering therapy
3217326|NCT01075581|Active Comparator|Topical administration|An an intranasal injection of saline will be used as control, and thereafter cotton pledgets soaked in 1 mL epinephrine 1:1,000 will be placed in the nasal cavity during surgery when necessary.
3217327|NCT01075581|Experimental|Intranasal injection|An intranasal injection of 8 mL epinephrine 1:100,000 will be performed as traditionally practiced in ESS. Thereafter, cotton pledgets soaked in 1 mL epinephrine 1:1,000 will be placed in the nasal cavity during surgery when necessary.
3217328|NCT01075555|Active Comparator|sorafenib|sorafenib
3217329|NCT01075555|Experimental|sorafenib + pravastatine|sorafenib + pravastatine
3217330|NCT01075542|Experimental|Toric intraocular lens|Bilateral Toric intraocular lens implantation in cataract surgery
3217331|NCT01075542|Other|Monofocal intraocular lens|Bilateral Monofocal intraocular lens implantation in cataract surgery
3217332|NCT01075529|No Intervention|fluoxetine|
3217333|NCT01075516||Standard Follow Up|ICD patients followed through periodic in-hospital visits
3217334|NCT01075516||Remote Follow Up|ICD patients followed with remote transmitters (Merlin@Home) that periodically communicate correct system functioning
3217335|NCT01075503|Experimental|retrograde infraclavicular|Patients were received retrograde infraclavicular brachial plexus block.
3217336|NCT01075503|Active Comparator|interscalene|Patients were received interscalene brachial plexus block.
3217337|NCT01075503|Active Comparator|supraclavicular|Patients were received supraclavicular brachial plexus block.
3217338|NCT01075490|Placebo Comparator|prematurely born, bupivacaine, placebo|
3217339|NCT01075490|Experimental|prematurely born, bupivacaine, clonidine|
3217340|NCT01075490|Placebo Comparator|term neonate, bupivacaine, placebo|
3217341|NCT01075490|Experimental|term neonate, bupivacaine, clonidine|
3217342|NCT01075477||Cohort|
3217343|NCT01075464|Experimental|A|
3217344|NCT01075464|Experimental|B|
3217345|NCT01075425|Experimental|Arm I|Patients receive belinostat IV over 30 minutes on days 1-5 and 8-12 and bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3217346|NCT01075412|Experimental|Group 2|Receives fourth [F18]Fluorothymidine (FLT) PET scan after 20 fractions of radiation therapy.
3217347|NCT01075412|Experimental|Group 1|Receives fourth [F18]Fluorothymidine (FLT) PET scan after 15 fractions of radiation therapy.
3217348|NCT01075399|Experimental|[F 18]HX4|[F18]HX4, 10 mCi, is administered in a single intravenous bolus injection, followed by a saline flush.
3217349|NCT01075386||Grade 2|Patients with Endometrial cancer of Grade 1 differentiation
3217350|NCT01075386||Benign|Patients without endometrial cancer
3217351|NCT01075386||Grade 1|Patients with Endometrial cancer of Grade 2 differentiation
3217352|NCT01075386||Grade 3|Patients with Endometrial cancer of Grade 3 differentiation
3217353|NCT01075347|Active Comparator|Autologous serum use|Patients treated with additional 20% autoserum after diabetic vitrectomy or penetrating keratoplasty
3217354|NCT01075347|Placebo Comparator|Non-autologous serum use|Patients treated with traditional medication(0.1% betamethasone, 0.3% gentamicin and 0.4% tropicamide eye drops application 4 times daily) after diabetic vitrectomy or penetrating keratoplasty
3217355|NCT01075334|Experimental|Porimore arm|Infertile men will receive 'Porimore' tablets for a period of time in which three intrauterine insemination cycles will be performed.
3217356|NCT01075334|Active Comparator|Folate and Zinc|
3217357|NCT01075321|Experimental|Arm I|Patients receive oral everolimus once daily and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3217358|NCT01075308|Experimental|SB939|SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
3217359|NCT01075295|Experimental|Lifestyle Intervention|
3217360|NCT01075295|Active Comparator|TAU|
3217361|NCT01075282|Experimental|LY2189265 1.5 mg|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
3217362|NCT01075282|Experimental|LY2189265 0.75 mg|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
3217363|NCT01075282|Active Comparator|Insulin Glargine|"Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
3217364|NCT01075269||Conventional open thyroidectomy group|All patients were told about the operative techniques involved in conventional open and robotic thyroidectomy, and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
3217365|NCT01075269||Robotic thyroidectomy group|All patients were told about the operative techniques involved in conventional open and robotic thyroidectomy, and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
3217366|NCT01075256|Active Comparator|5% calcium sodium phosphosilicate toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste.
3217367|NCT01075256|Active Comparator|7.5% calcium sodium phosphosilicate toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste.
3217368|NCT01075256|Placebo Comparator|Placebo toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with placebo toothpaste.
3217369|NCT01075243|Experimental|Paracetamol 1000mg|Paracetamol 1000mg
3217376|NCT01075204||Clarithromycin modified release|Patients with upper or lower respiratory tract infection were administered clarithromycin modified release 500 mg once daily for 7 days and then followed for a further 3 days, per routine clinical practice.
3217377|NCT01075191||HIV-infected participants|"HIV-infected participants taking lopinavir/ritonavir (Kaletra) and one other protease inhibitor.~Lopinavir/ritonavir (Kaletra) dosing and administration according to the Summary of Product Characteristics (three 133 mg/33 mg capsules twice daily or two 200 mg/50 mg tablets twice daily)."
3217378|NCT01075178||Palivizumab-treated subjects (CASES)|HSCHD infants, <2 yrs old at first dose of palivizumab
3217379|NCT01075178||Non-palivizumab-treated subjects (CONTROLS)|HSCHD infants, <2 yrs old that did not receive palivizumab
3217380|NCT01075165|Experimental|Silicone Spray|Apply spray silicone
3217381|NCT01075165|Placebo Comparator|Saline Spray|Apply Saline Spray
3217382|NCT01075152|Experimental|Earlier HIV Therapy|HIV therapy initiated at 7-13 days of cryptococcal meningitis diagnosis. HIV therapy consisting of a nucleoside with lamivudine and efavirenz.
3217383|NCT01075152|Active Comparator|Deferred HIV Therapy|"HIV therapy initiated at 5 weeks after cryptococcal meningitis diagnosis (+/- 1 week).~HIV therapy consisting of a nucleoside with lamivudine and efavirenz."
3217384|NCT01075139|Experimental|Brief Motivational Intervention|Subjects in this condition met one-on-one with a counselor for 30 minutes. Subjects received personalized feedback regarding their current physical activity levels and fruit/vegetable intake. Counselors used a motivational interviewing style to try to help resolve ambivalence about changing their current behaviors.
3217385|NCT01075139|Active Comparator|Educational information|Subjects in this condition received general educational information about the benefits associated with physical activity and fruit/vegetable intake.
3217386|NCT01075113|Experimental|Arm A|Sorafenib + Vorinostat. Patients receive sorafenib tosylate PO BID continuously and vorinostat PO QD, for 5 days each week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohort A has only one dose level: sorafenib 400 mg orally twice a day with vorinostat 300 mg orally. Cohort A was modified to include 2 dose levels: Dose level A1 (sorafenib 400 mg orally twice a day and vorinostat 200 mg orally once a day) and dose level A-1 (sorafenib 400 mg orally twice a day with vorinostat 100 mg orally once a day). The starting dose upon reopening after approval of this version will be dose level A-1a. Dose level A1 will only be used if dose level A-1a is not tolerable.
3217387|NCT01075113|Experimental|Arm B CLOSED|Reduced Dose 200mg Sorafenib + Vorinostat. Patients receive sorafenib tosylate PO BID continuously and vorinostat PO QD, for 5 days each week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohort B has 2 dose levels starting at the second dose level (sorafenib 200 mg orally twice a day with vorinostat 400 mg orally). Cohort B has been closed. Cohort B was intended to evaluate the possibility of dose intensification of vorinostat when patients were unable to tolerate standard dose sorafenib, and required dose-reduced sorafenib. The patients accrued to date in Cohort B were unable to tolerate therapy, and it has been determined that dose intensification of vorinostat is not possible, despite reducing the dose of sorafenib.
3217388|NCT01075100|Experimental|Weekly Ixabepilone +carboplatin|Subjects will receive ixabepilone and carboplatin on Days 1 and 8 of each 21-day cycle.
3217389|NCT01075087|Placebo Comparator|Placebo|(control group) will receive sterile normal saline in the block
3217390|NCT01075087|Active Comparator|Active comparator|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
3217391|NCT01075074|Active Comparator|Ropivacaine 0.05%|Subject received a bilateral transversus abdominis plane block block using 15 cc of 0.5% ropivacaine on each side
3217392|NCT01075074|Placebo Comparator|Normal Saline|Subjects received a bilateral transversus abdominis plane block using 15 cc of sterile normal saline.
3217393|NCT01075074|Active Comparator|Ropivacaine 0.25%|Subjects received a bilateral transversus abdominis plane block using 15cc of 0.25% ropivacaine on each side
3217394|NCT01075061|Other|healthy volunteers|healthy volunteers
3217395|NCT01075061|Other|Kallmann|Kallmann syndrome patients
3217396|NCT01075061|Other|Congenital Mirror Movement|patients with CMM
3217397|NCT01075048|Experimental|Phase 2: Tivantinib, cetuximab, irinotecan|Tivantinib in combination with irinotecan and cetuximab.
3217398|NCT01075048|Placebo Comparator|Phase 2: Placebo, cetuximab, irinotecan|Placebo in combination with irinotecan and cetuximab
3217399|NCT01075048|Experimental|Phase 1: Tivantinib, cetuximab, irinotecan|Tivantinib in combination with irinotecan and cetuximab.
3217400|NCT01075035||Normal Healthy Controls|Individuals with no history of Traumatic Brain Injury.
3217401|NCT01075035||Civilian TBI|Civilians who have had a Traumatic Brain Injury
3217402|NCT01075035||Military TBI|Combat military veterans who have had a Traumatic Brain Injury
3217403|NCT01075022|Experimental|Vitamin D|
3217404|NCT01075022|Placebo Comparator|Placebo|
3217405|NCT01074996|Active Comparator|S-1,|Subjects will receive S-1 until progression
3217406|NCT01074996|Experimental|S-1 plus Leucovorin|patients will receive S-1 plus Leucovorin until progression
3217407|NCT01074983||Written standard of care|
3217408|NCT01074983||Usual practice pattern|
3217409|NCT01074970|Active Comparator|Arm A: Cisplatin Monotherapy|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
3217410|NCT01074970|Active Comparator|Arm B: Combination Therapy|"Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles~Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles"
3217411|NCT01074957|Active Comparator|Incentive Spirometry|Incentive Spirometry group (IS) was oriented to take a deep breathing through Voldyne 5000TM (Sherwood Medical; St Loius, MO, USA) from Functional Residual Capacity (FRC) to Total Lung Capacity (TLC).
3217412|NCT01074957|Active Comparator|Exercise group|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
3217413|NCT01074957|Active Comparator|Breath-Stacking|Breath-Stacking group (BS) performed successive inspiratory efforts using a facial mask adapted to an unidirectional valve
3217414|NCT01074944|Experimental|Twice Daily (BID) Dose Regimen|Patients will receive either 50 mg BID or 100 mg BID
3217415|NCT01074944|Experimental|Once Daily (QD) Dose Regimen|Patients will receive either 100 mg QD or 200 mg QD
3217416|NCT01074931||Lopinavir/ritonavir group|This study is a non-interventional, observational study in which lopinavir/ritonavir is prescribed in the usual manner in accordance with the terms of China market authorization with regards to dose, population and indication. It is planned to enroll approximately 100 patients in total.
3217417|NCT01074918|Experimental|Potassium Magnesium Citrate|
3217418|NCT01074918|Active Comparator|Potassium Chloride|
3217419|NCT01074905|Active Comparator|Artesunate|2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.
3217420|NCT01074905|Active Comparator|Chloroquine|25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.
3217421|NCT01074905|Experimental|Chloroquine/Primaquine|Chloroquine 3 days and Primaquine 14 days
3217422|NCT01074892|Active Comparator|MPA 10 mg per oral cyclic for 6 months|The peroral treatment is used 10 days each month
3217423|NCT01074892|Active Comparator|MPA 10 mg per os continuous 6 months|Per oral MPA 10 mg is taken daily for 6 months
3217424|NCT01074892|Active Comparator|LNG-IUD for 6 months|Levonorgestrel impregnated IUD is inserted into the uterine cavity and kept in situ for 6 months
3217425|NCT01074879|Experimental|Whey protein|20 g whey protein + 20 g carbohydrates
3217426|NCT01074879|Experimental|Milk protein|20 g milk protein + 20 g carbohydrates
3217427|NCT01074879|Active Comparator|Carbohydrates|40 g carbohydrates
3217428|NCT01074866|No Intervention|Pressure support|Non invasive ventilation under pressure support (PS)
3217429|NCT01074866|Active Comparator|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally Adjusted ventilatory Assist
3217430|NCT01074853|Experimental|Propranolol|Chronic dose escalation of propranolol over period of 6 to 8 weeks.
3217431|NCT01074853|Placebo Comparator|Placebo|Matched placebo used for dose escalation period of 6 to 8 weeks
3217432|NCT01074840|Active Comparator|Peanut|Peanut flour will be given in increasing amounts.
3217433|NCT01074840|No Intervention|Control|Subjects will be enrolled who meet the inclusion/exclusion criteria and followed as matched controls. These subjects will not receive any treatment.
3217434|NCT01074827|Experimental|Treadmill group|Specific gait training on treadmill
3217435|NCT01074827|Experimental|Strength training group|Eight weeks of intensive strength training
3217436|NCT01074801|Active Comparator|Closed-loop|Subcutaneous insulin delivery to be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
3217437|NCT01074801|Active Comparator|Control arm|Subcutaneous insulin delivery to be administered according the standard insulin pump settings
3217438|NCT01074788|Experimental|mind body intervention group|
3217439|NCT01074775|Experimental|Challenge group|Recipients of three challenge infections with oral M bovis
3217440|NCT01074762|No Intervention|Routine general practice care|In the comparison group, doctors were free to choose any treatment and change it over time. The study coordinating centre did not contact comparison practices after the end of recruitment (late 1991) until 1995.
3217441|NCT01074749|Active Comparator|Optisense lead|Patients with an Accent pacemaker and an OptiSense atrial lead
3217442|NCT01074749|Active Comparator|Tendril lead|Patients with an Accent pacemaker and a Tendril atrial lead
3217443|NCT01074723|Experimental|b-cryptoxanthin|
3217444|NCT01074723|Experimental|phytosterols|
3217445|NCT01074723|Experimental|b-cryptoxanthin plus phytosterols|
3217446|NCT01074710|Experimental|C13-URA|administered C13-URA 50, 100, 200mg in same subjects
3217447|NCT01074710|Placebo Comparator|Placebo|2 same subjects
3217448|NCT01074697|Active Comparator|Fosaprepitant dimeglumine|
3217449|NCT01074697|Placebo Comparator|Saline water|
3217450|NCT01074671|Other|No control arm|There is no control arm as part of the study design.
3217451|NCT01074658||severe aortic valve stenosis|elderly patients with severe aortic valve stenosis requiring treatment
3217452|NCT01074645|No Intervention|Placebo|Placebo was the multivitamin capsule which was similar in appearance as of Tenofovir disoproxil fumarate and was given once a day till 3 month.
3217453|NCT01074645|Active Comparator|Tenofovir disoproxil fumarate (TDF)|Tenofovir disoproxil fumarate (TDF) is a potent, rapidly acting, oral acyclic nucleotide analogue, reverse transcriptase inhibitor that has been shown to be highly effective in suppressing hepatitis B virus replication. Tenofovir has also shown excellent activity against HBV in both LAM- naïve and LAM-resistant patients. Its efficacy has not been evaluated in patients of reactivation of hepatitis B who present as ACLF
3217454|NCT01074619|Experimental|1|Memantine
3217455|NCT01074619|Placebo Comparator|2|Placebo
3217456|NCT01074606|Experimental|Toric|AcrySof Toric Intraocular Lens (IOL)
3217457|NCT01074593|Experimental|Test|Bergamo - Interferon beta-1a
3217458|NCT01074593|Active Comparator|Comparator - Merck Serono|Merck Serono - Interferon beta-1a
3217459|NCT01074580||Deterioration, Crohn's disease|Patients > 18 years old with a deterioration of Crohn's disease defined by CDAI >150 and requiring treatment with systemic steroids or TNF alfa inhibitors
3217460|NCT01074567|Experimental|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
3217461|NCT01074554|Experimental|Antibiotic Regimen|"The Antibiotic Regimen consists of Levaquin 750 mg loading on day 1, then 500 mg po QD and Ethambutol 15-25 mg/kg for a maximum of 1200mg QD and Azithromycin 500mg on day 1, then 250 mg po QD and Rifampin 5-10 mg/kg for a maximum of 300mg po QD.~All four drugs are given concomitantly."
3217462|NCT01074554|Placebo Comparator|Placebo Regimen|The placebo regimen consists of Lactose tablets, one for each antibiotic with equivalent pills
3217463|NCT01074541|Active Comparator|Group 1|UV intensity 10 MIN
3217464|NCT01074541|Active Comparator|Group 2|UV intensity 5 MIN
3217465|NCT01074541|Active Comparator|Group 3|UV intensity 1 MIN
3217466|NCT01074541|Active Comparator|Group 4|UV intensity 20 MIN
3217467|NCT01074528|Experimental|mindfulness based stress reduction|8-week mindfulness based stress reduction program
3217468|NCT01074528|No Intervention|control group|patients who have to wait before entering the MBSR program or who do not want to follow this program
3217469|NCT01074502|Experimental|apremilast|apremilast 20 mgs twice a day for 12 weeks
3217470|NCT01074476|Experimental|1|Glucosamine sulphate tablets
3217471|NCT01074476|Placebo Comparator|2|Placebo tablets
3217472|NCT01074463|Experimental|1|Pramipexole Dihydrochloride 0.25 mg Tablets
3217473|NCT01074463|Active Comparator|2|Mirapex® 0.25 mg Tablets
3217474|NCT01074450|Experimental|1|Pramipexole Dihydrochloride 0.25 mg Tablets
3217475|NCT01074450|Active Comparator|2|Mirapex® 0.25 mg Tablets
3217476|NCT01074437|Other|Group A: Corticosteroid with Placebo|Group A will receive oral, liquid Prednisolone, which is the standard corticosteroid that we use here at Seattle Children's, and oral liquid placebo. The dose of prednisolone that Group A will receive will be 1-2mg/kg/day for 7 days and then the dose will be slowly reduced and then stopped after 3 weeks. This is a standard dose for IH treatment. Gastric prophylaxis (Zantac) will be given to help prevent any stomach problems associated with prednisolone. This treatment will be given for two months, as is our standard practice.
3217477|NCT01074437|Other|Group B: Corticosteroid with Propranolol|Group B will receive oral liquid prednisolone, and oral propranolol. As in Group A, the dose of prednisolone will be 1-2mg/kg/day for 7 days and then the dose will be slowly reduced and then stopped after 3 weeks. Oral liquid propranolol will be dosed at 2 mg/kg/day, following initiation in the Cardiology Clinic. Gastric prophylaxis (Zantac) will be given to help prevent any stomach problems associated with prednisolone.
3217478|NCT01074411|Experimental|Treatment (bortezomib, carboplatin)|Patients receive bortezomib IP and carboplatin IP on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3217479|NCT01074385|Other|Immediate Dignity Therapy|At registration, subjects will be mailed a questionnaire. The subject will then receive two separate dignity therapy sessions, about a week apart. Subjects will then be asked to complete a questionnaire 1-2 weeks after completing therapy sessions and one month after completing therapy sessions.
3217480|NCT01074385|Other|Wait List Dignity Therapy|At registration, subjects will be mailed a questionnaire. The subject will then receive two separate dignity therapy sessions; the first session will take place about 6 weeks after registration, with the second session occurring 1-3 weeks after the first. Subjects will then be asked to complete a questionnaire about one month after completing therapy sessions.
3217481|NCT01074372|Experimental|Cohort 1|Dose 1 versus placebo
3217482|NCT01074372|Experimental|Cohort 2|Dose 2 versus placebo
3217483|NCT01074372|Experimental|Cohort 3|Dose 3 versus placebo
3217484|NCT01074372|Experimental|Cohort 4|Dose 4 versus placebo
3217485|NCT01074359|Experimental|A0001|A0001 (0.75 g BID)
3217486|NCT01074359|Placebo Comparator|Placebo|Placebo
3217487|NCT01074320||Breast cancer patients on AIs|Breast cancer patients beginning Aromatase Inhibitor therapy
3217488|NCT01074307|Experimental|Low Dose Bisoprolol|
3217489|NCT01074307|Experimental|High Dose Bisoprolol|
3217490|NCT01074294|Placebo Comparator|Sugar pill|
3217491|NCT01074294|Experimental|OPC-34712|
3217492|NCT01074268|Experimental|IDeg OD|
3217493|NCT01074268|Active Comparator|IDet|
3217494|NCT01074255||Korean Participants Treated With EMEND (aprepitant)|Participants receiving EMEND on Treatment Days 1, 2, and 3 concomitantly with a corticosteroid and a 5-hydroxytryptamine 3 (5-HT3) antagonist.
3217495|NCT01074242||Rotateq|Korean Infants vaccinated with Rotateq in usual practice. The Rotateq vaccination series consists of 3 ready-to-use liquid (oral) doses with the first dose to be administered at age 6-12 weeks and subsequent doses to be administered at 4 to 10-week intervals.
3217496|NCT01074229|Placebo Comparator|Placebo|sterile normal saline as placebo
3217497|NCT01074229|Active Comparator|Drug .5% Ropivacaine|Instillation of 20 cc of 0.5% ropivacaine
3217498|NCT01074229|Active Comparator|20 cc of 0.25% ropivacaine|Instillation of 20 cc of 0.25% ropivacaine
3217499|NCT01074216|Experimental|vitamin D, vitamin D3|This is a Phase II study involving Stage IV colorectal cancer patients with serum vitamin D deficiency, to determine the ability to correct vitamin D deficiency and to maintain serum vitamin D levels (25-hydroxy vitamin D) once achieved.
3217500|NCT01074203|Experimental|Nitazoxanide arm|All patients will receive nitazoxanide
3217501|NCT01074190|Experimental|Group 1|spinal fentanyl 15 micrograms plus bupivacaine 2.5 mg followed by a patient controlled epidural analgesia (PCEA) maintenance infusion of bupivacaine 1mg/mL
3217502|NCT01074190|Experimental|Group 2|spinal fentanyl 15 micrograms plus bupivacaine 2.5 mg spinal followed by a PCEA infusion of fentanyl 1 micrograms/mL plus bupivacaine 0.8 mg/mL
3217503|NCT01074190|Active Comparator|Group 3|spinal fentanyl 15 micrograms plus bupivacaine 2.5mg followed by a PCEA infusion of fentanyl 2 micrograms/mL plus bupivacaine 0.625 mg/mL
3217504|NCT01074177|Experimental|BIBW 2992|BIBW 2992 Taken orally once a day
3217505|NCT01074164|Placebo Comparator|Control group|This group of subjects will serve as the control group and will follow a standard-of-care treatment regimen for AD, including the use of moisturizers and topical corticosteroids.
3217506|NCT01074164|Experimental|Accu-patch pellet|This group of subjects will follow a standard-of-care treatment regimen for AD, including the use of moisturizers and topical corticosteroids. Additionally, they will use a titanium pellet (accu-patch pellet) to self-apply pressure at the LI11 acupuncture pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times weekly for 1 month.
3217507|NCT01074151||Pregnant patients exposed to Cymbalta|Pregnant patients exposed to Cymbalta (duloxetine) at any time during pregnancy, beginning on or after the first day of the last menstrual period
3217508|NCT01074138|Experimental|Treatment|Subjects will be enrolled into a 28-day dose-escalation study. If no DLT's are observed during the first 28 days, subjects are eligible to continue treatment in the Extension Phase and can remain on treatment until toxicity occurs or until disease progression.
3217509|NCT01074125|Experimental|1 g/day|1 g/day KRX-0502 (ferric citrate)
3217510|NCT01074125|Experimental|6 g/day|6 g/day KRX-0502 (ferric citrate)
3217511|NCT01074125|Experimental|8 g/day|8 g/day KRX-0502 (ferric citrate)
3217512|NCT01074112||Abdominal Trauma|Patients with mechanism of injury that could produce abdominal bleeding
3217513|NCT01074112||Female Abdominal Pain|Female patients of child bearing age complaining of abdominal pain
3217514|NCT01074112||Difficult Vascular Access|Patients whom vascular access is needed but difficult
3217515|NCT01074112||Abdominal Aortic Anuerysm|Patients who complain of or are suspected of having an abdominal aortic aneurysm
3217516|NCT01074112||Pulseless Electrical Activity|Patients whom are in cardiac arrest and no pulse can be determined yet they show an electrical rhythm on the monitor
3217517|NCT01074112||Kidney Stones (Hydronephrosis)|Patients who complain of flank pain
3217518|NCT01074112||Plueral Effusion|Patients with a history of renal or hepatic problems and complain of difficulty breathing of an unknown etiology
3217519|NCT01074112||ETT placement|field intubated patients who need another means of verifying tube placement
3217520|NCT01074112||Transcutaneous Pacing|Patients who are being externally paced and need a method of determining mechanical capture
3217521|NCT01074112||Paramedic Discretion|Patients in whom the paramedic feels that an ultrasound study would provide useful data in their treatment
3217522|NCT01074099|Active Comparator|Control|CABG only
3217523|NCT01074099|Experimental|BMAC enhanced CABG|Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery
3217524|NCT01074086|Experimental|RAD 001|RAD 001 in day 1 and day 7 from 10 mg to 50 mg
3217525|NCT01074073|Other|Lithium/Lurasidone|Schizophrenia Patients
3217526|NCT01074060|Experimental|Arm I|"MOBILIZATION: Patients receive cyclophosphamide IV. Patients also receive filgrastim subcutaneously (SC) daily beginning approximately 24 hours later.~TREATMENT/APHERESIS: Beginning 10 days after cyclophosphamide, patients receive plerixafor IV over 30 minutes followed by filgrastim SC on each day of apheresis."
3217527|NCT01074047|Experimental|Azacitidine|Azacitidine daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
3217528|NCT01074047|Active Comparator|Conventional Care Regimen|Conventional Care Regimen
3217529|NCT01074034|Experimental|AV Therapy Assessment group|appropriate system performance of the atrial and ventricular tachyarrhythmia therapies in the ASSURE device
3217530|NCT01074021|Experimental|Nimotuzumab plus chemoradiotherapy|
3217531|NCT01074021|Placebo Comparator|placebo plus chemoradiotherapy|
3217532|NCT01074008|Experimental|ABT-450/r (50/100 mg) once daily (QD) + pegIFN/RBV|Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3217533|NCT01074008|Experimental|ABT-450/r (100/100 mg) once daily (QD) + pegIFN/RBV|Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3217534|NCT01074008|Experimental|ABT-450/r (200/100 mg) once daily (QD) + pegIFN/RBV|Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3217535|NCT01074008|Experimental|ABT-072 (100 mg) once daily (QD) + pegIFN/RBV|Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3217536|NCT01074008|Experimental|ABT-072 (300 mg) once daily (QD) + pegIFN/RBV|Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3217537|NCT01074008|Experimental|ABT-072 (600 mg) once daily (QD) + pegIFN/RBV|Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3217538|NCT01074008|Experimental|ABT-333 (400 mg) twice a day (BID) + pegIFN/RBV|Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3217539|NCT01074008|Experimental|ABT-333 (800 mg) twice daily (BID) + pegIFN/RBV|Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3217540|NCT01074008|Placebo Comparator|Placebo + pegIFN/RBV|Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3217541|NCT01073995|Active Comparator|Kenalog and Sensorcaine|"The following drugs will be administered during a one time injection of the appropriate spinal level based off clinical and radiographic information:~Intervention:~Kenalog 40 mg/ml and Sensorcaine 0.25% 1cc"
3217542|NCT01073995|Placebo Comparator|Saline|Saline injections will be used to mimic the Steroid dose
3217543|NCT01073982|Placebo Comparator|cherry flavored fruit drink|
3217544|NCT01073982|Experimental|tart cherry juice|
3217545|NCT01073969|Placebo Comparator|Control cereal|grain-based ready to eat cereal that does not contain active wheat bran extract
3217546|NCT01073969|Active Comparator|low dose|grain-based ready to eat cereal containing a low dose of wheat bran extract
3217547|NCT01073969|Active Comparator|High dose|grain-based ready to eat cereal that contains a high dose of wheat bran extract
3217548|NCT01073956|Placebo Comparator|Inactive electrotherapy|Inactive electrotherapy is applied to the painful points
3217549|NCT01073956|Active Comparator|Ultrasound|Ultrasound electrotherapy is applied to the painful points
3217550|NCT01073956|Active Comparator|Monopolar radiofrequency|Monopolar radiofrequency electrotherapy is applied to the painful points
3217551|NCT01073943|Experimental|PicoPrep|"Day Before method and consists of two separate doses: the first dose during the afternoon or early evening before the colonoscopy and the second dose 6 hours later during the evening before the colonoscopy."
3217552|NCT01073943|Active Comparator|HalfLytely|HalfLytely and Bisacodyl Tablets Bowel Prep Kit was used according to the approved labeled dosage and administration instructions. The two bisacodyl tablets were taken the day prior to the procedure and the HalfLytely was taken following the first bowel movement or 6 hours after the bisacodyl tablets.
3217553|NCT01073930|Experimental|PICOPREP|"Split Dose method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day, during the morning prior to the colonoscopy."
3217554|NCT01073930|Active Comparator|HalfLytely|HalfLytely and Bisacodyl Tablets Bowel Prep Kit was used according to the approved labeled dosage and administration instructions. The two bisacodyl tablets were taken the day prior to the procedure and the HalfLytely was taken following the first bowel movement or 6 hours after the bisacodyl tablets.
3217555|NCT01073917|Other|Spontaneous Breathing|Patients will be breathing spontaneously during anesthesia
3217556|NCT01073917|Other|Pressure controlled ventilation|Patients in the PPV group will be ventilated by pressure control (tidal volume 8-10 ml/kg, frequency 10-14, I:E 1:1, no PEEP, target CO2 4.5 kPa).
3217557|NCT01073917|Other|Pressure Support Ventilation|The patients in the PSV group will breathing spontaneously on the ventilator with assistance by inspiratory support pressure. The support pressure will be adjusted to achieve a tidal volume of 8-10 ml/kg.
3217558|NCT01073904|Experimental|Arm 1|
3217559|NCT01073904|Active Comparator|Arm 2|
3217560|NCT01073891|Active Comparator|Arm 1|
3217561|NCT01073891|Experimental|Arm 2|
3217562|NCT01073891|Experimental|Arm 3|
3217563|NCT01073865|Experimental|1|"Zoladex 10.8 mg (goserelin acetate) will be injected once every 12 weeks (± 7 days).~One oral tamoxifen 20 mg tablet also will be taken daily"
3217564|NCT01073865|Active Comparator|2|Zoladex 3.6 mg (goserelin acetate) will be injected once every 4 weeks (± 7 days). One oral tamoxifen 20 mg tablet will also be taken daily.
3217565|NCT01073852|Placebo Comparator|Placebo|Patients will be taking placebo medication throughout study.
3217566|NCT01073852|Active Comparator|Hydroxychloroquine|Patients will be taking hydroxychloroquine throughout study.
3217567|NCT01073839|Experimental|Cisplatin plus Gemcitabine|Patients after resection of cholangiocellular carcinoma will be allocated to treatment with cisplatin plus gemcitabine.
3217568|NCT01073826|Active Comparator|Tocilizumab|Infusion of Tocilizumab and sport intervention
3217569|NCT01073826|Active Comparator|Sitagliptin|Intake of Sitagliptin and sport intervention
3217570|NCT01073826|Placebo Comparator|Placebo|Intake of placebo and sport intervention
3217571|NCT01073813|Active Comparator|Minocycline 100mg|Patients are in one of three strata (currently on Glatiramer acetate (GA), Interferon beta (IFN), or neither disease modifying therapy (DMT). There will be a minimum of 12 patients per strata. Patients will be randomized within each strata in a 2:1 fashion to receive either Minocycline 100mg twice daily or no treatment.
3217572|NCT01073813|No Intervention|No treatment|Patients are in one of three strata (currently on Glatiramer acetate (GA), Interferon beta (IFN), or neither disease modifying therapy (DMT). There will be a minimum of 12 patients per strata. Patients will be randomized within each strata in a 2:1 fashion to receive either Minocycline 100mg twice daily or no treatment.
3217573|NCT01073800|Active Comparator|atorvastatin 80 mg|active treatment
3217574|NCT01073800|Placebo Comparator|placebo|
3217575|NCT01073787|Active Comparator|Normal saline|
3217576|NCT01073787|Experimental|Normal saline and possible medication|
3217577|NCT01073774|Experimental|Side by Side|
3217578|NCT01073774|Active Comparator|couples control condition|
3217579|NCT01073761|Experimental|Everybody|All Subjects will receive the same intervention
3217580|NCT01073748|Active Comparator|asthmatic subjects|Asthmatic children will be randomly exposed to paracetamol and placebo consecutively and their lung functions will be blindly compared.
3217581|NCT01073748|Other|Healthy children|Children with no asthma as control group.
3217582|NCT01073735||Cancer Survivors|Examine the construct validity, short-term stability, internal consistency and item-response performance of a health-related needs assessment self-report instrument for adult childhood cancer survivors.
3217583|NCT01073722|Active Comparator|Left double lumen tube|Traditionally, single lung ventilation is obtained with a double lumen tube (DLT). In our institution a polyvinyl DLT (Broncho-cath, Mallinckrodt,) without carinal hook, is used. This type of tube exists of a tube with two lumen with two distal cuffs. One lumen (called the bronchial lumen) extends some distance further, has a slight curvature and has a small blue cuff. The other lumen (called the tracheal lumen) has a larger cuff. A DLT tube exists in four sizes and one can choose in a left or a right configuration. Almost always, we use a left sided DLT. A DLT has a much larger diameter than a standard single lumen endotracheal tube
3217584|NCT01073722|Active Comparator|EZ-blocker|The EZ-blocker (EZB) is a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. It is intended for use in combination with a standard single lumen tube. After the EZB is advanced trough the distal end of the single lumen tube, both extensions spread out and find their way in the left and right main stem bronchi. The place where the two extensions are attached to the shaft now rests on the carina. Fiber optic bronchoscopy should be used for proper positioning. After placement of the EZB, one of the cuffs can be inflated to obtain lung separation under direct visual inspection with fiber optic bronchoscopy.
3217585|NCT01073709|Experimental|Test|Acetaminophen extended release gelcaps 650 mg of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
3217643|NCT01073319|Active Comparator|Rivastigmine 6 mg|
3217797|NCT01072279|Experimental|Burundi: T18|
3217586|NCT01073709|Active Comparator|Reference|Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)of McNeil Consumer & Specialty Pharmaceuticals, Division of MCNEIL-PPC, Inc. Fort Washington, PA 19034 USA
3217587|NCT01073696|Active Comparator|granisetron IV|
3217588|NCT01073696|Experimental|granisetron patch|
3217589|NCT01073683|Experimental|larynx preservation|Decision between surgery and Chemo-rt according to response to initial induction chemotherapy
3217590|NCT01073670|Active Comparator|Acetaminophen|Participants received a loading dose of acetaminophen (2600 mg) at induction followed by 1300 mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
3217591|NCT01073670|Experimental|Indomethacin|Participants were given 100 mg of indomethacin at induction and then 50 mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
3217592|NCT01073670|Experimental|Combination|Participants were given a loading dose of 1300 mg of acetaminophen and 50 mg of Indomethacin followed by 650mg of acetaminophen and 25 mg of indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
3217593|NCT01073657|Experimental|Supported Education|Veterans received supported education services. A Veteran peer met weekly as needed with a subject for up to six months in a psycho-social rehabilitation service for meeting education goals. Goals included choosing a college, getting admitted or enrolled, and maintaining enrollment and completing classes.
3217594|NCT01073657|Active Comparator|General Peer Support|Matched attention was provided by a Veteran peer who met weekly with Veterans but who focused on help with any personal goal (eg, employment, housing) but not on education.
3217595|NCT01073644||Sunitinb malate|
3217596|NCT01073631||1|Patients who are indicated for use of voriconazole tablet.
3217597|NCT01073618||A.|Patients who are indicated for VFEND according to drug package insert.
3217598|NCT01073605|Active Comparator|Genotonorm A|Continuous 0.7 IU/kg/week or 0.03 mg/kg/day
3217599|NCT01073605|Active Comparator|Genotonorm B|Continuous, 1.4 IU/kg/week or 0.06 mg/kg/day
3217600|NCT01073605|Active Comparator|Genotonorm C|Intermittent, 1.4 IU/kg/week or 0.06 mg/kg/day
3217601|NCT01073592||CNV patiens|
3217602|NCT01073579||Sabril®|All patients in the U.S. who are prescribed Sabril must participate in this patient registry in order to receive Sabril.
3217603|NCT01073566|Experimental|Finesse|Finesse Insulin Delivery Patch
3217604|NCT01073566|Active Comparator|Usual injection device|Pen/Syringe
3217605|NCT01073553|Experimental|Arm 1|
3217606|NCT01073553|Active Comparator|Arm 2|
3217607|NCT01073540|Experimental|Arm 1|
3217608|NCT01073540|Active Comparator|Arm 2|
3217609|NCT01073527|Active Comparator|Hypertonic saline-salbutamol combination|NaCl 5% - 4cc (with standard treatment - salbutamol 0.5cc)
3217610|NCT01073527|Placebo Comparator|normal saline-salbutamol combination|Standard treatment normal saline 4cc with salbutamol 0.5cc
3217611|NCT01073501|Placebo Comparator|Placebo|Placebo versus pregabalin
3217612|NCT01073501|Experimental|Pregabalin|Placebo versus pregabalin
3217613|NCT01073488|Experimental|EMONC: Community mobilization, HBLSS and Facility Improvement|The intervention group received training in community mobilization activities, Home Based Life Saving Skills (HBLSS) and facility improvement.
3217614|NCT01073488|No Intervention|Control|The control group did not receive an intervention, but collected outcome data through a baseline maternal/newborn birth registry.
3217615|NCT01073475||Pregnant women|Pregnant women in the MNH cluster
3217616|NCT01073475||Male and Female Infants|Male and Female Infants delivered in the clusters
3217617|NCT01073462||Paricalcitol IV|Participants with chronic kidney disease stage 5 with secondary hyperparathyroidism and cardiac morbidity received intravenous (IV) paricalcitol (Zemplar) prescribed according to current practice with regards to dose, population and indication for up to 2 years.
3217618|NCT01073449||Cardiac device|All patients implanted with a cardiac device, pacemaker(PM)or Implantable Cardioverter Defibrillator (ICD)
3217619|NCT01073436||Discontinuation|Subjects who agree to discontinue their tyrosine kinase inhibitor(TKI)therapy, namely,imatinib mesylate, dasatinib, or nilotinib,and then followed to see if they can maintain a durable remission.
3217620|NCT01073423|Experimental|Yoga|
3217621|NCT01073423|Active Comparator|Music Therapy|
3217622|NCT01073410||Healthy, non-asthmatic controls|People who are non-asthmatic and non-smokers.
3217623|NCT01073410||Asthmatics|People who have been diagnosed with asthma.
3217624|NCT01073397|Experimental|Behavioral|Weekly Integral Yoga sessions lasting 90 minutes for 10 weeks with home practice.
3217625|NCT01073397|Active Comparator|Health and Wellness Classes|Weekly classes on health and wellness lasting 90 minutes for 10 weeks, with additional home practice
3217626|NCT01073397|No Intervention|Waitlist|This group receives usual care for 10 weeks and is then randomized to one of the study arms.
3217627|NCT01073384|Experimental|BDP 3 mg|1 mg TID
3217628|NCT01073384|Experimental|BDP 6 mg|2 mg TID
3217629|NCT01073384|Experimental|BDP 9 mg|3 mg TID
3217630|NCT01073384|Experimental|BDP 12 mg|4 mg TID
3217631|NCT01073371|Active Comparator|liposome-encapsulated 3% prilocaine|
3217632|NCT01073371|Active Comparator|3% plain prilocaine|
3217633|NCT01073371|Active Comparator|3% prilocaine with 0,03IU/mL felypressin|
3217634|NCT01073358|No Intervention|Group A: No routine hilar lymphadenectomy|Resection of colorectal liver metastases without routine hilar lymphadenectomy
3217635|NCT01073358|Experimental|Group B: Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases.
3217636|NCT01073345||Major hepatic resection|Patients undergoing resection of > 2 liver segments
3217637|NCT01073345||Minor hepatic resection|Patients undergoing resection of </= 2 liver segments
3217638|NCT01073345||Control group|Patients undergoing exploratory laparotomy for hepatobiliary disease without resection (e.g. due to inoperable disease)
3217639|NCT01073332|Placebo Comparator|Placebo|The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
3217640|NCT01073332|Experimental|Arginine antioxidant supplements|Dietary Supplement: Niteworks
3217641|NCT01073319|Placebo Comparator|Placebo|Matching oral placebo capsule as control.
3217642|NCT01073319|Active Comparator|Rivastigmine 3 mg|
3217644|NCT01073306|Experimental|Dengue Virus Subtype 2 Vaccine|Participants will receive a single dose of investigational vaccine for dengue virus subtype 2.
3217645|NCT01073306|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine.
3217646|NCT01073293|Experimental|Concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1
3217647|NCT01073293|Experimental|Non-concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1
3217648|NCT01073280||undeterminated neurological disease, cerebral endoscopy|patients without neurological diagnosis that require cerebral , meningeal diagnosis
3217649|NCT01073267|Experimental|TSEBT|Total Skin Electron Beam Therapy (TSEBT) to dose of 12 Gy
3217650|NCT01073241|Active Comparator|transurethral prostatic resection|The patients' prostate was resected with the conventional Nesbit TURP.
3217651|NCT01073241|Experimental|ventral wall of urethra-preserving enucleation of prostate|The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.
3217652|NCT01073228|Active Comparator|EVP-6124 0.3 mg|one 0.3 mg capsule every day for 183 days
3217653|NCT01073228|Active Comparator|EVP-6124 1 mg|one 1 mg capsule every day for 183 days
3217654|NCT01073228|Active Comparator|EVP-6124 2 mg|one 2 mg capsule every day for 183 days
3217655|NCT01073228|Placebo Comparator|Placebo|Placebo every day for 183 days
3217656|NCT01073215|Active Comparator|Group Condition|
3217657|NCT01073215|Experimental|Self-Guided Condition|
3217658|NCT01073202|Active Comparator|ursodeoxycholic acid|
3217659|NCT01073202|Placebo Comparator|identical-appearing placebo|
3217660|NCT01073189|Experimental|Intra-Renal Fenoldopam|Intra-Renal Fenoldopam: Patients randomized to this wing will undergo placement of Angiodynamics Benefit catheter and receive intra-renal infusion of fenoldopm mesylate
3217661|NCT01073189|Active Comparator|Diuretic Control|Patients in the control group will be randomized to receive intra-venous diuretics as a comparator control
3217662|NCT01073176|Experimental|TEAMS|TEAMS has been designed to promote executive skills, memory and fine motor control, and includes game-like activities that allow for increases in task complexity.
3217663|NCT01073163|Experimental|Bendamustine with Rituximab|Participants were administered bendamustine intravenous (IV) infusion at 90 mg/m^2 on Days 1 and 2 of each 28-day cycle, and rituximab IV infusion at 375 mg/m^2 on Day 1 of each 28-day cycle.
3217664|NCT01073137||Diabetic Subjects|
3217665|NCT01073137||Non diabetic subjects|
3217666|NCT01073124|Active Comparator|Normal Saline|Normal Saline injected intraarticularly into the knee joint
3217667|NCT01073124|Experimental|Dilute Methylene Blue Dye|1 ml methylene blue dye per 500 ml normal saline injected intraarticularly into the knee
3217668|NCT01073111|Active Comparator|zotarolimus-eluting stents (ENDEAVOR®)|
3217669|NCT01073111|Active Comparator|sirolimus-eluting stents (CYPHER SELECT® PLUS)|
3217670|NCT01073111|Active Comparator|everolimus-eluting stents (PROMUS®)|
3217671|NCT01073085|Experimental|Web-based coaching|"Those in the coaching arm will benefit from e-mails with advice, information, support for smoking cessation. These mails will be adapted to their personal profile."
3217672|NCT01073085|Active Comparator|Self-help guide|"Those in the active comparator arm will be allowed to download a self-help guide with step-by-step advice for smoking cessation."
3217673|NCT01073072|Experimental|Tutomesh|Technique of abdominal wall reconstruction strengthened by Tutomesh®
3217674|NCT01073072|Active Comparator|conventional repair|Conventional technique to repair incisional or abdominal wall hernias
3217675|NCT01073059|Experimental|Valproic acid|
3217676|NCT01073046||Place Naso-Gastric/Jejunal Tube Group|In this group a silastic naso-gastric/jejunal tube is placed (Rusch® distributed by Teleflex Medical Srl)
3217677|NCT01073046||No Naso-Gastric/Jejunal Tube Group|In this group a silastic naso-gastric/jejunal tube is not placed
3217678|NCT01073033|Experimental|oral supplement1|Oral supplement for pregnant and lactating mothers
3217679|NCT01073033|Active Comparator|oral supplement 2|Oral supplement for pregnant and lactating mothers
3217680|NCT01073033|No Intervention|Reference|No oral supplementation during pregnancy and lactating.
3217681|NCT01073020|Active Comparator|Gastric Band vs Intensive Medical Diabetes & Weight Management|
3217682|NCT01073020|Active Comparator|RYGB vs Intensive Medical Diabetes & Weight Management|
3217683|NCT01073007|Experimental|Simvastatin|Simvastatin 40 mg daily for 3 months.
3217684|NCT01073007|Placebo Comparator|Placebo|
3217685|NCT01072981|Experimental|HyperAcute-Pancreas Immunotherapy + Standard of Care|*Adjuvant Standard of Care Treatment (SOC) consisting of gemcitabine with or without 5FU chemoradiation + HyperAcute Immunotherapy
3217686|NCT01072981|Active Comparator|Standard of Care alone|*Adjuvant Standard of Care Treatment (SOC) consisting of gemcitabine with or without 5FU chemoradiation Alone
3217687|NCT01072968|Experimental|BF2.649|BF2.649 capsules dosed at 5 mg, 10 mg, 20 mg
3217688|NCT01072968|Placebo Comparator|Placebo|Capsules of placebo containing lactose with low, medium and high dosage
3217689|NCT01072955|Experimental|heparin of bovine origin|5.000UI/mL bottle with 5mL
3217690|NCT01072955|Active Comparator|heparin of porcine origin|5000 USP Heparin Units / mL vial with 10 mL vial
3217691|NCT01072942|Experimental|Arm 1|
3217692|NCT01072942|Placebo Comparator|Arm 2|
3217693|NCT01072929|Experimental|Armodafinil 150 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 150 mg/day. The 150 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment.
3217694|NCT01072929|Experimental|Armodafinil 200 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 200 mg/day. The 200 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment. This treatment arm was discontinued via a protocol amendment.
3217794|NCT01072292|Active Comparator|Wellness Education|Wellness Education
3217695|NCT01072929|Placebo Comparator|Placebo|Participants were administered placebo and titrated to match the armodafinil treatment arms. Total treatment was 8 weeks.
3217696|NCT01072916||IBS|Subjects with IBS-D
3217697|NCT01072916||Healthy|Healthy Subjects
3217698|NCT01072903||IBS|Subjects with IBS
3217699|NCT01072903||Healthy|Healthy Controls
3217700|NCT01072890|Experimental|Temsirolimus and Pazopanib|
3217701|NCT01072877|Experimental|Polidocanol injectable foam 0.125%|Polidocanol injectable foam 0.125%
3217702|NCT01072877|Experimental|Polidocanol injectable foam 0.5%|Polidocanol injectable foam 0.5%
3217703|NCT01072877|Experimental|Polidocanol injectable foam 1.0%|Polidocanol injectable foam 1.0%
3217704|NCT01072877|Experimental|Polidocanol injectable foam 2.0%|Polidocanol injectable foam 2.0%
3217705|NCT01072877|Placebo Comparator|Vehicle|Injection of vehicle comparator
3217706|NCT01072864|Experimental|5 g of walnuts|
3217707|NCT01072864|Experimental|20 g of walnuts|
3217708|NCT01072864|Experimental|30 g of walnuts|
3217709|NCT01072864|Experimental|40 g of walnuts|
3217710|NCT01072851|Experimental|Multimedia educational tool|Multimedia education tool - A culturally competent video explaining the importance of and the process of colorectal cancer screening
3217711|NCT01072851|Experimental|Print educational tool|Print media - A culturally competent printed brochure explaining the importance of and the process of colorectal cancer screening
3217712|NCT01072851|Active Comparator|No intervention|Usual and customary waiting room process - Usual and customary office waiting period with access to standard nationally generated colorectal cancer screening informational material in the waiting room and/or exam room.
3217713|NCT01072838|Other|Dose Escalation|
3217714|NCT01072825||transgender people starting hormone treatment|
3217715|NCT01072812|Experimental|Posiphen® tartrate capsules|
3217716|NCT01072799|Experimental|Low dose H1N1|
3217717|NCT01072799|Experimental|Mid dose H1N1|
3217718|NCT01072799|Experimental|High dose H1N1|
3217719|NCT01072799|Placebo Comparator|Placebo|
3217720|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 1|Participants will receive the TetraVax-DV admixture 1 vaccine.
3217721|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 2|Participants will receive the TetraVax-DV admixture 2 vaccine.
3217722|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 3|Participants will receive the TetraVax-DV admixture 3 vaccine.
3217723|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 4|Participants will receive the TetraVax-DV admixture 4 vaccine.
3217724|NCT01072786|Placebo Comparator|Placebo|Participants will receive the placebo.
3217725|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 5|Participants will receive the TetraVax-DV admixture 5 vaccine.
3217726|NCT01072773|Experimental|Bortez/Cyc/Dex|Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.
3217727|NCT01072760|Experimental|K wire|
3217728|NCT01072747|Experimental|heparin of bovine origin|Laboratory Bergamo Ltda. 5.000UI/mL bottle with 5mL
3217729|NCT01072747|Active Comparator|heparin of porcine origin|APP Pharmaceuticals
3217730|NCT01072734|Experimental|Vaccine group|single group: all included patients will receive the vaccine
3217731|NCT01072721|Other|Fibrosis group|a single arm with the two interventions (elastometry and biopsy)
3217732|NCT01072695|Experimental|Arm 1|
3217733|NCT01072695|Experimental|Arm 2|
3217734|NCT01072695|Experimental|Arm 3|
3217735|NCT01072669|Active Comparator|ambrisentan|"drug arm~use of ambrisentan in limited scleroderma patients with raynaud's to evaluate digital microvascular flow"
3217736|NCT01072669|Placebo Comparator|sugar pill|those getting sugar pill to evaluate if the active drug improves digital microvascular flow in limited scleroderma patients
3217737|NCT01072656|Active Comparator|Treatment group|Active stimulation and programmed to the settings found to be optimal during the titration process.
3217738|NCT01072656|Sham Comparator|Control group|IPG is set to ON but the voltage is set to 0V.
3217739|NCT01072643|Experimental|Dexmedetomidine|To study safety of DEX with regard to effect on PVR; There will be 3 study groups (n=8 per group). The groups will be based on DEX doses as follows- Group 1 - Bolus 1 mcg/kg followed by infusion 0.7 mcg/kg/hr Group 2 - Bolus 1.5 mcg/kg followed by infusion 1.05 mcg/kg/hr Group 3 - Bolus 2 mcg/kg followed by infusion 1.4 mcg/kg/hr
3217740|NCT01072630|Placebo Comparator|Placebo|Participants were administered placebo and titrated to match the armodafinil treatment arms. Total treatment was 8 weeks.
3217741|NCT01072630|Experimental|Armodafinil 150 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 150 mg/day. The 150 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment.
3217742|NCT01072630|Experimental|Armodafinil 200 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 200 mg/day. The 200 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment. This treatment arm was discontinued via a protocol amendment.
3217743|NCT01072617|Experimental|Safety of rTMS in schizophrenia patients|Participants will receive repetitive transcranial magnetic stimulation via MagPro x100 device to the vermis of cerebellum twice a day over 5 days
3217744|NCT01072604|Experimental|Arm 1|
3217745|NCT01072604|Experimental|Arm 2|
3217746|NCT01072604|Active Comparator|Arm 3|
3217747|NCT01072604|Active Comparator|Arm 4|
3217748|NCT01072591|Experimental|1|
3217749|NCT01072591|Placebo Comparator|2|
3217750|NCT01072578|Experimental|1|
3217751|NCT01072578|Experimental|2|
3217752|NCT01072565|Active Comparator|SMBG Only|You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be blinded (neither you nor the study doctor will be able to see the CGM measurements until your final study visit). Only your SMBG measurements will be considered to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of less than 7%.
3217795|NCT01072279|Experimental|Burundi: T24|
3217796|NCT01072279|Experimental|Burundi: TNFP|
3217753|NCT01072565|Active Comparator|SMBG and CGM|You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be downloaded at each study visit and will be considered along with your SMBG measurements to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of 7%.
3217754|NCT01072552||Treated|Palivizumab treated
3217755|NCT01072552||Untreated|Palivizumab untreated
3217756|NCT01072539||Patients who have approved indications of Tygacil|"Approved indications of Tygacil~-complicated intraabdominal infection, complicated skin and skin structure infection, community-acquired bacterial pneumonia"
3217757|NCT01072526|Active Comparator|Intervention|Subjects will receive Euphrasia-based homeopathic therapy (Artificial Tears) in combination with cyclosporin solution (Restasis) .
3217758|NCT01072526|Placebo Comparator|Control|Subjects will receive placebo in combination with cyclosporin solution (Restasis) .
3217759|NCT01072513|Other|Semen analysis|Analysis of semen before and after proton radiation therapy.
3217760|NCT01072500|Active Comparator|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
3217761|NCT01072500|Active Comparator|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
3217762|NCT01072487|Experimental|Capnography|Arm with capnographic monitoring
3217763|NCT01072487|No Intervention|Standard|Standard monitoring.
3217764|NCT01072474|Experimental|Capnography|Arm with capnographic monitoring
3217765|NCT01072474|Placebo Comparator|Standard|Standard monitoring.
3217766|NCT01072461|Active Comparator|Train Paretic Hand and Arm Separate|Eight three hour training sessions of robotically facilitated hand and arm training in complex virtual environments, using activities that train the fingers in isolation and other activities that train the arm in isolation.
3217767|NCT01072461|Experimental|Train Paretic Hand and Arm Together|
3217768|NCT01072461|Experimental|Train Both Hands Together in VE|
3217769|NCT01072448|Experimental|Indacaterol 75 μg|Patients inhaled indacaterol 75 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3217770|NCT01072448|Placebo Comparator|Placebo to indacaterol|Patients inhaled placebo to indacaterol once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3217771|NCT01072435|Active Comparator|patient-controlled sedation|PCS
3217772|NCT01072435|Active Comparator|target-controlled infusion|TCI
3217773|NCT01072422|No Intervention|Usual care|20 of the 40 participating primary health care nurses will be randomly assigned to this group. They will identify 10 consecutive patients with COPD who smoke (n = 200 patients in total). The nurses will provide these patients with care as usual.
3217774|NCT01072422|Experimental|Protocol arm|20 of the 40 participating primary health care nurses will be randomly assigned to this arm. Each nurse will identify 10 consecutive patients with COPD who smoke (n = 200 total patients). The nurses will ask the patients to fill in the assessment protocol, TTQ. The nurses will then provide an intervention to each patient in the form of individual treatment on the basis of that patient's answers to the TTQ.
3217775|NCT01072409|Other|Single Arm|Single arm design
3217776|NCT01072396|Active Comparator|18 mcg tiotropium|Patient to receive 1 tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
3217777|NCT01072396|Placebo Comparator|Placebo|Patient to receive 1 placebo inhalation powder capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler
3217778|NCT01072396|No Intervention|Control|Age and gender matched control subjects to conduct incremental and constant work rate exercise tests for comparison to subjects with early stage COPD
3217779|NCT01072383|Experimental|BT061|receiving BT061 (active compound)
3217780|NCT01072383|Placebo Comparator|Placebo|receiving a placebo
3217781|NCT01072370|Active Comparator|Treatment Group 1|
3217782|NCT01072370|Sham Comparator|Treatment Group 2|
3217783|NCT01072357|Active Comparator|Avastin® (bevacizumab)|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 milliliter (mL) (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
3217784|NCT01072357|Placebo Comparator|0.9% NaCl & Refresh Liquigel|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% sodium chloride (NaCl). Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
3217785|NCT01072344|Experimental|Chamomile Extract|Pharmaceutical grade oral chamomile extract.
3217786|NCT01072344|Placebo Comparator|Placebo|Pharmaceutical grade lactose monohydrate.
3217787|NCT01072331|Experimental|MP-513 10 mg, once a day, for 4 weeks|
3217788|NCT01072331|Experimental|MP-513 20 mg, once a day, for 4 weeks|
3217789|NCT01072331|Placebo Comparator|Placebo of MP-513|
3217790|NCT01072318|Experimental|Letrozole, DFS|Efficacy evaluation of extended letrozole after 5 year fareston use
3217791|NCT01072305|Experimental|Intermittent pneumatic compression (IPC)|IPC from induction of general anesthesia to completion of skin closure.
3217792|NCT01072305|Placebo Comparator|control|IPC - placebo from induction of general anesthesia to closure of the skin
3217793|NCT01072292|Experimental|CBT-I|CBT-I
3217798|NCT01072279|No Intervention|Burundi: Control|
3217799|NCT01072279|Experimental|Guatemala: PROCOMIDA|
3217800|NCT01072279|Experimental|Guatemala: no family ration|
3217801|NCT01072279|Experimental|Guatemala: LNS|
3217802|NCT01072279|Experimental|Guatemala: Sprinkles|
3217803|NCT01072279|Experimental|Guatemala: reduced family ration|
3217804|NCT01072279|No Intervention|Guatemala: control|
3217805|NCT01072266|Experimental|INCB028060|Subjects will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group of patients may be enrolled and receive study drug. The initial cohort will be treated with 10 mg QD. The second cohort will be treated with 20 mg QD. The third cohort will be treated with 50 mg QD. Subsequent cohorts will be treated with two times the dose of the prior cohort to a limited toxicity level.
3217806|NCT01072253||eye amputated|lost an eye
3217807|NCT01072240||Cohort|
3217808|NCT01072227||Single Group|
3217809|NCT01072214|Experimental|1.6 mg|The actual dosage is 10 mg/ml (GW786034) given 4 times a day for a maximum daily dosage of 1.6mg
3217810|NCT01072214|Experimental|TBD COHORT 2|Dose escalation amount to be determined (TBD) after results from Cohort 1 analyzed
3217811|NCT01072214|Placebo Comparator|Placebo|Subjects will receive placebo (drops without drug).
3217812|NCT01072214|Experimental|TBD COHORT 3|Dose escalation amount to be determined (TBD) after results from Cohort 2 analyzed
3217813|NCT01072201|Experimental|Total toothpaste|Triclosan/copolymer/fluoride toothpaste
3217814|NCT01072201|Placebo Comparator|Ultrabrite toothpaste|Fluoride Toothpaste
3217815|NCT01072188|Active Comparator|ProClude Prophylaxis paste-A|Arginine Bicarbonate prophylaxis paste
3217816|NCT01072188|Placebo Comparator|Nupro-M Prophylaxis paste -B|Control prophylaxis paste (Fluoride free - placebo)
3217817|NCT01072175|Experimental|Arm Part A|Day 1: GSK2118436 75mg; Day 2 through Day 16: GSK1120212 2mg; Day 15: GSK2118436 75mg +GSK1120212 2mg Drug-drug interaction
3217818|NCT01072175|Experimental|Arm Part B|GSK2118436 + GSK1120212 Dose escalation to a maximum tolerated combination dose
3217819|NCT01072175|Experimental|Arm Part C|GSK2118436 + GSK1120212 cohort expansion for safety and efficacy
3217820|NCT01072162|Experimental|Arm B|25 mg powder for oral suspension single dose fasted.
3217821|NCT01072162|Experimental|Arm C|25 mg powder for oral suspension administered with a meal
3217822|NCT01072162|Experimental|Arm D|25 mg powder for oral suspension administered 2 hours prior to meal
3217823|NCT01072162|Experimental|Arm E|25 mg powder for oral suspension administered 2 hours after to meal
3217824|NCT01072162|Other|Arm A|Commercially available eltrombopag 25 mg tablet
3217825|NCT01072149|Experimental|50mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3217826|NCT01072149|Experimental|100mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3217827|NCT01072149|Experimental|200mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3217828|NCT01072149|Placebo Comparator|placebo|placebo
3217829|NCT01072136|Placebo Comparator|Placebo|Placebo.
3217830|NCT01072136|Experimental|Azithromycin/Cefixime|A single dose of cefixime 400 mg (1 tablet oral at 400 mg) and azithromycin 1 gram (2 tablets oral at 500 mg each).
3217831|NCT01072110||Group 1: Patients with diarrhea undergoing endoscopy|Standard video colonoscope.
3217832|NCT01072110||Group 2: Patients with diarrhea undergoing endoscopy.|Confocal laser endomicroscopy (CLE).
3217833|NCT01072097|Active Comparator|Atorvastatin|6 months atorvastatin 20mg/day treatment
3217834|NCT01072097|Placebo Comparator|Placebo|6 months placebo treatment
3217835|NCT01072084||Patients with food allergy|
3217836|NCT01072084||Healthy subjects|
3217837|NCT01072071|No Intervention|Control group|Patients will be receiving standard of care ICU treatment of their underlying disease according to internationally accepted guidelines and recommendations.
3217838|NCT01072071|Experimental|Furosemide group|patients will be receiving standard of care ICU treatment of their underlying condition according to international guidelines and recommendations. In addition, furosemide will be administered in continuous infusion as per protocol in order to achieve a preset target diuresis that is adjusted according to haemodynamic tolerance.
3217839|NCT01072058|Other|TNF blockers|
3217840|NCT01072045|Active Comparator|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses.
3217841|NCT01072045|Active Comparator|Prednisone|Oral prednisone , at a dose of 2mg/kg/day, divided in 2 doses.
3217842|NCT01072032|Experimental|Low-Reward|Low-Reward Anklebot training Group: The low reward-feedback group receives the Anklebot training with only immediate feedback on target successes, without cumulative scores and with minimal social interaction with the research team.
3217843|NCT01072032|Active Comparator|High-Reward|High-Reward Anklebot training Group: The high-reward group receives cumulative scores and abundant social interaction and are eligible for prizes during each training session and at completion of the study
3217844|NCT01072019|Active Comparator|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
3217845|NCT01072019|Active Comparator|MRI generated patient specific custom cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
3217846|NCT01072006||Control Group|Control group without traumatic brain injury (TBI) or post-traumatic stress disorder (PTSD)
3217847|NCT01072006||PTSD Group|PTSD (not TBI)
3217848|NCT01072006||TBI Group|TBI (no PTSD)
3217849|NCT01072006||TBI+PTSD Group|Combined TBI history and PTSD
3217850|NCT01071993|Active Comparator|atorvastatin|
3217851|NCT01071993|Placebo Comparator|placebo|
3217852|NCT01071980|Active Comparator|Specific resistance training|3 x 20 min a week of specific resistance training for 20 weeks
3217853|NCT01071980|No Intervention|Control|Control group
3217854|NCT01071967|Experimental|Community-based nurse care management|Participants randomized to receive the intervention worked with a nurse care manager who provided them with a comprehensive set of geriatric and chronic disease preventive services.
3217855|NCT01071967|No Intervention|Usual care|Participants randomized to the control group received usual care without the involvement of a nurse care manager.
3217856|NCT01071954|Other|Single Arm|Starting Dose of 1µg/kg romiplostim or previous dose administered weekly Individual Subject Dose Adjustment to a Maximum Dose of 10 µg/kg based on platelet count
3217857|NCT01071941|Experimental|Group 1|The first subjects will receive a single infusion of rRp450. Subsequent subjects will receive rRp450 as four doses administered every 1-2 weeks.
3217858|NCT01071928|Experimental|Docetaxel and ASA404 in Combination|
3217859|NCT01071915|Experimental|Degarelix 240/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenace of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
3217860|NCT01071902|Experimental|Moxidex|Moxidex otic solution
3217861|NCT01071902|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
3217862|NCT01071902|Placebo Comparator|Vehicle|Vehicle
3217863|NCT01071889|Other|Brotizolam|Treatment response will be evaluated for each treatment arm. Good Response (GR) - is considered as an improvement of 30% in efficacy parameters of Flumazenil treatment in comparison to placebo
3217864|NCT01071889|Other|Zolpidem|Treatment response will be evaluated for each treatment arm. Good Response (GR) - is considered as an improvement of 30% in efficacy parameters of Flumazenil treatment in comparison to placebo.
3217865|NCT01071876|Experimental|BF2.649|BF2.649 capsules dosed at 5mg, 10 mg, 20mg
3217866|NCT01071876|Placebo Comparator|Placebo|Capsules of Placebo containing lactose with low, medium and high dosage
3217867|NCT01071863||Rheumatoid Arthritis (RA) Patient Group|Patients with RA who have been refered for biological drug treatment
3217868|NCT01071863||Control Group|20 people of same age and sex as the RA patient cohort
3217869|NCT01071850|Experimental|ASP1941 lowest dose|oral tablet
3217870|NCT01071850|Experimental|ASP1941 low dose|oral tablet
3217871|NCT01071850|Experimental|ASP1941 high dose|oral tablet
3217872|NCT01071850|Experimental|ASP1941 highest dose|oral tablet
3217873|NCT01071850|Active Comparator|Metformin|oral tablet
3217874|NCT01071850|Placebo Comparator|Placebo|oral tablet
3217875|NCT01071837|Active Comparator|Re-Irradiation|33% of the patients will be randomized to reirradiation (RT) alone. They will receive 36 Gy (2 Gy per fraction)
3217876|NCT01071837|Experimental|Re-Irradiation + APG101|66% of the patients will be randomized to reirradiation (RT) + 400 mg APG101 weekly. They will receive 36 Gy (2 Gy per fraction) and 400 mg APG101 weekly as an intravenous infusion
3217877|NCT01071824|Active Comparator|Transverse coloplasty pouch (Short limb)|The short limb is the standard technique of transverse coloplasty pouch.
3217878|NCT01071824|Experimental|Transverse coloplasty pouch (Long limb)|The long limb relates to straight coloanal anastomosis.
3217879|NCT01071811|No Intervention|Control group|Participants assigned to the control group received a leaflet from the National Board of Health in Denmark recommending all adults to be physical active for 30 minutes each day of moderate intensity.
3217880|NCT01071811|Experimental|Pedometer group|Received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program, a handout with a summary of the pedometer program, and a calendar for registration of daily steps.
3217881|NCT01071798||Main Analysis Set|Participants who received at least one cycle of rituximab
3217882|NCT01071785|No Intervention|usual diet|no dietary or drug intervention. Patients followed their usual diet.
3217883|NCT01071785|Experimental|guar gum|guar gum
3217884|NCT01071772|Experimental|euglycemia|
3217885|NCT01071772|Experimental|hyperglycemia|
3217886|NCT01071759||pregnancy|
3217887|NCT01071746||Acute decompensation of cirrhosis|acute decompensation of liver function occuring secondary to precipitating events such as sepsis, GI bleed.
3217888|NCT01071733||ultrasound wrist|
3217889|NCT01071733||ultrasound finger|
3217890|NCT01071733||ultrasound ankle|
3217891|NCT01071720|Other|CKD-501 1mg (fed-fasted group)|CKD-501 1mg should be administered following a high-fat, high-caloric diet(fed condition) in one period and on an empty stomach(fasting condition) in the other period.
3217892|NCT01071720|Other|CKD-501 1mg (fasted-fed group)|CKD-501 1mg should be administered on an empty stomach(fasting condition) in one period and following a high-fat, high-caloric diet(fed condition) in the other period.
3217893|NCT01071707||Confirmed Diagnosis of IPF|Subjects in this cohort will continue beyond the screening visit(s) for longitudinal follow up visits for a minimum of 48 weeks and maximum of 80 weeks.
3217894|NCT01071707||No diagnosis of IPF|Subjects that complete screening visits and do not obtain a confirmed diagnosis of IPF will conclude the study at screening, at the time point where IPF is ruled out as a diagnosis.
3217895|NCT01071694||Group 1|
3217896|NCT01071681||Group 1|
3217897|NCT01071668||GEM-2 Cohort|Women who have a low risk pregnancy before onset of labor. Patients included in the study who will be hospitalized with spontaneous labor at term with intact membranes or preterm labor will be included in the study group. Patients with premature rupture of membranes or induction of labor will be analyzed separately.
3217898|NCT01071655|Experimental|2|"Patients with zero favorable genotype: BVZ + XELIRI.~Patients with one favorable genotype: TS 3'UTR +6bp/+6bp and ERCC1-118 T/T: BVZ + XELOX or TS 3'UTR +6bp/-6bp and ERCC1-118 C/T ó C/C: BVZ + FUIRI.~Patients with two favorable genotypes : BVZ + FUOX."
3217899|NCT01071655|Active Comparator|1|BVZ + XELOX
3217900|NCT01071642|No Intervention|continue ace-i and arb's versus dicontinue|
3217901|NCT01071642|Active Comparator|group b|
3217902|NCT01071642|Active Comparator|group c|
3217903|NCT01071629|Active Comparator|Combined interval and strength training|CHF Pts randomly designed at the combined interval and strength training group
3217904|NCT01071629|Active Comparator|Aerobic interval training|CHF Patients that randomly designed to participate at the interval training group
3217905|NCT01071577||Healthy Volunteers|Healthy volunteers wanting to donate BMSC for allogeneic use
3217906|NCT01071577||Patients|Patients donating BMSC for autologous use
3217907|NCT01071564|Experimental|Treatment (RO4929097 and vismodegib)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on day 1 or days -2, -1, and 1 of course 1 and days 1-3 and 8-10 of course 2 and all subsequent courses. Patients also receive vismodegib PO QD beginning day 8 of course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3217908|NCT01071551|Experimental|Lifestyle and health promotion|"The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care."
3217909|NCT01071551|Active Comparator|Physical activity only|Children allocated to this group will attend physical activity classes only.
3217910|NCT01071538|Experimental|Buprenorphine|Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
3217911|NCT01071525|Active Comparator|Niacin|Hypercholesterolemic patients with high-density lipoprotein (HDL) less than 40 mg% will receive Niacin\Laropiprant.
3217912|NCT01071525|No Intervention|Control|Maching subjects will receive no medication, Blood tests will be drawn for laboratory tests.
3217913|NCT01071512|Experimental|Tysabri|Natalizumab 300 mg IV every 4 weeks
3217914|NCT01071499|Active Comparator|1|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
3217915|NCT01071499|Active Comparator|2|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
3217916|NCT01071499|Active Comparator|3|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
3217917|NCT01071473|Other|Exercise Group|Survivors of childhood cancer treated with anthracyclines and known to have cardiomyopathy will participate in a 12 week exercise intervention.
3217918|NCT01071460|Other|SFA Stenting|
3217919|NCT01071447|Active Comparator|Rheumatologist-led clinic|Rheumatologist-led clinic: The subjects are seeing a rheumatologist after six months and after 12-months of intervention and have the possibility to contact the rheumatology clinic
3217920|NCT01071447|Experimental|Nurse-led clinic|The subjects are seeing a rheumatology nurse after six months and a rheumatologist after 12 months of intervention and have the possibility to contact the rheumatology nurse during the intervention.
3217921|NCT01071421||Control Group (B): Other Infections|Other infections admitted to the hospital
3217922|NCT01071421||Community Acquired Pneumonia (Group A)|Patients admitted to hospital with Community Acquired Pneumonia defined by respiratory symptoms, fever and lung infiltrates
3217923|NCT01071408|Experimental|Stroke Prevention Program + Usual Care|Stroke Prevention Care Program + Usual Care. The Stroke prevention care program is in addition, not a substitute for usual care. Persons randomized to this arm are eligible to all care, including care by stroke specialists, while enrolled in the intervention.
3217924|NCT01071408|No Intervention|Usual care|
3217925|NCT01071395|Experimental|Amantadine|Amantadine 100mg tab BID or TID for duration of study
3217926|NCT01071395|Placebo Comparator|Placebo|Placebo one tab BID or TID for duration of study
3217927|NCT01071369|Active Comparator|Xylocaine|0.5% Xylocaine
3217928|NCT01071369|Active Comparator|Xylocaine and Celestone|0.5% Xylocaine with 6 mg of non-particulate Celestone.
3217929|NCT01071356|Experimental|Intensive MI|9 hours of Motivational Interviewing + outpatient substance abuse treatment
3217930|NCT01071356|Active Comparator|Single session MI|1.5 hours of Motivational Interviewing + 8 hours of time equivalent nutrition classes +outpatient substance abuse treatment
3217931|NCT01071317|Experimental|Comprehensive care|Reinforcement of diagnosis, education, medications, and referral
3217932|NCT01071317|Active Comparator|Typical care|Usual care
3217933|NCT01071304|Experimental|All Participants|In Part 1, all participants received a single oral dose of 2 mg midazolam on Day -2. On Days 1-5, all participants received daily single oral doses of ridaforolimus 40 mg ( 4 x 10 mg tablets). On Day 5, all participants received a single oral dose of 2 mg midazolam coadministered with the dose of ridaforolimus. Participants had the option to continue into Part 2 of this study.
3217934|NCT01071291|Experimental|Arm A|Arm A will receive a Niaspan treatment in Period 1 and Placebo treatment in Period 2
3217935|NCT01071291|Experimental|Arm B|Arm B will receive a Placebo treatment in Period 1 and Niaspan treatment in Period 2
3217936|NCT01071278||Patients treated within a disease management program|Participant prescribed Tredaptive® for dyslipidemia and also participated in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
3217937|NCT01071278||Patients treated outside a disease management program|Participant prescribed Tredaptive® for dyslipidemia and did not participate in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
3217938|NCT01071265|Placebo Comparator|Sham RIPC|Inflation of thigh pneumatic tourniquet to <15 mmHg
3217939|NCT01071265|Active Comparator|Active RIPC|300 mmHg inflation of thigh pneumatic tourniquet for three cycles of 5 minutes each with 5 minutes of no inflation between cycles.
3217940|NCT01071252|Experimental|AIN457 1x25mg|
3217941|NCT01071252|Experimental|AIN457 3x25mg|
3217942|NCT01071252|Experimental|AIN457 3x75mg|
3217943|NCT01071252|Experimental|AIN457 3x150mg|
3217944|NCT01071252|Placebo Comparator|Placebo|
3217945|NCT01071239|Experimental|Bone marrow processing|Bone Marrow processing using the CliniMACs device
3217946|NCT01071226|Experimental|Stratum 1|Patients receiving an unrelated donor or partially matched related donor.
3218055|NCT01070459|Placebo Comparator|Follow-up control group|
3217947|NCT01071226|Experimental|Stratum 2|For the patient's whose donors are haploidentical or a 2 antigen mismatched where one of the mismatches includes DRB1
3217948|NCT01071200|Experimental|A|Subjects treated with r-hFSH and r-hLH (2:1 ratio of r-hFSH:r-hLH)
3217949|NCT01071200|Active Comparator|B|Subjects treated with r-hFSH alone
3217950|NCT01071187|Experimental|Varenicline|Treatment with varenicline with 0,5mg daily on day 1-3, 1mg daily on day 4-7 and 2mg daily on day 8-84.
3217951|NCT01071187|Placebo Comparator|Placebo|
3217952|NCT01071174|Placebo Comparator|Placebo Ring|Vaginal Ring containing no drug substance
3217953|NCT01071174|Experimental|Dapivirine Ring|Dapivirine Vaginal Ring 25mg
3217954|NCT01071161|Experimental|Azithromycin|
3217955|NCT01071161|Placebo Comparator|Placebo|
3217956|NCT01071148||Subgroup 1: Age < 35 years|Subjects who have experienced infertility and justifying IVF/ET treatment will be administered either Gonal-f or Pergoveris or Gonal-f and Luveris as per the discretion of the investigator.
3217957|NCT01071148||Subgroup 2: 42 > Age ≥ 35 years|Subjects who have experienced infertility and justifying IVF/ET treatment will be administered either Gonal-f or Pergoveris or Gonal-f and Luveris as per the discretion of the investigator.
3217958|NCT01071135|Experimental|Quetiapine XR|
3217959|NCT01071122|Experimental|Arm 1|
3217960|NCT01071122|Active Comparator|Arm 2|
3217961|NCT01071122|Active Comparator|Arm 3|
3217962|NCT01071109|Experimental|Therapeutic Massage|
3217963|NCT01071109|No Intervention|No therapeutic massage|
3217964|NCT01071096|Active Comparator|OnabotulinumtoxinA|Minimum dose of 155 international units (U) OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas.
3217965|NCT01071096|Placebo Comparator|Saline|155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas.
3217966|NCT01071083|Active Comparator|natalizumab|
3217967|NCT01071083|Placebo Comparator|IV placebo|
3217968|NCT01071083|Active Comparator|interferon β-1a, glatiramer acetate, or methylprednisolone|
3217969|NCT01071070|Active Comparator|Group 1|Initial dosing based on a formula of intact parathyroid hormone value/80 (where intact parathyroid hormone value is the baseline value in pg/mL).
3217970|NCT01071070|Active Comparator|Group 2|Dose determined by US paricalcitol injection package insert dosing instructions (starting dose at 0.04 microgram/kg)
3217971|NCT01071057|Active Comparator|Naloxone/morphine|Naloxone (12 µg/ml) mixed in a single infusion with morphine (1 mg/ml). The study solutions will be prepared by a pharmacist and diluted in saline to produce equal volumes to ensure proper blinding.
3217972|NCT01071057|Placebo Comparator|saline/morphine|Patients will be randomly assigned to one of two groups (Naloxone/morphine or saline/morphine) using computer-generated random numbers. On arrival to the PACU patients will be started on IV PCA and randomized study drug
3217973|NCT01071044|Active Comparator|Lisdexamfetamine Dimesylate|Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
3217974|NCT01071044|Placebo Comparator|Sugar pill|"Matching Placebo 30, 50 or 70 mg"
3217975|NCT01071031|Experimental|Group 1|Low Dose HIV-v with water for injection
3217976|NCT01071031|Experimental|Group 2|Low Dose HIV-v with adjuvant
3217977|NCT01071031|Experimental|Group 3|High Dose HIV-v with water for injection
3217978|NCT01071031|Experimental|Group 4|High Dose HIV-v with adjuvant
3217979|NCT01071031|Placebo Comparator|Group 5|Control group: adjuvant only or water for injection only
3217980|NCT01071018|Experimental|QOD Schedule|QOD Schedule, MK2206 every other day
3217981|NCT01071018|Experimental|QW Schedule|QW Schedule, MK2206 once weekly
3217982|NCT01071005|Experimental|Test|Lorelin Depot - Bergamo
3217983|NCT01071005|Active Comparator|comparator|Lupron Depot® - Abbott
3217984|NCT01070979|Experimental|Estradiol acetate (E3A)|
3217985|NCT01070979|Active Comparator|Estradiol|
3217986|NCT01070979|Active Comparator|Conjugated equine estrogens (CEE):|
3217987|NCT01070966||VYTORIN® 10/10 (ezetimibe 10 mg/simvastatin 10 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/10 (ezetimibe 10 mg/simvastatin 10 mg tablets)
3217988|NCT01070966||VYTORIN® 10/20 (ezetimibe 10 mg/simvastatin 20 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/20 (ezetimibe 10 mg/simvastatin 20 mg tablets)
3217989|NCT01070966||VYTORIN® 10/40 (ezetimibe 10 mg/simvastatin 40 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/40 (ezetimibe 10 mg/simvastatin 40 mg tablets)
3217990|NCT01070966||VYTORIN® 10/80 (ezetimibe 10 mg/simvastatin 80 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/80 (ezetimibe 10 mg/simvastatin 80 mg tablets)
3217991|NCT01070953||EZETROL® 10 mg|Participants with Hypercholesterolemia treated with EZETROL®
3217992|NCT01070940|Placebo Comparator|Isotonic saline infusion|
3217993|NCT01070940|Active Comparator|Intravenous L-NMMA dose 2|
3217994|NCT01070940|Active Comparator|Intravenous L-NMMA dose 3|
3217995|NCT01070940|Active Comparator|Intravenous L-NMMA dose 1|
3217996|NCT01070927|Experimental|cohort 1|
3217997|NCT01070927|Experimental|cohort 2|
3217998|NCT01070901||Organ transplant recipients|
3217999|NCT01070888|Experimental|Budesonide/Formoterol first|This arm will receive blinded budesonide/formoterol and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. The second study period will be budesonide and dummy inhaler.
3218000|NCT01070888|Active Comparator|Budesonide first|This arm will receive blinded budesonide and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. The second study period will be budesonide/formoterol and dummy inhaler.
3218001|NCT01070875|Active Comparator|UFH 5000 U three times per day|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous three times a day.
3218002|NCT01070875|Active Comparator|UFH 5000 U two times per day|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
3218003|NCT01070862|Experimental|thalidomide + dexamethasone|Thalidomide 200 mg/d at bedtime + Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
3218004|NCT01070862|Active Comparator|Vincristin, Adriamycin, Dexamethasone|
3218005|NCT01070862|Experimental|thalidomide, melphalan, endoxan, dexamethasone|
3218006|NCT01070862|Active Comparator|melphalan, endoxan, dexamethasone (MCDex)|
3218007|NCT01070862|Experimental|Thalidomide, Dexamethasone|
3218008|NCT01070862|No Intervention|watch and wait|
3218009|NCT01070849|Active Comparator|a) educational booklet|
3218010|NCT01070849|Active Comparator|b) IRENA|
3218011|NCT01070849|Experimental|c) RÜCKGEWINN|
3218012|NCT01070836||natalizumab|US participants with relapsing MS receiving commercial natalizumab
3218013|NCT01070823||Relapsing Multiple Sclerosis|Participants receiving or considering treatment with Tysabri® (natalizumab).
3218014|NCT01070810|Placebo Comparator|1|50 ml D5W
3218015|NCT01070810|Experimental|2|200mg Thiamine in 50ml D5W
3218016|NCT01070797|Experimental|Group A|Group A is for CMV seropositive donors.
3218017|NCT01070797|Experimental|Group B|Group B is for CMV seronegative donors.
3218018|NCT01070784|Experimental|1|
3218019|NCT01070784|Active Comparator|2|
3218020|NCT01070745|Experimental|Indomethacin for resistant PDA|Treatment with second course of indomethacin
3218021|NCT01070745|Experimental|Ibuprofen for resistant PDA|Ibuprofen as second course of therapy
3218022|NCT01070732|Experimental|Paracetamol|All patients will receive one single dose of 1000mg paracetamol.
3218023|NCT01070719||Relapsing form of MS treated with natalizumab|Only patients diagnosed with a relapsing form of Multiple Sclerosis (MS) and who are being treated with Tysabri (natalizumab) will be included in this Phase IV observational study.
3218024|NCT01070706|Experimental|Paclitaxel, Gemcitabine, Sunitinib|Paclitaxel, Gemcitabine, Sunitinib
3218025|NCT01070693|Experimental|Prolene Hernia System device|Inguinal hernia repair either with a bilayer mesh (PHS)
3218026|NCT01070693|Experimental|Lichtenstein|Inguinal hernia repair with the Lichtenstein technique
3218027|NCT01070680|Active Comparator|dexmedetomidine|sedative medicine
3218028|NCT01070680|Placebo Comparator|sodium chloride 0,9%|
3218029|NCT01070667|Experimental|Dronedarone|Patients will receive 400 mg of dronedarone per day for 3 months.
3218030|NCT01070667|Placebo Comparator|Placebo|Patients will receive a placebo tablet once per day for 3 months. AF burden and other parameters described will be monitored from the participants permanent pacemaker. Participants will also be asked to fill out symptom diaries and questionaires.
3218031|NCT01070654|Experimental|40/30 Recruitment Manoeuvre|Patients with respiratory failure that will be first ventilated for 30 minutes according to standardized baseline protective ventilation and after that will receive the recruitment manoeuvre
3218032|NCT01070641|Active Comparator|Carvedilol|Each patient will receive Carvedilol 12.5mg QD
3218033|NCT01070641|Active Comparator|Esophageal Variceal Band Ligation|Each patient will undergo for serial esophageal variceal band ligations after 3 weeks of last session till the eradication of varices
3218034|NCT01070628|Experimental|Stalevo (levodopa/carbidopa/entacapone)|"125mg or 75mg of levodopa during treatment period 1 in groups 1 and 2 respectively.~150mg or 100mg of levodopa during treatment period 2 in groups 1 and 2 respectively."
3218035|NCT01070628|Active Comparator|Sinemet (levodopa/carbidopa)|150mg or 100mg of levodopa during treatment period 3 in study groups 1 and 2 respectively
3218036|NCT01070602|Experimental|anterior corneal incision|
3218037|NCT01070589||Group 1: Obese|BMI>30
3218038|NCT01070589||Group 2: control|Group 2:Normal weight (BMI <25). age and gender matched.
3218039|NCT01070576||normal fracture healing|group in which normal fracture healing has occured
3218040|NCT01070576||atrophic|patients in which an atrophic non-union occured
3218041|NCT01070576||hypertrophic|patients in which a hypertrophic non-union occured
3218042|NCT01070563||Usual|CT angiography is performed 6 hours after the clinical diagnosis of brain death.
3218043|NCT01070563||TCD|When the diagnosis of brain death is made, TCD is performed and then every 2 hours until the flow patterns compatible with brain death are found. Then a CT angiography is performed.
3218044|NCT01070550||Cohort|Participants chronically infected with the hepatitis C virus including Genotypes 1 to 6.
3218045|NCT01070524|Experimental|CHF 5188 pMDI|
3218046|NCT01070524|Active Comparator|Budesonide extrafine pMDI|
3218047|NCT01070524|Active Comparator|Seretide(r) Evohaler(r)|
3218048|NCT01070511|Experimental|Tadalafil|
3218049|NCT01070511|Placebo Comparator|Placebo|
3218050|NCT01070498|Experimental|Trichuris suis ova (TSO)|
3218051|NCT01070485|Experimental|Radium-223 dichloride (Xofigo, BAY 88-8223)|Patients were to receive 4 intravenous administrations of Radium-223 at a dose of 50 kBq/kg body weight (b.w) at intervals of 4 weeks. Radium-223 was given as add-on therapy to existing bisphosphonate therapy.
3218052|NCT01070459|Placebo Comparator|Control group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
3218053|NCT01070459|Experimental|Aerobic exercise group|The patients continues their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heart rate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week training programme 4 information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
3218054|NCT01070459|Experimental|Follow-up first aerobic exercise group|
3218056|NCT01070459|Experimental|Follow-up second aerobic exercise group|
3218057|NCT01070446|Experimental|1|This study involves children with CF who will take a water soluble vitamin supplement of choline bitartrate, 2 gm per day with meals.
3218058|NCT01070433|Experimental|MEBO Wound Ointment (MEBO)|Topical application twice a day
3218059|NCT01070433|Active Comparator|Standard of Care|Topical application twice a day
3218060|NCT01070420|Active Comparator|FFR via central venous line|
3218061|NCT01070420|Experimental|FFR via peripheral vein|
3218062|NCT01070407|Experimental|Arm A, group 1|4 volunteers
3218063|NCT01070407|Experimental|Arm A, group 2|4 volunteers
3218064|NCT01070407|Experimental|Arm A, group 3|5 volunteers
3218065|NCT01070407|Experimental|Arm B, group 5|4 volunteers
3218066|NCT01070407|Experimental|Arm B, group 6|4 volunteers
3218067|NCT01070407|Experimental|Arm B, group 7|5 volunteers
3218068|NCT01070407|Experimental|Arm C, group 9|5 volunteers
3218069|NCT01070407|Experimental|Arm C, group 10|5 volunteers
3218070|NCT01070407|Experimental|Arm C, group 11|4 volunteers
3218071|NCT01070394|Experimental|LDX Treatment|Eligible participants received 12 weeks of open-label treatment. Those on treatment prior to baseline underwent a 7-day (for amphetamine or methylphenidate) or 28-day (for atomoxetine or other medications) washout period prior to initiating LDX treatment. The starting dose was 30mg/day, which could be titrated up by 20mg/day during visits 2-6 (for a maximum dose of 70mg/day). At discretion of investigator, the dose could be down-titrated by 20mg/day during visits 4-6. Once the dose was optimized (after visit 6), the dose was maintained for 8 weeks.
3218072|NCT01070381|Other|nelfilcon A / ocufilcon D|Nelfilcon A contact lenses worn first, with ocufilcon D contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
3218073|NCT01070381|Other|ocufilcon D / nelfilcon A|Ocufilcon D contact lenses worn first, with nelfilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
3218074|NCT01070368|Experimental|Food challenge, skin test|Skin test by two extract commercial, and in-house extract. and open challenge with wheat (except in patient with history of wheat anaphylaxis: assume as challenge positive)
3218075|NCT01070355|Placebo Comparator|Placebo|2 capsules twice daily
3218076|NCT01070355|Active Comparator|Eicosapentaenoic acid free fatty acid|2g daily (2 x 500mg capsules twice daily)
3218077|NCT01070342||Chidren ages 6 to 18|Children ages 6 to 18 years will be available for participation in this multicenter study. Subjects will be enrolled from community based general pediatric clinics and other well-child care areas within participating hospitals and clinics of the four participating sites. Enrollment will continue until a total of 85 subjects from each age category (6-<12 years and ≥12- <18 years) successfully complete the study.
3218078|NCT01070329|Experimental|Duloxetine|
3218079|NCT01070329|Placebo Comparator|Placebo|
3218080|NCT01070316|Experimental|Everolimus|Subjects will be administered study drug if they meet study criteria after 4 weeks of baseline phase. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily.
3218081|NCT01070303|Experimental|Adalimumab 40 mg every other week or every week|
3218082|NCT01070290|Experimental|1|ARQ 197
3218083|NCT01070290|Active Comparator|2|Investigator's choice of oxaliplatin, capecitabine or irinotecan
3218084|NCT01070277|Placebo Comparator|Placebo arm|"2 placebo pills X2 /day for 2 days followed by~1 placebo Pill X2 / day for 7 days"
3218085|NCT01070277|Experimental|Tinidazole and Albendazole treatment|Tinidazole 1 gram BID for 2 days followed by Albendazole 400mg BID for 7 days
3218086|NCT01070264|Experimental|Noni Juice|This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day
3218087|NCT01070251|Active Comparator|Existing state-sponsored PA program|standard children-focused gym lessons approach
3218088|NCT01070251|Active Comparator|Participatory intervention plus state-sponsored PA program|Participatory parent-focused intervention over nine months in addition to state-sponsored PA program
3218089|NCT01070225|Experimental|Hydrocortisone and Propranolol|Participant administered 10 or 20mg propranolol orally. Participants meeting the parameters are randomised to receive 400mg Hydrocortisone intravenously. Participant then receives Histamine PC10 challenge, Administered 5mg Salbutamol via nebuliser, administered 500mcg Ipratropium Bromide via nebuliser; visit end
3218090|NCT01070225|Placebo Comparator|Placebo and propranolol|identical to other arm but participant receive placebo injection as opposed to hydrocortisone
3218091|NCT01070212|Experimental|soft gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
3218092|NCT01070212|Experimental|firm gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
3218139|NCT01069900|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Subjects randomized to the moxifloxacin arm of this study received intravenous moxifloxacin plus ertapenem placebo (0.9 % sodium chloride [NaCl solution]) for a minimum of 3 days and, if switched to oral treatment, PO moxifloxacin plus PO amoxicillin/clavulanate placebo. Total treatment duration is 5-14 days.
3218223|NCT01069315|Experimental|Normal saline and High pressure|
3218093|NCT01070212|Experimental|no gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
3218094|NCT01070199|Experimental|liquid to liquid,|
3218095|NCT01070199|Experimental|liquid to solid,|
3218096|NCT01070199|Experimental|solid to liquid|
3218097|NCT01070199|Experimental|solid to solid|
3218098|NCT01070186|Experimental|Treatment|See intervention descriptions
3218099|NCT01070173||Short Stature|Poor linear growth
3218100|NCT01070173||Poor Weight Gain (Failure-To-Thrive)|Poor Weight Gain
3218101|NCT01070173||Isolated Gastrointestinal Symptoms|No growth symptoms
3218102|NCT01070160||A|Women with PCOS initiating Metformin and exposure to vaginal progesterone for 6-8 days prior ro Endometrium Biopsy
3218103|NCT01070160||B|Women with PCOS not planning initiating Metformin and exposure to vaginal progesterone for 6-8 days prior to Endometrium Biopsy
3218104|NCT01070160||Women with PCOS who previously initiated metformin|Women with PCOS who initiated metformin at least 3 months prior to enrollment who have completed a 6-10 day course of progesterone
3218105|NCT01070147|Experimental|Control|The control group will receive a paper-based printed asthma guideline.
3218106|NCT01070134|Experimental|Mindfulness-based Behavioural Therapy (MIBT)|
3218107|NCT01070134|Active Comparator|PT (psychodynamic therapy)|
3218108|NCT01070121||RA patients/participants|
3218109|NCT01070108|Active Comparator|Set 1|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
3218110|NCT01070108|Active Comparator|set 2|2nd set received ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
3218111|NCT01070108|Active Comparator|set 3|3rd set one group had ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
3218112|NCT01070095|Experimental|Electronic Asthma Action Plan System|Electronic Asthma Action Plan System (eAAPS)
3218113|NCT01070082||Adult ICU patients undergoing procedure|
3218114|NCT01070069|Active Comparator|Standard EVAR (IntuiTrak)|EVAR using standard vascular exposure for access
3218115|NCT01070069|Experimental|PEVAR (ProGlide closure)|Percutaneous EVAR facilitated by the ProGlide closure device
3218116|NCT01070069|Experimental|PEVAR (ProstarXL closure)|Percutaneous EVAR facilitated by the Prostar XL closure device
3218117|NCT01070056|Active Comparator|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
3218118|NCT01070056|Experimental|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension (HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
3218119|NCT01070043|Experimental|Amlodipine 5mg/Valsartan 80 mg|During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks.
3218120|NCT01070043|Active Comparator|Valsartan 160 mg|In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks.
3218121|NCT01070043|Other|Run-In Valsartan 80 mg|During run-in period, oral valsartan 80 mg once daily for 4 weeks.
3218122|NCT01070017|Experimental|Intervention: DOT-HAART|Intervention group will receive community-based monthly adherence visits, standard care, and DOT-HAART.
3218123|NCT01070017|No Intervention|No DOT-HAART|Control group receives community-based monthly adherence visits and standard care, but no DOT-HAART.
3218124|NCT01070004|Experimental|Blue light|Exposure to 460-nm monochromatic light (blue light)
3218125|NCT01070004|Experimental|Physical activity|15 minutes of physical activity at a low intensity
3218126|NCT01069991|Experimental|Patient education group|Patient education program delivered to high school students with persistent asthma.
3218127|NCT01069991|Experimental|Wait list control group|Control students received no intervention until the one year follow up period was completed.
3218128|NCT01069965|Experimental|6. BGP-15|400 mg BGP-15 + Placebo
3218129|NCT01069965|Experimental|5. BGP-15|200 mg BGP-15 BID
3218130|NCT01069965|Experimental|4. BGP-15|200 mg BGP-15 + Placebo
3218131|NCT01069965|Experimental|3. BGP-15|Two 50 mg BGP-15 capsules by mouth in the morning; and two 50 mg BGP-15 capsules by mouth in the evening
3218132|NCT01069965|Experimental|2. BGP-15|100 mg BGP-15 + placebo
3218133|NCT01069965|Experimental|1. Placebo|Placebo BID
3218134|NCT01069952|Experimental|Active DBS|Participants will receive deep brain stimulation.
3218135|NCT01069939|Experimental|Esomeprazole 20mg|Esomeprazole 20mg once daily oral
3218136|NCT01069939|Placebo Comparator|Placebo|Placebo once daily oral
3218137|NCT01069913|Active Comparator|BG00012|BG00012 Standard Formulation
3218138|NCT01069913|Active Comparator|BG00012 API|BG00012 API
3218218|NCT01069328|Experimental|Arm 2|
3218219|NCT01069328|Experimental|Arm 3|
3218140|NCT01069900|Active Comparator|Comparator Ertapenem|Subjects randomized to the comparator arm of this study received intravenous ertapenem plus moxifloxacin placebo (0.9 % NaCl solution) for a minimum of 3 days and, if switched to oral treatment, amoxicillin/clavulanate as an oral suspension plus PO moxifloxacin placebo. Total treatment duration is 5-14 days.
3218141|NCT01069887||adult with hematological malignancies|
3218142|NCT01069887||pediatrics with hematological malignancies|
3218143|NCT01069887||pediatrics receiving stem cell transplant|
3218144|NCT01069887||adult receiving stem cell transplant|
3218145|NCT01069874|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
3218146|NCT01069874|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
3218147|NCT01069861|Experimental|one|
3218148|NCT01069835||1|Non-small cell lung cancer patients
3218149|NCT01069822|Experimental|1|midazolam + AZD6765 IV solution
3218150|NCT01069822|Active Comparator|2|
3218151|NCT01069809|Experimental|AGS-004|HIV-1 Immune Therapy
3218152|NCT01069809|Placebo Comparator|Inactive Injection|Inactive Placebo Injection
3218153|NCT01069796|Experimental|Association bevacizumab paclitaxel capecitabine breast cancer|"bevacizumab 10 mg/kg in IV, D1 and D15~paclitaxel 80mg/m2 in IV, D1 to D8 and D15~capecitabine 1600mg/m2/D, per os, D1 to D5, Weeks 1,2 and 3"
3218154|NCT01069783|Experimental|A3309 low dose|
3218155|NCT01069783|Experimental|A3309 high dose|
3218156|NCT01069783|Placebo Comparator|Placebo|
3218157|NCT01069757|Experimental|ARQ 197 and Erlotinib|ARQ 197 and erlotinib hydrochloride
3218158|NCT01069744||Control Group|Control group When neonates are considered ready for oral feedings these feedings will be started with the standard oral feeding protocol for the NICU but without the NTrainer stimulation regimen described previously.
3218159|NCT01069744||NTrainer System|NTrainer Experimental Group When neonates are considered ready for oral feedings these feedings will be started simultaneously with the NTrainer therapy. Control and experimental interventions will not be initiated until the infant is in an optimal behavioral state, i.e., drowsy to quiet alert (NIDCAP state 3 or 4). Preterm infants in the experimental group will receive alternating 3-minute epochs of patterned oral somatosensory stimulation and null conditions using the NTrainer© during the tube (gavage) feeding session up to 4 times per day.
3218160|NCT01069731||Infants born at 30 to 36 weeks gestation|Infants will be considered eligible if they are born at 30 to 36 weeks gestation and have no exclusion criteria.
3218161|NCT01069718||Clinical Group|In the Clinical group bottle feedings will be attempted by the bedside nurses, using techniques suggested in the feeding plan. The Infant Feeding Specialist will observe at least one feeding per day to assure that the feeding plan is being adhered to. If, in the judgment of the person feeding the infant, the infant is unable to complete the bottle feeding, the remaining volume will be given via an indwelling gavage tube. During all gavage feedings, both total and partial, infants will be offered a pacifier to suck on.
3218162|NCT01069718||NTrainer Group|"In the NTrainer group, three feedings per day will be given via gavage tube while the infant is receiving NTrainer stimulation. The stimulation will be done by alternating 3 minute epochs of NTrainer stimulation with 3 minutes of sucking on a regular pacifier, up to a total time of 30 minutes.~Every other day, 15 minutes prior to a feeding that is not one of the study sessions, each infant's suck strength and coordination will be measured using the NTrainer device in its NeoSuck RT Assessment mode.~On the day after the study intervention period is completed each infant will be assessed by an investigator unaware of the infant's study group assignment."
3218163|NCT01069705|Experimental|TIPnew|
3218164|NCT01069692|Placebo Comparator|Arm 1|Placebo
3218165|NCT01069692|Experimental|Arm 3|
3218166|NCT01069692|Experimental|Arm 2|
3218167|NCT01069692|Experimental|arm 4|SBR759A
3218168|NCT01069692|Experimental|arm 5|
3218169|NCT01069653|Experimental|CDCA1-KIF20A-1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218170|NCT01069653|Experimental|CDCA1-KIF20A-2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (2mg) and KIF20A peptide(2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218171|NCT01069653|Experimental|CDCA1-KIF20A-3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (3mg) and KIF20A peptide(3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218172|NCT01069640|Experimental|URLC10-1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218173|NCT01069640|Experimental|URLC10-2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218174|NCT01069640|Experimental|URLC10-3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218175|NCT01069627|Experimental|1|
3218176|NCT01069614|Experimental|Skin stretching device|Skin stretching device
3218177|NCT01069601|Experimental|transplanted adults|male and female adults who have previously undergone solid organ transplantation or allogeneic or autologous BMT
3218178|NCT01069588||Calaxo|Received Calaxo screw
3218179|NCT01069588||Milagro|Received a Milagro screw
3218180|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (1mg), CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218220|NCT01069328|Experimental|Arm 4|
3218221|NCT01069328|Experimental|Arm 5|
3218222|NCT01069328|Experimental|Arm 6|
3218181|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (2mg), CDCA1 peptide (2mg) and KIF20A peptide(2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218182|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (3mg), CDCA1 peptide (3mg) and KIF20A peptide(3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218183|NCT01069562|Active Comparator|MANUAL|In the manual group isoflurane was administered using Tech 7 vapouriser. The dial setting was controlled by the anesthesiologist to achieve and maintain a BIS of 50 during anesthesia.
3218184|NCT01069562|Experimental|IAADS group|In this group, liquid isoflurane was injected into the circuit using a syringe pump controlled by the IAADS system.The IAADS system has the algorithm to regulate the rate of infusion of isoflurane such that BIS is achieved and maintained at 50 during anesthesia.
3218185|NCT01069549||subjects with diabetic nephropathy.|"Subjects with Type 2 Diabetes. Duration of diabetes should be more than or equal to 5 years. Age between 30 and 85 years. Diabetic nephropathy as defined by ADA.~Subject must be of north Indian origin.~Type 1 diabetes and kidney disease other than diabetes nephropathy are excluded form the study."
3218186|NCT01069549||Subjects without Diabetic nephropathy.|This group of subject with similar characteristics as group 1 without any evidence of nephropathy.
3218187|NCT01069536|Active Comparator|2 minutes bolus infusion|
3218188|NCT01069536|Active Comparator|15 minutes slow infusion|
3218189|NCT01069523|Placebo Comparator|Placebo|Patients will be started on 1 mg of guanfacine extended release matching placebo tablets at week 1. A physician blind to drug status will titrate the study medication in week 2-3 to a maximum of 4 mg (4 tablets).
3218190|NCT01069523|Experimental|Guanfacine Extended Release|Patients will be started on 1 mg of guanfacine extended release at week 1. A physician blind to drug status will titrate the study medication in week 2-3 to a maximum of 4 mg (4 tablets).
3218191|NCT01069510|Placebo Comparator|Placebo|
3218192|NCT01069510|Experimental|Spironolactone|Spironolactone 25 mg daily
3218193|NCT01069497|Experimental|Intervention Nursing Homes|Comprising 24 nursing homes implementing a specific infection prevention program
3218194|NCT01069497|No Intervention|Usual care Nursing Homes|
3218195|NCT01069484|Experimental|Postpartum pelvic floor muscle training|Beyond a customary leaflet (received from the postnatal ward) and the thorough initial instruction on how to contract the PFM correctly, the participants are given supervised pelvic floor muscle group training led by physiotherapists once a week. In addition, the participants train every day at home, with at least 3 sets of 8-12 contractions. Training period is 4 months.
3218196|NCT01069484|No Intervention|Control|Beyond the customary leaflet (received from the postnatal ward) and the thorough initial instruction on how to contract the PFM correctly, the control group participants received no further intervention. They were not discouraged from doing PFMT on their own.
3218197|NCT01069471|Experimental|HHD O1-EPA plus adjuvant|10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
3218198|NCT01069471|Experimental|HHD O1-EPA|10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA
3218199|NCT01069471|Experimental|LHD O1-EPA adjuvanted|2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
3218200|NCT01069471|Experimental|LHD O1-EPA|2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA
3218201|NCT01069458|Experimental|The High Protein Diet Group|The high protein diet (25% energy from protein, 55% energy from fat, 20% energy from carbohydrate) will be hypo-caloric and achieved by restricting the amount of sugar containing foods and drinks, reducing the intake of bread, rice, pasta, fruits and fruit-juices and increasing the intake of vegetables (instead of bread, rice, pasta and potatoes) and increasing the amounts of protein (from chicken, fish, and meat) and fat from oil and dressings for lunch and dinner and by choosing nuts and protein-rich yoghurts, egg, cheese, chicken wings, shellfish, fish and fish products as snacks.
3218202|NCT01069458|Active Comparator|The Low Fat Diet Group|The low fat diet (30% energy from fat, 20% energy from protein, 50% energy percent from carbohydrate) will be hypo-caloric and achieved by choosing low-fat diary and meat products, restricting amounts of visible fat and fatty snacks and increasing intake of whole meal bread, muesli, brown rice, whole meal pasta in the main meals and by choosing yoghurt with muesli, oat porridge with milk, fruits and hard bread with jam and soft gout-cheese as snacks.
3218203|NCT01069445|Active Comparator|Diet advices|will receive the Optimal Diet for Elderly
3218204|NCT01069445|Experimental|Diet advices + VSL-3|will receive the Optimal Diet for Elderly + VSL#3® probiotic blend
3218205|NCT01069445|Experimental|Diet advices + 5203-L|will receive the Optimal Diet for Elderly + AISA-5203-L fruit extracted terpene
3218206|NCT01069445|Experimental|Diet advices + Argan oil|will receive the Optimal Diet for Elderly + Argan oil
3218207|NCT01069432||Patients with CLL|Patients undergoing routine blood draws as part of their ongoing follow-up care for CLL at the Norris Cotton Cancer Center of DHMC.
3218208|NCT01069432||Normal Volunteers|Normal volunteers who have no history of active or prior hematologic malignancy.
3218209|NCT01069419||Cimzia|All patients will be treated with Cimzia according to normal clinical practice for the prescribing physician and as defined by the SmPC
3218210|NCT01069406||presence of uterine artery notch|patients with uterine artery notch during the 2nd and 3rd trimester
3218211|NCT01069393|Active Comparator|Standard DAFNE|Usual DAFNE course taught over 5 consecutive days in one week
3218212|NCT01069393|Experimental|DAFNE 5x1 day|DAFNE course taught 1 day a week for 5 consecutive weeks
3218213|NCT01069367|Experimental|Arm:1|
3218214|NCT01069354|Experimental|Radiesse® Mixed with Lidocaine|Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
3218215|NCT01069354|Active Comparator|Radiesse® without Lidocaine|Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
3218216|NCT01069341|Other|Treatment|All subjects enrolled received treatment with identical dosage of Ranibizumab
3218217|NCT01069328|Experimental|Arm 1|
3218224|NCT01069315|Experimental|Soap solution and High pressure|
3218225|NCT01069315|Experimental|Normal saline and Low pressure|
3218226|NCT01069315|Experimental|Soap solution and Low pressure|
3218227|NCT01069302|Active Comparator|High loading and high maintenance|Clopidogrel loading 600mg and maintenance 150mg for 7days
3218228|NCT01069302|Active Comparator|High loading and low maintenance|Clopidogrel loading 600mg and maintenance 75mg for 7days
3218229|NCT01069302|Active Comparator|Low loading and high maintenance|Clopidogrel loading 300mg and maintenance 150mg for 7days
3218230|NCT01069302|Active Comparator|Low loading and low maintenance|Clopidogrel loading 300mg and maintenance 75mg for 7days
3218231|NCT01069289|Experimental|1|Symbicort Turbuhaler 160/4.5 microgram, 2 inhalations twice daily
3218232|NCT01069289|Active Comparator|2|Oxis Turbuhaler 4.5 microgram, 2 inhalations twice daily
3218233|NCT01069276||Patients with clinical signs of stroke|Patients with clinical signs of stroke
3218234|NCT01069263|Active Comparator|Intravesical DMSO instillation|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
3218235|NCT01069263|Experimental|Hyperbaric Oxygen Therapy (HBOT)|Overall 60 treatments (5 days per weeks for 12 weeks). 90 minutes every session. Pressure of 2 atm. Inhalation of 100% oxygen.
3218236|NCT01069250||Brain injury|Patients after traumatic brain injury or spontaneous intracranial bleeding
3218237|NCT01069237||OPTI-FREE Replenish|Multi-Purpose Solution for soft contact lenses
3218238|NCT01069237||Clear Care|Lens Care Solution for contact lenses
3218239|NCT01069224||RC tear|This study will include a consecutive series of patients who met the study inclusion criteria. Study group patients will be diagnosed RC tear on clinical examination and imaging findings (US and MRI) that will be verified at arthroscopy in order to complete the enrollment.
3218240|NCT01069224||Control group|Control group will include patients suffering from shoulder instability that scheduled for elective surgical repair.
3218241|NCT01069211||ER expression : Low|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 3 or 4 point of total Allred score.
3218242|NCT01069211||ER expression : Intermediate|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 5 or 6 point of total Allred score.
3218243|NCT01069211||ER expression : High|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 7 or 8 point of total Allred score.
3218244|NCT01069198|Experimental|Intervention group|
3218245|NCT01069198|Placebo Comparator|Non-intervention group|Non-intervention group will receive placebo following the same schedule as intervention group.
3218246|NCT01069185|Experimental|Necessity endotracheal suctioning|Endotracheal suctioning depends on clinical manifestations
3218247|NCT01069185|Other|Routine endotracheal suctioning|Endotracheal suctioning every two hours
3218248|NCT01069172|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery group (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the femtosecond laser device. If necessary, ultrasound (U/S) phacoemulsification will also be applied to facilitate removal of the crystalline lens during cataract surgery.
3218249|NCT01069172|Active Comparator|CCC Surgery|For the continuous curvilinear capsulorhexis (CCC) group (CCC Surgery), subjects will receive the standard of care for CCC and U/S phacoemulsification surgery to facilitate removal of the crystalline lens during cataract surgery.
3218250|NCT01069159|Active Comparator|Propranolol|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive propranolol.
3218251|NCT01069159|Placebo Comparator|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
3218252|NCT01069146|Experimental|Mild therapeutic hypothermia|Sepsis treatment according to standard guidelines plus mild therapeutic hypothermia
3218253|NCT01069146|No Intervention|Control|Sepsis treatment according to standard guidelines
3218254|NCT01069133|Experimental|Rifaximin|
3218255|NCT01069120|Active Comparator|50 mg Proellex®|2, 25 mg capsules
3218256|NCT01069120|Active Comparator|25 mg Proellex®|1, 25 mg capsule
3218257|NCT01069107|Active Comparator|Consume of health services|One year follow-up of patients randomized to two different levels of health care
3218258|NCT01069094|Experimental|progenta 12.5 mg|Progenta (CDB-4124) 12.5 mg capsule
3218259|NCT01069094|Experimental|progenta 25 mg|Progenta (CDB-4124) 25 mg capsule
3218260|NCT01069094|Experimental|progenta 50 mg|Progenta (CDB-4124) 50 mg capsule
3218261|NCT01069094|Active Comparator|Lucron Depot|Lucron Depot, Leuprolide acetate for depot suspension
3218262|NCT01069094|Placebo Comparator|placebo|Placebo capsule
3218263|NCT01069081|Active Comparator|arm A|docetaxel and cisplatin chemotherapy
3218264|NCT01069081|Experimental|arm B|docetaxel and cisplatin chemotherapy combined with PPI 160mg per day.
3218265|NCT01069081|Experimental|arm C|docetaxel and cisplatin chemotherapy combined with PPI 200mg per day.
3218266|NCT01069055|Placebo Comparator|Placebo Control|Group I (Placebo Control) 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.
3218267|NCT01069055|Active Comparator|Lornoxicam|Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
3218268|NCT01069055|Active Comparator|Paracetamol|Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
3218269|NCT01069042|Active Comparator|preserved LVEF under ACEi treatment|preserved LVEF under ACEi treatment
3218270|NCT01069042|Experimental|Poor LVEF group|Poor LVEF under ACEi treatment
3218271|NCT01069029||Combined surgery|Patient which underwent combined surgery of MH and cataract extraction
3218272|NCT01069029||Successive surgery|Patients which underwent the two successive procedures
3218273|NCT01069016|Experimental|Sacral nerve modulation first|"Sacral nerve modulation is applied before the pudendal nerve stimulation. There is no wash-out period (pause) between the two treatments."
3218274|NCT01069016|Experimental|Pudendal nerve stimulation first|"Pudendal nerve stimulation is applied before the sacral nerve modulation. There is no wash-out period (pause) between the two treatments."
3218275|NCT01069003|Placebo Comparator|Placebo Arm|Subjects are randomized to receive 18 months of placebo thienopyridine and aspirin (ASA). Eligible subjects are without death, myocardial ischemia, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.
3218276|NCT01069003|Active Comparator|Thienopyridine Therapy|Subjects are randomized to receive 18 months of active thienopyridine and aspirin (ASA). Eligible subjects are without death, myocardial ischemia, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.
3218277|NCT01069003|Other|Surveillance Arm|Non randomized subjects followed through 24 months
3218278|NCT01068977|Experimental|Stage I|
3218279|NCT01068977|Experimental|Stage II|
3218280|NCT01068977|Experimental|Stage III|
3218281|NCT01068964|Experimental|0.03% Bimatoprost/0.5% Timolol in Same Bottle|Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
3218282|NCT01068964|Active Comparator|0.03% Bimatoprost and 0.5% Timolol in Separate Bottles|Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
3218283|NCT01068951|Active Comparator|Mesenchymal stem cells|Comparison of active treatment with autologous mesenchymal stem cells (in addition to standard treatment) to standard treatment of patients newly diagnosed with type 1 diabetes mellitus.
3218284|NCT01068951|No Intervention|Control|
3218285|NCT01068938||open angle glaucoma, glaucoma suspects|risk of progression, Latanoprost monotherapy
3218286|NCT01068925|Experimental|ARM 1|"Arm 1:~GSK1349572 QD for 5 days (Treatment A)."
3218287|NCT01068925|Experimental|ARM 2|ARM 2: TPV/RTV 500/200mg BID (Treatment B).
3218288|NCT01068925|Experimental|ARM 3|ARM 3: GSK1349572 50mg QD and TPV/RTV 500/200mg BID (Treatment C).
3218289|NCT01068912|Experimental|1: Experimental|Low-dose favipiravir regimen: 1000 mg favipiravir twice a day (BID) x 1 day, and 400 mg favipiravir BID x 4 days
3218290|NCT01068912|Experimental|2: Experimental|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
3218291|NCT01068912|Placebo Comparator|Placebo|Placebo
3218292|NCT01068899||Children|healthy children
3218293|NCT01068899||Adult|healthy adults
3218294|NCT01068886|No Intervention|no stent|no stent through pancreatic anastomosis
3218295|NCT01068886|Experimental|stent|stent through pancreatic anastomosis
3218296|NCT01068873|Experimental|open label single arm|Drug: lopinavir/ritonavir plus maraviroc
3218297|NCT01068860|Experimental|Canakinumab 150 mg + Metformin|Eligible participants received a single subcutaneous injection Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening
3218298|NCT01068860|Placebo Comparator|Placebo + Metformin|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening
3218299|NCT01068860|Experimental|Canakinumab 150 mg + Metforimin + Sulfonylurea|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
3218300|NCT01068860|Placebo Comparator|Placebo + Metforimin + Sulfonylurea|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
3218301|NCT01068860|Experimental|Canakinumab 150 mg + Met + Sulfonyl + Thiazolidinedione|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose, and a Thiazolidinedione (Thiaz)at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
3218302|NCT01068860|Placebo Comparator|Placebo + Met + Sulfonyl + Thiazolidinedione|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose, and a Thiazolidinedione (Thiaz)at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
3218303|NCT01068860|Experimental|Canakinumab 150 mg + Insulin|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus for 3 months prior to screening and be on a stable dose of Insulin, 2 insulin injections per day for a total daily dose of less than 100 U with or without Metformin (Met)for 3 months prior to screening
3218304|NCT01068860|Placebo Comparator|Placebo + Insulin|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus for 3 months prior to screening and be on a stable dose of Insulin, 2 insulin injections per day for a total daily dose of less than 100 U with or without Metformin (Met)for 3 months prior to screening
3218305|NCT01068860|Experimental|Canakinumab 150 mg in patients with IGT|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg. Patients must have had Impaired Glucose Tolerance (IGT) as defined by the World Health Organization (WHO) criteria confirmed at screening visit.
3218306|NCT01068860|Placebo Comparator|Placebo in patients with IGT|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had Impaired Glucose Tolerance (IGT) as defined by the World Health Organization (WHO) criteria confirmed at screening visit.
3218307|NCT01068847|Experimental|1|Receives 2-4 of the drugs listed under Intervention
3218308|NCT01068834||KIF6 tested|Recruited subjects, completing a valid KIF6 test with results
3218309|NCT01068834||KIF6 test naïve|Database matched cohort not receiving a KIF6 test
3218310|NCT01068821|Active Comparator|Egg crate foam mattress|Patients will be placed on egg-crate foam mattress instead of a gel pad by randomization. All other positioning and measurements, including outcomes measures will be the same as for the the primary experimental intervention (gel pad).
3218311|NCT01068821|Active Comparator|Gel pad|Patients will be placed on gel pad instead of egg-crate foam mattress by randomization. All other positioning and measurements, including outcomes measures will be the same as for the the primary experimental intervention (gel pad).
3218312|NCT01068808||Nonallergic rhinitis|Nonallergic rhinitis (negative skin prick test)
3218313|NCT01068795|No Intervention|enoxaparin fixed|enoxaparin dosage will be fixed during pregnancy
3218314|NCT01068795|Experimental|enoxaparin adjusted|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
3218315|NCT01068782|Experimental|Arm 1|
3218316|NCT01068782|Experimental|Arm 2|
3218317|NCT01068782|Experimental|Arm 3|
3218318|NCT01068782|Experimental|Arm 4|
3218319|NCT01068769|Experimental|Regorafenib|Regorafenib adminstered orally, 160 mg per day on days 1 through 21 of a 28 day cycle
3218320|NCT01068756|Other|Dapagliflozin/Rifampin|
3218321|NCT01068743|Other|Arm A (saxagliptin 2.5 mg + metformin 850 mg; Fasting)|A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fasted condition.
3218322|NCT01068743|Other|Arm B (saxagliptin 2.5 mg + metformin 850 mg FDC; Fasting)|A single oral dose of 2.5-mg saxagliptin/850-mg metformin fixed dose combination (FDC) administered in the fasted condition.
3218323|NCT01068743|Other|Arm C (saxagliptin 2.5 mg + metformin 850 mg; Fed)|A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fed condition.
3218324|NCT01068743|Other|Arm D (saxagliptin 2.5 mg + metformin 850 mg FDC; Fed)|A single oral dose of 2.5-mg saxagliptin/850-mg metformin FDC administered in the fed condition.
3218325|NCT01068730|Other|Treatment A|500 mg metformin (Diabex): Single oral dose of 500 mg metformin (Diabex) tablet administered in the fed condition
3218326|NCT01068730|Other|Treatment B|500 mg metformin (Glucophage™): Single oral dose of 500 mg metformin (Glucophage™) tablet administered in the fed condition
3218327|NCT01068730|Other|Treatment C|1000 mg metformin (Diabex): Single oral dose of 1000 mg metformin (Diabex) tablet administered in the fed condition
3218328|NCT01068730|Other|Treatment D|1000 mg metformin (Glucophage™): A Single oral dose of 1000 mg metformin (Glucophage™) tablet administered in the fed condition
3218329|NCT01068717|Other|Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fasted state
3218330|NCT01068717|Other|Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fasted state)|Single oral dose of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet administered in the fasted state
3218331|NCT01068717|Other|Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fed state
3218332|NCT01068717|Other|Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fed state)|Single oral dose of saxagliptin, 2.5 mg/metformin, 500 mg, FDC tablet administered in the fed state
3218333|NCT01068704|Active Comparator|BMS-690514 + Letrozole|
3218334|NCT01068704|Active Comparator|Lapatinib + Letrozole|
3218335|NCT01068678|Experimental|IDeg 3 times weekly (3TW)|
3218336|NCT01068678|Active Comparator|IGlar OD|
3218337|NCT01068665|Experimental|IDeg 200 U/mL OD|
3218338|NCT01068665|Active Comparator|IGlar OD|
3218339|NCT01068652|Active Comparator|Detemir + Met|Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.
3218340|NCT01068652|Active Comparator|BIAsp 30 + Met|Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.
3218341|NCT01068639||A|
3218342|NCT01068626|Active Comparator|Rosuvastatin|
3218343|NCT01068626|Placebo Comparator|Placebo for Rosuvastatin|
3218344|NCT01068613|Experimental|QAX028 high dose|
3218345|NCT01068613|Experimental|QAX028 low dose|
3218346|NCT01068613|Active Comparator|Tiotropium|
3218347|NCT01068613|Placebo Comparator|Placebo|
3218348|NCT01068600|Experimental|Indacaterol 75 µg|"Indacaterol 75 µg inhaled once daily in the morning via Concept1, a single dose dry powder inhaler (SDDPI), for 12 weeks.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
3218349|NCT01068600|Placebo Comparator|Placebo|"Placebo to indacaterol inhaled once daily in the morning via Concept1, a SDDPI, for 12 weeks.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
3218350|NCT01068587|Active Comparator|Erlotinib|
3218351|NCT01068587|Active Comparator|Foretinib plus Erlotinib|
3218352|NCT01068574||Single Observational Cohort|
3218353|NCT01068561|Experimental|Test group|open-label study of retinitis pigmentosa patients with best-corrected visual acuity (BCVA) worse than 20/200.
3218354|NCT01068548|No Intervention|Arm 1|pre-implementation of computer based intervention
3218355|NCT01068548|Experimental|Arm 2|post-implementation of computer based length of stay clinical reminder
3218356|NCT01068535||Women with Metabolic Syndrome|"Pre-menopausal women with Metabolic Syndrome~Age 35-50 and any 3 of the following:~Fasting triglycerides ≥ 150 mg/dL, Waist measurement ≥ 35 inches, HDL < 50mg/dL, Fasting glucose ≥ 100mg/dL but <126mg/dL or Blood pressure ≥ 130/85 or taking medication to treat high blood pressure."
3218437|NCT01068041|Active Comparator|D|1000mg active ingredient
3218357|NCT01068535||Non-Metabolic Syndrome (healthy) women|"Non-Metabolic syndrome pre-menopausal women age 35-50~Body Mass Index ≤ 25~Regular menstrual cycles (occur every 24-35 days)~Fasting glucose < 100mg/dL~HDL-C ≥ 50mg/dL~Waist measurement ≤ 35 inches~Fasting triglycerides < 150mg/dL"
3218358|NCT01068522|Experimental|ICP monitoring|Care based upon intracranial pressure.
3218359|NCT01068522|Active Comparator|Usual Care|Treatment based on clinical and imaging without intracranial pressure monitoring.
3218360|NCT01068509|Experimental|Non-randomized Cvac|Participants received 6-8 intradermal injections of Cvac at 4 sites along both upper arms and both thighs. The 6-8 injections contained ~ 60 × 10^6 dendritic cells. Following evaluation after the first dose, participants received additional injections as described for the randomized Cvac group below.
3218361|NCT01068509|Experimental|Randomized Cvac|Participants received 6-8 intradermal injections of Cvac at 4 sites along both upper arms and both thighs every 4 weeks for 24 weeks (7 doses at Weeks 8, 12, 16, 20, 24, 28, and 32), and then every 8 weeks for 24 weeks (3 doses at Weeks 40, 48, and 56). The 6-8 injections contained ~ 60 × 10^6 dendritic cells.
3218362|NCT01068509|No Intervention|Observational standard of care|Participants in this group did not receive any treatment during the study.
3218363|NCT01068483|Experimental|BKM120|Dose escalation followed by dose expansion
3218364|NCT01068470||patients with melanoma or kidney cancer|
3218365|NCT01068457||PTPS|Patients with pain after VATS
3218366|NCT01068457||Pain free|Patients reporting no pain late after VAT
3218367|NCT01068444|Experimental|Pioglitazone|Pioglitazone 30 mg/day for 6 months and 3 months of follow-up period after treatment
3218368|NCT01068444|Placebo Comparator|Placebo|Placebo 30 mg/day for 6 months and 3 months of follow-up period after treatment
3218369|NCT01068431|Active Comparator|trico bandage|Leg lymphedema stage 2-3
3218370|NCT01068431|Experimental|juxta fit compression device|leg lymphedema stage 2/3
3218371|NCT01068418|Experimental|Vitamin D3|15000IU of vitamin D3 daily: open-label, single-arm
3218372|NCT01068405|Experimental|Methotrexate|Patients with digital arthritis receiving methotrexate treatment at 10mg/week during 12 months
3218373|NCT01068405|Placebo Comparator|Placebo|Patients with digital arthritis receiving placebo at 10mg/week during 12 months
3218374|NCT01068392|Experimental|OXP|Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2HR D1 Prednisolone 100mg/Day D1-D5 Every 3 weeks Maximum 6 cycles of treatment will be given for this study. Subjects will be treated for at least 1 cycle and to a maximum of 6 cycles unless there is documented disease progression, unacceptable adverse events or withdrawal of consent.
3218375|NCT01068379|Experimental|Cryopexy|the cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
3218376|NCT01068379|Experimental|laser photocoagulation 4 weeks after|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
3218377|NCT01068353|Placebo Comparator|Placebo|
3218378|NCT01068353|Experimental|Etanercept|
3218379|NCT01068340||SBO Patients|Patients who develop small bowel obstruction requiring or not surgical intervention
3218380|NCT01068340||No SBO Patients|Patients who do not develop small bowel obstruction
3218381|NCT01068327|Experimental|Treatment (SRT, radiosensitizer, and chemotherapy)|See Detailed Description
3218382|NCT01068314|Experimental|Repetitive handgrip exercise|After baseline testing and randomization, subjects in this group are instructed to perform the intervention: daily repetitive handgrip exercise with upper arm compression band. Brachial artery endothelial function and venous compliance are tested at baseline and 6 weeks.
3218383|NCT01068314|No Intervention|No arm exercise|Time control. Subjects do usual activities without any exercise intervention. Brachial artery endothelial function and venous compliance are tested at baseline and 6 weeks.
3218384|NCT01068301|Other|Second Allogeneic Transplant Procedure Recipient|"Participants with Acute Lymphoblastic Leukemia (ALL); Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Chronic Myeloid Leukemia (CML); Juvenile Myelomonocytic Leukemia (JMML); Non-Hodgkin lymphoma (NHL) with evidence of bone marrow disease, receiving a second allogeneic transplant procedure.~Intervention: Plerixafor"
3218385|NCT01068288|Experimental|Expectant Management|Expectant Management
3218386|NCT01068288|Experimental|Operative management|Operative management
3218387|NCT01068275|Active Comparator|Lumbar plexus catheter|
3218388|NCT01068275|Active Comparator|femoral nerve catheter|
3218389|NCT01068275|Active Comparator|single-shot femoral block|
3218390|NCT01068262|Experimental|Panel A - Odanacatib|Panel A - Healthy male subjects receiving Odanacatib
3218391|NCT01068262|Placebo Comparator|Panel A - Placebo|Panel A - Healthy male subjects receiving placebo
3218392|NCT01068262|Experimental|Panel B - Odanacatib|Panel B - Healthy female subjects receiving Odanacatib
3218393|NCT01068262|Placebo Comparator|Panel B - Placebo|Panel B - Healthy female subjects receiving placebo
3218394|NCT01068249|Experimental|Letrozole + RAD001|Letrozole and RAD001 (Everolimus)
3218395|NCT01068236|Experimental|Healthy lifestyle intervention|lifestyle/weight-loss intervention for overweight (95th - 99th percentile) female adolescents (13-15 years of age at study entry) to a usual-care control condition. The intervention will be 20-sessions and combines group visits, individual telephone coaching calls, and tailored pediatric primary care providers (PCP) visits.
3218396|NCT01068236|No Intervention|Usual care|In the usual care control condition adolescents and their family will receive individualized feedback from the assessments as well as handouts outlining healthy means of maintaining / reducing weight for adolescents through improving nutrition and physical activity. In addition, these participants will be encouraged to seek any appropriate health care/education services available through Kaiser Permanente or in the community.
3218397|NCT01068223|Experimental|001|A:JNJ-39758979/Placebo #1 Single oral dose of JNJ-39758979 600 mg and Placebo
3218398|NCT01068223|Placebo Comparator|002|B: JNJ-39758979 Matching Placebo /Placebo #2 A single dose of 2 different Placebos JNJ-39758979 Matching Placebo and Placebo #2
3218438|NCT01068028|Placebo Comparator|Placebo for ORM-12741|
3218399|NCT01068223|Active Comparator|003|C:Cetirizine/JNJ-39758979 Matching Placebo Single oral dose of 10mg cetirizine and JNJ-39758979 Matching Placebo
3218400|NCT01068210|Experimental|Aerobic Training|A customized and supervised endurance exercise training program that will last 4 months (16 weeks). The regimen will be tailored to the individual fitness level. The exercise program will consist of three supervised sessions per week. During each session, the participant will cycle on a stationary bicycle at moderate intensity for approximately 30-60 minutes.
3218401|NCT01068210|Experimental|Resistance Training|A customized and supervised resistance exercise training program that will last 4 months (16 weeks). Resistance training will be performed on stationary weight machines, modification in equipment may be made by Exercise Physiologist. Patients will be progressively trained to perform two to three sets of 75-85% of maximal strength The participant will be trained to perform different resistance exercise, alternating between lower and upper body muscle groups. The exercise program will consist of three supervised sessions per week. Each session will last approximately 30-60 minutes.
3218402|NCT01068210|Experimental|Combined Aerobic and Resistance Training|A customized and supervised endurance exercise training program that will last 4 months (16 weeks). The regimen will be tailored to the individual fitness level, and will be a combination of Arm A and Arm B, described above. At each session, the participant will complete aerobic training on a stationary bicycle and also resistance training using stationary weight machines. The exercise program will consist of three supervised sessions per week. Each session will last approximately 30-90 minutes.
3218403|NCT01068210|Active Comparator|Progressive Stretching Group (Attention-Control)|A customized and supervised progressive stretching program that will last 4 months (16 weeks). The progressive stretching program will consist of a series of stretching exercises alternating between lower and upper body muscle groups/joints. This program will consist of three exercise sessions a week. Each session will last approximately 30-60 minutes.
3218404|NCT01068197|Experimental|Low glycemic load dietary plan|"The subjects and their parents will be given instructions, and specific examples, to lower the glycemic load of their diets by replacing high-GI sources of carbohydrates with low-GI food sources, replacing energy from carbohydrate with energy from protein and fat, and attempt to balance meals and snacks with low-GI carbohydrate, proteins and low-fat food sources. The objective will be to achieve macronutrient composition for the low-GL diet of 45-50% low-GI carbohydrates, 20-25% protein, and 30-35% fat. All subjects will receive sessions on behavior modification, increasing physical activity and reducing sedentary behavior.~At 3 months, subjects will be admitted to the GCRC for a 24 hour period for a meal study. They will be given standardized low-glycemic load diet for dinner, breakfast and lunch, followed by an ad lib snack platter. Their subjective, hormonal and metabolic responses will be serially measured."
3218405|NCT01068197|Active Comparator|Low fat diet|"For the low fat diet, subjects and their parents will be given instructions, and specific examples, to lower the fat content of their diet. The composition of the low-fat diet will be targeted to achieve 55-60% carbohydrates (with no discrimination by their glycemic index), 15-20% protein and 25-30% fat. All recruited children will receive sessions on behavior modification, increasing physical activity and reducing sedentary behavior.~At 3 months, subjects will be admitted to the GCRC for a 24 hour period for a meal study. They will be given standardized high-glycemic load diet for dinner, breakfast and lunch, followed by an ad lib snack platter. Their subjective, hormonal and metabolic responses will be serially measured."
3218406|NCT01068184|Experimental|1|
3218407|NCT01068184|Placebo Comparator|2|
3218408|NCT01068171|Active Comparator|shoe, plain dressing|post-op shoe with plain occlusive dressing
3218409|NCT01068171|Active Comparator|shoe, collagen|post-op shoe with collagen dressing
3218410|NCT01068171|Active Comparator|boot, plain dressing|air boot with occlusive dressing
3218411|NCT01068171|Active Comparator|boot, collagen|air boot with collagen dressing
3218412|NCT01068171|Active Comparator|monitored air boot, plain dressing|air boot with retention strap to monitor whether boot is removed with occlusive dressing
3218413|NCT01068171|Active Comparator|monitored boot with collagen|air boot with retention strap to monitor whether boot is removed with collagen dressing
3218414|NCT01068158|Experimental|0.5% Ivermectin Cream|Up to 4 ounces of topical Ivermectin Cream applied to hair and scalp on day 1
3218415|NCT01068158|Placebo Comparator|Vehicle control|Up to 4 ounces of topical control applied to hair and scalp on day 1.
3218416|NCT01068145|Experimental|Very low dose SCH 527123|
3218417|NCT01068145|Experimental|Low dose SCH 527123|
3218418|NCT01068145|Experimental|Medium dose SCH 527123|
3218419|NCT01068145|Experimental|High dose SCH 527123|
3218420|NCT01068145|Placebo Comparator|Placebo to match SCH 527123|
3218421|NCT01068145|Experimental|Low dose SCH 527123 (Part 2)|
3218422|NCT01068145|Experimental|Medium dose SCH 527123 (Part 2)|
3218423|NCT01068145|Experimental|High dose SCH 527123 (Part 2)|
3218424|NCT01068145|Placebo Comparator|Placebo (Part 2)|
3218425|NCT01068132|Experimental|1|Cetuximab+FOLFIRI: cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1, followed after 1 hour by FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
3218426|NCT01068119|Experimental|Same-day discharge|Same-day discharge following PCI
3218427|NCT01068106|Active Comparator|BPLES|Biodegradable polymer limus-eluting stents
3218428|NCT01068106|Active Comparator|PPLES|Permanent polymer limus-eluting stent
3218429|NCT01068080||Myocardial fatty acid metabolism, Insulin resistance|"Myocardial fatty acid metabolism was evaluated by myocardial fatty acid imaging using BMIPP SPECT.~Insulin resistance was evaluated by HOMA-IR."
3218430|NCT01068067|Experimental|pharmacogenetics plus SchE guided dosing|
3218431|NCT01068067|Active Comparator|standard dosing|
3218432|NCT01068054|Active Comparator|tacrolimus|Tacrolimus arm: active 0.1% tacrolimus eye ointment BID + placebo eye drops QID
3218433|NCT01068054|Active Comparator|cyclosporine|2% cyclosporine eye drops apply QID + placebo eye ointment apply bid
3218434|NCT01068041|Placebo Comparator|A|Placebo
3218435|NCT01068041|Active Comparator|B|250mg active ingredient
3218436|NCT01068041|Active Comparator|C|500mg active ingredient
3218439|NCT01068028|Experimental|ORM-12741|
3218440|NCT01068015|Experimental|Intervention|This arm receives free circumcision service, POL intervention, intensive HIV counseling and intensive condom promotion.
3218441|NCT01068015|No Intervention|usual|This arm receives no extra HIV prevention services.
3218442|NCT01068002||Control, normotensive, pregnancy|Control, normotensive, pregnancy
3218443|NCT01068002||hypertension, pregnancy, no treatment|hypertension, pregnancy, no treatment
3218444|NCT01068002||hypertension, pregnancy, drug treatment|hypertension, pregnancy, drug treatment
3218445|NCT01067989|Experimental|intervention|same treatment for all patients
3218446|NCT01067976|Experimental|Gadobutrol (Gadavist, BAY86-4875)|Patients first received an unenhanced MRM, followed by a gadobutrol-enhanced MRM. Gadobutrol was administered at the standard dose of 0.1 mmol/kg bw [0.1 ml/kg bw] as an intravenous injection (i.v.) injection at a rate of 2 ml/sec. UMRM and CMRM image sets were evaluated in a randomized fashion. After the evaluation of the UMRM or CMRM the respective XRM was added and evaluated together with the UMRM images.
3218447|NCT01067963|Experimental|Behavioral-education/counseling|"Computer assisted education and telephone counseling using motivational interviewing.~Computer assisted education and motivational interviewing"
3218448|NCT01067963|Placebo Comparator|Group talks/social chat|Group session talks on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
3218449|NCT01067950|Experimental|Isolated Pancreas Transplant|
3218450|NCT01067950|Active Comparator|Intensive Insulin Therapy|
3218451|NCT01067924|Experimental|Motivational interviewing|
3218452|NCT01067924|Active Comparator|Standard of care|
3218453|NCT01067911|Active Comparator|1|In this study subjects will consume test meals containing vegetable oils (soy) and butter
3218454|NCT01067911|Active Comparator|2|In this study subjects will consume test meals containing vegetable oils (flaxseed) and butter
3218455|NCT01067911|Active Comparator|3|In this study subjects will consume test meals containing vegetable oils (high oleic safflower) and butter
3218456|NCT01067911|Active Comparator|4|In this study subjects will consume test meals containing vegetable oils (canola) and butter
3218457|NCT01067898|Experimental|200 000 IU vitamin D3 every three months|
3218458|NCT01067898|Experimental|100 000 IU vitamin D3 every three months|
3218459|NCT01067898|Placebo Comparator|placebo every three months|
3218460|NCT01067859|Experimental|Arm 1|
3218461|NCT01067859|Experimental|Arm 2|
3218462|NCT01067859|Placebo Comparator|Arm 3|
3218463|NCT01067846|Experimental|DCS and Cognitive Behavioral Therapy|Subjects will receive 250 mg of Seromycin or D-cycloserine (DCS) prior to computerized cognitive behavioral therapy.
3218464|NCT01067846|Placebo Comparator|Placebo and Cognitive Behavioral Therapy|Subjects will receive a 250 mg identical looking placebo pill prior to computerized cognitive behavioral therapy.
3218465|NCT01067833|Placebo Comparator|Placebo|Placebo
3218466|NCT01067833|Experimental|Dose 1|K201
3218467|NCT01067833|Experimental|Dose 2|K201
3218468|NCT01067833|Experimental|Dose 3|K201
3218469|NCT01067820|Experimental|RVX000222, 200 mg daily|
3218470|NCT01067820|Placebo Comparator|Placebo|
3218471|NCT01067807|Experimental|Proellex Formulation 1|25 mg Proellex Gelucire and PEG (original formulation)
3218472|NCT01067807|Experimental|25 mg Proellex Formulation 2|25 mg Proellex coated with MCC
3218473|NCT01067807|Experimental|25 mg Proellex Formulation 3|25 mg Proellex blended with MCC
3218474|NCT01067807|Experimental|50 mg Proellex Formulation 3|50 mg Proellex blended with MCC
3218475|NCT01067794||pemetrexed + platinum|Patients with pemetrexed + platinum doublet, with or without additional targeted agents
3218476|NCT01067794||gemcitabine + platinum|Patients with gemcitabine + platinum doublet, with or without additional targeted agents
3218477|NCT01067794||taxanes + platinum|Patients with taxanes + platinum doublet, with or without additional targeted agents
3218478|NCT01067794||vinorelbine + platinum|Patients with vinorelbine + platinum doublet, with or without additional targeted agents
3218479|NCT01067794||others + platinum|Patients with other platinum-based doublet, with or without additional targeted agents
3218480|NCT01067781|Experimental|1|Two vaccination regimen with an LT patch (no swabbing)
3218481|NCT01067781|Experimental|2|Two vaccination regimen with an LT patch (with swabbing)
3218482|NCT01067781|Placebo Comparator|3|Two vaccination regimen with a placebo patch (no swabbing)
3218483|NCT01067781|Placebo Comparator|4|Two vaccination regimen with a placebo patch (with swabbing)
3218484|NCT01067768|Experimental|Daily review|In the intervention group a nurse reviewed daily, by using a checklist designed for this study, the indications and pertinence of the catheter. If it was not indicated she asked the doctor to order the removal of the catheter, but the doctor would make the final decision.
3218485|NCT01067768|No Intervention|Routine care|In the control group, the attending team would remove the catheter as routine, without any suggestion by the research protocol.
3218486|NCT01067755||Bronchoscopy, lung neoplasm|Patients who have been recommended for bronchoscopy for the purpose of obtaining a biopsy sample of a central or peripheral pulmonary lesion, diagnosing mediastinal or hilar lymphadenopathy or for lung fiducial placement.
3218487|NCT01067742||Subjects with Mucolipidosis Type IV|
3218488|NCT01067716|Experimental|Refractive Error|
3218489|NCT01067703|Active Comparator|RIPC|
3218490|NCT01067703|Sham Comparator|CONTROL|
3218491|NCT01067677|Experimental|Metoclopramide|rescue emetic therapy
3218492|NCT01067677|Experimental|Ondansetron|Rescue emetic therapy
3218493|NCT01067677|Experimental|Diphenhydramine|Rescue emetic therapy
3218494|NCT01067677|Placebo Comparator|Saline|Placebo
3218495|NCT01067664||Patients undergoing IVF with rFSH and GnRH antagonists|
3218496|NCT01067651|Active Comparator|Plaster of Paris (POP)|
3218497|NCT01067651|Active Comparator|semi-rigid fiberglass softcast (SRF, 3M Scotchcast)|
3218498|NCT01067638|Experimental|tranexamic acid|Tranexamic Acid on Postoperative Blood loss and Coagulation in Patients with Preoperative Anemia Undergoing Off-Pump Coronary Artery Bypass Graft
3218499|NCT01067625|Experimental|TOGA subjects|
3218500|NCT01067599|Active Comparator|Low nicotine|Conventional smokeless tobacco product with 1) NNN plus NNK of <2 μg/gram and nicotine levels of >5 mg/g wet weight
3218501|NCT01067599|Active Comparator|Medium nicotine|Conventional smokeless tobacco product with ) NNN plus NNK of <2 μg/gram and nicotine levels of 3-5 mg/g wet weight.
3218502|NCT01067599|Active Comparator|High nicotine|Conventional smokeless tobacco product with NNN plus NNK of <2 μg/gram and nicotine levels of <3 mg/g wet weight
3218503|NCT01067547|Experimental|iron sulfate|Oral iron sulfate 300mg tid
3218504|NCT01067547|Active Comparator|intravenous iron sulfate|intravenous iron sulfate 300 mg
3218505|NCT01067521|Experimental|GA 40 mg|
3218506|NCT01067521|Placebo Comparator|Placebo|
3218507|NCT01067508|Experimental|Fiji Water|Participants are asked to consume one liter of this silicon-rich water daily for three months.
3218508|NCT01067508|No Intervention|Aquafina Water|Participants are asked to drink one liter of this deionized water daily for three months.
3218509|NCT01067495|Experimental|Exercise|
3218510|NCT01067482||Glaucoma patients|
3218511|NCT01067482||Glaucoma suspect group|
3218512|NCT01067482||Normal population|
3218513|NCT01067469|Experimental|Standard Dose Bevacizumab|Bevacizumab 10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
3218514|NCT01067469|Experimental|Low Dose Bevacizumab + Lomustine|Bevacizumab 5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle. Lomustine starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
3218515|NCT01067456|No Intervention|Dedicated CT arm|Subjects in this arm will continue to receive standard of care - that is the dedicated CT protocol to rule out either aortic dissection or acute coronary syndrome or pulmonary embolism.
3218516|NCT01067456|Experimental|Comprehensive Cardiothoracic CT arm|The intervention consisted in a change of the routine CT protocol (as in dedicated CT protocol) to a comprehensive cardiothoracic CT protocol which includes changes in contrast injection and coverage to enable evaluation of the presence of acute coronary syndrome/aortic dissection/pulmonary embolism in a single scan.
3218517|NCT01067443|Experimental|Amb+SSG|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
3218518|NCT01067443|Experimental|Amb+Milt|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
3218519|NCT01067443|Experimental|Milt|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
3218520|NCT01067430|Active Comparator|Etoricoxib 90 mg|Subject will take Etoricoxib 90 mg for 14 days
3218521|NCT01067430|Active Comparator|Diclofenac|Film coated tablet 50 mgs given three times a day for 14 days
3218522|NCT01067417|Active Comparator|Hydroxychloroquine|
3218523|NCT01067417|Placebo Comparator|Placebo|
3218524|NCT01067404||2008-09 study TIV recipients|Infants and toddlers who participated in earlier clinical trial (TITRE) to evaluate dosing (0.25mL versus 0.5mL) of trivalent influenza vaccine (TIV)
3218525|NCT01067391|Active Comparator|tadalafil 20 mg|Oral study medication to be administered once to each participant
3218526|NCT01067391|Placebo Comparator|placebo|oral study medication to be administered once to each study participant
3218527|NCT01067378|Active Comparator|Expert instructor debriefing|Expert instructor debriefing
3218528|NCT01067378|Experimental|Peer-led debriefing|Peer-led debriefing
3218529|NCT01067365|Experimental|12.5 mg Androxal|12.5 mg Androxal daily
3218530|NCT01067365|Experimental|25 mg Androxal|25 mg Androxal daily
3218531|NCT01067352|Experimental|Group A (A1)|Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive Saizen at the daily dose of 0.035 milligram (mg)/kilogram (kg) (Group A1) or no treatment (Group A2) for two years.
3218532|NCT01067352|No Intervention|Group A (A2)|Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive no treatment (Group A2) for two years.
3218533|NCT01067352|No Intervention|Group B|Participants were allocated to Group B being third percentile (thus showing a spontaneous catch-up growth).
3218534|NCT01067339|Experimental|Darapladib|Subjects randomized to this arm will receive a darapladib tablet, 160 mg, by mouth, once per day for 6 months.
3218535|NCT01067339|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a placebo tablet matching the study drug, once per day for 6 months.
3218536|NCT01067326|Active Comparator|Aliskiren|150 mg Aliskiren once daily for a period of 4 months.
3218537|NCT01067326|Placebo Comparator|Placebo|1 pill per day by mouth for 4 months.
3218538|NCT01067313|Experimental|Dialyzer Ultraflux EMiC2|Dialyzer Ultraflux EMiC2 used in Continuous Hemodialysis
3218539|NCT01067313|Active Comparator|Dialyzer Ultraflux AV1000S|Dialyzer Ultraflux AV1000S used in continuous Hemofiltration
3218540|NCT01067300|Active Comparator|Double unit unrelated cord blood transplantation|Transplantation of unrelated cord blood units is done at least 24 hours after last chemotherapy and carried out during the same day. The unit presenting the best degree of HLA compatibility with the patient will be transfused in first. If the 2 units have the same degree of HLA compatibility with the recipient, the unit with the higher cell dose will be transfused in first. A 2 hours time interval between the 2 transfusions will be respected.
3218541|NCT01067300|Active Comparator|single unit unrelated cord blood transplantation|Transplantation of a single unrelated cord blood unit at least 24 hours after last chemotherapy
3218542|NCT01067287|Active Comparator|Group 1|Monoclonal antibody CT-011 will be given 1-3 months following autologous transplant. 3 doses will be given at 6 week intervals.
3218543|NCT01067287|Active Comparator|Group 2|Vaccination with DC/myeloma fusion cells will be given 1-3 months following autologous transplant. Vaccination will be given at 6 weeks intervals. The monoclonal antibody CT-011 will be given 1 week following each vaccination. 3 doses of CT-011 will be given at 6 week intervals.
3218653|NCT01066520|Experimental|Traumeel S gel|Traumeel S gel 2 g, 3 times daily topical during 14 days
3218654|NCT01066520|Active Comparator|Diclofenac gel|Diclofenac gel 2 g, 3 times daily topical during 14 days
3218544|NCT01067274|Experimental|R1 Arm A : ATRA|"Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN >1G/l over 2 days at minimum~All-trans retinoic acid (ATRA): 45mg/m2/day in two divided doses from D8 to D28"
3218545|NCT01067274|No Intervention|R1 Arm B : no ATRA|Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN >1G/l over 2 days at minimum
3218546|NCT01067274|Experimental|R2 Arm 1A : AZACITIDINE and ATRA|Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5 All-trans retinoic acid (ATRA): 45mg/m2/d in two divided doses from D8 to D21
3218547|NCT01067274|Experimental|R2 Arm 1B : AZACITIDINE and No ATRA|Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5
3218548|NCT01067274|Experimental|R2 Arm 2A : ATRA|Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5 All-trans retinoic acid (ATRA): 45mg/ m2/d in two divided doses from D8 to D21
3218549|NCT01067274|Experimental|R2 Arm 2B : no ATRA|Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5
3218550|NCT01067261|Experimental|TMNS and pelvic floor muscle training|This group will receive both the normal pelvic floor muscle training and the TMNS vibration therapy following their radical prostatectomy. Treatment with TMNS will start before the surgery and continue 6 weeks after the surgery.
3218551|NCT01067261|Active Comparator|Pelvic floor muscle training only|This group will receive the normal pelvic floor muscle training after prostatectomy only.
3218552|NCT01067248||COPD, osteoporosis|The subjects are divided into 6 groups of 20 subjects each, I: COPD patients with osteoporosis based on T-score and without vertebral fractures, II: COPD patients with osteoporosis based on T-score and vertebral fractures, III: COPD patients with vertebral fractures and without osteoporosis based on T-score, IV: COPD patients without osteoporosis based on T-score and without vertebral fractures, V: healthy controls with osteoporosis based on T-score and without vertebral fractures, VI: healthy controls without osteoporosis based on T-score and without vertebral fractures.
3218553|NCT01067235|Experimental|BF2.649 + Modafinil placebo|
3218554|NCT01067235|Experimental|BF2.649 + Modafinil|
3218555|NCT01067222|Experimental|BF2.649|
3218556|NCT01067222|Active Comparator|Modafinil|
3218557|NCT01067222|Placebo Comparator|Placebo|
3218558|NCT01067209||Diabetic/Obese Gastric bypass patients|Subjects with obesity including those with known diabetes or those with a high likelihood of diabetes who will undergo gastric bypass surgery.
3218559|NCT01067196||Observation and quality of life|Central Nervous System Tumors
3218560|NCT01067183|Experimental|breathing and biofeedback device|This group of physicians were trained in the use of the relaxation breathing technique and the biofeedback device, and then used this portable stress reduction tool on a daily basis with twice weekly visits with the research team. After the 28 day RCT, they were invited to continue to use the device at their discretion during a trial extension from day 28-56 to see if any effect measured was maintained.
3218561|NCT01067183|No Intervention|control arm|This group did not undergo training in the breathing technique and use of the PSMD during the RTC trial day 0-28, but were visited twice weekly by the research team to collect outcome data. During the trial extension Day 28-56, this group did undergo a 1 hr training session with the PSMD and invited to use it at their discretion over the 28 days. Effectiveness outcome data (day 28-56) was collected at day 56.
3218562|NCT01067170|Experimental|Pneumatic compression stockings|
3218563|NCT01067157|Other|A|"Other = Lifestyle intervention~A: Medical examination before and after inpatient therapy (clinic staff), questionnaires.~Further medical examination and questionnaires after 6 months, 1, 2, 5 and 10 years at home by pediatrics or general practitioner.~The lifestyle intervention includes an age-specific diet (1200-1800 kcal/d), 11 h/wk physical activity (walking, swimming, sports) and behavioural therapy."
3218564|NCT01067144|Placebo Comparator|Control|Active placebo given pre-operatively, followed by inactive placebo for 10 doses post-operatively
3218565|NCT01067144|Experimental|Gabapentin|1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.
3218566|NCT01067131|Experimental|PEV7C1, intravaginal|Vaccine containing virosomes intravaginally applied
3218567|NCT01067131|Placebo Comparator|PEV7C9, placebo, intravaginal|Placebo vaccine (excipient only) intravaginally applied
3218568|NCT01067131|Experimental|PEV7B2, intramuscular low dose|Intramuscular vaccine low dose of antigen
3218569|NCT01067131|Experimental|PEV7B1, intramuscular high dose|Intramuscular vaccine, high dose of antigen
3218570|NCT01067118|Active Comparator|Humalog U-100 Insulin|
3218571|NCT01067118|Experimental|LINjeta U-100|
3218572|NCT01067105|Experimental|ciclesonide|ciclesonide HFA 160 μg once daily
3218573|NCT01067092|Experimental|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
3218574|NCT01067092|Active Comparator|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
3218575|NCT01067079||Arm 1|
3218576|NCT01067066|Experimental|TPI 287 + Temodar|Starting dose of TPI 287 90 mg/m^2 IV on Days 1, 8, 15 + Temozolomide (Temodar) PO at 85 mg/m^2 on Days 1-5.
3218655|NCT01066507||Breast cancer|Slides containing breast cancer paraffin embedded tissue sections.
3218577|NCT01067053|Experimental|bevacizumab, capecitabine, oxaliplatin|"6 cycles (3 weeks each one) of:~bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.~capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.~oxaliplatin: 130/mg/m2(iv),1st day of each cycle.~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine"
3218578|NCT01067014||iO-Flex|
3218579|NCT01067001||2 Way Crossover|2 Way Crossover bioequivalence study
3218580|NCT01067001||Subjects will be randomly divided in to 2 groups.|A total of 18 normal, healthy, adult, human subjects will be enrolled in the study.
3218581|NCT01066988|Other|Right Eye|ORB Ocular Emulsion or SootheXP
3218582|NCT01066988|Other|Left Eye|ORB Ocular Emulsion or SootheXP
3218583|NCT01066975||young and fit|5 healthy subjects, age lower than 30 yrs and high physical fitness
3218584|NCT01066962|Active Comparator|darunavir/r + tenofovir/emtricitabine|
3218585|NCT01066962|Experimental|darunavir/r + raltegravir|
3218586|NCT01066949|Active Comparator|Support and discussion|The Support and Discussion protocol will consist of two integrated components: (a) brief educational materials presented at the start of each session, and (b) group leader facilitated discussion following presentation of the educational materials.
3218587|NCT01066949|Experimental|Behavioral Self management|Self-Regulation group sessions will be generally highly leader-directed though participants will be regularly encouraged to share their experiences dealing with the dialysis regimen. A consistent attempt will be made to focus all group discussion on self-regulatory principles as they relate to treatment adherence.Session material utilized by group-leaders will be highly structured and detailed across the seven sessions.
3218588|NCT01066923|Experimental|Daily ASA, Active cool, Acute ASA|Two weeks of daily aspirin therapy prior to exercise, active cooling following exercise, aspirin immediately post exercise
3218589|NCT01066923|Experimental|Daily ASA, Active cool, Acute placebo|Two weeks of daily aspirin therapy prior to exercise, active cooling following exercise, placebo immediately post exercise
3218590|NCT01066923|Experimental|Daily ASA, Passive cool, Acute ASA|Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, aspirin immediately post exercise
3218591|NCT01066923|Experimental|Daily ASA, Passive cool, Acute placebo|Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, placebo immediately post exercise
3218592|NCT01066923|Experimental|Daily placebo, active cool, Acute ASA|Two weeks of daily placebo prior to exercise, active cooling following exercise, aspirin immediately post exercise
3218593|NCT01066923|Experimental|Daily placebo, active cool, Acute placebo|Two weeks of daily placebo prior to exercise, active cooling following exercise, placebo immediately post exercise
3218594|NCT01066923|Experimental|Daily placebo, Passive cool, Acute ASA|Two weeks of daily placebo prior to exercise, passive cooling following exercise, aspirin immediately post exercise
3218595|NCT01066923|Placebo Comparator|Daily placebo, Passive cool, Acute placebo|Two weeks of daily placebo prior to exercise, passive cooling following exercise, placebo immediately post exercise
3218596|NCT01066910|Experimental|Parent-only|
3218597|NCT01066910|Active Comparator|Parent and child|
3218598|NCT01066897|Experimental|Pramipexole|Patients will receive 0.125 mg of pramipexole three times a day for the first week, 0.25 mg three times a day for the second week, and 0.5 mg three times a day for the third week. The dose will then be adjusted as needed by the treating physician (Dr. DeBattista), with a target range of 1.0 mg to 1.5 mg per day. Dose escalations will continue until 1) achievement of the primary endpoint (> 50% reduction from baseline on the HDRS scores; 2) intolerable side effects; or 3) completion of the 8-week study. Participants will be seen weekly the first four weeks and biweekly thereafter. Side effects, depression, and anhedonia will assessed at each visit.
3218599|NCT01066897|No Intervention|Healthy Controls|Non depressed, non-intervention comparison group
3218600|NCT01066884|Experimental|1|
3218601|NCT01066871|Experimental|Sprifermin (AS902330) 10 mcg|
3218602|NCT01066871|Experimental|Sprifermin (AS902330) 30 mcg|
3218603|NCT01066871|Experimental|Sprifermin (AS902330) 100 mcg|
3218604|NCT01066871|Placebo Comparator|Placebo|
3218605|NCT01066858||Maternal/infant antepartum exposure|"HIV-infected women exposed to TDF during pregnancy~Infants of HIV-infected women exposed to TDF during pregnancy"
3218606|NCT01066858||Maternal/infant postpartum exposure|"HIV-infected women exposed to TDF while breastfeeding~Infants of HIV-infected women exposed to TDF while breastfeeding"
3218607|NCT01066858||Maternal/infant antepartum no exposure|"HIV-infected women not exposed to TDF during pregnancy~Infants of HIV-infected women not exposed to TDF during pregnancy"
3218608|NCT01066858||Maternal/infant postpartum no exposure|"HIV-infected women not exposed to TDF during breastfeeding~Infants of HIV-infected women not exposed to TDF during breastfeeding"
3218609|NCT01066845||Patients prescribed Adcirca|all patients prescribed Adcirca during study period
3218610|NCT01066819||Cohort|Participants chronically infected with the hepatitis C virus including genotypes 1 to 6.
3218611|NCT01066806|Experimental|high calcium diet|
3218612|NCT01066806|Active Comparator|normal calcium diet|
3218613|NCT01066793||Cohort|Participants chronically infected with the hepatitis C virus including genotypes 1 to 6
3218614|NCT01066780|Experimental|Group A: ClearVoice Medium|Chronic use of ClearVoice MEDIUM for two weeks followed by chronic use of ClearVoice HIGH for two weeks.
3218615|NCT01066780|Experimental|Group B: ClearVoice High|Chronic use of ClearVoice HIGH for two weeks followed by chronic use of ClearVoice MEDIUM for two weeks.
3218616|NCT01066767|Experimental|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets Dr. Reddy's Laboratories Limited
3218617|NCT01066767|Active Comparator|Allegra|Allegra Tablets 180 mg Aventis Pharmaceuticals Inc.,
3218618|NCT01066754|Experimental|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets of Dr. Reddy's Laboratories Limited
3218619|NCT01066754|Active Comparator|Allegra|Allegra Tablets 180 mg of Aventis Pharmaceuticals Inc.,
3218620|NCT01066741|Experimental|Homeodent®|Mouthwash with Homeodent® is started on the first day of irradiation, then continued until the end of the irradiation period or until occurrence of grade ≥3 mucositis. In case of grade ≥3 mucositis, patients are instructed to mouthwash with Sodium Bicarbonate solution until complete disappearance of mucositis or until the end of irradiation.
3218791|NCT01065519|Active Comparator|2|Biolimus A9-eluting Biomatrix stent
3218621|NCT01066741|Active Comparator|1.4 % Sodium Bicarbonate solution|"Mouthwash with sodium bicarbonate is started on the first day of irradiation, then continued until the end of the irradiation period. In case of grade ≥3 mucositis, mouthwash is continued until complete disappearance of the mucositis or until the end of irradiation.~In both arms, after the end of irradiation, patients can receive treatment with Sodium Bicarbonate solution until complete disappearance of the mucositis."
3218622|NCT01066728|Active Comparator|Theophylline|Oral loading dose of 6 mg per kilogram of body weight of theophylline followed by a maintenance dose of 2 mg per kilogram every 8 hours plus room air by nasal prongs at 0.5 l/min for 3 days.
3218623|NCT01066728|Experimental|CO2 inhalation|Equivalent loading and maintenance volume of oral normal saline plus CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
3218624|NCT01066715|Placebo Comparator|Placebo|
3218625|NCT01066715|Experimental|XOMA 052|
3218626|NCT01066702|Experimental|NeoCart|Autologous cartilagenous tissue implant
3218627|NCT01066702|Active Comparator|Microfracture|surgical intervention
3218628|NCT01066689|Experimental|A|Patients randomized into the arm blind A. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
3218629|NCT01066689|Placebo Comparator|B|Patients randomized into the arm blind B. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
3218630|NCT01066676|Experimental|Dexibuprofen|Dexibuprofen 400 mg powder for oral suspension
3218631|NCT01066676|Active Comparator|Ibuprofen|Ibuprofen 400 mg powder for oral suspension
3218632|NCT01066663|Experimental|Pyrimethamine|Single daily oral 50 mg dose.
3218633|NCT01066650|Active Comparator|Endeavor Resolute|
3218634|NCT01066650|Active Comparator|Xience V|
3218635|NCT01066637|Experimental|Dosimetry Group|To determine its potential for use in humans, we measured 18F-NOS myocardial activity in patients after orthotopic heart transplantation (OHT) (3 women and 9 men) and normal healthy volunteers (2 women and 2 men), and correlated it with pathologic allograft rejection, tissue iNOS levels, and calculated human radiation dosimetry.
3218636|NCT01066637|Experimental|Kinetic Analysis Group|Measurement of myocardial levels of enzyme nitric oxide synthase(iNOS) using PET and 18F-NOS in post heart transplant patients (5 women and 5 men) undergoing endomyocardial biopsy as part of their normal post-transplant evaluation. Kinetic data of the tracer will be compared with the heart tissue measurements of iNOS measured by immunohistochemistry.
3218637|NCT01066624|Active Comparator|0.9% Sodium Chloride irrigation solution|Standard of care for prevention and management of oral mucositis (0.9% Sodium Chloride irrigation solution): Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study.
3218638|NCT01066624|Active Comparator|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion. After patients are done with the cryotherapy they will follow the standard of care for prevention and management of oral mucositis until the end of the study.
3218639|NCT01066624|Active Comparator|Calcium phosphate (Caphosol) mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
3218640|NCT01066611|Active Comparator|1|CAL-263
3218641|NCT01066611|Placebo Comparator|2|Placebo
3218642|NCT01066598|Experimental|Rituximab plus prednisone|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d Treat 61 Patients
3218643|NCT01066585|Experimental|0.5% Ivermectin Cream|
3218644|NCT01066585|Placebo Comparator|Vehicle control|
3218645|NCT01066572|Experimental|Lisinopril|Experimental
3218646|NCT01066572|Placebo Comparator|Placebo|Placebo Comparator
3218647|NCT01066559|Experimental|High flux polymethylmetacrylate membrane|
3218648|NCT01066559|Active Comparator|Polysulfone membranes|
3218649|NCT01066546|Experimental|Dimebon|
3218650|NCT01066533|Experimental|Mineral Trioxide Aggregate(MTA)|MTA is a proper material for direct pulp capping,treatment of tooth perforations,root end filling.It is a safe and biocompatible material,which can induce cementum formation on root surface.In direct pulp capping, MTA can induce dentinal bridge formation on the expose surface to preserve pulp vitality.Although MTA has superior biocompatibility compared with the conventional materials,it has a delayed setting time, poor handling characteristics and off-white color
3218651|NCT01066533|Experimental|NEC cement|NEC cement is a proper material for direct pulp capping and treatment of tooth perforation. It is a new dental material that combines reasonable biocompatibility of MTA with appropriate setting time,handling characteristics,chemical properties and color.Like MTA, NEC cement can induce dentinal bridge formation in direct pulp capping to preserve pulp vitality.
3218652|NCT01066520|Experimental|Traumeel S ointment|Traumeel S ointment 2 g, 3 times daily topical during 14 days
3218656|NCT01066494|Experimental|Single-arm|Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
3218657|NCT01066481|Experimental|PF-01913539 5 mg three times daily|PF-01913539 5 mg three times daily for 6 months
3218658|NCT01066481|Experimental|PF-01913539 20 mg three times daily|PF-01913539 20 mg three times daily for 6 months
3218659|NCT01066481|Placebo Comparator|Placebo|Placebo three times daily for 6 months
3218660|NCT01066468|Experimental|Gleevec/Glivec|
3218661|NCT01066442|Experimental|BF2.649 ( Pitolisant)|BF2.649 (5mg, 10 mg, 20 mg) in capsules
3218662|NCT01066442|Placebo Comparator|Placebo|Placebo of BF2.649 (5mg, 10mg, 20mg) in capsules
3218663|NCT01066429|No Intervention|Poor prognosis DLBCL|Newly diagnosed patients with DLBCL and an age-adjusted IPI 2-3
3218664|NCT01066416|Placebo Comparator|Medical therapy|Patients undergo surgery 6 months after randomization
3218665|NCT01066416|Experimental|Surgery|Patients undergo surgery at time of randomization
3218666|NCT01066403|Experimental|Pergolide|Patients will be randomly assigned to a sequence of treatments of either pergolide or placebo p.o. under continuous concomitant atypical neuroleptic therapy (stable at least 2 weeks prior trial begin).
3218667|NCT01066377|Experimental|Prebiotic and probiotic mix|Prebiotic: 8g/day, will be selected on the basis of ability to promote optimal growth and survival of the probiotic (inulin, fructooligosaccharides [FOS], galactooligosaccharides[GOS] and xylooligosaccharides[XOS] will be tested). Probiotic: 10^8 - 10^9 live bacteria/day, bifidobacterium longum bv. infantis CCUG52486.
3218668|NCT01066377|Placebo Comparator|Maltodextrin/milk powder|
3218669|NCT01066364|Placebo Comparator|Placebo (sugar) pill|Six tablets per day (identical to colesevelam)
3218670|NCT01066364|Experimental|Colesevelam arm|3.75 grams per day
3218671|NCT01066351|Experimental|Erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
3218672|NCT01066351|Placebo Comparator|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
3218673|NCT01066338||Normal karyotype|The patients were diagnosed as acute myeloid leukemia with normal karyotype.
3218674|NCT01066325|Experimental|NET|This arm will receive two 20-minutes sessions of NET 1 week apart. NET (Neuro Emotional Technique) is a non-invasive stress reduction technique.
3218675|NCT01066325|Active Comparator|Active Controls|This arm will receive two 20-minute sessions of stretching instructions 1 week apart.
3218676|NCT01066325|No Intervention|Inactive Controls|This arm will receive no intervention and no instructions.
3218677|NCT01066312||Practitioners|Healthcare practitioners who either use, have used or do not use MMT in practice
3218678|NCT01066312||Testees|Healthy adults with no experience with MMT
3218679|NCT01066299|Experimental|oxitocin nasal spray|oxytocin nasal spray
3218680|NCT01066299|Placebo Comparator|placebo|inactive nasal spray
3218681|NCT01066286||core binding factor positive|core binding factor positive acute myeloid leukemia
3218682|NCT01066273|Experimental|P-Stim device|Receiving the device that is activated
3218683|NCT01066260|Experimental|Probiotic|
3218684|NCT01066260|Placebo Comparator|Placebo|
3218685|NCT01066247|Active Comparator|Midazolam|intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
3218686|NCT01066247|Active Comparator|Morphine|intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
3218687|NCT01066234|Experimental|concurrent chemoradiotherapy|
3218688|NCT01066234|Active Comparator|chemotherapy only|
3218689|NCT01066221||Clostridium difficile patients|observational study
3218690|NCT01066208||WG classification|Patients with Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
3218691|NCT01066208||MPA classification|Patients with microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
3218692|NCT01066208||CSS classification|Patients with Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
3218693|NCT01066208||PAN classification|Patients with polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
3218694|NCT01066208||Control Classification|For each of the diseases being evaluated (WG, MPA, CSS, PAN, GCA, TAK), patients with the other 5 diseases will be the control group. Within these groups, 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
3218695|NCT01066208||WG diagnostic|Patients with a new presentation of Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
3218696|NCT01066208||MPA diagnostic|Patients with a new presentation of microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
3218697|NCT01066208||CSS diagnostic|Patients with a new presentation of Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
3218698|NCT01066208||PAN diagnostic|Patients with a new presentation of polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
3218699|NCT01066208||Control diagnostic|Patients without vasculitis, but presenting with similar features to the 6 different types of vasculitis being studied. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
3218700|NCT01066208||GCA classification|Patients with giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
3218701|NCT01066208||TAK classification|Patients with Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
3218702|NCT01066208||GCA diagnostic|Patients with a new diagnosis of giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
3218703|NCT01066208||TAK diagnostic|Patients with a new diagnosis of Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
3218704|NCT01066195|Experimental|gefitinib|
3218705|NCT01066195|Active Comparator|pemetrexed|
3218706|NCT01066182|Experimental|DHA supplement|3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
3218707|NCT01066182|Placebo Comparator|Sunflower oil capsule|The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
3218708|NCT01066169||Healthy volunteers|Healthy subjects without HIV, vaccinated with Pandemic Influenza A/H1N1
3218709|NCT01066169||HIV-infected patients|HIV-infected patients, vaccinated with Pandemic Influenza A/H1N1
3218710|NCT01066156|Experimental|Seroquel|This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
3218711|NCT01066143|Experimental|Seroquel XR|
3218712|NCT01066130|Experimental|Intensive treatment arm|Every second person with psychosocial problems was randomized into this arm. The intervention consisted of personalized, intensive psychosocial treatment provided by a medical social worker on the basis of the patient's problems for up to 2 years after inclusion.
3218713|NCT01066130|Experimental|Minimal treatment arm|Every second patient with psychosocial problems was assigned to this arm. Patients in this arm received minimal social support by a medical social worker.
3218714|NCT01066130|No Intervention|No need for psychosocial treatment|This arm consisted of individuals who did not need psychosocial treatment or measures. The need for such treatment and measures was determined at baseline for all persons included in the study.
3218715|NCT01066104|Placebo Comparator|Xolair placebo|Xolair placebo 150-375 mg is administered subcutaneously (SC) every 2 or 4 weeks depending on the patient's baseline serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg) ). Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site.
3218716|NCT01066104|Active Comparator|Xolair (omalizumab)|Xolair (omalizumab) 150-375 mg is administered subcutaneously (SC) every 2 or 4 weeks depending on the patient's baseline serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site.
3218717|NCT01066091|Placebo Comparator|mashed potatoes|Mashed potatoes is composed of potatoes and Skim milk powder.
3218718|NCT01066091|Experimental|Mashed potatoes + Oleic Acid|The test meal is mashed potatoes with 1g/Kg of weight of lipids with 75% of Oleic Acid
3218719|NCT01066091|Experimental|Mashed potatoes + Palmitic Acid|The test meal is mashed potatoes with 1g/Kg of weight of lipids with 39% of saturated fat with 32% of palmitic acid.
3218720|NCT01066078||CRT recipients|
3218721|NCT01066065||Raltegravir Cohort|Patients taking RAL 400 mg BID with Truvada
3218722|NCT01066065||Darunavir Cohort|Patients taking Darunavir 800 mg QD plus Norvir 100 mg QD with truvada
3218723|NCT01066052|Other|Group Q|Subjects with height <-2SD / standard height (sempé cohort) received 0.15 IU/kg/day
3218724|NCT01066052|Other|Group U|Subjects with height <-1 SD and >-2SD / standard height (sempé cohort) received 0.1 IU/kg/day
3218725|NCT01066039|Experimental|Bisoprolol|
3218726|NCT01066026|Experimental|Metallic cannula|
3218727|NCT01066026|Active Comparator|Standard needle|
3218728|NCT01066013|Experimental|Prospective Antimicrobial de-escalation arm|Antimicrobial de escalation team will assess therapy and make recommendations to (a) change to antibiotic(s) with narrow spectrum,(b) stop antibiotics, (c) order new cultures/investigations or (d) consult with specialists or ID service for full evaluation (if patient's condition is worsening).
3218729|NCT01066013|No Intervention|Restrospective control arm|The control subjects will be drawn from historic data of patients on the same medical unit(s) and will be matched based on age, antibiotics, sex, and infectious diseases diagnosis.
3218730|NCT01066000|Experimental|Mircera|
3218731|NCT01065987|Experimental|Tizanidine HCl 4 mg|Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited
3218732|NCT01065987|Active Comparator|Zanaflex|Zanaflex 4 mg Tablets
3218733|NCT01065974|Active Comparator|Behavior Therapy|"Behavioral treatment strategies will be utilized to facilitate adherence to the treatment goals in all three treatments. Participants in the BT condition will receive only the BT intervention. Strategies that will be emphasized are listed below:~Self monitoring~Stimulus control~Changing eating behaviors~Goal setting~Problem solving~Social support~Cognitive restructuring~Relapse prevention"
3218734|NCT01065974|Experimental|Behavior Therapy + Meal Replacements|The BT +MR condition will implement behavioral treatment strategies in a way that is nearly identical to that of the BT condition. However, participants in this condition also will use MRs during weight loss and weight loss maintenance.
3218735|NCT01065974|Experimental|Nutritrol|"Participants in this condition will be informed about the evidence indicating that the availability, structure and composition of foods they encounter or seek out in their daily lives will play a major role in determining their ability to maintain the weight they lose. We will present the treatment as an opportunity to make numerous changes to their personal food environment involving the variety, energy density, nutritional composition, and portion size of the foods they encounter in every day life.~The Nutritrol condition is comprised of several components:~Food structure~Energy density~Reduce variety of foods high in energy density and increase variety of foods low in energy density~Protein intake~Controlling the personal food environment~Individualized weight loss maintenance prescriptions"
3218736|NCT01065961|Active Comparator|Decadron|Subject will be given Decadron 0.2mg/kg intraoperatively. This dose will be followed by 4 mg. every 6 hours for the first 24 hours.
3218737|NCT01065961|Placebo Comparator|Saline|subject will be given a blinded dose of placebo saline intraoperatively followed by placebo doses every 6 hours for 24 hours.
3218738|NCT01065948|Experimental|Patients|
3218739|NCT01065935|Active Comparator|ALN-RSV01|
3218740|NCT01065935|Placebo Comparator|Normal saline|
3218741|NCT01065909||Diabetes type 2|
3218742|NCT01065909||Chronic Pain|
3218743|NCT01065909||Atrial Fibrillation|
3218744|NCT01065896||Group 1|
3218745|NCT01065883|Experimental|community health worker|community health workers will provide education in the home
3218746|NCT01065883|Active Comparator|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
3218747|NCT01065870|Experimental|Group I|Patients with only venous involvement Treated with 6 cycles og GTX and then surgery
3218748|NCT01065870|Experimental|Group II|Patients with arterial involvement and may have venous involvement with tumor treated with 6 cycles of GTX, thenb GX/RT and then surgery
3218749|NCT01065857|Experimental|Citrafleet|The day prior to the colonoscopy in two dose times, first at 15:00h and second at 20:00h.
3218750|NCT01065857|Active Comparator|Klean Prep|The day prior to the colonoscopy from 16:00h to 20:00h.
3218751|NCT01065857|Experimental|Citrafleet Exploratory|The day of the colonoscopy in two dose times, first at 06:00h and second at 09:00h.
3218752|NCT01065844|Experimental|Nelfinavir|1250 mg Nelfinavir twice daily Monday-Sunday
3218753|NCT01065831|Experimental|Lifestyle counseling|This MINT-TLC group will be asked to attend 12 weekly counseling meetings focused on weight loss (if overweight), limiting sodium, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained Lay Health Advisors. Participants will attend weekly group classes targeted at lifestyle changes for the first 12 weeks (intensive phase); followed by three individual MINT sessions conducted monthly for the following three months (maintenance phase). The MINT-TLC sessions aim to help participants make useful therapeutic lifestyle changes (TLC) and develop skills to maintain these changes long-term.
3218754|NCT01065831|Placebo Comparator|Health Education Control Condition|Participants randomized to this control condition will receive traditional, group health education classes for 12 weeks delivered by experts on various health topics unrelated to hypertension such as cancer, health insurance, and depression.
3218755|NCT01065818|Experimental|Fluoro-L-Thymidine|Injection pre-Neoadjuvant Therapy (CRT, CT, or RT) and post-3 weeks Neoadjuvant Therapy (CRT, CT, RT)(3 weeks from the start of Neoadjuvant Therapy) prior to surgery.
3218756|NCT01065805|Experimental|1|18F-FLT PET
3218757|NCT01065792||1|Patients with HIV-1 infection taking Stocrin
3218758|NCT01065779||FOSAMAX PLUS or FOSAMAX PLUS D|Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg/2800 IU) or FOSAMAX PLUS D (70 mg/5600 IU).
3218759|NCT01065766||All participants|Korean participants with type 2 diabetes mellitus treated with sitagliptin/metformin
3218760|NCT01065753|Experimental|Life-style modification|Life-style modification for 40 study subjects with metabolic syndrome in comparison to 25 non-obesity subjects for control.
3218761|NCT01065740|Experimental|patient education|individual and group meetings with explanations about the disease, lifestyle counseling ; coaching by phone at 1 and 4 months; medical consultation at 3 months; physical exercise with coaching
3218762|NCT01065740|No Intervention|Usual care|
3218763|NCT01065727|Experimental|mitoxantrone followed by immunomodulator|
3218764|NCT01065727|Active Comparator|natalizumab|
3218765|NCT01065714|Experimental|Hydrogel vehicle|Parallel designed study. Split body treatment
3218766|NCT01065714|Active Comparator|Eucerin Lotion|Parallel study design. Split body study.
3218767|NCT01065701|Active Comparator|1mcg/kg|1mcg/kg intranasal dexmedetomidine administered 45 minutes befoe anesthesia induction
3218768|NCT01065701|Active Comparator|2mcg/kg|2mcg/kg intranasal dexmedetomidine given 45 minutes prior to anesthetic induction
3218769|NCT01065688|Active Comparator|Roux-en Y|Roux-en Y reconstruction after distal gastrectomy
3218770|NCT01065688|Experimental|Billroth-I|Billroth-I reconstruction after distal gastrectomy
3218771|NCT01065662|Experimental|Cediranib and Temsirolimus|Please see interventions section.
3218772|NCT01065649|Experimental|Nortriptyline|20 NERD patients will be treated with nortriptyline 10 mg a day in the first 7 days and 25 mg a day in the following 14 days
3218773|NCT01065649|Placebo Comparator|Placebo|Placebo arm
3218774|NCT01065636|Experimental|Diet + Resistance Exercise Training|
3218775|NCT01065636|Experimental|Diet + Aerobic Exercise Training|
3218776|NCT01065636|Experimental|Diet + Combined Aerobic/Resistance Exercise|
3218777|NCT01065636|No Intervention|Control Group (No Diet/No Exercise)|
3218778|NCT01065623|Experimental|Arm 1|
3218779|NCT01065610|Experimental|Oxytocin|Intranasal Oxytocin, 24 IU
3218780|NCT01065610|Placebo Comparator|Placebo|
3218781|NCT01065597|Experimental|Nonconvulsive electrotherapy|Open label single arm study of nonconvulsive electrotherapy
3218782|NCT01065584||Standard immunosuppression|Patients receiving standard immunosuppression after liver transplantation including calcineurininhibitors
3218783|NCT01065584||Immunosuppression without calcineurininhibitors|Patients receiving immunosuppression after liver transplantation not based on calcineurininhibitors
3218784|NCT01065571|Experimental|carrageenan-free diet with placebo|This is the experimental arm in which subjects will be on a no-carrageenan diet and receive placebo capsules. This will test whether the no carrageenan diet leads to longer relapse-free interval for patients with ulcerative colitis.
3218785|NCT01065571|Active Comparator|carrageenan-free diet w/ carrageenan|The carrageenan-free diet with carrageenan supplement will mimic the carrageenan normally consumed in the diet. The study will permit blinded comparison of carrageenan-free vs. carrageenan consumption.
3218786|NCT01065558|Experimental|Ecopipam 12.5 - 200 mg/day|Patients were administered ecopipam on an escalated dosing schedule over 11 days starting at 12.5 mg/day and increasing to the maximal tolerated dose or to 200 mg/day.
3218787|NCT01065545|Experimental|Clofarabine|
3218788|NCT01065532|Active Comparator|1|SeQuent Please Drug-eluting balloon
3218789|NCT01065532|Active Comparator|2|Xience V Drug-eluting stent
3218790|NCT01065519|Active Comparator|1|drug-eluting stent
3218792|NCT01065506|Active Comparator|Standard Care plus Wellness Program|
3218793|NCT01065506|Active Comparator|Standard Care plus Exercise Program|
3218794|NCT01065493|Experimental|Software Assisted Lifestyle Counseling|
3218795|NCT01065493|Active Comparator|Lifestyle Counseling|Status quo smoking cessation counseling.
3218796|NCT01065480|Active Comparator|Live Teleconference Supervision|Clinicians from participating substance abuse treatment programs receive live supervision by MI trainer via teleconference while in session with client.
3218797|NCT01065480|Active Comparator|Taped Review Supervision|Clinicians from participating substance treatment programs audio record session with client and receive supervision after the session by MI trainer.
3218798|NCT01065467|Experimental|Treatment|LBH589
3218799|NCT01065454|Experimental|Riociguat (Adempas, BAY63-2521) up to 2 mg|Participants received riociguat up to 2 mg three times per day (tid) (increasing from 0.5 to 1 to 2 mg).
3218800|NCT01065454|Experimental|Riociguat (Adempas, BAY63-2521) up to 1 mg|Participants received riociguat up to 1 mg tid (increasing from 0.5 to 1 mg).
3218801|NCT01065454|Experimental|Riociguat (Adempas, BAY63-2521) fixed 0.5 mg|Participants received riociguat 0.5 mg tid (fixed dose).
3218802|NCT01065454|Placebo Comparator|Placebo|Participants received placebo tid.
3218803|NCT01065428||Weaning failure|Weaning failure:(1) failed SBT; (2) reintubation and /or resumption of support following successful extubation; or (3) die 48h following extubation.
3218804|NCT01065428||Weaning successful|Weaning successful:extubation and the absence of ventilatory support 48 h following the extubation
3218805|NCT01065415||control group|routine staging work-up with chest CT, PET/CT, and brain MRI
3218806|NCT01065415||study group|routine staging work-up plus whole body MRI for Coregistered MRI/PET
3218807|NCT01065402|Placebo Comparator|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
3218808|NCT01065402|Experimental|PPB-R-203-Based Meal|"PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. RS intake is associated with several changes in metabolism which may confer some health benefits.~PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition."
3218809|NCT01065389|Experimental|Prgressive Resistance Exercise Training|Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
3218810|NCT01065389|Active Comparator|Unstructured Resistance Exercise|Unstructured Resistance Exercise thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
3218811|NCT01065376|Experimental|on the day of hCG|cabergoline administration for 8 days on the day of hCG.
3218812|NCT01065376|Experimental|on the day after oocyte retrieval|cabergoline administration for 8 days on the day after oocyte retrieval
3218813|NCT01065363|Experimental|Lifestyle conseling|
3218814|NCT01065350|Active Comparator|Propofol|As part of the induction, patients will be given 2 milligrams of propofol per kilogram (mg/kg) of body weight. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL.
3218815|NCT01065350|Experimental|Ketofol|"As part of the induction, patients will be given 20 mL syringe of an admixture called ketofol, which combines ketamine and propofol in one syringe. The dose is weight-based such that ketamine will represent 0.75 mg/kg of the dose and propofol, 1.5 mg/kg of the dose."
3218816|NCT01065337|No Intervention|control group|patients received standard of care wound treatment according guideline of the American Diabetes Association (ADA)
3218817|NCT01065337|Active Comparator|bone marrow stem cells intraarterial|bone marrow stem cells administered intraarterial
3218818|NCT01065337|Active Comparator|tissue repair cells intramuscular|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intramuscular
3218819|NCT01065337|Active Comparator|tissue repair cells intraarterial|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intraarterial
3218820|NCT01065337|Active Comparator|bone marrow stem cells intramuscular|bone marrow stem cells administered intramuscular
3218821|NCT01065324||Anally inserted enteroscopy group|Anally inserted enteroscopy group
3218822|NCT01065324||Orally inserted enteroscopy group|Orally inserted enteroscopy group
3218823|NCT01065311|Experimental|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of certain aspects of cognitive behavioral therapy for depression (Beck et al., 1979) and components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
3218824|NCT01065311|Active Comparator|CBASP|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions.
3218825|NCT01065311|Active Comparator|Treatment-as-usual|"Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist"
3218826|NCT01065298||Group 1:Stem cell Recipient|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4U/Kg for blood glucose control. They will undergo stem cell therapy initialy and G-CSF therapy at 2 months
3218827|NCT01065298||Group-2: Controls|Type 2 Diabetes mellitus patients on full doses of vildagliptin+metformin+pioglitazone and on Insulin >0.4U/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1.
3218828|NCT01065285|Experimental|Evaluation of vaccines against flu|Evaluation of vaccines against flu
3218829|NCT01065272|Active Comparator|Ventolin - Dexamethasone group|Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Dexamethasone is also given daily for 5 days.
3218830|NCT01065272|Placebo Comparator|Ventolin - Placebo group|Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Placebo is also given daily for 5 days.
3218831|NCT01065259|Experimental|OROS MPH|the group treated by OROS MPH
3218832|NCT01065259|Active Comparator|atomoxetine|the group treated by atomoxetine
3218833|NCT01065259|No Intervention|control|the normal control with no intervention
3218834|NCT01065246|Experimental|catumaxomab|
3218835|NCT01065233||alcoholic cirrhosis with viral infection|patient with alcoholic cirrhosis with viral infection (300 patients)
3218836|NCT01065233||alcoholic cirrhosis without viral infection|patient with alcoholic cirrhosis without viral infection
3218837|NCT01065220|Experimental|hormone treatment for MtF|"cyproterone acetate~estradiol~alpha-5-reductase-inhibitor"
3218838|NCT01065220|Experimental|hormone treatment for FtM|"testosterone undecanoate~lynestrenol"
3218839|NCT01065207|No Intervention|patient|
3218840|NCT01065194|Experimental|Levosimendan|Chronic stable heart failure
3218841|NCT01065194|Placebo Comparator|Placebo|Chronic Stable Heart Failure
3218842|NCT01065168||endometrioma|ovarian endometrioma undergoing cystectomy
3218843|NCT01065155||Median central blood pressure|Median central blood pressure, lower median group 1 and higher group 2.
3218844|NCT01065129|Experimental|Dose Level 1|"AMD3100 320 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
3218845|NCT01065129|Experimental|Dose Level 2|"AMD3100 440 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
3218846|NCT01065129|Experimental|Dose Level 3|"AMD3100 560 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
3218847|NCT01065129|Experimental|Expanded DLT Cohort|After the MTD is determined, patients will be enrolled at the MTD dose of plerixafor. These patients will not receive G-CSF priming but will be treated with plerixafor and azacitidine for 2 cycles.
3218848|NCT01065116|Experimental|AL Blister-pack|
3218849|NCT01065116|Active Comparator|AL unit dose age specific pre-packs|
3218850|NCT01065103|Experimental|FFR measurement|
3218851|NCT01065090||training|one group will receive resistance training and one group the normal physiotherapeutic treatment
3218852|NCT01065090||physiotherapy|one group will receive resistance training and one group the normal physiotherapeutic treatment
3218853|NCT01065077|Experimental|Arm 1|
3218854|NCT01065077|Experimental|Arm 2|
3218855|NCT01065077|Experimental|Arm 3|
3218856|NCT01065077|Placebo Comparator|Arm 4|
3218857|NCT01065064|Experimental|RESTOR|Patients with cataract that had phacoemulsification and AcrySof® ReSTOR IOL implantation.
3218858|NCT01065051|Experimental|Riociguat (Adempas, BAY63-2521)|Participants received a single oral dose of 1 mg riociguat.
3218859|NCT01065051|Placebo Comparator|Placebo|Participants received a single oral dose of 1 mg placebo.
3218860|NCT01065038|Experimental|Anagrelide|
3218861|NCT01065038|Active Comparator|Hydroxyurea|
3218862|NCT01065025|Experimental|4SC-205|
3218863|NCT01065012|Experimental|Udenafil 50 mg|50 mg Udenafil
3218864|NCT01065012|Experimental|Udenafil 100 mg|100 mg Udenafil
3218865|NCT01065012|Experimental|Udenafil 150 mg|150 mg Udenafil
3218866|NCT01065012|Placebo Comparator|Placebo|Placebo Tablets matching Udenafil tablets
3218867|NCT01064999|Experimental|High intensity group|(RT 55Gy + CapOx) + a cycle of Xelox + Surgery
3218868|NCT01064999|Active Comparator|Low instensity group|(RT 50Gy + CapOx) + Surgery
3218869|NCT01064986|Placebo Comparator|A|IV Endotoxin plus saline vehicle (placebo)
3218870|NCT01064986|Active Comparator|B|IV Endotoxin plus IV hydrocortisone
3218871|NCT01064973|Experimental|STX209|STX209 (arbaclofen)
3218872|NCT01064960|Experimental|Treated leiomyomas|Pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure are treated with the Philips MR-guided HIFU system. Patients must have completed child bearing prior to enrolling in this study.
3218873|NCT01064934|Experimental|Lipid apheresis|Lipid apheresis
3218874|NCT01064934|Active Comparator|Standard care|Standard care
3218875|NCT01064921|Experimental|Arm I|Patients receive oral vorinostat on days 0-2 and cisplatin IV on days 7, 21 and 35. Patients undergo radiation therapy 5 days a week beginning on day 7. Patients also receive concurrent oral vorinostat along with the radiotherapy to be given 3 days per week (Monday, Tuesday, and Wednesday). Optional repeat tumor and normal mucosal biopsies will be performed and blood will be drawn for correlative studies.
3218876|NCT01064908||Carotid endarterectomy|Patients who are undergoing elective carotid endarterectomy under local anaesthesia
3218877|NCT01064895||Active Cohort|Patients receiving the Benephit device and targeted renal therapy.
3218878|NCT01064882|Experimental|bimatoprost ophthalmic solution 0.005%|bimatoprost ophthalmic sterile solution 0.005%
3218879|NCT01064882|Experimental|bimatoprost ophthalmic solution 0.015%|bimatoprost ophthalmic sterile solution 0.015%
3218880|NCT01064882|Active Comparator|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03%
3218881|NCT01064869|Experimental|Psycho-educational intervention|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~Motivational interviewing based on stages of change model to encourage change and adherence~Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
3218882|NCT01064869|No Intervention|usual care|Standard asthma management
3218883|NCT01064856|Experimental|Double-blind (DB) Adalimumab|Adalimumab 40 mg subcutaneous (SC) injection every other week (eow) up to Week 12 in double-blind period.
3218884|NCT01064856|Placebo Comparator|Double-blind Placebo|Placebo subcutaneous (SC) injection every other week (eow) up to Week 12 in the double-blind period.
3218885|NCT01064856|Experimental|Double-blind Adalimumab / Open-label Adalimumab|Adalimumab 40 mg SC injection eow up to Week 12 in double-blind period and from Week 12 to Week 156 in open-label period.
3218886|NCT01064856|Placebo Comparator|Double-blind Placebo / Open-label Adalimumab|Placebo SC injection every other week (eow) up to Week 12 in the double-blind period; adalimumab 40 mg subcutaneous injection eow from Week 12 to Week 156 in the open-label period.
3218887|NCT01064843||4 Imtec mini-dental implants (MDI)|4 Imtec MDI
3218888|NCT01064830|Active Comparator|topical cyclosporine suspension|apply 2 drops to 2 target nails under occlusion daily for 20 weeks
3218889|NCT01064830|Placebo Comparator|vehicle|apply to target nails daily under occlusion daily for 20 weeks
3218890|NCT01064817|Experimental|PRM-151|PRM-151 (recombinant human serum amyloid P, recombinant human pentraxin 2)
3218891|NCT01064817|Placebo Comparator|Placebo|Placebo
3218892|NCT01064804||relative bioavailability|
3218893|NCT01064791|Experimental|Arm 1|sotrastaurin (100mg bid) + tacrolimus + standard of care medications
3218894|NCT01064791|Experimental|Arm 2|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
3218895|NCT01064791|Experimental|Arm 3|sotrastaurin (300mg bid) + tacrolimus + standard of care medications
3218896|NCT01064791|Active Comparator|Arm 4|mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
3218897|NCT01064778|Active Comparator|Low GI|
3218898|NCT01064778|Experimental|High GI|
3218899|NCT01064765||Heart failure|Outpatients with heart failure, age 75 or less, left ventricular ejection fraction 40% or less, english speaking with no known dementia
3218900|NCT01064752||Minocycline|HIV-1 infected, not on anti-retroviral medication
3218901|NCT01064739|Experimental|Study Diet +/- fava beans|Participants underwent testing while on a methylxanthine-free diet providing 150 mEq sodium and 75 mEq potassium per day. The study involved a longitudinal design where the participants served as their own controls. Subjects consumed the standard fixed sodium diet on study day one. On study day two, participants ate 100 g of puréed fava beans and pods with study diet at breakfast (0800hr) and lunch (1200hr).
3218902|NCT01064726|Experimental|Ibuprofen|
3218903|NCT01064726|Experimental|Fluticasone propionate|
3218904|NCT01064726|Placebo Comparator|Placebo|
3218905|NCT01064713|Experimental|Tesetaxel|Therapy initiated at a flat dose of 40 mg for subjects in Cohort A and at a flat dose of 50 mg for subjects in Cohort B. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.
3218906|NCT01064700|No Intervention|Baseline|1 week period, in which subjects followed usual schedule, though they were asked to maintain a fairly stable sleep schedule. The baseline period was used for comparison with the experimental intervention.
3218907|NCT01064700|Experimental|Experimental Intervention|Randomized exposure to the 4-week experimental treatments.
3218908|NCT01064687|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
3218909|NCT01064687|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
3218910|NCT01064687|Active Comparator|Exenatide|"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
3218911|NCT01064687|Placebo Comparator|Placebo|"Placebo: subcutaneous (SC), once weekly for 26 weeks~LY2189265 (Dulaglutide): After 26 weeks, participants were randomized to receive either 0.75 milligrams (mg) or 1.5 mg, SC, once weekly for an additional 26 weeks (from week 26 through week 52).~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
3218912|NCT01064674||before renal transplantation|Patients with CKD IV° to V° who are actually registering for a renal transplantation in our department.
3218913|NCT01064661|Active Comparator|Blend probiotic of L-NCFM and B-LBi07|Blend probiotic pills of L-NCFM and B-LBi07 BID (2x10^10 cfu total bacteria per day)
3218914|NCT01064661|Active Comparator|Single probiotic of L-NCFM alone|Single probiotic pills of L-NCFM alone BID (2x10^10 cfu total bacteria per day)
3218915|NCT01064648|Experimental|Arm I (pemetrexed disodium, cisplatin, cediranib maleate))|Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cediranib maleate alone PO QD in the absence of disease progression or unacceptable toxicity.
3218916|NCT01064648|Active Comparator|Arm II (pemetrexed disodium, cisplatin, placebo)|Patients receive pemetrexed disodium and cisplatin as in arm I and placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive placebo alone PO QD in the absence of disease progression or unacceptable toxicity.
3218917|NCT01064635|Active Comparator|Letrozole for 3-2 years|Patients pre-treated with TAM for 2-3 years will receive letrozole 2,5 mg/die for 3-2 years. Total duration of early adjuvant endocrine therapy: 5 years
3218918|NCT01064635|Experimental|Letrozole for 5 year|Patients pre-treated with TAM for 2-3 years will receive letrozole 2,5 mg/die for additional 5 years. Total duration of early adjuvant endocrine therapy: 7 years for patients pretreated with 2 years of TAM and 8 years for patients pre-treated with 3 years of TAM
3218919|NCT01064622|Active Comparator|Arm I (gemcitabine hydrochloride and placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and placebo PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of disease progression, patients are unblinded and may crossover to arm II.
3218920|NCT01064622|Experimental|Arm II (gemcitabine hydrochloride and vismodegib)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and vismodegib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3218921|NCT01064609|Active Comparator|2. Biopsy with cryoprobes|Transbronchial cryobiopsy with a cryoprobe.
3218922|NCT01064609|Active Comparator|2.Biopsy with forceps|Transbronchial lung biopsy with conventional forceps.
3218923|NCT01064596||blood sample|Patient with 4 blood samples to measure anti-Xa activity
3218924|NCT01064583|Experimental|flavanol rich cocoa drink (596mg)|dissolved in water, twice daily intervention
3218925|NCT01064583|Experimental|flavanol poor cocoa drink ( 13mg)|dissolved in water, twice daily intervention
3218926|NCT01064544|Experimental|Starting with light therapy|Starts with 3 weeks of light therapy, followed by a control period
3218927|NCT01064544|Experimental|Ending with light therapy|Ends with 3 weeks of light therapy after a control period.
3218928|NCT01064531||MIS Mini Stem implant|Subject will be randomized to either MIS or Synergy implant.
3218929|NCT01064531||Synergy implant|Subject will be randomized to either Synergy or MIS implant.
3218930|NCT01064518|Active Comparator|Dose A|RT001 Topical Gel
3218931|NCT01064518|Placebo Comparator|Dose B|Placebo Comparator
3218932|NCT01064505|Experimental|QPI-1007|
3218933|NCT01064492|Experimental|ABC, ACB, BAC, BCA, CAB, and CBA|
3218934|NCT01064479|Experimental|Arm A = Chemo + Erlotinib|Docetaxel 75 mg/m2 intravenous (IV) followed by cisplatin 75 mg/m2 IV or carboplatin AUC 6 mg.min/ml on Day 1 of each 21 day cycle for a maximum of 6 cycles, plus erlotinib 150 mg orally (PO) daily continuously. A total of six cycles are planned, and a minimum of 4 cycles of chemotherapy are strongly encouraged. For patients with a complete or partial response or stable disease, erlotinib 150 mg PO daily will be continued beyond chemotherapy until disease progression.
3218935|NCT01064479|Placebo Comparator|Arm B = Chemo + Placebo|Docetaxel 75 mg/m2 IV followed by cisplatin 75 mg/m2 IV or carboplatin AUC 6 mg.min/ml on Day 1 of each 21 day cycle for a maximum of 6 cycles, plus placebo 150 mg PO daily continuously. A total of six cycles are planned, and a minimum of 4 cycles of chemotherapy are strongly encouraged. For patients with a complete or partial response or stable disease, placebo 150 mg PO daily will be continued beyond chemotherapy until disease progression.
3218936|NCT01064466|Experimental|ETOPOSIDE - Usual|"Etoposide Injection~Combined Chemotherapy~Etoposide Injection + Methotrexate Injection + Topotecan Injection~Usual Approach Group"
3218937|NCT01064466|Experimental|ETOPOSIDE - Study|"Etoposide Capsule~Combined Chemotherapy~Etoposide Capsule + Methotrexate Tablet + HYCAMTIN - Topotecan Capsule~Study Approach Group"
3218938|NCT01064453||Group 1|
3218939|NCT01064440|Experimental|Low Dose VM202|Patients in this group will receive 8mg total of VM202. Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
3218940|NCT01064440|Experimental|High Dose VM202|Patients in this treatment group will receive a total of 16mg VM202. Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 4mg of VM202 (16 injections of 0.5ml of VM202) Day42: 4mg of VM202 (16 injections of 0.5ml of VM202)
3218941|NCT01064440|Sham Comparator|Placebo|Patients in this group will receive a total of 8ml normal saline. Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
3218942|NCT01064427||Chemotherapy group|Breast cancer patients treated by adjuvant chemotherapy after their surgery. The time points of data collection are before the start of the first, second, fourth and sixth cycle of chemotherapy. If patients are treated by radiotherapy after the chemotherapy, there are 2 measurements points pre- and post radiotherapy.The others measurement points are at 12,18 and 24 months after surgery.
3218943|NCT01064427||No chemotherapy group|Breast cancer patients no treated by adjuvant chemotherapy after their surgery. For patients treated by radiotherapy after surgery, there are 2 measurement points pre- and post radiotherapy. The others measurement points are at 4,6,7,8,12,18 and 24 months after surgery.
3218944|NCT01064414|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks.
3218945|NCT01064414|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks.
3218946|NCT01064414|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 52 weeks.
3218947|NCT01064401|Experimental|Daclizumab High Yield Process 150 mg SC|Daclizumab High Yield Process (DAC HYP) 150mg subcutaneous (SC) injection once every 4 weeks plus placebo to IFN β-1a intramuscular (IM) injection once weekly for 96 to 144 weeks
3218948|NCT01064401|Active Comparator|IFN β-1a 30 µg IM|Interferon beta-1a (IFN β-1a) 30 µg IM once weekly plus placebo to DAC HYP SC once every 4 weeks for 96 to 144 weeks
3218949|NCT01064388|Experimental|1|
3218950|NCT01064388|Placebo Comparator|2|
3218951|NCT01064375|Experimental|CEA DNA prime (cohort I)|5 patients, tetwtCEA DNA intradermal delivery with electroporation, not previously vaccinated with CEA66 DNA. Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration. One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
3218952|NCT01064375|Experimental|CEA DNA boost (cohort II)|10 patients, tetwtCEA DNA intradermal delivery with electroporation, previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
3218953|NCT01064375|Experimental|CEA DNA prime + GM-CSF (cohort III)|5 patients, tetwtCEA DNA intradermal delivery with electroporation + GM-CSF, not previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
3218954|NCT01064362||Prophylaxis following major orthopedic surgery|Patients age 18 years and older in the PHARMO RLS database treated with either fondaparinux sodium or LMWH for thromboprophylaxis following hip fracture and/or hip/knee replacement surgery.
3219008|NCT01063998||p 2|Patients diagnosed with renal cancer and normal creatinine.
3218955|NCT01064349||Breast cancer patients with brain metastases|Female Erb2+ breast cancer patients with brain metastases diagnosed between January 2006 and December 2008 in 6 Asian countries (Indonesia, Korea, Malaysia, Philippines, Singapore, and Thailand).
3218956|NCT01064336||Pregnant women on eltrombopag|Any women with eltrombopag exposure during pregnancy that is reported prior to or after knowledge of the pregnancy outcome, substantiated by health care provider, and meeting the enrollment criteria: documentation that eltrombopag is being taken during pregnancy; timing of the prenatal exposure to eltrombopag (i.e. best estimation of which trimester in pregnancy that there was exposure to Eltrombopag for stratification and reporting purposes ); sufficient information to determine whether the pregnancy is being prospectively or retrospectively registered; whether the outcome of pregnancy was known at the time of the report; source of the report (i.e. health care professional, patient); full provider contact information to allow for follow-up (name, address, etc.)
3218957|NCT01064336||Infants|Infants through the first year of life whose mothers were exposed to eltrombopag during pregnancy.
3218958|NCT01064323|Other|Intermittent leg compression|Intermittent leg compression daily for 3 hrs a day for 4 weeks
3218959|NCT01064310|Experimental|pazopanib followed by sunitinib|800mg pazopanib orally for 10 weeks followed by 50mg sunitinib orally for 10 weeks
3218960|NCT01064310|Experimental|sunitinib followed by pazopanib|50mg sunitinib orally for 10 weeks followed by 800mg pazopanib orally for 10 weeks
3218961|NCT01064297||Women exposed to lamotrigine during pregnancy|
3218962|NCT01064284|Active Comparator|PLASMA DERIVED Factor VIII|Plasma-derived vWF/FVIII
3218963|NCT01064284|Active Comparator|rFVIII|Recombinant FVIII
3218964|NCT01064271|Experimental|Risperidone|Risperidone Tablets 1 mg of Dr Reddys Laboratories Limited
3218965|NCT01064271|Active Comparator|Risperdal®|Risperdal® Tablets, 1 mg of Janssen Pharmaceutica Products, L.P
3218966|NCT01064258|Active Comparator|fixed CPAP|subject will sleep with a fixed CPAP device at minimal pressure
3218967|NCT01064258|Experimental|autoCPAP|the subject will sleep connected to an autoCPAP device
3218968|NCT01064245|Experimental|Cough Variant Asthma|Those diagnosed with cough variant asthma.
3218969|NCT01064245|Experimental|Asthma|Those with diagnosed asthma.
3218970|NCT01064232|Experimental|Risperidone|Risperidone Tablets 1 mg of Dr Reddys Laboratories Limited
3218971|NCT01064232|Active Comparator|Risperdal|Risperdal® Tablets, 1 mg of Janssen Pharmaceutica Products, L.P
3218972|NCT01064219|Experimental|intrauterine hCG|intrauterine injection of 100 hCG followed by endometrial biopsy
3218973|NCT01064206||Buerger's disease patients|200 thromboangiitis obliterans patients (Buerger's disease or TAO)
3218974|NCT01064206||Control group|200 atheromatous arteritis patients
3218975|NCT01064193|Experimental|group 1 : IVF with biopsy|fresh IVF-embryo transfer treated with long protocol or antagonist protocol for the controlled ovarian hyperstimulation plus local injury to the endometrium of patients one menstrual cycle before the IVF
3218976|NCT01064193|Active Comparator|group 2|fresh IVF-embryo transfer treated with long protocol or antagonist protocol for the controlled ovarian hyperstimulation alone
3218977|NCT01064180|Experimental|Carvedilol|Carvedilol Tablets 25 mg of Dr Reddys Laboratories Limited
3218978|NCT01064180|Active Comparator|Coreg|Coreg Tablets 25 mg of GlaxoSmithKline
3218979|NCT01064167|Experimental|Tranexamic Acid group|
3218980|NCT01064167|Placebo Comparator|Control group|
3218981|NCT01064154|Experimental|Carvedilol|Carvedilol Tablets 25 mg of Dr Reddys Laboratories Limited
3218982|NCT01064154|Active Comparator|Coreg|Coreg Tablets 25 mg of GlaxoSmithKline
3218983|NCT01064141|Experimental|Group 1: Dengue Vaccine Group|Participants will receive CYD Dengue vaccine as Visits 1 and 2.
3218984|NCT01064141|Active Comparator|Group 2: Control Group|Participants will receive Control Vaccines. (Varicella at Visit 1 and Hepatitis A at Visit 2)
3218985|NCT01064141|Experimental|Group 3: Co-administration Group|Participants will receive CYD Dengue vaccine and childhood vaccines at Visit 1 and CYD Dengue vaccine at Visit 2.
3218986|NCT01064141|Experimental|Group 4: Sequential Administration Group|Participants will receive CYD Dengue vaccine and a Placebo vaccine at Visit 1 and CYD Dengue vaccine at Visit 2.
3218987|NCT01064128|Active Comparator|conventional laparoscopic hysterectomy|Three or four ports conventional laparoscopic hysterectomy
3218988|NCT01064128|Active Comparator|SPA laparoscopic hysterectomy|Single umbilical incision laparoscopic hysterectomy
3218989|NCT01064115|Experimental|Cetirizine|Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys Laboratories Limited
3218990|NCT01064115|Active Comparator|Zyrtec|Zyrtec Tablets 10 mg of Pfizer Labs
3218991|NCT01064102|Experimental|Cetirizine|Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys Laboratories Limited
3218992|NCT01064102|Active Comparator|Zyrtec|Zyrtec Tablets 10 mg of Pfizer Labs
3218993|NCT01064089|Experimental|HSP990|dose escalation
3218994|NCT01064076|Experimental|S-ICD System|This is a single arm study
3218995|NCT01064063|Active Comparator|AGC knee|Patients were randomised to receive an AGC Cruciate Retaining cement knee. This is the control group in the study; the AGC is the gold standard of Biomets' knee products.
3218996|NCT01064063|Experimental|Vanguard CR|Patients were randomised to receive a Vanguard Cruciate Retaining Knee from the Vanguard system which encompasses concepts used in the AGC family of knees. The Vanguard is specifically designed to give greater knees stability through use of more anatomic patello-femoral kinematics.
3218997|NCT01064050|Experimental|trachea-bronchial stent (Novatech)|
3218998|NCT01064050|No Intervention|control|
3218999|NCT01064037|Experimental|Arm 1|
3219000|NCT01064037|Experimental|Arm 2|
3219001|NCT01064037|Experimental|Arm 3|
3219002|NCT01064037|Placebo Comparator|Arm 4|
3219003|NCT01064024|Active Comparator|Phenazopyridine Hydrochloride Tablets, USP 200 mg|
3219004|NCT01064024|Placebo Comparator|Placebo|Matching placebo to the phenazopyridine hydrochloride tablets
3219005|NCT01064011|Other|External Ventricular drainage, Intraventricular Thrombolysis|
3219006|NCT01064011|Other|External Ventricular Drainage and Endoscopic Evacuation|
3219007|NCT01063998||Group 1|Patients demonstrate normal serum creatinine and no radiological evidence of a renal tumor.
3219009|NCT01063972|Experimental|Experimental 1|Experimental: 1 Centralized disease management
3219010|NCT01063972|Experimental|Experimental 2|Experimental: 2 Counseling alone
3219011|NCT01063959|Other|Safety|Chart review will evaluate the safety of the two procedures, incidence of complications operatively, hospital stay, and 6-week post-operative periods.
3219012|NCT01063959|Experimental|Weight Loss|Chart review will evaluate weight loss in subjects during the operative, 6-week post-operative, and follow-up of at least 18 months.
3219013|NCT01063959|Other|Insurance versus Private Pay|An insurance company issues an insurance policy to cover specific complications from the gastric bypass or the sleeve gastrectomy surgery which allows the surgeon to offer a fixed price to the patient. Comparison of surgical complications in subjects paying by insurance versus paying personally for the gastric bypass operation.
3219014|NCT01063946|Experimental|[14C]-AVE8062|Single, 30 minute, intravenous infusion of 25 mg/m² of [14C]-AVE8062 containing 1.85 MBq (50µCi) at the first cycle, followed by subsequent administrations with non-radiolabelled AVE8062 in combination with cisplatin every 3 weeks, according to the investigator's judgment.
3219015|NCT01063933|Experimental|Cohort I|Cohort I: >/= 12 years to < 18 years. Peramivir administered daily for five days or until the day of hospital discharge, whichever comes first.
3219016|NCT01063933|Experimental|Cohort II|Cohort II: >/= 6 years to < 12 years
3219017|NCT01063933|Experimental|Cohort III|Cohort III: >/= 2 years to < 6 years
3219018|NCT01063933|Experimental|Cohort V|Cohort V: >/= 91 days to < 181 days
3219019|NCT01063933|Experimental|Cohort VII|Cohort VII: birth to < 31 days
3219020|NCT01063933|Experimental|Cohort VI|Cohort VI: >/= 31 days to < 91 days
3219021|NCT01063933|Experimental|Cohort IV|Cohort IV: >/= 181 days to < 2 years
3219022|NCT01063920|Experimental|LT-NS001|LT-NS001 1200 mg b.i.d. p.o. for 12 weeks
3219023|NCT01063920|Active Comparator|Naprosyn®|Naprosyn® 500 mg b.i.d for 12 weeks
3219024|NCT01063907|Experimental|Phase 1: Cohort 1|Cohort 1: KW 2478 130 mg/m^2 and Bortezomib 1.0 mg/m^2
3219025|NCT01063907|Experimental|Phase 1: Cohort 2|Cohort 2: KW 2478 130 mg/m^2 and Bortezomib 1.3 mg/m^2
3219026|NCT01063907|Experimental|Phase 1: Cohort 3|Cohort 3: KW 2478 175 mg/m^2 and Bortezomib 1.0 mg/m^2
3219027|NCT01063907|Experimental|Phase 1: Cohort 4|Cohort 4: KW 2478 175 mg/m^2 and Bortezomib 1.3 mg/m^2
3219028|NCT01063907|Experimental|Phase 2|KW 2478 175 mg/m^2 and Bortezomib 1.0 mg/m^2
3219029|NCT01063894|Experimental|breakfast cereal|breakfast cereal and milk
3219030|NCT01063894|Placebo Comparator|water|water
3219031|NCT01063881|Experimental|Dapoxetine|Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity may be increased after 4 weeks to 60mg taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
3219032|NCT01063868|Experimental|001|Tapentadol extended release (ER) 100 150 200 250 mg twice daily for 52 weeks
3219033|NCT01063868|Active Comparator|002|Oxycodone controlled release (CR) 20 30 40 50 mg twice daily for 52 weeks
3219034|NCT01063855|Experimental|Dapoxetine + PDE5I|Dapoxetine 30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks + a PDE5I (phosphodiesterase-5 inhibitor) prescribed prior to study entry for the treatment of erectile dysfunction.
3219035|NCT01063855|Placebo Comparator|Placebo + PDE5I|Placebo tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks + a PDE5I (phosphodiesterase-5 inhibitor) prescribed prior to study entry for the treatment of erectile dysfunction.
3219036|NCT01063842|Experimental|001|tramadol hydrochloride / acetaminophen and placebo 1 tablet of tramadol/acetaminophen in the morning 1 tablet of placebo in the afternoon and evening for 3 days then 1 tablet of tramadol/acetaminophen in the morning evening and 1 tablet of placebo in the afternoon for 4 days then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
3219037|NCT01063842|Active Comparator|002|tramadol hydrochloride /acetaminophen 1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
3219038|NCT01063829|Experimental|Dose regimen 1|60 mg AIC246, one tablet per day
3219039|NCT01063829|Experimental|Dose regimen 2|120 mg AIC246, one tablet per day
3219040|NCT01063829|Experimental|Dose regimen 3|240 mg AIC246, one tablet per day
3219041|NCT01063829|Other|Placebo|Placebo arm
3219042|NCT01063816|Experimental|Arm 1|
3219043|NCT01063803|Experimental|Arm 1: ATN-103_30mg|
3219044|NCT01063803|Experimental|Arm 2: ATN-103_80 mg|
3219045|NCT01063790|No Intervention|Usual care|Patients undergoing elective inguinal hernia repair attend the pre-admission clinic no later than one week prior to surgery. During this visit they receive one-on-one pre-operative education from a registered nurse. It includes both verbal and written information. Verbal information provided to patients includes procedural information such as the admission process, and post-operative care in the post-anaesthetic care uni and day surgery unit. Post-discharge pain management information is minimal and consists of direction to not wait until the pain is severe before taking prescribed analgesics.
3219046|NCT01063790|Experimental|Individualized Education|
3219047|NCT01063777|Active Comparator|1|
3219048|NCT01063777|Active Comparator|2|
3219049|NCT01063764|Experimental|Levetiracetam|Open-label, single-arm
3219050|NCT01063751|Other|Tritanium® Primary Acetabular Shell|Tritanium® Primary Acetabular Shell
3219051|NCT01063738|Active Comparator|ICU Recovery Manual & placebo supplement|Patients will receive the standard self-directed rehabilitation package and a placebo nutritional supplement
3219052|NCT01063738|Experimental|ICU recovery manual & amino acid (AA) supplement|Patients will receive the standard self-directed rehabilitation package with the essential amino acid supplement
3219053|NCT01063738|Experimental|PEPSE & placebo supplement|Patients will receive the standard self-directed rehabilitation package plus PEPSE and the placebo nutritional supplement
3219054|NCT01063738|Experimental|PEPSE & AA supplement|Patients will receive the standard self-directed rehabilitation package plus PEPSE and the essential amino acid nutritional supplement
3219055|NCT01063725|Experimental|Femarelle|Women will receive Femarelle twice daily for 12 weeks
3219056|NCT01063725|Placebo Comparator|Placebo|Women will take placebo capsules twice daily for 12 weeks
3219057|NCT01063712|Other|Nit-Occlud PDA-R|Interventional, prospective clinical study, non randomized.
3219058|NCT01063699|Experimental|Lap Kasai|Patients in this arm had their necessary Kasai procedure in a laparoscopic way.
3219059|NCT01063686|No Intervention|Insemination cervical cap|
3219060|NCT01063673||Active runners|Observational follow-up study on 39 runners
3219061|NCT01063660|Experimental|Treosulfan|Patients with acute myeloid leukaemia (AML) according to WHO classification (> 20% myeloblasts in peripheral blood or bone marrow at initial diagnosis) with < 5% myeloblasts in the bone marrow, indicated for allogeneic transplantation
3219062|NCT01063647|Experimental|1|Treosulfan: 10 g/m² i.v. on 3 consecutive days (day -6 to -4)
3219063|NCT01063647|Experimental|2|Treosulfan:12 g/m² i.v. on 3 consecutive days (day -6 to -4)
3219064|NCT01063647|Experimental|3|Treosulfan: 14 g/m² i.v. on 3 consecutive days (day -6 to -4)
3219065|NCT01063621|Experimental|KW-6500|
3219066|NCT01063608|Experimental|Anti-H1N1v Vaccine|
3219067|NCT01063595|Experimental|Octaplas LG|Participants received 1200 mL of Octaplas LG intravenously once.
3219068|NCT01063595|Active Comparator|Octaplas SD|Participants received 1200 mL of Octaplas SD intravenously once.
3219069|NCT01063582||fighter pilots f-16|This group is made up of pilots from the F-16 Venezuelan military air force stationed in the Base Vicente Landaeta Gil de Barquisimeto, Lara State.
3219070|NCT01063582||aircraft maintenance personnel f-16|Staff responsible for the preparation of aircraft for the flight and maintenance in the hangar at the airbase Vicente Landaeta Gil de Barquisimeto, Lara. Venezuela
3219071|NCT01063569|Active Comparator|Oral hydrocortisone|
3219072|NCT01063569|Experimental|Continous subcutaneous hydrocortisone infusion|
3219073|NCT01063556|Experimental|1|
3219074|NCT01063556|Experimental|2|
3219075|NCT01063543||patients with blood sample|Patients with major orthopedic surgery and prophylactic doses of fondaparinux who have 3 blood sample during their hospitalization to measure anti-Xa activity
3219076|NCT01063530|Experimental|Diammine Silver Fluoride|Application fo diammine silver fluoride in cervical lesions
3219077|NCT01063530|Placebo Comparator|Distilled water|Application of distilled water in cervical lesions
3219078|NCT01063517|Experimental|1|Olaparib + paclitaxel
3219079|NCT01063517|Active Comparator|2|paclitaxel + placebo
3219080|NCT01063504|Active Comparator|Teriparatide 20 microgram daily for 2 months|
3219081|NCT01063504|Placebo Comparator|Placebo|
3219082|NCT01063491|Experimental|Early graft angiography after coronary artery bypass surgery|Treatment of any bypass graft abnormalities that are discovered will be performed if needed
3219083|NCT01063491|No Intervention|No early angiography after coronary artery bypass surgery|
3219084|NCT01063478|Experimental|RAD001, Chemotherapy, Radiation|RAD001 + Chemotherapy and Radiation
3219085|NCT01063465|Experimental|Early weightbearing|
3219086|NCT01063465|Experimental|Control group|
3219087|NCT01063452|Experimental|Truvalve|Atkinson Product Design urinary slide valve on the catheter
3219088|NCT01063452|Active Comparator|Control|Drainage bag on the catheter
3219089|NCT01063439|Experimental|BuEAM: Experimental|BuEAM: Experimental Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day Intervention: Drug: Busulfan, etoposide, cytarabine, and melphalan
3219090|NCT01063426|Experimental|Atorvastatin + enoxaparine arm|High dose atorvastatin arm before index surgery+ conventional enoxaparin
3219091|NCT01063426|Active Comparator|Conventional Enoxaprin|Conventional Enoxaparin before 12hr and on 1-7th day after index surgery
3219092|NCT01063413||Coleman Afterschool Program|Children enrolled in a community center-based after-school program.
3219093|NCT01063413||YMCA Fun Company|Children enrolled in a school-based after-school program.
3219094|NCT01063400||Activity monitoring|
3219095|NCT01063387|No Intervention|Sema4c positive +Common iliac lymph nodes control|"Sema4c Positive & Radical hysterectomy +Pelvic Radiotherapy "
3219096|NCT01063387|Active Comparator|Sema4c positive +Common iliac lymph nodes Experimental|"Sema4c Positive & Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation) "
3219097|NCT01063387|No Intervention|Sema4c Positive + PAN positive control arm|"Sema4c Positive &  Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation) "
3219098|NCT01063387|Experimental|Sema4c positive+ PAN positive Experimental|Sema4c Positive & Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation+ supraclavicular lymph nodes irradiation) '
3219099|NCT01063374|Active Comparator|low glycemic index, diabetic diet|low glycemic index, diabetic diet
3219100|NCT01063374|Active Comparator|high cereal fibre, diabetic diet|high cereal fibre, diabetic diet
3219101|NCT01063361|Experimental|Low glycemic Index Diet|Low glycemic Index Diet, emphasizing pulses
3219102|NCT01063361|Active Comparator|High Cereal Fibre Diet|
3219103|NCT01063348|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine - 600mg tablets by mouth (dosing 1200mg - 3000mg qd)
3219104|NCT01063348|Placebo Comparator|Placebo|Matching placebo taken daily
3219105|NCT01063283|Active Comparator|Group A|Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg and bevacizumab every 3 weeks for two doses
3219106|NCT01063283|Active Comparator|Group B|Carboplatin and Pemetrexed with Bevacizumab 15 mg/kg and bevacizumab every 3 weeks for two doses
3219107|NCT01063270|Active Comparator|Antibiotics|
3219108|NCT01063270|Active Comparator|Antibiotics and Laser treatment|
3219109|NCT01063257|Experimental|Cohort A|Clofarabine treatment at D1-D5
3219110|NCT01063257|Experimental|Cohort B|Clofarabine treatment at D1, D3, D5, D8, D10
3219111|NCT01063244|Active Comparator|FoleyBalloon|foley balloon placed in the cervix
3219112|NCT01063244|Active Comparator|foley balloon with weight|foley balloon with weight attached
3219113|NCT01063231|Experimental|1|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
3219114|NCT01063218|Other|Emollient|Only one arm: Emollient (Cetaphil Advanced) to be applied twice a day
3219115|NCT01063205|Placebo Comparator|Placebo|
3219116|NCT01063205|Active Comparator|N-Acetylcysteine (NAC) 1800 mg|
3219117|NCT01063205|Active Comparator|N-Acetylcysteine (NAC) 3600 mg|
3219118|NCT01063192|Active Comparator|Gemcitabine|Arm 1: Gemcitabine alone
3219119|NCT01063192|Active Comparator|GOFL|Arm 2: GOFL (Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
3219120|NCT01063179|Experimental|Arm A: VMPT|Induction therapy with nine 5-week courses of VELCADE/Melphalan/Prednisone/Thalidomide (V-MPT) followed by maintenance therapy with Thalidomide and VELCADE
3219121|NCT01063179|Active Comparator|VMP|"Induction therapy with nine 5-week courses of either VELCADE/Melphalan/Prednisone (V-MP).~No maintenance is scheduled."
3219122|NCT01063153|Experimental|Concerta|Open-Label Concerta (Osmotic Release Methylphenidate)
3219123|NCT01063153|No Intervention|Control group|Healthy subjects without ADHD will be assessed using EEG.
3219124|NCT01063140||RabAvert|
3219125|NCT01063140||Imovax|
3219126|NCT01063127||1|group A: 10 morbidly obese subjects who will undergo gastric banding will be studied basally, 1 week after low-calorie diet and 1 week after operation.
3219127|NCT01063127||2|group B: 10 morbidly obese subjects who will undergo gastric bypass will be studied basally, 1 week after low-calorie diet and 1 week after operation.
3219128|NCT01063114|Experimental|Proton Beam Radiation|Proton Beam Radiation
3219129|NCT01063101|Experimental|BAX 513|Capsule - one of 5 dose levels (per randomization) - BID (= twice a day)
3219130|NCT01063101|Placebo Comparator|Capsule (cellulose)|Capsule - one of 5 dose levels (per randomization) - BID
3219131|NCT01063088|Experimental|Vaccination|Single 0.5 mL intramuscular injection of PreFluCel 2009/2010
3219132|NCT01063075|Experimental|Cetuximab and Carboplatin (D)|"Group D:~Cycle 1 (1 week, combination therapy):~400 milligrams per square meter (mg/m ²) cetuximab administered intravenously (I.V) on week 1,day 1. Carboplatin area under the curve (AUC=5) administered I.V on week 1,day 1.~Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/ m ²/day administered starting on week 1, day 1.~After 1 cycle, participants may then receive cetuximab as determined by clinical exam or radiological imaging studies until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~After protocol amendment February 2014, any newly enrolled participants were placed into Group D only."
3219133|NCT01063075|Experimental|Cetuximab and Carboplatin (C)|"Group C: Cycle 1 (4 weeks, combination therapy): Carboplatin (AUC=5) administered I.V on week 1, day 1.1000 mg/m ²/day 5-FU administered as a 96-hour C.I. starting on week 1, day 1.~400 mg/m² cetuximab administered I.V on week 2, day 1. 250 mg/m ² cetuximab administered I.V on week 3 and 4, day 1.~Cycle 2-6 (3 weeks, combination therapy): Carboplatin (AUC=5) administered I.V on week1,day1.1000 mg/m ²/d 5-FU as a 96-hour C.I. starting on week1, day1. 250 mg/m ² cetuximab administered I.V on Week 1-3, day 1.~After 6 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
3219134|NCT01063075|Experimental|Cetuximab and Carboplatin (B)|"Group B:~Cycle 1 (3 weeks, single-agent cetuximab):~400 mg/m² cetuximab administered I.V on week 1, day 1. 250 mg/m ² cetuximab administered I.V on weeks 2 and 3, day 1.~Cycle 2 (3 weeks, combination therapy):~Carboplatin (AUC=5) administered I.V week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 250 mg/m ² cetuximab administered I.V weeks 1- 3,day 1.~After 6 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011,any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
3219135|NCT01063075|Experimental|Carboplatin and Cetuximab (A)|"Group A:~Cycle 1 (3 weeks, combination therapy):~Carboplatin (AUC=5) administered I.V on week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1.~400 mg/m ² cetuximab administered I.V on week 2, day 1. 250 mg/m ² cetuximab administered I.V on week 3, day 1.~Cycle 2 (3 weeks, combination therapy):~Carboplatin (AUC=5) administered I.V on week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 250 mg/m ² cetuximab administered I.V on weeks 1- 3, day 1.~After 7 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
3219136|NCT01063062|Experimental|tocilizumab|Participants received an 8 mg/kg tocilizumab intravenous (IV) infusion once every 4 weeks for 24 weeks (6 infusions). Participants taking concomitant methotrexate (MTX) at Baseline remained on a stable dose as per standard of care at the Investigator's discretion.
3219137|NCT01063049|Active Comparator|Nulytely|Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
3219138|NCT01063049|Experimental|Gatorade/Miralax + Placebo|Gatorade 64 oz (1/2 gallon), Miralax 306 g and a placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy as follows: Miralax 51 g and placebo at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
3219139|NCT01063049|Experimental|Gatorade/Miralax + Bisacodyl|Gatorade 64 oz (1/2 gallon), Miralax 306 g and Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy as follows: Miralax 51 g and Bisacodyl 10 mg at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
3219140|NCT01063036|Experimental|Entecavir + Tenofovir|
3219141|NCT01063023|Active Comparator|Arm A - Ortho Tri-Cyclen®|1 to 28 days
3219142|NCT01063023|Active Comparator|Arm B - Ortho Tri-Cyclen®|29 to 56 days
3219143|NCT01063023|Active Comparator|Arm C - Ortho Tri-Cyclen® + BMS-650032|"Ortho Tri-Cyclen®: 57 to 77 days~BMS-650032: 68 to 77 days"
3219144|NCT01063010|Placebo Comparator|Placebo|Placebo IV for 90 minutes (+ 15 minutes)
3219145|NCT01063010|Experimental|Bevicizumab|IV infusion over 90 minutes
3219146|NCT01062984|Active Comparator|Continuous Venovenous Hemofiltration|
3219147|NCT01062984|Active Comparator|Continuous Venovenouos Hemodialysis|
3219148|NCT01062971|Active Comparator|A|IOP Dorzolamide-Timolol-Brimonidine group
3219149|NCT01062971|Active Comparator|B|IOP dorzolamide-timolol group
3219150|NCT01062958||Arm #1 (Test group)|50 subjects administered Neevo® or Neevo®DHA daily
3219151|NCT01062958||Arm #2 (Control group)|50 subjects administered a prenatal vitamin daily
3219152|NCT01062945|Placebo Comparator|Placebo|
3219153|NCT01062945|Active Comparator|Doxazosin|
3219154|NCT01062932|Placebo Comparator|Placebo|
3219155|NCT01062932|Active Comparator|Cycloserine|
3219156|NCT01062919|Experimental|Epidural analgesia group|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
3219157|NCT01062919|Experimental|Wound Group|patients in the epidural analgesia group will receive ropivacaine 0.2% through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
3219158|NCT01062906|Placebo Comparator|Control|The control group receives intravenous fentanyl at the induction of anesthesia followed by a continuous infusion of lidocaine during the surgery.
3219159|NCT01062906|Active Comparator|Lidocaine|The Lidocaine group will receive lidocaine as bolus at the induction of anesthesia followed by a continuous infusion of lidocaine until the end of surgery
3219160|NCT01062893|Placebo Comparator|0 mls saline injected|NO SALINE INJECTED
3219161|NCT01062893|Active Comparator|15 mls saline|15ML SALINE ADMINISTERED EPIDURALLY
3219162|NCT01062867|Experimental|ORG25435|Infusion of intravenous anaesthetic agent to induce anaesthesia
3219163|NCT01062854|Experimental|Earplugs|Subjects randomized to this arm of the study will wear earplugs during their baseline sleep study (polysomnogram).
3219164|NCT01062854|No Intervention|Comparison group|Subjects randomized to the comparison arm will not wear earplugs during their baseline sleep study.
3219165|NCT01062841|Active Comparator|Intervention: Targeted Infection Control|Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
3219166|NCT01062841|No Intervention|Control|Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.
3219167|NCT01062828||Gestational age < 32 weeks|Premature infants with gestational age between <32 weeks regardless of birth weight
3219168|NCT01062815|Experimental|Cycling Parenteral Nutrition|Infants in the intervention cycling group will receive infusion of carbohydrate/amino acids and intralipid over a 20-hour period. During the 4-hour window period, infants in this group will receive dextrose solution only at the same rate calculated for the carbohydrate/amino acid infusion.
3219169|NCT01062815|Active Comparator|Continuous Parenteral Nutrition|Infants in this control group will receive infusion of carbohydrates/amino acids and intralipids continuously, over 24 hours.
3219170|NCT01062802|Placebo Comparator|Placebo|
3219171|NCT01062802|Active Comparator|Statin group|
3219172|NCT01062789|Other|Use of an optical breath-hold control device|This is a feasibility study that will use this new device in place of a different bellows-based breath-hold control device for a series patients undergoing CT-guided lung biopsy. The new belt will be used in all patients in our study.
3219173|NCT01062776|Placebo Comparator|5 ml/kg of fluid, no dehydration|Volunteers receive an intravenous infusion of acetated Ringers solution over 15 min without preceding deliberate dehydration with furosemide.
3219174|NCT01062776|Placebo Comparator|10 ml/kg of fluid, no dehydration|Volunteers receive an intravenous infusion of acetated Ringers solution over 15 min without preceding deliberate dehydration with furosemide.
3219175|NCT01062776|Experimental|5 ml/kg of fluid, dehydration|Volunteers receive an intravenous infusion of 5 ml/kg acetated Ringers solution over 15 min after being dehydrated with furosemide.
3219176|NCT01062776|Experimental|10 ml/kg of fluid, dehydration|Volunteers receive an intravenous infusion of 10 ml/kg acetated Ringers solution over 15 min after being dehydrated with furosemide.
3219177|NCT01062763|Experimental|addition of spironolactone|spironolactone is added to previous antihypertensive treatment
3219178|NCT01062763|Placebo Comparator|Placebo|Addition of placebo
3219179|NCT01062750|Other|adipose tissue derived stromal cells|
3219180|NCT01062737|Experimental|ASU (Avocado Soybean Unsaponifiable)|
3219181|NCT01062724|No Intervention|Trophamine|This group of neonates will be receive the Trophamine amino acids solution from Pisa laboratories as an active comparator with Primene. The infants in this group will receive, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat or daily enteral intake (ml/kg/d). Besides, the intake of breast milk or formula will be record, during the first 28 days of total parenteral nutrition.
3219182|NCT01062724|Experimental|Primene 10% from Baxter|This group of neonates will be receive the Primene amino acids solution (10 %) from Baxter laboratories as other active comparator with Trophamine. The infants in this group will receive, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat or daily enteral intake (ml/kg/d). Besides, the intake of breast milk or formula will be record, during the first 28 days of total parenteral nutrition.
3219183|NCT01062711|Other|Control group 0 g protein|Control group in which a placebo drink containing no protein is given following unilateral knee extension exercise
3219184|NCT01062711|Experimental|10g whey|10g whey protein given following unilateral knee extension exercise
3219185|NCT01062711|Experimental|20g whey|20g whey protein given following unilateral knee extension exercise
3219186|NCT01062711|Experimental|30g whey|30g whey protein given following unilateral knee extension exercise
3219187|NCT01062711|Experimental|40g whey|40g whey protein given following unilateral knee extension exercise
3219188|NCT01062711|Experimental|20g soy|20g soy protein given following unilateral knee extension exercise
3219189|NCT01062711|Experimental|40g soy|40g soy protein given following unilateral knee extension exercise
3219190|NCT01062698|Active Comparator|IV thrombolysis + thrombectomy|
3219191|NCT01062698|Active Comparator|IV thrombolysis|
3219192|NCT01062685||Shock Cohort|"The SHOCK cohort will meet the American College of Chest physicians/Society of Critical Care Medicine criteria for septic shock, specifically:~1) Suspected infection~2) Any two of four criteria of systemic inflammatory response:~a. Temperature > 100.4° or < 96.8° F~b. Heart rate > 90 beats/minute~c. Respiratory rate > 20 breaths/min. or PaCO2 < 32 mm Hg~d. WBC >12,000 or < 4000 cells/µL or > 10% bands~3) Hypotension despite adequate fluid resuscitation:~a. SBP < 90 mm Hg after 20cc/kg crystalloid"
3219239|NCT01062360|Placebo Comparator|Arm 4|
3219193|NCT01062685||Sepsis cohort|"The SEPSIS cohort will to meet:~1) Suspected infection~2) Any two of four criteria of systemic inflammatory response:~a. Temperature > 100.4° or < 96.8° F~b. Heart rate > 90 beats/minute~c. Respiratory rate > 20 breaths/min. or PaCO2 < 32 mm Hg~d. WBC >12,000 or < 4000 cells/µL or > 10% bands~3) Absence of refractory hypotension"
3219194|NCT01062685||Non-Infected controls|The third cohort will be comprised of uninfected ED control patients who met the criteria of no suspected infection, no SIRS criteria met and no evidence of hypoperfusion that are age and sex matched on a 1:1 basis with the shock cohort.
3219195|NCT01062659||chronic Hepatitis C|Patients with chronic Hepatitis C (CHC) Genotype 1-4 who are naive to antiviral treatment
3219196|NCT01062646|Experimental|Multimodal music therapy|Multimodal music therapy comprises 16 sessions single music therapy, group music therapy (max. 6 children/group), parent-child sessions, and parent counseling. The manualized treatment integrates music therapy, behavioral interventions, and family-oriented interventions.
3219197|NCT01062646|Active Comparator|community treatment as usual|
3219198|NCT01062633|Experimental|A, observation|dietary supplement
3219199|NCT01062633|Experimental|B|dietary supplement
3219200|NCT01062633|Experimental|C|dietary supplement
3219201|NCT01062620|Experimental|AXL1717|
3219202|NCT01062607||1|Patients diagnosed with Bipolar Disorder I or II (DSM-IV-TR) at any phase of the disorder with at least one mood event during the 12 months before the study start.
3219203|NCT01062607||2|Patients diagnosed with Bipolar Disorder I or II (DSM-IV-TR) at any phase of the disorder with at least one mood event during the 12 months before the study start receiving Seroquel extended release at some point during the retrospective period .
3219204|NCT01062594|Active Comparator|Supervised exercise group|
3219205|NCT01062594|No Intervention|Control group - no exercise|
3219206|NCT01062581||Transplant Recipients and Living Donors|"All transplant recipients receiving transplants at the University of Minnesota (kidney, pancreas, liver, heart, lung, islet, intestine). All ages.~All living donors donating an organ at the University of Minnesota (kidney, pancreas, liver, lung) (by law, living donors are required to be at least 18 years old)"
3219207|NCT01062568|Experimental|Obese group|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after ACTH, blood samples will be obtained for repeat hormone measurements.
3219208|NCT01062568|Experimental|Nonobese group|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after ACTH, blood samples will be obtained for repeat hormone measurements.
3219209|NCT01062555|Active Comparator|Phase I|
3219210|NCT01062555|Active Comparator|Phase I Substudy|The substudy is for patients who need to be on steroids long term
3219211|NCT01062555|Experimental|Phase II|
3219212|NCT01062555|Experimental|Phase II Substudy|The substudy is for patients who need to be on steroids long term
3219213|NCT01062542||Breast Cancer Survivors|
3219214|NCT01062542||Pediatric Cancer Survivors|
3219215|NCT01062542||Control group|
3219216|NCT01062529|Experimental|somatostatin|
3219217|NCT01062516|Active Comparator|1|oral esomeprazole 20 mg daily
3219218|NCT01062516|Active Comparator|2|oral famotidine 40mg daily
3219219|NCT01062490|Experimental|Treosulfan|Patients with myelodysplastic syndrome, (MDS) according to WHO classification (< 20 % myeloblasts in peripheral blood or bone marrow at initial diagnosis) indicated for allogeneic transplantation
3219220|NCT01062477|Experimental|Study Group 1|Participants will receive ACTACEL vaccine at 2, 3, and 4 months of age.
3219221|NCT01062477|Experimental|Study Group 2|Participants will receive ACTACEL vaccine at 3, 4, and 5 months of age.
3219222|NCT01062477|Active Comparator|Study Group 3|Participants will receive Wuhan DTaP and Act-HIB vaccines concomitantly at 3, 4 and 5 months of age.
3219223|NCT01062451|Placebo Comparator|Placebo|
3219224|NCT01062451|Active Comparator|Perindopril|
3219225|NCT01062451|Active Comparator|Candesartan|
3219226|NCT01062425|Experimental|Cediranib, TMZ, and RT|Cediranib (3 days) followed by radiation therapy (RT) + daily temozolomide (TMZ) + cediranib followed by cediranib monotherapy (4 weeks) followed by TMZ + cediranib for 12 cycle maximum.
3219227|NCT01062425|Active Comparator|Placebo, TMZ, and RT|Placebo (3 days) followed by radiation therapy (RT) + daily temozolomide (TMZ) + placebo followed by placebo monotherapy (4 weeks) followed by TMZ + placebo for 12 cycle maximum.
3219228|NCT01062399|Experimental|Ph I: RT + TMZ + RAD001 2.5 mg/day|Radiation therapy (RT), concurrent temozolomide (TMZ), and concurrent RAD001 2.5 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
3219229|NCT01062399|Experimental|Ph I: RT + TMZ + RAD001 5 mg/day|Radiation therapy, concurrent temozolomide, and concurrent RAD001 5 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
3219230|NCT01062399|Experimental|Ph I: RT + TMZ + RAD001 10 mg/day|Radiation therapy, concurrent temozolomide, and concurrent RAD001 10 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
3219231|NCT01062399|Active Comparator|Ph II: RT + TMZ|Radiation therapy and concurrent temozolomide followed by post-radiation temozolomide
3219232|NCT01062399|Experimental|Ph II: RT + TMZ + RAD001|Radiation therapy, concurrent temozolomide, and concurrent RAD001 10 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
3219233|NCT01062373|Active Comparator|TG-DHA|TG-DHA: lactating mothers and their newborn with mothers supplemented with Triglyceride enriched in docosahexaenoic acid
3219234|NCT01062373|No Intervention|Control|Control: lactating mothers and their newborn with no supplementation given to the mother
3219235|NCT01062373|Experimental|GPL-DHA|GPL-DHA: lactating mothers and their newborn with mothers supplemented with Glycerophospholipid enriched in docosahexaenoic acid
3219236|NCT01062360|Experimental|Arm 1|
3219237|NCT01062360|Active Comparator|Arm 2|
3219238|NCT01062360|Active Comparator|Arm 3|
3219240|NCT01062347|Experimental|zinc supplementation (20 mg/d, for 7 d)|
3219241|NCT01062334|Experimental|Microdialysis|
3219242|NCT01062321||Hepatitis-E, Pregnant & Non-pregnant|Pregnant,Acute Viral Hepatitis, Fulminant Hepatic Failure
3219243|NCT01062308|Experimental|Taping|The tri-pull method of taping was used.Taping was initiated by first applying three, two-inch wide and approximately ten-inch long, pieces of elastic adhesive tape strips. The first strip was applied from the mid-humerus deltoid tuberosity across the scapula. The second strip was applied from the deltoid tuberosity across the clavicle to the mid-clavicle, but before the supra-sternal notch. The third strip was placed from the deltoid tuberosity over the acromion process to the neck.
3219244|NCT01062308|Active Comparator|Sham Taping|This was done using the same tapes. Three strips of tapes were applied in same position without repositioning the joint. All other Physiotherapy measures like positioning, handling technique and range of motion exercises were equally done for both the groups.
3219245|NCT01062295|Experimental|Siesta-System|Use of Siesta-System
3219246|NCT01062295|Active Comparator|Standard headrest|Use of standard headrest
3219247|NCT01062282||Group 1|
3219248|NCT01062269|Active Comparator|Cholestyramine 4 grams|
3219249|NCT01062269|Active Comparator|Cholestyramine 12 grams|
3219250|NCT01062269|Placebo Comparator|Tang|
3219251|NCT01062256|Placebo Comparator|Placebo|Placebo
3219252|NCT01062256|Experimental|Guaifenesin|Guaifenesin
3219253|NCT01062256|Experimental|Buckwheat Honey|Buckwheat Honey
3219254|NCT01062243|Experimental|Brain Injury Education|The Brain Injury Inpatient Guide for Families and Caregivers (BIIG-FACS), developed by J. Niemeier and J. Kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation.
3219255|NCT01062230|Experimental|All patients|All participants enrolled.
3219256|NCT01062191|Experimental|Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing|Nanoflex Powder Dressing applied to joint
3219257|NCT01062191|Active Comparator|Aquacel AG, typical carboxymethylcellulose dressing|Sodium CMC dressing control applied to joint
3219258|NCT01062178|Experimental|comparison to biopsy|Comparing contrast enhanced US with biopsy result
3219259|NCT01062165|Experimental|Capsofungin|Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
3219260|NCT01062152|Experimental|Revlimid® in Combination with Telintra ®|Lenalidomide (Revlimid®) followed by Telintra® until MDS progression or lack of efficacy.
3219261|NCT01062139|Experimental|Petasites extract, levocetirizine|Cosalin (Petasites hybridus CO2 extract), Xarlin (levocetirizine) combination therapy group
3219262|NCT01062139|Active Comparator|Cosalin (Petasites hybridus CO2 extract)|Cosalin monotherapy
3219263|NCT01062113|Experimental|Celecoxib 400mg|
3219264|NCT01062113|Experimental|Celecoxib 200mg|
3219265|NCT01062113|Placebo Comparator|Placebo|
3219266|NCT01062100|Experimental|nuclear breast imaging|nuclear breast imaging using MBI Gamma camera
3219267|NCT01062087||Local anesthetic|Women who received local anesthetic during surgery in addition to general anesthesia
3219268|NCT01062087||No local anesthetic|Women who did not receive any local anesthetic during surgery, but did have general anesthesia
3219269|NCT01062074||Korean Participants Vaccinated with GARDASIL|Females and males 9-26 years old who are vaccinated with GARDASIL in usual practice. The GARDASIL vaccination series consists of three 0.5-mL intramuscular injections. The second and third doses are to be administered 2 months and 6 months after the first dose, respectively.
3219270|NCT01062061||VARIVAX|Attenuated live varicella vaccine was administered in usual practice. Recommended dosing is a single 0.5 mL subcutaneous injection in children 12 months to 12 years of age.
3219271|NCT01062048||All participants|Participants administered Januvia up to 100 mg once daily as monotherapy or combination therapy with a sulfonylurea or with insulin during the re-examination period (up to 6 years)
3219272|NCT01062035||ACP (advanced colon polyp) Group|Between the ages of 50 and 60 years old and have an ACP (advanced colon polyp)
3219273|NCT01062035||Control Group|Individuals between the ages of 50 and 60 years old who have had a negative screening colonoscopy.
3219274|NCT01062022|Active Comparator|Control - Standard of Care|Participation in the study will involve your child completing a questionnaire about (a) your family's background, descriptive information about people in your family, and previous major life events, (b) his/her current functioning, (c) his/her feelings before, during, and after the combat injury, and (d) his/her current social relationships and adjustment. Your child will be asked to complete the questionnaire during the baseline assessment, and at 6 months, 12 months, and 24 months after the original assessment.
3219275|NCT01062022|Active Comparator|FOCUS-CI|Those participants in the FOCUS-CI intervention will be part of a family skill-building/resiliency training program designed to provide information and skills training in a variety of forms, including clinician-led sessions, handouts, on-line training modules, and individual family care management. Study participation will also involve completing a questionnaire about (a) your family's background, descriptive information about people in your family, and previous major life events, (b) his/her current functioning, (c) his/her feelings before, during, and after the combat injury, and (d) his/her current social relationships and adjustment. Questionnaires will be completed during the baseline assessment, and at 6 months, 12 months, and 24 months after the baseline assessment.
3219276|NCT01062009|No Intervention|Control group|No intervention
3219277|NCT01062009|Active Comparator|Low dose group|250 mcg/kg/day supplemental IV zinc sulfate divided every 8 hours for 7 days
3219278|NCT01062009|Active Comparator|Medium dose group|500 mcg/kg/day supplemental IV zinc sulfate q8 hours for 7 days
3219279|NCT01062009|Active Comparator|High dose group|750 mcg/kg/day supplemental IV zinc sulfate q8 hrs for 7 days
3219280|NCT01061996|Experimental|1|
3219281|NCT01061983|Experimental|Deep Brain Stimulation|Participants will receive deep brain stimulation.
3219282|NCT01061957||Raltegravir patients|HIV patients who initiated raltegravir due to virological failure
3219283|NCT01061957||Haart naive patients|HIV patients initiating HAART for the first time
3219284|NCT01061931|Active Comparator|Arctic Front® catheter|
3219285|NCT01061931|Active Comparator|HD Mesh Ablator® catheter|
3219286|NCT01061918|Active Comparator|Tecnis MF|
3219287|NCT01061918|Active Comparator|ReSTOR|
3219288|NCT01061905|Experimental|Calorie information only|Posting calorie information of sugar-sweetened and zero-calorie beverages prominently on a poster.
3219289|NCT01061905|Experimental|Exercise Equivalent Information|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
3219290|NCT01061905|Experimental|Calorie and Exercise Equivalent information|Posting of both calorie and exercise equivalent information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
3219291|NCT01061866|Experimental|Thalidomide|Open-labeled preliminary trial
3219292|NCT01061853|Experimental|T|TOPICAL SIROLIMUS AND PETROLATUM IN ORABASE
3219293|NCT01061853|Active Comparator|C|TOPICAL BETAMETHASONE 0.05% in ORABASE AND PHOSAL
3219294|NCT01061840|Experimental|1 x 10 ^7 cells/injection|Vigil™
3219295|NCT01061840|Experimental|2.5 x 10 ^7 cells/injection|Vigil™
3219296|NCT01061840|Experimental|1 x 10^6 or 4 x 10^6 cells/injection|Vigil™
3219297|NCT01061827||Dementia|
3219298|NCT01061827||Depression|
3219299|NCT01061827||Control|
3219300|NCT01061814|Experimental|mipomersen|30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) SC daily
3219301|NCT01061814|Placebo Comparator|Placebo|30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) SC daily
3219302|NCT01061801|Experimental|Emotional expression, patient present|Caregivers are asked to talk about their deepest thoughts and feelings regarding the patient's transplant and their role as caregiver, in the presence of the patient (one session).
3219303|NCT01061801|Experimental|Emotional expression, patient absent|Caregivers are asked to talk about their deepest thoughts and feelings regarding the patient's transplant and their role as caregiver, in the absence of the patient (3 sessions).
3219304|NCT01061801|Active Comparator|Comparison|Caregivers are asked to talk about their plans for the upcoming week (time management, sessions 1 and 3) and positive aspects of their life (session 2).
3219305|NCT01061788|Experimental|Everolimus, AMG 479, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLC Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
3219306|NCT01061775|Experimental|Exenatide|5mcg of exenatide will be given twice a day for 4 weeks and increased to 10 mcg twice a day for 20 weeks.
3219307|NCT01061762|Experimental|Low Literacy Adherence Counseling|3-counseling sessions for medication adherence improvement tailored for people with poor literacy
3219308|NCT01061762|Active Comparator|Standard Adherence Counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
3219309|NCT01061762|Active Comparator|Health Counseling Comparison|3-sessions of health improvement counseling.
3219310|NCT01061749|Experimental|Treatment (selumetinib, cixutumumab)|Patients receive selumetinib PO BID on days 1-28 and cixutumumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3219311|NCT01061736|Experimental|Part A: SAR 100 mg qw|Sarilumab 100 mg subcutaneous (SC) injection weekly (qw) on top of MTX for 12 weeks.
3219312|NCT01061736|Experimental|Part A: SAR 150 mg qw|Sarilumab 150 mg SC injection qw on top of MTX for 12 weeks.
3219313|NCT01061736|Experimental|Part A: SAR 100 mg q2w|Sarilumab 100 mg SC injection every other week (q2w) alternating with placebo on top of MTX for 12 weeks.
3219314|NCT01061736|Experimental|Part A: SAR 150 mg q2w|Sarilumab 150 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.
3219315|NCT01061736|Experimental|Part A: SAR 200 mg q2w|Sarilumab 200 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.
3219316|NCT01061736|Placebo Comparator|Part A: Placebo qw|Placebo (for sarilumab) qw on top of MTX for 12 weeks.
3219317|NCT01061736|Experimental|Part B Cohort 1: Non-selected Doses|Sarilumab 100 mg qw, 150 mg qw or 100 mg q2w SC injections as in Part A on top of MTX up to dose selection. After dose selection, participants were not continued but were allowed to participate in the open-label, long-term, extension study SARIL-RA-EXTEND (LTS11210).
3219318|NCT01061736|Experimental|Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2)|Sarilumab 150 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
3219319|NCT01061736|Experimental|Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)|Sarilumab 200 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
3219320|NCT01061736|Experimental|Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2)|Placebo (for sarilumab) q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
3219321|NCT01061723|Placebo Comparator|Placebo|Placebo (for sarilumab) weekly (qw) for 12 weeks.
3219322|NCT01061723|Experimental|Sarilumab 100 mg q2w|Sarilumab 100 mg Subcutaneous (SC) injection alternating with placebo every other week (q2w) for 12 weeks.
3219323|NCT01061723|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg SC injection alternating with placebo q2w for 12 weeks.
3219324|NCT01061723|Experimental|Sarilumab 100 mg qw|Sarilumab 100 mg SC injection qw for 12 weeks.
3219325|NCT01061723|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection alternating with placebo q2w for 12 weeks.
3219326|NCT01061723|Experimental|Sarilumab 150 mg qw|Sarilumab 150 mg SC injection qw for 12 weeks.
3219327|NCT01061710||varenicline (Champix®)|Subjects who have been retreated with varenicline within 52 weeks and have been enrolled to varenicline protocol A3051109.
3219328|NCT01061684||NAFLD|pediatric patients with non-alcoholic fatty liver disease (NAFLD).
3219329|NCT01061671|Active Comparator|simvastatin|40 mgms of simvastatin daily
3219330|NCT01061671|Placebo Comparator|placebo|Matched placebo pill daily
3219331|NCT01061658|Experimental|Vaccine - High dosage|
3219332|NCT01061658|Experimental|Vaccine - Lower dosage|
3219333|NCT01061658|Placebo Comparator|Placebo|
3219334|NCT01061645|Experimental|MOC31-PE|
3219335|NCT01061606|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3219336|NCT01061593|Experimental|ATT+Immunoxel|TB patients with DS-TB, MDR-TB, XDR-TB or TB-HIV on standard ATT + Immunoxel honey lozenge once per day day
3219337|NCT01061593|Placebo Comparator|ATT+Placebo|TB patients with DS-TB, MDR-TB, XDR-TB or TB-HIV on standard ATT + Placebo lozenge made of corn syrup once/day
3219338|NCT01061580|Experimental|CABG plus BMAC Injection|Injection of Bone Marrow Aspirate Concentrate (BMAC) into ischemic myocardium following CABG during the same open procedure
3219339|NCT01061567||Male and female patients with Parkinson's disease|
3219340|NCT01061554|Experimental|Gastric stable emulsion|A gastric stable emulsion vehicle for administration of tri-glyceride based omega-3 oils
3219341|NCT01061554|Active Comparator|Soft gel capsule (TG)|Soft gel capsule for administration of tri-glyceride based omega-3 oils
3219342|NCT01061554|Active Comparator|Soft gel capsules (MPL)|Soft gel capsule for administration of marine phospholipids based omega-3 oils
3219343|NCT01061541|Experimental|Group A|
3219344|NCT01061541|Active Comparator|Group B|
3219345|NCT01061528|Experimental|New Smoking Cessation Counseling|"One 60-minute individual session~Seven 2-hour group sessions~Two individual brief telephone contacts over an eight-week period.~Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue even after the treatment sessions have ended. Standard nicotine patch dosing will be used."
3219346|NCT01061528|Active Comparator|Standard Smoking Cessation Counseling|"One 60-minute individual session~Seven 2-hour group sessions~Two individual brief telephone contacts over an eight-week period.~Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue even after the treatment sessions have ended. Standard nicotine patch dosing will be used."
3219347|NCT01061515|Experimental|Dose Level 1|"Intraperitoneal oxaliplatin 25 mg/m2 IP on day 1 of each cycle~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle~Capecitabine 850 mg/m2 PO BID on days 1-7 of each cycle.~Each cycle is 14 days long."
3219348|NCT01061515|Experimental|Dose Level 2|"Intraperitoneal oxaliplatin 50 mg/m2 IP on day 1 of each cycle~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle~Capecitabine 850 mg/m2 PO BID on days 1-7 of each cycle.~Each cycle is 14 days long."
3219349|NCT01061515|Experimental|Dose Level 3|"Intraperitoneal oxaliplatin 65 mg/m2 IP on day 1 of each cycle~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle~Capecitabine 850 mg/m2 PO BID on days 1-7 of each cycle.~Each cycle is 14 days long."
3219350|NCT01061515|Experimental|Dose Level 4|"Intraperitoneal oxaliplatin 85 mg/m2 IP on day 1 of each cycle~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle~Capecitabine 850 mg/m2 PO BID on days 1-7 of each cycle.~Each cycle is 14 days long."
3219351|NCT01061515|Experimental|Dose Level 5|"Intraperitoneal oxaliplatin 100 mg/m2 IP on day 1 of each cycle~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle~Capecitabine 850 mg/m2 PO BID on days 1-7 of each cycle.~Each cycle is 14 days long."
3219352|NCT01061502|Experimental|Procellera Wound Dressing|Dressing indicated for partial and full-thickness wounds. Dressing changes every 5-7 days, more frequently if needed
3219353|NCT01061502|Active Comparator|Opsite Transparent Adhesive Dressing|Polyurethane film dressing. Dressing changes every 5-7 days, more frequently if needed
3219354|NCT01061489|Experimental|sensory-cognitive training|
3219355|NCT01061489|Experimental|physical fitness|
3219356|NCT01061489|No Intervention|waiting list (control group)|
3219357|NCT01061476|Other|Single arm - Sleep apnea|"Participants with sleep apnea will be recruited for the study. Each participant will undergo 3 sleep studies to assess the effect of the Provent™ device. Participants will only use the device while they are in the sleep laboratory. They will not use the device at home between sleep studies .~Baseline sleep study (No device) - Assess the effects of no Provent™ on sleep apnea severity.~Treatment sleep study (Provent™ device used) - Assess the effects of Provent™ on sleep apnea severity~Physiology sleep study (Provent™ on/off) - Assess the physiological effects of the Provent™ device on breathing during sleep."
3219358|NCT01061463||Exposed group|French coronary interventional cardiologists and cardiologists specializing in cardiac arrhythmias treatments (electrophysiologists), occupationally exposed to X-Rays
3219359|NCT01061463||Unexposed group|French non-interventional cardiologists and non medical workers, not occupationally exposed to X-Rays
3219360|NCT01061450|Placebo Comparator|Placebo|Placebo
3219361|NCT01061450|Experimental|Simvastatin|Simvastatin 80 mg/day
3219362|NCT01061437|Active Comparator|Arm 1|Standard 14 day, 3-drug regimen
3219363|NCT01061437|Experimental|Arm 2|Concomitant Therapy - 5 day, 4-drug regimen
3219364|NCT01061437|Experimental|Arm 3|Sequential Therapy - 10 day, 4-drug regimen
3219365|NCT01061424|Active Comparator|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
3219366|NCT01061424|Experimental|community health worker|community health worker provides home visits for education
3219367|NCT01061411|Experimental|Treatment (sunitinib malate, dalteparin)|Patients receive sunitinib malate PO QD in weeks 1-4 and dalteparin SC QD in week 6 during course 1. In all subsequent courses, patients receive sunitinib malate PO QD in weeks 1-4 and dalteparin SC QD in weeks 1-6. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3219368|NCT01061398|Experimental|Cardiac CT Arm|Patients referred for stress imaging due to complaints consistent with possible angina, randomized to receive an additional cardiac CT scan.
3219369|NCT01061398|Active Comparator|No CT Arm|Patients with symptoms consistent with possible angina, randomized to receive the type of stress imaging test ordered by their physician.
3219370|NCT01061385|Experimental|ReShape Intragastric Balloon|Patients receiving the ReShape Intragastric Balloon
3219371|NCT01061385|Other|Control Arm|Weight loss using behavior modification (diet and exercise counseling) alone
3219372|NCT01061372|Placebo Comparator|Placebo|
3219373|NCT01061372|Experimental|Pregabalin 150 mg/day|
3219374|NCT01061372|Experimental|Pregabalin 300 mg/day|
3219435|NCT01060943|Experimental|TheraFill|atelocollagen filler
3219375|NCT01061359||Non-Interventional Study|Chemotherapy containing Epirubicin
3219376|NCT01061346|Experimental|High Fat Diet with Fructose|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
3219377|NCT01061346|Experimental|High Fat Diet with Glucose|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
3219378|NCT01061346|Experimental|Low Fat Diet with Glucose|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein.
3219379|NCT01061333|Experimental|Placebo|Placebo
3219380|NCT01061333|Experimental|Montelukast|Montelukast
3219381|NCT01061333|Experimental|Nedocromil|Nedocromil
3219382|NCT01061333|Experimental|Mometasone|Mometasone
3219383|NCT01061320|Active Comparator|alpha tocopherol|
3219384|NCT01061320|Placebo Comparator|placebo|
3219385|NCT01061307|Experimental|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
3219386|NCT01061294|Other|Advanced CustomVue™ iLASIK procedure|
3219387|NCT01061281|Active Comparator|Tecnis MF IOL|
3219388|NCT01061281|Active Comparator|Crystalens AO IOL|
3219389|NCT01061268|Experimental|BLINK™ tears|
3219390|NCT01061268|No Intervention|No topical artificial tear|
3219391|NCT01061242|No Intervention|Baseline|Post-Intensive Care Unit (ICU) neurocognitive testing and sleep survey performed on patients exposed to ad-lib Medical ICU environment.
3219392|NCT01061242|Experimental|Sleep Promotion Group|Post-ICU neurocognitive testing and sleep survey performed on patients exposed to interventions in the pre-existing MICU sleep quality improvement project.
3219393|NCT01061229|Experimental|Homeopathic drug, potency C12|
3219394|NCT01061229|Placebo Comparator|Placebo|
3219395|NCT01061216|Experimental|Intradermal insulin infusion (ID)|
3219396|NCT01061216|Active Comparator|Subcutaneous insulin infusion (SC)|
3219397|NCT01061203|Active Comparator|Grazax|Grazax tablet 75.000 SQ-T. One tablet per day for administration under the tongue.
3219398|NCT01061203|Placebo Comparator|Tablet with no active grass|Tablet with no active grass component. One tablet per day administered under the tongue.
3219399|NCT01061190|Active Comparator|Propranolol|
3219400|NCT01061190|Placebo Comparator|Placebo|
3219401|NCT01061177|Experimental|Nilotinib|This was a single-arm study; therefore all participants received nilotinib (AMN107) 300 mg bid given as two 150 mg capsules twice daily.
3219402|NCT01061164||HIV-infected infants, children, and adolescents|Infants, children, and adolescents with HIV infection who have participated in PACTG 219C and/or select IMPAACT studies.
3219403|NCT01061151|Active Comparator|Antepartum Arm A|Mothers received ZDV + sdNVP + TRV Tail
3219404|NCT01061151|Experimental|Antepartum Arm B|Mothers received Triple ARV (3TC-ZDV + LPV-RTV)
3219405|NCT01061151|Experimental|Antepartum Arm C|Mothers received Triple ARV (TRV + LPV-RTV)
3219406|NCT01061151|Other|Late Presenters|Registration to facilitate a structure to screen women and infants for randomization in the Postpartum Component.
3219407|NCT01061151|Experimental|Postpartum Arm A (Maternal Prophylaxis)|Mothers received prophylaxis [preferred regimen: TRV + LPV-RTV]. Infants received short-course NVP.
3219408|NCT01061151|Experimental|Postpartum Arm B (Infant Prophylaxis)|Infants received extended NVP.
3219409|NCT01061151|Experimental|Maternal Health Arm A (Continue triple ARVs)|Mothers continued receiving triple ARV regimen [preferred regimen: TRV + LPV-RTV].
3219410|NCT01061151|Active Comparator|Maternal Health Arm B (Discontinue triple ARVs)|Mothers discontinued triple ARV regimen.
3219411|NCT01061138||Screening Patients|Female patients scheduled for routine annual screening mammograms
3219412|NCT01061138||Biopsy Patients|Female patients scheduled for routine breast biopsy procedures
3219413|NCT01061125||Unblinded|Transtelephonic (TTM) monitoring weekly for 5 months Holter monitor recording at 4 months and at 12 months Implantable Loop Recorder (ILR) weekly reports
3219414|NCT01061125||Blinded|TTM and Holter Monitor conventional follow up Implantable Loop Recorder (ILR) unblinded at 5 months
3219415|NCT01061112||Crossover|Three study periods for all subjects.
3219416|NCT01061099|Active Comparator|Stratum A|Subjects with a diagnosis of Type II or Type III osteogenesis imperfecta who have previously undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.
3219417|NCT01061099|Active Comparator|Stratum B|Subjects with Type II or III osteogenesis imperfecta who have not undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.
3219418|NCT01061086||1|Patients over 18 years old admitted to the hospital with Acute Coronary Syndrome.
3219419|NCT01061073|Experimental|Omexel|
3219420|NCT01061073|Active Comparator|spasfon|
3219421|NCT01061060|Experimental|Beraprost group|Prostaglandin I2
3219422|NCT01061060|Placebo Comparator|Placebo group|
3219423|NCT01061021|Experimental|Integrated Intervention|Five small group + 2 individual counseling behavioral intervention to simultaneously address HIV transmission risk reduction and HIV treatment adherence in men and women living with HIV/AIDS.
3219424|NCT01061021|Active Comparator|Comparison Group|Five small group + 2 individual counseling session intervention that serves as an attention control group. Content included stress reduction, nutrition, and exercise for health improvement.
3219425|NCT01061008|Experimental|Handgrip exercise|Handgrip exercise - patients allocated to this intervention will carry out an eight week post operative progressive handgrip exercise training program
3219426|NCT01061008|Active Comparator|Treatment as usual|
3219427|NCT01060995||SmartConsent|Subjects receiving SmartConsent informed consent
3219428|NCT01060995||Standard consent|Subjects receiving standard consent
3219429|NCT01060982|Experimental|HIFU treatment|
3219430|NCT01060969|Active Comparator|Acetazolamide|acetazolamide 125 mg BID
3219431|NCT01060969|Experimental|Acetazolamide and Tadalafil|Intervention arm
3219432|NCT01060956|Active Comparator|Reporting on two bacteria in urine culture|The microbiology laboratory will report on the isolation and susceptibilities of two different bacteria in urine culture
3219433|NCT01060956|Placebo Comparator|"reporting mixed growth"|The microbiology laboratory will report on mixed growth in urine culture
3219434|NCT01060943|Active Comparator|KOKEN(collagen)|atelocollagen filler
3219436|NCT01060930|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust ~ 300 mcg/m3 - during intermittent exercise
3219437|NCT01060930|Experimental|Air exposure|1 hour exposure to filtered air during intermittent exercise
3219438|NCT01060904|Experimental|1|brentuximab vedotin combined with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
3219439|NCT01060904|Experimental|2|brentuximab vedotin combined with AVD (doxorubicin, vinblastine, dacarbazine)
3219440|NCT01060878|Experimental|Dose I|
3219441|NCT01060878|Experimental|Dose II|
3219442|NCT01060878|Experimental|Dose III|
3219443|NCT01060878|Placebo Comparator|Placebo|
3219444|NCT01060865|Experimental|Aliskiren|only one arm with the experimental drug [aliskiren]
3219445|NCT01060852|Experimental|Media Detective|10-lesson elementary school, substance use prevention program developed based upon the Message Interpretation Processing model designed to increase children's critical thinking skills about media messages and reduce intent to use tobacco and alcohol products.
3219446|NCT01060839|Experimental|Single session counseling|
3219447|NCT01060839|No Intervention|Standard of care|
3219448|NCT01060826|Experimental|somatostatin, intravenous bolus|A double- blind study designed to evaluate if the treatment with somatostatin in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will be randomized in two groups of treatment, one will receive somatostatin and another placebo.
3219449|NCT01060826|Placebo Comparator|Placebo, intravenous bolus|A double- blind study designed to evaluate if the treatment with somatostatin in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will be randomized in two groups of treatment, one will receive somatostatin and another placebo.
3219450|NCT01060813|Active Comparator|Exercise + Leucine|Patients will receive leucine 10 g/d po + exercise for 3 months
3219451|NCT01060813|Active Comparator|Leucine without exercise|patients will receive leucine 10 g/d po
3219452|NCT01060787||Fluocinolone Acetonide 0.59 mg|Participants who have had the fluocinolone acetonide (FA) drug delivery system 0.59 mg surgically implanted in the ocular vitreous chamber of one (1) eye for at least one (1) year.
3219453|NCT01060787||Fluocinolone Acetonide 2.1 mg|Participants who have had the fluocinolone acetonide (FA) drug delivery system 2.1 mg surgically implanted in the ocular vitreous chamber of one (1) eye for at least one (1) year.
3219454|NCT01060774|Experimental|Bupivacaine|0.5% bupivacaine/1:200,000 epinephrine
3219455|NCT01060774|Experimental|Lidocaine|2% lidocaine/1:200,000 epinephrine
3219456|NCT01060761|Active Comparator|Rehabilitation program|Counselling (supportive conversation with patient and their relatives together) Retreat Weekend (patient and their relatives together)
3219457|NCT01060761|No Intervention|Ususal treatment and support|Usual support and treatment at the hospital, no retreat Weekend.
3219458|NCT01060748|Experimental|ACE527|"First cohort: ACE527 vaccine doses of 9 x 10E10 cfu on study day 0 and 21 on an outpatient basis.~Second cohort: ACE527 vaccine dose of 9 x 10E10 cfu on study day 0 and 21 on an outpatient basis."
3219459|NCT01060748|Placebo Comparator|Placebo vaccine|"First cohort: Placebo vaccine on study day 0 and 21 on an outpatient basis.~Second cohort: Placebo vaccine on study day 0 and 21 on an outpatient basis."
3219460|NCT01060735|Experimental|Larger doses of vitamin D supplementation|The subjects enrolled in this arm will be supplemented during the third trimester of pregnancy with 2000IU vitamin D per day
3219461|NCT01060735|No Intervention|Conventional vitamin D supplementation|Regular supplementation during pregnancy with 400IU vitamin D
3219462|NCT01060722|Experimental|MOD-4023, dose level 1|
3219463|NCT01060722|Experimental|MOD-4023, dose level 2|
3219464|NCT01060722|Experimental|MOD-4023, dose level 3|
3219465|NCT01060709||elective colonoscopy and requiring sedation|
3219466|NCT01060696|Experimental|Hyoscine, Mefenamic acid, Placebo|Blind randomization to three groups. Mefenamic acid group Hyoscine group Placebo group
3219467|NCT01060683||Group 1: 15 patients|for elective hepatic resection
3219468|NCT01060683||Group 2: 15|for elective hepatic resection
3219469|NCT01060670|Experimental|Dermal Replacement Device|Device: INTEGRA® Dermal Regeneration Template
3219470|NCT01060670|Active Comparator|Moist Wound Therapy|0.9% Saline gel
3219471|NCT01060657||conventional (C) group|
3219472|NCT01060657||low dose (L) groups|
3219473|NCT01060631||patients with frontal or frontotemporal brain tumor.|
3219474|NCT01060631||patients without supratentorial brain tumor.|
3219475|NCT01060618|Experimental|Maraviroc + Trofile ESTA®|the patients have the Trofile ESTA® test performed and sent for evaluation. Once the results are obtained (about 1 month later), the patients take the medication Maraviroc during ten days. The viral load assessment throughout the Study help to make a prediction to assess if the patients would have a positive response Vs. CCR5 antagonist of a negative response
3219476|NCT01060605|Experimental|Rapamycin pre transplant|Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
3219477|NCT01060592|Experimental|Stoma Adjustment at Surgery|The first band adjustment will be made at surgery versus historical controls where the adjustment is not made for 3-4 weeks post-surgery. EndoFLIP device (FDA Device Listing Number : D091203)will be used to make the adjustment.
3219478|NCT01060592|No Intervention|Historic|Weight loss profile over time for 50 patients in the first 12 months after surgery as derived from historic control records. Band adjustments are made in a heuristic fashion during the year after surgery using the experience of surgeon alone
3219479|NCT01060579|Experimental|AR-12286 0.5% ophthalmic solution|
3219480|NCT01060579|Experimental|AR-12286 0.25% Ophthalmic Solution|
3219481|NCT01060579|Experimental|Latanoprost 0.005% ophthalmic solution|
3219482|NCT01060566|Experimental|VX-770|
3219483|NCT01060566|Experimental|Midazolam|
3219484|NCT01060566|Experimental|Rosiglitazone|
3219485|NCT01060566|Experimental|Fluconazole|
3219564|NCT01060072|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate ophthalmic suspension
3219486|NCT01060553|Experimental|Arm 1|The treatment program consisted of 24 semi-individualized acupuncture treatments over 12 weeks. It combines front and back treatments to avoid point fatigue (tolerance due to frequent use). The front treat-ment uses 11 needles, bilateral at acupuncture points LR3, PC6, HT7, ST36, SP6, and one at Yintang; the back treatment uses 14 needles, bilateral at points GB20, and BL14, 15, 18, 20, 21, and 23. There are 15 other points from which the flexibly prescribed points could be chosen
3219487|NCT01060553|No Intervention|wait list control|subjects were put on a wait list control. due to small numbers completing in both groups, the data from the wait list who completed acupuncture are combined with the experimental treatment group for analysis.
3219488|NCT01060540|Experimental|CR+G|conventional risk counseling (lifetime risk, fasting plasma glucose, and family history) plus genetic testing for type 2 diabetes
3219489|NCT01060540|Active Comparator|CR+EYE|conventional risk counseling (lifetime risk, fasting plasma glucose, and family history) plus eye disease counseling
3219490|NCT01060527||IBS-D|
3219491|NCT01060527||IBS-C|
3219492|NCT01060527||Controll|
3219493|NCT01060514|Experimental|Pazopanib + Vinorelbine|
3219494|NCT01060501|Active Comparator|5-FU|Standard arm Systemic drug administration of 5-FU (intravenous)
3219495|NCT01060501|Experimental|5-FU + folinic acid|Experimental arm Systemic drug administration of 5-FU + folinic acid (intravenous)
3219496|NCT01060501|Experimental|5-FU + Interferon-alpha|Experimental arm Systemic drug administration of 5-FU + interferon-alpha (intravenous)
3219497|NCT01060488|Active Comparator|Group 1:|
3219498|NCT01060488|Active Comparator|Group 2:|
3219499|NCT01060475|Experimental|A|Low dose LIM-0705 and tacrolimus.
3219500|NCT01060475|Experimental|B|High dose LIM-0705 and tacrolimus.
3219501|NCT01060475|Experimental|C|Placebo LIM-0705 and tacrolimus.
3219502|NCT01060475|Experimental|D|High dose LIM-0705 and placebo tacrolimus.
3219503|NCT01060462||001|Pts. w/ neutropenic fever associated w/ hematologic malignancy Itraconazole 200 mg twice daily for 2 days for a total of 4 doses then 200 mg once daily for 12 days. After 14 days of IV administration itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
3219504|NCT01060449|Other|LV lead low output|"Low output on left ventricular pacing lead.~Intervention: LV stimulus intensity"
3219505|NCT01060449|Other|LV lead high output|"High output on left ventricular lead~Intervention: LV stimulus intensity"
3219506|NCT01060423|Experimental|hepatic TACE with irinotecan eluting beads and iv cetuximab|Irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX)
3219507|NCT01060423|Active Comparator|iv cetuximab and irinotecan|systemic treatment with intravenous cetuximab and irinotecan
3219508|NCT01060410||Cyclophosphamide,low dose,continuous|
3219509|NCT01060397|Experimental|Extended Brief Intervention|FRAMES motivational interviewing approach
3219510|NCT01060397|Experimental|Control|Usual care
3219511|NCT01060384|Experimental|Phase 1/Phase II|All participants will receive the same dose of Ofatumumab. There will be three planned dose cohorts for the Lenalidomide in the Phase 1 portion of this trial. A maximum of 18 patients will be enrolled in to Phase 1. Three evaluable patients will be enrolled in to each of the dose cohorts with an additional 3 patients to be enrolled in the maximum tolerated dose (MTD). An additional 29 evaluable patients will be enrolled in to Phase II using the MTD for Lenalidomide that was determined in Phase 1.
3219512|NCT01060371||Spinocerebellar Ataxia 1|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
3219513|NCT01060371||Spinocerebellar Ataxia 2|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
3219514|NCT01060371||Spinocerebellar Ataxia 3|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
3219515|NCT01060371||Spinocerebellar Ataxia 6|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
3219516|NCT01060358||healthy|Healthy and active men and women between 21 and 45 years old with no history of low back pain or low back injury.
3219517|NCT01060345|Experimental|Women with Ductal Carcinoma in Situ|Women who have been diagnosed with ductal carcinoma in situ (DCIS)
3219518|NCT01060332||diabetics|
3219519|NCT01060306||Bare metal stent 1 month|Patients implanted with the bare metal stent Gazelle evaluated for neointimal coverage one month after implantation
3219520|NCT01060306||Biodegradable polymer stent 6 months|Patients implanted with the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) evaluated for neointimal coverage after full drug elution and polymer biodegradation (6 months)
3219521|NCT01060306||Biodegradable polymer stent 7 months|Patients implanted with the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) evaluated for neointimal coverage one month after full drug elution and polymer biodegradation (7 months)
3219522|NCT01060293|Active Comparator|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
3219523|NCT01060293|Active Comparator|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
3219524|NCT01060293|Active Comparator|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
3219525|NCT01060280|Active Comparator|Education group|Routine clinical practice (includes usual physiotherapy)plus education on active management.
3219526|NCT01060280|Active Comparator|Group GDS physiotherapy|Routine clinical practice (except usual physiotherapy, which is substituted for Group GDS)plus education on active management.
3219527|NCT01060280|Active Comparator|Individual GDS physiotherapy|Routine clinical practice (except for usual physiotherapy, which will be substituted by Group and Individual GDS) plus education on active management.
3219528|NCT01060267|Active Comparator|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
3219529|NCT01060267|No Intervention|Placebo Group endoscopic therapy|Endoscopic therapy of variceal bleeding.
3219530|NCT01060254|Experimental|JNJ-42160443|
3219531|NCT01060254|Placebo Comparator|Placebo|
3219532|NCT01060241|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
3219533|NCT01060241|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
3219534|NCT01060228|Other|001|paliperidone ER 1 tablet of 500 mg once daily on Day 1 and Day 15
3219535|NCT01060228|Other|002|divalproex sodium ER 2 tablets of 500 mg once daily from Days 5 through 18
3219536|NCT01060215|Active Comparator|Infusion|20cc saline infusion into the knee joint
3219537|NCT01060215|No Intervention|No infusion|
3219538|NCT01060202||Bortezomib|
3219539|NCT01060189|Experimental|Ulinastatin|1,000,000 units after anesthetic induction 1,000,000 units after heparinization 1,000,000 units after neutralization
3219540|NCT01060189|Experimental|Tranexamic Acid|15mg after heparinization 15mg after neutralization
3219541|NCT01060189|Experimental|Combination|"Ulinastatin 1,000,000 units after anesthetic induction 1,000,000 units after heparinization 1,000,000 units after neutralization~Tranexamic Acid 15mg after heparinization 15mg after neutralization"
3219542|NCT01060189|Placebo Comparator|Placebo|saline solution 50ml after anesthetic induction 50ml after heparinization 50ml after neutralization
3219543|NCT01060176|Experimental|High dosage|A loading dose of 30 mg/kg and a maintenance infusion of 20 mg/kg/h
3219544|NCT01060176|Experimental|Medium dosage|A loading dose of 20 mg/kg and a maintenance infusion of 15 mg/kg/h
3219545|NCT01060176|Experimental|Low dosage|A loading dose of 10 mg/kg and a maintenance infusion of 10 mg/kg/h
3219546|NCT01060176|Placebo Comparator|Control|Routine therapy without tranexamic acid
3219547|NCT01060163|Experimental|group ET|Patients receiving early CABG <=7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
3219548|NCT01060163|Placebo Comparator|group EP|Patients receiving early CABG <= 7 days of the cessation of clopidogrel, treated with placebo(saline solution)
3219549|NCT01060163|Experimental|group LT|Patients receiving late CABG >7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
3219550|NCT01060163|Placebo Comparator|group LP|Patients receiving late CABG >7 days of the cessation of clopidogrel, treated with placebo(saline solution)
3219551|NCT01060163|Experimental|group BT|Patients receiving CABG without preoperative clopidogrel exposure, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
3219552|NCT01060163|Placebo Comparator|group BP|Patients receiving CABG without preoperative clopidogrel exposure, treated with placebo(saline solution)
3219553|NCT01060150|Experimental|OROS Methylphenidate HCl|
3219554|NCT01060137|Experimental|001|fentanyl matrix Fentanyl transdermal patch 12 - 25mcg/hr can increase with 12 - 25mcg/h based on pain assessment
3219555|NCT01060124|Experimental|Transdermal Therapeutic System (TTS)-Fentanyl D-trans|
3219556|NCT01060111|Experimental|Topiramate Standard|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
3219557|NCT01060111|Experimental|Topiramate Slow|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
3219558|NCT01060111|Experimental|Topiramate Slow and Propranolol Booster|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion. Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
3219559|NCT01060098||Rheumatoid arthritis|
3219560|NCT01060098||Ankylosing Spondylitis|
3219561|NCT01060098||Psoriatic Arthritis|
3219562|NCT01060085||Breast Cancer|Women shown to have DCIS or invasive breast cancer by fine needle aspiration cytology and/or core needle biopsy.
3219563|NCT01060072|Experimental|Loteprednol etabonate|Loteprednol etabonate 0.5% ophthalmic suspension
3219565|NCT01060059||exenatide|The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide.
3219566|NCT01060059||basal insulin|The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin.
3219567|NCT01060046||Patients with previously implanted biologic mesh|All patients undergoing a repeat operation to repair a recurrent hernia or to revise a surgical site which has been previously repaired using a biologic mesh.
3219568|NCT01060046||Control patients|Any patient undergoing a surgical procedure where fascial biopsy would not compromise the integrity of the procedure.
3219569|NCT01060033|Other|Arm 1|"Clinical T1/T2-weighted MRI sequence per standard of care before treatment, during treatment per standard protocol, and at 3 months.~Patients may have one or all of the following sequences in addition to the standard MRI imaging:~MR Spectroscopy~Fat-saturation and Diffusion-Weighted Imaging~Dynamic Contrast Enhancement MRI (MR-DCE)~Diffusion Tensor Imaging (DTI)"
3219570|NCT01060020|Experimental|Sildenafil 40mg or 80mg|A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab. Each dose will be equally distributed among those with preserved (≥50%) and reduced (<50%) EF.
3219571|NCT01060007|Experimental|Neoadjuvant radiation followed by FOLFOX|"Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.~FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat ever other week for a total of 4 courses (this equals 6 weeks).~If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days."
3219572|NCT01059994|Placebo Comparator|placebo sildenafil young|
3219573|NCT01059994|Experimental|sildenafil young|
3219574|NCT01059994|Placebo Comparator|placebo sildenafil older|
3219575|NCT01059994|Experimental|sildenafil older|
3219576|NCT01059981||1|Dialysis patients
3219577|NCT01059981||2|Trauma patients
3219578|NCT01059981||3|Patients with carbon monoxide poisoning
3219579|NCT01059968||adolescent female endurance athletes|High school female cross country runners in San Diego.
3219580|NCT01059955|Experimental|Active treatment at day 0 and day 7|"Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and one at Day 7.~The three iontophoresis doses are:~Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA~Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA~Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA"
3219581|NCT01059955|Active Comparator|Active Treatment at Day 0, Sham Treatment at Day 7|"Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and a sham treatment Day 7.~The three iontophoresis doses are:~Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA~Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA~Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA"
3219582|NCT01059942||Hospitalist physicians/house-staff|Consented Academic Hospitalist and Internal Medicine Residency staff
3219583|NCT01059929|Active Comparator|Dexmedetomidine|Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
3219584|NCT01059929|Active Comparator|Propofol|Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
3219585|NCT01059903|Experimental|Rotigotine PR2.2.1 first|Rotigotine transdermal patch 4.5 mg/10 cm^2, test drug product PR2.2.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm^2, reference drug product PR2.1.1 separated by a washout phase of at least 5 days
3219586|NCT01059903|Experimental|Rotigotine PR2.1.1 first|Rotigotine transdermal patch 4.5 mg/10 cm^2, reference drug product PR2.1.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm^2, test drug product PR2.2.1 separated by a washout phase of at least 5 days
3219587|NCT01059890|Experimental|Cefotaxime|
3219588|NCT01059890|Experimental|Metrodinazole|
3219589|NCT01059890|Experimental|Ciprofloxacine|
3219590|NCT01059890|Experimental|Fosfocine|
3219591|NCT01059864|Experimental|Arm 1|
3219592|NCT01059864|Experimental|Arm 2|
3219593|NCT01059851|Experimental|Participants with Severe Renal Impairment (Part I)|"Participants with severe renal impairment will receive a~single dose of 20 mg open-label suvorexant during Part I of the~study."
3219594|NCT01059851|Experimental|Healthy Participants (Severe Impairment Controls) (Part I)|Healthy participants matched to participants with severe renal impairment will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
3219595|NCT01059851|Experimental|Participants with Moderate Renal Impairment (Part II)|Participants with moderate renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
3219596|NCT01059851|Experimental|Healthy Participants (Moderate Impairment Controls) (Part II)|Healthy participants matched to participants with moderate renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
3219597|NCT01059851|Experimental|Participants with Mild Renal Impairment (Part II)|Participants with mild renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
3219598|NCT01059851|Experimental|Healthy Participants (Mild Impairment Controls) (Part II)|Healthy participants matched to participants with mild renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
3219599|NCT01059838|Experimental|single subject|
3219600|NCT01059825|Placebo Comparator|Placebo|Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days
3219601|NCT01059825|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
3219602|NCT01059825|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
3219603|NCT01059825|Experimental|Ertugliflozin 10 mg|Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days
3219604|NCT01059825|Experimental|Ertugliflozin 25 mg|Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days
3219605|NCT01059825|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days
3219606|NCT01059812|Experimental|IDegAsp BID|
3219607|NCT01059812|Active Comparator|BIAsp 30 BID|
3219608|NCT01059799|Experimental|IDeg OD|
3219609|NCT01059799|Active Comparator|IGlar OD|
3219610|NCT01059786|Experimental|Arm 1|Rituximab + Bendamustine at 70 mg/m2 for initialtolerability study (closed)
3219611|NCT01059786|Experimental|Arm 2|Rituximab + Pentostatin at 70 mg/m2 for initialtolerability study (closed)
3219612|NCT01059786|Experimental|Arm 3|Rituximab + Bendamustine
3219613|NCT01059786|Active Comparator|Arm 4|Rituximab + Pentostatin
3219614|NCT01059773|Experimental|Immediate Methotrexate Cessation|Patients will receive ustekinumab by SC injection at Weeks 0, 4, 16, 28 and 40. The last dose of methotrexate will be taken anytime in the week prior to baseline (week 0).
3219615|NCT01059773|Active Comparator|Gradual Reduction of Methotrexate|Patients will receive ustekinumab by SC injection at Weeks 0, 4, 16, 28 and 40. Patients will gradually reduce the dose of methotrexate over the 4 week period after week 0.
3219616|NCT01059760|Other|Fasting Day First|28±4 hours of water-only fasting followed by 28±4 hours fed
3219617|NCT01059760|Other|Fed Day First|28± 4 hours fed followed by 28± 4 hours of fasting
3219618|NCT01059747||treatment group|
3219619|NCT01059721|Experimental|Soft tissue realignment|group cohort label
3219620|NCT01059708||CO poisoned children|Children, ages 6-16, who have been poisoned by carbon monoxide
3219621|NCT01059682|Experimental|Dalcetrapib|
3219622|NCT01059682|Placebo Comparator|Placebo|
3219623|NCT01059669||Patients|Patients with suspected Chronic Pancreatitis
3219624|NCT01059669||Control group|Healthy controls
3219625|NCT01059656|Experimental|1:Pazopanib|Pazopanib 800mg/j
3219626|NCT01059643|Experimental|LY2523355|
3219627|NCT01059630|Active Comparator|Bendamustine Alone|Participants will receive bendamustine 120 milligrams per meter square (mg/m^2) Intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.
3219628|NCT01059630|Experimental|Obinutuzumab + Bendamustine|"Induction phase: Participants will receive bendamustine 90 mg/m^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants will also receive obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6.~Maintenance phase: Participants with complete response (CR), partial response (PR) or stable response (SD) then will receive obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurs first)."
3219629|NCT01059617|Experimental|Flulaval/Arepanrix Group|subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
3219630|NCT01059617|Experimental|Flulaval/Unadjuvanted Arepanrix Group|subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
3219631|NCT01059617|Experimental|Placebo/Arepanrix Group|subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
3219632|NCT01059617|Experimental|Placebo/Unadjuvanted Arepanrix Group|subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
3219633|NCT01059604||Pregnant women exposed to sumatriptan, naratriptan, or combo|Women exposed to sumatriptan, naratriptan or the sumatriptan-naproxen combination treatment during pregnancy
3219634|NCT01059591|Experimental|Active|GSK424887 once daily
3219635|NCT01059591|Placebo Comparator|Placebo|Placebo once daily
3219636|NCT01059578|Experimental|Active|GSK206136 once daily
3219637|NCT01059578|Placebo Comparator|Placebo|Placebo once daily
3219638|NCT01059565|Experimental|AZLI|Participants were randomized to receive AZLI for up to 24 weeks and may have continued to receive AZLI during the open-label phase for up to an additional 24 weeks.
3219639|NCT01059565|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match AZLI for up to 24 weeks and may have switched to AZLI during the open-label phase for up to 24 weeks.
3219640|NCT01059552|Experimental|vorinostat|Dose escalation of vorinostat, cisplatin, pemetrexed and radiation
3219641|NCT01059539|Experimental|1|Cariprazine flexible dose, oral administration once daily for 16 weeks
3219642|NCT01059526||Patients naive to KALBITOR|HAE patients that have not been treated with KALBITOR (ecallantide) prior to enrollment in the study
3219643|NCT01059526||Patients non- naive to KALBITOR|HAE patients that have been treated with KALBITOR prior to enrollment in the study
3219644|NCT01059500|Other|Pilot Phase|First 300 patients will be assigned to arm 1 to test the accuracy of the webtool output.
3219645|NCT01059500|Experimental|Webtool output|Phase 2- Intervention, One group will receive the numeric PTP estimate from webtool output, the other groupwill not receive the nemuric PTP estimate
3219646|NCT01059487|Other|Traditional Chinese Medicine|Assessing efficacy of treating subjects/patients with Traditional Chinese Medicine (TCM) by administering SF-36v2 and PIQ-6 surveys to subjects/patients to create a baseline and then re-assessing quality of life achieved through TCM treatments by administering follow-up SF-12v2 and PIQ-6 surveys every four weeks
3219698|NCT01059019|Experimental|Treatment|20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day
3219647|NCT01059474|Experimental|DMPS|We will recruit 10 healthy adult volunteers, over 18 years of age, who eat at least three servings of fish per week (since this diet is associated with detectable levels of mercury in the urine which may rise following chelation). Patients with known allergies to DMPS or sulfa drugs or history of neurologic or renal disease will be excluded. We will also control for number of mercury containing dental amalgams. History will be obtained regarding any potential mercury exposures or recent vaccinations.
3219648|NCT01059461|Experimental|Cerebrolysin®, neuroregeneration|Injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
3219649|NCT01059448|Experimental|210mg AMG 827|AMG 827 210mg at baseline, week 1, week2, and every 2 weeks thereafter
3219650|NCT01059435|Placebo Comparator|A|Two female subjects in each of cohorts 1, 2, 3a, 4, 5, and 6a will receive placebo; two male subjects in each of cohorts 3b and 6b; and 1 female subject in each of cohorts 3c and 6c.
3219651|NCT01059435|Active Comparator|B|Two female subjects in each of cohorts 1, 2, 3a, 4, 5, and 6a will receive AMG 785; two male subjects in each of cohorts 3b and 6b; and 1 female subject in each of cohorts 3c and 6c.
3219652|NCT01059409|Experimental|Meniscal Allograft|
3219653|NCT01059396|Experimental|Propranolol|
3219654|NCT01059396|Experimental|carvedilol|
3219655|NCT01059396|Placebo Comparator|Placebo|
3219656|NCT01059383|Experimental|VECAM 40/300|
3219657|NCT01059383|Active Comparator|Esomeprazole 20 mg|
3219658|NCT01059370|Experimental|Autonomic dysrefleksia|Autonomic dysreflexia in SCI when emptying bowels or filling bladder
3219659|NCT01059357|Experimental|Transoral Robotic Surgery (TORS)|Transoral Robotic Surgery (TORS) using the Da Vinci Robotic Surgical System
3219660|NCT01059344|Experimental|Mesalamin|4.8g Mesalamin (800mg tablet)
3219661|NCT01059344|Placebo Comparator|Placebo|4.8g Placebo to Mesalamin (800 mg tablet)
3219662|NCT01059331|Experimental|Pregabalin|
3219663|NCT01059331|Placebo Comparator|Sugar pill|
3219664|NCT01059318|Experimental|RAD001 2.5mg|
3219665|NCT01059318|Experimental|RAD001 5mg|
3219666|NCT01059318|Experimental|RAD001 10mg|
3219667|NCT01059305|Experimental|Erlotinib|150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
3219668|NCT01059279||FMF patients|15 FMF patients with double mutations MEFV, mail sex, from the age from 18 to 30. treated with colchicine, without attacks not less than 2 months
3219669|NCT01059279||healthy people|Healthy individuals, that participated in the study of Heller Institute of Medical Research.
3219670|NCT01059266|Active Comparator|conventional regimen of PURETHAL Grasses|"Initial treatment:~6 incremental weekly subcutaneous doses of 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 ml (week 1, 2, 3, 4, 5, 6).~Maintenance treatment:~0.5 ml in intervals according to registered scheme (week 8, 10, 12, 16)."
3219671|NCT01059266|Experimental|rush regimen of PURETHAL Grasses|"Initial treatment:~3 incremental weekly subcutaneous doses of 0.1, 0.3, and 0.5 ml (week 1, 2, 3)~Maintenance treatment:~3 monthly doses of 0.5 ml (week 7, 11, 15)."
3219672|NCT01059253|Experimental|Training|15 training sessions
3219673|NCT01059188|Experimental|Cetuximab, Cisplatin, Docetaxel, Radiotherapy and Surgery|
3219674|NCT01059175|Experimental|CRT With Dual Site LV Pacing|Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
3219675|NCT01059175|Active Comparator|Standard CRT|Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
3219676|NCT01059162|Experimental|IOPtiMate|patients will undergo non-penetrating laser assisted filtering surgery by the IOPtiMate (OT-134) system
3219677|NCT01059149|Experimental|receive real rTMS|For real rTMS, pulses will be delivered at a frequency of 5 Hz for 6s with a 54s interval, with an intensity equal of 90% of the motor threshold as established at Baseline. 20-min real stimulation sessions will be administered 5 days a week for a period of 2 weeks
3219678|NCT01059149|Placebo Comparator|sham rTMS|For sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo procedures will be used administered 5 days a week for a period of 2 weeks.
3219679|NCT01059136|Experimental|1:Spironolactone|Aldosterone blockade on top of standard therapy
3219680|NCT01059136|No Intervention|2:Standard therapy|Standard therapy
3219681|NCT01059123|Experimental|1:Short treatment|amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day 6 days.
3219682|NCT01059123|Active Comparator|2:Usual treatment|amoxicillin 50 mg/kg/24H ; I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day up to day 14.
3219683|NCT01059110|Experimental|Salicylate ointment|Salicylate ointment under occlusion (pomade M.O Cochon®)
3219684|NCT01059110|Experimental|Imiquimod|Imiquimod : Aldara®
3219685|NCT01059110|Experimental|5-fluoro-uracil|5-fluoro-uracil cream : Efudix®
3219686|NCT01059110|Experimental|Cryotherapy|liquid nitrogen : Cryotherapy
3219687|NCT01059097|Active Comparator|High volume surgeons|high volume surgeons performed at least 18 PD/year.
3219688|NCT01059097|Active Comparator|Low volume surgeons|low volume surgeons performed less than 18 PD/year.
3219689|NCT01059071|Experimental|DFMO and Etoposide|
3219690|NCT01059058|Active Comparator|Test Group A: MI Paste Plus Group|
3219691|NCT01059058|Active Comparator|Test Group B: Fluoride Varnish Group|
3219692|NCT01059058|Placebo Comparator|Control Group|
3219693|NCT01059045|Experimental|Cryocontact therapy|
3219694|NCT01059045|No Intervention|Control|
3219695|NCT01059032|No Intervention|Unenhanced images|
3219696|NCT01059032|Other|Enhanced images|Enhanced images
3219697|NCT01059019|Sham Comparator|Control|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients.
3219699|NCT01059006|Experimental|PresbyLASIK|Male or female patients with presbyopic symptoms who underwent PresbyLASIK.
3219700|NCT01058993|Experimental|AMD3100 or plerixafor|SINGLE arm study with increasing doses of Plerixafor
3219701|NCT01058980|Active Comparator|Dormant PV conduction|"After PVI, dormant conduction will be evaluated using intravenous adenosine. If dormant conduction is present, the patients will be randomized to two parallel groups:~Group 1: No additional ablation~Group 2: Additional ablation until elimination of dormant conduction."
3219702|NCT01058980|Active Comparator|No dormant PV conduction|If no dormant conduction is documented, patients will be selected in a random fashion to be included in a registry (follow-up as planned for group 1 and 2 above). The registry group will allow for further assessment of the role of dormant conduction as a predictor of AF recurrence by comparing the success rate after ablation in patients without dormant conduction with those of Group 1 and 2.
3219703|NCT01058967||major trauma victims|Code 3 patients (highest acuity) admitted to hospital via air ambulance service
3219704|NCT01058941|Experimental|Lipoic acid and Omega-3 fatty acids|Three 1-gram fish oil capsules per day (2 capsules in the morning and 1 capsule in the evening) plus two lipoic acid (LA) capsules per day in the morning. Total daily dose of study drug: 675 mg DHA, 975 mg EPA, 600 mg LA.
3219705|NCT01058941|Placebo Comparator|Placebo|Three placebo oil capsules per day (2 capsules in the morning and 1 capsule in the evening) plus two placebo LA capsules per day in the morning.
3219706|NCT01058928||Group ID 7.5|Patients with a tracheal tube ID (internal diameter) 7.5 mm
3219707|NCT01058928||Group ID 8.0|Patients with a tracheal tube ID 8.0 mm
3219708|NCT01058915|Active Comparator|Rosuvastatin 5mg|Rosuvastatin 5mg/day for one year
3219709|NCT01058915|Active Comparator|Rosuvaststin 40mg|Rosuvastatin 40mg/day
3219710|NCT01058902|Placebo Comparator|Negative control|Not on aspirin pre operatively, but refuse to enter trial or have a contraindication to aspirin
3219711|NCT01058902|Experimental|Aspirin treatment|group randomised to aspirin
3219712|NCT01058902|Experimental|No aspirin treatment|Randomised to no aspirin
3219713|NCT01058902|Active Comparator|Positive control|Already on aspirin. just observational limb
3219714|NCT01058889|Experimental|Telemedical device|Patient will receive a blood glucose measurement device and a telemedical device to monitor blood glucose measurements.
3219715|NCT01058889|No Intervention|Treatment as usual|
3219716|NCT01058876|Experimental|Usual Cigarette|African American and White Smokers will smoke their usual cigarette and also undergo an oral pharmacokinetics protocol after administration of 3 mg deuteriumlabeled nicotine and 5 mg deuterium-labeled cotinine.
3219717|NCT01058876|Experimental|Low-yield Cigarette|"African American and White smokers will smoke a commercial cigarette with a machine-determined nicotine yield of approximately 50% of their usual brand."
3219718|NCT01058863|Experimental|Albuterol Spiromax® 90 mcg|A single dose of albuterol 90 mcg delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler. Placebo inhalers used to maintain the blind.
3219719|NCT01058863|Experimental|Albuterol Spiromax® 180 mcg|A single dose of albuterol 180 mcg delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler (2 inhalations). Placebo inhalers used to maintain the blind.
3219720|NCT01058863|Active Comparator|ProAir® HFA 90 mcg|A single dose of albuterol 90 mcg delivered with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.
3219721|NCT01058863|Active Comparator|ProAir® HFA 180 mcg|A single dose of albuterol 180 mcg delivered with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler (2 inhalations). Placebo inhalers used to maintain the blind.
3219722|NCT01058863|Placebo Comparator|Placebo Inhaler|Placebo delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler, and with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.
3219723|NCT01058850|Experimental|Rindopepimut (EGFRvIII Vaccine, CDX-110)|
3219724|NCT01058824|Active Comparator|Lincomycin - Active Comparative - Hard Gelatin Capsule|
3219725|NCT01058824|Experimental|Lincomycin - Study Drug - Hard Gelatin Capsule|
3219726|NCT01058785|Experimental|Lucanix|Patients will receive injections of Lucanix for each dose cohort.
3219727|NCT01058772|Experimental|INDUCTION of LABOUR|"At enrollment patients assigned to the induction group will be admitted to the obstetric ward and will undergo induction of labour as described in the intervention section.~Once patient's Bishop score exceeds 7 or regular contractions are diagnosed, patients will be transferred to the delivery ward for artificial rupture of membranes (ARM) or Oxytocin augmentation as indicated."
3219728|NCT01058772|No Intervention|EXPECTANT MANAGEMENT|"Patients enrolled in the conservative management arm will be followed up twice weekly for foetal wellbeing by Non-stress test and Biophysical profile. Patients will be followed up to 41+0 weeks.~Patients, who will not deliver by this gestational age, will be admitted for labour induction (see the above protocol). Induction of labour will be offered when non-reassuring foetal status is suspected. All patients in the conservative arm will undergo foetal weight ultrasound estimation prior to induction. Patients with estimated foetal weight over 4000 gr will be offered a C-section."
3219729|NCT01058759|Experimental|Arm B: Enoxaparin|
3219730|NCT01058759|Active Comparator|Arm A: No Enoxaparin|
3219731|NCT01058746|Active Comparator|pts undergoing pancreatic resection Restrictive arm|All patients will receive Normosol or equivalent solution, 0.5 ml/kg/fasted hour IV (approximately from 8am to time of induction) during induction of anesthesia. All patients will then receive maintenance fluids consisting of Normosol or equivalent solution at 6 ml/kg/operative hour. After randomization occurs, those patients randomized to the Restricted Arm will continue to receive Normosol or equivalent solution at 6ml/kg/operative hour.
3219732|NCT01058746|Active Comparator|pts undergoing pancreatic resection Liberal arm|All patients will receive Normosol or equivalent solution, 0.5 ml/kg/fasted hour IV (approximately from midnight to time of induction) during induction of anesthesia. All patients will then receive maintenance fluids consisting of Normosol or equivalent solution at 6 ml/kg/operative hour. Those patients randomized to the Liberal Arm will receive an additional Normosol bolus or equivalent solution equal to (another) 1.5 ml/kg/fasted hour IV (to bring the total to 2 ml/kg/fasted hour) plus an additional bolus of Normosol or equivalent solution 6ml/kg/operative hour to bring the hourly rate to 12ml/kg/operative hour with a maximum of 1000 ml/operative hour.
3219733|NCT01058733|Other|Internet|New clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
3219734|NCT01058720|Experimental|Vitamin D3|Patients would receive 2000 IU of vitamin D3 daily for 12 weeks
3219735|NCT01058707|Experimental|MLN0128|
3219736|NCT01058694|Experimental|Weekly SMS, brief message|Weekly SMS received on Monday at 12 noon
3219737|NCT01058694|Active Comparator|Control Group|Receives a phone, but no messages.
3219738|NCT01058694|Experimental|Daily SMS, Brief message|"Receive daily brief message at 12 noon: This is your reminder"
3219739|NCT01058694|Experimental|Daily SMS, Long Message|"Receive a daily long message at 12 noon: This is your reminder + encouragement"
3219740|NCT01058694|Experimental|Weekly SMS, Long Message|"Weekly message sent at 12 noon on Mondays: This is your reminder + encouragement"
3219741|NCT01058681|Other|isocaloric|impacts of isocaloric nutrition on LH pulsatility in euglycemic and hyperinsulinemic clamps
3219742|NCT01058681|Other|hypercaloric|impacts of hypercaloric nutrition on LH pulsatility in euglycemic and hyperinsulinemic clamps
3219743|NCT01058681|Other|per os and IV glucose during the clamp|impacts of per os glucose on LH pulsatility in euglycemic and hyperinsulinemic clamps
3219744|NCT01058668|Experimental|Cariprazine (3-6 mg/day)|Cariprazine 3 milligrams (mg) - 6 mg capsules oral administration, once per day for 3 weeks.
3219745|NCT01058668|Experimental|Cariprazine (6-12 mg/day)|Cariprazine 6 mg - 12 mg capsules oral administration, once per day for 3 weeks.
3219746|NCT01058668|Placebo Comparator|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
3219747|NCT01058655|Experimental|Phase I Cohort 1: Everolimus 5 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
3219748|NCT01058655|Experimental|Phase I Cohort 2: Everolimus 10 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
3219749|NCT01058655|Experimental|Phase I Cohort 3: Everolimus 10 mg + Tivozanib 1.5 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
3219750|NCT01058655|Experimental|Phase II: Everolimus 10 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
3219751|NCT01058642|Experimental|ADL5747|ADL5747 150 milligrams (mg) administered orally as 1 ADL5747 150-mg capsule and 1 placebo capsule twice daily (BID) for 14 days during 1 of 2 Treatment Periods.
3219752|NCT01058642|Placebo Comparator|Placebo|"Placebo: two placebo capsules administered orally BID for 14 days during 1 of 2 Treatment Periods.~Participants were also administered placebo orally BID during a 14-day washout period that took place between Treatment Period 1 and Treatment Period 2."
3219753|NCT01058642|Active Comparator|Pregabalin|Pregabalin administered orally as a dose of 1 pregabalin 75-mg capsule and 1 placebo capsule BID for the first 3 days, increased to a dose of 1 pregabalin 150-mg capsule and 1 placebo capsule BID for the last 11 days of 1 of 2 fourteen-day Treatment Periods, followed by a dose of 1 pregabalin 75-mg capsule and 1 placebo capsule BID for 3 days as a taper period.
3219754|NCT01058629|Experimental|SynergEyes A2 Hybrid Contact Lens|
3219755|NCT01058603|Active Comparator|D3|
3219756|NCT01058603|Experimental|D5|
3219757|NCT01058564|Experimental|Implant device|
3219758|NCT01058551|Experimental|Reveal XT ILR|Implantable Loop Recorder Insertion
3219759|NCT01058538|Experimental|L19IL2|
3219760|NCT01058525|Active Comparator|nerve block|median nerve block (6 ml lidocaine 1.5 % with adrenalin 1:200000)
3219761|NCT01058525|Experimental|median nerve block after hydro-dissection|median nerve block (6 ml lidocaine 1.5 % with adrenalin 1:200000) after hydro-dissection (glucose 5% solution)
3219762|NCT01058512|Experimental|Single|single-arm study
3219763|NCT01058499|Experimental|MBSR|
3219764|NCT01058486|Experimental|Activity-Self Management|
3219765|NCT01058486|No Intervention|Usual Care|
3219766|NCT01058473||Sickle Cell Disease|
3219767|NCT01058460|No Intervention|cytology|Subjects in the control arm will receive conventional cytology testing and HPV testing at baseline. Follow up management will be based on the cytology result according to current practice.
3219768|NCT01058460|Experimental|HPV-cytology|Subjects in the HPV-cytology arm will receive HPV testing and cytology testing at baseline. Follow up management will be based on both results.
3219769|NCT01058447|Experimental|1|
3219770|NCT01058434|Experimental|TKI258|
3219771|NCT01058421|Experimental|Intensive physical therapy|four week intervention of daily intensive physical therapy
3219772|NCT01058421|Active Comparator|control group|
3219773|NCT01058408|Experimental|Rad001 with cisplatin|
3219774|NCT01058395|Experimental|800 mg loading then 200 mg Q12|Minocycline 800 mg. loading followed by 200 mg. Q 12 hours.
3219775|NCT01058395|Experimental|800 mg loading then 400 mg Q12|Minocycline 800 mg. loading followed by 400 mg. Q 12 hours.
3219776|NCT01058382||Progesterone Vaginal Suppositories|
3219777|NCT01058382||Intramuscular Progesterone-in-Oil|
3219778|NCT01058369|Experimental|Deferasirox|
3219779|NCT01058356||IBD research group in KASID|KASID is Korean Association Study of Intestinal Disease. It has several research group suh as inflammatory bowel disease (IBD) research group.
3219780|NCT01058343|Experimental|IFN-K 1|IFN kinoid dose 1
3219781|NCT01058343|Experimental|IFN-K-2|IFN kinoid dose 2
3219782|NCT01058343|Experimental|IFN-K 3|IFN kinoid dose 3
3219783|NCT01058343|Experimental|IFN-K 4|IFN kinoid dose 4
3219784|NCT01058343|Placebo Comparator|Saline|saline at same dose as IFN K
3219785|NCT01058330|Active Comparator|Plyometric physical training|Individualized plyometric training program to increase strength, coordination, and bone density.
3219786|NCT01058330|No Intervention|Control Group|This group will have no intervention
3219787|NCT01058317|Experimental|Children treated with propranolol|
3219788|NCT01058304|Experimental|Group Physical Therapy for Knee OA|Group Physical Therapy for Knee OA
3219843|NCT01057927|Experimental|OC000459|
3219789|NCT01058304|Active Comparator|Individual Physical Therapy for Knee OA|Individual Physical Therapy for Knee OA
3219790|NCT01058291|Experimental|KW-6500|
3219791|NCT01058291|Placebo Comparator|KW-6500 Placebo|
3219792|NCT01058278|Active Comparator|Prednisone acetate 1%|A topic cortisone-based treatment
3219793|NCT01058278|Active Comparator|diclofenac 0.1%|an non-steroidal anti-inflammatory drug
3219794|NCT01058278|Placebo Comparator|Artificial Tears|Pharmasciences DIN: 02229570
3219795|NCT01058265|Experimental|Integrative|Integrative Medical care is defined as a comprehensive medical evaluation that emphasizes wellness and healing of the whole person as major goals above and beyond suppression of a specific somatic disease. The patient is viewed as a whole person with mind and spirit as well as body and these dimensions are incorporated into diagnosis and treatment plans. An integrative medicine evaluation includes four aspects of health: physical, emotional, mental and spiritual health. Maximum improvement in health is achieved by addressing each aspect through an integrated treatment plan. The evaluation generally takes 90-120 minutes.
3219796|NCT01058265|Active Comparator|Standard|Standard general medical evaluation.
3219797|NCT01058252||Letrozole, recFSH, IVC, Monitoring|Infertile couple following MSP with IVC
3219798|NCT01058239|Experimental|Rituximab plus Bortezomib|This is a single arm trial adding the new drug bortezomib to the standard drug rituximab
3219799|NCT01058213|Active Comparator|Aerobic training alone|8 weeks of gentle chair (sham) training followed by 8 weeks of interval aerobic training on a stationary bicycle
3219800|NCT01058213|Experimental|Sequential Resistance then Aerobic Training|8 weeks of resistance training of the lower body followed by 8 weeks of interval aerobic training on a stationary bicycle
3219801|NCT01058213|Active Comparator|Concurrent resistance and aerobic training|8 weeks of gentle chair (sham) exercise followed by 8 weeks of concurrent resistance training of the lower body and interval aerobic training on a stationary bicycle
3219802|NCT01058200|Active Comparator|vacuum extractor 'iCUP'|new vacuum extractor: sterile disposable plastic cup
3219803|NCT01058200|Sham Comparator|reference vacuum extractor|reference cup of the obstetrical ward: metallic cup
3219804|NCT01058187||Control|Marketed cow milk-based infant formula containing DHA and ARA
3219805|NCT01058187||Investigational 1|Cow milk-based infant formula with differing level of ARA from Control formula
3219806|NCT01058187||Investigational 2|Cow milk-based infant formula with a differing level of ARA from Control
3219807|NCT01058174|Experimental|micafungin|intravenous infusion
3219808|NCT01058174|Active Comparator|standard care|intravenous infusion
3219809|NCT01058161|Other|Suspects or affected by rheumatoid polyarthritis|
3219810|NCT01058161|Other|stiffening spondylitis with axial and peripheral infringement|
3219811|NCT01058161|Other|polyarthralgies with or without arthritis|Affected by connectivity with anti-nuclear antibody positive and / or specific antibodies, suffering of polyarthralgias with or without arthritis
3219812|NCT01058161|Other|Healthy control|
3219813|NCT01058161|Other|not inflammatory control|Presenting a degenerative osteoarthritis of the wrist traumatic comment, noticed radiologically, which will serve as not inflammatory control.
3219814|NCT01058122||Patients on the ward|
3219815|NCT01058109|Experimental|calcium group|dietary calcium intake of 1500 mg/d
3219816|NCT01058109|Experimental|calcium-rich diet (1500 mg/d)|calcium intake from food
3219817|NCT01058096|Experimental|Cariprazine|Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
3219818|NCT01058096|Placebo Comparator|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
3219819|NCT01058083|Experimental|BMS-770767 (Treatment A)|
3219820|NCT01058083|Experimental|BMS-770767 (Treatment B)|
3219821|NCT01058083|Experimental|BMS-770767 (Treatment C)|
3219822|NCT01058083|Experimental|BMS-770767 (Treatment D)|
3219823|NCT01058083|Placebo Comparator|Placebo (Treatment E)|
3219824|NCT01058070|Experimental|Implantable Device|
3219825|NCT01058057|Experimental|Atorvastatin|Atorvastatin 80mg seven days pre-treatment before PCI
3219826|NCT01058044|Experimental|adherence assessment group|evaluation of adherence using MEMS
3219827|NCT01058031|Experimental|Arm 1|MBSR
3219828|NCT01058018|Experimental|A - 100 mg per day RVX000222|Arm A: Treatment with RVX000222 at 50 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
3219829|NCT01058018|Experimental|B - 200 mg per day RVX000222|Arm B: Treatment with RVX000222 100 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
3219830|NCT01058018|Experimental|C - 300 mg per day RVX000222|Arm C: Treatment with RVX000222 150 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
3219831|NCT01058018|Placebo Comparator|D - Placebo|Arm D: Treatment with placebo for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
3219832|NCT01058005|Experimental|Natalizumab|
3219833|NCT01058005|Active Comparator|Interferon Beta-1a|
3219834|NCT01058005|Active Comparator|Glatiramer Acetate|
3219835|NCT01057992|Experimental|Implantable Device|
3219836|NCT01057979|Experimental|MET + CM for Exercise|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.
3219837|NCT01057979|Active Comparator|MET + Exercise Contracting|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
3219838|NCT01057966|Experimental|ICAPS AREDS Softgel Capsule - Full Strength|ICAPS Eye Vitamin and Mineral Supplement - Softgel
3219839|NCT01057966|Experimental|ICAPS AREDS Softgel Capsule - Half Strength|ICAPS Eye Vitamin and Mineral Supplement - Softgel (half -strength)
3219840|NCT01057966|Experimental|ICAPS AREDS coated tablets - Full Strength|ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets
3219841|NCT01057953|No Intervention|Patient|Blood sample for patient included
3219842|NCT01057940||PEJ placement|Patients who have failed conventional DPEJ placement and would otherwise require surgical intervention.
3219844|NCT01057927|Placebo Comparator|Placebo|
3219845|NCT01057914|Experimental|Supplemention|
3219846|NCT01057914|Experimental|Dietary advice|
3219847|NCT01057914|Experimental|Combination treatment|
3219848|NCT01057914|No Intervention|Usual care|
3219849|NCT01057901|Experimental|Flibanserin 100 mg|Flibanserin 100 mg administered at bedtime
3219850|NCT01057901|Placebo Comparator|Placebo|This is the matched placebo which will be administered two tablets daily at bedtime.
3219851|NCT01057888|Experimental|Autodialer|Autodialer reminder/recall
3219852|NCT01057888|Experimental|Letters|Mailed reminder letters
3219853|NCT01057888|No Intervention|Controls|Controls
3219854|NCT01057875|Experimental|coffee with caffeine|
3219855|NCT01057875|Placebo Comparator|decaffeinated coffee|Starbuck's Grande Pike Roast Decaf
3219856|NCT01057862|Experimental|Naltrexone|
3219857|NCT01057862|Placebo Comparator|Placebo|
3219858|NCT01057849|Experimental|Risperidone, Intensive|risperidone and intensive psychosocial intervention
3219859|NCT01057849|Active Comparator|risperidone, basic|risperidone and basic psychosocial support
3219860|NCT01057849|Experimental|olanzapine, intensive|olanzapine and intensive psychosocial intervention
3219861|NCT01057849|Active Comparator|olanzapine, basic|olanzapine and basic psychosocial support
3219862|NCT01057849|Experimental|aripiprazole, intensive|aripiprazole and intensive psychosocial intervention
3219863|NCT01057849|Active Comparator|aripiprazole, basiv|aripiprazole and basic psychosocial support
3219864|NCT01057836|Experimental|Neck strength training|
3219865|NCT01057836|Experimental|Neck endurance training|
3219866|NCT01057836|Active Comparator|Stretching|
3219867|NCT01057823||Inpatient Elders Age 50 and up|The study population is community-dwelling ambulatory patients age 50 or above hospitalized on the University of Chicago general medicine service. Exclusion criteria include: (1) transfer from the ICU or another hospital; (2) cognitively impaired; (3) not ambulatory; (4) residents of a nursing home or skilled nursing facility; (5) on bedrest; (6)documented sleep disorder in their medical history (i.e. obstructive sleep apnea, narcolepsy, etc).
3219868|NCT01057810|Experimental|Ipilimumab|
3219869|NCT01057810|Placebo Comparator|Placebo|
3219870|NCT01057797|Experimental|Upper Body Strength Training with Self-Efficacy|16 weeks of upper body strength training combined with an exercise-specific self-efficacy enhancing intervention
3219871|NCT01057797|Active Comparator|Upper body strength training|16 weeks of upper body strength training with weekly health education sessions
3219872|NCT01057797|Sham Comparator|Chair exercise|16 wks of gentle chair exercise with weekly health education
3219873|NCT01057784||Bariatric Surgery Patients|Patients undergoing bariatric surgery.
3219874|NCT01057784||Reproductive-Age Women - Bariatric Surgery Patients|This subgroup of patients will include 10 reproductive-age women.
3219875|NCT01057771|Experimental|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
3219876|NCT01057771|Experimental|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
3219877|NCT01057771|No Intervention|Waiting list control|Waiting list control subjects will be treated exactly like those in active intervention groups, but will not receive interventions.
3219878|NCT01057758|Placebo Comparator|PLACEBO|Half of the patients will be randomized to the placebo
3219879|NCT01057758|Active Comparator|Simvastatin|Half of the subjects will receive the active drug, Simvastatin.
3219880|NCT01057732||primary hyperparathyroidism|patients with primary hyperparathyroidism
3219881|NCT01057732||controls|subjects without primary hyperparathyroidism
3219882|NCT01057719|Experimental|Physiotherapy in Spain|Daily inpatient physiotherapy for four weeks in a warm climate
3219883|NCT01057719|Experimental|Physiotherapy in Norway|Daily inpatient physiotherapy for four weeks in a cold climate
3219884|NCT01057706|Experimental|9 months of chiropractic care and exercise|chiropractic, exercise
3219885|NCT01057706|Active Comparator|3 months of chiropractic care and exercise|chiropractic, exercise
3219886|NCT01057693|Experimental|pregabalin (Lyrica)|
3219887|NCT01057693|Placebo Comparator|Placebo|
3219888|NCT01057680|Experimental|creatine|This arm will involve creatine supplementation 0.1 g per kg body mass per day while participating in a resistance training program (1 hour per day, 3 days per week).
3219889|NCT01057680|Placebo Comparator|Sugar|This arm will involve placebo (maltodextrin) given every day while the participant does a resistance training program (1 hour per day, 3 days per week).
3219890|NCT01057667|Experimental|Arm A: With RO5024048|Patients in arm A will receive RO5024048 (1000mg orally twice daily) for 24 weeks in addition to Pegasys (180 micrograms sc weekly) and Copegus (1000mg or 1200mg orally daily).
3219891|NCT01057667|Active Comparator|Arm B: Standard treatment|Patients in arm B will receive standard treatment with Pegasys (180 micrograms sc weekly) and Copegus (1000mg or 1200mg orally daily) for 48 weeks.
3219892|NCT01057654|Experimental|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
3219893|NCT01057654|Active Comparator|Pravastatin|Pravastatin 40 mg per day
3219894|NCT01057641|Experimental|Spacer|"Implantation of a percutaneously implanted interspinous device (spacer)"
3219895|NCT01057641|Other|physiotherapy|The control group will receive at least physiotherapy and physical therapy (e.g. massage and fango). Under inpatient conditions therapy will last for seven days. After discharge physical therapy has to be continued for 5 weeks. A schedule will ensure the consistency of the physical therapy. The inpatient-treatment can be repeated every 6 months if necessary.
3219896|NCT01057628|Experimental|ASP1941 group|
3219897|NCT01057628|Placebo Comparator|placebo group|
3219898|NCT01057615|Experimental|Active Fish Oil + Vitamin C Placebo|Fifteen subjects will take 10 active fish oil capsules per day and 2 vitamin C placebo capsules per day for 3 weeks.
3219899|NCT01057615|Experimental|Fish Oil Placebo + Active Vitamin C|Fifteen subjects will take 10 fish oil placebo capsules per day and 2 active vitamin C capsules per day for 3 weeks.
3220002|NCT01056874|Active Comparator|Digoxin|
3219900|NCT01057615|Experimental|Active Fish Oil + Active Vitamin C|Following a 2-week washout period, all subjects from the other two arms (n=30) will take 10 active fish oil capsules per day and 2 active vitamin C capsules per day for 3 weeks.
3219901|NCT01057602||Normal community dwelling elders|Individuals age 65 and older who live in the community
3219902|NCT01057589|Experimental|Pemetrexed + Cisplatin + Cetuximab|"Participants will receive pemetrexed,cisplatin and cetuximab for up to 6 cycles (21 days per cycle) followed by optional maintenance of pemetrexed and cetuximab until disease progression. Optional maintenance therapy is permitted after at least 4 cycles of triplet combination therapy have been given. Cetuximab will be administered as an initial dose of 400 milligram per meter squared (mg/m^2) intravenous (IV) infusion and as a 250 mg/m^2 IV weekly dose thereafter.~As Standard of care dietary supplements included: 350 to 1000 micrograms (µg) oral Folic Acid 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed and 1000 µg vitamin B12 intramuscular injection (IM) during the week preceding the first dose of pemetrexed and every 9 weeks thereafter."
3219903|NCT01057576|Experimental|PMI 5011|An experimental group randomized to PMI 5011
3219904|NCT01057576|Placebo Comparator|Placebo|Placebo
3219905|NCT01057563|Active Comparator|BMS group|Patients undergoing PCI with BMS implantation
3219906|NCT01057563|Active Comparator|PRE-DEB group|Patients undergoing PCI with BMS implantation after lesion predilation with DEB
3219907|NCT01057563|Active Comparator|POST-DEB group|Patients undergoing PCI with BMS implantation followed by postdilation with DEB
3219908|NCT01057550|Active Comparator|Autologous Fascial Sling|Retropubic, bottom up autologous sling
3219909|NCT01057550|Active Comparator|TVT|Standard retropubic TVT
3219910|NCT01057550|Active Comparator|Pelvicol|Retropubic mid urethral sling made from Pelvicol
3219911|NCT01057537|Experimental|polypill|Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2.
3219912|NCT01057537|Active Comparator|Usual Care|Participants in the usual care arm will take their usual cardiovascular medications. The participants will be seen as needed by their usual doctor between study visits.
3219913|NCT01057524|Active Comparator|Usual Airway Clearance Technique|Two self administered treatment sessions a day and two treatments a day assisted by a Physiotherapist both using the patient's usual airway clearance method.
3219914|NCT01057524|Experimental|High Frequency Chest Wall Oscillation (HFCWO)|Two self administered treatments a day using HFCWO and two treatment sessions a day assisted by a Physiotherapist using their 'usual' airway clearance method.
3219915|NCT01057511|Active Comparator|progesterone|Each subject in this group will be give progesterone oil 20mg via intramuscular route once a day for 7 days totally
3219916|NCT01057511|Experimental|Crinone 8%|Each subjects in this group will be given Crinone 8% 90mg via vaginal route once a day for 7 days totally.
3219917|NCT01057498|Experimental|1a - RNS60 in Healthy Subjects|Single dose administration of nebulized RNS60 testing for bronchoconstriction in healthy human subjects.
3219918|NCT01057498|Experimental|1b: RNS60 in Mild Asthmatics|Single-dose administration of nebulized RNS60 testing for bronchoconstriction in mild asthmatics.
3219919|NCT01057498|Experimental|2e: RNS60 in mild-to-moderate asthmatics|RNS60 in mild-to-moderate asthmatics who are not currently taking a chronic asthma medication.
3219920|NCT01057485|Experimental|AF ablation and AV node ablation|Patients will receive the combined procedure of AF ablation as well as AV node ablation
3219921|NCT01057485|Active Comparator|AV node ablation|Patient will receive AV node ablation alone
3219922|NCT01057472||Term born babies|Term born babies
3219923|NCT01057472||Preterm babies ready for discharge|Preterm babies ready for discharge
3219924|NCT01057472||Preterm stable babies 1500 grams|Preterm stable babies 1500 grams
3219925|NCT01057459||Ancillary-Correlative (biomarkers and treatment outcomes)|Genomic DNA is extracted from previously collected blood samples for KIR and HLA genotyping and polymorphism analysis.
3219926|NCT01057433|Experimental|Pitavastatin|Healthy adult subjects
3219927|NCT01057420|Other|Inhalation of 80% Oxygen|Inhalation of 80% Oxygen by nonrebreathing reservoir face masks for 4 hours
3219928|NCT01057407|Experimental|ASP group|
3219929|NCT01057407|Active Comparator|Sevelamer group|
3219930|NCT01057394|Active Comparator|Radiofrequency Ablation|PVI using RF ablation
3219931|NCT01057394|Experimental|Visually Guided Ablation|PVI using visually guided ablation with an endoscopic ablation system
3219932|NCT01057381|Active Comparator|Dexmedetomidine 0.75 mcg/kg|Intraoperative administration for analgesia.
3219933|NCT01057381|Active Comparator|Dexmedetomidine 1mcg/kg|Intra-operative administration of dexmedetomidine 1 mcg/kg for analgesia
3219934|NCT01057381|Active Comparator|Morphine 50 mcg/kg|Intra-operative administration of morphine 50 mcg/kg for analgesia
3219935|NCT01057381|Active Comparator|Morphine 100mcg/kg|Intra-operative administration of morphine 100mcg/kg for analgesia
3219936|NCT01057368|Active Comparator|Mindfulness Based Stress Reduction|
3219937|NCT01057368|Active Comparator|Health Enhancement Program|
3219938|NCT01057368|No Intervention|Wait List Controls|
3219939|NCT01057368|Active Comparator|Long Term Meditators|
3219940|NCT01057355|Experimental|Cyst ethanol lavage|Subjects receiving the study intervention
3219941|NCT01057342|Experimental|Paclitaxel, Carboplatin, ASA404|
3219942|NCT01057329||Anorexia nervosa|36 severe AN patients treated with aripiprazole
3219943|NCT01057329||Anorexia|36 severe anorexia nervosa patients treated with olanzapine
3219944|NCT01057329||Attention Deficit Hyperactivity Disorder|30 ADHD patients treated with atomoxetine
3219945|NCT01057329||Depressive disorder|30 depressed patients treated with duloxetine
3219946|NCT01057316|Experimental|Study Group A|
3219947|NCT01057316|Experimental|Study Group B|
3219948|NCT01057316|Experimental|Study Group C|
3219949|NCT01057277|Experimental|RAD001(Afinitor)|Radiation 47 days Cisplatin day 1,8,15,22,29,36,43 RAD001 Day 1 according to assigned group to day 47
3220003|NCT01056874|Experimental|Digoxin + Maraviroc|
3219950|NCT01057264|Experimental|HAI Abraxane + Gemcitabine + Bevacizumab|HAI (hepatic arterial infusions) Abraxane with Gemcitabine + Bevacizumab
3219951|NCT01057251|Experimental|1|
3219952|NCT01057251|Placebo Comparator|2|
3219953|NCT01057238|Experimental|Intensive Communication|regular family meeting every 5 days.
3219954|NCT01057238|No Intervention|Control|usual care
3219955|NCT01057225|Experimental|Arm I|Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28.
3219956|NCT01057212|Experimental|Bevacizumab and Ixabepilone|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks. Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule to the remaining 40 patients.
3219957|NCT01057186||hereditary hypophosphatemia|Norwegian patients with hereditary hypophosphatemia.
3219958|NCT01057186||Hereditary hyperphosphatemia|Norwegian patients with hereditary hyperphosphatemia (hyperphosphatemic familial tumoral calcinosis and hyperphosphatemia hyperostosis syndrome).
3219959|NCT01057173|Experimental|Transcatheter Aortic Valve Implantation|
3219960|NCT01057173|Active Comparator|Surgical Aortic Valve Replacement|
3219961|NCT01057160|Experimental|intake of rizatriptan 10 mg|
3219962|NCT01057160|Active Comparator|previous used analgesic|
3219963|NCT01057147|Experimental|rebamipide 2% ophthalmic suspension|
3219964|NCT01057147|Placebo Comparator|placebo eye drops|
3219965|NCT01057121|Experimental|Lenalidomide|Patients receive lenalidomide PO once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3219966|NCT01057108|Active Comparator|ESRD: FOSTRAP Chewing Gum|
3219967|NCT01057108|Active Comparator|CKD: FOSTRAP Chewing Gum|
3219968|NCT01057108|Placebo Comparator|ESRD Matching Placebo|
3219969|NCT01057108|Placebo Comparator|CKD Matching Placebo|
3219970|NCT01057082|Experimental|Juven|Participants in the treatment arm will receive the dietary supplement Juven.
3219971|NCT01057082|Placebo Comparator|Placebo|
3219972|NCT01057069|Experimental|HRD; 1x ddAC, 2x tCTC|HRD positive tumors; irrespective of response; - a fourth course of AC followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
3219973|NCT01057069|Active Comparator|HRD; 3x CP|HRD tumors; any response to 3x ddAC; 3 courses of CP
3219974|NCT01057069|Active Comparator|non-HRD;3x CP|non-HRD tumors; unfavourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel
3219975|NCT01057069|Active Comparator|non-HRD; response; 3x ddAC|non-HRD tumors; favourable response to 3x ddAC; 3 more courses of ddAC
3219976|NCT01057069|Active Comparator|non-HRD; response; 3x CP|non-HRD tumors; favourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel
3219977|NCT01057056|No Intervention|control group|control group - receiving standard treatment
3219978|NCT01057043|No Intervention|Waiting list|In case of acute pain patients may take paracetamol as rescue medication, maximum dosage 2 gram per day.
3219979|NCT01057043|Experimental|Cupping|In case of acute pain patients may take paracetamol as rescue medication, maximum dosage 2 gram per day.
3219980|NCT01057030|Active Comparator|A1 (BMS-708163)|Healthy Japanese Subjects
3219981|NCT01057030|Placebo Comparator|A2 (Placebo)|Healthy Japanese Subjects
3219982|NCT01057030|Active Comparator|B1 (BMS-708163)|Healthy Non-Japanese Subjects
3219983|NCT01057030|Placebo Comparator|B2 (Placebo)|Healthy Non-Japanese Subjects
3219984|NCT01057017|Experimental|intervention|"Bevacizumab: 7.5mg/kg, IV over 30-90 minutes every 3 weeks until disease progression.~Panitumumab Dose Level 1: 6mg/kg over 60-120 minutes every 3 weeks until disease progression Dose Level 2: 9mg/kg over 60-120 minutes every 3 weeks until disease progression"
3219985|NCT01057004||all patients|chronical heart failure and EF ≤ 40 %
3219986|NCT01056991|Experimental|warming mattress|Patient warmed with electric mattress
3219987|NCT01056991|Active Comparator|warming blanket|Forced air warming blanket
3219988|NCT01056978||patients|Patients admitted in a palliative care unit
3219989|NCT01056965|Experimental|davunetide (Al-108, NAP) nasal spray|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with either davunetide 15 mg or placebo. Davunetide and placebo will be administered intranasally with a multi-dispensing, metered nasal spray pump device.
3219990|NCT01056965|Placebo Comparator|Placebo nasal spray|
3219991|NCT01056952|Experimental|Optiflow then CPAP|Standard low flow oxygen therapy then High flow oxygen nasal therapy (Optiflow)then Continuous positive airway pressure (CPAP)
3219992|NCT01056952|Experimental|CPAP then Optiflow|Standard low flow oxygen therapy then Continuous positive airway pressure (CPAP)then High flow oxygen nasal therapy (Optiflow)
3219993|NCT01056939|Active Comparator|NAVA|Children randomised in this arm will be treated with neurally adjusted ventilatory assist
3219994|NCT01056939|Active Comparator|Control|Patients randomized to control group will be treated with pressure controlled ventilation (PC) when they are newborns and older children in this group will be treated with pressure regulated volume controlled (PRVC) ventilation.
3219995|NCT01056926|Experimental|Nicotine Patch + Denic Smoking|Subjects will wear a nicotine patch and smoke denic cigarettes for 24 hours prior to scan
3219996|NCT01056926|Experimental|Placebo Patch + Denic Smoking|Subjects will wear a placebo patch and smoke denic cigarettes 24 hours prior to scan
3219997|NCT01056926|Experimental|Nicotine Patch + No Smoking|Subjects will wear a nicotine patch and not smoke for 24 hours prior to scan
3219998|NCT01056926|Experimental|Placebo Patch + No Smoking|Subjects will wear a placebo patch and not smoke for 24 hours prior to scan
3219999|NCT01056913|Other|NITI CAR27 (ColonRing)|
3220000|NCT01056900||Chondron Implantation|This clinical trial was a follow-up study involving 127 patients from 10 hospitals, for whom autologous chondrocyte transplantation was already performed. All the subjects were investigated as a single group
3220001|NCT01056887||Primary Polydip, D. insipidus|
3220004|NCT01056861||Cervical dystonia (torticollis)|Subjects meeting the criteria fot torticollis who are receiving botulinum toxin injections.
3220005|NCT01056861||Control|age matched controls with out cervical dystonia (torticollis)
3220006|NCT01056848||CK-LX3401|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia.
3220007|NCT01056848||CK-LX3405|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia
3220008|NCT01056848||CK-LX3430|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia
3220009|NCT01056835|No Intervention|control|
3220010|NCT01056822|Active Comparator|1|Mycophenolate mofetil
3220011|NCT01056822|Experimental|2|Miycophenolate sodium
3220012|NCT01056809|Active Comparator|Traditional strategy|First resection of the primary colorectal tumour, then treatment of metastases with chemotherapy and if possible surgery.
3220013|NCT01056809|Active Comparator|Alternative strategy|First treatment of metastases with chemotherapy and if possible surgery, later resection of primary colorectal tumour if hope for cure or if symptoms develope that necessitates treatment
3220014|NCT01056796|Experimental|CAR™ 27|Any patient with a diagnosis of colorectal cancer that has been previously radiated to the pelvic area (6-8 weeks prior to surgery) and that is electively scheduled for an open or laparoscopic total mesorectal excision (TME) and low anterior resection surgery (< 10cm from the anal verge) which requires the creation of an anastomosis, will be offered participation in this study.
3220015|NCT01056783|Experimental|OC000459|OC000459 100mg twice daily
3220016|NCT01056783|Placebo Comparator|Placebo|
3220017|NCT01056770|Experimental|Vaccinia-naive group|2.5 * 10^5 pfu/dose
3220018|NCT01056757|Experimental|Ribavirin|
3220019|NCT01056744|Active Comparator|DES|Implantation of a XIENCE® V everolimus eluting coronary stent (drug-eluting stent, DES)
3220020|NCT01056744|Active Comparator|BMS/DEB|Implantation of a Coroflex Blue® coronary stent (bare metal stent, BMS) postdilated with a Sequent Please® paclitaxel-eluting balloon (drug-eluting balloon, DEB)
3220021|NCT01056731|Experimental|Aliskiren and Aliskiren_HCTZ|aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg 25 mg
3220022|NCT01056718|Other|Nebivolol treatment|10 week open label nebivolol treatment.
3220023|NCT01056705|Experimental|Cohort 1: Experiment Infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections;
3220024|NCT01056705|Experimental|Cohort 2: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections;
3220025|NCT01056705|Experimental|Cohort 3: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections;
3220026|NCT01056705|Experimental|Cohort 4: Experiment infants|Biological: Oral Poliomyelitis Vaccine (OPV).3x0.1ml oral;
3220027|NCT01056705|Experimental|Cohort 5: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Salk strains). 3x0.5ml intramuscular injections;
3220028|NCT01056692|Active Comparator|Active compound|OC000459 orally
3220029|NCT01056692|Placebo Comparator|Placebo|Placebo given orally
3220030|NCT01056679|Experimental|AVD-Rev|Patients with intermediate stage HL receive 4 cycles of AVD-Rev followed by 30 Gy IF-RT Patientes with advanced stage HL receive 6 to 8 cycles of AVD-Rev followed by 30 GY IF-RT depending on the FDG-PET results
3220031|NCT01056666|Experimental|Conveen optima urisheaths|
3220032|NCT01056666|Placebo Comparator|absorbent protections|The patient use their usual absorbent protection as comparator. All brands are allowed.
3220033|NCT01056653|Experimental|Group A Teal|Standard Dose - Two intervention home visits (at 4 and 6 months of age)
3220034|NCT01056653|Experimental|Group B Purple|High Dose - Four intervention home visits (at 4, 5, 6, and 7 months of age)
3220035|NCT01056653|Sham Comparator|Group C Yellow|Comparison Group - One home visit, information only (at 4 months of age)
3220036|NCT01056640|Experimental|Home Telemonitoring|The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line. This device has video monitoring which allows a real time face to face interaction with the provider. This allows for an individualized home care plan based upon multiple concerns which have not been adequately studied.
3220037|NCT01056640|Active Comparator|Usual Care|The usual care intervention will include appropriate primary care and specialty office practice visits as required. It also includes home health care, timely post-hospital outpatient visits, a nurse generated phone call progress report within one business day of hospital dismissal, and standard clinic phone triage during business hours. It also involves a 24 hour nurse triage line for questions. Patients will be informed of the general options currently available to patients including the above as well as options for care in extended hours and at Mayo Express care.
3220038|NCT01056627|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
3220039|NCT01056627|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
3220040|NCT01056614|Experimental|Treatment (chemotherapy, PBSC transplant)|Patients receive fludarabine phosphate IV over 30 minutes on days -9 to -6, busulfan IV over 3 hours on days -5 to -2, and anti-thymocyte globulin IV over 6 hours on days -3 and -2 and over 4 hours on day -1. Patients undergo allogeneic PBSC transplant on day 0. Patients then receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and taper to day 180 and methotrexate IV on days 1, 3, 6, and 11.
3220041|NCT01056601|Experimental|Pancreatic Cancer Patients|Pancreatic cancer patients who received treatment with bortezomib and panobinostat after progressing on gemcitabine.
3220042|NCT01056588|Placebo Comparator|Control Condition|In this condition, participants will receive reinforcement for timely breath samples with no contingency for a specific breath CO level.
3220043|NCT01056588|Active Comparator|CO-Contingent|In this condition, participants will receive reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking.
3220044|NCT01056575|Experimental|OC000459|
3220278|NCT01054885|Experimental|Fluticasone Furoate Inhalation Powder|Inhaled Corticosteroid (ICS)
3220045|NCT01056549|Experimental|exenatide subcutaneous injection|Study A: lipoprotein turnover following subcutaneous exenatide administration, under conditions of pancreatic clamp. Study B: lipoprotein turnover study following subcutaneous placebo administration, under conditions of pancreatic clamp.
3220046|NCT01056536|Experimental|Structured intervention + free condoms|The subjects will receive a structured intervention on STI's and will be offered free condoms
3220047|NCT01056536|Active Comparator|Free condoms|Subjects will be offered free condoms at the end of the pre-travel consultation
3220048|NCT01056536|No Intervention|No intervention|The topic of STI's will not be actively discussed during the pretravel consultation
3220049|NCT01056523|Experimental|Ribavirin-Cytarabine arabinoside|Ribavirin will be given orally bid according to a dose escalation scheme daily for 28 days of a 28 day cycle Cytarabine arabinoside will be given 20 mg sc bid days 1 to 10 of a 28 day cycle
3220050|NCT01056510|Experimental|A|
3220051|NCT01056510|Experimental|B|
3220052|NCT01056497|Experimental|alpha lipoic acid|
3220053|NCT01056484|Experimental|Meditation|Mindfulness Based Relapse Prevention for Alcohol Dependence intervention + Standard of Care therapy
3220054|NCT01056484|Other|Wait-list control|Standard of Care therapy only
3220055|NCT01056471|Experimental|Low dose autologous mesenchymal cells|The dose of infused cells is 10e6 cells/Kg
3220056|NCT01056471|Experimental|High dose|The dose of infused cells is 4*10e6 cells/Kg
3220057|NCT01056471|No Intervention|Placebo Control|
3220058|NCT01056458|Active Comparator|Acupressure acupressure|
3220059|NCT01056458|Sham Comparator|sham acupressure|
3220060|NCT01056445|Active Comparator|carotid stenting and hemodynamic instability|27 patients undergone carotid stenting
3220061|NCT01056445|Active Comparator|carotid stenting without hemodynamic instability|no hemodynamic instability after carotid stenting
3220062|NCT01056419|Active Comparator|Total thyroidectomy|
3220063|NCT01056419|Active Comparator|Anti-thyroid drug|
3220064|NCT01056406|No Intervention|Control Group|Overweight and obese pregnant women who are randomly assigned to the control group will receive the current standard of optimal care in addition to 1 nutrition education session with the study nutritionist (a registered dietitian) at 6-16 weeks gestation.
3220065|NCT01056406|Experimental|Nutrition Education Group|Overweight and obese pregnant women randomly assigned to the nutrition education group, in addition to the current standard of optimal care, will receive twice monthly interaction with the study nutritionist (a registered dietitian) from 6-16 weeks gestation through 6 months postpartum.
3220066|NCT01056393|Experimental|ibalizumab 800mg Q2Weeks|Subject will receive 800mg of ibalizumab every 2 weeks administered by intravenous infusion. All patients also will receive optimized background regimen
3220067|NCT01056393|Experimental|ibalizumab 2000mg Q4Weeks|Subject will receive 2000mg of ibalizumab every 4 weeks administered by intravenous infusion. All patients also will receive optimized background regimen
3220068|NCT01056380|Active Comparator|Nitazoxanide|
3220069|NCT01056380|Placebo Comparator|Placebo|
3220070|NCT01056354||Influenza|Influenza A and subtypes such as H3N2 and 2009 H1N1 or influenza B
3220071|NCT01056354||Novel respiratory virus-1|MERS-CoV (Middle Eastern Respiratory Syndrome Coronavirus)
3220072|NCT01056354||Novel respiratory virus-2|SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus)
3220073|NCT01056341|Experimental|Propranolol oral solution|
3220074|NCT01056341|Placebo Comparator|Placebo|
3220075|NCT01056328|Experimental|St. Jude Medical Cardiac Ablation System|
3220076|NCT01056328|Active Comparator|FDA approved Open Irrigated Radio Frequency Ablation System|
3220077|NCT01056315|Experimental|A GRT3983Y|Participants randomly assigned to receive GRT3983Y.
3220078|NCT01056315|Placebo Comparator|B Placebo|Participants randomly assigned to placebo.
3220079|NCT01056302||Group 1|15 patients with maxillofacial trauma who underwent surgical repair at San Francisco VA Medical Center
3220080|NCT01056289|Active Comparator|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|
3220081|NCT01056289|Active Comparator|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|
3220082|NCT01056289|Placebo Comparator|Placebo|
3220083|NCT01056276|Experimental|Treatment|Bendamustine, Bortezomib,and Dexamethasone for 8 cycles or 2 cycles beyond a confirmed complete response, assessed by IMWG criteria. Patients with stable disease and no intolerable toxicity may continue maintenance therapy with Bortezomib and Dexamethasone until disease progression or intolerable toxicity.
3220084|NCT01056263||Non-Interventional Study|Subjects participating in this observational study originally participated in study A4061012 [NCT00076011], and may have also have participated in study A4061008 [NCT00828919].
3220085|NCT01056250|Other|SILS cholangiography|Performing cholangiography in all patients undergoing SILS cholecystectomy.
3220086|NCT01056237|Experimental|Multi-target therapy|(Tarcrolimus+mycophenolate mofetil)
3220087|NCT01056237|Active Comparator|Azathioprine|Aza
3220088|NCT01056224|Experimental|1.25 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
3220089|NCT01056224|Experimental|1.5 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
3220090|NCT01056224|Experimental|1.75 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.75 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
3220091|NCT01056224|Experimental|1 ug/kg normo-tensive 65-75 year olds|A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
3220092|NCT01056224|Experimental|1.25 ug/kg normo-tensive 65-75 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
3220093|NCT01056224|Experimental|1.5 ug/kg normo-tensive 65-75 year olds|"1.5 ug/kg normo-tensive 65-75 year olds~A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old."
3220094|NCT01056224|Experimental|1 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
3220095|NCT01056224|Experimental|1.25 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
3220096|NCT01056224|Experimental|1.5 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
3220097|NCT01056211|Active Comparator|hypopigmented scars treated with laser|patients with hypopigmented scars treated with Starlux 300 Lux 1540nm Fractional laser hand piece
3220098|NCT01056211|Placebo Comparator|hypopigmented scars treated without laser|patients with hypopigmented scars treated without laser
3220099|NCT01056211|Active Comparator|hypertrophic scars treated with laser|
3220100|NCT01056211|Placebo Comparator|hypertrophic scars not treated with laser|
3220101|NCT01056211|Active Comparator|scars due to grafts and reconstructions treated with laser|scars due to grafts and reconstructions in the head and neck region
3220102|NCT01056211|Placebo Comparator|grafts and reconstructions scars not treated with laser|scars due to grafts and reconstructions in the head and neck region
3220103|NCT01056198|Active Comparator|Santyl|2 mm Santyl applied once daily
3220104|NCT01056198|Sham Comparator|Control|Daily gauze and optional sharp debridement
3220105|NCT01056185||Influenza|Influenza A and subtypes such as H3N2 and 2009 H1N1 or influenza B
3220106|NCT01056185||Novel Respiratory Virus-1|MERS-CoV (Middle East Respiratory Syndrome Coronavirus
3220107|NCT01056185||Novel Respiratory Virus-2|SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus)
3220108|NCT01056172|Active Comparator|A. 24 weeks in RVR patients.|Peginterferon alfa-2a and weight-based ribavirin (800-1200mg/day) for 24 weeks in patients with RVR.
3220109|NCT01056172|Experimental|B. 16 weeks in RVR patients.|Peginterferon alfa-2a and weight-based ribavirin (800-1200mg/day) for 16 weeks in patients with RVR.
3220110|NCT01056159|Experimental|Albuterol dry powder inhaler|The participants will receive albuterol delivered with the a DPI (dry powder inhaler) and placebo with an HFA MDI inhaler (hydrofluoroalkane metered dose inhaler).
3220111|NCT01056159|Active Comparator|Albuterol HFA MDI|The participants will receive albuterol delivered with an HFA MDI inhaler (hydrofluoroalkane metered dose inhaler) and placebo with albuterol in a DPI (dry powder inhaler).
3220112|NCT01056146|Active Comparator|Internet Resources Comparison (IRC)|Participants will receive the Internet resource comparison group treatment
3220113|NCT01056146|Experimental|I-InTERACT|Participants will receive the internet-based parenting skills program.
3220114|NCT01056133|Experimental|Omega-3 capsules-Fish Oil|Omega-3 fatty acids in the form of fish oil capsules (2g/d)
3220115|NCT01056120||ENERGY-Population|"Patient population in standard clinical care, according to the instructions for use and the inclusion / exclusion criteria. Registry patients should be enrolled consecutively to represent a typical set of patients at each site.~The registry will collect clinical data from patients that have given their prior written consent. All data will be anonymized prior to data entry."
3220116|NCT01056107|Experimental|ROSE-010 30 mcg|A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
3220117|NCT01056107|Experimental|ROSE-010 100 mcg|A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
3220118|NCT01056107|Experimental|ROSE-010 300 mcg|A glucagon-like peptide-1 (GLP-1) analogue. A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
3220119|NCT01056107|Placebo Comparator|Placebo|Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
3220120|NCT01056094|Active Comparator|20mg Lutein|Dietary Supplement: 20mg Lutein; daily supplementation 12 week
3220121|NCT01056094|Active Comparator|10mg Lutein|Dietary Supplement: 10mg Lutein; daily supplementation 12 week
3220122|NCT01056094|Placebo Comparator|0mg Lutein|Dietary Supplement: 0mg Lutein; daily supplementation 12 week
3220123|NCT01056081|Experimental|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
3220124|NCT01056055||Suture anchor, Bone tunnel|Suture anchor group: patients who underwent the modified Brostrom procedure using suture anchor technique Bone tunnel group: patients who underwent the modified Brostrom procedure using bone tunnel technique
3220125|NCT01056042|Experimental|A|Intramuscular depot medroxyprogesterone acetate
3220126|NCT01056042|Active Comparator|B|ethinyl estradiol 30 micrograms combined with gestodene 75 micrograms
3220127|NCT01056029|Experimental|G-202|
3220128|NCT01056016|No Intervention|Wait-list control|Wait-list control group
3220129|NCT01056016|Experimental|ADHD Collaborative Intervention|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a Diagnostic and Statistical Manual-IV (DSM-IV) based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales. The intervention lasts for 6 months.
3220130|NCT01056003||all patients admitting endoscopy for EGD|
3220185|NCT01055587||severe burn injury|The investigators compare levels of biomarkers within the first 20 days in patients with and without complications following severe burn injury
3220131|NCT01055990|Other|Heathy,aged 18-60 years,|They are healthy, are 18-60 years of age, did not have a history of infection with the 2009 H1N1 virus, and are appropriate to vaccination, without any interdictions. And they guardians confirmed that they understood the study procedures, provided written informed consent, and agreed to comply with the following visit schedule. Woman participants all are not pregnant,with a negative pregnancy test before vaccination.
3220132|NCT01055990|Experimental|clinically critical H1N1 patients|The critical H1N1 patients as recipients whose conditions are confirmed according to current standard for critical H1N1 diagnosis. The study wll research H1N1 viral load in blood of critical H1N1 patients and swab nucleic acid testing parallelity; measure H1N1 viral Load in blood and swabs (adopting Real-time PCR method) of 5 to 10 victims; and the planned blood taking time is the tenth day since the fever begins.
3220133|NCT01055964|Experimental|Tacrobell|
3220134|NCT01055964|Active Comparator|Prograf|
3220135|NCT01055951|Experimental|Solo MicroPump|
3220136|NCT01055938|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
3220137|NCT01055938|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
3220138|NCT01055925|Active Comparator|MPV|
3220139|NCT01055925|Active Comparator|Aquacel|
3220140|NCT01055912|Experimental|Lixivaptan|Capsule, 100mg Lixivaptan or matching placebo once daily.
3220141|NCT01055912|Placebo Comparator|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
3220142|NCT01055899|Experimental|Dose 1|First dose of SC REGN88
3220143|NCT01055899|Experimental|Dose 2|Second dose of SC REGN88
3220144|NCT01055899|Experimental|Dose 3|Third dose of SC REGN88
3220145|NCT01055886|Active Comparator|Nicotine Patch|Nicotine patch given pre-quit attempt at weeks 4 through 6
3220146|NCT01055886|Placebo Comparator|placebo patch|placebo patch given pre-quit from weeks 4 through 6
3220147|NCT01055860||Robotic sacral colpopexy|Our study population will be women who underwent Robotic assisted laparoscopic sacral colpopexy at the Morristown Memorial Hospital for correction of pelvic organ prolapse using a synthetic polypropylene mesh.
3220148|NCT01055847|Experimental|AI 75 mg|Aztreonam for Inhalation 75 mg twice daily
3220149|NCT01055847|Experimental|AI 225 mg|Aztreonam for Inhalation 225 mg twice daily
3220150|NCT01055847|Placebo Comparator|Placebo|Placebo
3220151|NCT01055834|Experimental|Eszopiclone 3 mg tablet|
3220152|NCT01055834|Experimental|Eszopiclone 1 mg tablet|
3220153|NCT01055821|Active Comparator|Arm A|Standard of care (SOC)
3220154|NCT01055821|Experimental|Arm B|Vaccine and Standard of care
3220155|NCT01055821|Experimental|Arm C|vaccine and standard of care
3220156|NCT01055808||Type 2 diabetes treated with insulin|
3220157|NCT01055795|Experimental|Bevacizumab, Everolimus and LBH589|"Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589~3-6, All study drugs administered per dose level~3-6, All study drugs administered per dose level~3-6, All study drugs administered per dose level~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B & C; 30, Recommended Phase II Dose for all three compounds"
3220158|NCT01055782|Experimental|With endoguide|Colonoscopy completed with endoguide
3220159|NCT01055782|No Intervention|Without endoguide|Colonoscopy completed without endoguide
3220160|NCT01055769|Other|Group 1|Subjects will accept Linezolid OS 600 MG first, after 4 days wash-out, then will accept Linezolid tablet 600 MG.
3220161|NCT01055769|Other|Group 2|Subjects will accept Linezolid tablet 600 MG first, after 4 days wash-out, then will accept Linezolid OS 600 MG.
3220162|NCT01055756|Experimental|Test (Cloratadd D)|Loratadine + Pseudoephedrine sulfate Test
3220163|NCT01055756|Active Comparator|Comparator (Claritin D)|Loratadine + Pseudoephedrine Comparator
3220164|NCT01055743|Experimental|Radical resection + Fluorouracil Implants|
3220165|NCT01055743|Active Comparator|Radical resection|
3220166|NCT01055730||Pulmonary rehabilitation|
3220167|NCT01055717|Placebo Comparator|Placebo muffin made with no oats|
3220168|NCT01055717|Active Comparator|Test muffin made with AV-enriched oats|
3220169|NCT01055704|Experimental|Methylnaltrexone|
3220170|NCT01055704|Experimental|Codeine|
3220171|NCT01055704|Experimental|Methylnaltrexone + codeine|
3220172|NCT01055704|Placebo Comparator|Placebo|
3220173|NCT01055691|Experimental|1|Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
3220174|NCT01055691|Experimental|2|Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
3220175|NCT01055691|Experimental|3|Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
3220176|NCT01055691|Experimental|4|Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
3220177|NCT01055678|Experimental|All Patients|Single arm study analyzing tumor hypoxia after EF5 injection
3220178|NCT01055652|Experimental|1|
3220179|NCT01055639|Active Comparator|In-person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT). ACT is a psychotherapy intervention comprised of meditation, goal-setting, and behavior change.
3220180|NCT01055639|Experimental|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT). Sessions were delivered via videoconferencing system. ACT is a psychotherapy intervention comprised of meditation, goal-setting, and behavior change.
3220181|NCT01055613|Experimental|Experimental multi-purpose solution|Multi-purpose contact lens care solution.
3220182|NCT01055613|Active Comparator|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution.
3220183|NCT01055600|Experimental|Study|Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
3220184|NCT01055587||major abdominal surgery|The investigators compare the levels of biomarkers in patients with and without complications in the early postoperative course following major abdominal surgery
3220279|NCT01054885|Experimental|FF Inhalation Pwdr|Inhaled Corticosteroid (ICS)
3220186|NCT01055574||ProDisc-L|Subjects who received single-level ProDisc-L total disc replacement prior to physical capability evaluations
3220187|NCT01055574||anterior lumbar interbody fusion (AILF)|Subjects who received single-level anterior lumbar interbody fusion prior to physical capability evaluations
3220188|NCT01055561|Experimental|Patients|
3220189|NCT01055561|Experimental|Healthy volunteers|
3220190|NCT01055548||Parents of babies born before 33 weeks gestation|
3220191|NCT01055535|Experimental|Microplasmin|
3220192|NCT01055522|Experimental|ARM 1: L19IL2 + Dacarbazin|
3220193|NCT01055522|Experimental|ARM 2: L19IL2 + Dacarbazin|
3220194|NCT01055522|Active Comparator|ARM 3: Dacarbazin|DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first
3220195|NCT01055509|Experimental|Cognitive Adaptation Training|Cognitive adaptation training and treatment as usual
3220196|NCT01055509|No Intervention|Treatment as ususal|Pharmacological treatment, weekly contact to professionals (often in patient's homes), psychoeducation, social skill training in groups and psychosocial intervention with relatives.
3220197|NCT01055496|Experimental|Arm 1 (R-CVP)|Subjects in arm 1 will be enrolled in dose escalation cohorts that will initially evaluate an escalating dose of cyclophosphamide in combination with set doses of inotuzumab ozogamicin, vincristine, prednisone, and rituximab.
3220198|NCT01055496|Experimental|Arm 2 (R-GDP)|Subjects in arm 2 will be enrolled in dose escalation cohorts that will initially evaluate escalating doses of gemcitabine and/or cisplatinum in combination with set doses of inotuzumab ozogamicin, dexamethasone, and rituximab.
3220199|NCT01055483|Experimental|LBH589|
3220200|NCT01055470|Active Comparator|Diclofenac|Tab.Diclofenac 50 mg ,Orally, 12 hrly in morning and in evening after taking food for 3 months.
3220201|NCT01055470|Experimental|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
3220202|NCT01055457|Experimental|Experimental Multi-Purpose Solution|contact lens care solution
3220203|NCT01055457|Active Comparator|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
3220204|NCT01055444|Experimental|Heated lidocaine/tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
3220205|NCT01055431|Placebo Comparator|Control|Control bread
3220206|NCT01055431|Active Comparator|Teff bread|Teff bread
3220207|NCT01055418|Placebo Comparator|placebo|
3220208|NCT01055418|Experimental|Vitamin C|
3220209|NCT01055405|Experimental|Sildenafil plus pulmonary rehabilitation|
3220210|NCT01055405|Placebo Comparator|Placebo plus pulmonary rehabilitation|
3220211|NCT01055392|Experimental|Lithium|Patients received low doses of lithium salts (from 150 mg to 450 mg of lithium salts daily) to achieve sub-therapeutic lithium levels (target serum lithium level of 0,25 - 0,5 mEq/L). Lithium doses were administered twice a day. Lithium doses were titrated to achieve the target serum lithium levels within the first two weeks after study recruitment. After achieving the target serum lithium level, lithium salts doses remained stable until the end of the study.
3220212|NCT01055392|Placebo Comparator|Placebo|Identical placebo tablets were administered twice-a-day for two years.
3220213|NCT01055379|Experimental|Rasagiline|
3220214|NCT01055379|Placebo Comparator|Placebo|
3220215|NCT01055366|Experimental|Elazop (Azarga)|Elazop Treatment arm
3220216|NCT01055340|Experimental|Treatment sequence 1|OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min - Placebo
3220217|NCT01055340|Experimental|Treatment sequence 2|OXM 0.6 pmol/kg/min - Placebo - OXM 3.0 pmol/kg/min
3220218|NCT01055340|Experimental|Treatment sequence 3|Placebo - OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min
3220219|NCT01055340|Experimental|Treatment sequence 4|OXM 3.0 pmol/kg/min - Placebo - OXM 0.6 pmol/kg/min
3220220|NCT01055340|Experimental|Treatment sequence 5|Placebo - OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min
3220221|NCT01055340|Experimental|Treatment sequence 6|OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min - Placebo
3220222|NCT01055327||Infants/foetuses w/malformations registered in EUROCAT network|Pregnancies resulting in foetus/infant with malformation registered through participating registers within the EUROCAT network
3220223|NCT01055314|Experimental|Group 1 (chemotherapy, radiation therapy, cixutumumab)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-5, 7, 8, 11, 12, 15, 16, 20-24, 28, 29, 32, 33, 35, 38, 41-44, 47, 48, 50, and 51; irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 1, 4, 20, 23, 47, and 50; ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 of weeks 9, 13, 17, 26, and 30; doxorubicin hydrochloride IV over 1-15 minutes on days 1 and 2 of weeks 7, 11, 15, 28, and 32; cyclophosphamide IV over 30-60 minutes on day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41, and 44; dactinomycin IV over 1-5 minutes on day 1 of weeks 35, 38, 41, and 44; and cixutumumab IV over 1 hour on day 1 of weeks 1-51. Patients also undergo radiation therapy on days 1-5 of weeks 20-24.
3220224|NCT01055314|Experimental|Group 2 (chemotherapy, radiation therapy, temozolomide)|Patients receive vincristine sulfate, irinotecan hydrochloride, ifosfamide, etoposide, doxorubicin hydrochloride, cyclophosphamide, and dactinomycin and undergo radiation therapy as in group 1. Patients also receive temozolomide PO on days 1-5 of weeks 1, 4, 20, 23, 47, and 50.
3220225|NCT01055301|Experimental|treatment|"Ind (1cycle):~bort 1mg/m2 IV/SQ D1,4,8,11 D1-4: thalid 200mg/d & dex 20mg/d PO; cisplatin & dox 10mg/m2/d, cyclophos 400mg/m2/d, etoposide 40mg/m2/d contIV; enoxaparin 40mg/d SQ prn.~PBSC Coll: at recovery per local standard~Bridging (before/between trans/after Cons):~thal 50mg/d D1-21 & dex 20mg D1,8,15 PO~Tandem Trans (x2):~bort 1mg/m2 IV/SQ D-4,-1 D-4to-1: mel 50 mg/m2 IV, thal 200mg/d & dex 40mg/d PO PBSC >/=200x10^6 cells~Cons (1cycle):~same as Ind except cis/dox 7.5mg/m2/d, cyclo 300mg/m2/d, no enox~Maint(</= 3 yrs):~D1,8,15,22:bort 1mg/m2 IV/SQ, dex 20mg/d PO; len 20mg/d PO D1-20"
3220226|NCT01055275||Cook Iliac Branch Graft|Patients implanted with a Cook Iliac Branch Graft
3220227|NCT01055262|Experimental|Heatwrap 1|Experimental heatwrap device for the lower back
3220228|NCT01055249|Other|Group A|Ibuprofen 600 mg (active comparator); Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)
3220277|NCT01054898|Active Comparator|Usual community services|Standard care for abused women in the community
3220229|NCT01055249|Other|Group B|Oral Placebo (placebo comparator), Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)
3220230|NCT01055236|Placebo Comparator|hydroxyzine|
3220231|NCT01055236|Placebo Comparator|placebo|starch tablet
3220232|NCT01055223||Type 2 diabetes subjects|Type 2 diabetes subjects
3220233|NCT01055197|Experimental|PCI|Prophylactic Cranial Irradiation (PCI)
3220234|NCT01055197|Experimental|PCI + Consolidation RT|Prophylactic Cranial Irradiation (PCI) plus consolidative radiation therapy (RT) to locoregional and residual metastatic disease
3220235|NCT01055184|Experimental|2009 H1N1 Vaccine|Participants will be stratified by age into two groups: those between 60 and 70 years old, and those older than 70 years of age. All participants will receive the 2009 H1N1 vaccine.
3220236|NCT01055171|Active Comparator|Propranolol|Patients will receive Propranolol in this condition.
3220237|NCT01055171|Placebo Comparator|Placebo|Patient to receive placebo in this condition.
3220238|NCT01055158|Experimental|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes.
3220239|NCT01055158|Active Comparator|Control|Enhanced Usual Care
3220240|NCT01055145|Active Comparator|levofloxacin|Levofloxacin 750mg po per day for 3 months
3220241|NCT01055145|Active Comparator|moxifloxacin|Moxifloxacin 400mg po per day for 3 months
3220242|NCT01055132|Other|Etafilcon A toric contact lens/Nelfilcon A toric|Etafilcon A toric contact lens first, then nelfilcon A toric second
3220243|NCT01055132|Other|Nelfilcon A toric/ Etafilcon A toric|Nelfilcon A toric contact lens first, then etafilcon A toric toric second
3220244|NCT01055119|Active Comparator|Omega-3 fatty acids|
3220245|NCT01055119|Placebo Comparator|Olive oil|
3220246|NCT01055106|Active Comparator|1D|
3220247|NCT01055106|Active Comparator|3D|
3220248|NCT01055106|Active Comparator|5D|
3220249|NCT01055106|Active Comparator|Metronidazole|
3220250|NCT01055093||Diabetes Cohort|Prospectively followed cohort of newly diagnosed patients with diabetes mellitus, aged 18-69 years at inclusion into the study
3220251|NCT01055093||Control Cohort|Prospectively followed cohort of glucose tolerant humans, aged 18-69 years at inclusion into the study
3220252|NCT01055080|Placebo Comparator|Cow's milk formula|
3220253|NCT01055080|Active Comparator|Bovine insulin-free whey based formula|
3220254|NCT01055080|Active Comparator|Whey-based hydrolysed formula|
3220255|NCT01055067|Experimental|Tivantinib (ARQ 197)|3 capusles of 120 mg each, administered twice a day (once in the morning and once in the evening - total daily dose of 720 mg) in continuous 4-week cycles
3220256|NCT01055041|Experimental|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period .All three participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
3220257|NCT01055041|Experimental|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all three participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks
3220258|NCT01055041|Experimental|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
3220259|NCT01055028|Experimental|Regimen A / Treatment 1|"Participants were to receive paclitaxel 200 mg/m² intravenously over 3 hours every 21 days followed by bevacizumab 15 mg/kg intravenously over (cycle 1: 90 min; cycle 2: 60 min; cycles 3 to 6: 30 min) every 21 days x 6 cycles.~Maintenance bevacizumab (MB), 15 mg/kg once every 21 days intravenously for a maximum of 8 cycles, was initiated after the completion of paclitaxel + bevacizumab combination."
3220260|NCT01055028|Experimental|Regimen B / Treatment 2|"Patients were to receive paclitaxel 90 mg/m² weekly x 3 of a 28-day cycle followed by bevacizumab 15 mg/kg intravenously over (cycle 1: 90 min; cycle 2: 60 min; cycles 3 to 6: 30 min) every 21 days x 6 cycles.~Maintenance bevacizumab (MB), 15 mg/kg once every 21 days intravenously for a maximum of 8 cycles, was initiated after the completion of paclitaxel + bevacizumab combination."
3220261|NCT01055015|Experimental|1|Q8003, Flexible dose
3220262|NCT01055015|Experimental|2|Q8003, Low dose
3220263|NCT01055002|Active Comparator|Artemether/lumefantrine tablets|Artemether (20 mg) and Lumefantrine (120 mg) tablets: Four tablets taken as a single dose twice a day with fatty food for three days (total dose of 24 tablets in 6 doses) on days 6-8
3220264|NCT01055002|Active Comparator|Atovaquone/Proguanil HCl tablets|Atovaquone (250 mg) and Proguanil HCl (100 mg) tablets: Four tablets taken as a single dose daily for 3 days (total dose of 12 tablets) on days 6-8
3220265|NCT01054989|Active Comparator|Fat intravenously|Intravenous application of fat
3220266|NCT01054989|Active Comparator|Fat orally|Oral fat load
3220267|NCT01054989|Active Comparator|LPS intravenously|Lipopolysaccharide (LPS; US Standard Reference endotoxin)
3220268|NCT01054989|Placebo Comparator|Glycerol intravenously|Intrevenous glycerol infusion
3220269|NCT01054976|Experimental|Galantamine|
3220270|NCT01054950|Experimental|Education and counseling|Phone calls using behavioral techniques
3220271|NCT01054950|Placebo Comparator|Control|Single phone call
3220272|NCT01054937|Experimental|4SC-203|
3220273|NCT01054937|Placebo Comparator|Placebo|
3220274|NCT01054924||U.S. CRC screening population|
3220275|NCT01054911|Experimental|Sunitinib pill|Patients will receive six weeks of sunitinib and then subsequently continue for an additional 6 weeks if the evaluation at 6 weeks shows stable disease or objective response. Restaging CT scans will be performed again after 12 weeks of therapy to determine response in preparation for surgical resection anticipated to occur around week 14-16.
3220276|NCT01054898|Experimental|advocacy intervention|A 12-week telephone social support and empowerment intervention consisting of empowerment training, scheduled weekly telephone calls, and 24-hour access to a hotline for abused women
3220280|NCT01054885|Experimental|Fluticasone Furoate/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3220281|NCT01054885|Experimental|FF/GW642444 Inhalation Pwdr|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3220282|NCT01054885|Experimental|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
3220283|NCT01054885|Placebo Comparator|Placebo|Placebo
3220284|NCT01054872|Experimental|Monozygotic (MZ) Twins|Participants will receive the DNA vaccine at baseline and Months 1 and 2. They will then receive the rAd5 vaccine at Month 6.
3220285|NCT01054872|Experimental|Dizygotic (DZ) Twins|Participants will receive the DNA vaccine at baseline and Months 1 and 2. They will then receive the rAd5 vaccine at Month 6.
3220286|NCT01054859|Experimental|Treatment A|0.5 g/Kg alcohol plus 200 mg avanafil tablet
3220287|NCT01054859|Active Comparator|Treatment B|0.5 g/kg alcohol
3220288|NCT01054859|Active Comparator|Treatment C|200 mg avanafil tablet
3220289|NCT01054846|Experimental|Helmet and helmet education|Each participant preschool child received a free bicycle Bell helmet, manufactured by Bell Sports Inc., Rantoul IL, USA. In addition, classroom bicycle helmet education was provided to all participant children and their caregivers, consisting of a video on rules of biking and the importance of proper helmet use and a classroom melon drop demonstration with and without a helmet to participants and their caregivers.
3220290|NCT01054846|Active Comparator|Helmet education|Each child did not receive a bicycle Bell helmet but the child and his/her caregiver was given bicycle helmet education package as above.
3220291|NCT01054833|Experimental|Needleless sling|Needleless® sling
3220292|NCT01054820|Experimental|FLECTORA Patch (diclofenac epolamine topical patch) 1.3%|One patch applied every 12 hours
3220293|NCT01054807|Other|GalyfilconHL/Galyfilcon8.7/Galyfilcon8.3|Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A 8.3 BC (Experimental)
3220294|NCT01054807|Other|Galyfilcon8.7/Galyfilcon8.3/GalyfilconHL|Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)
3220295|NCT01054807|Other|GalyfilconHL/Galyfilcon8.3/Galyfilcon8.7|Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A 8.7 BC (Experimental)
3220296|NCT01054807|Other|Galyfilcon 8.7/Galyfilcon HL/Galyfilcon 8.3|Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator) /Galyfilcon A 8.3 BC (Experimental)
3220297|NCT01054807|Other|Galyfilcon8.3/GalyfilconHL/Galyfilcon8.7|Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.7 BC (Experimental)
3220298|NCT01054807|Other|Galyfilcon8.3/Galyfilcon8.7/GalyfilconHL|Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)
3220299|NCT01054794|Active Comparator|Stimulation ON|
3220300|NCT01054794|Sham Comparator|Stimulation OFF|
3220301|NCT01054768|Experimental|alpha-lipoic acid and acetyl-L-carnitine|LA and ALCAR 1400 mg tablet twice a day for 6 months.
3220302|NCT01054768|Placebo Comparator|Placebo|1400 mg placebo tablet twice a day for 6 months.
3220303|NCT01054742||Standard of Care PegIntron Plus Ribavirin [Part 2]|Participants who had relapsed during Part 1 of the study, had detectable HCV-RNA on Day 1 of Part 2 of the study, and who were re-treated during Part 2 of the study with standard of care PegIntron plus ribavirin for 48 weeks.
3220304|NCT01054729|Experimental|Sofosbuvir 100 mg+PEG+RBV|Participants received sofosbuvir 100 mg (1 x 100 mg tablet) and placebo to match sofosbuvir (3 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
3220305|NCT01054729|Experimental|Sofosbuvir 200 mg+PEG+RBV|Participants received sofosbuvir 200 mg (2 x 100 mg tablets) and placebo to match sofosbuvir (2 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
3220306|NCT01054729|Experimental|Sofosbuvir 400 mg+PEG+RBV|Participants received sofosbuvir 400 mg (4 x 100 mg tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
3220307|NCT01054729|Active Comparator|Placebo+PEG+RBV|Participants received placebo to match sofosbuvir (4 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
3220308|NCT01054703|Experimental|Ethmoid Sinus Spacer placement|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
3220309|NCT01054690|Experimental|Silver alloyed urinary catheter|
3220310|NCT01054690|Placebo Comparator|Silicone urinary catheter|
3220311|NCT01054677|Experimental|Educational intervention on antibiotic prescribing|The participants in this group received an educational intervention.
3220312|NCT01054677|No Intervention|No educational intervention|The participants in this group did not receive the educational intervention
3220313|NCT01054664||impaired liver enzymes|
3220314|NCT01054664||normal liver enzymes|
3220315|NCT01054664||hepatitis C antibodies positive|
3220316|NCT01054651|Experimental|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
3220317|NCT01054651|Active Comparator|Praziquantel|
3220318|NCT01054638||HIV infected patients: HAART naive or experienced|Patients with a claims diagnosis of HIV infection (HIV, AIDS, or ARC) in the NHI or Impact Databases, according to either of the 3-digit International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes 042 HIV disease and V08 Asymptomatic HIV infection status
3220319|NCT01054638||Patients with HIV infection HAART naïve|A naïve subcohort of patients consisting of HAART initiators. Among the primary cohort, we will exclude patients with a dispensing for any HAART in the 6-month baseline period prior to the cohort entry date.
3220320|NCT01054625|Experimental|zalutumumab 4 mg/kg|zalutumumab 4 mg/kg iv single infusion week 1,3, 4 and 5
3220321|NCT01054625|Experimental|zalutumumab 8 mg/kg|zalutumumab 8 mg/kg iv single infusion week 1, 3, 4 and 5
3220322|NCT01054625|Experimental|zalutumumab 16 mg/kg|zalutumumab 16 mg/kg iv single infusion week 1, 3, 4 and 5
3220323|NCT01054599|Experimental|Memantine|Subjects will randomly assigned to take either a placebo or memantine for 13 weeks. The assignment will be double-blind, neither the study members nor the subject will know if he/she is taking memantine or a placebo.
3220324|NCT01054599|Placebo Comparator|Sugar Pill|Subjects will be randomly assigned to take either memantine or a placebo. The study is double-blind, and neither the study members nor the subject will know if he/she is taking memantine or a placebo.
3220692|NCT01052103|Placebo Comparator|Placebo|
3220325|NCT01054586||HIV pts w/ HBV or HCV, w/ or w/o mild to moderate HI|Patients with HIV coinfected with HBV or HCV with or without mild to moderate HI who are enrolled in one of the participating HIV patient cohorts. These patients will be exposed to FPV/RTV or LPV/RTV.
3220326|NCT01054573|Experimental|Telaprevir + Standard Treatment|Telaprevir 750 mg orally (by mouth) every 8h for 12 weeks plus standard treatment. Standard treatment is 180 mcg subcutaneous (under the skin) injection pegylated interferon (Peg-IFN) alfa-2a and 1000-1200 mg twice daily ribavirin (RBV) for 48 weeks.
3220327|NCT01054560|Experimental|SOLITAIRE™ Device|The SOLITAIRE™ Device (investigational device) is the experimental arm
3220328|NCT01054560|Active Comparator|MERCI® Device|The MERCI® Device (control device) is commercially available.
3220329|NCT01054547|Placebo Comparator|Liposomal ropivacaine, topical|The topical anesthetics were applied at the region of right and left maxillary lateral incisors at the buccal mucosa.
3220330|NCT01054547|Placebo Comparator|Liposomal ropivacaine, palatal mucosa|Topical formulations were applied at the palatal mucosa at the right canine region and efficacy of topical formulations was accessed through insertion of a 30 gauge needle and injection of anesthetic solution.
3220331|NCT01054534|Other|Placement of interstim lead|Placement of interstim lead using US image fusion technology
3220332|NCT01054521|Experimental|Temperature-controlled RF (TCRF)|The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.
3220333|NCT01054521|Active Comparator|Bipolar RF (BRF)|The bipolar RF (BRF) probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
3220334|NCT01054508|Other|Tredaptive|Patients on Tredaptive are expected to have 15% increase in HDL cholesterol.
3220335|NCT01054495|Active Comparator|Acupuncture|Needle acupuncture at acupuncture point pericardium 6
3220336|NCT01054495|Sham Comparator|Sham acupuncture|Non-penetrating sham needling at acupuncture point pericardium 6
3220337|NCT01054495|Placebo Comparator|Laser acupuncture|Laser stimulation at acupuncture point pericardium 6
3220338|NCT01054482|Experimental|Pre-operative chemotherapy|Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op & Post-Op (total 4 cycles)
3220339|NCT01054482|Active Comparator|Pre-operative concurrent chemoradiation therapy|
3220340|NCT01054469|Placebo Comparator|TAP block with placebo|
3220341|NCT01054469|Active Comparator|TAP block with ropivacaine|
3220342|NCT01054456|Experimental|1|
3220343|NCT01054443|Placebo Comparator|placebo|
3220344|NCT01054443|Experimental|0.5 mg|
3220345|NCT01054443|Experimental|0.75 mg|
3220346|NCT01054443|Experimental|1.0 mg|
3220347|NCT01054430|Other|Normal|Subjects with normal hepatic function
3220348|NCT01054430|Other|Mild Hepatic Dysfunction|Subjects with mild hepatic impairment
3220349|NCT01054430|Other|Moderate hepatic dysfunction|Subjects with moderal hepatice impairment
3220350|NCT01054417||Appendicitis|Patients with suspected appendicitis who are to be operated upon by diagnostic laparoscopy
3220351|NCT01054404|Active Comparator|Furosemide|Furosemide 0.3 mg/kg
3220352|NCT01054404|Placebo Comparator|Placebo|Up to 5 mL saline
3220353|NCT01054391|Experimental|NEC Arm|Utilization of NEC (Neurovascular Embolization Cover) for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistulae
3220354|NCT01054365||Delayed Discharge Group (DDG)|D/C at least 24 hours after procedure or at usual discharge time (n =200)
3220355|NCT01054365||Early Discharge Group (EDG)|D/C 6 hours after procedure if no indication for extended stay after randomization (n=200)
3220356|NCT01054352|Experimental|001|JNJ38224342/placebo one of six (6) single ascending doses (25 100 300 600 1250 or 2000 mg) of JNJ 38224342 or matching placebo up to four (4) additional cohorts consisting of healthy male volunteers may be added
3220357|NCT01054352|Experimental|002|JNJ38224342/placebo multiple ascending oral doses (100 250 500 750 mg) of JNJ 38224342 or matching placebo administered for 14 consecutive days in healthy male or female volunteers.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
3220358|NCT01054352|Experimental|003|JNJ38224342 single oral 100mg dose of JNJ 38224342 as a solution versus a single oral dose of JNJ 38224342 as a capsule formulation with and without food in healthy male volunteers
3220359|NCT01054352|Experimental|004|JNJ38224342/placebo multiple oral doses of JNJ38224342 or matching placebo administered for up to 14 consecutive days in male and female volunteers number of days dosed and actual dose levels food requirements and regimens will be determined based on the data from Parts 1 2 and 3.
3220360|NCT01054339|Experimental|Low dose|rAAV1-CB-hAAT at dosage level of 6 x 10e11 vg/kg
3220361|NCT01054339|Experimental|Middle dose|rAAV1-CB-hAAT at dosage level of 1.9 x 10e12 vg/kg
3220362|NCT01054339|Experimental|High dose|rAAV1-CB-hAAT at dosage level of 6 x 10e12 vg/kg
3220363|NCT01054326|Experimental|Supervised physical therapy focusing of rotatorcuff exercises|Patients did specific exercises supervised by a physical therapists twice a week during two months. Focus was on early activation of rotator cuff and scapula stabilizers following different phases in a rehabilitation program Assessments before surgery,1 week after as well as 1,2,3 and 6 months after surgery.
3220364|NCT01054326|Active Comparator|Home exercises|Patients did home exercises following a programme during three months. Assessment considering shoulder function and pain was done before surgery, 1w after as well as 1,2,3 and 6 months after surgery,
3220365|NCT01054313|Experimental|Docetaxel + Sirolimus|Starting doses of Docetaxel 30 mg/m^2 IV every 3 weeks + Sirolimus 1 mg daily
3220366|NCT01054300|Experimental|Ertugliflozin (E) 2 mg/Placebo (P)→E 1 mg/E 1 mg|Period 1 (AM/PM) dose: E 2 mg/Placebo. Period 2 (AM/PM) dose: E 1 mg /E 1 mg. There was a >= 7 day washout period between Period 1 and Period 2.
3220367|NCT01054300|Experimental|E 1 mg/E 1 mg→E 2 mg/P|Period 1 (AM/PM) dose: E 1 mg/E 1 mg. Period 2 (AM/PM) dose: E 2 mg /Placebo. There was a >= 7 day washout period between Period 1 and Period 2.
3220693|NCT01052090|Experimental|Lifestyle counseling|
3220368|NCT01054300|Experimental|E 4 mg/P→E 2 mg/E 2 mg|Period 1 (AM/PM) dose: E 4 mg/Placebo. Period 2 (AM/PM) dose: E 2 mg /E 2 mg. There was a >= 7 day washout period between Period 1 and Period 2.
3220369|NCT01054300|Experimental|E 2 mg/E 2 mg→E 4 mg/P|Period 1 (AM/PM) dose: E 2 mg/E 2 mg. Period 2 (AM/PM) dose: E 4 mg /Placebo. There was a >= 7 day washout period between Period 1 and Period 2.
3220370|NCT01054287|Experimental|Falls prevention|
3220371|NCT01054287|Placebo Comparator|Usual care|
3220372|NCT01054274|Active Comparator|novel stent|Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.
3220373|NCT01054274|Experimental|conventional covered stent|Patients undergo placement of a conventional covered stent on day 1.
3220374|NCT01054261|Other|Normal|Normal renal function
3220375|NCT01054261|Other|Mild|Mild renal impairment
3220376|NCT01054261|Other|Moderate|Moderate renal impairment
3220377|NCT01054248|Experimental|MAS3|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
3220378|NCT01054248|Active Comparator|ALN+|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet)
3220379|NCT01054248|Experimental|DP|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
3220380|NCT01054235|Experimental|experimental|The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes). For control ,none of the intervention will be given.
3220381|NCT01054222|Other|Fesoterodine 4 mg|Dose determined as per previous drug regime in A0221045 and investigator's evaluation.
3220382|NCT01054222|Other|Fesoterodine 8 mg|Dose determined as per previous drug regime in A0221045 and investigator's evaluation.
3220383|NCT01054209|No Intervention|A|Control arm. Full standard care. No mattress warming. May receive warmed fluids if standard practise for clinician
3220384|NCT01054209|Active Comparator|B|Warming mattress activated otherwise same management as Arm A.
3220385|NCT01054196|Experimental|all patients|subjects will receive daily doses of lenalidomide starting on Day -5 of transplant and melphalan on Days -2 and -1.
3220386|NCT01054183|Experimental|Intubation using GlideScope Ranger|The study site has two critical care transport teams per shift and will, at shift change, assign intubation team A to use the GlideScope Ranger for all intubations on that day.
3220387|NCT01054183|Active Comparator|intubation using direct laryngoscopy|The study site has two critical care transport teams per shift and will, at shift change, assign intubation team B. Team B will do intubations using direct laryngoscopy only that day.
3220388|NCT01054170|Experimental|AZD9668|
3220389|NCT01054170|Placebo Comparator|Placebo|
3220390|NCT01054144|Experimental|Response Adapted Therapy|Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.
3220391|NCT01054118|Experimental|001|JNJ-38431055 Liquid suspension of JNJ-38431055 administered as a single dose
3220392|NCT01054118|Active Comparator|002|Sitagliptin 100 mg Capsule containing 100 mg of sitagliptin administered as a single dose
3220393|NCT01054118|Experimental|003|JNJ-38431055 + Sitagliptin 100 mg Liquid suspension of JNJ-38431055 administered as a single dose and capsule containing 100 mg of sitagliptin administered as a single dose
3220394|NCT01054118|Placebo Comparator|004|Placebo Placebo suspension and placebo capsule administered as single doses
3220395|NCT01054105|Other|Step I: BMPR-2 gene analysis|BMPR-2 gene analysis on 100 IPAH or heritable PAH Patients
3220396|NCT01054105|Active Comparator|Step-II: Iloprost and Exercise Echo|Illoprost inhalation for 3 months & Check-up before and after treatment; WHO functional classification Assessment of exercise capacity (6M walk test) Cardiopulmonary exercise echocardiography NT-proBNP
3220397|NCT01054092|Experimental|before meal group|ASP1941 will be administered before meal
3220398|NCT01054092|Experimental|after meal group|ASP1941 will be administered after meal
3220399|NCT01054079|Experimental|Treatment (cinacalcet hydrochloride)|Patients receive cinacalcet hydrochloride PO QD for 20 weeks in the absence of disease progression or unacceptable toxicity.
3220400|NCT01054053||1|children born between 06/04/2004 and 17/04/2008 and called to menBvac vaccination and living around Neufchatel en Bray.
3220401|NCT01054040|No Intervention|Standard nutrition cardiac care|Patients will receive standard care of group nutrition counselling and individual counselling if requested
3220402|NCT01054027|Experimental|0 Drop|Left eye dose
3220403|NCT01054027|Experimental|1 Drop|Left eye dose
3220404|NCT01054027|Experimental|2 drop|Left eye dose
3220405|NCT01054027|Active Comparator|3 drops|Right eye dose for all groups
3220406|NCT01054014|Experimental|001|JNJ-40346527/Placebo Single oral dose of JNJ-40346527 (either 10 50 150 300 600 or 1000mg) or Placebo
3220407|NCT01054014|Experimental|002|JNJ-40346527/Placebo JNJ-40346527 once daily oral dose for 14 days (either 50 150 300 500 or 750mg) or Placebo
3220408|NCT01054014|Experimental|003|JNJ-40346527 JNJ-40346527 150mg one dose either fasting (or with food) then after 7 days off treatment JNJ-40346527 150mg either with food (or fasting)
3220409|NCT01054001|Active Comparator|Early|men with on- demand sildenafil 100mg dosing from the early postoperative period
3220410|NCT01054001|Active Comparator|Delayed|men with on- demand sildenafil 100mg dosing from the delayed postoperative period
3220411|NCT01053988|Experimental|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3220412|NCT01053988|Experimental|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
3220413|NCT01053988|Experimental|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
3220414|NCT01053988|Placebo Comparator|Placebo|Placebo
3220415|NCT01053988|Experimental|FF/GW642444 Inhalation Pwdr|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3220416|NCT01053962|Experimental|SP-304 1.0 mg|Subjects receiving SP-304 1.0 mg for 14 consecutive days
3220417|NCT01053962|Experimental|SP-304 3.0 mg|Subjects receiving SP-304 3.0 mg for 14 consecutive days
3220418|NCT01053962|Experimental|SP-304 9.0 mg|Subjects receiving SP-304 9.0 mg for 14 consecutive days
3220419|NCT01053962|Placebo Comparator|Placebo|Subjects receiving Placebo for 14 consecutive days
3220420|NCT01053962|Experimental|SP-304 0.3 mg|Subjects receiving SP-304 0.3 mg for 14 consecutive days.
3220421|NCT01053949|Active Comparator|Drug on 21 days per 28 days cycle|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
3220422|NCT01053949|Active Comparator|Drug on 28 days per 28 days cycle|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
3220423|NCT01053936|Experimental|Bardoxolone methyl: 5 mg|
3220424|NCT01053936|Experimental|Bardoxolone methyl: 10 mg|
3220425|NCT01053936|Experimental|Bardoxolone methyl: 15 mg|
3220426|NCT01053936|Experimental|Bardoxolone methyl: 30 mg|
3220427|NCT01053936|Experimental|Bardoxolone methyl: 2.5 mg|
3220428|NCT01053923||MRI Scan|
3220429|NCT01053910|Experimental|Ramipril|Duration of treatment: 2 months 7 first days: 1.25mg once daily in patients with stable heart failure and 7 days 2.5mg once daily or 14 first days:2.5mg once daily in patients without heart failure for 14 more days:5mg once daily maintenance therapy for 1 month: 10 mg (5mg, 2 tablets)
3220430|NCT01053897|Experimental|GBT009|
3220431|NCT01053897|Placebo Comparator|Placebo|
3220432|NCT01053884|Other|Anidulafungin, safety, antifungal drug|single arm study
3220433|NCT01053871|Experimental|1|sedation using propofol
3220434|NCT01053871|Experimental|2|sedation using midazolam with fentanyl
3220435|NCT01053858|Active Comparator|bevacizumab|intravitreal bevacizumab or triamcinolone determined by single physician
3220436|NCT01053858|Active Comparator|triamcinolone|
3220437|NCT01053832|Other|Ventricular Pace Suppression- ON|
3220438|NCT01053832|Other|Ventricular Pace Suppression- OFF|
3220439|NCT01053819|Experimental|Etanercept|open label treatment(50 mg SQ)per Food and Drug Administration approval for 24 weeks
3220440|NCT01053793|Active Comparator|Glucose Standard|
3220441|NCT01053793|Experimental|Potato Variety|
3220442|NCT01053767|No Intervention|Arm 1|This is a phlebotomy study.
3220443|NCT01053741|Experimental|Seminal Fluid then Normosol|2.5 mL radiolabeled autologous seminal fluid administered rectally x1. Two week pause between interventions. Then 2.5 mL radiolabeled Normosol-R administered rectally X1.
3220444|NCT01053741|Experimental|Normosol then Seminal Fluid|2.5 mL radiolabeled Normosol-R administered rectally x1. Two week pause between interventions. Then 2.5 mL radiolabeled autologous seminal fluid administered rectally X1.
3220445|NCT01053728|Experimental|Cohort 1 : SAR161271 0.3 U/kg|Cross-over design of four formulation of SAR161271 0.3U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
3220446|NCT01053728|Experimental|Cohort 2 : SAR161271 0.6 U/kg|Cross-over design of four formulation of SAR161271 0.6U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
3220447|NCT01053728|Experimental|Cohort 3 : SAR161271 1.2 U/kg|Cross-over design of four formulation of SAR161271 1.2 U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
3220448|NCT01053702|Experimental|Dose 1|R475
3220449|NCT01053702|Experimental|Dose 2|R475
3220450|NCT01053702|Placebo Comparator|Dose 3|Placebo to match R475 dose
3220451|NCT01053689|Experimental|Glimepiride|Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited
3220452|NCT01053689|Active Comparator|Amaryl|Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc
3220453|NCT01053676|Experimental|Arm 1|
3220454|NCT01053676|Active Comparator|Arm 2|
3220455|NCT01053663|Experimental|1|
3220456|NCT01053637|Experimental|Hydrocodone/acetaminophen|Patients will receive 0.17 mg/kg hydrocodone component to a max of 10 mg hydrocodone.
3220457|NCT01053637|Placebo Comparator|Sugar water|Placebo
3220458|NCT01053611|Active Comparator|Group 1 BIS value 30|
3220459|NCT01053611|Active Comparator|Group 2 BIS value 30|
3220460|NCT01053611|Active Comparator|Group 3 BIS value 30|
3220461|NCT01053611|Active Comparator|Group 4 BIS valaue 30|
3220462|NCT01053611|Active Comparator|Group 1 BIS value 50|
3220463|NCT01053611|Active Comparator|Group 2 BIS value 50|
3220464|NCT01053611|Active Comparator|Group 3 BIS value 50|
3220465|NCT01053611|Active Comparator|Group 4 BIS value 50|
3220466|NCT01053611|Active Comparator|Group 1 BIS value 70|
3220467|NCT01053611|Active Comparator|Group 2 BIS value 70|
3220468|NCT01053611|Active Comparator|Group 3 BIS value 70|
3220469|NCT01053611|Active Comparator|Group 4 BIS value 70|
3220470|NCT01053585|Active Comparator|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
3220471|NCT01053585|Placebo Comparator|Placebo|Placebo suspension (single dose 90 minutes prior to physiologic measurement)
3220472|NCT01053572|Active Comparator|Celestone|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
3220473|NCT01053572|Active Comparator|sodium chloride solution|Group II will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and 0.9% sodium chloride solution to substitute for non-particulate Celestone
3220474|NCT01053572|Active Comparator|sodium choride solution|Group III will receive adhesiolysis, local anesthetic, normal sodium chloride solution instead of 10% hypertonic sodium chloride solution and non-particulate Celestone;
3220475|NCT01053572|Active Comparator|Double substitutes|Group IV will receive adhesiolysis, local anesthetic, and 0.9% sodium chloride solution to substitute for the 10% hypertonic sodium chloride, and 0.9% sodium chloride solution to substitute for non-particulate Celestone
3220476|NCT01053559|Other|certolizumab pegol|Subjects will receive FDA approved Cimzia injections as indicated on the product label. Subjects will undergo 3 wireless capsule endoscopies, one at screening,Day 84 and Day 168 as well as monthly bloodwork.
3220526|NCT01053208|Active Comparator|Advil|Advil PM 200 mg/38 mg Tablets of Wyeth
3220694|NCT01052077|Experimental|Brexipiprazole + ADT|OPC-34712 Tablets, Oral, 1 - 3 mg OPC-34712 + ADT
3220477|NCT01053546|Experimental|Arm I (Early exercise group)|Patients perform swallowing exercises comprising lingual press, head lift, breath hold, Masako swallow, high pitch e, effortful swallow, and neck stretch and massage for 2 weeks prior to beginning radiotherapy and again immediately after completion of radiotherapy.
3220478|NCT01053546|Experimental|Arm II (Late exercise group)|Patients begin performing swallowing exercises as in arm I 1 month after completion of radiotherapy.
3220479|NCT01053533|Experimental|Chinese herbal medicines plus western therapy|
3220480|NCT01053533|Active Comparator|western therapy|including supportive therapy and antivirus therapy when necessary
3220481|NCT01053520|Experimental|Sequence I|
3220482|NCT01053520|Experimental|Sequence II|
3220483|NCT01053520|Experimental|Sequence III|
3220484|NCT01053507|Active Comparator|Treximet|In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.
3220485|NCT01053507|Placebo Comparator|Placebo|In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.
3220486|NCT01053494|Active Comparator|Arm I (WAITLIST CONTROL GROUP)|Patients and caregivers receive standard of care and are offered the massage intervention after 8 weeks.
3220487|NCT01053494|Experimental|Arm II (TOUCH)|"Caregivers undergo a 60-minute training session on simple massage techniques, including the Massage Toolkit, comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist. Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks."
3220488|NCT01053494|Experimental|Arm III (TOUCH+)|"Caregivers undergo a 60-minute training session on simple massage techniques, including the Massage Toolkit, comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist. Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks. Caregivers also receive a 45-minute massage by the massage therapist."
3220489|NCT01053481|Experimental|Vitamin D|Vitamin D supplement
3220490|NCT01053468|Experimental|PA Behavior Intervention|Physical Activity Resource Kit
3220491|NCT01053468|Active Comparator|Standard Materials|Receive physical activity handout from the Canadian Public Health Agency
3220492|NCT01053455||Starting on NCPAP|randomized to start on NCPAP
3220493|NCT01053455||Starting on SiPAP|randomized to SiPAP
3220494|NCT01053442|Experimental|NaFeEDTA|The maize porridge is fortified with 2.5mg iron as NaFeEDTA
3220495|NCT01053442|Active Comparator|FeSO4|The maize porridge is fortified with 2.5 mg iron as ferrous sulphate plus ascorbic acid.
3220496|NCT01053429||observational cohort|
3220497|NCT01053416|No Intervention|observation|
3220498|NCT01053416|Experimental|Yag laser iridotomy|the enrolled eyes will undergo an iridotomy performed by using a Yag-laser
3220499|NCT01053403|Active Comparator|MDMA|
3220500|NCT01053390|Active Comparator|epirubicin,cisplatin,LV（Leucovorin）、5-FU (5-Fluorouracil)|conventional regimen
3220501|NCT01053390|Experimental|Somatotatin|Conventional chemotherapy regimen plus somatostatin
3220502|NCT01053377|Active Comparator|Tamiflu|
3220503|NCT01053377|Placebo Comparator|Placebo Tamiflu|
3220504|NCT01053364|Experimental|Implant|
3220505|NCT01053338|Experimental|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets of Dr. Reddy's
3220506|NCT01053338|Active Comparator|Advil|Advil PM 200 mg/38 mg Tablets of Wyeth
3220507|NCT01053325|Experimental|CTX in HIV-negative women|CTX daily prophylaxis in HIV-negative pregnant women
3220508|NCT01053325|Experimental|CTX in HIV-positive women|CTX daily prophylaxis in pregnant women who are infected with HIV
3220509|NCT01053325|Active Comparator|SP IPT in HIV-negative women|Intermittent Preventive Treatment with SP in HIV-negative pregnant women
3220510|NCT01053325|Active Comparator|IPT SP in HIV-positive women|Intermittent Preventive Treatment with SP in HIV-positive pregnant women
3220511|NCT01053325|Active Comparator|CTX in HIV-positive pregnant women with CD4<350|Daily prophylaxis with cotrimoxazole in HIV-positive pregnant women with CD4<350
3220512|NCT01053312|Experimental|1 flutemetamol|
3220513|NCT01053299|Active Comparator|No treatment|Every child, without exception, born in the peroid 1.2.1998 - 31.12.2006, still alive, will be called for to take a Xray of their hips aimed at comparing the ultrasound-values taken newborn.
3220514|NCT01053273|Active Comparator|Caudal epidural Injection|Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
3220515|NCT01053273|Active Comparator|Percutaneous Adhesiolysis|Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone
3220516|NCT01053260|Active Comparator|LEARN Program|Participants will receive weekly weight loss counseling based on the LEARN Program for Weight Management.
3220517|NCT01053260|Experimental|LEARN Plus Contingency Management|Participants will receive weekly counseling based on the LEARN Program for Weight Management plus contingency management. Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
3220518|NCT01053247|Experimental|Test|Test product that contains the active pharmaceutical ingredient
3220519|NCT01053247|Active Comparator|Reference|Reference product that contains active pharmaceutical ingredient
3220520|NCT01053247|Placebo Comparator|Vehicle|Placebo that contains no active pharmaceutical ingredient
3220521|NCT01053234|Experimental|Insulin aspart|
3220522|NCT01053234|Experimental|NPH insulin|
3220523|NCT01053221|Experimental|MPA monotherapy|Subjects will discontinue calcineurin inhibitor (cyclosporine or tacrolimus) and remain on MPA (mycophenolate mofetil or mycophenolate sodium) monotherapy
3220524|NCT01053221|Active Comparator|Control: MPA and CNI|Subjects will continue with their current immunosuppressive regimen of MPA (mycophenolate mofetil or mycophenolate sodium) and calcineurin inhibitor (cyclosporine or tacrolimus)
3220525|NCT01053208|Experimental|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets of Dr. Reddy's
3220527|NCT01053195|Experimental|Lifestyle counseling|In the project areas, lifestyle counseling will be given every three months to individuals having prediabetes and every six months to those with normal glucose levels.
3220528|NCT01053195|No Intervention|Control|No intervention activity will be assigned for participants enrolled from the control areas.
3220529|NCT01053182|Active Comparator|Ivor-Lewis|Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach
3220530|NCT01053182|Active Comparator|Sweet|Esophagectomy via Left Side Thoracotomy
3220531|NCT01053169||Prophylaxis Cohort|Patients with coagulopathy due to liver disease or other condition requiring correction of coagulopathy who require surgical or diagnostic intervention
3220532|NCT01053169||Treatment Cohort|Patients experiencing acute bleeding perioperatively
3220533|NCT01053156|Placebo Comparator|Placebo pill|All patients will be on placebo for 3 months in this crossover study.
3220534|NCT01053156|Experimental|Minocycline|All patients will be on minocycline for 3 months in this crossover trial.
3220535|NCT01053143|Experimental|Study Group|Participants aged 18 years and older at enrollment.
3220536|NCT01053130|Experimental|weight loss surgery|laparoscopic sleeve gastrectomy
3220537|NCT01053130|Active Comparator|Lifestyle Intervention|Diet and exercise with or without pharmacotherapy
3220538|NCT01053117|Experimental|Protocolized approach|Protocolized approach to convert catheter to arteriovenous fistula
3220539|NCT01053117|No Intervention|Current Care Model|
3220540|NCT01053104||capecitabine 2000mg/m2 (Colorectal)|capecitabine 2000mg/m2 d 1-14, q 3 weekly and oxaliplatin 130mg/m2 d1 q 3 weekly (CAPOX)
3220541|NCT01053104||capecitabine 2500mg/m2 (Colorectal)|capecitabine 2500mg/m2 d 1-14, q 3 weekly
3220542|NCT01053104||capecitabine 2000mg/m2 (Breast)|capecitabine 2000mg/m2d 1-14, q 3 weekly
3220543|NCT01053104||docetaxel 75mg/m2 (Breast)|capecitabine 2000mg/m2 d 1-14, q 3 weekly and docetaxel 75mg/m2 d1 q 3 weekly
3220544|NCT01053091|Experimental|Exercise|exercise
3220545|NCT01053091|No Intervention|Control|control
3220546|NCT01053078|Placebo Comparator|Naltrexone|Double blind placebo comparable
3220547|NCT01053078|Placebo Comparator|Placebo|
3220548|NCT01053065|Active Comparator|Atorvastatin 10 mg/day|Arm composed of 20 patients, receiving atorvastatin 10 mg/day
3220549|NCT01053065|Active Comparator|Atorvastatin 80 mg/day|Arm composed of 20 patients, receiving atorvastatin 80 mg/day
3220550|NCT01053065|Active Comparator|Cholestyramine - Sitosterol|Arm composed of 20 patients receiving cholestyramine 8 g/day plus sitosterol 2.5 g/day
3220551|NCT01053052|Experimental|Sonography with FemVue vs. HSG|FemVue sonography and HSG
3220552|NCT01053039|Active Comparator|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
3220553|NCT01053039|Placebo Comparator|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
3220554|NCT01053013|Experimental|Cancer macrobeads|Cancer macrobead placement in abdominal cavity
3220555|NCT01053000|Experimental|Lt. Arm Tazorac/Rt. Arm No Pretreatment|Apply Tazorac 0.1% gel for 1 week to the Left arm only and then receive ALA- PDT Treatment to both arms
3220556|NCT01053000|Experimental|Rt. Arm Tazorac/Lt. Arm No Pretreatment|Apply Tazorac 0.1% gel for 1 week to the Right arm only and then receive ALA- PDT Treatment to both arms
3220557|NCT01052987|Experimental|Tranilast|Tranilast tablets
3220558|NCT01052987|Active Comparator|Allopurinol|Allopurinol tablets
3220559|NCT01052987|Experimental|Combination|Tranilast plus Allopurinol
3220560|NCT01052987|Active Comparator|High dose Allopurinol|400 mg Allopurinol
3220561|NCT01052987|Experimental|High dose combination|Combination of Tranilast 300 mg and Allopurinol 400 mg
3220562|NCT01052974|Placebo Comparator|physiological serum|ropivacaïne controlled by placebo (physiological serum).
3220563|NCT01052974|Active Comparator|ropivacaine|ropivacaïne controlled by placebo (physiological serum).
3220564|NCT01052961|No Intervention|Non-intervention arm|patients may receive oseltamivir 75 mg bd for 5 days, decided by the managing physicians
3220565|NCT01052961|Active Comparator|oseltamivir, higher dose|oseltamivir 150 mg bd for 5 days for patients presented within 96 hours from onset
3220566|NCT01052948||Cohort 1|All persons who newly start one of the dopamine agonists (DA) after start of eligibility period
3220567|NCT01052948||Cohort 2|All persons who started levodopa after start of eligibility period and had not been treated with dopamine agonists anytime prior.
3220568|NCT01052948||Cohort 3|All persons with newly diagnosed hyperprolactinemia who had not been treated with dopamine agonists anytime prior.
3220569|NCT01052948||Cohort 4|healthy controls from general population matched on age, gender, index date and general practitioner (GP) practice to persons exposed to dopamine agonists
3220570|NCT01052935|No Intervention|Arm 1|This is a phlebotomy study.
3220571|NCT01052922|Active Comparator|2 sample InSure|
3220572|NCT01052922|Active Comparator|1 sample OC-Micron|
3220573|NCT01052922|Active Comparator|3 sample g-SENSA|
3220574|NCT01052909|Experimental|Glimepiride|Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited
3220575|NCT01052909|Active Comparator|Amaryl|Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc
3220576|NCT01052896|Experimental|Gabapentin|Half of the 100 patients enrolled will be placed on Gabapentin therapy to determine if they have improved dyspepsia symptoms.
3220577|NCT01052896|Placebo Comparator|Placebo|Half of the 100 patients will be placed on placebo look-alike of the gabapentin.
3220578|NCT01052883|Experimental|1|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A] then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment B]
3220579|NCT01052883|Experimental|2|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 [Treatment B] then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A]
3220649|NCT01052363|Experimental|Avastin + CA4P|
3220580|NCT01052883|Experimental|3|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C] then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D]
3220581|NCT01052883|Experimental|4|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D] then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C]
3220582|NCT01052870|Other|androgen receptor gene polymorphism|Medication response will be assessed according to androgen receptor genotype
3220583|NCT01052870|Active Comparator|finasteride|medication for treating androgenetic alopecia in women
3220584|NCT01052857|Experimental|1|acupuncture daily fo 7 days
3220585|NCT01052857|No Intervention|2|observation
3220586|NCT01052844|Placebo Comparator|Control group|"Placebo:~Five and four days before chemotherapy (day -5 and day -4): 1x daily~Three and two days before chemotherapy (day -3 and day -2): 2x daily~One day before to five days after chemotherapy ( day -1 to day 5): 3x daily"
3220587|NCT01052844|Experimental|Gabapentin|"Gabapentin 300mg:~Five and four days before chemotherapy (day -5 and day -4): 1x daily~Three and two days before chemotherapy (day -3 and day -2): 2x daily~One day before to five days after chemotherapy ( day -1 to day 5): 3x daily"
3220588|NCT01052831|Active Comparator|Naltrexone|For the first four weeks of the study, participants were administered naltrexone at 50mg per day. Participants not in response at week 4 were increased to 100mg per day for the remaining four weeks of the study.
3220589|NCT01052831|Placebo Comparator|Placebo|Participants received the placebo treatment which looked identical to active study medication.
3220590|NCT01052818||Stage IV NSCLC|Stage IV non small-cell lung cancer patients will be recruited for this protocol
3220591|NCT01052805||harvest nerve|harvest nerve from cadaveric donor and patients receiving nerve graft operation
3220592|NCT01052792|Experimental|Naproxen Sodium 550 mg Tablets|Naproxen Sodium 550 mg Tablets of Dr. Reddy's Laboratories Limited
3220593|NCT01052792|Active Comparator|Anaprox DS 550mg Tablets|Anaprox DS 550mg Tablets of Roche Pharmaceuticals Inc
3220594|NCT01052779|Experimental|Ferumoxytol|Participants received an IV injection of ferumoxytol (510 milligrams [mg], 17 milliliters [mL]) on Day 1 (Baseline). This was followed by a second injection of ferumoxytol (510 mg, 17 mL) 5±3 days later for a total cumulative dose of 1.02 grams (g).
3220595|NCT01052779|Active Comparator|Iron Sucrose|"Participants received iron sucrose based on hemodialysis status. Participants on hemodialysis received either slow IV injection or IV drip infusion of 100 mg of iron sucrose on Day 1 (Baseline) and at the following 9 consecutive hemodialysis sessions for a total cumulative dose of 1.0 g.~Participants not on dialysis received either slow IV injection or IV drip infusion of 200 mg of iron sucrose on Day 1 (Baseline) and at 4 subsequent visits on nonconsecutive days over a 14-day period for a total cumulative dose of 1.0 g."
3220596|NCT01052766|Experimental|PET/CT and BH PET/CT|In collaboration with the Department of Radiation Oncology and the Interventional Radiology Service, patients with lung or liver cancer or lung or liver metastases in whom FDG PET/CT is part of the clinical standard of care for disease evaluation and response assessment will be enrolled in this study. We will perform a clinical PET/CT and BH PET/CT (for two bed positions covering the entire chest) prior to, and again 1-2 weeks after SBRT or RFA. This early time point is chosen because a few weeks after the completion of treatment, acute radiation injury in the lung begins and will likely be detectable as abnormal uptake on follow-up PET imaging making it difficult to assess tumor recurrence.
3220597|NCT01052753||ADHD group|
3220598|NCT01052753||Control group|
3220599|NCT01052727|Other|overnight stay group|Group of patients who rests at least one night in Hospital
3220600|NCT01052727|Other|day-care Group|Group of patients who is discharged tha same day of operation
3220601|NCT01052714|No Intervention|Usual Care|Control group with time-matched study visits
3220602|NCT01052714|Active Comparator|Lifestyle Balance|Weight management group education and individual counseling
3220603|NCT01052714|Other|Usual Care then Lifestyle Balance|Participants originally randomized to Usual Care, allowed to change over to Lifestyle Balance at month 6 per their request.
3220604|NCT01052701|Active Comparator|Ribavirin plus Abacavir|Ribavirin plus Abacavir Administration intervention
3220605|NCT01052701|Active Comparator|Ribavirin alone|Ribavirin alone administration
3220606|NCT01052688||Pregnant Women|Pregnant women who have been definitively diagnosed as carrying a fetus with aneuploidy.
3220607|NCT01052675||Pharmacodependance cases|Case report from one of the French CEIP for drug and substance problematic use, abuse or dependence except alcohol and tobacco.
3220608|NCT01052662|Experimental|Memantine 30mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Memantine 5mg in the morning was started on week 2. The dose was titrated on a twice a day schedule until the target dose of 30 mg/day was achieved by week 4. The medication was discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
3220609|NCT01052662|Experimental|Memantine 15mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Memantine 5mg in the morning was started on week 2. The dose was titrated on a twice a day schedule until the target dose of 15 mg/day was achieved by week 4. The medication was discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
3220650|NCT01052350||Parkinson disease|individuals with Parkinson disease
3220651|NCT01052350||healthy control|individuals without Parkinson disease
3220652|NCT01052337|Active Comparator|propofol|
3220653|NCT01052337|Active Comparator|sevofluorane|
3220654|NCT01052311|Placebo Comparator|Placebo|Placebo pills once daily
3220695|NCT01052077|Placebo Comparator|Placebo + ADT|Placebo + ADT
3220610|NCT01052662|Placebo Comparator|Memantine 0mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Matching placebo capsule was started on week 2. The placebo capsules were given on a twice a day schedule until week 12 and then discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
3220611|NCT01052649||Healthy volunteers|
3220612|NCT01052636|No Intervention|Control group|Patients receive only routine hospital care
3220613|NCT01052636|Experimental|Experimental group|Patients receive regular hospital routine care and interdisciplinary intervention program
3220614|NCT01052623|Experimental|Growth hormone-testing (GH/IGF-1-testing)|"Patients (girls over 8 years and boys over 10 years) are primed with estradiol 1 mg orally for 2 days, to help avoid false results of growth hormone (GH) levels in blood samples. Then provocation testing is done, with two tests back to back. It determines blood levels of GH and the body's response to testing with drugs called arginine and clonidine. Patients are admitted to the pediatric inpatient unit and will have an intravenous (IV) line placed in the arm. Arginine is given by IV over 30 minutes, and blood samples are taken as indicated.~The next day, the clonidine test is performed according to current guidelines. Then the IGF-1 generation test is done to see if the patient has the ability to generate IGF-1 in response to injections of GH for 5 consecutive days."
3220615|NCT01052610|Active Comparator|Active group|Group of children with bronchial asthma and/ or allergic rhinitis 6-18 years old receiving annually house dust mites sublingual allergen extract
3220616|NCT01052610|Placebo Comparator|Placebo group|Group of children with bronchial asthma and/or allergic rhinitis 6-18 years old receiving placebo in sublingual applicator
3220617|NCT01052597|Placebo Comparator|Placebo|
3220618|NCT01052597|Experimental|Curcumin|
3220619|NCT01052584|Experimental|Chloroquine-P. vivax|P. vivax randomized to receive chloroquine 3-day regimen
3220620|NCT01052584|Experimental|Artemether-Lumefantrine: P. vivax|
3220621|NCT01052584|Experimental|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
3220622|NCT01052571|Active Comparator|Without Steroids|Group I patients receiving lumbar transforaminal epidural injections with an injection of local anesthetic (lidocaine 1% or bupivacaine 0.25%
3220623|NCT01052571|Active Comparator|steroids|Group II patients will receive lumbar transforaminal epidural injections with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
3220624|NCT01052558|Active Comparator|Cataract Surgery Only|
3220625|NCT01052558|Experimental|Treatment with Cataract Surgery & Stents|Ab interno trabecular micro-bypass stent surgery
3220626|NCT01052545|Experimental|Arm 1|Baseline surveillance for the clinical outcomes will begin in year 1 at the intervention site and continue for all 3 years of the project. Guideline distribution will begin in year 2 and continue throughout the project. Audit-feedback will occur during year 2 of the study at the intervention site. Feedback will be delivered to individual health care providers at the intervention site during year 2.Unit-level audit feedback will be delivered at the intervention site during years 2 and 3 of the study. Provider surveys of knowledge and attitudes concerning the ABU guidelines will be administered at the intervention site in years 2 and 3 of the project.
3220627|NCT01052545|No Intervention|Arm 2|At the control site, baseline surveillance for the clinical outcomes will begin in year 1 at the and continue for all 3 years of the project. Guideline distribution will begin in year 2 and continue throughout the project. Audit-feedback will not occur at the control site. Provider surveys of knowledge and attitudes concerning the ABU guidelines will be administered at the control site in year 3 of the project.
3220628|NCT01052532||Mitral Regurgitation pre&post operation|Patients with severe Mitral Regurgitation without evidence of ischemia are tested prior to surgery and after valve repair.
3220629|NCT01052519|No Intervention|obese control|
3220630|NCT01052519|Active Comparator|obese goal-directed|
3220631|NCT01052519|Active Comparator|non-obese goal directed|
3220632|NCT01052506|Placebo Comparator|Placebo|Single dose of saline solution (8 cohorts IV; 1 cohort SC)
3220633|NCT01052506|Experimental|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV; 1 cohort SC)
3220634|NCT01052480|Experimental|Plasma and Standard Care|Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies (Anti-Influenza Immune Plasma) in addition to standard care.
3220635|NCT01052480|Active Comparator|Standard Care|Participants will receive standard care.
3220636|NCT01052454|No Intervention|Wait list|Women assigned to the waitlist have the opportunity of taking the MBSR program at no cost following final study assessment
3220637|NCT01052454|Experimental|Mindfulness-based stress reduction|Women in the MBSR arm attend eight weekly MBSR classes
3220638|NCT01052441||CT Scan|Subjects with typical or atypical chest pain suspected of coronary artery disease and referred for an elective invasive coronary angiography (ICA), and scheduled to undergo CCTA before ICA or after ICA, if no intervention has been performed.
3220639|NCT01052428|Active Comparator|Toprol XL|beta 1 receptor blockade; generic name metoprolol succinate
3220640|NCT01052428|Placebo Comparator|Placebo|Pill that looks like Toprol XL but does not have the active ingredients
3220641|NCT01052415|No Intervention|Standard care|Service providers and HIV patients, offered intervention at the end of study
3220642|NCT01052415|Experimental|Intervention|Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
3220643|NCT01052402|Experimental|Dose A|Two intramuscular injections (21 days apart, i.e. Days 0 and 21) of H5N1 Influenza Vaccine (Dose A) followed by a heterologous booster vaccination (Dose A) on Day 360
3220644|NCT01052402|Experimental|Dose B|Two intramuscular injections (21 days apart, i.e. Days 0 and 21) of H5N1 Influenza Vaccine (Dose B) followed by a heterologous booster vaccination (Dose B) on Day 360
3220645|NCT01052389|Experimental|Aripiprazole|Aripiprazole (N05AX12)
3220646|NCT01052389|Experimental|Olanzapine|Olanzapine (N05AH03)
3220647|NCT01052389|Experimental|Haloperidol|Haloperidol (N05AD01)
3220648|NCT01052363|Experimental|CA4P + Avastin|
3220655|NCT01052311|Active Comparator|Active treatment|Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) = tredaptive once daily from day 1 to 30. From day 31 to day 90 2 g of extended-release niacin and 20 mg of laropiprant once daily.
3220656|NCT01052298|Experimental|Arm 1|
3220657|NCT01052298|Experimental|Arm 2|
3220658|NCT01052298|Experimental|Arm 3|
3220659|NCT01052298|Placebo Comparator|Arm 4|
3220660|NCT01052285|Placebo Comparator|Placebo|TAP block with 25 ml of saline Ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline.
3220661|NCT01052285|Active Comparator|Local infiltration|Ilioinguinal block with 10 ml of ropivacaine 0,375% Local infiltration with 40 ml of ropivacaine 0,375% Tap block with 25 ml of saline
3220662|NCT01052285|Experimental|Transversus abdominis plane block|25 ml of Ropivacaine 0,75%, Ilioinguinal block with 10 ml saline and local infiltration with 40 ml of saline.
3220663|NCT01052272|Active Comparator|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
3220664|NCT01052272|Active Comparator|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
3220665|NCT01052272|Active Comparator|Ramipril and Allopurinol|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily. It is anticipated that the starting dose of each drug will be initiated in hospital and that the second dose will be implemented prior to discharge from the hospital. The starting dose of Allopurinol is 300 mg daily.
3220666|NCT01052272|Active Comparator|Candesartan cilexetil and Allopurinol|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily. The starting dose of Allopurinol is 300 mg daily.
3220667|NCT01052259|Experimental|Deoxyspergualin, Treatment,|
3220668|NCT01052246|Experimental|Clindamycin 1% + benzoyl peroxide 5% & pulsed dye laser|
3220669|NCT01052246|Active Comparator|Clindamycin 1% + benzoyl peroxide 5%|
3220670|NCT01052233|Active Comparator|Arthroscopic partial meniscectomy|Arthroscopic partial resection of degenerative tear of medial meniscus
3220671|NCT01052233|Sham Comparator|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
3220672|NCT01052220|Experimental|BP Education and Self Regulation of BP|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will received a BP educational session at baseline and were asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI made weekly visits with the intervention participants in the HD unit to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
3220673|NCT01052220|No Intervention|Usual Care|Participants in the usual care group did not receive the intervention but continued to receive their standard care in the hemodialysis unit which involved follow-up by the medical provider and BP medication adjustments as needed. .
3220674|NCT01052207||Critically Ill Patients|Evaluation of Oxidative Stress, Glucocorticoid Receptor function, and Adrenal Insufficiency amongst critically ill pediatric patients. Serum, and when available endotracheal samples, will be obtained within 24 hours of admission and at 5 days provided patients are 1) still in the PICU and 2) blood draws and endotracheal aspirates are part of their standard of care. Endotracheal aspirates will be sent on day 14, 21, and 28 provided patients are intubated and require suctioning as part of their standard of care.
3220675|NCT01052207||Healthy Controls|Healthy controls will be evaluated and defined as those who do not have any chronic medical condition, are not on steroids (inhaled or oral), and have not received steroids or etomidate in the last month. Given the time and need for multiple lab draws low dose adrenocorticotropin (ACTH) testing will not be done in healthy patients, nor will tracheal aspirate samples be obtained.
3220676|NCT01052194|Experimental|25 mg b.i.d. VX-509|
3220677|NCT01052194|Experimental|50 mg b.i.d. VX-509|
3220678|NCT01052194|Experimental|100 mg b.i.d. VX-509|
3220679|NCT01052194|Experimental|150 mg b.i.d. VX-509|
3220680|NCT01052194|Placebo Comparator|Placebo|
3220681|NCT01052181|Experimental|Vitamin D supplementation|Cholecalciferol sachets 120,000 IU monthly for 12 months
3220682|NCT01052181|Placebo Comparator|placebo|placebo with same taste, color, odor
3220683|NCT01052168|Active Comparator|Speed Group|The Speed Group, (n=20) will train in laparoscopic suturing on the validated FLS suturing model until the expert level of speed (i.e. task duration < 70 seconds) has been achieved on two consecutive attempts.
3220684|NCT01052168|Experimental|Motion Group|The Motion Group, (n=20) will train in laparoscopic suturing until expert levels of motion (pathlength 6700 and smoothness 560) have been achieved.
3220685|NCT01052168|Experimental|Speed and Motion Group|The Speed and Motion Group (n=20) will train in laparoscopic suturing until expert levels of speed AND motion have been achieved.
3220686|NCT01052142|Experimental|Lipovaxin-MM|
3220687|NCT01052129|Experimental|Naproxen Sodium 550 mg Tablets|Naproxen Sodium 550 mg Tablets of Dr.Reddy's Laboratories Limited
3220688|NCT01052129|Active Comparator|Anaprox DS 550 mg Tablets|Anaprox DS 550 mg Tablets of Roche Pharmaceuticals Inc
3220689|NCT01052116|Active Comparator|Soy Isoflavone|Oral isoflavone supplement (100 mg/day)
3220690|NCT01052116|Placebo Comparator|Placebo|Matching placebo
3220691|NCT01052103|Experimental|LY2140023|
3220696|NCT01052064|Experimental|Transcranial magnetic stimulation|There are evidences that rTMS has a modulating effect in cortical and subcortical neural networks, reinforcing or depressing synaptic activity by mean of long term potentiation or depression like mechanism. Depression is the most study neuropsychiatric condition in which rTMS is useful as a therapeutic option; but in other diseases such as ADHD there are many pathophysiological elements that make it very likely that rTMS could be useful for symptomatic treatment modulating activity in prefrontal and basal ganglia neuronal networks.
3220697|NCT01052051|Active Comparator|calcium|Daily calcium supplementation
3220698|NCT01052051|Experimental|Vitamin D|Daily Calcium and Vitamin D supplementation
3220699|NCT01052038|Placebo Comparator|Group 1 Placebo|Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.
3220700|NCT01052038|Active Comparator|Group 2: Dexamethasone 0.05mg/kg|Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery
3220701|NCT01052038|Active Comparator|Group 3:Dexamethasone 0.1mg/kg|Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.
3220702|NCT01052025|Experimental|Curcumin|curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
3220703|NCT01052025|No Intervention|Placebo|
3220704|NCT01052012|Experimental|Active: SABER™-Bupivacaine|SABER™-Bupivacaine
3220705|NCT01052012|Active Comparator|Comparator: Bupivacaine HCl|Bupivacaine HCl
3220706|NCT01052012|Placebo Comparator|Placebo: SABER™-Placebo|SABER™-Placebo
3220707|NCT01051999|Experimental|Glutamine|Patients randomized to the glutamine arm will receive 0.7g/kg of oral glutamine powder per day
3220708|NCT01051999|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive 0.7g/kg of oral isonitrogenous L-alanine powder per day
3220709|NCT01051986|Active Comparator|SVG group|"patients who underwent off-pump coronary artery bypass using saphenous vein composite grafting based on the left internal thoracic artery~use saphenous vein as a composite graft connected to the left internal thoracic artery"
3220710|NCT01051986|Active Comparator|RITA group|"patient who underwent off-pump coronary artery bypass using right internal thoracic artery composite grafting based on the left internal thoracic artery~use right internal thoracic artery as a composite graft connected to the left internal thoracic artery"
3220711|NCT01051973|Experimental|Cognitive behavior therapy|
3220712|NCT01051973|Active Comparator|Stress management|
3220713|NCT01051960|Experimental|ambrisentan|ambrisentan dosed at either 5mg or 10mg orally once per day
3220714|NCT01051947|Experimental|Nebivolol|Nebivolol therapy for 2-6 weeks depending on blood pressure readings
3220715|NCT01051947|Experimental|Metoprolol|Metoprolol therapy for 2-6 weeks depending on blood pressure readings
3220716|NCT01051921|Experimental|CTS-1027, Peg IFN, Ribavirin|"Study drug (CTS-1027) plus Standard of Care treatment (pegylated interferon and ribavirin).~CTS-1027, 15 mg taken twice daily. Pegylated interferon, 180 μg injected once a week. Ribavirin, 1000 mg or 1200 mg daily (depending on patient weight), taken in two divided doses."
3220717|NCT01051895|Experimental|HPV testing|Women randomized to this arm will undergo high risk HPV DNA testing using Hybrid Capture 2®.
3220718|NCT01051895|Active Comparator|Routine colposcopy|Women will be followed in the colposcopy clinic as usual, with no standardized protocol, tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
3220719|NCT01051882|Experimental|MSC-NTF|
3220720|NCT01051869|Active Comparator|simple decompression|
3220721|NCT01051869|Active Comparator|anterior subcutaneous transposition|
3220722|NCT01051856|Active Comparator|SEAMGUARD with bioabsorbable staple|In this arm pancreatic transection will be executed using an endoscopic linear stapling device. The individual staple depth can be chosen by the operating surgeon. Bioabsorbable Mesh sleeves specifically manufactured for the chosen staple depth and cartridge length will be placed over the stapler before firing.
3220723|NCT01051856|Active Comparator|TissueLink with radiofrequency ablation|After pancreatic transection, with any method chosen by the operating surgeon, the pancreatic remnant will be treated with TissueLink alone for an ablation depth (thickness) of approximately 7 mm using electrosurgical generator settings of 100 W and a saline drip rate of 1-2 drops per second.
3220724|NCT01051830|Experimental|Interdisciplinary group|Diabetes intervention and rehabilitation program. The rehabilitation program includes geriatric consultation, the rehabilitation program (interventions to improve ROM, muscle strength and endurance, proprioceptive enhancement, balance capacity, aerobic and anaerobic capacity, flexibility, and body composition), and discharge-planning services. The DM intervention includes: dietary and DM education, blood pressure control, dyslipidemia management, a glycemic treatment regimen, and exercises.
3220725|NCT01051830|No Intervention|Control group|Routine care
3220726|NCT01051817|Experimental|AIN457|
3220727|NCT01051817|Placebo Comparator|Placebo|
3220728|NCT01051804|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
3220729|NCT01051804|Active Comparator|Optive|Optive Lubricant Eye Drops
3220730|NCT01051791|Experimental|Everolimus 10 mg daily|"The study of the efficacy of everolimus will proceed in two stages after the method of Simon1. In the first stage 15 patients will be accrued and treated. If 9 or fewer patients show clinical benefit the study will be terminated. If 10 or more patients show clinical benefit the study will proceed to the second stage, accruing an additional 26 patients. If the second stage is complete and a total of 29 or more patients show clinical benefit among the 41 patients treated, the treatment CBR for will be considered high enough to warrant further study. Conversely, if the evaluation of everolimus concludes at the first stage, or if 28 or fewer patients experience a clinical benefit after completing the second stage, the therapy will not be considered for further study.~1"
3220731|NCT01051778|Experimental|enoxaparin 40 mg plus low dose aspirin|
3220732|NCT01051778|Active Comparator|Heparin calcium 5,000 U twice daily plus low dose aspirin|
3220733|NCT01051765|Experimental|irinotecan/cisplatin|irinotecan 130mg/m2 d1 cisplatin: 30mg/m2, d1,d2 every three weeks
3220819|NCT01051128|Experimental|Spasticity. Baclofen|This study is a non-randomized, open-label, multi-center study of the Prometra Programmable Implantable Pump System in the administration of Lioresal® intrathecal (baclofen) in patients suffering from severe muscle spasticity of spinal origin.
3220734|NCT01051752||NTM infection|Patients with NTM infection are generally middle aged or higher aged, white males with COPD or bronchiectasis. They will be recruited from the outpatient clinics of University Centre for Chronic Diseases Dekkerswald, Tuberculosis Centre Beatrixoord or other outpatient clinics in The Netherlands. Both newly diagnosed and already treated patients with NTM disease will be recruited.
3220735|NCT01051739||Group 1|glaucoma
3220736|NCT01051739||Group 2|normal
3220737|NCT01051726|Experimental|Aromatherapy group 1|Participants will be given essential oil consisting of (Peppermint, Lavender, Clary Sage and Frankincense) together with a swab to put the oil on.
3220738|NCT01051726|Placebo Comparator|Control group 2|Participants receive a bottle of non essential oil and a swab.
3220739|NCT01051726|No Intervention|Control group 3|Standard maternity care to measure baseline.
3220740|NCT01051713|Experimental|Standard|"Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits."
3220741|NCT01051713|Experimental|Technology Supported condition|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
3220742|NCT01051713|No Intervention|Self-Guided|Participants in the Self-Guided condition will receive DPP DVDs (3 DVDs and 1 CD) at the beginning of the study. This condition will not receive any direct dietary or physical activity interventions outside of the DVDs. Although Self-Guided participants will be receiving the same 7% weight loss goal as the other two groups, they will not be receiving physical activity or diet goals. The DVDs cover the initial 12-weekly sessions of the DPP, with the sessions portrayed by professional actors. They will also be provided with a supplemental DVD which includes a manual for each of the 12 sessions. They will also be giving the Keeping Track booklets and asked to record their diet and activity daily.
3220743|NCT01051700|Experimental|5 mg|GW786034
3220744|NCT01051700|Experimental|10 mg|GW786034
3220745|NCT01051700|Experimental|20 mg|GW786034
3220746|NCT01051700|Placebo Comparator|Placebo|Placebo
3220747|NCT01051687|No Intervention|control skin patches|no intervention will be given to the patches
3220748|NCT01051687|Active Comparator|botulinum toxin A|Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.
3220749|NCT01051674|Experimental|High fiber diet|
3220750|NCT01051674|Experimental|Low-carbohydrate diet|
3220751|NCT01051661|Experimental|Group A|Subjects will receive 2 doses of an alternative formulation of GSK2340274A vaccine at a 21-day interval.
3220752|NCT01051661|Experimental|Group B|Subjects will receive 1 dose of an alternative formulation of GSK2340274A vaccine on Day 0 and 1 dose of saline placebo on Day 21
3220753|NCT01051661|Experimental|Group C|Subjects will receive 2 doses of an alternative formulation of GSK2340273A vaccine administered at a 21-day interval.
3220754|NCT01051648|Experimental|Triamcinolone acetenoide|Intra ocular injection of triamcinolone acetonide to visualize vitreous strands in the anterior chamber of the eye in complicated cataract surgery
3220755|NCT01051635|Experimental|A|LMP400 administered IV daily for 5 days perdose escalation table.
3220756|NCT01051635|Experimental|B|LMP776 administered IV daily for 5 days perdose escalation table.
3220757|NCT01051622|Experimental|PBMC Trafficking|In part B, Patients undergo a blood draw (up to150 mL) and the PBMC's are separated and selected or 99mTc-HMPAO labeling. The purified and labelled cells will be re-introduced into the patient by intravenous infusion and one SPECT scan and up to 8 serial planar scintigraphy scans will initially be conducted over up to 6 hours within 1 scan session. All suitable patients showing evidence of cellular uptake in the ileo-caecal region and/or small bowel at Visit 1 will be progressed to an identical second cell labeling and scanning session at Visit 2 (48 hours later). Subjects showing no evidence of cellular uptake in the ileo-caecal region or small bowel at Visit 1 (negative scan) will be withdrawn from the study and proceed to the follow-up.
3220758|NCT01051622|Experimental|T Lymphocyte Trafficking|"In part B, Patients undergo a blood draw (up to150 mL) and the T lymphocyte cells are separated and selected or 99mTc-HMPAO labeling. The purified and labelled cells will be re-introduced into the patient by intravenous infusion and one SPECT scan and up to 8 serial planar scintigraphy scans will initially be conducted over up to 6 hours within 1 scan session. All suitable patients showing evidence of cellular uptake in the ileo-caecal region and/or small bowel at Visit 1 will be progressed to an identical second cell labeling and scanning session at Visit 2 (48 hours later). Subjects showing no evidence of cellular uptake in the ileo-caecal region or small bowel at Visit 1 (negative scan) will be withdrawn from the study and proceed to the follow-up.~visit."
3220759|NCT01051609||Intervention Group|There is only one arm in this trial. Please see interventions for more detailed descriptions.
3220760|NCT01051596|Experimental|ABT-888 and temozolomide|Temozolomide Days 1-5 and ABT-888 Days 1-7 of each 28-day cycle
3220761|NCT01051583|Experimental|Avastin , diode laser cyclophotcoagulation|Intravitreal Avastin injection in conjunction with diode laser cyclophotocoagulation
3220762|NCT01051583|Active Comparator|Diode Laser cyclophotocoagulation|Diode laser cyclophotocoagulation to control intraocular pressure
3220763|NCT01051570|Experimental|Carboplatin, RAD 001 & Prednisone|"Carboplatin: AUC=4 by Calvert's formula (max dose 600 mg)*IV over 30-60 min, Day 1 of a 21 day cycle~RAD 001: 5 mg Orally daily, starting from Day 2 continuously~Prednisone 5 mg Orally twice daily, continuously"
3220764|NCT01051557|Experimental|Treatment (temsirolimus and perifosine)|"PHASE I: Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and perifosine PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive temsirolimus and perifosine as in phase I. Some patients may also undergo cytoreductive surgery."
3220765|NCT01051544|Active Comparator|von Willebrand factor-free FVIII concentrates|Patients treated with FVIII concentrates
3220766|NCT01051544|Active Comparator|FVIII/VWF concentrates|Patients treated with FVIII/VWF concentrates
3220767|NCT01051531|Experimental|Paliperidone palmitate|
3220768|NCT01051518|Experimental|CoreValve|
3220769|NCT01051505|Experimental|1|
3220770|NCT01051505|Placebo Comparator|2|
3220771|NCT01051479|Experimental|C11-Choline|
3220772|NCT01051466|Experimental|Duloxetine|
3220773|NCT01051466|No Intervention|Healthy Participants|
3220774|NCT01051440|Placebo Comparator|Placebo|Subjects will receive placebo for lisdexamfetamine.
3220775|NCT01051440|Active Comparator|Lisdexamfetamine|Subjects will start with 20 mg per day of lisdexamfetamine and may increase to a maximum of 40 mg.
3220776|NCT01051427|Active Comparator|Nasal catheter|In this arm will be the patients with epistaxis that cannot be stopped with anterior nasal packing and are randomized not to put Surgiflo. So they receive the usual treatment with a nasal catheter balloon into the nose.
3220777|NCT01051427|Experimental|Surgiflo|In this arm will be the patients with epistaxis that cannot be stopped with anterior nasal packing and are randomized to put into the nose Surgiflo.
3220778|NCT01051414|Experimental|BMS-790052 + BMS-650032|
3220779|NCT01051401|Experimental|Arm I (rosuvastatin)|Patients receive rosuvastatin PO once daily for 3 months in the absence of disease progression or unacceptable toxicity.
3220780|NCT01051401|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO once daily for 3 months in the absence of disease progression or unacceptable toxicity.
3220781|NCT01051388|Active Comparator|Group I|Low-dose PPI (Rabeprazole sodium 10 mg)
3220782|NCT01051388|Active Comparator|Group II|High-dose PPI (Rabeprazole sodium 20 mg)
3220783|NCT01051388|Active Comparator|Group III|Non-PPI (Gefarnate)
3220784|NCT01051375|Experimental|Waitlist Group|The intervention involves completion of a single workshop, provision of psychoeducational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list, within a month of our receiving the referral.
3220785|NCT01051375|No Intervention|Standard of Care|These patients continue to receive the standard of care while awaiting formal assessment.
3220786|NCT01051362|No Intervention|PLD and Carboplatin|Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
3220787|NCT01051349|Experimental|BIIB019|150 mg subcutaneous injection every 4 weeks for up to 6 years or until availability of commercial product (whichever is sooner).
3220788|NCT01051336|Experimental|TARIS Placebo|
3220789|NCT01051336|Sham Comparator|Sham Procedure|
3220790|NCT01051323||1|
3220791|NCT01051310|Experimental|CoreValve|
3220792|NCT01051297||VTE -PROSPECTIVE|Patients diagnosed with VTE
3220793|NCT01051297||sleep study group -PROSPECTIVE|patients undergoing sleep study
3220794|NCT01051297||VTE-Retrospective|patients with VTE , chart review
3220795|NCT01051297||OSA-retrospective|PATIENT WITH OSA -CHART REVIEW
3220796|NCT01051297||OSA group -PROSPECTIVE|patients diagnosed with OSA
3220797|NCT01051284|Experimental|Cyberknofe and Gemcitabine|Cyberknife radiation and 6 cycles Gemcitabine
3220798|NCT01051271|Active Comparator|diphenhydramine|
3220799|NCT01051271|Placebo Comparator|saline|
3220800|NCT01051245|Active Comparator|Case management|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
3220801|NCT01051245|Placebo Comparator|Usual care group|Usual care provided by primary care physician and/or specialist. Free access to diabetes educational workshops. Regular delivery of educational brochures (not personally targeted).
3220802|NCT01051232|Placebo Comparator|Cohort 1|PF-00868554 (filibuvir) 100 mg or placebo
3220803|NCT01051232|Placebo Comparator|Cohort 2|PF-00868554 (filibuvir) 300 mg or placebo
3220804|NCT01051232|Placebo Comparator|Cohort 3|PF-00868554 (filibuvir) 500 mg or placebo
3220805|NCT01051219|Active Comparator|Losartan, daily medication|50 milligrams Losartan to be taken orally daily
3220806|NCT01051219|Placebo Comparator|Placebo|A matched placebo will be given for patients to take once daily
3220807|NCT01051193|Experimental|TRI476|TRI476
3220808|NCT01051180||Doppler|Those patients where the doppler was randomised to be on
3220809|NCT01051180||Non doppler patients|those with no doppler guidance
3220810|NCT01051167|Experimental|Cetuximab + Folfox-6-regime|"Cetuximab 500 mg/m² administered as an intravenous infusion over 120 minutes on day 1 every 2 weeks. Combined with the following FOLFOX-6-regime:~Oxaliplatin 85 mg/m² i.v. for 2 h on day 1, Folinic acid 400 mg/m² i.v. for 2 h concurrently with Oxaliplatin on day 1, Fluorouracil 400 mg/m² i.v. bolus after Folinic Acid on day 1, followed by Fluorouracil 2400 mg/m² i.v. over 46 h."
3220811|NCT01051154|Active Comparator|Docosahexaenoic acid (DHA)|This group will be receive the DHA supplement
3220812|NCT01051154|Placebo Comparator|Placebo|This group will be receive placebo
3220813|NCT01051141|Active Comparator|CBI in ED with AMET at 3 months|computer brief intervention (CBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
3220814|NCT01051141|Active Comparator|CBI in ED with EUC at 3 months|
3220815|NCT01051141|Active Comparator|IBI in ED with AMET at 3 months|
3220816|NCT01051141|Active Comparator|IBI in ED with EUC at 3 months|
3220817|NCT01051141|Active Comparator|EUC in ED with AMET at 3 months|
3220818|NCT01051141|No Intervention|EUC in ED with EUC at 3 months|
3220820|NCT01051115|Experimental|Dasatinib|Patients will be treated with dasatinib monotherapy 100mg daily. At four weeks patients will be re-evaluated. Patients with less than a partial response will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib.
3220821|NCT01051102|Experimental|IDegAsp|
3220822|NCT01051102|Active Comparator|BIAsp 30|
3220823|NCT01051089|Experimental|Lifestyle modification|supervised exercise with diet education
3220824|NCT01051089|No Intervention|Control|Control (ordinary care with usual education)
3220825|NCT01051076|Experimental|Factor VIII and von Willebrand Factor|
3220826|NCT01051063|Experimental|Group A|Patients receiving 24 doses of the study treatment over a period of approximately 4 years.
3220827|NCT01051050|Other|Mandatory use of surgery wiki|Mandatory participation in journal club wiki which will include adding to and reviewing the information posted on the wiki. Contribution to the wiki will be required at least once during the study period.
3220828|NCT01051050|Other|Voluntary use of surgery wiki|Voluntary participation in the journal club wiki
3220829|NCT01051037|Experimental|Arm 1|Subjects will undergo PET/CT simulation, 3 Fraction SBRT, RFA, and then undergo follow up.
3220830|NCT01051024|Experimental|A|Diamel
3220831|NCT01051024|Placebo Comparator|B|Placebo
3220832|NCT01051011|Experimental|1|
3220833|NCT01051011|Experimental|2|
3220834|NCT01051011|Active Comparator|3|
3220835|NCT01050998|Experimental|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 milligram (mg) injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
3220836|NCT01050998|Experimental|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
3220837|NCT01050998|Experimental|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
3220838|NCT01050998|Experimental|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
3220839|NCT01050998|Placebo Comparator|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
3220840|NCT01050985|Experimental|temsirolimus and capecitabine|Treatment with the combination of temsirolimus and capecitabine
3220841|NCT01050972|Experimental|Cognitive and physical program|Experimental: Cognitive and physical program. Non randomized residents in the territory of Piedmont (Piemonte) Italy.
3220842|NCT01050946|Other|Haploidentical/cord transplant|Haploidentical/cord transplant with the precondition regimen at discretion of treating physician.
3220843|NCT01050933|Experimental|Carbon Monoxide|Healthy volunteers will receive 250 ppm of carbon monoxide by face mask. This dose will be administered for 1 hour with continuous COHb monitoring. At baseline and at each half hour time point, a blood sample will be drawn to be analyzed by the gas chromatograph. After 1 hour, the volunteer will be excused and asked to return in 4 hours and this procedure repeated. At any point, if the COHb level reaches 10%, administration of CO will be terminated.
3220844|NCT01050920||Blood Collection|
3220845|NCT01050907|Experimental|miltefosine|
3220846|NCT01050894||osteoarthritis patients|
3220847|NCT01050881||Positive Blood Donors|Blood donors testing positive for HIV, HBV, HCV or HTLV in 2008 and 2009. Donors and patients notified of increased risk of vCJD in 2005.
3220848|NCT01050868|Experimental|Single Arm|
3220849|NCT01050855|Experimental|RIC: Distal Campath|"Day Treatment~Day - 22 Inpatient: Alemtuzumab (Campath) test dose IV or SQ (subcutaneously) over 2 hours~Day - 21 to-19 Alemtuzumab IV/ SQ~Day - 7 to -3 Readmission to hospital Fludarabine IV~Day - 2 Melphalan IV~Day - 1 Begin cyclosporine infusion~Day 0 Transplant: Bone marrow or cord blood infusion"
3220850|NCT01050855|Experimental|RIC:Intermediate Campath|"Day Treatment~Day - 14 to-10 Inpatient: Alemtuzumab (Campath) IV or SQ (subcutaneously)~Day - 7 to -3 Fludarabine IV~Day - 2 Melphalan 140 mg/m2 IV~Day - 1 Cyclosporine infusion starts~Day 0 Transplant: Bone marrow or cord blood infusion"
3220851|NCT01050855|Experimental|RIC: Mini Busulfan|"Day Treatment~Day - 8 Alemtuzumab (Campath) IV or SQ (subcutaneously)~Day - 7 Alemtuzumab (Campath) IV or SQ (subcutaneously)~Day - 6 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV~Day - 5 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV~Day - 4 Alemtuzumab (Campath) IV or SQ (subcutaneously) Fludarabine IV~Day - 3 Fludarabine IV~Day - 2 Fludarabine IV Cyclosporine infusion~Day - 1 Rest~Day 0 Transplant: Bone marrow or cord blood infusion"
3220852|NCT01050842|Experimental|Arm I|Patients receive oral bicalutamide and oral raloxifene on days 1-28.
3220853|NCT01050829|Experimental|Arm 1|
3220854|NCT01050829|Active Comparator|Arm 2|
3220855|NCT01050816|Experimental|Chondron implantation|ankle cartilage defect patients who had CHONDRON transplantation
3220856|NCT01050803|Experimental|FDSME group|In the FDSME group, sessions will be held interactive; and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions.
3220857|NCT01050803|Active Comparator|Control group|
3220858|NCT01050790|Experimental|Aza Len Lymphapheresis SCT ALI|Azacitidine will be administered to all the patients subcutaneously at a dose of 75 mg/m2 daily for five days(day 1-5). These cycles will be repeated at 28 day intervals depending on hematopoietic recovery. Starting on day 6 patients will receive lenalidomide 15 mg PO daily until day 21. No drug will be administered from day 22 to day 28. Lymphapheresis will occur after cycles 2 and 3.Patients will undergo a stem cell collection approximately two weeks after complete myeloid recovery from the third cycle of therapy. Stem Cell Transplant (SCT) will occur per transplant center protocols. Post-transplant single or tandem autologous lymphocyte infusions (ALI) will be performed no earlier than 30 days post-transplant and no later than 40 days.
3220859|NCT01050777|Experimental|Liposomal Paromomycin|Liposomes containing 10% Paromomycin
3220860|NCT01050777|Experimental|Liposomal meglumine antimoniate|Liposomes containing meglumine antimonate
3220861|NCT01050777|Placebo Comparator|Placebo|
3220862|NCT01050764|Experimental|T-reg Cell Infusion after Allogeneic Stem Cell Transplant|
3220863|NCT01050751|Experimental|Lersivirine (new formulation)|
3220864|NCT01050751|Active Comparator|Lersivirine (old formulation)|
3220865|NCT01050738|Active Comparator|Intracapsulare position|
3220866|NCT01050738|Active Comparator|Extracapsulare position|
3220867|NCT01050725||Radiation therapy patients|Individuals receiving radiation therapy as definitive or neo-adjuvant therapy for selected malignancies, including head and neck, lung, esophageal, rectal cervical and prostate cancers.
3220868|NCT01050712|Experimental|Carbon Monoxide|
3220869|NCT01050712|Placebo Comparator|Synthetic Air|
3220870|NCT01050699|Experimental|Dexmedetomidine|Dexmedetomidine plus saline
3220871|NCT01050699|Active Comparator|Usual Care|Midazolam and Fentanyl
3220872|NCT01050686|Active Comparator|subcutaneous wound drain|subcutaneous wound drain inserted
3220873|NCT01050686|Experimental|no subcutaneous wound drain|no subcutaneous wound drain inserted
3220874|NCT01050673|Active Comparator|VERSAJET|Excision with VERSAJET™ Hydrosurgery System
3220875|NCT01050673|Active Comparator|Conventional Therapy|Conventional operating room excision will consist of sharp instrumentation and electrocautery techniques, with the use of pulse lavage at the investigator's discretion. The type of sharp instrumentation, together with the brand of pulse lavage will be recorded.
3220876|NCT01050660|Active Comparator|3 gm/kg/day intravenous lipid emulsion|
3220877|NCT01050660|Experimental|Intravenous Fat Emulsion-restricted|
3220878|NCT01050647|Active Comparator|17-hydroxyprogesterone caproate|Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation
3220879|NCT01050647|Placebo Comparator|Castor oil injections|Weekly injections of Caster Oil (placebo)
3220880|NCT01050634||Observational|
3220881|NCT01050608||Sprixx Device Group|Treatment group utilizing multimodal hand hygiene device
3220882|NCT01050608||Standard Hand Hygiene Group|Utilizing wall mounted dispensers and CDC based guidelines.
3220883|NCT01050595|Active Comparator|Methylnaltrexone Bromide|
3220884|NCT01050595|Placebo Comparator|Placebo|
3220885|NCT01050582|Experimental|Risperidone|Risperidone as per local prescribing practices
3220886|NCT01050582|Experimental|Other atypical antipsychotic drugs|Other atypical antipsychotic drugs as per local prescribing practices
3220887|NCT01050569|Active Comparator|VLNC Cigarette|Very Low Nicotine Content Cigarette. Dosage: 0.05 mg to 0.09 mg nicotine yield cigarette; Frequency: Daily; Duration: 6 weeks.
3220888|NCT01050569|Active Comparator|Nicotine Patch|21 mg nicotine patch. Dosage: 21 mg; Frequency: Daily; Duration: 6 weeks.
3220889|NCT01050569|Experimental|VLNC Cigarette plus Nicotine Patch|Very Low Nicotine Content Cigarette plus 21 mg Nicotine Patch. Patch Dosage: 21 mg; Cigarette Dosasge: 0.05 to 0.09 mg nicotine yield; Frequency: Daily; Duration: 6 weeks
3220890|NCT01050556|Placebo Comparator|Placebo|Placebo daily
3220891|NCT01050556|Experimental|Folic Acid 400 ug|400 µg folic acid daily
3220892|NCT01050556|Experimental|Folic Acid 800 ug|800 µg folic acid daily
3220893|NCT01050556|Experimental|Creatine|creatine daily
3220894|NCT01050556|Experimental|Creatine + Folic Acid|creatine + folic acid daily
3220895|NCT01050543|Experimental|Sugammadex|
3220896|NCT01050543|Active Comparator|Neostigmine|
3220897|NCT01050530|Experimental|OPC-41061|
3220898|NCT01050530|Placebo Comparator|Placebo|
3220899|NCT01050517|Active Comparator|1|albendazole + ivermectin + praziquantel
3220900|NCT01050517|Placebo Comparator|2|albendazole + ivermectin + (1 week later) praziquantel
3220901|NCT01050504||Ancillary-correlative (blood and tissue collection)|Patients undergo collection of blood and tissue samples for analysis via mutation mapping, DNA sequencing, gene expression microarray, and gene profiling.
3220902|NCT01050491|Placebo Comparator|sitaxsentan, airway remodeling|Blinded, randomised placebo-controlled trial involving two parallel groups of severe asthmatic patients with irreversible airflow obstruction (FEV1≤ 70% of predicted) .
3220903|NCT01050491|Placebo Comparator|placebo, airway remodeling|Blinded, randomised placebo-controlled trial involving two parallel groups of severe asthmatic patients with irreversible airflow obstruction (FEV1≤ 70% of predicted) .
3220904|NCT01050478|Experimental|Paliperidone ER|Paliperidone ER: recommended dose: 6 mg/day. Can be 9 mg/day for patients with an acute exacerbation of schizophrenia. A benzodiazepine for sedation and/or rescue medication can be added with a maximum of 7.5 mg/day, at the investigators' discretion.
3220905|NCT01050465|Active Comparator|email|Patients randomized to this arm will receive an email health information prescription.
3220906|NCT01050465|Active Comparator|paper|Patients randomized to this arm will receive a paper health information prescription.
3220907|NCT01050452|Placebo Comparator|1|albendazole treatment
3220908|NCT01050452|Active Comparator|2|mebendazole treatment
3220909|NCT01050452|Active Comparator|3|ivermectin treatment
3220910|NCT01050452|Active Comparator|4|albendazole + ivermectin treatment
3220911|NCT01050452|Active Comparator|5|mebendazole + ivermectin treatment
3220912|NCT01050439|Experimental|UDAlloSCT + Therapy|This is a non-randomized study to test the safety and response of unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT) with either myleoablative (full intensity) or reduced intensity conditioning therapy in patients with selected malignant and non-malignant disorders. UDAlloSCT has been performed in both adults and children as an alternative transplant for patients who lack and HLA-matched family donor in both malignant and non-malignant disease with varying degrees of response.
3220913|NCT01050426|Active Comparator|Group 1|UFT/LV + RT
3220914|NCT01050426|Active Comparator|Group 2|UFT/LV + RT + Cetuximab
3220915|NCT01050413||1|colon cancer, prostate cancer, lung cancer, ovarian cancer
3220916|NCT01050400||Observant|Individuals within this group will receive pharmacotherapy according to the established institutional guidelines.
3220917|NCT01050400||Prospective CYP2D6 genetic screening|Individuals within the prospective group will receive their CYP2D6 genotype results prior to pharmacotherapy and their analgesic regimen will be tailored to their genetic results.
3220918|NCT01050374|Placebo Comparator|1|albendazole + praziquantel
3220919|NCT01050374|Active Comparator|2|mebendazole + praziquantel
3220920|NCT01050361|Experimental|EGHEM|The intervention group will be called EGHEM - Echo Guided HEmodyanmic Management - and will receive their intraoperative maintenance fluid and possible drug therapy (furosemide) based on their hourly intraoperative LVDD grade.
3220921|NCT01050361|No Intervention|SHEM|"The control group will be~called SHEM - Standard HEmodynamic Management - and will NOT receive the study intervention, but will receive standard anesthesia and hemodynamic management based on current standards within the institution."
3220922|NCT01050348|Active Comparator|Atorvastatin calcium|Patients will receive study medication upon admission to hospital prior to percutaneous intervention of the culprit artery
3220923|NCT01050348|Placebo Comparator|Sugar Pill|Patients will receive study medication upon admission to hospital prior to percutaneous intervention of the culprit artery
3220924|NCT01050335||Surgical resident or attending|
3220925|NCT01050322|Active Comparator|Capecitabine Lapatinib|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
3220926|NCT01050322|Experimental|Vinorelbine Lapatinib|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
3220927|NCT01050322|Experimental|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
3220928|NCT01050309|Active Comparator|Cervix|
3220929|NCT01050309|Active Comparator|colon|
3220930|NCT01050309|Active Comparator|Intravenous|
3220931|NCT01050283|Experimental|1|[18F]-FDG-PET/CT (Computed Tomography) Imaging
3220932|NCT01050270|Other|Ondansetron /acetylcysteine 20.25h|Ondansetron followed by conventional acetylcysteine regimen
3220933|NCT01050270|Other|Placebo/acetylcysteine 20.25h|placebo followed by conventional acetylcysteine regimen
3220934|NCT01050270|Other|Ondansetron/acetylcysteine 12h|ondansetron followed by modified acetylcysteine regimen
3220935|NCT01050270|Other|Placebo/acetylcysteine 12h|placebo followed by modified acetylcysteine regimen
3220936|NCT01050257|Experimental|Oseltamivir (TAMIFLU®) 100 mg|Oseltamivir (TAMIFLU®) 100 mg intravenous (IV) infused over 2 hours, two times a day (every 12 hours) for 5 days. At the discretion of the investigator after 3 days of treatment (6 doses), participants could either continue IV treatment or switch to 75 mg oral oseltamivir twice daily to complete the 5 days of treatment. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug (IV or oral) for up to 5 days.
3220937|NCT01050257|Experimental|Oseltamivir (TAMIFLU®) 200 mg|Oseltamivir (TAMIFLU®) 200 mg intravenous (IV) infused over 2 hours, two times a day (every 12 hours) for 5 days. At the discretion of the investigator after 3 days of treatment (6 doses), participants could either continue IV treatment or switch to 150 mg oral oseltamivir twice daily for 5 days. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug (IV or oral) for up to 5 days.
3220938|NCT01050257|Experimental|Oseltamivir Open Label|Moderate/Severe renal impaired participants received open label oseltamivir IV or oseltamivir capsules at reduced doses for 5 days as per protocol. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug as per protocol.
3220939|NCT01050244|Experimental|Soy Protein|30g of soy protein from whole soybean soymilk powder given daily for 3 weeks
3220940|NCT01050244|Placebo Comparator|Milk Protein|30g of milk protein from whole milk powder given daily for 3 weeks
3220941|NCT01050231|Experimental|1|Robotic group(Type I)
3220942|NCT01050231|Active Comparator|2|Robotic group (Type II)
3220943|NCT01050218|Other|DVS SR Open Label|Daily dose of 100mg or 200mg at the investigators discretion. Subjects already randomized at a dose of 400mg may continue at that dose level.
3220944|NCT01050205|Active Comparator|Current Intervention|"Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD). Upon choosing, participants will be randomly assigned to Current intervention Arm in which case they will receive the intervention immediately."
3220945|NCT01050205|Active Comparator|Delayed Intervention|"Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD). Upon choosing, participants will be randomly assigned to Delayed Intervention Arm in which case they will receive delayed intervention at 6 months."
3220946|NCT01050166||Labeled islets|Type 1 diabetic recipients after islet transplantation with islets labeled by iron contrast agent
3220947|NCT01050153|Active Comparator|Control (standard of care)|Dalteparin sodium 5000IU subcutaneously daily
3220948|NCT01050153|Experimental|TEG-guided thromboprophylaxis|Dalteparin sodium plus/minus anti-platelet medication (aspirin) per a TEG-guided algorithm
3220949|NCT01050140|Experimental|fructose|25% dietary energy from fructose
3220950|NCT01050140|Active Comparator|glucose|25% dietary energy from glucose
3220951|NCT01050127|Experimental|Low dose ABT-436|ABT-436 or placebo administered once daily for 7 days.
3220952|NCT01050127|Experimental|Mid Dose ABT-436|ABT-436 or placebo administered once daily for 7 days.
3220953|NCT01050127|Experimental|High Dose ABT-436|ABT-436 or placebo administered once daily for 14 days.
3220954|NCT01050114|Other|ARM 1: onaBoNT-A injection + placebo|onaBoNT-A 200 U (treatment 1)/ onaBoNT-A 200 U (treatment 2)/ onaBoNT-A 200 U (treatment 3) and placebo oral capsule daily
3220955|NCT01050114|Other|ARM 2: Placebo injection + oxybutynin ER|Placebo injection (treatment 1)/ onaBoNT-A 200 U (treatment 2)/ onaBoNT-A 200 U (treatment 3) and oxybutynin ER 10 mg capsule daily
3220956|NCT01050101|Placebo Comparator|High GI low fiber meal|No fiber control meal
3220957|NCT01050101|Active Comparator|Low GI high fiber viscous meal|80:20 ratio of viscous polysaccharide fiber to insoluble non-viscous producing fiber
3220958|NCT01050101|Active Comparator|Low GI high fiber non-viscous meal|20:80 ratio of viscous polysaccharide fiber source to insoluble non-viscous producing fiber
3220959|NCT01050088|Experimental|Sucrose|5cc sucrose solution
3220960|NCT01050088|Placebo Comparator|Saline|5cc saline p/o
3220961|NCT01050075|Experimental|Arm I|Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks during courses 3 and 4.
3220962|NCT01050075|Experimental|Arm II|Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients then undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks.
3220963|NCT01050062||Micombi® Combination Tablet AP|
3220964|NCT01050062||Micombi® Combination Tablet BP|
3220965|NCT01050049||Before guidelines implemented|
3220966|NCT01050049||After guidelines implemented|
3220967|NCT01050036|Experimental|HCT recipients|"Patient with CBF AML will be eligible in his/her 1st complete remission (CR1) status. Patients who have relapsed or have achieved 2nd complete remission should not be included in this study.~1st postremission therapy after CR1 will be performed with high-dose cytarabine (HDAC) chemotherapy, consisting of intravenous cytarabine 3 g/m2 infusion during 3 hours twice a day on days 1, 3, and 5.~After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information."
3220968|NCT01050023|Experimental|1 - Active Treatment|Provant device activated to emit RF energy
3220969|NCT01050023|Sham Comparator|2 - Inactive Treatment|Provant device not activated to emit RF energy
3220970|NCT01050010|Other|Dedicated extremity MRI|Structural deterioration radiographic assessed by dedicated extremity MRI
3220971|NCT01049997||NSTEMI75+|Patients, 75 years old or older, with Non ST Elevation Myocardial Infarction (NSTEMI)
3220972|NCT01049984|Experimental|Rasagiline 1 mg|Participants took a 1 mg rasagiline tablet orally each day for 18 weeks.
3220973|NCT01049984|Placebo Comparator|Placebo|Participants took a matching placebo tablet once daily for 18 weeks.
3220974|NCT01049971|Active Comparator|no wound protector|instead of wound protector, a woven drape is applied
3220975|NCT01049971|Experimental|wound protector|after minilaparotomy, wound protector is applied
3220976|NCT01049945|Experimental|Arm I|Patients receive dexamethasone orally or IV on days 1, 8, 15, and 22; bendamustine hydrochloride IV over 30 minutes on days 1 and 2; and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3220977|NCT01049932|Experimental|All subjects|TMC278LA 600mg injected intramuscularly (i/m)
3220978|NCT01049919|Experimental|Concentrated bone marrow aspirate (cBMA)|Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
3220979|NCT01049919|Sham Comparator|Placebo control (sham)|Placebo procedure (sham) consists of simulated bone marrow aspiration followed by simulated intramuscular injections into the affected limb
3220980|NCT01049906|Active Comparator|Nerve stimulation and Ultrasound|
3220981|NCT01049906|Active Comparator|Ultrasound without nerve stimulation|
3220982|NCT01049893|Experimental|AC220|Dose finding study. Number of arms dependant upon dose limiting toxicities.
3220983|NCT01049880|Experimental|Ascorbate|
3220984|NCT01049854|Experimental|Thiotepa/Cyclophosphamide/ATG|Full intensity with TBI
3220985|NCT01049854|Experimental|Busulfan/Melphalan/ATG|Full intensity without TBI
3220986|NCT01049854|Experimental|Busulfan/Fludarabine/Alemtuzumab|Reduced Intensity Chemotherapy
3220987|NCT01049854|Experimental|Fludarabine/Cyclophosphamide/ATG|Reduced Intensity Chemotherapy for Fanconi Anemia
3220988|NCT01049841|Experimental|perifosine + temsirolimus|This is a single arm, phase I study. Eligible patients will receive a loading dose of oral perifosine on the first day, followed by a maintenance dose starting on the second day until progression. Each patient is assigned to a group according to their body surface area (BSA). Temsirolimus will be combined with perifosine at four dose levels to determine the MTD for the combination therapy. Temsirolimus dosing will start on the same day as the perifosine load.
3220989|NCT01049828||Slightly or Non-Bothered Tinnitus Group|
3220990|NCT01049815|Experimental|Sevelamer hydrochloride|
3220991|NCT01049815|Active Comparator|Calcium carbonate|
3220992|NCT01049802|Experimental|Active rTMS|Experimental subjects will receive subthreshold or suprathreshold rTMS to contralesional hemisphere for up to 20 minutes at 1 Hz followed by task oriented arm and hand therapy to affected limb.
3220993|NCT01049802|Placebo Comparator|Sham rTMS|Subject will receive sham rTMS to contralesional hemisphere for up to 20 minutes followed by task-oriented arm and hand rehabilitation to affected limb
3220994|NCT01049789|Active Comparator|TAU|Sites participating in Phase I and Phase II will be randomized to implement this treatment method or the other treatment method. All ATN 080 participants at a site randomized to implement TAU will receive that treatment method.
3220995|NCT01049789|Experimental|COMB|Sites participating in Phase I and Phase II will be randomized to implement this treatment method or the other treatment method. All ATN 080 participants at a site randomized to implement COMB will receive that treatment method.
3220996|NCT01049776|Experimental|Pazapanib (GW786034)|
3220997|NCT01049763|Experimental|Regimen A|oseltamivir 75 mg single dose
3220998|NCT01049763|Active Comparator|Regimen B|oseltamivir 150 mg single dose
3220999|NCT01049750||type 2 diabetic patients|males; type 2 diabetic patients
3221000|NCT01049724||PRK|Those patients undergoing photorefractive keratectomy
3221001|NCT01049724||LASIK|Those undergoing Laser-assisted insitu keratomileusis
3221002|NCT01049711||erythropoietin|
3221003|NCT01049698|Active Comparator|1. Resistance Training|3 d/wk resistance training
3221004|NCT01049698|Experimental|2. Resistance Training + Diet|Resistance training plus caloric restriction
3221005|NCT01049685|Active Comparator|Efavirenz Group|Naïve-treatment HIV patients, who started therapy with Efavirenz
3221006|NCT01049685|Active Comparator|Lopinavir/r Group|Naïve-treatment HIV patients, who started therapy with Lopinavir/ritonavir
3221007|NCT01049672|Active Comparator|Alfentanil|Hospice in-patients who require subcutaneous strong opioid administration will be given alfentanil
3221008|NCT01049672|Active Comparator|Diamorphine|Hospice in-patients who require strong opioids will be given diamorphine
3221009|NCT01049659|Other|neuropsychological tests|neuropsychological assessment of children around their second birthday
3221010|NCT01049646|Active Comparator|Angiotensin II|
3221011|NCT01049646|Placebo Comparator|Saline infusion|
3221012|NCT01049620|Experimental|Xelox+RAD001|
3221013|NCT01049607|Active Comparator|Clamp-Crush technique|
3221014|NCT01049607|Experimental|Stapler hepatectomy|
3221015|NCT01049594||Preterm infants|Delivery at less than 33 completed weeks of gestation
3221016|NCT01049581|Experimental|pediatric aquatic therapy|The children of the PAT group participated in a 1 hour/time, twice-per-week, 12-week, PAT program in addition to conventional rehabilitation programs
3221017|NCT01049581|No Intervention|conventional therapy|The children included in the control group continued with their original rehabilitation programs
3221018|NCT01049568|Experimental|Cell Phone Intervention|
3221019|NCT01049568|No Intervention|Control|"Control group participants will participate in all on-study evaluations, except the intervention exit interviews.~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization."
3221020|NCT01049555|Other|Alzheimer and apathy|Alzheimer's disease patients with apathy
3221021|NCT01049555|Other|alzheimer without disease|Alzheimer's disease patients without apathy
3221022|NCT01049555|Other|Case control|subject without apathy neither Alzheimer's disease
3221023|NCT01049542|Experimental|Astressin 2B|Healthy volunteers will receive incremental doses of intra arterial Astressin 2B (a selective and potent Urocortin 2 & 3 antagonist). This serves as a dose finding Protocol for Astressin 2B, which will be used in subsequent protocols.
3221024|NCT01049529|Placebo Comparator|Placebo group|This group is receiving sunflower oil (the excipient for DHA)
3221025|NCT01049529|Active Comparator|DHA group|This group is receiving the docosahexaenoic acid (DHA) supplement
3221026|NCT01049516|Other|Minimal Contact Control|
3221027|NCT01049516|Experimental|PE-Massed|
3221028|NCT01049516|Active Comparator|PE-Spaced|
3221029|NCT01049516|Active Comparator|Present-Centered Therapy (PCT)|
3221030|NCT01049503|Active Comparator|Caries-active 550 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
3221031|NCT01049503|Active Comparator|Caries-active 550 ppm F, pH 4.5|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
3221032|NCT01049503|Active Comparator|Caries-active 1100 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
3221033|NCT01049503|Active Comparator|Caries-inactive 550 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
3221034|NCT01049503|Active Comparator|Caries-inactive 550 ppm F, pH 4.5|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
3221035|NCT01049503|Active Comparator|Caries-inactive 1100 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
3221036|NCT01049490|Active Comparator|Intramuscular|15 mcg H1N1 vaccine delivered via intramuscular injection (control)
3221037|NCT01049490|Active Comparator|Intradermal|Intradermal: H1N1 vaccine delivered via intradermal injection: Experimental
3221038|NCT01049477|Experimental|Music therapy|Experimental arm includes women undergoing cesarean section delivery listening to music before and after c/s. STAI will be completed pre and post operatively.
3221039|NCT01049477|No Intervention|No music group|Subjects will not listen to music before and after c/s. STAI will be completed pre and post operatively.
3221040|NCT01049464|Placebo Comparator|5%D/W|The patients in this group will receive 5%D/W 20 ml intravenous in 10 min and then 5%D/W 100 ml infusion in 6 hours as the placebo drug.
3221041|NCT01049464|Experimental|Magnesium sulphate|The patients in this group will receive 2g of Magnesium sulphate diluted with 5%D/W into 20 ml solution, infusion intravenously in 10 min then 6g of Magnesium sulphate diluted with 5%D/W into 100 ml solution, infusion intravenously in 6 hours
3221042|NCT01049451|Experimental|ACTH IM monthly|Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
3221043|NCT01049451|Active Comparator|MP IV monthly|Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months.
3221044|NCT01049438|Experimental|Nasal, body, and systemic decolonization|
3221045|NCT01049425|Active Comparator|Epirubicin and Cyclophosphamid followed by Docetaxel|4 cycles of EC on day one every three weeks followed by 4 cycles of Docetaxel on day one every three weeks
3221046|NCT01049425|Experimental|Combination of Docetaxel and Cyclophosphamid|intravenous infusion on day one every three weeks
3221047|NCT01049412|Experimental|LY2605541 First, Then Insulin Glargine|Participants received LY2605541 for 8 weeks, followed by insulin glargine for 8 weeks.
3221048|NCT01049412|Active Comparator|Insulin Glargine First, Then LY2605541|Participants received insulin glargine for 8 weeks, followed by LY2605541 for 8 weeks.
3221049|NCT01049399|Placebo Comparator|Placebo|once daily administration of powder for oral suspension.
3221050|NCT01049399|Experimental|NP031112 800 mg|Group dosed with 800 mg once daily for 52 weeks
3221051|NCT01049399|Experimental|NP031112 600 mg|Group treated with 600 mg once daily for 52 weeks
3221052|NCT01049386|Active Comparator|Sugar absorption test|In 150 mL of water four different sugars will be dissolved. Absorption will be calculated based on concentrations of sugars in 0-5 hours urine and 0-24 h collected urine.
3221053|NCT01049386|Experimental|Sugar absorption test and high-fat breakfast|In 150 mL of water four different sugars will be dissolved. Absorption will be calculated based on concentrations of sugars in 0-5 hours urine and 0-24 h collected urine. Subjects will eat a high-fat breakfast together with the sugar drink, to investigate the disturbance caused by fat in intestinal absorption.
3221054|NCT01049373|Experimental|Lymphdiaral Basistropfen (HDC)|HDC (Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X), each 10 drops t.i.d. for 15 weeks.
3221055|NCT01049373|Placebo Comparator|Placebo Solution|10 drops t.i.d. for 15 weeks
3221056|NCT01049360|Experimental|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID)
3221057|NCT01049360|Experimental|Aclidinium 400 μg / formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID)
3221058|NCT01049360|Experimental|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID)
3221059|NCT01049360|Active Comparator|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily
3221060|NCT01049360|Placebo Comparator|Placebo|Placebo twice-daily
3221061|NCT01049347|Active Comparator|amitriptyline|
3221062|NCT01049347|Active Comparator|paroxetine|
3221063|NCT01049334|Experimental|flurbiprofen 8.75 mg lozenge|Participants sucked flurbiprofen 8.75mg lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
3221064|NCT01049334|Placebo Comparator|Placebo lozenge|Participants sucked vehicle placebo lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
3221065|NCT01049321|Experimental|DASH diet|DASH: Dietary approaches to stop hypertension eating plan
3221066|NCT01049321|Placebo Comparator|Diabetic diet|Diabetic diet: a usual diabetic diet
3221067|NCT01049308||Heart Failure|veteran population with documented heart failure
3221068|NCT01049295|Experimental|oil fish pearls|patients with invasive breast cancer who received 640 mg oil fish pearls 3 times a day
3221069|NCT01049295|Placebo Comparator|placebo|patient with invasive breast cancer who received corn oil pearls as placebo 3 times a day
3221070|NCT01049282|Experimental|12 TST negative volunteers antigen only|
3221071|NCT01049282|Experimental|12 TST negative volunteers|
3221072|NCT01049282|Experimental|12 BCG vaccinated volunteers|
3221073|NCT01049282|Experimental|12 with Latent TB infection >= 2 years ago|
3221074|NCT01049269||1:one group|
3221075|NCT01049243|Other|Fluocinonide Cream 0.1%|Fluocinonide Cream 0.1% open label
3221076|NCT01049230|Experimental|Proton beam radiation|Radiation therapy with proton beam
3221077|NCT01049217|Experimental|Active drug|
3221078|NCT01049217|Placebo Comparator|Control|
3221079|NCT01049204|Active Comparator|Group 1|Nadir CD4 count >200 cells/µl blood and randomised to Maraviroc 150mg BD
3221080|NCT01049204|Placebo Comparator|Group 2|Nadir CD4 count >200 cells/µl blood and randomised to placebo twice daily for 24 weeks
3221081|NCT01049204|Active Comparator|Group 3|Nadir CD4 count ≤200 cells/µl blood and randomised to Maraviroc 150mg BD
3221082|NCT01049204|Placebo Comparator|Group 4|Nadir CD4 count ≤200 cells/µl blood and randomised to placebo twice daily for 24 weeks
3221083|NCT01049191||Fracture|Subjects experiencing a prior osteoporotic fracture.
3221084|NCT01049191||Control|These will be age and bone density matched controls to the fracture group.
3221085|NCT01049178|Experimental|Oral silymarin dose|Dose escalation study
3221086|NCT01049178|Placebo Comparator|placebo|A randomized, double-masked, placebo-controlled cross-over clinical pilot investigation of an inducer of endogenous antioxidant enzymes, silymarin, in humans with atopic asthma.
3221087|NCT01049165|Active Comparator|Arm 1 (BMS-813160 or placebo)|
3221088|NCT01049165|Active Comparator|Arm 2 (BMS-813160 or placebo)|
3221089|NCT01049165|Active Comparator|Arm 3 (BMS-813160 or placebo)|
3221090|NCT01049165|Active Comparator|Arm 4 (BMS-813160 or placebo)|
3221091|NCT01049165|Active Comparator|Arm 5 (BMS-813160 or placebo)|
3221092|NCT01049165|Active Comparator|Arm 6 (BMS-813160 or placebo)|
3221093|NCT01049165|Active Comparator|Arm 7 [14C] BMS-813160|
3221094|NCT01049165|Active Comparator|Arm 8 (BMS-813160 or placebo)|
3221095|NCT01049165|Active Comparator|Arm 9 (BMS-813160 or placebo)|
3221096|NCT01049152||nondiabetic patients|nondiabetic patients with ESRD undergone hemodialysis
3221097|NCT01049152||diabetic patients|diabetic patients with ESRD undergone hemodialysis
3221098|NCT01049139|No Intervention|No Supplemental Information|Participants will be administered a standard HIV vaccine trial consent form but no additional information.
3221099|NCT01049139|Experimental|Supplemental information with 1-sided message|Participants will be administered a standard HIV vaccine trial consent form and supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
3221100|NCT01049139|Experimental|Supplemental information with 2-sided messages|Participants will be administered a standard HIV vaccine trial consent form and supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
3221101|NCT01049126||Late stage endometrial cancer|
3221102|NCT01049113|Experimental|ON 013105|ON 013105 administered intravenously as 2-hour infusion once a week for 3 weeks of 3-week cycles. This is dose escalation study; starting dose is 17 mg.
3221103|NCT01049100|Experimental|operative staging (A)|operative staging and systemic lymphadenectomy, paraaortal and pelvine, laparoscopic or open
3221104|NCT01049100|No Intervention|Standard (B)|No surgical intervention. Clinical Staging (FIGO) CT Abdomen / pelvic enlarged or suspicious lymphnodes--> CT controlled biopsy and histological analysis.
3221105|NCT01049074|Experimental|Verus acupuncture|
3221106|NCT01049074|Sham Comparator|Sham acupuncture|
3221107|NCT01049061|Experimental|MORAb-003|
3221108|NCT01049048|Placebo Comparator|Control|This group receives placebo chocolate cookies with no vitamin D3 added.
3221945|NCT01043276|Experimental|Treatment D|
3221109|NCT01049048|Experimental|Vitamin D3|This group receives 2500 IU of Vitamin D3 added to a chocolate cookie daily.
3221110|NCT01049035|Experimental|TetraMen-T Group 1|Participants will receive TetraMen-T vaccine at 2, 4, 6, and 12 Months
3221111|NCT01049035|Experimental|TetraMen-T Group 2|Participants will receive TetraMen-T vaccine at 2, 4, 6, and 15 Months.
3221112|NCT01049035|Experimental|TetraMen-T Group 3|Participants will receive TetraMen-T vaccine at 2, 4, and 12 Months
3221113|NCT01049035|Experimental|TetraMen-T Group 4|Participants will receive TetraMen-T vaccine at 6 and 12 Months
3221114|NCT01049035|Experimental|TetraMen-T Group 5|Participants will receive TetraMen-T vaccine at 12 Months
3221115|NCT01049035|Other|Study Group 6|Participants will not receive TetraMen-T vaccine; Only routine vaccines at 2, 4, 6, and 12 Months
3221116|NCT01049035|Other|Study Group 7|Participants will not receive TetraMen-T vaccine; Only routine Vaccines at 2, 4, 6, and 15 Months.
3221117|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 1|
3221118|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 2|
3221119|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 3|
3221120|NCT01049009|Active Comparator|Nebivolol followed by Metoprolol XL|Subjects are randomized to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after cross over.
3221121|NCT01049009|Active Comparator|Metoprolol XL followed by Nebivolol|Subjects are randomized to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after cross over.
3221122|NCT01048996||Non ALI/ARDS|Those patient who enrolled in the study but did not develop ALI or ARDS during their hospital course.
3221123|NCT01048996||ALI/ARDS|Those patients who enrolled in the study and developed ALI or ARDS during their hospital course.
3221124|NCT01048983|Other|Questionnaires and Phone Calls|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
3221125|NCT01048983|Active Comparator|Curcumin Only|
3221126|NCT01048983|Active Comparator|Armodafinil Only|
3221127|NCT01048983|Active Comparator|Minocycline Only|
3221128|NCT01048983|Active Comparator|Bupropion Only|
3221129|NCT01048983|Active Comparator|Curcumin + Armodafinil|
3221130|NCT01048983|Active Comparator|Curcumin + Minocycline|
3221131|NCT01048983|Active Comparator|Curcumin + Bupropion|
3221132|NCT01048983|Active Comparator|Armodafinil + Minocycline|
3221133|NCT01048983|Active Comparator|Armodafinil + Bupropion|
3221134|NCT01048983|Active Comparator|Minocycline + Buproprion|
3221135|NCT01048983|Active Comparator|Curcumin + Armodafinil + Minocycline|
3221136|NCT01048983|Active Comparator|Curcumin + Armodafinil + Bupropion|
3221137|NCT01048983|Active Comparator|Curcumin + Minocycline + Bupropion|
3221138|NCT01048983|Active Comparator|Armodafinil + Minocycline + Bupropion|
3221139|NCT01048983|Active Comparator|Curcumin + Armodafinil + Minocycline + Bupropion|
3221140|NCT01048970|Other|Control arm|Patients will receive nutritional assessment one week prior to treatment until completing two cycles
3221141|NCT01048970|Experimental|EPA-DHA arm|Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
3221142|NCT01048944|Active Comparator|Bupropion SR|150 mg bid bupropion SR
3221143|NCT01048944|Active Comparator|Nicotine Patch|21mg, 14mg, 7mg
3221144|NCT01048944|Placebo Comparator|Placebo Patch and Placebo Pill|Individuals were placed on both a placebo patch that were the same size as active patches given to the Nicotine Patch group and were also given placebo pills were the same size and identically packaged as the active pills (bupropion) given to the Bupropion SR group.
3221145|NCT01048944|No Intervention|Delayed-quit control|Smoke for 67 days while others have quit, then quit.
3221146|NCT01048931|Experimental|single-port LAVH|single port LAVH
3221147|NCT01048918||No Treatment|
3221148|NCT01048905|Experimental|Pharmacokinetics|8 hour pharmacokinetics after glutamine supplementation
3221149|NCT01048905|Experimental|Treatment|Patients will receive an 8-week course of oral L-glutamine 10 grams TID
3221150|NCT01048892|Experimental|Treatment (NTX-010)|
3221151|NCT01048879|Other|ECMO alone|Patients receiving oseltamivir and Extracorporeal Membrane Oxygenation (ECMO) therapy (patients were already receiving oseltamivir and ECMO due to an illness)- Procedure/Surgery: pharmacokinetic blood sampling
3221152|NCT01048879|Other|CVVHD Alone|"Patients receiving Continuous Venovenous Hemodialysis(CVVHD) and oseltamivir (Patients were already receiving oseltamivir and CVVHD as a result of an illness).~Procedure/Surgery: pharmacokinetic blood and dialysate sampling"
3221153|NCT01048879|Other|CVVHD + ECMO|"Patient receiving oseltamivir and ECMO and CVVHD (patients were already receiving oseltamivir, ECMO, and CVVHD as part of an illness).~Procedure/Surgery: pharmacokinetic blood and dialysate sampling"
3221154|NCT01048866|Experimental|flurbiprofen 8.75 mg lozenge|Participants were instructed to suck one study (flurbiprofen 8.75 mg) lozenge and efficacy assessments were taken in the clinic. Upon discharge, participants were instructed to use another study medication lozenge every 3-6 hours, up to a total of 5 study lozenges in 24 hours. Following efficacy assessments, participants were again instructed to use study medication lozenge every 3-6 hours, up to a total of 5 study lozenges per day (plus rescue medication if needed) for the remaining time in the 7 day study.
3221155|NCT01048866|Placebo Comparator|placebo lozenge|Participants were instructed to suck one study (placebo) lozenge and efficacy assessments were taken in the clinic. Upon discharge, participants were instructed to use another lozenge every 3-6 hours, up to a total of 5 study lozenges in 24 hours. Following efficacy assessments, participants were again instructed to use a lozenge every 3-6 hours, up to a total of 5 study lozenges per day (plus rescue medication if needed) for the remaining time in the 7 day study.
3221156|NCT01048853|Experimental|Conservative Surgery|Removal of the pelvic lymph nodes (pelvic lymphadenectomy)
3221195|NCT01048541|Active Comparator|SpeediCath catheter|Standard treatment
3221196|NCT01048541|Experimental|Test product|
3221946|NCT01043276|Experimental|Treatment E|
3221157|NCT01048840||Subject with History of GERD|Children and adolescents ages 12-17 years, inclusive, seen at Children's Hospital, Boston or Massachusetts General Hospital between 1977 and 1990 for symptoms of GERD and also had biopsies and / or a pH probe that was positive for GERD.
3221158|NCT01048840||Controls with out GERD|Individuals that do not have a history of GERD or other GI problems prior to age 21 and whose date of birth are with in a year of a subjects
3221159|NCT01048827|Experimental|experimental|dose-escalation Busulfan
3221160|NCT01048814||Ovarian, Peritoneal, Fallopian Cancer|Recurrent, Peristent or Refractory
3221161|NCT01048801|Active Comparator|Rapid diagnostic test and treatment|
3221162|NCT01048801|Other|Treatment without rapid daignostic test|
3221163|NCT01048788|Experimental|OPC|
3221164|NCT01048762|Active Comparator|supervised exercise training|Intervention: supervised exercise training and dyspnea counseling in groups for 10 weeks Instruction on home based exercise training
3221165|NCT01048762|Sham Comparator|one instruction on homebased exercises|One instruction on home based exercise training and dyspnea management
3221166|NCT01048749|Active Comparator|aquatic vertical supsension|Spinal height measurement using a stadiometer following aquatic vertical suspension
3221167|NCT01048749|Active Comparator|land-based supine flexion condition|Spine height will be measured with a stadiometer following completion of the supine land-based flexion position.
3221168|NCT01048736|Active Comparator|Exercise|All treatment groups will receive 4d/wk of exercise
3221169|NCT01048736|Experimental|Exercise + Diet (-250 kcal/d deficit)|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; ~4.5 kg weight loss),
3221170|NCT01048736|Experimental|Exercise + Diet (-600 kcal/d deficit)|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; ~10.9 kg weight loss)
3221171|NCT01048723|Experimental|RAD001 Administration|RAD001 was administered orally as once daily dose of 10 mg PO daily x 2 weeks (14 X 10 mg tablets) continuously from study day 1 until the end of therapy (2 weeks later) or unacceptable toxicity.
3221172|NCT01048710||Tomofix_small|Surgical treatment using TomoFix TM Small
3221173|NCT01048710||Conservative treatment|"In the control group, patients who refused to have surgery will be allowed to be treated using different options of conservative treatment. The frequency of applications depends on the hospital and will therefore be documented in the study. An arthroscopy is not obligatory under this treatment group, but is permitted.~The following conservative treatment methods are allowed:~Physical therapy~Specific exercises for the muscles~Injections into the knee joint~Brace~Medication~No therapy"
3221174|NCT01048697|Experimental|Ethambutol|"All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):~40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) > 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)"
3221175|NCT01048684|Active Comparator|20% Mannitol 0.7 g/kg (low-dose)|Study subjects will be randomized to receive an infusion of 20% mannitol 0.7g/kg over 30 minutes after induction of general anesthesia.
3221176|NCT01048684|Experimental|20% Mannitol 1.4 g/kg (high dose)|Study subjects will be randomized to receive an infusion of 20% mannitol 1.4 g/kg over 30 minutes after induction of general anesthesia.
3221177|NCT01048671||Antiretroviral combination therapy including raltegravir|Participants received ARV combination treatment including raltegravir. Treatment of participants was at the discretion of the investigator who provided standard care in a real life setting.
3221178|NCT01048658|Active Comparator|Sevoflurane|Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
3221179|NCT01048658|Placebo Comparator|No Sevoflurane|Subject receives standard of care drug regimens for anesthesia with this procedure.
3221180|NCT01048645|Placebo Comparator|P/PC arm|Patients were assigned to receive placebo (P/PC) 1 week prior to treatment until completing two cycles
3221181|NCT01048645|Experimental|RA/PC arm|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two cycles
3221182|NCT01048632|Experimental|Oxandrolone|Following clinical evaluation, all patients will be receive oxandrolone in addition to their usual medications. Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
3221183|NCT01048619|Experimental|ON 01910.Na|The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
3221184|NCT01048606|Active Comparator|Placeco + exercise|Placebo (no phytoestrogen): Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day) Exercise (three 1h-sessions/week)
3221185|NCT01048606|Active Comparator|Phytoestrogens without exercise|Phytoestrogens (70mg/day of soy isoflavone) Without exercise (no structured exercise session)
3221186|NCT01048606|Experimental|Phytoestrogens + exercise|Phytoestrogens (70 mg/day soy isoflavone) Exercise (1h-sessions 3 times/week)
3221187|NCT01048606|No Intervention|Placebo without exercise|Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day) No exercise
3221188|NCT01048593|Experimental|Dose 1|114ug
3221189|NCT01048593|Experimental|Dose 2|513ug
3221190|NCT01048593|Experimental|Dose 3|684ug
3221191|NCT01048580|Experimental|Perifosine +Capecitabine|One cycle of therapy will be defined as 3 weeks (21 days). Perifosine 50 mg qd (Days 1-21) + Capecitabine 1000 mg/m2 BID (Days 1-14).
3221192|NCT01048567|Active Comparator|Lactobacillus acidophilus/rhamnosus|
3221193|NCT01048567|Placebo Comparator|Placebo|
3221194|NCT01048554|Other|Temozolomide/Bevacizumab|Patients will be treated with a combination of temozolomide at 75 mg/m2/day for six continuous weeks, followed by a two-week rest period and bevacizumab 10 mg/kg every 2 weeks without interruption. Cycles will be repeated every 8 weeks. Patients will be restaged every 8 weeks.
3221197|NCT01048528|Experimental|Stress Management|Stress Management and Relaxation Training workshops
3221198|NCT01048528|No Intervention|Wait-list|Wait-list comparison group
3221199|NCT01048515|Experimental|Caffeine|
3221200|NCT01048515|Placebo Comparator|Placebo|
3221201|NCT01048502|Experimental|Fenofibrate (Tricor) (145 mg/day)|Participants will be given 1 fenofibrate (Tricor) 145mg and 4 fish oil placebos - supplies of study drug will be provided to last 8 weeks.
3221202|NCT01048502|Placebo Comparator|Placebo|Participants will be given 5 placebo pills (4 fish oil placebo and 1 fenofibrate placebo) - supplies of study drug will be provided to last 8 weeks.
3221203|NCT01048502|Experimental|Lovaza (900 mg/day)|Participants will be given 1 Lovaza capsule, 3 Fish oil placebo capsules, and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
3221204|NCT01048502|Experimental|Lovaza (3,600 mg/day)|Participants will be given 4 Lovaza capsules and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
3221205|NCT01048489|Other|Lifestyle counseling|
3221206|NCT01048489|No Intervention|No counseling|
3221207|NCT01048476|Active Comparator|Group L20|Dietary Supplement: 20mg Lutein; daily supplementation one year
3221208|NCT01048476|Active Comparator|Group L10|Dietary Supplement: 10mg Lutein; daily supplementation one year
3221209|NCT01048476|Placebo Comparator|Group Placebo|Dietary Supplement: Placebo, 0 mg Lutein
3221210|NCT01048476|Active Comparator|Active Comparator: Group LZ|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
3221211|NCT01048463|Placebo Comparator|EN|The subjects take in 150g of Nutriall per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d. During the test period patients are treated with the first course of XELOX.
3221212|NCT01048463|Experimental|ENLDEPA|The subjects take in the same dose of Nutriall for the same duration as those in EN group. In addition, they take in 3 grams of EPA per day during the 21 days of treatment. The patients are treated with the first course of XELOX.
3221213|NCT01048463|Experimental|ENHDPEA|The subjects take in the same dose of supportan for the same duration as those in EN group. In addition, they take in 6 grams of EPA per day during the 21 days of treatment. The patients are treated with the first course of XELOX.
3221214|NCT01048450|Experimental|Treatment|Those who were diagnosed with hallux limitus/rigidus (end stage degeneration at the 1st metatarsal phalangeal joint)
3221215|NCT01048437|No Intervention|Standard transplant education|Missouri Kidney Program's standard Patient Education Program (PEP) transplant module.
3221216|NCT01048437|Experimental|Transplant education with video|Explore Transplant transplant module featuring video
3221217|NCT01048437|Experimental|Transplant education with speakers|Explore Transplant transplant module featuring live guest speakers.
3221218|NCT01048424|Experimental|Paced respiration|Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a Urinary Incontinence pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.
3221219|NCT01048424|Placebo Comparator|Control|Participants will be given a Urinary Incontinence pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.
3221220|NCT01048411|Active Comparator|Naja-comp.|s.c. injection of naja comp (homeopathic remedy) three times a week
3221221|NCT01048411|Placebo Comparator|Placebo|s.c. injection of placebo (NaCl-solution) three times a week
3221222|NCT01048398|Experimental|Remifentanil|
3221223|NCT01048398|Active Comparator|Paracetamol|intravenous paracetamol 1g
3221224|NCT01048385|Experimental|CoQ10|This group will be treated concomitantly with Coenzyme Q10
3221225|NCT01048385|Placebo Comparator|Control|Treated with capsules containing the vehicle.
3221226|NCT01048372||Early HIV infection|HIV infected adults with early evidence of suppressed cell-mediated immunity but whose disease has not progressed far enough to indicate antiretroviral therapy.
3221227|NCT01048372||Control|Healthy adults without HIV infection.
3221228|NCT01048359|Experimental|Brief Intervention|30-45 minute motivational interviewing based intervention with feedback addressing drug use, injury prevention and HIV risk.
3221229|NCT01048359|Active Comparator|Brief advice|This condition of the experiment acts a control and will be a short session in which the therapist will provide brief advice about drug use and give the patient a pamphlet.
3221230|NCT01048359|Experimental|Brief Intervention plus Booster|30-45 minute motivational interviewing based intervention with feedback addressing drug use, injury prevention and HIV risk plus a brief phone booster session at 1 month post-intake to review feedback, 2) assess progress, 2) renew motivation to change, and 3) evaluate and affirm commitment to change.
3221231|NCT01048346|Experimental|supported employment|Study consists of one experimental group and one control group. The intervention group received IPS
3221232|NCT01048333|Experimental|Formoterol, then Salmeterol, then Placebo|Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Placebo Diskus and Placebo Turbuhaler
3221233|NCT01048333|Experimental|Salmeterol, then Palcebo, then Formoterol|Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Placebo Diskus and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus
3221234|NCT01048333|Experimental|Placebo, then Formoterol, then Salmeterol|Placebo Diskus and Placebo Turbuhaler first,then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
3221235|NCT01048333|Experimental|Formoterol, then Placebo, then Salmeterol|Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Placebo Diskus and Placebo Turbuhaler, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
3221236|NCT01048333|Experimental|Salmeterol, then Formoterol, then Placebo|Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Placebo Diskus and Placebo Turbuhaler
3221237|NCT01048333|Experimental|Placebo, then Salmeterol, then Formoterol|Placebo Diskus and Placebo Turbuhaler first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus
3221238|NCT01048320|Other|Treatment|Gemcitabine plus Oxaliplatin in combination with imatinib mesylate
3221884|NCT01043679|Active Comparator|Utapine|Efficacy and Safety of Utapine
3221239|NCT01048307|Experimental|Prontosan wound irrigation solution|"Prontosan® Wound Irrigation Solution (experimental group):~cleansing the wound bed at dressing change with Prontosan® Wound Irrigation Solution; a sterile gauze dressing impregnated with the Prontosan® solution will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~placing the primary dressing (Profore® WCL): the dressing will be impregnated with Prontosan® Wound Irrigation Solution;~fixing the dressing to the wound using multilayered elastic compression bandaging (Profore®bandaging system)."
3221240|NCT01048307|Placebo Comparator|Saline irrigation (standard care control)|"Saline (control group):~cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system)."
3221241|NCT01048294|Active Comparator|Standard Light Treatment|30 min of Standard bright light treatment (color 5000K)
3221242|NCT01048294|Experimental|Blue enriched Light treatment 20 min|20 minutes of Blue enriched light treatment (color 17000K)
3221243|NCT01048294|Experimental|Blue enriched light treatment 30 min|30 minutes of Blue enriched light treatment (color 17000K)
3221244|NCT01048268|Experimental|Healthy volunteers|
3221245|NCT01048268|Experimental|Patients with Type 1 diabetes mellitus|
3221246|NCT01048268|Experimental|Patients with type 2 diabetes mellitus|
3221247|NCT01048255|Experimental|VX-765|
3221248|NCT01048242|Experimental|Ramelteon|Ramelteon 8 mg oral before bedtime
3221249|NCT01048242|Placebo Comparator|sugar pill|
3221250|NCT01048229|Experimental|Rasagiline|
3221251|NCT01048229|Active Comparator|Pramipexole|pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
3221252|NCT01048203|Experimental|ABR-215050|
3221253|NCT01048190|Experimental|Infants I-1|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains). Group I-1: 15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
3221254|NCT01048190|Experimental|Infants I-2|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
3221255|NCT01048190|Experimental|Infant I-3|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
3221256|NCT01048177|Experimental|Treatment|
3221257|NCT01048164|Active Comparator|10 Massages|This group consists of individuals that wear lead aprons, and they will receive ten, 30-minute scheduled massage appointments during the hours the participant is working in the cardiac lab, over a 10 week period.
3221258|NCT01048164|Active Comparator|5 Massages|This group consists of individuals that wear lead aprons, and they will receive five, 30-minute scheduled massage appointments, during the hours the participant is working in the cardiac lab, over a 5 week period. This arm will not receive massages for the first 5 weeks and then will receive their massages during the second 5 week period.
3221259|NCT01048164|No Intervention|Control Group|This group will consist of those individuals that wear lead aprons with no desire to participate in the massage study yet are willing to provide information through questionnaires. They will be given the same questionnaire as those in the two massage therapy arms of the study, at the beginning, middle, and end of study.
3221260|NCT01048151|Experimental|Single|TNFerade™ Biologic + Radiation
3221261|NCT01048138|Experimental|Biperiden Lactate|5mg IV(in the vein)every 6 hours for 10 days
3221262|NCT01048138|Placebo Comparator|Placebo|5mg IV(in the vein)every 6 hours for 10 days
3221263|NCT01048125|Experimental|Study group|Subjects with documented stress cardiomyopathy who would serve as the study group. Sympathetic Nerve Activity; Mental StrCold Pressor Testess Test (Color Word Test); The Modified Oxford Technique for Baroreflex Sensitivity; Cold Pressor Test; Echocardiographic evaluation
3221264|NCT01048125|Active Comparator|Control|Control subjects will be age and sex matched otherwise healthy people with no prior cardiac disease or other severe medical conditions. Sympathetic Nerve Activity; Mental Stress Test (Color Word Test); The Modified Oxford Technique for Baroreflex Sensitivity; Cold Pressor Test; Echocardiographic evaluation
3221265|NCT01048112|Experimental|Repeated dose group|Will receive one dose of Campylobacter jejuni strain CG8421 at day 0 and a second dose at approximately day 98.
3221266|NCT01048112|Active Comparator|Single dose group|Will receive one dose of Campylobacter jejuni strain CG8421
3221267|NCT01048099|Experimental|PRO Onc Assay and Treatment|Blood specimens tested for circulating tumor cells followed by systemic treatment based on assay results with either trastuzumab or pertuzumab
3221268|NCT01048086|Experimental|Retinoic Acid|
3221269|NCT01048086|Placebo Comparator|Placebo|
3221270|NCT01048047|Experimental|aliskiren/amlodipine|aliskiren, 300 mg/amlodipine 10 mg
3221271|NCT01048047|Active Comparator|amlodipine|amlodipine 10 mg
3221272|NCT01048034|Experimental|Azacitidine +/- erythropoetin|
3221273|NCT01048021||Supraclavicular Block|
3221274|NCT01048008|Experimental|4-DM-CHOC-PEN|"DM-CHOC-PEN is an intervention and will be dosed @ 39 mg/M2,escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
3221275|NCT01047995|Active Comparator|Group 1|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
3221276|NCT01047995|Active Comparator|Group 2|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2,~Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
3221277|NCT01047982|Active Comparator|myo-inositol|
3221278|NCT01047982|Placebo Comparator|placebo|acid folic 400 mcg twice per day
3221279|NCT01047956|Experimental|MethNAC|Methadone and N-acetylcysteine for opioids abstaining
3221280|NCT01047956|Active Comparator|Methadone|Methadone alone
3221281|NCT01047943|Experimental|Psoriasis therapy|
3221282|NCT01047930|Other|AM-Ex; PM-Ex; C|within subject design, with each participant receiving all three conditions
3221283|NCT01047917|Experimental|Meditation DVD|All participants will receive a Meditation DVD to practice at home daily for a total of 4 weeks.
3221284|NCT01047904|Experimental|Iontophoresis-treated|Healthy volunteers will evaluate reliability and performance of Iontophoresis System in delivery of local anesthesia to the TM.
3221285|NCT01047891|Experimental|Experimental|
3221286|NCT01047865||pancreas-kidney transplant|pancreas-kidney transplant recipients with type 1 diabetes.
3221287|NCT01047852|Experimental|NIV|
3221288|NCT01047852|No Intervention|Control|
3221289|NCT01047839|Experimental|>=2 months to <3 years|IC51 0.25 ml, 2 i.m. vaccinations at Day 0 and 28
3221290|NCT01047839|Experimental|>=3 to <12 years|IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28
3221291|NCT01047839|Experimental|>=12 to <18 years|IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28
3221292|NCT01047826|Experimental|M.I.P.O. Group|subjects who have been randomized to the M.I.P.O. group
3221293|NCT01047826|Experimental|Intramedullary Nail group|Subjects who have been Randomized to the I.M. group
3221294|NCT01047813||Type 2 diabetes|This group contains 25 participants with type 2 diabetes
3221295|NCT01047813||control group|This group contains 25 participants withput type 2 diabetes. The control group is matched with age, education and lifestyle to the diabetes group.
3221296|NCT01047800|Experimental|Counseling group|Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician
3221297|NCT01047800|No Intervention|Control|Usual management in GI specialty clinic
3221298|NCT01047787||CHF Patients|Congestive Heart Failure Patients
3221299|NCT01047774|Experimental|Soy protein|
3221300|NCT01047774|Placebo Comparator|Milk protein|
3221301|NCT01047761|Experimental|exercise|Multimodal exercises that include walking, breathing exercises, dynamic balance, and core strengthening.
3221302|NCT01047748|Active Comparator|intra-fetal injection|Subjects will receive an intra-fetal digoxin injection one day prior to their second-trimester surgical abortion
3221303|NCT01047748|Active Comparator|intra-amniotic injection|Subjects will receive an intra-amniotic digoxin injection one day prior to their second-trimester surgical abortion
3221304|NCT01047735|Experimental|Roux-en-Y Gastric Bypass Surgery|Roux-en-Y Gastric Bypass Surgery
3221305|NCT01047735|Experimental|Laparoscopic Adjustable Gastric Banding|Laparoscopic Adjustable Gastric Banding
3221306|NCT01047735|Experimental|Lifestyle/Behavioral Weight Loss|Lifestyle Weight Loss Intervention
3221307|NCT01047722|Active Comparator|Patient drinks aspirin in Gatorade.|Patient drinks Gatorade containing 325 mg aspirin. Bleeding Volume Test is done one hour later.
3221308|NCT01047722|Placebo Comparator|Gatorade Placebo|Patient ingests Gatorade and one hour later a Bleeding Volume Test is performed
3221309|NCT01047709|Experimental|positional therapy|Avoidance of supine positioning.
3221310|NCT01047709|No Intervention|Control|Position ad lib.
3221311|NCT01047696|No Intervention|Open fire|Households continuing to use an open fire for cooking and heating
3221312|NCT01047696|Experimental|Chimney stove|Households randomized to receive a chimney stove (plancha) for cooking and heating
3221313|NCT01047683|Placebo Comparator|Placebo|
3221314|NCT01047683|Experimental|AMR101 (ethyl icosapentate) - 2 g/day|
3221315|NCT01047683|Experimental|AMR101 (ethyl icosapentate) - 4 g/day|
3221316|NCT01047670|Experimental|1|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
3221317|NCT01047670|Placebo Comparator|2|placebo
3221318|NCT01047657|Experimental|weight loss|
3221319|NCT01047657|No Intervention|Control|
3221320|NCT01047644|Experimental|3-month flushing schedule|3-month port-flushing schedule
3221321|NCT01047631|Experimental|Functional circuit training and lifestyle counseling|
3221322|NCT01047631|Active Comparator|Health education and independent walking|
3221323|NCT01047618||Thromboembolism|
3221324|NCT01047605|Experimental|PP1|Neurapas balance
3221325|NCT01047605|Experimental|PP2|Pascoflair 425 mg
3221326|NCT01047605|Placebo Comparator|PL1|P-Tabletten weiß
3221327|NCT01047592|Active Comparator|sarcosine|
3221328|NCT01047592|Active Comparator|sarcosine+ BE|
3221329|NCT01047592|Placebo Comparator|Placebo|
3221330|NCT01047579|Other|Rivastigmine transdermal|
3221331|NCT01047566|Experimental|Addition of dronedarone|Addition of Dronedarone to existing rate control medication (beta blocker and/or calcium antagonist)
3221332|NCT01047566|Active Comparator|Dose Increase|Dose increase of existing rate control medication (beta blocker or calcium antagonist or digoxin)
3221333|NCT01047553|Experimental|1|Formoterol 9 μg/dose
3221334|NCT01047540|Experimental|Dose regimen 1|
3221335|NCT01047540|Experimental|Dose regimen 2|
3221336|NCT01047540|Experimental|Dose regimen 3|
3221337|NCT01047540|Experimental|Dose regimen 4|
3221338|NCT01047540|Placebo Comparator|Placebo|
3221339|NCT01047527|Active Comparator|8 weeks transdermal nicotine|8 weeks of transdermal nicotine
3221340|NCT01047527|Active Comparator|24 weeks transdermal nicotine|24 weeks of transdermal nicotine
3221341|NCT01047527|Experimental|52 weeks transdermal nicotine|52 weeks of transdermal nicotine
3221342|NCT01047514|Experimental|Online Chronic Disease Self-management|6 week, online, small group online self-management workshop
3221343|NCT01047501|Placebo Comparator|Placebo|
3221344|NCT01047501|Experimental|AMR101 (ethyl icosapentate) - 2 g/day|
3221345|NCT01047501|Experimental|AMR101 (ethyl icosapentate) - 4 g/day|
3221346|NCT01047488|Active Comparator|Imipramine|Imipramine tablets and placebo capsules to pregabalin
3221347|NCT01047488|Active Comparator|Pregabalin|Pregabalin capsules and placebo tablets to imipramine
3221348|NCT01047488|Experimental|Imipramine plus pregabalin|Imipramine tablets and pregabalin capsules
3221349|NCT01047488|Placebo Comparator|Placebo|Placebo tablets to imipramine and placebo capsules to pregabalin
3221885|NCT01043666|Experimental|YM178 group|oral
3221350|NCT01047475|Active Comparator|MB-6+FOLFOX4|MB-6 6 capsules tid be taken with meals plus FOLFOX4, will be given for 16 weeks
3221351|NCT01047475|Placebo Comparator|Placebo+FOLFOX4|Placebo, 6 capsules tid be taken with meals plus FOLFOX4, will be given for 16 weeks
3221352|NCT01047462|Active Comparator|Laparoscopic lavage|
3221353|NCT01047462|Active Comparator|Primary resection|
3221354|NCT01047449|Active Comparator|SVG harvest - conventional, placebo|
3221355|NCT01047449|Experimental|SVG harvest - no-touch, fish oils|
3221356|NCT01047449|Placebo Comparator|SVG harvest - no-touch, placebo|
3221357|NCT01047449|Active Comparator|SVG harvest - conventional, fish oils|
3221358|NCT01047436|Experimental|ArTiMist (artemether sublingual spray)|
3221359|NCT01047436|Active Comparator|Intravenous Quinine|
3221360|NCT01047423|Experimental|Simvastatin|40mg Simvastatin once daily for 12 weeks followed by 4 week washout period followed by placebo for 12 weeks
3221361|NCT01047423|Placebo Comparator|Placebo|Placebo for 12 weeks followed by 4 week washout period followed by 40mg Simvastatin once daily for 12 weeks
3221362|NCT01047410|No Intervention|Usual care|Patients assigned to the usual care group receive the standard medical care (usual care) during the 15 months lasting study period. Physical training does not form a part of the usual care of renal transplant and dialysis patients. After randomisation, patients assigned to the usual care group receive the advice to meet the 'Nederlandse Norm Gezond Bewegen (NNGB), i.e. the advice to perform 30 minutes of moderately intense physical activity at at least five but preferably all days of the week.
3221363|NCT01047410|Experimental|Exercise intervention|The exercise intervention in this group is identical to the exercise-only group. Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
3221364|NCT01047410|Experimental|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
3221365|NCT01047397|Experimental|Group 1|Active Drug
3221366|NCT01047397|Placebo Comparator|Group 2|Placebo
3221367|NCT01047384|Experimental|Experimental|acupuncture-moxibustion therapy
3221368|NCT01047384|Active Comparator|Regular therapy|Regular therapy
3221369|NCT01047371||Patients with Osteoarthrosis|All consecutive patients scheduled for total hip or knee arthroplasty
3221370|NCT01047358||ajuvant group|adjuvant setting after two to three years of tamoxifen
3221371|NCT01047358||palliative group|palliative setting after progression of disease with anti-estrogen therapy
3221372|NCT01047345|Experimental|9vHPV Vaccine|Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.
3221373|NCT01047345|Placebo Comparator|Placebo|Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.
3221374|NCT01047332|Active Comparator|Uncovered Wallstent|Endoscopically-placed biliary self-expanding metal stent (SEMS) (uncovered type).
3221375|NCT01047332|Experimental|Partially Covered Wallstent|Endoscopically-placed biliary self-expanding metal stent (SEMS) (partially covered type).
3221376|NCT01047319|Experimental|Experimental: Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
3221377|NCT01047306||No Treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIA to identify potential surrogate endpoints for future ERT trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral and imaging measures.
3221378|NCT01047293|Experimental|All patients|All participants enrolled.
3221379|NCT01047280|Placebo Comparator|Safflower oil|This arm of the study constitutes the control phase
3221380|NCT01047280|Experimental|Clarinol G-80®|
3221381|NCT01047280|Experimental|G-c9, t11|
3221382|NCT01047254|Active Comparator|Bupropion|Buproprion 150-300 mg in a flexible dose
3221383|NCT01047254|Placebo Comparator|placebo capsule|Placebo
3221384|NCT01047241|Experimental|Intranasal sufentanil/ketamine|Intranasal combination of sufentanil and ketamine. Dose of sufentanil 0.5 mcg/kg and ketamine 0.5 mg/kg, single dose.
3221385|NCT01047215|Active Comparator|Aripipazole|Heart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication
3221386|NCT01047215|Active Comparator|Quetiapine|Heart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication
3221387|NCT01047202|Experimental|Group 1: 7.5 μg pandemic influenza A/H1N1 vaccine|120 subjects to receive two doses of 7.5 μg pandemic influenza A/H1N1 vaccine 21 days apart
3221388|NCT01047202|Experimental|Group 2 : 15 μg pandemic influenza A/H1N1 vaccine|120 subjects to receive two doses of 15 μg pandemic influenza A/H1N1 vaccine 21 days apart
3221389|NCT01047202|Sham Comparator|Group 3 : 7.5 μg seasonal trivalent vaccine|60 subjects to receive two doses of 7.5 μg seasonal trivalent vaccine 21 days apart
3221390|NCT01047189|Experimental|1|Ziana gel (clindamycin phosphate 1.2% and tretinoin 0.025%) applied once daily for 12 weeks
3221391|NCT01047189|Active Comparator|2|Generic clindamycin 1% gel plus tretinoin 0.025% cream
3221392|NCT01047176||1|Male or female > 18 year of age with indication to PCI
3221393|NCT01047163||Statin|Men aged 65-75yr on Simvastatin therapy presenting with muscle soreness
3221394|NCT01047163||Control|Men, aged 65-75yr not on Statin therapy
3221395|NCT01047150||Tetrofosmin Rest patients|Patients that had a Rest myocardial perfusion study using Tc99m tetrofosmin
3221396|NCT01047150||Sestamibi stress patients|Patients that had a stress myocardial perfusion imaging study using Tc99m Sestamibi
3221397|NCT01047150||Tetrofosmin stress patients|Patients that had a stress myocardial perfusion imaging study using Tc99m Tetrofosmin
3221398|NCT01047150||Sestamibi rest patients|Patients that had a rest myocardial perfusion imaging study using Tc99m Sestamibi
3221399|NCT01047137|Placebo Comparator|Control|Participants will meet with a psychiatry resident once a week for six consecutive weeks for general supportive therapy, which will not provide psychological stress intervention.
3221400|NCT01047137|Experimental|Intervention|Participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques.
3221401|NCT01047124|Experimental|Intervention|Specialist mood disorders team: treatment plan according to need
3221402|NCT01047124|No Intervention|Treatment as usual|
3221403|NCT01047111|Active Comparator|Ivor-Lewis Procedure|Arm A: Esophagectomy was conducted through right side thoracotomy plus midline laparotomy approach:Ivor-Lewis Procedure.
3221404|NCT01047111|Active Comparator|Sweet Procedure|Arm B: Esophagectomy was conducted through left side thoracotomy or thoracoabdominal incision: Sweet Procedure
3221405|NCT01047098|Experimental|Iron with meals|Prenatal vitamin without iron plus capsule containing 27 mg of iron taken with meals
3221406|NCT01047098|Experimental|Iron between meals|Prenatal vitamin without iron plus capsule containing 27 mg of iron taken between meals
3221407|NCT01047098|Placebo Comparator|Placebo|Prenatal vitamin without iron plus capsule containing calcium carbonate (placebo) taken between meals
3221408|NCT01047085|Active Comparator|Control group|Control group: Impedance pH measurements of healthy controls are performed to compare the results with the study group.
3221409|NCT01047085|Experimental|Study group|Study group: Pre-operative and post-operative impedance pH measurements are performed to patients in which elective cholecystectomy is planned.
3221410|NCT01047072|Experimental|Arm I (transplant)|Patients receive fludarabine IV on days -4 to -2. Patients undergo total-body irradiation on day 0. Patients then undergo peripheral blood stem cell transplantation on day 0. Patients receive GVHD prophylaxis comprising tacrolimus PO twice daily on days -3 to 180 and taper and mycophenolate mofetil PO three times daily on days 0-28 and then twice daily until day 180 and taper.
3221411|NCT01047072|Active Comparator|Arm II (nontransplant)|Patients receive mycophenolate mofetil PO twice daily for 16 months, rituximab IV on days 1 and 15 and then repeated at 6 months, and cyclophosphamide IV at 28-32 day intervals or orally once daily for 16 months.
3221412|NCT01047059|Experimental|Trial Intervention|150mg Erlotinib daily, 15mg/kg b.w. Bevacizumab on d1, d22, d43 as medication FDG-PET, FLT-PET and DCE-MRI as diagnostical tools
3221413|NCT01047046||SNM device placement|Patients who have undergone a placement of a SNM device to treat refractory OAB. A retrospective chart review will be performed on all patients who underwent a one or two-stage placement of an SNM device, which includes an implantable pulse generator (IPG), for refractory urge incontinence and urgency frequency symptoms. The patients will be those of Dr. Karen Noblett, having their device placed after 2001.
3221414|NCT01047033|Active Comparator|Microcredit only|
3221415|NCT01047033|Experimental|Microcredit plus health education|Thirty minutes of a health education module administered to clients by loan officer at their monthly group meetings over the course of 8 months.
3221416|NCT01047020||ALL survivors|The study sample for this research will be recruited from participants in an institutionally funded cohort study, St. Jude Life, as well as from active ACT patients that meet eligibility criteria. The young adults in St. Jude Life are a highly motivated group who were followed in the After Completion of Therapy Clinic until age 18 years and a minimum of 10 years after their treatment ended if they were older than age 11 at the end of therapy
3221417|NCT01047020||Comparison Group|Potentially eligible comparison group participants will be recruited from the parent, older sibling, relative or friend population who accompany the ACT patient for follow-up at SJCRH. Parents (or siblings, relatives or friends who are 18 years or older) of children in remission, both from the active follow-up cohort (within five years of last treatment) and the After Completion of Therapy (ACT) cohort will be invited to complete the same assessments that the ALL survivor participants will complete. Comparison group participants are frequency matched to potentially eligible participants by race/ethnicity (white, black, other) age group (18 to 29, 30-39, 40-49 years) and gender.
3221418|NCT01047007|Experimental|Part 1:MK-1775 65 mg BID|Participants received 65 mg of MK-1775 administered orally twice a day (BID) on Days 1-5 of a 21-day cycle.
3221419|NCT01047007|Experimental|Part 2 A1:MK-1775 20 mg BID+5-FU 1000 mg|Participants received 20 mg of MK-1775 administered orally BID on Days 1-5 of a 21-day cycle and 1000 mg/m^2/day of 5-FU administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle.
3221420|NCT01047007|Experimental|Part 2 A2:MK-1775 20 mg QD+5-FU 1000 mg|Participants received 20 mg of MK-1775 administered orally once a day (QD) on Days 1-5 of a 21-day cycle and 1000 mg/m^2/day of 5-FU administered as an IV infusion on Days 1-4 of a 21-day cycle.
3221421|NCT01047007|Experimental|Parts 2B +3:MK-1775+5-FU+CDDP|Participants were to receive 20 mg or 65 mg of MK-1775 administered either BID or QD on Days 1-5 of a 21-day cycle; 1000 mg/m^2/day of 5-FU administered as an IV infusion on Days 1-4 of a 21-day cycle; and 60 mg/m^2 to 100 mg/m^2 of CDDP administered as an IV infusion on Day 1.
3221422|NCT01046994|Experimental|surgery|biliopancreatic diversion
3221423|NCT01046994|Active Comparator|standard medical care|patients treated according to the rules of good clinical practice
3221424|NCT01046981|Experimental|Tumescent Antibiotic Delivery|TAD followed by sequential serum and interstitial tissue fluid sampling for antibiotic concentration of subsequent 24 hours
3221425|NCT01046981|Experimental|Intravenous Antibiotic Delivery|Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum and interstitial tissue fluid sampling for antibiotic concentration of subsequent 24 hours.
3221426|NCT01046968|Experimental|Lepticore|
3221427|NCT01046955|Active Comparator|1mg/kg Thymoglobulin|LD kidneys receiving 1mg/kg Thymoglobulin for 7 days starting at the day of surgery.
3221428|NCT01046955|Active Comparator|Campath-1H at 0.3 mg/kg|Recipients of LD kidneys receiving Campath-1H at 0.3 mg/kg once on the day of surgery and again 3 days post-operatively.
3221583|NCT01045837|Active Comparator|Prednisolone and Gluten free diet|Gluten free diet and prednisolone in the dose of 1 mg/kg/d over a period of 4 weeks.
3221429|NCT01046955|Active Comparator|Zenapax 1 mg/kg|Recipients of LD kidneys receiving Zenapax 1mg/kg on the day of surgery followed by the same dose every 2 weeks for a total of 5 dosages.
3221430|NCT01046942|Experimental|Clopidogrel+Aspirin, hypercoagulabel|
3221431|NCT01046942|Active Comparator|Aspirin,hypercoagulabel control|
3221432|NCT01046929|Experimental|limonene|
3221433|NCT01046916|Experimental|TAK-700|
3221434|NCT01046903||1|
3221435|NCT01046890|Experimental|darunavir/ritonavir + root of Echinacea purpurea|darunavir/ritonavir + root of Echinacea purpurea
3221436|NCT01046877|Experimental|Tympanostomy Tube placement|Tympanostomy Tube Delivery System (TTDS) used for placement of tympanostomy tubes in patients indicated for such treatment for chronic Otitis Media with Effusion (OME) or recurrent Acute Otitis Media(AOM).
3221437|NCT01046864|Experimental|Arm 1|
3221438|NCT01046864|Experimental|Arm 2|
3221439|NCT01046864|Experimental|Arm 3|Japanese Population
3221440|NCT01046851|Active Comparator|Nopan|
3221441|NCT01046851|Placebo Comparator|Placebo|
3221442|NCT01046838|Placebo Comparator|Placebo|placebo 3 x daily
3221443|NCT01046838|Active Comparator|sildenafil|40 mg sildenafil 3 x daily
3221444|NCT01046825|Other|Group A|"Completely resected stage I or completely resected abdominal stage II lesions.~Group A will include: COPAD x 2 cycles."
3221445|NCT01046825|Other|Group B|"All cases not eligible for Group A or Group C. (Murphy Stage III and non-CNS Stage IV)~Group B will include the intervention COP, COPD M3, CYM as follows:~Pre-Phase: COP~Induction: COPAD M3 x 2 cycles~Consolidation: CYM x 2 cycles."
3221446|NCT01046825|Other|Group C|"Any CNS involvement and/or bone marrow involvement ≥ 25% blasts. For CNS involvement one or more of the following applies:~Any L3 blasts in CSF~Cranial nerve palsy (if not explained by extracranial tumor)~Clinical spinal cord compression~Isolated intracerebral mass~Parameningeal extension: cranial and/or spinal~Group C will include the intervention COP, COPADM8, CYVE as follows:~Pre-Phase: COP~Induction: COPADM8 cycle 1~Induction: COPADM8 Cycle 2~Consolidation: CYVE x 2 cycles~and Maintenance"
3221447|NCT01046799|Experimental|Entecavir|
3221448|NCT01046786|Active Comparator|Group A|Intraspinal injection of 1.6 million cord blood mononuclear cell
3221449|NCT01046786|Active Comparator|Group B|Intraspinal injection of 3.2 million cord blood mononuclear cell
3221450|NCT01046786|Active Comparator|Group C|Intraspinal injection of 6.4 million cord blood mononuclear cell
3221451|NCT01046786|Active Comparator|Group D|Intraspinal injection of 6.4 million cord blood mononuclear cell plus 30 mg/kg methylprednisolone
3221452|NCT01046786|Active Comparator|Group E|Intraspinal injection of 6.4 million cord blood mononuclear cell plus 30 mg/kg methylprednisolone plus 6 week course of oral lithium, titrated to maintain 0.6-1.0 mM serum level
3221453|NCT01046773|Active Comparator|Children with Crohn's disease less than 35 kg|These are children ages 8 to 18 years inclusive, with mild to moderately active Crohn's disease.
3221454|NCT01046773|Active Comparator|Children with Crohn's disease 35 kg or greater|These are children ages 8 to 18 years inclusive, with mild to moderately active Crohn's disease.
3221455|NCT01046760||Rolandic Epilepsy|Patients older than seven years old with clinical and electroencephalographic diagnosis of Rolandic Epilepsy
3221456|NCT01046747|Active Comparator|Pre-drill|These pins will be pre-drilled
3221457|NCT01046747|Active Comparator|No pre-drill|these pins will not be pre-drilled, but will rely on the self drilling function of the pin for insertion
3221458|NCT01046734||Adult Community|
3221459|NCT01046734||Adult Hospital|
3221460|NCT01046734||Children Hospital|
3221461|NCT01046734||Children Community|
3221462|NCT01046721|Active Comparator|Exenatide|subcutaneous administration of Exenatide (0.02ml)
3221463|NCT01046721|Placebo Comparator|0.9% Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
3221464|NCT01046708|Experimental|micronized progesterone|
3221465|NCT01046708|No Intervention|no utrogestan|
3221466|NCT01046695|Active Comparator|TENS Unit|"This arm will be adding the use of the TENS unit for 48 hours in addition to standard care for their post operative pain control.~Patient's primary area of postoperative pain was determined by nursing personnel. Four electrodes were placed on or around the area of maximum pain. The TENS unit was turned on, 1 of 5 frequency patterns selected and the impulse turned up until the patient could feel the impulse. The location of the electrodes, the pattern, and/or the intensity of the TENS unit were adjusted until the patient achieved maximum comfort with the sensation."
3221467|NCT01046695|No Intervention|Control Arm|This arm will have standard care for their post operative pain control.
3221468|NCT01046682|Active Comparator|Salsalate|
3221469|NCT01046682|No Intervention|Usual care|
3221470|NCT01046669|Sham Comparator|Control|
3221471|NCT01046669|Experimental|Treatment|Two (2) PMX cartridges will be administered approximately 24 hours apart.
3221472|NCT01046643|Active Comparator|Estrogen followed by Placebo|Estrogen treatment with Estradiol (E2) followed by Placebo.
3221473|NCT01046643|Active Comparator|Progesterone followed by Placebo|Progesterone (P10) treatment followed by Placebo.
3221474|NCT01046643|Active Comparator|Placebo followed by Estrogen|Placebo followed by Estrogen treatment with Estradiol (E2)
3221475|NCT01046643|Active Comparator|Placebo followed by Progesterone|Placebo followed by Progesterone (P10) treatment.
3221476|NCT01046630|Experimental|1|single infusion
3221477|NCT01046630|Active Comparator|2|single infusion
3221478|NCT01046630|Placebo Comparator|3|single infusion
3221479|NCT01046604|No Intervention|No treatment|This is the group of patients that will not undergo any treatment with Lovaza prior to mitral valve repair surgery. This is the 'control' group.
3221480|NCT01046604|Active Comparator|Lovaza treated|This arm will be the group of patients that will be treated with Lovaza prior to undergoing mitral valve repair surgery.
3221481|NCT01046591||Cleft|Those with a repaired cleft palate
3221482|NCT01046591||Comparison|Those without a cleft palate repair
3221483|NCT01046578|Experimental|Single Dose 12mm follicle|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 12 mm
3221584|NCT01045837|Placebo Comparator|Gluten free diet|Gluten free alone will be given in this group
3221484|NCT01046578|Experimental|Single Dose 18mm follicle|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 18 mm
3221485|NCT01046578|Experimental|Single Dose Post Ovulation|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated 24-48 post ovulation
3221486|NCT01046578|Experimental|Multi Dose 12mm follicle|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 12 mm
3221487|NCT01046578|Experimental|Multi Dose 18mm follicle|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 18 mm
3221488|NCT01046578|Experimental|Multi Dose Post Ovulation|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated 24-48 hours post ovulation
3221489|NCT01046578|No Intervention|Control|No intervention given, followed for course of study on a natural cycle
3221490|NCT01046565|Active Comparator|Differin® Cream 0.1%|Adapalene Cream 0.1% - apply once daily on one side of the face for 3 weeks
3221491|NCT01046565|Active Comparator|Differin® Lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face
3221492|NCT01046552|Active Comparator|PES/LC|preoperative ES followed by LC within the same hospital admission
3221493|NCT01046552|Active Comparator|LC/IOES|laparoscopic cholecystectomy with intraoperative ercp under the same anesthesia
3221494|NCT01046539|Active Comparator|RDC-0313 + Buprenorphine|Cohort 1 (1 and 4 mg) + 8 mg Cohort 2 (dependent on Cohort 1 results)
3221495|NCT01046539|Placebo Comparator|Placebo|
3221496|NCT01046500|Active Comparator|metformin|
3221497|NCT01046500|Active Comparator|myo-inositol|
3221498|NCT01046474|Experimental|reducing beverages and sugar and increase physical activity|reduction of beverages and sugar and increasing physical activity
3221499|NCT01046474|No Intervention|control -no intervention|
3221500|NCT01046461|Experimental|Ramosetron, Aprepitant, Dexamethasone|
3221501|NCT01046448||4C|Children with chronic kidney disease stage IIIb to V (GFR 10 to 45 ml/min/1.73m²) at screening.
3221502|NCT01046435|Placebo Comparator|Supragingival scaling plus placebo|Plaque control instructions, supra gingival scaling and two placebos
3221503|NCT01046435|Experimental|Root planing plus antibiotics|Plaque control instructions, subgingival scaling,root planing, metronidazole 250 mg and amoxicillin 500 mg. three times a day for 7 days
3221504|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment A)|
3221505|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment B)|
3221506|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment C)|
3221507|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment D)|
3221508|NCT01046422|Placebo Comparator|Placebo ± metformin (Treatment E)|
3221509|NCT01046409||Main vessel, side branch vessel|
3221510|NCT01046396|Active Comparator|Differin® Cream 0.1%|Adapalene Cream 0.1% - apply once daily on one side of the face for 3 weeks
3221511|NCT01046396|Active Comparator|Differin® Lotion 0.1%|Adapalene Lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
3221512|NCT01046383|Experimental|IMN1207|"Dietary Supplement: IMN1207~Stratum A: CRP <40 mg/L and WBC < 11x109/L (i.e. subjects with relatively low levels of inflammation).~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation."
3221513|NCT01046383|Placebo Comparator|Casein|"Dietary Supplement: Casein.~Stratum A: CRP <40 mg/L and WBC < 11x109/L (i.e. subjects with relatively low levels of inflammation).~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation."
3221514|NCT01046370|Experimental|ARP intervention|
3221515|NCT01046370|No Intervention|No intervention|
3221516|NCT01046357|Experimental|Active|AZD7687 oral suspension
3221517|NCT01046357|Experimental|Placebo|placebo oral suspension
3221518|NCT01046331||Adult H1N1|Patients admitted to adult ICU with confirmed or suspected H1N1 Influence infection
3221519|NCT01046331||Pediatric H1N1|Patients admitted to pediatric ICU with confirmed or suspected H1N1 Influenza infection
3221520|NCT01046318|Experimental|OPC-262 5 mg|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
3221521|NCT01046305||Part 1: Interview & Questionnaires|Patients interviews and questionnaires about CML symptoms once.
3221522|NCT01046305||Part 2: Symptoms Rating|Importance of symptoms to CML patients rated by physicians, nurses, patients, and caregivers.
3221523|NCT01046305||Part 3: MDASI-CML Questionnaires|Patients questionnaires about CML symptoms over 1 year using M. D. Anderson Symptom Inventory (MDASI) module (the MDASI-CML)
3221524|NCT01046292|Experimental|Ginkgo biloba|
3221525|NCT01046292|Placebo Comparator|Placebo control|
3221526|NCT01046279||Glioma Patient receiving Bevacizumab|Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV)assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
3221527|NCT01046266|Experimental|A|
3221528|NCT01046266|Active Comparator|B|
3221529|NCT01046253|Experimental|Investigational Test Product|Lansoprazole 30 mg Delayed-Release Capsule
3221530|NCT01046253|Active Comparator|Reference Listed Drug|Prevacid® 30 mg Delayed-Release Capsule
3221531|NCT01046240|Active Comparator|Intravenous palonosetron|Intravenous palonosetron: control arm (standard treatment)
3221532|NCT01046240|Experimental|subcutaneous palonosetron|subcutaneous palonosetron
3221533|NCT01046227||Serology after Novel H1N1 vaccination|This study is designed to investigate the antibodies titers before and after the novel H1N1 influenza vaccination in pediatric haemato-oncology patients.
3221534|NCT01046214|Experimental|Budeprion XL™|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
3221535|NCT01046214|Active Comparator|Wellbutrin XL®|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
3221536|NCT01046201||Obese Children|
3221585|NCT01045811|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
3221886|NCT01043666|Placebo Comparator|placebo group|oral
3221537|NCT01046188|Experimental|Web-based Teaching Group|Patients randomized to the intervention group will receive a unique login and password to a link on the Ottawa Fertility Centre website. This will allow them access to a secure site containing required teaching modules. They will then complete an interactive teaching tool that contains the same educational content as the traditional presentation. Patients will be able to access a module that is specific to their stimulation protocol. The teaching tool does not need to be completed all at one time. Once completed, the information can still be accessed as many times as required.
3221538|NCT01046188|Active Comparator|Control group|Participants randomized to the control arm of the study will participate in a traditional didactic teaching session. This session will be carried out by the nurse educator. This session will be attended by up to 10 other couples that may or may not be participating in the study. The nurse educator administering the session will not know which couples are participating in the study. Slides shown and information conveyed will be the same as that provided to the web-based group, however all three stimulation protocols will be presented to the participants regardless of their actual treatment protocol.
3221539|NCT01046175|Experimental|Airstacking with manual resuscitator|Air-stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
3221540|NCT01046175|Active Comparator|Air-stacking with ventilator|Air-stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a ventilator.
3221541|NCT01046162|Active Comparator|Tafil Tablets 2 mg Pharmacia Upjohn|
3221542|NCT01046162|Active Comparator|Xanax Tablets 2 mg Pfizer LLC|
3221543|NCT01046149|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
3221544|NCT01046149|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
3221545|NCT01046136|Active Comparator|Mucinex|
3221546|NCT01046136|Placebo Comparator|placebo|
3221547|NCT01046123|Experimental|Whole brain radiotherapy|whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy
3221548|NCT01046110|Experimental|IDeg OD|
3221549|NCT01046110|Experimental|DPP-IV inhibitor|
3221550|NCT01046097||Synflorix Group|Subjects receiving Synflorix™ according to local Prescribing Information. Subjects were administered with Synflorix by investigators in the course of their normal clinical practice. The vaccination schedule consisted of three doses/two doses/one dose or the booster dose of 10Pn-PD-DiT to be administered as per the local PI. First dose of the vaccine could be administered to infants as early as 6 weeks of age and minimum interval between subsequent primary doses was 4 weeks.
3221551|NCT01046084|Experimental|Investigational Test Product|Lansoprazole 30 mg Delayed-Release Capsule
3221552|NCT01046084|Active Comparator|Reference Listed Drug|Prevacid® 30 mg Delayed-Release Capsule
3221553|NCT01046071|Experimental|transversus abdominis plane block|transversus abdominis plane block with ropivacaine
3221554|NCT01046071|Placebo Comparator|block with saline|20 ml of isotonic saline bilateral
3221555|NCT01046058|Experimental|Panel A: TMC435 150 mg|Participants enrolled in Panel A had moderate hepatic failure and received TMC435 150 mg once daily for 7 days.
3221556|NCT01046058|Experimental|Panel B: TMC435 150 mg|Participants enrolled in Panel B had severe hepatic impairment and received TMC435 150 mg once daily for 7 days after the safety of TMC435 150 mg once daily for 7 days was evaluated in participants enrolled in Panel A.
3221557|NCT01046045|Active Comparator|Everolimus|before and after everolimus; in other words, comparison of specified outcome before and after treatment with everolimus
3221558|NCT01046045|Active Comparator|Calcineurin-inhibitor immunosuppression|Cyclosporin-based immunosuppression without everolimus
3221559|NCT01046032|Active Comparator|Metformin|Drug (including placebo)
3221560|NCT01046032|Placebo Comparator|Sugar pill|Drug (including placebo)
3221561|NCT01046006|Experimental|Treatment|BDR will be administered in one 21-day treatment cycle followed by four 35-day treatment cycles to patients with WM. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of Bortezomib, dexamethasone 40mg iv and Rituximab 375 mg/m2 iv will be administered. A total of 8 infusions of rituximab will be administered. Subsequently patients rated as CR, PR, MR or SD will be followed without any treatment until there is evidence of progressive disease.
3221562|NCT01045993|Active Comparator|1|Heat device
3221563|NCT01045993|Sham Comparator|2|Placebo arm
3221564|NCT01045993|Active Comparator|3|Marketed analgesic
3221565|NCT01045993|Placebo Comparator|4|(Oral) Placebo comparator
3221566|NCT01045980|Experimental|Bioimpedance and Vitamin D|
3221567|NCT01045980|Experimental|Usual care and Vitamin D|Vitamin D3
3221568|NCT01045980|Experimental|Bioimpedance and Placebo|
3221569|NCT01045980|Placebo Comparator|Usual Care and Placebo|
3221570|NCT01045967|Experimental|Invesigational Test Product|Lansoprazole 30 mg delayed-release Capsules
3221571|NCT01045967|Active Comparator|Reference Listed Drug|Prevacid® 30 mg delayed-release Capsules
3221572|NCT01045941|Experimental|Patients with distal pancreatic cancer|Patients with distal pancreatic cancer amenable to a laparoscopic distal pancreatectomy
3221573|NCT01045928|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-21 and rituximab IV on day 1of courses 1, 3, 5, 7, 9, and 11.
3221574|NCT01045915|Experimental|Plasmid AMEP electrotransfer|
3221575|NCT01045902|Experimental|Arm 1|
3221576|NCT01045902|Active Comparator|Arm 2|
3221577|NCT01045889|Experimental|R-CHOP + PBSCT|All patients will receive chemoimmunotherapy with Rituximab + CHOP regimen for 6 cycles followed by high dose cyclophosphamide and stem cell collection, then high dose therapy with BEAM conditioning regimen and peripheral blood stem cell transplantation
3221578|NCT01045876|Experimental|Dexamethasone|
3221579|NCT01045876|Placebo Comparator|Placebo|
3221580|NCT01045863|Experimental|PART A: Ascending Cohorts|Single ascending dose cross-over. (0.05, 0.15, 0.5, 1.5, 5, 15 mg)
3221581|NCT01045863|Experimental|PART B: Food effect|Food effect on PF-03382792 PK
3221582|NCT01045863|Experimental|PART C: CSF Cohort|Optional CSF Cohort
3221586|NCT01045811|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
3221587|NCT01045798|Experimental|Caspofungin|caspofungin acetate
3221588|NCT01045798|Placebo Comparator|Placebo|normal saline
3221589|NCT01045785||aspirin responsive|PFA Col/EPI normal
3221590|NCT01045785||aspirin resistance|PFA Col/epi showed resistance
3221591|NCT01045772|Experimental|IL-1 trap|
3221592|NCT01045746|Experimental|Group 1|T0, Stochastic resonance whole-body vibration A intervention over four weeks, three time a week;T1, 16 days wash-out period; T2, Stochastic resonance whole-body vibration B intervention over four weeks, three times week, T3
3221593|NCT01045746|Experimental|Group 2|T0, Stochastic resonance whole-body vibration B intervention over four weeks, three time a week;T1, 16 days wash-out period;T2, Stochastic resonance whole-body vibration A intervention over four weeks, three times week, T3
3221594|NCT01045733|Experimental|IQ Toric IOL|AcrySof IQ Toric intraocular lens (IOL) randomly assigned to one eye, with AcrySof IQ Aspheric IOL with Limbal Relaxing Incision (LRI) procedure in the fellow eye for contralateral implantation.
3221595|NCT01045733|Active Comparator|IQ Aspheric IOL + LRI|AcrySof IQ Aspheric intraocular lens (IOL) with Limbal Relaxing Incision (LRI) procedure randomly assigned to one eye, with AcrySof IQ Toric IOL in the fellow eye for contralateral implantation
3221596|NCT01045720|Placebo Comparator|Placebo Comparator|
3221597|NCT01045720|Experimental|ChinesMed|
3221598|NCT01045707|Experimental|IDegAsp OD|
3221599|NCT01045707|Experimental|IGlar OD|
3221600|NCT01045694|Experimental|Botulinum Toxin Type A|Arm investigates the efficacy of Botulinum Toxin A injection for the treatment of basal thumb joint arthritis
3221601|NCT01045694|Active Comparator|Steroid - Triamcinolone Acetonide|Arm uses the standard of care - Steroid injection - as an active comparator to the experimental injection of Botulinum Toxin A for the treatment of basal thumb joint arthritis
3221602|NCT01045694|Placebo Comparator|Lidocaine|Arm uses plain lidocaine injection to serve as a baseline for evaluating the efficacy of Botulinum toxin as compared to steroid injection for the treatment of basal thumb joint arthritis.
3221603|NCT01045681|Experimental|BVD|Bendamustine, Velcade and Dexamethasone
3221604|NCT01045668|Active Comparator|Clinical VT ablation|
3221605|NCT01045668|Active Comparator|clinical VT and substrate ablation|
3221606|NCT01045655|Experimental|MOMCare intervention|Depression care treatment with study depression care specialist (brief interpersonal psychotherapy or pharmacotherapy)
3221607|NCT01045655|No Intervention|Care Plus|Usual care group; referral to community mental health treatment
3221608|NCT01045642|Active Comparator|Prilosec 20 mg Tablets|
3221609|NCT01045642|Experimental|Omeprazole Magnesium DR 20 mg Capsules|
3221610|NCT01045629||SchizoComp|Competence Ability of schizophrenia
3221611|NCT01045629||NonSchizoComp|Competence of Non-schizophrenia
3221612|NCT01045616||Prematurity|
3221613|NCT01045590|Active Comparator|glibenclamide + Rosiglitazone|glibenclamide plus rosiglitazone
3221614|NCT01045590|Placebo Comparator|glibenclamide + placebo|
3221615|NCT01045577|Active Comparator|Masitinib (AB1010)|Masitinib (AB1010)
3221616|NCT01045577|Placebo Comparator|Placebo mactching masitinib|Placebo matching masitinib
3221617|NCT01045564|Experimental|A|One dose of study vaccine (GSK 1557484A) on Day 0, Day 182, and Day 364
3221618|NCT01045564|Experimental|B|One dose of study vaccine (GSK 1557484A) on Day 0, Day 91, and Day 364
3221619|NCT01045564|Experimental|C|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
3221620|NCT01045564|Experimental|D|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
3221621|NCT01045564|Experimental|E|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
3221622|NCT01045551|Experimental|Apremilast 20 mg (twice per day)|All subjects will receive Apremilast 20mg taken orally twice per day.
3221623|NCT01045538|Experimental|Vorinostat plus XP|Vorinostat 200~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
3221624|NCT01045525|Experimental|Phlebotomy + lifestyle and diet advices|
3221625|NCT01045525|Active Comparator|Lifestyle and diet advices|
3221626|NCT01045512|Active Comparator|statins, standardised physical training|
3221627|NCT01045512|No Intervention|to continue with current lifestyle|
3221628|NCT01045499|Experimental|laparoscopic gastric banding|Adolescent patients who have undergone laparoscopic adjustable gastric banding. Weight, BMI, and co-morbidity data will be compared to patient's pre-operative values.
3221629|NCT01045486|Active Comparator|Group A|Group A received active medication (ATP mixed probiotics) for 6 weeks followed by a crossover to 6 weeks of placebo after 4-weeks washout period.
3221630|NCT01045486|Placebo Comparator|Group B|Group B received placebo medication for 6 weeks followed by a crossover to 6 weeks of active medication (ATP mixed probiotics) after 4-weeks washout period.
3221631|NCT01045460|Experimental|1|aMILs
3221632|NCT01045460|Experimental|2|aMILs + allogeneic myeloma vaccine
3221633|NCT01045447|Experimental|IDegAsp OD|
3221634|NCT01045447|Active Comparator|IGlar OD|
3221635|NCT01045434|Experimental|Omeprazole Magnesium DR 20 mg Capsules|Omeprazole Magnesium DR 20 mg Capsules of Dr Reddys Laboratories Limited
3221636|NCT01045434|Active Comparator|Prilosec 20 mg Tablets|Prilosec 20 mg Tablets of Procter and Gamble
3221637|NCT01045421|Experimental|MLN8237 (Alisertib)|MLN8237 administered as an enteric-coated tablet (ECT)
3221638|NCT01045408|Placebo Comparator|Berry|
3221639|NCT01045408|Placebo Comparator|Placebo|
3221640|NCT01045395|Placebo Comparator|Corn starch, 90mg/d|Corn starch, 90mg/d
3221641|NCT01045395|Experimental|Unique Marine Algae Concentrate (UMAC). 90mg/d|
3221642|NCT01045395|Experimental|Golden brown algae, 90mg/d|
3221643|NCT01045382|Experimental|Mensenchymal Stem Cells|"Efficacy of MSC infusion on one-year overall survival of patients transplanted with HLA-mismatched PBSC.~Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2 Gy total body irradiation.~MSC cells (1,5-3,0 x 10E6 MSC/Kg BW) will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
3221644|NCT01045382|Placebo Comparator|Placebo|"Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2Gy total body irradiation.~Isotonic solution will be injected will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
3221645|NCT01045369|Experimental|Kaletra And Intelence|This is a Phase IV, 48-week, open-label, pilot study in 30 ARV-naïve patients examining the safety, viral response, and tolerability of Kaletra® and Intelence™ tablets.
3221646|NCT01045356||children less than 2 months old|
3221647|NCT01045356||children 2 months to 12 months old|
3221648|NCT01045356||Children > 2 months old and less than or equal to 20 kg|
3221649|NCT01045343|Active Comparator|Control Arm|
3221650|NCT01045343|Experimental|Integrated Diagnostics Arm|
3221651|NCT01045330|No Intervention|Usual Care Group|Usual care consists of standard hospital services provided by physicians, nurses, and support staff (e.g., physical therapist, dietitian) in the general surgery units.
3221652|NCT01045330|Experimental|Experimental Group|The intervention consisted of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
3221653|NCT01045317|Experimental|intravenous or oral administration|
3221654|NCT01045304|Experimental|Gencitabine + iniparib twice weekly|"Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles.~Iniparib, 5.6 mg/kg IV over 60 minutes on Days 1, 4, 8 and 11 of 3-week cycles"
3221655|NCT01045304|Experimental|Gencitabine + iniparib weekly|"Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles.~Iniparib, 11.2 mg/kg IV over 60 minutes on Days 1 and 8 of 3-week cycles"
3221656|NCT01045291|Active Comparator|Fusion Pacing OFF|Subjects initially randomized to the Fusion Pacing OFF Arm will receive the Fusion Pacing software download at the implant visit, but the Fusion Pacing software will be programmed OFF. At 4 months subjects in this arm will crossover to the Fusion Pacing ON Arm.
3221657|NCT01045291|Experimental|Fusion Pacing ON|Subjects initially randomized to the Fusion Pacing ON Arm will receive the Fusion Pacing software download at the implant visit, and the Fusion Pacing software will be programmed ON. At 4 months subjects in this arm will crossover to the Fusion Pacing OFF Arm.
3221658|NCT01045265||Raltegravir treated men|Single group study of seminal plasma pharmacokinetics of raltegravir in men receiving chronic raltegravir therapy
3221659|NCT01045252||congenital heart disease|Neonates that are enrolled in the NICU and are confirmed of congenital heart diseases.
3221660|NCT01045252||sepsis|Neonates that are enrolled in the NICU and are diagnosed as sepsis.
3221661|NCT01045252||Health|Neonates that are enrolled in the NICU and have no congenital heart diseases and sepsis.
3221662|NCT01045239|Experimental|Micropulse 577 nm yellow diode laser|
3221663|NCT01045239|Active Comparator|532 nm green diode laser|
3221664|NCT01045226|Experimental|Arm I|Patients undergo proton radiotherapy once daily 5 days a week for approximately 9 weeks in the absence of disease progression or unacceptable toxicity.
3221665|NCT01045213|Experimental|Proactive Integrated Care|COPD education, self-management education, remote monitoring (Health Buddy, pulse oximeter, pedometer, spirometer) and enhance communication with cell phone contact with a coordinator.
3221666|NCT01045200||Follow-up|Patients curatively operated for rectal cancer
3221667|NCT01045187|Other|endometrial cancer|Patients are treated with electronic brachytherapy for an FDA cleared indication.
3221668|NCT01045174|Active Comparator|Breath-Actuated Nebulizer|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer.
3221669|NCT01045174|Active Comparator|Conventional continuous-ouput nebulizer|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer
3221670|NCT01045161|Experimental|1|Aclidinium bromide 200 μg dose twice per day, inhaled for 12 weeks of treatment At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks
3221671|NCT01045161|Experimental|2|Aclidinium bromide 400 μg dose twice per day, inhaled for 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 400 μg will continue to receive open label 400µg aclidinium bromide for 40 weeks
3221672|NCT01045161|Placebo Comparator|3|Dose-match placebo, oral inhalation twice per day for 12 weeks of treatment. At week 12, patients who were on placebo will receive open label 400µg aclidinium bromide for 40 weeks
3221673|NCT01045148|Other|CyberKnife Radiosurgery|CyberKnife Radiosurgery
3221674|NCT01045135||first time delivery|Women giving birth to their first child
3221675|NCT01045122|Other|Propofol|Is an alkylphenol, is primarily indicated for use as a general anesthetic and has minimal analgesic properties.
3221676|NCT01045122|Other|Dexmedetomidine|Dexmedetomidine is an alpha-2 adrenoreceptor agonist that has sedative, hypnotic, and analgesic effects.
3221677|NCT01045109|Experimental|open-label vitamin D3|One arm: open-label receiving vitamin D3 4,000 IU daily
3221678|NCT01045096|Experimental|Dexlansoprazole 15 mg QD|
3221679|NCT01045096|Experimental|Dexlansoprazole 30 mg QD|
3221680|NCT01045096|Experimental|Dexlansoprazole 60 mg QD|
3221681|NCT01045083|Experimental|1|
3221682|NCT01045070||coronary heart disease|
3221683|NCT01045057|Experimental|Puncture Set and Flexible Protector|Provox Vega Puncture Set is used to create the primary puncture and insert the prosthesis during total laryngectomy
3221684|NCT01045044||Breast cancer, chemotherapy|Up to 15 women with breast cancer who are to undergo systemic anthracycline based chemotherapy.
3221685|NCT01045044||Normal control|Up to 15 normal, healthy women.
3221686|NCT01045031||Controls|"Controls were subsequently contacted via personal contact and three additional advertisements (two in an Austrian newspaper (Krone) and one in an Austrian bicyclist journal (Bicyclist Sports). The controls were matched according to age, sex and years of education"
3221723|NCT01044732|Experimental|Group A - COLO, then TER|"Complete examination with standard colonoscope (COLO) followed by complete examination with Third Eye Retroscope (TER) used in conjunction with standard colonoscope"
3221687|NCT01045031||marathon athletes|Runners participating in the 2008 Wachau half marathon (21,2 km) and the Vienna City marathon (42,5 km) as well as bicyclists participating at the Corinthian marathon (180km). Inclusion criteria:1) participation in at least one of these 3 marathons in the preceding two years,2)still in continuous training during the recruitment phase (at least 2 hours/week), 3) aged over 60. Exclusion criteria:(a) present or past exposure to neurotoxic substances (b) if they did not speak German as their native language (c) diseases that markedly affect CNS functions (d) manifest cardiovascular disease, (e) chronic alcoholism (daily alcohol intake > 60 g or diagnosed history of alcoholism) and (f) unwillingness to give informed consent.
3221688|NCT01045018|Active Comparator|mesalamine 400 mg tablet|
3221689|NCT01045018|Active Comparator|Asacol 400 mg Delayed Release Tablet|
3221690|NCT01045018|Placebo Comparator|Placebo delayed release tablet|
3221691|NCT01045005|Active Comparator|Type 1 Diabetes|Subjects with type 1 diabetes mellitus who are administered oxygen and carbon dioxide
3221692|NCT01045005|Active Comparator|Control Subjects|Healthy volunteers administered oxygen and carbon dioxide via respiratory apparatus
3221693|NCT01044992|Experimental|Drug and radiation|Levodopa and H215O PET
3221694|NCT01044966|Experimental|ITV DepoCyt + metronomic TMZ|Patients will undergo an induction phase of intraventricular (ITV) DepoCyt, using the dosage determined from the Phase I portion of the study every two weeks (+/- 3 days) for one month (Cycles 1, 2). Patients with stable disease (clinically and radiographically), not exhibiting systemic toxicity, will undergo a three month consolidation phase of ITV DepoCyt, for one month (Cycles 3-6). Patients without progression or toxicity will undergo maintenance therapy using ITV DepoCyt every four weeks (+/- 3 days) for a maximum of 8 months (cycles 7-14) or until recurrence or toxicity ensues. Oral metronomic Temozolomide dosing of 75 mg/m2 daily for 21 days followed by 7 days off will be given throughout the Induction, Consolidation, and Maintenance Phases of the ITV DepoCyt described above.
3221695|NCT01044953||Soccer Players|German professional soccer players
3221696|NCT01044940||Birth asphyxia|Babies suffering from birth asphyxia
3221697|NCT01044940||Blood transfusion|Babies who receives blood transfusion
3221698|NCT01044940||Heart Surgery|Babies who need heart surgery
3221699|NCT01044927|Experimental|Proactive Integrated Care|COPD-specific education, self-management instruction, remote monitoring and enhanced communication with a coordinator
3221700|NCT01044927|Active Comparator|Standard Care Control|No intervention other that measurements taken at 0, 3, 6 and 9 months of the study.
3221701|NCT01044901||Subjects with Sickle Cell Disease|
3221702|NCT01044901||Healthy Volunteers|
3221703|NCT01044875|Active Comparator|green laser 532 nm conventional|Current type of laser used for treatment of proliferative diabetic retinopathy
3221704|NCT01044875|Active Comparator|Yellow 577 nm laser|new laser wavelength for treatment of PDR
3221705|NCT01044862|Active Comparator|Aromatase Inhibitors (AI)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
3221706|NCT01044862|Active Comparator|Clomiphene Citrate (CC)|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
3221707|NCT01044862|Active Comparator|Follicle Stimulating Hormone (FSH)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
3221708|NCT01044836|Experimental|Etanercept|
3221709|NCT01044823||Adult RA|
3221710|NCT01044823||pediatric JRA|
3221711|NCT01044810||Simultaneous interruption (Exposure gr)|stopped all drugs in NNRTI-based regimens simultaneously after allergic reactions to NVP-based regimens, and later started EFV-based regimens
3221712|NCT01044810||Naive (Control group)|HIV-1-infected patients who started EFV-based regimens as their initial ARV regimens.
3221713|NCT01044810||staggered interruption (exposure group)|"after having allergic reactions to NVP-based regimens, stopped NNRTIs first, continued the other NRTIs for a period of time, i.e. staggered interruption, and later started EFV-based regimens"
3221714|NCT01044771|Other|change from tenofovir to raltegravir|"Single arm study:~Tenofovir containing nucleoside backbone changed over to raltegravir in all patients"
3221715|NCT01044758|Experimental|aMCI_62.5mg drug first, then placebo|"Amnestic MCI:~62.5mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
3221716|NCT01044758|Experimental|aMCI_Placebo first, then 62.5mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 62.5mg levetiracetam twice daily (two weeks)"
3221717|NCT01044758|Experimental|aMCI_125mg drug first, then placebo|"Amnestic MCI:~125mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
3221718|NCT01044758|Experimental|aMCI_Placebo first, then 125mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 125mg levetiracetam twice daily (two weeks)"
3221719|NCT01044758|Experimental|aMCI_250mg drug first, then placebo|Amnestic MCI: 250mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)
3221720|NCT01044758|Experimental|aMCI_Placebo first, then 250mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 250mg levetiracetam twice daily (two weeks)"
3221721|NCT01044758|Placebo Comparator|Control_Placebo first, then placebo|"Healthy control:~placebo capsule twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
3221722|NCT01044745|Experimental|Treatment (Rituximab and allogeneic HCT transplant)|"CONDITIONING REGIMEN: Patients receive one of the following conditioning regimens as per the transplant physician: cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive rituximab IV on days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Patients also receive tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.~TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0."
3221768|NCT01044420|Experimental|mFOLFIRI|
3221724|NCT01044732|Active Comparator|Group B - TER, then COLO|"Complete examination with Third Eye Retroscope (TER) used in conjunction with standard colonoscope, followed by complete examination with standard colonoscope (COLO) alone"
3221725|NCT01044719|Active Comparator|10 days|
3221726|NCT01044719|Active Comparator|14 days|
3221727|NCT01044719|Active Comparator|21 days|
3221728|NCT01044706|Experimental|Bicalutamide 50 mg Tablet|Bicalutamide 50 mg Tablet
3221729|NCT01044706|Active Comparator|Casodex® 50 mg Tablet|Casodex® 50 mg Tablet
3221730|NCT01044693|Placebo Comparator|Placebo capsule|Placebo capsule
3221731|NCT01044693|Experimental|Nebivolol 5 mg|Nebivolol 5 mg capsule
3221732|NCT01044693|Active Comparator|Metoprolol tartrate 50 mg|Metoprolol tartrate 50 mg single oral dose
3221733|NCT01044693|Active Comparator|Sildenafil 25 mg|Sildenafil 25 mg single oral dose
3221734|NCT01044680|Experimental|Nutriose|17 g NUTRIOSE consumed twice daily for 12 weeks
3221735|NCT01044680|Placebo Comparator|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
3221736|NCT01044667|Other|Patients taking Myfortic|Lung transplant patients converted from MMF to Myfortic as part of standard of care treatment will have GI and Quality of Life assessments done at the time of conversion to Myfortic and at 60 days, 90 days and 180 days.
3221737|NCT01044654|Experimental|Cohort 1|3 Subjects will receive a single infusion of 0.5-1.0 x 1010 SB-728-T
3221738|NCT01044654|Experimental|Cohort 2|3 Subjects will receive a single infusion of 2.0 x 1010 SB-728-T
3221739|NCT01044654|Experimental|Cohort 3|3 Subjects will receive a single infusion of 3.0 x 1010 SB-728-T
3221740|NCT01044654|Experimental|Cohort 4|Up to 4 HAART failure subjects will receive a single intravenous infusion of 0.5 to 3.0 x 1010 SB-728-T
3221741|NCT01044654|Experimental|Cohort 5|"Up to 20 subjects with heterozygote CCR5 delta-32 mutation will receive a single intravenous infusion of 0.5 to 3.0 x 1010 SB-728-T.~Cohort 5 subjects will undergo a structured treatment interruption 2 months following infusion in which their anti-retroviral therapy will be discontinued for 16 weeks. HAART will be reinstituted in subjects whose CD4+ cell counts drop to <350 cells/mm3 and/or whose HIV-RNA increases to >100,000 on three consecutive weekly measurements.~At the end of the STI, subjects with a sustained detectable viral load will be reinstituted on HAART. Subjects with HIV RNA levels below the limit of detection will remain off HAART. Subjects with an undetectable viral load will remain off HAART until HIV RNA levels are detectable or their CD4 count drops below 350 cell/mm3 on three consecutive weekly measurements."
3221742|NCT01044628|Experimental|Nocturnal oxygen therapy (N-O2)|Oxygen will be delivered overnight to the patients to allow their oxygen saturation to be >90%
3221743|NCT01044628|Sham Comparator|Sham concentrator|Sham therapy with ambient air will be given to the patients at night
3221744|NCT01044615||Mild traumatic brain injury patients|Subjects who have a verifiable diagnosis of mild traumatic brain injury sustained within 24 months prior to enrollment
3221745|NCT01044615||Normal Control|Normal, healthy adults with no history of brain injury.
3221746|NCT01044602|Active Comparator|Best Medical Management|Patients elect to treat obesity and type 2 diabetes mellitus through best medical management.
3221747|NCT01044602|Active Comparator|Surgical Treatment|Patients with type 2 diabetes mellitus choice to treat obesity with Roux-en-Y gastric bypass.
3221748|NCT01044589|Experimental|Biodesign Tissue Repair Graft|Biodesign Tissue Repair Graft
3221749|NCT01044589|Active Comparator|Overlapping Sphincter Repair|Control
3221750|NCT01044576||Multiple Sclerosis|Patients with relapsing-remitting or secondary progressive multiple sclerosis
3221751|NCT01044563|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
3221752|NCT01044563|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
3221753|NCT01044550|Other|Treatment|Laparoscopy on a group of randomly selected patients with left thoracoabdominal stab wounds to obtain the incidence of occult diaphragm injury
3221754|NCT01044550|Active Comparator|Control|Assess the incidence and clinical outcome of delayed diaphragm visceral herniation in the study group.
3221755|NCT01044537|Placebo Comparator|Placebo|In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo.
3221756|NCT01044537|Experimental|PF-04937319|In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo. There will be approximately 6 dosing levels of PF-04937319
3221757|NCT01044524|Experimental|1|SLV 334
3221758|NCT01044511|Experimental|Home visit|After SEMS placement, 2 home visits and a phonecall are made by a specialist nurse
3221759|NCT01044511|Active Comparator|Standard|Standard contact via Hotline and traditional referring methods
3221760|NCT01044498|Experimental|Tocilizumab 8 mg/kg + Ortho-Novum® 1/35 (Group 1)|Patients with rheumatoid arthritis received Ortho-Novum® 1/35 daily on Days 1-21 of 3 consecutive 28-day cycles. On the first day of Cycle 2, patients received tocilizumab 8 mg/kg administered intravenously.
3221761|NCT01044498|Other|Ortho-Novum® 1/35 (Group 2)|Healthy volunteers received Ortho-Novum® 1/35 tablets daily on Days 1-21 of one 28-day cycle.
3221762|NCT01044485|Other|lapatinib + docetaxel|"dose level Lapatinib (OD) Docetaxel (q3wks) Systematic Growth factor Minus 0 1250 mg 75 mg/m2 + systematic growth factor support~0, 1250mg 75 mg/m2 No~+1 1500mg 75mg/m2 No~Minus +1* 1500mg 75mg/m2 + systematic growth factor support~+2 1250mg 100mg/m2 No~Minus +2* + systematic growth factor support~+3 1500mg 100mg/m2 No~Minus +3* + systematic growth factor support~Apart within the minus dose levels, G-CSF support should be added only as rescue strategy if severe neutropenia occurred during the first cycle of studied dose.Patients will receive 4 cycles of the association. In case of benefit of the treatment, they should continue the treatment with lapatinib until progression.* patients will be included at level minus X only if 2 DLT out of 6 patients based on febrile neutropenia occurred at level X"
3221763|NCT01044459|Experimental|Aclidinium Bromide 200 µg|aclidinium bromide, inhaled, 52 weeks of treatment
3221764|NCT01044459|Experimental|Aclidinium Bromide 400 µg|aclidinium bromide, inhaled, 52 weeks of treatment
3221765|NCT01044446|Experimental|Icodextrin|peritoneal dialysate
3221766|NCT01044446|Active Comparator|Glucose-based dialysate|peritoneal dialysate
3221767|NCT01044433|Experimental|Arm I|Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14.
3221769|NCT01044394|Experimental|same day, reduced volume PEG-ELS prep|Patients with colonoscopies scheduled in the afternoon will complete 2 liters of PEG-ELS solution the morning of their colonoscopy.
3221770|NCT01044381|Experimental|Luliconazole Solution, 10%|
3221771|NCT01044368|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
3221772|NCT01044368|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
3221773|NCT01044355|Active Comparator|auto-titrating|Patients being treated for 6 weeks with auto-titrating continuous airway pressure.
3221774|NCT01044355|Active Comparator|Fixed|Patients receiving 6 weeks of treatment with fixed continuous positive airway pressure.
3221775|NCT01044342|Experimental|A|Single dose of AZD1446 10 mg
3221776|NCT01044342|Experimental|B|Single dose of AZD1446 80 mg
3221777|NCT01044342|Active Comparator|C|Single Dose of Donepezil 5 mg
3221778|NCT01044342|Placebo Comparator|D|Single dose of placebo to match AZD1446
3221779|NCT01044329|Active Comparator|Intravitreal bevacizumab|
3221780|NCT01044329|Active Comparator|Intravitreal triamcinolone|
3221781|NCT01044316|Active Comparator|Arm 1|
3221782|NCT01044316|Active Comparator|Arm 2|
3221783|NCT01044303|Experimental|Myfortic Escalation|Participants EC-MPS dose was escalated to a minimum daily dose of 1440mg or equivalent, with the maximum dose never exceeding the manufacturer's recommendations.
3221784|NCT01044290|Experimental|Outlook Intervention|"Subjects in the first group (Life Completion) completed a psychosocial intervention which consisted of meeting with the facilitator three times for 45-60 minutes each. In the first session, subjects were asked to discuss issues related to life review. In session two, participants spoke about issues of regret and forgiveness. In the final session, subjects focused on heritage and legacy."
3221785|NCT01044290|Active Comparator|Attention Control|"The subjects in the second group (attention control) met with a facilitator three times for 45 minutes and listened to a non-guided relaxation CD."
3221786|NCT01044290|No Intervention|Treatment as Usual|"Subjects in the third group (treatment as usual) were exposed to no intervention or attention control during the intervention window."
3221787|NCT01044277|Experimental|Group A|"Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo~Other name Gluthathione peroxidases"
3221788|NCT01044277|Experimental|Group B|"Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo~Other name Gluthathione peroxidases"
3221789|NCT01044277|Placebo Comparator|Group C|Placebo-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo
3221790|NCT01044264|Active Comparator|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Test product
3221791|NCT01044264|Active Comparator|DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Reference product
3221792|NCT01044264|Placebo Comparator|Placebo|
3221793|NCT01044251|Placebo Comparator|Placebo|10 days of treatment with placebo in a bid fashion that will look like the study medication.
3221794|NCT01044251|Experimental|Frovatriptan|Frovatriptan 2.5 mg po bid for 10 days
3221795|NCT01044238|Experimental|active medication (methylphenidate)|Condition receiving active medication: 18mg/day during week 1; 36mg/day during week 2; 54mg/day during remainder of study
3221796|NCT01044238|Placebo Comparator|Placebo|Condition randomly assigned to receive placebo, provided to appear identical to active medication
3221797|NCT01044225|Active Comparator|Cilengitide EMD 121974|A dose of 2000 mg by iv administration 2 weekly.
3221798|NCT01044225|Active Comparator|Cetuximab|An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
3221799|NCT01044212|Active Comparator|Docusate|Docusate is the standard of care regimen
3221800|NCT01044212|Experimental|Bowel medications|Docusate, Miralax, Metamucil wafers, Bisacodyl suppository
3221801|NCT01044199|Experimental|1: Pre-EP ID|Group of participants receiving PCEC rabies vaccine intradermally with the Pre-Exposure schedule.
3221802|NCT01044199|Active Comparator|2: Pre-EP IM|Group of participants receiving PCEC rabies vaccine intramuscular with the Pre-Exposure schedule.
3221803|NCT01044199|Experimental|3: Booster ID|Group of participants receiving PCEC rabies vaccine intradermally with the Booster schedule.
3221804|NCT01044199|Active Comparator|4: Booster IM|Group of participants receiving PCEC rabies vaccine intramuscular with the Booster schedule.
3221805|NCT01044186|Experimental|ICL670|
3221806|NCT01044160||Oncology Group|The study will recruit from outpatient clinics with procedures designed to obtain a representative sample of research participants, in terms of diagnosis and time since diagnosis.
3221807|NCT01044160||Control Group|The study will first identify a large cohort of children who are willing to participate, and then call them back individually as they are found to match participants in the cancer group.
3221808|NCT01044147|Experimental|VLM-S|"Participants in this arm receive standard lifestyle coaching, which is delivered on a specified schedule. They will also receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle."
3221809|NCT01044147|Experimental|VLM-M|"Participants in this arm receive modulated lifestyle coaching, where coaching frequency may be adjusted according to whether the participant is meeting program goals for program use and targeted behaviors. They will also receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle."
3221810|NCT01044147|Active Comparator|OGR|Participants in this arm will receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle, but not personalized lifestyle coaching.
3221845|NCT01043926|Experimental|Participants with Moderate Hepatic Insufficiency (Part I)|Participants with moderate hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
3221846|NCT01043926|Experimental|Healthy Participants (Part I)|Healthy participants matched to participants with moderate hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
3221811|NCT01044134|Experimental|Diet + Water|"Participants will be counseled to follow a standard weight-reducing diet including consumption of 1) ample vegetables, fruits, and legumes; 2) whole rather than refined grains; and 3) high-quality proteins at most meals and snacks. Moreover, we will recommend limiting intake of added fats and sugars and avoiding juices and sugar-sweetened beverages (per standard practice). Participants will also be counseled to increase their water intake to 8 cups per day, consistent with the popular 8 × 8 recommendation (eight 8-oz glasses of water)."
3221812|NCT01044134|Active Comparator|Diet|Participants will be counseled on the same standard weight-reducing diet, as described above, with no specific advice regarding water consumption. Furthermore, no specific dietary recommendations will be provided on altering fluid/beverage intake, other than to decrease calorie-containing beverages as noted above. When participants ask for a recommendation regarding water intake, they will be advised that drinking plain water is the best way to satisfy thirst and instructed to drink when thirsty.
3221813|NCT01044121|Experimental|Mattress Firmness|
3221814|NCT01044108|Experimental|Trial, part 1 (males only)|
3221815|NCT01044108|Experimental|Trial, part 2 (males and females)|
3221816|NCT01044095|Active Comparator|Autologous prime boost regimen 1|FluMist® live intranasal vaccine (LAIV) 0.2mL (0.1mL per nostril): 2 doses separated by 8 weeks (+/- 7 days)
3221817|NCT01044095|Active Comparator|Autologous prime boost regimen 2|Fluzone® inactivated seasonal influenza virus vaccine intramuscularly: 2 doses separated by 8 weeks (+7 days)
3221818|NCT01044095|Experimental|Heterologous prime boost regimen 1|FluMist® live, intranasal vaccine single dose, followed by Fluzone® inactivated influenza virus vaccine 8 weeks (+/-7 days) later
3221819|NCT01044095|Experimental|Heterologous prime boost regimen 2|Fluzone® inactivated seasonal influenza virus vaccine single dose, followed by FluMist® live, intranasal seasonal influenza vaccine 0.2mL 8 weeks (+/- 7 days) later
3221820|NCT01044082|Experimental|controlled cord traction|Controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs.
3221821|NCT01044082|Active Comparator|clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
3221822|NCT01044069|Experimental|Pts with B Cell Acute Lymphoblastic Leukemia|This is a phase I study. Patients with CD19+ ALL (CR, relapsed, MRD, or refractory) are eligible for enrollment. B-ALL patients in first CR will be enrolled but only treated if they develop MRD or a frank relapse, while patients with MRD or with documented relapsed/refractory disease are eligible for immediate treatment. The T cell doses originally proposed in this study were based on doses administered safely in prior autologous T cell adoptive therapy trials but the dose has been modified based on the toxicities observed in patients with morphologic evidence of disease. Patients will be treated with different doses of T cells depending on the amount of disease at the time of T cell infusion. Patients in Cohort 1 (<5% blasts in the BM) will continue to receive 10^6 19-28z+ T cells/kg as previously. Patients in Cohort 2 (≥5% blasts in the BM) will receive the reduced dose of 1x106 19-28z+ T cells/kg).
3221823|NCT01044056|Active Comparator|Levonorgestrel/ethinylestradiol oral contraceptive pill|Microgynon(R), 1 tablet every day for 21 days; each tablet contains 0.150 mg levonorgestrel (LNG) and 0.030 mg ethinylestradiol (EE).
3221824|NCT01044056|Active Comparator|Norelgestrominum and ethinylestradiol contraceptive patch|Evra(TM), One patch applied on lower abdomen for 7 days for 3 consecutive weeks, 3 patches in total. Each patch contains 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
3221825|NCT01044056|Active Comparator|Etonogestrel and ethinylestradiol contraceptive vaginal ring|Nuvaring(R), Place the ring in the vagina for 21 days, remove for one week. Repeat with new Ring. Dose: per ring 11.7 mg ENG and 2.7 mg EE releasing a daily average amount of 0.120 mg ENG and 0.015 mg EE.
3221826|NCT01044030|Experimental|Xylitol syrup|
3221827|NCT01044030|Placebo Comparator|Placebo|
3221828|NCT01044017|Experimental|A|
3221829|NCT01044017|Experimental|B|
3221830|NCT01044017|Placebo Comparator|C|
3221831|NCT01044004|Experimental|Post treatment remission armodafinil|Armodafinil 150 mg/day for 13 weeks
3221832|NCT01044004|Placebo Comparator|Post treatment remission placebo|Placebo 150mg/day for 13 weeks
3221833|NCT01044004|Experimental|Chemotherapy armodafinil|Armodafinil 150 mg/day for 13 weeks
3221834|NCT01044004|Placebo Comparator|Chemotherapy placebo|Placebo 150mg/day for 13 weeks
3221835|NCT01043991|Experimental|EPO|single bolus of EPO, 150 µg
3221836|NCT01043991|Placebo Comparator|Placebo|NaCl
3221837|NCT01043978|Experimental|Novel nipple|
3221838|NCT01043978|Active Comparator|Coventional nipple|
3221839|NCT01043965|Active Comparator|Diabetes|Type 2 diabetes patients without obstructive coronary disease. Interventional group: lifestyle changes and treatment with metformin.
3221840|NCT01043965|No Intervention|Control|Control group - normal, healthy individuals.
3221841|NCT01043952|Active Comparator|Control|"Patients receive general anesthesia with Propofol and Remifentanil following clinical practice.~Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects.~Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters."
3221842|NCT01043952|Experimental|Bispectral Index Monitor|"Patients receive a general anesthesia with Propofol and Remifentanil where the amount of anesthetics administered is decided taking into consideration the Bispectral Index Monitor.~Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects.~Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters."
3221843|NCT01043939|Active Comparator|Purple Grape Juice First|After 4 week run-in period, drink 6 ounces of purple grape juice twice daily, then 4 week washout, week 12 drink 6 ounces of clear apple juice for 4 weeks twice daily
3221844|NCT01043939|Active Comparator|Apple Juice First|After 4 week run-in period, drink 6 ounces of clear apple juice twice daily, then 4 week washout, week 12 drink 6 ounces of purple grape juice for 4 weeks twice daily
3221887|NCT01043666|Experimental|tolterodine ER group|oral
3221847|NCT01043926|Experimental|Participants with Mild Hepatic Insufficiency (Part II)|Participants with mild hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part II of the study (if conducted).
3221848|NCT01043926|Experimental|Healthy Participants (Part II)|Healthy participants matched to participants with mild hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part II of the study (if conducted).
3221849|NCT01043913|Experimental|Guaraná extract 50mg q12 hours|Guaraná extract pills of 50mg q12 hours for 21 days
3221850|NCT01043913|Placebo Comparator|Placebo 1 tab q12 hours|Placebo pills 1 tab q12 hours for 21 days
3221851|NCT01043900|Placebo Comparator|Sham rTMS|Patients with stable medication regimen receiving 30 daily sessions of PLACEBO rTMS delivered to the right dorsolateral prefrontal cortex
3221852|NCT01043900|Active Comparator|Active rTMS|Patients with stable medication regimen receiving 30 daily sessions of active rTMS delivered to the right dorsolateral prefrontal cortex
3221853|NCT01043887|Experimental|Patients with Moderate Hepatic Insufficiency|Patients with moderate hepatic insufficiency (a score of 7 to 9 on the Child-Pugh's scale) received a single 10 mg dose of ridaforolimus.
3221854|NCT01043887|Experimental|Healthy Control Subjects|Healthy control subjects were matched by race, age, gender, and body mass index (BMI) to the patients with moderate hepatic insufficiency. The healthy control subjects also received a single 10 mg dose of ridaforolimus.
3221855|NCT01043874|Experimental|Nilotinib|400 mg BID
3221856|NCT01043848|Experimental|Early pudendal stimulation|Subjects in this arm will start with the intervention within 2 weeks after SCI
3221857|NCT01043848|Experimental|Late pudendal stimulation|Subjects in this arm will start with the intervention 12 weeks after SCI
3221858|NCT01043848|No Intervention|Control|Subjects in this arm will be treated according to standard therapy but will receive no pudendal stimulation
3221859|NCT01043835|Experimental|Laparoscopy-assisted gastrectomy|
3221860|NCT01043835|Active Comparator|Open gastrectomy|
3221861|NCT01043809|No Intervention|1|Randomly selected schools will not receive handwashing intervention
3221862|NCT01043809|Experimental|2|Randomly selected schools will get standard commercial school-based handwashing promotion
3221863|NCT01043809|Experimental|3|Randomly selected schools will receive standard commercial school-based handwashing promotion program, plus an added level of handwashing promotion (varies by country)
3221864|NCT01043796|Experimental|Insecticide treated nets and wall liners|
3221865|NCT01043796|Active Comparator|Insecticide treated nets alone|
3221866|NCT01043770|Experimental|Group lifestyle education|Multi-component behaviour change intervention
3221867|NCT01043770|No Intervention|Routine care|Routine care
3221868|NCT01043757|Experimental|Control|1) Control Group. Receives daily step goals via emails and has access to the study website to allow them to track their progress. Eligible for check-in incentives.
3221869|NCT01043757|Experimental|Fixed|"Receives control intervention plus are incentivized to attain their daily step goals through daily lotteries:~Each day, we will draw a two-digit number. If the first digit OR the second digit of this daily number matches the participant's lucky number, they win the small jackpot. If both digits match, they receive the large jackpot. Participants who meet their step goal for the day and who upload their data will be entered into the same lottery each day, where the small jackpot is $10 and the large jackpot is $100."
3221870|NCT01043757|Experimental|Ascending|"Receives control intervention plus incentivized to attain daily step goals through lotteries:~Each day, we will draw a two-digit number. If the first digit OR the second digit of this daily number matches the participant's lucky number, they win the small jackpot. If both digits match, they receive the large jackpot.~Participants can increase their daily jackpots by meeting their step goals. Those who meet their goal for the first day of the week and who upload their data will be entered into a lottery where the small jackpot is $4 and the large jackpot is $40; if they successfully meet their step goal on the first day of the week, the jackpots for the second day increase to $6/$60, and so on such that if they reach their goals each day, the jackpots on day seven will reach $16/$160."
3221871|NCT01043757|Experimental|Decreasing|"Receives control intervention plus incentivized to attain daily step goals through lotteries:~Daily drawing procedure same as Ascending condition; structure of incentives is different: Participants can decrease their daily jackpots by failing to meet their step goals. Those who meet their goal for the first day of the week and who upload their data will be entered into a lottery where the small jackpot is $16 and the large jackpot is $160; if they successfully meet their step goal on the first day of the week, the jackpots will remain at $16/$160; if they do not meet their goal the jackpots will decrease to $14/$140, and so on such that if they fail to reach their goals each day, the jackpots on day seven will decrease to $4/$40."
3221872|NCT01043744|Experimental|Artemether-Lumefantrine|Receive artemether-lumefantrine with direct observation of am dose on days 0, 1, and 2 of study
3221873|NCT01043744|No Intervention|No treatment|No antimalarial treatment given on day 0.
3221874|NCT01043731||Ginven indication for laparoscopic anterior resection|
3221875|NCT01043718|Experimental|More-Intensive|
3221876|NCT01043718|Active Comparator|Less-Intensive|
3221877|NCT01043705||CIED replacement with CRT and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with a CRT and the TYRX Anti-bacterial envelope, with or without lead revision.
3221878|NCT01043705||CIED replacement with ICD and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with an ICD and the TYRX Anti-bacterial envelope, with or without lead revision.
3221879|NCT01043705||CIED replacement with ICD or CRT and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with an ICD or CRT and the TYRX Anti-bacterial envelope, with or without lead revision.
3221880|NCT01043705||CIED replacement w/ CRT & no TYRX|(Retrospective Case-Control Arm) Patients who have undergone CIED replacement with a CRT and no TYRX Anti-bacterial envelope, with or without lead revision/addition.
3221881|NCT01043705||CIED replacement w/ CRT & TYRX vs. Case Match Arm|Patients who have undergone CIED replacement with a CRT and TYRX Anti-bacterial envelope, with or without lead revision/addition. Cohort is TYRX Case, Matched to Retrospective Case-Control Arm)
3221882|NCT01043692|Experimental|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
3221883|NCT01043679|Active Comparator|Seroquel|Efficacy and Safety of Seroquel
3221888|NCT01043653||Maryland Assessment of Recovery in Serious Mental Illness|Individuals with serious mental illness treated in mental health outpatient programs
3221889|NCT01043640|Experimental|Transplant Patients|Includes patients who received allogeneic stem cell transplantation following treatment plan of Campath-1H, cyclophosphamide, cyclosporine A, mycophenolate mofetil, and busulfan.
3221890|NCT01043614|Experimental|Peer group education|Small groups of female college freshmen facilitated by peer educators
3221891|NCT01043601|Experimental|Inhaled PT005 7.2 µg|
3221892|NCT01043601|Experimental|Inhaled PT005 9.6 µg|
3221893|NCT01043601|Placebo Comparator|Inhaled Placebo|
3221894|NCT01043601|Active Comparator|Formoterol Fumarate 12 µg (Foradil Aerolizer)|
3221895|NCT01043588|Other|1 : TURP|Surgery: TransUrethral Resection of the Prostate
3221896|NCT01043588|Other|2 : PVP|Surgery: Photo selective Vaporization of the Prostate
3221897|NCT01043575|Experimental|1|Rifapentine
3221898|NCT01043575|Active Comparator|2|Rifampin
3221899|NCT01043562||Pediatric ICD pts|Inclusion criteria for study participants included: 1) weight ≤60 kg, 2) new or existing ICD system, and 3) clinically necessary assessment of the defibrillation efficacy of the ICD system. Transvenous systems utilized a high-voltage ICD coil with active-fixation lead attached to the right ventricular endocardial surface, whereas non-transvenous systems depended upon a high-voltage shocking coil placed within the pericardial, subcutaneous or pleural space. To be included in the post-shock pacing portion of the study, adequate sinus and AV node function had to be present at baseline. Exclusion criteria included 1) tenuous hemodynamic status felt to warrant abbreviation of the defibrillation efficacy testing or 2) inability to induce fibrillation during defibrillation threshold testing (DFT).
3221900|NCT01043549|Active Comparator|Stimulation|Repetitive transcranial stimulation of the posterior parietal cortex
3221901|NCT01043549|Sham Comparator|Sham stimulation|
3221902|NCT01043536|Experimental|radiotherapy + temozolomide|"Radiotherapy:~dose given at PTV-g will be 70 Gy/28 fractions level 1 75 Gy/30 fractions level 2 80 Gy/32 fractions level 3~dose given at PTV-a will be 56 Gy/28 fractions level 1 60 Gy/30 fractions level 2 60.8 Gy/32 fractions level 3~Chemotherapy:~temozolomide given at the dose of 75mg/m2"
3221903|NCT01043523||Group 1|
3221904|NCT01043510|Experimental|A1, first period|
3221905|NCT01043510|Active Comparator|A2, second period|
3221906|NCT01043510|Active Comparator|B1, first period|
3221907|NCT01043510|Experimental|B2, second period|
3221908|NCT01043484|Experimental|A|Bevacizumab + Capecitabine + Radiotherapy
3221909|NCT01043484|Active Comparator|B|Capecitabine + Radiotherapy
3221910|NCT01043471|Experimental|Chewing gum|
3221911|NCT01043471|Placebo Comparator|Water|
3221912|NCT01043458|Experimental|1|ABT-126 Low Dose
3221913|NCT01043458|Experimental|2|ABT-126 High Dose
3221914|NCT01043458|Experimental|3|Placebo for ABT-126
3221915|NCT01043445|Experimental|GPR119 agonist, 2-oleoyl glycerol|2-oleoyl glycerol; 2g. and vehicle
3221916|NCT01043445|Active Comparator|Oleic acid|oleic acid; 3.2g and vehicle
3221917|NCT01043445|Placebo Comparator|Vehicle|5 ml. of glycerol and 5 ml 96% ethanol
3221918|NCT01043432||Moderate/severe TBI and history of suicidal behavior Group 1|Moderate/severe TBI and history of suicidal behavior
3221919|NCT01043432||Moderate/Severe TBI and no history of suicidal behaviorGroup|Moderate/Severe TBI and no history of suicidal behavior
3221920|NCT01043432||No TBI and a history of suicidal behavior Group 3|No TBI and a history of suicidal behavior
3221921|NCT01043432||No TBI and no history of suicidal behavior Group 4|No TBI and no history of suicidal behavior
3221922|NCT01043419|Experimental|LENOXe™ (xénon 100 % v/v)|Influence of LENOXe™ (xénon 100 % v/v) anesthesia on Sympathetic Nervous Activity and Security under LENOXe™ (xénon 100 % v/v) anesthesia
3221923|NCT01043406|Experimental|Single Arm, Device Implant|
3221924|NCT01043393|Experimental|Psoriasis involving 10-15% BSA|Patients 18 years of age or older with a confirmed diagnosis of moderate to severe plaque psoriasis having involvement of 10-15% of their body surface area.
3221925|NCT01043393|Experimental|Psoriasis involving >15% of BSA|Patients 18 years of age or older with a confirmed diagnosis of moderate to severe plaque psoriasis having involvement of >15% of their body surface area.
3221926|NCT01043380|Experimental|LZ group|
3221927|NCT01043380|Active Comparator|L group|
3221928|NCT01043367|Experimental|A|Deprexil
3221929|NCT01043367|Placebo Comparator|B|Placebo
3221930|NCT01043354|Experimental|stage-matched intervention|Transtheoretical Model-based stage-matched intervention
3221931|NCT01043354|Experimental|framing effects intervention|counseling based on prospect theory
3221932|NCT01043354|Active Comparator|attention placebo intervention|counseling about general health topics
3221933|NCT01043341|Active Comparator|behavioral|the women received a folder about HPV infection and vaccines and answered a questionaire about sexual behavior, HPV infection and vaccines.
3221934|NCT01043341|No Intervention|no intervention|the women answered a questionaire about sexual behavior, HPV infection and vaccines
3221935|NCT01043328||GROUP OSCC|"The study group is composed by patients with a condition that requires a procedure/surgery for oral squamous cell carcinoma treatment.~INTERVENTIONS: Collect blood, saliva and oral tissue."
3221936|NCT01043328||CONTROL GROUP|"Group without oral squamous cell carcinoma but with a condition that requires prosthetic procedure/surgery.~INTERVENTIONS: Collect blood, saliva and oral tissue."
3221937|NCT01043315||Hospitalized Cardiac Patient|Adults admitted to Coronary intensive unit being treated for acute cardiovascular conditions
3221938|NCT01043302||Surgery+chemotherapy|Primary mass was resected and systemic chemotherapy was performed as an adjuvant treatment
3221939|NCT01043302||Chemotherapy|Only treated with chemotherapy
3221940|NCT01043289|Experimental|Bright light therapy|Early morning white light @ 7,000 lux for 60 minutes daily (4.2 x 10^5 lux-min) for 5 weeks
3221941|NCT01043289|Placebo Comparator|Dim red light|Early morning dim red light @ 70 lux for 60 minutes daily (3.0 x 10^3 lux-min) for 5 weeks
3221942|NCT01043276|Experimental|Treatment A|
3221943|NCT01043276|Experimental|Treatment B|
3221944|NCT01043276|Experimental|Treatment C|
3221947|NCT01043263|Experimental|EN3324 (axomadol)|
3221948|NCT01043263|Placebo Comparator|Placebo|
3221949|NCT01043250||Risperidone|Receiving risperidone treatment
3221950|NCT01043250||Olanzapine|Receiving olanzapine treatment
3221951|NCT01043250||Aripiprazole|Receiving aripiprazole
3221952|NCT01043224|Experimental|Clobetasol propionate plus calcipotriol|
3221953|NCT01043185|Experimental|A|AZD3355 30 mg
3221954|NCT01043185|Experimental|B|AZD3355 90 mg
3221955|NCT01043185|Experimental|C|AZD3355 120 mg
3221956|NCT01043185|Experimental|D|AZD3355 240 mg
3221957|NCT01043185|Placebo Comparator|E|Placebo
3221958|NCT01043172|Experimental|Gemcitabine|Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
3221959|NCT01043146|Active Comparator|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
3221960|NCT01043146|Placebo Comparator|placebo|intravenous 0.9 % NaCl
3221961|NCT01043133|Experimental|Intervention group|
3221962|NCT01043133|No Intervention|Control Group|
3221963|NCT01043120|Experimental|Barusiban|
3221964|NCT01043120|Placebo Comparator|Placebo|
3221965|NCT01043107||Compuer radiaton group|
3221966|NCT01043107||control group|
3221967|NCT01043094|Experimental|Pitavastatin 4mg renal impaired|Subjects with severe renal impairment (glomerular filtration rate [GFR] of 15 to 29 mL/min/1.73 m2, inclusive) who are not being treated with hemodialysis
3221968|NCT01043094|Active Comparator|Pitavastatin 4mg healthy subjects|Healthy subjects (GFR greater than or equal to 90 mL/min/1.73 m2)
3221969|NCT01043068|Experimental|Pain control|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
3221970|NCT01043055||Breast Cancer Patients|
3221971|NCT01043055||Healthy Control Group|
3221972|NCT01043042||Hospitalized patients|patients hospitalized at VUH between 4/1/2008 to 10/31/2009
3221973|NCT01043029|Experimental|aleglitazar|
3221974|NCT01043029|Active Comparator|pioglitazone|
3221975|NCT01043016|Experimental|Photocyanine injection|Patients receive intravenous injection of Photocyanine injection from dosage of 0.1 mg/kg,0.2 mg/kg,0.33 mg/kg,0.5 mg/kg to 0.6 6mg/kg till the dose-limiting effect occur.
3221976|NCT01043003|Experimental|Arm I|Patients and caregivers undergo the Bilingual Breast Cancer Educational Intervention (BBCEI) comprising teaching sessions over 50-65 minutes about 4 specific domains (i.e., physical, psychological, social, and spiritual well being) once weekly during month 1 and also undergo evaluation sessions at months 1, 4, and 7. Patients and caregivers receive reinforcement telephone calls every other week.
3221977|NCT01043003|Active Comparator|Arm II|Patients and caregivers undergo usual care comprising evaluation sessions at months 1, 4, and 7. Patients and caregivers may undergo the 4 BBCEI teaching sessions during month 7. Patients and caregivers receive reinforcement telephone calls every other week.
3221978|NCT01042990|Active Comparator|Home Exercise Only|Participants receive education and instruction on a home exercise program which they do on their own, with intermittent encouragement from study personnel.
3221979|NCT01042990|Experimental|APA|Participants exercise in a gym setting 3x/week for six months, performing gait and balance exercises along with a progressive walking program.
3221980|NCT01042990|Experimental|APA+TM|Participants exercise in a gym setting 3x/week for six months, performing a combined program of adaptive physical activity (gait and balance training) and progressive treadmill walking.
3221981|NCT01042977|Experimental|1|dapagliflozin 10 mg tablet
3221982|NCT01042977|Placebo Comparator|2|matching placebo tablet
3221983|NCT01042951|Active Comparator|ShanChol Cholera Vaccine|
3221984|NCT01042951|Placebo Comparator|Placebo|
3221985|NCT01042938|Active Comparator|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks).
3221986|NCT01042938|Placebo Comparator|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks).
3221987|NCT01042925|Experimental|Arm 1|XL147 in combination with trastuzumab
3221988|NCT01042925|Experimental|Arm 2|XL147 in combination with trastuzumab and paclitaxel
3221989|NCT01042899|Experimental|Teen Online Problem Solving (TOPS)|Web intervention
3221990|NCT01042899|Experimental|Teen Online Problem Solving---Teen Only|Web Intervention
3221991|NCT01042899|Active Comparator|Internet Resources Comparison|Web Intervention
3221992|NCT01042886|Experimental|Family plus community focused intervention|
3221993|NCT01042886|Active Comparator|Standard Behavioral Weight Loss Maintenance Intervention|
3221994|NCT01042873|Other|Intravenous dobutamine|3 hours infusion of dobutamine
3221995|NCT01042860|Active Comparator|supplement|lutein supplement
3221996|NCT01042860|Placebo Comparator|placebo|Placebo
3221997|NCT01042834||Air pollution|The subjects will have to live in districts where important atmospheric pollution is established
3221998|NCT01042821|Active Comparator|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
3221999|NCT01042821|Active Comparator|Group 2|The flap comprised mucosa, submucosa only
3222000|NCT01042808||1|HIV-1 Infected patients treated with Isentress
3222001|NCT01042795|Experimental|Continuous Daily Dosing of Sunitinib|
3222002|NCT01042782|Experimental|RAD-MitC|RAD001 orally daily 5mg or 7.5mg or 10mg Mitomycin C 5mg/m2 every 3 weeks
3222003|NCT01042769|Experimental|Aleglitazar|
3222004|NCT01042769|Placebo Comparator|Placebo|
3222005|NCT01042743|Experimental|RAP|individuals who underwent robot-assisted surgery for primary right-sied colon cancer
3222006|NCT01042743|Active Comparator|LAP|Individuals who underwent laparoscopic surgery for primary right-side colon cancer
3222007|NCT01042730|Active Comparator|Pitavastatin 1 mg daily|
3222008|NCT01042730|Active Comparator|Pitavastatin 4 mg daily|
3222009|NCT01042717|Experimental|Plerixafor|Plerixafor 16 hours
3222010|NCT01042704|Experimental|Bendamustine, Lenalidomide and Dexamethasone|Treatment with Bendamustine in combination with Lenalidomide and Dexamethasone will be administered on an outpatient basis. Each treatment cycle will be 28 days dosed according to the Dose Escalation Schema.
3222011|NCT01042691|Experimental|Oxaliplatin|Subjects who are planning to undergo surgery for placement of HAI therapy pump will be considered for enrollment. Standard HAI therapy requires a laparotomy and placement of an intrahepatic arterial catheter that is connected to one of several commercially available subcutaneous electronic pumps. The pump is then used to deliver FUDR and Leucovorin directly to the liver, usually beginning four weeks after surgery and lasts on average for a period of six to twelve months after the study. This study will examine the addition of a one hour isolated hepatic perfusion with oxaliplatin to this standard treatment
3222012|NCT01042678|Experimental|MP0112 (0.04 mg)|Single 0.04 mg intravitreal injection of MP0112 in the study eye.
3222013|NCT01042678|Experimental|MP0112 (0.15 mg)|Single 0.15 mg intravitreal injection of MP0112 in the study eye.
3222014|NCT01042678|Experimental|MP0112 (0.4 mg)|Single 0.4 mg intravitreal injection of MP0112 in the study eye.
3222015|NCT01042678|Experimental|MP0112 (1.0 mg)|Single 1.0 mg intravitreal injection of MP0112 in the study eye.
3222016|NCT01042678|Experimental|MP0112 (2.0 mg)|Single 2.0 mg intravitreal injection of MP0112 in the study eye.
3222017|NCT01042678|Experimental|MP0112 (3.6 mg)|Single 3.6 mg intravitreal injection of MP0112 in the study eye.
3222018|NCT01042665||primary open angle glaucoma|"Patients with glaucomatous optic neuropathy defined as narrowing of the neuroretinal rim, notching, excavation, or RNFL defect; and repeatable standard automated perimetry abnormality defined as a glaucoma hemifield test (GHT) outside normal limits or pattern standard deviation (PSD) outside 95% normal limits were included."
3222019|NCT01042665||Ocular Hypertensive group|Ocular hypertension defined as an intraocular pressure ≥ 24 mm Hg and ≤ 32 mm Hg in one eye and IOP ≥ 22 mm Hg and ≤ 32 mm Hg in the fellow eye, with normal optic disc, normal visual field defined as follows mean Deviation (MD) or Pattern Standard Deviation (PSD) of p>5%, normal Glaucoma Hemifield Test (GHT) and reliable visual field exam
3222020|NCT01042652|Active Comparator|Nevirapine|
3222021|NCT01042652|Experimental|Raltegravir|
3222022|NCT01042639|Active Comparator|physical activity once a day|
3222023|NCT01042639|Experimental|physical activity twice a day|
3222024|NCT01042639|No Intervention|control|
3222025|NCT01042626|Experimental|Normocalcemic Hyperparathyroidism|
3222026|NCT01042626|Experimental|Hypercalcemic Hyperparathyroidism|
3222027|NCT01042626|Active Comparator|Healthy subjects|
3222028|NCT01042613|Other|Group A|Research participants are randomly assigned into group A (Accuvein AV300 assisted intravenous catheter insertion)
3222029|NCT01042613|Other|Group B|(standard technique of insertion of the intravenous cannula)
3222030|NCT01042600|Active Comparator|Endotracheal intubation|Endotracheal tube insertion for surfactant administration, following morphine and atropine pre-medication
3222031|NCT01042600|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
3222032|NCT01042587|Active Comparator|bright light|Bright light has been shown to entrain circadian rhythm so our treatment arm will use thirty minutes of early morning exposure to bright blue light for a four week period.
3222033|NCT01042587|Sham Comparator|red light|Low level red light is a weak entrainment stimulus of circadian rhythm. Elders in the control group will be exposed to low level red light as a placebo for thirty minutes daily for four weeks.
3222034|NCT01042561|Placebo Comparator|placebo|This group will recieve the current standard of care for infants in the NICU, recieving infant formula that provides less than 400 IU of vitamin D a day.
3222035|NCT01042561|Experimental|Vitamin d|This group will recieve standard of care infant formulas that provide less than 400 IU of vitamin D a day, in addition they will be supplemented with 400 IU of vitamin D3 daily.
3222036|NCT01042535|Experimental|Treatment (vaccine therapy, 1-methyl-d-tryptophan)|Participants receive adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine ID in weeks 1, 3, 5, and 10, and then every 3 weeks for 6 total doses. Participants also receive 1-methyl-d-tryptophan (indoximod) orally (PO) daily (QD) on days 1-21. Treatment with 1-methyl-d-tryptophan repeats every 28 days (patients with stable disease) for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3222037|NCT01042522|Experimental|Arm I (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3222038|NCT01042522|Experimental|Arm II (bleomycin sulfate, etoposide phosphate, cisplatin)|Patients receive bleomycin sulfate IV on day 1 and etoposide IV over 1 hour and cisplatin IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3222039|NCT01042509|Experimental|Alemtuzumab and rituximab|Patients with chronic GVHD after first-line therapy failure will receive Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25. THE STUDY HAVE ONLY ONE ARM.
3222040|NCT01042496|Active Comparator|Bipolar Group|Subjects underwent proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC) before and after treatment with Lamotrigine.
3222041|NCT01042496|Active Comparator|Control Group|Subjects underwent proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).
3222042|NCT01042470||control group|female patients without pelvic organ prolapse, stage 0 or I (POP-Q)
3222043|NCT01042470||pelvic organ prolapse|female patients with pelvic organ prolapse stage II or higher (POP-Q)
3222044|NCT01042457|Other|Mycophenolate mofetil|
3222045|NCT01042444|Experimental|Embolic Protection Device|The study will involve up to 20 patients to be enrolled using the GARDEX system during clinically indicated percutaneous intervention of SVG and followed through 30 days post procedure. Patients will be enrolled at up to 3 investigative sites. The study is a prospective multi center registry with sequential enrollment of qualified patients who consent to participate and meet the eligibility criteria.
3222046|NCT01042431||Ward population|Patients hospitalized in the Orthopedics B Ward in the Hillel Yaffe Medical Center that choose to participate in the study
3222047|NCT01042418|Experimental|Whole kernel breakfast|
3222048|NCT01042418|Placebo Comparator|Wheat reference breakfast|
3222049|NCT01042418|Active Comparator|Milled kernel breakfast|
3222050|NCT01042392|Active Comparator|Ramipril|"In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.~In period II (double-blind treatment, randomized): Ramipril 5 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to Ramipril 10 mg only if BP remained ≥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.~In period III (double-blind withdrawal): At visit 4, part of patients received the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
3222051|NCT01042392|Experimental|Aliskiren|"In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.~In period II (double-blind treatment, randomized): Aliskiren 150 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to aliskiren 300 mg only if BP remained ≥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.~In period III (double-blind withdrawal ): At visit 4, part of the patients received the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
3222052|NCT01042392|Placebo Comparator|Placebo to Ramipril|In period III (double-blind withdrawal ): At visit 4, part of patients from Ramipril arm received placebo to Ramipril for 1 day. The study ended at visit 5 (48 hours later than visit 4).
3222053|NCT01042392|Placebo Comparator|Placebo to Aliskiren|In period III (double-blind withdrawal ): At visit 4, part of the patients from Aliskiren arm received placebo to Aliskiren for 1 day. The study ended at visit 5 (48 hours later than visit 4).
3222054|NCT01042379|Active Comparator|Standard Therapy|Paclitaxel, Herceptin followed by Doxorubicin and Cyclophosphamide treatment depending on HR/HER-2 status.
3222055|NCT01042379|Experimental|AMG 386 with or without Trastuzumab|Arm is closed.
3222056|NCT01042379|Other|AMG 479 plus Metformin|Arm is closed.
3222057|NCT01042379|Experimental|MK-2206 with or without Trastuzumab|Arm is closed.
3222058|NCT01042379|Experimental|T-DM1 and Pertuzumab|Arm is closed.
3222059|NCT01042379|Active Comparator|Pertuzumab and Trastuzumab|Novel Control Investigational Agent
3222060|NCT01042379|Experimental|Ganetespib|Arm is closed.
3222061|NCT01042379|Other|ABT-888|Arm is closed.
3222062|NCT01042379|Other|Neratinib|Arm is closed.
3222063|NCT01042379|Experimental|PLX3397|Arm is closed.
3222064|NCT01042379|Experimental|Pembrolizumab 4 cycle|Arm is closed.
3222065|NCT01042379|Experimental|Talazoparib plus Irinotecan|Arm is closed.
3222066|NCT01042379|Experimental|Patritumab with or without Trastuzumab|Arm is closed.
3222067|NCT01042379|Experimental|Pembrolizumab 8 cycle|Novel Investigational Agent
3222068|NCT01042379|Experimental|SGN-LIV1A|Novel Investigational Agent
3222069|NCT01042379|Experimental|Durvalumab plus Olaparib|Novel Investigational Agent
3222070|NCT01042366|Experimental|Vaccine co-cultured with melanoma cells|Dendritic Cells co-cultured with melanoma cells injected as a vaccine intra/peri-nodally under ultrasound guidance
3222071|NCT01042366|Experimental|Vaccine pulsed with tumor cell lysates|Dendritic Cells pulsed with tumor cell lysates were injected as a vaccine intra/peri-nodally under ultrasound guidance
3222072|NCT01042366|Experimental|Vaccine fused with tumor cells|Dendritic Cells fused with tumor cells were injected as a vaccine intra/peri-nodally under ultrasound guidance
3222073|NCT01042353|Experimental|E test|
3222074|NCT01042353|Active Comparator|standard culture method|
3222075|NCT01042340|Experimental|Intervention with energy dense formula|Patients were randomised to intervention with the energy dense formula Calogen.
3222076|NCT01042340|No Intervention|Control group|The patients that were randomised to control group were assigned to ordinary treatment.
3222077|NCT01042327|Experimental|dialyzer comparison|"Stable chronic kidney dialysis patients, currently dialyzing on the main Royal Free hospital dialysis unit will be asked to participate in the study. It is aimed to recruit 15 patients currently dialysing using the Fresenius FX100 dialyzer, who have used Fresenius polysulphone membranes for > 3 months.~During a mid week dialysis session, dialysis adequacy will be assessed by on line clearance, and samples of both blood and dialysate taken to assess, both clearances and bio-compatibility.~Thereafter patients would be switched to dialyse using the ELISIOTM-H dialyzer, but continue with the same dialysis prescription, and after 3 months, measurements repeated"
3222078|NCT01042314|Experimental|Donepezil and BMS-708163|
3222079|NCT01042301|Experimental|Long-term type 1 diabetic patients|Long-term type 1 diabetic patients
3222080|NCT01042301|Active Comparator|control patients|control patients
3222081|NCT01042301|Experimental|diabetic and transplanted patients|diabetic and transplanted patients
3222082|NCT01042301|Experimental|subjects with high risk for diabetes|subjects with high risk for diabetes
3222083|NCT01042301|Experimental|patients with recent type 1 diabetes|patients with recent type 1 diabetes
3222084|NCT01042301|Experimental|patients with Latent Autoimmune Diabetes|patients with Latent Autoimmune Diabetes
3222085|NCT01042288|Experimental|Carboplatin/Pemetrexed/Panitumumab|Systemic Therapy
3222086|NCT01042275||TOT|transobturator sling, outside-in (TOT)
3222087|NCT01042275||TVT-O|Tension-free transobturator tape, inside-out (TVT-O)
3222088|NCT01042275||IVS|retropubic Intravaginal Sling (IVS)
3222089|NCT01042275||TVT|retropubic tension-free vaginal tape (TVT)
3222090|NCT01042275||REMEEX|Re-adjustable mechanical external sling (REMEEX)
3222091|NCT01042262|Experimental|Oxygen Group|Subjects received 100% oxygen via nasal cannula (flow =2 L/min)
3222092|NCT01042262|Placebo Comparator|Control Group|Subjects were attached to a nasal cannula without any oxygen flow.
3222093|NCT01042249|Experimental|Treatment|Treated with Pelvic Floor Muscle Training in 12 weeks
3222094|NCT01042249|No Intervention|Control|Receives standard rehabilitation after stroke
3222095|NCT01042236|Experimental|Arm 1|
3222186|NCT01041599||Hypertensive patients|Patients with essential hypertension
3222187|NCT01041599||Healthy subjects|Healthy subjects
3222188|NCT01041586|Experimental|BTVA|
3222096|NCT01042210||Mothers, preeclampsia|Mothers with preeclampsia diagnosed according to the Guidelines by the Czech Society of obstetrics and gynecology as development of hypertension after the 20th week of pregnancy (systolic blood pressure, ≥140 mmHg; and/or diastolic blood pressure, ≥90 mmHg; measured at rest on two consecutive occasions at least 24 h apart) in previously normotensive women, and the onset of proteinuria (>300 mg of urinary protein/L over 24 h).
3222097|NCT01042210||Newborns, physiological pregnancy-delivery|The newborns from the physiological pregnancies with spontaneous, uncomplicated delivery.
3222098|NCT01042210||Newborns, pregnancy with preeclampsia|Newborns from the pregnancies complicated by preeclampsia.
3222099|NCT01042210||Mothers, Physiological pregnancy-labour|The cohort of non-preeclamptic mothers with physiological, uncomplicated conception, pregnancy and delivery.
3222100|NCT01042197|Active Comparator|2|Body surface area: 12 %
3222101|NCT01042197|Active Comparator|1|Body surface area: 6 %
3222102|NCT01042197|Active Comparator|3|Body surface area: 24 %
3222103|NCT01042197|Active Comparator|4|Body surface area: 6 %
3222104|NCT01042197|Active Comparator|5|Body surface area: 12 %
3222105|NCT01042197|Active Comparator|6|Body surface area: 24 %
3222106|NCT01042197|Active Comparator|7|Body surface area: 6 %
3222107|NCT01042197|Active Comparator|8|Body surface area: 12 %
3222108|NCT01042197|Active Comparator|9|Body surface area: 24 %
3222109|NCT01042184|Experimental|Group A|Group A: Sequential therapy for 14 days D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bid
3222110|NCT01042184|Experimental|Group B: Sequential therapy for 10 days|
3222111|NCT01042184|Active Comparator|Group C: Triple therapy for 14 days|
3222112|NCT01042158|Other|Tadalafil and ambrisentan upfront therapy|This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease (PAH-SSD).
3222113|NCT01042145|Active Comparator|Prednisone|Prednisone, 2mg/kg for 3 days
3222114|NCT01042145|Active Comparator|Dexamethasone|Dexamethasone, 0.6mg/kg for one day, then placebo for 2 days
3222115|NCT01042132|Active Comparator|1) IMN and EF/IMN|"Two parts of the study are randomized;~1)initial intramedullary reaming and primary external fixation with secondary intramedullary nailing"
3222116|NCT01042132|Active Comparator|2) TR and RIA|Two parts of the study are randomized; 2)traditional reaming (TR)is compared to a new reaming device, RIA, which is a reamer connected to suction and flushing for prevention of increased intramedullary pressure
3222117|NCT01042119||Botox|patients who received intravesical injections of botulinum neurotoxin type A
3222118|NCT01042106|Experimental|DSP-8658|DSP-8658 2.5, 10, 20, 40 mg once daily
3222119|NCT01042106|Placebo Comparator|Placebo|Placebo 2.5, 10, 20, and 40 mg doses once daily
3222120|NCT01042093|Active Comparator|ROP/EPI/TOR/CLO|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
3222121|NCT01042093|Active Comparator|ROP/EPI/TOR|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml)
3222122|NCT01042093|Active Comparator|ROP/EPI/CLO|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
3222123|NCT01042093|Active Comparator|ROP/EPI|Ropivacaine 5mg/ml (49.25ml) Epinephrine 1 mg/ml (0.5 ml)
3222124|NCT01042080|Active Comparator|PSV-ET 25|Pressure support ventilation with expiratory trigger set at 25 %.
3222125|NCT01042080|Active Comparator|PSV-ET 50|Pressure support ventilation with expiratory cycling set at 50 %.
3222126|NCT01042080|Experimental|NAVA|NAVA level is adjusted to achieve similar peak inspiratory pressure levels than during PSV.
3222127|NCT01042067||Warfarin treatment group|Open label study. Patients in need of warfarin treatment (standard indications) are included in the study at the onset of warfarin treatment.
3222128|NCT01042054|Active Comparator|Epidural|Patients will follow a standard optimised recovery protocol, including epidural analgesia for the first 48 hours postoperatively.
3222129|NCT01042054|Experimental|Wound catheter|Patients will follow a standard optimised recovery protocol, but analgesia in the first 48 hours will be delivered through local anaesthetic wound catheters and additional patient-controlled analgesia, instead of epidural analgesia.
3222130|NCT01042041|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily. Beginning 2 weeks later, patients undergo chemoembolization with cisplatin, doxorubicin hydrochloride, and mitomycin C. Chemoembolization repeats once a month for up to 4 procedures in the absence of disease progression or unacceptable toxicity.
3222131|NCT01042028|Experimental|Phase II: Arm A|Regime A-ICE On progression or unacceptable toxicity patients can cross-over from regime A to regime B
3222132|NCT01042028|Active Comparator|Arm B|Arm B: CapOx On progression or unacceptable toxicity patients can cross-over from regime B to regime A.
3222133|NCT01042015|Active Comparator|Concurrent controls|These subjects would undergo standard resuscitative efforts.
3222134|NCT01042015|Experimental|Emergency preservation and resuscitation|These subjects would undergo the complete EPR protocol, including rapid induction of hypothermia, resuscitative surgery, and resuscitation with cardiopulmonary bypass.
3222135|NCT01042002|Experimental|High intensity exercise|
3222136|NCT01042002|No Intervention|Control|
3222137|NCT01041989|No Intervention|Standard health counseling at baseline|
3222138|NCT01041989|Experimental|Lifestyle counseling|Multi-domain lifestyle counseling including nutritional guidance, increased physical activity, cognitive training, increased social activity and intensive monitoring of vascular and metabolic risk factors.
3222139|NCT01041976|Experimental|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
3222189|NCT01041573|Experimental|IC51 0.5 mL|Japanese Encephalitis Vaccine 6mcg im. at day 0 and day 28
3222190|NCT01041573|Experimental|IC51 0.25 mL|Japanese Encephalitis Vaccine 3mcg im. at day 0 and day 28
3222331|NCT01040637|Experimental|TD-1211 OIC dose level 4|Ascending doses
3222140|NCT01041976|Placebo Comparator|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
3222141|NCT01041963|Active Comparator|Enalapril|
3222142|NCT01041963|Active Comparator|Enalapril plus Losartan|
3222143|NCT01041963|Placebo Comparator|Control|Drug: antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Administration of antihypertensive agents will select as follows : CCB→β-blocker→α-blocker-->hydralazine
3222144|NCT01041950|Experimental|Lumbar drainage|
3222145|NCT01041950|No Intervention|Control|
3222146|NCT01041937|Active Comparator|Cemented Tibia|Assessing the clinical outcomes of the different type of fixation
3222147|NCT01041937|Active Comparator|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
3222148|NCT01041911|Active Comparator|Euphorbia 50 mg|This arm subjects will be given 50 mg Euphorbia prostrata
3222149|NCT01041911|Active Comparator|Euphorbia 100 mg|In this arm subjects will be given 100 mg Euphorbia
3222150|NCT01041911|Active Comparator|Euphorbia 200 mg|In this arm subject will be given 200 mg Euphorbia tablets
3222151|NCT01041911|Placebo Comparator|Placebo|In this arm subjects will be given placebo tablets
3222152|NCT01041885|Experimental|INSTRUCT|INSTRUCT scaffold implantation
3222153|NCT01041872|Active Comparator|Propofol Astrazeneca|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
3222154|NCT01041872|Experimental|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
3222155|NCT01041872|Experimental|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
3222156|NCT01041872|Experimental|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
3222157|NCT01041872|Experimental|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
3222158|NCT01041872|Experimental|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
3222159|NCT01041859|Experimental|Tapentadol Extended Release (ER)|
3222160|NCT01041859|Placebo Comparator|Placebo|
3222161|NCT01041846||Decitabine|
3222162|NCT01041833|Experimental|atRA group|atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
3222163|NCT01041833|Placebo Comparator|Placebo Group|Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
3222164|NCT01041820|Experimental|Exercise group|Children will participate in a 10-week moderate to vigorous exercise program
3222165|NCT01041820|No Intervention|non-exercising|Participants will receive no intervention
3222166|NCT01041807||All participants|Participants with hypertension treated with amlodipine/losartan(Cozaar XQ)
3222167|NCT01041794||1|
3222168|NCT01041781|Experimental|Arm I|Patients receive gemcitabine hydrochloride* IV on days 1 and 8 OR pemetrexed disodium* IV on day 1. Patients also receive carboplatin IV on day 1 and oral celecoxib twice daily on days 1-21.
3222169|NCT01041781|Active Comparator|Arm II|Patients receive gemcitabine hydrochloride* OR pemetrexed disodium* and carboplatin as in arm I. Patients also receive oral placebo twice daily on days 1-21.
3222170|NCT01041768|Active Comparator|antidiabetic medical therapy|
3222171|NCT01041768|Experimental|Bariatric Surgery|
3222172|NCT01041755|Experimental|Intravenous infusion of L- Ornithine L- Aspartate|a) 20 g L-ornithine-L-aspartate
3222173|NCT01041755|Active Comparator|Lactose enemas|b) 20% Lactose enemas
3222174|NCT01041742|Experimental|OPCAB|
3222175|NCT01041729|Experimental|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
3222176|NCT01041729|Active Comparator|Control|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment"
3222177|NCT01041690|Experimental|Bevacizumab|
3222178|NCT01041677|Experimental|001|R256918 10 mg capsule twice daily
3222179|NCT01041677|Experimental|002|R256918 15 mg capsule twice daily
3222180|NCT01041677|Placebo Comparator|003|placebo placebo capsule twice daily
3222181|NCT01041638|Experimental|Treatment (Ch14.18, GM-CSF, IL-2, isotretinoin)|Patients receive sargramostim SC or IV over 2 hours on days 0-13 of courses 1, 3, and 5; monoclonal antibody Ch14.18 IV over 10 hours on days 3-6 of courses 1, 3, and 5 and on days 7-10 of courses 2 and 4; and isotretinoin PO BID on days 11-24 of course 1, on days 14-27 of courses 2, 4, and 6, and on days 10-23 of courses 3 and 5. Patients also receive aldesleukin IV continuously on days 0-3 and on days 7-10 of courses 2 and 4. Treatment repeats every 24-32 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3222182|NCT01041625|Experimental|Apremilast|Apremilast 20 mg PO administered BID over 12 weeks
3222183|NCT01041612|Active Comparator|Group A: C-SEMS, inserted above SO|-In group A, SO should be preserved without sphincterotomy, but small infundibulotomy with needle knife can be accepted for cannulation.
3222184|NCT01041612|Active Comparator|Group B: C-SEMS, inserted across SO|-In group B, small sphincterotomy (50% incision) will be done after biliary cannulation.
3222185|NCT01041599||Diabetic patients|Hypertensive and normotensive patients with type 2 diabetes mellitus
3222191|NCT01041573|Active Comparator|Havrix 720|Havrix®720 0.5 ml im. at day 0 and month 7
3222192|NCT01041573|Active Comparator|Prevnar|Prevnar 0.5 ml im. at day 0 and day 56 and month 7 or 0.5 ml im. at day 0, day 28 and day56 and month 7-13
3222193|NCT01041560||Stoke|Hemiplegia with unilateral changes in tone and muscle strength
3222194|NCT01041547||Healthy adults|healthy adults with BMI below 32, between ages 19-60 yrs, both males and females
3222195|NCT01041534||Adjustable Gastric Band (AGB) surgery|Patients who have undergone adjustable gastric band (AGB) surgery at the UWMC or other sites that have agreed to cooperate with our site (letter of cooperation and HIPAA waiver approved by our IRB) between April 1, 2007 and July 1, 2008.
3222196|NCT01041521|Experimental|Lovaza (omega three fatty acid)|"Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.~Other Names:~Lovaza was previously known as Omacor (omega-3-acid ethyl esters) capsules"
3222197|NCT01041521|No Intervention|sugar pill|"Dietary Supplement: sugar pill~2 capsules given twice daily Arms: sugar pill"
3222198|NCT01041508|Active Comparator|A|Stratum A are those patients with related stem cell donors.
3222199|NCT01041508|Active Comparator|B|Stratum B are those patients with unrelated stem cell donors.
3222200|NCT01041495|Experimental|cyclobenzaprine ER|
3222201|NCT01041495|Placebo Comparator|placebo|
3222202|NCT01041482|Experimental|sorafenib|To study the efficacy of Sorafenib as an adjuvant therapy for reducing recurrence rate in locally advanced renal-cell carcinoma (RCC) after radical nephrectomy.
3222203|NCT01041469||with abnormalities|Down syndrome patients presenting with at least one sign of auto immune abnormality
3222204|NCT01041469||without abnormality|Down syndrome patients without any sign of recognized auto immune condition
3222205|NCT01041456||complicated and/or failed BPD|
3222206|NCT01041443|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive FdCyd IV over 3 hours and THU IV over 3 hours on days 1-10. Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.
3222207|NCT01041430|Active Comparator|Day Surgery Group|discharge planned on day of surgery, inguinal hernia repair
3222208|NCT01041430|Active Comparator|Inpatient Group|overnight admission at the hospital, inguinal hernia repair
3222209|NCT01041417|Experimental|GM-CSF|Subjects will receive GM-CSF 500μg (Sargramostim (Leukine), Sanofi Aventis) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks
3222210|NCT01041417|Placebo Comparator|Placebo|Subjects will receive a saline injection (placebo) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks
3222211|NCT01041404|Experimental|Trastuzumab, Fluoropyrimidine, Cisplatin|Participants received an initial loading dose of 8 milligrams per kilogram (mg/kg) trastuzumab i.v. on Day 1 of cycle, followed by 6 mg/kg i.v. every 3 weeks until disease progression; 800 mg/m2 fluorouracil i.v. on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.
3222212|NCT01041404|Active Comparator|Fluoropyrimidine, Cisplatin|Participants received 800 milligrams per square meter (mg/m2) fluorouracil intravenous (i.v.) on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine orally (p.o.) twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.
3222213|NCT01041391||Surgical treatment for Lumbar disc herniation|Patients who had or will have surgery for Lumbar disc herniation
3222214|NCT01041391||Non-surgical treatment for Lumbar disc herniation|Patients that have chosen conservative treatment for lumbar disc herniation
3222215|NCT01041365||Healthy adolescents|Healthy adolescent African American and Caucasian females, ages 14-18
3222216|NCT01041352|Active Comparator|Endotracheal group|airway management: endotracheal tube
3222217|NCT01041352|Active Comparator|laryngeal mask group|airway management: laryngeal mask
3222218|NCT01041339||acute chest pain ST elevation|patients admitted with acute chest pain sharing ST elevation in ER-ECG and elevated troponin
3222219|NCT01041339||controls|asymptomatic patients
3222220|NCT01041326|Experimental|Leve 1 Radiation|Subjects in Group 1 will receive 39.6 Gy (at 1.8 Gy/fx) to the whole pelvis. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
3222221|NCT01041326|Experimental|Level 2 Radiation|Subjects in Group 2 will receive 45 Gy (at 1.8 Gy/fx) to the whole pelvis. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
3222222|NCT01041326|Experimental|Level 3 Radiation|Subjects in Group 3 will receive 45 Gy to the whole pelvis, followed by a boost to the prostate and periprostatic tissue, for total doses of 50.4 Gy. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
3222223|NCT01041326|Experimental|Level 4 Radiation|Subjects in Group 4 will receive 45 Gy to the whole pelvis, followed by a boost to the prostate and periprostatic tissue, for total doses of 54 Gy. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
3222224|NCT01041313|Active Comparator|Opiate Naive|Subjects who have not taken opiate medication in previous 6 weeks before surgery
3222225|NCT01041313|Active Comparator|Opiate tolerant|Subjects who have taken opiate medications for the 6 weeks before surgery
3222226|NCT01041287|Active Comparator|Nebivolol/ Metoprolol|"Subjects were randomized to nebivolol for 3 months. They crossed over to take 3 months of metoprolol succinate. The initial 5 mg daily dose of nebivolol was titrated to 10 mg daily after 2 weeks if their BP remained >125/80, and subsequently titrated to 20 mg daily after another 2 weeks if the BP remained >125/80. Similarly, the initial 50 mg daily dose of metoprolol succinate was titrated to 100 mg daily after 2 weeks if BP remained >125/80, and further increased to 200 mg after 2 weeks if BP remained >125/80."
3222227|NCT01041287|Active Comparator|Metoprolol/Nebivolol|"Subjects were randomized to metoprolol succinate for 3 months. They crossed over to take 3 months of nebivolol. The initial 5 mg daily dose of nebivolol was titrated to 10 mg daily after 2 weeks if their BP remained >125/80, and subsequently titrated to 20 mg daily after another 2 weeks if the BP remained >125/80. Similarly, the initial 50 mg daily dose of metoprolol succinate was titrated to 100 mg daily after 2 weeks if BP remained >125/80, and further increased to 200 mg after 2 weeks if BP remained >125/80."
3222228|NCT01041274|Experimental|Citalopram|Participants will receive a daily dose of citalopram, with flexible dosing as determined by clinician, for 12 months.
3222229|NCT01041274|Placebo Comparator|Placebo|Participants will receive a daily dose of placebo for 12 months.
3222230|NCT01041261|No Intervention|Control arm|Subjects will be issued control study product (Carnation Instant Breakfast, no sugar added)
3222231|NCT01041261|Experimental|Treatment arm|Medical food
3222232|NCT01041248|Experimental|Tocilizumab|
3222233|NCT01041235|Experimental|ATI-1123|
3222234|NCT01041222|Experimental|Arm 1|0.15 mg ISIS 333611 continuous intrathecal infusion over 12 hours
3222235|NCT01041222|Experimental|Arm 2|0.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours
3222236|NCT01041222|Experimental|Arm 3|1.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours
3222237|NCT01041222|Experimental|Arm 4|3.0 mg ISIS 333611 continuous intrathecal infusion over 12 hours
3222238|NCT01041222|Placebo Comparator|Placebo (phosphate buffered saline)|
3222239|NCT01041209|Experimental|BPS|BPS guidance
3222240|NCT01041209|Active Comparator|Guideline|Enforced guidelines
3222241|NCT01041196||perforated ulcer after gastric bypass|
3222242|NCT01041183|Active Comparator|group I|0.3 mg IV ramosetron
3222243|NCT01041183|Active Comparator|group II|0.1 mg oral ramosetron
3222244|NCT01041183|Active Comparator|group III|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron
3222245|NCT01041157|Experimental|1|resistance training
3222246|NCT01041144|Experimental|Lifestyle counseling|
3222247|NCT01041131||Failed and/or Complicated VBG|
3222248|NCT01041105||Gastric bypass after previous Nissen|
3222249|NCT01041092|Placebo Comparator|sugar pill|
3222250|NCT01041092|Active Comparator|raloxifene hydrochloride|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
3222251|NCT01041079||Chronic marginal ulcer after RYGB|Patients with intractable or chronic marginal ulcer disease after gastric bypass complaining of abdominal pain, GI bleeding, obstruction, perforation and penetration. Sometimes with other associated diagnosis such as narcotic and tobacco dependence, protein-calorie malnutrition, excessive weight loss, poor pouch emptying syndrome, weight regain, inadequate initial weight loss, severe dumping syndrome among others.
3222252|NCT01041066|Active Comparator|group L|0.4 mg/kg labetalol
3222253|NCT01041066|Active Comparator|group N|20 ㎍/kg nicardipine
3222254|NCT01041027|Experimental|Treatment (paclitaxel, carboplatin, radiation therapy)|"CHEMOTHERAPY (weeks 1-9, 13-21): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 3 courses during weeks 13-21.~RADIATION THERAPY (weeks 8-13 or 8-15): Patients with stage I disease undergo HDR brachytherapy once weekly for a total of 5 fractions during weeks 8-13. All other patients undergo EBRT QD 5 days a week for a total of 25 fractions during weeks 8-12 and HDR brachytherapy once weekly for a total of 3 fractions during weeks 13-15."
3222255|NCT01041014|Experimental|Professional medical interpreter|Limited English proficient Spanish-speaking patients seen in the treatment arm were provided with the services of a professionally-trained medical interpreter to facilitate communication between the patient and emergency department staff
3222256|NCT01041014|No Intervention|Control, Usual Language Services|Patients randomized to the control arm receive the services of the emergency departments' usual language services (i.e., a telephone language line or ad hoc interpreters).
3222257|NCT01041001|Experimental|Cartistem|A single dose of 500㎕/㎠ of cartilage defect
3222258|NCT01041001|Active Comparator|Microfracture treatment|
3222259|NCT01040988||Pacemaker|Patients meeting entry criteria with a pacemaker in place.
3222260|NCT01040988||ICD|Patients meeting entry criteria with an ICD in place.
3222261|NCT01040975|Experimental|Motivational Interviewing intervention|Web-based intervention targeting MD communication and Summary Report
3222262|NCT01040975|No Intervention|Control|MD receives Summary Report only
3222263|NCT01040962||Falls Risk Assessment, Diabetic Peripheral Neuropathy Patients|
3222264|NCT01040949|Active Comparator|a self help smoking cessation guide|Guia, a culturally relevant self-help smoking cessation guide in Spanish
3222265|NCT01040949|Experimental|couple-based counseling for smoking cessation plus Guia|couple-based counseling for smoking cessation plus Guis, culturally relevant self-help smoking cessation guide for Latinos
3222266|NCT01040936|Active Comparator|conventional group|patients will be treated by atorvastation 20mg/d after randomization, and continued for one year.
3222267|NCT01040936|Experimental|intensive group|patient will be loaded with 80mg atorvastatin, continued by atorvastatin 40mg/d for 30d, then receive atorvastatin 20mg/d for the following 11 months.
3222268|NCT01040923||Cardiac CT|All patients in the study will be those presenting themselves for cardiac CT angiography who meet the proper inclusion / exclusion criteria
3222269|NCT01040910|Active Comparator|cannabis smoking for IBD|patients with active disease receiving active cannabis for smoking
3222270|NCT01040910|Placebo Comparator|patients smoking non active cannabis|patients with active disease receiving cannabis from which active ingredients have been chemically removed
3222271|NCT01040897|Active Comparator|Active Control Arm|At Active Comparative Sites, Pediatric Residents will be trained to address injury prevention issues using The Injury Prevention Program (TIPP) approach
3222272|NCT01040897|Experimental|Health Communication and Obesity Prevention|Pediatric Residents will be training in effective health communication skills and given a toolkit of literacy/numeracy sensitive educational materials to use with families with children age 2 months to18 months during each well child visit
3222273|NCT01040884|Experimental|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
3222274|NCT01040871|Experimental|VR-CAP|VR-CAP arm received rituximab 375 mg/m2 IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, VELCADE 1.3 mg/m2 IV on Days 1, 4, 8, and 11, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.
3222275|NCT01040871|Active Comparator|R-CHOP|R-CHOP received rituximab 375 mg/m2IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, vincristine 1.4 mg/m2 (maximum total of 2 mg) IV on Day 1, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.Prednisone
3222276|NCT01040858|Experimental|Cognitive Strategies Training|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study). Cognitive Strategies training consisted of interactive didactic presentations, in-class discussions, and activities that introduced participants to a variety of cognitive strategies and external aids.
3222277|NCT01040858|Placebo Comparator|Placebo comparison group|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
3222278|NCT01040845|Experimental|Oral Contraceptive with Colchicine then Placebo|
3222279|NCT01040845|Placebo Comparator|Oral Contraceptive with Placebo then Colchicine|
3222280|NCT01040832|Experimental|Cetuximab plus EMD 1201081|
3222281|NCT01040832|Active Comparator|Cetuximab monotherapy|
3222282|NCT01040819|Experimental|Pioglitazone 15 mg|Patients will receive PIO 15 mg/d for two months. Serum and urine samples for 6-keto-PGF1a and 15-epi-lipoxin A4 will be taken at baseline, one month and 2 months.
3222283|NCT01040819|Experimental|Pioglitazone 30 mg/d|Patients will receive PIO 15 mg/d for one month. Then, dose will be increased to 30 mg/d for an additional month. Serum and urine samples for 6-keto-PGF1a and 15-epi-lipoxin A4 will be taken at baseline, one month and 2 months.
3222284|NCT01040806|Experimental|Health coaching|Patients with poorly controlled diabetes will receive counseling from a peer health coach -- a patient with diabetes trained in health coaching
3222285|NCT01040806|Active Comparator|Usual care|Patients will receive usual care
3222286|NCT01040793|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
3222287|NCT01040793|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
3222288|NCT01040793|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled orally from the Respimat inhaler
3222289|NCT01040780|Experimental|Icotinib|125 mg three times daily (375 mg per day) by mouth
3222290|NCT01040780|Active Comparator|Gefitinib|250 mg every 24 hours by mouth
3222291|NCT01040767|Active Comparator|Class|
3222292|NCT01040767|Active Comparator|Web|
3222293|NCT01040767|No Intervention|Control|
3222294|NCT01040754|Active Comparator|Acupuncture|
3222295|NCT01040754|No Intervention|Waitlist Control|
3222296|NCT01040741||Group 1: 6-23 months|
3222297|NCT01040741||Group 2: 2-8 years|
3222298|NCT01040741||Group 3: 9-17 years|
3222299|NCT01040741||Group 4: 18-44 years|
3222300|NCT01040741||Group 5: 45-60 years|
3222301|NCT01040741||Group: >60 years|
3222302|NCT01040728|Experimental|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
3222303|NCT01040728|Experimental|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
3222304|NCT01040728|Active Comparator|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
3222305|NCT01040728|Placebo Comparator|Placebo|Olodaterol placebo and/or Tiotropium placebo inhaled once daily
3222306|NCT01040715|Experimental|TNFa Kinoid dose 1|
3222307|NCT01040715|Experimental|TNFa Kinoid dose 2|
3222308|NCT01040715|Experimental|TNFa Kinoid dose 3|
3222309|NCT01040702|Experimental|ADHD -MPH|adults with ADHD diagnosis who receive a single dose of Methylphenidate
3222310|NCT01040702|Placebo Comparator|ADHD-placebo|adults with ADHD diagnosis who received placebo
3222311|NCT01040702|Experimental|non-ADHD-MPH|healthy adults who received a single dose of Methylphenidate
3222312|NCT01040702|Placebo Comparator|non-ADHD-placebo|healthy adults who received placebo
3222313|NCT01040689|Placebo Comparator|Placebo|olodaterol placebo and/or Tiotropium placebo inhaled once daily
3222314|NCT01040689|Experimental|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
3222315|NCT01040689|Experimental|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
3222316|NCT01040689|Active Comparator|Tiotropium 18 mcg|18mcg inhaled once daily from Handihaler
3222317|NCT01040676|No Intervention|Control Group|"Patients in this (the control group) will be eligible to receive the intervention (see Intervention Group) after 12 weeks (essentially when the trial is over)."
3222318|NCT01040676|Experimental|Intervention Group|Patients in the intervention group will receive automated telephone calls at regular intervals twice a week. The system will be programmed to call them at these intervals until contact. The ATNS system will solicit information from them in a culture specific manner, inquiring as to what foods they are eating each meal, each day, and each month. The ATNS system will then make proactive suggestions regarding low glycemic index foods, giving encouragement and feedback as appropriate.
3222319|NCT01040663|Other|Dash Diet|Subjects receive DASH diet for 4 weeks
3222320|NCT01040663|Other|Low GI Diet|Subjects will receive Low GI diet for 4 weeks
3222321|NCT01040663|Other|Western Style Diet|Subjects will receive western style diet for 4 weeks
3222322|NCT01040650||Normal Controls|Normal Controls
3222323|NCT01040650||Statin associated myopathy|subjects with statin associated myopathy
3222324|NCT01040637|Experimental|TD-1211 dose level 1|Ascending doses
3222325|NCT01040637|Experimental|TD-1211 dose level 2|Ascending doses
3222326|NCT01040637|Experimental|TD-1211 dose level 3|Ascending doses
3222327|NCT01040637|Experimental|TD-1211 dose level 4|Ascending doses
3222328|NCT01040637|Experimental|TD-1211 OIC dose level 1|Ascending doses
3222329|NCT01040637|Experimental|TD-1211 OIC dose level 2|Ascending doses
3222330|NCT01040637|Experimental|TD-1211 OIC dose leve 3|Ascending doses
3222332|NCT01040637|Experimental|TD-1211 OIC dose level 5|Ascending doses
3222333|NCT01040637|Placebo Comparator|Placebo|Ascending doses
3222334|NCT01040624|Experimental|High-risk arm A (HR-A)|< 15% risk of + lymph nodes (LN)
3222335|NCT01040624|Experimental|HR-B|> 15% risk of + LN
3222336|NCT01040611|Experimental|Music therapy|This study examined the effectiveness of music therapy on anxiety, depression and physiological responses for patients with tuberculosis.
3222337|NCT01040611|No Intervention|Placebo|No music therapy apply to this arm
3222338|NCT01040585||Central America and the Caribbean|Panama, Costa Rica, Honduras, El Salvador and Nicaragua
3222339|NCT01040572||Obesity recidivism after gastric bypass|
3222340|NCT01040559|Experimental|Idarubicin|Dose escalation: level0 = idarubicin 5mg, level1 = idarubicin 10mg, level2 = idarubicin 15mg, level3 = idarubicin 20mg, level4 = idarubicin 25mg
3222341|NCT01040546|Experimental|Individualized education|Individualized consultation of health problem, dietary intake and exercise
3222342|NCT01040546|Experimental|Grouped education|Grouped consultation of health problem, dietary intake and exercise
3222343|NCT01040533||Failed / complicated jejunoileal bypass|
3222344|NCT01040507||primary laparoscopic gastric bypass|
3222345|NCT01040494|Experimental|Aliskiren, add-on|HF patients will be randomized to receive add-on aliskiren 150 mg for 6 months
3222346|NCT01040494|Placebo Comparator|placebo, add-on|patients will be randomized to receive add-on placebo for 6 months
3222347|NCT01040481||Malabsorptive distal gastric bypass|
3222348|NCT01040468|Active Comparator|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss
3222349|NCT01040468|Active Comparator|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss
3222350|NCT01040468|Active Comparator|Intensive Lifestyle Modification|Lifestyle intervention for weight loss
3222351|NCT01040455|Experimental|lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
3222352|NCT01040455|Placebo Comparator|placebo|placebo once daily for eight weeks
3222353|NCT01040442|Experimental|vibration stimuli|
3222354|NCT01040429|Active Comparator|Clonidine capsula|
3222355|NCT01040429|Placebo Comparator|Lactose capsula|
3222356|NCT01040416||Bleeding marginal ulcer after RYGB|
3222357|NCT01040403|Experimental|olodaterol (BI 1744) low and placebo|low dose inhaled olodaterol orally once daily from the Respimat inhaler
3222358|NCT01040403|Experimental|olodaterol (BI 1744) low and low tio|low dose inhaled olodaterol and low dose inhaled tiotropium, both from the Respimat inhaler and once daily
3222359|NCT01040403|Experimental|olodaterol (BI 1744) low and medium tio|low dose inhaled olodaterol and medium dose inhaled tiotropium, both from the Respimat inhaler and once daily
3222360|NCT01040403|Experimental|olodaterol (BI 1744) low and high tio|low dose inhaled olodaterol and high dose inhaled tiotropium, both from the Respimat inhaler and once daily
3222361|NCT01040403|Experimental|olodaterol (BI 1744) high and placebo|high dose inhaled olodaterol orally once daily from the Respimat inhaler
3222362|NCT01040403|Experimental|Olodaterol (BI 1744) high and low tio|high dose inhaled olodaterol and low dose inhaled tiotropium, both from the Respimat inhaler and once daily
3222363|NCT01040403|Experimental|Olodaterol (BI 1744) high and medium tio|high dose inhaled olodaterol and medium dose inhaled tiotropium, both from the Respimat inhaler and once daily
3222364|NCT01040403|Experimental|Olodaterol (BI 1744) high and high tio|high dose inhaled olodaterol and high dose inhaled tiotropium, both from the Respimat inhaler and once daily
3222365|NCT01040377||Inadequate initial weight loss after gastric bypass|
3222366|NCT01040364||Interna hernia after primary gastric bypass|
3222367|NCT01040351|Experimental|1: Hydrosalpinx needle aspiration|After the retrieval of oocytes an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely .
3222368|NCT01040351|No Intervention|2. no aspiration|IVF-ET is done without prior aspiration of hydrosalpingeal fluid
3222369|NCT01040338||OPRM1 A118G AA genotype|Individuals with the AA genotype at the OPRM1 A118G polymorphism.
3222370|NCT01040338||OPRM1 A118G AG or GG genotype|Individuals with the */G allele at the OPRM1 A118G polymorphism
3222371|NCT01040325|Experimental|Active|358 subjects receive a two vaccination regimen with an LT patch
3222372|NCT01040325|Placebo Comparator|Placebo|358 subjects receive a two vaccination regimen with placebo patch
3222373|NCT01040312||UGT1A1 genotpyed patients|
3222374|NCT01040299|Experimental|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
3222375|NCT01040299|Sham Comparator|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
3222376|NCT01040299|Active Comparator|control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
3222377|NCT01040286|Experimental|Flurbiprofen Chip|
3222378|NCT01040286|Active Comparator|Chlorhexidine chip|
3222379|NCT01040273|Experimental|Experiment|Anesthetics intraarticular injection
3222380|NCT01040273|Placebo Comparator|Placebo|saline intraarticular injection
3222381|NCT01040260|Experimental|Contingency management|Use of tangible rewards for verified abstinence
3222382|NCT01040260|Active Comparator|Counseling plus nicotine patches|Counseling plus nicotine patches
3222383|NCT01040247|Experimental|Day 0 Embryo Transfer|Embryo transfer will be performed on the same day as oocyte aspiration and fertilization
3222384|NCT01040247|Active Comparator|Day 2,3 Embryo Transfer|Embryo Transfer will be performed 2 or 3 days after oocyte aspiration and fertilization
3222385|NCT01040234||Active pain treatment|Bilateral dual TAP block
3222386|NCT01040221|Experimental|Trichuris Suis Ova (TSO)|the eggs of intestinal helminthes (trichuris suis ova) administered as 2500 ova doses every two weeks.
3222387|NCT01040221|Placebo Comparator|Placebo|placebo dosage received every two weeks.
3222388|NCT01040208|Experimental|flibanserin 50 mg to 100 mg qhs|Patient to receive one tablet of flibanserin 50 mg and one tablet of flibanserin placebo qhs for 14 days then will receive 2 flibanserin tablets of 50 mg qhs
3222389|NCT01040208|Experimental|flibanserin 100 mg qhs|Patient to receive 2 flibanserin tablets of 50 mg qhs
3222390|NCT01040208|Experimental|placebo 2 tablets qhs|Patient to receive 2 placebo tablets of 50 mg qhs
3222391|NCT01040195|Active Comparator|Combination DMARD|All patients included in the study, will be started on Sulfasalazine 1 gm once daily and in the absence of side effects increased to 2gm daily. All patients will also receive folic acid 5 mg thrice weekly. At the end of four weeks the patients will be reassessed with baseline hemogram, SGPT, SGOT and serum Creatinine. In the absence of any contraindication, patients will be randomized into two groups Group 1 to receive Combination Disease Modifying therapy with Sulfasalazine, Methotrexate and hydroxychloroquine (HCQ). Patient will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day.
3222392|NCT01040195|Placebo Comparator|Placebo|All patients included in the study, will be started on Sulfasalazine 1 gm once daily and in the absence of side effects increased to 2gm daily All patients will also receive folic acid 5 mg twice weekly. At the end of four weeks the patients will be reassessed with baseline hemogram, SGPT, SGOT and serum Creatinine. Group 2 patients will receive Sulfasalazine and placebo for methotrexate and hydroxychloroquine.
3222393|NCT01040182||ischemic stroke patients|
3222394|NCT01040182||healthy subjects without cerebrovascular disease|
3222395|NCT01040169|Placebo Comparator|Nupro C Prophylaxis paste|Fluoride Free
3222396|NCT01040169|Experimental|ProClude Prophylaxis paste|Arginine
3222397|NCT01040156||LAmb|
3222398|NCT01040156||Cas|
3222399|NCT01040130|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
3222400|NCT01040130|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
3222401|NCT01040130|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler
3222402|NCT01040117|Experimental|Sensory-motor Integration Training|
3222403|NCT01040117|Active Comparator|Conventional neurorehabilitation|
3222404|NCT01040104||Regular wound healing, young|Regular skin repair, controlled wound healing conditions in young individuals
3222405|NCT01040104||Regular wound healing, aged|Regular skin repair, controlled wound healing conditions in aged individuals
3222406|NCT01040104||Hypertrophic scarring, young|Skin repair with and without hypertrophic scarring in young individuals
3222407|NCT01040104||Hypertrophic scarring, aged|Skin repair with and without hypertrophic scarring in aged individuals
3222408|NCT01040104||Non-diabetic, young|Skin repair in non-diabetic young individuals
3222409|NCT01040104||Non-diabetic, aged|Skin repair in non-diabetic aged individuals
3222410|NCT01040104||Diabetic, young|Skin repair in young diabetic individuals
3222411|NCT01040104||Diabetic, aged|Skin repair in aged diabetic individuals
3222412|NCT01040091|Active Comparator|HIV-Infected Participants|HIV-infected participants will receive FTC, TDF, and EFV for 60 days by prescription from their physicians. Participants will receive Truvada (FTC/TDF) and EFV for the first 30 days. After Day 30, participants may switch to the TDF/FTC/EFV co-formulation through Day 60 as directed by their physician.
3222413|NCT01040091|Active Comparator|HIV-Uninfected Participants|HIV-uninfected participants will receive Truvada (FTC/TDF) for 30 days.
3222414|NCT01040078|Experimental|7.5ug H1N1 vaccine|360 subjects to receive two doses 7.5ug H1N1 influenza vaccine on Day 0 and Day 21.
3222415|NCT01040078|Experimental|15ug H1N1 vaccine|360 subjects to receive two doses 15ug H1N1 influenza vaccine on Day 0 and Day 21.
3222416|NCT01040078|Placebo Comparator|seasonal influenza vaccine|180 subjects to receive two doses seasonal influenza vaccine on Day 0 and Day 21.
3222417|NCT01040052|Experimental|Study Group|
3222418|NCT01040039||HCV+HIV+|
3222419|NCT01040039||HCV+HIV-|
3222420|NCT01040026|Experimental|NK cell infusions|10 NK cell infusions day 3-30; Treatment with in vitro expanded haploidentical NK cells
3222421|NCT01040013|Experimental|Laparoscopy|Laparoscopic Left-Sided Colectomy
3222422|NCT01040013|Active Comparator|laparotomy|Laparotomic Left-Sided Colectomy
3222423|NCT01040000|Experimental|NPC-1C/NEO-102|
3222424|NCT01039974|Experimental|Cohorts 1-2|Cohorts 1 and 2 will complete both periods Period 1 GSK962040 single dose Period 2 Ketoconazole repeat dose (10 days), GSK962040 single dose
3222425|NCT01039961|Experimental|1 mg IV|Unit Dose Strength: 0.4 mg/mL
3222426|NCT01039961|Experimental|?mg IV|dose to be determined based on PK of first IV dose
3222427|NCT01039961|Experimental|15 mg (oral)|two 7.5 mg tablets
3222428|NCT01039948|Experimental|Phase 2: AV-299 + gefitinib|Phase 2: AV-299 (formerly SCH 900105) administered IV at RP2D (as determined by Phase 1b portion) in combination with gefitinib 250 mg/day orally.
3222429|NCT01039948|Active Comparator|Phase 2: Gefitinib|Phase 2: Gefitinib 250 mg/day, orally.
3222430|NCT01039922||1|Patients with a histologically confirmed diagnosis of a neuroendocrine tumor irrespective of primary tumor location or of a merkel cell carcinoma.
3222431|NCT01039909|Placebo Comparator|Placebo|"The Placebo treatment group will be administered 8 placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days.~During the clinic visits, the subjects will receive placebo approximately 15 minutes following the start of consumption of a standardized meal. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following the start of consumption of a standardized meal. Test material should be administered with approximately 400 mL of water at approximately the same time every dosing day. Subjects must wait at least 2 hours before consuming additional calories."
3222483|NCT01039584|Placebo Comparator|Placebo|vehicle of the test product; applied intravaginally once within 48 hours of randomization
3222484|NCT01039584|Experimental|Test Product|Butoconazole Nitrate Vaginal Cream; applied intravaginally once within 48 hours of randomization
3222485|NCT01039584|Active Comparator|Reference Product|Gynazole 1 Vaginal Cream; applied intravaginally once within 48 hours of randomization
3222432|NCT01039909|Active Comparator|2.0g SRT2104|"The 2.0g SRT2104 treatment group will be administered 8 SRT2104 0.25g capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days.~During the clinic visits, the subjects will receive SRT2104 approximately 15 minutes following the start of consumption of a standardized meal. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following the start of consumption of a standardized meal. Test material should be administered with approximately 400 mL of water at approximately the same time every dosing day. Subjects must wait at least 2 hours before consuming additional calories."
3222433|NCT01039896|Experimental|Group1|SLM0807
3222434|NCT01039896|Experimental|Group2|SLM0807 and HKB0701
3222435|NCT01039883|Experimental|1|Subjects randomized to study product sequence 1 will receive the single albaconazole 400-mg tablet during the first dosing period and the four 100-mg albaconazole capsules during the second dosing period.
3222436|NCT01039883|Experimental|2|Subjects randomized to study product sequence 2 will receive the four 100-mg albaconazole capsules during the first dosing period and the single albaconazole 400-mg tablet during the second dosing period.
3222437|NCT01039870|Experimental|PVB|Paravertebral block initiated at the later part of thoracotomy is used for postoperative pain control
3222438|NCT01039870|Active Comparator|TEA|Thoracic epidural block initiated before the surgical incision is used for postoperative pain control.
3222439|NCT01039857|Other|Structured solution focused therapy|Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy
3222440|NCT01039857|Experimental|Integrative clarification therapy|Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
3222441|NCT01039844|Experimental|Weekly LOC-paclitaxel Injection|LOC-paclitaxel IV by a 1 hour infusion on Day 1, 8, 15, 22 and 29; repeated every 42 days (6 weeks) per cycle.
3222442|NCT01039831||Patients with Parkinson's Disease|Consecutive patient sampling
3222443|NCT01039818|Active Comparator|Radiodine-200µCi|A subgroup of patients with Graves' Disease and goiter ≥48ml treated with 200µCi of ¹³¹I/ml thyroid tissue, corrected by 24h-RAIU, from a randomized controlled trial run at our institution between February 1997 and March 2000, serves as a historical control.
3222444|NCT01039818|Experimental|Radiodine-250µCi|Patients with Graves' Disease and goiter ≥48ml, prospectively assigned to receive 250 µCi of ¹³¹I/ml thyroid tissue, corrected by 24h-RAIU.
3222445|NCT01039805|Experimental|Cohort 1|Subjects randomized to either GSK962040 (50 mg) or placebo
3222446|NCT01039805|Experimental|Cohort 2|Subjects randomized to either GSK962040 (75 mg) or placebo
3222447|NCT01039792|Placebo Comparator|Placebo|Placebo
3222448|NCT01039792|Experimental|Active|Active Methyl B12
3222449|NCT01039779|Active Comparator|Lower-extremity exercise training|This training will be tailored by physical therapists for each participant. A series of exercises will be applied to increase the stability of the trunk muscles and to strengthen the leg muscles.
3222450|NCT01039779|Active Comparator|Tai chi exercise|Yang-style tai chi with 18 movements will be taught every week over the 6-month intervention period at a subject's residence by tai chi instructors
3222451|NCT01039766|Experimental|oxytocin|
3222452|NCT01039766|Placebo Comparator|Placebo|
3222453|NCT01039740|Experimental|Responders|Reponders is a patients group who showed 50% or greater decrease in the HAM-D score at 6 weeks after treating with mirtazapine
3222454|NCT01039740|Experimental|Non-responders|Non-responders is a patients group who did not show 50% or greater decrease in the HAM-D score at 6 weeks after treating with mirtazapine
3222455|NCT01039727|No Intervention|care as usual|care as usual
3222456|NCT01039727|Experimental|autosuggestive support|care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')
3222457|NCT01039727|Experimental|autosuggestive support ++|care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
3222458|NCT01039714||Total Thyroidectomy|
3222459|NCT01039701|Experimental|1|AZD1446 60mg once daily + donepezil 10mg
3222460|NCT01039701|Experimental|2|AZD1446 60mg three times daily + donepezil 10mg
3222461|NCT01039701|Experimental|3|AZD1446 30mg three times daily + donepezil 10mg
3222462|NCT01039701|Placebo Comparator|4|placebo + donepezil 10mg
3222463|NCT01039688|Experimental|5 mg BID CP-690,550|
3222464|NCT01039688|Experimental|10 mg BID CP-690,550|
3222465|NCT01039688|Active Comparator|methotrexate|
3222466|NCT01039675|Experimental|GSK573719/GW642444|
3222467|NCT01039675|Placebo Comparator|Placebo|
3222468|NCT01039662|Experimental|Oolong tea containing L-arabinose and indigestible dextrin|
3222469|NCT01039662|Placebo Comparator|Oolong tea|
3222470|NCT01039649||Lung Radiation|Patients with tumors in the lung that require radiation therapy
3222471|NCT01039636|Experimental|FBS0701 - 5 escalating doses|5 escalating doses of FBS0701 in 5 cohorts of 4 patients each.
3222472|NCT01039610|Experimental|Part A|GSK945237 2400mg single dose
3222473|NCT01039610|Experimental|Part B Cohort 1|GSK945237 400 mg QD, 7 Days 4 subjects GSK945237:2 subjects Placebo
3222474|NCT01039610|Experimental|Part B Cohort 2|GSK945237 400 mg QD, 14 Days 4 subjects GSK945237:2 subjects Placebo
3222475|NCT01039610|Experimental|Part B Cohort 3|GSK945237 400 mg BID, 14 Days 4 subjects GSK945237:2 subjects Placebo
3222476|NCT01039610|Experimental|Part B Cohort 4|GSK945237 800 mg BID, 14 Days 9 subjects GSK945237:3 subjects Placebo
3222477|NCT01039610|Experimental|Part B Cohort 5|GSK945237 1200 mg BID, 14 Days 9 subjects GSK945237:3 subjects Placebo
3222478|NCT01039610|Experimental|Part B Cohort 6|GS945237 1600 mg QD, 14 Days 9 subjects GSK945237:3 subjects Placebo
3222479|NCT01039610|Active Comparator|Part C|Linezolid 600 mg BID, 14 Days 9 subjects Linezolid:3 subjects Placebo
3222480|NCT01039610|Active Comparator|Part D|"2 period crossover Period 1: Placebo 1 day; GSK945237 dose to be determined, 5 Days Period 2: Placebo 5 days; moxifloxacin 400 mg single dose~16 subjects"
3222481|NCT01039597|Experimental|Active study drug|ORE1001 300 mg oral capsules
3222482|NCT01039597|Placebo Comparator|Placebo control|300 mg oral capsules containing placebo material
3222486|NCT01039558|Active Comparator|lansoprazole + ecabet sodium|
3222487|NCT01039558|Placebo Comparator|lansoprazole + placebo|
3222488|NCT01039545|Active Comparator|antibiotic|Norfloxacin for three days, followed by fosfomycin on day 4 if deemed necessary
3222489|NCT01039545|Experimental|symptomatic|Diclofenac retard for three days, followed by fosfomycin on day 4 if deemed necessary
3222490|NCT01039532||Basal Bolus regimen|Basal Bolus regimen
3222491|NCT01039532||Biphasic human insulin|Biphasic human insulin
3222492|NCT01039519|Experimental|ganetespib 200 mg/m^2|Ganetespib (STA-9090) 200 mg/m^2 intravenous infusion once weekly for 3 consecutive weeks followed by one week dose free interval (3 weeks on and 1 week off represent a treatment cycle). Treatment continues until disease progression or unacceptable toxicity.
3222493|NCT01039506||UGT1A1 genotpyed patients|
3222494|NCT01039493||Patients|
3222495|NCT01039493||Providers|
3222496|NCT01039480||dual therapy (ASS/CLO)|patients with a prescription for dual antiplatelet therapy with aspirin AND clopidogrel
3222497|NCT01039480||clopidogrel users (CLO)|patients with a prescription for clopidogrel
3222498|NCT01039480||aspirin users (ASP)|patients with a prescription for aspirin
3222499|NCT01039467|Active Comparator|Search AV+|Search AV+ used in dual chamber pacemaker
3222500|NCT01039467|Active Comparator|MVP|Managed Ventricular Pacing (MVP) used in dual chamber pacemaker
3222501|NCT01039454|Placebo Comparator|Placebo|2 way cross over.
3222502|NCT01039454|Active Comparator|Active|2 Way cross over
3222503|NCT01039441|Placebo Comparator|instillation of normal saline 50ml under the diaphragm|
3222504|NCT01039441|Experimental|the instillation of 0.5% bupivacaine under the diaphragm|
3222505|NCT01039441|Experimental|CO2 removal by means of a pulmonary recruitment maneuver|
3222506|NCT01039441|Experimental|the instillation of bupivacaine + CO2 removal by maneuver|
3222507|NCT01039428|Experimental|HS219|
3222508|NCT01039428|Placebo Comparator|Placebo|
3222509|NCT01039402||1|Adults ≥ 50 years old
3222510|NCT01039389|Experimental|Collateral promotion; PCI after 6 months|
3222511|NCT01039389|Experimental|Collateral promotion; PCI at baseline|
3222512|NCT01039376|Experimental|ARM A: Ofatumumab|Ofatumumab Treatment: 300 mg IV Week 1 followed by 1000 mg IV Week 2 1000 mg IV (a dose every 8 weeks for up to 2 years following the first 1000 mg dose)
3222513|NCT01039376|Other|ARM B: Observation and assessments as per Arm A|Disease status assessments to determine subject response or progression will be performed approximately every 8 weeks for up to 2 years for both arms according to IWCLL criteria
3222514|NCT01039363|Experimental|Vorinostat|Vorinostat combined with salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat maintenance
3222515|NCT01039337|Active Comparator|Hip school|This group will receive hip school during the intervention period of 6 weeks.
3222516|NCT01039337|Active Comparator|Hip School and Manual Treatment|This group receives both hip school and manual treatment during the 6 weeks.
3222517|NCT01039337|Active Comparator|Minimal control intervention|An information leaflet including exercises.
3222518|NCT01039324|Experimental|Intermediate Intervention (arm #1)|Care transition reports sent to primary care clinics, care transition letters sent to patients, release of information requests about care transitions sent on behalf of primary care clinics.
3222519|NCT01039324|Experimental|Full Intervention (arm #2)|E-mail notices sent to care managers about care transitions plus care transition reports sent to primary care clinics, care transition reports sent to patients, release of information requests about care transitions sent on behalf of primary care clinics.
3222520|NCT01039324|Experimental|Control (arm #3)|"Subjects assigned to the control group will receive usual care which is the standard of care coordination currently existent between patients, providers and care managers."
3222521|NCT01039311||Optical Coherence Tomography|Examine OCT images and compare them to conventional biopsies in same subject.
3222522|NCT01039298|Active Comparator|A|"All subjects in this study will receive surgery to treat their oral lesions. The margins (or boundaries) of the tissue to be removed during surgery will be defined by 2 different procedures (or study arms) in the operating room.~The Control arm. Surgical boundaries for oral lesions will be defined under regular white light."
3222523|NCT01039298|Experimental|B|"All subjects in this study will receive surgery to treat their oral lesions. The margins (or boundaries) of the tissue to be removed during surgery will be defined by 2 different procedures (or study arms) in the operating room.~The FV arm (experimental arm). Surgical boundaries for oral lesions will be defined by FV."
3222524|NCT01039285|Experimental|Surfactant instillation|2.5 ml/kg of Surfactant will be instilled in the trachea
3222525|NCT01039285|Placebo Comparator|Placebo instillation|2.5 ml/kg of Air will be instilled in the trachea
3222526|NCT01039272||oral cancer|patients with oral squamous cell carcinoma
3222527|NCT01039272||control group|healthy patients without any oral pathology
3222528|NCT01039259||subjects with lip piercing|
3222529|NCT01039259||subjects with tongue piercing|
3222530|NCT01039233|Experimental|Bicalutamide 50 mg Tablet|
3222531|NCT01039233|Active Comparator|Casodex® 50 mg Tablet|
3222532|NCT01039207|Experimental|Treatment (rilotumumab)|Patients receive rilotumumab IV over 30-60 minutes on days 1 and 14. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Tumor tissue and blood samples may be collected periodically for further laboratory analysis.
3222533|NCT01039194|Active Comparator|galantamine 8 mg (ER)|
3222534|NCT01039194|Active Comparator|galantamine 16 mg (ER)|
3222535|NCT01039194|Active Comparator|BMS-708163|
3222536|NCT01039168|Active Comparator|Workplace dialogue|Clinical examination and dialogue with supervisor to find solutions to reduce job-person mismatch and facilitate return to work
3222537|NCT01039168|Sham Comparator|Care as usual|No intervention besides of the care as usual being available for the patient
3222538|NCT01039155|Experimental|Treatment (azacitidine, oxaliplatin)|Patients receive azacitidine IV over 15-30 minutes on days 1-5 and oxaliplatin IV over 2 hours on days 2-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3222539|NCT01039142|Active Comparator|25 mg acitretin|capsule acitretin 25 mg/day will be administered to each patient for a period of 12 weeks
3222540|NCT01039142|Active Comparator|35 mg acitretin|capsule acitretin 35 mg/day will be administered to each patient for a period of 12 weeks
3222541|NCT01039142|Active Comparator|50 mg acitretin|capsule acitretin 50 mg/day will be administered to each patient for a period of 12 weeks
3222542|NCT01039129|Experimental|Endoscopic Cholecystectomy|20 patients in this arm will undergo cholecystectomy, or removal of the gallbladder, through this experimental approach. This arm will compose of patients with symptomatic gallstones (cholelithiasis).
3222543|NCT01039129|Experimental|Endoscopic Appendectomy|Participants will with chronic appendicitis will undergo appendectomy through this experimental approach.
3222544|NCT01039129|Experimental|Endoscopic Peritoneoscopy|20 patients in this arm will undergo diagnostic peritoneoscopy with or without biopsy for any indication.
3222545|NCT01039116|Experimental|Level of intervention intensity|"High Intensity: Behavioral Experimental:Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.~Active Comparator: Low-intensity Participants were provided with educational materials 4 times yearly."
3222546|NCT01039103|Experimental|Nanocort|PEG-liposomal prednisolone sodium phosphate (Nanocort) 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
3222547|NCT01039103|Active Comparator|Solu-Medrol|Methylprednisolone (Solu-Medrol) 1 g, IV, infusion over 2 hours on days 1, 2 and 3
3222548|NCT01039090|Active Comparator|Per os dopaminergic treatment|
3222549|NCT01039090|Experimental|Continuous Apomorphine infusion|
3222550|NCT01039077|Active Comparator|Single incision laparoscopic gastric banding|Patients in this group will undergo laparoscopic gastric banding through a single periumbilical incision.
3222551|NCT01039077|Active Comparator|Five port laparoscopic gastric banding|Patients in this group will undergo conventional laparoscopic gastric banding using 5 small incisions.
3222552|NCT01039051|Experimental|Diet and Lifestyle counseling|increasing consumption of vegetables and fruits; maintaining energy balance through reducing excessive energy from meat, eggs and brown sugar and increasing energy expenditure from appropriate physical activity, such as doing maternal keep-fit exercises.
3222553|NCT01039025|Experimental|TMC|Topotecan, Melphalan, and Cyclophosphamide
3222554|NCT01039012|Other|Tai Chi plus Standard Care|
3222555|NCT01039012|Other|Standard Care|
3222556|NCT01038999||A HIV1-infected naive patients|
3222557|NCT01038999||B HIV1-infected patients|in 1st line of ARV therapy for at least 12 months
3222558|NCT01038999||C= control Non infected HIV volunters|
3222559|NCT01038986||CureXcell treated|Patients with chronic and/or refractory wounds for at least 4 weeks with no improvement that have been referred by their physician for CureXcell treatment
3222560|NCT01038960|Experimental|Exercise training|training
3222561|NCT01038960|No Intervention|Not training|No organized training
3222562|NCT01038947|Experimental|Uricase-PEG 20|Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner. The study will enroll both single dose cohorts and multi-dose cohorts.
3222563|NCT01038934|Experimental|buccal cytobrhsh|healthy young
3222564|NCT01038921|Experimental|Melatonin|Melatonin 8mg one hour before bedtime for 10 weeks
3222565|NCT01038921|Placebo Comparator|Placebo|Placebo administered 1 hour before bedtime for 10 weeks
3222566|NCT01038908|Active Comparator|1|Each patient will receive an injection of technetium-99m sulfur colloid directed subareolar or around the tumor. The material will be prepared as per manufacturer's specifications. The dose will be 20mBq given the same day of 80mBq given the day before. The Nuclear Medicine Department at St Paul's Hospital will perform the injection as per normal sentinel lymph node mapping protocol.
3222567|NCT01038908|Active Comparator|2|Each patient will receive an injection of technetium-99m sulfur colloid directed subareolar or around the tumor. The material will be prepared as per manufacturer's specifications. The dose will be 20mBq given the same day of 80mBq given the day before. The Nuclear Medicine Department at St Paul's Hospital will perform the injection as per normal sentinel lymph node mapping protocol.
3222568|NCT01038895|Active Comparator|Ramipril|10 mg/daily
3222569|NCT01038895|Experimental|Aliskiren|300 mg/ daily
3222570|NCT01038882|Active Comparator|Midazolam|The patients of this arma receives midazolam before the flexible bronchoscopy to maintain conscious sedation
3222571|NCT01038882|Placebo Comparator|Physiological serum|
3222572|NCT01038869|Experimental|Azelaic acid 15% (Finacea)|Open label pilot study, Topical gel to be appiled twice daily for 16 weeks
3222573|NCT01038856|Experimental|+JAK2V61F mutation|Patients with MPN diagnoses and polycythemia vera who also have a confirmed JAK2V617F mutation
3222574|NCT01038843|Experimental|VA106483 1mg|
3222575|NCT01038843|Experimental|VA106483 2mg|
3222576|NCT01038843|Experimental|VA106483 4mg|
3222577|NCT01038843|Placebo Comparator|Sugar pill|
3222578|NCT01038817|Active Comparator|fluoride varnish|"Duraphat:~Application of fluoride varnish on one side of the mandibles (left or right, randomly selected)"
3222579|NCT01038817|No Intervention|control|no application on the other side
3222580|NCT01038804|Experimental|A. YM155 plus docetaxel|
3222581|NCT01038804|Active Comparator|B. docetaxel alone|
3222582|NCT01038791|Active Comparator|usual ventilation|application of usual mechanical ventilation without humidification system
3222583|NCT01038791|Experimental|heated humidifier|mechanical ventilation with heated humidifier
3222584|NCT01038791|Experimental|heat and moisture exchanger|mechanical ventilation with heat and moisture exchanger
3222585|NCT01038778|Experimental|Treatment (entinostat, aldesleukin)|"Patients receive entinostat PO every 2 weeks beginning on day -14 and high-dose aldesleukin IV every 8 hours on days 1-5 and 15-19. Courses repeat every 84 days* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients with evidence of tumor shrinkage may receive up to 3 courses of high-dose aldesleukin therapy. Patients with stable disease by RECIST version 1.0 criteria, but without evidence of tumor shrinkage after two courses will receive only entinostat until disease progression is documented."
3222685|NCT01038141|Active Comparator|Milligan Morgan|
3222586|NCT01038765|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
3222587|NCT01038765|No Intervention|Waiting list control group|3-month waiting list group
3222588|NCT01038752|Experimental|Suramin|This group will receive the combination of non-cytotoxic suramin with docetaxel and carboplatin.
3222589|NCT01038752|Placebo Comparator|Standard of care|This group will receive placebo with docetaxel and carboplatin.
3222590|NCT01038739|Experimental|A|
3222591|NCT01038739|Experimental|B|
3222592|NCT01038739|Placebo Comparator|C|
3222593|NCT01038726|Active Comparator|Exercise Training|
3222594|NCT01038726|Active Comparator|Combined Cognitive/Exercise Training|
3222595|NCT01038726|Active Comparator|Cognitive Training|
3222596|NCT01038726|Active Comparator|Combined Low Intensity Training|
3222597|NCT01038713|Experimental|Resectable; plastic stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive a plastic biliary stent to relieve their biliary obstruction.
3222598|NCT01038713|Experimental|Resectable; uncovered metal stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive an uncovered metal biliary stent to relieve their biliary obstruction.
3222599|NCT01038713|Experimental|Resectable; fully covered metal stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive a fully-covered metal biliary stent to relieve their biliary obstruction.
3222600|NCT01038713|Experimental|Unresectable; uncovered metal stent|Patients determined to have surgically non-resectable malignancy presenting with malignant biliary obstruction randomized to receive an uncovered metal biliary stent to relieve their biliary obstruction.
3222601|NCT01038713|Experimental|Unresectable; fully covered metal stent|Patients determined to have surgically non-resectable malignancy presenting with malignant biliary obstruction randomized to receive a fully-covered metal biliary stent to relieve their biliary obstruction.
3222602|NCT01038687|Experimental|A3309 15 mg|Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.
3222603|NCT01038687|Experimental|A3309 20 mg|Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.
3222604|NCT01038687|Placebo Comparator|Placebo|Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.
3222605|NCT01038674|Experimental|Anti-IL-20|
3222606|NCT01038674|Placebo Comparator|Placebo|
3222607|NCT01038661|Experimental|First line treatment: docetaxel 75 mg/m² + cisplatin 75 mg/m²|Docetaxel 75 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
3222608|NCT01038661|Experimental|First line treatment:: docetaxel 60 mg/m² + cisplatin 75 mg/m²|Docetaxel 60 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
3222609|NCT01038661|Experimental|Maintenance treatment: docetaxel (60 mg/m2)|Docetaxel 60 mg/m² on day 1, repeated every 3 weeks until progressive disease or up to 6 cycles
3222610|NCT01038661|Active Comparator|Maintenance treatment: best supportive care (BSC)|BSC until progressive disease
3222611|NCT01038648|Placebo Comparator|1|Advice life style at baseline only
3222612|NCT01038648|Active Comparator|sitagliptin arm : 2|"100mg/day sitagliptin~advice on life style modification at baseline only"
3222613|NCT01038635|Experimental|5-Azacytidine + Lenalidomide|5-Azacytidine 75 mg/m^2 by vein daily x 5 days on days 1 to 5. Lenalidomide starting dose 10 mg orally daily x 5 days on days 6 to 10.
3222614|NCT01038622|Active Comparator|L-arginine|5-day L-arginine treatment (200 mg/kg)
3222615|NCT01038622|Placebo Comparator|placebo|5-day placebo treatment
3222616|NCT01038609|Placebo Comparator|Placebo|1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release) plus 1 placebo capsule (for morphine extended release), administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
3222617|NCT01038609|Active Comparator|Acetaminophen|1 dose of 1 placebo capsule (for morphine extended release) plus 1 acetaminophen tablet, administered once every 12 hours, and 1 dose of 1 acetaminophen tablet, administered once every 6 hours (for a total of 8 doses).
3222618|NCT01038609|Active Comparator|Morphine Extended Release|1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release) plus 1 morphine extended release capsule, administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
3222619|NCT01038609|Active Comparator|Morphine Extended Release / Acetaminophen|1 dose of 1 morphine extended release capsule plus 1 acetaminophen tablet, administered once every 12 hours, and 1 dose of 1 acetaminophen tablet, administered once every 6 hours (for a total of 8 doses).
3222620|NCT01038609|Experimental|Hydrocodone/Acetaminophen Extended Release|1 dose of 1 hydrocodone/acetaminophen extended release tablet plus 1 placebo capsule (for morphine extended release), administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
3222621|NCT01038596||osteoarthritic donors|pelvic compartment advanced-stage (Kellgren and Lawrence grade 3 or 4) osteoarthritic donors
3222622|NCT01038596||healthy donors|age-matched healthy donors
3222623|NCT01038583||Aspirin|100 mg enteric-coated aspirin
3222624|NCT01038583||Placebo|Placebo
3222625|NCT01038570|Experimental|Oxytocin|
3222626|NCT01038570|Placebo Comparator|Physiological serum|
3222627|NCT01038557|Active Comparator|Refrigerated RBCs 0-14 days old|
3222628|NCT01038557|Active Comparator|Regrigerated RBCs 15-42 days old|
3222629|NCT01038557|Experimental|Frozen RBCs|
3222630|NCT01038531|Active Comparator|low-tidal-volume ventilation|Goal tidal volume is 6 cc/kg ideal body weight.
3222631|NCT01038531|Experimental|APRV|APRV allows spontaneous breathing.
3222632|NCT01038518||Health2010|Cross-sectional general population study
3222633|NCT01038505|Active Comparator|Tacrolimus and Myfortic|Immunosuppressive
3222634|NCT01038505|Active Comparator|Tacrolimus and Sirolimus|Immunosuppressive
3222686|NCT01038141|Active Comparator|Recto Anal Repair|
3222635|NCT01038492|Experimental|p16 Methylation in Sputum Testing|"Patients tested for smoking-related changes in their breathing~shown a presentation on development of lung cancer~complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic detail~given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing~a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits~patients are called again at three months and asked about any changes in their attitudes or smoking habits"
3222636|NCT01038479|Active Comparator|Childsmile programme with xylitol|Childsmile program with maternal xylitol consumption;
3222637|NCT01038479|Placebo Comparator|Childsmile programme only|Childsmile programme
3222638|NCT01038466||CHAT trial participants|CHAT trial participants whose data was used in the final data analysis for the CHAT study
3222639|NCT01038453|Active Comparator|Cholecalciferol (Vitamin D3) 35 µg|Dietary Supplement: Cholecalciferol (Vitamin D3) 35 µg per day
3222640|NCT01038453|Active Comparator|Cholecalciferol (Vitamin D3) 70 µg|Dietary supplement: Cholecalciferol (Vitamin D3) 70 µg per day
3222641|NCT01038453|Placebo Comparator|placebo|
3222642|NCT01038440|Placebo Comparator|Control|
3222643|NCT01038440|Active Comparator|EPA 0.5 g/d|
3222644|NCT01038440|Active Comparator|EPA 1.5 g/d|
3222645|NCT01038440|Active Comparator|EPA 3.0 g/d|
3222646|NCT01038440|Experimental|SDA 0.5 g/d|
3222647|NCT01038440|Experimental|SDA 1.5 g/d|
3222648|NCT01038440|Experimental|SDA 3.0 g/d|
3222649|NCT01038440|Experimental|SDA 6.0 g/d|
3222650|NCT01038427|Experimental|Mometasone Furoate Nasal Spray (Lek d.d.)|
3222651|NCT01038427|Active Comparator|Nasonex® Nasal Spray|
3222652|NCT01038427|Placebo Comparator|Placebo Nasal Spray|
3222653|NCT01038414|Placebo Comparator|Brief-Duration Counseling|3-Month Duration
3222654|NCT01038414|Active Comparator|Moderate Duration Counseling|6-Month Duration
3222655|NCT01038414|Active Comparator|Extended Duration Counseling|12-Month Duration
3222656|NCT01038401|Other|HIV-1-infected patients on effective HAART|
3222657|NCT01038401|Other|Non Infected HIV Volunteers|
3222658|NCT01038388|Experimental|Bortezomib, lenalidomide, dexamethasone, vorinostat|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11; lenalidomide by mouth once a day on days 1-14; dexamethasone by mouth once a day on days 1, 2, 4, 5, 8, 9, 11, and 12; and vorinostat by mouth on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~After 8 courses, patients may receive maintenance therapy comprising lenalidomide by mouth once a day on days 1-21, dexamethasone by mouth once a day on days 1, 2, 8, and 9, and bortezomib IV over 3-5 seconds or subcutaneously on days 1 and 8. Courses may repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3222659|NCT01038375||Adherence counseling|
3222660|NCT01038375||Usual care|
3222661|NCT01038362|Active Comparator|Almonds|National Cholesterol Education Program Step I diet plus almonds for 6 weeks
3222662|NCT01038362|Placebo Comparator|No Almonds|National Cholesterol Education Program Step 1 diet without almonds for 6 weeks
3222663|NCT01038336|Experimental|Multimedia HLPP|Multimedia Hearing Loss Prevention Program (HLPP)
3222664|NCT01038336|Active Comparator|Hearing Conservation Brochure|Hearing Conservation Brochure (HCB)
3222665|NCT01038336|No Intervention|Standard-of-Care|Standard-of-Care (SoC)
3222666|NCT01038323|Experimental|CBT and milnacipran|Subjects randomized to this group will receive a combination of eight telephone sessions of Cognitive Behavior Therapy (CBT) and a 21-week regimen of milnacipran.
3222667|NCT01038323|Placebo Comparator|CBT and placebo|Subjects randomized to this arm will receive a series of eight telephone sessions of Cognitive Behavioral Therapy (CBT) along with a 21-week regimen of a placebo(sugar pill)medication.
3222668|NCT01038323|Active Comparator|Educational with milnacipran|Subjects randomized to this group will receive a series of eight educational phone calls regarding fibromyalgia along with a 21-week regimen of milnacipran.
3222669|NCT01038297|Experimental|EXC 001|
3222670|NCT01038297|Placebo Comparator|Placebo|
3222671|NCT01038284|Sham Comparator|Control|
3222672|NCT01038284|Active Comparator|Patient education|
3222673|NCT01038271|Active Comparator|Standard Palliative Care Group|
3222674|NCT01038271|Active Comparator|Integrated Palliative Care Group|
3222675|NCT01038258|Other|No arms|No arms
3222676|NCT01038219||fever measurements|"1000 estimates and measurements of children's body temperatures will be carried out by parents and nurses in children's emergency and pediatric units as part of the routine work. The estimates and the measurements will be carried out on children who are referred to an emergency unit and who are hospitalized in the pediatric department-- both boys and girls of all ages. A patient might be measured several times.~The measurements will be gathered in the course of one year. Before the routine taking of temperature, the accompanying parent will be asked to estimate the patient's temperature by feeling his forehead (with the back of the hand, the palm, lips). The parent will record his evaluation (without telling the nurse). Afterwards the nurse will do a similar evaluation (excepting the lip test), record it, and then the routine temperature measurement will be taken."
3222677|NCT01038206|Experimental|Family Function Intervention|Familias Unidas Intervention Program
3222678|NCT01038206|No Intervention|Treatment as Usual|The Public School system mandates that all high school students receive at least 5 lessons (55 minutes each) per year of HIV prevention.
3222679|NCT01038193||aSAH patients|Cognitive assessment
3222680|NCT01038180||pacemaker group|
3222681|NCT01038167|Experimental|Part A|Part A will be administered in two periods, separated by a washout. In Period 1, subjects will receive cyclosporine alone. In Period 2, subjects will receive cyclosporine in combination with telaprevir.
3222682|NCT01038167|Experimental|Part B|Part B will be administered in two periods, separated by a washout. In Period 1, subjects will receive tacrolimus alone. In Period 2, subjects will receive tacrolimus in combination with telaprevir.
3222683|NCT01038154|No Intervention|control|Not Receive pravastatin
3222684|NCT01038154|Experimental|Pravastatin|
3222687|NCT01038128|Experimental|Memantine|Memantine, 10-40 mg daily
3222688|NCT01038115|Active Comparator|Cryoballoon|
3222689|NCT01038115|Active Comparator|Radiofrequency|
3222690|NCT01038115|Active Comparator|Cryoballoon + Radiofrequency together|
3222691|NCT01038102|Active Comparator|PUFA diet|Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%)
3222692|NCT01038102|Active Comparator|SFA diet|Diet high in saturated fat (15 E%)
3222693|NCT01038089|Experimental|resveratrol|Resveratrol
3222694|NCT01038076|Experimental|MedCHEC Tablet Computer & Adherence Care|Patients assigned to the intervention answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates provider and patient reports. Patients may be referred to an Adherence Care Manager on the basis of the reports. In addition, patients will receive standard information about adherence.
3222695|NCT01038076|No Intervention|Adherence Information Only|Patients assigned to the active comparator arm will receive standard information about adherence.
3222696|NCT01038063|Experimental|Artemether-lumefantrine|Children in this study arm will be treated with artemether-lumefantrine during a three year follow-up period each time a child develops uncomplicated malaria.
3222697|NCT01038063|Active Comparator|Dihydroartemisinin-piperaquine|Children in this study arm will be treated with dihydroartemisinin-piperaquine during a three year follow-up period each time a child develops uncomplicated malaria.
3222698|NCT01038024|Experimental|Antioxidant Supplements|
3222699|NCT01037998|Active Comparator|A|Iressa 250 mg daily treatment plus UFUR twice daily treatment
3222700|NCT01037998|No Intervention|B|Gefitinib 250 mg daily treatment
3222701|NCT01037985|Experimental|EXC 001|
3222702|NCT01037985|Placebo Comparator|Placebo|
3222703|NCT01037972||Whole body vibration|
3222704|NCT01037972||Conventional physiotherapy|
3222705|NCT01037959|Active Comparator|Norfloxacin|Patients with severe cirrhosis treated with norfloxacin
3222706|NCT01037959|Placebo Comparator|Placebo|Patients with severe cirrhosis treated with placebo
3222707|NCT01037946|No Intervention|Standard Care Arm|Families living with HIV, offered intervention at the end of study (24 months after recruitment)
3222708|NCT01037946|Experimental|Intervention|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
3222709|NCT01037933|Active Comparator|Humor intervention|"A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player."
3222710|NCT01037933|Active Comparator|Non-humor intervention|"A 45-minute non-humorous DVD The A to Z of Steam Railways using a portable DVD player."
3222711|NCT01037920|Experimental|Intervention|subjects in the intervention arm will complete a self-affirmation exercise prior to a physician visit
3222712|NCT01037920|Active Comparator|Control|subjects in the intervention arm will complete a sham exercise prior to a physician visit
3222713|NCT01037907|Experimental|BGC20-0134 (Pleneva TM)|Structured lipid
3222714|NCT01037907|Placebo Comparator|Placebo control|Placebo - dummy pill
3222715|NCT01037894|Experimental|Acupuncture|Acupuncture and conventional rehabilitation
3222716|NCT01037894|Active Comparator|Control|Conventional rehabilitation only
3222717|NCT01037881|Experimental|LEO 29102 0.03 mg/g cream|
3222718|NCT01037881|Experimental|LEO 29102 0.1 mg/g cream|
3222719|NCT01037881|Experimental|LEO 29102 0.3 mg/g cream|
3222720|NCT01037881|Experimental|LEO 29102 1.0 mg/g cream|
3222721|NCT01037881|Experimental|LEO 29102 2.5 mg/g cream|
3222722|NCT01037881|Placebo Comparator|LEO 29102 cream vehicle|
3222723|NCT01037881|Active Comparator|Elidel® cream (pimecrolimus) 10 mg/g|
3222724|NCT01037868|Experimental|Supportive SMS messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
3222725|NCT01037868|No Intervention|No supportive SMS text message|Patients in the non-intervention group would also receive text messages once every fortnight thanking them for participating in the study and a monthly phone call which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
3222726|NCT01037855||Group 1: 6-23 months|
3222727|NCT01037855||Group 2: 2-8 years|
3222728|NCT01037855||Group 3: 9-17 years|
3222729|NCT01037855||Group 4: 18-44 years|
3222730|NCT01037855||Group 5: 45-60 years|
3222731|NCT01037855||Group: >60 years|
3222732|NCT01037842|Active Comparator|Metformin+Mitiglinide|mitiglinide 10 mg three times a day added to metformin 500 mg three times a day
3222733|NCT01037842|Placebo Comparator|Metformin+Placebo|placebo three times a day added to metformin 500 mg three times a day
3222734|NCT01037829||Pregnancy women|Comparison of pregnancy outcomes between (Novartis) H1N1 vaccinated women and (Novartis) H1N1 unvaccinated women.
3222735|NCT01037816|Active Comparator|FS-67 patch|One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
3222736|NCT01037816|Placebo Comparator|Placebo Patch|One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
3222737|NCT01037790|Experimental|Arm 1|Metastatic breast cancer
3222738|NCT01037790|Experimental|Arm 2|Metastatic colorectal cancer that harbors the Kras or BRAF mutation
3222739|NCT01037790|Experimental|Arm 3|Advanced or metastatic esophageal and/or gastric cancer
3222740|NCT01037790|Experimental|Arm 4|Cisplatin-refractory, unresectable germ cell tumors
3222741|NCT01037790|Experimental|Arm 5|Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation , CCND2 amplification OR any other functional alteration at the G1/S checkpoint.
3222742|NCT01037777||presymptomatic carriers|
3222743|NCT01037777||non carrier relatives|
3222803|NCT01037309|Experimental|PRO044, cohort 2|Subcutaneous injection of maximally 1.5 mg/kg on day 1, 8, 15, 22 and 29.
3222744|NCT01037764|Experimental|alloHCT|alloHCT arm: For HLA-matched sibling HCT, if a patient is 55 years old or less and without co-morbidity, the patient will receive Bu-Cy conditioning therapy and be transplanted with bone marrow cells. Patients who are older than 55 years or with co-morbidity will receive Bu-Flu-ATG conditioning and be transplanted with mobilized peripheral blood hematopoietic cells. For HLA-matched unrelated donor or HLA-mismatched familial donor HCT, the patient will receive Bu-Flu-ATG conditioning and well be transplanted with mobilized peripheral blood hematopoietic cells.
3222745|NCT01037751||Interview + Questionnaires|1-on-1 interview + Questionnaires, Part 1 of Study
3222746|NCT01037751||Questionnaires|Questionnaires Only, Part 2 of Study
3222747|NCT01037738|Active Comparator|ACS - Orthokin|Autologous conditioned serum (ACS) - Orthokin containing endogenous anti-inflammatory cytokines including IL-1Ra and growth factors (IGF-1, PDGF and TGF-ß1, among others) in the liquid blood phase.
3222748|NCT01037738|Placebo Comparator|Placebo|Physiologic solution
3222749|NCT01037725|Experimental|AZD5847 oral suspension|Active
3222750|NCT01037725|Placebo Comparator|Placebo to AZD5847|Placebo
3222751|NCT01037712|Experimental|ZELITREX|ZELITREX
3222752|NCT01037712|Placebo Comparator|Placebo|placebo
3222753|NCT01037699|Active Comparator|FSH YOUNGER|
3222754|NCT01037699|Active Comparator|FSH OLDER|
3222755|NCT01037699|Experimental|FSH LH YOUNGER (Recombinant Luteotrophin alfa)|
3222756|NCT01037699|Experimental|FSH LH OLDER|
3222757|NCT01037686|Other|PD, DBS, healthy controls|Patients with idiopathic PD before or after DBS surgery (during on or off-stimulation) and healthy controls.
3222758|NCT01037673|Experimental|PT progressive exercises|A progressive program of movement and strength exercises for the rotator cuff and scapular muscles combined with mobilisation of the joint capsule when needed
3222759|NCT01037673|Active Comparator|Movement exercises neck and shoulder|General movements for the neck and shoulder,
3222760|NCT01037660|Experimental|Metformin|Metformin
3222761|NCT01037647||Type 2 diabetic men|Men with type 2 diabetes
3222762|NCT01037647||Healthy men|Healthy men
3222763|NCT01037634|Experimental|Oseltamivir|Participants will receive Oseltamivir to treat influenza.
3222764|NCT01037595|Experimental|turmeric|turmeric 500 mg tid orally for 8 weeks
3222765|NCT01037595|Placebo Comparator|plasebo|placebo tid orally for 8 weeks
3222766|NCT01037582|Experimental|Trial part 1|
3222767|NCT01037582|Experimental|Trial part 2|
3222768|NCT01037556|Experimental|Arm 1: PR104|
3222769|NCT01037543|Experimental|Cohort 1|1.1 mcg/kg of HM10460A, placebo, or Neulasta
3222770|NCT01037543|Experimental|Cohort 2|3.3 mcg/kg HM10460A, placebo or Neulasta
3222771|NCT01037543|Experimental|Cohort 3|10 mcg/kg of HM10460A, placebo, or Neulasta
3222772|NCT01037543|Experimental|Cohort 4|30 mcg/kg of HM10460A, placebo, or Neulasta
3222773|NCT01037543|Experimental|Cohort 5|90 mcg/kg or HM10460A, placebo, or Neulasta
3222774|NCT01037543|Experimental|Cohort 6|270 mcg/kg of HM10460A, placebo, or Neulasta
3222775|NCT01037530|Experimental|Ramipril|
3222776|NCT01037517|Active Comparator|Successful Mobilizers|Successful Mobilizers are defined as having a peripheral blood CD34 > 10X106/L.
3222777|NCT01037517|Experimental|Poor Mobilizers|Poor Mobilizer are defined as patients who on Day -1 have a peripheral blood [CD34] ≤ 10 X106/L
3222778|NCT01037504|Experimental|A|Drug: AZD5423
3222779|NCT01037504|Placebo Comparator|B|Drug: Placebo
3222780|NCT01037491|Active Comparator|aspirin|Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD.patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks.
3222781|NCT01037491|Active Comparator|clopidogrel|Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD.patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks.
3222782|NCT01037478|Experimental|Resminostat (4SC-201)|oral administration
3222783|NCT01037465|Active Comparator|N-acetylcysteine|N-acetylcysteine
3222784|NCT01037465|Placebo Comparator|Placebo|Placebo
3222785|NCT01037452|Experimental|Combination product|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg tablet
3222786|NCT01037452|Active Comparator|PPI alone|Lansoprazole
3222787|NCT01037452|Active Comparator|Antacid alone|Calcium carbonate/magnesium hydroxide
3222788|NCT01037452|Placebo Comparator|Placebo|Placebo
3222789|NCT01037426|Other|Study group|Falls before versus after pacemaker implant
3222790|NCT01037413|Experimental|EXC 001|
3222791|NCT01037413|Placebo Comparator|Placebo|
3222792|NCT01037400||Total Knee Replacement Patients|Forty men and women ages 18-75 undergoing unilateral (n = 20) or bilateral (n = 20) knee replacement surgery with no musculoskeletal injury requiring medical attention in the past 3 months or producing pain in the previous 2 weeks and no inflammatory disease other than osteoarthritis.
3222793|NCT01037387|Active Comparator|Control|Conventional treatment for COPD
3222794|NCT01037387|Experimental|NIMV group|NIMV: Conventional treatment plus noninvasive mechanical ventilation
3222795|NCT01037374|Experimental|Difficult Airway Assessment Form|
3222796|NCT01037348|Experimental|ranibizumab 0.5mg|
3222797|NCT01037335|Placebo Comparator|control group|10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly.
3222798|NCT01037335|Active Comparator|intramuscular morphine|10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly
3222799|NCT01037335|Active Comparator|donor site morphine|5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
3222800|NCT01037322|Active Comparator|cannabidiol in drops|cannabidiol given in drops of olive oil sub lingual 5 mg twice daily
3222801|NCT01037322|Placebo Comparator|placebo in drops|olive oil given in drops sub lingual
3222802|NCT01037309|Experimental|PRO044, cohort 1|Subcutaneous injection of 0.5 mg/kg on day 1, 8, 15, 22 and 29.
3222804|NCT01037309|Experimental|PRO044, cohort 3|Subcutaneous injection of maximally 5 mg/kg on day 1, 8, 15, 22 and 29.
3222805|NCT01037309|Experimental|PRO044, cohort 4|Subcutaneous injection of maximally 8 mg/kg on day 1, 8, 15, 22 and 29.
3222806|NCT01037309|Experimental|PRO044, cohort 5|Subcutaneous injection of maximally 10 mg/kg on day 1, 8, 15, 22 and 29
3222807|NCT01037309|Experimental|PRO044, cohort 6|Subcutaneous injection of maximally 12 mg/kg on day 1, 8, 15, 22 and 29
3222808|NCT01037309|Experimental|PRO044, cohort 7|Intravenous injection of maximally 1.5 mg/kg on day 1, 8, 15, 22 and 29
3222809|NCT01037309|Experimental|PRO044, cohort 8|Intravenous injection of maximally 5 mg/kg on day 1, 8, 15, 22 and 29
3222810|NCT01037309|Experimental|PRO044, cohort 9|Intravenous injection of maximally 8 mg/kg on day 1, 8, 15, 22 and 29
3222811|NCT01037296|Other|manual ablation|
3222812|NCT01037296|Experimental|robotic ablation|
3222813|NCT01037283|Other|Interpersonal and Social Rhythm Therapy|All participants receive eight sessions of Interpersonal and Social Rhythm Therapy.
3222814|NCT01037244|Placebo Comparator|Placebo|
3222815|NCT01037244|Experimental|Udenafil 50 mg|
3222816|NCT01037244|Experimental|Udenafil 100 mg|
3222817|NCT01037244|Experimental|Udenafil 150 mg|
3222818|NCT01037231|Experimental|Oxabact (tm)|
3222819|NCT01037231|Placebo Comparator|Placebo|
3222820|NCT01037218|Experimental|Udenafil 50 mg|50 mg Udenafil tablet plus 100 & 150 mg placebo tablets
3222821|NCT01037218|Experimental|Udenafil 100 mg|100 mg Udenafil tablet plus 50 & 150 mg placebo tablets
3222822|NCT01037218|Experimental|Udenafil 150mg|150 mg Udenafil tablet plus 50 & 100 mg placebo tablets
3222823|NCT01037218|Placebo Comparator|Placebo|50, 100 & 150 mg placebo tablets
3222824|NCT01037205|Active Comparator|DAS181 High Dose|DAS181 Dry Powder 10 mg qd x 3 days
3222825|NCT01037205|Active Comparator|DAS181 Low Dose|DAS181 Dry Powder 10 mg Day 1 Lactose Placebo Day 2 and Day 3
3222826|NCT01037205|Placebo Comparator|Lactose Placebo|Lactose (Respitose ML006 (DMV-Fonterra)) 1 capsule qd x 3 days
3222827|NCT01037192|Experimental|Vanco once daily|Subject receives vancomycin 30 mg/kg dose
3222828|NCT01037192|Active Comparator|Vanco twice daily|Subject receives vancomycin 15 mg/kg twice daily
3222829|NCT01037179|Experimental|AL-4943A|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, 2 drops instilled in each eye twice daily for 10 weeks
3222830|NCT01037166|Experimental|Entecavir (0.5 mg)|
3222831|NCT01037166|Experimental|Entecavir (1mg)|
3222832|NCT01037140|Active Comparator|cholecalciferol|
3222833|NCT01037140|Placebo Comparator|placebo|
3222834|NCT01037127|Experimental|Cohort A|Subjects who have had previous treatment with a BRAF inhibitor.
3222835|NCT01037127|Experimental|Cohort B|Subjects who have had previous chemotherapy or immunotherapy without a BRAF inhibitor.
3222836|NCT01037114|Experimental|Twinrix Group|"Subjects who received 2 doses of Twinrix™ (lot A, B or C) in the primary study.~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Twinrix Group for data analyses during the first long-term follow-up NCT00289718 and this long-term follow-up.~A challenge dose of the Havrix™ or Engerix™-B vaccines can be administered in this study based on serology results at each time point."
3222837|NCT01037101|Active Comparator|IVET+DCS|
3222838|NCT01037101|Experimental|VRET+DCS|
3222839|NCT01037101|Experimental|VRET+Placebo|
3222840|NCT01037101|Active Comparator|IVET+Placebo|
3222841|NCT01037101|No Intervention|Wait-List|3 weeks Wait-List
3222842|NCT01037088|Experimental|Mild dose cannabis|3.53% THC by weight
3222843|NCT01037088|Experimental|Low dose cannabis|1.29% THC by weight
3222844|NCT01037088|Placebo Comparator|Placebo cannabis|placebo marijuana
3222845|NCT01037062|Experimental|Entecavir|
3222846|NCT01037049|No Intervention|Group 1|Patients who have surgery at 6 weeks after radiotherapy/chemoradiotherapy
3222847|NCT01037049|Experimental|Group 2|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy
3222848|NCT01037036|Experimental|Latanoprost Punctal Plug Delivery System followed by Xalatan|Subjects will have the Latanoprost Punctal Plug Delivery System placed for 4 week or until loss of efficacy. After removal of the Latanoprost Punctal Plug Delivery system, subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
3222849|NCT01037023||Patients administrated Topotecan|There is only one group. This group includes patients administrated Topotecan
3222850|NCT01036932|Active Comparator|G-CSF group|Patients with Acute on chronic liver failure after baseline investigations for the etiology of the acute event and the underlying chronic disease were given Granulocyte Colony Stimulating Factor therapy for a total duration of one month.
3222851|NCT01036932|Placebo Comparator|Placebo|After baseline characterization and work up for underlying acute and chronic liver disease, patients were given placebo along with the standard therapy
3222852|NCT01036893|No Intervention|oral contraceptives without prucalopride|
3222853|NCT01036893|Active Comparator|oral contraceptives with prucalopride|prucalopride
3222854|NCT01036854|Experimental|Regime 1|Regime 1 will be orally administered once daily in the morning over 6 consecutive days.
3222855|NCT01036854|Active Comparator|Regime 2|Regime 2 will be orally administered twice daily at 12 hours interval (morning and evening) over 6 consecutive days
3222856|NCT01036854|Active Comparator|Regime 3|Regime 3 will be orally administered three times daily at 8 hour intervals (morning, afternoon, evening) over 6 consecutive days.
3222857|NCT01036854|Experimental|Regime 4|Regime 4- Day 1- a single dose will be given. Day 2- one placebo capsule; Day 3- a single dose will be given . Day 4 & 5- two placebo capsules on each day; Day 6- a single does will be given.
3222858|NCT01036841|Active Comparator|desmopressin tablet|
3222859|NCT01036841|Experimental|desmopressin MELT-formulation|
3222860|NCT01036802|Active Comparator|Warfarin|Patients on the active treatment arm will be anticoagulated using the vitamin K antagonist, warfarin
3222861|NCT01036802|Placebo Comparator|Placebo|matching active products
3222862|NCT01036724||Carto 3|Those subjects whose cases use the CARTO 3 EP Navigation System.
3223627|NCT01030692|Active Comparator|Rivastigmine 3 mg|Rivastigmine 3 mg
3222863|NCT01036724||NAVX|Those subjects whose cases use the NAVX(TM) EP Navigational System.
3222864|NCT01036659|Active Comparator|Ecallantide in conjunction with Conventional Therapy|
3222865|NCT01036659|Placebo Comparator|Conventional therapy and placebo|
3222866|NCT01036659|No Intervention|Historical Evaluation|
3222867|NCT01036646||BSTE-0125-Original Protocol|
3222868|NCT01036646||BSTE-0125.a-Amended Protocol|
3222869|NCT01036633||Control Group no mucositis|Control patients with multiple myeloma who are not currently receiving chemotherapy and who do not suffer from oral mucositis
3222870|NCT01036633||Non-control Group Mucositis|Patients with multiple myeloma suffering from WHO Grade 3/4 Oral Mucositis
3222871|NCT01036594|Experimental|Ketoconazole, Hydrocortisone|
3222872|NCT01036594|Experimental|Ketoconazole, dexamethasone|
3222873|NCT01036529|Experimental|Precision Spinal Cord Stimulator|Spinal Cord Stimulation
3222874|NCT01036529|Active Comparator|Back Surgery|Discectomy, laminotomy, laminectomy, foraminotomy, fusion with or without instrumentation
3222875|NCT01036490|No Intervention|Control|Control group
3222876|NCT01036490|Experimental|Exercise|Exercise Group
3222877|NCT01036438|Placebo Comparator|Mepilex product|
3222878|NCT01036438|Active Comparator|Mepilex Ag|
3222879|NCT01036412|Experimental|Chlorhexidine Gel Therapy|Following 2 x 5-minute applications of 2.5 ml in clinic, 2 x 5.0 ml syringes of 1% chlorhexidine gluconate gel, self-administered for a 5-minute application Week 2 & Week 4
3222880|NCT01036399|Experimental|Revlimid|"Oral Revlimid is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.~After this induction phase, the CR, PR and SD will continue Revlimid with the same schedule for other 8 months."
3222881|NCT01036360||physical activity|
3222882|NCT01036321|Active Comparator|Purified Isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler. 40 mg daily.
3222883|NCT01036321|Placebo Comparator|Methyl cellulose blend|Placebo.
3222884|NCT01036308|Experimental|TypTop|Lupinus albus Typ Top (lupin kernel fibre, dietary fibre content: 83%)
3222885|NCT01036308|Experimental|Soy fibre|Glycine max Hefeng (soy fibre; dietary fibre content: 77%)
3222886|NCT01036308|Experimental|Boregine|Lupinus angustifolius Boregine (lupin kernel fibre, dietary fibre content: 87%)
3222887|NCT01036282|Experimental|Computerized Cognitive Remediation|Two arms: 1. Computerized Cognitive Remediation treatment using COGPACK. and 2. PositScience. Each arm is further randomized to either MindReader or no Mindreader.(Social Cognition Training).
3222888|NCT01036282|Experimental|CRT + Social Cognition Training|Two 45-minute sessions of Computerized Cognitive Remediation using COGPACK, one 45-minute discussion session, plus one 45 minute Mind Reader Interactive Guide to Emotions per week for 12 weeks. compared to two 45-minute sessions of PositScience, plus one 45-min Discussion session plus one minute of Mind Reader, Interactive Guide to Emotions
3222889|NCT01036243|Experimental|Test formula 1|Hydrolyzed formula with probiotics
3222890|NCT01036243|Active Comparator|test formula 2|acidified hydrolyzed formula.
3222891|NCT01036243|Active Comparator|Test formula 3|hydrolyzed formula without probiotics
3222892|NCT01036243|Active Comparator|reference product|standard infant formula
3222893|NCT01036139|Experimental|BF2.649 (pitolisant)|BF2.649 (5mg, 10 mg, 20 mg) in capsules
3222894|NCT01036139|Placebo Comparator|Placebo|Placebo of BF2.649 (5mg, 10mg, 20mg) in capsules
3222895|NCT01036113|Experimental|Experimental: EZN-2208|Experimental: EZN-2208 EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
3222896|NCT01036087|Experimental|PNC + FEC|"PNC = Panitumumab + Nab-paclitaxel + Carboplatin, and~FEC = 5-fluorouracil, epirubicin, and cyclophosphamide"
3222897|NCT01036061|Experimental|GSK618334 low Dose|GSK618334 Low Dose
3222898|NCT01036061|Experimental|GSK618334 Medium Dose|GSK618334 medium dose arm
3222899|NCT01036061|Experimental|GSK618334 High Dose|GSK618334 High Dose Arm
3222900|NCT01036061|Experimental|GSK618334 Placebo|Placebo for all 3 dose levels
3222901|NCT01036048||cabg disease|pts with saphenous vein graft disease
3222902|NCT01036035|Active Comparator|Treatment B|Study drug
3222903|NCT01036035|Active Comparator|Treatment D|Study drug
3222904|NCT01036035|Placebo Comparator|Treatment E|Placebo
3222905|NCT01036035|Active Comparator|Treatment A|Study Drug
3222906|NCT01036035|Active Comparator|Treatment C|Study Drug
3222907|NCT01036022|Experimental|Group 2|ASACOL 800mg t.i.d.
3222908|NCT01036022|Experimental|Group 1|GSK1399686 at 3-4 dose levels
3222909|NCT01036022|Experimental|Group 3|Placebo
3222910|NCT01036009|No Intervention|Group I: Observation|Group I (observation): Patients with full donor chimerism and no evidence of MRD continue to undergo clinical monitoring for acute and chronic graft-vs-host disease and relapse until 3 years post-transplant. Patients undergo repeat chimerism testing at 12 and 24 months post-transplant.
3222911|NCT01036009|Experimental|Group II: Intervention|Group II (intervention): Patients undergo withdrawal of immunosuppression and receive donor lymphocyte infusions between days 60-365 post-transplant (or until full donor chimerism is achieved). Patients also undergo clinical monitoring and repeat chimerism testing as in group I.
3222912|NCT01035983|Experimental|Frovatriptan 2.5 mg|Frovatriptan 2.5 mg tablets administered orally 2 x 2.5 mg twice daily (loading dose) on day 1, followed by 2.5 mg twice daily days 2 to 6.
3222913|NCT01035944|Experimental|HemCon Operating Room|The HemCon dressing is the intervention for the HemCon Operating Room arm. The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
3222914|NCT01035944|Active Comparator|Control Operating Room|The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
3223039|NCT01034930|Active Comparator|Retentive Anchors|23 patients will receive as retention system for overdentures Retentive Anchors (Straumann).
3223088|NCT01034501|Active Comparator|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
3222915|NCT01035944|Experimental|HemCon Bedside|The intervention for the HemCon Beside arm is the HemCon Dressing. The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
3222916|NCT01035944|Active Comparator|Control Bedside.|The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
3222917|NCT01035905|Experimental|Nelfilcon A|Nelfilcon A contact lens
3222918|NCT01035905|Active Comparator|Narafilcon A|Narafilcon A contact lens
3222919|NCT01035879|Experimental|MBX-2982 25 mg|
3222920|NCT01035879|Experimental|MBX-2982 100 mg|
3222921|NCT01035879|Experimental|MBX-2982 300 mg|
3222922|NCT01035879|Active Comparator|Sitagliptin 100 mg|
3222923|NCT01035879|Placebo Comparator|Placebo|
3222924|NCT01035801|Experimental|IN105|Prandial Oral Insulin
3222925|NCT01035801|Active Comparator|Insulin Lispro Injection|
3222926|NCT01035788|Experimental|Mindfulness-Based CBCT|Mindfulness Based Cognitive Behavioral Conjoint Therapy for PTSD
3222927|NCT01035788|Active Comparator|CBCT Communication Skills|CBCT for PTSD - Communication Skills
3222928|NCT01035775|Experimental|Insertion|Inspection on colonoscope insertion in addition to inspection during withdrawal from the cecum.
3222929|NCT01035775|Active Comparator|Withdrawal|Inspection during withdrawal (usual care) without deliberate inspection during insertion.
3222930|NCT01035749|Experimental|AREPANRIX-ADJUVANTED F1 2D GROUP|Subjects received 2 doses of Arepanrix ™ formulation 1 adjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
3222931|NCT01035749|Experimental|AREPANRIX-ADJUVANTED F2 2D GROUP|Subjects received 2 doses of Arepanrix ™ formulation 2 adjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
3222932|NCT01035749|Experimental|AREPANRIX-ADJUVANTED F2 3D GROUP|Subjects received 3 doses of Arepanrix ™ formulation 2 adjuvanted vaccine on Day 0, Day 21 and Day 182 (booster).
3222933|NCT01035749|Experimental|AREPANRIX-UNADJUVANTED F2 2D GROUP|Subjects received 2 doses of Arepanrix ™ unadjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
3222934|NCT01035671|Experimental|Low Dose|A0001 (0.5 g BID)
3222935|NCT01035671|Experimental|High Dose|A0001 (0.75 g BID)
3222936|NCT01035671|Placebo Comparator|Placebo|Placebo
3222937|NCT01035658|Experimental|Dose Level 1|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (40mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
3222938|NCT01035658|Experimental|Dose Level -1|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (30mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
3222939|NCT01035658|Experimental|Dose Level 1 Sequential|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (30mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
3222940|NCT01035658|Experimental|Dose Level 2 Sequential|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (40mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
3222941|NCT01035645|Experimental|GSK1070806 or placebo|This is a single dose escalating study. On enrolment into the study, each subject will be assigned to a group. These groups will be aligned to specific dose levels of GSK1070806. All subjects will be randomised to receive either a single intravenously administered dose of GSK1070806 or matching placebo (saline). The randomisation is generated by GSK prior to study start.
3222942|NCT01035619|Experimental|Moxidectin|
3222943|NCT01035606|Experimental|Goal-oriented Attention Regulation Training|training in goal-directed attention regulation
3222944|NCT01035606|Active Comparator|Education|brain health education
3222945|NCT01035606|Experimental|Technology-assisted Goal-directed Self-Regulation Training|computer-assisted training in goal-directed attention regulation
3222946|NCT01035593|Active Comparator|Standard of Care (PP + IVIG)|Plasmapheresis and IVIG 100mg/kg every other day x 5 treatments
3222947|NCT01035593|Experimental|PP + IVIG + rhC1INH|Plasmapheresis + 100mg/kg IVIG every other day x 5 treatments plus rhC1Inh 100u/kg IV daily x 7 consecutive days (once daily on PP days, twice daily on non-PP days).
3222948|NCT01035580|Experimental|curcurim|This was a 3 + 3 dose escalation trial starting at 500 mg of cur cumin capsules administered daily intravaginally for 14 days. The dose increased after safety was demonstrated in 3 subjects by 500 mg up to a max of 2000 mgs.
3222949|NCT01035567|Active Comparator|Hybrid revascularization|
3222950|NCT01035567|Active Comparator|Coronary Artery Bypass Grafting|
3222951|NCT01035554|Active Comparator|Usual Care (UC) + Printed Materials (PM)|If the participant is assigned to UC, they will receive standard care. They will not receive a HBPM to use for the study, but will be given one to keep at the 3 month Follow-Up Visit. If they are also assigned to PM, they will then be given written materials (pamphlets from the NIH) and will be asked to review the information in its entirety. The coordinator will be available to answer any questions they might have.
3222952|NCT01035554|Experimental|UC + Self-Paced Program Instruction (SPPI)|If the participant is assigned to UC, they will receive standard care. They will not receive a HBPM to use for the study, but will be given one to keep at the 3 month Follow-Up Visit. If they are also assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials from the National Institutes of Health.
3223628|NCT01030692|Active Comparator|Rivastigmine 6 mg|Rivastigmine 6 mg
3222953|NCT01035554|Experimental|Home Blood Pressure Monitor (HBPM) + PM|If the participant is assigned to HBPM, they will be asked to use the monitor once a day in the morning and once before they go to bed any 3 days of the week, each week of the study (total = 12 weeks). They will be asked to record their BP values in diaries they will be given to take home with them. If they are also assigned to PM, they will then be given written materials (pamphlets from the NIH) regarding hypertension education and will be asked to review the information in its entirety. The coordinator will be available to answer any questions they might have.
3222954|NCT01035554|Experimental|HBPM + SPPI|"If the participant is assigned to HBPM, they will be asked to use the monitor once a day in the morning and once before they go to bed any 3 days of the week, each week of the study (total = 12 weeks). They will be asked to record their BP values in diaries they will be given to take home with them.~If they are also assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the PM from the National Institutes of Health."
3222955|NCT01035541||P group|Fluid Management according to measurements with PiCCO®
3222956|NCT01035541||C group|Conventional fluid management
3222957|NCT01035528|Active Comparator|insulin glargine|antidiabetic treatment with Lantus o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
3222958|NCT01035528|Active Comparator|metformin|use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
3222959|NCT01035515|Experimental|Arm One|Arm 1 of 6 cross-over arms
3222960|NCT01035515|Experimental|Arm Two|Arm 2 of 6 cross-over arms
3222961|NCT01035515|Experimental|Arm Three|Arm 3 of 6 cross-over arms
3222962|NCT01035515|Experimental|Arm Four|Arm 4 of 6 cross-over arms
3222963|NCT01035515|Experimental|Arm Five|Arm 5 of 6 cross-over arms
3222964|NCT01035515|Experimental|Arm Six|Arm 1 of 6 cross-over arms
3222965|NCT01035502|Experimental|Elacytarabine plus idarubicin|
3222966|NCT01035489|Active Comparator|CRT; RV apical lead placement|Right ventricular apical lead placement in CRT
3222967|NCT01035489|Active Comparator|CRT; RV high posterior septum|High posterior septal lead placement in CRT
3222968|NCT01035476|Experimental|Data Card Report|Patients receive detailed reports of acceptance and adherence, with linked recommendations to optimize NIPPV.
3222969|NCT01035476|No Intervention|Standard NIPPV Care|Patients receive routine monitoring and care related to NIPPV.
3222970|NCT01035463|Experimental|Treatment (stem cell transplantation)|"PRE-CONDITIONING (patients with CD20+ NHL): Patients receive rituximab IV per standard of care.~PREPARATIVE REGIMEN: Patients receive carmustine IV on day -6, etoposide IV BID and cytarabine IV BID on days -5 through -2, and melphalan IV on day -1.~AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: Patients undergo stem cell infusion on day 0.~MAINTENANCE THERAPY: Beginning approximately 100 days post-transplant, patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity."
3222971|NCT01035450|Experimental|Everolimus-eluting stent|
3222972|NCT01035450|Active Comparator|Sirolimus-eluting stent|
3222973|NCT01035437|Experimental|HPPH|HPPH
3222974|NCT01035411|Experimental|1|AZD9668 2X30mg tablet
3222975|NCT01035385|Experimental|FOFLOX4,resectable liver metastasis from CRC|
3222976|NCT01035372|Experimental|dried plum|subjects will have 25% by weight (~ 600 kcal if eat 2500 kcal diet) of their usual diet substituted by dried plum powder
3222977|NCT01035359|Active Comparator|external fixation|Operation with external fixation and optional addition of k-wire
3222978|NCT01035359|Experimental|Volar plate|Operation with a Synthes volar two column plate (TCP)
3222979|NCT01035346|Experimental|A|
3222980|NCT01035346|Placebo Comparator|B|
3222981|NCT01035333|Experimental|orlistat 60mg|Patients assigned to treatment group for up to 6 months of therapy.
3222982|NCT01035320|Experimental|simvastatin + ezetimibe|Cross-over study with placebo only run-in period. All patients participate in this arm with simvastatin + ezetimibe either as first treatment period (8-10 weeks)or second treatment period (8-10 weeks). The primary comparison is ezetimibe vs. placebo on top of simvastatin. A secondary comparison will be simvastatin vs. placebo run-in.
3222983|NCT01035307||Genomic and Proteomic Profiling|
3222984|NCT01035294|Experimental|mindfulness based intervention|
3222985|NCT01035294|Active Comparator|usual care (UC)|
3222986|NCT01035281|Experimental|Nabilone|A one-week screening period will occur, during which pain scores and sleep scores will be tabulated. Following screening, a 4-week period of single blind treatment with flexible dosing of nabilone at 0.5 - 4 mg/day will initiate.
3222987|NCT01035281|Placebo Comparator|Placebo|All subjects who experience at least a 30% reduction in their weekly mean pain score during the single blind flexible dosing phase will be considered a responder, and will be further continued in the study. During the double-blind portion of the study, subjects randomized to nabilone will continue on the dose of nabilone achieved at the completion of the single-blind phase, and this dose will be maintained throughout the double-blind phase. Subjects randomized to placebo will receive 1 mg of nabilone daily for one week, followed by 4 consecutive weeks of placebo. This dose of nabilone will permit a tapering for those subjects achieving a higher daily dose of nabilone during the single-blind phase, or will maintain those who were taking only 1 mg per day in the single-blind phase, preventing an abrupt termination of treatment in subjects who are randomized into the placebo portion.
3222988|NCT01035268|Experimental|surgery by fatty tissue transfer|
3222989|NCT01035268|No Intervention|simple supervision|
3222990|NCT01035255|Experimental|LCZ696|single-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks. Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization. LCZ696 200mg BID during double blind treatment period
3223040|NCT01034930|Active Comparator|Magnets|23 patients will receive Magnets (Straumann) as retention system for overdenture.
3223041|NCT01034930|Active Comparator|Locator System|23 patients will receive Locator System (Straumann) as retention for the mandibular overdenture.
3222991|NCT01035255|Active Comparator|Enalapril|single-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks. Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization. Enalapril 10 mg BID during double blind treatment period
3222992|NCT01035242|Experimental|"association splitting"|Association splitting (6 sessions) delivered by psychologists.
3222993|NCT01035242|Active Comparator|cognitive remediation|CogPack training(6 sessions) delivered by either psychologists or psychology students at an advanced master level.
3222994|NCT01035229|Experimental|Everolimus + Best Supportice Care (BSC)|Patients were assigned to the Everolimus + BSC arm in a ratio of 2:1 over the Placebo arm. Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the investigational drug. In addition to taking Everolimus, all patients also received BSC as per normal local practice.
3222995|NCT01035229|Placebo Comparator|Placebo + Best Supportive Care|Placebo Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the control drug. In addition to taking Placeb Everolimus, all patients also received BSC as per normal local practice.
3222996|NCT01035216|Experimental|GNKG168|The starting dose will be 0.25 mg/kg. If the dose is tolerable, subsequent cohorts will be enrolled and treated with 0.5, 0.75, 1.0 and 1.5 mg/kg. If 0.25 mg/kg proves to be intolerable, the dose will be reduced to 0.15 mg/kg.
3222997|NCT01035203|Active Comparator|Cognitive behavioural therapy|
3222998|NCT01035203|Experimental|Exercise|Endurance training (walking on a treadmill) 3 x weekly for 4 weeks
3222999|NCT01035190|Experimental|inhaled Budesonide|
3223000|NCT01035177||Control|Women without hip fracture, matched on age to the cases
3223001|NCT01035177||Patient|Female patients aged 60 and older with hip fracture
3223002|NCT01035164|Experimental|Arm 1|
3223003|NCT01035164|Experimental|Arm 2|
3223004|NCT01035164|Experimental|Arm 3|
3223005|NCT01035151|Experimental|Bundled Intervention|
3223006|NCT01035151|Experimental|Delayed Control|
3223007|NCT01035138|Experimental|Drug: semagacestat|
3223008|NCT01035125|No Intervention|Waiting list|
3223009|NCT01035125|Experimental|Self-management program|One week self-management program
3223010|NCT01035112||MRI|Contrast-enhanced MRI using the standard department of Radiology MRI screening procedures. The duration of scanning may be variable, but will not exceed 90 minutes.
3223011|NCT01035099|Experimental|Titrated dose Letrozole|Patients who are randomized to the titrated dose of Letrozole, will start gonadotropins in the evening of day #2 of their menstrual cycle with injectable follicle stimulating hormone (FSH) and human menopausal gonadotropin (HMG). Oral Letrozole will be added to the stimulation in the following titrated regimen.
3223012|NCT01035099|Active Comparator|Fixed dose Letrozole|Patients who are randomized to fixed dose Letrozole will start Letrozole 5mg daily (orally) on the second day of their menstrual cycle and then gonadotropins on the fourth day of their menstrual cycle.
3223013|NCT01035086|Experimental|Boregine|Intervention: Lupinus angustifolius Boregine; 25 g lupin kernel fibre per day over 4 weeks; lupin kernel fibre was incorporated in different food
3223014|NCT01035086|Active Comparator|Reference|Intervention: Reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood ingredients); 25 g citrus fibre per day over 4 weeks; the citrus fibre was incorporated in different food
3223015|NCT01035086|Placebo Comparator|Placebo|different food without added fibre
3223016|NCT01035073|Experimental|Duloxetine|
3223017|NCT01035060||Older Adult|Healthy Men and Women Over 70 Years of Age
3223018|NCT01035060||Young Adult|Healthy Men and Women Aged 18-30 Years
3223019|NCT01035047|No Intervention|Inpatient Care|This is the comparison arm. Patients are admitted to the hospital and undergo usual care.
3223020|NCT01035047|Experimental|CDU-CMR Protocol|Patients will be transferred to the clinical decision unit and undergo a stress cardiac MRI evaluation.
3223021|NCT01035034|Experimental|One-stop hybrid coronary revasularization|Percutaneous Coronary Intervention; Coronary Artery Bypass
3223022|NCT01035034|Active Comparator|PCI with stenting|Percutaneous Coronary Intervention
3223023|NCT01035021|Active Comparator|group N|Anesthesia is induced with propofol and remifentanil and LMA is inserted by the standard technique according to eht manufacturer's instruction. Rocuronium is administered for the operation.
3223024|NCT01035021|Active Comparator|group R|Anesthesia is induced with a propofol and remifentanil and rocuronium 0.06 mg/kg is injected. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction.
3223025|NCT01035008|Experimental|Diagnostic|The investigators are testing a new method called confocal laser endomicroscopy to see if it can detect pre-cancerous abnormalities in the lining of the cysts found in your pancreas. This will involve using a very thin fiber-shaped microscope which will be passed through a needle during the EUS procedure.
3223026|NCT01034995|Experimental|SSR125543 20 mg|1 capsule of SSR125543 20 mg + 1 capsule of placebo
3223027|NCT01034995|Experimental|SSR125543 50 mg|1 capsule of SSR125543 50 mg + 1 capsule of placebo
3223028|NCT01034995|Experimental|SSR125543 100 mg|2 capsules of SSR125543 50 mg
3223029|NCT01034995|Active Comparator|escitalopram 10 mg|1 capsule of escitalopram 10 mg + 1 capsule of placebo
3223030|NCT01034995|Placebo Comparator|placebo|2 capsules of placebo
3223031|NCT01034982|Experimental|1|tosylate salt tablet
3223032|NCT01034982|Experimental|2|free suspension
3223033|NCT01034982|Experimental|3|tosylate salt tablet
3223034|NCT01034982|Experimental|4|free suspension
3223035|NCT01034969||Participants with hereditary angioedema (HAE)|All participants with hereditary angioedema (HAE) who are administered Cinryze (C1 inhibitor [human]) or Firazyr (Icatibant) for the treatment or prevention of angioedema attacks in routine clinical practice will be included into the study.
3223036|NCT01034956||Facial Soft Tissue Filler Patients|Patients previously treated by Principal Investigator with facial soft tissue fillers within the past 2 years
3223037|NCT01034943|Active Comparator|External fixation|Operation with external fixation and optional addition of k-wire
3223038|NCT01034943|Active Comparator|Volar plate|Operation with Synthes volar two column plate (TCP)
3223042|NCT01034917|Experimental|Etravirine group|To switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
3223043|NCT01034917|Active Comparator|Control group|Continue with the same antiretroviral regimen
3223044|NCT01034904||Patients|Patients who have moderate or severe Hemophilia A, living in Canada and who are using Helixate FS either on-demand or prophylaxis
3223045|NCT01034878|Experimental|Sunitinib|50 mg once daily 6 weeks cycle 4 weeks on and 2 weeks off
3223046|NCT01034865||HCC PTS|Patients with HCC with either: (i) a hepatic mass larger or equal to 5cm, or; (ii) a hepatic mass lesion confirmed by fine needle aspirate (FNA) or by pathology in the cases of surgical resection, or; (iii) a hepatic mass lesion with characteristic CT or MRI or angiographic appearance.
3223047|NCT01034865||LD|Patients with chronic liver disease without evidence of HCC
3223048|NCT01034852||Surgical ablation|Patients undergoing surgical ablation for Atrial Fibrillation that have failed one or more previous attempts at catheter ablation for Atrial Fibrillation
3223049|NCT01034839||acute myeloid leukemia, adults|Adults treated for acute myeloid leukemia in our hospital between 1978 and 2007
3223050|NCT01034826||life style modification|everyone in this study was advised about their life style, diet, exercise habits.
3223051|NCT01034813||Burn Range of motion|burn patients with hypertropic scar
3223052|NCT01034813||control range of motion|control subjects without scaring
3223053|NCT01034787|Experimental|Open Label CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of every 90-day cycle for up to 4 cycles or until disease progression or intolerance of toxicity.
3223054|NCT01034774|Active Comparator|ACHN-490 Injection|ACHN-490 Injection will be given either 1 or 5 consecutive days at a dose of 15mg/kg.
3223055|NCT01034774|Placebo Comparator|Placebo is Normal Saline|Placebo will be given either 1 or 5 consecutive days to mask when ACHN-490 Injection is given.
3223056|NCT01034761|Experimental|Pop-up alerts|Providers will receive pop-up alerts in the electronic medical record when prescribing one of the specified medications from the Beers list.
3223057|NCT01034761|No Intervention|Usual care|
3223058|NCT01034748|Experimental|1|Single 45 mg oral dose of [14C]PF-00299804
3223059|NCT01034735|Experimental|Arm A|
3223060|NCT01034735|Experimental|Arm B|
3223061|NCT01034735|Experimental|Arm C|
3223062|NCT01034722||Western Diet|Volunteer mothers with western diet.
3223063|NCT01034722||Vegetarians|volunteer mothers with vegetarians diet
3223064|NCT01034722||Bedouins|Volunteer mothers who are Bedouins
3223065|NCT01034709||Symptomatic|Subjects with a confirmed CMV viremia by the site's CMV-LDT as well as CMV symptoms
3223066|NCT01034709||Asymptomatic|Subjects who must have been serologically positive for CMV IgG prior to transplantation and do not have any CMV symptoms
3223067|NCT01034683|Experimental|Esophageal Carcinoma|
3223068|NCT01034670|Experimental|endoscopy arm|imaging performed in conjunction with the regularly scheduled endoscopy during which the newer imaging techniques will be used to detect premalignant conditions. includes wide field fluorescence, microscopy, Raman spectroscopy and/or ultrasound.
3223069|NCT01034657|Experimental|LBH589|During the core phase, all participants received oral LBH589 40 mg (30 mg after a protocol amendment) for 4 months. During the randomization phase, participants with hematological improvement of the erythropoetic system (HI-E) and participants with stable disease, who were randomized to single agent LBH589, continued on single agent LBH589 40mg/30mg for an additional 4 months.
3223070|NCT01034657|Experimental|LBH589 + Epoetin Alfa|During the randomized phase, participants randomized to LBH589 + Epoetin Alfa (ESA) received oral LBH589 40mg/30mg + ESA 30000 international units (IU)/week injected subcutaneously for 4 months.
3223071|NCT01034644||PRISMS patients|This single group includes all the patients from the PRISMS study
3223072|NCT01034631|Active Comparator|Combination Arm A: Everolimus + BNC105P|Combination Arm A: Everolimus 10 mg, BNC105P MTD (from Phase 1 study) 21 day cycle
3223073|NCT01034631|Active Comparator|Sequential Arm B:Everolimus followed by BNC105P Monotherapy|"Sequential Arm B: Everolimus 10 mg, 21 day cycle~Patients to receive BNC105P monotherapy at 16 mg/m2 following progression or intolerable toxicity on everolimus therapy."
3223074|NCT01034618|Placebo Comparator|Placebo|
3223075|NCT01034618|Experimental|Intact protein|
3223076|NCT01034618|Experimental|Protein hydrolysate|
3223077|NCT01034605|Experimental|inulin|oligofructose
3223078|NCT01034592|Experimental|Lenalidomide|Subjects will initially receive lenalidomide 2.5 mg, and may escalate up to 2.5 mg/wk up to 5 mg 3x/wk, depending toxicity and response.
3223079|NCT01034579|Other|Rebif® Cohort|
3223080|NCT01034579|Other|Copaxone® Cohort|
3223081|NCT01034566|Experimental|Arm I|Patients undergo proton beam radiotherapy 5 days a week for 6 (preoperative patients) or 8 (post-operative patients) weeks in the absence of disease progression or unacceptable toxicity.
3223082|NCT01034553|Experimental|Arm I|Patients receive oral aurora A kinase inhibitor MLN8237 once daily on days 1-14 and bortezomib IV on days 1, 4, 8 and 11.
3223083|NCT01034540|Experimental|POM3|POM3 for the first six weeks of treatment. Placebo for the second six weeks of treatment
3223084|NCT01034540|Placebo Comparator|Placebo|Placebo for the first six weeks of treatment. POM3 for the second six weeks of treatment
3223085|NCT01034527|Experimental|Neuromuscular Training|Combination of exercises and phases designed to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
3223086|NCT01034527|Sham Comparator|Speed Training|Speed training protocol Sham training will consist of sagittal plane only running drills designs solely to enhance sprint speed. A sham sagittal plane sprint training protocol that will be instituted with the teams that are randomly selected for sham treatment. Five phases will be utilized to facilitate progressions designed to improve the athletes' forward sprinting speed. Training volume will be approximately equivalent for the TNMT and sham protocols. They each will take athletes approximately 30 minutes to complete
3223087|NCT01034514|Experimental|4DCT arm|Patients breathe in 99mTc-DTPA and then undergo ventilation scans using a SPECT scanner over 2 hours. Patients also receive 99mTc-MAA IV and then undergo perfusion scans using a SPECT scanner over 2 hours. Patients may also undergo a pre- and post-treatment Xe-CT ventilation scan over 15 minutes and a pre-treatment 4D-CT scan over 5-10 minutes.
3223089|NCT01034501|Sham Comparator|sham procedure|Not activation of laser device
3223090|NCT01034488|Active Comparator|Heparin sodium - APP|5000UI / mL
3223091|NCT01034488|Experimental|Heparin - Eurofarma|5000 UI/ mL
3223092|NCT01034475|Experimental|CPI-613|CPI-240 mg/m2
3223093|NCT01034462|Experimental|1|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing.
3223094|NCT01034462|Placebo Comparator|2|Matching placebo capsules, oral administration, once daily dosing.
3223095|NCT01034436|Placebo Comparator|Low intake of ALA and triacylglycerols|Sunflower oil
3223096|NCT01034436|Experimental|high intake of ALA and triacylglyceroles|Canola and linseed oils
3223097|NCT01034436|Experimental|high intake of ALA and diacylglycerols|Canola and linseed oils
3223098|NCT01034423|Experimental|omega-3 high quality|
3223099|NCT01034423|Experimental|omega-3 low quality|
3223100|NCT01034423|Placebo Comparator|placebo|
3223101|NCT01034410|Active Comparator|Control|cytarabine 2g/m2 bid Days 4-7
3223102|NCT01034410|Experimental|AS1411-40|AS1411 40mg/kg/day d1-7 plus cytarabine 2g/m2 bid days 4-7
3223103|NCT01034410|Experimental|AS1411-80|AS1411 80mg/kg/day d1-7, cytarabine 2g/m2 bid days 4- 7/ bid d4-7
3223104|NCT01034397|Experimental|1|
3223105|NCT01034397|Placebo Comparator|2|
3223106|NCT01034371|Experimental|One-stop hybrid revasularization|
3223107|NCT01034371|Active Comparator|Off-pump coronary artery bypass|
3223108|NCT01034358|Experimental|Human Papillomavirus Vaccine|The Gardasil HPV vaccine was administered in 3 doses: baseline, 2 months, and 6 months.
3223109|NCT01034345|Experimental|Sirolimus|Patients randomized to this arm will discontinue maintenance immunosuppression based on calcineurin inhibitors and start treatment with sirolimus.
3223110|NCT01034345|Active Comparator|Calcineurin inhibitor|Patients randomized to this arm will keep the same maintenance immunosuppression based on calcineurin inhibitors.
3223111|NCT01034332|Experimental|One-cycle induction chemotherapy|TP-HDFL, TP-CCRT, Esophagectomy
3223112|NCT01034319|Experimental|Diabetes Genetic Counseling|Subjects will have been genotyped and will received genetic counseling based on their results
3223113|NCT01034319|Placebo Comparator|No Genotyping or Counseling|Patients will not be genotyped and will therefore not receive genetic counseling
3223114|NCT01034306|Experimental|CF101 1 mg|
3223115|NCT01034306|Placebo Comparator|Placebo|
3223116|NCT01034293|Experimental|low feeding frequency (3x)|
3223117|NCT01034293|Experimental|High feeding frequency (14x)|
3223118|NCT01034267|Experimental|1|(Open-label) F2695 SR capsules, oral administration, once daily, flexible dosing
3223119|NCT01034254|Experimental|influenza vaccine|Pregnant women assigned to the intervention group will receive one dose of seasonal influenza vaccine at the time of enrollment. The vaccine that will be given will be the current seasonal influenza recommended vaccine at the time of enrollment.
3223120|NCT01034254|Placebo Comparator|saline placebo|Pregnant women assigned to the control group will receive one dose of placebo (normal saline).
3223121|NCT01034241|Experimental|Control|Diet consists of 15% dairy protein and low Glycemic Index (GI < 40), 55 En% carbohydrates and 30 En% fat
3223122|NCT01034241|Experimental|High dairy protein|Diet consists of 25% dairy protein and low GI (GI < 40), 45 En% carbohydrates and 30 En% fat
3223123|NCT01034241|Experimental|vegetable protein|Diet consists of 15 En% vegetable protein and low GI (GI < 40), 55 En% carbohydrates and 30 En% fat
3223124|NCT01034241|Experimental|High GI|Diet consists of 15 En% dairy protein and high GI(GI > 60, 55 En% carbohydrates and 30 En% fat
3223125|NCT01034228|Active Comparator|Isoleucine|Glucose ORS with L-Isoleucine
3223126|NCT01034228|Placebo Comparator|ORS without Isoleucine|ORS without Isoleucine for the treatment of diarrhoea in children
3223127|NCT01034215|Active Comparator|Imagery Practice, live trainer|Patients attend a five week training program, with the instructor in the room with them, and actively practice imagery techniques, both in the classroom, and daily, outside of the classroom. Classes are four hours a week for five weeks. Patients practice what they learn for a full 17 weeks, beginning with the first week of class.
3223128|NCT01034215|Active Comparator|"Envision the Rhythms of Life /video"|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD.
3223129|NCT01034215|No Intervention|Waitlist Control Group|No treatment delivery during the 17 weeks of testing live delivery (trainer in the room with patients) vs. distance delivery (trainer delivers program via telemedicine/videoconferencing equipment)
3223130|NCT01034202|Experimental|Norditropin® SimpleXx® 0.02 mg/kg + NNC126-0083|
3223131|NCT01034202|Experimental|Norditropin® SimpleXx® 0.04 mg/kg + NNC126-0083|
3223132|NCT01034202|Placebo Comparator|Norditropin® SimpleXx® 0.02 mg/kg + placebo|
3223133|NCT01034202|Placebo Comparator|Norditropin® SimpleXx® 0.04 mg/kg + placebo|
3223134|NCT01034202|Experimental|NNC126-0083|
3223135|NCT01034202|Placebo Comparator|Placebo|
3223136|NCT01034189|Experimental|Targeted therapy|Concurrent chemoradiotherapy with cetuximab, paclitaxel, and cisplatin followed by, if feasible, esophagectomy
3223137|NCT01034176|Active Comparator|Levofloxacin|Levofloxacin 500 mg every day (dose adjusted for renal function) for 30 days
3223138|NCT01034176|Placebo Comparator|placebo|placebo identical to levofloxacin drug daily for 30 days
3223139|NCT01034163|Experimental|Panobinostat (PAN)|Participants received 45 mg orally 3 times a week (TIW), every other week (QOW),
3223140|NCT01034163|Placebo Comparator|Placebo|Participants received matching placebo to PAN TIW, QOW.
3223141|NCT01034150|Active Comparator|Somatosensory stimulation|Active group
3223142|NCT01034150|Placebo Comparator|Control group|Placebo stimulation
3223143|NCT01034137|Experimental|Tocilizumab + Methotrexate|Participants will receive intravenous (IV) TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + oral capsules of MTX 10-30 mg/week in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week. The weekly dose of MTX will be taken on one particular day of the week.
3223144|NCT01034137|Active Comparator|Tocilizumab + Placebo Methotrexate|Participants will receive IV TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + weekly oral matching placebo MTX capsules in climbing dosages. The weekly dose of placebo MTX will be taken on one particular day of the week.
3223145|NCT01034137|Active Comparator|Methotrexate + Placebo Tocilizumab|Participants will receive weekly oral MTX in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week + matching placebo TCZ IV 8 mg/kg every four week for a maximum of 26 infusions. The weekly dose of MTX will be taken on one particular day of the week.
3223146|NCT01034124|Placebo Comparator|Water|
3223147|NCT01034124|Active Comparator|Cranberry juice|
3223148|NCT01034111|Experimental|Sitagliptin|Sitagliptin as add-on therapy to a stable dose of metformin
3223149|NCT01034098||Post-menopausal women|Post-menopausal women (without hormone replacement therapy)
3223150|NCT01034046|Active Comparator|Insulin Sensitive Study Participants|Insulin sensitive subjects stratified using fasting insulin levels.
3223151|NCT01034046|Active Comparator|Insulin Resistant Study Subjects|Insulin resistant subjects stratified using fasting insulin levels.
3223152|NCT01034007|Experimental|Tissue Engineered Vascular Grafts|
3223153|NCT01033994|Experimental|AS902330|
3223154|NCT01033994|Placebo Comparator|Placebo|
3223155|NCT01033981||Central America and Caribbean|Dominican Republic, Guatemala, Panama, Costa Rica, Honduras, Trinidad & Tobago
3223156|NCT01033955|Experimental|Drug (Rosuvastatin) Crestor|The first dose of encapsulated study drug or placebo (day 1) will be administered within 4 hours of randomization as a loading dose of 40 mg. The placebo will be identical in appearance to Rosuvastatin. Thereafter, doses of 20 mg will be administered daily starting on the next calendar day at 10 pm daily (+/- 4 hours) as a maintenance dose from days 2 to 14. If the patient is of Asian descent, is <18 years, or serum creatinine is greater than or equal to 248 μmol/L (2.8 mg/dL) dose adjustments will be made according to a dose adjustment algorithm.
3223157|NCT01033955|Placebo Comparator|Placebo|An identical appearing placebo will be administered to patients in the second study arm.
3223158|NCT01033942|Experimental|FTC/TDF as PrEP|Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
3223159|NCT01033942|Placebo Comparator|Placebo Pill Control|Blinded administration of placebo pill; HIV behavioral intervention
3223160|NCT01033942|Active Comparator|No Pill Control|Subjects receive HIV behavioral intervention but no pill.
3223161|NCT01033929|Experimental|0.01µg C-Tb|12-24 patients depending on a safety evaluation will receive a low dose of 0.01 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.
3223162|NCT01033929|Experimental|0.1µg C.Tb|12-24 patients depending on a safety evaluation will receive a high dose of 0.1 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.
3223163|NCT01033916|No Intervention|STRICT Glucose Control (80-120 mg/dL)|The STRICT arm of the study will have a target Blood Glucose level ranging from 80-120 mg/dL. This is currently the standard of care for post CABG patients.
3223164|NCT01033916|Active Comparator|LIBERAL (Target Glucose:121-180 mg/dL)|
3223165|NCT01033903|Experimental|Misoprostol 800 micrograms intravaginally|
3223166|NCT01033903|No Intervention|expectant managment|
3223167|NCT01033877|Experimental|TdaP vaccine|
3223168|NCT01033877|Active Comparator|Td vaccine|
3223169|NCT01033864|Experimental|MMF, Prednisone|Participants received mycophenolate mofetil (MMF) orally (PO) at a dose of 1 gram per day (g/day) twice daily (BID), and prednisone, PO, up to 5 milligrams per day (mg/day) for at least 1 month.
3223170|NCT01033864|Active Comparator|EC-MPS|Participants received mycophenolate sodium (EC-MPS), PO, at a dose of 720 mg/day BID, and prednisone PO up to 5 mg/day for at least 1 month.
3223171|NCT01033851|Active Comparator|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is an 8-week group intervention that trains participants in mindfulness meditation techniques.
3223172|NCT01033851|Active Comparator|Stress Management Education|Stress Management Education (SME) is an 8-week group intervention that educates participants about stress physiology and health lifestyle changes.
3223173|NCT01033838|Active Comparator|laparoscopic-assisted rectosigmoid resection|
3223174|NCT01033838|Experimental|laparoscopic rectosigmoid resection and transrectal retrieval|
3223175|NCT01033825|Experimental|Ciclesonide HFA Nasal Aerosol 320 mcg|Ciclesonide HFA Nasal Aerosol 320 mcg once daily
3223176|NCT01033825|Experimental|Ciclesonide HFA Nasal Aerosol 160 mcg|Ciclesonide HFA Nasal Aerosol 160 mcg once daily
3223177|NCT01033825|Placebo Comparator|HFA Nasal Aerosol placebo|HFA Nasal Aerosol Placebo once daily
3223178|NCT01033825|Experimental|Ciclesonide Aqueous Nasal Spray 200 mcg|Ciclesonide Aqueous Nasal Spray 200 mcg once daily
3223179|NCT01033825|Placebo Comparator|AQ Nasal Spray Placebo|AQ Nasal Spray Placebo once daily
3223180|NCT01033825|Active Comparator|Placebo HFA plus Dexamethasone 6 mcg|Placebo HFA plus Dexamethasone 6 mg once daily
3223181|NCT01033825|Active Comparator|Placebo AQ plus Dexamethasone 6 mg|Placebo AQ plus Dexamethasone 6 mg once daily
3223182|NCT01033812||Index Recruiter|Young African American or Latina women who served as index recruiters in ATN 067 and members of their female friendship network members who tested HIV positive based on HIV screening and a confirmatory test result that was conducted in ATN 067.
3223183|NCT01033812||Male Sexual Partners|Any male partner who engaged in at least one episode of oral, vaginal or anal sex during the course of their lifetime with an 084 index recruiter.
3223184|NCT01033799|Sham Comparator|Control Product|
3223185|NCT01033799|Active Comparator|Tested Product|
3223186|NCT01033760|Experimental|arm 1|darunavir, ritonavir, emtricitabine/tenofovir, maraviroc, raltegravir
3223187|NCT01033760|Active Comparator|arm 2|darunavir, ritonavir, emtricitabine/tenofovir
3223188|NCT01033747|Experimental|Deferasirox|Deferasirox group consists of all participants who were initially randomized to 10 and 20 mg/kg/day deferasirox orally daily in the main study and remained on the same treatment during the comparative prolongation study (NCT00379483) and at the beginning of the 5-year non-comparative study
3223624|NCT01030718|Experimental|dasatinib (CML-AP/BP)|CML - Accelerated Phase and Blast Phase
3223189|NCT01033747|Experimental|Deferasirox Crossover|Deferasirox Crossover group consists of participants who were initially randomized to 40 mg/kg/day deferoxamine (DFO)subcutaneously in the main study and comparative prolongation study and crossed over to 5mg/kg/day to 30 mg/kg/day deferasirox orally daily at the beginning of the 5-year non-comparative extension study
3223190|NCT01033734|Experimental|Single arm|
3223191|NCT01033708|Active Comparator|treatment as usual|Treatment as usual
3223192|NCT01033708|Experimental|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
3223193|NCT01033669||Dry Powder Inhalers|
3223194|NCT01033656|Experimental|Anakinra|experimental drug of study
3223195|NCT01033656|Active Comparator|comparator|comparators:methotrexate, azathioprine, leflunomide or supfasalazine
3223196|NCT01033643|Experimental|Panel A|0.25 mg MK3614 or Placebo
3223197|NCT01033643|Experimental|Panel B|0.50 mg and 0.25 mg MK3614 or Placebo
3223198|NCT01033643|Experimental|Panel C|0.50 mg and 0.25 mg MK3614 or Placebo
3223199|NCT01033643|Experimental|Panel D|0.50 mg MK3614 or Placebo
3223200|NCT01033643|Experimental|Panel E|0.50 mg, 0.25 mg and 0.75 mg MK3614 or Placebo
3223201|NCT01033630|Placebo Comparator|Placebo|Image-matched placebo of active treatment
3223202|NCT01033630|Active Comparator|D&G 1g|Randomly allocated into three groups, D&G capsule 1g/day
3223203|NCT01033630|Active Comparator|D&G 2g|Randomly allocated into three groups, D&G capsule 2g/day
3223204|NCT01033617|Placebo Comparator|Placebo|Saline solution with autologous plasma.
3223205|NCT01033617|Experimental|CD133+ stem cells|Autologous CD133+ intramyocardial injection at time of coronary artery bypass grafting.
3223206|NCT01033604|Experimental|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
3223207|NCT01033604|Active Comparator|Split skin graft alone|Full thickness defects treated with split skin graft alone.
3223208|NCT01033591|Experimental|Exercise|Supervised exercise + Optimized treatment according to the European Society of Cardiology guidelines
3223209|NCT01033591|Other|Control|Optimized treatment according to the European Society of Cardiology guidelines
3223210|NCT01033578|No Intervention|Control|Receive hepatectomy and thrombectomy alone, no postoperative adjuvant treatments
3223211|NCT01033578|Experimental|PVIC Group|Portal Vein Infusion Chemotherapy (PVIC): 5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) was continuously infused into portal vein through tube by a infusion pump implanted in operation. Treatment started 2 weeks after the operation and was repeated every 4 weeks for six cycles.
3223212|NCT01033578|Experimental|TACE Group|Transcatheter Arterial Chemoembolization (TACE): 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles.
3223213|NCT01033578|Experimental|PVIC+TACE Group|Combination of PVIC and TACE. PVIC started 2 weeks after operation and TACE started 6 weeks after operation. Both PVIC and TACE were repeated at 8 weeks intervals for 3 cycles.
3223214|NCT01033565|Experimental|Natrol|Subjects receive Natrol (sustained release melatonin) 5mg tablet 30 minutes prior to bedtime for 10 to 14 days
3223215|NCT01033552|Experimental|Transplant in Epidermolysis Bullosa|
3223216|NCT01033539|Active Comparator|Placebo control|Placebo control without probiotics ATCC PTA 4659
3223217|NCT01033539|Active Comparator|ATCC PTA 4659 Low dose|
3223218|NCT01033539|Active Comparator|ATCC PTA 4659 high dose|
3223219|NCT01033526|Placebo Comparator|Arm 2|
3223220|NCT01033526|Experimental|Arm 1|
3223221|NCT01033513||Literature Only (Control)|The participants on this arm served as the control group. Five types of literature were mailed to the participants in the literature only arm. A letter was included with the materials thanking participants for their participation, requesting that the participants read the literature, and encouraging them to contact the RDs with any questions. The Clinical Study Manager's telephone number was provided for questions about diet or lifestyle changes. The RDs documented all contacts with participants on a phone summary. Other than the delivery of literature and responses to specific questions asked by the participant or the participant's primary caregiver through telephone calls, the RDs had no further interaction with the participant until the conclusion of the participant's trial period.
3223222|NCT01033513||Meals Only|Participants in the meals only arm received a pre-intervention assessment (but no nutrition counseling). The RDs gave the participants in the meals only arm a phone number and encouraged them to phone with questions or problems, especially problems associated with the meals. Subsequently, the meals only participants received seven diagnosis-appropriate therapeutic meals a week, delivered once per week. The meals were specially designed to address the participants' medical diagnoses. They were developed using the ADA MNT protocols for caloric and nutrient content requirements for individuals with the specified diagnoses, in addition to meeting AoA Nutrition Program dietary requirements. The meals were provided primarily in frozen form. However, some shelf-stable and refrigerated components were also included. In conformance with AoA regulations, appropriate meals were also offered to the spouse of any participant receiving a therapeutic meal.
3223223|NCT01033513||MNT Only|The participants in this arm received MNT from the project RDs, who employed the Hyperlipidemia Medical Nutrition Therapy MNT Protocol, developed by ADA (2002). Because ADA had not finalized MNT protocols for hypertension, the RDs followed the protocol for hyperlipidemia for participants diagnosed with either hyperlipidemia or hypertension, with adjustments, as appropriate, to benefit those individuals who were diagnosed with hypertension.All MNT sessions were in the participants' homes, and if a caregiver was required for the individual to participate in the project, every effort was made to include this person in the MNT sessions. The MNT intervention took place over at least three sessions, and, in conformance with the ADA protocol, each participant received individualized counseling and education.
3223224|NCT01033513||Meals and MNT|The participants assigned to the MNT plus meals arm received both of the interventions, as described above.
3223629|NCT01030692|Active Comparator|Huperzine A 0.4 mg|Huperzine A 0.4 mg
3223225|NCT01033500|Experimental|SIK|Basiliximab induction with maintenance immunosuppression consisting of belatacept, sirolimus or everolimus, and mycophenolate after simultaneous islet kidney transplantation.
3223226|NCT01033487|Placebo Comparator|Placebo|
3223227|NCT01033487|Active Comparator|active comparator|
3223228|NCT01033487|Experimental|PF-03635659|
3223229|NCT01033474||donor eggs|
3223230|NCT01033474||infertile patients|
3223231|NCT01033461|Experimental|calcium and probiotic|intervention
3223232|NCT01033461|Experimental|probiotic|intervention
3223233|NCT01033461|Placebo Comparator|placebo|placebo, no intervention
3223234|NCT01033448|Experimental|Single arm|
3223235|NCT01033435||chronic Hemodialysis patients, treated in our unit.|
3223236|NCT01033435||chronic Hemodialysis patients , No intervention|chronic Hemodialysis patients, treated in our unit.
3223237|NCT01033422|Experimental|CF101|CF101 (1 or 2 mg) orally q12 hours
3223238|NCT01033422|Placebo Comparator|Placebo|matching placebo orally q12 hours
3223239|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^7|Arm 1 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^7 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^7 CFU oral dosage through Day 28.
3223240|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^8|Arm 2 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^8 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^8 CFU oral dosage through Day 28.
3223241|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^9|Arm 3 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^9 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^9 CFU oral dosage through Day 28.
3223242|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^10|Arm 4 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^10 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^10 CFU oral dosage through Day 28.
3223243|NCT01033396|Experimental|PF-03654764 + Allegra|
3223244|NCT01033396|Experimental|PF-03654764|
3223245|NCT01033396|Active Comparator|Allegra-D|
3223246|NCT01033396|Placebo Comparator|Placebo|
3223247|NCT01033383|Placebo Comparator|3 placebo capsules|3 placebo capsules qd
3223248|NCT01033383|Experimental|1 cranberry capsule & 2 placebo capsules|1 active cranberry capsule and 2 placebo capsules qd
3223249|NCT01033383|Experimental|2 cranberry capsules & 1 placebo capsule|2 active cranberry capsules and 1 placebo capsules qd
3223250|NCT01033383|Experimental|3 cranberry capsules|3 active cranberry capsules qd
3223251|NCT01033370|Other|Open label, non-randomized, pilot study|All subjects who provide consent for trial participation with an acute aortic emergency and elevated BP (systolic blood pressure [SBP] ≥120 mm Hg) requiring IV antihypertensive therapy for up to 48 hours will be administered an infusion of clevidipine to evaluate the efficacy and safety of the IV drug.
3223252|NCT01033357|Active Comparator|Graft, Vascular Wrap|Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
3223253|NCT01033357|Placebo Comparator|Graft|Lifespan® ePTFE Vascular Graft Only
3223254|NCT01033344|Placebo Comparator|Placebo|Solution resembling active solution but without peptides
3223255|NCT01033344|Experimental|Group 1|Cat-PAD dose group 1
3223256|NCT01033344|Experimental|Group 2|Cat-PAD Dose group 2
3223257|NCT01033318|Experimental|Part 1 A-1|"Part 1; Panel A; Sequence 1:~2 mg MK1809 / placebo / 50 mg MK1809 / 150 mg MK1809 / 100 mg Losartan"
3223258|NCT01033318|Experimental|Part 1 A-2|"Part 1; Panel A; Sequence 2:~Losartan / 10 mg MK1809 / placebo / 150 mg MK1809 / 280 mg MK1809"
3223259|NCT01033318|Experimental|Part 1 A-3|Part 1; Panel A; Sequence 3 2 mg MK1809 / 10 mg MK1809 / Losartan / Placebo / 280 mg MK1809
3223260|NCT01033318|Experimental|Part 1 A-4|Part 1; Panel A; Sequence 4 2 mg MK1809 / Losartan / 50 mg MK1809 / 150 mg MK1809 / Placebo
3223261|NCT01033318|Experimental|Part 1 A-5|"Part 1; Panel A; Sequence 5:~Placebo / 10 mg MK1809 / 50 mg MK1809 / Losartan / 280 mg MK1809"
3223262|NCT01033318|Experimental|Part 1 B-1|"Part 1; Panel B; Sequence 1:~5 mg MK1809 / Placebo / 100 mg MK1809 / 210 mg MK1809 / Placebo with food"
3223263|NCT01033318|Experimental|Part 1 B-2|"Part 1; Panel B; Sequence 2:~5 mg MK1809 / 25 mg MK1809/ Placebo / Losartan / 25 mg MK1809 with food"
3223264|NCT01033318|Experimental|Part 1 B-3|"Part 1; Panel B; Sequence 3:~5 mg MK1809 / Losartan / 100 mg MK1809 / 210 mg MK1809 / Losartan with food"
3223265|NCT01033318|Experimental|Part 1 B-4|"Part 1; Panel B; Sequence 4:~Losartan / 25 mg MK1809/ 100 mg MK1809 / Placebo / 25 mg MK1809 with food"
3223266|NCT01033318|Experimental|Part 1 B-5|"Part 1; Panel B; Sequence 5:~Placebo / 25 mg MK1809/ Losartan / 210 mg MK1809 / 25 mg MK1809 with food"
3223267|NCT01033318|Experimental|Part 2 C-1|"Part 2; Panel C; Sequence 1:~50 mg MK1809 / Placebo / 150 mg MK1809 / 210 mg MK1809 / Losartan"
3223268|NCT01033318|Experimental|Part 2 C-2|"Part 2; Panel C; Sequence 2:~50 mg MK1809 / 100 mg MK1809/ Placebo / Losartan / 280 mg MK1809"
3223269|NCT01033318|Experimental|Part 2 C-3|"Part 2; Panel C; Sequence 3:~Losartan / 100 mg MK1809/ 150 mg MK1809 / 210 mg MK1809 / Placebo"
3223270|NCT01033318|Experimental|Part 2 C-4|"Part 2; Panel C; Sequence 4:~50 mg MK1809 / Losartan / 150 mg MK1809 / Placebo / 280 mg MK1809"
3223271|NCT01033318|Experimental|Part 2 C-5|"Part 2; Panel C; Sequence 5:~Placebo / 100 mg MK1809/ Losartan / 210 mg MK1809 / 280 mg MK1809"
3223272|NCT01033305|Placebo Comparator|Placebo|
3223273|NCT01033305|Experimental|CyCol™|
3223274|NCT01033292|Experimental|BSI-201|BSI-201 in combination with gemcitabine and carboplatin.
3223275|NCT01033279|No Intervention|Usual care|Patients followed by usual care at the hospital's anticoagulation clinic
3223276|NCT01033279|Experimental|Self-management|Self-monitoring and self-adjustment of oral anticoagulation according to predefined algorithms
3223277|NCT01033266|Other|CPAP|
3223625|NCT01030718|Experimental|dasatinib (Ph+ ALL)|Ph+ Acute Lymphoblastic Leukemia
3223278|NCT01033253|Experimental|Computerized Tailored Intervention|Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
3223279|NCT01033253|No Intervention|Control|Computerized assessments of Transtheoretical Model constructs at 0, 2, 6, and 12 months
3223280|NCT01033240|Experimental|Safety Cohort 1 CS-1008 and sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (2 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth [PO] twice daily [BID]) over 4 weeks observation, and may continue treatment until progression.
3223281|NCT01033240|Experimental|Treatment Group 1 CS-1008 and sorafenib|Combination of CS-1008 and sorafenib. Treatment Group 1: CS-1008 (6 mg/kg [or as determined] loading, 2 mg/kg/week maintenance) + sorafenib twice daily {BID} (N=50)
3223282|NCT01033240|Active Comparator|Treatment Group 3 with sorafenib alone|Combination of CS-1008 and sorafenib. Treatment Group 3: sorafenib BID (N=50)
3223283|NCT01033240|Experimental|Safety Cohort 2 CS-1008 and sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (4 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth [PO] twice daily [BID]) over 4 weeks observation, and may continue treatment until progression.
3223284|NCT01033240|Experimental|Safety Cohort 3 CS-1008 and sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (6 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth [PO] twice daily [BID]) over 4 weeks observation, and may continue treatment until progression.
3223285|NCT01033240|Experimental|Treatment Group 2 with CS-1008 and sorafenib|Combination of CS-1008 and sorafenib. Treatment Group 2: CS-1008 (6 mg/kg [or as determined] loading, 6 mg/kg/week [or maximum tolerated dose {MTD}] maintenance) + sorafenib BID (N=50)
3223286|NCT01033227|No Intervention|No drug|No study drug administered
3223287|NCT01033227|Experimental|Sodium nitrite injection, USP|Administration if sodium nitrite injection, USP
3223288|NCT01033214|Experimental|TAArget Thoracic Stent Graft|those treated with the investigational device
3223289|NCT01033201||Lung transplant|All lung transplant patients presenting for screening/surveillance and diagnostic bronchoscopies at Mayo Clinic Florida are eligible for participation.
3223290|NCT01033188|Active Comparator|Single-bundle technique|Anatomic single-bundle technique
3223291|NCT01033188|Active Comparator|Double-bundle technique|Anatomic double bundle technique
3223292|NCT01033175|Other|COPD patients with ACD|"In the 1st part of this clinical study the prevalence ACD in COPD subjects will be estimated in a consecutive population of COPD subjects who will visit the hospital's pulmonary clinics as outpatients. During the first visit, subjects will give a detailed medical history and will undergo clinical examination and pulmonary function testing 15 minutes post-bronchodilation. Eligible patients will then undergo peripheral venous blood analysis. The first 30 COPD subjects from the population described above, fulfilling the criteria of ACD will constitute the first arm (group of cases).ACD is defined by low Hb levels (men: <13 mg/dl, women: <12 mg/dl), no other cause of anemia present, normal or increased serum ferritin and decreased total iron binding capacity."
3223293|NCT01033175|Other|COPD patients without ACD|"Thirty matched patients with COPD without ACD from the initial cohort will constitute the second arm (the controls)"
3223294|NCT01033162|No Intervention|Usual Care|A group using a Basic ICCS provided by KPNW
3223295|NCT01033162|Experimental|Intervention|A group using an enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)
3223296|NCT01033149|Other|N-acetylcysteine|open label N-acetylcysteine, flexible dose
3223297|NCT01033136|Experimental|MCET-V|Multiple Channel Exposure Therapy -Veterans (MCET-V) is a 12-session cognitive-behavioral treatment for persons with comorbid PTSD and panic attacks. It is an integrated treatment designed to target panic and PTSD symptoms simultaneously.
3223298|NCT01033136|Active Comparator|CPT|Cognitive Processing Therapy (CPT) is a 12-session cognitive-behavioral treatment for persons with PTSD. It is a gold-standard cognitive behavioral intervention designed to target PTSD symptoms.
3223299|NCT01033123|Experimental|BSI-201|BSI-201 in combination with gemcitabine and carboplatin.
3223300|NCT01033097|Experimental|DNK333 5 mg|
3223301|NCT01033097|Placebo Comparator|Placebo to DNK333 5mg|
3223302|NCT01033097|Experimental|DNK333 25 mg|
3223303|NCT01033097|Placebo Comparator|Placebo to DNK333 25 mg|
3223304|NCT01033097|Experimental|DNK333 100 mg|
3223305|NCT01033097|Placebo Comparator|Placebo to DNK333 100 mg|
3223306|NCT01033097|Active Comparator|Betamethasone 4 mg|
3223307|NCT01033097|Experimental|DNK333 1 mg|
3223308|NCT01033097|Placebo Comparator|placebo 1mg|
3223309|NCT01033084|Experimental|Sham stimulation / sertraline|In this arm, patients will receive sham stimulation and sertraline 50mg/day. In sham stimulation, the tDCS device is set in the same fashion as the active stimulation, but the device is turned off after one minute of stimulation.
3223310|NCT01033084|Sham Comparator|Sham stimulation / placebo pill|"Placebo pills are sugar pills having the same size and shape of the active pills.~In sham stimulation, the tDCS device is set in the same fashion as the active stimulation, but the device is turned off after one minute of stimulation."
3223311|NCT01033084|Experimental|Active stimulation / Sertraline|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~Patients will receive Sertraline 50mg/day."
3223351|NCT01032837|Experimental|Oseltamivir standard dose 10 days|Adults and children 13 years and older received 75 mg oseltamivir and a placebo capsule twice daily for 10 days. Children aged 1 - 12 years received a weight-based dose (from 30 to 75 mg) oseltamivir suspension and placebo suspension orally twice daily for 10 days.
3223439|NCT01032148|Experimental|LBH589|LBH589 administered orally as once daily dose of 20 mg po q M, W, F on a q 28 day cycle, escalating to a maximum dase of 60 mg
3223312|NCT01033084|Experimental|Active stimulation / placebo pill|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~Placebo pills are sugar pills having the same size and shape of the active pill"
3223313|NCT01033071|Experimental|Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD|
3223314|NCT01033071|Experimental|Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD|
3223315|NCT01033071|Active Comparator|Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD|
3223316|NCT01033058|Active Comparator|usual care|
3223317|NCT01033058|Experimental|intensive statin treatment|
3223318|NCT01033032|Experimental|Amrubicin Phase I/II|Systemic therapy with amrubicin
3223319|NCT01033019|Experimental|LDE225 0.75%|Participants topically applied 0.75% LDE225 cream twice daily for 6 weeks.
3223320|NCT01033019|Placebo Comparator|Vehicle|Participants topically applied matching placebo cream twice daily for 6 weeks.
3223321|NCT01033006|Active Comparator|Arm 1: catheter injection|40 ml of LA through the catheter
3223322|NCT01033006|Active Comparator|Arm 2: transarterial injection|30 ml deep and 10 ml superficial to the artery
3223323|NCT01033006|Active Comparator|Arm 3: catheter and transarterial injection|20 + 10 ml transarterial block and 10 ml through the catheter
3223324|NCT01032993|Active Comparator|Coenzyme Q10|600 mg of CoQ10 taken as 300 mg (three 100 mg wafers) two times daily. Study wafers: ChewQ (Tishcon Corp, Westbury, NY) are chewable wafers each containing 100 mg of Coenzyme Q10 (ubidecarenone USP). All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
3223325|NCT01032993|Placebo Comparator|Placebo|Placebo was manufactured by the manufacturer of ChewQ, Tishcon Corp (Westbury, NY), included the same excipients, but no active CoQ10, and looked and tasted identical to active agent. All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
3223326|NCT01032980||HUMENZA Vaccine Group|Participants vaccinated with HUMENZA according to the recommendations provided in the product leaflet and local recommendations.
3223327|NCT01032980||PANENZA Vaccine Group|Participants vaccinated with PANENZA according to the recommendations provided in the product leaflet and local recommendations.
3223328|NCT01032967|Active Comparator|Surgery, esophagectomy|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
3223329|NCT01032967|Active Comparator|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
3223330|NCT01032954|Active Comparator|125 to 170 U of BT-A|
3223331|NCT01032954|Active Comparator|171 to 210 U of BT-A|
3223332|NCT01032954|Active Comparator|211 to 250 U of BT-A|
3223333|NCT01032941|Placebo Comparator|Placebo|Patients in this group will be given placebo 2 packets BID for 8 weeks.
3223334|NCT01032941|Experimental|VSL#3|Patients in this group will be given 2 packets of VSL#3 BID for 8 weeks.
3223335|NCT01032928|Experimental|Respiratory Phase Training|Chronically dysphagic, medically stable patients at least 6 months post treatment for head and neck cancer with non-optimal respiratory-swallowing patterns participated in up to 8 sessions of respiratory phase training to learn an optimal respiratory - swallow phase pattern
3223336|NCT01032915|Experimental|AIN457 300mg s.c weekly for 3 weeks|AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
3223337|NCT01032915|Experimental|AIN457 300mg s.c at baseline and Week 2|AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
3223338|NCT01032915|Experimental|AIN457 150mg s.c at baseline and Week 2|AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
3223339|NCT01032915|Placebo Comparator|Placebo s.c weekly for 3 weeks|Placebo s.c weekly for 3 weeks then every 2 weeks
3223340|NCT01032902||Known HIV positive|Patients from HIV clinics with documented infections
3223341|NCT01032902||High Risk for Infection with HIV|Patients from defined HIV high-risk populations - i.e. intravenous drug users, or patients presenting with symptoms of sexually transmitted disease.
3223342|NCT01032902||Low-Risk for Infection with HIV|"Individuals not known to belong to any of the defined high-risk groups - i.e. healthy patients presenting for routine physicals or other unrelated non-life threatening illnesses, or individuals from a general low risk population such as students, employees of academic or other institutions, etc…"
3223343|NCT01032889|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3223344|NCT01032889|Experimental|Deoxycholic acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3223345|NCT01032889|Experimental|Deoxycholic acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3223346|NCT01032876|Experimental|Deep Hypothermic Circulatory Arrest|
3223347|NCT01032876|Experimental|Antegrade Cerebral Perfusion|
3223348|NCT01032863||Young healthy Indian adults|Persons aged between 25 and 40 years of age who are relatives of patients being treated in Amrita Institute of Medical Sciences (Inpatient or Outpatient) and voluntary blood donors at the same institute who are willing to participate in the study.
3223349|NCT01032850|Experimental|Arm 1: Sorafenib & Capecitabine|Intervention: Sorafenib & Capecitabine: Sorafenib twice a day by mouth (400mg) Capecitabine twice a day by mouth (850mg)
3223350|NCT01032837|Experimental|Oseltamivir standard dose 5 days|Adults and children 13 years and older received 75 mg oseltamivir and a placebo capsule twice daily for 5 days. Children aged 1 - 12 years received a weight-based dose (from 30 to 75 mg) oseltamivir suspension and placebo suspension orally twice daily for 5 days. Participants received matching placebo for the second 5 days of treatment.
3223436|NCT01032174||Amoxiclav 1000 mg|Acute Bacterial Maxillary Sinusitis
3223437|NCT01032161||Delirium|Delirium was determined by RASS-PAEDS
3223352|NCT01032837|Experimental|Oseltamivir high dose 5 days|Adults and children 13 years and older received 150 mg (2 x 75 mg) oseltamivir capsules twice daily for 5 days. Children aged 1 - 12 years received a weight-based dose (from 60 to 150 mg) oseltamivir suspension orally twice daily for 5 days. Participants received matching placebo for the second 5 days of treatment.
3223353|NCT01032837|Experimental|Oseltamivir high dose 10 days|Adults and children 13 years and older received 150 mg (2 x 75 mg) oseltamivir capsules twice daily for 10 days. Children aged 1- 12 years received a weight-based dose (from 60 to 150 mg) oseltamivir suspension orally twice daily for 10 days.
3223354|NCT01032824|Experimental|Intervention|Individual telephone counseling intervention.
3223355|NCT01032824|Other|Group Arm|Attention-matched comparison arm
3223356|NCT01032824|Other|Book Arm|Information-matched control arm.
3223357|NCT01032811||Study Participants|St. Jude Children's Research Hospital patients from Leukemia, Neuro-Oncology, Radiation Oncology, and After Completion of Therapy (ACT) clinics.
3223358|NCT01032785||Healthy term newborn|Any healthy term newborn born in Wolfson Medical Center
3223359|NCT01032772|Experimental|CHOICES Plus Intervention|A two session intervention utilizing a motivational interviewing approach to encourage changes in alcohol use, contraceptive use, and smoking. The interventions will (a) provide norms-based-but personalized-feedback, (b) encourage attendance at a contraceptive counseling visit, (c) encourage participation in the smoking cessation program, (c) increase motivation to change each of the target behaviors, (d) decrease temptation to engage in risk behaviors, (e) increase confidence to avoid risk behaviors, and (f) develop a personalized, tailored change plan.
3223360|NCT01032772|Active Comparator|Information|Women in the information condition receive advice and educational material from the research assistant about women's health and related referrals.
3223361|NCT01032759|Active Comparator|Memantine|
3223362|NCT01032759|Placebo Comparator|Placebo|Placebo
3223363|NCT01032733|Experimental|Lifestyle Counseling|In the experimental condition, participants attended a group-based weight management session plus three supervised exercise sessions each week.
3223364|NCT01032733|Placebo Comparator|Educational Control|Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss.
3223365|NCT01032720|Experimental|Ultrasound-guided knee CS injection|Ultrasound will be used to image knee joint and guide needle for intra-articular knee CS injection.
3223366|NCT01032720|Sham Comparator|Sham Ultrasound knee CS injection|CS knee injection will be performed in the same method as the US-guided knee injection but the US machine will be turned off.
3223367|NCT01032694||Z-max treated group|Patients with Community-Acquired Pneumonia
3223368|NCT01032694||Amoxiclav treated group|Patients with Community-Acquired Pneumonia
3223369|NCT01032681|Experimental|Group 1|Dose escalation of EMD 521873 monotheraphy 3 doses per cycle
3223370|NCT01032681|Experimental|Group 2|Low dose CPA + Dose escalation of EMD 521873 three doses per cycle
3223371|NCT01032681|Experimental|Group 3|Dose escalation of EMD 521873 monotheraphy 1 dose per cycle
3223372|NCT01032668|Experimental|high dose clopidogrel|
3223373|NCT01032655|Experimental|sequential, susceptibility guided|single arm
3223374|NCT01032642|Experimental|thin catheter group|group of women where thin catheter will be used for hysterosalpingography
3223375|NCT01032629|Placebo Comparator|Placebo|Each patient will receive placebo (inactive medication) on background standard of care for diabetes once daily for the duration of the study
3223376|NCT01032629|Experimental|Canagliflozin (JNJ-28431754) 100 mg|Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily on background standard of care for diabetes once daily for the duration of the study
3223377|NCT01032629|Experimental|Canagliflozin (JNJ-28431754) 300 mg|Each patient will receive canagliflozin (JNJ-28431754) 300 mg once daily on background standard of care for diabetes once daily for the duration of the study
3223378|NCT01032616|Experimental|Study Period 1|AA given by parenteral and enteral routes with tracer 1-13C phenylalanine given to observe differences
3223379|NCT01032616|Experimental|Study Period 2|AA given by parenteral and enteral routes with tracer 1-13C phenylalanine given to observe differences
3223380|NCT01032603|Active Comparator|Bilateral lateral rectus recession|Bilateral lateral rectus recession surgery
3223381|NCT01032603|Active Comparator|Unilateral lateral rectus recession|Unilateral lateral rectus recession w/ medial rectus resection surgery
3223382|NCT01032590|Experimental|Arm I|Arm I (12-week Internet-based weight-loss intervention): After a baseline evaluation, subjects will start a 12 week Internet-based weight-loss intervention.
3223383|NCT01032590|Active Comparator|Arm II|Arm II (wait-list control): Patients are instructed to continue their usual dietary and physical activity routines during a 12-week wait period. After the waiting period, patients receive the Internet-based weight-loss intervention for 12 weeks as in arm I.
3223384|NCT01032577||cardiomyopathy, with implant indications|30-50 volunteers age >18, male and female with ability to give informed consent, who are expected to live more than one year, with indication for defibrillator implant and who are not pacemaker dependent.
3223385|NCT01032551|Experimental|Vascular Access Patient Decision Aid|The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
3223386|NCT01032551|No Intervention|Usual Care|"The control group (those not randomized to the PtDA) will have usual care. Usual care involves a brief discussion, just prior to the CA procedure, with the treating physician, regarding the patient's eligibility for both vascular accesses, followed by the advantages and disadvantages of both. The details and duration of the discussion is left to the discretion of the treating physician as per their individual standard of care. There will be no access to a formal PtDA in this group."
3223387|NCT01032538||Patients with knee osteoarthritis|Patients with knee osteoarthritis that are about to get an operation with oxford unicondylar knee
3223438|NCT01032161||no Delirium|no Delirium was determined by RASS-PAEDS
3223388|NCT01032512|Experimental|IMMUNE-ENHANCING|"40 patients will be instructed to consume 600 ml of the special immune-enhancing formula plus 20 g glutamine (Supportan R + Glutamine plus R, which contain 900 Kcal and 60 g protein/day, with 24.4 g glutamine, 2,2 g arginine and 4.4 g of omega 3 fatty acids, in a lower volume due to its higher energy density)."
3223389|NCT01032512|Sham Comparator|CONTROL|40 patients that do not agree to participate, do not have enough time before the operation, do not tolerate the product and/or drink less than 100 cc/day.
3223390|NCT01032499|Active Comparator|oxytetracycline|
3223391|NCT01032499|Experimental|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
3223392|NCT01032486||Azilect|Subjects with a diagnosis of idiopathic Parkinson's disease eligible to Azilect® treatment based on the investigator's clinical assessment and according to the Canadian product monograph.
3223393|NCT01032473||GAD|Children between the ages of 7-11 years diagnosed with Generalized Anxiety Disorder (GAD)
3223394|NCT01032473||Control|Children between the ages of 7-11 years free of significant medical or behavioral problems (matched to children diagnosed with GAD based on age, gender, and ethnicity).
3223395|NCT01032460|Active Comparator|macintosh|
3223396|NCT01032460|Active Comparator|C-MAC|
3223397|NCT01032460|Active Comparator|Airtraq|
3223398|NCT01032434|Experimental|sertraline|sertraline: 50-200mg/day
3223399|NCT01032421||GNRH|Observational (IVF is not done as part of the study)
3223400|NCT01032408|Experimental|HIV-1 Infected Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria®), the first on Study Day 1, and the second on Study Day 22
3223401|NCT01032408|Experimental|HIV-1 Infected Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22
3223402|NCT01032408|Experimental|Healthy Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria®), the first on Study Day 1, and the second on Study Day 22
3223403|NCT01032408|Experimental|Healthy Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22
3223404|NCT01032395|Experimental|Chronic Disease Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria® or Fluad®), the first on Study Day 1, and the second on Study Day 22.
3223405|NCT01032395|Experimental|Chronic Disease Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.
3223406|NCT01032395|Experimental|Healthy Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria® or Flaud®), the first on Study Day 1, and the second on Study Day 22.
3223407|NCT01032395|Experimental|Healthy Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.
3223408|NCT01032382|Active Comparator|Paromomycin Alone Treatment|
3223409|NCT01032382|Active Comparator|WR 279,396|
3223410|NCT01032369|Experimental|CBT|with behavioral intervention-CBT.
3223411|NCT01032369|Other|Without CBT|Without behavioral intervention-CBT
3223412|NCT01032356|Experimental|Dynasplint|Patients will be treated with the current standard of care and the Wrist Extension Dynasplint.
3223413|NCT01032343|Active Comparator|Omega-3 PUFA capsule|
3223414|NCT01032343|Placebo Comparator|Gelatine capsule|
3223415|NCT01032330|No Intervention|Observation|Patients randomized to the observation group will receive no treatment (other than refractive correction).
3223416|NCT01032330|Active Comparator|Occlusion Therapy|
3223417|NCT01032317|Other|Single-arm Study|This study was completed prior to the implementation of the requirement for specific identification of study arms. As the requirement was not made retroactive to completed studies, we believe this study to be exempt from the stipulation. Also, per PRS definition, since this is for a single-arm/feasibility study, the data elements are optional.
3223418|NCT01032304|Experimental|Erdosteine|600 mg/day for 12 months
3223419|NCT01032304|Placebo Comparator|Placebo|Placebo for 12 months
3223420|NCT01032291|Experimental|lenalidomide plus cetuximab|Combination therapy of lenalidomide plus cetuximab
3223421|NCT01032291|Experimental|lenalidomide|Single agent therapy of lenalidomide
3223422|NCT01032278|Experimental|Cardiac Biomarker Testing|Biomarker testing for cardiac biomarkers, B-type natriuretic peptide (BNP) and Troponin I (TnI), and symptom questionnaires of participants undergoing anthracycline-based chemotherapy.
3223423|NCT01032265|Active Comparator|Web-based treatment|Web-based treatment with information (including life style), PFMT, elements of CBT and regular mail contact with an urotherapist
3223424|NCT01032265|Active Comparator|Pamphlet treatment|Information (including life style), and PFMT exercises.
3223425|NCT01032252|No Intervention|observational|Control group: followed by monthly falls calenders and four testing periods
3223426|NCT01032252|Experimental|Exercise group|16 week intervention, and followed by monthly fall calenders as well as 4 testing periods
3223427|NCT01032239|Active Comparator|ITB therapy|Intrathecal Baclofen therapy (Intrathecal baclofen + implantable pump)
3223428|NCT01032239|No Intervention|Best Medical Treatment (BMT)|Use one or a combination oral antispastic medication.
3223429|NCT01032213|Placebo Comparator|group C|control group
3223430|NCT01032213|Experimental|group M|magnesium group
3223431|NCT01032200|Experimental|Arm I - Armodafinil|Patients receive oral armodafinil once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.
3223432|NCT01032200|Placebo Comparator|Arm II - Placebo|Patients receive oral placebo once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.
3223433|NCT01032187|Active Comparator|Meglumine antimoniate|20mg/kg/day IV for 20 days
3223434|NCT01032187|Experimental|Anfo B|Amphotericin B-deoxycholate, 1mg/kg/day IV for 14 days
3223435|NCT01032174||Azithromycin SR|Acute Bacterial Maxillary Sinusitis
3223440|NCT01032135|Active Comparator|1-MI-IOP Engaged|Randomized to treatment as usual, and they attend regularly but dropped out of treatment after randomization.
3223441|NCT01032135|Experimental|2-MI-IOP Non-Engaged|Randomized to treatment as usual, and do not attend.
3223442|NCT01032135|Active Comparator|3-MI-PC Engaged|Randomized to treatment choice, but remain attending treatment as usual then dropped out of treatment after randomization.
3223443|NCT01032135|Experimental|4-MI-PC Non-engaged|Randomized to treatment choice, and do not attend treatment as usual, so the choice option is used.
3223444|NCT01032122|Experimental|rituximab|
3223445|NCT01032109|Experimental|Bevacizumab|
3223446|NCT01032083|Active Comparator|Citalopram|An SSRI antidepressant
3223447|NCT01032083|Placebo Comparator|Placebo|
3223448|NCT01032070|Experimental|Erlotinib|Erlotinib was administered orally at a dose of 85 mg/m^2 per day continuously until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity.
3223449|NCT01032070|Active Comparator|Etoposide|Etoposide 50 mg/m^2 per day was administered orally for 21 days followed by a 7-day rest period until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity.
3223450|NCT01032057|Active Comparator|Gemcitabine|GEMCAP induction chemotherapy (28 day cycle of IV gemcitabine 1000mg/m2 day 1, 8,15 and capecitabine 830mg/m2 bd for 21 days po) followed by gemcitabine 300mg/m2 weekly (IV) + 50.4Gy radiation over five and half weeks (1.8Gy per fraction, Monday-Friday)
3223451|NCT01032057|Active Comparator|chemoradiotherpay with capecitabine|GEMCAP induction chemotherapy (28 day cycle of IV gemcitabine 1000mg/m2 day 1, 8,15 and capecitabine 830mg/m2 bd for 21 days po), followed by capecitabine 830mg/m2 bd (po, Mon-Fri) + 50.4Gy radiation over five and half weeks (1.8Gy per fraction, Monday-Friday)
3223452|NCT01032044|Active Comparator|Standard endoscopic evaluation|Standard high-definition white light endoscopy guided evaluation
3223453|NCT01032044|Experimental|pCLE-guided evaluation|Endoscopic evaluation of BE guided by probe-based Confocal Laser Endomicroscopy (pCLE guided evaluation)
3223454|NCT01032031|Active Comparator|Green tea + vit C high dose|
3223455|NCT01032031|Placebo Comparator|Placebo|
3223456|NCT01032018|Active Comparator|Referred Care|Immediately after the initial post-ACS screening, the participant's physician will be notified in writing if the participant is depressed according to the BDI. Depending upon the physician's own evaluation of the participant, he or she may elect to defer depression treatment, initiate it, or to refer the patient to a mental health specialist.
3223457|NCT01032018|Experimental|Stepped Care|Stepped Care participants will be given a description of the choices available in this arm, including choosing antidepressant medication and/or telephone-based, Problem-Solving Therapy (PST). If the patient is randomized to Stepped Care, their physician will be informed that depression treatment is being provided by the trial. Patients will select their preferred treatment approach. Depression symptoms will be monitored to determine whether the patient is improving relative to his/her baseline score. Relapse monitoring and maintenance therapy will continue for the duration of the study.
3223458|NCT01032005|Placebo Comparator|Fortified salt|Common table salt that has been fortified with iodine only
3223459|NCT01032005|Experimental|Double fortified salt|Common table salt that has been fortified with iron and well as the usual iodine
3223460|NCT01031992|Experimental|Group I|First verum (3 times 1 g Tranexamic acid daily) for three months, than placebo for 3 months.
3223461|NCT01031992|Experimental|Group II|First placebo for 3 months, than verum for 3 months (3 times 1 g Tranexamic acid daily).
3223462|NCT01031979|Experimental|Yohimbime Group|Patients will take one 21.6 mg. dose of yohimbine one hour before first imaginal exposure in PE.
3223463|NCT01031979|Placebo Comparator|Placebo Group|Patients will take a placebo one hour before first imaginal exposure in PE.
3223464|NCT01031966|Active Comparator|H1N1sw monovalent vaccine|
3223465|NCT01031966|Experimental|Thymosin alpha 1 3.2mg|
3223466|NCT01031966|Experimental|Thymosin alpha 1 6.4 mg|
3223467|NCT01031953|Experimental|Fosaprepitant|
3223468|NCT01031940|Active Comparator|macintosh|
3223469|NCT01031940|Active Comparator|C-MAC|
3223470|NCT01031940|Active Comparator|Airtraq|
3223471|NCT01031914|Experimental|Paced Breathing Sleep/Wake detection|All subjects enrolled will have oobstructive sleep apnea (OSA) and will be current Continuous Positive Airway Pressur (CPAP) users.
3223472|NCT01031901|Placebo Comparator|TSC Placebo Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating alone to facial angiofibromas
3223473|NCT01031901|Experimental|TSC 1% Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to facial angiofibromas
3223474|NCT01031901|Experimental|TSC 5% Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to facial angiofibromas
3223475|NCT01031901|Placebo Comparator|NF1 Placebo Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating alone to cutaneous neurofibromas
3223476|NCT01031901|Experimental|NF1 1% Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to cutaneous neurofibromas
3223477|NCT01031901|Experimental|NF1 5% Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to cutaneous neurofibromas
3223478|NCT01031888|Active Comparator|1|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy receiving topical insulin eye drops in addition to conventional postoperative eye drops
3223479|NCT01031888|Active Comparator|2|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for penetrating keratoplasty receiving topical insulin eye drops in addition to conventional postoperative eye drops
3223480|NCT01031888|Placebo Comparator|3|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy treated with conventional postoperative eye drops
3223481|NCT01031888|Placebo Comparator|4|corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for penetrating keratoplasty receiving conventional postoperative eye drops
3223482|NCT01031862|Other|Healthy Volunteers|12 healthy volunteers
3223626|NCT01030692|Placebo Comparator|Placebo|Placebo capsules as control
3223483|NCT01031849|Experimental|Kaletra, all patients|Patients will change actual treament for monotherapy LPV/r. They only will take Kaletra 2/day
3223484|NCT01031836|Experimental|MEDI-545 1.0 mg/kg|Cohort 1
3223485|NCT01031836|Experimental|MEDI-545 3.0 mg/kg|Cohort 2
3223486|NCT01031836|Experimental|MEDI-545 10.0 mg/kg|Cohort 3
3223487|NCT01031836|Experimental|MEDI-545 100 mg|Cohort 4
3223488|NCT01031836|Experimental|MEDI-545 600 mg|Cohort 5
3223489|NCT01031836|Experimental|MEDI-545 1,200 mg|Cohort 6
3223490|NCT01031823|Experimental|Social Skills Training|All participants will take part in this arm of the study.
3223491|NCT01031810|Other|tranylcypromine|patients will receive treatment with tranylcypromine
3223492|NCT01031797||High SLEDAS|High SLE disease activity score
3223493|NCT01031797||Low SLEDAS|SLE patient with low score
3223494|NCT01031784|Experimental|Holmium-166 microspheres, intra-arterial|intra-arterial administration of holmium-166 microspheres in the liver
3223495|NCT01031758|Other|Group 1|Group 1 is comprised of 6 healthy subjects with HDL-C levels between the 25th and 75th percentile.
3223496|NCT01031758|Other|Group 2|Group 2 is comprised of 6 healthy subjects with high HDL-C levels > 75th percentile.
3223497|NCT01031758|Other|Group 3|Group 2 is comprised of 6 healthy subjects with low HDL-C levels < 25th percentile.
3223498|NCT01031745|Experimental|Contingency|
3223499|NCT01031745|Active Comparator|Control|
3223500|NCT01031732|Experimental|Two-incision|MIS-2 THA
3223501|NCT01031732|Experimental|Watson-Jones|MIS-WJ
3223502|NCT01031732|Experimental|MIS-AL|
3223503|NCT01031732|Experimental|MIS-PL|
3223504|NCT01031719|Experimental|Group A: High Risk Population|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
3223505|NCT01031719|Experimental|Group B: High Risk Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
3223506|NCT01031719|Experimental|Group C: Healthy Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
3223507|NCT01031719|Experimental|Group D: Healthy Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
3223508|NCT01031706|Experimental|Hypertonic saline|6% NaCl, 4 ml TID via eFlow
3223509|NCT01031706|Placebo Comparator|Placebo|0.12% x 4ml via eFlow nebulizer
3223510|NCT01031693|Active Comparator|Group A|Active TMS
3223511|NCT01031693|Sham Comparator|Group B|Sham TMS
3223512|NCT01031680|Experimental|1|Dapagliflozin 10 mg tablet
3223513|NCT01031680|Placebo Comparator|2|Matching placebo tablet
3223514|NCT01031628|Active Comparator|Arm A|Patients with blood level less than 1100 will continue imatinib 400 mg daily
3223515|NCT01031628|Active Comparator|Arm B|Patients with blood level less than 1100 dose adjust imatinib mesylate to goal blood level ≥1100 ng/mL
3223516|NCT01031628|Active Comparator|Arm C|Patients with blood level ≥1100 will continue imatinib 400 mg daily
3223517|NCT01031628|Active Comparator|Arm D|Patients with tumors that harbor exon 9 mutations will continue imatinib mesylate at 400 mg or dose escalate up to 800 mg daily
3223518|NCT01031615|Experimental|Child and Family Traumatic Stress Interv|4-session secondary prevention model that focuses on family communication about symptoms of a child aged 7-16.
3223519|NCT01031615|Active Comparator|Psychoeducational Comparison|4-sessions focused on individual child using psychoeducation and relaxation skills
3223520|NCT01031602||Psych Needs Assessment|Female Sexual Function Index (FSFI), Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire given to underserved and minority women with a gynecologic cancer or premalignant condition.
3223521|NCT01031550|Active Comparator|standard anesthetic management|standard anesthetic management with propofol 100-150mcg/kg/min
3223522|NCT01031550|Experimental|preconditioning with 2 MAC isoflurane group|After induction, anesthesia will be maintained with 1MAC (minimum alveolar concentration) of Isoflurane according to age and end-expiratory concentration. Thirty minutes before the anticipated inflow occlusion and commencement of liver transaction, Isoflurane concentration will be gradually increased to 2 MAC over a period of 5 minutes (induction) and maintained at 2 MAC for 10 minutes (preconditioning). Then the concentration of Isoflurane will be decreased to 1 MAC during next 15 minutes (washout).
3223523|NCT01031537|Other|FSME-IMMUN 0.5mL Baxter|FSME-IMMUN 0.5mL Baxter is non-US licensed vaccine for tick-borne encephalitis virus. The FSME-IMMUN 0.5mL Baxter is available as 0.5mL in a pre-loaded vaccine syringe. All participants received active vaccine using a rapid immunization schedule, with vaccine administration on Days 0, 14, 161 and 245. Participants that tested seropositive for tick-borne encephalitis virus or subjects that developed positive viral neutralizer titers after the 3rd or 4th vaccine were given a booster of FSME-IMMUN 0.5mL Baxter vaccine at 3, 6 and 9 years after enrollment.
3223524|NCT01031524|Experimental|vaccine|30 µg of PfCS102 formulated in Montanide ISA 720
3223525|NCT01031524|Placebo Comparator|adjuvant|Montanide ISA 720
3223526|NCT01031511|Experimental|Treatment Group - CBT|
3223527|NCT01031511|No Intervention|Control Group|
3223528|NCT01031498|Active Comparator|Ondansetron: Standard of Care|Standard of care, Ondansetron 8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
3223529|NCT01031498|Experimental|Palonosetron Group 1 (5 Days)|Palonosetron once a day 0.25 mg IV injection for 5 days, given over 30 seconds, 30 minutes before chemotherapy treatment.
3223530|NCT01031498|Experimental|Palonosetron Group 2 (3 Days)|Palonosetron once a day 0.25 mg IV injection on Days 1, 3, and 5 of chemotherapy treatment, given over 30 seconds, 30 minutes before chemotherapy treatment.
3223531|NCT01031485|Active Comparator|Spread with milk peptides and plant sterols|
3223532|NCT01031485|Placebo Comparator|Standard spread|
3223533|NCT01031472|Experimental|Part A|Subjects will be randomized in a three way crossover design to either a single dose of GSK2248761 100mg Gelucire capsule administered with food and a single dose of 100mg of formulation 1 or a single dose of 100mg of formulation 3 administered in the fed and fasted state
3223622|NCT01030731|Active Comparator|Ceftobiprole (healthy subjects)|Ceftobiprole 250 mg single dose over 2 hours.
3223534|NCT01031472|Experimental|Part B|A total of twelve subjects who complete Part A will participate in Part B. Subjects from Part A will be asked to participate on a first come first serve basis until there are 12 subjects, at which time enrolment to Part B will be closed. Part B will be a 2 way cross over study design. Subjects will be randomized to one of a single dose of GSK2248761 100mg Formulation 2 or 4 (based on the evaluation of Part A data) administered with food or in the fasted state. Subjects in Part B will not receive the reference formulation since they previously received this in Part A
3223535|NCT01031459||Group 1|
3223536|NCT01031446|Experimental|Treatment|
3223537|NCT01031420|Experimental|dose dense MVAC|standard doses of MVAC given every 14 days x 3.
3223538|NCT01031394|Active Comparator|Group 1|1 aerobic and 1 resistance training per week
3223539|NCT01031394|Active Comparator|Group 2|2 aerobic and 2 resistance training each per week
3223540|NCT01031394|Active Comparator|Group 3|3 aerobic and 3 resistance training per week
3223541|NCT01031381|Other|Rad001/Bevacizumab|Patients will receive RAD001 by mouth everyday and Bevacizumab IV every 14 days until clinical progression.
3223542|NCT01031368|Experimental|Treatment (chemotherapy, G-CSF, cord blood infusion)|"INDUCTION THERAPY: Patients receive clofarabine IV over 1 hour and cytarabine hydrochloride IV over 2 hours on days 1-5. Patients receive an infusion of non-HLA matched ex vivo expanded cord blood progenitors on day 6. G-CSF is administered SC on days 0-5 and from day 7 until blood counts recover. Treatment modifications may apply according to response.~CONSOLIDATION THERAPY: Patients receive clofarabine IV over 1 hour and cytarabine hydrochloride IV over 2 hours on days 1-5. Patients also receive G-CSF SC beginning on day 0 and continuing until blood counts recover."
3223543|NCT01031355|Experimental|Arm 1|
3223544|NCT01031355|Active Comparator|Arm 2|
3223545|NCT01031355|Active Comparator|Arm 3|
3223546|NCT01031342|Experimental|Early colonoscopy|Colonoscopy performed within 12 hours of presentation
3223547|NCT01031342|Active Comparator|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
3223548|NCT01031329||Complicated Acute otitis media Group|"This group was divided into 3 sub-groups.~One sub-group includes treatment failure subjects who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment or reappearance of symptoms within 10 days following the end of antibiotic treatment.~The second sub-group includes subjects with recurrent acute otitis media, who have had new episodes of acute otitis media within the past 6 months or the fourth (or greater) new episode within the past year.~The third sub-group includes subjects with spontaneous otorrhoea if perforation has occurred < 24 hours prior to the visit."
3223549|NCT01031316|Experimental|Nondisclosure|
3223550|NCT01031316|Active Comparator|Disclosure|
3223551|NCT01031303|Experimental|Study Group|
3223552|NCT01031290|Experimental|Group A|Active TMS
3223553|NCT01031290|Sham Comparator|Group B|Sham TMS
3223554|NCT01031264||Social drinkers|
3223555|NCT01031225|Experimental|1|
3223556|NCT01031199|Experimental|Arm 1|
3223557|NCT01031199|Experimental|Arm 2|
3223558|NCT01031186|Experimental|Cohort 1, Session 1|In Dosing Session 1, the subjects will be administered 0.5 mg GSK356278 and placebo in a fasted state.
3223559|NCT01031186|Experimental|Cohort 1, Session 2|In Dosing Session 2, the subjects will be administered GSK356278 (0.5 mg and 1.5 mg) and placebo in a fasted state.
3223560|NCT01031186|Experimental|Cohort 1, Session 3|In Dosing Session 3, the subjects will be administered GSK356278 (1.5 mg and 4 mg) and placebo in a fasted state.
3223561|NCT01031186|Experimental|Cohort 1, Session 4|In Dosing Session 4, the subjects will be administered GSK356278 (4 mg and 8 mg) and placebo in a fasted state.
3223562|NCT01031186|Experimental|Cohort 1, Session 5|In Dosing Session 5, the subjects will be administered GSK356278 8 mg and placebo in a fasted state.
3223563|NCT01031186|Experimental|Cohort 2, Session 1|In Dosing Session 1, the subjects will be administered 8 mg GSK356278 and placebo in a fasted state.
3223564|NCT01031186|Experimental|Cohort 2, Session 2|In Dosing Session 2, the subjects will be administered GSK356278 (8 mg and 16 mg) and placebo in a fasted state.
3223565|NCT01031186|Experimental|Cohort 2, Session 3|In Dosing Session 3, the subjects will be administered GSK356278 (16 mg and 30 mg) and placebo in a fasted state.
3223566|NCT01031186|Experimental|Cohort 2, Session 4|In Dosing Session 4, the subjects will be administered GSK356278 (30 mg and 50 mg) and placebo in a fasted state.
3223567|NCT01031186|Experimental|Cohort 2, Session 5|In Dosing Session 5, the subjects will be administered GSK356278 50 mg and placebo in a fasted state. The subjects will undergo food assessment session in Session 5 incase they experience nausea. In food assessment session, the subjects will receive a dose of GSK356278 after a standard breakfast.
3223568|NCT01031147||Magnetic resonance angiography|Three-dimensional time-of-flight magnetic resonance angiography(3D−TOF−MRA) was used to detect the intracranial aneurysms in this study
3223569|NCT01031134|Experimental|Shared Decision Making|1 in person session followed by 2 telephone calls 1 and 2 weeks later.
3223570|NCT01031134|Active Comparator|Usual Care|Physician Usual Care of depressed patients.
3223571|NCT01031108|Other|Type 2 Diabetic Group|The Type 2 Diabetic Treatment Group will be randomized to receive test material (2.0g SRT2104 or placebo) in the form of 8 capsules per day for 28 days. After 28 days of dosing, subjects will cross over to receive placebo or 2.0g SRT2104 for an additional 28 days. Dosing of SRT2104 or placebo will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized morning meal (220 cc of Ensure Plus®). Subjects must wait at least 1-2 hours after dosing before consuming additional calories. Water is permitted ad libitum.
3223572|NCT01031108|Other|Otherwise Healthy Cigarette Smoking Group|The Otherwise Healthy Cigarette Smoking Treatment Group will be randomized to receive test material (2.0g SRT2104 or placebo) in the form of 8 capsules per day for 28 days. After 28 days of dosing, subjects will cross over to receive placebo or 2.0g SRT2104 for an additional 28 days. Dosing of SRT2104 or placebo will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized morning meal (220 cc of Ensure Plus®). Subjects must wait at least 1-2 hours after dosing before consuming additional calories. Water is permitted ad libitum.
3223573|NCT01031095|Experimental|Low dose intracoronary heparin|Low dose intracoronary heparin: In this group elective coronary intervention was performed with low dose intracoronary Heparin
3223574|NCT01031095|Active Comparator|Standard treatment arm|Standard treatment arm: In this group elective coronary intervention performed with standard dose intravenous heparin
3223575|NCT01031082||HIV-negative Group|This group is sub-divided into two sub-groups. One sub-group includes HIV-negative/ presumed negative subjects with a new episode of acute otitis media who have not yet received antibiotic therapy for the episode and the other sub-group includes HIV-negative/ presumed negative subjects with treatment failure who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment.
3223576|NCT01031082||HIV-positive Group|This group is sub-divided into two sub-groups. One sub-group includes HIV-positive subjects with a new episode of acute otitis media who have not yet received antibiotic therapy for the episode and the other sub-group includes HIV-positive subjects with treatment failure who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment.
3223577|NCT01031069|Experimental|Group Cervarix|3 doses of the study vaccine administered according to a Day 0, Week 6, and Month 6 vaccination schedule.
3223578|NCT01031069|Active Comparator|Group Gardasil|3 doses of the study vaccine administered according to a Day 0, Week 6, and Month 6 vaccination schedule.
3223579|NCT01031043|Experimental|Topical Bethanechol|patients will be given either 5 mg (first phase) or 10 mg (second phase) of bethanechol in 1 ml of solution containing an absorption enhancer. Administration will be performed by throat spray device
3223580|NCT01031017|Placebo Comparator|placebo|group taking placebo
3223581|NCT01031017|Active Comparator|study group|group taking progesterone
3223582|NCT01031004|Experimental|narafilcon B|contact lens
3223583|NCT01031004|Active Comparator|etafilcon A|contact lens
3223584|NCT01030991||HFpEF|HFpEF cohort (observational study)
3223585|NCT01030978|Experimental|Family-based Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
3223586|NCT01030978|Active Comparator|Standard Diet & Activity Education (Control)|
3223587|NCT01030965|Experimental|GSK573719 125mcg|125mcg once-daily via novel dry powder inhaler
3223588|NCT01030965|Experimental|GSK573719 250mcg|250mcg once-daily via novel dry powder inhaler
3223589|NCT01030965|Experimental|GSK573719 500mcg|500mcg once-daily via novel dry powder inhaler
3223590|NCT01030965|Placebo Comparator|Placebo|once-daily via novel dry powder inhaler
3223591|NCT01030952|Experimental|Nateglinide|Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
3223592|NCT01030952|Active Comparator|Acarbose|Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
3223593|NCT01030939|Experimental|Cohort 1: SB-649868|Healthy adult male subjects
3223594|NCT01030939|Experimental|Cohort 2|Healthy adult female subjects
3223595|NCT01030939|Experimental|Cohort 3|Healthy male elderly subjects
3223596|NCT01030939|Experimental|Cohort 4|Healthy female elderly subjects
3223597|NCT01030926|Experimental|A1, first period|
3223598|NCT01030926|Active Comparator|A2, second period|
3223599|NCT01030926|Active Comparator|B1, first period|
3223600|NCT01030926|Experimental|B2, second period|
3223601|NCT01030913||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
3223602|NCT01030900|Experimental|1|EPOCH + Rituximab + campath every 3 weeks for six cycles
3223603|NCT01030887|Active Comparator|Exercise Programme|This will consist of an 8-week exercise programme, performed twice per week.
3223604|NCT01030887|Placebo Comparator|Usual Care|Standard practice including opportunistic exercise advice and patients' self-directed physical activity
3223605|NCT01030874|No Intervention|Arm 1|Usual rehab care
3223606|NCT01030874|Experimental|Arm 2|Treatment for, and prevention of, orthostatic hypotension
3223607|NCT01030861|Active Comparator|teplizumab|Intravenous infusions of teplizumab given for 14 consecutive days. Each infusion takes about 30 minutes and is followed by a 2 hour observation period.
3223608|NCT01030861|Placebo Comparator|Placebo infusion|Intravenous infusion of placebo (saline) will be given for 14 consecutive days. Infusions will take approximately 30 minutes and will be followed by a two hour observation period.
3223609|NCT01030848||Patients with knee osteoarthritis|
3223610|NCT01030822|Experimental|Group A|Subjects previously primed with pneumococcal vaccine GSK1024850A in the first year of life and receiving a booster dose of GSK1024850A at 9-18 months of age.
3223611|NCT01030822|Experimental|Group B|Subjects previously primed with pneumococcal vaccine GSK1024850A in the first year of life and receiving a booster dose of GSK1024850A at 15-18 months of age.
3223612|NCT01030822|Experimental|Group C|Unprimed subjects receiving a catch-up vaccination (2+1 schedule) in the second year of life.
3223613|NCT01030809|No Intervention|Usual Care practice|Patients managed according to usual care practices
3223614|NCT01030809|Active Comparator|Treatment Algorithm|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
3223615|NCT01030783|Experimental|tivozanib (AV-951)|
3223616|NCT01030783|Active Comparator|sorafenib|
3223617|NCT01030770|Experimental|Arm A (treatment)|Arm A: Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls) (Lucentis®)
3223618|NCT01030770|Placebo Comparator|Arm B (control):|Arm B: Single subconjunctival injection of 0.05mls of 0.9% sodium chloride (Minims Saline®)
3223619|NCT01030757|Experimental|Tomotherapy|Intervention: Stereotactic Body Radiation Therapy using Tomotherapy. Tomotherapy treatment: A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the PTV.
3223620|NCT01030744||Gestational Diabetes|Women with gestational diabetes who are referred to and followed in the Vanderbilt Eskind Diabetes Clinic and are participants in the gestational diabetes educational program.
3223621|NCT01030731|Experimental|Ceftobiprole (end-stage renal disease subjects).|Ceftobiprole 250mg single dose over 2 hours.
3223623|NCT01030718|Experimental|dasatinib (CML-CP)|CML - Chronic Phase
3223630|NCT01030692|Active Comparator|Huperzine A 0.8 mg|Huperzine A 0.8 mg
3223631|NCT01030679|Experimental|CKD-501 0.5mg|
3223632|NCT01030679|Experimental|CKD-501 1mg|
3223633|NCT01030679|Experimental|CKD-501 2mg|
3223634|NCT01030679|Placebo Comparator|Placebo|
3223635|NCT01030666|Experimental|doxycycline|"The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects~modified/simplified papilla preservation flap; scaling~Prefgel/Emdogain~0.12% chlorhexidine gluconate solution~Ibuprofen 400 mg (if necessary)~1% chlorhexidine gluconate gel (if necessary)"
3223636|NCT01030666|Placebo Comparator|placebo|"The patients of the control group will take placebo once a day for 7 days after regenerative therapy of an infrabony defect~modified/simplified papilla preservation flap; scaling~Prefgel/Emdogain~0.12% chlorhexidine gluconate solution~Ibuprofen 400 mg (if necessary)~1% chlorhexidine gluconate gel (if necessary)"
3223637|NCT01030653|Experimental|Voriconazole low dose first then high dose|Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (200 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (300 mg Every 12 Hours x 7 Doses)
3223638|NCT01030653|Experimental|Voriconazole high dose first then low dose|Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (300 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (200 mg Every 12 Hours x 7 Doses)
3223639|NCT01030640|Placebo Comparator|placebo|formulation without active drug
3223640|NCT01030640|Active Comparator|tanezumab|
3223641|NCT01030614|Active Comparator|Dexamethasone group|One hundred five patients were randomized to receive intravenous dexamethasone (8 mg) before laparoscopic cholecystectomy
3223642|NCT01030614|Placebo Comparator|Placebo group|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
3223643|NCT01030601|No Intervention|Control|Diabetics undergoing routine cataract surgery
3223644|NCT01030601|Experimental|Treatment|Diabetics undergoing cataract surgery with injection of 0.5mg in 0.05cc of dexamethasone at the end of surgery
3223645|NCT01030575|Experimental|Inositol low volume|10 mg/kg/day Intravenous inositol 5%
3223646|NCT01030575|Experimental|Inositol mid-level volume|40 mg/kg/day Intravenous inositol 5%
3223647|NCT01030575|Experimental|Inositol high volume|80 mg/kg/day Intravenous inositol 5%
3223648|NCT01030575|Placebo Comparator|Placebo|Glucose 5% given in volumes equal to that of the comparator drug
3223649|NCT01030562||Control Arm|Subjects with an on-time interval between Dose 1 and 2 and an on-time interval between Dose 2 and 3.
3223650|NCT01030562||Experimental/Primary Arm 3|This primary arm will consist of subjects receiving the second dose substantially late/third dose substantially late.
3223651|NCT01030562||Experimental/Primary Arm 2|This primary arm will consist of subjects receiving the second dose substantially late/third dose on time.
3223652|NCT01030562||Experimental/Primary Arm 1|This primary arm will consist of subjects receiving the second dose on time/third dose substantially late.
3223653|NCT01030562||Alternate Arm|Subjects who meet eligibility requirements but do not fit into any of the primary experimental arms.
3223654|NCT01030536|Experimental|CAT-8015 20 microgram per kilogram (mcg/kg)|Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
3223655|NCT01030536|Experimental|CAT-8015 30 mcg/kg|Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
3223656|NCT01030536|Experimental|CAT-8015 40 mcg/kg|Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
3223657|NCT01030536|Experimental|CAT-8015 50 mcg/kg|Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
3223658|NCT01030536|Experimental|CAT-8015 60 mcg/kg|Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
3223659|NCT01030523|Experimental|Short Implants|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
3223660|NCT01030523|Active Comparator|Long Implants|ASTRA TECH Implants System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm)
3223661|NCT01030510|Active Comparator|group R|In group R, remifentanil was infused first before administrating propofol and rocuronium
3223662|NCT01030510|Active Comparator|group P|in group P, remifentanil was administered last after the propofol and rocuronium injection
3223663|NCT01030484||NAFLD|adult patients with non-alcoholic fatty liver disease (NAFLD).
3223664|NCT01030471|Experimental|Lifestyle counseling|
3223665|NCT01030471|No Intervention|Wait list control group|
3223666|NCT01030458|Experimental|amlodipine plus valsartan|In the experimental group, Exforge will be used in two dosage steps, respectively, amlodipine 5 mg plus 160 mg valsartan and amlodipine 10 mg plus 160 mg valsartan.
3223667|NCT01030458|Active Comparator|hydrochlorothiazide plus bisoprolol|In the reference group, the Lodoz will be used in two dosage steps, respectively 6.25 mg hydrochlorothiazide plus 5 mg or 6.25 mg hydrochlorothiazide plus 10 mg bisoprolol
3223668|NCT01030445||Elevated Mean Arterial Blood Pressure|Mean arterial pressure greater than 1 standard deviation above the mean based on age
3223669|NCT01030445||Decrease Mean Arterial Blood Pressure|Mean arterial pressure greater than 1 standard deviation below the mean based on age
3223670|NCT01030445||Normal Mean Arterial Blood Pressure|Mean arterial pressure within the standard deviation of the mean based on age
3223671|NCT01030432|Experimental|Phase 2a: Arm 1|
3223672|NCT01030432|Placebo Comparator|Phase 2a: Arm 2|
3223673|NCT01030432|Experimental|Phase 2b: Arm 1|
3223674|NCT01030432|Placebo Comparator|Phase 2b: Arm 2|
3223675|NCT01030419|Experimental|FlexToBa physical activity DVD|Participants in this arm will receive a physical activity program delivered by DVD that focuses on exercises targeting flexibility, toning and balance. These exercises will be progressive in nature throughout the six months and will also focus on modifications for all ability levels. Participants will be provided with three DVDs including: an Introduction to physical activity, Sessions 1-3, and Sessions 4-6, which they will be asked to watch and participate in over the course of six months.
3223676|NCT01030419|Placebo Comparator|Usual care-Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 12-month follow-up testing.
3223677|NCT01030406|Active Comparator|Treatment A|
3223678|NCT01030406|Active Comparator|Treatment B|
3223679|NCT01030406|Experimental|Treatment C|
3223680|NCT01030406|Experimental|Treatment D|
3223681|NCT01030406|Placebo Comparator|Treatment E|
3223682|NCT01030393|Experimental|intrauterine hCG|"Experimental arm : intrauterine injection of 100 iu(group1)or 200 iu (group2) of hCG before embryo transfer.~Intrauterine injection of 500 iu hCG before embryo transfer"
3223683|NCT01030380|Experimental|Slendertone Face NMES|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
3223684|NCT01030380|No Intervention|Control Group: No NMES|Control Group: No NMES over the course of 12 weeks.
3223685|NCT01030367|Experimental|1|PETN
3223686|NCT01030367|Experimental|2|ISDN
3223687|NCT01030367|No Intervention|3|
3223688|NCT01030354|Active Comparator|Dietary Intervention and Higher protein meal replacement|A higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass
3223689|NCT01030354|Active Comparator|Dietary Intervention and Standard Protein Meal Replacement|Standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
3223690|NCT01030341|Experimental|CGMS and insulin pump|Continuous glucose monitoring in conjunction with insulin pump
3223691|NCT01030328|Active Comparator|TriLipix + Atorvastatin|Two tables of TriLipix + Atorvastatin taken once a day by mouth.
3223692|NCT01030328|Placebo Comparator|2|2 sugar pills
3223693|NCT01030315|Experimental|Cohort 1|The lowest dose level of HM10760A
3223694|NCT01030315|Experimental|Cohort 2|Second dose level of HM10760A
3223695|NCT01030315|Experimental|Cohort 3|Third dose level of HM10760A
3223696|NCT01030315|Experimental|Cohort 4|Fourth dose level of HM10760A
3223697|NCT01030315|Experimental|Cohort 5|The highest dose level of HM10760A
3223698|NCT01030302||001|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
3223699|NCT01030289|Active Comparator|real tDCS First Visit|On the First Visit, A single 20-minute tDCS session will be conducted using 2.0mA current. Using the international 10-20 EEG system, the anode will be placed over F4, which corresponds to the right dorsolateral prefrontal cortex (DLPFC), and the cathode will be placed over F3, which corresponds to the left dorsolateral prefrontal cortex. Electrodes will be standard sponge electrodes soaked In a sterile solution of .9% sodium chloride insulated by a latex casing.
3223700|NCT01030289|Sham Comparator|sham tDCS First Visit|On the First Visit, For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
3223701|NCT01030289|Active Comparator|real tDCS Second Visit|Participant returns for the second visit 48-72 hours after completing the first visit. A single 20-minute tDCS session will be conducted using 2.0mA current. Using the international 10-20 EEG system, the anode will be placed over F4, which corresponds to the right dorsolateral prefrontal cortex (DLPFC), and the cathode will be placed over F3, which corresponds to the left dorsolateral prefrontal cortex. Electrodes will be standard sponge electrodes soaked In a sterile solution of .9% sodium chloride insulated by a latex casing.
3223702|NCT01030289|Sham Comparator|sham tDCS Second Visit|Participant returns for the second visit 48-72 hours after completing the first visit. For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
3223703|NCT01030276|Experimental|Bright light|
3223704|NCT01030276|Placebo Comparator|"Inactive placebo-light"|
3223705|NCT01030263|Experimental|CEM|Biopsies obtained with fluorescence-aided confocal endomicroscopy.
3223706|NCT01030263|Other|RFQ|Random four-quadrant biopsies.
3223707|NCT01030250||Under 65 years|Breast cancer patients receiving adjuvant chemotherapy. Those under 65 years of age will be prospectively evaluated for outcome.
3223708|NCT01030250||Over 65 years|Breast cancer patients receiving adjuvant chemotherapy. Those over 65 years of age will be prospectively evaluated for outcome.
3223709|NCT01030237|Experimental|FID 114657|FID 114657
3223710|NCT01030237|Active Comparator|Soothe XP Lubricant Eye Drops|Soothe XP Lubricant Eye Drops
3223711|NCT01030224|Experimental|AZD9742 IV Infusion|Active
3223712|NCT01030224|Placebo Comparator|Placebo to AZD9742 IV Infusion|Placebo
3223713|NCT01030211|Active Comparator|Platelet transfusion|4 units of platelets for patients with platelet count <20x10^3/uL
3223714|NCT01030211|Other|Supportive care|No platelet transfusion for patients with platelet count <20x10^3/uL
3223715|NCT01030198|Experimental|Fresh surgical scars|Treatment of scars
3223716|NCT01030198|Experimental|Mature scars|Treatment of scars
3223717|NCT01030185|Experimental|NovaShunt's Automated Fluid Shunt|The Automated Fluid Shunt (AFS) Device
3223718|NCT01030159||001|
3223719|NCT01030146|Other|NeilMed® Sinus Rinse™ System|NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
3223720|NCT01030133|Active Comparator|Real TMS|
3223721|NCT01030133|Sham Comparator|Sham TMS|
3223722|NCT01030120|Active Comparator|etanercept|etanercept 50mg BIW
3223723|NCT01030120|Placebo Comparator|placebo|matching placebo
3223724|NCT01030107||Children with Insufficient Sleep|Children who sleep approximately 9-10 hours/night
3223725|NCT01030094||Topiramate|Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
3223726|NCT01030094||Carbamazepine|Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
3223727|NCT01030094||Valproic acid|Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
3223728|NCT01030094||Normal Control|Healthy female participants will be observed in Normal control group.
3223729|NCT01030081|Experimental|Amlodipine (Norvasc®)|
3223730|NCT01030081|Active Comparator|Nifedipine GITS (Adalat® XL 30)|
3223731|NCT01030068|Experimental|Yoga|Yoga plus smoking cessation
3223732|NCT01030068|Active Comparator|Wellness|Health & Wellness classes plus smoking cessation therapy
3223733|NCT01030055|Experimental|TKI258 - bioavailability|
3223734|NCT01030055|Experimental|TKI258 - food|
3223735|NCT01030042|Experimental|Cetuximab/Irinotecan|Cetuximab/irinotecan followed, after progression, by FOLFOX-4 (Oxaliplatin, leucovorin and 5-fluorouracil)
3223736|NCT01030042|Active Comparator|FOLFOX 4|FOLFOX-4 (Oxaliplatin, leucovorin and 5-fluorouracil) followed, after progression, by irinotecan/cetuximab
3223737|NCT01030029|Active Comparator|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
3223738|NCT01030029|Placebo Comparator|pstim device without acupuncture|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
3223739|NCT01030016|Experimental|atenolol|subjects received 6 weeks of atenolol
3223740|NCT01029990|Experimental|Telephone arm|A midwife tries to contact the woman by telephone and offer her an appointment for a PAP-smear
3223741|NCT01029990|Experimental|Self-test arm|
3223742|NCT01029990|No Intervention|Control arm|No intervention other than what is routine in the screening program
3223743|NCT01029964|Active Comparator|6-9 years|Age at start of treatment
3223744|NCT01029964|Active Comparator|10-13 years|Age at start of treatment
3223745|NCT01029964|Active Comparator|14-16 years|Age at start of treatment
3223746|NCT01029964|No Intervention|Control 6-9 years|Untreated control group
3223747|NCT01029938|Active Comparator|Covered stent|The Willis covered stent specifically designed for intracranial vasculature was developed by our institution and the MicroPort Medical Company (Shanghai, China), and coil embolization, which has been widely applied for nearly two decades, is currently the endovascular approach that is first recommended for intracranial aneurysm treatment.
3223748|NCT01029938|Active Comparator|Coil|Coil embolization, which has been widely applied for nearly two decades, is currently the endovascular approach that is first recommended for intracranial aneurysm treatment.
3223749|NCT01029925|Experimental|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart.
3223750|NCT01029912|Experimental|CCNMES|Contralaterally Controlled Neuromuscular Electrical Stimulation (CCNMES) Electrical Stimulator
3223751|NCT01029912|Active Comparator|Cyclic NMES|Cyclic Neuromuscular Electrical Stimulation (NMES) Electrical Stimulator
3223752|NCT01029886|Experimental|1|
3223753|NCT01029886|Active Comparator|2|
3223754|NCT01029873|Experimental|ALT-801|
3223755|NCT01029847|Placebo Comparator|Placebo|
3223756|NCT01029847|Active Comparator|Adalimumab|TNF-alpha inhibitor
3223757|NCT01029834|Experimental|Intervention- Lifestyle family based|Behavioral family based
3223758|NCT01029834|Active Comparator|Information control|Child intervention only
3223759|NCT01029821|Other|Low-Molecular-Weight Heparin for DVT|Low-Molecular-Weight Heparin for DVT Prophylaxis after Open Reduction and Internal Fixation of ankle fractures
3223760|NCT01029795|Experimental|LY2599506|Combinations of 50-milligram (mg) or 100-mg capsules of LY2599506 or matching placebo capsules (each dose contains at least 1 capsule of active drug). LY2599506 will be administered, based on predefined glycemic targets, in escalating doses from 100 mg/day up to 800 mg/day.
3223761|NCT01029795|Active Comparator|Glyburide|Combinations of 2.5-mg capsules of Glyburide or matching placebo capsules (each dose contains at least 1 capsule of active drug). Glyburide will be administered, based on predefined glycemic targets, in escalating doses from 5 mg/day up to 20 mg/day.
3223762|NCT01029782|Active Comparator|IV cefazolin plus oral probenecid and placebo cephalexin|
3223763|NCT01029782|Active Comparator|Oral cephalexin and saline IV plus probenecid placebo|
3223764|NCT01029769|Active Comparator|initial olanzapin|
3223765|NCT01029769|Active Comparator|initial amisulpride|
3223766|NCT01029769|Active Comparator|early responders|
3223767|NCT01029769|Active Comparator|early non-responders switched|
3223768|NCT01029769|Active Comparator|ealy non-responders non-switched|
3223769|NCT01029756|Active Comparator|Macintosh Laryngoscope|
3223770|NCT01029756|Active Comparator|Pentax AWS Videolaryngoscope|
3223771|NCT01029743||Group 1|
3223772|NCT01029743||Group 2|
3223773|NCT01029730|Experimental|Bendamustine/Bortezomib/Rituximab|Treatment for all patients will be given in cycles of 28 days (4 weeks). All patients will receive treatment with bendamustine, bortezomib, and rituximab for a maximum of 6 cycles. Rituximab should be administered first.
3223774|NCT01029717|Experimental|Standard polyurethane Central Venous Catheter|"Standard polyurethane Central Venous Catheter~All CVCs used in the trial are CE marked medical devices used for their intended purpose."
3223775|NCT01029717|Active Comparator|Antibiotic impregnated polyurethane CVC|"Antibiotic impregnated polyurethane CVC (minocycline and rifampicin)~All CVCs used in the trial are CE marked medical devices used for their intended purpose."
3223776|NCT01029717|Active Comparator|Heparin bonded polyurethane CVC|"Heparin bonded polyurethane CVC~All CVCs used in the trial are CE marked medical devices used for their intended purpose."
3223777|NCT01029704|Experimental|EGT0001442|
3223778|NCT01029704|Placebo Comparator|Placebo|
3223779|NCT01029691|Experimental|Positive Airway Pressure (compliant)|This arm was women who used auto-titrating positive airway pressure (APAP) for at least 4 hours per night
3223780|NCT01029691|No Intervention|Standard care|
3223781|NCT01029691|Experimental|Positive Airway Pressure (non-compliant)|No one was assigned to this arm, but for results data quality purposes, women assigned to PAP who were explicitly non-compliant (used less than 4 hours per night), were analyzed separately from women who were compliant with the PAP assignment.
3223782|NCT01029678|Experimental|experimental|
3223783|NCT01029665||CDH survivors|School age (ages 4-6) Congenital Diaphragmatic Hernia survivors treated at Duke University Medical Center.
3223784|NCT01029652|Experimental|Canakinumab 150 mg|"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive re-dose of study drug on demand upon occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after previous dose. Patients completing 12 weeks core study were allowed to continue treatment in another 12-week extension for any new gout flare on demand with same treatment as assigned in core study.~After completing the first extension, patients were offered to enter second extension study, whereby all patients were treated open-label on demand with canakinumab 150 mg sc upon new flare for 1 year for a total duration of 18 months following randomization in core study. Patients completing first 12 weeks extension study were allowed to continue to be treated in another single-arm, open-label 48 weeks extension when all patients from both treatment arms received canakinumab on demand"
3223785|NCT01029652|Active Comparator|Triamcinolone acetonide 40 mg|"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.~Patients under this arm who agreed to continue to 2nd extension period of 12 months, were switched to canakinumab 150 mg sc for any new gout flare during this period Triamcinolone acetonide was not to be administered in the 48-week session."
3223786|NCT01029639|No Intervention|Treatment|Diabetic patients will complete hypoglycemia unawareness questionnaires at baseline and quarterly thereafter to monitor and assess progress with complications resulting from their diabetes. Comparisons will be performed on low blood sugar incidences reported by subjects requiring heath care intervention other than by the subject themselves.
3223787|NCT01029639|Experimental|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
3223788|NCT01029626|Other|Endoscopy|If the Glasgow-Blatchford score is zero, the endoscopy is delayed as an outpatient
3223789|NCT01029613||Rheumatoid arthritis|
3223790|NCT01029600|Active Comparator|Arthroscopic Capsulotomy|Arthroscopic capsular release
3223791|NCT01029600|Active Comparator|Distention with steroid|Arthrographic distention with contrast, saline, steroid and local anaesthetic
3223792|NCT01029587|Experimental|Eculizumab|Patients will receive eculizumab in conjunction with systemic anticoagulation before and after kidney transplant operation
3223793|NCT01029574|Experimental|Rotator cuff repair plus PRP|Conventional arthroscopic repair of rotator cuff with application of PRP.
3223794|NCT01029574|Placebo Comparator|Rotator cuff repair alone|Conventional arthroscopic repair of rotator cuff without application of PRP
3223795|NCT01029561|Active Comparator|CPAP and diet|The patients with severe OSA (AHI>=30) who do not fulfill the specific exclusion criteria wil be randomized. In the CPAP and diet arm, patients wil receive Continuous Positive air pressure therapy and the regular dietary treatment.
3223796|NCT01029561|Active Comparator|Diet|The diet arm wil receive the Conventional diet treatment that usually receive the patients included in the Bariatric Surgery Program
3223797|NCT01029535|Experimental|Juvederm® VOLUMA™|Juvederm® VOLUMA™ injected in both sides of face (up to 4 mL per side) at Investigator's discretion to achieve at least a 2-point improvement in the Mid-face Volume Deficit Scale. Participants who completed Week 8 of Phase 1 were eligible to participate in Phase 2 and could receive an additional optional treatment if applicable.
3223798|NCT01029522|Experimental|Lipilou 20mg|
3223799|NCT01029522|Active Comparator|Lipitor 20mg|
3223800|NCT01029509|Experimental|OPB-31121|OPB-31121 200 mg twice daily for 21 days followed by 7 days of rest
3223801|NCT01029483|Experimental|Low carbohydrate diet|6 week ad libitum low carbohydrate diet; research diet provided at 120% of estimated energy requirement for weight maintenance; carbohydrate intake limited to 28g/d
3223802|NCT01029483|Active Comparator|High Carbohydrate Diet-ad libitum|High complex carbohydrate diet (55% carbohydrate, 18% protein, 27% fat. 120% of estimated energy needs for weight maintenance provided, participants allowed to eat as much or as little as desired to satisfy appetite
3223803|NCT01029483|Active Comparator|High Carbohydrate Diet-Energy-matched|High carbohydrate diet (55% carbohydrate, 18% protein and 27% fat). Energy intake restricted to ~68% of energy needs for weight maintenance. Participants required to eat all food provided and nothing else
3223804|NCT01029470|Experimental|Luveris|Those subjects who experience hyponresponse to FSH stimulation during mid-follicle phase after pituitary downregulation will receive Luveris 75IU or 150IU IH injection daily till HCG day.
3223805|NCT01029444|Experimental|Insulin|Brittle diabetic patients or patients with uncontrolled blood sugars will complete blood sugar diaries weekly and have hemoglobin A1c lab tests performed quarterly to evaluate progress in stabilizing blood sugars.
3223806|NCT01029431|Experimental|1|All subjects will have both Air-Q ILA & PLMA
3223807|NCT01029418|Experimental|AZD6244 and sorafenib|AZD6244+ sorafenib
3223808|NCT01029405|Active Comparator|1. AN2728 Ointment B|2%, administered twice daily
3223809|NCT01029405|Placebo Comparator|2. AN2728 Ointment B Vehicle|
3223810|NCT01029405|Active Comparator|3. AN2728 Ointment B|2%, administered once daily
3223811|NCT01029405|Active Comparator|4. AN2728 Ointment B|0.5%, administered twice daily
3223812|NCT01029405|Active Comparator|5. AN2728 Ointment B|0.5%, administered once daily
3223813|NCT01029392|Experimental|Required Vitamin D|Those children whose Vitamin D level was low (<30 ng/mL) are given Vitamin D supplementation
3223814|NCT01029392|No Intervention|Normal Vitamin D|Those children whose Vitamin D level was normal (50-80 ng/mL) did not receive Vitamin D supplementation
3223815|NCT01029379||200 patients,ASA 1|
3223816|NCT01029366|Experimental|CART-19 CLL|CART-19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion days 0, 1, 2 and 11 in the absence of disease progression or unacceptable toxicity.Minimum/maximum total dose: 1.5x10^7 / 5x10^9 administered to patients with chronic Lymphocytic Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL).
3223817|NCT01029366|Experimental|CART-19 ALL|CART-19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion days 0, 1, 2 and 11 in the absence of disease progression or unacceptable toxicity.Minimum/maximum total dose: 1.5x10^7 / 5x10^9 administered to patients with chronic Lymphocytic Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL).
3223818|NCT01029353|Active Comparator|Laparotomy|
3223819|NCT01029353|Active Comparator|Peritoneal drain placement|
3223820|NCT01029340|Experimental|Arm 1: Recombinant Factor VIII (BAY81-8973) then Kogenate FS|Part A - Arm 1: Participants first received one single intravenous (IV) injection of BAY81-8973 50 IU/kg, then 1 single IV injection of Kogenate FS (BAY14-2222) 50 IU/kg with a wash-out period of at least 2-3 days in between
3223821|NCT01029340|Experimental|Arm 2: Kogenate FS then Recombinant Factor VIII (BAY81-8973)|Part A - Arm 2: Participants first received one single intravenous (IV) injection of Kogenate FS (BAY14-2222) 50 IU/kg, then 1 single IV injection of BAY81-8973 50 IU/kg with a wash-out period of at least 2-3 days in between
3223822|NCT01029340|Experimental|Arm 3: Recombinant Factor VIII by CS/EP then by CS/ADJ|Part B - Arm 3: Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months
3223823|NCT01029340|Experimental|Arm 4: Recombinant Factor VIII by CS/ADJ then by CS/EP|Part B - Arm 4:. Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay Per European Pharmacopeia for 6 months
3223824|NCT01029340|Experimental|Arm 5: Recombinant Factor VIII by CS/EP|Part C - Arm 5: Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
3223825|NCT01029327||Healthy subjects|
3223826|NCT01029314||Cardiopulmonary bypass surgery|Thirty to fifty cardiac surgery patients undergoing cardiopulmonary bypass will have serial triplicate temperatures taken by both the Genius 2 tympanic thermometer and the Exergen-TAT 5000 temporal artery thermometer at predetermined perioperative time points. These temperature readings will be compared to at least one core temperature (i.e., pulmonary artery).
3223827|NCT01029301|Experimental|Experimental: Endymed study group|
3223828|NCT01029288|Active Comparator|Statin Choice Decision Aid|Subjects will receive an intervention of Statin Choice Decision Aid and usual care for antihyperglycemic medication discussion with their clinician.
3223829|NCT01029288|Active Comparator|Diabetes Medication Choice Decision Aid|Subjects will receive an intervention of Diabetes Medication Choice Decision Aid and usual care for lipid therapy medication discussion with their clinician.
3223830|NCT01029275|Experimental|Arm A|pre-operative medical treatment with Sandostatin
3223831|NCT01029275|No Intervention|Arm B|pituitary surgery as a first line treatment
3223832|NCT01029262|Experimental|Arm #1 - Lenalidomide plus placebo|Lenalidomide 10 mg by mouth (PO) daily plus 2 placebo capsules for participants with a creatinine clearance ≥ 60 mL/min for at least 168 days until disease progression, intolerable side effects or withdrawal of consent. Lenalidomide 5 mg PO daily plus 2 placebo capsules for participants with a creatinine clearance ≥ 40 and < 60 mL/min.
3223833|NCT01029262|Placebo Comparator|Arm #2 - placebo|Three placebo capsules once daily for at least 168 days until disease progression occurred, intolerable side effects or withdrawal of consent.
3223834|NCT01029249||ACTG A5257 participants|Participants in this study will also be enrolled in ACTG A5257.
3223835|NCT01029223|Experimental|ivabradine|
3223836|NCT01029223|Experimental|metoprolol|
3223837|NCT01029223|Placebo Comparator|placebo|
3223838|NCT01029197|Experimental|CBT Intervention|The CBT intervention includes psychoeducation and coping and social skills delivered in a group format, and exposure therapy delivered in individual sessions
3223839|NCT01029197|Active Comparator|Treatment as Usual|The TAU Condition will receive usual services at the community clinic, which may include medications, individual or group therapy
3223840|NCT01029184|Active Comparator|complete non allergenic cereals|existing commercialized product
3223841|NCT01029184|Experimental|complete non allergenic cereals plus|commercialised product with the addition of a novel ingredient
3223842|NCT01029171|Experimental|1|OEP (Otago Exercise Program; home-based balance and strength retraining program)
3223843|NCT01029171|Active Comparator|2|CON (control; usual care)
3223844|NCT01029158|Experimental|1a|250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
3223845|NCT01029158|Experimental|1b|250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
3223846|NCT01029158|Experimental|1c|250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
3223847|NCT01029158|Experimental|1d|500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
3223848|NCT01029158|Experimental|2a|250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then 250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
3223849|NCT01029158|Experimental|2b|500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
3223850|NCT01029158|Experimental|2c|500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
3223851|NCT01029158|Experimental|2d|500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then 500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose (i.e. two doses in total).
3223852|NCT01029145||1|Bipolar patients that experience a new episode of any type
3223853|NCT01029132|Experimental|non-responder group|patients who did not maintained or improved cognitive function
3223854|NCT01029132|Experimental|responder group|patients who maintained or improved cognitive function
3223855|NCT01029080||Sepsis|All patients with sepsis defined by actually sepsis guidelines
3223856|NCT01029067|Active Comparator|Cognitive Remediation|Computerized cognitive remediation (CogPack training). A fixed series is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with group MCT, eight sessions are administered. Each session lasts approximately 45-60 minutes.
3223857|NCT01029067|Experimental|Metacognitive Training|The group metacognitive training program (MCT) is fully documented (Moritz, Woodward, & Metacognition Study Group, 2007; VanHam Campus Press) and can be obtained in more than 15 languages cost-free via the following link: www.uke.de/mkt. The group program is delivered to groups of 3-10 patients by trained psychologists addressing delusion-related metacognitive biases (e.g., jumping to conclusions). The eight modules are presented via a video projector using pdf-converted Power-Point slides. Each group session lasts approximately 45-60 minutes. Individualized MCT (MCT+) follows group sessions and accords to the general guidelines for cognitive-behavioral therapy. For each patient, 8 one-to-one sessions were carried in addition to one session relating to the medical history.
3223858|NCT01029054|Experimental|carfilzomib, lenalidomide w/dexamethasone|"Phase I: carfilzomib will be taken with a combination of lenalidomide plus dexamethasone in a series of escalating dosages to determine the maximum tolerated dose level~Phase II: carfilzomib will be given at the MTD established in the Phase I portion of the study"
3223859|NCT01029041|Experimental|Strengthening exercise|This group does global strengthening exercise
3223860|NCT01029041|Experimental|Stretching exercise|This group does global stretching exercise
3223861|NCT01029041|No Intervention|Control|This group does nor do any kind of exercise during the study
3223862|NCT01029015||Group 1 -OAB|Subjects with overactive bladder (OAB)
3223863|NCT01029015||Group 2 - Insomnia|Subjects with insomnia
3223864|NCT01029015||Group 3 - Normal|Normal Subjects
3223865|NCT01029002|Experimental|Vitamin D 50000 IU|Patients randomized to this arm will receive 50,000 IU of ergocalciferol in one unmarked pill once weekly.
3223866|NCT01029002|Placebo Comparator|Placebo|Patients randomized to this arm will receive a placebo pill once weekly.
3223867|NCT01028989|Other|Reduced Glycemic Load Diet|"36-40% fat; 40-42% carbohydrate; 18-22% protein~Glycemic Load <=46 per 1000 calories"
3223868|NCT01028989|Other|Standard Diet|"25-27% fat; 55-57% carbohydrate; 18-22% protein~Glycemic Load >=77 per 1000 calories"
3223869|NCT01028976|Placebo Comparator|Placebo|Two tablets, daily, for 8 weeks
3223870|NCT01028976|Experimental|Vitamin C|Two tablets, daily, for 8 weeks
3223871|NCT01028963|Placebo Comparator|Placebo|
3223872|NCT01028963|Active Comparator|Active control|
3223873|NCT01028963|Experimental|Active Study Medication (Group C)|CCX140-B
3223874|NCT01028963|Experimental|Active Study Medication (Group D)|CCX140-B
3223875|NCT01028950|Experimental|YM150 group|
3223876|NCT01028937|Experimental|Hyperopia|The NTK Optimal Keratoplasty System/Procedure is indicated for the temporary improvement of distance uncorrected visual acuity (in patient eyes that have manifest refraction, spherical equivalent equal to +1.0 to +2.5 Diopters, with less than or equal to 0.75 Diopters of refractive astigmatism (minus cylinder format) and with uncorrected distance visual acuity less than 20/40 but greater than or equal to 20/80. Patients must be at least 40 years of age with a documented stability of refraction for the prior 12 months, as demonstrated by a change of less than or equal to 0.5 Diopters in MRSE. The magnitude of D-UCVA improvement by Opti-K treatment may diminish over time, caused by some regression of effect in addition to natural progressive loss of accommodation and, for most patients, progressive hyperopic shift with increasing age.
3223877|NCT01028924|Experimental|Teduglutide 5 mg|Treatment A, subcutaneous injection
3223878|NCT01028924|Experimental|Teduglutide 20 mg|Treatment B, subcutaneous injection
3223879|NCT01028924|Placebo Comparator|Placebo|subcutaneous injection
3223880|NCT01028924|Active Comparator|Moxifloxacin|400 mg, oral
3223881|NCT01028911|Experimental|PF-03654746|
3223882|NCT01028911|Placebo Comparator|Placebo|
3223883|NCT01028885|Experimental|Arm I|"Patients undergo MRI and CT scan-based simulation for treatment planning with endorectal balloon target immobilization. The treatment target volumes and surrounding organs at risk are contoured, treatment plan developed and approved.~Patients then undergo 39 fractions of image-guided intensity-modulated radiotherapy over 8 weeks. Patients also undergo weekly MRI scans of the pelvis (in the planned treatment position) during radiotherapy."
3223884|NCT01028872|Sham Comparator|Sensar IOL|
3223885|NCT01028872|Active Comparator|Tecnis IOL|
3223886|NCT01028872|Active Comparator|AcrySof IQ|
3223887|NCT01028859|Experimental|CKD-516 inj|
3223888|NCT01028846|Active Comparator|Diazoxide|administered orally
3223889|NCT01028846|Active Comparator|Glyburide|administered orally
3223890|NCT01028846|Active Comparator|Vagal Nerve Stimulator|VNS device
3223891|NCT01028833|Experimental|Power mobility|Intervention included provision of power wheelchair and power mobility training program. Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
3223892|NCT01028833|No Intervention|Control|Children in the control group will not receive any additional intervention, but will continue to receive the early intervention or other services they were receiving prior to enrollment in this study.
3223893|NCT01028820|Experimental|Open-Label, Flexible-Dose Aripiprazole|This is a single group assignment pharmacodynamics study in which all study participants are given an open-label, flexible dose of aripiprazole for up to 8 weeks.
3223894|NCT01028807|Experimental|1. Experimental group: Early feeding:|After 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
3223895|NCT01028807|Active Comparator|Control group : Obligatory 5 day fasting|Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
3223896|NCT01028794|Experimental|autologous bone marrow mononuclear cell|On day 7-10 after stroke, patient has 25ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.
3223897|NCT01028794|Experimental|autologous bone marrow mononuclear cells|On day 7-10 after stroke, patient has 50ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.
3223898|NCT01028781|Other|Thalidomide|Thalidomide was administered and pain reports were recorded over the course of 6 months.
3223899|NCT01028768|Experimental|Teduglutide|
3223900|NCT01028755|Experimental|Arm 1|
3223901|NCT01028729|Experimental|Endostar with chemotherapy|All eligible patients will receive Endostar in combination with Gemcitabine plus Platinum-based chemotherapy for 4 cycles (21 days for each cycle). Endostar treatment will continue after completion of chemotherapy cycles until disease progression.
3223902|NCT01028716|Experimental|Treatment (nonmyeloablative HCT, TBI)|Patients receive fludarabine IV over 30-60 minutes daily on days -6 through -2 and cyclophosphamide IV over 1-2 hours on days -6, -5, and 3-4. Patients undergo total-body irradiation on day -1. Patients undergo donor peripheral blood stem cell transplant on day 0. Patients then receive tacrolimus IV once daily or PO BID on days 5-180 (may be continued if active GvHD is present), mycophenolate mofetil IV or PO TID on days 5-35 (may be continued if GvHD present), and filgrastim IV beginning on day 5 until the ANC is >= 1,000/mm^3 for three consecutive days.
3223903|NCT01028703||Donors|"110 will be cases that undergo uninephrectomy"
3223904|NCT01028703||Controls|"110 controls"
3223905|NCT01028690|Active Comparator|Lactobacillus reuteri|L. reuteri is one species of lactobacillus that naturally inhabits the gastrointestinal tract of humans
3223906|NCT01028690|Placebo Comparator|placebo|Placebo will be delivered in a chewable tablet form (1.5g per dose)
3223907|NCT01028677|Experimental|intranasal spray with oxytocin|Twice daily intranasal oxytocin spray (24 IU, 6 insufflations/dose) for 6 weeks
3223908|NCT01028677|Placebo Comparator|intranasal spray without oxytocin|Twice daily intranasal spray without oxytocin (six 0.1 ml insufflations/dose) for 6 weeks.
3223909|NCT01028664|Experimental|Glaucoma or ocular hypertension patients|
3223910|NCT01028651||Portopulmonary hypertension|
3223911|NCT01028638||Renal Cancer|Renal Cancer patients treated with everolimus
3223912|NCT01028625|Active Comparator|Cognitive Behavior Therapy|
3223913|NCT01028625|Other|Usual Care|Participants who are randomly assigned to usual care will receive whatever treatment (if any) for depression their own physician may prescribe. In most cases, treatment (if any is provided) is likely to consist of a serotonin reuptake inhibitor (SSRI) antidepressant such as sertraline or citalopram.
3223914|NCT01028612|Experimental|thermal ablation with external beam radiation|
3223915|NCT01028599|Experimental|Exercise|
3223916|NCT01028586|Active Comparator|Arm 1|Number of Cycles: until progression or unacceptable toxicity develops.
3223917|NCT01028586|Active Comparator|Arm 2|Number of Cycles: until progression or unacceptable toxicity develops.
3223918|NCT01028586|Placebo Comparator|Arm 3|Placebo
3223919|NCT01028573|Active Comparator|Group 1|4L of PEG-ELS (Golytely) consumed on the evening before colonoscopy
3223920|NCT01028573|Experimental|Group 2|2L of PEG-ELS (Golytely) consumed on the evening before and 2L consumed on the morning of colonoscopy
3223921|NCT01028573|Experimental|Group 3|238g of PEG-3350 mixed with 2L of Gatorade
3223922|NCT01028573|Experimental|Group 4|1L of PEG-3350 + Gatorade
3223923|NCT01028560|Active Comparator|No immunotherapy, receive standard of care asthma treatment|This group consists of children who do not receive allergy immunotherapy. Both groups - the experimental as well as the control group receive otherwise standard of care asthma and allergy treatment
3223924|NCT01028560|Experimental|Allergen immunotherapy|This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile. The maximum number of injections at each visit is 1-3 injections per child. In addition to allergy immunotherapy. this group receives standard of care asthma and allergy treatment
3223925|NCT01028547|Active Comparator|dexamethasone 8mg|
3223926|NCT01028547|Placebo Comparator|normal saline|
3223927|NCT01028534|Active Comparator|ARB plus increased ARB|angiotensin II receptor blockers for the first 3 months and increasing dose of angiotensin II receptor blockers for the next 3 months
3223928|NCT01028534|Active Comparator|ARB plus CCB|angiotensin II receptor blockers for the first 3 months and adding calcium channel blockers for the next 3 months
3223929|NCT01028534|Active Comparator|CCB plus ARB|calcium channel blockers for the first 3 months and adding angiotensin II receptor blockers for the next 3 months
3223930|NCT01028521|Experimental|CM3.1-AC100|
3223931|NCT01028521|Placebo Comparator|Placebo|
3223932|NCT01028508|Active Comparator|PHARM|lithium and venlafaxine
3223933|NCT01028508|Experimental|STABLE|ECT + VLF + Li
3223934|NCT01028495|Experimental|gemcitabine and RX-0201|"Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.~RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off."
3223935|NCT01028482|Experimental|sertraline, psychotherapy|"both study groups will receive concomitant psychotherapy treatment. There will be 2 main comparison groups: 1) an sertraline treated group and 2) a drug placebo - controlled group. While this design lacks a blinded drug-only condition, we will have an open drug-only arm that will be of considerable value. Furthermore, while a true placebo group is also lacking, and a certain response to psychotherapy is expected, we believe that the drug condition will show a definite superiority to the psychotherapy + placebo condition. The rational for including psychotherapy in the treatment protocol is the fact that this is a well-established treatment for PPD, and for ethical considerations it is unreasonable not to administer any active treatment to women suffering from PPD. It is our conviction that this is the only design, albeit its limitations, which will allow a comparison between medication-treated vs. placebo-treated PPD patients."
3223936|NCT01028482|Placebo Comparator|placebo, psychotherapy|"both study groups will receive concomitant psychotherapy treatment. There will be 2 main comparison groups: 1) an sertraline treated group and 2) a drug placebo - controlled group. While this design lacks a blinded drug-only condition, we will have an open drug-only arm that will be of considerable value. Furthermore, while a true placebo group is also lacking, and a certain response to psychotherapy is expected, we believe that the drug condition will show a definite superiority to the psychotherapy + placebo condition. The rational for including psychotherapy in the treatment protocol is the fact that this is a well-established treatment for PPD, and for ethical considerations it is unreasonable not to administer any active treatment to women suffering from PPD. It is our conviction that this is the only design, albeit its limitations, which will allow a comparison between medication-treated vs. placebo-treated PPD patients."
3223937|NCT01028469|Experimental|Artelon MTP Spacer|Metatarsophalageal hemi-implant
3223938|NCT01028456|Placebo Comparator|100 lux|100 lux / 30 minutes day
3223939|NCT01028456|Experimental|Light Therapy 10,000 lux|10,000 lux / 30 minutes a day for 3 months
3223940|NCT01028443|Active Comparator|Cyclosporine A 2%|
3223941|NCT01028443|Placebo Comparator|Artificial tears|
3223942|NCT01028430||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
3223943|NCT01028417|Experimental|Group 1|Group 1 receives the intervention - insertion of platinum microcoil followed by nodule excision
3223944|NCT01028417|No Intervention|Group 2|Group 2 receives the standard of care - nodule excision, but without the microcoil insertion
3223945|NCT01028404|Experimental|Trial part 1|
3223946|NCT01028404|Experimental|Trial part 2|
3223947|NCT01028391|Experimental|Sitagliptin + Pioglitazone|
3223948|NCT01028391|Active Comparator|Pioglitazone + Placebo|
3223949|NCT01028378|Experimental|Topography-guided LASIK|Topography-guided LASIK for Myopia or Hyperopia
3223950|NCT01028365||No treatment|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
3223951|NCT01028352|Other|Duloxetine|
3223952|NCT01028339|Active Comparator|Mannitol|
3223953|NCT01028339|Experimental|Hypertonic saline|
3223954|NCT01028326|Experimental|Group A|Group A of children will receive 2 doses of PCV10 vaccine, one at the time of enrolment and one 2 months later, followed by a dose of DTaP vaccine 4 months later
3223955|NCT01028326|Experimental|Group B|Group B of children will receive PCV10 vaccine, followed by a dose of DTaP vaccine after 2 months, and another dose of PCV10 4 months later.
3223956|NCT01028326|Active Comparator|Group C|Group C of children will receive a dose of hepatitis A vaccine, followed by a dose of DTaP vaccine after 2 months, and another dose of hepatitis A 4 months later, along with a dose of PCV10.
3223957|NCT01028313|Experimental|1|Systemic Therapy
3223958|NCT01028300|Other|ProDisc L|
3223959|NCT01028287|Active Comparator|ACTH-16 units|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
3223960|NCT01028287|Active Comparator|ACTH-32 units|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
3223961|NCT01028274|Placebo Comparator|Placebo|
3223962|NCT01028274|Experimental|Investigational Product 1|
3223963|NCT01028274|Experimental|Investigational Product 2|
3223964|NCT01028261|Experimental|ZGN-433|
3223965|NCT01028261|Placebo Comparator|Normal Saline|
3223966|NCT01028248|Active Comparator|2.0 mg Ranibizumab|
3223967|NCT01028248|Active Comparator|0.5 mg Ranibizumab|
3223968|NCT01028235||Obstructive Dysphagia|Patients who complained of dysphagia, which had an obstructive etiology for their symptoms at the time of endoscopy (ring, mass, stricture, etc)
3223969|NCT01028235||Non-obstructive Dysphagia|Patients whose endoscopy was normal and without any obvious etiology for their symptoms noted.
3223970|NCT01028222|Experimental|Nilotinib|400 mg twice daily
3223971|NCT01028222|Active Comparator|DTIC|850 mg/m2 IV every 3 weeks
3223972|NCT01028209|Experimental|Assess [18F] PBR06 and PET imaging|
3223973|NCT01028196||1 - schizophrenia|Psychiatrists will enrol patients meeting inclusion/exclusion criteria with schizophrenia as they routinely attend the clinic or are examined in hospital in a consecutively manner.
3223974|NCT01028196||2 - recurrent depression|Psychiatrists will enrol patients meeting inclusion/exclusion criteria with recurrent depression as they routinely attend the clinic or are examined in hospital in a consecutively manner.
3223975|NCT01028183||Extremely Premature Infants|< 30 weeks gestation (N=5000)
3223976|NCT01028183||Premature Infants|30-36 weeks gestation (N=2000)
3223977|NCT01028183||Hospitalized Term Infants|>=37 weeks gestation (N=2000)
3223978|NCT01028183||Healthy Term Infants|>=37 weeks gestation (N=1000)
3223979|NCT01028170|Experimental|Furosemide with Hypertonic Saline|Furosemide with 150 mL of 2.4% NaCl
3223980|NCT01028170|Active Comparator|Pulse Furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
3223981|NCT01028157|Placebo Comparator|General Health Control|
3223982|NCT01028157|Experimental|HIV Risk Reduction & Relapse Prevention|
3223983|NCT01028144|Experimental|ACT Program|Motivational and Behavioral Skills Physical activity after-school program
3223984|NCT01028144|Active Comparator|General Health|General health education after-school program
3223985|NCT01028131|No Intervention|Control|Participants randomized by the computer into this condition will only view the 20-minute video clips of music and tv videos.
3223986|NCT01028131|Experimental|Computerized brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model (ask, advise, assess, assist & arrange) and Motivational Interviewing.
3223987|NCT01028131|Experimental|Contingency Management Alone|Participants randomized by the computer into this condition will view a 20-minute music and tv video clip after completing the brief assessment. The research assistant will then briefly describe the CM process, with some time to discuss questions regarding procedure to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
3223988|NCT01028131|Experimental|Combined Brief Intervention and CM|Combined intervention. Participants in this condition will receive both the brief intervention and the brief description of the CM process.
3223989|NCT01028118|Other|Therapy for Women reporting violence|Asking about life experience with violence and Cognitive Behavior Therapy.
3223990|NCT01028105|No Intervention|No MRSA screening, Group b|Standard of care
3223991|NCT01028105|Other|MRSA screening, Group a|MRSA preoperative screening
3223992|NCT01028092|Active Comparator|Control|anti R-IL2 induction + Mycophenolate Mofetil + cyclosporine A + corticosteroids
3223993|NCT01028092|Experimental|CNI-free|Thymoglobulin + Mycophenolate Mofetil + everolimus + corticosteroids
3223994|NCT01028092|Experimental|Switch|anti R-IL2 + Mycophenolate Mofetil + (Cyclosporine then Everolimus) + corticosteroids
3223995|NCT01028079|Active Comparator|Arm 2|
3223996|NCT01028079|Placebo Comparator|Arm 3|
3223997|NCT01028079|Experimental|Arm 1|
3223998|NCT01028066|Active Comparator|Traditional|Traditional nutritional counseling
3223999|NCT01028066|Experimental|Behavioral|Dialogic nutritional counseling
3224000|NCT01028053|Experimental|Flutemetamol (18F) Injection|Flutemetamol (18F) Injection
3224001|NCT01028040|Experimental|AZD3043|
3224002|NCT01028027|Experimental|Loteprednol and tobramycin|Loteprednol etabonate and tobramycin ophthalmic suspension
3224003|NCT01028027|Active Comparator|Tobramycin and dexamethasone|Tobramycin and dexamethasone ophthalmic suspension
3224004|NCT01028014|Active Comparator|Pseudoephedrine|Pseudoephedrine 120mg extended release tablets
3224005|NCT01028014|Active Comparator|Solifenacin|Solifenacin 5mg capsule
3224006|NCT01028014|Active Comparator|Tamsulosin|Tamsulosin 0.4mg capsule
3224007|NCT01028014|Active Comparator|Imipramine|Imipramine 25mg tablet
3224008|NCT01028014|Active Comparator|Cyclobenzaprine|Cyclobenzaprine 10mg tablet
3224009|NCT01028014|Placebo Comparator|Lactose capsules|Sham
3224010|NCT01027962|Other|ICBT Program|Intensive Computerized Brain Training using software packages donated by Posit Science.
3224011|NCT01027962|No Intervention|Control Intervention|Commercially available computer games that do not contain violent stimuli but are appealing to youth between 10 and 19 years of age.
3224012|NCT01027962|No Intervention|Healthy Control Group|No participation in computer activity.
3224013|NCT01027949|Experimental|Treprostinil diethanolamine (UT-15C)|All open will receive active study drug
3224014|NCT01027936||Normal Healthy Volunteers|
3224015|NCT01027923|Experimental|Dose Level 1|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 320 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
3224016|NCT01027923|Experimental|Dose Level 2|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 420 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
3224017|NCT01027923|Experimental|Dose Level 3|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 560 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
3224018|NCT01027910|Experimental|PCI-24781 without mandated GCSF|PCI-24781 in combination with doxorubicin without mandated GCSF
3224019|NCT01027910|Experimental|PCI-24781 with mandated GCSF|PCI-24781 in combination with doxorubicin with mandated GCSF
3224020|NCT01027897|Experimental|Doripenem group|Patients will receive doripenem for the treatment of their infection
3224021|NCT01027884|Placebo Comparator|Placebo|Placebo 900 mg/day
3224022|NCT01027884|Experimental|Idebenone|Idebenone 900 mg/day
3224023|NCT01027871|Experimental|LY2605541 Dosing Algorithm 1|Participants took both LY2605541 and their pre-study insulin for first several days
3224024|NCT01027871|Experimental|LY2605541 Dosing Algorithm 2|Participants took only LY2605541 with first dose doubled
3224025|NCT01027871|Active Comparator|Insulin glargine|
3224026|NCT01027858|Experimental|1|AT (aerobic-based exercise training)
3224027|NCT01027858|Active Comparator|2|CON (control; usual care)
3224028|NCT01027845|Experimental|10Pn Group|
3224029|NCT01027845|Active Comparator|DTPa Group|
3224030|NCT01027832|No Intervention|Control arm|no intervention
3224031|NCT01027832|Experimental|Experimental arm|antibiotics
3224032|NCT01027819|Active Comparator|Mobile bearing|Mobile bearing type between polyethylene insert and tibial component MB type will be randomly used in total knee arthroplasty
3224033|NCT01027819|Active Comparator|Fixed bearing|Fixed bearing type between polyethylene insert and tibial component FB type will be randomly used in total knee arthroplasty
3224034|NCT01027806|Active Comparator|Montelukast|
3224035|NCT01027806|Placebo Comparator|Placebo|
3224036|NCT01027793|Active Comparator|Tretinoin|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
3224037|NCT01027793|Active Comparator|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center.
3224038|NCT01027780|Active Comparator|Mindfulness-Based Stress Reduction|Participation in the Mindfulness-Based Stress Reduction (MBSR) program following the initial assessment period, just prior to the start of the immunological measures.
3224039|NCT01027780|No Intervention|Wait-list control|Wait-list control participants were offered MBSR training after completion of their primary assessments periods.
3224040|NCT01027767||Surgery/Radiation Arm|Patients that have had surgery along with radiation therapy
3224041|NCT01027767||Surgery Arm|Patients that have had surgery of a benign lesion.
3224042|NCT01027754|Experimental|Varenicline|Drug treatment in combination with telephone quitline referral and brief individual counseling based on PHS guidelines at weeks 2, 4, 8, and 12
3224043|NCT01027754|Placebo Comparator|Placebo|Matched placebo capsules in combination with telephone quitline referral and brief individual counseling based on PHS guidelines at weeks 2, 4, 8, and 12
3224044|NCT01027741|Experimental|Phone Referral|Participants receive phone referral to cancer control and prevention services.
3224045|NCT01027741|Experimental|Tailored Cancer Communication|Participants will receive phone referral to cancer control and prevention services as well as tailored materials in the mail.
3224046|NCT01027741|Experimental|Cancer Control Navigator|Participants will receive phone referral to cancer control and prevention services as well as a personal cancer control navigator.
3224047|NCT01027741|No Intervention|Control|Participants receive only recommendation to talk to health care professional.
3224048|NCT01027728|Experimental|CCX354-C|
3224049|NCT01027715|Experimental|EEG seizure treatment group|EEG data available to physicians. Treatment based on EEG seizures. Treatment will be dictated by the detailed treatment protocol. Standard antiepileptic medications will be used.
3224050|NCT01027715|No Intervention|Clinical Seizure treatment Group|Seizure treatment in this group will be based on standard care - treating clinical seizures only. While EEG data will be collected in this group, the data will not be available to the treating physicians. A one-hour EEG report will be available to the treating team. Continuous EEG monitoring and treatment will only be allowed if the initial EEG shows status.
3224051|NCT01027702|Experimental|Infusion of donor lymphocytes|Patients will receive an infusion of donor lymphocyte after T-cell depleted transplant.
3224052|NCT01027689|Active Comparator|Alprazolam commercial immediate release oral tablet|
3224053|NCT01027689|Experimental|Alprazolam test sublingual tablet|
3224054|NCT01027676|Experimental|study arm|single arm Gefitinib plus vorinostat
3224055|NCT01027663|No Intervention|Iron Deficiency Anemia|
3224056|NCT01027663|No Intervention|Hereditary Hemochromatosis|
3224057|NCT01027663|Active Comparator|Iron Supplements|
3224058|NCT01027650|Experimental|Stage 1 Cohort 1|AGN208397 intravitreal injection 75 ug on Day 1.
3224059|NCT01027650|Experimental|Stage 1 Cohort 2|AGN208397 intravitreal injection 300 ug on Day 1.
3224060|NCT01027650|Experimental|Stage 1 Cohort 3|AGN208397 intravitreal injection 600 ug on Day 1.
3224061|NCT01027650|Experimental|Stage 1 Cohort 4|AGN208397 intravitreal injection 900 ug on Day 1.
3224062|NCT01027650|Experimental|Stage 2 Arm 1|AGN208397 intravitreal injection 600 ug on Day 1.
3224063|NCT01027650|Experimental|Stage 2 Arm 2|AGN208397 intravitreal injection 450 ug on Day 1.
3224064|NCT01027650|Experimental|Stage 2 Arm 3|AGN208397 intravitreal injection 300 ug on Day 1.
3224065|NCT01027650|Active Comparator|Stage 2 Arm 4|Dexamethasone 700 ug intravitreal implant on Day 1.
3224066|NCT01027637|Experimental|Alloderm reconstruction|All patients recieving the intervention Alloderm for breast reconstruction
3224067|NCT01027624||Hyperchlesterolaemia|Participants undertreated with hypercholesterolaemia
3224068|NCT01027611|Experimental|proparacaine HCL 0.5%|
3224069|NCT01027611|Experimental|proparacaine + lidocaine|
3224070|NCT01027611|Experimental|lidocaine gel|
3224071|NCT01027598|Experimental|Erlotinib + Pazopanib|"Erlotinib: 150 mg orally daily~Pazopanib: 600 mg orally daily"
3224072|NCT01027598|Placebo Comparator|Erlotinib + Placebo|"Erlotinib: 150 mg orally daily~Placebo: orally daily"
3224073|NCT01027572|Experimental|Thalamic stimulation|Patients in Vegetative or Minimally Conscious State
3224074|NCT01027559|Active Comparator|Depressed Group: CBT|Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.
3224075|NCT01027559|No Intervention|Healthy Control Group|Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.
3224076|NCT01027559|Active Comparator|Depressed Group: SRT|Depressed participants randomized to receive the antidepressant sertraline (SRT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.
3224077|NCT01027546|Placebo Comparator|placebo, tranexamic acid|
3224078|NCT01027533||Restor +3|patients will be implanted bilaterally with Restor + 3
3224079|NCT01027533||restor +4|Patients will be implanted bilaterally with Restor +4
3224080|NCT01027520|Experimental|Intervention|Application of Coban dressing
3224081|NCT01027494||Treatment|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension, 4 drops in outer ear canal of infected ear(s) while awake 2 times per day for 7 days
3224082|NCT01027494||Healthy|No intervention
3224083|NCT01027468|No Intervention|group 1|bevacizumab intravitreal injection
3224084|NCT01027455|Placebo Comparator|Dry Cold|Dry (0% relative humidity) and cold (20 degrees Celsius - Room Temperature) carbon dioxide gas intraperitoneal insufflation for laparoscopic appendicectomy
3224085|NCT01027455|Experimental|Humidification|Humidified (98% relative humidity) and warm (37 degrees Celsius) carbon dioxide gas intraperitoneal insufflation for laparoscopic appendicectomy
3224086|NCT01027442|Placebo Comparator|Conventional implant placement method|"The patients in ths group will be treated by conventional, free-hand implant placement"
3224087|NCT01027442|Active Comparator|Computer-guidedimplant placement|In this group, the patients will be treated by implants placed via computer generated SLA guides
3224088|NCT01027429|Active Comparator|procaine penicillin and gentamicin|Procaine penicillin, 50,000 IU/kg by intramuscular injection plus gentamicin, 5 mg/kg intramuscular injection, both given once daily for 7 days
3224089|NCT01027429|Experimental|Amoxicillin and gentamicin|Oral amoxicillin (80-90 mg/kg) divided twice daily and intramuscular gentamicin, 5 mg/kg once daily, both given for 7 days
3224090|NCT01027429|Experimental|procaine penicillin, gentamicin, and amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
3224091|NCT01027416|No Intervention|No Intervention|
3224092|NCT01027416|Active Comparator|Tamoxifen|Tamoxifen 20 mg orally 1x/day for 4 weeks
3224093|NCT01027403||Healthy volunteers|
3224094|NCT01027403||Acute decompensated heart failure|
3224095|NCT01027390|Experimental|1 hr training 50% supervision|1 hr training 50% supervision
3224096|NCT01027390|Experimental|3 x 20 min training 50% supervision|3 x 20 min training 50% supervision
3224097|NCT01027390|Experimental|3 x 20 min training initial instructions|3 x 20 min training initial instructions
3224098|NCT01027390|Experimental|10 x 6 min training 50% supervision|10 x 6 min training 50% supervision
3224099|NCT01027390|No Intervention|reference|no training
3224100|NCT01027377|Experimental|A|Cohort to receive a single low dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single low dose intravenous injection of rFVIIIFc with safety and PK assessments
3224101|NCT01027377|Experimental|B|Cohort to receive a single high dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single high dose intravenous injection of rFVIIIFc with safety and PK assessments
3224102|NCT01027364|Experimental|Fixed Weekly Interval|"50 IU/kg rFIXFc via intravenous (IV) injection once every 7 days initially, then at a dose indicated by the participant's baseline pharmacokinetic (PK) assessment that ensured a target trough of 1% to 3% above baseline or higher, as clinically indicated. Adjustments to the initial weekly dose of rFIXFc (50 IU/kg) were to be made based on baseline PK assessments, occurrence of spontaneous bleeding episodes, and the trough levels, which were to be monitored at Weeks 4, 16, 26, and 39.~Prior to the first dose of rFIXFc, participants in the Sequential PK subgroup were to receive a single dose of 50 IU/kg BeneFIX administered IV in the clinic, followed by PK sampling. A single dose of 50 IU/kg rFIXFc was administered following a 120-hour washout from BeneFIX, followed by PK sampling for a baseline PK profiling. At Week 26 (±1 week) subjects were to receive a single dose of 50 IU/kg rFIXFc for repeat PK profiling."
3224103|NCT01027364|Experimental|Individualized Interval|100 IU/kg rFIXFc via IV injection once every 10 days initially, then at an interval derived from the baseline PK assessment that ensured a target trough of 1% to 3% above baseline or higher, as clinically indicated. Adjustments to the initial 10-day interval were to be made based on baseline PK assessments and trough levels, which were monitored at Weeks 4, 16, 26, and 39.
3224104|NCT01027364|Experimental|On Demand|20 to 100 IU/kg rFIXFc via IV injection, or the dose indicated by the participant's baseline PK to target a plasma level of 20% to 100%, as needed for the treatment of mild to severe bleeding episodes
3224105|NCT01027364|Experimental|Surgery|The surgical period and dosing are dependent on the type of surgery the participant undergoes. Participants who started the study in one of the other treatment arms prior to surgery will return to the original treatment arm. Participants who joined the study in the Surgery arm will be assigned to one of the other treatment arms following post-operative rehabilitation.
3224106|NCT01027351|Experimental|5rMenB|Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV) (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.
3224107|NCT01027351|Experimental|5rMenB+OMV NZ|Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.
3224108|NCT01027351|Experimental|3rMenB|Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine without OMV (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.
3224109|NCT01027351|Experimental|3rMenB+OMV NZ|Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.
3224110|NCT01027351|Experimental|Naive_4042|Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 40 and 42 months of age in the present study.
3224111|NCT01027351|Experimental|Naive_6062|Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 60 and 62 months of age in the present study.
3224112|NCT01027338|Experimental|Tai Chi Exercise|
3224113|NCT01027338|No Intervention|Usual Care|
3224114|NCT01027325|Experimental|High CHO/Low Amylose|55% Carbohydrate (11.2% Amylose, 26.3% Amylopectin) 20% Protein 25% Fat
3224115|NCT01027325|Experimental|Low Carbohydrate/Hi Amylose|40% Carbohydrate (26.3% Amylose, 11.2% Amylopectin) 20% Protein 40% Fat
3224116|NCT01027325|Experimental|High CHO/High Amylose|55% Carbohydrate (26.3% Amylose, 11.2% Amylopectin) 20% Protein 25% Fat
3224117|NCT01027325|Experimental|Low Carbohydrate/Low Amylose|40% Carbohydrate (11.2% Amylose, 26.3% Amylopectin) 20% Protein 40% Fat
3224118|NCT01027325|Active Comparator|Baseline|40% Carbohydrate 20% Protein 40% Fat
3224119|NCT01027312||Glaucoma Patients|Glaucoma patients covering the entire range of visual field loss from none to advanced.
3224120|NCT01027312||Control Group|Aged matched people with no eye diseases.
3224121|NCT01027299|Active Comparator|Standard pacing|Standard pacing settings prescribed by the cardiac surgeon or intensivist after revascularisation.
3224122|NCT01027299|Active Comparator|BiVentricular pacing (BiV).|The group of patients receiving biventricular pacing after cardiac surgery.
3224123|NCT01027286|Experimental|Vitagel|
3224124|NCT01027286|No Intervention|Control|No Vitagel used.
3224125|NCT01027273|Experimental|Peer-Led Stroke Recurrence Prevention Education|The intervention group will participate in a 6-session course held over a 6-week period. The Prevent Return of Stroke Workshop, led by trained peer educators, aims to help participants control the risk factors for stroke, thereby preventing recurrence of strokes.
3224126|NCT01027273|Placebo Comparator|Usual Care (Delayed Intervention)|The control group will be offered the chance to take part in the 6-week session intervention after 12 months after enrollment into the trial.
3224127|NCT01027260|Active Comparator|Itopride 50 mg|
3224128|NCT01027260|Active Comparator|Itopride 100 mg|
3224129|NCT01027260|Placebo Comparator|Placebo|
3224130|NCT01027234|Experimental|1|
3224131|NCT01027234|Placebo Comparator|2|
3224132|NCT01027221|No Intervention|0|primarily resectable pancreatic cancer patients
3224133|NCT01027221|Active Comparator|0,5 Gy|neoadjuvant Radiation of 0,5 Gy two days before resection
3224134|NCT01027221|Active Comparator|2 Gy|neoadjuvant Radiation of 2 Gy 2 days before resection
3224135|NCT01027221|Active Comparator|5 Gy|neoadjuvant Radiation of 5 Gy 2 days before resection
3224136|NCT01027208|Experimental|Ixabepilone|
3224137|NCT01027195|Placebo Comparator|Standard Bovie Electrocautery|Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.
3224138|NCT01027195|Experimental|Bipolar Radiofrequency|Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (<100 degrees Celsius) than standard Bovie electrocautery.
3224139|NCT01027182|No Intervention|Raltegravir|
3224140|NCT01027169|Experimental|Arm 1|subjects with mild hepatic impairment
3224141|NCT01027169|Experimental|Arm 2|subjects with moderate hepatic impairment
3224142|NCT01027169|Experimental|Arm 3|matched subjects with normal hepatic function
3224143|NCT01027156|Experimental|High Intensity Exercise|
3224144|NCT01027143|Experimental|omega-3 fatty acids|3 softgels (EPA, DHA) twice daily
3224145|NCT01027143|Placebo Comparator|control|Soybean oil: 3 matched softgel caps twice daily
3224146|NCT01027130||healthy control|240 female subjects without preeclampsia
3224147|NCT01027130||preeclampsia|120 female subjects with preeclampsia
3224148|NCT01027117|Active Comparator|Treatment A|Revatio 20 mg intact tablet. This is the reference treatment arm.
3224149|NCT01027117|Experimental|Treatment B|Treatment B: Revatio 20 mg crushed tablet mixed with apple sauce.
3224150|NCT01027117|Experimental|Treatment C|Treatment C: Revatio 20 mg extemporaneously prepared suspension (EP).
3224151|NCT01027091||patients with positive slope|patients with positive slope in the levels of free serum calcium levels between 6th and 12th postoperative hour
3224152|NCT01027091||patients with negative or no slope|patients with negative or no slope in the levels of free serum calcium levels between 6th and 12th postoperative hour.
3224153|NCT01027078||OSA|patients diagnosed with obstructive sleep apnea who do not have existing cardiovascular disease
3224154|NCT01027078||control|patients without obstructive sleep apnea who are matched in weight and age to the OSA patients
3224155|NCT01027065|Experimental|Tritherapy: CYT107+ vaccine+ antiviral|
3224156|NCT01027065|Experimental|Bitherapy: CYT107 + antiviral|
3224157|NCT01027052|Active Comparator|Hamburger meat patty with Spice Blend|Hamburger meat patty containing spice blend will be consumed on 3 seperate occasions
3224158|NCT01027052|Placebo Comparator|Hamburger meat patty with salt|Hamburger meat patty containing salt will be consumed on 3 seperate occasions
3224159|NCT01027039||Patients using noise-reducing headphones|Patients using noise-reducing headphones
3224160|NCT01027039||Patients using no headphones|Patients using no headphones
3224161|NCT01027039||Patients using headphones with music|Patients using headphones with music
3224162|NCT01027026|Experimental|Group 1 Fast Track Group|The patients are discharged the same day after coronary angiography to the refering Hospital
3224163|NCT01027026|Active Comparator|Group 2: Ordinary care|Ordinary Cardiology care in the Intervention hospital
3224164|NCT01027013|Experimental|rebamipide 2% ophthalmic suspension|
3224165|NCT01027013|Placebo Comparator|Placebo eye drops|
3224166|NCT01027000|Experimental|Treatment (Combination of chemotherapy and transplant)|See detailed description
3224167|NCT01026987|Experimental|Related Donors: G-CSF & AMD3100|G-CSF 10 ug/kg SC daily for 5 days. AMD3100 320 mcg/kg IV over 30 min on Day 5. Leukapheresis on Day 5.
3224168|NCT01026987|Other|Recipient|Stem Cell Infusion on Day 0
3224169|NCT01026974|Experimental|4rMenB|Subjects received three primary doses of rMenB vaccine (at the age of 6-8 months; 2 months after and at 12 months) in parent study (NCT00433914) and one booster dose of rMenB vaccine at 40 months of age in the present study.
3224170|NCT01026974|Experimental|4rMenB+OMV NZ|Subjects received three primary doses of rMenB+OMV NZ vaccine (at the age of 6-8months; 2 months after and at 12 months) in parent study (NCT00433914) and one booster dose of rMenB+OMV NZ vaccine at 40 months of age in the present study.
3224171|NCT01026974|Experimental|Naive_4042|Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.
3224172|NCT01026974|Experimental|Naive_6062|Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study.
3224173|NCT01026961|Experimental|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate
3224174|NCT01026961|Active Comparator|Phenylephrine hydrochloride|Phenylephrine hydrochloride 10mg
3224175|NCT01026948||Propess and Monica AN24 care package|Women who are eligible and consent to recruitment will receive the Propess and Monica AN24 care package for outpatient induction of labour
3224176|NCT01026935|Experimental|sutured mesh|200 patients are randomized to inguinal hernia repair with sutured light weight (38g/m2) polypropylene mesh (Lichtenstein repair)
3224177|NCT01026935|Experimental|non-sutured mesh|200 patients are randomized to receive a light weight mesh that adheres to tissues with polylactic micro hooks without sutures
3224178|NCT01026922||SmartPill Participants|It is a single-center study, children aged 8-17 years with severe upper GI symptoms (ie, nausea, vomiting, retching, abdominal pain) referred for antroduodenal manometry (ADM) studies underwent a wireless motility capsule (smartpill) test. The scintigraphic gastric emptying study was done when clinically indicated either at the time of the ADM or at a different time within 1 year of the wireless motility capsule test. In summary, we studied symptomatic adolescents using scintigraphic gastric emptying studies, ADM, and the wireless motility capsule test, with the goal of identifying the diagnostic yield of each test and exploring how they compare in detecting motor abnormalities in the GI tract.
3224179|NCT01026909|Experimental|Injection|Patients in this arm receive one single dose of Triamcinolone hexacetonide injectable suspension (Aristopan), USP, 20mg/mL Parenteral. They will aso be enrolled in physical therapy.
3224180|NCT01026909|No Intervention|Control|Patients will be enrolled in physical therapy
3224181|NCT01026896|Experimental|Affected Arm Therapy + Mental Practice|
3224182|NCT01026896|Active Comparator|Affected Arm Therapy + Stroke Information|
3224183|NCT01026883|Other|Healthy subjects|Hematocrit level of each subject will be assessed by two different techniques
3224184|NCT01026870|Active Comparator|Mometasone furoate (MF) metered-dose inhaler 100 mcg BID|2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks
3224185|NCT01026870|Placebo Comparator|Placebo metered-dose inhaler BID|2 inhalations from a matching placebo inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
3224186|NCT01026857|Experimental|PLC Colon release tablet 1 g|40 patients each arm
3224187|NCT01026857|Experimental|PLC colon release tablet 2 g|40 patients each arm
3224188|NCT01026857|Placebo Comparator|Placebo PLC colon release tablet 2 g|40 patients each arm
3224189|NCT01026844|Experimental|Erlotinib plus hydroxychloroquine|erltoinib 150mg per day plus HCQ in esclating doses of 400mg, 600mg, 800mg and 1000mg per day
3224190|NCT01026844|Experimental|Hydroxychloroqine|hydroxychloroquine given at escalating doses of 400mg, 600mg, 800mg and 1000mg per day
3224191|NCT01026831|Experimental|Tafluprost|Preservative-free tafluprost
3224192|NCT01026831|Active Comparator|timolol maleate|Preservative-free timolol maleate
3224193|NCT01026818|Experimental|Tadalafil daily [5 milligrams (mg)]|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
3224194|NCT01026818|Experimental|Tadalafil on demand (20 mg)|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
3224195|NCT01026818|Placebo Comparator|Placebo|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
3224196|NCT01026805||Hysteroscopic Morcellator|11 women previously receiving hysteroscopic myomectomy or polypectomy using the hysteroscopic morcellator device.
3224197|NCT01026792|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. For complete responders, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity or for 2 courses after complete response criteria are first met. For other patients, treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3224198|NCT01026779||Cases of rotavirus gastroenteritis|Patients will be eligible as cases if they have been identified by the investigator's ongoing rotavirus surveillance studies as having been hospitalized with laboratory-confirmed rotavirus gastroenteritis between January 1, 2007 and June 31, 2009. To be eligible as a case, the child must meet the following criteria: 1) immunocompetent; 2) born after April 15, 2006 (to select a population that would have been in the age group eligible for at least 1 dose of RV5 (RotaTeq); and 3) > 2 months of age on the day of admission.
3224199|NCT01026779||Control Subjects|Three controls for each case will be identified using KIDSNET, the state child health registry. Controls will be matched to cases by age and county of residence at birth.
3224200|NCT01026766||Non obese/ Warming blankets|
3224201|NCT01026766||Non obese/ Warming intravenous fluids|
3224202|NCT01026766||Obese/ Warming intravenous fluids|
3224203|NCT01026766||Obese/ Warming blankets|
3224204|NCT01026753|No Intervention|FOBT by laboratory requisition or directly by PCP|The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit.
3224205|NCT01026753|Experimental|FOBT by lab req. or directly from PCP + study magnet|The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit. The family physician provides each patient with a study magnet containing a PHCC telephone number and study specific website address.
3224206|NCT01026740|Experimental|001|Ceftobiprole 500 mg, single infusion over 2 hours
3224207|NCT01026727|Experimental|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|MPC-4326 300 mg or 400mg BID plus a 2-3 drug optimized background regimen (OBR)for 24 weeks.
3224208|NCT01026727|Active Comparator|3-4 drug antiretroviral drugs|3-4 commercially available antiretroviral (ARV)drugs for 24 weeks.
3224209|NCT01026714|Experimental|flurbiprofen 50mg po|
3224210|NCT01026714|Experimental|flurbiprofen 50 mg po + CYP2C9 inducer|
3224211|NCT01026714|Experimental|flurbiprofen 50 mg po + CYP2C9 inhibitor|
3224212|NCT01026701||001|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
3224213|NCT01026688|Experimental|Intervention|
3224214|NCT01026688|Other|Control|
3224215|NCT01026675||Pregnant women 6-13 weeks|
3224216|NCT01026662||Abdominoplasty|Subjects scheduled for abdominoplasty surgery
3224217|NCT01026649|Experimental|2 stage|Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
3224358|NCT01025726|Active Comparator|General Health|General Health Education Intervention
3224218|NCT01026649|Active Comparator|1 stage|Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
3224219|NCT01026636|Experimental|Ceftobiprole|Ceftobiprole 7mg/kg - 15mg/kg per day as 2h infusion
3224220|NCT01026623|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 60-70 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3224221|NCT01026610|Experimental|LB80380 90 mg|LB80380 90 mg (90 mg + placebo), once daily oral dose
3224222|NCT01026610|Experimental|LB80380 150 mg|LB80380 150 mg (60 mg + 90 mg), once daily oral dose
3224223|NCT01026610|Active Comparator|entecavir 0.5 mg|entecavir 0.5 mg, once daily oral dose
3224224|NCT01026597|Experimental|Cohort 1|Dose 1 versus placebo
3224225|NCT01026597|Experimental|Cohort 2|Dose 2 versus placebo
3224226|NCT01026597|Experimental|cohort 3|Dose 3 versus placebo
3224227|NCT01026597|Experimental|cohort 4|Dose 4 versus placebo
3224228|NCT01026597|Experimental|cohort 5|Dose 5 versus placebo
3224229|NCT01026584|Other|drug|
3224230|NCT01026571||Bicuspid aortic valve|Collection of patients who are known to have bicuspid aortic valve disease, diagnosed by prior cardiac imaging
3224231|NCT01026558|Active Comparator|Ceftobiprole (not morbidly obese subjects)|Ceftobiprole 500 mg single-dose over 2 hours.
3224232|NCT01026558|Experimental|Ceftobiprole (morbidly obese subjects)|Ceftobiprole 500 mg single-dose over 2 hours.
3224233|NCT01026545|Experimental|Cohort 1|
3224234|NCT01026545|Experimental|Cohort 2|
3224235|NCT01026545|Experimental|Cohort 3|
3224236|NCT01026545|Experimental|Cohort 4 (optional)|If intermediate or repeat dose level is needed; dose will not exceed 1100 mg.
3224237|NCT01026545|Experimental|Cohort 5 (Japanese)|
3224238|NCT01026545|Experimental|Cohort 6 (Japanese)|
3224239|NCT01026532|Other|Segmental antigen challenge|Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
3224240|NCT01026519|Experimental|Dose 1|Active dose
3224241|NCT01026519|Experimental|Dose 2|Active dose
3224242|NCT01026519|Experimental|Dose 3|Active 3
3224243|NCT01026519|Placebo Comparator|Dose 4|Placebo dose
3224244|NCT01026493|Experimental|Phase I: Dose Level 1|ABT-888 20 mg x 21 days plus temozolomide 60 mg x 21 days
3224245|NCT01026493|Experimental|Phase I: Dose Level 2a|ABT-888 40 mg x 21 days plus temozolomide 60 mg x 21 days
3224246|NCT01026493|Experimental|Phase I: Dose Level 2b|ABT-888 20 mg x 21 days plus temozolomide 75 mg x 21 days
3224247|NCT01026493|Experimental|Phase I: Dose Level 3|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
3224248|NCT01026493|Experimental|Phase II: Arm 1/BEV-NAIVE|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
3224249|NCT01026493|Experimental|Phase II: Arm 2/BEV-NAIVE|ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days
3224250|NCT01026493|Experimental|Phase II: Arm 1/BEV-FAILURE|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
3224251|NCT01026493|Experimental|Phase II: Arm 2/BEV-FAILURE|ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days
3224252|NCT01026480||IPAA Patients|Patients who have had their IPAA procedures performed by Dr. Becker
3224253|NCT01026467||Supportive Care (frailty index, geriatric assessment, chemo)|Patients complete a frailty index and geriatric assessment prior to beginning chemotherapy. Patients receive standard-of-care chemotherapy comprising carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 2 courses
3224254|NCT01026454|Active Comparator|acyclovir|acyclovir 400 mg orally twice daily
3224255|NCT01026454|Active Comparator|valacyclovir|valacyclovir 1.5 g orally twice daily
3224256|NCT01026441|Other|Treatment for cellulite and circumference reduction|All subjects will be treated with the device
3224257|NCT01026428|Experimental|Safinamide + Levodopa|
3224258|NCT01026428|Placebo Comparator|Placebo + Levodopa|
3224259|NCT01026415|Experimental|1|midazolam +/- brentuximab vedotin
3224260|NCT01026415|Experimental|2|brentuximab vedotin +/- rifampin
3224261|NCT01026415|Experimental|3|brentuximab vedotin +/- ketoconazole
3224262|NCT01026415|Experimental|4|special populations
3224263|NCT01026402|Experimental|AZD2014|AZD2014 dose escalation phase in Part A and expansion phase in Part B.
3224264|NCT01026389|Active Comparator|Gadovist|Patient received contrast-enhanced MRA with Gadovist
3224265|NCT01026389|Experimental|Dotarem, interventional|Patients received contrast-enhanced MRA with Dotarem
3224266|NCT01026363|Experimental|ergocalciferol|Ergocalciferol intervention arm
3224267|NCT01026363|Experimental|calcitriol|calcitriol intervention arm
3224268|NCT01026350|Experimental|study group|
3224269|NCT01026337|Experimental|Arm I|"Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.~Patients undergo dynamic contrast-enhanced MRI at baseline and after the first 4 weeks of sunitinib malate."
3224270|NCT01026324|Experimental|Treatment (dinaciclib)|Patients receive dinaciclib IV over 4 hours on day 1. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
3224271|NCT01026311|Placebo Comparator|placebo|
3224272|NCT01026311|Active Comparator|Coenzyme Q10|200mg of coenzyme Q10
3224273|NCT01026298|No Intervention|Control Group|8 weeks, no intervention for OSA
3224274|NCT01026298|Active Comparator|CPAP group|8-week randomized-controlled period of CPAP treatment
3224275|NCT01026285||antipsychotic treatment|Risperidone Long-Acting injectable or oral antipsychotics According to label
3224276|NCT01026272||healthy subjects|subjects with no sign of inflammatory disease, or diagnosis of MS
3224277|NCT01026272||Patients with MS|
3224356|NCT01025726|Experimental|Full Intervention|Police Patrolled Walking Program plus Social Marketing Intervention
3224278|NCT01026259|Experimental|Local incision warming|Local warming applied to surgical incision for 6 treatments beginning in post anesthesia recovery through the second postoperative day.
3224279|NCT01026259|Active Comparator|No warming to surgical incision|Incisions covered with same postoperative dressing as in Arm 1 but without warming treatments.
3224280|NCT01026246|Experimental|Group B: 20 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 20 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
3224281|NCT01026246|Experimental|Group A: 5 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 5 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
3224282|NCT01026246|Experimental|Group C: 80 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 80 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
3224283|NCT01026233|Experimental|1|brentuximab vedotin
3224284|NCT01026220|Experimental|Regimen I (consolidation therapy)|Patients receive 2 more courses of ABVE-PC comprising doxorubicin hydrochloride IV over 1-120 minutes and cyclophosphamide IV over 30-60 minutes on days 1 and 2; bleomycin sulfate IV over at least 10 minutes or subcutaneously (SC) and vincristine sulfate IV on days 1 and 8; etoposide IV over 1-2 hours on days 1-3; oral prednisone twice daily on days 1-7; and filgrastim SC or IV daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression.
3224285|NCT01026220|Experimental|Regimen II (consolidation therapy)|Patients receive ifosfamide IV continuously on days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, and filgrastim SC or IV beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression. Patients then receive 2 more courses of ABVE-PC in the absence of unacceptable toxicity or disease progression.
3224286|NCT01026220|Experimental|Induction: all patient|All patients receive ABVE-PC induction therapy then they are assigned to Group 2 (RER), Group 3 (SER) or taken off study if they develop progressive disease.
3224287|NCT01026207||Chronic Obstructive Pulmonary Disease|Patients recruited from the Pneumology Clinic of UNIFESP, diagnosed with COPD stage II and III of Global Initiative for Chronic Obstructive Lung Disease, stable for three months, and with symptoms suggestive of Obstructive Sleep Apnea Syndrome.Patients has been underwent one night by polysomnography and one night with portable monitoring.
3224288|NCT01026194|Placebo Comparator|Placebo / Teneli + Pio|
3224289|NCT01026194|Experimental|Teneli / Teneli + pio|
3224290|NCT01026181||LSG|Laparoscopic Sleeve Gastrectomy
3224291|NCT01026181||LRYGB|Laparoscopic Roux-en-Y Gastric Bypass
3224292|NCT01026181||LAGB|Laparoscopic Adjustable Gastric Banding
3224293|NCT01026155|Experimental|Respiratory muscle traininig|Low caloric diet and physical activities + Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
3224294|NCT01026155|Active Comparator|Control|Low caloric diet and physical activities
3224295|NCT01026142|Active Comparator|A: Capecitabine + Trastuzumab|
3224296|NCT01026142|Experimental|B: Capecitabine + Trastuzumab + Pertuzumab|
3224297|NCT01026129|Experimental|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of remifentanil 0.25 mcg/kg before emergence of a desflurane-based anesthesia.
3224298|NCT01026129|Experimental|Remifentanil 0.5 mcg/kg|Administration of a bolus dose of remifentanil 0.5 mcg/kg before emergence of a desflurane-based anesthesia.
3224299|NCT01026129|Active Comparator|Lidocaine|Bolus dose of intravenous remifentanil 1mg/kg given once before emergence of general anesthesia.
3224300|NCT01026103|Experimental|Tri Staple|This is a single arm study.
3224301|NCT01026090|Experimental|Dronedarone pre-cardioversion|Dronedarone 400 mg twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion
3224302|NCT01026090|Placebo Comparator|Placebo pre-cardioversion|Placebo (for dronedarone) twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion
3224303|NCT01026077||Fibromyalgia/prospective pregnancies|Women taking Savella during pregnancy. Register prospectively, provide verbal consent.
3224304|NCT01026064|Experimental|Part C- Azithromycin|2 x 250 mg once daily over 3 days
3224305|NCT01026064|Placebo Comparator|Part C- Placebo|Once daily over 3 days
3224306|NCT01026038|Experimental|1|1 dose (0.5 mL), IM of 13vPnC vaccine.
3224307|NCT01026025|Experimental|Duet TRS|This is a single arm study.
3224308|NCT01026012|Experimental|Combined Protocol|patient with submaximal symptom limited maximal exercise testing will also be administered regadenoson pharmacological stress test.
3224309|NCT01025999||RYGB|UWMC patients undergoing RYGB surgery with routine placement of Gastrostomy tube.
3224310|NCT01025986||Noninfectious Uveitis|
3224311|NCT01025973||Diabetes Mellitus|Patients with type 1, type 2 or gestational diabetes mellitus
3224312|NCT01025973||Normal pregnancy|Patient without diabetes mellitus
3224313|NCT01025960|Other|Standard Inspection Colonoscopy|The colonoscope will be inserted rapidly to reach the cecum. Inspection of the large bowel will occur during the withdrawal of the colonoscope.
3224314|NCT01025960|Active Comparator|Dual Inspection Colonoscopy|The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
3224315|NCT01025947||Study group|Patients with cryptogenic stroke (TOAST criteria) and with an implantable EKG loop recorder implanted
3224316|NCT01025934|Active Comparator|7 days|
3224317|NCT01025934|Active Comparator|20 days|
3224318|NCT01025934|Sham Comparator|sham|
3224319|NCT01025921|Placebo Comparator|Inhaled colistin|They will receive inhaled colistin three times daily for 10 days.
3224320|NCT01025921|Placebo Comparator|Inhaled normal saline|Inhaled normal saline three times daily for 10 days
3224321|NCT01025908|Experimental|Cognitive Behavioral Therapy|25 panic disorder patients
3224322|NCT01025908|Active Comparator|Supportive psychotherapy|25 panic disorder agoraphobia
3224323|NCT01025895|Active Comparator|single bundle|acl reconstruction - single bundle technique
3224324|NCT01025895|Experimental|double bundle|acl reconstruction - double bundle technique
3224357|NCT01025726|Experimental|Walking Only|Police Patrolled Walking Only Intervention
3224325|NCT01025882|Experimental|Regimen 1|Patients undergo a single fraction of margin-intensive stereotactic body radiotherapy (SBRT) on day 1. Patients undergo pancreatoduodenectomy between days 15-43.
3224326|NCT01025882|Experimental|Regimen 2|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Patients undergo a single fraction of SBRT between days 21-28 followed by pancreatoduodenectomy between days 35-63.
3224327|NCT01025869|Other|Stent System|Cinatra™ Corolimus Eluting Coronary Stent System
3224328|NCT01025856|Active Comparator|high fibre/low glycemic index diet - P A|patients will follow for two months a diet high fibre/low glycemic index without physical activity program
3224329|NCT01025856|Active Comparator|Rich in MUFA diet - PA|Patients will follow for two months a rich in MUFA diet without a physical activity program.
3224330|NCT01025856|Active Comparator|high fibre/low glycemic index diet+PA|Patients will follow for two months a high fibre and low glycemic index diet associated with a physical activity program.
3224331|NCT01025856|Active Comparator|Rich in MUFA diet+PA|Patients will follow for 2 months a rich in MUFA diet with a physical activity program.
3224332|NCT01025843|Experimental|Pbo → 5 mg → Candesartan → 24 mg → 38 mg|Placebo in Period 1; 5 mg MK-5478 in Period 2; Candesartan in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
3224333|NCT01025843|Experimental|1 mg → 5 mg → 12 mg → Candesartan → Pbo|1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Candesartan in Period 4; and Placebo in Period 5. There was a minimum 7 days washout between periods.
3224334|NCT01025843|Experimental|1 mg → Candesartan → Pbo → 24 mg → 38 mg|1 mg MK-5478 in Period 1; Candesartan in Period 2: Placebo in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
3224335|NCT01025843|Experimental|1 mg → 5 mg → 12 mg → Pbo → Candesartan|1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Placebo in Period 4; and Candesartan in Period 5. There was a minimum 7 days washout between periods.
3224336|NCT01025843|Experimental|Pbo→ 8 mg→ 18 mg → 2 mg fed→Candesartan|Placebo in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Candesartan in Period 5. There was a minimum 7 days washout between periods.
3224337|NCT01025843|Experimental|2 mg→Pbo → Candesartan → Pbo fed→38 mg|2 mg MK-5478 in Period 1; Placebo in Period 2; Candesartan in Period 3; Placebo in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
3224338|NCT01025843|Experimental|2 mg→Candesartan→Pbo→Candesartan fed→38 mg|2 mg MK-5478 in Period 1; Candesartan in Period 2; Placebo in Period 3; Candesartan in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
3224339|NCT01025843|Experimental|2 mg → 8 mg → 18 mg → 2 mg fed → Pbo|2 mg MK-5478 in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Placebo in Period 5. There was a minimum 7 days washout between periods.
3224340|NCT01025843|Experimental|Candesartan→8 mg→ 18 mg →2 mg fed→38 mg|Candesartan in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
3224341|NCT01025843|Experimental|Candesartan→Pbo → 12 mg → 24 mg→38 mg|Candesartan in Period 1; Placebo in Period 2; 12 mg MK-5478 in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
3224342|NCT01025830|Experimental|Generic|generic fixed dose combination of Stavudine, Lamivudine and Nevirapine (Triomune)
3224343|NCT01025830|Active Comparator|Brand|3 separate single pills of Zerit (Stavudine)Epivir (Lamivudine) Viramune (Nevirapine)
3224344|NCT01025817|Experimental|Everolimus (EVR) & low dose of tacrolimus|Everolimus (EVR) and tacrolimus treatment arm: Therapeutic drug monitoring of everolimus and tacrolimus was mandatory throughout the study. From Day 5 onwards, the everolimus 0.75 mg b.i.d. dose was increased if the trough level was < 3 ng/mL, or reduced if the trough level was > 8 ng/mL. Tacrolimus was initiated according to local practice. In this treatment arm, the tacrolimus dose was adjusted from Day 3 onwards, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From Month 2 until Month 6, the target tacrolimus trough level was 3 ng/mL to 6 ng/mL. After Month 6, the tacrolimus dose was adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL.
3224345|NCT01025817|Active Comparator|Mycophenolate mofetil & standard dose tacrolimus|Mycophenolate mofetil and tacrolimus (MMF) treatment arm: MMF dose was initiated at 1 g b.i.d. (2 g/day). Adjustments were to be made for adverse events including, but not limited to, gastrointestinal intolerance and decrease in WBC. MMF trough or AUC was not used to adjust dosing. In this group, tacrolimus was initiated according to local practice. Tacrolimus dose was adjusted from Day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 12 ng/mL. From Month 2 until Month 6, target tacrolimus trough level was reduced to 7 - 10 ng/mL. After Month 6, target level of tacrolimus was reduced to 5 - 8 ng/mL.
3224346|NCT01025804||Infants|
3224347|NCT01025791|Experimental|MK8266|MK8266
3224348|NCT01025791|Placebo Comparator|Placebo|Placebo
3224349|NCT01025778|Experimental|Remission induction and haplo-SCT|Remission induction with Clofaranie, Etoposide and Cyclophosphamide combination followed by haplidentical stem cella transplantation if remission achieved.
3224350|NCT01025765|No Intervention|Standard care of CHC|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
3224351|NCT01025765|Experimental|Pioglitazone|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
3224352|NCT01025765|Experimental|Acarbose|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
3224353|NCT01025765|Experimental|Metformin|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
3224354|NCT01025752|Experimental|Arm 1|Ten session IVR-based cognitive behavior therapy intervention for chronic low back pain
3224355|NCT01025752|Active Comparator|Arm 2|Ten session face to face cognitive behavior therapy for chronic low back pain
3224359|NCT01025713|Experimental|1|GS-9411 2.4 mg
3224360|NCT01025713|Experimental|2|GS-9411 4.8 mg
3224361|NCT01025713|Placebo Comparator|Placebo|Placebo
3224362|NCT01025700|Experimental|Cesemat|
3224363|NCT01025700|No Intervention|Placebo|
3224364|NCT01025687|Experimental|glucose beverage|
3224365|NCT01025687|Experimental|noncaloric beverage with TV|
3224366|NCT01025687|Experimental|glucose beverage with TV|
3224367|NCT01025687|Experimental|noncaloric beverage|
3224368|NCT01025674|Experimental|7 Treatment Schools|The Positive Action program was implemented over 6 years, starting with Grade 3, then continuing through Grade 8.
3224369|NCT01025674|No Intervention|7 Control Schools|Standard educational practice
3224370|NCT01025661|No Intervention|Waiting list control|The waiting list controls did not receive any intervention during the study period.
3224371|NCT01025648|Experimental|T1 - E004 90 mcg/actuation|T1 - E004 (epinephrine inhalation aerosol) 90 mcg/actuation - treatment by 2 actuations of E004 at 90 mcg/actuation
3224372|NCT01025648|Experimental|T2 - E004 125 mcg/actuation|E004 (epinephrine inhalation aerosol), 125 mcg, 2 actuations
3224373|NCT01025648|Experimental|T3 - 160 mcg/actuation|E004 (epinephrine inhalation aerosol), 160 mcg - E004 (epinephrine inhalation aerosol), 160 mcg/ actuation, 2 actuations
3224374|NCT01025648|Experimental|T4 - 220 mcg/actuation|E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations
3224375|NCT01025648|Active Comparator|A - Active control|epinephrine inhalation aerosol, CFC propelled 220 mcg Epinephrine Inhalation Aerosol, CFC-MDI, 2 actuations
3224376|NCT01025648|Placebo Comparator|P, Placebo HFA|E004 placebo single treatment with 2 inhalations
3224377|NCT01025635|Experimental|Azelaic acid foam, 15% (BAY39-6251)|Participants received azelaic acid foam, 15% topically twice daily for 12 weeks
3224378|NCT01025635|Placebo Comparator|Vehicle foam|Participants received vehicle foam topically twice daily for 12 weeks
3224379|NCT01025596|Experimental|CYT107|
3224380|NCT01025583|Active Comparator|group 1 (standard ORS)|Children with acute diarrhea receive standard hypotonic ORS.
3224381|NCT01025583|Active Comparator|Group 2 (hypotonic super-ORS)|Children with acute diarrhea receive hypotonic super-ORS containing zinc and prebiotics.
3224382|NCT01025570|Experimental|Gem/Bos|"Gemcitabine 1000 mg/m2, D1,8,15 of each cycle~Bostutinib 400 mg daily concurrently with Gemcitabine"
3224383|NCT01025557|Experimental|Chocolate milk|
3224384|NCT01025557|Experimental|Milk|
3224385|NCT01025557|Experimental|Infant formula|
3224386|NCT01025557|Experimental|Soy beverage|
3224387|NCT01025557|Experimental|Water|
3224388|NCT01025544|Active Comparator|Arm 1|
3224389|NCT01025544|Active Comparator|Arm 2|
3224390|NCT01025531||patients with newly diagnosed Hepatitis C|Hepatitis C patients newly diagnosed
3224391|NCT01025518|Experimental|resistance training and dietary supplement|
3224392|NCT01025518|Placebo Comparator|Resistance training and placebo ingestion|12 weeks of resistance training and placebo ingestion
3224393|NCT01025492|Active Comparator|Trilipix|Trilipix (fenofibric acid) 135 mg tablet orally, once daily for 12 weeks
3224394|NCT01025492|Placebo Comparator|Placebo|Matching placebo tablet orally, once daily for 12 weeks
3224395|NCT01025466|Active Comparator|rivastigmine patch monotherapy|
3224396|NCT01025466|Active Comparator|Combination therapy with memantine|
3224397|NCT01025453|Experimental|Pts getting Temsirolimus and Sorafenib|We propose a phase II study to evaluate the efficacy of the combination sorafenib with temsirolimus in patients with thyroid cancer of follicular cell origin (e.g., papillary, follicular, Hurthle cell). A maximum of 36 subjects will be evaluated during the study. Restaging scans, with evaluation of response, will be done every 2 cycles (8 weeks of treatment). Treatment will continue until clinical disease progression, unacceptable toxicity, treatment delay > 4 weeks, or at the discretion of the treating physician or patient.
3224398|NCT01025440|Active Comparator|CPAP|"Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA.~Dose: The CPAP pressure will be set to the individual subject's therapeutic pressure -as determined by PSG on Night 2.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)"
3224399|NCT01025440|Active Comparator|HFCPAP|"Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA.~Dose: During HF CPAP 35 L/min wil be administered.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)"
3224400|NCT01025427|Active Comparator|Elite controller|Ten elite controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
3224401|NCT01025427|Active Comparator|Non-controller|Ten untreated non-controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
3224402|NCT01025401|No Intervention|Motor manifestations during seizures|
3224403|NCT01025362|Experimental|Lactation counseling|"Intervention arm: The mother and child health centres will implement The Baby-Friendly Initiative to improve their lactation counseling.~Other Names: The Baby Friendly Community Health Service"
3224404|NCT01025362|Active Comparator|Standard care|The comparison group was mother and child health centres which continued offering standard care.
3224405|NCT01025349|Experimental|metastatic breast cancer|Patients with histological or cytological proven metastatic breast cancer were recruited. The previous hormonal therapy for metastatic breast cancer or cytotoxic therapy was allowed. The Her2/Neu over-expressive status should be negative. Patients with brain metastasis are excluded.
3224406|NCT01025336|Other|23vPS Naive|Group 1.1 13vPnC/13vPnC Group 1.2 13vPnC/23vPS Group 2 23vPS/13vPNC
3224407|NCT01025336|Other|Prior 23vPS>/= 5 years|Group 1 13vPnC/13vPnC Group 2 23vPS/13vPnC
3224408|NCT01025323|Active Comparator|Minimal Intervention Group|Participants in this arm receive advice and printed guidelines but no counseling or systematic instruction.
3224454|NCT01024972|Placebo Comparator|Placebo|Equiosmolar volume (5% Mannitol)
3224455|NCT01024959|Experimental|PCA3 Assay|
3224853|NCT01022151|Placebo Comparator|Placebo [group P]|
3224409|NCT01025323|Active Comparator|Enhanced Intervention Group|Participants in this group receive advice and the same printed guidelines as the Minimal Intervention Group, together with dietary and physical activity counseling provided by a dietician and/or coordinator, periodic professional reviews of their progress and systematic instruction.
3224410|NCT01025297|Experimental|CYT107|
3224411|NCT01025284|Experimental|Part A LY2523355|8 milligrams per square meter (mg/m²) per dose based on participant's body surface area, administered intravenously as a 1-hour infusion on Days 1, 5, 9 of each 21-day cycle, until disease progression or unacceptable toxicity.
3224412|NCT01025284|Experimental|Part B LY2523355|5 or 6 mg/m² per dose based on participant's body surface area, administered intravenously as a 1-hour infusion on Days 1, 2, 3 plus granulocyte colony-stimulating factor (G-CSF) support administered subcutaneously beginning on Day 4 of each 21-day cycle, until disease progression or unacceptable toxicity.
3224413|NCT01025271|Other|open label|patients meeting entry criteria enrolled and pk samples obtained around dosing of daptomycin
3224414|NCT01025258|Active Comparator|frequent clinic visits|
3224415|NCT01025245|Experimental|remifentanil, MgSO4|Experimental 1 : Intraoperative remifentanil infusion at 0.2 ㎍/㎏/min and MgSO4 30 mg/kg IV at the induction followed by intraoperative infusion at 10 mg/kg/hr Drug : remifentanil, MgSO4 Experimental 2 : Intraoperative remifentanil infusion at 0.2 ㎍/㎏/min and normal saline Drug : remifentanil Active comparator : Intraoperative remifentanil infusion at 0.05 ㎍/㎏/min and normal saline Drug : remifentanil
3224416|NCT01025232|Active Comparator|4 Week Re-treatment|Subjects can receive re-treatment every 4 weeks if there is persistent or recurrent intraretinal, subretinal, or sub-RPE fluid on any OCT modality, or any evidence of hemorrhage on clinical evaluation. Subjects will go no longer than 12 weeks without treatment.
3224417|NCT01025232|Active Comparator|6 Week Re-treatment|Subjects can receive re-treatment every 6 weeks if there is persistent or recurrent intraretinal, subretinal, or sub-RPE fluid on any OCT modality, or any evidence of hemorrhage on clinical evaluation. Every 6 weeks regimen will test potential longer duration of action of 2.0 mg ranibizumab. Subjects will go no longer than 12 weeks without treatment.
3224418|NCT01025206|Experimental|BI-505|
3224419|NCT01025193|Experimental|Belimumab|Belimumab will be administered intravenously at a dose of 10mg/kg on days 0, 14, 28 and every 28 days for up to 52 weeks to normalize alloantibody levels in sensitized patients awaiting kidney transplantation. Subjects who are not able to undergo transplantation before the end of the treatment period will have final follow-up evaluation 8 weeks after the last dose of belimumab is administered.
3224420|NCT01025180|Other|Procalcitonin level|duration of the antibiotic treatment guided by procalcitonin level
3224421|NCT01025180|No Intervention|physician's appreciation|duration of the antibiotic treatment based on physician's appreciation
3224422|NCT01025167|Experimental|Test|Supportan(R) (500 ml)/disease-specific enteral tube feed for oncologic patients with special key substrates
3224423|NCT01025167|Placebo Comparator|Control|Fresubin(R) energy fibre (500 ml)/a nutritionally complete enteral standard feed (isoenergetic)
3224424|NCT01025154|Experimental|Clofarabine, Cytarabine + Idarubicin|Induction Cycle: Clofarabine 20 mg/m^2 intravenous (IV) daily for 5 days; Idarubicin 10 mg/m^2 IV daily for 3 days; Cytarabine 1 g/m^2 IV daily for 5 days
3224425|NCT01025141|Experimental|MINISCREW|device
3224426|NCT01025141|Active Comparator|Reference|dental anchorage
3224427|NCT01025128|Active Comparator|group A low D|ultra-Orthodox clinics patients aged 18-39 with lowest vitamin D levels
3224428|NCT01025128|No Intervention|group A high D|ultra-Orthodox clinics patients aged 18-39 with highest vitamin D levels
3224429|NCT01025128|Active Comparator|group B low D|mixed population clinics patients aged 18-39 with lowest vitamin D levels
3224430|NCT01025128|No Intervention|group B high D|mixed population clinics patients aged 18-39 with highest vitamin D levels
3224431|NCT01025115|Experimental|A|Diamel
3224432|NCT01025115|Placebo Comparator|B|Placebo
3224433|NCT01025102|Experimental|Naropin 0.1%|
3224434|NCT01025089|Experimental|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|This is a multicenter, open-label phase II trial of neoadjuvant chemotherapy and concurrent cetuximab in patients with clinical Masaoka stage II-IVA thymoma or thymic carcinoma.. Patients will initially receive weekly cetuximab for 4 weeks to assess tumor response to cetuximab alone. Patients will then undergo weekly cetuximab along with concurrent CAP for 4 cycles. At the completion of this regimen, patients will undergo surgical resection and the specimen will be evaluated for CPR.
3224435|NCT01025076|Experimental|StomaphyX Group|"Primary Roux-en-Y gastric bypass with evidence of enlarged gastric pouch volume or enlarged stoma diameter of ≥ 20 mm via endoscopy or fluoroscopy.~Patients also demonstrate a weight regain of 15% of excess body weight loss."
3224436|NCT01025063||Lucentis (PRN group)|
3224437|NCT01025063||Lucentis (3 Injections over three months)|
3224438|NCT01025063||PDT (Reduced Fluence) and Lucentis|
3224439|NCT01025050|Experimental|Group A|In this group the smallest ring diameter will be applied.
3224440|NCT01025050|Experimental|Group B|In this group the intermediate ring diameter will be applied.
3224441|NCT01025050|Experimental|Group C|In this group the biggest ring diameter will be applied.
3224442|NCT01025037|Other|Conexa Reconstructive Tissue Matrix|Conexa will be placed as a soft tissue reinforcement at the rotator cuff repair site
3224443|NCT01025024||POAG group|Elevated intraocular pressure normal open angle glaucomatous optic nerve head abnormality glaucomatous visual field defect
3224444|NCT01025024||Normal control|Normal intraocular pressure No optic disc abnormality No visual field defect No significant ocular and systemic disease
3224445|NCT01025011||healthy volunteers, anemic patients|healthy volunteers from the eye and gynecology department pregnant patients with anemia
3224446|NCT01024998|Experimental|2 x 10^8 vector genomes (vg) AAV2-sFLT01|
3224447|NCT01024998|Experimental|2 x 10^9 vector genomes (vg) AAV2-sFLT01|
3224448|NCT01024998|Experimental|6 x 10^9 vector genomes (vg) AAV2-sFLT01|
3224449|NCT01024998|Experimental|2 x 10^10 vector genomes (vg) AAV2-sFLT01|
3224450|NCT01024985||multiple sclerosis|
3224451|NCT01024985||neuromyelitis optica|
3224452|NCT01024985||controls|
3224453|NCT01024972|Experimental|Dantrolene|Dantrolene 1.25mg/kg IV every 6 hours x 7 days
3224456|NCT01024946|Experimental|Pts getting everolimus|This is a multicenter, open label, phase II study of everolimus as a second or third line therapy for the treatment of advanced malignant pleural mesothelioma, which will also evaluate Merlin/NF2 loss as a biomarker to predict sensitivity to everolimus. Patients who have disease progression after one or two prior chemotherapy regimens will be eligible. In the first stage of this design, 19 patients will be accrued. If 6 or less patients among the first 19 patients show clinical benefit, then the study will be terminated and declared negative. If 7 or more patients show clinical benefit, than an additional 20 patients will be accrued to the second stage. At the end of the study, if 17 or more patients show clinical benefit out of a total of 39 patients enrolled, the regimen will be considered worthy of further investigation.
3224457|NCT01024933|Placebo Comparator|Educational and Behavioral|The Education and Behavioral Contract (Control group) will receive an educational workbook and behavioral contract. Each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
3224458|NCT01024933|Experimental|PASA group-intervention|The PASA group (Positive Affect/Self-Affirmation/Motivational Interviewing) will receive a positive-affect and self-affirmation intervention with motivational interviewing.These patients will also receive an educational workbook and behavioral contract. This is the intervention.
3224459|NCT01024920|Experimental|BIBF 1120|Non-marketed substance: Twice daily oral doses of 200mg BIBF 1120 given continuously.
3224460|NCT01024920|Active Comparator|sunitinib|Marketed substance: Once a day oral doses of 50mg sunitinib given in repeated 6 week cycles: 4 weeks active, 2 weeks rest.
3224461|NCT01024907|Experimental|Arm I|Patients undergo proton beam radiation therapy for 6 weeks in the absence of disease progression or unacceptable toxicity.
3224462|NCT01024894|Experimental|CYT107|
3224463|NCT01024881|Active Comparator|group 1|neutral shoulder position during infraclavicular subclavian catheterization
3224464|NCT01024881|Experimental|group 2|lowered shoulder position during infraclavicular subclavian catheterization
3224465|NCT01024868||TAP block|Patients before undergoing laparoscopic or other abdominal surgery
3224466|NCT01024855|Experimental|RevitaLens OcuTec Multipurpose Solution (Investigational MPS)|
3224467|NCT01024855|Active Comparator|Opti-Free RepleniSH Multipurpose Solution (MPS, Control)|
3224468|NCT01024842|Experimental|Low dose vaccinees|Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10^8 pfu.
3224469|NCT01024842|Experimental|High dose vaccinees|Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10^8 pfu.
3224470|NCT01024842|Placebo Comparator|Low dose placebo|Individuals will receive three intramuscular injections of low dose placebo
3224471|NCT01024842|Placebo Comparator|High dose placebo|Individuals will receive three intramuscular injections of high dose placebo
3224472|NCT01024829|Other|Whole tumor boost|Patients in this arm will receive radiotherapy (66Gy) in 24 fractions of 2.75 Gy with an integrated boost to the primary tumor as a whole
3224473|NCT01024829|Other|Boost 50% SUV area|Patients in this arm receive radiotherapy (66Gy) in 24 fractions of 2.75Gy with an integrated boost to the 50% SUVmax area of the primary tumor (of the pre-treatment FDG-PET-CT scan)
3224474|NCT01024816|Experimental|Restorative yoga intervention|
3224475|NCT01024816|Active Comparator|Stretching group|
3224476|NCT01024790|Experimental|Exercise group|
3224477|NCT01024790|No Intervention|Usual care|
3224478|NCT01024777|Active Comparator|High dose cholecalciferol|Patients in the high dose arm will receive 10,000 international units of cholecalciferol daily.
3224479|NCT01024777|Active Comparator|Low dose cholecalciferol|Patients enrolled in the low dose arm will receive up to 1000 international units of cholecalciferol daily.
3224480|NCT01024751|Experimental|Bausch & Lomb Multi-Purpose Solution|Multi-Purpose Solution to be used for disinfecting contact lenses.
3224481|NCT01024751|Active Comparator|Ciba's Multi-Purpose Solution|Multi-Purpose Solution to be used for disinfecting contact lenses.
3224482|NCT01024738|Placebo Comparator|Fluoride toothpaste|negative control toothpaste
3224483|NCT01024738|Active Comparator|Triclosan/Fluoride toothpaste|positive control toothpaste (Total toothpaste)
3224484|NCT01024738|Active Comparator|Chlorhexidine Oral Rinse|positive control oral rinse
3224485|NCT01024725||Not (yet) vaccinated persons|The participants do not want to take the vaccine (available only in the national vaccination campaign) or have not received it yet
3224486|NCT01024725||Vaccinated persons|The participants have taken the vaccine according to the national vaccination campaign
3224487|NCT01024699||XLIF|This group will have the XLIF procedure done.
3224488|NCT01024699||MAS TLIF|This group will have the MAS TLIF procedure done.
3224489|NCT01024686|Experimental|p52-p36- GAP Vaccine|
3224490|NCT01024686|No Intervention|Infectivity Control|
3224491|NCT01024686|Experimental|p52-p36- GAP Vaccine + Infectivity Challenge|
3224492|NCT01024673||patients with H1N1|patients who are clinical found to be positive for H1N1 will be enrolled
3224493|NCT01024660|Active Comparator|1|5 mg Donepezil (first 14 days), 10 mg Donepezil (next 70 days)
3224494|NCT01024660|Placebo Comparator|2|
3224495|NCT01024647|Active Comparator|Loss of Reponse Reinduction Responders|Loss of Response Reinduction Responders:certolizumab pegol (Cimzia) 200 mg every 2 weeks
3224496|NCT01024647|Active Comparator|Response loss Reinduction Non-Responders|Response Loss Reinduction Non-Responders:certolizumab pegol(Cimzia) 400 mg every 2 weeks
3224497|NCT01024647|Active Comparator|Responders|Responders: certolizumab pegol(Cimzia) 400 mg every 4 weeks
3224498|NCT01024647|Active Comparator|Non-Responders|Non-Responders: certolizumab pegol (Cimzia) 400 mg every 2 weeks
3224499|NCT01024634|Other|African American Group|A group of young African American males and females
3224500|NCT01024634|Other|Caucasian Group|a group of young Caucasian men and women
3224501|NCT01024621|Experimental|1|confocal laser endomicroscopy
3224502|NCT01024621|Active Comparator|2|standard endoscopy
3224503|NCT01024608|Experimental|BDP HFA 320 µg/day|During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning.
3224854|NCT01022151|Active Comparator|Aminophylline 2 mg/Kg [group A2]|
3224504|NCT01024608|Placebo Comparator|Placebo|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily each morning.
3224505|NCT01024595||Without treatment|
3224506|NCT01024582|Experimental|accelerated partial breast irradiation|pre-operative radiation of the in situ tumor in the breast
3224507|NCT01024569|Experimental|Wellness Recovery Action Planning (WRAP)|WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks. Topics include: Introduction to WRAP, Developing a Wellness Toolbox, Creating a Daily Maintenance Plan, Identifying Triggers, Identifying Early Warning Signs, Managing When Things Break Down, and Crisis Planning. Coursework is interactive, using lecture, question and answer, group discussion, and individual or group exercises. Each session includes a lecture on recovery topics such as self-esteem, changing negative thoughts to positive ones, peer support, and lifestyle issues.
3224508|NCT01024569|No Intervention|Comparison Wait-List Group|Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend WRAP groups after their final research interview.
3224509|NCT01024543|Sham Comparator|Placebo|Placebo
3224510|NCT01024543|Experimental|Angiotensin II|Angiotensin II
3224511|NCT01024543|Active Comparator|Phenylephrine|Phenylephrine
3224512|NCT01024517|Experimental|Single oral dose, solution|
3224513|NCT01024517|Experimental|Single oral dose, solid, fasted|
3224514|NCT01024517|Experimental|Single oral dose, solid, fed.|
3224515|NCT01024504|Experimental|XELOX/Avastin|Capecitabine Oxaliplatin Bevacizumab
3224516|NCT01024491|Experimental|paroxetine 15mg|Active treatment with daily dose of paroxetine 15mg.
3224517|NCT01024491|Experimental|paroxetine 20 mg|Active treatment daily dose of paroxetine 20 mg
3224518|NCT01024491|Experimental|placebo|placebo
3224519|NCT01024465|Experimental|ReShape Duo Balloon|Patients seeking weight loss with a starting BMI in the 30-40 range, received the ReShape Duo Balloon
3224520|NCT01024452|Experimental|DAWN AC|
3224521|NCT01024452|Active Comparator|Hamilton Nomogram|
3224522|NCT01024439|Active Comparator|single port|Patients will undergo transumbilical single incision laparoscopic appendicectomy.
3224523|NCT01024439|Active Comparator|conventional Lap|Patients will undergo conventional laparoscopic appendicectomy.
3224524|NCT01024426|Experimental|Health Facility intervention|In the clusters randomized to enhanced health facility-based care, the intervention is designed to address these barriers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
3224525|NCT01024426|Other|Standard of care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
3224526|NCT01024413|Experimental|erlotinib|erlotinib 150 mg oral till disease progression
3224527|NCT01024413|Active Comparator|gefitinib|gefitinib 250mg oral till disease progression.
3224528|NCT01024400|Experimental|vaccine|
3224529|NCT01024387|Experimental|AMG 479|Patients receive AMG 479 at a dose of 18 mg/kg administered IV on day 1 (± 3 days) of every 3-week cycle. Treatment should continue until disease progression, unacceptable toxicity or withdrawal of consent.
3224530|NCT01024361|No Intervention|Routine|Routine protocol of the service
3224531|NCT01024361|Experimental|CPAP-DR|Infants randomized to this arm will have nasal CPAP installation at delivery room before the 15th minute of life
3224532|NCT01024348|Active Comparator|Tramadex-OD|Patients will undergo knee arthroscopy under spinal anesthesia without any opioid. 30 minutes prior to surgery and 24 hours afterwards, patients will take a tablet of 100 mg Tramadex-OD. Breakthrough pain will be managed with 1 gr paracetamol (per os) as needed.
3224533|NCT01024348|Active Comparator|Control group|Patients will undergo knee arthroscopy under spinal anesthesia without any opioid.Postoperative pain will be managed throughout the study with 1 gr paracetamol (per os) every 6 hours as required.
3224534|NCT01024335|Active Comparator|Naltrexone and placebo|A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month while placebo will be taken daily for the first 5 weeks of treatment.
3224535|NCT01024335|Experimental|Naltrexone and dronabinol|A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month (the total of two injections, once at the end of hospitalization, and once at end of first month of outpatient treatment), while dronabinol (15 mg bid) will be taken daily for the first 5 weeks of treatment.
3224536|NCT01024322||Ciprofloxicine or Vigamox or other.|
3224537|NCT01024322||Nonsteroidal (Acular, Voltaren Xibrom, etc)|
3224538|NCT01024322||Steroid (FML, Pred Forte, Flarex, etc.)|
3224539|NCT01024309|Active Comparator|Mini-Posterior Approach|Mini-Posterior surgical approach for total hip arthroplasty
3224540|NCT01024309|Experimental|Direct Anterior Approach|Direct Anterior surgical approach for total hip arthroplasty
3224541|NCT01024296|Experimental|Gastric Bypass Surgery Patients|Surgical site closure using Port Close device
3224542|NCT01024270|Experimental|sublingual, oral and vaginal administration of misoprostol|
3224543|NCT01024257|Experimental|conjunctival autograft plus beta-irradiation|
3224544|NCT01024257|Active Comparator|conjunctival autograft|
3224545|NCT01024244|Placebo Comparator|0 milligrams (mg) Placebo|Participants received 2 placebo capsules by mouth (po), twice daily (BID), prior to morning and evening meals for 12 weeks.
3224546|NCT01024244|Experimental|100 mg LY2599506|Participants received 50-mg capsules of LY2599506 po BID (One 50 mg LY2599506 capsule + 1 matching placebo capsule), prior to morning and evening meals for 12 weeks.
3224547|NCT01024244|Experimental|200 mg LY2599506|Participants received two 50-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks.
3224855|NCT01022151|Active Comparator|Aminophylline 3 mg/Kg [group A3]|
3224548|NCT01024244|Experimental|400 mg LY2599506|Participants received two 100-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks.
3224549|NCT01024244|Experimental|200 mg LY2599506 once daily|Participants received 200-mg of LY2599506 po once daily (QD) (Two 100 mg LY2599506 capsules prior to morning meal, 2 matching placebo capsules prior to evening meal for 12 weeks).
3224550|NCT01024231|Experimental|Cohort 1: BMS-936558 (0.3 mg/kg)+Ipilimumab (3 mg/kg)|"BMS-936558 (MDX1106-04) 0.3 mg/kg solution, 60 minutes intravenous infusion every 3 (q3) weeks for 21 weeks in induction and every 12 (q12) weeks for 84 weeks in maintenance~Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
3224551|NCT01024231|Experimental|Cohort 2: BMS-936558 (1 mg/kg)+Ipilimumab (3 mg/kg)|"Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance~BMS-936558 (MDX1106-04) 1 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance"
3224552|NCT01024231|Experimental|Cohort 3: BMS-936558 (3 mg/kg)+Ipilimumab (3 mg/kg)|"Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance~BMS-936558 (MDX1106-04) 3 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance"
3224553|NCT01024231|Experimental|Cohort 4: BMS-936558 (10 mg/kg)+Ipilimumab (3 mg/kg)|"BMS-936558 (MDX1106-04) 10 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance~Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
3224554|NCT01024231|Experimental|Cohort 5: BMS-936558 (10 mg/kg)+Ipilimumab (10 mg/kg)|"BMS-936558 (MDX1106-04) 10 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance~Ipilimumab (BMS-734016) 10 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
3224555|NCT01024231|Experimental|Cohort 6: BMS-936558 (1 mg/kg)|BMS-936558 (MDX1106-04) 1 mg/kg solution, 60 minutes intravenous infusion, once q2 weeks for a total maximal duration of 96 weeks
3224556|NCT01024231|Experimental|Cohort 7: BMS-936558 (3 mg/kg)|BMS-936558 (MDX1106-04) 3 mg/kg solution, 60 minutes intravenous infusion, once q2 weeks for a total maximal duration of 96 weeks
3224557|NCT01024231|Experimental|Cohort 8: Nivolumab+Ipilimumab|"Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg solution intravenously q3 weeks, 4 doses for 12 weeks~Followed by Nivolumab 3 mg/kg solution alone intravenously q2 weeks, 48 doses for a maximum of 96 weeks"
3224558|NCT01024192|Experimental|1|Zolpidem 12.5mg tablet at bed time during 12 weeks
3224559|NCT01024179|Active Comparator|Group B: CTO|Chronic total occlusion
3224560|NCT01024179|Active Comparator|Group A : Non-CTO|"Non-chronic total occlusion :~Fibrous plaque+fibro-calcific plaque + Lipid plaque(<2 quadrants )~Lipid-rich plaque ( ≥2 quadrants )"
3224561|NCT01024166||Patient|Patient computer system use questionnaire
3224562|NCT01024166||Caregiver|Caregiver computer system use questionnaire
3224563|NCT01024166||Healthcare Provider|Physician and Nurse computer system use questionnaire
3224564|NCT01024153|Experimental|Active video game play|
3224565|NCT01024140|Experimental|Escitalopram|Flexible dose (5-20mg/day) of escitalopram monotherapy.
3224566|NCT01024127||Ancillary-correlative (predictors of AML treatment outcomes)|Germline DNA is obtained from previously collected peripheral blood or bone marrow samples for array-based genotyping studies, including genome-wide association studies (single nucleotide polymorphisms) and fine mapping genotyping. Clinical trial simulations are performed to test the clinical applicability of using genetic variation data in the management of infectious complications.
3224567|NCT01024114||Positive MBI scan|Women who are previously enrolled in an MBI study that present with a positive MBI scan.
3224568|NCT01024101|Experimental|Paclitaxel|
3224569|NCT01024088||GBS PATIENT|
3224570|NCT01024088||CONTROL|
3224571|NCT01024075|Placebo Comparator|Saline|Sinufoam is mixed with saline and placed within the ethmoid cavity at the completion of sinus surgery
3224572|NCT01024075|Active Comparator|Dexamethasone|Sinufoam is mixed with dexamethasone and placed within the ethmoid cavity at the completion of sinus surgery
3224573|NCT01024062|Experimental|Paclitaxel|
3224574|NCT01024049||Asymptomatic LVD|patients over 18 years old with patients with cardiovascular risk (obesity, diabetes, dyslipidemia, arterial hypertension, age, gender, familial history) and asymptomatic left ventricular dysfunction (LVD).
3224575|NCT01024049||healthy controls|individuals over 18 years old free of disease and treatments.
3224576|NCT01024049||patients with cardiovascular risk|patients with cardiovascular risk (obesity, diabetes, dyslipidemia, arterial hypertension, age, gender, familial history)
3224577|NCT01024049||chronic heart failure patients|patient with chronic heart failure
3224578|NCT01024049||acute heart failure patients|acute heart failure patients
3224579|NCT01024036|Experimental|Siltuximab+best supportive care (BSC)|Siltuximab 11 mg/kg will be administered as a 1-hour intravenous infusion every 3 weeks + BSC.
3224580|NCT01024036|Placebo Comparator|Placebo+BSC|Placebo will be administered as a 1-hour intravenous infusion every 3 weeks + BSC. Participants who do not respond to placebo during the blinded treatment period will have option to crossover and receive siltuximab 11 mg/kg which will be administered by 1-hour intravenous infusion every 3 weeks + BSC during the unblinded treatment period.
3224581|NCT01024023|Active Comparator|PPAM Aid|Suitable participants randomised to the treatment arm will receive the non articulated pneumatic early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
3224582|NCT01024023|Active Comparator|AMA Aid|Suitable participants randomised to the treatment arm will receive the articulated early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
3224856|NCT01022151|Active Comparator|Aminophylline 4mg/Kg [group A4]|
3224857|NCT01022151|Active Comparator|Aminophylline 5 mg/Kg [group A5]|
3224583|NCT01024010|Experimental|Arm A|Patients receive ofatumumab IV on days 1-2 of course 1 and on day 1 of courses 2-6. Patients also receive pentostatin IV over 30 minutes on day 1, cyclophosphamide IV over 30 minutes on day 1, and pegfilgrastim subcutaneously on day 2.
3224584|NCT01024010|Experimental|Arm B|"Arm B: Experimental Patients receive ofatumumab IV on days 1-2 of course 1 and on day 1 of courses 2-6. Patients also receive pentostatin IV over 30 minutes on day 1, cyclophosphamide IV over 30 minutes on day 1, and pegfilgrastim subcutaneously on day 2. Patients receive ofatumumab IV on day 1 of courses 7-12.~Interventions:~Drug: pentostatin~Drug: cyclophosphamide~Biological: ofatumumab~Procedure: laboratory biomarker analysis~Other: flow cytometry~Genetic: protein expression analysis"
3224585|NCT01023997||primary open-angle glaucoma|
3224586|NCT01023997||ocular hypertension patients|
3224587|NCT01023997||normal controls|
3224588|NCT01023997||Exfoliation patients|patients with exfoliation syndrome or exfoliative glaucoma
3224589|NCT01023984|Active Comparator|TEM - Transanal Endoscopic Microsurgery|TEM under general anesthesia
3224590|NCT01023984|Active Comparator|ESD - Endoscopic Submucosal Dissection|ESD under sedation
3224591|NCT01023971||Group A|Patients investigated with mfERG and MP-1
3224592|NCT01023971||Group B|Patients investigated by Laser Doppler Flowmetry
3224593|NCT01023958|Experimental|single arm|open label
3224594|NCT01023945|Experimental|ASP1941 high dose group|oral
3224595|NCT01023945|Experimental|ASP1941 low dose group|oral
3224596|NCT01023945|Placebo Comparator|Placebo group|oral
3224597|NCT01023932||Auditory Neuropathy Patients|
3224598|NCT01023919|Active Comparator|Group B: Non-DM|Coronary artery disease with diabetes mellitus
3224599|NCT01023919|Active Comparator|Group A: DM|Coronary artery disease with diabetes mellitus
3224600|NCT01023906||18-49 years|Younger
3224601|NCT01023906||50-85 years|Older
3224602|NCT01023893||End-stage renal disease|
3224603|NCT01023880|Experimental|1|CEP-18770
3224604|NCT01023867|Experimental|Alzheimer's disease group|Patients with Alzheimer's disease treated donepezil
3224605|NCT01023867|Experimental|Mixed Dementia group|Patients with Mixed Dementia treated donepezil
3224606|NCT01023854|Experimental|Continuous Paravertebral block|Continuous Paravertebral block
3224607|NCT01023854|Placebo Comparator|Placebo|Placebo
3224608|NCT01023841|Active Comparator|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
3224609|NCT01023841|Placebo Comparator|Vehicle Sterile Solution|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
3224610|NCT01023828||TOBACCO SMOKING|Group of patients with diagnosis of NSCLC and exposure to tabacco smoking
3224611|NCT01023828||WOOD SMOKE|Patients whit diagnosis of NSCLC and exposure to wood smoke
3224612|NCT01023828||TABACCO SMOKING AND WOOD SMOKE|Patients whit diagnosis of NSCLC and exposure to tabacco smoking and wood smoke
3224613|NCT01023828||WHITOUT EXPOSURE|Patients whit diagnosis of NSCLC and whitout exposure to risk factor
3224614|NCT01023815|Experimental|Group A -Once-a-day regimen|"Everolimus: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole daily dose of everolimus was taken in the morning, at the same time of the CsA and steroid dosing. At the Rand+1W visit, the everolimus dose was adjusted to reach and maintain everolimus blood levels between 5 and 8 ng/mL until end of Month 12.~Cyclosporine: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole cyclosporine daily dose was taken in the morning. The dose was then adjusted to maintain C2 levels between 350 and 700 ng/mL.~Prednisone: In patients randomized to Group A before Amendment 1 approval, the dose of prednisone was kept stable at 5 mg/day in the morning."
3224615|NCT01023815|Experimental|Group B - Steroid Withdrawal group|"Everolimus: after randomization the everolimus dose was adjusted, if necessary, to maintain a C0 within 6-10 ng/mL until M12.~Cyclosporine:after randomization the cyclosporine dose was adjusted to maintain CsA C2 levels within 300-500 ng/mL until M12.~Prednisone: starting from Visit 5 (day 90 ± 28 days), oral prednisone was tapered until complete stop. It was recommended to taper prednisone by 1 mg/week until complete stop in 5 to 6 weeks."
3224616|NCT01023815|Active Comparator|Group C - Standard twice-a-day group|"Everolimus: after randomization the everolimus dose was adjusted, if necessary, in order to maintain a C0 within 6-10 ng/mL until M12.~Cyclosporine: after randomization the cyclosporine dose was gradually adjusted to reach and maintain C2 blood levels of 200-450 ng/mL between Month 6 and Month 12.~Prednisone: the dose of prednisone was kept stable at 5 mg/day in the morning."
3224617|NCT01023815|Experimental|Not Randomized Population (NRP)|"NRP defined in whom a renal transplantation was performed, received at least one dose of study drug (everolimus) but who did not qualify for randomization at Visit 5, Day 90. This group was addressed as not randomized patients (NRP) and described with respect to baseline characteristics, treatment and outcome variables."
3224618|NCT01023802||Neoadjuvant therapy for breast cancer|Women who present to the Internal Medicine Breast Cancer Clinic with breast cancer and who after discussion with the consulting surgeon and oncologist have agreed to undergo neoadjuvant chemotherapy or neoadjuvant hormone therapy.
3224619|NCT01023789|Experimental|ABSORB BVS|Absorb Bioresorbable Vascular Scaffold (BVS) System implantation in the treatment of coronary artery disease
3224620|NCT01023776|Other|live monovalent H1N1 vaccine|A/California/07/09 live monovalent H1N1 vaccine 0.2 given intranasally, 2 doses given 28 days apart
3224621|NCT01023763|No Intervention|Usual care|"Nursing home residents who require intravenous fluids and intravenous antibiotics was treated as usual (hospital admissions for intravenous treatment).~In control nursing homes that had not completed the training program (intervention period), nursing home residents who require intravenous fluids and intravenous antibiotics was treated as usual. The majority of these patients were admitted to hospital for intravenous treatment. A few nursing homes or nursing home departments had sufficient expertise and capacity to provide treatment locally."
3224669|NCT01023477|Experimental|Chloroquine Standard Dose (500mg/week)|Patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month standard dose chloroquine (500 mg/week).
3224858|NCT01022151|Active Comparator|Doxapram 1 mg/kg [group D]|
3224622|NCT01023763|Other|A training program in iv treatment|"A structured training program in intravenous treatment in nursing homes:~Each of 30 participating nursing homes sequentially received theory and practical training in intravenous treatment. In nursing homes that had completed the training program (intervention period), and had sufficient expertise and capacity, nursing home residents in need of intravenous fluids or antibiotics were treated locally; otherwise they were hospitalized."
3224623|NCT01023750||Fenofibrate|
3224624|NCT01023737|Experimental|Hydroxychloroquine and Vorinostat|Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily and HCQ will be administered starting on Day 2 of Cycle 1 and both will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
3224625|NCT01023724|Active Comparator|bromfenac 0.09%|bromfenac 0.09% drops to be given pre operatively for one day BID, and then postoperatively for 14 days.
3224626|NCT01023724|Active Comparator|Acuvail|Acuvail to be given preoperatively at BID for one day pre op and then post operatively for 14 days.
3224627|NCT01023711|Other|Inactivated H1N1 Vaccine|Subject will recieve 0.5 mL IM injection of Inactivated H1N1 vaccine
3224628|NCT01023698|Experimental|photocoagulation|Laser photocoagulation
3224629|NCT01023685|Experimental|CAD106|
3224630|NCT01023672|Other|Armodifinil|150-250 mg armodafinil by mouth daily
3224631|NCT01023659|Active Comparator|Bupropion + motivational emails|participants receive Zyban (300mg/day) plus weekly motivational emails for 12 weeks.
3224632|NCT01023659|Active Comparator|Varenicline + motivational emails|participants receive Champix (2mg/day) plus weekly motivational emails for 12 weeks.
3224633|NCT01023659|Active Comparator|Motivational emails|participants receive weekly motivational emails for 12 weeks.
3224634|NCT01023646|Other|carbohydrate load|Food challenge - Carbohydrate load
3224635|NCT01023646|Other|Carbohydrate + Protein|Food challenge - carbohydrate + protein
3224636|NCT01023646|Other|Carbohydrate + Fat|Food challenge - carbohydrate + fat
3224637|NCT01023646|Other|Fiber|Food challenge - carbohydrate + fiber
3224638|NCT01023633|Active Comparator|Arm A: FOLFOX 4 continuous (Oxaliplatin, LV, 5-FU)|The arm A (FOLFOX4 continuous arm):receive FOLFOX4 every 2 weeks until progression or for maximum 24 cycles.
3224639|NCT01023633|Experimental|Arm B: FOLFOX4 Stop and go (Oxaliplatin, LV, 5-FU)|The arm B will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles
3224640|NCT01023620|Experimental|Pioglitazone|10 male patients with lipodystrophy taking daily Pioglitazone 45 mg
3224641|NCT01023620|No Intervention|Observation/Comparison|10 male patients with lipodystrophy not taking daily Pioglitazone
3224642|NCT01023607|Active Comparator|Group A:|Atorvastatin 20mg
3224643|NCT01023607|Experimental|Group B:|Atorvastatin 60mg
3224644|NCT01023607|Active Comparator|Group C:|Rosuvastatin 10mg
3224645|NCT01023594|Active Comparator|External stent|Feeding tube insert at pancreatojejunostomy site as a stent. And stent tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall.
3224646|NCT01023594|Active Comparator|Internal stent|short(5cm)internal stent insertion at pancreatojejunostomy site
3224647|NCT01023581|Placebo Comparator|Placebo|Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
3224648|NCT01023581|Experimental|Alogliptin 25 QD|Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
3224649|NCT01023581|Experimental|Alogliptin 12.5 BID|Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
3224650|NCT01023581|Active Comparator|Metformin 500 BID|Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.
3224651|NCT01023581|Active Comparator|Metformin 1000 BID|Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.
3224652|NCT01023581|Experimental|Alogliptin 12.5 BID + Metformin 500 BID|Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.
3224653|NCT01023581|Experimental|Alogliptin 12.5 BID + Metformin 1000 BID|Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.
3224654|NCT01023568|Active Comparator|Macintosh blade|Intubation with Macintosh blade laryngoscope
3224655|NCT01023568|Active Comparator|Glidescope|Intubation with Glidescope laryngoscope
3224656|NCT01023568|Active Comparator|Truview PCD|Intubation with the Truview PCD laryngoscope
3224657|NCT01023555|No Intervention|0.5cc 2 Bottles|
3224658|NCT01023555|Active Comparator|1cc single bottle|
3224659|NCT01023542|Active Comparator|1|Basiliximab 20 mg day 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low level cyclosporine [start at day 5 after OLT, trough-level 100-150 ng/mL (CsA)] + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx.
3224660|NCT01023542|Active Comparator|2|Basiliximab 20 mg Tag 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx + low-level cyclosporine (start within 30 days after LTx; trough level 100-150ng/mL (CsA).
3224661|NCT01023542|Experimental|3|Basiliximab 20 mg Tag 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx + everolimus (start within 30 days after LTx; trough-level 6-10 ng/mL).
3224662|NCT01023529||Prostate cancer|Patients with incurable prostate cancer requiring palliation of symptoms from a soft-tissue pelvic tumor.
3224663|NCT01023529||Rectal Cancer|Patients with incurable rectal cancer requiring palliation of symptoms from a soft-tissue pelvic tumor.
3224664|NCT01023516|Experimental|1|
3224665|NCT01023516|Placebo Comparator|2|
3224666|NCT01023503||1|Adults, with a new statin prescription or a change in their stain treatment
3224667|NCT01023490|Placebo Comparator|Placebo|
3224668|NCT01023490|Active Comparator|Vitamin D|34,500 IU vitamin D per week
3224850|NCT01022177|Active Comparator|diabetics|subjects with HbA1c >7,0 and pathological glucose tolerance testing
3224670|NCT01023477|Experimental|Chloroquine Low Dose (250mg/week)|Patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month low dose chloroquine (250mg/week).
3224671|NCT01023464|Other|Period 1|FID 114657 or SootheXP
3224672|NCT01023464|Other|Period 2|FID 114657 or SootheXP
3224673|NCT01023438|Experimental|Assisted uptitration|Uptitration of recommended drugs by primary care physician with specialist support
3224674|NCT01023438|Active Comparator|Usual care|Usual communication strategy from cardiologist to primary care physician
3224675|NCT01023425|Experimental|switching group|switching patients with Alzheimer's disease(AD) from galantamine or rivastigmine to donepezil because they were not responding adequately
3224676|NCT01023425|Experimental|naive group|naive patients with AD who initiated therapy with donepezil
3224677|NCT01023412|Active Comparator|Nutritional product|Oral nutritional supplement containing immuno nutrients
3224678|NCT01023412|Placebo Comparator|Isocaloric control|Isocaloric and isonitrogenous control without immuno nutrients
3224679|NCT01023399|Experimental|Artesunate + Amodiaquine|"Oral fixed combination of artesunate (AS) and amodiaquine (AQ)~Once daily, dose according to age~Infants 2-11 months: AS 25/AQ 67,5 mg (3 tablets/ blister)~Toddlers 1-5 years: AS 50/AQ 135 mg (3 tablets/ blister)~Children: 6-13 years: AS 100/AQ 270 mg (3 tablets/ blister)~Adults: >= 14 years: AS 100/AQ 270 mg (6 tablets/ blister)~3 day-treatment"
3224680|NCT01023373|Experimental|B:PTRS|B: the same medical therapy, as previously described in group A, associated with PTRS
3224681|NCT01023373|Active Comparator|A:medical therapy|hypotensive drugs, statins and antiplatelet therapy
3224682|NCT01023360|Experimental|Clopidogrel and proton pump inhibitors|all participating healthy people should receive clopidogrel and 3 kinds of PPI sequentially with one week interval between each PPI.
3224683|NCT01023347|Active Comparator|Paclitaxel (Genexol®) and Cisplatin|
3224684|NCT01023347|Experimental|Paclitaxel loaded polymeric micelle (Genexol-PM®) & Cisplatin|
3224685|NCT01023334|Experimental|Intraocular lidocaine,topical anesthesia,MSICS|experimental group:manual small incision cataract surgery under topical anesthesia with intracameral lidocaine
3224686|NCT01023334|Experimental|intracameral balanced salt solution,topical anesthesia,MSICS|control group:manual small incision cataract surgery under topical anesthesia with intracameral balanced salt solution.
3224687|NCT01023321|Experimental|1|single ascending doses
3224688|NCT01023321|Placebo Comparator|2|single dose placebo
3224689|NCT01023321|Experimental|3|multiple dose, 7 or 14 days, oral solution
3224690|NCT01023321|Placebo Comparator|4|multiple dose, 7 or 14 days, oral solution
3224691|NCT01023308|Experimental|Panobinostat + Bortezomib|
3224692|NCT01023308|Placebo Comparator|Placebo + Bortezomib|
3224693|NCT01023295|Placebo Comparator|Placebo|single dose
3224694|NCT01023295|Experimental|15 mg/m^2|15 mg/m^2 fosbretabulin, single dose
3224695|NCT01023295|Experimental|25 mg/m^2|25 mg/m^2 fosbretabulin, single dose
3224696|NCT01023295|Experimental|35 mg/m^2|35 mg/m^2 fosbretabulin, single dose
3224697|NCT01023295|Experimental|45 mg/m^2|45 mg/m^2 fosbretabulin, single dose
3224698|NCT01023282|Experimental|ACR325|
3224699|NCT01023282|Placebo Comparator|Placebo|
3224700|NCT01023269|Other|ON / OFF|Stimulation ON for 4 weeks, followed by stimulation OFF for 4 weeks.
3224701|NCT01023269|Other|OFF / ON|Stimulation OFF for 4 weeks, followed by stimulation ON for 4 weeks.
3224702|NCT01023256|Experimental|Group 1: MOR103, experimental|Biological: MOR103 0.3 mg/kg or placebo
3224703|NCT01023256|Experimental|Group 2: MOR103, experimental|Biological: MOR103 1.0 mg/kg or placebo
3224704|NCT01023256|Experimental|Group 3: MOR103, experimental|Biological: MOR103 1.5 mg/kg or placebo
3224705|NCT01023243|Placebo Comparator|1 CAre of the Feet for Those at Risk|secular trends for physician documentation in the medical record for care of the feet for high risk patients
3224706|NCT01023243|Active Comparator|Care of the feet for those at risk|the impact of 1) patient survey regarding last foot exam, tobacco and aspirin use on documentation of foot exam and 2) patient education material: Care of the Foot For Those at Risk, on documentation of foot examination in the medical record
3224707|NCT01023243|Active Comparator|Impact of Quality Survey|Impact of patient survey regarding last foot exam, tobacco and aspirin use on documentation of foot exam in the medical record
3224708|NCT01023230|Experimental|DV-601|
3224709|NCT01023217|Experimental|Adefovir plus Entecavir|Adefovir + Entecavir for 104 weeks
3224710|NCT01023217|Active Comparator|Adefovir plus Lamivudine|Adefovir + Lamivudine for 52 weeks, and thereafter, Adefovir + Entecavir for 52 more weeks
3224711|NCT01023204|Experimental|Paclitaxel|
3224712|NCT01023191|Active Comparator|Percutaneous insertion|To undergo insertion of catheter using percutaneous technique under local anaesthetic
3224713|NCT01023191|Active Comparator|Open insertion|To undergo insertion of catheter using open technique under general anaesthetic
3224714|NCT01023178|Active Comparator|Vivelle-Dot|17Beta Estradiol - transdermal
3224715|NCT01023178|Active Comparator|Premarin|Conjugated estrogens
3224716|NCT01023178|Active Comparator|Estrace|17beta Estradiol
3224717|NCT01023165|Experimental|IV bolus insulin, metabolic integrity|Diabetic patients will complete diagnostic testing and complete quality of life questionnaires at baseline and every six months thereafter while enrolled in the study to monitor and assess progress with metabolic integrity and complications resulting from their diabetes. Comparisons will be performed on lab values performed at baseline and every six months thereafter. Supervising physician may request testing be performed more frequently as deemed medically necessary, testing may include retinal photography, nerve conduction and labs. Meds and medical intervention information is collected weekly at the Intravenous Bolus Insulin treatment sessions. An annual evaluation is performed to review clinical data collected and evaluate progress for analysis and comparison.
3224718|NCT01023152|Experimental|Automated cuff-inflator|
3224719|NCT01023139|No Intervention|Standard of care (SOC)|No intervention following phase 1 of the study is done during this 2nd phase. Participants will have their height and weights examined at 3 month and 6 month following end of phase 1. During these two visits, they will receive counseling from the physician regarding food choices and exercise maintenance.
3224720|NCT01023139|Experimental|Continuing Behavioral Therapy (CoBT)|This arm follows the end of the phase 1 which incorporates behavioral therapy, nutrition counseling and pharmacotherapy with Sibutramine while medically supervised. Participants randomized to this arm no longer receive medication and will receive behavioral therapy once a month and then evaluated at 3 months and six months for weight loss maintenance.
3224721|NCT01023126|No Intervention|EO|Exercise three times a week, one under supervision and two freely chosen by the participant
3224722|NCT01023126|Experimental|EGT|Exercise three times a week, one under supervision and two freely chosen by the participant
3224723|NCT01023113|Experimental|PASCAL laser, PRP in 2-3 sitting at 3 days interval.|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery by PASCAL laser
3224724|NCT01023113|Active Comparator|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery by conventional laser
3224725|NCT01023100|Experimental|Open label|
3224726|NCT01023087||Treatment|Patients with sepsis treated with polymyxin E (colistin)
3224727|NCT01023087||Control|Patients with sepsis treated with other, non-nephrotoxic antibiotic medication
3224728|NCT01023074|No Intervention|Non-MS Control|Non-MS control group
3224729|NCT01023074|Active Comparator|MS: Auditory Training|MS group receiving auditory training
3224730|NCT01023074|Placebo Comparator|MS: Control Activity|MS group not receiving auditory training, doing control activity
3224731|NCT01023061|Experimental|Treatment (antihormone therapy and radiation therapy)|Patients receive abiraterone acetate and prednisone daily for 24 weeks. Patients also receive leuprolide acetate or goserelin in weeks 1 and 13. Patients undergo external beam radiotherapy starting in week 15 for 8.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3224732|NCT01023048|Experimental|PGD testing|
3224733|NCT01023035|Experimental|Treated/Not Randomized|Participants received 4 weeks of PEG2b/RBV followed by 24 or 44 weeks of boceprevir plus PEG2b/RBV depending on Hepatitis C Virus RNA (HCV-RNA) levels. Participants continued with this treatment if their serum hemoglobin remained >10 g/dL throughout the 28- or 48-week treatment period.
3224734|NCT01023035|Experimental|Ribavirin Dose Reduction|After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Ribavirin (RBV) Dose Reduction Arm received reduced doses of RBV for management of the anemia in combination with PEG2b and boceprevir therapies.
3224735|NCT01023035|Experimental|Erythropoietin Use|After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Erythropoietin Use Arm received erythropoietin for management of the anemia in addition to PEG2b/RBV and boceprevir therapies.
3224736|NCT01023022||Medtronic CareLink® Network|"Patients with implanted Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices, who will be monitored by the Medtronic CareLink® System.~The System consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website."
3224737|NCT01023009||eye occlusion|
3224738|NCT01022996|Experimental|RAD001|"Patients with a history of classical Hodgkin lymphoma (ie, nodular sclerosing, mixed cellularity, lymphocyte-rich, lymphocyte-depleted) whose disease had progressed after receiving high-dose chemotherapy with AHSCT (if eligible) and/or after therapy with a gemcitabine- or vinorelbine- or vinblastine-containing regimen, were enrolled into this study. All patients were assigned to a daily dose of everolimus 10 mg (two 5-mg tablets), selfadministered orally and continuously from Cycle 1 Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death, or discontinuation from the study for any other reason.~A treatment cycle consisted of 28 days."
3224739|NCT01022983|Active Comparator|Levosimendan|
3224740|NCT01022983|Placebo Comparator|Povidon, waterfree etanol, glucosis 5%|
3224741|NCT01022970|Placebo Comparator|Placebo|
3224742|NCT01022970|Active Comparator|QAX576|
3224743|NCT01022957|Experimental|Study group|Neurological, ophthalmological, olfactive exams and cerebral MRI
3224744|NCT01022944|Other|Group 2 :|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
3224745|NCT01022944|Other|Group 1|Children with chronic middle ear effusion having adenoidectomy.
3224746|NCT01022918|Experimental|Bevacizumab/Irinoecan|"Neoadjuvant Treatment Patient will receive bevacizumab 10mg/kg plus irinotecan 125mg/m² 4 times every two weeks.~Radiochemotherapy Then they will receive conformational radiotherapy for 6 weeks (30 Gy, 2Gy/fractions) associated with Temodal ( 75mg/m²/day) from first day up to the end of radiotherapy and 4 injections of Avastin (15mg/kg Day 1, day 15, day 29 and day 43).~Adjuvant treatment:~Patients will receive bevacizumab 15mg/kg plus irinotecan 125mg/m² 12 times every two weeks."
3224747|NCT01022918|Active Comparator|Stupp|patient will receive 6 weeks chemotherapy treatment associating conformational 30 Gy (2Gy/ fraction)and Temodal(75mg/m²/day, followed by 6 months adjuvant therapy consisting in 5 days every 28 days of Temodal (150-200mg/m².
3224748|NCT01022905|Experimental|High-risk patients ( 5 cohorts)|
3224749|NCT01022905|Active Comparator|Healthy controls|
3224750|NCT01022892||Phase 1 - Pilot phase|Total of 10 patients currently undergoing EVAR Surveillance. These 10 patients include 5 patients with endoleak known from a recent CT scan and 5 patients with no endoleak and shrinking aneurysm.
3224751|NCT01022892||Phase 2 - Blinded from CT Scan|This phase of study involves recruitment of 150 patients currently under post-EVAR surveillance. The physicians and ultrasound technologists will be blinded to the result of the CT Scan when performing and interpreting the CUS. The current schedule for EVAR Surveillance will be maintained so that an individual may receive more than one enhanced CT Scan and CUS during the 18 months of the study.
3224752|NCT01022853|Experimental|BIBF 1120 and BI 6727|Finding Maximum Tolerated Dose of BI 6727 in combination with BIBF 1120
3224753|NCT01022840|Placebo Comparator|Placebo|Placebo as saline solution
3224754|NCT01022840|Experimental|Low dose|S-Ketamine
3224755|NCT01022840|Active Comparator|High dose|
3224851|NCT01022177|Active Comparator|healthy|healthy subjects with HbA1c <7,0 and negative glucose tolerance testing
3224756|NCT01022827|Experimental|posterior shoulder stiffness massage group|The inclusion criteria of patients with glenohumeral internal rotation limitation and posterior shoulder stiffness were: [1] limitation of internal rotation ROM compared to the sound side; [2] mild glenohumeral joint hypomobility according to joint play assessment; [3] stiffness in the posterior shoulder region.
3224757|NCT01022827|Placebo Comparator|posterior shoulder stiffness placebo group|
3224758|NCT01022814||Pregnant woman|
3224759|NCT01022801|Experimental|Entecavir (0.01 mg)|
3224760|NCT01022801|Experimental|Entecavir (0.1 mg)|
3224761|NCT01022801|Experimental|Entecavir (0.5 mg)|
3224762|NCT01022788|Experimental|Home-based counselling visits by volunteers|Home-based counselling in pregnancy and the first few days of life to encourage women and families to adopt key newborn care behaviours
3224763|NCT01022788|No Intervention|Standard care through existing health system|
3224764|NCT01022775|Experimental|1: Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
3224765|NCT01022775|Active Comparator|2: Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
3224766|NCT01022762|Active Comparator|repaglinide|1 mg repaglinide twice daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 4 mg three times daily
3224767|NCT01022762|Active Comparator|gliclazide|80 mg gliclazide once daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 160 mg twice daily
3224768|NCT01022749|Experimental|2|patients with IBD receiving immunosuppressants (TNF blockers excluded) (n=100)
3224769|NCT01022749|Experimental|3|patients with IBD receiving immunosuppressants including TNF blockers (n=100)
3224770|NCT01022749|Experimental|1|patients with IBD not receiving immunosuppressant (n=100)
3224771|NCT01022749|Active Comparator|4|patients with IBD receiving immunosuppressants including TNF blockers (n=20)
3224772|NCT01022736|Experimental|gabapentin|patients scheduled for cardiac bypass surgery will be administered gabapentin (600mg, orally). Blood will be drawn and plasma gabapentin levels determined 1 hour before surgery, 10 minutes into surgery, 10 minutes before separation from bypass, 30 minutes following bypass, and then before and 2 hours after each dose of gabapentin.
3224773|NCT01022723||Lung Cancer patients|Lung Cancer (particular focus on non smokers with adenocarcinoma)
3224774|NCT01022723||Patients with Nasopharyneal carcinoma|Patients with Nasopharyneal carcinoma
3224775|NCT01022723||Breast Cancer patients|Breast cancer patients
3224776|NCT01022723||Prostate Cancer patients|Prostate cancer patients
3224777|NCT01022723||Colorectal Cancer patients|Colorectal cancer patients
3224778|NCT01022723||Gastric Cancer patients|Gastric cancer patients
3224779|NCT01022710||Group 1|Veterans with sensorineural hearing loss
3224780|NCT01022697|Active Comparator|A|Glucose drink
3224781|NCT01022697|No Intervention|B|Fasting
3224782|NCT01022684||Healthy patients|
3224783|NCT01022671|Experimental|Belotecan|Single arm
3224784|NCT01022658|Active Comparator|detemir|Insulin detemir at dinner or bedtime
3224785|NCT01022658|Active Comparator|aspart|Insulin aspart before each meal
3224786|NCT01022658|Active Comparator|detemir and aspart|
3224787|NCT01022645||Levonorgestrel IUD|
3224788|NCT01022645||Copper IUD or Tubal Ligation|
3224789|NCT01022632|Active Comparator|Fluoxetine|Fluoxetine : 20 mg Once a day in morning after taking food for 6 weeks
3224790|NCT01022632|Experimental|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
3224791|NCT01022632|Experimental|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
3224792|NCT01022619||Premature labor|Women at the third trimester of pregnancy with premature contractions and cervical dilation of effacement
3224793|NCT01022619||Control|Women at the third trimester of pregnancy with uncomplicated pregnancy
3224794|NCT01022619||Pre-eclampsia|Women at the third trimester with pre-eclampsia
3224795|NCT01022619||Gestational diabets|Women at the third trimester of pregnancy with gestational diabetes requiring insulin
3224796|NCT01022606|Other|Patients with walking limitation|Patients with claudication and Walking-Induced Transient Hack (W.I.T.H.) tcpO2 profiles are tested on treadmill with invasive pO2 arterial sampling and body temperature recording
3224797|NCT01022580|Active Comparator|Infasurf surfactant (ONY, Inc.)|Infants already receiving inhaled nitric oxide will receive scheduled doses of late surfactant (Infasurf) on study days 0, 2, 4, 6 and 8.
3224798|NCT01022580|Sham Comparator|sham|Infants already receiving inhaled nitric oxide will not receive additional doses of late surfactant (Infasurf).
3224799|NCT01022567|Active Comparator|Operative treatment|Regular open appendicectomy
3224800|NCT01022567|Active Comparator|Antibiotic treatment|Ertapenem 1 g i.v. x 1 three days
3224801|NCT01022541|Other|This is a single arm study|This is a single arm study
3224802|NCT01022528|Experimental|Dexamethasone|
3224803|NCT01022528|Placebo Comparator|Saline|
3224804|NCT01022515||patients with pheochromocytoma|Patients with pheochromocytoma / paraganglioma are being followed as recommended according to international standards. No intervention is expected except regular measurement of plasma CgA (as usual) and EM66 (research purpose) levels.
3224805|NCT01022515||Patients with essential hypertension|Patients with essential hypertension will be selected as controls. EM66 and CgA plasma levels will be assessed in these patients after having excluded the presence of a pheochromocytoma / paraganglioma with normal urinary metanephrines / normetanephrines excretion levels.
3224806|NCT01022502|Active Comparator|refined indigo naturalis ointment|Refined indigo naturalis ointment was applied topically to one of 2 bilaterally symmetrical psoriatic plaque lesions of the same patient for 8 weeks, starting on the date of enrollment in the study
3224807|NCT01022502|Active Comparator|crude indigo naturalis ointment|Crude indigo naturalis ointment was applied topically to one of 2 bilaterally symmetrical psoriatic plaque lesions of the same patient for 8 weeks, starting on the date of enrollment in the study
3224808|NCT01022489|Experimental|Transcranial magnetic stimulation: rTMS|rTMS : 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
3224809|NCT01022489|Placebo Comparator|placebo (sham coil) treatment|
3224810|NCT01022476|Experimental|Raltegravir potassium|raltegravir 400 mg twice a day
3224811|NCT01022463|Active Comparator|Ivabradine|Crossover study to compare ivabradine and atenolol
3224812|NCT01022463|Placebo Comparator|Atenolol|
3224813|NCT01022437|Experimental|Geranium Oil and component PN-34|
3224814|NCT01022424|Experimental|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
3224815|NCT01022411|Experimental|A|Brown rice
3224816|NCT01022411|Placebo Comparator|B|White rice
3224817|NCT01022398|Experimental|Vitamin D|Subjects will receive Vitamin D supplementation 10,000 international units of cholecalciferol (vitamin D3) by mouth weekly
3224818|NCT01022398|Placebo Comparator|Placebo|Subjects will receive placebo (an exact replica of the vitamin D capsule that does not contain any medically active substance) by mouth weekly
3224819|NCT01022385|No Intervention|12-hour fast|
3224820|NCT01022385|Active Comparator|24-hour low-residual diet and 12-hour fast|
3224821|NCT01022372||control group|
3224822|NCT01022372||endometriosis group|
3224823|NCT01022372||endometrioma group|
3224824|NCT01022359|Active Comparator|Tesio Catheter|Patients randomised to receive the established catheter type in use at our centre [control]
3224825|NCT01022359|Active Comparator|LifeCath|Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)
3224826|NCT01022346|Placebo Comparator|Placebo|Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
3224827|NCT01022346|Experimental|RO5217790|RO5217790 will be administered at a dose of 5*10^7 plaque forming unit (pfu) subcutaneously on Days 1, 8, and 15.
3224828|NCT01022333|Experimental|DIM group (BRCA1 carriers)|This group will have up to 100 women who are carriers of a BRCA1 deleterious mutation. To ensure safety, women in this group will not be able to participate in the study if they are under medications with warfarin, theophylline, or anticonvulsants; or if they are pregnant, breast-feeding or planning to become pregnant within 6 months of the research project. Women in this group will receive 300 mg per day of Rx Balance BioResponse DIM for six weeks. Supplements will be given free of charge. A blood sample (20cc) and a urine sample (20cc) will be collected from these women during two clinic visits; the second visit will be during the six weeks of DIM supplementation (4-6 weeks after the first clinic visit).
3224829|NCT01022333|No Intervention|No DIM group (BRCA1 carriers)|This group will have up to a 100 women who are carriers of a BRCA1 deleterious mutation. This group will not receive DIM. Women that choose not to take DIM will be in this group. A blood sample (20cc) and a urine sample (20cc) will be collected from these women during two clinic visits; the second visit will be 4-6 weeks after the first clinic visit.
3224830|NCT01022333|No Intervention|General Control Group|This group will have up to 100 women who do not carry a BRCA1 mutation but who come from BRCA1 carrier family (a family with at least one individual that has tested positive for a BRCA1 mutation). A control subject is considered negative for a BRCA1 mutation if she has been confirmed by direct DNA sequencing to not be a carrier of this gene. A blood sample (20cc) and a urine sample (20cc) will be collected from these women at a single clinic visit.
3224831|NCT01022320|Experimental|Surgical outcome|20 consecutive cases of patients who underwent the lateral pharyngoplasty
3224832|NCT01022307||Group 1: no history of TBI|184 participants with no history of traumatic brain injury (TBI).
3224833|NCT01022307||Group 2: with a history of TBI|28 patients with a history of TBI. Most of these patients had suffered mild TBI.
3224834|NCT01022294|Experimental|Arm 1|Inhalation of nitrousoxide-oxygen during the first experimental session; inhalation of atmospheric air during the second session
3224835|NCT01022294|Experimental|Arm 2|Inhalation of atmospheric air during the first experimental session; inhalation of nitrousoxide-oxygen during the second session
3224836|NCT01022281||Normal Controls|Normal age matched controls without exfoliation
3224837|NCT01022281||Exfoliation Syndrome|Patients with exfoliation syndrome
3224838|NCT01022268||Infection, inflammation or allergy|"Children presenting via any means to St Mary's Hospital; this would include the A&E department, the general and infectious disease wards and the paediatric intensive care unit.~Children needing blood tests for any clinical reason Children who, in the clinical judgement of the doctor assessing them, have presented because of a condition consistent with an infectious, inflammatory or allergic process"
3224839|NCT01022268||controls|children who do not have an infectious, inflammatory or allergic condition, who anyway require blood tests for clinical reasons
3224840|NCT01022255|Experimental|Arm 1|
3224841|NCT01022242|Placebo Comparator|Placebo|Placebo is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
3224842|NCT01022242|Experimental|PXL01|PXL01 is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
3224843|NCT01022229|Experimental|Compound Natural Health Product|15 study participants who will receive the compound natural health product.
3224844|NCT01022229|Placebo Comparator|Placebo|15 participants will receive placebo natural health product.
3224845|NCT01022216|Active Comparator|V.A.C.® Therapy|Vacuum Assisted Closure device that utilizes controlled negative pressure
3224846|NCT01022216|Experimental|Procellera™ Wound Dressing with V.A.C.® Therapy|Procellera wound dressing used as a primary contact layer on the wound bed, used in conjunction with NPWT
3224847|NCT01022203|Experimental|Structured Approach Therapy|Couple-Based Intervention called Structured Approach Therapy provides skills training to couple so they can reduce PTSD.
3224848|NCT01022203|Active Comparator|PTSD Family Education|Couple-Based Education called PTSD Family Education teaches couple about PTSD symptoms, related problems, and treatment.
3224849|NCT01022190|Experimental|Drug: Etoricoxib (Arcoxia, MSD), 90 mg.|Intervention drug: Etoricoxib (Arcoxia, MSD), 90 mg, orally, one time a day, for a 7 day period.
3224859|NCT01022138|Experimental|HER2Bi-armed activated T cells/Cyclophosphamide/biomarker|"HER2Bi-armed activated T cells Immediately after pheresis, the lymphocytes are activated with soluble monoclonal anti-CD3 antibody, which cross-links the CD3 receptors on T cells and activates them.~Cyclophosphamide After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide~Laboratory biomarker analysis The association between the [18F]-FDG PET/CT assessments (percent changes from baseline in SUVpeak) and immunologic biomarker changes as well as tumor response will be explored."
3224860|NCT01022112|Experimental|TA-7284-Low|
3224861|NCT01022112|Experimental|TA-7284-Low-middle|
3224862|NCT01022112|Experimental|TA-7284-High-middle|
3224863|NCT01022112|Experimental|TA-7284-High|
3224864|NCT01022112|Placebo Comparator|Placebo|
3224865|NCT01022099|Active Comparator|navigated TKA|
3224866|NCT01022099|Other|conventional TKA|
3224867|NCT01022086||early stage/adjuvant|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
3224868|NCT01022086||locally advanced/neoadjuvant|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
3224869|NCT01022086||metastatic|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
3224870|NCT01022086||anthracycline-containing|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
3224871|NCT01022086||non-anthracycline containing|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
3224872|NCT01022073||Globus Pallidus interna Group|Cohort of subjects who received DBS-GPi as part of the CSP 468 intervention trial, and still have their device working and in place.
3224873|NCT01022073||Subthalamic Nucleus Group|Cohort of subjects who received DBS-STN as part of the CSP 468 intervention trial, and still have their device working and in place.
3224874|NCT01022060|Experimental|A|Renalof
3224875|NCT01022060|Placebo Comparator|B|Placebo
3224876|NCT01022047|Experimental|Noex|The patients shall use the NOEX drug only once a day (one application in each nostril) during the 12 weeks of treatment
3224877|NCT01022047|Active Comparator|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
3224878|NCT01022034|Active Comparator|Pexy group|This group of patients with full thickness rectal prolapse will receive standard sacral rectopexy with mesh or sutures
3224879|NCT01022034|Sham Comparator|Non-pexy group|These patients will receive full rectal mobilization from the sacrum but without rectopexy
3224880|NCT01022021|Active Comparator|rituximab|
3224881|NCT01022021|Active Comparator|bendamustine|bendamustine, 90 mg/M2
3224882|NCT01022008|Experimental|Osteodistraction techniques|Osteodistraction techniques
3224883|NCT01021995|Experimental|echinacea|
3224884|NCT01021995|Placebo Comparator|placebo|
3224885|NCT01021982||Glaucoma|Glaucoma Patients with visual field defects
3224886|NCT01021982||Retinitis Pigmentosa|Retinitis Pigmentosa Patients with visual field defects
3224887|NCT01021956|Experimental|WST11 (STAKEL)|Single doses of 2.5 mg/kg of STAKEL® in combination with transpupilar illumination of the macula at escalating doses from 12.5 to 75 Joules/cm².
3224888|NCT01021943|Placebo Comparator|Placebo|Half of the subjects will be assigned to receive either spironolactone or placebo for 6 months
3224889|NCT01021943|Active Comparator|spironolactone|Half of the subjects will be randomized to receive spironolactone for 6 months
3224890|NCT01021930|Active Comparator|Group A: DM|Coronary artery disease with diabetes mellitus
3224891|NCT01021930|Active Comparator|Group B: Non-DM|Coronary artery disease without diabetes mellitus
3224892|NCT01021917||Other Dieters (OD)|Those participating in weight loss programs other than Medifast Direct or Take Shape For Life.
3224893|NCT01021917||Take Shape For Life (TSFL)|Those using Medifast meal replacement products for weight loss while working closely with a Take Shape For Life certified Health Coach.
3224894|NCT01021917||Medifast Direct (MD)|Those using Medifast meal replacement products specifically for weight loss that were purchased directly from the company and individually monitored by the customer.
3224895|NCT01021891|Experimental|Non-Diabetic Subj. w/o COPD|Single dose, 30 units
3224896|NCT01021891|Experimental|Non-Diabetic Subj. with COPD|Single dose, 30 units
3224897|NCT01021878|Experimental|icodextrin|glucose sparing alternative dialysis solution
3224898|NCT01021878|Active Comparator|dextrose|dianeal, Control group, standard treatment
3224899|NCT01021865||With type 2 Diabetes|
3224900|NCT01021865||Without type 2 diabetes|
3224901|NCT01021852|Experimental|MK-6096 2.5 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 2.5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for overnight polysomnography (PSG) recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment for the remaining 11 days. During Treatment Period 2, participants receive dose-matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
3225830|NCT01015027|Experimental|Dose 1|(3:1, active:placebo)
3224902|NCT01021852|Experimental|Placebo/MK-6096 2.5 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment for the remaining 11 days. During Treatment Period 2, participants receive MK-6096 2.5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
3224903|NCT01021852|Experimental|MK-6096 5 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
3224904|NCT01021852|Experimental|Placebo/MK-6096 5 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
3224905|NCT01021852|Experimental|MK-6096 10 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 10 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
3224906|NCT01021852|Experimental|Placebo/MK-6096 10 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 10 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
3224907|NCT01021852|Experimental|MK-6096 20 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 20 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
3224908|NCT01021852|Experimental|Placebo/MK-6096 20 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 20 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
3224909|NCT01021839|Active Comparator|Bovine Carotid Artery Graft|
3224910|NCT01021839|Active Comparator|Expanded Polytetrafluoroethylene Grafts|
3224911|NCT01021826||Hip and knee replacements recipients|Osteoarthritis patients undergoing elective primary hip and knee replacement and being followed-up in this study.
3224912|NCT01021813|Experimental|Suvorexant|After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to <65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the Treatment Phase.
3224913|NCT01021813|Placebo Comparator|Placebo|After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the Treatment Phase.
3224914|NCT01021800|Experimental|Cell infusion|
3224915|NCT01021774|Active Comparator|Advancement flap surgery|
3224916|NCT01021774|Active Comparator|Collagen plug|
3224917|NCT01021761|Active Comparator|Xibrom|Xibrom to be given 1 drop 2 times (BID) the day before surgery and 3 doses pre op the day of surgery prior to surgery
3224918|NCT01021761|Active Comparator|Nevanac|Nevanac to be given 1 drop 2 times (BID) the day before surgery and 3 doses pre op the day of surgery prior to surgery
3224919|NCT01021761|Active Comparator|Acuvail|Acuvail to be given preoperatively. One drop 2 times (BID), 1 day pre op and day of surgery 3 doses prior to surgery.
3224920|NCT01021748|Experimental|MK-2206 45 mg QOD + AZD6244 75 mg QD|Participants receive MK-2206 45 mg oral tablets once every other day (QOD) PLUS AZD6244 75 mg oral capsules once daily (QD) starting on Day 1 of each 28-day cycle.
3224921|NCT01021748|Experimental|MK-2206 45 mg QOD + AZD6244 75 mg BID|Participants receive MK-2206 45 mg oral tablets QOD PLUS AZD6244 75 mg oral capsules twice daily (BID) starting on Day 1 of each 28-day cycle.
3224922|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 50 mg BID|Participants receive MK-2206 90 mg oral tablets once weekly (QW) PLUS AZD6244 50 mg oral capsules BID starting on Day 1 of each 28-day cycle.
3224923|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 75 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 75 mg oral capsules QD starting on Day 1 of each 28-day cycle.
3224924|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 75 mg BID|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 75 mg oral capsules BID starting on Day 1 of each 28-day cycle.
3224925|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
3224926|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 150 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 150 mg oral capsules QD starting on Day 1 of each 28-day cycle.
3224927|NCT01021748|Experimental|MK-2206 100 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 100 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
3224928|NCT01021748|Experimental|MK-2206 135 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 135 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
3224929|NCT01021735|Active Comparator|Anti-TNF therapy|Etanercept or adalimumab by s/c injection
3224930|NCT01021735|Experimental|Rituximab therapy|Rituximab given by IV infusion
3224931|NCT01021722|Experimental|Modified suture technique|Sutured in a modified manner
3224932|NCT01021722|No Intervention|Historical sphincter group|The outcome of historical sphincter tears
3224933|NCT01021722|No Intervention|Normal primaparous deliveries|Normal deliveries
3224934|NCT01021709|Experimental|tDCS with alternative electrode montage|Treating major depression with either alternative tDCS electrode montage.
3224935|NCT01021696|No Intervention|Treatment as usual|Control group
3224936|NCT01021696|Active Comparator|Paracetamol|Intervention group
3224937|NCT01021696|Active Comparator|Morphine|Intervention group, individual pain treatment
3224938|NCT01021696|Active Comparator|Buprenorphine plaster|Intervention group, individual pain treatment
3224939|NCT01021696|Active Comparator|Pregabalin|Intervention group, individual pain treatment
3224940|NCT01021683||Itraconazole|Participants who have been receiving itraconazole will be observed prospectively. Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
3224941|NCT01021670||001|Dapoxetine hydrochloride One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks
3224942|NCT01021670||002|Alternate care/non-dapoxetine hydrochloride treatment(s) As prescribed or directed
3224943|NCT01021657||Glaucoma|
3224944|NCT01021644|Experimental|aerobic exercise-training|
3224945|NCT01021644|Active Comparator|stretch exercise|
3224946|NCT01021631|Active Comparator|Liberal Transfusion Strategy|Liberal Group - transfusion when hematocrit is lower than 30%
3224947|NCT01021631|Active Comparator|Restrictive Transfusion Strategy|Restrictive Group - transfusion when hematocrit is lower than 24%
3224948|NCT01021618|Active Comparator|Vasodilator-exercise stress|Four-minute infusion of dipyridamole (0.56 mg/kg) followed by symptom-limited exercise; injection of technetium-99m labeled radiopharmaceutical at peak hyperemia or peak exercise followed by SPECT myocardial perfusion imaging
3224949|NCT01021618|Experimental|Exercise-vasodilator stress|Symptom-limited exercise followed by a bolus intravenous injection of regadenoson (0.4 mg/5 mL) in patients failing to achieve a standard clinical endpoint; injection of technetium-99m labeled radiopharmaceutical 15 seconds after administration of regadenoson (or at peak exercise if regadenoson not administered) followed by SPECT myocardial perfusion imaging.
3224950|NCT01021592||001|
3224951|NCT01021579|Active Comparator|Metformin plus Simvastatin|PCOS patients(n=42) will be assigned to the simvastatin (20mg/day) plus metformin (500mg three times a day, n=42; group 1)
3224952|NCT01021579|Placebo Comparator|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
3224953|NCT01021566|Experimental|Combined hemoperfusion-hemodialysis|On admission thirty patients will receive the combined hemoperfusion-hemodialysis treatment regimen three hours everyday for three days.
3224954|NCT01021566|Active Comparator|Methadone, conventional treatment for opiate detoxification|On admission thirty patients receive the 10-day methadone treatment regimen.
3224955|NCT01021553|Placebo Comparator|placebo|placebo
3224956|NCT01021553|Active Comparator|50 mg|50 mg GSK557296
3224957|NCT01021553|Active Comparator|150 mg|150 mg GSK557296
3224958|NCT01021527|Experimental|Treatment Sequence 1|A-B-C-C
3224959|NCT01021527|Experimental|Treatment Sequence 2|B-C-A-C
3224960|NCT01021527|Experimental|Treatment Sequence 3|C-A-B-C
3224961|NCT01021527|Experimental|Treatment Sequence 4|A-C-B-C
3224962|NCT01021527|Experimental|Treatment Sequence 5|B-A-C-C
3224963|NCT01021527|Experimental|Treatment Sequence 6|C-B-A-C
3225142|NCT01020032|Experimental|Music therapy|"Individual receptive music therapy by U sequence method"
3224964|NCT01021514||Type 2 DM, Healthy control|Type 2 DM patients are treating in the Diabetic Clinic of Korea university Guro hospital, and their age- and sex-matched healthy controls are underwent a routine health checkup at Korea university Guro hospital.
3224965|NCT01021514||Type 2 DM, Heatlhy control|
3224966|NCT01021501|Experimental|nifedipine controlled release tablets|Prospective, open, non-randomized, non-controlled study to evaluate the effect and safety of nifedipine controlled release tablets in hypertensive patients on chronic maintenance hemodialysis and the influence of hemodialysis on the plasma concentration of nifedipine
3224967|NCT01021488|Experimental|Experimental: Rosuvastatin + enoxaparin arm|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
3224968|NCT01021488|Active Comparator|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
3224969|NCT01021475|Experimental|Usual drug FD therapy + Visceral Manipulation|
3224970|NCT01021475|Active Comparator|Usual drug FD therapy|
3224971|NCT01021462|Experimental|Period 1 + Period 2|graded infusion of intravenous glucose
3224972|NCT01021449||Control|Healthy subjects
3224973|NCT01021449||Schizophrenia|Schizophrenic patients
3224974|NCT01021436|Experimental|Amikacin inhalation solution|Subjects received 125 mg/mL of aerosolized amikacin via the PDDS clinical device at a nominal dose of 400 mg every 12 h for 7-14 days
3224975|NCT01021423|Experimental|Lenalidomide|Lenalidomide - 15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
3224976|NCT01021423|Experimental|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
3224977|NCT01021410||Acetaminophen Group|Subjects who completed COMIRB 06-1265 and were assigned to the acetaminophen treatment group for that study.
3224978|NCT01021397|Experimental|1|Participants will receive one dose of vaccine virus at study entry and between Weeks 22 and 27
3224979|NCT01021397|Placebo Comparator|2|Participants will receive one dose of vaccine virus placebo at study entry and between Weeks 22 and 27
3224980|NCT01021384|Other|Problem Solving Education|
3224981|NCT01021371|Experimental|Patient interview and communication to GP from hospital|Intervention group: The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group about their rehabilitation needs and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus.
3224982|NCT01021371|No Intervention|Control group: Usual practice, no intervention|
3224983|NCT01021358|Experimental|Arm A (ABT-263 and Ketoconozole)|
3224984|NCT01021332|Experimental|Total Group|Participants who received at least one dose of open-label fixed dose combination (FDC) treatment
3224985|NCT01021319||Acute ischemic stroke|Patients with acute ischemic stroke confirmed by acute or follow-up MRI with defined andwell-known symptom onset.
3224986|NCT01021306|Active Comparator|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner.
3224987|NCT01021306|Active Comparator|Dental Care & Self Care|Intraoral splints are removable orthopedic appliances fabricated of hard acrylic resin positioned between the remaining teeth of the patient. They are designed in theory to support the function of the TMJ and relieve associated pain. Stabilization splints are believed to function by stabilizing the intracapsular structure of the TMJ, reducing activity of masticatory muscles, distributing occlusal forces, and reducing bruxism (teeth grinding).
3224988|NCT01021306|Sham Comparator|Sham AMCT & Self Care|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except no thrust will be delivered. Self-care only participants successfully completing the 6 month assessment will be given the option for RIST or AMCT for one month.
3224989|NCT01021306|Placebo Comparator|Self-care only group|All patients will be offered the self-care checklist of homecare approaches at baseline. Self-care only participants successfully completing the 6 months assessment will be given the option for RIST or AMCT for one month.
3224990|NCT01021293|Experimental|Poliorix Group|Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Poliorix™ (IPV) vaccine at 2, 3 and 4 months of age, administered intramuscularly into the anterolateral side of the right thigh.
3224991|NCT01021293|Active Comparator|Control Group|Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Oral Poliomyelitis Vaccine (OPV) at 2, 3 and 4 months of age, according to the vaccination policy recommended in China.
3224992|NCT01021280||Type II BS|Adolescents and young adults with type II Bartter syndrome
3224993|NCT01021280||Type IV BS|Adolescents and adults with type IV Bartter syndrome
3224994|NCT01021280||Controls|Age and sex- matched controls
3224995|NCT01021267|Experimental|Saw palmetto berry extract|Saw palmetto berry extract, organic saw palmetto, ethanolic extract 96%
3224996|NCT01021241|Experimental|Uricase-PEG 20|Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner
3224997|NCT01021228||group1|continuous volatile anesthesia (sevoflurane) during the liver resection
3224998|NCT01021228||group2|continuous intravenous anesthesia (propofol) during the liver resection
3224999|NCT01021228||group3|preconditioning volatile anesthesia (sevoflurane) 30 minutes before ischemia (inflow occlusion)
3225000|NCT01021215|Experimental|Arm I: Zileuton|Zileuton 1200 mg twice orally twice a day on days 1-6.
3225001|NCT01021215|Experimental|Arm II: Zileuton and Celecoxib|Combined Zileuton 1200 mg twice daily plus Celecoxib 200 mg twice daily on days 1-6.
3225002|NCT01021202|Experimental|Early tracheostomy|Percutaneous dilation tracheostomy < 72h on mechanical ventilation
3225003|NCT01021202|Experimental|Late tracheostomy|Percutaneous dilation tracheostomy > 10 days on mechanical ventilation
3225004|NCT01021189|Experimental|1|AZD1446
3225005|NCT01021189|Placebo Comparator|2|Placebo
3225006|NCT01021176|Placebo Comparator|0mg 0 spray|No Diltiazem
3225007|NCT01021176|Active Comparator|2mg 2 Spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 2mg/2 spray Diltiazem
3225008|NCT01021176|Active Comparator|4mg 4 Spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 4mg/4 spray Diltiazem
3225009|NCT01021176|Active Comparator|8mg 8 spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 8mg/8 spray Diltiazem
3225010|NCT01021163|Placebo Comparator|N-acetylcysteine , saline|
3225011|NCT01021150|Experimental|Ombrabulin/cisplatin|AVE8062 combined with 75 mg/m2 of cisplatin will be administered once in every 3 weeks, with 30-minute intravenous infusion
3225012|NCT01021137||TBI & Blast|OEF/OIF Veterans complaining of dizziness and/or imbalance with history of blast exposure and a diagnosis of mild TBI
3225013|NCT01021137||Blast Only|OEF/OIF Veterans complaining of dizziness and/or imbalance with history of blast exposure without TBI
3225014|NCT01021137||TBI Only|OEF/OIF Veterans complaining of dizziness and/or imbalance with a history of mild TBI and no blast exposure
3225015|NCT01021137||Healthy Controls|Age and gender matched control subjects with no complaints of dizziness and/or imbalance or history of TBI or blast exposure
3225016|NCT01021124||QFT (+) vs QFT (-)|
3225017|NCT01021111|Experimental|Activity Training with Feedback|Subject is tested prior to training and retested with feedback training designed to modify the mechanics of landing during jumping and running activities
3225018|NCT01021098||Natural History Study|The core Natural History Study of ILI is an observational, longitudinal cohort study using data from clinical findings, medical chart review, and diagnostic, virologic and immunologic laboratories to describe the epidemiology and immunology of ILI. This study aims to describe the clinical history of influenza and other viral respiratory pathogens in a population of US military active duty members and their dependents. The primary focus will be the etiology, natural history and immunology of ILI in otherwise healthy adults and children. We will recruit subjects with ILI in both the outpatient and inpatient setting, and will serially collect biological specimens (e.g. nasal/throat swabs, blood, rectal swabs) over a 28-day period. In addition, we will collect a single buccal (cheek) swab.
3225019|NCT01021098||HIV-Positive Cohort|In addition, given a number of human immunodeficiency virus (HIV)-infected subjects who serve in the active duty force, we will also examine a subset of HIV-positive military beneficiaries as part of this consortium. An additional objective of the study will be to descriptively examine the clinical and laboratory characteristics of ILI events among HIV-infected persons using the military's substantial experience in following a stable HIV-infected population. We will recruit subjects with ILI in both the outpatient and inpatient setting, and will serially collect biological specimens (e.g. nasal/throat swabs, blood, rectal swabs) over a 28-day period. In addition, we will collect a single buccal (cheek) swab.
3225020|NCT01021085||Pregnant women|Pregnant women who have conceived via ART and are between days 36 and 56 of gestation
3225021|NCT01021072|Experimental|MTD|The study will utilize a standard 3+3 design for dose escalation. Once the maximum tolerated dose has been reached, an expansion cohort, as well as tumor specific expansion cohorts will be explored.
3225022|NCT01021059|Experimental|1|rh IL-15 daily for 12 days of 42 days cycle.
3225023|NCT01021046|Experimental|GCCT,corneal allograft survival ,DALK|experimental group: deep anterior lamellar keratoplasty using glycerin-cryopreserved corneal tissue
3225024|NCT01021046|Experimental|FCT,corneal allograft survival ,DALK|control group: deep anterior lamellar keratoplasty using fresh corneal tissue
3225025|NCT01021020|Experimental|1|Colchicine (fasted)
3225026|NCT01021020|Experimental|2|Colchicine (fed)
3225027|NCT01021020|Active Comparator|3|Colchicine/Probenecid (fasted)
3225028|NCT01021007|Placebo Comparator|A|control mouthrinse
3225029|NCT01021007|Experimental|B|new prototype mouthrinse
3225030|NCT01020994|Experimental|LAS41003|
3225031|NCT01020994|Active Comparator|LAS189962|
3225032|NCT01020994|Active Comparator|LAS189961|
3225033|NCT01020981||Group 1|Michigan State Army National Guard soldiers who have returned from OEF/OIF deployments starting December 2008
3225034|NCT01020981||Group 2|Indiana State Army National Guard soldiers who have returned from OEF/OIF deployments starting December 2008
3225035|NCT01020968|Experimental|Ixmyelocel-T|The treatment arm of the study will receive catheter-based injections of the study cellular product.
3225036|NCT01020968|Placebo Comparator|Vehicle Control|will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control.
3225037|NCT01020955|Active Comparator|NutropinAq and Increlex|NutropinAq (0.15 mg/day for 1 month, 0.3 mg/day for 5 months) and Increlex (15 µg/kg/day for 1 month and 30 µg/kg/day for 5 months).
3225038|NCT01020955|Placebo Comparator|NutropinAq and placebo|NutropinAq (0.15 mg/day for 1 month, 0.3 mg/day for 5 months) and placebo for 6 months.
3225039|NCT01020942|Experimental|Pretreatment|
3225040|NCT01020942|No Intervention|Control|
3225041|NCT01020916|Experimental|Target Temperature 33°C|
3225042|NCT01020916|Active Comparator|Target Temperature 36°C|
3225043|NCT01020903|Active Comparator|Aprepitant|
3225044|NCT01020903|Placebo Comparator|Placebo|
3225045|NCT01020877|Experimental|1|Metronidazole Vaginal Gel
3225046|NCT01020877|Active Comparator|2|MetroGel-Vaginal®
3225047|NCT01020864|Experimental|Chemotherapy|"Patients will be treated with Cetuximab, Carboplatin and Vinorelbine i.v. day 1, every 2nd week.~Patients will be treated until progression and/or in case of unacceptable toxicity or if the patient wishes to stop treatment."
3225048|NCT01020851|Experimental|tailored intervention|Participants in this arm will receive 6 monthly telephone calls of a behaviorally tailored intervention based on the transtheoretical model.
3225049|NCT01020851|Active Comparator|attention placebo|Participants in this arm will receive 6 monthly telephone delivered counseling sessions about general health topics
3225050|NCT01020838|Experimental|Florbetaben (BAY94-9172)|
3225051|NCT01020825||ASCs|Patients randomized to experimental treatment (ASC transplantation) in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
3225052|NCT01020825||Fibrin glue|Patients randomized to the control treatment (application of fibrin glue) in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
3225053|NCT01020825||ASCs + Fibrin Glue|Patients randomized to the control treatment (application of fibrin glue) + intralesional injection of ASCs in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
3225054|NCT01020812|Experimental|Stereotactic body radiotherapy (SBRT)|"SBRT will be delivered on Varian's linear accelerator with On-Board Imaging (OBI) capabilities. The tumor will be tracked with the ethiodol material from the TACE procedure, and respiratory gating will be used to minimize motion due to respiration. Treatment will be given in either 3 or 5 fractions . SBRT will take place after the treatment planning and within 12 weeks of the last TACE procedure.~Doses: 45 Gy at 15 Gy/fraction , 36 Gy at 12 Gy/fraction, 45 Gy at 9 Gy/fraction, 40 Gy at 8 Gy/fraction"
3225055|NCT01020799|Experimental|AZD7268|The AZD7268 15 mg BID arm consisted of 3 AZD7268 5 mg capsules dosed orally in the morning and evening. In addition, 2 placebo tablets to match encapsulated escitalopram tablets were dosed orally in the morning only.
3225056|NCT01020799|Placebo Comparator|Placebo|The placebo arm consisted of 3 placebo capsules to match AZD7268 capsules dosed orally in the morning and evening. In addition, 2 placebos to match encapsulated escitalopram tablets were dosed orally in the morning only.
3225057|NCT01020799|Active Comparator|Escitalopram|The escitalopram 20 mg QD arm consisted of 3 placebo to match AZD7268 capsules dosed orally in the morning and evening. In addition, during Week 1, one encapsulated 10-mg escitalopram tablet and 1 placebo to match encapsulated escitalopram tablet were dosed orally in the morning only. During Weeks 2 through 4, two encapsulated 10-mg escitalopram tablets were dosed orally in the morning only.
3225058|NCT01020786|Experimental|Pemetrexed + Carboplatin|After four 21-day cycles of Pemetrexed plus Carboplatin treatment, Pemetrexed monotherapy is continued until study discontinuation.
3225059|NCT01020773|Active Comparator|SBT group|In the SBT group, the patients underwent a 1 hr SBT with inspiratory PS of 7 cmH2O with other settings remaining constant (FiO2, PEEP, trigger sensitivity). The patients who tolerated the SBT underwent immediate extubation.
3225060|NCT01020773|No Intervention|no-SBT group|In no-SBT group, as soon as a patient met readiness criteria, he or she underwent extubation without SBT process.
3225061|NCT01020760|No Intervention|No posture|Patients will undergo routine phacoemulsification, pars plana vitrectomy, ILM peel and gas fluid exchange with 14% C3F8. They will be advised to avoid supine posturing for seven days after surgery, but will not be advised to posture in the face down or prone position.
3225062|NCT01020760|Experimental|Face down posture|Patients will undergo routine phacoemulsification, pars plana vitrectomy, ILM peel and gas fluid exchange with 14% C3F8. They will be advised to posture in the face down or prone position for 50 minutes per hour for seven days.
3225063|NCT01020734|Experimental|transplantation|perform allogeneic HCT for patients with AML in CR1; then analyze various pre-transplantation variable, including donor type, for correlation to outcomes
3225064|NCT01020721||Glaucoma|South korean patients with primary congenital glaucoma
3225065|NCT01020695||PTSD veterans|18 PTSD veterans
3225066|NCT01020695||controls|20 controls
3225067|NCT01020656||group 1|patients with no anticoagulants used as the control group
3225068|NCT01020656||group 2|patients treated with anticoagulant therapy (warfarin, fluindone, acenocoumarol)
3225069|NCT01020656||group 3|patients treated with aspirin
3225070|NCT01020656||group 4|patients treated with clopidogrel therapy
3225071|NCT01020656||group 5|patients treated with both anticoagulant and aspirin medications
3225072|NCT01020656||group 6|patients treated with both anticoagulant and clopidogrel medications
3225073|NCT01020656||group 7|patients treated with both aspirin and clopidogrel medications
3225074|NCT01020643|Experimental|controlled sedation using propofol|
3225075|NCT01020630|Experimental|Sunitinib|25 mg (2 capsules of 12.5 mg) for oral administration
3225076|NCT01020630|Placebo Comparator|Placebo|2 capsules for oral administration
3225077|NCT01020591|Active Comparator|Osteopathic evaluation|osteopathic evaluation of motion and tissue mobility
3225078|NCT01020591|Experimental|Osteopathic evaluation with treatment|osteopathic evaluation of motion and tissue mobility followed by osteopathic manual therapy release of the tight or restricted tissues
3225079|NCT01020578||Impaired glucose tolerance|Patients diagnosed with impaired glucose tolerance
3225080|NCT01020578||Control|Patients with normal blood glucose
3225081|NCT01020565|Experimental|Entecavir (0.1 mg)|
3225082|NCT01020565|Experimental|Entecavir (0.5 mg)|
3225083|NCT01020539|Experimental|Matched Family Donor|"Patients will receive a reduced intensity fludarabine (6 days)/busulfan (2 days) conditioning regimen followed by a stem cell transplant from a related family donor using bone marrow or cord blood stem cells. Then followed by Gemtuzumab Ozogamicin, once at about 2-6 months post alloSCT and once at least 2 months after the first dose. Patients with JMML will also receive cis-retinoic acid (Isotretinoin).~During and following transplantation patients will receive methylprednisolone for immune suppression. Graft-versus-host-disease (GVHD) prophylaxis will consist of tacrolimus, mycophenolate mofetil and additionally methotrexate in recipients of unrelated adult transplants."
3225084|NCT01020539|Experimental|Unrelated Donor|"Patients will receive a reduced intensity fludarabine (6 days)/busulfan (2 days) conditioning regimen followed by a stem cell transplant from an unrelated donor using matched bone marrow or cord blood stem cells.Then followed by Gemtuzumab Ozogamicin, once at about 2-6 months post alloSCT and once at least 2 months after the first dose. Patients with JMML will also receive cis-retinoic acid (Isotretinoin).~During and following transplantation patients will receive methylprednisolone for immune suppression and unrelated donor transplant recipients will additionally receive Anti-Thymocyte Globulin. GVHD prophylaxis will consist of tacrolimus, mycophenolate mofetil and additionally methotrexate in recipients of unrelated adult transplants."
3225085|NCT01020526|Experimental|Pregabalin|
3225086|NCT01020474|Placebo Comparator|Placebo|
3225087|NCT01020474|Experimental|drug-pregabalin|
3225088|NCT01020461|Experimental|Venous blood sampling|To use Accuvein to improve the effectiveness of venous blood sampling
3225089|NCT01020461|Experimental|Peripheral IV catheter placement|To use Accuvein to improve the effectiveness of placing peripheral IV catheter
3225090|NCT01020448|Experimental|Triptorelin (Decapeptyl®) 22.5 mg|
3225091|NCT01020435|Active Comparator|Spinal Manipulation High Velocity|This non-rotary upper cervical procedure uses an impulse thrust with a controlled depth (high velocity). The participant's head is supported by a specially designed cushion and the doctor usually approaches the participant from in front of his or her head to contact soft tissue over the atlas transverse process, posterior to the lateral mass or occasionally on the C2 lamina or spinous process, with the pisiform process of one hand. The thrust is delivered by a contraction of the triceps muscles of both arms, which straightens the arms and applies the thrust to the participant.
3225092|NCT01020435|Placebo Comparator|Sham Spinal Manipulation|The sham assessment procedures will be similar to the active group. It has been developed and validated by Vernon et al.
3225093|NCT01020422|No Intervention|Breast hypertrophy|Patients with macromastia will be evaluated in regard to sexual function and depression predictors at 3 moments: initial interview, after 3 months and after 6 months
3225094|NCT01020422|Experimental|Reduction Mammaplasty|Breast hypertrophy patients randomized to this group will immediately be scheduled for reduction mammaplasty and will be will be evaluated in regard to sexual function and depression predictors preoperatively and 3 and 6 months postoperatively
3225095|NCT01020409||cardiac surgery with CPB use|Adult patients, who signed the informed consent, intervention: first-time scheduled heart surgery with CPB use.
3225096|NCT01020396|Experimental|1|Metronidazole Vaginal Gel, 0.75% (Teva Pharmaceuticals, USA)
3225097|NCT01020396|Active Comparator|2|MetroGel-Vaginal® metronidazole vaginal gel, 0.75% (3M Pharmaceuticals)
3225098|NCT01020370||Alemtuzumab Group|
3225099|NCT01020370||Interferon Beta-1a SC Group|
3225100|NCT01020357|Active Comparator|caffeine|
3225101|NCT01020357|Placebo Comparator|placebo|
3225102|NCT01020344|Active Comparator|Lung volume reduction surgery|This group will receive lung volume reduction surgery
3225103|NCT01020344|No Intervention|No lung volume reduction surgery|This group will not receive LVRS during the 3 months of the study
3225104|NCT01020331|Experimental|ACTIVE|
3225105|NCT01020305|Experimental|Temsirolimus + Bicalutamide|"Temsirolimus 25 mg administered intravenously (IV) once weekly for 12 weeks~Casodex (bicalutamide) administered 50 mg/day orally (PO)"
3225106|NCT01020279|Other|Parallel Group A|Celecoxib 200 mg (Active Comparator) ; Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)
3225107|NCT01020279|Other|Parallel Group B|oral Placebo (Placebo Comparator); Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)
3225108|NCT01020266|Active Comparator|Electroacupuncture|
3225109|NCT01020266|Sham Comparator|Control|
3225110|NCT01020253|Active Comparator|Alendronate medication|
3225111|NCT01020253|Active Comparator|Alfacalcidol medication|
3225112|NCT01020253|No Intervention|Non-medication|
3225113|NCT01020240|No Intervention|Avaliation|This group will have 15 women in puerperium and will be realize an interview to avalide the cesarean discomforts in immediate puerperium. These dates will be use for elaborate the orientations guide.
3225114|NCT01020240|No Intervention|Orientation|In this group will be realize an interview to avalide the cesarean discomforts in immediate puerperium or in the first post operatory and in the second post operatory wil be realize a new interview.
3225115|NCT01020240|Experimental|Guide|in This group wiil be realize an interview to avalide the cesarean discomforts in immediate puerperium or in the first post operatory, will be realize the orientations and the guide will be give, and in the second post operatory will be realize a new interview.
3225116|NCT01020227|Experimental|Integrative Therapies|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
3225117|NCT01020227|No Intervention|Standard Care|Patients were given no intervention but were contacted at 6 weeks and 6 months for data collection purposes
3225118|NCT01020214|Experimental|1|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
3225119|NCT01020214|Active Comparator|2|Benicar HCT® Tablets 40 mg/25 mg
3225120|NCT01020201||PONV group|patients with postoperative nausea and vomiting
3225121|NCT01020201||Control group|patients without postoperative nausea and vomiting
3225122|NCT01020175|Other|Bone marrow transplantation|Patients received bone marrow transplantation
3225123|NCT01020175|Other|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
3225124|NCT01020162|Active Comparator|Non-surgical|TENS, amitriptyline, gabapentin.
3225125|NCT01020162|Active Comparator|Surgical intervention|Resection of the ilioinguinal nerve
3225126|NCT01020136|Experimental|Sequence 1 (BABA)|Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: B -> A -> B -> A
3225127|NCT01020136|Experimental|Sequence 2 (ABAB)|Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: A -> B-> A -> B
3225128|NCT01020123|Experimental|1|AZD1656
3225129|NCT01020123|Experimental|2|AZD1656
3225130|NCT01020123|Experimental|3|AZD1656
3225131|NCT01020123|Experimental|4|AZD1656
3225132|NCT01020123|Experimental|5|AZD1656
3225133|NCT01020123|Placebo Comparator|6|
3225134|NCT01020123|Active Comparator|7|Glipizide administered to 1 group of patients
3225135|NCT01020084||Control|Subjects with normal salivary flow rate
3225136|NCT01020084||Hyposalivation|Subjects presenting low salivary flow rate as a side effect of systemic isotretinoin therapy.
3225137|NCT01020071|Other|laser treatment|laser peripheral iridotomy and laser peripheral iridoplasty
3225138|NCT01020058|Active Comparator|Lichtenstein in local anesthesia (LLA)|Patient operated in local anesthesia, with an anterior mesh repair according to Lichtenstein
3225139|NCT01020058|Active Comparator|TEP|Patient receives a totally extraperitoneal laparoscopic repair
3225140|NCT01020045||HIV-seropositive, HIV seronegative|No intervention - biologic samples were collected from both HIV positive and HIV negative subjects
3225141|NCT01020045||Treatment naive subjects|HIV-seropositive subjects naive to antiretroviral therapy. HIV-seronegative subjects otherwise healthy.
3225143|NCT01020019|Experimental|Lofexidine and Dronabinol|Maintained at 1.8mg/day Lofex. and 60 mg/day of Dronabinol
3225144|NCT01020019|Placebo Comparator|Placebo|Lofex. matched placebo Dronabinol placebo
3225145|NCT01020006|Active Comparator|Gemcitabine|Subjects receive Gemcitabine 1000 mg/m2 weekly intravenous infusion.
3225146|NCT01020006|Experimental|PCI-27483 + Gemcitabine|"Part A: Subjects received PCI-27483 0.8 mg/kg BID as initial dose and may be escalated to 1.2, and 1.5 mg/kg BID. At the same time, subjects received Gemcitabine 1000 mg/m2 weekly intravenous infusion.~Part B: Subjects received the PCI-27483 at 1.2 mg/kg BID and Gemcitabine 1000 mg/m2 weekly intravenous infusion."
3225147|NCT01019993|Active Comparator|good pulmonary functions (group N)|The patients were allocated if they have forced vital capacity (FVC %) and/or forced expiratory volume in 1 sec (FEV1%) of 80% of predicted or more
3225148|NCT01019993|Active Comparator|pulmonary dysfunction (group PD)|The patients were allocated if they have FVC and/or FEV1 of 50%-79% of predicted
3225149|NCT01019980|Experimental|Diclofenac potassium|
3225150|NCT01019980|Active Comparator|Acetaminophen|
3225151|NCT01019941|Other|1st cycle:CKD-810 -> 2nd cycle:Taxotere inj.|
3225152|NCT01019941|Other|1st cycle:Taxotere inj.-> 2nd cycle:CKD-810|
3225153|NCT01019928|Experimental|First AZD1386, then washout, then placebo|
3225154|NCT01019928|Experimental|First placebo, then washout, then AZD1386|
3225155|NCT01019915|Other|Heart failure patients. Intervention CRT|CRT implantation in heart failure. Effect of intervention after 6 months of treatment.
3225156|NCT01019889|Experimental|Placebo|Placebo (encapsulated starch + lactose)
3225157|NCT01019889|Experimental|SCRT(Socheongryong-tang )|encapsulated Socheongryong-tang extract
3225158|NCT01019889|Experimental|YPS (Yeongyopaedok-san)|Encapsulated Yeongyopaedok-san extract
3225159|NCT01019876|Experimental|Fludarabine|
3225160|NCT01019876|Experimental|Cyclohosphamide 200|
3225161|NCT01019876|Experimental|Cyclophosphamide 40|
3225162|NCT01019876|Experimental|Cyclophosphamide 30|
3225163|NCT01019863|Experimental|Oxaliplatin|oxaliplatin associated with Rituxan,Gemcitabine, and Dexamethasone in patients with refractory or relapsed Non hodgkinien lymphoma
3225164|NCT01019850|Other|Treatment for All Patients|Patients on study will receive vorinostat orally once daily on days 1 to 14. The starting dose level is 180 mg/M2. The maximum dose is 400 mg. Patients will receive 131- I Metaiodobenzylguanidine on day 3, 1hr after vorinostat dosing. Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg. Peripheral Blood Stem Cell Infusion is planned for 2 weeks after MIBG infusion (day 17). The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing. Patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines.
3225165|NCT01019837|Experimental|Monovalent MF59- Adjuvanted vaccine|Focetria (Monovalent MF59-Adjuvanted vaccine) 7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate Intra muscular
3225166|NCT01019824|Experimental|Low Dose|160 mg dose
3225167|NCT01019824|Experimental|High Dose|320 mg dose
3225168|NCT01019824|Placebo Comparator|Placebo|Placebo Comparator
3225169|NCT01019798|Experimental|open label|
3225170|NCT01019785|Active Comparator|High dose Vitamin D|
3225171|NCT01019785|Sham Comparator|Low dose Vitamin D|
3225172|NCT01019772|Experimental|LBVH0101|
3225173|NCT01019772|Active Comparator|Hiberix|
3225174|NCT01019759|No Intervention|No add-on AF-surgery|patient undergoing only scheduled valve and/or coronary bypass surgery
3225175|NCT01019759|Experimental|PV isolation|patient undergoing add-on epicardial microwave energy pulmonary vein isolation
3225176|NCT01019746|Experimental|control propofol administration|
3225177|NCT01019733|Experimental|Patients|Children whom will receive intrathecal autologous stem cells
3225178|NCT01019707|Placebo Comparator|Sugar pill|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
3225179|NCT01019707|Active Comparator|Atomoxetine|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
3225180|NCT01019694|Experimental|Combivent Respimat 20/100 microgram(mcg)|patient to take 1 inhalation 4 times a day
3225181|NCT01019694|Active Comparator|Combivent CFC-MDI 36/206 microgram-mcg|patient to take 2 inhalations 4 times a day
3225182|NCT01019694|Active Comparator|Atrovent HFA 42 mcg + Albuterol HFA|patient to take 2 inhalations of each 4 times a day
3225183|NCT01019681|Experimental|UBC injection into one leg of PVD pt|25 participants with severe peripheral vascular disease in leg(s) and they do not qualify for surgical treatment.
3225184|NCT01019668|Active Comparator|verteporfin PDT, half-dose|use different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
3225185|NCT01019668|Active Comparator|verteporfin PDT, half-fluence|use different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
3225186|NCT01019655|Experimental|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
3225187|NCT01019655|No Intervention|Control|No intervention other than usual care at the study site
3225188|NCT01019642|Experimental|Vitamin D|Cholecalciferol, 4,000 IU/d for 6 months
3225189|NCT01019642|Placebo Comparator|Placebo|placebo
3225190|NCT01019616|Experimental|Chemotherapy|
3225191|NCT01019616|No Intervention|Control|
3225192|NCT01019603|Experimental|1|Tazarotene foam 0.1%
3225193|NCT01019603|Active Comparator|2|Tazaroc Gel 0.1%
3225194|NCT01019590|Experimental|1|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
3225195|NCT01019590|Active Comparator|2|Benicar HCT ® Tablets 40 mg/25 mg
3225196|NCT01019577|Experimental|Ixabepilone|
3225197|NCT01019564|Experimental|Easy Rub MPS|Complete Easy Rub Formula MPS
3225198|NCT01019564|Active Comparator|Aquify MPS|
3225199|NCT01019551|Experimental|ARM A : ART intensification alone|Raltegravir PO 400 mg BID Maraviroc PO 150, 300 or 600 mg BID depending on the concomitant ART regimen
3225200|NCT01019551|Experimental|ARM B : ART intensification + Immunomodulation|Raltegravir PO 400 mg BID during 56 weeks Maraviroc PO 150, 300 or 600 mg BID depending on the concomitant ART regimen during 56 weeks 3 weekly injections of r-hIL-7 (CYT107) at a 20 micrograms/kg dose starting at Week 8
3225201|NCT01019525||Mouth Breathing|Children aged between 8-12 years, with clinical diagnosis of mouth breathing
3225202|NCT01019525||Nasal Breathing|Children aged between 8-12 years old, with normal breathing
3225203|NCT01019499|Active Comparator|berry products|Berry products
3225204|NCT01019499|Placebo Comparator|control products|Control products
3225205|NCT01019486|Experimental|Type 1 Diabetic Subjects|Regadenoson 400mcg slow IV bolus to identify assess myocardial blood flow (MBF). Stratified by coronary calcium score of below 100 or greater than score of 100 for low and high risk individuals respectively.
3225206|NCT01019486|Active Comparator|Nondiabetic Subjects|Regadenoson myocardial perfusion imaging (MPI) Intervention: Regadenoson (400mcg slow IV bolus) stress to assess myocardial blood flow (MBF) and MPI to identify occult coronary artery disease (CAD). These individuals serve as an active control with higher risk non-diabetic individuals with scores greater than 100.
3225207|NCT01019473|Experimental|AFQ056A|
3225208|NCT01019473|Placebo Comparator|Placebo|
3225209|NCT01019447|Active Comparator|Study group|The study group in which Triclosan-coated polyglactin 910 antimicrobial sutures will be used.
3225210|NCT01019447|Active Comparator|Control group|The control group in which polyglactin 910 antimicrobial sutures will be used.
3225211|NCT01019434|Other|Temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
3225212|NCT01019434|Experimental|Temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
3225213|NCT01019421|Experimental|Lu AE58054|
3225214|NCT01019421|Placebo Comparator|Placebo|
3225215|NCT01019408|Active Comparator|CQ25|Falciparum positive patients receiving standard 3-day treatment course of CQ 25mg/kg.
3225216|NCT01019408|Active Comparator|CQ40|Falciparum positive patients receiving a 5-day treatment course of CQ 40 mg/kg.
3225217|NCT01019395|Experimental|Group 1|Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion.
3225218|NCT01019395|Experimental|Group 2|Group 2: Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion
3225219|NCT01019395|Experimental|Group 3|Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion.
3225220|NCT01019382|Experimental|All patients|All patients entering the trial
3225221|NCT01019369|Experimental|Self Administration of DMPA|Self administration of subcutaneous depot medroxyprogesterone acetate
3225222|NCT01019369|Active Comparator|Clinic administration of DMPA|Clinic administration (routine care) of DMPA
3225223|NCT01019356|Experimental|Rosiglitazone|Lean and obese PCOS women
3225224|NCT01019356|Active Comparator|Acarbose|Obese PCOS women
3225225|NCT01019356|No Intervention|Control|Obese and lean healthy women evaluated only at baseline
3225226|NCT01019330||Femoral|Subjects receiving femoral artery cardiac catheterization
3225227|NCT01019330||Radial|Subjects receiving radial artery cardiac catheterization
3225228|NCT01019317|Experimental|Cytarabine + Fludarabine|Fludarabine 15 mg/m^2 intravenous (IV) every 12 hours for 5 days; Cytarabine 0.5 grams/m^2 IV over 2 hours every 12 hours for 5 days.
3225229|NCT01019291|Experimental|NO2|NO2 400 µg/m3
3225230|NCT01019291|Experimental|Formaldehyde|Formaldehyde 100 µg/m3
3225231|NCT01019291|Experimental|NO2 + Formaldehyde|mixture of Formaldehyde and NO2
3225232|NCT01019291|Placebo Comparator|Placebo|
3225233|NCT01019265|Experimental|Norspan patch (Buprenorphine TDS)|
3225234|NCT01019265|Active Comparator|TramadolSR tab (Tridol SR tab)|
3225235|NCT01019252|Experimental|CBT for ADHD first, then follow-up|Participants received Cognitive Behavioral Therapy following randomization.
3225236|NCT01019252|No Intervention|Wait list first, then CBT for ADHD|Cross-over: Participants were assigned to a wait list after the initial assessment. They received Cognitive Behavioral Therapy after the 4 month assessment.
3225237|NCT01019239|Experimental|Laparoscopic Washout|Two 5mm ports will be placed in the suprapubic and right lower quadrants to facilitate triangulation of instruments during manipulation and lavage. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. Peritoneal lavage will be performed in all four quadrants using at least 4 litres of warmed saline until the drainage is clear. Two non-suction Penrose drains will be placed. Intravenous antibiotics will be continued for a minimum of 72hours and oral antibiotics will be continued for one week. Oral fluids will be commenced on the first postoperative day and diet will be introduced subsequently, depending on clinical status. Early mobilisation will be encouraged.
3225238|NCT01019239|Active Comparator|Conventional Treatment|Operative procedure will be similar to that previously described.Patients randomised to the second arm will undergo standard management (according to local preference) which will consist of Hartmanns Procedure or Primary resection of the diseased segment and anastomosis. Post operative care will be standardised between arms as described in the protocol
3225239|NCT01019226||cardiac MRI|Ischemic cardiomyopathy, non ischemic cardiomyopathy, myocarditis, cardiomyopathy
3225240|NCT01019213|Placebo Comparator|Septal pacing|Septal lead will be activated.
3225241|NCT01019213|Experimental|His-pacing|His lead will be activated 80 ms before septal lead
3225270|NCT01018992|Experimental|GSK561679|Adult women with DSM-IV-defined PTSD will receive GSK561679 at a fixed dose of 350 mg/day for 6-weeks
3225728|NCT01015768|Experimental|Test eye|Uses ReNu Multiplus as multipurpose soaking solution
3225242|NCT01019200||Psoriasis|Individuals with a diagnosis of psoriasis as confirmed by the principle investigator will comprise the psoriasis or case group. Participants must meet inclusion and exclusion criteria as defined below. This group will consist of 100 individuals.
3225243|NCT01019200||Control|Individuals without psoriasis, but meeting inclusion and exclusion criteria, will be selected to be within the control group. For each patient with psoriasis within the psoriasis group, an age, sex, and BMI-matched control will be selected. The group will consist of 100 individuals.
3225244|NCT01019174|Active Comparator|oral application|oral application Cyclophosphamide
3225245|NCT01019174|Active Comparator|intravenous application|intravenous application Cyclophosphamide
3225246|NCT01019161|Experimental|AZD1152|100 mg Lyophile 5 mL Diluent
3225247|NCT01019161|Experimental|C14 AZD1152|AZD1152 radiolabelled IV solution. 1.05 mg/ml will be presented as a 15 ml fill in a 20 ml vial.
3225248|NCT01019135|Active Comparator|Women-Only Cardiac Rehabilitation|The women-only CR programs include on-site group exercise training sessions 1-2 days/week. Participants are encouraged to walk at home on alternate days of the week. Education sessions are also given in a group format, wherein participants engage in on-site female-only group exercise sessions, as well as female-only group education sessions.
3225249|NCT01019135|Active Comparator|Co-ed Cardiac Rehabilitation|The traditional hospital-based co-ed CR programs include on-site group exercise training sessions 1-2 days/week. Participants are encouraged to walk at home on alternate days of the week. Education sessions are also given in a group format.
3225250|NCT01019135|Active Comparator|Home-Based Cardiac Rehabilitation|In the monitored home-based programs, patients attend an intake appointment where an exercise test is performed as the basis for exercise prescription. Patients are given written guidelines for aerobic conditioning based on their treadmill test. Patients are cautioned about symptoms, and taught how to check their heart rate during walking sessions. Patients are provided with reading materials regarding CVD, risk factors and lifestyle modification. These are discussed with an allied health professional from the home-based CR program by telephone during weekly scheduled telephone calls.
3225251|NCT01019109||Titanium rod|Titanium rods used as a part of PSF construct
3225252|NCT01019109||CoCr Rod|Cobalt Chrome rods used as a part of PSF construct
3225253|NCT01019083|Placebo Comparator|zinc supplementation-Placebo|Determine if the immunogenicity of oral typhoid can be enhanced in children by introducing zinc supplementation: Our recent studies on the interactions of oral cholera vaccine with breast milk and zinc provide some basis for improving immunogenicity, but additional work is needed to improve many of the oral vaccines. In this study we also plan to evaluate if the immune response to Cholera and Vivotif can be enhanced by supplementation with zinc using methods described earlier. We would like to study children, 2-5 years of age for this purpose.
3225254|NCT01019083|Placebo Comparator|Anti Parasite Drug- Placebo|There is a high burden of enteric parasites in the gut of people living in densely populated areas of less developed countries. The effect of concurrent parasitic infestations on immune responses has not been studied widely, although it is an area of utmost importance for natural protection as well as vaccine immuno-prophylaxis. In this study we plan to determine the impact of pretreatment with antiparasitic agents (albendazole and secnidazole) on the immunogenicity of the oral cholera and typhoid vaccines in children, 2-5 years of age
3225255|NCT01019083|Experimental|Effect of Arsenic in Dukoral- Control|In this study, we aim to evaluate if immunogenicity of the oral cholera vaccine is modified in children living in a high arsenic contaminated area in Bangladesh. The plan is to study children 2-5 year old living in Shahrasti thana near Matlab where the tubewell water is highly contaminated with arsenic and this study will not be randomized double-blind, and compare their responses with responses of age matched children living in arsenic free area, such as in Mirpur area of Dhaka city. We only plan to study the effect of Dukoral vaccinees since this vaccine has been widely studied in Bangladesh. If an impact of arsenic is seen on immune response to this vaccine, future studies could be done with other vaccines including Vivotif.
3225256|NCT01019083|Experimental|zinc supplementation|Determine if the immunogenicity of oral typhoid can be enhanced in children by introducing zinc supplementation: Our recent studies on the interactions of oral cholera vaccine with breast milk and zinc provide some basis for improving immunogenicity, but additional work is needed to improve many of the oral vaccines. In this study we also plan to evaluate if the immune response to Cholera and Vivotif can be enhanced by supplementation with zinc using methods described earlier. We would like to study children, 2-5 years of age for this purpose.
3225257|NCT01019083|Experimental|administration of antiparasitic drugs|There is a high burden of enteric parasites in the gut of people living in densely populated areas of less developed countries. The effect of concurrent parasitic infestations on immune responses has not been studied widely, although it is an area of utmost importance for natural protection as well as vaccine immuno-prophylaxis. In this study we plan to determine the impact of pretreatment with antiparasitic agents (albendazole and secnidazole) on the immunogenicity of the oral cholera and typhoid vaccines in children, 2-5 years of age
3225258|NCT01019083|Experimental|Effect of arsenic on Dukoral response|In this study, we aim to evaluate if immunogenicity of the oral cholera vaccine is modified in children living in a high arsenic contaminated area in Bangladesh. The plan is to study children 2-5 year old living in Shahrasti thana near Matlab where the tubewell water is highly contaminated with arsenic and this study will not be randomized double-blind, and compare their responses with responses of age matched children living in arsenic free area, such as in Mirpur area of Dhaka city. We only plan to study the effect of Dukoral vaccinees since this vaccine has been widely studied in Bangladesh. If an impact of arsenic is seen on immune response to this vaccine, future studies could be done with other vaccines including Vivotif.
3225259|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh A|
3225260|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh B|
3225261|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh C|
3225262|NCT01019070|Active Comparator|BMS-650032 in Healthy Subjects|
3225263|NCT01019044||Rectal mucosa biopsy|Rectal mucosa samples collection
3225264|NCT01019018|Active Comparator|Stevens cannula|Subtenon with stevens cannula
3225265|NCT01019018|Experimental|Olive tip|Olive tip group
3225266|NCT01019005|Experimental|Tibial|
3225267|NCT01019005|Experimental|Wound|
3225268|NCT01019005|No Intervention|Sham|
3225269|NCT01018992|Placebo Comparator|Placebo|Adult women with DSM-IV defined PTSD will receive matching placebo for 6 weeks
3225271|NCT01018979|Experimental|TG-0054 (2.24 mg/kg)|TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
3225272|NCT01018979|Experimental|TG-0054 (3.14 mg/kg)|TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
3225273|NCT01018966|Experimental|Ixabepilone|
3225274|NCT01018953|Experimental|BIM 23A760|This dose adaptive study is planned to treat up to 20 patients in each starting dose cohort, with a maximum of three starting dose cohorts. The doses planned to be assessed are 1, 2, 4, 6 and 8 mg, however, the maximum starting dose will be 4 mg. The starting dose of the first cohort will be 1 mg; the first cohort will include at least five patients. After the first fifteen patients have been treated for 4 weeks, the results will be reviewed by a Data Review Committee. An extension phase (Part B) is planned for those subjects completing the initial study and fulfilling specific eligibility criteria (symptoms control, willingness to participate, safety and tolerability).
3225275|NCT01018940||Plavix|
3225276|NCT01018940||Prasugrel|
3225277|NCT01018927||Additional MRI images|Prospective review of 100 CMR studies performed on multiple myeloma patients referred for cardiac evaluation by MRI. Three additional MRI images will be performed to determine the role of cardiac MR (CMR) in detecting features of early myocardial infiltration
3225278|NCT01018914|Active Comparator|Prograf with Myfortic|
3225279|NCT01018914|Experimental|Advagraf with Myfortic|
3225280|NCT01018888|Experimental|Keratoprosthesis|
3225281|NCT01018862|Active Comparator|MP03-36 (0.15% solution)|822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
3225282|NCT01018862|Active Comparator|MP03-33 (0.10% solution)|548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
3225283|NCT01018862|Placebo Comparator|Placebo|0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
3225284|NCT01018849|Active Comparator|Vitamin D (cholecalciferol)|Subjects receive 150,000 IU of Vitamin D3 every 2 months
3225285|NCT01018849|Placebo Comparator|Placebo|Subject will receive a placebo - an exact replica of the Vitamin D3 capsule that does not contain the active ingredient, Vitamin D3
3225286|NCT01018836|Experimental|Riluzole; Radiation Therapy|
3225287|NCT01018823|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, oral, once daily for 14 days
3225288|NCT01018823|Experimental|Ertugliflozin up to 5 mg|Ertugliflozin up to 5 mg, oral, once daily for 14 days
3225289|NCT01018823|Experimental|Ertugliflozin up to 25 mg|Ertugliflozin up to 25 mg, oral, once daily for 14 days
3225290|NCT01018823|Experimental|Ertugliflozin up to 100 mg|Ertugliflozin up to 100 mg, once daily for 14 days
3225291|NCT01018823|Placebo Comparator|Placebo|Placebo to Ertugliflozin once daily for 14 days
3225292|NCT01018810|Experimental|180 mg LY2525623|
3225293|NCT01018810|Placebo Comparator|Intravenous Placebo|
3225294|NCT01018810|Placebo Comparator|Subcutaneous Placebo|
3225295|NCT01018810|Experimental|3 mg LY2525623|
3225296|NCT01018810|Experimental|10 mg LY2525623|
3225297|NCT01018810|Experimental|30 mg LY2525623|
3225298|NCT01018810|Experimental|90 mg LY2525623|
3225299|NCT01018797|Experimental|INTRASTROMAL CORNEAL RING SEGMENT|Eighteen eyes of 18 patients, 8 men and 10 women, with high levels (> 5 diopters [D]) of postkeratoplasty astigmatism were studied in a nonrandomized, retrospective, observational case series. PK was performed to treat keratoconus in 15 patients, corneal scar after trauma in 2 patients, and Fuchs endothelial dystrophy in 1 patient.
3225300|NCT01018784|Experimental|MORAb-009|
3225301|NCT01018771|Experimental|Actifuse ABX|Actifuse ABX bone substitute
3225302|NCT01018771|Active Comparator|INFUSE, plus Mastergraft granules|
3225303|NCT01018758|Experimental|palonosetron|
3225304|NCT01018745|Experimental|BMS-907351 (XL184)|
3225305|NCT01018732|Experimental|I: MenACWY-CRM vaccine|Subjects had been given one dose of Meningococcal ACWY (MenACWY) vaccine conjugated to CRM197 (cross-reactive material-mutant of diptheria toxin) 5 years ago. All subjects were given one dose of the Men ACWY in the present study.
3225306|NCT01018732|Experimental|II: Licensed Polysaccharide Meningococcal vaccine|Subjects had been given one dose of a licensed MenACWY polysaccharide meningococcal vaccine (Menomune) 5 years ago. All subjects were given one dose of Men ACWY vaccine in the present study.
3225307|NCT01018732|Experimental|III: Meningococcal Naive|Subjects were age matched with groups 1 and 2 (age inclusive: 16 years to 23 years) and enrolled at visit 1 and given one dose of Men ACWY vaccine during the present study.
3225308|NCT01018719||Left side breast cancer|
3225309|NCT01018719||Right side breast cancer|
3225310|NCT01018706||STEMI patients treated with PCI|Four hundred patients with STEMI treated with primary PCI or rescue PCI.
3225311|NCT01018693|Experimental|VAK694 AND Immunotherapy (alutard)|
3225312|NCT01018693|Experimental|: VAK694 placebo AND Immunotherapy (alutard)|
3225313|NCT01018693|Experimental|VAK694 placebo AND Immunotherapy (alutard) placebo|
3225314|NCT01018680|Placebo Comparator|Placebo|
3225315|NCT01018680|Experimental|Duloxetine|
3225316|NCT01018667||CRT group|
3225317|NCT01018667||OPT group|
3225318|NCT01018654|Experimental|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
3225319|NCT01018654|Active Comparator|Standard Cognitive-Behavioral Treatment|Standard Cognitive-Behavioral Treatment for Substance Abuse
3225320|NCT01020708|Active Comparator|Comparator|Mesalamine enema
3225321|NCT01020708|Experimental|ALTH12-1:4|ALTH12-1:4 experimental treatment dose
3225322|NCT01020708|Experimental|ALTH12-2:4|ALTH12-2:4 experimental treatment dose
3225323|NCT01020487|Experimental|Part 1: Paricalcitol|Participants received a single 3 µg dose of paricalcitol capsules on Study Day 1.
3225324|NCT01020487|Placebo Comparator|Part 2: Placebo|Participants received placebo capsules three times a week (TIW) for 12 weeks during the double-blind treatment phase. From Weeks 12 to 24 participants received open-label paricalcitol at an initial dose of 1 µg three times a week. Doses could be increased in 1 μg increments every 4 weeks based on chemistry evaluations to target Kidney Disease Outcomes Quality Initiatives (KDOQI) target levels.
3225440|NCT01018030|Placebo Comparator|Placebo Nasal Spray|
3225772|NCT01015456|Experimental|1|Oral mycophenolate sodium 1440 mg per day for 12 months
3225325|NCT01020487|Experimental|Part 2: Paricalcitol|Participants received paricalcitol three times a week for 12 weeks during the double-blind treatment period and during the open-label period (Weeks 12-24). The initial dose of paricalcitol was 1 µg TIW. Doses could be increased in 1 μg increments every 4 weeks based on chemistry evaluations to target KDOQI target levels.
3225326|NCT01020383|Experimental|ALX-0081|
3225327|NCT01020383|Active Comparator|GPIIb/IIIa inhibitor|
3225328|NCT01020097|Other|Arm I|Patients undergo fluorine F-18 EF5 positron emission tomography imaging. Scana are performed 180 minutes following injection.
3225329|NCT01019512|Active Comparator|Arm I|Patients undergo complex decongestive therapy comprising daily compression garment (sleeve and glove) use, daily manual lymphatic drainage (self-administerd), and nighttime bandaging with low stretch Comprilan bandages.
3225330|NCT01019512|Experimental|Arm II|Patients undergo daily compression with garments (sleeve and glove), nighttime bandaging with low stretch Comprilan bandages, and daily Flexitouch treatment over 1 hour every evening.
3225331|NCT01019512|Experimental|Arm III|Patients undergo daily compression with garments (sleeve and glove) and daily Flexitouch treatment over 1 hour every evening.
3225332|NCT01019278|Experimental|Arm I|Patients undergo external proton beam radiotherapy once daily, 5 times per week, for up to 9 weeks. Patients also receive cisplatin IV once weekly for 6 weeks during radiotherapy.
3225333|NCT01019187|Placebo Comparator|Arm I|Patients receive oral placebo twice daily for 47 days.
3225334|NCT01019187|Experimental|Arm II|Patients receive oral armodafinil twice daily for 47 days.
3225335|NCT01019187|Experimental|Arm III|Patients receive oral placebo twice daily for 47 days. Patients undergo cognitive behavioral therapy for insomnia comprising sleep restriction therapy, stimulus control instruction, sleep hygiene guidelines, and a session of cognitive therapy for 7 weeks.
3225336|NCT01019187|Experimental|Arm IV|Patients receive oral armodafinil twice daily for 47 days. Patients undergo cognitive behavioral therapy for insomnia as in Arm III for 7 weeks.
3225337|NCT01019122||Dexa Scan|Eligible patients from 2003 study will receive a follow-up Dexa scan.
3225338|NCT01018901|Experimental|Arm I|Patients and their partners complete surveys. Sexual function of men is assessed by the International Index of Erectile Function; sexual function of women is assessed by the Female Sexual Function Index.
3225339|NCT01018875|Experimental|Arm 1, Dose 1, ABT-288|Low Dose
3225340|NCT01018875|Experimental|Arm 2, Dose 2, ABT-288|High dose
3225341|NCT01018875|Active Comparator|donepezil|
3225342|NCT01018875|Placebo Comparator|sugar pill|
3225343|NCT01018641|Experimental|1|SA3Ag in both stage 1 and stage 2
3225344|NCT01018641|Experimental|2|SA3Ag in stage 1 followed by placebo in stage 2.
3225345|NCT01018641|Placebo Comparator|3|Placebo in both stage 1 and stage 2
3225346|NCT01018641|Experimental|4|SA3Ag in stage 1 and no vaccine in stage 2.
3225347|NCT01018641|Placebo Comparator|5|Placebo in stage 1 and no vaccine in stage 2.
3225348|NCT01018628|Active Comparator|Cohort 1 - Dose Level A (25 mg/day)|Cohort 1 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 25 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 25 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
3225349|NCT01018628|Active Comparator|Cohort 2 - Dose Level B (75 mg/day)|Cohort 2 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 75 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 75 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
3225350|NCT01018628|Active Comparator|Cohort 3 - Dose Level C (250 mg/day)|Cohort 3 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 250 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 250 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
3225351|NCT01018628|Active Comparator|Cohort 4 - Dose Level D (500 mg/day)|Cohort 4 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 500 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 500 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
3225352|NCT01018628|Active Comparator|Cohort 5 - Dose Level E (1000 mg/day)|Cohort 5 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 1000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 1000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
3225537|NCT01017211|Experimental|auricular acupuncture protocol|
3225353|NCT01018628|Active Comparator|Cohort 6 - Dose Level F (2000 mg/day)|Cohort 6 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 2000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 2000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
3225354|NCT01018628|Active Comparator|Cohort 7 - Dose Level G (3000 mg/day)|Cohort 7 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 3000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 3000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
3225355|NCT01018628|Active Comparator|Cohort 8 - Dose Level H (500 mg/day in fed state)|Cohort 8 will be administered at approximately the same time every dosing day and 30 minutes following the start of consumption of a standardized high-fat meal. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The dose of SRT2379 administered to subjects in the fed state is planned to be 500 mg, however this may be modified upwards or downwards following evaluation of safety and pharmacokinetic data from earlier cohorts. The fed cohort will be the final cohort dosed in the study.
3225356|NCT01018615|Experimental|low dose silymarin and low dose EGCG|
3225357|NCT01018615|Experimental|high dose silymarin and low dose EGCG|
3225358|NCT01018602|Active Comparator|vildagliptin|
3225359|NCT01018602|Placebo Comparator|inactive pill without active agent|participants receive an inactive pill without active agent, but undergo the same examinations, visits and tests as the group treated with vildagliptin.
3225360|NCT01018589|Experimental|A|Cicatrix cream
3225361|NCT01018576|Experimental|Delayed cord clamping|
3225362|NCT01018563|Experimental|MORAb-003|Maintenance infusions of MORAb-003 every 3 weeks
3225363|NCT01018550|Experimental|AMG 853|
3225364|NCT01018550|Placebo Comparator|Placebo|
3225365|NCT01018524|Active Comparator|small hernias - suture repair|
3225366|NCT01018524|Active Comparator|small hernias - mesh repair|
3225367|NCT01018524|Active Comparator|large hernias - sublay mesh|
3225368|NCT01018524|Active Comparator|large hernias - onlay mesh|
3225369|NCT01018511|Placebo Comparator|Placebo|Participants received 3 tablets once a day for 12 weeks. Placebo tamsulosin hydrochloride oral controlled absorption system (OCAS) 0.4 mg tablet; Placebo fixed dose combination (FDC) tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
3225370|NCT01018511|Active Comparator|TOCAS 0.4 mg|Participants received 3 tablets once a day for 12 weeks. Tamsulosin hydrochloride OCAS (TOCAS) 0.4 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
3225371|NCT01018511|Experimental|FDC 0.4 mg/6 mg|Participants received 3 tablets once a day for 12 weeks. Placebo TOCAS 0.4 mg tablet; FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
3225372|NCT01018511|Experimental|FDC 0.4 mg/9 mg|Participants received 3 tablets once a day for 12 weeks. Placebo TOCAS 0.4 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
3225373|NCT01018498|Experimental|Restricted FODMAPs diet|Restricted fermentable substrate diet for 1 week
3225374|NCT01018485|Experimental|Botulinum Toxin First Dose|Blinded and Randomized injection of 20 upper limbs with Botulinum Toxin Type A
3225375|NCT01018485|Experimental|Botulinum Toxin Second Dose|20 patients will receive Placebo as first dose and Botulinum Toxin as second dose injection 3 months after initiation of the study
3225376|NCT01018472|Experimental|Bifidobacterium infantis|
3225377|NCT01018472|Placebo Comparator|Placebo|
3225378|NCT01018459|Experimental|Group D: 10^11 vp/mL or placebo|10 subjects will receive 10^11 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
3225379|NCT01018459|Experimental|Group A: 10^9 vp/mL or placebo|10 subjects will receive 10^9 viral particles (vp)/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
3225380|NCT01018459|Experimental|Group B: 10^10 vp/mL or placebo|10 subjects will receive 10^10 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
3225381|NCT01018459|Experimental|Group C: 5 x 10^10 vp/mL or placebo|10 subjects will receive 5 x 10^10 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
3225382|NCT01018446|Experimental|Busulfan, Pharmacokinetic|To develop a method to determine optimal dose of busulfan through pharmacokinetic study in hematopoietic stem cell transplantation.
3225383|NCT01018433|Experimental|T-SIB|Treatment for self-injurious behaviors; study intervention
3225384|NCT01018433|Other|Treatment as Usual|
3225385|NCT01018420|Experimental|Colchicine|
3225386|NCT01018420|Active Comparator|Moxifloxacin|
3225387|NCT01018407|Experimental|Discrete Trial Training|Targets nonverbal imitation, match-to-sample, verbal imitation, imitation of play activities, receptive language, and expressive language. 5 hours per week of individual instruction for 4 months (Two 30-minute sessions per day, five days per week) with reductions in classroom pull out sessions in months 5 and 6 with implementation of 1 hour per week of in-home parent training for the last 2 months.
3225538|NCT01017211|Sham Comparator|sham auricular acupuncture|
3225388|NCT01018407|Experimental|Interpersonal Developmental Approach|Targets Joint Attention and Symbolic Play. 5 hours per week of individual instruction for 4 months (Two 30-minute sessions per day, five days per week) with reductions in classroom pull out sessions in months 5 and 6 with implementation of 1 hour per week of in-home parent training for the last 2 months.
3225389|NCT01018394|Active Comparator|nicotine lozenges|40 subjects will be assigned to receive nicotine lozenges for 8 weeks. They will use the nicotine lozenges ad lib, up to 8 lozenges per day.
3225390|NCT01018394|Active Comparator|tobacco free snuff|41 subjects will receive tobacco free snuff for 8 -12 weeks. The tobacco-free snuff will be used ad lib - as needed.
3225391|NCT01018381|Active Comparator|Conventional Therapy|Conventional therapy is given, including PEIT, TOCE, PEIT + TOCE, TOCE + RFA for hepatocellular carcinoma or Entecavir for hepatitis B virus.
3225392|NCT01018381|Experimental|Conventional Therapy plus MGN-3|
3225393|NCT01018368|Experimental|VX-770|
3225394|NCT01018368|Experimental|Rifampin|
3225395|NCT01018355|Experimental|Device closure of PFO|Device closure of PFO followed by 6 month treatment with clopidogrel 75 mg and 75 - 150 mg of aspirin daily followed by a life long treatment with dipyridamol 200 mg twice daily plus 75-150 mg aspirin daily
3225396|NCT01018355|Active Comparator|Medical anticoagulative treatment|Life long treatment with dipyridamol 200 mg twice daily plus 75-150 mg aspirin daily
3225397|NCT01018342|Experimental|1|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
3225398|NCT01018342|Active Comparator|2|Macrobid® Capsules 100 mg
3225399|NCT01018329|Experimental|I|Patients undergo multimodality MRI imaging at baseline, weeks 1, 2, 3, 5, and 6 and then 4-6 weeks after completion of radiation therapy.Patients undergo MRI imaging at baseline, weeks 1, 2, 3, 5, 6 and then 6 weeks after radiation therapy.
3225400|NCT01018303|Experimental|Antioxidant-enriched multivitamin supplement|
3225401|NCT01018290||Navigated TMS examination|20 patients with brain tumor in the vicinity of the central motor region scheduled for elective surgery will undergo pre-operative Navigated TMS examination to determine the localization of primary motor cortex and motor representation areas of specific muscles
3225402|NCT01018264|Experimental|solifenacin succinate (VESIcare)|
3225403|NCT01018264|Placebo Comparator|placebo|
3225404|NCT01018251|Experimental|Arm I|Patients undergoing definitive surgery after cancer diagnosis undergo 3'-deoxy-3'-[18F] fluorothymidine (FLT)-PET prior to definitive surgery. Patients undergoing neoadjuvant chemotherapy prior to definitive surgery undergo FLT-PET prior to and after completion of neoadjuvant chemotherapy
3225405|NCT01018238|Placebo Comparator|Placebo arm|
3225406|NCT01018238|Experimental|Cohort 1|
3225407|NCT01018238|Experimental|Cohort 2|
3225408|NCT01018238|Experimental|Cohort 3|
3225409|NCT01018238|Experimental|Cohort 4|
3225410|NCT01018225|Experimental|darifenacin|
3225411|NCT01018225|Placebo Comparator|Sugar Pill|
3225412|NCT01018212|Experimental|A|Cicatrix cream
3225413|NCT01018199|Experimental|Group 1- C-reactive protein (CRP) guided antibiotic therapy|Intervention on antibiotic therapy will be based on circulating RCP levels
3225414|NCT01018199|Active Comparator|Group 2 - procalcitonin (PCT) guided antibiotic therapy|Intervention on antibiotic therapy will be based on circulating PCT levels
3225415|NCT01018186|Experimental|Fluticasone furoate/GW642444|
3225416|NCT01018186|Active Comparator|Fluticasone propionate|
3225417|NCT01018173|Placebo Comparator|placebo|
3225418|NCT01018173|Experimental|taspoglutide|
3225419|NCT01018160||001|
3225420|NCT01018147|Experimental|CT Imaging|Patients undergo 4-D, 4-dimensional computed tomography, CT imaging prior to radiotherapy sessions and once a week at the end of treatment.
3225421|NCT01018134|Experimental|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered once daily to affected area
3225422|NCT01018134|Experimental|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered twice daily to affected area
3225423|NCT01018134|Experimental|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered once daily to affected area
3225424|NCT01018134|Experimental|Desoximetasone 0.25% twice daily|Desoximetasone topical spray 0.25% administered twice daily to affected area
3225425|NCT01018134|Placebo Comparator|Vehicle once daily|Vehicle administered to affected areas once daily
3225426|NCT01018134|Placebo Comparator|Vehicle twice daily|Vehicle administered to affected areas twice daily
3225427|NCT01018121|Experimental|Clinic and Home Behavioral Intervention|
3225428|NCT01018121|Active Comparator|Pediatrician Counseling|
3225429|NCT01018108|Other|I|Patients undergo acupuncture twice weekly for 2 weeks and then once weekly for 6 weeks. Patients undergo single photon emission computed tomography imaging with iodine 123-I ADAM before and after completion of acupuncture.
3225430|NCT01018095|Active Comparator|Single dose|Metronidazole 2 gm single dose
3225431|NCT01018095|Active Comparator|7 day dose|Metronidazole 500 mg dose x 7 days
3225432|NCT01018069|Active Comparator|AEG35156|Patient receive AEG35156 prior to chemotherapy
3225433|NCT01018069|Sham Comparator|Control|Patients receive chemotherapy only
3225434|NCT01018056|Experimental|D-serine (glutamate agonist)|24 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive D-serine for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
3225435|NCT01018056|Experimental|Riluzole (glutamate antagonist)|24 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive riluzole for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
3225436|NCT01018056|Placebo Comparator|Placebo|12 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive placebo for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
3225437|NCT01018043||001|Adult Cancer Patients Tracking anemia management in Adult Cancer Patients
3225438|NCT01018030|Experimental|FFNS 110 mcg QD|
3225439|NCT01018030|Experimental|FFNS 110 mcg BID|
3225441|NCT01018017|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered eight SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following consumption of a standard morning meal at home (200 cc of Ensure Plus®).
3225442|NCT01018017|Placebo Comparator|Placebo|The placebo treatment group will be administered eight placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following consumption of a standard morning meal at home (200 cc of Ensure Plus®).
3225443|NCT01017991|Experimental|Infant formula with probiotic|Infant formula with probiotic for 0 to 12 months of age
3225444|NCT01017991|Placebo Comparator|Standard infant formula|Infant formula for 0 to 12 months of age
3225445|NCT01017978|Other|MRI Scan|MRI scan of soft tissue tumor
3225446|NCT01017952|Experimental|FF/GW642444 Inhalation Powder 100/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3225447|NCT01017952|Experimental|FF/GW642444 Inhalation Powder 50mcg/25mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3225448|NCT01017952|Experimental|FF/GW642444 Inhalation Powder 200/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3225449|NCT01017952|Experimental|GW642444 25mcg QD|Long Acting Beta Agonist(LABA)
3225450|NCT01017939|Experimental|Group A: abiraterone + prednisone + dextromethorphan|Group A will assess the effect of multiple doses of abiraterone acetate plus prednisone on CYP2D6 using 2 single doses of dextromethorphan hydrobromide as a probe drug.
3225451|NCT01017939|Experimental|Group B: abiraterone + prednisone + theophylline|Group B will assess the effect of multiple doses of abiraterone acetate plus prednisone on CYP1A2 using 2 single doses of theophylline as a probe drug.
3225452|NCT01017926|Active Comparator|Triazolam Reference Arm|There will be a clearance period of at least 3 days between the two phases of the study.
3225453|NCT01017926|Experimental|Triazolam Trial Arm|
3225454|NCT01017913|Active Comparator|Electrotherapy equipment|The TENS equipment was calibrated on 20 hertz frequency, and a pulse width of 330 ms with two channels.
3225455|NCT01017913|Active Comparator|electrotherapy equipment|The CI was adjusted with 4000 HZ bases frequency, modulation frequency range 20 HZ, ∆F10 HZ, slope 1/1 and quadripolar manner.
3225456|NCT01017913|No Intervention|Control|The patients of the Control group stayed without any treatment in the same period
3225457|NCT01017887||Airseal port for laparoscopic surgery|Airseal access port for laparoscopic surgery with standard ports.
3225458|NCT01017887||Standard Laparoscopy ports|Uses standard laparoscopy ports.
3225459|NCT01017874|Experimental|Pemetrexed + Cisplatin + Gefitinib|
3225460|NCT01017874|Active Comparator|Gefitinib|
3225461|NCT01017861||Pregnant, 12th week|Pregnant women in the 12th week of pregnancy.
3225462|NCT01017861||Pregnant, 28th week|Pregnant women in the 28th week of pregnancy.
3225463|NCT01017861||Pregnant, full term|Pregnant women at full term, in hospital for an elective cesarean section.
3225464|NCT01017861||Non pregnant women|Non pregnant women
3225465|NCT01017848||Adults, nondiabetics|adults who are nondiabetic, no CKD, no urinary tract infection, no bladder dysfunction
3225466|NCT01017835||statin treatment, isolated hypertension|treatment with statins, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking
3225467|NCT01017835||placebo treatment, isolated hypertension|treatment with placebo, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking
3225468|NCT01017809|Other|Oxali/Topotecan|Patients enrolled to NYU 03-67 will be receiving Oxaliplatin 85 mg/m2 IV over 120 minutes on Day 1 and 15 Topotecan 0.4mg/m2/day CIV from D1 to 15 (in addition to the assigned intervention)
3225469|NCT01017796|Experimental|A. Experimental|1200mg acetylcysteine and 2g ascorbic acid at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
3225470|NCT01017796|Placebo Comparator|B. Control|200ml 0,9% normal saline IV
3225471|NCT01017783|Other|Healthy Choices|
3225472|NCT01017783|Experimental|Diet Substitution A|
3225473|NCT01017783|Experimental|Diet Substitution B|
3225474|NCT01017770|Experimental|Artemether -lumefantrine|Experimental Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso
3225475|NCT01017770|Experimental|Artesunate-amodiaquine|Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso
3225476|NCT01017757||Renal transplant patients|
3225477|NCT01017731|Experimental|IMC-1121B|"Active-control participants (first 16 participants) will receive one dose of moxifloxacin orally 7 days before the first treatment with ramucirumab. All participants will undergo triplicate electrocardiogram (ECG) tests (consisting of three individual ECGs performed consecutively within a period of 4 minutes) and vital signs at various times over the trial period.~For Cycle 1, all participants will also receive 2 infusions of diphenhydramine before ramucirumab therapy (the first infusion is 1 day before therapy and the second infusion is 15 minutes before therapy). For Cycles 2, 3, and 4, all participants will receive diphenhydramine 15 minutes before ramucirumab therapy. For Cycle 5 and beyond, diphenhydramine infusions before ramucirumab therapy are at the investigator's discretion. Ramucirumab [10 milligrams per kilogram (mg/kg)] intravenously over 60 minutes, once every 3 weeks for minimum of 9 weeks without a break in between."
3225478|NCT01017692||Lumbar Spinal Stenosis|Subjects who have undergone or will undergo an MRI, with symptoms of LSS
3225479|NCT01017679|Experimental|1|Oral Drug gefitinib(Iressa) 500 mg Everyday
3225480|NCT01017679|Active Comparator|2|Oral Drug gefitinib(Iressa) 250 mg Everyday
3225481|NCT01017666|Experimental|Rosiglitazone 8mg PO|Cohort 1
3225482|NCT01017666|Experimental|Midazolam 2mg PO, Warfarin 25mg PO|Cohort 2
3225483|NCT01017653|Experimental|Panitumumab and irinotecan|
3225484|NCT01017640|Experimental|Arm I (veliparib)|Patients receive veliparib PO BID in the absence of disease progression or unacceptable toxicity.
3225539|NCT01017198|Experimental|BIIB021 and Food|The food phase will assess the effect of a high fat meal on the pharmacokinetics of BIIB021.
3225485|NCT01017640|Experimental|Arm II (veliparib and mitomycin C)|Patients receive veliparib PO BID on days 1-7, 1-14, or 1-21. Patients also receive mitomycin C IV over 10-20 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3225486|NCT01017627|Other|Early anemia management|Upon return to the dialysis unit following hospitalization, patients will be immediately identified and have immediate implementation of the unit anemia protocol rather than waiting for the next regularly scheduled unit labs and regular follow-up. Thus, labs will be obtained within the first 3-7 days following hospitalization and appropriate titration of Epo and iron medications within the 7 days after discharge from hospital and under the direction of the pre-specified algorithm used in the patient's facility; all drug dosing will comply with package insert instructions
3225487|NCT01017627|Other|case control|"Each case will be data-matched to an intra-facility (primary control), and then an inter-facility (validation control) control patient. Matching criteria will be by age, gender, diabetic status, attending nephrologist, length of hospitalization stay, and hospital discharge date (to minimize the difference in the date between the case and control). These patients did not have early intervention but followed the usual practice of waiting for the next regularly scheduled dialysis unit labs with anemia management to follow using the regular unit algorithm."
3225488|NCT01017614|Experimental|Monofer|"administered as intravenous infusions (A1)~administered as intravenous bolus injections (A2)"
3225489|NCT01017614|Active Comparator|Iron Sulphate|tablets administered orally
3225490|NCT01017601|Experimental|Arm I|Patients receive a single dose of Seneca Valley virus-001 (NTX-010) IV over 1 hour on day 1.
3225491|NCT01017601|Placebo Comparator|Arm II|Patients receive a single dose of placebo IV over 1 hour on day 1.
3225492|NCT01017588|Experimental|back exercise|strengthening back exercise
3225493|NCT01017575|Experimental|Arm A (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
3225494|NCT01017575|Experimental|Arm B (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
3225495|NCT01017575|Placebo Comparator|Arm C (Placebo, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
3225496|NCT01017575|Experimental|Arm D (Daclatasvir, plus peginterferon alfa-2a, Ribavirin)|Non-Responder
3225497|NCT01017575|Experimental|Arm E (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Non-Responder
3225498|NCT01017562||condition of joint implant|
3225499|NCT01017549|Other|Treatment|This is a single arm study where all patients are treated with FDA cleared electronic brachytherapy treatment.
3225500|NCT01017536|Placebo Comparator|Placebo|Thirteen subjects received placebo vaccine that did not contain any AERAS-402.
3225501|NCT01017536|Experimental|Investigational Vaccine|Thirteen subjects received active vaccine 3 x 10^10 vp AERAS-402.
3225502|NCT01017523|Experimental|1 (Couples)|Diabetes self-management education, telephone support and behavior change for couples.
3225503|NCT01017523|Active Comparator|2 (Individual)|Diabetes self-management education, telephone support and behavior change for individuals.
3225504|NCT01017523|Placebo Comparator|3 (Control)|Diabetes self-management education only.
3225505|NCT01017497|Experimental|1mm margin|GTV expanded by 1 mm
3225506|NCT01017497|Experimental|3mm margin|GTV expanded by 3 mm
3225507|NCT01017484|Experimental|DASH|The Dietary Approaches to Stop Hypertension Dietary pattern.
3225508|NCT01017484|Experimental|Control|The typical American diet as estimated from the NHANES survey.
3225509|NCT01017471|Experimental|control|carpal tunnel release using standard incision
3225510|NCT01017458|Experimental|1|MK0773 + placebo injection
3225511|NCT01017458|Active Comparator|2|placebo to MK0773 + testosterone injection
3225512|NCT01017458|Placebo Comparator|3|placebo to MK0773 + placebo injection
3225513|NCT01017445|Experimental|Quadricep strengthening exercise|Quadricep strengthening exercise
3225514|NCT01017419||Audiology counseling|
3225515|NCT01017406|Experimental|Plantar fascia stretching exercise|Patient perform plantar fascia stretching 3 times per day
3225516|NCT01017393|Experimental|ketamine|epidural ketamine added to the patient controlled epidural analgesia regimen
3225517|NCT01017393|Active Comparator|ketamine free|epidural ketamine NOT added to the patient controlled epidural analgesia regimen
3225518|NCT01017380|Experimental|placebo|identical placebo
3225519|NCT01017367|Experimental|MDX-1100|MDX-1100 10 mg/kg administered i.v. over 60 minutes on days 1, 15, 29, 43, 57, and 71
3225520|NCT01017367|Placebo Comparator|Placebo|Placebo (saline) administered i.v. over 60 minutes on days 1, 15, 29, 43, 57, and 71
3225521|NCT01017354|Experimental|High-dose vitamin D3|monthly high-dose vitamin D3 supplement dose (60'000 IU/month, equivalent to 2000 IU daily)
3225522|NCT01017354|Experimental|standard vitamin D + 25(OH)D|standard vitamin D3 supplement dose combined with 25(OH)D (24'000 IU/month, equivalent to 800 IU daily PLUS 300 mcg 25(OH)D, equivalent to 10 mcg per day)
3225523|NCT01017354|Active Comparator|standard vitamin D|standard vitamin D3 supplement dose (24'000 IU/month, equivalent to 800 IU daily)
3225524|NCT01017341|No Intervention|No hip protector|no hip protector
3225525|NCT01017328||surgery with general anesthesia|
3225526|NCT01017315|Experimental|No application of baby talcum|control
3225527|NCT01017302|Experimental|1|
3225528|NCT01017302|Placebo Comparator|2|
3225529|NCT01017302|Experimental|3|
3225530|NCT01017302|Placebo Comparator|4|
3225531|NCT01017289|Experimental|Quantum|In this single arm study, the Quantum nailing system will be used in all patients.
3225532|NCT01017276|Experimental|ASP group|
3225533|NCT01017263|Active Comparator|Open label Vyvanse|Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
3225534|NCT01017250|Experimental|Stereotactic Radiosurgery|Avastin and Radiosurgery
3225535|NCT01017237|Active Comparator|Dex plus midazolam|Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg i.v.
3225536|NCT01017237|Active Comparator|Dex plus midazolam and ketamine|Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg and 0.25 mg/kg ketamine i.v.
3225540|NCT01017198|Experimental|BIIB021 and Antacid|Antacid phase will assess the effect of an antacid on the pharmacokinetics of BIIB021.
3225541|NCT01017185|Experimental|Oncolytic virotherapy, intratumoral injection of HF10|
3225542|NCT01017159|Active Comparator|Subcutaneous immunoglobulin|
3225543|NCT01017159|Placebo Comparator|Saline|
3225544|NCT01017146|Experimental|1|Tazarotene foam, 0.1%
3225545|NCT01017146|Placebo Comparator|2|Vehicle Foam
3225546|NCT01017133|Other|Arm I|With 6 weeks prior to surgery, patients undergo fluorine F18 (18F)-EF5 PET at 10 minutes and 90 minutes after injection of 18F-EF5. Patients also undergo fludeoxyglucose F18 (18F-FDG) PET at 1 hour and 3 hours after injection of 18F-FDG.
3225547|NCT01017120|Experimental|1|Tazarotene foam, 0.1%
3225548|NCT01017120|Placebo Comparator|2|Vehicle Foam
3225549|NCT01017107|Experimental|Activated protein C|
3225550|NCT01017094|Experimental|dry dressing|local application
3225551|NCT01017081|Active Comparator|Control|Non-mandatory request to maintain lateral positioning to improve air exchange, to cough in order to clear secretion, and to perform diaphragmatic and deep breathing, for five minutes, once a day, during hospital stay.
3225552|NCT01017081|Experimental|Physiotherapy|"Physiotherapy: Children younger than 5 years: Manual Thoracic vibration (TV), thoracic compression (TC), positive expiratory pressure (PEP), and forced exhalation with the glottis open (huffing). Children aged 5 years or older: same procedures in addition to the ventilatory patterns, and a forced expiratory technique (FET), consisting of one or two huffs (forced expirations) followed by a period of relaxed, controlled diaphragmatic breathing, three times per day, for 10 to 12 minutes, during hospital admission."
3225553|NCT01017068|Experimental|A1 (glaucoma)|
3225554|NCT01017068|Experimental|A2 (glaucoma)|
3225555|NCT01017068|Experimental|A3 (glaucoma)|
3225556|NCT01017068|Experimental|A1 (normals)|
3225557|NCT01017068|Experimental|A2 (normals)|
3225558|NCT01017068|Experimental|A3 (normals)|
3225559|NCT01017055||Voice and Swallowing Evaluations|
3225560|NCT01017042|Experimental|colchicine|colchicine 1.2mg by mouth initially then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
3225561|NCT01017029|Active Comparator|Immediate introduction of everolimus|
3225562|NCT01017029|Experimental|Delayed introduction of everolimus|delayed introduction) + Cyclosporin + steroids
3225563|NCT01017003|Experimental|1|0.6mg colchicine tablet
3225564|NCT01017003|Experimental|2|colchicine 0.6mg q12 hours for 10 days
3225565|NCT01016977|Active Comparator|Duac & taz|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
3225566|NCT01016977|Active Comparator|Acanya & taz|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
3225567|NCT01016964|Sham Comparator|Sham Device|Sham device
3225568|NCT01016964|Active Comparator|LLT Device 2009 12 Beams|HairMax LaserComb 2009 model 12 beam
3225569|NCT01016951|Experimental|A|AZD9164
3225570|NCT01016951|Placebo Comparator|B|Placebo
3225571|NCT01016938||Group I|This is a pilot study and there is only one group.
3225572|NCT01016925|No Intervention|Control|
3225573|NCT01016925|Experimental|femoral tunnelized perineural catheter|
3225574|NCT01016912|Experimental|Arm A (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
3225575|NCT01016912|Experimental|Arm B (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
3225576|NCT01016912|Placebo Comparator|Arm C (Placebo, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
3225577|NCT01016912|Experimental|Arm D (BMS-790052, plus peginterferon alfa-2b, Ribavirin)|Non-Responder
3225578|NCT01016912|Experimental|Arm E (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Non-Responder
3225579|NCT01016899||Non-melanoma skin cancer|Early stage squamous or basal cell carcinoma
3225580|NCT01016886|Experimental|1|
3225581|NCT01016873|Experimental|16 Gy IRay|16 Gy IRay + PRN Lucentis®
3225582|NCT01016873|Sham Comparator|Sham 16 Gy IRay|Sham 16 Gy IRay + PRN Lucentis®
3225583|NCT01016873|Experimental|24 Gy IRay|24 Gy IRay + PRN Lucentis®
3225584|NCT01016873|Sham Comparator|Sham 24 Gy IRay|Sham 24 Gy IRay + PRN Lucentis®
3225585|NCT01016860|Experimental|OSI-906 and/or irinotecan|Dose Escalation Phase: Treatment for Cycle 1 will commence on Day -3 of a 21-day cycle (3 weeks) when a single dose OSI-906 is given with full pharmacokinetics(PK) sampling at predetermined time points. Irinotecan will be administered intravenously over 90 minutes on Day 1 and Day 8 with full PK sampling on Day 1. The institution of oral dosing of OSI-906 2-4, 8-10, 15-17 (for cycle 1 only) will be given followed by full PK sampling of both drugs on Day 8. Pre-dose samples of OSI-906 will be drawn on Cycle 1 Days 8, 10, 15, 17 and Cycle 2 Days 1, 8, 10, 15 and 17. For Cycle 2 and thereafter, both drugs will be administered starting on Day 1.
3225586|NCT01016847|Active Comparator|leukotriene receptor antagonist (LTRA) montelukast|Montelukast (LTRA) administered with moderate dose of inhaled steroid
3225587|NCT01016847|Placebo Comparator|Sugar Pill|High dose of inhaled steroid administered with sugar pill
3225588|NCT01016834|Other|Sumavel(R) DosePro(R)|Single arm study (Sumavel DosePro)
3225589|NCT01016821|Other|Oxycodone, labour pain|
3225590|NCT01016808|Experimental|Q8003 12 mg/8 mg|Combination
3225591|NCT01016808|Active Comparator|Morphine sulfate 12 mg|Single component
3225592|NCT01016808|Active Comparator|Oxycodone HCl 8 mg|Single component
3225593|NCT01016795|Active Comparator|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
3225594|NCT01016795|Active Comparator|Cyclophosphamide and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
3225595|NCT01016782|Experimental|Test|Test product that contains active pharmaceutical ingredient
3225596|NCT01016782|Active Comparator|Reference|Reference product that contains active pharmaceutical ingredient
3225597|NCT01016782|Placebo Comparator|Vehicle|Placebo that contains no active pharmaceutical ingredient
3225598|NCT01016769|Experimental|Temsirolimus + Weekly Paclitaxel + Carboplatin|"In Part 1 (Phase I) of the study, the primary endpoint is to establish the phase II recommended dose for the combination of temsirolimus + weekly paclitaxel + carboplatinPart 1 (Phase I) features a standard 3 + 3 phase I dose escalation design. Up to 3 dose levels are planned in the Phase I portion of the study.~In Part 2 (Phase II) of the study, the primary endpoint is to determine the objective response rate (CR or PR) after two cycles (approximately 6 weeks) of treatment with the combination of temsirolimus + weekly paclitaxel + carboplatin as palliative therapy for recurrent or metastatic HNSCC. A two-stage design will be employed."
3225599|NCT01016743|Active Comparator|Active repetitive transcranial Stimulation|Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).
3225600|NCT01016730|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3225601|NCT01016717|Active Comparator|Omeprazole|Patients will be taking omeprazole tablets 40 mg QD for 30 days
3225602|NCT01016717|Active Comparator|Pantoprazole|Patients will be taking Pantoprazole tablets 40 mg QD for 30 days
3225603|NCT01016704|No Intervention|Control|
3225604|NCT01016704|Experimental|Incentive|
3225605|NCT01016691|Experimental|High Dose Drug Device/ bimatoprost 0.03%|drug device containing 65 micrograms of bimatoprost released over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
3225606|NCT01016691|Experimental|Low Dose Drug Device / bimatoprost 0.03%|drug device containing 45 micrograms of bimatoprost released over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
3225607|NCT01016691|Other|Placebo Device / bimatoprost 0.03%|placebo drug device worn over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
3225608|NCT01016678|Other|Active, Active, Active, Placebo|One fifth of the 105 subjects will be randomized to this arm and treat their four migraines in this order. First three will be treated with Active Treximet and the last or 4th migraine will be treated with Placebo.
3225609|NCT01016678|Other|Active, Active, Placebo, Active|This is another of the five treatment arms. One fifth of the 105 subjects will be randomized to this group and will treat the first two migraines with Active drug, Treximet, and then the third migraine with placebo and the last (4th) migraine with Treximet.
3225610|NCT01016678|Other|Active, Placebo, Active, Active|Approximately one fifth of the 105 subjects will be randomized to this group and treat their first migraine with Active Treximet and the second migraines with Placebo. The final two migraines treated will be with Active study drug.
3225611|NCT01016678|Other|Placebo, Active, Active, Active|One fifth of the 105 subjects will be randomized to this treatment arm, where they will treat the first headache with placebo and the remaining three migraines will be treated with Active treximet.
3225612|NCT01016678|Other|Active, Active, Active, Active|One fifth of the subject will treat all their migraines with Active Treximet.
3225613|NCT01016665|Placebo Comparator|Placebo|Placebo
3225614|NCT01016665|Other|Tamoxifen|Tamoxifen 20 mg day 26 days
3225615|NCT01016665|Other|Anastrozole|Anastrozole 1mg 26 days
3225616|NCT01016652|Other|etafilcon A multifocal / etafilcon A sphere|period 1: etafilcon A multifocal worn, period 2: etafilcon A sphere worn.
3225617|NCT01016652|Other|etafilcon A sphere / etafilcon A multifocal|period 1: etafilcon A sphere worn, period 2: etafilcon A multifocal worn.
3225618|NCT01016639|Experimental|Chemoradiotherapy|
3225619|NCT01016626|Experimental|CKD-4101 tablet|
3225620|NCT01016626|Active Comparator|Mycophenolate Mofetil capsule|
3225621|NCT01016613||Chronic Kidney Disease Cohort|chronic kidney disease patients with any type of kidney disease
3225622|NCT01016613||Matched Control Group|Healthy controls
3225623|NCT01016613||Trios|First degree relatives of pediatric chronic kidney disease cohort members
3225624|NCT01016600|Experimental|Cohort 1|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 25 mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
3225625|NCT01016600|Experimental|Cohort 2|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 50 mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
3225626|NCT01016600|Experimental|Cohort 3|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
3225627|NCT01016600|Experimental|Phase II|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 75 mg/m2 (dose determined in Phase I) mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
3225628|NCT01016587||COPD patients|Not hospitalized COPD patients, degree 2-4.
3225629|NCT01016574|Other|women with stage I or II breast cancer|
3225630|NCT01016561|Experimental|Arm I|Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.
3225631|NCT01016548|Experimental|Two doses of vaccine|Second dose is given 21 days after the initial dose. The same dose and route of administration are used.
3225632|NCT01016548|Active Comparator|One dose of vaccine|Given at baseline only.
3225633|NCT01016535||Children, Health Professionals|
3225634|NCT01016522|Experimental|KetoCal|KetoCal tube feeding formula
3225635|NCT01016509|No Intervention|control|No hyperglycemia patient group
3225636|NCT01016509|Active Comparator|Insulin 1|Conventional insulin treatment
3225637|NCT01016509|Experimental|Insulin|Intensive insulin treatment
3225828|NCT01015040|Experimental|solifenacin succinate suspension (fasting)|
3225638|NCT01016496|Experimental|Action observation plus repetition|Observation of actions and repetition of the same actions
3225639|NCT01016496|Active Comparator|repetition only|repetition of gestures
3225640|NCT01016483|Experimental|Safety Run-in Part: Regimen 1|Subjects will receive pimasertib capsule orally once daily (qd) doses of 15, 30, 45, 68, 90, and 120 milligram (mg) on Day 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15,16, 17, 18, 19, 22, 23, 24, 25, 26 and gemcitabine 1000 milligram per square meter (mg/m^2) intravenous (IV) infusion for 30 minutes on Days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (1 Cycle = 8 weeks).
3225641|NCT01016483|Experimental|Safety Run-in Part: Regimen 2|Subjects will receive pimasertib capsule orally twice daily (bid) doses of 60 and 75 mg continuously for a 28-day cycle and gemcitabine 1000 mg/m^2 intravenous (IV) infusion for 30 minutes on Days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (1 Cycle = 8 weeks) (bid - continuous regimen).
3225642|NCT01016483|Active Comparator|Phase II: Arm 1 (Gemcitabine + Placebo)|Subjects will receive gemcitabine 1000 mg/m^2 IV infusion on for 30 minutes on Day 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (Cycle 1) then on Days 1, 8, and 15 of a 28-day cycle and placebo matched to pimasertib orally bid - continuous regimen.
3225643|NCT01016483|Experimental|Phase II: Arm 2 (Gemcitabine + Pimasertib)|Subjects will receive gemcitabine 1000 mg/m^2 IV infusion for 30 minutes on Day 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (Cycle 1) then on Days 1, 8, and 15 of a 28-day cycle and pimasertib capsule orally bid - continuous regimen.
3225644|NCT01016470|Placebo Comparator|B|Placebo
3225645|NCT01016470|Experimental|A|VIUSID/ALZER. The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with early PD by UPDRS motor
3225646|NCT01016444||Albuterol responsive|Those who respond clinically to albuterol.
3225647|NCT01016444||Albuterol unresponsive|Albuterol non-responsiveness is defined as a failure of the PEFR in an acutely ill asthmatic to exceed 40% of predicted following ≥7.5 mg of albuterol (2.5 mg albuterol aerosols q.20 min x3).
3225648|NCT01016431|Experimental|Rate adaptive|Patients will have their ICD programmed in a AAI-R mode, with peak atrial rate set at 85% of age-adjusted predicted maximal HR
3225649|NCT01016431|Active Comparator|Control|ICDs will be programmed in the usual VVI backup pacing mode at 40 bpm
3225650|NCT01016418|Experimental|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
3225651|NCT01016405||Severity of dry eye in patients undergoing cataract surgery|
3225652|NCT01016366|Experimental|Lu AA24493|
3225653|NCT01016366|Placebo Comparator|Placebo|
3225654|NCT01016340|Active Comparator|MCS-5|Group 1: MCS-5 5 mg/day for 16 weeks;Group 2: MCS-5 10 mg/day for 16 weeks;Group 3: MCS-5 20 mg/day for 16 weeks
3225655|NCT01016340|Placebo Comparator|Placebo|Group 4: Placebo for 16 weeks
3225656|NCT01016327|Experimental|1|
3225657|NCT01016314|Experimental|Aspen Spinous Process System|Subjects randomized to the Aspen study arm will have the Aspen device implanted as supplemental posterior fixation only and according to the manufacturer's recommendations.
3225658|NCT01016314|Active Comparator|Pedicle Screw Fixation|Subjects randomized to the pedicle screw group will have the pedicle screws implanted according to the standard procedures and practices at that institution. The procedure may be performed according to surgeon preference, including a traditional open, minimally invasive or percutaneous approach. Only pedicle screws cleared by FDA for this indication will be used in this study.
3225659|NCT01016301|Active Comparator|Pharmacist service,|The pharmacist service consists of medication review, drug treatment discussion with the patient, and a medication report.
3225660|NCT01016301|No Intervention|Control|Usual care
3225661|NCT01016288||22 G Needle EUS-FNA|Patients referred for an EUS examination and EUS-FNA of a solid mass lesion adjacent to the upper GI tract using a 22 G needle
3225662|NCT01016288||25 G Needle EUS-FNA|Patients referred for an EUS examination and EUS-FNA of a solid mass lesion adjacent to the upper GI tract using a 25 G needle
3225663|NCT01016275||Iliac lesions TASC A or B|All lesion types belonging to the iliac TASC A or B.
3225664|NCT01016262|Experimental|MAX-002 suppositories|
3225665|NCT01016262|Placebo Comparator|Placebo suppositories|
3225666|NCT01016262|Active Comparator|Canasa® suppositories|
3225667|NCT01016249|Active Comparator|Treatment 1. 5% Saline + Epinephrine|Nebulization with 4ml of 5% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
3225668|NCT01016249|Other|Treatment 3. 3% Saline + Epinephrine|Nebulization with 4ml of 3% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
3225669|NCT01016249|Other|Treatment 2 . 0.9% Saline + Epinephrine|Nebulization with 4ml of 0.9% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
3225670|NCT01016223|Active Comparator|Beclomethasone dipropionate inhaler|
3225671|NCT01016223|Placebo Comparator|Matched inhaler|
3225672|NCT01016210|Experimental|60 infertile women|Candidates for IVF-ET treatment
3225673|NCT01016210|No Intervention|control|no treatment
3225674|NCT01016197|Active Comparator|Conservative|Four weeks of splinting followed by mobilisation.
3225675|NCT01016197|Experimental|Surgery|Surgical repair of the tendon with a bone anchor followed by four weeks of splinting and then mobilisation.
3225676|NCT01016184|Active Comparator|vitamin D|
3225677|NCT01016184|Active Comparator|placebo|
3225678|NCT01016158|Experimental|umbilical cord serum eyedrops|patients with recurrent corneal erosions were treated with 20% umbilical cord serum eye drops 3 to 4 times a day in addition to artificial tears
3225679|NCT01016145|Active Comparator|First generation antipsychotic|Subjects randomized to this arm will receive treatment with haloperidol or chlorpromazine.
3225680|NCT01016145|Experimental|Second generation antipsychotics|Subjects randomized to this arm will receive treatment with a second-generation antipsychotic: risperidone or olanzapine or aripiprazole or quetiapine or ziprasidone
3225681|NCT01016119|Placebo Comparator|Placebo|In this group we will use Placebo cream, in the early rehabilitations in the upper extremity
3225682|NCT01016119|Experimental|Folrex|In this group we will use Folrex cream, in the early rehabilitations in the upper extremity
3225683|NCT01016106|Active Comparator|AA pts AD and IV|African American patients with a diagnosis of atopic dermatitis and ichthyosis vulgaris. During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT
3225684|NCT01016106|Active Comparator|AA patients (controls)|African American patients with no personal or family history of ichthyosis vulgaris or atopy. During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT
3225685|NCT01016093|Experimental|Intervention|Patients in this arm received zoledronic acid.
3225686|NCT01016093|Placebo Comparator|Control|Patients in this arm received placebo as control group
3225687|NCT01016080|Active Comparator|oral glutathione|glutathione, 500 mg, taken orally twice daily
3225688|NCT01016080|Placebo Comparator|placebo capsules|identical-appearing placebo capsules
3225689|NCT01016067|Experimental|INFUSE/MASTERGRAFT|Patients received INFUSE/MASTERGRAFT granules with rigid internal fixation.
3225690|NCT01016067|Active Comparator|Autograft bone|Patients received autograft bone with rigid internal fixation.
3225691|NCT01016054|Experimental|A. PLD plus AGS-8M4|Women with platinum resistent ovarian cancer
3225692|NCT01016054|Experimental|B. Carboplatin and gemcitabine plus AGS-8M4|Women with platinum sensitive ovarian cancer
3225693|NCT01016041|Experimental|everolimus stent|
3225694|NCT01016041|Active Comparator|paclitaxel eluting|
3225695|NCT01016028||Questionnaire + Sensory Tests + Interview|
3225696|NCT01016015|Experimental|Treatment (cixutumumab and temsirolimus)|Patients receive cixutumumab IV over 60 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3225697|NCT01016002|Experimental|Intervention|
3225698|NCT01015989|Active Comparator|CARE+ Kenya brief computer risk assessment session (control)|
3225699|NCT01015989|Active Comparator|Full CARE+ Spanish computer-counseling group|
3225700|NCT01015976|Experimental|Post bariatric surgery|Roux en Y bariatric surgery
3225701|NCT01015976|Other|Control|No surgery
3225702|NCT01015963||Ancillary-correlative (DNA sample analysis)|Blood samples collected on clinical trial CLB-9871 are examined via ABCC2 and SLC01B3 genotyping using TaqMan analysis. Other genes related to the pharmacokinetics and side effects of docetaxel may be considered for future genotyping. In some cases, panels of drug response SNPs on high-density arrays may be genotyped.
3225703|NCT01015950|Experimental|Pumpy'Sup|Lipid-based nutrient supplement
3225704|NCT01015950|Experimental|SCSB|Processed, fortified, cereal-based food blend (SCSB for malnourished children)
3225705|NCT01015950|Experimental|Misola|Locally processed, fortified food blend (Misola)
3225706|NCT01015950|Active Comparator|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, oil) and a multiple micronutrient powder (Mix-Me) are provided to simulate the currently recommended enhanced home-prepared rehabilitation food mixture (farines enrchies) according to the national Mali CMAM protocol."
3225707|NCT01015937|Active Comparator|Turmeric|"diabetic nephropathy patient~more than 300 mg/proteinuria"
3225708|NCT01015937|Active Comparator|ACE inhibitor + ATI blocker|"diabetic nephropathy~more than 300 mg/day proteinuria"
3225709|NCT01015924|Active Comparator|Elastic Stable Intramedullary Nailing|Operative intervention with closed or open reduction and intramedullary stabilization of midshaft clavicle fractures
3225710|NCT01015924|Active Comparator|Plate osteosynthesis|Open reduction and plate fixation of midshaft clavicle fractures
3225711|NCT01015911|Experimental|1|SGN-75
3225712|NCT01015898|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
3225713|NCT01015872|Experimental|CPAP|the subjects introduced with CPAP treatment
3225714|NCT01015859|No Intervention|DDD long AV delay|Pacemaker is programmed in DDD mode with long AV delay (250 msec)
3225715|NCT01015859|Active Comparator|AAI SafeR|Pacemaker is programmed in AAI SafeR mode
3225716|NCT01015846|Experimental|Intervention|
3225717|NCT01015846|Active Comparator|Core stability exercise|Traditional core stability exercise
3225718|NCT01015833|Experimental|Arm I (doxorubicin hydrochloride, sorafenib tosylate)|Patients receive doxorubicin hydrochloride IV on day 1 and sorafenib tosylate PO QD or BID on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, patients may continue to receive sorafenib tosylate PO QD or BID in the absence of disease progression or unacceptable toxicity.
3225719|NCT01015833|Experimental|Arm II (sorafenib tosylate)|Patients receive sorafenib tosylate PO QD or BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3225720|NCT01015820|Experimental|Cancer group|Participants in this group had pathologically confirmed pancreatic adenocarcinoma. They received an EGD with EUS. During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
3225721|NCT01015820|Other|Control group|Participants in this group were without pancreatic adenocarcinoma. Participants in the control group received an EGD with EUS for the indication of abdominal pain. During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
3225722|NCT01015807|Placebo Comparator|Placebo|Sterile Saline used for TAP block = Bupivacaine Placebo + Clonidine Placebo
3225723|NCT01015807|Active Comparator|TAP (Bupi)|2x20mL 0.375% Bupivacaine + 2x1mL of 0.9% NaCl = 150mg Bupivacaine + Clonidine Placebo
3225724|NCT01015807|Active Comparator|Clo-TAP (Bupi + Clon)|2x20mL 0.375% Bupivacaine + 2x1mL Clonidine = 150mg Bupivacaine + 150µg Clonidine
3225725|NCT01015794|Experimental|Adrenergic agonist|
3225726|NCT01015781|Experimental|Arm 1|Progressive Tinnitus Management
3225727|NCT01015781|Other|Arm 2|Wait List Control
3225829|NCT01015040|Experimental|solifenacin succinate suspension (fed)|
3225729|NCT01015768|Active Comparator|Control|A new lens (PureVision) is soaked for 2 hours in non-preserved saline
3225730|NCT01015755|Experimental|thirst intervention|
3225731|NCT01015742|Experimental|Experimental|Stem cell Transplant using two unrelated umbilical cord blood units.
3225732|NCT01015729|Active Comparator|1|Esomeprazole 20 mg/ASA 81 mg Fixed Dose Combination Capsule
3225733|NCT01015729|Active Comparator|2|Esomeprazole Clinical Trial Capsule 20 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
3225734|NCT01015729|Active Comparator|3|Esomeprazole MUPS Tablet 20 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
3225735|NCT01015716|Active Comparator|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
3225736|NCT01015716|Experimental|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
3225737|NCT01015703|Experimental|CoVaccine HT|
3225738|NCT01015690||unexplained infertility|patients with unexplained infertility
3225739|NCT01015690||healthy controls|women who wish to conceive, no more tha 3 previous cycles, age above 18
3225740|NCT01015690||references|lesbian women with a regular cycle without use of anticonception and not at risk of becoming pregnant
3225741|NCT01015677|Experimental|MK-6913 75 mg|MK-6913 75 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 1 and Stage 2)
3225742|NCT01015677|Active Comparator|17-β estradiol 1 mg|17β-estradiol 1 mg tablet and matching placebo for MK-6913 75 mg capsule once daily for 4 weeks (Stage 1 and Stage 2)
3225743|NCT01015677|Placebo Comparator|Placebo|Matching placebo for MK-6913 75 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 1 and State 2)
3225744|NCT01015677|Experimental|MK-6913 25 mg|MK-6913 25 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 2)
3225745|NCT01015651|Active Comparator|remifentanil-2|In this group, patients are receiving a continuous i.v. infusion of remifentanil according to a target effect site concentration of 2 ng/ml.
3225746|NCT01015651|Active Comparator|remifentanil-4|In this group, patients are receiving a continuous i.v. infusion of remifentanil according to a target effect site concentration of 4 ng/ml.
3225747|NCT01015638|Experimental|Clindamycin and BPO 5% gel|Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
3225748|NCT01015638|Active Comparator|Clindamycin phosphate and BPO 2.5% gel|Once Daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel.
3225749|NCT01015625|Other|A: Surgical Therapy|Local therapy consists of lumpectomy or mastectomy with or without radiotherapy (according to center tumor board decision) with a resection free margin of at least 1 mm or more demonstrated on paraffin embedded histological sections. Intraoperative frozen sections are allowed but not definitive for margin assessment. Sentinel node biopsy may be performed and has always to be followed by axillary dissection of level I and II (axillary surgery level I and II is mandatory).
3225750|NCT01015625|Other|B: Surgery on Demand|In Arm B (no local therapy) it may be necessary to perform local therapy on demand (surgery, radiotherapy). Reasons may be uncontrolled bleeding or infected exulcerations with a septic component and no treatment benefit from conservative therapy. This will be considered as protocol deviation. However, the patient's follow up is recorded and data are available for analyses as intention to treat.
3225751|NCT01015612|Experimental|Medtronic CoreValve® System Implantation|Patients with symptomatic severe aortic stenosis who have an elevated surgical risk
3225752|NCT01015599|Experimental|HOP'N After-School Program|After-school program with daily physical activity following CATCH guidelines, daily fruit/vegetable snack, and weekly nutrition and physical activity education based on social cognitive theory.
3225753|NCT01015586|Experimental|Lamotrigine|Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks
3225754|NCT01015586|Placebo Comparator|Placebo|Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks
3225755|NCT01015573|Experimental|healthy subjects|
3225756|NCT01015560|Experimental|treatment|MLN1202 8mg/kg IV Days 1, 15, 29 given as 1 6 week cycle
3225757|NCT01015547|Experimental|Infliximab plus Methotrexate|infliximab 3-5 mg/kg every 6 weeks, plus methotrexate 15 mg/m2 weekly given orally (dose escalation if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.
3225758|NCT01015547|Experimental|Combination of DMARDs|methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75), plus standard doses of sulfasalazine and hydroxychloroquine. no oral prednisolone. intra-articular steroids allowed.
3225759|NCT01015547|Active Comparator|Methotrexate alone|Conventional drug therapy: methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.
3225760|NCT01015534|Experimental|Whole brain irradiation plus Temozolomide|Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks, and a fixed dose of oral Temozolomide, 1h before each fraction of whole brain irradiation, 200 mg on Monday, Wednesday, Friday; 300 mg on Tuesday, and Thursday. Without adjuvant cycles of Temozolomide.
3225761|NCT01015534|Active Comparator|Whole brain irradiation|Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks
3225762|NCT01015521|Experimental|Aminoflavone Prodrug|Aminoflavone to treat ER positive breast cancer patients
3225763|NCT01015521|Experimental|Aminoflavone Prodrug with pretreatment|Aminoflavone Prodrug to treat Triple Negative Breast Cancer
3225764|NCT01015508|Other|High predisposition|High predisposition for weight regain
3225765|NCT01015508|Other|low predisposition|low predisposition for weight regain
3225766|NCT01015508|Other|Medium predisposition|Medium predisposition for weight regain
3225767|NCT01015495|Experimental|ranibizumab|
3225768|NCT01015482|Experimental|Remifentanil|Remifentanil Infusion
3225769|NCT01015482|Active Comparator|Midazolam|Active Placebo
3225770|NCT01015469|Active Comparator|Group A|Conventional laparoscopic Roux-en-Y gastric bypass (Golden Standard)
3225771|NCT01015469|Experimental|Group B|Conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring
3225773|NCT01015456|Active Comparator|2|Intravenous cyclophosphamide monthly for 6 months
3225774|NCT01015443|Experimental|Investigational Arm|Tecemotide (L-BLP25) + Single low dose cyclophosphamide + Best supportive care (BSC)
3225775|NCT01015443|Placebo Comparator|Control Arm|Saline + Placebo + Best supportive care (BSC)
3225776|NCT01015430|Placebo Comparator|Placebo (for RO4917523 ascending doses)|
3225777|NCT01015430|Placebo Comparator|Placebo (for RO4917523 fixed dose)|
3225778|NCT01015430|Experimental|RO4917523 ascending doses|
3225779|NCT01015430|Experimental|RO4917523 fixed dose|
3225780|NCT01015417|Active Comparator|Amoxicillin clavulanic acid|Postoperative administration of 2g of Augmentin, 3 times daily for 5 days.
3225781|NCT01015417|Other|No medication|no postoperative antibiotics
3225782|NCT01015404|Experimental|Experimental H|high volume (0.6mL、0.3% Trafermin)
3225783|NCT01015404|Experimental|Experimental L|low volume (0.2mL、0.3% Trafermin)
3225784|NCT01015391|Experimental|T2|
3225785|NCT01015391|Active Comparator|AZA|
3225786|NCT01015378||Diverticulitis of the sigmoid colon - first episode|
3225787|NCT01015365|Other|Surgical revision|Surgical cementless One-stage revision of the chronic infected hip arthroplasty
3225788|NCT01015352|Active Comparator|Arm A|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days for 6 courses and 12 additional maintenance courses in responders.
3225789|NCT01015352|Active Comparator|Arm B|"Azacitidine: 75mg/sqm SQ per day for 5 days every 28 days for 6 courses AND~Epoetin beta : 60000U weekly SQ injections (to be adapted according to Hb as described above)~12 additional maintenance courses are planned in responders"
3225790|NCT01015339|Active Comparator|Cisplatin plus capecitabine|
3225791|NCT01015339|Experimental|Paclitaxel plus Capecitabine|
3225792|NCT01015326||Expert Interviews|Expert cohort consists of providers with expertise in administering epidermal growth factor receptor inhibitors (EGFRI) or treating patients with EGFRI-associated skin toxicities. Experts will be asked open-ended questions about symptoms and issues as they relate to HRQL in patients with EFGRI skin toxicities. Experts will then be presented with a pool of potential items and will be asked through interview and questionnaire to relate items according to how common and how important they are when occurring in patients with this condition.
3225793|NCT01015326||Patient Interviews|Patient cohort will consist of those treated with an epidermal growth factor receptor inhibitor (EGFRI) and referred to a specialized dermatology clinic for skin rash management. Patients will be asked open-ended questions about symptoms and issues as they relate to their HRQL to elicit personal experiences about how EGFRI skin toxicities and its treatment affects patients. Patients will be asked through interview and questionnaire to rate items according to how often they are experienced and how important they are to the patient.
3225794|NCT01015313|Experimental|intensive sodium management|
3225795|NCT01015313|No Intervention|standard care|
3225796|NCT01015287|Experimental|Non pre-treatment|A placebo oral loading dose is given at the time of diagnosis and a 60 milligrams (mg) oral loading dose of prasugrel is given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.
3225797|NCT01015287|Experimental|Split Loading Dose|A 30 mg oral loading dose of prasugrel is given at diagnosis and a 30 mg oral dose of prasugrel is given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days
3225798|NCT01015274||Healthy control male|
3225799|NCT01015261|Experimental|Bone Marrow Transplantation|
3225800|NCT01015261|Active Comparator|Chemotherapy|
3225801|NCT01015248|Experimental|Rituximab and Bendamustine|
3225802|NCT01015235|Placebo Comparator|Arm 1: Placebo|Placebo
3225803|NCT01015235|Active Comparator|A2: KAI-1678|Test Drug
3225804|NCT01015235|Active Comparator|A3: Ketorolac|Active Comparator
3225805|NCT01015222|Experimental|Dasatinib, Bevacizumab + Paclitaxel|"Dose Escalation Starting Dose Levels: 50 mg Dasatinib daily by mouth (PO), 5 mg/kg Bevacizumab IV on Day 1 and 15; Paclitaxel 40 mg/m2 IV on Day 1, 8 and 15~Dose Expansion Starting Dose Levels: Maximum tolerated dose from Dose Escalation."
3225806|NCT01015209|Active Comparator|Cohort 1: 18 healthy subjects|18 healthy subjects receiving Chitosan- N- Acetylcysteine eye drops at a dose of 0.1%, 0.2% or 0.3% (6 subjects per group)
3225807|NCT01015209|Active Comparator|Cohort 2: 12 healthy patients|12 healthy subjects receiving Chitosan- N- Acetylcysteine eye drops at a dose of 0.1%, 0.2% or 0.3%
3225808|NCT01015196|Active Comparator|Idarubicine|
3225809|NCT01015196|Experimental|Daunorubicine|
3225810|NCT01015183|Experimental|Intervention|Received Zinc Sulfate
3225811|NCT01015183|Placebo Comparator|Control|Control group
3225812|NCT01015170|Experimental|Bupropion HCl|Up to 8 week of bupropion SR (150mg BID) + counseling.
3225813|NCT01015157|Active Comparator|Standard stapling without reinforcement|Standard Echelon 60 linear stapling with GOLD cartridges
3225814|NCT01015157|Active Comparator|Seamguard gastric stapling line reinforcement|
3225815|NCT01015144||Atorvastatin|
3225816|NCT01015144||No statin|
3225817|NCT01015131|Experimental|All Participants|18F-FLT-PET imaging
3225818|NCT01015118|Experimental|BIBF 1120|patients to receive BIBF 1120 standard dose twice daily PO in combination with combination with carboplatin and paclitaxel
3225819|NCT01015118|Placebo Comparator|Placebo|patients to receive capsules identical to those containing BIBF 1120 in combination with combination with carboplatin and paclitaxel
3225820|NCT01015105||patients with hip fracture|
3225821|NCT01015092||unselected HIV outpatient attendees|All HIV patients attending for general HIV care at 2 London Hospitals
3225822|NCT01015079||Entire Taiwan women|
3225823|NCT01015066|Active Comparator|buprenophine/naloxone|Participants with this arm will receive 4-16 mg/d buprenorphine/naloxone (Suboxone).
3225824|NCT01015066|Experimental|Naltrexone|Participants assigned to this arm will receive 50 mg/d naltrexone.
3225825|NCT01015053|Experimental|Regional block|"An ultrasound-guided rectus sheath block will be performed by the regional block anesthesiologist in the regional block arm."
3225826|NCT01015053|Active Comparator|Wound infiltration|"Local wound infiltration will be performed by the surgeon in the wound infiltration arm."
3225827|NCT01015040|Active Comparator|solifenacin succinate tablet (fasting)|
3225831|NCT01015027|Experimental|Dose 2|(3:1, active:placebo)
3225832|NCT01015027|Experimental|Dose 3|(3:1, active:placebo)
3225833|NCT01015027|Experimental|Dose 4|(3:1, active:placebo)
3225834|NCT01015014|Active Comparator|AN3365|
3225835|NCT01015014|Placebo Comparator|Saline|
3225836|NCT01015001|Active Comparator|Active rTMS|1Hz rTMS sessions applied to the left temporoparietal cortex of the subjects
3225837|NCT01015001|Placebo Comparator|Sham rtms|Same number of pulses but applied with and angled coil (90 degrees) and placed over the fronto´temporal region
3225838|NCT01014988|Other|Single Arm|A single arm open-label design has been selected to achieve the primary objective of providing regulatory authorities with safety data on IV zanamivir in an expedited manner. This study design also facilitates the provision of safety data on a real-time basis, if necessary.
3225839|NCT01014975|Experimental|20 mg Plasmin (Human)|20 mg of Plasmin (Human)
3225840|NCT01014975|Experimental|40 mg Plasmin (Human)|40 mg of Plasmin (Human)
3225841|NCT01014975|Experimental|80 mg Plasmin (Human)|80 mg of Plasmin (Human)
3225842|NCT01014962|Experimental|Albaconazole 400 mg cohort 1|Albaconazole 400 mg
3225843|NCT01014962|Placebo Comparator|Placebo cohort 1|Placebo once daily
3225844|NCT01014962|Experimental|Albaconozole 400 mg cohort 2|Albaconozole 400 mg every 12 hours
3225845|NCT01014962|Placebo Comparator|Placebo cohort 2|Placebo every 12 hours
3225846|NCT01014962|Experimental|Albaconozole 400 mg cohort 3|Albaconozole 400 mg every 8 hours
3225847|NCT01014962|Placebo Comparator|Placebo cohort 3|Placebo every 8 hours
3225848|NCT01014949|Other|Control, Diabetes and Metabolic Syndrome|
3225849|NCT01014936|Experimental|MSC2156119J Regimen 1|Subjects will be administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.
3225850|NCT01014936|Experimental|MSC2156119J Regimen 2|Subjects will be administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.
3225851|NCT01014936|Experimental|MSC2156119J Regimen 3|Subjects will be administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.
3225852|NCT01014923|Experimental|Intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
3225853|NCT01014923|No Intervention|Control|Parents receive a Department of Transportation booklet on teen driving
3225854|NCT01014910|Active Comparator|Continuous pulse oximetry monitoring|Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.
3225855|NCT01014910|Active Comparator|Intermittent pulse oximetry monitoring|Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
3225856|NCT01014897|Experimental|subcortical|Subcortical stroke patients will receive tDCS stimulation and sham in random order
3225857|NCT01014897|Experimental|cortical|subjects will receive active and sham tDCS in random order
3225858|NCT01014884|Other|Control Group|The control group will receive usual care as provided by your Health Plan.
3225859|NCT01014884|Other|Intervention group|Additional visits will be conducted by a member of the multidisciplinary team (case manager/nurse, social worker and/or pharmacist that will be either face to face or by telephone.
3225860|NCT01014871|Other|intra-individual comparison|
3225861|NCT01014858|Experimental|Donepezil|5mg of Donepezil for the first 8 weeks raising to 10mg thereafter if patient adjusted to 5mg dose. 10mg does continues for the remainder of the study.
3225862|NCT01014858|Placebo Comparator|Placebo|Patient commences medication to match appearance of 5mg donepezil for first 8 weeks then 10mg for the remainder of the study.
3225863|NCT01014845|Experimental|Hepatitis E vaccine|Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
3225864|NCT01014845|Placebo Comparator|HBV vaccine|Hepatitis B vaccine, containing 5mcg of HBsAg recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
3225865|NCT01014832|Experimental|Uncontrolled diabetes|Uncontrolled diabetes
3225866|NCT01014806|Experimental|Low dose|
3225867|NCT01014806|Experimental|High dose|Investigational Influenza VLP Vaccine 60ug/strain
3225868|NCT01014806|Active Comparator|TIV|Trivalent Influenza Vaccine 15ug/strain, Commercially Licenced
3225869|NCT01014793||Responders to cabergoline|patients with active disease under octreotide treatment received addition of increasing doses of cabergoline (1.0, 2.0 and 3.5mg/week)
3225870|NCT01014780||Normal (non-dry) dry eye subjects|These are healthy individuals, age 18 and above, who do not exhibit dry eyes by signs and symptoms
3225871|NCT01014780||Dry eye subjects|These are subjects, age 18 years and above, who do exhibit signs and symptoms of dry eye.
3225872|NCT01014767|Experimental|Standard Arm (1)|Alternating chemotherapy cycles with etoposide 100 mg/m2 over 1 hour on days 1-5, carboplatin 350 mg/m2 over 2 hours on day 2 and 3, vincristine 1.5 mg/m2 on day 5 alternating with: etoposide 100 mg/m2 over 1 hour on days 1-5, cyclophosphamide 1 g/m2 over 1 hour on day 2 and 3, vincristine 1.5 mg/m2 on day 5. Six blocks are given in 4 week intervals (day1 to day1). Radiation is given between the second and the third cycle only to a small subgroup of patients defined by age histology staging and response to the first to cycles of chemotherapy.
3225873|NCT01014767|Experimental|Doxorubicin/cisplatin arm (2)|Doxorubicin 25 mg/m²/day over 12 hrs on days 1-3, Dactinomycin 45 µg/kg/day (max. 2 mg), i.v. on day 1, and Cisplatin 70 mg/m²/d over 6 hrs on day 4, and Vincristine 1.5 mg/m²/day (max. 2 mg), i.v. on days 8, 15. An identical second cycle is started on day 28 if the side effects allow it. The further treatment is identical to the standard arm with four more cycles of chemotherapy following radiation in some of the patients in all treatment arms.
3225874|NCT01014767|Experimental|Methotrexate Arm (3)|Methotrexate 5g/m^2 over 24 hours with leucovorin rescue at hour 42 given three times on days 1 15 and 29. The further treatment is identical in all four treatment arms.
3225875|NCT01014767|Experimental|Temozolomide Irinotecan arm (4)|Temozolomide is given at 150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day x 5 days as one hour infusions. Two of these cycles are followed by the common radiation - four cycle chemotherapy protocol.
3225876|NCT01014754||NSF|Biopsy-proven diagnosis of NSF
3225877|NCT01014754||Kidney dysfunction plus gadolinium exposure|Those on dialysis or with eGFR ≤ 30 ml/min/1.73 m2 who have had a medical imaging procedure using GBCA in the 2 years prior to skin biopsy.
3225878|NCT01014754||Kidney dysfunction without gadolinium exposure|Those on dialysis or with eGFR ≤ 30 ml/min/1.73 m2 who have never been exposed to GBCA and have had skin biopsy.
3225879|NCT01014754||Normal kidney function with gadolinium exposure|Those with normal kidney function who have undergone a medical imaging procedure using Gd-based contrast agent (GBCA) in the 2 years prior to a skin biopsy.
3225880|NCT01014754||Normal kidneys without gadolinium exposure|Those with normal kidney function who have never been exposed to GBCA and have had a skin biopsy.
3225881|NCT01014754||Controls|Existing skin tissue from neonatal skin (<6 months) will be used as controls, as they presumably have never been exposed to gadolinium
3225882|NCT01014741|Experimental|Ibutilide arm|
3225883|NCT01014741|Placebo Comparator|Placebo arm|
3225884|NCT01014728|Active Comparator|Intravenous anesthesia|Intravenous anesthesia with propofol for endoscopic sinus surgery
3225885|NCT01014728|Active Comparator|Inhalation anesthesia|Inhalation anesthesia with sevoflurane for endoscopic sinus surgery
3225886|NCT01014715|Other|Single Arm|Phase II-Preoperative Radiation followed by Lumpectomy
3225887|NCT01014702|Experimental|Laser Treatment|
3225888|NCT01014702|Active Comparator|Phacoemulsifcation|
3225889|NCT01014689|Active Comparator|Adapalene 0.1% / BPO 2.5% gel|
3225890|NCT01014689|Placebo Comparator|Adapalene 0.1% / BPO 2.5% Vehicle Gel|
3225891|NCT01014676|Active Comparator|Probiotic milk|
3225892|NCT01014676|Placebo Comparator|Standard milk|
3225893|NCT01014663|Active Comparator|Therapeutic Exercise|
3225894|NCT01014663|Active Comparator|Non-Contact Boxing Training|
3225895|NCT01014650|Placebo Comparator|IV normal saline|Single IV dose of normal saline as a control for safety and tolerability observations
3225896|NCT01014650|Experimental|IV GLYX-13|Single IV dose of GLYX-13
3225897|NCT01014650|Experimental|SC GLYX-13|Single SC dose
3225898|NCT01014637|Active Comparator|Amorolfine 5%|
3225899|NCT01014637|Experimental|RV4104A-cylcopiroxolamine-ciclopirox|
3225900|NCT01014624|Experimental|prasugrel|prasugrel 10mg administered for 7 days
3225901|NCT01014624|Active Comparator|clopidogrel|clopidogrel 75mg administered for 7 days
3225902|NCT01014611||Class II NYHA Heart Failure|Fraction of ejection between 40% and 30%
3225903|NCT01014611||Class III NYHA Heart Failure|Fraction of ejection lower than 30%
3225904|NCT01014611||Healthy volunteers|Matched with patients on age and physical activity
3225905|NCT01014598|Experimental|Treatment (cisplatin)|Patients receive cisplatin intra-arterially via isolated lung suffusion over 2 hours. Beginning approximately 2 weeks later (6-8 weeks if indicated for patients with sarcoma undergoing surgery after cisplatin), patients receive standard chemotherapy regimen.
3225906|NCT01014585|Placebo Comparator|1|Placebo tablets administered orally twice daily
3225907|NCT01014585|Experimental|2|Milnacipran tablets administered orally twice daily
3225908|NCT01014572|Experimental|Aerobic Exercise Training + Placebo|
3225909|NCT01014572|Experimental|Tai Chi and/or Yoga Training + Placebo|
3225910|NCT01014572|Experimental|Aerobic Exercise Training + Alagebrium|
3225911|NCT01014572|Experimental|Tai Chi and/or Yoga Training + Alagebrium|
3225912|NCT01014559|Active Comparator|Prolonged release tablet|OxyCodone Naloxone controlled release tablet
3225913|NCT01014559|Active Comparator|Tablet|Oxycodone PR Tablets
3225914|NCT01014546|Experimental|Treatment (arsenic trioxide with or without ascorbic acid)|Patients receive arsenic trioxide PO QD in orange juice on days 1-21. Patients may also receive ascorbic acid PO QD on days 1-21. Treatment repeats every 28 days for up to 168 days in the absence of disease progression or unacceptable toxicity.
3225915|NCT01014533|Placebo Comparator|Placebo|After 3 nights in the UM sleep lab and randomization, this arm receives placebo for one week. They then return to the sleep lab for the same procedures.
3225916|NCT01014533|Active Comparator|Gabapentin|After spending 3 baseline nights in the UM sleep lab, alcohol dependent subjects are randomized. This arm receives gabapentin . On nights 1 and 2 of medication, the dose is 600 mg by mouth 30 min before bedtime. On nights 3-10, the dose is 1200 mg by mouth 30 min before bedtime. On nights 8-10 of medication, subjects return to the UM sleep lab and complete 3 sleep nights with the same procedures. On night 11, the dose is reduced to 600 mg by mouth 30 min before bedtime, and then stopped.
3225917|NCT01014520|Experimental|Gabapentin|Neurontin
3225918|NCT01014520|Experimental|Amitriptyline|Elavil
3225919|NCT01014507|Active Comparator|A|
3225920|NCT01014507|Experimental|B|
3225921|NCT01014494|Experimental|Active - Adaprev|Adaprev (Class III medical device)
3225922|NCT01014494|No Intervention|Standard Care|No different treatment to normal
3225923|NCT01014481|Experimental|start antiretroviral treatment|the optimal timing to initiate antiretroviral therapy in HIV-infected patients who are receiving tuberculosis treatment between at 4 weeks and at 12 weeks after tuberculosis treatment
3225924|NCT01014468|Active Comparator|Ranibizumab|Intravitreal injection of Ranibizumab (3 monthly injection followed by monthly injections as long as required)
3225925|NCT01014468|Active Comparator|Bevacizumab|Intravitreal injection of Bevacizumab (3 monthly injection followed by monthly injections as long as required)
3225926|NCT01014455|Experimental|CO reminder|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
3226002|NCT01013909|Placebo Comparator|Arm 3|
3226003|NCT01013909|Placebo Comparator|Arm 4|
3225927|NCT01014455|Placebo Comparator|no CO reminder|a brief intervention that recommends fasting but does not mention that CO will be checked
3225928|NCT01014442|Experimental|Mycophenolate Mofetil; Cystic Fibrosis|Participants with cystic fibrosis will receive mycophenolate mofetil 1.5 g, orally (PO), BID from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.
3225929|NCT01014442|Experimental|Mycophenolate Mofetil; Other|Participants with COPD, emphysema, idiopathic pulmonary fibrosis, or A1AD will receive mycophenolate mofetil 1.5 g, PO, BID, from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.
3225930|NCT01014429|Experimental|1|
3225931|NCT01014416|Experimental|Arm 1|Single dose, Tolvaptan 15mg or Placebo/day
3225932|NCT01014416|Experimental|Arm 2|Single dose, Tolvaptan 30mg or Placebo/day
3225933|NCT01014416|Experimental|Arm 3|Single dose, Tolvaptan 60mg or Placebo/day
3225934|NCT01014403|Experimental|enoxaparin 30 mg SQ q12 hours|Enoxaparin started at 24 hours post-injury and continued until 96 hours post-injury.
3225935|NCT01014403|Placebo Comparator|placebo|vehicle administered sq q 12 hours
3225936|NCT01014390|Experimental|WallFlex Biliary RX FC Stent System|The WallFlex Biliary RX Fully Covered Stent System is being evaluated for treatment of benign biliary strictures.
3225937|NCT01014364|Experimental|Corticosteroids|Hydrocortisone
3225938|NCT01014364|Placebo Comparator|Control|isotonic saline
3225939|NCT01014351|Experimental|Paclitaxel/Carboplatin/Everolimus|Systemic Therapy using everolimus, paclitaxel and carboplatin given during a 21-day treatment cycle
3225940|NCT01014338|Active Comparator|ACE-inhibitor|
3225941|NCT01014338|Placebo Comparator|Sugar Pill|
3225942|NCT01014325|Experimental|Allergen extract|
3225943|NCT01014325|Placebo Comparator|Placebo|
3225944|NCT01014312|Experimental|Depression Care Management (DCM)|Participants will receive Depression Care Management.
3225945|NCT01014312|Active Comparator|Enhanced Care|Participants will receive the standard of care from their primary care physicians enhanced by a summary of the study's diagnostic interview.
3225946|NCT01014286||Advanced Adenocarcinoma|Stage IV adenocarcinoma who have undergone biopsy with remnant tissue.
3225947|NCT01014273|Active Comparator|Trans-femoral access|Femoral artery PCI access site
3225948|NCT01014273|Active Comparator|Trans-radial access|Radial artery PCI access site
3225949|NCT01014260|Placebo Comparator|Placebo|placebo
3225950|NCT01014260|Active Comparator|Doxycycline|Doxycycline
3225951|NCT01014247|Active Comparator|Arm 1|
3225952|NCT01014247|Placebo Comparator|Arm 2|
3225953|NCT01014234|Experimental|Rapamycin|Maintenance treatment with rapamycin + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.
3225954|NCT01014234|Active Comparator|cyclosporine|Maintenance treatment with cyclosporine + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.
3225955|NCT01014221|Experimental|Acupuncture group|acupuncture administered in 8 sessions over 4 weeks
3225956|NCT01014221|Active Comparator|Steroid group|2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
3225957|NCT01014208|Experimental|OFATUMUMAB + DHAP CHEMOTHERAPY REGIMEN|This study is a parallel arm study, with ofatumumab + DHAP. The Investigators are required to prospectively choose to treat all of their subjects with either DHAP chemotherapy regimens in combination with ofatumumab. All subjects will receive the same ofatumumab regimen and dose.
3225958|NCT01014208|Active Comparator|RITUXIMAB + DHAP CHEMOTHERAPY REGIMEN|This study is a parallel arm study, with rituximab + DHAP. The Investigators are required to prospectively choose to treat all of their subjects with either DHAP chemotherapy regimens in combination with rituximab. All subjects will receive the same rituximab regimen and dose.
3225959|NCT01014195||Group 1|"Survivors of pediatric leukemia treated on Total Therapy Protocol XV (TOTXV) at St. Jude Children's Research Hospital (SJCRH), who are ≥ 8 years of age and ≥ 5 years from diagnosis.~Intervention: Neurocognitive and behavioral evaluation"
3225960|NCT01014182||Early PCI|Routine invasive strategy with early PCI performed in STEMI patients within 24 hours from successful fibrinolysis
3225961|NCT01014182||Standard Therapy|Standard therapy in STEMI patients with fibrinolysis and/or conventional ischaemic-guided therapy.
3225962|NCT01014169|No Intervention|Usual care|Mothers in the control group will receive the nursing discharge newborn information from the nurse practitioner [sometimes via a Spanish interpreter, if required] according to current standard of care, which includes verbal information and written handouts.
3225963|NCT01014169|Experimental|Note taking|The mothers in the intervention group will be given a pen and encouraged to take written notes in the notes section of the discharge envelope using their language of preference when receiving the standard newborn information.
3225964|NCT01014156|Experimental|epoprostenol intraveneously|epoprostenol iv versus placebo iv, both on top of low molecular weight heparin
3225965|NCT01014143|Placebo Comparator|Fluoride toothpaste|Negative control
3225966|NCT01014143|Active Comparator|Triclosan/Fluoride toothpaste|positive control toothpaste
3225967|NCT01014143|Active Comparator|Chlorhexidine Oral Rinse|Positive Control mouthrinse
3225968|NCT01014130|Active Comparator|Arm 2|Conventionally Fractionated Radiotherapy (ConRT) - Standard of Care
3225969|NCT01014130|Experimental|Arm 1|Hypofractionated radiotherapy (HypoRT) - Investigational
3225970|NCT01014117|Placebo Comparator|Placebo|"The Placebo treatment group will be administered eight oral placebo capsules once daily for 7 days.~A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days."
3226004|NCT01013909|Active Comparator|Arm 5|
3226132|NCT01013012|Active Comparator|Group A|Group A : saline 1 ml + ramosetron 6μg/kg
3226133|NCT01013012|Experimental|Group B|Group B : dexamethasone 4 mg + ramosetron 6μg/kg
3225971|NCT01014117|Active Comparator|Placebo and 2.0g SRT2104|This treatment group will be administered eight oral placebo capsules once daily for 6 days followed by 2.0g SRT2104 administered as eight oral SRT2104 capsules on Day 7. A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days.
3225972|NCT01014117|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered eight oral SRT2104 capsules once daily for 7 days. A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days.
3225973|NCT01014104|Experimental|Case|Administration of Methylprednisolone
3225974|NCT01014104|Sham Comparator|Control|
3225975|NCT01014091|Experimental|GSK2340272A F1 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 1 (F1) in the deltoid region of the arm, according to a 0-21 day schedule.
3225976|NCT01014091|Experimental|GSK2340272A F1 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 1 (F1) in the deltoid region of the arm, according to a 0-21 day schedule.
3225977|NCT01014091|Experimental|GSK2340272A F2 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 2 (F2) in the deltoid region of the arm, according to a 0-21 day schedule.
3225978|NCT01014091|Experimental|GSK2340272A F2 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 2 (F2) in the deltoid region of the arm, according to a 0-21 day schedule.
3225979|NCT01014091|Experimental|GSK2340272A F3 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 3 (F3) in the deltoid region of the arm, according to a 0-21 day schedule.
3225980|NCT01014091|Experimental|GSK2340272A F3 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 3 (F3) in the deltoid region of the arm, according to a 0-21 day schedule.
3225981|NCT01014078|Experimental|Azithromycin Ophthalmic Solution, 1%|
3225982|NCT01014078|Placebo Comparator|Placebo|
3225983|NCT01014065||1|Patients with renal cell carcinoma scheduled to receive sunitinib
3225984|NCT01014039|Active Comparator|Flexible Sigmoidoscopy Screening arm|Intervention by flexible sigmoidoscopy screening
3225985|NCT01014039|No Intervention|Control arm|No intervention (no screening)
3225986|NCT01014013|Experimental|ertapenem sodium (MK0826)|ertapenem sodium
3225987|NCT01014013|Active Comparator|ceftriaxone sodium|ceftriaxone sodium
3225988|NCT01014000|Active Comparator|Empirical|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
3225989|NCT01014000|Experimental|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
3225990|NCT01013974|Experimental|GSK573719 250 microgram (μg) arm|Each subject will receive the first dose of GSK573719 250 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
3225991|NCT01013974|Experimental|GSK573719 500 μg arm|Each subject will receive the first dose of GSK573719 500 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
3225992|NCT01013974|Experimental|GSK573719 1000 μg arm|Each subject will receive the first dose of GSK573719 1000 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
3225993|NCT01013974|Placebo Comparator|Placebo|Each subject will receive GSK573719 matching placebo on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
3225994|NCT01013961|Active Comparator|Arm A (standard dose)|"Patients receive alemtuzumab subcutaneously (SC) on days 1-3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 and standard-dose rituximab 375 mg/m^2/week intravenously (IV) on days 8, 15, 22, and 29 in cycle 1 (33-day cycle). In cycle 2 and subsequent cycles (28-day cycle), patients receive alemtuzumab SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 and standard-dose rituximab IV on days 3, 10, 17, and 24. Treatment repeats every 28 days for up to 3 cycles.~Alemtuzumab dose for cycle 1 week 1 requires a 'dose ramp' (3 mg day 1, 10 mg day2, and 30 mg day 3 of cycle 1) and then is 30 mg 3 times a week."
3225995|NCT01013961|Experimental|Arm B (low dose)|"Patients receive alemtuzumab SC on days 1-3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 and low-dose rituximab at 20 mg/m^2 IV on days 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 in cycle 1 (33-day cycle). In cycle 2 and subsequent cycles (28-day cycle), patients receive alemtuzumab SC and low-dose rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 3 cycles.~Alemtuzumab dose for cycle 1 week 1 requires a 'dose ramp' (3 mg day 1, 10 mg day2, and 30 mg day 3 of cycle 1) and then is 30 mg 3 times a week."
3225996|NCT01013948||N/A (Survey study)|
3225997|NCT01013935|Active Comparator|Full CARE+ Spanish computer-counseling group|
3225998|NCT01013935|Active Comparator|Brief risk assessment study group only (control)|
3225999|NCT01013922||No treatment|Patients with a smoking history of 15 pack years or more.
3226000|NCT01013909|Experimental|Arm 1|
3226001|NCT01013909|Experimental|Arm 2|
3226005|NCT01013896|Active Comparator|Cystic Fibrosis Education|This intervention is designed to increase knowledge and enhance the skills needed to optimize CF-management. The strategies used to achieve improved adherence include providing didactic education and skills training, and proscriptively using behavioral modification strategies, such as positive reinforcement for desired behaviors, and problem-solving training to overcome barriers.
3226006|NCT01013896|Experimental|Motivational Interviewing|The Counselor's overarching goal for the intervention is to motivate and assist the participant to improve his/her adherence to the CF pulmonary medications. The intervention will begin by providing the patient personal feedback on their adherence (using pharmacy refill data) and health outcomes (e.g., trajectory of lung function values, frequency of exacerbations) as well as clinic-level figures showing the association between adherence and health outcomes.
3226007|NCT01013883||systolic dysfunction|patients having left ventricular systolic dysfunction on echocardiography
3226008|NCT01013883||distolic heart failure|patients with clinical heart failure and preserved LV systolic dysfunction
3226009|NCT01013870|Experimental|MTBI subjects randomized to drug|"Of 200 MTBI subjects enrolled, 1:1 randomization will be used to assign half (i.e 100) to the treatment arm of the phase II drug trial of atorvastatin. These subjects will receive a daily weight-based dose of atorvastatin 1mg/kg (up to 80 mg) for seven days and started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving a placebo.~NOTE: The 100 Orthopedic Injury subjects recruited for and participating in the Observational studies are not included in the Medication study portion of this protocol."
3226010|NCT01013870|Placebo Comparator|MTBI subjects randomized to placebo|"Of 200 MTBI subjects enrolled, 1:1 randomization will be used to assign half (i.e 100) to the placebo arm of the phase II drug trial of atorvastatin. These subjects will receive a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug.~NOTE: The 100 Orthopedic Injury subjects recruited for and participating in the Observational studies are not included in the Medication study portion of this protocol."
3226011|NCT01013857|Active Comparator|Health coaching|Phone patients every week to discuss medication adherence
3226012|NCT01013857|Experimental|Health coaching plus home-titration|Health coaches call patients every week to discuss medication adherence and to intensify medications if appropriate according to physician-created algorithm
3226013|NCT01013844|Active Comparator|Solo Learning|Participant learning alone (without partner).
3226014|NCT01013844|Active Comparator|Dyadic Learning|Participant and partner learning together.
3226015|NCT01013831|Experimental|Prevention (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
3226016|NCT01013818|Experimental|HGS1029|
3226017|NCT01013805|Experimental|Arm 1|Integrated Preoperative Radiotherapy (external beam radiotherapy) and Chemotherapy (Oxaliplatin, Fluorouracil and Leucovorin), then surgical resection.
3226018|NCT01013792|Experimental|Non-adherent Wound Dressing|The non-adherent dressing is the same as the Tegaderm Matrix dressing, with potassium chloride, rubidium chloride, calcium chloride, zinc chloride, potassium citrate and citric acid removed. This dressing is a Class I medical device (21 CFR Sec. 878.4020 Occlusive wound dressing) that is exempt from premarket notification procedures.
3226019|NCT01013792|Active Comparator|Tegaderm Matrix Dressing with PHI|A commercial wound dressing to be used per manufacturer's instructions for use.
3226020|NCT01013779|Experimental|Arm A|Conventional radical radiotherapy in this trial means that those patients with microscopic disease receive a dose of 50Gy using daily incremental fractions of 2Gy over 25 fractions and those with macroscopic disease receive 54Gy in 27 fractions.
3226021|NCT01013766|Other|AM/PM/BID|Subjects will receive a dose of 100mg in the AM on Day 1, followed by a dose of 100mg in the PM on Day 4, and a dose of 50mg BID on Day 6.
3226022|NCT01013766|Other|PM/AM/BID|Subjects will receive a dose of 100mg in the PM on Day 1, followed by a dose of 100mg in the AM on Day 4, followed by 50mg BID on Day 6.
3226023|NCT01013753|Experimental|Olodaterol (BI 1744) low|Low dose inhaled orally once daily from the Respimat inhaler
3226024|NCT01013753|Experimental|Olodaterol (BI 1744) very low|Very low dose inhaled orally once daily from the Respimat inhaler
3226025|NCT01013753|Experimental|Olodaterol (BI 1744) medium|Medium dose inhaled orally once daily from the Respimat inhaler
3226026|NCT01013753|Experimental|Olodaterol (BI 1744) high|High dose inhaled orally once daily from the Respimat inhaler
3226027|NCT01013753|Active Comparator|Formoterol 12 mcg|12mcg inhaled twice daily from the Aerolizer inhaler
3226028|NCT01013753|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
3226029|NCT01013740|Experimental|Lapatinib + Vinorelbine|Lapatinib + Vinorelbine
3226030|NCT01013740|Active Comparator|Lapatinib + Capecitabine|Lapatinib + Capecitabine
3226031|NCT01013727|Experimental|Postural Reconstruction|
3226032|NCT01013727|Active Comparator|muscular stretching|
3226033|NCT01013714|Active Comparator|Routine Care + Cardiac Sympathetic Denervation (CSD)|"Patients in this arm receive routine care and undergo cardiac sympathetic denervation. The procedure must be scheduled to occur within one month of randomization.~Follow-up Visits~Surgical follow up will occur at 2 weeks after the CSD procedure.~All patients are followed at the ICD clinic every 6 months up to 18 months.~Information regarding ICD therapy and arrhythmias will be obtained from ICD interrogations at the follow up visits.~VT Ablation is permitted in both arms for ICD shock after optimization."
3226034|NCT01013714|Placebo Comparator|Routine Care|"Patients in this arm remain on prescribed drug regimen and will not undergo CSD.~Follow-up Visits~Medical follow up will occur at 2 weeks after randomization.~All patients are followed at the ICD clinic every 6 months up to 18 months.~Information regarding ICD therapy and arrhythmias will be obtained from ICD interrogations at the follow up visits.~VT Ablation is permitted in both arms for ICD shock after optimization."
3226035|NCT01013701|Active Comparator|Fluticasone Furoate|nasal steroid
3226036|NCT01013701|Placebo Comparator|Placebo|nasal spray vehicle without drug
3226077|NCT01013415|Experimental|ARM 3|HAART, IL-2, T cells
3226404|NCT01011062|Experimental|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
3226037|NCT01013688|Experimental|left atrial RF ablation groups|Excised the left atrial appendage Encircling the left pulmonary veins and an extension to the posterior mitral valve annulus From the left atrial appendage to the left superior pulmonary vein A connecting line between both islands of pulmonary veins From the middle of the mitral valve ablation line down towards the base of the atria ligament of Marshall
3226038|NCT01013688|Experimental|Bi-atrial radiofrequency ablation group|In the basis of left atrial group,excised the right atrial appendage; from the amputated right atrial appendage towards the inferior vena cava; from the midterm of interatrial septum to the AV groove; ablation between the superior and inferior caval cannulation sites; radiofrequency ablation for Waterston's groove
3226039|NCT01013688|No Intervention|Amiodarone group|No radiofrequency ablation procedure during the valve surgery; Amiodarone 200 mg/day for 12 months after surgery
3226040|NCT01013675|Experimental|1|15 mcg hemagglutinin (HA) per viral strain; 0.5 mL single dose
3226041|NCT01013675|Active Comparator|2|15 mcg hemagglutinin (HA) per viral strain; 0.5 mL single dose
3226042|NCT01013662|Active Comparator|glycemic control between 180 and 220 mg/dl|
3226043|NCT01013662|Active Comparator|glycemic control for levels between 80 and 110 mg/dl|
3226044|NCT01013649|Active Comparator|Arm I (gemcitabine hydrochloride or combination chemotherapy)|Patients receive either gemcitabine hydrochloride or allowable combination chemotherapy per standard of care for 5 months.
3226045|NCT01013649|Experimental|Arm II (gemcitabine hydrochloride, erlotinib hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 4/2/14)
3226046|NCT01013649|Experimental|Arm III (chemotherapy)|Patients receive the same treatment as in arm I for 1 month.
3226047|NCT01013649|Experimental|Arm IV (chemotherapy, chemoradiotherapy)|Patients receive the same treatment as in arm I for 1 month. Beginning within 7-21 days after completion of chemotherapy, patients undergo radiotherapy (3-dimensional conformal radiotherapy or intensity-modulated radiotherapy) 5 days per week for 5.5 weeks (28 fractions). During radiotherapy, patients receive either capecitabine PO BID 5 days per week or fluorouracil IV continuously for 5.5 weeks or until radiotherapy is completed.
3226048|NCT01013636||Anaplasma|
3226049|NCT01013623|Active Comparator|Best Medical Therapy|The best medical therapy group will not initially undergo surgery, but will be treated with the therapy that medical oncologists or surgeons feel is best for the patient. This treatment may include standard or experimental therapies.
3226050|NCT01013623|Active Comparator|Surgery Alone|The surgery alone group will undergo complete resection (surgical removal) of all known disease, if possible. After surgery, patients will be followed regularly and monitored for disease recurrence.
3226051|NCT01013623|Active Comparator|Surgery + BCG|The Surgery + BCG group will first have a complete resection (surgical removal) of all known disease, if possible. After recovery from surgery, two doses of BCG will be given two weeks apart. Each dose is given as 8 separate injections into the skin (called intradermal injections).
3226052|NCT01013610|Active Comparator|Multiple Dose|
3226053|NCT01013610|Placebo Comparator|Placebo|
3226054|NCT01013597|Experimental|LBH589|
3226055|NCT01013584|Active Comparator|1,000 IU|1,000 IU/day of vitamin D3
3226056|NCT01013584|Active Comparator|5,000 IU|5,000 IU/day of vitamin D3
3226057|NCT01013584|Active Comparator|10,000 IU|10,000 IU/day of vitamin D3
3226058|NCT01013571|Experimental|1|12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; health care professional-managed
3226059|NCT01013571|Experimental|2|12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; patient-managed
3226060|NCT01013558|Active Comparator|remifentanil|
3226061|NCT01013558|Placebo Comparator|saline|
3226062|NCT01013545|Experimental|JAE-EMT|The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist. This intervention condition uses spoken language as the mode of communication. Individual, single word targets will be selected based on the child's level of language production and specific interests. The targets are systematically modeled in response to child actions and attention during play. A sequence of milieu teaching prompts will also be used to elicit targets from the child when use of the target language is functional for the child.
3226063|NCT01013545|Experimental|JAE-AAC|The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist. The mode of communication introduced in this intervention condition is a developmentally chosen augmentative communication device. These devices are provided with a set of individually selected visual-graphic symbols and a relevant lexicon. The use of the device is taught within natural communicative exchanges within play routines and daily activities.
3226064|NCT01013532|Experimental|Cilostazol+ Probucol|100mg cilostazol bid plus probucol plus placebo of aspirin
3226065|NCT01013532|Active Comparator|Aspirin + Probucol|aspirin plus placebo cilostazol plus probucol
3226066|NCT01013532|Experimental|Cilostazol|cilostazol plus placebo of aspirin
3226067|NCT01013532|Active Comparator|Aspirin|aspirin plus placebo of cilostazol
3226068|NCT01013506|Experimental|Letrozole +/-goserelin, OSI-906 (Arm I )|Patients receive oral letrozole once daily on days 1-28 plus subcutaneous goserelin (the latter for pre-menopausal women only) on day 1 and oral IGF-1R inhibitor OSI-906 twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3226069|NCT01013506|Experimental|Letrozole +/- goserelin, OSI-906, erlotinib (Arm II)|Patients receive oral letrozole and subcutaneous goserelin (the latter for pre-menopausal women only) and oral IGF-1R inhibitor OSI-906 as in arm I. Patients also receive oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3226070|NCT01013493||myopic|
3226071|NCT01013493||non myope-healthy|
3226072|NCT01013480|Active Comparator|STX209|
3226073|NCT01013467|Active Comparator|color coded bloodpressure booklet|
3226074|NCT01013454|Experimental|Varenicline transdermal delivery system|
3226075|NCT01013415|Experimental|ARM 1|HAART, IL-2
3226076|NCT01013415|Experimental|ARM 2|HAART, T cells
3226078|NCT01013402|Experimental|volunteers for insulin hypoglycemia test|None of the subjects had diabetes mellitus or any other metabolic diseases. They were not taking any medicine and they did not have anemia or polycythemia. Also none of the patients had any condition causing hypoxia or any compromise in peripheral circulation.
3226079|NCT01013389|Experimental|Actifuse ABX|Actifuse ABX bone substitute
3226080|NCT01013389|Active Comparator|INFUSE, plus master granules (MGG)|synthetic bone substitute used in posterolateral instrumented lumber fusion with interbody fusion
3226081|NCT01013376|Experimental|Active|Topical administration of MC-1101
3226082|NCT01013376|Placebo Comparator|Vehicle|Vehicle
3226083|NCT01013363|No Intervention|No music|Participants will not use the digital music player during their procedure.
3226084|NCT01013363|Experimental|Music|Participants will use the digital music player during their procedure.
3226085|NCT01013350||Cladribine|This is an observational study. Subjects who had already participated in the cladribine clinical trials will be observed.
3226086|NCT01013337|Experimental|Arm I (Acupuncture)|Patients undergo 10, 20-minute sessions of acupuncture over 8 weeks (twice weekly for 2 weeks and 6 weekly treatments).
3226087|NCT01013337|Sham Comparator|Arm II (Placebo)|Patients undergo 10, 20-minute sessions of sham acupuncture treatments over 8 weeks (twice weekly for 2 weeks and 6 weekly treatments) via Streitberger needles at non-acupuncture points.
3226088|NCT01013337|No Intervention|Arm III (Control)|Wait-list control patients are contacted by phone at the same frequency as real and placebo acupuncture groups for data collection at weeks 1, 4, and 8.
3226089|NCT01013324|Experimental|Single Arm|All subjects will receive single-agent XL147 dosed daily
3226090|NCT01013311||Cardiac Sarcoidosis|Patients with Cardiac Sarcoidosis who had an ICD implanted
3226091|NCT01013298|Experimental|Video-guided PCT|Patients that will be extubated and re-intubated with the ETT-TVT, and monitored throughout intubation and PCT
3226092|NCT01013285|Experimental|bevacizumab, temozolomide, external beam radiation|
3226093|NCT01013272|Active Comparator|Entecavir|Ongoing entecavir 0.5mg daily
3226094|NCT01013272|Active Comparator|Lamivudine|Switch to lamivudine 100mg daily
3226095|NCT01013259|Placebo Comparator|Placebo|
3226096|NCT01013259|Experimental|Mutaflor|
3226097|NCT01013246|Experimental|Video game play|
3226098|NCT01013233|Experimental|training|Patients in this group start the cognitive training over 6 weeks directly after randomization.
3226099|NCT01013233|Placebo Comparator|control|In this control group begin the training in a cross-over design 7 weeks after randomization.
3226100|NCT01013220|Experimental|Depression Product Detailing|Employers receive education on how to purchase high quality depression management products to improve the quality of depression treatment depressed employees receive. Materials delivered in this arm of the study are available at www.caremanagementfordepression.org
3226101|NCT01013220|Placebo Comparator|Depression HEDIS Detailing|Employers receive education on how to obtain and use HEDIS depression indicators to encourage health plans to improve the quality of depression treatment depressed employees receive
3226102|NCT01013207|Experimental|Nexus (S9) CPAP device|"Fifty subjects with obstructive sleep apnea (OSA), established on CPAP therapy (≥ 6 months) were recruited into this study. These patients use their CPAP device every night while sleeping to treat their OSA.~Nexus (S9) is a new CPAP device with improved humidification system (heated tube and climate control), reduced noise, improved comfort of breathing and new user interface. During the study, patients will use this CPAP every night in place of their own CPAP for a period of 4 weeks. Compliance data from the Nexus will then be compared to the patient's usual CPAP pre trialling Nexus and post trialling Nexus."
3226103|NCT01013194|Experimental|Treated patients|Cirrhotic patients treated with Human Fetal Liver Cell Transplantation.
3226104|NCT01013194|No Intervention|Control patients|Cirrhotic patients on Standard therapy.
3226105|NCT01013168|Experimental|OncoSorb® column|
3226106|NCT01013142|Experimental|MN-221|
3226107|NCT01013142|Placebo Comparator|MN-221 Placebo|
3226108|NCT01013116|Experimental|modified allergen extract of house dust mites|
3226109|NCT01013116|Placebo Comparator|Placebo|
3226110|NCT01013103|Other|Atorvastatin, Ischemic Heart Disease|
3226111|NCT01013103|Placebo Comparator|Atorvastatin vs Placebo Cardiac Surgery|
3226112|NCT01013090|Active Comparator|Epidural crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-epidural anesthesia in patients undergoing Cesarean section
3226113|NCT01013090|Active Comparator|Epidural colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-epidural anesthesia in patients undergoing Cesarean section
3226114|NCT01013090|Active Comparator|Spinal crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-spinal anesthesia in patients undergoing Cesarean section
3226115|NCT01013090|Active Comparator|Spinal colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-spinal anesthesia in patients undergoing Cesarean section
3226116|NCT01013090|Active Comparator|CSEA crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-CSEA anesthesia in patients undergoing Cesarean section
3226117|NCT01013090|Active Comparator|CSEA colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-CSEA anesthesia in patients undergoing Cesarean section
3226118|NCT01013077|Experimental|Optive|Commercial drop.
3226119|NCT01013077|Experimental|Soothe|Commercial drop.
3226120|NCT01013077|Experimental|New Emulsion|New formulation.
3226121|NCT01013064|Experimental|Cohort1|
3226122|NCT01013064|Experimental|Cohort2|
3226123|NCT01013064|Experimental|Cohort3|
3226124|NCT01013064|Experimental|Cohort4|
3226125|NCT01013064|Experimental|Cohort5|
3226126|NCT01013064|Experimental|Cohort6|
3226127|NCT01013051||Post Gastric Bypass|
3226128|NCT01013051||Obese Controls|age, BMI, gender matched
3226129|NCT01013038|Active Comparator|Conventional percutaneous coronary intervention|
3226130|NCT01013038|Experimental|Thrombus aspiration|
3226131|NCT01013025||Patients treated with Vantas implant|Patients were enrolled if they had had a Vantas implant placed for treatment of adenocarcinoma of the prostate, and if the patients were scheduled for explant of the implant, and the physician had difficulty locating the implant.
3226134|NCT01012999|Experimental|Intranasal sufentanil, pain relief|Intranasal sufentanil administered at a dose of 0.5 mcg/kg times one dose at beginning of thirty minute period
3226135|NCT01012986||2nd Grade|students of 2nd grade
3226136|NCT01012986||4th Grade|students of 4th Grade
3226137|NCT01012973|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.
3226138|NCT01012973|Sham Comparator|Sham treatment|Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.
3226139|NCT01012960|Placebo Comparator|Placebo|Placebo= normal saline
3226140|NCT01012960|Active Comparator|methylnaltexone|peripheral opioid antagonist
3226141|NCT01012947|Experimental|Lifestyle Counseling Usual Care|Usual care participants in the group A received no additional services.
3226142|NCT01012947|Experimental|Lifestyle Counseling Telephone, Bimonth|Participants in the group B received bimonthly telephonic care management based on manual.
3226143|NCT01012947|Experimental|Lifestyle Counseling Telephone, Month|Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.
3226144|NCT01012947|Experimental|Lifestyle Counseling Visit, Bimonth|Participants in the group D received health educator-initiated visit counseling bimonthly.
3226145|NCT01012947|Experimental|Lifestyle Counseling Visit, Reward|Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
3226146|NCT01012934|Experimental|1|Alendronate Sodium Tablets, 70 mg
3226147|NCT01012934|Active Comparator|2|Fosamax Tablets, 70 mg
3226148|NCT01012921|Active Comparator|Bio-Gide® membrane|Bio-Gide® membrane This is a biodegradable bilayer membrane for bone and tissue regeneration. It has a natural collagen structure and is of porcine origin
3226149|NCT01012921|Experimental|MembraGel|MembraGel The Straumann membrane is a synthetic degradable barrier membrane
3226150|NCT01012908|Experimental|Norzyme|Pancreatic Enzymes - Norzyme (Bergamo)
3226151|NCT01012908|Active Comparator|Creon (Solvay)|Pancreatic Enzymes - Creon (Solvay)
3226152|NCT01012895|Experimental|Arm 1: Sentinel A|BMS-790052 (60mg) once daily + BMS-650032 (600 mg) twice daily
3226153|NCT01012895|Experimental|Arm 2: Sentinel B|BMS-790052 (60mg) once daily + BMS-650032 (600mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
3226154|NCT01012895|Experimental|Arm 3: Expansion A1|BMS-790052 (60mg) once daily + BMS-650032 (200mg) twice daily
3226155|NCT01012895|Experimental|Arm 4: Expansion A2|BMS-790052 (60mg) once daily + BMS-650032 (200mg) once daily
3226156|NCT01012895|Experimental|Arm 5: Expansion B1|BMS-790052 (60mg) once daily + BMS-650032 (200 mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
3226157|NCT01012895|Experimental|Arm 6: Expansion B2|BMS-790052 (60mg) once daily + BMS-650032 (200 mg) once daily + Pegylated-interferon alfa-2a + Ribavirin
3226158|NCT01012895|Experimental|Arm 7: Expansion B3|BMS-790052 (60 mg) once daily + BMS-650032 (200 mg) twice daily + Ribavirin
3226159|NCT01012882|Experimental|sublingual application of allergen extract|
3226160|NCT01012882|Placebo Comparator|sublingual application of placebo|
3226161|NCT01012869|Experimental|everolimus-eluting stent|patients undergoing treatment of a coronary chronic total occlusion (at least 3-months old) using everolimus-eluting stents (Xience, Abbott Vascular) or Promus (Boston Scientific)
3226162|NCT01012856|Active Comparator|Cognitive-Behavioral Therapy for Depression (CBT)|
3226163|NCT01012856|Experimental|Exposure-Based Cognitive Therapy for Depression (EBCT)|
3226164|NCT01012843|Active Comparator|Antibiotic|Patients who received antibiotic treatment after abscess drainage
3226165|NCT01012843|Placebo Comparator|Placebo|Patients who received placebo after abscess drainage
3226166|NCT01012830|Experimental|Huperzine A|200 micrograms (mcg) of HuperzineA taken twice daily.
3226167|NCT01012817|Experimental|Treatment (veliparib and topotecan hydrochloride)|Patients receive veliparib PO on days 1-3, 8-10, and 15-17 (veliparib is omitted on days 1-3 of course 2) and topotecan hydrochloride IV over 30 minutes on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3226168|NCT01012791|Experimental|Zumba exercise group|
3226169|NCT01012791|No Intervention|Non-Zumba exercise group|
3226170|NCT01012778|Experimental|Climbup ADHD and Dyslexia Program|"Open label - intervention with pre and post parameters collected~Intervention: Yoga, Meditation, Play therapy for children with ADHD and Dyslexia twice a week in classroom with 6 week and 12 month, primary outcomes in terms of Vanderbilt ADHD scores"
3226171|NCT01012765|Experimental|Indacaterol - placebo - tiotropium|In treatment period 1, patients received indacaterol 150µg once daily; in treatment period 2, patients received placebo to indacaterol once daily; in treatment period 3, patients received tiotropium 18µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
3226172|NCT01012765|Experimental|Placebo - Tiotropium - Indacaterol|In treatment period 1, patients received placebo to indacaterol once daily; in treatment period 2, patients received tiotropium 18µg once daily; in treatment period 3, patients received indacaterol 150µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
3226187|NCT01012661|Experimental|Radiesse® Mixed with Lidocaine|Injectable Dermal Filler. The same 50 participants received both the treatment device and the control device at the same time (left and right sides of face).
3226173|NCT01012765|Experimental|Tiotropium - indacaterol - placebo|In treatment period 1, patients received tiotropium 18µg once daily; in treatment period 2, patients received indacaterol 150µg once daily; in treatment period 3, patients received placebo to indacaterol once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
3226174|NCT01012765|Experimental|Placebo - indacaterol - tiotropium|In treatment period 1, patients received placebo to indacaterol once daily; in treatment period 2, patients received indacaterol 150µg once daily; in treatment period 3, patients received tiotropium 18µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
3226175|NCT01012765|Experimental|Indacaterol - tiotropium - placebo|In treatment period 1, patients received indacaterol 150µg once daily; in treatment period 2, patients received tiotropium 18µg once daily; in treatment period 3, patients received placebo to indacaterol once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
3226176|NCT01012765|Experimental|Tiotropium - placebo - indacaterol|In treatment period 1, patients received tiotropium 18µg once daily; in treatment period 2, patients received placebo to indacaterol once daily; in treatment period 3, patients received indacaterol 150µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
3226177|NCT01012752|Active Comparator|modified allergen extract|
3226178|NCT01012752|Placebo Comparator|Placebo|
3226179|NCT01012739|Experimental|Indacaterol 150μg-placebo-Indacaterol 60μg-Indacaterol 120μg|In treatment period 1, patients received indacaterol 150 μg via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received placebo to indacaterol via the Concept1 DPI; in treatment period 3, patients received indacaterol 60 μg via the Simoon DPI; and in treatment period 4, patients received indacaterol 120 μg via the Simoon DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3226180|NCT01012739|Experimental|Indacaterol 60μg-Indacaterol 150μg-Indacaterol 120μg-placebo|In treatment period 1, patients received indacaterol 60 μg via the Simoon dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 150 μg via the Concept1 DPI; in treatment period 3, patients received indacaterol 120 μg via the Simoon DPI; and in treatment period 4, patients received placebo to indacaterol via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3226181|NCT01012739|Experimental|Indacaterol 120μg-Indacaterol 60μg-placebo-Indacaterol 150μg|In treatment period 1, patients received indacaterol 120 μg via the Simoon dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 60 μg via the Simoon DPI; in treatment period 3, patients received placebo to indacaterol via the Concept1 DPI; and in treatment period 4, patients received indacaterol 150 μg via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3226182|NCT01012739|Experimental|Placebo-Indacaterol 120μg- Indacaterol 150μg- Indacaterol 60μg|In treatment period 1, patients received placebo to indacaterol via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 120 μg via the Simoon DPI; in treatment period 3, patients received indacaterol 150 μg via the Concept1 DPI; and in treatment period 4, patients received indacaterol 60 μg via the Simoon DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3226183|NCT01012713|Experimental|Open-Label Treatment|All patients will receive treatment with Clobex Spray, Vectical Ointment, and Excimer Laser
3226184|NCT01012700|No Intervention|intranasal or IV|Each study group consists of 12 volunteers randomized in a 2:1 ratio to receive poly ICLC or placebo: in group 1, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, subcutaneously; and in group 2, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, intranasally. A total of up to 24 volunteers will be enrolled in the study.
3226185|NCT01012700|Active Comparator|Hiltonol (poly ICLC)|Each study group consists of 12 volunteers randomized in a 2:1 ratio to receive poly ICLC or placebo: in group 1, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, subcutaneously; and in group 2, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, intranasally. A total of up to 24 volunteers will be enrolled in the study.
3226186|NCT01012674|Experimental|Dotarem and TOF MRA|Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.
3226188|NCT01012661|Active Comparator|Radiesse® without Lidocaine|Injectable Dermal Filler. The same 50 participants received both the treatment device and the control device at the same time (left and right sides of face.
3226189|NCT01012635||Neurofeedback, tDCS (2 levels), Self-hypnosis, Meditation|
3226190|NCT01012622|Experimental|OROS Methylphenidate Hydrochloride|
3226191|NCT01012609|Experimental|pts with high-grade astrocytoma|This is a 2-group parallel (high-grade astrocytoma, diffuse pontine tumor), single stage study investigating cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan in pediatric and young adult patients. Optional exploratory components of the study include (1) correlation of tumor molecular markers with outcome, (2) CSF proteomics, and (3) assay of serum cytokine levels in patients who develop a cetuximab-associated rash.
3226192|NCT01012609|Experimental|pts with diffuse pontine tumor|This is a 2-group parallel (high-grade astrocytoma, diffuse pontine tumor), single stage study investigating cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan in pediatric and young adult patients. Optional exploratory components of the study include (1) correlation of tumor molecular markers with outcome, (2) CSF proteomics, and (3) assay of serum cytokine levels in patients who develop a cetuximab-associated rash.
3226193|NCT01012596||Creighton Model|New and return users of the Creighton Model FertilityCare System, a method of Natural Family Planning.
3226194|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 7.5 mcg H1N1v full MF59 adjuvant|
3226195|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 3.75 mcg H1N1v half MF59 adjuvant|
3226196|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 15 mcg H1N1v unadjuvanted|
3226197|NCT01012557|Active Comparator|Non-pregnant mothers, 7.5 mcg H1N1v full MF59 adjuvant|
3226198|NCT01012544|Active Comparator|stent thrombosis patients|Patients with a history of a stent thrombosis
3226199|NCT01012544|Active Comparator|Patients without a history of a stent thrombosis|Patients without a history of stent thrombosis
3226200|NCT01012531|Active Comparator|highly polymerized allergen extract|
3226201|NCT01012531|Placebo Comparator|Placebo|
3226202|NCT01012518|Active Comparator|Conventional PCT|PCT performed without video guidance, as conventionally performed
3226203|NCT01012518|Experimental|Video-assisted PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
3226204|NCT01012505||20 preterm infants|20 preterm infants without active disease
3226205|NCT01012492|Experimental|Abatacept|Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
3226206|NCT01012479|Experimental|Candesartan QD + Hydrochlorothiazide QD|
3226207|NCT01012453|No Intervention|Hand Eczema in health care workers|
3226208|NCT01012440|Experimental|Beast cancer subjects|Subject will have assessment of neoadjuvant chemotherapy treatment response by both MRI and PEM to compare methods
3226209|NCT01012427|Experimental|Patients with 3.0 cm or smaller renal cancer|The interventions in this study are part of clinical care and include percutaneous image-guided biopsy, percutaneous renal tumor cryoablation, CT/MR imaging of the ablation bed, and repeat pathologic sampling of the tumor bed with percutaneous biopsy. The cryoablation is done as the therapeutic intervention in patients with small renal cancer. The CT/MR imaging is done to evaluate the treatment for residual disease after the ablation. The repeat biopsy (e.g. three cores) is done to confirm that the neoplasm has been eradicated. These patients have continued imaging, and if necessary, percutaneous biopsy to ensure no recurrent disease.
3226210|NCT01012414|Experimental|oral paricalcitol 2 mcg daily|oral paricalcitol 2 mcg daily
3226211|NCT01012414|Placebo Comparator|Placebo|one oral placebo drug daily
3226212|NCT01012401|Experimental|CHESS with Clinician Report + Internet access|An Internet-based system, Comprehensive Health Enhancement Support System for Lung Cancer(CHESS-LC) integrates over 14 services to provide tailored cancer information, support, and interactive tools.
3226213|NCT01012401|Active Comparator|Usual care with Internet access|Control group patients will be given a list of URLs for 10-high quality lung cancer-related sites
3226214|NCT01012388|Experimental|Radiesse|
3226215|NCT01012375|Experimental|1|AZD1446 tid
3226216|NCT01012375|Experimental|2|AZD1446 tid
3226217|NCT01012375|Experimental|3|AZD1446 qd
3226218|NCT01012375|Placebo Comparator|4|Matching placebo capsule
3226219|NCT01012362|Experimental|Optimum Tolerated Dose Determination|"Patient receives assigned dose level:~Dose Level 1 = 400 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 2 = 400 milligrams (mg) of pazopanib and ixabepilone 40 mg/m2. Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 4 = 800 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2."
3226220|NCT01012362|Experimental|Optimum Tolerated Dose Confirmation|Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2.
3226221|NCT01012349|Experimental|Test|Administration of GeoLab Association (acetylsalicylic acid, sodium bicarbonate and citric acid)
3226222|NCT01012349|Active Comparator|Comparator|Acetylsalicylic acid - (Aspirin - Bayer)
3226223|NCT01012336|Experimental|Aprepitant|
3226224|NCT01012323|Experimental|NewGam|Participants received NewGam 200-800 mg/kg intravenously every 3 weeks (17 infusions) or 4 weeks (13 infusions) for 1 year.
3226225|NCT01012310|Experimental|Cohort 1|
3226226|NCT01012310|Experimental|Cohort 2|
3226227|NCT01012310|Experimental|Cohort 3|
3226228|NCT01012310|Experimental|Cohort 4|
3226229|NCT01012297|Experimental|Arm I Gem+Doce+Placebo|Patients receive a placebo IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim subcutaneously (SC) on days 9-15 or pegfilgrastim SC on day 9 or 10.
3226230|NCT01012297|Experimental|Arm II Gem+Doce+Bev|Patients receive bevacizumab IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10.
3226231|NCT01012284|Experimental|Panel A|8 patients with moderate hepatic impairment classified as moderate as per the Child Pugh Classification.
3226347|NCT01011452|Active Comparator|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
3226232|NCT01012284|Experimental|Panel B|8 healthy participants who will match to patients with hepatic impairment in Panel A with regards to sex, age (more or less to 5 years), and body mass index.
3226233|NCT01012258|Experimental|Cetuximab|All eligible subjects will receive cetuximab treatment only during week 1 of the treatment course and concomitant cetuximab and boost radiotherapy (RT) during week two to week seven of the treatment course
3226234|NCT01012245||patients with glaucoma and ocular hypertension|
3226235|NCT01012232|Active Comparator|low volume local anesthetic|bolus injection of local anesthetic in low volume/high concentration (10 mL, 10 mg/mL)
3226236|NCT01012232|Experimental|high volume local anesthetic|bolus injection of ropivacaine in high volume/low concentration (20 ml, 5 mg/mL)
3226237|NCT01012219|Experimental|Period 1|In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).
3226238|NCT01012219|Experimental|Period 2|In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).
3226239|NCT01012219|Experimental|Period 3|
3226240|NCT01012206|No Intervention|Control group|Children in control group obtained no lifestyle counseling (intervention).
3226241|NCT01012206|Active Comparator|Intervention group|Children in the intervention group and their parents were given lifestyle counseling and participated in an intervention program regarding food habits and physical activity.
3226242|NCT01012193|Active Comparator|adjunctive cilostazol|adjunctive cilostazol 100mg bid to dual antiplatelet therapy
3226243|NCT01012193|Active Comparator|high maintenance-dose clopidogrel|double dose of clopidogrel 150mg/day
3226244|NCT01012167|Active Comparator|1: galantamine/placebo-oxytocin|Subjects randomized to galantamine will receive galantamine and placebo-oxytocin
3226245|NCT01012167|Active Comparator|2: oxytocin/placebo-galantamine|Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine
3226246|NCT01012167|Placebo Comparator|3: placebo-galantamine /placebo-oxytocin|Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin
3226247|NCT01012154|Experimental|All patients|
3226248|NCT01012102|Experimental|Group 1|EMD 640744 30μg and Montanide® ISA 51 VG
3226249|NCT01012102|Experimental|Group 2|EMD 640744 100μg and Montanide® ISA 51 VG
3226250|NCT01012102|Experimental|Group 3|EMD 640744 300μg and Montanide® ISA 51 VG
3226251|NCT01012089|Experimental|Daptomycin|Pediatric patients on hemodialysis or peritoneal dialysis with suspected or confirmed infection and who were receiving standard of care antibiotics were also eligible to receive a single dose of daptomycin 5mg/kg IV. Serial blood draws were obtained to assess daptomycin pharmacokinetics
3226252|NCT01012076|Active Comparator|Active Control|The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning. Over the course of the intervention, parent and interventionist cover a hierarchy of intervention topics, aiming to improve the parent's ability to successfully promote the child's social and emotional competency.
3226253|NCT01012076|Experimental|Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). Over the course of the intervention, parent and interventionist cover a hierarchy of intervention topics, aiming to promote the ability of the parent-child dyad to successfully manage shared toy play.
3226254|NCT01012063|Experimental|group IE|The group IE received iron sucrose and erythropoietin-β (Epo-β) during the operation
3226255|NCT01012063|Placebo Comparator|group C|The group C received saline as same method.
3226256|NCT01012050|Experimental|NV Group|Performed nebulization coupled with noninvasive ventilation
3226257|NCT01012050|Active Comparator|NEB group|Performed nebulization alone.
3226258|NCT01012037|Experimental|linagliptin low dose|linagliptin low dose twice daily
3226259|NCT01012037|Placebo Comparator|placebo|placebo matching linagliptin
3226260|NCT01012037|Experimental|linagliptin medium dose|linagliptin medium dose once daily
3226261|NCT01012011||Group 1|
3226262|NCT01011985||AVF|Initial access is an AVF
3226263|NCT01011985||AVG|Initial vascular access is an AVG
3226264|NCT01011985||TC|Initial vascular access is a tunneled catheter, with or without a maturing AVF or AVG
3226265|NCT01011972|Experimental|XMT-1107|Dose escalation groups of XMT-1107, I.V. (in the arm) beginning at 6 mg/m^2, doubling in dose to 24 mg/m^2, then 40 mg/m^2, then 60 mg/m^2, then 80 mg/m^2 with subsequent doses at 33% of the previous until disease progression or unacceptable side effects are experienced.
3226266|NCT01011959|Active Comparator|1|dose 1 vs. placebo
3226267|NCT01011959|Active Comparator|2|dose 2 vs. placebo
3226268|NCT01011959|Active Comparator|3|dose 3 vs. placebo
3226269|NCT01011959|Active Comparator|4|dose 4 vs. placebo
3226270|NCT01011959|Active Comparator|5|dose 5 vs. placebo
3226271|NCT01011959|Active Comparator|6|dose 6 vs. placebo
3226272|NCT01011946|Experimental|Positron Emission Mammography|
3226273|NCT01011933|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Blood and archived tumor tissue samples are collected for biomarker studies.
3226274|NCT01011920|Experimental|MTX+ AraC|Arm A Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3
3226275|NCT01011920|Experimental|Ara-C +Rituximab|Arm B Rituximab 375 mg/m2 conventional infusion d -5 & 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3
3226276|NCT01011920|Experimental|Ara-C + rituximab+thiotepa|Arm C Rituximab 375 mg/m2 conventional infusion d -5 & 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3 Thiotepa 30 mg/m2 30 min. Infusion d 4
3226277|NCT01011920|Experimental|WBRT 36 Gy +/- boost 9 Gy|ARM D: WBRT with 36 Gy in the case of CR to primary chemotherapy or the same WBRT dose followed by a tumor-bed boost of 9 Gy with 1-2 cm of margin surrounding enhanced residual lesion (total tumor-bed dose 45 Gy) in patients who achieved a PR or SD after primary chemotherapy. Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions.
3226278|NCT01011920|Experimental|BCNU + Thiotepa + APBSCT|Arm E BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6 Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 & -4 Reinfusion of PBSC ≥5 x 106 CD34+ cells/kg day 0
3226279|NCT01011907|Experimental|varenicline|Drug: varenicline (Chantix) 12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
3226280|NCT01011907|Placebo Comparator|placebo|Drug: placebo for varenicline 12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
3226281|NCT01011894|Experimental|pts getting lenalidomide|Patients with intermediate or high-risk chronic lymphocytic leukemia (≥ 65 years old) will receive lenalidomide until disease progression at the 20mg dose level (recognizing that progression at this dose requires non-protocol alternate therapy) or unacceptable toxicity.
3226282|NCT01011881||patients with pleuritis|
3226283|NCT01011868|Experimental|BI 10773 low dose|Patients receive BI 10773 low dose daily
3226284|NCT01011868|Experimental|BI 10773 high dose|Patients receive BI 10773 high dose daily
3226285|NCT01011868|Placebo Comparator|placebo|Patients receive placebo to match BI 10773 daily
3226286|NCT01011855|Active Comparator|Radiant warmer bed sequence 1|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
3226287|NCT01011855|Active Comparator|Radiant warmer bed sequence 2|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
3226288|NCT01011855|Active Comparator|Radiant warmer bed sequence 3|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
3226289|NCT01011855|Active Comparator|Radiant warmer bed sequence 4|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
3226290|NCT01011855|Experimental|Radiant warmer bed sequence 5|Clinical care provided on three different types of cleared radiant warmer beds with infant temperature measurements taken for 20 hours on each of the three radiant warmer beds.
3226291|NCT01011855|Experimental|Radiant warmer bed sequence 6|Clinical care provided on three different types of cleared radiant warmer beds with infant temperature measurements taken for 20 hours on each of the three radiant warmer beds.
3226292|NCT01011842|Experimental|radiation therapy arm|
3226293|NCT01011829|Active Comparator|Varenicline|"Varenicline:~0.5 mg daily for days 1-3~0.5 mg twice daily for days 4-7~1 mg twice daily from day 8 until end of week 8."
3226294|NCT01011829|Placebo Comparator|Placebo|8 weeks of daily matching oral placebo in tablet form
3226295|NCT01011816|Experimental|BIOSTAT BIOLOGX|One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc
3226296|NCT01011816|Placebo Comparator|Saline|One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc
3226297|NCT01011803|Experimental|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were [diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
3226298|NCT01011790|Experimental|Stress Management Tool|All subjects will use the Healing Rhythms™ meditation program for 4 weeks.
3226299|NCT01011777|Experimental|Autologous Muscle Derived Cells|Surgeon will endoscopically inject previously harvested autologous muscle derived cells (MDC) into the same bladder exstrophy patient's urinary sphincter to improve outflow resistance and rhabdosphincter contractility. We will assess tolerability and induction of continence.
3226300|NCT01011764|Active Comparator|SKILLS group|The SKILLS intervention targets a specific set of social skills over 8 bi-weekly sessions. The intervention is delivered to a small group of children with autism at school during lunchtime. The content delivered to the group of young children with autism including lessons developed from a manual by Seattle Children's Hospital Research Foundation. Children are given weekly homework assignments to reinforce the topics discussed in the group sessions.
3226301|NCT01011764|Experimental|ENGAGE group|The ENGAGE intervention targets two social domains, and two learning contexts. The two social domains are peer acceptance and social engagement with peers. The social group will be small and include children with ASD as well as their typical peers. There will be a greater number of typical peers included to model social behaviors and foster friendships. The typical peers will be selected based on results from the friendship survey and teacher nominations. The two learning contexts are direct instruction in a group social skills format during lunchtime and individualized embedded generalization activities in the school day.
3226302|NCT01011751|Experimental|Cyproterone acetate|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, cyproterone acetate 50 mg, tablet-in-capsule, along with cyproterone acetate placebo-matching capsule, orally, once daily in the morning and cyproterone acetate 50 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Cyproterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks.
3226348|NCT01011452|Placebo Comparator|Placebo|
3226349|NCT01011439|Experimental|Milciclib Maleate (PHA-848125AC)|100 and 50 mg Capsule 150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle
3226350|NCT01011426|Active Comparator|Bisacodyl|
3226351|NCT01011426|Placebo Comparator|empty opague capsule|
3226405|NCT01011062|Experimental|Losartan + hyperinsulinaemia|
3226303|NCT01011751|Experimental|Medroxyprogesterone acetate|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, medroxyprogesterone acetate 10 mg, tablet-in-capsule, along with medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning and medroxyprogesterone acetate 10 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks.
3226304|NCT01011751|Experimental|Venlafaxine|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, venlafaxine 75 mg, capsule, orally, once daily in the morning and venlafaxine placebo-matching capsule, orally, once daily in the evening for 8 weeks. Venlafaxine 37.5 mg, capsule, orally, once daily in the evening for the next 2 weeks.
3226305|NCT01011738||Cohort|
3226306|NCT01011725|Experimental|Postmenopausal Women- Active Agent Group|
3226307|NCT01011725|Placebo Comparator|Postmenopausal Women- Placebo|Placebo
3226308|NCT01011699|Active Comparator|sevelamer|"Titration phase with sevelamer (Renagel) with the aim of phosphatemia control in 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week)."
3226309|NCT01011699|Active Comparator|nicotinamide|"Titration phase with nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of nicotinamide dose up to 4 tablets, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week)."
3226310|NCT01011686|Experimental|ANT-SM|autologous adipose-derived stem cell
3226311|NCT01011673|Active Comparator|Ketorolac|Ketorolac 30mg IVSS
3226312|NCT01011673|Active Comparator|Metoclopramide|metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
3226313|NCT01011660|Active Comparator|A,1,IV|A means active; 1 means Amlodipine+Amiloride Compound; IV means phase IV
3226314|NCT01011660|Active Comparator|A,2,IV|A means active; 2 means Amlodipine+Telmisartan; IV means phase IV
3226315|NCT01011660|Active Comparator|A,3,IV|A means active; 3 means Amlodipine+Amiloride Compound with or no Simvastatin; IV means phase IV
3226316|NCT01011660|Active Comparator|A,4,IV|A means active; 4 means Amlodipine+Telmisartan with or no Simvastatin; IV means phase IV
3226317|NCT01011647||Acute coronary conditions|"Patients hospitalized with the following conditions~Unstable angina~Acute myocardial infarction~Congestive heart failure"
3226318|NCT01011634|Active Comparator|Moderate sedation|
3226319|NCT01011634|Active Comparator|Oral medication|
3226320|NCT01011621|Experimental|0.5% prednisolone acetate cream|
3226321|NCT01011621|Active Comparator|0.1% betamethasone valerate cream|
3226322|NCT01011608|Experimental|Medical Food Supplement|Medical food supplement to be given in divided portions in morning, afternoon and evening
3226323|NCT01011608|Active Comparator|standard hospital food|standard hospital diet
3226324|NCT01011582||Novel H1N1 influenza|
3226325|NCT01011582||Seasonal influenza|
3226326|NCT01011569||cage|patient who underwent stand alone cage insertion after discectomy
3226327|NCT01011569||plate|patient who underwent plate fixation and autologous ilia bone graft after discectomy
3226328|NCT01011556|Active Comparator|20 mcg Subcutaneous Teriparatide|Received 20 micrograms (mcg) subcutaneously once daily in an unblinded manner.
3226329|NCT01011556|Experimental|30 mcg Transdermal Teriparatide|Received 30 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
3226330|NCT01011556|Experimental|50 mcg Transdermal Teriparatide|Received 50 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
3226331|NCT01011556|Experimental|80 mcg Transdermal Teriparatide|Received 80 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
3226332|NCT01011543|Active Comparator|Endoscopic approach|CT thorax is done in all patients to localize the exact anatomical site of the disease. This evaluation is followed by fluoroscopy-guided bronchoscopy for BAL (bronchoalveolar lavage) and TBB (transbronchial biopsies). A sputum sample immediately after the endoscopy will be collected if possible.
3226333|NCT01011543|Active Comparator|Induced sputum|Sputum induction after administration of 6-8 mL 3% NaCl aerosol by an ultrasonic nebulizer; sputum will be collected 15-30 minutes after administration of the aerosol. This process will be done twice in every patient.
3226334|NCT01011530|Experimental|MLN4924|MLN4924 via IV infusion
3226335|NCT01011517|Experimental|grape seed supplement|Nature's Pearl 650 mg, two capsules daily
3226336|NCT01011517|Placebo Comparator|placebo|placebo
3226337|NCT01011491|Experimental|Medifast 5 & 1 Plan|Medifast's 5 & 1 Plan is a meal replacement plan for weight loss and weight maintenance.
3226338|NCT01011491|Active Comparator|Food-based|The food-based arm followed a meal plan of self-selected foods that provided the same number of calories as the Medifast 5 & 1 plan.
3226339|NCT01011478|Placebo Comparator|Group 1: placebo|Patients receive oral placebo once daily for 5 years.
3226340|NCT01011478|Experimental|Group 2: rosuvastatin|Patients receive oral rosuvastatin once daily for 5 years.
3226341|NCT01011465|Experimental|Oxytocin|One primary experimental manipulation is the receipt of intranasal oxytocin vs placebo spray prior to participation in a psychosocial stress protocol
3226342|NCT01011465|Placebo Comparator|Placebo|The comparison condition for receipt of oxytocin is receipt of a saline intranasal spray
3226343|NCT01011465|Experimental|Social Support|Participants bring a friend to the laboratory who sits with them while they engage in the stress protocol tasks
3226344|NCT01011465|Placebo Comparator|No Social Support|Individuals in this condition do not have a friend present while they are engaging in the laboratory protocol.
3226345|NCT01011465|Other|Female Gender|Effects of oxytocin and social support are examined among women versus men
3226346|NCT01011465|Other|Male Gender|Consider effects of oxytocin and social support in men versus women
3226352|NCT01011413|Active Comparator|600mg Efavirenz|Eligible patients will be centrally randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
3226353|NCT01011413|Experimental|400mg Efavirenz|Eligible patients will be centrally randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
3226354|NCT01011387|Other|NPWT system|Negative pressure wound therapy
3226355|NCT01011348|Other|Placebo vs Q10 100mg vs Q10 300mg|
3226356|NCT01011348|Other|Q10 100mg vs Placebo vs Q10 300mg|
3226357|NCT01011348|Other|Placebo vs. Q10 300mg vs. Q10 100mg|
3226358|NCT01011348|Other|Q10 300mg vs. Placebo vs. Q10 100mg|
3226359|NCT01011335|Experimental|Active Vaccine|Monovalent rAT or Monovalent rLukS-PV or Bivalent rLukS-PV / rAT
3226360|NCT01011335|Placebo Comparator|Placebo with Alum|
3226361|NCT01011335|Placebo Comparator|Saline Placebo|
3226362|NCT01011322|Experimental|LT-02 Dose 1|0.2g IMP per dose
3226363|NCT01011322|Experimental|LT-02 Dose 2|0.4g IMP per dose
3226364|NCT01011322|Experimental|LT-02 Dose 3|0.8g IMP per dose
3226365|NCT01011322|Placebo Comparator|Sugar pill|placebo matching to 0g of IMP,
3226366|NCT01011309|Experimental|LEISH-F2 + MPL-SE vaccine|Recombinant three antigen Leishmania polyprotein + MPL-SE adjuvant
3226367|NCT01011309|Active Comparator|Sodium stibogluconate (SSG)|20 mg/kg/day IV for 20 days
3226368|NCT01011296|Experimental|Single IV Dose 1|
3226369|NCT01011296|Experimental|Single IV Dose 2|
3226370|NCT01011296|Experimental|Single IV Dose 3|
3226371|NCT01011283|Active Comparator|1|
3226372|NCT01011283|Active Comparator|2|
3226373|NCT01011270||Back pain|The aim of this study was to investigate the effect of rehabilitation of the dynamic ;(RDM) in balance and balance of industrial operators. The sample consisted of industrial operators, individuals with low back pain, referred to the industry of Physical Therapy
3226374|NCT01011270||Balance|the treatment with RDM reflected in significant improvement in back pain and postural balance of industrial operators.
3226375|NCT01011257|Active Comparator|Aspirin 81 mg, 1 tab twice daily|All participants to take one aspirin (81mg per tab) twice daily.
3226376|NCT01011257|Active Comparator|Clopidogrel 75 mg 1 tab daily|Only stable CAD participants will take Clopidogrel (75mg per tab) daily.
3226377|NCT01011244|Experimental|ADIPOPLUS|patients with a fistula in Crohn's disease
3226378|NCT01011218|Experimental|Brief Behavioral Therapy for Insomnia (BBT-I)|2 Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone
3226379|NCT01011218|Experimental|Armodafinil|150 mg once a day
3226380|NCT01011218|Experimental|BBT-I + Armodafinil|2 BBT-I sessions in person and additional brief BBT-I sessions over the phone + 150 mg Armodafinil once a day
3226381|NCT01011218|Placebo Comparator|Placebo|Placebo for Armodafinil
3226382|NCT01011205|Experimental|Dosing Regimen 1|Advagraf + MMF + Corticosteroids (Bolus)
3226383|NCT01011205|Experimental|Dosing Regimen 2|Advagraf + MMF + Basiliximab + Corticosteroids (Bolus)
3226384|NCT01011205|Experimental|Dosing Regimen 3|Advagraf (5 days delay) + MMF + Basiliximab + Corticosteroids (Bolus)
3226385|NCT01011192||ke0 of 0.26 min-1|Individual volunteers using Marsh's pharmacokinetic target-controlled infusion model with ke0 of 0.26 min-1 (Asena PK® - Cardinal Health)
3226386|NCT01011192||ke0 of 1.21 min-1|Individual volunteers using Marsh's pharmacokinetic target-controlled infusion model with ke0 of 1.21 min-1 (Primea Orchestra® - Fresenius-Kabi basis)
3226387|NCT01011179|Experimental|Internet-based JIA Self-Management Program|
3226388|NCT01011179|Active Comparator|Attention Control Group|
3226389|NCT01011166|Experimental|IDX184 50 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 50 mg or placebo once daily (QD) in combination with Peg-IFN/RBV on Days 14-28 and Peg-IFN/RBV on Days 14-28.
3226390|NCT01011166|Experimental|IDX184 100 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 50 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV alone on Days 14-28.
3226391|NCT01011166|Experimental|IDX184 100 mg BID + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 100 mg or placebo twice daily (BID) in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV alone on Days 14-28.
3226392|NCT01011166|Experimental|IDX184 150 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 150 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
3226393|NCT01011166|Experimental|IDX184 200 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 100 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
3226394|NCT01011166|Experimental|IDX184 200 mg BID + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 200 mg or placebo BID in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
3226395|NCT01011153||All Dermatologists|
3226396|NCT01011140||Online Survey|Survey of Palliative care physicians from Latin America and Spain
3226397|NCT01011127||pravastatin|
3226398|NCT01011127||rosuvastatin|
3226399|NCT01011114|Active Comparator|Cincalcet|cinacalcet will be titrated as needed to achieve serum phosphorus of > 2.5 mg/dl randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at ~ 2.5 mg/l.
3226400|NCT01011114|Placebo Comparator|Control|"subjects will receive placebo pill titrated as needed to achieve phosphorus > 2.5 mg/dl.~randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at ~ 2.5 mEq/l."
3226401|NCT01011088||Early phase|Psychoses within the first 3 months after baby born
3226402|NCT01011088||Delayed phase|Psychoses > 3 months to one year after baby born
3226403|NCT01011075|Experimental|Imatinib mesylate + Paclitaxel|Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses bracketing each paclitaxel infusion (days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
3226850|NCT01007851|Experimental|GnRH agonist|
3226406|NCT01011062|Placebo Comparator|Saline|Infusion of Saline as a volume control intervention
3226407|NCT01011049|Experimental|Group 1: Fluzone ID After Fluzone ID|Participants will receive Fluzone intradermal (ID) following Fluzone ID in Study FID31
3226408|NCT01011049|Experimental|Group 2: Fluzone IM After Fluzone ID|Participants will receive Fluzone intramuscular (IM) following Fluzone ID in Study FID31
3226409|NCT01011049|Experimental|Group 3: Fluzone IM After Fluzone IM|Participants will receive Fluzone intramuscular (IM) following Fluzone IM in Study FID31
3226410|NCT01011049|Experimental|Group 4: Fluzone ID After Fluzone IM|Participants will receive Fluzone intradermal (ID) following Fluzone intramuscular (IM) in Study FID31
3226411|NCT01011036|Other|1|
3226412|NCT01011036|Other|2|
3226413|NCT01011036|Other|3|
3226414|NCT01011023|Experimental|WITHOUT NASOGASTRIC TUBE|1. Experimental group (EG): without NGT, by removing the NGT at the end of the surgery, once the stomach had been aspirated,
3226415|NCT01011023|Active Comparator|WITH NASOGASTRIC TUBE|2. Control group (CG): with NGT, with radiographic corroboration of correct placement after the surgery. Both groups were given: 5-day fasting because it was the therapeutic gold standard at our hospital and our country, intravenous solutions and antibiotics for 5 days, ranitidine, and analgesics, without use of any antiemetic drug. Once the fasting period ended, in the CG the NGT was clamped and withdrawn, and in both groups oral fluids and diet were started. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
3226416|NCT01011010|Other|Single Arm|Single Arm Trial
3226417|NCT01010997||Dry AMD|Intermediate AMD subjects
3226418|NCT01010997||Wet - treated AMD|AMD subjects under treatments
3226419|NCT01010984|Experimental|Transcatheter Arterial Chemoembolization|TACE using LC beads loaded with Doxorubicin
3226420|NCT01010971|Experimental|Ciclesonide HFA Nasal Aerosol 160 μg|160 μg once daily
3226421|NCT01010971|Experimental|Ciclesonide HFA Nasal Aerosol 80 μg|80 μg once daily
3226422|NCT01010971|Placebo Comparator|Placebo|Placebo
3226423|NCT01010958|Experimental|Valproate|Valproic Acid taken orally, daily to reach serum levels between 50 to 100 µg/mL.
3226424|NCT01010945|Experimental|erlotinib, gemcitabine, nab-paclitaxel|
3226425|NCT01010932|Experimental|Dotarem and TOF MRA|Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.
3226426|NCT01010906|Experimental|Mild Hepatic Insufficiency (HI)|Participants with mild hepatic insufficiency (HI) administered a single 300 mg oral tablet of vaniprevir
3226427|NCT01010906|Experimental|Healthy Control to Mild HI|Healthy, matched to mild HI, control participants administered a single 300 mg oral tablet of vaniprevir
3226428|NCT01010906|Experimental|Moderate HI|Participants with moderate HI administered a single 300 mg oral tablet of vaniprevir
3226429|NCT01010906|Experimental|Healthy Control to Moderate HI|Healthy, matched to moderate HI, control participants administered a single 300 mg oral tablet of vaniprevir
3226430|NCT01010906|Experimental|Severe HI|Participants with severe HI administered a single 200 mg oral tablet of vaniprevir
3226431|NCT01010906|Experimental|Healthy Control to Severe HI|Healthy, matched to severe HI, control participants administered a single 200 mg oral tablet of vaniprevir
3226432|NCT01010893|Experimental|Influenza vaccination|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose).
3226433|NCT01010893|Experimental|Influenza vaccination and co-vaccination|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).
3226434|NCT01010867|Experimental|Lactobacillus plantarum|There is a single intervention arm in this study. Target accrual for the intervention is 30 subjects. Subjects receive supplementation with Lactobacillus plantarum strains 299 and 299v.
3226435|NCT01010854|Experimental|VPA FEC100|Valproic Acid with FEC100
3226436|NCT01010841|Active Comparator|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
3226437|NCT01010841|Experimental|Low-glycemic-load diet + medical food|Modified Mediterranean-style, low-glycemic-load diet + medical food
3226438|NCT01010828|Active Comparator|Tri-Vector Approach|
3226439|NCT01010828|Experimental|Mini Mid-Vastus Approach|
3226440|NCT01010815||UC group|clinically and microscopically confirmed UC patients between the age of 19 and 75 years
3226441|NCT01010815||Control group|normal healthy controls
3226442|NCT01010802|Experimental|Erythropoietin|"There are evidences of neuroprotecting therapeutic alternatives in such substances as erythropoietin (EPO) which is a well-known cytokine as a hematopoietic growth factor, so, it is therefore important to control tissular oxygenation. It is considered that EPO protects the neurons by a combination of several mechanisms.~EPOrh is used with high effectiveness in the treatment of anemias with deficiency of erythropoietin."
3226443|NCT01010789|Experimental|Armodafinil|Flexible dose 150-250mg/day
3226444|NCT01010789|Placebo Comparator|Mathing Placebo|
3226445|NCT01010776|Experimental|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 milligram (mg) will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
3226446|NCT01010763|Experimental|M2a Magnum|Total HIp Arthroplasty using with the M2a Magnum Large Metal Articulation is an ultra-high performance metal-on-metal articulation with a big ball (greater than or equal to 38mm) in acetabulums as small as 44mm.
3226447|NCT01010763|Active Comparator|M2a Taper|Total Hip Arthroplasty using with the M2a Taper Acetabular System consists of a titanium outer shell with cobalt chromium (Co-Cr-Mo) metallic liner, which articulates with with a cobalt chromium (Co-Cr-Mo) modular femoral head.
3226448|NCT01010750|Active Comparator|LDX + MAS-IR Placebo|Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
3226449|NCT01010750|Active Comparator|MAS-IR + LDX Placebo|Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
3226450|NCT01010750|Placebo Comparator|Placebo|Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
3226451|NCT01010737|Experimental|Multimeric-001 250 mcg|250mcg of Multimeric-001 was administered twice at an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
3226452|NCT01010737|Active Comparator|Adjuvant: Montonide isa 51 VG|Adjuvanted PBS was administered twice with a 19-23 day interval via the IM route to 10 participants and then a TIV boost was administered.
3226453|NCT01010737|Active Comparator|Placebo|PBS was administered twice with a 19-23 day interval via the IM route to 10 participants and then a TIV boost was administered.
3226454|NCT01010737|Experimental|Multimeric-001 500 mcg|500mcg of M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
3226455|NCT01010737|Experimental|Adjuvanted Multimeric-001 500mcg|5000mcg of Adjuvanted M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
3226456|NCT01010737|Experimental|Adjuvanted Multimeric-001 250mcg|250mcg of Adjuvanted M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
3226457|NCT01010724|Experimental|bIAP|Dosage 200 IU bIAP/kg: 1000 IU prior to anaesthesia administered as a bolus followed by intravenous continuous infusion of 5,6 IU/kg/hr for approximately 36 hours.
3226458|NCT01010724|Placebo Comparator|Placebo|
3226459|NCT01010711|Other|migraine dietary supplement|"the average days of migraine during a 4 week-run-in-period are compared with the average days of migraine during intervention with a specific dietary supplement from week 8 - 12"
3226460|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 1|formulation 1
3226461|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 2|formulation 2
3226462|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 3|formulation 3
3226463|NCT01010698|Active Comparator|cimetidine (or acyclovir) reference|reference product
3226464|NCT01010672|Experimental|Ridaforolimus 40 mg|
3226465|NCT01010659|Experimental|Lacrimal Tube|Dacryocystorhinostomy with silicone lacrimal intubation
3226466|NCT01010646|Experimental|GP1N IFN alfa-2bXL 27 MUI + Ribavirin|IFN alfa-2bXL 27 MUI, powder and solvent for solution injection
3226467|NCT01010646|Experimental|GP2N IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI, powder and solvent for solution injection
3226468|NCT01010646|Active Comparator|GP3N IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg,administered once a week for 12 weeks by subcutaneous injections
3226469|NCT01010633|Experimental|Loteprednol Etabonate|Loteprednol etabonate
3226470|NCT01010633|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate
3226471|NCT01010620||Screening|Screening Assessment battery. Specific to study(or studies) the individual is screening for.
3226472|NCT01010607|Experimental|Vibraton Mirror (VM)|subjects will receive tendon vibration AND mirror therapy
3226473|NCT01010607|Active Comparator|Mirror (M)|Subjects will receive treatment only with Mirror, together with sham vibration (over bone instead of tendon)
3226474|NCT01010607|Sham Comparator|Sham (S)|Opaque board instead of mirror, bone vibration instead of tendon vibration
3226475|NCT01010594|Active Comparator|Fruit restricted|Type 2 diabetics are advised to restrict their fruit intake to two pieces or less daily.
3226476|NCT01010594|Active Comparator|Fruit ad libitum|Type 2 diabetics are advised to eat at least two pieces of fruits daily
3226477|NCT01010581|Experimental|SC12267 (4SC-101) + Methotrexate|
3226478|NCT01010581|Placebo Comparator|Placebo + Methotrexate|
3226479|NCT01010568|Experimental|Ofatumumab and Bendamustine|Ofatumumab and Bendamustine
3226480|NCT01010555|Active Comparator|lotrafilcon B|Lotrafilcon B contact lens randomly assigned to one eye, with balafilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear senofilcon A contact lens randomly assigned to one eye and enfilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
3226481|NCT01010555|Active Comparator|balafilcon A|Balafilcon A contact lens randomly assigned to one eye, with lotrafilcon B contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear senofilcon A contact lens randomly assigned to one eye and enfilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
3226482|NCT01010555|Active Comparator|senofilcon A|Senofilcon A contact lens randomly assigned to one eye, with enfilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear lotrafilcon B contact lens randomly assigned to one eye and balafilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
3226483|NCT01010555|Active Comparator|enfilcon A|Enfilcon A contact lens randomly assigned to one eye, with senofilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear lotrafilcon B contact lens randomly assigned to one eye and balafilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
3226484|NCT01010542|Active Comparator|ILV-095|
3226485|NCT01010542|Placebo Comparator|placebo|
3226486|NCT01010529|Experimental|occupational therapy|
3226487|NCT01010529|No Intervention|No occupational therapy|Patients and their caregivers in the control group will have no occupational therapy intervention until their last measurement has taken place (3 months).
3226488|NCT01010516|Active Comparator|High-dose rosuvastatin|40 mg of rosuvastatin
3226489|NCT01010516|Active Comparator|Stain plus fenofibrate|existing statin plus micronized fenofibrate 200 mg
3226490|NCT01010516|Active Comparator|Statin plus niacin ER/laropiprant|existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
3226491|NCT01010503|Experimental|Single Arm|
3226492|NCT01010490|Experimental|Torsional ultrasound|Torsional ultrasound with the INFINITI phacoemulsification system (Alcon Lab, USA)
3226493|NCT01010490|Active Comparator|Longitudinal ultrasound (INFINITI)|Longitudinal ultrasound with the INFINITI phacomachine (Alcon Lab, USA)
3226494|NCT01010490|Active Comparator|Longitudinal ultrasound (LEGACY)|Longitudinal ultrasound with the LEGACY phacomachine (Alcon Lab, USA)
3226495|NCT01010477|Experimental|Nicotine Nasal Spray|Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. . Nasal spray will be used from the TQD through the end of Week 20.
3226496|NCT01010477|Placebo Comparator|Placebo nasal spray|Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Nasal spray will be used from the TQD through the end of Week 20.
3226497|NCT01010464|Experimental|Adhesion Reduction Plan|Lysis of adhesions and application of Seprafilm
3226498|NCT01010464|No Intervention|Standard Management|Standard management and no application of Seprafilm
3226499|NCT01010451|Experimental|Antimicrobial pulpotomy|Pulpotomy of primary molars with pulp inflammation or necrosis due to carious lesions using an antimicrobial paste
3226500|NCT01010451|Active Comparator|Calcium hydroxide pulpectomy|Pulpectomy of primary molars with pulp inflammation or necrosis due to carious lesions using a calcium hydroxide paste as intracanal medication
3226501|NCT01010438||Adults|Adult patients referred for sleep studies, including both patients with suspected OSA and patients that have been invited to a sleep lab for reasons not related to OSA such as insomnia, para-insomnia and similar.
3226502|NCT01010438||Children (1-17)|Pediatric patients referred for sleep studies, including both patients with suspected OSA and patients that have been invited to a sleep lab for reasons not related to OSA such as insomnia, para-insomnia and similar.
3226503|NCT01010425|Experimental|ACP-001, dose-level 1|
3226504|NCT01010425|Experimental|ACP-001, dose-level 2|
3226505|NCT01010425|Experimental|ACP-001, dose-level 3|
3226506|NCT01010425|Experimental|ACP-001, dose-level 4|
3226507|NCT01010412|Experimental|Ultrasound|Ultrasound guided nerve localization through direct visualization of the nerves and surrounding structures.
3226508|NCT01010412|Active Comparator|Nerve Stimulation|Standard of Care
3226509|NCT01010399|Experimental|Boosted Lexiva with Lovaza|
3226510|NCT01010386|Placebo Comparator|atmospheric (20%) oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
3226511|NCT01010386|Active Comparator|physiologic (5%) oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
3226512|NCT01010373|Experimental|AS101 infusions|In addition to induction chemotherapy AS101 will be given intravenously. The patient will also receive AS101 infusions during the time break till the next chemotherapy course, as long as the patient does not achieve complete remission and the platelet count is <20,000/μl; ANC <1000. AS101 will be administered likewise up to two consolidation or equivalent chemotherapy courses (re-induction or salvage in the event that no CR is achieved following first induction chemotherapy), i.e., total of three chemotherapy courses.
3226513|NCT01010347|Active Comparator|Splint|Preformed velcro volar splints are compared to traditional circumferential casting.
3226514|NCT01010347|Placebo Comparator|Cast|The circumferential cast is the standard of treatment against which the splint is compared.
3226515|NCT01010334|Active Comparator|Arm 1|Standard of Care Treatment
3226516|NCT01010334|Experimental|Arm 2|Treatment Arm of a separate protocol (physician discretion)
3226517|NCT01010321||all study Population|all
3226518|NCT01010308|Experimental|Intervention Group:|"The patients in this study are infants aged 1 month to 1 year of age with head and neck hemangiomas currently causing /or with impending function loss (e.g. vision, airway obstruction, feeding, etc), or hemangiomas currently causing/or with potential for facial disfigurement~Infants aged 1 month to 1 year of age with head and neck hemangiomas that received treatment with systemic propranolol in the past 2 years as a control group"
3226519|NCT01010308|No Intervention|Historical control group|Ten infants (1-12 months of age) treated with propranolol will be identified from a Dermatology Database. Patients will be considered as controls if they were treated with propranolol before 1 year of age and had digital photography documentation of their hemangioma.
3226520|NCT01010308|No Intervention|Angiogenesis marker control group|The angiogenesis marker control group will consist of 6 -10 patients seen in the Dermatology clinic for conditions other than IH and not receiving corticosteroids or beta blockers.
3226521|NCT01010295|Experimental|doxycycline|doxycycline 100 mg twice daily for 3 weeks
3226522|NCT01010282|Active Comparator|Glycerin and Polysorbate 80 based artificial tear|Glycerin and Polysorbate 80 based artificial tear
3226523|NCT01010282|Experimental|Artificial Tears Formulation 1|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear
3226524|NCT01010282|Experimental|Artificial Tears Formulation 2|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear
3226525|NCT01010269|Active Comparator|Vanguard Complete Knee|Vanguard Completed Knee with Microplasty Tibial Tray is designed to hold the tibial knee bearings in a microplsty knee procedure. The Co-Cro-Mo trays are designed with a shorter stem.
3226526|NCT01010269|Active Comparator|Vanguard High Flex RP|VGRD High Flex RP knee is an extension to the exsting Vanguard Knee and has been specifically desinged to facilitate greather than 135 degrees of knee flextion as required by certain patients.
3226527|NCT01010256||Subjects diagnosed with CMML|Subjects ages 18 and older with a CMML diagnosis based on the WHO 2009 criteria, and who have signed an informed consent are eligible to participate in the study population of this clinical trial. A total of 12 patients will be consented.
3226528|NCT01010256||Control Group|The control group will consist of subjects ages 18 years or older who are healthy (i.e. no hematologic disorders) and have signed an informed consent. A total of 10 healthy control subjects will be consented.
3226529|NCT01010230|Placebo Comparator|LMHF mechanical stimulation placebo device|The placebo device is identical in appearance and function to the active platform; except when activated, it emits the same sound as the active device but does not deliver the vibration.
3226851|NCT01007851|Placebo Comparator|Saline|
3226530|NCT01010230|Active Comparator|LMHF mechanical stimulation|"Low magnitude, high frequency mechanical stimulation device (vibrating) platform"
3226531|NCT01010217|Experimental|Haploidentical related|Arm 1 - Stem Cell Transplantation (SCT), Melphalan 140 mg/m^2 , Thiotepa 5 mg/kg, Fludarabine 40 mg/m^2 + high-dose post-transplant cyclophosphamide 50 mg/kg/day
3226532|NCT01010217|Experimental|1 Antigen Mismatch Related or Unrelated|Arm 2 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide.
3226533|NCT01010217|Experimental|Matched Unrelated Donor (MUD)|Arm 3 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide
3226534|NCT01010204|Experimental|Varenicline|We will be comparing Varenicline to placebo in a double-blind placebo controlled, randomized study.
3226535|NCT01010204|Placebo Comparator|Placebo|We will be using placebo in a randomized, controlled, and blinded trial to compare to varenicline in subjects with bipolar disorder.
3226536|NCT01010191|Experimental|Cellulose pill|The active intervention is a sugar pill.
3226537|NCT01010191|No Intervention|No treatment|The control arm is wait list control
3226538|NCT01010178|Experimental|Macrolid, Theophylline, Corticosteroids|Approved drug in this setting
3226539|NCT01010165||septic arthritis|
3226540|NCT01010165||crystal arthritis|
3226541|NCT01010165||rheumatismal disease|
3226542|NCT01010152|Experimental|Codeine Sulfate|30 mg tablet
3226543|NCT01010152|Active Comparator|Tylenol #3|30 mg tablet
3226544|NCT01010126|Experimental|Treatment (temsirolimus, bevacizumab)|Patients receive temsirolimus IV on days 1, 8, 15, and 22, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3226545|NCT01010113|Placebo Comparator|Test formula 1|Standard formula with prebiotics
3226546|NCT01010113|Experimental|test product|Infant formula with synbiotics
3226547|NCT01010100|Experimental|Arm 1|
3226548|NCT01010100|Placebo Comparator|Arm 2|
3226549|NCT01010087|Active Comparator|Standard Oseltamivir dose 75 mg bid|Standard dosing
3226550|NCT01010087|Experimental|High Dose Oseltamivir arm 225mg bid|High dose arm of the study
3226551|NCT01010061|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
3226552|NCT01010061|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
3226553|NCT01010061|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
3226554|NCT01010048|Experimental|progesterone,tamsulosin,propantheline Bromide and nifedipine|different effect of these drugs use to treat urinary calculus after ESWL
3226555|NCT01010035||type 2 diabetes|patients with diagnosis of Type 2 diabetes mellitus
3226556|NCT01010035||Control|non type 2 diabetes mellitus
3226557|NCT01010022|Experimental|1|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
3226558|NCT01010022|Active Comparator|2|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
3226559|NCT01010009|Experimental|Resveratrol 250mg|
3226560|NCT01010009|Experimental|Resveratrol 500mg|
3226561|NCT01010009|Placebo Comparator|Placebo|
3226562|NCT01009996||Coronary bifurcation lesions|
3226563|NCT01009983|Experimental|Arm 1|Patients receive paclitaxel IV and carboplatin IV on days 1, 8, and 15. Patients also receive panitumumab IV on days 1 and 15.
3226564|NCT01009970|Experimental|1|R-COMP
3226565|NCT01009957|Experimental|Everolimus|Everolimus + standard therapy for CKD
3226566|NCT01009957|No Intervention|Control|Standard therapy for CKD
3226567|NCT01009944|Experimental|Lisinopril, Atenolol|
3226568|NCT01009931|Experimental|TPA + Dexamethasone and CMT|12-O-tetradecanoylphorbol-13-acetate (TPA) plus Dexamethasone & Choline magnesium trisalicylate (Trilisate)
3226569|NCT01009918|Experimental|Arm I lisinopril|Patients receive oral lisinopril once daily.
3226570|NCT01009918|Experimental|Arm II Coreg CR®|Patients receive oral Coreg CR® once daily.
3226571|NCT01009918|Placebo Comparator|Arm III placebo|Patients receive oral placebo once daily.
3226572|NCT01009905||A|
3226573|NCT01009892|Active Comparator|Codeine Sulfate, 30 mg|tablet
3226574|NCT01009892|Active Comparator|Codeine Sulfate, 60 mg|tablet
3226575|NCT01009892|Active Comparator|Codeine Sulfate, 15 mg|tablet
3226576|NCT01009879|Experimental|Etanercept|
3226577|NCT01009866|Experimental|MR1-1|All subjects are enrolled onto this arm. All subjects will receive MR1-1.
3226578|NCT01009840|Experimental|IV busulfan|Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.
3226579|NCT01009827||AMTU Clients|All HIV-infected adolescents and young adults engaged in care at the 15 sites and their affiliates who are between 12 and 24 years of age, inclusive, are aware of their HIV status and understand written and/or verbal English will be eligible for inclusion in the study. In addition, new patients who have their initial clinic visit within the enrollment period will also be eligible for participation.
3226580|NCT01009814|Experimental|Group 1|BMS-663068 and ritonavir
3226581|NCT01009814|Experimental|Group 2|BMS-663068 and ritonavir
3226582|NCT01009814|Experimental|Group 3|BMS-663068 and ritonavir
3226583|NCT01009814|Experimental|Group 4|BMS-663068 and ritonavir
3226584|NCT01009814|Experimental|Group 5|BMS-663068
3226758|NCT01008475|Experimental|Safety part: EMD 525797 750 mg + SoC|EMD 525797 750 mg in combination with cetuximab and irinotecan
3226585|NCT01009801|Active Comparator|Arm I|Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
3226586|NCT01009801|Experimental|Arm II|Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
3226587|NCT01009788|Experimental|TMZ/ABT888|Combination therapy with temozolomide and veliparib
3226588|NCT01009775|Experimental|YM155 plus docetaxel|
3226589|NCT01009762|Placebo Comparator|Saline|Sterile saline for injection is used as placebo arm. It is administered i.m. in the same way as for the active vaccine, week 0, 2, 4, 8.
3226590|NCT01009762|Active Comparator|AFO-18 vaccine|the intervention is injection of the experimental therapeutic peptide vaccine (AFO-18) consisting of 18 peptides in CAF01 adjuvant intra muscularly (i.m.) week 0, 2, 4, 8
3226591|NCT01009749|Experimental|MESA|
3226592|NCT01009749|Active Comparator|MESH|
3226593|NCT01009684||DNG/EV|Users of the oral contraceptive containing Dienogest and Estradiol valerate
3226594|NCT01009684||Other OCs|Users of oral contraceptives (OCs) containing other progestins and estrogens
3226595|NCT01009671|Experimental|ART 44|Evaluation of safety and efficacy at D-8, D0, W2, W4 and W12
3226596|NCT01009671|Active Comparator|ART 50|Evaluation of safety and efficacy at D-8, D0, W2, W4 and W12
3226597|NCT01009658|Active Comparator|MSG first|
3226598|NCT01009658|Placebo Comparator|NaCl first|
3226599|NCT01009645|Experimental|Fact Only|The educational message used will contain facts only.
3226600|NCT01009645|Experimental|Fact and Myth|The educational material seen by this arm will contain facts and myths only.
3226601|NCT01009645|Experimental|Fact, Myth, Why|The educational material seen by this arm will contain myths, facts, and refutations of the myths.
3226602|NCT01009645|Placebo Comparator|Control|This arm will receive fact/myth educational materials originally developed and used by the CDC.
3226603|NCT01009632|Experimental|Voice rest|
3226604|NCT01009632|Experimental|Resonant voice exercise|
3226605|NCT01009632|Experimental|Spontaneous speech|
3226606|NCT01009619|Experimental|Azithromycin|250 mg daily for 5 days, followed by 250 mg three times a week (Mon.-Wed.-Fri.) until the end of study
3226607|NCT01009619|Placebo Comparator|Placebo|PLacebo daily for 5 days, followed by placebo three times a week (Mon.-Wed.-Fri.) until end of study.
3226608|NCT01009606|Active Comparator|Arm 1 : Control : usual strategy|
3226609|NCT01009606|Experimental|Arm 2: Comparator : modified strategy|
3226610|NCT01009593|Experimental|ABT-869|
3226611|NCT01009593|Active Comparator|Sorafenib|
3226612|NCT01009580|Experimental|IDegAsp BID|
3226613|NCT01009580|Experimental|BIAsp 30 BID|
3226614|NCT01009567|Sham Comparator|Control|Receive human albumin 20% infusion
3226615|NCT01009567|Experimental|Cabergoline|Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval
3226616|NCT01009554|Experimental|Potassium Oxylate|1.5% potassium oxalate sensitive mouthwash
3226617|NCT01009554|Active Comparator|Sodium Fluoride|Sodium Fluoride Dentifrice
3226618|NCT01009541|Experimental|Pregabalin controlled release, 82.5 mg|
3226619|NCT01009541|Experimental|Pregabalin controlled release, 165 mg|
3226620|NCT01009541|Experimental|Pregabalin controlled release, 330 mg|
3226621|NCT01009541|Other|Pregabalin immediate release, 150 mg|Reference Treatment
3226622|NCT01009528|Experimental|Intervention|Admission to electronic feedback system
3226623|NCT01009528|No Intervention|control|Control group. No special attention
3226624|NCT01009515|Experimental|Chemotherapy Combination|Chemotherapy Combination of paclitaxel, carboplatin, temozolomide: Carboplatin at an AUC of 5 on Day 1, paclitaxel at 175 mg/m2 on Day 1, and temozolomide at 125 mg/m2 Day 2-Day 6, on a 28 day cycle.
3226625|NCT01009502|Experimental|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
3226626|NCT01009476||001|
3226627|NCT01009476||002|
3226628|NCT01009463|Experimental|FF/GW642444 Inhalation Powder 100/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3226629|NCT01009463|Experimental|FF/GW642444 Inhalation Powder 200/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3226630|NCT01009463|Experimental|FF/GW642444 Inhalation Powder 50mcg/25mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3226631|NCT01009463|Experimental|GW642444 25mcg QD|Long Acting Beta Agonist(LABA)
3226632|NCT01009450|Active Comparator|LC was done using traditional method|LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
3226633|NCT01009450|Active Comparator|LC was done using harmonic ACE|LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
3226634|NCT01009437|Active Comparator|Control Arm - No Ritonavir|Five ER+, HER2- breast cancer patients meeting all study eligibility will be enrolled prior to the start of phase I recruitment to act as controls (no ritonavir will be given-will receive therapeutic conventional surgery) to confirm that anesthesia does not affect EET levels. Core biopsies, surgical tumor/normal tissue and pre- and post- surgery blood samples will be collected for comparison with the treatment group.
3226635|NCT01009437|Experimental|Ritonavir - Escalating Doses (I)|"Standard phase I dose escalation (with therapeutic conventional surgery) will be used with 3 levels of ritonavir given - 200 mg bid, 400 mg bid, and 600 mg bid for the following groups:~ER+, HER2-~ER+, HER2+~ER-, HER2+~ER-, PR+, HER2-~ER-, PR-, HER2-"
3226753|NCT01008501||Experimental|Individuals with recurrent or sporadic hydatidiform moles and their first-degree family members. Sometimes additional family members are also enrolled.
3226636|NCT01009437|Experimental|Ritonavir - Maximum Tolerated Dose (II)|Phase II: Once the maximum tolerated dose (MTD) of ritonavir is established, 19 ER+, HER2- patients will be enrolled at MTD during the phase II component along with therapeutic conventional surgery.
3226637|NCT01009424|Experimental|1|R7103 (dose 1) followed by placebo or placebo followed by R7103 (dose 1)
3226638|NCT01009424|Experimental|2|R7103 (dose 2) followed by placebo or placebo followed by R7103 (dose 2)
3226639|NCT01009424|Experimental|3|R7103 (dose 3) followed by placebo or placebo followed by R7103 (dose 3)
3226640|NCT01009424|Experimental|4|R7103 (dose 4) followed by placebo or placebo followed by R7103 (dose 4)
3226641|NCT01009424|Experimental|5|R7103 (dose 5) followed by placebo or placebo followed by R7103 (dose 5)
3226642|NCT01009424|Experimental|6|R7103 (dose 6) followed by placebo or placebo followed by R7103 (dose 6)
3226643|NCT01009411||Control|Patients in active phase of labor not augmented
3226644|NCT01009411||Augmented|Augmentation leading to normal progress
3226645|NCT01009411||Caesarean section|Augmentation leading to Caesarean section
3226646|NCT01009385|Active Comparator|prone position|
3226647|NCT01009385|Active Comparator|sitting position|
3226648|NCT01009372|Experimental|breaks during laparoscopic surgery|Intraoperative Breaks were instituted in the intervention group. The other group operated conventionally without breaks
3226649|NCT01009359|Experimental|Arm 1|
3226650|NCT01009359|Experimental|Arm 2|
3226651|NCT01009359|Experimental|Arm 3|
3226652|NCT01009346|Experimental|RAD001|Daily RAD001 in combination with weekly cetuximab and cisplatin/ carboplatin on Day 1, 8 of each 28 day cycle.
3226653|NCT01009333|Experimental|Low InterStim rate setting at 5.2 Hz|
3226654|NCT01009333|Experimental|Medium InterStim rate setting at 14 Hz|
3226655|NCT01009333|Experimental|High InterStim rate setting at 25 Hz|
3226656|NCT01009320||Pacemaker with magnets|Patients with pacemakers who will be tested for magnetic interference with a magnetic drape.
3226657|NCT01009294|Experimental|Ataluren (PTC124)|Experimental Ataluren (PTC124) PO 20-,20-,40-mg/kg TID
3226658|NCT01009281|Experimental|AIN457|
3226659|NCT01009255|Experimental|GSK239512|Oral tablets
3226660|NCT01009255|Placebo Comparator|Placebo|Placebo to match GSK239512.
3226661|NCT01009242|Experimental|0.1mg/kg and 1mg/kg CDP6038 IV and Placebo IV|Cohort 1, Group 1 will compare 0.1mg/kg, 1mg/kg CDP6038 and placebo IV.
3226662|NCT01009242|Experimental|1 mg/kg CDP6038 SC and Placebo SC|Cohort 1, Group 2 will compare 1mg/kg CDP6038 and placebo sc.
3226663|NCT01009242|Experimental|Optimized CDP6038 SC|Cohort 2, Group 3 will compare optimized sc doses of CDP6038 based on outcome of Cohort 1 with placebo.
3226664|NCT01009229|Other|1|
3226665|NCT01009216|Experimental|ABT-384|
3226666|NCT01009203|Experimental|Temsirolimus and Erlotinib|Erlotinib (Tarceva) at 150 mg by mouth daily + Temsirolimus (Torisel) at 15 mg intravenously weekly. Each cycle is comprised of 28 days
3226667|NCT01009190|Experimental|ARM A|Carboplatin plus PF-01367338
3226668|NCT01009190|Experimental|ARM A EXPANSION|Carboplatin plus PF-01367338
3226669|NCT01009177|Experimental|Bosentan|
3226670|NCT01009177|Placebo Comparator|Placebo|
3226671|NCT01009151|Experimental|Heart Care Self Tracker|Web-based Home Tele-monitoring system
3226672|NCT01009138|Experimental|Diabetes-Specific CBT (DS-CBT)|Cognitive Behavioral Intervention (Group) focusing on Diabetes-Specific Problems
3226673|NCT01009138|Active Comparator|Standard Diabetes Education|Standard Diabetes Education Lessons will be given to quantify the unspecific antidepressive Effects of Participation in Group Sessions with social Contact and Acquisition of Knowledge.
3226674|NCT01009125|Experimental|$2 cash incentive|
3226675|NCT01009125|Experimental|$5 cash incentive|
3226676|NCT01009112|Experimental|CBT for Insomnia|"Patients change their sleep times and habits in order to reduce alertness and over thinking when they are trying to sleep. This helps them learn how to sleep overnight in one solid block of time"
3226677|NCT01009112|Experimental|Imagery Rehearsal Therapy|"Patients rescript the narrative of a nightmare to eliminate the distressing elements and create a new pleasant dream scene. They then rehearse this scene in their imagination at least twice each day. This reduces the frequency and intensity of the target nightmare and often reduces other nightmares, too."
3226678|NCT01009112|Experimental|Prolonged Exposure|This behavioral treatment for PTSD involves 1) systematic and repeated exposure to objects and situations that are avoided due to trauma-related distress, 2) prolonged, repeated recounting of trauma memories through visualization, and 3)therapist-guided discussions of thoughts and emotions related to the exposure exercises. The goals of PE are to reduce the anxiety and distress elicited by trauma-related memories and situations, show patients these memories and situations are distinct from the trauma, and teach patients they can tolerate the distress caused by these memories and situations.
3226679|NCT01009112|Active Comparator|Suportive Care Therapy|This is an active therapy where the focus of the intervention is on helping patients better understand their emotional response to their PTSD and sleep symptoms.
3226680|NCT01009099|Experimental|Arm 1|exercise training with breathing retraining
3226681|NCT01009099|Active Comparator|Arm 2|exercise training
3226682|NCT01009086|Experimental|Placebo|Participants will receive subcutaneous (SC) injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants will cross over to receive SC injections of ustekinumab 45 mg at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 88. If early escape, SC injections of 45 mg ustekinumab will be given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 88. For participants entering early escape, a SC placebo injection will be given at Week 24 to maintain the blind.
3226683|NCT01009086|Experimental|Ustekinumab 45 mg|Participants will receive SC injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, SC injections of 90 mg ustekinumab will be given at Week 16 and every 12 weeks thereafter with the last dose at Week 88. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
3226754|NCT01008488|Active Comparator|Antibiotic|
3226755|NCT01008488|No Intervention|No antibiotic|
3226756|NCT01008475|Experimental|Safety part: EMD 525797 250 mg + Standard of Care (SoC)|EMD 525797 250 mg in combination with cetuximab and irinotecan
3226684|NCT01009086|Experimental|Ustekinumab 90 mg|Participants will receive SC injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, the same dosage schedule will continue. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
3226685|NCT01009073|Experimental|Arm A (ABT-263 and erlotinib)|
3226686|NCT01009073|Experimental|Arm B (ABT-263 and irinotecan)|
3226687|NCT01009073|Experimental|Arm C (ABT-263 monotherapy)|
3226688|NCT01009060|Experimental|GSK239512|Repeat dose.
3226689|NCT01009060|Placebo Comparator|Placebo|Repeat dose. Placebo to match GSK239512
3226690|NCT01009047|Experimental|Paliperidone extended-release (ER)|Paliperidone ER will be administered as oral capsule at a dose of 6 milligram (mg) for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
3226691|NCT01009047|Active Comparator|Aripiprazole|Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
3226692|NCT01009034||12 male HIV-positive patients|Male HIV-positive patients who have been receiving stable antiretroviral therapy that includes maraviroc for a minimum of three months.
3226693|NCT01009021|Other|Placebo first (scheme 2)|scheme 2 patients (n=15) received a brown-coated tablet of saccharine (placebo) 45 minutes before the first PRP episode [placebo treatment episode (PTE)] at baseline to the right eye and two weeks after received one 50 mg tablet of potassium diclofenac 45 minutes before the second PRP episode [diclofenac treatment episode (DTE)] to the left eye
3226694|NCT01009021|Other|Diclofenac first (scheme 1)|scheme 1 patients (n=15) received one 50 mg tablet of potassium diclofenac 45 minutes before the first PRP episode [diclofenac treatment episode (DTE)] at baseline to the right eye and two weeks after received an identical brown-coated tablet of saccharine (placebo) 45 minutes before the second PRP episode [placebo treatment episode (PTE)] to the left eye
3226695|NCT01009008|Experimental|Post-mastectomy|Post-mastectomy patients undergoing expander reconstruction
3226696|NCT01008995|Experimental|001|placebo Subcutaneous injection at Week 0 and 4,ustekinumab 45 mg subcutaneous injection at Week 12 and 16
3226697|NCT01008995|Experimental|002|placebo Subcutaneous injection at Week 12,ustekinumab 45 mg subcutaneous injection at Week 0 4 and 16
3226698|NCT01008982|Experimental|single arm|
3226699|NCT01008956|Experimental|Single Group|Subjects enrolled in this group will be stratified by age (18 to 40 years and 41 to 64 years)
3226700|NCT01008943|Experimental|1|
3226701|NCT01008930|Experimental|PEM Scan|HR PEM images (High Resolution PEMFlex Solo II scan images)
3226702|NCT01008917|Experimental|single treatment-non randomized study|Phase I study is to test the safety of the combination of sorafenib with temsirolimus at different dose levels
3226703|NCT01008904|Experimental|Supportive care (magnesium oxide)|Patients receive magnesium oxide by mouth daily or twice daily for 4 weeks.
3226704|NCT01008891|Active Comparator|Group 1|Standard Rigid Fixation plus Autograft
3226705|NCT01008891|Experimental|Group 2|Standard Rigid Fixation plus Augment™ Injectable
3226706|NCT01008865|Experimental|Studer Pouch|Studer Pouch orthotopic urinary diversion
3226707|NCT01008865|Experimental|T-Pouch|T-Pouch orthotopic urinary diversion
3226708|NCT01008852|Experimental|Treatment Group 1|
3226709|NCT01008852|Experimental|Treatment Group 2|
3226710|NCT01008852|Experimental|Treatment Group 3|
3226711|NCT01008852|Experimental|Treatment Group 4|
3226712|NCT01008852|Placebo Comparator|Treatment Group 5|
3226713|NCT01008839||Old age group of healthy women|Old women over 70 years old
3226714|NCT01008839||young group of healthy women|aged 25-35 years
3226715|NCT01008826|Experimental|glucoraphanin-rich broccoli extract|
3226716|NCT01008826|Experimental|sulforaphane-rich broccoli extract|
3226717|NCT01008813|Experimental|adjuvanted A(H1N1)v influenza vaccine|Two injections at day 0 and day 21
3226718|NCT01008813|Experimental|non-adjuvanted A(H1N1)v influenza vaccine|Two injection at day 0 and day 21
3226719|NCT01008800|Experimental|Center-Based classroom intervention|Four days a week for 2.5 hours a day the child will participate in a classroom with peers in an attempt to increase social communication, language abilities, and other skills. Parents will also receive education sessions 1-3 times per month for 1-2 hours each. Treatment will last for 6 months.
3226720|NCT01008800|Active Comparator|Parent Training|Parents are taught strategies on how to interact with their children to increase their skills. Parent training sessions are given 2 times a month at our center and once a month at home for 60-90 minutes each. Treatment will last for 6 months.
3226721|NCT01008787|No Intervention|Focus Group|Qualitative interviews examining social support for PA conducted with African American (AA) women recruited from Wheeler Avenue Baptist Church located in Houston used to design Culturally-Appropriate Peer-based Motivational Interviewing (CAPMI) intervention.
3226722|NCT01008787|Active Comparator|Intervention Group 1|CAPMI Intervention: Training + Weekly Partner Questionnaire + Interview + PA Newsletter
3226723|NCT01008787|Active Comparator|Intervention Group 2|Interview + PA Newsletter
3226724|NCT01008774|Experimental|A|
3226725|NCT01008774|Active Comparator|B|
3226726|NCT01008774|No Intervention|C|
3226727|NCT01008761|Active Comparator|Zithromax, 100 mgmgs; 5mls suspension|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
3226728|NCT01008761|Placebo Comparator|Suspension placebo,|placebo (suspension produced by CDC Edmonton.) given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days.
3226729|NCT01008748|Experimental|Smoking Cessation Treatment|Nicotine replacement therapy (NRT), self-help materials, + brief in-person and telephone counseling, all conducted in Spanish. Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
3226730|NCT01008735||women with hodgkin lymphoma treated with chemotherapy|
3226757|NCT01008475|Experimental|Safety part: EMD 525797 500 mg + SoC|EMD 525797 500 mg in combination with cetuximab and irinotecan
3226896|NCT01007500|Experimental|Group Dexamethasone|
3226731|NCT01008709|Placebo Comparator|Teleflex HemoLock clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur
3226732|NCT01008709|Active Comparator|Aesculap U-Clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur.
3226733|NCT01008696|Experimental|Rabeprazole|Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
3226734|NCT01008696|Active Comparator|Lansoprazole|Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
3226735|NCT01008683||Stem cell and and heart transplant patients|Stem cell and and heart transplant patients
3226736|NCT01008670||Device Implant Recipients|Patients undergoing CRT implantation, or candidates for future CRT devices currently undergoing ICD or pacemaker implantation.
3226737|NCT01008657|Experimental|"extranodular no touch multipolar RFA"|
3226738|NCT01008657|Active Comparator|intranodular multipolar RFA|
3226739|NCT01008644|Experimental|Saline|The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min.
3226740|NCT01008644|Experimental|Water|The subjects will drink tap water for 2 hours, the volume calculated as 20ml/kg/hour
3226741|NCT01008631|Experimental|dialysis|Two doses of sodium thiosulfate
3226742|NCT01008631|Experimental|healthy volunteer|One dose of sodium thiosulfate
3226743|NCT01008618|Experimental|Fentanyl (Titration period)|One-day adhesive transdermal patch containing fentanyl (JNS020QD) applied to chest, abdomen, upper arm and thigh and replaced every day, starting at the dose of 12.5 microgram per hour (mcg/hr) for at least first 2 days, which will be increased by 12.5 mcg/hr at one time based on the medical examination of number of rescue treatments and visual analog scale (VAS) score of the participants. The dose will be increased up to maximum of 50 mcg/hr. The treatment will be continued for 10-29 days and then the eligible participants from this group will be randomly assigned to either of the two groups in the double-blind period.
3226744|NCT01008618|Experimental|Fentanyl (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to fentanyl group, will be administered one-day adhesive transdermal patch containing fentanyl, applied to chest, abdomen, upper arm and thigh and replaced every day, the dose of which will be same as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will be continued for 12 weeks.
3226745|NCT01008618|Placebo Comparator|Placebo (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to placebo group, will be administered one-day adhesive transdermal placebo patch indistinguishable from fentanyl in appearance, applied to chest, abdomen, upper arm and thigh and replaced every day. The dose of fentanyl (from titration period) will be gradually decreased to prevent withdrawal symptoms and the dose of the matching placebo will be gradually increased up to same dose as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will continue for 12 weeks.
3226746|NCT01008605|Experimental|Caverject Impulse|representative users
3226747|NCT01008592||Group 1|Subjects with chronic idiopathic urticaria exhibiting dermatographism.
3226748|NCT01008566|Experimental|Treatment (cixutumumab, sorafenib tosylate)|Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22 and oral sorafenib tosylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3226749|NCT01008553|Experimental|Fentanyl (Titration period)|One-day adhesive transdermal patch (patch containing a drug that is put on the skin so the drug will enter the body through the skin) containing fentanyl (JNS020QD) applied to chest, abdomen, upper arm and thigh and replaced every day, starting at the dose of 12.5 microgram per hour (mcg/hr) for at least first 2 days, which will be increased by 12.5 mcg/hr at one time based on the medical examination of number of rescue treatments and visual analog scale (VAS) score of the participants. The dose will be increased up to maximum of 50 mcg/hr. The treatment will continue for 10-29 days and then the eligible participants from this group will be randomly assigned to either of the two groups in the double-blind period.
3226750|NCT01008553|Experimental|Fentanyl (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to fentanyl group, will be administered one-day adhesive transdermal patch containing fentanyl, applied to chest, abdomen, upper arm and thigh and replaced every day, the dose of which will be same as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will be continued for 12 weeks.
3226751|NCT01008553|Placebo Comparator|Placebo (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to placebo group, will be administered one-day adhesive transdermal placebo patch indistinguishable from fentanyl in appearance, applied to chest, abdomen, upper arm and thigh and replaced every day. The dose of fentanyl (from titration period) will be gradually decreased to prevent withdrawal symptoms and the dose of the matching placebo will be gradually increased up to same dose as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will continue for 12 weeks.
3226752|NCT01008527|Experimental|Infusion and Peptide Administration|Patients get the study drug Oncovir poly IC:LC with or without CP 870-893. Up to 6 groups of 3 to 10 patients each will be treated in this study. The first group (between 3 and 6 patients) gets peptide vaccine with poly IC:LC. Second, third and fourth groups of 3 to 6 patients receive peptide vaccine with poly IC:LC and the antibody CP 870,893 at increasing doses from 0.01, 0.025 and 0.05 mg/kg. CP 870-893 will be given to 10 patients at a dose of 0.1 mg/kg to patients in the fifth group, and 0.2 mg/kg to the sixth group. The CP 870,893 will be given as an intravenous infusion over 30 minutes and will be given once every 2 weeks for the first 6 infusions. CP-870-893 will then be given every 4 to 6 weeks for 3 injections. The final 3 injections of CP 870,893 will be given every 8 to 12 weeks. These infusions will take place on weeks 1, 3, 5, 7, 9, 11, 17, 21, 25, 33, 41, and 53 for a total of 12 infusions.
3226759|NCT01008475|Experimental|Safety part: EMD 525797 1000 mg + SoC|EMD 525797 1000 mg in combination with cetuximab and irinotecan
3226760|NCT01008475|Experimental|Randomized part: EMD 525797 500 mg + SoC|EMD 525797 500 mg in combination with cetuximab and irinotecan
3226761|NCT01008475|Experimental|Randomized Part: EMD 525797 1000 mg + SoC|EMD 525797 1000 mg (or dose as defined by safety monitoring committee (SMC)] in combination with cetuximab and irinotecan.
3226762|NCT01008475|Other|Randomized Part: SoC|Cetuximab and irinotecan
3226763|NCT01008462|Experimental|Treatment (autologous HCT, donor HCT)|See Detailed Description
3226764|NCT01008449|Active Comparator|Absorbable Subcuticular Surgical Suture|Patients in this arm will receive absorbable subcuticular suture for wound closure of cesarean deliveries.
3226765|NCT01008449|Active Comparator|Surgical staples|Patients in this arm will receive surgical staples for wound closure.
3226766|NCT01008436|Active Comparator|Control|Traditional best-practice surgical hemostasis
3226767|NCT01008436|Experimental|Omni-stat Celox|Administration of 6 gr of Omni-stat Celox intraoperatively at the time of Hemostasis
3226768|NCT01008423|Experimental|Budesonide|Budesonide rectal foam
3226769|NCT01008423|Placebo Comparator|Placebo|Placebo foam
3226770|NCT01008410|Experimental|Budesonide|Budesonide rectal foam
3226771|NCT01008410|Placebo Comparator|Placebo|Placebo foam
3226772|NCT01008397|Experimental|AHIST for seasonal allergic rhinitis|AHIST for SAR: each green tablet contains 12mg chlorpheniramine tannate.
3226773|NCT01008384|No Intervention|placebo|
3226774|NCT01008384|Experimental|Vitamin D3|Vitamin D3 given for 8 weeks
3226775|NCT01008371||Obese|Healthy obese subjects
3226776|NCT01008371||Non-obese|Healthy non-obese subjects
3226777|NCT01008345|Experimental|ezetimibe|will receive the active treatment with ezetimibe and statin
3226778|NCT01008345|Placebo Comparator|placebo|
3226779|NCT01008332|Experimental|Cohort 1|ToleroMune HDM, subjects to receive either active or placebo comparator
3226780|NCT01008332|Experimental|Cohort 2|ToleroMune HDM, subjects to receive either active or placebo comparator
3226781|NCT01008332|Experimental|Cohort 3|ToleroMune HDM, subjects to receive either active or placebo comparator
3226782|NCT01008332|Experimental|Cohort 4|ToleroMune HDM, subjects to receive either active or placebo comparator
3226783|NCT01008332|Experimental|Cohort 5|Toleromune HDM, subjects to receive either active or placebo comparator
3226784|NCT01008319|Active Comparator|Traditional Administration|The traditional approach to ovulation induction with clomiphene citrate involves administration of 50mg/day for five days (starting on cycle day 3, 4, or 5). If ovulation does not occur then a progestin is prescribed to induce menses (which occurs within one week of stopping the progestin) and then a higher dose of medication is used in the next cycle.
3226785|NCT01008319|Experimental|Stair-Step Administration|The stair-step protocol the dose of clomiphene citrate would be increased without administering progestin and inducing a period. This would eliminate the days of progestin (10 days) and the waiting for the period (usually 3 to 7 days) and finally waiting to start clomiphene citrate on cycle day 3 at the earliest (3 more days) for a total of up to 20 days difference for the 100 mg dose of clomid. If they did not ovulate on 100mg, then the process repeats and another 20 days before they start 150mg. Therefore, the time to ovulation and pregnancy may be reduced, and hopefully pregnancy, by using the stair-step protocol. This method utilizes ultrasound monitoring for follicle development before increasing the dose of clomiphene citrate.
3226786|NCT01008306||Renal transplanted children and young adults|"Renal transplanted children and adolescents (2-18yrs) transplanted between 1993-2006.~Renal transplanted young adults aged 20-35 yrs old, transplanted from 1983 onwards."
3226787|NCT01008293|Experimental|VSL#3|
3226788|NCT01008293|Active Comparator|Lactulose|30-60 ml of lactulose per day (2 months) to ensure 2-3 soft stools
3226789|NCT01008280|Experimental|Baclofen|baclofen 10 mg po tid
3226790|NCT01008280|Placebo Comparator|Placebo|placebo given tid
3226791|NCT01008267||SWL under general anesthesia|Patients who failed in SWL under sedation(a standard protocol), will undergo a second SWL process under general anesthesia.
3226792|NCT01008267||SWL under general selective anesthesia|Patients who failed in SWL under sedation(a standard protocol), will undergo a second SWL process under general selective anesthesia, using a bronchial blocker.
3226793|NCT01008254|Experimental|Musical prompt|
3226794|NCT01008254|Active Comparator|Delayed musical prompt|
3226795|NCT01008254|No Intervention|No musical prompt|
3226796|NCT01008241||Adult Residents of South Florida|Persons 18 years of age or older, residing in Broward or Miami-Dade Counties.
3226797|NCT01008228|Active Comparator|tube thoracic drainage|drainage performed with tube drainage CH 16 or ch 20
3226798|NCT01008228|Experimental|exsufflation|exsufflation with a specific thoracentesis system
3226799|NCT01008215|Experimental|Algorithm|Algorithm (available in paper version and web-based version) will be used for warfarin maintenance dosing.
3226800|NCT01008215|No Intervention|Care as usual|Control group
3226801|NCT01008150|Active Comparator|Arm 1: paclitaxel + trastuzumab then A C|4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Trastuzumab concurrently with paclitaxel weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Following paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
3226802|NCT01008150|Experimental|Arm 2: paclitaxel + neratinib then A C|4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
3226846|NCT01007877|Placebo Comparator|Placebo Energy Drink|During a 15 minute break, subjects consume a placebo energy drink
3226847|NCT01007877|Experimental|Red Bull Energy Drink|during a 15 minute break, subjects consume Red Bull Energy Drink
3226848|NCT01007864|Experimental|piribedil|
3226849|NCT01007864|Active Comparator|pramipexole or ropinirole|
3226803|NCT01008150|Experimental|Arm 3: paclitaxel + trastuzumab + neratinib then A C|4 cycles of paclitaxel 80 mg/m2 on days 1, 8, and 15 of a 28 day cycle. Trastuzumab concurrently with paclitaxel, weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Neratinib 200 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/trastuzumab/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
3226804|NCT01008137|Experimental|Group 1: Day 0-PANFLU.1; Day 21-ANFLU|50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.
3226805|NCT01008137|Experimental|Group 2: Day 0-ANFLU; Day 21-PANFLU.1|50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.
3226806|NCT01008137|Experimental|Group 3: Day 0-PANFLU.1+ANFLU|50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.
3226807|NCT01008124|Experimental|Liberatory Maneuver|Liberatory Maneuver
3226808|NCT01008124|Placebo Comparator|Placebo Maneuver|Placebo Maneuver
3226809|NCT01008111|Active Comparator|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
3226810|NCT01008111|Placebo Comparator|Dermabond-Placebo Comparator|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
3226811|NCT01008098|Experimental|PTSD group|
3226812|NCT01008085|Experimental|Self-expanding stent|Stentys stent
3226813|NCT01008085|Active Comparator|Balloon-expandable stent|VISION/Driver
3226814|NCT01008072||without buprenorphine preparation|
3226815|NCT01008072||with buprenorphine preparation|
3226816|NCT01008059|Experimental|grapefruit juice|Control (no pretreatment), liver and gut CYP3A induction (rifampin 500 mg daily for 5d), liver and gut CYP3A inhibition (ketoconazole 400 mg daily for 3d), gut only CYP3A inhibition (grapefruit juice the night before and morning of study days)
3226817|NCT01008059|Experimental|Delayed alfentanil|Alfentanil (0.5-1 mg IV bolus) followed 3 hours later by 1-4 mg oral deuterium-labeled (d3) alfentanil on each study visit.
3226818|NCT01008059|Experimental|Concomitant alfentanil|Alfentanil (0.5-1 mg IV bolus) together with 1-4 mg oral deuterium-labeled (d3) alfentanil on each study visit.
3226819|NCT01008046|Experimental|combined N-acetyl cysteine - CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
3226820|NCT01008046|Active Comparator|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles.
3226821|NCT01008033|Experimental|IDP-108|
3226822|NCT01008033|Placebo Comparator|Vehicle|
3226823|NCT01008020|No Intervention|Dietary supplement: placebo|
3226824|NCT01008020|Active Comparator|Tea catechin extracts|
3226825|NCT01008007|Experimental|A|Viusid in combination with the conventional treatment for acute fever of viral etiology
3226826|NCT01008007|Active Comparator|B|Conventional treatment for acute fever of viral etiology
3226827|NCT01007994|Active Comparator|New Medication|A new anti-hypertensive medication (enalapril, propranolol or isradipine) will be added at 8pm.
3226828|NCT01007994|No Intervention|Control|Subjects in the control group will continue to take their medications as usual.
3226829|NCT01007981||CRT device|Patients with Cardiac Resynchronization Therapy(CRT) device implanted in the last 5 years will be studied by the new echo modality.Study doesn't involve acute device implantation.
3226830|NCT01007968|Experimental|HDACi|
3226831|NCT01007955||Severely Obese|Severely obese individuals scheduled to undergo gastric bypass surgery
3226832|NCT01007929|Experimental|1|14C-AZD1236
3226833|NCT01007916|Other|Lotrafilcon B / Habitual|Lotrafilcon B contact lenses worn first, with habitual contact lenses worn second. Both products worn bilaterally as often as is typical for habitual lenses, and in the same modality as is typical for habitual lenses, as prescribed by regular eye care practitioner, with extended wear not to exceed 6 nights.
3226834|NCT01007916|Other|Habitual / Lotrafilcon B|Habitual contact lenses worn first, with lotrafilcon B lenses worn second. Both products worn bilaterally as often as is typical for habitual lenses, and in the same modality as is typical for habitual lenses, as prescribed by regular eye care practitioner, with extended wear not to exceed 6 nights.
3226835|NCT01007903|No Intervention|Usual Care|
3226836|NCT01007903|Experimental|Tai Chi|
3226837|NCT01008189|Active Comparator|Self study comparison group|Caregivers and children and adolescents each received three books about coping with grief after the death of a loved one and a syllabus to guide reading
3226838|NCT01008189|Experimental|Family Bereavement Program|12- session group for caregivers and bereaved children and adolescents plus 2 individual sessions
3226839|NCT01008163|Experimental|1|YY-351, PO, 1T tid. / Placebo, 1T tid.
3226840|NCT01008163|Experimental|2|YY-351. PO, 2T bid. / Placebo 2T qd.
3226841|NCT01008163|Experimental|3|YY-351, PO, 2T tid.
3226842|NCT01008163|Placebo Comparator|4|Placebo, PO, 2T tid.
3226843|NCT01007942|Experimental|Everolimus + vinorelbine + trastuzumab|Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
3226844|NCT01007942|Placebo Comparator|placebo + vinorelbine + trastuzumab|Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only
3226845|NCT01007877|No Intervention|No break|
3226852|NCT01007838|Experimental|Chronic kidney disease progressive resistance training group|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
3226853|NCT01007838|Sham Comparator|Chronic kidney disease sham exercise group|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
3226854|NCT01007838|Experimental|Healthy controls progressive resistance training group|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
3226855|NCT01007838|Sham Comparator|Healthy controls sham exercise group|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
3226856|NCT01007812|Other|Lotrafilcon B / Comfilcon A|Lotrafilcon B silicone hydrogel, toric, soft contact lenses worn for one week, followed by Comfilcon A silicone hydrogel, toric, soft contact lenses worn for one week.
3226857|NCT01007812|Other|Comfilcon A / Lotrafilcon B|Comfilcon A silicone hydrogel, toric, soft contact lenses worn for one week, followed by Lotrafilcon B silicone hydrogel, toric, soft contact lenses worn for one week.
3226858|NCT01007799|Placebo Comparator|Placebo|Placebo pills to take for 12 weeks
3226859|NCT01007799|Active Comparator|Vitamin D|Vitamin D supplement for 12 weeks
3226860|NCT01007773|Experimental|Dexmedetomidine|In conjunction with conventional sedative and analgesic agents.
3226861|NCT01007773|Active Comparator|Standard of Care|Patients randomized to conventional sedation will have as the main pharmacologic agents to achieve sedation and analgesia propofol and fentanyl, respectively.
3226862|NCT01007760|Placebo Comparator|Room air|
3226863|NCT01007760|Active Comparator|Low dose exposure second-hand smoke|
3226864|NCT01007760|Active Comparator|High dose exposure second-hand smoke|
3226865|NCT01007747|Experimental|Geranium oil|
3226866|NCT01007734||1|
3226867|NCT01007721|Experimental|BI 671800 ED 100 mg|2 capsules of BI 671800 ED 25 mg plus 2 capsules of BI 671800 ED placebo (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
3226868|NCT01007721|Experimental|BI 671800 ED 400 mg|2 capsules of BI 671800 ED 100 mg plus 2 capsules of placebo (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
3226869|NCT01007721|Active Comparator|Montelukast 10 mg|1 over-encapsulated montelukast 10 mg tablet (qd in the morning) plus 4 capsules of BI 671800 ED placebo (bid in the morning and evening) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
3226870|NCT01007721|Active Comparator|Fluticasonepropionate nasal spray 200¿g|Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 ¿g per nostril) plus 4 capsules of BI 671800 ED placebo (bid in the morning and evening) plus 1 overencapsulated montelukast placebo tablet (qd in the morning)
3226871|NCT01007721|Placebo Comparator|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening), plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
3226872|NCT01007721|Experimental|BI 671800 ED 800 mg|4 capsules of BI 671800 ED 100 mg (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
3226873|NCT01007708|Experimental|IDP-108|
3226874|NCT01007708|Placebo Comparator|Vehicle|
3226875|NCT01007695|Experimental|All patients|All participants enrolled.
3226876|NCT01007682|No Intervention|Screening for working memory capacity|
3226877|NCT01007682|Experimental|Distressing movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
3226878|NCT01007669|Active Comparator|Reference|Health check only
3226879|NCT01007669|Experimental|Intervention|Physical activity and Health check
3226880|NCT01007656|Experimental|GD Antrodia camphorata|"GD Antrodia Camphorata is the extract from mycelium of the fungus Antrodia Camphorata which is an endemic species in Taiwan. According to the literatures, mycelium of Antrodia camphorata is beneficial to health. Moreover, the study product GD Antrodia Camphorata has been approved by Department of Health, Taiwan as a health supplement (approval number A00124)."
3226881|NCT01007643|Experimental|Wii Fit (TM) Interactive Video Game|Wii Fit (TM) Interactive Video Game
3226882|NCT01007643|Active Comparator|Traditional Home Exercise Program|Traditional Home Exercise Program
3226883|NCT01007630|Active Comparator|Rasagiline|0.5mg of Rasagiline for 14 days, then switch to 1mg of Rasagiline for remainder of the study (approximately 10 weeks total).
3226884|NCT01007630|Placebo Comparator|Placebo|0.5mg of placebo for 14 days, then switch to 1mg of placebo for remainder of the study (approximately 10 weeks total)
3226885|NCT01007604|Active Comparator|Exercise and lifestyle counselling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
3226886|NCT01007604|Experimental|PCD with peristaltic pulse waveform|Daily use for two hours
3226887|NCT01007591|Active Comparator|LEO 80190 ointment|
3226888|NCT01007591|Active Comparator|Hydrocortisone 10 mg/g ointment|
3226889|NCT01007578|Experimental|Paclitaxel treatment|Paclitaxel-coated balloon catheter angioplasty treated subjects
3226890|NCT01007565|Experimental|periarticular injection, pain level|
3226891|NCT01007552|Experimental|Gemcitabine, Capecitabine and Bevacizumab|Estimate the toxicity of the regimen, and estimate the quality of life (QOL).
3226892|NCT01007539|Experimental|CDP-choline|
3226893|NCT01007539|Placebo Comparator|Placebo (fructose)|
3226894|NCT01007526|Experimental|1|Patients who are planned to be treated with CCRT plus VIDL chemotherapy and/or autologous stem cell transplantation
3226895|NCT01007513||At risk patient for preterm delivery|Patient referred to the MFM clinic for a risk evaluation for preterm delivery.
3226897|NCT01007500|Active Comparator|Group Ondansetron|
3226898|NCT01007461|Experimental|IK-1001|IK-1001 Sodium Sulfide (Na2S) for Injection
3226899|NCT01007461|Placebo Comparator|Placebo|0.9% Sodium Chloride (NaCl)
3226900|NCT01007448|Active Comparator|bexarotene 150mg/m2/day|
3226901|NCT01007448|Active Comparator|bexarotene 300 mg/m2/day|
3226902|NCT01007435|Experimental|(A) Tocilizumab 8 mg/kg + placebo to methotrexate|Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.
3226903|NCT01007435|Experimental|(B) Tocilizumab 8 mg/kg + methotrexate|Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
3226904|NCT01007435|Experimental|(C) Tocilizumab 4 mg/kg + methotrexate|Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
3226905|NCT01007435|Active Comparator|(D) Placebo to tocilizumab + methotrexate|Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.
3226906|NCT01007422||Supportive Care|
3226907|NCT01007409|Active Comparator|Group B|Period 1: fed control → Period 2: fasted control
3226908|NCT01007409|Active Comparator|Group A|Period 1: fasted control → Period 2: fed control
3226909|NCT01007396|Other|new healthcare workers|doctors and nurses who were newly hired in 2008 at the Samsung Medical Center
3226910|NCT01007383|Experimental|LEO 27847 oral solution (0.05 mg/mL)|LEO 27847
3226911|NCT01007383|Experimental|LEO 27847 oral solution (0.75 mg/mL)|LEO 27847
3226912|NCT01007383|Placebo Comparator|LEO 27847 oral solution (placebo)|Placebo
3226913|NCT01007370|Active Comparator|LMA-Fastrach|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of LMA-Fastrach (sizes 3,4 or 5), establishment of ventilation~Evaluation of glottic view through LMA-Fastrach using fibrescope (one out of ten patients)~Tracheal intubation through the LMA-Fastrach~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
3226914|NCT01007370|Active Comparator|I-gel|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of I-gel (sizes 3,4 or 5), establishment of ventilation~Evaluation of glottic view through I-gel using fibrescope (one out of ten patients)~Tracheal intubation through the I-gel~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
3226915|NCT01007357|No Intervention|Body MRI healthy volunteers|Body MRI to optimize sequences in healthy individuals and in disorder subjects
3226916|NCT01007344|Active Comparator|flaxseed|2 muffins and 1 slice of bread for a total of 30g flaxseed per day
3226917|NCT01007344|Placebo Comparator|whole wheat flour|2 muffins and 1 slice of bread containing whole wheat flour per day
3226918|NCT01007318|Active Comparator|Single port|Single port through the transumbilical incision was made by wound retractor combined with surgical glove and then 3 trocal was inserted to the finger part of the surgical glove. Laparoscopic instrument was working through the single port and resected appendix removed through it.
3226919|NCT01007318|Active Comparator|3 port|3 port laparoscopic appendectomy was done by conventional method
3226920|NCT01007305|Experimental|Bilateral salpingo-oophorectomy|Removal of both ovaries and fallopian tubes at the time of hysterectomy for benign conditions.
3226921|NCT01007305|Active Comparator|Ovarian conservation|No ovaries or fallopian tubes removed at the time of hysterectomy for benign conditions.
3226922|NCT01007292|Experimental|YM155 plus rituximab|
3226923|NCT01007279|Active Comparator|CLOPIDOGREL|
3226924|NCT01007279|Experimental|ROSUVASTATIN|
3226925|NCT01007266|Other|Group A|Buddy Group - Individuals with type 2 diabetes receive conventional diabetes treatment and are assigned a patient partner (Buddy)
3226926|NCT01007266|Active Comparator|Group B|Individuals receive conventional treatment for type 2 diabetes
3226927|NCT01007253|Other|FF/PL, PL/OLO, FF/OLO, PL/PL|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL)~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO), and~placebo (PL) nasal spray and PL eye drops (PL/PL)."
3226928|NCT01007253|Other|PL/OLO, FF/OLO, PL/PL, FF/PL|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),~placebo (PL) nasal spray and PL eye drops (PL/PL), and~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL)."
3226929|NCT01007253|Other|FF/OLO, PL/PL, FF/PL, PL/OLO|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),~placebo (PL) nasal spray and PL eye drops (PL/PL),~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL), and~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO)."
3226930|NCT01007253|Other|PL/PL, FF/PL, PL/OLO, FF/OLO|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~placebo (PL) nasal spray and PL eye drops (PL/PL),~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL),~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO), and~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO)."
3226931|NCT01007240|Experimental|soft liner with nano particles|the obturators of this patients will be relined with soft liner, with incorporated nano particles. after a week, the soft liner will be taken off, and will be checked for bacterial adhesion.
3226932|NCT01007227|Other|Lifestyle instruction|
3226933|NCT01007214|Experimental|Prostate cancer|A total of 30 patients diagnosed with prostate cancer who have elected to undergo radical prostatectomy are enrolled over a six year period.
3226978|NCT01007019|Experimental|YH4808 800mg|"1.Single dose~2.12 volunteers were administered YH4808 800mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
3226979|NCT01007019|Placebo Comparator|Placebo|
3226934|NCT01007201|Experimental|H1N1 vaccine of 15 μg HA on Day 0 and 21|15 μg HA (0.5 mL) per injection, 2 injections 50 children (aged over 3 years old to 6 years old) and 50 children/teenagers (aged over 6 years old to 18 years old) were assigned to receive two injections of H1N1 vaccine 3 weeks apart
3226935|NCT01007201|Experimental|H1N1 vaccine of 7.5 μg HA on Day 0 and 21|7.5 μg HA (0.25 mL) per injection, 2 injections 50 toddlers (aged over 1 year old to 3 years old) were assigned to receive two injections of H1N1 vaccine 3 weeks apart
3226936|NCT01007188|Active Comparator|1.5PD|average American diet plus 1.5 oz per day almonds
3226937|NCT01007188|Other|Base|average American diet without almonds
3226938|NCT01007188|Active Comparator|3.0PD|average American diet plus 3.0 oz per day almonds
3226939|NCT01007175|Experimental|Cohort 1|
3226940|NCT01007175|Experimental|Cohort 2|
3226941|NCT01007175|Experimental|Cohort 3|
3226942|NCT01007175|Experimental|Cohort 4|
3226943|NCT01007175|Experimental|Cohort 5|
3226944|NCT01007149|Experimental|Omalizumab|Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.
3226945|NCT01007149|Placebo Comparator|Placebo|Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks.
3226946|NCT01007136|Experimental|tDCS and occupational therapy|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
3226947|NCT01007136|Sham Comparator|Sham and occupational therapy|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
3226948|NCT01007123|Experimental|A3309 low dose|Administered once daily for the duration of the study
3226949|NCT01007123|Experimental|A3309 intermediate dose|Administered once daily for the duration of the study.
3226950|NCT01007123|Experimental|A3309 high dose|Administered once daily for the duration of the study
3226951|NCT01007123|Placebo Comparator|Placebo|Administered once daily for the duration of the study
3226952|NCT01007110|Active Comparator|Docosahexaenoic Acid (DHA)|Docosahexaenoic Acid (DHA)
3226953|NCT01007110|Placebo Comparator|Placebo|soy/corn oil placebo
3226954|NCT01007097|Experimental|TAK-875 6.25 mg QD|
3226955|NCT01007097|Experimental|TAK-875 25 mg QD|
3226956|NCT01007097|Experimental|TAK-875 50 mg QD|
3226957|NCT01007097|Experimental|TAK-875 100 mg QD|
3226958|NCT01007097|Experimental|TAK-875 200 mg QD|
3226959|NCT01007097|Active Comparator|Glimepiride 2 mg or 4mg QD|
3226960|NCT01007097|Placebo Comparator|Placebo QD|
3226961|NCT01007084|Experimental|Propranolol|
3226962|NCT01007084|Placebo Comparator|Sugar pill|
3226963|NCT01007071|Experimental|Growth hormone|Subjects randomized to growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Dose adjustments based on serum insulin-like growth factor-1 (IGF-1) levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 standard deviation (SD) to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
3226964|NCT01007071|Placebo Comparator|Placebo|Subjects randomized to placebo for 16 weeks. As noted above, placebo subjects will be initiated on a daily subcutaneous injection, with dose changes based on changes in active drug subjects.
3226965|NCT01007058||Response Markers|Urine Collection and Bladder wash of Bladder Cancer Patients with Treatment of BCG or BCG plus interferon
3226966|NCT01007045||"Clinically likely"|Subjects deemed clinically likely to have DVT based on modified Well's criteria
3226967|NCT01007045||"Clinically unlikely"|Subjects deemed clinically unlikely to have DVT based on modified Well's criteria
3226968|NCT01007032|Experimental|IMC-A12|Pts will receive I.V. IMC-A12 every 2 or 3 weeks. A cycle is defined as 6 weeks, with radiological evaluation of tumor response after each cycle. After the 1st cycle, pts with a complete response (CR), PR, or SD will continue to receive IMC-A12 at their cohort dose and schedule until there is evidence of progressive disease (PD), or until other withdrawal criteria are met. A minimum of 3 pts will be enrolled in each cohort. The starting dose in Cohort 1 will be 6 mg/kg every 2 weeks. Dose escalation from Cohort 1 to Cohort 2 (10 mg/kg every 2 weeks) will occur once at least 3 pts in Cohort 1 have completed 1 cycle of therapy . Enrollment into Cohort 3 (starting dose: 15 mg/kg administered every 3 weeks) will not proceed until at least 3 pts have completed one cycle of therapy (as defined above) in Cohort 2. Similarly, pts will be enrolled in Cohort 4 once at least 3 pts have completed once cycle of therapy in Cohort 3; pts in Cohort 4 will receive 20 mg/kg given every 3 weeks.
3226969|NCT01007019|Experimental|YH4808 30mg|"1.Single dose~2.12 volunteers were administered YH4808 30mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
3226970|NCT01007019|Experimental|YH4808 50mg|"1.Single dose~2.12 volunteers were administered YH4808 50mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
3226971|NCT01007019|Experimental|YH4808 100mg|"1.Single dose~2.12 volunteers were administered YH4808 100mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
3226972|NCT01007019|Experimental|YH4808 200mg|"1.Single dose~2.12 volunteers were administered YH4808 200mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
3226973|NCT01007019|Experimental|YH4808 400mg|"1.Single dose~2.12 volunteers were administered YH4808 400mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
3226974|NCT01007019|Experimental|YH4808 100mg(repeat doses)|"1.Repeat doses~2.12 volunteers were administered YH4808 100mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
3226975|NCT01007019|Experimental|YH4808 200mg(repeat doses)|"1.Repeat doses~2.16 volunteers were administered YH4808 200mg or active/placebo comparators.(YH4808:active:placebo=8:6:2)"
3226976|NCT01007019|Experimental|YH4808 400mg(repeat doses)|"1.Repeat dose~2.12 volunteers were administered YH4808 400mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
3226977|NCT01007019|Experimental|YH4808 600mg|"1.Single dose~2.12 volunteers were administered YH4808 600mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
3226980|NCT01007019|Active Comparator|Esomeprazole 40mg|
3226981|NCT01007006|Experimental|TMRDU|Telepharmacy Robotic Medicine Delivery Unit (TMRDU) group will receive TMRDU plus medication management
3226982|NCT01007006|No Intervention|Control|Control arm will receive only medication management, no TMRDU.
3226983|NCT01006993|Experimental|NeuroFlo Treatment|
3226984|NCT01006980|Experimental|Vemurafenib|
3226985|NCT01006980|Active Comparator|Dacarbazine|
3226986|NCT01006967|Active Comparator|ActiveStep|Subjects will use the ActiveStep treadmill as part of their physical therapy program for balance
3226987|NCT01006967|Active Comparator|Standard physical therapy|Subjects will receive a standard physical therapy program for gait and balance.
3226988|NCT01006954|Active Comparator|Flare Up|Flare up protocol in poor responders for IVF/ICSI
3226989|NCT01006954|Experimental|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
3226990|NCT01006941|Experimental|Trichuris suis ova|
3226991|NCT01006928||Mothers|Mother of infants in NICU
3226992|NCT01006915|Experimental|Surgical decompression|Surgical decompression of the common peroneal, tibial, and deep peroneal nerves
3226993|NCT01006915|No Intervention|Standard medical care|Standard diabetic care and medical care provided for diabetic sensorimotor polyneuropathy
3226994|NCT01006902||Individuals age 65 or older|Individuals age 65 or older receiving chemotherapy for cancer or short term androgen deprivation therapy for individuals 65 or older with prostate cancer.
3226995|NCT01006889|Experimental|Exenatide (twice daily)|Patients with T2DM well-controlled on an intensified insulin regimen for the previous 6 months by the will have their insulin aspart discontinued and replaced for exenatide twice daily while continuing the bedtime detemir insulin. Safety and efficacy parameters will be measured before and after 6 months of treatment.
3226996|NCT01006876|Active Comparator|Study Arm|Patients receive continuous Coumadin therapy throughout the study.
3226997|NCT01006876|Active Comparator|Control Arm|Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
3226998|NCT01006863|Active Comparator|Ephedrine 0.15 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 1.5 mg/kg of ephedrine
3226999|NCT01006863|Active Comparator|Ephedrine 0.1 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 1 mg/kg of ephedrine
3227000|NCT01006863|Active Comparator|Ephedrine 0.07 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 0.7 mg/kg of ephedrine
3227001|NCT01006863|Placebo Comparator|Placebo|received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution
3227002|NCT01006863|Active Comparator|Phenylephrine|received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/kg of phenylephrine
3227003|NCT01006824|Experimental|1|Capsule Endoscopy
3227004|NCT01006824|Active Comparator|2|Dedicated small bowel contrast radiography
3227005|NCT01006811|Experimental|modified Atkins diet|
3227006|NCT01006798|Experimental|Cohort 1|three vaccinations of 10^7vp Ad4-H5-Vtn or placebo
3227007|NCT01006798|Experimental|Cohort 2|three vaccinations of the 10^8vp Ad4-H5-Vtn or placebo
3227008|NCT01006798|Experimental|Cohort 3|three vaccinations of 10^9 Ad4-H5-Vtn or placebo
3227009|NCT01006798|Experimental|Cohort 4|three vaccinations of 10^10 Ad4-H5-Vtn or placebo
3227010|NCT01006798|Experimental|Cohort 5|three vaccinations of 10^11 Ad4-H5-Vtn or placebo
3227011|NCT01006785|Experimental|Treatment I|DLBS1425 150 mg three times daily
3227012|NCT01006785|Experimental|Treatment II|DLBS1425 300 mg three times daily
3227013|NCT01006772|No Intervention|Control Group|Control group patients receive usual clinical practice provided by Stroke Unit at Stobhill Hospital in Glasgow. They receive physiotherapy and early mobilisation as deemed appropriate to treat their oown impairments.
3227014|NCT01006772|Experimental|Experimental group|Intervention Group patients receive custom made solid ankle foot orthosis (AFO)treatment.
3227015|NCT01006759|Experimental|leprosy disability|intervention of a series of cases with leprosy that made treatment in a Clinical Hospital
3227016|NCT01006746||ICD patient and Home Monitoring|Patients primo implanted with ICD
3227017|NCT01006733|Experimental|Target INR 1.8 and Pharmacogenetic|The target International Normalized Ratio (INR) is 1.8. Warfarin initiation is via Pharmacogenetic dosing.
3227018|NCT01006733|Experimental|Target INR 2.5 and Pharmacogenetic|The target INR is 2.5. Warfarin initiation is via Pharmacogenetic dosing.
3227019|NCT01006733|Experimental|Target INR 1.8 and Clinical|The target INR is 1.8. Warfarin initiation is via clinical dosing.
3227020|NCT01006733|No Intervention|Target INR 2.5 and Clinical|The target INR is 2.5. Warfarin initiation is via clinical dosing.
3227021|NCT01006720||Sgx 0.25|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
3227022|NCT01006720||Sgx 0.5|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
3227023|NCT01006720||Sgx 0.75|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
3227024|NCT01006720||Sgx 1.0|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
3227025|NCT01006720||Sgx 1.25|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
3227026|NCT01006720||Neo 10|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
3227027|NCT01006720||Neo 25|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
3227028|NCT01006720||Neo 40|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
3227029|NCT01006720||Neo 55|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
3227030|NCT01006720||Neo 70|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
3227031|NCT01006720||Saline|Saline group: Saline as placebo
3227032|NCT01006707|Other|Ondansetron, then Placebo|Some participants received ondansetron pretreatment during the second session, and then placebo during the third session.
3227033|NCT01006707|Other|Placebo, then Ondansetron|Some participants received placebo pretreatment during the second session, and then ondansetron pretreatment during the third session.
3227034|NCT01006694|Active Comparator|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
3227035|NCT01006694|Experimental|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
3227036|NCT01006681|Experimental|Monovalent MF59-Adjuvanted vaccine|
3227037|NCT01006668|Experimental|Sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
3227038|NCT01006668|Active Comparator|Propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary
3227039|NCT01006655|Placebo Comparator|placebo, adenosine challenge test|Controlled or partially controlled multiple trigger wheezing children received 4 weeks of placebo, preceded and succeeded by AMP challenge test,
3227040|NCT01006655|Active Comparator|Qvar, adenosine challenge test|Patients will receive 4 weeks of inhale QVAR (HFA beclomethasone) 100µg through a spacer device, twice a day
3227041|NCT01006642||Healthy controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
3227042|NCT01006642||Functional dyspepsia-EPS|Functional dyspepsia-EPS(epigastric pain syndrome) Patients admitted to outpatient department with symptoms meeting ROME III criteria
3227043|NCT01006642||Functional dyspepsia-PDS|Functional dyspepsia-PDS(postprandial distress syndrome) Patients admitted to outpatient department with symptoms meeting ROME III criteria
3227044|NCT01006629|Experimental|palivizumab|palivizumab 15 mg/kg intramuscularly every 30 days for 3 to 5 injections
3227045|NCT01006616|Experimental|Navarixin 10 mg|Participants receive navarixin 10 mg, as one navarixin 10 mg capsule and two placebo capsules, administered orally once daily (QD) for up to 2 years
3227046|NCT01006616|Experimental|Navarixin 30 mg|Participants receive navarixin 30 mg, as one navarixin 30 mg capsule and two placebo capsules, administered orally QD for up to 2 years
3227047|NCT01006616|Experimental|Navarixin 50 mg|Participants receive navarixin 50 mg, as two navarixin 10 mg capsules and one navarixin 30 mg capsule, administered orally QD for up to 2 years
3227048|NCT01006616|Placebo Comparator|Placebo|Participants receive placebo to navarixin, as three placebo capsules, administered orally QD for up to 2 years
3227049|NCT01006603|Experimental|1|Saxagliptin 5 mg
3227050|NCT01006603|Active Comparator|2|Glimepiride 1 - 6 mg
3227051|NCT01006590|Experimental|1|Saxagliptin 5 mg
3227052|NCT01006590|Active Comparator|2|Metformin 500 -1000 mg
3227053|NCT01006577|Other|colon j pouch|Control intervention: Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
3227054|NCT01006577|Experimental|side-to-end anastomosis (STE)|Experimental intervention: Low anterior resection for rectal cancer < 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon is closed with a linear stapler. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
3227055|NCT01006551|Experimental|Ziprasidone|
3227056|NCT01006538|Experimental|Arm A (treatment)|Arm A: A single surgical procedure with epimacular brachytherapy using the VIDION® System, with Lucentis® (0.5 mg) administered on a monthly basis as required.
3227057|NCT01006538|Active Comparator|Arm B (control):|Arm B: Lucentis® (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria below.
3227058|NCT01006525||Insomniacs|Primary insomniacs, ages 21-70, in good general health.
3227059|NCT01006499|Placebo Comparator|Placebo group|Receiving standard treatment plus placebo (5 mls/Kg of normal saline intravenously given over 4 hours).
3227060|NCT01006499|Active Comparator|Pentoxifylline group|Standard treatment plus 6 mg/Kg of Pentoxifylline intravenously (given over 4 hours) daily for three days.
3227061|NCT01006499|Active Comparator|Pentaglobin group|Standard treatment plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days
3227062|NCT01006499|Active Comparator|Pentoxifylline plus Pentaglobin group|Standard treatment plus 6 mg/Kg of Pentoxifylline plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days.
3227063|NCT01006486|Experimental|Anticoagulation clinic|Anticoagulation clinic, including all procedures related to a standardized use of coumarins.
3227064|NCT01006486|Active Comparator|Standard care|Standard use of coumarins, as prescribed by their physicians.
3227065|NCT01006473|Experimental|Exercise training group|Exercise training is performed in subgroups of 6 patients supervised by two physiotherapists. Exercise prescription consisted of a 15-min warm-up, walking up to 30 min, followed by a 15-min cooling-down. The exercise intensity during the first 2 weeks corresponds to 55% at 65% of the HR peak reached at the baseline exercise test. In posterior sessions, individual adjustments are performed with gradual increases in order to reach the adequate target HR training intensity, as determined by the Karvonen formula {(maximal HR - HR at rest) x 50 to 70% + HR at rest}. Exercise training is performed in the morning, three times a week (on alternate days) for a total of 12 weeks (36 sessions).
3227066|NCT01006473|No Intervention|Inactive control group|No intervention
3227067|NCT01006460|Experimental|Adapt 232|
3227068|NCT01006460|Experimental|Arctic root group|
3227069|NCT01006460|Active Comparator|Ginseng group|
3227070|NCT01006460|Placebo Comparator|Placebo group|
3227071|NCT01006447|Active Comparator|Instructor contact 1 class|
3227072|NCT01006447|Active Comparator|Instructor contact 4 classes|
3227073|NCT01006434||Thrombolysis group (Pilot phase)|Patients receiving intravenous thrombolysis for acute ischemic stroke. Pilot phase (100 Patients).
3227074|NCT01006434||Thrombolysis group|Patients receiving intravenous thrombolysis for acute ischemic stroke.
3227251|NCT01005251|Placebo Comparator|Placebo|PPI+ Placebo
3227075|NCT01006408|Active Comparator|Low Level Laser|Low Level Laser twice a week for 8 weeks
3227076|NCT01006408|Sham Comparator|Placebo and Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
3227077|NCT01006395|Active Comparator|zoledronic acid|intervention
3227078|NCT01006395|Placebo Comparator|Placebo|
3227079|NCT01006382||Adolescents and young adults with food allergy|Adolescents aged 13-21 years with a diagnosis of food allergy
3227080|NCT01006369|Experimental|FOLFOX6 + Bevacizumab + Hydroxychloroquine|
3227081|NCT01006369|Experimental|XELOX + Bevacizumab + Hydroxychloroquine|
3227082|NCT01006356|Experimental|Hydromorphone hydrochloride (HCl) oral osmotic system (OROS)|Hydromorphone HCl OROS 8 milligram (mg) once daily for 2 weeks.
3227083|NCT01006343|Experimental|Higher Protein (HP)|Subjects will be required to follow their seven day menu plan for the 12 weeks of intervention. The HP menus will contain 30% protein, 45% carbohydrate, and 25% fat. Subjects in the HP group will be provided with portioned, cooked and frozen pork products as part of their HP menu plan.
3227084|NCT01006343|Experimental|Lower Protein (LP)|Subjects will be required to follow their seven day menu plan for the 12 weeks of intervention. The LP group menus will contain 18% protein, 57% carbohydrate, 25% fat. The LP group will follow a lacto-ovo vegetarian menu with no striated tissue foods. Subjects in the LP group will be provided with selected, portioned dairy products.
3227085|NCT01006330||Elderly medical inpatients|
3227086|NCT01006317|No Intervention|Control|Financial coverage of MCH care within the local reimbursement system (CMS).
3227087|NCT01006317|Experimental|Clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
3227088|NCT01006317|Experimental|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
3227089|NCT01006317|Experimental|Financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
3227090|NCT01006291|Experimental|IDeg OD FF|
3227091|NCT01006291|Experimental|IDeg OD|
3227092|NCT01006291|Experimental|IGlar OD|
3227093|NCT01006278||Surgical group with knee pain|patients 18 years of age or greater with a history of knee pain for more than three but less than six months who failed conservative management with the presence of mechanical symptoms including locking, catching, or giving way; positive physical exam findings including joint line tenderness, McMurray's exam, or Steinman's exam; and MRI of the knee positive for meniscus tear in a location correlating with physical examination. Exclusion criteria were as follows: the presence of high grade gonarthrosis including Kellgren-Lawrence grade IV; a history of prior knee surgery or trauma; ligamentous incompetence on examination or MRI; and diagnosis of inflammatory arthritides, crystalline arthropathies, or other rheumatologic diseases.
3227094|NCT01006278||Group 2|volunteer group
3227095|NCT01006265|Experimental|ACT-128800 Dose 1|ACT-128800 Dose 1
3227096|NCT01006265|Experimental|ACT-128800 Dose 2|ACT-128800 Dose 2
3227097|NCT01006265|Experimental|ACT-128800 Dose 3|ACT-128800 Dose 3
3227098|NCT01006265|Placebo Comparator|Placebo|Matching placebo
3227099|NCT01006252|Experimental|Tasisulam-sodium|Individualized tasisulam-sodium dose was dependent on participant's height, weight, and gender. Dose was adjusted based on laboratory parameters. Treatment was administered intravenously on Day 1 of a 28-day cycle, until disease progression.
3227100|NCT01006252|Active Comparator|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m^2) administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
3227101|NCT01006239||Biorepository|Patients undergoing surgical resection of a solid tumor.
3227102|NCT01006226|Experimental|64Cu-ATSM PET|
3227103|NCT01006213|Experimental|Lifestyle counseling vs motivational intervention|
3227104|NCT01006200||Structural /dynamic airway obstruction|Obstructive granulation tissue formation after SEMS implantation was defined as granulation tissue obstructing the lumen of the SEMS under bronchoscopic examination.
3227105|NCT01006187|Active Comparator|Group 1|1 liposomal lidocaine 4% cream .
3227106|NCT01006187|Active Comparator|Group 2|Vapocoolant spray
3227107|NCT01006187|Active Comparator|Group 3|Rubbing adjacent to the injection site
3227108|NCT01006187|Active Comparator|Group 4|Distraction by means of self-selected reading material or internet
3227109|NCT01006174|Experimental|A|Subjects will be assigned to consume 3 grams soybean oil, 8 grams canola oil, and 20 grams butter that is added to a salad.
3227110|NCT01006174|Experimental|B|Subjects will be assigned to consume 8 grams soybean oil, 20 grams canola oil, and 3 grams butter that is added to a salad.
3227111|NCT01006174|Experimental|C|Subjects will be assigned to consume 20 grams soybean oil, 3 grams canola oil, and 8 grams butter that is added to a salad.
3227112|NCT01006161|Experimental|Low dose SCH 527123|
3227113|NCT01006161|Experimental|Medium dose SCH 527123|
3227114|NCT01006161|Experimental|High dose SCH 527123|
3227115|NCT01006161|Placebo Comparator|Placebo|
3227116|NCT01006148|Experimental|Bone substitute|Enrollees will receive Allogenix Plus(TM), a demineralized bone matrix, to fill in calvarial gaps after cranial vault remodeling and fronto-orbital advancement.
3227117|NCT01006135||COPD patients|
3227118|NCT01006122|Placebo Comparator|Placebo|
3227119|NCT01006122|Active Comparator|PF-03654746|At the end of the second arm of the study, the patient will have completed the study and have a 7-10 day follow-up visit.
3227120|NCT01006096|Experimental|Erlotinib|
3227121|NCT01006096|Placebo Comparator|Placebo tablets|
3227122|NCT01006083||Low-risk patients, not on APAs|Patients not at risk of coronary and/or cerebrovascular disease, and not consuming APAs
3227123|NCT01006083||High-risk patients, not on APAs|Patients at high risk for cardio/cerebrovascular disease (diabetes mellitus, cigarette smoking, hypercholesterolemia, hypertension, morbid obesity), but not taking APAs.
3227252|NCT01005238|Active Comparator|telbivudine|patients in this arm will continue to take telbivudine
3227124|NCT01006083||APA for primary prevention|High-risk patients with cardiovascular risk factors (as above), in whom APA is prescribed as primary prevention of coronary artery disease (CAD).
3227125|NCT01006083||APA for secondary prevention|Patients with a history of a coronary syndrome (stable/unstable angina); MI; transient ischemic attack (TIA)/stroke; severe carotid artery stenosis/stenting; or peripheral vascular disease, on APAs for secondary prevention.
3227126|NCT01006070||Patients with existing spinal fractures|Myeloma patients with documented x-ray evidence of spinal fractures.
3227127|NCT01006070||Patients without spinal fractures|Myeloma patients with bony disease in the spine without existing fractures.
3227128|NCT01006057|Experimental|ESRD|
3227129|NCT01006057|Experimental|Mild|
3227130|NCT01006057|Experimental|Moderate|
3227131|NCT01006057|Experimental|Normal|
3227132|NCT01006057|Experimental|Severe|
3227133|NCT01006044|Experimental|Vaccination|Autologous Dendritic cells loaded with tumor lysate
3227134|NCT01006031|Experimental|PegIFN alfa-2a and Ribavirin|HIV-coinfected patients with compensated cirrhosis by hepatitis C virus, genotype 1 or 4.
3227135|NCT01006018|Experimental|Sitagliptin + Pioglitazone PLACEBO|"Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth~+ pioglitazone PLACEBO daily by mouth"
3227136|NCT01006018|Experimental|Sitagliptin + Pioglitazone|"Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth~+ pioglitazone (TZD) 15 mg daily by mouth"
3227137|NCT01006018|Placebo Comparator|PLACEBO|"Sitagliptin (DPP-IV inhibitor) PLACEBO daily by mouth~+ pioglitazone (TZD) PLACEBO daily by mouth"
3227138|NCT01005992|Experimental|Laser treated scar|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
3227139|NCT01005992|Active Comparator|Standard scar management|The standard scar management arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
3227140|NCT01005979|Experimental|A|
3227141|NCT01005966|Other|Run in|Placebo
3227142|NCT01005966|Experimental|Sodium Fluoride Toothpaste|Sodium fluoride toothpaste
3227143|NCT01005966|Active Comparator|Amine Fluoride Toothpaste|Amine Fluoride
3227144|NCT01005966|Other|675ppmf toothpaste|Dose response
3227145|NCT01005966|Active Comparator|Sodium monofluorophosphate/sodium fluoride Toothpaste|Sodium monofluorophosphate/sodium fluoride Toothpaste
3227146|NCT01005966|Placebo Comparator|0 ppmf toothpaste|
3227147|NCT01005953||Professionals treating autistic children|Special educators, occupational therapists, speech pathologists, behavior analysts who work with children on the spectrum.
3227148|NCT01005953||Families with autistic children (3-10)|
3227149|NCT01005940|Experimental|Mandibular advancement device|Subject is evaluated when receiving intervention with mandibular advancement device.
3227150|NCT01005940|No Intervention|No mandibular advancement device|Subject is evaluated when not receiving treatment with mandibular advancement device.
3227151|NCT01005927|Placebo Comparator|No Fructooligosaccharide|0 g fructooligosaccharide added to calcium-containing beverage
3227152|NCT01005927|Active Comparator|3 g Fructooligosaccharide|3 g fructooligosaccharide added to calcium-containing beverage
3227153|NCT01005914|Experimental|Group 1|"Drug:cyclophosphamide Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3~Drug:cytarabine Day 2 & 3: 3g/m2 IV over 2 hours q12 X 4~Drug:dexamethasone Day 1-4; 11-14: 40 mg daily~Drug:doxorubicin hydrochloride Day 4: 50 mg/m2 IV over 2 hours~Drug:imatinib mesylate 600 mg/day~Drug:methotrexate Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion~Drug: methylprednisolone Day 1-3: 50mg IV BID~Drug: pegaspargase Day 3/Day4: 2,500 IU/ m2 IV~Drug: vincristine sulfate Day 4 & 11: 2 mg IV"
3227154|NCT01005901|Experimental|Glycopyrronium bromide|Glycopyrronium bromide 50µg delivered once daily via Single Dose Dry Powder Inhaler (SDDPI). At visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.
3227155|NCT01005901|Placebo Comparator|Placebo|Placebo delivered once daily via SDDPI. At Visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.
3227156|NCT01005888|Experimental|C1INH-nf First, then Placebo|1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by matching placebo (saline) administered IV every 3 to 4 days for 12 weeks.
3227157|NCT01005888|Experimental|Placebo First, then C1INH-nf|Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by 1,000 U of C1INH-nf administered IV every 3 to 4 days for 12 weeks.
3227158|NCT01005875|Experimental|Radiation followed by Sorafenib|Radiation therapy, stereotactic body radiation therapy followed by Sorafenib
3227159|NCT01005862|Experimental|PF-04360365|
3227160|NCT01005862|Placebo Comparator|Placebo|single dose administered intravenously
3227161|NCT01005849|Experimental|Protecflor|
3227162|NCT01005849|Placebo Comparator|Placebo|
3227163|NCT01005836|Experimental|Cognitive-behavioral therapy: Anxiety|CBT for child anxiety. Coping Cat.
3227164|NCT01005836|Other|Usual care: Anxiety|Usual clinic care
3227165|NCT01005836|Experimental|Cognitive behavioral therapy: depression|CBT for youth depression. The Primary and Secondary Control Enhancement Training protocol.
3227166|NCT01005836|Other|Usual care: Depression|Usual clinic care for depression
3227167|NCT01005823|Active Comparator|LEO 29102 cream 0.3 mg/g|
3227168|NCT01005823|Active Comparator|LEO 29102 cream 1.0 mg/g|
3227169|NCT01005823|Active Comparator|LEO 29102 cream 2.5 mg/g|
3227170|NCT01005823|Placebo Comparator|LEO 29102 placebo cream|
3227171|NCT01005810|Active Comparator|N-Acetylcysteine|
3227172|NCT01005810|Placebo Comparator|Placebo|
3227173|NCT01005797|Experimental|Expansion A|Expansion A -RCC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
3227174|NCT01005797|Experimental|Expansion B|Expansion B -NSCLC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
3227175|NCT01005797|Experimental|Expansion C|Expansion C -STS cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
3227176|NCT01005784|Active Comparator|fixed|
3227177|NCT01005784|Experimental|flexible|
3227178|NCT01005771|Experimental|GF-001001-00 2%|
3227179|NCT01005771|Experimental|GF-001001-00 1%|
3227180|NCT01005771|Experimental|GF-001001-00 0.25%|
3227181|NCT01005771|Placebo Comparator|Placebo|
3227182|NCT01005745|Experimental|TIL With High Dose IL-2|"Day -7 and -6: Cyclophosphamide 60 mg/kg/day I.V. in 250 ml NS over approximately 2 hours. Mesna 20 mg/kg with D5W or NS at 125 ml/hour infused intravenously over 24 hours.~Day -5 to Day -1: Fludarabine 25 mg/m^2 intravenous piggyback (IVPB0 daily over approximately 30 minutes for 5 days.~Day 0: T cell infusion in 250-1000 ml NS over approximately 15-60 minutes depending on volume to be infused.~Days 1-5: High dose IL-2, 720,000 IU/kg IV bolus (about 15 minutes) every 8-16 hours for up to 15 doses, beginning approximately 12-16 hours after T cell infusion."
3227183|NCT01005719|Experimental|Zegerid|Participants receiving Zegerid (omeprazole/sodium bicarbonate) in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants also took approximately 2 oz of water with their medication.
3227184|NCT01005719|Active Comparator|Prevacid®|Participants receiving Prevacid® (lansoprazole) in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants also took approximately 2 oz of water with their medication.
3227185|NCT01005719|No Intervention|No treatment|Participants receiving No treatment in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants took approximately 2 oz of water once daily for 7 days.
3227186|NCT01005706|Active Comparator|Tacrolimus Withdrawal Arm|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
3227187|NCT01005706|Active Comparator|Tacrolimus Minimization Arm|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
3227188|NCT01005680|Experimental|Pemetrexed plus Cisplatin|
3227189|NCT01005680|Active Comparator|Gemcitabine plus Cisplatin|
3227190|NCT01005667|Experimental|BirthTrack Monitor|
3227191|NCT01005667|No Intervention|Control - no BirthTrack Monitor|
3227192|NCT01005641|Experimental|A|phase II
3227193|NCT01005628||001|bortezomib Injection into a vein 1.3 mg/m2 twice a week for 21 days
3227194|NCT01005615|Sham Comparator|No FES Cycling|
3227195|NCT01005615|Active Comparator|FES Cycling|
3227196|NCT01005602|Experimental|Digoxin Dosing per Nomogram|Subjects will have their digoxin maintenance dose determined according to the nomogram we have developed.
3227197|NCT01005602|Other|Standard Digoxin Dosing|This arm represents historical control subjects in whom the dose of digoxin was determined at the physician's discretion using traditional dosing methods.
3227198|NCT01005576|Experimental|Conditioning regimen|Hydroxyurea days -50 to -21 Alemtuzumab days -21 to -19 Fludarabine days -8 to -4 Thiotepa day -4 Melphalan day -3 Stem cell infusion day 0
3227199|NCT01005563|Experimental|Arm 1: Beef/Pork|Participants consuming diet with beef/pork as predominate sources of protein
3227200|NCT01005563|Experimental|Arm 2: Soy/Legumes|Participants consuming diet with soy/legumes as predominate sources of protein
3227201|NCT01005550|Experimental|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
3227202|NCT01005550|Experimental|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
3227203|NCT01005550|Experimental|10 mg of ropivacaine|10 mg of ropivacaine are used for the spinal anaesthesia
3227204|NCT01005550|Experimental|12 mg of ropivacaine|12 mg of ropivacaine are used for the spinal anaesthesia
3227205|NCT01005511|Experimental|Grindcare|24 patients receiving active treatment
3227206|NCT01005511|Placebo Comparator|Placebo treatment|24 patients receive a placebo treatment
3227207|NCT01005498|Experimental|Low carbohydrate diet (F)|The group attended to low carbohydrate diet
3227208|NCT01005498|Active Comparator|Traditional diet (K)|The group attended to traditional diet
3227209|NCT01005485||Group A|Patients undergoing open vascular surgery on arterial structures to better define optimal laboratory and collection techniques for isolation of CECs.
3227210|NCT01005485||Group B|Healthy controls will be recruited from the general medical population, community.
3227211|NCT01005485||Acute Myocardial Infarction|Patients with acute myocardial infarction with or without ST segment deviation.
3227212|NCT01005472|Experimental|sunitinib malate, temozolomide|
3227213|NCT01005459|Active Comparator|tetracaine 2mg|
3227214|NCT01005459|Active Comparator|Bupivacaine 2 mg|
3227215|NCT01005446||RSP Device|Post Market Study
3227216|NCT01005433|Active Comparator|Dexmedetomidine 0.6 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia
3227253|NCT01005238|Experimental|lamivudine|patients in this arm will take lamivudine
3227217|NCT01005433|Active Comparator|Dexmedetomidine 0.4 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 4 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia
3227218|NCT01005433|Active Comparator|Dexmedetomidine 0.2 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia.
3227219|NCT01005433|Placebo Comparator|Placebo|The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 20 min before induction of anesthesia
3227220|NCT01005420|Experimental|Blueberry Powder|"A blueberry smoothie will be consumed at the breakfast and dinner meals.~Nutritional Value:(based on one 16oz smoothie and subjects had to consume two a day)~206.4 Kcals~40.3 g Carbohydrate~11.5 g Protein~0.08 g Fat~0.05 g Sat fat~4.2 g Fiber~Ingredients:~245.0 g Dannon Light & Fit yogurt~105 .0 g Skim milk~22.5 g Freeze-dried blueberry powder~5.0 g Imitation vanilla flavor~1.0 g Splenda~16 oz plastic cup with lid~Smoothie total weight - 378.5 g"
3227221|NCT01005420|Placebo Comparator|Placebo|"A placebo smoothie will be consumed at the breakfast and dinner meals.~Nutritional Value:(based on one 16oz smoothie and subjects had to consume two a day)~201.3 Kcals~40.3 g Carbohydrate~10.7 g Protein~0.08 g Fat~0.05 g Sat fat~4.3 g Fiber~Ingredients:~245.0 g Dannon Light & Fit yogurt~105 .0 g Skim milk~5.0 g Benefiber~12.0 g Sugar~4.0 g Artificial blueberry flavor(liquid & powder)~1.5 g Red food color~0.7 g Blue food color~16 oz plastic cup with lid~Smoothie total weight - 373.2 g"
3227222|NCT01005407|Experimental|HEPLISAV and/or Placebo|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
3227223|NCT01005407|Active Comparator|Engerix-B(1)|1.0 mL Engerix-B
3227224|NCT01005394||Navigated TMS|single arm study where all subjects will be studied using the Navigated TMS device
3227225|NCT01005381|Experimental|Small Particle Size Calcium Carbonate|Subjects are given small particle size calcium carbonate supplement twice daily (total of 625 mg/d from supplement).
3227226|NCT01005381|Active Comparator|Large Particle Size Calcium Carbonate|Subjects are given a large particle size calcium carbonate supplement twice daily (total of 625 mg/d from supplement).
3227227|NCT01005381|Placebo Comparator|Calcium Placebo|Subjects are given two placebo tablets daily, which are identical to the large and small particle size calcium carbonate supplements.
3227228|NCT01005381|Active Comparator|No Vitamin D supplement|Subjects are given calcium carbonate supplement once daily (325 mg/d from supplement).
3227229|NCT01005381|Experimental|Vitamin D supplement|Subjects are given a calcium supplement once daily (325 mg/d from supplement) with 1000 IU/d vitamin D supplement.
3227230|NCT01005368||Group 1|Blood and bone marrow is collected at baseline, 3 months after completion of induction therapy, 2 months after completion of consolidation therapy, 1 year after completion of study treatment, and at disease relapse. Samples are analyzed by FISH for interphase cytogenetics, PCR for IgV_H mutational status, flow cytometry for surface expression of CD38 cells, western blot to assess Mcl-1, Bcl-2, BAK-1, ATM, ZAP-70, and Bar expression, and sequencing for p53 and ATM function.
3227231|NCT01005355|Experimental|IMC-1121B|Participants receiving IMC-1121B intravenously
3227232|NCT01005342|Experimental|Mixture of fiber|Single intake of a mixture of spray-dried oat drink, rye bran and sugar beet fiber
3227233|NCT01005342|Experimental|Sugar beet fiber|Single intake of sugar beet fiber
3227234|NCT01005342|Experimental|Rye bran|Single intake of rye bran
3227235|NCT01005342|Experimental|Oat bran|Single intake of oat bran
3227236|NCT01005342|Experimental|Spray-dried oat drink|Single intake of spray-dried oat drink
3227237|NCT01005342|Placebo Comparator|Control|Single intake of a meal with no added fiber
3227238|NCT01005329|Experimental|Treatment (IMRT, cisplatin,bevacizumab,carboplatin,paclitaxel)|Patients undergo pelvic IMRT once daily, 5 days a week, for 5 weeks. Patients may also undergo optional nodal boost radiotherapy and/or vaginal brachytherapy boost. Patients also receive concurrent cisplatin IV over 1 hour on days 1 and 29 and bevacizumab IV over 30-90 minutes on days 1, 15, and 29. Beginning 4-6 weeks after completing IMRT, cisplatin, and bevacizumab, patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment with carboplatin and paclitaxel repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3227239|NCT01005316||Cohort A: Non-Sensitized|"Cohort A will include participants who are alloantibody Luminex(TM) LABScreen. There is no study mandated care or treatment. All care given is clinical site standard of care. All sites follow a similar standard of care regimen. Non-sensitized recipients receive steroid-free maintenance immunosuppression:~Induction Therapy (anti-T cell antibody induction)~Tacrolimus (Prograf®)~Mycophenolate Mofetil- MMF (CellCept®)."
3227240|NCT01005316||Cohort B: Sensitized|"Cohort B will include participants who are alloantibody positive (Sensitized) as determined by Luminex LabScreen for Class I or Class II with specificities identified by single antigen testing.~There is no study mandated care or treatment. All care given is clinical site standard of care. All sites follow a similar standard of care regimen.~Sensitized recipients receive:~Induction Therapy (anti-T cell antibody induction)~Intraoperative plasma exchange/pheresis~Short-term post-operative plasmapheresis~Post-transplant course of intravenous immunoglobulin (IVIG) therapy~Maintenance corticosteroids (Prednisone)~Tacrolimus (Prograf®)~Mycophenolate Mofetil-MMF (CellCept®)."
3227241|NCT01005303|Placebo Comparator|Placebo|
3227242|NCT01005303|Active Comparator|Micronutrient|
3227243|NCT01005290|Experimental|Combination pill|A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
3227244|NCT01005290|Active Comparator|Ramipril|A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
3227245|NCT01005264|Active Comparator|non-removable fiberglass|Softcast3M®, 3M Health Care, St. Paul, MN (USA) were used for construction of the pressure-relief apparatus
3227246|NCT01005264|Active Comparator|Stabil-D®|Composed of a specifically designed rigid, boat shaped, and fully rocker bottom sole
3227247|NCT01005251|Experimental|60 mg|PPI+lesogaberan (AZD3355) 60 mg bid
3227248|NCT01005251|Experimental|120 mg|PPI+lesogaberan (AZD3355) 120 mg bid
3227249|NCT01005251|Experimental|180 mg|PPI+lesogaberan (AZD3355) 180 mg bid
3227250|NCT01005251|Experimental|240 mg|PPI+lesogaberan (AZD3355) 240 mg bid
3227254|NCT01005225||Solid tumors|Participants 18 years of age or older who have been diagnosed with a solid tumor or benign hyperplasia that needs surgical removal will be included in this study.
3227255|NCT01005199|Experimental|Arm A: Sorafenib standard|• Arm A (standard treatment): Sorafenib 2 x 400 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (46 patients).
3227256|NCT01005199|Experimental|Arm B: Sorafenib + everolimus|• Arm B (investigational treatment): Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (60 patients)
3227257|NCT01005186|Experimental|Active|Active
3227258|NCT01005186|Experimental|Active 2|Active
3227259|NCT01005173||Group A|Subjects receiving recommended doses of acetaminophen in the hospital. 140 Subjects
3227260|NCT01005173||Group B|Healthy Volunteers - No acetaminophen exposure within 14 days of enrollment 23 Subjects
3227261|NCT01005173||Group C|Acetaminophen Overdose Subjects - Hospitalized 90 Subjects
3227262|NCT01005160|Experimental|CKD501|
3227263|NCT01005147|Experimental|Tranexamic acid arm|
3227264|NCT01005147|Placebo Comparator|Control arm|Will receive a placebo in place of tranexamic acid treatment
3227265|NCT01005121|Experimental|colchicine|patients will receive 2 mg of colchicine daily
3227266|NCT01005095|Experimental|High dose vitamin D|800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
3227267|NCT01005095|Active Comparator|Low dose vitamin D|800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
3227268|NCT01005082|Experimental|Low salt diet plus water therapy|
3227269|NCT01005082|Active Comparator|water therapy alone|
3227270|NCT01005069|Experimental|Treatment I|
3227271|NCT01005069|Experimental|Treatment II|
3227272|NCT01005069|Experimental|Treatment III|
3227273|NCT01005069|Experimental|Treatment IV|
3227274|NCT01005069|Placebo Comparator|Placebo|
3227275|NCT01005056||Marvelon®|Single arm study. All participants receive Marvelon® according to the approved dosage and administration method.
3227276|NCT01005043|Experimental|heavy ion radiotherapy|Heavy ion radiotherapy of osteosarcoma with 60 to 66 GyE (20-22 days). Before and after radiotherapy, but not during radiotherapy, chemotherapy is recommended to standard therapy protocols like EURAMOS 1 which is not part of this study.
3227277|NCT01005030||PostCEPT Subjects|Subjects with current Parkinson Disease Diagnosis currently enrolled in PostCEPT study
3227278|NCT01005030||Control Subjects|Non-blood relatives of PostCEPT Subjects matched for age and other demographics
3227279|NCT01005017|Active Comparator|Percutanous RF lesioning|Radiofrequent lesioning uses a high frequency alternating current to heat tissues leading to thermal coagulation. It produces predictable and accurate lesions of the splanchnic nerves.
3227280|NCT01005017|No Intervention|Optimal medical treatment|
3227281|NCT01005004|Experimental|HuCNS-SC cells|Intracerebral implantation of HuCNS-SC via direct injection during surgery
3227282|NCT01004991|Experimental|All patients|subjects will receive azacytidine dose dependent on dose-escalation schedule at time of enrollment - all will receive standard dose RCHOP
3227283|NCT01004978|Experimental|Arm I (sorafenib tosylate and TACE)|Patients receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of sorafenib tosylate is reached, patients undergo TACE comprising doxorubicin hydrochloride, mitomycin C, and cisplatin (closed to accrual as of 10/1/2010); conventional chemoembolization comprising doxorubicin hydrochloride only; or chemoembolization comprising doxorubicin-eluting beads. Treatment with TACE repeats approximately every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3227284|NCT01004978|Active Comparator|Arm II (placebo and TACE)|Patients receive placebo PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of placebo is reached, patients undergo TACE as in Arm I.
3227285|NCT01004965||Group 1|"Samples are obtained: 1) pretreatment, 2) at the time of documentation of refractory disease in acute myeloid leukemia (AML) patients who do not achieve complete response (CR) after induction therapy, and 3) at the time of first relapse in patients who achieve CR.~Marrow cells are preferentially used for all samples, but peripheral blood is acceptable if marrow is not available and the blood contains 20% or more blasts."
3227286|NCT01004952||screening questionnaire|This study will involve two phases. Guided by EDTM, we will first build models of decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing)using in-home ethnographic interviews with 25 melanoma FDRs (Phase I). In Phase II, we will test the validity of each composite model. This will be completed using EMA data collection with 60 different melanoma FDRs from Phase I who will report on their sunscreen use, shade-seeking, use of hat, and use of UVR protective clothing and decision-making regarding these outcomes via interactive voice response (IVR) system and audio narrative diaries (using a digital voice recorder). We will examine the validity of each model and examine the influence of theory-driven affective and cognitive predictors of UVR protection maintenance across time.
3227287|NCT01004939||fondaparinux prescribed subjects|fondaparinux prescribed subjets
3227288|NCT01004926|Experimental|Echelon|
3227289|NCT01004900|Active Comparator|Trabeculoplasty|
3227290|NCT01004900|Active Comparator|Control (Medication)|
3227291|NCT01004887||Single group|Patients with newly diagnosed high-grade gliomas participating in NCCTG/Alliance or Mayo protocols. Previously collected blood and tissue samples are analyzed via PCR, IHC, flow cytometry, and FISH.
3227292|NCT01004874|Experimental|Bevacizumab, XRT, Temozolomide, Topotecan|Patients are treated with standard radiation therapy and daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation. Following completion of radiation therapy, patients have a MRI and, if there is no evidence of disease progression, patients receive 12 cycles of Avastin, temozolomide, and topotecan. Beginning a minimum of 14 days after the last radiation treatment, the Avastin is dosed at 10 mg/kg every other week; temozolomide is given at 150 mg/m2 daily the first 5 days in combination with topotecan on days 2 through 6 at 1.5 mg/ m2 for patient not taking EIAEDs and 2.0 mg/ m2 for patients taking EIAEDs on days 2-6 of each 28-day.
3227293|NCT01004861|Experimental|PLX3397|
3227332|NCT01004458|No Intervention|Waiting list group|The waiting list group served as referents during the trial
3227333|NCT01004445|Experimental|Arm 1|
3227294|NCT01004848|Experimental|Peer-Led Lifestyle Education on Weight Loss|"Project HEED (Help Educate to Eliminate Diabetes), a community-based, peer-led weight loss program for overweight adults with pre-diabetes.~The intervention group will participate in an 8-session course held over a 10-week period. Project HEED (Help Educate to Eliminate Diabetes), led by trained peer educators, aims to help participants lose weight, thereby preventing their progression to diabetes."
3227295|NCT01004848|Placebo Comparator|Delayed Intervention|The control group will be offered the chance to participate in the 8-session course 1 year after enrollment into the trial.
3227296|NCT01004835||Migraine Disease|Patients 10 to 18 years of age with the diagnosis of Migraine disease and at least one of their biologic parents will be included in this study.
3227297|NCT01004822|Experimental|Active Drug|Weekly infusions of CVX-241 at specified doses
3227298|NCT01004809||Dutasteride|Patients administrated dutasteride with male hair loss
3227299|NCT01004770|Experimental|1 (AH113111 Injection)|
3227300|NCT01004770|Active Comparator|2 (Visipaque Injection)|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
3227301|NCT01004757|Active Comparator|LOGI diet|diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled, aerobic exercise
3227302|NCT01004757|Active Comparator|Low Fat diet|cross over design of three weeks Low Fat diet followed by two weeks LOGI diet always combined with heart rate controlled aerobic exercise
3227303|NCT01004744|Experimental|Presurgical anastrozole|1mg PO daily for two weeks prior to surgery
3227304|NCT01004731|Experimental|Cetuximab in combination with Carboplatin/Gemcitabine|Approximately 30 patients with advanced NSCLC will be enrolled. Patients will receive 3-week cycles of Cetuximab in combination with Carboplatin/Gemcitabine.
3227305|NCT01004718|Experimental|Arm I|Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration.
3227306|NCT01004705|Experimental|Fixed Dose Combination Pill|Once daily oral dose of combination of acetylsalicylic acid, simvastatin, and ramipril (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 or 10 mg ramipril)
3227307|NCT01004705|Active Comparator|Simvastatin|Once daily oral dose of Simvastatin 40 mg
3227308|NCT01004666||Women with equivocal findings on Mammography, US and/or MRI|Women with equivocal findings on Mammography, US and/or MRI
3227309|NCT01004666||Discrepancy between clinical examination and imaging|Women with discrepancy between clinical examination and breast imaging
3227310|NCT01004666||Women with dense breast|Women with dense breast
3227311|NCT01004666||Women in high risk for Breast Cancer|Women in high risk for Breast Cancer. Including patients with genetic high risk and/or strong family history.
3227312|NCT01004653|Experimental|H1N1 influenza A Vaccine (Split virion), Inactivated|15 μg H1N1 influenza A Vaccine (Split virion), Inactivated
3227313|NCT01004640||Group 1|"Peripheral blood samples and bone marrow aspirates are collected at baseline and at 3, 6, and 9 months after starting therapy. If patient continues to receive protocol treatment after 9 months, additional peripheral blood samples are collected every 6 months and bone marrow aspirates are taken annually. In the event of disease progression (blast crisis), an additional peripheral blood sample and bone marrow aspirate are collected.~Samples are examined by quantitative Southern blot analysis with probes to BCR, quantitative reverse transcriptase-polymerase chain reaction analysis for BCR/ABL fusion transcripts, and cytogenetic analysis."
3227314|NCT01004627|No Intervention|Control group - selective duplex|Patients will receive a duplex ultrasound only if specifically requested following physical examination.
3227315|NCT01004627|Experimental|Obligatory Duplex scan|Patients will receive a duplex ultrasound regardless of clinical findings. Arterial and venous duplex ultrasound examination
3227316|NCT01004614|Experimental|Cohort 1|24 subjects (12 subjects per sequence) will receive treatment A) one 5 mg amlodipine 3rd OD tablet (test) with water and treatment B) one 5 mg amlodipine 2nd OD tablet (reference) with water.
3227317|NCT01004614|Active Comparator|Cohort 2|24 subjects (12 subjects per sequence) will receive treatment C) one 5 mg amlodipine 3rd OD tablet (test) without water, and treatment D) one 5 mg amlodipine 2nd OD tablet (reference) without water
3227318|NCT01004601|Active Comparator|low dose docetaxel|Low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)
3227319|NCT01004601|Active Comparator|Pemetrexed|Pemetrexed (500 mg/m2 every 3 weeks)
3227320|NCT01004588|Experimental|Protein drink|protein drink
3227321|NCT01004588|Placebo Comparator|Placebo drink|Placebo drink
3227322|NCT01004575|Experimental|Kaname|patients treated with Kaname stent
3227323|NCT01004549||Bilateral intraocular lens implantation.|
3227324|NCT01004536|No Intervention|no treatment|The other half of cesarean section wound that is to be left untreated.
3227325|NCT01004536|Experimental|silicone gel|Randomly-designated half of cesarean section wound that is to be subject to application ot silicone gel
3227326|NCT01004523||Single group|Previously preserved paraffin-embedded tissue blocks are obtained and used for biomarker studies. Blood samples obtained during treatment are also obtained. Loss of heterozygosity of specific chromosomal regions are performed using PCR analysis of microsatellite repeats (41,118-120) on DNA extracted from the paraffin-embedded archival specimens. FISH and flow cytometry may also be used to assess chromosomal loss of deletion. Immunohistochemistry is also performed.
3227327|NCT01004510|Experimental|Zoledronic Acid|Zometa administered as a 15 minute IV infusion of either 4 mg, 3.5mg, 3.3 mg or 3.0 mg every 4 weeks based on the patient's baseline calculated creatinine clearance(CrCl)using the Cockcroft-Gault formula.
3227328|NCT01004497|Experimental|Modified Hyper-CVAD + Dasatinib|Dasatinib: 100 mg once daily, PO, for 4 weeks Cyclophosphamide: 300 mg/m2, IV, every 12 hours, days 1~3 Vincristine: 1.4 mg/m2/day (maximum 2 mg/day), IV, days 4 & 11 Daunorubicin: 45 mg/m2/day, IV, days 4 & 11 Dexamethasone: 40 mg/day, IV, days 1~4 & days 11~14 Cytarabine: 2 g/m2, IV, every 12 hours, days 1~5 Mitoxantrone: 12 mg/m2/day, IV, days 1~2
3227329|NCT01004484|Active Comparator|Yogurt with probiotics and inulin|A probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10^7 cfu/g; 5x10^9 cfu/serving) and Inulin (3gr/serving).
3227330|NCT01004484|Placebo Comparator|Placebo|Acidified dairy snack without yogurt cultures, probiotic or inulin.
3227331|NCT01004458|Active Comparator|Early treatment group|The experimental group receiving CBT
3227335|NCT01004445|Placebo Comparator|Arm 3|
3227336|NCT01004432|Experimental|Open-label (OL) Overall Group: Golimumab 50 mg SC + MTX|All enrolled and dosed participants receive golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks + Methotrexate (MTX) from Week 0 to Week 12.
3227337|NCT01004432|Experimental|Double blind (DB) Group 2a: Golimumab 50mg SC & Placebo IV+MTX|Participants, who do not achieve Disease Activity Score in 28 joints (DAS28) good response at Week 16, will be randomly assigned to receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 16 to Week 48, along with placebo matched to golimumab intravenous infusion (IV) at Week 16, 20, 28, 36, and 44.
3227338|NCT01004432|Experimental|DB Group 2b: Golimumab 2mg/kg IV & Placebo SC + MTX|Participants, who do not achieve DAS28 good response at Week 16, will be randomly assigned to receive golimumab 2 milligram per kilogram (mg/kg) intravenous infusion (IV) + MTX, at Week 16, 20, 28, 36 and 44, along with placebo matched to golimumab SC injection every 4 weeks from Week 16 to Week 48.
3227339|NCT01004432|Experimental|OL Group 1: Golimumab 50 mg SC + MTX|Participants, who achieve DAS28 good response at Week 16, will receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 16 to Week 48.
3227340|NCT01004432|Experimental|OL Study Extension Group: Golimumab 50 mg SC + MTX|Participants who complete the main study (Week 0 to Week 52), do not meet lack of efficacy criteria, and participate in the OL study extension, will receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 52 to Week 72.
3227341|NCT01004419|Experimental|Vandetanib plus fulvestrant|vandetanib by mouth once daily for 28 days plus fulvestrant intra-muscular injection each cycle
3227342|NCT01004406|Experimental|Arm 1|Patients undergoing clinically indicated, non-emergent coronary angiography and PCI with IVUS-VH of target coronary artery for ACS.
3227343|NCT01004406|Experimental|Arm 2|Patients undergoing clinically indicated, non-emergent coronary angiography and PCI with IVUS-VH of target coronary artery for ACS.
3227344|NCT01004393|Experimental|Methylnaltrexone bromide|A single dose of methylnaltrexone will be administered subcutaneously to eligible subjects based on weight at the study entry. Since we will include subjects at all stages of cancer management, administering this study drug is considered experimental. We will use the dose approved by FDA, i.e., 0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg.
3227345|NCT01004380|Experimental|Farletuzumab|2.5 mg/kg once weekly administered i.v. during the Combination treatment period and 7.5 mg/kg Q3W administered i.v. during the Maintenance period
3227346|NCT01004367|Experimental|1|Environmental- and individual based components carried out in the school.
3227347|NCT01004354|Experimental|Vitamin D|
3227348|NCT01004341|Other|Family-based weight control|Group-based family therapy for weight loss in children age 8-12 years.
3227349|NCT01004328|Experimental|Intervention Group 1|All participants
3227350|NCT01004315|Experimental|KUC-7483|
3227351|NCT01004315|Placebo Comparator|Placebo|
3227352|NCT01004315|Active Comparator|Tolterodine|
3227353|NCT01004302|Sham Comparator|Sham surgery|
3227354|NCT01004302|Active Comparator|Active radiosurgery|
3227355|NCT01004289|Active Comparator|Control|Primary angioplasty and stenting without additional intervention.
3227356|NCT01004289|Experimental|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion.
3227357|NCT01004276|Experimental|Improved module|
3227358|NCT01004276|No Intervention|Standard module|
3227359|NCT01004263|Experimental|Rizatriptan|Rizatriptan benzoate
3227360|NCT01004250|Experimental|Study Treatment|
3227361|NCT01004237|Active Comparator|pravastatin|
3227362|NCT01004237|Active Comparator|valsartan|
3227363|NCT01004237|Active Comparator|pravastatin combined with valsartan|
3227364|NCT01004224|Experimental|BGJ398|
3227365|NCT01004211|Active Comparator|Standard transurethral resection|Patients will be submitted to standard white light transurethral resection and/or cold cup biopsies of all visible lesions known or suspected to be bladder cancer; 6 random cold cup biopsies from healthy mucosa of bladder trigone, anterior, posterior and lateral walls will be taken in case of a second transurethral resection of newly diagnosed high grade non muscle invasive bladder cancer or of recurrent high grade non muscle invasive bladder cancer
3227366|NCT01004211|Experimental|Narrow band imaging transurethral resection|The system will be switched to narrow band imaging by simply pushing a button. Transurethral resection and/or cold cup biopsies of all visible lesions known or suspected to be bladder cancer will be performed; 6 random cold cup biopsies from healthy mucosa of bladder trigone, anterior, posterior and lateral walls will be taken in case of a second transurethral resection of newly diagnosed high grade non muscle invasive bladder cancer or of recurrent high grade non muscle invasive bladder cancer.
3227367|NCT01004198|Experimental|MP4OX - 250|250 mL dose
3227368|NCT01004198|Experimental|MP4OX - 500|500 mL dose
3227369|NCT01004198|Active Comparator|Ringers Lactate solution|500 mL dose
3227370|NCT01004185|Experimental|High Dose|2.0 - 4.8 g/day Asacol dependent on body weight
3227371|NCT01004185|Experimental|Low Dose|1.2 - 2.4 g/day Asacol dependent upon body weight
3227372|NCT01004172|Experimental|carboplatin, bevacizumab, trastuzumab (if HER2+)|"Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration was 28 days.~carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only~*8mg/kg loading dose in cycle 1 for some participants"
3227373|NCT01004159|Experimental|cetuximab with irinotecan|
3227374|NCT01004146|Placebo Comparator|Control group|Patients assigned to the control group were educated on the proper technique of using the incentive spirometer and were instructed to use it for 3 breaths once per day to become able to use the device properly and consistently.
3227375|NCT01004146|Experimental|Experimental Group|Patients assigned to the experimental group were instructed to use the spirometer by inhaling as slowly and deeply as possible in a set of 10 times and to repeat the process at least 5 times every day until the day of surgery.
3227376|NCT01004133||Subjects 80 years of age or older without chronic diseases.|
3227379|NCT01004107|Experimental|Radiesse Injectable Dermal Filler|Device: Radiesse Injectable Dermal Filler
3227380|NCT01004107|Active Comparator|Delayed Treatment|Cross over to treatment with Radiesse Injectable Dermal Filler at 3 Months
3227381|NCT01004094|Experimental|simple goal setting|This group will only set a goal.
3227382|NCT01004094|Experimental|goal setting plus action intentions|This group will set goals and form action intentions (plans) to facilitate goal attainment.
3227383|NCT01004094|Experimental|goal setting plus coping intentions|This group will set goals and form coping intentions (plans) to facilitate goal attainment.
3227384|NCT01004094|Experimental|goal setting plus action intentions plus coping intentions|This group will set goals, form action intentions (plans), and form coping intentions (plans) to facilitate goal attainment.
3227385|NCT01004081|Experimental|BIIB021 BID + exemestane|BIIB021 100 mg BID + exemestane 25 mg QD
3227386|NCT01004081|Experimental|BIIB021 TIW + exemestane|BIIB021 450 mg TIW + exemestane 25 mg QD
3227387|NCT01004068|Experimental|SET-diet plus clomiphene|Structured exercise program plus hypocaloric diet for two months and received one-cycle of clomiphene citrate for one cycle
3227388|NCT01004068|Active Comparator|Clomiphene citrate|One month of observation followed by one-cycle of clomiphene citrate therapy
3227389|NCT01004068|Experimental|SET plus diet|Lifestyle modifications for two months.
3227390|NCT01004055|Experimental|Procellera™ Wound Dressing|
3227391|NCT01004055|Active Comparator|ACTICOAT™|
3227392|NCT01004055|Active Comparator|Mepilex® Ag|
3227393|NCT01004042|Active Comparator|Depressed subjects|Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.
3227394|NCT01004042|Active Comparator|Non Depressed subjects|Subjects with no diagnosis of depression
3227395|NCT01004029|Placebo Comparator|Vehicle|Castor Oil
3227396|NCT01004029|Active Comparator|Hydroxyprogesterone Caproate Injection, 250 mg/mL|HPC 250 mg/mL in oil
3227397|NCT01004016|Placebo Comparator|Placebo|
3227398|NCT01004016|Experimental|KPS-0373|
3227399|NCT01004003|Experimental|BIBF 1120|Phase I dose escalation and phase II using dose determined in phase I ( 200 mg BID)
3227400|NCT01004003|Active Comparator|Sorafenib|
3227401|NCT01003990|Experimental|Atazanavir|
3227402|NCT01003990|Experimental|Atazanavir/Ritonavir|
3227403|NCT01003990|Active Comparator|Lopinavir/Ritonavir|Ritonavir-boosted Lopinavir (LPV/RTV 400/100 mg) administered twice a day (BID) with Tenofovir/ Emtricitabine (TDF/FTC).
3227404|NCT01003977||Xience V|Patients treated with a Xience V everolimus-eluting stent
3227405|NCT01003964|Experimental|ERCC1 negative - GP|Gemcitabine (1250 mg/m2) IV on D 1, 8. Cisplatin (75 mg/m2) IV on D1 every 3 weeks.
3227406|NCT01003964|Experimental|ERCC1 positive - IP|Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks
3227407|NCT01003964|Experimental|ERCC1 positive - GP|Gemcitabine (1250 mg/m2) IV on day1, 8 Cisplatin (75 mg/m2) IV on day1 every 3 weeks
3227408|NCT01003964|Experimental|ERCC1 negative - IP|Irinotecan (65 mg/m2) IV on day1, 8 Cisplatin (30 mg/m2) IV on day 1, 8 every 3 weeks
3227409|NCT01003951|Experimental|Acupuncture|Each patient will receive two acupuncture treatments each week for four consecutive weeks. At the end of four weeks, the intervention will be complete.
3227410|NCT01003938|Experimental|topotecan and erlotinib|Topotecan 0.4 mg/m^2/day administered via continuous infusion for 9 days beginning on Day 1, every 21 days cycle; erlotinib 150 mg daily for 9 days every 21 days cycle. Both drugs will be given for a minimum of 2 cycles.
3227411|NCT01003925||Usual Care|Patients randomized to the control group will be sent the post-test measures suitably modified to reflect the fact that they did not participate in the conjoint analysis program. Four weeks after the post-test measures are completed, a staff member will call the subject to complete a 10 minute follow-up questionnaire to assess if any changes in treatment have occurred and to take further measurements (same measurements given to treatment group).
3227412|NCT01003925||Conjoint Analysis Group|Patients randomized to the experimental group will meet the research staff to complete the conjoint analysis software and post-test measures. The post-test measures include preparedness for decision-making, personal uncertainty, osteoarthritis knowledge, arthritis self-efficacy, and satisfaction with the results of the conjoint analysis program. The in-person visit takes approximately 60 minutes to complete. Four weeks after the in-person visit, a staff member will call the subject to complete a 10 minute follow-up questionnaire to assess if any changes in treatment have occurred and to take further measurements (i.e. global pain assessment, arthritis self-efficacy, personal uncertainty, and osteoarthritis knowledge).
3227413|NCT01003899|Experimental|afatinib (BIBW 2992)|patient to receive afatinib(BIBW 2992) po QD in an open-label manner
3227414|NCT01003886||Open Label|Adult male diagnosed with BPH and prescribed with Doxazosin mesylate GITS
3227415|NCT01003873||Bypass gastric|First arm is represented by obese patients that will be studied before and after a gastric bypass. They will be studied before surgery as well as 1 month and 6 months after surgery.
3227416|NCT01003873||Lifestyle intervention|The second group is represented by obese patients that will be studied before lifestyle intervention, 6 months after the beginning of the intervention and after a time that will allow patients to lose the same amount of weight that patients that had been through surgery had lost one month after surgery.
3227417|NCT01003873||Control subjects|The third group is a control group of normal weight people that will be studied at one time and after 6 months with stable weight.
3227418|NCT01003860||0.5% Ropivicaine (150 mg)|
3227419|NCT01003860||0.75% Ropivicaine (225 mg)|
3227420|NCT01003847|Active Comparator|fenofibrate|
3227421|NCT01003847|Active Comparator|fatty acid|drug
3227422|NCT01003847|Active Comparator|Placebo|
3227423|NCT01003834|Placebo Comparator|Control|Screening only
3227424|NCT01003834|Active Comparator|Assessment|Screening plus assessment
3227425|NCT01003834|Experimental|Computer Intervention|Screening, assessment, and computer-delivered intervention
3227426|NCT01003834|Active Comparator|Therapist Intervention|Screening, Assessment, and therapist-delivered intervention
3227427|NCT01003808|Experimental|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
3227428|NCT01003795||Promus|Patients treated with at least one Promus, everolimus-eluting, Stent
3227429|NCT01003769|Experimental|Treatment (lenalidomide in combination with AT-101)|Patients receive lenalidomide PO QD on days 1-21. Beginning in course 2, patients also receive AT-101 PO BID on days 1-3. Treatment repeats every 28 days for up to 11 courses (49-56 days for course 12 or last course of treatment) in the absence of disease progression or unacceptable toxicity.
3227430|NCT01003756|Experimental|Knee Intervention|Patients undergoing Total Knee Replacement. Exercise 8-10 weeks preoperatively
3227431|NCT01003756|No Intervention|Knee Control|Patients undergoing Total Knee Replacement. Receives standard instructions
3227432|NCT01003756|Experimental|Hip Intervention|Patient undergoing Total Hip Replacement. Exercise 8-10 weeks preoperatively
3227433|NCT01003756|No Intervention|Hip Control|Patients undergoing Total Hip Replacement. Receives standard instructions
3227434|NCT01003730|Active Comparator|1|High tidal volume (15mL/kg PBW0 with low PEEP (3cm H2O
3227435|NCT01003730|Active Comparator|2|Low tidal volume (6mL/kg PBW) and high PEEP (3cm H2O)
3227436|NCT01003730|Active Comparator|3|low tidal volume (6mL/kg PBW) and high PEEP (10cm H2O)
3227437|NCT01003717||Endeavor|Patients treated with at least 1 Endeavor, zotarolimus-eluting, Stent as the primary treatment for acute coronary syndrome
3227438|NCT01003704||General Anesthesia only|
3227439|NCT01003704||Peripheral nerve block|
3227440|NCT01003704||spinal|
3227441|NCT01003691|Experimental|Arm 1|
3227442|NCT01003678|Experimental|Level 1|1 mg daily for 5 consecutive days followed by 23 days off drug
3227443|NCT01003665||Intensive Care treatement|ASA status 3 or 4 patients with invasive blood pressure measurement on the intensive care unit
3227444|NCT01003652||Harmonic Focus /conventional haemostasis|
3227445|NCT01003652||Harmonic Focus|
3227446|NCT01003652||new surgical device|
3227447|NCT01003652||Harmonic Focus / conventional haemostasis|Harmonic Focus group refers to the use of ultracision shears for haemostasis and conventional haemostasis group refers to the tie-and-clamp technique in total thyroidectomy
3227448|NCT01003639|Active Comparator|Acetazolamide|Acetazolamide given in escalating doses
3227449|NCT01003639|Placebo Comparator|Sugar pill|"Given in escalating dose (number of pill)"
3227450|NCT01003626|Experimental|IFP Measurement|Tumor interstitial fluid pressure (IFP) assessments
3227451|NCT01003613|Active Comparator|Tranilast|CAT with FG and Tranilast and MMC 0.02%
3227452|NCT01003613|Placebo Comparator|Control|CAT with FG and MMC 0.02%
3227453|NCT01003600||Questionnaire|This study is a cross-sectional survey study to be administered to adults who completed treatment for nonmetastatic colorectal cancer at MSKCC or at Queens Cancer Center (QCC) at Queens Hospital between 6 months and 2 years ago and have no evidence of disease at the time of study enrollment.
3227454|NCT01003587|Experimental|District health information package|
3227455|NCT01003587|No Intervention|No Intervention|
3227456|NCT01003574|Other|Control Arm|Control arm will receive standard care for risk of cardiac sequelae - a mailed, tailored (neither generic nor targeted) print summary of individualized information about the survivor's treatment, late effects risks, and recommended follow-up and lifestyle modifications.
3227457|NCT01003574|Other|Test Arm|Test arm will receive standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
3227458|NCT01003561|Experimental|ultrasonographic exam|
3227459|NCT01003548|Active Comparator|Static culture|Embryos individually cultured in microdrops of 40 microliters of G-IVFplus series V
3227460|NCT01003548|Experimental|Smart plataform|Embryos culture in dynamics microfluidic culture system
3227461|NCT01003535||[123I]5-IA-85380 SPECT|
3227462|NCT01003522|Other|Treatment Arm A|Stenting of central lesion and subsequent standard palliative treatment and dyspnoea symptom control
3227463|NCT01003522|Other|Treatment Arm B|Standard palliative treatment and standard dyspnoea symptom control.
3227464|NCT01003509|No Intervention|study, control|Control: Only modified shouldice repair performed Study: Modified Shouldice + Moloney repairs performed
3227465|NCT01003509|No Intervention|modified shouldice and double|one arm is only modified shouldice, other one is double
3227466|NCT01003496|Active Comparator|Treatment as Usual (TAU)|
3227467|NCT01003496|Experimental|TAU + Long-Term Recovery Management (LTRM)|
3227468|NCT01003483|Experimental|orlistat|
3227469|NCT01003470|Experimental|acupuncture|
3227470|NCT01003470|Active Comparator|rehabilitation|
3227471|NCT01003470|Active Comparator|acupuncture and rehabilitation|
3227472|NCT01003457||detrusor overactivity|
3227473|NCT01003444|Experimental|Cohort 1|Muscle biopsy in healthy volunteers
3227474|NCT01003431|Experimental|1|RotaTeq™ + DTwP
3227475|NCT01003431|Active Comparator|2|Rotarix™ + DTwP
3227476|NCT01003431|Active Comparator|3|RotaTeq™ + DTaP
3227477|NCT01003418|Experimental|Group A|Subjects will receive two doses of investigational vaccine regimen according to a 0-28 day schedule
3227478|NCT01003418|Experimental|Group B|Subjects will receive two doses of investigational vaccine regimen according to a 0-4 month schedule
3227479|NCT01003405|Experimental|KUC-7483|
3227480|NCT01003392||Normal|Normal volunteers, with no diagnosed chronic disease.
3227481|NCT01003392||Coronary artery disease|Group of patients with diagnosed coronary artery disease.
3227482|NCT01003392||Diabetes|Diabetic patients.
3227483|NCT01003379|Experimental|TC-5619|TC-5619 capsules will be administered once a day in a forced titration scheme at 1 mg for 4 weeks, 5 mg for 4 weeks and 25 mg for 4 weeks (12 weeks total).
3227484|NCT01003379|Placebo Comparator|Placebo|
3227485|NCT01003366|Experimental|bevel down|approaching the IJV with the needle bevel facing down
3227486|NCT01003366|Active Comparator|bevel up|approaching the IJV with the needle bevel facing up
3227487|NCT01003340|Experimental|Wee Wheezers asthma education|6 lesson asthma education delivered at home by Community Health Workers
3227488|NCT01003327|Other|I-gel inserted first|The I-gel airway is insewrted first, then the LMA-Unique
3227489|NCT01003327|Other|LMA-Unique inserted first|LMA-Unique airway is inserted first, then the I-gel
3227490|NCT01003314|Experimental|Group 1|
3227491|NCT01003314|Experimental|Group 2|
3227492|NCT01003301|Experimental|Omalizumab|Active treatment: Experimental This arm will receive treatment with omalizumab at the dose FDA-approved for the treatment of allergic asthma.
3227493|NCT01003301|Placebo Comparator|Placebo|This arm will receive treatment with a placebo injections based on the FDA-approved dosing schedule approved for omalizumab for the treatment of allergic asthma.In general injection number and frequency are determined by a subject's weight and IgE level.
3227494|NCT01003288|Experimental|Pandemic influenza H1N1 vaccine|Influenza vaccine
3227495|NCT01003275|Active Comparator|Paricalcitol followed by placebo|Participants will receive paricalcitol for 8 weeks, then an 8-week wash-out, then placebo for 8 weeks.
3227496|NCT01003275|Active Comparator|Placebo followed by paricalcitol|Participants will receive placebo for 8 weeks, then an 8-week wash-out, then paricalcitol for 8 weeks.
3227497|NCT01003262|Experimental|Emergency Department Observation|The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria
3227498|NCT01003262|Active Comparator|Unstructured, inpatient evaluation|
3227499|NCT01003249|Active Comparator|Baclofen, Then Placebo|Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. There will be a washout period after three week. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group. Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg
3227500|NCT01003249|Placebo Comparator|Placebo, Then Baclofen|Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. There will be a washout period after three week. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group. Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg
3227501|NCT01003236|Placebo Comparator|placebo|1 tablet 3 times daily
3227502|NCT01003236|Experimental|Milk Thistle extract|1 tablet of the extract (equivalent to 140 mg silymarin) 3 times per day
3227503|NCT01003223|Experimental|PKM modeling with graphical report|
3227504|NCT01003210|Experimental|Homeopathic ear drops|Commercially available homeopathic ear drops
3227505|NCT01003210|No Intervention|standard therapy|standard therapy for otitis media, no ear drops
3227506|NCT01003197||complication group < III|
3227507|NCT01003197||complication group >= III|
3227508|NCT01003184|Experimental|1|
3227509|NCT01003184|Active Comparator|2|
3227510|NCT01003171|Experimental|MCS-2|
3227511|NCT01003158|Experimental|Monotherapy part|AZD8931 monotherapy
3227512|NCT01003158|Experimental|Combination part|AZD8931 plus paclitaxel
3227513|NCT01003145|Experimental|H1N1 vaccine of 15 μg HA on Day 0|"15 μg HA (0.5 mL) per injection, 1 injection~50 adults (aged 18~60 years) were assigned to receive one injection of H1N1 vaccine"
3227514|NCT01003145|Experimental|H1N1 vaccine of 15 μg HA on Day 0 and 21|"15 μg HA (0.5 mL) per injection, 2 injections~50 adults (aged 18~60 years) and 50 elders (aged over 60 years) were assigned to receive two injections of H1N1 vaccine 3 weeks apart"
3227515|NCT01003145|Experimental|H1N1 vaccine of 30 μg HA on Day 0 and 21|"30 μg HA (1 mL) per injection, 2 injections~50 adults (aged 18~60 years) and 50 elders (aged over 60 years) were assigned to receive two injections of H1N1 vaccine 3 weeks apart"
3227516|NCT01003132|No Intervention|Treatment As Usual|Treatment as usual as determined by the clinical team responsible for the individual's care
3227517|NCT01003132|Active Comparator|Acceptance and Commitment Therapy|Up to 10 sessions of Acceptance and Commitment Therapy plus treatment as usual
3227518|NCT01003119|Experimental|A CHESS|Those in the ACHESS arm will also be given a smart-phone with access to the ACHESS system (the intervention) for a full 12 months. The ACHESS intervention includes: 1) the Core CHESS system that has been tested in several diseases, 2) a proactive computer-based relapse prevention system, 3) data transfer from the phone to a computer accessible by the patient's counselor/care manager, and 4) systems for the patient to maintain contact with his/her Care Manager
3227519|NCT01003119|No Intervention|Usual Care|Those randomized into the Usual Care group will receive usual medical care.
3227520|NCT01003106|Experimental|BRVO- Ranibizumab 0.5mg alone|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg of ranibizumab alone as per protocol without laser photocoagulation.
3227521|NCT01003106|Experimental|BRVO- Pro re nata (prn) ranibizumab with laser|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, and additional laser photocoagulation if required.
3227522|NCT01003106|Experimental|BRVO- Ranibizumab 2.0mg alone|Branch retinal vein occlusion patients randomized to this group will receive 2.0mg of ranibizumab alone as per protocol without laser photocoagulation.
3227523|NCT01003106|Experimental|BRVO- Pro re nata (prn) ranibizumab|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, without additional laser photocoagulation.
3227524|NCT01003106|Experimental|CRVO- Ranibizumab 0.5mg alone|Central retinal vein occlusion patients randomized to this group will receive 0.5mg of ranibizumab alone as per protocol without laser photocoagulation
3227525|NCT01003106|Experimental|CRVO- Pro re nata (prn) ranibizumab with laser|Central retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, and additional laser photocoagulation if required.
3227526|NCT01003106|Experimental|CRVO- Ranibizumab 2.0mg alone|Central retinal vein occlusion patients randomized to this group will receive 2.0mg of ranibizumab alone as per protocol without laser photocoagulation.
3227583|NCT01002651|Experimental|Wheat Bran Extract (low dose)|
3227527|NCT01003106|Experimental|CRVO- Pro re nata (prn) ranibizumab|Central retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, without additional laser photocoagulation.
3227528|NCT01003093|Experimental|Antigen group + high adjuvans|The antigen group + high adjuvans group received two injections of antigen (Ag85B + ESAT-6) + IC31 (500 nmol KLK + 20 nmol ODN1a) two months apart.
3227529|NCT01003093|Experimental|Antigen group|The antigen group received two injections of antigen (Ag85B + ESAT-6) two months apart.
3227530|NCT01003093|Experimental|Antigen + low adjuvans group|The antigen group + low adjuvans group received two injections of antigen (Ag85B + ESAT-6) + IC31 (100 nmol KLK + 4 nmol ODN1a) two months apart.
3227531|NCT01003080|Experimental|TKA with the Aquamantys for hemostasis|This arm will receive the total knee arthroplasty with the Aquamantys device used for hemostasis.
3227532|NCT01003080|Active Comparator|TKA without the Aquamantys for hemostasis|This group will receive total knee arthroplasty using the standard treatment for hemostasis.
3227533|NCT01003067|No Intervention|No Mesh|
3227534|NCT01003067|Experimental|Mesh Implementation|
3227535|NCT01003054|Experimental|Autologous Transplantation|Busulfan 130 mg/m^2 intravenous (IV) every 24 hours Days -7 to -4; Cyclophosphamide 60 mg/kg over 4 hours Day -3 and -2; Imatinib Mesylate Starting dose 100 mg/day, and Autologous Stem Cell Transplantation on Day 0.
3227536|NCT01003041||lifestyle counseling|in the future parents will be advised to expose their infants to phonetic sounds in order to develop their phonetic categories in the future
3227537|NCT01003028|Experimental|Limited|Limit the maximum plasma concentration target to 9.8 ng/ml
3227538|NCT01003028|Active Comparator|Control|Use 20 ng/ml as max plasma concentration
3227539|NCT01003015|Experimental|Arm 1|
3227540|NCT01003002||PD Cohort|The cohort for this study is Parkinson's disease patients that are beginning oral levodopa treatment within one month of the screening visit. This cohort has not previously (to the screening visit) been treated with oral levodopa.
3227541|NCT01002989||All eligible patients|"Subjects assessed for hypertension, were subjected to the measurement of ankle brachial index (ABI) by two methods:~Doppler~WatchBP Office oscillometric The order for performing the two methods was randomized."
3227542|NCT01002963|Experimental|PF-04418948 30 mg|
3227543|NCT01002963|Experimental|PF-04418948 100 mg|
3227544|NCT01002963|Experimental|PF-04418948 300 mg|
3227545|NCT01002963|Experimental|PF-04418948 1000 mg|
3227546|NCT01002963|Experimental|PF-04418948 3000 mg|
3227547|NCT01002963|Experimental|PF-04418948 4500 mg|
3227548|NCT01002963|Experimental|PF-04418948 6000 mg|
3227549|NCT01002950|Experimental|ACU-4429 tablet|
3227550|NCT01002950|Placebo Comparator|Matching placebo tablet|
3227551|NCT01002937||Tumour tissue, renal cell carcinoma|> 2mm x 2mm of tumour tissue obtained from paraffin blocks taken from biopsies or nephrectomy specimens.
3227552|NCT01002924|Experimental|All Participants|All participants invited to enroll on study will receive EC145 (vintafolide) 2.5 mg by intravenous bolus on Monday, Wednesday, and Friday of Weeks 1 and 3 in each 4-week cycle.
3227553|NCT01002911|Experimental|Aggressive Antibiotic therapy|Patients receive preoperative intravenous antibiotics, intracavitary antibiotics during surgery and postoperative antibiotics.
3227554|NCT01002911|Active Comparator|Conventional Antibiotic Therapy|Preoperative intravenous antibiotics
3227555|NCT01002898|Experimental|lopinavir/ritonavir|
3227556|NCT01002872|Active Comparator|Lanthanum Carbonate|
3227557|NCT01002872|Placebo Comparator|Placebo|
3227558|NCT01002859|Active Comparator|cyclosporin|Intravenous cyclosporin injection.
3227559|NCT01002859|Placebo Comparator|Pacebo|Intravenous injection of NaCl solution.
3227560|NCT01002846|Experimental|traditional acupuncture|Procedure : ST 36 and PC 6 are selected, subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth
3227561|NCT01002846|Sham Comparator|sham acupuncture|Procedure : Beside 1cm of ST 36 and PC 6 are selected( not meridian point), subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
3227562|NCT01002833|Experimental|PfA|Exposure of human volunteers to bites of mosquitoes infected with the A strain of Plasmodium falciparum
3227563|NCT01002833|Experimental|PfB|Exposure of human volunteers to bites of mosquitoes infected with the B strain of Plasmodium falciparum
3227564|NCT01002833|Active Comparator|NF54|Exposure of human volunteers to bites of mosquitoes infected with the NF54 strain of Plasmodium falciparum
3227565|NCT01002820|Experimental|participants|all subjects participating in 0602 are receiving ganaxolone for seizure control
3227566|NCT01002807|Other|FDC of dapagliflozin/metformin XR|
3227567|NCT01002807|Other|FDC of dapagliflozin/reduced mass metformin XR|
3227568|NCT01002807|Other|dapagliflozin and Glucophage® XR|
3227569|NCT01002794|Experimental|Arthroscopic partial meniscectomy|Standard arthroscopic partial meniscectomy - NGD 1
3227570|NCT01002794|Experimental|Exercise Therapy|Supervised neuromuscular- and strength training
3227571|NCT01002768|Experimental|IDeg|
3227572|NCT01002768|Experimental|IGlar|
3227573|NCT01002755|Experimental|Lenalidomide + Ofatumumab|Lenalidomide 10 mg daily up to 24 cycles (cycle = 28 day); Ofatumumab IV infusions 300 mg week 1; 1,000 mg week 2, 3 and 4, then monthly during months 2-6 and once every two months during months 7-24.
3227574|NCT01002742|Experimental|Placebo|Corticosteroids with placebo
3227575|NCT01002742|Experimental|Mycophenolate Mofetil|Corticosteroids with Mycophenolate Mofetil
3227576|NCT01002703|Experimental|RBP|Lenalidomide and Bendamustine and Prednisone
3227577|NCT01002690|Experimental|Etoricoxib|10-13 days treatment with etoricoxib
3227578|NCT01002677|Experimental|Curriculum|
3227579|NCT01002677|Active Comparator|Self-directed|
3227580|NCT01002664|Active Comparator|MCS-2|Drug Name: MCS-2 Dosage: 2 soft-gel capsules Frequency: Qd per day after dinner Duration: 12 weeks
3227581|NCT01002664|Placebo Comparator|Placebo|Drug Name: MCS-2 placebo Dosage: 2 soft-gel capsules Frequency: Qd per day after dinner Duration: 12 weeks
3227582|NCT01002651|Experimental|Wheat Bran Extract (high dose)|
3227584|NCT01002651|Placebo Comparator|placebo|
3227585|NCT01002638|Experimental|Occlusive Dressing|
3227586|NCT01002638|Active Comparator|Surgery|
3227587|NCT01002625|Experimental|1. PF-04457845 followed by placebo|PF-04457845 followed by placebo
3227588|NCT01002625|Experimental|2. Placebo followed by PF-04457845|Placebo followed by PF-04457845
3227589|NCT01002599|Experimental|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
3227590|NCT01002599|Active Comparator|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
3227591|NCT01002586|Experimental|Wii-Fit arm|Half hour daily, five days a week, for 8 weeks
3227592|NCT01002586|Active Comparator|Walking arm|Half hour daily, five days a week, for 8 weeks
3227593|NCT01002573|Experimental|ibuprofen|Ibuprofen, 10 mg/kg
3227594|NCT01002573|Active Comparator|Acetaminophen|Acetaminophen, 10mg/kg
3227595|NCT01002560||Malignant melanoma tumour tissue|
3227596|NCT01002560||Benign pigmented lesions & other skin cancers|Normal skin, benign melanocytic tumours, and skin cancers from lineages other than melanocytic, to be used as negative controls
3227597|NCT01002547|Placebo Comparator|Arm 1|Diabetic with proven NASH by biopsy
3227598|NCT01002547|Active Comparator|Arm 2|Diabetic with proven NASH by biopsy
3227599|NCT01002547|Other|Arm 3|Diabetic with proven NASH by biopsy
3227600|NCT01002534|No Intervention|baseline|visit 1
3227601|NCT01002534|Active Comparator|Vardenafil|nasal instillation of Vardenafil ( visit 2 or 3)
3227602|NCT01002534|Placebo Comparator|Placebo|Nasal instillation of placebo (visit 3 or 2)
3227603|NCT01002521||Cases|Persons With Diabetes (PWD) who have current non-healing ulcer(s)
3227604|NCT01002521||Controls|Persons With Diabetes (PWD) with no current ulcers and no history of ulcers
3227605|NCT01002495|Experimental|Cohort 1|Eight endocardial injection for a total dose of 1mg VM202
3227606|NCT01002495|Experimental|Cohort 2|Eight endocardial injections for a total dose of 2mg VM202
3227607|NCT01002495|Experimental|Cohort 3|Twelve endocardial injections for a total dose of 3mg VM202
3227608|NCT01002482|Experimental|CGAO-based Glucose Control|Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.
3227609|NCT01002482|Active Comparator|Standard-Care Glucose Gontrol|Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.
3227610|NCT01002469|Experimental|sodium [1-13C] acetate|
3227611|NCT01002456|Other|Level 1: site-specific information|provide site-specific information on nonadherence
3227612|NCT01002456|Other|Level 2: site-, patient-specific info|provide site- and patient-specific information on nonadherence
3227613|NCT01002443|Active Comparator|H. pylori eradication|
3227614|NCT01002443|Placebo Comparator|placebo|
3227615|NCT01002430|Experimental|Gene therapy|
3227616|NCT01002430|No Intervention|Control|Control patients will have electroanatomic mapping procedure but no gene injections.
3227617|NCT01002417|Placebo Comparator|Placebo|Both the phase 2b and phase 3 parts of the study have the placebo arm.
3227618|NCT01002417|Active Comparator|MCS-2 15 mg/day|For the phase 2b part of the study. It can also be used in the phase 3 part of the study if MCS-2 15 mg/day is selected as the optimal dosage.
3227619|NCT01002417|Active Comparator|MCS-2 30 mg/day|For the phase 2b part of the study. It can also be used in the phase 3 part of the study if MCS-2 30 mg/day is selected as the optimal dosage.
3227620|NCT01002404|Active Comparator|angled tipped guide wire|angled tipped guide wire used to deep biliary cannulation
3227621|NCT01002404|Active Comparator|straight tipped guidewire|straight guide wire used to deep biliary cannulation
3227622|NCT01002391|Experimental|Postoperative day 1|Dressing is removed on the first postoperative day
3227623|NCT01002391|Experimental|Postoperative day 6|Dressing is removed on the sixth postoperative day
3227624|NCT01002378|Experimental|Arm 1|
3227625|NCT01002378|Experimental|Arm 2|
3227626|NCT01002378|Experimental|Arm 3|
3227627|NCT01002365|Active Comparator|Post op care|
3227628|NCT01002365|Active Comparator|Oxygen administration- different %|
3227629|NCT01002339|Experimental|Tacrolimus with rapid steroid withdrawal|Basiliximab induction. Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
3227630|NCT01002339|Active Comparator|Tacrolimus with steroids minimization|Basiliximab induction.Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
3227631|NCT01002339|Experimental|CsA with steroid minimization|Basiliximab induction. Ciclosporin A (CsA) plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
3227632|NCT01002326|Experimental|Cognitive-Behavioral Therapy|
3227633|NCT01002313||normal control|
3227634|NCT01002313||Patient treatment group|Treatment with prednisone
3227635|NCT01002287|Experimental|SprayShield Adhesion Barrier|SprayShield Adhesion Barrier
3227636|NCT01002287|Sham Comparator|Control|Good Surgical Technique Alone
3227637|NCT01002274|Experimental|MCS-2|2 soft-gel capsules Qd for 40 weeks
3227638|NCT01002261||Liver cirrhosis / healthy subjects|10 patients with liver cirrhosis and 10 sex and age-matched healthy subjects
3227639|NCT01002261||Liver cirrhosis and healthy subjects|Patients with liver cirrhosis and healthy subjects
3227640|NCT01002248|Experimental|Perifosine added to combination|"Perifosine added to the combination of Bortezomib and Dexamethasone. Perifosine is is supplied as a film-coated tablet containing 50 mg of active ingredient. Perifosine will be administered orally on an outpatient basis throughout the study. Daily administration will be one 50 mg tablet.~The first dose of perifosine should be taken on the same day that bortezomib and dexamethasone are administered (Cycle 1 Day 1)."
3227694|NCT01001832|Active Comparator|Intravenous (IV) abatacept, 125 mg|
3227695|NCT01001819||1|Chronic Rhinosinusitis w/o nasal polyps
3227696|NCT01001819||2|No sinus disease
3227641|NCT01002248|Placebo Comparator|Perifosine Placebo added to combination|Perifosine placebo added to the combination of Bortezomib and Dexamethasone. The placebo for perifosine is provided in 256 mg white to off-white, round, biconvex film-coated tablets to permit a blinded trial with perifosine 50 mg film coated tablets. Placebo will be administered orally on an outpatient basis throughout the study. Daily administration will be one perifosine placebo tablet. The first dose of placebo should be taken on the same day that bortezomib and dexamethasone are administered (Cycle 1 Day 1).
3227642|NCT01002235|Experimental|Cohort 1|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 4 mg.
3227643|NCT01002235|Experimental|Cohort 2|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 8mg.
3227644|NCT01002235|Experimental|Cohort 3|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 16mg.
3227645|NCT01002222|Experimental|MCS-2|
3227646|NCT01002209|Sham Comparator|Sham Hyperbaric Oxygen Treatment|
3227647|NCT01002209|Experimental|Hyperbaric oxygen treatment (HBO)|
3227648|NCT01002196|Experimental|stimulus fading procedures|
3227649|NCT01002196|Active Comparator|guidance of defocused communication|
3227650|NCT01002183|No Intervention|single arm|Fos-clin/Arte
3227651|NCT01002157|Experimental|Vitamin K2 supplementation|
3227652|NCT01002157|Placebo Comparator|Placebo control|
3227653|NCT01002131||Digital Volume tomography|three-dimensional digital imaging using cone beam tomography (CBCT)
3227654|NCT01002118|Placebo Comparator|Placebo|4 capsules inert oil Placebo each day for 16 weeks
3227655|NCT01002118|Active Comparator|Omega-3 Fatty Acid Ethyl Esters|4 capsules Omega-3 Fatty Acid Esters each day for 16 weeks
3227656|NCT01002105|Experimental|Baclofen|The study was a double-blind, placebo-controlled, randomized trial comparing 50 mg/day of baclofen to placebo over 12 weeks, in addition to a low-intensity psychosocial intervention program, with 26-week and 52-week follow-up observations.
3227657|NCT01002105|Other|Psychosocial intervention|Intervention of the addition of placebo to low-intensity psychosocial intervention program. This was the control group
3227658|NCT01002092|Active Comparator|Chemotherapy|
3227659|NCT01002092|Experimental|Endostar plus Chemotherapy|
3227660|NCT01002079|Experimental|BMS-708163|
3227661|NCT01002079|Other|Rifampin|
3227662|NCT01002079|Experimental|Rifampin + BMS-708163|
3227663|NCT01002053||Diabetics with peripheral neuropathy|Patients with diabetes and peripheral neuropathy.
3227664|NCT01002040|Active Comparator|One Dose Influenza vaccine|Arepanrix H1N1 Influenza vaccine (one dose)
3227665|NCT01002040|Active Comparator|Two Doses Influenza vaccine|Arepanrix H1N1 Influenza vaccine (2 doses, 3 weeks apart)
3227666|NCT01002027|Active Comparator|CBT-counselling with Nurse|CBT-counselling with Maternal Health Nurse, adjunctive to management by general medical practitioner
3227667|NCT01002027|Active Comparator|CBT-Counselling by Psychologist|CBT-counselling with Psychologist, adjunctive to management by general medical practitioner
3227668|NCT01002027|No Intervention|Routine management|Ongoing management by general medical practitioner
3227669|NCT01002014|Experimental|Nipple Sparing Mastectomy|Patients who undergo nipple sparing mastectomy with preservation of the nipple areolar complex.
3227670|NCT01001988|Experimental|Study group|Participants received a single dose of JE-CV administered in Study JEC02. In Study JEC05 there were yearly visits with blood samples taken for immunogenicity assessment.
3227671|NCT01001975|Experimental|SPF Testing|Following Food and Drug Administration (FDA) guidelines for SPF testing, exposure control and product-protected site erythema responses are scored after 16 to 24 hours post-exposure to full spectrum light (Ultraviolet B radiation [UVB] and UVA).
3227672|NCT01001975|Experimental|UVA Protection Testing|Determination of Ultraviolet A Protection Factor (PFA). Following FDA guidelines, test sites exposed to UVA are scored for pigmentation responses 2 to 4 hours post-exposure.
3227673|NCT01001962|Active Comparator|Metformin|527 Patients treated with Metformin 850x2mg titrated to 1000x2mg Daily oral
3227674|NCT01001962|Active Comparator|Empagliflozin|527 Patients treated with empagliflozin 10mg titrated to 25 mg Daily oral
3227675|NCT01001949|Experimental|Wheat Bran Extract|
3227676|NCT01001949|Placebo Comparator|placebo|
3227677|NCT01001936|Experimental|1|
3227678|NCT01001923|Experimental|REGN475/SAR164877|REGN475/SAR164877, single injection, dose depending on the participant's body weight
3227679|NCT01001923|Placebo Comparator|Placebo|Placebo (for REGN475/SAR164877), single injection
3227680|NCT01001910|Experimental|Treatment (pemetrexed disodium, carboplatin)|Patients receive pemetrexed disodium IV over 8-15 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
3227681|NCT01001897|Experimental|misoprostol|400 micrograms of misoprostol inserted buccally or vaginally prior to IUD insertion
3227682|NCT01001897|Placebo Comparator|Placebo|Troches identical to experimental drug inserted buccally or vaginally prior to IUD insertion
3227683|NCT01001884|Experimental|counseling|caregiver psychoeducational consultation program (CPCP)
3227684|NCT01001871|Experimental|Vitamin/mineral fortificant with iron|
3227685|NCT01001871|Placebo Comparator|Vitamin/mineral fortificant without iron|
3227686|NCT01001858|Active Comparator|Domiciliary group|In this group OSA diagnosis was performed at patient's home by mean of non-attended RP. All follow-up visits were conducted by a trained nurse in patient's home.
3227687|NCT01001858|Active Comparator|Hospital Group|In this group diagnosis was made by in-hospital PSG. Follow-up was performed at hospital by a specialist Physician
3227688|NCT01001858|Active Comparator|Mixed Group|In this group diagnosis was made by home RP, and follow-up at hospital
3227689|NCT01001845|No Intervention|Lifestyle counseling|
3227690|NCT01001845|Active Comparator|vit E|200mg 2 times per day for 3 weeks
3227691|NCT01001845|Experimental|Milk Thistle extract|1 tablet (equivalent to 140 mg silymarin) 3 times a day for 3 weeks
3227692|NCT01001845|Experimental|vit E + Milk Thistle Extract|200mg vit E twice a day + 1 tablet of Milk Thistle extract 3 times a day for 3 weeks
3227693|NCT01001832|Active Comparator|Subcutaneous (SC) abatacept, 125 mg|
3227697|NCT01001806|Active Comparator|Acuvail|Acuvail to be given preoperatively. One drop 2 times daily (BID), 1 day pre op and day of surgery 3 doses prior to surgery
3227698|NCT01001806|Active Comparator|Xibrom|Xibrom to be given 1 drop 2 times daily (BID) the day before surgery and 3 doses the day of surgery prior to surgery
3227699|NCT01001806|Active Comparator|Nevanac|One day before surgery 1 drop 2 times daily (BID), then 3 doses the day of surgery
3227700|NCT01001780|Experimental|Pentostatin, Cyclophosphamide, Rituximab|
3227701|NCT01001767|Active Comparator|Lovaza|Lovaza 1 gram by mouth twice a day for 24 weeks.
3227702|NCT01001767|Placebo Comparator|Placebo|Placebo capsule by mouth twice a day x 24 weeks.
3227703|NCT01001754|Experimental|PEG-rIL-29 at 120 µg|
3227704|NCT01001754|Experimental|PEG-rIL-29 at 180 µg|
3227705|NCT01001754|Active Comparator|Peginterferon alfa-2a at 180 µg|
3227706|NCT01001728|Active Comparator|Prone Position|Patients will lie on their fronts on an in-house designed board comprising an arm positioning device registerable to the couch-top, together with a styrofoam/ memory foam mattress. The ipsilateral breast will drop through an aperture in the mattress. The distance from the nipple to the superior, inferior and lateral aspects of the aperture will be recorded along with the distance of the nipple from the couch-top. Arms will be extended as far as possible above the head and the position of the arm immobilisation handles recorded. The head will be turned to the contralateral side. The contralateral breast will be pulled laterally such that it is as flat as possible beneath the patient. Measurements will be taken in order to relate the position of the bi-lateral tattoos to the orthogonal lasers. A fourth tattoo will be marked on the patient's back in line with the A-P laser. The position will be reproduced at treatment using measurements from the tattoo to the laser.
3227707|NCT01001728|Active Comparator|Supine position|For the supine position, patients will be positioned on a customized supine breast board co-registerable to the couch-top to CT and the treatment machines. Arms will be placed above the head in supports. Arm and head position will be recorded along with the angle of the board (which is adjusted such that the sternum is parallel to the couch-top). Tattoos will be marked bi-laterally and medially in a defined relationship to orthogonal lasers. The position will be reproduced at treatment using the above measurements, tattoos and lasers.
3227708|NCT01001715|Experimental|REGN475/SAR164877|REGN475/SAR164877, single injection, dose depending on the participant's body weight
3227709|NCT01001715|Placebo Comparator|Placebo|Placebo (for REGN475/SAR164877), single injection
3227710|NCT01001702|Experimental|Oral Aripiprazole|Flexible dose of oral aripiprazole between 5 mg and 30 mg once daily for 72 months.
3227711|NCT01001689|Experimental|Nutritional counseling + exercise groups|Women in this arm will receive 2 telephone consultations on nutritional health during pregnancy, be invited to 2 evening meetings with nutritional topics and have access to a password protected internet site with topics related to nutrition and fitness in pregnancy. They will also be enrolled in an exercise group which will meet twice weekly, and be encouraged to exercise on their own 1-2 times each week.
3227712|NCT01001689|No Intervention|control|Women in this arm of the study will receive routine pregnancy care.
3227713|NCT01001676|Active Comparator|Conventional Balloon Angioplasty|
3227714|NCT01001676|Experimental|Drug Eluting Balloon Angioplasty|
3227715|NCT01001663|Experimental|FemoSeal®|Closure device for femoral artery access closure
3227716|NCT01001663|Active Comparator|Manual compression|Conventional manual compression
3227717|NCT01001650|Experimental|Group 1|4 doses of 7,500 PfSPZ/immunization.
3227718|NCT01001650|Experimental|Group 2|4 doses of 30,000 PfSPZ/immunization
3227719|NCT01001650|Experimental|Group 3|4 doses of 135,000 PfSPZ/immunization
3227720|NCT01001650|Experimental|Group 4|4 or 6 doses of 135,000 PfSPZ/immunization.
3227721|NCT01001637|Active Comparator|curcumin|
3227722|NCT01001637|Placebo Comparator|Placebo|
3227723|NCT01001624|Experimental|A|Melanil facial cream
3227724|NCT01001624|Active Comparator|B|Hydroquinone 2% cream
3227725|NCT01001611|Experimental|CKD-501 0.5mg|
3227726|NCT01001611|Placebo Comparator|Placebo|
3227727|NCT01001598|Other|danazol|Subjects with either Fanconi anemia or Dyskeratosis congenita
3227728|NCT01001585|Experimental|slow induction with sevoflurane|Only children with a BIS greater than 95 prior to inhalation of sevoflurane will be included in the study. Inductions will be done using a tight fitting mask with continuous monitoring of end tidal gas concentrations. During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached. Inspired sevoflurane will be increased only after end tidal concentration of sevoflurane is constant for at least one minute. Each induction (except for the patients requiring very low doses of sevoflurane) will take approximately 10 minutes.
3227729|NCT01001572|Active Comparator|Valsartan 160 mg|One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks
3227730|NCT01001572|Experimental|Valsartan/amlodipine 160/5 mg|One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks
3227731|NCT01001572|Other|Single-Blind Run-In Valsartan 160 mg|Single-Blind Run-In treatment with one capsule Valsartan 160 mg taken orally once daily at approximately 9:00 AM for 4 weeks.
3227732|NCT01001559||Deplin + antidepressant|Deplin in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)
3227733|NCT01001559||Antidepressant alone|SSRI or SNRI alone
3227734|NCT01001546|Experimental|Arm 1|Internet-based smoking cessation
3227735|NCT01001546|Other|Arm 2|Clinic-based smoking cessation
3227736|NCT01001533||Children sedated by DEX|All pediatric patients (1 month to 18 years of age) eligible for Radiology Sedation Service for CT scan and Nuclear Medicine Scan procedure.
3227737|NCT01001520|Placebo Comparator|Placebo (Sugar Pill)|11-day placebo-controlled medication period
3227738|NCT01001520|Active Comparator|Tolcapone|11-day phase, tapered dosing scheduled (Day 1: 100mg three times daily, Days 2-8: 200mg three times daily, Day 9: 200mg twice daily, Day 10: 200mg once daily, Day 11: 100mg once daily); oral dosing; medication is encapsulated by the University of Pennsylvania's Investigational Drug Service (IDS)
3227949|NCT00999986|Active Comparator|cyclophosphamide|
3227739|NCT01001507|Experimental|Integrated HIV/FP services|Family planning services are integrated into HIV care and treatment services at this facility.
3227740|NCT01001507|No Intervention|Standard (non-integrated), referral-based, services|Patients from the HIV care and treatment clinic will be referred for family planning services, and will not receive FP services by the HIV care provider
3227741|NCT01001494|Experimental|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation
3227742|NCT01001494|Experimental|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation
3227743|NCT01001494|Placebo Comparator|Placebo|Placebo
3227744|NCT01001481||001|
3227745|NCT01001468|Experimental|VB-201 20 mg|
3227746|NCT01001468|Experimental|VB-201 80 mg|
3227747|NCT01001468|Placebo Comparator|Placebo|Single daily dose of oral placebo
3227748|NCT01001455||blood pressure monitor|Cuff circumference:22cm-36cm
3227749|NCT01001455||stethoscopy|Cuff circumference: 22cm-36cm
3227750|NCT01001442|Experimental|BT062|
3227751|NCT01001429|Active Comparator|Propofol|propofol 1mg/kg as a bolus intravenously followed by an infusion of 25-100 ug/kg/min
3227752|NCT01001429|Experimental|dexmedetomidine infusion|Subject will receive a bolus of0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug.
3227753|NCT01001403|Experimental|nafamostat|The Nafamostat mesilate group received 0.2 mg/kg of nafamostat mesilate intravenously 1 min before reperfusion of the liver graft.
3227754|NCT01001403|Placebo Comparator|Control|The control group received 10 ml of normal saline (same volume as nafamostat)intravenously 1 min before reperfusion of the liver graft.
3227755|NCT01001390|Other|Group One|Group one will take a six minute walk test with AFO device, and after a rest of fifteen minutes, they will take another six minute walk test without AFO, with similar speed to the previous test.
3227756|NCT01001390|Other|Group Two|Group two will take a six minute walk test without AFO device, and after a rest of fifteen minutes, they will take another six minute walk test with AFO, with similar speed to the previous test.
3227757|NCT01001377|Active Comparator|Cetuximab|"Cetuximab 400 mg/m^2 as an initial dose, followed by 250 mg/m^2 intravenously (IV) every 7 days.~Participants were treated until disease progression, intolerability, withdrawal of consent, or death."
3227758|NCT01001377|Experimental|Panitumumab|Panitumumab 6 mg/kg IV every 14 days. Participants were treated until disease progression, intolerability, withdrawal of consent, or death.
3227759|NCT01001364|Experimental|Formoterol/Budesonide|
3227760|NCT01001364|Active Comparator|Foraseq|
3227761|NCT01001351|Placebo Comparator|Placebo|
3227762|NCT01001351|Experimental|PRT-201|
3227763|NCT01001338|Experimental|RDEA594 200 mg qd|RDEA594 200 mg qd plus allopurinol qd
3227764|NCT01001338|Experimental|RDEA594 200 mg, 400 mg qd|"RDEA594 200 mg then 400 mg qd plus allopurinol qd.~Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after protocol amendment 16 dated 07 October 2015."
3227765|NCT01001338|Placebo Comparator|Matching Placebo|"RDEA594 matching placebo qd plus allopurinol qd, then allopurinol qd alone in open label period.~Patients on allopurinol qd alone were discontinued after protocol amendment 16 dated 07 October 2015."
3227766|NCT01001338|Experimental|RDEA594 600 mg qd|"RDEA594 200 mg then 400 mg then 600 mg plus allopurinol qd~Patients on lesinurad 600 mg had their dose changed to lesinurad 200 mg after protocol amendment 16 dated 07 October 2015."
3227767|NCT01001325|Experimental|Seasonal influenza vaccination|Receipt of Fluviral seasonal (2009-2010, Canadian) influenza vaccination as per manufacturers specification
3227768|NCT01001325|Placebo Comparator|Placebo|0.5 mL normal saline
3227769|NCT01001312|Experimental|Daxor Blood Volume Analysis|Subjects in this treatment arm will receive guideline recommended treatment based on direct blood volume measurement for assessment of volume status.
3227770|NCT01001312|Active Comparator|Clinical volume status assessment|Subjects in this treatment arm will receive guideline recommended treatment based on clinical assessment of volume status.
3227771|NCT01001299|Experimental|Single arm|
3227772|NCT01001286|Active Comparator|Youth Club|The intervention will be compared to a waitlist comparison group. The group will enter NFE after the four-month posttest. During the four months, the youth will be offered a biweekly recreational youth club. The club will be led by Jordanian university student volunteers out of community-based organizations. Club activities will take place approximately every two weeks, including games, sports, arts and crafts, cultural activities, and trips. The Club will not include any significant education components or youth empowerment methodology--the hypothesized active ingredients of QS NFE.
3227773|NCT01001286|Experimental|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
3227774|NCT01001273|Experimental|Study Group|Hyperinsulinemic Normoglycemic Clamp will be started at the time of surgery (before incision) and will be continue for 3 days.
3227775|NCT01001273|No Intervention|Control Group|Patients in the control group will receive standard care.
3227776|NCT01001260||No Aspirin Treatment|
3227777|NCT01001260||81 mg Aspirin Treatment|
3227778|NCT01001260||325 mg Aspirin|
3227779|NCT01001234|Experimental|Stage 1: rizatriptan|
3227780|NCT01001234|Placebo Comparator|Stage 1: placebo|
3227781|NCT01001234|Experimental|Stage 2: rizatriptan|
3227782|NCT01001234|Placebo Comparator|Stage 2: placebo|
3227783|NCT01001221|Experimental|Cabazitaxel + gemcitabine|"Cabazitaxel and gemcitabine on Day 1 then gemcitabine alone on Day 8 every 3 weeks until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision.~On Day 1, cabazitaxel was given either first followed by gemcitabine (part 1a) or after gemcitabine with 1 hour gap between the two infusions (part 1b). Required premedication with antihistamine, corticosteroid and H2 antagonist was administered intravenously 30 minutes before each dose of cabazitaxel."
3227945|NCT01000025|Placebo Comparator|Placebo|Patients receive oral placebo once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3227784|NCT01001208|Experimental|Etanercept Plus Methotrexate|Participants received 50 mg etanercept twice weekly (BIW) for the first 12 weeks and then 50 mg etanercept once weekly (QW) for the second 12 weeks. Participants also received active methotrexate titrated as follows: 7.5 mg per week (3 capsules) for weeks 1 and 2, 10 mg per week (4 capsules) for weeks 3 and 4, and then up to 15 mg per week (6 capsules) or the maximum tolerated dose for the remainder of the 24-week treatment period.
3227785|NCT01001208|Active Comparator|Etanercept Plus Placebo|Participants received 50 mg etanercept twice weekly (BIW) for the first 12 weeks and then 50 mg etanercept once weekly (QW) for the second 12 weeks. Participants also received oral placebo that was the same number of capsules per week as the methotrexate dosing regimen.
3227786|NCT01001195|Experimental|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
3227787|NCT01001195|Experimental|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
3227788|NCT01001195|Experimental|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
3227789|NCT01001195|Active Comparator|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
3227790|NCT01001182||Non interventional|Patients with RA diagnosis receiving any treatment for RA (DMARDS or biologics)
3227791|NCT01001169|Experimental|GSK2340274A_F1 6M-9Y GROUP|Healthy male or female Japanese children, between and including 6 months to 9 years of age, who received two doses of GSK2340274A vaccine (formulation 1), administered intramuscularly into the deltoid region of the arm (intramuscularly into the anterolateral part of the thigh for subjects below 12 months of age at the entry of the study), according to 0, 21-day schedule. Within this group, enrolment of subjects was stratified by age into two subgroups, from 6 to 35 months and from 3 to 9 years.
3227792|NCT01001169|Experimental|GSK2340274A_F2 10Y-17Y GROUP|Healthy male or female Japanese children, between and including 10 to 17 years of age, who received two doses of GSK2340274A vaccine (formulation 2), administered intramuscularly into the deltoid region of the arm, according to 0, 21-day schedule.
3227793|NCT01001143|Experimental|Dose Level 1|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.~Bexarotene 100 mg/m2 PO daily for each 28 day cycle."
3227794|NCT01001143|Experimental|Dose Level 2|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.~Bexarotene 200 mg/m2 PO daily for each 28 day cycle."
3227795|NCT01001143|Experimental|Dose Level 3|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.~Bexarotene 300 mg/m2 PO daily for each 28 day cycle."
3227796|NCT01001130||fluticasone furoate group|Korean patients administered fluticasone furoate according to the Prescription information
3227797|NCT01001117|Experimental|Laser treated|Eye treated with LensAR Laser System
3227798|NCT01001117|Active Comparator|Control Eye|Contralateral eye treated with conventional phaco-emulsification
3227799|NCT01001104|Experimental|0.75 mg LY2189265|
3227800|NCT01001104|Experimental|0.5 mg LY2189265|
3227801|NCT01001104|Experimental|0.25 mg LY2189265|
3227802|NCT01001104|Placebo Comparator|Placebo|
3227803|NCT01001091|Experimental|AL-38583 0.01%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
3227804|NCT01001091|Experimental|AL-38583 0.05%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
3227805|NCT01001091|Experimental|AL-38583 0.2%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
3227806|NCT01001091|Placebo Comparator|AL-38583 Vehicle|AL-38583 ophthalmic solution vehicle, 1 drop instilled in each eye 3 times per day for 2 weeks
3227807|NCT01001091|Active Comparator|MAXIDEX|Dexamethasone ophthalmic suspension, 0.1%, 1 drop instilled in each eye 3 times per day for 2 weeks
3227808|NCT01001078|Active Comparator|I-Gel supraglottic airway device|Group in which the I-Gel will be used in the first and second attempts to secure the airway. If a third attempt is needed, the LMA Supreme will be used. If the third attempt fails, a standard endotracheal tube will be used.
3227809|NCT01001078|Active Comparator|LMA Supreme supraglottic airway device|Group in which the LMA Supreme will be used in the first and second attempts to secure the airway. If a third attempt is needed, the I-Gel will be used. If the third attempt fails, a standard endotracheal tube will be used.
3227810|NCT01001078|Active Comparator|Standard endotracheal tube|A Standard endotracheal tube will be inserted in case both other airway devices (LMA Supreme and iGel) devices fail to provide adequate ventilation.
3227811|NCT01001052|Experimental|Colcrys™ - young subjects (18-30 yrs)|One single dose of Colcrys™ 0.6mg taken by mouth on day 1
3227812|NCT01001052|Experimental|Colcrys™ - elderly subjects (≥60 yrs)|One single dose of Colcrys™ 0.6mg taken by mouth on day 1
3227813|NCT01001039||control|Patients seen in the Otology clinic who have not had sinus surgery in the past 2 months or a history of sinusitis in the last 6 months.
3227814|NCT01001039||cases|Patients seen in the Rhinology Clinic with a complaint of facial pain. They must have evidence of chronic sinusitis.
3227815|NCT01001026|Other|1|Adults: One doses of H1N12009 vaccine
3227816|NCT01001026|Other|2|Children: Two doses of H1N12009 vaccine given 3 weeks apart
3227817|NCT01001013|Experimental|LC15-0444 200 mg|LC15-0444 200 mg
3227818|NCT01001013|Experimental|Pioglitazone 30 mg|Pioglitazone 30 mg
3227819|NCT01001013|Experimental|LC15-0444 200 mg + pioglitazone 30 mg|LC15-0444 200 mg + pioglitazone 30 mg
3227820|NCT01000987|Experimental|varenicline|varenicline 1mg/day or 2mg/day
3227821|NCT01000987|Placebo Comparator|placebo|placebo
3227866|NCT01000623|Active Comparator|Arm III|Patients receive oral placebo once or twice daily in weeks 2-8. Patient see a therapist once a week to learn hypnosis in weeks 2-5. Patients continue hypnosis at home in weeks 6-8.
3227946|NCT00999999|Active Comparator|Standard|Standard dural closure
3227950|NCT00999973|Active Comparator|Mitomycin c 0.02%|
3227822|NCT01000974|Experimental|Hiberix Group|Pooled group of subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of 3 different lots of Hiberix® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age The Hiberix® vaccine was administered intramuscularly in the right thigh. Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.
3227823|NCT01000974|Active Comparator|ActHIB Group|Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of ActHIB® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The ActHIB® vaccine was administered intramuscularly in the right thigh. The Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.
3227824|NCT01000974|Active Comparator|Pentacel Group|Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of Pentacel® vaccine co-administered with 3 doses of Prevnar13® vaccine, 2 or 3 doses of Engerix™-B vaccine at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The Pentacel® vaccine was administered intramuscularly in the right thigh. The Engerix™-B vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally. If subjects in the Pentacel Group had received a birth dose of Hepatitis B vaccine then they were to receive Engerix™-B vaccine only at 2 and 6 months of age.
3227825|NCT01000961|Experimental|RP103 Q12H|
3227826|NCT01000961|Active Comparator|Cystagon® Q6H|
3227827|NCT01000948|Experimental|ZD4054|The study had only one arm: intervention
3227828|NCT01000935|Active Comparator|Platelet Rich Plasma|The platelet concentrate extracted from patient's own blood (PRP) will be applied to the surgical site after completion of the repair.
3227829|NCT01000935|Placebo Comparator|Surgical repair (standard-of-care)|Patients will have a rotator cuff repair without the PRP application.
3227830|NCT01000922|Experimental|Regular Human Insulin|Single injection
3227831|NCT01000922|Experimental|Lispro|Single injection
3227832|NCT01000922|Experimental|VIAject|Single injection
3227833|NCT01000922|Experimental|VIAject 50%|Single injection
3227834|NCT01000922|Experimental|VIAject/Insulin glargine|Single injection
3227835|NCT01000922|Experimental|Insulin Glargine/VIAject|Single injection
3227836|NCT01000896|Experimental|AZD0530 + carboplatin and paclitaxel|AZD0530 in combination with carboplatin and paclitaxel
3227837|NCT01000870|Experimental|Access MNI-513 and PET Imaging|
3227838|NCT01000857|Experimental|Open label treatment with 2-period crossover design|"Group 1: Paroxetine CR 25 mg/day for 14 days / Paroxetine IR 20 mg/day for 14 days.~Group 2: Paroxetine IR 20 mg/day for 14 days / Paroxetine CR 25 mg/day for 14 days.,~PK results will be compared between the Paroxetine CR treatment period and the Paroxetine IR treatment period."
3227839|NCT01000831|Active Comparator|Adjuvanted Arepanrix 2 doses|Two doses of adjuvanted H1N1 Arepanrix vaccine given 3 weeks apart
3227840|NCT01000818|Experimental|Period 1|MK0518
3227841|NCT01000818|Experimental|Period 2|famotidine + MK0518
3227842|NCT01000818|Experimental|Period 3|omeprazole + MK0518
3227843|NCT01000805|Experimental|Duloxetine|
3227844|NCT01000805|Placebo Comparator|Placebo|
3227845|NCT01000792|Experimental|Levocetirizine|Levo 5 mg o.d.
3227846|NCT01000779|Active Comparator|Endoscopic Variceal Ligation|endoscopic therapy to obliterate varices
3227847|NCT01000779|Active Comparator|Propranolol|drugs to decrease portal pressure
3227848|NCT01000766||Acute drug-induced liver injury|
3227849|NCT01000753||Observational (specimen collection)|See Detailed Description
3227850|NCT01000740|Experimental|1|Long term survivors who has been used IRESSA for more than 3 years and are still on gefitinib treatment
3227851|NCT01000740|No Intervention|2|Long term survivors who has been used IRESSA for more than 3 years but have already terminated from EAP
3227852|NCT01000740|No Intervention|3|Fast-progressors who defined as no more than 1 follow-up visit after recruitment with the reason of discontinuation being
3227853|NCT01000727|Experimental|Darapladib 160 mg|Single daily oral tablet
3227854|NCT01000727|Placebo Comparator|Placebo|Single daily oral tablet
3227855|NCT01000688|Experimental|vildagliptin treatment first, acarbose treatment second|
3227856|NCT01000688|Experimental|acarbose treatment first, vildagliptin treatment second|
3227857|NCT01000662|Active Comparator|ARM 1 daily boost|Radiation Therapy
3227858|NCT01000662|Active Comparator|ARM 2 weekly boost|Radiation Therapy
3227859|NCT01000649|Experimental|FE 202158 1.25|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 1.25 ng/kg/min.~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
3227860|NCT01000649|Experimental|FE 202158 2.5|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 2.5 ng/kg/min.~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
3227861|NCT01000649|Experimental|FE 202158 3.75|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 3.75 ng/kg/min.~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
3227862|NCT01000649|Placebo Comparator|PLCBO|Patients in the arm received an intravenous infusion for up to 7 days of placebo.
3227863|NCT01000636|Experimental|Metvix PDT|
3227864|NCT01000623|Experimental|Arm I|Patients receive oral venlafaxine once or twice daily in weeks 2-8. Patients see a therapist once a week to learn hypnosis in weeks 2-5. Patients continue hypnosis at home in weeks 6-8.
3227865|NCT01000623|Active Comparator|Arm II|Patients receive oral venlafaxine once or twice daily in weeks 2-8. Patients see a therapist once a week to learn focused attention in weeks 2-5. Patients continue focused attention at home in weeks 6-8.
3227867|NCT01000623|Active Comparator|Arm IV|Patients receive oral placebo once or twice daily in weeks 2-8. Patient see a therapist once a week to learn focused attention in weeks 2-5. Patients continue focused attention at home in weeks 6-8.
3227868|NCT01000610|Experimental|single arm|
3227869|NCT01000597|Other|Treatment Y|Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).
3227870|NCT01000597|Other|Treatment Z|A single intravenous dose of 250mcg FF given over 20 minutes (Day 1).
3227871|NCT01000584|Other|1|Group A: One dose of the licensed H1N1 vaccine and one dose of the seasonal influenza vaccine given concurrently
3227872|NCT01000584|Other|2|Group B: One dose of seasonal influenza vaccine given 3 weeks after administration of one dose of the licensed H1N1 vaccine
3227873|NCT01000571||H1N1 pandemic influenza vaccine recipient|Children and young adults between the ages of 6 months and 21 years and 13 kg or greater in body weight with underlying conditions of cancer, HIV, sickle cell disease or receipt of a stem cell transplant more than a year prior to study entry and who will receive inactivated H1N1 swine-origin monovalent influenza vaccine in the winter/fall of 2009-2010 as part of their routine clinical care.Target total accrual of up to 400 children and young adults stratified based on their underlying diagnosis as follows: 150 children or young adults with cancer, 100 with human immunodeficiency virus (HIV), 100 with sickle cell disease, and 50 with receipt of a stem cell transplant more than a year prior to study entry.
3227874|NCT01000545|Placebo Comparator|placebo gelcaps + best medical treatment|Patient will receive 4 placebo gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
3227875|NCT01000545|Active Comparator|SLX 500LRU/day + best medical treatment|Patient will receive 1 SLX gelcap and 3 placebo gelcaps twice a day.Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
3227876|NCT01000545|Active Comparator|SLX 1000LRU/day + best medical treatment|Patient will receive 2 SLX gelcaps and 2 placebo gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
3227877|NCT01000545|Active Comparator|SLX 2000LRU/day + best medical treatment|Patient will receive 4 SLX gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
3227878|NCT01000532||Pacemaker therapy|
3227879|NCT01000519|Active Comparator|Aerobic Training|50 minutes of aerobic training, 18 sessions within 2 months period
3227880|NCT01000519|Experimental|Progressive Resistance Training|50 minutes of progressive resistance training consisting of nine resistance exercises, each conducted 3 sets of 10 repetitions. 18 sessions over 2 months period.
3227881|NCT01000506|Active Comparator|Mepolizumab 750mg|Mepolizumab 750mcg i.v. every 4 weeks
3227882|NCT01000506|Active Comparator|Mepolizumab 250mg|Mepolizumab 250mcg i.v. every 4 weeks
3227883|NCT01000506|Active Comparator|Mepolizumab 75mg|Mepolizumab 75mcg i.v. every 4 weeks
3227884|NCT01000506|Placebo Comparator|Placebo|Placebo saline every 4 weeks i.v.
3227885|NCT01000493|Experimental|Orvepitant 60 mg|60 mg/day
3227886|NCT01000493|Placebo Comparator|Placebo|
3227887|NCT01000480|Experimental|Pemetrexed|Pemetrexed and cisplatin are given as induction therapy followed after by pemetrexed and cisplatin with concurrent radiotherapy.
3227888|NCT01000467|Active Comparator|2|Group 2(probucol 500mg BID)
3227889|NCT01000467|Active Comparator|1|Group 1(Probucol 250mg)
3227890|NCT01000467|Active Comparator|3|Group 3(Probucol 500mg once daily)
3227891|NCT01000441|Active Comparator|arm 1 (2d anti-TNF):|infliximab, etanercept, adalimumab
3227892|NCT01000441|Active Comparator|arm 2 (other biotherapy)|abatacept, rituximab or tocilizumab
3227893|NCT01000415|Experimental|Cisplatin plus gemcitabine|Experimental arm: neoadjuvant chemotherapy (cisplatin plus gemcitabine) followed by surgery Control arm: concurrent chemoradiation (cisplatin/carboplatin)during standard radiation
3227894|NCT01000402|Other|Psychopharmacotherapy|No specific arms; Treatment decision based on available guidelines
3227895|NCT01000376|Experimental|Group 1|
3227896|NCT01000376|Experimental|Group 2|
3227897|NCT01000363||Spanish speaking group|Diabetes medical group visits will be held at the Grady North DeKalb satellite clinic the third Thursday of the month starting in October 2009. There will be two cohorts of patients- English speaking patients and Spanish speaking patients. Each group will be scheduled for 4 2-hour group visits throughout a period of 9 months. These visits will be every 8 weeks for each group. During the visit, the patient will be seen by a physician, attend a diabetes education session, re-fill their diabetes medications, get orders for labs due, vaccinations and diabetes-related referrals.
3227898|NCT01000363||English speaking group|"Each group will be scheduled for 4 2-hour group visits throughout a period of 9 months. These visits will be every 8 weeks for each group. During the visit, the patient will be seen by a physician, attend a diabetes education session, re-fill their diabetes medications, get orders for labs due, vaccinations and diabetes-related referrals.~This visit will only focus on the patient's diabetes care. Each patient will continue to see their regular physician for their health care.~All of the services that will be provided at the medical group visit are standard of care and are the same that the patient will receive in a one-on-one visit. However, this format will allow the patient to been seen by the physician and receive diabetes education in one visit."
3227899|NCT01000350|Experimental|Exercise Post Saline|Saline infusion 1L hours before exercise test
3227900|NCT01000350|Placebo Comparator|Placebo|Placebo given prior to exercise test
3227901|NCT01000337|Active Comparator|sevoflurane|Volatile anesthetic
3227902|NCT01000337|Active Comparator|Propofol|Intravenous anesthetic
3227903|NCT01000324|Experimental|Twinrix Group|Pooled group of subjects from groups who were vaccinated with either Lot 1, Lot 2 or Lot 3 of Twinrix in the primary study according to a 0, 1, 6-Month schedule
3227947|NCT00999999|Experimental|Experimental|Experimental dural closure, adding of Investigational Medicinal Product (IMP)
3227904|NCT01000311|Experimental|MenACWY-CRM + Routine Vaccines|"Infants received 3 doses of MenACWY-CRM at 2, 4 and 6 months as a infant series vaccination and a toddler dose at 12 months of age.~Infants also received routine vaccines - 3 doses each of DTaP-IPV/Hib, HBV and PCV at 2, 4 and 6 months; and 1 dose each of PCV and MMR at 12 months."
3227905|NCT01000311|Experimental|Routine Vaccines|"Infants received routine vaccines - 3 doses each of DTaP-IPV/Hib, HBV and PCV at 2, 4 and 6 months; and 1 dose each of PCV and MMR at 12 months.~In addition subjects were offered a dose of MenACWY-CRM at 18 months as a benefit of participating in this study. However, blood was not drawn for immunogenicity analysis after this dose."
3227906|NCT01000298|Placebo Comparator|Placebo|
3227907|NCT01000298|Experimental|Amoxicillin|
3227908|NCT01000298|Experimental|cefdinir|cefdinir
3227909|NCT01000285|Experimental|Arm 1|"Bortezomib 1.0 mg/m2 intravenous (IV) Days 1-4~Etoposide 50 mg/m2/d 96 hour continuous intravenous infusion (CIVI) on Days 1-4~Vincristine 0.4 mg/m2/d 96 hour CIVI on Days 1-4~Doxorubicin 10 mg/m2/d 96 hour CIVI on Days 1-4~Prednisone 60 mg/m2/d PO on Days 1-5~Cyclophosphamide 375 mg/m2 IV on Day 5~Raltegravir 400 mg PO twice per day (BID) every day starting with cycle 2 therapy for the entire duration of the cycle.~Cycles will be repeated every 21-28 days for 2 cycles beyond best response, or a maximum of 6 cycles."
3227910|NCT01000259||Ancillary-Correlative|Previously collected tumor tissue samples are analyzed for TIL via immunohistochemistry and double immunofluorescence assays using standard immunostaining.
3227911|NCT01000246|Experimental|influenza vaccine day 4|influenza vaccine day 4 of chemotherapy
3227912|NCT01000246|Experimental|influenza vaccine day 16|influenza vaccine day 16 of chemotherapy
3227913|NCT01000246|Active Comparator|influenza vaccine|influenza vaccine in patients with heartfailure
3227914|NCT01000233|Active Comparator|Phytine (Phytate)|300 mg tid* 24 months
3227915|NCT01000233|Placebo Comparator|Placebo|
3227916|NCT01000220|Active Comparator|Omeprazole|
3227917|NCT01000220|Placebo Comparator|placebo|
3227918|NCT01000207|Experimental|1|Dose ranging
3227919|NCT01000207|Experimental|2|Dose ranging
3227920|NCT01000194|Experimental|High polyunsaturated fat meal|A high fat milkshake containing 55g of fat, mainly PUFA
3227921|NCT01000194|Experimental|High monounsaturated fat meal|A high fat milkshake containing 55g of fat, mainly MUFA
3227922|NCT01000194|Experimental|High saturated fat meal|A high fat milkshake containing 55g of fat, mainly SFA
3227923|NCT01000181||Patients undergoing carotid endarterectomy|
3227924|NCT01000168|Experimental|Treadmill therapy|"Patients assigned to the Treadmill therapy group received daily 30 minutes specific walking training on treadmill with body weight support alternatively overground, and 30 minutes functional training, treated by a physiotherapist."
3227925|NCT01000168|Active Comparator|Conventional walking therapy|Patients assigned to the comparative conventional walking therapy group received daily 30 minutes specific traditional walking training overground and 30 minutes functional training, treated by a physiotherapist.
3227926|NCT01000155|Experimental|Vorinostat|Patients received vorinostat in a pulsed fashion, once a day for 3 consecutive days every week to a maximum dose of 400 mg per dose (1200 mg/wk), for 12 to 16 weeks at the maximum dose. The first 3 patients were enrolled in an intrapatient dose escalation schedule of 100 mg/d, then 200 mg/d, each for 3 consecutive days a week for 4 weeks, and then 400 mg/d, 3 consecutive days per week for 16 weeks. The last 2 patients were enrolled to receive 400 mg/d, 3 consecutive days per week for 12 weeks, without an initial dose escalation.
3227927|NCT01000142|No Intervention|Treatment as Usual Control Group|
3227928|NCT01000142|Sham Comparator|Light Touch Group|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
3227929|NCT01000142|Experimental|Standard OMT Group|
3227930|NCT01000116|Active Comparator|Fibrin glue|
3227931|NCT01000116|Active Comparator|Tacks|
3227932|NCT01000103|Active Comparator|1: Real rTMS treatment|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
3227933|NCT01000103|Sham Comparator|2: Sham rTMS treatment|Simulation of rTMS
3227934|NCT01000090||Acromegaly patients, somatostain analogues|
3227935|NCT01000090||Acromegaly patients, surgery|
3227936|NCT01000077||Discarded Operating Room Tissue|The purpose of this research study is to use the discarded (tissue that would normally be thrown out) tissue from your surgery in order to obtain cells that can be grown in a laboratory to study how to use cells like these to fix sick and diseased organs. We will test if these cells can be used to build new and healthy tissues. This technique is called tissue engineering. In this study we will be comparing cells obtained from different individuals.
3227937|NCT01000077||Discarded Placenta|During a standard surgery or delivery of a baby unneeded tissue is usually discarded. We would like to explore the opportunity to grow the cells of these discarded tissues in the laboratory. The cells will be placed in special dishes and supplemented with a mixture of salts and nutrients that were designed to allow the cells to survive outside the body and grow. This procedure is called tissue culture of cells. We will attempt to isolate a population of cells from the tissue culture and study them in the laboratory.
3227938|NCT01000064|Active Comparator|Vyvanse|"Vyvanse capsule, 30-70 mg, each morning for 6 weeks.~Placebo capsule each morning for 6 weeks.~Brain scans (fMRI) performed at baseline, 6th week visit and 12th week visit."
3227939|NCT01000064|Placebo Comparator|Placebo|"Vyvanse capsule, 30-70 mg, each morning for 6 weeks.~Placebo capsule each morning for 6 weeks.~Brain scans (fMRI) performed at baseline, 6th week visit and 12th week visit."
3227940|NCT01000051|Experimental|Eltrombopag|Starting dose 50 mg/day orally for 8 weeks
3227941|NCT01000051|Placebo Comparator|Placebo|Once a day orally for 8 weeks
3227942|NCT01000038|Experimental|Wii-Fit Intervention|Intervention: Subjects in this arm participate in Wii-Fit exercises
3227943|NCT01000038|Active Comparator|Walking Intervention|Intervention: Subjects in this arm participate in walking
3227944|NCT01000025|Active Comparator|PF-00299804|Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3227951|NCT00999973|Placebo Comparator|Placebo|
3227952|NCT00999960|Active Comparator|1: without simulator|without simulator
3227953|NCT00999960|Experimental|2: with simulator|with simulator
3227954|NCT00999921|Experimental|Tamoxifen|10 mg once daily from 5th day to 25th day of menstrual cycle for 3 months
3227955|NCT00999921|Experimental|Evening Primrose Oil|1000 mg daily for 3 months
3227956|NCT00999908|Experimental|Indacaterol 150 μg-tiotropium 18 μg-placebo|Patients received indacaterol 150 μg once. After a 5-9 days washout period, patients received tiotropium 18 μg once. After a second 5-9 days washout period, patients received placebo (matching indacaterol) once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3227957|NCT00999908|Experimental|Tiotropium 18 μg-placebo-indacaterol 150 μg|Patients received tiotropium 18 μg once. After a 5-9 days washout period, patients received placebo (matching indacaterol) once. After a second 5-9 days washout period, patients received indacaterol 150 μg once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3227958|NCT00999908|Experimental|Placebo-indacaterol 150 μg-tiotropium 18 μg|Patients received placebo (matching indacaterol) once. After a 5-9 days washout period, patients received indacaterol 150 μg once. After a second 5-9 days washout period, patients received tiotropium 18 μg once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3227959|NCT00999895||Antipsychotic outpatients with schizophrenia|Switched treatment of antipsychotic outpatients with schizophrenia
3227960|NCT00999882|Experimental|AZD8055|Dose escalation
3227961|NCT00999869|Experimental|Botulinum toxin A|At first visit, patients will be randomized by blocked randomization into 2 sides of scalp. Experimental side will be injected with botulinum toxin A ( Botox) 2 units per 6.05 cm2 of lesion ( Concentration 2 units of Botox per 0.1 ml of normal saline ).
3227962|NCT00999869|Active Comparator|Triamcinolone acetonide|At visit0, patients will be injection with triamcinolone acetonide concentration at 10 mg/ml on the comparison side
3227963|NCT00999856|Active Comparator|Cohort 1|In the Cohort 1 an uncoated Insert and the photometer version 1 is used. Twelve trial subjects are appointed into 4 subgroups. The difference between these subgroups is the wearing time of the insert.
3227964|NCT00999856|Active Comparator|Cohort 2|Cohort 2 consists of 12 trial subjects who are appointed to 2 subgroups. One group will wear the insert for a minimum of 12 month and the other group for a minimum duration of 18 month. In Cohort 2 an improved insert is used. The photometer will be the same than in cohort 1.
3227965|NCT00999856|Active Comparator|Cohort 3|Cohort 3 only differs in the used photometer from cohort 2.
3227966|NCT00999856|Active Comparator|Cohort 4|Twelve trial subjects are appointed to two subgroups that differ in the minimum wearing duration of the insert (12 month and 18 month). In Cohort 4 a new insert will be tested together with a better photometer.
3227967|NCT00999856|Active Comparator|Cohort 5|The difference between Cohort 5 and Cohort 4 is that the best tested insert and the best evaluated photometer will be used.
3227968|NCT00999830|Experimental|IPH 2101 0.2 mg/kg|One infusion of IPH2101 every 4 weeks at the dose of 0.2 mg/kg by intravenous route over 1 hour, for 4 or up to 8 cycles.
3227969|NCT00999830|Experimental|IPH2101 2.0 mg/kg|One infusion of IPH2101 every 4 weeks at the dose of 2 mg/kg by intravenous route over 1 hour, for 4 or up to 8 cycles.
3227970|NCT00999817|Other|A|Single 30 mg dose of dextromethorphan
3227971|NCT00999817|Experimental|B|Single 45 mg dose of PF-00299804 plus a single 30 mg oral dose of dextromethorphan
3227972|NCT00999804|Experimental|24-week arm|Participants will receive 24-weeks of lapatinib plus trastuzumab. Participants who are estrogen receptor (ER) and/or progesterone receptor (PR) positive will also receive endocrine therapy.
3227973|NCT00999804|Active Comparator|12-week arm|Participants will receive 12-weeks of lapatinib plus trastuzumab. Participants who are estrogen receptor (ER) and/or progesterone receptor (PR) positive will also receive endocrine therapy.
3227974|NCT00999791|Active Comparator|Avastin|
3227975|NCT00999791|Active Comparator|Diclofenac|
3227976|NCT00999778|Active Comparator|Caregiver Education Intervention|10 1:1,one hour sessions weekly for 10 weeks with parent and interventionist. Behavioral education strategies will be targeted
3227977|NCT00999778|Active Comparator|Caregiver-Mediated Intervention|One hour 1:1 with parent, child and interventionist, each week, for 10 weeks social communication and joint engagement strategies will be targeted
3227978|NCT00999765||Bipolar Disorder - stable|
3227979|NCT00999752|Active Comparator|Arm A|Nebivolol to reach blood pressure control
3227980|NCT00999752|Active Comparator|Arm B|Hydrochlorothiazide for blood pressure control
3227981|NCT00999739|Experimental|two vaccines|people allocated to arm two vaccines will receive one dose of heptavalent pneumococcal conjugate vaccine at day 0 and 23-valent polysaccharide vaccine at week4 , 110 HIV-infected people will be included Intervention: administration of two vaccines
3227982|NCT00999739|Experimental|One vaccine|people allocated to arm one will receive only one doses of pneumococcal polysaccharide 23-valent vaccine. 110 HIV-infected adults will be included in this arm Intervention: administration of one vaccine
3227983|NCT00999713|Experimental|Calfactant|Endotracheal calfactant administration
3227984|NCT00999713|Placebo Comparator|Placebo (air)|Endotracheal air administration
3227985|NCT00999700|Experimental|ARM A|Induction chemotherapy: TCF (Vermorken, N Eng J Med 2007) Definitive treatment: RT + C-mab (Bonner, N Eng J Med 2006)
3227986|NCT00999700|Active Comparator|ARM B|RT + Cddp (RTOG, Adelstein, J Clin Oncol 2003)
3227987|NCT00999687|Experimental|Indigo naturalis extract in oil|In all participants, indigo naturalis extract in oil was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 24 weeks.
3227988|NCT00999648|Experimental|Manual therapy|Myofascial trigger point pressure release
3227989|NCT00999648|Placebo Comparator|Control|Placebo myofascial trigger point pressure release
3227990|NCT00999635|Experimental|Custom made insole|Custom made functional moulded insole
3227991|NCT00999635|Active Comparator|Prefabricated Insole|Prefabricated accommodative moulded insole
3228348|NCT00997152|Experimental|Dose 1 JTT-654|
3227992|NCT00999609|Experimental|AAV2-hRPE65v2,voretigene neparvovec-rzyl|voretigene neparvovec rzyl, 1.5 E11 vector genomes, per eye, administered by subretinal injection in a volume of 0.3mL, 6-18 days apart
3227993|NCT00999609|No Intervention|Control|No intervention
3227994|NCT00999596||FFDM (Full Field Digital Mammography)|Mammograms from the Philips Digital System
3227995|NCT00999583|Experimental|EPO|five injections maximum of 40000 UI EPO
3227996|NCT00999583|Active Comparator|Control|Classical take care
3227997|NCT00999570||Patients operated by AR trained surgeons|patients who had their total knee replacements performed by surgeons who have completed a fellowship training in adult reconstruction surgery
3227998|NCT00999570||Patients operated by non-AR surgeons|patients who had their total knee replacements performed by orthopaedic surgeons who did not complete an adult reconstruction fellowship training
3227999|NCT00999557|Experimental|Arm I|Patients apply topical bimatoprost ophthalmic solution to base of upper eyelid margins OR to eyebrow region once daily for 4 months in the absence of unacceptable toxicity.
3228000|NCT00999557|Placebo Comparator|Arm II|Patients apply topical placebo solution to base of upper eyelid margins OR to eyebrow region once daily for 4 months in the absence of unacceptable toxicity.
3228001|NCT00999544|Experimental|Placebo aprepitant/0 mg oxycodone IN PO|Placebo aprepitant/Placebo oxycodone IN/PO
3228002|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 15 IN 0 PO|Placebo aprepitant/ oxycodone 15 IN 0 PO
3228003|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 30 IN 0 PO|Placebo aprepitant/ oxycodone 30 IN 0 PO
3228004|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 0 IN 20 PO|Placebo aprepitant/ oxycodone 0 IN 20 PO
3228005|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 0 IN 40 PO|Placebo aprepitant/ oxycodone 0 IN 40 PO
3228006|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 0 IN 0 PO|Aprepitant 40 mg/ oxycodone 0 IN 0 PO
3228007|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 0 IN 20 PO|Aprepitant 40 mg/ oxycodone 0 IN 20 PO
3228008|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 0 IN 40 PO|Aprepitant 40 mg/ oxycodone 0 IN 40 PO
3228009|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 15 IN 0 PO|Aprepitant 40 mg/ oxycodone 15 IN 0 PO
3228010|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 30 IN 0 PO|Aprepitant 40 mg/ oxycodone 30 IN 0 PO
3228011|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 0 IN 0 PO|Aprepitant 200 mg/ oxycodone 0 IN 0 PO
3228012|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 0 IN 20 PO|Aprepitant 200 mg/ oxycodone 0 IN 20 PO
3228013|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 0 IN 40 PO|Aprepitant 200 mg/ oxycodone 0 IN 40 PO
3228014|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 15 IN 0 PO|Aprepitant 200 mg/ oxycodone 15 IN 0 PO
3228015|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 30 IN 0 PO|Aprepitant 200 mg/ oxycodone 30 IN 0 PO
3228016|NCT00999531|Experimental|1|GS-9411 9.6 mg
3228017|NCT00999531|Experimental|2|GS-9411 4.8 mg
3228018|NCT00999531|Experimental|3|GS-9411 2.4 mg
3228019|NCT00999531|Placebo Comparator|4|Saline Placebo
3228020|NCT00999518|Experimental|Group 1|
3228021|NCT00999518|Experimental|Group 2|
3228022|NCT00999518|Experimental|Group 3|
3228023|NCT00999518|Experimental|Group 4|
3228024|NCT00999518|Placebo Comparator|Group 5|
3228025|NCT00999505|Active Comparator|Amantadine|Amantadine 200mg twice a day
3228026|NCT00999505|Placebo Comparator|Placebo|Placebo capsules twice a day
3228027|NCT00999479|Experimental|Monophasic OCP|Patients randomized to this study arm will receive combined oral contraceptive pills. Patients will follow up at 2, 6, 12, 18 and 24 months. On follow up visits pts will have clinical assessment with vaginal and rectal examinations and with transvaginal ultrasonography. As a measure of compliance, patients will return their empty pill packages
3228028|NCT00999479|Placebo Comparator|Placebo|Patients assigned to this arm will use non-hormonal, barrier contraceptives to prevent pregnancy.Patients will follow up at 2, 6, 12, 18 and 24 months. On follow up visits pts will have clinical assessment with vaginal and rectal examinations and with transvaginal ultrasonography. As a measure of compliance, patients will return their empty pill packages.
3228029|NCT00999466|Experimental|1|AZD8848 (30 μg PILOT part and 60 μg MAIN part)
3228030|NCT00999466|Placebo Comparator|2|Placebo
3228031|NCT00999453|Experimental|LDL-cholesterol 70 mg/dL or lower|'Experimental arm' is defined as patients treated to lower the level of low-density lipoprotein to 70 mg/dl or lower. 'Control arm' is defined as patients treated to lower low-density lipoprotein to a level of 100 mg/dl or lower.
3228032|NCT00999453|Active Comparator|LDL-cholesterol 100 mg/dL or lower|'Experimental arm' is defined as patients treated to lower the level of low-density lipoprotein to 70 mg/dl or lower. 'Control arm' is defined as patients treated to lower low-density lipoprotein to a level of 100 mg/dl or lower.
3228033|NCT00999440|Experimental|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done.Patients who start with any opiate and then switch to methadone, move to methadone follow up
3228034|NCT00999427|Experimental|A|The randomly selected group of subjects who will receive the intervention. The radiologist performing the transrectal prostate biopsy on these subjects will have a gauze soaked with Povidone-iodine over his/her index finger, and will insert this into the rectum. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin to the other. This will be allowed to dry for 2 minutes before proceeding with the biopsy.
3228035|NCT00999427|No Intervention|B|The randomly selected group of subjects who will receive the standard of care biopsy without any added intervention.
3228036|NCT00999401|Experimental|sapacitabine and seliciclib|Sequential or concomitant administration of sapacitabine and seliciclib
3228037|NCT00999375|Experimental|Group A|
3228038|NCT00999375|Active Comparator|Group B|
3228039|NCT00999362||Early kidney-transplant recipients|Patients receiving a kidney transplantation at Aarhus University Hospital, Skejby and receiving tacrolimus as part of their immunosuppressive regime.
3228040|NCT00999362||stable kidney transplant recipients|Tacrolimus treated kidney-transplant recipients from the out-door clinic at Aarhus University Hospital, Skejby and more than two years after transplantation
3228041|NCT00999349|Experimental|Silymarin (LEGALON)|
3228042|NCT00999349|Placebo Comparator|Placebo|
3228043|NCT00999336|Active Comparator|Group H|Healthy subjects matched to the renal impairment groups
3228044|NCT00999336|Experimental|Group A|Patients with mild renal impairment
3228045|NCT00999336|Experimental|Group B|Patients with moderate renal impairment
3228046|NCT00999336|Experimental|Group C|Patients with severe renal impairment
3228047|NCT00999323||coronary artery disease|patients who have been revascularized by PCI with stent implantation due to an acute coronary syndrome
3228048|NCT00999310||Klinefelter syndrome|
3228049|NCT00999310||Control men|
3228050|NCT00999310||Control women|
3228051|NCT00999310||parents of Klinefelter groupe|
3228052|NCT00999297|Placebo Comparator|Sugar pill (Placebo o mg/d)|0 mg/d sugar pill
3228053|NCT00999297|Active Comparator|Dihydrocapsiate|Drug 3 mg/d or 9 mg/d including Placebo
3228054|NCT00999297|Active Comparator|3 mg/d or 9 mg/d Dihydrocapsiate|Drug including Placebo
3228055|NCT00999284|Placebo Comparator|Placebo|Sham infusion of sodium chloride 0.9%
3228056|NCT00999284|Active Comparator|Low dose arm|Infusion of 0.3 mg/kg/h ZK200775 over 4 hours
3228057|NCT00999284|Active Comparator|High dose arm|Infusion of 0.75 mg/kg/h ZK200775 over 4 hours
3228058|NCT00999271||Healthy subjects|30 healthy subjects without family history of diabetes or gastrointestinal disease, a normal oral glucose tolerance test (OGTT) and no intake of medicine
3228059|NCT00999258|Active Comparator|sirolimus|the subjects will undergo conversion from tacrolimus to sirolimus OR they will continue to receive tacrolimus.
3228060|NCT00999258|No Intervention|tacrolimus|
3228061|NCT00999245|Other|High Demand / Low Infusion|PCA dosing plan
3228062|NCT00999245|Other|Low Demand / High Infusion|PCA plan for Low Demand / High Infusion
3228063|NCT00999232|Experimental|Erythromycin|
3228064|NCT00999232|Placebo Comparator|Placebo|
3228065|NCT00999219|Experimental|FK199B-first group|
3228066|NCT00999219|Experimental|Zolpidem-first group|
3228067|NCT00999206|Experimental|1|
3228068|NCT00999206|Experimental|2|
3228069|NCT00999206|Experimental|3|
3228070|NCT00999206|Active Comparator|4|
3228071|NCT00999193|Active Comparator|Conservative Treatment|
3228072|NCT00999193|Experimental|ORIF w. locking plate, no luxation|
3228073|NCT00999193|Experimental|Hemiarthroplasty, no luxation|
3228074|NCT00999180|Active Comparator|Btx-A and Kinesiotherapy|The botulinum toxin group will have the syringe filled with botulinum toxin type A (Dysport). During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training.
3228075|NCT00999180|Placebo Comparator|Saline and Kinesiotherapy|The control group will have the syringe filled with saline.During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training.
3228076|NCT00999167|Experimental|HPN-100|
3228077|NCT00999167|Placebo Comparator|Placebo|
3228078|NCT00999141|Experimental|FS VH S/D 4 s-apr|One side of face will be treated with the investigational product (FS VH S/D 4 s-apr) as an adjuvant to the standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
3228079|NCT00999141|No Intervention|Standard of Care (SoC)|Other side of face will receive standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
3228080|NCT00999128|Experimental|Part 1|
3228081|NCT00999128|Experimental|Part 2|
3228082|NCT00999115|Experimental|Allogenic ASCs|Intralesional dose of 20 million cells at baseline with a possible second administration of 40 million in case of incomplete fistula closure following week 12 assessment.
3228083|NCT00999102|Active Comparator|Nebivolol then Metoprolol|"Nebivolol will be given at a dose of 5 mg and 10mg daily. After 8 weeks, participants will then be given metoprolol succinate will be given at a dose of 50 mg daily for 4 weeks, then 100 mg daily for 4 weeks.Identical-appearing pills will be given, and the drugs will be given in randomized order without a placebo run-in. At the end of each 4-week treatment period on each drug, subjects will undergo a treadmill stress test (using the standard Cornell protocol), complete Quality of Life and fatigue questionnaires, and have blood drawn and frozen for later analysis for drug levels.~At the end of 8 weeks of treatment on each drug, subjects will undergo echocardiography and applanation tonometry (non-invasive measurement of aortic blood pressure) to assess heart function."
3228084|NCT00999102|Active Comparator|Metoprolol then Nebivolol|"Metoprolol succinate will be given at a dose of 50 mg daily for 4 weeks, then 100 mg daily for 4 weeks. After 8 weeks, the participants will take nebivolol, dosage will be 5 mg and 10mg daily. Identical-appearing pills will be given, and the drugs will be given in randomized order without a placebo run-in. At the end of each 4-week treatment period on each drug, subjects will undergo a treadmill stress test (using the standard Cornell protocol), complete Quality of Life and fatigue questionnaires, and have blood drawn and frozen for later analysis for drug levels.~At the end of 8 weeks of treatment on each drug, subjects will undergo echocardiography and applanation tonometry (non-invasive measurement of aortic blood pressure) to assess heart function."
3228085|NCT00999089|Active Comparator|CCAB|Conventional Coronary Artery Bypass
3228086|NCT00999089|Active Comparator|OPCAB|Off-Pump Coronary Artery Bypass
3228087|NCT00999089|Active Comparator|PACAB|Pump-Assisted Coronary Artery Bypass
3228088|NCT00999076||Sputum with positive AFB smear|
3228089|NCT00999050|Experimental|diabetic pts <35BMI|All patients will be in a single arm receiving bypass surgery to assist with diabetes management
3228090|NCT00999037|Experimental|Renvela|Daily renvela with meals for 12 weeks
3228091|NCT00999037|Placebo Comparator|placebo|
3228092|NCT00999024||Healthy subjects|20 healthy subjects will be included
3228093|NCT00999024||COPD Patients|20 Patients with Grade IV COPD will be included
3228094|NCT00999011|Active Comparator|One 20 minute period of activity daily|passive and/or active range of motion, chair sitting, sitting at edge of bed, standing and walking
3228095|NCT00999011|Active Comparator|Two periods of 20 minute activity daily|passive and/or active range of motion, chair sitting, sitting at edge of bed, standing and walking
3228096|NCT00998998|Experimental|1|6 or 12 month old infants with iron deficiency anemia assigned to receive home stimulation program via weekly home visits over 1 year
3228097|NCT00998998|Active Comparator|2|6 or 12 month old infants with iron deficiency anemia assigned to surveillance (weekly visits to monitor health and iron supplement) over 1 year
3228098|NCT00998998|Experimental|3|Nonanemic infants identified at 6 or 12 months assigned to receive home stimulation program via weekly home visits over 1 year
3228099|NCT00998998|Active Comparator|4|Nonanemic infants identified at 6 and 12 months assigned to surveillance (weekly visits to monitor health) over 1 year
3228100|NCT00998985|Experimental|400 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 400 mg Grazoprevir or Placebo
3228101|NCT00998985|Experimental|600 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 600 mg Grazoprevir or Placebo
3228102|NCT00998985|Experimental|800 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 800 mg Grazoprevir or Placebo
3228103|NCT00998985|Experimental|400 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 400 mg Grazoprevir or Placebo
3228104|NCT00998985|Experimental|600 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 600 mg Grazoprevir or Placebo
3228105|NCT00998985|Experimental|800 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 800 mg Grazoprevir or Placebo
3228106|NCT00998985|Experimental|200 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 200 mg Grazoprevir or Placebo
3228107|NCT00998985|Experimental|100 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 100 mg Grazoprevir or Placebo
3228108|NCT00998985|Experimental|50 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 50 mg Grazoprevir or Placebo
3228109|NCT00998985|Experimental|200 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 200 mg Grazoprevir or Placebo
3228110|NCT00998985|Experimental|100 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 100 mg Grazoprevir or Placebo
3228111|NCT00998985|Experimental|50 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 50 mg Grazoprevir or Placebo
3228112|NCT00998985|Experimental|30 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 30 mg Grazoprevir or Placebo
3228113|NCT00998985|Experimental|10 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 10 mg Grazoprevir or Placebo
3228114|NCT00998972|No Intervention|control|control arm without any specific intervention
3228115|NCT00998972|Experimental|N-acetylcysteine|administration of 600 mg intravenous N-acetyl cysteine before and 2 hours after angiography performed for the diagnosis of brain death
3228116|NCT00998959|Experimental|Mindfulness based stress reduction and problem solving therapy|
3228117|NCT00998959|Other|Psychoeducation|
3228118|NCT00998933|Experimental|1|
3228119|NCT00998920|Experimental|10mg BID|S-equol capsule, oral, single dose
3228120|NCT00998920|Experimental|20 mg BID|
3228121|NCT00998920|Experimental|40mg BID|
3228122|NCT00998920|Experimental|80 mg BID|
3228123|NCT00998920|Experimental|160 mg BID|
3228124|NCT00998920|Placebo Comparator|Placebo|
3228125|NCT00998907|Active Comparator|PDS II|PDS II® loop suture is used for abdominal wall closure
3228126|NCT00998907|Experimental|PDS plus|"antibacterial coated PDS plus is used for abdominal wall closure"
3228127|NCT00998894||decision-support alerts|In patients experiencing a Triple Low (a combination of low MAC, low MAP, and low BIS), a warning alert will be generated for clinicians.
3228128|NCT00998894||routine practice|In patients experiencing a Triple Low (a combination of low MAC, low MAP, and low BIS), a warning alert will not be generated for clinicians.
3228129|NCT00998881|Experimental|Teneligliptin 20 mg|Teneligliptin 20 mg, orally, once daily
3228130|NCT00998881|Placebo Comparator|Placebo|Teneligliptin placebo-matching tablets, orally, once daily
3228131|NCT00998868||hemiplegia|patients with hemiplegia, without other musculoskeletal disorders of the shoulder
3228132|NCT00998855||Adolescents|Post pubertal, sedentary lean and obese Hispanic adolescents
3228133|NCT00998842||healthy subjects|five male, five female, ages 18-64
3228134|NCT00998829||Study population|The group comprises the entire study population
3228135|NCT00998816|Placebo Comparator|Placebo capsules|one placebo capsule will be administered 1 hour before lateral thoracotomy, 12 hours following the thoracotomy and then every 12h BID for 10 days following lateral thoracotomy.
3228136|NCT00998816|Active Comparator|pregabalin capsules|Pregabalin capsules (150mg) will be administered one hour before lateral thoracotomy, 12 hours following the thoracotomy and then every 12 hours (BID) for 10 days following lateral thoracotomy.
3228137|NCT00998803||Immunocompromised participants|Immunocompromised (<= 21 years of age) due to cancer, receipt of stem cell transplant, human immunodeficiency virus (HIV) or Sickle cell disease
3228138|NCT00998777|Experimental|Shoulder Strengthening|The shoulder strengthening program is a 6-week intervention aimed to improve shoulder and scapular stabilizer strength and scapular kinematics. The program includes 10 exercises: shoulder flexion, Ys,Ts,Ws, Throwing Acceleration, Throwing Deceleration, Low Rows, Dynamic Hug, IR @ 90, and ER @ 90. The program also includes 2 stretches: sleeper stretch and corner stretch.
3228139|NCT00998764|Experimental|Bapineuzumab 0.5 mg/kg|
3228140|NCT00998751|Experimental|masitinib (AB1010)|oral masitinib 7.5 mg/kg/day
3228141|NCT00998738|Experimental|Arm I (calcium gluconate, magnesium sulfate)|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and after each ixabepilone administration.
3228142|NCT00998738|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV over 30 minutes immediately before and after each ixabepilone administration.
3228143|NCT00998725||HIV+ARV+|
3228144|NCT00998725||HIV+ARV-|
3228145|NCT00998725||HIV negative|
3228146|NCT00998712||1|Black women in the third trimester of a pregnancy complicated by gestational diabetes.
3228147|NCT00998712||2|Black women in the third trimester of a normal, uncomplicated pregnancy.
3228148|NCT00998712||3|White women in the third trimester of a pregnancy complicated by gestational diabetes.
3228149|NCT00998712||4|White women in the third trimester of a normal, uncomplicated pregnancy.
3228150|NCT00998699|Active Comparator|XOMA 052|
3228151|NCT00998699|Placebo Comparator|Placebo|
3228152|NCT00998686|Experimental|dutogliptin/PHX1149T|
3228153|NCT00998686|Active Comparator|sitagliptin|
3228154|NCT00998673|Experimental|Arm 1|
3228155|NCT00998673|Other|Arm 2|
3228156|NCT00998660|Experimental|Patients receiving an Activa RC implant|
3228157|NCT00998647||with modified ultrafiltration|"elective cardiac surgery patients undergoing complex surgical intervention:~coronary artery bypass grafting AND valve surgery double valve surgery aortic surgery Re-Dos"
3228158|NCT00998647||without modified ultrafiltration|"elective cardiac surgery patients undergoing complex surgical intervention:~coronary artery bypass grafting AND valve surgery double valve surgery aortic surgery Re-Dos"
3228159|NCT00998634|Experimental|LITHIUM CARBONATE 150 and/or 300 mg|
3228160|NCT00998634|Placebo Comparator|PLACEBO|
3228161|NCT00998621||Hepatitis C infection|
3228162|NCT00998621||Hepatitis C + HIV infections|
3228163|NCT00998608|Experimental|HR|risperidone 2mg/d + haloperidol 2mg/d
3228164|NCT00998595|Experimental|Promotora|This group receives additional education and proactive follow-up by removing barriers to already existing services and reminders by a lay community health workers (Promotora)
3228165|NCT00998595|No Intervention|Standard of Care|These subjects receive the routine standard of postpartum care
3228166|NCT00998582|Active Comparator|Abacavir|Participants randomized to this arm will continue abacavir and their other HIV medications with no changes
3228167|NCT00998582|Experimental|Tenofovir|Participants randomized to this arm will switch from taking abacavir (co-formulated with lamivudine as Epzicom) and start taking tenofovir (co-formulated with emtricitabine as Truvada), and continue their other HIV medications
3228168|NCT00998569|Experimental|Neurocognitive Enhancement|neurocongnitive enhancement
3228169|NCT00998569|Other|Wait List|no intervention
3228170|NCT00998556|Experimental|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks, thereafter the patients continue to be observed in the follow-up part of the study up to month 6. The study medication is taken on top of standard therapy for heart failure. Part of this therapy are ACE inhibitors. ACE inhibitors are potentially harmful for the baby when getting into the breast milk, as bromocriptine stops milk production, no additional drug is needed.
3228171|NCT00998556|No Intervention|Control Group|The control group will receive standard therapy for heart failure. Part of this therapy are ACE inhibitors. Since ACE inhibitors are potentially harmful for the baby when getting into the breast milk, it is necessary to stop lactation in the control group as well.To stop lactation, application of bromocriptine (2.5mg/day) for up to one week.
3228172|NCT00998543||Smallpox Vaccine (LISTER Strain) Group|Participants were vaccinated with the second-generation smallpox vaccine in Study VVL04 (NCT 00258947).
3228173|NCT00998530||African American HIV+|African American women with HIV and infected with Trichomonas
3228174|NCT00998530||Caucasian HIV-|Caucasian women who are HIV negative and infected with Trichomonas
3228175|NCT00998530||African American HIV-|African American women who are HIV negative and are infected with Trichomonas
3228176|NCT00998517|Active Comparator|Soy/peanut fortified spread|
3228177|NCT00998517|Experimental|Milk fortified corn/soy blend|
3228178|NCT00998517|Active Comparator|Supplementary Plumpy®|
3228179|NCT00998504|Placebo Comparator|placebo|starch pill
3228180|NCT00998504|Active Comparator|resVida|synthetic pill containing 75 mg of resveratrol
3228181|NCT00998478|Experimental|Activity prescription|
3228182|NCT00998478|No Intervention|Normal Curriculum|Followed normal curriculum including physical education
3228183|NCT00998465||Obese, hypertension|Obese patients with hypertension and a body mass index 40-50 kg/m2
3228184|NCT00998465||Control|Control subjects without hypertension and body mass index < 30 kg/m2
3228185|NCT00998465||Obese, normotension|Obese patients without hypertension and a BMI between 40-50 kg/m2
3228186|NCT00998452|No Intervention|MOVE!|Participants will receive the usual VA MOVE! Program. These elements include a baseline assessment, brief clinic counseling session about weight, printed targeted health information on weight management and behaviors, and opportunities to participate in group sessions at the VA site and telephone follow-up from MOVE! clinic staff.
3228187|NCT00998452|Active Comparator|MOVE*VETS|Participants will receive the same MOVE! program as the control group plus 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from volunteer veteran peer counselors.
3228188|NCT00998439|Experimental|Paclitaxel coated balloon catheter|
3228189|NCT00998439|Active Comparator|uncoated balloon catheter (POBA)|
3228190|NCT00998426|Experimental|All study participants|Study procedures will occur one timebetween post-op day 1 and post-op day 7. Study procedures to include blood glucose monitoring prior to and after (various time points for 2 hours after) infusion with HBIG.
3228191|NCT00998413|Experimental|Multifaceted intervention|Multifaceted intervention:physical exercise, nutrition, and behavioural intervention.
3228192|NCT00998413|No Intervention|Control|standard usual care
3228193|NCT00998400|No Intervention|Clinical Management|Control group
3228194|NCT00998400|Experimental|CBT + WBT|Patients treated with Cognitive-Behavioral Therapy in combination with Well-Being Therapy and lifestyle modification
3228195|NCT00998387||medical ICU|admitted to medical ICU at Seoul National University Hospital longer than 24 hours
3228196|NCT00998374||Pyloric-sparing vs. non-pyloric sparing|Pyloric: SG & DS Non-pyloric: RYGB
3228197|NCT00998361|Experimental|Stem Cell Transplant|All the patient who are affected by refractory or resistant or relapsed Soft tissue sarcoma o Ewing sarcoma who find an HLA compatible allogeneic donor and are submitted to Stem cell transplantation
3228349|NCT00997152|Experimental|Dose 2 JTT-654|
3228350|NCT00997152|Placebo Comparator|Placebo|
3228198|NCT00998348|No Intervention|Comparison Group|The comparison group will receive children's picture books (1 per month for the duration of the 8-month program).
3228199|NCT00998348|Experimental|Parenting Program|The parenting program is an 8-month obesity prevention intervention for parents with preschool-age children.
3228200|NCT00998335|Active Comparator|Insulin detemir only|Patients with uncontrolled T2DM are treated with insulin detemir for 6 months. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl. This group will receive Long-acting bedtime insulin detemir (Levemir).
3228201|NCT00998335|Experimental|Insulin detemir plus aspart|After baseline evaluations, insulin detemir will be given at bedtime and titrated to achieve a fasting plasma glucose between 80-100 mg/dl. After 3 months patients will be admitted to assess the metabolic effects of intervention. After this, insulin aspart (insulin detemir plus aspart) will be added before breakfast, lunch and dinner titrated to normalize the postprandial plasma glucose. After another 3 months patients are readmitted and all study procedures repeated. This group will receive Insulin detemir and pre-meal insulin aspart.
3228202|NCT00998309||Azithromycin SR|Patients taking Azithromycin.
3228203|NCT00998296|Experimental|BIBW 2992 + BIBF 1120|This is a phase I dose escalation clinical trial and the data obtained shall determine the MTD for the combination of BIBW 2992/BIBF 1120 in 28-day of treatment.
3228204|NCT00998283|Experimental|Cohort 1|Administration of HM10460A 5μg/kg or Placebo
3228205|NCT00998283|Experimental|Cohort 2|Administration of HM10460A 15μg/kg or placebo
3228206|NCT00998283|Experimental|Cohort 3|Administration of HM10460A 45μg/kg or placebo
3228207|NCT00998283|Experimental|Cohort 4|Administration of HM10460A 135μg/kg or placebo
3228208|NCT00998283|Experimental|Cohort 5|Administration of HM10460A 350μg/kg or placebo
3228209|NCT00998270|Active Comparator|Autologous arm|
3228210|NCT00998270|Experimental|Allogeneic arm|
3228211|NCT00998257||Group 1|
3228212|NCT00998244|Experimental|Very Low Carbohydrate Diet|Very Low Carbohydrate Diet
3228213|NCT00998244|Active Comparator|Low Fat Diet|Low Fat Diet
3228214|NCT00998231|Active Comparator|Major Depressive Episode (MDE)|20 subjects with major depressive episode will be included and followed during a 6 months interval which includes 4 visits (at the inclusion, 2 and 8 weeks later and finally 6 month later)
3228215|NCT00998231|Active Comparator|Control|20 subjects without major depressive episode will be included and followed during a 6 months interval which includes 4 visits (at the inclusion, 2 and 8 weeks later and finally 6 month later)
3228216|NCT00998218|Experimental|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) for 4 weeks
3228217|NCT00998218|Placebo Comparator|Sugar pill|Placebo comparator BID for 4 weeks.
3228218|NCT00998205|Other|Dobutamine stress echo (DSE)|Dobutamine intravenous infusion would be undertaken starting at 10 micrograms/kg per minute in three minute intervals increased to 20, 30, 40 or 50 micrograms/kg per minute or to a peak heart rate response of at least 85% age predicted maximum heart rate. If at the end of the Dobutamine protocol, there is inadequate heart rate response, intravenous atropine boluses of 0.5 milligrams (maximum 1.0 mg) would be used as needed to achieve a heart rate of at least 85% of age predicted maximum heart rate.
3228219|NCT00998179|Active Comparator|Acu-TENS|Application of Acu-TENS prior to exercise
3228220|NCT00998179|Placebo Comparator|Placebo-TENS|Application of Acu-TENS (without electrical output from the machine) prior to exercise
3228221|NCT00998166|Experimental|Pemetrexed, Cisplatin, Bevacizumab|Chemotherapy infusion on Day 1 of a 3-week cycle
3228222|NCT00998153|Experimental|1|RRFT
3228223|NCT00998153|Active Comparator|2|Usual care
3228224|NCT00998114|Experimental|Exercise and diastolic dysfunction|Aerobic exercise for 30-45 minutes five times a week for six months
3228225|NCT00998088|Experimental|Erythropoietin|
3228226|NCT00998088|No Intervention|Control arm|
3228227|NCT00998088|Experimental|cell saver|
3228228|NCT00998088|Experimental|drain|
3228229|NCT00998088|Experimental|Erythropoietin and cell saver|
3228230|NCT00998088|Experimental|Erythropoietin and drain|
3228231|NCT00998075|Active Comparator|1|Esomeprazole 40 mg/ASA 325 mg Fixed Dose Combination Capsule
3228232|NCT00998075|Active Comparator|2|Esomeprazole Clinical Trial Capsule 40 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
3228233|NCT00998075|Active Comparator|3|Esomeprazole MUPS Tablet 40 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
3228234|NCT00998062||1|Data from epidemiological studies performed after the year 2000 with patients between 35 and 74 years old
3228235|NCT00998049|Experimental|Plerixafor|"Plerixafor 160mg/kg/dose by IV on days 5-8~Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8."
3228236|NCT00998036|Experimental|Temsirolimus, cisplatin, erlotinib|Cisplatin and temsirolimus will be administered weekly on days one and eight of a three week cycle. Erlotinib will be taken by mouth daily.
3228237|NCT00998023|Experimental|Mynx VCD|Mynx Vascular Closure Device
3228238|NCT00998023|Active Comparator|AngioSeal VCD|AngioSeal Vascular Closure Device
3228239|NCT00998010|Experimental|Experimental|Patients receive bortezomib IV on days 1, 4, 8, 11, 29, 32, 36, and 39 and oral temozolomide on days 1-42.Patients undergo external-beam fractionated regional radiotherapy 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.2-6 weeks after radiotherapy, patients receive bortezomib IV on days 1, 4, 8, and 11 and oral temozolomide on days 1-5.Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3228240|NCT00997997||Group 1|
3228241|NCT00997984|Experimental|Extended-release Guanfacine Hydrochloride (SPD503) AM|
3228242|NCT00997984|Experimental|placebo|
3228243|NCT00997984|Experimental|SPD503 PM|
3228244|NCT00997971|Experimental|Modilac Rose 1|Infant formula with partially hydrolysed rice protein
3228245|NCT00997958|Experimental|CellCept|Administered in tablet form twice daily one hour after eating.
3228246|NCT00997945|Experimental|1|ZD4054 (Zibotentan) 10mg
3228247|NCT00997932|Other|Complete Cohort|The complete cohort of all women enrolled and stated they wanted an LNG-IUS between 48 and 72 hours of vaginal delivery.
3228248|NCT00997919|Experimental|A|
3228249|NCT00997919|Experimental|B|
3228250|NCT00997906|Experimental|Arm I|Patients receive cisplatin IV over 2 hours once weekly on weeks 1-8 and undergo intensity-modulated radiotherapy once daily, 5 days a week, on weeks 1-7 (6½ weeks for a total of 33 fractions).
3228251|NCT00997906|Experimental|Arm II|Patients receive induction chemotherapy comprising gemcitabine hydrochloride IV over 30 minutes, carboplatin IV over 1 hour, and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning at least 3 weeks after the last dose of induction chemotherapy, patients receive cisplatin and undergo radiotherapy as in arm I.
3228252|NCT00997893|Experimental|Estradiol/Medroxyprogesterone Acetate|"Women in estradiol intervention group will take one active estradiol pill (1 mg) and one placebo pill at dinner, for a total daily dose of 1 mg estradiol and 0 mg Novasoy®. The UIC investigational drug service will obtain the estradiol tablets through the regular Hospital Pharmacy Purchases vendor, will encapsulate them, and will manufacture an identical appearing placebo to maintain blind.~Medroxyprogesterone acetate (MPA): The UIC IDS will dispense MPA (10 mg/d for 10 days) at the time of randomization. This progestin treatment is necessary to protect the uterine lining. These pills will be encapsulated in order to maintain blind ."
3228253|NCT00997893|Experimental|Phytoestrogen|Phytoestrogen: Women in the phytoestrogen intervention group will take one active Novasoy® (55 mg) pill at breakfast and active Novasoy® (55 mg) pill at dinner, for a total daily dose of 110 mg Novasoy® and 0 mg estradiol. The UIC Investigational Drug Service will obtain the Novasoy® tablets from Archer Daniels Midland and will encapsulate the tablets to maintain blind.
3228254|NCT00997893|Placebo Comparator|Placebo|Placebo: Women in this intervention group will take one placebo pill at breakfast and one placebo pill at dinner, for a total daily dose of 0 mg Novasoy® and 0 mg estradiol. The UIC investigational drug service will encapsulate the placebo tablets (lactose) in the same manner that they will encapsulate the estradiol and Novasoy® tablets to maintain blind.
3228255|NCT00997880|Experimental|Rosuvastatin calcium 40mg|high-dose (40mg rosuvastatin)
3228256|NCT00997880|Active Comparator|Rosuvastatin calcium10mg|low-dose statin (10mg rosuvastatin)
3228257|NCT00997867|Active Comparator|Catheter 0-1cm past needle tip|Patients will be receiving a sciatic (popliteal), femoral, or interscalene nerve block and will be randomized to having the catheter placed 0-1cm past the needle tip. The patient will be called the following day by research staff to assess their post-surgical pain.
3228258|NCT00997867|Active Comparator|Catheter placed 5-6cm past needle tip|Patients will be receiving a sciatic (popliteal), femoral, or interscalene nerve block and will be randomized to having the catheter placed 5-6cm past the needle tip. Patients will be called the following day by research staff to assess their post-surgical pain.
3228259|NCT00997854|Active Comparator|Group 1 Bolus Feeds|This group will receive feeds administered by bolus method over no more than 30 minutes per feed.
3228260|NCT00997854|Experimental|Group 2- Slow Infusion Feeds|This group will receive feeds administered by slow infusion over pump for 2 hours.
3228261|NCT00997841|Active Comparator|POC algorithm|cardiac surgery patients suffering from increased perioperative bleeding and being treated following Point of Care based algorithm
3228262|NCT00997841|Active Comparator|conventional algorithm|cardiac surgery patients suffering from increased perioperative bleeding and being treated following conventional coagulation management algorithm
3228263|NCT00997828|Experimental|everolimus-eluting stent|everolimus-eluting stent
3228264|NCT00997828|Active Comparator|coronary artery bypass graft surgery|coronary artery bypass graft surgery
3228265|NCT00997815|Experimental|Botulinum toxin A|The area of alopecia is splited into experimental and control sides by blocked randomization. Experimental sides injected with botulinum toxin A at 2 units per 0.1 ml of dilution with normal saline entire all area.
3228266|NCT00997815|Placebo Comparator|Placebo|Using normal saline
3228267|NCT00997802|Other|CT colonography and optical colonoscopy|
3228268|NCT00997789|Experimental|Rebamipide, Serum concentration, Tablet|The test preparation, Rebamide® (containing 100 mg of rebamipide; lot No. KP005; expiration date, April 2010; Kyungdong Pharmaceutical Company, Seoul, Korea) and the reference preparation, Mucosta® (containing 100 mg of rebamipide; lot No. MC704067; expiration date, May 2010; Korea Otsuka Pharmaceuticals Co., Ltd., Seoul, Korea)
3228269|NCT00997776|Experimental|Exercise|High intensity lower extremity exercise
3228270|NCT00997776|Sham Comparator|Attention control|lower extremity TENS
3228271|NCT00997763|Active Comparator|XIENCE V|everolimus-eluting stent
3228272|NCT00997763|Active Comparator|CYPHER|Using Cypher stent
3228273|NCT00997750|Experimental|Lornoxicam|Lornoxicam 8mg/day and 12mg/day for 15 days
3228274|NCT00997737|Experimental|DB, VI and FV|Breathing exercises
3228275|NCT00997724|Experimental|a-VATS|Patients with NSCLC underwent assisted-VATS sleeve lobectomy with bronchoplasty.
3228276|NCT00997711|Experimental|Cypher|Sirolimus-eluting stent
3228277|NCT00997685|Experimental|Capecitabine plus oxaliplatin，mCRC|
3228278|NCT00997672|Experimental|Lithium CARBONATE 150 and/or 300 mg|
3228279|NCT00997672|Placebo Comparator|Placebo|Placebo comparator
3228280|NCT00997659|Experimental|chromium picolinate|
3228281|NCT00997646||Patients in hospitalist-run ward|Patients was admitted from ER to a hospitalist-run ward.
3228282|NCT00997646||Patients in conventional ward|Patients was admitted from ER to a non hospitalist-run ward.
3228283|NCT00997633||Peritoneal carcinomatosis|Patients undergoing cytoreductive surgery and intraperitoneal chemotherapy treatment
3228284|NCT00997620|Placebo Comparator|Placebo|Placebo treatment given as a once daily dose intranasally.in subjects with active seasonal allergic rhinitis.
3228285|NCT00997620|Experimental|Fluticasone Furoate|IFluticasone Furoate 110 mcg given intranasly once daily in am as an active treatment of seasonal allergic rhinitis
3228286|NCT00997607|Experimental|Ebola vaccine only|Participants will receive only the Ebola vaccine or a placebo injection.
3228287|NCT00997607|Experimental|Marburg vaccine only|Participants will receive only the Marburg vaccine or a placebo injection.
3228288|NCT00997607|Experimental|Ebola and Marburg vaccine|Participants will receive both the Ebola and Marburg vaccines, one in each arm or placebo injections.
3228289|NCT00997594|Active Comparator|Adrenal radiofrquency (RF) ablation|Patients who wll receive adrenal RF ablation.
3228351|NCT00997126|Active Comparator|Propofol|Propofol 1m g/kg IV followed by 0.5 mg/kg IV prn sedation
3228290|NCT00997594|Active Comparator|Abdominal RF ablation other than adrenal gland|Patients who will receive abdominal radiofrequency ablation other than adrenal gland.
3228291|NCT00997581|Experimental|apremilast|Experimental treatment for acute gout
3228292|NCT00997581|Active Comparator|indomethacin|Medication currently used for the treatment of acute gout
3228293|NCT00997568||TEE Procedure|Patients who have been scheduled for a TEE procedure by their physician
3228294|NCT00997555|Experimental|bronchoscopy intervention group|Group undergoing scheduled bronchoscopy.
3228295|NCT00997555|No Intervention|Control group|Standard treatment without scheduled bronchoscopy.
3228296|NCT00997542|Active Comparator|Allopurinol|
3228297|NCT00997542|Placebo Comparator|Placebo|
3228298|NCT00997529|Experimental|1|
3228299|NCT00997516|Experimental|SILS appendectomy|The study population will consist of patients who come to the emergency room with acute abdominal pain and are found to have acute appendicitis on the basis of clinical evaluation and CT of the abdomen/pelvis.
3228300|NCT00997516|Active Comparator|Conventional laparoscopic appendectomy|The study population will consist of patients who come to the emergency room with acute abdominal pain and are found to have acute appendicitis on the basis of clinical evaluation and CT of the abdomen/pelvis.
3228301|NCT00997490|Experimental|Verum|Neurapas balance, film-coated tablet
3228302|NCT00997490|Placebo Comparator|Placebo|
3228303|NCT00997477|Experimental|Formoterol and Budesonide|
3228304|NCT00997451|Experimental|Behavioral Self-Management|Cognitive-behavioral self-management
3228305|NCT00997451|Active Comparator|Symptom Monitoring|
3228306|NCT00997451|No Intervention|Standard Medical Care|
3228307|NCT00997438|Experimental|MS - Secondary Progressive|1200 mg of Lipoic acid supplement
3228308|NCT00997438|Experimental|MS - Relapsing Remitting|1200mg of Lipoic acid supplement
3228309|NCT00997438|Experimental|Healthy Controls|1200 mg of Lipoic acid supplement
3228310|NCT00997425|Experimental|Door Cover/Floor Cover|Baseline One (14 days), First Intervention (14 days), Baseline Two (14 days), Second Intervention (14 days)
3228311|NCT00997412|Experimental|MA|MA group: 1 tablet AZA placebo and 4 tablets MA (180mg/tab,720 mg/day) twice daily
3228312|NCT00997412|Active Comparator|AZA|AZA group: 1 tablet AZA (50mg/tab) and 4 tablets MA placebo twice daily
3228313|NCT00997399|Experimental|LBH589|
3228314|NCT00997386|Experimental|busulfan, and melphalan, and alemtuzumab|Three drug regimen using busulfan, and melphalan, and alemtuzumab.
3228315|NCT00997373|Experimental|Letrozole|letrozole 2.5 mg PO daily for 2-3 weeks prior to hysterectomy.
3228316|NCT00997373|No Intervention|control|no treatemtn prior to hysterectomy
3228317|NCT00997360|Experimental|1|PKI-179
3228318|NCT00997347|Experimental|64-70 days' gestational age|Women whose pregnancies are estimated to have a gestational age of 64-70 days
3228319|NCT00997347|No Intervention|57-63 days' gestational age|Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range.)
3228320|NCT00997334|Experimental|Erlotinib|Erlotinib was given at a dose of 150mg orally once per day for 28 days (+/- 3 days); Patients are treated until disease progression or until unaccepted drug toxicity.
3228321|NCT00997321|Active Comparator|Propofol|propofol 1 milligram per kilogram intravenous bolus followed by 0.5 millligrams per kilogram as needed for mooderate procedural sedation
3228322|NCT00997321|Active Comparator|Ketamine|ketamine 1 milligram per kilogram followed by 0.5 millgram per kilogram as needed for moderate procedural sedation
3228323|NCT00997308|Experimental|AZD1446 Low|Low dose of AZD1446
3228324|NCT00997308|Experimental|AZD1446 High|High dose of AZD1446
3228325|NCT00997308|Placebo Comparator|Placebo|
3228326|NCT00997295||Heat moisture exchanger (HME)|This group was submitted to general anesthesia with low flow gas and heat moisture exchanger
3228327|NCT00997295||Low flow gas (LFG)|This group was submitted to general anesthesia with only low flow gas
3228328|NCT00997295||Humidity of the respiration|"Heat and moisture group:~The first group (G1)will be submitted to low flow gas anesthesia and heat and moisture exchanger (HME)~Control group:~The second group(G2)Will be submitted to low flow gas anesthesia"
3228329|NCT00997295||HME and LFG|
3228330|NCT00997282|Experimental|OPC-262 2.5 mg|orally administered once daily for 24 weeks
3228331|NCT00997282|Experimental|OPC-262 5 mg|orally administered once daily for 24 weeks
3228332|NCT00997282|Placebo Comparator|Placebo|orally administered once daily for 24 weeks
3228333|NCT00997269|Experimental|CoQ-10 supplementation|
3228334|NCT00997269|Placebo Comparator|CoQ-10 placebo supplementation|
3228335|NCT00997256|Experimental|Verum|Neurapas balance, film-coated tablets
3228336|NCT00997256|Placebo Comparator|Placebo|Film-coated sugar-pill
3228337|NCT00997243|Experimental|5-azacytidine and Lintuzumab|"Cycle 1- 5-azacytidine (Vidaza, AZA) 75mg/m2 IV/SC(subcutaneous)daily on days 1-7.~Subsequent Cycles (cycles to be repeated every 28 days) AZA 75mg/m2 IV/SC daily on days 1-7."
3228338|NCT00997204|Experimental|Icatibant- Naive Treatment Phase|Single subcutaneous injection of icatibant, 30 mg
3228339|NCT00997204|Experimental|icatibant- Self administration Phase|Single subcutaneous injection of icatibant, 30 mg
3228340|NCT00997191|Active Comparator|Laser Group|Focal / grid Laser photocoagulation in diabetic macular edema
3228341|NCT00997191|Experimental|Triamcinolone group|Intravitreal triamcinolone associated to laser photocoagulation for diabetic macular edema
3228342|NCT00997191|Experimental|Bevacizumab group|Intravitreal Bevacizumab associated to laser photocoagulation for diabetic macular edema
3228343|NCT00997178|Experimental|Non-surgical periodontal therapy|Non-surgical periodontal therapy consisted of scaling and root planing plus chlorhexidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months
3228344|NCT00997178|Other|Delayed non-surgical periodontal therapy|No periodontal treatment for 6 months
3228345|NCT00997165||Metabolic syndrome (MS)|Patients suspected of metabolic syndrome without sleep apnea or liver steatosis
3228346|NCT00997165||MS with sleep apnea|Metabolic syndrome with sleep apnea
3228347|NCT00997165||MS with Liver steatosis|Metabolic syndrome with liver steatosis
3228352|NCT00997126|Active Comparator|Alfentanil|Sedation using alfentanil 10 ug/kg followed by 5 ug/kg prn sedation
3228353|NCT00997113|Active Comparator|Propofol|propofol only for deep procedural sedation
3228354|NCT00997113|Active Comparator|Propofol/alfentanil|Propofol with alfentanil for deep procedural sedation
3228355|NCT00997100|Other|ABR-215757|
3228356|NCT00997087|Placebo Comparator|Sugar Pill, Placebo|
3228357|NCT00997087|Active Comparator|Flumazenil|
3228358|NCT00997074|Experimental|ibuprofen|the group will receive 2 tablets of ibuprofen 400 mg at the time of misoprostol administration. The information about the effect of the analgesics on the pain, and on the course of medical abortion, will be prospectively gathered from questionnaires completed by the study participants
3228359|NCT00997074|No Intervention|placebo|this group will receive 2 placebo tablets together with the misoprostol
3228360|NCT00997061||HYCAMTIN|
3228361|NCT00997048|Experimental|Laying open|
3228362|NCT00997048|Active Comparator|Sinus excision|
3228363|NCT00997035|Active Comparator|Oral Voriconazole|
3228364|NCT00997035|Placebo Comparator|Placebo|
3228365|NCT00997022|Experimental|Sorafenib|Daily sorafenib taken orally
3228366|NCT00997009|Experimental|Arm A|chemotherapy plus cetuximab
3228367|NCT00997009|Active Comparator|Arm B|chemotherapy
3228368|NCT00996996|Experimental|open-label, single arm|Tositumomab and Iodine I 131 Tositumomab
3228369|NCT00996983|Experimental|A|
3228370|NCT00996957|Experimental|ACE-041|Patients assigned to 1 of 9 possible dosing groups
3228371|NCT00996944|Experimental|Ropinirole IR|
3228372|NCT00996944|Placebo Comparator|Placebo|
3228373|NCT00996931|Experimental|Lenalidomide|
3228374|NCT00996918|Experimental|Bapineuzumab 0.5 mg/kg|bapineuzumab
3228375|NCT00996918|Experimental|Bapineuzumab 1.0 m/kg|bapineuzumab
3228376|NCT00996905|No Intervention|Beginner Conventional (BC)|Beginner level (residents) doing epidural insertions the conventional way (ie. no ultrasound scanning)
3228377|NCT00996905|Experimental|Beginner Ultrasound (BU)|Beginner level (residents) doing epidural insertions with the help of ultrasound scanning.
3228378|NCT00996905|No Intervention|Experienced Conventional|Experienced level (fellows) doing epidural insertions the conventional way.
3228379|NCT00996905|Experimental|Experienced Ultrasound|Experienced level (fellows) doing epidural insertions with the help of ultrasound scanning.
3228380|NCT00996892|Experimental|Dose Escalation Stage 1: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 20 milligrams [mg]) and pictilisib capsules (at a starting dose of 80 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
3228381|NCT00996892|Experimental|Dose Escalation Stage 1A: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D.Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
3228382|NCT00996892|Experimental|Dose Escalation Stage 1B: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 40 mg) and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
3228383|NCT00996892|Experimental|Dose Expansion Stage 2: Cobimetinib + Pictilisib|Participants will received cobimetinib capsules and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR) T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; and KRAS mutant colorectal cancer (CRC).
3228384|NCT00996892|Experimental|Dose Expansion Stage 2A: Cobimetinib + Pictilisib|Participants received cobimetinib capsules on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1A. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant NSCLC; EGFR T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; KRAS mutant CRC, and KRAS mutant endometrioid carcinoma.
3228385|NCT00996892|Experimental|Dose Expansion Stage 2B: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules and pictilisib capsules from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1B. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant endometrioid carcinoma.
3228386|NCT00996879|Experimental|Midazolam + BMS-791325|
3228387|NCT00996866|Placebo Comparator|Placebo|Half of subjects will be randomized to the placebo group.
3228388|NCT00996866|Active Comparator|Vitamin D3|This is the study group that receives Vitamin D supplementation.
3228389|NCT00996853||Total vaccinated cohort|The Total vaccinated cohort will include all subjects with at least one vaccine administration documented.
3228390|NCT00996840|Experimental|Cohort 1 - SB-681323 Intravenous 3mg|3mg SB-681323 Intravenous administration, infused over 4 hours
3228391|NCT00996840|Experimental|Cohort 2 - SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
3228392|NCT00996840|Experimental|Cohort 3 - SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
3228393|NCT00996840|Experimental|Cohort 4 - SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
3228394|NCT00996840|Experimental|Combined Placebo|Placebo to match intervention
3228395|NCT00996814|Experimental|Proactive Ethics Intervention|These patients have an ethics consultant involved in their care beginning on the fifth day of treatment in the ICU
3228396|NCT00996814|No Intervention|Usual Care|These patients receive usual care in the ICU.
3228397|NCT00996801|Placebo Comparator|Placebo|Participants received either matching placebo to alendronate (administered orally, once-weekly) or matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
3228398|NCT00996801|Experimental|MK-5442 5 mg|Participants received 5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
3228399|NCT00996801|Experimental|MK-5442 7.5 mg|Participants received 7.5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
3228400|NCT00996801|Experimental|MK-5442 10 mg|Participants received 10 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
3228401|NCT00996801|Experimental|MK-5442 15 mg|Participants received 15 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
3228402|NCT00996801|Active Comparator|Alendronate 70 mg|Participants received 70 mg alendronate (orally, once-weekly) plus matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
3228403|NCT00996788|Experimental|Rebamipide|Rebamipide 100 mg tid for 28 days
3228404|NCT00996775|Active Comparator|standard care only|standard care only - harmful effects of alcohol use and NIAAA limits
3228405|NCT00996775|Experimental|Brief alcohol intervention|Group receiving brief alcohol intervention
3228406|NCT00996762|Experimental|Part 1-3|2-period crossover, Period 1 (D1-7) will receive either the commercial formulation or the alternative formulation. Period 2 (D1-7) will receive the formulation not received in Period 1. There will be 3 parts with 3 different alternative formulations. Subjects will only participate in one part.
3228407|NCT00996749|Experimental|Treatment (omega-3 fatty acid)|Patients receive long-term omega-3 PUFA supplementation PO.
3228408|NCT00996736|Active Comparator|Topical Natamycin|
3228409|NCT00996736|Experimental|Topical Voriconazole|
3228410|NCT00996723|Other|1|
3228411|NCT00996697|Active Comparator|Triple therapy|Symbicort and tiotropium
3228412|NCT00996697|Placebo Comparator|Combination therapy|Symbicort and placebo
3228413|NCT00996684|Experimental|microplasmin, intravitreal injection|Subjects will receive one intravitreal injection of microplasmin on Day 0.
3228414|NCT00996684|Placebo Comparator|Placebo|Subjects will receive one intravitreal injection of the placebo on Day 0.
3228415|NCT00996671|Experimental|Dose Escalation Cohorts|single dose administration escalating doses starting at 20 mg and continue escalation; the highest dose in this study will not exceed the mean Day 1 exposure in male dogs at the NOAEL dose (6 mg/kg/day).
3228416|NCT00996671|Experimental|Food effect Cohort|Dose to be selected based on emerging safety and PK data; subjects will be given FDA standard high fat meal followed by single dose of study drug.
3228417|NCT00996658|Experimental|Linagliptin|Linagliptin tablets once daily
3228418|NCT00996658|Placebo Comparator|Placebo|Placebo tablets once daily
3228419|NCT00996645|No Intervention|Feedback report only|This arm will receive performance feedback reports but no worksheet to facilitate goal-setting and action plans.
3228420|NCT00996645|Experimental|Goal-Setting Worksheet|This arm will receive a theory-informed worksheet to facilitate the development of goals and action plans in response to the performance feedback reports.
3228421|NCT00996632|Experimental|A|Patients were operated using an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
3228422|NCT00996632|Active Comparator|B|Patients were operated using a conventional diarthermy knife
3228423|NCT00996619||People undergoing GI tract endoscopy|
3228424|NCT00996606|Experimental|Tocilizumab in Active RA|Participants with active RA will receive tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions will be given from Baseline to Week 44, and participants will be assessed through Week 48.
3228425|NCT00996593|Experimental|open-label, single arm|
3228426|NCT00996580|Experimental|DR-103|"Four 91-day cycles of the DR-103 regimen:~42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by;~21 days combination therapy of 25 mcg EE/150 mcg LNG followed by;~21 days combination therapy of 30 mcg EE/150 mcg LNG followed by;~7 days of 10 mcg EE."
3228427|NCT00996567|Experimental|Cetuximab (Erbitux)|
3228428|NCT00996554|Experimental|Double-Layer-Suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
3228429|NCT00996554|Active Comparator|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread).
3228430|NCT00996541|Experimental|Intervention|
3228431|NCT00996541|Placebo Comparator|Control|
3228432|NCT00996528|Experimental|Philani Intervention Program|
3228433|NCT00996528|No Intervention|Standard Care|No intervention during study. Referral to clinic-based health care that is delivered by the province. Offered intervention at end of study, i.e. after 18 months.
3228434|NCT00996515|Experimental|Cohort 5|Erlotinib 150mg/day PO Day 1-28 and Vidaza 100mg/m2/day SQ Day 1-4 and 15-18
3228435|NCT00996515|Experimental|Cohort 4|Erlotinib 200 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day SQ 1-4 and 15-18
3228436|NCT00996515|Experimental|Cohort 3|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-3 and 15-17
3228437|NCT00996515|Experimental|Cohort 2|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-2 and 15-16
3228438|NCT00996515|Experimental|Cohort 1|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1 and 15
3228602|NCT00995358|Experimental|vaccination|
3228439|NCT00996502|Experimental|Combination regimen|"Bevacizumab, Erlotinib, Docetaxel, Prednisone (dose escalation)~Phase I:~Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid~Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid~Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid"
3228440|NCT00996489|Experimental|Coaptite|
3228441|NCT00996476|Experimental|TMC12/PR24 50 mg|Participants received TMC435 50 mg once daily with PegIFNa-2a and ribavirin (PR) for 12 weeks followed by PR until Week 24 Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
3228442|NCT00996476|Experimental|TMC12/PR24 100 mg|Participants received TMC435 100 mg once daily plus PegIFNa-2a and ribavirin (PR) for 12 weeks followed by PR until Week 24. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
3228443|NCT00996476|Experimental|TMC24/PR24 50 mg|Participants received TMC435 50 mg once daily plus PegIFNa-2a and ribavirin (PR) for 24 weeks. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435, PR) at Week 24. All other participants continued PR until Week 48.
3228444|NCT00996476|Experimental|TMC24/PR24 100 mg|Participants received TMC435 100 mg once daily plus PegIFNa-2a and ribavirin (PR) for 24 weeks. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
3228445|NCT00996476|Experimental|PR48 Control|Participants received PegIFNa-2a and ribavirin (PR) for 48 weeks (PR48 control group)
3228446|NCT00996463|Active Comparator|IL SSG|Intralesional sodium stibogluconate
3228447|NCT00996463|Experimental|ETC+MWT|Electro-thermo-coagulation with subsequent moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
3228448|NCT00996463|Experimental|MWT|Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
3228449|NCT00996437|Placebo Comparator|Saline Injection|Saline injection at baseline, 4 and 8 weeks
3228450|NCT00996437|Active Comparator|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks
3228451|NCT00996424|Experimental|Acetylcysteine|Inhalation with N-Acetylcysteine
3228452|NCT00996424|Placebo Comparator|normal saline|Inhalation with normal saline solution
3228453|NCT00996411|Experimental|Salvinorin A|
3228454|NCT00996398|Experimental|Cold water immersion|14°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
3228455|NCT00996385|Experimental|Velcade plus Eloxatin|Six 20-day cycles
3228456|NCT00996372|Experimental|flibanserin 100mg|flibanserin 100mg po qd
3228457|NCT00996372|Placebo Comparator|placebo|placebo one tablet po qd
3228458|NCT00996359|Experimental|Irradiated allogeneic lymphocytes after Total Body Irradiation|
3228459|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 1, Level 1|"Arm 1, Level 1: Irinotecan intravenously at 80 mg/m2 + Temsirolimus intravenously at 15 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
3228460|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 1, Level 2|"Arm 1, Level 2: Irinotecan intravenously at 80 mg/m2 + Temsirolimus intravenously at 20 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
3228461|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 2, Level 1|"Arm 1, Level 2: Irinotecan intravenously at 50 mg/m2 + Temsirolimus intravenously at 25 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
3228462|NCT00996333|Experimental|Gemzar, Taxotere, Xeloda|"Gemcitabine, Docetaxel, Capecitabine:~Gemzar intravenously on Day 4 and 11 Taxotere intravenously on Day 4 and 11 Xeloda tablet taken orally every day for 14 days"
3228463|NCT00996320|Experimental|Intervention Schedule|Interns on the intervention schedule work the a modified ICU schedule averaging about 60 hours per week over 4 weeks, with maximum scheduled shift length 16 hours.
3228464|NCT00996320|No Intervention|Traditional Schedule|Interns on the traditional schedule work the usual ICU schedule averaging about 80 hours per week over 4 weeks, with maximum shift length 30 hours.
3228465|NCT00996307|Experimental|3.75_(50)MF59|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
3228466|NCT00996307|Experimental|7.5_(0)MF59|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
3228467|NCT00996307|Experimental|7.5_(50)MF59|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
3228468|NCT00996307|Experimental|15_(0)MF59|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
3228469|NCT00996294|Experimental|surgery|patients will be submitted to biliopancreatic diversion or gastric bypass
3228470|NCT00996281|Experimental|Azilsartan Medoxomil and Chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily for up to 52 weeks.~For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of azilsartan medoxomil 80 mg and chlorthalidone 25 mg."
3228471|NCT00996281|Active Comparator|Olmesartan Medoxomil and Hydrochlorothiazide QD|"Participants in the United States:~Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg.~Participants in Europe:~Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 20 mg and hydrochlorothiazide 25 mg."
3228472|NCT00996268|Experimental|Part A|Three groups of sixteen healthy subjects will be randomized to single doses of 3 different formulations of GSK2212836.
3228473|NCT00996268|Experimental|Part B|Four cohorts of at least 10 subjects will participate in a 2-week repeat dose period with 4 dose levels (based on data obtained in Part A) of the GSK2212836 test formulations or placebo.
3228474|NCT00996255|Experimental|Dose-Escalation|
3228475|NCT00996242|Experimental|L-lysine|
3228476|NCT00996229|Experimental|Caloric restriction + placebo supplementation|
3228477|NCT00996229|Experimental|Omega-3 supplementation|
3228478|NCT00996229|Placebo Comparator|Placebo supplementation|
3228479|NCT00996229|Experimental|Resveratrol supplementation|
3228480|NCT00996216|Experimental|Open-label eltrombopag|Open-label eltrombopag with dose titrations to support adequate platelet counts.
3228481|NCT00996203|Experimental|1|
3228482|NCT00996190|Active Comparator|Phenylephrine Intermittent Bolus|Bolus syringe will contain 120 micrograms/mL of phenylephrine. Infusion solution bag will contain placebo (saline solution).
3228483|NCT00996190|Active Comparator|Phenylephrine Continuous Infusion|Infusion solution bag will contain 120 micrograms/mL of phenylephrine. Bolus syringe will contain placebo (saline solution).
3228484|NCT00996177|Experimental|IONSYS|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem
3228485|NCT00996177|Active Comparator|Patient-Controlled Analgesia|IV Morphine Patient-Controlled Analgesia (IV PCA)
3228486|NCT00996164|Experimental|flibanserin 100 mg|flibanserin 100mg po qd
3228487|NCT00996164|Placebo Comparator|Placebo|placebo 1 tab po qd
3228488|NCT00996138|Other|Arm 1|Dose ranging
3228489|NCT00996138|Other|Arm 2|Dose ranging
3228490|NCT00996125|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix vaccine. Cervarix vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
3228491|NCT00996125|Experimental|Placebo Group|Subjects received 3 doses of placebo. Placebo vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
3228492|NCT00996112||Historical|
3228493|NCT00996112||Prospective|
3228494|NCT00996099|Active Comparator|CGM-eMPC|
3228495|NCT00996099|Other|Control|
3228496|NCT00996086||CRT device-recipients|
3228497|NCT00996073|Active Comparator|Autograft|Lumbar Interbody Fusion with Autograft
3228498|NCT00996073|Experimental|Low Dose|Lumbar Interbody Fusion with NeoFuse-Low Dose
3228499|NCT00996073|Experimental|High Dose|Lumbar Interbody Fusion with NeoFuse-High Dose
3228500|NCT00996060|Experimental|Hydralazine and Valproic Acid|Starting dose of Hydralazine is 25 mg orally daily, days 1-28. (See Intervention for Dose Escalation Schema) Valproic acid 250 mg orally three times per day for days -14 through -8, then 500 mg orally three times per day daily for days -7 through 28, with the dose titrated to keep the serum level between 0.4 and 0.7 mM.
3228501|NCT00996034|Experimental|Healthy Smoker|There is only one arm to the study. All subjects will receive NicVax, [123I]5-I-A-85380,and Nicotine bitartrate.
3228502|NCT00996021|Experimental|Arm 1|This is a three way crossover study with 3 periods. Subjects will receive a single dose of either GSK1349572 250 mg suspension, placebo suspension or moxifloxacin 400 mg tablet in each of the three periods. The order in which the treatments are given will be randomized. There is a screening visit within 30 days prior to the first dose of study drug and a follow-up visit within 10-14 days after the last dose of study drug.
3228503|NCT00996008|Placebo Comparator|Placebo only|Subjects will apply placebo cream to all 4 target lesions
3228504|NCT00996008|Active Comparator|Active plus placebo|Subjects will receive CT 327 on 2 of 4 target lesions located on one side of their body. On the remaining 2 target lesions on the other side of their body, placebo will be applied.
3228505|NCT00995995||All patients|
3228506|NCT00995969|Placebo Comparator|Placebo only|Subjects will apply placebo cream to both target lesions
3228507|NCT00995969|Active Comparator|Active plus placebo|Subjects will apply CT 327 to one target lesion and placebo to the other target lesion
3228508|NCT00995930|Placebo Comparator|Placebo|subcutaneous (SQ) monthly
3228509|NCT00995930|Experimental|ACZ885|150 mg SQ monthly
3228510|NCT00995917|Experimental|Vitamin K acupoint injection|Participants will receive the vitamin K intervention within 2 days of the onset of painful menstrual cramps.
3228511|NCT00995917|Sham Comparator|Saline Injection|Participants will receive the saline treatment within 2 days of the onset of painful menstrual cramps.
3228512|NCT00995904|Experimental|Treatment A, then Treatment B, then Treatment C|Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
3228513|NCT00995904|Experimental|Treatment A, then Treatment C, then Treatment B|Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
3228514|NCT00995904|Experimental|Treatment B, then Treatment A, then Treatment C|Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
3228515|NCT00995904|Experimental|Treatment B, then Treatment C, then Treatment A|Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 4
3228516|NCT00995904|Experimental|Treatment C, then Treatment A, then Treatment B|"Study visits were separated by 3-7 day intervals.~Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4"
3228603|NCT00995345|Experimental|Dose 1: KRP-104 40 mg|Tablet, once-daily for 24 weeks
3228604|NCT00995345|Experimental|Dose 2: KRP-104 80 mg|Tablet, once-daily for 24 weeks
3228517|NCT00995904|Experimental|Treatment C, then Treatment B, then Treatment A|Study visits were separated by 3-7 day intervals. Treatment C: 21ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 2; Treatment B: 42ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 4
3228518|NCT00995878|Active Comparator|Focused Ultrasound (MRgFUS)|
3228519|NCT00995878|Active Comparator|Uterine Artery Embolization (UAE)|
3228520|NCT00995865|Active Comparator|High dose|
3228521|NCT00995865|Active Comparator|Mid Dose|
3228522|NCT00995865|Placebo Comparator|Placebo|NaCl Injectable 0.9%
3228523|NCT00995852|Active Comparator|bilateral|"Treatment arm B - incomplete bilateral treatment of in total two lobes (contralateral).~The study will only use Intrabronchial Valves™"
3228524|NCT00995852|Active Comparator|unilateral|Treatment arm A - unilateral treatment with complete closure of the worst lobe of the lungs
3228525|NCT00995839|Experimental|continuous terlipressin|
3228526|NCT00995839|Experimental|vasopressin|
3228527|NCT00995839|Experimental|terlipressin bolus dose|
3228528|NCT00995826|Placebo Comparator|placebo|
3228529|NCT00995826|Experimental|CS-8958 DPI|
3228530|NCT00995800|Active Comparator|Fluticasone propionate / Formoterol fumarate|
3228531|NCT00995800|Placebo Comparator|Fluticasone propionate / Formoterol fumarate placebo|
3228532|NCT00995787|Experimental|AZD1656|
3228533|NCT00995787|Placebo Comparator|Placebo|
3228534|NCT00995774|Experimental|Robotic then Conventional|robotic arm therapy first, conventional therapy second
3228535|NCT00995774|Experimental|Conventional then Robotic|conventional therapy first, robotic therapy second
3228536|NCT00995761|No Intervention|biweekly schedule|docetaxel 40mg/m2 on day 1,15 every 4weeks cisplatin 40mg/m2 on day 1,15 every 4weeks
3228537|NCT00995735||Transgastric|Patients submitted to Transgastric NOTES surgery
3228538|NCT00995735||Transvaginal|Patients submitted to Transvaginal surgery
3228539|NCT00995722|Experimental|Prednisone + Pyridostigmine|Corticosteroid
3228540|NCT00995722|Placebo Comparator|Placebo + Pyridostigmine|Matched, inactive substance
3228541|NCT00995709|Experimental|AIN457C 300 mg every 2 week dosage regimen|AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg each. every 2 weeks
3228542|NCT00995709|Experimental|AIN457C 300 mg monthly dosage regimen|AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg e
3228543|NCT00995709|Placebo Comparator|Placebo|Placebo was administered in 2 s.c. injections every 2 weeks
3228544|NCT00995696|Experimental|PhaST|Group receiving PhaST IVR phone calls.
3228545|NCT00995696|No Intervention|Usual Care|Group NOT receiving IVR phone calls.
3228546|NCT00995683|Experimental|half sodium lactate|infusion of 0.5 ml/kg/day during 48 hours
3228547|NCT00995683|Active Comparator|isotonic sodium chloride|infusion of 0.5 ml/kg during 48 hours
3228548|NCT00995670|Experimental|Sevoflurane and Glucose|"Endothelial function will be measured via forearm blood flow (FBF). Subjects may get I/R injury (ischemia) without glucose or sevoflurane (placebo); I/R with glucose only (glucose trial); I/R with sevoflurane only (sevo trial); I/R with glucose and sevoflurane (combo trial). Baseline FBF was taken in every trial before any intervention, and FBF was taken during intervention and post I/R.~Glucose: 5% dextrose will be infused at 12 ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 1 hr to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent I/R injury.~Sevoflurane: 1 minimum alveolar concentration (MAC) for 20 min (after 1 hr glucose and before I/R) 26 volunteers were studied 67 times in this arm."
3228549|NCT00995670|Experimental|Vitamin C and Glucose|"To determine if vitamin C can restore the impairment of the endothelium (FBF) caused by the glucose (dextrose infusion). All subjects received glucose and I/R injury (ischemia), either with or without vitamin C. Control baseline FBF was taken in every trial before any intervention, and FBF was taken during intervention and post I/R.~Placebo data were the placebo studies from the Sevoflurane and Glucose arm, when appropriate; new subjects (not enrolled in Sevoflurane and Glucose arm) underwent a separate placebo trial.~Glucose: 5% dextrose will be infused at 12ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 60 min.~Vitamin C: 1 gm iv bolus injection 5 min before I/R injury 16 volunteers were studied 25 times in this arm."
3228550|NCT00995670|Experimental|Statins and Glucose|"Volunteers ingested a 40 mg simvastatin (statin) pill for the two evenings prior to study day and the morning of the study to determine the effect of simvastatin on modulating the I/R injury during hyperglycemia (high glucose). Volunteers were studied with statin alone and with statin and glucose.~Placebo data were the placebo studies from the Sevoflurane and Glucose arm, when appropriate; new subjects (not enrolled in Sevoflurane and Glucose arm) underwent a separate placebo trial.~Glucose: 5% dextrose will be infused at 12ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 60 min.~Statin: 40 mg of simvastatin 17 volunteers were studied 31 times in this arm."
3228551|NCT00995657|Active Comparator|High dose ICS|Fluticasone Propionate 250mcg bid
3228552|NCT00995657|Active Comparator|Low dose ICS|Fluticasone propionate 50mcg bid
3228553|NCT00995631|No Intervention|Premenopausal, Control|Premenopausal women randomized to Control (delayed liposuction surgery)
3228554|NCT00995631|Active Comparator|Premenopausal, Surgery|Premenopausal women randomized to surgery (femoral lipectomy)
3228555|NCT00995631|No Intervention|Postmenopausal, Control|Postmenopausal women randomized to Control (delayed liposuction surgery)
3228556|NCT00995631|Active Comparator|Postmenopausal, Surgery|Postmenopausal women randomized to surgery (femoral lipectomy)
3228557|NCT00995618|Experimental|Tranilast|Tranilast tablets
3228558|NCT00995618|Active Comparator|Febuxostat|Febuxostat tablets
3228559|NCT00995618|Experimental|Combination|Tranilast plus febuxostat
3228560|NCT00995605|Experimental|Groups SAD|AMAP102 or Placebo as single ascending doses in five groups
3228561|NCT00995605|Experimental|Groups MAD|AMAP102 or Placebo as multiple ascending doses twice daily for seven days in two groups
3228605|NCT00995345|Experimental|Dose 3: KRP-104 100 mg|Tablet, once-daily for 24 weeks
3228606|NCT00995345|Experimental|Dose 4: KRP-104 20/120mg|Tablet, once-daily for 24 weeks (dose switch from 20 to 120 mg at week 12)
3228562|NCT00995592|Experimental|Mentor mothers|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
3228563|NCT00995592|No Intervention|Control|Control cases were visited and their infants were weighed 4 times over one year period. After one year, mothers were provided Philani nutrition intervention program.
3228564|NCT00995579||Healthy college volunteers|
3228565|NCT00995566||Thelin Registry Patients|
3228566|NCT00995553|Experimental|Cognitive Remediation|A 48-session working memory focused cognitive remediation program is conducted. Training tasks have been selected from 3 software programs, PSS CogRehab, BrainTrain, and custom made N-back tasks.
3228567|NCT00995553|Placebo Comparator|Computer Skills|This is a 48-session, time matched comparison group in which participants practice keyboarding skills and the fundamentals of Microsoft Office Word, Powerpoint, and Excel programs.
3228568|NCT00995540|Placebo Comparator|Placebo|Placebo subcutaneous injection tid for 12 weeks
3228569|NCT00995540|Active Comparator|100 mg INGAP Peptide tid|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
3228570|NCT00995540|Active Comparator|200 mg INGAP Peptide tid|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
3228571|NCT00995514||Clopidogrel|Patients receiving clopidogrel 75 mg/day as prescribed by their physician, and are extensive metabolizers by CYP2C19 genotype
3228572|NCT00995514||Prasugrel|Patients receiving prasugrel 5 or 10 mg/day as prescribed by their physician
3228573|NCT00995501|Active Comparator|Intensive Glucose Control, Dexamethasone, light anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Light anesthesia target BIS of 55"
3228574|NCT00995501|Active Comparator|Intensive Glucose Control, Dexamethasone, Deep anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Deep anesthesia target BIS of 35"
3228575|NCT00995501|Active Comparator|Intensive Glucose Control, placebo, Light anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Light anesthesia target BIS of 55"
3228576|NCT00995501|Active Comparator|Conventional Glucose Control, Dexamethasone, Light anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Light anesthesia target BIS of 55"
3228577|NCT00995501|Active Comparator|Intensive Glucose Control, Placebo, Deep anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Deep anesthesia target BIS of 35"
3228578|NCT00995501|Active Comparator|Conventional Glucose Control, Dexamethasone, Deep anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Deep anesthesia target BIS of 35"
3228579|NCT00995501|Active Comparator|Conventional Glucose Control, Placebo, Light anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Light anesthesia target BIS of 55"
3228580|NCT00995501|Placebo Comparator|Conventional Glucose Control, Placebo, Deep anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Deep anesthesia target BIS of 35"
3228581|NCT00995488|Experimental|ABI-007|ABI-007 combined with Carboplatin, and Gemcitabine
3228582|NCT00995475|Experimental|Inhaled corticosteroid|
3228583|NCT00995475|Placebo Comparator|Placebo control|
3228584|NCT00995462|No Intervention|Control|
3228585|NCT00995462|Experimental|Small-group seminar for 2 years|
3228586|NCT00995462|Experimental|Small-group seminars for 1 year followed by email intervention|
3228587|NCT00995449|Experimental|KB003 70 mg|
3228588|NCT00995449|Experimental|KB003 200 mg|
3228589|NCT00995449|Experimental|KB003 600 mg|
3228590|NCT00995449|Placebo Comparator|Placebo|
3228591|NCT00995436|Active Comparator|Extraoral anchorage|The intervention is the placement of Headgear, to be worn 100 hours per week
3228592|NCT00995436|Active Comparator|Miniscrews|The intervention is the of miniscrews to supplement anchorage
3228593|NCT00995436|Active Comparator|Nance palatal arch|Anchorage supplemented by Nance palatal arch fixing molars together with an arch
3228594|NCT00995423|Active Comparator|CoroflexTM|highly flexible CoroflexTM Please-Stent features
3228595|NCT00995423|Active Comparator|TAXUS|Paclitaxel-eluting stent
3228596|NCT00995410|Experimental|PA32540 tablet|325 mg enteric coated (EC) ASA and 40 mg omeprazole to be taken by mouth once daily
3228597|NCT00995397|Experimental|Dexchlorpheniramine 1% lotion|
3228598|NCT00995397|Active Comparator|Dexchlorpheniramine 1% cream|
3228599|NCT00995384|Other|CT scan|CT Scan for endocarditis patients. All patients receive intervention.
3228600|NCT00995371|Active Comparator|Vertos mild® Minimally-Invasive Lumbar Decompression|Patients in the Vertos mild® treatment group will be treated by appropriately trained physicians in accordance with the product labeling and indications for use.
3228601|NCT00995371|Active Comparator|Epidural Steroid Injection|Patients in the Epidural Steroid Injection (ESI) group will have ESI performed by appropriately trained physicians in accordance with product labeling and indications for use.
3228607|NCT00995345|Placebo Comparator|Placebo|Tablet, once-daily for 24 weeks
3228608|NCT00995332|Experimental|ATRA+valproc acid+low-dose cytarabine|
3228609|NCT00995319||radiation patients|cancer patients with radiotherapy concerning the head and neck area/oral cavity
3228610|NCT00995306|Active Comparator|1|Civamide Cream 0.075%
3228611|NCT00995306|Active Comparator|2|Civamide Cream 0.01%
3228612|NCT00995293|Experimental|Docetaxel Cisplatin 5-Fluorouracil (DCF)|"4 cycles of the following products every 3 weeks (unless disease progression/relapse or unacceptable toxicity occured or the patient refused treatment):~Docetaxel 60mg/m² on day 1~Cisplatin 75mg/m² on day 1~5-FU 750mg/m²/day on day 1 to day 5"
3228613|NCT00995293|Experimental|Cisplatin 5-Fluorouracil (CF)|"4 cycles of the following products every 3 weeks (unless disease progression/relapse or unacceptable toxicity occured or the patient refused treatment):~Cisplatin 75mg/m² on day 1~5-FU 750mg/m²/day on day 1 to day 5"
3228614|NCT00995280|Active Comparator|1|Single lumen needle use in oocyte retrieval
3228615|NCT00995280|Active Comparator|2|Double lumen needle with follicle flushing during oocyte retrieval
3228616|NCT00995267|Experimental|behavioral intervention|Behavioral intervention arm comprises 5 joint parent-child school-based nutritional activities in which nutritional information was combined with Adler's behavioral concepts. and a 5-session parental workshop.
3228617|NCT00995267|No Intervention|control arm|
3228618|NCT00995254|No Intervention|Control group|Control group will ONLY receive SHI after completion of the study
3228619|NCT00995254|Experimental|Intervention group|Intervention group will receive smoking hygiene intervention (SHI) at three individualized contacts.
3228620|NCT00995241|Experimental|Raltegravir 800 mg / 24 hours|Raltegravir 800 mg / 24 hours
3228621|NCT00995215|Experimental|Spinal Cord Stimulation|The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.
3228622|NCT00995202|Sham Comparator|Standard Monitoring|In the standard monitoring arm, abdominal ultrasound examination is performed every 3 months for 3 years, then every 6 months for 2 years, then annually. A Chest X-ray is performed every 6 months for 3 years then annually for 2 years.
3228623|NCT00995202|Experimental|Intensive monitoring|A thoraco-abdominal-pelvic CT scan alternating with abdominal ultrasound is performed every 3 months for 3 years, then every 6 months for 2 years. CEA levels are measured every 3 months for 3 years, then every 6 months for 2 years.
3228624|NCT00995189|Experimental|OFR|Opti-Free RepleniSH contact lens care solution used for 30 days
3228625|NCT00995189|Active Comparator|RNM|ReNu MultiPlus contact lens care solution used for 30 days
3228626|NCT00995176||1|Women residing in areas from defined geographic areas with high HIV prevalence and poverty
3228627|NCT00995176||2|Men residing in areas from defined geographic areas with high HIV prevalence and poverty
3228628|NCT00995150|Experimental|LNG20|LNG20 levonorgestrel-releasing intrauterine system
3228629|NCT00995150|Active Comparator|Mirena|Levonorgestrel-releasing intrauterine system for contraception
3228630|NCT00995137|Experimental|relapse B-Lineage ALL|"All patients meeting the eligibility criteria.~Intervention: NK Cell Infusion"
3228631|NCT00995124|Experimental|NeutraLice Lotion|Single application of head lice product.
3228632|NCT00995124|Experimental|NeutraLice Advance|single application of head lice product
3228633|NCT00995124|Active Comparator|Moov Head Lice Solution|Single application for head lice with 10 min application time.
3228634|NCT00995098|Experimental|Early enteral nutrition|Twenty patient will be enrolled into this arm. Enteral nutrition administration will start within 24 hours after admission through naso-jejunal tube and continue for 7 days after admission.Naso-jejunal tube will be set up by endoscopy.
3228635|NCT00995098|Active Comparator|Control: Parenteral Nutrition|Twenty patient will be enrolled into this arm. PN administration will start within 24 hours after admission and continue for 7 days after admission.Parenteral nutrition will be administered through subclavian central venous catheter.
3228636|NCT00995085|Experimental|Metadoxine SR|Metadoxine is a pyrolate salt of Pyridoxine
3228637|NCT00995072|Experimental|Arm A|Nebivolol 5 mg daily for 12 weeks followed by Metoprolol succinate 100 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to metoprolol.
3228638|NCT00995072|Experimental|Arm B|Metoprolol succinate 100 mg daily for 12 weeks followed by nebivolol 5 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to nebivolol.
3228639|NCT00995059|Experimental|Arm 1|CONDITIONING: Patients receive bortezomib IV and then undergo fractionated total-body irradiation on days -5 and -2. Patients receive thymoglobulin IV over 6 hours on days -5 to -2 and melphalan IV over 30 minutes on days -4 to -3. ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -3, patients receive oral sirolimus and taper beginning on day 61. Beginning on day -2, patients receive oral or IV tacrolimus and taper beginning on day 101.
3228640|NCT00995046|Active Comparator|usual prophylaxis regimen|All patients will receive their usual prophylaxis regimen during the first 6 months
3228641|NCT00995046|Experimental|individually tailored prophylaxis regimen|All patients will receive an individually tailored prophylaxis regimen in accordance with TGT results during the second 6 month-period.
3228642|NCT00995033|Experimental|NicVAX conjugate vaccine|
3228643|NCT00995033|Placebo Comparator|Placebo|Biological
3228644|NCT00995020|Experimental|SWETZ|The intervention administered in this arm is the straight wire excision of the transformation zone, a electrosurgical method to perform a cone biopsy using a 1 cm straight wire of 0.20 mm wire. The activated wire is used in much the same way as a cold knife or laser beam fashioning the surgical specimen to achieve two centimeters cm at cervical canal..
3228645|NCT00995020|Active Comparator|LLETZ cone|The intervention administered in this arm is the large loop excision of transformation zone as a cone biopsy, performed using a large loop electrode of 2 cm depth, applied to the cervix to achieving two centimeters at cervical canal .
3228646|NCT00995007|Active Comparator|Group 2|Sequential Group (carboplatin followed by vandetanib)
3228647|NCT00995007|Active Comparator|Group 1|Combo Group (both drugs together)
3228648|NCT00994994|Active Comparator|Tranexamic acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit.
3228649|NCT00994994|Placebo Comparator|Placebo|same volume of normal saline was given.
3228650|NCT00994981|Experimental|magnesium|Using a table of random numbers, the patients were randomized to receive magnesium solution or normal saline. Allocation concealment was ensured using sequentially numbered, sealed opaque envelopes. Immediately after patient's arrival in the operating room, an anesthesiologist who was not involved in this study opened the envelopes and prepared the study solution outside the operating room.
3228651|NCT00994981|Placebo Comparator|normal saline|Using a table of random numbers, the patients were randomized to receive magnesium solution or normal saline. Allocation concealment was ensured using sequentially numbered, sealed opaque envelopes. Immediately after patient's arrival in the operating room, an anesthesiologist who was not involved in this study opened the envelopes and prepared the study solution outside the operating room.
3228652|NCT00994955|Experimental|selective retina therapy (SRT)|Focal laser treatment with an SRT-Laser which selectively affects the retinal pigment epithelium while sparing the photoreceptor layer.
3228653|NCT00994929|Experimental|Neumega (Oprelveken, Interleukin 11)|Neumega (Oprelveken, interleukin-11 (IL-11) 25 microgram/kilogram by subcutaneou injection once daily for four days, followed on day 4 DDAVP 0.3 microgram/kilogram intravenously 30 minutes after neumega
3228654|NCT00994903|Placebo Comparator|Placebo|Placebo tablets (Inert calcium lactate)
3228655|NCT00994903|Experimental|Simvastatin|40mg of Simvastatin given 3-7 days pre-op and continued till 14 days post-op
3228656|NCT00994890|Experimental|Tanezumab 2.5 mg|
3228657|NCT00994890|Experimental|Tanezumab 5 mg|
3228658|NCT00994890|Experimental|Tanezumab 10 mg|
3228659|NCT00994877||Septic Patients|
3228660|NCT00994877||Healthy Control|
3228661|NCT00994864|Other|adjuvant FOLFOX (1 pre-operative cycle)|One cycle of preoperative standard FOLFOX chemotherapy followed by eleven cycles post-operatively. PET/CT before and after the pre-operative chemotherapy cycle.
3228662|NCT00994851|Experimental|SENNA+ CASSIA|Daily administration (capsule) of Naturetti (SENNA+ CASSIA) at bedtime, during 30 days
3228663|NCT00994851|Placebo Comparator|Placebo|Daily administration (capsule) of placebo at bedtime, during 30 days
3228664|NCT00994838|Active Comparator|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
3228665|NCT00994838|No Intervention|standard diet|
3228666|NCT00994825|Placebo Comparator|Placebo|"Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%"
3228667|NCT00994825|Experimental|Levosimendan|Levosimendan
3228668|NCT00994812|Experimental|Metformin|
3228669|NCT00994799||ranibizumab group|patients receiving intravitreal ranibizumab for diabetic macular edema
3228670|NCT00994799||laser|patients receiving macular grid-pattern laser therapy
3228671|NCT00994786|Experimental|pregabalin|
3228672|NCT00994786|Placebo Comparator|Placebo|
3228673|NCT00994773|Experimental|Simvastatin|Simvastatin orally
3228674|NCT00994773|Experimental|Simvastatin and tenofovir|Simvastatin combined with tenofovir
3228675|NCT00994773|Experimental|Simvastatin and entecavir|Simvastatin combined with entecavir
3228676|NCT00994760||GENISIS|
3228677|NCT00994747|Active Comparator|Group EEEEEEE|Infant is fed Enfamil from 0.5-7.5 months of life
3228678|NCT00994747|Experimental|Group ENEEEEE|Infant is fed Enfamil during 0.5-1.5 months of life, Nutramigen from 1.5-2.5 months of life and then Enfamil 2.5-7.5 of life.
3228679|NCT00994747|Experimental|Group EENEEEE|Infant is fed Enfamil 0.5-2.5 months of life, Nutramigen from 2.5-3.5 months of life and then Enfamil from 3.5 to 7.5 months of life
3228680|NCT00994747|Experimental|Group EEENEEE|Infant is fed Enfamil from 0.5-3.5 months of life, Nutramigen from 3.5-4.5 months of life and then Enfamil from 4.5-7.5 months of life.
3228681|NCT00994747|Experimental|Group ENNNEEE|Infant if fed Enfamil from month 0.5-1.5 months of life, Nutramigen from 1.5 to 3.5 months of life and then Enfamil again 3.5-7.5 months of life.
3228682|NCT00994747|Experimental|Group NNNNNNN|Infant is fed Nutramigen from 0.5-7.5 months of life.
3228683|NCT00994734|No Intervention|clinic administration of mifepristone|
3228684|NCT00994734|Experimental|home administration of mifepristone|
3228685|NCT00994721||pancreatic cancer|resected pancreatic cancer
3228686|NCT00994682|Active Comparator|Pioglitazone|After all patients receive dietary counseling at the research unit (CTSA), patients with prediabetes or type 2 diabetes mellitus (T2DM) and NASH will be started on pioglitazone (or placebo) in a randomized, double-blind,placebo-controlled study design. Pioglitazone will be given at 30 mg/day for the first 2 months and titrated to 45 mg/day thereafter (if well tolerated).
3228687|NCT00994682|Placebo Comparator|Placebo|After dietary counseling to all patients at the research unit (CTSA), patients with prediabetes or type 2 diabetes mellitus (T2DM) and NASH will be started on pioglitazone (or placebo) in a randomized, double-blind,placebo-controlled study design. Pioglitazone will be given at 30 mg/day for the first 2 months and titrated to 45 mg/day thereafter (if well tolerated).
3228688|NCT00994669||healthy control male|
3228689|NCT00994669||lung cancer male|
3228690|NCT00994656||posterior spinal fusion subject|Subject will have a history of either idiopathic or neuromuscular scoliosis who is now scheduled to have a posterior spinal fusion.
3228691|NCT00994643|Experimental|Treatment (Interleukin Therapy, Monoclonal Antibody)|Patients receive interleukin-2 SC twice weekly and rituximab IV once weekly in weeks 5-8 and 25-28. Courses repeat every 4 weeks for up to 7 months in the absence of disease progression or unacceptable toxicity.
3228692|NCT00994630||BP I patients manic phase|
3228693|NCT00994617|Experimental|Combination Therapy|Patients treated with combination therapy of Hydrochlorthiazide plus Losartan. Losartan will be force-titrated from 50 to 100mg, Hydrochlorothiazide will be force-titrated from 12.5mg to 25mg
3228694|NCT00994617|Active Comparator|Monotherapy|Initial monotherapy Hydrochlorothiazide 12.5mg -25mg Crossed over with Losartan 50 -100mg at 8 weeks
3228695|NCT00994604|Experimental|broccoli sprout extract|This a before and after treatment study. The subjects will consumer broccoli sprout extract (BSE) for two weeks (14d). Lung function and Chest CT will be performed before and after BSE consumption.
3228696|NCT00994591|Experimental|Pharmacokinetic dosing|
3228697|NCT00994578|No Intervention|Internet Only|Patients assigned to the internet only group will enter the initial CHESS portal which will take them to a window displaying a standard web search engine and common cancer information sites. We will monitor their internet usage via logins to the CHESS portal.
3228698|NCT00994578|Experimental|CHESS|Participants in the CHESS arm will be given access to the University of Wisconsin CHESS website, modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support. The participant's usage of the site will be monitored.
3228699|NCT00994578|Experimental|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each visit, and access to the patient's audio-recorded conversations for review. The participant's usage of the site will be monitored.
3228700|NCT00994578|Experimental|CHESS/COPE|Participants in the CHESS+COPE arm will receive training in, and access to, both components on the CHESS website, with the accompanying levels of support. The participant's usage of the site will be monitored.
3228701|NCT00994565|No Intervention|Usual care|
3228702|NCT00994565|Active Comparator|Activity monitoring and distance counseling|
3228703|NCT00994552|Active Comparator|Pressure support ventilation|Pressure support ventilation
3228704|NCT00994552|Active Comparator|Pressure control ventilation|Pressure control ventilation
3228705|NCT00994526|Placebo Comparator|Ham|
3228706|NCT00994526|Experimental|Ham + calcium|
3228707|NCT00994526|Experimental|Ham + vitamin E|
3228708|NCT00994513|Active Comparator|ALA|alpha lipoic acid 1200 mg/day
3228709|NCT00994513|Placebo Comparator|Placebo|placebo 1200 mg/day
3228710|NCT00994500|Experimental|Treatment (vorinostat, bortezomib)|Patients receive oral vorinostat once daily on days 1-5 and 8-12 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3228711|NCT00994487|Experimental|Breastfed child|Female, normal weight, 3 to 5 year old children, exclusively breastfed from birth to 3 months of age
3228712|NCT00994487|Active Comparator|Bottle Fed Child|Female, normal weight, 3 to 5 year old children, exclusively bottle fed from birth to 3 months of age
3228713|NCT00994474|Active Comparator|Fractional carbon dioxide laser treatment|
3228714|NCT00994474|Active Comparator|Fractional Er:YAG laser treatment|
3228715|NCT00994461|Experimental|Celecoxib|
3228716|NCT00994461|Active Comparator|Loxoprofen|
3228717|NCT00994461|Placebo Comparator|Placebo|
3228718|NCT00994448|Experimental|Bupropion|
3228719|NCT00994448|Placebo Comparator|Placebo (sugar pill)|
3228720|NCT00994422|Experimental|0.5% ivermectin cream|
3228721|NCT00994422|Placebo Comparator|vehicle control|
3228722|NCT00994396|Placebo Comparator|Placebo pill|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos
3228723|NCT00994396|Experimental|Vitamin D|4000 IU vitamin D3 (cholecalciferol) per day for 6 months.
3228724|NCT00994370||liver cancer|Patients referred for SIRT will be considered for this investigation. These patients will predominantly have stage IV colorectal metastases with liver dominant metastases or hepatocellular carcinoma. A team of oncologists, interventional radiologists, radiation oncologists and oncologic surgeons will determine that the patients are not candidates for surgical resection or ablative therapy. The patients will then be screened to confirm the patient's eligibility to receive standard of care SIRT treatment. SIRT treatment and imaging studies included in this investigation are standard of care for the patients' liver dominant disease.
3228725|NCT00994357|Experimental|Real-time Continuous Glucose Monitoring|Real-time Continuous Glucose Monitoring at five times for up to 6 days during pregnancy, and during delivery, in addition to standard monitoring and treatment.
3228726|NCT00994357|Active Comparator|Control group|Standard monitoring and treatment of diabetic patients during pregnancy.
3228727|NCT00994344|Experimental|Darunavir/ritonavir|to switch from the triple therapy based regimens to Darunavir/ritonavir
3228728|NCT00994344|Active Comparator|Lopinavir/ritonavir|to switch from the triple therapy based regimens to Lopinavir/ritonavir
3228729|NCT00994331|Active Comparator|Group A-CT Coregistration|5 subjects with CT co-registration in a magnetically navigated PCI (Group A)
3228730|NCT00994331|Active Comparator|Group B-Angiographic|5 subjects with angiographic co-registration in a magnetically navigated PCI (Group B)
3228731|NCT00994331|Active Comparator|Group C-Standard Angiography|5 subjects with standard angiography in a conventional PCI (Group C)
3228732|NCT00994318|Experimental|FCM (high ferritin target)|Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 400 - 600 mcg/L
3228733|NCT00994318|Experimental|FCM (low ferritin target)|Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 100 - 200 mcg/L
3228734|NCT00994318|Active Comparator|Oral Iron|Ferrous sulphate 100 mg iron twice daily, continuous
3228735|NCT00994305|Active Comparator|N-acetylcysteine|N-acetylcysteine 600 mg bid po 0-7 PO
3228736|NCT00994305|Sham Comparator|control|No treatment: standard care provided. No N-acetylcysteine administration.
3228737|NCT00994292|Experimental|1. YM150 Dose V, twice daily|
3228738|NCT00994292|Experimental|2. YM150 Dose W, once daily|
3228739|NCT00994292|Experimental|3. YM150 Dose X, twice daily|
3228740|NCT00994292|Experimental|4. YM150 Dose Y, once daily|
3228741|NCT00994292|Experimental|5. YM150 Dose Y, twice daily|
3228742|NCT00994292|Experimental|6. YM150 Dose Z, once daily|
3228743|NCT00994292|Placebo Comparator|7. Placebo|
3228744|NCT00994279|Active Comparator|Arm 1: Yoga Intervention|Yoga Intervention
3228745|NCT00994279|Active Comparator|Arm 2: Educational Wellness Group|Educational Wellness Group
3228746|NCT00994266|Experimental|A|Diamel
3228747|NCT00994266|Placebo Comparator|B|Placebo
3228748|NCT00994253|Experimental|Aliskiren|"Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day.~Patients will be assigned to the treatment arm containing aliskiren. The prescribed drugs will include: Lisinopril 40mg + amlo 5mg + aliskiren 150-300mg"
3228749|NCT00994253|Active Comparator|Hydrochlorothiazide|"HCTZ will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day.~Patients will be assigned to the treatment arm containing HCTZ. The prescribed drugs will include: Lisinopril 40mg + amlo 5mg + HCTZ 12.5-25mg"
3228750|NCT00994240|Active Comparator|ED&C times 3 cycles|
3228751|NCT00994240|Active Comparator|ED & C times 1 cycle|
3228752|NCT00994227|Experimental|surgery|
3228753|NCT00994214|Experimental|BIM 23A760 1 mg|
3228754|NCT00994214|Experimental|BIM 23A760 2 mg|
3228755|NCT00994214|Experimental|BIM 23A760 4 mg|
3228756|NCT00994214|Experimental|BIM 23A760 6 mg|
3228757|NCT00994175|Experimental|Pioglitazone, Then Placebo|Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the first treatment phase, followed by 45 mg daily for an additional 14 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the placebo phase for 16 weeks in the second treatment phase to receive the placebo.
3228758|NCT00994175|Experimental|Placebo, Then Pioglitazone|Placebo was administered for 16 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the Pioglitazone treatment group. Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the treatment phase, followed by 45 mg daily for an additional 14 weeks.
3228759|NCT00994162|Experimental|Negative Pressure Wound Therapy|Application of NPWT therapy to the wound
3228760|NCT00994149|Experimental|Diazoxide|Infants in this are will receive 10mg/kg/d of diazoxide divided and given every eight hours
3228761|NCT00994149|Placebo Comparator|Ora-plus|Liquid suspension modified to match intervention. Given every eight hours. Provided in shielded syringes.
3228762|NCT00994136|Experimental|Normal saline|In the intervention group the use of heparin as locking solution in the catheter lumen (or lumina) when the catheter is not longer in use is omitted. Catheters are locked under positive pressure with normal saline in stead injecting an extra volume of heparinised saline (100IU/ml).
3228763|NCT00994136|No Intervention|Heparin lock|
3228764|NCT00994123|Experimental|Phase 1: Dose-Escalation|Escalating doses of MM-121 (QOW IV) and erlotinib (daily PO)
3228765|NCT00994123|Active Comparator|Phase 2: Control|Erlotinib (daily)
3228766|NCT00994123|Experimental|Phase 2: Treatment|MM-121 (QOW IV) and erlotinib (daily PO)
3228767|NCT00994110|Experimental|SOM230|This is a randomized, double-blind, placebo controlled phase III trial of SOM230 vs. saline placebo in patients undergoing pancreaticoduodenectomy or distal pancreatectomy with or without splenectomy at Memorial Sloan-Kettering Cancer Center.
3228768|NCT00994110|Placebo Comparator|placebo|This is a randomized, double-blind, placebo controlled phase III trial of SOM230 vs. saline placebo in patients undergoing pancreaticoduodenectomy or distal pancreatectomy with or without splenectomy at Memorial Sloan-Kettering Cancer Center.
3228769|NCT00994097|Experimental|A: NGR-hTNF + cisplatin/gemcitabine or cisplatin/pemetrexed|NGR-hTNF with cisplatin/gemcitabine regimen in patients with squamous histology or with cisplatin/pemetrexed regimen in patients with nonsquamous histology
3228770|NCT00994097|Active Comparator|B: cisplatin/gemcitabine or cisplatin/pemetrexed|Cisplatin/gemcitabine regimen is administered in patients with squamous histology and cisplatin/pemetrexed regimen is administered in patients with nonsquamous histology
3228771|NCT00994084|Active Comparator|Lifestyle modification|This arm receives the intervention program that includes structured physical activities and nutrition and behavior lessons
3228772|NCT00994084|Placebo Comparator|Control|This arm receives no intervention
3228773|NCT00994058|Experimental|Intevention with Inhibitor|
3228774|NCT00994045|Active Comparator|Fresh Frozen Plasma|
3228775|NCT00994045|Experimental|Fibrinogen concentrate|
3228776|NCT00994032|Active Comparator|vertebroplasty|
3228777|NCT00994032|Active Comparator|Medical Treatment|
3228778|NCT00994006|Active Comparator|Magnesium oxide tables|Subjects will be instructed to take Magnox 520 qd
3228779|NCT00994006|Active Comparator|Magnesium citrate tablets|Subjects will be instructed to take magnesium diasporal tablets t.i.d.
3228780|NCT00993993||"group early intervention"|
3228781|NCT00993993||"group late intervention"|
3228782|NCT00993980|Experimental|1|qigong
3228783|NCT00993980|Active Comparator|2|exercise therapy
3228784|NCT00993967|Experimental|Idebenone|1350 mg/day or 2250 mg/day for patients weighing ≤45 kg or >45 kg, respectively.In case of poor tolerability, dose reduction to 450 mg/day or 900 mg/day, respectively, were allowed.
3228785|NCT00993954|Experimental|Nurse Reduction|Patients randomized to reduction by nurse.
3228786|NCT00993954|Active Comparator|Physician Reduction|Patients randomized to treatment by Emergency Department Physician in traditional ED manner
3228787|NCT00993941|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were randomly assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
3228788|NCT00993941|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were randomly assigned to Group B were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as Bone Mesenchymal Stem Cells(BMSC) transplantation via portal vein.
3228789|NCT00993928|Experimental|Arm A: Home-based sleep intervention with Device #1|Participants listen to a pre-recorded mp3 device #1 before retiring to sleep. Only patients in Arm A will have assigned bed and wake times based on their baseline diary.
3228790|NCT00993928|Active Comparator|Arm B: Home-based sleep intervention with Device #2|Participants will listen to a pre-recorded mp3 device #2 before retiring to sleep. At the end of the study, participants assigned to pre-recorded mp3 device #2 will be offered pre-recorded mp3 device #1 for their own use.
3228905|NCT00993226|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 1b|double-blind
3228791|NCT00993915||Main group|Newly diagnosed or known coronary artery disease and known dislipidemia and high risk of cardiovascular complications
3228792|NCT00993902|Sham Comparator|Single IUI|Single IUI will be carried on after 36-38 hours of HCG administration
3228793|NCT00993902|Active Comparator|Double IUI|
3228794|NCT00993889|Experimental|VR during Physical Therapy|The subject will receive virtual reality during painful physical therapy sessions.
3228795|NCT00993889|Experimental|VR background pain|The subjects receives virtual reality, not during a physical therapy procedure, another time of the day for background pain.
3228796|NCT00993889|Experimental|No VR|The subject will receive the usual standard treatment. At the end of the study, before being discharged from the hospital, the subject can experience the VR, not during a procedure.
3228797|NCT00993876|Experimental|Selective serotonin reuptake inhibitor (SSRI)|citalopram
3228798|NCT00993876|Experimental|Serotonin-norepinephrine reuptake inhibitor (SNRI)|reboxetine
3228799|NCT00993876|Active Comparator|IPT|interpersonal psychotherapy
3228800|NCT00993863|Placebo Comparator|Placebo|
3228801|NCT00993863|Experimental|ADL5859 30 mg|
3228802|NCT00993863|Experimental|ADL5859 100 mg|
3228803|NCT00993863|Experimental|ADL5859 200 mg|
3228804|NCT00993863|Active Comparator|ibuprofen 400 mg|
3228805|NCT00993850|Other|Bipolar disorder education|Psychoeducation
3228806|NCT00993850|Other|Cognitive behavioral therapy|Cognitive behavioral therapy for insomnia
3228807|NCT00993837|Experimental|conversion|
3228808|NCT00993824|Placebo Comparator|Welchol then Placebo|3.75 grams of colesevelam HCl (Welchol) at evening meal for 12 weeks, and then crossover to placebo at evening meal for 12 weeks.
3228809|NCT00993824|Placebo Comparator|Placebo then Welchol|Placebo taken for 12 weeks at evening meal, and then crossover to 3.75 grams of colesevelam HCl taken at evening meal fro 12 weeks.
3228810|NCT00993811|Experimental|Circumcision|Males undergoing circumcision
3228811|NCT00993798|Experimental|SABER-Bupivacaine Treatment 1a|double-blind
3228812|NCT00993798|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 1b|double-blind
3228813|NCT00993798|Active Comparator|Bupivacaine HCl Treatment 1c|double-blind
3228814|NCT00993798|Experimental|SABER-Bupivacaine Treatment 2a|double-blind
3228815|NCT00993798|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 2b|double-blind
3228816|NCT00993798|Active Comparator|Bupivacaine HCl Treatment 2c|double-blind
3228817|NCT00993785|Experimental|OTW Catheter System|
3228818|NCT00993759|No Intervention|No treatment|
3228819|NCT00993759|Experimental|3804-250A lotion|
3228820|NCT00993746|Active Comparator|Bupivacaine plus lidocaine|Group 1: bupivacaine 20 ml plus lidocaine 10 ml
3228821|NCT00993746|Experimental|Bupivacaine alone|Group 2: bupivacaine 30 ml
3228822|NCT00993733|Experimental|CVVHDF on-line|CVVHDF using a central water treatment plant, providing dialysate directly to the patient. They will perform a continuous veno-venous haemodiafiltration.
3228823|NCT00993733|Experimental|classical CVVHDF|CVVHDF using a mobile generator with dialysate bags. They will perform a continuous veno-venous haemodiafiltration.
3228824|NCT00993720|Experimental|type 1 DM with betacell function: Liraglutide|
3228825|NCT00993720|Experimental|type 1 DM without betacell function: Liraglutide|
3228826|NCT00993720|No Intervention|type 1 DM without betacell function: Insulin|
3228827|NCT00993707|Active Comparator|0.01% CTX-100 (formerly ETX-100)|
3228828|NCT00993707|Active Comparator|0.03% CTX-100 (formerly ETX-100)|
3228829|NCT00993707|Placebo Comparator|Placebo|
3228830|NCT00993681|Experimental|1|900 subjects will receive a two vaccination regimen with an LT patch
3228831|NCT00993681|Placebo Comparator|2|900 subjects will receive a two vaccination regimen with a placebo patch
3228832|NCT00993668|Placebo Comparator|Placebo|Placebo
3228833|NCT00993668|Experimental|Cimzia|Certolizumab pegol
3228834|NCT00993655|Active Comparator|IV carboplatin + IV paclitaxel|ARM 1: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intravenous day 1; Paclitaxel 60 mg/m2 intravenous day 8. Cycles given Q 21 days x 3 cycles
3228835|NCT00993655|Active Comparator|IP cisplatin + IV/IP paclitaxel|ARM 2: Paclitaxel 135 mg/m2 intravenous day 1 plus Cisplatin 75 mg/m2 intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles (Phase II cisplatin arm closed to accrual on 2014-FEB-03)
3228836|NCT00993655|Active Comparator|IP carboplatin + IV/IP paclitaxel|ARM 3: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles
3228837|NCT00993642|Experimental|All Participants|
3228838|NCT00993629|Active Comparator|Arm 1|adjunctive pregnenolone
3228839|NCT00993629|Placebo Comparator|Arm 2|adjunctive placebo
3228840|NCT00993616|Experimental|Treatment|Patients receive belinostat IV over 30 minutes on days 1-5 and carboplatin IV over 30-60 minutes on day 3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who are clinically responding or who, in the opinion of their physician, would continue to benefit from treatment may continue treatment beyond 6 courses.
3228841|NCT00993603|Experimental|Lifestyle programme.|8 month lifestyle programme.
3228842|NCT00993590|Experimental|M CHESS group|The intervention group will receive access for 12 months to M-CHESS via a smartphone to: (1) contact their case managers and primary provider; (2) communicate with the managed care organization case managers; (3) communicate with peers; (4) share information about changes in health status; (5) receive reminders to take medications and complete medical follow-up; (6) receive feedback on use of their asthma action plan; (7) receive tailored inquiries and insights regarding attendance or use of asthma resources; and (8) access audio and video versions of asthma educational materials and lower reading level versions of text materials; (9) provide monthly study outcome data monthly for 12 months.
3228843|NCT00993590|Active Comparator|Control group|The control group will receive standard care plus a smartphone for 12 months; they will provide study outcome data monthly for the next 12 months.
3228844|NCT00993577|Experimental|Exercises|Global Postural Reeducation Static Stretching Exercises
3228845|NCT00993564||Selective head cooled infants cooled|Infants with HIE who have undergone head cooling for the amelioration of HIE
3228846|NCT00993564||Selective head cooled infants rewarmed|Same infants after rewarming
3228847|NCT00993551|Experimental|12 month surgery|Infants will receive primary surgery at age 12 months using a standardized technique
3228848|NCT00993551|Experimental|6 month surgery|Infants will receive primary surgery at age 6 months using a standardized technique.
3228849|NCT00993538|Experimental|1|
3228850|NCT00993525|Experimental|Intravitreal anti-VEGF|Intravitreal injection of 0.5 mg of ranibizumab
3228851|NCT00993512|Experimental|TPCS2a|No comparative treatment is given in this open-label phase I, dose escalating safety study
3228852|NCT00993499|Experimental|BIBW 2992 + Sirolimus|Dose escalation of the combination BIBW 2992 plus Sirolimus.
3228853|NCT00993486|Experimental|L1 (dose 1.0x10E4 T-cells/kg)|
3228854|NCT00993486|Experimental|L2 (dose 5.0x10E4 T-cells/kg)|
3228855|NCT00993486|Experimental|L3 (dose 1.3x10E5 T-cells/kg)|
3228856|NCT00993486|Experimental|L4 (dose 3.2x10E5 T-cells/kg)|
3228857|NCT00993486|Experimental|L5 (dose 7.9x10E5 T-cells/kg)|
3228858|NCT00993486|Experimental|L6 (dose 2.0x10E6 T-cells/kg)|
3228859|NCT00993486|Experimental|L7 (dose 5.0x10E6 T-cells/kg)|
3228860|NCT00993473|Experimental|Lantus (insulin glargine)|Lantus given as basal insulin once a day in the morning by subcutaneous injection
3228861|NCT00993473|Active Comparator|NPH insulin|Neutral Protamine Hagedorn (NPH) human insulin given as basal insulin either once or twice per day generally in the morning and /or at bedtime by subcutaneous injection
3228862|NCT00993460||Normal body weight|Female subjects, ages 21-65 yrs, with BMI of 21-27 kg/m2 with normal glucose tolerance.
3228863|NCT00993460||Roux-en-Y gastric bypass|Female subjects ages 21-65 with insulin resistance and scheduled for Roux-en-Y gastric bypass at Vanderbilt University Medical Center will be studied before and 4-6 weeks after surgery.
3228864|NCT00993447|Experimental|CYD Dengue Vaccine Group|Sanofi pasteur's CYD Dengue vaccine group (Dengvaxia®)
3228865|NCT00993447|Sham Comparator|Control Vaccine Group|
3228866|NCT00993434|Active Comparator|Kid STRIDE Booklet|
3228867|NCT00993434|Placebo Comparator|Safety Booklet|
3228868|NCT00993421|Placebo Comparator|placebo|
3228869|NCT00993421|Experimental|LY377604 (75 mg)|
3228870|NCT00993421|Active Comparator|sibutramine (30 mg)/metoprolol (200 mg)|
3228871|NCT00993421|Experimental|LY377604 (40 mg)/sibutramine (30 mg)|
3228872|NCT00993421|Experimental|LY377604 (75 mg)/sibutramine (30 mg)|
3228873|NCT00993421|Experimental|LY377604 (15 mg)/sibutramine (30 mg)|
3228874|NCT00993421|Experimental|LY377604 (75 mg)/sibutramine (15 mg)|
3228875|NCT00993408|Experimental|ACT-293987 (NS-304) and matching placebo|"Subjects will be randomized to the study following screening.~Each subject will then undergo an acute hemodynamic study with right heart catheterization after a single oral administration of ACT-293987 (NS-304)on Day 0. The objectives are to collect data about the drug effect on the right heart hemodynamic parameters (PVR, calculated SVR and PVR/SVR) measured by right heart catheterization after single oral dose administration of NS-304 and to assess the safety and tolerability of a single oral dose of NS-304."
3228876|NCT00993395|Experimental|Peer Mentor Intervention|peer mentor-based disease management focusing on three domains: medical care, recovery, and social stabilization
3228877|NCT00993382|Experimental|Celivarone 50 mg|Celivarone, 50 mg once daily up to 10-15 days before the common study end date
3228878|NCT00993382|Experimental|Celivarone 100 mg|Celivarone, 100 mg once daily up to 10-15 days before the common study end date
3228879|NCT00993382|Experimental|Celivarone 300 mg|Celivarone, 300 mg once daily up to 10-15 days before the common study end date
3228880|NCT00993382|Active Comparator|Amiodarone|Amiodarone, 600 mg once daily for 10 days (loading dose) then 200 mg once daily up to 10-15 days before the common study end date
3228881|NCT00993382|Placebo Comparator|Placebo|Matching placebo once daily up to 10-15 days before the common study end date
3228882|NCT00993369||Healthy newborns conceived naturally|
3228883|NCT00993369||Healthy newborns conceived with IVF|
3228884|NCT00993356|Other|Group 2|After a baseline evaluation, patients underwent transsphenoidal surgery (direct surgery group).
3228885|NCT00993356|Experimental|Group 1|Patients received lanreotide for 16 weeks before the surgical resection [starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH > 5 mU/L on GH day curve (GHDC)] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
3228886|NCT00993343|Active Comparator|Cyclosporine + Methotreaxte|
3228887|NCT00993343|Active Comparator|sirolimus + tacrolimus|
3228888|NCT00993330||1|20 healthy subjects between 18 and 40 years
3228889|NCT00993330||2|20 healthy subjects between 41 and 50 years
3228890|NCT00993330||3|20 healthy subjects between 51 and 60 years
3228891|NCT00993330||4|20 healthy subjects between 61 and 70 years
3228892|NCT00993330||5|20 healthy subjects between 71 and 80 years
3228893|NCT00993330||6|20 healthy subjects between 81 and 90 years
3228894|NCT00993317|Placebo Comparator|Placebo of CDP870+MTX|
3228895|NCT00993317|Experimental|CDP870 200mg+MTX|
3228896|NCT00993304|Experimental|A|
3228897|NCT00993304|Placebo Comparator|B|
3228898|NCT00993291|No Intervention|Baseline frequency|Baseline DBS frequency
3228899|NCT00993278|Active Comparator|Low-Carbohydrate (Modified Atkins) Diet|
3228900|NCT00993278|Active Comparator|Low-Fat (Heart Healthy) Diet|
3228901|NCT00993265|Experimental|N-acetylcysteine (NAC)|Patients randomized to this arm will receive N-Acetylcysteine, at a standard dose titrated to 2400 mg. They will receive NAC in addition to the medication regimen they are on at enrollment.
3228902|NCT00993265|Placebo Comparator|Placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
3228903|NCT00993239|Experimental|Birinapant (TL32711)|
3228904|NCT00993226|Experimental|SABER-Bupivacaine Treatment 1a|double-blind
3228906|NCT00993226|Active Comparator|Bupivacaine HCl Treatment 1c|double-blind
3228907|NCT00993226|Experimental|SABER-Bupivacaine Treatment 2a|double-blind
3228908|NCT00993226|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 2b|double-blind
3228909|NCT00993226|Active Comparator|Bupivacaine HCl Treatment 2c|double-blind
3228910|NCT00993213|Active Comparator|Liposuction|Standard of Care with Liposuction
3228911|NCT00993213|Sham Comparator|No Liposuction|Standard of Care without Liposuction'
3228912|NCT00993200|Active Comparator|Warfarin, control|Subjects naive to warfarin therapy with anticipated warfarin duration of at least 12 weeks managed by usual care dosing.
3228913|NCT00993200|Experimental|Warfarin: PERMIT|Subjects naive to warfarin therapy with anticipated warfarin duration of at least 12 weeks managed by warfarin pharmacogenetic dosing (warfarin dosing using genetic information incorporated into the PERMIT algorithm).
3228914|NCT00993187|Experimental|Sitagliptin/Metformin FDC|Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks.
3228915|NCT00993187|Active Comparator|Glimepiride|Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day.
3228916|NCT00993174|Experimental|Topical anesthesia|Patients undergo strabismus surgery for esotropia using topical anesthesia (instillation of drops plus gel)
3228917|NCT00993174|Active Comparator|Sub-Tenon's anesthesia|Patients undergo surgery for strabismus (esotropia) using sub-Tenon's administration of anesthetic (xylocaine)
3228918|NCT00993161|Experimental|patients|Patients with neuromuscular disorder and controls
3228919|NCT00993161|Experimental|Controls|healthy controls
3228920|NCT00993148|Experimental|Maraviroc plus darunavir/ritonavir|Single arm open label trial of maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily for 96 weeks
3228921|NCT00993122|Active Comparator|ribavirin pre-treatment|patient will receive ribavirin in monotherapy for 8 weeks before the combined 48 weeks antiviral therapy
3228922|NCT00993122|Active Comparator|combined stardard therapy|patients will receive the standard combined therapy with ribavirin and pegylated interferon for 48 weeks
3228923|NCT00993109|Experimental|Arm 1|
3228924|NCT00993109|Active Comparator|Arm 2|
3228925|NCT00993096|Experimental|IDegAsp low|
3228926|NCT00993096|Experimental|IDegAsp middle|
3228927|NCT00993096|Experimental|IDegAsp high|
3228928|NCT00993096|Experimental|BIAsp 30 low|
3228929|NCT00993096|Experimental|BIAsp 30 middle|
3228930|NCT00993096|Experimental|BIAsp 30 high|
3228931|NCT00993083|Experimental|Vaccinated|14 volunteers (2 in lead safety group and 12 in main study group) to receive MVA-NP+M1 via the IM route. Volunteers will then be challenged with Influenza 30 days post vaccination.
3228932|NCT00993083|No Intervention|Control|12 volunteers who will not receive vaccine but will also be challenged with Influenza on day 30
3228933|NCT00993070|Experimental|Capsaicin|
3228934|NCT00993070|Placebo Comparator|placebo|
3228935|NCT00993057|Active Comparator|Q1 hour protocol|change of insulin infusion every hour
3228936|NCT00993057|Active Comparator|Q30min protocol|change of insulin infusion every 30 minutes
3228937|NCT00993044|Experimental|Single Arm|
3228938|NCT00993031|Experimental|Group A|ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg
3228939|NCT00993031|Active Comparator|Group B|ZDV 300mg/3TC 150mg/EFV 600mg
3228940|NCT00993018|Experimental|JNJ-42160443 (1 mg)|JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
3228941|NCT00993018|Experimental|JNJ-42160443 (3 mg)|JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
3228942|NCT00993018|Experimental|JNJ-42160443 (10 mg)|JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
3228943|NCT00993018|Placebo Comparator|Placebo|Placebo will be administered as a single, subcutaneous injection every 28 days for up to 52 weeks.
3228944|NCT00993005|Experimental|A|Cicatrix
3228945|NCT00993005|Placebo Comparator|B|Placebo
3228946|NCT00992992|Experimental|Tositumomab and Iodine I 131 Tositumomab followed by CHOP|Tositumomab and Iodine I 131 Tositumomab followed by CHOP
3228947|NCT00992979|Experimental|Therapeutic Massage|
3228948|NCT00992979|Active Comparator|Relaxation Control|Relaxation Control Session
3228949|NCT00992953|Experimental|Virtual Reality Therapy|10 Weeks of Virtual Reality Exposure with Stimulus Control, with up to twice a week, 90 min sessions
3228950|NCT00992953|Active Comparator|Treatment As Usual|Traditional Therapy and Psychiatric Medication
3228951|NCT00992940|Experimental|Patient-Controlled Sedation/Analgesia|Patient controls the amount of sedation and analgesia delivered, according to their own requirements.
3228952|NCT00992940|Active Comparator|Anesthetist-Controlled Sedation/Analgesia|Patient sedation and analgesia requirements are delivered by the anesthetist.
3228953|NCT00992927|Experimental|CPIHD|Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
3228954|NCT00992927|Active Comparator|CRIHD|Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
3228955|NCT00992914|Active Comparator|Lidocaine injection|Stellate Ganglion Injection with Lidocaine
3228956|NCT00992914|Placebo Comparator|saline injection|Superficial subcutaneous injection
3228957|NCT00992901|Experimental|Exendin-(9-39)|To evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion
3229068|NCT00992108|Active Comparator|Lidocaine|lidocaine injection group
3228958|NCT00992901|Experimental|atropine|To evaluate the effect of neural activation on insulin secretion and glucose metabolism
3228959|NCT00992901|Experimental|GLP-1 and GIP|to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones
3228960|NCT00992888|Experimental|albumin liver dialysis|
3228961|NCT00992888|No Intervention|Standard medial care without dialysis|
3228962|NCT00992862|Experimental|Moexipril HCl 15mg Tablets|
3228963|NCT00992862|Active Comparator|Univasc® 15mg Tablets|
3228964|NCT00992849|Experimental|Bevacizumab|Arm type to experimental based on single group assignment. Bevacizumab (trade name Avastin, Genentech/Roche) is a humanized monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF).VEGF is a chemical signal that stimulates the growth of new blood vessels.
3228965|NCT00992836|Experimental|Influenza A (H1N1) 2009 monovalent vaccine|All participants received two doses of the H1N1 influenza virus vaccine, administered 21 days apart.
3228966|NCT00992823|Active Comparator|Group 1:iron weekly supplementation|
3228967|NCT00992823|Active Comparator|Group 2: cycle supplementation|two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
3228968|NCT00992810|Experimental|Lateral-to-Medial Approach|Needle approach to the brachial plexus nerves will be made using a lateral-to-medial direction.
3228969|NCT00992810|Experimental|Medial-to-Lateral Approach|Needle approach to the brachial plexus nerves will be made using a lateral-to-medial direction.
3228970|NCT00992797|Experimental|Cholecalciferol|
3228971|NCT00992797|Placebo Comparator|Placebo|
3228972|NCT00992784|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A
3228973|NCT00992784|Active Comparator|Fluarix elderly Group|Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine
3228974|NCT00992784|Active Comparator|Fluarix young Group|Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine
3228975|NCT00992771|Experimental|Varneicline|
3228976|NCT00992771|Placebo Comparator|Placebo|
3228977|NCT00992758|Experimental|Treatment, Non-Randomized, Open Label|Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
3228978|NCT00992745|Experimental|Previous ProstaScint®|Subjects with a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 alone.
3228979|NCT00992745|Experimental|No Previous ProstaScint®|Subjects without a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 and 111-In capromab pendetide imaging.
3228980|NCT00992732|Experimental|HQK-1004 + Valganciclovir|
3228981|NCT00992719|Active Comparator|Group 3: Non-pregnant Women: 15 mcg H1N1 Vaccine|100 non-pregnant women to receive 15 mcg inactivated H1N1 vaccine.
3228982|NCT00992719|Experimental|Group 2: Pregnant Women: 30 mcg H1N1 Vaccine|100 pregnant women to receive 30 mcg inactivated H1N1 vaccine.
3228983|NCT00992719|Experimental|Group 1: Pregnant Women: 15 mcg H1N1 Vaccine|100 pregnant women to receive 15 mcg inactivated H1N1 vaccine.
3228984|NCT00992693|Experimental|Treatment with IV Ribavirin|In this open label treatment study, the investigators intend to treat all subjects who present with a tentative diagnosis of VHF and meet entry criteria with a 10 day course of IV Ribavirin.
3228985|NCT00992680|Experimental|Group A|Anastomotic Coupler System + standard of care per GOLD
3228986|NCT00992680|No Intervention|Group B|Standard of care per GOLD alone
3228987|NCT00992667|Experimental|Asthmatics|Ten nonsmoking patients, suffering from mild bronchial asthma participated in the study (mean age 30±9 years, 5 men, 5 women). Asthma was diagnosed based on GINA 2008 criteria. The patients were free of any medication, at least 7 days before, and had not suffered from any infectious diseases including upper respiratory tract infections for at least 3 months prior to the study. Patients who did not meet these criteria were excluded from the study.
3228988|NCT00992641|Experimental|Experimental diet|Diet based on Nordic recommendations: rich in whole grain products, berries, fruits and vegetables, recommended fat quality. Realised based on eating habits of each Nordic country.
3228989|NCT00992641|Active Comparator|Control diet|Diet based on the information of the current dietary intake and food consumption in Nordic countries.
3228990|NCT00992628|Active Comparator|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
3228991|NCT00992628|Active Comparator|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
3228992|NCT00992615|Experimental|Arm 20 cores|
3228993|NCT00992615|Active Comparator|arm 12 cores|
3228994|NCT00992602|Experimental|Treatment (liposomal cytarabine, high-dose methotrexate)|See Detailed Description
3228995|NCT00992589|Experimental|Rabeprazole sodium 5 mg|
3228996|NCT00992589|Experimental|Rabeprazole sodium 10 mg|
3228997|NCT00992589|Placebo Comparator|Placebo|
3228998|NCT00992563|Experimental|AL-39324 Concentration Level A|AL-39324 ophthalmic suspension, single intravitreal injection
3228999|NCT00992563|Experimental|AL-39324 Concentration Level B|AL-39324 ophthalmic suspension, single intravitreal injection
3229000|NCT00992563|Experimental|AL-39324 Concentration Level C|AL-39324 ophthalmic suspension, single intravitreal injection
3229001|NCT00992563|Experimental|AL-39324 Concentration Level D|AL-39324 ophthalmic suspension, single intravitreal injection
3229002|NCT00992563|Experimental|AL-39324 Concentration Level E|AL-39324 ophthalmic suspension, single intravitreal injection
3229003|NCT00992563|Active Comparator|Lucentis|Ranibizumab 10 mg/mL solution, single intravitreal injection
3229004|NCT00992550|Experimental|Hookah visit, then cigarette visit|4-day inpatient stays for profile of biomarker excretion
3229005|NCT00992550|Experimental|Cigarette visit, then Hookah visit|4-day inpatient stay for profile of biomarker excretion
3229006|NCT00992537|Experimental|IDeg|
3229007|NCT00992537|Experimental|IDegAsp|
3229008|NCT00992537|Active Comparator|IAsp|
3229009|NCT00992524|Active Comparator|Oral Titrated Misoprostol Solution|
3229010|NCT00992524|Active Comparator|Vaginal Misoprostol|
3229011|NCT00992511|Experimental|D-INI-1D group|Subjects receiving one dose of initial process-manufactured GSK2340272A vaccine
3229012|NCT00992511|Experimental|D-INI-2D group|Subjects receiving two doses of initial process-manufactured GSK2340272A vaccine
3229013|NCT00992511|Experimental|D-NEW-1D|Subjects receiving one dose of new process-manufactured GSK2340272A vaccine
3229014|NCT00992511|Experimental|D-NEW-2D|Subjects receiving two doses of new process-manufactured GSK2340272A vaccine
3229015|NCT00992485|Experimental|autologous adipose derived stem cell|
3229016|NCT00992472|Experimental|Prochlorperazine suppositories, 25mg|
3229017|NCT00992472|Active Comparator|Compazine® suppositories, 25mg|
3229018|NCT00992459|Experimental|Buphenyl (NaPBA) /HPN 100 Placebo|Subjects in Arm A were randomly assigned to receive NaPBA + HPN 100 placebo for 2 weeks and then crossed over to receive HPN 100 + NaPBA Placebo for 2 weeks.
3229019|NCT00992459|Experimental|HPN-100/NaPBA Placebo|Subjects in Arm B were randomly assigned to receive HPN-100 + NaPBA placebo for 2 weeks and then crossed over to receive NaPBA + HPN 100 placebo for 2 weeks.
3229020|NCT00992446|Experimental|Treatment (chemotherapy, ASCT, bortezomib, vorinostat))|All patients receive carmustine IV over 3 hours on day -7; cytarabine IV BID over 3 hours and etoposide IV BID over 2 hours on days -6 to -3; and melphalan IV over 30 minutes on day -2. Only patients with history of CD20+ NHL receive additional rituximab IV on days -19 and -12. Patients undergo ASCT on day 0. Patients then receive bortezomib IV on days 2 and 8, and vorinostat PO QD on days 1-14. Treatment with bortezomib and vorinostat repeats for total of 12 courses in the absence of disease progression or unacceptable toxicity.
3229021|NCT00992433|Experimental|Group 2, 30 mcg|CD4<200, n=60; CD4 greater than or equal to 200, n=60. 30 mcg H1N1 vaccine on Day 0 and Day 21.
3229022|NCT00992433|Experimental|Group 1, 15 mcg|CD4<200, n=60; CD4 greater than or equal to 200, n=60. 15 micrograms (mcg) H1N1 vaccine on Day 0 and Day 21.
3229023|NCT00992420||GRAVITAS Study Arm A|"Tailored clopidogrel regimen - total first day dose 600-mg, then 150-mg every day for 6 months"
3229024|NCT00992420||GRAVITAS Study Arm B|"Standard clopidogrel regimen - a placebo loading dose (six placebo tablets) and then clopidogrel 75-mg and 1 placebo tablet every day for 6 months."
3229025|NCT00992420||GRAVITAS Study Arm C|Responders: A random sample of clopidogrel responders treated with a placebo loading dose (six placebo tablets) and then the standard clopidogrel regimen of 75-mg and 1 placebo tablet every day for 6 months.
3229026|NCT00992407|Experimental|Risperidone long acting injectables|
3229027|NCT00992407|Active Comparator|Risperidone tablets|
3229028|NCT00992394|Other|Arm 1|Subjects randomized to arm 1 stop their etanercept treatment on entry into the study and may be retreated by etanercept 50 mg once weekly after medical review and agreement between the subject and the investigator
3229029|NCT00992394|Other|Arm 2|Subjects randomized to arm 2 in which subjects continue on treatment with etanercept at 25 mg once weekly, but with the option to have their drug treatment increased to 50 mg once weekly after medical review and agreement between the subject and the investigator
3229030|NCT00992381|Experimental|1|PN400
3229031|NCT00992381|Active Comparator|2|Naproxen
3229032|NCT00992368|Active Comparator|reduction mammaplasty|submitted to surgery
3229033|NCT00992368|No Intervention|not reduction mammaplasty|not submitted to surgery
3229034|NCT00992355|Active Comparator|Tobramycin 0.3% - Dexamethasone 0.1%|
3229035|NCT00992355|Active Comparator|Tobramycin-Dexamethasone plus Ketorolac tromethamine|
3229036|NCT00992342|Experimental|PF-03893787 5 mg|
3229037|NCT00992342|Experimental|PF-03893787 15 mg|
3229038|NCT00992342|Experimental|PF-03893787 50 mg|
3229039|NCT00992329|Experimental|ciprofloxacin tab1|formulation 1
3229040|NCT00992329|Experimental|ciprofloxacin tab2|formulation 2
3229041|NCT00992329|Experimental|ciprofloxacin tab 3|formulation 3
3229042|NCT00992329|Active Comparator|ciprofloxacin reference|reference product
3229043|NCT00992316||Pf-04531083|To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04531083 In Healthy Male Subjects
3229044|NCT00992290|Experimental|Lactobacillus GG|
3229045|NCT00992290|Placebo Comparator|Placebo|
3229046|NCT00992277|Experimental|Facial|Skin rejuvenation treatments
3229047|NCT00992264|Experimental|Message Tone|"Prescriptive or Motivational~Persons are randomized to receive intervention content written in either a prescriptive or motivational tone."
3229048|NCT00992264|Experimental|Testimonials|Persons are randomized to receive a personally tailored testimonial or not.
3229049|NCT00992264|Experimental|Navigation|"Dictated or Non-Dictated~Persons are randomly assigned to be able to freely navigate the website or to have their navigation of the website pre-determined based on their baseline readiness to quit smoking."
3229050|NCT00992264|Experimental|Proactive Outreach|"Email or No-Email communication~Persons are randomized to receive periodic email reminders to return to the intervention website or not."
3229051|NCT00992238|Experimental|Flavoxate Hydrochloride Tablets, 100mg|
3229052|NCT00992238|Active Comparator|Urispas® Tablets, 100mg|
3229053|NCT00992225|Experimental|LY573636-sodium|
3229054|NCT00992212|Experimental|Group A (Seasonal TIV + 7.5mcg HA+ full dose MF59)|
3229055|NCT00992212|Experimental|Group B (Ajuvanted Seasonal TIV + 7.5mcg HA+ full dose MF59)|
3229056|NCT00992212|Experimental|Group C (7.5mcg HA+ full dose MF59)|
3229057|NCT00992212|Experimental|Group D (7.5mcg HA+ full dose MF59 + Seasonal TIV)|
3229058|NCT00992212|Experimental|Group E (3.75mcg HA+ ½ dose MF59+ Seasonal TIV)|
3229059|NCT00992199|No Intervention|control arm|adjuvant intravenous system chemotherapy
3229060|NCT00992199|Experimental|IP Chemo arm|adjuvant system intravenous chemotherapy combined with adjuvant intraperitoneal chemotherapy
3229061|NCT00992186|Experimental|Carlumab|
3229062|NCT00992173|Experimental|Ultratrace Iobenguane I 131|
3229063|NCT00992160|Experimental|Active|Vestipitant 15mg once daily
3229064|NCT00992160|Placebo Comparator|Placebo|Placebo
3229065|NCT00992147|Experimental|autologous cultured adipocytes|
3229066|NCT00992121|Other|Part I and 2 week dosing Part II|Part I - bevacizumab 3 infusions at 2 week intervals Part II - pazopanib dosing 2 weeks in 3-week cycles
3229067|NCT00992121|Other|Part I and 3 week dosing Part II|Part I - bevacizumab 3 infusions at 2 week interval, Part II - pazopanib dosing 3 weeks in 3-week cycles
3229070|NCT00992082|Active Comparator|Group LIA|Local Infiltration Analgesia
3229071|NCT00992082|Active Comparator|Group M|Intrathecal morphine
3229072|NCT00992069|Experimental|TMC207 alone and with EFV|Participants will receive single-dose TMC207 alone and then single-dose TMC207 with EFV.
3229073|NCT00992056|Experimental|Metoprolol/Nebivolol|Metoprolol/Nebivolol: Metoprolol 50 mg titrated to 100 mg then nebivolol 5 mg titrated to 10 mg
3229074|NCT00992056|Experimental|Nebivolol/Metoprolol|Metoprolol 50 mg titrated to 100 mg then Nebivolol 5 mg titrated to 10 mg
3229075|NCT00992043|Placebo Comparator|exercise and placebo|
3229076|NCT00992043|Experimental|exercise and creatine|
3229077|NCT00992030|Experimental|ARM A|Rituximab plus ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles
3229078|NCT00992030|Active Comparator|ARM B|ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles followed by involved field irradiation
3229079|NCT00992017|Experimental|H1N1 vaccine|Pregnant women enrolled received two doses of H1N1 vaccine, administered 21 days apart.
3229080|NCT00992004|Experimental|Arantal®|Highly bioavailable turmeric extract (food supplement)
3229081|NCT00992004|Placebo Comparator|Placebo|Same capsule without the active ingredients (only excipients)
3229082|NCT00991978|Experimental|89Zr-bevacizumab PET|89Zr-bevacizumab PET
3229083|NCT00991965||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
3229084|NCT00991952|Experimental|Arm A (irinotecan hydrochloride, alvocidib)|Patients receive irinotecan hydrochloride IV over 30 minutes and alvocidib IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3229085|NCT00991952|Active Comparator|Arm B (irinotecan hydrochloride)|Patients receive irinotecan hydrochloride as in Arm A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3229086|NCT00991939|Experimental|High dose pulse dexamethasone|
3229087|NCT00991939|Active Comparator|Standard prednisone therapy|
3229088|NCT00991926||orlistat plus normo-caloric diet|10 subjects received normo-caloric diet plus + orlistat (Xenical, Roche, UK) at a dose of 120 mg tid. The duration of follow-up was 10 days
3229089|NCT00991926||normo-caloric diet|10 subjects received normo-caloric diet without the additional treatment. The duration of follow-up was 10 days
3229090|NCT00991913||Delirium|Delirium was determined by CAM
3229091|NCT00991913||no Delirium|no Delirium was determined by CAM
3229092|NCT00991900||Healthy subjects|
3229093|NCT00991887|No Intervention|No Radiation Therapy (XRT)|This group will not receive radiation therapy after surgery.
3229094|NCT00991887|Active Comparator|Radiation Therapy (XRT)|Radiotherapy will be administered no later than 72 hours postoperatively.
3229095|NCT00991861|Experimental|LAS41007 o.d.|Once daily
3229096|NCT00991861|Experimental|LAS41007 b.i.d.|Twice daily
3229097|NCT00991861|Active Comparator|LAS106521|
3229098|NCT00991848|Experimental|Lidocaine|Patients received 240 mg lidocaine diluted in 125 mL 0.9% saline. The solutions were infused over a period of 1 h, once a week, for 4 weeks (T1, T2, T3 and T4).
3229099|NCT00991822|Active Comparator|1|Patients with open angle glaucoma
3229100|NCT00991822|Active Comparator|2|Patients with open angle glaucoma
3229101|NCT00991809|Experimental|Alfentanil|Subjects received a series of acute alfentanil administrations each session (15 mcg/kg IM per session), with sessions spaced at 3-4 day intervals.
3229102|NCT00991809|Active Comparator|Diphenhydramine|Subjects received a series of acute diphenhydramine administrations each session (25 mg IM per session), with sessions spaced at 3-4 day intervals.
3229103|NCT00991796|Experimental|CS-1008|CS-1008 with carboplatin and paclitaxel
3229104|NCT00991796|Placebo Comparator|Placebo|Placebo with carboplatin and paclitaxel
3229105|NCT00991770|Experimental|Massage Therapy|Massage therapy provided by a certified Massage Therapist
3229106|NCT00991770|Active Comparator|Control|Empathic support conversation
3229107|NCT00991757|Experimental|001|carisbamate Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
3229108|NCT00991744|Experimental|Liposomal cytarabine|Intrathecal liposomal cytarabine (25 - 50 mg) combined with intrathecal prednisolone sodium succinate and oral dexamethasone 6 times during maintenance treatment for high-risk ALL
3229109|NCT00991744|Active Comparator|Intrathecal triple|Intrathecal methotrexate, cytarabine and prednisolone
3229110|NCT00991731|Active Comparator|Faith-based|Faith-based interventions incorporate tenets of the faith-based organization (e.g., religious beliefs, scriptural references) and involve the faith-based organization in the planning of the intervention from beginning to end
3229111|NCT00991731|Active Comparator|Non-faith-based|A curriculum designed for delivery without biblical references. In the traditional teachings of how to increase physical activity.
3229112|NCT00991731|No Intervention|Control|"This group will receive a printed pamphlet Energize Yourself! Stay Physically Active, published by the National Heart Lung and Blood Institute, that encourages participation in at least 30 minutes of daily physical activity all at once or in bouts lasting 10 minutes at a time."
3229113|NCT00991718|Experimental|A|On Day 1, subjects received a single oral dose of non-labeled GDC-0449 and a single IV tracer dose of 14C-GDC-0449.
3229114|NCT00991718|Experimental|B|On Day 1, subjects received a single oral dose of 14C-GDC-0449.
3229115|NCT00991718|Experimental|C|On Days 1−7, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects also received a single IV tracer dose of 14C-GDC-0449.
3229116|NCT00991718|Experimental|D|On Days 1−6, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects received a single oral dose of 14C-GDC-0449.
3229117|NCT00991705|Other|Group B|Atorvastatin (7 days) → Fimasartan + Atorvastatin (7 days)
3229118|NCT00991705|Other|Group A|Fimasartan (7 days) → Fimasartan + Atorvastatin (7 days)
3229119|NCT00991692|Experimental|Treatment dosage levels examined|
3229120|NCT00991679||Normal control subjects|Normal control subjects who did not show the clinical symptom and findings of dry eye syndrome.
3229171|NCT00991276|Active Comparator|pramipexole|
3229886|NCT00986232|Experimental|3|ProQuad (high dose)
3229121|NCT00991679||dry eye patients|Patients with dry eye syndrome who had symptoms of dry eye for more than 3 months, low tear film break up time (BUT, ≤7 sec), low Schirmer test (<10 mm), low tear clearance rate (<8X), and positive fluorescein or rose bengal vital staining (≥3) and were not treated with anti-inflammatory agents such as topical cyclosporine or steroids were included in the study.
3229122|NCT00991666|Experimental|1|AMD Patients
3229123|NCT00991666|Active Comparator|2|healthy controls
3229124|NCT00991653||Breast cancer|Diagnosed with breast cancer 1/1/2003 - 31/12/2007.
3229125|NCT00991640|No Intervention|Control|No intervention
3229126|NCT00991640|Experimental|Preceptorships|Preceptorships with e-learning
3229127|NCT00991627|Active Comparator|Pharmacological|Patients in this group will receive a basal infusion of ephedrine. Hypotension will be treated for a reduction in systolic blood pressure 20% below baseline values.
3229128|NCT00991627|Experimental|Non-Pharmacological|Patients in this group will undergo uterine lateral displacement through the use of a wedge-shaped cushion placed under their right hip. Hypotension will be treated for a reduction in systolic blood pressure 40% below baseline values.
3229129|NCT00991614||EVOLUTION® Duodenal Stent|
3229130|NCT00991601|Experimental|biopsy arm|patients with tumors in liver and/or pancreas
3229131|NCT00991588||PCL, posterolateral reconstruction|All patients who are entered into study who receive a PCL and/or posterolateral knee ligament reconstruction
3229132|NCT00991575||Diabetes, type 1|
3229133|NCT00991549|Experimental|1|interdisciplinary weight loss intervention
3229134|NCT00991549|Active Comparator|2|Small group seminars without interdisciplinary intervention
3229135|NCT00991536||Chronic respiratory failure|Patients with restrictive pulmonary disorders leading to progressive hypercapnic respiratory failure and requiring nocturnal non-invasive ventilation
3229136|NCT00991523|Experimental|sweetened beverage|
3229137|NCT00991523|Placebo Comparator|placebo control|placebo
3229138|NCT00991510|Experimental|Reference/Test/Test|"The reference product was CellCept® and test product was Myfenax®. In period I, participants received CellCept on Days 1-14. In period II, participants crossed-over to receive Myfenax on Days 15-28. In period III, participants received Myfenax until the end of the study (Days 29-112).~Doses of mycophenolate mofetil were at least 500 mg twice daily, morning and evening."
3229139|NCT00991510|Experimental|Test/Reference/Reference|"The test product was Myfenax® and the reference product was CellCept®. In period I, participants received Myfenax on Days 1-14. In period II, participants crossed-over to receive CellCept on Days 15-28. In period III, participants received CellCept until the end of the study (Days 29-112).~Doses of mycophenolate mofetil were at least 500 mg twice daily, morning and evening."
3229140|NCT00991497|Active Comparator|24 hours compression bandaging|
3229141|NCT00991497|Active Comparator|5 days compression bandaging|
3229142|NCT00991484||control group|
3229143|NCT00991484||individuals from hernia-family|
3229144|NCT00991471|Experimental|Interaction with MDRN STAT|Interaction with MDRNSTAT at triage to obtain orders for investigations and/or treatment
3229145|NCT00991471|Experimental|Control: No MDRNSTAT|Control group
3229146|NCT00991458|Experimental|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
3229147|NCT00991458|Experimental|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
3229148|NCT00991458|Placebo Comparator|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
3229149|NCT00991445|Active Comparator|Group MIS|Minimal Invasive Surgery
3229150|NCT00991445|Active Comparator|Conventional Exposure|
3229151|NCT00991432||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
3229152|NCT00991419|Experimental|A|[18F]4694
3229153|NCT00991406|Experimental|Arm 1|Case-control study: pre- and post-stimulation (FES).
3229154|NCT00991393||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
3229155|NCT00991380|Experimental|Lifestyle counselling|
3229156|NCT00991380|Active Comparator|Usual Care|
3229157|NCT00991367|Experimental|A|Cicatrix
3229158|NCT00991367|Placebo Comparator|B|Placebo
3229159|NCT00991354|Experimental|Group 1|Participants will receive 3 mg of PENNVAX-B vaccine or placebo at Months 0, 1, and 3.
3229160|NCT00991354|Experimental|Group 2|Participants will receive 3 mg of PENNVAX-B vaccine and 1 mg of IL-12 vaccine or placebo at Months 0, 1, and 3.
3229161|NCT00991354|Experimental|Group 3|Participants will receive 3 mg of PENNVAX-B vaccine and 1 mg of IL-12 vaccine or placebo at Months 0, 1, and 3.
3229162|NCT00991341|Active Comparator|Shorter-storage red blood cell units|Red blood cell units stored <= 10 days
3229163|NCT00991341|Active Comparator|Longer-storage red blood cell units|Red blood cell units stored >= 21 days
3229164|NCT00991328|Active Comparator|Cerebral Desaturation, i.e; SctO2 < 60 % for 5 minutes|Once the cerebral desaturation is established, the study personnel will attempt to optimize the level of oxygen within the brain of the study patients.
3229165|NCT00991328|No Intervention|Patients with SctO2 less than 60 %.|The study patients will not get any intervention in this arm if the Sct02 falls below 60%
3229166|NCT00991302|Experimental|CAP-IT|"Participants received the modified CAP-IT adherence intervention in addition to standard care.~Modified client adherence profiling and intervention tailoring (CAP-IT): Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)"
3229167|NCT00991302|No Intervention|Standard care|Participants received standard care.
3229168|NCT00991289|Experimental|NTZ/PEG/RBV|Participants received nitazoxanide (NTZ) alone for 4 weeks followed by 48 weeks of NTZ with pegylated interferon (PEG) and ribavirin (RBV). Participants who did not achieve early virologic response (EVR) at Week 16 or had detectable hepatitis C virus (HCV) viral load at Week 28 discontinued treatment.
3229169|NCT00991276|Experimental|pregabalin|
3229170|NCT00991276|Placebo Comparator|placebo|
3229172|NCT00991263||Group 1|Tissue blocks from CALGB-9344 and CALGB-9741 are utilized to purify RNA to be tested in the PAM50 assay (a 50-gene quantitative PCR assay, that provides an intrinsic breast cancer subtype diagnosis) and generate risk of relapse (ROR) scores. For more information, see Details section.
3229173|NCT00991250|Experimental|SentoClone®|SentoClone®: Specific tumour-reactive lymphocytes located in lymph nodes directly draining primary tumours or metastases are identified and expanded. These lymphocytes are infused to the patient to treat metastatic disease.
3229174|NCT00991250|Active Comparator|Temodal® or Dacarbazine Medac®|"To be decided by each centre as one of the following:~Temodal® (temozolomide)~Dacarbazine Medac® (dacarbazine) The reference treatment regimen should follow the general guiding principles for each of the two reference treatments."
3229175|NCT00991237|Experimental|Pain reduction|
3229176|NCT00991224|Experimental|Arm 1|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir >200 and a recorded historical viral load setpoint, will receive a WT-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption.
3229177|NCT00991224|Experimental|Arm 2|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir >200 and a recorded historical viral load setpoint, will receive a α/6-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption.
3229178|NCT00991224|Experimental|Arm 3|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir >200. Subject will undergo an 16 week treatment interruption during which a single infusion of WT-gag-TCR modified autologous T cells at 8 weeks post STI.
3229179|NCT00991224|Experimental|Arm 4|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir of >200. Subject will undergo a 16-week treatment interruption during which a single infusion of α/6-gag-TCR modified autologous T cells at 8 weeks post STI.
3229180|NCT00991211|Experimental|Bendamustine + Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
3229181|NCT00991211|Active Comparator|CHOP + Rituximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w
3229182|NCT00991198|Experimental|A|Aria Regimens 0.5% conc
3229183|NCT00991198|Experimental|B|Aria Regimen (5 products) 0.25% conc
3229184|NCT00991198|Placebo Comparator|C|Aria Regimen Control without O2
3229185|NCT00991172|Placebo Comparator|placebo injection|
3229186|NCT00991172|Experimental|active|subcutaneous injection of REGN475
3229187|NCT00991172|Experimental|active 2|subcutaneous injection of REGN475
3229188|NCT00991159|Experimental|RN316|
3229189|NCT00991146|Experimental|canakinumab|
3229190|NCT00991133|Experimental|Clofarabine|Patients received a maximum of 2 cycles of the intravenous (IV) 5-drug regimen (clofarabine, etoposide,cyclophosphamide, PEG-asparaginase, and vincristine) plus intrathecal methotrexate, and then entered follow-up. Patients who achieved complete remission (CR) or complete remission with incomplete platelet recovery (CRp) after 1 cycle of study drugs were eligible to receive a second cycle of study drugs upon recovery of peripheral blood counts, and patients who did not have leukemic progression were eligible to receive a second treatment cycle at the investigator's discretion.
3229191|NCT00991107|Experimental|HE3286|HE3286 20 mg (10 mg BID)
3229192|NCT00991094||Data Collection|Collection of normal-tissue toxicity data and symptom data during and after clinical proton treatment at University of Texas MDACC and of the corresponding proton dose distribution data.
3229193|NCT00991081|Active Comparator|Standard treatment|"Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling.~A self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail~A standard 8-week course of genetically-tailored pharmacotherapy~Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)~Participants with the A2 allele (CC) were assigned to receive bupropion"
3229194|NCT00991081|Experimental|Genetic feedback plus standard treatment|"In addition to the standard treatment, participants in this arm received the following interventions:~Genetic feedback, verbal - During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment~Genetic feedback, printed - After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype"
3229195|NCT00991068|Experimental|Synera|Synera topical patch
3229196|NCT00991055|Experimental|Pioglitazone|
3229197|NCT00991055|Placebo Comparator|Placebo|
3229198|NCT00991042|Other|cytokine levels|Serum levels of pro-inflammatory cytokines were measured using the Enzyme Linked Immuno Sorbent Assay (ELISA) technique in 23 patients with pain due to herniated disk disease (G1) as well as in 10 control healthy subject
3229199|NCT00991029|Active Comparator|clopidogrel|Patients assigned to clopidogrel in addition to aspirin
3229200|NCT00991029|Placebo Comparator|placebo|Patients assigned to placebo in addition to aspirin
3229201|NCT00991016|Experimental|PF-04805712|
3229202|NCT00991003|Experimental|Colon capsule endoscopy and colonoscopy|Patients underwent CCE on day 1 and conventional colonoscopy on day 2
3229203|NCT00990990|Experimental|Cohort 1|
3229204|NCT00990990|Experimental|Cohort 2|
3229205|NCT00990990|Experimental|Cohort 3|
3229206|NCT00990990|Experimental|Cohort 4|
3229207|NCT00990990|Experimental|Cohort 5|
3229208|NCT00990990|Experimental|Cohort 6 (optional)|
3229209|NCT00990990|Experimental|Linezolid Cohort|
3229210|NCT00990977|No Intervention|controls|assessment only
3229211|NCT00990977|Experimental|cases|MBSR including brief information session and assessments
3229212|NCT00990951|Experimental|Senna alexandrina and associations|Association of Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub
3229213|NCT00990938|Placebo Comparator|Saline|If randomized to placebo the patient will receive a subcutaneous injection once per week for 4 weeks
3229214|NCT00990938|Experimental|IMO-2125|If randomized to receive the experimental treatment, IMO-2125, the patient will receive a subcutaneous injection once per week for 4 weeks
3229215|NCT00990925|Experimental|Weight Loss Education Group|Involvement in weekly manualized, educational group on nutrition and lifestyle modifications to help with weight loss.
3229216|NCT00990925|Other|Usual Care|Treatment as usual
3229217|NCT00990912|Experimental|Carboplatin|
3229218|NCT00990912|Experimental|Irinotecan (12 (9) mg/m²/day)|
3229219|NCT00990912|Active Comparator|Irinotecan (10 (10) mg/m²/day|
3229220|NCT00990886|Experimental|001|Oxybutynin chloride 15 mg once daily for 12 weeks
3229221|NCT00990886|Placebo Comparator|002|Placebo Once daily for 12 weeks
3229222|NCT00990860|Experimental|Sorafenib|
3229223|NCT00990847|Experimental|Procaterol|Procaterol inhalation solution 50 micro g per 0.5 mL diluted in 2mL of NaCl 0.9%, so that the volume of the inhalation solution will be similar to that of the comparator drug. The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.
3229224|NCT00990847|Active Comparator|Salbultamol|Salbultamol inhalation solution for nebulization containing 2.5 mg in 2.5 mL aqueous solution. The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.
3229225|NCT00990834|Experimental|Statin exposure|Subjects' endpoints will be measured before and after one to eight months of statin exposure.
3229226|NCT00990821|Experimental|Part I, Panel A|100 mg MK-0517 (nonpolysorbate 80 formulation [non-PS80]) or placebo → 150 mg MK-0517 (non- PS80) or placebo → 125 mg aprepitant
3229227|NCT00990821|Experimental|Part I, Panel B|100 mg MK-0517 (PS80 formulation [PS80]) or placebo → 150 mg MK-0517 (PS80) or placebo → 125 mg aprepitant
3229228|NCT00990821|Experimental|Part I, Panel C|40 mg MK-0517 (non-PS80) or placebo → 40 mg aprepitant
3229229|NCT00990821|Experimental|Part II|2 mg midazolam → 100 mg MK-0517 (PS80) + 2 mg midazolam
3229230|NCT00990821|Experimental|Part III, Panel 1, Treatment Sequence 1|125 mg aprepitant → 90 mg MK-0517 (PS80)
3229231|NCT00990821|Experimental|Part III, Panel 1, Treatment Sequence 2|40 mg MK-0517 (non-PS80) → 125 mg aprepitant
3229232|NCT00990821|Experimental|Part III, Panel 2|40 mg MK-0517 (non-PS80)
3229233|NCT00990821|Experimental|Part IV|40 mg MK-0517 (non-PS80 formulation)
3229234|NCT00990821|Experimental|Part V, Treatment Sequence 1|125 mg aprepitant → 100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80 formulation)
3229235|NCT00990821|Experimental|Part V, Treatment Sequence 2|100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80) → 125 mg aprepitant
3229236|NCT00990821|Experimental|Part V, Treatment Sequence 3|115 mg MK-0517 (PS80) → 125 mg aprepitant → 100 mg MK-0517 (PS80)
3229237|NCT00990821|Experimental|Part V, Treatment Sequence 4|125 mg aprepitant → 115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80)
3229238|NCT00990821|Experimental|Part V, Treatment Sequence 5|100 mg MK-0517 (PS80) → 125 mg aprepitant → 115 mg MK-0517 (PS80)
3229239|NCT00990821|Experimental|Part V, Treatment Sequence 6|115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80) → 125 mg aprepitant
3229240|NCT00990808|Experimental|Panel A|Period 1: atorvastatin + placebo to MK0859; Period 2: atorvastatin + MK0859
3229241|NCT00990808|Experimental|Panel B|Period 1: placebo to atorvastatin + placebo to MK0859; Period 2: MK0859 + placebo to atorvastatin
3229242|NCT00990795|Experimental|Cyclosporine|Cyclosporine Group: Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
3229243|NCT00990795|Placebo Comparator|Placebo|Placebo: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
3229244|NCT00990782|Experimental|Single Arm|PillCam ESO Capsule Endoscope - all patients receive capsule endoscopy before and after RFA procedure.
3229245|NCT00990769|Experimental|"High-normal BIS (Lighter anesthesia)"|Depth of anesthesia is titrated to a BIS of 55-60
3229246|NCT00990769|Experimental|"Low-normal BIS (Deeper anesthesia)"|Depth of anesthesia is maintained at a BIS level of 40-45
3229247|NCT00990756|Experimental|PF-03526299 1.396 mg|
3229248|NCT00990756|Experimental|PF-03526299 4mg|
3229249|NCT00990743|Experimental|SYL040012|
3229250|NCT00990730||rheumatoid arthritis subjects|60 subjects with rheumatoid arthritis, defined by American College of Rheumatology Criteria, enrolled in the UCSF RA cohort
3229251|NCT00990730||healthy controls|20 matched controls without rheumatoid arthritis
3229252|NCT00990717|Experimental|NK-92 cells|Preparation of irradiated NK-92 cells suspended in a saline and plasma solution. NK-92 working cell bank was established from a master cell bank supplied by Conkwest Inc. (San Diego CA).
3229253|NCT00990704|Experimental|Paricalcitol|2 mcg adjusted by +/- 1 mcg, up to a maximum of 7 mcg, administered 3 times per week through intravenous catheter immediately before completion of dialysis
3229254|NCT00990704|Active Comparator|Maxacalcitol|5 or 10 mcg adjusted by +/- 2.5 mcg, up to a maximum of 20 mcg, administered 3 times per week through intravenous catheter immediately before completion of dialysis
3229255|NCT00990691|Experimental|Desipramine high dose|"12 patients with Rett syndrome receiving a daily dose of desipramine correlated with the weight :~From 15 to 25 kg : 50 mg ;~From 26 to 35 kg : 75 mg ;~From 36 to 45 kg : 100 mg ;~> 46 kg : 150 mg."
3229256|NCT00990691|Experimental|Desipramine low dose|"12 patients with Rett syndrome receiving a daily dose of desipramine correlated with the weight :~From 15 to 25 kg : 25 mg ;~From 26 to 35 kg : 50 mg ;~From 36 to 45 kg : 75 mg ;~> 46 kg : 100 mg."
3229257|NCT00990691|Placebo Comparator|Placebo|12 patients with Rett syndrome receiving a daily dose of placebo.
3229258|NCT00990678|Experimental|"Strong vitamin D"|Calcium 400 Mg + Vitamin D3 10 microg, 3 times daily Rocaltrol 1.25 mg to 2.5 mg daily
3229259|NCT00990678|Active Comparator|Vitamin D|calcium 400 mg + 10 microgram Vitamin D3, 3 times daily
3229260|NCT00990678|Placebo Comparator|Calcium|Tablet Calcium 400 mg x 3 daily
3229261|NCT00990665|Experimental|CRT-D and LV lead|
3229359|NCT00989846||lung disease|patients with various chronic or acute lung diseases
3229262|NCT00990652|Experimental|Bortezomib + Temozolomide|Patients receive an injection of bortezomib 1.7mg/m^2 on days 1, 4 and 8. Patients then undergo their standard of care surgery on day 8 or 9 to remove the tumor. Once recovered from surgery, patients receive combination treatment with temozolomide and bortezomib in periods called cycles (1 cycle = 28 days). Temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle, and bortezomib injections are given on days 7 and 21 of each cycle.
3229263|NCT00990639|Experimental|candesartan+UDCA group|oral candesartan(8 mg/day) in addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months
3229264|NCT00990639|Placebo Comparator|UDCA group|ursodeoxycholic acid(UDCA,600 mg/day)only for 6 months
3229265|NCT00990626||1|Schizophrenic outpatients
3229266|NCT00990613|Other|Cohort 1|
3229267|NCT00990613|Other|Cohort 2|
3229268|NCT00990600|Experimental|Simplified one pill regimen|Fixed dose combination of tenofovir + emtricitabine + efavirenz
3229269|NCT00990587|Experimental|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at escalating doses depending on when they enter into the trial.
3229270|NCT00990574|Active Comparator|spinal anesthesia group (SAG)|Participants will undergo the standard procedures involved in placement of a spinal anesthetic in the sitting position.
3229271|NCT00990574|Active Comparator|The WSCG (wiley spinal catheter group)|The WSCG (wiley spinal catheter group) will undergo the standard procedures involved in placement of a spinal anesthetic in the sitting position.
3229272|NCT00990561|Active Comparator|Twice Daily Ultravate|Patients will apply both Ultravate ointment and LacHydrin lotion twice daily
3229273|NCT00990561|Active Comparator|Once daily Ultravate|Patients will apply Ultravate ointment once daily, but will use LacHydrin lotion twice daily
3229274|NCT00990548||Cardiovascular Service Line patients|Patients admitted to the Cardiovascular Service Line at a major teaching hospital during a consecutive 11-month period.
3229275|NCT00990535|Experimental|Octreotide-LAR|Patients will receive every 21 days an injection of octreotide-LAR 30 mg until progression is documented.
3229276|NCT00990522|Experimental|debridement|monthly vs weekly debridement
3229277|NCT00990509|Experimental|Albumin|
3229278|NCT00990509|Placebo Comparator|Placebo|
3229279|NCT00990496|Experimental|GBM Treatment|
3229280|NCT00990457|Active Comparator|Low-carbohydrate Diet Plus Exercise|Participants will follow a low-carbohydrate weight loss diet plus participate in a supervised exercise training program for 6 months.
3229281|NCT00990457|Active Comparator|Low-Fat, Low-Calorie Diet Plus Exercise|Participants will follow a low-calorie, low-fat weight loss diet plus participate in a supervised exercise training program for 6 months.
3229282|NCT00990444|Placebo Comparator|Placebo|Treatment with vehicle capsule containing excipients only, taken in conjunction with standard meal.
3229283|NCT00990444|Active Comparator|Oral Insulin in Dextran|Treatment with fixed insulin dose taken in conjunction with standard meal.
3229284|NCT00990431|Active Comparator|Carbon dioxide laser treatment|
3229285|NCT00990431|Active Comparator|Erbium:YAG laser treatment|
3229286|NCT00990405|Experimental|Lansoprazole+Clarithromycin+Amoxycillin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
3229287|NCT00990392|Experimental|Polysporin Triple Therapy|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
3229288|NCT00990392|Placebo Comparator|Placebo|Petroleum jelly
3229289|NCT00990379||Controls|Healthy men and women, 18 years of age or older, who have no history of significant medical conditions.
3229290|NCT00990379||HIV positive|Men and women, 18 years of age or older, who have been diagnosed with HIV infection. Patients may be on or off of ARVs.
3229291|NCT00990379||Parkinson's Disease|Men and women, 18 years of age or older, who have been diagnosed with Parkinson's Disease.
3229292|NCT00990366|Active Comparator|biliary stent without an antireflux valve|patients with biliary obstruction who need a biliary stent, selected for the stent without an antireflux valve arm
3229293|NCT00990366|Active Comparator|biliary stent with an antireflux valve|patients with biliary obstruction, who need a biliary stent, selected for the stent with an antireflux valve arm
3229294|NCT00990353||Prism adaptation therapy|Patients receive prism adaptation therapy by protocol (Frassinetti et al., 2002)
3229295|NCT00990353||Bromocriptine pharmacotherapy|Patients receive bromocriptine pharmacotherapy by protocol (Barrett et al., 1999)
3229296|NCT00990340|Active Comparator|Tev-Tropin® needle-free|needle-free injection method (T-jet®)for 14 days before cross-over to other arm
3229297|NCT00990340|Active Comparator|Tev-Tropin® by Needle-syringe|needle-syringe injection method for 14 days before cross-over to other arm
3229298|NCT00990327|Experimental|Apadenoson|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson or the active comparator: adenosine.
3229299|NCT00990327|Active Comparator|Adenosine|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson or the active comparator: adenosine.
3229300|NCT00990314|Experimental|B.I.D|Beraprost Sodium Modified Release Tablet, 60mcg, B.I.D (twice a day dosing)
3229301|NCT00990314|Experimental|Q.I.D|Beraprost Sodium Modified Release Tablet, 60mcg, q.i.d (four times a day dosing)
3229302|NCT00990301|Experimental|Moexipril HCl/ Hydrochlorothiazide 15mg/25mg Tablets|
3229303|NCT00990301|Active Comparator|Uniretic® 15mg/25mg Tablets|
3229304|NCT00990288|Experimental|Hemostatic Matrix|2 vials of Floseal applied once at the end of surgery
3229305|NCT00990288|No Intervention|Control|No intervention.
3229306|NCT00990275|Experimental|Post-alcohol|
3229307|NCT00990262||Acute Chest Pain|Patients who presented to the emergency department with acute chest pain, with negative initial biomarkers and normal or non-ischemic ECG
3229360|NCT00989833|Active Comparator|A|budesonide 400yg + terbutaline 0.4 mg as-needed
3229361|NCT00989833|Active Comparator|B|placebo + terbutaline 0.4 mg as-needed
3229362|NCT00989833|Active Comparator|C|placebo + budesonide/formoterol 160/4.5 yg as-needed
3229363|NCT00989820|No Intervention|Surgery|This is the standard arm. Surgery without hyperbaric oxygen treatment
3229308|NCT00990249|Experimental|Busulfan + Clofarabine + Stem Cell Transplant|"Busulfan test dose 32 mg/m^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.~Clofarabine 40 mg/m^2 by vein over 1 hour daily Day -6 through Day -3. Thymoglobulin 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors.~Stem cell infusion on Day 0."
3229309|NCT00990236|No Intervention|Group 1|standard dose enoxaparin thromboprophylaxis (30 mg twice daily)
3229310|NCT00990236|Experimental|Group 2|enoxaparin, modified dose based on results of the TEG test
3229311|NCT00990223|Experimental|Cohort 1|Healthy Volunteers - eplerenone versus placebo.
3229312|NCT00990197|Active Comparator|Day 1|Patients randomized to wearing the patch on day 1 will apply a patch on the morning of their treatment day and keep it on for 24 hours. These patients will not wear a patch on day 2.
3229313|NCT00990197|Active Comparator|Day 2|Patients randomized to wearing the patch on day 2 will apply a patch on the morning of their treatment day and keep it on for 24 hours. These patients will not wear a patch on day 1.
3229314|NCT00990184|Experimental|Colesevelam Hydrochloride|
3229315|NCT00990171||PD-BCM|"Patients at National Taiwan University Hospital (NTUH)~Patients who have received PD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years"
3229316|NCT00990158|Active Comparator|Low dose vitamin K + usual warfarin|Low dose oral vitamin K (0.150 mg orally once daily) + warfarin continuation with usual warfarin monitoring
3229317|NCT00990158|Placebo Comparator|Usual warfarin therapy + placebo|Patients continue usual warfarin and take one placebo per day
3229318|NCT00990145|Experimental|Intervention|EDP-322 v. Placebo
3229319|NCT00990132|Active Comparator|Long term oxygen therapy|LTOT will be established as per current national guidelines
3229320|NCT00990132|Experimental|Home mechanical ventilation|Patients will be set up on LTOT as per national guidelines and nocturnal non-invasive ventilation in accordance with study protocol.
3229321|NCT00990119|Experimental|High FLow Therapy|Use of High Flow Therapy for support of Respiratory Insufficiency
3229322|NCT00990106|Active Comparator|prazosin hydrochloride|"prazosin Pfizer Minipress~oral capsules~Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose."
3229323|NCT00990106|Placebo Comparator|placebo|"placebo~oral capsules~Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose."
3229324|NCT00990093|Experimental|test intermittent catheter|CH 12 hydrophilic coated catheter
3229325|NCT00990093|Experimental|intermittent catheter|CH 12 hydrophilic coated catheter
3229326|NCT00990080|Active Comparator|Group 1|Pediacel® at 2 and 4 months of age followed by Infanrix™-IPV/Hib at 6 months.
3229327|NCT00990080|Active Comparator|Group 2|Infanrix™-IPV/Hib at 2 months of age followed by Pediacel® at 4 and 6 months.
3229328|NCT00990067|Other|duloxetine, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
3229329|NCT00990054|Experimental|plerixafor|
3229330|NCT00990041||PBMC|
3229331|NCT00990041||periodontitis|
3229332|NCT00990028|Experimental|Rosuvastatin|20 mg oral during 10 days
3229333|NCT00990028|Placebo Comparator|Placebo|
3229334|NCT00990015|Experimental|PF-04308515|
3229335|NCT00990015|Placebo Comparator|Placebo|
3229336|NCT00990002||Control|A children's milk-based beverage
3229337|NCT00990002||experimental probiotic 1|children's milk-based beverage containing a bioactive ingredient
3229338|NCT00990002||experimental probiotic 2|children's milk-based beverage containing a different bioactive ingredient
3229339|NCT00989989|Experimental|Adjunctive treatment|Adjunctive administration of ranibizumab 0.5 mg intravitreal injections and active laser.
3229340|NCT00989989|Experimental|Monotherapy treatment|Monotherapy ranibizumab 0.5 mg intravitreal injections plus sham laser.
3229341|NCT00989989|Active Comparator|Laser control|Active laser treatment plus sham intravitreal injections.
3229342|NCT00989976|Other|8.5 h sleep|Subjects will have normal sleep times
3229343|NCT00989976|Other|restricted bedtimes|4.5 h bedtimes
3229344|NCT00989963|Experimental|Maximum Tolerated Dose (MTD)|Patients in the MTD treatment group will dose escalate weekly by 60µg b.i.d. until they reach the maximum dose of 600µg b.i.d. or they reach an intolerable dose which requires them to down-titrate by 60µg b.i.d. In these instances and at the Investigator's discretion, further attempts at dose escalation may be made.
3229345|NCT00989963|Experimental|Low Fixed Dose|The low dose group will receive 60µg twice a day(b.i.d.)
3229346|NCT00989963|Experimental|High Fixed Dose|Patients in the high dose group will dose escalate weekly by 60µg twice a day (b.i.d.) until they reach the fixed dose of 240µg b.i.d. Once patients in these treatment groups have reached their assigned maximum dose of active drug,
3229347|NCT00989950|Experimental|Daytrana 9 hr wear|
3229348|NCT00989950|Experimental|Daytrana 10 hr wear|
3229349|NCT00989950|Experimental|Daytrana 11 hr wear|
3229350|NCT00989950|Experimental|Daytrana 12 hr wear|
3229351|NCT00989937|Experimental|Group 1|20 IU BID for the first week, 40 IU BID for the following two weeks, one week washout, 3 week placebo trial
3229352|NCT00989937|Placebo Comparator|Group 2|Three week placebo trial, one week washout, 20 IU BID for the fifth week, 40 IU BID for the following two weeks
3229353|NCT00989924||Diabetes mellitus|The Diabetic patient who receives follow-up at NTUH diabetics caring network
3229354|NCT00989911|Experimental|Bosentan|Bosentan
3229355|NCT00989898|Active Comparator|Closed-loops at Dinner|Automated closed-loop control starts at 18:00
3229356|NCT00989898|Active Comparator|Closed-loop at Bedtime|Automated closed-loop control starts at 21:00
3229357|NCT00989885||Obstructive Sleep Apnea|475 patients that sought the CESF to probable diagnosis of some sleep disorder, subsequently diagnosed with Obstructive Sleep Apnea.
3229358|NCT00989859||Plethysmographic monitoring|Plethysmographic monitoring
3229364|NCT00989820|Experimental|Hyperbaric oxygen therapy with surgery|Intervention arm. Hyperbaric oxygen therapy with surgery.
3229365|NCT00989794|Experimental|GelrinC|GelrinC one step implantation to the femoral condyle lesion
3229366|NCT00989781|Experimental|PCOS women|"Each subject will undergo pelvic 3D ultrasound followed by an iv recombinant human chorionic gonadotropin (r-hCG) stimulation test. One month later the r-hCG test will be repeated 24 hr after an injection of recombinant human follicle stimulating hormone (FSH).~After 1 month, subjects will receive a 7 hr dose-response infusion of adrenocorticotropin (ACTH) with blood sampling. Dexamethasone will be given prior to ACTH.~After 1 month, subject will receive r-hCG as described above followed the next day by an oral glucose tolerance test (OGTT). Subsequently, subjects will take Diazoxide 3 times a day for 2 weeks. At weekly intervals (2 weeks), the r-hCG stimulation test will be repeated followed the next day by an OGTT as described above."
3229367|NCT00989781|Experimental|Normal women|"Each subject will undergo pelvic 3D ultrasound followed by an iv recombinant human chorionic gonadotropin (r-hCG) stimulation test. One month later the r-hCG test will be repeated 24 hr after an injection of recombinant human follicle stimulating hormone (FSH).~After 1 month, subjects will receive a 7 hr dose-response infusion of adrenocorticotropin (ACTH) with blood sampling. Dexamethasone will be given prior to ACTH.~After 1 month, subject will receive r-hCG as described above followed the next day by an oral glucose tolerance test (OGTT). Subsequently, subjects will take Diazoxide 3 times a day for 2 weeks. At weekly intervals (2 weeks), the r-hCG stimulation test will be repeated followed the next day by an OGTT as described above."
3229368|NCT00989768|Experimental|Botulinum toxin type - A|Dysport® compared to Botox®
3229369|NCT00989755|Experimental|Fax to Quit plus Enhanced Academic Detailing (F2Q + EAD)|Clinics in this group receive Fax to Quit materials and in person training from a Regional Outreach Specialist (ROS). The ROS also provides on-going training/technical assistance and performance feedback.
3229370|NCT00989755|Placebo Comparator|Fax to Quit alone|Clinics in this group receive Fax to Quit materials and can download materials from a website.
3229371|NCT00989742|Active Comparator|Doxycycline|
3229372|NCT00989742|Placebo Comparator|Placebo|
3229373|NCT00989729|Active Comparator|Methylprednisolone|75 patients will receive a single preoperative dosage of Methylprednisolone
3229374|NCT00989729|Placebo Comparator|Physiological Saline|75 patients will receive a single preoperative dosage of Physiological Saline
3229375|NCT00989716|Active Comparator|Glyceryl trinitrate transdermal patch|
3229376|NCT00989716|Experimental|Continue or stop pre-stroke antihypertensives|
3229377|NCT00989703|Experimental|1|GLPG0259 25/50/75 mg/day for 14 days
3229378|NCT00989703|Placebo Comparator|2|placebo for 14 days
3229379|NCT00989677||Rheumatoid Arthritis|
3229380|NCT00989664|Experimental|open-label single arm|Tositumomab and Iodine-131 Tositumomab radioimmunotherapy for chemotherapy-refractory low-grade B-cell lymphomas and low-grade lymphomas that have transformed to higher grade histologies.
3229381|NCT00989651|Experimental|Regimen I (paclitaxel, carboplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes (beginning in course 2) on day 1. Patients also receive veliparib PO BID on days 1-21. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment with bevacizumab repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
3229382|NCT00989651|Experimental|Regimen II (paclitaxel, carboplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Patients also receive carboplatin, bevacizumab, and veliparib as in Regimen I. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment with bevacizumab repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
3229383|NCT00989651|Experimental|Regimen III (paclitaxel, cisplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 3 hours on day 1 and IP on day 8, and cisplatin IP on day 1 or 2. Patients also receive bevacizumab and veliparib as in Regimen I. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
3229384|NCT00989638||Women at high risk for breast cancer|
3229385|NCT00989625|Active Comparator|10mg Sumatriptan/60mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
3229386|NCT00989625|Active Comparator|30mg Sumatriptan/180mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
3229387|NCT00989625|Active Comparator|85mg Sumatriptan/500mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
3229388|NCT00989612|Experimental|GSK2340274A GROUP|Healthy subjects, aged 20 to 64 years, male and female, received 2 doses of GSK2340274A vaccine, injected intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3229389|NCT00989599|Experimental|compress of Chamomilla recutita infusion|Patients who developed phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
3229390|NCT00989599|Active Comparator|compress of lukewarm water|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
3229391|NCT00989586|Experimental|Phase I|Phase I portion of the study, a standard 3+3 dose escalation schema will be followed. Patients will receive veltuzumab IV weekly on day 1 for 4 doses and milatuzumab weekly on for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab alone on day 1 and milatuzumab alone on day 2 to prevent overlapping infusion reactions. Starting week 2, veltuzumab will be given on day 1 and milatuzumab will be given on day 4.
3229438|NCT00989248|Experimental|comparation VE/VO2 and VE/VCO2|
3229439|NCT00989235|Active Comparator|Abatacept (10 mg/Kg)|
3229440|NCT00989235|Active Comparator|Abatacept (5 mg/Kg)|
3229887|NCT00986232|Active Comparator|4|M-M-R II + PUVV
3229392|NCT00989586|Experimental|Phase II|Patients will receive veltuzumab IV weekly for 4 doses and milatuzumab IV weekly on day 2 of week 1 and on day 4 of weeks 2-4 for 4 total doses during induction therapy. Patients may continue on therapy to receive extended induction therapy provided they do not experience significant toxicity or rapid disease progression during the initial 4 week induction.
3229393|NCT00989573|Placebo Comparator|Placebo|oral administration of placebo once-daily for 8weeks
3229394|NCT00989573|Experimental|OPC-6535 25 mg|oral administration of OPC-6535 25 mg once-daily for 8 weeks
3229395|NCT00989573|Experimental|OPC-6535 50 mg|oral administration of OPC-6535 50mg once-daily for 8 weeks
3229396|NCT00989560|Active Comparator|Active arm|
3229397|NCT00989560|No Intervention|Standard care arm|
3229398|NCT00989547|Active Comparator|A|
3229399|NCT00989547|No Intervention|B|
3229400|NCT00989534|Experimental|Sleep loss and circadian alignment|Sleep restriction without circadian misalignment
3229401|NCT00989534|Experimental|Sleep loss and circadian misalignment|
3229402|NCT00989521|Placebo Comparator|placebo|normal saline for inhalation
3229403|NCT00989521|Active Comparator|PUR003|PUR003 for inhalation
3229404|NCT00989508|Experimental|Perhexiline|Pre-operative administration of Perhexiline tablets according to dosing schedule
3229405|NCT00989508|Placebo Comparator|Placebo marked PEXSIG|Pre-operative administration of placebo tablets according to dosing schedule
3229406|NCT00989495|Experimental|Brace - Randomized|Participants were randomized to be braced
3229407|NCT00989495|No Intervention|Observation - Randomized|Participants were randomized to be observed only
3229408|NCT00989495|Experimental|Brace - preference based|Participants chose to be braced
3229409|NCT00989495|No Intervention|Observation - preference-based|Participants chose to be observed only
3229410|NCT00989482|Experimental|Computer Kiosk Eduction|
3229411|NCT00989469|Experimental|Sorafenib and irinotecan|
3229412|NCT00989456|Experimental|exercise and education|Supervised physical exercise in groups, plus a self management education programme (patient education).
3229413|NCT00989456|Active Comparator|exercise only|Supervised physical exercise in groups.
3229414|NCT00989443|Experimental|Cidofovir|
3229415|NCT00989430|Experimental|Prism Adaptation Treatment|Two weeks of prism adaptation treatment followed by 4 weekly assessments and long-term follow-ups at the 3rd and 6th months.
3229416|NCT00989430|No Intervention|Control: Standard Rehabilitation Care|Participants will continue with their standard inpatient rehabilitation care. They will be assessed with cognitive and functional scales for tracking their recovery.
3229417|NCT00989417|Active Comparator|CONTROL Group - Without Home Monitoring|Patients receiving the standard of care. Due to safety concerns, the patients are followed every 6 months after a first follow-up, which is performed between 1 and 3 months after implantation.
3229418|NCT00989417|Experimental|ACTIVE GROUP With Home Monitoring|After a first follow-up (between 1 and 3 months after implantation), the patients are followed one time per year. Within this period, the additional ICD follow-up or therapeutic intervention will be primarily triggered on cardio-reports reception, Data/IEGM-online analysis on internet site or patient/physician call.
3229419|NCT00989404|Experimental|Period|10 mg BID Zanamivir or placebo for 5 days
3229420|NCT00989391|Experimental|Cohort 1|Subjects will be assigned to receive either PF-03654764 or placebo.
3229421|NCT00989391|Experimental|Cohort 2|Subjects will be assigned to receive either PF-03654764 or placebo.
3229422|NCT00989391|Experimental|Cohort 3|Subjects will be assigned to receive either PF-03654764 or placebo.
3229423|NCT00989378||control|normal healthy men and women
3229424|NCT00989365|Other|Patient cousenling|Improve medicine use Self control asthma crisis Ambient hygiene
3229425|NCT00989339|Experimental|Twenty-four Hour TPN and Saline Infusion|Subjects will be admitted to the Grady research center on the evening before each study. The next morning, after an overnight fast, they will receive, in random order, Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr. The interval between admissions will be 1 month.
3229426|NCT00989326|Active Comparator|CONTROL group|The patients receive standard of care for 18 months. The CONTROL group patients will be equipped with Home Monitoring. However, the Home Monitoring data will not be used for patient surveillance; i. e. the patient will be followed in the conventional manner.
3229427|NCT00989326|Experimental|ACTIVE group|The patients are followed by Home monitoring only. Every patient must be seen by his physician 18 months after enrolment for regular follow-up. Within this period, the additional Pace Maker follow-up or therapeutic intervention will be primarily triggered on cardio-reports reception or patient/physician call
3229428|NCT00989313||1|
3229429|NCT00989300|Experimental|Treatment group|patients received clopidogrel 75 mg with rabeprazole 20 mg, omeprazole 20 mg, or placebo in a crossover manner
3229430|NCT00989300|Placebo Comparator|Placebo group|
3229431|NCT00989287|Experimental|GSK2340272A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3229432|NCT00989287|Experimental|GSK2340269A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3229433|NCT00989274|Active Comparator|Vaccine Sanofi A(H1N1) 15 ug & trivalent|120 participants selected by random
3229434|NCT00989274|Active Comparator|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|120 participants selected in random form
3229435|NCT00989274|Active Comparator|Vaccine Sanofi A(H1N1) 7.5 ug|120 participants selected in random form
3229436|NCT00989261|Experimental|AC220 cohort1|"FLT3-ITD positive and negative populations will be divided into 2 cohorts as follows:~Cohort 1: Patients who are ≥60 years of age who are relapsed after 1 first-line chemotherapy regimen (with or without consolidation) and after CR1 <12 months or are primary refractory to first-line chemotherapy."
3229437|NCT00989261|Experimental|AC220 cohort2|Cohort 2: Patients who are ≥18 years of age (note this includes patients ≥60 years of age) who are relapsed or refractory after 1 second-line (salvage) regimen or are relapsed or refractory after HSCT.
3229441|NCT00989222|Other|Volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
3229442|NCT00989222|Other|External fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
3229443|NCT00989209|Active Comparator|A: myofunctional prior to botulinum|All the facial paralysis patients received treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol. To the participants of Group A, botulinum toxin was applied after myofunctional therapy.
3229444|NCT00989209|Active Comparator|B: myofunctional after botulinum|All the facial paralysis patients received treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol. To the participants of Group B, botulinum toxin was applied before myofunctional therapy.
3229445|NCT00989196|Experimental|Human-cl rhFVIII|
3229446|NCT00989196|Active Comparator|Kogenate FS|
3229447|NCT00989170|Experimental|Family Program for the Prevention of Weight Gain|Use of an enhanced Family Program on the prevention of weight gain in families with overweight children.
3229448|NCT00989170|Active Comparator|No enhanced Family Program|
3229449|NCT00989157|Experimental|Active drug|All subjects received drug. Single arm.
3229450|NCT00989131|Experimental|Paclitaxel, micellar (Paclical®)|
3229451|NCT00989131|Active Comparator|Paclitaxel, CrEL (Taxol®)|
3229452|NCT00989118|Experimental|Laser treatment|
3229453|NCT00989118|Active Comparator|Endometrioma cystectomy|
3229454|NCT00989092|Other|Observational Group|Participants in the observation group were evaluated once every 2 weeks for the first 12 weeks (test period). No darbepoetin alfa was administered to the observation group during this period. Darbepoetin alfa could be initiated at a dose of 3.0 μg/kg once every 2 weeks beginning with the first visit after the test period at which the participants hemoglobin concentration was less than or equal to 11.0 g/dL. The dose of darbepoetin alfa could be increased to 5.0 μg/kg once every 2 weeks after 6 weeks of darbepoetin alfa treatment in participants with a hemoglobin change from baseline of less than 1.0 g/dL.
3229455|NCT00989092|Active Comparator|21 week treatment group|Participants in the treatment group received darbepoetin alfa subcutaneously (SC) at a dose of 3.0 μg/kg once every 2 weeks for 21 weeks. The dose of darbepoetin alfa could be increased at week 7 (to 5.0 μg/kg once every 2 weeks) or at week 13 (to 9.0 μg/kg once every 2 weeks) in participants with a hemoglobin change from baseline of less than 1.0 g/dL who dose escalated at week 7.
3229456|NCT00989079|Experimental|Cohort 1 Sequence 1|Period 1 (fasted) Placebo → Period 2 (fasted) ertugliflozin (E) 10 mg → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
3229457|NCT00989079|Experimental|Cohort 1 Sequence 2|Period 1 (fasted) E 0.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
3229458|NCT00989079|Experimental|Cohort 1 Sequence 3|Period 1 (fasted) E 0.5 mg → Period 2 (fasted) E 10 mg → Period 3 (fasted) Placebo → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
3229459|NCT00989079|Experimental|Cohort 2 Sequence 1|Period 1 (fasted) Placebo → Period 2 (fasted) E 30 mg → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.
3229460|NCT00989079|Experimental|Cohort 2 Sequence 2|Period 1 (fasted) E 2.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.
3229461|NCT00989079|Experimental|Cohort 2 Sequence 3|Period 1 (fasted) E 2.5 mg → Period 2 (fasted) E 30 mg → Period 3 (fasted) Placebo. Each dose of study drug will be separated by a minimum of 7 days.
3229462|NCT00989053|Active Comparator|escitalopram|
3229463|NCT00989053|Placebo Comparator|placebo|
3229464|NCT00989027|No Intervention|No treatment|A control sample from each patient (no uterotonic drug applied) will be measured concurrently with samples treated with various drugs.
3229465|NCT00989027|Active Comparator|Treatment|Samples from each patient will be bathed in solutions containing varying concentrations of either oxytocin, carboprost and ergonovine, and contractility will be measured.
3229466|NCT00989014|Experimental|CD07805/47 0.5% Topical Gel|0.5% Topical Gel
3229467|NCT00989014|Experimental|CD07805/47 0.18% Topical Gel|0.18% Topical Gel
3229468|NCT00989014|Experimental|CD07805/47 0.07% Topical Gel|0.07% Topical Gel
3229469|NCT00989014|Placebo Comparator|CD07805/47 Vehicle Topical Gel|Vehicle Topical Gel
3229470|NCT00989001|Experimental|Vernakalant|Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
3229471|NCT00989001|Placebo Comparator|Placebo|Placebo (saline) administered IV at same volume and rate as per dosing schedule for vernakalant
3229472|NCT00988988|Active Comparator|Steroid Cream|1% steroid cream
3229473|NCT00988988|Active Comparator|AGEE cream|AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled
3229474|NCT00988988|Active Comparator|placebo|inactive cream
3229475|NCT00988975|Active Comparator|Pelvicol graft|
3229476|NCT00988975|No Intervention|No graft material|No graft material
3229477|NCT00988962|No Intervention|High-Risk No Treatment|
3229478|NCT00988962|Experimental|High-Risk Treatment|
3229479|NCT00988962|No Intervention|Low-Risk|
3229480|NCT00988949|Experimental|PF-04455242 18 mg|Subjects in this arm will receive a single 18 mg oral dose of PF-04455242 prior to spiradoline challenge
3229481|NCT00988949|Placebo Comparator|Placebo|Subjects in this arm will receive placebo prior to spiradoline challenge.
3229482|NCT00988949|Experimental|PF-04455242 30 mg|Subjects in this arm will receive a single 30 mg oral dose of PF-04455242 prior to spiradoline challenge.
3229483|NCT00988936|Experimental|[F-18]RDG-K5|
3229484|NCT00988923|Experimental|group a: Hyperthermia (HT)|HT were treated for 20 minutes per session, a total of 8 sessions with device;
3229485|NCT00988923|No Intervention|group b: No intervention|device was switched in off, only bolus was active
3229486|NCT00988910||Group 1|
3229487|NCT00988910||Group 2|
3229645|NCT00987974|Placebo Comparator|placebo 3days|8 Subjects will use placebo for 3 days.
3229488|NCT00988897|Experimental|1|"Patients will receive modified FOLFOX-6 regimen:~oxaliplatin 85mg/m2, day 1 (given as a 2-hour infusion)~LV 400mg/m2, day 1 (given as a 2-hour infusion simultaneous to oxaliplatin)~5-FU given as a bolus IV 400mg/m2 dose on day 1 followed by 2400mg/m2 continuous infusion over 46 hours (day 1 and 2)~A cycle is defined as 2 weeks. Patients will receive cycles of modified FOLFOX-6 regimen every 2 weeks up to a maximum of 8 cycles. Use of bevacizumab is at the discretion of the treating physician."
3229489|NCT00988884|Experimental|Concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1
3229490|NCT00988884|Experimental|Non-concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1
3229491|NCT00988871||Liver transplantation (LT) recipients|LT recipients who had both PICC and CICC at the same time according to the LT protocol of our hospital
3229492|NCT00988858|Experimental|LY2603618 and Pemetrexed|
3229493|NCT00988845|Experimental|Indole-3-carbinol|
3229494|NCT00988832||Infliximab|Infliximab as prescribed by a physician in normal practice for Crohn's disease
3229495|NCT00988819||No treatment|
3229496|NCT00988806|Active Comparator|Levosimendan|infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours.
3229497|NCT00988806|Placebo Comparator|Placebo|infusion of placebo for 24 hours.
3229498|NCT00988793|Active Comparator|Laparoscopic distal pancreatectomy|Comparison between two different types of surgery, open vs. laparoscopic distal pancreatectomy
3229499|NCT00988793|Active Comparator|Open distal pancreatectomy|Comparison between two different types of surgery, open vs. laparoscopic distal pancreatectomy
3229500|NCT00988780|Experimental|Maraviroc|"Maraviroc 600mg po BID~Background antiretroviral regimen (Efavirenz 600mg QD + Tenofovir 300 mg /Emtricitabine 200 mg QD) plus Maraviroc 600 mg BID"
3229501|NCT00988780|Placebo Comparator|Placebo|"Placebo po BID~Background antiretroviral regimen (Efavirenz 600mg QD + Tenofovir 300 mg /Emtricitabine 200 mg QD plus Placebo po BID"
3229502|NCT00988767|Experimental|intramuscular injections|Patients received 4 injections of DNA vaccine at M0, M2, M4 and M10
3229503|NCT00988754|Active Comparator|A|Medical examination once per year, school and family-based lifestyle intervention including a weekly health lesson, school-affiliation to sports clubs and regularly trainings for teachers and parents
3229504|NCT00988754|No Intervention|B|Medical examination and information on a healthy lifestyle.
3229505|NCT00988741|Experimental|ARQ 197|
3229506|NCT00988741|Placebo Comparator|placebo|
3229507|NCT00988728|Experimental|SCH 900435|SCH 900435 (Org 25935): a Glycine Uptake Inhibitor
3229508|NCT00988728|Placebo Comparator|Placebo|
3229509|NCT00988728|Active Comparator|Olanzapine|
3229510|NCT00988715|Experimental|Treatment (PRIT, transplant)|Patients undergo pretargeted radioimmunotherapy comprising a test dose of BC8-SA conjugate IV on day -22 and 111In-DOTA-biotin IV on day -20, followed by a therapy dose of BC8-SA conjugate IV on day -14 and 90Y-DOTA-biotin IV on day -12. Patients receive fludarabine phosphate IV on days -4 to -2. Patients undergo TBI and then peripheral blood stem cell transplant on day 0. Patients with matched related donors receive cyclosporine IV on days -3 to 56 and taper to day 180 and mycophenolate mofetil PO BID on days 0-27. Patients with matched unrelated donors receive cyclosporine IV on days -3 to 100 and taper to day 180 and mycophenolate mofetil PO TID on days 0-40 and taper to day 96.
3229511|NCT00988702|Experimental|Dan Tian Breathing|subjects received one-month's training on the Dan Tian Breathing
3229512|NCT00988702|Active Comparator|Progressive muscle relaxation training|Subjects received one-month's conventional progressive muscle relaxation training
3229513|NCT00988689|Experimental|Soup with no added starch|
3229514|NCT00988689|Experimental|Soup + 50 g of whole grain starch|
3229515|NCT00988689|Experimental|Soup + 50 g of high amylose corn starch|
3229516|NCT00988689|Experimental|Soup + 50 g of regular corn starch|
3229517|NCT00988689|Experimental|Soup + 50 g maltodextrin starch|
3229518|NCT00988676||colonoscopy|
3229519|NCT00988663|Active Comparator|Memantine arm|Patient receiving ECT and Memantine
3229520|NCT00988663|Placebo Comparator|placebo|25 patients receiving ECT will will receive placebo
3229521|NCT00988650|Active Comparator|North American diet|Control North American diet for five weeks in isocaloric conditions
3229522|NCT00988650|Experimental|Mediterranean diet|Mediterranean diet for five weeks in isocaloric conditions
3229523|NCT00988650|Experimental|weight loss period|Weight loss period of 20-week (minimum 5% reduction in body weight)
3229524|NCT00988650|Active Comparator|Weight stabilizing mediterranean diet|Mediterranean diet for five weeks in isocaloric weight stabilizing conditions
3229525|NCT00988637|Other|1) Vectical™ Ointment and Clobex® Spray|Vectical™ Ointment weekdays & Clobex® Spray weekends regimen
3229526|NCT00988637|Other|2) Clobex® Spray and Vectical™ Ointment|Clobex® Spray morning and Vectical™ Ointment evening regimen
3229527|NCT00988624|Experimental|Period 1|
3229528|NCT00988624|Experimental|Period 2|
3229529|NCT00988624|Experimental|Period 3|
3229530|NCT00988624|Experimental|Period 4|
3229531|NCT00988624|Experimental|Period 5|
3229532|NCT00988598|Active Comparator|PF-04447943|
3229533|NCT00988598|Placebo Comparator|Placebo|
3229534|NCT00988585|Placebo Comparator|Olive Oil|Olive Oil 600 mg/day
3229535|NCT00988585|Active Comparator|EPA 1800|1800 mg/day
3229536|NCT00988585|Active Comparator|DHA|DHA 600 mg/day
3229537|NCT00988585|Active Comparator|EPA 600|EPA 600 mg/day
3229538|NCT00988572|Experimental|Intervention group|Vestibular rehabilitation, twice a week for 9 weeks
3229539|NCT00988572|No Intervention|Control group|The patients in the control group does nothing, except for normal treatment for their wrist fracture.
3229540|NCT00988559|Experimental|PMED Delivery - groups 1 and 2|Subjects will receive pNGVL4a-CRT/E7(detox) via gene gun at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
3229888|NCT00986219||Asthma Language between patients and physicians|
3229541|NCT00988559|Experimental|IM injections - groups 5 and 6|Subjects will receive pNGVL4a-CRT/E7(detox) intramuscularly at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
3229542|NCT00988559|Experimental|Intralesional delivery - group 3 and 4|Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
3229543|NCT00988559|Experimental|Intralesional delivery + imiquimod - group 7|Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally and imiquimod applied to the cervix at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
3229544|NCT00988546|Other|1|exam documentation performed using dictation
3229545|NCT00988546|Experimental|2|exam documentation performed using computer based template
3229546|NCT00988533|Experimental|0.5% Ivermectin Cream|
3229547|NCT00988520|Experimental|0.6 mg/kg intubation dose under sevoflurane|
3229548|NCT00988520|Experimental|0.9 mg/kg intubation dose under sevoflurane|
3229549|NCT00988520|Experimental|continuous dose following 0.6 mg/kg intubation dose + propofol|
3229550|NCT00988520|Experimental|continuous dose following 0.9 mg/kg intubation dose + propofol|
3229551|NCT00988507|Experimental|Ferroquine high dose + artesunate|Ferroquine at 6 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
3229552|NCT00988507|Experimental|Ferroquine medium dose + artesunate|Ferroquine at 4 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
3229553|NCT00988507|Experimental|Ferroquine low dose + artesunate|Ferroquine at 2 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
3229554|NCT00988507|Experimental|Ferroquine alone at medium dose|Ferroquine at 4 mg/kg/d OD alone for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
3229555|NCT00988494|Experimental|High concentration|DE-105 high concentration
3229556|NCT00988494|Experimental|Low concentration|DE-105 low concentration
3229557|NCT00988494|Placebo Comparator|Placebo|DE-105 placebo
3229558|NCT00988468|Experimental|Manual Therapy|Subjects will receive oscillatory (grade 1 & 2) manual knee mobilization for 15 minutes at various knee range of motion positions.
3229559|NCT00988468|Experimental|Therapeutic Exercise|Subjects will perform 15 minutes of combined resistance exercise and aerobic exercise.
3229560|NCT00988468|Placebo Comparator|Control|Subjects will watch a 15 minute instructional video on a health topic.
3229561|NCT00988455|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
3229562|NCT00988442|Experimental|Enhanced nursing telephone support with standard care|Participants received enhanced nursing telephone support plus care as usual.
3229563|NCT00988442|Active Comparator|Standard care|Participants received care as usual.
3229564|NCT00988429|Active Comparator|800 mg QD Eslicarbazepine acetate|tablets
3229565|NCT00988429|Active Comparator|1200 mg QD Eslicarbazepine acetate|tablets
3229566|NCT00988429|Placebo Comparator|Placebo|tablets
3229567|NCT00988403|Experimental|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
3229568|NCT00988403|Experimental|Fructan - 10 grams|Subjects will consume 10 grams of fructan
3229569|NCT00988403|Experimental|Fructan - 12.5 grams|Subjects will consume 12.5 grams of fructan
3229570|NCT00988403|Experimental|5 grams Fructan|"Experimental - 5 grams Fructan~Subjects will consume 5 grams of Fructan."
3229571|NCT00988390|Other|Intervention, mothers living with HIV|Mothers living with HIV, Cognitive-behavioral intervention delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions)
3229572|NCT00988390|No Intervention|Control, mothers living with HIV|Mothers living with HIV, offered intervention at end of study (18 months after recruitment)
3229573|NCT00988390|No Intervention|Control, non-HIV-infected mothers|Neighborhood control mothers not infected with HIV, did not receive any intervention
3229574|NCT00988377|Experimental|10 g whey protein|
3229575|NCT00988377|Experimental|20 g whey protein|
3229576|NCT00988377|Experimental|30 g whey protein|
3229577|NCT00988377|Experimental|40 g whey protein|
3229578|NCT00988377|Experimental|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
3229579|NCT00988364|Active Comparator|Ezetimibe|Randomly chosen participants will receive ezetimibe 10mg daily for 3 months.
3229580|NCT00988364|Active Comparator|Simvastatin|Randomly chosen participants will receive Simvastatin 20mg daily for 3 months.
3229581|NCT00988364|Active Comparator|Vytorin|Randomly chosen participants will receive Vytorin 20/10mg daily for 3 months.
3229582|NCT00988364|Placebo Comparator|Placebo|Randomly chosen participants will receive Placebo tab 1 daily for 3 months.
3229583|NCT00988351|Active Comparator|PSG CPAP titration then CPAP treatment|Patients diagnosed with sleep apnea will have a continuous positive airway pressure (CPAP) titration with polysomnography (PSG) followed by continuous positive airway pressure (CPAP) Treatment
3229584|NCT00988351|Active Comparator|Auto-Adjusting Positive Airway Pressure|Following diagnosis of obstructive sleep apnea patients will be have auto-adjusting positive airway pressure treatment without a titration.
3229585|NCT00988338|Other|Trinity Evolution|
3229586|NCT00988325|Experimental|Oseltamivir 3 mg|infants 3 to <12 months
3229587|NCT00988325|Experimental|Oseltamivir 2.5 mg|infants 1 to <3 months of age
3229588|NCT00988325|Experimental|Oseltamivir 2 mg|infants 0 to 30 days (post natal) of age
3229589|NCT00988312|Experimental|s.c. vaccination|vaccine given subcutaneously
3229590|NCT00988312|Experimental|i.v. vaccination|vaccines are given intravenously
3229591|NCT00988286|Experimental|CEP|
3229592|NCT00988273||Control|In patients undergoing endoscopy for indications other than Crohn's disease or ulcerative colitis
3229593|NCT00988273||Diseased group|Patients with Crohn's disease or ulcerative colitis undergoing endoscopy.
3229594|NCT00988260|Experimental|Ganirelix 0.125 mg|
3229595|NCT00988260|Experimental|Ganirelix 0.25 mg|
3229596|NCT00988260|Experimental|Ganirelix 0.5 mg|
3229597|NCT00988247|Experimental|BDP HFA 320 µg/day|During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning.
3229598|NCT00988247|Placebo Comparator|Placebo|During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily each morning.
3229599|NCT00988234|Experimental|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
3229600|NCT00988234|Experimental|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
3229601|NCT00988234|Experimental|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
3229602|NCT00988234|Experimental|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
3229603|NCT00988221|Experimental|Tocilizumab 10 mg/kg in patients weighing < 30 kg|Patients received tocilizumab 10 mg/kg intravenously every 4 weeks.
3229604|NCT00988221|Experimental|Tocilizumab 8 mg/kg in patients weighing < 30 kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.
3229605|NCT00988221|Experimental|Tocilizumab 8 mg/kg in patients weighing ≥ 30 kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.
3229606|NCT00988221|Placebo Comparator|Placebo|Patients received placebo to tocilizumab intravenously every 4 weeks.
3229607|NCT00988208|Experimental|Docetaxel, Prednisone, Lenalidomide (DPL)|25 mg lenalidomide orally once each day on Days 1-14; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice daily on each day of the treatment cycle
3229608|NCT00988208|Experimental|Docetaxel and Prednisone (DP)|Oral placebo once each day on Days 1-14 of the treatment cycle; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice each day on each day of the treatment cycle
3229609|NCT00988195|Experimental|PEG-BCT-100|Pegylated Recombinant Human Arginase I
3229610|NCT00988182|Experimental|whey protein, 5g|
3229611|NCT00988182|Experimental|whey protein, 10g|
3229612|NCT00988182|Experimental|whey protein, 20g|
3229613|NCT00988182|Experimental|whey protein, 40g|
3229614|NCT00988182|Experimental|water control|
3229615|NCT00988169|Experimental|oral erlotinib and pulsed doses of oral AT-101|This will be an open-label, single institution, phase II trial. The study will assess the efficacy of the combination of the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and the novel pan-Bcl-2 inhibitor, AT-101, in treatment-naïve advanced (Wet Stage IIIB and IV)NSCLC patients with EGFR activating mutations A planned pause of 21 days will be performed after enrollment of the 10th and 20th patient to assess for excessive toxicity.
3229616|NCT00988156|Active Comparator|Eslicarbazepine acetate|To receive Eslicarbazepine acetate in addition to concomitant therapy
3229617|NCT00988156|Placebo Comparator|Placebo|To receive placebo in addition to concomitant therapy
3229618|NCT00988143|Experimental|Study Group 1|Participants will receive the 2009-2010 Trivalent Influenza Vaccine (TIV) (Pediatric dose have no preservatives)
3229619|NCT00988143|Active Comparator|Study Group 2|Participants will receive the 2008-2009 Trivalent Influenza Vaccine (TIV)
3229620|NCT00988143|Active Comparator|Study Group 3|Participants will receive the Quadrivalent Influenza Vaccine (QIV)
3229621|NCT00988117|Experimental|Rivastigmine Patch 9.5 cm2|
3229622|NCT00988104|Active Comparator|Cognitive Behavioral Therapy|
3229623|NCT00988104|Active Comparator|Supportive Counseling|
3229624|NCT00988091|Placebo Comparator|IA-SA|Each participant received a single intra-articular (IA) injection of buffered saline (SA) into the target knee, and was followed for a total of 26 weeks in the double-blind period. Participants had the option of continuing into the open-label period in which they could receive a single intra-articular injection of 1.2% sodium hyaluronate (IA-BioHA) into the target knee and be followed for an additional 26 weeks.
3229625|NCT00988091|Experimental|IA-BioHA|Each participant received a single intra-articular (IA) injection of 1.2% sodium hyaluronate (BioHA) into the target knee, and was followed for a total of 26 weeks in the double-blind period. Participants had the option of continuing into the open-label period in which they received a single intra-articular injection of 1.2% sodium hyaluronate (IA-BioHA) into the target knee and were followed for an additional 26 weeks.
3229626|NCT00988078|Experimental|Metformin|Metformin 500mg three times a day for six months
3229627|NCT00988078|Placebo Comparator|Placebo|1 capsule three times a day for six months
3229628|NCT00988065|Experimental|Sugammadex 4 mg/kg|Participants were to receive one dose of sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
3229629|NCT00988065|Experimental|Sugammadex 16 mg/kg|Participants were to receive one dose of sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
3229630|NCT00988065|Placebo Comparator|Placebo|Participants were to receive one dose of placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
3229631|NCT00988052|Experimental|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
3229632|NCT00988039|Active Comparator|bPI + 2NRTIs|
3229633|NCT00988039|Experimental|bPI + raltegravir|
3229634|NCT00988039|Experimental|bPI monotherapy|
3229635|NCT00988026|Experimental|Minocycline 100 mg|Minocycline
3229636|NCT00988026|Active Comparator|Lymecycline 300 mg|Group B: Lymecycline
3229637|NCT00988013|Experimental|IM-TMI (3Gy)|Patients will receive 3Gy per day for 1 day (total of 3Gy).
3229638|NCT00988013|Experimental|IM-TMI (6Gy)|Patients will receive 3Gy per day for 2 days (for a total of 6Gy).
3229639|NCT00988013|Experimental|IM-TMI (9Gy)|Patients will receive 3Gy per day for 3 days (for a total of 9Gy).
3229640|NCT00988013|Experimental|IM-TMI (12Gy)|Patients will receive 3Gy per day for 4 days (for a total of 12Gy).
3229641|NCT00988000|Other|Alternative appointment system|Alternative of telephone consultation (instead of face to face) offered as an initial consultation to new referrals
3229642|NCT00987987|Experimental|1|1
3229643|NCT00987974|Experimental|rosuvastatin 3days|8 Subjects will use rosuvastatin 20 mg/day for 3 days
3229644|NCT00987974|Active Comparator|atorvastatin 3 days|8 Subjects will use atorvastatin 80 mg/day for 3 days.pj
3229646|NCT00987974|Experimental|rosuvastatin 7 days|8 Subjects will use rosuvastatin 20 mg/day for 7 days.
3229647|NCT00987974|Active Comparator|atorvastatin 7 days|8 Subjects will use atorvastatin 80 mg/day for 7 days.
3229648|NCT00987974|Placebo Comparator|placebo 7 days|8 Subjects will use placebo for 7 days.
3229649|NCT00987961|No Intervention|Treatment as usual|Participants in this arm will receive the standard detox treatment for individuals hospitalized with opioid dependence.
3229650|NCT00987961|Experimental|Linkage|Participants in this arm will receive a maintenance schedule of Suboxone during their hospital stay, and an appointment with an outpatient Suboxone provider for after their discharge.
3229651|NCT00987948|Experimental|Maraviroc|
3229652|NCT00987935|Experimental|Nintedanib (BIBF 1120)|Phase I dose escalation and phase II using dose determined in phase I
3229653|NCT00987935|Active Comparator|Sorafenib|Twice daily dosing in phase II
3229654|NCT00987922|Experimental|Hypothermia|
3229655|NCT00987922|No Intervention|Control|
3229656|NCT00987909|Placebo Comparator|Placebo|Solution resembling the active solutions, but without allergen extract
3229657|NCT00987909|Experimental|Cat hair allergen extract, dose group 1|
3229658|NCT00987909|Experimental|Cat hair allergen extract, dose group 2|
3229659|NCT00987909|Experimental|Cat hair allergen extract, dose group 3|
3229660|NCT00987896|Experimental|Megachannel Application|Colonoscopy with loaded Megachannel is performed
3229661|NCT00987883||Malnutrition cohort|The patients with undernutrition
3229662|NCT00987883||Well nourished cohort|Patient that well nourished and without undernutrition
3229663|NCT00987870|Experimental|BFH772 cream 1%|
3229664|NCT00987870|Placebo Comparator|Placebo to BFH772 cream 1%|
3229665|NCT00987870|Experimental|BFH772 ointment 1%|
3229666|NCT00987870|Placebo Comparator|Placebo to BFH772 ointment|
3229667|NCT00987870|Active Comparator|calcipotriol/betamethasone ointment|
3229668|NCT00987857|Active Comparator|2 yearly endoscopies|Two years endoscopies
3229669|NCT00987857|Experimental|endoscopy at need|Endoscopy only when patient reports symptoms
3229670|NCT00987831|Experimental|Blood drawing only Group C|Healthy controls, age, sex and ethnicity matched to the active study participants were recruited for two time blood donation as controls for the biomarker studies
3229671|NCT00987831|Experimental|Group A SLE prospective study|In Group A SLE patients enter with active disease. Any immune suppressant (e.g. methotrexate, azathioprine or mmf) is withdrawn and after blood drawing, depomedrol up to 160 mg IM is given. This may be repeated for a maximum of 160mg up to four times total in the first two weeks. Depomedrol is expected to last 1-3 months, serial biomarkers will be drawn until time of flare, at which time biomarkers will be drawn, patient is defined as meeting endpoint and new treatment initiated. Patients may elect to continue to donate blood samples per protocol up to one year.
3229672|NCT00987831|Experimental|Group B SLE one blood donation|SLE patients who meet the same entry criteria as Group A could elect to donate blood one time and not to continue in the prospective protocol. No extra intervention was performed other than blood draw and medical records review. This allowed an extension of cross sectional comparisons between biomarker changes related to background treatments by combining Group A baseline data with Group B data.
3229673|NCT00987818|Experimental|PCT guided antibiotic therapy|
3229674|NCT00987818|Placebo Comparator|Standard antibiotic therapy|
3229675|NCT00987805|Experimental|Banhasasim-tang|
3229676|NCT00987805|Placebo Comparator|Placebo drug|The placebo of this study is corn-starch granules. It has the same form, color, flavor and amount like experimental herbal extracted formula
3229677|NCT00987792||Group 1|
3229678|NCT00987779|Experimental|Period I: Tablet(400 mg single dose)|Period I: Tablet in fasting state, Period II: Liquid formulation in fasting state, Period III: Liquid formulation in fed state
3229679|NCT00987779|Experimental|Period I: Liquid formulation(400 mg single dose)|Period I: Liquid formulation in fasting state, Period II: Tablet in fasting state, Period III: Liquid formulation in fed state
3229680|NCT00987766|Experimental|Treatment|Gemcitabine + Oxaliplatin + Erlotinib
3229681|NCT00987753|Experimental|infusion of L-377202|
3229682|NCT00987740|Experimental|Hemolung Respiratory Assist System|
3229683|NCT00987727|Experimental|1|carboxymethylcellulose 0.5% and glycerin 0.9% (OPTIVE® MD)
3229684|NCT00987727|Active Comparator|2|sodium hyaluronate 0.18% (VISMED® Multi)
3229685|NCT00987714|Experimental|Protocolized Care|Algorithm to manage Pulse Pressure Variation, Cardiac Index, and Mean Arterial Pressure will be used in these donors.
3229686|NCT00987714|No Intervention|Standard Care|This is the Organ Procurement Organization current practices.
3229687|NCT00987701|Active Comparator|Crystalloid resuscitation|Crystalloid (Ringer's lactate) will be delivered before (15min) or after (15min) neuraxial anesthesia
3229688|NCT00987701|Active Comparator|Colloid resuscitation|Colloid (6% hydroxyethyl starch ) will be delivered before (15min) or after (15min) neuraxial anesthesia
3229689|NCT00987688|Experimental|Hypothermia|Early and sustained hypothermia.
3229690|NCT00987688|No Intervention|Normothermia|Standard management
3229691|NCT00987662|Active Comparator|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP>135/85 mmHg add HCZ 12.5 mg.
3229692|NCT00987662|Active Comparator|Amplodipine|Treatment with amlodipine 10 mg for 4 weeks. If BP>135/85 mmHg add hydrochlorothiazide 12.5 mg
3229693|NCT00987636|Experimental|R1|Standard Risk R1: in a randomised trial, to examine whether add-on treatment with zoledronic acid in addition to induction and maintenance chemotherapy improves event-free survival in patients with localised Ewing sarcoma and good histological response or with initial tumour volume <200 mL compared to no add-on treatment.
3229694|NCT00987636|Experimental|R2|High Risk R2: in a randomised trial, to examine whether high-dose chemotherapy using busulfan-melphalan with autologous stem cell reinfusion, compared with standard chemotherapy, improves event-free survival in patients with localised Ewing sarcoma and poor histological response or tumour volume ≥200 mL (R2loc). In patients with pulmonary metastases high dose busulfan-melphalan chemotherapy with autologous stem cell reinfusion is randomised versus standard chemotherapy plus whole lung irradiation (R2pulm).
3229784|NCT00987077|No Intervention|control group|Patients randomized to control group achieve no treatment and are followed up for three months.
3229695|NCT00987636|Experimental|R3|Very High Risk R3: in a randomised trial, to examine whether the addition of high dose chemotherapy using treosulfan-melphalan followed by autologous stem cell reinfusion to eight cycles of standard adjuvant chemotherapy, compared to eight cycles of standard adjuvant chemotherapy alone, improves event-free survival in patients with primary disseminated disease.
3229696|NCT00987623|Experimental|nelfilcon A|Commercially marketed contact lens worn in both eyes on a daily wear, daily disposable basis for one week.
3229697|NCT00987623|Active Comparator|narafilcon A|Commercially marketed contact lens worn in both eyes on a daily wear, daily disposable basis for one week.
3229698|NCT00987610|Active Comparator|slender guidewire|Percutaneous coronary intervention (PCI) using guidewires with small distal tip equal to 0.010 inch or less
3229699|NCT00987610|Active Comparator|normal guidewire|Percutaneous coronary intervention (PCI) using guidewires with normal distal tip equal to 0.014 inch
3229700|NCT00987597|Experimental|cognitive behavioural approach|specific technique of cigarette exposure and nicotinic treatment adjustment
3229701|NCT00987597|Active Comparator|usual approach|recommendations and nicotinic substitutes
3229702|NCT00987571||Carpal Tunnel patients|These patients have documented carpal tunnel syndrome
3229703|NCT00987571||Normal Subjects|These individuals have no carpal tunnel syndrome
3229704|NCT00987558|Experimental|Treatment Sequence A|Simvastatin 80mg treatment period followed by Simvastatin 80 mg + eslicarbazepine acetate 800 mg treatment period
3229705|NCT00987558|Experimental|Treatment Sequence B|Simvastatin 80mg + eslicarbazepine acetate 800 mg treatment period followed by Simvastatin 80 mg treatment period
3229706|NCT00987545|Placebo Comparator|Placebo|
3229707|NCT00987545|Experimental|QAX576|
3229708|NCT00987532|Experimental|parent intervention plus gym lessons|Parent-focused participatory preschool intervention in addition to twice weekly gym lessons over 6 months. The participatory intervention includes parents, teachers and children.
3229709|NCT00987532|Active Comparator|gym lessons only|Twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
3229710|NCT00987519||Acute bronchiolitis|Patients with acute bronchiolitis - the presence of nasal discharge, cough, wheezing and/or crackles on lung auscultation.
3229711|NCT00987519||Acute gastroenteritis|Patients with 3 or more loose or liquid stools in 24 hours prior to entering the study.
3229712|NCT00987519||Febrile convulsion|Patients with a cerebral paroxysm accompanied by fever without signs of central nervous system infection.
3229713|NCT00987519||Control group|Patients referred to pediatric surgery for elective surgical procedure - judged to be free of clinical signs and symptoms of infection.
3229714|NCT00987506||XIENCE V®|Participants receiving XIENCE V® EESS
3229715|NCT00987493|Experimental|Treatment with rituximab, bendamustine and lenalidomide|
3229716|NCT00987480|Experimental|chemotherapy-based cytoreductive regimen plus a CD34+ selected|This phase II trial is designed to investigate the safety and efficacy of a chemotherapy-based cytoreductive regimen plus a CD34+ selected T-cell depleted peripheral blood stem cell (PBSC) stem cell transplant for the treatment of patients with Fanconi anemia and severe hematologic disease.
3229717|NCT00987467|Experimental|Cyclosporine 0.05% ophthalmic|cyclosporine 0.05% ophthalmic eye drops will be used starting with 1 drop in both eyes 6 times daily for first month, followed by 1 drop in both eyes 4 times daily for the following month, then will be adjusted by clinician as needed for appropriate disease control
3229718|NCT00987454|Active Comparator|Erythropoietin|Epoetin alfa 40,000 international units will be given by subcutaneous injection to eligible patients, allocated to the treatment arm, on Study Days 1; 8 and15 during the intensive care unit stay.
3229719|NCT00987454|Placebo Comparator|Placebo|Sodium Chloride 0.9% in m/L will be given by subcutaneous injection to eligible patients, allocated to the placebo arm, on Study Days 1; 8 and15 during the intensive care unit stay.
3229720|NCT00987441|Active Comparator|Local anesthetic plus opioid 1|Local anesthetic (ropivacaine 0.125%) plus first opioid dose (sufentanil 0.3 microgram/ml) delivered peridural space
3229721|NCT00987441|Active Comparator|Local anesthetic plus opioid 2|Local anesthetic (ropivacaine 0.125%) plus second opioid dose (sufentanil 0.4 microgram/ml) delivered peridural space
3229722|NCT00987441|Active Comparator|Local anesthetic plus opioid 3|Local anesthetic (ropivacaine 0.125%) plus third opioid dose (sufentanil 0.5 microgram/ml) delivered peridural space
3229723|NCT00987441|Active Comparator|Local anesthetic 1 plus opioid|First local anesthetic dose (ropivacaine 0.0625%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
3229724|NCT00987441|Active Comparator|Local anesthetic 2 plus opioid|Second local anesthetic dose (ropivacaine 0.1875%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
3229725|NCT00987441|Active Comparator|Local anesthetic 3 plus opioid|Third local anesthetic dose (ropivacaine 0.25%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
3229726|NCT00987428|Experimental|groupe 1|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
3229727|NCT00987428|Active Comparator|Groupe 2|usual procedure
3229728|NCT00987415|Active Comparator|allopurinol|Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
3229729|NCT00987415|Placebo Comparator|sugar pill|Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
3229730|NCT00987402|Active Comparator|Plain soap and water|Surgical hand preparation with plain soap and water
3229731|NCT00987402|Active Comparator|Alcohol based hand rubs|Surgical hand preparation with alcohol based alcohol hand rub
3229732|NCT00987389|Other|No Plasma Exchange|Participants in this arm do not undergo plasma exchange
3229733|NCT00987389|Experimental|Plasma Exchange|
3229734|NCT00987376|Experimental|1|Prostate cancer patients
3229735|NCT00987363|Experimental|Low dose (1x10 E8)|Dose of 1x10 E8 autologous bone marrow-derived mononuclear cells
3229736|NCT00987363|Experimental|Intermediate dose (5x10 E8)|Dose of 5x10 E8 autologous bone marrow-derived mononuclear cells
3229737|NCT00987363|Experimental|High dose (1x10 E9)|Dose of 1x10 E9 autologous bone marrow-derived mononuclear cells
3229738|NCT00987363|No Intervention|Control|Conventional treatment established by the good clinical practice
3229889|NCT00986206||Biomarker testing|Collect serum for biomarker testing for LAP and HE4 and discovery of new biomarkers.
3229739|NCT00987350|Active Comparator|Trivalent influenza vaccine by needle and syringe|Thirty volunteers will receive 1 intramuscular (IM) dose of licensed trivalent inactivated 2009-10 seasonal influenza vaccine by the standard needle and syringe method
3229740|NCT00987350|Experimental|Trivalent influenza vaccine by jet injection|Thirty volunteers will receive 1 intramuscular (IM) dose of licensed trivalent inactivated 2009-10 seasonal influenza vaccine by the experimental method of jet injection
3229741|NCT00987337|Experimental|Arm A|"Filibuvir 300 mg BID + pegIFN/RBV x 24 weeks (subjects with undetectable HCV RNA at week 4)~- or - Filibuvir 300 mg BID + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks (subjects with detectable HCV RNA at week 4)"
3229742|NCT00987337|Experimental|Arm B|"Filibuvir 600 mg BID + pegIFN/RBV x 24 weeks (subjects with undetectable HCV RNA at week 4)~- or - Filibuvir 600 mg BID + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks (subjects with detectable HCV RNA at week 4)"
3229743|NCT00987337|Placebo Comparator|Arm C|Placebo + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks
3229744|NCT00987324|Experimental|Paclitaxel-eluting stent|Paclitaxel-eluting stent (Taxus)
3229745|NCT00987324|Active Comparator|Plain Balloon|plain balloon angioplasty
3229746|NCT00987324|Experimental|Paclitaxel-eluting balloon|SeQuent Please
3229747|NCT00987311|Active Comparator|1-Test product A|1-Dairy product containing probiotics A (test product A)
3229748|NCT00987311|Active Comparator|2-Test product B|2-Dairy product containing probiotics B (test product B)
3229749|NCT00987311|Sham Comparator|3-Control|3-Dairy product without probiotics (control)
3229750|NCT00987298||Visceral fat mass|The study population will include adult men and women, ages 18 to 90 years. All subjects will be recruited at Oregon Health and Science University (OHSU). Subjects will represent a wide range of BMI values (18.5 - 40 kg/m2).
3229751|NCT00987285|Experimental|Computer Assisted Self Management plus Social Support|an interactive, automated self-management (ASM) program that uses web and interactive voice recognition (IVR) media combined with enhanced support in the form of group Diabetes Care Management visits and live follow up phone calls from Diabetes Care Managers
3229752|NCT00987285|No Intervention|Usual care|will receive a health-risk appraisal, interactive CD-ROM program that provides standardized advice on behavior change, but not the hypothesized key intervention processes of goal setting, barriers identification, problem solving, or social environmental support.
3229753|NCT00987285|Experimental|Computer Assisted Self Management|An interactive, automated self-management (ASM) program that uses web and interactive voice recognition (IVR) media.
3229754|NCT00987272|Experimental|Pataday+Pataday Vehicle|Olopatadine Hydrochloride Ophthalmic Solution 0.2%, 1 drop in 1 eye and Olopatadine 0.2% Vehicle in the contralateral eye
3229755|NCT00987272|Active Comparator|Patanol+Patanol Vehicle|Olopatadine Hydrochloride Ophthalmic Solution, 0.1%, 1 drop in 1 eye and Olopatadine 0.1% Vehicle in the contralateral eye
3229756|NCT00987259||Post MI patients|Patients recruited following a successfully reperfused myocardial infarction using primary angioplasty.
3229757|NCT00987246|Experimental|LAS41005|
3229758|NCT00987246|Active Comparator|LAS106521|
3229759|NCT00987246|Placebo Comparator|Placebo|
3229760|NCT00987233|Experimental|triamcinolone acetonide aqueous nasal spray|
3229761|NCT00987233|Active Comparator|Nasacort® AQ Nasal Spray|
3229762|NCT00987233|Placebo Comparator|Placebo|
3229763|NCT00987220||Placebo|
3229764|NCT00987220||donepezil (Aricept)|
3229765|NCT00987207|Experimental|cyclosporine|a single bolus of 2.5 mg/kg, administered before aortic cross-declamping
3229766|NCT00987207|No Intervention|Control|No cyclosporine A is administered before aortic cross-declamping
3229767|NCT00987181||Angiography high risk|Patients with multiple risk factors, positive non-invasive test, or known pre-existing coronary artery/vascular disease. Patients with diabetes mellitus will be identified, and subject to a sub-group analysis.
3229768|NCT00987181||Angiography Low Risk|Patients with chest pain symptoms, minimal risk factors, and inconclusive evidence of myocardial ischaemia on non-invasive testing.
3229769|NCT00987168|Experimental|Sandostatine LP|
3229770|NCT00987155|Experimental|high intensity interval training|8 weeks of high intensity 4 times 4 interval training at 85-90% of peak heart rate during hybrid cycling
3229771|NCT00987142|Experimental|CX501|Cultured chimeric skin
3229772|NCT00987142|Active Comparator|Non adherent dressing|Occlusive non adherent dressing
3229773|NCT00987116|Active Comparator|Starting dose Prednisone Azathioprine|Classical Strategy
3229774|NCT00987116|Active Comparator|Starting dose Prednisone - Azathioprine|Rapid strategy
3229775|NCT00987103|Experimental|Sublingual - Rectal - Oral|Administration order of rank: Sublingual - Rectal - Oral
3229776|NCT00987103|Experimental|Sublingual - Oral - Rectal|Administration order of rank: Sublingual - Oral - Rectal
3229777|NCT00987103|Experimental|Oral - Sublingual - Rectal|Administration order of rank: Oral - Sublingual - Rectal
3229778|NCT00987103|Experimental|Oral - Rectal - Sublingual|Administration order of rank: Oral - Rectal - Sublingual
3229779|NCT00987103|Experimental|Rectal - Sublingual - Oral|Administration order of rank: Rectal - Sublingual - Oral
3229780|NCT00987103|Experimental|Rectal - Oral - Sublingual|Administration order of rank: Rectal - Oral - Sublingual
3229781|NCT00987090|Active Comparator|Alzheimer Disease|subjects who have developed symptoms of Alzheimer Disease aged from 45 to 85 years old
3229782|NCT00987090|Placebo Comparator|Control|subjects without symptoms of Alzheimer Disease aged from 45 to 85 years old.
3229783|NCT00987077|Experimental|Selective Retinatherapy (SRT)|Treatment was performed with the SRT-Laser system (Medical Laser Center Lübeck, Germany), which consists of a Q-switched frequency doubled Nd:YLF laser (527nm), operating with a pulse repetition rate of 100 Hz. The pulse duration (full width at half maximum) was 1.7 µs. The laser energy was transmitted via fiber to a Lumenis slitlamp allowing the application of a fixed spot size diameter of 200 µm in air. A Mainster central field contact lens with a magnification of 1.05 was used for all irradiations. Per foot switch, 30 pulses are emitted, the pulse energy was chosen by the physician up to a maximum of 370 µJ. According to the treatment protocol, prior to each treatment 5 test shots with increasing energy were applied adjacent to the vessel arcades, in each patient in order to determine the appropriate pulse energy for treatment by recording the OA-value.
3229785|NCT00987077|Experimental|crossover|After 3 months follow up patients of control group with persistence of disease activity were allocated to crossover group and received either SRT. Crossover group was followed up for further 3 months.
3229786|NCT00987064|Active Comparator|Temperature controlled Laminar Airflow|Active treatment with Temperature controlled Laminar Airflow (TLA)
3229787|NCT00987064|Placebo Comparator|Placebo TLA|Placebo treatment with TLA (no filtration function)
3229788|NCT00987051|Experimental|1|Patients with endometrial cancer
3229789|NCT00987038|Other|PF-04171327 and Midazolam|
3229790|NCT00987025|Experimental|Telehealth|Telehealth participants will be recruited from centers that have a telehealth blood pressure station installed. Participants will be asked to use the station once per week. Blood pressure measures will be monitored by nurse researchers - out of range values will result in appropriate medical recommendations.
3229791|NCT00987025|Active Comparator|Control|Control participants will receive education material.
3229792|NCT00987012|Experimental|Pomegranate juice|
3229793|NCT00987012|Placebo Comparator|Placebo drink|
3229794|NCT00986999|Experimental|rosuvastatin|rosuvastatin 10 mg qd increased to 20 mg qd as tolerated
3229795|NCT00986986|Experimental|Active Drug (extended release niacin)|Subjects in this arm will be given 12 weeks of extended release niacin. Intervention: extended release niacin (Niaspan) starting at 500 mg by mouth daily and titrated to a maximum dose of 1500 mg by mouth daily. Titration will depend on patient tolerability.
3229796|NCT00986986|No Intervention|Observation|Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin
3229797|NCT00986973|Experimental|Sapropterin (KUVAN)|All subjects will receive Sapropterin (KUVAN) therapy at a dose of 20/mk/kg/day for four months.
3229798|NCT00986960|Active Comparator|Adrenocorticotropin hormone|
3229799|NCT00986960|Placebo Comparator|Placebo|
3229800|NCT00986947|Experimental|IvIg with Rituximab|
3229801|NCT00986921|Experimental|mifepristone|women in the mifepristone are would take mifepristone 200 mg for cervical preparation the day before their procedure, and not have dilators inserted. In this group, the sstandard procedure of osmotic dilator insertion is NOT performed.
3229802|NCT00986921|Active Comparator|Osmotic dilator insertion|Women assigned to this arm would have the standard procedure for cervical preparation, which is insertion of osmotic dilators the day before the abortion procedure
3229803|NCT00986882|Experimental|SAF312A (2 doses in part B; 5 - 6 doses in part C)|
3229804|NCT00986882|Placebo Comparator|Placebo|
3229805|NCT00986882|Active Comparator|Ibuprofen|
3229806|NCT00986869||echocardiogram|All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
3229807|NCT00986856|Experimental|Fucidin® cream|
3229808|NCT00986856|Placebo Comparator|Fucidin® cream vehicle|
3229809|NCT00986843|Experimental|HM30181AK tablet + Irinotecan tablets|HM30181AK tablet + Irinotecan tablets
3229810|NCT00986817|Experimental|Terlipressin|
3229811|NCT00986817|Placebo Comparator|Placebo|
3229812|NCT00986804|Experimental|Level 1|Decitabine 5.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
3229813|NCT00986804|Experimental|Level 2|Decitabine 7.5 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
3229814|NCT00986804|Experimental|Level 3|Decitabine 10.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
3229815|NCT00986804|Experimental|Level 4|Decitabine 15.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
3229816|NCT00986791|No Intervention|Control group|Treatment as usual
3229817|NCT00986791|Experimental|GSP-A|Gold-Standard-Program for Alcohol cessation intervention (GSP-A): 6-week intensive patient education program with pharmaceutical support
3229818|NCT00986778|Active Comparator|Lamivudine plus Adefovir|
3229819|NCT00986778|Active Comparator|Entecavir|
3229820|NCT00986778|Experimental|Entecavir plus Adefovir|
3229821|NCT00986765|Experimental|Lovenox® , 4000 UI/day (+ Aspegic®)|Lovenox® (enoxaparin), 4000 UI/day (+ Aspegic® (Aspirin), 100 mg)
3229822|NCT00986765|Active Comparator|Aspegic ®, 100 mg/day|Aspegic® (Aspirin),100 mg/day
3229823|NCT00986752|Active Comparator|Stenting|Due to randomization one nitinol stent will be implanted after dilation with a conventional balloon.
3229824|NCT00986752|Experimental|Stenting after PEB|Due to randomization one nitinol stent will be implanted after dilation with a Paclitaxel eluting balloon.
3229825|NCT00986752|Experimental|Atherectomy|The third randomization arm is Atherectomy.
3229826|NCT00986700|Other|different types of bad time food|Different types of bad time food
3229827|NCT00986687||Vitrified oocytes|
3229828|NCT00986687||Control oocytes|
3229829|NCT00986674|Experimental|Arm I (carboplatin, paclitaxel, cetuximab)|Patients receive carboplatin IV over 15-30 minutes and paclitaxel IV over 3 hours on days 1 and 22 and cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cetuximab alone on days 1, 8, 15, 22, 29, and 36. Treatment with cetuximab repeats every 42 days in the absence of disease progression or unacceptable toxicity.
3229830|NCT00986674|Experimental|Arm II (carboplatin, paclitaxel, cixutumumab)|Patients receive carboplatin and paclitaxel as in arm I. Patients also receive cixutumumab IV over 1 hour on days 1, 15, and 29. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cixutumumab alone on days 1, 15, and 29. Treatment with cixutumumab repeats every 42 days in the absence of disease progression or unacceptable toxicity.
3229831|NCT00986674|Experimental|Arm III (carboplatin, paclitaxel, cetuximab, cixutumumab)|Patients receive carboplatin, paclitaxel, and cetuximab as in arm I. Patients also receive cixutumumab as in arm II. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cetuximab as in arm I and cixutumumab as in arm II.
3229832|NCT00986661|Experimental|PV-10 Injection (Intralesional)|Subjects in each of three cohorts will receive a single dose of PV-10 to one Target Lesion.
3229883|NCT00986245|Active Comparator|Ropinirole PR BID first, and then QD|Give Ropinirole prolonged release (PR) twice-daily (BID) dosing, and then once-daily (QD) dosing
3229884|NCT00986232|Experimental|1|ProQuad (low dose)
3229833|NCT00986609|Experimental|Arm I|Patients receive MUC-1 peptide vaccine subcutaneously and poly-ICLC vaccine intramuscularly in weeks 0, 4, 8, 12, 52, and 56, in the absence of disease progression or unacceptable toxicity. Patients may receive additional vaccines in weeks 34 and 38 if anti-MUC1 immunity falls below the two-fold enhancement from baseline
3229834|NCT00986596|Active Comparator|vitamin D3|vitamin D3 capsule 4000 IU p.o. daily
3229835|NCT00986596|Placebo Comparator|placebo|microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
3229836|NCT00986583|Other|Statin use group|Patients taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.
3229837|NCT00986583|Other|non statin use|Patients not taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.
3229838|NCT00986570|Experimental|Xeomin®|Botulinum Toxin A
3229839|NCT00986544|Sham Comparator|Absence of drain|
3229840|NCT00986544|Active Comparator|Drain|drain positioned in the subhepatic space after laparoscopic cholecystectomy
3229841|NCT00986531|Experimental|1|80 mg AZD8529
3229842|NCT00986531|Placebo Comparator|2|Placebo
3229843|NCT00986518|Experimental|adaptive cell immunotherapy|
3229844|NCT00986505|Experimental|Lidocaine|Comparison between intravenous lidocaine and saline infusion
3229845|NCT00986479|Experimental|AZD6765 (150 mg) / Placebo|Patients randomized to receive a single intravenous (iv) infusion of AZD6765 (150 mg) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of placebo (saline solution) over 60 minutes during the second period.
3229846|NCT00986479|Placebo Comparator|Placebo / AZD6765 (150 mg)|Patients randomized to receive a single intravenous (iv) infusion of placebo (saline solution) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of AZD6765 (150 mg) over 60 minutes during the second period.
3229847|NCT00986466|Experimental|exercise with vitamin D 800 IU/d|
3229848|NCT00986466|Active Comparator|exercise with placebo|
3229849|NCT00986466|Active Comparator|no exercise with vitamin D 800 IU/d|
3229850|NCT00986466|Placebo Comparator|no exercise with placebo|
3229851|NCT00986453|Experimental|PlasmaBlade arm|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
3229852|NCT00986453|Active Comparator|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
3229853|NCT00986440|Experimental|CS-7017|
3229854|NCT00986440|Placebo Comparator|Placebo|Placebo matching CS-7017
3229855|NCT00986427|Active Comparator|1|Subjects will apply Restasis® to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
3229856|NCT00986427|Placebo Comparator|2|Subjects will apply Refresh® Dry Eye therapy to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
3229857|NCT00986414|Experimental|AFQ056-10mg|
3229858|NCT00986414|Experimental|AFQ056-25mg|
3229859|NCT00986414|Experimental|AFQ056-50mg|
3229860|NCT00986414|Experimental|AFQ056-75mg|
3229861|NCT00986414|Experimental|AFQ056-100mg|
3229862|NCT00986414|Placebo Comparator|Placebo|
3229863|NCT00986401|Experimental|Glucophage® then Sanctura XR® (AB)|Treatment Period 1: Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD) for 4 days + Glucophage® (500 mg, BID) for 3.5 days.
3229864|NCT00986401|Experimental|Sanctura XR® then Glucophage® (BA)|Treatment Period 1: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD for 4 days) + Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Glucophage® (500 mg, BID) for 3.5 days.
3229865|NCT00986375|Experimental|Intervention Group (IG)|Patients in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
3229866|NCT00986375|Active Comparator|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
3229867|NCT00986362|Experimental|Ocriplasmin|
3229868|NCT00986362|Placebo Comparator|Placebo|
3229869|NCT00986349|Experimental|Diabetes|Single Arm
3229870|NCT00986336|Experimental|001|
3229871|NCT00986336|Experimental|002|
3229872|NCT00986336|Experimental|003|
3229873|NCT00986336|Experimental|004|
3229874|NCT00986323|Active Comparator|Temeperature controlled Laminar Airflow|Active treatment with Temperature controlled Laminar Airflow (TLA)
3229875|NCT00986323|Placebo Comparator|Placebo TLA|Placebo TLA treatment
3229876|NCT00986310|Active Comparator|fluoxetine|Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo (one pill), to be started one week prior to the scheduled hospital admission date. The dose will be increased to two pills per day on day 1 of hospitalization bringing the total dose of fluoxetine to 40 mg/day in patients randomized to receive this medication. On the day of discharge from the hospital, the study medication will be reduced to 1 pill per day and the patient will be instructed to stop the medication one week following discharge.
3229877|NCT00986310|Placebo Comparator|Placebo|Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo (one pill), to be started one week prior to the scheduled hospital admission date. The dose will be increased to two pills per day on day 1 of hospitalization. On the day of discharge from the hospital, the study medication will be reduced to 1 pill per day and the patient will be instructed to stop the medication one week following discharge.
3229878|NCT00986297|Other|arm one|IGRT
3229879|NCT00986284|Experimental|Gefitinib, Neoadjuvant therapy|Patients with EGFR mutation will be recruited and treated with gefitinib.
3229880|NCT00986271|Other|With and without MODS developement|EVLI was determinated by PiCCO plus system.
3229881|NCT00986258|Experimental|Tapentadol Prolonged Release|"Other Names:~Nucynta~Palexia"
3229882|NCT00986245|Active Comparator|Ropinirole PR QD first, then BID|Give Roipinirole prolonged release (PR) once-daily (QD) dose first, then twice-daily (BID) dosing
3229885|NCT00986232|Experimental|2|ProQuad (middle dose)
3229890|NCT00986193|Active Comparator|Conventional Aortic Valve Surgery|Insertion of a biological valve
3229891|NCT00986193|Experimental|Transapical Aortic Valve Implantation|Transapical implantation of an Edwards SAPIENtm valve
3229892|NCT00986180|Experimental|001|NUCYNTA 50 75 or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
3229893|NCT00986180|Active Comparator|002|Oxycodone IR 5 10 or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
3229894|NCT00986167|Experimental|Quetiapine XR|The study population will be patients admitted to the acute psychiatry inpatient wards of St Vincent's or the Alfred and determined by a Psychiatrist to be experiencing a psychotic illness (including mania with psychotic features and drug-induced psychosis) and acting in an aggressive manner (determined by a score of at least 1 on the OAS).
3229895|NCT00986154|Experimental|heparin/edoxaban tosylate|
3229896|NCT00986154|Active Comparator|heparin/warfarin|
3229897|NCT00986141||laser trabeculoplasty|Subjects with POAG and on medical treatment who are undergoing SLT
3229898|NCT00986141||Surgery|Glaucoma laser treatment
3229899|NCT00986128|Experimental|001|
3229900|NCT00986128|Experimental|002|
3229901|NCT00986115|Active Comparator|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
3229902|NCT00986115|Placebo Comparator|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
3229903|NCT00986102|Other|001|doripenem 500mg vial by injection every 8 hours for 5 to 14 days
3229904|NCT00986089||women who have an IUD placed at the time of c-section|
3229905|NCT00986076|Experimental|Enoxaparin infusion|"Congenital Cataract Surgery with IOL implantation~Intraocular infusion of Enoxaparin"
3229906|NCT00986076|Placebo Comparator|Balanced Salt Solution Infusion|Congenital Cataract Surgery with IOL implantation Intraocular infusion of Balanced Salt Solution
3229907|NCT00986063|Active Comparator|Standard of care|AIDS patients taking care with standard of care
3229908|NCT00986063|Experimental|Genetic test|AIDS patients who required highly active antiretroviral therapy(HAART) whom genotype status will be determined before initiation of HAART
3229909|NCT00986050|Active Comparator|Bare metal stent (BMS)|
3229910|NCT00986050|Active Comparator|Drug eluting stent (DES)|
3229911|NCT00986050|Active Comparator|Abciximab|
3229912|NCT00986050|No Intervention|No abciximab|
3229913|NCT00986037|Experimental|IV ABT-308 in asthmatics|ABT-308 single escalating doses in mild to moderate asthmatics
3229914|NCT00986037|Experimental|SC ABT-308 in asthmatics|ABT-308 multiple SQ doses in mild to moderate asthmatics
3229915|NCT00986037|Experimental|IV ABT-308 in healthy volunteers|ABT-308 single escalating IV doses in healthy volunteers
3229916|NCT00986024|Experimental|aerobic exercise|
3229917|NCT00986024|Experimental|strength training|
3229918|NCT00986024|No Intervention|control group|
3229919|NCT00985998|Experimental|Nimotuzumab|
3229920|NCT00985985|Experimental|2mg nicotine lozenge|2 mg nicotine lozenge
3229921|NCT00985985|Placebo Comparator|2 mg placebo|2 mg placebo
3229922|NCT00985985|Experimental|4 mg nicotine lozenge|4 mg nicotine lozenge
3229923|NCT00985985|Placebo Comparator|4 mg placebo|4 mg placebo
3229924|NCT00985972||Intervention|Groups of school intervention that involves a combination of the physical activity and nutrition education in subjects 6 to 18 years of age
3229925|NCT00985972||Control|Groups included in the same school communities that serve as reference for individuals involved in intervention.
3229926|NCT00985959|Experimental|Phase I: JNJ-26866138 0.7 mg/m2|JNJ-26866138 0.7 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles.
3229927|NCT00985959|Experimental|Phase I: JNJ-26866138 1.0 mg/m2|JNJ-26866138 1.0 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
3229928|NCT00985959|Experimental|Phase I: JNJ-26866138 1.3 mg/m2|JNJ-26866138 1.3 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
3229929|NCT00985959|Experimental|Phase II: JNJ-26866138 1.3 mg/m2|JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5-9 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
3229930|NCT00985946|Experimental|panobinostat|This is a single arm trial. All patients will take panobinostat
3229931|NCT00985933|Experimental|1|180 mg of AZD8529
3229932|NCT00985933|Experimental|2|50 mg AD8529
3229933|NCT00985933|Placebo Comparator|3|Placebo
3229934|NCT00985920|Experimental|Tranexamic acid, 1.5 g|1.5 g of tranexamic acid in 50 cc of normal saline solution is given to the patients.
3229935|NCT00985920|Experimental|Tranexamic acid, 3.0 g|3.0 g of tranexamic acid in 50 cc of normal saline is given to the patients.
3229936|NCT00985920|Placebo Comparator|Placebo, saline|50 cc of sterile normal saline solution is given to the patients.
3229937|NCT00985907|Experimental|Doxil® + Melphalan + Velcade (DMV)|
3229938|NCT00985894|Experimental|Teledermatology|Online Telemedicine Group
3229939|NCT00985894|Active Comparator|Usual Care|Conventional in-office care
3229940|NCT00985881|Experimental|Arm 1: stochastic resonance|Mechanical stochastic resonance
3229941|NCT00985881|Other|Arm 2: current clinical practice|Current clinical practice
3230024|NCT00985296||Ragweed + Dust Mite - CAC|
3229942|NCT00985855|Experimental|Cisplatin, vinorelbine|patients will receive induction chemotherapy (cisplatin, docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and vinorelbine associated with a weekly cetuximab infusion during the radiotherapy.
3229943|NCT00985855|Experimental|Cisplatin, etoposide|patients will receive induction chemotherapy (cisplatin, docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and etoposide associated with a weekly cetuximab infusion during the radiotherapy.
3229944|NCT00985842|Other|Arm 1|Comparison of five different clinically used suspension and socket systems
3229945|NCT00985829|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
3229946|NCT00985816|Active Comparator|L reuteri DSM 17938|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties (Connolly, 2005). The placebo consists of an identical formulation except that the L. reuteri is not present. This dose of the oil formulation with L. reuteri has been shown to induce significant colonisation in infants and is well-tolerated (Abrahamsson et al., 2007; Savino et al., 2007; Indrio et al., 2008).
3229947|NCT00985816|Placebo Comparator|Placebo|
3229948|NCT00985803|No Intervention|Group Control|
3229949|NCT00985803|Experimental|Endurance|
3229950|NCT00985803|Experimental|Cardiovascular|
3229951|NCT00985790|Experimental|GSK2321138A Group|"Subjects aged between 18 and 47 months received the GSK2321138A. Primed subjects (subjects who had received a 2-dose priming immunization with Fluarix™ vaccine in study NCT00764790 - or the GSK2321138A-Primed Group) received 1 dose of GSK2321138A vaccine at Day 0. Unprimed subject (subjects who had not received any 2-dose priming influenza immunization in any previous year - or the the GSK2321138A-Unprimed Group) received 2 doses of GSK2321138A vaccine at Days 0 and 28. The GSK2321138A vaccine was administered intramuscularly in the deltoid of the right arm."
3229952|NCT00985790|Active Comparator|Fluarix Group|"Subjects aged between 18 and 47 months received the Fluarix™ vaccine. Primed subjects (subjects who had received a 2-dose priming immunization with Fluarix™ vaccine in study NCT00764790 - or the Fluarix-Primed Group) received 1 dose of Fluarix™ vaccine at Day 0. Unprimed subject (subjects who had not received any 2-dose priming influenza immunization in any previous year - or the the Fluarix-Unprimed Group) received 2 doses of Fluarix™ vaccine at Days 0 and 28. The Fluarix™ vaccine was administered intramuscularly in the deltoid of the right arm."
3229953|NCT00985777|Experimental|Phase I Dose Escalation|Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days and one dose on Day 15.
3229954|NCT00985764||placental previa|
3229955|NCT00985751|Experimental|Group 1|
3229956|NCT00985751|Experimental|Group 2|
3229957|NCT00985751|Experimental|Group 3|
3229958|NCT00985751|Experimental|Group 4|
3229959|NCT00985751|Experimental|Control Group|
3229960|NCT00985738|Experimental|Dutasteride|The drug, Dutasteride, will be administered at 0.5 mg dose and given everyday (QD), for 3 months.
3229961|NCT00985738|Placebo Comparator|Placebo|The placebo group will receive a placebo drug for 3 months, instead of the intervention drug, Dutasteride.
3229962|NCT00985725|Experimental|Active|SPD489
3229963|NCT00985725|Placebo Comparator|Placebo|Placebo
3229964|NCT00985712|Experimental|HumaPen Luxura|Participant's insulin dose of Insulin Lispro or Huminsulin Normal is delivered subcutaneously via HumaPen Luxura daily for 24 weeks
3229965|NCT00985712|Experimental|HumaPen Memoir|Participant's insulin dose of Insulin Lispro or Huminsulin Normal is delivered subcutaneously via HumaPen Memoir daily for 24 weeks
3229966|NCT00985686|Experimental|Study Arm|Arm where participants began the LEAP Project intervention upon recruitment for an 8 week period.
3229967|NCT00985686|Active Comparator|Waitlist Arm|"Arm where participants received the LEAP Project intervention after an 8 week wait period.~At 8 weeks, the results from the wait-list arm (no intervention) were compared to the results of the study arm (intervention completed)."
3229968|NCT00985673|Experimental|Flulaval/placebo/unadjuvanted Arepanrix Group|subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
3229969|NCT00985673|Experimental|Flulaval/placebo/Arepanrix Group|subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
3229970|NCT00985673|Experimental|Flulaval/unadjuvanted Arepanrix/placebo Group|subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
3229971|NCT00985673|Experimental|Flulaval/Arepanrix/placebo Group|subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
3229972|NCT00985673|Experimental|Unadjuvanted Arepanrix/placebo/Flulaval Group|subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
3230073|NCT00985023|Experimental|Bioabsorbable screw fixation|
3229973|NCT00985673|Experimental|Arepanrix/placebo/Flulaval Group|subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
3229974|NCT00985660|Experimental|Test:|Nisoldipine ER Tablets, 30 mg
3229975|NCT00985660|Active Comparator|Reference|Sular Extended-release Tablets, 30 mg
3229976|NCT00985647|Active Comparator|3TC 300mg/150mg|Group 1: Participants will be administered 3TC 300 mg once daily orally for 10 days. A 10 day wash‐out period will follow (days 11‐20). From day 21, participants will be administered 3TC 150 mg once daily for 10 days
3229977|NCT00985647|Active Comparator|3TC 150mg/300mg|Group 2: Participants will be administered 3TC 150 mg once daily orally for 10 days. A 10 day wash‐out period will follow (days 11‐20). From day 21, participants will be administered 3TC 300 mg once daily for 10 days
3229978|NCT00985634|Experimental|LeGoo|Subjects in this arm, which is assigned at random, will receive the study device.
3229979|NCT00985634|Active Comparator|Control|Subjects in this arm will not receive the study device, but receive the standard of care for vessel occlusion (vessel loops.)
3229980|NCT00985621|Experimental|1|
3229981|NCT00985621|Experimental|2|
3229982|NCT00985621|Active Comparator|3|
3229983|NCT00985621|Placebo Comparator|4|
3229984|NCT00985608|Active Comparator|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
3229985|NCT00985608|Active Comparator|Group A: NCA 600mg +antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
3229986|NCT00985569||Lubiprostone|Subjects switching from current bowel medicines to lubiprostone
3229987|NCT00985556|Experimental|Arm I|Patients receive oral S-1 twice daily on days 1-14 and oxaliplatin IV over 2 hours on day 1.
3229988|NCT00985556|Experimental|Arm II|Patients receive oral capecitabine twice daily on days 1-14 and oxaliplatin as in arm I.
3229989|NCT00985543|Active Comparator|LPV/r 400/100 mg|Lopinavir/ritonavir 400/100 mg twice daily (2 heat-stable 200/50 mg tablets twice daily (BID))
3229990|NCT00985543|Experimental|LPV/r 200/150 mg|Lopinavir/ritonavir 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID)
3229991|NCT00985543|Experimental|LPV/r 200/50 mg|Lopinavir/ritonavir 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID)
3229992|NCT00985530|Experimental|Arm 1|Tamibarotene + Arsenic Trioxide
3229993|NCT00985517|Experimental|CERE-120|
3229994|NCT00985517|Sham Comparator|Sham Surgery|Neurosurgical procedure that mimics the procedure for CERE-120 delivery. No injections are performed during sham surgery.
3229995|NCT00985504|Experimental|Duloxetine|
3229996|NCT00985504|Active Comparator|Escitalopram|
3229997|NCT00985491|Experimental|Device|All patients will be implanted with the Endobarrier Liner device.
3229998|NCT00985478|Experimental|A|SLV342 suspension or capsule
3229999|NCT00985478|Placebo Comparator|B|matching placebo
3230000|NCT00985465|Experimental|Pn-Pn group|subjects from the Pn-Pn group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in the Malian centre of study NCT00678301, receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A
3230001|NCT00985465|Experimental|Zil-Pn group|subjects from the unprimed group of the NCT00678301 Malian study centre, not previously vaccinated with any pneumococcal vaccine, receiving two doses of pneumococcal conjugate vaccine GSK1024850A
3230002|NCT00985452|Other|Group 2: Intervention|Subjects in Group two will received an activated GlowCaps system, which will remind them to take their medication.
3230003|NCT00985452|Other|Group 3: Intervention/financial incentive|Subjects in group 3 will receive an activated GlowCaps system, which will provide them with reminders to take their medication, Subjects in group 3 will also receive an additional financial incentive, the amount will be based on how often they remembered to take their medication during the 6-month study.
3230004|NCT00985452|Other|Group 1: Control|Subjects in group one will receive a de-activated GlowCaps system, which will not provide the reminder service.
3230005|NCT00985439|Experimental|Diclofenac Test (lower dose)|One 18-mg Diclofenac Test Capsule and 1 placebo capsule
3230006|NCT00985439|Experimental|Diclofenac Test (upper dose)|One 35-mg Diclofenac Test Capsule and 1 placebo capsule
3230007|NCT00985439|Active Comparator|Celecoxib 400 mg|
3230008|NCT00985439|Placebo Comparator|Placebo|
3230009|NCT00985426|Experimental|HEPLISAV and Placebo|0.5 mL HEPLISAV and Placebo
3230010|NCT00985426|Active Comparator|Engerix-B|2.0 mL Engerix-B
3230011|NCT00985400|Experimental|Exercise Program|Arm I (exercise program): Oncologist advice; Resistance bands & pedometer with written/DVD instructions for resistance exercise twice a week for 16 weeks. Brief moderate-intensity walks multiple times a day for a total of 30 minutes increasing steps weekly by 10% to reach a minimum of 10,000 steps a day. Monthly newsletters; Telephone counseling weekly for 4 weeks then monthly for 12 weeks; and tailored message telephone prompts once every 2 weeks during last 12 weeks of the study intervention.
3230012|NCT00985400|Experimental|Relaxation Intervention|Arm II (relaxation program): Oncologist advice; Written/CD audio instructions on diaphragmatic breathing and guided imagery. Practice relaxation techniques for 15 minutes/day, 5-7 days/week, for 16 weeks. Monthly newsletters, telephone counseling, and tailored-message telephone prompts as in arm I.
3230013|NCT00985387||Solifenacin treatment|Male and female OAB patients who were treated with solifenacin
3230014|NCT00985374|Experimental|1|
3230015|NCT00985361|Experimental|Vitamin D 2000 international units daily|
3230016|NCT00985361|Active Comparator|Vitamin C 500mg daily|
3230017|NCT00985348|Experimental|Treatment 1/Treatment 2|
3230018|NCT00985348|Experimental|Treatment 2/Treatment 1|
3230019|NCT00985335|Experimental|External Application of Neem-based Cream|Non Controlled, non-randomized, single group pilot study.
3230020|NCT00985322|Experimental|ACE inhibitor Ramipril|
3230021|NCT00985322|Active Comparator|non-RAS inhibitor antihypertensive therapy|
3230022|NCT00985296||Ragweed+ Dust Mite+ CAC w/ DM|
3230023|NCT00985296||Ragweed + Dust Mite + CAC w/Saline|
3230025|NCT00985283|Experimental|Preventive home visit|receives preventive home visit intervention 4 times over 1 year
3230026|NCT00985283|Active Comparator|comparison group|receives information packets on local services for older adults and health promotion material twice during 1 year
3230027|NCT00985270|Active Comparator|Rifampicin|
3230028|NCT00985270|Placebo Comparator|Placebo|
3230029|NCT00985257|Other|Subjects with diabetes|Subjects with diabetes (or parents/guardians, if applicable)and healthcare professionals (HCPs) use a new blood glucose monitoring system. Subjects were 4 to 24 years of age with type 1 and type 2 diabetes.
3230030|NCT00985244|Active Comparator|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin
3230031|NCT00985244|Placebo Comparator|Placebo|Subjects in this group will receive 3 times a week placebo
3230032|NCT00985231|Experimental|PureVision Multi-Focal contact lenses|
3230033|NCT00985231|Active Comparator|SofLens59 contact lens|
3230034|NCT00985218|Experimental|experimental arm|Embryos cultured in SMART System
3230035|NCT00985218|Active Comparator|Control|Embryos cultured in microdrops in dishes
3230036|NCT00985205|Experimental|Enteral Glutamine|0.5 g/kg/day mixed in water and given via nasogastric or feeding tube as boluses q 4 hrs or TID or QID if po
3230037|NCT00985205|Placebo Comparator|Placebo|Mixed in with water and given via nasogastric or feeding tube as boluses q 4hrs or TID or QID if po
3230038|NCT00985192|Experimental|Everolimus|Patients receive oral everolimus once daily on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity
3230039|NCT00985179|Experimental|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
3230040|NCT00985179|No Intervention|Waiting control group (WCG)|
3230041|NCT00985166|Experimental|1|ProQuad + Placebo
3230042|NCT00985166|Active Comparator|2|M-M-R II + Placebo
3230043|NCT00985166|Active Comparator|3|M-M-R II + Varivax
3230044|NCT00985153|Experimental|1|ProQuad Lot 1
3230045|NCT00985153|Experimental|2|ProQuad Lot 2
3230046|NCT00985153|Experimental|3|ProQuad Lot 3
3230047|NCT00985153|Active Comparator|4|M-M-R II + Varivax
3230048|NCT00985140||12 Gy TSEBT|Prospective assignment to receive 12 Gy total skin electron beam therapy (TSEBT) for mycosis fungoides
3230049|NCT00985127|Experimental|40 mg|40 mg BCX4208
3230050|NCT00985127|Experimental|80 mg|BCX4208
3230051|NCT00985127|Experimental|120 mg|BCX4208
3230052|NCT00985127|Placebo Comparator|sugar pill|
3230053|NCT00985127|Experimental|160mg|BCX4208
3230054|NCT00985127|Experimental|240mg|BCX4208
3230055|NCT00985127|Experimental|320mg|BCX4208
3230056|NCT00985114|Experimental|Device|EndoBarrier implanted for 6 months. Subject followed for 6 months after device was explanted.
3230057|NCT00985114|Active Comparator|Diet + Lifestyle counseling|Multidisciplinary lifestyle and nutritional counseling for 12 months
3230058|NCT00985101||diabetes no complications|
3230059|NCT00985101||diabetes with complications|
3230060|NCT00985088|Experimental|GSK2340274A F1_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 1 (F1) of GSK2340274A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
3230061|NCT00985088|Experimental|GSK2340274A F2_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 2 (F2) of GSK2340274A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
3230062|NCT00985088|Experimental|GSK2340274A F2_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 2 (F2) of GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline placebo at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
3230063|NCT00985088|Experimental|GSK2340274A F1_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 1 (F1) of GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline placebo at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
3230064|NCT00985088|Experimental|GSK2340273A F1_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 1 (F1) of GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
3230065|NCT00985088|Experimental|GSK2340273A F2_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 2 (F2) of GSK2340273A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
3230066|NCT00985088|Experimental|GSK2340273A F2_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 2 (F2) of GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline at Day 21, administered intramuscularly into the deltoid region of the dominant arm. Subjects above (>) 60 years old received an additional dose of Formulation 2 (F2) of GSK2340273A vaccine after Day 42, administered into the deltoid region of the non-dominant arm.
3230067|NCT00985088|Experimental|GSK2340273A F3_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 3 of GSK2340273A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
3230068|NCT00985062|Active Comparator|Mild Ovarian Stimulation|
3230069|NCT00985062|Active Comparator|Conventional Ovarian Stimulation|
3230070|NCT00985036||Glioma|patients who are diagnosed with and are being treated for glioma
3230071|NCT00985036||meningioma|patients who are diagnosed with and are being treated for meningioma
3230072|NCT00985023|Active Comparator|Steel screw fixation|
3230074|NCT00984997|Experimental|Surgery + Radiotherapy + Chemotherapy|"Surgery followed by radiotherapy and chemotherapy started at the beginning of radiotherapy. Segmentectomy or lobectomy with en bloc resection of the involved chest. Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week. Cisplatin 50 mg/M^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.~Etoposide given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29. Prophylactic Cranial Irradiation 25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional."
3230075|NCT00984984|Experimental|methylprednisolone PO|
3230076|NCT00984984|Active Comparator|methylprednisolone IV|
3230077|NCT00984971|Experimental|Tenofovir|
3230078|NCT00984971|Placebo Comparator|HEC Placebo|
3230079|NCT00984971|Other|Open label tenofovir tablet|
3230080|NCT00984958|Other|Bulkamid|Injection with Bulkamid
3230081|NCT00984958|Other|expectance|The expectance arm will after 2 month have the same treatment as the treatment arm
3230082|NCT00984945|Active Comparator|H5 VLP vaccine 5 µg|
3230083|NCT00984945|Active Comparator|H5 VLP vaccine 10 µg|
3230084|NCT00984945|Active Comparator|H5 VLP vaccine 20 µg|
3230085|NCT00984945|Placebo Comparator|Placebo (Formulation buffer)|
3230086|NCT00984932|Experimental|Rosuvastatin|
3230087|NCT00984906|Other|Empty Easyhaler type A|
3230088|NCT00984906|Other|Empty Easyhaler type B|
3230089|NCT00984906|Other|Empty Turbohaler|
3230090|NCT00984893||Zoledronic acid|
3230091|NCT00984893||Oral Bisphosphonates|
3230092|NCT00984880|Experimental|1|Intravenous solution given as a single ascending bolus dose
3230093|NCT00984880|Experimental|2|Intravenous solution given as a single ascending bolus dose followed by a single infusion
3230094|NCT00984867|Active Comparator|1|Dapagliflozin 10 mg tablet
3230095|NCT00984867|Placebo Comparator|2|Matching placebo tablet
3230096|NCT00984854|Experimental|Intradermal Juvidex|
3230097|NCT00984854|Placebo Comparator|Placebo (vehicle)|
3230098|NCT00984841|Experimental|Tailored letter|Patients in the tailored letter group received by mail a tailored letter detailing their diabetes measures, together with enclosed orders for lab tests when due, and reminder of or scheduling for an office appointment.
3230099|NCT00984841|Active Comparator|Usual Care|Patients in the usual care group were part of a practice wide quality improvement process.
3230100|NCT00984828|Experimental|vel 8 - ASCT|8 cycles of velcade with ASCT
3230101|NCT00984828|Active Comparator|vel4 - ASCT|4 cycles of velcade with ASCT
3230102|NCT00984815|Experimental|HZT-501|Open-label treatment with HZT-501
3230103|NCT00984802|Experimental|Low dose|
3230104|NCT00984802|Experimental|Mid Dose|
3230105|NCT00984802|Experimental|High Dose|
3230106|NCT00984802|Placebo Comparator|Placebo|
3230107|NCT00984789|Experimental|Arm 1|
3230108|NCT00984789|Active Comparator|Arm 2|
3230109|NCT00984763|Experimental|Group 1|AMA1-C1/Alhydrogel® + CPG 7909 vaccine given twice two months apart followed by malaria parasite challenge
3230110|NCT00984763|No Intervention|Group 2|Control: malaria parasite challenge without prior vaccinations
3230111|NCT00984750|Experimental|1|Statin and acetyl-L-carnitine
3230112|NCT00984750|Placebo Comparator|2|Statin and placebo
3230113|NCT00984724|Experimental|Standard Treatment|Standard Treatment (ST): Mailed Packet with standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months). Referral to Quitline.
3230114|NCT00984724|Experimental|MAPS-6|Standard Treatment (ST) plus 6 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 6 MAPS proactive telephone counseling sessions over 2-year period.
3230115|NCT00984724|Experimental|MAPS-12|Standard Treatment (ST) plus 12 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 12 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline.
3230116|NCT00984724|Experimental|Standard Treatment + NRT|Standard Treatment (ST): Mailed Packet with standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months). Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
3230117|NCT00984724|Experimental|MAPS-6 + NRT|Standard Treatment (ST) plus 6 proactive telephone counseling sessions; delivered 4 times (at Baseline, 6, 12, and 18 months). 6 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline. Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
3230118|NCT00984724|Experimental|MAPS-12 + NRT|Standard Treatment (ST) plus 12 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 12 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline. Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
3230119|NCT00984698|Experimental|Structured Therapy|Cognitive Behavioral Social Rhythm Group Therapy is designed to improve mood and sleep by stabilizing social rhythms, increasing exposure to ambient light, changing dysfunctional bed/bedtime associations, activating the imagery system by changing nightmare content, and challenging dysfunctional automatic thoughts that might contribute to behavioral inactivation and nonadherence to the therapy protocol. There is no discussion of past traumatic events.
3230120|NCT00984698|Active Comparator|Unstructured Therapy|Present Centered Group Therapy includes education about the typical symptoms and features associated with PTSD and MDD, with a focus on how these symptoms affect interpersonal relationships. It uses the group format to decrease isolation, normalize symptoms, and provide the experience of giving and receiving support. Some relaxation training is provided early in therapy. There is no discussion of past traumatic events.
3230121|NCT00984685||depression|Patients diagnosed with depression before April 15, 2009
3230122|NCT00984672||Bone morphogenetic protein within an interbody cage|Transforaminal Lumbar Interbody Fusion with the use of BMP
3230123|NCT00984672||Other bone grafting techniques within cage (non-BMP)|Use of iliac crest autograft, allograft, or local autogenous bone grafting within the cage during Transforaminal Lumbar Interbody Fusion.
3230124|NCT00984659|Experimental|FSC|Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day
3230125|NCT00984659|Experimental|SAL|Salmeterol 50mcg DISKUS twice a day
3230126|NCT00984659|Placebo Comparator|Placebo|Placebo DISKUS twice a day
3230127|NCT00984646|Experimental|Intradermal Prevascar|
3230128|NCT00984646|Placebo Comparator|Placebo (vehicle)|
3230129|NCT00984633|Experimental|0.6 mg/kg intubation dose + sevoflurane|
3230130|NCT00984633|Experimental|0.9 mg/kg intubation dose + sevoflurane|
3230131|NCT00984633|Experimental|0.6 mg/kg intubation dose + propofol|
3230132|NCT00984633|Experimental|0.9 mg/kg intubation dose + propofol|
3230133|NCT00984620|Experimental|short arm|patients to receive BI201335 with PegIFN/RBV for 12 wks followed by 12 weeks PegIFN/RBV with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)
3230134|NCT00984620|Experimental|long arm|patients to receive BI201335 with PegIFN/RBV for 24 wks with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)
3230135|NCT00984607|Experimental|barium sulfate tablet|After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring.
3230136|NCT00984594|Other|Primary injury site|CR-Plug will be placed in the site of the primary injury
3230137|NCT00984594|Other|Backfill site|Autograft will be placed in the site of the primary injury; CR Plug will be placed in the harvest site
3230138|NCT00984581|Experimental|Intradermal avotermin|
3230139|NCT00984581|Placebo Comparator|Placebo|
3230140|NCT00984568|Experimental|Top-Hold|Level 1: Infliximab IV 5 mg/kg at Weeks 0, 2, and 6, and every 8 weeks thereafter. Level 2: Infliximab IV 5 mg/kg every 4 weeks. Level 3: Prednisolone induction + AZA 2.0-2.5 mg/kg/day.
3230141|NCT00984568|Active Comparator|Step-Up|Level 1: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral 5-aminosalicylic acid (5-ASA) 2 g/day. Level 2: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral azathioprine (AZA) at a dose of 2.0-2.5 mg/kg/day. Level 3: Infliximab 5 mg/kg at Weeks 0, 2, and 6 and every 8 weeks thereafter.
3230142|NCT00984555||A1 (Inoculation with 7 timepoints)|Semen exposure via inoculation, Vaginal swabs at 7 time points
3230143|NCT00984555||A2 (Inoculation with 4 timepoints)|Semen exposure via inoculation, Vaginal swabs at 4 time points
3230144|NCT00984555||B1 (intercourse with 7 timepoints)|Semen exposure via unprotected intercourse, Vaginal swabs at 7 time points
3230145|NCT00984555||B2 (Intercourse with 4 timepoints)|Semen exposure via unprotected intercourse, Vaginal swabs at 4 time points
3230146|NCT00984542|Experimental|Bendamustine|
3230147|NCT00984529||1|Cardiologist´s office patients
3230148|NCT00984516|Experimental|Intradermal Juvidex|
3230149|NCT00984516|Placebo Comparator|Placebo (vehicle)|
3230150|NCT00984503|Experimental|Intradermal Juvista|
3230151|NCT00984503|Placebo Comparator|Placebo|
3230152|NCT00984503|Experimental|Intradermal and topical Juvista|
3230153|NCT00984503|Placebo Comparator|Intradermal and topical placebo|
3230154|NCT00984490|Experimental|Metformin|Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery
3230155|NCT00984477|Experimental|1|AZD5122 oral suspension (part A and B)
3230156|NCT00984477|Placebo Comparator|2|Placebo oral suspension (part A)
3230157|NCT00984477|Experimental|3|AZD5122 oral and IV infusion (part B)
3230158|NCT00984438|Experimental|BCNU wafter followed by chemotherapy|Surgical Implantable BCNU wafer followed by Chemotherapy with Irinotecan and Bevacizumab for up to one year
3230159|NCT00984425|Experimental|Lapatinib and Sorafenib 1° level of dose|Lapatinib 750 mg/die + Sorafenib 200 mg bid
3230160|NCT00984425|Experimental|Lapatinib and Sorafenib 2° level of dose|2° level (II cohort): Lapatinib 1000 mg/die + Sorafenib 200 mg bid
3230161|NCT00984425|Experimental|Lapatinib and Sorafenib 3° level of dose|3° level (III cohort): Lapatinib 1000 mg/die + Sorafenib 400 mg bid
3230162|NCT00984425|Experimental|Lapatinib and Sorafenib 4° level of dose|4° level (IV cohort): Lapatinib 1250 mg/die + Sorafenib 400 mg bid
3230163|NCT00984412|Experimental|AATT|
3230164|NCT00984399|Experimental|vaginal 17β-estradiol, questionnaire , symptom checklist|This is a prospective longitudinal pilot study, and the targeted patient population is postmenopausal women with breast cancer being treated with adjuvant aromatase inhibitors who are initiated on vaginal 17β-estradiol to relieve symptoms of atrophic vaginitis.
3230165|NCT00984386|Experimental|Intradermal Zesteem|
3230166|NCT00984386|Placebo Comparator|Placebo|
3230167|NCT00984360|Experimental|A118G|
3230168|NCT00984360|Experimental|Wild-type|
3230169|NCT00984347|Active Comparator|Oxytocin induction|women in need for induction of labor due to medical indications, will receive continuous IV oxytocin
3230170|NCT00984347|Active Comparator|Breast Stimultion|nipple stimulation with a breast pump, calibrated at the lowest suction strength,operated alternately: 15 min one breast, 15 min second breast, 15 min rest, till appearance of regular uterine contractions (3 contractions in 10 min). the manipulation will continue for 3 hours of regular contractions.
3230171|NCT00984334|Placebo Comparator|Capsules with no active drug|Placebo capsules once daily for three weeks then twice daily for three weeks.
3230172|NCT00984334|Active Comparator|Naloxone SR 2.5 mg capsules|Naloxone SR 2.5 mg capsules once daily for three weeks then twice daily for three weeks.
3230173|NCT00984334|Experimental|Naloxone SR 10mg capsules|Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
3230174|NCT00984334|Experimental|Naloxone SR 20 mg capsules|Two Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
3230175|NCT00984334|Experimental|Naloxone SR 5mg capsules|Naloxone SR 5 mg capsules once daily for three weeks then twice daily for three weeks.
3230176|NCT00984321|Experimental|Psychoeducational Intervention Group|
3230177|NCT00984321|Experimental|Expressive Writing Intervention|
3230178|NCT00984321|Active Comparator|Control Group|
3230179|NCT00984308|Experimental|Intervention|The intervention group received unattended polysomnography and auto-titrating CPAP if sleep apnea was diagnosed
3230180|NCT00984308|Other|Control|The control group received usual clinical care which may include receipt of sleep diagnostic and therapeutic services
3230181|NCT00984295|Experimental|1|ProQuad + Tripedia + Comvax at Day 0 (Concomitant)
3230182|NCT00984295|Experimental|2|ProQuad at Day 0, Tripedia + Comvax at Day 42(Nonconcomitant)
3230183|NCT00984295|Active Comparator|3|Varivax + M-M-R II at Day 0, Tripedia + Comvax at Day 42 (Control)
3230184|NCT00984282|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (12 hours apart without food), 28 days comprise a cycle
3230185|NCT00984282|Placebo Comparator|Placebo|Participants received 2 tablets of Sorafenib-matching placebo orally twice daily (12 hours apart without food), 28 days comprise a cycle
3230186|NCT00984269|No Intervention|No Tourniquet|Patients undergoing hand/wrist surgery without the use of a tourniquet.
3230187|NCT00984269|Experimental|Tourniquet|Patients undergoing hand/wrist surgery with the use of a tourniquet.
3230188|NCT00984256|Experimental|Drug|"5 groups, each group receiving Malarone tablet(s) (250/100mg)prior to challenge.~Group 1 - 1 tablet 1 day before challenge Group 2 - 1 tablet 4 days before challenge Group 3 - 1 tablet 7 days before challenge Group 4 - 2 tablets 7 days before challenge Group 5 - 4 tablets 7 days before challenge"
3230189|NCT00984256|Placebo Comparator|Control -no prophylaxis|
3230190|NCT00984243|Experimental|Photodynamic Therapy|PHOTODYNAMIC THERAPY (PDT)
3230191|NCT00984230|No Intervention|Breastfeeding (Reference)|
3230192|NCT00984230|Active Comparator|Basic starter formula: BSF|
3230193|NCT00984230|Experimental|BSF + Lactoferrin + Probiotics + OS|
3230194|NCT00984230|Experimental|BSF + Lactoferrin + Probiotics|
3230195|NCT00984217|Experimental|Panitumumab|Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-8 doses).
3230196|NCT00984204|Experimental|Treatment arm|
3230197|NCT00984191|Experimental|99mTc positive|99mTechnetium-MIBI SPECT-CT positive compare : Scan - Pathologic report
3230198|NCT00984191|Experimental|99mTc Negative_Neck dissection|99mTc Negative but have neck dissection indication compare : 99mTc - Pathologic report
3230199|NCT00984191|Experimental|99mTc Negative_No neck dissection|99mTc Negative and No other indication for neck dissection compare : 99mTc - 7. 131I (post-treatment) whole body scan
3230200|NCT00984178|No Intervention|Control group|standard treatment
3230201|NCT00984178|Experimental|Bone marrow mononuclear progenitors|intracoronary transplantation of bone-marrow mononuclear progenitor cells
3230202|NCT00984178|Experimental|GCSF|progenitor cells mobilization through Granulocite- Colony Stimulating Factor treatment (G-CSF)
3230203|NCT00984178|Experimental|GCSF plus bone marrow mononuclear cells|combined treatment (intracoronary transplantation plus cell mobilization with G-CSF).
3230204|NCT00984165|Experimental|Donor Lymphocyte Infusion/Radiation|Subjects will receive a unmanipulated donor lymphocyte infusion (DLI) on Day 1 after radiation (single, 8-Gy fraction to the maximum number of lesions).
3230205|NCT00984165|Active Comparator|Radiation/No Donor Lymphocyte Infusion|Subjects will receive radiation (single, 8-Gy fraction to the maximum number of lesions).
3230206|NCT00984165|Active Comparator|Donor Lymphocyte Infusion - Control|Subjects will receive a unmanipulated donor lymphocyte infusion (DLI) on Day 0.
3230207|NCT00984165|Active Comparator|Donor Lymphocyte Infusion - Donor|Healthy subjects who donated lymphocytes for infusion on a treatment Arm.
3230208|NCT00984152|Active Comparator|1|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
3230209|NCT00984152|Active Comparator|2|TDF/FTC + Efavirenz (Atripla) Once-Daily
3230210|NCT00984139|Experimental|Engerix-B Group|Subjects who were vaccinated with 3 doses of Engerix-B in infancy and who received a single challenge dose of Engerix-B , intramuscularly in the deltoid region of the non-dominant arm, at 12-13 years of age (Day 0).
3230211|NCT00984126|Experimental|Turoctocog alfa|
3230212|NCT00984113|Experimental|A-Patients with mild renal impairment|
3230213|NCT00984113|Experimental|B-Healthy subjects matched to Group A|
3230214|NCT00984113|Experimental|C-Patients with moderate renal impairment|
3230215|NCT00984113|Experimental|D-Healthy subjects matched to Group C|
3230216|NCT00984113|Experimental|E-Patients with severe renal impairment|
3230217|NCT00984113|Experimental|F-Healthy subjects matched to Group E|
3230218|NCT00984100|Experimental|Notes Transvaginal Cholecystectomy|Patients who undergo a NOTES Transvaginal cholescystectomy.
3230219|NCT00984087|Experimental|Active rTMS treatment|
3230220|NCT00984061|Experimental|colchicine alone|colchicine baseline pharmacokinetics
3230221|NCT00984061|Experimental|colchicine with clarithromycin|colchicine pharmacokinetics in presence of clarithromycin
3230222|NCT00984048||FOLFOX, XELOX or FOLFIRI +/- bevacizumab|Patients are scheduled to receive first-line treatment for metastatic disease. They should be receiving at least one component of either FOLFOX, XELOX or FOLFIRI regimen with or without bevacizumab.
3230223|NCT00984035||Prospecitive Analysis|Patients currently receiving cisplatin as treatment for their cancer.
3230224|NCT00984035||Restrospective Analysis|Patients that have previously received cisplatin as treatment for their cancer.
3230225|NCT00984022|Active Comparator|Iodoform dressing|Iodoform dressing for cutaneous abscess
3230226|NCT00984022|Active Comparator|Aquacel dressing|Aquacel dressing for cutaneous abscess
3230227|NCT00984009|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
3230228|NCT00984009|Experimental|Colchicine with Grapefruit Juice|colchicine pharmacokinetics in presence of grapefruit juice
3230229|NCT00983996|Experimental|1|Alendronate Sodium Tablets, 10 mg
3230230|NCT00983996|Active Comparator|2|Fosamax Tablets, 10 mg
3230231|NCT00983983|Experimental|High fat/high calorie|High fat/high calorie diet: Oxepa
3230232|NCT00983983|Active Comparator|High calorie|High calorie diet: Jevity 1.5
3230233|NCT00983983|Placebo Comparator|Control|Control diet: Jevity 1.0
3230274|NCT00983697|Experimental|FDG PET/CT|Planning for Therapeutic conventional surgery of the N0 neck is documented prior to and immediately after review of the fludeoxyglucose F 18 (FDG)-PET/CT scan completed per protocol.
3230332|NCT00983437|Experimental|Armodafinil|Armodafinil tablets 150 mg or 250 mg administered orally, once daily in the morning.
3230234|NCT00983970|Experimental|Interactive video cycling|Interactive video cycling arm utilized the Gamebike that interfaced a Sony Play Station 2 with a stationary bicycle and a 42 inch flat screen TV. The Gamebike has a handle bar mounted game controller allowing the participant to play most Sony Play Station 2 raced-based video games. The Gamebike reads the participants' speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks.Participants were told that they could exercise at any intensity or duration that they desired, and reading materials were provided for those who did not chose to exercise for the full 60 minute session.
3230235|NCT00983970|Active Comparator|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device.
3230236|NCT00983957|Experimental|BMS-790052 plus Ortho Tri-Cyclen®|
3230237|NCT00983944|Experimental|Arm I (EPOCH-R)|Patients receive rituximab IV on day 1; etoposide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV continuously over 96 hours on days 1-4; cyclophosphamide IV over 30 minutes on day 5; and oral prednisone twice daily on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3230238|NCT00983944|Experimental|Arm II (R-VACOP-B)|Patients receive rituximab IV and doxorubicin hydrochloride IV on day 1 of weeks 1, 3, 5, 7, 9, and 11; cyclophosphamide IV over 30 minutes on day 1 of weeks 1, 5, and 9; etoposide IV over 1 hour on day 1 and then orally on days 2 and 3 of weeks 3, 7, and 11; bleomycin sulfate IV and vincristine sulfate IV on day 1 of weeks 2, 4, 6, 8, 10, and 12; and oral prednisone on days 1-7 of week 1 and then every other day in weeks 2-10.
3230239|NCT00983931|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
3230240|NCT00983931|Experimental|Colchicine with Cyclosporine|-colchicine pharmacokinetics in presence of cyclosporine
3230241|NCT00983918|Active Comparator|Desflurane|General Anesthesia with Desflurane
3230242|NCT00983918|Active Comparator|Sevoflurane|General Anesthesia with Sevoflurane
3230243|NCT00983918|Active Comparator|Isoflurane|General Anesthesia with Isoflurane
3230244|NCT00983918|Active Comparator|Propofol|General Anesthesia with Propofol
3230245|NCT00983905|Active Comparator|Theophylline alone|baseline theophylline kinetics
3230246|NCT00983905|Experimental|Theophylline with steady-state Colchicine|theophylline pharmacokinetics upon administration with colchicine at steady-state
3230247|NCT00983892|Experimental|CarePartners+|Patients receive automated telephonic symptom assessment and symptom management advice; caregivers receive the intervention (Intervention = access to a caregiver Web site that updates them on patient's symptoms and provides tailored problem solving advice).
3230248|NCT00983892|No Intervention|CarePartners-|Patients receive automated telephonic symptom assessment and symptom management advice; caregivers receive nothing (i.e. no access to the caregiver website, or 'intervention').
3230249|NCT00983866|Experimental|Tailored Telephone Counseling|
3230250|NCT00983866|No Intervention|Standard Trial Recruitment Procedures|
3230251|NCT00983853|Experimental|Part A|The dose of ribavirin used (fixed versus weight-based) is region dependent
3230252|NCT00983853|Experimental|Part B|The dose of ribavirin used (fixed versus weight-based) is region dependent
3230253|NCT00983840|Experimental|Family Eats|8-session program on health eating
3230254|NCT00983840|Active Comparator|Family eats- plain|Family eats without role model stories and goal setting
3230255|NCT00983827|Experimental|Aquatic treadmill training|Aquatic treadmill training (ATT) is a pool-based treadmill training that combines the three concepts of unweighting the body, treadmill training, and the resistance effects of water into one modality.
3230256|NCT00983814|Experimental|Droxidopa+Carbidopa|Droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) in combination with carbidopa (25mg or 50mg TID)
3230257|NCT00983814|Placebo Comparator|Placebo|Placebo
3230258|NCT00983801|Experimental|Ixabepilone|
3230259|NCT00983788|Experimental|Bezafibrate|
3230260|NCT00983788|Placebo Comparator|Placebo|
3230261|NCT00983775|Experimental|healthy low dose insulin|16 healthy non-diabetic volunteers. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight.
3230262|NCT00983775|Experimental|healthy high dose insulin|16 healthy non-diabetic volunteers. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight.
3230263|NCT00983775|Experimental|type 1 diabetes mellitus|16 people with type 1 diabetes mellitus. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight.
3230264|NCT00983762||MIS knee arthroplasty|Persons scheduled for Minimally Invasive Surgery Mini-Incision (MIS) Total Knee Arthroplasty (TKA)
3230265|NCT00983762||Unicompartmental knee arthroplasty|Persons scheduled for Unicompartmental knee arthroplasty
3230266|NCT00983762||Standard knee arthroplasty|Persons scheduled for Standard Para-patellar surgery TKA
3230267|NCT00983762||Heathly knee subjects|Persons with healthy knees
3230268|NCT00983749|Experimental|Full-pressure ECP|"Patients in the Full-pressure ECP arm receive a 1-hour treatment of ECP at full pressure, which will be applied in a tiered, dose-escalating manner up to 300mmHg, while assessments are made."
3230269|NCT00983749|Sham Comparator|Sham-pressure ECP|A 1-hour treatment of ECP at an inactive pressure (75mmHg)
3230270|NCT00983736|Experimental|Active|
3230271|NCT00983736|Placebo Comparator|Placebo|
3230272|NCT00983710|Experimental|1|Participants will receive a new patient education program designed to help men manage side-effects related to treatment for localized prostate cancer. The intervention will be targeted to low health literacy men.
3230273|NCT00983710|Active Comparator|2|Usual care, including a booklet on coping with localized prostate cancer. After the 6-month primary outcome data are collected, control group men will be offered the opportunity to cross-over and receive the new educational intervention.
3230331|NCT00983450|Experimental|CONTROL|People after a first ischemic or hemorrhagic stroke, up to 60 days following the event.
3230275|NCT00983684|Experimental|Intra-operative radiotherapy|A single fraction of radiotherapy given intra-operatively and targeted to the tissues at the highest risk of local recurrence.
3230276|NCT00983684|Active Comparator|Post-operative radiotherapy|Standard post-operative radiotherapy.
3230277|NCT00983671||children with asthma|children with diagnosed asthma, age 6-18 years
3230278|NCT00983671||cystic fibrosis|children with cystic fibrosis, age 6-18 years
3230279|NCT00983671||chronic lung disease|children with chronic lung disease, also known as bronchopulmonary dysplasia, age 6-18 years
3230280|NCT00983671||pneumonia|children with clinical signs of pneumonia, age 6-18 years
3230281|NCT00983658|Experimental|huMAb OX40L|
3230282|NCT00983658|Placebo Comparator|Placebo|
3230283|NCT00983645|Active Comparator|Neoral|Neoral is a pill indicated for the prophylaxis of organ rejection in kidney transplants
3230284|NCT00983645|Active Comparator|Prograf|Prograf is a medication used for the prophylaxis of rejection in allogeneic kidney transplants and may be used concomitantly with adrenal corticosteroids.
3230285|NCT00983632|Experimental|vagus stimulation|electrical vagus stimulation to X.nerve on neck
3230286|NCT00983619|Experimental|Dose Escalation: Cohort 1 (FL/MM)|Subjects are dosed with Dose level 1 of active drug.
3230287|NCT00983619|Experimental|Dose Escalation: Cohort 2 (FL/MM)|Subjects will be dosed with Dose level 2 of active drug.
3230288|NCT00983619|Experimental|Dose Esc: Cohort 3 (FL/MM/CLL/DLBCL)|Subjects will be dosed with dose level 3 of active drug.
3230289|NCT00983619|Experimental|Dose Escalation: Cohort 4 (CLL/DLBCL/FL)|Subjects will be dosed with dose level 4 of active drug.
3230290|NCT00983619|Experimental|Dose Esc: Cohort 5 (FL/MM/CLL/DLBCL)|Subjects will be dosed with dose level 5 of active drug.
3230291|NCT00983619|Experimental|Dose Esc: Cohort 6 (FL/MM/CLL/DLBCL)|Subjects will be dosed with dose level 6 of active drug.
3230292|NCT00983619|Experimental|Dose Expansion: Cohort 7 (FL)|Subjects will be dosed with MTD or OBD determined for FL.
3230293|NCT00983619|Experimental|Dose Expansion: Cohort 8 (CLL)|Subjects will be dosed with MTD or OBD determined for CLL.
3230294|NCT00983619|Experimental|Dose Expansion: Cohort 9 (DLBCL)|Subjects will be dosed with MTD or OBD determined for DLBCL.
3230295|NCT00983619|Experimental|Dose Escalation: Cohort 10 (CLL)|Subjects will be dosed with Dose Level 1 of active drug for CLL dose escalation.
3230296|NCT00983619|Experimental|Dose Escalation: Cohort 11 (CLL)|Subjects will be dosed with Dose Level 2 of active drug for CLL dose escalation.
3230297|NCT00983619|Experimental|Dose Expansion: Cohort 12 (CLL)|Subjects will be dosed with Dose Level 3 of active drug for CLL dose escalation.
3230298|NCT00983619|Experimental|Dose Expansion: Cohort 13 (CLL)|Subjects will be dosed with Dose Level 4 of active drug for CLL dose escalation.
3230299|NCT00983619|Experimental|Dose Expansion: Cohort 14 (CLL)|Subjects will be dosed based on the MTD identified in the dose escalation CLL phase (Cohorts 10-13)
3230300|NCT00983619|Experimental|Dose Esc: Cohort 15 (Agressive Lymphoma)|Subjects are dosed with dose level 1 of active drug and 375 mg/m2 of rituximab.
3230301|NCT00983619|Experimental|Dose Esc: Cohort 16 (Agressive Lymphoma)|Subjects are dosed with dose level 2 of active drug and 375 mg/m2 of rituximab.
3230302|NCT00983619|Experimental|Dose Exp: Cohort 17 (Agressive Lymphoma)|Subjects are dosed with MTD identified in the dose escalation phase (Cohorts 15-16) and 375 mg/m2 of rituximab.
3230303|NCT00983619|Experimental|anti-CD20 Refract Aggressive Lymphoma Cohort 18|Subject will be dosed based on MTD identified in dose escalation (Cohorts 1-6)
3230304|NCT00983606||1|32 to 35 WGA Infants less than six months of age by RSV season peak.
3230305|NCT00983593|Experimental|Group Therapy|Group therapy following the Mind-Body Bridging program.
3230306|NCT00983580|Experimental|Arm I (acetylsalicylic acid and eflornithine)|Patients receive acetylsalicylic acid PO once daily and eflornithine PO twice daily on days 1-28.
3230307|NCT00983580|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO three times daily on days 1-28.
3230308|NCT00983567|Experimental|Teen web|Main web - with all components
3230309|NCT00983567|Active Comparator|Minimal teen web|Teen web minus behavioral components
3230310|NCT00983554|No Intervention|Placebo|
3230311|NCT00983554|Experimental|Anastrazole and Testosterone|
3230312|NCT00983554|Experimental|Dutasteride and Testosterone|
3230313|NCT00983554|Experimental|Testosterone|
3230314|NCT00983541|Experimental|All patients|All participants enrolled.
3230315|NCT00983515|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
3230316|NCT00983515|Experimental|Colchicine with Ritonavir|-colchicine pharmacokinetics in presence of steady-state ritonavir
3230317|NCT00983502||Integrative Medicine|Patients of MD practitioners trained in Complementary and Alternative Medicine
3230318|NCT00983502||Naturopath Doctors|Patients of practitioners who are not MD's and are trained in Naturopathic Medicine
3230319|NCT00983502||Chronic Fatigue Specialists|Patients of MD's who specialize in treating Chronic Fatigue and related conditions
3230320|NCT00983502||Control Group|Patients treated by primary care MDs in practice-based research networks
3230321|NCT00983489|Active Comparator|counselling|counselling: Breast feeding counselling will be done to mothers
3230322|NCT00983489|Active Comparator|Video demonstration|Video demonstration to mothers on the advantages of exclusive breast feeding
3230323|NCT00983489|No Intervention|Standard Care|Standard care includes the routine care provided to the neonates as per hospital protocol
3230324|NCT00983476|Experimental|Arm 1|in-person MOVE! SMI
3230325|NCT00983476|Experimental|Arm 2|web-based MOVE! SMI
3230326|NCT00983476|No Intervention|Arm 3|usual care + educational handouts regarding weight loss
3230327|NCT00983463||Obese, bariatric surgery, liver biopsy|Obese subjects approved and scheduled for bariatric surgery at Vanderbilt University Medical Center
3230328|NCT00983463||Normal BMI, abdominal surgery, liver biopsy|Normal weight subjects having elective abdominal surgery at Vanderbilt University Medical Center.
3230329|NCT00983463||Liver transplantation donors and recipients|All livers made available for implantation or explantation will be eligible.
3230330|NCT00983450|Experimental|study group|People after a first ischemic or hemorrhagic stroke, up to 60 days following the event.
3230333|NCT00983424|Experimental|Treatment arm|Cyclosporine A + nab-paclitaxel
3230334|NCT00983411||Healthy and OHS subjects|10 healthy subjects: 20 to 60 years old 10 patients with Obesity hypoventilation syndrome: 20 to 70 years old treated with nocturnal non invasive ventilation for at least three months.
3230335|NCT00983398|Experimental|Treatment (mannitol, melphalan, carboplatin, STS)|Patients receive mannitol IA over 30 seconds, melphalan IA over 10 minutes, and carboplatin IA over 10 minutes. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats every 4-6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3230336|NCT00983385|Experimental|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol IR tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
3230337|NCT00983372|Active Comparator|Colchicine alone|-colchicine baseline pharmacokinetics
3230338|NCT00983372|Experimental|Colchicine with steady-state Diltiazem|-colchicine pharmacokinetics in presence of steady-state diltiazem
3230339|NCT00983359|Experimental|Treatment (conformal stereotactic radiation therapy)|Patients undergo conformal stereotatic radiation
3230340|NCT00983346|Experimental|All patients|All participants enrolled.
3230341|NCT00983333|Experimental|Web-based communication tool for health care professionals|
3230342|NCT00983333|Experimental|Web-based communication training tool for patients|
3230343|NCT00983333|No Intervention|Usual care for patient participants|
3230344|NCT00983320|Experimental|medication|quetiapine
3230345|NCT00983320|Placebo Comparator|placebo|placebo
3230346|NCT00983307|Experimental|Erlotinib and radiotherapy|Patients will be treated with Erlotinib and hypofractionated radiotherapy.
3230347|NCT00983294|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
3230348|NCT00983294|Experimental|Colchicine with steady-state Azithromycin|colchicine pharmacokinetics in presence of steady-state azithromycin
3230349|NCT00983281||Hextend|Patients that received Hextend as part of their fluid resuscitation.
3230350|NCT00983281||Standard of Care|Patients that received standard fluid resuscitation but no Hextend.
3230351|NCT00983268|Experimental|Treatment Arm|
3230352|NCT00983255|Experimental|SAD/ Part A|Single IV infusions of placebo or TR-701 FA given at 50, 100, 200, and 400 mg.
3230353|NCT00983255|Experimental|MAD / Part B|Multiple IV infusion of placebo or TR-701 FA given daily for 7 days at 200 and 400 mg.
3230354|NCT00983255|Experimental|Bioavailability / Part C|TR-701 FA tablet given once orally as a 200 mg tablet or TR-701 FA for injection given once as a 200 mg IV infusion.
3230355|NCT00983255|Experimental|Venous Tolerability/ Part D|IV infusions of placebo and 200 mg TR-701 FA given daily for 3 days,
3230356|NCT00983242|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
3230357|NCT00983242|Experimental|Colchicine with Verapamil HCl ER|colchicine pharmacokinetics in presence of steady-state verapamil
3230358|NCT00983229|Active Comparator|CTrach|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~Insertion of CTrach (sizes 3,4 or 5), establishment of ventilation.~Direct evaluation of laryngeal view through CTrach~Tracheal intubation through CTrach LMA~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
3230359|NCT00983229|Active Comparator|Intubating Laryngeal Mask Airway (ILMA)|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~Insertion of ILMA (sizes 3,4 or 5), establishment of ventilation.~Evaluation of laryngeal view through ILMA using fibrescope~Tracheal intubation through ILMA using fibrescope.~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
3230360|NCT00983229|Active Comparator|I-gel|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~Insertion of I-gel (sizes 3,4 or 5), establishment of ventilation.~Evaluation of laryngeal view through I-gel using fibrescope~Tracheal intubation through I-gel using fibrescope~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
3230361|NCT00983216|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
3230362|NCT00983216|Experimental|Colchicine with Steady-State Ketoconazole|-colchicine pharmacokinetics in presence of steady-state ketoconazole
3230363|NCT00983203|Experimental|FID 114657|FID 114657
3230364|NCT00983203|Active Comparator|Soothe XP Lubricant Eye Drops|Soothe XP Lubricant Eye Drops
3230365|NCT00983190|Other|Single Group Assignment|
3230366|NCT00983177|Active Comparator|colchicine|
3230367|NCT00983177|Placebo Comparator|Lactose capsule|
3230368|NCT00983164|No Intervention|group I|group I - controls
3230369|NCT00983164|Experimental|group II|group II - patients with hepatitis C without treatment
3230370|NCT00983164|Experimental|group III|group III - patients with hepatitis C treated weekly with pegylated interferon combined with daily ribavirin
3230371|NCT00983151|Experimental|Active|
3230372|NCT00983151|Placebo Comparator|Placebo|
3230373|NCT00983138|Experimental|recombinant asparaginase|
3230374|NCT00983125|Experimental|clonidine|
3230375|NCT00983125|Other|no clonidine|
3230376|NCT00983112|Experimental|Evicel|
3230377|NCT00983112|Placebo Comparator|Placebo|
3230431|NCT00982657|Experimental|Phase II - Arm A|CVX-060 + sunitinib
3230432|NCT00982657|Active Comparator|Phase II - Arm B|sunitinib alone
3230433|NCT00982644|Experimental|IDeg OD|
3230378|NCT00983073|Experimental|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol IR tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
3230379|NCT00983060|Experimental|NIM811|
3230380|NCT00983060|Placebo Comparator|Placebo|
3230381|NCT00983047|Active Comparator|Docetaxel|The chemotherapy treatment:Docetaxel was administered every 3 weeks 75mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\PR\SD. No more than 4 cycles chemotherapy was given.
3230382|NCT00983047|Experimental|Nimotuzumab and Docetaxel|"The chemotherapy treatment:Docetaxel was administered every 3 weeks 75mg/m2,efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\PR\SD.No more than 4 cycles chemotherapy was given.~Nimotuzumab treatment:Dose of 200mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxic."
3230383|NCT00983034|Active Comparator|Membranous nephropathy|Patients with primary membranous nephropathy diagnosed by biopsy
3230384|NCT00983034|Active Comparator|IgA nephropathy|Patients with IgA nephropathy diagnosed by biopsy
3230385|NCT00983034|Active Comparator|Focal segmental glomerulosclerosis|Patients with primary focal segmental glomerulosclerosis diagnosed by biopsy
3230386|NCT00983021|Experimental|A|
3230387|NCT00983021|Experimental|B|
3230388|NCT00983021|Active Comparator|C|
3230389|NCT00983021|Experimental|D|
3230390|NCT00983008|Experimental|Protected Time Group|Interns working 30 hour shifts every 3rd night and an average of 80 hours per week in a medical intensive care unit.
3230391|NCT00982995|Experimental|Palonosetron|Palonosetron 0.25 mg I.V. bolus
3230392|NCT00982982|Active Comparator|THC and Iomazenil|"Iomazenil: 3.7 μg/kg intravenously over 10 minutes~Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. It is administered intravenously for 10 minutes"
3230393|NCT00982982|Placebo Comparator|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
3230394|NCT00982969||TB suspected|Soldiers who are clinically suspected with tuberculosis
3230395|NCT00982930|Experimental|TIPnew|
3230396|NCT00982917|Experimental|teachers taught curriculum|Teachers taught Stamp-in-Safety curriculum
3230397|NCT00982917|Experimental|teachers do not learn curriculum|Teachers are not taught Stamp-in-Safety curriculum
3230398|NCT00982904|Experimental|Fexinidazole|
3230399|NCT00982904|Placebo Comparator|Placebo|
3230400|NCT00982891|Experimental|Morphine, low dose, in addition to conventional treatment|Morphine dose titration
3230401|NCT00982878|Experimental|Maraviroc|
3230402|NCT00982865|Experimental|MSC1936369B Regimen 1|Orally once daily on Days 1 to 5, 8 to 12 and 15 to 19 of a 21-day cycle.
3230403|NCT00982865|Experimental|MSC1936369B Regimen 2 and Regimen 2 Food Effect|"Orally once a day on Days 1 to 15 of a 21-day cycle.~Orally once a day from Day 1 to 21."
3230404|NCT00982865|Experimental|MSC1936369B Regimen 3 once daily|Orally once a day from Day 1 to 21.
3230405|NCT00982865|Experimental|MSC1936369B Regimen 3 twice daily|Orally twice a day from either Days 1 to 15 of a 21-day cycle (similar to Regimen 2) or up to Day 21 (similar to Regimen 3).
3230406|NCT00982852||Acute|Patients in acute need for angioplasty or left heart catheterization.
3230407|NCT00982852||Chronic or non-acute|Patients will planned angioplasty or left heart catheterization.
3230408|NCT00982839|Active Comparator|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
3230409|NCT00982839|Experimental|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
3230410|NCT00982826|Experimental|1|ABT-072 tablet single ascending dose
3230411|NCT00982826|Experimental|2|Placebo tablet
3230412|NCT00982826|Experimental|3|ABT-072 tablet administered under non-fasting conditions.
3230413|NCT00982826|Experimental|4|ABT-072 tablet administered under fasting conditions
3230414|NCT00982826|Experimental|5|ABT-072 tablet multiple ascending dose
3230415|NCT00982800|Placebo Comparator|Placebo Sugar Pill|"Patients are stratified based on their initial pain score in the recovery room. patients with a pain numeric rating scale of greater than or equal to 7/10 are stratified to the high group. then randomized to receive gabapentin 200 mg tid x 9 doses, or placebo x 9 doses. Patients with a pain score equal to or less than 6/10 are stratified to the low group, then randomized to receive gabapentin 200mg tid x 9 doses or placebo x 9 doses.~All patients receive Acetaminophen 1gm every 6 hours for 3 days, Celecoxib 400mg as a loading dose then 200mg twice a day for 3 days. Patients also receive patient controlled analgesia (PCA) of hydromorphone for 24 hrs, then are transitioned to oxycodone 5-15 mg every 2 hours as needed."
3230416|NCT00982800|Active Comparator|Gabapentin 200 mg tid x 9 doses|
3230417|NCT00982787|Experimental|1|
3230418|NCT00982787|Placebo Comparator|2|
3230419|NCT00982748|Active Comparator|Group B|Study participants in this arm attend yoga breathing classes once per week over the span of one chemotherapy cycle.
3230420|NCT00982748|Experimental|Group A|Participants in this study arm attend weekly yoga breathing classes during two consecutive cycles of chemotherapy
3230421|NCT00982722|Experimental|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2
3230422|NCT00982722|Active Comparator|calciumcarbonate|calcium carbonate 500 mg x 2
3230423|NCT00982709|Active Comparator|Exercise Types|comparing two different exercise programs for PD
3230424|NCT00982696|Experimental|Single Arm|Opioid Growth Factor (OGF)
3230425|NCT00982670||Systemic lupus erythematosus|Patients should fulfill the diagnostic criteria of the 1997 American College of Rheumatology for systemic lupus erythematosus
3230426|NCT00982670||Normal control|Age- and sex-matched health volunteers will serve as controls.
3230427|NCT00982657|Experimental|Cohort 1|CVX-060 + sunitinib
3230428|NCT00982657|Experimental|Cohort 2|CVX-060 + sunitinib
3230429|NCT00982657|Experimental|Cohort 3|CVX-060 + sunitinib
3230430|NCT00982657|Experimental|Expanded cohort|CVX-060 + sunitinib
3230434|NCT00982644|Active Comparator|IGlar OD|
3230435|NCT00982631|Experimental|temsirolimus/PLD|temsirolimus (Torisel) with pegylated liposomal doxorubicin (PLD,Doxil,Caelyx);a dose escalating study in a 3+3 design
3230436|NCT00982618|Experimental|LIDOCAINE group|LIDOCAINE group : Beside general anesthesia, patients will receive intravenous lidocaine bolus 1.5 mg/kg just prior induction and an infusion of lidocaine 2mg/kg/h will be started and maintained during the whole surgical procedure. Entering the recovery room, this infusion will be decreased at the rate of 1mg/kg/hour for the 48 first hours
3230437|NCT00982618|Experimental|Epidural Group|Epidural Group: Beside general anesthesia, patient will receive epidural freezing medication for 48 hours.
3230438|NCT00982618|Active Comparator|PCA group|Beside general anesthesia, the patients will receive neither lidocaine nor epidural catheter. The patients will receive the same analgesia protocol consisting of PCA morphine for a total duration of 48 hours.
3230439|NCT00982605||non small cell lung cancer|cancer patients
3230440|NCT00982592|Experimental|Arm I (FOLFOX regimen and placebo)|Patients receive FOLFOX chemotherapy comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil bolus and then IV over 46-48 hours on day 1. Patients also receive placebo PO QD on days 1-14. Courses repeat every 2 weeks in the absence of unacceptable toxicity or disease progression.
3230441|NCT00982592|Experimental|Arm II (FOLFOX regimen and vismodegib)|Patients receive FOLFOX chemotherapy as in arm I. Patients also receive vismodegib PO on days 1-14. Courses repeat every 2 weeks in the absence of unacceptable toxicity or disease progression.
3230442|NCT00982579|Experimental|Vaccinees|Vaccinated at 20 weeks of age (n=24)
3230443|NCT00982579|No Intervention|Controls|No experimental vaccine (n=24)
3230444|NCT00982566|Experimental|Sequence I|
3230445|NCT00982566|Experimental|Sequence II|
3230446|NCT00982566|Experimental|Sequence III|
3230447|NCT00982566|Experimental|Sequence IV|
3230448|NCT00982566|Experimental|Sequence V|
3230449|NCT00982566|Experimental|Sequence VI|
3230450|NCT00982566|Experimental|Sequence VII|
3230451|NCT00982566|Experimental|Sequence VIII|
3230452|NCT00982566|Experimental|Sequence IX|
3230453|NCT00982566|Experimental|Sequence X|
3230454|NCT00982566|Experimental|Sequence XI|
3230455|NCT00982566|Experimental|Sequence XII|
3230456|NCT00982566|Experimental|Sequence XIII|
3230457|NCT00982566|Experimental|Sequence XIV|
3230458|NCT00982566|Experimental|Sequence XVI|
3230459|NCT00982566|Experimental|Sequence XV|
3230460|NCT00982553|Other|Ribavirin then Raltegravir + Ribavirin|Treatment
3230461|NCT00982540|No Intervention|preemptive|Patients with persistent fever and neutropenia despite appropriate antibacterial therapy
3230462|NCT00982527|Placebo Comparator|Placebo|Saline blinded infusion
3230463|NCT00982527|Active Comparator|Fenoldopam|Drug infusion
3230464|NCT00982514||Standard dose asparaginase|Children who according to the protocol NOPHO ALL 2008 receive standard dose asparaginase
3230465|NCT00982514||Reduced dose asparaginase|Children who receive reduced dose asparaginase according to NOPHO ALL 2008
3230466|NCT00982501|Experimental|WS® 1442 900 mg|
3230467|NCT00982501|Experimental|WS® 1442 1800 mg|
3230468|NCT00982501|Active Comparator|Nordic walking training 2x30 min|
3230469|NCT00982501|Active Comparator|Nordic walking training 4x45 min|
3230470|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Chronic phase|Participants with chronic phase disease continued on the previous study dose of dasatinib, ranging from 50 mg once daily (QD) to 120 mg twice daily (BID).
3230471|NCT00982488|Other|Imatinib, 400 mg BID, Chronic phase|Participants with chronic phase disease received 400 mg of imatinib twice BID.
3230472|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, AP|Participants with advanced phase disease, accelerated phase (AP), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
3230473|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, MBP|Participants with advanced phase disease, myeloid blast cell (MBP), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
3230474|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, Ph+ ALL|Participants with advanced phase disease, Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
3230475|NCT00982475|Active Comparator|PVI with robotic navigation|
3230476|NCT00982475|Placebo Comparator|PVI manually|
3230477|NCT00982462|Placebo Comparator|Corn oil placebo|Micro-encapsulated powder containing corn oil placebo.
3230478|NCT00982462|Experimental|Long-chain polyunsaturated fatty acids|Micro-encapsulated powder containing 1:1 ratio of the omega-3 long-chain polyunsaturated fatty acids, docosahexaenoic acid (DHA) and the omega-6 fatty acid, arachidonic acid (ARA) from algal and fungal sources, respectively.
3230479|NCT00982449|Active Comparator|4 mCi of I-FIAU|GROUP B 1-3 days after any chemotherapy that may activate viral TK, 4 mCi of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT.
3230480|NCT00982449|Active Comparator|2 mCi of I-FIAU|GROUP A 1-3 days after any chemotherapy that may activate viral TK, 2 mCi of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT.
3230481|NCT00982436|Experimental|Neoadjuvant/Concomitant Chemoradiation|Three cycles of docetaxel/carboplatin neoadjuvant chemotherapy followed by chemoradiotherapy for 7 weeks with weekly carboplatin
3230482|NCT00982423|Experimental|Furosemide|Subjects received their clinically prescribed dose of furosemide for a 3 week stabilization period, then were assessed for cardiorenal and humoral function. Subjects then had a 50% reduction of the furosemide dose for a 3 week stabilization period, and were assessed for cardiorenal and humoral function again.
3230483|NCT00982410|Experimental|Arm 1|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
3230484|NCT00982410|Placebo Comparator|Arm 2|educational supportive group
3230485|NCT00982397|Experimental|Single-chamber detetction|Patients implanted with a Protecta VR-ICD.
3230486|NCT00982397|Experimental|Dual-chamber detection|Patients implanted with a Protecta DR-ICD or CRT-D.
3230535|NCT00982020|Experimental|Olanzapine/standard behavioral weight intervention|
3230487|NCT00982384|Experimental|Disease management|Comprehensive disease management in addition to best care according to clinical guidelines for COPD patients
3230488|NCT00982384|Active Comparator|Best care|Best care according to clinical guidelines for COPD patients
3230489|NCT00982371||Controls|female; >65 years old; BMI >25kg/m2; postmenopausal >5 yrs; NO clinical diagnosis of type 2 diabetes for >5 years (according to Canadian Diabetes Association criteria)
3230490|NCT00982371||Type 2 Diabetes|female; >65 years old; BMI >25kg/m2; postmenopausal >5 yrs; clinical diagnosis of type 2 diabetes for >5 years (according to Canadian Diabetes Association criteria)
3230491|NCT00982358|Placebo Comparator|Placebo|
3230492|NCT00982358|Active Comparator|Valsartan|
3230493|NCT00982345|Other|Open label Quetiapine|Open-label Quetiapine XL 50 - 400 mg daily treatment 8 weeks
3230494|NCT00982332|Active Comparator|betamethasone|patients treated with a single intramuscular injection of betamethasone
3230495|NCT00982332|Placebo Comparator|isotonic sodium chloride solution|
3230496|NCT00982319|Experimental|Broccoli sprout extract|Patients will be randomized to 14 day intervention of broccoli sprout extract and mango juice consisting of a dose of 100 µmols of sulforaphane dissolved in 150 mL mango juice once a day.
3230497|NCT00982319|Placebo Comparator|Mango juice|Patients will be randomized to 14 day intervention of 150 mL mango juice without broccoli sprout extract extract once a day.
3230498|NCT00982293|Active Comparator|Active fields|
3230499|NCT00982293|Sham Comparator|Inactive device|"Placebo treated group, will receive the 3 times weekly for 13 weeks (39) sessions, however, the device will not be on."
3230500|NCT00982280|Experimental|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol IR tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
3230501|NCT00982267|Experimental|SU014813|
3230502|NCT00982254|Experimental|Oral Insulin|oral insulin capsule formulation
3230503|NCT00982254|Active Comparator|Subcutaneous Insulin|Subcutaneous injection of regular human insulin
3230504|NCT00982241|Active Comparator|normal fluid intake|1500 ml /day (+/- 300 ml) for 2,5 days
3230505|NCT00982241|Active Comparator|high fluid intake|2400 ml/day (+/- 300 ml )for 2,5 days
3230506|NCT00982241|Active Comparator|low fluid intake|fluid intake 900 ml/day (+/- 300ml) for 2,5 days
3230507|NCT00982228|Experimental|IDeg OD|
3230508|NCT00982228|Active Comparator|IGlar OD|
3230509|NCT00982202|Experimental|PGZ|
3230510|NCT00982202|Placebo Comparator|Placebo|
3230511|NCT00982189|Experimental|Lisinopril|Lisinopril 10mg once daily
3230512|NCT00982189|Placebo Comparator|Lisinopril Placebo|Placebo pill (matched to lisinopril) once daily
3230513|NCT00982189|Experimental|Pravastatin|Pravastatin 20mg once daily
3230514|NCT00982189|Placebo Comparator|Pravastatin placebo|Placebo pill (matched to pravastatin) once daily
3230515|NCT00982176||1|
3230516|NCT00982150|Experimental|Talampanel|Talampanel 50mg tid
3230517|NCT00982137|Experimental|ChimeriVax™-JE then STAMARIL®|Participants will receive ChimeriVax™-JE on Day 0 and STAMARIL® on Day 30
3230518|NCT00982137|Experimental|STAMARIL® then ChimeriVax™-JE|Participants will receive STAMARIL® on Day 0 and ChimeriVax™-JE on Day 30
3230519|NCT00982137|Experimental|ChimeriVax™-JE and STAMARIL®, then Diluent|Participants will receive ChimeriVax™-JE and STAMARIL® on Day 0 and diluent on Day 30.
3230520|NCT00982137|Experimental|Diluent then ChimeriVax™-JE and STAMARIL®|Participants will receive Diluent on Day 0 and ChimeriVax™-JE and STAMARIL® on Day 30.
3230521|NCT00982124|Experimental|Treatment Arm (only)|Zoledronic acid infusion
3230522|NCT00982111|Experimental|Necitumumab + Pemetrexed + Cisplatin|Necitumumab + Pemetrexed + Cisplatin
3230523|NCT00982111|Active Comparator|Pemetrexed + Cisplatin|Pemetrexed + Cisplatin
3230524|NCT00982098|Experimental|Early Rehabilitation|"Before surgery: 15 minutes pelvic floor muscle training and 15 minutes biofeedback, for 4 sessions.~After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).~Patients will be instructed to carry on exercises at home for the following 11 months."
3230525|NCT00982098|No Intervention|Counseling and home-based exercises|"Before surgery: 15 minutes pelvic floor muscle training and 15 minutes biofeedback, for 4 sessions.~After surgery: Patients will be instructed to carry on pelvic floor exercises at home for the year after prostatectomy."
3230526|NCT00982085||Soldiers|Soldiers: The soldiers who respond the questionnaires
3230527|NCT00982072|Active Comparator|prednisolone|prednisolone tablets
3230528|NCT00982072|Experimental|tacrolimus|tacrolimus tablets
3230529|NCT00982059||All|All patients enrolled in the study will be undergoing the same procedures.
3230530|NCT00982046|Active Comparator|ACUVUE OASYS|Acuvue Oasys contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
3230531|NCT00982046|Active Comparator|AIR OPTIX AQUA|Air Optix Aqua contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
3230532|NCT00982046|Active Comparator|Biofinity|Biofinity contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
3230533|NCT00982033|Active Comparator|Aliskiren|50 % of subjects participating in this trial will be on the active medication, Aliskiren 300mg qd, the other 50% will be on placebo.
3230534|NCT00982033|Placebo Comparator|Placebo|50% of subjects will be randomized to placebo.
3230536|NCT00982020|Experimental|Olanzapine/intense behavioral weight intervention|
3230537|NCT00982007|Experimental|Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)|Intravenous (IV) iron
3230538|NCT00982007|Active Comparator|Cohort 1 (Group B) - Ferrous Sulfate|Oral iron - Ferrous Sulfate tablets
3230539|NCT00982007|Active Comparator|Cohort 2 (Group D) - IV Iron (standard of care)|Other IV iron
3230540|NCT00982007|Experimental|Cohort 2 (Group C) - Ferric Carboxymaltose (FCM)|Intravenous (IV) iron
3230541|NCT00981994|Experimental|Electronic Decision Support|Use of electronic decision support to provide the treatment algorithm for providers managing patients with acute respiratory infections.
3230542|NCT00981994|Experimental|Paper Decision Support|Use of paper based tools to provide the treatment algorithm for providers managing patients with acute respiratory infections.
3230543|NCT00981994|No Intervention|Usual Care|Usual Care
3230544|NCT00981981|Placebo Comparator|Control|Wheat bran cereal
3230545|NCT00981981|Active Comparator|3g high MW|Cereal containing 3g high molecular weight oat beta glucan
3230546|NCT00981981|Active Comparator|4g medium MW|Cereal containing 4g oat beta glucan with medium molecular weight
3230547|NCT00981981|Active Comparator|3g medium MW|Cereal containing 3g oat beta glucan with medium molecular weight
3230548|NCT00981981|Active Comparator|4g low MW|Cereal containing 4g oat beta glucan with low molecular weight
3230549|NCT00981968|Experimental|Japanese Cohort|Single and multiple oral doses of sitaxentan sodium or placebo in 12 healthy subjects.
3230550|NCT00981968|Experimental|Western Cohort|Single oral dose of sitaxentan sodium in 10 healthy subjects.
3230551|NCT00981955|Active Comparator|75mg caffeine|
3230552|NCT00981955|Active Comparator|50mg l-theanine|
3230553|NCT00981955|Active Comparator|75mg caffeine and 50mg l-theanine|
3230554|NCT00981955|Placebo Comparator|0mg caffeine/l-theanine|
3230555|NCT00981929|Active Comparator|Tramadol|CYP2D6 metric
3230556|NCT00981929|Active Comparator|Omeprazole, losartan, caffeine|CYP2C19, CYP2C9 and CYP1A2 metrics
3230557|NCT00981929|Active Comparator|Tramadol, omeprazole, losartan and caffeine|CYP2D6, CYP2C19, CYP2C9 and CYP1A2 metrics
3230558|NCT00981903|Experimental|VTE Treatment Group|
3230559|NCT00981903|No Intervention|Control|
3230560|NCT00981890|Experimental|Sunitinib|
3230561|NCT00981877|Active Comparator|1|This group will receive S. Boulardii Probiotic and Oral rehydration as needed
3230562|NCT00981877|Active Comparator|2|This group will receive a mixed Probiotic preparation and oral rehydration as needed
3230563|NCT00981877|Placebo Comparator|3|This group will receive a placebo, and oral rehydration as needed
3230564|NCT00981864|Experimental|Concurrent Boost RT|
3230565|NCT00981851|Active Comparator|beta 2 agonist + anticholinergic aerosol|
3230566|NCT00981851|Placebo Comparator|placebo inhalation|
3230567|NCT00981838|Experimental|1|Rituximab (375 mg/m2).
3230568|NCT00981825|Placebo Comparator|A|fluoride toothpaste control
3230569|NCT00981825|Active Comparator|B|triclosan/fluoride toothpaste
3230570|NCT00981812|Experimental|PEM Breast Biopsy|All patients underwent PEM biopsy.
3230571|NCT00981786|Active Comparator|Brinzolamide/Timolol therapy|Chronic therapy for 3 months with brinzolamide/timolol drops given twice daily added to travoprost drops
3230572|NCT00981786|Active Comparator|Brimonidine/Timolol therapy|Chronic therapy for 3 months with brimonidine/timolol drops given twice daily added to travoprost drops
3230573|NCT00981773|Experimental|Immediate switch|"Continue current boosted protease inhibitor~Switch NRTI backbone to maraviroc 150 mg bid"
3230574|NCT00981773|Active Comparator|Continue current antiretroviral therapy|Continue current antiretroviral regimen until week 12 then switch therapy as per arm 1.
3230575|NCT00981747|Experimental|Sildenafil|
3230576|NCT00981747|Experimental|Losartan|
3230577|NCT00981747|Experimental|Sildenafil and Losartan|
3230578|NCT00981747|Placebo Comparator|Placebo|
3230579|NCT00981721|Experimental|1|cediranib 20mg
3230580|NCT00981721|Experimental|2|cediranib 30mg
3230581|NCT00981708|Experimental|Treatment|Lenalidomide, Dexamethasone and cyclophosphamide
3230582|NCT00981695|Experimental|Vaccinees|18 breast-fed and 18 formula-fed infants at the age of 20 weeks
3230583|NCT00981695|No Intervention|Controls|18 breast-fed and 18 formula-fed infants at the age of 20 weeks
3230584|NCT00981682|Experimental|SER120 (desmopressin)|
3230585|NCT00981669|Experimental|rotavirus vaccine|3 doses with 6 weeks interval
3230586|NCT00981669|Placebo Comparator|placebo|3 doses with 6 weeks interval
3230587|NCT00981656|Experimental|TURBT + Concurrent RT + Chemotherapy|Transurethral resection of the bladder tumor (TURBT) + Concurrent Radiation Therapy (RT) + Chemotherapy
3230588|NCT00981643|Experimental|Multiple Sclerosis, Meditation group|Multiple Sclerosis, Meditation instruction and practice group
3230589|NCT00981643|No Intervention|Multiple Sclerosis, Control group|Multiple Sclerosis, Control group
3230590|NCT00981643|Experimental|Peripheral Neuropathy, Meditation group|Peripheral Neuropathy, Meditation instruction and practice group
3230591|NCT00981643|No Intervention|Peripheral Neuropathy, Control group|Peripheral Neuropathy, Control group
3230592|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 1|Participants received ChimeriVax™-JE (Japanese Encephalitis) a dose of 3.0 log10 Plaque-forming units (PFU) on Day 0.
3230593|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 2|Participants received ChimeriVax™-JE a dose of 4.0 log10 PFU on Day 0.
3230594|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 3|Participants received ChimeriVax™-JE a dose of 5.0 log10 PFU on Day 0.
3230595|NCT00981630|Placebo Comparator|Placebo|Participants received ChimeriVax diluent, 0.5 mL on Day 0.
3230596|NCT00981617|Experimental|ALKS33 (RDC-0313) (1 mg)|1 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
3230597|NCT00981617|Experimental|ALKS33 (RDC-0313) (2.5 mg)|2.5 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
3230598|NCT00981617|Experimental|ALKS33 (RDC-0313) (10 mg)|10 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
3230702|NCT00980863|No Intervention|waiting control group|
3230599|NCT00981617|Placebo Comparator|Placebo|Matching placebo (capsules without active study drug) provided for daily oral administration
3230600|NCT00981604|Active Comparator|SILS Cholecystectomy|Single Incision Laparoscopic Cholecystectomy
3230601|NCT00981604|Active Comparator|Standard Laparoscopic Cholecystectomy|4 port laparoscopic cholecystectomy
3230602|NCT00981591|Experimental|Inhaled Iloprost|
3230603|NCT00981591|Placebo Comparator|Inhaled Placebo|
3230604|NCT00981578|Experimental|ExAblate 2100 Treatment|ExAblate 2100 ablation for the treatment of painful bone metastases.
3230605|NCT00981565|Active Comparator|Operative|
3230606|NCT00981565|Active Comparator|Conservative|
3230607|NCT00981552|Other|Cervix Cancer|Patients treated with cervical cancer in 2008 at Sunnybrook Odette Cancer Centre
3230608|NCT00981539|Active Comparator|treatment : receives pre operative enema|one arm will receive pre operative enema
3230609|NCT00981539|No Intervention|no enema|this group will not receive pre operative enema
3230610|NCT00981526|Experimental|A: Telmisartan|(existing Clozapine or Olanzapine treatment) + (Telmisartan)
3230611|NCT00981526|Placebo Comparator|B: Placebo|(existing Clozapine or Olanzapine treatment) + (Placebo)
3230612|NCT00981513|Active Comparator|Influenza vaccination|Live attenuated influenza vaccine (seasonal and pandemic strains) by nasal spray
3230613|NCT00981513|Placebo Comparator|Saline placebo|Saline nasal spray
3230614|NCT00981500||Gastric Bypass|morbidly obese subjects undergoing gastric bypass surgery
3230615|NCT00981500||gastric banding|morbidly obese subjects undergoing laparoscopic gastric banding surgery
3230616|NCT00981500||sleeve gastrectomy|morbidly obese subjects undergoing sleeve gastrectomy
3230617|NCT00981487|Experimental|Fed|A single oral dose of EUR-1025 (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The Ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast.
3230618|NCT00981487|Experimental|Fasting|A single oral dose of EUR-1025 (1 x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.
3230619|NCT00981474|Active Comparator|Control|Blood pressure targets during cardiopulmonary bypass based on institutional standards of empiric management.
3230620|NCT00981474|Experimental|Intervention|Blood pressure management based on cerebral autoregulation data.
3230621|NCT00981461|Active Comparator|LLT Device 2009 9 Beam|HairMax LaserComb
3230622|NCT00981461|Sham Comparator|control device|control device
3230623|NCT00981448|Experimental|Zinc supplement|
3230624|NCT00981435|Experimental|Artificial Tears|Topical artificial tears dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
3230625|NCT00981435|Experimental|Non-steroidal anti-inflammatory|Topical ketorolac 0.5% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
3230626|NCT00981435|Experimental|Steroid|Topical prednisolone 1% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
3230627|NCT00981422||Glaucoma patients|POAG patients selected by an ophthalmologist from the Glaucoma Service, Ophthalmology Institute, University of Parma
3230628|NCT00981422||Healthy|healthy subjects with negative history for (a) neurodegenerative diseases, (b) autoimmune diseases, (c) cancer, (d) viral infection, (e) diabetes, and (f) systemic inflammation
3230629|NCT00981409|Experimental|Fondaparinux|
3230630|NCT00981409|Other|unfractionated heparin|
3230631|NCT00981396|Active Comparator|CBT|Cognitive Behavioral Therapy
3230632|NCT00981396|Experimental|EFT|Emotional Freedom Techniques, a novel but efficacious stress-reduction technique
3230633|NCT00981383|Experimental|Treatment|Omega-3 Fatty Acid Supplement, 1.9 g ω-3 FAs daily
3230634|NCT00981383|Placebo Comparator|Placebo|Matching placebo, less than 0.12 g ω-3 FAs daily
3230635|NCT00981370|Other|Single Arm study|Single Arm study, all subjects to receive study medication, deferasirox (Exjade).
3230636|NCT00981357|Experimental|PF-04457845 followed by placebo|
3230637|NCT00981357|Experimental|Placebo followed by PF-04457845|
3230638|NCT00981357|Active Comparator|Naproxen followed by placebo|
3230639|NCT00981357|Active Comparator|Placebo followed by Naproxen|
3230640|NCT00981331|Experimental|Subtalar joint manipulation|Each subject in this group will recieve a subtalar joint manipulation to their symptomatic ankle
3230641|NCT00981331|Sham Comparator|Sham Manipulation|Each subject in this group will recieve a sham subtalar joint manipulation to their symptomatic ankle
3230642|NCT00981318|Other|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid|single arm
3230643|NCT00981305|Experimental|Lactate-containing Vaginal Lubricant|apply 3cc of lactate-containing vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)
3230644|NCT00981305|Placebo Comparator|Placebo|apply 3cc of placebo vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)
3230645|NCT00981292|Active Comparator|135mg EGCG|
3230646|NCT00981292|Active Comparator|270mg EGCG|
3230647|NCT00981292|Placebo Comparator|0mg EGCG|
3230648|NCT00981279||HIV seroposite patients|Seroposite HIV patients that take their treatment at the Clinical Hospital of The Federal University of Goias, and have their records in the hospital.
3230649|NCT00981266|Other|Augmentation|"The study population will consist of women aged 22 or over who are undergoing primary breast augmentation.~The Augmentation cohort will include candidates for general breast enlargement, post-lactational involution and/or asymmetry."
3230650|NCT00981266|Other|Augmentation Revision|"The study population will consist of women aged 22 or over who are undergoing augmentation revision.~The Augmentation Revision cohort will include candidates with previous augmentation with silicone-filled or saline-filled implants."
3230651|NCT00981253|Experimental|SMT-enhanced Cardiac Rehabilitation|Standard exercise-based cardiac rehabilitation with weekly stress management training for 12 weeks.
3230652|NCT00981253|Active Comparator|Standard Cardiac Rehabilitation|Standard cardiac rehabilitation consisting of supervised exercise for 12 weeks.
3230703|NCT00980850|Experimental|Groups A1 and A2|Baxter vaccine
3230704|NCT00980850|Experimental|Groups B1 and B2|GSK vaccine
3230755|NCT00980434||1|patients with neurological symptoms
3230653|NCT00981240|Experimental|Dose escalation|Cohorts of 3 to 6 patients will be included at each dose level. The starting dose is 1.2mg/m2/day. The dose will be increased in new cohorts of patients according to toxicities observed during the first 4-week treatment period. The escalation process will continue until the MTD is determined. Additional 15 patients will be included at the MTD.
3230654|NCT00981227|Experimental|ESL 400 mg twice-daily|ESL 400 mg twice-daily
3230655|NCT00981227|Experimental|ESL 800 mg once-daily|ESL 800 mg once-daily
3230656|NCT00981227|Experimental|ESL 600 mg twice daily|ESL 600 mg twice daily
3230657|NCT00981227|Experimental|ESL 1200 mg once daily|ESL 1200 mg once daily
3230658|NCT00981227|Experimental|ESL 800 mg twice daily|ESL 800 mg twice daily
3230659|NCT00981227|Placebo Comparator|placebo|placebo
3230660|NCT00981214|Experimental|EUR-1008 (APT-1008)|
3230661|NCT00981201|Experimental|Celecoxib + Placebo|
3230662|NCT00981201|Experimental|Celecoxib + Celecoxib|
3230663|NCT00981201|Active Comparator|Placebo + Celecoxib|
3230664|NCT00981201|Placebo Comparator|Placebo + Placebo|
3230665|NCT00981175|Experimental|Study Group 1: ChimeriVax™-JE Vaccine first, then Placebo|Participants received ChimeriVax™-JE on Day 0 and ChimeriVax diluent on Day 28
3230666|NCT00981175|Experimental|Study Group 2: Placebo first, then ChimeriVax™-JE Vaccine|Participants received ChimeriVax diluent on Day 0 and ChimeriVax™-JE on Day 28.
3230667|NCT00981162|Experimental|Treatment (sorafenib tosylate and everolimus)|Patients receive everolimus PO once daily and sorafenib tosylate PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3230668|NCT00981149|Experimental|duloxetine study drug|Drug
3230669|NCT00981149|Placebo Comparator|Placebo|Placebo
3230670|NCT00981136|Active Comparator|SILS|Single Incision Laparoscopic Surgery (SILS) where a single incision in the umbilicus is all that is used to remove the appendix. The specific methods (staple/tie/port use/etc) will vary depending on surgeon.
3230671|NCT00981136|Active Comparator|3 port|Standard laparoscopic appendectomy with 3 ports and intracorporeal stapling.
3230672|NCT00981123||1|
3230673|NCT00981110|Active Comparator|Mepore Self-adhesive absorbent dressing|Mepore Self-adhesive absorbent dressing
3230674|NCT00981110|Experimental|AQUAGEL Ag Hydrofiber Wound Dressing|AQUAGEL Ag Hydrofiber Wound Dressing
3230675|NCT00981097||Specimen Collection|Subjects with a diagnosis of HIV and an untreated aggressive B-cell lymphoma.
3230676|NCT00981084|Experimental|armodafinil and placebo|All participants will receive one dose of armodafinil and one dose of placebo in a cross-over design
3230677|NCT00981071||A platoon with TB outbreak|
3230678|NCT00981058|Experimental|Necitumumab + Gemcitabine + Cisplatin|
3230679|NCT00981058|Active Comparator|Gemcitabine + Cisplatin|
3230680|NCT00981045|Experimental|Ferric Carboxymaltose (FCM)|2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
3230681|NCT00981045|Active Comparator|Iron Sucrose (Venofer)|5 doses of 200 mg for a total cumulative dose of 1000 mg
3230682|NCT00981032|Experimental|Pre-visit Summary|Patients in this arm will receive a pre-visit summary prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
3230683|NCT00981032|Experimental|Clinical Decision Sharing Tool|Patients in this arm will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
3230684|NCT00981019||mortality*incidence*5-year survival*early stage|Physicians will be faced in scenarios about screening with information on mortality and 5-year survival, followed by information on mortality*incidence and 5-year survival*early stage in a random order.
3230685|NCT00981006|Experimental|human cardiac stem cell therapy|single administration of 0.5 million cells/kg(patient body weight) of human cardiac stem cells and 200 microgram of bFGF at coronary artery bypass grafting (CABG)
3230686|NCT00980980|No Intervention|Arm 1: Usual Care-Active Surveillance|Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+
3230687|NCT00980980|Active Comparator|Arm 2: Targeted Decolonization|Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
3230688|NCT00980980|Active Comparator|Arm 3: Universal Decolonization|Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance, Continuation of Contact Precautions for MRSA+
3230689|NCT00980954|Experimental|Arm I: Cisplatin/Radiation Therapy|Patients undergo standard EBRT or IMRT to the pelvis once daily 5 days a week for 5-6 weeks. Patients also receive concurrent cisplatin IV over 1 hour once weekly for 6 weeks.
3230690|NCT00980954|Experimental|Arm II: Cisplatin/Radiation Therapy + Carboplatin/Paclitaxel|Patients receive chemoradiotherapy as in arm I. Beginning 4-6 weeks after completion of chemoradiotherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3230691|NCT00980941|Experimental|Soup with no added starch|
3230692|NCT00980941|Experimental|Soup + 50 g of whole grain starch|
3230693|NCT00980941|Experimental|Soup + 50 g of high amylose corn starch|
3230694|NCT00980941|Experimental|Soup + 50 g of regular corn starch|
3230695|NCT00980941|Experimental|Soup + 50 g maltodextrin starch|
3230696|NCT00980915||At risk for Acute Lung Injury|"Controls-High risk patients at risk of Acute Lung Injury(ALI) but do not develop ALI~Cases-High risk patients that do develop Acute Lung Injury"
3230697|NCT00980889|Active Comparator|steel|Insertion of Metalic Steel Stent, Wallstent® in malignant distal bile duct obstruction
3230698|NCT00980889|Active Comparator|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
3230699|NCT00980876|Active Comparator|Cipro HC|Reference product
3230700|NCT00980876|Experimental|Ciprofloxacin HCl and Hydrocortisone|Test product
3230701|NCT00980863|Active Comparator|Lifestyle intervention to increase physical activity|
3230705|NCT00980824|Experimental|therapy|Cognitive behavioural therapy. Six sessions of structured focused therapy.
3230706|NCT00980824|Active Comparator|Standard treatment|referral to specialised or generic mental health service
3230707|NCT00980798|Experimental|001|OROS hydromorphone HCl 4 to 32 mg taken orally once daily for 16 weeks
3230708|NCT00980798|Placebo Comparator|002|Placebo placebo tablet once daily for 16 weeks
3230709|NCT00980785|Placebo Comparator|Placebo|Matching Placebo
3230710|NCT00980785|Experimental|Active|Ramipril 5mg/day
3230711|NCT00980759|Experimental|EFI(Extended-Field Irradiation)|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
3230712|NCT00980759|Experimental|Pelvic RT|Pelvic Irradiation with chemotherapy(cisplatin)
3230713|NCT00980746|Experimental|ESL 400 mg BID|ESL 400 mg twice daily (BID)
3230714|NCT00980746|Experimental|ESL 800 mg QD|ESL 800 mg once-daily (QD)
3230715|NCT00980746|Experimental|ESL 600 mg BID|Eslicarbazepine 600 mg twice daily
3230716|NCT00980746|Experimental|ESL 1200 mg QD|Eslicarbazepine acetate 1200 mg once daily
3230717|NCT00980746|Experimental|ESL 800 mg BID|Eslicarbazepine acetate 800 mg twice daily
3230718|NCT00980746|Placebo Comparator|Placebo|Placebo
3230719|NCT00980733|Active Comparator|Fortified Yoghurt|Yoghurt with fortification of Micronutrients, yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
3230720|NCT00980733|Placebo Comparator|Yoghurt|Plain Yoghurt same as in fortified arm but without fortification
3230721|NCT00980733|No Intervention|Control|Non blinded group given no intervention
3230722|NCT00980707|Experimental|inhaled corticosteroid|All asthmatics will start inhaled corticosteroids.
3230723|NCT00980694|Experimental|Ubiquinol|up to 600 mg per day, oral capsules for 8 weeks
3230724|NCT00980681|Experimental|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg.
3230725|NCT00980681|Other|Time Of Flight|Each subject will undergo a TOF Magnetic Resonance Angiography
3230726|NCT00980655|Experimental|1|
3230727|NCT00980642|Other|General anesthesia|Temperature is measured by Draeger double-sensor and esophageal stethoscope temperature sensor every 5-min during the surgery.
3230728|NCT00980642|Other|Regional anesthesia|Temperature is measured by Draeger double-sensor and Foley catheter temperature sensor every 5-min during the surgery.
3230729|NCT00980616|Experimental|Ropivacaine, serum, adrenalin|235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin.
3230730|NCT00980616|No Intervention|No infiltration|B: no infiltration
3230731|NCT00980603|Active Comparator|docetaxel|
3230732|NCT00980603|Experimental|doctaxel plus cisplatin|
3230733|NCT00980603|Experimental|docetaxel plus S-1|
3230734|NCT00980590|Experimental|Airway Scope|Intubation with Airway Scope
3230735|NCT00980590|Active Comparator|Macintosh laryngoscope|Intubation with Macintosh laryngoscope
3230736|NCT00980577|Active Comparator|NS|stimulating catheter will be inserted using stimulator
3230737|NCT00980551|Experimental|Topotecan/Vincristine with subtenon Carboplatin|
3230738|NCT00980538|Experimental|001|Etravirine Dosed by weight up to a maximum dose of 200 mg bid until accessed by other means
3230739|NCT00980525||IL-1 genotype positive|There are three known IL-1 genes arranged in a cluster on human chromosome 2q13. Although the clinical application is still debatable, polymorphism in the IL-1 gene cluster was found to be associated with increased susceptibility to periodontal diseases. Conflicting studies demonstrate that a possible relationship between IL-1 genotype and clinical parameters of gingivitis may exist.This study will involve 15 subjects who are genotype positive and 15 subjects who are genotype negative.
3230740|NCT00980525||IL-1 genotype negative|There are three known IL-1 genes arranged in a cluster on human chromosome 2q13. Although the clinical application is still debatable, polymorphism in the IL-1 gene cluster was found to be associated with increased susceptibility to periodontal diseases. Conflicting studies demonstrate that a possible relationship between IL-1 genotype and clinical parameters of gingivitis may exist.This study will involve 15 subjects who are genotype positive and 15 subjects who are genotype negative.
3230741|NCT00980512|Experimental|Parent Training|Parent Training of foster parents
3230742|NCT00980512|No Intervention|Control|Control group
3230743|NCT00980486||BMI <30|BMI <30
3230744|NCT00980486||BMI 30-39|BMI 30-39
3230745|NCT00980486||BMI >40|BMI >40
3230746|NCT00980473|Active Comparator|Iridoplasty|
3230747|NCT00980473|Active Comparator|Control (Medication)|
3230748|NCT00980460|Experimental|High-risk group (regimen H)|Patients receive up front VIT chemotherapy comprising vincristine sulfate IV on days 1 and 8 and irinotecan hydrochloride IV over 90 minutes on days 1-5, and temsirolimus IV over 30 minutes on days 1 and 8. Treatment with VIT repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Responding patients then receive 6 courses of C5VD with 4 courses of VIT in between each 2-course block and non-responding patients receive 6 courses of C5VD in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection or liver transplant after course 4 of C5VD followed by 2 courses of adjuvant C5VD.
3230749|NCT00980460|Experimental|Intermediate-risk group (regimen F)|Patients receive C5VD chemotherapy comprising cisplatin IV over 6 hours on day 1, fluorouracil IV on day 2, vincristine sulfate IV on days 2, 9, and 16, and doxorubicin hydrochloride IV over 15 minutes on days 1-2. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo surgical resection after course 2 OR surgical resection or liver transplantation after course 4 of C5VD. (closed to accrual as of 3/12/2012)
3230750|NCT00980460|Experimental|Low-risk group (regimen T)|Patients undergo surgery and then receive adjuvant cisplatin IV over 6 hours on day 1, fluorouracil IV on day 2, and vincristine sulfate IV on days 2, 9, and 16. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
3230751|NCT00980460|Experimental|Very low-risk group|Patients undergo surgery and then receive no further treatment.
3230752|NCT00980447|Experimental|UMN-0501 45µg|Recombinant H5N1 vaccine 45µg
3230753|NCT00980447|Experimental|UMN-0501 90µg|Recombinant H5N1 vaccine 90µg
3230754|NCT00980447|Experimental|UMN-0501 135µg|Recombinant H5N1 vaccine 135µg
3230756|NCT00980434||2|patients without neurological symptoms
3230757|NCT00980421|Experimental|IT|Iron Tablet group (12.5 mg/d) + Placebo Biscuit
3230758|NCT00980421|Experimental|IZ|Iron (12.5mg/d)+Zinc (10 mg/d) Tablet Group + Placebo Biscuit
3230759|NCT00980421|Experimental|IB|Iron Fortified Biscuit Group(12.5 mg/d)+ Placebo Tablet
3230760|NCT00980421|Placebo Comparator|CO|Placebo Tablet + Placebo Biscuit
3230761|NCT00980408|Placebo Comparator|Sugar pill, behavioral glutamic acid|Placebo condition for D-Cycloserine
3230762|NCT00980408|Placebo Comparator|Sugar pill, fMRI, glutamic acid|Placebo condition for D-Cycloserine, fMRI
3230763|NCT00980408|Placebo Comparator|Sugar pill, memantine, behavioral|Placebo condition Memantine, behavioral
3230764|NCT00980408|Placebo Comparator|Sugar pill, memantine, fMRI|Placebo condition Memantine, fMRI
3230765|NCT00980408|Active Comparator|D-Cycloserine behavioral|
3230766|NCT00980408|Active Comparator|D-Cycloserine, fMRI|
3230767|NCT00980408|Active Comparator|Memantine, behavioral|
3230768|NCT00980408|Active Comparator|Memantine, fMRI|
3230769|NCT00980395|Experimental|VCR (Velcade, Cladribine and Rituximab)|"Rituximab 375 mg/m2 IV day1~Cladribine 4 mg/m2 IV over 2 hours days 1-5~Bortezomib 1.3 mg/m2 IV days 1 and 4~Repeat every 28 days for a maximum of 6 cycles"
3230770|NCT00980369||Chronic anal fissures|Group A: with vertical incision Group B: with parallel incision
3230771|NCT00980369||Parallel incision, vertical insicion|
3230772|NCT00980356|Active Comparator|Vildagliptin, 50 mg, peroral|
3230773|NCT00980356|Placebo Comparator|Placebo pill|
3230774|NCT00980343|Experimental|Arm I (pre-surgery vismodegib)|"Patients receive oral Hedgehog antagonist GDC-0449 (vismodegib) once daily for 7 days before therapeutic conventional surgery. Beginning within 28 days after surgical resection, all patients receive oral Hedgehog antagonist GDC-0449 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study; laboratory biomarker analysis"
3230775|NCT00980343|Experimental|Arm II (no vismodegib pre-surgery)|"Patients do not receive treatment before therapeutic conventional surgery.~Beginning within 28 days after surgical resection, all patients receive oral Hedgehog antagonist GDC-0449 (vismodegib) once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Other: laboratory biomarker analysis"
3230776|NCT00980330|Experimental|TMC435 100 mg 12 Wks + PR48|Participants will receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.
3230777|NCT00980330|Experimental|TMC435 100 mg 24 Wks + PR48|Participants willl receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.
3230778|NCT00980330|Experimental|TMC435 100 mg 48 Wks + PR48|Participants will receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
3230779|NCT00980330|Experimental|TMC435 150 mg 12 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.
3230780|NCT00980330|Experimental|TMC435 150 mg 24 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.
3230781|NCT00980330|Experimental|TMC435 150 mg 48 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
3230782|NCT00980330|Placebo Comparator|Placebo 48 Wks + PR48|Participants will receive Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
3230783|NCT00980304|Experimental|Rituximab in combination with ICE as salvage therapy|
3230784|NCT00980278|Active Comparator|sinus lift plus dental implant|"Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.~Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.~Biological/Vaccine: N/A; only sinus augmentation and dental implant"
3230785|NCT00980278|Experimental|sinus lift plus BRCs and dental implant|"transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.~Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.~Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant"
3230786|NCT00980252|Experimental|CBT|UK-based intervention
3230787|NCT00980239|Experimental|Group 1|Group 1 = Irinotecan + Bevacizumab
3230788|NCT00980239|Experimental|Group 2|Group 2 = Irinotecan, Bevacizumab + Oxaliplatin
3230789|NCT00980239|Experimental|Group 3|Group 3 = Irinotecan, Bevacizumab + Cetuximab
3230790|NCT00980213||sunitinib|advanced renal cell cancer patients treated with sunitinib as first-line therapy
3230791|NCT00980200|Experimental|C/E/A/B/D|GW642444 Dose 2 QD/GW642444 Dose 4 QD/placebo/GW642444 Dose 1 BD/GW642444 Dose 3 QD
3230792|NCT00980200|Experimental|D/C/E/A/B|GW642444 Dose 3 QD/GW642444 Dose 2 QD/GW642444 Dose 4 QD/placebo/GW642444 Dose 1 BD
3230793|NCT00980200|Experimental|A/B/C/D/E|placebo/GW642444 Dose 1 BD/GW642444 Dose 2 QD/GW642444 Dose 3 QD/GW642444 Dose 4 QD
3230794|NCT00980200|Experimental|B/A/D/E/C|GW642444 Dose 1 BD/placebo/GW642444 Dose 3 QD/GW642444 Dose 4 QD/GW642444 Dose 2 QD
3230795|NCT00980200|Experimental|E/D/B/C/A|GW642444 Dose 4 QD/GW642444 Dose 3 QD/GW642444 Dose 1 BD/GW642444 Dose 2 QD/placebo
3230796|NCT00980187|Active Comparator|Hydrochlorothiazide|
3230797|NCT00980187|Experimental|Indapamide SR|
3230798|NCT00980174|Placebo Comparator|2|Subjects will receive placebo for denosumab (SC injection every 6 months) for 1 year (double-blind phase) followed by 60 mg denosumab (SC injection every 6 months) for 1 year (open-label phase)
3230799|NCT00980174|Experimental|1|60 mg denosumab (SC injection every 6 months) for 1 year (double-blind phase) followed by 60 mg denosumab(SC injection every 6 months) for 1 year (open-label phase). These subjects will be on denosumab for a total of 2 years.
3230800|NCT00980161||Peg-IFN + RBV with SVR|HCV patients receiving peginterferon alfa-2a and ribavirin with sustained virologic response
3230801|NCT00980161||Peg-IFN + RBV without SVR|HCV patients receiving peginterferon alfa-2a and ribavirin without sustained virologic response
3230802|NCT00980148|Experimental|Arm2|Doxycycline 100 mg oral twice a day (BID) for 7 days; 153 subjects
3230803|NCT00980148|Experimental|Arm 1|Azithromycin 1 gm oral single dose; 153 subjects
3230804|NCT00980135|Experimental|Arm 1|
3230805|NCT00980135|Experimental|Arm 2|
3230806|NCT00980135|Other|Arm 3|
3230807|NCT00980109|Placebo Comparator|placebo oseltamivir|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
3230808|NCT00980109|Active Comparator|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
3230809|NCT00980109|Placebo Comparator|placebo inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
3230810|NCT00980109|Active Comparator|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
3230811|NCT00980083|Placebo Comparator|Placebo|
3230812|NCT00980083|Active Comparator|Exendin(9-39)|
3230813|NCT00980070|Experimental|Positioning Device|use of positioning device
3230814|NCT00980070|Active Comparator|Control|institutional standard of care
3230815|NCT00980057|Experimental|Adaptive CRT (aCRT) Pacing|Cardiac resynchronization therapy (CRT) with adaptive pacing
3230816|NCT00980057|Active Comparator|Standard Biventricular Pacing|Cardiac resynchronization therapy (CRT) with biventricular pacing only (without adaptive pacing)
3230817|NCT00980044|Experimental|Tramadol 200 mg then placebo|Tramadol 200 mg daily for 1 week then placebo given for 1 week
3230818|NCT00980044|Placebo Comparator|Placebo for two weeks|Medication
3230819|NCT00980044|Experimental|Tramadol 600 mg then placebo|Tramadol 600 mg daily given for 1 week given then placebo given for 1 week
3230820|NCT00980031|Placebo Comparator|Lactose Tablet|Compounded capsule using Lactose Monohydrate Powder
3230821|NCT00980031|Active Comparator|Eplerenone|25 mg tablet placed in a capsule filled with Lactose Monohydrate Powder.
3230822|NCT00980018|Experimental|nilotinib|To measure improvement of (CTCAE grading scale) of imatinib related chronic low grade non hematologic Adverse Event after switch to treatment with nilotinib at End of Cycle 3
3230823|NCT00980005|Experimental|Flulaval Group|"subjects received Flulaval™ vaccine according to their priming status and age:~3-8 years: primed subjects 1 dose at Day 0; unprimed subjects 1 dose at Day 0 and a second dose at Day 28~9-17 years: 1 dose at Day 0 Flulaval vaccine was administered intramuscularly into the non-dominant deltoid."
3230824|NCT00980005|Active Comparator|Fluzone Group|"subjects received Fluzone® Sanofi Pasteur's vaccine according to their priming status and age:~3-8 years: primed subjects 1 dose at Day 0; unprimed subjects 1 dose at Day 0 and a second dose at Day 28~9-17 years: 1 dose at Day 0 Fluzone vaccine was administered intramuscularly into the non-dominant deltoid."
3230825|NCT00979992|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3230826|NCT00979979||HCV patients|HCV patients with detectable viremia; all sera are tested both by Abbott RealTime HCV genotype II test and by direct HCV sequencing both at 5'UTR and NS5B
3230827|NCT00979979||Non-HCV patients|Patient without evidence of HCV infection (negative both for anti-HCV and HCV RNA); all sera are both tested by Abbott RealTime HCV genotype II test and by direct HCV sequencing at 5'UTR and NS5B
3230828|NCT00979966|Experimental|A|Temsirolimus
3230829|NCT00979966|Experimental|B|Sunitinib
3230830|NCT00979953|Experimental|ADL5859|One 50-milligrams (mg) ADL5859 capsule, one 100-mg ADL5859 capsule, and 2 placebo capsules administered orally twice daily (BID) for 14 days
3230831|NCT00979953|Experimental|ADL5747|One 150-mg ADL5747 capsule and 3 placebo capsules administered orally BID for 14 days
3230832|NCT00979953|Active Comparator|Oxycodone CR|"One 10-mg Oxycodone controlled release (CR) capsule and 3 placebo capsules administered orally BID Days 1 through 4~One 20-mg Oxycodone CR capsule and 3 placebo capsules administered orally BID Days 5 through 14"
3230833|NCT00979953|Placebo Comparator|Placebo|Four placebo capsules administered orally BID for 14 days
3230834|NCT00979940|No Intervention|No atorvastatin|Patients do not receive Atorvastatin prior to PCI in cath lab
3230835|NCT00979940|Experimental|atorvastatin|Atorvastatin 80mg po given prior to PCI in cath lab
3230836|NCT00979927|Placebo Comparator|Saline|
3230837|NCT00979927|Active Comparator|SPC3649|
3230838|NCT00979914|Experimental|Patient education programme|Patients with osteoarthritis who were referred to the patient education programme.The patients followed the patient education programme.
3230839|NCT00979914|No Intervention|Control|Patients randomized to control group
3230840|NCT00979901|Experimental|1|montelukast
3230841|NCT00979901|Experimental|2|loratadine
3230842|NCT00979901|Placebo Comparator|3|placebo
3230843|NCT00979901|Experimental|4|montelukast/loratadine
3230844|NCT00979875|Experimental|Lispro+PH20, Lispro, Glulis+PH20, Glulis, Aspart+PH20, Aspart|"All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C). Each intervention was separated by a 3- to 14-day washout.~Intervention A: Participants received a single, subcutaneous (SC) injection of 95 units per milliliter (U/mL) Lispro + 5 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20 (PH20) and a single, SC injection of 95 U/mL Lispro alone 3 to 14 days apart.~Intervention B: Participants received a single, SC injection of 95 U/mL Glulisine (Glulis) + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Glulis alone 3 to 14 days apart.~Intervention C: Participants received a single, SC injection of 95 U/mL Aspart + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Aspart alone 3 to 14 days apart."
3230891|NCT00979576|Experimental|BIBF 1120 BID + Pemetrexed|Phase I part: Find MTD by using low, medium or high BIBF 1120 twice daily and 500mg/m^2 pemetrexed once every 3 weeks
3230845|NCT00979862|Experimental|Treatment cediranib maleate, cilengitide)|"Part A (dose finding): Patients receive cediranib maleate PO once daily on days 1-28 and cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Part B (dose expansion): Patients are assigned to 1 of 2 groups according to prior anti-VEGF therapy (yes vs no). Patients in both groups receive cediranib maleate (administered at the safe dose determined in part A) and cilengitide as in part A."
3230846|NCT00979849|Experimental|A|AZD8683
3230847|NCT00979849|Placebo Comparator|B|Placebo
3230848|NCT00979836|Experimental|Calcium Dobesilate|
3230849|NCT00979836|Placebo Comparator|Placebo|The placebo is a capsule with the same presence of experimental drug.
3230850|NCT00979823|Experimental|Early SimCare Diabetes Group|This group will receive an email web-link to 3 simulated learning cases each month for 6 months. After 6 months (18 total learning cases), they will then complete 4 simulated assessment cases, a diabetes knowledge survey, and a satisfaction survey.
3230851|NCT00979823|Active Comparator|Delayed SimCare Diabetes Group|Beginning in the spring of 2011, residents in this group will receive an email web-link to complete 4 simulated assessment cases and a diabetes knowledge survey. They will subsequently be sent 3 learning cases a month for 6 months and a satisfaction survey to complete.
3230852|NCT00979810|Experimental|18F-FLT PET scan|This is a pilot study intended to collect preliminary data on 15 patients diagnosed with untreated high-grade glioma who are scheduled to undergo surgical resection.
3230853|NCT00979797|Experimental|Maternal & Child Health|Community-based interventions to promoto Maternal and Child Survival in collaboration with GoB, Donors and NGOs.
3230854|NCT00979784|Active Comparator|1|
3230855|NCT00979784|Experimental|2|
3230856|NCT00979771|Experimental|GSK706769|100 mg GSK706769 twice daily orally (BID) for 28 days
3230857|NCT00979771|Placebo Comparator|Placebo|GSK706769 matched-placebo twice daily orally (BID) for 28 days
3230858|NCT00979758|Sham Comparator|Atorvastatin|Atorvastatin routine dose
3230859|NCT00979758|Placebo Comparator|Intensive Atorvastatin|Atorvastatin Intensive dose
3230860|NCT00979758|Active Comparator|Atorvastatin+Transplantation|Atorvastatin routine dose+ Mononuclear cells Transplantation
3230861|NCT00979758|Experimental|Intensive Atorvastatin+Transplantation|Atorvastatin intensive dose+ Mononuclear cells Transplantation
3230862|NCT00979745|Experimental|Afamelanotide|
3230863|NCT00979745|Placebo Comparator|Placebo|
3230864|NCT00979732|Active Comparator|GSE capsule active|Grape seed extract capsule 150 mg/BID
3230865|NCT00979732|Placebo Comparator|GSE capsule placebo|placebo grape seed extract capsule 150 mg/BID
3230866|NCT00979732|Active Comparator|GSE beverage active|grape seed extract beverage 150 mg/BID
3230867|NCT00979732|Placebo Comparator|GSE beverage placebo|grape seed extract placebo beverage 150 mg/BID
3230868|NCT00979719|Experimental|Intervention Group (IG)|Patients in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
3230869|NCT00979719|Placebo Comparator|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, & Fuchs, 2007) Göhner, W. & Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.
3230870|NCT00979719|No Intervention|Passive Control Group (PCG)|patients are asked to answer the questionnaires only
3230871|NCT00979706|Active Comparator|HAART|Patients assigned to this arm will receive standard HAART
3230872|NCT00979706|Experimental|HAART + Immunotherapy|Patients assigned to this arm will receive HAART plus cyclosporin A during the first two months and after that will receive IFN, GM-CSF and IL-2.
3230873|NCT00979693|Experimental|Full Dose|Participant will receive 25 mg psilocybin during two day-long sessions of psychotherapy in combination with psilocybin, with each session scheduled seven to 14 days apart.
3230874|NCT00979693|Active Comparator|Active Placebo|The participant will receive 4 mg psilocybin during two day-long sessions of psychotherapy in combination with psilocybin, with sessions scheduled seven to 14 days apart.
3230875|NCT00979680|Active Comparator|High-dose Radiotherapy|
3230876|NCT00979680|Active Comparator|Chemo-radiotherapy|
3230877|NCT00979667|Experimental|Oseltamivir|
3230878|NCT00979667|Experimental|Zanamivir|
3230879|NCT00979667|Placebo Comparator|Placebo of Oseltamivir|
3230880|NCT00979654|Experimental|Sifalimumab (MEDI-545) 500 or 600 milligram (mg)|All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
3230881|NCT00979641|Experimental|chemotherapy|i.v. biweekly bevacizumab 10 mg/kg and docetaxel 50 mg/square meter
3230882|NCT00979628|Experimental|Basal Plus Regimen|glargine subcutaneously once daily plus corrective doses of glulisine subcutaneously before meals and bedtime as needed
3230883|NCT00979628|Experimental|Basal Bolus|glargine subcutaneously once daily plus glulisine subcutaneously before meals (plus corrective doses of glulisine as needed)
3230884|NCT00979628|Active Comparator|sliding scale regular insulin (SSRI)|sliding scale regular insulin subcutaneously four-times daily in patients with T2DM admitted to general medicine and surgery wards.
3230885|NCT00979615|Experimental|1|Olopatadine HCL Nasal Spray, 0.6%
3230886|NCT00979615|Active Comparator|2|Azelastine HCl Nasal Spray, 137 mcg
3230887|NCT00979602|Experimental|GSK2340274A Group|Healthy male or female subjects between and including 18 to 60 years of age and older (>60 years) and between 18 to 64 years of age and older (>64 years), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.
3230888|NCT00979602|Experimental|GSK2340273A Group|Healthy male or female subjects between and including 18 to 60 years of age and older (>60 years) and between 18 to 64 years of age and older (>64 years), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.
3230889|NCT00979589|Active Comparator|Combination Clopidogrel and asprin|
3230890|NCT00979589|Placebo Comparator|Asprin and placebo|
3230892|NCT00979576|Experimental|BIBF 1120 BID (RD) + Pemetrexed|PHase II part: Study arm
3230893|NCT00979576|Experimental|BIBF 1120 BID(Placebo) + Pemetrexed|Phase II part: Comparator arm
3230894|NCT00979550|Experimental|Aldara cream|Imiquimod (Aldara cream) will be applied nightly for four weeks after standard of care laser treatment for port wine stain.
3230895|NCT00979550|Placebo Comparator|non-medicated petroleum cream|Non-medicated petroleum cream will be applied nightly for four weeks after standard of care laser treatment for port wine stain.
3230896|NCT00979537|Experimental|Test: Nisoldipine ER Tablets, 40 mg|Nisoldipine Extended-release Tablets, 40 mg
3230897|NCT00979537|Active Comparator|Reference: Sular Tablets 40 mg|Sular Tablets, 40 mg
3230898|NCT00979524|Experimental|Comprehensive Mental Health Services|Intervention group participants will receive an array of mental health education and services based on their level of need. Study participants will fall into low, moderate, or elevated risk based on results of baseline screening. Services will be provided to each group as specified below. Low risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) education activities to promote knowledge and change attitudes around mental health; Moderate risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) Short-term mental health services delivered by the LCSW-C, (c) Depression prevention intervention, (d) Education activities to promote knowledge and change attitudes around mental health; High risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) Mental health treatment services, (c) Education activities to promote knowledge and change attitudes around mental health.
3230899|NCT00979524|Active Comparator|Usual Care (Employment Training Services)|"Newly enrolling Westside YO members will receive usual care services, which constitute a moderate level of mental health services and supports. The usual care services related to mental health at the Westside will include (1) the ACASI screen for all newly enrolling Westside YO members, (2) the initial visit with a LCSW-C, and (3) mental health training for Westside Case Advocates. More extensive mental health educational activities and services (e.g., additional sessions with LCSW-C, SOS Club) provided to the intervention group will not be available at the Westside YO Center during the initial study period. Also, Eastside Case Advocates will receive more extensive and ongoing mental health training."
3230900|NCT00979511|Experimental|1 Hi-Calcium milk & exercise|
3230901|NCT00979511|Experimental|2 Hi-calcium milk with passive exercise|
3230902|NCT00979511|Experimental|3Low-Calcium with exercise|
3230903|NCT00979511|Experimental|4 Low-calcium milk with passive exercise|
3230904|NCT00979472|Experimental|with urgency|
3230905|NCT00979472|Experimental|without urgency|
3230906|NCT00979459|Experimental|MK-1006 80 mg DFC|Participants received a single dose of four 20 mg dry filled capsules of MK-1006
3230907|NCT00979459|Experimental|MK-1006 80 mg FCT|Participants received a single dose of two 40 mg film coated tablets of MK-1006
3230908|NCT00979446|Experimental|Guided|
3230909|NCT00979446|Active Comparator|Self-directed|
3230910|NCT00979433|Experimental|Bubble CPAP|All neonates randomised to bubble CPAP will be put on Bubble CPAP following initial extubation in first week of life.
3230911|NCT00979433|Other|Conventional CPAP|All neonates randomly allocated to conventional/ventilator derived CPAP.
3230912|NCT00979420||HIV treatment|
3230913|NCT00979407|Experimental|GSK2340272A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3230914|NCT00979407|Experimental|GSK2340274A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340274A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3230915|NCT00979394||Patients with type 2 diabetes|
3230916|NCT00979381||1|Patients with metastasized renal cell carcinoma or GIST who have been treated with sunitinib or sorafenib for at least 4 weeks
3230917|NCT00979381||2|patients with metastasized RCC who did not receive a systemic treatment for their RCC (nephrectomy is allowed)
3230918|NCT00979381||3|healthy volunteers
3230919|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 1)|
3230920|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 2)|
3230921|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 3)|
3230922|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 4)|
3230923|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 5)|
3230924|NCT00979342|Experimental|Cervical Block, 6 injection sites|Subject will receive a cervical block of 1% lidocaine and 0.25% bupivacaine, with injections in the following locations: 2cc at 12:00, 10cc at 3:00, 10 cc at 9:00, 5 cc at 4:00, 5 cc at 8:00, and 5 cc at 6:00.
3230925|NCT00979342|Experimental|Cervical Block, 2 injection sites|Subject will receive a cervical block of 1% lidocaine and 0.25% bupivacaine, with injections in the following locations: 10 cc at 4:00, and 10 cc at 8:00.
3230926|NCT00979342|Experimental|Ibuprofen q. 8 hours|Subjects will receive a post procedure pain management regimen of ibuprofen 800 mg every 8 hours, for the first 24 hours and then PRN.
3230927|NCT00979342|Experimental|Ibuprofen PRN|Subjects will receive a post procedure pain management regimen of ibuprofen 800 mg PRN.
3230928|NCT00979329||mRCC or GIST treated with sunitinib/sorafenib|
3230929|NCT00979316|Experimental|BMS-708163 (800 mg)|
3230930|NCT00979316|Experimental|BMS-708163 (200 mg)|
3230931|NCT00979316|Placebo Comparator|Placebo|
3230932|NCT00979316|Active Comparator|Moxifloxacin|
3230933|NCT00979303|No Intervention|Control Group|Control Patients - Undergo ablation procedures with radiation/fluoroscopy only
3230934|NCT00979303|Experimental|Study Group|Study Group Patients - Undergo ablation procedures using intracardiac echocardiography and 3D navigational system in addition to radiation.
3230935|NCT00979290||Separate anti-TB drugs|
3230936|NCT00979290||Fix-dosed combination anti-TB drugs|
3230937|NCT00979264|No Intervention|Control|Standard quality improvement approaches available through participation in Get With the Guidelines - Heart Failure.
3230977|NCT00978939|Active Comparator|Standard Drainage Arm|Patients will drain up to 1 liter of pleural fluid every other day
3230938|NCT00979264|Active Comparator|Intervention|Enhanced and/or intensive quality improvement approaches, coupled with standard approaches available through participation in Get With the Guidelines - Heart Failure.
3230939|NCT00979251|Experimental|ADS-8902|Amantadine and Ribavirin administered with Oseltamivir phosphate
3230940|NCT00979251|Active Comparator|Comparator|Oseltamivir Phosphate
3230941|NCT00979238|Other|Group 1|"All participants who meet the eligibility requirements.~Intervention: Gene Transfer and drug (scAAV2/8-LP1-hFIXco)."
3230942|NCT00979225|Experimental|Medication report|Medication reports delivered to providers at the point of care
3230943|NCT00979225|Experimental|Med. report plus care manager notices|Medication reports delivered to providers at the point of care and notices sent electronically to care managers
3230944|NCT00979225|No Intervention|Control|
3230945|NCT00979212|Active Comparator|Induction CT+RT|Chemotherapy (paclitaxel and carboplatin) plus radiation therapy followed by surgery (if operable) followed by consolidation chemotherapy (paclitaxel and carboplatin)
3230946|NCT00979212|Experimental|Induction CT+RT+Panitumumab|Panitumumab plus chemotherapy (paclitaxel and carboplatin) plus radiation therapy followed by surgery (if operable) followed by consolidation chemotherapy (paclitaxel and carboplatin)
3230947|NCT00979199|Other|Non invasive cardiac imaging|Intervention: Non invasive cardiac imaging. 'Anatomical' information provided by CTCA is obtained in every patient together with the 'functional' information provided by stress radionuclide cardiac imaging (SPECT or PET), to assess myocardial perfusion, and/or by stress MRI or ECHO imaging to assess myocardial contraction.
3230948|NCT00979173|Experimental|AC480|Patients who are not on enzyme inducing anti-epileptic drugs (EIAEDs) and are scheduled to undergo salvage surgical resection treated with preoperative AC480 at 300 mg BID followed by post-surgical AC480 at 300 mg BID.
3230949|NCT00979160|Experimental|Dasatinib|Patient will be treat at a starting dose of 20mg once daily, that can be escalated up to 100mg once daily.
3230950|NCT00979147|Experimental|Modular Metal Tibial Baseplate|Patients who were randomized to receive the modular polished tibial baseplate/XLK TKA
3230951|NCT00979147|Active Comparator|All Polyethylene Tibial Baseplate|Patients who were randomized to receive the nonmodular APT/GVF TKA design.
3230952|NCT00979134|Experimental|Part A|Ascending doses of AZD4547 administered orally to patients to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD)
3230953|NCT00979134|Experimental|Part B|Dose expansion phase, at the RD defined in Part A
3230954|NCT00979134|Experimental|Part C|Expansion phase in patients with FGFR1 and FGFR2 amplified tumours commencing at the RD defined from Part A
3230955|NCT00979121|Active Comparator|Rosuvastatin|"Half of the subjects were randomized to the active drug (Rosuvastatin).~Dosage, Form, and Frequency: drug was provided as 10mg tablets and administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). An initial 40mg loading dose was administered followed by a daily 20 mg maintenance dose. Maintenance dosing was adjusted for renal failure not compensated by renal replacement therapy.~Duration: drug was administered daily until:~28 days after randomization or 3 days after ICU discharge (whichever comes first),~Discharge from study hospital,~Death"
3230956|NCT00979121|Placebo Comparator|Placebo|"Half of the subjects were randomized to placebo.~10mg tablets identical to active drug were administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). Dosage, frequency, and duration was provided in the same manner as the active drug."
3230957|NCT00979108|Active Comparator|Standard exercise|Subjects will be instructed in neck and postural exercises.
3230958|NCT00979108|Experimental|Over-door traction and exercise.|Subjects will receive traction utilizing an over-the-door traction unit in addition to neck and postural exercises.
3230959|NCT00979108|Experimental|Mechanical traction and exercise|Mechanical cervical traction will be utilized in addition to neck and postural exercises.
3230960|NCT00979095||Multiple hernia|Patients with more than 3 primary hernias
3230961|NCT00979095||Control group|Patients without hernias
3230962|NCT00979069|Experimental|Aerobic Group|12 weeks of aerobic exercise 3 times a week
3230963|NCT00979069|No Intervention|Control Group|No contact control
3230964|NCT00979056|Experimental|Rifaximin|
3230965|NCT00979056|Placebo Comparator|Lactose|
3230966|NCT00979043|Active Comparator|Dietary weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
3230967|NCT00979043|Active Comparator|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
3230968|NCT00979043|Active Comparator|Dietary weight-loss & exercise|Participants received both the dietary weight-loss and exercise interventions for 18-months
3230969|NCT00979043|No Intervention|Health lifestyle control|The healthy-lifestyle control served as the usual care comparison group. For 3 months, participants met monthly with a health educator to discuss topics such as osteoarthritis, obesity, and exercise. Regular phone contact was maintained during months 4-18.
3230970|NCT00979017|Experimental|Avastin in combination with temozolomide and irinotecan|Avastin 10 mg/kg every 14 days. Temozolomide 200 mg/m2 daily x 5 days in a 28-day cycle. Irinotecan dose depends on whether the patient is on an enzyme-inducing antiepileptic drug (EIAED). EIAED 340 mg/m2 every other week and no EIAED 125 mg/m2 every other week. Irinotecan dose also depends on if the patient has the UGT 1A1 polymorphism (7/7). If so, they do not metabolize the irinotecan normally, so these patients will start out at a two dose level reduction. EIAED starting dose will be 275 mg/m2 and no EIAED starting dose will be 75 mg/ m2.
3230971|NCT00979004|Experimental|ICA-105665|
3230972|NCT00978978|Active Comparator|Propofol, endoscopies, liver diseases|Propofol, endoscopies, liver diseases
3230973|NCT00978978|Active Comparator|midazolam and fentanyl, endoscopies, liver diseases|Control: midazolam and fentanyl, endoscopies, liver diseases
3230974|NCT00978965||All patients|
3230975|NCT00978952|Experimental|Investigational Group|Use of Large Diameter Advanta™ V12 Covered Stent.
3230976|NCT00978939|Experimental|Aggressive Drainage Arm|Patients will drain up to 1 liter of pleural fluid everyday
3230978|NCT00978913|Experimental|DC vaccination and Cyclophosphamide|
3230979|NCT00978900|Active Comparator|Acesulfame K|
3230980|NCT00978900|Active Comparator|Sucralose|
3230981|NCT00978900|Active Comparator|Aspartame|
3230982|NCT00978900|Active Comparator|Glucose|
3230983|NCT00978900|Active Comparator|Fructose|
3230984|NCT00978900|Placebo Comparator|Water|
3230985|NCT00978887|Experimental|A|Retorna (facial cream)
3230986|NCT00978887|Placebo Comparator|B|Placebo (facial cream)
3230987|NCT00978861|Experimental|whitening|30% Hydrogen peroxide
3230988|NCT00978848||Women seeking emergency contraception|Women seeking emergency contraception
3230989|NCT00978848||Women seeking urine pregnancy testing|Women seeking urine pregnancy testing
3230990|NCT00978835|Experimental|Nurse case management|Telephone calls by a nurse every two months to assess adherence to diet, physical activity, and pill-taking regimens. The nurse will then identify barriers to adherence to these recommendations and use motivational interviewing approaches to offer solutions to the barriers identified. No changes to medication are made.
3230991|NCT00978835|Active Comparator|Nurse Education|Didactic, non-interactive education by a nurse on general health topics.
3230992|NCT00978822|Experimental|Clevidipine butyrate injectable emulsion|
3230993|NCT00978809|Active Comparator|Semont|BPPV patients treated by Semont maneuver by a physical therapist.
3230994|NCT00978809|No Intervention|control|healthy volunteers.
3230995|NCT00978809|Active Comparator|Epley maneuver|BPPV patients treated with Epley maneuver by a physical therapist.
3230996|NCT00978796|Active Comparator|Sitagliptin|Patients will receive sitagliptin for 4 weeks and then cross over to sugar pill
3230997|NCT00978796|Placebo Comparator|Sugar pill|Subjects will receive sugar pill for 4 weeks and then cross over to active sitagliptin
3230998|NCT00978783|Active Comparator|speaking valve|
3230999|NCT00978783|Active Comparator|Positive end expiratory pressure|
3231000|NCT00978757|Experimental|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
3231001|NCT00978757|Placebo Comparator|Placebo|Placebo: saline solution
3231002|NCT00978731|Experimental|Dasatinib|
3231003|NCT00978718|Placebo Comparator|Arm I|Patients receive oral placebo daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
3231004|NCT00978718|Experimental|Arm II: 200 μg selenium (Se) as high-Se Baker's yeast daily|Patients receive 200 μg of oral selenium (Se) as high-Se Baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
3231005|NCT00978718|Experimental|Arm III: 400 μg Se as high-Se baker's yeast daily|Patients receive 400 μg of oral Se as high-Se baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
3231006|NCT00978692|Experimental|Toric orthokeratology lenses|Children wearing toric ortho-k lenses at night for correcting astigmatism and myopia will be the study group
3231007|NCT00978692|Other|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive error will be serve as control group
3231008|NCT00978679|Experimental|Orthokeratology|Myopic children wearing orthokeratology at night will be the study group
3231009|NCT00978679|Other|Others|Myopic children wearing single-vision spectacles in the daytime will serve as control group
3231010|NCT00978653|Experimental|Allopurinol|Hyperuricemic (uric acid (UA)>7 mg/dL), nondiabetic CKD patients without any comorbidity, age<60 years with creatinine clearance (CrCl) between 20 and 60ml/min were evaluated.
3231011|NCT00978640|Experimental|fasting and exercise|36 h fast and 1 h ergometer cycling 50% VO2max
3231012|NCT00978640|Experimental|exercise|1 h ergometer cycling 50% VO2max
3231013|NCT00978627|Experimental|IDegAsp OD|
3231014|NCT00978627|Active Comparator|IDet|
3231015|NCT00978614|Experimental|Neramexane, Placebo, Moxifloxacin|
3231016|NCT00978601|Experimental|Multimodal analgesic protocol group|Women who received the multimodal analgesic protocol during minimally invasive myomectomy.
3231017|NCT00978601|No Intervention|No use of multimodal analgesic protocol group|Women who did not receive the multimodal analgesic protocol during minimally invasive myomectomy.
3231018|NCT00978588|Experimental|HES 130/0.4|
3231019|NCT00978588|Active Comparator|5% albumin|
3231020|NCT00978575|Active Comparator|Intravenous iron|
3231021|NCT00978575|Active Comparator|Oral iron|
3231022|NCT00978575|Placebo Comparator|Isotonic Sodium and placebo tablets|
3231023|NCT00978562|Experimental|Diagnostic (DSC-MRI with ferumoxytol, DCE-MRI with gadolinium)|Patients receive ferumoxytol and gadolinium IV and then undergo DSC-MRI and DCE-MRI. An optional MRI without injection of a contrast agent may be obtained after 20-24 hours at the discretion of the clinician. Patients may receive up to 3 more scans at least 3 weeks apart over up to 2 years.
3231024|NCT00978536|Other|group 1|MS with cortical cognitive troubles
3231025|NCT00978536|Other|group 2|MS with subcortical cognitive troubles
3231026|NCT00978536|Other|group 3|MS in the early stage of the disease when cognitive troubles are absent or inconspicuous
3231027|NCT00978523|Experimental|Treatment with AR-12|This is a single-agent, open-label, Phase 1, dose-escalation study in adult patients with advanced or recurrent solid tumors or lymphoma. Patients will receive orally administered AR-12 once daily for 28 consecutive days. The first dosing cycle will be followed by at least a 7 day off-treatment period; however, no off-treatment period will be scheduled between subsequent treatment cycles
3231028|NCT00978497|Placebo Comparator|1|Peginterferon and ribavirin + placebo BID for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
3231029|NCT00978497|Experimental|2|ANA598 200 mg BID + Peginterferon and ribavirin for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
3231030|NCT00978497|Experimental|3|ANA598 400mg BID + Peginterferon and ribavirin for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
3231031|NCT00978484|Active Comparator|Static Virtual Reality|Exposure Therapy using a still computer image
3231032|NCT00978484|Experimental|Dynamic Virtual Reality|Virtual Reality Exposure Therapy using full, immersive Virtual Reality
3231289|NCT00976729|Experimental|2.0 mg/kg i.v.|
3231033|NCT00978471|Experimental|experimental arm thiotepa|4 courses of conventional chemotherapy followed by high-dose Thiotepa with peripheral stem cell rescue. Surgical resection of all tumor masses will be performed as soon as possible.
3231034|NCT00978471|Other|Reference arm|4 courses of conventional chemotherapy. Surgical resection of all tumor masses will be performed as soon as possible.
3231035|NCT00978458|Active Comparator|Arm I|Patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily 5 days a week for 5½ weeks (28 fractions).
3231036|NCT00978458|Experimental|Arm II|Patients undergo radiotherapy as in arm I and receive concurrent oral temozolomide once daily for 5½ weeks. Beginning 28 days after completion of chemoradiotherapy, patients receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3231037|NCT00978445|Experimental|Home/Standard|all participants recieved vMetric protocol at home and in clinical setting, in this ARM the standard protocol was at home first then in clinic INR and interaction with a care giver.
3231038|NCT00978445|Experimental|Standard/Home|all participants recieved vMetric protocol at home and in clinical setting, in this ARM the standard protocol was an in clinic INR and interaction with a care giver, then the Home protocol was as described.
3231039|NCT00978432|Experimental|Arm 1a (RAD001 followed by LBH589)|"Part 1a: Sequential single agent therapy with RAD001 and LBH589. Each agent will be given for four-six 28-day cycles.~Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period.~Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease.~There will be a 1-6 week 'washout' period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient's best interest."
3231040|NCT00978432|Experimental|Arm 1b (LBH589 followed by RAD001)|"Part 1b: Sequential single agent therapy with LBH589 and RAD001 . Each agent will be given for four-six 28-day cycles.~Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period.~Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease.~There will be a 1-6 week 'washout' period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient's best interest."
3231041|NCT00978432|Experimental|Doublet (Combination RAD001 and LBH589)|Subjects will receive the doublet of RAD001 and LBH589 given in two to thirteen, 28-day cycles. Subjects will be evaluated for the disease status after completion of cycle two and then after every 4 cycles. Subjects with progressive disease will stop after 2 cycles. Subjects with stable disease or better may receive up to 13 cycles. LBH589 will start at 15mg po three days a week at least 2 days apart such as on days M/W/F or T/Th/Sat and RAD001 will start at 7.5mg po daily.
3231042|NCT00978419|Active Comparator|Rosuvastatin|Rosuvastatin
3231043|NCT00978419|Placebo Comparator|Placebo|Placebo
3231044|NCT00978393|Experimental|A|
3231045|NCT00978393|Experimental|B|
3231046|NCT00978393|Experimental|C|
3231047|NCT00978393|Experimental|D|
3231048|NCT00978393|Experimental|E|
3231049|NCT00978393|Experimental|F|
3231050|NCT00978380|Experimental|A|
3231051|NCT00978367|Experimental|Drug, intradermal avotermin (Juvista)|
3231052|NCT00978367|Placebo Comparator|Placebo (vehicle)|
3231053|NCT00978354|Active Comparator|Furosemide|Furosemide intravenous continuous infusion
3231054|NCT00978354|Placebo Comparator|Normal Saline|Normal saline titrated continuous intravenous infusion
3231055|NCT00978341|Experimental|Pregabalin|
3231056|NCT00978341|Other|Placebo|
3231057|NCT00978328||001|oxycodone immediate release (OXYRX) Characteristics of pts. receiving prescription medications containing OXYRX
3231058|NCT00978315|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
3231059|NCT00978315|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
3231060|NCT00978302|Placebo Comparator|Placebo (vehicle)|
3231061|NCT00978302|Experimental|Avotermin|
3231062|NCT00978263|Experimental|Glargine|Initial basal Insulin therapy was according to the dose administrated at bedtime in the last day hospitalization. basal Insulin doses were titrated every 3 days to achieve target FPG values between 80 and 130 mg/dl.
3231063|NCT00978263|Experimental|metformin-based Oral Antidiabetic Drugs|Subject in metformin-based OAD group was visited every two weeks in the first month and the every four weeks for another five months. The subjects will start with Metformin 425mg bid, The dosage was titrated (up to 850mg bid) based on the fasting blood glucose every two weeks. If the patients fail to achieve the target, gliclazide-MR (Diamicron, Servier), or glimepiride (Amaryl, Sanofi-Aventis) would be added.
3231064|NCT00978250|Experimental|1|FdCyd (100 mg/m2) + THU (350 mg/m2) administered 5 days/week for 2 weeks in 28-daycycles
3231065|NCT00978237|Active Comparator|EFV and Fixed combinations of analogues|EFV + Fixed combinations of analogue tenofovir + emtricitabine, or abacavir + lamivudine
3231066|NCT00978237|Experimental|LPV/r and combination of analogues.|
3231067|NCT00978224|Experimental|A|Viusid in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet
3231068|NCT00978224|Placebo Comparator|B|Placebo in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet
3231069|NCT00978211|Experimental|DOTA-TOC|Treatment arm
3231070|NCT00978198|Experimental|Part 1|single administration
3231071|NCT00978198|Experimental|Part 2|multiple administration
3231072|NCT00978159|Active Comparator|esomeprazole|esomeprazole 20 mg
3231073|NCT00978159|Active Comparator|Famotidine|famotidine 40 mg
3231074|NCT00978146|Experimental|Desmoid tumor|Patients with desmoid tumors
3231075|NCT00978133|Active Comparator|Skin Staples|Skin closure with skin staples
3231076|NCT00978133|Experimental|Dermabond|Closure of abdominal wound with dermabond (2-octylcyanoacrylate)
3231077|NCT00978120|Experimental|H1N1 vaccine high dose|Participants will be stratified according to asthma severity and will receive the high dosage of the H1N1 vaccine.
3231078|NCT00978120|Experimental|H1N1 vaccine low dose|Participants will be stratified according to asthma severity and will receive the low dosage of the H1N1 vaccine.
3231079|NCT00978081|Experimental|Arm I|Patients receive oral aminolevulinic acid and then undergo continuous photodynamic therapy 4-6 hours later.
3231080|NCT00978081|Experimental|Arm II|Patients receive aminolevulinic acid as in arm I and then undergo fractionated photodynamic therapy 4-6 hours later.
3231081|NCT00978068|Experimental|Group 1|LPV/r + 2 NRTIs
3231082|NCT00978068|Active Comparator|Group 2|NVP or EFV + 2 NRTIs
3231083|NCT00978055|Experimental|1|Liothyronine Sodium Tablets, 50 mcg
3231084|NCT00978055|Active Comparator|2|Cytomel® Tablets, 50 mcg
3231085|NCT00978042|Experimental|VOLUMA® XC Treatment Arm|Participants treated with JUVÉDERM® VOLUMA® XC Injectable Gel, volume determined by the investigator (up to 12 mLs) at study start. Participants were eligible for re-treatment if applicable.
3231086|NCT00978042|Other|Control Arm_No Treatment then VOLUMA® XC|No treatment for 6 months, then participants were treated with JUVÉDERM® VOLUMA® XC Injectable Gel, volume determined by the investigator (up to 12 mLs). Participants were eligible for re-treatment if applicable.
3231087|NCT00978029|Placebo Comparator|Placebo|Matching placebo tablet sublingual, once daily
3231088|NCT00978029|Experimental|SCH 39641 6 Amb a 1-U|6 Units Short Ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) in an AIT, sublingual, once daily
3231089|NCT00978029|Experimental|SCH 39641 12 Amb a 1-U|12 Amb a 1-U in an AIT, sublingual, once daily
3231090|NCT00978016|Experimental|arbaclofen placarbil-Cohort 1|"arbaclofen placarbil 20 mg QD with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
3231091|NCT00978016|Experimental|arbaclofen placarbil-Cohort 2|"arbaclofen placarbil 40 mg QD with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
3231092|NCT00978016|Experimental|arbaclofen placarbil-Cohort 3|"arbaclofen placarbil 20 mg BID with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
3231093|NCT00978016|Experimental|arbaclofen placarbil-Cohort 4|"arbaclofen placarbil 30 mg BID with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
3231094|NCT00978016|Placebo Comparator|Placebo-Cohort 5|"Placebo dose with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
3231095|NCT00977964|Experimental|Milk Based Protein Formula Process A|
3231096|NCT00977964|Experimental|Milk Based Protein Formula Process B|
3231097|NCT00977964|Experimental|Milk Based Protein Formula Process C|
3231098|NCT00977964|Experimental|Milk Based Protein Formula Process D|
3231099|NCT00977964|Experimental|Milk Based Protein Formula Process E|
3231100|NCT00977964|Experimental|Milk Based Protein Formula Process F|
3231101|NCT00977951|Experimental|Intradermal avotermin|
3231102|NCT00977951|Placebo Comparator|Placebo (vehicle)|
3231103|NCT00977938|Placebo Comparator|12m DAPT Study Arm|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
3231104|NCT00977938|Active Comparator|30m DAPT Study Arm|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine treatment in addition to aspirin.
3231105|NCT00977925|Experimental|Fibrin Pad|
3231106|NCT00977925|Active Comparator|Standard of Care|
3231107|NCT00977912|Experimental|"Milk containing B. Lactis"|"Milk = Breast-milk from the mother, pasteurized breast-milk from a donor, or preterm formula."
3231108|NCT00977912|Placebo Comparator|"Milk containing placebo"|"Milk = Breast-milk from the mother, pasteurized breast-milk from a donor, or preterm formula."
3231109|NCT00977886|Placebo Comparator|Placebo|
3231110|NCT00977886|Experimental|ELB353|
3231111|NCT00977873|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
3231112|NCT00977873|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
3231113|NCT00977860|Other|SBRT|
3231114|NCT00977847|Experimental|Interactive Voice Response Practice|"The introductory letter to patients will allow them an opportunity to opt-out of the study using a toll-free number. If they do not opt-out within 2 weeks of receiving the letter, the IVR system will make up to 15 call attempts over a 2 week period to reach the patient. The system will make outbound calls during preset hours. The system continuously checks the call list for the next scheduled call. Once contact is made, the spoken script greets the patient by name, authenticates identify, and will ask the patient the programmed questions. The IVR server will send completed family history assessments to the patients EHR as an HL7 compliant summary note as well as transmitting the separate coded responses for each condition/ family member to coded family history fields in the EHR."
3231191|NCT00977327|Other|Intraoperative MR|Use of intraoperative MR during resection of intraaxial tumor, Glioma
3231192|NCT00977327|Other|Intraoperative Ultrasound|Use of intraoperative ultrasound during resection of intraaxial tumor, Glioma
3231245|NCT00977015|Experimental|Treatment A - PF-04764793|PF-04764793 using inhaler A
3231115|NCT00977847|Experimental|Wireless Tablet PC Practice|Patients will receive an info letter in advance of their visit explaining the project with description of what information they will be asked to provide. Study staff will train the practice staff to hand out and collect the tablets for the patient. Staff will be trained to verify a patient's identity to ensure that the family history is sent to the correct EHR record. The initial screen of the tablet PC portal will include a paragraph of informed consent, and patients in this practice will be given the opportunity to decline participation. For patients who participate, the completed family history data will be transmitted to the patient's EHR as an HL7 compliant note and transmitting separate coded responses for each condition/ family member to coded family history fields.
3231116|NCT00977847|Experimental|Internet Portal Practice|Patients in this practice will receive the informational letter either by email or mail one month before their scheduled visit. It will have directions to access the MFHP website and how to transfer data through the hospitals secure internet portal (Patient Gateway). About 1/3 of patients are signed up to use this service. Those who do not have a Patient Gateway account will be provided with directions on how to establish this service. Patients will be required to have a Gateway account to ensure that the MFHP data file is sent securely to the correct EHR record. Patients in this arm will receive an initial email or letter with a single follow-up reminder sent 2 weeks later. For patients who participate, the completed family history data will be transmitted to the patient's EHR.
3231117|NCT00977847|Active Comparator|Usual Care Physician Assesment Practice|Usual standard family history assessments will be conducted by physicians during the patient visit. This arm will allow us to account for any temporal trends in family history assessment.
3231118|NCT00977834||Group 1|Patients with lymphoma or lung cancer
3231119|NCT00977834||Group 2|Caregivers
3231120|NCT00977821|Active Comparator|fresh|Embryo transfer with fresh oocytes
3231121|NCT00977821|Experimental|Frozen|Embryo transfer with vitrified oocytes
3231122|NCT00977808|Experimental|Closed-Loop Model Predictive Control (MPC)|Insulin dosing was performed by a model-predictive control (MPC) algorithm.
3231123|NCT00977808|Placebo Comparator|Open-Loop|Insulin dosing was performed by the patient (using their normal routine and personal insulin pump) under a physician's supervision.
3231124|NCT00977795|Experimental|Tumor fluorescence|A single arm in this open-label study where all patients are treated with the study drug. Areas of the brain that are fluorescent and areas that are not fluorescent are evaluated for presence of tumor cells
3231125|NCT00977769|Experimental|carbetocin 100 µg|Carbetocin injection, 100µg, single injection
3231126|NCT00977769|Active Comparator|oxytocin 5 u|Oxytocin 5U, injection, single injection
3231127|NCT00977769|Placebo Comparator|placebo (NaCl)|Saline single injection
3231128|NCT00977756||Group G|Participants will receive a medication regimen including RAL + ATV + RTV.
3231129|NCT00977756||Group H|Participants will receive a medication regimen including RAL + TDF.
3231130|NCT00977756||Group I|Participants will receive a medication regimen including ETV + DRV + RTV.
3231131|NCT00977756||Group J|Participants will receive a medication regimen including MVC + ATV + RTV.
3231132|NCT00977756||Group K|Participants will receive a medication regimen including MVC + LPV + RTV.
3231133|NCT00977756||Group L|Participants will receive a medication regimen including MVC + RAL + ETV.
3231134|NCT00977756||Arm M|Participants will receive a medication regimen of DRV
3231135|NCT00977756||Arm N|Participants will receive a medication regimen of DRV
3231136|NCT00977756||Arm O|Participants will receive a medication regimen of unboosted ATV
3231137|NCT00977756||Arm P|Participants will receive a medication regimen of RPV
3231138|NCT00977756||Arm Q|Participants will receive a medication regimen of RPV
3231139|NCT00977730|Active Comparator|Protandim|
3231140|NCT00977730|Placebo Comparator|Sugar pill|
3231141|NCT00977717||FOLFOX|Stage III colorectal cancer patients who are treated with adjuvant FOLFOX chemotherapy
3231142|NCT00977704|Active Comparator|Restylane and Perlane|Restylane and Perlane administered by injection. Recommended volume of 6.0 mL. Injection on study day 1 with an optional touch up on study day 14.
3231143|NCT00977678||Open access gastroscopy|Patients referred to open access gastroscopy
3231144|NCT00977678||Conventional outpatient gastroscopy|Gastroscopy after preceding appointment
3231145|NCT00977665|Experimental|rasagiline mesylate|rasagiline tablet, 1 mg/day for up to 48 weeks.
3231146|NCT00977665|Placebo Comparator|placebo|placebo tablet for up to 48 weeks.
3231147|NCT00977652|Active Comparator|Active stimulation|Percutaneous posterior tibial nerve stimulation
3231148|NCT00977652|Sham Comparator|sham stimulation|Inefficient percutaneous posterior tibial nerve stimulation
3231149|NCT00977626|Experimental|Part 1 AZD2423 or Placebo|AZD2423 or Placebo Oral Solution, multiple dosing during 10-14 days
3231150|NCT00977626|Experimental|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
3231151|NCT00977626|Experimental|Part 3 - AZD2423|AZD2423 Oral solution single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
3231152|NCT00977613|Other|life style counseling|Treated stage 2 and 3 colorectal cancer patients were counseled to exercise at least to the equivalent of 18 metabolic hours per week and were assessed over 6 months.
3231153|NCT00977600|Experimental|GT4P-F|GT4P-F (80% GT4P) was supplied as an odorless, colorless, tasteless liquid oil in 125 ml bottles. This formulation was designed to be mixed in water and create a self-emulsifying suspension, thus administered in water for the trial. The administered dose was calculated to contain the number of moles of PBA equivalent to 3 g/m2 of PBA. GT4P-F was mixed in 50 ml of water, taken orally, and then the cup rinsed with 50 ml of water and taken orally. GT4P-F was stored at ambient temperature away from light.
3231154|NCT00977600|Experimental|GT4P-API|GT4P-API was supplied as an odorless, colorless, tasteless oil in 125 ml bottles. The administered dose was calculated to contain the number of moles of PBA equivalent to 3 g/m2 of PBA. GT4P-API was taken orally and washed down with 100 ml of water. GT4P-API was stored at ambient temperature, away from light.
3231243|NCT00977028|Experimental|Tumescent Lidocaine with liposuction|Determine maximum safe mg/kg dosage of tumescent lidocaine with liposuction
3231244|NCT00977028|Experimental|Tumescent Lidocaine No Liposuction|Determine maximum safe mg/kg dosage of tumescent lidocaine without liposuction
3231155|NCT00977600|Active Comparator|Ammonul|Ammonul® was supplied as single-use glass vials of 10% sodium phenylacetate and 10% sodium benzoate for intravenous injection. Ammonul® was diluted before use with sterile dextrose injection 10% to a concentration of 9 mg/ml. Once diluted it was kept at room temperature and used within 24 hours. The dose was 2.75 g/m2 and was administered as an intravenous infusion over a 120-minute period. Ammonul® was stored at 25°C, within a range of 15-30°C.
3231156|NCT00977600|Active Comparator|Buphenyl|Sodium phenylbutyrate or Buphenyl® was supplied as a white powder in 250 g bottles. The required amount of powder (equivalent to 3 g/m2 of PBA) was weighed out, mixed in 100 ml of water, and administered orally. Doses were calculated on a weight/volume basis and corrected for sodium content and purity. Buphenyl® was stored at ambient temperature.
3231157|NCT00977587|Active Comparator|Saccharomyces Cerevisiae CNCM I-3856|2 weeks of treatment with Saccharomyces Cerevisiae CNCM I-3856 1 capsule twice a day, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).
3231158|NCT00977587|Placebo Comparator|placebo|"Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~Calcium phosphate, Dibasic 472.0 mg~Maltodextrin DE14 112.1 mg~Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day"
3231159|NCT00977574|Experimental|Arm I (paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3231160|NCT00977574|Experimental|Arm II (paclitaxel, carboplatin, temsirolimus)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3231161|NCT00977574|Experimental|Arm III (ixabepilone, carboplatin, bevacizumab)|Patients receive ixabepilone IV over 1 hour, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3231162|NCT00977561|Experimental|Arm A|Figitumumab (CP-751,871) Plus Chemotherapy [Cisplatin (Or Carboplatin) And Etoposide] All drugs to be administered on a 21 day cycle
3231163|NCT00977561|Active Comparator|Arm B|Chemotherapy [Cisplatin (Or Carboplatin) And Etoposide] All drugs to be administered on a 21 day cycle
3231164|NCT00977548|Experimental|Erlotinib Treatment|Erlotinib was given as an oral 150 mg daily dose for 16 weeks. The dose was adjusted for diarrhea, rash and pulmonary toxicity.
3231165|NCT00977522|Experimental|PF-03463275|
3231166|NCT00977522|Placebo Comparator|Placebo|
3231167|NCT00977496||Nasal Swab|New chronic hemodialysis patients with no evidence of nasal carriage of Staphylococcus aureus from Boston Dialysis Center Inc., the outpatient hemodialysis clinic of Tufts Medical Center
3231168|NCT00977483|Experimental|Drug: Thioctic Acid|600mg tablet Thioctic Acid (alpha-lipoic acid) once daily throughout the trial
3231169|NCT00977483|Placebo Comparator|Drug: Placebo|1 tablet once daily throughout the trial
3231170|NCT00977470|Experimental|Erlotinib|Erlotinib 150 mg oral daily
3231171|NCT00977470|Experimental|Erlotinib and Hydroxychloroquine|Erlotinib 150 mg oral daily plus Hydroxychloroquine (HCQ) 1000 mg oral daily
3231172|NCT00977457|Experimental|Diagnostic (specimen collection)|Patients receive prostatic massage and undergo a digital rectal examination. Laboratory assessments are performed and blood samples are collected for molecular biology testing. On the day of the scheduled prostatectomy, a second blood collection is performed prior to surgery.
3231173|NCT00977444|Experimental|kondrium|intraarticular injections once month
3231174|NCT00977444|Experimental|kondrium f|
3231175|NCT00977444|Active Comparator|corticosteroid|intraarticular injections once month
3231176|NCT00977431|Experimental|Regimen U|BIBW2992 + Radiotherapy
3231177|NCT00977431|Experimental|Regimen M|BIBW2992 + Temozolomide + Radiotherapy
3231178|NCT00977418|No Intervention|No intervention|Seniors undergo all testing but remain current lifestyle
3231179|NCT00977418|Experimental|Training|Groups will undergo either physical or mental training. Physical training is 1 hour aerobic training 3 times per week for 12 weeks. Mental training is 1 hour Strategic Memory Advanced Reasoning Training 3 times per week.
3231180|NCT00977405|No Intervention|Control|Primary closure after standard washing of wound with chlorhexidine solution
3231181|NCT00977405|Experimental|Collatamp G|Primary closure of wound with collatamp G in subcutaneous layer
3231182|NCT00977379|Active Comparator|WBRT Followed by Standard of Care|Participants will receive 3000 centi-Gray (cGy) WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) followed by standard of care therapy at the discretion of the treating oncologist starting no earlier than 2 weeks after completion of WBRT. The participants will be followed during the treatment until the halting of standard of care for any reason (central nervous system [CNS] or extra-cranial tumor progression, unacceptable toxicity, change of therapeutic strategy, withdrawal of participant consent, or death).
3231183|NCT00977379|Experimental|WBRT+Capecitabine Followed by Capecitabine Maintenance|Participants will receive 3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) concurrent with capecitabine 825 milligrams per square meter (mg/m^2) orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by capecitabine 1000 mg/m^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2, one week after completion of WBRT and continuing until the halting of capecitabine for any reason (CNS or extra-cranial progression, unacceptable toxicity, withdrawal of participant consent or death).
3231184|NCT00977366|Active Comparator|Hydrochloric acid infusion|
3231185|NCT00977366|Placebo Comparator|Saline|
3231186|NCT00977353|Experimental|sarcosine|sarcosine
3231187|NCT00977353|Active Comparator|citalopram|citalopram
3231188|NCT00977340|Experimental|Imagery Rehearsal Treatment|Imagery Rehearsal Treatment; 1 session on-site and 4 weeks of individual daily training; following principles Krakow and Zadra (2006)
3231189|NCT00977340|Experimental|Confrontation|Confrontation with nightmare content, until fear reaction habituates; 1 session on-site and 4 weeks of individual daily training
3231190|NCT00977340|Placebo Comparator|Imagination|Imagination of a safe and pleasant site; 1 session on-site and 4 weeks of individual daily training
3231288|NCT00976729|Experimental|1.0 mg/kg i.v.|
3231193|NCT00977314|Experimental|SoundBite Hearing System|The objective of this study was to assess the safety and effectiveness of the SoundBite hearing system by Sonitus Medical and to support its intended use for the treatment of unilateral hearing loss. The SoundBite hearing system is a Bone Conduction Device (BCD) and is occasionally referred to as such in the protocol and within this report.
3231194|NCT00977301|Experimental|fosamprenavir/ritonavir/olanzapine|single dose of 15 mg olanzapine after 13 days of fosamprenavir/ritonavir 700mg/100mg BID
3231195|NCT00977301|Active Comparator|single dose olanzapine|Single dose of 10 mg olanzapine
3231196|NCT00977288|Experimental|1|MK0859 10 mg + placebo
3231197|NCT00977288|Experimental|2|MK0859 40 mg + placebo
3231198|NCT00977288|Experimental|3|MK0859 100 mg + placebo
3231199|NCT00977288|Experimental|4|MK0859 300 mg + placebo
3231200|NCT00977288|Experimental|5|MK0859 10 mg + atorvastatin 10mg
3231201|NCT00977288|Experimental|6|MK0859 40 mg + atorvastatin 10mg
3231202|NCT00977288|Experimental|7|MK0859 100 mg + atorvastatin 10mg
3231203|NCT00977288|Experimental|8|MK0859 300 mg + atorvastatin 10mg
3231204|NCT00977288|Placebo Comparator|9|Placebo + atorvastatin 10mg
3231205|NCT00977288|Placebo Comparator|10|Placebo
3231206|NCT00977262|Experimental|Healthy control subjects, High saturated fat shake|
3231207|NCT00977262|Experimental|Healthy control subjects, High Monounsaturated fat shake|
3231208|NCT00977262|Experimental|Healthy control subjects, High Polyunsaturated fat shake|
3231209|NCT00977262|Experimental|Healthy obese subjecs, High saturated fat shake|
3231210|NCT00977262|Experimental|Healthy obese subjects, High monounsaturated fat shake|
3231211|NCT00977262|Experimental|Healthy obese subjects, High polyunsaturated fat shake|
3231212|NCT00977262|Experimental|Obese diabetes type 2 subjects, High Saturated fat shake|
3231213|NCT00977262|Experimental|Obese diabetes type 2 subjects, High Monounsaturated fat shake|
3231214|NCT00977262|Experimental|Obese diabetes type 2 subjects, High polyunsaturated fat shake|
3231215|NCT00977249|Active Comparator|varenicline|"Varenicline for 12 weeks.~The treatment schedule for varenicline is:~Varenicline tablets, 0.5 mg x 1 daily, day 1-3 Varenicline 0.5 mg x 2, day 4-6 Varenicline 1 mg x 2, day 7 up to 12 weeks"
3231216|NCT00977249|Placebo Comparator|placebo|Placebo for 12 weeks
3231217|NCT00977236|Experimental|Orthokeratology lenses|Children wearing orthokeratology at night for partial correction and spectacles at daytime for residual refractive error will be study group
3231218|NCT00977236|Other|Single-vision spectacle lenses|Children wearing single-vision spectacles in the daytime for correcting the refractive error will serve as control group
3231219|NCT00977223|Experimental|Aprepitant|7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
3231220|NCT00977223|Placebo Comparator|placebo|7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
3231221|NCT00977210|Experimental|OXi4503|
3231222|NCT00977197|Active Comparator|Pregabalin|"Subjects randomized to this arm will receive the following dosage:~75 mg (one tablet) twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study."
3231223|NCT00977197|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo matching the study drug.
3231224|NCT00977184|Experimental|Real rTMS|
3231225|NCT00977184|Sham Comparator|Sham rTMS|
3231226|NCT00977171|Experimental|Droxidopa|
3231227|NCT00977158||Throat Swab|Infants who have been diagnosed with cystic fibrosis
3231228|NCT00977145|Experimental|intratumoral IFN-gamma plus MELITAC 12.1,|intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1, an emulsion of a mixture of 12 class I MHC-restricted melanoma-derived peptides (12-MP) and a class II MHC-restricted tetanus toxoid-derived helper peptide (Peptide-tet).
3231229|NCT00977132|Experimental|Lenalidomide|Lenalidomid in combination valproic acid
3231230|NCT00977119||Capecitabine|Women with breast cancer receiving capecitabine as treatment for their breast cancer.
3231231|NCT00977106|Experimental|1|
3231232|NCT00977106|Placebo Comparator|2|
3231233|NCT00977106|Experimental|3|
3231234|NCT00977093|Experimental|Perfusion CMR examination|All patients will undergo perfusion CMR examination, single-photon emission computed tomography, and conventional invasive coronary angiography.
3231235|NCT00977080|Active Comparator|IV Paricalcitol|Participants in the IV stratum received intravenous (IV) paricalcitol and, if hypercalcemia (calcium >= 10.5 mg/dL), received 30 mg of oral cinacalcet. Paricalcitol was dosed at 0.07 mcg/kg with titration every 2 weeks.
3231236|NCT00977080|Active Comparator|Cinacalcet (at sites with IV paricalcitol)|Participants in the IV stratum received 30 mg of oral cinacalcet daily with a low-dose vitamin D receptor activator (VDRA) (doxercalciferol IV 1 mcg 3 times weekly (TIW) at sites in the US and alfacalcidol capsules 0.25 mcg daily at sites in Russia).
3231237|NCT00977080|Active Comparator|Oral paricalcitol|Participants in the oral stratum received oral paricalcitol and, if hypercalcemia (calcium >= 10.5 mg/dL), received 30 mg of oral cinacalcet. Paricalcitol was dosed at mcg = IPTH/60 3 times weekly (TIW) with titration every 2 weeks.
3231238|NCT00977080|Active Comparator|Cinacalcet (at sites with oral paricalcitol)|Participants in the oral stratum received 30 mg of oral cinacalcet daily with a low-dose vitamin D receptor activator (VDRA) (alfacalcidol capsules 0.25 mcg daily).
3231239|NCT00977067|Experimental|A|
3231240|NCT00977054|Experimental|DFPP and Peg-IFN + RBV|Double filtration plasmapheresis (Day 1, Day 2, Day 4, Day 8, and Day 9 from the onset of treatment; overall 5 session, each session for 4 hours) and weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1 to week 48; body weight < 75 kg, 1,000 mg/day and body weight >= 75 kg, 1,200 mg/day)
3231241|NCT00977054|Active Comparator|Peg-IFN + RBV|Weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1-48; body weight < 75 kg, 1,000 mg/day and body weight >=75 kg, 1,200 mg/day)
3231242|NCT00977041|Experimental|Neurofeedback|See Intervention description below.
3231246|NCT00977015|Active Comparator|Treatment B - PF-04764793|PF-04764793 using inhaler B
3231247|NCT00977002|Experimental|PPNIV|Patient randomized to this group will be ventilated with Positive Pressure Noninvasive Ventilation post extubation
3231248|NCT00977002|Active Comparator|O2I|Patient randomized to this group will be submitted to traditional oxygen therapy post extubation
3231249|NCT00976989|Experimental|T+P Concomitant Anthracycline-based chemotherapy|5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab (T) and pertuzumab (P) every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
3231250|NCT00976989|Experimental|T+P Sequential Anthracycline-based chemotherapy|FEC every three weeks for three cycles, followed by docetaxel, trastuzumab (T) and pertuzumab (P) every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.
3231251|NCT00976989|Experimental|T+P Concomitant Non-Anthracycline chemotherapy|Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab (P) every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
3231252|NCT00976976|Experimental|DXP|
3231253|NCT00976963|Active Comparator|Fosfomycin|Mix sachet with 1/2 glass cold water and stir. Drink immediatley
3231254|NCT00976963|Active Comparator|TMP/SMX|Sulfamethoxazole-Trimethoprim 800-160 MG Oral Tab (TMP/SMX) Take one twice daily for 3 days for urinary tract infection
3231255|NCT00976950||Patients with HIV-1 infection|
3231256|NCT00976937|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide along with sitagliptin placebo: lixisenatide 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24 along with placebo matching to sitagliptin 100 milligram (mg) capsule orally QD up to Week 24.
3231257|NCT00976937|Active Comparator|Sitagliptin|Sitagliptin along with 2-step initiation regimen of volume matching lixisenatide placebo: sitagliptin 100 mg capsule orally QD up to Week 24 along with volume matching lixisenatide placebo 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
3231258|NCT00976924|Experimental|Andon|Andon blood glucose test strips with test meter
3231259|NCT00976924|Active Comparator|Lifescan|Lifescan blood glucose test strips with test meter
3231260|NCT00976911|Active Comparator|1|
3231261|NCT00976911|Experimental|2|
3231262|NCT00976898|Experimental|Proton Beam Irradiation|This is a single arm study. All study participants will receive proton radiation therapy.
3231263|NCT00976885||Subjects with normal health|
3231264|NCT00976885||Subjects with Stroke|
3231265|NCT00976872|Active Comparator|omega-3|"omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA"
3231266|NCT00976872|Placebo Comparator|placebo|hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
3231267|NCT00976859|No Intervention|Waitlist control group|
3231268|NCT00976859|Experimental|Imagery Modification|Via a internet research patients collect data on skin renewal which is discussed afterwards; in a guided imagery modification the patients imagines the process of skin renewal and the building of new skin cells
3231269|NCT00976846|Experimental|Baxter Xenium XPH 210|Device: Baxter Xenium XPH 210 dialyzer
3231270|NCT00976833|Active Comparator|Usual Care|Usual Care
3231271|NCT00976833|Other|Standardized Rehabilitation|Intervention arm to receive Standardized Rehabilitation Therapy
3231272|NCT00976820|Experimental|Arepanrix/F1 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh [for children under (<) 12 months of age]. The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
3231273|NCT00976820|Experimental|Arepanrix/F2 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children < 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
3231274|NCT00976820|Experimental|GSK2340273A/F1 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children < 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
3231275|NCT00976820|Experimental|GSK2340273A/F2 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children < 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
3231276|NCT00976807|No Intervention|Control|
3231277|NCT00976807|Experimental|Intervention|Pulmonary Rehabilitation
3231278|NCT00976794|Experimental|lithium plus carbamazepine|combination of the two drugs in standard dosage
3231279|NCT00976794|Active Comparator|lithium plus valproate|combination of the two drugs in standard dosage
3231280|NCT00976768|Experimental|FOLFIRI arm|Patients receiving FOLFIRI
3231281|NCT00976755|Experimental|Arm A: Everolimus|"Everolimus:~10mg daily"
3231282|NCT00976742|Experimental|Endurance Exercise Training|
3231283|NCT00976729|Placebo Comparator|Placebo i.v.|
3231284|NCT00976729|Experimental|0.03 mg/kg i.v.|
3231285|NCT00976729|Experimental|0.09 mg/kg i.v.|
3231286|NCT00976729|Experimental|0.25 mg/kg i.v.|
3231287|NCT00976729|Experimental|0.5 mg/kg i.v.|
3231290|NCT00976729|Placebo Comparator|Placebo s.c.|
3231291|NCT00976729|Experimental|0.25 mg/kg s.c.|
3231292|NCT00976729|Experimental|0.5 mg/kg s.c.|
3231293|NCT00976716|Experimental|Celecoxib|
3231294|NCT00976703|Active Comparator|weighted bag|For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.
3231295|NCT00976703|Active Comparator|leg taping|For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
3231296|NCT00976690|Active Comparator|1|Azathioprine : 2mg/kg/day
3231297|NCT00976690|Active Comparator|2|Mesalazine : 4g/day
3231298|NCT00976677|Active Comparator|Arm I|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes (with or without bevacizumab IV over 30-90 minutes) on day 1. Patients also receive placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with stable or responding disease may continue to receive placebo (with or without bevacizumab) as above in the absence of disease progression or unacceptable toxicity.
3231299|NCT00976677|Experimental|Arm II|Patients receive paclitaxel and carboplatin (with or without bevacizumab) as in arm I. Patients also receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with stable or responding disease may continue to receive erlotinib hydrochloride (with or without bevacizumab) as above in the absence of disease progression or unacceptable toxicity.
3231300|NCT00976664|Active Comparator|Orthotic group|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period.
3231301|NCT00976664|Other|Shoe Orthotic Wait group|The group serves as a cross-over control group. Subjects are asked to avoid any new therapies for the first 6 weeks of the 12 week study and during the last 6 weeks they are fitted for the custom-made shoe orthotics.
3231302|NCT00976651|Active Comparator|Recombinant FSH|Patients undergo a standard antagonist protocol for in-vitro fertilisation, and are stimulated with recombinant gonadotropins. Histology and gene expression is studied on the endometrium.
3231303|NCT00976651|Experimental|human chorionic gonadotropin|"Patients undergo an antagonist protocol for in-vitro fertilisation and are stimulated with recombinant gonadotropins. When the patient has an estradiol value of 600 ng/L or more and when the patient has at least 6 follicles of 12 mm, the administration of gonadotropins is stopped and replaced by low dose human chorionic gonadotropins.~Histology and gene expression is studied on the endometrium"
3231304|NCT00976638|Active Comparator|Chromogenic Arm|Active surveillance of colonization with MRSA or VRE by chromogenic agar with isolation of positive patients.
3231305|NCT00976638|Active Comparator|Molecular Arm|Active surveillance of colonization with MRSA and VRE by PCR; and of ESBL by chromogenic agar with isolation of positive patients
3231306|NCT00976625|No Intervention|1|Control group without intervention. Treatment group with aortic valve replacement.
3231307|NCT00976625|Other|2|
3231308|NCT00976612||Nilotinib|Patients who receive nilotinib with failure to both imatinib and sunitinib
3231309|NCT00976599|Experimental|CP-690,550 + methotrexate|
3231310|NCT00976599|Placebo Comparator|Placebo + methotrexate|
3231311|NCT00976586||Patients wiht Incontinentia Pigmenti|Patients wiht Incontinentia Pigmenti
3231312|NCT00976573|Experimental|Arm I (bevacizumab, paclitaxel, and carboplatin)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, paclitaxel IV over 60 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3231313|NCT00976573|Experimental|Arm II(bevacizumab, paclitaxel, carboplatin, and everolimus)|Patients receive bevacizumab, paclitaxel, and carboplatin as in Arm I. Patients also receive everolimus PO QD on 3 days a week. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3231314|NCT00976560|Experimental|GW856553|GW856553 7.5 mg BID
3231315|NCT00976560|Placebo Comparator|Placebo|Matching Placebo BID
3231316|NCT00976547||Tinnitus patients|Group of 48 tinnitus patients
3231317|NCT00976534|Experimental|1|
3231318|NCT00976534|Placebo Comparator|2|
3231319|NCT00976521|Experimental|Local infusion, thrombus aspiration|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter following thrombus aspiration.
3231320|NCT00976521|Experimental|Local infusion, no aspiration|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter and no aspiration
3231321|NCT00976521|Active Comparator|No local infusion, thrombus aspiration|No local infusion of abciximab, thrombus aspiration.
3231322|NCT00976521|Active Comparator|No local infusion, no aspiration|No local infusion abciximab and no thrombus aspiration
3231323|NCT00976508|Experimental|1|
3231324|NCT00976495|Experimental|Dapagliflozin|
3231325|NCT00976495|Active Comparator|Hydrochlorothiazide|
3231326|NCT00976482||Pacemaker|Patients currently implanted with permanent Pacemaker according to guidelines
3231327|NCT00976469|Experimental|Dose A (3.75 µg HA antigen, 0.25 mL)|Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5 µg) of H1N1 pandemic influenza vaccine at a 21-day interval.
3231328|NCT00976469|Experimental|Dose B (7.5µg HA antigen, 0.5 mL)|Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5µg) of H1N1 pandemic influenza vaccine at a 21-day interval. A booster vaccination with a licensed seasonal trivalent influenza vaccine for the season 2010/2011 will be administered to at least 30 subjects in each age stratum (who have received Dose B) at 360 days after the first vaccination.
3231329|NCT00976456|Active Comparator|Bevacizumab + Pemetrexed|Bevacizumab + Pemetrexed
3231330|NCT00976456|Active Comparator|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab + Pemetrexed + Carboplatin
3231331|NCT00976443|Placebo Comparator|Placebo (normal saline)|Gastric injections of normal saline
3231332|NCT00976443|Active Comparator|BTA 100 U|Gastric injections of botulinum toxin A, 100 Units
3231333|NCT00976443|Active Comparator|BTA 300 U|BTA 300 U, gastric injections under EUS guidance
3231334|NCT00976430|Experimental|Therapy for Parkinson's disease|Stem cell derived from the bone marrow of the patient will be stereotactically transplanted in the striatum.These stem cell are the expected to grow up into dopamine secreting neural cells.
3231335|NCT00976417||1. Patients in the control group|
3231336|NCT00976417||2. Patients in the intervention group|
3231337|NCT00976404|Active Comparator|Maraviroc + raltegravir intensification|ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)
3231338|NCT00976404|Experimental|Maraviroc + raltegravir intens. plus DNA + HIV-rAd5 vaccine|ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)
3231339|NCT00976391|Active Comparator|albiglutide + insulin glargine|albiglutide in combination with insulin glargine
3231340|NCT00976391|Active Comparator|insulin glargine + preprandial lispro insulin|insulin glargine in combination with preprandial lispro insulin
3231341|NCT00976378|Experimental|0.05 mg/kg NOX-A12|
3231342|NCT00976378|Experimental|0.15 mg/kg NOX-A12|
3231343|NCT00976378|Experimental|0.45 mg/kg NOX-A12|
3231344|NCT00976378|Experimental|1.35 mg/kg NOX-A12|
3231345|NCT00976378|Experimental|2.7 mg/kg NOX-A12|
3231346|NCT00976378|Experimental|5.4 mg/kg NOX-A12|
3231347|NCT00976378|Experimental|10.8 mg/kg NOX-A12|
3231348|NCT00976378|Experimental|5.4 mg/kg NOX-A12 plus apheresis|
3231349|NCT00976365|Experimental|THL-P|Solution for study only.
3231350|NCT00976365|Placebo Comparator|Sugar pill|THL-p
3231351|NCT00976352|Experimental|rAAV1-CMV-GAA administration-cohort 1|rAAV1-CMV-GAA (study agent) Administration: 1.0 x 10e12 vector genomes. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.
3231352|NCT00976352|Experimental|rAAV1-CMV-GAA administration-cohort 2|rAAV1-CMV-GAA (study agent) Administration: 5.0 x 10e12 vector genomes Cohort 2 = 6 subjects. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.
3231353|NCT00976339|Experimental|Cholecalciferol 20,000 IU|Participants will receive Cholecalciferol 20,000 IU (2 capsules) weekly for one year.
3231354|NCT00976339|Experimental|Cholecalciferol 30,000 IU|Participants will receive Cholecalciferol 30,000 IU (3 capsules) weekly for one year.
3231355|NCT00976326|Experimental|A: Healthy volunteers|
3231356|NCT00976326|Experimental|B: Subjects with mild liver impairment|
3231357|NCT00976326|Experimental|C: Subjects with moderate liver impairment|
3231358|NCT00976326|Experimental|D: Subjects with severe liver impairment|
3231359|NCT00976313||1|male patients
3231360|NCT00976313||2|female patients
3231361|NCT00976300|Experimental|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months.
3231362|NCT00976300|Active Comparator|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals).
3231363|NCT00976287|Active Comparator|Conserved Therapy|Conserved Therapy
3231364|NCT00976287|Experimental|Interventional Therapy|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
3231365|NCT00976274|Placebo Comparator|starch capsule|
3231366|NCT00976274|Experimental|Korea red ginseng|
3231367|NCT00976261|Experimental|GSK1614235|Glucose lowering agent under investigation.
3231368|NCT00976261|Active Comparator|Sitagliptin|Glucose lowering comparator
3231369|NCT00976261|Placebo Comparator|Placebo|Placebo to match GSK1614235 and placebo to match Sitagliptin
3231370|NCT00976248|Experimental|RAD001|RAD001, oral, 10 mg, daily
3231371|NCT00976235|Experimental|IMT|
3231372|NCT00976222|Other|1 Arm Ranibizumab|
3231373|NCT00976209|Experimental|Phenylephrine Hydrochloride Extended Release Tablets, 30 mg|
3231374|NCT00976209|Active Comparator|Phenylephrine Hydrochloride Immediate Release Tablets, 10 mg|
3231375|NCT00976183|Experimental|Vorinostat|All study patients will receive the indicated dose of Vorinostat in conjunction with paclitaxel and carboplatin.
3231376|NCT00976170|Experimental|1|
3231377|NCT00976157||Ventilator-associated pneumonia|
3231378|NCT00976144|Experimental|GSK573719, GW642444, GSK573719+GW642444, placebo|This is a four-way cross-over study. Subjects, healthy volunteers, will receive a single dose of GSK573719 (500ug), GW642444 (50ug), GSK573719 (500ug)+GW642444 (50ug) administered concurrently, or placebo at each of the four treatment periods. There is a minimum wash-out period of seven days between doses. On enrolment into the study, subjects will be assigned to one of four treatment sequences which are based on a Williams design in accordance with the randomization schedule generated by GSK prior to study start.
3231379|NCT00976131|Placebo Comparator|Arm A|Cycle 3 of doxorubicin with Coenzyme Q10, Cycle 4 with Coenzyme Q10 Placebo
3231380|NCT00976131|Experimental|Arm B|Cycle 3 of doxorubicin with Coenzyme Q10 Placebo, Cycle 4 with Coenzyme Q10
3231381|NCT00976118|Placebo Comparator|placebo|
3231382|NCT00976118|Experimental|oral masitinib (AB1010)|masitinib (AB1010) 3 or 6 mg/kg/day
3231383|NCT00976105|Active Comparator|Part A: Zolpidem or placebo|This part is designed to examine the acute effects of up to 10mg of a known hypnotic sedative drug (Zolpidem) on cognitive and mood changes sensitve to sedation and tiredess.
3231384|NCT00976105|Experimental|Part B: GSK1521498 or placebo|At least 15 hours after Part A is completed subjects will enter Part B of the study.
3231385|NCT00976092|Experimental|Prasugrel + Bivalirudin|60 mg prasugrel plus bivalirudin
3231386|NCT00976092|Active Comparator|Clopidogrel + Heparin|clopidogrel as loading and heparin
3231387|NCT00976079|Experimental|Active TENS|Active TENS therapy for 4 weeks plus standard physical therapy for same time period.
3231388|NCT00976079|Placebo Comparator|Placebo TENS|Placebo TENS for 4 weeks plus standard physical therapy for same time period.
3231389|NCT00976079|No Intervention|Control Group|No TENS, standard physical therapy for 4 weeks.
3231390|NCT00976066|Experimental|GSK1521498|Subjects will receive a dose of the experimental compound GSK1521498
3231391|NCT00976066|Active Comparator|Naltrexone|Subjects will receive a dose of the licensed pharmaceutical product, Naltrexone
3231392|NCT00976053|Active Comparator|SPECT myocardial perfusion imaging|
3231393|NCT00976053|Active Comparator|PET myocardial perfusion imaging|
3231394|NCT00976040|Experimental|Early antiretroviral therapy|Subjects randomized to this arm will initiate antiretroviral therapy within 7 days of enrollment.
3231395|NCT00976040|No Intervention|Standard antiretroviral therapy|Subjects randomized to this arm will initiate antiretroviral therapy approximately 4 weeks after enrollment.
3231396|NCT00976027|Experimental|Fluzone® High Dose Group|
3231397|NCT00976027|Active Comparator|Fluzone® Group|
3231398|NCT00976014||Intensive Lipid-lowering therapy|Subjects on intensive long-term lipid lowering therapy (lowering LDL-C plus raising of HDL-C).
3231399|NCT00976014||Usual Care|"Subjects with Atherosclerosis who have been on conventional standard of care treatment."
3231400|NCT00976001|Other|Follow-up at an out-patient stroke unit|Information, measurement of handicap, further rehabilitation efforts, drug therapy for secondary prevention of stroke.
3231401|NCT00976001|Other|Follow-up with the general practitioner|
3231402|NCT00975988||TYKERB® tablets|There is only one group. This group includes patients administrated TYKERB® tablets
3231403|NCT00975975|Experimental|Basiliximab|Basiliximab will be given by IV on Day +7 post transplant for recipients of matched unrelated cells. Basiliximab will be given by IV on Day +9 post transplant for recipients of matched related cells.
3231404|NCT00975962|Experimental|Thrombolysis + Remote perconditioning|"Remote perconditioning (rIPerC) undertaken in ambulance on rute to hospital in case of suspected stroke.~The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC."
3231405|NCT00975962|Active Comparator|Thrombolysis|Thrombolysis without pretreatment with remote perconditioning
3231406|NCT00975949||Fluconazole Group|These subjects received fluconazole in our NICU fluconazole prophylaxis study during 1998-2000
3231407|NCT00975949||Placebo Group|These subjects received a placebo during our NICU fluconazole prophylaxis study during 1998-2000
3231408|NCT00975936|Experimental|[14C]-GSK706769|Single dose of 50µg [14C]-GSK706769 containing 250 nCi
3231409|NCT00975936|Experimental|[14C]-GSK706769 + Ketoconazole|An oral, 5-day repeat dose of 200 mg Ketoconazole (Q12) with a concomitant single oral dose of 50 µg [14C]-GSK706769 containing 250 nCi on day 3.
3231410|NCT00975923|Experimental|Collaborative Group|Quality Improvement Virtual Learning Collaborative with Interactive Teleconferences and Tool Kit
3231411|NCT00975923|Active Comparator|Tool Kit Group|Tool Kit of Evidence-Based Guidelines, Education Seminars, and Aide for Quality Improvement Methods
3231412|NCT00975910|Placebo Comparator|Saline|
3231413|NCT00975910|Active Comparator|Lidocaine|
3231414|NCT00975884|Experimental|Group A|Subjects receiving GSK2340272A vaccine according to a 0, 21 days schedule
3231415|NCT00975884|Experimental|Group B|Subjects receiving GSK2340272A vaccine according to a 0, 6 months schedule
3231416|NCT00975858|Active Comparator|Percutaneous Coronary Intervention|
3231417|NCT00975858|Experimental|Off Pump Coronary Artery Bypass Surgery|
3231418|NCT00975845||BioCleanse Tibialis Tendon Allograft|Tibialis Tendon allograft from donor 18-65 years old
3231419|NCT00975832||women with polycystic ovary syndrome|
3231420|NCT00975832||women without polycystic ovary syndrome|
3231421|NCT00975832||women from 18-40 years of age|
3231422|NCT00975819|Experimental|Sirolimus|
3231423|NCT00975806|Experimental|Cohort A|Participants received an oral dose of lenalidomide MTD (mg) capsule administered in combination with a single dose of sunitinib 37.5 mg on days 1-21 of each 21-day cycle
3231424|NCT00975806|Experimental|Cohorts F and G|Participants received an oral daily dose of lenalidomide on Days 1 to 21 in combination with a single oral daily dose of sunitinib 37.5 mg on days 1 to 14 or days 1 to 21 of each 21-day cycle
3231425|NCT00975793|No Intervention|Standard Care|Randomised allocation of standard care at the clinician's discretion in accordance with current best practice.
3231426|NCT00975793|Experimental|Early Goal Directed Therapy|Randomised allocation of early goal-directed therapy (EGDT).
3231427|NCT00975780|Experimental|enhanced oral care|
3231428|NCT00975780|Active Comparator|Usual care|The usual oral care provided at the nursing home
3231429|NCT00975767|Experimental|MGCD265+erlotinib|
3231430|NCT00975767|Experimental|MGCD265+docetaxel|
3231431|NCT00975754|Experimental|1|Pulmicort pMDI
3231432|NCT00975754|Experimental|2|Budesonide pMDI
3231433|NCT00975754|Experimental|3|Budesonide pMDI + Aerochamber Zero-stat spacer
3231434|NCT00975754|Experimental|4|Pulmicort repulses via Spira Nebuliser
3231435|NCT00975754|Experimental|5|Pulmicort Turbohaler
3231436|NCT00975741|Experimental|Monodose device|Mometasone furoate 400 µg DPI capsules administered through a monodose device.
3231437|NCT00975741|Active Comparator|Multidose device|Mometasone furoate 400 µg DPI capsules administered through a multidose device
3231438|NCT00975728|Experimental|Group 1 Product 825 (2-servings day)|30 subjects drinking 2 servings day of Product 825 for 8 weeks
3231439|NCT00975728|Experimental|Group 1 Product 824 (2 servings-day)|30 subjects drinking 2 servings-day of Product 824 for 8 weeks
3231440|NCT00975728|Experimental|Group 2 Product 825 (1 serving-day)|30 subjects drinking 1 serving-day of Product 825 for 8 weeks
3231441|NCT00975728|Experimental|Gruop 2 Product 824 (1 serving-day)|30 subjects drinking 1 serving-day of Product 824 for 8 weeks
3231442|NCT00975715|Experimental|TRI476|Participants received TRI476 based on body weight with titration up to the maintenance dose, in addition to their traditional antiepileptics dosage.
3231443|NCT00975715|Placebo Comparator|Placebo|Participants received placebo to TRI476 without any adjustment to the dosing regimen, in addition to their traditional antiepileptics dosage.
3231444|NCT00975702|No Intervention|No RIPC Group|This group is the control group or the comparator group with RIPC
3231445|NCT00975702|Experimental|RIPC Group|In this group deceased donors will receive Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet of the lower limb prior to organ recovery.
3231446|NCT00975676|Experimental|Triptorelin plus tamoxifen|Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.
3231447|NCT00975676|Experimental|Triptorelin plus exemestane|Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years.
3231448|NCT00975663|Experimental|1|Optimized TDM of tacrolimus and MMF dosing
3231449|NCT00975663|Active Comparator|2|Current tacrolimus and MMF dosing strategies
3231450|NCT00975650|Experimental|Test 8.0, Ref 5.0, Test 14.0, Test 11.0|Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days;
3231451|NCT00975650|Experimental|Test 11.0, Test 8.0, Ref 5.0, Test 14.0|Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days
3231452|NCT00975650|Experimental|Test 14.0, Test 11.0, Test 8.0, Ref 5.0|Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days;
3231453|NCT00975650|Experimental|Ref 5.0, Test 14.0, Test 11.0, Test 8.0|Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days
3231454|NCT00975637|Experimental|140 mg SC|140 mg SC
3231455|NCT00975637|Experimental|70 mg SC|70 mg SC
3231456|NCT00975637|Experimental|280 mg SC|280 mg SC
3231457|NCT00975637|Placebo Comparator|210 mg SC|210 mg SC
3231458|NCT00975637|Experimental|Placebo|Placebo
3231459|NCT00975611|Active Comparator|Amantadine 100mg BID|Subjects take amantadine 100mg tablets twice per day (BID)
3231460|NCT00975611|Active Comparator|Amantadine, 200mg BID|Subjects take amantadine 200mg tablets twice per day (BID)
3231461|NCT00975611|Placebo Comparator|Amantadine, placebo BID|Subjects take placebo tablets twice per day (BID)
3231462|NCT00975585|Active Comparator|senofilcon A both eyes|soft contact lens worn daily for 2 weeks, with a 2-week replacement regimen.
3231463|NCT00975585|Active Comparator|lotrafilcon B both eyes|soft contact lens worn daily for 4 weeks, with a 4-week replacement regimen
3231464|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 7.5 μg|
3231465|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 15 μg|
3231466|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 30 μg|
3231467|NCT00975572|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|
3231468|NCT00975572|Placebo Comparator|Placebo control|
3231469|NCT00975572|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|
3231470|NCT00975559||Normal volunteers|Normal study volunteers with no prior history of coronary artery disease
3231471|NCT00975559||Apical Ballooning Syndrome|Women who have had a documented Apical Ballooning event as shown by coronary angiogram
3231472|NCT00975559||Coronary Endothelial Dysfunction|Patients who have been diagnosed with Endothelial Dysfunction via a coronary angiogram with acetylcholine challenge
3231473|NCT00975559||Myocardial Infarction|Women diagnosed with a Myocardial Infarction who subsequently had a Percutaneous Intervention
3231474|NCT00975533|Experimental|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM. The device is intended to improve glycemic control and induce weight loss.
3231475|NCT00975533|Active Comparator|Control|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
3231476|NCT00975520|Active Comparator|Radiation Therapy|Investigational Treatment
3231477|NCT00975520|Other|Observation|Observation
3231478|NCT00975507|Experimental|1|ProQuad™ (V221) + Placebo Followed by ProQuad™
3231479|NCT00975507|Active Comparator|2|M-M-R™ II + VARIVAX™
3231480|NCT00975494|Active Comparator|sildenafil|sildenafil 50 mg three times/day
3231481|NCT00975494|Placebo Comparator|Placebo|Placebo
3231482|NCT00975481|Experimental|dimebon 20 mg|
3231483|NCT00975481|Experimental|dimebon 40 mg|
3231484|NCT00975481|Experimental|dimebon 60 mg|
3231485|NCT00975481|Placebo Comparator|placebo|
3231486|NCT00975481|Active Comparator|alprazolam 1 mg|
3231487|NCT00975481|Active Comparator|alprazolam 3 mg|
3231488|NCT00975468|Active Comparator|Pressure-Controlled Ventilation|The patients' lungs ventilation will be initiated with a peak airway pressure that provided a tidal volume of 8 ml.kg-1. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
3231489|NCT00975468|Placebo Comparator|Volume Controlled Ventilation|The patients' lungs will ventilated with a tidal volume of 8 ml.kg-1. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
3231490|NCT00975455||Subjects with hematuria|
3231491|NCT00975442|Experimental|Eccentric training|
3231492|NCT00975442|Placebo Comparator|Forearm band|
3231538|NCT00975117|Placebo Comparator|Placebo|
3231493|NCT00975429|Experimental|WST11 - 4mg (TOOKAD® Soluble)|4mg/kg Treatment with WST11-mediated VTP
3231494|NCT00975429|Experimental|WST11 - 6mg|6mg/kg Treatment with WST11-mediated VTP
3231495|NCT00975416|Placebo Comparator|Methadone|Intranasal oxytocin administered in the context of cognitive behavioral therapy to methadone dependent outpatients
3231496|NCT00975416|Placebo Comparator|Outpatient Cocaine|Intranasal oxytocin administered in the context of cognitive behavioral therapy to cocaine dependent outpatients
3231497|NCT00975416|Placebo Comparator|Inpatient Cocaine|Intranasal oxytocin administered in the context of cognitive behavioral therapy to cocaine dependent inpatients
3231498|NCT00975403|Experimental|Dead space breathing|
3231499|NCT00975403|Sham Comparator|Room air breathing|
3231500|NCT00975390|Experimental|1|Carbohydrate ingestion
3231501|NCT00975390|Experimental|2|Carbohydrate and protein ingestion
3231502|NCT00975390|Experimental|3|Carbohydrate and caffeine ingestion
3231503|NCT00975377|No Intervention|No hair removal|Patients randomized to the no hair removal cohort will not undergo any preoperative hair removal.
3231504|NCT00975377|Active Comparator|Hair clipping|Patients in the clipping cohort undergo hair removal at the surgical site. Hair removal will occur on the day of surgery immediately prior to the scheduled operation.
3231505|NCT00975364||blood sampling|Consented volunteers provide a one-off blood sample
3231506|NCT00975351|Experimental|IV dose of 5-methyltetrahydrofolic acid|IV test dose of 13C5-labelled 5-methyltetrahydrofolic acid to all eligible volunteers, followed by regular blood samplings over 2hr period taken via a cannula.
3231507|NCT00975338||Prospective LIFEspan|LIFEspan youths with Cerebral Palsy or Acquired Brain Injury
3231508|NCT00975338||Prospective Non-LIFEspan|LIFEspan youths with Spina Bifida
3231509|NCT00975338||Retrospective Non-LIFEspan|Non-LIFEspan youths with Cerebral Palsy or Acquired Brain Injury
3231510|NCT00975338||LIFEspan Staff|All staff affiliated with the LIFEspan model of linked transition care
3231511|NCT00975338||Caregivers|Parents of participating youths
3231512|NCT00975325|Active Comparator|"Yohimbine, Yohimbine Spiegel"|
3231513|NCT00975325|Active Comparator|Yohimbine Yocon-Glenwood|
3231514|NCT00975312|Experimental|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand.
3231515|NCT00975299|Experimental|Arm 1|
3231516|NCT00975299|Experimental|Arm 2|
3231517|NCT00975286|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
3231518|NCT00975286|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
3231519|NCT00975273|Experimental|Breathing Training|Patients will receive biofeedback assisted breathing training
3231520|NCT00975273|Active Comparator|Breathing Awareness|Patients will receive biofeedback assisted breathing awareness training.
3231521|NCT00975247|Active Comparator|Received Booklet|Patients who have received colonoscopy preparation booklet
3231522|NCT00975247|No Intervention|Did not receive booklet|Patients who did not receive colonoscopy preparation booklet
3231523|NCT00975234|Experimental|Skeletal myoblasts|Patients who are receiving skeletal myoblasts
3231524|NCT00975234|Placebo Comparator|Placebo|Revascularisation surgery
3231525|NCT00975221|Experimental|Cinacalcet|Participants received cinacalcet at a starting dose of 30 mg orally BID and were eligible for a dose titration once every 3 weeks during the 12-week dose-titration phase based on corrected total serum calcium concentration and safety assessments. Participants continued to receive cinacalcet for another 16 weeks during the efficacy assessment phase and then continued into the open-label extension phase and received cinacalcet at a starting dose of 30 mg BID for 24 weeks. The dose of cinacalcet could have been increased or decreased as needed to maintain a corrected total serum calcium concentration within the normal range through Week 52.
3231526|NCT00975221|Placebo Comparator|Placebo|Participants received placebo orally twice a day (BID) for 12 weeks during the dose titration phase and for another 16 weeks during the efficacy assessment phase. Participants then continued into the open-label extension phase and received cinacalcet at a starting dose of 30 mg BID for 24 weeks. The dose of cinacalcet could have been increased or decreased as needed to maintain a corrected total serum calcium concentration within the normal range through Week 52.
3231527|NCT00975195|Experimental|fluticasone high dose|fluticasone priopionate high dose and tiotropium inhalation and salmeterol xinafoate
3231528|NCT00975195|Experimental|fluticasone medium & low doses|fluticasone priopionate medium and high doses; and tiotropium inhalation; and salmeterol xinafoate; and placebo matched to fluticasone priopionate
3231529|NCT00975182|Experimental|A|
3231530|NCT00975169||TZDs User|
3231531|NCT00975156|Experimental|Lokomat Intervention|Lokomat gait training (five days a week for eight weeks for a total of 40 sessions).
3231532|NCT00975156|Active Comparator|Standard of Care|Conventional physical therapy focusing on gait training for five days a week for eight weeks for a total of 40 sessions.
3231533|NCT00975143|Experimental|CIP-Isotretinoin|
3231534|NCT00975143|Active Comparator|Isotretinoin|
3231535|NCT00975130|Experimental|SC-GLM50|In Part 1 of the study, participants received subcutaneous golimumab treatment at a dose of 50 mg once monthly for 6 months in combination with background DMARD treatment.
3231536|NCT00975130|Experimental|IV GLM 2 mg/kg + GLM50-SC|After 6 months of treatment in study Part 1, participants with good or moderate response but not in remission will receive intravenous (IV) golimumab at a dose of 2 mg/kg once monthly for a period of 6 months or until remission is achieved. Participants will receive IV GLM at a dose of 2 mg/kg at the start of Month 7, and then at the start of Month 8 and Month 10 if the subject has not achieved remission at any of these IV administration visits. If remission is achieved, participants were switched to subcutaneous golimumab at a dose of 50 mg once monthly until study end, in combination with background DMARD treatment.
3231537|NCT00975130|Experimental|GLM50-SC|After 6 months of treatment in study Part 1, participants with good or moderate response but not in remission will receive subcutaneous golimumab at a dose of 50 mg once monthly for a period of 6 months, in combination with background DMARD treatment.
3231539|NCT00975117|Experimental|Spermotrend|
3231540|NCT00975104|Experimental|AMG 745 0.3 mg/kg|0.3 mg/kg AMG 745
3231541|NCT00975104|Experimental|AMG 745 1.0 mg/kg|1.0 mg/kg, AMG 745
3231542|NCT00975104|Placebo Comparator|Placebo|Placebo
3231543|NCT00975104|Experimental|AMG 745 3.0 mg/kg|3.0 mg/kg, AMG 745
3231544|NCT00975091|Active Comparator|Entecavir 0.5|
3231545|NCT00975091|Active Comparator|Entecavir 1.0|
3231546|NCT00975078|Experimental|adrenal insufficiency|
3231547|NCT00975065|Experimental|Galvus group|"the combination of metformin plus Vildagliptin:~vildagliptin 50 mg bid plus metformin 1500mg~Additional SU therapy(After 12th week only under the following conditions): If A1c is ≥ 7.0% or investigator determines that the patient have metabolic problems at 12th week of therapy, investigator can prescribe additional sulfonylurea(glimepiride) to the current therapy."
3231548|NCT00975065|Active Comparator|Diabex group|"metformin alone arm:~metformin 1500mg plus metformin 500mg or 1000mg~Additional SU therapy(After 12th week only under the following conditions): If A1c is ≥ 7.0% or investigator determines that the patient have metabolic problems at 12th week of therapy, investigator can prescribe additional sulfonylurea(glimepiride) to the current therapy"
3231549|NCT00975052|Active Comparator|A|Sitagliptin alone
3231550|NCT00975052|Active Comparator|B|Metformin alone
3231551|NCT00975052|Experimental|C|Sitagliptin and metformin concomitantly
3231552|NCT00975052|Placebo Comparator|D|Placebo
3231553|NCT00975039|Experimental|WST11|Treatment with WST11-mediated VTP
3231554|NCT00975026|Active Comparator|Massages|Chair massage for 30 minutes once a week.
3231555|NCT00975026|Active Comparator|Massages + Stretches|Chair massage for 30 minutes once a week in addition to stretching exercises, to be done twice daily for 20 minutes.
3231556|NCT00975026|No Intervention|No Intervention|
3231557|NCT00975013||Bone Density Study Group|Morbidly obese, (BMI >40 kg/m2, or 35 kg/m2 with comorbidities) female patients who have given consent to undergo additional testing including bone densitometry, and lab testing preoperatively and at 6 and 12 months after undergoing elective laparoscopic roux-en-Y gastric bypass.
3231558|NCT00975000|Experimental|Cinacalcet|Participants received cinacalcet at a starting dose of 30 mg orally once daily for 52 weeks. Cinacalcet dose was titrated every 4 weeks during the dose-titration phase and during study visits in the maintenance phase based on intact parthyroid hormone (iPTH) values, corrected total serum calcium values, and safety assessments.
3231559|NCT00975000|Placebo Comparator|Placebo|Participants received placebo orally once daily for 52 weeks.
3231560|NCT00974987|Experimental|Treatment group|BNCT(boron neutron capture therapy), XRT(X-ray radiation treatment) and TMZ(temozolomide) treatment
3231561|NCT00974974|Experimental|IPX066|Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IPX066.
3231562|NCT00974974|Active Comparator|IR CD-LD|Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IR CD-LD (active comparator).
3231563|NCT00974961|Active Comparator|Levobupivacaine|Lumbar puncture with Levobupivacaine for spinal anesthesia
3231564|NCT00974961|Active Comparator|Bupivacaine|Lumbar puncture with Bupivacaine for spinal anesthesia
3231565|NCT00974948|Active Comparator|Neurolysis|Patients will undergo EUS followed by EUS-guided, bilateral neurolysis with bupivicaine and absolute alcohol.
3231566|NCT00974948|No Intervention|Conventional therapy|EUS will be performed with no celiac plexus neurolysis.
3231567|NCT00974935|Experimental|Cohort 1|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01 mcg intramuscular.
3231568|NCT00974935|Experimental|Cohort 2|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.1 mcg intramuscular.
3231569|NCT00974935|Experimental|Cohort 3|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.5 mcg intramuscular.
3231570|NCT00974935|Experimental|Cohort 4|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 2.5 mcg intramuscular.
3231571|NCT00974935|Experimental|Cohort 5|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 10 mcg intramuscular.
3231572|NCT00974935|Experimental|Cohort 6|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 20 mcg intramuscular.
3231573|NCT00974935|Experimental|Cohort 7|Two doses of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 20 mcg intramuscular 21 days apart.
3231574|NCT00974922|Active Comparator|Phase I: Aliskiren|Two weeks of single-blind placebo, followed by randomization in a double-blind fashion to Aliskiren 150 mg to 300 mg once daily for 6 weeks
3231575|NCT00974922|Active Comparator|Phase I: Cholecalciferol|Two weeks of single-blind placebo, followed by randomization in a double-blind fashion to Cholecalciferol (3000 I.U.) once daily for 6 weeks
3231576|NCT00974922|Active Comparator|Phase II: Aliskiren and Vitamin D3|Aliskiren 150-300 mg orally once daily and Cholecalciferol 3000 I.U. in combination once daily for 6 weeks
3231577|NCT00974909|Active Comparator|Treatment group|Treatment group
3231578|NCT00974909|Sham Comparator|sham group|Sham group
3231579|NCT00974896|Experimental|AMG 479 + Sorafenib cohorts|The aim is to determine the safety, tolerability and PK of AMG 479 with sorafenib. AMG 479 will be given bi-weekly; sorafenib will be given daily.
3231580|NCT00974896|Experimental|AMG 479 + Erlotinib cohorts|The aim is to determine the safety, tolerability and PK of AMG 479 with erlotinib. AMG 479 will be given bi-weekly; erlotinib will be given daily.
3231581|NCT00974883||Suspected GCA|Patients who present with new onset of headache and suspected diagnosis of GCA. They will all require a temporal artery biopsy to assist in the diagnosis
3231582|NCT00974883||Training cohort|Patients with any condition or healthy volunteers who are willing to consent ot have their temporal and axillary arteries examined using ultrasound, for training purposes
3231583|NCT00974870|Experimental|needling treatment|Needling treatment applied to half of the face at each study visit
3231584|NCT00974870|No Intervention|Control|No treatment applied to half of the face
3231635|NCT00974519|Placebo Comparator|Placebo|Placebo, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
3231689|NCT00974103|Experimental|Chiropractic treatment, exercise|Chiropractic treatment and exercise
3231585|NCT00974857|Active Comparator|Study group|"Pre-dialytic overhydration(OH) will be estimated by Body Composition Monitor (BCM) at least once a month.~If OH is positive, dry weight will be reached by ultrafiltration without regard to the level of blood pressure.~If OH is negative and:~Systolic blood pressure(SBP)< 100 mmHg with/or intradialytic hypotension episodes(IDHE) and/or clothing and/or erythrocytosis(htc>36%);dry weight will be increased.~SBP normal(100-150 mmHg) w/o IDHE and clothing and erythrocytosis;dry weight will not be changed.~SBP normal(100-150 mmHg) with IDHE and/or clothing and/or erythrocytosis;dry weight will be increased.~SBP>150 mmHg captopril test(CT)will be done. If CT is positive, ACEI/ ARBs will be used and dry weight will be increased if IDHE and/or clothing and/or erythrocytosis(htc>36%) are present.~If CT is negative, BCM measurement will be repeated and if same,ABPM will be performed for confirmation."
3231586|NCT00974857|Other|Control Group|BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
3231587|NCT00974831|Experimental|AA Drink|Amino Acid Drink Mixture
3231588|NCT00974831|Placebo Comparator|Glucose drink|
3231589|NCT00974818|Experimental|pts getting Mitomycin C (MMC)|Patients will receive a induction course of 6 cycles of weekly intravesical therapy of MMC, followed by a maintenance schedule consisting of 3 weekly cycles of the same drug at 3, 6, 12, 18, and 24 months.
3231590|NCT00974818|Experimental|pts getting Bacillus Calmette-Guerin (BCG)|Patients will receive a induction course of 6 cycles of weekly intravesical therapy of either BCG, followed by a maintenance schedule consisting of 3 weekly cycles of the same drug at 3, 6, 12, 18, and 24 months.
3231591|NCT00974805|Experimental|Seretide 500 Accuhaler|Seretide 500 Accuhaler one inhalation BD
3231592|NCT00974779|Experimental|HCO dialyzer|Hemodialysis with the HCO1100 hemodialyzer membrane with high molecular weight cut off.
3231593|NCT00974779|Active Comparator|Placebo|Regular dialysis using a polyamide high-flux hemodialyzer
3231594|NCT00974766|Active Comparator|Low-dose glucocorticoid|Low-dose steroid
3231595|NCT00974766|Active Comparator|High-dose glucocorticoid|High-dose steroid
3231596|NCT00974753|Placebo Comparator|PPV-MP + Placebo (Saline drops)|PPV-MP= pars plana vitrectomy membrane peel
3231597|NCT00974753|Active Comparator|PPV-MP + Ketorolac 0.5%|PPV-MP= pars plana vitrectomy membrane peel
3231598|NCT00974753|Placebo Comparator|PhacoVit-MP + Placebo (Saline drops)|PhacoVit-MP= phacovitrectomy membrane peel
3231599|NCT00974753|Active Comparator|PhacoVit-MP + Ketorolac 0.5%.|PhacoVit-MP= phacovitrectomy membrane peel
3231600|NCT00974740|Placebo Comparator|atorvastatin matching placebo|atorvastatin matching placebo
3231601|NCT00974740|Experimental|atorvastatin|40 mg atorvastatin for 4 weeks (run-in period), then 80 mg atorvastatin, total treatment period was 18 months
3231602|NCT00974727|Experimental|Gardening Program|
3231603|NCT00974727|No Intervention|Control|Subjects received the standard of care for the summer.
3231604|NCT00974714|Experimental|1|Oral L-arginine 2 g twice a day, for 14 weeks
3231605|NCT00974714|Placebo Comparator|2|oral placebo twice a day for 14 weeks
3231606|NCT00974701|Experimental|Patients to undergo PillCam procedure|Patients presenting to ER with acute overt upper GI bleeding
3231607|NCT00974688|Active Comparator|Group 1|
3231608|NCT00974688|Active Comparator|Group 2|
3231609|NCT00974675|Experimental|CAT-354 1 mg/kg|CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
3231610|NCT00974675|Experimental|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
3231611|NCT00974675|Experimental|CAT-354 10mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
3231612|NCT00974675|Placebo Comparator|Placebo|Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.
3231613|NCT00974662|Experimental|WST11|Treatment with WST11-mediated VTP
3231614|NCT00974649|No Intervention|Included in questionnaire study|
3231615|NCT00974636|Experimental|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day for two weeks
3231616|NCT00974636|Placebo Comparator|Ususal Salt Diet|Usual salt intake (approximately >180-200 mmol/day in the average American diet).
3231617|NCT00974623||Spinal Fusion|Patients who undergo a planned spinal fusion procedure requiring approved bone grafting materials (e.g., bone grft substitutes, allograft or autograft).
3231618|NCT00974610||Breast|
3231619|NCT00974610||Lung|
3231620|NCT00974610||Melanoma|
3231621|NCT00974610||Pancreatic|
3231622|NCT00974610||Colorectal|
3231623|NCT00974584|Experimental|GDC-0941+Paclitaxel+Carboplatin|Bevacizumab-ineligible non-small cell lung cancer (NSCLC) participants may receive up to 6 cycles (21-day cycle) of combination chemotherapy with paclitaxel and carboplatin along with GDC-0941
3231624|NCT00974584|Experimental|GDC-0941+Paclitaxel+Carboplatin+Bevacizumab|Bevacizumab-eligible NSCLC particpants may receive up to 6 cycles of combination chemotherapy with paclitaxel and carboplatin along with GDC-0941 and bevacizumab.
3231625|NCT00974584|Experimental|GDC-0941+Pemetrexed+Cisplatin|Bevacizumab-ineligible NSCLC participants may receive up to 6 cycles of combination chemotherapy with pemetrexed and cisplatin along with GDC-0941.\n
3231626|NCT00974584|Experimental|GDC-0941+Pemetrexed+Cisplatin+Bevacizumab|Bevacizumab-eligible NSCLC participants may receive up to 6 cycles of combination chemotherapy with pemetrexed and cisplatin along with GDC-0941 and bevacizumab.\n
3231627|NCT00974571|Experimental|1|montelukast
3231628|NCT00974571|Active Comparator|2|cetirizine
3231629|NCT00974571|Placebo Comparator|3|placebo
3231630|NCT00974558|Experimental|fan directed to cheeks|Blow draft of air generated by fan across cheeks
3231631|NCT00974532|Active Comparator|Subjects with normal kidney function|eGFR > 60 ml/min/m²
3231632|NCT00974532|Experimental|CKD late Stage 3 and Stage 4|eGFR 15-40 ml/min/m²
3231633|NCT00974519|Active Comparator|Fuzheng 3|Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
3231634|NCT00974519|Active Comparator|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
3231854|NCT00973037||CYP2D6|CYP2D6 genotype
3231636|NCT00974506|Active Comparator|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine therapy by general practitioner
3231637|NCT00974506|Active Comparator|Routine care therapy|Routine care therapy by general practitioner
3231638|NCT00974493|Active Comparator|Oral antibiotics|
3231639|NCT00974493|Active Comparator|Intravenous antibiotics|
3231640|NCT00974480|Experimental|Redermic|Cream was applied twice a day every day, morning and evening for 24 weeks.
3231641|NCT00974480|Active Comparator|Rejuva-A|Week 1, Rejuva-A cream was applied to face in the evening twice a week. Weeks 2 & 3, Rejuva-A cream was applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream was applied to the face in the evening every other day. In cases of intolerance, returned to the previous dosage and remained there until the end of study. Hydrating cream was applied to the face in the morning every day for 24 weeks.
3231642|NCT00974480|Active Comparator|Combination of Redermic and Rejuva-A|Week 1, Rejuva-A cream was applied to face in the evening twice a week. Weeks 2 & 3, Rejuva-A cream was applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream was applied to the face in the evening every other day. In cases of intolerance, returned to the previous dosage and remained there until the end of study. Redermic was applied every evening when Rejuva-A™ was not applied, as well as every morning.
3231643|NCT00974467|Experimental|After The Injury website|
3231644|NCT00974467|Other|Usual care|Treatment as usual
3231645|NCT00974454|Active Comparator|Fuzheng 2|Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
3231646|NCT00974454|Placebo Comparator|Placebo|Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
3231647|NCT00974441|Experimental|Divalproex Sodium|500 mg Extended Release Tablet
3231648|NCT00974441|Active Comparator|Depakote®|500 mg Extended Release Tablet
3231649|NCT00974428|Active Comparator|Wobenzym® N and placebo|Wobenzym® N 2 tablets of the treatment and 2 placebo tablets three times per day
3231650|NCT00974428|Active Comparator|Wobenzym® N|Wobenzym® N 4 tablets three times per day
3231651|NCT00974428|Placebo Comparator|Placebo|Placebo 4 tablets three times per day
3231652|NCT00974415|Experimental|treatment|CO2 treatment
3231653|NCT00974415|Sham Comparator|sham|sham treatment
3231654|NCT00974402|Experimental|Patients with PTSD Symptoms|Patients with Post-Traumatic Stress Disorder (PTSD) symptoms willing to undergo Cognitive Behavioral Therapy in a primary care setting.
3231655|NCT00974376|Experimental|Gabapentin 1200mg/day|1200mg/day of gabapentin for 12 weeks given in conjunction with 12 weeks of manual-guided behavioral counseling.
3231656|NCT00974376|Placebo Comparator|Placebo|1200mg/day of placebo for 12 weeks given in conjunction with 12 weeks of manual-guided behavioral counseling.
3231657|NCT00974363|Experimental|Group A|Subjects who received GSK Biologicals' meningococcal vaccine 134612 in the primary vaccination study 109069.
3231658|NCT00974363|Active Comparator|Group B|Subjects who received MencevaxTM ACWY in the primary vaccination study 109069.
3231659|NCT00974350|Experimental|Group 1: SABER™-Bupivacaine|2.5 mL SABER™-Bupivacaine /Once
3231660|NCT00974350|Experimental|Group 2: SABER™-Bupivacaine|5.0 mL SABER™-Bupivacaine /Once
3231661|NCT00974350|Placebo Comparator|Group 3: SABER™-Placebo|2.5 mL or 5.0 mL SABER™-Placebo/Once
3231662|NCT00974337||Shock|"Preterm VLBW infants with shock (BP <3rd centile for gestation and birth weight with at least one of the following:~Prolonged capillary refill time (>3sec)~Reduced urine output (<1 mL/kg/hr)~Metabolic acidosis (Base deficit >5)"
3231663|NCT00974337||No shock|Hemodynamically stable infant with normal blood pressure, capillary refill time, and urine output
3231664|NCT00974324|Experimental|treatment|endostar combined with CHOP regimen
3231665|NCT00974311|Experimental|Enzalutamide|Formerly MDV3100
3231666|NCT00974311|Placebo Comparator|Placebo|
3231667|NCT00974298||Elbow replacement|There are no other arms other then an uncemented total elbow replacement.
3231668|NCT00974285|Active Comparator|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
3231669|NCT00974285|Placebo Comparator|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
3231670|NCT00974272|Experimental|Exenatide|
3231671|NCT00974272|Placebo Comparator|Placebo|
3231672|NCT00974259|Experimental|pBrO2 and ICP management|Treatment protocol based on pBrO2 and ICP values.
3231673|NCT00974259|Active Comparator|ICP management|Treatment protocol based on ICP values only.
3231674|NCT00974246|Experimental|COPD, ECF residents, Advair diskus|open label treatment with Advair diskus in COPD patients
3231675|NCT00974233|Experimental|Induction/Maintenance chemotherapy|Bendamustine + rituximab induction therapy followed by lenalidomide maintenance therapy
3231676|NCT00974220|Placebo Comparator|placebo|nebulized 0.9% saline placebo
3231677|NCT00974220|Experimental|fentanyl|nebulized fentanyl citrate (50 mcg)
3231678|NCT00974194|Experimental|SinglePort CCK|CCK using Triport
3231679|NCT00974194|Active Comparator|LS CCK|CCK using three or four trocars
3231680|NCT00974181|Active Comparator|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Conor Medsystems COSTAR™ stent loaded with the antiproliferative compound paclitaxel (10 µg), pre-mounted on a rapid exchange, percutaneous transluminal coronary angioplasty balloon catheter.
3231681|NCT00974181|Active Comparator|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Conor Medsystems COSTAR™ stent loaded with the antiproliferative compound paclitaxel (30 µg), pre-mounted on a rapid exchange, percutaneous transluminal coronary angioplasty balloon catheter.
3231682|NCT00974168|Active Comparator|A|Radiation Cumulative BED ≤ 100 Gy2
3231683|NCT00974168|Active Comparator|B|Cumulative BED ≤ 130 Gy2
3231684|NCT00974155|Experimental|EMC (Early Medication Change)|
3231685|NCT00974155|Active Comparator|TAU (Therapy As Usual)|
3231686|NCT00974142|Experimental|Cyclosporine|
3231687|NCT00974142|Placebo Comparator|Placebo|
3231688|NCT00974129||Patients with Infantile Hemangiomas|
3231690|NCT00974103|Experimental|Exercises|Exercise advise
3231691|NCT00974090|Placebo Comparator|Placebo / Teneli + SU|
3231692|NCT00974090|Experimental|Teneli / Teneli + SU|
3231693|NCT00974077|Other|Wait List Control|Patients do ot receive psychotherapy. The wait list control group will be assessed according to study protocol and offered MBCT after 6 month
3231694|NCT00974077|Experimental|Mindfulness Based Cognitive Therapy|The published protocol of MBCT will be used. This is an eight week group program. Participants learn mindfulness techniques but also cognitive techniques to prevent new depressive episodes
3231695|NCT00974064||A-Healthy Non smokers|Healthy nonsmokers. Defined as non-smokers by self report and urine cotinine levels consistent with a nonsmoker (urine cotinine <5 ng/mL).
3231696|NCT00974064||B-Healthy smoker|"Healthy current smokers. Subjects categorized as healthy according to criteria under Collection (#1204012331) protocol."
3231697|NCT00974064||C-Healthy smoker to quit|Healthy smokers willing to quit. Defined by self-report and urine cotinine levels consistent with an active smoker (urine cotinine >50 ng/mL).
3231698|NCT00974064||D-Current smoker w. COPD|Current smokers with COPD. COPD as defined by the GOLD criteria and currently smoking as defined by self-report and urine cotinine levels consistent with an active smoker (urine cotinine >50 ng/mL)
3231699|NCT00974064||E-Current COPD smoker to quit|Current smokers with COPD willing to stop smoking. Subjects have COPD as defined by the GOLD criteria
3231700|NCT00974051|Active Comparator|Control|Subjects complete the same exercise routine, however no treatment is given at 9:00pm.
3231701|NCT00974051|Experimental|Terbutaline|Subjects complete same exercise routine. At 9:00pm, an oral dose of 2.5 mg of Terbutaline is administered.
3231702|NCT00974051|Experimental|20% Basal Insulin Reduction|All subjects complete the same exercise session. At 9:00pm, subject's basal rate is decreased by 20% for six hours.
3231703|NCT00974038|Experimental|CBT, SP|cognitive behavioral therapy, supportive psychotherapy
3231704|NCT00974025|Experimental|Vitamin C|High-dose Vitamin C in 4 age-based doses will be given in two-daily doses for four weeks
3231705|NCT00974025|Placebo Comparator|Placebo|Placebo will be given in two-daily doses for four weeks
3231706|NCT00974012|Experimental|Divalproex Sodium|500 mg Extended Release Tablet
3231707|NCT00974012|Active Comparator|Depakote®|500 mg Extended Release Tablet
3231708|NCT00973999|Experimental|Injection into salivary gland|
3231709|NCT00973986|Active Comparator|CYP3A4*1/*1|
3231710|NCT00973986|Active Comparator|CYP3A4*1/*1G|
3231711|NCT00973986|Active Comparator|CYP3A4*1G/*1G|
3231712|NCT00973973|Experimental|NBI-56418 150 mg q.d.|
3231713|NCT00973973|Placebo Comparator|Placebo|
3231714|NCT00973947|Other|Control|Immobilisation: Standard headrest plus individual customised mask (orfit)
3231715|NCT00973947|Other|TRial Arm|Immobilisation: Customised headrest plus individual customised mask (orfit)
3231716|NCT00973934|Experimental|Magnetic Seizure therapy (MST)|Eligible patients will be randomized to receive either a course of thrice weekly MST using either a focal or non focal stimulating coil.
3231717|NCT00973934|Active Comparator|Right Unilateral Electroconvulsive Therapy|
3231718|NCT00973921||Stent deployment evaluation|The study group consisted of patients that underwent IVUS guided stent implantation. Stent deployment evaluation was done with the experimental StentOptimizer as well as IVUS and QCA.
3231719|NCT00973908|Active Comparator|VSL#3|Patients will receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
3231720|NCT00973908|Placebo Comparator|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
3231721|NCT00973882|Experimental|Carboplatin-Etoposide|
3231722|NCT00973856|Experimental|PURELL VF481|Warts are equally distributed between products so that an equal number of warts treated on each person (2, 4, or 6), when possible one (1) product will be assigned to each hand to minimize treatment confusion for the participants
3231723|NCT00973856|Placebo Comparator|Placebo Solution|"Warts are equally distributed between products so that an equal number of warts treated on each person (2, 4, or 6), when possible one (1) product will be assigned to each hand to minimize treatment confusion for the participants~One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed"
3231724|NCT00973830|Experimental|Carve-In|Patients in this arm are given the Diabetes Guide and engage in six sessions of brief counseling with a nurse or medical assistant from their clinic. Counseling focuses on behavioral changes patients can make to improve their diabetes.
3231725|NCT00973830|Experimental|Carve-Out|Patients in this arm are given the Diabetes Guide and engage in six sessions of brief counseling over-the-phone with a diabetes health educator stationed in Chicago, IL. Counseling focuses on behavioral changes patients can make to improve their diabetes.
3231726|NCT00973830|No Intervention|Control|Patients in this arm receive standard care. They receive no Diabetes Guide or brief counseling sessions
3231727|NCT00973817|Experimental|ELAD|Use of ELAD for up to 6 days to stabilize liver function plus standard of care treatment plus standard of care treatment. Standard of care for acute on chronic hepatitis patients including medications and treatments typically given to patients admitted with acute hepatitis (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
3231728|NCT00973817|Other|Standard of care|Standard of care for acute on chronic hepatitis patients including medications and treatments typically given to patients admitted with acute hepatitis (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
3231729|NCT00973791|Active Comparator|Prior crystalloid|Crystalloid (Ringer's Lactate) was given before spinal anesthesia
3231730|NCT00973791|Active Comparator|Posterior crystalloid|Crystalloid (Ringer's Lactate) was given after spinal anesthesia
3231731|NCT00973791|Active Comparator|Prior colloid|Colloid (6% hydroxyethyl starch) was given before spinal anesthesia
3231732|NCT00973791|Active Comparator|Posterior colloid|Colloid (6% hydroxyethyl starch) was given after spinal anesthesia
3231733|NCT00973765|Active Comparator|bactrim DS (800/160) 2 pills po BID x 7 days|active comparator
3231734|NCT00973765|Placebo Comparator|Matched placebo 2 pills po BID x 7 days|placebo
3231735|NCT00973752|Experimental|Experimental|All patients treated on same arm
3231736|NCT00973739|Experimental|Lapatinib|"Lapatinib PO dosed according to age:~Children/adolescents (less than 18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO twice daily~Adults (18 years of age or older): 1,500 mg PO once daily~Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment."
3231737|NCT00973726|Other|Glucose|Subjects are given an oral glucose tolerance test.
3231738|NCT00973713|Experimental|RAD001 10mg/d|
3231739|NCT00973700|Experimental|2x7.5adj|Two doses of MF59 adjuvanted (adj) A/H1N1
3231740|NCT00973700|Experimental|7.5adj_1_8|MF59 adjuvanted (adj) A/H1N1 on days 1 and 8
3231741|NCT00973700|Experimental|7.5adj_1_22|MF59 adjuvanted (adj) A/H1N1 on study days 1 and 22
3231742|NCT00973700|Experimental|15_1_22|A/H1N1 on study days 1 and 22
3231743|NCT00973700|Experimental|2x15_1_22|Two doses of A/H1N1 (one in each arm) on study days 1 and 22
3231744|NCT00973687|Placebo Comparator|10 mg/mL Unsweetened Formulation|no prior vomiting
3231745|NCT00973687|Experimental|1 mg/mL Ora Sweet Formulation|no prior vomiting
3231746|NCT00973687|Active Comparator|10 mg/mL Unsweetened with prior vomiting|with prior vomiting
3231747|NCT00973687|Experimental|1 mg/mL Ora Sweet with prior vomiting|with prior vomiting
3231748|NCT00973674|Experimental|Premarin|
3231749|NCT00973674|Placebo Comparator|Placebo|
3231750|NCT00973661|Experimental|Electronic tools|
3231751|NCT00973661|No Intervention|Usual care|
3231752|NCT00973635|No Intervention|Traditional training|"Patients of subjects with no detailed curriculum for handoff skills during non-intervention months.~Learners provided a brief outline of how to perform discharge summaries (handout).~Learners given two core articles describing some of the communication issues regarding handoff safety.~Handoff teaching left to discretion of the subintern's team (typically the see one, do one, teach one method).~No feedback given to these subinterns on their performance of their handoff skills."
3231753|NCT00973635|Experimental|Intervention|Group that receives educational intervention.
3231754|NCT00973622|Experimental|Smokers|Healthy adult smokers aged 19-55 who are not currently interested in quitting smoking.
3231755|NCT00973622|Experimental|Non-smokers|Healthy adult non-smokers aged 19-55
3231756|NCT00973609|Active Comparator|Fluoropyrimidine + Bevacizumab|Standard therapy
3231757|NCT00973609|Experimental|Bevacizumab monotherapy|
3231758|NCT00973609|Experimental|No maintenance treatment|
3231759|NCT00973583|Active Comparator|vitamin D|
3231760|NCT00973583|Placebo Comparator|placebo|
3231761|NCT00973570|Experimental|"Intervention group"|"The intervention group benefits from the TABADO program"
3231762|NCT00973570|No Intervention|"Control group"|"The control group not benefit from any specific intervention other than the treatment and education usually available"
3231763|NCT00973557||Taking Bevacizumab|Patients who are currently being treated for cancer by the drug Bevacizumab.
3231764|NCT00973544||control|drains would be removed when daily discharge will be below 20 cc for 2 consecutive days
3231765|NCT00973544||study|drains will be removed on post operative day (POD) 10
3231766|NCT00973531|Other|Ambulatory APAP and SMT|Subjects placed on the APAP machine
3231767|NCT00973531|Other|Titration Polysomnogram with CPAP and SMT|Subjects placed on CPAP machine
3231768|NCT00973518||Alzheimer's Disease subjects|Subjects diagnosed with dementia of Alzheimer's type (DSM-IV-TR).
3231769|NCT00973518||Healthy Control subjects|Age & gender-matched subjects determined to be healthy.
3231770|NCT00973505||CYP19|CYP19 genetic polymorphism
3231771|NCT00973492||patients with functional insulinotherapy|There is only one group in this study. The participants will attend a functional insulinotherapy class.
3231772|NCT00973479|Experimental|Group I: Placebo + Methotrexate (MTX)|Participants will receive placebo at Weeks 0, 4, 12, and 16. Participants will cross over to golimumab at Week 24, and receive administrations at Weeks 24, 28, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will be eligible for early escape (receive golimumab) at Week 16 if they demonstrate a less than 10 percent improvement in both tender and swollen joint count. These participants will receive golimumab at Weeks 16, 20, and every 8 weeks thereafter.
3231773|NCT00973479|Placebo Comparator|Group II: Golimumab + Methotrexate (MTX)|Participants will receive golimumab at Weeks 0, 4, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will receive a placebo infusion at Week 16 and Week 24 to maintain the blind.
3231774|NCT00973466||HIV-infection|All HIV-infected patients attending the Clinic for Infectious Diseases at Berne university hospital, having been sexually active during the past 12 months and having given written informed consent
3231775|NCT00973453|Other|Slow regimen|
3231776|NCT00973453|Other|Intermediate regimen|
3231777|NCT00973453|Other|Fast regimen|
3231778|NCT00973414|Active Comparator|Prior crystalloid|Crystalloid (Ringer's Lactate) was given before CSEA
3231779|NCT00973414|Active Comparator|Posterior crystalloid|Crystalloid (Ringer's Lactate) was given after CSEA
3231780|NCT00973414|Active Comparator|Prior colloid|Colloid (6% hydroxyethyl starch) was given before CSEA
3231781|NCT00973414|Active Comparator|Posterior colloid|Colloid (6% hydroxyethyl starch) was given after CSEA
3231782|NCT00973401||Diabetic individuals|
3231783|NCT00973375||Endeavor group and Excel group|Endeavor group: measurements from the vessels implanted Endeavor stent(s). Excel group: measurements from the vessels implanted Excel stent(s).
3231784|NCT00973362|Other|Adjunct (i.e. Normal Pap)|The Adjunct study will evaluate APTIMA HPV Assay clinical performance for detecting high-risk HPV types in female subjects 30+ years of age with negative (NILM) cytology results from routine Pap testing. This will be accomplished by evaluating the assay performance compared to known cervical disease status at baseline and after a 3-year follow-up period. A comparator FDA-Approved HPV DNA test is reported.
3231855|NCT00973024|Experimental|JNJ-42160443 1 mg|
3231856|NCT00973024|Experimental|JNJ-42160443 3 mg|
3231857|NCT00973024|Experimental|JNJ-42160443 6 mg/3mg|
3231858|NCT00973024|Experimental|JNJ-42160443 10 mg|
3231785|NCT00973362|Other|ASC-US|The ASC-US study will evaluate the APTIMA HPV Assay clinical performance for detecting high-risk HPV types in subjects with ASC-US Pap test results from routine Pap testing and known cervical disease status (based on colposcopic biopsy results). A comparator FDA-Approved HPV DNA test is reported. There is no follow-up period.
3231786|NCT00973349|Experimental|3.75_(50)MF59|50% of MF59 with 3.75 µg A/H1N1 antigen
3231787|NCT00973349|Experimental|7.5 w/o MF59|0% of MF59 with 7.5 µg A/H1N1 antigen
3231788|NCT00973349|Experimental|7.5_(50)MF59|50% of MF59 with 7.5 µg A/H1N1 antigen
3231789|NCT00973349|Experimental|7.5_(100)MF59|100% of MF59 with 7.5 µg A/H1N1 antigen
3231790|NCT00973349|Experimental|15 w/o MF59|0% of MF59 with 15 µg A/H1N1 antigen
3231791|NCT00973349|Experimental|15_(50)MF59|50% of MF59 with 15 µg A/H1N1 antigen
3231792|NCT00973349|Experimental|15_(100)MF59|100% of MF59 with 15 µg A/H1N1 antigen
3231793|NCT00973349|Experimental|30 w/o MF59|0% of MF59 with 30 µg A/H1N1 antigen
3231794|NCT00973336|Experimental|Calcium and vitamin D|Intervention
3231795|NCT00973336|No Intervention|No treatment (control)|
3231796|NCT00973323|Experimental|Arm 1|
3231797|NCT00973323|Experimental|Arm 2|
3231798|NCT00973323|Experimental|Arm 3|
3231799|NCT00973323|Active Comparator|Arm 4|
3231800|NCT00973310|Experimental|Combined Treatment arm|All the patients received oral erlotinib and concurrent radiation therapy
3231801|NCT00973297|Experimental|Falls prevention|
3231802|NCT00973297|No Intervention|Control group|Routine rehabilitation treatment
3231803|NCT00973284|Experimental|Norwalk VLP Vaccine 100 µg|Norwalk Virus-like Particle (VLP) Vaccine 100 µg, dry powder, intranasally using a delivery device with a puff of air, 50 µg in each nostril, on Days 0 and 21 in the Vaccination Stage. Norwalk Virus, 48 Reverse Transcription Polymerase Chain Reaction (RT-PCR) units, solution, orally, on Day 42 in the Challenge Stage.
3231804|NCT00973284|Placebo Comparator|Placebo|Norwalk VLP placebo-matching vaccine, dry powder, intranasally using a delivery device with a puff of air, 50 µg in each nostril, on Days 0 and 21 in the Vaccination Stage. Norwalk Virus, 48 RT-PCR units, solution, orally, on Day 42 in the Challenge Stage.
3231805|NCT00973271|Experimental|290 mg DCCR|
3231806|NCT00973271|Experimental|435 mg DCCR|
3231807|NCT00973271|Active Comparator|135 mg fenobric acid|
3231808|NCT00973271|Placebo Comparator|Placebo|
3231809|NCT00973258|Experimental|Nutritional Intervention|Nutritional intervention
3231810|NCT00973258|Experimental|Physical Exercise|Physical exercise training intervention
3231811|NCT00973258|Experimental|Cognitive Training|Cognitive training intervention
3231812|NCT00973258|Experimental|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
3231813|NCT00973258|Placebo Comparator|Control Group|Participants will receive their usual diet and placeboes.
3231814|NCT00973245|Experimental|Arm 1|
3231815|NCT00973245|Experimental|Arm 2|
3231816|NCT00973245|Active Comparator|Arm 4|
3231817|NCT00973245|Experimental|Arm 3|
3231818|NCT00973232|Experimental|Part A, Arm A|
3231819|NCT00973232|Experimental|Part A, Arm B|
3231820|NCT00973232|Active Comparator|Part A, Arm C|
3231821|NCT00973232|Active Comparator|Part A, Arm D|
3231822|NCT00973232|Experimental|Part B, Arm E|
3231823|NCT00973232|Active Comparator|Part B, Arm F|
3231824|NCT00973232|Active Comparator|Part B, Arm G|
3231825|NCT00973219|Active Comparator|Peg-Interferon alfa 2a + Adefovir|50 HBeAg negative chronic hepatitis B patients with low viral load will receive Peg-Interferon alfa 2a + Adefovir for a period of 48 weeks.
3231826|NCT00973219|Active Comparator|Peg-Interferon alfa 2a + Tenofovir|50 HBeAg negative chronic hepatitis B patients with low viral load will receive Peg-Interferon alfa 2a + Tenofovir for a period of 48 weeks.
3231827|NCT00973219|No Intervention|no treatment|50 HBeAg negative chronic hepatitis B patients with low viral load will not receive treatment during a period of 48 weeks
3231828|NCT00973193|Experimental|panitumumab|
3231829|NCT00973180|Experimental|Enhanced Label|Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
3231830|NCT00973180|No Intervention|Standard Label|Subjects in this arm will receive their prescriptions labeled with a standard label.
3231831|NCT00973167|No Intervention|Control|Remains sedentary with normal lifestyle
3231832|NCT00973167|Experimental|Treatment|Receive LMHFV treatment for 18 months.
3231833|NCT00973154|Active Comparator|Prednisone|Drug
3231834|NCT00973154|Placebo Comparator|Placebo|
3231835|NCT00973141|Experimental|JNJ-42160443 1mg every 4 weeks|
3231836|NCT00973141|Experimental|JNJ-42160443 3mg every 4 weeks|
3231837|NCT00973141|Experimental|JNJ-42160443 3mg every 8 weeks|
3231838|NCT00973141|Experimental|JNJ-42160443 6mg every 8 weeks|
3231839|NCT00973141|Experimental|JNJ-42160443 10mg every 8 weeks|
3231840|NCT00973141|Placebo Comparator|Matching placebo every 4 or 8 weeks|
3231841|NCT00973128|Experimental|Group 1|Group 1: Cutaneous leishmaniasis patients randomized in Corte to receive antimony (20mg/daily for 10 days) plus GM-CSF Treatment: antimony (20mg/daily for 10 days) plus GM-CSF (400 µg, divided in two doses a week apart)
3231842|NCT00973128|Active Comparator|Group 2|Group 2: antimony in standard dose plus saline administered in an identical fashion to the GM-CSF.
3231843|NCT00973115|Experimental|Simvastatin CR 20mg- morning administration|
3231844|NCT00973115|Active Comparator|Simvastatin CR 20mg- evening administration|
3231845|NCT00973102|Experimental|Premarin IV|
3231846|NCT00973102|Placebo Comparator|Placebo|
3231847|NCT00973089|No Intervention|Complete caries removal|Control group
3231848|NCT00973089|Other|Incomplete caries removal|Test group
3231849|NCT00973076|Experimental|AZD8055|AZD8055 will be administered orally
3231850|NCT00973063|No Intervention|conventional gloving|
3231851|NCT00973063|Experimental|routine sterile gloving|
3231852|NCT00973050|Experimental|Bicalutamide (test)|Bicalutamide Tablet, 50 mg
3231853|NCT00973050|Active Comparator|Casodex® (reference)|Casodex® Tablet, 50 mg
3231860|NCT00972998|Experimental|Healthy individuals|
3231861|NCT00972985|Experimental|modafinil|All healthy control subjects receive modafinil in this crossover design
3231862|NCT00972985|Experimental|methylphenidate|All healthy control subjects receive methylphenidate in this crossover design
3231863|NCT00972985|Experimental|lorazepam|All healthy control subjects receive lorazepam in this crossover design
3231864|NCT00972985|Placebo Comparator|placebo|All healthy control subjects receive placebo in this crossover design
3231865|NCT00972972|Active Comparator|dietary supplement|Extracts of bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.)
3231866|NCT00972972|Placebo Comparator|placebo dietary supplement|Placebo juice extracts
3231867|NCT00972959|Experimental|Bortezomib/Dexamethasone/Zoledronic Acid|"For this study, Velcade will be administered at the standard dose of 1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle.~Dexamethasone will be administered at a dose of 12 mg/m2 p.o., on days 1-2, 4-5, 8-9 and 11-12 of the same cycle.~Zoledronic acid will be administered at a dose of 4 mg, iv (15-minute infusion), every 28 days for up to 8 cycles, and then every 28 days for the next 18 months"
3231868|NCT00972946|Experimental|Administration of labelled cells|MRI scanning before and after administration of iron-labelled cells
3231869|NCT00972946|Experimental|Administration of Endorem|MRI scanning before and after intravenous administration of Endorem
3231870|NCT00972933|Experimental|Ipilimumab|Induction ipilimumab 10 mg/kg IV day 0, 21 (baseline, week 3) Maintenance Ipilimumab 10 mg/kg IV days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
3231871|NCT00972920|Active Comparator|Blind TAP block|"TAP block technique as first described by McDonnell. Sterile field obtained with chlorhexidine wash and use of sterile gloves. Identification of triangle of Petit just above iliac crest and between external oblique and latissimus dorsi muscles. Insertion of regional anaesthesia needle perpendicular to skin, and its advancement until sensation of two 'pops' indicating advancement of needle through both external oblique and internal oblique muscle layers.~After confirmation of negative aspiration the local anaesthetic is injected slowly, (1mg/kg of levobupivacaine), concentration 2.5 mg/mL. Repeat procedure bilaterally (to a maximum dose of 2mg/kg of levobupivacaine)."
3231872|NCT00972920|Active Comparator|Ultrasound-guided TAP block|"Technique as described by Hebbard. Sterile field obtained with chlorhexidine wash and use of sterile gloves. Ultrasound probe covered with sterile sheath.~Identification of triangle of Petit with USS probe perpendicular to skin. Insertion of regional anaesthesia needle transversely to the probe, using in-plane (IP) technique, moving posteriorly. Advancement of the needle under ultrasound control until its tip is located between internal oblique and transversus abdominis muscle layers."
3231873|NCT00972907|Experimental|Treatment|Nifedipine coated suppositories BID.
3231874|NCT00972868|Experimental|COPD|Thirty adult (> 18 years of age) patients in acute hypercapnic respiratory failure resulting from COPD and requiring Noninvasive Positive Pressure Ventilation (NPPV)
3231875|NCT00972855|Experimental|Bicalutamide|Bicalutamide 50 mg Tablet
3231876|NCT00972855|Active Comparator|Casodex®|Casodex® 50 mg Tablet
3231877|NCT00972829|Experimental|Crestor|Crestor 10 or 20 milligrams
3231878|NCT00972829|Active Comparator|Ezetimibe|Ezetimibe 5 or 10 milligrams
3231879|NCT00972816|Experimental|3.75_(50)MF59|3.75 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
3231880|NCT00972816|Experimental|7.5_(0) MF59|7.5 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
3231881|NCT00972816|Experimental|7.5_(50) MF59|7.5 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
3231882|NCT00972816|Experimental|7.5_(100) MF59|7.5 μg A/H1N1 antigen with 100% MF59 adjuvant administered on study day 1 and day 22
3231883|NCT00972816|Experimental|15_(0) MF59|15 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
3231884|NCT00972816|Experimental|15_(50)MF59|15 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
3231885|NCT00972816|Experimental|15_(100) MF59|15 μg A/H1N1 antigen with 100% MF59 adjuvant administered on study day 1 and day 22
3231886|NCT00972816|Experimental|30_(0) MF59|30 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
3231887|NCT00972803|Experimental|pistacia Mutica|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
3231888|NCT00972803|Placebo Comparator|placebo|The subjects were asked to use a mouthwash containing Placebo twice a day for 4 days.
3231889|NCT00972803|Active Comparator|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
3231890|NCT00972790|Sham Comparator|Control Group|The patients in the control arm will receive sham nerve blocks with 20 ml of saline + epinephrine 1:200,000, in a manner identical to that described for the treatment group.
3231891|NCT00972790|Active Comparator|Intervention Group|The patients in the intervention group will receive bilateral scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000.
3231892|NCT00972777|Experimental|Besifloxacin|0.6% ophthalmic suspension
3231893|NCT00972777|Placebo Comparator|Vehicle|
3231894|NCT00972764||Control|
3231895|NCT00972764||Laryngomalacia Cases|
3231896|NCT00972738|Experimental|1|montelukast
3231897|NCT00972738|Active Comparator|2|loratadine
3231898|NCT00972738|Placebo Comparator|3|placebo
3231899|NCT00972725|Experimental|GSK732461+Nivaquine Group|Subjects received a single dose of Nivaquine® tablets orally, 2 days prior to receiving a booster dose of the GSK732461 vaccine.
3231900|NCT00972725|Active Comparator|GSK732461 Group|Subjects received a booster dose of the GSK732461 vaccine intramuscularly, in the deltoid region of the non-dominant arm.
3231901|NCT00972712|Experimental|A|Bortezomib and Tipifarnib
3231902|NCT00972699|Experimental|Mentor Mothers Intervention|In the intervention arm, participants will receive the Department of Health-delivered Prevention of Mother to Child Transmission (PMTCT) program plus the Project Masihambisane mentor mothers support program. HIV positive mentor mothers, who have been through the PMTCT program, will be recruited and trained to deliver the intervention to pregnant mothers living with HIV.
3231903|NCT00972699|No Intervention|Control|Mothers living with HIV in the standard of care control clinics will receive the Department of Health-delivered PMTCT program.
3231904|NCT00972686|Experimental|GSK2126458|GSK2126458 will be dosed continuously (every day) for the duration a 28 day cycle. The 28 day cycles will continue until the subjects withdraw from the study.
3231905|NCT00972673|Experimental|arm 1|In Arm 1 subjects will receive 200, 400 or 800 microgram of powdered inhalation of GW685698X once daily for 7 days from Day 5 to Day 11.
3231906|NCT00972673|Placebo Comparator|arm 2|In Arm 2 subjects will receive Placebo powdered inhalation once daily for 7 days from Day 5 to Day 11.
3231907|NCT00972660|Active Comparator|Control group|"Patients with newly diagnosed extensive cGVHD receive prednisone and cyclosporine or tacrolimus.~Patients with refractory extensive cGVHD receive primary treatment (eg,prednisone and cyclosporine or tacrolimus, or plus mycophenolate mofetil, or methotrexate.)"
3231908|NCT00972660|Experimental|Mesenchymal stem cell (MSC)|"Patients with newly diagnosed extensive cGVHD receive MSC plus prednisone and cyclosporine or tacrolimus.~Patients with refractory extensive cGVHD receive MSC plus their primary immunosuppressive treatment (eg. prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate.)"
3231909|NCT00972647|No Intervention|Unguided|Fluoroscopy images taken without laser beam guidance
3231910|NCT00972647|Experimental|Laser guided|Fluoroscopy images taken with laser beam guidance
3231911|NCT00972621|Experimental|Vitrax II|Investigational dispersive viscoelastic
3231912|NCT00972621|Active Comparator|Viscoat|Marketed control dispersive viscoelastic
3231913|NCT00972595|Experimental|A|clinical trial formulation
3231914|NCT00972595|Active Comparator|B|non-U.S. marketed formulation
3231915|NCT00972582|Experimental|Leucine|
3231916|NCT00972569|Active Comparator|BNP with PDE-V|BNP (Nesiritide) will be infused starting at 0.0025 g/Kg/min IV for 3 hours, if tolerated increased to 0.005 g/kg/min for 45 hours without bolus with PDEV inhibition, they will also receive Sildenafil 12.5 mg at timepoints 0,12, 24 and 36 hours
3231917|NCT00972569|Active Comparator|BNP (Nesiritide) will be infused at 0.005 u/Kg/min IV for 48 h|BNP (Nesiritide) will be infused at 0.025 ug/Kg/min IV for 3 hours then 0.005ug/kg/min 45 hours without bolus. No PDE-V is given.
3231918|NCT00972569|No Intervention|standard care|Patients randomized to this group will continue to receive therapy at the discretion of the heart failure specialist who is managing the patient (with the exception of BNP and low dose dopamine). Blood and Urine will be collected after the patient has been randomized for 48 hours
3231919|NCT00972556|Experimental|GMTA|
3231920|NCT00972556|Active Comparator|20% FC|
3231921|NCT00972543|Active Comparator|Raptiva|Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
3231922|NCT00972543|Placebo Comparator|Placebo|Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
3231923|NCT00972530|No Intervention|Activity|Normal activity without restrictions
3231924|NCT00972530|Active Comparator|immobilisation|48 hours postinjection rest
3231925|NCT00972517|Experimental|Group A|Subjects receiving alternative dose of GSK23440272A vaccine
3231926|NCT00972504|Active Comparator|GSK835726 (10mg)|10mg oral dose
3231927|NCT00972504|Active Comparator|GSK1004723 (1000mcg)|1000mcg nasal spray solution
3231928|NCT00972504|Active Comparator|Cetirizine 10mg|10mg cetirizine as active comparator
3231929|NCT00972504|Placebo Comparator|placebo|placebo
3231930|NCT00972491|Other|0 sec, 60 sec, 90 sec|LMA will be inserted at 0, 60, and 90 seconds after eyelash reflex disappears
3231931|NCT00972478|Experimental|Treatment (combination chemotherapy)|Patients receive vorinostat PO once daily on days 1-5 or 1-9 (according to dose level), rituximab IV, cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 3. Patients also receive prednisone PO once daily on days 3-7. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
3231932|NCT00972452|Experimental|Exercise|5-10d exercise training
3231933|NCT00972439|Active Comparator|Ortho-Novum® 1/35|Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.
3231934|NCT00972439|Active Comparator|Ovcon Fe®|Ovcon Fe® is an oral contraceptive that contains less progestin.
3231935|NCT00972426|Experimental|Treatment A Group|Mikelan LA + Xalatan
3231936|NCT00972426|Active Comparator|Treatment B Group|Timoptol XE + Xalatan
3231937|NCT00972413|Experimental|Group I|
3231938|NCT00972413|Experimental|Group II|
3231939|NCT00972413|Experimental|Group III|
3231940|NCT00972387|Active Comparator|Order 1|Supplement order for each time trial run, 1-4 respectively: CHO, CHO-P, CHO-CHO, PLA
3231941|NCT00972387|Active Comparator|Order 2|Supplement order for each time trial run, 1-4 respectively: CHO-P, CHO-CHO, PLA, CHO
3231942|NCT00972387|Active Comparator|Order 3|Supplement order for each time trial run, 1-4 respectively: CHO-CHO, PLA, CHO, CHO-P
3231943|NCT00972387|Active Comparator|Order 4|Supplement order for each time trial run, 1-4 respectively: PLA, CHO, CHO-P, CHO-CHO
3231944|NCT00972374|Experimental|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
3231945|NCT00972374|Experimental|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
3231946|NCT00972374|Sham Comparator|Sham (no implant)|Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
3231947|NCT00972348|Experimental|Access to Personal Health Record|Full access to the Personal Health Record including lists of diagnoses, medications and laboratory values.
3231948|NCT00972348|Active Comparator|No access to the PHR|No access to the PHR but patients will complete surveys.
3231949|NCT00972335|Experimental|Combination Therapy|"Everolimus; this drug will be dosed at 10 mg orally DAILY for the duration of the study.~Bevacizumab; this drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study"
3231950|NCT00972322|Experimental|MK-8245 50 mg|MK-8245, 50 mg, twice daily for 28 days
3231951|NCT00972322|Placebo Comparator|Placebo|Placebo to MK-8245, 50 mg, twice daily
3231952|NCT00972309|Experimental|1|TARP pepties
3231953|NCT00972309|Experimental|2|TARP dendritic cells
3231954|NCT00972296||Persons with hemophilia with ankle pain|
3231955|NCT00972283|Experimental|IDeg OD|
3231956|NCT00972283|Active Comparator|IGlar OD|
3231957|NCT00972270|Experimental|IMPELLA LP 2.5|
3231958|NCT00972270|Active Comparator|Intra-Aortic Balloon Pump|
3231959|NCT00972257|Active Comparator|Drug: Dorzolamide/Timolol|
3231960|NCT00972257|Active Comparator|Treatment with Brimonidine/Timolol|
3231961|NCT00972244|Experimental|1|1mg dapagliflozin
3231962|NCT00972244|Experimental|2|2.5mg dapagliflozin
3231963|NCT00972244|Experimental|3|5mg dapagliflozin
3231964|NCT00972244|Experimental|4|10mg dapagliflozin
3231965|NCT00972244|Placebo Comparator|5|Placebo
3231966|NCT00972231||Thalassemia Group|Patients suffering from Thalassemia Major and patients with Thalassemia Intermedia
3231967|NCT00972231||Sickle Cell Group|Patients with Sickle Cell Anemia and Sickle Cell Thalassemia
3231968|NCT00972218|Experimental|Enteropathic spondyloarthritis|Patients have concomitant inflammatory spinal symptoms and inflammatory bowel disease.
3231969|NCT00972205|Experimental|Paclitaxel and CBT-1|
3231970|NCT00972192|Active Comparator|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and counseling immediately after the baseline interview. Patients underwent phlebotomy and serologic testing and results were disclosed the following day with post-test counseling (before they were discharged from the hospital).
3231971|NCT00972192|No Intervention|HIV testing post-discharge|Participants who were randomized to the control group were given a referral card and an appointment, by the interviewers, to return for free HIV testing and counseling at Mulago hospital one week after discharge. Participants who returned had their transport reimbursed.
3231972|NCT00972179|Active Comparator|AMG 157|Six subjects in each cohort (cohorts 1 to 6) will receive AMG 157 for a total of 36 subjects.
3231973|NCT00972179|Placebo Comparator|AMG 157 Placebo|Two subjects in each cohort (cohorts 1 to 6) will receive placebo, for a total of 12 subjects.
3231974|NCT00972153|No Intervention|No device used|
3231975|NCT00972153|Sham Comparator|Device attached, not activated|
3231976|NCT00972153|Experimental|Device deployed and activated|
3231977|NCT00972140|Experimental|Formoterol-HFA|Formoterol-HFA pMDI 12µg twice daily
3231978|NCT00972140|Active Comparator|Formoterol-DPI|Formoterol-DPI 12µg twice daily
3231979|NCT00972114|Experimental|CABG combined cardiomyoplasty|Coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
3231980|NCT00972114|Active Comparator|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
3231981|NCT00972114|Active Comparator|CABG alone|Coronary artery bypass graft surgery alone
3231982|NCT00972101|Experimental|Regimen 1: No TBI|High Dose Chemotherapy without Total Body Irradiation (TBI)
3231983|NCT00972101|Experimental|Regimen 2: TBI|High Dose Chemotherapy with Total Body Irradiation (TBI)
3231984|NCT00972088|Other|capsule endoscopy|patients eligible according to inclusion criteria who underwent a capsule endoscopy
3231985|NCT00972075|Experimental|Circadin|Circadin is 2 mg of prolonged release melatonin
3231986|NCT00972075|Placebo Comparator|Placebo|
3231987|NCT00972062|Placebo Comparator|Placebo cream|Cream base used in compounding medications into cream media
3231988|NCT00972062|Experimental|Herbal Cream|Herbal cream (Bach's Rescue Remedy Cream) applied to skin site reactions from MS medications
3231989|NCT00972049|Experimental|1|Capsule administered once orally
3231990|NCT00972049|Placebo Comparator|2|Capsule administered once orally
3231991|NCT00972036|Experimental|Unresectable colon cancer patients with liver metastases|This study will be performed to evaluate the safety of Selective Internal Radiation Therapy (SIRT) in patients with liver only colorectal cancer metastases that have received hepatic arterial infusion pump and have progressed through at least one line of chemotherapy.
3231992|NCT00972023|Experimental|DHEA, surgical resection|Day-14 (approx. 2 wks prior to surgery): begin a 2 week course of DHEA; Day-7 (approx. 1 wk after starting treatment): answer question about pill diary; Day 0 (approx. 2 wks after starting treatment, within 48 hours prior to surgery;
3231993|NCT00971997|Experimental|Lispro 50/50|
3231994|NCT00971984||Alpha thalassemia patients|Patients diagnosed with alpha thalassemia mutations and anemia
3231995|NCT00971971|No Intervention|Control|Traditional SLED
3231996|NCT00971971|Experimental|Profiling|dialysate temperature reduction with Na and ultrafiltration (UF) profiling
3231997|NCT00971958|Active Comparator|Mogen Clamp|
3231998|NCT00971958|Active Comparator|Plastibell|
3231999|NCT00971958|Active Comparator|AccuCirc|AccuCirc is a device approved by the FDA for circumcision of male infants up to ten days of life.
3232000|NCT00971945|Experimental|Paclitaxel|
3232001|NCT00971932|Experimental|Cetuximab + Cisplatin/Carboplatin + Fluorouracil (5-FU)|
3232002|NCT00971906|Experimental|low dose of antigen + low dose of adjuvant|
3232003|NCT00971906|Experimental|high dose of antigen + high dose of adjuvant|
3232004|NCT00971906|Experimental|high dose of antigen|
3232005|NCT00971893||Methylprednisolone Group|
3232006|NCT00971880||Patients receiving blood transfusions|All the patients with blood disorders that require blood transfusions
3232007|NCT00971867|Experimental|Paclitaxel|
3232008|NCT00971854|Experimental|60 Hz stimulation|Experimental reduced frequency pallidal stimulation
3232009|NCT00971854|No Intervention|130 Hz stimulation|Current standard pallidal stimulation setting
3232010|NCT00971841|Experimental|Paclitaxel|One hour intravenous infusion on Days 1, 8, 15, 22, 29, 36, followed by 1 week of rest (6 weeks on, 1 week off). One treatment course consists of 49 days. Day 1 dose same level as last dose of original Study CA139-540 (100mg/m2, 80 mg/m2, or 60 mg/m2). Treatment to continue until disease progression or unacceptable toxicity apparent.
3232067|NCT00971477|Active Comparator|Usual Care|Conventional in-office care
3232159|NCT00970879|Experimental|cotrimoxazole (high)|CD4 cell count≥350/mm3
3232160|NCT00970879|Active Comparator|mefloquine|CD4 cell count≥350/mm3
3232161|NCT00970879|Experimental|cotrimoxazole (low)|CD4 cell count<350/mm3
3232011|NCT00971828||Idiopathic inflammatory myopathy|IIM patients will be recruited via the Adult Onset Myositis clinic, Salford Royal NHS Foundation Trust. Suitable patients will be asked if they are willing to partake in the study, via a letter, including a patient information leaflet. If willing, they will contact our study co-ordinator, who will facilitate the visit to the WTCRF. The patient will then sign a consent form and be able to enter the study.
3232012|NCT00971815|Active Comparator|escitalopram|A pill containing Escitalopram
3232013|NCT00971815|Placebo Comparator|placebo|a placebo pill
3232014|NCT00971802|Experimental|Cohort 1|Healthy volunteers - PF-03882845 versus Placebo
3232015|NCT00971802|Experimental|Cohort 2|Healthy volunteers - PF-03882845 versus Placebo
3232016|NCT00971802|Experimental|Cohort 3|Healthy volunteers - PF-03882845 versus Placebo
3232017|NCT00971802|Experimental|Cohort 4|Healthy volunteers - PF-03882845 versus Placebo
3232018|NCT00971789|Experimental|Sirolimus Patients|sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects.
3232019|NCT00971763|Experimental|R-GCVP|"Up to 6 x 21 day cycles of R-GCVP:~Gemcitabine 750mg/m^2 days 1 & 8 (increasing to 875mg/m^2 for cycle 2 & 1g/m^2 for subsequent cycles if tolerated satisfactorily)~Cyclophosphamide 750mg/m^2 day 1~Vincristine 1.4mg/m^2 day 1 (capped at 2mg)~Prednisolone 100mg/day days 1-5~Rituximab 375mg/m^2 day 1~Neulasta 6mg day 9"
3232020|NCT00971750||Ultrasound Study Group|Patients with no history of gallbladder surgery who are undergoing elective laparoscopic roux-en-Y gastric bypass that have consented to undergo a preoperative transabdominal ultrasound in addition to routine preoperative assessment for surgery.
3232021|NCT00971737|Active Comparator|Arm I|Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.
3232022|NCT00971737|Experimental|Arm II|Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.
3232023|NCT00971724|Placebo Comparator|Placebo|Treatment with placebo for 15 days
3232024|NCT00971724|Experimental|Prednisolone 7.5 mg daily|Treatment with prednisolone 7.5 mg daily for 15 days
3232025|NCT00971724|Experimental|Prednisolone 15 mg daily|Treatment with prednisolone 15 mg daily for 15 days
3232026|NCT00971724|Experimental|Prednisolone 30 mg daily|Treatment with prednisolone 30 mg daily for 15 days
3232027|NCT00971724|Experimental|Prednisolone 75 mg|Treatment with prednisolone 75 mg for a single day
3232028|NCT00971724|Experimental|Prednisolone 15 mg twice daily|Treatment with prednisolone 15 mg twice daily for a single day
3232029|NCT00971711|Experimental|Probiotic|To determine the safety and effectiveness of the probiotic VSL#3 in adults with irritable bowel syndrome (IBS).
3232030|NCT00971698||Sickle Cell Patients|Patients with homozygous Sickle Cell Anemia
3232031|NCT00971698||Sickle Cell Thalassemia|Patients with Sickle Cell Thalassemia
3232032|NCT00971685|Experimental|Lenalidomide plus Dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
3232033|NCT00971672||Toddlers from Jewish origin|Toddlers from Jewish origin aged 18 to 36 months
3232034|NCT00971672||Toddlers from non Jewish origin|Toddlers aged 18 to 36 months belonging to non Jewish (Arab) population
3232035|NCT00971659|Experimental|insulin glargine + exenatide + metformin|
3232036|NCT00971659|Experimental|Insulin glargine + sitagliptin + metformin|
3232037|NCT00971659|Active Comparator|insulin glargine + metformin|
3232038|NCT00971646||OAB|Patients with overactive bladder syndrome
3232039|NCT00971646||Osteoporosis|Patients with osteoporosis
3232040|NCT00971633|Experimental|1|Treatment Sequence A-B-C
3232041|NCT00971633|Experimental|2|Treatment Sequence B-C-A
3232042|NCT00971633|Experimental|3|Treatment Sequence C-A-B
3232043|NCT00971633|Experimental|4|Treatment Sequence A-C-B
3232044|NCT00971633|Experimental|5|Treatment Sequence B-A-C
3232045|NCT00971633|Experimental|6|Treatment Sequence C-B-A
3232046|NCT00971620|Experimental|BTX-A|BTX-A intralesional injection
3232047|NCT00971620|Experimental|Placebo/Saline|Saline intralesional injection
3232048|NCT00971607|Active Comparator|1|Sevoflurane
3232049|NCT00971607|Placebo Comparator|2|Oxygen
3232050|NCT00971594|Experimental|WL+AEX|Weight loss plus aerobic exercise
3232051|NCT00971581|Experimental|FDC KETOPROFEN+OMEPRAZOLE|One capsule of Ketoprofen 200 mg + Omeprazole 20 mg FDC once daily Treatment duration: 4 weeks
3232052|NCT00971568||Urine sample|To prepare for SELDI-TOF we will use 15 samples. Each sample (25ul) will be analyzed with the Luminex 100 IS (MiraiBio, South San Francisco, CA) using a LINCOplex cytokine/che-
3232053|NCT00971555||Late preterm|Late preterm infants admitted to the NICU
3232054|NCT00971542|Experimental|low dose of antigen + low dose of adjuvant|
3232055|NCT00971542|Experimental|high dose of antigen + high dose of adjuvant|
3232056|NCT00971542|Experimental|high dose of antigen|
3232057|NCT00971529||lifestyle|70 volunteers were double-blinded, placebo-controlled and randomized into 2 groups (smoking with tea filters or regular filters).
3232058|NCT00971529||tea filter|The investigators then recruited 59 volunteers with longer smoking history and stronger desire for quitting smoking for smoking cessation test using the tea filter.
3232059|NCT00971516|Active Comparator|Diabetes|compare cytokines between diabetes and non diabetes patients
3232060|NCT00971516|Active Comparator|Implants|Compare implant healing phases
3232061|NCT00971503|Sham Comparator|saline injection|
3232062|NCT00971503|Experimental|Autologous bone marrow implantation|
3232063|NCT00971490|Experimental|Group 1|
3232064|NCT00971490|Placebo Comparator|Group 2|
3232065|NCT00971490|Sham Comparator|Group 3|
3232066|NCT00971477|Experimental|Teledermatology|Online Telemedicine Group
3232068|NCT00971464|Experimental|Eccentric viewing|"Eccentric viewing is the use of a retinal locus other than the anatomical fovea for fixation in cases when there is central vision loss. This other area (or areas) is called the preferred retinal locus (PRL). In eccentric viewing the patient is aware that they are looking to the side or using their side vision. Most patients with a dense central scotoma will develop eccentric viewing naturally over time. It is thought, however, that, in many cases the naturally developed PRL is not in the ideal position. The four components of eccentric viewing that will be taught are: 1) The optimal direction for eccentric viewing 2) Using large objects to teach eccentric viewing 3) Repetitive practicing of the technique and 4) Maintaining the eye in the eccentric viewing position."
3232069|NCT00971464|Active Comparator|CCTV arm|A CCTV is an electro-optical device mainly used for reading, but which can also be used for writing or viewing pictures. It is comprised of a video camera which faces downwards towards the reading material and which inputs the image to a digital monitor. Magnification is variable over a large range. By means of a zoom lens and the brightness, contrast, and image polarity (black letters on white or white on black) can be controlled to provide the best combination of viewing conditions for an individual user. The significant advantages of CCTV over optical magnifiers are that it provides high levels of magnification with a greater field of view (compared to the equivalent optical device), allows reading at a more normal viewing distance of about 40 - 50 cms and allows binocular viewing.
3232070|NCT00971451|Experimental|knee joint cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
3232071|NCT00971451|Experimental|TENS|continuous TENS for duration of the 1 hour exercise session
3232072|NCT00971451|No Intervention|No intervention|no modality intervention; just exercise
3232073|NCT00971438|Experimental|Diagnostic imaging|Patients with a scoring suggesting an equivocal diagnosis of acute appendicitis are randomised to either diagnostic imaging (US or CT) or a repeat examination after 4-8 hours in-hospital observation.
3232074|NCT00971438|Active Comparator|Repeat examination after observation|Patients with a clinical scoring suggesting an equivocal diagnosis of appendicitis are randomised to either 4-8 hours of in-hospital observation or diagnostic imaging (US or CT)
3232075|NCT00971425|Experimental|Placebo-Pandemrix-Fluarix Group|Subjects received one dose of placebo intramuscularly in the deltoid region of the dominant arm at Day -21, 2 doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21, and 1 dose of Fluarix intramuscularly in the deltoid region of the dominant arm at Day 42.
3232076|NCT00971425|Experimental|Fluarix-Pandemrix-Placebo Group|Subjects received 1 dose of Fluarix intramuscularly in the deltoid region of the dominant arm at Day -21, 2 doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid of the non-dominant arm at Day 0 and 21, and 1 dose of placebo intramuscularly in the deltoid of the non-dominant arm at Day 42.
3232077|NCT00971399|Experimental|RMS|ramosetron 0.1mg q.d. SL on D1-5
3232078|NCT00971399|Active Comparator|ODS|ondansetron 8mg, b.i.d SL on D1-5
3232079|NCT00971386|Other|Normal Healthy Subjects|Normal healthy subjects without history, signs-symptoms or diagnosis of heart failure
3232080|NCT00971386|Other|Chronic Ambulatory Heart Failure|Diagnosis of Chronic Heart Failure and currently on optimal medical therapy
3232081|NCT00971386|Other|Acute Heart Failure|Patients admitted to the hospital with acute congestive heart failure.
3232082|NCT00971373|Experimental|Exp Scrubs|antimicrobial impregnated scrubs
3232083|NCT00971373|No Intervention|Non-antimicrobial scrubs|Non-antimicrobial scrubs
3232084|NCT00971360||Conversion disorder|
3232085|NCT00971360||Healthy control|
3232086|NCT00971347|Active Comparator|Nutrition brochure|Control participants will receive only a nutrition brochure, Finding Your Way to a Healthier You, based on a USDHHS/USDA publication, Dietary Guidelines for Americans 2005.
3232087|NCT00971347|Experimental|Chewing gum + nutrition brochure|Participants in the experimental arm will be instructed to incorporate gum chewing in their diet with a goal of at least 90 minutes per day. The schedule is 20 minutes each after breakfast, lunch and dinner plus 10 minutes mid-morning, mid-afternoon and 1 to 2 hours after dinner. Experimental participants also will be told to chew gum instead of unplanned eating in response to hunger, cravings, preoccupation with eating, or negative feelings.
3232088|NCT00971321|Experimental|Group A|Subjects in this group will receive investigational vaccine regimen according to a protocol specified schedule different from Group B
3232089|NCT00971321|Experimental|Group B|Subjects in this group will receive investigational vaccine regimen according to a protocol specified schedule different from Group A
3232090|NCT00971308|Experimental|BMS-824393 (Panel 1)|
3232091|NCT00971308|Experimental|BMS-824393 (Panel 2)|
3232092|NCT00971308|Experimental|BMS-824393 (Panel 3)|
3232093|NCT00971308|Experimental|BMS-824393 (Panel 4)|
3232094|NCT00971308|Experimental|BMS-824393 (Panel 5)|
3232095|NCT00971295|Experimental|Treatment Sequence A|Eslicarbazepine acetate + Metformin period followed by washout period followed by Metformin period
3232096|NCT00971295|Experimental|Treatment Sequence B|Metformin period followed by washout period followed by Eslicarbazepine acetate + Metformin period
3232097|NCT00971282|Experimental|intra-individual comparison|
3232098|NCT00971256||Bladder cancer patients|Bladder cancer patients from one Beaumont Urologist.
3232099|NCT00971243|Experimental|MP-513 Lowest Dose and Metformin|
3232100|NCT00971243|Experimental|MP-513 Low Dose and Metformin|
3232101|NCT00971243|Experimental|MP-513 Medium Dose and Metformin|
3232102|NCT00971243|Experimental|MP-513 High Dose and Metformin|
3232103|NCT00971243|Placebo Comparator|Placebo and Metformin|
3232104|NCT00971230|Experimental|FTC/TDF- Daily|FTC/TDF dosed daily
3232105|NCT00971230|Experimental|FTC/TDF-Intermittent|FTC/TDF dosed intermittently
3232106|NCT00971230|Placebo Comparator|Placebo-Daily|Placebo dosed daily
3232107|NCT00971230|Placebo Comparator|Placebo-Intermittent|Placebo dosed intermittently
3232153|NCT00970944|Experimental|Amantadine HCL|100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4.
3232154|NCT00970944|Placebo Comparator|Placebo|
3232155|NCT00970931|Placebo Comparator|placebo|
3232108|NCT00971217|Experimental|Exercise|"Participants will engage in 2 exercise sessions each week for 10 weeks. Each session will last 50 minutes and will commence with a 5 minute warm up on the bike or treadmill and conclude with a 5 minute cool down. The participants will be required to exercise on their own without interference from others. Participants will wear heart rate monitors to ensure that they are exercising to moderate intensity (70-80% of age predicted maximum heart rate).~Exercise: Aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines."
3232109|NCT00971217|Experimental|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a web-site specifically aimed at young men once per week and complete the set cognitive-behavioural tasks.
3232110|NCT00971217|Experimental|Combined Exercise/Online CBT|Participants will simultaneously par-take in both the exercise and the online CBT conditions already outlined.
3232111|NCT00971217|No Intervention|Control|Individuals will be advised that the start of their intervention will be delayed by 10 weeks. After 10 weeks individuals in the control condition will be given the opportunity to avail of an induction session in the gym and subsequently use the gym facilities for three sessions if they so desire. Participants will be asked to refrain from exercise for the 10 week study period.
3232112|NCT00971204|Experimental|Treatment with HeartLight System|Treatment of paroxysmal atrial fibrillation (PAF) with HeartLight System
3232113|NCT00971191|Experimental|treatment|Patients treated with brief exposure to PF-00299804 prior to surgical resection
3232114|NCT00971178|Active Comparator|Local Dexmedetomidine|
3232115|NCT00971178|Placebo Comparator|Normal Saline|
3232116|NCT00971178|Active Comparator|IV dexmedetomidine|
3232117|NCT00971165|Active Comparator|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily for 18 months
3232118|NCT00971165|Experimental|losartan|Oral losartan up to 100 mg daily, once a day, for 18 month
3232119|NCT00971152|Active Comparator|450 IU daily dose of gonadotrophin|
3232120|NCT00971152|Experimental|600 IU daily dose of gonadotrophin|
3232121|NCT00971139|Experimental|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
3232122|NCT00971139|No Intervention|Control group|Patients receiving usual care
3232123|NCT00971126|Experimental|Single Group Assignment|
3232124|NCT00971113|Experimental|sc-FOS+Sideritis euboea group|Jelly supplemented with short chain fructooligosaccharides and Sideritis euboea extract
3232125|NCT00971113|Placebo Comparator|placebo group|Jelly without short-chain fructooligosaccharides and Sideritis euboea
3232126|NCT00971100|Experimental|low dose of antigen + low dose of adjuvant|
3232127|NCT00971100|Experimental|high dose of antigen + high dose of adjuvant|
3232128|NCT00971100|Experimental|high dose of antigen|
3232129|NCT00971087|Other|Biopsy|subjects presenting for a breast biopsy procedure, subject will be imaged before her biopsy procedure with the investigational 2D plus 3D mammography system
3232130|NCT00971087|Other|screening|subjects presenting for routine asymptomatic mammograms and will then have an investigational 2D plus 3D mammogram
3232131|NCT00971074|Experimental|Hylan G-F 20|Single injection of Hylan G-F 20 into the affected knee.
3232132|NCT00971074|Sham Comparator|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
3232133|NCT00971061|Experimental|MSPI|Molteno single-plate implant
3232134|NCT00971061|Active Comparator|AVI|Ahmed valve implant
3232135|NCT00971048|Experimental|HP828-101|
3232136|NCT00971048|Active Comparator|Standard of Care|For DFU SoC is a hydrogel. For PU SoC is a hydrocolloid gel.
3232137|NCT00971035|Experimental|A|
3232138|NCT00971035|Experimental|B|
3232139|NCT00971035|Experimental|C|
3232140|NCT00971035|Placebo Comparator|D|
3232141|NCT00971022||Low-income Populations|
3232142|NCT00971009|Experimental|OPPC service|A practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
3232143|NCT00971009|Experimental|WebChoice IHCA|WebChoice is an interactive health communications application (IHCA) that in addition to offer a practice-integrated nurse administered online patient-provider communication (OPPC) service, allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
3232144|NCT00971009|No Intervention|Control group|The control group receives usual care
3232145|NCT00970996|Experimental|Biochemotherapy|Abraxane with Cisplatin, Temozolomide, interleukin-2 and interferon a2b
3232146|NCT00970983|Active Comparator|QUART|Patients in this arm will receive quadrantectomy, axillary dissection and radiotherapy (the current standard therapy).
3232147|NCT00970983|Experimental|QURT (SN-)|Patients will receive quadrantectomy, sentinel node investigation and radiotherapy. Selective axillary dissection will be performed if sentinel node is positive.
3232148|NCT00970970||Von Hippel Lindau|Adult patients with Von Hippel-Lindau disease
3232149|NCT00970957|Experimental|Central RVO - Macular edema - Avastin|Patients with Macular edema secondary to CENTRAL Retinal Vein Occlusion that will be treated with intravitreal injection of avastin once per month during the first 3 months. Re-treatments will be given as per protocol.
3232150|NCT00970957|Sham Comparator|Central RVO - Macular edema - Sham|Patients with Macular edema secondary to CENTRAL Retinal Vein Occlusion that will have a sham procedure performed. Injection without needle.
3232151|NCT00970957|Experimental|Branch RVO - Macular edema - Avastin|Patients with Macular edema secondary to BRANCH Retinal Vein Occlusion that will be treated with intravitreal injection of avastin once per month during the first 3 months. Re-treatments will be given as per protocol.
3232152|NCT00970957|Sham Comparator|Branch RVO - Macular edema - Sham|Patients with Macular edema secondary to BRANCH Retinal Vein Occlusion that will have a sham procedure performed. Injection without needle.
3232156|NCT00970931|Experimental|chlortalidone-amiloride|
3232157|NCT00970918|Experimental|1|
3232158|NCT00970905|Experimental|Aprepitant & Ondansetron|
3232162|NCT00970879|Active Comparator|mefloquine & cotrimoxazole|CD4 cell count<350/mm3
3232163|NCT00970866|Active Comparator|Iron and Folic Acid (IFA)|
3232164|NCT00970866|Active Comparator|Multiple Micronutrient (MMN)|
3232165|NCT00970866|Active Comparator|Lipid-based Nutrient Supplements (LNS)|
3232166|NCT00970853|Active Comparator|Control|Control group
3232167|NCT00970853|Experimental|MOM Program home visiting|Mixed professional support home visiting program.
3232168|NCT00970840|Experimental|LNS-20gM or LNS-P&L|
3232169|NCT00970827|Active Comparator|1|Leg postconditioning
3232170|NCT00970827|Active Comparator|2|Arm postconditioning
3232171|NCT00970827|Placebo Comparator|3|Control group
3232172|NCT00970814|Active Comparator|Levetiracetam XR|Group received Levetiracetam
3232173|NCT00970814|Placebo Comparator|Sugar Pill|Placebo
3232174|NCT00970788|No Intervention|verbal group|Verbal description of goals of care.
3232175|NCT00970788|Experimental|Video group|Video decision aid.
3232176|NCT00970775|Experimental|1. AZD2423|
3232177|NCT00970775|Placebo Comparator|2. Placebo|
3232178|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.1 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.
3232179|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.15 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.
3232180|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.2 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.
3232181|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.1 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.
3232182|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.15 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.
3232183|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.2 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.
3232184|NCT00970762|Active Comparator|Vecuronium 0.1 INT, 0.025 MNT|Participants in this group received a 0.1 mg/kg intubating dose of vecuronium followed by 0.025 mg/kg maintenance dose of vecuronium.
3232185|NCT00970749||history of chlamydia infection|Women who self-reported a history of cervical infection with Chlamydia trachomatis
3232186|NCT00970749||no history of chlamydia infection|Women who self-reported no history of cervical infection with Chlamydia trachomatis
3232187|NCT00970736||1|20 healthy participants between 60 and 80 years of age. Ten men and 10 women.
3232188|NCT00970723|Experimental|intensive treatment|with a systematic screening for sleep apnea and/or uncontrolled high blood pressure, and intensified intervention on both anomalies if detected
3232189|NCT00970723|Active Comparator|conventional treatment|in accordance with national guidelines
3232190|NCT00970710|Experimental|Lifestyle counseling|VACOPP (Vaasa Childhood Obesity Primary Prevention Study): Intensified lifestyle counseling including physical activity and nutritional information beginning during maternity health care and continuing during child health care clinic visits.
3232191|NCT00970697|Experimental|becaplermin gel|application of a continuous thin layer of becaplermin gel (Regranex Gel®) during 8 weeks. The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment.
3232192|NCT00970697|Active Comparator|Duoderm Hydrogel™|application of a continuous thin layer of hydrogel dressing (Duoderm Hydrogel®), during 8 weeks. Duoderm Hydrogel™ is a sodium carboxymethylcellulose aqueous-based gel, similar in composition to becaplermin excipient.
3232193|NCT00970684|Experimental|Bevacizumab, Docetaxel, and Gemcitabine|Treatment repeats every 21 days for up to 6 courses.
3232194|NCT00970658|Experimental|Salonsip|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
3232195|NCT00970658|Active Comparator|Sabiá|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
3232196|NCT00970645|Active Comparator|traditional mediastinoscopy/thoracoscopy|Traditional Mediastinoscopy used to detect or stage lung cancers.
3232197|NCT00970645|Active Comparator|EBUS/EUS|Minimal invasive technique for staging/detecting lung cancer.
3232198|NCT00970632|Placebo Comparator|Placebo|Placebo tablet with tamsulosin dose orally (po) once daily (QD) and placebo capsule with tadalafil dose po QD for 12 weeks
3232199|NCT00970632|Experimental|Tadalafil 5 milligram (mg)|Tadalafil 5 mg tablet po QD and placebo capsule po QD for 12 weeks
3232200|NCT00970632|Active Comparator|Tamsulosin 0.4 mg|Tamsulosin 0.4 mg capsule po QD and placebo tablet po QD for 12 weeks
3232201|NCT00970619|No Intervention|Conventional anticoagulation therapy|Conservative treatment consists of an initial treatment with therapeutic doses of LMWH in combination with vitamin K-antagonists, followed by treatment with vitamin K-antagonist alone (after completing LMWH treatment of at least 5-7 days and after an INR above 2 has been reached on two consecutive measurements). Or alternatively the new direct activated factor X inhibitors can be used as anticoagulation therapy. Anticoagulant treatment will be installed according to national and international guidelines (ACCP 2008 [23], CBO 2008 [24]) tailored based on the character of the event (6 months of therapy for idiopathic DVT and 3 months for provoked DVT).
3232202|NCT00970619|Experimental|Ekos Endowave system thrombolysis|Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
3232203|NCT00970606|Placebo Comparator|Placebo tablet|Placebo
3232204|NCT00970606|Experimental|Rosuvastatin (crestor)|Experimental arm
3232205|NCT00970593|Placebo Comparator|OAP-189|
3232206|NCT00970593|Placebo Comparator|2|
3232207|NCT00970580|Experimental|BIIB022 in Combination with Paclitaxel and Carboplatin|BIIB022 in Combination with Paclitaxel and Carboplatin
3232208|NCT00970567|Other|Arm 1|stop after positive ketone bodies in urine
3232209|NCT00970567|Other|Arm 2|stop after positive ketone bodies in blood, normal therapy
3232210|NCT00970567|Other|Arm 3|stop after positive ketone bodies in blood, additional therapy
3232211|NCT00970554|Active Comparator|Patching only|
3232212|NCT00970554|Experimental|Patching plus telescope group|
3232213|NCT00970541|Active Comparator|Cinnamon Supplementation|A 500mg (consumed as two, 250mg capsules) of cinnamon extract (Cinnamon Bark P.E> 20:1) will be consumed before meals, three times per day.
3232214|NCT00970541|Placebo Comparator|Placebo|A 500 mg placebo (wheat flour) will be consumed before meals, three times per day.
3232215|NCT00970528|Experimental|Arm 1|
3232216|NCT00970528|Active Comparator|Arm 2|
3232217|NCT00970515|Experimental|Laparoscopic approach|group A: Laparoscopic approach
3232218|NCT00970515|Active Comparator|Open approach|group B: Open anterior approach
3232219|NCT00970502|Experimental|erlotinib + celecoxib|
3232220|NCT00970489|Experimental|Omega-3 fatty acid capsules|
3232221|NCT00970489|Placebo Comparator|Olive Oil capsule|
3232222|NCT00970463||GH|Patients with GHD
3232223|NCT00970463||Pegvisomant and Somatostatin analogues|Acromegaly
3232224|NCT00970450|Experimental|Paracetamol|
3232225|NCT00970450|Experimental|Paracetamol/Tropisetron|
3232226|NCT00970450|Placebo Comparator|Saline|Proband will receive Saline
3232227|NCT00970450|Active Comparator|Tropisetron|Proband will receive Tropisetron alone
3232228|NCT00970437|Active Comparator|CBASP|CBASP as the experimental intervention will follow a manual (McCullough, 2000; German version: Schramm et al., 2006). The approach is specifically tailored for the treatment of chronic forms of depression, particularly with early-onset by focusing on the problems resulting from an inhibition of maturation in early childhood and by using the therapeutic relationship in a personal, disciplined way as well as other specific techniques (e.g. Interpersonal Discrimination Exercise, Situation Analysis). CBASP integrates behavioural, cognitive, and interpersonal strategies.
3232229|NCT00970437|Placebo Comparator|SYSP|The comparator for CBASP is SYSP, a system of supportive psychotherapy, an active but less specific, manualized control treatment. SYSP - defined as non-interpersonal and non-cognitive-behavioral therapy - resembles supportive clinical management, client-centered therapy, counseling, and psychoeducation about depression. There is no specific explanatory mechanism for treatment effect offered to the patient and it does not focus on specific themes.
3232230|NCT00970424|Placebo Comparator|1|placebo, oral tablet administered once daily on background of pioglitazone
3232231|NCT00970424|Experimental|2|dutogliptin, oral tablet administered once daily on background of pioglitazone
3232232|NCT00970411|Experimental|KRN951|
3232233|NCT00970398|No Intervention|Reference group|Human milk breastfeeding
3232234|NCT00970398|Active Comparator|Control formula|Standard infant formula, with no Osteopontin supplemented.
3232235|NCT00970398|Active Comparator|Formula with 50% Osteopontin|Infant formula supplemented with bovine milk Osteopontin at 50% level of that of breast milk.
3232236|NCT00970398|Active Comparator|Formula with 100% Osteopontin|Infant formula supplemented with bovine milk Osteopontin at 100% level of that of breast milk.
3232237|NCT00970385|Active Comparator|CHOP 21|"Induction therapy CHOP every 21 days:~cyclophosphamide 750 mg/m2 intravenously (IV) day 1~doxorubicin 50 mg/m2 IV day 1~vincristine 1,4 mg/m2 (maximum 2 mg) day 1~prednisone 100 mg/m2/D from D1 to D5."
3232238|NCT00970385|Experimental|VIP/ABVD arm|"VIP cycle:~etoposide 100 mg/m2/D IV from D1 to D3~ifosfamide 1000 mg/m2/D from D1 to D5~cisplatin 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD cycle:~doxorubicin50 mg/m2/D on D1 and D14~bleomycin 10 mg/m2/D~vinblastine 10 mg/m2/D~dacarbazine 375 mg/m2/D Each alternating cycle was repeated three times for a total of 6 cycles (3 VIP, 3 rABVD)."
3232239|NCT00970372||Involuntary patients|Compulsory treated patients according to the Norwegian Social and Welfare Act of 1992. Most patients have dualdiagnosis.
3232240|NCT00970372||Voluntary patients|Voluntary patients on the same wards. Most patients have dual-diagnosis.
3232241|NCT00970359|Experimental|pts with thyroid cancer with and without BRAF mutation|Patients receive selumetinib orally (PO) twice daily (BID) for 4 weeks. Within 1 month, patients with adequate RAI uptake may receive 131I per standard of care and continue selumetinib until 2 days following 131I.
3232242|NCT00970346|Experimental|Inhaled OligoG CF-5/20|
3232243|NCT00970333|Experimental|assess [18F]-FEPPA PET imaging|
3232244|NCT00970320|No Intervention|Control group, RCT2|Participants reporting anal incontinence 6 months postpartum receiving written information only for 6 months. After 6 months they are offered the same intervention as the intervention group, i.e. PFMT for 6 months.
3232245|NCT00970320|Active Comparator|Intervention group, RCT 2|Participants reporting anal incontinence 6 months postpartum receiving pelvic floor muscle training (PFMT) for 6 months (+6 months).
3232246|NCT00970320|No Intervention|Control group, RCT3|Women with obsteric anal sphincter injury receiving written information only for 6 months. After 6 months they are offered the same intervention as the intervention group, i.e. PFMT for 6 months.
3232247|NCT00970320|Active Comparator|Intervention group, RCT 3|Women with obsteric anal sphincter injury receiving pelvic floor muscle training (PFMT) for 6 months (+6 months).
3232248|NCT00970320|No Intervention|Prevalence Study|1571 primiparae delivering at Ostfold Hospital Trust or St. Olav's Hospital during the period May 2009 to December 2010.
3232249|NCT00970307|Experimental|GSK2202083A + SYNFLORIX GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of GSK2202083A vaccine and Synflorix™ vaccine at 2, 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. GSK2202083A and Synflorix™ vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
3232352|NCT00969553|Experimental|BI 6727|Schedule A
3232353|NCT00969540|Active Comparator|Active Mattress Cover|Subjects in this arm will be given the placebo mattress cover followed active mattress cover .
3232250|NCT00970307|Active Comparator|INFANRIX HEXA + MENJUGATE GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 2, 3 and 4 months of age, 2 doses of Menjugate® vaccine at 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. Infanrix hexa™ and Menjugate® vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
3232251|NCT00970307|Active Comparator|INFANRIX HEXA + SYNFLORIX GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of Infanrix hexa™ vaccine and Synflorix™ vaccine at 2, 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. Infanrix hexa™ and Synflorix™ vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
3232252|NCT00970294|Experimental|Health Promotion Program|Supervised exercise, educational sessions, dietary counseling
3232253|NCT00970281|Experimental|10 mg Olanzapine|
3232254|NCT00970281|Placebo Comparator|Placebo|
3232255|NCT00970268|Experimental|1|Aclidinium bromide dose, inhaled, for 52 weeks of treatment
3232256|NCT00970268|Experimental|2|Aclidinium bromide dose, inhaled, for 52 weeks of treatment
3232257|NCT00970255|Active Comparator|Frenotomy|
3232258|NCT00970255|Sham Comparator|Sham Frenotomy|
3232259|NCT00970229|Experimental|Assess [123I]MNI-420 and SPECT Imaging|To assess [123I]MNI-420 and SPECT Imaging in PD, HD subjects and similarly aged healthy subjects.
3232260|NCT00970203|Experimental|Cohort A|"3 months of androgen ablation followed at PSA progression by 3 months of the combination of androgen ablation + DC1 vaccine~AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells"
3232261|NCT00970203|Experimental|Cohort B|"3 months of the combination of androgen ablation + DC1 vaccine followed at PSA progression by 3 months of androgen ablation~AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells"
3232262|NCT00970177|Experimental|low dose of antigen + low dose of adjuvant|
3232263|NCT00970177|Experimental|high dose of antigen + high dose of adjuvant|
3232264|NCT00970177|Experimental|high dose of antigen|
3232265|NCT00970138|Experimental|A 850|apatinib 850 mg qd, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3232266|NCT00970138|Experimental|B 425|apatinib 425 mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3232267|NCT00970138|Placebo Comparator|C pla|placebo bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3232268|NCT00970125|Experimental|Cancer subjects|
3232269|NCT00970112|Placebo Comparator|Placebo|Placebo 1 hour before surgery
3232270|NCT00970112|Experimental|Etoricoxib|Etoricoxib 1 hour before surgery
3232271|NCT00970112|Experimental|Dexamethaone|Dexamethasone 1 hour before surgery
3232272|NCT00970099|Active Comparator|Exercise|12 week exercise regimen
3232273|NCT00970099|Placebo Comparator|non-exercise|Normal lifestyle routine with no exercise for 12 weeks.
3232274|NCT00970086|Experimental|transversus abdominal plane block|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures with ultrasound, insertion of the stimuplex needle G22, 50mm, in an in-plane approach and administration of 0.4ml/kg levobupivacaine 0.25%."
3232275|NCT00970073|Experimental|Delayed CNI Group 1|Thymoglobulin 3mg total, administered on Days 0 and 2 (after transplant), plus MMF and corticosteroids. CNI administration delayed until 10 days post transplant. tacrolimus 3-8 (trough concentration)
3232276|NCT00970073|Experimental|Delayed CNI Group 2|Thymoglobulin 4.5mg total, plus MMF and corticosteroids. CNI therapy delayed until 10 days post transplant.tacrolimus 3-8 (trough concentration)
3232277|NCT00970073|Active Comparator|Early CNI / Control Arm|Standard post liver transplant therapy to include: tacrolimus 8-12 (trough concentration) initiated within 48 hours post-transplant, plus mycophenolate mofetil (MMF) and corticosteroids to be administered within 24 hours after transplant (Day 0).
3232278|NCT00970060|Experimental|Exercise program|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
3232279|NCT00970047||Pregnant females|Women who are pregnant and between 6 and 16 weeks of gestation and who are 18 to 64 years of age.
3232280|NCT00970034||AF|Patients with degenerative mitral valve regurgitation and permanent atrial fibrillation who require mitral valve repair or replacement.
3232281|NCT00970034||SR|Patients with degenerative mitral valve regurgitation and maintaining sinus rhythm who require mitral valve repair or replacement.
3232282|NCT00970021|Placebo Comparator|Water with artificial colour|Placebo
3232283|NCT00970021|Active Comparator|Extract of agaricus blazei Murill|Agaricus blazei Murill
3232284|NCT00970008|Active Comparator|Massage 30 min - 2x wk for 4 wks & 1x wk for 4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
3232285|NCT00970008|Active Comparator|Massage 60 min - 2x wk for 4 wks & 1x wkly for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
3232286|NCT00970008|Active Comparator|Massage 30 min sessions - 1x/wk for 8wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
3232287|NCT00970008|Active Comparator|Massage 60 min sessions - 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
3232288|NCT00970008|No Intervention|Usual Care Control|Continue on usual care for eight (8) week period.
3232289|NCT00969995||migraine1|50 subjects with migraine without aura
3232290|NCT00969995||migraine 2|50 subjects with migraine with aura
3232291|NCT00969995||tension|50 subjects with tension headache
3232292|NCT00969995||cluster|50 subjects with cluster headache
3232293|NCT00969995||Healthy|50 healthy subjects
3232294|NCT00969982|Experimental|mifepristone+misoprostol|200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 10 doses within 48 hours (maximum 5 doses per 24 hours).
3232295|NCT00969982|Active Comparator|misoprostol|Placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion up to a maximum of 10 doses within 48 hours (maximum 5 doses per 24 hours).
3232296|NCT00969969|Active Comparator|Arthrodesis|Fusion
3232297|NCT00969969|Experimental|Cartiva|Synthetic Cartilage Implant
3232298|NCT00969956||Group A|150 Type 1 Diabetes, duration of 15 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 2 years (+/- 2 years) (50% women / men)
3232299|NCT00969956||Group B|150 Type 1 Diabetes, duration of 20 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 7 years (+/- 2 years) (50% women / men)
3232300|NCT00969956||Group C|150 Type 1 Diabetes, duration of 25 years (+/- 2 years) and 150 Type 2 Diabetes duration of 12 years (+/- 2 years) (50% women / men)
3232301|NCT00969956||Group D|50 LADA (Late Autoimmune Diabetes in Adults), debut after 35 years of age, duration of 5-10 years (50% women / men)
3232302|NCT00969943||Cocaine-dependent Men|
3232303|NCT00969943||Cocaine-dependent Women|
3232304|NCT00969943||Control Men|
3232305|NCT00969943||Control Women|
3232306|NCT00969930||healthy controls|
3232307|NCT00969930||BD type I patients|
3232308|NCT00969917|Experimental|IPI-504|IPI 504 administered twice weekly for 2 weeks followed by 1 week off treatment
3232309|NCT00969904|Active Comparator|1|
3232310|NCT00969904|Placebo Comparator|2|
3232311|NCT00969891||AML patients in induction treatment|
3232312|NCT00969878|Placebo Comparator|Placebo injection|TA-CD placebo will be administered intra muscular. A total of 5 injections will be given over 12 weeks (i.e., at Day 1 and at the beginning of Weeks 3, 5, 9 and 13).
3232313|NCT00969878|Experimental|TA-CD Vaccination|TA-CD 400 μg will be administered intramuscular. A total of 5 injections will be given over 12 weeks (i.e., at Day 1 and at the beginning of Weeks 3, 5, 9 and 13).
3232314|NCT00969865||Individualized Managment Group|Participants receiving, in addition to standard of care, blood tests for markers of heart disease, DNA and RNA analysis, and coronary artery calcium scan.
3232315|NCT00969865||Standard Management Group|Participants who receive standard of care.
3232316|NCT00969852|Experimental|Sertraline|Single Arm
3232317|NCT00969839|Experimental|Intramedullary Fixation System|Humeral fractures to be treated with the Intramedullary Fixation System
3232318|NCT00969826|Experimental|GCPGC 30 μg/kg|Ten volunteers were administered GCPGC 30 μg/kg or placebo (active:placebo=8:2)
3232319|NCT00969826|Experimental|GCPGC 100 μg/kg|Ten volunteers were administered GCPGC 100 μg/kg or placebo (active:placebo=8:2)
3232320|NCT00969826|Experimental|GCPGC 300 μg/kg|Ten volunteers would be administered GCPGC 300 μg/kg or placebo (active:placebo=8:2)
3232321|NCT00969826|Experimental|Neulasta 100 μg/kg|Eight volunteers were administered Neulasta 100 μg/kg
3232322|NCT00969813|Experimental|Normal hepatic function|
3232323|NCT00969813|Experimental|Mild hepatic impairment|
3232324|NCT00969813|Experimental|Moderate hepatic impairment|
3232325|NCT00969800|Experimental|Active Cleverin Gel|Active Cleverin Gel, which generates chlorine dioxide gas, is placed in a room of subject.
3232326|NCT00969800|Sham Comparator|Inactive Cleverin Gel|Inactive Cleverin Gel is placed in a room of subject. It does not generate chlorine dioxide gas.
3232327|NCT00969787|Experimental|DWP05195|
3232328|NCT00969761|Experimental|A. BI 6727-cisplatin|patient to receive 3-weekly infusion escalating dose of BI 6727 combined to cisplatin
3232329|NCT00969761|Experimental|B. BI 6727-carboplatin|patient to receive 3-weekly infusion escalating dose of BI 6727 combined to carboplatin
3232330|NCT00969735|Active Comparator|Cryoablation|Deflectable over-the-wire cryoablation balloon catheter (Arctic Front®, Cryocath Technologies)
3232331|NCT00969735|Active Comparator|Radiofrequency ablation|Open irrigation ablation catheter (Navistar® Thermo-cool®, Biosense Webster Inc).
3232332|NCT00969722|Experimental|ARM I|Intravenous MAb-3F8 plus Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
3232333|NCT00969722|Active Comparator|ARM II|Oral 13-cis-Retinoic Acid (RA) plus Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
3232334|NCT00969709|Experimental|1|40 mg Levomilnacipran ER capsules, low dose, oral administration, once daily.
3232335|NCT00969709|Experimental|2|80 mg Levomilnacipran ER capsules, medium dose, oral administration, once daily dosing
3232336|NCT00969709|Experimental|3|120 mg Levomilnacipran ER capsules, high dose, oral administration, once daily dosing
3232337|NCT00969709|Placebo Comparator|4|Matching placebo capsules, oral administration, once daily.
3232338|NCT00969696|Active Comparator|Galatamine|Galantamine is used for the treatment of mild to moderate Alzheimer's disease and various other memory
3232339|NCT00969696|Placebo Comparator|Sugar Pill|Sugar Pill
3232340|NCT00969683|Active Comparator|Double lumen tube without a hook|Broncho-Cath™, Mallinckrodt France, Parc d'Affaires Technopolis, 3 avenue du Canada, Bât Sigma, Les Ulis, 91975 Courtaboeuf Cedex
3232341|NCT00969683|Experimental|Double lumen tube with a hook|Broncho-Cath™, Mallinckrodt France, Parc d'Affaires Technopolis, 3 avenue du Canada, Bât Sigma, Les Ulis, 91975 Courtaboeuf Cedex
3232342|NCT00969644|Active Comparator|GH|
3232343|NCT00969644|Active Comparator|Pegvisomant|
3232344|NCT00969631|Experimental|Metformin-CC|
3232345|NCT00969631|Active Comparator|Laparoscopic ovarian diathermy (LOD)|
3232346|NCT00969618|Experimental|Atomoxetine|
3232347|NCT00969605|Active Comparator|Pressure support ventilation|
3232348|NCT00969605|Active Comparator|Adaptive support ventilation|
3232349|NCT00969592|Active Comparator|insulin glulisine, insulin aspart|insulin glulisine administration during first glucose clamp, insulin aspart administration during second glucose clamp
3232350|NCT00969592|Active Comparator|insulin aspart, insulin glulisine|insulin aspart administration during first euglycemic clamp, insulin glulisine administration during second clamp
3232351|NCT00969566|Experimental|Metformin+Sitagliptin|Initial combination of metformin and sitagliptin
3232354|NCT00969540|Placebo Comparator|Placebo Mattress Cover|Subjects in this arm will be given the active mattress cover followed by the placebo mattress cover.
3232355|NCT00969527|Experimental|A|Oncoxin + Viusid
3232356|NCT00969527|Placebo Comparator|B|
3232357|NCT00969514||Robotic cystectomy|Patients undergoing robotic laparoscopic cystectomy at Beaumont Hospital-RO
3232358|NCT00969501|Experimental|EUFLEXXA|ACTIVE CONTROL
3232359|NCT00969488|Experimental|high protein diet group|"Women in high protein diet will be stimulate to consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group. The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats). The experimental groups will also receive six cans of sardine to increase the women's commitment to the study.~Both women group will receive a nutritional plan based on an 1800 kcal diet."
3232360|NCT00969488|Active Comparator|normal protein diet group|The control group will receive a diet to lose weight with norma protein intake and will receive 2kg of pasta to increase the women's commitment to the study. The nutritional plan based on an 1800 kcal diet.
3232361|NCT00969475|No Intervention|Control|Half of each subject's wound will not be treated.
3232362|NCT00969475|Experimental|Laser resurfacing|Half of each subject's wound will be treated with a fractional CO2 laser.
3232363|NCT00969462|No Intervention|Doxorubicin|Single arm
3232364|NCT00969449|Experimental|Arm 1|
3232365|NCT00969449|Active Comparator|Arm 2|
3232366|NCT00969436|Experimental|Priorix-Tetra Group|Subjects received 2 doses of Priorix-Tetra® vaccine, 1 at Day 0 and 1 at Month 6, administered subcutaneously in the left anterolateral thigh.
3232367|NCT00969436|Experimental|Priorix/ Priorix-Tetra Group|Subjects received 1 dose of Priorix™ vaccine at Day 0 and 1 dose of Priorix-Tetra® vaccine at Month 6, both administered subcutaneously in the left anterolateral thigh.
3232368|NCT00969436|Active Comparator|Control Group|Subjects received 1 dose of Priorix™ vaccine at Day 0 and 1 dose of Priorix™ vaccine co-administered with Varilirix™ vaccine at Month 6, administered subcutaneously in the left and right anterolateral thigh.
3232369|NCT00969423|Experimental|5 mm equipment|5 mm videoscopic equipment
3232370|NCT00969423|Experimental|10 mm|Use of standard 10 mm VATS equipment
3232371|NCT00969410|Experimental|AV-299 administered IV (monotherapy)|Subjects will be enrolled sequentially and treated with AV-299 (formerly SCH 900105) in dose escalating cohorts. Accrual to the next cohort will occur only if <= 1 out of 6 subjects experiences a dose-limiting toxicity (DLT) during the first 2 cycles. If >= 2 subjects in the same dose cohort experience a DLT during the first 2 cycles, dose-escalation will be terminated.
3232372|NCT00969397|Experimental|Topical Antiangiogenic|Topical Antiangiogenic Agents
3232373|NCT00969397|Experimental|Pulsed Dye Laser|Pulsed Dye Laser
3232374|NCT00969384|Experimental|waist circumferences|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
3232375|NCT00969384|Experimental|Lifestyle counseling|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
3232376|NCT00969371|Experimental|Tetraflex Study|patients in Study arm received TetraFlex Lens
3232377|NCT00969371|Active Comparator|Control|commercially approved PCIOL implanted
3232378|NCT00969345|Sham Comparator|Control Group|Stretching exercises performed twice a day for 10 minutes (4 months)
3232379|NCT00969345|Active Comparator|Respiration Group|Respiratory Yoga exercises performed twice a day for 10 minutes (4 months)
3232380|NCT00969332|Experimental|Omegaven|0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
3232381|NCT00969319||Group 1|
3232382|NCT00969306|Active Comparator|Chloroquine|Patients receive Chloroquine
3232383|NCT00969280|Experimental|Standardized Acupuncture group|
3232384|NCT00969280|Placebo Comparator|Non-acupoint shallow penetration group|
3232385|NCT00969267|Experimental|Stimulation A|with needle A stimulation
3232386|NCT00969267|Active Comparator|Stimulation B|with stimulation
3232387|NCT00969267|Sham Comparator|Stimulation C|without needle
3232388|NCT00969254|Experimental|Pílulas de Lussen|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pílulas de Lussen®~** Drug B: placebo."
3232389|NCT00969254|Active Comparator|Pyridium®|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pyridium®~** Drug B: placebo."
3232390|NCT00969228|Experimental|Rotarix Group|Subjects received 2 oral doses of Rotarix according to a 0, 1 or 2-month schedule.
3232391|NCT00969228|Placebo Comparator|Placebo Group|Subjects received 2 oral doses of placebo according to a 0, 1 or 2-month schedule.
3232392|NCT00969215|Experimental|Laser treatment|Half of each subject's scar will be treated with a fractional CO2 laser.
3232393|NCT00969215|No Intervention|No treatment|Half of each subject's scar will not be treated.
3232394|NCT00969202|Experimental|Stereotactic Radiosurgery using NovalisTx|Single arm study using the Novalis Tx to perform radiosurgery to treat low grade prostate cancer.
3232395|NCT00969189||Children|between 10 and 30 kgs
3232396|NCT00969189||Infants|between 5 - 10 kg
3232397|NCT00969176|No Intervention|paracetamol|not applicable, since all included cases will receive intravenous paracetamol
3232398|NCT00969163|Experimental|1|2.5 mg testosterone gel
3232399|NCT00969163|Experimental|2|300 ug testosterone gel
3232400|NCT00969163|Placebo Comparator|3|placebo gel
3232401|NCT00969150|Placebo Comparator|2|Matching placebo capsules, oral administration, once daily dosing.
3232402|NCT00969150|Experimental|1|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing.
3232403|NCT00969137|Active Comparator|Nicotine|Intravenous Nicotine
3232404|NCT00969137|Placebo Comparator|Saline|Saline infusion
3232405|NCT00969124|Experimental|Third Eye Retroscope|All subjects underwent the same intervention, consisting of examination of the colon using a colonoscope along with the Third Eye Retroscope device, with removal of any polyps that were detected during the procedure.
3232406|NCT00969111|Experimental|Postop Non-High Risk|Proton to 66.6 CGE
3232407|NCT00969111|Experimental|Postop High Risk|IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE
3232408|NCT00969111|Experimental|Salvage Non-High Risk|Proton to 70.2 CGE
3232409|NCT00969111|Experimental|Salvage High Risk|IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE
3232410|NCT00969085|Experimental|Curcumin|
3232411|NCT00969072|Experimental|GI198745|
3232412|NCT00969059|Placebo Comparator|PLACEBO|Eligible participant with at least moderate intensity of pain (an average daily pain score of ≥ 4 on the 11 point PI-NRS at baseline) will receive placebo for 28 days.
3232413|NCT00969059|Experimental|Active|Eligible participant with at least moderate intensity of pain (an average daily pain score of ≥ 4 on the 11 point PI-NRS at baseline) will receive 7.5 mg twice daily (bid) GW856553 for 28 days.
3232414|NCT00969046|Experimental|Bolus|20 min bolus infusion
3232415|NCT00969046|Experimental|CIV-1d|1 day continuous infusion
3232416|NCT00969046|Experimental|CIV-5d|5 day continuous infusion
3232417|NCT00969033|Experimental|CS-1008 with irinotecan|CS-1008 and irinotecan
3232418|NCT00969033|Active Comparator|irintoecan|irinotecan alone
3232419|NCT00969020|Active Comparator|Telemedicine|RRS via telemedicine. By developing the concept of Remote Rehabilitation Support (RRS) the investigators will try to bring preoperative education of the patient, dissemination of information and postoperative support to a new level.
3232420|NCT00969020|No Intervention|Standard|The standard procedure for THA used under The Lundbeck Center for fast track hip and knee surgery
3232421|NCT00969007|Experimental|Lifestyle counseling|
3232422|NCT00968994|Experimental|exSALT SD7™ Wound Dressing|The exSALT™ SD7 Wound Dressing provides an antimicrobial barrier that inhibits microbial growth in the dressing. The exSALT™ SD7 Wound Dressing consists of 3 layers: two non-adherent polyethylene mesh wound contact layers and one absorbent core made of polyester. All three layers are silver coated. The concentration of silver on the exSALT™ SD7 Wound Dressing is approximately 0.4 mg/cm2 (2.5% w/w).
3232423|NCT00968994|Active Comparator|Xeroform® Petrolatum Dressing|Xeroform® Petrolatum Dressing (Xeroform® / Control Dressing) is fine mesh gauze impregnated with 3% Bismuth Tribromophenate in a special petrolatum blend. The dressing is a non adherent dressing that clings and conforms to all body parts.
3232424|NCT00968981|Experimental|A|
3232425|NCT00968981|Experimental|B|
3232426|NCT00968981|Experimental|C|
3232427|NCT00968968|Experimental|Arm 1: Lapatinib plus Trastuzumab|
3232428|NCT00968968|Active Comparator|Arm 2: Trastuzumab|
3232429|NCT00968955|Active Comparator|Local infiltration with ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
3232430|NCT00968955|Placebo Comparator|Local infiltration with saline|Local infiltration with saline (150 ML) (placebo)
3232431|NCT00968942|Active Comparator|Dose A|RT001
3232432|NCT00968942|Placebo Comparator|Dose B|Placebo
3232433|NCT00968929|Experimental|r-SK group|Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
3232434|NCT00968929|Active Comparator|UK group|Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
3232435|NCT00968916|Experimental|1|"Level 1:~15.5 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 2:~25 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 3:~35 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 4:~50 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal"
3232436|NCT00968903|Active Comparator|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
3232437|NCT00968903|Placebo Comparator|Saline|Saline iv pre-operatively in equivalent volume (placebo)
3232438|NCT00968890|Experimental|Pandemrix+Fluarix and Pandemrix+Placebo|Subjects received two doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm co-administered with Fluarix™ on Day 0 and with a placebo on Day 21 intramuscularly in the deltoid region of the dominant arm.
3232439|NCT00968890|Experimental|Pandemrix+Placebo and Pandemrix+Fluarix|Subjects received two doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm co-administered with a placebo on Day 0 and with Fluarix™ on Day 21 intramuscularly in the deltoid region of the dominant arm.
3232440|NCT00968877|Active Comparator|Cholecalciferol|
3232441|NCT00968877|Placebo Comparator|Placebo|
3232442|NCT00968864|Experimental|CliniMACS® (T cell depletion)|Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.
3232443|NCT00968851|Active Comparator|EVP-6124 0.3 mg|one 0.3 mg capsule every day for 84 days
3232444|NCT00968851|Active Comparator|EVP-6124 1.0 mg|one 1.0 mg capsule every day for 84 days.
3232445|NCT00968851|Placebo Comparator|Placebo|Placebo every day for 84 days
3232446|NCT00968838|Experimental|Non-radiated White Blood Cell Transfusion|Four (4) non-radiated white blood cell transfusions. Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.
3232447|NCT00968838|Experimental|White Blood Cell Transfusion|Four (4) standard white blood cell transfusions (with radiation). Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.
3232448|NCT00968825|Active Comparator|Dose D|RT001
3232449|NCT00968825|Placebo Comparator|Dose E|Placebo
3232450|NCT00968812|Active Comparator|Glimepiride|Each patient will receive glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.
3232451|NCT00968812|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.
3232452|NCT00968812|Experimental|Canagliflozin 300 mg|Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.
3232453|NCT00968799|Experimental|HIPEC treatment|"Cytoreduction~Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with cisplatin~Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution. Perfusion volume depends on body size (3 - 6 l).~If cisplatin amount exceeds the equivalent of 62.5 mg/m² body surface, cisplatin is dosed by body surface (62.5 mg/m²)(safety margin).~Perfusion is performed with the open or Coliseum technique for 90 min."
3232454|NCT00968786|No Intervention|no home monitoring|no automated measuring devices for patients use at home
3232455|NCT00968773|Experimental|The Rebound hernia repair device with no fixation|Competent adults who have a unilateral, bilateral inguinal hernia that is primary in nature.
3232456|NCT00968773|Active Comparator|Standard Hernia Mesh using fixation|Competent adults who have a unilateral or bilateral inguinal hernia that is primary in nature.
3232457|NCT00968760|Experimental|CD19-specific T cell Infusion without IL-2|"Conditioning Regimen of Chemotherapy (Carmustine, Cytarabine, Etoposide, and Melphalan), Stem Cell Transplant, and Gene Transfer~Group 1 - low dose of T cells without IL-2.~Group 3 - higher dose of T cells without IL-2."
3232458|NCT00968760|Experimental|CD19-specific T cell Infusion with IL-2|"Conditioning Regimen of Chemotherapy (Carmustine, Cytarabine, Etoposide, and Melphalan), Stem Cell Transplant, and Gene Transfer~Group 2 - higher dose of T cells with IL-2.~Group 4 - higher dose of T cells with IL-2."
3232459|NCT00968747|Experimental|Fasting (Healthy).|Participants will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily and two fat samples will be obtained by a trained surgeon. (We are no longer recruiting for Study Arm A).
3232460|NCT00968747|Experimental|Fasting (NAFLD)|Participants with liver-biopsy diagnosed non-alcoholic fatty liver disease (NAFLD) will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily, and participants will have an MRI before and after the fast.
3232461|NCT00968747|Experimental|Hypocaloric diet (NAFLD)|Participants will follow a low-calorie diet until they lose 3-5% of their body weight. Participants will have weekly outpatient visits at Beth Israel Deaconess Medical Center in Boston, MA for weight measurements. Participants will have blood drawn before and after the diet. Participants will also have an MRI before and after the diet.
3232462|NCT00968747|Experimental|Oral carbohydrate challenge|Participants will fast for 16 hours overnight then ingest drinks containing fructose, glucose or a mixture of fructose and glucose. Blood will be drawn postprandially at specified timepoints for up to 5 hours
3232463|NCT00968734|Experimental|Low fat meal|
3232464|NCT00968734|Experimental|Hight fat meal|
3232465|NCT00968721||IBD patients|
3232466|NCT00968708|Experimental|Placebo|Alogliptin placebo matching tablets, orally, once daily. Participants continued to receive standard of care for cardiovascular disease and diabetes according to regional guidelines.
3232467|NCT00968708|Experimental|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for participants with normal or mildly impaired renal function as defined by estimated glomerular filtration rate (eGFR) ≥ 60 mL/min). Alogliptin 12.5 mg, tablets, orally, once daily for participants with moderately impaired renal function (eGFR ≥30 and <60 mL/min). Alogliptin 6.25 mg, tablets, orally, once daily for participants with severely impaired renal function or end stage renal disease (eGFR <30 mL/min). Participants continued to receive standard of care for cardiovascular disease and diabetes according to regional guidelines.
3232468|NCT00968695|Experimental|Albumin|
3232469|NCT00968669|Experimental|MEDI528 30 mg|MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
3232470|NCT00968669|Experimental|MEDI528 100 mg|MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
3232471|NCT00968669|Experimental|MEDI528 300 mg|MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
3232472|NCT00968669|Experimental|Placebo|Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
3232473|NCT00968643|Active Comparator|Arm I (control)|Patients undergo radiotherapy to the area of spinal cord compression once daily for 5 days (total of 20 Gy).
3232474|NCT00968643|Experimental|Arm II|Patients undergo a single fraction of radiotherapy to the area of spinal cord compression (total of 10 Gy).
3232475|NCT00968630|Experimental|Treatment (HIV-specific immune reconstitution after HCT)|Patients undergo leukapheresis for analysis of HIV-1 latent reservoir at baseline and at days +90, +180, +365, and +730, and then annually thereafter as feasible.
3232476|NCT00968617|Experimental|MK2578 1.0 mcg/kg|MK2578
3232477|NCT00968617|Experimental|MK2578 2.0 mcg/kg|MK2578
3232478|NCT00968617|Experimental|MK2578 3.6 mcg/kg|MK2578
3232479|NCT00968617|Active Comparator|Darbepoetin alfa|darbepoetin alfa
3232480|NCT00968604|Experimental|BikDD Nanoparticle|BikDD Nanoparticle starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
3232481|NCT00968591|Experimental|RAD001|
3232482|NCT00968578|Active Comparator|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
3232483|NCT00968578|Placebo Comparator|Saline|Saline iv pre-operatively in equivalent volume (placebo)
3232484|NCT00968565|Experimental|Citrate|Sodium citrate will be infused as the blood enters the ECMO circuit and calcium chloride will be infused as the blood leaves the ECMO circuit and enters the patient
3232485|NCT00968552||Patients undergoing stent placement|Patients who are scheduled to undergo stent placement via endoscopy as part of their routine medical care.
3232486|NCT00968539|Experimental|GSK2340272A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3232487|NCT00968539|Experimental|GSK2340269A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3232488|NCT00968526|Experimental|Group A|
3232489|NCT00968526|Experimental|Group B|
3232490|NCT00968513|Active Comparator|Usual Care|(N=150) brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
3232491|NCT00968513|Experimental|Brief Treatment|(N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization.
3232492|NCT00968513|Experimental|Extended Treatment|(N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
3232493|NCT00968500||Parents Who Have Lost a Child to Cancer|The overall goal of the proposed cross-sectional study is to obtain information necessary to the development of an effective Meaning-Centered Grief Intervention for parents who lost a child to cancer. In order to identify a subset of parents with whom we will conduct qualitative interviews with a subset of participants to address Aims 1 and 2, we will first screen participants to determine their levels of Prolonged Grief Disorder symptoms using a quantitative assessment (PG-13). The screening measure (PG-13) and the additional questionnaires included in the quantitative battery of measures will be analyzed to achieve Aim 3.
3232494|NCT00968487|Experimental|Lyophilized Plasma|
3232495|NCT00968487|Active Comparator|Fresh Frozen Plasma|
3232496|NCT00968461|Experimental|Phenethyl Isothiocyanate (PEITC)|Starting dose 40 mg capsules by mouth, 4 times a day, on Days 1-3 and 8-10 of each cycle.
3232497|NCT00968448|Active Comparator|Training|respiratory muscle training (pressure threshold loading)
3232498|NCT00968448|Sham Comparator|sham training|training with low resistance
3232499|NCT00968435|Experimental|(IMRT) + cisplatin + bevacizumab + cetuximab|This is a single-institution, non-randomized, phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab + cetuximab.
3232500|NCT00968422|Experimental|Low dose ABT-384|
3232501|NCT00968422|Experimental|Mid dose ABT-384|
3232502|NCT00968422|Experimental|High dose ABT-384|
3232503|NCT00968422|Placebo Comparator|Placebo|
3232504|NCT00968409|Other|FFNP-PET/CT Imaging|All subjects will receive an injection of F-18-FFNP followed by PET/CT imaging, laboratory testing and safety testing.
3232505|NCT00968396|Experimental|Stem Cell Collection + Transplantation|Apheresis: On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation. Co-culture Stem Cell Infusion on Day 0. Melphalan 100 mg/m^2 IV over 30 minutes daily on Days -2 and -1.
3232506|NCT00968383|Active Comparator|Optimal medical therapy|Conventional medical management, including aspirin, clopidogrel, statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) and/or aldosterone antagonist and risk factor modification
3232507|NCT00968383|Experimental|PCI with optimal medical therapy|Conventional medical management, including aspirin, clopidogrel, statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) and/or aldosterone antagonist and risk factor modification plus percutaneous coronary intervention and coronary stenting
3232508|NCT00968370|Active Comparator|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
3232509|NCT00968370|Other|Hospital management|Hospital management: all children admitted at the hospital will be managed with injection Ceftriaxone and other micronutrients for the total duration of hospitalization as per approved protocol.
3232510|NCT00968357|Experimental|SCV-07|Cohort 1: SCV-07 0.1 mg/kg. Cohort 2: 1.0 mg/kg per day administered SC
3232511|NCT00968344|Experimental|Leucine|
3232512|NCT00968344|Placebo Comparator|Placebo|
3232513|NCT00968331|Experimental|REVLIMID plus RITUXIMAB|"Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.~Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles."
3232514|NCT00968318|Other|Rate of seroma formation|Excision of strip of deep fascia was assessed regarding the rate of seroma formation with tissue expander insertion
3232515|NCT00968305||Children with asthma|African American children with clinically diagnosed stable asthma
3232516|NCT00968292|Experimental|Congenital/Traumatic|Individuals who were born with a limb deficiency or who have had a traumatic amputation.
3232517|NCT00968292|Experimental|Dysvascular/Diabetic|Individuals who have had an amputation as a result of vascular disease.
3232518|NCT00968279||Atrial Fibrillation|
3232519|NCT00968266|Experimental|Group intervention|"In short, the intervention consists of two group sessions moderated by a pharmacist. During these sessions, patients' self-perceived needs to take medication ('necessity beliefs'), concerns about taking medication ('concern beliefs'), and practical barriers are discussed. To explore a patient's individual ambivalence regarding his/her beliefs and barriers, the pharmacist uses Motivational Interviewing techniques. In between the sessions, participants make a homework assignment about their own beliefs and barriers, and eight weeks after the second session, a follow-up call to the individual patients is made by the pharmacist.~Patients in the experimental arm also receive a brochure about the DMARDs they currently use (see: control arm)"
3232520|NCT00968266|Active Comparator|Control arm: usual care|In the control arm, patients receive a brochure about the DMARDs they are currently using.
3232521|NCT00968253|Experimental|Phase I: RAD001 + Combination Chemo|"Optimal dose finding of Everolimus (RAD001) beginning dose 5 mg + two different chemotherapy combinations during alternating cycles, Hyper-CVAD on Cycles 1, 3, 5, & 7 and Methotrexate & Cytarabine (Ara-C) during Cycles 2, 4, 6, & 8.~First chemotherapy combination Hyper-CVAD = Cyclophosphamide, Vincristine, Adriamycin (doxorubicin), and Dexamethasone; Second chemotherapy combination Methotrexate and Ara-C."
3232522|NCT00968253|Experimental|Phase II: MTD RAD001 + Combination Chemo|MTD dose of Everolimus + two different chemotherapy combinations during alternating cycles, Hyper-CVAD on Cycles 1, 3, 5, & 7 and Methotrexate & Ara-C during Cycles 2, 4, 6, & 8.
3232523|NCT00968227|Experimental|Transfusion|
3232572|NCT00967733|Active Comparator|High ALA-Low Linoleic|
3232573|NCT00967733|Placebo Comparator|Low ALA-Low Linoleic|
3232524|NCT00968214||Single group|DNA from blood specimens that have been previously collected from patients are analyzed for single nucleotide polymorphisms.
3232525|NCT00968201|Experimental|1|Montelukast
3232526|NCT00968201|Placebo Comparator|2|Placebo
3232527|NCT00968188|Experimental|Active intervention|Highly interactive, motivational, culturally tailored, online HIV prevention.
3232528|NCT00968188|Active Comparator|Information only|Medically fact based online intervention.
3232529|NCT00968175|Active Comparator|Group 1: CPN + analgesic therapy|Receives ultrasound guided celiac plexus neurolysis (CPN) in addition to standard analgesic therapy
3232530|NCT00968175|No Intervention|Analgesic therapy alone|Will not receive ultrasound guided celiac plexus neurolysis (CPN); only standard analgesic therapy for pain management
3232531|NCT00968162|Experimental|Dose de-escalation|
3232532|NCT00968149|Experimental|1|Montelukast
3232533|NCT00968149|Placebo Comparator|2|Placebo
3232534|NCT00968136||a short-term trial of the ketogenic diet|
3232535|NCT00968136||long-term trial of the ketogenic diet.|
3232536|NCT00968110|Experimental|Xolair|All patients will receive Xolair treatment for 16 weeks.
3232537|NCT00968071|Experimental|Decitabine + Gemtuzumab Ozogamicin|Decitabine 20 mg/m^2 intravenously (IV) over an hour and half daily for 5 days, Gemtuzumab Ozogamicin 3 mg/m^2 IV on day 5.
3232538|NCT00968045|Placebo Comparator|Placebo|100 ml infusion of saline is given during 15 minutes after anesthesia induction before start of surgery.
3232539|NCT00968045|Experimental|Study drug|Fibrinogen 2g in 100 ml sterile water given during 15 minutes after anestesiainduction before surgery start
3232540|NCT00968019||Presillion stent|Patients treated with the Presillion stent in up to two de novo coronary artery lesions
3232541|NCT00968006|Experimental|Treatment|Sitagliptin 100 mg once daily for 4 weeks
3232542|NCT00968006|No Intervention|Control|No change in anti-diabetic treatment regimen for at least 4 weeks.
3232543|NCT00967993||KRX-0502 (ferric citrate)|"KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate. All patients initiated on study drug will start with a fixed dose of KRX-0502 (ferric citrate) of 6 caplets per day.~Patients will be titrated at Visits 4, 5, and 6 based on serum phosphorus lab results. If serum phosphorus levels go below normal, there will be a decrease in pills; if serum phosphorus levels go above normal, there wil be an increase in pills. The maximum number of KRX-0502 (ferric citrate) caplets per day will be 12, or 12 g/day of ferric citrate.~Patients will take study drug orally with meals or snacks or within one hour after their meals or snacks."
3232544|NCT00967980|Active Comparator|1. Femoral Nerve Block|Patients will be randomized with a computer program to receive a femoral catheter. The catheter will be placed using standard technique. The time of catheter placement will be recorded as well as the pain/discomfort of catheter placement as reported by the patient on a 0-10 scale where 0=no pain/discomfort and 10=worst imaginable pain/discomfort.
3232545|NCT00967980|Active Comparator|2. Psoas Compartment Catheter|Patients will be randomized with a computer program to receive a psoas compartment catheter. The catheter will be placed using standard technique. The time of catheter placement will be recorded as well as the pain/discomfort of catheter placement as reported by the patient on a 0-10 scale where 0=no pain/discomfort and 10=worst imaginable pain/discomfort.
3232546|NCT00967967|Other|Mometasone furoate and desloratadine|Mometasone and desloratadine treatment
3232547|NCT00967941|Active Comparator|Ancef|
3232548|NCT00967941|Active Comparator|Vancomycin and Cefazolin|
3232549|NCT00967941|Active Comparator|Daptomycin and Cefazolin|
3232550|NCT00967928|Experimental|Single arm|All subjects receive RAD001 in combination with standard field whole pelvic radiation and cisplatin.
3232551|NCT00967915|Experimental|Frenotomy|Group of neonates that will receive frenotomy for tongue-tie
3232552|NCT00967915|Sham Comparator|No frenotomy|Group of infants that will undergo sham procedure (no frenotomy performed)
3232553|NCT00967902|Experimental|Combo|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
3232554|NCT00967902|Active Comparator|Taxus® Liberté® Stent|Commercially available product
3232555|NCT00967863|Experimental|Arm I|Patients undergo 80 Gy of conformal or intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
3232556|NCT00967863|Experimental|Arm II|Patients undergo 70 Gy of conformal or intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
3232557|NCT00967850|Experimental|Intravitreal Bevacizumab|Intravitreal injections of bevacizumab
3232558|NCT00967850|Active Comparator|Visudyne|Photodynamic Therapy with Visudyne
3232559|NCT00967837|Experimental|Diabetes with non healing wounds|To determine and monitor progress of diabetic patients with non healing wounds that have failed conventional 60 day treatment respond to pulsatile intravenous insulin therapy in improving and completing healing in non healing wounds
3232560|NCT00967811|Experimental|1. Formulation E1|Formulation E1 of Latanoprost-PPDS
3232561|NCT00967811|Experimental|2. Formulation E2|Formulation E2 of Latanoprost-PPDS
3232562|NCT00967798|Experimental|Sitagliptin|"CF patients receiving Sitagliptin.~Intervention: Dose is 100 mg taken orally once a day in the morning with breakfast. Duration is one year or until converted to CF diabetes, whichever comes sooner."
3232563|NCT00967798|Placebo Comparator|Sugar pill|"CF patients receiving placebo.~Intervention: Placebo is taken orally once a day in the morning with breakfast. Duration is one year or until converted to CF diabetes, whichever comes sooner."
3232564|NCT00967772|Experimental|Naftopidil|
3232565|NCT00967759|Experimental|Decongex Plus|
3232566|NCT00967759|Active Comparator|Bronpheniramine isolated|
3232567|NCT00967759|Active Comparator|Fenilefrine isolated|
3232568|NCT00967746|Experimental|ENG-MIUS low|Low dose: ENG-MIUS containing 38 mg ENG with a skin thickness of approximately 350 μm
3232569|NCT00967746|Experimental|ENG-MIUS intermediate|Intermediate dose: ENG-MIUS containing 61 mg ENG with a skin thickness of approximately 140 μm
3232570|NCT00967746|Experimental|ENG-MIUS high|High dose: ENG-MIUS containing 72 mg ENG with a skin thickness of approximately 50 μm
3232571|NCT00967746|Active Comparator|Multiload|Multiload-cu 375®
3232574|NCT00967733|Active Comparator|High ALA-High Linoleic|
3232575|NCT00967733|Placebo Comparator|Low ALA-High Linoleic|
3232576|NCT00967720||Barriers, Adherence, Asthma|
3232577|NCT00967707|Active Comparator|Gabapentin + venlafaxine|
3232578|NCT00967707|Active Comparator|Gabapentin + donepezil|
3232579|NCT00967694|Experimental|Nitrous oxide administration|All 20 healthy volunteers had their intraocular pressure (IOP) measured at baseline and then after 3, 6, 9, and 12 minutes of nitrous oxide administration, and then after 5, 10, and 15 minutes of breathing room air. There was therefore only one study arm, with each individual serving as their control for baseline and then intervention values of IOP measurement.
3232580|NCT00967681|Experimental|A|Oncoxin, a nutritional supplement
3232581|NCT00967681|Placebo Comparator|B|
3232582|NCT00967668|Experimental|ASPIRE-Phone Lifestyle Coaching|Phone-based coaching using small change approach to improve physical activity and diet. Initial treatment of 3 months, followed by 21 months of follow-up phone support (phone-only ASPIRE-VA).
3232583|NCT00967668|Experimental|ASPIRE-Group Lifestyle Coaching|On-site weekly group visits using small change approach to improve physical activity and diet. Initial treatment of 3 months, followed by 21 months of follow-up phone support (phone-only ASPIRE-VA).
3232584|NCT00967668|Active Comparator|MOVE! Usual Care|Usual care MOVE!, which consists of weekly on-site group visits that follow MOVE! protocols with unstructured follow-up phone support
3232585|NCT00967642|No Intervention|standard treatment|glycemia before meals and subcutaneous regular insulin if higher than 200 mg/dl
3232586|NCT00967642|Other|Intravenous Insulin|intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
3232587|NCT00967629|Other|Sevelamer Carbonate crossover|Participants will be patients with stage II-IV CKD due to diabetic nephropathy randomized to start either with sevelamer carbonate or calcium carbonate
3232588|NCT00967629|Other|Calcium Carbonate crossover|Participants will be patients with stage II-IV CKD due to diabetic nephropathy randomized to start either with sevelamer carbonate or calcium carbonate
3232589|NCT00967616|Experimental|CS7017 plus FOLFIRI|CS7017 plus irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
3232590|NCT00967616|Active Comparator|FOLFIRI|irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
3232591|NCT00967603|No Intervention|observation|no therapy until progression
3232592|NCT00967603|Experimental|sunitinib|sunitinib until progression or for a maximum of 6 months
3232593|NCT00967590|Experimental|1|
3232594|NCT00967590|Placebo Comparator|2|
3232595|NCT00967577|Experimental|J591|
3232596|NCT00967564||001|epidemiologic study QoL assessment
3232597|NCT00967551|Active Comparator|Micronutrient Sprinkles without zinc|Micronutrient sprinkles without zinc
3232598|NCT00967551|Experimental|Micronutrient sprinkles with zinc|Micronutrient sprinkles with zinc gluconate
3232599|NCT00967538|Experimental|Etanercept|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
3232600|NCT00967525|Experimental|1|Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.
3232601|NCT00967512|Experimental|cenersen, idarubicin, cytarabine|cenersen, idarubicin, cytarabine
3232602|NCT00967512|Placebo Comparator|placebo, idarubicin, cytarabine|placebo, idarubicin, cytarabine
3232603|NCT00967499|Active Comparator|1|
3232604|NCT00967499|Active Comparator|2|
3232605|NCT00967486|Active Comparator|Routine Shunt|These patients are called routine as the routine method of carotid endarterectomy is used.
3232606|NCT00967486|Active Comparator|Selective Shunt|These patients are selectively used for shunting or not shunting based on systolic pressure < 40mmHg. This group is further used as subgroup analysis.
3232607|NCT00967473|Experimental|Toric Intraocular Lens|ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Models SN60T9/SN60T8
3232608|NCT00967460|No Intervention|Control group: No intervention|No intervention, regular childcare program
3232609|NCT00967460|Experimental|Intervention group|Promoting unstructured spontaneous PA through an adaptation of the built environment and the provision of a supportive social environment
3232610|NCT00967434|Active Comparator|Group A- atorvastatin in pre and postop|Atorvastatin 80 mg administered daily for at least 7 preoperative days, 80 mg on day of surgery and 80 mg daily for up to 7 postoperative days.
3232611|NCT00967434|Active Comparator|Group B- Atorvastatin postop|Placebo administered for up to 7 preoperative days, atorvastatin 80 mg administered on day of surgery and daily for up to 7 postoperative days.
3232612|NCT00967434|Placebo Comparator|Group C- Placebo|Patients receive placebo daily for up 7 preoperative days, placebo on day of surgery and placebo daily for up to 7 postoperative days.
3232613|NCT00967421|Experimental|BAC 0.5|BAC level 0.5 g/dL (drink + placebo pill)
3232614|NCT00967421|Experimental|BAC 1.0|BAC level 1.0 g/dL (drink + placebo pill)
3232615|NCT00967421|Placebo Comparator|placebo|BAC level 0,0 g/dL (placebo drink+ placebo pill)
3232616|NCT00967408|Experimental|Rehabilitation + Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
3232617|NCT00967408|Placebo Comparator|Rehabilitation + Placebo|Rehabilitative treatment + Non active Placebo tablets for 6 months
3232618|NCT00967395|Experimental|Healing|patients receive healing while blindfolded and with hearing protector. The healer is behind a screen and not allowed to speak with the subject.
3232619|NCT00967395|Sham Comparator|Sham healing|Same design of room as with the healing, while in this case a student is behind the screen
3232620|NCT00967395|No Intervention|Control|Business as usual in the third arm
3232621|NCT00967382|No Intervention|Control|"Subjects randomized to control will receive identical obstetrical care and follow-up, but not antenatal dalteparin.~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
3232788|NCT00966095||men scheduled for prostate biopsy|
3232841|NCT00965705|Active Comparator|Dialectical Behavioral Therapy|
3232622|NCT00967382|Active Comparator|dalteparin sodium|"Subjects randomized to the treatment group will receive daily injections of dalteparin during the antenatal period. They will be taught how to self-administer sub-cutaneous injections of dalteparin 5000 IU once daily (o.d.) until gestational age 20, then twice daily (bid) until 37 weeks gestation or onset of labour.~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
3232623|NCT00967369|Experimental|Bortezomib + Ifosfamide + Carboplatin + Etoposide|Treatment consists of Bortezomib plus ICE (ifosfamide, carboplatin, etoposide) chemotherapy (BICE)
3232624|NCT00967369|Experimental|Ifosfamide + Carboplatin + Etoposide|Treatment consists of ICE (ifosfamide, carboplatin, etoposide) chemotherapy
3232625|NCT00967356|Experimental|A|AZD5985
3232626|NCT00967356|Placebo Comparator|B|Placebo
3232627|NCT00967343|Experimental|ATIR|
3232628|NCT00967330|Experimental|1|
3232629|NCT00967330|Active Comparator|2|
3232630|NCT00967317|Experimental|Auris-Sedina|"Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor."
3232631|NCT00967317|Active Comparator|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
3232632|NCT00967304|Experimental|1 Discontinue OAT or AAA|"Patients classified as being at low risk of recurrent VTE by the HER DOO2rule.~If the clinical decision rule indicates that a patient is at low recurrence risk (<3% per year); anticoagulant therapy will be withdrawn and the participant will then be followed for 1 year for any VTE recurrence and/or bleeding."
3232633|NCT00967304|No Intervention|2 Observation arm|"Men and patients classified as being at high risk of recurrent VTE by the HER DOO2rule.~If the clinical decision rule indicates that a patient is at high recurrence risk then the decision to continue or discontinue anticoagulant therapy will be left to the discretion of physicians and patients as per current standard of care and this decision recorded. High risk patients (females classified as being at high risk of recurrent VTE by the CDR, and all males) will then be followed as an observational cohort for 1 year for any VTE recurrence and/or bleeding."
3232634|NCT00967278||Off-Pump|Patients with coronary artery disease undergoing elective off-pump CABG
3232635|NCT00967265|Experimental|Introduction seminar|Psychoeducation for patients on waiting list
3232636|NCT00967265|Active Comparator|Usual care|Usual care
3232637|NCT00967252||atorvastatin 10 mg or equivalent dose|Patients already taking atorvastatin 10 mg or equivalent dose in another statin who is undergoing high risk surgery
3232638|NCT00967252||atorvastatin 20 mg or equivalent dose|Patients already taking atorvastatin 20 mg or equivalent dose in another statin who is undergoing high risk surgery
3232639|NCT00967252||atorvastatin 40 mg or equivalent dose|Patients already taking atorvastatin 40 mg or equivalent dose in another statin who is undergoing high risk surgery
3232640|NCT00967252||atorvastatin 80 mg or equivalent dose|Patients already taking atorvastatin 80 mg or equivalent dose in another statin who is undergoing high risk surgery
3232641|NCT00967252||non-statin group|Patients who are not taking or cannot take a statin drug who is undergoing high risk surgery
3232642|NCT00967226|Experimental|propranolol for treatment of hemangiomas|Assessing efficacy and tolerability of propranolol in management of symptomatic hemangiomas
3232643|NCT00967226|Active Comparator|Prednisolone|Assessing efficacy and tolerability of prednisolone in management of symptomatic hemangiomas and comparing to propranolol.
3232644|NCT00967213|Experimental|Ranibizumab|three session of monthly injection of Lucentis® (week 0, 4, 8). After 4 weeks from third injection, a session of verteporfin PDT (week 12) and fourth injection of Lucentis® (week 16) will be added at intervals of 4 weeks. Two more combined treatment with verteporfin PDT and Lucentis® injection 4 weeks apart can be added at the treating physician's discretion in 3-month intervals (week 28, week 40).
3232645|NCT00967187|Experimental|MPC-4326 200 mg BID X 14 Days|
3232646|NCT00967187|Experimental|MPC-4326 300 mg BID X 14 Days.|
3232647|NCT00967174|Experimental|Three Treatments Applied to Lower Back|Treatments were applied on the lower back, according to treatment sequence, daily for 21 days.
3232648|NCT00967161|Experimental|Evolution Medial Pivot Knee|20 Patients will receive the EMP Knee Implant
3232649|NCT00967161|Active Comparator|Triathlon PS Knee|20 Patients will receive the Triathlon PS Knee
3232650|NCT00967148|Experimental|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
3232651|NCT00967148|Active Comparator|Standard of care|The control arm will receive a subcutaneous injection of 4,500 U of tinzaparin daily beginning with the first postoperative dose and continued for the duration of hospitalization.
3232652|NCT00967135|Experimental|Pregabalin|Study subjects will be randomized to receive on the morning of surgery, at least 30 minutes before induction, a 150 mg oral dose of pregabalin. Patients will then receive a 150 mg oral dose of pregabalin on the evening of the surgery. Subsequently, patients will receive a 150 mg oral dose of pregabalin twice daily on the following four postoperative days.
3232653|NCT00967135|Placebo Comparator|Placebo|Study subjects will be randomized to receive a matching placebo on the morning of surgery, at least 30 minutes before induction. Patients will then receive a placebo on the evening of the surgery. Subsequently, patients will receive a placebo twice daily on the following four postoperative days.
3232654|NCT00967122|No Intervention|No Arm|
3232655|NCT00967109|Active Comparator|Allowed drop in hemoglobin to 4,5-5,5 mmol/L|Transfusion with red blood cells to level between 4.5-5.5 mmol/L
3232656|NCT00967109|Experimental|Allowed drop in hemoglobin to 5,5-6,5 mmol/L|Transfusion with red blood cells to level between 5.5-6.5 mmol/L
3232688|NCT00966875|Experimental|80 mg LY2439821 (TNFa-IR population)|80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. [Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR)]
3232784|NCT00966121|Active Comparator|Endoscopic band ligation|Perform endoscopic band ligation (EBL) until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
3232657|NCT00967096|Experimental|1|The primary clinical endpoint to be assessed in this study will be the proportion of Rifaximin doses successfully administered. Because of mucositis, compliance with oral agents, even those that are well tolerated in other settings, may be limited in the early post-transplant period. Thus, it will be important to demonstrate the feasibility of administering Rifaximin to BMT patients before embarking on larger scale studies. Secondary outcomes will include AGVHD, event-free survival, overall survival, non-relapse mortality, neutrophil and platelet engraftment.
3232658|NCT00967083||family caregivers of lung cancer patients|In this 2-year pilot study, we plan to screen family caregivers of lung cancer patients within 4 to 6 weeks after the a new visit to the thoracic clinic. We will screen spouses, adult children, and other family members using the HAD-18 to determine their level of anxiety and depressive symptoms at enrollment.
3232659|NCT00967070|Experimental|Both Treatments Applied on Lower Back|Treatments were applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
3232660|NCT00967057|Experimental|Arm I (induction therapy)|Patients receive idarubicin IV over 1 hour on days 1 and 2; oral dexamethasone twice daily on days 1-5 and 15-19; intrathecal (IT) methotrexate on days 1 and 8; vincristine sulfate IV on days 3, 10, 17, and 24; and pegaspargase intramuscularly (IM) on days 3 and 17 or asparaginase IM on days 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25.
3232661|NCT00967057|Experimental|Arm II (induction therapy)|Patients receive mitoxantrone IV over 1 hour on days 1 and 2. Patients also receive dexamethasone, methotrexate, vincristine sulfate, and pegaspargase or asparaginase as in arm I.
3232662|NCT00967044|Experimental|Panobinostat + Everolimus|Panobinostat (LBH589) Plus Everolimus (RAD001)
3232663|NCT00967031|Experimental|Lapatinib + capecitabine|lapatinib 1250mg/day + capecitabine 2000mg/m2/day
3232664|NCT00967018|Experimental|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. For patients treated with goserelin in the previous trials (CS28, CS30 and CS31),a starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to the end of the trial. For patients treated with degarelix in the previous trials, maintenance doses of 80 mg (20 mg/mL) degarelix were continued and were administered as single 4 mL s.c. injections at 28 day intervals to the end of the trial.
3232665|NCT00967005|Experimental|N Acetyl Cysteine|The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and PG symptoms in nicotine dependent pathological gamblers.
3232666|NCT00967005|Placebo Comparator|Sugar Pill|
3232667|NCT00966992|No Intervention|Arm 1 (No Zometa)|Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. All interventions on this arm are standard of care.
3232668|NCT00966992|Experimental|Arm 2 (Zometa)|Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. Women randomized to zoledronic acid will receive 4 mg intravenously (IV) with their first dose chemotherapy and 3, 6 and 9 months after completion of radiation (total of 4 doses) along with scheduled follow-up dual-energy X-ray absorptiometry (DEXA) and biomarker studies.
3232669|NCT00966979|Other|Triathlon PKR|All subjects enrolled will receive the Triathlon PKR device.
3232670|NCT00966966|Experimental|1|SAM-531_gemfibrozil
3232671|NCT00966953|Placebo Comparator|Fluoride Toothpaste|fluoride control
3232672|NCT00966953|Active Comparator|Total/Whitening|positive control
3232673|NCT00966953|Experimental|antibacterial plant extract 1|Honokiol
3232674|NCT00966953|Experimental|antibacterial plant extract 2|magnolol
3232675|NCT00966940|Other|Travoprost-to-tafluprost|Travoprost first, with tafluprost second. Each product dosed for six weeks.
3232676|NCT00966940|Other|Tafluprost-to-travoprost|Tafluprost first, with travoprost second. Each product dosed for six weeks.
3232677|NCT00966927||subjects with spina bifid|subjects with spina bifid between 14 and 21 years old referred to Unit for Care of Spina Bifid Hospital of Parma
3232678|NCT00966914|Placebo Comparator|Placebo|Placebo in combination with cisplatin and either paclitaxel or docetaxel
3232679|NCT00966914|Active Comparator|Tavocept (BNP7787)|Tavocept (BNP7787) in combination with cisplatin and either docetaxel or paclitaxel
3232680|NCT00966901|Experimental|Three Treatment Sites UV Exposed|All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)
3232681|NCT00966888|Experimental|Arm I|Beginning 12 weeks after mastectomy or 6 weeks after adjuvant chemotherapy, patients undergo radiotherapy 5 days a week for 3-5 weeks in the absence of disease progression or unacceptable toxicity.
3232682|NCT00966888|Active Comparator|Arm II|Patients receive standard of care and observation only.
3232683|NCT00966875|Experimental|3 mg LY2439821 (bDMARD-naive population)|3 milligrams (mg) LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. [Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)]
3232684|NCT00966875|Experimental|10 mg LY2439821 (bDMARD-naive population)|10 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
3232685|NCT00966875|Experimental|30 mg LY2439821 (bDMARD-naive population)|30 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
3232686|NCT00966875|Experimental|80 mg LY2439821 (bDMARD-naive population)|80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
3232687|NCT00966875|Experimental|180 mg LY2439821 (bDMARD-naive population)|180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
3232785|NCT00966121|Active Comparator|EBL+Propranolol|Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
3232786|NCT00966108||Healthy subjects|
3232689|NCT00966875|Experimental|180 mg LY2439821 (TNFa-IR population)|180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
3232690|NCT00966875|Placebo Comparator|Placebo (bDMARD-naive population)|Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
3232691|NCT00966875|Placebo Comparator|Placebo (TNFa-IR population)|Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
3232692|NCT00966849|Experimental|Conditional Cash Transfer|Vulnerable households in this arm will receive conditional cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
3232693|NCT00966849|Experimental|Unconditional Cash Transfer|Vulnerable households in this arm will receive unconditional cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
3232694|NCT00966849|Other|Control|Vulnerable households in this arm will not receive cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
3232695|NCT00966836|Experimental|Pre-emptive everolimus|
3232696|NCT00966836|Experimental|Prophylaxis mycophenolate|
3232697|NCT00966836|Experimental|Prophylaxis Everolimus|
3232698|NCT00966836|Active Comparator|Pre-emptive mycophenolate|
3232699|NCT00966823|Experimental|Detachable balloon|Intervention: Fetuses treated with endoscopic tracheal occlusion
3232700|NCT00966810|Experimental|CML allogeneic stem cell transplantation|Patients with chronic myeloid leukemia suitable for allogeneic stem cell transplantation with a matched related donor.
3232701|NCT00966771||IUD|Women presenting for emergency contraception who select the copper IUD
3232702|NCT00966771||Oral levonorgestrel|Women presenting for emergency contraception who select oral levonorgestrel
3232703|NCT00966758|Other|1|
3232704|NCT00966745|Active Comparator|milrinone|milrinone infusion
3232705|NCT00966745|Placebo Comparator|placebo|
3232706|NCT00966732|Experimental|yoga condition|assigned to start the yoga program right away
3232707|NCT00966732|No Intervention|wait-list control condition|This condition will control for any effects of symptom measurement reactivity in patients receiving routine fibromyalgia medical care. After the 3-month assessment, the yoga intervention program will be provided to these patients.
3232708|NCT00966719|Active Comparator|Lactation Consultant|"In hospital meeting with lactation consultant~1 to 3 follow up visits at weekly intervals with lactation consultant"
3232709|NCT00966719|No Intervention|current treatment for jaundice|Babies will receive current standard of care for jaundice (IV fluids and phototherapy)
3232710|NCT00966706|Experimental|Arm I|Patients receive cisplatin, gemcitabine hydrochloride, and docetaxel on days 1 and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3232711|NCT00966706|Experimental|Arm II|Patients receive cisplatin, gemcitabine hydrochloride, and epirubicin hydrochloride on days 1and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3232712|NCT00966693|Experimental|Lenalidomide + Thalidomide + Dexamethasone|Lenalidomide 15 mg daily by mouth on Days 1-21 followed by 7-day rest every 28 day cycle for Cycles 1-8. Thalidomide 100 mg daily by mouth on Days 1-28 of Cycles 1-8. Dexamethasone 40 mg by mouth on Days 1-4, 9-12, and 17-20 of Cycles 1-2, and 40 mg by mouth on Days 1, 8, 15, and 21 of Cycles 3-8.
3232713|NCT00966680||1|Observational study comparing the speed of general versus spinal anesthesia during emergency cesarean
3232714|NCT00966667||cancer survivor|cancer survivor
3232715|NCT00966654|Placebo Comparator|Saline|Saline
3232716|NCT00966654|Active Comparator|GLP-1|GLP-1 (7-36) amide
3232717|NCT00966641|Experimental|PL 3100|Active experimental drug
3232718|NCT00966641|Active Comparator|Naproxen|Active comparator
3232719|NCT00966628|Active Comparator|Ringer's lactate|
3232720|NCT00966628|Experimental|Hypertonic sodium lactate|
3232721|NCT00966615|Experimental|Balance group|peritoneal dialysis with neutral peritoneal dialysis solution with minimal glucose-degradation-product
3232722|NCT00966615|Active Comparator|Control group|conventional PD solution
3232723|NCT00966602|Experimental|Treatment Period 1|
3232724|NCT00966602|Experimental|Treatment Period 2|
3232725|NCT00966602|Experimental|Treatment Period 3|
3232726|NCT00966589|Sham Comparator|conservative treatment|physiotherapy
3232727|NCT00966589|Active Comparator|surgery|laparoscopic hernioplasty (TEP)
3232728|NCT00966576|Experimental|Brinzolamide/Timolol Maleate Fixed Combination|
3232729|NCT00966563|Active Comparator|Mangafodipir treatment|Treatment will be undertaken with a ready-to use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI. Formulation content: MnDPDP 10 mmol/ml.
3232730|NCT00966563|Placebo Comparator|NaCl 0.9%|
3232731|NCT00966550|Active Comparator|Tomato|Tomato with high carb/fat meal
3232732|NCT00966550|Placebo Comparator|Non-Tomato|Non-tomato with high carb/fat meal
3232733|NCT00966524|Experimental|Video|Teaching tracheal intubation to medical students using video-guided feedback during the procedure.
3232734|NCT00966524|Active Comparator|Standard|Teaching tracheal intubation to medical students using direct visualization feedback during the procedure.
3232735|NCT00966511||Lung resection candidates|Study participants will be patients who are candidates for lung resection (lobectomy or greater)
3232781|NCT00966160|Active Comparator|NNRTI|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over a 56-week run-in and a 420-week follow-up
3232782|NCT00966147|Experimental|Lidco group|All patients monitored by the lidco system and treated to optimize oxygen delivery
3232783|NCT00966134||probands|
3232736|NCT00966498|Experimental|1|This study is a single-arm, non-randomized trial. Peripheral blood stem cells will be harvested by mobilization with chemotherapy followed by G-CSF. Following adequate peripheral blood stem cell collection, the patients would be transplanted using the conditioning regimen consisting of thiotepa and cyclophosphamide (tandem one) and busulfan and melphalan (tandem two). They will receive G-CSF post transplant. There will be 6-8 weeks interval between tandem transplants. All patients would be carefully observed for any toxicity, transplant-related complications, relapse and disease-free survival.
3232737|NCT00966485|Active Comparator|80 mg ASA dose|6 months post stent on 80 mg ASA
3232738|NCT00966485|Active Comparator|500 mg ASA dose|6 months posr stent on ASA alone
3232739|NCT00966472|Experimental|Erlotinib + Rosuvastatin|To determine the recommended phase II dose (RP2D) of rosuvastatin that can be given in combination with standard erlotinib treatment in patients with advanced incurable squamous cell cancer and NSCLC.
3232740|NCT00966459|Other|1|
3232741|NCT00966446|Experimental|Unsupervised Decolonization|Households undergo decolonization for MRSA. The intervention includes applying Mupirocin ointment twice daily for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided.
3232742|NCT00966446|Experimental|Supervised Decolonization|Households undergo decolonization for MRSA. The intervention includes applying Mupirocin ointment twice daily for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Study staff is in contact with household members during this intervention to ensure compliance.
3232743|NCT00966446|No Intervention|No Intervention|Households do not undergo active MRSA decolonization protocol
3232744|NCT00966433|Experimental|Spontaneous ventilation|Pt's will be allowed to breathe spontaneously through the PLMA during surgery without the assistance of positive pressure ventilation.
3232745|NCT00966433|Experimental|Pressure support ventilation|Pt's will receive positive pressure assistance with each spontaneous breath through the PLMA.
3232746|NCT00966433|Active Comparator|Pressure control ventilation|Pt.'s will be placed on the ventilator and ventilated with pressure control. through the PLMA.
3232747|NCT00966420|Experimental|mucosa resection|
3232748|NCT00966407||Healthy Young Adults|College-age (18-35 years) participants recruited from Howard University, East Carolina University, and University of Massachusetts, Amherst, University of Calgary, Winston-Salem University
3232749|NCT00966394||ADHD medication|Children with ADHD and pharmacologic treatment
3232750|NCT00966394||ADHD without medication|Children with ADHD without pharmacologic treatment
3232751|NCT00966394||healthy|Healthy children ASA1
3232752|NCT00966381|No Intervention|Control|The minimal care group will receive standard public health information on nutrition from the American Heart Association twice during the 16-week intervention. Upon completion of the endpoint measurement (20 wks postpartum), they will be given all intervention materials.
3232753|NCT00966381|Experimental|Exercise Group|The intervention group will participate in a 16-week exercise and diet intervention from 4 to 20 wks postpartum. The PI will travel to the participant's homes three times per week during the 16-week intervention to guide mothers with the exercise program, ensure dietary compliance, and provide social support. The 16-wk exercise protocol consists of strength training three times per week and walking 10,000 steps per day at least five days per week.
3232754|NCT00966368|Experimental|IDeg E|
3232755|NCT00966368|Experimental|IDeg M|
3232756|NCT00966355|Active Comparator|Terlipressin|treat with terlipressin IV for 5 days and endoscopic treatment
3232757|NCT00966355|Active Comparator|Somatostatin|treat with somatostatin IV for 5 days and endoscopic treatment
3232758|NCT00966355|Active Comparator|Octreotide|treat with octreotide IV for 5 days and endoscopic treatment
3232759|NCT00966342|Other|Vaccine|Everyone gets licensed Influenza vaccine
3232760|NCT00966329|Experimental|to switch from the NNRTI/PI to maraviroc|to switch from the NNRTI/PI to maraviroc
3232761|NCT00966329|Active Comparator|to continue with the same approach|to continue with the same approach
3232762|NCT00966316|Experimental|pathway|aspirin，Chinese herbs；acupuncture；rehabilitation；health education；
3232763|NCT00966303|Experimental|Cardiac Rehabilitation|9 patients with cardiomyopathy in functional class III or IV, submitted to an 8-week program with exercises and respiratory muscle training.
3232764|NCT00966290|Experimental|ACC group|Anticoagulant clinic-based shared-care group
3232765|NCT00966290|Active Comparator|UC group|Usual care group
3232766|NCT00966277|Experimental|Group 1: Dalteparin|Dalteparin 5000 units subcutaneous, by injection under the skin, daily for 16 weeks.
3232767|NCT00966277|No Intervention|Group 2: Control|No study drug.
3232768|NCT00966264|Active Comparator|LNG-IUS|Levonorgestrel releasing intrauterine system
3232769|NCT00966264|Other|Hysterectomy|Hysterectomy
3232770|NCT00966251|Experimental|CT-011|
3232771|NCT00966238|Experimental|VAX125|HA1 influenza vaccine
3232772|NCT00966225|Experimental|One gram LIP-01 per day|One gram LIP-01 per day for 12 weeks
3232773|NCT00966225|Experimental|Two grams LIP-01 per day|Two grams LIP-01 per day for 12 weeks
3232774|NCT00966225|Experimental|0.333 grams LIP-01 per day|0.333 grams LIP-01 per day for 12 weeks
3232775|NCT00966212|No Intervention|health promotion materials|
3232776|NCT00966212|Active Comparator|print parent education|
3232777|NCT00966199|Experimental|Hypertensive elderly|community dwelling hypertensive elderly from general practices
3232778|NCT00966186|Active Comparator|Standard technique|Proseal laryngeal mask airway was inserted according to the manufacture's instruction manual (insertion with help of index finger insertion)
3232779|NCT00966186|Experimental|Rotational technique|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was fel
3232780|NCT00966160|Active Comparator|PI|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over a 56-week run-in and a 420-week follow-up
3232787|NCT00966108||Glaucoma patients|
3232789|NCT00966082|Active Comparator|Endoscopic band ligation|Perform endoscopic band ligation (EBL) until eradication of esophageal varices, and then follow-up endoscopy with 3-6 months interval
3232790|NCT00966082|Active Comparator|endoscopic band ligation+Propranolol|Perform endoscopic band ligation (EBL) until eradication of esophageal varices, and then follow-up endoscopy with 3-6 months interval, with propranolol
3232791|NCT00966069|Active Comparator|Healthcare worker visit|"Healthcare worker performs home visit when study child has acute respiratory illness to collect a respiratory swab (nasopharyngeal swab).~At the healthcare worker home visit, the HCW will collect the nasopharyngeal swab, and a parent will collect an anterior nasal swab. The HCW swab is to be returned immediately to the laboratory, and the parent collected swab was placed in a post box for return to the laboratory by surface mail."
3232792|NCT00966069|Experimental|Parent collection|Home collection of respiratory swab (anterior nose) and mailed return when study subject has an acute respiratory illness.
3232793|NCT00966056|Active Comparator|Mitomycin C|Cases recruited into this arm receive topical application of mitomycin c (1mg/ml)following surgical synechiolysis
3232794|NCT00966056|Active Comparator|Teflon septal splint|Cases recruited into this arm receive insertion of teflon internal nasal septal splint following surgical synechiolysis
3232795|NCT00966030|Experimental|1|MK0974 Tablet
3232796|NCT00966030|Active Comparator|2|MK0974 Liquid filled capsule
3232797|NCT00966017||DS|Those with Down syndrome
3232798|NCT00966017||Non-DS|Healthy controls
3232799|NCT00966004|Experimental|YM178 group|oral
3232800|NCT00966004|Placebo Comparator|Placebo group|oral
3232801|NCT00966004|Active Comparator|tolterodine group|oral
3232802|NCT00965991|Active Comparator|Metformin|
3232803|NCT00965991|Active Comparator|Glyburide|
3232804|NCT00965978|Experimental|Low dose group|Receives low dose of ONO-5920/YM529 with and without food
3232805|NCT00965978|Experimental|High dose group|Receives high dose of ONO-5920/YM529 with and without food
3232806|NCT00965965|Experimental|Experimental patient education document|
3232807|NCT00965965|Active Comparator|Traditional patient education document|
3232808|NCT00965926|Experimental|Low dose group|3 way cross-over. Fasting, normal diet and high-fat diet
3232809|NCT00965926|Experimental|High dose group|3 way cross-over. Fasting, normal diet and high-fat diet
3232810|NCT00965913|Experimental|Three Interventions on Lower Back|Three treatments were applied on the lower back, according to treatment sequence, daily for 21 days
3232811|NCT00965900|Active Comparator|Endoscopic band ligation|Endoscopic band ligation until eradication of esophageal varices with 4 weeks interval, and then follow-up endoscopy with 3-6 months interval until 36 months after enrollment
3232812|NCT00965900|Active Comparator|Propranolol|start with 20 mg b.i.d, and adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min. After reaching target HR, then follow-up according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)
3232813|NCT00965900|Active Comparator|EBL+Propranolol|"EBL until eradication of esophageal varices with 4 weeks interval, and then follow-up endoscopy with 3-6 months interval until 36 months after enrollment~start with 20 mg of propranolol b.i.d, and adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min. After reaching target HR, then follow-up according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
3232814|NCT00965887|Active Comparator|1|MK0974 Ethanolate
3232815|NCT00965887|Active Comparator|2|MK0974 Hydrate
3232816|NCT00965874|Experimental|Magnesium Sulfate high dose infusion|9 g Magnesium sulfate infusion over 30 minutes
3232817|NCT00965874|Active Comparator|Magnesium Sulfate low dose infusion|4.5 magnesium sulfate infusion over 30 minutes
3232818|NCT00965874|Placebo Comparator|placebo|serum salin
3232819|NCT00965861||1|The SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date.
3232820|NCT00965848|Experimental|Nosocomial Pneumonia|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with nosocomial pneumonia up to maximum of 14 days.
3232821|NCT00965848|Experimental|Complicated Intra-Abdominal Infections|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with complicated intra-abdominal infections up to maximum of 14 days.
3232822|NCT00965848|Experimental|Complicated Urinary Tract Infections|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with complicated urinary tract infections up to maximum of 10 days.
3232823|NCT00965835||DS|Those with Down syndrome
3232824|NCT00965835||Non-DS|Healthy controls
3232825|NCT00965822|Active Comparator|1|
3232826|NCT00965822|Placebo Comparator|2|
3232827|NCT00965809|Experimental|ACTIVE THC|Subjects will take 5MG of THC in 6 drops of olive oil orally.
3232828|NCT00965809|Placebo Comparator|Placebo|Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
3232829|NCT00965796|Experimental|Lidocaine, pain intensity and Saline|(2 mg/kg/h) and patients of group 2 (n = 20) received 0.9% saline infusion throughout the surgical procedure
3232830|NCT00965783|Experimental|1|Sleep time restriction
3232831|NCT00965783|Experimental|2|Sleep time extension
3232832|NCT00965770||IUD|Repeat abortion rate in women receiving IUDs immediately post-abortion
3232833|NCT00965757|Experimental|1|
3232834|NCT00965757|Placebo Comparator|2|
3232835|NCT00965744|Experimental|Vessel sealing system LigaSure (VS group)|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
3232836|NCT00965744|No Intervention|Conventional hand-tied method (CH group)|Patients in CH group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the conventional hand-tied method.
3232837|NCT00965731|Active Comparator|Erlotinib|
3232838|NCT00965731|Experimental|Erlotinib + PF-02341066|
3232839|NCT00965705|Active Comparator|Guided Self Help|
3232840|NCT00965705|Active Comparator|Cognitive Behavioral Therapy|
3232845|NCT00965601|Active Comparator|CTB Group|Subjects will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
3232846|NCT00965601|No Intervention|Usual Care|Subjects will not receive any type of intervention
3232847|NCT00965588|Experimental|Vaccine (UB 311)|
3232848|NCT00965575|Experimental|Melatonin|Subjects will take sustained release melatonin 30 minutes prior to bedtime for four weeks
3232849|NCT00965575|Placebo Comparator|Placebo|Subjects will take a placebo 30 minutes before bedtime for four weeks
3232850|NCT00965562|Active Comparator|I|Fluoxetine
3232851|NCT00965562|Active Comparator|II|Calcium
3232852|NCT00965562|Placebo Comparator|III|
3232853|NCT00965549|Experimental|Lantus + Apidra basal plus one|"Before randomization (common with arm 2):~A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy.~8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued.~After randomization:~24 weeks of treatment period: Insulin (Lantus®) + metformin (if applicable) + a single injection of insulin glulisine (Apidra®), the latter administered at the patients largest meal of the day"
3232854|NCT00965549|Active Comparator|NovoMix 30 Biphasic|"Before randomization (common with arm 1):~A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy.~8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued.~After randomization:~24 weeks of treatment period: Insulin aspart/ insulin protamine crystallised insulin aspart (NovoMix® 30) + metformin (if applicable)"
3232855|NCT00965536||1|Seroquel
3232856|NCT00965536||2|Seroquel Prolong
3232857|NCT00965523|Experimental|Eribulin Mesylate|
3232858|NCT00965510|Experimental|Care Coordination|Patients receive care coordination to improve their diabetes.
3232859|NCT00965510|No Intervention|control|patients with type II diabetes receive usual health care
3232860|NCT00965497|Experimental|Escitalopram|All patients will receive escitalopram 20 mg daily.
3232861|NCT00965484|Experimental|Genotropin pen|All subjects will receive genotropin pen to use for 2 months.
3232862|NCT00965471|Experimental|managed group|
3232863|NCT00965471|Placebo Comparator|control group|
3232864|NCT00965458|Experimental|Alefacept|Subjects in this group receive weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
3232865|NCT00965458|Placebo Comparator|Placebo|Subjects in this group received weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
3232866|NCT00965445||cardiac surgery with CPB|
3232867|NCT00965432|Placebo Comparator|Placebo|
3232868|NCT00965432|Active Comparator|STX107|
3232869|NCT00965419|Experimental|Edivoxetine|All enrolled participants were administered starting dose of 0.1 milligram per kilogram per day (mg/kg/day), or participant specific known stable dose, rollover participants (LNBJ [No NCT number]) and (LNBF [NCT00922636]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
3232870|NCT00965406|Placebo Comparator|glucose insulin potassium (GIK)|Glucose + insulin +6 potassium (GIK) infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours.
3232871|NCT00965406|Experimental|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
3232872|NCT00965406|No Intervention|Control group|No intervention and patients were treated with updated international recommendations of acute coronary syndrome.
3232873|NCT00965393|Placebo Comparator|1|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times. Systemic infusion of placebo (saline).
3232874|NCT00965393|Active Comparator|2|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times. Systemic infusion of bradykinin receptor antagonist (HOE-140).
3232875|NCT00965367|Experimental|Acustimulation|
3232876|NCT00965367|No Intervention|Standard treatment group|
3232877|NCT00965354||Influenza diagnosis|Patients admitted to hospital with a suspected or confirmed influenza diagnosis on admission
3232878|NCT00965341|Active Comparator|Testosterone|Testosterone Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
3232879|NCT00965341|Placebo Comparator|Placebo|Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
3232880|NCT00965328|Active Comparator|hemofiltration at 4L/h|Hemofiltration was started at 4L/h and crossed over to 2L/h after 60 minutes of hemofiltration
3232881|NCT00965328|Active Comparator|hemofiltration at 2L/h|hemofiltration was started at 2L/h and crossed over to 4L/h after 60 min
3232882|NCT00965302|Active Comparator|Intensive medical management of Type 2 DM|Intensive medical management of Type II diabetes will include visits every three months for a year with an endocrinologist, with lifestyle counseling, weight management, regular exercise, and glucose control forming the core of the medical therapy.
3232883|NCT00965302|Experimental|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy is performed as part of a bariatric surgical program emphasizing healthy dietary choices, regular exercise, and glucose control.
3232884|NCT00965289|Experimental|HDT combined with rituximab before ASCT|The study treatment consisted on 2 courses of high-dose R-CHOP-like regimen, followed by a course of high-dose methotrexate with cytarabin. For patients who achieved at least a PR, ASCT started with a BEAM regimen.
3232885|NCT00965263|Experimental|Low dose Vaccine|All participants were vaccinated four times: in week 1, 3, 5, and 9. Dose: 82ul
3232886|NCT00965263|Experimental|High Dose Vaccine|All participants were vaccinated four times: in week 1, 3, 5, and 9. Dose: 360ul
3232887|NCT00965250|Experimental|Thymoma|Patients will receive IMC-A12 at a dose of 20 mg/kg intravenously once every three weeks. The most common tumors of the thymus are thymomas (well differentiated neoplasms and moderately differentiated neoplasms) and thymic (poorly differentiated neoplasms) carcinomas.
3232888|NCT00965250|Experimental|Thymic Carcinoma|Patients will receive IMC-A12 at a dose of 20 mg/kg intravenously once every three weeks. The most common tumors of the thymus are thymomas (well differentiated neoplasms and moderately differentiated neoplasms) and thymic (poorly differentiated neoplasms) carcinomas.
3232889|NCT00965237|Other|Multifocal CL / Single vision CL + reading glasses|Lotrafilcon B multifocal contact lenses (CL) worn first, with lotrafilcon B single vision contact lenses (CL) and over-reader spectacles worn second. Both contact lens products worn bilaterally on a daily wear basis; over-reader spectacles worn on an as-needed basis.
3232890|NCT00965237|Other|Single vision CL + reading glasses / Multifocal CL|Lotrafilcon B single vision contact lenses (CL) and over-reader spectacles worn first, with lotrafilcon B multifocal contact lenses (CL) worn second. Both contact lens products worn bilaterally on a daily wear basis; over-reader spectacles worn on an as-needed basis.
3232891|NCT00965224|Experimental|standard therapy + vaccination|
3232892|NCT00965224|No Intervention|standard therapy|
3232893|NCT00965198||Clearlink Arm, EUH|Standard catheter access device at Emory University Hospital
3232894|NCT00965198||VLINK Arm, EUHM|Novel, silver-coated catheter access device at Emory University Hospital Midtown
3232895|NCT00965198||Clearlink, EUM|Standard catheter access device at at Emory University Hospital Midtown
3232896|NCT00965198||VLINK Arm, EUH|Novel, silver-coated catheter access device at Emory University Hospital
3232897|NCT00965185|Experimental|Atorvastatin|20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
3232898|NCT00965185|Placebo Comparator|placebo|
3232899|NCT00965172|Experimental|Caphosol|Caphosol (calcium phosphate)
3232900|NCT00965172|Active Comparator|Baking Soda|Control Group (standard of care)
3232901|NCT00965146|Experimental|Scorpio® CR Total Knee System|Scorpio® CR Total Knee System Study Device
3232902|NCT00965133|No Intervention|Normal daily activity|
3232903|NCT00965120|Placebo Comparator|1|Ischaemia 20 minutes. Blood pressure cuff will be inflated to 200mmHg around the upper arm for 20 minutes to induce ischaemia. Systemic infusion of placebo (saline).
3232904|NCT00965120|Active Comparator|2|Ischaemia 20 minutes. Blood pressure cuff will be inflated to 200mmHg around the upper arm for 20 minutes to induce ischaemia. Systemic infusion of bradykinin receptor antagonist (HOE-140).
3232905|NCT00965107|Experimental|Thiopental|Thiopental for induction of anaesthesia.
3232906|NCT00965107|Active Comparator|Propofol|Propofol for induction of anaesthesia.
3232907|NCT00965094|Experimental|Everolimus|At BL1, all study patients received induction therapy with basiliximab (Simulect®; 2x20mg on day 0 - 2 hours prior to transplantation, and on day 4 after transplantation) and commenced an immunosuppressive regimen consisting of MPA (Myfortic®; target dose: 1440 mg/day, which was also the maximum daily dose) + tacrolimus (Prograf®; based on C0-h levels; Table 9-2) and with corticosteroids. AT BL2 [Month 3 (+1 week) after transplantation], eligible patients were randomized, using living and cadaveric donation as stratum. Patients were switched to the CNI-free regimen. Everolimus was added to the patients immunosuppressive regimen and tacrolimus was removed successively.
3232908|NCT00965094|Active Comparator|Reference Therapy|At BL1, all study patients received induction therapy with basiliximab (Simulect®; 2x20mg on day 0 - 2 hours prior to transplantation, and on day 4 after transplantation) and commenced an immunosuppressive regimen consisting of MPA (Myfortic®; target dose: 1440 mg/day, which was also the maximum daily dose) + tacrolimus (Prograf®; based on C0-h levels; Table 9-2) and with corticosteroids. AT BL2 [Month 3 (+1 week) after transplantation], eligible patients were randomized, using living and cadaveric donation as stratum. Patients continued on the prior immunosuppressive regimen consisting of MPA + tacrolimus with corticosteroids.
3232909|NCT00965081|Experimental|Duloxetine|
3232910|NCT00965081|Placebo Comparator|Placebo|
3232911|NCT00965055|Placebo Comparator|Atorvastatin|
3232912|NCT00965055|Experimental|Atorvastatin/Ezetimibe|
3232913|NCT00965042|Experimental|Ceftobiprole|Ceftobiprole 500 mg by 2 hour intravenous infusion every 8 hours for 7 days
3232914|NCT00965016|Sham Comparator|No Hypothermia, No intervention, ECMO|No hypothermia used during ECPR
3232915|NCT00965016|Active Comparator|Hypothermia, intervention, ECMO|Hypothermia + intervention
3232916|NCT00965016|Active Comparator|Hypothermia, no intervention, ECMO|Hypothermia without intervention after ECMO
3232917|NCT00965003|Experimental|MRI scan with surface coil|Patients with known laryngeal cancer, with suspected cartilage involvement by conventional computed tomography scanning, who undergo high resolution magnetic resonance imaging enhanced with a surface coil placed over the larynx.
3232918|NCT00964990|Experimental|001|JNJ-42160443 SC injection (1 3 or 10 milligrams) once every 28 days
3232919|NCT00964990|Placebo Comparator|002|Placebo SC injection once every 28 days
3232920|NCT00964977|No Intervention|no irradiation|Patients within this arm only receive curative intended radical surgery
3232921|NCT00964977|Active Comparator|Radiation|Patients receive radiation within 6 weeks after curative intended radical surgery.
3232922|NCT00964964|Experimental|SIBA 3W|
3232923|NCT00964964|Experimental|SIBA OD|
3232924|NCT00964951|Experimental|Group 3: 15 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
3232925|NCT00964951|Experimental|Group 1: 3.75 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
3232926|NCT00964951|Experimental|Group 4: 7.5 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
3232927|NCT00964951|Experimental|Group 2: 7.5 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
3232928|NCT00964951|Experimental|Group 5: 15 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
3232929|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 1)|
3232930|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 2)|
3232931|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 3)|
3232932|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 4)|
3232933|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 5)|
3232934|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 6)|
3232935|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 7)|
3232936|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 8)|
3232937|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 9)|
3232938|NCT00964912|Active Comparator|BMS-820836 (Part 2, Panel A)|
3232939|NCT00964912|Active Comparator|BMS-820836 (Part 2, Panel B)|
3232940|NCT00964886|Experimental|Arm 1|desipramine hydrochloride
3232941|NCT00964886|Experimental|Arm 2|cognitive behavioral therapy
3232942|NCT00964886|Experimental|Arm 3|desipramine hydrochloride and cognitive behavioral therapy
3232943|NCT00964886|Placebo Comparator|Arm 4|anticholinergic medication; active placebo
3232944|NCT00964873|Experimental|1 Part 1|
3232945|NCT00964860|No Intervention|Brushing Only|Brushing Only with an Oral B manual toothbrush and Crest Cavity Protection, sodium fluoride dentifrice
3232946|NCT00964860|Experimental|Brushing + Flossing|Brushing with an Oral B manual toothbrush and Crest Cavity Protection, sodium fluoride dentifrice, plus flossing with Glide floss
3232947|NCT00964847|Active Comparator|Blood pressure education/walking program|
3232948|NCT00964847|Active Comparator|Combined intervention|
3232949|NCT00964847|Experimental|Yoga Exercise Program|
3232950|NCT00964834|Experimental|Doxycycline and Valortim|Randomized such that sixteen volunteer subjects to be renadomized to receive Doxycycline and Valortim
3232951|NCT00964834|Experimental|Placebo Antibiotic and Valortim|Randomized such that four volunteer subjects to receive Placebo Antibiotic and Valortim.
3232952|NCT00964834|Experimental|Placebo Antibiotic and Placebo Valortim|Randomized such that four volunteer subjects to receive Placebo Antibiotic and Placebo Valortim.
3232953|NCT00964821||Flu vaccine|Patients and normal volunteers who have received a flu vaccine
3232954|NCT00964821||Non-vaccine|Patients and normal volunteers who have not received the flu vaccine
3232955|NCT00964808|Experimental|Buprenorphine|Double dummy; Group A: Active Buprenorphine and placebo oxycodone
3232956|NCT00964808|Experimental|Oxycodone|"Double Dummy:~Group B: Placebo Buprenorphine and Active Oxycodone"
3232957|NCT00964795|Experimental|Open-label Intravitreal Aflibercept Injection|Open-label Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) 2mg (40 mg/mL) was administered no more frequently than every 4 weeks, but no less frequently than every 12 weeks until amendment 4. Starting with amendment 4, Intravitreal Aflibercept Injection was administered no less frequently than every 8 weeks. Within these limits, the investigator would determine the interval of Intravitreal Aflibercept Injection administration on an as-needed basis according to the protocol-suggested re-treatment criteria, however the injections must have occurred at least every 12 weeks prior to amendment 4, and at least every 8 weeks starting from amendment 4 as noted above.
3232958|NCT00964782|Experimental|Sildenafil|Sildenafil dosage will be 0.5mg/kg (max 20mg)
3232959|NCT00964782|Placebo Comparator|placebo|Patient will receive a look-alike placebo
3232960|NCT00964769|Experimental|Pneumococcal polysaccharide vaccine|The immunogenic response to the pneumococcal polysaccharide vaccine was compared between children, adults and elderly.
3232961|NCT00964756|Experimental|Gene therapy|
3232962|NCT00964743|Experimental|Intrathecal DepoCyt and Oral Sorafenib|This is a single arm pilot study. Investigators planned to enroll approximately 10 patients to receive concurrent intrathecal DepoCyt and oral Sorafenib. DepoCyt: through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses (a total of 10 DepoCyt treatments). Oral Sorafenib: at 400 mg twice a day throughout the treatment course until disease progression or death.
3232963|NCT00964730|Experimental|Talampanel|
3232964|NCT00964730|Placebo Comparator|Placebo|
3232965|NCT00964730|Other|Moxifloxacin|
3232966|NCT00964717|Active Comparator|Chiropractic|Real Chiropractic treatment
3232967|NCT00964717|Sham Comparator|Sham Chiropractic|stimulation utilizing 'activator' thumper
3232968|NCT00964717|No Intervention|No treatment|No add on therapy - patients lay down for a period of 15 minutes without any treatment or intervention
3232969|NCT00964704|Experimental|Single Arm|
3232970|NCT00964691|Active Comparator|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
3232971|NCT00964691|Active Comparator|IPTp with Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
3232972|NCT00964678|Experimental|carvedilol|Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI
3232973|NCT00964665|Experimental|Group 1 ABF656 900ug Q2w|
3232974|NCT00964665|Experimental|Group 2 ABF656 900ug Q4w|
3232975|NCT00964665|Experimental|Group 3 AB656 1200ug Q4w|
3232976|NCT00964665|Experimental|Group 4 ABF656 1500ug Q4w|
3232977|NCT00964665|Active Comparator|Group 5 Pegasys® 180µg qw|
3232978|NCT00964652|Experimental|PD Group|Nine subjects with idiopathic PD, previously diagnosed by one specialist physician participated in this study.
3232979|NCT00964639|Placebo Comparator|Saline|
3232980|NCT00964639|Active Comparator|Naropin|
3232981|NCT00964600|Experimental|TAP blockade|bilateral TAP blockade at the end of cesarean delivery
3232982|NCT00964600|No Intervention|No TAP|These patients would have usual analgesic drugs after cesarean
3232983|NCT00964587|Active Comparator|Usual Care|Packet of standard print patient education materials on CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA).
3232984|NCT00964587|Experimental|Self Study|One 90-minute educational session. Print materials and DVDs for self-study
3233259|NCT00962637|Active Comparator|3|AndroGel®
3232985|NCT00964587|Experimental|Group Problem-Solving Training|One 90-minute education session. Group problem-solving training (eight, 90-minute sessions)
3232986|NCT00964587|Experimental|Individual Problem-Solving Training|One 90-minute education session. Individual problem-solving training (eight, 60-minute sessions)
3232987|NCT00964574|Experimental|APIDRA + LANTUS basal|The 2 first weeks, patients will receive subcutaneous injection of Insulin Glulisine and Insulin Glargine once daily in hospital. The rest of the treatement is to be take at home until week 12
3232988|NCT00964561|Experimental|Ciprofloxacin and Valortim|First two subjects to receive treatment arm of Ciprofloxacin and Valortim. Total of sixteen volunteers to be randomized to receive Ciprofloxacin and Valortim.
3232989|NCT00964561|Experimental|Placebo Antibiotic and Valortim|Randomized such that four subjects to receive Placebo Antibiotic and Valortim.
3232990|NCT00964561|Experimental|Placebo Antibiotic and Placebo Valortim|Randomized such that 4 subjects to receive Placebo Antibiotic and Placebo Valortim.
3232991|NCT00964548|Experimental|Dantrolene (low dose)|
3232992|NCT00964548|Experimental|Dantrolene (high dose)|
3232993|NCT00964535|Experimental|Budesonide/formoterol Easyhaler|
3232994|NCT00964535|Experimental|Charcoal and Budesonide/formoterol EH|
3232995|NCT00964535|Active Comparator|Symbicort Turbohaler|
3232996|NCT00964535|Active Comparator|Charcoal and Symbicort Turbohaler|
3232997|NCT00964522|No Intervention|Standard care|The arm A is the one of standard education and care.
3232998|NCT00964522|Active Comparator|Nurse education and care program|The arm B will receive programmed education and care about the chemotherapy by a nurse of the Medical Oncology service before the beginning of the treatment and in each cycle, in a specific nurse consultation.
3232999|NCT00964496|Active Comparator|Thalidomide Group|
3233000|NCT00964496|Other|Iron-controlled Group|
3233001|NCT00964483|Experimental|DASH materials|Participant randomized to a 12-week, group-based lifestyle intervention using modified DASH materials and intervention delivery approaches to help them adopt the DASH diet. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium.
3233002|NCT00964483|Active Comparator|Delayed intervention|"The intervention participants will receive an NHLBI brochure entitled Your Guide to Lowering Blood Pressure. They will then receive the modified DASH materials and the intervention at the end of the study, following the intervention group's completion of the study."
3233003|NCT00964457|Active Comparator|Capecitabine, oxaliplatin|
3233004|NCT00964457|Active Comparator|capecitabine, oxaliplatin and cetuximab|capecitabine, oxaliplatin ane cetuximab
3233005|NCT00964431|Experimental|Indomethacin Test (lower dose)|
3233006|NCT00964431|Experimental|Indomethacin Test (upper dose)|Single dose
3233007|NCT00964431|Active Comparator|Celecoxib 400 mg|
3233008|NCT00964431|Placebo Comparator|Placebo|
3233009|NCT00964418|Experimental|IDeg|
3233010|NCT00964418|Active Comparator|IGlar|
3233011|NCT00964405|Experimental|LAMA|After randomization subject will inhale either GSK233705 50, 100 or 200 microgram once daily for 7 days.
3233012|NCT00964405|Placebo Comparator|Placebo|After randomization subjects will inhale placebo once daily for 7 days.
3233013|NCT00964392|Experimental|More-Experienced Physicians (MEP)|Physicians who perform greater than or equal to 50 atrial fibrillation ablation procedures per year.
3233014|NCT00964392|Experimental|Less-Experienced Physicians (LEP)|Physicians who perform less than 50 atrial fibrillation ablation procedures per year.
3233015|NCT00964379|Active Comparator|intraperitoneal colostomy|
3233016|NCT00964379|Active Comparator|extraperitoneal colostomy|
3233017|NCT00964366|Experimental|Clindamycin/BPO gel|Once-daily applications of clindamycin/BPO gel to the randomized side of the face either left or right.
3233018|NCT00964366|Active Comparator|Dapsone gel|Twice-daily applications of dapsone gel to one side of the face.
3233019|NCT00964353|Active Comparator|Clinically Guided Cohort|Estimated Effective Warfarin dosing calculations are based on clinical data algorithms
3233020|NCT00964353|Experimental|Pharmacogenetically Guided Cohort|Estimated Effective Warfarin dosing calculations are based on genetic and clinical data algorithms.
3233021|NCT00964340|Placebo Comparator|Placebo|The Placebo treatment group will be administered eight placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
3233022|NCT00964340|Active Comparator|0.5g SRT2104|The 0.5g SRT2104 treatment group will be administered 2 SRT2104 capsules with 6 matching placebo capsules, for a total of 8 capsules per day. 0.5g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
3233023|NCT00964340|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered 8 SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
3233024|NCT00964314|Experimental|five elements music|Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.
3233025|NCT00964314|Active Comparator|western music|Listening western music based on conventional therapy in China.
3233026|NCT00964314|No Intervention|Without music|no music therapy will be done in the arm.
3233027|NCT00964301|Experimental|Intervention Group|Participants, caregivers and school nurse will attend telemedicine education sessions at school.
3233028|NCT00964301|Active Comparator|Usual care|Usual care participant will receive routine care from their primary care provider.
3233029|NCT00964288|Other|Period 1|
3233030|NCT00964288|Other|Period 2|
3233031|NCT00964288|Other|Period 3|
3233032|NCT00964288|Other|Period 4|
3233033|NCT00964275|Experimental|Arm I|Patients undergo diagnostic fludeoxyglucose F 18 PET in addition to standard methods.
3233034|NCT00964275|Active Comparator|Arm II|Patients only undergo standard diagnostic methods.
3233035|NCT00964262|Experimental|SR Exenatide (PT302)|Intervention: Drug: SR Exenatide (PT302)
3233036|NCT00964249|Experimental|LABA|After randomization subject will inhale either 12.5 microgram or 25 microgram GW642444M once daily for 7 days.
3233037|NCT00964249|Placebo Comparator|Placebo|After randomization subjects will inhale placebo once daily for 7 days.
3233038|NCT00964236||Sapropterin|Individuals with phenylketonuria (PKU) who are beginning treatment with Kuvan (sapropterin).
3233039|NCT00964236||Control|Healthy individuals without phenylketonuria (PKU).
3233040|NCT00964223|Experimental|Duac gel|Subjects will apply Duac gel once a day to one-half of their face and and apply Epiduo gel on the other side of their face once daily for the first 2 weeks.
3233041|NCT00964223|Active Comparator|Epiduo gel|Subjects will apply Duac gel once a day to one-half of their face and and apply Epiduo gel on the other side of their face once daily for the first 2 weeks.
3233042|NCT00964197|Experimental|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
3233043|NCT00964184|Experimental|Drug|1 gm metformin per day
3233044|NCT00964184|Other|control|lifestyle intervention
3233045|NCT00964158|Experimental|Group A|
3233046|NCT00964145||Nulliparous female patients|Nulliparous female patients ages 21-70 years old.
3233047|NCT00964132|Experimental|NRX194204|
3233048|NCT00964106|Experimental|Probe drugs|"Caffeine 100 mg CYP1A2 Pioglitazone 15 mg CYP2C8 Flurbiprofen 40 mg CYP2C9 Omeprazole 20 mg CYP2C19 Dextromethorphan 45 mg CYP2D6 Midazolam 3 mg (Part 1, Part 2 Cohorts B and C)~1 mg (Part 2 Cohort A) CYP3A4/5 Rosuvastatin 10 mg OATP1B1"
3233049|NCT00964106|Experimental|Default Inhibitors|A Ketoconazole 400 mg once-daily Day 1 through Day 9 CYP3A4 B Fluconazole 400 mg x1 dose on Day 1 200 mg once-daily Day 2 through Day 9 CYP2C9 C Rifampin 600 mg x1 dose on Day 1 and Day 8 OATP1B1
3233050|NCT00964093|No Intervention|No intervention|
3233051|NCT00964080|Experimental|Study of MBP-426/leucovorin/5-FU|Study of MBP-426/leucovorin/5-FU. MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered ata dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
3233052|NCT00964067|Active Comparator|Treadmill group|Interval exercise performed on treadmills, supervised
3233053|NCT00964067|Active Comparator|Exercise groups|Supervised and organised in groups of ten
3233054|NCT00964067|Active Comparator|home-based exercise|Interval training at home, free choice of modality
3233055|NCT00964054|Experimental|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
3233056|NCT00964054|Active Comparator|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
3233057|NCT00964041|Experimental|D-cycloserine|Participants will receive D-cycloserine weekly, one hour before any assessments, for eight weeks.
3233058|NCT00964041|Placebo Comparator|Placebo|Participants will receive placebo weekly, one hour before any assessments, for eight weeks.
3233059|NCT00964028|Experimental|INFANRIX-IPV/HIB M2-M3-M4 GROUP|Healthy male or female subjects between and including 60 and 90 days of age at the time of the first vaccination, received 3 doses of Infanrix-IPV/Hib™ vaccine at 2, 3 and 4 months of age (M2-M3-M4), administered intramuscularly into the upper right side of the thigh.
3233060|NCT00964028|Experimental|INFANRIX-IPV/HIB M3-M4-M5 GROUP|Healthy male or female subjects between and including 60 and 90 days of age at the time of the first vaccination, received 3 doses of Infanrix-IPV/Hib™ vaccine at 3, 4 and 5 months of age (M3-M4-M5), administered intramuscularly into the upper right side of the thigh.
3233061|NCT00964015|Active Comparator|Starch group|Patients randomized to the Starch group will receive Voluven (6% Hydroxyethyl Starch 130/0.4) for their intravenous bolus and fluid resuscitation requirements.
3233062|NCT00964015|Active Comparator|Saline group|Patients randomized to the Saline group will receive 0.9% Normal Saline for their intravenous fluid bolus and resuscitation requirements
3233063|NCT00963989|Experimental|Penumbra Device Arm|
3233064|NCT00963976|Experimental|Target systolic BP < 150 mmHg|Systolic blood pressure will be reduced to <150 mmHg within 1 hour of randomization.
3233065|NCT00963976|Active Comparator|Target systolic BP < 180 mmHg|Systolic blood pressure will be reduced, to <180 mmHg within 1 hour of randomization.
3233066|NCT00963963|Active Comparator|health promotion materials|Parents receive health promotion booklets
3233067|NCT00963963|Active Comparator|attention-controlled parent print materials|Booklets on adolescent sexuality and health
3233068|NCT00963963|Experimental|audio-CD parent education|audio-CDs on parenting practices
3233069|NCT00963950|Experimental|Intervention group|transvaginal cholecystectomy
3233070|NCT00963950|Active Comparator|laparoscopic cholecystectomy|Laparoscopic cholecystectomy (4 port)
3233071|NCT00963937|Active Comparator|Sumatriptan 25 mg|
3233072|NCT00963937|Active Comparator|Sumatriptan 50 mg|
3233073|NCT00963937|Placebo Comparator|Placebo|
3233074|NCT00963924|Experimental|D-cycloserine|Participants will receive D-cycloserine weekly, one hour before the first cognitive remediation session of the week, for eight weeks.
3233075|NCT00963924|Placebo Comparator|Placebo|Participants will receive placebo weekly, one hour before the first cognitive remediation session of the week, for eight weeks.
3233076|NCT00963898|Experimental|Mental Retardation|
3233077|NCT00963885|Placebo Comparator|Part 1: Placebo|Placebo in combination with standard doses of Pegasys and Copegus.
3233078|NCT00963885|Experimental|Part 1: RO5190591 300mg po|RO5190591 300mg po every 8 hours in combination with standard doses of Pegasys and Copegus.
3233260|NCT00962637|Placebo Comparator|4|Placebo
3233261|NCT00962611|Experimental|Copanlisib|
3233079|NCT00963885|Experimental|Part 1: RO5190591 600mg po|RO5190591 600mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
3233080|NCT00963885|Experimental|Part 1: RO5190591 900mg po|RO5190591 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
3233081|NCT00963885|Placebo Comparator|Part 2: Placebo|If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive placebo in combination with standard doses of Pegasys and Copegus.
3233082|NCT00963885|Experimental|Part 2: RO5190591 300mg po|If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
3233083|NCT00963872|Experimental|Complement Fragment 3A - Small Cell Dose|Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
3233084|NCT00963872|Experimental|Complement Fragment A - Larger Cell Dose|Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
3233085|NCT00963859|Experimental|Robotic-assisted laparoscopic surgery|Robotic-assisted laparoscopic extended pelvic lymph node dissection
3233086|NCT00963846|Placebo Comparator|placebo|
3233087|NCT00963846|Experimental|huperzine 0.2 mg BID|
3233088|NCT00963846|Experimental|huperzine 0.4 mg BID|
3233089|NCT00963846|Experimental|huperzine 0.8 mg BID|
3233090|NCT00963833||Group 1|
3233091|NCT00963820|Experimental|0.24 mg/m^2|Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate
3233092|NCT00963820|Experimental|0.48 mg/m^2|Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3233093|NCT00963820|Experimental|0.80 mg/m^2|Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3233094|NCT00963820|Experimental|1.20 mg/m^2|Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period.
3233095|NCT00963820|Experimental|1.68 mg/m^2|Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3233096|NCT00963820|Experimental|2.23 mg/m^2|Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3233097|NCT00963820|Experimental|2.97 mg/m^2|Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3233098|NCT00963820|Experimental|3.95 mg/m^2|Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3233099|NCT00963820|Experimental|Relapsed and Refractory (RR)|Ixazomib citrate, 2.97 mg/m^2 established Maximum Tolerated Dose (MTD), capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3233100|NCT00963820|Experimental|VELCADE-Relapsed (VR)|Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3233101|NCT00963820|Experimental|PI naïve|Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3233102|NCT00963820|Experimental|Carfilzomib|Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3233103|NCT00963807|Experimental|Treatment|Patients receive docetaxel IV and cisplatin IV on day 1. Treatment repeats every 3 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo FDG PET/CT, FLT PET/CT, and thoracic CT at baseline and the end of cycles 1 and 2 and then undergo surgery.
3233104|NCT00963794|Other|Electromagnetic measurement|Electromagnetic measurement to detect rectal cancer.
3233105|NCT00963781|Experimental|Six months DAPT|All patients will be assigned to 6 months of DAPT
3233106|NCT00963768|Experimental|Cohort 1|JNJ-28431754 30 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
3233107|NCT00963768|Experimental|Cohort 2|JNJ-28431754 100 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
3233108|NCT00963768|Experimental|Cohort 3|JNJ-28431754 300 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
3233109|NCT00963768|Experimental|Cohort 4|JNJ-28431754 600 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
3233110|NCT00963768|Experimental|Cohort 5|JNJ-28431754 at 30 mg/day, 100 mg/day, or 300 mg/day or placebo (the dose level to be determined from the prior cohort of patients tested and considered to be well tolerated).
3233264|NCT00962585|Placebo Comparator|Placebo|Placebo
3233111|NCT00963755||Primary prostate cancer|Patients referred with a suspicion of prostate cancer based on elevated PSA and rectal examination in whom a prostate biopsy is planned and radical prostatectomy is envisioned in the event of a positive biopsy finding
3233112|NCT00963755||Prostate cancer relapse|Patients previously treated for prostate cancer and being investigated for biochemical relapse, (mostly in the Urology and Radiation Therapy Department, but not exclusively), for whom surgical or radiation therapy is envisioned in the event of a positive FCH-PET finding
3233113|NCT00963742|Experimental|Lenstec Softec HD IOL implantation|390 eyes of 390 study subjects all receiving the investigational IOL; IOL implanted after surgical removal of cataract
3233114|NCT00963729|Experimental|Arm I|Patients receive fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3233115|NCT00963729|Experimental|Arm II|Patients receive oral letrozole daily for 18-23 weeks until day of surgery.
3233116|NCT00963716|Experimental|Hot biopsy|Hot biopsy i.e. Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
3233117|NCT00963716|Active Comparator|Cold biopsy|Cold biopsy i.e. Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
3233118|NCT00963703|Experimental|Rituximab|
3233119|NCT00963690|Experimental|CloSys HD with standard compression|CloSys Arm
3233120|NCT00963690|Active Comparator|Standard compression alone|Manual compression arm
3233121|NCT00963677|Experimental|Intubation without difficulty|The patients are not predicted for difficult intubation
3233122|NCT00963677|Experimental|Difficult intubation|The patients will be anticipated for difficult intubation without difficult ventilation
3233123|NCT00963664|Experimental|Interferon and lovastatin treatment|Patients receive outpatient treatment with lovastatin (oral) and interferon alfa-2b (subcutaneous injection) as per protocol parameters.
3233124|NCT00963651||Suspicion of pulmonary nodules|Eligible participants will include those referred for x-ray computed tomography (CT) of the chest for suspicion of a pulmonary nodule or other unrelated reasons.
3233125|NCT00963638|Experimental|MagTabSR|
3233126|NCT00963638|Placebo Comparator|Sugar Pill|
3233127|NCT00963625|Experimental|Blastocyst transfer in PTEC cycle|Transfer of two blastocysts derived from thawed bipronuclear oocytes that were subject to post-thaw extended culture (PTEC).
3233128|NCT00963625|Active Comparator|Fresh blastocyst transfer.|Transfer of two fresh autologous blastocysts following controlled ovarian stimulation.
3233129|NCT00963612|Other|Single Arm|"In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo Liver BOLD-MRI before hepatic resection."
3233130|NCT00963599|Experimental|1|montelukast/loratadine
3233131|NCT00963599|Experimental|2|loratadine
3233132|NCT00963599|Experimental|3|montelukast
3233133|NCT00963599|Placebo Comparator|4|placebo
3233134|NCT00963586||HNC Maastricht|Patients treated for HNC in the University Hospital Maastricht/MAASTRO clinic, the Netherlands
3233135|NCT00963586||HNC Groningen|Patients treated for HNC in the University Medical Center Groningen, the Netherlands
3233136|NCT00963573|Experimental|loratadine/betamethasone oral solution|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
3233137|NCT00963560|Experimental|ReSTOR +3|Bilateral implantation of ReSTOR +3 Intraocular Lens (IOL)
3233138|NCT00963560|Active Comparator|Crystalens HD|Bilateral implantation of Crystalens HD Intraocular Lens (IOL)
3233139|NCT00963560|Active Comparator|Crystalens AO|Bilateral implantation of Crystalens AO Intraocular Lens (IOL)
3233140|NCT00963547|Experimental|1|Part 1: MK2206 + trastuzumab
3233141|NCT00963547|Experimental|2|Part 2: MK2206 + trastuzumab + lapatinib
3233142|NCT00963534|Experimental|lenalidomide, bendamustine, rituximab|
3233143|NCT00963508|Experimental|Malathion Gel|Malathion gel 0.5% 30 minute application
3233144|NCT00963508|Active Comparator|Nix Crème Rinse|Nix Crème Rinse applied to scalp for 10 minutes
3233145|NCT00963495|Experimental|Clioquinol|Patients will take Clioquniol at various doses depending on which dose level they come into the study at. Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
3233146|NCT00963482|Experimental|Intervention group|Cognitive-behavioural smoking cessation program
3233147|NCT00963482|Other|Control group|Autogenic training
3233148|NCT00963469|Experimental|1|montelukast
3233149|NCT00963469|Active Comparator|2|loratadine
3233150|NCT00963469|Placebo Comparator|3|placebo
3233151|NCT00963443|Experimental|Arm 1|
3233152|NCT00963443|Active Comparator|Arm 2|
3233153|NCT00963443|Active Comparator|Arm 3|
3233154|NCT00963443|Placebo Comparator|Arm 4|
3233155|NCT00963430|Experimental|Group 2: 30 mcg H1N1 vaccine|60 subjects to receive 30 mcg of inactivated H1N1 vaccine on Day 0 and Day 21.
3233156|NCT00963430|Experimental|Group 1: 15 mcg H1N1 vaccine|60 subjects to receive 15 mcg of inactivated H1N1 vaccine on Day 0 and Day 21.
3233157|NCT00963417|Active Comparator|Triptorelin plus tamoxifen|Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus tamoxifen for 5 years.
3233158|NCT00963417|Experimental|Triptorelin plus exemestane|Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus exemestane for 5 years.
3233159|NCT00963404|Experimental|Tumor-boost|Image-guided tumorboost of the bladder cancer.
3233160|NCT00963391|Experimental|ABHS use|Centers assigned to the intervention group were provided with ABHS dispensers with a gel solution with ethyl alcohol at 62% as active ingredient (Purell®, GOJO Industries, Dayton, Ohio). Proper safety measures were followed. Standardized ABHS training workshops for staff and children in centers allocated to the intervention were carried out simultaneously with dispenser installation. Thirty minute refresher sessions about ABHS technique were provided to staff and children on a monthly basis, for a total of 8 sessions per center.
3233262|NCT00962598|Placebo Comparator|Corn Oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment.
3233161|NCT00963391|No Intervention|No treatment|Centers assigned to the control group received no hand hygiene recommendations other than to continue with current hand hygiene practices and no further information on hand hygiene other than the general information received before trial initiation was provided.
3233162|NCT00963365|Experimental|AZD6765 oral solution|Active
3233163|NCT00963365|Experimental|AZD6765 IV infusion|Active
3233164|NCT00963365|Placebo Comparator|Placebo to AZD6765 oral solution|Placebo
3233165|NCT00963365|Placebo Comparator|Placebo to AZD6765 IV infusion|Placebo
3233166|NCT00963352||Patients operated for colon cancer|
3233167|NCT00963339||Dry AMD|subjects diagnosed as intermediate AMD in at least one eye
3233168|NCT00963313||Adalimumab, injection|Adalimumab, one injection every fourteen days during 24 weeks.
3233169|NCT00963287|Experimental|bascial prescription|Decoction ,two times a day,one bag of decoction one time
3233170|NCT00963287|Placebo Comparator|low does of bascial decoction|Decoction ,two times a day, one bag decoction of one time
3233171|NCT00963274|Experimental|bortezomib + romidepsin|Bortezomib via a short intravenous infusion (3-5 seconds) followed by romidepsin via a 4 hour intravenous infusion weekly x 3 every 4 weeks. In order to identify appropriate doses, different subjects will be treated with different drug doses and observed for the effects, especially the side effects associated with higher doses.
3233172|NCT00963261|Experimental|psycho-oncological intervention|stepped care psycho-oncological intervention
3233173|NCT00963261|No Intervention|control group|
3233174|NCT00963235|Experimental|1|
3233175|NCT00963222|Active Comparator|with atherosclerosis/ vitamin A|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive 25000 IU/day vitamin A
3233176|NCT00963222|Placebo Comparator|with atherosclerosis/ placebo|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive placebo
3233177|NCT00963222|Active Comparator|without atherosclerosis/ vitamin A|patients in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive 2500 Iu/day vitamin A
3233178|NCT00963222|Placebo Comparator|without athrosclerosis/ placebo|patients in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive placebo
3233179|NCT00963209|Experimental|Tamoxifen|
3233180|NCT00963196|Active Comparator|One unsuccessful trial|Patients with one unsuccessful previous antidepressant trial
3233181|NCT00963196|Active Comparator|One successful trial|Patients with one previous successful antidepressant trial
3233182|NCT00963196|Active Comparator|No previous trial|Patients with no prior antidepressant therapy
3233183|NCT00963183|Experimental|A|Drug: AZD5423
3233184|NCT00963183|Placebo Comparator|B|Drug: Placebo
3233185|NCT00963157|Experimental|Group 1: 3.75 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
3233186|NCT00963157|Experimental|Group 5: 15 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
3233187|NCT00963157|Experimental|Group 4: 7.5 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
3233188|NCT00963157|Experimental|Group 2: 7.5 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
3233189|NCT00963157|Experimental|Group 3: 15 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
3233190|NCT00963131|Experimental|antioxidant tablets|the study arm received antioxidant tablets (Icaps) for 3 months or until the resolution of the disease
3233191|NCT00963131|Placebo Comparator|placebo tablets|the control arm received placebo tablets for 3 months or until the resolution of the disease
3233192|NCT00963118|Placebo Comparator|placebo|Rice powder based nutrition bar
3233193|NCT00963118|Experimental|Angelica keiskei|Angelica keiskei (green leafy vegetable) based nutrition bar
3233194|NCT00963118|Experimental|Glycine max|Glycine max (black soybeans) based nutrition bar
3233195|NCT00963118|Experimental|Angelica keiskei + Glycine max|Angelica keiskei (green leafy vegetable) and glycine max (black soybeans) based nutrition bar
3233196|NCT00963105|Active Comparator|Treatment Arm 1|"Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily~Subjects will continue treatment until disease progression or unacceptable toxicity"
3233197|NCT00963105|Active Comparator|Treatment Arm 2|"Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily~Subjects will continue treatment until disease progression or unacceptable toxicity"
3233198|NCT00963105|Active Comparator|Treatment Arm 3|"Treatment Arm 3: 15 mg →20 mg →25 mg/daily~Subjects will continue treatment until disease progression or unacceptable toxicity"
3233199|NCT00963079|Experimental|Blastocyst transfer in PTEC cycle|Transfer of two blastocysts derived from thawed bipronuclear oocytes that were subject to post-thaw extended culture (PTEC).
3233200|NCT00963079|Active Comparator|Fresh blastocyst transfer|Transfer of two fresh autologous blastocysts following controlled ovarian stimulation.
3233201|NCT00963066|Active Comparator|Pressure Support ventilation|
3233202|NCT00963066|Experimental|NAVA flow triggering|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with flow triggering
3233203|NCT00963066|Experimental|NAVA EMG triggering|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with trigger adjusted on diaphragmatic electromyogram
3233204|NCT00963053|Experimental|VA111913 100mg twice daily|
3233205|NCT00963053|Placebo Comparator|Starch pill|
3233206|NCT00963040|Experimental|Syntocinon®|
3233207|NCT00963040|Placebo Comparator|Sterile water|
3233208|NCT00962988|Experimental|Cost-Free Group|
3233209|NCT00962988|Other|Prescription Only Group|
3233210|NCT00962975|Experimental|Single Arm|
3233263|NCT00962598|Experimental|Omega-3 Fatty Acids|The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d.
3233211|NCT00962962|Other|Low-Amount/Moderate Intensity Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week
3233212|NCT00962962|Other|High-Amount/Moderate-Intensity Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week
3233213|NCT00962962|Other|High-Amount/Vigorous-Intensity Exercise|Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week
3233214|NCT00962962|Other|Low-Amount/Moderate-Intensity Exercise + Diet|"Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week~Diet - The CLI sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight."
3233215|NCT00962949|Experimental|Control|Healthy controls
3233216|NCT00962949|Experimental|Postural Tachycardia Syndrome|Patients with Postural Tachycardia Syndrome
3233217|NCT00962936|Experimental|CT-011|
3233218|NCT00962910|Experimental|Pathway|A care pathway will be implemented in this experimental group.
3233219|NCT00962910|No Intervention|Usual Care|Usual Care will be provided.
3233220|NCT00962897||Surgical Bypass Group|Those patients that underwent bypass of blockage in the thigh with surgery.
3233221|NCT00962897||Stent-graft group|Patients that underwent treatment of blockage in the thigh with balloon angioplasty and stent placement.
3233222|NCT00962884|Experimental|ITD breathing device|Breathing through the Res-Q-Gard ITD device from Advanced Circulatory Systems Inc.
3233223|NCT00962884|Sham Comparator|Sham Device|Breathing device similar to active Res-Q-Gard device but with one-way resistance valve removed.
3233224|NCT00962871|Active Comparator|1|
3233225|NCT00962871|Experimental|2|
3233226|NCT00962871|Experimental|3|
3233227|NCT00962871|No Intervention|4|
3233228|NCT00962845|Experimental|Hydroxychloroquine|Patients must have tumor accessible for pre-treatment biopsy (see 5.1.2). Patients will be enrolled on the trial, undergo biopsy of their tumors if no banked tumor is available, and then begin an oral dose of HCQ at the dose of 200 mg twice daily. At the end of two weeks the patients will undergo resection of their tumors. HCQ will be given to the patients up to the day of the operation but not resumed postoperatively.
3233229|NCT00962832|Placebo Comparator|Part 1 - Placebo intravenously|Participants received placebo intravenously every 4 weeks for 24 weeks.
3233230|NCT00962832|Experimental|Part 1 - Rontalizumab 750 mg intravenously|Participants received rontalizumab 750 mg intravenously every 4 weeks for 24 weeks.
3233231|NCT00962832|Placebo Comparator|Part 2 - Placebo subcutaneously|Participants received placebo subcutaneously every 2 weeks for 24 weeks.
3233232|NCT00962832|Experimental|Part 2 - Rontalizumab 300 mg subcutaneously|Participants received rontalizumab 300 mg subcutaneously every 2 weeks for 24 weeks.
3233233|NCT00962832|Experimental|Part 3 - Rontalizumab 750 mg intravenously|Participants received rontalizumab 750 mg intravenously every 4 weeks for 120 weeks.
3233234|NCT00962819||cross-sectional|College-aged students who were immunized with MMR.
3233235|NCT00962806|Active Comparator|Exercise|8 week intensive exercise group
3233236|NCT00962806|Other|Control Lifestyle counseling|Lifestyle counseling without intensive exercise
3233237|NCT00962780|Experimental|1|3 doses of 13vPnC and 1 dose of 23vPS, each dose given approximately 1 month apart
3233238|NCT00962767|Experimental|a|2 doses of gemtuzumab ozogamicn administered at monthly intervals
3233239|NCT00962767|Active Comparator|b|2 years maintenance therapy with intermittent ATRA plus 6-Mercaptopurine (6-MP) and methotrexate (MTX)
3233240|NCT00962754|No Intervention|physician insight fluid balance|physician has insight in fluid balance chart, this is standard practice
3233241|NCT00962754|Experimental|fluid balance data masked to physician|physician no insight in the fluid balance chart
3233242|NCT00962741|Experimental|1|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
3233243|NCT00962728|Experimental|ITD breathing device|Breathing through the Res-Q-Gard ITD device from Advanced Circulatory Systems Inc.
3233244|NCT00962728|Sham Comparator|Sham Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
3233245|NCT00962715|Experimental|TIV|TIV (Influenza Vaccine Trivalent Inactivated) alone
3233246|NCT00962715|Experimental|TIV + PEGrIFN-α|TIV + Pegylated Interferon
3233247|NCT00962715|Experimental|TIV + IFNα|TIV + Interferon
3233248|NCT00962702|Experimental|Exclusion of Left Atrial Appendage|Exclusion of Left Atrial Appendage
3233249|NCT00962689||Chronic Rhinosinusitis|Patients with chronic rhinosinusitis as defined by American Academy of Otolaryngology-Head and Neck Surgery and American Rhinologic Society guidelines
3233250|NCT00962689||Control Group|Patients undergoing endoscopic sinus surgery for diseases other than chronic rhinosinusitis (i.e., access to pituitary gland, etc)
3233251|NCT00962676||immunocompromised group|
3233252|NCT00962676||non-immunocompromised group|
3233253|NCT00962663|Experimental|ICA-105665|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
3233254|NCT00962663|Active Comparator|Ibuprofen|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
3233255|NCT00962663|Placebo Comparator|Placebo|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
3233256|NCT00962650|Experimental|NOTES Toolbox|Multiple devices designed for trans-orifice use during surgical procedures; used for transvaginal cholecystectomy in this trial
3233257|NCT00962637|Experimental|1|Androxal™ 12.5 mg
3233258|NCT00962637|Experimental|2|Androxal™ 25 mg
3233265|NCT00962585|Experimental|S-equol 10 mg BID|S-equol 20 mg total daily dose
3233266|NCT00962585|Experimental|S-equol 50 mg BID|S-equol 100 mg total daily dose
3233267|NCT00962585|Experimental|S-equol 150 mg BID|S-equol 300 mg total daily dose
3233268|NCT00962546||CTA/CTP|Patients undergo CTA/CTP imaging prior to cerebral angiography
3233269|NCT00962533|Experimental|ROADMAP Group (Group I)|"Patients were to take telbivudine 600 mg orally daily from Baseline.At Week 24, patients in Group I were split into Group I-A or Group I-B based on their virologic load:~Group I-A: This group of patients was those with HBV DNA ≥300 copies/mL at Week 24 and adefovir was to be added at Week 28;~Group I-B: This group of patients was those with HBV DNA <300 copies/mL at Week 24. Telbivudine monotherapy was to be continued until there was a viral breakthrough (confirmed by two examinations with at least 1 month interval with compliance factor excluded) and then adefovir was to be added;~The total treatment duration was 104 weeks."
3233270|NCT00962533|Active Comparator|SOC (Standard of Care) Group (Group II)|patients were to take telbivudine 600 mg monotherapy from Baseline until Week 104. If viral breakthrough (defined as HBV DNA 1 log10 above nadir) was confirmed (by two examinations with at least a 1 month interval with compliance factor excluded), adefovir 10 mg daily was to be added.
3233271|NCT00962520|Experimental|Study Treatment Arm|This study is a phase II trial of erlotinib in combination with chemoradiation in patients with resected stage I/II adenocarcinoma of the pancreas who are candidates for adjuvant chemoradiation. Eligible patients will receive adjuvant treatment with erlotinib 100 mg plus Capecitabine 800 mg/m2 PO BID (5 days on/ 2 days off regimen) and External Beam Radiation Therapy (EBRT) at doses of 50.4 Gy in 28 fractions after pancreatectomy (Dosing for capecitabine and erlotinib was amended after considering the toxicity profile of the first 6 patients). Approximately 4-8 weeks after the conclusion of chemoradiation, it is recommended patients will continue treatment with 4 cycles of gemcitabine 1000 mg/m2 days 1, 8, and 15 every 28 days plus daily erlotinib 100 mg.
3233272|NCT00962494|Experimental|online workshop|
3233273|NCT00962481|Active Comparator|Bimosiamose|
3233274|NCT00962481|Placebo Comparator|Placebo|
3233275|NCT00962468|Experimental|Pathway|A care pathway will be implemented in this experimental group.
3233276|NCT00962468|No Intervention|Usual care|Usual care will be provided.
3233277|NCT00962455|Experimental|e-learning & performance feedback|Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality
3233278|NCT00962455|Active Comparator|Usual practice|Usual practice regarding spirometry execution in family practice
3233279|NCT00962442|Active Comparator|nutritional support + N-Acétylcysteine|N-Acétylcysteine 300 mg/kg intravenously for 14 days Beside usual meals, patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days
3233280|NCT00962442|Placebo Comparator|nutritional support + placebo|placebo perfusion for 14 days Beside usual meals patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days
3233281|NCT00962429|Active Comparator|Lipoic acid|alpha lipoic acid
3233282|NCT00962429|Placebo Comparator|Placebo|sugar pill
3233283|NCT00962416|Active Comparator|1|Biolimus eluting Stent (Biomatrix)
3233284|NCT00962416|Active Comparator|2|Bare metal stent (Gazelle)
3233285|NCT00962403|Experimental|Yoga treatment|
3233286|NCT00962403|No Intervention|Waitlist|Waitlist control, no active treatment, treatment as usual, active treatment offered after waitlist control period. This study began as a single arm treatment trial and then transitioned to a randomized controlled trial.
3233287|NCT00962390|Experimental|150mg S-equol|
3233288|NCT00962390|Experimental|50mg S-equol|
3233289|NCT00962390|Experimental|10 mg S-equol|
3233290|NCT00962390|Placebo Comparator|Placebo|
3233291|NCT00962377|Other|AlloMap Molecular testing|Gene expression profiling in the monitoring of asymptomatic heart transplant patients for acute cellular rejection.
3233292|NCT00962377|Active Comparator|Endomyocardial biopsy|Right ventricular endomyocardial biopsy in the monitoring of asymptomatic heart transplant patients for acute cellular rejection
3233293|NCT00962364||AMI|Patients with acute myocardial infarction treated with intracoronary administration of bone marrow derived cells
3233294|NCT00962364||ICM|Patients with ischemic cardiomyopathy treated with intracoronary administration of bone marrow derived cells
3233295|NCT00962364||DCM|Patients with dilated cardiomyopathy treated with intracoronary administration of bone marrow derived cells
3233296|NCT00962351|Other|Metal-on-Polyethylene|
3233297|NCT00962351|Other|Metal-on-Metal, 28mm femoral head|
3233298|NCT00962351|Other|Metal-on-Metal, 36mm femoral head|
3233299|NCT00962338||lap. inguinal herniorrhaphy|Patients undergoing planned lap. inguinal herniorrhaphy
3233300|NCT00962325|Experimental|Activity behaviors counseling|
3233301|NCT00962325|No Intervention|Standard care control|6 weeks of standard preoperative care
3233302|NCT00962312|Experimental|Capecitabine and Lapatinib|
3233303|NCT00962299|Active Comparator|Beclomethasone|Inhaled corticosteroids
3233304|NCT00962299|Placebo Comparator|Placebo|Placebo Comparator
3233305|NCT00962286|Experimental|Furosemide, obesity, glomerular hyperfiltration|
3233306|NCT00962273|Experimental|Pandemic Stress Vaccine - Interactive|
3233307|NCT00962273|Active Comparator|Pandemic Stress Vaccine - Didactic|
3233308|NCT00962273|No Intervention|Wait list|Some participants are assigned to an eight week waiting condition prior to the course commencing.
3233309|NCT00962247|Experimental|Sedentary; usual, 25% reduced, 50% reduced|The initial 3 weeks of the study, children were asked to maintain their usual targeted sedentary behaviors (TV, video game, computer use) measured by a television reduction device (TV Allowance). The following 3 weeks children were asked to reduce their targeted sedentary behaviors (TV, video game, computer use) by 25% from the usual sedentary condition using a television reduction device (TV Allowance). The final 3 weeks of the study, children were asked to reduce their targeted sedentary behaviors (TV, video game, computer use) by 50% from the usual sedentary condition using a television reduction device (TV Allowance)
3233310|NCT00962234||Metabolism|Lung cancer patients who exhibit abnormalities in lipid measures.
3233311|NCT00962221||subclinical hypothyroidism|Patients with subclinical hypothyroidism
3233408|NCT00961571|Experimental|sunitinib and cepecitabine|Administration of sunitinib and capecitabine
3233312|NCT00962208|Experimental|orthokeratology lenses|Children wearing orthokeratology at night for correcting of refractive error will be study group
3233313|NCT00962208|Other|single-vision spectacle lenses|Children wearing single-vision spectacles in the daytime for correcting the refractive error will serve as control group
3233314|NCT00962195|Experimental|purple sweet potato juice|Daily oral intake of 3x 125 ml of PSP-juice for a period of 8 weeks
3233315|NCT00962195|Placebo Comparator|Control juice|Daily oral intake of 3x 125 ml of control juice for a period of 8 weeks
3233316|NCT00962182|Experimental|Enzyme treatment|Enzyme for 12 weeks
3233317|NCT00962182|Placebo Comparator|Placebo control|Placebo enzyme for 12 weeks
3233318|NCT00962182|Experimental|Enzyme + gluten|Enzyme and 500 mg gluten b.i.d. for 12 weeks
3233319|NCT00962169|Experimental|Quality improvement program|
3233320|NCT00962169|Experimental|Electronic patient device (EPD)|
3233321|NCT00962156|Experimental|HES 130/0.4|Volume expansion
3233322|NCT00962156|Active Comparator|Ringer acetate|Volume expansion
3233323|NCT00962143|Active Comparator|Achilles repair without OrthADAPT Augmentation|Achilles repair without OrthADAPT Augmentation
3233324|NCT00962143|Experimental|Achilles repair with OrthADAPT augmentation|Achilles repair with OrthADAPT augmentation
3233325|NCT00962130|Experimental|Blood Glucose Measurement|Subjects have sensors placed on skin before surgery and these sensors will measure the subject's glucose until the third day after surgery when they are removed.
3233326|NCT00962117||Obese/Non-obese|
3233327|NCT00962104|Experimental|Atomoxetine|
3233328|NCT00962104|Placebo Comparator|Placebo|
3233329|NCT00962091|Experimental|MLN8237- Part A|Oral solution vs Powder in Capsule (PIC)
3233330|NCT00962091|Experimental|MLN8237- Part B|Oral Solution MLN8237 Fed, Oral Solution MLN8237 Fasted
3233331|NCT00962091|Experimental|MLN8237- Part C|Enteric Coated Tablet (ECT) MLN8237 Fed, ECT MLN8237 Fasted
3233332|NCT00962078|Other|interval training|interval training in lung transplant candidates
3233333|NCT00962078|Other|Continuous Training|continuous training in lung transplant candidates
3233334|NCT00962065|Experimental|Low Dose|A low dose of LX4211; daily oral intake for 28 days
3233335|NCT00962065|Experimental|High Dose|A high dose of LX4211; daily oral intake for 28 days
3233336|NCT00962065|Placebo Comparator|Placebo|Matching placebo dosing with daily oral intake for 28 days
3233337|NCT00962039|Experimental|Citalopram|
3233338|NCT00962026|Experimental|Rilonacept|
3233339|NCT00962013|Other|Restoration® Modular|All subjects were enrolled into a single arm and received the Restoration® Modular Revision Hip System to replace the femoral portion of a failed previous implant.
3233340|NCT00962000|Other|600 mL/min|Dialysis Flow Rate Start 600mL/min Subject starting dialysis flow rate set at 600mL/min. ABAB sequence where A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min and B represents three consecutive treatments with a dialysate flow rate of 800 mL/min.
3233341|NCT00962000|Other|800 mL/min|Dialysis Flow Rate Start 800mL/min Subject starting dialysis flow rate set at 800mL/min. BABA sequence where B represents three consecutive treatments with a dialysate flow rate of 800 mL/min and A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min.
3233342|NCT00961987|Experimental|Collaborative model|Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.
3233343|NCT00961987|Active Comparator|Usual care|At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
3233344|NCT00961974|No Intervention|Standard Care|"Routine diabetes support and education from diabetes health care team~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
3233345|NCT00961974|Experimental|Care Plus|"Routine diabetes support and education from diabetes health care team~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
3233346|NCT00961974|Experimental|Care Ultra|"Routine diabetes support and education from diabetes health care team~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
3233347|NCT00961961|Experimental|Lithium plus Fluoxetine|
3233348|NCT00961961|Active Comparator|Lithium plus Placebo|
3233349|NCT00961922|Experimental|Neurofeedback|Children in this group receive 30 sessions of neurofeedback
3233350|NCT00961922|Sham Comparator|Placebo feedback|The children in this group receive 30 sessions of placebo feedback, based on muscular tension.
3233351|NCT00961922|No Intervention|Siblings|The siblings will be tested 1 time, they will function as a healthy control group.
3233352|NCT00961909|Experimental|1active|
3233353|NCT00961909|Placebo Comparator|1placebo|
3233354|NCT00961909|Experimental|2active|
3233355|NCT00961909|Placebo Comparator|2placebo|
3233356|NCT00961896|Active Comparator|LDE225 (applied in parallel with vehicle) [Part I]|Participants were exposed to both topically applied 0.75% LDE225 cream and LDE225 vehicle cream twice daily for 28 days where each treatment was randomized to two different test areas on each participant.
3233357|NCT00961896|Placebo Comparator|Vehicle cream (applied in parallel with LDE225 [Part I]|Participants were exposed to both topically applied 0.75% LDE225 cream and LDE225 vehicle cream twice daily for 28 days where each treatment was randomized to two different test areas on each participant.
3233358|NCT00961896|Active Comparator|LDE225 0.25% [Part II]|Participants were exposed to topically applied 0.25% LDE225 cream twice daily for 6 weeks.
3233359|NCT00961896|Active Comparator|LDE225 0.75% [Part II]|Participants were exposed to topically applied 0.75% LDE225 cream twice daily where some basal cell carcinomas (BCCs) were teated for 6 weeks and some BCCs were treated for 9 weeks.
3233406|NCT00961597|Experimental|Meniscus repair with PRP|Meniscus repair for tears extending into the red/white region with PRP
3233407|NCT00961597|Active Comparator|Meniscus repair without PRP|
3233360|NCT00961883|Experimental|1|Thirty participants will receive injections in the following order: NYVAC-B for injections one and two, placebo for injection three, and rAd5 for the fourth and final injection. Two participants in this group will receive placebo vaccines only.
3233361|NCT00961883|Experimental|2|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
3233362|NCT00961883|Experimental|3|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
3233363|NCT00961883|Experimental|4|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
3233364|NCT00961870|Experimental|Healthy postmenopausal women|Forearm vibration will be applied in women without postmenopausal osteoporosis
3233365|NCT00961870|Experimental|Osteoporotic postmenopausal women|Forearm vibration will be applied in women with postmenopausal osteoporosis
3233366|NCT00961870|Experimental|Healthy young adult women|Forearm vibration will be applied in healthy young adult women
3233367|NCT00961870|Experimental|Healthy young adult men|Forearm vibration will be applied in healthy young adult men
3233368|NCT00961857|Active Comparator|Treatment A|Individual Tablets of 50 mg sitagliptin and 500 mg metformin
3233369|NCT00961857|Experimental|Treatment B|Sitagliptin/metformin 50 mg/500 mg tablet
3233370|NCT00961857|Active Comparator|Treatment C|Individual Tablets of 50 mg sitagliptin and 1000 mg metformin
3233371|NCT00961857|Experimental|Treatment D|sitagliptin/metformin 50 mg/1000 mg tablet
3233372|NCT00961844|Experimental|DC vaccine + Temozolomide|Dendritic cell loaded with h-TERT mRNA, survivin mRNA and autologous tumor cell mRNA, lymphodepletion treatment and T cell expansion and reinfusion.
3233373|NCT00961831|Experimental|Arm 1|
3233374|NCT00961831|Experimental|Arm 2|
3233375|NCT00961805|Experimental|Dance Group|Belly dance
3233376|NCT00961805|No Intervention|Control Group|Waiting list
3233377|NCT00961792|Experimental|Beverage with Heavy Alcohol Dose|Beverage containing 0.8 g/kg alcohol
3233378|NCT00961792|Experimental|Beverage with Low Alcohol Dose|Beverage containing 0.4 g/kg alcohol
3233379|NCT00961792|Placebo Comparator|Beverage with No alcohol (Placebo)|Beverage containing 0.0 g/kg alcohol to act as placebo
3233380|NCT00961792|Experimental|Beverage with Diphenhydramine|Beverage containing 1.5 standard dose of Diphenhydramine (Benadryl)
3233381|NCT00961792|Experimental|Beverage with Caffeine|Beverage containing the equivalent of 1.5 times participant's average caffeine consumption
3233382|NCT00961779|Placebo Comparator|Placebo (Normal saline infusion)|
3233383|NCT00961779|Experimental|NNZ-2566|NNZ-2566 reconstituted in bicarbonate buffer and normal saline. 6/8 subjects in each cohort (5 cohort in total) to receive NNZ-2566 experimental treatment.
3233384|NCT00961766|Experimental|BG00010 (Neublastin)|Participants may be randomized to escalating doses of BG00010 or matching placebo
3233385|NCT00961766|Placebo Comparator|Placebo|Participants may be randomized to escalating doses of BG00010 or matching placebo
3233386|NCT00961753|Experimental|Optimized Ibuprofen|
3233387|NCT00961753|Active Comparator|Standard Ibuprofen|
3233388|NCT00961740|Other|Cognitive Behavioral Therapy|Design: 49 children (aged 8-12)with obesity was recruited, the children were randomly assigned to a group that started a cognitive behavioural intervention immediately after recruitment, and another group that received the same treatment after a 12-week wait list condition. For further description of the treatment, see summary. Arm 1 (this arm) started receiving a cognitive behavioural intervention immediately after randomization.
3233389|NCT00961740|Other|12-weeks waitlist condition|After an initial pre-assessment no contact were made before assessment after 12-weeks and start of intervention after this assessment. After the 12-week waitlist condition the families were offered the same familibased cognitive behavioral intervention as in arm one.
3233390|NCT00961727||PEWS System of Care|
3233391|NCT00961714|Experimental|OsseoFix|
3233392|NCT00961675|Active Comparator|FST201|
3233393|NCT00961675|Active Comparator|Ciprodex|
3233394|NCT00961662|Experimental|2.5 active|2.5 Active - 2.5 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
3233395|NCT00961662|Active Comparator|5.0 mid dose|5.0 mid dose - 5.0 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
3233396|NCT00961662|Active Comparator|7.5 high dose|7.5 high dose - 7.5 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
3233397|NCT00961649|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
3233398|NCT00961649|Active Comparator|Brinz|Brinzolamide ophthalmic suspension, 1% and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
3233399|NCT00961649|Active Comparator|Brim|Brimonidine tartrate ophthalmic solution, 0.2% and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
3233400|NCT00961649|Active Comparator|Brinz+Brim|Brinzolamide ophthalmic suspension, 1% and brimonidine tartrate ophthalmic solution, 0.2%: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
3233401|NCT00961636|Experimental|ERN/LRPT|"One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg~tablets daily (2g/40 mg total) for 28 weeks"
3233402|NCT00961636|Experimental|ERN/LRPT then ERN|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks then Two 1g tablets ERN (2g total) once daily for 12 weeks.
3233403|NCT00961636|Placebo Comparator|Placebo|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks.
3233404|NCT00961610||Internet support group Intervention|
3233405|NCT00961610||Control group|
3233409|NCT00961558|No Intervention|Observation arm|Patient will not to undergo any form of Assisted Reproductive Technologies for a period of 6 months
3233410|NCT00961558|Other|Surgery Arm|Patients will have varicocelectomy within 1 month of assessment and will not undergo any form of Assisted Reproductive Technologies for a period of 6 months after surgery
3233411|NCT00961532|Experimental|DDAVP|DDAVP 0.4 mcg/kg intravenously in 250 mL NS over 30 minutes
3233412|NCT00961506|Experimental|LESS cholecystectomy|LESS cholecystectomy
3233413|NCT00961506|Active Comparator|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
3233414|NCT00961493|Experimental|1|
3233415|NCT00961493|Active Comparator|2|
3233416|NCT00961480|Active Comparator|Treatment A|50 mg sitagliptin and 500 mg metformin as individual tablets
3233417|NCT00961480|Experimental|Treatment B|sitagliptin/metformin 50 mg/500 mg tablet
3233418|NCT00961480|Active Comparator|Treatment C|50 mg sitagliptin and 1000 mg metformin as individual tablets
3233419|NCT00961480|Experimental|Treatment D|sitagliptin/metformin 50 mg/1000 mg tablet
3233420|NCT00961480|Active Comparator|Treatment E|50 mg sitagliptin and 850 mg metformin as individual tablets
3233421|NCT00961480|Experimental|Treatment F|sitagliptin/metformin 50 mg/850 mg tablet
3233422|NCT00961467|Experimental|RMPT (Arm A -thalidomide 50 mg/day)|
3233423|NCT00961467|Experimental|RMPT (Arm B - thalidomide 100 mg/day)|
3233424|NCT00961441|Experimental|Children 12-16 years old|
3233425|NCT00961441|Experimental|Adults 18-55 years old|
3233426|NCT00961415|Experimental|Part 1|
3233427|NCT00961415|Experimental|Part 2A|
3233428|NCT00961415|Active Comparator|Part 2B|
3233429|NCT00961402|Experimental|Wellness Control|Participants will receive health and wellness information and no exercise information.
3233430|NCT00961402|Experimental|Exercise Intervention|Intervention will include motivational telephone-based intervention to increase exercise to 5 days per week for 30 minutes or more each session.
3233431|NCT00961389||delirious patients|minimal any positive CAM-ICU score during ICU admission
3233432|NCT00961389||non-delirious patients|without any positive CAM-ICU score during ICU admission
3233433|NCT00961376|Active Comparator|Cohort A|PBMC re-infusion
3233434|NCT00961376|Experimental|Cohort B|CD25 depletion
3233435|NCT00961363|Experimental|Sitagliptin|Sitagliptin
3233436|NCT00961363|Placebo Comparator|Placebo|Placebo
3233437|NCT00961350|Experimental|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
3233438|NCT00961350|Active Comparator|EC Aspirin|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
3233439|NCT00961337|Experimental|Vaccination township|Shinwu township was randomly designated as intervention township which freely vaccinated on grade 1-4 and 5-9 students.
3233440|NCT00961337|No Intervention|Control townships|Guanyin township was designated as control township which only provide free vaccination on grade 1-4 students.
3233441|NCT00961324|Experimental|IDeg|
3233442|NCT00961324|Experimental|IGlar|
3233443|NCT00961311|Experimental|Trial Arm|All patients with systematic ischemic heart disease with stenotic lesions that are amenable to percutaneous treatment.
3233444|NCT00961298|Experimental|Duloxetine|Two weeks of placebo run in followed by 12 weeks of Duloxetine.
3233445|NCT00961272||HIV-infected, pre-menopausal women|
3233446|NCT00961259|Experimental|Fenofibric Acid 35 mg (1 x 35 mg tab)|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
3233447|NCT00961259|Experimental|Fenofibric Acid 105 mg (3 x 35 mg tab)|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
3233448|NCT00961259|Experimental|Fenofibric Acid 105 mg (1 x 105 mg tab)|1 x 105 mg tablet administered after an overnight fast of at least 10 hours
3233449|NCT00961246|Active Comparator|general health information group|participants received general health information
3233450|NCT00961246|Experimental|individually-tailored intervention|participants received individually-tailored intervention
3233451|NCT00961233|Experimental|inhaled/swallowed budesonide|
3233452|NCT00961233|Active Comparator|viscous/swallowed budesonide|
3233453|NCT00961220|Experimental|Treatment (O6-benzylguanine, carmustine)|Patients receive O6-benzylguanine IV over 1 hour and apply topical carmustine to the total skin surface (excluding the lips, eyelids, and ulcerated lesions) 1 hour after completing O6-benzylguanine infusion on days 1-2. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3233454|NCT00961207|Active Comparator|Aliskiren in Macroalbuminuria|Aliskiren 150 mg daily for 2 weeks and then increased to 300 mg daily for 4 weeks.
3233455|NCT00961207|Active Comparator|Aliskiren Microalbuminuria|Aliskiren 150 mg daily for 2 weeks and then increased to 300mg daily for 4 weeks
3233456|NCT00961194|Placebo Comparator|placebo|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
3233457|NCT00961194|Experimental|dose of ketamine tested = 0.35 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
3233458|NCT00961194|Active Comparator|dose of ketamine tested = 0.7 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
3233459|NCT00961194|Active Comparator|dose of ketamine tested = 1.4 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
3233460|NCT00961181|Experimental|Paclitaxel Releasing Balloon|Percutaneous coronary intervention with paclitaxel releasing balloon
3233461|NCT00961168|Experimental|Lung-Protective Ventilation|Lung-Protective Ventilation comparing volume vs. pressure control
3233462|NCT00961155|Active Comparator|cyklezonid|children will receive 160 mcg once daily cyklezonid for 3 months
3233463|NCT00961155|Active Comparator|montelukast sodium|children will receive 5 or 10 mg montelukast sodium for 3 months
3233464|NCT00961155|Placebo Comparator|placebo|children will receive placebo for 8 weeks out of allergy season to house dust mite
3233465|NCT00961155|Active Comparator|formoterol|children will receive formoterol aerolzol 12mcg twice daily for 3 months
3233466|NCT00961129||patients with colorectal cancer|patients with colorectal cancer in any stage or survivors
3233467|NCT00961116|Experimental|Fenofibric Acid (Fibricor™)|1 x 105 mg fenofibric acid (Fibricor™)tablet administered after an overnight fast of at least 10 hours
3233468|NCT00961116|Experimental|Fenofibrate (Tricor®)|1 x 145 mg fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
3233469|NCT00961103||SMA II and SMA III|patients with SMA II and SMA III
3233470|NCT00961051|Experimental|Investigational MPS|Investigational multipurpose disinfecting solution (study MPS)
3233471|NCT00961051|Active Comparator|Predicate MPS|Opti-Free RepleniSH multipurpose disinfecting solution (predicate MPS)
3233472|NCT00961038|Experimental|Arm 1|
3233473|NCT00961038|Experimental|Arm 2|
3233474|NCT00961038|Placebo Comparator|Arm 3|
3233475|NCT00961025|Placebo Comparator|Placebo|
3233476|NCT00961025|Experimental|DA-1229|DA-1229
3233477|NCT00961012|Experimental|Intervention|"Experimenter A places the subject in the High Fowler's position by raising the foot of the bed to its highest position, 50 degrees, and the head of the bed to its highest position, 60 degrees. Experimenter A sets the timer for 8 minutes as per pressure mapping protocol. For more stable values, a settling time of 8 minutes is required to factor in creep of the pressure mapping sensors and mattress. Experimenter A aims the laser beam to the top of the scapulae where the subject's shoulder meets the mattress surface. Experimenter B initiates a FSA file with the subject's number, takes a pressure reading once 8 minutes is up, measures the trunk displacement, obtains spirometry readings as per protocol, and takes a measure of discomfort. Experimenter B leaves the room, Experimenter A sets the timer for 5 minutes and opens the randomization/ allocation envelope."
3233478|NCT00961012|No Intervention|Control group|"Experimenter A reminds the subject to remain immobile.~For both intervention and control group. After the five-minute period, experimenter A calls experimenter B to return. Experimenter B takes a pressure reading, measures the trunk displacement, obtains spirometry readings, and takes a measure of discomfort."
3233479|NCT00960999|Experimental|Single-fraction SBRT (34 Gy)|Single-fraction stereotactic body radiation therapy (SBRT) of 34 Gy
3233480|NCT00960999|Experimental|Multiple-fraction SBRT (48 Gy)|Multiple-fraction stereotactic body radiation therapy (SBRT) given in four daily 12 Gy fractions for a total dose of 48 Gy
3233481|NCT00960986|Experimental|Duloxetine 60 mg with food|Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks
3233482|NCT00960986|Experimental|Duloxetine 60 mg without food|Duloxetine 60 mg capsule po QD without food for 8 weeks
3233483|NCT00960986|Experimental|Duloxetine 30 mg with food|Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks
3233484|NCT00960986|Experimental|Duloxetine 30 mg without food|Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks
3233485|NCT00960973|Experimental|Vitamin K|Vitamin K supplementation (menatetrenone 30 mg, 3 times a day for 4 weeks)
3233486|NCT00960973|Placebo Comparator|Placebo control|Placebo control
3233487|NCT00960960|Experimental|Part 1 (Cohort 1-2): Pictilisib 60 mg +Paclitaxel +Bevacizumab|Pictilisib 60 mg will be administered orally (PO) once daily (QD) for 21 consecutive days of each 28-day cycle (21+7 schedule) with paclitaxel 90 milligrams per meter square (mg/m^2) intravenously (IV) on Days 1, 8, and 15 and bevacizumab 10 milligrams per kilogram (mg/kg) IV on Days 1 and 15 of each 28-day cycle. In Cohort 1 (Part 1), pictilisib will be evaluated with paclitaxel only; participants in Cohort 1 (Part 1) will be eligible to receive bevacizumab starting at Cycle 2. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
3233488|NCT00960960|Experimental|Part 1 (Cohort 3): Pictilisib 100 mg+ Paclitaxel + Bevacizumab|Pictilisib 100 mg will be administered PO QD for 21 consecutive days of each 28-day cycle (21+7 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
3233489|NCT00960960|Experimental|Part 2 (Arm A: Cohort 1a): Pictilisib 165 mg + Paclitaxel|Pictilisib 165 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity
3233490|NCT00960960|Experimental|Part 2 (Arm A: Cohort 2a): Pictilisib 250 mg + Paclitaxel|Pictilisib 250 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
3233491|NCT00960960|Experimental|Part 2 (Arm A: Cohort 3a): Pictilisib 330 mg + Paclitaxel|Pictilisib 330 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
3233492|NCT00960960|Experimental|Part2(Arm B:Cohort 1b):Pictilisib 200mg+Paclitaxel+Bevacizumab|Pictilisib 200 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
3233493|NCT00960960|Experimental|Part2(Arm B:Cohort 2b):Pictilisib 250mg+Paclitaxel+Bevacizumab|Pictilisib 250 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
3233494|NCT00960960|Experimental|Part2(Arm B:Cohort 3b):Pictilisib 260mg+Paclitaxel+Bevacizumab|Pictilisib 260 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
3233495|NCT00960960|Experimental|Part2(Arm C:Cohort 1c):Pictilisib 180mg+Paclitaxel+Trastuzumab|Pictilisib 180 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and trastuzumab 2-4 mg/kg IV on Days 1, 8, 15, and 22 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
3233496|NCT00960960|Experimental|Part2(Arm C:Cohort 2c):Pictilisib 260mg+Paclitaxel+Trastuzumab|Pictilisib 260 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and trastuzumab 2-4 mg/kg IV on Days 1, 8, 15, and 22 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
3233497|NCT00960960|Experimental|Part 3: Pictilisib 260 mg + Letrozole|Pictilisib 260 mg will be administered PO QD continuously with letrozole 2.5 mg PO QD for each 28-day cycle. Study treatment will continue until disease progression or unacceptable toxicity.
3233498|NCT00960934|Experimental|MK-5442 2.5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.
3233499|NCT00960934|Experimental|MK-5442 5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.
3233500|NCT00960934|Experimental|MK-5442 7.5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.
3233501|NCT00960934|Experimental|MK-5442 10 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.
3233502|NCT00960934|Experimental|MK-5442 15 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.
3233503|NCT00960934|Placebo Comparator|Placebo|Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.
3233504|NCT00960921|Experimental|Iron group|Patients with high altitude pulmonary hypertension receive six intravenous infusions of iron sucrose, administered on days 0, 4, 8, 12, 16 and 20 of the study. The total study period is 28 days. Pulmonary artery systolic pressure is measured before each infusion, and again on day 28.
3233505|NCT00960921|Placebo Comparator|Saline group|Patients with high altitude pulmonary hypertension receive six intravenous infusions of normal saline, administered on days 0, 4, 8, 12, 16 and 20 of the study. The total study period is 28 days. Pulmonary artery systolic pressure is measured before each infusion, and again on day 28.
3233506|NCT00960908||Resolute|Prospective recruitment of Resolute arm will start in March 2009
3233507|NCT00960908||Endeavor|The retrospective recruiting period of Endeavor arm comprises a fixed 2-year time between January 2006 and December 2008. The patients, who were treated with Endeavor in that period, will be enrolled if they agree to participate in this study.
3233508|NCT00960882|Experimental|DMMET-01|
3233509|NCT00960869|Experimental|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole dosed once daily (QD)
3233510|NCT00960869|Active Comparator|EC-Aspirin 325 mg|EC-Aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole) dosed once daily (QD)
3233511|NCT00960856|Experimental|Fenofibric Acid 105 mg - Low-Fat Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
3233512|NCT00960856|Experimental|Fenofibric Acid 105 mg - Standard Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a standard breakfast.
3233513|NCT00960856|Experimental|Fenofibric Acid 105 mg - High-Fat/High-Calorie Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
3233514|NCT00960856|Experimental|Fenofibric Acid 105 mg - Fasted State|Fenofibric Acid 105 mg tablet administered after an overnight fast of at least 10 hours
3233515|NCT00960843|Active Comparator|Conventional Adjustment Group|Subject whose band adjustments will be made via conventional standard of care (e.g., volume, hunger).
3233516|NCT00960843|Active Comparator|Intraband Pressure Arm|Subjects whose band adjustments will be guided by intraband pressure readings.
3233517|NCT00960830|Placebo Comparator|mirtazapine|
3233518|NCT00960830|Placebo Comparator|mirtazapine, sugar pill|
3233519|NCT00960817|Active Comparator|1. Routine treatment|Control group
3233520|NCT00960817|Experimental|2. Dipyridamole treatment|Group that receives Dipyridamole treatment
3233521|NCT00960804|Experimental|Tanezumab 5 mg|
3233522|NCT00960804|Experimental|Tanezumab 10 mg|
3233523|NCT00960804|Placebo Comparator|Placebo|
3233524|NCT00960791|Experimental|1|14C-labelled AZD1656
3233525|NCT00960778|Experimental|Women- denicotinized cigarette|Treatment-seeking nicotine-dependent women will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues after four days of denicotinized cigarette (less than 0.5 gram nicotine) use.
3233526|NCT00960778|Experimental|Men- denicotinized cigarette|Treatment-seeking nicotine-dependent men will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues after four days of denicotinized cigarette (less than 0.5 gram nicotine) use.
3233561|NCT00960531|Experimental|ACC-001 (10mcg) + QS-21|ACC-001 (10mcg) + QS-21
3233527|NCT00960778|Experimental|Women -nicotine patch|Treatment-seeking nicotine-dependent women will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues under after receiving three days of a 21 mg nicotine patch.
3233528|NCT00960778|Experimental|Men- nicotine patch|Treatment-seeking nicotine-dependent men will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues under after receiving three days of a 21 mg nicotine patch.
3233529|NCT00960778|Other|Women baseline|Treatment-seeking nicotine-dependent women will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues at a baseline visit with no intervention.
3233530|NCT00960778|Other|Men baseline|Treatment-seeking nicotine-dependent men will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues at a baseline visit with no intervention.
3233531|NCT00960765||Roux-En-Y Gastric Bypass|
3233532|NCT00960765||Gastric Banding|
3233533|NCT00960765||Sucessful Response to RYGB|
3233534|NCT00960765||Failed Response to RYGB|
3233535|NCT00960752|Active Comparator|Group 1: gp100 and MAGE-3 + R848|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
3233536|NCT00960752|Active Comparator|Group 2: gp100 and MAGE-3|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
3233537|NCT00960752|Active Comparator|Group 3-Metastatic Melanoma: gp100 + MAGE-3 + R848|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
3233538|NCT00960739|Experimental|Topotecan / 131-iodine MIBG association|"The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle). *~Iobenguane I 131: 444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity up to 11,100 MBq per injection. *~A dosimetry is performed during hospitalization.~A second dose of 131-iodine MIBG (maximum 11 100 MBq) is administered to D21 so as to obtain a total body irradiation of 4 Gy. *~Autologous hematopoietic stem cell transplantation : Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG.~If the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled."
3233539|NCT00960726|Experimental|NOV-002|
3233540|NCT00960713||The RITAI cohort|Every patient treated by rituximab off-label for auto-immune diseases in the public hospitals of the Midi-Pyrénées County (South of France) is eligible for the study, whatever the dose and planned infusions number. The enrolment is definitive when the first rituximab infusion begins. Follow-up visits are planned at months 1, 3, 6, 12 and 18 after the first infusion. At each visit, the investigators will record the adverse events that have occurred since the last visit. Serious or unexpected adverse events will be systematically monitored and declared to the Department of Pharmacology Pharmacovigilance unit and to Health Authorities (AFSSAPS). Imputability will be quoted according to the French method. A biological collection will be constituted to allow pharmaco-immunological studies.
3233541|NCT00960687|Experimental|Fenofibric Acid (Fibricor™)|1 x 105 mg fenofibric acid (Fibricor™)tablet administered 30 minutes after the initiation of a standard breakfast.
3233542|NCT00960687|Experimental|Fenofibrate (Tricor®)|1 x 145 mg fenofibrate (Tricor®) tablet administered 30 minutes after the initiation of a standard breakfast.
3233543|NCT00960674|Experimental|Tactile massage|A gentle form of massage given once a week for three weeks
3233544|NCT00960674|Experimental|Relaxation|Relaxation (by the use of a CD with relaxation exercises used at least once a week for 10 weeks)
3233545|NCT00960661|Experimental|Exenatide (BET)|Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET)
3233546|NCT00960661|Active Comparator|Insulin Lispro (BBT)|Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT)
3233547|NCT00960648||Xience/Promus|Active prospective registration of patients receiving everolimus eluting stent
3233548|NCT00960648||Cypher|Retrospective historical controls that received sirolimus-eluting stent
3233549|NCT00960635|Active Comparator|calcitriol|
3233550|NCT00960635|Placebo Comparator|pill without agent|
3233551|NCT00960622|Experimental|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
3233552|NCT00960622|Active Comparator|Combivir or Trizivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months or Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
3233553|NCT00960609||caval confluence HV involvement|Patients carriers of primary or metastatic tumour with direct contact or invasion of one HV at the caval confluence.
3233554|NCT00960583|Experimental|Exercise program|"Exercise program comprising muscle strengthening, cardiovascular training and stretching exercises.~Program duration : 12 weeks Sessions frequency : twice per week Session duration : 1h30"
3233555|NCT00960583|Active Comparator|Routine follow-up|Routine follow-up after functional multidisciplinary rehabilitation by attending physician (Advice to stay active)
3233556|NCT00960570|Active Comparator|Efavirenz Alone|Baseline Efavirenz pharmacokinetics.
3233557|NCT00960570|Experimental|Efavirenz with Steady State Fenofibric Acid|Efavirenz pharmacokinetics in the presence of steady state Fenofibric Acid.
3233558|NCT00960557|Experimental|Combretastatin A1 Diphosphate|
3233559|NCT00960544|Experimental|Capecitabine|Capecitabine - Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
3233560|NCT00960531|Experimental|ACC-001 (3mcg) + QS-21|ACC-001 (3mcg) + QS-21
3233562|NCT00960531|Experimental|ACC-001 (30mcg) + QS-21|ACC-001 (30mcg) + QS-21
3233563|NCT00960518|Placebo Comparator|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
3233564|NCT00960518|Experimental|TACE+adefovir|patients received adefovir, at a dose of 10 mg daily after TACE treatment, for 48 weeks
3233565|NCT00960505|Experimental|Alternate day fasting (ADF)|Fast day diet: 25% energy intake, Feast day diet: Ad libitum energy intake (alternating days)
3233566|NCT00960505|Experimental|Calorie restriction (CR)|75% energy intake every day
3233567|NCT00960505|Active Comparator|Control|Usual diet
3233568|NCT00960492|Experimental|Arm 1|XL184 will be initiated at the start of the 6-7 week concurrent phase of RT (+TMZ; some subjects found to have specific gene activity in their tumor tissue may not receive TMZ), given as a single agent during the rest phase (4 weeks), if applicable, and continued subsequently in the maintenance phase.
3233569|NCT00960492|Experimental|Arm 2|XL184 will be initiated during the maintenance phase with TMZ
3233570|NCT00960492|Experimental|MTD Expansion|XL184 will be initiated at the start of the 6-7 week concurrent phase of RT (+TMZ; some subjects found to have specific gene activity in their tumor tissue may not receive TMZ), given as a single agent in the rest phase (4 weeks), if applicable, and continued subsequently in the maintenance phase. Subjects in this group will receive XL184 and TMZ at the maximally tolerated dose levels determined in Arms 1 and 2.
3233571|NCT00960479|Experimental|1|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)
3233572|NCT00960479|Active Comparator|2|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)
3233573|NCT00960466|Active Comparator|Usual Care Arm|The usual care group will receive their Chemotherapy or Radiotherapy as normal.
3233574|NCT00960466|Experimental|DT&PL arm|"During the second week of radiotherapy/second cycle of chemotherapy, patients in the Distress Thermometer and Problem List (DT&PL) arm of the study will complete the DT&PL (estimated 15 minutes to complete) with the trained radiographer/nurse.~The DT&PL assessment will be repeated at the end of therapy fractions/cycles. This will elicit concerns about post-therapy issues and facilitate continuity of care between the cancer team and primary care. Depending on the duration of therapy, therapists may choose to use the DT&PL at other points during patient care. A copy of the DT&PL will be stored in the medical record to track the frequency of use and to check that those assigned to usual care were not monitored with the DT&PL."
3233575|NCT00960453|Other|Sitagliptin 25mg|Repeated administrations for 4 days
3233576|NCT00960453|Other|Sitagliptin 50mg|Repeated administrations for 4 days
3233577|NCT00960453|Other|Sitagliptin 100mg|Repeated administrations for 4 days
3233578|NCT00960440|Experimental|Sequence 1|
3233579|NCT00960440|Experimental|Sequence 2|
3233580|NCT00960440|Placebo Comparator|Sequence 3|
3233581|NCT00960440|Placebo Comparator|Sequence 4|
3233582|NCT00960414|Experimental|SHINE A|
3233583|NCT00960414|Active Comparator|SHINE B|
3233584|NCT00960401||cardiac counseling|10 left sided breast cancer patients 10 right sided breast cancer patients
3233585|NCT00960401||coronary artery evaluation|10 left sided breast cancer 10 right sided breast cancer
3233586|NCT00960375|Experimental|BTSCS|BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
3233587|NCT00960375|Active Comparator|StSST|The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide test at the start of each group meeting. StSST groups provide education about smoking and support for quitting.
3233588|NCT00960362|Placebo Comparator|A|
3233589|NCT00960362|Experimental|B|Intravenous cohort 1; 0.01 mg/kg
3233590|NCT00960362|Experimental|C|Intravenous cohort 2; 0.1 mg/kg
3233591|NCT00960362|Experimental|D|Intravenous cohort 3; 0.6 mg/kg
3233592|NCT00960362|Experimental|E|Intravenous cohort 4; 3.0 mg/kg
3233593|NCT00960362|Experimental|F|Intravenous cohort 5; 10 mg/kg
3233594|NCT00960362|Experimental|G|Intravenous cohort 6; 30 mg/kg
3233595|NCT00960349|Other|Treatment A|Cediranib 20mg + Cisplatin + S-1
3233596|NCT00960349|Other|Treatment B|Cediranib 20mg + Cisplatin + Capecitabine
3233597|NCT00960336|Experimental|single arm|
3233598|NCT00960323|Active Comparator|Colchicine Alone|baseline colchicine pharmacokinetics
3233599|NCT00960323|Experimental|Colchicine with Atorvastatin|Colchicine pharmacokinetics in the presence of atorvastatin at steady state.
3233600|NCT00960310|Experimental|1|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
3233601|NCT00960310|Active Comparator|2|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
3233602|NCT00960297|Experimental|Carboplatin/Paclitaxel/Bevacizumab|Preoperative chemotherapy and bevacizumab
3233603|NCT00960284|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
3233604|NCT00960284|Experimental|Arm II|Patients receive cisplatin IV over 1 hour and epirubicin hydrochloride IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Patients also receive fluorouracil IV continuously beginning on day 1 or oral capecitabine. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
3233605|NCT00960271||NON SMALL CELL LUNG CANCER|Non small cell lung cancer, with clinical N2 disease, otherwise operable.
3233607|NCT00960245|Experimental|1|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
3233608|NCT00960245|Active Comparator|2|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
3233609|NCT00960232|Experimental|Vitamin D|vitamin D 40.000 IU per weel
3233610|NCT00960232|Placebo Comparator|Placebo|Placebo
3233611|NCT00960219|Experimental|DAAOI-1|
3233612|NCT00960219|Placebo Comparator|placebo|
3233613|NCT00960206|Experimental|Trident®System|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
3233614|NCT00960206|Experimental|ABC System|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
3233615|NCT00960206|Active Comparator|Control|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
3233616|NCT00960193|Active Comparator|Colchicine Alone|baseline colchicine pharmacokinetics
3233617|NCT00960193|Experimental|Colchicine with Seville Orange Juice|colchicine pharmacokinetics in presence of Seville orange juice
3233618|NCT00960180|Experimental|1|
3233619|NCT00960180|Placebo Comparator|2|
3233620|NCT00960167|Experimental|Dose Level I|42 Gy in 12 fractions.
3233621|NCT00960167|Experimental|Dose Level II|49 Gy in 14 fractions.
3233622|NCT00960167|Experimental|Dose Level III|56 Gy in 16 fractions.
3233623|NCT00960167|Experimental|Dose Level IV|63 Gy in 18 fractions.
3233624|NCT00960154|Experimental|PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
3233625|NCT00960154|Active Comparator|SOC|The SOC consists of scalpel for the skin incision and traditional electrosurgery for the entirety of the subcutaneous dissection.
3233626|NCT00960141|Experimental|1|montelukast
3233627|NCT00960141|Active Comparator|2|loratadine
3233628|NCT00960141|Placebo Comparator|3|placebo
3233629|NCT00960128||A|Adult cohort
3233630|NCT00960128||B|Paediatric cohort
3233631|NCT00960115|Experimental|Tecemotide (L-BLP25) + Cyclophosphamide|Active
3233632|NCT00960115|Placebo Comparator|Placebo + Saline|Control
3233633|NCT00960102|Active Comparator|bilateral cochlear implant|
3233634|NCT00960102|Active Comparator|cochlear implant and hearing aid|
3233635|NCT00960102|Active Comparator|bilateral hearing aid|
3233636|NCT00960089|Experimental|LIQUICURE|Medical Device
3233637|NCT00960076|Experimental|1|Saxagliptin
3233638|NCT00960076|Active Comparator|2|Metformin Extended Release
3233639|NCT00960063|Experimental|Temozolomide+Irinotecan+Robatumumab|Participants receive temozolomide 100 mg/m^2/day intravenously (IV) on Days 1-5 PLUS irinotecan 10 mg/m^2/day IV on Days 1-5 and Days 8-12 PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
3233640|NCT00960063|Experimental|Vincristine+Doxorubicin+Cyclophosphamide+Robatumumab|Participants receive vincristine 2 mg/m^2 (maximum 2 mg) IV on Day 1 PLUS cyclophosphamide 1200 mg/m^2 IV on Day 1 PLUS doxorubicin hydrochloride 75 mg/m^2 IV continuously over 48 hours PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
3233641|NCT00960063|Experimental|Ifosfamide+Etoposide+Robatumumab|Participants receive ifosfamide 1800 mg/m^2 per day IV PLUS etoposide 100 mg/m^2 per day IV on Days 1-5 PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
3233642|NCT00960037|Experimental|Vitamin D|Vitamin D3 supplementation based on baseline 25(OH)D level
3233643|NCT00960037|Placebo Comparator|Placebo|
3233644|NCT00960024|Experimental|Individual Placement and Support-vocational rehabilitation|
3233645|NCT00960024|Active Comparator|Vocational rehabilitation available at study site|
3233646|NCT00960011|Experimental|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
3233647|NCT00960011|Active Comparator|POLYPROPYLENE|Use of Polypropylene mesh for open inguinal hernia repair
3233648|NCT00959998|Active Comparator|Relaxation acupressure|
3233649|NCT00959998|Experimental|High Intensity Stimulating Acupressure|
3233650|NCT00959998|Experimental|Low Intensity Stimulating Acupressure|
3233651|NCT00959985|No Intervention|Group 1A|Mild Lymphedema: Only required to meet with the lymphedema physical therapist
3233652|NCT00959985|Active Comparator|Group 1B|Mild Lymphedema: Fitted for compression sleeve
3233653|NCT00959985|Active Comparator|Group 2A|Moderate lymphedema: Fitted with a compression sleeve
3233654|NCT00959985|Active Comparator|Group 2B|Moderate Lymphedema: Fitted with compression sleeve and instructed to wear a short-stretch compression bandage
3233655|NCT00959972|Experimental|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
3233656|NCT00959972|Experimental|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
3233657|NCT00959959|Experimental|650 mg TOK-001|
3233658|NCT00959959|Experimental|1300 mg TOK-001|
3233659|NCT00959959|Experimental|1950 mg TOK-001|
3233660|NCT00959959|Experimental|975 mg TOK-001|
3233661|NCT00959959|Experimental|975 mg TOK-001, supplement|
3233662|NCT00959959|Experimental|1950 mg TOK-001, split dose|
3233663|NCT00959959|Experimental|2600 mg TOK-001|
3233664|NCT00959959|Experimental|2600 mg TOK-001, split dose|
3233665|NCT00959946|Experimental|1|In part 1 (phase 1), ascending and descending multiple oral doses of bosutinib + capecitabine. Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14 + bosutinib 200 mg QD; capecitabine 625 mg/m2 BID on days 1-14 + bosutinib 300 mg QD. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID and bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
3233666|NCT00959933|Experimental|1|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)
3233667|NCT00959933|Active Comparator|2|Rebetol 200 Capsules (Schering Corporation, U.S.A.)
3233668|NCT00959920|Active Comparator|Indwelling foley catheter|Insertion of an indwelling foley catheter when bladder emptying is necessary. The indwelling catheter will remain in place until the time of delivery.
3233824|NCT00958789|Other|Triathlon TS Knee|Triathlon TS Knee System
3233669|NCT00959920|Active Comparator|Intermittent straight catheterization|Intermittent straight catheterization will be performed as needed during labor.
3233670|NCT00959907|Active Comparator|BoNT A1 (4U)|BoNT A1 (4U): Botulinum toxin A (Dysport®)4 units
3233671|NCT00959907|Active Comparator|BoNT-A2 (2U)|BoNT-A2(2U): Botulinum toxin A (Botox®) 2 units
3233672|NCT00959894|Experimental|Etravirine 400 mg once daily|Etravirine 400 mg once daily with fixed dose tenofovir/emtricitabine (Truvada) one tablet once daily
3233673|NCT00959881|Experimental|Donepezil plus placebo|
3233674|NCT00959881|Experimental|Donepezil plus begacestat|
3233675|NCT00959855|Experimental|Pulmonary Rehabilitation|Pulmonary rehabilitation classes based on the British Thoracic Society guidelines will be undertaken for two hours for 16 sessions within an eight week period.
3233676|NCT00959855|No Intervention|Pulmonary Rehabiliation|The control group will be assessed in the same time frame without participating in the rehabilitation class. They will avail of the next available class after the 12 month assessment.
3233677|NCT00959842|Experimental|Lovaza|Lovaza was given as the only agent; there was no comparator agent or arm
3233678|NCT00959829|Placebo Comparator|silence|"The control group listened silence and was evaluated the same things."
3233679|NCT00959816|Experimental|Single Dose (Part 1)|
3233680|NCT00959816|Experimental|Multiple Dose (Part 2)|
3233681|NCT00959803|Experimental|Single dose|3 way crossover with randomized placebo substitution to evaluate single escalating oral doses of PF 04447943 in 9 healthy young adult subjects.
3233682|NCT00959803|Experimental|Multiple dose|3:1 active PF 04447943 to placebo randomization in 8 healthy elderly subjects.
3233683|NCT00959790|Experimental|High vegetable dose|Consumption of 200 grams of vegetables daily, for four weeks.
3233684|NCT00959790|Experimental|Low vegetable dose|Consumption of 50 grams of vegetables daily, for four weeks.
3233685|NCT00959790|Active Comparator|Weight loss interventio|Consumption of - 1000 kcal daily, for four weeks to be used as a positive control for the vegetables interventions.
3233686|NCT00959777|Experimental|DA-3031|
3233687|NCT00959777|Active Comparator|filgrastim|
3233688|NCT00959764|Experimental|Oral calcitonin and placebo nasal spray|Intervention: Oral calcitonin tablet (along with placebo intranasal spray)
3233689|NCT00959764|Active Comparator|Intranasal calcitonin & oral placebo|Intervention: Commercially available, active comparator, intranasal calcitonin-salmon (plus matching oral placebo tablet).
3233690|NCT00959764|Placebo Comparator|Placebo: tablet & intranasal spray|Intervention: Both oral matching placebo tablets and matching intranasal placebo spray
3233691|NCT00959751|Experimental|NXN-188 600 mg|3 x 200 mg capsules, PRN
3233692|NCT00959751|Placebo Comparator|Placebo|3 x 0 mg capsules, PRN
3233693|NCT00959738|Other|A|diverting loop ileostomy with rod
3233694|NCT00959738|Other|B|diverting loop ileostomy without rod
3233695|NCT00959725|Experimental|Intravitreal infliximab.|
3233696|NCT00959712|No Intervention|Control|Subjects are given a pedometer and step count log in which to record their daily step counts for 1 year.
3233697|NCT00959712|Active Comparator|ECA Interaction|"Subjects are given pedometers and step count logs in which to record their daily steps for 1 year. Subjects are also given a tablet computer and instructed to interact with the ECA (Embodied Conversational Agent) Tanya every day for 2 months."
3233698|NCT00959699|Placebo Comparator|PegIFN-2b + RBV|PegIFN-2b (1.5 µg/kg/week subcutaneously) plus RBV (600-1400 mg/day, orally, divided into two daily doses) for 4 weeks followed by placebo to boceprevir plus PegIFN-2b/RBV for 44 weeks with 24 weeks post-treatment follow-up (Control Arm). Participants who do not achieve HCV-RNA <9.3 IU/mL by Treatment Week 24 (TW24) are eligible to cross-over and receive boceprevir along with the PegIFN-2b and RBV for up to 44 weeks.
3233699|NCT00959699|Active Comparator|PegIFN-2b + RBV + Boceprevir|PegIFN-2b (1.5 µg/kg/week subcutaneously) plus RBV (600- 1400 mg/day, orally, divided into two daily doses) for 4 weeks followed by boceprevir (800 mg, orally, 3 times per day) plus PegIFN-2b/RBV for 44 weeks with 24 weeks post-treatment follow-up.
3233700|NCT00959686|Experimental|Bendamustine|Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
3233701|NCT00959660|Active Comparator|Exercise Training|Exercise participants will undergo a 1-hour supervised exercise program 3 times per week for 20 weeks consisting primarily of walking exercise using an individualized exercise prescription based on the initial exercise stress testing results.
3233702|NCT00959660|Active Comparator|Dietary Intervention|A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb) weight loss per week.
3233703|NCT00959660|Active Comparator|Attention control|Attention control participants will be provided a counseling session regarding general health education at baseline and will be contacted by staff via telephone every 2 weeks to discuss general health status.
3233704|NCT00959660|Active Comparator|Diet and Exercise|A hypocaloric diet will be developed to achieve a 2450 kcal/week deficit in addition to undergoing a 1-hour supervised exercise program 3 times per week for 20 weeks consisting primarily of walking exercise using an individualized exercise prescription based on the initial exercise stress testing results.
3233705|NCT00959647|Experimental|Vismodegib 150 mg|Participants received 150 mg vismodegib orally once a day until disease progression, intolerable toxicity, or withdrawal from the study. If a participant had been receiving combination chemotherapy and/or biotherapy (FOLFOX, FOLFIRI, bevacizumab) in a parent study, the same combination chemotherapy and/or biotherapy as specified in the parent study could be continued in this study at the discretion of the investigator.
3233706|NCT00959634|Experimental|1|Dose 1 BID
3233707|NCT00959634|Experimental|2|Dose 2 BID
3233708|NCT00959634|Placebo Comparator|3|Placebo BID
3233709|NCT00959621|Active Comparator|ASA|The patients received either Enoxaparine+placebo, Enoxaparine+ASA (Aspirin 100 mg) or ASA alone.ASA or placebo were blinded in the two first groups.
3233710|NCT00959621|Active Comparator|Klexane|Clexane (enoxaparine) 40 mg sc
3233711|NCT00959621|Active Comparator|Aspirin and Enoxaparine|
3233712|NCT00959608|Active Comparator|Basic|Basic program participants receive 10-15 minute PCP weight management counseling at approximately four month intervals for up to 24 months and weight management materials.
3233761|NCT00959205|Experimental|CARTO 3D|CARTO (3D Electroanatomic imaging)
3233713|NCT00959608|Experimental|Basic Plus|Half of study participants are randomly assigned to Basic Plus program, where in addition to receiving the same intervention as the Basic program participants, the Basic Plus participants also receive counseling from a lifestyle coach at the primary care provider's office (monthly in year 1 and bimonthly in year 2).
3233714|NCT00959595|Experimental|EMLA cream|
3233715|NCT00959595|Placebo Comparator|Placebo cream|A placebo cream identical in appearance and consistency to the experimental cream
3233716|NCT00959582|Experimental|1|18-F-FDG PET/CT imaging
3233717|NCT00959569|Experimental|esmolol|the study group will receive esmolol (1-3 mg/kg)
3233718|NCT00959569|Placebo Comparator|normosaline|normosaline (same ml of the study drug)
3233719|NCT00959543|Other|waterpolo players|30 throwing shoulders of waterpolo players
3233720|NCT00959543|Other|controle group|15 healthy patients (non waterpolo players); 30 shoulders
3233721|NCT00959530|Experimental|lingualized|complete denture fabricated by lingualized occlusion scheme
3233722|NCT00959530|Placebo Comparator|Full Bilaterally Balanced Articulation|complete denture fabricated by Full Bilaterally Balanced Articulation scheme
3233723|NCT00959517|Experimental|CQ|
3233724|NCT00959517|Experimental|CQ+PQ|
3233725|NCT00959517|Experimental|CQ + AS|
3233726|NCT00959517|Experimental|SP|
3233727|NCT00959517|Experimental|SP + PQ|
3233728|NCT00959517|Experimental|SP + AS|
3233729|NCT00959491||Colonoscopy indication|All outpatients referred to colonoscopy according to inclusion criteria in the specified period time of one year .
3233730|NCT00959478|Experimental|Educational tool & Carbon Monoxide Alarm|"Parents will be randomly assigned into a control and intervention group. Both groups will complete a computer based survey at enrollment and at their home visits occuring two weeks and approximately six months following enrollment. Participants will be given the following materials at enrollment.~Intervention:~Fast Facts about Carbon Monoxide Educational Tool~Kidde Nighthawk Carbon Monoxide Alarm~Control:~- Central Ohio Poison Control Center Flyer"
3233731|NCT00959465|Experimental|Cohort 1/Dose Level A|Subjects in Cohort 1 will be randomized 1:1 to receive two vaccinations of Dose A or Dose B of H1N1 pandemic influenza vaccine at a 21-day interval.
3233732|NCT00959465|Experimental|Cohort 1/Dose B|Subjects in Cohort 1 will be randomized 1:1 to receive two vaccinations of Dose A or Dose B of H1N1 pandemic influenza vaccine at a 21-day interval.
3233733|NCT00959465|Experimental|Cohort 2/Dose C|A second cohort may be enrolled with all subjects in this cohort receiving two vaccinations of Dose C of H1N1 pandemic influenza vaccine at a 21-day interval.
3233734|NCT00959452|Experimental|Psychotherapy|
3233735|NCT00959439|Experimental|1|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)
3233736|NCT00959439|Active Comparator|2|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)
3233737|NCT00959426|Experimental|PF-04620110|
3233738|NCT00959426|Placebo Comparator|Placebo Comparator|
3233739|NCT00959413||A|Participants who have a CD4 count of 200 cells/mm3 or less and a viral load greater than 1,000 copies/ml
3233740|NCT00959413||B|Participants who have a CD4 count of 200 cells/mm3 or less and a viral load of 1,000 copies/ml or less
3233741|NCT00959413||C|Participants will have a CD4 count that is greater than 200 cells/mm3 and a viral load that is greater than 1,000 copies/ml
3233742|NCT00959413||D|Participants will have a CD4 count that is greater than 200 cells/mm3 and a viral load that is 1,000 copies/ml or less
3233743|NCT00959400|Experimental|Fentanyl Transdermal|
3233744|NCT00959387|Experimental|Induction TP chemotherapy followed by CRT|paclitaxel 175mg/m2 as a 3-h infusion on Day 1, and cisplatin 80mg/m2 as a 2-h infusion on Day 1 three weekly followed by concurrent chemoradiotherapy based on cisplatin. All patient were given adequate hydration and antiemetics. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
3233745|NCT00959374|Active Comparator|V-loc and Monocryl|Subjects served as their own control, and they were randomized to receive an intervention of a standard closure using 3-0 Monocryl™ on one side of the body and the test closure device, V-Loc 180/90, on the other side. The standard closure technique was agreed on by study investigators for control side, and included mandatory closure of the deep dermal layer with interrupted 3-0 Monocryl™ sutures, spaced no further than 2 cm apart, followed by closure of the intradermal layer with running 3-0 Monocryl™ sutures. The test closure side, closure of the deep dermal layer was optional. If deep dermal sutures were used, interrupted 3-0 Monocryl™ sutures were required to be placed no closer than 5 cm apart followed by closure of the intradermal layer with test device, V-Loc 180/90.
3233746|NCT00959361|Experimental|pharmaceutical care|consultation with the pharmacists
3233747|NCT00959361|No Intervention|control|usual care without consultation with the pharmacists
3233748|NCT00959348||Asthma|Asthma patients on inhaled corticosteroids
3233749|NCT00959348||Control|Select matched controls from the general population database of Cardiovascular Risk Factor Prevalence Study 2 (CRISPS2)
3233750|NCT00959335|Active Comparator|2|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
3233751|NCT00959335|Experimental|1|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
3233752|NCT00959309|Experimental|Intervention|
3233753|NCT00959309|Active Comparator|Control|
3233754|NCT00959296||Patients with a device implant|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
3233755|NCT00959283||Ancillary-correlative|Patients undergo peripheral blood collection periodically for biomarker analysis. Samples are analyzed for GATA1 mutations by real-time PCR, polymorphisms, cytogenetics, and K-RAS mutations, gene expression, drug sensitivity patterns, and minimal residual disease by flow cytometry.
3233756|NCT00959257||Asthma|Asthma patients on inhaled corticosteroids
3233757|NCT00959257||Control|Select matched controls from the general population database of Cardiovascular Risk Factor Prevalence Study 2 (CRISPS2)
3233758|NCT00959218|Experimental|Dronabinol|
3233759|NCT00959218|Placebo Comparator|Placebo|
3233760|NCT00959205|Active Comparator|Angiography|Conventional fluoroscopically guided activation mapping
3233762|NCT00959192|Experimental|ACC-001 + QS-21|Active vaccine + adjuvant, IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
3233763|NCT00959192|Placebo Comparator|QS-21|Adjuvant, IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
3233764|NCT00959179||Device therapy patients for CHF.|enroll all consecutive patients undergoing implantable cardioverter defibrillator (ICD) and ICD with biventricular pacemaker (CRT-D) implantation for heart failure from in-patient and out-patient referral setting
3233765|NCT00959179||ICD and CRT-D patients|enroll all consecutive patients undergoing implantable cardioverter defibrillator (ICD) and ICD with biventricular pacemaker (CRT-D) implantation for heart failure from in-patient and out-patient referral setting
3233766|NCT00959166||1|HIV positive men with acute HCV infection
3233767|NCT00959166||2|HIV positive men who do not have acute HCV
3233768|NCT00959166||3|Healthy controls
3233769|NCT00959153|Experimental|Kidney stones|Kidney stones
3233770|NCT00959140|Experimental|CD3+ T-cell depletion|CD3+ T-cell depletion
3233771|NCT00959127|Experimental|ARRY-438162 (MEK 162)|
3233772|NCT00959114|Experimental|ALV003|ALV003 is an orally administered mixture of two recombinant proteases (cysteine endoprotease B-isoform 2 and prolyl endopeptidase) engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues common in gluten.
3233773|NCT00959114|Placebo Comparator|Placebo comparator|Excipients for ALV003 absent the experimental compounds
3233774|NCT00959101|Experimental|A|
3233775|NCT00959101|Experimental|B|
3233776|NCT00959101|Active Comparator|C|
3233777|NCT00959088||1|HIV-infected individuals with suspected TB co-infection.
3233778|NCT00959075|Experimental|Oral thiamin supplementation|Vitamin B1 (Oral thiamin) 100mg BID for 6 months
3233779|NCT00959075|Placebo Comparator|Sugar pill|oral placebo 1 tablet BID for 6 months
3233780|NCT00959062|Experimental|clonidine|
3233781|NCT00959062|Placebo Comparator|placebo|
3233782|NCT00959049|Experimental|Afluria Cohort A|Age 6 months to < 3 years
3233783|NCT00959049|Experimental|Afluria Cohort B|Age 3 to < 9 years
3233784|NCT00959049|Experimental|Afluria Cohort C|Age 9 to < 18 years
3233785|NCT00959049|Active Comparator|Fluzone Cohort A|Age 6 months to < 3 years
3233786|NCT00959049|Active Comparator|Fluzone Cohort B|Age 3 to < 9 years
3233787|NCT00959049|Active Comparator|Fluzone Cohort C|Age 9 to < 18 years
3233788|NCT00959036|Experimental|Treatment Group 1|ATN-103 10 mg every 4 weeks until week 12
3233789|NCT00959036|Experimental|Treatment Group 2|ATN-103 10 mg every 8 weeks until week 12
3233790|NCT00959036|Experimental|Treatment Group 3|ATN-103 30 mg every 4 weeks until week 12
3233791|NCT00959036|Experimental|Treatment Group 4|ATN-103 80 mg every 4 weeks until week 12
3233792|NCT00959036|Experimental|Treatment Group 5|ATN-103 80 mg every 8 weeks until week 12
3233793|NCT00959036|Placebo Comparator|Treatment Group 6|Placebo every 4 weeks
3233794|NCT00959010|Experimental|Omega 3 Premium|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA
3233795|NCT00959010|Placebo Comparator|Placebo|capsules containing middle chain triglycerides
3233796|NCT00958997||Type 1 diabetic subjects|Patients with Type 1 diabetes who have a diagnosis of Type 1 diabetes mellitus defined by ADA criteria or judgment of physician
3233797|NCT00958997||Healthy control subjects|Age-weight-BMI matched to the subjects with type-1 diabetes
3233798|NCT00958971|Experimental|TKI258|
3233799|NCT00958958|Other|Quality improvement program|"There are multifaceted Interventions for the clinic hospital team Including~Distribution of educational materials~Case manager~Reminders~Practical training"
3233800|NCT00958958|No Intervention|Hospital standard treatment|Hospital standard treatment
3233801|NCT00958945||FloSeal - Knee - control|100 Historical Control Patients, knees - no FloSeal (retrospective)
3233802|NCT00958945||FloSeal - Knee - 5ml|100 Patients, knees - 5mL FloSeal (retrospective)
3233803|NCT00958945||FloSeal - Knee - 10ml|100 Patients, knees- 10mL FloSeal (prospective)
3233804|NCT00958945||FloSeal - Hip - Control|100 Historical Control patients, hips—no FloSeal (retrospective)
3233805|NCT00958945||FloSeal - Hip - 5ml|100 retrospective patients, hips—5mL of FloSeal (retrospective)
3233806|NCT00958932|Experimental|Speech recognition (TEAM intervention)|
3233807|NCT00958932|Active Comparator|Speech recognition (Usual care)|
3233808|NCT00958919|Experimental|naloxone|
3233809|NCT00958919|Placebo Comparator|normal saline|
3233810|NCT00958906|Experimental|Intravitreal infliximab|
3233811|NCT00958893|Experimental|25 mg Proellex|25 mg Proellex daily
3233812|NCT00958880|Placebo Comparator|Sugar Pill|Participants will receive placebo (sugar pill) augmented Group Cognitive Behavioral Therapy
3233813|NCT00958880|Experimental|Yohimbine Hydrochloride|Participants will receive Yohimbine Hydrochloride augmented Group Cognitive Behavioral Therapy
3233814|NCT00958867|Experimental|1|Six-month, twice-weekly aerobic training (AT) program
3233815|NCT00958867|Experimental|2|Six-month, twice-weekly resistance training (RT) program
3233816|NCT00958867|Active Comparator|3|Six-month, twice-weekly stretch & relax (S & R; control) program
3233817|NCT00958841|Experimental|pasireotide LAR 60mg|Patients received pasireotide LAR at 60 mg approximately once every 28 days for 6 months during the core treatment period and additional treatment cycles up to a total of 48 months during the extension phase.
3233818|NCT00958828|Other|Nelfilcon A / Narafilcon A|Nelfilcon A contact lenses, then Narafilcon A contact lenses
3233819|NCT00958828|Other|Narafilcon A / Nelfilcon A|Narafilcon A contact lenses, then Nelfilcon A contact lenses
3233820|NCT00958815||HIV-seronegative with no CVD risk factors|Healthy, 35-60 yr old HIV-seronegative men and women with no CVD risk factors (normal fasting glucose tolerance, normal fasting lipid/lipoprotein levels, normotensive, waist circumference <102cm (men) and <88cm (women).
3233821|NCT00958815||HIV+ with CVD risk factors|35-60 yr old HIV-infected men and women with insulin resistance, dyslipidemia, hypertension, and central adiposity.
3233822|NCT00958802|Placebo Comparator|Arm A|Chondrocyte culture with FBS medium
3233823|NCT00958802|Experimental|Arm B|Chondrocyte culture with PRP
3233825|NCT00958776|Experimental|Peramivir+SOC|"Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.~Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care."
3233826|NCT00958776|Placebo Comparator|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
3233827|NCT00958763|Experimental|Motivational Interviewing, Single - MIS|
3233828|NCT00958763|Experimental|Motivational Interviewing, Group - MIG|
3233829|NCT00958763|Other|Usual Care Group - UCG|
3233830|NCT00958750|Active Comparator|5% MTF|5% minoxidil topical foam used once daily
3233831|NCT00958750|Active Comparator|2% MTS|2% minoxidil topical solution twice daily use
3233832|NCT00958737|Experimental|Arm I|"Patients receive modified FOLFOX 6 comprising oxaliplatin IV 85 mg/m² over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1. Treatment repeats every 14 days for 6 courses (3 months).~Patients receive XELOX comprising oxaliplatin IV 130 mg/m² over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which will be administered orally at a dose of 1000 mg/m2 twice-daily (equivalent to a total daily dose of 2000 mg/m2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment)"
3233833|NCT00958737|Experimental|Arm II|Patients receive modified FOLFOX 6 or XELOX as in arm I. Treatment repeats every 14 days for 12 courses (6 months)or regarding XELOX every 21 days for 8 courses (6 month).
3233834|NCT00958724|Experimental|Neratinib and Vinorelbine|Neratinib: 240 mg administered daily by mouth continuously, Vinorelbine: 25 mg/m^2 administered IV on Day 1 and 8 of 21 day cycle
3233835|NCT00958711|Experimental|Biologic - Unite Biomatrix|
3233836|NCT00958711|Active Comparator|Saline and Gauze|
3233837|NCT00958698|Experimental|Arm I (nurse-assisted intervention module)|Patients are given password-protected access to their own web-based message board to communicate with a research nurse. The nurse leads patients through WRITE Symptoms? intervention module, with personalized support and advice. The nurse will encourage the patient to try new selected strategies, continue with effective strategies, and work with local health care providers in an ongoing process to improve symptom management.
3233838|NCT00958698|Experimental|Arm II (self-directed intervention module)|Patients are given password-protected access to an interactive web-based computer program that will lead them through a modified WRITE Symptoms? intervention module (comprising the same elements as in arm I) without guidance and individualized recommendations from a nurse. Patients work through 3 selected symptoms using the WRITE Symptoms? intervention module over approximately 4 weeks. The program will generate an encouragement for the patient to try new selected strategies, continue with effective strategies, and continue the new approach to symptom management with local health care providers in an ongoing process to improve symptom management.
3233839|NCT00958698|Active Comparator|Arm III (standard care from local provider)|Patients are given password-protected access to online questionnaires. Patients are prompted monthly to complete online questionnaires. Patients receive standard symptom management from their local health care providers.
3233840|NCT00958685|Experimental|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
3233841|NCT00958685|Experimental|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
3233842|NCT00958659||Ancillary-Correlative (gene expression profiling)|Previously collected samples are analyzed for 59 prognostic genes by real-time quantitative PCR-based gene expression profiling.
3233843|NCT00958646|Experimental|Osteopathic Manipulation|Standardized OMT procedure
3233844|NCT00958646|Placebo Comparator|Placebo|Light touch placebo procedure
3233845|NCT00958633|Active Comparator|8 week arm|"During the double-blind phase, all patients will continue treatment with their anti-manic medication(s)and will be randomized to one of two treatment arms for up to 52 weeks:~Group 1 patients randomized to the 8 week arm will discontinue antidepressant treatment after 8 weeks, as recommended in current clinical practice guidelines. The antidepressant will be tapered in a double-blind manner beginning at 6 weeks, and will be substituted with placebo by 8 weeks.~Escitalopram 10 - 30 mg Wellbutrin XL 150 - 450 mg"
3233846|NCT00958633|Active Comparator|52 week arm|"During the double-blind phase, all patients will continue treatment with their anti-manic medication(s) and will be randomized to one of two treatment arms for up to 52 weeks:~Group 2 patients randomized to the 52 week arm will continue treatment with their antidepressant medication for 52 weeks, or until withdrawal from the study.~Escitalopram 10 - 30 mg Wellbutrin XL 150 - 450 mg"
3233847|NCT00958620|Active Comparator|Active ESWT|
3233848|NCT00958620|Sham Comparator|Sham ESWT|
3233849|NCT00958607|Active Comparator|Self-Directed Program|
3233850|NCT00958607|Active Comparator|Stroke Support Person|
3233851|NCT00958607|No Intervention|Standard Care|"Participants in this arm receive Standard Care which consists of being given a copy of the Heart& Stroke Foundation's stroke resource titled Let's Talk About Stroke"
3233852|NCT00958581|Placebo Comparator|Normal Saline|Patients infused with normal saline before and during the surgical procedure as a placebo.
3233853|NCT00958581|Experimental|Tranexamic acid|Patients receive TXA before and during the surgical case.
3233854|NCT00958581|Experimental|Epsilon Aminocaproic Acid|Patients will receive EACA before and during the surgical case.
3233855|NCT00958568|Experimental|Olanzapine and Fluoxetine combination (OFC)|
3233856|NCT00958568|Active Comparator|Fluoxetine|
3233857|NCT00958542|Experimental|Surgical Arm|Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
3233858|NCT00958542|No Intervention|Non-Surgical Arm|Non-Surgical No intervention - Includes patients who have either refused to have surgery or have not been recommended to have surgery at this point. These patients will continue to be monitored closely, however, will not receive any other intervention.
3233859|NCT00958529|Experimental|inulin|0, 5, 10 g inulin
3233860|NCT00958516|Experimental|LEO 29102 cream|
3233861|NCT00958503|Placebo Comparator|Placebo|Placebo
3233862|NCT00958503|Active Comparator|Thiamphenicol|Active comparator
3233863|NCT00958490|Active Comparator|First walking group|Group walking at 2 months postop
3233864|NCT00958490|Active Comparator|Second group walking|Group walking at 3 months postop
3233865|NCT00958477|Experimental|EMD 525797|
3233866|NCT00958464||1|MRI protocol on 2 separate occasions
3233867|NCT00958451|Active Comparator|Paricalcitol|Arm 1: 40 patients will be assigned to paricalcitol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.
3233868|NCT00958451|Active Comparator|Ergocalciferol|Arm 2: 40 patients will be assigned to the Ergocalciferol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.
3233869|NCT00958438|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept ) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
3233870|NCT00958438|Experimental|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.
3233871|NCT00958438|Experimental|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
3233872|NCT00958425|Experimental|Hyaluronic acid gel|
3233873|NCT00958425|Active Comparator|Saline|
3233874|NCT00958412|Experimental|Proellex®|25 mg Proellex®
3233875|NCT00958399|Placebo Comparator|No fiber|No fiber added to study products
3233876|NCT00958399|Experimental|Resistant Starch|Muffins, cereal, and bars made with a resistant starch
3233877|NCT00958399|Experimental|Resistant starch + soluble fiber|Muffins, cereal, and bars made with a mixture of resistant starch and a soluble fiber
3233878|NCT00958399|Experimental|Fiber made from corn starch|Muffins, cereal, and bars made with novel corn fiber
3233879|NCT00958399|Experimental|Fiber made from corn starch + soluble fiber|Muffins, cereal, and bars made with a mixture of novel corn fiber and a soluble fiber
3233880|NCT00958386|Experimental|1|Panitumumab+irinotecan
3233881|NCT00958360|Experimental|Arm 1|Interdisciplinary Low Vision Rehabilitation: Low vision examination, prescription and dispensing of low vision devices, low vision therapy and homework.
3233882|NCT00958360|Active Comparator|Arm 2|Basic Low Vision Care: Low vision examination, prescription and dispensing of low vision devices without low vision therapy or assigned homework.
3233883|NCT00958347|Other|Omnifit HA Hip Stem|Participants underwent total hip replacement surgery using the Omnifit HA Hip Stem.
3233884|NCT00958334|Experimental|Proellex 25 mg|Proellex® 12.5 mg capsules twice a day
3233885|NCT00958334|Experimental|Proellex 12.5 mg|Proellex® 12.5 mg capsules once a day
3233886|NCT00958334|Placebo Comparator|Placebo|capsule once a day
3233887|NCT00958321|Experimental|3-DCRT|Patients will receive a total dose of 60-66 Gy in 30-33 fractions with 3-DCRT
3233888|NCT00958308|Placebo Comparator|Placebo|Two capsules of placebo (devoid of microorganisms) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
3233889|NCT00958308|Active Comparator|BIO-K+ CL-1285|Two probiotic capsules (BIO-K+ CL-1285®) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
3233890|NCT00958308|Other|BIO-K+ CL-1285® & placebo|One probiotic capsule (BIO-K+ CL-1285®) and one placebo capsule (devoid of microorganisms) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
3233891|NCT00958282|Active Comparator|lisdexamfetamine/Behavior Therapy|lisdexamfetamine 70mg/day plus Behavior Therapy
3233892|NCT00958282|Placebo Comparator|placebo|Placebo Comparator once per day
3233893|NCT00958269|Experimental|dutogliptin (double-blind, placebo-controlled period)|weeks 1-26
3233894|NCT00958269|Experimental|dutogliptin (single-blind, active-controlled period)|weeks 27-52
3233895|NCT00958269|Placebo Comparator|placebo (double-blind, placebo-controlled period)|weeks 1-26
3233896|NCT00958269|Placebo Comparator|placebo (single-blind, active-controlled period)|weeks 27-52
3233897|NCT00958269|Active Comparator|sitagliptin (single-blind, active-controlled period)|weeks 27-52
3233898|NCT00958256|Experimental|Bortezomib with Cyclophosphamide and Rituximab|Bortezomib 1.3 mg/m^2 intravenously (IV) on Days 1, 4, 8, and 11 of the cycle; Cyclophosphamide 300 mg/m^2 IV every 12 hours on Days 2, 3, and 4, and Rituximab 375 mg/m^2 IV on Day 1. Mesna 600 mg/m^2 for 3 days, G-CSF 5 micrograms/kg subcutaneously daily for 7 days after last dose of Bortezomib. Cycles repeated every 21 days for up to six cycles.
3233899|NCT00958243|Placebo Comparator|Placebo|Placebo
3233900|NCT00958243|Experimental|CSL425 (7.5 mcg)|7.5 mcg of hemagglutinin antigen per dose
3233901|NCT00958243|Experimental|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose
3233946|NCT00957970|Active Comparator|Stemmed femoral component|IPS, proximal anatomical fit stemmed femoral component
3233947|NCT00957957||1|Participants having elective Roux-en-Y gastric bypass surgery (RYGBP)
3233902|NCT00958230|Experimental|dCell Vascular Patch|This Xenograft device is manufactured from Porcine Pericardium Tissue which has been decellularised leaving a scaffold style structure for ingrowth of human endothelial cells after placement into the operative site.
3233903|NCT00958217|Experimental|Cognitive Processing Therapy-Modified|12 individually delivered sessions of Cognitive Processing Therapy-Modified (CPT-M) provided once weekly following initial group delivery of 12 sessions of Integrated Cognitive Behavioral Therapy
3233904|NCT00958217|Active Comparator|Integrated Cognitive Behavioral Therapy|12 individually delivered sessions of Integrated Cognitive Behavioral Therapy (ICBT) once weekly following initial group delivery of 12 sessions of ICBT
3233905|NCT00958217|No Intervention|Integrated Cognitive Behavioral Group Therapy|All participants were enrolled in an initial group-delivered Integrated Cognitive Therapy Group, consisting of 12 sessions over approximately 12 weeks prior to randomization to one of the study individually delivered interventions (CPT-M or ICBT). Individuals who were no longer participating in the study at the end of group sessions were not randomized.
3233906|NCT00958204|Experimental|1|Light treatment using a fluorescent light box (30 minutes daily) plus a placebo pill every day
3233907|NCT00958204|Experimental|2|Negative ion generator (30 minutes daily) plus 20 mg of fluoxetine per day
3233908|NCT00958204|Active Comparator|3|Light treatment using a fluorescent light box (30 minutes daily) plus 20 mg of fluoxetine per day
3233909|NCT00958204|Placebo Comparator|4|Negative ion generator (30 minutes daily) plus placebo pill every day
3233910|NCT00958191|Other|Trident® X3 Polyethylene Insert|Participants who received the Trident® X3 Polyethylene Insert.
3233911|NCT00958178|Experimental|Rebreathing method of preoxygenation|Subjects will breathe Oxygen through a close fitting mask, but the flow will be low so that they rebreathe some of their expired air. After 30 seconds, the flow will be turned up so that they will breathe 100% Oxygen.
3233912|NCT00958178|Active Comparator|T method of preoxygenation|Tidal breathing of 100% oxygen through a well fitting facemask, for 4 minutes.
3233913|NCT00958165|Experimental|EAS-AC|PVI with EAS-AC
3233914|NCT00958152|Experimental|Cohort 1|
3233915|NCT00958152|Experimental|Cohort 2|
3233916|NCT00958152|Experimental|Cohort 3|
3233917|NCT00958139|Experimental|Permethrin treatment of clothing|0.5% permethrin sprayed one time on uniform shorts, pants, and socks
3233918|NCT00958139|Sham Comparator|Placebo|Water sprayed on uniform shorts, pants, and socks
3233919|NCT00958126|Experimental|CSL425 (7.5 mcg)|7.5 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
3233920|NCT00958126|Experimental|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
3233921|NCT00958126|Experimental|CSL425 (30 mcg)|30 mcg of hemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
3233922|NCT00958126|Placebo Comparator|Placebo|Vaccine diluent. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
3233923|NCT00958113||Autoimmune Thyroid Disease|Patients with Hashimoto's disease or Graves' disease
3233924|NCT00958113||Unaffected Population|Population not known to be affected by Hashimoto's Disease or Graves' Disease
3233925|NCT00958100|Experimental|Tenofovir Emtricitabine Raltegravir|Patients switching to raltegravir with tenofovir+emtricitabine as backbone
3233926|NCT00958100|Experimental|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
3233927|NCT00958100|Experimental|Abacavir free|Patients switched to raltegravir whose backbone therapy should not be randomized in order to avoid the use of abacavir (HLA-B*5701 positive patients,Framingham score 20% or higher)
3233928|NCT00958087||Sarcoidosis with cardiac involvement|
3233929|NCT00958087||Dilated cardiomyopathy|
3233930|NCT00958087||Sarcoidosis without cardiac involvement|
3233931|NCT00958087||Healthy controls|
3233932|NCT00958074|Experimental|Cohort I (>=65 years old)|200 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
3233933|NCT00958074|Experimental|Cohort II (<65 years old)|400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
3233934|NCT00958061||Vietnam-Era Women Veterans|For this study we will use a cohort of women who are on a roster of Vietnam Era women veterans (4,644 Vietnam, 1,213 near Vietnam, 5,465 non-Vietnam) previously identified and characterized by a review of their military personnel records and link it to a list of 8,061 women who presumably served in Southeast Asia. This final cohort could potentially contain approximately 14,000 women. After deceased individuals are removed from the active cohort and contact information is updated, we estimate that there could be approximately 10,000 women to whom the informed consent and mailed survey will be initially mailed.
3233935|NCT00958048|Experimental|2|ALS with non-invasive ventilation
3233936|NCT00958048|No Intervention|1|ALS without non-invasive ventilation
3233937|NCT00958035|Experimental|LATISSE®|bimatoprost ophthalmic 0.03% solution
3233938|NCT00958035|Placebo Comparator|Placebo|vehicle sterile solution
3233939|NCT00958022|Experimental|LBH589 and carboplatin with etoposide|"The main goal during the Phase I portion of this research study is to find out the highest and safest dose of LBH589 that can be given in combination with carboplatin with etoposide in subjects with lung cancer without causing severe side effects. The main goal of the Phase II portion of this study is to find how lung cancer responds to the LBH589 in combination with carboplatin and etoposide.~This study will also investigate how the body processes the combination of LBH589 and carboplatin with etoposide."
3233940|NCT00957996|Experimental|Peramivir 300 mg|Peramivir 300 mg twice daily
3233941|NCT00957996|Experimental|Peramivir 600 mg|Peramivir 600 mg once daily
3233942|NCT00957983|Active Comparator|BGC20-1531 200mg|
3233943|NCT00957983|Placebo Comparator|sugar pill|
3233944|NCT00957983|Active Comparator|BGC20-1531 400mg|
3233945|NCT00957970|Active Comparator|Stemless femoral component|Stemless PROXIMA femoral component
3233995|NCT00957580|Experimental|Regimen 1 (Part 2)|
3233948|NCT00957957||2|Participants having elective gastric banding surgery (GB)
3233949|NCT00957944|Experimental|Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)|Two single applications of rotigotine patches from two different manufacturing sites in the order A-B separated by a washout phase of at least 5 days
3233950|NCT00957944|Experimental|Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)|Two single applications of rotigotine patches from two different manufacturing sites in the order B-A separated by a washout phase of at least 5 days
3233951|NCT00957931|Experimental|Mesenchymal stromal cells|
3233952|NCT00957918|Experimental|Nicotine|Active drug is nicotine dihydrate bitartrate, provided as an oral capsule at escalating doses, 1 mg to 6 mg, once every 6 hours
3233953|NCT00957918|Placebo Comparator|placebo|Subjects in this arm receive placebo capsules orally
3233954|NCT00957905|Experimental|Part A (alvocidib and oxaliplatin)|Patients receive alvocidib IV over 1 hour and oxaliplatin IV over 2 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3233955|NCT00957905|Experimental|Part B (alvocidib and FOLFOX)|Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours followed by fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3233956|NCT00957879|Active Comparator|ergocalciferol|Weekly ergocalciferol for 12 weeks
3233957|NCT00957879|Active Comparator|calcitriol|Daily calcitriol for 12 weeks
3233958|NCT00957853|Experimental|Group 1: Cetuximab|Cetuximab: 400 mg/m2 i.v. over 120 minutes on week 1, and 250 mg/m2 on week 2 and 3 i.v. over 60 minutes
3233959|NCT00957853|Experimental|Group 2: IMC-A12|IMC-A12: 6 mg/kg/week i.v. over 1 hour on weeks 1 and 2 and 3.
3233960|NCT00957853|Experimental|Group 3: Cetuximab + IMC-A12|"Cetuximab: 400 mg/m2 i.v. over 120 minutes on week 1, and 250 mg/m2 on week 2 and 3 i.v. over 60 minutes.~IMC-A12: 6 mg/kg/week i.v. over 1 hour on weeks 1 and 2 and 3."
3233961|NCT00957840|Other|Omaya reservoir group- observational|These infants have been identified with severe enough post hemorrhagic ventricular dilation (PHVD) that they require a reservoir placed for serial cerebro-spinal fluid (CSF) removal. There is no randomization, and infants are compared to a baseline. Observational data will be collected to include NIRS and aEEg which will be done twice weekly, and CSF will be analyzed with each reservoir tap for protein biomarkers.
3233962|NCT00957827|Experimental|keflex|keflex 500mg twice a day for five days
3233963|NCT00957827|Placebo Comparator|placebo|
3233964|NCT00957814|Experimental|Control|Usual care with medical and nursing staff
3233965|NCT00957814|Experimental|Intervention|Usual care with medical and nursing staff and additional nutritional guidance about diet and its relationship with disease, sources of nutrients, and reduction of dietary sodium and fats. Enforcement of the nutritional guidance was performed after 4 weeks.
3233966|NCT00957801|Active Comparator|Testosterone injection|Testosterone enanthate given as a single 100 mg Intramuscular (IM) injection
3233967|NCT00957801|Active Comparator|Testosterone gel|Testosterone topical gel (Androgel 1%) 10 mg administered daily for seven days
3233968|NCT00957801|Active Comparator|Testosterone injection and Medrol 6 day dose pack|Testosterone enanthate given as a single 100mg Intramuscular (IM) injection. Medrol 6 day dose pack was administered as directed with daily doses decreasing by 4mg per day with an additional 4mg given on day 7. Day one dose: 24mg, day two dose: 20mg, day three dose: 16mg, day four dose: 12mg, day five dose: 8mg, day six dose: 4 mg, day seven dose: 4mg.
3233969|NCT00957801|Active Comparator|Medrol 6 day dose pack|Medrol 6 day dose pack was administered as directed with daily doses decreasing by 4mg per day with an additional 4mg given on day 7. Day one dose: 24mg, day two dose: 20mg, day three dose: 16mg, day four dose: 12mg, day five dose: 8mg, day six dose: 4 mg, day seven dose: 4mg.
3233970|NCT00957788|Experimental|Cohort 0|
3233971|NCT00957788|Experimental|Cohort 1|
3233972|NCT00957788|Experimental|Cohort 2|
3233973|NCT00957788|Experimental|Cohort 3|
3233974|NCT00957775|Active Comparator|Usual care|Participants will receive the usual care (e.g., individual therapy, group therapy, self-help groups) provided at the treatment site.
3233975|NCT00957775|Experimental|Computer-delivered ACRA|Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
3233976|NCT00957762||Body Composition|120 subjects will help create the regression models. The remaining 50 subjects will be recruited to determine if the equations work for the population.
3233977|NCT00957749|Experimental|cPMP|
3233978|NCT00957736||Allogeneic stem cell transplant|Stem cells from a genetically non-identical donor transplanted into a patient.
3233979|NCT00957723|Other|Triathlon® CR Total Knee System|Participants receive the Triathlon® CR Total Knee System
3233980|NCT00957710|Other|langauge therapy|Naming therapy
3233981|NCT00957684|Experimental|ESL 400 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
3233982|NCT00957684|Experimental|ESL 800 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
3233983|NCT00957684|Experimental|ESL 1200 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
3233984|NCT00957684|Placebo Comparator|placebo|Placebo matching tablets
3233985|NCT00957684|Experimental|ESL - PART II|During Part II of the study all patients received Eslicarbazepine Acetate (ESL), including those who had been treated with placebo during Part I. ESL was supplied as scored 800 mg tablets; once daily administration by oral route.
3233986|NCT00957671|Experimental|Human Growth Hormone|recombinant human growth hormone (rhGH) self administered daily for one year
3233987|NCT00957658|Other|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem Study Device
3233988|NCT00957619|Active Comparator|pentoxyfilline group|pentoxyfilline group
3233989|NCT00957619|Placebo Comparator|placebo group|placebo group
3233990|NCT00957593|Active Comparator|Oxytocin|Continuation of oxytocin per protocol once the patient reaches active labor
3233991|NCT00957593|Active Comparator|Oxytocin discontinuation|Oxytocin will be stopped once the patient reaches active labor
3233992|NCT00957580|Experimental|Regimen 1 (Part 1)|
3233993|NCT00957580|Experimental|Regimen 2 (Part 1)|
3233994|NCT00957580|Experimental|Regimen 3 (Part 1)|
3233996|NCT00957580|Experimental|Regimen 2 (Part 2)|
3233997|NCT00957554|Experimental|irbesartan/amlodipine|Before randomisation: irbesartan 150 mg for 7 to 10 days (common in the 2 arms) then After randomisation: irbesartan/amlodipine 150/5 mg fixed combination for 5 weeks followed by irbesartan/amlodipine 300/5 mg fixed combination for additional 5 weeks
3233998|NCT00957554|Active Comparator|irbesartan|Before randomisation: irbesartan 150 mg for 7 to 10 days (common in the 2 arms) then After randomisation: irbesartan 150 mg for 5 weeks followed by irbesartan 300 mg for 5 additional weeks
3233999|NCT00957541|Experimental|CRT Therapy|All patients will receive CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
3234000|NCT00957528|Placebo Comparator|Placebo|Weekly placebo treatment for a duration of 5 months.
3234001|NCT00957528|Experimental|Monthly Cycled Testosterone|A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.
3234002|NCT00957528|Experimental|Continuous Testosterone|Weekly testosterone treatment for a duration of 5 months
3234003|NCT00957502|Experimental|One year aged staples|Subjects implanted with sterile staples aged to approximately one year.
3234004|NCT00957502|Experimental|18 month aged staples|Subjects implanted with sterile staples aged to approximately 18 months.
3234005|NCT00957489|Experimental|Functional appliance|
3234006|NCT00957476|Active Comparator|Omega-3 Fish Oil|800mg DHA & 1200mg EPA
3234007|NCT00957476|Placebo Comparator|Placebo|Wheat germ oil
3234008|NCT00957463||smoker, with high apnea-hypopnea index|subjects who smoke either in the past or currently, with confirmed moderate-severe OSA
3234009|NCT00957463||smoker, mild OSA or without OSA|subjects who smoke either in the past or currently, with mild OSA or without OSA
3234010|NCT00957463||nonsmoker, with high apnea-hypopnea index|subjects who never smoke, with confirmed moderate-severe OSA
3234011|NCT00957463||nonsmoker, with mild OSA or without OSA|subjects who never smoke, with mild OSA or without OSA
3234012|NCT00957450||1|"Impact of organ motion~Characterize the impact of normal organ motion in the pelvic on tumour movement, during treatment. This will be assessed in patients with pelvic cancer."
3234013|NCT00957437|Experimental|Part A: 3 way crossover|AZD1305: ER test formulation 1 (w/wo food) and reference formulation
3234014|NCT00957437|Experimental|Part B1: single arm|AZD1305: ER test formulation 1
3234015|NCT00957437|Experimental|Part B2: 3 way crossover|AZD1305: ER test formulation 2 (w/wo food) and reference formulation
3234016|NCT00957424|Other|Overall|Single-armed study
3234017|NCT00957411|Active Comparator|Arm I|Patients receive cisplatin IV over 1 hour once weekly during weeks 1-6. Patients also undergo pelvic radiotherapy 5 days a week during weeks 2-5 or 2-6.
3234018|NCT00957411|Experimental|Arm II|Patients receive cisplatin and undergo radiotherapy as in arm I. Patients also receive cetuximab IV over 1 hour once weekly during weeks 1-6.
3234019|NCT00957398||IBS-D|12 IBS-D patients who will all undergo MTS.
3234020|NCT00957398||IBS-C|12 IBS-C patients who will all undergo MTS.
3234021|NCT00957385|Active Comparator|A|Arm A will receive Revlimid.
3234022|NCT00957385|No Intervention|B|Arm B will not receive Revlimid but an observational arm
3234023|NCT00957372|Experimental|ESL 800 mg daily (Part I)|ESL 800mg daily
3234024|NCT00957372|Experimental|ESL 1200 mg daily (Part I)|ESL 1200mg daily
3234025|NCT00957372|Placebo Comparator|placebo (Part I)|placebo
3234026|NCT00957372|Experimental|ESL - Open-label Extension (Part II)|All patients were treated with only ESL during Part II.
3234027|NCT00957359|Experimental|Psilocybin|Drug intervention
3234028|NCT00957359|Active Comparator|Niacin|Active control
3234029|NCT00957346|Experimental|Mifepristone + Misoprostol|200 mg mifepristone followed by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
3234030|NCT00957346|Placebo Comparator|Misoprostol|Placebo resembling 200mcg mifepristone followed by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses
3234031|NCT00957333||case|ketamine + Cystitis
3234032|NCT00957320|Experimental|1|"Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL. The dose of sirolimus will be dose escalated following standard phase 1 statistical methods.~For patients with active CNS leukemia, intrathecal methotrexate, hydrocortisone and cytarabine (triple IT) will be administered weekly, with leucovorin rescue at the treating physician's discretion."
3234033|NCT00957294||Schizophrenia|Patients with first-episode schizophrenia age 18-45 years
3234034|NCT00957294||Depression|First-time hospitalized patients with depression age 18-45 years
3234035|NCT00957294||healthy controls|Healthy controls matched on age and gender (18-45 years)
3234036|NCT00957281||Asthma|Asthma patients on inhaled corticosteroids
3234037|NCT00957268|Experimental|Alogliptin 12.5 mg (age 10 to < 14 years)|Alogliptin 12.5 mg, tablets, orally, 1 dose only.
3234038|NCT00957268|Experimental|Alogliptin 25 mg (age 10 to < 14 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
3234039|NCT00957268|Experimental|Alogliptin 12.5 mg (age 14 to < 18 years)|Alogliptin 12.5 mg, tablets, orally, 1 dose only.
3234040|NCT00957268|Experimental|Alogliptin 25 mg (age 14 to < 18 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
3234041|NCT00957268|Experimental|Alogliptin 25 mg (age 18 to 65 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
3234042|NCT00957255|Active Comparator|RCR without augmentation|Rotator cuff repair without OrthoADAPT augmentation
3234043|NCT00957255|Experimental|RCR with augmentation|Rotator cuff repair with OrthoADAPT augmentation
3234044|NCT00957242|Active Comparator|warfarin|Oral warfarin titrated to an international normalization ratio (INR) of 2-3
3234045|NCT00957242|Placebo Comparator|placebo|Oral placebo (1mg or 2.5mg)
3234046|NCT00957229|Placebo Comparator|Sugar pill|placebo pill by mouth once daily
3234047|NCT00957229|Experimental|GDC-0449|vismodegib 150MG by mouth once daily
3234048|NCT00957216|Placebo Comparator|sugar pill|
3234049|NCT00957216|Active Comparator|Coenzyme Q10|The CoQ10 arm will be compared with the placebo arm to determine if high-dose CoQ10 is safe and well tolerated in subjects with sporadic adult-onset spinocerebellar ataxias
3234050|NCT00957203|Experimental|Istradefylline|
3234051|NCT00957190|Experimental|Cosopt|Cosopt ('Dorzolamide 20 mg and Timolol 5 mg) bid And Xalatan hs Vs Xalatan hs Alone
3234052|NCT00957177|Placebo Comparator|Placebo|Placebo
3234053|NCT00957177|Active Comparator|Pregabalin group|Receiving 300mg pregabalin preoperative
3234054|NCT00957164|Active Comparator|Pain Treatment Only|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
3234055|NCT00957164|Active Comparator|PTSD Treatment Only|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
3234056|NCT00957164|Active Comparator|Combined Pain and PTSD Treatment|This treatment arm will involve 5 sessions each of the Pain-Only and PTSD-Only treatments described above.
3234057|NCT00957164|No Intervention|Treatment as Usual|The treatment as usual group will complete the assessments given in each of the other study arms, but will not participate in treatment through the study. Instead, participants randomized to this group will be encouraged to seek treatment for pain and/or PTSD through existing channels. Referrals for treatment will be made for those with clinically significant symptoms for pain and/or PTSD at intake.
3234058|NCT00957125|Experimental|Epirubicin Docetaxel Bevacizumab|"Epirubicin and docetaxel i.v. infusion q 3 weeks for 2 cycles.~If complete response this treatment continues for 4 cycles, totally 6 cycles.~If partial response or stable disease, epirubicin and docetaxel and bevacizumab i.v. infusion q 3 weeks for 4 cycles.~If progressive disease after the first 2 cycles individualized treatment."
3234059|NCT00957112|Experimental|Arm I|Patients undergo a 20-minute acupuncture session once a week for 6 weeks. Patients also receive written information about fatigue and its possible management.
3234060|NCT00957112|No Intervention|Arm II|Patients receive standard care. They also receive written information about fatigue as in arm I.
3234061|NCT00957112|Experimental|Arm A|Patients receive treatment as in arm I for 4 more weeks.
3234062|NCT00957112|No Intervention|Arm B|Patients receive standard care as in arm II for 4 more weeks.
3234063|NCT00957112|Experimental|Arm C|Patients learn to self-acupuncture and do so weekly for 4 more weeks.
3234064|NCT00957099||Imaging|Women diagnosed with breast cancer having pre-treatment MRI for spread of disease
3234065|NCT00957086|Active Comparator|Nimotuzumab|Comprising Adjuvant Cisplatin, Concurrent RT and Nimotuzumab
3234066|NCT00957086|Placebo Comparator|Placebo|Comprising Adjuvant Cisplatin, Concurrent RT and Placebo
3234067|NCT00957073|Experimental|Rheos Device|Rheos Baroreflex Activation System
3234068|NCT00957073|Active Comparator|Medical Management|Medical Management Therapy
3234069|NCT00957060|Experimental|glimepiride|The initial dose is 2 mg once a day. At week 2, the dose can be increased to 4 mg once a day according to the titration. At week 4 and 12, the dose can be increased from 2 mg to 4 mg or from 4 mg to 6 mg according to the titration.
3234070|NCT00957060|Active Comparator|sitagliptin|100 mg once a day. The dose will not be titrated.
3234071|NCT00957047|Experimental|ESL 400 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 400 mg tablets for Part I
3234072|NCT00957047|Experimental|ESL 800 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 800-mg tablets for Part I
3234073|NCT00957047|Experimental|ESL 1200 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 400-mg and 800-mg tablets for Part I
3234074|NCT00957047|Placebo Comparator|placebo|Placebo tablets matching the 400-mg and 800-mg active substance tablets were supplied
3234075|NCT00957047|Experimental|ESL - Part II|All patients in Part II (Open-label Extension ) received ESL on an open-label basis, starting at 800 mg once daily.
3234076|NCT00957034|Placebo Comparator|placebo|placebo patch
3234077|NCT00957034|Experimental|300 µg/day testosterone|300 micrograms/day transdermal testosterone patch
3234078|NCT00957034|Experimental|450 µg/day testosterone|450 micrograms/day transdermal testosterone patch
3234079|NCT00957021|Other|Triathlon® PS Total Knee System|Triathlon® PS Total Knee System
3234080|NCT00957008|Experimental|A - GWL|Group Weight Loss Program (GWL) - Participants in this group attended a 14-session group weight loss program administered by trained facilitators plus 6 one-on-one telephone sessions with a facilitator.
3234081|NCT00957008|Experimental|B - GWL+SWA|Group weight loss program plus use of the Senseware Armband - Participants in this group attended a 14-session group weight loss program administered by trained facilitators plus 6 one-on-one telephone sessions with a facilitator and wore a SenseWear Armband. The SenseWear system includes the Armband, a real-time display device, and a personalized Weight Management Solutions web account. Participants received training in using the Armband and were asked to wear it at least 16 hours per day.
3234082|NCT00957008|Experimental|C - SWA Alone|Use of the senseware armband alone program - The intervention for the SWA Alone group was the SenseWear system includes the Armband, a real-time display device, and a personalized Weight Management Solutions web account. Participants received training in using the Armband and were asked to wear it at least 16 hours per day.
3234083|NCT00957008|No Intervention|D - Standard Care|Standard Care - Participants in this group received a self-directed weight loss manual that focused on cognitive and behavior change principles and learning activities based on Active Living Every Day and Healthy Eating Every Day
3234084|NCT00956969|Experimental|Anger awareness and expression|Training for anger awareness and expression
3234085|NCT00956969|Active Comparator|Relaxation Training|Teach patients relaxation training
3234086|NCT00956969|No Intervention|No-treatment control|Assessment only control condition
3234087|NCT00956956|Experimental|PF-04455242 treatment|
3234088|NCT00956956|Placebo Comparator|Placebo|
3234089|NCT00956943|Active Comparator|21mg transdermal nicotine + placebo patch|21mg transdermal nicotine + placebo patch
3234090|NCT00956943|Experimental|42mg transdermal nicotine|42mg transdermal nicotine
3234091|NCT00956930|Experimental|Arm I (radioembolization)|Patients undergo radioembolization with yttrium Y 90 glass microspheres by hepatic artery infusion for approximately 1-3 courses.
3234092|NCT00956930|Experimental|Arm II (transarterial chemoembolization [TACE])|Patients undergo TACE with mitomycin C, doxorubicin hydrochloride, and cisplatin by hepatic artery infusion for approximately 1-3 courses.
3234093|NCT00956917|Active Comparator|Akern EFG|
3234094|NCT00956917|Active Comparator|RJL device|
3234095|NCT00956904|Experimental|3-D TRUS navigation software during T-RALP|
3234096|NCT00956891||group A|autologous MSCs transplantation were performed plus medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin)
3234097|NCT00956891||group B|only medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin) were performed without autologous MSCs transplantation.
3234098|NCT00956878||Cancer Pain Patients|
3234099|NCT00956865|Active Comparator|Voucher|Voucher for transportation reimbursement
3234100|NCT00956865|Active Comparator|Voucher and call|Voucher for transportation and telephone calls
3234101|NCT00956865|Active Comparator|Voucher and call and contact|Voucher for transportation, telephone calls, and a contact at the senior center
3234102|NCT00956852||Lung cancer|Non-small cell lung cancer patients undergoing surgical lung resections
3234103|NCT00956839|Active Comparator|Group A|IM Vitamin D3 3,00,000 Units single dose
3234104|NCT00956839|Active Comparator|Group B|IM vitamin D3 6,00,000 Units single dose
3234105|NCT00956839|Active Comparator|Group C|Oral vitamin D3 500 Units/ day
3234106|NCT00956826|Experimental|Electrode added to device|With an electrode and a regular vacuum device
3234107|NCT00956813|Experimental|Arm I|Patients receive oral flaxseed in the form of a bar similar to a granola bar once daily.
3234108|NCT00956813|Placebo Comparator|Arm II|Patients receive oral placebo bar once daily.
3234109|NCT00956800|Experimental|telemedicine/study group|
3234110|NCT00956800|Active Comparator|control group|
3234111|NCT00956787|Experimental|Treatment with AR-67|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days.
3234112|NCT00956774|Active Comparator|Balloon Catheter|
3234113|NCT00956774|Active Comparator|Cervical Vacuum Cup|
3234114|NCT00956774|Active Comparator|acorn-tipped cannula|
3234115|NCT00956761|Experimental|1|
3234116|NCT00956748|Active Comparator|Ciprodex otic solution|ciprofloxacin 0.3% / dexamethasone 0.1% otic solution
3234117|NCT00956748|Experimental|Ciprodex with 2% NAC|Ciprodex otic solution (ciprofloxacin 0.3% / dexamethasone 0.1%) augmented with 2% N-acetylcysteine
3234118|NCT00956735|Experimental|Pistachio Diet|Incorporates 3.0 oz (2 servings) of pistachios into a daily diet
3234119|NCT00956735|No Intervention|Non-Pistachio|Does not incorporate pistachios into a daily diet
3234120|NCT00956722|Experimental|Treatment|Active treatment with Bovine colostrum
3234121|NCT00956709|Active Comparator|Levobupivacaïne 0,5 %|
3234122|NCT00956709|Active Comparator|Ropivacaïne 0,5%|
3234123|NCT00956696||Topiramte|single arm, flexible dosing
3234124|NCT00956683|Experimental|Ultrasound|Ultrasound guided infraclavicular block
3234125|NCT00956683|Active Comparator|Dual Endpoint Nerve Stimulator|Nerve stimulator guided dual endpoint infraclavicular block
3234126|NCT00956670|Experimental|Supportive care (lymphedema assessment)|"Patients with vulvar cancer undergo a radical vulvectomy or hemi-vulvectomy followed immediately by an ipsilateral or bilateral inguinal-femoral lymphadenectomy. (Closed to accrual as of June 9, 2014)~Patients with cervical cancer undergo a radical hysterectomy or trachelectomy and bilateral pelvic lymphadenectomy +/- para-aortic nodal sampling via vaginal, laparoscopic, or open route.~Patients with endometrial cancer undergo a laparoscopic-assisted vaginal hysterectomy, a total laparoscopic hysterectomy, or total abdominal hysterectomy with pelvic lymphadenectomy +/- para-aortic node sampling.~Patients undergo limb measurements at baseline, weeks 4-6, and at 3, 6, 9, 12, 18, and 24 months."
3234127|NCT00956644|Experimental|irbesartan/amlodipine|Before randomisation : amlodipine 5 mg for 7 to 10 days (common to 2 arms) then After randomisation : irbesartan/amlodipine 150/5 mg fixed combination for 5 weeks followed by irbesartan/amlodipine 150/10 mg fixed combination for 5 additional weeks
3234128|NCT00956644|Active Comparator|amlodipine|Before randomisation : amlodipine 5 mg for 7 to 10 days (common to 2 arms) then After randomisation : amlodipine 5 mg for 5 weeks followed by amlodipine 10 mg for 5 additional weeks
3234129|NCT00956631|Other|interlaminar decompression|Commercially available product (mild® Device Kit) used to perform interlaminar decompression
3234130|NCT00956605|Experimental|EEG biofeedback intervention|
3234131|NCT00956605|Active Comparator|Non EEG biofeedback computerized attention training|
3234132|NCT00956605|No Intervention|waitlist control|
3234133|NCT00956592|Active Comparator|CMAC Video laryngoscope|Subjects will have their intubation attempted first with the CMAC video laryngoscope
3234134|NCT00956592|Active Comparator|Macintosh blade|Patients will have their first intubation attempted utilizing the conventional Macintosh design laryngoscope blade
3234135|NCT00956579||1|Participants with a neurodevelopmental disorder.
3234136|NCT00956579||2|Participants WITHOUT a neurodevelopmental disorder.
3234137|NCT00956566|Active Comparator|low fat hypocaloric diet|
3234138|NCT00956566|Active Comparator|Low carbohydrate hypocaloric diet|
3234139|NCT00956553|Active Comparator|Cervarix|Three doses of Cervarix at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.
3234140|NCT00956553|Active Comparator|Gardasil|Three doses of Gardasil at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.
3234188|NCT00956202|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Influenza vaccine formulation 3
3234189|NCT00956189|Experimental|Amisulpride|A slow plateau cross-titration method was used to switch original antipsychotics to Amisulpride.
3234141|NCT00956540|Experimental|Deflating|Deflating tracheal cuff (total air suction under negative pressure using a syringe) during periods of disconnection from mechanical ventilation in the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support. During ventilatory support the tracheal cuff remain pressurized (30 mmHg).
3234142|NCT00956540|No Intervention|Not deflating|The tracheal cuff remain inflated all the time during the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support
3234143|NCT00956540|Experimental|Deflating 2|Deflating tracheal cuff during periods of disconnection from mechanical ventilation in the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate mange the airway.
3234144|NCT00956540|No Intervention|Not deflating 2|The tracheal cuff remain inflated all the time during the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate mange the airway.
3234145|NCT00956527|Experimental|Modified traditional martial arts training|"Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in at risk youth) and how these issues relate to martial arts concepts."
3234146|NCT00956514|Experimental|Transcranial Magenetic Stimulation|All subjects will be assigned to active, open-label treatment with the NeuroStar TMS System for 6 weeks (30 treatment sessions).
3234147|NCT00956488|Experimental|supported treadmill ambulation training|
3234148|NCT00956462|Experimental|NSAID|
3234149|NCT00956462|Active Comparator|Steroids|
3234150|NCT00956449|Experimental|1|
3234151|NCT00956436|Experimental|Sorafenib Monotherapy|Sorafenib Monotherapy
3234152|NCT00956436|Experimental|Sorafenib with BIIB022|Sorafenib with BIIB022
3234153|NCT00956423|Experimental|moderate-intensity exercise training|
3234154|NCT00956423|Active Comparator|low-intensity stretching|
3234155|NCT00956410|Experimental|CAD106|
3234156|NCT00956397|Active Comparator|Control Participants|
3234157|NCT00956397|Active Comparator|FD Participants|
3234158|NCT00956397|Placebo Comparator|FD (Placebo) Participants|
3234159|NCT00956384|Experimental|One-stage dermal matrix/implant|One-stage breast reconstruction with dermal matrix and implant
3234160|NCT00956384|Active Comparator|Two-stage tissue expander/implant|Two-stage breast reconstruction with tissue expander and implant
3234161|NCT00956371|Placebo Comparator|P|
3234162|NCT00956371|Experimental|E|
3234163|NCT00956358||Pre-HSCT|Haematological conditions requiring haemopoietic stem cell transplantation
3234164|NCT00956358||Post-HSCT with BOS|Occurence of bronchiolitis obliterans syndrome after haemopoietic stem cell transplantation
3234165|NCT00956358||Control|Healthy HSCT donors
3234166|NCT00956345|Experimental|25U/kg|
3234167|NCT00956345|Experimental|50U/kg|
3234168|NCT00956345|Experimental|100U/kg|
3234169|NCT00956332|Experimental|MGA - Low therapeutic dose|
3234170|NCT00956332|Experimental|MGA - Intermediate therapeutic dose|
3234171|NCT00956319|Experimental|Zolpidem group|
3234172|NCT00956319|Active Comparator|Estazolam group|
3234173|NCT00956306|Experimental|Child-Pugh A|
3234174|NCT00956306|Experimental|Child-Pugh B|
3234175|NCT00956306|Experimental|Healthy Volunteers|
3234176|NCT00956293|Active Comparator|Control group|During the pre-randomized treatment phase, all participants received a CNI-based regimen consisting of basiliximab, mycophenolic acid (MPA), cyclosporin A (CsA) and corticosteroids (optional). Upon randomization, participants in this group continued with a CNI-based regimen of MPA and CsA.
3234177|NCT00956293|Experimental|Everolimus group|During the pre-randomized treatment phase, all participants received a CNI-based regimen consisting of basiliximab, mycophenolic acid (MPA), cyclosporin A (CsA) and corticosteroids (optional). Upon randomization, participants in this group made a stepwise switch to a CNI-free regimen of everolimus and MPA.
3234178|NCT00956267|Experimental|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
3234179|NCT00956267|Active Comparator|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
3234180|NCT00956254|Experimental|Fentanyl sublingual spray 100 µg|Participants received a single administration of fentanyl sublingual spray 100 µg sublingually.
3234181|NCT00956241|Other|j-pouch coloanal anastomosis|although a j-pouch coloanal anastomosis is a common type of anastomosis, a comparison with the side-to-end has not been made.
3234182|NCT00956241|Other|side-to-end coloanal anastomosis|in the Netherlands, the side-to-end anastomosis is the standard procedure to perform an anastomosis in case of rectal resection. therefore, the side-to-end group was our control group
3234183|NCT00956228|Experimental|Radioimmunoguided IMRT|All patients recieved Intensity Modulated Radiotherapy to the prostate with 75.6 Gy in 42 fractions. Additionally, they recieve a concurrent boost to the region of the prostate which enhanced on the prostascint scan to 82 Gy.
3234184|NCT00956215|Active Comparator|80mg of Aprepitant|Patients will be randomized to receive 80mg of Aprepitant with 50 ml of water no later than 30 minutes before induction of anesthesia.
3234185|NCT00956215|Placebo Comparator|80 mg of placebo|. Patients will be randomized to placebo with 50 ml of water no later than 30 minutes before induction of anesthesia.
3234186|NCT00956202|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 Influenza vaccine formulation 1 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
3234187|NCT00956202|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 Influenza vaccine formulation 2 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
3234837|NCT00951392|Experimental|successful aging|
3234190|NCT00956189|Experimental|Aripiprazole|A slow plateau cross-titration method was used to switch original antipsychotics to Aripiprazole.
3234191|NCT00956176|Experimental|Cidofovir|
3234192|NCT00956163|Experimental|Diagnostic (fluorine F 18 sodium fluoride PET)|Patients undergo technetium Tc 99m methylene diphosphonate bone scan, fluorine F 18 sodium fluoride PET/CT scan, and whole-body MRI for the detection of bone metastases. Patients with discordant imaging results (negative bone scan and positive PET/CT scan and/or MRI) undergo additional imaging at 6, 12, 18, and 24 months.
3234193|NCT00956150|Active Comparator|60 GWS Rifaximin|
3234194|NCT00956150|Placebo Comparator|60 GWS Placebo|
3234195|NCT00956150|Experimental|Healthy Control|Patient is a healthy control and will not be on study intervention. Asked to perform Lactulose Breath Test to compare results with GWS patients.
3234196|NCT00956137|Experimental|Ultrasound|Use of ultrasound to identify vertebral interspaces for needle insertion.
3234197|NCT00956137|Active Comparator|Palpation|Use of manual palpation to identify vertebral landmarks and vertebral interspaces for needle insertion.
3234198|NCT00956124||uveitic patients|
3234199|NCT00956124||patients with diabetes|
3234200|NCT00956111|Experimental|split-virion, adjuvanted H1N1 vaccine of 7.5 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
3234201|NCT00956111|Experimental|split-virion, adjuvanted H1N1 vaccine of 15 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
3234202|NCT00956111|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
3234203|NCT00956111|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
3234204|NCT00956111|Experimental|whole-virion, adjuvanted H1N1 vaccine of 5 μg|100 adults to receive whole-virion, adjuvanted H1N1 vaccine of 5 μg on day 0 and 21.
3234205|NCT00956111|Experimental|whole-virion, adjuvanted H1N1 vaccine of 10 μg|"200 participants: 100 adults to receive whole-virion, adjuvanted H1N1 vaccine of 10 μg on day 0 and 21.~100 elders to receive whole-virion, adjuvanted H1N1 vaccine of 10 μg on day 0 only."
3234206|NCT00956111|Placebo Comparator|Placebo control|100 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
3234207|NCT00956098|Placebo Comparator|placebo|
3234208|NCT00956098|Experimental|oltipraz|
3234209|NCT00956085|Experimental|Memantine|Open label memantine titrated in 5mg increments weekly to target dose of 10mg po bid for up to 6 weeks. Memantine was continued to 12 weeks in those with treatment response,13 either previous response to ketamine (≥ 35% Y-BOCS reduction 1 week after IV ketamine) or current response to memantine (≥ 35% Y-BOCS reduction from pre- to post-6 weeks of memantine).
3234210|NCT00956072|Experimental|Arm I|Patients undergo surgery of residual disease.
3234211|NCT00956072|Active Comparator|Arm II|Patients receive imatinib mesylate therapy according to standard of care.
3234212|NCT00956059|Experimental|prednisone, MMF and FK506|
3234213|NCT00956059|Active Comparator|prednisone|
3234214|NCT00956046|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 Influenza vaccine formulation 1 at Visits 1 and 2; and a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
3234215|NCT00956046|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 Influenza vaccine formulation 2 at Visits 1 and 2; and a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
3234216|NCT00956046|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Influenza vaccine formulation 3
3234217|NCT00956033||Patients with multiple myeloma|
3234218|NCT00956020|Experimental|Treatment|Skin injection with platelet rich fibrin matrix on the inner aspect of the upper arm, with biopsies over a period from 30 minutes to 12 weeks after treatment.
3234219|NCT00956007|Active Comparator|Arm I: Intensity-Modulated Radiotherapy|Patients undergo intensity-modulated radiotherapy (IMRT) once daily 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
3234220|NCT00956007|Experimental|Arm II: IMRT plus cetuximab|Patients undergo IMRT as in arm I. Patients also receive cetuximab IV over 1-2 hours once weekly beginning at least 5 days prior to the start of IMRT and continuing for 4 weeks after the completion of IMRT (for a total of 11 doses) in the absence of disease progression or unacceptable toxicity.
3234221|NCT00955981|Experimental|RDEA594 200 mg qd for 28 days|
3234222|NCT00955981|Experimental|RDEA594 200 mg, 400 mg|RDEA594 200 mg qd for 7 days followed by 400 mg qd for 21 days
3234223|NCT00955981|Experimental|RDEA594 200 mg, 400 mg and 600 mg|RDEA594 200 mg qd for 7 days followed by 400 mg qd for 7 days followed by 600 mg qd for 14 days
3234224|NCT00955981|Placebo Comparator|Matching placebo|RDEA594 matching placebo qd for 28 days
3234225|NCT00955968|Experimental|Continue HAART|Continue receiving HAART within 0-42 days after delivery or other pregnancy outcome.
3234226|NCT00955968|Active Comparator|Stop HAART|Stop receiving HAART within 0-42 days after delivery or other pregnancy outcome and resume HAART when protocol specified criteria were met.
3234227|NCT00955955|Experimental|6(S)-5-MTHF(Deplin)|"Participants will receive 15 mg/day of Deplin, a medical food, for 8 weeks.~The SPCD approach, is modified and conducted as follows:~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
3234313|NCT00955305|Experimental|Arm B (CPB+cixutumumab)|Patients receive carboplatin, paclitaxel, and bevacizumab as in Arm A. Patients also receive cixutumumab (IMC-A12) IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Treatment with bevacizumab and cixutumumab may continue in the absence of disease progression or unacceptable toxicity.
3234314|NCT00955292|Experimental|Quarfloxin|
3234228|NCT00955955|Experimental|Placebo/Deplin|"Participants will receive placebo for the first 4 weeks, and then 15 mg/day of Deplin (6(S)-5-MTHF) for the next 4 weeks.~The SPCD approach, is modified and conducted as follows:~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
3234229|NCT00955955|Experimental|Placebo/Placebo|"Participants will receive placebo for both phases of the study.~The SPCD approach, is modified and conducted as follows:~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
3234230|NCT00955942|Experimental|Arm I|Patients consume flaxseed muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.
3234231|NCT00955942|Placebo Comparator|Arm II|Patients consume placebo muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.
3234232|NCT00955929|Experimental|PRN Sildenafil|Placebo QHS (blinded) and sildenafil 100mgs (open-label) as required for sexual relations. The placebo will be omitted on nights that 100mgs is used. Placebo will start within 24-48 hours post-surgery.
3234233|NCT00955929|Experimental|Nightly Sildenafil Arm|Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery.
3234234|NCT00955929|Experimental|Combination Therapy Arm|Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL), at initial dose of 5 units (0.05ml) will be given; the first 2 injections will be done in the MSKCC urology outpatient clinic (if needed, the investigator can determine appropriate amount of injections for patient training).
3234235|NCT00955916|Experimental|CLAG Regimen with Gleevec®|Combined chemotherapy treatment (CLAG regimen) with Gleevec® (imatinib mesylate).
3234236|NCT00955903|Experimental|Weight Loss|Participants receive Exercise and Reduced Calorie Diet Interventions
3234237|NCT00955903|Active Comparator|Control|Participants receive Exercise Intervention
3234238|NCT00955903|Active Comparator|Weight Maintenance|Participants receive Exercise and a Weight Maintenance Diet Interventions
3234239|NCT00955890|No Intervention|control arm|anthracycline chemotherapy only
3234240|NCT00955890|Experimental|low dose dexrazoxane group|anthracycline chemotherapy plus low dose dexrazoxane(10:1)
3234241|NCT00955890|Experimental|middle dose dexrazoxane group|anthracycline chemotherapy plus middle dose dexrazoxane(15:1)
3234242|NCT00955877|Experimental|DepoDur80|DepoDur will be administered at 80μg/kg (not to exceed 5 mg total/patient) under direct vision in the L1 laminectomy defect prior to wound closure.
3234243|NCT00955877|Experimental|DepoDur120|DepoDur will be administered at 120μg/kg (not to exceed 10 mg total/patient) under direct vision in the L1 laminectomy defect prior to wound closure.
3234244|NCT00955877|Placebo Comparator|Control|Preservative-free normal saline (2.5ml) will be placed in the L1 laminectomy defect and also dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter prior to wound closure.
3234245|NCT00955851||Pneumonia patients|The study group will consist of individuals diagnosed with pneumonia and admitted to the Medicine ward under the Pneumonia Core Measure Protocol.
3234246|NCT00955838|Experimental|Manus|
3234247|NCT00955838|Experimental|BCI_Manus|
3234248|NCT00955825|Experimental|300 IR|300 IR grass pollen allergen extract tablet
3234249|NCT00955825|Placebo Comparator|Placebo|Pacebo tablet
3234250|NCT00955812|Experimental|OPB-31121|OPB-31121 50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
3234251|NCT00955799|Experimental|Neramexane mesylate|Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day
3234252|NCT00955799|Placebo Comparator|Placebo|Placebo: identical placebo tablets
3234253|NCT00955786|Experimental|CX-3543|
3234254|NCT00955773|Experimental|Group I|20 to 30 solid tumor subjects will be dosed with GSK1120212 in combination with everolimus to identify Maximum Tolerated Dose. Subjects will continue on study drug until disease progression or withdraw consent.
3234255|NCT00955773|Experimental|Group II|20 subjects with pancreatic cancer will receive the recommended dose identified in group I. Subjects will remain on study drug until disease progression or withdrawal from consent.
3234256|NCT00955773|Experimental|Group III|Approximately 40 lung cancer subjects will receive the recommended dose identified in group I. Subjects will remain on study until disease progression or withdrawal of consent.
3234257|NCT00955747|Placebo Comparator|Sugar Substitute Splenda|1.5 g Sugar Substitute Splenda, dissolved in 125 ml of water three times per day. If intestinal problems occur, the dose should be reduced to 1 g dissolved in water tid or additionally reduced to 0.5 g dissolved in 125 ml of water tid if problems still persisted, until patients adapted to treatment.
3234258|NCT00955747|Experimental|Tagatose|15 g Tagatose dissolved in 125 ml of water three times a day. The Tagatose dosage will be decreased to 10 g dissolved in 125 ml of water tid or decreased additionally to 5 g Tagatose dissolved in 125 ml of water tid, if needed due to gastrointestinal effects, until patients adapt to the treatment
3234259|NCT00955734|Experimental|Early motion|This group of patients will begin wrist motion 1 week after surgery.
3234260|NCT00955734|Active Comparator|Immobilization|This group will be casted for 6 weeks after surgery
3234261|NCT00955721|Experimental|Phase 1: GEMOX + Sorafenib|"Gemcitabine and Oxaliplatin (GEMOX) and Sorafenib.~Gemcitabine: 1000 or 750 mg/m2, IV, Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.~Oxaliplatin: 100 or 75 mg/m2, IV, Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.~Sorafenib: 200 mg, Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops."
3234262|NCT00955721|Experimental|Phase 2 - RPTD GEMOX + Sorafenib|"Recommended Phase Two Dose (RPTD) of Gemcitabine and Oxaliplatin (GEMOX) and Sorafenib:~Gemcitabine: Recommended Phase II Dose determined from Phase I, Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.~Oxaliplatin: Recommended Phase II Dose determined from Phase I, Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.~Sorafenib: Recommended Phase II Dose determined from Phase I, Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops."
3234263|NCT00955708||Implants|Patients successfully implanted with the ACUITY Spiral Lead
3234264|NCT00955682|Experimental|Group A|Subjects who received GSK vaccine 134612 in the primary vaccination study 109069 and will be boosted 4 years after primary vaccination with the same meningococcal vaccine as given in the primary study.
3234265|NCT00955682|Active Comparator|Group B|Subjects who received Meningitec™ vaccine in the primary vaccination study 109069 and will be boosted 4 years after primary vaccination with the same meningococcal vaccine as given in the primary study.
3234266|NCT00955669|Active Comparator|Symptoms and Objective Examination|
3234267|NCT00955656||primary care providers|"Primary care providers who receive the survey will be the primary care provider identified by study participants enrolled in our ongoing study entitled, Asthma in the Delta Region of Arkansas: Characterization of Disease and Impact of Environmental Factors (ARIA#53054)"
3234268|NCT00955643|Experimental|hyperbaric therapy|Hyperbaric therapy by oxygen
3234269|NCT00955643|Experimental|dental scaling and root planing|dental scaling and cleaning
3234270|NCT00955630|Active Comparator|Monthly injections|3 monthly injections of ranibizumab followed by prn injections
3234271|NCT00955630|Active Comparator|PRN injections|injections of ranibizumab on a prn basis from the start of the study
3234272|NCT00955617|Experimental|Dotarem / Gadovist|Contrast-enhanced MRA - Imaging examination contrast enhanced-MRA first with Dotarem in period 1 then with Gadovist in period 2
3234273|NCT00955617|Experimental|Gadovist / Dotarem|Contrast-enhanced MRA - Imaging examination contrast enhanced-MRA first with Gadovist in period 1 then with Dotarem in period 2
3234274|NCT00955604||Group R+AD|Group R+AD Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) for at least 14 days
3234275|NCT00955604||Group R|At least 2 months of rasagiline
3234276|NCT00955604||Group AD|At least 2 months of Anti-PD and Rasagiline
3234277|NCT00955591|Other|swab test|
3234278|NCT00955578||Segmental Dysplastic Nevi|One patient who has been diagnosed with SDN and has had previous biopsies in the past, comparing to current biopsies
3234279|NCT00955565|Experimental|Navigated|
3234280|NCT00955565|Active Comparator|Conventional|
3234281|NCT00955552|Active Comparator|Condroflex|
3234282|NCT00955552|Experimental|Glucosamine/chondroitin sulphate|Glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association (Eurofarma) T.I.D. before each meal
3234283|NCT00955539|Active Comparator|CRT group 1|
3234284|NCT00955539|Active Comparator|CRT group 2|
3234285|NCT00955526|Experimental|Istradefylline 20mg|
3234286|NCT00955526|Experimental|Istradefylline 40mg|
3234287|NCT00955526|Placebo Comparator|Placebo|
3234288|NCT00955513|Experimental|diclofenac diethylamine gel 2.32% gel twice a day|drug
3234289|NCT00955513|Experimental|diclofenac diethylamine gel 2.32% gel three times a day|drug
3234290|NCT00955513|Placebo Comparator|placebo|placebo
3234291|NCT00955500|Active Comparator|Normal-protein diet|Daily diet containing 35 kcal/kg/day, 0.7 grams of proteins/kg/day + 30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams).
3234292|NCT00955500|Active Comparator|Low-protein diet|Daily diet containing 35 kcal/kg/day, 0.7 grams of proteins/kg/day + 30 grams of oral maltodextrine
3234293|NCT00955487|Experimental|Inhaled Nitric Oxide (iNO)|Participants will receive a low concentration of iNO until they are 30 weeks corrected gestational age or for 14 days if they were born at 29 weeks or more.
3234294|NCT00955487|Placebo Comparator|Nitrogen (placebo)|Participants will receive nitrogen (placebo) while in the hospital.
3234295|NCT00955474|Experimental|Quetiapine|Patients assigned to receive Quetiapine
3234296|NCT00955474|Active Comparator|Quetiapine and SSRI|Patients assigned to receive Quetiapine and SSRI
3234297|NCT00955461|Experimental|Laser treatment|Split-Face Comparison of an Electro-optic Q-Switched Nd: YAG Laser to a Fractionated Laser
3234298|NCT00955448|Experimental|SIS Mesh (Cook Medical)|Anterior prolapse repair will be reinforced using SIS mesh
3234299|NCT00955448|Active Comparator|No-mesh|Anterior prolapse repair with no mesh reinforcement
3234300|NCT00955409|Other|1|ACC-001(3µg) + QS21
3234301|NCT00955409|Other|2|ACC-001(10µg) + QS21
3234302|NCT00955409|Other|3|ACC-001(30µg) + QS21
3234303|NCT00955396|Other|Period 1|
3234304|NCT00955396|Other|Period 2|
3234305|NCT00955383|Active Comparator|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
3234306|NCT00955383|Placebo Comparator|Placebo|Matching placebo
3234307|NCT00955357|Experimental|First Add-on|Lacosamide added to first adequate monotherapy (no history of Antiepileptic Drug [AED] polytherapy) and epilepsy diagnosis < or = 24 months at Screening.
3234308|NCT00955357|Experimental|Later Add-on|Lacosamide added to 1 to 3 Antiepileptic Drugs (AEDs) (with tentatives of at least 2 prior AED treatment regimens) and epilepsy diagnosis > or = 5 years at Screening.
3234309|NCT00955344|Experimental|Web-based intervention (eToolbox)|This arm will allow diplomats of the American Board of Internal Medicine to complete the Practice Improvement Module that will embed a link to the web-based intervention (eToolbox).
3234310|NCT00955344|Active Comparator|Practice Improvement Module|This arm will allow diplomats of the American Board of Internal Medicine to complete the Practice Improvement Module without any link to the Web-based eToolbox.
3234311|NCT00955318|Experimental|KW-6500|
3234312|NCT00955305|Active Comparator|Arm A (CPB)|Patients receive carboplatin intravenously (IV) over 30 minutes, paclitaxel IV over 3 hours, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Treatment with bevacizumab may continue in the absence of disease progression or unacceptable toxicity.
3234315|NCT00955279|Placebo Comparator|Placebo|Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
3234316|NCT00955279|Experimental|Golimumab|Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
3234317|NCT00955279|Experimental|Ustekinumab|Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
3234318|NCT00955266|Active Comparator|Calcium Chloride|Calcium chloride, 10mg/kg
3234319|NCT00955266|Placebo Comparator|Placebo|Normal saline
3234320|NCT00955253|Experimental|Drug and Placebo|All patients will receive a single dose of drug and a single dose of placebo on separate days of the trial period. The order in which they receive these will be randomized.
3234321|NCT00955227|No Intervention|Statins only|In this arm- 15 Patients with heart disease and hypercholesterolemia will receive standard statin treatment as determined by the Cardiologist. Patients in this arm will be excluded if they are on ezetimibe.
3234322|NCT00955227|Active Comparator|Statins and ezetimibe|In this arm- 15 Patients with heart disease and hypercholesterolemia will receive standard statin treatment as determined by the Cardiologist. In addition, these patients will be on ezetimibe.
3234323|NCT00955227|Experimental|Statins and flax oil only|In this arm- 15 Patients receiving standard statin treatment as determined by their cardiologist will also receive two flaxseed oil capsules/day each containing 500 mg of ALA.
3234324|NCT00955227|Experimental|Statins and ezetimibe and flax oil|In this arm- 15 Patients with heart disease and hypercholesterolemia that are on standard statin treatment as determined by their cardiologist, will also receive (as an intervention) ezetimibe and flaxseed oil capsules containing 500mg of ALA.
3234325|NCT00955214|Experimental|2.5mm Paclitaxel-eluting stent|
3234326|NCT00955201|No Intervention|Arm 1|Sedentary Control Group
3234327|NCT00955201|Experimental|Arm 2|Aerobic Exercise Group
3234328|NCT00955201|Experimental|Arm 3|Isokinetic Strength Exercise Group
3234329|NCT00955201|Experimental|Arm 4|Combined Aerobic and Isokinetic Strength Exercise Group
3234330|NCT00955175|Experimental|Group 1|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 24 fractions (total of 72 Gy).
3234331|NCT00955175|Experimental|Group 2|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 22 fractions (total of 66 Gy).
3234332|NCT00955175|Experimental|Group 3|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 20 fractions (total of 60 Gy).
3234333|NCT00955162|Active Comparator|Subutex|
3234334|NCT00955162|Experimental|Suboxone|
3234335|NCT00955149|Experimental|Arm A|Erlotinib (Tarceva) 25 mg by mouth once daily.
3234336|NCT00955149|Experimental|Arm B|Erlotinib (Tarceva) 50 mg by mouth once daily for 6 months
3234337|NCT00955136|Experimental|High MI impulses, myocardial infarction, echocardiography|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
3234338|NCT00955123||Active inflammatory bowel disease|Patients with moderate to severe active inflammatory bowel disease (ulcerative colitis and Crohn's disease)
3234339|NCT00955110|Experimental|Oxymorphone ER 15 mg|15mg
3234340|NCT00955110|Active Comparator|Oxycodone CR 30 mg|30mg
3234341|NCT00955110|Placebo Comparator|Placebo|
3234342|NCT00955110|Experimental|Oxymorphone ER 30mg|30mg
3234343|NCT00955110|Active Comparator|Oxycodone CR 60mg|60mg
3234344|NCT00955097|Experimental|Definity Contrast Dye|During liver surgery Definity contrast dye will be administered follwed by an ultrasound to better detect liver tumors
3234345|NCT00955071|No Intervention|Control|
3234346|NCT00955071|Active Comparator|Exercise: LVLI|low volume, low intensity
3234347|NCT00955071|Active Comparator|Exercise: HVLI|high volume, low intensity
3234348|NCT00955071|Active Comparator|Exercise: LVHI|low volume, high intensity
3234349|NCT00955058|Active Comparator|cyproterone compound|Before and after treatment
3234350|NCT00955058|Experimental|oral contraceptive pill|Treatment
3234351|NCT00955045|Experimental|istradefylline|
3234352|NCT00955032|Experimental|High-Frequency Repetitive Transcranial Magentic Stimulation|High-Frequency repetitive transcranial magnetic stimulation patients randomized to this treatment will receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of Motor Evoked Potential (MEP) threshold, respectively.
3234353|NCT00955032|Sham Comparator|Sham Repetitive Transcranial Magentic Stimulation|Sham repetitive transcranial magnetic stimulation patients randomized to receive the sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
3234354|NCT00955006|Experimental|Group 1|Participants will receive three injections of VRC-HIVDNA-016-00-VP at Months, 0, 1, and 2 and one injection of VRCHIVADV014-00-VP at Month 6.
3234355|NCT00954993|Experimental|Vaniprevir 600 mg - 300 mg|For each participant in period 1, 600 mg of Vaniprevir was taken twice daily on Days 1-3 and a single dose of Vaniprevir 600 mg was taken on Day 4. Period 1 was followed by a minimum 30-day, up to approximately 140 day, washout interval. In period 2, 300 mg of Vaniprevir was taken twice daily by each participant on Days 1-3 and a single dose of Vaniprevir 300 mg was taken on Day 4.
3234356|NCT00954980||Endovenous Sclerotherapy|For those who have been diagnosed with varicose veins of the leg and have been scheduled to undergo an endovenous sclerotherapy procedure
3234499|NCT00953940|No Intervention|No treatment|Habitual therapy
3234357|NCT00954967|No Intervention|Usual care|The subjects in the control group will receive the usual care for smoking cessation in diabetic smokers.
3234358|NCT00954967|Experimental|Lifestyle Counseling|The intervention is based on lifestyle advice, motivational interviewing and the use of medications, using the Clinical Practice Guidelines of the Catalan Institute of Health. Health professionals in the intervention group receive a training on the abovementioned techniques.
3234359|NCT00954954|Active Comparator|Standard|Knees that will be implanted with standard posterior stabilized RP-MB knee prostheses
3234360|NCT00954954|Active Comparator|High-flexion|Knees that will be implanted with high-flexion posterior stabilized RP-MB knee prostheses
3234361|NCT00954941|Experimental|Group 1: Ondansetron|Ondansetron 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.
3234362|NCT00954941|Active Comparator|Group 2: Ondansetron + Aprepitant|Ondansetron 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy. Aprepitant 125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
3234363|NCT00954928||Anticoagulated patients|Those patients taking Coumadin, Plavix, Aspirin, Lovenox.
3234364|NCT00954928||Control patients|Those patients having hand or wrist surgery who do not take any anticoagulant medication.
3234365|NCT00954915|Experimental|teplizumab|Anti CD-3 monoclonal antibody
3234366|NCT00954902|Sham Comparator|No spice, no stress|Subject are given placebo capsules and told they contain an antioxidant concentrate
3234367|NCT00954902|Sham Comparator|No Spice, Stress|Subjects are given placebo capsules and told they are receiving an equivalent amount of an antioxidant concentrate.
3234368|NCT00954902|Experimental|Spice, no stress|
3234369|NCT00954902|Experimental|Spice and Stress|
3234370|NCT00954889|Experimental|Tamsulosin|
3234371|NCT00954889|Placebo Comparator|placebo|
3234372|NCT00954850||Severe asthmatics|Main study group
3234373|NCT00954850||Mild-moderate asthmatics|Control group
3234374|NCT00954837|Other|Fine needle aspiration|Patient with solid nodules more than 10 mm in diameter will be biopsied by ultrasound-guided fine-needle aspiration(FNA)after consultation with an endocrinologist or ENT specialist.
3234375|NCT00954824|Experimental|Endotoxin (LPS)|Single administration low-dose (3 ng/kg) endotoxin (LPS).
3234376|NCT00954811|Active Comparator|HCG for ovulation triggering and luteal progesterone|conventional triggering with HCG and conventional luteal support with progesterone
3234377|NCT00954811|Experimental|Agonist triggering and rec-LH luteal support plus progesterone|new method of triggering with GnRH-agonist and proof of concept intervention with novel way of luteal support with rec-LH plus the usual co-treatment with progesterone
3234378|NCT00954798|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 vaccine formulation 1 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13.
3234379|NCT00954798|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 vaccine formulation 2 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13.
3234380|NCT00954798|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 vaccine formulation 3
3234381|NCT00954785|Placebo Comparator|Placebo drug|
3234382|NCT00954785|Experimental|Etoricoxib|
3234383|NCT00954785|Active Comparator|Diclofenac|
3234384|NCT00954772||Staged Bilateral STN DBS|
3234385|NCT00954772||Simultaneous Bilateral STN DBS|
3234386|NCT00954759|Experimental|Chiropractic treatment|Manipulation and/or mobilisation
3234387|NCT00954759|Placebo Comparator|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
3234388|NCT00954746||Follow-up|Subjects Previously Treated with AA4500
3234389|NCT00954733|Experimental|All participants|All participants, one arterial blood draw
3234390|NCT00954720||Patient undergoing transplant|Patients with acute leukemia or MDS undergoing ablative stem cell transplantation. No intervention.
3234391|NCT00954707|Placebo Comparator|12m DAPT Group|
3234392|NCT00954707|Active Comparator|30m DAPT Group|
3234393|NCT00954694|Experimental|introductory exercise regimen|sedentary adults will be introduced to an introductory fitness regimen using the NuStep
3234394|NCT00954681|Experimental|quetiapine treatment|Open label treatment with quetiapine
3234395|NCT00954668|Experimental|immediate angiography|Immediate invasive angiography < 2 h after randomization
3234396|NCT00954668|Active Comparator|early invasive angiography|early invasive angiography 12-72 h after randomization
3234397|NCT00954655||Group 1|Tumor samples are used for polymorphism and mutation analysis.
3234398|NCT00954642|Experimental|A|
3234399|NCT00954642|Experimental|B|
3234400|NCT00954629|Experimental|2PX|Pain medication
3234401|NCT00954629|Placebo Comparator|Placebo|
3234402|NCT00954603|Experimental|quetiapine|atypical antipsychotic drug
3234403|NCT00954603|Active Comparator|haloperidol|typical antipsychotic drug
3234404|NCT00954590|Experimental|Dimebon (latrepirdine)|Dimebon, 20 mg orally three times daily
3234405|NCT00954590|Placebo Comparator|Placebo|Placebo orally three times daily
3234406|NCT00954551||All adult patients with SAH in ICU|All adult patients admitted for an expected ICU stay of more than 24 hrs over a 6-month period (tentative) between xx and xx 2009 with a diagnosis of SAH will be prospectively evaluated.
3234407|NCT00954538|Experimental|Part I, Healthy Participants|Healthy participants will receive a single intravenous (IV) dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part I of the study
3234408|NCT00954538|Experimental|Part II, HE and AD Participants|HE and AD participants will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part II of the study
3234409|NCT00954538|Experimental|Part III, HE and AD Participants|HE and AD participants will receive two separate IV doses of ~150 megabecquerel (MBq) [18F]MK-3328 in Part III of the study
3234410|NCT00954525|Experimental|Intravenous Vitamin C|
3234411|NCT00954512|Experimental|Regimen A: FOLFIRI (± Cetuximab) + Robatumumab|Participants with colorectal adenocarcinoma receive FOLFIRI (Irinotecan 180 mg/m^2+ folinic acid 400 mg/m^2+ 5-fluorouracil [5-FU] 400 mg/m^2 bolus followed by 2400 mg/m^2 intravenous [IV] infusion over 46 hours) (± cetuximab initial dose of 400 mg/m^2 IV followed by once-weekly doses of 250 mg/m^2 IV) PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 2-week cycle.
3234412|NCT00954512|Experimental|Regimen B: Carboplatin + Paclitaxel + Robatumumab|Participants with non-small cell lung cancer receive carboplatin administered at an area under the curve (AUC) of 6 mg/mL/min IV PLUS paclitaxel 225 mg/m^2 IV PLUS robatumumab 15 mg/kg IV on Day 1 of each 3-week cycle.
3234413|NCT00954512|Experimental|Regimen C: Epirubicin + Cisplatin + 5-FU + Robatumumab|Participants with gastric adenocarcinoma receive epirubicin 50 mg/m^2 IV PLUS cisplatin 60 mg/m^2 IV PLUS 5-FU 200 mg/m^2/day administered via a 21-week continuous IV infusion PLUS robatumumab 15 mg/kg IV on Day 1 of each 3-week cycle.
3234414|NCT00954512|Experimental|Regimen D: Trastuzumab + Robatumumab|Participants with human epidermal growth factor receptor 2 positive (Her2+) breast cancer receive trastuzumab 4 mg/kg IV once every week PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle.
3234415|NCT00954512|Experimental|Regimen E: mTor Inhibitor (Everolimus) + Robatumumab|Participants with renal cell cancer receive mammalian target of rapamycin (mTor) inhibitor (everolimus) 10 mg orally once per day PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle.
3234416|NCT00954512|Experimental|Regimen F: Gemcitabine (± Erlotinib) + Robatumumab|Participants with pancreatic adenocarcinoma receive gemcitabine 1000 mg/m^2 IV on Days 1, 8, 15, 22, 29, 36, and 43 in Cycle 1 and on Days 1, 8 and 15 in subsequent cycles (± erlotinib 100 mg per day orally) PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle. (Cycle 1 is 8 weeks.)
3234417|NCT00954499|Active Comparator|Standard care|
3234418|NCT00954499|Experimental|Tactile stimulation|
3234419|NCT00954486|Experimental|Epoetin alfa, 10,000 units/week|Epoetin alfa is a recombinant erythropoietin.
3234420|NCT00954473||Ancillary-correlative (osteosarcoma genetic risk)|Blood samples undergo polymorphism analysis of common single-nucleotide polymorphisms and haplotypes to examine genetic variation, gene-gene interactions, and the population structure.
3234421|NCT00954447|Experimental|Linagliptin|patient receives a tablet with intended final marketed dose
3234422|NCT00954447|Placebo Comparator|Placebo|patient receives a tablet identical to those containing Linagliptin
3234423|NCT00954434|Experimental|red wine|intervention: dietary supplement intake of red wine on a daily basis, 1 glass/day for women, 2 for men
3234424|NCT00954434|No Intervention|total abstention from alcohol|
3234425|NCT00954421|Experimental|Deep Brain Stimulation|Multiple Sclerosis Tremor treated with VIM and VO Deep Brain Stimulation
3234426|NCT00954408||Patients with dystonia|Patients with dystonia, 21-100 years of age.
3234427|NCT00954395||1. anticoagulation suspension|eligible patients undergo measurement of residual venous obstruction (RVO) with compression ultrasound (CUS) in case of a previous deep vein thrombosis (DVT) and/or of pulmonary artery pressure (PAP) with echocardiography in case of previous pulmonary embolism (PE). In patients with RVO is less < 4 mm in case of a previous DVT and/or PAP is normal with echocardiography in case of previous PE and in those who have undergone additional 6 months of therapy for previously altered RVO, D-dimer is measured during anticoagulation. If D-dimer is below age and gender cut-offs , anticoagulation is interrupted and D-dimer is then re-assessed after 15, 30, 60 and 90 days. If all the D-dimer measurements are below the cut-offs, anticoagulation is definitely interrupted and patients are followed-up for two years.
3234428|NCT00954395||2. anticoagulation prolongation|If RVO is greater than 4 mm at CUS of the lower limbs and/or PAP is increased (> 35 mmHg, > 40 mmHg in the elderly or obese), anticoagulation is prolonged for additional 6 months and the measures of RVO and/oR PAP are repeated. In those in whom PAP is altered also after 6 months of additional therapy, anticoagulation is prolonged. In patients with RVO is less < 4 mm in case of a previous DVT and/or PAP is normal with echocardiography in case of previous PE and in those who have undergone additional 6 months of therapy for previously altered RVO, D-dimer is measured during anticoagulation. If D-dimer is above age and gender cut-offs , anticoagulation is prolonged. If D-dimer is below the cut-offs , anticoagulation is interrupted and D-dimer is then re-assessed after 15, 30, 60 and 90 days. If one of these D-dimer measurement is above the cut-off , anticoagulation is resumed for at least 6 months and patients are re-evaluated.
3234429|NCT00954382||IQ trend|all subjects
3234430|NCT00954369|Experimental|[F-18]W372|Approximately twenty (20) adult subjects including ten (10) healthy volunteers and ten (10) high probability AD subjects, as defined by protocol criteria
3234431|NCT00954356|Experimental|XPF-001|
3234432|NCT00954356|Placebo Comparator|Placebo|
3234433|NCT00954343|Experimental|Group I|
3234434|NCT00954343|Experimental|Group II|
3234435|NCT00954343|Experimental|Group III|
3234436|NCT00954343|Experimental|Group IV|
3234437|NCT00954343|No Intervention|Group V|
3234438|NCT00954330|Experimental|surgery|All twenty-five patients underwent ligament repair, where the ruptured ends of the FTA (in 11 cases) or FTA and FC (in 14 cases) ligaments were rejoined by using absorbable sutures. A supine position and a tourniquet were used. A curvilinear skin incision of 5-10 cm was made; the retinacular structures were incised and the hematoma was removed.
3234439|NCT00954330|Active Comparator|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle
3234440|NCT00954317|Active Comparator|Low epidural|epidural placed in the lower lumbar vertebral column
3234441|NCT00954317|Experimental|high epidural|high epidural
3234442|NCT00954304|Experimental|1mg group|Administration of HM30181AK 1mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
3234443|NCT00954304|Experimental|5mg group|Administration of HM30181AK 5mg on day 4 and Loperamide 16mg(Loperamide 2mg x 8cap) on day 1,4,8,11,15
3234444|NCT00954304|Experimental|10mg group|Administration of HM30181AK 10mg(HM30181AK 5mg x 2tab)on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
3234445|NCT00954304|Experimental|15mg group|Administration of HM30181AK 15mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
3234446|NCT00954304|Experimental|60mg group|Administration of HM30181AK 60mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
3234447|NCT00954291||Granisetron|14 mg Granisetron
3234448|NCT00954278|Experimental|sorafenib|
3234449|NCT00954265|Active Comparator|Urinary-HCG group|These patients received u-HCG for ovulation triggering during ovarian stimulation for IVF
3234450|NCT00954265|Experimental|Recombinant HCG group|These patients received rec-HCG for ovulation triggering during ovarian stimulation for IVF
3234451|NCT00954252|Experimental|Test Article|
3234452|NCT00954252|Placebo Comparator|Placebo|
3234453|NCT00954226|Experimental|Standard Dose Erlotinib|Standard Dose: 1 tablet of 150 mg erlotinib once a day, every day leading up to surgery.
3234454|NCT00954226|Experimental|Higher Dose Erlotinib|Higher Dose: 200 mg or 300 mg in 2 tablets once a day, every day leading up to surgery.
3234455|NCT00954213|Experimental|DIR/Floortime parent intervention|
3234456|NCT00954200|Placebo Comparator|Placebo|
3234457|NCT00954200|Active Comparator|ibuprofen|
3234458|NCT00954187|Experimental|Gabapentin|Neurontin
3234459|NCT00954187|Experimental|Pregabalin|Lyrica
3234460|NCT00954174|Experimental|Arm I (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1.
3234461|NCT00954174|Experimental|Arm II (paclitaxel, ifosfamide)|Patients receive ifosfamide IV over 1 hour on days 1-3 followed by paclitaxel as in Arm I.
3234462|NCT00954161|Experimental|first aid and helping behaviour|The helping behaviour training is given after 24 hours first aid training and aims to sensitise participants towards a helping reaction and teach participants how to deal with barriers to helping
3234463|NCT00954161|Active Comparator|first aid only|This group receives training in first aid only without training in helping behaviour.
3234464|NCT00954148|Active Comparator|PET/CT follow-up|PET/CT with history and physical exams at 3,9,18,36,60 months only
3234465|NCT00954148|Other|conventional follow-up|NCCN recommendations
3234466|NCT00954135|Active Comparator|letrozolo+cyclophosphamide|
3234467|NCT00954135|Experimental|letrozolo+sorafenib+cyclophosphamide|
3234468|NCT00954122|Experimental|Quetiapine XR|Quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards.
3234469|NCT00954109|Experimental|Exercise|exercise - supervised exercise (treadmill walking or cycle ergometer use)
3234470|NCT00954096|Experimental|Transdermal nicotine patch or placebo|A single blood specimen (85ml) will be drawn. They will be asked to empty their bladder. The patch will be applied. Following application of the patch, heart rate and blood pressure will be measured every 15 minutes for the 1st hour, every 30 minutes for the next 3 hours and hourly after that until the end of the study. Urine will be collected in two 4-hour aliquots. FMD will be measured after approximately 6 hours of nicotine exposure. After 8 hours exposure, following the end of the 2nd urine collection, the patch will be removed and the subject discharged. Following a minimum of 2 weeks (maximum 8 weeks) washout, the subject will repeat the study, receiving the other patch.
3234471|NCT00954083|Experimental|DIR/Floortime intervention|1=DIR/Floortime intervention
3234472|NCT00954083|Active Comparator|routine care|2=routine care
3234473|NCT00954070||Case (subjects with NERD)|The investigators cases are subjects with confirmed NERD and include male or female patients aged between 21 and 65 years, who present with typical clinical manifestations of gastroesophageal reflux and have no esophageal mucosal breaks upon conventional white-light endoscopy examination but show evidence of pathologic gastroesophageal reflux on 24-hr pH monitoring.
3234474|NCT00954070||Control|Healthy individuals aged between 21 and 65 years who are asymptomatic for GERD and other digestive diseases
3234475|NCT00954057|Experimental|LIPO-102|Intraorbital Injection
3234476|NCT00954057|Placebo Comparator|Placebo|Intraorbital Injection
3234477|NCT00954044|Experimental|Exercising Together|Partnered progressive resistance exercise
3234478|NCT00954044|Placebo Comparator|Usual Care|Usual Care Control
3234479|NCT00954031||case|hospitalized patients, adult or child, including the diagnosis of APA was made, after consulting their physician.
3234480|NCT00954031||The control group|"Two patients witnesses will be matched to each case:~Chronological criterion: consultation for a sore throat 10 days (± 3 days) before the date of hospitalization of cases, between 13 and J-J-7.~Age criteria: year of birth ± 5 years Geographical criteria: living in the same department, failing in an adjacent Department Social criteria: beneficiary or otherwise of the CMU, to avoid a selection bias leading social most frequently at the onset of the APA"
3234481|NCT00954018||Cystic Fibrosis patient during outpatient clinic visit|
3234482|NCT00954018||Cystic Fibrosis patients during hospitalization|
3234483|NCT00954018||CF patients about to have sinus surgery and bronchoscopy|
3234484|NCT00954005|Experimental|Rituximab, Gemcitabine and Oxaliplatin|Drug: Rituximab on day 0 or 1 of each 28-day cycle Drug: Gemcitabine on day 1 and 15 of each 28-day cycle Drug: Oxaliplatin on day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²) of each 28-day cycle
3234485|NCT00953979|Active Comparator|Sulfasalazine|Sulfasalazine is a drug in treatment RA, AS and ulcerative colonitis. In this study, Sulfasalazine is used to act as an active comparator to access the efficacy of kunxian capsule.
3234486|NCT00953979|Placebo Comparator|placebo|The placebo capsule was used to be a comparator of kunxian capsule
3234487|NCT00953966|Other|Starch 1|Starch 1
3234488|NCT00953966|Other|Starch 2|Starch 2
3234489|NCT00953966|Other|Starch 3|Starch 3
3234490|NCT00953966|Other|Starch 4|Starch 4
3234491|NCT00953966|Other|Starch 5|Starch 5
3234492|NCT00953966|Other|Starch 6|Starch 6
3234493|NCT00953966|Other|Starch 7|Starch 7
3234494|NCT00953953||Acutely Decompensated Systolic HF|Patients with moderate or severe Heart Failure (defined ast NYHA class III or IV).
3234495|NCT00953953||Chronic HF Patients on Dialysis|Patients who have heart failure (defined as NYHA class II, III, or IV) and are on dialysis.
3234496|NCT00953953||Ambulary Chronic HF|Patients with diagnosis of chronic heart failure (NYHA class II and III) who are on optimal medical therapy.
3234497|NCT00953953||Acutely Decompensated Diastolic HF|Patients with moderate or severe Heart Failure (defined ast NYHA class III or IV).
3234498|NCT00953940|Experimental|Isotonic saline|Isotonic saline
3234500|NCT00953927|Experimental|Investigational Vaccine|MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.
3234501|NCT00953927|Placebo Comparator|Control Group|Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.
3234502|NCT00953914|Experimental|Pyridostigmine|
3234503|NCT00953914|Placebo Comparator|Placebo|If a subject is randomized to placebo, he will receive placebo pills 3 times daily for 1 day.
3234504|NCT00953888|Experimental|Active|AZD5069 oral solution
3234505|NCT00953888|Placebo Comparator|Placebo|Placebo oral solution
3234506|NCT00953862|Experimental|Atomoxetine Treatment Arm|Patients who were identified as having adult ADHD on the ACDS were offered an open label treatment trial with atomoxetine, up to 120 mg/day over 10 weeks. Atomoxetine was titrated over a period of four weeks based upon clinical response and observed side-effects. All patients receiving atomoxetine gave written informed consent prior to participation and were assessed for ADHD symptoms via the Adult Investigator Adult ADHD Symptom Rating Scale (AISRS) every 1-2 weeks. All patients received a physical exam, review of systems and routine blood work prior to treatment. Data were analyzed for patients completing at least 2 weeks of atomoxetine therapy. Treatment response was pre-hoc defined as having a >=30% reduction in total AISRS scores from baseline.
3234507|NCT00953849|Experimental|Arm 1: Celecoxib|Celecoxib treatment prior to surgery
3234508|NCT00953849|Experimental|Arm 2: Calcitriol|Treatment with Calcitriol prior to surgery
3234509|NCT00953849|Experimental|Arm 3: Celecoxib plus Calcitriol|Treatment with Celecoxib plus Calcitriol prior to surgery.
3234510|NCT00953849|No Intervention|Arm 4: No Treatment|no treatment prior to surgery
3234511|NCT00953810|No Intervention|control|General heart failure population staying under regular care of their primary care physician
3234512|NCT00953810|Active Comparator|Intervention|Like control plus one education training regarding heart failure aspects and management
3234513|NCT00953784|No Intervention|1|Standard management
3234514|NCT00953784|Active Comparator|2|Extended management: with no bowel prep except enema,restricted fluids, increased O2,body warming and use of skin protectors during surgery as previously described
3234515|NCT00953771|Experimental|Danazol, Plex, Steroids|Everyone will receive Danazol with plasma exchange and corticosteroids
3234516|NCT00953758|Experimental|1|
3234517|NCT00953745|Active Comparator|Depressed Participants|"Subjects with treatment-resistant depression (TRD) will be administered the Hamilton Depression Rating Scale (HAM-D 17) for entry and will receive escitalopram combined with an adjunctive placebo capsule for 8 weeks.~Subjects who fail to respond will continue to receive escitalopram and additionally change to receive a placebo tablet resembling the active augmentation agent Aripiprazole (ARP) for 2 weeks.~Subjects who fail to respond to escitalopram after the 2 phase placebo treatment will enter the ARP augmentation phase of the study and will receive escitalopram augmentation with ARP.~Subjects will have 3 neuroimaging scans: F-DOPA PET, raclopride PET, and functional MRI conducted after 10 weeks of treatment and repeated after 6 weeks of ARP treatment."
3234518|NCT00953745|No Intervention|Control Participants|Non-depressed, age- and sex-matched subjects without a DSM-IV Axis I diagnosis will serve as controls. They will not receive antidepressant, ARP, or any drug augmentation and will be used as quality control to compare the pre-ARP and post-ARP treatment brain images.
3234519|NCT00953732||1|
3234520|NCT00953719|Active Comparator|36 mm|36 mm ceramic head on ceramic acetabular liner
3234521|NCT00953719|Other|28 mm ceramic-on-polyethylene|28 mm ceramic-on-polyethylene historical control
3234522|NCT00953706|Placebo Comparator|Placebo|Placebo matched to ivacaftor tablet orally every 12 hours (q12h) for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).
3234523|NCT00953706|Experimental|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally q12h for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).
3234524|NCT00953680|Active Comparator|losartan /HCTZ combination tablet|single dose losartan 100 mg/HCTZ 12.5 mg combination tablet
3234525|NCT00953680|Active Comparator|losartan tablet + HCTZ capsule|Single dose losartan 100 mg tablet + HCTZ 12.5 mg capsule
3234526|NCT00953667|Experimental|Niacin and Endotoxin|All subjects are expected to have the same interventions- Niacin and Endotoxin.
3234527|NCT00953654|Experimental|Strength Training|Lower-body strength training exercise twice weekly for 6 weeks at an intensity progressing from 50% to 75% predicted one-repetition maximum
3234528|NCT00953654|Experimental|Endurance Training|Six-week lower-body dynamic cycling exercise condition completed twice weekly and matched to the strength training arm on total work completed, total time actively engaged in exercise and load progression.
3234529|NCT00953654|No Intervention|Waiting List Control|Waiting list control condition in which participants will maintain their current lifestyle and will not enter a six-week exercise training intervention, but will complete outcome measures along the same time progression as the intervention arms.
3234530|NCT00953641|Active Comparator|Pre-Menopausal 1|Pre-Menopausal group, receiving Misoprostol
3234531|NCT00953641|Placebo Comparator|Pre-Menopausal 2|Patients will insert a placebo vaginal suppository 12h or more prior to the endometrial biopsy
3234532|NCT00953641|Active Comparator|Post-Menopausal 1|Post-Menopausal patients will insert a Misoprostol vaginal suppository 12h or more prior to the endometrial biopsy
3234533|NCT00953641|Placebo Comparator|Post-Menopausal 2|Placebo vaginal suppository prior to the endometrial biopsy
3234534|NCT00953628|Active Comparator|o Group A=uHCG ovul trig|HCG for triggering
3234535|NCT00953628|Experimental|o Group B=recHCG ovul trig|recombinant HCG for triggering
3234536|NCT00953615|Experimental|Thalidomide|Participants will be treated with Thalidomide, starting at a dose of 100 mg per day, increasing the dose by 100 mg every 14 days to a maximum of 400 mg per day.
3234537|NCT00953589|Experimental|Locteron ® PANEL A|PANEL A: Locteron™ 480 µg dosed every 2 weeks in two subcutaneous injections (160 µg and 320 µg)
3234538|NCT00953589|Experimental|Locteron ® PANEL B|PANEL B: Locteron™ 480 µg dosed every two weeks in single subcutaneous injections
3234539|NCT00953589|Active Comparator|PEG-Intron® PANEL A|PEG-Intron® 1.5 µg/kg body weight weekly subcutaneous injection
3234540|NCT00953589|Active Comparator|PEG-Intron® PANEL B|PEG-Intron® 1.5 µg/kg body weight weekly subcutaneous injection
3234541|NCT00953576|Experimental|KHAD+L|Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib
3234542|NCT00953563|No Intervention|compression therapy|
3234543|NCT00953563|Active Comparator|Biologic with compression therapy|
3234544|NCT00953550|Experimental|Rocuronium-Sugammadex|
3234545|NCT00953550|Active Comparator|Succinylcholine|
3234546|NCT00953537|Other|capecitabine|
3234547|NCT00953524|Experimental|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1
3234548|NCT00953524|Experimental|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2
3234549|NCT00953524|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Vaccine formulation 3
3234550|NCT00953524|Placebo Comparator|Placebo Group|Participants will receive a placebo vaccine
3234551|NCT00953511|Other|genetic|
3234552|NCT00953498|Active Comparator|pioglitazone|treatment with pioglitazone (dose from 30 mg:day to 45 mg/day)
3234553|NCT00953498|Active Comparator|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
3234554|NCT00953433|Experimental|Endoflex tube|Use of Endoflex tube for intubation.
3234555|NCT00953433|Active Comparator|Endotracheal tube with stylet|Use of conventional endotracheal tube with a stylet for intubation.
3234556|NCT00953420|Experimental|Chemotherapy and Immunotherapy|"Docetaxel 60 mg/m2 IV on Day 1~Carboplatin with target AUC of 5 (mg/ml x min) on Day 1~Dexamethasone 5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1~After cycle 1, subsequent cycles of chemotherapy may start once ANC > 1000 and platelets > 100,000 post nadir~Up to an additional 2 cycles of chemotherapy, given per the above schedule, may be given if the EBV-specific cytotoxic T lymphocytes product is not available after the initial 4 cycles"
3234557|NCT00953407|Experimental|Nelfilcon A|Nelfilcon A contact lens
3234558|NCT00953407|Active Comparator|Narafilcon A|Narafilcon A contact lens
3234559|NCT00953407|Active Comparator|Etafilcon A|Etafilcon A contact lens
3234560|NCT00953407|Active Comparator|Omafilcon A|Omafilcon A contact lens
3234561|NCT00953407|Active Comparator|Hilafilcon B|Hilafilcon B contact lens
3234562|NCT00953394|Experimental|treatment arm|continuous 5 fluouracil infusion plus long-acting octreotide
3234563|NCT00953381|Experimental|5 mg ilaprazole|
3234564|NCT00953381|Experimental|10 mg ilaprazole|
3234565|NCT00953381|Experimental|20 mg ilaprazole|
3234566|NCT00953381|Active Comparator|20 mg omeprazole|
3234567|NCT00953368|Active Comparator|Remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
3234568|NCT00953368|Placebo Comparator|control|sham placement of a blood-pressure cuff around the upper limb without inflation
3234569|NCT00953355|Experimental|Folate|Folate plus metformin
3234570|NCT00953355|Placebo Comparator|Placebo|Placebo plus metformin
3234571|NCT00953342|Experimental|Aerobic exercise|12 weeks of supervised aerobic exercise and standard care
3234572|NCT00953342|Placebo Comparator|Usual care|12 weeks of standard care
3234573|NCT00953329|Experimental|Alefacept 15 mg IM qweek|Alefacept will be given to subjects with plaque psoriasis who have failed treatment with Fnbrel.
3234574|NCT00953316||at-risk infants|Includes all children born at less than 37 weeks gestation and other high risk newborns such as those with a history of breathing problems and/or low tone.
3234575|NCT00953303|Experimental|glucocorticoid|
3234576|NCT00953303|Active Comparator|Standard care|
3234577|NCT00953290|Experimental|Treated Thigh|The thigh treated with the RF device
3234578|NCT00953290|No Intervention|Untreated Thigh|The untreated thigh
3234579|NCT00953277|Experimental|Avance Nerve Graft|Processed Human Nerve Tissue Scaffold
3234580|NCT00953264|Experimental|life style intervention|
3234581|NCT00953251||patients with acute coronary syndrome|patients with acute coronary syndrome
3234582|NCT00953251||Non-STEMI and unstable angina|
3234583|NCT00953225|Experimental|Vitamin D3|4,000 IU vitamin D3 daily for one year
3234584|NCT00953225|Placebo Comparator|Placebo|Placebo daily for one year
3234585|NCT00953212|Active Comparator|Group A|Beta Blockers, Ascorbic Acid and Amiodarone
3234586|NCT00953212|Active Comparator|Group B|Beta Blockers and Ascorbic Acid
3234587|NCT00953212|Active Comparator|Group C|Beta Blockers and Amiodarone
3234588|NCT00953212|Active Comparator|Group D|Beta Blockers alone
3234589|NCT00953199|Experimental|Lidocaine|Study subjects receive a 1:1 combination of 5 ml Diatrizoate 60% and 5 ml Lidocaine Hydrochloride 2%
3234590|NCT00953199|Active Comparator|Normal Saline|The control arm receives a 1:1 combination of 5 ml Diatrizoate and 5ml saline.
3234591|NCT00953186|Active Comparator|HBOT|100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks
3234592|NCT00953186|Placebo Comparator|Placebo|air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks
3234593|NCT00953173||LapBand|Patients who have already consented to receive the LAP-BAND AP® Adjustable Gastric Banding System
3234594|NCT00953160|Experimental|RF treatment|Abdomen, flank or thigh treated with RF device
3234595|NCT00953147|Experimental|Ciclesonide HFA 80 mcg once daily|Ciclesonide HFA nasal aerosol will be supplied in a 40 mcg canister, to be administered as 1 puff in each nostril (80 mcg per day).
3234596|NCT00953147|Experimental|Ciclesonide HFA 160 mcg once daily|Ciclesonide HFA nasal aerosol will be supplied in a 80 mcg canister, to be administered as 1 puff in each nostril (160 mcg per day).
3234597|NCT00953147|Placebo Comparator|Placebo once daily|The placebo HFA nasal aerosol is identical to active drug, but does not contain ciclesonide.
3234598|NCT00953134|Experimental|1|IFA - Iron and Folic Acid (60 mg of ferrous fumarate and 400 mcg folic acid)
3234599|NCT00953134|Active Comparator|2|FA - Folic Acid (400 mcg folic acid)
3234600|NCT00953121|Experimental|Cohort A-Grade IV No Failure|Recurrent GBM patients who have not previously failed bevacizumab, irinotecan, or carboplatin
3234836|NCT00951392|Experimental|Problematic aging|
3234601|NCT00953121|Experimental|Cohort B-Grade III No Failure|Recurrent Grade 3 malignant glioma patients who have not previously failed either bevacizumab, irinotecan or carboplatin
3234602|NCT00953121|Experimental|Cohort C-Failed Prior Therapy|Recurrent Grade IV GBM patients who have failed prior bevacizumab therapy, but not prior CPT-11 or carboplatin therapies
3234603|NCT00953108|Experimental|quetiapine|
3234604|NCT00953108|Active Comparator|escitalopram|
3234605|NCT00953095|Experimental|Caregiver Mediated Model (CMM)|focuses on joint attention/engagement intervention using an established evidence based treatment (Kasari et al., 2006). It involves meeting the parent and child in their home for one hour, twice a week for 12 weeks. In this intervention, the parent-child pair meet with the interventionist (as opposed to the group training in the CEM condition). Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input and coaching from the interventionist) as they implement these techniques with their child.
3234606|NCT00953095|Experimental|Caregiver Education Model (CEM)|focuses on teaching parents information about autism, behavior modification, and community services using a manualized approach (Brereton & Tonge, 2005). Parents will receive information on child development each week, and will be able to ask questions and discuss the information vis-à-vis their own child. This intervention is manualized (Brereton & Tonge 2005). In the CEM condition, parents meet in a group (without their children) in a community-based setting to receive the intervention. Intervention sessions occur once a week for 2 hours.
3234607|NCT00953056|Experimental|Cohort I - RotaTeq™, Adults|Adults randomized to receive a single dose of RotaTeq™.
3234608|NCT00953056|Placebo Comparator|Cohort I - Placebo, Adults|Adults randomized to receive a single dose of matching placebo to RotaTeq™.
3234609|NCT00953056|Experimental|Cohort II - RotaTeq™, Children|Children randomized to receive a single dose of RotaTeq™.
3234610|NCT00953056|Placebo Comparator|Cohort II - Placebo, Children|Children randomized to receive a single dose of matching placebo to RotaTeq™.
3234611|NCT00953056|Experimental|Cohort III - RotaTeq™, Infants|Infants randomized to receive 3 doses of RotaTeq™.
3234612|NCT00953056|Placebo Comparator|Cohort III - Placebo, Infants|Infants randomized to receive 3 doses of matching placebo to RotaTeq™.
3234613|NCT00953043|Active Comparator|Lubiprostone|Subjects randomized to this arm received 24 micrograms of lubiprostone per day for three days.
3234614|NCT00953043|Placebo Comparator|Placebo|Subjects randomized to this arm received placebo medication for three days.
3234615|NCT00953030|Experimental|COACH|"web-based risk assessments with an action plan that is negotiated with a Coach who provides personalized follow-up reinforcement"
3234616|NCT00953030|Experimental|RealAge|a web-based health risk assessment and risk profile with disease-specific follow-up reinforcement modules
3234617|NCT00953030|No Intervention|light health education control|
3234618|NCT00953017|Active Comparator|Miralax plus Amitiza|106 patients randomized to Miralax plus Amitiza will take one 24mcg gelcap of Amitiza at noon the day prior to their colonoscopy. On the day prior to the colonoscopy, the patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
3234619|NCT00953017|Active Comparator|Miralax plus Dulcolax|107 patients randomized to Miralax plus Dulcolax will take two 5mg tablets of Dulcolax at noon the day prior to their colonoscopy. On the day prior to the colonoscopy, the patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
3234620|NCT00953017|Active Comparator|Miralax|106 patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
3234621|NCT00953017|Active Comparator|Golytely (polyethylene glycol)|106 patients will take 1 gallon of golytley (Polyethylene glycol) and drink 1/2 of the solution at 4 p.m. The remaining 1/2 of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy
3234622|NCT00953004|Experimental|fiber drink|
3234623|NCT00953004|Experimental|fiber bread|
3234624|NCT00953004|Experimental|placebo|
3234625|NCT00952978|Experimental|10 mg ilaprazole|
3234626|NCT00952978|Active Comparator|20 mg omeprazole|
3234627|NCT00952965||blood pressure monitor|wrist circumference: 14cm-25cm
3234628|NCT00952965||stethoscopy|wrist circumference: 14cm-25cm
3234629|NCT00952913|Experimental|1|Bosutinib
3234630|NCT00952913|Experimental|2|bosutinib + lansoprazole
3234631|NCT00952900|Experimental|Early Biobehavioral Intervention|This intervention involves the use of non-invasive treatment modalities such as relaxation/biofeedback, stress management, and cognitive coping skills. It is based upon previous clinical research studies demonstrating the efficacy of this intervention in allowing acute TMD patients to better cope with stress and lifestyle issues that produce the TMD pain/discomfort.
3234632|NCT00952900|Active Comparator|Attention Control Group|This intervention involves the presentation of helpful information to patients that explains etiology and potential treatment modalities used to modify/reduce TMD pain/discomfort.
3234633|NCT00952900|No Intervention|No Active Treatment Comparison Group|Unlike the other two treatment groups, that involve high-risk acute TMD patients, this group includes low-risk acute TMD patients. Past studies have shown that these low risk patients do not need any early intervention in order to prevent chronicity.
3234634|NCT00952887|Experimental|ACE-031|8 dosing groups
3234635|NCT00952887|Placebo Comparator|Placebo|
3234636|NCT00952861|Active Comparator|Doxycycline|Doxycycline 200 mg QD in 5 days
3234637|NCT00952861|Placebo Comparator|Placebo|Matching placebo QD i 5 days
3234638|NCT00952848|Experimental|MC5-A Scramble instrument|Treatment of chronic neuropathic pain with the MC5-A device
3234639|NCT00952835||asthma and rhinitis control|
3234640|NCT00952822|Experimental|1|ADVATE reconstituted in 2 mL sterile water for infusion
3234641|NCT00952822|Active Comparator|2|ADVATE reconstituted in 5 mL sterile water for infusion
3234642|NCT00952796|Experimental|1|patients with intra-abdominal infection treated with moxifloxacin 400mg once daily
3234643|NCT00952796|Active Comparator|2|patients with intra-abdominal infection treated with ampicillin/sulbactam 1.5g 4 times daily
3234644|NCT00952783||1|
3234645|NCT00952770|Experimental|Atorvastatin|Group receiving atorvastatin 20mg/day
3234646|NCT00952770|Active Comparator|Simvastatin/Ezetimibe|Group receiving simvastatin/ezetimibe 10/10mg
3234647|NCT00952757||1.|Patients diagnosed of schizophrenia or bipolar disorder with APS-related hyperprolactinaemia who have been switched to quetiapine based on the clinician's judgement
3234648|NCT00952731|Experimental|oral placebo, afimoxifene|4-hydroxytamoxifen gel 2mg/breast applied daily. Oral placebo taken daily.
3234649|NCT00952731|Active Comparator|tamoxifen citrate, placebo gel)|Placebo gel applied to the breasts daily. 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules).
3234650|NCT00952718|No Intervention|Control|No intervention.
3234651|NCT00952718|Experimental|Inspiratory muscle training|With intervention.
3234652|NCT00952705|Experimental|Q/LAIV-BFS (MEDI8662)|Q/LAIV-BFS (quadrivalent influenza vaccine) (MEDI8662) was supplied in the blow-fill-seal delivery system that delivers a nominal dose of 0.2 mL into a single nostril. Each dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), B/Victoria (B/Malaysia/2506/2004), and B/Yamagata (B/Florida/4/2006).
3234653|NCT00952705|Active Comparator|FluMist/B/Yamagata|FluMist/B/Yamagata was administered intranasally using a Becton Dickinson Accuspray™ device. A total volume of 0.2 mL was administered intranasally (approximately 0.1 mL into each nostril). Each dose contained 10^7.0 ± 0.5 FFU of each of 3 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), and B/Yamagata (B/Florida/4/2006)
3234654|NCT00952705|Active Comparator|FluMist/B/Victoria|FluMist/B/Victoria was administered intranasally using a BD Accuspray™ device. A total volume of 0.2 mL was administered intranasally (approximately 0.1 mL into each nostril). Each dose contained 10^7.0 ± 0.5 FFU of each of 3 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), and B/Victoria (B/Malaysia/2506/2004).
3234655|NCT00952679|Experimental|experimental arm|
3234656|NCT00952666|Experimental|Device|Both the Robot-Assisted Laparoscopic Radical Prostatectomy (RALRP) and the Transrectal Ultrasound (TRUS) are common performed procedures, but are normally performed separately. In this proposed feasibility study, the procedures will be combined.
3234657|NCT00952653|Experimental|DVS SR|
3234658|NCT00952640|Active Comparator|vitamin A directly post-partum|200.000 IU of vitamin A within 3 days of delivery
3234659|NCT00952640|Experimental|vitamin A delayed|200.000 IU vitamin A 6 weeks post-partum
3234660|NCT00952627|Experimental|Pycnogenol|200 mg/day
3234661|NCT00952627|Placebo Comparator|Control|placebo
3234662|NCT00952614|Experimental|Retisert for Retinal Vein Occlusion|0.59 mg Fluocinolone Acetonide (Retisert implant) for Retinal Vein Occlusion
3234663|NCT00952601|Experimental|Modified Atkins Diet|Patients are started on the modified Atkins diet at 15 grams per day.
3234664|NCT00952588|Experimental|AZD1152 1200 mg|AZD1152 1200 mg, iv, 7 day infusion monotherapy
3234665|NCT00952588|Active Comparator|LDAC 20 mg|LDAC 20 mg, sc, bd, 10 days (400mg per cycle)
3234666|NCT00952575|Active Comparator|polyclonal anti-D immunoglobulin|
3234667|NCT00952575|Experimental|Monoclonal anti-D immunoglobulin|
3234668|NCT00952562|Active Comparator|cholecalciferol|3000 IU cholecalciferol per day for 16 weeks
3234669|NCT00952562|Placebo Comparator|placebo|
3234670|NCT00952549|Experimental|Facial Yoga Toning Program|Patients will be instructed on 18 exercises which are intended to strengthen and tone the muscles of facial expression. DVD is provided.
3234671|NCT00952536|Active Comparator|Triple therapy|Daily Juice Plus+ with 2 vegetable & 2 fruit & 2 berry capsule (test group 1)
3234672|NCT00952536|Active Comparator|Dual Therapy|Juice Plus+ with 2 vegetable & 2 fruit & 2 placebo capsule (test group 2)
3234673|NCT00952536|Placebo Comparator|Control|Daily Placebo in the form of 6 capsules (control group)
3234674|NCT00952523|Experimental|Tretinoin & Adapalene-Benzoyl Peroxide|Tretinoin and Adapalene-Benzoyl Peroxide facial gels applied once daily in a split face model
3234675|NCT00952510||Whiplash patients|The cohort is based on 100 whiplash patients which underwent the measure procedure to obtain cervical range of motion.
3234676|NCT00952497|Experimental|Cisplatin, Capecitabine, Telatinib|
3234677|NCT00952484|Active Comparator|2 mg/kg|2 mg/kg subcutaneous injection three times per week.
3234678|NCT00952484|Active Comparator|3 mg/kg|3 mg/kg subcutaneous injection three times per week.
3234679|NCT00952471|No Intervention|Baseline Period|Patients in the baseline period were cared for using the standard historical electronic order set.
3234680|NCT00952471|Active Comparator|Post Intervention Period|Patients in the Post intervention period were cared for with evidence-bsed modified order set changes
3234681|NCT00952458|Experimental|BIS monitoring|Dosing of sedatives with BIS monitoring
3234682|NCT00952458|No Intervention|Standard monitoring|Dosing of sedatives without BIS monitoring
3234683|NCT00952445|Experimental|T0903131 Besylate|1.0 mg
3234684|NCT00952445|Experimental|T0903131 Besylate|10.0 mg
3234685|NCT00952445|Placebo Comparator|Placebo|Once daily, oral
3234686|NCT00952432|Active Comparator|ACUPUNCTURE|ACUPUNCTURE
3234687|NCT00952432|Active Comparator|MEDICATION|Carbamazepine
3234688|NCT00952419|Experimental|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1
3234689|NCT00952419|Experimental|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2
3234690|NCT00952419|Placebo Comparator|Placebo Group|Participants will receive a placebo vaccine
3234691|NCT00952406||Survey of Women PFDs|Women with PFDs
3234692|NCT00952393|Other|Pharmacokinetic|This single arm examines the pharmaco-kinetics of the release of 3-2,4 dimethoxy-benzilidene anabaseine in a hypomellose sustained release formulation.
3234693|NCT00952380|Other|Single Arm|Single arm open-label
3234694|NCT00952367||Per-protocol population|In all, 3641 participants were enrolled; however, 38 were excluded because of violation of inclusion/exclusion criteria and 3 participants were excluded for unavailability of nasopharyngeal swab sample. The record presents demographic and result data for 3600 participants in the per-protocol population. These participants completed collection of the nasopharyngeal swab sample, the Epidemiology questionnaire, and 24 hours safety observation.
3234695|NCT00952354||research group|60 children aged from 3 to 10 years, both genders, observed in a symbolic play situation with their language therapists
3234696|NCT00952341|Experimental|Aprepitant (MK-0869)|
3234697|NCT00952341|Placebo Comparator|Standard Therapy|
3234698|NCT00952328|Experimental|Limited Formula|Participants will supplement feedings with early limited formula following nursing
3234699|NCT00952328|No Intervention|Control|Participants are instructed to continue exclusively breastfeeding; no use of formula
3234700|NCT00952315|Active Comparator|Stonebreaker|Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
3234701|NCT00952315|Active Comparator|Lithoclast Select|Lithoclast Select will be used to breakup and remove kidney stone. Duration will be timed and documented.
3234702|NCT00952315|Active Comparator|Cyberwand|The dual probe Cyberwand device will be used to fragment and remove the kidney stone. Duration will be timed and documented.
3234703|NCT00952302|Placebo Comparator|CMS - placebo first|Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive a placebo (saline) infusion first followed by iron infusion.
3234704|NCT00952302|Experimental|CMS - iron|Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive an iron infusion first followed by placebo (saline) infusion.
3234705|NCT00952302|Placebo Comparator|SLR - placebo|Sea level residents (SLR) taken to high altitude for one week, and receiving placebo (saline) infusion on Day 3 at high altitude.
3234706|NCT00952302|Experimental|SLR - iron|Sea level residents (SLR) taken to high altitude for one week, and receiving iron infusion on Day 3 at high altitude.
3234707|NCT00952289|Experimental|Ruxolitinib|Participants received ruxolitinib orally twice a day. The starting dose was determined based on Baseline platelet count. Patients with Baseline platelet count > 200,000/μL began a dose regimen of 20 mg twice daily. Patients with Baseline platelet count of 100,000/μL to 200,000/μL (inclusive) began a dose regimen of 15 mg twice daily. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily. Patients receiving benefit could continue treatment until the later of marketing approval or when the last randomized patient remaining in the study had completed Week 144 (36 months).
3234708|NCT00952289|Placebo Comparator|Placebo|Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting certain protocol requirements detailed below were given the opportunity to cross over to ruxolitinib treatment.
3234709|NCT00952276|Experimental|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1 (with adjuvant)
3234710|NCT00952276|Experimental|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2 (with adjuvant)
3234711|NCT00952276|Active Comparator|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 vaccine formulation 3
3234712|NCT00952276|Active Comparator|A/H1N1 Vaccine Group 4|Participants will receive A/H1N1 vaccine formulation 4
3234713|NCT00952276|Placebo Comparator|Placebo Group 5|Participants will receive a placebo vaccine
3234714|NCT00952263|Experimental|MBL-HCV1|
3234715|NCT00952250|Active Comparator|Targeted Feedback Reports|Conventional feedback reports
3234716|NCT00952250|Experimental|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement.
3234717|NCT00952237|Experimental|IL-2 and GM-CSF for Mobilization|Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
3234718|NCT00952224||Acute myocardial infarction patients|Patients undergoing primary percutaneous coronary intervention in ST-elevation myocardial infarction plus magnetic resonance imaging
3234719|NCT00952211|Active Comparator|CPAP|CPAP at therapeutic pressure
3234720|NCT00952211|Sham Comparator|sub-therapeutic CPAP|CPAP administered at sub-therapeutic pressure
3234721|NCT00952198|Experimental|ARRY-403|
3234722|NCT00952198|Placebo Comparator|Placebo|
3234723|NCT00952159||Not Poor metabolizer|
3234724|NCT00952159||Poor metabolizer|
3234725|NCT00952146|Experimental|Transgastric peritoneoscopy|Only one arm, feasibility study
3234726|NCT00952133|Experimental|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery.
3234727|NCT00952133|Placebo Comparator|Palonosetron only|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Intravenous Palonosetron and Saline solution
3234728|NCT00952120|Experimental|GSUC|Gauze-based wall suction negative pressure wound therapy for 4-5 days
3234729|NCT00952120|Active Comparator|Vacuum-assisted closure|Vacuum-assisted closure (VAC) negative pressure wound therapy using commercially available device (KCI, Inc) for 4-5 days
3234730|NCT00952107|Experimental|Imaging system operation|
3234731|NCT00952094|Active Comparator|KRN1493 50mg group|KRN1493 50mg single oral administration
3234732|NCT00952094|Active Comparator|KRN1493 75mg group|KRN1493 75mg single oral administration
3234733|NCT00952094|Active Comparator|KRN1493 100mg group|KRN1493 100mg single oral administration
3234734|NCT00952081|Experimental|clevidipine,brain tumor,hypertension|21 or older, Clevidipine in brain tumor resection, epilepsy focus resection during acute hypertension under general anesthesia
3234735|NCT00952068|Experimental|Tramadol Contramid® OAD 200mg|1 Tramadol Contramid® OAD 200mg tablet daily.
3234736|NCT00952055||Patients diagnosed with acute coronary syndrome (ACS)|
3234737|NCT00952042|Experimental|Heavy slow resistance training|12 wks of heavy slow resistance training. training three times per week. each session: 3 heel-raise exercises. 12-6RM. Slow contractions.
3234738|NCT00952042|Active Comparator|Eccentric resistance training|12 wks of eccentric resistance training. 3 x 15 Eccentric heel-raises performed twice daily.
3234739|NCT00952029|Experimental|Maintenance with bevacizumab|FOLFIRI + Avastin and during the chemotherapy-free interval maintenance with bevacizumab
3234740|NCT00952029|Active Comparator|No maintenance with bevacizumab|FOLFIRI + Avastin and during the chemotherapy-free interval NO maintenance
3234741|NCT00952003|Experimental|interventional arm|Oxaliplatin, Irinotecan and Bevacizumab for 3 cycles followed by Docetaxel and Bevacizumab for a further 3 cycles. Upon completion of the combination therapy cycles Bevacizumab will be continued until progression.
3234742|NCT00951977||Subjects who have formerly donated a kidney|
3234743|NCT00951977||Matched community control Subjects|
3234744|NCT00951964|Other|1|patients receive the treatment in first and placebo in second part of study
3234745|NCT00951964|Other|2|patients receive placebo in first and treatment in second part of study
3234746|NCT00951951|Active Comparator|Anterior Surgical Approach|(AMIS)
3234747|NCT00951951|Active Comparator|Posterior Approach Group|Posterior surgical approach for total hip replacement.
3234748|NCT00951925||No Treatment|
3234749|NCT00951912|Placebo Comparator|Placebo|10g soy protein isolated powder patch by mouth everyday for 6months
3234750|NCT00951912|Experimental|Daidzein|10g soy protein isolated plus 50mg daidzein powder patch by mouth everyday for 6 months
3234751|NCT00951912|Experimental|Genistein|10g soy protein isolated plus 50mg genistein powder patch by mouth everyday for 6 months
3234752|NCT00951899|Experimental|Colesevelam|Treatment with colesevelam hydrochloride in addition to Metformin and Diet
3234753|NCT00951899|Placebo Comparator|Placebo|Treatment with placebo in addition to Metformin and Diet
3234754|NCT00951873|Experimental|A|
3234755|NCT00951873|Placebo Comparator|B|
3234756|NCT00951873|Experimental|C|
3234757|NCT00951860||Newborn|Every child born in the CHU of Saint-Étienne (inborn), any term of its birth, in the hospital neonatal unit at the time of registration (after 37 weeks corrected for prematurity) or in the maternity
3234758|NCT00951847|Experimental|1|Oxcarbazepine oral suspension 300 mg/5 mL of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
3234759|NCT00951847|Active Comparator|2|Trileptal® (oxcarbazepine) oral suspension 300 mg/5 mL of Novartis
3234760|NCT00951834|Experimental|Epigallocatechin-Gallate|"Months 1-3: 200 mg EGCG/die (200-0-0 mg)~Months 4-6: 400 mg EGCG/die (200-0-200 mg)~Months 7-9: 600 mg EGCG/die (400-0-200 mg)~Months 10-18: 800 mg EGCG/die (400-0-400 mg)~add-on to Donepezil."
3234761|NCT00951834|Placebo Comparator|Placebo|add-on to Donepezil.
3234762|NCT00951821|Experimental|Concurrent treatment|Concurrent treatment - experimental condition: Adolescent participants and their parents will receive concurrent cognitive behavioral therapy.
3234763|NCT00951821|Active Comparator|Adolescent treatment only|Adolescent treatment only - Active Comparator: Only adolescent participants will receive cognitive behavioral therapy.
3234764|NCT00951808|Active Comparator|Blood Transfusion Trial Cohort|Twenty participants will receive a blood transfusion while in the hospital.
3234765|NCT00951808|Active Comparator|Standard Care Trial Cohort|Twenty participants will not receive a blood transfusion and will receive standard care.
3234766|NCT00951808|Active Comparator|Standard Care Observational Cohort|Approximately 300 participants who are ineligible for or decline the blood transfusion part of the study will participate in the observational portion of the study and receive standard care.
3234767|NCT00951795||Adults|Adult men and women over age of 18
3234768|NCT00951795||Pediatrics|Pediatric boys and girls ages 12-18
3234769|NCT00951782|Active Comparator|High frequency TMS + smoking cue|
3234770|NCT00951782|Sham Comparator|Sham TMS + smoking cue|
3234771|NCT00951782|Active Comparator|Low frequency TMS +smoking cue|
3234772|NCT00951782|Sham Comparator|Sham TMS - no cue|
3234773|NCT00951782|Active Comparator|High frequency TMS - no cue|
3234774|NCT00951782|Active Comparator|Low frequency - no cue|
3234775|NCT00951769||Control,|Control
3234776|NCT00951769||DAS: Difficult Airway Society, UK|DAS difficult airway algorithm
3234777|NCT00951769||Australian|Australian difficult airway algorithm
3234778|NCT00951756|Other|High Fat Low Fiber Diet|
3234779|NCT00951756|Other|Low Fat High Fiber Diet|
3234780|NCT00951743|Experimental|Adaptavir Treatment|MDAPTA (Adaptavir) will be administered intranasally at 0.01 mg twice per day. Individuals with plasma viral load (PCR Roche Amplicor Ultrasensitive assay) less than 200 copies/mL, sustained for the previous 90 days, with CD4>350 cells/mm3 will be eligible to participate.
3234781|NCT00951743|Placebo Comparator|Placebo|Placebo will be administered intranasally at 0.01 mg twice per day. Individuals with plasma viral load (PCR Roche Amplicor Ultrasensitive assay) less than 200 copies/mL, sustained for the previous 90 days, with CD4>350 cells/mm3 will be eligible to participate.
3234782|NCT00951730||Down syndrome|Adult and children with Down syndrome.
3234783|NCT00951717|No Intervention|Treatment as usual|Participants will receive standard postpartum education and discharge materials provided by the hospital and a list of community and Internet resources by mail.
3234784|NCT00951717|Experimental|Behavioral education|Participants will receive behavioral education on postpartum depression and a list of community and Internet resources by mail.
3234785|NCT00951704||Cardiac arrest|
3234786|NCT00951691|Experimental|Enhanced acute medical rehabilitation|Participants will receive enhanced acute medical rehabilitation.
3234787|NCT00951691|Active Comparator|Treatment as usual|Participants will receive treatment as usual.
3234788|NCT00951678||ER patients|"Subjects must be 18 yrs or older, male or female, and must have the anatomy that we will be examining. Patients will be given the option of enrolling in the study whilst being cared for in Tampa General Hospital Emergency Room.~We anticipate enrolling normal, healthy volunteers, elderly persons (>65) not cognitively impaired, persons with social, economic or educational disadvantages , and persons who do not understand English fluently."
3234789|NCT00951665|Experimental|Phase lb Regimen 1|Participants received trastuzumab emtansine (T-DM1) every three weeks (Q3W) + paclitaxel weekly (QW) intravenously.
3234790|NCT00951665|Experimental|Phase Ib Regimen 2|Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously.
3234791|NCT00951665|Experimental|Phase Ib Regimen 3|Participants received T-DM1 QW + paclitaxel QW intravenously.
3234792|NCT00951665|Experimental|Phase Ib Regimen 4|Participants received T-DM1 QW + paclitaxel QW + pertuzumab Q3W intravenously.
3234793|NCT00951665|Experimental|Phase IIa Group A|Participants received maximum tolerated dose (MTD) from Phase 1b i.e. T-DM1 3.6mg/kg Q3W + paclitaxel 80mg/m^2 QW intravenously.
3234794|NCT00951665|Experimental|Phase IIa Group B|Participants received MTD from Phase 1b i.e. T-DM1 3.6mg/kg Q3W + paclitaxel 80mg/m^2 QW + pertuzumab Q3W intravenously.
3234795|NCT00951652|Experimental|CBT plus supportive listening|14 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques and the second hour will be supportive listening
3234796|NCT00951652|Active Comparator|CBT plus Interpersonal and emotional processing therapy|14 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques and the second hour will be Interpersonal and emotional processing therapy
3234797|NCT00951639|Experimental|5g Cassia cinnamon|Experimental treatment group
3234798|NCT00951639|Active Comparator|50 minutes endurnace exercise|Endurance exercise treatment known to influence blood glucose
3234799|NCT00951639|Placebo Comparator|5g Cellulose|Placebo equivalent in weight and appearance to experimental treatment
3234800|NCT00951600|Experimental|1|Oxcarbazepine oral suspension 300 mg/5mL of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
3234801|NCT00951600|Active Comparator|2|Trileptal® (oxcarbazepine) oral suspension 300 mg/5mL of Novartis
3234802|NCT00951587|Experimental|1|Patients that are indicated for colonoscopy or who are suspected or known to suffer from colonic diseases.
3234803|NCT00951574|Placebo Comparator|saline solution|Pre-filled syringes of 0.4 ml, 1 subcutaneous injection/day (every 24 hours).
3234804|NCT00951574|Experimental|nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
3234805|NCT00951561|Experimental|Vipon|
3234806|NCT00951561|Active Comparator|Ibuprofen|
3234807|NCT00951548|Experimental|VSL#3|Probiotic preparation VSL#3
3234808|NCT00951548|Placebo Comparator|placebo|Corn Starch
3234809|NCT00951535|Other|Arm A|Treatment will be delivered in 1.8 Gy fractions; dose escalation will be in 1.8 Gy increments from 75.6 Gy to a maximum 81 Gy.
3234810|NCT00951522|Experimental|1|GS-9411 2.4 mg
3234811|NCT00951522|Experimental|2|GS-9411 4.8 mg
3234812|NCT00951522|Experimental|3|GS-9411 7.2 mg
3234813|NCT00951522|Experimental|4|GS-9411 9.6 mg
3234814|NCT00951522|Placebo Comparator|5|Placebo
3234815|NCT00951509||Condition 1 (PC Screens with No Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
3234816|NCT00951509||Condition 2 (PC Screens with Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
3234817|NCT00951509||Condition 3 (VR Screens with No Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
3234818|NCT00951509||Condition 4 (VR Screens with Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
3234819|NCT00951509||Condntion 5 (Real-world driving)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
3234820|NCT00951496|Experimental|Arm I (paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1 in courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone in courses 7-22 in the absence of disease progression or unacceptable toxicity.
3234821|NCT00951496|Experimental|Arm II (paclitaxel, bevacizumab, carboplatin IP)|Patients receive paclitaxel as in Arm I and carboplatin IP on day 1. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
3234822|NCT00951496|Experimental|Arm III (paclitaxel IP, bevacizumab, cisplatin IP)|Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IP on day 2, and paclitaxel IP on day 8. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
3234823|NCT00951483|Experimental|Intervention Cohort|Patients will undergo baseline psychological and laboratory tests then receive Quetiapine-XR(Seroquel-XR) with flexible dosing at the discretion of the treating physician based on clinical response and tolerability. The dose range will be from 50-300mg. The total duration of the treatment will be 12 weeks.
3234824|NCT00951483|No Intervention|Healthy Control|Participants without major depressive disorder or anxiety are enrolled as a comparison group without intervention.
3234825|NCT00951470|Other|No CDT|CDT=complete decongestive therapy
3234826|NCT00951470|Other|Modified CDT Program|CDT=complete decongestive therapy
3234827|NCT00951470|Other|Full CDT Program|CDT=complete decongestive therapy
3234828|NCT00951457|Experimental|Overall study|"Dose escalation phase:~Days -3, -2, -1: 3 - 10 - 30 mg Alemtuzumab s.c.~Treatment phase:~Bendamustine 70 mg/m2 i.v. on d1 + d2 repeat every 28 days for 4 cycles~Alemtuzumab 30 mg s.c. 3x per week (days 1, 3, 5) continuously in parallel with chemotherapy cycles for a maximum of 16 weeks"
3234829|NCT00951444|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and MK-0646 IV over 60 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients with stable disease or partial or complete response may then receive MK-0646 alone on days 1 and 15. Treatment with MK-0646 repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3234830|NCT00951444|Active Comparator|Arm II|Patients receive gemcitabine hydrochloride and carboplatin as in arm I. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients may crossover to arm upon disease progression.
3234831|NCT00951431|Experimental|PPI|
3234832|NCT00951431|Placebo Comparator|Control|
3234833|NCT00951405|Experimental|A|
3234834|NCT00951405|Experimental|B|
3234835|NCT00951405|Experimental|C|
3234838|NCT00951379|Experimental|Arm I (Pioglitazone Hydrochloride)|Three (3) Pioglitazone 15 mg capsules by mouth once daily for 24 weeks
3234839|NCT00951379|Placebo Comparator|Arm II (Placebo)|Three (3) placebo capsules by mouth once daily for 24 weeks
3234840|NCT00951366||Bronchopulmonary Dysplasia (BPD)|
3234841|NCT00951353||Pediatric Renal Transplant Recipients|
3234842|NCT00951340|Active Comparator|CBT with listening therapy|Participants will receive CBT with listening therapy.
3234843|NCT00951340|Experimental|CBT with emotional processing and interpersonal therapy|Participants will receive CBT with emotional processing and interpersonal therapy.
3234844|NCT00951301|Active Comparator|mangosteen juice|subjects randomized 1:1 to this arm will receive juice containing the mangosteen ingredient
3234845|NCT00951301|Placebo Comparator|placebo juice|subjects randomized 1:1 to this arm will receive specially prepared juice not containing mangosteen ingredient
3234846|NCT00951288|Active Comparator|Saffron|Crocus Sativus extract
3234847|NCT00951288|Placebo Comparator|Placebo|Placebo comparator
3234848|NCT00951275|Experimental|1|
3234849|NCT00951262|Experimental|life review|a life review program includes 3-session life review and formulation of a life review book as a gift for advanced cancer patients.
3234850|NCT00951262|No Intervention|controlled group|the subjects in the controlled group do not receive the life review program
3234851|NCT00951249|Experimental|A|HIV-infected and uninfected black MSM
3234852|NCT00951236|Active Comparator|One injection|
3234853|NCT00951236|Active Comparator|Two Injections|
3234854|NCT00951223||Patients with Chronic Hepatitis C|HCV positive patients who have failed previous HCV therapy This observational prospective registry is designed to evaluate the safety, adherence, and efficacy of prescribed, patientadministered therapy with Infergen® (Interferon alfacon-1) and other prescribed therapies in patients chronically infected with HCV. The primary endpoint for efficacy will be the SVR rate at 24 weeks after therapy ends. Safety will be assessed by monitoring AEs, reduction/discontinuation of therapy because of AEs, routine laboratory results and by other means determined by the Investigator
3234855|NCT00951210|Experimental|PLX-PAD low dose|IM injection Single treatment; multiple injections
3234856|NCT00951210|Experimental|PLX-PAD high dose|IM injection Double treatment; multiple injections
3234857|NCT00951197||elderly subjects retired from agriculture|
3234858|NCT00951171|Experimental|Cervical occulsion|Insemination Eliptosphere catheter filled with 1cc of air for 15 minutes. H/S Eliptosphere by Copper surgical (U.S. Patent No. 5,624,399)
3234859|NCT00951171|Active Comparator|Standard IUI|Insemination with TOmcat catheter
3234860|NCT00951158|Experimental|CLA|Open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. oral dose 7.5 g/day 28 day cycle
3234861|NCT00951132|Experimental|2|Rosuvastatin
3234862|NCT00951132|Placebo Comparator|1|Placebo
3234863|NCT00951119|Experimental|resperate device|"Resperate© is a device that helps to slow down breathing. This device can measure the breathing patterns through a breathing sensor mounted on the upper abdomen or chest. Furthermore, music-like sound patterns can be composed similar to this breathing pattern, which the patient can hear through the headphones of the Resperate©. By prolonging the expiration, which can be voluntarily used by the user, the frequency of respiration can be slowed down and become more stable (aim<10 breathings per minute)."
3234864|NCT00951119|Sham Comparator|control device|Resperate device without slowing of breathing
3234865|NCT00951106|Experimental|Pyrimethamine/sulfdoxine (Fansidar)|Pyrimethamine/sulfdoxine (Fansidar)
3234866|NCT00951093||Patients assessed for GERD|Patients who had an open gastric bypass were assessed for GERD before and after surgery following the Montreal Consensus through a validated questionnaire in Portuguese language
3234867|NCT00951080|Experimental|SNaP Wound Care System|
3234868|NCT00951080|Active Comparator|Traditional NPWT System|
3234869|NCT00951067|Active Comparator|Group A|Exercise, Elevation, and Garment Compression
3234870|NCT00951067|Active Comparator|Group B|Pneumatic Compression Device (B)
3234871|NCT00951067|Active Comparator|Group C|Pneumatic Compression Device (C)
3234872|NCT00951067|Active Comparator|Group D|Pneumatic Compression Device (D)
3234873|NCT00951067|Active Comparator|Group E|Pneumatic Compression Device (E)
3234874|NCT00951041|Experimental|Group A|Subjects receiving GSK2340272A vaccine.
3234875|NCT00951041|Experimental|Group B|Subjects receiving GSK2340269A vaccine.
3234876|NCT00951028|Active Comparator|Enhanced treatment as usual|Participants will receive the life-steps intervention and treatment as usual.
3234877|NCT00951028|Experimental|CBT for adherence and depression (CBT-AD)|Participants will receive the life-steps and CBT-AD interventions.
3234878|NCT00951028|Active Comparator|ISP for adherence and depression (ISP-AD)|Participants will receive the life-steps and ISP-AD interventions.
3234879|NCT00951015|Experimental|10 mg GSK1349572|subjects will receive GSK1349572 10mg once daily blinded to dose
3234880|NCT00951015|Experimental|25mg GSK1349572|subjects will receive GSK1349572 25mg once daily blinded to dose
3234881|NCT00951015|Experimental|50mg GSK1349572|subjects will receive GSK1349572 50mg once daily blinded to dose
3234882|NCT00951015|Other|efavirenz control|efavirenz will serve as the internal control arm
3234883|NCT00951002||acellualr dermal matrix|patients treated with acellular dermal matrix plug
3234884|NCT00950989|Experimental|AMG 827 210 mg|210 mg AMG 827
3234885|NCT00950989|Experimental|AMG 827 140 mg|140 mg AMG 827
3234886|NCT00950989|Experimental|AMG 827 70 mg|70mg AMG 827
3234887|NCT00950989|Placebo Comparator|Placebo|Placebo
3234888|NCT00950976|Experimental|Citrulline|
3234889|NCT00950976|Placebo Comparator|lemonade|Equal volume and flavor to citrulline.
3234890|NCT00950963|Experimental|Phone Counseling|The telephone outreach intervention was considered an adjunct to usual care. The study nurse focused on optimizing lipids utilizing published guidelines through phone contact.
3234937|NCT00950664|Experimental|Dysport® to Botox®|Dysport® injection in first intervention period and Botox® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA)
3235065|NCT00949923|No Intervention|Control|No tea capsules
3234891|NCT00950963|Active Comparator|Standard Care|Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
3234892|NCT00950950|Placebo Comparator|B|Eleven female subjects will receive placebo.
3234893|NCT00950950|Active Comparator|A|Eleven female subjects will receive AMG 785.
3234894|NCT00950937||HIV Group|HIV infected persons
3234895|NCT00950937||Control Group|Non HIV-infected persons
3234896|NCT00950924|Experimental|Bifocal Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
3234897|NCT00950924|Placebo Comparator|Single Vision Soft Contact Lenses|Subjects will be fitted with single vision soft contact lenses with goal of corrected emmetropia at a distance of 20 feet.
3234898|NCT00950911|Experimental|1|
3234899|NCT00950885|Placebo Comparator|Placebo|placebo control group will receive 4 doses of identically-appearing capsules containing cellulose
3234900|NCT00950885|Experimental|Low dose melatonin|0.5 mg melatonin
3234901|NCT00950885|Experimental|High dose melatonin|3.0 mg melatonin
3234902|NCT00950872|Experimental|Duet TRS|Subjects receive Duet TRS
3234903|NCT00950859|Experimental|GSK1349572 Cohort I|Single Arm, Cohort I
3234904|NCT00950859|Experimental|GSK1349572 Cohort II|Single Arm, Cohort II
3234905|NCT00950846|Experimental|Umbilical Cord Blood Transplant Treatment Plan|Busulfan, Cytoxan, Fludarabine, Cord Blood Stem Cell Infusion
3234906|NCT00950833|Active Comparator|AP-AP Group|subjects from the AP-AP group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in study NCT00496015, receiving an additional dose of pneumococcal conjugate vaccine GSK1024850A for immune memory assessment
3234907|NCT00950833|Active Comparator|NAP-pre Group|subjects from the NAP-pre group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in study NCT00496015 receiving an additional dose of pneumococcal conjugate vaccine GSK1024850A for immune memory assessment
3234908|NCT00950833|Active Comparator|Unprimed Group|Age-matched subjects from the unprimed group of the NCT00496015 study, not previously vaccinated with any pneumococcal vaccine, receiving two doses of pneumococcal conjugate vaccine GSK1024850A
3234909|NCT00950820|Experimental|Panitumumab + XELOX|KRAS mutational status wild-type: Panitumumab plus Oxaliplatin and Capecitabine (XELOX)
3234910|NCT00950820|Other|XELOX (KRAS mutational status wt)|KRAS mutational status wild-type: Oxaliplatin and Capecitabine (XELOX)
3234911|NCT00950820|Other|XELOX (KRAS mutational status mutant)|KRAS mutational status mutant: Oxaliplatin and Capecitabine (XELOX)
3234912|NCT00950807|Placebo Comparator|Placebo|Placebo
3234913|NCT00950807|Active Comparator|Tiotropium|Tiotropium
3234914|NCT00950807|Experimental|Arm 1|GSK573719 1000mcg once daily
3234915|NCT00950807|Experimental|Arm 2|GSK573719 500mcg once daily
3234916|NCT00950807|Experimental|Arm 3|GSK573719 250mcg once daily
3234917|NCT00950807|Experimental|Arm 4|GSK573719 125mcg once daily
3234918|NCT00950807|Experimental|Arm 5|GSK573719 62.5 mcg once daily
3234919|NCT00950807|Experimental|Arm 6|GSK573719 250mcg twice daily
3234920|NCT00950807|Experimental|Arm 7|GSK573719 125mcg twice daily
3234921|NCT00950807|Experimental|Arm 8|GSK573719 62.5mcg twice daily
3234922|NCT00950794|Active Comparator|Hokunalin(tulobuterol) tape|Hokunalin(tulobuterol) tape: long-acting Beta2-agonist
3234923|NCT00950794|Experimental|Salmeterol(408DP-02)|Salmeterol(408DP-02)：long-acting Beta2-agonist
3234924|NCT00950781||Group|Group
3234925|NCT00950768|Active Comparator|Mel100|
3234926|NCT00950768|Experimental|Mel200|
3234927|NCT00950755|Experimental|Tositumomab and Iodine I 131 Tositumomab (anti-B1 antibody)|In the first phase (dosimetric dose) patients will receive an infusion of unlabeled Anti B1 Antibody (450 mg) followed by an infusion of Anti B1 Antibody (35 mg) which has been trace-labeled with 5 mCi of Iodine 131. Whole body gamma camera scans will be obtained following the dosimetric dose. Using the dosimetric data, a patient-specific dose of Iodine 131 Anti B1 Antibody to deliver the desired total body dose of radiotherapy will be calculated. In the second phase, (radioimmunotherapeutic dose), patients will receive an infusion of unlabeled Anti B1 Antibody (450 mg) followed by an infusion of 35 mg Anti B1 Antibody labeled with the patient-specific dose of Iodine 131 to deliver a whole body dose of 75 cGy. Patients will be treated with saturated solution potassium iodide, Lugol's solution, or potassium iodide tablets starting at least 24 hours prior to the first infusion and continuing for 14 days following the last infusion of Iodine 131 Anti B1 Antibody.
3234928|NCT00950742|Experimental|BIBW 2992 + Trastuzumab|Find maximum tolerated dose of the non-marketed substance:BIBW 2992 given orally with fixed weekly infusion doses of 2mg/kg Herceptin. Escalating doses of BIBW 2992 starting at 20mg daily.
3234929|NCT00950729|Active Comparator|Driving with Running Shoes|
3234930|NCT00950729|Active Comparator|Driving with Plaster cast|
3234931|NCT00950729|Active Comparator|Driving with Aircast|
3234932|NCT00950716|Active Comparator|Usual care|The 'control arm' will receive standard usual care with clinicians' follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
3234933|NCT00950716|Active Comparator|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
3234934|NCT00950690||Study Drug - Xalatan 0.005% eye drops|
3234935|NCT00950677|Active Comparator|exenatide|exenatide one dose
3234936|NCT00950677|Active Comparator|pramlintide|pramlintide one dose
3235064|NCT00949923|Active Comparator|tea capsules|3 tea capsules daily for 3 weeks
3234938|NCT00950664|Experimental|Botox® to Dysport®|Botox® injection in first intervention period and Dysport® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA)
3234939|NCT00950651|Experimental|1 Tramadol HCl Contramid® Once A Day|
3234940|NCT00950651|Active Comparator|2 Tramadol HCl Twice a day (SR)|
3234941|NCT00950638|Active Comparator|dose comparison|
3234942|NCT00950638|Active Comparator|Dose comparison|
3234943|NCT00950625|Active Comparator|intraperitoneal lignocaine|Intraperitoneal lignocaine will be compared with intraperitoneal bupevacaine for pain control after laparoscopic cholecystectomy
3234944|NCT00950625|Active Comparator|intraperitoneal bupevacaine|intraperitoneal lignocaine will be compared with intraperitoneal bupevacaine after laparoscopic cholecystectomy
3234945|NCT00950612|Experimental|Group A|
3234946|NCT00950612|Placebo Comparator|Group B|
3234947|NCT00950599|Experimental|Saxagliptin (2.5 mg)|
3234948|NCT00950599|Experimental|Saxagliptin (5 mg)|
3234949|NCT00950599|Experimental|Saxagliptin (10 mg)|
3234950|NCT00950599|Experimental|Saxagliptin (20 mg)|
3234951|NCT00950599|Experimental|Saxagliptin (40 mg)|
3234952|NCT00950599|Experimental|Saxagliptin (100 mg)|
3234953|NCT00950599|Placebo Comparator|Placebo|
3234954|NCT00950586|Experimental|Cohort 1|14 days dosing
3234955|NCT00950586|Experimental|Cohort 2|Single dose followed by 14 days repeat dosing
3234956|NCT00950586|Experimental|Cohort 3|Up to 28 days repeat dosing with drug interaction
3234957|NCT00950573||hemodialysis|patients treated with conventional hemodialysis
3234958|NCT00950573||peritoneal dialysis|patients treated with peritoneal dialysis
3234959|NCT00950573||nocturnal hemodialysis|patients treated with frequent nocturnal hemodialysis
3234960|NCT00950573||kidney transplantation|patients treated with renal transplantation
3234961|NCT00950560||inpatient|
3234962|NCT00950560||outpatient|
3234963|NCT00950560||emergency patient|
3234964|NCT00950547|Active Comparator|Control|Traditional Chest drains
3234965|NCT00950547|Experimental|CARDIOPAT|CARDIOPAT Cell Saver after Surgery
3234966|NCT00950534|Experimental|General Practitioner initiation with insulin glargine|Patients will be prescribed insulin glargine by their Investigator and they will be taught how to administer insulin glargine according to Australian guidelines. Patients will be treated for 24 weeks.
3234967|NCT00950534|Active Comparator|Usual standard of care|Patients will be treated by their Investigator with the usual standard of care for 24 weeks (e.g., OAD dose titration, addition of a second or third OAD, or referral to an endocrinologist)
3234968|NCT00950521|Active Comparator|PBSC Treatment|Patients in PBSC treatment will receive brain implant of autologous peripheral blood stem cell(CD34+) plus convention stroke treatment that include rehabilitation and antiplatelet medication
3234969|NCT00950521|Active Comparator|Control|Control group receive conventional stroke treatment that include rehabilitation and antiplatelet medication
3234970|NCT00950508|Active Comparator|High volume plasma exchange|3 successive plasma exchanges over 3 days
3234971|NCT00950508|Placebo Comparator|Standard medical treatment|
3234972|NCT00950495|Active Comparator|Mandibular advancement device (MAD)|an MAD is placed in the mouth prior to sleep. After waking up in the morning, the appliance is removed.
3234973|NCT00950495|Active Comparator|nasal CPAP|The device is turned on, and the nasal mask is placed on the nose prior to sleep. After waking up in the morning, the device is turned off and the mask is removed
3234974|NCT00950495|Placebo Comparator|placebo|the placebo appliance is placed in the mouth prior to sleep. After waking up in the morning, the appliance is removed.
3234975|NCT00950482|Active Comparator|TA|Active TA
3234976|NCT00950482|Active Comparator|AA|Alternative Acupuncture
3234977|NCT00950482|Active Comparator|WC|Waiting Group
3234978|NCT00950469||patients with acute coronary syndrome|"94 consecutive patients without ST-segment elevation admitted to the Chest Pain Unit of the University of Heidelberg were enrolled with symptoms suggestive of ACS.~Unstable angina and non-ST-segment elevation myocardial infarction were diagnosed using the joint European Society of Cardiology/American College of Cardiology/American Heart Association/World Heart Federation Task Force redefinition of myocardial infarction guidelines. Patients with ST-segment elevation were excluded."
3234979|NCT00950456||H1N1 Pandemic Influenza Vaccine|Subjects will be enrolled and vaccinated according to national policy and standard practice.
3234980|NCT00950443|Experimental|1|Children with upper airway obstruction
3234981|NCT00950443|Active Comparator|2|Children without upper airway obstruction
3234982|NCT00950430|Experimental|PiB PET, FDG PET, Tau PET|
3234983|NCT00950417|Experimental|Esophageal Cancer|
3234984|NCT00950404|Active Comparator|Viagra 50 mg tablet, administered with water.|
3234985|NCT00950404|Experimental|Formulation B ODT tablet 50 mg, administered without water.|
3234986|NCT00950404|Experimental|Formulation C ODT tablet 50 mg, administered without water.|
3234987|NCT00950404|Experimental|Formulation D ODT tablet 50 mg, administered without water.|
3234988|NCT00950391|Experimental|Tacrolimus|Treatment with tacrolimus following nerve repair/reconstruction
3234989|NCT00950378||CVI|Varicose veins, varicose veins with leg swelling, venous stasis skin color changes, no open ulcers
3234990|NCT00950378||No treatment|Subjects with no venous disease CEAP (clinical etiology antomy pathophysiology)Class 0
3234991|NCT00950365|Active Comparator|A|Pemetrexed Monotherapy
3234992|NCT00950365|Experimental|B|Pharmacodynamic separation of pemetrexed and erlotinib
3234993|NCT00950352|Experimental|Citicoline|In a double-blind randomization design, subjects with methamphetamine dependence will be treated with citicoline or placebo for 8-9 weeks.
3234994|NCT00950352|Placebo Comparator|Placebo|In a double-blind randomization design, subjects with methamphetamine dependence will be treated with citicoline or placebo for 8-9 weeks.
3235062|NCT00949949|Experimental|Cohort II (everolimus, gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 1 hour on days 1 and 8 and everolimus PO once daily or 3 times weekly.
3234995|NCT00950339|Experimental|4 weeks of omeprazole, 20mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
3234996|NCT00950339|Experimental|4 weeks of famotidine 40mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
3234997|NCT00950339|Experimental|4 weeks of pantoprazole 40mg once daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
3234998|NCT00950326|Active Comparator|B1-Physio|In Group B1, patients will be given physiotherapy of the hip or knee joint three times a week
3234999|NCT00950326|Experimental|A1 Hydro|In this group patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region.
3235000|NCT00950326|Active Comparator|C- Hydro & Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
3235001|NCT00950313|Active Comparator|Self Assessment|Patients are approached and asked to complete a risk score that will determine their current risk of diabetes and the likelihood of requiring further testing.
3235002|NCT00950313|Active Comparator|Electronic risk score|Patients diabetes riks is determined based on their data held on practice systems. Patients are then invited for further testing based on this score.
3235003|NCT00950300|Active Comparator|Herceptin IV + Chemotherapy|Participants will receive Herceptin via IV infusion for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin IV will be given on Day 1 of each 21-day cycle, as 8 milligrams per kilogram (mg/kg) for a loading dose during Cycle 1 and as 6 mg/kg during subsequent cycles.
3235004|NCT00950300|Experimental|Herceptin SC + Chemotherapy|Participants will receive Herceptin via SC injection for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin SC will be given on Day 1 of each 21-day cycle, as a 600-milligram (mg) fixed dose.
3235005|NCT00950287||cohort|One group of preterm infants
3235006|NCT00950274|Active Comparator|CD133+ autologous bone marrow stem cells|
3235007|NCT00950274|Placebo Comparator|Placebo|
3235008|NCT00950261|Experimental|tri-weekly cisplatin|Patients in this arm will postoperatively receive cisplatin 75mg/m2 intravenously every 3 weeks, 3 cycles with radiation
3235009|NCT00950235|Other|Usual Care|This arm will receive one additional nutrition counseling session that typically received in the health system. This arm will be compared to our intervention group
3235010|NCT00950235|Experimental|Weight Management Counseling|In-person and group session counseling
3235011|NCT00950222|Experimental|1:Imipenem/Amikacin|"patients will receive as empirical therapy for VAP imipenem associated with amikacin.After primary outcome measure, antibiotic therapy will be left at the discretion of the physician in charge of the patient.~Imipenem: recommended usual dosage for VAP treatment, IV (in the vein), every 8 hours~Amikacin: recommended usual dosage for VAP treatment (20mg/kg), IV (in the vein), single dose (at H0) for the 48 first hours of treatment"
3235012|NCT00950209|Active Comparator|euglycaemic hyperinsulinic clamp|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l."
3235013|NCT00950209|Active Comparator|euglycaemic hyperinsulinic clamp with Endolipide and heparin|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l but will be also infused with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids."
3235014|NCT00950209|Active Comparator|hyperglycaemic hyperinsulinic clamp|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose."
3235015|NCT00950196|Experimental|amantadine (PKMERZ)|
3235016|NCT00950183|Other|Foot and Ankle Surgery|Please note that the study was terminated prior to randomization of patients.
3235017|NCT00950170|Experimental|1|The investigator treats subjects with ReFacto AF in the usual care setting.
3235018|NCT00950157|Experimental|"Directive open question statement"|"Survey describes the surrogate outcome of the drug along with a directive warning (i.e., stating the issue and why it matters) for drugs shown to improve surrogate outcomes.~This directive warning mentions that it is not known whether the drug will help patients feel better, and that readers should ask their doctor if there is an available drug shown to improve patient outcomes."
3235019|NCT00950157|Experimental|Non-directive open question statement|"Survey describes the surrogate outcome of the drug along with a non-directive warning (i.e., stating the issue only) for drugs shown to improve surrogate outcomes.~This non-directive warning mentions only that it is not known whether the drug will help patients feel better."
3235020|NCT00950157|Experimental|No open question statement|Survey only describes the surrogate outcome of the drug.
3235063|NCT00949949|Experimental|Cohort III (MTD)|Patients receive treatment as in cohort II.
3235021|NCT00950131|Experimental|Directive new drug warning|"Survey contains information about when the drug was approved by the FDA (2009)and a directive warning (i.e., stating the issue and why it matters) for new drugs.~This directive warning mentions that serious drug side effects may emerge only after the drug is already on the market, and the reader should ask their doctor there is an available drug with a longer track record."
3235022|NCT00950131|Experimental|Non-directive new drug warning|"Survey contains information about when the drug was approved by the FDA (2009) and a non-directive warning (i.e., just stating the issue) for new drugs.~This non-directive warning mentions only that serious drug side effects may emerge only after the drug is already on the market."
3235023|NCT00950131|Experimental|No new drug warning|Survey contains information about when the drug was approved by the FDA (2009) only.
3235024|NCT00950118||Congenital Diaphragmatic Hernia (CDH)|Humans affected with congenital diaphragmatic hernia (CDH)
3235025|NCT00950118||Unaffected|Healthy family members of individuals affected with congenital diaphragmatic hernia (CDH)
3235026|NCT00950105|Experimental|CPSI-2364 1 mg p.o.|Single dose
3235027|NCT00950105|Experimental|CPSI-2364 10 mg p.o.|single dose
3235028|NCT00950105|Experimental|CPSI-2364 30 mg p.o.|single dose
3235029|NCT00950105|Experimental|CPSI-2364 90 mg|single dose
3235030|NCT00950105|Experimental|CPSI-2364 270 mg p.o.|single dose
3235031|NCT00950092|Other|Treatment|
3235032|NCT00950079|Experimental|Sodium bicarbonate|sodium bicarbonate
3235033|NCT00950079|Active Comparator|Saline|saline infusion
3235034|NCT00950066|Placebo Comparator|Placebo|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with placebo once a day."
3235035|NCT00950066|Active Comparator|Irbesartan 150mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 150 mg once a day."
3235036|NCT00950066|Active Comparator|Irbesartan 150 mg / Amlodipine 5 mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 150 mg / Amlodipine 5 mg once a day."
3235037|NCT00950066|Active Comparator|Amlodipine|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Amlodipine 5 mg once a day."
3235038|NCT00950066|Active Comparator|Irbesartan 300 mg|"Active Comparator: Irbesartan~Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 300 mg once a day."
3235039|NCT00950066|Active Comparator|Irbesartan 300 mg / Amlodipine 5 mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 300 mg / Amlodipine 5 mg once a day."
3235040|NCT00950053|Active Comparator|Achilles decompression & debridement|
3235041|NCT00950053|Active Comparator|Achilles decompression,debride&FHLtransf|Achilles tendon decompression and debridement augmented with FHL transfer. The preferred skin incision will be followed by central-splitting Achilles debridement, resection of a Haglund's lesion if present and pathologic, followed by FHL harvest for patients in group 2. The fixation technique in group 2 will utilize an interference screw for the FHL. For all patients, the Achilles will be reattached with lateral and medial suture anchors (just distal to interference screw in FHL patients).
3235042|NCT00950040|Experimental|Brief alcohol intervention|Brief alcohol intervention delivered in 2 15-minute in-person sessions and 2 5-minute telephone sessions.
3235043|NCT00950040|Active Comparator|General Health Education|General health education intervention delivered in 2 15-minute in-person sessions and 2 5-minute telephone sessions.
3235044|NCT00950027|Experimental|povidone iodine|Povidone iodine
3235045|NCT00950027|Placebo Comparator|placebo|
3235046|NCT00950014|Experimental|Percentage format only|Numbers are presented in percentage format (e.g., 35%, 0.2%) only.
3235047|NCT00950014|Experimental|Fixed frequency format only|Numbers are presented in fixed frequency format only (5 out of 1000, 0.6 out of 1000). Denominators remains the same for each number.
3235048|NCT00950014|Experimental|Variable frequency format|Frequency denominators are adjusted to keep the numerator greater than 1, so they may change throughout the survey (e.g., 6 out of 1000, 42 out of 100)
3235049|NCT00950014|Active Comparator|Fixed combination format|Numbers are presented with both percentages and frequencies, and frequency denominators remain fixed (e.g., _ out of 1000).
3235050|NCT00950014|Experimental|Variable combination format|Numbers are presented with both percentages and frequencies, but frequency denominators may vary (e.g., _ out of 1000, _ out of 100).
3235051|NCT00950001|Experimental|Stereotactic Radiosurgery (SRS)|Receive stereotactic radiosurgery (SRS) to area of brain where metastasis removed.
3235052|NCT00950001|Active Comparator|Magnetic Resonance Imaging (MRI)|Observed with routine post operative magnetic resonance imaging (MRI) scans only.
3235053|NCT00949988|Active Comparator|Dasatinib - 100 mg (Phase I)|Dasatinib - 100 mg (Phase I)
3235054|NCT00949988|Active Comparator|Dasatinib - 70 mg (Phase I)|Dasatinib - 70 mg (Phase I)
3235055|NCT00949975|Active Comparator|1|AZD9668 active treatment
3235056|NCT00949975|Active Comparator|2|AZD9668 active treatment
3235057|NCT00949975|Active Comparator|3|AZD9668 active treatment
3235058|NCT00949975|Placebo Comparator|4|AZD9668 placebo treatment
3235059|NCT00949962|Active Comparator|Arm I|Patients undergo post-operative conformal external beam irradiation for 6.5 weeks.
3235060|NCT00949962|Experimental|Arm II|Beginning on day -5 to -3, patients receive an antiandrogen for 2-4 weeks. Beginning on day 0, patients receive leuprolide acetate subcutaneously once (6-month depot) and undergo conformal external beam irradiation 5 times weekly for 6.5 weeks.
3235061|NCT00949949|Experimental|Cohort I (everolimus and gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and everolimus PO once daily or 3 times weekly.
3235066|NCT00949910|Experimental|Erlotinib|Erlotinib will be given as a single agent in this expanded access program (EAP) to participants with inoperable, locally advanced, recurrent, or metastatic NSCLC. Treatment will continue until unacceptable toxicity, disease progression, or withdrawal for any other reason.
3235067|NCT00949897|Active Comparator|Biofoam|
3235068|NCT00949897|Active Comparator|Iliac Crest Allograft with locked plate|
3235069|NCT00949884|Experimental|Olmesartan|Olmesartan 20 mg once daily for four weeks followed by 40mg one daily for four weeks.
3235070|NCT00949884|Placebo Comparator|Placebo followed by Olmesartan|Placebo capsule of olmesartan once daily for 2 weeks, followed by olmesartan 20 mg once daily for two weeks, followed by olmesartan 40 mg for 4 weeks
3235071|NCT00949884|Active Comparator|Losartan|Losartan 50 mg once daily for four weeks, followed by losartan 100 mg once daily for four weeks
3235072|NCT00949832|Active Comparator|Vitamin D + Calcium|Vitamin D and calcium supplementation
3235073|NCT00949832|Placebo Comparator|Calcium|Calcium supplementation
3235074|NCT00949832|Active Comparator|Vitamin D2|Vitamin D2 response
3235075|NCT00949832|Active Comparator|Vitamin D3|Vitamin D3 response
3235076|NCT00949819||no treatment|Men with previously untreated, early stage prostate cancer.
3235077|NCT00949806|Experimental|Administrated|All patients included will receive an intradermal administration of BNT
3235078|NCT00949793|Experimental|All patients|
3235079|NCT00949780|Active Comparator|chloral hydrate , sedative|
3235080|NCT00949767|Experimental|BMS-866949 (Panel 1)|
3235081|NCT00949767|Experimental|BMS-866949 (Panel 2)|
3235082|NCT00949767|Experimental|BMS-866949 (Panel 3)|
3235083|NCT00949767|Experimental|BMS-866949 (Panel 4)|
3235084|NCT00949767|Experimental|BMS-866949 (Panel 5)|
3235085|NCT00949767|Experimental|BMS-866949 (Panel 6)|
3235086|NCT00949767|Experimental|BMS-866949 (Panel 7)|
3235087|NCT00949754|Active Comparator|histamine|histamine in saline administered ID as active control for Apitox
3235088|NCT00949754|Experimental|Apitox pure honeybee venom|ID study drug
3235089|NCT00949728|Other|Fibrin glue|
3235090|NCT00949715|Active Comparator|RV Mid-Septal Pacing|Pacing lead located in the right ventricle at the middle of the muscle separating the right and left sides of the heart
3235091|NCT00949715|Active Comparator|RV Apical Pacing|Pacing lead located at the bottom of the right ventricle of the heart, in the right ventricular apex
3235092|NCT00949702|Experimental|Single arm|
3235093|NCT00949689|Experimental|Cognitive Behavioral Therapy for insomnia and depression|cognitive behavioral therapy for insomnia followed by cognitive behavioral therapy for depression
3235094|NCT00949689|Active Comparator|contol|participants will receive sleep hygiene, time management techniques and cognitive therapy for depression
3235095|NCT00949676||Heart Failure|
3235096|NCT00949663|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
3235097|NCT00949663|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
3235098|NCT00949663|Experimental|Type 2 Diabetes Mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
3235099|NCT00949650|Experimental|BIBW 2992|BIBW 2992 tablet once daily until progression
3235100|NCT00949650|Active Comparator|Cisplatin/Pemetrexed|Cisplatin and Pemetrexed IV once every 3 weeks for up to 6 cycles
3235101|NCT00949637|Experimental|Scouting curricular implementation|Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
3235102|NCT00949637|Active Comparator|Standard-care attentional control|Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
3235103|NCT00949624|Experimental|Cohort 1|60 mg BID/ 75 mg/m2
3235104|NCT00949624|Experimental|Cohort 2|100 mg BID/75 mg/m2
3235105|NCT00949624|Experimental|Cohort 3|100 mg BID/100 mg/m2
3235106|NCT00949624|Experimental|Cohort 4b|CP-868,596 + AG-013736 + TXT 75
3235107|NCT00949611|Experimental|FRAX + Decision Aid|
3235108|NCT00949611|No Intervention|Usual care|
3235109|NCT00949611|Experimental|FRAX estimated fracture risk|
3235110|NCT00949598|Experimental|Arm I|Patients receive oral letrozole once daily for 16 weeks.
3235111|NCT00949598|Experimental|Arm II|Patients receive oral tamoxifen citrate once daily for 16 weeks.
3235112|NCT00949585|Other|Dietary potassium intake: 100 mmol/day|Participants will be given one of two diets: one contains 100 mmol of potassium per day, and the other contains 40 mmol of potassium per day
3235113|NCT00949585|Other|Dietary potassium intake: 40 mmol/day|Diet containing 40 mmol/day of potassium
3235114|NCT00949572|Experimental|Intramuscular administration|Intramuscular injection of HPV vaccine proteins
3235115|NCT00949572|Experimental|Sublingual administration|Sublingual administration of HPV vaccine proteins
3235116|NCT00949546||placebo controlled|A randomized, double-blind trial of 3 months duration comparing etanercept 50 mg sc twice weekly to placebo in 20 patients with HS. Patients will be randomized with equal allocation to the two treatment groups.
3235117|NCT00949533|Experimental|Standard Dose|Oseltamivir capsule will be administered orally at a dose of 75 mg BID in adult participants and children will receive oseltamivir powder for oral suspension dose (at 12 milligrams/ milliliter [mg/mL]) based on their body weight with a starting dose of 30 mg BID to a maximum dose of 75 mg BID; for 5 days.
3235202|NCT00948779|Other|antibiotics|antibiotic education for children in an emergency care unit: Patient and family's therapeutic education to improve the use of antibiotics at home.
3235118|NCT00949533|Active Comparator|Double Dose|Oseltamivir capsule will be administered orally at a dose of 150 mg BID in adult participants and children will receive oseltamivir powder for oral suspension dose (at 12 mg/mL) based on their body weight with a starting dose of 60 mg BID to a maximum dose of 150 mg BID; for 5 days.
3235119|NCT00949507||anaesthesia using propofol|the children are anaesthetized using intravenous anaesthesia with propofol and remifentanil; a binasal catheter is used for administration of oxygen during the anaesthesia
3235120|NCT00949507||anaesthesia using sevoflurane|the patients are anaesthetized using sevoflurane 1 MAC; a laryngeal mask is used
3235121|NCT00949494|Active Comparator|Synvisc|
3235122|NCT00949494|Placebo Comparator|Placebo|
3235123|NCT00949481|Experimental|Supply|In each country, this arm will be comprised of women attending family planning clinics within the 5 facilities randomized to this group.
3235124|NCT00949481|Experimental|Demand|In each country, this arm will be comprised of women attending immunization clinics within the 5 facilities randomized to this group.
3235125|NCT00949481|No Intervention|Control|In each country, this arm will be comprised of women attending family planning and immunization clinics in 5 facilities randomized to this group.
3235126|NCT00949468||Keratitis group|37 patients with keratitis
3235127|NCT00949468||Control Study Group|37 control volunteers
3235128|NCT00949455|Experimental|Arm I|Patients receive oral lapatinib ditosylate once daily in the absence of disease progression or unacceptable toxicity.
3235129|NCT00949455|Placebo Comparator|Arm II|Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity.
3235130|NCT00949442|Experimental|1|"Before randomization (common with arm 2):~2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride~After randomization:~36 weeks of study treatment phase: Insulin Glargine + OAD(s) at stable dose"
3235131|NCT00949442|Active Comparator|2|"Before randomization (common with arm 1):~2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride~After randomization:~36 weeks of study treatment phase: NPH + OAD(s) at stable dose"
3235132|NCT00949403||Obese Females (pre-bariatric surgery)|Twenty obese females (18-45 years of age, BMI > or equal to 45) who are scheduled to undergo bariatric surgery at Barnes-Jewish Hospital will be screened for enrollment over 2 years.
3235133|NCT00949390||Phase I and CAM Survey|Complementary and alternative medicine (CAM) in patients with advanced malignancies currently treated on University of Texas MD Anderson Cancer Center Phase I clinical trials.
3235134|NCT00949377|Experimental|Methylnaltrexone Bromide|
3235135|NCT00949377|Placebo Comparator|Normal Saline|
3235136|NCT00949364|Experimental|Pomalidomide|Every patient will remain on treatment until disease progression for at least 12 cycles, withdrawal of patient's informed consent or the occurrence of unacceptable toxicity. If a patient may benefit from treatment with pomalidomide the investigator together with the principle investigator will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision. This additional treatment will be performed within the follow-up period of the study, data will be collected and duration will be maximally 12 cycles.
3235137|NCT00949351|Placebo Comparator|Aliskiren|
3235138|NCT00949338|Active Comparator|Arm I|Patients empty their bladders and consume 6 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a bladder volume instrument (BVI) periodically during treatment.
3235139|NCT00949338|Experimental|Arm II|Patients empty their bladders and consume 3 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a BVI periodically during treatment.
3235140|NCT00949325|Experimental|Temsirolimus plus Liposomal Doxorubicin|Single arm: Temsirolimus is administered IV in cohorts of sequentially escalating cohorts at doses between 15 and 50 mg/M2 (body surface area), once weekly. Liposomal doxorubicin is administered IV at a dose of 30 mg per M2 (body surface area) once every 28 days. Treatment may continue with both drugs for 2 years. Treatment with Temsirolimus may continue beyond 2 years.
3235141|NCT00949312||Stage II unresected Colon Cancer|
3235142|NCT00949273||cylindrical abdominoperineal resection|patients underwent cylindrical abdominoperineal resection for advanced very low rectal cancer
3235143|NCT00949273||abdominoperineal resection|patients underwent conventional abdominoperineal resection for advanced very low rectal cancer
3235144|NCT00949260||Normal, Non-Pregnant|Normal, non-pregnant patients will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
3235145|NCT00949260||Normal, Pregnant|Normal, pregnant patients in their 3rd trimester will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
3235146|NCT00949260||Pregnant, PIH|Pregnant patients in their 3rd trimester with pregnancy-induced hypertension that has not been treated will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
3235147|NCT00949247|Experimental|Docetaxel,Carboplatin,Trastuzumab and Bevacizumab|
3235148|NCT00949234|Other|Open-Label|This was an open-label demonstration project. Therefore, medications were not blinded and participants were made aware of the regimen they received for PEP.
3235149|NCT00949221|Other|Group 1|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months
3235150|NCT00949221|Other|Group 2|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Intensive strategy using continuous glucose monitoring for 12 months
3235151|NCT00949221|Other|Group 3|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring).
3235152|NCT00949208||A|The study population will consist of healthy volunteers who fulfill all the inclusion criteria and do not meet any of the exclusion criteria.
3235153|NCT00949195||COPD patients|COPD patients with severe obstruction performed the tests.
3235154|NCT00949195||Healthy subjects|Age-matched healthy subjects performed the same test also.
3235287|NCT00948129|Experimental|Standard Care|Group 1 - Standard Care (SC) approach
3235155|NCT00949182|Experimental|Sorafenib Tosylate, Doxorubicin, Mytomicin C|Micro and Macro arteriolar blockade of hepatocellular carcinoma (HCC): Treatment with Sorafenib 400mg two weeks prior to embolization HACE which includes the use of agents such as Doxorubicin Hydrochloride and Mytomicin C, continuing same Sorafenib dose after the procedure (dose adjustment according to tolerance).
3235156|NCT00949169||Carrotid IMT group according to maximal IMT|We defined increased IMT group as whom had maximal IMT ≥ 1.0 mm.
3235157|NCT00949156||Retrospective cohort|The 198 cases of CP with primary surgery in our hospital (since July, 1997 until now) were divided into three topographical groups based on the pre-operative MRI, intraoperative findings and the tumor-membrane relationship. The presurgical manifestation, the different surgical approach, intraoperative techniques, and postoperative complication were described and analyzed to establish a normalized surgical treatment of individual CP patient, which has the highest rate of the totally tumoral resection and the lowest rate of the hypothalamic injury.
3235158|NCT00949156||Prospective cohort|The anticipated 40 cases of CP were surgical treated by our standard procedure, which is recruited in the prospective cohort. With the long-term follow up, QOL including the cognition, circadian rhythm, endocrine, Water-Electrolyte, and body weight et al were evaluated to assess the rationality of the treatment. Then according to the results, the surgical treatment was modified, and the endocrinic substitution therapy was also been developed.
3235159|NCT00949143|Experimental|forward position|
3235160|NCT00949143|Experimental|rear position|
3235161|NCT00949130|Experimental|NXL103|BID for 7-14 days orally
3235162|NCT00949130|Active Comparator|Linezolid|BID for 7-14 days orally
3235163|NCT00949117|Experimental|Arm I- cyproheptadine hydrochloride|Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
3235164|NCT00949117|Experimental|cyproheptadine HCl & PediaSure or Ensure|Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (> 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
3235165|NCT00949104|Active Comparator|Sucrose|1 ml of 24% sucrose was administered 2 minutes before the procedure
3235166|NCT00949104|Placebo Comparator|Placebo|Double distilled water
3235167|NCT00949091|Experimental|1|
3235168|NCT00949078|Experimental|Open Label Omalizumab Group A|Omalizumab was dosed according to package insert. Patients who have a decrease in peanut allergen induced basophil histamine release (Pn-BHR) to less than 20% of baseline will be assigned to this group.
3235169|NCT00949078|Experimental|Open Label Omalizumab Group B|Omalizumab was dosed according to package insert. Patients who do not have a decrease in peanut allergen induced basophil histamine release (Pn-BHR) to less than 20% of baseline will be assigned to this group.
3235170|NCT00949065|Active Comparator|Intravenous immunoglobulins (IvIg)|3 x 0.36-0.44g/Kg IvIg every 4 weeks, then 3 months washing out, then 3x NaCl 0.9% every 4 weeks
3235171|NCT00949065|Placebo Comparator|NaCl 0.9%|NaCl 0.9%, 3x, every 4 weeks, then 3 months washing out, then 0.36-0.44g/Kg IvIg, 3x, every 4 weeks
3235172|NCT00949039|Experimental|Chemotherapy|Isolated pelvis perfusion
3235173|NCT00949039|Active Comparator|Control|Standard treatment
3235174|NCT00949026|Experimental|A|
3235175|NCT00949000|Other|ICD Implant|Implantation of a commercially available AnalyST or AnalyST Accel ICD
3235176|NCT00948987|Experimental|Aspirin|single dose of aspirin 325 mg p.o.
3235177|NCT00948974|Active Comparator|cognitive therapy|cognitive therapy and exposure
3235178|NCT00948974|Active Comparator|acceptance and committment therapy|acceptance and commitment therapy and exposure
3235179|NCT00948935|Experimental|Chemotherapy|Gemcitabine (Days 1, 8), irinotecan (days 1, 8) and panitumumab (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
3235180|NCT00948922|Other|Autologous Stem Cell Transplant|Autologous Stem Cell Transplant: Melphalan+Bortezomib followed by Autologous Rescue.
3235181|NCT00948922|Other|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant: Fludarabine+Melphalan+Bortezomib followed by Allogeneic Rescue.
3235182|NCT00948909|Placebo Comparator|A. Sugar Pill|
3235183|NCT00948909|Experimental|B. ABT-126|
3235184|NCT00948909|Experimental|C. ABT-126|
3235185|NCT00948909|Active Comparator|D. donepezil|
3235186|NCT00948896|Experimental|1|
3235187|NCT00948896|Experimental|2|
3235188|NCT00948896|Experimental|3|
3235189|NCT00948896|No Intervention|4|
3235190|NCT00948883||Patient-Case|Transplanted patient with cancer
3235191|NCT00948883||Patient-Control|Transplanted patient without cancer
3235192|NCT00948870|Experimental|Shugan Decoction|
3235193|NCT00948870|Placebo Comparator|low does of Shugan decoction|
3235194|NCT00948857|Experimental|DHEA active treatment|Dehydroepiandrosterone 25 mg tid po
3235195|NCT00948857|Placebo Comparator|DHEA Placebo|Blinded placebo
3235196|NCT00948818|Experimental|Linaclotide|Linaclotide 290 micrograms
3235197|NCT00948818|Placebo Comparator|Placebo|Matching placebo
3235198|NCT00948805|Experimental|GnRH agonist|3,6 mg of goserelin acetate (GnRH agonist) will be administered on the 21st day of the menstrual cycle previous to ovarian stimulation. 250 mg of hCG will be administered on the first day of menses and a starting dose of 150 IU of FSH will be started 2 days later as a part of a long ovarian stimulation protocol. Ovulation will be triggered with a 250 mg of hCG when at least 2 follicles attain 18mm and to accommodate oocyte retrieval within 36 hours.
3235199|NCT00948805|Active Comparator|Control|250 mg of hCG will be administered on the first day of menses and a starting dose of 150 IU of FSH will be started 2 days later as a part of a long ovarian stimulation protocol. Ovulation will be triggered with a 250 mg of hCG when at least 2 follicles attain 18mm and to accommodate oocyte retrieval within 36 hours.
3235200|NCT00948792|Active Comparator|Long transfusion group|This group of thrombocytopenic neonates who (as determined by the attending physician) are in need of a platelet transfusion will receive the transfusion over a period of two hours.
3235201|NCT00948792|Experimental|Short transfusion group|This group of thrombocytopenic neonates who (as determined by the attending physician) are in need of a platelet transfusion will receive the transfusion over a period of 30 minutes.
3236509|NCT00939744||EAU2|Women who will have a c-section at the CHUS
3235203|NCT00948779|Experimental|the antipyretic therapy|antibiotic education for children in an emergency care unit: Patient and family's therapeutic education to improve the antipyretic therapy at home.
3235204|NCT00948766|Experimental|Rivastigmine 13.3 mg/24 h transdermal patch|In the core study, patients were titrated to the rivastigmine 13.3 mg/24 h dose in 2 steps. For Weeks 1-4, patients received rivastigmine 4.6 mg/24 h. For Weeks 5-8, patients received rivastigmine 9.5 mg/24 h and placebo. For Weeks 9-24, patients received rivastigmine 13.3 mg/24 h and placebo. In the extension study, all patients were switched to rivastigmine 9.5 mg/24 h for a 4-week titration period and were then titrated up to 13.3 mg/24 h for a further 20 weeks of treatment.
3235205|NCT00948766|Active Comparator|Rivastigmine 4.6 mg/24 h transdermal patch|In the core study, patients received rivastigmine 4.6 mg/24 h daily. For Weeks 1-4, patients received rivastigmine 4.6 mg/24 h. For Weeks 5-24, patients received rivastigmine 4.6 mg/24 h and placebo. No patients received this treatment in the extension study.
3235206|NCT00948753|Experimental|Maraviroc + standard GVHD prophylaxis|Maraviroc 300 mg bid (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stell-cell infusion.
3235207|NCT00948740|Experimental|ergocalciferol|After signing informed consent, all participants who meet the study criteria will receive ergocalciferol 50,000 IU weekly for 8 weeks. After completing the ergocalciferol course, participants will take a maintenance dose of cholecalciferol 1,000 IU daily.
3235208|NCT00948727|Experimental|Dose adjustment according CN activity|
3235209|NCT00948714|Experimental|Case|
3235210|NCT00948714|Active Comparator|Control|
3235211|NCT00948701|Experimental|Phone-based PA program (RTR Plus)|"The PA intervention consists of PA counseling, matched to participants' motivational readiness, plus educational materials. RTR volunteers or coaches will be asked to contact participants by telephone once a week for 12 weeks. The purpose of these calls is to build a supportive relationship with the participant, monitor PA participation, identify any health concerns, assist the participant to identify relevant barriers to PA and help her to problem solve to overcome such barriers."
3235212|NCT00948701|Active Comparator|Standard RTR services (RTR)|RTR volunteers will contact the participants in this group by telephone once a week, providing support and information integral to RTR. The volunteers will also review the educational materials sent to all participants receiving RTR services. This will allow the volunteers to build a relationship with the participants over 12 weeks and ensure that these participants receive a minimal intervention, reducing the risk of attrition at the 12-week assessment.
3235213|NCT00948688|Experimental|Vorinostat, 5-FU, Radiation Therapy|Vorinostat at varying doses; orally, days 1-7, weeks 1-6 5-FU 225 mg/m2/day; intravenous; days 1-5, weeks 1-6 until completion of radiation therapy; Radiation therapy; 180cGy daily Monday-Friday; 28 days of treatment (6 weeks)
3235214|NCT00948675|Experimental|Pemetrexed + Carboplatin + Pemetrexed|Pemetrexed and Carboplatin followed by Pemetrexed
3235215|NCT00948675|Active Comparator|Paclitaxel + Carboplatin + Bevacizumab|Paclitaxel, Carboplatin, and Bevacizumab followed by Bevacizumab
3235216|NCT00948662|Experimental|1|active arm/healthy young
3235217|NCT00948662|Placebo Comparator|2|placebo arm
3235218|NCT00948662|Other|3|ketoconazole interaction evaluation
3235219|NCT00948649|Active Comparator|Varenicline|Participants will complete a 21-day study phase that will include a 10-day drug run-up and monitoring phase (days 1-10), a 3-day abstinence phase (days 11-13), and a programmed lapse (day 14) followed by a 7-day observation phase in which participants are asked to remain abstinent and will receive modest monetary reinforcement for doing so (days 15-21).
3235220|NCT00948649|Placebo Comparator|Placebo|Participants will complete a 21-day study phase that will include a 10-day drug run-up and monitoring phase (days 1-10), a 3-day abstinence phase (days 11-13), and a programmed lapse (day 14) followed by a 7-day observation phase in which participants are asked to remain abstinent and will receive modest monetary reinforcement for doing so (days 15-21).
3235221|NCT00948636||Related Donors|Related Hematopoietic Stem Cell Donors
3235222|NCT00948623|Experimental|1|
3235223|NCT00948623|Sham Comparator|2|
3235224|NCT00948610|Placebo Comparator|Placebo|Placebo—participant will receive placebo saline solution via IV route.
3235225|NCT00948610|Active Comparator|Remicade|Remicade—Participant will be given 10 mg/kg of drug via IV route.
3235226|NCT00948584|Experimental|insulin titration by specialized system|Insulin dose titration system by using a SMS automatically produced by a knowledge matrix
3235227|NCT00948571||head down, laparoscopic|20 patients with laparoscopic surgery (radical robotic prostatectomy) in head down position
3235228|NCT00948571||head down, open|"20 patients undergoing opensurgery (open radical prostatectomy) in head down position."
3235229|NCT00948571||horizontal, open|"20 patients undergoing open surgery in horizontal position (open hemicolectomy)"
3235230|NCT00948545||No treatment|Observing individuals pre and post bariatric surgery
3235231|NCT00948519|Experimental|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
3235232|NCT00948519|Active Comparator|Laser only|same as above, without ICG
3235233|NCT00948506|Placebo Comparator|1% topical cidofovir|1% topical cidofovir to one side of the face and placebo to the other side of the face
3235234|NCT00948506|Placebo Comparator|3% topical cidofovir|3% topical cidofovir to one side of the face and placebo to the other side of the face
3235235|NCT00948467|Experimental|TAK-733|
3235236|NCT00948454||Light smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Subjects will bring their own cigarettes on that day and smoke their regular amount. Female subjects will also have a pregnancy test done on the test day.
3235288|NCT00948129|Experimental|Enhanced Care|Group 2 - Enhanced Care (EC) approach
3235289|NCT00948129|Experimental|Intensive Care|Group 3 - Intensive Care (IC) approach
3236510|NCT00939731|Experimental|PIC|
3235237|NCT00948454||Heavy Smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Subjects will bring their own cigarettes on that day and smoke their regular amount. Female subjects will also have a pregnancy test done on the test day.
3235238|NCT00948454||Non Smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Female subjects will also have a pregnancy test done on the test day.
3235239|NCT00948441|Experimental|Group 1|25% ethanol for 12 weeks; wash out period for 4 weeks; heparin lock for 12 weeks
3235240|NCT00948441|Experimental|Group 2|heparin lock for 12 weeks; wash out period for 4 weeks; 25% ethanol lock for 12 weeks
3235241|NCT00948428|Active Comparator|Generic Imiquimod|imiquimod cream, 5%
3235242|NCT00948428|Active Comparator|Aldara™|Aldara™ (imiquimod) cream, 5%
3235243|NCT00948428|Placebo Comparator|Vehicle cream|Vehicle cream (Actavis)
3235244|NCT00948415|Experimental|SURI Enhanced|
3235245|NCT00948415|Active Comparator|SURI Standard|
3235246|NCT00948402|Experimental|metformin|
3235247|NCT00948402|Active Comparator|oral contraceptive|
3235248|NCT00948389|Active Comparator|Dasatinib|
3235249|NCT00948389|Active Comparator|Lomustine|
3235250|NCT00948376||Patients|All ages
3235251|NCT00948376||Fetuses|
3235252|NCT00948363|Active Comparator|Kiwi fruits|
3235253|NCT00948363|Placebo Comparator|Apple|
3235254|NCT00948350|Active Comparator|translaryngeal injection|translaryngeal injection of local anesthetics before the awake intubation
3235255|NCT00948350|Active Comparator|spray as you go|local anesthetics are given through the fiberoptic during awake intubation
3235256|NCT00948337|Experimental|Photonovella of Secondary Cancer Screening|
3235257|NCT00948337|Active Comparator|Photonovella of Dietary Suppelment of Cancer survivor|
3235258|NCT00948324|Active Comparator|CSII|CSII: Patients in continuous subcutaneous insulin infusion group received insulin analogue with an insulin pump along.
3235259|NCT00948324|Active Comparator|ALA|ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD.
3235260|NCT00948324|Active Comparator|RSG|RSG:CSII combined with three months rosiglitazoneor 4mg QD.
3235261|NCT00948324|Active Comparator|MET|MET:CSII combined with metformin 500mg BID-TID.
3235262|NCT00948298|Placebo Comparator|Placebo|
3235263|NCT00948298|Experimental|Vitamin D|
3235264|NCT00948285|Experimental|MRI|Preoperative staging with mammogram, ultrasound, and MRI, followed by surgery (n=200)
3235265|NCT00948285|No Intervention|Non-MRI|Preoperative staging with mammogram and ultrasound alone, followed by surgery (n=200)
3235266|NCT00948272|Experimental|VRVg Group|
3235267|NCT00948272|Active Comparator|Verorab Group|
3235268|NCT00948259|Experimental|NP031112|Patients will receive 400 mg of NP031112 for 4 weeks, if tolerated, they will receive 600 mg for 4 additional weeks. Patients that tolerate this dose will receive 800 mg for 6 weeks and the patients that tolerate this will escalate to 1000 mg for an additional 6 weeks. Patients that are not eligible for dose escalation will remain on the tolerated dose for the remainder of the study.
3235269|NCT00948259|Placebo Comparator|Placebo|Patients will receive 400 mg for 4 weeks, if tolerated, they will receive 600 mg for 4 additional weeks. Patients that tolerate this will receive 800 mg for 6 weeks and the patients that tolerate this will escalate to 1000 mg for an additional 6 weeks. Patients that are not eligible for escalation will remain on the tolerated dose for the remainder of the study.
3235270|NCT00948246||Easyband|Subjects who had the Easyband device implanted laparoscopically.
3235271|NCT00948233||Intervention|Educational video game
3235272|NCT00948233||Standard Care|Pamphlets on stopping tobacco use
3235273|NCT00948220|Experimental|Treatment|Chronic hepatitis C patients on standard antiviral therapy with peginterferon alfa-2a and ribavirin
3235274|NCT00948220|No Intervention|Control|Chronic hepatitis C patients without standard antiviral therapy
3235275|NCT00948207|Experimental|My Living Story|"My Living Story elicits a dignity-enhancing life story via a telephone interview, and delivers the edited transcript on the patient's personal miLivingStory social network. miLivingStory also provides a direct link to miStory, a life review education website with links to high quality websites that provide cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks.~miLivingStory and miStory are both password protected."
3235276|NCT00948207|Active Comparator|My Own Resources|"My Own Resources offers usual care access to high quality websites that provide cancer information, databases to do your own research, social support, and interactive planning tools. Participants will receive access to the website miOwnResources."
3235277|NCT00948194|No Intervention|No nitric oxide|This arm will not receive nitric oxide, but will receive other standard inhaled anesthetics
3235278|NCT00948194|Experimental|Nitric Oxide|Will receive Nitric oxide and other standard inhaled anesthetics
3235279|NCT00948181||Surgeon|To detect the degree of intraoperative stress, venous blod will be drawn from one surgeon during 8 pheochromocytoma resections.
3235280|NCT00948181||Anesthesiologist|To detect the degree of intraoperative stress, venous blood will be drawn from one anesthesiologist during 8 pheochromocytoma resections.
3235281|NCT00948181||Patients with pheochromocytoma|Venous blood will be drawn from 8 patients with pheochromocytoma during tumor resection.
3235282|NCT00948155|Experimental|Varenicline before placebo|"Drug (Varenicline (Chantix)): Placebo~Intervention to be administered is: participants will receive standard dosing regimen of Varenicline for 21 days total, followed by 14-day washout and 21 days of placebo. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21."
3235283|NCT00948155|Experimental|Placebo then Varenicline|"Placebo: Drug Varenicline (Chantix)~Intervention to be administered is: participants will receive 21 days of placebo, followed by 14-day washout and standard dosing regimen of Varenicline for 21 days total. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21.~Intervention 'Drug (Varenicline (Chantix)): Placebo'"
3235284|NCT00948142|Active Comparator|Linezolid|600 mg BID
3235285|NCT00948142|Experimental|CEM-102 Regimen A|
3235286|NCT00948142|Experimental|CEM-102 Regimen B|
3236511|NCT00939731|Experimental|IRT|
3235290|NCT00948116||Diabetes mellitus, renal impairment|Patients with both diabetes mellitus and eGFR <60 ml/min
3235291|NCT00948103|Placebo Comparator|Oxygen|
3235292|NCT00948103|Active Comparator|Nitrous Oxide|
3235293|NCT00948090|Experimental|IV Busulfan|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant
3235294|NCT00948077|Active Comparator|Treatment A|"Study agents (Rifater+EMB) will be given approximately 45 minutes prior to the breakfast."
3235295|NCT00948077|Experimental|Treatment B|"Study agents (Rifater+EMB) will be given approximately 45 minutes after the breakfast is finished."
3235296|NCT00948064|Experimental|Vorinostat with Azacitidine|ARM A: Azacitidine 75 mg/m^2/day by vein over 15 - 30 minutes daily for 5 days (Days 1 - 5). Vorinostat 200 mg by mouth three time a day with food for 5 days (Days 1 - 5). Courses repeated every 3 to 8 weeks.
3235297|NCT00948064|Experimental|Azacitidine|ARM B: Azacitidine 75 mg/m^2 /day by vein over 15 - 30 minutes daily for 5 days (Days 1 - 5). Courses repeated every 3 to 8 weeks.
3235298|NCT00948051|Experimental|Fructo-oligosaccharides|
3235299|NCT00948051|Placebo Comparator|Placebo|
3235300|NCT00948038|Active Comparator|Soy|Soy-based supplement to normal diet
3235301|NCT00948038|Experimental|Milk|Milk-based supplement to normal diet
3235302|NCT00948025|Active Comparator|Avance Nerve Graft|Commercially available Avance Nerve Graft for repair of nerve gap
3235303|NCT00948025|Active Comparator|Hollow Tube Conduit|Commercially available hollow tube conduit for repair of nerve gap.
3235304|NCT00948012||Patients without pulmonary hypertension|Patients with sickle cell with normal response of pulmonary artery pressure to exercise
3235305|NCT00948012||Exercise-induced pulmonary hypertension|Patients with sickle-cell anemia with exercise-induced pulmonary hypertension.
3235306|NCT00947999||Healthy Control Group|Subjects in particular group will not have a diagnosis of SCI and do not experience chronic pain. Subjects in this group will be matched roughly to subjects in the SCI chronic pain group based on age, gender and race/ethnicity.
3235307|NCT00947999||Subjects with SCI and Chronic Pain|Individuals recruited into this particular group will have a diagnosis of a spinal cord injury and experience pain on a daily basis with an average intensity of 4 out of 10 on a 0-10 scale.
3235308|NCT00947999||Subjects with SCI and No Chronic Pain|Subjects in particular group will have a diagnosis of SCI and not have chronic pain. Subjects in this group will be matched roughly to subjects in the SCI chronic pain group based on age, gender and race/ethnicity.
3235309|NCT00947986|Experimental|Johnson's Baby Shampoo|1% diluted solution
3235310|NCT00947973|Experimental|Challenging Horizons Program after-school model|Participants will receive the CHP after-school model.
3235311|NCT00947973|Experimental|Challenging Horizons Program consultation model|Participants will receive the CHP consultation model.
3235312|NCT00947973|No Intervention|Community care|Participants will have access to standard community care.
3235313|NCT00947960|Other|Active/Placebo|Subjects receive 1-2 grams/kilogram body weight triheptanoin divided into 4 equal doses taken with meals and snack for 6 months crossing over to receive placebo vegetable oil at the same dose and frequency for the next 6 months during the randomization phase.
3235314|NCT00947960|Other|Placebo/Active|Subjects receive 1-2 grams/kilogram body weight placebo vegetable oil divided into 4 equal doses taken with meals and snack for 6 months crossing over to receive triheptanoin at the same dose and frequency for the next 6 months during the randomization phase.
3235315|NCT00947947|Experimental|intervention media condition|Received a stage tailored DVD-based intervention
3235316|NCT00947947|Placebo Comparator|standard of care|received only clinical standard of care
3235317|NCT00947934|Experimental|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation.
3235318|NCT00947921|Active Comparator|Plasty|Patients treated with restrictive Annuloplasty
3235319|NCT00947921|Active Comparator|Prosthesis|Patients treated with valve replacement
3235320|NCT00947908|Experimental|A|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
3235321|NCT00947895|Active Comparator|Methylprednisolone|Intravenous (IV) methylprednisolone (Solumedrol) 1000 mg daily for 3 days.
3235322|NCT00947895|Active Comparator|ACTH|Intramuscular (IM) ACTH 80 mg/day for 5 days.
3235323|NCT00947882|Placebo Comparator|Placebo|
3235324|NCT00947882|Experimental|Degarelix 10 mg|
3235325|NCT00947882|Experimental|Degarelix 20 mg|
3235326|NCT00947882|Experimental|Degarelix 30 mg|
3235327|NCT00947856|Experimental|BV Retreatment|Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (retreatment after relapse)
3235328|NCT00947856|Experimental|BV Extension|Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (continued treatment)
3235329|NCT00947843|Placebo Comparator|aspirin+placebo|aspirin protect (Bayer) 100mg + placebo clopidogrel 75mg for 1mo
3235330|NCT00947843|Active Comparator|aspirin+pregrel|pregrel is a generic brand name of clopidogrel
3235331|NCT00947843|Active Comparator|Aspirin+Plavix|plavix is a original brand name of clopidogrel
3235332|NCT00947817|Experimental|patient|
3235333|NCT00947817|Other|control|
3235334|NCT00947804||1. Patients with symptoms of ACS|Patients whom present emergently to the Cardiac Catheterization Lab with current symptoms of Acute Coronary Syndrome (ACS), whom at the time of admission to the cardiac catheterization lab are believed to be suffering from STEMI, NSTEMI, or Unstable Angina, with the possible need for emergency Percutaneous Coronary Intervention (PCI), or Coronary Artery Bypass Grafting (CABG).
3236634|NCT00938730|Experimental|3. YM150, Dose X, twice daily|
3235335|NCT00947804||2. Patients without symptoms of ACS|Non-emergency patients presenting to the Cardiac Catheterization Lab for elective coronary angiography, and possible PCI. These are patients whom may have experienced typical or atypical ACS symptoms intermittently, and have elected to have cardiac catheterization to rule out obstructive CAD. Patients in this group will be selected randomly, with consent obtained, prior to cardiac catheterization.
3235336|NCT00947791|Experimental|Ketamine/Midazolam|Patients receive both treatment conditions (ketamine and midazolam) in a single arm, crossover design. Patients are randomized to ketamine-midazolam. Each treatment occurs as a single intravenous infusion on one treatment day. The two treatment conditions occur 2 weeks apart.
3235337|NCT00947791|Experimental|Midazolam/Ketamine|Patients receive both treatment conditions (ketamine and midazolam) in a single arm, crossover design. Patients are randomized to midazolam-ketamine. Each treatment occurs as a single intravenous infusion on one treatment day. The two treatment conditions occur 2 weeks apart.
3235338|NCT00947778|Active Comparator|session of training 1|Arm from which members will perform their training session after the first session of evaluation
3235339|NCT00947778|Active Comparator|Session of training 2|Arm from which members will perform their training session after the second session of evaluation
3235340|NCT00947765|Experimental|Autologous blood injection group|This is the study group in whom autologous blood injection was injected at lateral epicondylitis site.
3235341|NCT00947765|Active Comparator|Local corticosteroid injection group|This is the control group in whom the commonly used treatment modality-local corticosteroid injection was given at lateral epicondyle site.
3235342|NCT00947752|Active Comparator|F1 Glatiramer acetate 20mg/1.0ml|
3235343|NCT00947752|Experimental|F2 Glatiramer acetate 20mg/0.5ml|
3235344|NCT00947739|Experimental|Cohort 1|80 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48)PO, DAILY
3235345|NCT00947739|Experimental|Cohort 2|160 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
3235346|NCT00947739|Experimental|Cohort 3|320 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
3235347|NCT00947739|Experimental|Cohort 4|640 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
3235348|NCT00947739|Experimental|Cohort 5a|1280 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
3235349|NCT00947739|Experimental|Cohort 6|2560 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3235350|NCT00947739|Experimental|Cohort 7|18 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3235351|NCT00947739|Experimental|Cohort 8|36 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3235352|NCT00947739|Experimental|Cohort 9|72 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3235353|NCT00947739|Experimental|Cohort 10|144 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3235354|NCT00947739|Experimental|Cohort 11|288 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3235355|NCT00947739|Experimental|Cohort 12|576 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3235356|NCT00947739|Experimental|Cohort 13|750mg/m2 PO Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3235357|NCT00947739|Experimental|Cohort 14|1000mg/m2 PO Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3235358|NCT00947739|Experimental|Cohort 5b|1280 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3235359|NCT00947713|Experimental|Low dose hCG group|
3235360|NCT00947713|Active Comparator|Clomiphen citrate plus HMG|
3235361|NCT00947700|No Intervention|Assessment & Monitoring|No Intervention. Parent-Child participants in assessment and monitoring visits but does not receive any study provided treatment.
3235362|NCT00947700|Experimental|Assessment, Monitoring + Intervention|Parent-Child participants in assessment and monitoring visits but also the Promoting First Relationships PFR intervention (http://pfrprogram. Org). PFR is a 10 weekly 60-85 minute in-home visits by a masters level mental health provider trained in the PFR curriculum. The PFR curriculum focuses on increasing parenting sensitivity using attachment theory-informed, strength-based consultation strategies. The curriculum is fully manualized and fidelity was assessed according to the manual.
3235363|NCT00947687|Experimental|PUR003|
3235364|NCT00947687|Placebo Comparator|Placebo|
3235365|NCT00947674|Experimental|Cellsorba EX|
3235366|NCT00947674|Sham Comparator|Sham treatment|
3235367|NCT00947661|Experimental|SPARC0912|Test drug
3235368|NCT00947661|Experimental|Reference0912|Reference drug
3235369|NCT00947648|Other|"Raw Group"|Participants will eat cooked food and the addition of raw fruits and vegetables.
3235370|NCT00947648|Other|"Cooked Group"|Participants will eat only cooked foods.
3235371|NCT00947635|Experimental|Islet transplant|People with Type 1 diabetes undergoing islet transplantation
3235372|NCT00947635|Experimental|Liver transplant|People with liver failure undergoing liver transplantation
3235373|NCT00947635|Experimental|Control|Healthy normal people which serve as control group
3235374|NCT00947622|Placebo Comparator|Placebo stimulation|Placebo stimulation at the occipital head area for 1800 seconds at 0 mA, three times a week, during one week (with seconds of stimulation to get onset tingling sensation)
3235375|NCT00947622|Experimental|Effective transcranial stimulation|Effective stimulation at the occipital head are for 1800 seconds at 2 mA, 3 times a week for 1 week
3235376|NCT00947609||HIV-infected and HIV-uninfected children|HIV-infected and HIV uninfected children with recent exposure to adults with active tuberculosis will be referred to the two study sites (HIV-NAT/Chulalongkorn and Queen Sirikit) for eligibility screening and enrollment in the study.
3235377|NCT00947596|Experimental|Atropine Dry Powder Inhaler|
3235378|NCT00947596|Active Comparator|Atropen Autoinjector|
3235379|NCT00947570|Experimental|Cognitive behavioral therapy|Participants with panic disorder or generalized anxiety disorder (GAD) will receive a course of individual cognitive behavioral therapy targeted at their principal disorder.
3235380|NCT00947557|Active Comparator|Dutogliptin|Dutogliptin
3235381|NCT00947557|Placebo Comparator|Placebo|Placebo
3235382|NCT00947544|Experimental|HPN-100 and NaPBA|1 week of NaPBA treatment followed by 1 week of HPN-100 treatment.
3235383|NCT00947531|Experimental|Cerebrolysin|
3235384|NCT00947531|Placebo Comparator|0.9% Saline Solution|
3236065|NCT00942786||No treatment|Consecutive patients undergoing emergency surgery
3235385|NCT00947518|Experimental|Chlorhexidine skin cleansing|Wiping the skin (except the face) once immediately after birth using baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)
3235386|NCT00947518|Placebo Comparator|Saline skin cleansing|Wiping the skin (except the face) once immediately after birth using baby wipes containing normal saline
3235387|NCT00947518|No Intervention|No skin cleansing|No skin application
3235388|NCT00947505|Active Comparator|HairMax LaserComb 2009, 7 Beam|Lower level laser phototherapy medical device with 7 laser beams
3235389|NCT00947505|Active Comparator|Control Device|Identical to the Active device, but with 7 LED's instead of lasers
3235390|NCT00947479|Other|continuous positive airway pressure (CPAP)|CPAP will be applied in all patients
3235391|NCT00947466|Experimental|Patch|
3235392|NCT00947453|Experimental|montelukast group|Identified patients with asthma to recieve Montelukast 10 mg (Merck Sharp & Dohme Ltd, Herts, UK) at 0800 am once daily for 8 weeks.
3235393|NCT00947440|Active Comparator|Tablet 1 vs. Capsule|Single dose of 2 x 50 mg tablets (Tablet 1) vs. 100 mg ABT-072 (contents of capsules) suspended in liquid.
3235394|NCT00947440|Active Comparator|Tablet 2 vs. Capsule|Single dose of 2 x 50 mg tablets (Tablet 2) vs. 100 mg ABT-072 (contents from capsules) suspended in liquid.
3235395|NCT00947427|Placebo Comparator|Placebo|Placebo solution given by subcutaneous injection on monthly basis for 12 months
3235396|NCT00947427|Experimental|Canakinumab|Subcutaneous injection of canakinumab at dose of 2.0 mg/kg given monthly of 12 months
3235397|NCT00947414|Active Comparator|Shockwave plus strength training|6 sessions of extracorporeal shock wave plus daily gluteal strength exercises
3235398|NCT00947414|Sham Comparator|Sham extracorporeal shock wave plus gluteal strength exercise|SHAM extracorporeal shock wave plus gluteal strength exercise
3235399|NCT00947401||elective post surgery patients|
3235400|NCT00947388|Experimental|Bendamustine plus Alemtuzumab|
3235401|NCT00947375|Experimental|Starch|In these study participants are randomly (by chance) assigned for two treatment arms of a clinical trial.
3235402|NCT00947375|No Intervention|Lifestyle councelling|May be required to comply with US Public Law 110-85, Section 801
3235403|NCT00947362|Experimental|ETC + DAC N-055|
3235404|NCT00947362|Active Comparator|ETC + physiological saline|
3235405|NCT00947349|Experimental|BI 201335 NA low TN|patient to receive a capsule containing low dose of BI 201335 NA/Drug for treatment-naive (TN) patients
3235406|NCT00947349|Experimental|BI 201335 NA high TN|patient to receive a capsule containing high dose of BI 201335 NA/Drug for treatment-naive (TN )patients
3235407|NCT00947349|Experimental|BI 201335 NA high TE|patient to receive a capsule containing high dose of BI 201335 NA/Drug for treatment-experienced (TE) patients
3235408|NCT00947349|Placebo Comparator|Placebo in Treatment Naive (TN) Patients|
3235409|NCT00947336|Active Comparator|Norfloxacin + Synbiotic|
3235410|NCT00947336|Placebo Comparator|Norfloxacin + Placebo|
3235411|NCT00947323|Placebo Comparator|placebo|
3235412|NCT00947323|Experimental|Simvastatin|Treatment arm.
3235413|NCT00947310|Experimental|A|Standard ICD Programming
3235414|NCT00947310|Experimental|B|High rate cutoff
3235415|NCT00947310|Experimental|C|Long ICD duration delay
3235416|NCT00947297|Experimental|HPN-100|Patients who were treated with HPN-100
3235417|NCT00947284|Experimental|Women|Both arms of this study will receive identical interventions. The only difference will be the sex of the participants in each study arm.
3235418|NCT00947284|Experimental|Men|Both arms of this study will receive identical interventions. The only difference will be the sex of the participants in each study arm
3235419|NCT00947271|Experimental|DVD 1 plus assessment 1|Participants will view educational DVD 1 and complete the first version of the study assessment.
3235420|NCT00947271|Experimental|DVD 1 plus assessment 2|Participants will view educational DVD 1 and complete the second version of the study assessment.
3235421|NCT00947271|Experimental|DVD 2 plus assessment 1|Participants will view educational DVD 2 and complete the first version of the study assessment.
3235422|NCT00947271|Experimental|DVD 2 plus assessment 2|Participants will view educational DVD 2 and complete the second version of the study assessment.
3235423|NCT00947245|Experimental|BMS-791325 - Part A, Dose 1|
3235424|NCT00947245|Experimental|BMS-791325 - Part A, Dose 2|
3235425|NCT00947245|Experimental|BMS-791325 - Part A, Dose 3|
3235426|NCT00947245|Experimental|BMS-791325 - Part B, Dose 1|
3235427|NCT00947245|Experimental|BMS-791325 - Part B, Dose 2|
3235428|NCT00947245|Experimental|BMS-791325 - Part B, Dose 3|
3235429|NCT00947232|Experimental|Motivational interviewing|Motivational interviewing for people aging with multiple sclerosis or spinal cord injury to increase physical activity and decrease depression.
3235430|NCT00947232|Active Comparator|Education|Education about physical activity for people aging with multiple sclerosis or spinal cord injury to decrease depression.
3235431|NCT00947219|Active Comparator|HairMax LaserComb 2009, 12 Beam|Low Level Laser Medical Device 2009 with 12 laser beams
3235432|NCT00947219|Active Comparator|HairMax LaserComb 2009 9 Beam|Low Level Laser Mecial Device 2009 with 9 laser beams
3235433|NCT00947219|Active Comparator|Control device|The control device appears identical to the active device, but utilizes 9 LED lights instead of laser lights. The randomized devices are blinded to the study investigator and distributed in a blinded manner to the participants.
3235434|NCT00947206|Experimental|LHWO about CRC|The intervention group participants will be exposed to 2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt.
3235435|NCT00947206|Active Comparator|Nutrition education + CRC brochure|The comparison group will receive a bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
3235436|NCT00947180|Active Comparator|Electrogalvanic stimulation|High voltage electrical stimulation was delivered through an anal plug to induce relaxation of pelvic floor muscles.
3235437|NCT00947180|Active Comparator|Digital massage|The therapist massaged the levator ani muscles by applying firm pressure with a gloved finger and rotating from left to right.
3236066|NCT00942773|Active Comparator|CYP2C19 extensive metabolizer|
3235438|NCT00947180|Experimental|Biofeedback|Electromyographic (EMG) activity was recorded from a probe in the anal canal, averaged and displayed to patients to help them learn to relax pelvic floor muscles during straining.
3235439|NCT00947167|Experimental|Pertuzumab and Erlotinib|
3235440|NCT00947154|Experimental|Open-label aripiprazol|Aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
3235441|NCT00947141|Experimental|Group A|"Group A: (low level infection) has 2 arms:~Start treatment when 2 consecutive levels CMV PCR >200copies / ml~Monitor (Treatment starts when CMV PCR >3,000 copies / ml (current site clinical protocol))"
3235442|NCT00947141|Experimental|Group B|"Group B: (patients receiving pre-emptive therapy) has 2 arms:~Stop treatment when 2 levels CMV PCR <3,000 copies / ml~Monitor (Treatment stops when there are 2 consecutive levels of CMV PCR <200 copies / ml (current site clinical protocol))"
3235443|NCT00947128|Experimental|1|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
3235444|NCT00947128|Active Comparator|2|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
3235445|NCT00947115|Experimental|Cervarix 15-25 years group|Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)
3235446|NCT00947115|Experimental|Cervarix 26-45 years group|Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)
3235447|NCT00947115|Experimental|Cervarix 46-55 years group|Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)
3235448|NCT00947102||Pancreatic tubular adenocarcinoma|Patients with pancreatic tubular adenocarcinoma
3235449|NCT00947089|Experimental|group A-the treatment group|Group A-patients have their wound, the site of the previous stoma, wad with ORC
3235450|NCT00947089|Active Comparator|group B-the control group|control group-patients have their wound wad with iodoform gauze
3235451|NCT00947076|Experimental|1|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)
3235452|NCT00947076|Active Comparator|2|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)
3235453|NCT00947063|Experimental|1|Promethazine HCl 50 mg Tablets (Sandoz, Inc)
3235454|NCT00947063|Active Comparator|2|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)
3235455|NCT00947050|Active Comparator|rest first|rest first, cfi, exercise, cfi
3235456|NCT00947050|Active Comparator|exercise first|ex first
3235457|NCT00947037|Experimental|Extension|Open label extension, 1 arm
3235458|NCT00947024|Experimental|1|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.
3235459|NCT00947024|Active Comparator|3|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.
3235460|NCT00947024|Experimental|2|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.
3235461|NCT00947011|Placebo Comparator|Placebo|
3235462|NCT00947011|Active Comparator|Januvia|
3235463|NCT00946998|Active Comparator|Sertraline|Patients with predialysis Chronic Kidney Disease stages 3-5 and with major depressive episode
3235464|NCT00946998|Placebo Comparator|Placebo|Patients with predialysis Chronic Kidney Disease stages 3-5 and with major depressive episode
3235465|NCT00946985|Experimental|001|paliperidone palmitate 50 75 100 or 150 mg eq. monthly injection for 2 years
3235466|NCT00946985|Active Comparator|002|oral risperidone 2 4 6 or 8 mg tabs once daily for two years
3235467|NCT00946959|Experimental|cardiac surgery|This arm will include patients older than 18 years and candidate to cardiac surgery.
3235468|NCT00946959|No Intervention|cardiac angiography|Patients older than 18 years who undergo coronary angiogram. This arm will include patients with coronary revascularization and patients without coronary revascularization.
3235469|NCT00946946|Experimental|Azathioprine|2.0-2.5 mg/kg/BW azathioprine tablets/day AND mesalazine placebo tablets
3235470|NCT00946946|Active Comparator|Mesalazine|4g mesalazine tablets/day AND azathioprine placebo tablets
3235471|NCT00946933|Placebo Comparator|Placebo|0.025 g/kg/day of NaCl (sodium chloride)
3235472|NCT00946933|Active Comparator|High salt diet|0.2 g/kg/day of NH4Cl (ammonium chloride)
3235473|NCT00946920|Experimental|Degarelix 240 mg/480 mg|
3235474|NCT00946920|Active Comparator|Goserelin acetate|
3235475|NCT00946907|Active Comparator|aspirin|
3235476|NCT00946907|Placebo Comparator|placebo|
3235477|NCT00946894|Experimental|Total thyroidectomy|Patients who underwent total thyroidectomy
3235478|NCT00946894|Experimental|Dunhill operation|Patients who underwent unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
3235479|NCT00946894|Active Comparator|Bilateral subtotal thyroidectomy|Patients who underwent bilateral subtotal thyroidectomy
3235480|NCT00946881|Experimental|WST11 (TOOKAD® Soluble)|WST11-mediated-VTP The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers using 753 nm laser light at escalating fixed energy doses
3235481|NCT00946868||Intermittent claudication patients|Patients with intermittent claudication with metabolic syndrome and patients with intermittent claudication without metabolic syndrome.
3235482|NCT00946855||soccer players|players of the first two German soccer leagues
3235483|NCT00946842|Experimental|Panel A: Treatment Sequence ABC|Participants will receive the 3 treatments (Treatment A,B and C) in sequence ABC with food and subsequent treatments will be separated by 4 weeks.
3235534|NCT00946569|Experimental|Treatment A (JNJ39758979)|Participants will receive JNJ39758979 300mg once daily for 12 weeks.
3235484|NCT00946842|Experimental|Panel A: Treatment Sequence ACB|Participants will receive the 3 treatments (Treatment A,B and C) in sequence ACB with food and subsequent treatments will be separated by 4 weeks.
3235485|NCT00946842|Experimental|Panel A: Treatment Sequence BAC|Participants will receive the 3 treatments (Treatment A,B and C) in sequence BAC with food and subsequent treatments will be separated by 4 weeks.
3235486|NCT00946842|Experimental|Panel A: Treatment Sequence BCA|Participants will receive the 3 treatments (Treatment A,B and C) in sequence BCA with food and subsequent treatments will be separated by 4 weeks.
3235487|NCT00946842|Experimental|Panel A: Treatment Sequence CBA|Participants will receive the 3 treatments (Treatment A,B and C) in sequence CBA with food and subsequent treatments will be separated by 4 weeks.
3235488|NCT00946842|Experimental|Panel A: Treatment Sequence CAB|Participants will receive the 3 treatments (Treatment A,B and C) in sequence CAB with food and subsequent treatments will be separated by 4 weeks.
3235489|NCT00946842|Experimental|Panel B: Treatment Sequence DEF|Participants will receive the 3 treatments (Treatment D,E and F) in sequence DEF with food and subsequent treatments will be separated by 4 weeks.
3235490|NCT00946842|Experimental|Panel B: Treatment Sequence DFE|Participants will receive the 3 treatments (Treatment D,E and F) in sequence DFE with food and subsequent treatments will be separated by 4 weeks..
3235491|NCT00946842|Experimental|Panel B: Treatment Sequence EDF|Participants will receive the 3 treatments (Treatment D,E and F) in sequence EDF with food and subsequent treatments will be separated by 4 weeks.
3235492|NCT00946842|Experimental|Panel B: Treatment Sequence EFD|Participants will receive the 3 treatments (Treatment D,E and F) in sequence EFD with food and subsequent treatments will be separated by 4 weeks.
3235493|NCT00946842|Experimental|Panel B: Treatment Sequence FDE|Participants will receive the 3 treatments (Treatment D,E and F) in sequence FDE with food and subsequent treatments will be separated by 4 weeks.
3235494|NCT00946842|Experimental|Panel B: Treatment Sequence FED|Participants will receive the 3 treatments (Treatment D,E and F) in sequence FED with food and subsequent treatments will be separated by 4 weeks.
3235495|NCT00946816|Active Comparator|Anorexia Nervosa|
3235496|NCT00946816|Active Comparator|Obesity|
3235497|NCT00946816|Active Comparator|Healthy volunteers|
3235498|NCT00946803|Experimental|PC-CB Intervention|Patient-Controlled Cognitive-Behavioral Intervention
3235499|NCT00946803|No Intervention|Wait list|Wait list control group. Offered PC-CB Intervention after the study.
3235500|NCT00946790|Experimental|1|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)
3235501|NCT00946790|Active Comparator|2|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)
3235502|NCT00946777|Experimental|Systane® Ultra|
3235503|NCT00946764|Experimental|1|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)
3235504|NCT00946764|Active Comparator|2|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)
3235505|NCT00946751|Experimental|1|Levetiracetam Tablets, 750 mg (Sandoz Inc.)
3235506|NCT00946751|Active Comparator|2|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)
3235507|NCT00946738|Active Comparator|physical therapy|
3235508|NCT00946738|No Intervention|control|
3235509|NCT00946725|Experimental|1|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)
3235510|NCT00946725|Active Comparator|2|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)
3235511|NCT00946712|Experimental|Arm I (chemo +/- bevacizumab)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes with or without bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients receiving bevacizumab may continue to receive bevacizumab (as above) in the absence of disease progression or unacceptable toxicity.
3235512|NCT00946712|Experimental|Arm II (chemo, cetuximab, +/- bevacizumab)|Patients receive paclitaxel and carboplatin with or without bevacizumab as in Arm I. Patients also receive cetuximab IV over 1-2 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients may continue to receive cetuximab with or without bevacizumab (as above) in the absence of disease progression or unacceptable toxicity.
3235513|NCT00946699|Experimental|1|MEDI-551
3235514|NCT00946699|Experimental|2|MEDI-551
3235515|NCT00946699|Experimental|3|MEWDI-551
3235516|NCT00946699|Experimental|4|MEDI-551
3235517|NCT00946699|Experimental|5|MEDI-551
3235518|NCT00946699|Placebo Comparator|6|Placebo
3235519|NCT00946686|Experimental|1|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)
3235520|NCT00946686|Active Comparator|2|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)
3235521|NCT00946673|Experimental|vorinostat & stereotactic radiosurgery|
3235522|NCT00946647|Experimental|Panobinostat + 5-Azacytidine|"In phase I: Panobinostat : Escalating doses starting with 20 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.~In phase II: Panobinostat : Rapid Phase II doses at 30 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.~In both phases, dose of 5-Azacytidine will be 75 mg/m^2, subcutaneously Daily for Day 1 to Day 7."
3235523|NCT00946647|Active Comparator|5-Azacytidine|Dose of 5-Azacytidine : 75 mg/m^2 subcutaneously daily from Day 1 to Day 7.
3235524|NCT00946634|Experimental|Ozone Gas|Endodontic protocol preconized by University of Sao Paulo associated to ozone gas 40 mg/L
3235525|NCT00946634|Active Comparator|Control|Regular endodontic protocol preconized by University of Sao Paulo
3235526|NCT00946634|Experimental|Aqueous Ozone|Endodontic protocol preconized by University of Sao Paulo associated to Aqueous ozone 40mg/L
3235527|NCT00946621|Experimental|1|Ramipril 10 mg Capsule (Sandoz)
3235528|NCT00946621|Active Comparator|2|Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)
3235529|NCT00946608|Experimental|1|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)
3235530|NCT00946608|Experimental|2|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)
3235531|NCT00946608|Active Comparator|3|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)
3235532|NCT00946595|Active Comparator|efavirenz/emtricitabin/tenofovir|
3235533|NCT00946595|Experimental|lopinavir/ritonavir|
3235535|NCT00946569|Placebo Comparator|Treatment B (Placebo)|Participants will receive matching placebo once daily for 12 weeks.
3235536|NCT00946556|Placebo Comparator|Placebo|Participants will be assigned 2 months of placebo or active drug, with an intervening one month washout period.
3235537|NCT00946556|Experimental|Valacyclovir|Participants will be assigned 2 months of placebo or active drug, with an intervening one month washout period.
3235538|NCT00946530|Experimental|Bright Light|received bright light
3235539|NCT00946530|Placebo Comparator|Control|received regular light
3235540|NCT00946517||Parents|Parents or caregivers of type 1 diabetics
3235541|NCT00946517||Child|Type 1 diabetics
3235542|NCT00946504|Experimental|1|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)
3235543|NCT00946504|Active Comparator|2|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)
3235544|NCT00946491|Experimental|1|Haloperidol 10 mg Tablets (Cord Laboratories)
3235545|NCT00946491|Active Comparator|2|Haldol 10 mg Tablets (McNeil Pharmaceuticals)
3235546|NCT00946478|Active Comparator|Pimecrolimus|
3235547|NCT00946478|Sham Comparator|Vehicle cream|
3235548|NCT00946465|Experimental|1|Ramipril 10 Capsule (Sandoz)
3235549|NCT00946465|Active Comparator|2|Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)
3235550|NCT00946426||Diagnostic|Hyperinsulinemic euglycemic clamp
3235551|NCT00946413|Experimental|CBT plus parent education|
3235552|NCT00946413|Experimental|CBT alone|
3235553|NCT00946400||Suspected HIT|Those who are clinically suspected of having HIT will be enrolled in this study.
3235554|NCT00946387|Experimental|1|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
3235555|NCT00946387|Active Comparator|2|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
3235556|NCT00946361||Diagnostic|
3235557|NCT00946348|Experimental|Dronabinol|Dronabinol 10mg or 15 mg
3235558|NCT00946348|Active Comparator|Cannabis|Cannabis cigarette
3235559|NCT00946335|Experimental|Treatment (veliparib, temozolomide)|"Patients receive oral ABT-888 twice daily and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for 13-26 courses in the absence of disease progression or unacceptable toxicity.~Blood samples are collected for pharmacokinetics and further laboratory analysis."
3235560|NCT00946322|Experimental|Arm 1: CTAP|Couple-Based Treatment for Alcohol Use Disorders and PTSD
3235561|NCT00946309|Experimental|High Sulforaphane Extract|
3235562|NCT00946309|Placebo Comparator|Placebo|
3235563|NCT00946296|Active Comparator|Potassium Iodide|8 drops of Potassium Iodide in a glass of water, by mouth, daily for 7 days prior to operation.
3235564|NCT00946296|No Intervention|No Treatment|The experimental group receives no treatment.
3235565|NCT00946283|Experimental|Lactobacillus GG|Open label trial of Culturelle (Lactobacillus GG) administered to patients after engraftment, post allogeneic stem cell transplantation.
3235566|NCT00946270|Experimental|CC-4047|CC-4047 0.5 mg orally daily. Prednisone given during first 3 cycles of therapy. It will be dosed orally at the dose of 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
3235567|NCT00946257|Experimental|Cohort 1|0.3 mg dose
3235568|NCT00946257|Experimental|Cohort 2|0.6 mg dose
3235569|NCT00946257|Experimental|Cohort 3|1.2 mg dose
3235570|NCT00946257|Experimental|Cohort 4|1.8 mg dose
3235571|NCT00946257|Experimental|Cohort 5|2.4 mg dose
3235572|NCT00946257|Experimental|Cohort 6|3.0 mg dose
3235573|NCT00946244||Term infants|Healthy term infants
3235574|NCT00946244||Usual care program|VLBW preterm infants who received usual medical care during hospitalization after birth
3235575|NCT00946244||Clinic-based intervention program|VLBW preterm infants who received specific early intervention program delivered at clinic before 1 year of corrected age (in previous study)
3235576|NCT00946244||Home-based intervention program|VLBW preterm infants who received specific early intervention program delivered at home before 1 year of corrected age (in previous study)
3235577|NCT00946231||Heart Failure|Subjects admitted to the hospital with decompensated heart failure.
3235578|NCT00946218||Part A|Children with presumptive dengue infection enrolled for empiric cost modeling with retrospective clinical estimation and comparison of test performance to the standard of care.
3235579|NCT00946218||Part B|Children with definitive dengue infection enrolled for gene expression analysis.
3235580|NCT00946205|Experimental|Laparoscopic anterior mesh rectopexy|
3235581|NCT00946205|Active Comparator|Laparoscopic posterior rectopexy|
3235582|NCT00946192|Experimental|Estrogen Patch|17Beta-estradiol transdermal patch twice weekly application for 12 months
3235583|NCT00946192|Active Comparator|Estrogen Pill|One pill containing estrogen and progesterone taken daily for 21 days followed by placebo pills only for 7 days; regimen repeated for 12 months.
3235584|NCT00946192|Sham Comparator|Control|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
3235585|NCT00946179|Experimental|Group 1|Participants aged 18 to 60 years at enrollment
3235586|NCT00946179|Experimental|Group 2|Participants aged 61 years or older at enrollment
3235587|NCT00946166|Placebo Comparator|Placebo Control|Subjects receive standard treatment for pneumonia and a simvastatin-like placebo
3235588|NCT00946166|Experimental|Simvastatin|Subjects receive simvastatin in addition to standard pneumonia treatment
3235589|NCT00946153|Experimental|1|
3235590|NCT00946140||Patients with ovarian cancer currently undergoing treatment|All of the patients will be treated per their treatment protocols by their physicians and they will be referred to this study for the DCE-MRI scans at baseline, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
3235591|NCT00946127||Shunt Arm|Ventriculoperitoneal Shunt
3235592|NCT00946127||ETV arm|Endoscopic Third Ventriculostomy
3235593|NCT00946101|Active Comparator|MEDI3414 [Influenza A (H1N1) vaccine]|MEDI3414- Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 FFU (fluorescent focus units) of influenza virus type A/California/07/2009.
3236067|NCT00942773|Active Comparator|CYP2C19 heterozygous extensive metabolizer|
3235594|NCT00946101|Placebo Comparator|Placebo|Placebo - Placebo was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer
3235595|NCT00946088|Active Comparator|Progesterone|Progesterone 400mg per vagina qhs.
3235596|NCT00946088|Placebo Comparator|Polyethylene glycol&hydrogenated vegetable oil|Polyethylene glycol&hydrogenated vegetable oil per vagina
3235597|NCT00946062|Active Comparator|regular O&M-training|orientation and mobility training in use of the identification cane as provided by mobility trainers
3235598|NCT00946062|Experimental|standardised O&M-training|standardised orientation and mobility training in use of the identification cane as provided by mobility trainers who received instruction in using the standardised protocol
3235599|NCT00946049|Experimental|Vicryl Plus|
3235600|NCT00946049|Active Comparator|Vicryl|
3235601|NCT00946023|Experimental|Transplant|Non-myeloablative allogeneic bone marrow transplant (BMT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD (graft vs host disease) prophylaxis. Rituximab will be given as post-transplant maintenance.
3235602|NCT00946010||1|Click here for more information about this study: Investigation of Hepatitis B and Hepatitis C in Taiwan
3235603|NCT00945997|Active Comparator|A|
3235604|NCT00945997|Active Comparator|B|
3235605|NCT00945984||LESS|Patients who underwent LESS radical nephrectomy
3235606|NCT00945984||Conventional laparoscopy|Patients who underwent conventional laparoscopic radical nephrectomy
3235607|NCT00945971|Experimental|Physical activity|The intervention group will participate in an exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be performed at the start and in the end of this study.
3235608|NCT00945958|Experimental|SPARC0913|
3235609|NCT00945945|Experimental|DLX30-PLA|Per the protocol, patients randomized to the duloxetine group were to receive duloxetine for the entire 13-week acute treatment period. Patients were to start at a 30 mg daily (QD) dose of duloxetine for 1 week, then increase to 60 mg QD of duloxetine for the following 12 weeks. However, due to a study drug labeling error, patients randomized to this group received 30 mg of duloxetine for the initial 1-week, but received placebo instead of receiving 60 mg QD of duloxetine for the next 12 weeks. The resulting unintended, mixed treatment group was labeled as DLX30-PLA throughout this document. Per protocol, the last week of the study (week 14) was intended to be a 1-week taper period. Patients in this treatment group were to receive 30 mg QD of duloxetine during that week, and that did occur per protocol.
3235610|NCT00945945|Placebo Comparator|PLA-DLX60|Per the protocol, patients randomized to the placebo group were to receive placebo for the entire 13-week acute treatment period. Patients were to start on placebo for the first week, then continue on placebo for the following 12 weeks. However, due to a study drug labeling error, patients in this group received placebo for the initial 1-week, but received 60 mg QD of duloxetine instead of receiving placebo for the next 12 weeks. The resulting unintended, mixed treatment group was labeled as PLA-DLX60 throughout this document. Per protocol, the last week of the study (week 14) was intended to be a 1-week taper period. Patients in this treatment group were to receive placebo that week, and that did occur per protocol.
3235611|NCT00945932|Experimental|28 day repeat dose|
3235612|NCT00945906|Experimental|FXIII|Subjects were administered FXIII Concentrate (Human) by intravenous (IV) infusion approximately every 28 days to maintain a trough FXIII level of approximately 5 to 20%.
3235613|NCT00945893|Experimental|MEDI3414 [Influenza A (H1N1) vaccine]|MEDI3414 - Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 fluorescent focus units (FFU) of live, attenuated influenza virus reassortant A/California/7/2009 strain that was propagated in chicken eggs. H1N1 monovalent influenza vaccine (MEDI3414) contained no preservatives and no adjuvants.
3235614|NCT00945893|Placebo Comparator|Placebo|Placebo -Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
3235615|NCT00945854|Active Comparator|Wholegrain cereal diet|Treatment with a diet based on wholegrain cereals and foods with low glycemic index
3235616|NCT00945854|Active Comparator|Refined cereal diet|Treatment with a diet based on refined cereals and foods with high glycemic index
3235617|NCT00945841|Other|1|
3235618|NCT00945828|Experimental|Annual Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study.
3235619|NCT00945828|Experimental|Quarterly Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study.
3235620|NCT00945815|Experimental|treatment|AraC 1 g/m2/d IV Days 1-5 clofarabine 40 mg/m2/d IV Days 2-6 epratuzumab 360 mg/m2/d IV Days 7, 14, 21, 28 acetaminophen 650 mg/d PO Days 7, 14, 21, 28 diphenhydramine 50 mg/d IV Days 7, 14, 21, 28 IT methotrexate 12 mg IT at least 1 wk apart during induction All give 1 cycle
3235621|NCT00945802|Experimental|FST-201 (dexamethasone 0.1%) Otic Suspension|
3235622|NCT00945802|Active Comparator|ciprofloxacin 0.3%, dexamethasone 0.1%|
3235623|NCT00945789|Experimental|EPO HIE Group|Infants with hypoxic ischemic encephalopathy receive human recombinant erythropoietin
3235624|NCT00945789|No Intervention|Control HIE|Infants with hypoxic ischemic encephalopathy who do not receive treatment drug (EPO)
3235625|NCT00945789|Other|Healthy Controls|Healthy newborn without hypoxic ischemic encephalopathy
3235626|NCT00945776|Active Comparator|Weekly phone calls|Will be called weekly to answer questions regarding usage.
3235627|NCT00945776|Active Comparator|Frequently asked questions|Providing written general answers to commonly asked questions.
3235628|NCT00945776|Active Comparator|Usual care|
3235629|NCT00945763|Placebo Comparator|placebo|
3235630|NCT00945763|Experimental|N1539 15 mg|
3235631|NCT00945763|Experimental|N1539 30 mg|
3235632|NCT00945763|Experimental|N1539 60 mg|
3235633|NCT00945763|Active Comparator|Motrin|
3235813|NCT00944528|Experimental|Single dose radiosurgery: Dose Level 2|A single 18 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
3235634|NCT00945750|Experimental|Sequence 1: FCT with water → CT without water → CT with water|Participants received famotidine 20 mg FCT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 3).
3235635|NCT00945750|Experimental|Sequence 2: CT without water → CT with water → FCT with water|Participants received famotidine 20 mg CT as a single dose without water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 3).
3235636|NCT00945750|Experimental|Sequence 3: CT with water → FCT with water → CT without water|Participants received famotidine 20 mg CT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 3).
3235637|NCT00945750|Experimental|Sequence 4: FCT with water → CT with water → CT without water|Participants received famotidine 20 mg FCT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 3).
3235638|NCT00945750|Experimental|Sequence 5: CT without water → FCT with water → CT with water|Participants received famotidine 20 mg CT as a single dose without water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 3).
3235639|NCT00945750|Experimental|Sequence 6: CT with water → CT without water → FCT with water|Participants received famotidine 20 mg CT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 3).
3235640|NCT00945737|Active Comparator|Soy protein|
3235641|NCT00945737|Placebo Comparator|Milk protein|
3235642|NCT00945724|Experimental|R-CHOP, Depocyte, Methotrexate|
3235643|NCT00945711||1|Eating Disorder Diabetes Mellitus T1 patients
3235644|NCT00945711||2|Eating Disorder only patients
3235645|NCT00945698|Other|ST-DI (Delayed intervention)|"1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
3235646|NCT00945698|Experimental|LNS-10gM|"140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
3235647|NCT00945698|Experimental|LNS-20gM|"280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
3235648|NCT00945698|Experimental|LNS-20gNoM|"280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
3235649|NCT00945698|Experimental|LNS-40gM|"560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
3235650|NCT00945698|Experimental|LNS-40gNoM|"560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
3235651|NCT00945685|Experimental|Endymion study group|
3235652|NCT00945672|Experimental|PF-04360365 10 mg/kg|
3235653|NCT00945672|Experimental|PF-04360365 7.5 mg/kg|
3235654|NCT00945672|Placebo Comparator|placebo|
3235655|NCT00945659|Active Comparator|Standard Care|"Standard Care constitutes intensified diabetes management, an enrollment criterion for the study, consisting of either continuous subcutaneous insulin infusion (insulin pump) or multiple daily injections using a basal-bolus approach. All patients must be using carbohydrate counting and have prescribed correction factors for targeted insulin bolus dose adjustments."
3235656|NCT00945659|Active Comparator|Continuous Glucose Sensor|Patients will have the same diabetes management regimen as those in the Standard Care group. In addition they will be given a continuous glucose sensor, receive expert instruction in its use, and be guided by a physician and diabetes educator in achieving glycemic benefits through retrospective and real-time interpretation of CGS results and by learning to respond judiciously to the various CGS alarms.
3235657|NCT00945659|Experimental|CGS + Behavior Therapy|Patients in the use group will receive the same medical management as the Continuous Glucose Sensor group above. In addition, they will have 6 scheduled encounters with a behavior therapist that are designed to reduce or eliminate typical behavioral and/or psychological barriers to optimal use of CGS as part of diabetes care.
3235658|NCT00945646|Experimental|FST-201 (dexamethasone 0.1%) Otic Suspension|
3235659|NCT00945646|Placebo Comparator|vehicle|
3235660|NCT00945620|Placebo Comparator|right side|The trans-abdominis block will be placed in every pat with one side being injected with ropivicaine, the other side placebo injection. Hence is subject can serve as their own control. Subjects will receive additional pain medications as needed
3235661|NCT00945620|Placebo Comparator|Left side|The trans-abdominis block will be placed in every pat with one side being injected with ropivicaine, the other side placebo injection. Hence is subject can serve as their own control. Subjects will receive additional pain medications as needed
3235705|NCT00945282|Experimental|Cohort 1|In Cohort 1 subjects will receive either GSK2248761 30 mg or placebo once a day for 7 days. On Day 8 subjects will receive either Kaletra or HAART for 28 days. The doctor will choose the most appropriate medications for HAART.
3235706|NCT00945282|Experimental|Cohort 2|In Cohort 2 subjects will receive either GSK2248761 in the range of 10 mg - 20 mg or 40 mg - 90 mg or placebo once a day for 7 days. On Day 8 subjects will receive either Kaletra or HAART for 28 days. The doctor will choose the most appropriate medications for HAART. The dose for Cohort 2 will be determined following evaluation of results from Cohort 1. Cohort 2 may not be done.
3235662|NCT00945607|Experimental|Guided Relaxation Training|"Eligible subjects who have been randomized to the intervention arm will be scheduled for GRT introduction and training with a research staff member. The GRT sessions will consist of six weekly on-site sessions in which the subject is provided instructions and then allowed to listen to the GRT CD. Subjects will be instructed to conduct independent GRT sessions at home, twice daily, at least four hours apart, for the duration of the study. Subjects will also be instructed that on the days of one-on-one sessions with a research staff member at TCCC, that they will only be required to perform the independent session once at home.~Subjects will be provided with a diary to record the date and time of each independent GRT session performed at home. Subjects will be instructed to bring their completed diary with them at each subsequent visit."
3235663|NCT00945607|No Intervention|Standard of Care(SOC)|Eligible subjects who are randomized to the SOC arm will not receive the GRT sessions. During the six week treatment phase, these subjects will only receive SOC provided to all subjects newly diagnosed with breast cancer at TCCC. This consists of an education session with the nurse or nurse practitioner. In addition, they will also be provided with supportive care and symptom management as needed. This arm will also be provided with a diary to record their stress level at least twice daily.
3235664|NCT00945594|Experimental|Flexible cystoscopy|16F flexible cysto urethroscope (Storz, Culver city, CA)
3235665|NCT00945594|Experimental|Rigid cystoscopy|17F, 70° scope (Storz, Culver city, CA)
3235666|NCT00945581|Experimental|AN777|Powder twice a day
3235667|NCT00945581|Placebo Comparator|Placebo powder|Powder twice a day
3235668|NCT00945568|Experimental|Aminolaban EN|Aminoleban EN™ was administered at a dose of 100 g per day commencing two weeks prior to surgery. A 100 g dose of Aminoleban EN™ contains 13.0 g of free amino acids, 13.0 g of gelatin hydrolysate, 1.0 g of casein, 62.1 g of carbohydrate, 7.0 g of lipid, glycyrrhizin, and other components, producing 420 kcal. The AEN group included 40 patients who were administered 100 g of Aminoleban EN™ as 50 g during the day and 50 g as a late evening snack.
3235669|NCT00945568|No Intervention|Control|The patients were divided into two groups including one group administered Aminoleban (the AEN group) and a control group given no additional dietary supplementation. The total caloric energy intake per day during the study period was assumed to be equal to Aminolaban EN group.
3235670|NCT00945555||All participants|Participants with febrile neutropenia who received antibacterial treatment per investigator's judgment
3235671|NCT00945542|Other|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
3235672|NCT00945542|Experimental|Preemptive transfusion|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. This corresponds to an FFP:RBC transfusion ratio of 1:1.~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
3235673|NCT00945516|Active Comparator|Flared end FCSEMS|Flared end FCSEMS will be inserted for the benign bile duct stricture.
3235674|NCT00945516|Active Comparator|Anchoring FCSEMS|Anchoring FCSEMS will be inserted for benign bile duct stricture
3235675|NCT00945503|Experimental|GSK1018921|All subjects will received a dose of GSK1018921 and will peforme three PET scans using the ligand [11C]GSK931145, but in order to obtain adequate sampling of the exposure-time-occupancy curves, a range of doses will be evaluated, and the timing of the post-dose scans will differ between subjects.
3235676|NCT00945490|Experimental|NX-1207|
3235677|NCT00945490|Placebo Comparator|Placebo|
3235678|NCT00945477|Experimental|Advanced prostate cancer, treatment, pazopanib|Pazopanib
3235679|NCT00945464||No treatment|Women over the age of 30 undergoing breast imaging at the Scripps Polster Breast Care Center.
3235680|NCT00945451|Experimental|CyberKnife irradiation|
3235681|NCT00945438|Experimental|Group 1|Participants aged 18 to 59 years at enrollment.
3235682|NCT00945438|Experimental|Group 2|Participants aged 60 years or older at enrollment.
3235683|NCT00945425|Experimental|1|Low dose or placebo, twice daily
3235684|NCT00945425|Experimental|2|Low dose or placebo, once daily
3235685|NCT00945425|Experimental|3|Middle dose or placebo, twice daily
3235686|NCT00945425|Experimental|4|High dose or placebo, once daily
3235687|NCT00945412|Experimental|Micropolysaccharide Hemospheres (MPH)|
3235688|NCT00945412|Active Comparator|Electrocautery|
3235689|NCT00945399|Experimental|Autologous Chondrocytes Implantation|
3235690|NCT00945399|Active Comparator|Microfracture|
3235691|NCT00945360|Experimental|aromatase inhibitors: Letrozole|All consenting patients will be started on Letrozole at a dose of 2.5 mg/day for 8 weeks.
3235692|NCT00945347|No Intervention|Baseline|Visit 1
3235693|NCT00945347|Active Comparator|Miglustat|Nasal instillation of Miglustat (visit 2 or 3)
3235694|NCT00945347|Placebo Comparator|Placebo|Nasal instillation of placebo (visit 3 or 2)
3235695|NCT00945334|Experimental|Group 1|Group 1 will receive neomycin (500 mg po bid) and placebo (tid) for 14 days
3235696|NCT00945334|Experimental|Group 2|Group 2 will receive neomycin (500 mg po bid) and rifaximin (550mg po tid) for 14 days
3235697|NCT00945321|Active Comparator|1|aprepitant 165 mg
3235698|NCT00945321|Active Comparator|2|aprepitant 185 mg
3235699|NCT00945321|Experimental|3|fosaprepitant 150 mg
3235700|NCT00945321|Experimental|4|aprepitant with food
3235701|NCT00945308|Active Comparator|Eptifibatide (intracoronary)|
3235702|NCT00945308|Active Comparator|Eptifibatide (intravenous)|
3235703|NCT00945295|Active Comparator|Cohort #1|Cohort 1 will receive BoNT-A plus rehabilitation therapy for the duration of the study (for up to 2 injections of BoNT-A).
3235704|NCT00945295|Active Comparator|Cohort #2|Cohort 2 will receive BoNT-A alone
3235753|NCT00944918|Active Comparator|3|exemestane alone
3235707|NCT00945269|Experimental|Treatment (cellular adoptive immunotherapy)|Patients receive autologous T-cell IV over 30-60 minutes on days 0 and 28 and low-dose aldesleukin SC twice daily on days 0 to 13 and 28 to 41. Beginning 4-6 days before second T-cell infusion, patients receive denileukin diftitox IV over 30 minutes on days 1-3.
3235708|NCT00945256|Active Comparator|Young Aerobic Exercise|45 minutes of treadmill walking at 40% VO2 peak
3235709|NCT00945256|Active Comparator|Elderly Aerobic Exercise|45 minutes of treadmill walking at 40% VO2 peak
3235710|NCT00945256|Active Comparator|Young Sodium Nitroprusside|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
3235711|NCT00945256|Active Comparator|Elderly Sodium Nitoprusside|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
3235712|NCT00945256|Active Comparator|Elderly Sodium Nitroprusside and Amino Acid Drink|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min and 7.5g amino acid drink taken orally
3235713|NCT00945243|Other|Treatment|Treatment of cervical DDD with the Zero-P device
3235714|NCT00945230|Experimental|Actigraphic Neurosurgical Outcomes|Actigraphic measurements that will be obtained by attaching the actigraphic watch device to the individual's non-dominant wrist and operationally defined repeated observational measurements. All measurements will continue through a baseline period and continue through the identified post surgical period. Actigraphic measurements will occur every 30 seconds with brief periods of non-measurement during the actual neurosurgical procedure and periods when the actigraphic device has reached storage capacity (approximately every 22 days) when data is retrieved and the device prepared resume measurements.
3235715|NCT00945217||Postmenopausal women|women with natural menopause
3235716|NCT00945204|Experimental|access to intermediate care clinics|
3235717|NCT00945204|No Intervention|usual care|
3235718|NCT00945191|Experimental|CS-1008 with paclitaxel and carboplatin|CS-1008 will be administered with paclitaxel and carboplatin.
3235719|NCT00945178|Experimental|Part A: A|AZD1386
3235720|NCT00945178|Experimental|Part A: B|Placebo for AZD1386
3235721|NCT00945178|Experimental|Part B: A|Naproxen
3235722|NCT00945178|Experimental|Part B: B|Placebo for Naproxen
3235723|NCT00945165|Experimental|Exercise|
3235724|NCT00945165|Experimental|No exercise|
3235725|NCT00945152|Experimental|Drug Vancogel,Treatment,Kill MRSA,Heal|Treatment of open wounds with Vancogel(R) 1.25-1.50% to eliminate MRSA. End point is: a negative culture report after 1-3 topical applications. The infected wounds with MRSA will be treated with the Vancomycin 1.25 to 1.50% complex gel formulation and will have conventional management in order to heal the wound. Vancogel is anticipated to accelerate wound healing by eliminating MRSA. A randomized, double blind study protocol approved by FDA.
3235726|NCT00945152|Placebo Comparator|Placebo|Half of the patients in the study will be given a placebo consisting of all ingredients in Vancogel except the active principal Vancomycin in order to compare their clinical efficacy in rate of wound healingafter 1-3 applications
3235727|NCT00945139|Experimental|Single Arm: Doxil and Avastin|Patients receive both agents, doxil and Avastin.
3235728|NCT00945113|Experimental|Treatment group|attendance at one-week speech therapy group
3235729|NCT00945100|Active Comparator|Control|2 hours daily patching
3235730|NCT00945100|Active Comparator|Intensified treatment|42 hours per week of patching (averaging 6 hours daily)
3235731|NCT00945074|Experimental|Condition 1|"Condition 1:~Subjects receive Standard Acu/Moxa (fixed protocol)"
3235732|NCT00945074|Experimental|Condition 2: Individualized Acupuncture/Moxibustion|"Condition 2:~Subjects receive Individualized Acupuncture/Moxibustion (patient-oriented, based on traditional Chinese medicine diagnosis)."
3235733|NCT00945074|Sham Comparator|Condition 3: Control|"Condition 3:~Subjects receive Sham Acupuncture/Placebo Moxibustion (control group)"
3235734|NCT00945061|Experimental|Group 1|Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.
3235735|NCT00945061|Experimental|Group 2|Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.
3235736|NCT00945035|Active Comparator|A|Etoricoxib, 20% tablet
3235737|NCT00945035|Active Comparator|B|Etoricoxib, 30% tablet
3235738|NCT00945022|Experimental|Lipsus|
3235739|NCT00945009|Experimental|Arm 1 (Bilateral Wilms Tumors)|Patients start with three drug chemotherapy (Regimen VAD; vincristine, dactinomycin and doxorubicin) and are evaluated and six and 12 weeks for feasibility of undergoing a partial nephrectomy/renal sparing surgery. At week 12 definitive surgery takes place followed by chemotherapy and radiation therapy based on histology and stage. Treatment continues for 25 or 31 weeks depending on histology. Patients are followed for up to 10 years following end of therapy.
3235740|NCT00945009|Experimental|Arm 2 (Unilateral High Risk tumors bilaterally predisposed)|Patients start with either 2 drug or three drug chemotherapy (Regimen VA, VAD) and are evaluated a 6 and 12 weeks for feasibility of undergoing a partial nephrectomy. At week 12 definitive surgery takes place followed by chemotherapy.
3235741|NCT00945009|Experimental|Arm 3 (DHPLN)|Patients with this rare disease are diagnosed based on cross-sectional imaging characteristics and undergo 2 drug chemotherapy (Regimen;VA). Patients are reassessed at 6 weeks and 12 weeks. If disease has responded or stayed stable chemotherapy is completed for 19 weeks (Regimen EE4A). If disease has progress a biopsy is performed to assess histology and adjust therapy based on the biopsy. This therapy may include, nephrectomy, chemotherapy or radiation therapy.
3235742|NCT00944996|Active Comparator|antidepressant|
3235743|NCT00944996|No Intervention|Healthy volunteers|
3235744|NCT00944970|Other|binodenoson then adenosine|binodenoson (experimental); adenosine (active comparator)
3235745|NCT00944970|Other|adenosine then binodenoson|adenosine (active comparator); binodenoson (experimental)
3235746|NCT00944970|Active Comparator|adenosine then adenosine|
3235747|NCT00944957|Experimental|Raltegravir first|Patients treated with Raltegravir for first 2 weeks
3235748|NCT00944957|Experimental|Efavirenz first|Patients treated with Efavirenz for first 2 weeks
3235749|NCT00944944||Gyn Pts with lymphedema|
3235750|NCT00944944||Gyn Pts without Lymphedema|
3235751|NCT00944918|Experimental|1|fulvestrant and anastrozole
3235752|NCT00944918|Experimental|2|fulvestrant and placebo
3235754|NCT00944905|Experimental|MDX-1203|Accelerated titration design (ATD)of 6 dose levels. Subjects will be assigned to a dose level in the order they enter the study
3235755|NCT00944892|Experimental|Dose 1|
3235756|NCT00944892|Experimental|Dose 2|
3235757|NCT00944892|Experimental|Dose 3|
3235758|NCT00944892|Placebo Comparator|Placebo|
3235759|NCT00944879||HPV vaccine|Those choosing to receive the HPV vaccine
3235760|NCT00944879||no HPV vaccine|Those choosing not to receive the HPV vaccine
3235761|NCT00944866||RA with drug|
3235762|NCT00944866||RA without drug|
3235763|NCT00944853|Experimental|Zinc syrup|Liquid Zinc Syrup (ZnSO4) solution provided daily
3235764|NCT00944853|Experimental|Zinc tablet|Dispersible zinc tablets provided daily
3235765|NCT00944853|Placebo Comparator|Placebo|Liquid placebo supplement provided daily
3235766|NCT00944840|Active Comparator|SP and amodiaquine|Study subjects received intermittent preventive treatment with SP plus amodiaquine.
3235767|NCT00944840|Placebo Comparator|SP placebo plus amodiaquine placebo|Intermittent preventive treatment with SP placebo and amodiaquine placebo
3235768|NCT00944827|Experimental|GTE|The experimental group will receive 20 mg atorvastatin (Lipitor) daily and 600 mg. of pure catechin in capsules
3235769|NCT00944827|Placebo Comparator|CON|The control group will receive 20 mg atorvastatin (Lipitor) and Placebo in identical capsules containing 600 mg placebo for 12 weeks
3235770|NCT00944814|Experimental|LNS with zinc|LNS containing 10 mg zinc per 20 g dose of LNS
3235771|NCT00944814|Placebo Comparator|LNS without zinc|LNS containing no zinc
3235772|NCT00944801|Experimental|Pegylated Liposomal Doxorubicin|Radiotherapy is planned with dedicated computed tomography and three-dimensional planning systems and delivered to the gross tumor volume with a 2 to 3 cm margin for the clinical target volume. After a 4-week break, patients receive adjuvant TMZ 150 to 200 mg/m2 day 1 to 5 in 28 days until tumor progression or up to at least 12 cycles. In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
3235773|NCT00944788|Experimental|qi-gong|
3235774|NCT00944788|No Intervention|Usual care|
3235775|NCT00944775|Experimental|exercise training|10-month exercise training program
3235776|NCT00944775|No Intervention|controls|usual care sedentary lifestyle
3235777|NCT00944762|Experimental|Ecosystem Focused Therapy (EFT)|Participants will receive EFT.
3235778|NCT00944762|Active Comparator|Education in stroke and depression|Participants will receive education in stroke and depression.
3235779|NCT00944749|Experimental|Single Arm|
3235780|NCT00944736|Active Comparator|VSL#3|
3235781|NCT00944736|Placebo Comparator|Placebo|
3235782|NCT00944723|Experimental|Zinc-fortified bread (10 mg zinc/d)|Daily consumption of zinc fortified bread for 1 month
3235783|NCT00944723|Experimental|Zinc fortified bread (20 mg zinc/d)|Daily consumption of zinc fortified bread for 1 month.
3235784|NCT00944723|Experimental|Zinc supplemented group|Daily consumption of non-fortified bread and daily intake of zinc supplement (10 mg zinc/d)
3235785|NCT00944723|Placebo Comparator|Non-fortified group|Daily consumption of non-fortified bread and a placebo supplement for 1 month.
3235786|NCT00944710|Active Comparator|Intensified treatment|Weekend atropine 1% with plano lens over the sound eye
3235787|NCT00944710|Active Comparator|Control|Weekend atropine 1%
3235788|NCT00944697|Placebo Comparator|Tablets|A placebo tablet to match the active reference treatment
3235789|NCT00944697|Active Comparator|Tablet|Oxycodone Naloxone tablets
3235790|NCT00944684|Experimental|A|PegIFN-alpha 2a + RBV (commenced according to kidney function) adjusted to plasma levels. Treatment with erythropoetin 3x3,000IU/week up to 3x10,000IU/week in case of hemolytic anemia
3235791|NCT00944684|Active Comparator|B|PegIFN-alpha 2a + RBV (weight based; 1,000 or 1,200 mg/day)
3235792|NCT00944671|Active Comparator|A|Famotidine/antacid combination tablet with water
3235793|NCT00944671|Experimental|B|Famotidine/Antacid EZ Chew tablet without water
3235794|NCT00944671|Experimental|C|Famotidine/Antacid EZ Chew tablet with water
3235795|NCT00944658|Active Comparator|Apremilast|
3235796|NCT00944658|Placebo Comparator|Sugar pill|
3235797|NCT00944645|Active Comparator|A|MK0524A Source 1 (Phase III manufacturing site)
3235798|NCT00944645|Active Comparator|B|MK0524A Source 2 (commercial manufacturing site)
3235799|NCT00944632|Active Comparator|Zk 245186 0.01% ointment|Active treatment, lowest dose
3235800|NCT00944632|Active Comparator|ZK 245186 0.03% ointment|Active comparator middle dose
3235801|NCT00944632|Active Comparator|ZK 245186 0.1% ointment|Active comparator highest dose
3235802|NCT00944632|Placebo Comparator|Vehicle ointment|Placebo comparator
3235803|NCT00944619|Experimental|Closed loop (algorithm)|Subcutaneous delivery of Novorapid insulin, dose calculated by computer-driven control algorithm, based on continuous glucose sensor readings
3235804|NCT00944619|Placebo Comparator|Open loop|Subcutaneous delivery of Novorapid insulin according to usual pump regime
3235805|NCT00944606|Active Comparator|Vitamin D|
3235806|NCT00944606|Placebo Comparator|Placebo|
3235807|NCT00944593|Experimental|300kcal liquid Nutrient|300kcal liquid nutrient delivered by NJ tube over 60 minutes before ingestion of a standard oral liquid nutrient test meal
3235808|NCT00944593|Placebo Comparator|Normal Saline|Normal Saline delivered via NJ tube over 60 minutes ahead of a standard liquid nutrient test meal
3235809|NCT00944580|Experimental|Vaccine Intervention|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine: A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
3235810|NCT00944554|Placebo Comparator|Placebo|Group given placebo.
3235811|NCT00944554|Experimental|Varenicline|Experimental group given varenicline dosing.
3235812|NCT00944528|Experimental|Single dose radiosurgery: Dose Level 1|A single 15 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
3235814|NCT00944528|Experimental|Single dose radiosurgery: Dose Level 3|A single 21 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
3235815|NCT00944515|Active Comparator|azithromycin|azithrimycin 3 days/week
3235816|NCT00944515|Placebo Comparator|placebo|placebo 3 days/week
3235817|NCT00944502|Experimental|Dexamethasone and complex vitamins|"Group A: Vitatonus dexa injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group B: Vitatonus DEXA tablet:~1 tablet orally every 8 hours for 10 days."
3235818|NCT00944502|Active Comparator|Dexamethasone|"Group C: Dexamethasone Injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group D: Dexamethasone tablet:~1 tablet orally every 8 hours for 10 days."
3235819|NCT00944489||1|Patients with diagnosis of essential hypertension under the criteria established by the Joint National Committee VII (9) and those patients under pharmacological treatment with the same therapeutic regime during at least the last 6 months.
3235820|NCT00944476||Pts/volunteers getting regular MRI exam|Fat-free MRI images utilizing standard magnetization transfer imaging will be acquired on 10 patients known or suspected sarcoma of the of the extremity or trunk, in addition to their traditional clinical MRI. In addition, we will perform the same scans on 4 volunteers who have no history of sarcoma.
3235821|NCT00944463|Experimental|Gemcitabine+simvastatin|Gemcitabine and simvastatin
3235822|NCT00944463|Placebo Comparator|Gemcitabine+Placebo|Gemcitabine plus Placebo
3235823|NCT00944450|Active Comparator|1|Sitagliptin anhydrous formulation
3235824|NCT00944450|Active Comparator|2|Sitagliptin monohydrate FMI formulation
3235825|NCT00944437|Active Comparator|Helmet|Patients in this group will receive continuous positive airway pressure delivered through a helmet connected to a high-flow reservoir system.
3235826|NCT00944437|Experimental|Mask|Patients in this group will receive continuous positive-airway pressure delivered through a novel full-face mask connected to a high-flow system. Expiratory pressure will be maintained using an expiratory valve connected to a T-tube.
3235827|NCT00944424|Experimental|Arm A|Arm A = Docetaxel + High dose Vitamin D2
3235828|NCT00944424|Active Comparator|Arm B|Docetaxel + Standard dose Vitamin D2
3235829|NCT00944398|Experimental|Zinc fortified group|Daily consumption of zinc-fortified complementary food
3235830|NCT00944398|Placebo Comparator|Non-fortified group|Daily consumption of non-fortified complementary food and placebo supplement.
3235831|NCT00944398|Experimental|Zinc supplement group|Daily consumption of zinc supplement and non-fortified complementary food.
3235832|NCT00944385|Experimental|ulinastatin|Administer with 30,000U /ulinastatin
3235833|NCT00944385|Placebo Comparator|C group|administer normal saline
3235834|NCT00944372|Experimental|Group 1|Control, age greater than or equal to 18 with normal renal function
3235835|NCT00944372|Experimental|Group 2|Age 18 to less than 65 with mild renal impairment
3235836|NCT00944372|Experimental|Group 3|Age 18 to less than 65 with moderate to severe renal impairment
3235837|NCT00944372|Experimental|Group 4|Age 18 to less than 65 with end stage renal impairment
3235838|NCT00944372|Experimental|Group 5|Age 65 to less than 75 with mild renal impairment
3235839|NCT00944372|Experimental|Group 6|Age 65 to less than 75 with moderate to severe renal impairment
3235840|NCT00944372|Experimental|Group 7|Age 65 to less than 75 with end stage renal impairment
3235841|NCT00944372|Experimental|Group 8|Age greater than or equal to 75 with mild renal impairment
3235842|NCT00944372|Experimental|Group 9|Age greater than or equal to 75 with moderate to severe renal impairment
3235843|NCT00944372|Experimental|Group 10|Age greater than or equal to 75 with end stage renal impairment
3235844|NCT00944359|Experimental|Daily preventive Zn; placebo treatment|7 mg zinc per day for 12 months and placebo supplement during diarrhea episode
3235845|NCT00944359|Experimental|Therapeutic Zn; daily placebo|20 mg of zinc for 10 days during episodes of diarrhea and daily placebo supplement
3235846|NCT00944359|Experimental|Intermittent Zn; placebo treatment|10 mg zinc for 10 days every 3 months, daily placebo during 80 days of 3 months period and placebo during diarrhea episode
3235847|NCT00944359|Active Comparator|Surveillance control group|Surveillance control group will be randomly assigned to intervention groups every 3 months
3235848|NCT00944359|No Intervention|Non-intervention|Standard care provided by health system
3235849|NCT00944333|Experimental|Clopidogrel 6|6 month dual antiplatelet therapies in patients after second generation DES implantation
3235850|NCT00944333|Experimental|Clopidogrel 12|12 month dual antiplatelet therapies in patients after second generation DES implantation
3235851|NCT00944307|Active Comparator|raltegravir alone|Subjects will receive a single dose of 400 mg raltegravir orally
3235852|NCT00944307|Experimental|raltegravir plus antacid|Subjects will receive a single dose of 400mg raltegravir orally simultaneously with an antacid
3235853|NCT00944294|Other|binodenoson then adenosine|binodenoson (experimental); adenosine (active comparator)
3235854|NCT00944294|Other|adenosine then binodenoson|adenosine (active comparator); binodenoson (experimental)
3235855|NCT00944281|Experimental|LNS-Zn5|Daily intake of 20 g LNS containing 5 mg of zinc and a daily placebo supplement
3235856|NCT00944281|Experimental|LNS-Zn10|Daily intake of 20 g LNS containing 10 mg of zinc and a daily placebo supplement
3235857|NCT00944281|Placebo Comparator|LNS-Zn0|Daily intake of 20 g LNS containing 0 mg of zinc and a daily placebo supplement
3235858|NCT00944281|Experimental|Suppl-Zn5|Daily intake of zinc supplement containing 5 mg of zinc and 20 g LNS containing 0 mg of zinc
3235859|NCT00944281|No Intervention|Delayed intervention group|Standard care from age 8 to 18 months. Daily consumption of LNS from age 18 to 28 months.
3235860|NCT00944268|Experimental|Liquid and solid|
3235861|NCT00944255||RA with drug|
3235862|NCT00944255||RA without drug|
3235863|NCT00944229|Active Comparator|1 Drug Treatment - LOVAZA|Drug Treatment - LOVAZA 4 gm q24 for 8 weeks
3235864|NCT00944229|Placebo Comparator|2 placebo|Placebo 4 capsules q24 for 8 weeks
3235865|NCT00944216|Experimental|Treatment|
3235866|NCT00944203|Experimental|Test Area|Test Area = Standard Treatment plus Ipomea pes-caprae oinment
3235867|NCT00944203|No Intervention|Control Area|Control = Standard Treatment
3236068|NCT00942773|Active Comparator|CYP2C19 poor metabolizer|
3235868|NCT00944190|Experimental|Self-management Intervention|Telephone based self management intervention targeted at pain, fatigue, depression, and cognitive difficulties.
3235869|NCT00944190|Active Comparator|Education|Education about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
3235870|NCT00944164|Experimental|Healthy eating/physical activity|
3235871|NCT00944164|Active Comparator|Safety/Injury prevention|
3235872|NCT00944151|Placebo Comparator|Single injection with Saline infused TAP catheter|Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given normal saline in infusion pump, attached to catheter.
3235873|NCT00944151|Active Comparator|Single injection with Ropivicaine infused TAP catheter|Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given 0.2% ropivicaine in infusion pump, attached to catheter
3235874|NCT00944138|Experimental|Mindful meditation|Participants assigned to the mindful meditation plus standard care arm will receive individualized instruction on mindful meditation at the time they are randomized to this arm. The participants will be led through a 20 minute relaxation exercise. They will then be led through a brief eating exercise where they will be instructed to eat the food very slowly and pay attention to how the food tastes and the sensations of swallowing the food. This is done to enhance the person's awareness of what and how they are eating and enhance their intuitive sense of satiety. Finally, they will receive an MP3-player with several relaxation instructional audios loaded on the MP3 player.
3235875|NCT00944138|Active Comparator|Music for relaxation|Participants assigned to the control arm will receive the dietary counseling and will be told that relaxation can help reduce appetite. However, techniques to relax will not be taught. Instead, participants will be encouraged to sit quietly listening to music (of their choice) every day for 20 minutes. Participants assigned to the standard care arm will receive an MP3-player and will be given a choice of selection of music that they can load on their MP3 player (classical music, country music, jazz, etc.).
3235876|NCT00944125|Active Comparator|Dual Site LV Pacing|Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.
3235877|NCT00944125|Active Comparator|BiV Pacing|Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.
3235878|NCT00944112|Experimental|Restrictive RBC Transfusion Group|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70g/L with a target Hb concentration of 71-90g/L during the intervention period.
3235879|NCT00944112|Experimental|Liberal RBC Transfusion Group|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90g/L with a target Hb concentration of 91-110g/L during the intervention period.
3235880|NCT00944099|Experimental|Grazing|participants will be given an eating frequency prescription to eat every 2 to 3 hours
3235881|NCT00944099|Experimental|Three Meals|participants will be given an eating frequency prescription of eating 3 meals per day
3235882|NCT00944086||Recruitment Manoeuvre ,Laparoscopy|
3235883|NCT00944073|Experimental|Group 2: 30 mcg H1N1 Vaccine|300 subjects to receive 30 mcg of Inactivated H1N1 Vaccine on Day 0 and Day 21.
3235884|NCT00944073|Experimental|Group 1: 15 mcg H1N1 Vaccine|300 subjects to receive 15 mcg of Inactivated H1N1 Vaccine on Day 0 and Day 21.
3235885|NCT00944060|Experimental|lifestyle intervention|Control group: usual WIC care
3235886|NCT00944047|Experimental|Intervention Arm|Nab-paclitaxel, trastuzumab, doxorubicin, cyclophosphamide, Growth Factor Support, Surgery
3235887|NCT00944034|Experimental|B+R246_12|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.
3235888|NCT00944034|Experimental|B+R246_18|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.
3235889|NCT00944034|Experimental|B+R246_24|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.
3235890|NCT00944034|Experimental|B246_12|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.
3235891|NCT00944034|Experimental|B246_18|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.
3235892|NCT00944034|Experimental|B246_24|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.
3235893|NCT00944034|Experimental|B+R234_12|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.
3235894|NCT00944034|Experimental|B+R234_18|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.
3235895|NCT00944034|Experimental|B+R234_24|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.
3235896|NCT00944034|Experimental|B12 14|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.
3235897|NCT00944034|Experimental|B18 20|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.
3235898|NCT00944034|Experimental|B24 26|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.
3235899|NCT00944021|Experimental|PA-824 50 mg/qd|
3235900|NCT00944021|Experimental|PA-824 100mg/qd|
3235901|NCT00944021|Experimental|PA-824 150mg/qd|
3235902|NCT00944021|Experimental|PA-824 200mg/qd|
3235903|NCT00944021|Active Comparator|Rifafour e-275mg|
3235904|NCT00944008|Experimental|Depocyte|
3235905|NCT00943995|Other|Treatment Arm|Getting Growth Hormone therapy TIW instead of nightly in the Pediatric Tanner 1 Hemodialysis population.
3235906|NCT00943969|Other|obemo|
3235907|NCT00943956|Experimental|Everolimus|Everolimus + radiation
3236635|NCT00938730|Experimental|4. YM150, Dose Y once daily|
3235908|NCT00943943|Experimental|G-CSF and Plerixafor with Sorafenib|G-CSF 10 mcg/kg adjusted body weight subcutaneous injection. Plerixafor fixed dose of 240 mcg/kg adjusted body weight subcutaneous injection in abdomen. Patients will receive the 1st doses of G-CSF and Plerixafor on day 1. G-CSF and Plerixafor every other day for 7 total doses, repeated every 28 days. Sorafenib starting dose 400 mg twice daily orally after G-CSF/Plerixafor injections.
3235909|NCT00943930||Marijuana-dependent volunteers|
3235910|NCT00943917|Experimental|ITCA 650 20 mcg/day|
3235911|NCT00943917|Experimental|ITCA 650 40 mcg/day|
3235912|NCT00943917|Active Comparator|Exenatide Injection|
3235913|NCT00943917|Experimental|ITCA 650 20/20|
3235914|NCT00943917|Experimental|ITCA 650 20/60|
3235915|NCT00943917|Experimental|ITCA 650 40/40|
3235916|NCT00943917|Experimental|ITCA 650 40/80|
3235917|NCT00943917|Experimental|Ex Inj/ITCA 650 40|
3235918|NCT00943917|Experimental|Ex Inj/ITCA 650 60|
3235919|NCT00943904|Experimental|Interstim stimulation|Patients who receive the interstim implant in order to evaluate effectiveness of treatment
3235920|NCT00943891||Tumor biopsies|
3235921|NCT00943878|Experimental|Group 3: H1N1+placebo; H1N1+TIV; placebo|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + placebo; Day 21, 15 mcg H1N1 Vaccine + trivalent influenza vaccine (TIV); and Day 42, placebo.
3235922|NCT00943878|Experimental|Group 1: H1N1+placebo; H1N1+placebo; TIV|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + placebo; Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, trivalent influenza vaccine (TIV).
3235923|NCT00943878|Experimental|Group 2: H1N1+TIV; H1N1+placebo; placebo|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + trivalent influenza vaccine (TIV); Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, placebo.
3235924|NCT00943878|Experimental|Group 4: TIV+placebo; H1N1+placebo; H1N1|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, trivalent influenza vaccine (TIV) + placebo; Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, 15 mcg H1N1 vaccine.
3235925|NCT00943865|Active Comparator|hypocaloric diet + exercise advice|Group 1 (control: tailored hypocaloric diet and exercise advised): patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant. Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
3235926|NCT00943865|Experimental|pragmatic diet+ pedometer 10000 steps|Group 2 (pragmatic diet + step counter) - Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control. Subjects were provided with pedometers and were instructed to perform at least 10.000 steps daily, diary recorded.
3235927|NCT00943865|Experimental|pragmatic diet + fitness|Group 3 (pragmatic diet + fitness) - They received the same diet intervention (low carbohydrates, high protein and vegetables style diet and favoring daily brazilian cook habits colored handbook) and hand sized portion control instructions of group 2. They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions.
3235928|NCT00943852|Active Comparator|1|losartan 100 mg
3235929|NCT00943852|Active Comparator|2|ISMN 60 mg
3235930|NCT00943852|Active Comparator|3|losartan 100 mg + ISMN 15 mg
3235931|NCT00943852|Active Comparator|4|losartan 100 mg + ISMN 60 mg
3235932|NCT00943852|Placebo Comparator|5|Placebo
3235933|NCT00943839|Experimental|SUVEGIL|
3235934|NCT00943826|Experimental|Bevacizumab + RT + Temozolomide|In the Concurrent Phase participants will receive radiotherapy (RT) in daily fractions of 2 Gy to be given 5 days per week for 6 weeks and temozolomide 75 mg/m^2 daily from the first day to the last day of radiotherapy (it may continue for a maximum of 49 days in case of delay to the end of radiation therapy) and bevacizumab 10 mg/kg IV every 2 weeks for 6 weeks. There will be a 4 week treatment break. Participants will then enter the Maintenance Phase where they receive six 28-day cycle of bevacizumab 10 mg/kg IV q2w and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants will then enter the Monotherapy Phase where they will receive bevacizumab 15 mg/kg IV q3w until disease progression/unacceptable toxicity.
3235935|NCT00943826|Placebo Comparator|Placebo + RT + Temozolomide|In the Concurrent Phase participants will receive radiotherapy in daily fractions of 2 Gy to be given 5 days per week for 6 weeks and temozolomide 75 mg/m^2 daily from the first day to the last day of radiotherapy (it may continue for a maximum of 49 days in case of delay to the end of radiation therapy) and placebo IV every 2 weeks for 6 weeks. There will be a 4 week treatment break. Participants will then enter the Maintenance Phase where they will receive six 28-day cycle of placebo IV q2w and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants will then enter the Monotherapy Phase where they will receive placebo IV q3w until disease progression/unacceptable toxicity.
3235972|NCT00943527||2|Women Initiating Hormone Therapy and have had a negative mammogram preformed at the Mayo Clinic Rochester within the last year.
3235973|NCT00943527||3|Women Initiating Tamoxifen who have had a negative mammogram preformed at the Mayo Clinic Rochester.
3235974|NCT00943501|Experimental|I.a|
3235975|NCT00943501|Placebo Comparator|I.b|
3235936|NCT00943813||Patients in clinic waiting room|When patients are approached in the clinic, they will be given the permission form and asked to participate in the assessment through allowing video-recording and completing the survey. Procedures will be similar to our current operations, with the RSA starting the video-recording equipment before the fellow enters the room and stopping it when the fellow leaves the room. One additional step will be added: When the RSA goes into the room to turn off and remove the video-recording equipment, she will also give the patient the survey, to complete. We expect this survey to take no longer than 5 minutes. In our experience, it is usually at least 10 minutes from when the fellow leaves the room until the attending comes back into the room. Thus, we believe there will be sufficient time for the patient to complete the survey.
3235937|NCT00943800|Experimental|Good Risks patients|For patients transplanted in remission.
3235938|NCT00943800|Experimental|High Risk Patients eligible for radiation|
3235939|NCT00943800|Experimental|High Risk Patients not eligible for radiation|
3235940|NCT00943787|Other|SMBG followed by clamp|One month of self-monitored blood glucose (SMBG) field data was used to calculate measures of glucose variability and risk of hypoglycemia, while the hyperinsulinemic, euglycemic and hypoglycemic clamp procedure was used to evaluate insulin sensitivity and epinephrine response during induced hypoglycemia.
3235941|NCT00943774||All subjects|All subject participants
3235942|NCT00943761|Experimental|Vaniprevir 300 mg b.i.d. + peg-IFN + RBV|Participants received vaniprevir 300 mg twice daily (b.i.d.) in combination peg-IFN 180 mcg weekly and ribavirin (1000 or 1200 mg) administered as a divided dose twice daily.
3235943|NCT00943761|Experimental|Vaniprevir 600 mg b.i.d. + peg-IFN + RBV|Participants received vaniprevir 600 mg b.i.d. in combination peg-IFN 180 mcg weekly and ribavirin (1000 or 1200 mg) administered as a divided dose twice daily.
3235944|NCT00943748|Active Comparator|deferiprone|deferiprone 30 mg/kg/day
3235945|NCT00943748|Placebo Comparator|placebo|placebo : 30 mg/kg/day, in 2 liquid doses
3235946|NCT00943735||Fesoterodine arm|subjects who present with OAB symptoms during medical office visits and who appear to be candidates for fesoterodine therapy
3235947|NCT00943722|Experimental|9- to 15-Year-Old Females (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
3235948|NCT00943722|Experimental|9- to 15-Year-Old Females (Lot 2)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 2.
3235949|NCT00943722|Experimental|9- to 15-Year-Old Females (Lot 3)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 3.
3235950|NCT00943722|Experimental|9- to 15-Year-Old Males (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
3235951|NCT00943722|Experimental|16- to 26-Year-Old Females (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
3235952|NCT00943709|Experimental|Arm I|Patients with goal blood glucose 80-14 mg/dL receive the Robert Wood Johnson Hospital IV insulin infusion protocol followed by insulin glargine and insulin glulisine (Apidra™) subcutaneously for 4 weeks.
3235953|NCT00943709|Active Comparator|Arm II|Patients with goal blood glucose < 250 mg/dL are started on subcutaneous insulin sliding scale at the discretion of the treating physician with blood glucose monitoring and adjustment according to the insulin sliding scale.
3235954|NCT00943683|Experimental|1|Montelukast
3235955|NCT00943683|Placebo Comparator|2|Placebo
3235956|NCT00943670|Experimental|T-DM1 / T-DM1 + pertuzumab|"Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg.~From Cycle 4, participants with early progressive disease (demonstrated prior to the end of Cycle 6) could receive combined pertuzumab and trastuzumab emtansine. Pertuzumab was administered after trastuzumab emtansine by IV infusion at a loading dose of 840 mg on Day 1, starting at the cycle after tumor progression was determined, followed by 420 mg IV infusion every 3 weeks in subsequent cycles.~Participants who met criteria for ongoing clinical benefit were allowed to continue study treatment in the absence of disease progression or unacceptable toxicity for up to 1 year."
3235957|NCT00943631|Experimental|Group 2: H1N1 Vaccine 30 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 30 mcg of H1N1 vaccine on Days 0 and 21.
3235958|NCT00943631|Experimental|Group 1: H1N1 Vaccine 15 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 15 mcg of H1N1 vaccine on Days 0 and 21.
3235959|NCT00943618|Active Comparator|Group 1|Varenicline and Bupropion
3235960|NCT00943618|Placebo Comparator|Group 2|Varenicline and Placebo
3235961|NCT00943618|Placebo Comparator|Group 3|Placebo that looks like varenicline and a placebo that looks like bupropion.
3235962|NCT00943605|Active Comparator|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
3235963|NCT00943605|Experimental|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
3235964|NCT00943592|Experimental|Treatment|
3235965|NCT00943579|Experimental|Kuvan®|Kuvan® (sapropterin) will be administered to all subjects at 20 mg/kg/day for 16 weeks.
3235966|NCT00943566|Experimental|Sufentanil Transdermal Delivery System|Experimental drug
3235967|NCT00943566|Active Comparator|Control|Sustained release morphine sulfate
3235968|NCT00943553|Experimental|1|
3235969|NCT00943553|Experimental|2|
3235970|NCT00943540|Experimental|Raltegravir BID-QD|"Week 1-4~600 mg of atazanavir to be taken once daily~400 mg of raltegravir to be taken twice daily~300 mg of lamivudine (or 200 mg of emtricitabine) to be taken once daily~Week 5-8~600 mg of atazanavir to be taken once daily~800 mg of raltegravir to be taken once daily~300 mg of lamivudine (or 200 mg of emtricitabine) to be taken once daily"
3235971|NCT00943527||1|Premenopausal Women who are not taking hormones or birth control. Ages 35-45 who have had a negative mammograph performed at the Mayo Clinic in Rochester within the last year.
3235976|NCT00943501|Experimental|II.a|
3235977|NCT00943501|Placebo Comparator|II.b|
3235978|NCT00943488|Experimental|Group 1: H1N1 Vaccine 15 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 15 mcg of H1N1 vaccine on Days 0 and 21.
3235979|NCT00943488|Experimental|Group 2: H1N1 Vaccine 30 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 30 mcg of H1N1 vaccine on Days 0 and 21.
3235980|NCT00943475|Active Comparator|anaesthesia, circumcision|
3235981|NCT00943462||Glioblastoma Multiforme (GBM)|We will conduct a prospective study on 20 consecutive patients who are seen at the Hôpital Notre‑Dame neuro-oncology clinic for a diagnosis of GBM and who meet our inclusion criteria. We will meet with the eligible patients in order to provide them with a detailed description of the study procedures as well as to have them sign a consent form.
3235982|NCT00943449|Experimental|4SC-201|
3235983|NCT00943449|Experimental|4SC-201 + Sorafenib|
3235984|NCT00943436|Active Comparator|Active males|Males who participate in at least 30 minutes of physical activity on 5 or more days per week for the last month.
3235985|NCT00943436|Active Comparator|Inactive males|Males who participate in less than 1 hour of physical activity per week for the last month.
3235986|NCT00943423|Active Comparator|Arm I|Within 6 weeks after completion of course 3 of chemotherapy, patients undergo involved field radiotherapy to disease areas.
3235987|NCT00943423|Experimental|Arm II|Patients receive no further treatment.
3235988|NCT00943410|Active Comparator|Surgical Candidate|After 5 consecutive weeks of treatment with Radiation and Herceptin, these subjects will receive mastectomy excision
3235989|NCT00943410|Active Comparator|Non-Surgical Candidate|After 5 weeks of consecutive treatment with radiation and herceptin, these subjects will not be eligible for surgery. They will continue with radiation and herceptin for an additional 2 weeks.
3235990|NCT00943397|Experimental|1|Montelukast
3235991|NCT00943397|Active Comparator|2|Usual Care
3235992|NCT00943384|Experimental|chronOS Strip|This is a single arm, outcome study for treatment of patients with degenerative disc disease (DDD), with or without stenosis, with interbody fusion, posterolateral pedicle screw system, and the study device (chronOS Strip).
3235993|NCT00943371|Experimental|1|MK6349
3235994|NCT00943371|Placebo Comparator|2|Placebo to MK6349
3235995|NCT00943358|Active Comparator|Vaccine|adjuvanted influenza vaccine
3235996|NCT00943358|Active Comparator|Vaccine 2|non-adjuvanted vaccine
3235997|NCT00943345|Active Comparator|GS dual sugar permeability test|"Golden standard GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
3235998|NCT00943345|Other|Multi sugar test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
3235999|NCT00943345|Other|Protein test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
3236000|NCT00943345|Other|PEG test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
3236001|NCT00943332||spica casting|
3236002|NCT00943332||intramedullary nailing|
3236003|NCT00943332||submuscualr plating|
3236004|NCT00943319|Experimental|Busulfan and fludarabine|Intravenous busulfan (Busulfan®) in combination with fludarabine
3236005|NCT00943306|Experimental|lomitapide|Maximum tolerated dose of lomitapide in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.
3236006|NCT00943293|Experimental|Vaccine|
3236007|NCT00943280||1 EGD|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to EGD.
3236008|NCT00943280||2 Transnasal|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to Transnasal endoscopy.
3236009|NCT00943280||3 PillCam|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to PillCam.
3236010|NCT00943267|Experimental|Activated protein C|
3236011|NCT00943267|Placebo Comparator|Saline|
3236012|NCT00943254|Experimental|Arm 1|"Patients randomized to this arm receive the diagnosis of metabolic syndrome and subsequent education using paper-based and DVD materials"
3236013|NCT00943254|Experimental|Arm 2|"Patients in this arm receive the diagnosis of metabolic syndrome and subsequent education using paper-based material"
3236014|NCT00943254|No Intervention|Arm 3|Patients randomized to control receive the diagnosis of individual cardiovascular risk factors with paper-based educational material
3236015|NCT00943228|Experimental|mycophenolate mofetil|mycophenolate mofetil 2000mg BID (4g/day) for 14 days, followed by mycophenolate 1000mg BID (2g/day) thereafter
3236016|NCT00943202|Experimental|Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine; Day 21: 15 mcg H1N1 vaccine; Day 42: TIV.
3236017|NCT00943202|Experimental|Group 2: Day 0-H1N1+TIV; Day 21-H1N1|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine + TIV; Day 21: 15 mcg H1N1 vaccine.
3236018|NCT00943202|Experimental|Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1|150 subjects to receive-Day 0: TIV; Day 21: 15 mcg H1N1 vaccine; Day 42: 15 mcg H1N1 vaccine.
3236019|NCT00943202|Experimental|Group 3: Day 0-H1N1; Day 21-H1N1+TIV|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine; Day 21: 15 mcg H1N1 vaccine + TIV.
3236020|NCT00943176|Placebo Comparator|Sugar Pill|
3236021|NCT00943176|Experimental|Modafinil|
3236022|NCT00943150|Experimental|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
3236023|NCT00943150|Active Comparator|Standard of Care (SOC)|The scalpel and electrocautery will be used for the abdominoplasty procedure.
3236024|NCT00943137|Experimental|5-FU dosage adjustments|The dose of continuous infusion 5-FU will be adjusted every cycle until patients reached the therapeutic plasma range (450 to 550 microgram/L).
3236064|NCT00942799|Experimental|Study Drug: Genz-644282 (21-day dosing schedule)|Genz-644282 (Each cohort will be based on dose-escalation)
3236025|NCT00943124|Experimental|MK0524B then Simvastatin + MK0524A|"Period 1: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg).~Period 2: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets."
3236026|NCT00943124|Experimental|Simvastatin + MK0524A then MK0524B|"Period 1: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets.~Period 2: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg)."
3236027|NCT00943111|Experimental|Investigational|Eliglustat tartrate
3236028|NCT00943111|Active Comparator|Imiglucerase|
3236029|NCT00943098|Experimental|Diclofenac HPBCD s.c. 75mg/ml|
3236030|NCT00943098|Active Comparator|Voltarol 75mg/3ml i.m.|
3236031|NCT00943085|Experimental|Family-focused therapy|Participants will receive family-focused therapy.
3236032|NCT00943085|Active Comparator|Brief educational treatment|Participants will receive one session of diagnostic feedback, recommendations for continued treatment, and crisis intervention as needed.
3236033|NCT00943072|Experimental|VEGF Trap-Eye|Monthly IVT injection of VEGF Trap-Eye 2.0 mg until Week 24 Primary Endpoint
3236034|NCT00943072|Sham Comparator|Sham|Monthly Sham IVT injection until Week 24 Primary Endpoint
3236035|NCT00943059|Experimental|Acipimox|Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.
3236036|NCT00943059|Placebo Comparator|Cellulosum mycrocryst capsula|Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.
3236037|NCT00943033|Experimental|Mindfulness-Based Cognitive Therapy plus treatment as usual|
3236038|NCT00943033|No Intervention|MBCT Waitlist plus Treatment as Usual|
3236039|NCT00943020|Active Comparator|Nutricia PreOp + Lipid|Nutricia PreOp + Lipid
3236040|NCT00943020|Active Comparator|Nutrica PreOP + Glutamine|Nutrica PreOP + Glutamine
3236041|NCT00943020|Experimental|Nutricia PreOP|Nutricia PreOP: carbohydrate only drink
3236042|NCT00943007|Active Comparator|Conventional Neuronavigation|Standard form of neuronavigation: based on preoperative MRI without intraoperative correction for brain shift
3236043|NCT00943007|Experimental|Intraoperative MRI|Standard neuronavigation plus intraoperative MRI to correct for brain shift
3236044|NCT00942994|Experimental|Triple Therapy (Aliskiren/Amlodipine/HCTZ)|At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg.
3236045|NCT00942994|Active Comparator|Dual Therapy (Aliskiren/Amlodipine)|At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg.
3236046|NCT00942968|Experimental|1|
3236047|NCT00942955||CLT|The patients whose blood are analyzed by conventional central laboratory.
3236048|NCT00942955||POCT|the patients group whose lab analyze by POCT device.
3236049|NCT00942929||Adolescents hospitalized for anorexia nervosa|Adolescent 12-18 years old, fulfilling the DSM IV criteria for anorexia nervosa, hospitalized for medical stabilization and/ or initiation of refeeding
3236050|NCT00942929||Controls|Adolescents 12-18 years old without anorexia nervosa hospitalized for reasons other than those involving the respiratory system and with no underlying lung disease
3236051|NCT00942916||Patients with confirmed diagnosis of NTM pulmonary disease|Those with sputum mycobacterial culture yielded the same NTM species for at least two sets within one year.
3236052|NCT00942916||Patients with not definite NTM pulmonary disease|Those who had sputum culture yielded NTM but did not satisfy the criteria for diagnosis with NTM pulmonary disease.
3236053|NCT00942903|Experimental|Compliant HME users|Laryngectomized patients who are currently compliant (24/7) users of a Provox HME
3236054|NCT00942890|Experimental|NMES plus Standard Rehab Protocol|"NMES (EMPI 300PV stimulator) plus standard of care intervention. NMES is to the quadriceps muscle of the residual and intact limb plus rehabilitation. Therapy is 12-wks of NMES home training w/ the EMPI 300PV muscle stimulator. Participants perform training at home for 5days/wk; sessions consisted of 15 to 20 min. of NMES to each leg eliciting15 contractions/leg (10 seconds on:50 seconds off), plus a 5-minute patient treatment log, 5x/wk for 12-wks. Each contraction will be elicited by an electrical impulse generated by a battery-operated device. Two 3 X 5 electrodes are placed over the quadriceps muscle group. Participants will train at 30-40% of MVC during weeks 1-6, and 40-50% of MVC during weeks 7-12; incremental increases will be made at the study visits."
3236055|NCT00942890|Active Comparator|Standard Rehab Protocol|TMARP standard of care intervention: 12 weeks of the Traditional Military Amputee Rehabilitation Program (TMARP). TMARP training starts 1 week after surgical closure of the residual limb. Physical Therapy performs Pre-Prosthetic Training for about 6 weeks, preparing for the prosthetic. After pre-prosthetic training, patients are fitted with their prosthetic leg and began post-prosthetic training with PT. The training focus is lower limb prosthetic proficient in ambulation.
3236056|NCT00942877|Experimental|Treatment|Pediatric patients (<16 years old) will be treated with 12 mg/m2/day once a day for 28 days (28-day cycles).
3236057|NCT00942851|Experimental|active|AH-8 containing topical intervention
3236058|NCT00942851|Placebo Comparator|placebo|topical intervention WITHOUT AH-8
3236059|NCT00942825|Experimental|A CBP501 +Cisplatin + Pemetrexed|CBP501 25 mg/m2 + Cisplatin 75 mg/m2 + Pemetrexed 500mg/m2
3236060|NCT00942825|Active Comparator|B Cisplatin + Pemetrexed|Cisplatin + Pemetrexed
3236061|NCT00942812|Experimental|Intervention|A diarrhea Pack comprising of low osmolality ORS, Zinc, water purification sachets and pictorial chart.
3236062|NCT00942812|Other|Control|Standard Care through National LHW (Lady Health Workers)program
3236063|NCT00942799|Experimental|Study Drug: Genz-644282 (28-day dosing schedule)|Genz-644282 (Each cohort will be based on dose-escalation)
3236069|NCT00942760||Research MRI|High Grade Glioma patients who show progression based on MRI
3236070|NCT00942747|Experimental|Temsirolimus|Weekly IV temsirolimus
3236071|NCT00942734|Experimental|RAD001 + Erlotinib|RAD001 1 tablet (5 mg) by mouth every day of each 28 day study cycle. Erlotinib one tablet (150 mg) by mouth every day of each 28 day study cycle.
3236072|NCT00942721|Experimental|Web-based CBT for PPD|Participants will receive Web-based CBT for PPD.
3236073|NCT00942708|Other|Fluoxetine|Fluoxetine will be added starting at 20 mg and titrated as tolerated to 80 mg daily.
3236074|NCT00942695|Other|base|average American diet without pistachios
3236075|NCT00942695|Active Comparator|1.5PD|average American diet plus 1.5 oz per day pistachios
3236076|NCT00942695|Active Comparator|3.0PD|average American diet plus 3.0 oz per day pistachios
3236077|NCT00942682|Experimental|Sorafenib and RAD001|"Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have neuroendocrine tumors, not everyone who participates in this research study will receive the same dose of the study drug. The dose the participant will be given will depend on the number of participants who have been enrolled in the study.~Each treatment cycle lasts 28 days. Participants will take RAD001 orally once a day in the morning. Participants will take sorafenib orally twice daily.~Participants will remain on this research study as long as they continue to benefit from the study medications."
3236078|NCT00942669|Experimental|SleepStrip OTC(TM)|Participants will receive the SleepStrip OTC(TM) for a night (or two) test at home, before or after undergoing an independent PSG test at the Sleep lab. The reading of both methods will be analyzed.
3236079|NCT00942643|No Intervention|no treatment|being observed at 4 weeks and 12 weeks
3236080|NCT00942643|Active Comparator|CPAP treatment|a machine delivers positive airway pressure into the upper airway via nasal mask
3236081|NCT00942617|Experimental|40 mg non-enteric coated aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
3236082|NCT00942604|Active Comparator|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
3236083|NCT00942604|Placebo Comparator|Vehicle gel|Vehicle gel once daily for 2 consecutive days
3236084|NCT00942591|Experimental|1|Interferon beta-1b AND atorvastatin
3236085|NCT00942591|Active Comparator|2|Interferon beta-1b
3236086|NCT00942578|Experimental|Single Arm|A two dose level escalation of Lenalidomide from 15mg to 20mg to 25mg- standard 3+3 dose escalationapproach in combination with docetaxel, Bevacizumab and prednisone.
3236087|NCT00942565|Active Comparator|Tramadol/acetaminophen|The tramadol and acetaminophen combination was given to patients at the same day after surgery.
3236088|NCT00942565|Active Comparator|acetaminophen|Acetaminophen was used as active control.
3236089|NCT00942539|Experimental|Midazolam|Administration of Midazolam prior Lumbar Puncture
3236090|NCT00942526|No Intervention|1|no intervention with perioperative oral anti-infective agent or water for gargling
3236091|NCT00942526|Sham Comparator|2|perioperative gargling with water
3236092|NCT00942526|Experimental|3|perioperative oral gargling with oral anti-infective agent for seven days
3236093|NCT00942500|Experimental|Post-conditioning|
3236094|NCT00942500|No Intervention|Conventional primary PCI|
3236095|NCT00942487|Experimental|Nebivolol|
3236096|NCT00942487|Active Comparator|Metoprolol|
3236097|NCT00942474|Experimental|Research Arm|Facilitate nerve stimulation lead placement with the nerve access tool
3236098|NCT00942461|Active Comparator|Laparoscopic Surgery group|Group of patients that are operated with laparoscopic approach
3236099|NCT00942461|Active Comparator|Open surgery Group|Group of patients operated with open approach
3236100|NCT00942448|Experimental|Diclofenac HPBCD s.c. 25mg/ml|
3236101|NCT00942448|Experimental|Diclofenac HPBCD s.c. 50mg/ml|
3236102|NCT00942448|Active Comparator|Diclofenac HPBCD s.c. 75mg/ml|
3236103|NCT00942448|Placebo Comparator|Placebo s.c. (1ml)|
3236104|NCT00942435|Experimental|YM150 group|
3236105|NCT00942435|Active Comparator|mechanical prophylaxis group|
3236106|NCT00942422|Experimental|defined green tea catechin extract / correlative analysis|Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3236107|NCT00942409|Experimental|Ad-ISF35|Ad-ISF35, intranodal injection, 3.3 x 10^10 ISF35 viral particles, every 2-4 weeks up to six total injections.
3236108|NCT00942396|Experimental|mammography|Women must be at least 40 years of age, presenting for routine breast cancer screening or presenting with one or both breasts scored 4 or 5 on the BI-RADS scale as a result of SFM either for routine breast cancer screening or for follow-up or diagnostic mammography
3236109|NCT00942383|Experimental|IOUS-USEI|Receive additional intraoperative ultrasound using the Siemens Anteras to acquire ultrasound elasticity imaging plus standard of care intraoperative ultrasound
3236110|NCT00942370||accelerometric device|
3236111|NCT00942357|Experimental|Arm I (cisplatin, radiation therapy, paclitaxel, carboplatin)|Patients receive cisplatin IV on days 1 and 29. Patients also undergo radiation therapy QD, 5 days a week, for 5-6 weeks. Some patients may then undergo brachytherapy over 2-3 weeks. Beginning within 8 weeks after completion of chemoradiotherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3236112|NCT00942357|Active Comparator|Arm II (paclitaxel and carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3236113|NCT00942331|Active Comparator|Arm I (gemcitabine hydrochloride, cisplatin, placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV and placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive placebo IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
3236153|NCT00942071|Experimental|2. MVA-NP+M1 IM|16 volunteers to receive MVA-NP+M1 via IM route
3236114|NCT00942331|Experimental|Arm II (gemcitabine hydrochloride, cisplatin, bevacizumab)|Patients receive gemcitabine hydrochloride and cisplatin as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
3236115|NCT00942318|Experimental|PPE|PPE : CSII +/- Metformin.
3236116|NCT00942318|Active Comparator|injections|INJ: basal/bolus MDI +/- Metformin
3236117|NCT00942305|Placebo Comparator|Placebo|
3236118|NCT00942305|Experimental|CMX001|
3236119|NCT00942292|Active Comparator|Lipidem (fish oil)|Lipidem (TPN containing fish oil)
3236120|NCT00942292|Active Comparator|Lipofundin (TPN)|Control arm (no fish oil)
3236121|NCT00942266|Experimental|Arm I|Patients receive low-dose oral vorinostat once daily on days 1-3, leucovorin calcium IV over 2 hours on day 2, and fluorouracil IV over 46 hours on days 2 and 3. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
3236122|NCT00942266|Experimental|Arm II|Patients receive high-dose oral vorinostat once daily on days 1-3 and leucovorin calcium and fluorouracil as in arm I. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
3236123|NCT00942253|Experimental|Dopamine Agonist Group|"Dialysis patients will receive dopamine agonist for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist and aerobic intradialytic exercise.~Patients will be given evening doses of dopamine agonists, 2 hours before bedtime. The dopamine agonists' dose will be 0.25 mg/dose and remain constant until the end of the study."
3236124|NCT00942253|Placebo Comparator|Placebo Group|"Dialysis patients will receive placebo for 24 weeks following a 24 weeks period of combined treatment with placebo and aerobic intradialytic exercise.~Patients will be given evening doses of placebo, 2 hours before bedtime."
3236125|NCT00942240|Experimental|ACU-4429 tablet|
3236126|NCT00942240|Placebo Comparator|matching placebo tablet|
3236127|NCT00942227|Active Comparator|Extension oriented treatment approach|Extension exercises. Subjects are instructed in a progression of extension oriented movements for the lumbar spine. Manual therapy may be added to further increase extension movement and/or reduction of symptoms.
3236128|NCT00942227|Experimental|Mechanical traction plus extension-oriented treatment|Mechanical lumbar traction will be utilized in addition to extension oriented exercises. Subjects are also instructed in a progression of extension oriented movements for the lumbar spine. Manual therapy may be added to increase extension movement and/or reduce radicular symptoms.
3236129|NCT00942201|Active Comparator|Single dose dexamethasone|Single dose dexamethasone 0.6 mg/kg, rounded to nearest 2 mg, max 16 mg administered in ED
3236130|NCT00942201|Active Comparator|Two dose dexamethasone|First dose in ED, a prescription for second dose to be administered on Day 3 after discharge
3236131|NCT00942188|Experimental|0.6 milligrams (mg) LY2189102|
3236132|NCT00942188|Experimental|18 mg LY2189102|
3236133|NCT00942188|Experimental|180 mg LY2189102|
3236134|NCT00942188|Placebo Comparator|Placebo|0.9% Sodium Chloride
3236135|NCT00942175|Other|Regimen A|Clopidogrel 75 mg QD
3236136|NCT00942175|Other|Regimen B|Clopidogrel 75 mg QD and Lansoprazole 30 mg QD
3236137|NCT00942175|Other|Regimen C|Clopidogrel 75 mg QD and Dexlansoprazole 60 mg QD
3236138|NCT00942175|Other|Regimen D|Clopidogrel 75 mg QD and Omeprazole 80 mg QD
3236139|NCT00942175|Other|Regimen E|Clopidogrel 75 mg QD and Esomeprazole 40 mg QD
3236140|NCT00942162|Experimental|Single Group|Patients will receive a treatment consisting of 24 injections of the GSK2132231A immunotherapeutic
3236141|NCT00942149|Experimental|Daptomycin cohort|
3236142|NCT00942136|Experimental|Cohort 1, Sequence 1|Subjects in Cohort 1, Sequence 1 will receive a single dose of GSK134972 50 mg after a fast of 10 hours in Period 1. Following a 7 day washout, they will receive a single dose of GSK134972 50 mg after a high fat meal in Period 2. After the last PK sample is collected in Period 2, they will receive a single daily dose of omeprazole 40 mg for 5 days. On Day 5 they will receive a single dose of GSK134972 50 mg 2 hours after the omeprazole dose. Subjects will have a screening visit 30 days prior to the first dose and a follow-up visit 7-14 days after the last dose of medication.
3236143|NCT00942136|Experimental|Cohort 2|Subjects will receive a single dose of either GSK1349572 250 mg or placebo as a suspension. Subjects will have a screening visit within 30 days prior to the dose of study medication and a follow up visit 7-14 days after the dose of study medication.
3236144|NCT00942136|Experimental|Cohort 1, Sequence 2|Subjects in Cohort 1, Sequence 2 will receive a single dose of GSK134972 50 mg after a a high fat meal in Period 1. Following a 7 day washout, they will receive a single dose of GSK134972 50 mg after fast of 10 hours in Period 2. After the last PK sample is collected in Period 2, they will receive a single daily dose of omeprazole 40 mg for 5 days. On Day 5 they will receive a single dose of GSK134972 50 mg 2 hours after the omeprazole dose. Subjects will have a screening visit 30 days prior to the first dose and a follow-up visit 7-14 days after the last dose of medication.
3236145|NCT00942110|Experimental|CPAP|
3236146|NCT00942097|Placebo Comparator|Nutritional plus Placebo (homeopathy)|Nutritional oriented diet for pregnancy period add homeopathic preparation from inert substance.
3236147|NCT00942097|Active Comparator|Nutr and Homeop Sulph Puls Lyc Lackt Con Sep Nuxv Calcc Phos|Nutrition oriented diet for pregnancy period add active homeopathic medication (Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos)
3236148|NCT00942084|Active Comparator|Protocol V2&up-Grp1-Acyclo10 mg/kg IVq12|Gestational Age 23-29 weeks Postnatal Age < 14 days Dosage 10 mg/kg IV q12 Number of Infants 8
3236149|NCT00942084|Active Comparator|Protocol V2&up-Grp2_Acyclo20 mg/kg IVq12|Gestational Age 23-29 weeks Postnatal Age 14-44 days Dosage 20 mg/kg IV q12 Number of Infants 8
3236150|NCT00942084|Active Comparator|Protocol V2&up-Grp3-Acyclo20 mg/kg IVq8|Gestational Age 30-34 weeks Postnatal Age <45 days Dosage 20 mg/kg IV q8 Number of Infants 4
3236151|NCT00942084|Other|Protocol V1-Grps1-4-Acyclo 500 mg/m2 IVq8h|All patients in protocol V1 were to be dosed with 500 mg/m2 IV q8h. Protocol V1 Group 1: Gestational Age: 23-29 Weeks; PNA: <14 days; Protocol V1 Group 2: Gestational Age: 30-42 Weeks; PNA: <14 days; Protocol V1 Group 3: Gestational Age: 23-29 Weeks; PNA: 14-60 days; Protocol V1 Group 4: Gestational Age: 30-42 Weeks; PNA: 14-60 days
3236152|NCT00942071|Experimental|1. MVA-NP+M1 ID|12 volunteers to receive MVA-NP+M1 via ID route
3236154|NCT00942071|Experimental|3. MVA-NP+M1 IM upper age group|30 volunteers to receive MVA-NP+M1 via IM route
3236155|NCT00942058||CA9 level|Serum and urinary CA9 level
3236156|NCT00942019||obese smokers|BMI > 30 kg/m2 CO ≥ 15 ppm
3236157|NCT00942019||non-obese smokers|BMI < 25 kg/m2 CO ≥ 15 ppm
3236158|NCT00942019||obese non-smokers|BMI > 30 kg/m2 CO ≤ 6 ppm
3236159|NCT00942019||non-obese non-smokers|BMI < 25 kg/m2 CO ≤ 6 ppm
3236160|NCT00942006|Active Comparator|LNB-doxycycline|
3236161|NCT00942006|Active Comparator|LNB-ceftriaxone|
3236162|NCT00941993|Experimental|local anesthesia|tympanic membrane local anesthesia delivery system
3236163|NCT00941967|Experimental|Arm I|Patients receive oral sorafenib tosylate as in arm I. Patients also receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV over 2 hours on day 2. Treatment with gemcitabine hydrochloride and oxaliplatin repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3236164|NCT00941967|Experimental|Arm II|Patients receive oral sorafenib tosylate twice daily on days 1-14.
3236165|NCT00941954|Experimental|Lifestyle counseling|A group−based structured educational programme.
3236166|NCT00941954|Active Comparator|Control|Written Information (booklet).
3236167|NCT00941941|Experimental|Non-mesh Hernia Repair|Reinforcement with a strip of external oblique aponeurosis
3236168|NCT00941941|Active Comparator|Mesh Hernia Repair|Polypropylene mesh placement
3236169|NCT00941928|Experimental|Haploidentical NK cells + Epratuzumab|Haploidentical donor-derived NK cell infusion, Epratuzumab 360 mg/m^2 once a day by vein (IV) on Day -4, Day -1 and Days 3, 6, 10, 13 and 17, and low-dose interleukin-2 (IL-2) Subcutaneous injections three times a week for 9 doses on Days 0 to 21; Fludarabine 25 mg/m^2 once a day IV on Day -6 through Day -2 over 30 minutes; Cyclophosphamide 60 mg/kg once a day IV on Days -5 and -4 over 2 hours. Mesna 12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
3236170|NCT00941915|Experimental|Stereotactic Radiotherapy|Five fractions of 7.4 Gy each
3236171|NCT00941902||Patients scheduled to bariatric surgery|
3236172|NCT00941889|Placebo Comparator|Placebo|Patients who are in the control group received a placebo of saline in the upper extremity at initial visit, 2 months and 6 months after enrollment.
3236173|NCT00941889|Active Comparator|Gardasil|The treatment group received a 0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity at initial visit, and again at two months and six months after enrollment.
3236174|NCT00941876|Experimental|A. Facilitated Referral|Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
3236175|NCT00941863|Experimental|Sorafenib 100 mg (50-mg tablet)|Dose-escalation cohort 1: Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
3236176|NCT00941863|Experimental|Sorafenib 200 mg (50-mg tablet)|Dose-escalation cohort 2: Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
3236177|NCT00941863|Experimental|Sorafenib 400 mg (50-mg tablet)|Dose-escalation cohort 3: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
3236178|NCT00941863|Experimental|Sorafenib 400 mg (200-mg tablet)|Dose-escalation cohort 4: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet). Treatment were planned until primary completion date (PCD).
3236179|NCT00941863|Experimental|Sorafenib 400 mg (Expansion)|Dose-expansion cohort: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion. Treatment were planned until primary completion date (PCD). 25 of 119 participants from the Expansion Phase, were still on the treatment as of 31 May 2005. Of these, 6 subjects were continuing to receive sorafenib in combination with carboplatin and/or paclitaxel and 19 subjects were receiving single-agent sorafenib until 18 Sep 2008.
3236180|NCT00941850|Experimental|Triple site CRT|These patients will continue to receive CRT via existing device but will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced
3236181|NCT00941850|No Intervention|Optimised medical and device therapy|These patients will receive optimised medical and device therapy.
3236182|NCT00941837|Experimental|Olive Oil|
3236183|NCT00941837|Experimental|Coconut oil|
3236184|NCT00941837|Experimental|Palm Olein|
3236185|NCT00941798|Experimental|QMF149 Twisthaler® 500/400|QMF149 Twisthaler® (indacaterol maleate 500 µg/mometasone furoate 400 µg), once daily (QD)
3236186|NCT00941798|Active Comparator|Mometasone Twisthaler®|Mometasone Twisthaler®, 400 µg QD
3236187|NCT00941785|Experimental|DHA-PQ|Three monthly administrations of dihydroartemisinin (DHA) plus piperaquine (PQ) in August, September and October.
3236188|NCT00941785|Active Comparator|SP-AQ|Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine
3236189|NCT00941759||Known or suspected Stage IV disease & an intact primary|Pt will be asked to undergo a research core needle biopsy of the primary tumor. If pts are not agreeable to a research biopsy then the original diagnostic biopsy material will be requested. They will also undergo a diagnostic biopsy of a metastatic site, if not already performed, and a blood draw as appropriate for correlative science studies. Additionally, patients will complete a general medical questions form at the time of enrollment.
3236190|NCT00941759||Unsuspected metastatic disease W/I 3 months of primary b|A blood sample will be collected and patients will complete a general medical questions form at the time of enrollment. Paraffin tissue from the prior surgical procedure will be obtained as Tissue sample. Paraffin tissue from the diagnostic biopsy of a metastatic site will also be obtained. In the event that fresh frozen tissue is available for either site this will also be requested.
3236191|NCT00941746|Experimental|Lowest dose of PG110|single, slow intravenous infusion
3236192|NCT00941746|Experimental|Second dose of PG110|single, slow intravenous infusion
3236193|NCT00941746|Experimental|Third dose of PG110|single, slow intravenous infusion
3236194|NCT00941746|Experimental|Fourth dose of PG110|single, slow intravenous infusion
3236195|NCT00941746|Experimental|Fifth dose of PG110|single, slow intravenous infusion
3236196|NCT00941746|Experimental|Top dose of PG110|single, slow intravenous infusion
3236197|NCT00941746|Experimental|Placebo|single, slow intravenous infusion that matches PG110 in appearance
3236198|NCT00941746|Experimental|Seventh Dose of PG110|single, slow intravenous infusion
3236199|NCT00941746|Experimental|Eight Dose of PG110|single, slow intravenous infusion
3236200|NCT00941733|Experimental|Drug Eluting Balloon|Intervention: IN.PACT Amphirion™
3236201|NCT00941733|Active Comparator|Standard PTA|Intervention: Standard PTA
3236202|NCT00941720|Experimental|Busulfan Treatment|
3236203|NCT00941707|Experimental|JNJ-38518168|
3236204|NCT00941707|Placebo Comparator|Placebo|
3236205|NCT00941694|Experimental|Self-Management Intervention|Will receive 6 asthma self-management group or individual session over a 7 week period
3236206|NCT00941694|Placebo Comparator|Control|Group will receive 3 phone calls not related to asthma self management over a 7 week period
3236207|NCT00941681|Experimental|Cohort 1: MR 50 mg BID|Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.
3236208|NCT00941681|Experimental|Cohort 2: IR 37.5 mg TID|Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.
3236209|NCT00941681|Experimental|Cohort 3: MR 100 mg BID|Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days
3236210|NCT00941668|Active Comparator|Total Toothpaste|Triclosan/Copolymer/fluoride toothpaste
3236211|NCT00941668|Placebo Comparator|Fluoride toothpaste|sodium monofluorophosphate toothpaste
3236212|NCT00941655|Experimental|Surgery + HIPEC + Systemic Chemotherapy|"Surgery -gastric resection, metastasectomy, and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m^2 intravenous (IV) over 5 minutes. Leucovorin 20 mg/m^2 IV and Oxaliplatin 460 mg/m^2 diluted in 2.0 L/m^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Irinotecan 165 mg/m^2 IV over 90 minutes, Oxaliplatin 85 mg/m^2 over 120 minutes, Leucovorin 200 mg/m^2 IV 120 minutes, 5FU 3200 mg/m^2 continuous IV infusion over 48 hours."
3236213|NCT00941655|Experimental|Systemic Chemotherapy Alone|Irinotecan 165 mg/m^2 IV over 90 minutes, Oxaliplatin 85 mg/m^2 over 120 minutes, Leucovorin 200 mg/m^2 IV 120 minutes, 5FU 3200 mg/m^2 continuous IV infusion over 48 hours.
3236214|NCT00941642|Active Comparator|Lovaza|Single blind, active treatment arm Lovaza, is the only fish oil supplement approved by the FDA. The Lovaza treatment group will take 4g of Lovaza daily for a minimum of 48 weeks.
3236215|NCT00941642|Placebo Comparator|Placebo|Single blind, Placebo arm study drug will contain 994.0 mg of corn oil and 6mg of alpha tocopherol as an excipient in a soft gelatin capsule shell. Subjects will take 4g daily for a minimum of 48 weeks.
3236216|NCT00941629|Active Comparator|Cognitive Processing Therapy FTF|Cognitive Processing Therapy delivered in traditional face-to-face sessions (FTF)
3236217|NCT00941629|Experimental|Cognitive Processing Therapy TMH|Cognitive Processing Therapy delivered over videoconferencing equipment to a distant location (or telemental health; TMH)
3236218|NCT00941616|Experimental|PK|Includes subjects participating in the pharmacokinetic component of the study.
3236219|NCT00941616|Experimental|Prophylaxis|Includes subjects receiving 12 months of prophylactic therapy.
3236220|NCT00941616|Experimental|On-demand|Includes subjects receiving 12 months of on-demand treatment.
3236221|NCT00941616|Experimental|Cross-over to prophylaxis|"Includes subjects completing 12 months of on-demand treatment (the On-demand arm) who cross-over to prophylactic therapy for an additional 12-month period."
3236222|NCT00941603|Experimental|SCH 900271 15 mg|Participants receive SCH 900271 15 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
3236223|NCT00941603|Experimental|SCH 900271 10 mg|Participants receive SCH 900271 10 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
3236224|NCT00941603|Experimental|SCH 900271 5 mg|Participants receive SCH 900271 5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
3236225|NCT00941603|Experimental|SCH 900271 2.5 mg|Participants receive SCH 900271 2.5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
3236226|NCT00941603|Experimental|SCH 900271 1 mg|Participants receive SCH 900271 1 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
3236227|NCT00941603|Placebo Comparator|Placebo|Participants receive two placebo tablets once daily in the morning with water in a fasted state for 8 weeks
3236228|NCT00941590||Patients with tick borne encephalitis.|
3236229|NCT00941577|Experimental|AIR645|AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor) solution (diluent: physiologic saline solution)
3236230|NCT00941577|Placebo Comparator|Physiologic saline solution|Physiologic saline solution
3236231|NCT00941564|Experimental|Commercially available infant formula A|Varying fat blend from comparator product
3236232|NCT00941564|Active Comparator|Commercially available infant formula B|
3236233|NCT00941551||Group A|receiving levothyroxine postoperatively
3236234|NCT00941551||Group B|not-receiving levothyroxine postoperatively
3236235|NCT00941538||Screening, Control|
3236236|NCT00941525|Other|Ocular hypertensives|"This study includes two groups.~Subjects with ocular hypertension and~Controls. Group 2 undergoes only 1 visit (visit 1) without any intervention. Group 1 undergoes visit 1 without intervention. Then they receive treatment (1 eyedrop of latanoprost (0.005%) dosed once a day in both eyes at 8:00pm for a 4-weeks period for 1 month) and undergo the visit 2 under the effect of treatment."
3236237|NCT00941499|Experimental|Group 1|HAI oxaliplatin in combination with HAI 5-fluorouracil and IV bevacizumab
3236238|NCT00941499|Experimental|Group 2|HAI oxaliplatin in combination with IV 5-fluorouracil, leucovorin, bevacizumab, and cetuximab
3236239|NCT00941499|Experimental|Group 3|HAI oxaliplatin in combination with IV bevacizumab.
3236240|NCT00941499|Experimental|Group 4|HAI oxaliplatin in combination with IV bevacizumab and cetuximab.
3236241|NCT00941486|Experimental|FST-100 (0.1% dexamethasone) Ophthalmic Suspension|
3236242|NCT00941486|Placebo Comparator|Vehicle|
3236243|NCT00941473|Active Comparator|Epidural Steriod Injection|This study focuses on the changes in bone mineral density over time of the cohort previously described in the inclusion criteria (post-menopausal white women)
3236244|NCT00941460|Experimental|one week on one week off|One week on temozolomide is followed by a week without temozolomide.
3236245|NCT00941460|Experimental|three weeks on, one week off|Temozolomide is given over 3 weeks, followed by a week without temozolomide.
3236246|NCT00941447|Experimental|Self-Regulation|Self Regulation Arm focuses on increasing participants self-monitoring blood glucose (SMBG) AND awareness of self-regulatory approaches to managing diabetes.
3236247|NCT00941447|Experimental|Self-Monitoring|Self-Monitoring Arm focuses on increasing participants self-monitoring blood glucose (SMBG) and providing nutrition education ONLY.
3236248|NCT00941434|Experimental|RUTF|Children with Severe malnutrition will be treated with Ready to use therapeutic food (RUTF) till their weight for age z scores are no longer in severe malnutrition group
3236249|NCT00941421|Other|videocapsul and OGDFE|Each patient have a Fiberoptic endoscopy by videocapsul, followed by one traditional oeso-gastro-duodenal fiberoptic endoscopy
3236250|NCT00941408||Diagnostic tumor core biopsy|
3236251|NCT00941395|Experimental|Smokers|Smoking Cessation Intervention
3236252|NCT00941395|Experimental|Non-Smokers|Smoking Prevention Intervention
3236253|NCT00941382|Experimental|Sibutramin-Metformin|Sibutramine-metformin therapy in a single tablet
3236254|NCT00941382|Active Comparator|Sibutramine|Sibutramine monotherapy
3236255|NCT00941382|Active Comparator|Metformin|Metformin monotherapy
3236256|NCT00941369|Experimental|1|Insulin glargine: Lantus® (100 U/ml) in TactiPen® re-usable pen
3236257|NCT00941369|Active Comparator|2|Neutral Protamine Hagedorn basal insulin: Insuman® Basal (100 I.U./ml) in TactiPen® re-usable pen
3236258|NCT00941356|Experimental|1|Bio-K+ CL1285 contains 50 billion of live bacteria
3236259|NCT00941356|Placebo Comparator|2|placebo devoid of bacteria
3236260|NCT00941343|Experimental|1|XATRAL 10mg OD
3236261|NCT00941330|Experimental|A: Exemestane|ARM A: Patients will be treated with exemestane.
3236262|NCT00941330|Active Comparator|B: Docetaxel and Cytoxan|ARM B: Patients will be treated with docetaxel and cytoxan.
3236263|NCT00941304|Active Comparator|Standard Opioid|Oxycodone 5-mg oral capsule and 2 buccal placebo films
3236264|NCT00941304|Experimental|High Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.5-mg modified formulation 1, buccal placebo film, and oral placebo capsule
3236265|NCT00941304|Experimental|Mid Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.5-mg modified formulation 2, buccal placebo film, and oral placebo capsule
3236266|NCT00941304|Experimental|Low Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.25-mg modified formulation 2, buccal placebo film, and oral placebo capsule
3236267|NCT00941304|Placebo Comparator|Placebo|Oral placebo capsule and 2 buccal placebo films
3236268|NCT00941291||vitrectomy in pseudophakic eyes|
3236269|NCT00941291||vitrectomy and cataract:combined procedure|
3236270|NCT00941291||vitrectomy followed by cataract extraction|
3236271|NCT00941291||vitrectomy on phakic eyes|
3236272|NCT00941278|Experimental|PH-10 Treatment|
3236273|NCT00941265|Other|levodopa 100 mg and benserazide 25 mg|2 weeks with Daily CAT on list A+ levodopa and benserazide
3236274|NCT00941265|Other|placebo|2 weeks with Daily CAT on list B + placebo.
3236275|NCT00941252|Active Comparator|Imiquimod|topical therapy for 16 weeks with imiquimod containing therapy
3236276|NCT00941252|Placebo Comparator|Placebo|topical therapy for 16 weeks with a placebo containing vaginal suppository
3236277|NCT00941239|Experimental|metformin ER|Extended Release Metformin
3236278|NCT00941239|Active Comparator|metformin|Immediate release metformin
3236279|NCT00941226||Cerebral Palsy|Those kids who have cerebral palsy and are helped by carers
3236280|NCT00941213|Active Comparator|Monopolar Electrosurgery|Preparation during the operation with Monopolar Electrosurgery
3236281|NCT00941213|Experimental|Ultrasound scissors|Preparation during the operation with ultrasound scissors
3236282|NCT00941200||Blood collection|
3236283|NCT00941187||patients after a first episode of pulmonary embolism|
3236284|NCT00941174|Active Comparator|Capsule: 400 microg 13C5-Calcium-L-Leucovorin|
3236285|NCT00941174|Active Comparator|IV Injection: : 100 microg 13C5-Calcium-L-Leucovorin|
3236286|NCT00941161|Experimental|combination|long acting Metformin/Glimepiride
3236287|NCT00941161|Active Comparator|metformin|metformin hydrocloride
3236288|NCT00941161|Active Comparator|glimepiride|glimepiride
3236289|NCT00941148|Active Comparator|Insulin glargine|Insulin glargine, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
3236290|NCT00941148|Active Comparator|NPH Insulin|NPH Insulin, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
3236291|NCT00941148|Active Comparator|Insulin detemir|Insulin detemir, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
3236292|NCT00941122||MRSA/VRE patients|patients known to be colonized with MRSA/VRE
3236293|NCT00941109|Experimental|1|
3236294|NCT00941109|Experimental|2|
3236295|NCT00941109|Experimental|3|
3236296|NCT00941109|Experimental|4|
3236297|NCT00941083|Experimental|RAL QD 800 mg/24 hs|
3236298|NCT00941083|Active Comparator|RAL BID 400 mg/12 hs|
3236299|NCT00941083|Experimental|RAL BID to QD|
3236300|NCT00941070|Experimental|Treatment (cisplatin, triapine, radiation therapy)|"Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, and 30 and triapine IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Patients also undergo pelvic external beam radiotherapy 5 days a week during weeks 1-5. Patients may undergo parametrial boost radiation and intracavitary low-dose or high-dose rate brachytherapy as clinically indicated.~Patients undergo whole-body F-18 fluorodeoxyglucose-PET/CT imaging at baseline, at 3 months after completion of study treatment, and at disease progression. Patients complete Sexual Function-Vaginal Changes Questionnaire and a smoking behavior questionnaire at baseline, at 3 months after completion of study treatment, and at disease progression."
3236301|NCT00941057|Experimental|Estradiol + dienogest + levomefolate|Treatment A
3236302|NCT00941057|Active Comparator|Estradiol + dienogest|Treatment B
3236303|NCT00941057|Active Comparator|Levomefolate|Treatment C
3236304|NCT00941044|Experimental|non-invasive NAVA|application of non-invasive neurally adjusted ventilatory assist in healthy volunteers
3236305|NCT00941031|Experimental|Induction Single Dose|"Induction with single injection - Single: secukinumab (AIN457) 150 mg s.c. administered at Week 1, Baseline through Week 12"
3236306|NCT00941031|Experimental|Induction Monthly Dose|"Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9, Baseline through Week 12"
3236307|NCT00941031|Experimental|Induction Early Loading Dose|"Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5, Baseline through Week 12"
3236308|NCT00941031|Placebo Comparator|Placebo Dose|Placebo administered at weeks 1, 2, 3, 5, 9, Baseline through Week 12
3236309|NCT00941018|Experimental|SAD cohort 1|Single ascending dose (SAD) cohort 1 will participate in three dosing periods separated by 2 weeks. Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control. The starting dose will be 300 mg. Subsequent doses will be determined by the pk and safety data from previous cohorts.
3236310|NCT00941018|Experimental|SAD cohort 2|SAD cohort 2 will participate in three dosing periods separated by 2 weeks. Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control. The doses to be administered will be determined by the pk and safety data from previous cohorts.
3236311|NCT00941018|Experimental|MAD cohort 1|Multiple ascending dose (MAD) cohort 1 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous SAD cohorts.
3236312|NCT00941018|Experimental|MAD cohort 2|MAD cohort 2 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.
3236313|NCT00941018|Experimental|MAD cohort 3|MAD cohort 3 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohorts.
3236314|NCT00941018|Experimental|MAD cohort 4|MAD cohort 4 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.
3236315|NCT00941005|Experimental|Electroacustimulation|Received electroacustimulation at the wrist using a small, battery-powered electroacustimulation device.
3236316|NCT00941005|Sham Comparator|Control|Received a device that was not turned on.
3236317|NCT00940992|Experimental|DER 45 EV Gel, 1%|DER 45 EV Gel, 1% topically applied once daily to face for 12 weeks
3236318|NCT00940992|Placebo Comparator|Vehicle|Placebo Gel applied topically once a day for 12 weeks
3236319|NCT00940992|Experimental|DER 45 EV Gel, 5%|DER 45 EV Gel, 5% applied topically once a day for 12 weeks
3236320|NCT00940979|No Intervention|No use of integuseal|
3236321|NCT00940979|Experimental|Use of Integuseal|Application of a layer of Integuseal (Cyanoacrylate) from a ready to use applicator preoperative before incision Polymerisation immobilise the bacteria that survived the conventional skin preparation This way there will be les contamination of the wound.
3236322|NCT00940966|Experimental|energy restricted very-low carbohydrate|non-energy restricted ketogenic diet .
3236323|NCT00940966|Active Comparator|ADA diet|standard ADA diet
3236324|NCT00940966|Active Comparator|low glycemic index|restricted ketogenic diet
3236325|NCT00940953|Experimental|Captisol-Enabled Budesonide + Azelastine|
3236326|NCT00940953|Active Comparator|Rhinocort Aqua+Astelin|
3236327|NCT00940953|Placebo Comparator|Placebo|
3236328|NCT00940940|Experimental|Live attenuated herpes zoster vaccine|
3236329|NCT00940940|Placebo Comparator|Placebo|
3236330|NCT00940914|Other|pain disorders|patients with Parkinson's disease presenting pain disorders
3236331|NCT00940914|Other|without pain disorders|patients with Parkinson's disease without pain disorders
3236332|NCT00940901|Experimental|sildenafil|Participants assigned to this arm were given sildenafil 50 mg tablet daily for 16 weeks.
3236333|NCT00940901|Placebo Comparator|placebo|Participants assigned to this arm were given a placebo pill for the first 8 weeks, and then Sildenafil 50 mg for weeks 9-16.
3236334|NCT00940888||No treatment: ICD/CRTD-indicated|
3236335|NCT00940875|Experimental|1|
3236336|NCT00940875|Active Comparator|2|
3236337|NCT00940862|Experimental|adalimumab|A total of 20 patients will be randomized to adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
3236338|NCT00940862|Active Comparator|Non-systemic treatment.|A total of 10 patients will be randomized to non systemic therapy for psoriasis (topical treatments and/or UVB phototherapy).
3236339|NCT00940849|Experimental|Dietary Supplement: Plant sterol containing drink|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
3236340|NCT00940836|Active Comparator|Resfenol|"Patients in this arm will receive 15 capsules containing a combination described below. They are instructed to take one capsule at 7, 11, 15, 19 and 23h every day, starting after baseline evaluation. The duration of the treatment goes from 48 to 72 hours, depending on patient availability for the second evaluation.~Patients also receive co interventional acetaminophen pills, that they are allowed to take in case of persisting pain or fever, up to 4 times a day."
3236341|NCT00940836|Placebo Comparator|Placebo|"Patients in this arm will receive 15 capsules of placebo, that they are instructed to take in the same posology and in the same duration than the active comparator.~Patients also receive co interventional acetaminophen pills, that they are allowed to take in case of persisting pain or fever, up to 4 times a day."
3236342|NCT00940823|Active Comparator|Ahmed FP7 Valve|Ahmed valve glaucoma drainage device implant for treatment of refractory glaucoma.
3236343|NCT00940823|Active Comparator|Baerveldt-350 Tube|Baerveldt tube glaucoma drainage device implant for treatment of refractory glaucoma.
3236344|NCT00940810|Experimental|PDD procedure|
3236345|NCT00940810|Active Comparator|Conservative Care|
3236346|NCT00940797|Experimental|DMMET-01|
3236347|NCT00940797|Placebo Comparator|Control|
3236348|NCT00940784|Experimental|Clopidogrel|Subjects will be randomized to clopidogrel (oral-75 mg per day) in addition to low dose aspirin and hydroxyurea
3236349|NCT00940784|Placebo Comparator|Placebo|Subjects will be randomized placebo in addition to low dose aspirin and hydroxyurea
3236350|NCT00940771|Experimental|boosted atazanavir|
3236351|NCT00940758|Experimental|PEP02|
3236449|NCT00940173|Other|Group 1|Dose Group 1 (Receiving a dose of 10,000 IEQ/kg of DIABECELL(R))
3236352|NCT00940745|Experimental|Stereotactic Aspiration and Thrombolysis|To position haematoma's location, drills several millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
3236353|NCT00940745|Active Comparator|conservative treatment|dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
3236354|NCT00940732|Experimental|Destigmatisation and Mental Health Literacy|
3236355|NCT00940732|Experimental|Help-seeking list|
3236356|NCT00940732|Experimental|Feedback|
3236357|NCT00940732|No Intervention|Control|
3236358|NCT00940719|Experimental|Vitamin D3|Patients receive 1dd 500ug vitamin D3 for 3 months
3236359|NCT00940706|Experimental|Physical activity in groups|Exercises of physical activity
3236360|NCT00940706|Experimental|Activity monitoring with accelerometers|Each subject will wear the accelerometer 24 hours a day for 4 days The activity will be recorded and analyzed
3236361|NCT00940706|Active Comparator|Treadmill|Treadmill with safety adaptations for handicapped persons
3236362|NCT00940693|Active Comparator|duloxetine|
3236363|NCT00940693|Placebo Comparator|placebo|
3236364|NCT00940680|Experimental|amlodipine/losartan 5/100mg|
3236365|NCT00940680|Active Comparator|losartan 100mg|
3236366|NCT00940667|Experimental|amlodipine/losartan 5/50mg|
3236367|NCT00940667|Active Comparator|amlodipine 5mg|
3236368|NCT00940654||Patients with fever|
3236369|NCT00940654||Patients without any fever|
3236370|NCT00940641|Experimental|1|IV dose of AZD7325
3236371|NCT00940641|Experimental|2|14C oral dose of AZD7325
3236372|NCT00940628|Experimental|1|
3236373|NCT00940628|Other|2|
3236374|NCT00940615|Experimental|1|participants in the aerobic exercise intervention
3236375|NCT00940615|Active Comparator|2|participants in the stretching/toning control condition
3236376|NCT00940602|Experimental|Deferasirox, iron chelator|At least 210 male or female patients, ≥ 18 years of age with low/int-1 MDS, as determined by IPSS score, who have serum ferritin >1000 mcg/L at screening. will be assigned to one of the two arms in a ratio of 2:1, deferasirox or matching placebo.
3236377|NCT00940602|Placebo Comparator|Placebo|Matching placebo will be administered orally
3236378|NCT00940589|Experimental|Circadin|Drug
3236379|NCT00940589|Placebo Comparator|Placebo|drug
3236380|NCT00940576|Experimental|mare´s milk|oral intake of of 250 ml mare´s milk
3236381|NCT00940576|Placebo Comparator|placebo drink|oral intake of of 250 ml placebo drink
3236382|NCT00940563|Experimental|Imatinib|
3236383|NCT00940550|Experimental|Prolonged-release melatonin 2 mg|
3236384|NCT00940550|Active Comparator|Temazepam 20 mg|
3236385|NCT00940550|Active Comparator|Zolpidem 10 mg|
3236386|NCT00940550|Placebo Comparator|Placebo|
3236387|NCT00940537||NAFLD|Non-diabetic, obese with diagnosed NAFLD (HTGC greater or equal to 5.5%)
3236388|NCT00940537||Non-NAFLD|Non-diabetic, obese with no previous diagnosis of NAFLD
3236389|NCT00940524|Experimental|Chemotherapy|A phase I study designed to determine the dose of dasatinib that can be safely administered with cytarabine and high-dose mitoxantrone in Ph+ ALL / lymphoid blast crisis of known chronic myelogenous leukemia patients.
3236390|NCT00940511|Experimental|Coordinated care|Individuals will be passively enrolled in Medicaid managed care. Those who do not opt out of managed care will be provided with care coordination.
3236391|NCT00940511|No Intervention|Usual care|The usual care group will remain in fee-for-service Medicaid and receive services normally available through that system.
3236392|NCT00940498|Experimental|1|PF-05212384 (also known as PKI-587)
3236393|NCT00940485|Experimental|Peginterferon alfa-2a + entecavir|Participants received PEGASYS® (peginterferon alfa-2a)180 micrograms (mcg) subcutaneously once weekly for 48 weeks, plus entecavir 0.5 milligram (mg) orally once daily for 8 weeks.
3236394|NCT00940485|Active Comparator|Entecavir|Participants received entecavir 0.5 mg orally once daily for 48 weeks.
3236395|NCT00940472|Experimental|Experimental Drug|DMMET-01 + Diet
3236396|NCT00940472|Active Comparator|Metformin|Metformin + Diet
3236397|NCT00940459|Experimental|Acuvue Oasys|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
3236398|NCT00940459|Experimental|Biofinity|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
3236399|NCT00940459|Experimental|Air Optix|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
3236400|NCT00940459|Experimental|PureVision|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
3236401|NCT00940459|Active Comparator|Acuvue 2|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
3236402|NCT00940446|Experimental|Insorb staples|Subcuticular Absorbable staples
3236403|NCT00940446|Active Comparator|Control|Metal staple wound closure
3236404|NCT00940433|Active Comparator|open properitoneal|patients undergoing open properitoneal hernia repair
3236405|NCT00940433|Active Comparator|Lechtenstien repair|Patients undergoing Lechtestien hernia repair
3236406|NCT00940433|Active Comparator|Laparoscopic transperitoneal repair|Patients undergoing TAPP repair
3236407|NCT00940433|Active Comparator|Lap totally extraperitoneal approach|Patients undergoing TEP approach
3236408|NCT00940420|Experimental|A|
3236409|NCT00940420|Experimental|B|
3236410|NCT00940394|Other|standard care|Families receive routine community and family mental health care services
3236411|NCT00940394|Experimental|mutual support group|bi-weekly, 12-session, family-led mutual support group
3236412|NCT00940394|Active Comparator|psychoeducation group|bi-weekly, 12-session, family psychoeducation group program
3236450|NCT00940173|Other|Group 2|Dose Group 2 (Receiving a dose of 15,000 IEQ/kg of DIABECELL(R))
3236636|NCT00938730|Experimental|5. YM150, Dose Y twice daily|
3236413|NCT00940381|Experimental|Sirolimus + Cetuximab|Sirolimus beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle. Cetuximab Beginning dose 100 mg/m^2 by vein over two hours on Day 1, and 65 mg/m^2 on Days 8, 15 and 22 for a 28 day cycle.
3236414|NCT00940368|Experimental|Ginger arm|"The patients in this arm will be randomly selected in each cycle of chemotherapy. The unit of randomization is the cycle of chemotherapy. In each cycle of chemotherapy of all patients recruited in the study will be categorized using the computer generated random numbers. The patients in the ginger arm; Group A will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group A:~Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram ginger powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram ginger powder per day"
3236415|NCT00940368|Placebo Comparator|Placebo arm|"Patients (children and adolescents) will be included in this arm after randomization of the cycle of chemotherapy of the patient. Starch powder/Glucose powder is used as placebo.The patients in the placebo arm; Group B will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group B:~Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram placebo powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram placebo powder per day"
3236416|NCT00940355|Experimental|Intervention pulmonary nurse|group III: intervention conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, increasing motivation to engage in additional treatment, and improving health status.
3236417|NCT00940355|No Intervention|Usual care|group II: usual care as delivered by the outpatient clinic.
3236418|NCT00940342|Experimental|Treated and Relapsed - Group 1|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
3236419|NCT00940342|Experimental|Treated and High-Risk for Progression - Group 2|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
3236420|NCT00940342|Experimental|70 Years of Age and Refused Chemo - Group 3|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
3236421|NCT00940329|Active Comparator|Treatment A|
3236422|NCT00940329|Active Comparator|Treatment B|
3236423|NCT00940316|Experimental|Arm A|Patients receive oral erlotinib hydrochloride once daily on days 1-14, panitumumab IV over 30-90 minutes on day 1, and irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
3236424|NCT00940316|Experimental|Arm B|Patients receive oral erlotinib hydrochloride once daily on days 1-14 and panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients receive irinotecan hydrochloride as in arm A.
3236425|NCT00940316|Experimental|Arm C|Patients receive erlotinib hydrochloride and panitumumab as in arm B.
3236426|NCT00940303|Experimental|1|
3236427|NCT00940290|Other|GRADE system|A clinical recommendation built and graded with the GRADE working group system
3236428|NCT00940290|Other|SIGN grading system|A clinical recommendation built and graded with the Scottish Intercollegiate Guidelines Network system
3236429|NCT00940290|Other|NICE grading system|A clinical recommendation built and graded with National Institute of Clinical Excellence grading system
3236430|NCT00940290|Other|CEBM-Oxford|A clinical recommendation built and graded with the Centre for Evidence-Based Medicine grading system
3236431|NCT00940277|Experimental|Enhanced Couples Group|Enhanced Couples Group: consists of eight 90-minute sessions, conducted weekly. ECG has a didactic educational content presented by the group leader or practice of specific relationship communication, relationship support, and couple-focused stress management. ECG participants are also given instruction about what types of behaviors are unsupportive and training in how to not behave in an unsupportive manner.
3236432|NCT00940277|Experimental|Support Group|Support Group: 8 weekly 90-minute group counseling sessions. Using a standard approach to supportive therapy, the group interventionists will focus on encouraging participants to share their experiences with cancer, express their emotions related to the experience, voice problems they have in coping with the cancer, and offer support and advice to other members of the group. The co-facilitators will facilitate expression of affect and the sharing of the group's common issues related to cancer. Each session has a broad topic for discussion. Topics include communication with health care providers, issues related to occupational life, and coping with medical procedures and treatment. No formal or didactic information will be provided.
3236433|NCT00940264||Given indication for cholecystectomy|
3236434|NCT00940251|Placebo Comparator|CORN STARCH|
3236435|NCT00940251|Active Comparator|Mersina, Diet and exercise|
3236436|NCT00940225|Experimental|Arm 1|RDT Open-Label
3236437|NCT00940225|Experimental|Arm 2|RDT Randomized Blinded-XL184
3236438|NCT00940225|Placebo Comparator|Arm 3|RDT Randomized Blinded
3236439|NCT00940225|Experimental|Non-Randomized Expansion (NRE) Cohorts|Drug: XL184
3236440|NCT00940212|Experimental|A|AZD2423
3236441|NCT00940212|Experimental|B|Placebo
3236442|NCT00940199||Standard of Care|I:Application of L-M-X topical anesthetic cream 4% to the breast within one hour of sub-areaolar injection of 4 ml 99mTc-sulfur colloid (1 mCi in normal saline)
3236443|NCT00940199||1 mCi in sodium bicarbonate|II. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in sodium bicarbonate)
3236444|NCT00940199||1 mCi in 1% Lidocaine|III. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in 1% Lidocaine)
3236445|NCT00940199||1 mCi in sodium bicarbonate + 1% Lidocaine|IV. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in sodium bicarbonate + 1% Lidocaine)
3236446|NCT00940186||pikamilone|
3236447|NCT00940186||dosage|low dosage group: administrate pikamilone tablet 50 mg; middle dosage group: administrate pikamilone tablet 100 mg; hige dosage group: administrate pikamilone tablet 200 mg.
3236448|NCT00940186||tablet|
3236508|NCT00939757|Experimental|2. mirabegron, higher dose|
3236451|NCT00940173|Other|Group 3|Dose Group 3 (Receiving a dose of 20,000 IEQ/kg of DIABECELL(R))
3236452|NCT00940173|Other|Group 4|Dose Group 4 (Receiving a dose of 5,000 IEQ/kg of DIABECELL(R))
3236453|NCT00940160|Active Comparator|QAX576 1 mg/kg|
3236454|NCT00940160|Active Comparator|QAX576 3 mg/kg|
3236455|NCT00940160|Active Comparator|QAX576 10 mg/kg|
3236456|NCT00940160|Placebo Comparator|Placebo|
3236457|NCT00940147||1|patients with OAC, Score finding
3236458|NCT00940147||2|patients without OAC, Score finding
3236459|NCT00940134|Placebo Comparator|placebo|Study participants will receive a 3 hour IV infusion of saline while fasting.
3236460|NCT00940134|Experimental|PYY3-36 + GLP-1|Study participants will receive a 3 hour IV infusion of (GLP-1 + PYY3-36) while fasting.
3236461|NCT00940134|Active Comparator|GLP-1|Study participants will receive a 3 hour IV infusion of PYY3-36 while fasting.
3236462|NCT00940134|Active Comparator|PYY3-36|Study participants will receive a 3 hour IV infusion of PYY3-36 while fasting.
3236463|NCT00940121|Experimental|1. mirabegron, low dose|
3236464|NCT00940121|Experimental|2. mirabegron, middle dose|
3236465|NCT00940121|Experimental|3. mirabegron, higher dose|
3236466|NCT00940108|Experimental|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
3236467|NCT00940108|Experimental|CSL425 (30 mcg)|30 mcg of hemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
3236468|NCT00940095|Experimental|Clazosentan 5 mg/h|Continuous intravenous infusion of clazosentan (5 mg/h) started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
3236469|NCT00940095|Experimental|Clazosentan 15 mg/h|Continuous intravenous infusion of clazosentan (15 mg/h) started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
3236470|NCT00940095|Placebo Comparator|Placebo|Continuous intravenous infusion of placebo matching clazosentan started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
3236471|NCT00940082||youth control group|healthy people which ages from 30 to 59
3236472|NCT00940082||youth diabetes group|type 1 and type 2 diabetes patients which ages from 30 to 59
3236473|NCT00940082||the elderly diabetes group|type 1 and type 2 diabetes patients which ages from 60 to 90
3236474|NCT00940082||elderly control group|healthy people which ages from 60 to 90
3236475|NCT00940069|Experimental|TS high expression genotype|TS high expression genotype delivered to pemetrexed 500 mg/m2 and cisplatin 75 mg/m2,for not less than 4 cycle, administered intravenously every 3 weeks.
3236476|NCT00940069|Experimental|TS low expression genotype|TS low expression genotype delivered to pemetrexed 500 mg/m2 and cisplatin 75 mg/m2,for not less than 4 cycle, administered intravenously every 3 weeks.
3236477|NCT00940056|Experimental|Endoscopic ablation of atrial fibrillation|
3236478|NCT00940056|Active Comparator|Rate control|
3236479|NCT00940043||Rupture of fetal membranes|women with rupture of fetal membranes before onset of labor
3236480|NCT00940030|Experimental|MBP+enema|mechanical bowel preparation and enema
3236481|NCT00940030|Active Comparator|enema|
3236482|NCT00940017|Experimental|1|
3236483|NCT00940004|Active Comparator|cytokine matured DC|vaccination with autologous dendritic cells matured with standard cytokine cocktail and electroporated with mRNA encoding tumor associated antigens
3236484|NCT00940004|Experimental|TLR ligand matured DC|vaccination with autologous TLR-ligand matured dendritic cells electroporated with mRNA encoding tumor associated antigens
3236485|NCT00939991|Experimental|1|Phase I- Bevacizumab will be administered intravenously every other week. Temozolomide will be administered on a continuous daily dosing schedule. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen.
3236486|NCT00939978|Active Comparator|Venoferrum|
3236487|NCT00939978|Placebo Comparator|saline|
3236488|NCT00939952|Active Comparator|ertapenem 500 mg IV x1|All patients will receive ertapenem 500 mg IV once.
3236489|NCT00939939|Experimental|sitagliptin|
3236490|NCT00939939|Active Comparator|glimepirid|
3236491|NCT00939913|Placebo Comparator|intravenous N-acetlycysteine|"intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)as compared to placebo~Acetadote provided by Cumberland Pharmaceuticals Inc."
3236492|NCT00939913|Placebo Comparator|Placebo|Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
3236493|NCT00939900|Experimental|aclasta|aclasta group
3236494|NCT00939900|No Intervention|control|control group
3236495|NCT00939887|Experimental|Treatment|
3236496|NCT00939874|Experimental|Raltegravir|
3236497|NCT00939861|Experimental|1|laparoscopy
3236498|NCT00939861|Experimental|2|laparotomy
3236499|NCT00939848|Experimental|B|The experimental arm will consist of cisplatin 25 mg/m2 plus gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle with cediranib 20mg oral daily (continuous dosing).
3236500|NCT00939848|Placebo Comparator|Arm A|The control arm will consist of cisplatin 25 mg/m2 plus gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle with a matching placebo 20mg oral daily (continuous dosing)
3236501|NCT00939822|Experimental|Active|40 mg. Simvastatin/day
3236502|NCT00939822|Placebo Comparator|Placebo|Matching Placebo
3236503|NCT00939809|Experimental|Treatment (urokinase-derived peptide A6)|Patients receive A6 subcutaneously once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3236504|NCT00939796|Experimental|Tympanostomy Tube Delivery System (TTDS)|Tympanostomy tube placement with Acclarent tube delivery system
3236505|NCT00939783|Experimental|Dimebon 20 mg TID|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
3236506|NCT00939770|Experimental|Treatment (Crizotinib)|
3236507|NCT00939757|Experimental|1. mirabegron, lower dose|
3236512|NCT00939718|Active Comparator|Vitamin B12 with antidepressants|Subjects in this arm will receive vitamin B12 supplement (injectable)along with their routine antidepressant treatment as prescribed by their primary physicians. subjects will be blind to their arm allocation and will receive injections in a concealed manner with injection vials covered with foil.
3236513|NCT00939718|Placebo Comparator|Placebo injections dextrose water|Subjects in this arm will receive placebo injections which will contain only dextrose water. They will also receive 6 injections on a weekly basis and the injection vials will be covered with foil to ensure masking.
3236514|NCT00939705|Experimental|Torrent Topiramate|
3236515|NCT00939705|Active Comparator|Topamax|
3236516|NCT00939692|Experimental|Torrent Topiramate|tablet containing 25 mg of topiramate (Torrent Pharmaceuticals)
3236517|NCT00939692|Active Comparator|Topamax|tablet containing 25 mg of topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.)
3236518|NCT00939679|Experimental|Earlier gastric bypass surgery (7 weeks)|These patients will undergo gastric bypass surgery 7 weeks after starting a low calorie diet, and will continue the low calorie diet for 3 weeks following surgery.
3236519|NCT00939679|Active Comparator|Later gastric bypass surgery (10 weeks)|These patients will undergo gastric bypass surgery 10 weeks after starting a low calorie diet.
3236520|NCT00939666|Experimental|Wait&see or TEM with intensive follow-up|All patients will be included in this arm
3236521|NCT00939640|Active Comparator|Dietary intervention|Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
3236522|NCT00939627|Placebo Comparator|Arm I (cetuximab and placebo)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 and oral placebo twice daily on days 1-21.
3236523|NCT00939627|Experimental|Arm II (cetuximab and sorafenib tosylate)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 and oral sorafenib tosylate twice daily on days 1-21.
3236524|NCT00939601|Active Comparator|Motivational Enhancement Therapy|MET will involve counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
3236525|NCT00939601|Active Comparator|Educational Counseling|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
3236526|NCT00939601|No Intervention|Standard Care|
3236527|NCT00939588|Experimental|Aliskiren and Valsartan|
3236528|NCT00939588|Active Comparator|Telmisartan and Ramipril|
3236529|NCT00939575||Preeclampsia|Women hospitalized for pre-eclampsia after 20 0/7 weeks of gestation. The diagnosis of preeclampsia include a combination of the following criteria: after 20 weeks of gestation in a previously normotensive woman, a diastolic blood pressure > 90 mmHg recorded twice at least four hours apart or > 110 mmHg, with proteinuria > 300 mg/24h or > 30 mg / mmol protein / urinary creatinine in a urine sample or factor (s) serious maternal / fetal (according to SOGC consensus ).
3236530|NCT00939575||control|Women will be matched to women with pre-eclampsia according to gestational age at diagnosis of preeclampsia, maternal age (in stratum of 5 years), gender, ethnicity (4 categories: Caucasian, black, Asian and other) and body mass index (5 classes: <20, 20-25, 26-30, 31-35 and <35). Patients of this group should be at low risk of obstetric complications at recruitment and planning to deliver at the CHUS.
3236531|NCT00939562|Experimental|doxycycline monohydrate tablet|
3236532|NCT00939562|Active Comparator|doxycycline carragenate tablet|
3236533|NCT00939549|Experimental|High-dose cyclohosphamide|
3236534|NCT00939536|Experimental|Torrent's Zolpidem Tartrate Tablets 10 mg|Normal Healthy Human Subjects receiving Torrent's Zolpidem Tartrate Tablets 10 mg
3236535|NCT00939536|Active Comparator|Sanofi-Synthelabo's Ambien® 10 mg Tablets|Normal Healthy Human Subjects receiving Sanofi-Synthelabo's Ambien® 10 mg Tablets
3236536|NCT00939523|Experimental|Lapatinib|All participants will be asked to take Lapatinib daily for a total of six months during the research study.
3236537|NCT00939510|Experimental|Lenalidomide (RevlimidTM ) and GM-CSF|
3236538|NCT00939484|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO once daily on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
3236539|NCT00939471|Other|Relieva™ Balloon Sinuplasty™ System|Balloon Dilation of sinus ostium
3236540|NCT00939445|Active Comparator|Online HDF|Online HDF
3236541|NCT00939445|Active Comparator|Short Daily Hemodialysis|Short Daily Hemodialysis
3236542|NCT00939432||Gender|male/female
3236543|NCT00939432||Age|18-100 years
3236544|NCT00939432||Educational level|primary school, secondary school, university
3236545|NCT00939419|Other|Health worker TB care group|
3236546|NCT00939419|Other|Community health worker TB care group|
3236547|NCT00939419|Other|Self-administered treatment group|
3236548|NCT00939406|No Intervention|Control|Control group consists of subjects randomized to the control arm who will receive lumbar decompression surgery (laminotomy or laminectomy) alone
3236549|NCT00939406|Experimental|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
3236550|NCT00939393|Active Comparator|FESS in OR with or without balloons|Functional Endoscopy Sinus Surgery
3236551|NCT00939393|Active Comparator|Balloon sinuplasty in physician office|Balloon Sinuplasty in physician office using Acclarent devices
3236552|NCT00939380|Experimental|P-SCIP|Arm I (Parent Social-Cognitive Intervention Program [P-SCIP]): Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns. Participants receive a laptop computer and a CD-ROM after the first session.
3236592|NCT00939042|Active Comparator|1|PCI plus BNNC Therapy after acute myocardial infarction
3236593|NCT00939042|Active Comparator|2|Percutaneous Coronary Intervention after acute myocardial infarction
3236553|NCT00939380|Experimental|BPC|"Arm II (Best-recommended Psychosocial Care [BPC]): Participants undergo usual care and receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD, and 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks."
3236554|NCT00939367|Experimental|Test|Torrent's Zolpidem TartrateTablets 10 mg
3236555|NCT00939367|Active Comparator|Reference|Sanofi-Synthelabo Inc's Ambient® Tablets 10 mg
3236556|NCT00939341|Experimental|1|Symbicort Turbuhaler 160/4.5 µg delivered dose
3236557|NCT00939289||Adults with T1DM|Adults (18+ years-old) diagnosed with type 1 diabetes mellitus; treated with multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy
3236558|NCT00939276|Experimental|NEVANAC|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
3236559|NCT00939276|Placebo Comparator|Nepafenac Vehicle|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
3236560|NCT00939263||1|cohorts 1 (item weighting phase): 100 children with Eosinophilic Esophagitis, 150 adults with Eosinophilic Esophagitis
3236561|NCT00939263||2|cohorts 2 (evaluation phase): 200 children with Eosinophilic Esophagitis, 200 adults with Eosinophilic Esophagitis
3236562|NCT00939250|Experimental|Diabetes and depression intervention|Measurement based care for diabetes and depression, disease self management for diabetes and depression
3236563|NCT00939250|Active Comparator|Diabetes intervention|Measurement based care for diabetes, disease self management for diabetes
3236564|NCT00939237|Experimental|Active Ateronon|7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
3236565|NCT00939237|Placebo Comparator|Placebo|placebo dietary supplement supplied as one capsule taken daily
3236566|NCT00939224||Cohort Phase 1|Cardiac Catheterization
3236567|NCT00939211|Experimental|AZD9164 100 mcg First, then Placebo for Spririva|1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
3236568|NCT00939211|Experimental|AZD9164 400 mcg First, then Placebo for Spiriva|1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
3236569|NCT00939211|Experimental|AZD9164 1200 mcg First, then Placebo for Spiriva|1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
3236570|NCT00939211|Active Comparator|Spiriva 18 mcg First, then Placebo for AZD9164|1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)
3236571|NCT00939211|Placebo Comparator|Placebo for Spiriva First, then Placebo for AZD9164|1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)
3236572|NCT00939198|Experimental|Na-ASP-2 Hookworm Antigen Skin Test|All participants will be skin tested with Na-ASP-2 skin test reagent applied to their arms, using both the prick-puncture and intradermal techniques.
3236573|NCT00939185||Azithromycin group|
3236574|NCT00939172|Experimental|TTP607|
3236575|NCT00939159|Experimental|LBH589|LBH589 20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.
3236576|NCT00939146|Other|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
3236577|NCT00939146|Other|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
3236578|NCT00939133|Active Comparator|Tretinoin microsphere 0.04% gel|
3236579|NCT00939133|Placebo Comparator|Vehicle gel|
3236580|NCT00939120|Experimental|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
3236581|NCT00939120|Placebo Comparator|placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
3236582|NCT00939107|Experimental|McKenzie exercises|McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
3236583|NCT00939107|Active Comparator|Spinal manipulation|Spinal manipulation in combination with information of clinical findings and advice about back care
3236584|NCT00939094|Experimental|A|
3236585|NCT00939094|Placebo Comparator|B|
3236586|NCT00939081|Active Comparator|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
3236587|NCT00939081|Experimental|Adaptive recommendation|The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
3236588|NCT00939068|Experimental|Telbivudine|Drug administration and follow up: the subjects in Telbivudine group start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continue to one month after delivery.And their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.
3236589|NCT00939068|Other|Control|The pregnant subjects in Control group are intervented with no drugs, but their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.
3236590|NCT00939055|Experimental|StomaphyX|Post-Roux-en-Y revisional surgery using the StomaphyX device.
3236591|NCT00939055|Sham Comparator|Sham Procedure|No intervention
3236594|NCT00939029|Active Comparator|Active|2 nicotine patches each at 21 mg/day for a total of 42 mg/day for 8 weeks
3236595|NCT00939029|Placebo Comparator|placebo|2 patches (containing non active ingredients) per day for 8 weeks
3236596|NCT00939016|Active Comparator|High SD/ Low DR|This group contains females that exhibit characteristics of high social desirability and low dietary restraint.
3236597|NCT00939016|Active Comparator|High SD/ High Dr|This group contains females that exhibit characteristics of high social desirability and high dietary restraint.
3236598|NCT00939016|Active Comparator|Low SD/ High DR|This group contains females that exhibit characteristics of low social desirability and high dietary restraint.
3236599|NCT00939016|Active Comparator|Low SD/ Low DR|This group contains females that exhibit characteristics of low social desirability and low dietary restraint.
3236600|NCT00939003|Experimental|Adalimumab|
3236601|NCT00939003|Placebo Comparator|Placebo|
3236602|NCT00939003|Experimental|Open-label Adalimumab|
3236603|NCT00938990|Active Comparator|Midazolam|
3236604|NCT00938990|Experimental|Etomidate|
3236605|NCT00938977|Active Comparator|CPAP|Response to treatment before/after treatment in patients with OSAS and SOH
3236606|NCT00938977|Active Comparator|Bilevel support ventilation|Before and after effect of Bilevel support ventilation in patients with SOH without OSA
3236607|NCT00938964|Experimental|Lidocaine|Lidocaine infusion for 48 hours
3236608|NCT00938964|Placebo Comparator|Placebo|Normal saline infusion for 48 hours
3236609|NCT00938951|Experimental|Systane® Ultra|Systane® Ultra
3236610|NCT00938938|Experimental|Press guide plus press release|Participants in the intervention group will receive a press guide (a one-page summary of study findings written by the investigators) in addition to the journal's full narrative press release for the selected article, a copy of the article's abstract, and a link to the full text of the journal article.
3236611|NCT00938938|No Intervention|Press release only|Participants in the control group will receive the journal's full narrative press release for the selected article, a copy of the article's abstract, and a link to the full text of the journal article.
3236612|NCT00938925|Experimental|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
3236613|NCT00938925|Experimental|nail lacqer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
3236614|NCT00938912|Experimental|Lacosamide|Subjects and their caregivers may chose to receive Lacosamide oral solution (syrup) or Lacosamide tablets. The maximum duration of LCM administration will be approximately 2 years.
3236615|NCT00938886|Experimental|Naltrexone|50 mg daily naltrexone for 10 weeks
3236616|NCT00938886|Placebo Comparator|Placebo|Daily matched placebo pill
3236617|NCT00938873||Mindfulness Based Cognitive Therapy|The present study will use participants who have experienced more than three episodes of depression as judged by South London and Maudsley NHS Trust. No restrictions are placed in terms of participants' use of antidepressant medication. Participants will be 18 to 65 years old and would have participated in an MBCT course run by South London and Maudsley NHS Trust.
3236618|NCT00938860|Experimental|Neoral|Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
3236619|NCT00938860|Active Comparator|tacrolimus|Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
3236620|NCT00938834|Active Comparator|CFQ Qigong training group|"Qigong training con- sisted of an initial workshop conducted over three con- secutive half-days by a qualified CFQ instructor. Participants received training in level 1 CFQ; this con- sisted of instruction in seven key movements known as the hexagram and ancillary exercises. Hexagram move- ments consist of choreographed movements that emphasize softness, relaxation, downward releases and full body distribution of qi. Once initial training was complete, participants were asked to practice CFQ at home for 45 to 60 minutes per day for eight weeks; time could be broken up into shorter sessions during the day. Participants returned for a 60 minute weekly review/group practice sessions for these eight weeks."
3236621|NCT00938821||Caudal Block|Review of charts of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B).
3236622|NCT00938808|Active Comparator|One per day, Formula diet|The Cambridge Programme. Formula diet One-daily
3236623|NCT00938808|Experimental|Repeated formula diet|Dietary instruction (low-energy diet) 3x5 weeks per year
3236624|NCT00938795|Other|Uncertainty Management Intervention|The Uncertainty Management Intervention will consist of six 30-minute phone calls with a study educator to discuss issues of psychological distress, uncertainty management, symptom control, self efficacy for symptom management, and quality of life.
3236625|NCT00938795|Other|Comparison Conditions for Liver Disease|Six 30-minute telephone calls that provide structured education about liver disease.
3236626|NCT00938782|Active Comparator|Active Monitoring with SEDLine Monitor|Patient group randomized to active monitoring with SEDLine monitor for titration of anesthesia.
3236627|NCT00938782|No Intervention|Blinded monitoring with SeEDLine Monitor|Patient group randomized to blinded monitoring with SEDLine monitor for titration of anesthesia. Data captured but not used for titration of anesthesia.
3236628|NCT00938769|Other|Self-Efficacy Training for Caregivers|The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.
3236629|NCT00938769|Other|Comparison Conditions for Caregivers|Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for support.
3236630|NCT00938743|Active Comparator|Atomoxetine|Treatment with a final dosis of 40-80mg atomoxetine daily
3236631|NCT00938743|No Intervention|Waiting list|
3236632|NCT00938730|Experimental|1. YM150, Dose W, twice daily|
3236633|NCT00938730|Experimental|2. YM150, Dose X, once daily|
3236637|NCT00938730|Experimental|6. YM150, Dose Z, once daily|
3236638|NCT00938730|Active Comparator|7. Warfarin|
3236639|NCT00938717|Placebo Comparator|Placebo|
3236640|NCT00938717|Experimental|290 μg Linaclotide|
3236641|NCT00938704|Active Comparator|1|carboxymethylcellulose 0.5%, glycerin 0.9%
3236642|NCT00938704|Active Comparator|2|sodium hyaluronate 0.18%
3236643|NCT00938691|Experimental|Tepha|
3236644|NCT00938691|Active Comparator|Vicryl|
3236645|NCT00938678|Experimental|Treatment Group 1|
3236646|NCT00938678|Active Comparator|Treatment Group 2|
3236647|NCT00938665||Control Group|
3236648|NCT00938665||AD Group|
3236649|NCT00938652|Active Comparator|Arm G/C|gemcitabine/carboplatin on Days 1 and 8 of 21-day cycle(s)
3236650|NCT00938652|Experimental|Arm G/C/I|gemcitabine/carboplatin on Days 1 and 8, plus iniparib on Days 1, 4, 8, and 11 of 21-day cycle(s)
3236651|NCT00938639|Experimental|CSL425 (15 mcg)|15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
3236652|NCT00938639|Experimental|CSL425 (30 mcg)|30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
3236653|NCT00938626|Experimental|Armed-activated T cells/Immunotherapy|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
3236654|NCT00938613|Experimental|Captisol-Enabled Budesonide|32 ug/spray
3236655|NCT00938613|Active Comparator|Rhinocort Aqua|32 ug/spray
3236656|NCT00938613|Placebo Comparator|Placebo|posphate buffered saline
3236657|NCT00938600|Experimental|A1 - non-pregnant single-dose|
3236658|NCT00938600|Experimental|A2 - non-pregnant; weekly dose|
3236659|NCT00938600|Experimental|B1 - pregnant; single-dose|
3236660|NCT00938600|Experimental|B2 - pregnant; weekly dose|
3236661|NCT00938600|Active Comparator|C1 - active control; pregnant women|
3236662|NCT00938587|Experimental|PF-04171327 10 mg|
3236663|NCT00938587|Experimental|PF-04171327 25 mg|
3236664|NCT00938587|Active Comparator|Prednisone|
3236665|NCT00938587|Placebo Comparator|Placebo|
3236666|NCT00938574|Experimental|Drug Atu027|
3236667|NCT00938561||With and without Chronic Kidney Disease|A cohort of 10 patients subjects with and without kidney disease exhibiting a broad range of age and kidney function
3236668|NCT00938548|Placebo Comparator|Placebo|Patients receive oral Placebo 1 hour prior to surgery, and 12 hours later
3236669|NCT00938548|Experimental|Pregabalin|Patients receive oral pregabalin 1 hour prior to surgery, and 12 hours later
3236670|NCT00938535|Experimental|Obesity Prevention|
3236671|NCT00938535|No Intervention|Usual Care|This arm includes usual care.
3236672|NCT00938522|Experimental|Cilostazol loading|
3236673|NCT00938522|Placebo Comparator|Placebo|
3236674|NCT00938483|Experimental|Extensively hydrolyzed infant formula|New extensively hydrolyzed formula, NPS-202
3236675|NCT00938483|Active Comparator|Infant formula - Extensively hydrolyzed Nutramigen Lipil|Currently marketed extensively hydrolyzed formula (Nutramigen Lipil)
3236676|NCT00938470|Experimental|Arm I (combination chemotherapy, radiation therapy, surgery)|Patients receive docetaxel IV over 1 hour and oxaliplatin IV over 2 hours on day 1. Patients also receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. After completion of the second course, patients receive fluorouracil IV continuously on days 1-5 and oxaliplatin IV over 2 hours on days 1, 15, and 29. Patients also undergo radiotherapy 5 days a week for 5.5 weeks in the absence of disease progression or unacceptable toxicity. Approximately 4-12 weeks after completion of radiotherapy, patients undergo surgery.
3236677|NCT00938470|Active Comparator|Arm II (oxaliplatin, fluorouracil, radiation, and surgery)|Patients receive fluorouracil IV continuously on days 1-5 and oxaliplatin IV over 2 hours on days 1, 15, and 29. Patients also undergo radiotherapy and then surgery as in Arm I.
3236678|NCT00938457|Experimental|Arm I|Patients undergo either percutaneous placement of metallic fiducial markers within the liver or respiratory-correlated cone-beam computed tomography for stereotactic targeting and planning. Patients then undergo single-fraction stereotactic body radiotherapy over approximately 1 hour within 1 week of the marker placement.
3236679|NCT00938444||Patients with moderate to severe RA|Patients with moderate to severe RA treated with Tocilizumab
3236680|NCT00938431|Experimental|Lacosamide - Age 5 - 11 years|Cohort 1 (Age 5 - 11 years); up to 8 mg/kg/day
3236681|NCT00938431|Experimental|Lacosamide - (Age 12 - 17 years)|Cohort 2 (Age 12 - 17 years); 12 mg/kg/day.
3236682|NCT00938431|Experimental|Lacosamide (Age 2 - 4 years)|Cohort 3 (Age 2 - 4 years); 12 mg/kg/day.
3236683|NCT00938431|Experimental|Lacosamide (Age 5 - 11 years)|Cohort 4 (Age 5 - 11 years); 12 mg/kg/day.
3236684|NCT00938431|Experimental|Lacosamide (Age 1 month - < 2 years)|Cohort 5 (Age 1 month to < 2 years); 12 mg/kg/day
3236685|NCT00938405|Experimental|Colesevelam HCl|Beginning at Visit 1, two weeks after screening, subjects in the active treatment group will take 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
3236686|NCT00938405|Placebo Comparator|Comparison group|Beginning at Visit 1, two weeks after screening, subjects in the comparison group will be administered placebo, taking 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
3236687|NCT00938392|Experimental|FluNG Aged Group|Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).
3236688|NCT00938392|Experimental|FluNG Fresh Group|Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).
3236689|NCT00938379|Experimental|20% deet insect repellent|experimental intervention
3236690|NCT00938379|Placebo Comparator|lotion without repellent active|
3236723|NCT00938158|Experimental|Stage 1 moderate/severe renal function|Subject with estimated GFR >= 20 mL/min and less than 50 mL/min
3236724|NCT00938158|Experimental|Stage 2 normal renal function|Subject with GFR greater than 80 mL/min
3236774|NCT00937755||risperidone|risperidone monotherapy, 2-4 mg/day
3236691|NCT00938366|Experimental|Cladribine followed by Cladribine + Pantoprazole|Subjects will receive a single dose of cladribine10 milligram (mg) orally on Day 1. After a wash out period of 10-25 days, subjects will receive pantoprazole 40 mg orally for 2 consecutive days. On Day 2 of the pantoprazole administration, a single dose of cladribine 10 mg will be administered orally 3 hours after the second pantoprazole dose.
3236692|NCT00938366|Experimental|Cladribine + pantoprazole followed by Cladribine|Subjects will receive pantoprazole 40 mg orally for 2 consecutive days. On Day 2 of the pantoprazole administration, a single dose of cladribine 10 mg will be administered orally 3 hours after the second pantoprazole dose. After a wash out period of 10-25 days, subjects will receive a single dose of cladribine 10 mg orally.
3236693|NCT00938353|Experimental|BDP UDV|
3236694|NCT00938353|Placebo Comparator|Placebo|
3236695|NCT00938340|Experimental|Whole walnut|85g whole walnuts, ground, incorporated into inert food carrier
3236696|NCT00938327||Rotarix Group|Subjects who have received 2 oral doses (or a second dose for subjects who had already received the first dose prior to joining the study) of Rotarix™ at an interval of not less than 4 weeks between the doses.
3236697|NCT00938314|Experimental|NTx®-265 Low Dose|hCG 385 µg (10,000 international unit [IU]), subcutaneously (SC), on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, intravenously (IV), on Day 7, 8, and 9 of study participation
3236698|NCT00938314|Experimental|NTx®-265 Medium Dose|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
3236699|NCT00938314|Experimental|NTx®-265 High Dose|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
3236700|NCT00938314|Placebo Comparator|Saline Placebo|
3236701|NCT00938301|Active Comparator|Treatment|2 cohorts will recieve single rising doses of PF-04455242 or placebo in a cross-over fashion.
3236702|NCT00938301|Placebo Comparator|Placebo|2 cohorts will receive single rising doses of PF-04455242 or placebo in a cross-over fashion.
3236703|NCT00938288|Other|1|Single group
3236704|NCT00938275|Experimental|0.5g SRT2104|"Cohort 1 (10 males) & Cohort 2 (10 females) must attend the clinic on 4 separate treatment visits during the study; each treatment visit will be one week apart. At each treatment visit, subjects will receive one of the following 4 treatments:~A) 0.5g SRT2104 administered as an oral suspension in the fasted state B) 0.5g SRT2104 administered as an oral suspension following consumption of a standard meal C) 0.5g SRT2104 administered as two 0.25g capsules in the fasted state D) 0.5g SRT2104 administered as two 0.25g capsules following consumption of a standard meal.~For treatments A and C, subjects will have fasted for at least 10 hours overnight. Water will be restricted from 1h prior to dosing until 1h post dose. A light lunch will be provided 4h post dose. For treatments B and D, subjects will receive SRT2104 within 30 min following the start of consumption of a standardized non high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat)."
3236705|NCT00938262|Experimental|Fimasartan, Ketoconazole, Rifampicin|
3236706|NCT00938249|Experimental|Monascus Garlic Fermented Extract|
3236707|NCT00938249|Placebo Comparator|Placebo|
3236708|NCT00938236|Other|Inhaled cyclosporine|Extended access to inhaled cyclosporine for patients from treatment and control arms of Phase 3 study CIS001
3236709|NCT00938223|Active Comparator|4-peptide vaccine|Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A 2) and a tetanus helper peptide.
3236710|NCT00938223|Active Comparator|12-peptide vaccine|Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.
3236711|NCT00938210|No Intervention|Laparoscopic surgery|Patients undergoing laparoscopic colonic surgery are compared with a historical cohort of patients undergoing similar open colonic surgery (right hemicolectomy and sigmoid resections).
3236712|NCT00938197|Active Comparator|Part A|
3236713|NCT00938197|Active Comparator|Part B|
3236714|NCT00938184|Experimental|Treatment sequence A/B/C|Eligible subjects will be randomized in sequence A/B/C and will receive A: single tablet of paroxetine 12.5 milligrams, B: single tablet of paroxetine 25 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
3236715|NCT00938184|Experimental|Treatment sequence A/C/B|Eligible subjects will be randomized in sequence A/C/B and will receive A: single tablet of paroxetine 12.5 milligrams, C: two tablets of paroxetine 25 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
3236716|NCT00938184|Experimental|Treatment sequence B/A/C|Eligible subjects will be randomized in sequence B/A/C and will receive B: single tablet of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
3236717|NCT00938184|Experimental|Treatment sequence B/C/A|Eligible subjects will be randomized in sequence B/C/A and will receive B: single tablet of paroxetine 25 milligrams, C: two tablets of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
3236718|NCT00938184|Experimental|Treatment sequence C/A/B|Eligible subjects will be randomized in sequence C/A/B and will receive C: two tablets of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
3236719|NCT00938184|Experimental|Treatment sequence C/B/A|Eligible subjects will be randomized in sequence C/B/A and will receive C: two tablets of paroxetine 25 milligrams, B: single tablet of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
3236720|NCT00938171|Active Comparator|local anesthesia|local anesthesia with propofol sedation Target-controlled infusion (TCI) system will be used to maintain proper sedation level)
3236721|NCT00938171|Active Comparator|General anesthesia|Patients receiving general anesthesia
3236722|NCT00938158|Experimental|Stage 1 normal renal function|Subject with estimated glomerular filtration rate (GFR) greater than 80 milliliter per minute (mL/min)
3236725|NCT00938158|Experimental|Stage 2 moderate renal impairment|Subject with estimated GFR >= 30 mL/min and less than 50 mL/min
3236726|NCT00938158|Experimental|Stage 2 subjects requiring hemodialysis|Subjects who require hemodialysis
3236727|NCT00938158|Experimental|Stage 2 severe renal impairment not requiring hemodialysis|Subjects with GFR less than 30 mL/min
3236728|NCT00938158|Experimental|Stage 2 mild renal impairment|Subjects with GFR >= 50 mL/min and <= 80 mL/min
3236729|NCT00938145|Experimental|MRI+surgery|3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI
3236730|NCT00938145|Experimental|MRI+surgery+chemotherapy|3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI/chemotherapy
3236731|NCT00938132|Experimental|Fimasartan|
3236732|NCT00938119||Diabetes patients with PCI|this is single group
3236733|NCT00938106|Experimental|(MR BT) in Cervix Cancer|
3236734|NCT00938093|Active Comparator|Cognitive-behavioral therapy|cognitive-behavioral therapy
3236735|NCT00938093|Placebo Comparator|Enhanced usual care|enhanced usual care
3236736|NCT00938080|Experimental|AG013: one mouth rinse/day|
3236737|NCT00938080|Experimental|AG013: three mouth rinses/day|
3236738|NCT00938080|Experimental|AG013: six mouth rinses/day|
3236739|NCT00938080|Placebo Comparator|one mouth rinse/day|
3236740|NCT00938080|Placebo Comparator|three mouth rinses/day|
3236741|NCT00938080|Placebo Comparator|six mouth rinses/day|
3236742|NCT00938067|Experimental|Staying Connected: Care Management|The intervention combines case management, psychopharmacological and culturally appropriate and individually tailored trauma support activities with evidence-based treatments.A key feature is the provision of a continuous healing relationship by a care management treatment team.The care manager, informed by the Native healer interviews, will provide a culturally appropriate and ongoing helping relationship to each intervention patient in the weeks and months post-injury and will remain in close contact with the trauma survivor subject for 6 months.Together, the care manager and trauma survivor subject will work on a plan to readjust to daily activities. The care management team will also coordinate psychopharmacological interventions for PTSD and related co-morbidities with primary care and or other community providers.
3236743|NCT00938041|Experimental|Retreatment of NHL with Iodine-131 Anti-B1 Antibody|Patients with non-Hodgkin's lymphoma who previously responded with a duration of response of at least 3 months to Iodine-131 Anti-B1 Antibody therapy will undergo two phases of study. In the first phase, patients will receive a dosimetric dose of unlabeled Anti-B1 Antibody (450 mg) followed by Anti-B1 Antibody (35 mg) which has been radiolabeled with 5 mCi of Iodine-131. Whole body gamma camera scans will be obtained after the dosimetric dose and data from three imaging time points will be used to calculate a patient-specific dose to deliver the desired total body dose of radiotherapy. In the second phase, patients will receive the therapeutic dose of unlabeled Anti-B1 Antibody (450 mg) followed by 35 mg of Anti-B1 Antibody labeled with the patient-specific dose to deliver the desired whole body dose of radiation. Patients will be treated with thyroid blocking medication at least 24 hours prior to the first infusion and continuing for 14 days following the last infusion.
3236744|NCT00938028||Microbiome, Metabolome, Stool, Toddler|healthy infant stool samples
3236745|NCT00938015||PsA Patients (New)|New patients
3236746|NCT00938015||PsA Patients|CU patients
3236747|NCT00937976|Other|Control-delayed periodontal therapy|
3236748|NCT00937976|Other|Intensive Periodontal Therapy|
3236749|NCT00937963|Experimental|Palm Oil|Traditional palm oil normally used in foods
3236750|NCT00937950|Experimental|Cervarix Group|Subjects vaccinated with 3 doses of Cervarix in the NCT00122681 study, who displayed normal cervical cytology but tested positive for oncogenic HPV infection or were pregnant, so that no cervical sample could be collected at their last visit.
3236751|NCT00937937|Experimental|Arm I|Patients receive dinaciclib IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3236752|NCT00937924|Placebo Comparator|1|Control. Normal Saline Injections.
3236753|NCT00937924|Experimental|2|Diphenhydramine injections given as adjunct sedative.
3236754|NCT00937924|Experimental|3|Promethazine given as an adjunct sedative.
3236755|NCT00937911|Experimental|YM150 group|
3236756|NCT00937898|Experimental|DASH Diet|High fruit and vegetable, low sodium diet
3236757|NCT00937898|Active Comparator|Average American Diet|Typical American diet (16% protein, ~50% carbohydrate, 33% fat)
3236758|NCT00937885|Experimental|Implementation of reminiscence|Individual and group reminiscence sessions held with residents, supplemented by reminiscence boxes, posters and exhibitions.
3236759|NCT00937885|No Intervention|Usual nursing care|
3236760|NCT00937872|Experimental|SRT2104|Single arm with crossover from single dose of oral suspension formulation to single dose intravenous formulation.
3236761|NCT00937859|Experimental|SER120|SER120
3236762|NCT00937859|Placebo Comparator|Placebo|
3236763|NCT00937846|Experimental|GSK1034702|Single oral 5 mg dose in liquid formulation
3236764|NCT00937833|Experimental|Urethrovesical Sling|Surgisis Male Sling placed at the time of prostatectomy
3236765|NCT00937833|Active Comparator|Control|Prostatectomy
3236766|NCT00937820|Experimental|YM150 group|
3236767|NCT00937807|Active Comparator|sévoflurane|hypnotic use in standard general anesthesia
3236768|NCT00937807|Experimental|LENOXe™ (xénon 100 % v/v)|Safety of use in terms of hemodynamic stability to the LENOXe™ (xénon 100 % v/v) within the framework of the carotid surgery on the old person
3236769|NCT00937794||No treatment|This is a screening study designed to evaluate the behavioral, physical, and neurodevelopmental status in pediatric patients with Hunter syndrome who have early signs and symptoms of CNS involvement and who are currently receiving treatment with Elaprase.
3236770|NCT00937768|Experimental|Arm A (antihormone therapy)|Patients receive leuprolide acetate IM on day 1 OR goserelin acetate SC on day 1. Courses repeat every 3 months for 9 months in the absence of disease progression or unacceptable toxicity.
3236771|NCT00937768|No Intervention|Arm B (no antihormone therapy)|Patients undergo observation every 3 months for 9 months.
3236772|NCT00937755||olanzapine|olanzapine 10-20 mg/day
3236773|NCT00937755||quetiapine|quetiapine 300-600 mg/day
3236775|NCT00937742|Experimental|Non-tomato products|Non-tomato products (i.e. teriyaki marinade, sprite, applesauce) to be consumed daily in replace of tomato products
3236776|NCT00937729||enfuvirtide|all patients would received enfuvirtide and and optimised background
3236777|NCT00937716||Diagnosis of Schizophrenia|Patients with a diagnosis of schizophrenia that have been off antipsychotic medicine and would like to resume treatment will be enrolled in the study.
3236778|NCT00937716||Healthy Volunteers|Healthy Volunteers without a psychiatric diagnosis, central nervous system condition, serious head injury, or current drug use will be matched on an individual basis to schizophrenic participants and used as a control population.
3236779|NCT00937703|Placebo Comparator|Group1: Control group|face to face visit à T4mounths
3236780|NCT00937703|Active Comparator|Group2: IVS Group|face to face visit at T4mounths plus telephone visits each 2 weeks
3236781|NCT00937703|Active Comparator|Group3: PDAphone group|PDA system face to face visit at T4mounths plus telephone visits each 2 weeks
3236782|NCT00937690||infrared imaging of cutaneous lesions|patients and volunteers with cutaneous lesions, with and without clinically detectable melanoma, and with one or more palpable cutaneous lesions
3236783|NCT00937677||1|63 patients with relapsing-remitting Multiple Sclerosis who are enrolled in the TOUCH program and have been taking Tysabri monotherapy for 2 years.
3236784|NCT00937677||2|22 age- and sex-matched normal controls who completed 1 year follow-up.
3236785|NCT00937664|Other|AZD7762 + gemcitabine|AZD7762 administered alone and in combination with gemcitabine
3236786|NCT00937651|Placebo Comparator|Placebo|Placebo, 3 tablets
3236787|NCT00937651|Active Comparator|BR-A-657•K 20 mg group|Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
3236788|NCT00937651|Active Comparator|BR-A-657•K 60 mg group|Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
3236789|NCT00937651|Active Comparator|BR-A-657•K 180 mg group|Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
3236790|NCT00937638|Experimental|Modified-DASH Diet|
3236791|NCT00937638|Experimental|BOLD diet|
3236792|NCT00937638|Experimental|BOLD-X|
3236793|NCT00937612|Experimental|concurrent chemoradiation|patients who has 3 or more minor risk factors of recurrence, and will receive postoperative chemoradiation.
3236794|NCT00937599|Experimental|Brazil Nuts|The first group consumed the brazil nuts and the other group placebo (lactose pills)
3236795|NCT00937586||Newly diagnosed patients|Patients with newly diagnosed prostate cancer.
3236796|NCT00937573||Xience V|Percutaneous coronary intervention with Xience V stent placement
3236797|NCT00937573||Historical BMS|Percutaneous coronary intervention with bare metal stent placement prior to availability of Cypher, Taxus, or Xience V drug eluting stents at WFUBMC
3236798|NCT00937573||Historical DES|Percutaneous coronary intervention with drug eluting stent placement prior to availability of Xience V drug eluting stents at WFUBMC
3236799|NCT00937573||Contemporary BMS|Percutaneous coronary intervention with bare metal stent placement after Xience V drug eluting stents were available for use at WFUBMC
3236800|NCT00937573||Contemporary DES|Percutaneous coronary intervention with Cypher or Taxus drug eluting stent placement after Xience V drug eluting stents were available for use at WFUBMC
3236801|NCT00937560|Experimental|Bevacizumab + paclitaxel + carboplatin|Participants received 6-8 (at the investigator's discretion) 3-week cycles of bevacizumab 7.5 mg/kg intravenously (iv) on Day 1 of each cycle, paclitaxel 80 mg/m^2 iv on Days 1, 8, and 15 of each cycle, and carboplatin iv to an area under the curve of 6 on Day 1 of each cycle. The initial dose of carboplatin was calculated according to the Calvert formula (mg = [glomerular filtration rate + 25] x 6). Following the combination treatments, participants received up to 17 3-week cycles of bevacizumab 7.5 mg/g iv alone.
3236802|NCT00937534|Active Comparator|Part A|Young male healthy volunteer
3236803|NCT00937534|Active Comparator|Part B|Elderly male healthy volunteer
3236804|NCT00937521|Other|1|Vaccine candidate formulation I
3236805|NCT00937521|Other|2|Vaccine candidate formulation II
3236806|NCT00937521|Other|3|Vaccine candidate formulation III
3236807|NCT00937521|Other|4|Vaccine candidate formulation IV
3236808|NCT00937521|Other|5|Vaccine candidate formulation V
3236809|NCT00937521|Other|6|Vaccine candidate formulation VI
3236810|NCT00937521|Other|7|Control
3236811|NCT00937521|Other|8|Vaccine candidate formulation I with antipyretic
3236812|NCT00937508|Placebo Comparator|Smoking counseling, Placebo|
3236813|NCT00937508|Experimental|Smoking counseling, Varenicline|
3236814|NCT00937495|Experimental|Treatment (vorinostat, bortezomib)|Patients receive 400 mg vorinostat orally once daily on days 1-14. Patients also receive 1.3 mg/m^2 bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3236815|NCT00937482|Experimental|Treatment (cediranib maleate and WBRT)|Patients receive oral cediranib maleate on day 1. Patients undergo whole-brain radiotherapy 5 days a week for 3 weeks beginning on day 3. Treatment continues treatment in the absence of disease progression or unacceptable toxicity.
3236816|NCT00937469|Experimental|Social sk. tr., parent tr.,standard tr.|
3236817|NCT00937469|Active Comparator|Standard treatment|
3236818|NCT00937456|Experimental|Laparoscopically-assisted esophagectomy|Laparoscopically-assisted esophagectomy: standard abdominal procedure of gastric mobilisation but through laparoscopic route. Right thoracotomy as usual.
3236819|NCT00937456|Active Comparator|Open esophagectomy|Conventional open esophagectomy: Esophagectomy with extended 2-field lymphadenectomy through laparotomy and right thoracotomy (Ivor-Lewis standard procedure)
3236820|NCT00937443||Walking Exercise Group|Walking Exercise Group versus Control Group
3236821|NCT00937430|Experimental|Bowel preparation group|Patients randomized to this arm will perform a bowel preparation prior to their pelvic organ prolapse surgery.
3236822|NCT00937430|No Intervention|No Bowel preparation group|Patients randomized to this group will not be performing a bowel preparation prior to their pelvic organ prolapse surgery.
3236823|NCT00937417|Experimental|Arm 1|vandetanib and docetaxel
3236824|NCT00937404|Experimental|IPV Group|
3236858|NCT00937157|Other|1|Patients diagnosed with multiple sclerosis who have the presence of at least 1 or more Gd enhancing lesions and/or acute relapse.
3236825|NCT00937391|Experimental|Gadopentetate dimeglumine (Magnevist, BAY86-6661)|For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
3236826|NCT00937378|Experimental|SER120|
3236827|NCT00937378|Placebo Comparator|Placebo|
3236828|NCT00937365|Active Comparator|Exercise|Specific strengthening exercises demonstrated to improve pregnancy-related low back pain are taught to participants of this arm. Additionally, each participant will be evaluated and additional exercises will be prescribed relevant to her particular needs. Study participants of this arm are asked to perform the exercises at home at least once a day. Exercise is recorded in a diary. Participants follow the same study visit schedule as the two other arms.
3236829|NCT00937365|Experimental|Spinal Manipulation|Women randomized to this arm will be evaluated for spinal subluxations and, if appropriate, treated with chiropractic manipulation. Type of manipulation is determined by presentation. Woman may be manipulated with high velocity low amplitude thrust, blocking, activator, or other appropriate means of manipulating.
3236830|NCT00937365|Experimental|Neuroemotional technique (NET)|"Neuroemotional technique (NET) is a mind-body technique which combines elements of chiropractic medicine, Chinese medicine, and behavioral psychology. Muscle response testing, a form of functional neurology, and visceral somatic reflexes are used to ascertain whether the pain or dysfunction experienced by the participant has an emotional component. If an emotional component is present, it is identified and the original triggering occurrence is identified. The participant creates a snapshot of that original occurrence and while she holds that image in her mind spinal levels which innervate the associated organ are adjusted."
3236831|NCT00937352|Active Comparator|Bapineuzumab 0.5 mg/kg|0.5 mg/kg
3236832|NCT00937352|Active Comparator|Bapineuzumab 1.0 mg/kg|1.0 mg/kg
3236833|NCT00937339|Active Comparator|Control|The control group will perform the same exercises on the vibration platform, as in the experimental group. However, the vibration device will be turned off during the exercises.
3236834|NCT00937339|Experimental|Whole body vibration|Subjects in the experimental group will undergo whole body vibration (1 session per day, 3 sessions per week) for 8 weeks. The vibration loading will be carried out using the Jet-Vibe System (Danil SMC Co., Ltd., Seoul, Korea). The vibration protocol used in this study will be 30Hz. While standing on the vibration platform, patients will be instructed to repeat the following set of light exercises: (1) light squatting,(2)deep squatting , (3) side-to-side weight-shift, (4) Forward and backward weight-shift, (5) forward lunge, (6) marching on the spot. The total duration of exposure of whole body vibration per session will be about 10 minutes.
3236835|NCT00937326|Placebo Comparator|Placebo|"The Placebo treatment group will be administered eight placebo capsules per day.~Placebo will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
3236836|NCT00937326|Active Comparator|Arm1 - 0.25g|"The 0.25g SRT2104 treatment group will be administered one SRT2104 capsules with 7 placebo capsules, for a total of 8 capsules per day.~0.25g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
3236837|NCT00937326|Active Comparator|Arm2 - 0.5g|"The 0.5g SRT2104 treatment group will be administered two SRT2104 capsules with 6 placebo capsules, for a total of 8 capsules per day.~0.5g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
3236838|NCT00937326|Active Comparator|Arm3 - 1g|"The 1g SRT2104 treatment group will be administered four SRT2104 capsules with four placebo capsules, for a total of 8 capsules per day.~1g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
3236839|NCT00937326|Active Comparator|Arm4 - 2g|"The 2g SRT2104 treatment group will be administered eight SRT2104 capsules per day.~2g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
3236840|NCT00937313||Champagne wine|
3236841|NCT00937313||Placebo|alcohol with sparkling mineral water
3236842|NCT00937287||youth and caregivers|
3236843|NCT00937274|Experimental|Test product|
3236844|NCT00937274|Active Comparator|Commercial product|
3236845|NCT00937274|Placebo Comparator|Standard care|
3236846|NCT00937261|Experimental|Risperdal|Risperdal 2-8mg per day
3236847|NCT00937261|Experimental|Invega|Invega 6-12mg per day
3236848|NCT00937248|Experimental|Interventional|Patient randomized to be immobilized using a prone pillow and simple ankle fixation device with a CVID.
3236849|NCT00937248|Active Comparator|Standard Arm|Patient randomized to be immobilized using a prone pillow and simple ankle fixation device without a CVID
3236850|NCT00937235|Experimental|Integrated Treatment|Prolonged Exposure + Varenicline + Medication Management Counseling
3236851|NCT00937235|Active Comparator|Varenicline|Varenicline + Medication Management Counseling
3236852|NCT00937196|Active Comparator|Histaminum hydrochloricum globuli|To allow double-blind administration of the placebo pills going along with verbal suggestions of a blood-pressure-lowering effect
3236853|NCT00937196|Experimental|Placebo globuli|
3236854|NCT00937196|No Intervention|No treatment|
3236855|NCT00937170|Experimental|Gender Specific LPS flex|Participants in this arm will receive the Zimmer LPS flex Gender Specific Implant design
3236856|NCT00937170|Active Comparator|LPS flex|Participants in this arm will receive the Zimmer High Flex LPS implant
3236857|NCT00937170|Active Comparator|Triathlon|Participants in this arm will receive the Stryker Triathlon Implant design
3236859|NCT00937144|Experimental|viagra|viagra versus placebo will be given to patients with sickle cell anemia
3236860|NCT00937144|Placebo Comparator|placebo|viagra versus placebo will be given to patients with sickle cell anemia
3236861|NCT00937118||Injury Management|Patients with full thickness duodenal laceration undergoing laparotomy and surviving more then 72 hours at our level 1 trauma center in the years 1989-2009. Patients requiring pancreaticoduodenectomy were excluded.
3236862|NCT00937105|Active Comparator|ReNu Multiplus and lotrafilcon A lenses|ReNu Multiplus contact lens care solution
3236863|NCT00937105|Active Comparator|Clear Care solution and lotrafilcon A lenses|Clear Care Contact Lens Care Solution
3236864|NCT00937092|Active Comparator|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
3236865|NCT00937092|Active Comparator|low-dose dopamine + low-dose furosemide|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
3236866|NCT00937066||1|Adult patients 18-65 years with moderate to severe uncontrolled asthma
3236867|NCT00937053|Experimental|Hemoglobin below 120 g/dL|
3236868|NCT00937053|Active Comparator|Hemoglobin below 70 g/dL|
3236869|NCT00937040|Experimental|001|OROS MPH Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
3236870|NCT00937040|Placebo Comparator|002|Placebo Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
3236871|NCT00937027|Active Comparator|Aminopterin one 1.0 mg tablet|
3236872|NCT00937027|Active Comparator|Aminopterin 1 four 0.25 mg tablets|
3236873|NCT00937014|Active Comparator|Standard infant formula|
3236874|NCT00937014|Experimental|Test formula|
3236875|NCT00937001|Experimental|Biopsy/Ultrasound|
3236876|NCT00936988|Experimental|cinacalcet|
3236877|NCT00936975|Experimental|18F-Fluoride PET|Patients undergo fluorine F 18 sodium fluoride PET scan at baseline and then at 12 weeks after initiation of treatment with dasatinib. Dasatinib was administered under a concurrent protocol and was not considered part of the intervention on this protocol
3236878|NCT00936962|Experimental|Group 1 NeisVac C vaccine - 0 doses|NeisVac C (Meningococcal C) vaccine - 0 doses
3236879|NCT00936962|Experimental|Group 2 NeiscVac C - 2 doses|2 priming doses of NeisVac C vaccine at 2 and 4 mths of age
3236880|NCT00936962|Experimental|Group 3 NeiscVac C - 1 dose|1 priming dose of NeisVac C vaccine at 2 mths of age
3236881|NCT00936949|Active Comparator|posterolateral approach|The posterolateral approach was described by many authors, but all share a common muscular interval in reference to the gluteus medius tendon. Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.
3236882|NCT00936949|Active Comparator|modified lateral approach|The operative technique described modified lateral approach as described by Mulliken et al.
3236883|NCT00936936|Experimental|Cycle # 1|"First Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)~HD Cycle #1: Gemcitabine/Docetaxel/Melphalan/Carboplatin + PBPC"
3236884|NCT00936936|Experimental|Cycle #2|"Second Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)~HD Cycle #2: Ifosfamide/Carboplatin/Etoposide + PBPC"
3236885|NCT00936923|Active Comparator|furosemide1|Patients will take furosemide 60mg per day for 1 years and undergo a study assessment at 3, 6, 12, 18, 24 months .
3236886|NCT00936923|Active Comparator|furosemide 2|Patients will take 120mg furosemide per day for 1 years and undergo a study assessment at 3, 6, 12, 18, 24 months .
3236887|NCT00936923|No Intervention|control|Patients in control group will not take furosemide
3236888|NCT00936910|Experimental|Antifungal lock-treated patients|Intestinal failure and other patients with poor IV access and central line fungal-related infections will receive intravenous systemic antifungal therapy plus the instillation of Ambisome locks into the infected catheter.
3236889|NCT00936897|Active Comparator|Ibandronate|Ibandronate 150mg PO QM (tablet)
3236890|NCT00936897|Experimental|Denosumab|denosumab 60mg Subcutaneous Q6M (pre-filled syringe)
3236891|NCT00936884|Experimental|1|MOA728 QOD
3236892|NCT00936884|Placebo Comparator|2|Placebo QOD
3236893|NCT00936871|Experimental|Part A|Lersivirine Tolerability
3236894|NCT00936871|Experimental|Part B|Thorough QTc
3236895|NCT00936858|Experimental|RAD001|RAD001 will be administered orally as once daily dose of 10 mg (one 10mg tablet or two 5mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity.
3236896|NCT00936845||Females with Hemophilia|Females with severe or moderate Hemophilia A or B.
3236897|NCT00936819|Placebo Comparator|Plasma-Lyte A and 25% autologous plasma|
3236898|NCT00936819|Experimental|Autologous EPCs|
3236899|NCT00936819|Experimental|Autologous EPCs Transfected with human eNOS|
3236900|NCT00936806||Unilateral intracranial tumor|Subjects with unilateral intracranial tumor
3236901|NCT00936806||Control group|Subjects without intracranial pathology
3236902|NCT00936780|Experimental|Infinnium-Core™ Paclitaxel eluting Coronary Stent|
3236903|NCT00936767|Experimental|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
3236904|NCT00936767|Active Comparator|Artesunate/Mefloquine (MAS3)|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
3236905|NCT00936754|Experimental|Treatment|Single administration of 500 mg of encapsulated brown seaweed powder, taken 30 minutes before test meal
3236906|NCT00936754|Placebo Comparator|Placebo|Single administration of encapsulated placebo, taken 30 minutes before test meal
3236907|NCT00936741|Experimental|Mifepristone|Mifepristone 300mg to 1200mg once daily
3236908|NCT00936728|Experimental|Arm A (white wine)|Patients consume white wine twice daily for 3-4 weeks.
3236909|NCT00936728|Active Comparator|Arm B (non-wine nutritional supplement)|Patients receive an oral non-wine nutritional supplement (e.g., Boost or Ensure) twice daily for 3-4 weeks.
3236910|NCT00936715|Experimental|FTC/TDF|
3236911|NCT00936702|Experimental|Treatment (carboplatin, paclitaxel, and everolimus)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Patients also receive everolimus PO QD on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3236912|NCT00936689|Sham Comparator|Traditional TACE|Chemoembolization by standard technique: epirubicin (maximum dose of 75 mg) conjugated with an oil-based contrast medium (Lipiodol) at the maximum dose of 15 ml + gelatin sponge particles(particles of transient embolization material, required to obstruct the treated vessel).
3236913|NCT00936689|Active Comparator|TACE with microsphere|
3236914|NCT00936676||Rasagiline mesylate|Enrollment by invitation to participates from the ADAGIO trial
3236915|NCT00936663|Experimental|Sitagliptin 100 mg daily|sitagliptin 100 mg daily
3236916|NCT00936663|Placebo Comparator|placebo|placebo
3236917|NCT00936650|Experimental|cinacalcet|
3236918|NCT00936650|Placebo Comparator|placebo|
3236919|NCT00936637|Experimental|Extensively hydrolyzed infant formula|
3236920|NCT00936624|Experimental|SOTB07 100mg|
3236921|NCT00936624|Experimental|SOTB07 200mg|
3236922|NCT00936624|Placebo Comparator|Placebo|
3236923|NCT00936624|Active Comparator|Montelukast 10mg|
3236924|NCT00936611|Experimental|LBH589|
3236925|NCT00936598|Experimental|zolpidem|Participants randomized to the zolpidem (intervention) group will receive the FDA approved dose of zolpidem, (10 mg for women <65; 5 mg for women > or = 65 years). For the purposes of this double-blind trial, zolpidem (e.g., Roxane Laboratories) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.
3236926|NCT00936598|Placebo Comparator|sugar pill|Participants randomized to the sugar pill (control) group will receive placebo. For the purposes of this double-blind trial, placebo (sugar) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.
3236927|NCT00936585|Other|Immunologic Monitoring|Blood draws and colonoscopy performed on patients enrolled in both intervention arms of the main study
3236928|NCT00936572|Experimental|high dose|high dose of probiotics (109 cfu)
3236929|NCT00936572|Experimental|low dose|low dose of probiotics (107 cfu)
3236930|NCT00936572|Placebo Comparator|probiotics|Maltodoxtrin
3236931|NCT00936559|Experimental|1|Arm A
3236932|NCT00936559|Experimental|2|Arm B
3236933|NCT00936559|Experimental|3|Arm C
3236934|NCT00936546|Experimental|Rituximab|
3236935|NCT00936520|Experimental|Dose 1|SAR 1118 dose 0.1%
3236936|NCT00936520|Experimental|Dose 2|SAR 1118 dose 1.0%
3236937|NCT00936520|Experimental|Dose 3|SAR 1118 dose 5.0%
3236938|NCT00936507|Experimental|Low-ED, small portion|
3236939|NCT00936507|Experimental|Low-ED, large portion|
3236940|NCT00936507|Experimental|High-ED, small portion|
3236941|NCT00936507|Experimental|High-ED, large portion|
3236942|NCT00936494|No Intervention|Control|No inferior turbinate surgery.
3236943|NCT00936494|Other|Intervention|Intervention group: Cold ablation inferior turbinate reduction utilizing radiofrequency ablation surgery (CITR).
3236944|NCT00936481||Healthy controls|18 years or older with body mass index between 25-45
3236945|NCT00936481||Obstructive Sleep Apnea Group|Age 18 years or older with body mass index between 25 and 45
3236946|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (3.75ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 3.75ug given by IM injection to the upper deltoid.
3236947|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (7.5ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 7.5ug given by IM injection to the upper deltoid.
3236948|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (25ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 25ug given by IM injection to the upper deltoid.
3236949|NCT00936468|Experimental|Fluzone® vaccine alone|One vaccination on Day 0 with Fluzone vaccine at 45 ug given by IM injection in the upper deltoid.
3236950|NCT00936455||Telemedicine|Telemedicine evaluated patients
3236951|NCT00936455||Telephone|Telephone evaluated patients
3236952|NCT00936442||Group A|Standard treatment: 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
3236953|NCT00936442||Group B|Standard treatment + educational material: 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice plus reception of educational material on regular basis.
3236954|NCT00936429|Experimental|10 µg DEN1-80E + 3.5 mg Alhydrogel|Administration of 10 µg DEN1-80E vaccine at Weeks 0, 4, and 8.
3236955|NCT00936429|Experimental|50 µg DEN1-80E + 3.5 mg Alhydrogel|Administration of 50 µg DEN1-80E vaccine at Weeks 0, 4, and 8.
3236956|NCT00936429|Placebo Comparator|Placebo|Administration of placebo vaccine at Weeks 0, 4, and 8.
3236957|NCT00936416|Experimental|GFR and RBF followed by MRI|Subjects will undergo GFR and renal blood flow estimation by Inulin and PAH clearance method, followed by a MRI test. The MRI examination will be performed on the same day as the inulin/PAH procedure.
3236958|NCT00936403|Experimental|NNC126-0083|
3236959|NCT00936403|Active Comparator|Norditropin NordiFlex®|
3236960|NCT00936390|Active Comparator|Arm I|Patients undergo external-beam radiation therapy (EBRT) once daily on days 1-5. Some patients instead receive EBRT with high-dose rate or low-dose rate brachytherapy implant.
3236961|NCT00936390|Experimental|Arm II|Patients receive androgen-deprivation therapy comprising luteinizing-hormone releasing-hormone (LHRH) agonist (leuprolide, goserelin, buserelin, or triptorelin) subcutaneously or as an injection every 1 to 3 months AND an oral antiandrogen therapy (flutamide 3 times daily or bicalutamide once daily) for 6 months. Beginning 8 weeks after the first LHRH injection, patients undergo radiotherapy as in arm I.
3236962|NCT00936377|Experimental|Dexmedetomidine, low dose|Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
3236963|NCT00936377|Experimental|Dexmedetomidine, high dose|Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
3236964|NCT00936377|Placebo Comparator|Placebo|Normal saline
3236965|NCT00936364|Experimental|Group I (Stage I of study)|Patients fast for 24 hours on day -1
3236966|NCT00936364|Experimental|Group II (Stage I of study)|Patients fast for 48 hours on days -2 and -1
3236967|NCT00936364|Experimental|Group III (Stage I of study)|Patients fast for 72 hours on days -3, -2, and -1
3236968|NCT00936364|Experimental|Group IV (Stage I of study)|Patients undergo a modified 48-hour fast with minimal caloric intake on day -2 and -1
3236969|NCT00936351|Experimental|Arm 1|Mindfulness Meditation
3236970|NCT00936351|Active Comparator|Arm 2|Support Group that involves discussion of work-related issues in which participants are facilitated to assist each other with problem solving and offer support
3236971|NCT00936338|Active Comparator|splint|
3236972|NCT00936338|Active Comparator|joint mobilization self exercise|
3236973|NCT00936312||Females with Hemophilia|Females with severe or moderate Hemophilia A or B
3236974|NCT00936312||Control group|Male subjects with severe Hemophilia A or B and female subjects with mild (20-60%) Hemophilia A or B.
3236975|NCT00936299|Active Comparator|Bupropion + cognitive behavioral therapy|Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive bupropion + CBT.
3236976|NCT00936299|Placebo Comparator|Placebo + cognitive behavioral therapy|Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive placebo + CBT.
3236977|NCT00936286|Experimental|Respiratory Muscle Training|
3236978|NCT00936273||Suspected sleep apnea syndrome|Outpatients with suspected sleep apnea syndrome, age > 18 year
3236979|NCT00936260|Experimental|alendronate 6 years|
3236980|NCT00936260|Experimental|alendronate 5 years|No treatment during year 6th
3236981|NCT00936260|Experimental|alendronate 5 years, not continued|No treatment during year 5th
3236982|NCT00936260|Experimental|alendronate 4 years|No treatment during year 5th and 6th
3236983|NCT00936260|Experimental|alendronate 5 years, uncontinued|No treatment during year 4th
3236984|NCT00936260|Experimental|alendronate 4 years, not continued|No treatment during year 4th and 6th
3236985|NCT00936260|Experimental|alendronate 4 years, uncontinued|No treatment during year 4th and 5th
3236986|NCT00936260|Experimental|Alendronato 3 years|No treatment during the last 3 years
3236987|NCT00936247|Experimental|1|HES 130/0.42 + Sterofundin ISO
3236988|NCT00936247|Active Comparator|2|Albumin + NaCl 0.9%
3236989|NCT00936234|Active Comparator|Vildagliptin|starting with vildagliptin for 30 days followed by placebo for 30 days
3236990|NCT00936234|Placebo Comparator|Placebo|starting with placebo for 30 days followed by vildagliptin for 30 days
3236991|NCT00936221|Active Comparator|1|AZD6244 in combination with dacarbazine
3236992|NCT00936221|Placebo Comparator|2|Placebo in combination with dacarbazine
3236993|NCT00936208||Essential hypertensive men and women|
3236994|NCT00936195|Active Comparator|Atripla (R)|
3236995|NCT00936195|Active Comparator|Combivir (R) + Kaletra (R) or Aluvia (R)|
3236996|NCT00936182|Experimental|Fluconazole|
3236997|NCT00936182|Placebo Comparator|Placebo|Placebo capsule daily for 30 days
3236998|NCT00936169|Experimental|IVUS optimised stent implantation|
3236999|NCT00936169|Active Comparator|angiographically guided DES implantation|
3237000|NCT00936156|Experimental|Chemotherapy|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
3237001|NCT00936143|Experimental|infliximab|200mg infliximab inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
3237002|NCT00936130||Lifestyle counseling|This group will be comprised of participants on a low calorie diet program.
3237003|NCT00936130||Weight Loss Surgery|This group will be comprised of participants having weight loss surgery: Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy.
3237004|NCT00936117|Experimental|Posaconazole|Posaconazole 200 mg (liquid) by mouth 3 times per day.
3237005|NCT00936104||SP in PDAC|Side population cells isolated from resection specimens obtained from patients with pancreatic cancer
3237006|NCT00936091|Placebo Comparator|placebo|125 schoolchildren were allocated randomly to receive placebo
3237007|NCT00936091|Active Comparator|vitamin A supplement|125 children received vitamin A supplements capsules (200 000 IU)
3237008|NCT00936078||Non-donors/controls|People who have not donated a kidney.
3237009|NCT00936078||Living Kidney Donors|
3237010|NCT00936065|Active Comparator|Group A|
3237011|NCT00936065|Experimental|Group B|
3237012|NCT00936065|Active Comparator|Group C|
3237013|NCT00936039|Experimental|unloading|2 weeks of unloading
3237014|NCT00936013|Experimental|oseltamivir|single antiviral treatment
3237015|NCT00936013|Experimental|oseltimivir and chinese medicinal herbs|combination treatment
3237016|NCT00936000|Active Comparator|protandim therapy for 7 days|
3237017|NCT00936000|Placebo Comparator|placebo arm|Individuals will receive a placebo equivalent in two equally divided doses for seven days
3237018|NCT00935987|Experimental|CYT387|
3237062|NCT00935662|Placebo Comparator|Placebo|Placebo for AZD8329 oral solution
3237063|NCT00935649|Experimental|Randomized great toe|Subjects with both great toes infected. Right/left randomized to treatment / no treatment
3237019|NCT00935961|Experimental|RAD001 + docetaxel + cisplatin|In this phase I trial, the primary endpoint will be considered to be reached when we have described a phase II recommended dose of RAD001 given with docetaxel + cisplatin as induction chemotherapy for head and neck cancer. Up to 3 dose levels of daily RAD001 will be studied. A standard 3 + 3 phase I dose escalation design will be used. The phase II recommended dose will be determined according to the dose escalation plan.
3237020|NCT00935948|Active Comparator|Imescard ointment|
3237021|NCT00935948|Placebo Comparator|Placebo|
3237022|NCT00935935||HIV older than 50 years|
3237023|NCT00935922|Placebo Comparator|Soybean oil bar|A nutrition bar enriched with soybean oil
3237024|NCT00935922|Experimental|Flaxseed bar with low lignans|A nutrition bar enriched with flaxseed oil
3237025|NCT00935922|Experimental|Flaxseed bars with high lignans|A nutrition bar enriched with flaxseed oil and high lignans
3237026|NCT00935896|No Intervention|high VT group|
3237027|NCT00935896|Experimental|Low tidal volume|
3237028|NCT00935883|Placebo Comparator|Saline|Randomized patients in the drusen or the GA cohort will receive placebo saline infusions as a comparator
3237029|NCT00935883|Active Comparator|Eculizumab|Randomized patients in the drusen or the GA cohort will receive active treatment with eculizumab
3237030|NCT00935870||A|DEPRESSED LATERAL CONDYLE FRACTURE
3237031|NCT00935870||B|BENIGN BONE TUMOR
3237032|NCT00935870||C|SPINAL FUSION
3237033|NCT00935857|Experimental|Balloon Colonoscopy|Colonoscopy using the single balloon colonoscopy system (novel endoscope to facilitate difficult colonoscopy).
3237034|NCT00935857|Active Comparator|Standard Colonoscopy|Colonoscopy using a standard adult colonoscope
3237035|NCT00935844|Experimental|TAK-901 Arm|
3237036|NCT00935831|Experimental|Subjects with renal impairment, non-dialysis|Subjects with moderate to severe renal impairment equivalent to National Kidney Foundation Kidney Disease Outcomes Quality Initiative stage 3 and stage 4 who are not undergoing dialysis will be included. Subjects will receive single 50 mg and 150 mg oral doses of GSK1278863A across two dosing periods in a single-blind, randomized sequence. Doses of GSK1278863A will be given as 25 mg and 100 mg tablets, with matching placebo tablets to maintain treatment blinding.
3237037|NCT00935831|Experimental|Healthy volunteers|Healthy subjects will be matched to the moderate and severe renally impaired subjects for gender, age, and BMI. Subjects will receive single 50 mg and 150 mg oral doses of GSK1278863A across two dosing periods in a single-blind, randomized sequence. Doses of GSK1278863A will be given as 25 mg and 100 mg tablets, with matching placebo tablets to maintain treatment blinding.
3237038|NCT00935831|Experimental|Hemodialysis dependent subjects|The arm will consist of subjects with severe renal impairment (end-stage renal failure) who have been on stable hemodialysis treatment scheduled three times per week. Subjects will receive single oral doses of 150 mg GSK1278863A in each of 2 dosing periods in an open-label, fixed sequence. GSK1278863A will be administered just prior to receiving scheduled hemodialysis in Dosing Period 1. In Dosing Period 2, subjects will receive a single oral dose of GSK1278863 the morning after completion of a scheduled hemodialysis session.
3237039|NCT00935818|Active Comparator|varenicline and buproprion SR|Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
3237040|NCT00935818|Placebo Comparator|varenicline and placebo|Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
3237041|NCT00935805||Treatment|124 patients attending the primary care unit included after formal consent.
3237042|NCT00935792|Experimental|Arm I|Patients receive oral everolimus thrice weekly for 9 weeks and alemtuzumab subcutaneously thrice weekly for 8 weeks.
3237043|NCT00935779||Gastric cancer|patients with operable local gastric adenocarcinoma were studied
3237044|NCT00935779||Control group|patients operated on for benign diseases served as controls, randomly selected among patients with chronic gastro-esophageal reflux disease who were considered good candidates for antireflux surgery and properly matched in sex and age to study group
3237045|NCT00935766|Placebo Comparator|Sugar Pill|4 tabs of placebo dependent on randomization
3237046|NCT00935766|Active Comparator|Omega 3|omega-3-acid ethyl esters and instructed to take 4 1 mg capsules daily
3237047|NCT00935753|Experimental|Kuvan|10mg/kg Kuvan for 5 days followed by 20mg/kg Kuvan for a total of 60 days
3237048|NCT00935740||Age-Matched Healthy Controls|Age-Matched Healthy Controls
3237049|NCT00935740||Heart Failure|Subjects with LVEF < 40%
3237050|NCT00935727|Other|1|normally functioning transplanted kidneys
3237051|NCT00935727|Other|2|transplanted kidney undergoing known rejection or other known abnormality
3237052|NCT00935727|Other|3|transplanted kidney with unknown diagnosis
3237053|NCT00935714|Active Comparator|Muscle Group|Exercise
3237054|NCT00935714|Active Comparator|Sequence|Exercise
3237055|NCT00935701|Experimental|Acupuncture and Acupressure|In Phase 1, 10 children with ASD will receive acupressure for four weeks. At week 5, they will be introduced to acupuncture which will be continued throughout the rest of the study as tolerated. In Phase 2, 40 children with ASD will receive acupressure twice weekly for 12 weeks. Parents will be trained in the acupressure techniques and will be asked to do this daily, at bedtime, and/or as requested by the child or deemed needed by the parent. Children will begin to be assessed for their ability to participate in acupuncture treatment between weeks 5 and 7 at the discretion of the acupuncturist. By week 7, all children will have been introduced to acupuncture/needling. If needling is still refused at this time, acupressure will continue for the remainder of the study.
3237056|NCT00935688|Experimental|Rapid diagnostic tests|malaria diagnosis by rapid diagnostic test
3237057|NCT00935688|No Intervention|Clinic Microscopy|malaria diagnosed with field light-microscopy
3237058|NCT00935688|No Intervention|Clinical Diagnosis|Malaria diagnosed on the basis of clinical symptoms alone (i.e. not laboratory diagnosis)
3237059|NCT00935675|Active Comparator|Antidepressant treatment|
3237060|NCT00935675|Placebo Comparator|Placebo|
3237061|NCT00935662|Experimental|AZD8329|AZD8329 oral solution
3237064|NCT00935649|No Intervention|Untreated Toe|
3237065|NCT00935623|Experimental|Cohort 1|The first cohort will be challenged with 5 bites from P. vivax-infected mosquitoes each carrying at least a grade 2 sporozoite infection (>10 sporozoites in salivary gland).
3237066|NCT00935623|Experimental|Cohort 2|If the first cohort has less than 100% infectivity rate, the second cohort will be challenged with up to 10 grade 2 infective bites to ensure 100% infectivity rate.
3237067|NCT00935610|Active Comparator|Immunocal|20g of Immunocal
3237068|NCT00935610|Placebo Comparator|Casein|20g of Casein
3237069|NCT00935597|Experimental|Group 1|Patients with Minimal Residual Disease or Minimal Volume Relapse post allogeneic stem cell transplant will receive MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) by infusion
3237070|NCT00935597|Experimental|Group 2|Patients with greater than Minimal Residual Disease or Minimal Volume Relapse post allogeneic stem cell transplant will receive MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) by infusion in conjunction with donor lymphocyte infusion (DLI)
3237071|NCT00935584|Other|PACE Study|"The study utilized a quasi-experimental pre-post intervention design. The intervention provided was physician education to improve EMR use and communication.~Physician training in patient-centered EMR use was developed. The conceptual model of patient-centered communication will provide the underlying framework for the training aimed at improving physicians interviewing and communication skills."
3237072|NCT00935571||Group I, Group II|"Group I: anesthetized with TIVA (Propofol + Remifentanil)~Group II: anesthetized with inhalation (sevoflurane)"
3237073|NCT00935558|Experimental|Aromatase inhibitor and DC vaccination|the HLA-A2 positive patients will be treated with AI, DC vaccines, Zadaxin and IL-2
3237074|NCT00935558|Active Comparator|Aromatase inhibitor|the HLA-A2 negative patients will receive AI only
3237075|NCT00935545|Experimental|Open Label|
3237076|NCT00935532|Experimental|exenatide once weekly|
3237077|NCT00935532|Active Comparator|insulin glargine|
3237078|NCT00935519|Other|ceramic bearing|Survival rate of THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 5 years follow-up.
3237079|NCT00935506|Experimental|Clopidogrel + Aspirin|
3237080|NCT00935493|Experimental|Guanfacine 0.1 mg po qhs|
3237081|NCT00935493|Experimental|Guanfacine 0.5 mg po qhs|
3237082|NCT00935493|Placebo Comparator|Placebo po qhs|
3237083|NCT00935480|Experimental|HAART+Raltegravir 12 months (+/-) Maraviroc|
3237084|NCT00935480|No Intervention|HAART|
3237085|NCT00935467|Other|Saxagliptin|
3237086|NCT00935441|Experimental|Telemonitoring|Case management with home telemonitoring for blood sugar and blood pressure plus home HbA1c measurement
3237087|NCT00935441|Active Comparator|Usual case management|Case management
3237088|NCT00935415|Active Comparator|Montelukast|capsules prepared in blindness
3237089|NCT00935415|Placebo Comparator|Placebo|matched placebo
3237090|NCT00935402|Experimental|Short Sleep|Subjects are permitted to spend 4 hours in bed per night for 5 consecutive nights. Subjects are inpatients for a period of 6 days.
3237091|NCT00935402|Active Comparator|Regular Sleep|Subjects are permitted to spend 9 hours in bed per night for 5 nights. Subjects are inpatients for a period of 6 days.
3237092|NCT00935389|Experimental|immunosuppressor|TW 30mg,q.d.*3 months and reduced into 20mg b.i.d
3237093|NCT00935376|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP)to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
3237094|NCT00935376|Experimental|Mindfulness Meditation Program|Mindfulness Meditation Program (MMP) is based on Mindfulness-Based Stress Reduction (MBSR), which teaches participants mindfulness skills such as meditation and yoga. Mindfulness may be defined as paying attention in a particular way, on purpose, in the present moment, and nonjudgmentally. The goal of MBSR is to provide participants with experiential tools and mindfulness practices to assist them to become more mindful of themselves, others and their external environment. The techniques are easy to learn and teach individuals to be aware of the present moment, with an open mind in which they can perceive their thoughts, physical sensations, and emotions nonjudgmentally.
3237095|NCT00935376|Active Comparator|Sleep Education Program|The Sleep Education Program (SEP) will serve as the control intervention in which participants will receive classes informing them how to change their habits to improve their sleep, and what to do if they have concerns about their sleep quality.
3237096|NCT00935363|Experimental|glyburide + fluconazole|
3237097|NCT00935363|Experimental|glyburide + rifampin|
3237098|NCT00935363|Active Comparator|glyburide|
3237099|NCT00935363|Experimental|glyburide + fluconazole + rifampin|
3237100|NCT00935350|Placebo Comparator|1|Control White bread containing 50g available carbohydrate
3237101|NCT00935350|Placebo Comparator|2|White bread and milk control
3237102|NCT00935350|Placebo Comparator|3|Granola control
3237103|NCT00935350|Placebo Comparator|4|Cornflakes and milk control
3237104|NCT00935350|Placebo Comparator|5|White rice control
3237105|NCT00935350|Placebo Comparator|6|Fruit yogurt control
3237106|NCT00935350|Placebo Comparator|7|Turkey dinner control
3237107|NCT00935350|Experimental|8|Granola
3237108|NCT00935350|Experimental|9|Cornflakes and milk
3237109|NCT00935350|Experimental|10|White Rice
3237110|NCT00935350|Experimental|11|Fruit yogurt
3237111|NCT00935350|Experimental|12|Turkey dinner
3237112|NCT00935350|Placebo Comparator|13|White Bread
3237113|NCT00935350|Placebo Comparator|14|White bread
3237114|NCT00935350|Experimental|15|Granola
3237115|NCT00935337|Experimental|Mind-Body Bridging Program|Mind Body Bridging subjects will be accessed with questionnaires and medical history evaluations for the impact of MBBP over the past 6 months since undertaking the program.
3237116|NCT00935337|Active Comparator|Sleep Hygiene|Sleep Hygiene subjects will be accessed with questionnaires and medical history evaluations for the impact of SH over the past 6 months since undertaking the program.
3237117|NCT00935324||Group A: patients following allo-SCT|Patients scheduled for allo-SCT fulfilling all inclusion criteria
3237118|NCT00935324||Group B - healthy controls|healthy voluntary blood donors
3237119|NCT00935311|Experimental|ABT-712|1 dose of 1 ABT-712 extended-release tablet plus 1 placebo tablet, followed by 1 dose of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
3237120|NCT00935311|Active Comparator|Hydrocodone/Acetaminophen|2 doses of 1 hydrocodone/acetaminophen immediate-release tablet plus 1 placebo tablet, administered once every 6 hours for 12 hours (for a total of 2 doses).
3237121|NCT00935311|Placebo Comparator|Placebo|2 doses of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
3237122|NCT00935298|Experimental|T|"The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation.After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5*1/*3 and *1/*1 ,expressors; CYP3A5*3/*3 nonexpressor）.~The objective is to determine the initial dosage Range of tacrolimus in Chinese renal transplantation patients by genotyping of the cytochrome P450 3A5"
3237123|NCT00935272|Experimental|Treatment|Restylane® Treatment
3237124|NCT00935272|No Intervention|Non-Treatment|Non-Treatment Arm
3237125|NCT00935259|Experimental|Simvastatin 40 mg first, then placebo|Simvastatin 40 mg tablets once daily for 2 weeks followed by placebo for 2 weeks
3237126|NCT00935259|Placebo Comparator|Placebo first, then simvastatin 40 mg once daily|Placebo for 2 weeks followed by simvastatin 40 mg once daily for 2 weeks
3237127|NCT00935246|Experimental|Antidepressant treated group|Antidepressant treated group: depressed patients treated with Escitalopram
3237128|NCT00935246|No Intervention|other antidepressant treated group|other Antidepressant treated group: depressed patients treated with other antidepressant without escitalopram
3237129|NCT00935220|Experimental|linagliptin|Pharmacokinetic (PK)/Pharmacodynamic (PD) investigation
3237130|NCT00935207||Pediatric Pain Diary|Patients will be give a pain diary to complete.
3237131|NCT00935194|Experimental|blank|do not take antiviral therapy
3237132|NCT00935194|Experimental|Oseltamivir|antiviral therapy
3237133|NCT00935194|Experimental|chinese medicinary herbs|antiviral therapy
3237134|NCT00935194|Experimental|oseltalmivir and chinese medicinal herbs|combination antiviral therapy
3237135|NCT00935181|Experimental|exercise training program|The exercise training program consisted of three 90-minute sessions per week for eight weeks. Each session consisted of a stretching exercise, resistance that patients started at 70% of the initial one-repetition maximum (1RM: the maximum load which can be moved only once over the full range of motion without compensatory movements) in the first week (3x8 repetitions). Every week the load was increased by 5% of the 1RM, and endurance training (treadmill walking speed was set at 60% of the average speed obtained from the 6MWT (6MWTpeak) for 10 mins in the first week and was increased to 20 mins in week 8
3237136|NCT00935168|Experimental|Hydroxy-ethyl starch|Intravenous fluid resuscitation with 6% Hydroxy-ethyl starch (130/0.4)
3237137|NCT00935168|Active Comparator|Saline|Intravenous fluid resuscitation with saline (0.9% sodium chloride)
3237138|NCT00935155|Experimental|Acupuncture|Acupuncture in combination with exercise therapy
3237139|NCT00935155|Active Comparator|exercises|Coordination, mobilizing, endurance, strength
3237140|NCT00935129|Experimental|OmniPod system|At this arm patients will be treated with the OmniPod system for 12 weeks
3237141|NCT00935129|Active Comparator|patient's conventional pump|At this arm patients will be treated with their conventional pump for 12 weeks
3237142|NCT00935116|Active Comparator|etoricoxib|"G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery"
3237143|NCT00935103|Active Comparator|Psychoeducation|Psycheducation
3237144|NCT00935103|No Intervention|Control|
3237145|NCT00935090|Experimental|3'-deoxy-3'-[18F]fluorothymidine|The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body.
3237146|NCT00935077|Experimental|24 Month PPCM BP|A 24 month long physician/pharmacist collaborative intervention is implemented to manage hypertension
3237147|NCT00935077|Experimental|9 Month PPCM BP|A 9 month long physician/pharmacist collaborative intervention is implemented to manage hypertension
3237148|NCT00935077|Sham Comparator|PPCM Asthma|A 9 month long physician/pharmacist collaborative intervention is implemented to manage asthma
3237149|NCT00935077|No Intervention|BP Control Arm|No PPCM intervention
3237150|NCT00935064|Active Comparator|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
3237151|NCT00935064|Placebo Comparator|Placebo|
3237152|NCT00935051|Experimental|Arm 1|There is only one group of patients. Thus there is only one arm. Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. A numeric photograph of the wound will be taken at week 0, week 4 and week 12.
3237153|NCT00935025|Experimental|1, AZD1305|
3237154|NCT00935025|Placebo Comparator|2, Placebo|
3237155|NCT00935012|Experimental|Open-Label|
3237156|NCT00934999|Active Comparator|Burch|Patients will receive a Burch urethropexy at the time of an abdominal sacral colpopexy.
3237157|NCT00934999|Experimental|Mid-urethral sling|Patients will receive a mid-urethral sling at the time of an abdominal sacral colpopexy.
3237158|NCT00934973|Active Comparator|mebeverine + no website|Mebeverine 135mg tds for 6 weeks
3237159|NCT00934973|Active Comparator|methylcellulose + no website|methylcellulose 3 tablets twice a day for 6 weeks
3237160|NCT00934973|Placebo Comparator|placebo + no website|placebo tablets
3237161|NCT00934973|Active Comparator|mebeverine + CBT website minimal support|mebeverine 135mg tds and access to website
3237162|NCT00934973|Active Comparator|methylcellulose + CBT website|methylellulose 3 tablets twice a day and access to website
3237163|NCT00934973|Placebo Comparator|placebo + CBT website minimal support|placebo tablets and access to website
3237164|NCT00934973|Active Comparator|mebeverine + CBT website with support|mebeverine 135mg tds and access to website with nurse support session
3237165|NCT00934973|Active Comparator|methylcellulose + CBT website support|methylcellulose 3 tablets twice a day and access to website with nurse support
3237166|NCT00934973|Placebo Comparator|placebo + CBT website with support|placebo tablets and access to website with nurse support
3237167|NCT00934947|Placebo Comparator|Sugar pill|
3237168|NCT00934947|Experimental|Propranolol, Propanolol ER|
3237169|NCT00934934|Placebo Comparator|Placebo|Saline will serve as the placebo solution since the active comparator is clear and colourless.
3237170|NCT00934934|Active Comparator|Antifungal|Patient will receive a dose daily for a total of 14 days
3237171|NCT00934921|Experimental|Ondansetron|Ondansetron HCl 8 mg Orally Disintegrating Tablet (test) dosed in first period followed by Zofran® 8 mg ODT (reference) dosed in second period
3237172|NCT00934921|Active Comparator|Zofran®|Zofran® 8 mg ODT (reference) dosed in first period followed by Ondansetron HCl 8 mg Orally Disintegrating Tablet (test) dosed in second period
3237173|NCT00934908|Placebo Comparator|1|"Non-active sugar pill"
3237174|NCT00934908|Active Comparator|2|Green Tea Capsules
3237175|NCT00934895|Experimental|Phase I / Phase II|"Phase I:~Abraxane will be given by IV for 30 minutes on the first day of the first three weeks of each 28 day cycle.~RAD001 will be given by tablet. The first group of patients will receive RAD001 once daily depending on side effects seen drug could be increased later to twice a day for a 28 day cycle.~Once a safe and effective drug range is established, the study moves into Phase II.~Phase II:~The maximum tolerated dose (established in Phase I) will be given as scheduled below and we will measure the effectiveness of the study drug combination.~Abraxane will be given by IV (intravenous infusion) for 30 minutes on the first day of the first three weeks of each 28 day cycle (Day 1, Day 8, and Day 15 of each cycle).~RAD001 will be given by tablet based on the dose established in the Phase I part of the study."
3237176|NCT00934882|Experimental|Arm 1|
3237177|NCT00934869||Metacarpal Shaft Fractures|
3237178|NCT00934856|Experimental|MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (over 2 days)|Participants with human epidermal growth factor receptor 2 (HER2)-positive MBC will receive docetaxel (Doc) 75 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Day 1 and T-DM1 2.4 milligrams per kilogram (mg/kg) IV infusion on Day 2 of Cycle 1 followed by T-DM1 75 mg/m^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 75 mg/m^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
3237179|NCT00934856|Experimental|MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (over 2 days)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m^2 IV infusion on Day 1 and T-DM1 2.4 mg/kg IV infusion on Day 2 of Cycle 1 followed by T-DM1 60 mg/m^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
3237180|NCT00934856|Experimental|MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (same day)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m^2 IV infusion and T-DM1 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
3237181|NCT00934856|Experimental|MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (same day)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m^2 IV infusion and T-DM1 3.6 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 will be stopped and T-DM1 3.6 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
3237182|NCT00934856|Experimental|LABC: T-DM1 + Doc (Doublet Regimen)|Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg IV infusion and docetaxel 60/75/100 mg/m^2 IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.
3237183|NCT00934856|Experimental|LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)|Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg Iv infusion, docetaxel 60/75 mg/m^2 IV infusion, and pertuzumab 840 mg (for Cycle 1) or 420 mg (for remaining cycles) IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.
3237184|NCT00934843|Experimental|Single dose steroid|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB) machine in the first month of life that receive ONE dose intravenous methylprednisolone (IVMP) prior to heart surgery.
3237185|NCT00934843|Experimental|Two Dose steroid|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB) machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
3237186|NCT00934830|Active Comparator|Antibiotic|
3237187|NCT00934830|Experimental|Therapeutic ultrasound|
3237188|NCT00934817|Experimental|TR sequential group|Amaryl-M 1/500 mg in period 1, Amaryl-M 2/500 mg in period 2
3237189|NCT00934817|Active Comparator|RT sequential group|Amaryl-M 2/500 mg in period 1, Amaryl-M 1/500 mg in period 2
3237190|NCT00934804|Experimental|Comparative Diagnostic system|Galilei dual Scheimpflug analyzer
3237191|NCT00934791|Active Comparator|Control Group|Tacrolimus, mycophenolate mofetil, and prednisone
3237192|NCT00934791|Active Comparator|Sirolimus Group|Sirolimus, mycophenolate mofetil, and prednisone
3237193|NCT00934778|Experimental|Bronchoscopy|
3237194|NCT00934752|Experimental|Lutonix Catheter|
3237195|NCT00934739|No Intervention|Control|Standard postoperative concurrent chemoradiotherapy
3237196|NCT00934739|Experimental|Thalidomide, Celebrex|Adjuvant anti-angiogenesis therapy
3237197|NCT00934739|Active Comparator|Cyclophosphamide, Dexamethasone|Adjuvant anti-angiogenesis therapy
3237198|NCT00934726||1 group, schizophrenia patients|Patients with schizophrenia according to ICD-10(diagnostic and statistical manual of mental disorders)
3237199|NCT00934713|Active Comparator|montelukast|montelukast 4 mg once per day for 8 weeks
3237200|NCT00934700|Experimental|Combination of hypothermia and xenon|Combination of hypothermia and inhaled xenon
3237201|NCT00934700|No Intervention|Hypothermia and standard intensive care|Hypothermia and standard intensive care
3237202|NCT00934687|Experimental|clostridium botulinum toxin type A neurotoxin complex|A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.
3237203|NCT00934687|Placebo Comparator|0.9% sodium chloride NaCl solution|0.9% NaCl solution will be injected like the experimental compound
3237204|NCT00934674|Experimental|1|Commercial Tablet manufactured by Excella
3237205|NCT00934674|Experimental|2|Clinical Tablet manufactured by Wyeth Montreal
3237206|NCT00934661|Experimental|Extended Release Epidural Morphine|Four mg (0.4 ml) of EREM will be delivered to the epidural space and flushed with 1 ml of saline
3237207|NCT00934661|Placebo Comparator|Placebo Group|The epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
3237208|NCT00934648|Experimental|1|
3237209|NCT00934635|Active Comparator|002|Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 2 hours
3237210|NCT00934635|Active Comparator|003|Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 2 hours
3237211|NCT00934635|Active Comparator|004|Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 2 hours
3237212|NCT00934635|Active Comparator|005|Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 24 hours
3237213|NCT00934635|Active Comparator|006|Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 24 hours
3237214|NCT00934635|Active Comparator|007|Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 24 hours
3237215|NCT00934635|Active Comparator|008|Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 24 hours
3237216|NCT00934635|Other|009|PET Scan PET Scan
3237217|NCT00934635|Active Comparator|001|Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 2 hours
3237218|NCT00934622|Experimental|AcrySof® ReSTOR® Aspheric IOL|AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL)
3237219|NCT00934609|Experimental|Training|12 weeks of endurance training on the cycle ergometer under supervision on a physician
3237220|NCT00934609|No Intervention|Control|Control condition
3237221|NCT00934596|Experimental|Lund de-airing|Lund de-airing technique
3237222|NCT00934596|Active Comparator|Carbon-dioxide insufflation|carbon-dioxide insufflation will be provided to the open mediastinal wound in a standardized manner
3237223|NCT00934583|Experimental|Image and Mood (IaM) program|Participants will participate in the IaM program.
3237224|NCT00934583|No Intervention|Wait-list control|Participants will be placed on a wait list until after participants in the IaM group have completed all assessments. After that, these participants will be offered the option to complete the IaM program.
3237225|NCT00934570|Active Comparator|Metformin, Standard exercise|Lifestyle intervention with metformin and standard exercise program.
3237226|NCT00934570|Placebo Comparator|Placebo, Standard exercise|Lifestyle intervention with placebo and standard exercise program
3237227|NCT00934570|Active Comparator|Metformin, Intensive exercise|Lifestyle intervention with metformin and intensive exercise
3237228|NCT00934570|Placebo Comparator|Placebo, Intensive exercise|Lifestyle intervention with placebo and intensive exercise program.
3237229|NCT00934557|Experimental|Good prognosis/mismatched donor/BM|
3237230|NCT00934557|Experimental|Good prognosis/mismatched donor/PB|
3237231|NCT00934557|Experimental|Poor prognosis/matched donor/BM|
3237232|NCT00934557|Experimental|Poor prognosis/matched donor/PB|
3237233|NCT00934557|Experimental|Poor prognosis/mismatched donor/BM|
3237234|NCT00934557|Experimental|Poor prognosis/mismatched donor/PB|
3237235|NCT00934557|Experimental|Good prognosis/matched donor/BM|
3237236|NCT00934557|Experimental|Good prognosis/matched donor/PB|
3237237|NCT00934544|Experimental|INC424/INCB018424|Starting dose of 15 mg BID or 20 mg BID were selected with starting dose based on baseline platelet count. Dose titration ranging from 5 mg BID to a maximum dose of 25 mg BID was permitted during the study based on safety and efficacy. Tablets were to be taken 12 hours apart. Administration instructions were provided at study visits.
3237238|NCT00934544|Active Comparator|Best Available Therapy (BAT)|Best-available Investigator-selected therapy included a combination of available agents to treat the disease and/or its symptoms, and was selected by the investigator for each subject. Therapy changed at different times during the treatment phase. No experimental agents (e.g. those not approved for the treatment of any indication) were allowed. BAT also included the option of no treatment.
3237239|NCT00934531|Experimental|Donepezil|participants with MCI receiving donepezil
3237240|NCT00934531|Placebo Comparator|Placebo|Participants with MCI receiving placebo
3237241|NCT00934518|Experimental|Radiation and Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
3237242|NCT00934492|Active Comparator|Cotrimoxazole dispersible tablet|Children between 2-6 months will receive single dispersible tablet of 120mg,daily while children over 6 months to 5 years will receive 240 mg dispersible tablet daily for six months.
3237243|NCT00934492|Placebo Comparator|Placebo dispersible tablet|Children between 2-6 months will receive single dispersible Placebo tablet of 120mg,daily while children over 6 months to 5 years will receive 240 mg dispersible Placebo tablet daily for six months.
3237244|NCT00934479|No Intervention|Healthy Subjects|Healthy subjects completed a baseline 1-week diary of stool and defecatory characteristics, fasting breath for hydrogen and methane and a stool sample for pyrosequencing. Otherwise, the healthy subjects received no intervention.
3237286|NCT00934180|Active Comparator|Zofran®|Zofran® 8 mg ODT (reference) dosed in first period followed by Ondansetron HCl 8 mg OD Tablet (test) dosed in second period
3237287|NCT00934167|Experimental|Test|Hipolabor
3237288|NCT00934167|Active Comparator|Comparator|5.000 USP/mL - APP
3237289|NCT00934154|Experimental|Thalidomide|MPT
3237290|NCT00934154|Active Comparator|Control|MP
3237417|NCT00933101||HgbA1c <8|Adolescents with HgbA1c < or equal to 8% for the previous 12 months
3237245|NCT00934479|Experimental|Constipated Subjects|"Subjects with constipation included those with chronic constipation (CC) and those with constipation predominant irritable bowel syndrome (C-IBS). They completed a baseline 1-week diary of stool and defecatory characteristics, fasting breath for hydrogen and methane and a stool sample for pyrosequencing.~Following baseline test and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.~Following the 4-weeks treatment with lubiprostone, they completed another stool diary, fasting breath test, and stool sample for pyrosequencing."
3237246|NCT00934466|Experimental|1|MK2637 120 mg
3237247|NCT00934466|Experimental|2|MK2637 50 mg
3237248|NCT00934466|Placebo Comparator|3|Placebo
3237249|NCT00934466|Active Comparator|4|Dextromethorphan 220 mg
3237250|NCT00934466|Active Comparator|5|Dextromethorphan 110 mg
3237251|NCT00934453|Experimental|LGG|Lactobacillus rhamnosus GG (LGG) capsules containing 1x10^10 LGG per capsule will be given to volunteers with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis.
3237252|NCT00934453|Placebo Comparator|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis.
3237253|NCT00934440|Experimental|Dose Escalation: 5-azacitidine|A traditional 3+3 dose escalation trial was implemented. Successive cohorts of patients (3 participants/cohort) received bevacizumab at the standard dose of 10mg/kg in combination with escalating doses of 5-azacitidine. If no dose limiting toxicity (DLT) is seen, subsequent patients will be treated at the next dose level. If one DLT is seen, an additional three patients will be accrued at that dose level. If two or more DLTs are seen at one dose level, then the previous dose level will be chosen for phase IIA. If two DLT's are seen at dose level 1, the trial will end. The standard 5-azacitidine dose is 75mg/m2/day for 7 days. If no DLT is seen at dose level 3, then we will proceed with the phase IIA portion of the study.
3237254|NCT00934427|Active Comparator|Vascana|
3237255|NCT00934427|Placebo Comparator|Vehicle|
3237256|NCT00934414|Experimental|Smokers|
3237257|NCT00934414|Experimental|Non-Smokers|
3237258|NCT00934388|Experimental|Mesh placed in pre peritoneal plane|
3237259|NCT00934388|Active Comparator|No mesh placed|
3237260|NCT00934375|Experimental|1|
3237261|NCT00934375|Placebo Comparator|2|
3237262|NCT00934362|Other|Lucinactant first, then placebo|Active treatment first, then washout period, then placebo treatment
3237263|NCT00934362|Other|Placebo treatment first, then lucinactant treatment|0.9% NaCl vehicle treatment first, then washout period, then lucinactant treatment
3237264|NCT00934349||Patient|Native to the Comoro Archipelago (Grande Comore, Mayotte, Anjouan, Mohéli) fulfilling the clinical definition of the dry beriberi.
3237265|NCT00934349||Control|Native to the Comoro Archipelago, living in the same household as the patient, sharing the same meals. Free from beriberi and with normal neurological examination.
3237266|NCT00934336|Experimental|preprandial injection|pre-prandial injection of an ultra-fast-acting analog during 3 months, then post-prandial injection of an ultra-fast-acting analog during 3 other months.
3237267|NCT00934336|Experimental|post-prandial injection|post-prandial injection of an ultra-fast-acting analog during 3 months then pre-prandial injection of an ultra-fast-acting analog during 3 other months.
3237268|NCT00934323|Experimental|TR sequential group|Amaryl M SR 1/500 mg in period 1 and Amaryl M SR 2/500 mg in period 2
3237269|NCT00934323|Active Comparator|RT sequential group|Amaryl M SR 2/500 mg in period 1 and Amaryl M SR 1/500 mg in period 2
3237270|NCT00934310||Ambulatory Surgical Patients 1|"The nature of the operating room time out for ambulatory surgical patients will be examined before implementation of the World Health Organization's Surgical Safety Checklist."
3237271|NCT00934310||Ambulatory Surgical Patients 2|"The nature of the operating room time out for ambulatory surgical patients will be examined after implementation of the World Health Organization's Surgical Safety Checklist.Ambulatory surgical patients"
3237272|NCT00934297||Pilot group|Real-time US imaging with simultaneous display of dynamically corresponding MR images (from a previous MRI screening) will be used to re-locate the lesion previously reported as occult under a second-look ultrasound screening.
3237273|NCT00934284|Active Comparator|Injection only|Participants receive a therapeutic selective nerve root block and advice to return to normal activity as tolerated.
3237274|NCT00934284|Experimental|Injection plus physical therapy|Participants are referred to physical therapy within one week of receiving a therapeutic selective nerve root block. Physical therapy consists of end-range movements in a directional preference and/or mechanical traction to reduce radicular symptoms.
3237275|NCT00934271||Fractionated stereotactic radiotherapy|patients with active acromegaly
3237276|NCT00934245|Active Comparator|Inactivated Polio Vaccine (IPV)|Inactivated trivalent poliovirus vaccine (IPV) age Dose # doses/year 1 # doses year 2 and 3 6 mo -8y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
3237277|NCT00934245|Experimental|Inactivated Trivalent Influenza Vaccine|Inactivated split virion trivalent influenza vaccine (TIV) age Dose # doses year 1 # doses year 2 and 3 6-35 mo 0.25 ml 2 1 3-8 y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
3237278|NCT00934245|No Intervention|Surveillance arm|Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members.
3237279|NCT00934232|Experimental|Busulfan|Busulfex given to patients who are either ≥65 years or have renal insufficiency
3237280|NCT00934219|Active Comparator|High dose Lovaza|Lovaza 4 g twice a day, if not effective then 4 g 3 times a day
3237281|NCT00934219|Active Comparator|Standard Dose|2 g twice a day
3237282|NCT00934206|Experimental|Training|One month of endurance training (running / walking at 60 % heart rate reserve for 45 min 4 times per week)
3237283|NCT00934193|Active Comparator|Gabapentin|
3237284|NCT00934193|Placebo Comparator|Placebo|
3237285|NCT00934180|Experimental|Ondansetron|Ondansetron HCl 8 mg OD Tablet (test) dosed in first period followed by Zofran® 8 mg ODT (reference) dosed in second period
3237418|NCT00933101||HgbA1c >10|Adolescents with HgbA1c > or equal to 10% for previous 12 months
3237291|NCT00934141|Experimental|Interest Circle Call + Website|Interest Circles are monthly teleconferences where agency change leaders discuss change-related issues and progress. Circles address how to improve timeliness, continuation, admissions, dropouts and transitions. They also address specialty topics (e.g., programs for women, adolescents). Participants discuss successes, failures, and challenges, and get advice and assignments for their improvement plans. Meeting summaries appear on the Web site. Interest Circles are inexpensive, but are they are sufficient? Should Interest Circles prove effective, they would provide a low-cost, convenient diffusion approach.
3237292|NCT00934141|Experimental|Coaching + Website|Coaching assigns an expert in process improvement to work with an agency to make, sustain, and spread process improvement efforts. Consultations focus on executive directors, change leaders and improvement teams. Coaches help agencies address key issues, but also broker relationships with other agencies, offer process improvement training, and promote the innovations to make and how to make them. Coaching takes place during site visits, monthly phone conferences, and via email.
3237293|NCT00934141|Experimental|Full: LS, Coaching, ICC, Website|Learning Session, Coaching, Interest Circle Calls, Website, see descriptions above
3237294|NCT00934141|Experimental|Learning Session + Website|Learning Sessions occur bi-annually as change teams convene to learn and gather support from each other and outside experts who offer advice on how best to adopt the innovations and learn about new directions for the collaborative (e.g., the need to create business cases for improvements). Learning Sessions and Interest Circles (see below) have similar objectives—to help agencies learn and gather support from each other and from outside experts.
3237295|NCT00934128|Experimental|Group 1: BiPAP then Vapotherm|Bilevel positive airway pressure device (BiPAP) then Vapotherm air delivery.
3237296|NCT00934128|Experimental|Group 2: Vapotherm then BiPAP|Vapotherm air delivery then BiPAP.
3237297|NCT00934102|Active Comparator|Lotrafilcon A|Lotrafilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
3237298|NCT00934102|Active Comparator|Narafilcon A|Narafilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
3237299|NCT00934102|Active Comparator|Galyfilcon A|Galyfilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
3237300|NCT00934089|Experimental|PF-04217329 + placebo|Active study drug + latanoprost vehicle
3237301|NCT00934089|Experimental|PF-04217329 + latanoprost|Active study drug + latanoprost
3237302|NCT00934076|Experimental|AT-101 plus Erlotinib|"Subjects will begin study treatment at 150 mg of erlotinib taken once daily in a continuous regimen expressed in 3 week cycles.~Subjects will begin treatment with oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis."
3237303|NCT00934063||A|
3237304|NCT00934063||B|
3237305|NCT00934050|Experimental|ELND005|
3237306|NCT00934037|Other|Combined CT Angiography and Myocardial Perfusion|Single Arm study. All patients underwent combined CT Angiography and Myocardial Perfusion.
3237307|NCT00934011|Experimental|Group 1 - C-reactive protein (CRP) guided ab therapy|Intervention on antibiotic therapy will be based on circulating CRP levels
3237308|NCT00934011|Active Comparator|Group 2 - procalcitonin (PCT) guided ab therapy|Intervention on antibiotic therapy will be based on circulating PCT levels
3237309|NCT00933998|Experimental|Metanx|Metanx bid for 2 weeks then daily. Compare to non treated patient population
3237310|NCT00933985|Experimental|Treatment (obatoclax, vincristine, doxorubicin, dexrazoxane)|"STRATUM 1 (dose-escalation): Patients receive obatoclax mesylate IV over 3 hours on days 1 and 8 and vincristine sulfate IV, doxorubicin hydrochloride IV, and dexrazoxane hydrochloride IV on day 8 of course 1 (28 days). Drugs are administered on day 1 of subsequent courses and repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.~STRATUM 2: Patients receive obatoclax mesylate (at starting dose in stratum 1), vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride as in stratum 1.~STRATUM 3: Patients receive obatoclax mesylate (at the MTD determined in stratum 1), vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride as in stratum 1."
3237311|NCT00933972|Experimental|1 (normal)|
3237312|NCT00933972|Experimental|2 (mild)|
3237313|NCT00933972|Experimental|3 (moderate)|
3237314|NCT00933972|Experimental|4 (severe)|
3237315|NCT00933959|Experimental|Mind-Body Bridging Program|"Subjects will undergo two approximately 1.5 hr training sessions using MBBP spaced one week apart at the VASLCHCS. Each training session will comprise a number of objectives:~Session 1:~The patient will discover the underlying cause of the insomnia.~The patient will learn how to use easy to apply tools to quieten the mind to sleep soundly.~Session 2:~The patient will learn how to reduce daytime stress.~The patient will experience a greater sense of self.~To be maximally effective, the participant should master these objectives and practice MBBP on a daily basis. Bridging and all the other MBBP techniques can be implemented at any time throughout the day and right up to the onset of sleep."
3237316|NCT00933959|Active Comparator|Sleep Hygiene|Participants in the sleep hygiene arm will receive a 1 hr class directing them to the importance of following a list of up to 15 points (tips) for getting to sleep. These points include: limiting alcohol and caffeine intake before bed, using the bed only for sleeping, and having regular bedtimes. Once the instructor has gone over this list and has described in detail each of the 15 points, the class will have an opportunity to ask questions. The participant will be encouraged to learn and practice the objectives of the sleep hygiene class on a daily basis.
3237317|NCT00933946|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
3237318|NCT00933933|Experimental|ARCHITECT HIV Ag/Ab Combo Specificity|Specimens collected from normal apparently healthy individuals at low risk for HIV infection will be tested by the investigational HIV test and FDA-licensed HIV test.
3237319|NCT00933933|No Intervention|ARCHITECT HIV Ag/Ab Combo Sensitivity|Specimen with confirmed positive HIV Antigen, HIV-1 antibody, or HIV-2 antibody will be tested by the investigational HIV test.
3237320|NCT00933933|Experimental|ARCHITECT HIV Ag/Ab Combo Reactivity|Specimen collected from individuals at risk for HIV infection will be tested by the investigational HIV test.
3237321|NCT00933920|Active Comparator|Fed Group|
3237322|NCT00933920|Active Comparator|Fasted group|
3237452|NCT00932867||Group 1|
3237323|NCT00933907|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Dermacyd PH_DESILSTY_FR (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
3237324|NCT00933881||Gestational Diabetes Mellitus (GDM)|
3237325|NCT00933868|Experimental|Magnesium infusion in patients breathing 100% oxygen|Patients will be given six infusions over three weeks. Each infusion will last between 4 and 10 minutes. They will then return to clinic in 1,2 and 3 months for the same tests (but no infusions will be given).
3237326|NCT00933868|Placebo Comparator|Placebo infusion|The patients will receive six placebo infusions after which they will return to clinic at one, two and three months. At the conclusion of the trial those patients who received placebo may elect to receive the active treatment in another (open label) trial that will begin shortly after this one concludes.
3237327|NCT00933855||communication training workshop|"The patient intervention is a 1 hour communication workshop entitled: Getting the Most out of your Doctor's Visit. The workshops will be offered to both patients and family members, but data will be collected only for patients. The workshops will be held on location at Queens Cancer Center."
3237328|NCT00933842|Experimental|Dermacyd PH_DESILSTY_FL (Lactic Acid)|Dermacyd PH_DESILSTY_FL (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample
3237329|NCT00933829|No Intervention|Non-absorbable arm|uses non-absorbable suture such as Prolene to repair lacerations
3237330|NCT00933829|Active Comparator|Absorbable Suture Arm|uses absorbable sutures to repair lacerations
3237331|NCT00933816|Experimental|Sorafenib with Low-dose FP|
3237332|NCT00933790|Active Comparator|2EHRZ3/4HR3|Regimen 3. Intermittent - 2EHRZ3/4HR3 (E 1200mg, H 600 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg given thrice weekly)
3237333|NCT00933790|Experimental|2EHRZ7/4HR7|Regimen 1. Daily - 2EHRZ7/4HR7 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg daily)
3237334|NCT00933790|Experimental|2EHRZ7/4HR3|Regimen 2. Part Daily - 2EHRZ7/4HR3 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg daily in the intensive phase followed by H-600 mg ,R-450/600 mg in the continuation phase thrice weekly)
3237335|NCT00933777|Experimental|Therapy with everolimus and sorafenib|Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg
3237336|NCT00933751||Patients before emergent major abdominal surgery|
3237337|NCT00933725|Experimental|TCM intervention|Particle of compound Chinese herbs and TCM emotion treatment and tablet placebo of Tibolone
3237338|NCT00933725|Active Comparator|Western intervention|Tibolone and supportive psychotherapy and Particle placebo of compound Chinese herbs
3237339|NCT00933712|Experimental|Dermacyd Silver Floral (Lactic Acid)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
3237340|NCT00933699|Experimental|Dermacyd PH_DESILSTY_FL (Lactic Acid)|Treatment duration: 21 consecutive days
3237341|NCT00933686|Active Comparator|Saizen®|
3237342|NCT00933686|Active Comparator|Placebo + Saizen®|
3237343|NCT00933673|Experimental|L-DICE|
3237344|NCT00933660|Active Comparator|Control-1|ERC-training by instructor
3237345|NCT00933660|No Intervention|Control-2|No intervention
3237346|NCT00933660|Experimental|Experimental-1|Web-based training only
3237347|NCT00933660|Experimental|Experimental-2|Web-based training with a personal training manikin
3237348|NCT00933647|Experimental|Yerba Mate Tea|Subjects will drink 1000ml/day of yerba mate tea for 8 weeks.
3237349|NCT00933647|Active Comparator|Green Tea|Subjects will drink 1000ml/day of green tea for 8 weeks.
3237350|NCT00933647|Placebo Comparator|Apple Tea|Subjects will drink 1000ml/day of apple tea for 8 weeks.
3237351|NCT00933634|Experimental|electrical cardioversion|Patients were sedated with propofol and external cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula). Patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
3237352|NCT00933634|Active Comparator|propafenone|Propafenone (2 mg/kg bolus) was administered iv to obtain pharmacologic sinus rhythm conversion.
3237353|NCT00933621|Experimental|Autologous Bone Marrow infusion|Percutaneous intracoronary autologous bone marrow infusion
3237354|NCT00933608|Experimental|memantine|after a period of gradual dose increase from 5 mg/day, participants will be asked to take memantine (20mg/day) for 16 weeks 10 mg in the morning, 10 mg at night
3237355|NCT00933608|Placebo Comparator|Placebo|dose increase to match active drug, after that 1 tablet in the morning, 1 tablet at night, to match active drug
3237356|NCT00933595|Experimental|Smoking Cessation|The overall smoking cessation rate for the intervention is 18.8 at 3 months, 13.1 at 6 months and 10.0 at 12 months.
3237357|NCT00933569|Experimental|Dermacyd Silver Floral (Lactic Acid)|Aplication of Dermacyd Silver Floral (Lactic Acid) during 21 consecutive days
3237358|NCT00933556|Experimental|probiotic|subjects will be given a powder formulation of a probiotic VSL#3 to be taken once a day, at a dose of 6 gms
3237359|NCT00933556|Placebo Comparator|sugar pill|placebo identical to the active product will be given
3237360|NCT00933543|Experimental|Visonac cream with PDT|Active treatment, Light dose 37 J/cm2.
3237361|NCT00933543|Placebo Comparator|Vehicle cream with PDT|Placebo treatment, Light dose 37 J/cm2.
3237373|NCT00933465|Experimental|tablets first followed by syrup|first 6 weeks of study using tablets, then followed by assessment, and then the next 6 weeks using syrup, followed by assessment
3237374|NCT00933465|Experimental|Syrup first followed by tablets|first 6 weeks of study using syrup, then followed by assessment, and then the next 6 weeks using tablets, followed by assessment
3237375|NCT00933452|Experimental|low dose group|single oral administer 15mg duloxetine
3237376|NCT00933452|Experimental|moderate dose group/multiple dose group|single oral duloxetine 30mg, after that repeat 7 oral duloxetine 30mg/d
3237377|NCT00933452|Experimental|high dose group/crossover group|single oral duloxetine 60mg, after that single oral innovator duloxetine 60mg
3237378|NCT00933439|Experimental|Duloxetine|
3237362|NCT00933530|Experimental|Cohort 1 - Dose Level A (0.03g/day)|"0.03g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.03g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.03g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
3237363|NCT00933530|Experimental|Cohort 2 - Dose Level B (0.1g/day)|"0.1g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.1g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.1g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
3237364|NCT00933530|Experimental|Cohort 3 - Dose Level C (0.25g/day)|"0.25g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.25g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.25g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
3237365|NCT00933530|Experimental|Cohort 4 - Dose Level D (0.5g/day)|"0.5g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.5g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.5g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
3237366|NCT00933530|Experimental|Cohort 5 - Dose Level E (1.0g/day)|"1.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 1.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 1.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
3237367|NCT00933530|Experimental|Cohort 6 - Dose Level F (2.0g/day)|"2.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 2.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 2.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
3237368|NCT00933530|Experimental|Cohort 7 - Dose Level G (3.0g/day)|"3.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 3.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 3.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period."
3237369|NCT00933504|Experimental|Dermacyd Silver Floral (Lactic Acid)|Lactic Acid sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample
3237370|NCT00933491||Diabetic|Type II Diabetes
3237371|NCT00933491||Control|Non-diabetics
3237372|NCT00933478||Patients with Patulous Eustachian Tube Dysfunction|
3237416|NCT00933114||Functional Imaging|Functional imaging with MRI and PET
3237644|NCT00931580|Experimental|4,000 IU|Vitamin D3 tablet, 4,000 IU
3237379|NCT00933426|Experimental|Lenalidomide and Paclitaxel|"Phase I: Up to 5 differing doses of Lenalidomide tested plus fixed dose of Paclitaxel.~Phase II: Lenalidomide at highest tolerated dose from Phase I plus Paclitaxel."
3237380|NCT00933413|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Application of Lactic acid during 21 consecutive days
3237381|NCT00933400|Active Comparator|Traditional Strategy (Group A)|In the traditional-care arm (Group A), all management and disposition decisions will be made by the healthcare providers caring for the participant. Participants will receive disposition (admit to hospital, admit to cardiac diagnostic unit, or discharge to home), diagnostic testing (none, stress testing, or cardiac catheterization), and treatment according to the team caring for the participant.
3237382|NCT00933400|Experimental|CT Coronary Angiography (Group B)|"In the study CT coronary angiography-based rapid rule out arm (Group B), participants will receive initial cardiac troponin and creatinine tests. Upon return of normal laboratory values (including a calculated creatinine clearance), the participants will receive a CT coronary angiography an estimated 90 minutes or as soon as the CT scanner is available following the initial values assessment. Participants with negative test results will be discharged unless other indications for admission per standard of care and follow up will comprise telephone interviews 30 days and 1 year after triage/presentation. Participants with positive test results will be admitted to the hospital for further management as dictated by the admitting team."
3237383|NCT00933387|Experimental|open label|an open-labelled, single-arm
3237384|NCT00933374|Experimental|Paclitaxel and RAD001|175 mg /m3 paclitaxel every 3 weeks and 10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
3237385|NCT00933361|Experimental|ghrelin|Ghrelin, a 28 amino acid peptide discovered in 1999, is predominantly secreted by gastric endocrine cells and is an endogenous ligand for the growth hormone secretagogue (GHS) receptor. When administered peripherally it stimulates growth hormone secretion, food intake, triggers a positive energy balance, produces weight gain through a central mechanism involving hypothalamic neuropeptides and has anti-inflammatory effects
3237386|NCT00933348|Active Comparator|OPAL A plus standard wound care|
3237387|NCT00933348|Placebo Comparator|Placebo plus standard wound care|
3237388|NCT00933335|Experimental|Single Arm|Patients will first receive an abbreviated course of three cycles of fludarabine (25 mg/m2 for 5 days every 5 weeks). Iodine I 131 tositumomab will be initiated 6 to 8 weeks after completion of fludarabine. Patients will undergo dosimetry studies to determine the appropriate patient-specific activity of iodine I 131 tositumomab required to deliver a fixed dose of 75 cGy. The dose will be attenuated to 65 cGy for patients with platelet counts between 100,000 and 150,000/micoliter.
3237389|NCT00933322|Active Comparator|ruminant TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter containing ruminant TFA and with 15-20g rape oil for balancing the essential fatty acids.
3237390|NCT00933322|Active Comparator|industrial TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter containing TFA from PHVO and with 15-20g rape oil for balancing the essential fatty acids.
3237391|NCT00933322|Placebo Comparator|without TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter without TFA and with 15-20g rape oil for balancing the essential fatty acids.
3237392|NCT00933309|Experimental|Group 1|Exemestane alone
3237393|NCT00933309|Experimental|Group 2|Exemestane plus Avandamet
3237394|NCT00933296||A Patients with the Schnitzler syndrome|Patients with the Schnitzler syndrome
3237395|NCT00933296||B Control subjects:|B1 healthy B2 other diseases
3237396|NCT00933283|Experimental|Telaprevir + Methadone|Patients will receive telaprevir 750 mg orally, every 8 hours from Day 1 to Day 7, along with methadone 30 to 130 mg, once daily.
3237397|NCT00933270|Experimental|SUPERA® Nitinol Stent System|Implantation of SUPERA nitinol stent using the SUPERA® Nitinol Stent System
3237398|NCT00933257|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Dermacyd PH_DESILSTY_FR (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
3237399|NCT00933244|Other|High Dose Vitamin D3|"Loading Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take daily for 15 days and placebo gel-caps (white) to take daily for 15 days.~Maintenance Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take two times a month for 350 days and placebo gel-caps (white) to take daily for 350 days."
3237400|NCT00933244|Other|Low Dose Vitamin D3|"Loading Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 15 days plus placebo gel-caps (yellow) to take daily for 15 days.~Maintenance Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 350 days plus placebo gel-caps (yellow) to take two times a month for 350 days."
3237401|NCT00933244|Placebo Comparator|Placebo|"Loading Dose: Placebo gel-caps (yellow) to take daily for 15 days plus placebo gel-caps (white) to take daily for 15 days.~Maintenance Dose: Placebo gel-caps (yellow) to take two times a month for 350 days plus placebo gel-caps (white) to take daily for 350 days."
3237402|NCT00933231|Active Comparator|Standard dose Advagraf with ACEi/ARB|Standard dose Advagraf will be evaluated with ACEi/ARB
3237403|NCT00933231|Active Comparator|Standard dose Advagraf without ACEi/ARB|Standard dose Advagraf will be evaluated without ACEi/ARB
3237404|NCT00933231|Experimental|Low-dose Advagraf with ACEi/ARB|Low dose Advagraf will be evaluated with ACEi/ARB
3237405|NCT00933231|Experimental|Low-dose Advagraf without ACEi/ARB|Low dose Advagraf will be evaluated without ACEi/ARB
3237406|NCT00933218|Active Comparator|polyphenols (non-alcoholic beer)|
3237407|NCT00933218|Placebo Comparator|beverage without polyphenols|
3237408|NCT00933192||Group 1: young healthy patients|
3237409|NCT00933192||Group 2: old healthy patients|
3237410|NCT00933179|Experimental|Arm 1|
3237411|NCT00933179|Active Comparator|Arm 2|
3237412|NCT00933166|Experimental|Lotrafilcon A|Investigational contact lens worn in both eyes for three months
3237413|NCT00933153|Active Comparator|Meals on Wheels|Participants will receive two meals daily from Meals on Wheels.
3237414|NCT00933153|Experimental|Meals on Wheels + Ensure Plus supplement|Participants will receive two meals from Meals on Wheels daily plus Ensure Plus supplements with meals.
3237415|NCT00933140||HIV infected women|HIV infected women between ages 18 - 64 years of age due for cervical cancer screening were enrolled.
3237419|NCT00933075|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also usedas a control sample.
3237420|NCT00933062|Active Comparator|SRT2104|Subjects will receive a dose of 2.0 g SRT2104 (administered as eight 250 mg capsules) on eight occasions during the study; once as a single dose (study day 1) during Treatment Period 1, and once per day for seven consecutive days (study days 15 to 21) during Treatment Period 2.
3237421|NCT00933062|Placebo Comparator|Placebo|Subjects will receive placebo on eight occasions during the study; once as a single dose (study day 1) during Treatment Period 1, and once per day for seven consecutive days (study days 15 to 21) during Treatment Period 2.
3237422|NCT00933049|Active Comparator|Cotrimoxazole|Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole) + Amoxicillin placebo
3237423|NCT00933049|Active Comparator|Amoxicillin|Amoxicillin (25 mg/kg/dose) + Cotrimoxazole placebo
3237424|NCT00933036|Experimental|Treatment arm|Crosstrees Pod System for PVA.
3237425|NCT00933023|Experimental|Mild steroid|1%hydrocortisone for 8 weeks
3237426|NCT00933023|Experimental|Potent Steroid|
3237427|NCT00932984|Experimental|Dermacyd Silver Floral (Lactic Acid)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
3237428|NCT00932971|Placebo Comparator|PEG-IFN alfa-2a plus placebo|Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus placebo once daily, orally
3237429|NCT00932971|Active Comparator|PEG-IFN alfa-2a plus Tenofovir|Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus Tenofovir disoproxilfumarat 245mg once daily, orally
3237430|NCT00932958||All comers >18 yrs old|This study is observational, studying patients who are already scheduled to undergo CCTA. Minors and those unable to consent to the study are excluded.
3237431|NCT00932945|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Treatment duration: 21 consecutive days
3237432|NCT00932932||PWS not receiving Growth Hormone|
3237433|NCT00932932||Control subjects healthy or obese|
3237434|NCT00932932||PWS subjects starting Growth Hormone|
3237435|NCT00932919|Experimental|Thought field therapy|24 randomly selected patients will be treated with 5 sessions of standard Thought field therapy.
3237436|NCT00932919|Active Comparator|Cognitive therapy|Treatment with Cognitive therapy, 12 sessions with manualized therapy according to David Clark's model.
3237437|NCT00932919|Other|Wait list|24 patients will be randomly selected to 3 months on a wait list, thereafter randomly selected to either Cognitive therapy or Thought field therapy.
3237438|NCT00932906|Placebo Comparator|Instructor based training; <21 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
3237439|NCT00932906|Placebo Comparator|Instructor based training; 21-50 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
3237440|NCT00932906|Placebo Comparator|Instructor based training; >50 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
3237441|NCT00932906|Experimental|Video Skill Training; <21 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
3237442|NCT00932906|Experimental|Video Skill Training; 21-50 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
3237443|NCT00932906|Experimental|Video Skill Training; >50 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
3237444|NCT00932906|Experimental|Video scenario training; <21 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
3237445|NCT00932906|Experimental|Video scenario training; 21-50 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
3237446|NCT00932906|Experimental|Video scenario training; >50 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
3237447|NCT00932906|Experimental|Video demonstration training; <21 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
3237448|NCT00932906|Experimental|Video demonstration training; 21-50 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
3237449|NCT00932906|Experimental|Video demonstration training; >50 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
3237450|NCT00932893|Experimental|PF-02341066|
3237451|NCT00932893|Active Comparator|Pemetrexed or Docetaxel|Investigator selection of either pemetrexed or docetaxel as the active comparator
3237453|NCT00932854|Experimental|EBUS|All patients in the trial will undergo EBUS for the diagnosis of isolated mediastinal lymphadenopathy. If this investigation is negative then the patient will be referred for mediastinoscopy.
3237454|NCT00932841|Placebo Comparator|Placebo|
3237455|NCT00932841|Active Comparator|VSL#3 90 billion bacteria|
3237456|NCT00932841|Active Comparator|VSL#3 900 billion bacteria|
3237457|NCT00932828|Experimental|Peanut oral immunotherapy|Newly diagnosed allergic children receiving peanut flour as oral immunotherapy for the treatment of peanut allergy.
3237458|NCT00932802||Group 1|
3237459|NCT00932776|Experimental|TBA|
3237460|NCT00932776|Active Comparator|Control|
3237461|NCT00932750|Placebo Comparator|MOS Weight maintenance|
3237462|NCT00932750|Placebo Comparator|MOS weight loss|
3237463|NCT00932737|Active Comparator|HBB 20mg 1-5 tablets per episode|patient to receive 1-5 tablets containing 20mg HBB per APC episode
3237464|NCT00932737|Placebo Comparator|Placebo|patient to receive a tablet identical to those containing HBB and take 1-5 tablets per episode
3237465|NCT00932724|Experimental|CY-503|
3237466|NCT00932724|Placebo Comparator|Placebo|
3237467|NCT00932711|Experimental|Educational intervention|Subjects in this group will receive educational brochures about management of COPD
3237468|NCT00932698|Experimental|Arm 1: Oral IXAZOMIB|
3237469|NCT00932685|Active Comparator|2. Video Game|
3237470|NCT00932685|Active Comparator|1. Midazolam 0.5mg/kg|
3237471|NCT00932672|Experimental|Atkins group|Men assigned to the Atkins diet will be asked to restrict carbohydrate intake to <20 grams/day. We will use an established clinical program directed by Dr. Eric Westman which implements this diet using a trained clinical nutritionist. No other dietary restrictions will be placed on the subjects. They will measure their urinary ketones at home weekly using urinary ketone strips. Subjects will meet with the nutritionist monthly during the 6 months of the study. Subjects in the Atkins arm will also be asked to walk at a brisk pace for 30 minutes a day, 5 days a week and will be provided a pedometer to measure the number of steps taken per day.
3237472|NCT00932672|No Intervention|Control group|Subjects assigned to the control group will be asked to make no changes in their dietary habits. At the completion of the study subjects will meet with the nutritionist and receive standard nutrition AHA recommendations.
3237473|NCT00932659||Hemodialysis patients|This is a single arm observational study. The single arm consists of adult hemodialysis patients without a prior history of cardiac arrhythmias who will be implanted with a continuous cardiac monitoring device (REVEAL, Medtronic) for an FDA approved indication.
3237474|NCT00932646|Experimental|BI1744 (Olodaterol)|Medium Dose once Daily
3237475|NCT00932646|Experimental|BI 1744 (Olodaterol)|Low Dose once Daily
3237476|NCT00932646|Placebo Comparator|Placebo|Placebo once Daily
3237477|NCT00932646|Active Comparator|Foradil|12 mcg twice daily
3237478|NCT00932620|Active Comparator|Simvastatin 40 mg|All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily
3237479|NCT00932620|Active Comparator|Simvastatin 10 mg plus ezetimibe 10 mg|All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily
3237480|NCT00932607|Active Comparator|Staloral Birch|"Start with 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
3237481|NCT00932607|Experimental|SUBLIVAC Birch|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
3237482|NCT00932594|Active Comparator|1.Arthrocentesis only|Patients only have Arthrocentesis, but without adjusting the pressure of the TMJ
3237483|NCT00932594|Active Comparator|3.Arthroscopic Treatment|Patient receives Arthroscopic treatments without adjusting the TMJ pressure
3237484|NCT00932594|Active Comparator|4.Arthroscopic with Adjust Pressure|Arthroscopic Treatment with Adjust TMJ Pressure Treatment, during the Arthroscopic treatment adjust the pressure of TMJ to normal value
3237485|NCT00932594|Active Comparator|5.The TMJ Orperation Treatment|The TMJ Operation Treatment without adjusting the pressure of TMJ
3237486|NCT00932594|Active Comparator|6.The TMJ Operation with Adjust Pressure|The TMJ Operation with Adjust TMJ Pressure Treatment, during the treatments to adjust the TMJ pressure to normal value
3237487|NCT00932594|Active Comparator|7.Bite Plate Treatment|Bite Plate Treatment for Temporomandibular Disorders without adjusting the pressure of TMJ
3237488|NCT00932594|Active Comparator|8.Bite Plate with Adjust pressure|Bite Plate and Adjust Pressure Treatment for Temporomandibular Disorders, during the treatments adjust the pressure of TMJ to normal value
3237489|NCT00932594|Active Comparator|2.Arthrocentesis with adjust pressure|Arthrocentesis with adjust pressure according to the pressure of TMJ
3237490|NCT00932581||Full Exam|The first group will receive the full motor examination section in its original order.
3237491|NCT00932581||Subscale|The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
3237492|NCT00932555||Group 1|
3237493|NCT00932542|Experimental|Eutectic mixture|
3237494|NCT00932542|Placebo Comparator|placebo|
3237495|NCT00932542|Active Comparator|Medicaina|
3237496|NCT00932529|Active Comparator|Olanzapine|
3237497|NCT00932529|Active Comparator|Quetiapine|
3237498|NCT00932529|Active Comparator|Risperidone|
3237499|NCT00932529|Active Comparator|Ziprasidone|
3237500|NCT00932516|Active Comparator|South Beach Diet™ with SBD™ Products|
3237501|NCT00932516|Active Comparator|South Beach Diet™ alone|
3237502|NCT00932516|Active Comparator|Calorie restricted diet w/ SBD™ Products|
3237503|NCT00932516|Active Comparator|Calorie Restricted Diet alone|
3237504|NCT00932503|No Intervention|PDS II|PDS II® loop suture was used for abdominal wall closure
3237505|NCT00932503|Active Comparator|Vicryl plus|"antiseptic coated Vicryl plus was used for abdominal wall closure"
3237506|NCT00932490|Experimental|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and an advanced practice nurse will suggest individualized strategies to overcome barriers to adherence
3237507|NCT00932490|No Intervention|Control|
3237508|NCT00932477|Experimental|Artificial Tear Formulation 1|Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
3237509|NCT00932477|Experimental|Artificial Tear Formulation 2|Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
3237510|NCT00932477|Active Comparator|Glycerin and Polysorbate 80 based artificial tear|Glycerin and Polysorbate 80 based artificial tear
3237511|NCT00932464|Experimental|1|Neratinib Fasted
3237512|NCT00932464|Experimental|2|Neratinib Fed
3237513|NCT00932451|Experimental|PF-0231066|
3237514|NCT00932438|Experimental|Irinotecan Beads with FOLFOX6|
3237515|NCT00932438|Active Comparator|FOLFOX6/Avastin alone|
3237516|NCT00932425|Experimental|Outpatient cardiac monitoring|Patients will be assigned to wear a portable outpatient cardiac telemetry device for 21 days
3237517|NCT00932425|No Intervention|Control|Patients will be discharged home with standard clinical follow-up
3237518|NCT00932412|Experimental|CLARA|Clofarabine / Intermediate-Dose Cytarabine (CLARA) with G-CSF given during each sequence of chemotherapy in order to increase the blast priming.
3237519|NCT00932412|Active Comparator|HDAC|High-Dose Cytarabine (HDAC) with G-CSF given during each sequence of chemotherapy in order to increase the blast priming.
3237520|NCT00932399||Group 1|Underwent a procedure at a VA medical facility in VISN 20 for a lower limb amputation between 1997 and 2008
3237521|NCT00932399||Group 2|No history of lower limb amputation
3237522|NCT00932386|Experimental|dexmedetomidine Hcl infusion|Dexmedetomidine is a highly selective alpha-2 adrenoreceptor agonist, which possesses hypnotic, sedative, anxiolytic, sympatholytic and analgesic properties.
3237523|NCT00932386|Placebo Comparator|normal saline|
3237524|NCT00932373|Experimental|1|
3237525|NCT00932360|Sham Comparator|Transient Placebo|
3237526|NCT00932360|Active Comparator|Active TENS|
3237527|NCT00932360|No Intervention|No Treatment|
3237528|NCT00932347|Experimental|Mouthwash A|Mouthwash A: Camellia sinensis mouthwash
3237529|NCT00932347|Placebo Comparator|Mouthwash B|Mouthwash B: Placebo mouthwash
3237530|NCT00932334|Experimental|TALK Plus|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
3237531|NCT00932334|Experimental|TALK Standard|Participants receive and educational video and booklet about living kidney donation
3237532|NCT00932334|Other|Usual Care|Participants receive their usual medical care
3237533|NCT00932321|Experimental|24 Day NA/EE|Norethindrone acetate 1 mg /ethinyl estradiol 20 mcg for 24 days of each 28 day cycle
3237534|NCT00932321|Active Comparator|21 Day NA/EE|Norethindrone acetate 1 mg/ethinyl estradiol 20 mcg for 21 days of each 28 day cycle
3237535|NCT00932308|Active Comparator|1|Western-style, high-fat, low-calcium diet (WD)
3237536|NCT00932308|Active Comparator|2|Prudent, low-fat, calcium sufficient diet (PD)
3237537|NCT00932295|Active Comparator|Own brand cigarette|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
3237538|NCT00932295|Sham Comparator|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
3237539|NCT00932295|Experimental|Electronic cigarette Version One C7|"10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)"
3237540|NCT00932295|Experimental|Electronic cigarette version 2: NJ|"10 puffs from a so-called electronic cigarette named NJOY (16 mg cartridge; 30 second inter puff interval)"
3237541|NCT00932282|Active Comparator|12 month maintenance of PnOIT|"Randomized subjects who will stay on the maintenance dose of oral peanut immunotherapy (PnOIT) for 12 months.~The study has 4 phases: anti-IgE therapy before immunotherapy (Omalizumab), an initial desensitization day(s), a buildup period, and a daily home maintenance phase with a final dose of 8000mg peanut flour (~50% peanut protein). Then all subjects will be randomized to an additional 1 or 2 years (12 or 24 months) of maintenance OIT. An OFC will be performed at the end of the long-term maintenance in all groups."
3237542|NCT00932282|Active Comparator|24 month maintenance of PnOIT|"All subjects will be on the same intervention until Randomization. Randomized subjects who will stay on the maintenance dose of peanut oral immunotherapy (PnOIT) for 24 months.~The study has 4 phases: anti-IgE therapy before immunotherapy (Omalizumab), an initial desensitization day(s), a buildup period, and a daily home maintenance phase with a final dose of 8000mg peanut flour (~50% peanut protein). Then all subjects will be randomized to an additional 1 or 2 years (12 or 24 months) of maintenance OIT. An OFC will be performed at the end of the long-term maintenance in all groups."
3237543|NCT00932269||Seroimmunity 2007|Cord blood from 400 newborns, 1800 children (2 - 18 years) and 2400 adults (above 18 years), randomly selected and stratified in age groups, from which blood samples are taken.
3237544|NCT00932269||Sub Study|800 immigrated children (14 - 16 years) from which blood samples are taken.
3237545|NCT00932256|Experimental|STAHIST for seasonal allergic rhinitis|STAHIST for seasonal allergic rhinitis: each white, scored tablet contains pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, and atropine sulfate .24mg
3237546|NCT00932230|Experimental|Group 1|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
3237547|NCT00932217|Active Comparator|filgrastim|patients mobilized with filgrastim
3237548|NCT00932217|Active Comparator|lenograstim|patients mobilized with lenograstim
3237639|NCT00931593|Experimental|volunteers|"This is a descriptive study to compare two techniques (manometry with perfused dentsleeve probe vs high resolution manometry for the identification of tLESr). Each subject is his own control.~The date of perfused manometry is randomized to avoid bias due to examinations' order."
3237549|NCT00932204|Experimental|Active stimulation|"For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d)."
3237550|NCT00932204|Sham Comparator|Sham stimulation|For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area.
3237551|NCT00932191|Active Comparator|Ultrasound phacoemulsification|Cataract nucleus is removed using standard amounts of ultrasound energy.
3237552|NCT00932191|Active Comparator|Reduced ultrasound phacoemulsification|Cataract nucleus removal using less ultrasound energy and more mechanical energy.
3237553|NCT00932178|Experimental|Calmer Life|Skills-based intervention to reduce anxiety and worry in adults age 50+.
3237554|NCT00932165||Exemestane|Patients taking Exemestane Tablets.
3237555|NCT00932152|Active Comparator|Arm B, Group 1|Best supportive care only: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support PRN
3237556|NCT00932152|Active Comparator|Arm B, Group 2|Best supportive care and Bevacizumab 15mg/kg every 21 days
3237557|NCT00932152|Experimental|Arm A, Group 1|Fulvestrant and anastrozole only
3237558|NCT00932152|Experimental|Arm A, Group 2|Fulvestrant, anastrozole and Bevacizumab
3237559|NCT00932139|Experimental|Electro-acupuncture control|"Blood pressure will be recorded before and after each EA treatment for 8 weeks. The course is a once a week 8-week treatment.~Intervention is the Electro-acupuncture control treatment."
3237560|NCT00932139|Experimental|Electro-acupuncture test|"Blood pressure will be recorded before and after each EA treatment for 8 weeks. The course is a once a week 8-week treatment.~Intervention is the active Electro-acupuncture treatment."
3237561|NCT00932126|Experimental|1|
3237562|NCT00932113|Active Comparator|Adalimumab|Dosing will be on day 1 and then weekly. For the injections, dosing will occur according to product recommendations. Patients will receive 80mg adalimumab (2 pre-filled syringes, each with 40mg) on day 1, and then 40mg on week 1 and then every 2 weeks (from week 1 through week 15).
3237563|NCT00932113|Active Comparator|Methotrexate (MTX)|Patients will be dosed according to the CHAMPION study in single weekly doses of methotrexate: 7.5mg at week 0, 10mg at week two, and 15mg at week 4 for all patients. For each subject if the PASI did not decrease by at least 50% from baseline (PASI-50) at week 8, dosing will be increased to 20mg per week; the dose will be maintained at 15mg per week if PASI-50 was achieved at week 8. If PASI-50 was not achieved at week 12, dosing will be increased to 25mg per week; the dose will be maintained at 20mg per week if the PASI-50 was achieved at week 12. All patients on methotrexate will also receive a dietary supplement of oral folate (5mg per week). Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study.
3237564|NCT00932100|Experimental|REG1-a|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
3237565|NCT00932100|Experimental|REG1-b|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
3237566|NCT00932100|Experimental|REG1-c|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
3237567|NCT00932100|Experimental|REG1-d|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
3237568|NCT00932100|Active Comparator|Heparin|Heparin per standard of care at the local institution
3237569|NCT00932087||type 2 diabetics with metabolic syndrome|
3237570|NCT00932087||metabolic syndrome without diabetes|
3237571|NCT00932087||type 1 diabetes|
3237572|NCT00932087||control|
3237573|NCT00932074|Experimental|3% KP-413 Ointment|
3237574|NCT00932074|Experimental|1% KP-413 Ointment|
3237575|NCT00932074|Placebo Comparator|Placebo|
3237576|NCT00932061|Active Comparator|Traditional Acupuncture|Acupuncture sites will be used for active intervention.
3237577|NCT00932061|Sham Comparator|Sham Treatment|Sham acupuncture is used.
3237578|NCT00932048|No Intervention|Control|
3237579|NCT00932048|Experimental|Atorvastatin|
3237580|NCT00932035|Experimental|Arm I (reverse mapping guided axillary lymph node dissection)|Patients receive isosulfan blue dye SC and then undergo reverse mapping-guided axillary lymph node dissection.
3237581|NCT00932035|Active Comparator|Arm II (control)|Patients undergo standard axillary lymph node dissection and then receive isosulfan blue dye SC.
3237582|NCT00932022|Experimental|trospium chloride XR 60 mg|Placebo capsule taken orally once daily for 2 weeks followed by trospium chloride extended release (XR) 60 mg capsule taken orally once daily for 12 weeks.
3237583|NCT00932022|Placebo Comparator|placebo|Placebo capsule taken orally once daily for 14 weeks.
3237584|NCT00932009||Human papillomavirus|Tanzanian men with HPV and Tanzanian men without
3237585|NCT00931996|Experimental|Antipsychotic|Antipsychotic
3237586|NCT00931970||Dialysis modality|
3237587|NCT00931957|Active Comparator|Etanercept-MTX-Prednisolone|Methotrexate + Prednisolone + Etanercept
3237588|NCT00931957|Other|B, MTX-Prednisolone|Methotrexate + Prednisolone
3237589|NCT00931944|Experimental|KNS-760704 300 mg/day|Open-label KNS-760704 (150 mg Q12H)
3237590|NCT00931931|Experimental|HSV1716 - Intratumoral route|Research participants with localized disease receiving HSV1716 as an intratumoral injection
3237591|NCT00931931|Experimental|HSV1716 - intravenous|Research participants with metastatic disease receiving HSV1716 intravenously
3237592|NCT00931918|Active Comparator|RCHOP|RCHOP [rituximab, cyclophosphamide, doxorubicin, prednisone] administered as follows: rituximab 375 mg/m^2 intravenous (IV) infusion, cyclophosphamide 750 mg/m^2 IV infusion, doxorubicin 50 mg/m^2 IV injection and vincristine 1.4 mg/m^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
3237640|NCT00931580|Placebo Comparator|Placebo|placebo tablet
3237641|NCT00931580|Experimental|400 IU|Vitamin D3 tablet, 400 IU
3237593|NCT00931918|Experimental|Vc-RCHOP|Vc-RCHOP [bortezomib (VELCADE®), rituximab, cyclophosphamide, doxorubicin, prednisone] administered as follows: bortezomib (VELCADE ®) 1.3 mg/m^2 administered intravenous (IV) push on Days 1 and 4 of each cycle with RCHOP administered as follows: rituximab 375 mg/m^2 intravenous (IV) infusion, cyclophosphamide 750 mg/m^2 IV infusion, doxorubicin 50 mg/m^2 IV injection and vincristine 1.4 mg/m^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
3237594|NCT00931905|Experimental|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used, and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.
3237595|NCT00931905|Placebo Comparator|hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol.
3237596|NCT00931892|Experimental|Low gluten group|Subjects will eat 3g of gluten per day
3237597|NCT00931892|Experimental|High gluten group|Subjects will eat 10g of gluten per day
3237598|NCT00931879|Placebo Comparator|Placebo|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
3237599|NCT00931879|Active Comparator|omega-3-ethyl esters 4g|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
3237600|NCT00931866|Experimental|Diclofenac Sodium Patch|
3237601|NCT00931866|Placebo Comparator|Topical Placebo Patch|
3237602|NCT00931853|Experimental|SENNA + CASSIA (Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
3237603|NCT00931840|Experimental|EZN-2208|"EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.~PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL."
3237604|NCT00931840|Experimental|Cetuximab + EZN-2208|Cetuximab will be administered as an i.v. infusion on weekly basis. EZN-2208 administered as i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
3237605|NCT00931840|Active Comparator|Irinotecan + cetuximab|Cetuximab will be administered weekly as an i.v. infusion. Irinotecan will be administered as an i.v. infusion on Weeks 1 and 2 and repeated every 3 weeks.
3237606|NCT00931827||Group 1|
3237607|NCT00931827||Group 2|
3237608|NCT00931814|Other|exercise|
3237609|NCT00931801|Experimental|Intervention Arm No.1|
3237610|NCT00931801|Experimental|Intervention Arm No.2|
3237611|NCT00931801|Active Comparator|Control Arm|Continue baseline regimen
3237612|NCT00931788|Experimental|Intensive pharmacist case management|
3237613|NCT00931788|Active Comparator|Usual care|
3237614|NCT00931775|Placebo Comparator|Citalopram + placebo|Citalopram 20 mg/day t.i.d
3237615|NCT00931775|Experimental|Citalopram + pindolol|Citalopram 20 mg/day t.i.d Pindolol 15 mg/day t.i.d.
3237616|NCT00931762|Experimental|Panobinostat|Panobinostat will be administered orally once a day on Monday, Wednesday and Friday at a fixed dose of 40 mg.
3237617|NCT00931749|Experimental|Low intensity Ultrasound group|
3237618|NCT00931749|Sham Comparator|Sham ultrasound group|
3237619|NCT00931736|Active Comparator|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
3237620|NCT00931736|Active Comparator|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and < 50 kg, otherwise 300 mg for those weighing < 36 kg. Total duration of treatment is for 4 months.
3237621|NCT00931723|Active Comparator|1|Seroquel XR and Lithium
3237622|NCT00931723|Placebo Comparator|2|Seroquel XR and placebo
3237623|NCT00931710|Experimental|Valsartan/amlodipine/HCTZ|Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study.
3237624|NCT00931710|Active Comparator|Losartan/HCTZ|Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study.
3237625|NCT00931697|Experimental|AD 452 (+) mefloquine|
3237626|NCT00931697|Active Comparator|Racemic mefloquine|
3237627|NCT00931697|Placebo Comparator|Placebo|
3237628|NCT00931671|Other|Exercise|Exercise
3237629|NCT00931645|No Intervention|Complete responders|watch and wait policy
3237630|NCT00931645|Experimental|arm 2: complete responders patients|ABMT : TBI, 10 grays d-3-1 & cyclophosphamide 60 mg/sqm d-5-4
3237631|NCT00931645|Experimental|Non CR patients arm 3|Rescue chemotherapy and ABMT (see arm 2)
3237632|NCT00931645|Active Comparator|Non CR patients at random : arm 4|Rescue DHAP, F+C
3237633|NCT00931632|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide
3237634|NCT00931632|Placebo Comparator|Placebo|Nitrogen Placebo
3237635|NCT00931606|Experimental|1|ACE-011 Treatment Group (Dose Level 1)
3237636|NCT00931606|Experimental|2|ACE-011 Treatment Group (Dose Level 2)
3237637|NCT00931606|Experimental|3|ACE-011 Treatment Group (Dose Level 3)
3237638|NCT00931606|Placebo Comparator|4|Placebo
3237642|NCT00931580|Experimental|1,000 IU|Vitamin D3 tablet, 1,000 IU
3237643|NCT00931580|Experimental|2,000 IU|Vitamin D3 tablet, 2,000 IU
3237645|NCT00931567|Active Comparator|Vaselitulle|after surgery, the loss of substance is treated using vaseline dressing
3237646|NCT00931567|Experimental|Autologous platelets gel|after surgery, the loss of substance is treated with Autologous platelets gel
3237647|NCT00931554|Active Comparator|Early drain removal|Drain removal in postoperative day 3
3237648|NCT00931554|Active Comparator|Standard drain removal|Drain removal on postoperative day 5
3237649|NCT00931541|Experimental|A|AZD6088 oral solution
3237650|NCT00931541|Experimental|B|Placebo oral solution
3237651|NCT00931528|Experimental|Tadalafil|Tadalafil
3237652|NCT00931528|Placebo Comparator|Placebo|Placebo
3237653|NCT00931515|Experimental|NuBac|NuBac device implanted at the L4/5 level
3237654|NCT00931515|Active Comparator|Prodisc-L|Prodisc-L implanted at the L4/5 level.
3237655|NCT00931489|Active Comparator|Wet AMD Patients Responders|Dilated eye exam once a month for 7 months; visual acuity and OCT once a month for 7 months; Lucentis(R)/ranibizumab injection once each month for the Baseline and Month 1-3 visits, then as needed at Month 4 and 5; 3 Tbls. blood draw at Baseline, Month 3 and Month 6 visits.
3237656|NCT00931489|No Intervention|Normal Population|Dilated eye exam and 3 Tbls. blood draw at first and only study visit.
3237657|NCT00931489|Active Comparator|Wet AMD Patients Acute Non-responders|Participants in this Group will have not responded to 4 prior injections of Lucentis(R)/ranibizumab or other anti-VEGF treatment. Dilated eye exam at Month 4; visual acuity and OCT at Months 4-6; injection of anti-VEGF treatment as needed at Months 4 and 5; 3 Tbls. blood draw at Month 4
3237658|NCT00931489|No Intervention|Dry AMD Population|Dilated eye exam and 3 Tbls. blood draw at first and only study visit.
3237659|NCT00931489|Active Comparator|Wet AMD Patients Chronic Non-responderes|Participants in this Group will have not responded to 4 or more prior injections of Lucentis(R)/ranibizumab or other anti-VEGF treatment. One visit at Month 4: Dilated eye exam with visual acuity and OCT; injection of anti-VEGF as needed; 3 Tbls. blood drawn
3237660|NCT00931463|Active Comparator|Ritonavir-boosted lopinavir and 2N(t)RTI|This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.
3237661|NCT00931463|Experimental|Ritonavir-boosted lopinavir and raltegravir|This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.
3237662|NCT00931450|Active Comparator|Group 1|Patients receive oral exemestane and oral placebo once daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
3237663|NCT00931450|Experimental|Group 2|Patients receive oral exemestane once daily and oral sunitinib malate once daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
3237664|NCT00931437|Experimental|vitamin K-rich dairy product|one single intake of a dairy product containing several K-vitamins: phylloquinone, menaquinone-7,8,9-and 10.
3237665|NCT00931424|Experimental|reconstruction|patients in this group will have both valve reconstruction and superficial vein surgery
3237666|NCT00931424|No Intervention|unreconstruction|patients in this group will only have superficial vein surgery
3237667|NCT00931411|Experimental|Formulation 609580 20 then 609209|Formulation 609580 20 cream is applied topically to the entire body twice a day, morning and evening, after bathing for 42 days. This is followed by the same application of formulation 609209 for 2 weeks. Dosage is at the discretion of the parent applying the cream to the child.
3237668|NCT00931411|Active Comparator|Formulation 609209 then 609580 20|Formulation 609209 cream is applied topically to entire body, twice a day, morning and evening, after bathing for 42 days. This is followed by the same application of formulation 609580 20 for 2 weeks. Dosage is at the discretion of the parent applying the cream to the child.
3237669|NCT00931398|Experimental|Methylphenidate HCl (Concerta)|
3237670|NCT00931398|Placebo Comparator|Placebo|
3237671|NCT00931385|Experimental|BI 1744 (Olodaterol) Low Dose|BI1744 Low Dose once daily
3237672|NCT00931385|Experimental|BI 1744 (Olodaterol) Med Dose|BI 1744 Med Dose once daily
3237673|NCT00931385|Placebo Comparator|Placebo|Placebo once daily
3237674|NCT00931385|Active Comparator|Foradil|Foradil 12 mcg twice daily
3237675|NCT00931372|Experimental|Sequence 1: AVE0010/Placebo|"Period 1: lixisenatide 20 µg in 200 µL, one single dose~Period 2: placebo 200 µL, one single dose"
3237676|NCT00931372|Experimental|Sequence 2: Placebo/AVE0010|"Period 1: placebo 200 µL, one single dose~Period 2: lixisenatide 20 µg in 200 µL, one single dose"
3237677|NCT00931359|Experimental|Treatment with DTS-G2 System|Subjects receive treatment with the DTS-G2 System (an energy-based medical device) in both axilla. Multiple treatment sessions may be used.
3237678|NCT00931359|Sham Comparator|Sham treatment|All elements of the treatment are given except that no energy is delivered. Multiple treatment sessions may be used.
3237679|NCT00931346|Experimental|FTC/TDF Daily|Daily dosing
3237680|NCT00931346|Experimental|FTC/TDF Intermittent|Dosed intermittently
3237681|NCT00931346|Placebo Comparator|Placebo Daily|Placebo dosed daily
3237682|NCT00931346|Placebo Comparator|Placebo Intermittent|Placebo dosed intermittently, orally.
3237683|NCT00931333|Experimental|1|
3237684|NCT00931320||3000 patients|Who have at least made 1 visit to the outpatient clinic within previous 6 months .
3237685|NCT00931307|Experimental|Lotrafilcon A|
3237686|NCT00931281|Active Comparator|1|ABT-450/ritonavir
3237687|NCT00931281|Placebo Comparator|2|Placebo for ABT-450/placebo for ritonavir
3237688|NCT00931268|Other|Macrolane VRF 30|Open label, baseline-controlled, one treatment session with injection of Macrolane VRF30 to each buttock, not exceeding 400 ml per subject.
3237689|NCT00931255|Active Comparator|Tacrolimus|Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
3237690|NCT00931255|Active Comparator|Sirolimus|5 mg, PO , daily
3237691|NCT00931242|Experimental|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
3237899|NCT00929708|Placebo Comparator|5|Placebo
3237692|NCT00931229|Experimental|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines.
3237693|NCT00931216|Experimental|Integrated ANC, PMTCT and HIV Services|HIV care and treatment services are integrated into antenatal care (ANC) services for women testing positive within the ANC at this facility.
3237694|NCT00931216|No Intervention|Non-Integrated Services|Women testing positive in the ANC department are referred for care at the HIV clinic. HIV care and treatment services are not provided within the ANC at facilities randomized to this arm.
3237695|NCT00931177||Dehydrated children|children with dehydration
3237696|NCT00931164|Experimental|Sodium oxybate|"The study is an open-label, Phase I/II trial designed to obtain additional safety and pharmacokinetic parameters for use of sodium oxybate in children and adolescents afflicted with AHC.~Given the limited number of children carrying the diagnosis of AHC, typical controls will not be available for our study. In lieu of this, the subjective recording of ictal episodes in the 6 week period prior to drug initiation will serve as reference in determining drug efficacy."
3237697|NCT00931151|Experimental|Casein|Protein source in the high fat meal is casein
3237698|NCT00931151|Experimental|Milk soluble protein|Protein source in the high fat meal are milk soluble protein
3237699|NCT00931151|Experimental|Alpha lactalbumin|Protein source in the high fat meal is alpha-lactalbumin
3237700|NCT00931138|Active Comparator|Arm1 = Aracytine + Daunorubicin|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
3237701|NCT00931138|Active Comparator|Arm 3 = Aracytine And Idarubicin|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
3237702|NCT00931138|Active Comparator|Arm 2 = Aracytine And Idarubicin|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
3237703|NCT00931125|Active Comparator|vitrectomy with ranibizumab|Patients receiving adjunct preoperative intravitreal ranibizumab (3±1 days) before vitrectomy surgery
3237704|NCT00931125|Placebo Comparator|vitrectomy without ranibizumab|Patients receiving sham treatment before vitrectomy as a comparator arm
3237705|NCT00931112|Other|exercise|
3237706|NCT00931099||Low risk pregnant women|300 women in the third trimester of a singleton uncomplicated pregnancy, who attend a low risk obstetric surveillance
3237707|NCT00931099||High risk pregnant women|100 women hospitalized at the Antenatal department due to pregnancy related hypertensive disorder, IUGR, diabetes mellitus or premature labor
3237708|NCT00931099||Pregnant women in labor|200 women of a singleton uncomplicated full term pregnancy will be recruited during labor at the delivery room
3237709|NCT00931099||Newborns|400 newborns belong to women in first two groups
3237710|NCT00931073|Experimental|Period 1|
3237711|NCT00931073|Experimental|Period 2|
3237712|NCT00931073|Experimental|Period 3|
3237713|NCT00931060|Experimental|Branched chain amino acids|Patients with cirrhosis. Healthy subjects age and sex matched
3237714|NCT00931034|Active Comparator|South Beach Diet with SBD Products|
3237715|NCT00931034|Active Comparator|ADA Diabetes meal plan|
3237716|NCT00931021|Active Comparator|Varenicline (Chantix)|
3237717|NCT00931021|Active Comparator|Nicotine Patch|
3237718|NCT00931008|Experimental|SID530|Study participants who meet eligibility criteria will be randomized to one of two treatment sequences, SID530 or Taxotere (i.e., SID530 on Day 1 followed by Taxotere on Day 21 or Taxotere on Day 1 followed by SID530 on Day 21)
3237719|NCT00931008|Active Comparator|Taxotere|Study participants who meet eligibility criteria will be randomized to one of two treatment sequences, SID530 or Taxotere (i.e., SID530 on Day 1 followed by Taxotere on Day 21 or Taxotere on Day 1 followed by SID530 on Day 21)
3237720|NCT00930995|Active Comparator|A|
3237721|NCT00930995|Placebo Comparator|B|
3237722|NCT00930982|Experimental|Ciprofloxacin Inhale (BAYQ3939)|32.5 mg ciprofloxacin hydrated corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice daily
3237723|NCT00930982|Placebo Comparator|Placebo|Inhalation of matching placebo twice a day
3237724|NCT00930956|Active Comparator|Dextrose|30 g of carbohydrate via Sun-Dex OGTT beverage
3237725|NCT00930956|Experimental|RS Type 2|30g Resistant Starch Type 2 (Hi-Maize 260, National Starch)
3237726|NCT00930956|Experimental|RS Type 4 (cross linked)|30g of cross linked RS type 4 (Fibersym RW, MGP Ingredients, Inc.)
3237727|NCT00930930|Experimental|Cisplatin and Paclitaxel + RAD001|Cisplatin 25 mg/m2 IV weekly + RAD001 5 mg PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + RAD001 5 mg PO daily for 11 weeks
3237728|NCT00930930|Active Comparator|Cisplatin and Paclitaxel + Placebo|Cisplatin 25 mg/m2 IV weekly + placebo PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + placebo PO daily for 11 weeks
3237729|NCT00930917|Experimental|cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
3237730|NCT00930917|Active Comparator|wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
3237731|NCT00930917|Other|conventional group|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
3237732|NCT00930891|Active Comparator|Arm A|4 additional cycles of chemotherapy
3237733|NCT00930891|Experimental|Arm B|4 additional cycles of chemotherapy + bevacizumab
3237734|NCT00930878||Promus|Patients intended to be treated with a Promus™ stent system
3237735|NCT00930878||Endeavor|Patients intended to be treated with an Endeavor™ stent system (excluded the Endeavor™ Resolute™ stent)
3237736|NCT00930878||Cypher|Patients intended to be treated with a Cypher™ stent system
3237737|NCT00930865|Active Comparator|Bumetanide|
3237738|NCT00930865|Active Comparator|Dapagliflozin|
3237739|NCT00930865|Active Comparator|Bumetanide + Dapagliflozin|
3237740|NCT00930839||Controls|Normal, healthy controls, males and females, ages 30-80
3237741|NCT00930813|Experimental|Lutonix Catheter|Paclitaxel coated Balloon Catheter
3237742|NCT00930813|Active Comparator|Standard uncoated Balloon Angioplasty Catheter|uncoated angioplasty balloon
3237743|NCT00930800|Other|Exercise|Dance Dance Revolution (DDR)
3237744|NCT00930787|Experimental|Strattice Reconstructive Tissue Matrix|Use of Strattice Reconstructive Tissue Matrix to support hernia repair
3237745|NCT00930787|Active Comparator|Proceed Surgical Mesh|Use of Proceed Surgical Mesh to support hernia repair
3237746|NCT00930774|Experimental|FM System|Provision of FM assistive device
3237747|NCT00930774|Experimental|Auditory Training|Provision of auditory training
3237748|NCT00930774|Experimental|FM System and Auditory Training|Provision of FM assistive device and auditory training
3237749|NCT00930774|No Intervention|Standard-of-Care|Standard-of-care informational counseling
3237750|NCT00930761|No Intervention|Control|
3237751|NCT00930761|Experimental|Music therapy|
3237752|NCT00930735||Myocardial fibrosis, outcomes|Groups with none and variable amounts of myocardial fibrosis
3237753|NCT00930722||quinapril|quinapril
3237754|NCT00930709|Active Comparator|Active strength training and stretching|Active strength training and stretching
3237755|NCT00930709|Active Comparator|Botulinum toxin type A injections|Botulinum toxin type A injections
3237756|NCT00930696|Experimental|Extensive Abdominal Lavage|women with full thickness excision of deep endometriosis involving the bowel
3237757|NCT00930696|Active Comparator|Standard Rinsing|women with full thickness excision of deep endometriosis involving the bowel
3237758|NCT00930683|Other|1|MEDI-546
3237759|NCT00930683|Other|2|MEDI-546
3237760|NCT00930683|Other|3|MEDI-546
3237761|NCT00930683|Other|4|MEDI-546
3237762|NCT00930683|Other|5|MEDI-546
3237763|NCT00930683|Other|6|MEDI-546
3237764|NCT00930683|Other|7|MEDI-546
3237765|NCT00930683|Other|8|MEDI-546
3237766|NCT00930683|Other|9|MEDI-546
3237767|NCT00930670|Experimental|Rosuvastatin-omeprazole|Rosuvastatin-omeprazole
3237768|NCT00930670|Experimental|Rosuvastatin-pantoprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
3237769|NCT00930670|Experimental|Rosuvastatin-esomeprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
3237770|NCT00930670|Active Comparator|Rosuvastatin-ranitidine|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300 mg for 11 months
3237771|NCT00930670|Experimental|Atorvastatin-omeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
3237772|NCT00930670|Experimental|Atorvastatin-pantoprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40mg for 11 months
3237773|NCT00930670|Experimental|Atorvastatin-esomeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
3237774|NCT00930670|Active Comparator|Atorvastatin-ranitidine|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
3237775|NCT00930644|Experimental|teduglutide|0.05 mg/kg/day
3237776|NCT00930618|Experimental|IMN|Isosorbide mononitrate
3237777|NCT00930618|Placebo Comparator|Placebo|Administration of placebo of IMN
3237778|NCT00930605|Experimental|Alemtuzumab combination with CHOP and ESHAP|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5. CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
3237779|NCT00930592||Children with Psoriasis|Children and adolescents from 10-17 years of age with moderate to severe psoriasis.
3237780|NCT00930592||Control: children with warts|Children and adolescents from 10-17 years of age with warts.
3237781|NCT00930579|Experimental|Metformin|
3237782|NCT00930566|Experimental|Extracorporal Photopheresis|
3237783|NCT00930553|Experimental|Previously treated with alemtuzumab|Alemtuzumab 12 mg per day administered through IV, once a day for 3 consecutive days (participants might receive additional cycles of alemtuzumab upon documented evidence of resumed disease activity, but not within same 12-month period)
3237784|NCT00930553|Experimental|Previously treated with interferon beta-1a (Rebif®)|Alemtuzumab 12 mg per day administered through IV, once a day for 5 consecutive days during the first cycle and 12 mg per day administered through IV, once a day for 3 consecutive days during the second cycle, 12 months later. Participants might qualify for as-needed retreatment (12 mg per day administered through IV, once a day for 3 consecutive days) after their second fixed annual cycle.
3237785|NCT00930514|Active Comparator|Rituximab IV 375 mg/m^2 (Stage 1: Cohort A)|
3237786|NCT00930514|Active Comparator|Rituximab IV 375 mg/m^2 (Stage 2: Cohort E)|
3237787|NCT00930514|Experimental|Rituximab SC 1400 mg (Stage 2: Cohort F)|
3237788|NCT00930514|Experimental|Rituximab SC 375 mg/m^2 (Stage 1: Cohort B)|
3237789|NCT00930514|Experimental|Rituximab SC 625 mg/m^2 (Stage 1: Cohort C)|
3237790|NCT00930514|Experimental|Rituximab SC 800 mg/m^2 (Stage 1: Cohort D)|
3237791|NCT00930501||Cancer patients|women 5-45 yr olf pre and post chemotherapy
3237792|NCT00930488||Group 1|
3237793|NCT00930462|No Intervention|Conventional colonoscopy|No cap fitted on the colonoscopes for this group.
3237794|NCT00930462|Experimental|Cap-assisted colonoscopy|
3237795|NCT00930449|Experimental|Cogmed Working Memory Training Program|
3237796|NCT00930449|Active Comparator|Academy of Math® program|
3237797|NCT00930449|Active Comparator|Special Education/Individualized Tutoring|
3237798|NCT00930436|Active Comparator|Saline infusion|Saline will be given as an active control agent to compare with sodium bicarbonate. Each bag of solution will be blinded, and given in the same manner.
3237799|NCT00930436|Experimental|Sodium Bicarbonate|Infusion of sodium bicarbonate will be given prior to,during and after the contrast agent for a total of 6 to 10 hours
3237800|NCT00930423||cases|patients with endstage renal failure due to atypical uraemic syndrome treated with hemodialysis.
3237801|NCT00930423||controls|patiënts with endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.
3237802|NCT00930410|Experimental|endomicroscopy|Utilisation of an intra-ductal confocal endomicroscopy during the endoscopic Retrograde Cholangio-Pancreatography
3237803|NCT00930397||Low risk women|Women without any personal risk.
3237804|NCT00930397||High risk women|Women at high risk for pre-eclampsia with personal of pre-eclampsia and/or IUGR in a previous pregnancy, diabetes, auto-immune syndrome such as lupus, hypertension, renal insufficiency and anti-phospholipid.
3238026|NCT00928837|Experimental|flavocoxid 500 mg|medical food product
3237805|NCT00930384||Psoriasis group|All adult patients fulfilling inclusion criteria will be considered as cases in which psoriasis is detected and diagnosed by our principal investigator based on the clinical criteria accepted by American Academy of Dermatology. They will have an abdominal ultrasound performed by a radiologist to assess for the presence of nonalcoholic fatty liver disease. They will be referred to the research clinic to have a blood drawn.
3237806|NCT00930384||Control group|For every case an age, sex and body mass index (BMI range - kg/m2) matched control will be selected from the same dermatologic/radiologic clinic. The controls will be invited to voluntarily participate and informed consent will be obtained for performing ultrasonography and analytical tests to ensure the absence of manifest hepatic disease.
3237807|NCT00930358|Experimental|MEOPA|MEOPA : equimolar nitrous oxide/oxygen mixture
3237808|NCT00930358|Active Comparator|General anesthesia|Gold standard
3237809|NCT00930345|Other|SUTENT before nephrectomy|
3237810|NCT00930332|Active Comparator|Arm A: Methadone|"Level 1: 1 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA** per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 3: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)"
3237811|NCT00930332|Active Comparator|Arm B: Methadone|"Level 1: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)"
3237812|NCT00930319||1|Patients with Advanced Hormone-dependent Prostate Carcinoma treated with Firmagon according to SPC
3237813|NCT00930306|Experimental|1|12 AZD2066 Capsule, 2 mg & 8 mg 2 Caffeine Tablet, 2 x 50 mg 2 Tolbutamide Tablet, half of 500 mg 2 Omeprazole Tablet, 20 mg 2 Midazolam Tablet, 7.5 mg 2 Metoprolol Tablet, 100 mg 2 Bupropion Tablet, 150 mg
3237814|NCT00930293|Experimental|Personalized Depression Care|Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication (citalopram) treatment.
3237815|NCT00930293|Active Comparator|Standard Depression Care|Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication (citalopram) treatment.
3237816|NCT00930280||Hemorrhagic stroke cases|People who have had a hemorrhagic stroke, specifically an intracerebral hemorrhage, and live within a 100 mile radius of the University of Cincinnati.
3237817|NCT00930280||Healthy Control Subjects|Healthy volunteers who are randomly identified in the same 100 mile radius of the University of Cincinnati and have not had a hemorrhagic stroke.
3237818|NCT00930254|Experimental|Ultrasound|Vascular puncture guided by vascular ultrasound
3237819|NCT00930241|Experimental|Advagraf|Advagraf® (one daily dose of Tacrolimus)
3237820|NCT00930241|Active Comparator|Prograf|Prograf® (two daily doses of Tacrolimus)
3237821|NCT00930228|Experimental|Flutamide|Flutamide 250 mg taken by mouth twice a day for 4 weeks. Flutamide is an androgen-receptor blocker.
3237822|NCT00930228|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
3237823|NCT00930215|Experimental|D961H 40 mg gelatin capsule|2 way crossover
3237824|NCT00930215|Experimental|D961H 40 mg HPMC capsule|2 way crossover
3237825|NCT00930202|Experimental|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
3237826|NCT00930202|No Intervention|Standard Care|No intervention
3237827|NCT00930176|Experimental|Human Coagulation FACTOR X|
3237828|NCT00930163|Experimental|1|
3237829|NCT00930163|Placebo Comparator|2|
3237830|NCT00930150|Experimental|Posit Science Intervention|Participants will receive targeted cognitive training and participate in a bridging group.
3237831|NCT00930150|Active Comparator|Control|Participants will play commercially available computer games and participate in weekly groups to discuss health and wellness.
3237832|NCT00930137|Experimental|High dairy trans fat|a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal)
3237833|NCT00930137|Active Comparator|Low dairy trans fat diet|a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)
3237834|NCT00930124|Experimental|1|Group 1 will receive Conventional orthognathic surgery
3237835|NCT00930124|Active Comparator|2|Group 2 will receive distraction osteogenesis
3237836|NCT00930111|Active Comparator|2 weeks|Attending physicians are physician-of-records for traditional inpatient ward team (housestaff and medical students) for 2 weeks.
3237837|NCT00930111|Placebo Comparator|4 weeks|Attending physicians are physician-of-records for traditional inpatient ward team (housestaff and medical students) for 4 weeks.
3237838|NCT00930085|Experimental|SELDI-TOF MS|The proteic profiling is performed by SELDI-TOF mass spectroscopy.
3237839|NCT00930072|Experimental|Block|
3237840|NCT00930072|No Intervention|Standard Care|
3237841|NCT00930059|Experimental|PF-04447943|
3237842|NCT00930059|Placebo Comparator|Placebo|
3237843|NCT00930046|Active Comparator|Ropivacaine group|Patients in this group will receive ropivacaine via the wound catheter for the first 48hrs after surgery
3237844|NCT00930046|Placebo Comparator|Normal Saline Group|Will receive an infusion of normal saline for 48hrs post-operatively via the wound catheter.
3237845|NCT00930033|Active Comparator|A|Nephrectomy + sunitinib
3237846|NCT00930033|Experimental|B|Sunitinib alone
3237847|NCT00930020|Placebo Comparator|matching placebo pill|matching placebo
3237848|NCT00930020|Active Comparator|Oral minocycline|Minocycline 200mg
3237849|NCT00930007||Hyperandrogenemic|Girls with elevated free testosterone concentrations
3237850|NCT00930007||Controls|Girls with normal free testosterone concentrations
3237851|NCT00929994||Exercise|Participants in this group will participate in Cardiac Rehabilitation, carrying out an exercise program which will last 6 months and combine both resistance and aerobic training.
3237852|NCT00929981||Oral Methylprednisolone|
3237853|NCT00929968|Placebo Comparator|Placebo to VAK694|
3237854|NCT00929968|Experimental|VAK694|
3237855|NCT00929968|Active Comparator|Fluticasone propionate|
3237856|NCT00929955|Active Comparator|Ondansetron|
3237857|NCT00929955|Active Comparator|Simvastatin|
3237858|NCT00929955|Placebo Comparator|Placebo|
3237859|NCT00929942|Experimental|DV Stent|"Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented."
3237860|NCT00929929|Experimental|L-Leucine|This arm receives a supplement of leucine along with a progressive resistance exercise program.
3237861|NCT00929929|Placebo Comparator|Maltodextrin|This arm receives a supplement of maltodextrin along with a progressive resistance exercise program.
3237862|NCT00929916||AM dosing of MoviPrep®|Take prep morning of exam
3237863|NCT00929916||PM/AM dosing of MoviPrep®|half of the volume of prep(1L) solution the evening prior, and half (1L) the morning of, colonoscopy.
3237864|NCT00929903|Experimental|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3237865|NCT00929890|Active Comparator|Lifestyle counseling|Patients will receive dietary counseling and a general advice on physical activity
3237866|NCT00929890|Experimental|Exercise training|patients will receive dietary counseling and will be enrolled in supervised exercise training
3237867|NCT00929877|Experimental|Ketoprofen lysinate 12.5 mg|
3237868|NCT00929877|Experimental|Ketoprofen lysinate 6.25 mg|
3237869|NCT00929877|Placebo Comparator|Matching placebo|
3237870|NCT00929864|Active Comparator|Abatacept|
3237871|NCT00929864|Active Comparator|Adalimumab|
3237872|NCT00929851|Experimental|BDP/FF|Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose inhaler
3237873|NCT00929851|Active Comparator|Formoterol fumarate|Formoterol fumarate 12 µg per metered dose
3237874|NCT00929838|Experimental|Diabetes Knowledge/Information Arm|Subjects randomized to the diabetes knowledge/information arm will complete 12 diabetes education modules over a 12-week period. The educational materials were developed based on guidelines for diabetes education by the American Diabetes Association. The content is based on the principles of the Adult Learning Theory. The information is designed to be relevant, person centered, and presented in a non-threatening manner. The modules are designed to be delivered via telephone in 10-15 minutes, so that the maximum contact time per telephone call including introduction and closing would not exceed 30 minutes.
3237875|NCT00929838|Experimental|Motivation/Behavioral Skills Arm|The motivation/behavioral skills intervention consists of patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions), patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools), and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks. The behavioral skills training will be focused on 4 behaviors - physical activity, diet, medication adherence, and glucose self-monitoring. Guided by subjects' current problem areas and preferences, subjects will be asked to choose 1 of 4 behaviors to focus on every 3 weeks (4 behaviors over 12 weeks).
3237876|NCT00929838|Experimental|Combined Intervention Arm|The combined intervention group will receive weekly telephone-delivered diabetes knowledge/information, patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions), patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools), and behavioral skills training delivered via telephone. The behavioral skills training will be focused on 4 behaviors and guided by subjects' current problem areas and preferences, subjects will be asked to choose 1 of 4 behaviors to focus on every 3 weeks. The combined intervention group telephone sessions will last for 30 minutes.
3237877|NCT00929838|Sham Comparator|Usual Care Arm|The usual care group will receive weekly telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention. Patients in the usual care group will continue to receive any usual diabetes education provided by the clinic staff; however, they will not receive targeted diabetes knowledge/information, activation, empowerment, or behavioral skills training.
3237878|NCT00929825|Experimental|Elastomers|Patients will use hyperboloid as mechanical salivary stimuli. Patients will chew hyperboloid 3 times a day
3237879|NCT00929825|Experimental|TENS|TENS is a eletric stimuli that will be use in the skin near to parotid glands. Patients will receive TENS treatment as eletric salivary stimuli. Patients will receive TENS stimuli once a day for 15 days
3237880|NCT00929825|Experimental|Elastomers+TENS|Patients will receive TENS plus hyperboloid as eletric and mechanical treatment for salivary stimuli
3237881|NCT00929825|No Intervention|No therapy (control)|Patients will not receive intervention
3237882|NCT00929812|Active Comparator|Glucagon hydrochloride|GlucaGen® 1 mg/1 ml intramuscularly
3237883|NCT00929812|Placebo Comparator|Placebo|1 ml NaCl 0.9%
3237884|NCT00929799|Experimental|Growth Hormone|Therapy with recombinant human GH (Genotropin® 1 mg = 3 IU, Pfizer Inc., NY, USA) daily by subcutaneous injection using a Genotropin pen at maximal GH dose of 0.003 mg/kg/day in patients with severe GHD
3237885|NCT00929786||2|"Cases - those patients who develop DIH while on regular treatment with anti-TB drugs.~Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs."
3237886|NCT00929773|Active Comparator|Erchonia PL2000 Laser|Low level laser light energy comprised of 1 milliWatts (mW) of red light (635 nm).
3237887|NCT00929773|Placebo Comparator|Placebo laser|inactive light
3237888|NCT00929760|Active Comparator|nephrologists|Combined management PCP: nephrologists (at least 4 nephrology visits/year)
3237889|NCT00929760|Active Comparator|Primary Care Physicians|Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG
3237890|NCT00929747|Active Comparator|Toric IOL|AcrySof IQ Toric IOL
3237891|NCT00929747|Active Comparator|Limbal Relaxing Incision|AcrySof IQ with Limbal Relaxing Incision
3237892|NCT00929734|Experimental|Rosuvastatin|
3237893|NCT00929734|Placebo Comparator|Placebo|
3237894|NCT00929721|Other|Subjects with Community-Acquired Pneumonia|Subjects with Community-Acquired Pneumonia
3237895|NCT00929708|Experimental|1|AZD3199 low dose
3237896|NCT00929708|Experimental|2|AZD3199 intermediate dose
3237897|NCT00929708|Experimental|3|AZD3199 high dose
3237898|NCT00929708|Active Comparator|4|Formoterol 2x4.5 microgram bid
3237900|NCT00929695|Experimental|Arm I (Low-dose)|Patients receive low-dose prednisone or methylprednisolone once or twice daily in the absence of disease progression or unacceptable toxicity.
3237901|NCT00929695|Active Comparator|Arm II (Standard-dose)|Patients receive standard-dose prednisone or methylprednisolone once or twice daily in the absence of disease progression or unacceptable toxicity.
3237902|NCT00929682|Experimental|Levobupivacaine 0.568mg.mL|
3237903|NCT00929682|Other|Levobupivacaine 1.136mg.mL|
3237904|NCT00929669|Experimental|Pasireotide LAR|80 mg IM once monthly
3237905|NCT00929656|Experimental|Real rTMS|Real rTMS + unimanual paretic UE training
3237906|NCT00929656|Active Comparator|Sham rTMS|Sham rTMS + unimanual paretic UE training
3237907|NCT00929643||1|
3237908|NCT00929630|Experimental|glue (Tissucol ) treatment|patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
3237909|NCT00929630|Active Comparator|Seton treatment|patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
3237910|NCT00929617|Experimental|1: exercise with 2 counseling types|Patients will participate in 12 individual exercise sessions with an exercise specialist; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
3237911|NCT00929617|Other|2. Usual Care - written materials|Patients will receive written materials about exercise for cancer survivors
3237912|NCT00929604|No Intervention|Standard of care|Standard of care arm: utilizes the current standard of care per Zambian national guidelines to determine treatment failure and eligibility for second-line ART. HIV-1 viral load measurement is performed if the criteria for either immunologic (i.e., CD4+ lymphocyte count-based) or clinical treatment failure are fulfilled. If both immunologic and clinical treatment failure criteria are fulfilled, the ART regimen is changed to second-line without VL testing.
3237913|NCT00929604|Experimental|Routine HIV-1 viral load testing|Routine viral load testing arm: Routine HIV viral load testing at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30 and 36 months thereafter.
3237914|NCT00929591|Active Comparator|tamoxifen for five years|tamoxifen for five years
3237915|NCT00929591|Experimental|CAF followed by tamoxifen for five years|intermittent CAF X 6 courses followed by tamoxifen for five years
3237916|NCT00929591|Experimental|CAF with concurrent tamoxifen for five years|intermittent CAF X 6 courses with concurrent tamoxifen for five years
3237917|NCT00929578|Placebo Comparator|Placebo|The sterile placebo: Bacteriostatic Sodium Chloride for Injection.
3237918|NCT00929578|Active Comparator|Fluphenazine|This will be an ascending dose study with the first cohort of 5 subjects dosed at 100 µg/mL, followed by cohorts at 500 and 2500 µg/mL. Dosing will be on Days 0, 7 and 14 and will consist of 5, or 10, 100 µL injections into the psoriatic lesion. The number of injections will depend on the lesion size. As this is a vehicle controlled study, subjects will receive intralesional injections of both drug and placebo, each into a separate target plaque, in a randomized fashion.
3237919|NCT00929565||Lung cancer|Comparison between individuals with and without pulmonary malignancy
3237920|NCT00929552|Experimental|Fish oil|Daily dose = 6g fish oil baked into rye bread and wheat rolls. Participants were asked to consume two slices of rye bread and one wheat roll pr day. The fish oil was micro-incapsulated.
3237921|NCT00929552|Active Comparator|Vegetable oil (Mix of canola, palm and soy oil)|Daily dose = 6g vegetable oil baked into rye bread and wheat rolls. Participants were asked to consume two slices of rye bread and one wheat roll pr day.
3237922|NCT00929539|Experimental|Dose 1 JTT-130|
3237923|NCT00929539|Experimental|Dose 2 JTT-130|
3237924|NCT00929539|Experimental|Dose 3 JTT-130|
3237925|NCT00929539|Placebo Comparator|Placebo|
3237926|NCT00929526|Experimental|Cervarix Group|subjects received 3 doses of Cervarix™ vaccine in primary vaccination study NCT00316693.
3237927|NCT00929526|Placebo Comparator|Aimmugen Group|subjects received 3 doses of Aimmugen ™ vaccine in primary vaccination study NCT00316693.
3237928|NCT00929500|Experimental|MAST program|Mixed Aerobic and Strength Training program (MAST): Each exercise session consisted of 10 minutes of warm-up, 15-30 minutes of interval aerobic training by cycle ergometer according to the program, 20 minutes of strength training exercises, and 10 minutes of cool-down by stretching.
3237929|NCT00929500|No Intervention|UC|Usual Care (UC) with Educational Lectures: No exercise sessions.
3237930|NCT00929487|Experimental|Contact lens solution #1|
3237931|NCT00929487|Experimental|Contact lens solution #2|
3237932|NCT00929487|Experimental|Contact lens solution #3|
3237933|NCT00929487|Experimental|Contact lens solution #4|
3237934|NCT00929487|Active Comparator|Saline/blister pack solution|
3237935|NCT00929474|Experimental|QuickOpt|
3237936|NCT00929474|Active Comparator|Control|
3237937|NCT00929461|Other|Omega-3 group|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
3237938|NCT00929461|Other|Omega 3 + Omega 6 group|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter.
3237939|NCT00929448||Immunoglobulin|
3237940|NCT00929435||MRSA surveillance|Newly recruited resident physicians will be monitored for a year with nasal swabs monthly.
3237941|NCT00929422||spinal cord injury 1|
3237942|NCT00929422||spinal cord injury 2|
3237943|NCT00929422||spinal cord injury 3|
3237944|NCT00929422||normal control|
3237945|NCT00929409|Active Comparator|Peroral iron - ferrous sulfate tablets|Peroral iron given as one tablet of ferrous sulfate 100 mg two times daily
3238027|NCT00928811|Other|Control|Standard of care administration with Simulect (basiliximab)being administered as per induction therapy on day of transplant and day 4.
3237946|NCT00929409|Active Comparator|Ferric carboxymaltose|Intravenous infusion of Ferric Carboxymaltose (Ferinject), the given dose is adapted according to the individual patient's requirement. No other form of iron supplementation is given.
3237947|NCT00929396|Experimental|Latent TB infection group|The latent TB group will receive two injections of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart.
3237948|NCT00929396|Experimental|BCG vaccinated group|The BCG vaccinated group will receive two vaccinations of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart
3237949|NCT00929370|Experimental|GSK1018921|Glycine Transporter-1 inhibitor to modulate the NMDA receptor.
3237950|NCT00929357||1|DMARDs
3237951|NCT00929357||2|Biologics
3237952|NCT00929344|Experimental|Duloxetine|
3237953|NCT00929344|Experimental|Pregabalin|
3237954|NCT00929344|Placebo Comparator|Placebo|
3237955|NCT00929331|Experimental|Fluviral Adult Group|Subjects aged between 18 and 60 years who received one dose of Fluviral® (2009-2010 season) intramuscularly in the deltoid region of the non-dominant arm
3237956|NCT00929331|Experimental|Fluviral Elderly Group|Subjects over 60 years of age who received one dose of Fluviral ® (2009-2010 season) intramuscularly in the deltoid region of the non-dominant arm
3237957|NCT00929318|Active Comparator|benign|patients after surgery because of a benign disease
3237958|NCT00929318|Active Comparator|DTC|Patients after thyroidectomy because of papillary carcinoma of the thyroid gland
3237959|NCT00929305|Placebo Comparator|Placebo laser|inactive laser light
3237960|NCT00929305|Active Comparator|Erchonia PL2000|The Erchonia PL2000 Laser emits 1 milliWatt (mW) of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
3237961|NCT00929292|Experimental|Modilac Dahlia 1|Formula enriched with alpha-lactalbumin and containing a probiotic
3237962|NCT00929292|Placebo Comparator|Modilac 1|Regular milk
3237963|NCT00929279|Active Comparator|Abciximab bolus plus infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen.
3237964|NCT00929279|Experimental|bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
3237965|NCT00929266|Experimental|1|"The choice of conducting the study in healthy volunteers and not in patients is based on the necessity to have a healthy physiological context avoiding any situation which could lead to hemolysis. As the protocol requires mobilization with a growth factor, the donors of peripheral stem cells (PSC) receive G-CSF.~Direct intravenous injection of labeled cRBC in a volume of 1 mL will be administered to the subjects."
3237966|NCT00929253|Active Comparator|Computer delivered CRA + CM + Suboxone|"In this arm, participants are administered Suboxone and therapy is delivered by a computer. Fluency training is provided. The participant then listens through headphones and reads the information on the screen. They progress through various modules that involve education regarding high risk situations for potential use drug and skills to deal with those situations. In addition, skills for dealing with anxiety and anger are also provided. Videos are displayed that have examples of real-left situations. HIV/AIDS education is also provided. The program is interactive with the participant being required to answer short questions at the end of each module and prompts for homework worksheets are provided. These participants receive vouchers for providing drug negative urine samples."
3237967|NCT00929253|Active Comparator|Therapist delivered CRA + CM + Suboxone|In this arm of the study, the participants receive vouchers for providing a drug negative urine sample. These participants, however, do not have computer deliver therapy, only therapist delivered therapy.
3237968|NCT00929240|Active Comparator|Avastin (bevacizumab)|
3237969|NCT00929240|Experimental|Avastin (bevacizumab) + Xeloda (capecitabine)|
3237970|NCT00929214|Experimental|Standard Therapy + Local Therapy|Systemic Standard Therapy (chemotherapy and/or endocrine therapy) + Local Therapy (surgery and/or radiation)
3237971|NCT00929201|Active Comparator|Sita + Met then Sita/Met FDC|Participants receive sitagliptin (Sita) 50 mg and metformin (Met) 500 mg individual tablets administered concomitantly as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin/metformin (Sita/Met) 50/500 mg FDC tablet administered as a single dose during Period 2.
3237972|NCT00929201|Active Comparator|Sita/Met FDC then Sita + Met|Participants receive sitagliptin/Metformin 50 mg/500 mg FDC tablet administered as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 2.
3237973|NCT00929188|Experimental|001|JNJ-42160443 Type=1 unit=mg number=10 form=solution for injection route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
3237974|NCT00929188|Placebo Comparator|002|Placebo Form=solution for injection route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
3237975|NCT00929175|Active Comparator|active CPAP|auto-PAP with therapeutic pressure
3237976|NCT00929175|Sham Comparator|sham-CPAP|auto-PAP with pressure less than 1cm H2O
3237977|NCT00929162|Experimental|ZD4054 + paclitaxel + carboplatin|ZD4054 10mg oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks
3237978|NCT00929162|Placebo Comparator|Placebo + paclitaxel + carboplatin|Placebo oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks
3237979|NCT00929136|Experimental|Endotoxin|
3237980|NCT00929123|Experimental|neural mobilization|manual therapy technique known to directly stress the median nerve
3237981|NCT00929123|Placebo Comparator|sham neural mobilization|manual therapy technique known to directly stress the median nerve without any stimulation.
3237982|NCT00929123|Active Comparator|Healthy Controls|People without carpal tunnel syndrome for comparison
3237983|NCT00929110|Experimental|Glycopyrronium bromide 50 μg|Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3238028|NCT00928811|Experimental|Simulect|"Simulect (basiliximab) intravenously day of transplant and day 4.~Chronic Simulect (basiliximab) administration monthly for one year duration.~Concomitant decrease in Prograf administration."
3237984|NCT00929110|Placebo Comparator|Placebo to glycopyrronium bromide|Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3237985|NCT00929110|Active Comparator|Tiotropium 18 μg|Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3237986|NCT00929097|Experimental|Implementation aids|
3237987|NCT00929097|Active Comparator|Control|
3237988|NCT00929084|Other|Survivor Stories Arm|Women in the Survivor Stories intervention arm will be given the Survivor Stories Tablet to take home for two weeks at three different time points over a two year period.
3237989|NCT00929084|Other|Control Arm|Women in the Control Arm will receive standard care.
3237990|NCT00929071|Experimental|Pain assessment for Evolence/topical anesthetic|Assess injection pain severity for a one time 1.0 mL injection of Evolence with 0.2 ml of topical anesthetic, applied 30 minutes prior to injection, to the left nasolabial fold of each participant .
3237991|NCT00929071|Experimental|Pain assessment for Evolence/Lidocaine|Assess injection pain severity for a one time 1.0 mL injection of Evolence mixed with 0.18 mL of 2% lidocaine (0.3% final lidocaine-HCl) in the right nasolabial fold of each participant.
3237992|NCT00929058|Experimental|Bevacizumab|
3237993|NCT00929045|Experimental|Growth Hormone|
3237994|NCT00929032||Liver transplant recipient|Liver transplant recipient
3237995|NCT00929019|Experimental|dendritic cell vaccination|HLA-A2.1 positive patient will receive 3 biweekly intradermal/intravenous vaccination with autologous mRNA transfected mature dendritic cells, followed by a DTH skin test for monitoring purposes. One such cycle is repeated every 6 months if no signs of progression, up to a total of 3 cycles.
3237996|NCT00929019|No Intervention|control arm|For comparison, HLA-A2.1 negative patients will be monitored for clinical response (secondary endpoint).
3237997|NCT00929006|Experimental|Micronized progesterone suspension|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
3237998|NCT00929006|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
3237999|NCT00928993||Main group|pediatric patients receiving overnight sleep study
3238000|NCT00928980|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy and withdrawal of antidepressant medication between the 4th and 5th session, patients being off medication until the end of study period (15 months).
3238001|NCT00928980|Experimental|Combination|Mindfulness Based Cognitive Therapy combined with the use of antidepressant medication during the study (15 months).
3238002|NCT00928980|Active Comparator|Optimal Medical Care|Treatment with optimal medical care: therapeutic dose of antidepressant medication during at least 15 months, administered in accordance with current guidelines.
3238003|NCT00928967||Group 1|
3238004|NCT00928954|Active Comparator|Gabapentin|Increasing dose to 300 mg four times per day (total of 1200 mg/day)
3238005|NCT00928954|Active Comparator|Memantine|Increasing dose over two weeks to 20 mg twice/day (total of 40 mg/day).
3238006|NCT00928941|Experimental|Arm 1|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units.
3238007|NCT00928941|Active Comparator|Arm 2|A computer game control condition will be implemented for 3-4 training exercises a week for 40 hours.
3238008|NCT00928928|Active Comparator|Open group|Group of patients operated with open approach for colorectal cancer
3238009|NCT00928928|Active Comparator|laparoscopic group|Group of patients operated with laparoscopic approach for colorectal cancer
3238010|NCT00928915|Experimental|Prothrombin complex concentrate (PCC)|intravenously, 30 IU/kg
3238011|NCT00928915|Experimental|Fresh frozen plasma (FFP)|intravenously, 20ml/kg
3238012|NCT00928902|Active Comparator|Peptides with GM-CSF-in-adjuvant, with upfront IL-2|Each of the peptides plus tetanus toxoid peptide, plus GM-CSF in adjuvant, administered subcutaneously and intradermally. Systemic low-dose IL-2 will be administered daily for 6 weeks, beginning at week 1 and ending at week 7.
3238013|NCT00928902|Active Comparator|Peptides plus GM-CSF-in-adjuvant, delayed IL-2|"Peptides plus GMCSF-in-adjuvant, with delayed IL-2.~Each of the peptides plus tetanus toxoid peptide, plus GM-CSF in adjuvant, administered subcutaneously and intradermally. Systemic low-dose IL-2 will be administered daily for 6 weeks, beginning at week 4 and ending at week 10."
3238014|NCT00928889|Experimental|Nateglinide 120 mg|Nateglinide was taken orally 3 times daily, 10 minutes before meals for 4 weeks.
3238015|NCT00928889|Active Comparator|Acarbose 50 mg|Acarbose 50 mg was taken orally 3 times daily, with the first bite of food at meals for 4 weeks.
3238016|NCT00928876|Experimental|Anakinra group|Anakinra 150 mg/day during four weeks
3238017|NCT00928876|Placebo Comparator|Placebo|Placebo during four weeks
3238018|NCT00928863||Haemorrhagia post partum|Women with a high risk for haemorrhagia post partum.
3238019|NCT00928850|Active Comparator|urethral irrigation but no fascial suturing, QOL forms|The anterior two-thirds of the urethra is divided exposing a Foley catheter that was placed at the beginning of the procedure. Irrigation of the urethra may prevent spread of prostate cancer cells to tissue that is not removed during surgery. The urethra is irrigated with 60 cc of sterile water as it is withdrawn from the patient to 'wash' the urethra.
3238020|NCT00928850|Active Comparator|fascial suturing but no urethral irrigation, QOL forms|For patients undergoing fascial suturing only, after the initial placement of the suture through the urethra a second bite is taken deeply into the fascia of the lateral pelvic fascia.
3238021|NCT00928850|Active Comparator|both urethral irrigation and fascial suturing, QOL forms|
3238022|NCT00928850|Active Comparator|neither urethral irrigation nor fascial suturing, QOL forms|
3238023|NCT00928837|Active Comparator|flavocoxid 250 mg|Medical Food product
3238024|NCT00928837|Active Comparator|Naproxen|antiinflammatory
3238025|NCT00928837|Placebo Comparator|Placebo|Placebo
3238029|NCT00928798|Experimental|rapamycin|one facial side rapamycin and one facial side placebo
3238030|NCT00928785|Experimental|REPEVAX|
3238031|NCT00928785|Active Comparator|Monovalent tetanus vaccine|
3238032|NCT00928772|Active Comparator|Alpha-Stim intervention|One hour Alpha-Stim intervention with sham midazolam
3238033|NCT00928772|Sham Comparator|Sham Alpha-Stim with midazolam|Sham Alpha-Stim intervention with real midazolam administration
3238034|NCT00928772|Placebo Comparator|Placebo|No Alpha-Stim and only topical anesthetics
3238035|NCT00928759||peripubertal obese girls|Peripubertal obese girls, aged 8 - 16 years, who are obese (BMI-for-age percentile greater or equal to 95)
3238036|NCT00928746|Other|ATROVENT 42mcg|
3238037|NCT00928733|Experimental|alcohol|Intraduodenal infusion of ethanol
3238038|NCT00928733|Other|Ethanol|
3238039|NCT00928733|Experimental|Placebo|Intraduodenal infusion of tap water
3238040|NCT00928720|Active Comparator|CES device|Participants will use the device for 60 minutes each day for 8 weeks.
3238041|NCT00928720|Sham Comparator|Sham device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device.
3238042|NCT00928720|No Intervention|Usual care alone|No intervention; participants will receive usual medical care
3238043|NCT00928707|Experimental|GIVINOSTAT + MTD Hydroxyurea_1|50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
3238044|NCT00928707|Experimental|GIVINOSTAT + MTD Hydroxyurea_2|50 mg b.i.d. of GIVINOSTAT + MTD of HU monotherapy
3238045|NCT00928694|Active Comparator|1|Fenofibrate U.S. Formulation
3238046|NCT00928694|Active Comparator|2|Fenofibrate UK Formulation
3238047|NCT00928681|Other|0.03 mg/kg or placebo iv|
3238048|NCT00928681|Other|0.1 mg/kg or placebo iv|
3238049|NCT00928681|Other|0.3 mg/kg or placebo iv|
3238050|NCT00928681|Experimental|1.0 mg/kg or placebo iv|
3238051|NCT00928681|Other|3.0 mg/kg or placebo sc|
3238052|NCT00928681|Other|10 mg/kg or placebo iv|
3238053|NCT00928681|Other|0.3 mg/kg or placebo sc|
3238054|NCT00928681|Other|0.1 mg/kg or placebo iv (multiple dose)|
3238055|NCT00928681|Other|0.3 mg/kg or placebo iv (multiple dose)|
3238056|NCT00928681|Other|3.0 mg/kg or placebo iv|
3238057|NCT00928681|Other|0.1 mg/kg or placebo sc|
3238058|NCT00928681|Other|0.3 mg/kg or placebo sc (multiple dose)|
3238059|NCT00928668|Experimental|Olodaterol (BI1744) Low|Single dosing of low dose Olodaterol inhaled orally from Respimat Device
3238060|NCT00928668|Experimental|Olodaterol (BI1744) Medium Low|Single dosing of medium low dose Olodaterol inhaled orally from Respimat Device
3238061|NCT00928668|Experimental|Olodaterol (BI1744) Medium High|Single dosing of medium high dose Olodaterol inhaled orally from Respimat Device
3238062|NCT00928668|Experimental|Olodaterol (BI 1744) High|Single dosing of high dose Olodaterol inhaled orally from Respimat Device
3238063|NCT00928668|Placebo Comparator|Placebo|Single dosing of Olodaterol placebo inhaled orally from Respimat Device
3238064|NCT00928655|Experimental|acetazolamide|combination of acetazolamide and nocturnal continuous positive airway pressure ventilation
3238065|NCT00928655|Placebo Comparator|placebo capsules|combination of placebo and nocturnal continuous positive airway pressure ventilation
3238066|NCT00928642|Experimental|Oral Imatinib plus intravenous gemcitabine|"All research subjects receive oral imatinib 400mg days 1-5 and 8-12 of a 21 day cycle.~All research subjects received IV gemcitabine 1000mg/m2 days 3 and 10 of a 21-day cycle. .~All subjects had epithelial ovarian cancer or primary peritoneal carcinomatosis and had failed to respond to prior chemotherapy or progressed after prior chemotherapy."
3238067|NCT00928629|Other|All Subjects|ABI Screening Test Population: Subjects of either sex, any race, with at least two of the specified CVD risk factors, with no overt cardiovascular disease.
3238068|NCT00928616|Experimental|plant sterol esters|Participants consume plant sterol ester supplemented margarine (3 g/day)
3238069|NCT00928616|Placebo Comparator|Placebo|Placebo is a non-sterol ester supplemented margarine
3238070|NCT00928603|Experimental|cryotherapy|Focal Cryotherapy of localized tumor of prostate after spatial definition by in-house extended perineal core biopsy using a template biopsy strategy under local or general anesthesia
3238071|NCT00928590|Experimental|DuoTrav APS|Travoprost/Timolol Maleate Fixed Combination solution, 1 drop in the study eye(s) once daily, at 9 AM, for 12 months
3238072|NCT00928577||ACAM2000 Smallpox Vaccine Group|Participants are vaccinia vaccine-naive and have received ACAM2000 Smallpox vaccine as part of their Service Member readiness process.
3238073|NCT00928577||Other vaccinia vaccine Group|Participants did not receive ACAM2000 Smallpox vaccine as part of their Service Member readiness process because they are still protected by previous vaccinia vaccination or are ineligible for current ACAM2000 vaccination either because of recency of prior vaccinia vaccination or for reasons solely attributable to conditions or characteristics of their contacts (such as a healthy soldier who is married to someone with a contraindicated condition).
3238074|NCT00928564|Active Comparator|Pudendal Block|8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
3238075|NCT00928564|Placebo Comparator|Placebo|5ml of saline at each block site
3238076|NCT00928551|Experimental|1|
3238077|NCT00928538|No Intervention|Usual NFP Care|Usual NFP care includes pregnancy planning and contraceptive advice during nurse home visits, with the prescription and dispensing of contraceptives provided through the women's primary care settings.
3238078|NCT00928538|Experimental|Enhanced NFP Care|Enhanced NFP intervention includes usual NFP care plus the intervention that includes contraceptive administration and distribution in the home
3238079|NCT00928525|Experimental|Imatinib Mesylate|Patients affected by Desmoid Tumor and Chondrosarcoma will receive Imatinib Mesylate 800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
3238080|NCT00928512|Experimental|Secukinumab 25mg|Secukinumab 25mg s.c. q4wk
3238081|NCT00928512|Experimental|Secukinumab 75mg|Secukinumab 75mg s.c. q4wk
3238082|NCT00928512|Experimental|Secukinumab 150mg|Secukinumab 150mg s. c. q4wk
3238083|NCT00928512|Experimental|Secukinumab 300mg|Secukinumab 300mg s.c. q4wk
3238084|NCT00928512|Placebo Comparator|Secukinumab Placebo|Secukinumab Placebo s.c. q4wk
3238085|NCT00928499|Other|Interstim - continuous|Continuous stimulation
3238086|NCT00928499|Other|Interstim - cyclic|Cyclic stimulation
3238087|NCT00928486|Experimental|Lenalidomide and Dexamethasone|Lenalidomide 25mg by mouth (PO) once daily (QD) on Days 1-21 of each 28 day cycle; When creatinine (CrCl) clearance <60 mL/min, the initial dose was 10mg and the dose could be increased to 15mg after 2 cycles if the investigator judged therapeutic effect was insufficient and tolerability was acceptable. Dexamethasone 40 mg by PO once QD on days 1-4, 9-12 and 17-20 of each 28 day cycle for the first 4 cycles and Days 1-4 for the remaining cycles beginning at Cycle 5.
3238088|NCT00928473|Experimental|Lifestyle counseling|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
3238089|NCT00928460||Regular preanesthesia evaluation|Patients are evaluated by the anesthesiologist according to current protocol, including routine preoperative ECG.
3238090|NCT00928460||New preanesthesia evaluation|Patients are evaluated by the anesthesiologist according to a new protocol, in which a routine preoperative ECG is no longer provided.
3238091|NCT00928447|Active Comparator|1|Treatment effect of rHuPH20 injection on the exposure to topical nickel allergen
3238092|NCT00928447|Placebo Comparator|2|Treatment effect of placebo control injection on the exposure to topical nickel allergen
3238093|NCT00928434|Experimental|DI (Degarelix Intermittent)|"Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.~Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 were administered.~During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered."
3238094|NCT00928434|Experimental|DC (Degarelix Continuous)|"Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.~Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall"
3238095|NCT00928434|Active Comparator|LC (Leuprolide Continuous)|"Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0, administered intramuscular (i.m.) into a large muscle, as per manufacturer's labeling directions.~One injection of 22.5 mg leuprolide 3-month depot was administered i.m. as per manufacturer's labeling directions at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).~On Investigator's discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels."
3238096|NCT00928421|Experimental|Varisolve 0.125%|
3238097|NCT00928408||Cinacalcet|
3238098|NCT00928395|Active Comparator|Urgent PC|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
3238099|NCT00928356|Experimental|Hybrid CABG/PCI|Patients undergo hybrid, same sitting CABG/PCI as described.
3238100|NCT00928356|Other|Off-pump CABG|Standard of Care Off Pump CABG
3238101|NCT00928343|Experimental|GLPG0187|Single dose
3238102|NCT00928343|Placebo Comparator|Placebo|
3238103|NCT00928330|Experimental|A|
3238104|NCT00928330|Experimental|B|
3238105|NCT00928330|Experimental|C|
3238106|NCT00928317|Experimental|ART621 A|ART621 0.75mg/kg per week
3238107|NCT00928317|Experimental|ART621 B|ART621 1.5 mg/kg per week
3238108|NCT00928317|Experimental|ART621 C|ART621 3.0mg/kg per week
3238109|NCT00928317|Placebo Comparator|Placebo arm|
3238110|NCT00928304|Experimental|Florbetaben (BAY94-9172)|
3238111|NCT00928291|Experimental|Group 1 - PCT group|interventions on antibiotic therapy will be based on circulating PCT levels
3238112|NCT00928291|Active Comparator|Group 2 - Control group|antibiotic therapy will be guided by appropriate guidelines, and will be left at the discretion of caregivers.
3238113|NCT00928278|Experimental|Treatment A - PF-04764793|PF-04764793 using inhaler A
3238114|NCT00928278|Active Comparator|Treatment B - PF-04764793|PF-04764793 using inhaler B
3238115|NCT00928278|Experimental|Treatment C - PF-04764793|PF-04764793 using inhaler A
3238116|NCT00928278|Active Comparator|Treatment D - PF-04764793|PF-04764793 using inhaler B
3238117|NCT00928252|Experimental|Received 18F-fluorocholine PET/CT|IV fluorine-18 labeled methylcholine before PET/CT
3238118|NCT00928239|Experimental|1|Arm1: Laparoscopic repair of vaginal vault prolapse. Laparoscopic sacropexy procedure as described in previous publication(Sarlos D, Brandner S, Kots L, Gygax N, Schaer G. Laparoscopic sacrocolpopexy for uterine and post-hysterectomy prolapse: anatomical results, quality of life and perioperative outcome-a prospective study with 101 cases. Int Urogynecol JPelvic Floor Dysfunct. 2008 Oct;19(10):1415-22. Epub 2008 Jun 7. PubMed PMID: 18536861) with attachment to the caudal part of the vagina and the apex.
3238119|NCT00928239|Active Comparator|2|Arm 2: Laparoscopic repair of vaginal vault prolapse. Laparoscopic sacropexy procedure as described in previous publication(Sarlos D, Brandner S, Kots L, Gygax N, Schaer G. Laparoscopic sacrocolpopexy for uterine and post-hysterectomy prolapse: anatomical results, quality of life and perioperative outcome-a prospective study with 101 cases. Int Urogynecol JPelvic Floor Dysfunct. 2008 Oct;19(10):1415-22. Epub 2008 Jun 7. PubMed PMID: 18536861) with attachment of the dorsal mesh at distal end of vagina at dorsal vaginal wall
3238120|NCT00928226|Experimental|Arm 1|Participants who have brain metastasis 4.2 to 14.1 cm3 and are surgical candidates will have surgical resection of the tumor followed by fractionated stereotactic radiosurgery.
3238121|NCT00928226|Experimental|Arm 2|Participants who have brain metastasis 14.2 to 33.5 cm3 and are surgical candidates will have surgical resection of the tumor followed by fractionated stereotactic radiosurgery.
3238122|NCT00928226|Experimental|Arm 3|Participants who have brain metastasis 4.2 to 14.1 cm3 and are not surgical candidates will be treated with fractionated stereotactic radiosurgery only.
3238123|NCT00928226|Experimental|Arm 4|Participants who have brain metastasis 14.2 to 33.5 cm3 and are not surgical candidates will be treated with fractionated stereotactic radiosurgery only.
3238124|NCT00928213|Experimental|1|Control not treated, no placebo
3238125|NCT00928213|Experimental|2|Patient treated with low molecular weight heparin after repeated pregnancy loss
3238126|NCT00928213|Experimental|3|Patient super from first trimester bleeding treated with progesterone
3238127|NCT00928187|Active Comparator|Arm A|emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
3238128|NCT00928187|Active Comparator|Arm B|abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
3238129|NCT00928187|Active Comparator|Arm C|emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
3238130|NCT00928174|Experimental|Single Arm|Fluorine-18 fluorocholine IV in conjunction with PET/CT imaging, up to 3 doses.
3238131|NCT00928161|No Intervention|Group 1|Patients with no acid reflux.
3238132|NCT00928161|Active Comparator|Group 2|Patients with acid reflux.
3238133|NCT00928148|Experimental|SPD465 (50 or 75 mg)|
3238134|NCT00928148|Active Comparator|Immediate Release Amphetamine salt (25 mg)|
3238135|NCT00928148|Placebo Comparator|Placebo|
3238136|NCT00928135|Active Comparator|7% Hypertonic saline|5 ml of 7% saline twice daily
3238137|NCT00928135|Experimental|Hypertonic xylitol|5 ml of 15% xylitol twice daily
3238138|NCT00928122|Experimental|1 / Presbyopia|Presbyopic patients, slightly hyperopes
3238139|NCT00928122|Experimental|2 / Myopia|Myopic patients without Astigmatism
3238140|NCT00928122|Experimental|3 / Hyperopia|Hyperope patients without Astigmatism
3238141|NCT00928122|Experimental|4 / Myopia with Astigmatism|Myopic patients incl. Astigmatism
3238142|NCT00928122|Experimental|5 / Hyperopia with Astigmatism|Hyperope patients incl. Astigmatism
3238143|NCT00928109|Experimental|Cognitive Behavioral Couples Therapy (CBCT)|CBCT is a 20-week program consisting of 1-hour sessions between a couple and a therapist. In this program, couples learn about ways to communicate about their relationship in the context of experiencing anorexia nervosa. CBCT focuses on couple-specific skills such as communication and targets relationship domains such as exercise, body image and sexuality, eating together as a couple, and broader relationship concerns outside of anorexia nervosa.
3238144|NCT00928109|Active Comparator|Family Supportive Therapy|Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
3238145|NCT00928083|Experimental|Part A - 50 mg Single Dose|OZ439 Single doses of 50mg (capsules)
3238146|NCT00928083|Experimental|Part A - 100mg Single Dose|OZ439 Single doses of 100mg (capsules)
3238147|NCT00928083|Experimental|Part A - 200mg Single Dose|OZ439 Single doses of 200mg (capsules)
3238148|NCT00928083|Experimental|Part A - 400mg Single Dose|OZ439 Single doses of 400mg (capsules)
3238149|NCT00928083|Experimental|Part A - 400mg Single Dose + Food|OZ439 Single doses of 400mg (capsules) administered with food.
3238150|NCT00928083|Experimental|Part A - 400mg AD Single Dose|OZ439 Single doses of 400mg (aqueous dispersion)
3238151|NCT00928083|Experimental|Part A - 800mg Single Dose|OZ439 Single doses of 800mg (capsules)
3238152|NCT00928083|Experimental|Part A - 800mg AD Single Dose|OZ439 Single doses of 800mg (aqueous dispersion)
3238153|NCT00928083|Experimental|Part A - 1200mg Single Dose|OZ439 Single doses of 1200mg (capsules)
3238154|NCT00928083|Experimental|Part A - 1600mg AD Single Dose|OZ439 Single doses of 800mg (aqueous dispersion)
3238155|NCT00928083|Placebo Comparator|Part A - Placebo|Placebo control for Single rising Part A
3238156|NCT00928083|Experimental|Part B - 800mg AD Single Dose Fed|Single dose of OZ439 800mg aqueous dispersion administered under fed conditions
3238157|NCT00928083|Experimental|Part B - 800mg AD Single Dose Fast|Single dose of OZ439 800mg aqueous dispersion administered under fast conditions
3238158|NCT00928083|Experimental|Part C - 200mg AD Multiple Dose|200mg aqueous solution OZ439 or placebo once daily for 3 days fasted
3238159|NCT00928083|Experimental|Part C - 400mg AD Multiple Dose|400mg aqueous solution OZ439 or placebo once daily for 3 days fasted
3238160|NCT00928083|Experimental|Part C - 800mg AD Multiple Dose|800mg aqueous solution OZ439 or placebo once daily for 3 days fasted
3238161|NCT00928083|Placebo Comparator|Part C - Placebo|Placebo control for Multiple rising Part C
3238162|NCT00928070|Experimental|Fesoterodine|
3238163|NCT00928070|Placebo Comparator|Placebo|
3238164|NCT00928057|Experimental|4 mm / 8 mm PN|Subjects randomized to this study arm used either the 4mm PN or the 8mm PN for 3 weeks, then switched to the alternate PN for another 3 weeks. Order of PN use was randomly determined.
3238165|NCT00928057|Experimental|4 mm / 5 mm PN|Subjects randomized to this study arm used either the 4mm PN or the 5mm PN for 3 weeks, then switched to the alternate PN for another 3 weeks. Order of PN use was randomly determined.
3238166|NCT00928044||control groups|They had regular menstrual cycles and no history of pelvic surgery. None had any endocrine disorders (e.g. PCOS) and received any kind of medication that could affect the results within the preceding 6 months, and any woman who had a suspected pathologic lesion in the ovary or menopausal symptoms was excluded.
3238167|NCT00928044||operation group|1. They had regular menstrual cycles and no history of pelvic surgery. None had any endocrine disorders (e.g. PCOS) and received any kind of medication that could affect the results within the preceding 6 months, and any woman who had a suspected pathologic lesion in the ovary or menopausal symptoms was excluded. 2. Operations were performed for benign ovarian tumors, leiomyoma or adenomyosis
3238168|NCT00928018|Active Comparator|Sirolimus-Containing Regimen|"The Sirolimus containing arm will consist of the following drugs:~Experimental Arm: tacrolimus + sirolimus + low-dose methotrexate~Tacrolimus: Administered orally at a dose of 0.05 mg/kg based on ABW bid starting on day -3.~Sirolimus:Given as a loading oral dose of 12 mg on day -3, then as a daily maintenance dose of 4 mg starting on day -2.~Methotrexate: Administered by intravenous bolus infusion, per institutional standard, at a dose of 5 mg/m2 on days +1, +3 and +6."
3238227|NCT00927732|Experimental|hydroquinidine|As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.
3238365|NCT00926835|Experimental|Paroxetine|Paroxetine monotherapy
3238169|NCT00928018|Active Comparator|Sirolimus-Free regimen|"There are two choices for the Sirolimus free arm:~Control Arm 1: tacrolimus + methotrexate~Tacrolimus:Administered orally at a dose of 0.05 mg/kg based on ABW bid starting on day -3.~Methotrexate:Administered by intravenous bolus infusion at a dose of 5 mg/m2 on days +1, +3 and +6. For patients receiving stem cells from unrelated donors, an additional dose will be given on day +11.~Control Arm 2: cyclosporine + MMF~Cyclosporine: administered orally at a dose of 6 mg/kg based on ABW bid starting on day -3.~MMF:administered at a dose of 3gm daily orally (or intravenously if the patient cannot tolerate oral administration) divided in 2 or 3 doses (bid or tid) depending on physician preference starting on day 3."
3238170|NCT00928005|Active Comparator|Weight loss diet|Participants will follow a low-calorie, low-fat weight loss diet for 6 months.
3238171|NCT00928005|Active Comparator|Weight loss diet plus exercise|Participants will follow a low-calorie, low-fat weight loss diet plus participate in a supervised exercise training program for 6 months.
3238172|NCT00927992||Patients with haemophilia who undergo liver transplantation|Patients with haemophilia who underwent liver transplantation and who have been followed up at any site in Spain.
3238173|NCT00927979|Experimental|Ropivacaine|
3238174|NCT00927979|Placebo Comparator|Water for injection|
3238175|NCT00927966|Experimental|RAD001 in combination with figitumumab|
3238176|NCT00927953|Experimental|MGAWN1|30 mg/kg single intravenous infusion of MGAWN1
3238177|NCT00927953|Placebo Comparator|Placebo - Normal Saline|single intravenous infusion of saline placebo
3238178|NCT00927940|Experimental|Drug Eluting Stent|All patients may have one or two lesions, if the two lesions are located in separate coronary arteries. A patient with one or two lesions treated with stents of diameter 2.5mm - 3.5mm will be designated in this study.
3238179|NCT00927927|Experimental|SD 0.0002 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.0002 mg/kg
3238180|NCT00927927|Experimental|SD 0.0012 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.0012 mg/kg
3238181|NCT00927927|Experimental|SD 0.007 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.007 mg/kg
3238182|NCT00927927|Experimental|SD 0.035 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.035 mg/kg
3238183|NCT00927927|Experimental|SD 0.175 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.175 mg/kg
3238184|NCT00927927|Experimental|SD 0.7 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.7 mg/kg
3238185|NCT00927927|Experimental|SD 2.5 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 2.5 mg/kg
3238186|NCT00927927|Experimental|SD 7.5 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 7.5 mg/kg
3238187|NCT00927927|Experimental|SD Placebo|Subjects were injected once with placebo
3238188|NCT00927927|Experimental|MD 0.02 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg
3238189|NCT00927927|Experimental|MD 0.3 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg
3238190|NCT00927927|Experimental|MD 1.0 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg
3238191|NCT00927927|Experimental|MD 1.6 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg
3238192|NCT00927927|Experimental|MD 4.0 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg
3238193|NCT00927927|Experimental|MD Placebo|Subjects were injected biweekly four times with placebo
3238194|NCT00927914|Experimental|Ranirestat 80 mg|Two 80 mg Ranirestat tablets, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
3238195|NCT00927914|Experimental|Ranirestat 40 mg|One 40 mg tablet of Ranirestat and a matching placebo, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
3238196|NCT00927914|Placebo Comparator|Placebo|Two placebo tablets, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
3238197|NCT00927901|Experimental|Indacaterol (ind) maleate-placebo-ind xinafoate-ind acetate|In treatment period 1, patients received indacaterol maleate 400 μg; in treatment period 2, patients received placebo to indacaterol; in treatment period 3, patients received indacaterol xinafoate 400 μg; and in treatment period 4, patients received indacaterol acetate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3238198|NCT00927901|Experimental|Indacaterol (ind) xinafoate-ind maleate-ind acetate-placebo|In treatment period 1, patients received indacaterol xinafoate 400 μg; in treatment period 2, patients received indacaterol maleate 400 μg; in treatment period 3, patients received indacaterol acetate 400 μg; and in treatment period 4, patients received placebo to indacaterol 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3238199|NCT00927901|Experimental|Indacaterol (ind) acetate-ind xinafoate-placebo-ind maleate|In treatment period 1, patients received indacaterol acetate 400 μg; in treatment period 2, patients received indacaterol xinafoate 400 μg; in treatment period 3, patients received placebo to indacaterol; and in treatment period 4, patients received indacaterol maleate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3238228|NCT00927732|Placebo Comparator|capsules of sugar|As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.
3238229|NCT00927719||ACAM2000® vaccinia vaccine Cohort|Participants had received ACAM2000®, vaccinia virus Smallpox vaccine.
3238230|NCT00927706|Experimental|Immediate intervention|Subjects and their caregivers randomized to this arm receive the intervention immediately after baseline data is collected.
3238200|NCT00927901|Experimental|Placebo-indacaterol (ind) acetate-ind maleate-ind xinafoate|In treatment period 1, patients received placebo to indacaterol; in treatment period 2, patients received indacaterol acetate 400 μg; in treatment period 3, patients received indacaterol maleate 400 μg; and in treatment period 4, patients received indacaterol xinafoate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3238201|NCT00927888|Active Comparator|1 - Bupivacaine Block|3 ml of 0.25% Bupivacaine with Epi 1:100,000 (A block)
3238202|NCT00927888|Placebo Comparator|2 - Placebo|Normal saline with Epi 1:100,000 (B block)
3238203|NCT00927875|Experimental|All Subjects|
3238204|NCT00927862|Active Comparator|Standard IWPC warfarin dosing algorithm|Standard International Warfarin Pharmacogenetics Consortium (IWPC) warfarin dosing algorithm.
3238205|NCT00927862|Experimental|Modified IWPC warfarin dosing algorithm|Modified International Warfarin Pharmacogenetics Consortium (IWPC) warfarin dosing algorithm
3238206|NCT00927862|Other|Historical controls|The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records database of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic (PG)-guided cohorts (July 2008 through December 2010). Patients ≥18 years old initiating warfarin therapy with a baseline and at least 1 follow-up international normalized prothrombin time ratio (INR) level between days 3-14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG based.
3238207|NCT00927849|Active Comparator|surgical group lateral sphincterotomy|underwent closed lateral internal sphincterotomy (LIS) under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
3238208|NCT00927849|Active Comparator|Glycerin trinitrate group|all were instructed to apply the Glycerin trinitrate group (GTN) ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.
3238209|NCT00927849|Active Comparator|botulinum toxin injection|All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
3238210|NCT00927836|Experimental|AX200|
3238211|NCT00927836|Placebo Comparator|Placebo|
3238212|NCT00927823|Experimental|PF-04691502 Treatment|
3238213|NCT00927810|Experimental|canakinumab|
3238214|NCT00927797|Experimental|Immunochemotherapy, Maintencance|
3238215|NCT00927784|Sham Comparator|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media alone (placebo).
3238216|NCT00927784|Experimental|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs in sequential cohorts.
3238217|NCT00927771|Experimental|Azelaic Acid|
3238218|NCT00927771|Active Comparator|Hydroquinone|
3238219|NCT00927758|Active Comparator|Sequence 1: Flu/Sal- 250mcg/50mcg ->100mcg/50mcg->500mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
3238220|NCT00927758|Active Comparator|Sequence 2: Flu/Sal- 500mcg/50mcg ->250mcg/50mcg->100mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
3238221|NCT00927758|Active Comparator|Sequence 3: Flu/Sal- 100mcg/50mcg ->250mcg/50mcg->500mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
3238222|NCT00927758|Active Comparator|Sequence 4: Flu/Sal- 250mcg/50mcg ->500mcg/50mcg->100mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
3238223|NCT00927758|Active Comparator|Sequence 5: Flu/Sal- 500mcg/50mcg ->100mcg/50mcg->250mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
3238224|NCT00927758|Active Comparator|Sequence 6: Flu/Sal- 100mcg/50mcg ->500mcg/50mcg->250mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
3238225|NCT00927745|Experimental|With AutoFlow|Assist-controlled ventilation with activation of AutoFlow mode
3238226|NCT00927745|Active Comparator|Without AutoFlow|Assist-controlled ventilation without activation of AutoFlow mode
3238278|NCT00927381||Minimal/Moderate Envenomation|Severity Score less than 5
3238231|NCT00927706|Experimental|Delayed Intervention|Subjects and their caregivers who are randomized to this group will receive the intervention after baseline measurements are administered twice (6 weeks apart).
3238232|NCT00927693|Experimental|Scan group|"Scan group undergoes complete cardiac risk assessment and CAC scanning at baseline."
3238233|NCT00927693|No Intervention|No scan group|"No scan group undergoes only complete cardiac risk assessment (without CAC scan) at baseline."
3238234|NCT00927680||Colorectal cancer cases|
3238235|NCT00927680||Controls|
3238236|NCT00927667|Experimental|Arm 1|
3238237|NCT00927667|Experimental|Arm 2|
3238238|NCT00927667|Experimental|Arm 3|
3238239|NCT00927667|Experimental|Arm 4|
3238240|NCT00927667|Experimental|Arm 5|
3238241|NCT00927654|Experimental|Iloprost|
3238242|NCT00927654|Placebo Comparator|Isotonic Sodium Chloride solution 0.9 %|
3238243|NCT00927641|Active Comparator|Ketoprofen Patch (HKT-500)|Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
3238244|NCT00927641|Placebo Comparator|Placebo Patch|Two placebo patches placed on target ankle once daily for 14 days
3238245|NCT00927628||Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular hole. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were >40-years-of-age.
3238246|NCT00927615|Experimental|intracoronary abciximab|intracoronary administration of abciximab (0.25 mg/kg body weight)
3238247|NCT00927615|Active Comparator|intravenous abciximab|intravenous administration of abciximab (0.25 mg/kg body weight)
3238248|NCT00927602|Experimental|fondaparinux|
3238249|NCT00927589|Experimental|1|
3238250|NCT00927576||Control subjects|Control subjects = 237. These subjects underwent extensive testing with computerized neuropsychological tests including digit span testing, spatial span testing, simple reaction time testing, choice reaction time testing, finger tapping, verbal fluency, design fluency, verbal list learning, questionnaire completion, and the trail making test.
3238251|NCT00927576||TBI patients|TBI patients N = 28. These patients underwent extensive testing with computerized neuropsychological tests including digit span testing, spatial span testing, simple reaction time testing, choice reaction time testing, finger tapping, verbal fluency, design fluency, verbal list learning, questionnaire completion, and the trail making test.
3238252|NCT00927563|Experimental|Tolcapone|Tolcapone 100-300mg/day
3238253|NCT00927550|Experimental|lithium plus usual care|
3238254|NCT00927550|Active Comparator|usual care without lithium therapy|
3238255|NCT00927537||Group 1|
3238256|NCT00927537||Group 2|
3238257|NCT00927524|Active Comparator|Apidra (insulin glulisine)|Administration of Apidra at three meals during a 24 hour period.
3238258|NCT00927524|Active Comparator|70/30 insulin|Administration of 73/30 insulin at three meals during a 24 hour period.
3238259|NCT00927511|Experimental|A - Dose Tritation|Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity
3238260|NCT00927511|Active Comparator|B- Control|Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
3238261|NCT00927498|Active Comparator|Arm A Daunorubicin and Cytarabine|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4."
3238262|NCT00927498|Experimental|Arm B Daunorubicin and Cytarabine and Mylotarg|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1."
3238263|NCT00927485|Experimental|Curcumin|Curcumin
3238264|NCT00927485|Placebo Comparator|Placebo|Placebo (sugar pills)
3238265|NCT00927472|Experimental|Malathion Gel|Malathion gel 0.5% 30 minute application
3238266|NCT00927472|Active Comparator|Nix Creme Rinse|Nix applied to scalp for 10 minutes
3238267|NCT00927459|Experimental|PRO-040201|PRO-040201 with placebo control in each cohort
3238268|NCT00927459|Placebo Comparator|Placebo|PRO-040201 with placebo control in each cohort
3238269|NCT00927446||Endoscopy screening|Patients with tissue diagnosis of head and neck cancer undergo endoscopy screening with conventional white light system first. Then the entire esophagus is examined under the NBI system by another endoscopist, who is blinded to the result of the conventional endoscopy.
3238270|NCT00927433|No Intervention|Standard care|Patients received standard education about fatigue by clinicians.
3238271|NCT00927433|Experimental|Education arm|Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions.
3238272|NCT00927420||1|Patients diagnosed with bipolar disorder I or II (DSM-IV) in ambulatory settings
3238273|NCT00927407|Experimental|Malathion gel 0.05%|Malathion gel 0.5% topical treatment for head lice
3238274|NCT00927407|Active Comparator|Malathion lotion 0.5%|Malathion lotion 0.5% treatment for head lice
3238275|NCT00927394|Experimental|Combination Therapy: Aliskiren + Valsartan|To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day)for 8 weeks. 1 tablet of Aliskiren 150 mg + 1 tablet of placebo Aliskiren 150 mg + 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg daily for 2 weeks. Forced titrated to: 2 tablets of Aliskiren 150 mg + 2 capsules of Valsartan 160 mg daily for 6 weeks
3238276|NCT00927394|Active Comparator|Monotherapy: Valsartan|To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day) for 8 weeks. 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg + 2 tablets of placebo Aliskiren 150 mg daily for 2 weeks. Forced titrated to: 2 capsules of Valsartan 160 mg + 2 tablets of placebo Aliskiren 150 mg daily for 6 weeks.
3238277|NCT00927381||Severe envenomation|Patients with a calculated severity score of 5 or 6 were included in this group.
3238279|NCT00927368|Active Comparator|Ultrasound guidance alone|The Tuohy needle was inserted in out-plane approach. Needle placement was considered adequate when the tip was visualized beneath the fascia iliaca; the catheter was then introduced 5 cm beyond the needle tip. Electrical stimulation was not used.
3238280|NCT00927368|Active Comparator|Ultrasound guidance needle stimulation|For the ultrasound guidance and needle stimulation arm, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA (2 Hz, pulse width 0.1 msec). Subsequently, the catheter was threaded 5 cm beyond the needle tip without additional electrical stimulation
3238281|NCT00927368|Active Comparator|Ultrasound guidance+catheter stimulation|For the ultrasound guidance and catheter stimulation group, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA. At that point, the peripheral nerve stimulator was then disconnected from the stimulating needle and connected to the proximal end of the catheter. The catheter was then advanced 5 cm past the needle tip. If the motor response disappeared during catheter advancement, the catheter was withdrawn slightly until the response returned. Needle orientation and catheter advancement were adjusted as necessary to elicit quadriceps contractions via the catheter with a stimulating current ≤0.5 mA.
3238282|NCT00927355|Active Comparator|Pioglitazone|half of the diabetic patients will be randomized to pioglitazone treatment for 6 months starting out with 15mg qd for 4 weeks and dose increased to 30mg (2 tablets) qday if no adverse effects noted at the four week mark by study physician.
3238283|NCT00927355|Placebo Comparator|Placebo|"The other half will be randomized to placebo for 6 months. The placebo pills also start out with one 15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician."
3238284|NCT00927342|Active Comparator|Vivostat|
3238285|NCT00927342|Active Comparator|BioGlue|
3238286|NCT00927329|Experimental|dust mite|
3238287|NCT00927316|Active Comparator|Active arm|E. coli 83972 bacteriuria
3238288|NCT00927316|Placebo Comparator|Placebo arm|Monitoring
3238289|NCT00927303||Group 1|Intervention 1 Sequence of observers: observer1, observer 2, observer 1, observer 2
3238290|NCT00927303||group 2|intervention 1 sequence of observers: observer 2, observer 1, observer 2, observer 1
3238291|NCT00927303||group 3|intervention 2 sequence of observers: 1,2,1,2
3238292|NCT00927303||group 4|intervention 2 sequence of observers: 2,1,2,1
3238293|NCT00927303||group 5|intervention 1 sequence of observers 1,1,2,2
3238294|NCT00927303||group 6|intervention 1 sequence of observers 2,2,1,1
3238295|NCT00927303||group 7|intervention 2 sequence of observers: 1,1,2,2
3238296|NCT00927303||group 8|intervention 2 sequence of observers: 2,2,1,1
3238297|NCT00927290|Active Comparator|1|Pioglitazone, 16 weeks before and during antiviral combination therapy
3238298|NCT00927290|Placebo Comparator|2|Pioglitazone placebo, 16 weeks before and during antiviral combination therapy
3238299|NCT00927277|Placebo Comparator|placebo laser|inactive light on the laser device.
3238300|NCT00927277|Active Comparator|Erchonia (R) LipoLASER PL|The Erchonia(R) LipoLASER PL is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
3238301|NCT00927264|Experimental|Behavioral|"Motivational Interviewing Intervention Plus Education~Caregivers will receive a home-based motivational interviewing intervention for ETS reduction plus an educational program for ETS reduction."
3238302|NCT00927264|Active Comparator|Education Only|Caregivers will receive only educational program for ETS reduction.
3238303|NCT00927251|Experimental|Model 4296 LV Lead|Non-randomized study
3238304|NCT00927238|Experimental|XL TDR|The XL TDR is indicated for reconstruction of the disc following discectomy in skeletally mature subjects with symptomatic degenerative disc disease (DDD) of the lumbar spine at one level from L1-L5. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history radiographic studies.
3238305|NCT00927238|Other|Outcomes from lumbar fusion study|
3238306|NCT00927225|Active Comparator|active|subcutaneous wound infiltration with 50 mL ropivacaine 0.2%
3238307|NCT00927225|Placebo Comparator|placebo|subcutaneous wound infiltration with 50 mL saline
3238308|NCT00927212|Experimental|Group 1|2% AS101 ointment
3238309|NCT00927212|Experimental|Group 2|4% AS101 ointment
3238310|NCT00927199|Experimental|High-Oleic Canola Oil|
3238311|NCT00927199|Experimental|High-Oleic Canola/Flaxseed Oil Blend|
3238312|NCT00927199|Active Comparator|Western Diet|
3238313|NCT00927186|Experimental|Teriparatide|
3238314|NCT00927186|Active Comparator|Zoledronic Acid|
3238315|NCT00927173|Sham Comparator|Sham|Sham treatment
3238316|NCT00927173|Active Comparator|Active|Active Deep Transcranial Magnetic Stimulation treatment
3238317|NCT00927160||MACE group|Elderly patients admitted to the Mobile Acute Care of the Elderly Unit.
3238318|NCT00927160||Usual Care group|Elderly patients admitted to the general medicine service in the hospital
3238319|NCT00927147|Experimental|BNCT plus cetuximab|Patients treated with BNCT followed by cetuximab administration
3238320|NCT00927121|Active Comparator|Group 1 : G_1|G_1: stimulation for 4 - 6 hours a day, 4 tones per sequence
3238321|NCT00927121|Active Comparator|Group 2 :G_2|G_2: stimulation for 4 - 6 hours a day with 12-tone sequences
3238322|NCT00927121|Active Comparator|Group3 : G_3|G_3: stimulation for 4 - 6 hours a day, 4 tones per sequence with a signal controlled by EEG measurement
3238323|NCT00927121|Active Comparator|Group 4 : G_4|G_4: stimulation for 1 hour a day, 4 tones per sequence
3238324|NCT00927121|Placebo Comparator|Group5 : G_5|G_5: stimulation with placebo-tone
3238325|NCT00927095|Active Comparator|Continuous OC (EE/DROS)|Continuous daily oral drospirenone (DROS; 3mg) + ethinyl estradiol (EE; 20ug)
3238326|NCT00927095|Active Comparator|Intermittent OC (EE/DROS)|Interrupted (21 days active - 7 days placebo) oral DROS (20ug)/EE(3mg)
3238327|NCT00927095|Placebo Comparator|Placebo|Continuous daily oral placebo
3238328|NCT00927082|Experimental|PEG-IFN 90mcg 24 Wks|Participants received Pegasys (Pegylated interferon alfa-2a [PEG-IFN]) 90 micrograms (mcg) subcutaneously (SC) once a week for 24 weeks in Study WV19432 and entered follow-up (FU) Study MV22430.
3238329|NCT00927082|Experimental|PEG-IFN 180mcg 24 Wks|Participants received PEG-IFN 180 mcg SC once a week for 24 weeks in Study WV19432 and entered FU Study MV22430.
3238330|NCT00927082|Experimental|PEG-IFN 90mcg 48 Wks|Participants received PEG-IFN 90 mcg SC once a week for 48 weeks in Study WV19432 and entered FU Study MV22430.
3238331|NCT00927082|Experimental|PEG-IFN 180mcg 48 Wks|Participants received PEG-IFN 180 mcg SC once a week for 48 weeks in Study WV19432 and entered FU Study MV22430.
3238332|NCT00927069|Experimental|Group A|Patients who have shown an unsatisfactory response to 3 months of etanercept 50 mg twice a week without dose reduction prior to screening.
3238333|NCT00927069|Experimental|Group B|Patients who showed a satisfactory response to 3 months or more of etanercept 50 mg twice a week followed by a loss of response after dose reduction to 50 mg etanercept once a week prior to screening.
3238334|NCT00927069|Experimental|Group A dose increase at Week 12|Patients in group A who - after 12 weeks of adalimimab 40 mg every other week in this study - failed to reach a physician's global assessment (PGA) of clear or almost clear and had a dose increase to 40 mg adalimimab every week for another 12 weeks.
3238335|NCT00927069|Experimental|Group B dose increase at Week 12|Patients in group B who - after 12 weeks of adalimimab 40 mg every other week in this study - failed to reach a physician's global assessment (PGA) of clear or almost clear and had a dose increase to 40 mg adalimimab every week for another 12 weeks.
3238336|NCT00927056|Active Comparator|Minimally Invasive Microdiscectomy|
3238337|NCT00927056|Active Comparator|Conventional Open Microdiscectomy|
3238338|NCT00927043||1|
3238339|NCT00927030|Experimental|Pharmacokinetic|We hope to target 12 of the 30 children to be enrolled for this study to participate in a pharmacokinetic arm of the study. These 12 children would be receiving overnight sleep studies prior to receiving the first dose of melatonin and again at about every 3 week intervals each time the dose increases until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. During the sleep studies an intravenous catheter will be placed in the child's arm to sample small amounts of blood throughout the day (about 3 teaspoons of blood)to allow us to look at how melatonin is produced in children with autism who have sleep problems.
3238340|NCT00927030|Placebo Comparator|flavored inert liquid|Of the 30 targeted participants, 18 will be randomized at the first three week dosing period {1mg of melatonin}. The randomization will be single blind to the parent in a 5:1 ratio (15 children will receive melatonin, and 3 children will receive a flavored placebo at the first 3-week period only). After the initial 3-week dose cycle of 1 mg, all children randomized to placebo will begin 3 mg of melatonin and will continue in dose increase (6mg, 9 mg)until they meet the criteria of falling asleep within 30 minutes of bedtime 5/7 nights per week. No child will take more than 9 mg.
3238341|NCT00927017|Active Comparator|Liquorice 66 g/day|Liquorice given 66 grams per day for two weeks
3238342|NCT00927017|Active Comparator|Liquorice 102 g/day|Liquorice given 102 grams per day for two weeks
3238343|NCT00927004|Experimental|Etoricoxib 60 mg|
3238344|NCT00927004|Placebo Comparator|Sugar pill|
3238345|NCT00926991||traumatic rib fractures|
3238346|NCT00926978|Other|Radiopharmacokinetics|"1-2 mCi I-124 orally, once per day, twice total 0.9mg rhTSH intravenous injection, once per day, four total~After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is < 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
3238347|NCT00926965|Experimental|Olanzapine group|randomized to Olanzapine group with dose range of 2.5-30mg/day
3238348|NCT00926965|Experimental|Amisulpiride group|the subjects were randomized to the amisulpiride group with dose range of 100 to 800mg/day
3238349|NCT00926965|Active Comparator|FGA group|The subjects were randomized to maintain the conventional antipsychotics
3238350|NCT00926952|Experimental|MAL-PDT 90 min incubation, no occlusion|Patients had 2-4 g of Methylaminolevulinate (MAL) spread on the entire face without occlusion and waited 90 minutes prior to photodynamic therapy (PDT) using red light.
3238351|NCT00926939|Experimental|Abstinence Contingent (AC)|This group will receive vouchers contingent on smoking reduction and smoking abstinence (confirmed through video submissions). Abstinence is defined as a CO sample of 4ppm or less.
3238352|NCT00926939|Experimental|Submission Contingent (SC)|This group receives vouchers for submitting videos of their CO breath test.
3238353|NCT00926926|Experimental|Active OTG|
3238354|NCT00926926|Placebo Comparator|Placebo|
3238355|NCT00926913||Group 1|
3238356|NCT00926900|Active Comparator|D-cycloserine|
3238357|NCT00926900|Placebo Comparator|Placebo|
3238358|NCT00926887|Sham Comparator|Placebo Laser|Placebo Laser is an inactive light
3238359|NCT00926887|Active Comparator|Erchonia EML Laser|Erchonia EML Laser uses two 7mW red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2.
3238360|NCT00926874||1|patients who presented an ischaemic stroke(full stroke or TIA)
3238361|NCT00926874||2|patients who present an acute coronary syndrome (ACS).
3238362|NCT00926861||Dry AMD|male or female persons aged over 50 years with dry age-related macular degeneration
3238363|NCT00926848|Experimental|PaTH intervention group|"The PaTH intervention group for patients and partners consisted of participation in a structured and formal cardiac rehabilitation program:~18-36 exercise sessions~18 educational sessions. The intervention consisted of patients and partners participating together in a formal cardiac rehabilitation program when typically just patients participate. In addition, partners were asked to make the same healthy eating and exercise changes that patients did to meet guidelines for health."
3238364|NCT00926848|Active Comparator|Usual care group|"The usual care group intervention for patients only consisted of participation in a structured and formal cardiac rehabilitation program:~18-36 exercise sessions and 18 educational sessions~Partners participated in the 18 educational sessions only."
3238366|NCT00926835|Active Comparator|Escitalopram|Escitalopram monotherapy
3238367|NCT00926835|Active Comparator|Venlafaxine|Venlafaxine monotherapy
3238368|NCT00926835|Active Comparator|Paroxetine+Bupropion|
3238369|NCT00926835|Active Comparator|Paroxetine+Lamotrigine|
3238370|NCT00926835|Active Comparator|Paroxetine+Lithium|
3238371|NCT00926835|Active Comparator|escitalopram+mirtazapine|
3238372|NCT00926835|Active Comparator|Escitalopram+Aripiprazole|
3238373|NCT00926835|Active Comparator|Paroxetine + Venlafaxine|
3238374|NCT00926809|Active Comparator|Eradication|Helicobacter pylori eradication
3238375|NCT00926809|Placebo Comparator|No eradication|No eradication for Helicobacter pylori
3238376|NCT00926796|Experimental|Regimen B: gemifloxacin plus azithromycin|Gemifloxacin 320 mg by mouth one time plus azithromycin 2 gm by mouth one time.
3238377|NCT00926796|Experimental|Regimen A: gentamicin plus azithromycin|Gentamicin 240 mg intramuscular (IM) one time for patients greater than 45 kg or 5 mg/kg IM one time for patients less than or equal to 45 kg plus azithromycin 2 gm by mouth one time.
3238378|NCT00926783|Active Comparator|(1) targeted CFAE ablation|
3238379|NCT00926783|Active Comparator|(2) generalized CFAE ablation|
3238380|NCT00926770||Pretem infants (GG < 37+0)|
3238381|NCT00926757|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of chemotherapy, and will be continued until 3 months after completion of the chemotherapy.
3238382|NCT00926757|Active Comparator|Therapeutic arm|In patients with HBV reactivation and ALT flare > 100 U/L, entecavir 0.5mg daily will be prescribed for the cases till hepatitis remission
3238383|NCT00926744|Experimental|Intervention|Physically inactive participants receiving both physical activity and dietary counseling
3238384|NCT00926744|No Intervention|Active|Physically active participants receiving only dietary counseling
3238385|NCT00926744|No Intervention|Control|Physically inactive participants receiving only dietary counseling
3238386|NCT00926731|Experimental|1|AZD1152 variable dose in combination with 20 mg of LDAC. (The LDAC is given twice daily.)
3238387|NCT00926718|Experimental|Dose 1a|
3238388|NCT00926718|Experimental|Dose 2a|
3238389|NCT00926718|Experimental|Dose 3a|
3238390|NCT00926718|Experimental|Dose 1b|
3238391|NCT00926718|Experimental|Dose 2b|
3238392|NCT00926718|Experimental|Dose 3b|
3238393|NCT00926705|Active Comparator|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
3238394|NCT00926705|Experimental|Dexmedetomidine and Fentanyl|This group received a combination of Dexmedetomidine (1 ug/kg) and Fentanyl (1.79 ug/kg). Total number of patients in this group 24.
3238395|NCT00926692||Healthy Subjects|All subjects are considered healthy
3238396|NCT00926653||Depressed|Elderly participants with depression
3238397|NCT00926653||Control|Elderly participants who have never experienced depression
3238398|NCT00926640|Experimental|1|Belinostat dose escalation
3238399|NCT00926640|Experimental|2|Belinostat UGT1A1 wild type/*28 variant
3238400|NCT00926640|Experimental|3|Belinostat UGT1A1*60 or 2/3/4 variant
3238401|NCT00926627|Placebo Comparator|Placebo|placebo b.i.d.
3238402|NCT00926627|Experimental|Bosentan|62.5 mg/125 mg bosentan b.i.d.
3238403|NCT00926614|Experimental|Pioglitizone and Atorvastatin|Pioglitazone and Atorvastatin added to standard of care Pegasys and weight based ribavirin
3238404|NCT00926588|Experimental|Stepped Care|Patients received automated pain monitoring. A nurse care manager partnering with a physician pain specialist decide on treatment changes collaborating with primary care physicians. Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are used.
3238405|NCT00926588|No Intervention|Usual Care|Patients receive usual care for pain from their primary care physician
3238406|NCT00926575|Experimental|orBec®|Investigational drug
3238407|NCT00926575|Placebo Comparator|Placebo|Control
3238408|NCT00926562|Experimental|Iopromide|Drug: Ultravist 370 mgl/ml, injection of intra-artery during cardiac interventional operation
3238409|NCT00926562|Active Comparator|Iodixanol|Drug: Visipaque 320 mgl/ml, injection of intra-artery
3238410|NCT00926549|Experimental|spectral domain-OCT|Spectral domain-OCT scanning performed.
3238411|NCT00926536|Experimental|C-arm CT + DSA as needed'|In the group of subjects randomized in this group, the image guidance component of the procedure will be conducted by the acquisition of 3D CT-like images during a trans-hepatic arterial injection of iodinated contrast agent for road mapping the tumor feeding vessels and supplemented by DSA as needed by the operating physician as imaging guidance for planning tumor(s) treatment approach.
3238412|NCT00926536|Active Comparator|DSA only|In the group of subjects randomized in this group, present standard of care, i.e DSA imaging only will be used by the operating physician to map out the tumor vessels and used for treatment approach. Additional 3D CT-like images will be obtained, but only used if the operator cannot perform adequate planning using DSA alone.
3238413|NCT00926523||Healthy Controls|Subjects are made up of healthy adults
3238414|NCT00926523||Affected|Subjects have Pulmonary Hypertension
3238415|NCT00926510|Experimental|Language Toolkit|Language toolkit composed of simple tools that parents can use to interact with child and help language acquisition.
3238416|NCT00926510|Placebo Comparator|2|Safety counseling and smoke detector
3238417|NCT00926497|Experimental|Procalcitonin group|Antibiotic therapy is discontinued when two consecutive Procalcitonin values are below predefined age-adjusted cut-off values. Antibiotic therapy could be prolonged despite fulfilled Procalcitonin criteria at the discretion of the attending physician.
3238418|NCT00926497|No Intervention|Standard group|Standard treatment for suspected neonatal early-onset sepsis based on conventional laboratory parameters
3238419|NCT00926484||Tooth Mousse|
3238420|NCT00926484||fluoride varnish|
3238421|NCT00926484||Tooth Mousse + fluoride varnish|
3238422|NCT00926471|Experimental|Cognitive Behavioral Therapy (CBT) Program|Participants will receive a treatment program involving CBT plus adjunctive group counseling and parent training.
3238470|NCT00926185|Experimental|0.1% Lifitegrast|Lifitegrast
3238423|NCT00926471|No Intervention|Wait list control|Participants will be placed on a 12-week wait list with no active treatment
3238424|NCT00926445||Preterm (BW < 1500 grams)|
3238425|NCT00926445||Critically ill term newborn|ventilation > 48 hours
3238426|NCT00926445||Healthy term newborn|
3238427|NCT00926432|Other|Healthy volunteers|Small group of aged healthy volunteers
3238428|NCT00926432|Other|Patients|Patients consulting for spine disorders that may or may not have postural troubles
3238429|NCT00926419|Experimental|Varicella (1/5 dose) - ID - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
3238430|NCT00926419|Experimental|Varicella (1/5 dose) - ID - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
3238431|NCT00926419|Experimental|Varicella (2/5 dose) - ID - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.25 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
3238432|NCT00926419|Experimental|Varicella (2/5 dose) - ID - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.25 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
3238433|NCT00926419|Active Comparator|Varicella (full dose) - SC - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.5 ml Subcutaneous administration with Disposable Needle-free Syringe Jet Injector
3238434|NCT00926419|Active Comparator|Varicella (full dose) - SC - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.5 ml Subcutaneous administration with Disposable Needle Syringe
3238435|NCT00926419|Experimental|Hepatitis A (1/5 dose) ID - Injector|Hepatitis A virus vaccine, inactivated, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
3238436|NCT00926419|Experimental|Hepatitis A (1/5 dose) ID - Syringe|Hepatitis A virus vaccine, inactivated, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
3238437|NCT00926419|Active Comparator|Hepatitis A (full dose) IM - Injector|Hepatitis A virus vaccine, inactivated, Single dose, 0.5 ml Intramuscular administration with Disposable Needle-free Syringe Jet Injector
3238438|NCT00926419|Active Comparator|Hepatitis A (full dose) IM - Syringe|Hepatitis A virus vaccine, inactivated, Single dose, 0.5 ml Intramuscular administration with Disposable Needle Syringe
3238439|NCT00926393|Active Comparator|Quetiapine Immediate Release (IR)|Quetiapine 25, 100, 200 and 300 mg
3238440|NCT00926393|Active Comparator|Quetiapine Extended Release (XR)|Quetiapine 50, 200, 300
3238441|NCT00926380|Experimental|denosumab ONLY|
3238442|NCT00926380|Experimental|teriparatide (Forteo®) ONLY|
3238443|NCT00926380|Experimental|denosumab and teriparatide (Forteo®)|
3238444|NCT00926367|Experimental|Clinidamycin/ Benzoyl Peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide (BPO).
3238445|NCT00926367|Active Comparator|Benzoyl peroxide and adapalene|Once-daily applications, to the randomized side of the face either left or right, of benzoyl peroxide (BPO) and adapalene
3238446|NCT00926354|Experimental|AS101 infusion|Twenty patients who developed thrombocytopenia after a chemotherapy course will receive i.v. infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen, during the following 4 chemotherapy courses.
3238447|NCT00926354|No Intervention|Control group|Twenty patients who developed thrombocytopenia during chemotherapy course will be treated according to standard of care and will not receive the investigational product. Their medical condition will be followed and a complete blood count will be performed routinely once weekly.
3238448|NCT00926341|No Intervention|Active control|1. Active Control: (n=20), intervention: no intervention
3238449|NCT00926341|Active Comparator|PIO arm|PIO arm (n=30), Pioglitazone 30 mg/day, given for 24 weeks.
3238450|NCT00926341|Active Comparator|Telmi arm|Telmia arm (n=30): Tab. Telmisartan 40 mg/day given for 2 weeks.
3238451|NCT00926328|Active Comparator|A -Experimental toothpaste|triclosan/copolymer/fluoride toothpaste
3238452|NCT00926328|Placebo Comparator|B - control toothpaste|sodium fluoride only toothpaste (placebo)
3238453|NCT00926315|Experimental|calcitriol|calcitriol supplementation (0.25 mcg 2x/d)
3238454|NCT00926302|Experimental|Test drug|Levetiracetam one period
3238455|NCT00926302|Active Comparator|Reference drug|Keppra one period
3238456|NCT00926289|Active Comparator|Telmisartan|Telmisartan 80 mg
3238457|NCT00926289|Experimental|Telmisartan/hydrochlorothiazide|Telmisartan80mg/Hydrochlorothiazide25mg
3238458|NCT00926276|Active Comparator|Surgical Treatment Group-Fundoplication|Re-evaluated 1 month post-op Re-evaluated 2 months post-op
3238459|NCT00926276|Active Comparator|Medical Therapy|Treated by primary clinician for GERD Re-evaluated 1 month Proceed to Fundoplication if GERD persist by pH-MII Re-evaluated at 2 months (1 month post-op) Worsening BPD will be given option of immediate surgery
3238460|NCT00926263|Experimental|10 mg/kg cohort|
3238461|NCT00926263|Experimental|20 mg/kg cohort|
3238462|NCT00926263|Experimental|20/20 mg/kg cohort|
3238463|NCT00926250|Experimental|PS-IPC supplementation|
3238464|NCT00926250|Placebo Comparator|Placebo supplementation|
3238465|NCT00926237|Sham Comparator|Active/Sham Protocol|All subjects complete the initial three weeks of rTMS sessions, which include 8 active sessions and 4 sham sessions. Subjects receive sham stimulation first to prevent carry forward effects of active treatment. Active and sham weeks are separated for each subject by an interval of no less than 21 days.
3238466|NCT00926237|Active Comparator|Maintenance rTMS|Subjects who respond to either week of active rTMS have the option of participating in a maintenance rTMS program involving up to 8 additional sessions of therapy, each consisting of 3 days of rTMS treatment. Maintenance sessions will be scheduled with three weeks separating each treatment.
3238467|NCT00926211|Experimental|Computer-Assisted|Hair harvest using the computer-assisted system
3238468|NCT00926211|Active Comparator|Manual Harvest|Hair harvesting via manual technique
3238469|NCT00926185|Placebo Comparator|Placebo|Placebo Ophthalmic Solution
3238680|NCT00924612|Experimental|Fasting|
3238471|NCT00926185|Experimental|1.0% Lifitegrast|Lifitegrast
3238472|NCT00926185|Experimental|5.0% Lifitegrast|Lifitegrast
3238473|NCT00926159||ICD eligible|Patients with Ejection Fraction (EF) of 35% or less as determined by cardiac echocardiogram or cardiac nuclear scan.
3238474|NCT00926146|Experimental|NCMIT|Nurse Case Management Plus Contingency Management and Tracking and the HBV vaccine
3238475|NCT00926146|Active Comparator|SCMIT|Standard with Contingency Management and Tracking (SCMT) and HBV vaccine
3238476|NCT00926133||STEMI patients|Patients with acute STEMI treated by PCI without previously known type 2 diabetes.
3238477|NCT00926120|Experimental|Mogroside sweetener|All subjects will received Mogroside. Mogroside sweetener administered at a dosage level of 5 g every 6 hours for 14 days.
3238478|NCT00926094||1|
3238479|NCT00926094||2|
3238480|NCT00926081|No Intervention|Best medical treatment|Patients with peripheral artery disease receiving best medical treatment only
3238481|NCT00926081|Active Comparator|Supervised exercise training|Patients with peripheral artery disease receiving best medical treatment plus supervised exercise training
3238482|NCT00926068|Experimental|HO/03/03 10µg|
3238483|NCT00926068|Placebo Comparator|Placebo|
3238484|NCT00926055|No Intervention|Control|
3238485|NCT00926055|Active Comparator|Ezetimibe|
3238486|NCT00926055|Experimental|Ezetimibe/Simvastatin|
3238487|NCT00926042||Healthy Control|Healthy control group for research on autoimmune diseases
3238488|NCT00926029|Placebo Comparator|Fluoride control -A|Winterfresh Gel
3238489|NCT00926029|Active Comparator|Triclosan/Fluoride - B|Positive control (Total toothpaste)
3238490|NCT00926029|Experimental|Triclosan/fluoride/metal salt- C|test toothpaste
3238491|NCT00926016|Active Comparator|pioglitazone|Treatment with pioglitazone 45 mg a day for 3 months
3238492|NCT00926016|No Intervention|No intervention|Monitoring period without pioglitazone for 3 months
3238493|NCT00926003|Experimental|CCRT intervention|
3238494|NCT00926003|No Intervention|Control|
3238495|NCT00925990|Experimental|CTS-1027 + ribavirin|Study drug plus ribavirin
3238496|NCT00925990|Experimental|CTS-1027 + placebo|Study drug plus placebo for ribavirin
3238497|NCT00925977|Active Comparator|insulin Glargine + insulin Apidra|insulin Glargine + insulin Apidra
3238498|NCT00925977|Active Comparator|Insulin NPH + Insulin Apidra|12 weeks treatment with Insulin NPH + Insulin Apidra
3238499|NCT00925964||Patients exposed|Patients with Systolic Pressure Index <0,9 ou >1,4.
3238500|NCT00925964||Patients not exposed|Patients with Systolic Pressure Index >0,9 ou <1,4.
3238501|NCT00925951|Experimental|Wet Cupping|
3238502|NCT00925951|No Intervention|Waiting Control|They can't use any other specific treatment except exercises and behavior modification (we'll offer a brochure which includes exercise method and directions about behavior modifications).
3238503|NCT00925938|Experimental|Misoprostol vaginal priming insert (MVPI)|One vaginal insert administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit. The initial dose is 400 mcg and dose will be adjusted between 100 - 1600 mcg after each study cohort based on safety and efficacy criteria as assessed by the Data and Safety Monitoring Board (DSMB).
3238504|NCT00925938|Placebo Comparator|MVPI Placebo|One vaginal insert of placebo administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit.
3238505|NCT00925925||Normal Birth Weight (NBW)|Term, healthy infants born at normal birth weights
3238506|NCT00925925||Low Birth Weight (LBW)|Infants born at > or equal to 34 0/7 weeks with a birth weight at < or equal to 10% for gestational age at birth (Small for Gestational Age, SGA)
3238507|NCT00925912|Active Comparator|1|"spinal anesthesia: Active Comparator~The SA group were received a subarachnoid block with 1.5-2.0 ml of 0.5% bupivacaine."
3238508|NCT00925912|Experimental|2|Perianal block with 0.25% bupivacaine
3238509|NCT00925899|Experimental|Melatonin|20 mg
3238510|NCT00925899|Placebo Comparator|Placebo|
3238511|NCT00925886|Experimental|Acrysof Toric intraocular lens|A One piece, acrylic intraocular lens is implanted in the lens bag.
3238512|NCT00925873|Active Comparator|1|"Control arm without fludarabine~Induction course: Ara-C 100mg/m2 days 1-7, idarubicin 8mg/m2 days 1-5, GM-CSF (molgramostim, Novartis) 5 microg/kg days 1 to neutrophil recovery;~Consolidation course: Ara-C 1g/m2 q12h days 1-3, idarubicin 10mg/m2 days 2-3;~and 3 quarterly reinduction courses during maintenance including Ara-C 80mg/m2 days 1-5, CCNU 40mg and mitoguazone 350mg/m2 day 1, ± fludarabine days 1-2."
3238513|NCT00925873|Experimental|2|"Fludarabine arm~The same regimen with fludarabine 20 mg/m2/day IV for 30 minutes~induction course + fludarabine days 2-7;~consolidation course + fludarabine days 4-5;~during reinduction courses + fludarabine days 1-2."
3238514|NCT00925860|Experimental|non invasive ventilation approach|pure hypoxemic patients admitted to ICU treated by non-positive pressure mechanical ventilation
3238515|NCT00925860|No Intervention|conventionally ventilated|pure hypoxemic patients treated by conventional ventilatory support
3238516|NCT00925847|Experimental|1|
3238517|NCT00925834|Placebo Comparator|Sodium chloride|"Control arm A: Hidden intracoronary infusion of 5ml sodium chloride"
3238518|NCT00925834|Experimental|Sodium chloride and verbal suggestions|"Experimental arm A: Open intracoronary infusion of 5ml sodium chloride plus the suggestion of a vasodilatory effect on coronary vessels"
3238519|NCT00925834|Active Comparator|Nitroglycerin|"Control arm B: Hidden intracoronary infusion of 0.01mg nitroglycerin in 5 ml sodium chloride"
3238520|NCT00925834|Experimental|Nitroglycerin and verbal suggestions|"Control arm B: Open intracoronary infusion of 0.01 mg nitroglycerin in 5 ml sodium chloride plus the suggestion of a vasodilatory effect on cardiac vessels"
3238521|NCT00925821|Experimental|Allogeneic stem cell transplant|Second scheduled transplantation performed from an HLA-matched MRD or MUD after conditioning with treosulfan and fludarabine
3238522|NCT00925821|Active Comparator|High-dose melphalan chemotherapy|Second high-dose melphalan therapy followed by transplantation of peripheral blood stem cells
3238523|NCT00925808||Unsuspected VTE|Prevalence of unsuspected VTE in oncology patients on routine staging CT scans of the thorax, abdomen and pelvis
3238524|NCT00925795|Active Comparator|Group A (1. EVOO; 2. ROO)|
3238525|NCT00925795|Active Comparator|Group B (1. ROO; 2. EVOO)|
3238526|NCT00925782|Other|Melphalan-Alkeran|Subjects begin with treatment Melphalan and crossover to treatment Alkeran
3238527|NCT00925782|Other|Alkeran-Melphalan|Subjects begin with treatment Alkeran and crossover to treatment Melphalan.
3238528|NCT00925769|Experimental|1|
3238529|NCT00925756|Experimental|maraviroc|Maraviroc will be added to patient's existing HIV treatment regimen dose-adjusted to background HIV medications
3238530|NCT00925743|Experimental|1|"5, 15, 20 or 25 mg/m2~one injection of cabazitaxel on day 1 of each cycle (3 weeks)"
3238531|NCT00925730|Experimental|Pimecrolimus cream 1%|Pimecrolimus
3238532|NCT00925717||2500 patients|Who have records of clinic visit with endocrine internal medicines of nationwide secondary/tertiary hospitals within the last six months.
3238533|NCT00925704|Active Comparator|Calcitriol|
3238534|NCT00925704|Experimental|Lanthanum carbonate + calcitriol|
3238535|NCT00925704|Experimental|Sevelamer carbonate + calcitriol|
3238536|NCT00925691|Active Comparator|APICAL|implantation at the apex
3238537|NCT00925691|Experimental|SEPTAL|implantation at the interventricular septum
3238538|NCT00925678|Experimental|1|
3238539|NCT00925678|Placebo Comparator|2|
3238540|NCT00925665||Glidescope|Patients intubated with the Glidescope technique
3238541|NCT00925665||Macintosh|Patients intubated via the conventional direct laryngoscopy with a Macintosh laryngoscope
3238542|NCT00925652|Experimental|1. Diet Intervention Arm|The dietary intervention will focus on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber.
3238543|NCT00925652|Experimental|2. Diet and exericise intervention arm|The dietary intervention will focus on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber. Patients randomized to the diet and exercise groups will also have a target physical activity goal of 180 minutes of moderate-intensity activity each week.
3238544|NCT00925652|Experimental|3. Bevicizumab, CM, and diet intervention|Participants will receive Bevacizumab treatment, cyclophosphamide and methotrexate treatment and well as the dietary intervention that will focus on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber.
3238545|NCT00925652|Experimental|4. Bevacizumab, CM, diet and exercise|Participants will receive bevacizumab, cyclophosphamide and methotrexate treatment and well as the dietary intervention that will focus on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber and will also have a target physical activity goal of 180 minutes of moderate-intensity activity each week.
3238546|NCT00925639|Experimental|Isoflavone|Patients will receive daily doses of 150 mg of concentrated extract of soy per os
3238547|NCT00925639|Placebo Comparator|Control|Patients will receive daily placebo pills
3238548|NCT00925626|Experimental|Sub - Vastus arthrotomy|Sub-vastus arthrotomy
3238549|NCT00925626|Active Comparator|Mid-Vastus arthrotomy|Mid-vastus arthrotomy
3238550|NCT00925613|No Intervention|Control|The double lumen tube is kept until extubation; there is no exchange with any tracheal tube or LMA.
3238551|NCT00925613|Active Comparator|Proseal|The double lumen tube is exchanged with a Proseal (LMA) before emergence according to the study protocol.
3238552|NCT00925613|Active Comparator|Tracheal tube|The double lumen tube is exchanged with a tracheal tube before emergence according to the study protocol.
3238553|NCT00925600|Placebo Comparator|Placebo|Participants received placebo administered by subcutaneous injection on Day 1 and at Month 6.
3238554|NCT00925600|Experimental|Denosumab|Participants received denosumab 60 mg administered by subcutaneous injection on Day 1 and at Month 6.
3238555|NCT00925587|Active Comparator|Q2W|Q2W administration of darbepoetin alfa.
3238556|NCT00925587|Active Comparator|QM|QM administration of darbepoetin alfa
3238557|NCT00925561||No treatment|
3238558|NCT00925548|Experimental|Investigational Arm|"Investigational Arm:~Pretreatment (Single Dose): 300 milligrams per square meter (mg/m^2) up to a maximum dose of 600 mg of intravenous cyclophosphamide~tecemotide (L-BLP25) plus Hormonal Therapy (Standard Dose)"
3238559|NCT00925548|Active Comparator|Control Arm|"Control Arm:~Pretreatment (Single Dose): sodium chloride (NaCl) 9 grams per liter (g/L) infusion~Placebo plus Hormonal Therapy (Standard Dose)"
3238560|NCT00925535|Active Comparator|Treatment A|Lersivirine
3238561|NCT00925535|Active Comparator|Treatment B|Rifabutin
3238562|NCT00925535|Experimental|Treatment C|Lersivirine and Rifabutin
3238563|NCT00925522|Experimental|Therapy Cool Path Duo Cardiac Ablation System|All patients who are eligible receive cardiac ablation procedure for Ischemic Ventricular Tachycardia
3238564|NCT00925496||Standard PROMOS prosthesis|Patients receiving a standard PROMOS prosthesis
3238565|NCT00925496||Reverse PROMOS prosthesis|Patients receiving a reverse PROMOS prosthesis
3238566|NCT00925483|Experimental|daily long|daily long (4 hours, 6 times weekly) dialysis for 6 months
3238567|NCT00925483|Experimental|daily short|daily short (2 hours 6 times weekly) dialysis for 6 months
3238568|NCT00925483|Experimental|alternate day conventional|alternate day conventional (4 hours, 3 times weekly) dialysis for 6 months
3238569|NCT00925483|Experimental|alternate day long|alternate day long (8 hours, 3 times weekly) dialysis for 6 months
3238570|NCT00925470||1|
3238571|NCT00925457||001|Current Domperidone Current domperidone at any dose regardless of proton pump inhibitor status
3238572|NCT00925457||002|Current proton pump inhibitor (PPI) Current PPI and not current dapoxetine
3238573|NCT00925457||003|No Intervention Neither current domperidone nor current PPI
3238574|NCT00925444|Experimental|FOREseal|
3238575|NCT00925444|Active Comparator|Stapling|
3238576|NCT00925431|Experimental|Lifestyle Modification|Behavioral: cognitive-motivational enhancement to lifestyle management plus nutritional education.
3238577|NCT00925431|Active Comparator|Supportive education|General fibromyalgia education plus nutritional education.
3238578|NCT00925418|No Intervention|Without Glove|Patients do not use frozen glove during chemotherapy with Taxotere®
3238579|NCT00925418|Experimental|With Glove|Patients use frozen glove during chemotherapy with Taxotere®
3238580|NCT00925405||Breast MRI Screening|
3238581|NCT00925392|Experimental|Doripenem 500 mg|
3238582|NCT00925392|Experimental|Doripenem 1000 mg|
3238583|NCT00925366|Other|Shoulder rotator cuff tear|Shoulder rotator cuff tear
3238584|NCT00925353|Experimental|lidocaine gel|
3238585|NCT00925340|Experimental|1 - Family Check Up|Brief family intervention that employs Motivational Interviewing.
3238586|NCT00925340|Active Comparator|2 - Psychoeducation|
3238587|NCT00925327|Experimental|Corneal collagen cross-linking with riboflavin and UVA light|
3238588|NCT00925314|Experimental|Transgenic Lymphocyte Immunization|Open Label, Single Arm
3238589|NCT00925301|Experimental|Galafold (AT1001) Oral Capsule|Migalastat HCl 150 mg capsule is taken every other day for 6 months and optional 6 month treatment extension
3238590|NCT00925301|Placebo Comparator|Placebo Oral Capsule|Placebo capsule is taken every other day for 6 months.
3238591|NCT00925288|Active Comparator|Regular schedule|Duration: Gardasil HPV vaccine administered intramuscularly at 0,2,6 months
3238592|NCT00925288|Experimental|Modified Schedule|Duration: Gardasil HPV vaccine administered intramuscularly at 0,3,6 months
3238593|NCT00925275|Experimental|Dosimetric|
3238594|NCT00925262|Experimental|Cognitive Processing Therapy|An adaptation of cognitive behavioral therapy, focusing on treatment for persons suffering mental health effects of trauma
3238595|NCT00925262|Experimental|Behavioral Activation|A form of counseling therapy that emphasizes enhancing pleasurable behaviors and minimizing negative behaviors as a means to reducing depression symptomatology.
3238596|NCT00925262|Experimental|non-specific counseling|a collection of counseling skills suitable for a broad range of mental health and psychosocial problems and not designed for specific disorders. This particular version was developed by a collaborator -Heartland Alliance - for use with torture survivors.
3238597|NCT00925262|No Intervention|wait control|persons in this study arm will not receive active treatment as part of the study but will be monitored during the study and offered treatment after 3-5 months of waiting.
3238598|NCT00925249||1|The study group will consist of RA patients of the Walter Reed Army Medical Center (WRAMC) rheumatology clinic being considered for treatment with anti-TNF alpha therapy. We will enter patients into the study over a projected course of 12-24 months or until we reach the statistical requirement of 60 subjects.
3238599|NCT00925249||2|The control group will consist of healthy subjects without known immune-dysregulation or history of treatment with biologic agents who present to the WRAMC Allergy- Immunology clinic for routine screening TST as a part of current WRAMC policy.
3238600|NCT00925223||irritable bowel syndrome|patients with diarrhea-predominant IBS will be enrolled in this group.
3238601|NCT00925223||control group|patients with colon cancer or colon polyp will be enrolled as control group.
3238602|NCT00925210|Experimental|Sequential pEBUS - ENB|
3238603|NCT00925184||medical students, graduate year,|medical students at graduate year will be invited to participate in this study.
3238604|NCT00925171|Experimental|Pulmonary Rehabilitation Group|Intervention with exercise management
3238605|NCT00925171|No Intervention|Control Group|"Patients will receive the standard advice to undertake strength and endurance exercises at home and invitation to attend the Norwich Breath Easy Group~Patients will be stratified according to whether the initial programme took place in the outpatient hospital or community setting"
3238606|NCT00925158|Experimental|Surgical instrument (DAME)|Surgical dissector instrument created to malar elevation.
3238607|NCT00925145||1|
3238608|NCT00925132|Experimental|Temozolomide, Decitabine, Panobinostat|"Temozolomide - given each cycle.~Decitabine - 6 cohorts with dose escalation.~Panobinostat - 6 cohorts with dose escalation."
3238609|NCT00925119|Experimental|Atenolol|Participants will receive atenolol for 8 weeks.
3238610|NCT00925106|Active Comparator|Celebrex capsule|Commercial capsule
3238611|NCT00925106|Experimental|D1|Test formulation D1
3238612|NCT00925106|Experimental|D2|Test formulation D2
3238613|NCT00925106|Experimental|D3|Test formulation D3
3238614|NCT00925093|Active Comparator|Vancomycin|Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample
3238615|NCT00925093|Active Comparator|Teicoplanin|Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample
3238616|NCT00925093|Active Comparator|Linezolid|Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
3238617|NCT00925080||A|
3238618|NCT00925067|Experimental|lightweight TiMesh|
3238619|NCT00925067|Experimental|lightweight VyproII|
3238620|NCT00925067|Experimental|Heavyweight Marlex|
3238621|NCT00925054|Experimental|rAvPAL-PEG|Subjects will be given rAvPAL-PEG in varying doses not to exceed 5 mg/kg/week until efficacy is reached or until maximum tolerable dose has been reached.
3238622|NCT00925028|Experimental|Group A|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. After four months the groups will switch to the alternate management strategy.
3238623|NCT00925028|Experimental|Group B|Patients of group B will continue to be managed by their physician. After four months the groups will switch to the alternate management strategy.
3238624|NCT00925015|Experimental|Cetux/Irin - Dmab 10 mg/kg|After treatment with Cetuximab (Cetux) and Irinotecan (Irin), Dalotuzumab (Dmab) was administered as an intravenous infusion at 10 mg/kg in Cycle 1 on Days 22, 29 and 36; followed in subsequent cycles by treatment with 10 mg/kg on Days 1, 8, 15, 22, 29 and 36. Each cycle was 6 weeks long.
3238625|NCT00925015|Experimental|Cetux/Irin - Dmab 15/7.5 mg/kg|After treatment with Cetux/Irin, Dmab was administered as an intravenous infusion at 15 mg/kg in Cycle 1 on Days 8, 22 and 36; followed in subsequent cycles by treatment with 7.5 mg/kg on Days 8, 22 and 36. Each cycle was 6 weeks long.
3238626|NCT00925015|Experimental|Dmab 10 mg/kg - Cetux/Irin (DDI)|Dmab was administered in each cycle as an intravenous infusion at 10 mg/kg once weekly on Days 1, 22 and 29; followed by treatment with Cetux/Irin. For Drug-Drug Interaction (DDI). Each cycle was 6 weeks long.
3238627|NCT00925002|Active Comparator|Open-Label|
3238628|NCT00924989|Experimental|Arm A: OSI-906|150 mg twice daily
3238629|NCT00924989|Placebo Comparator|Arm B: Placebo|Matching placebo twice daily
3238681|NCT00924612|Experimental|Very low fat diet|
3238682|NCT00924612|Experimental|Low fat diet|
3238683|NCT00924612|Experimental|Normal diet|
3238684|NCT00924612|Experimental|High fat diet|
3238630|NCT00924976|Experimental|1|Subjects will be offered the Steps for Achieving Financial Empowerment (SAFE) which helps facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
3238631|NCT00924976|No Intervention|2|Representative payeeship as usual
3238632|NCT00924963|Experimental|Jet injection lidocaine|J-Tip jet injection of 1% buffered lidocaine
3238633|NCT00924963|Placebo Comparator|Jet injection saline|J-Tip jet injection of sterile saline
3238634|NCT00924963|Active Comparator|Lidocaine cream|Lidocaine 4%cream applied for 30 minutes prior to IV insertion or venipuncture
3238635|NCT00924950|Active Comparator|Taclonex Ointment/Hydrogel Patch Applied Topically Once Daily|Taclonex ointment once daily used to treat one psoriatic plaque, along with the Hydrogel Patch used once daily.
3238636|NCT00924950|Active Comparator|Taclonex Ointment Topically Once Daily|
3238637|NCT00924937|Active Comparator|Low Fat Diet|Dietary Intervention with a Low fat diet: <30% fat (12% monounsaturated fatty acids; 6-8%polyunsaturated fatty acids; <10% saturated fatty acids)
3238638|NCT00924937|Experimental|Mediterranean Diet|Dietary Intervention with a Mediterranean Diet: 35-38% fat (22% monounsaturated fatty acids; 6% polyunsaturated fatty acids; <10% saturated fatty acids).
3238639|NCT00924924|Experimental|Act Healthy!|Immediate treatment group of six-weeks of classes in self-management training for healthy behaviors
3238640|NCT00924924|Active Comparator|Delayed treatment control|Delayed self-management training group - begins following completion of the experimental group training
3238641|NCT00924911|Experimental|Part 1|A 4 way crossover of three GSK1322322 tablet formulations and GSK1322322 powder in bottle
3238642|NCT00924911|Experimental|Part 2|A 3 way crossover of a GSK1322322 tablet with a high fat meal, with Ranitidine, and with Ranitidine and Vitamin C.
3238643|NCT00924898|Experimental|Acute HIV Treatment Group|Single arm, open label study in which all participants received the same study treatment with efavirenz, emtricitabine, and tenofovir DF
3238644|NCT00924885|Experimental|Thin Follicle Aspiration Needle|
3238645|NCT00924885|Active Comparator|Standard Follicle Aspiration Needle|
3238646|NCT00924872|Experimental|intervention|receive wheelchair skills training
3238647|NCT00924872|No Intervention|control|no formalized wheelchair skills training provided
3238648|NCT00924859||1|Patients with clinical suspicion of CVT
3238649|NCT00924846|Active Comparator|HFOV plus iNO|HFOV plus iNO: high frequency oscillatory ventilation plus inhaled nitric oxide
3238650|NCT00924846|Active Comparator|CMV plus iNO|CMV (conventional mechanical ventilation) iNO (inhaled nitric oxide)
3238651|NCT00924833|Placebo Comparator|placebo|Placebo tablets. One tablet twice daily.
3238652|NCT00924833|Active Comparator|2: Carvedilol|Carvedilol 25 mg tablets. One tablet twice daily.
3238653|NCT00924833|Active Comparator|3: Nebivolol|Nebivolol 5 mg tablets. One nebivolo tablet daily. One placebo tablet daily.
3238654|NCT00924820|Experimental|Bevacizumab|Bevacizumab 10 mg/kg by vein over about 1 hour, every 2 weeks.
3238655|NCT00924807|Experimental|Androgen Depr, Radiotherapy, Sorafenib|Everyone will receive Leuprolide acetate, Bicalutamide,Sorafenib and radiotherapy.
3238656|NCT00924794||Cohort A|Women aged 18 years and above, diagnosed with high grade lesions or microinvasive cervical carcinomas in primary conization performed and registered in the Cancer Registry of Norway, and presenting with recurrent conization with high grade lesions or microinvasive cervical carcinoma or invasive cervical carcinoma.
3238657|NCT00924781|Experimental|MK2578 1 mcg for every 600 U of Epogen at Baseline|Participants were randomized to receive treatment every week (QW).
3238658|NCT00924781|Experimental|1 mcg of MK2578 for every 600 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
3238659|NCT00924781|Experimental|MK2578 1 mcg for every 350 U of Epogen at Baseline|Participants were randomized to receive treatment QW.
3238660|NCT00924781|Experimental|1 mcg of MK2578 for every 350 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
3238661|NCT00924781|Experimental|MK2578 1 mcg for every 200 U of Epogen at Baseline|Participants were randomized to receive treatment QW.
3238662|NCT00924781|Experimental|1 mcg of MK2578 for every 200 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
3238663|NCT00924768|Experimental|Endotoxin|Inhalation of 20K EU CCRE
3238664|NCT00924742|Experimental|Test drug|
3238665|NCT00924729|Active Comparator|Moxifloxacin 0.5% ophthalmic solution|
3238666|NCT00924729|Active Comparator|Besifloxacin 0.6% ophthalmic suspension|
3238667|NCT00924703|Experimental|rAvPAL-PEG|rAvPAL-PEG in varying doses dependent on safety and efficacy.
3238668|NCT00924690|Experimental|1|Behavioral Message Arm
3238669|NCT00924690|Active Comparator|2|Generic Message Arm
3238670|NCT00924677|Sham Comparator|lidocaine|Local injection with lidocaine through the RF cannula without activation of RF generator.
3238671|NCT00924677|Active Comparator|lidocaine, radiofrequency current|After lidocaine injection through the RF cannula, the temperature of the electrode tip was raised to 70℃ for 90 seconds by RF generator.
3238672|NCT00924664|Experimental|Tanezumab 20 mg|
3238673|NCT00924664|Experimental|Tanezumab 10 mg|
3238674|NCT00924651|Experimental|Standard Care + EXCAP|Personalized exercise prescription
3238675|NCT00924651|No Intervention|Standard Care|Wait list control
3238676|NCT00924638|Active Comparator|Continuous Monitoring|Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
3238677|NCT00924638|No Intervention|Control Arm|Follow-up at the same frequency, but with no Insertable Cardiac Monitor
3238678|NCT00924625|Experimental|Neuromuscular electrical stimulation|NMES will be used as in clinical practice based on an evidence-based approach. NMES will be applied at the participant's maximum tolerance. Participants will receive 3 treatments/week for 12 weeks with at least 48h between training sessions.
3238679|NCT00924625|Active Comparator|Volitional exercises|VE will be used as in clinical practice based on an evidence-based approach. VE program will be the one shown to positively affect muscle hypertrophy and will follow the resistance training principles. Participants will receive 3 treatments/week for 12 weeks with at least 48h between training sessions
3238685|NCT00924599|Experimental|Intervention Group-English|Intervention Group will be learning how to lose weight through healthy eating and moderate exercise. The goal is to get participants to lose 7% of body weight and increase physical activity to 2 1/2 hours per week. This group will be meeting one time per week for twelve weeks, and then one time per month until conception.
3238686|NCT00924599|Experimental|Intervention Group-Spanish|Intervention Group will be learning how to lose weight through healthy eating and moderate exercise. The goal is to get participants to lose 7% of body weight and increase physical activity to 2 1/2 hours per week. This group will be meeting one time per week for twelve weeks, and then one time per month until conception.
3238687|NCT00924599|Active Comparator|Lifestyle education-English|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
3238688|NCT00924599|Active Comparator|Lifestyle education-Spanish|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
3238689|NCT00924586|Placebo Comparator|P|
3238690|NCT00924586|Experimental|E|
3238691|NCT00924573|Experimental|1|"Metformin on top of glimepiride~Twice a day with 2-6 mg of daily dose for glimepiride and 500-750mg of daily dose for metformin for 24 weeks"
3238692|NCT00924573|Placebo Comparator|2|"Placebo on top of glimepiride~Twice a day with 2-6 mg of daily dose for glimepiride and 2-3 tablets of placebo for 24 weeks"
3238693|NCT00924560|Experimental|91-day Levonorgestrel Oral Contraceptive|Participants received a 91-day regimen consisting of 84 consecutive days of active combination tablets containing 150 μg levonorgestrel (LNG)/30 μg ethinyl estradiol (EE), followed by 7 days of 10 μg EE tablets for a total of 52 weeks (4 consecutive 91-day cycles).
3238694|NCT00924560|Active Comparator|28-day Levonorgestrel Oral Contraceptive|Participants received a 28-day regimen consisting of 21 consecutive days of active combination tablets containing 100 μg LNG/20 μg EE followed by 7 days of placebo tablets for a total of 52 weeks (13 consecutive 28-day cycles).
3238695|NCT00924560|No Intervention|Untreated Control|Participants received no oral contraceptives during the study.
3238696|NCT00924547|Experimental|Docosahexanoic Acid Supplement|In this arm, participants took two different doses of a DHA supplement. Each dose of the DHA supplement was taken for 4 weeks.
3238697|NCT00924547|Placebo Comparator|Placebo|In this arm, participants took a placebo pill that did not contain any DHA.
3238698|NCT00924534|Placebo Comparator|1|
3238699|NCT00924534|Experimental|2|
3238700|NCT00924534|Experimental|3|
3238701|NCT00924534|Experimental|4|
3238702|NCT00924521|Active Comparator|Refined grain|Participants in this group will receive only refined grains as typically consumed in the average American diet.
3238703|NCT00924521|Experimental|Whole grain diet|Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
3238704|NCT00924508|Experimental|Patch + cream, patch alone, cream alone|This is a single arm study. Each subject will have 3 target lesions; one treated with TAC 0.1% cream and hydrogel patch (occlusion), the second treated with cream alone, and the third treated with occlusion alone.
3238705|NCT00924495|Active Comparator|Cortical function|Activity/inhibition of the cortex
3238706|NCT00924495|Active Comparator|Cortical regulation|
3238707|NCT00924482|Other|Single Arm - Device|Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery
3238708|NCT00924469|Experimental|Abiraterone plus leuprolide plus prednisone|Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day up to Week 24. Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks up to Week 24. Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks.
3238709|NCT00924469|Active Comparator|Leuprolide then abiraterone plus leuprolide plus prednisone|Leuprolide acetate will be administered at a dose of 22.5 mg as intramuscular injection once every 12 weeks up to Week 24. From Week 13 to 24, abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day with prednisone tablets administered orally as 5 mg once daily.
3238710|NCT00924456|Experimental|Transcendental Meditation program|a natural effortless mental technique practiced sitting quietly 20 minutes twice a day
3238711|NCT00924443|Experimental|Clofarabine|Clofarabine 30 mg/m^2/day intravenously over 1 hour for 5 days every 28 to 42 days (one cycle), then 20mg/m^2/day intravenously over 1 hour for 5 days every 29 to 43 days for the second and subsequent cycles, up to a maximum of 3 cycles.
3238712|NCT00924430|Other|1|
3238713|NCT00924430|Other|2|
3238714|NCT00924417|No Intervention|Routine Care|Parent given brief description of what entails routine care with peripheral IV placement.
3238715|NCT00924417|Experimental|Distraction|"Parent given brief teaching session on concept of distraction, and parent and child given 3 distraction toys/tools to assist with peripheral intravenous line placement."
3238716|NCT00924404|Experimental|Xylitol|isotonic xylitol for sinus rinse
3238717|NCT00924404|Active Comparator|Saline|saline for sinus rinse
3238718|NCT00924391|Active Comparator|dairy milk|Control phase with 1% milk.
3238719|NCT00924391|Experimental|phytosterol enhanced soy based beverage|Treatment phase where control-phase diets are provided with phytosterol enhanced soy based beverage.
3238720|NCT00924352|Experimental|Ixabepilone + Dasatinib|"Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level − 1;12 mg/m2,Dose Level − 2;12 mg/m2.~Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level − 1;100 mg QD,Dose Level − 2;70 mg QD."
3238721|NCT00924339|Placebo Comparator|Rapeseed oil|Control-Group (n = 15) : Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
3238849|NCT00923000|Active Comparator|Nalbuphine|
3238722|NCT00924339|Experimental|Soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
3238723|NCT00924326|Experimental|Single Arm|Patients will receive fludarabine and cyclophosphamide chemotherapy (NMA) for lymphocyte-depletion followed by anti-CD19- CAR-transduced T cells
3238724|NCT00924313|Experimental|11C-acetate for Prostate Cancer Patients|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
3238725|NCT00924300||patients|children and/or adolescents with psychiatric disorder
3238726|NCT00924300||controls|typically-developing children/adolescents
3238727|NCT00924287|Experimental|Metastatic Cancer|Cancer that has invaded other parts of the body
3238728|NCT00924274|Experimental|Lifestyle counseling|
3238729|NCT00924274|Active Comparator|sunflower oil|
3238730|NCT00924261|Experimental|Hip Stretching|Kneeling Hip flexor stretch - 3 minutes a day, daily, for 10 weeks
3238731|NCT00924261|Experimental|Shoulder Stretch|Shoulder Stretch - 3 minutes daily for 10 weeks
3238732|NCT00924248||Group 1|
3238733|NCT00924222|Experimental|Sevoflurane|
3238734|NCT00924222|Experimental|Propofol|
3238735|NCT00924209|Experimental|Stage IIIA lung cancer patients|Non-squamous cell non small cell lung cancer treated with 1250 mg/m^2 gemcitabine dose for two doses on day 1 and day 8 every 21 days,80 mg/m^2 cisplatin day 1 every 21 days for 3 cycles, 7.5 mg/kg bevacizumab on day 1 every 21 days for first 2 cycles only, and 100 mg/m^2 intravenous, and 100 mg/m^2 etoposide intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
3238736|NCT00924183||Treatment-as-usual|All patients will receive treatment as usual: antidepressant medication and/or cognitive behavioral therapy (CBT). Patients' results will be compare to their own baseline measurements.
3238737|NCT00924170|Experimental|Fludarabine and Cyclophosphamide/LMB-2|Administer cycle 1 with Fludarabine and Cyclophosphamide (FC) alone. Two weeks after starting cycle 1, begin up to 6 cycles of FC plus LMB-2 at minimum 20-day intervals.
3238738|NCT00924118|Experimental|Sodium Nitrite|Dose escalation of sodium nitrite.
3238739|NCT00924118|No Intervention|Open Control|Standard therapy
3238740|NCT00924105|Experimental|1|
3238741|NCT00924105|Placebo Comparator|2|
3238742|NCT00924079|Experimental|nalbuphine|
3238743|NCT00924066|Experimental|Squamous and Nonsquamous participants|"Squamous cell carcinoma is a histologic subtype of cervical cancer. Squamous cell carcinoma of the cervix (80%) is much more common than adenocarcinoma of the cervix.~Non squamous carcinoma is a histologic subtype of cervical cancer. It is the second most common form of cervical cancer; consists of adenocarcinoma, adenosquamous and non squamous (not otherwise specified) subtypes.~All participants in both arms received ixabepilone 6 mg/m^2 x 5 days, each cycle."
3238744|NCT00924053|Experimental|EGT0001474|
3238745|NCT00924053|Placebo Comparator|Placebo|
3238746|NCT00924040|Experimental|BL22 Immunotherapy|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
3238747|NCT00924027|Experimental|Gynecologic|Endometrial and cervical cancer
3238748|NCT00924027|Experimental|Pulmonary|Lung Cancer
3238749|NCT00924027|Experimental|Breast|Breast Cancer
3238750|NCT00924027|Experimental|Prostate|Prostate Cancer
3238751|NCT00924014|Active Comparator|Conivaptan|Conivaptan will be given via IV bolus
3238752|NCT00924014|Active Comparator|Furosemide|Furosemide will be given via IV bolus
3238753|NCT00924014|Active Comparator|conivaptan and furosemide|on day 3 subjects will receive both study drugs
3238754|NCT00924001|Experimental|Metastatic Melanoma|Melanoma that has invaded deep into the skin, lymph nodes, or other parts of the body.
3238755|NCT00923975|Other|Intended Users of the Software|Young adults, parents/guardians of young people under age 18, and healthcare professionals who work with this population would be intended users of the data management program. The DIDGET World Reports software is used to upload blood glucose results from the DIDGET Blood Glucose Monitoring System so that intended users can identify patterns in their diabetes management.
3238756|NCT00923962|Active Comparator|Type 2 Diabetes patients|
3238757|NCT00923962|Active Comparator|Healthy|
3238758|NCT00923962|Active Comparator|Artherosclerosis|
3238759|NCT00923949|Experimental|Pioglitazone|45 mg tablet daily by mouth for six weeks
3238760|NCT00923936|Active Comparator|KS;classic/HIV+not improved on antiviral|Kaposi's Sarcoma (KS) in patients who are Human immunodeficiency virus (HIV) Negative, HIV infected with stable disease for one year despite antiretroviral therapy or progressive disease despite 4 months of antiretroviral therapy.
3238761|NCT00923936|Active Comparator|All other advanced HIV-asociated KS|All other patients with advanced acquired immune deficiency syndrome (AIDS)-associated KS
3238762|NCT00923923|Experimental|levels of stress|
3238763|NCT00923910|Other|Donors|Related and unrelated donors undergo lymphapheresis to prepare cellular vaccines and to donate lymphocytes for infusion.
3238764|NCT00923910|Experimental|Recipients|Participants receive donor lymphocytes and vaccines prepared from donors.
3238765|NCT00923897|Experimental|RT for Liver Mets and HCC|
3238766|NCT00923871|Experimental|Cone Beam CT|
3238767|NCT00923858||Control - participants from cycles 1 & 2|no intervention. Control group is composed of participants from Cohort I (recruited during our first grant cycle) and from Cohort II (recruited during our second grant cycle). Continued observation is planned for those controls, partial tears and full tears who enrolled in study at age 65 years or younger and have less than 11 years of follow up.
3238768|NCT00923858||Cuff Tear Cohort III|These participants are being recruited from our clinical population and have been scheduled to undergo a standard of care rotator cuff repair and post op therapy. One shoulder has been indicated for rotator cuff repair and the contralateral shoulder is asymptomatic. Both shoulders will be monitored.
3238769|NCT00923845|Other|Donors|A sibling who is 6/6 HLA --matched with the recipient. Donors undergo donor lymphocyte harvest and stem cell mobilization and harvest.
3238770|NCT00923845|Other|Recipients|Recipients undergo induction therapy, allogeneic stem cell therapy and GVHD prophylaxis.
3238771|NCT00923819|Experimental|Group A|Laparoscopic Gastric Bypass
3238850|NCT00923000|Active Comparator|Morphine|
3238772|NCT00923819|Active Comparator|Group B|Standard conservative treatment. Patients from Child Obesity Registry of Vestfold.
3238773|NCT00923806|Experimental|Gene Therapy Treatment|
3238774|NCT00923793|Active Comparator|Titanium|Titanium implant for cranioplasty. Titanium implants are used since 10 years in Germany because of their high biocompatibility and accuracy of fit.
3238775|NCT00923793|Experimental|Hydroxylapatite|Hydroxylapatite (CustomBone) implant Hydroxylapatite implants are used since about 3 years in Germany. As this material is very similar to human bone structure an improved osteointegration has been observed.
3238776|NCT00923702|Other|2 doses of vaccine|The participants will receive two doses of the vaccine at Day 1 and Day 180.
3238777|NCT00923702|Other|3 doses of vaccine|The participants will receive three doses of the vaccine at Day 1, Day 60, and Day 180.
3238778|NCT00923676|Active Comparator|Fenofibrate|Fenofibrate pills
3238779|NCT00923676|Active Comparator|Rosuvastatin|Rosuvastatin pills
3238780|NCT00923676|Active Comparator|fenofibrate + rosuvastatin|fenofibrate pills + rosuvastatin pills
3238781|NCT00923663|Experimental|Lenalidomide|Lenalidomide administered orally at a dose of 25 mg daily
3238782|NCT00923624|Active Comparator|staff emails|Attention control that includes staff sending emails with information about using health information technology system.
3238783|NCT00923624|Experimental|study nurse messages|A series of 6 proactive secure messages and 3 proactive booster messages (for a total of 9 secure and personalized messages) sent by the study nurse via the EMR patient web portal.
3238784|NCT00923611|Placebo Comparator|Placebo|3 tablets of placebo will be taken 30minutes after breakfast for 8 weeks
3238785|NCT00923611|Active Comparator|Fimasartan 20mg|2 tablets of placebo and 1 tablets of fimasartan 20mg will be taken 30minutes after breakfast for 8 weeks
3238786|NCT00923611|Active Comparator|Fimasartan 60mg|3 tablets of fimasartan 20mg will be taken 30minutes after breakfast for 8 weeks
3238787|NCT00923611|Active Comparator|Fimasartan 120mg|3 tablets of fimasartan 40mg will be taken 30minutes after breakfast
3238788|NCT00923611|Active Comparator|Fimasartan 240mg|3 tablets of fimasartan 80mg will be taken 30minutes after breakfast for 8 weeks
3238789|NCT00923598|Active Comparator|1) 0.1% Ropivicaine on Right Leg|Patients will be randomized ot 0.1% Ropivicaine infusion on the right leg and therefore 0.4% Ropivicain in fusion for the left leg for pain due to bilateral TKA. The outcome measures will be measured on both legs, starting with the right leg each time. The infusion will last for the two days following surgery, that the patient is staying in the hospital.
3238790|NCT00923598|Active Comparator|2) 0.4% Ropivicaine on Right Leg|Patients will be randomized ot 0.4% Ropivicaine infusion on the right leg and therefore 0.1% Ropivicain in fusion for the left leg for pain due to bilateral TKA. The outcome measures will be measured on both legs, starting with the right leg each time. The infusion will last for the two days following surgery, that the patient is staying in the hospital.
3238791|NCT00923572||Group 1|
3238792|NCT00923559|Experimental|Mother-Infant Psychoanalytic treatment;MIP|MIP intervention
3238793|NCT00923559|Active Comparator|TAU|Treatment as usual
3238794|NCT00923533|Active Comparator|Part A|Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
3238795|NCT00923533|Active Comparator|Part B|Hydrochlorothiazide (7day) Hydrochlorothiazide + Fimasartan (7day)
3238796|NCT00923520|Experimental|1|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
3238797|NCT00923494|Active Comparator|Group R20|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
3238798|NCT00923494|Active Comparator|Group R30|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
3238799|NCT00923494|Active Comparator|Group R40|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
3238800|NCT00923481|Experimental|Multi-kinase inhibitor Fostamatinib Disodium (R935788)|200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
3238801|NCT00923442||1|Patients (from birth to 75 years old) diagnosed with any hematologic malignancy or pre malignant condition
3238802|NCT00923429|Active Comparator|S-A|
3238803|NCT00923429|Active Comparator|S-A+stretch|
3238804|NCT00923429|Experimental|S-A+stretch+manther|
3238805|NCT00923429|Experimental|S-A+stretch+manther+sterinject|
3238806|NCT00923416||Prostate Cancer|
3238807|NCT00923403|Placebo Comparator|Placebo Comparator|control dairy milk
3238808|NCT00923403|Experimental|experimental|plant sterol enriched soymilk
3238809|NCT00923364|Experimental|Recipients and Healthy Related Donors|Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.
3238810|NCT00923351|Experimental|Arm A - Participants who did not receive rhIL-7|Six patients with Ewings sarcoma family or tumors (ESFT) participants will receive cytotoxic/lympholytic therapy with cyclophosphamide and fludarabine (if cluster of differentiation 4 (CD4) count > 200 cells/mcl). Participant will receive Tumor lysate/keyhole limpet hemocyanin (KLH) pulsed dendritic cell vaccine followed by Infusion of 8H9/CD25 depleted autologous lymphocyte infusion on Day 1, followed by Tumor lysate/KLH pulsed dendritic cell vaccine on week 4, 6, 8, 10, and 12.
3238811|NCT00923351|Experimental|Arm B - Participants who received rhIL-7|"Eight patients with rhabdomyosarcoma, fifteen patients with Ewings sarcoma family or tumors (ESFT), two patients with desmoplastic small round cell tumor, and one patient with synovial cell sarcoma participants will receive CYT107 20 mcg/kg/dose subcutaneous (SQ) (approx. 48h prior to vaccine[Day 0]), Tumor lysate/KLH pulsed dendritic cell vaccine followed by Infuse 8H9/CD25 depleted autologous lymphocyte infusion on Day 2, followed by CYT107 20 mcg/kg/dose SQ on days 14, 28 and 42 (± 7 days), and Tumor lysate/KLH pulsed dendritic cell vaccine on Days 16, 30, 44, 56, and 70 (± 7 days).~Apheresis/flow cytometry/delayed type of hypersensitivity (DTH) responses for immune endpoint monitoring (skin tests) will be performed on Week 8, 14, 20 (Arm A) and on Days 42, 84 and 126 (+/- 7 days) (Arm B); and radiographic studies for clinical restaging will be performed on Week 8 and 20 (Arm A) and Days 42 and 126 (+/- 7 days) (Arm B)."
3238812|NCT00923338|Experimental|Vesico-vaginal fistula plug|Vesico-vaginal fistula plug
3238813|NCT00923312|Experimental|CV9201|CV9201 is composed of five formulated mRNAs (drug product components) encoding antigens that are overexpressed or exclusively expressed in NSCLC cells.
3238814|NCT00923273|Experimental|Treatment level 1 - 3mg load|Sirolimus 3mg load/1mg/day; Pemetrexed 375mg/m^2
3238815|NCT00923273|Experimental|Treatment level 2 - 6 mg load|Sirolimus 6mg load/2mg/day; Pemetrexed 375mg/m^2
3238816|NCT00923273|Experimental|Treatment level 3 - 6mg load|Sirolimus 6mg load/2mg/day; Pemetrexed 375mg/m^2
3238817|NCT00923273|Experimental|Treatment level 4 - 10 mg load|Sirolimus 10mg load/3mg/day; Pemetrexed 500mg/m^2
3238818|NCT00923273|Experimental|Treatment level 5 - 15 mg load|Sirolimus 15mg load/5mg/day; Pemetrexed 500mg/m^2
3238819|NCT00923260|Experimental|Roux-en-Y Gastric Bypass/Omentectomy|Laparoscopic Roux-en-Y Gastric Bypass with omentectomy
3238820|NCT00923260|Active Comparator|Roux-en-Y Gastric Bypass alone|
3238821|NCT00923247|Experimental|Phase 1 - vandetanib and bortezomib|Patients will be treated with vandetanib and bortezomib to find the maximally tolerated dose
3238822|NCT00923247|Active Comparator|Phase 2 B - vandetanib alone|Patients will be treated with vandetanib alone.
3238823|NCT00923247|Active Comparator|Phase 2 A - vandetanib and bortezomib at the MTD|Patients will be treated with vandetanib and bortezomib at the maximally tolerated dose (MTD) of the Phase I study
3238824|NCT00923234|Experimental|Azacitidine and Lenalidomide|Azacitidine 75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles and Lenalidomide 10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
3238825|NCT00923195|Experimental|TBI 600cGy + PBL + HD IL-2+gp100:154-162|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population). One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14. Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).Radiation: 2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute.
3238826|NCT00923195|Experimental|TBI 600cGy+PBL+HD IL-2+MART-1:26-35(27L)|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population). One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14. Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).Radiation: 2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute.
3238827|NCT00923182|Experimental|Alemtuzumab|The starting dose of alemtuzumab was 3 mg. The dose was gradually escalated on a daily basis (3 mg, 10 mg, and then 30 mg) until the patient tolerated a dose of 30 mg IV infusion over 2 hours. All subsequent doses of alemtuzumab were 30 mg IV 3 times a week (every other day).
3238828|NCT00923156|Experimental|Aliskiren|In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1. In double blind phase (Period 2), patients received aliskiren (150 mg once daily) up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site and matching placebo of ramipril capsules.
3238829|NCT00923156|Experimental|Ramipril|"In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1.~In double blind phase (Period 2), patients received ramipril 10 mg capsule o.d and matching placebo of aliskiren tablet."
3238830|NCT00923156|Experimental|Aliskiren plus Ramipril|"In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1.~In double blind phase (period 2), patients received ramipril (10 mg once daily capsule) and aliskiren (150 mg once daily tablet) up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site"
3238831|NCT00923130|Experimental|Bevacizumab with Ixabepilone|Bevacizumab 15mg/kg every 3 weeks Ixabepilone given on days 1,2,3,4 and 5 of each three week cycle at a dose of 6mg/m(2)/day
3238832|NCT00923117|Experimental|Bevacizumab resistant patients|Patients who had tumor progression while treated with bevacizumab.
3238833|NCT00923117|Experimental|Bevacizumab naive patients|Patients with progressive tumor who have not been treated with bevacizumab.
3238834|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 20mg/5mg/12.5mg|olmesartan medoxomil 20mg / amlodipine besylate 5 mg / hydrochlorothiazide 12.5mg
3238835|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/12.5mg|
3238836|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/25mg|
3238837|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/12.5mg|
3238838|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/25mg|
3238839|NCT00923091|Experimental|olmesartan/amlodipine 20mg/5mg|olmesartan medoxomil 20mg / amlodipine besylate 5mg
3238840|NCT00923091|Experimental|olmesartan/amlodipine 40mg/5mg|
3238841|NCT00923091|Experimental|olmesartan/amlodipine 40mg/10mg|
3238842|NCT00923078|Experimental|Auditory-Visual Train Order|4 weeks (20 sessions) of auditory cognitive training (Brain Fitness) followed by 4 weeks (20 sessions) of visual cognitive training (Insight)
3238843|NCT00923078|Experimental|Visual-Auditory Train Order|4 weeks (20 sessions) of visual cognitive training (Insight) followed by 4 weeks (20 sessions) of auditory cognitive training (Brain Fitness)
3238844|NCT00923039||Exposed/ Not exposed|
3238845|NCT00923013|Experimental|A|Cladribine with immediate Rituximab
3238846|NCT00923013|Active Comparator|B|Cladribine with Rituximab delayed by at least 6 months after Cladribine if and when minimal residual disease is detected
3238847|NCT00923013|Experimental|C|Non-randomized group receving Cladribine with immediate Rituximab
3238848|NCT00923000|Experimental|Nubian with Long dan xie gan tang 3g|
3238851|NCT00923000|Experimental|Morphine with Long dan xie gan tang|
3238852|NCT00923000|Experimental|Nubian with Long dan xie gan tang 3g tid|
3238853|NCT00922987||Lyrica|Adult patients with partial seizures (type of epilepsy). Inclusion criteria according to Summary of Product Characteristics
3238854|NCT00922974|Experimental|Arm I (phase III)|Patients undergo 1 high-dose image-guided radiosurgery or SBRT treatment over 60 minutes.
3238855|NCT00922974|Active Comparator|Arm II (phase III)|Patients undergo 1 standard-dose external beam radiotherapy treatment over 5 minutes.
3238856|NCT00922961|Experimental|cellular apoptosis|
3238857|NCT00922948|Experimental|Cryoablation|
3238858|NCT00922948|Active Comparator|Radiofrequency ablation|Radiofrequency ablation
3238859|NCT00922935|Experimental|Cresco early loading|The implants must be restored (loaded) with a permanent screw retained fixed partial denture (FPD) at 10 days of post surgery
3238860|NCT00922935|Experimental|Cresco late loading|"Healing caps will be placed until loading. The minimum waiting time is 4 weeks, but not before try ins to ensure a perfect fit. The implants must be restored (loaded) with a permanent screw retained fixed partial denture (FPD) within 42-56 days (6 to 8 weeks) of surgery."
3238861|NCT00922935|Active Comparator|Straumann system late loading|Straumann components loading at 6-8 weeks post surgery
3238862|NCT00922909|Active Comparator|2|Day 1 : morning : Medication on ; Stimulation : off afternoon : Medication : on ; Stimulation : on Day 2 : morning : Medication : off ; Stimulation : off afternoon : medication : off ; stimulation : on
3238863|NCT00922909|Active Comparator|3|Day 1 : morning : Medication off ; Stimulation : on afternoon : Medication : off ; Stimulation : off Day 2 : morning : Medication : on ; Stimulation : on afternoon : medication : on ; stimulation : off
3238864|NCT00922909|Active Comparator|4|Day 1 : morning : Medication off ; Stimulation : off afternoon : Medication : off ; Stimulation : on Day 2 : morning : Medication : on ; Stimulation : off afternoon : medication : on ; stimulation : on
3238865|NCT00922909|Active Comparator|1|Day 1 : morning : Medication on ; Stimulation on afternoon : Medication on ; Stimulation off Day 2 : morning : Medication off ; Stimulation on afternoon : Medication off ; Stimulation off
3238866|NCT00922896|Experimental|GPE|Gemcitabine-Cisplatin-Erlotinib
3238867|NCT00922883|Experimental|Eltrombopag|Eltrombopag (Promacta): Subjects commenced eltrombopag at a dose of 50 mg, which was increased by 25 mg every 2 weeks if the platelet count had not increased by 20 × 103/µL, to a maximum dose of 150 mg.
3238868|NCT00922870|Active Comparator|Standard treatment|
3238869|NCT00922870|Experimental|Cascade|
3238870|NCT00922857|Experimental|Respiratory rehabilitation|
3238871|NCT00922844|Active Comparator|Sevoflurane|Administration of the volatile anesthetic Sevoflurane.
3238872|NCT00922844|Active Comparator|Isoflurane|Administration of the volatile anesthetic Isoflurane.
3238873|NCT00922818||Radical perineal prostatectomy patients|Radical perineal prostatectomy patients
3238874|NCT00922805|Active Comparator|fiber-enriched formula then fiber-free formula|Subjects first receive a fiber-enriched formula for one week but then will be crossed over and receive a fiber-free formula
3238875|NCT00922805|Active Comparator|fiber-free formula then fiber-enriched formula|Subjects receive first formula only then will be crossed over and receive a fiber-enriched formula
3238876|NCT00922792|Experimental|A|
3238877|NCT00922792|Experimental|B|
3238878|NCT00922779|Experimental|1|
3238879|NCT00922766||1.0|
3238880|NCT00922753|Active Comparator|BiPAP6 assisted preoxygenation|
3238881|NCT00922753|Active Comparator|BiPAP4 assisted preoxygenation|
3238882|NCT00922753|Active Comparator|Standard preoxygenation (VS)|
3238883|NCT00922740|Placebo Comparator|Sugar pill|
3238884|NCT00922740|Experimental|VA106483 1 mg|
3238885|NCT00922740|Experimental|VA106483 2 mg|
3238886|NCT00922740|Experimental|VA106483 4 mg|
3238887|NCT00922727|Active Comparator|L. reuteri|Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment and maintenance of a well-functioning gastro-intestinal (GI) tract microflora and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment. The oil drops contain a dietary supplement of Lactobacillus reuteri DSM 17938.
3238888|NCT00922727|Placebo Comparator|Sunflower Oil|Placebo will be the equivalent number of drops of suspended sunflower oil (without LR), provided by Biogaia.
3238889|NCT00922714|Experimental|Glutamine|Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
3238890|NCT00922714|Placebo Comparator|Control|saline
3238891|NCT00922701|Experimental|Peritoneal Dialysis Solution|
3238892|NCT00922688|Active Comparator|Dipeptiven Arm Enteral|
3238893|NCT00922688|Placebo Comparator|Placebo Arm Enteral and Intravenously|
3238894|NCT00922688|Active Comparator|Dipeptiven ARM Intravenously|
3238895|NCT00922675|Experimental|Postconditioning|Active arm:Postconditioning protocol before routine PCI/stenting of an occluded coronary artery
3238896|NCT00922675|Other|Control|Control arm: Routine PCI/stenting of an occluded coronary artery without postconditioning
3238897|NCT00922649|Other|A|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen of ≥ 2 OAs
3238898|NCT00922649|Other|B|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen of basal insulin ± OAs
3238899|NCT00922649|Other|C|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen basal-bolus insulin ± OAs
3238900|NCT00922636|Active Comparator|Methylphenidate|Extended-release methylphenidate 18 milligrams per day (mg/day) to 54 mg/day, based on weight, given once daily (QD) and orally (po) as a capsule for the 8-week double-blind treatment phase, followed by 2 weeks of placebo in the taper phase.
3238901|NCT00922636|Placebo Comparator|Placebo|
3238902|NCT00922636|Experimental|LY2216684 (0.1 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of placebo in the taper phase.
3238961|NCT00922168||Cardiac Surgeries: CABG, valve replacements|
3239428|NCT00918398|Experimental|4|AZD1981, 500 mg oral tablet B
3238903|NCT00922636|Experimental|LY2216684 (0.2 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of tapering in the taper phase.
3238904|NCT00922636|Experimental|LY2216684 (0.3 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of tapering in the taper phase.
3238905|NCT00922623|Experimental|Belotero®|
3238906|NCT00922610|Experimental|1|
3238907|NCT00922597||Group 1|
3238908|NCT00922584|Experimental|sorafenib|Patients with stage IIIB/IV NSCLC who failed EGFR-TKI therapy will receive oral sorafenib 400 mg twice daily until disease progression or unacceptable toxicity.
3238909|NCT00922571|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the OptiMedica Catalys™ Precision Laser System (Catalys System)
3238910|NCT00922558|No Intervention|normal children|Normal children ages 5-12 years.
3238911|NCT00922558|Experimental|postural control|
3238912|NCT00922532|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide
3238913|NCT00922532|Placebo Comparator|Nitrogen|Nitrogen Placebo
3238914|NCT00922519||1|
3238915|NCT00922506|Experimental|doxazosin plus tolterodine SR 2 mg|doxazosin plus tolterodine SR(2 mg, qd) for 12 weeks
3238916|NCT00922506|Experimental|doxazosin plus tolterodine SR 4 mg|doxazosin plus tolterodine SR(4 mg,qd) for 12 weeks
3238917|NCT00922480|Active Comparator|2|Losartan group
3238918|NCT00922480|Active Comparator|1|Fimasartan 60mg, 120mg
3238919|NCT00922467|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
3238920|NCT00922467|Experimental|Esmolol|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and esmolol
3238921|NCT00922454|Experimental|Talent Stent-Graft|
3238922|NCT00922454|Experimental|Cook Zenith Stent-Graft|
3238923|NCT00922441|Experimental|Fimasartan 1|Fimasartan 60 mg group
3238924|NCT00922441|Experimental|Fimasartan 2|Fimasartan 120 mg group
3238925|NCT00922441|Active Comparator|Valsartan|Reference (Valsartan 80 mg) group
3238926|NCT00922428||Observational group|Patients suffering from rheumatic disorders of different types and origins, especially those with arthralgia, myalgia, lumbago, or other diagnoses.
3238927|NCT00922415||cases|patients at least 18 years of age, with confirmed Crohn's disease undergoing intestinal resection for complicated Crohn's disease
3238928|NCT00922402|Experimental|Treatment|All patients will be submitted to a shared intensive protocol of insulin infusion supported by continuous glucose monitoring
3238929|NCT00922389|Experimental|G-CSF + Stem cells|
3238930|NCT00922389|Other|No stem cell group|
3238931|NCT00922389|Active Comparator|Standerd theraphy|Any therapy for diabetic foot CLI which is routinely practiced and accepted in India
3238932|NCT00922376|Active Comparator|T+ Intervention|The intervention group patients will use the T+ telemedicine application whilst completing repeated measures aiming to compare them to a control group receiving standard care.
3238933|NCT00922376|No Intervention|Usual care|The control group will be receiving the standard care offered by the NHS to patients suffering from diabetes.
3238934|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 alone|
3238935|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|
3238936|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|
3238937|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 + 625/125 µg CAF01|
3238938|NCT00922350|Experimental|heliox|The patients in this group underwent nebulization with heliox carried by the trunk erect
3238939|NCT00922350|Experimental|heliox+posture|The patients in this group carried out the mist carried by heliox and the trunk tilted forward
3238940|NCT00922350|Experimental|oxygen+posture|The patients in this group carried out the mist carried by oxygen and the trunk tilted forward
3238941|NCT00922350|Active Comparator|oxygen|The patients in this group carried out the mist carried by the oxygen and the trunk upright
3238942|NCT00922337||MGuard|eligible patients implanted with minimum one MGuard stent
3238943|NCT00922324|Experimental|STP206|STP206 administered either as a single dose or as a daily dose for seven consecutive days
3238944|NCT00922324|Placebo Comparator|Vehicle Control|STP206 vehicle administered as either a single dose or as a daily dose for 7 consecutive days
3238945|NCT00922311|Experimental|Aliskiren|
3238946|NCT00922285|Experimental|Art Therapy|
3238947|NCT00922272|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
3238948|NCT00922272|Placebo Comparator|Placebo|Placebo
3238949|NCT00922259|Experimental|H7N7 Vaccine|Participants will be administered two doses of the candidate live influenza A H7N7 vaccine
3238950|NCT00922246|No Intervention|control group|Conscript used their own ankle boots instead of custom made insoles.
3238951|NCT00922246|Experimental|shoe insoles|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length. The insole was strong enough to fill the arch area thus providing support to the mid foot. It also influences the position of the foot. The insoles were individually customized by heating the polyethylene in form of individual foot with standing and walking in them. The conscripts were advised to use these insoles in their ankle boot.
3238952|NCT00922233|Experimental|Levonorgestrel|0.75 mg of levonorgestrel within 24 hours of sex
3238953|NCT00922220|Active Comparator|stationary bike|Participants rode a stationary bike for five minutes
3238954|NCT00922220|Active Comparator|lumbar extension exercises|Participants performed four sets of fifteen lumbar extension exercises over five minutes
3238955|NCT00922220|Experimental|spinal manipulative therapy|Participants received spinal manipulative therapy to the low back
3238956|NCT00922207|Experimental|1|
3238957|NCT00922207|Experimental|2|
3238958|NCT00922207|Placebo Comparator|3|
3238959|NCT00922181|Experimental|MWA|Patients undergoing MWA for hepatic metastases smaller than 3 cm, without underlying liver disease
3238960|NCT00922181|Active Comparator|RFA|Patients undergoing RFA for hepatic metastases smaller than 3 cm, without underlying liver disease
3238962|NCT00922155|No Intervention|EBUS|After the PPLs been localized by endobronchial ultrasound(EBUS), patients in the EBUS group received transbronchial biopsy and bronchial washing at the bronchus located by EBUS.
3238963|NCT00922155|Active Comparator|EBUS-GS|After PPLs been localized by EBUS, the EBUS and guide sheath were then inserted to localize the lesion again. Transbronchial biopsy and brushing were done through the guide sheath after the probe been removed.
3238964|NCT00922129|Experimental|Conversion to sirolimus|
3238965|NCT00922129|Active Comparator|Calcineurim inhibitor reduction|
3238966|NCT00922116|Experimental|1|
3238967|NCT00922103|Experimental|INRA|Patients treated for medical refractory Ulcerative Colitis
3238968|NCT00922103|Active Comparator|IPAA|Patients treated for medical refractory Ulcerative Colitis
3238969|NCT00922064|Experimental|ECT|
3238970|NCT00922051|Experimental|Group 1|Application of Acu-TENS
3238971|NCT00922051|Placebo Comparator|Group 2|
3238972|NCT00922038|Experimental|High reward|
3238973|NCT00922038|Experimental|Low reward|
3238974|NCT00922038|No Intervention|Control|
3238975|NCT00922025||1|Male patients with non-small cell lung cancer (NSCLC) of adeno histology
3238976|NCT00922012|Experimental|Electromagnetic stimulation|Electromagnetic stimulation therapy
3238977|NCT00921986||Arrhythmias|Patients with arrhythmias
3238978|NCT00921986||Control Subjects|Subjects that do not have a history of cardiac arrhythmias.
3238979|NCT00921973|Active Comparator|VAX102|Simultaneous administration of VAX102 1 ug i.m. plus TIV
3238980|NCT00921973|Placebo Comparator|Placebo|
3238981|NCT00921960|No Intervention|Usual Care|Usual Care will involve ongoing management from the general practitioner, nurse-led assessment of cardiovascular risk at the general practice and referral to specialist services as deemed necessary.
3238982|NCT00921960|Other|Intervention|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate
3238983|NCT00921947|Experimental|VAX102 IM|VAX102 given as 1 µg intramuscular (i.m.)
3238984|NCT00921947|Experimental|VAX102 SC|VAX102 given as a 2 µg subcutaneous (s.c.) dose
3238985|NCT00921934||Vitamin C|Adult patients suffering from acute viral infection, especially herpes zoster, presenting themselves in Primary Care Centers or hospitals all over Germany, and who are treated with standard therapy and add-on vitamin C.
3238986|NCT00921921|Experimental|Extra-fine particle steroid inhaler|
3238987|NCT00921921|Placebo Comparator|Placebo control|
3238988|NCT00921908||epidural catheter|subfascial placement of a triple-orifice epidural catheter
3238989|NCT00921908||multiholed catheter|subfascial placement of a multi-orifice 15 cm catheter
3238990|NCT00921895|Experimental|Device Testing|Patients with conjunctivitis will be tested with the RPS Adeno Detector IV
3238991|NCT00921882||Oral glucose tolerance test|oral glucose tolerance test performed 48 hours post-partum and 8 weeks post-partum.
3238992|NCT00921869|Experimental|1|
3238993|NCT00921856|No Intervention|CAD|Patients admitted with suspicion of CAD and proof of CAD after coronary angiography.
3238994|NCT00921856|Experimental|No-CAD|Patients admitted with suspicion of CAD but without proof of CAD after coronary angiography will undergo intracoronary acetylcholine provocation test.
3238995|NCT00921843|Experimental|Methadone|Methadone administration 0.1mg/kg, 0.2mg/kg or 0.3 mg/kg
3238996|NCT00921830|Experimental|Ibuprofen|ibuprofen
3238997|NCT00921804|Experimental|1|AZD8529 40 mg
3238998|NCT00921804|Placebo Comparator|2|Placebo
3238999|NCT00921804|Other|3|Risperidone 4 mg (2mg on Day 1)
3239000|NCT00921791|Experimental|Home Blood Pressure Monitoring|Automatic oscillometric device for blood pressure measurement at home plus usual care.
3239001|NCT00921791|Experimental|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists plus usual care.
3239002|NCT00921791|Active Comparator|Pharmaceutical care|Consultations with the pharmacists plus usual care.
3239003|NCT00921791|Active Comparator|Control|Usual care: participants are instructed to keep on their current antihypertensive medication and receive non-pharmacological recommendations for hypertension treatment.
3239004|NCT00921765|Placebo Comparator|Placebo + Placebo|Saline single bolus dose iv + saline single bolus dose iv
3239005|NCT00921765|Active Comparator|Placebo + Ketamine|Saline single bolus dose followed by single bolus dose of ketamine 0.2 mg/kg bw
3239006|NCT00921765|Active Comparator|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
3239007|NCT00921765|Active Comparator|Naloxone + Ketamine|Single bolus dose of ketamine 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
3239008|NCT00921752||Patients at high cardiovascular risk|
3239009|NCT00921739|Experimental|IMRT concurrent with chemotherapy|6 fractions of esophageal sparing IMRT weekly for 5-6 weeks (dependent on dose cohort) concurrent with standard chemotherapy: Cisplatin 50 mg/m2 /d intravenously (IV) on days 1, 8, 29, and 36. Etoposide 50 mg/m2 /d IV on days 1 through 5 and 29 through 33.
3239010|NCT00921726|Experimental|1|Participants will receive treatment in the following order: Study Regimens A, B, C, D
3239011|NCT00921726|Experimental|2|Participants will receive treatment in the following order: Study Regimens B, A, C, D
3239012|NCT00921713|Active Comparator|Enhanced Usual Care|An extensive packet of information including cancer education materials and treatment resources will be mailed to patients.
3239013|NCT00921713|Experimental|Oncology Nurse Care Management|In addition to this mailed information packet, patients in OCNM will be contacted by an experienced Oncology nurse with additional training in self-management support and psychosocial care. The intervention nurse, supported by a Medical Oncologist and Clinical Psychologist, will work closely with patients, their primary care physicians, and other clinicians to assure that patient needs discussed are met. The nurses will be trained in and employ proven counseling and psychotherapeutic approaches-behavioral activation and problem-solving treatment. The multi-component intervention will be based on the Chronic Care Model's six elements (health care organization, community resources, self-management support, delivery system design, decision support, and clinical information system).
3239014|NCT00921700|Experimental|Ibuprofen + Paracetamol|Single oral dose of ibuprofen 400 mg + paracetamol (acetaminophen) 1000 mg
3239015|NCT00921700|Experimental|Ibuprofen + Paracetamol + Codeine|Single oral dose of ibuprofen 400 mg + paracetamol (acetaminophen) 1000 mg + codeine 60 mg
3239016|NCT00921700|Active Comparator|Paracetamol + Codeine|Single oral dose of paracetamol (acetaminophen) 1000 mg + codeine 60 mg
3239017|NCT00921700|Placebo Comparator|Placebo|Single oral dose of lactose as placebo
3239018|NCT00921687|Experimental|Multifactorial intervention|The multifactorial intervention will consist of a CKD lecture, the CKD reference card, academic detailing, and access to the CKD registry.
3239019|NCT00921687|Active Comparator|Education only|Providers in the education only arm will receive a CKD lecture and be given a CKD reference card.
3239020|NCT00921674|Experimental|Ivermectin|ivermectin
3239021|NCT00921661|Experimental|AVE0005 (aflibercept)|
3239022|NCT00921648||Mr Q, 40 years old|Dementia, sensory aphasia, irritability, hallucination MRI showed cortical lesion, mesial temporal lobe atrophy.
3239023|NCT00921648||Mr Guo,35 years old|Dementia, sensory aphasia, tremor, gait disturbance MRI showed cortical lesion, enlarged ventricle, white matter lesion, cerebral atrophy
3239024|NCT00921648||Mr Zhang,40 years old|Dementia, apraxia of speech, gatism , irritability, insomnia, gait disturbance MRI showed white matter lesion, cerebral atrophy.
3239025|NCT00921648||Mr Liu,40 years old|Dementia, apraxia of speech, irritability, insomnia MRI showed normal.
3239026|NCT00921648||Mr Zhang,54 years old|Dementia, apraxia of speech MRI showed white matter lesion, cerebral atrophy.
3239027|NCT00921635|Experimental|Maintain hemoglobin level above 120 g/L|Hemoglobin level from 120 g/L to 130 g/L
3239028|NCT00921635|Active Comparator|Maintain hemoglobin level above 100 g/L|Hemoglobin level from 100 g/L to 110 g/L
3239029|NCT00921622|Active Comparator|Vitamin D|1000 IU twice daily for up to 10 days
3239030|NCT00921622|Active Comparator|Vitamin C|500 mg twice daily for up to 10 days
3239031|NCT00921609||Acromegaly peri- and post-op patients|All patients will undergo the same procedures throughout the study.
3239032|NCT00921596|Other|Totally endoscopic cardiac operation|Patients with cardiac diseases undergo cardiac operations with totally endoscopic and cardiopulmonary bypass
3239033|NCT00921583||1|Examination of dental implants 20 years in function
3239034|NCT00921570|Experimental|Amlodipine|
3239035|NCT00921570|Experimental|Valsartan|
3239036|NCT00921570|Experimental|Valsartan+Amlodipine|
3239037|NCT00921557|Experimental|1A: Alendronate/Alendronate|Participants received alendronate for 96 weeks and calcium carbonate/vitamin D for 144 weeks
3239038|NCT00921557|Experimental|1B: Alendronate/Placebo|Participants received alendronate for 48 weeks followed by placebo for 48 weeks and calcium carbonate/vitamin D for 144 weeks
3239039|NCT00921557|Experimental|2: Placebo/Alendronate|Participants received placebo for 48 weeks followed by alendronate for 48 weeks and calcium carbonate/vitamin D for 144 weeks
3239040|NCT00921544|Active Comparator|Oral Sucrose|Oral sucrose administered 2 mins prior to eye exam
3239041|NCT00921544|Placebo Comparator|Sterile water|0.2 mls of sterile water
3239042|NCT00921531|Experimental|Thalidomide and TACE|Thalidomide is used for adjuvant therapy for TACE
3239043|NCT00921531|Active Comparator|TACE only|
3239044|NCT00921518|Placebo Comparator|Normal Saline|This group will receive isotonic saline at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
3239045|NCT00921518|Active Comparator|Sodium Bicarbonate|This arm two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
3239046|NCT00921505|Active Comparator|Ibuprofen 400 mg|Ibuprofen oral single dose
3239047|NCT00921505|Active Comparator|Ibuprofen 1200 mg|Ibuprofen oral single dose
3239048|NCT00921505|Active Comparator|Paracetamol (acetaminophen) 1000 mg|Paracetamol (acetaminophen) oral single dose
3239049|NCT00921505|Active Comparator|Ibuprofen 400 mg + paracetamol 1000 mg|Paracetamol (acetaminophen) + ibuprofen oral single dose
3239050|NCT00921492|Experimental|Low-frequency electro-acupuncture|
3239051|NCT00921492|Active Comparator|Meeting a therapist - attention|
3239052|NCT00921479||Females|Norwegian females Caucasian origin, between the age of 18 and 45, who are candidates for surgical removal of one mandibular 3. molar.
3239053|NCT00921479||Males|Norwegian males of Caucasian origin, between the age of 18 and 45, who are candidates for surgical removal of one mandibular 3. molar
3239054|NCT00921466||Hospital Patients/Hospital Employees|
3239055|NCT00921466||Hospital employees|A group of 10 hospital employees used as baseline
3239056|NCT00921453||Intervention 1|Participants using the prototype to receive expert system guided tailored internet information about the type of headache of a family member who provided anamnesis data for a common kind of headache.
3239057|NCT00921453||Control 1|Participants using search engines and portals to gather internet information about the type of headache of a family member who provided anamnesis data for a common kind of headache.
3239058|NCT00921453||Intervention 2|Participants using the prototype to receive expert system guided tailored internet information about the type of headache of a family member who provided anamnesis data for a less common kind of headache.
3239059|NCT00921453||Control 2|Participants using search engines and portals to gather internet information about the type of headache of a family member who provided anamnesis data for a less common kind of headache.
3239060|NCT00921427|Active Comparator|VRT and active tDCS|Patients will receive tDCS (noninvasive brain stimulation) concurrently with vision restoration therapy. TDCS is delivered using a small battery-operated device. Electrical leads from the device are connected to saline soaked sponges that are placed at strategic locations on the skull corresponding to areas of the brain that need to be stimulated (in this case, the visual cortex). The dosage will be set to 2 mA/min for 30 minutes, twice a day for 3 days a week for 12 weeks.
3239429|NCT00918385|Active Comparator|1|High Androgen Receptor (AR) activity
3239061|NCT00921427|Sham Comparator|VRT combined with sham tDCS|Patients will receive sham tDCS concurrently with vision restoration therapy. Electrical leads from the tDCS device will be connected to saline soaked sponges placed at strategic locations on the skull, in a similar maner as in the active tDCS group. Current will be turned on for 30 seconds but will be slowly ramped down and turned off. Treatment will continue for 3 days a week for 12 weeks.
3239062|NCT00921414|Active Comparator|1|observation : 3 years maintenance period with assesments and surveillance every 2 months
3239063|NCT00921414|Experimental|2|maintenance period infusions of Rituximab 375 mg/m2/2 months and assessement and surveillance
3239064|NCT00921401|Experimental|Asthma Feedback|Each month and before all visits with their asthma care provider, participants will be encouraged to go online and answer a series of questions regarding the types of asthma medications they use and how often they use them, asthma symptoms they have experienced, emergency department visits in the past year, the care they have received for their asthma (e.g., specialist visits) in the past year, and the planned date of their next visit with their asthma care provider. Participants will receive tailored feedback about what questions they should ask their doctor during a subsequent visit, whether or not they should schedule a visit sooner, and links to read more about each recommendation.
3239065|NCT00921401|Active Comparator|Preventive Feedback|Each month and before all visits with their primary care provider, participants will be encouraged to go online and answer a series of questions regarding their preventive care. They will receive tailored feedback regarding preventive services, such as pap testing, cancer screenings, and flu shots. Participants will receive tailored feedback regarding preventive services (e.g., cancer screening) that they should discuss with their primary care provider.
3239066|NCT00921388|Experimental|1|Exercise program
3239067|NCT00921388|Other|2|Relaxation program
3239068|NCT00921375|Experimental|Tuly, uric acid lowering drug|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
3239069|NCT00921362||1|Schizophrenia patients under Seroquel treatment
3239070|NCT00921349|Experimental|Ligation+Nadolol|"Multi-ligators were applied. Patients received regular ligation treatment at an interval of 3-4 weeks until variceal obliteration.~Intervention; ligation of varices plus beta blockers (Nadolol)."
3239071|NCT00921349|Active Comparator|Nadolol only|
3239072|NCT00921336|Experimental|KW-2450|
3239073|NCT00921323|Placebo Comparator|Control|The control group will be advised to continue to be physically active and record daily steps
3239074|NCT00921323|Active Comparator|Goal-setting group|This intervention group would be instructed to increase their daily step count by at least 20% above their baseline gradually over 3 months.
3239075|NCT00921310|Experimental|Phase I Dose Level 1 (pemetrexed + temsirolimus)|"-Dose Level 1~Pemetrexed 500mg/m^2 intravenous (IV) on Day 1 of each 21 day cycle~Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle"
3239076|NCT00921310|Experimental|Phase I Dose Level -1 (pemetrexed + temsirolimus)|"Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle~Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle"
3239077|NCT00921310|Experimental|Phase 2 (pemetrexed + temsirolimus)|"Phase 2 dose will be the maximum tolerated dose found in the Phase I portion of the study.~Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle~Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle"
3239078|NCT00921297|Active Comparator|Immediate Cataract Surgery|Subjects randomly selected into the Immediate Surgery group will have their cataract surgery scheduled one month from the time their initial study visits are completed. The subjects will be followed monthly for a period of 6 months for surgical and non-surgical adverse events. At the 6-month point, subjects will receive a final comprehensive eye exam and neuropsychological testing. The research partners will complete final activities of daily living and resource utilization questionnaires.
3239079|NCT00921297|No Intervention|Delayed Cataract Surgery|Subjects selected into the Delayed Surgery group will be asked to delay their surgery for 6 months after their initial study visits. At 6 months, this group will also undergo the same testing as the Surgery Group.
3239080|NCT00921284|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
3239081|NCT00921284|Experimental|dexmedetomidine|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and dexmedetomidine
3239082|NCT00921271||At risk for compartment syndrome.|"Patients admitted to Selly Oak Hospital, Birmingham, Uk, meeting one or more of the following inclusion criteria:~Patients with one or more of the following injuries:~tibial fracture.~crush injury/soft tissue injury to lower limb without fracture.~pelvic fracture.~major vascular injury below the aortic bifurcation.~2 or more long bone fractures.~Any patient sustaining a traumatic injury with a base deficit ≥ 6 mEq/L within 12 hours of Hospital admission.~Any patient receiving ≥ 6 units packed red blood cells within 12 hours of hospital admission."
3239083|NCT00921258||control group|Patient with latent prostate cancer who agree to be controled instead of to be treated
3239084|NCT00921245||Group 1|
3239085|NCT00921232|Other|dyad|life-ending patient and its caregiver
3239086|NCT00921219|Experimental|Ivermectin|ivermectin
3239087|NCT00921206|Active Comparator|VAX102 given i.m.|Universal influenza candidate vaccine
3239088|NCT00921206|Active Comparator|VAX102 given s.c.|Universal influenza candidate vaccine
3239089|NCT00921180|Experimental|Entecavir and peginterferon|Entecavir 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52
3239090|NCT00921180|Active Comparator|Placebo and peginterferon|Placebo 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52
3239091|NCT00921167|Experimental|Bevacizumab/Irinotecan|
3239092|NCT00921154|Experimental|Ivermectin|Ivermectin
3239093|NCT00921141||study population|Patient with cancer requiring a long-term central venous catheter
3239094|NCT00921115|Experimental|Arimidex + Faslodex|"Patients will have an Oncotype Dx performed and if the RS is <25, they will receive Anastrazole and Fulvestrant for 16 weeks.~On day 28, subjects will be evaluated for side effects and a needle core biopsy (optional) will be obtained. Response evaluation will occur every 28 days. All treatment will continue for 4 months followed by breast surgery. After surgery, patients will be off study and will receive additional breast cancer therapy per their treating physician. Patients who develop progressive disease on protocol will be removed from the study and treated by their treating physician. The protocol will be closed after the last accrued patient has had surgery."
3239095|NCT00921102|Placebo Comparator|Control|Patients in this group will receive both an intrathecal and intravenous injection of saline solution, as a placebo comparator.
3239096|NCT00921102|Experimental|Intrathecal Atropine|Patients in this group will receive intrathecal atropine as a prophylactic antiemetic agent. They will also receive intravenous saline solution to maintain blinding.
3239097|NCT00921102|Active Comparator|IV Atropine|Patients in this group will receive a small dose of atropine via the intravenous route to examine its possible antiemetic activity. They will also receive intravenous saline solution to maintain blinding.
3239098|NCT00921089||Hemodialysis group|End stage renal disease patients aged lower than 70 years, treated for more than 6 months with hemodialysis
3239099|NCT00921089||Control group|Normotensive healthy controls
3239100|NCT00921076|Active Comparator|Ankle Arthoplasty|Patients will undergo a Total Ankle Replacement procedure
3239101|NCT00921076|Active Comparator|Ankle fusion|Patients will undergo an Ankle Arthrodesis procedure
3239102|NCT00921063|Experimental|PD 0332334 250 mg|
3239103|NCT00921063|Experimental|PD 0332334 100 mg|
3239104|NCT00921063|Placebo Comparator|placebo|
3239105|NCT00921063|Active Comparator|Alprazolam extended release|
3239106|NCT00921050|Experimental|Levothyroxine|Half of participants randomly assigned, take a pill daily, bimonthly thyroid test
3239107|NCT00921050|Placebo Comparator|Placebo|Half of participants randomly assigned, take a pill daily, bimonthly thyroid test
3239108|NCT00921037|Experimental|Erbium YAG Laser|Patients with Neurofibromatosis Type 1 (Recklinghausen)
3239109|NCT00921024|Experimental|1|CXA-101
3239110|NCT00921024|Active Comparator|2|Ceftazidime
3239111|NCT00921011||Perimenopausal women|Women at the beginning stages of menopause
3239112|NCT00920998|Experimental|1. Z-338|3-way cross-over study (drug administration 3-times in fasted and 2 fed conditions)
3239113|NCT00920985|Experimental|Arm 1|
3239114|NCT00920985|Active Comparator|Arm 2|
3239115|NCT00920972|Experimental|Matched related HSCT for hemoglobinopathies|
3239116|NCT00920972|Experimental|Unrelated HSCT for thalassemia|
3239117|NCT00920972|Experimental|Minimally mismatched unrelated HSCT for hemoglobinopathies|
3239118|NCT00920972|Experimental|Minor mismatched unrelated HSCT for non-malignant disorders|
3239119|NCT00920959|Experimental|Fluticasone propionate/salmeterol combination|study drug
3239120|NCT00920959|Experimental|Fluticasone propionate|study drug
3239121|NCT00920959|Experimental|Placebo|placebo
3239122|NCT00920946|Placebo Comparator|Placebo|
3239123|NCT00920946|Experimental|Dimebon|
3239124|NCT00920933|Experimental|AIN457|
3239125|NCT00920933|Placebo Comparator|Placebo|
3239126|NCT00920933|Active Comparator|oral corticosteroid|
3239127|NCT00920907|Experimental|Ipilimumab (Process B)|Reference
3239128|NCT00920907|Experimental|Ipilimumab (Process C)|Test
3239129|NCT00920894|Experimental|yoghurt type minidrink containing plant stanol ester|
3239130|NCT00920894|Placebo Comparator|yoghurt type minidrink without plant stanol ester|
3239131|NCT00920881||Diabetes|
3239132|NCT00920868|Experimental|Dasatinib 50mg|Cohort 1
3239133|NCT00920855|Experimental|Bendamustine and Bortezomib|Bendamustine in escalating doses of 50, 70 or 90 mg/m^2 as combination therapy with bortezomib at 1.0 mg/m^2/dose administered for up to eight 28 day cycles.
3239134|NCT00920829|Active Comparator|A118G A/A with Naltrexone|Individuals with the OPRM1 genotype Asn40 are given naltrexone 50 mg after 2 days at 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
3239135|NCT00920829|Placebo Comparator|A118G A/A with Placebo|Individuals with the OPRM1 genotype Asn40 are given Placebo for 16 weeks with Medication Management in 16 weeks
3239136|NCT00920829|Active Comparator|A118G Any G with Naltrexone|Individuals with the OPRM1 genotype Any G (Asp) are given naltrexone 50 mg after 2 days of naltrexone 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
3239137|NCT00920829|Placebo Comparator|A118G Any G with Placebo|Individuals with the OPRM1 genotype Any G (Asp) are given 50 mg naltrexone after 2 days at 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
3239138|NCT00920816|Experimental|A|
3239139|NCT00920816|Active Comparator|B|
3239140|NCT00920803|Active Comparator|5g SRT501|5.0 g of SRT501 will be administered once daily as an oral reconstituted powder, for 14 days at the same time each day. On Days 1 and 2, SRT501 will be administered approximately 15-30 minutes following the consumption of a standardized breakfast. On all other days, SRT501 will be administered approximately 15-30 minutes following the consumption of the evening meal. Following the course of SRT501 administration, subjects will undergo scheduled surgical removal of their metastatic liver disease as well as non-diseased tissue. Due to scheduling and surgical availability, subjects can receive SRT501 for a minimum of 10 days and a maximum of 21 days.
3239141|NCT00920803|Placebo Comparator|Placebo|Placebo will be administered once daily as an oral reconstituted powder, for 14 days at the same time each day. On Days 1 and 2, placebo will be administered approximately 15-30 minutes following the consumption of a standardized breakfast to allow for PK sample collection. On all other days, placebo will be administered approximately 15-30 minutes following the consumption of the evening meal. Following the course of placebo administration, subjects will undergo scheduled surgical removal of their metastatic liver disease as well as non-diseased tissue. Due to scheduling and surgical availability, subjects can receive placebo for a minimum of 10 days and a maximum of 21 days.
3239142|NCT00920790|Experimental|KW-0761|
3239143|NCT00920777|Experimental|8 weeks CBT|
3239144|NCT00920777|Active Comparator|Control group|
3239145|NCT00920777|Experimental|16 weeks CBT|
3239146|NCT00920764|Active Comparator|A|
3239147|NCT00920764|Active Comparator|B|
3239148|NCT00920764|Active Comparator|C|
3239149|NCT00920764|Placebo Comparator|D|
3239150|NCT00920751|Experimental|Water infusion|Water infusion in lieu of air insufflation during colonoscope insertion
3239151|NCT00920751|Active Comparator|Air insufflation|Conventional air insufflation colonoscopy
3239152|NCT00920738||Cancer Survivors|Subjects who are cancer survivors must have survived childhood cancer (diagnosed < or = 18 years) for a minimum of 5 years and be in remission.
3239153|NCT00920738||Healthy Siblings of Cancer Survivor|Healthy populations similar in age and gender distribution, derived from a frequency matched control population of 350 healthy siblings.
3239154|NCT00920725|Active Comparator|Subcutaneous Insulin|Aspart Insulin administered subcutaneously 0.2 units/kg/sq every 2 hours
3239155|NCT00920725|Active Comparator|IV Regular Insulin|Intravenous Regular Insulin 0.1 units/kg/hour
3239156|NCT00920725|Active Comparator|Intravenous Novolog Insulin|Intravenous Novolog Insulin 0.1 units/kg/hour
3239157|NCT00920712|Experimental|Weiqi decoction|
3239158|NCT00920712|Placebo Comparator|low dose of Weiqi decoction|
3239159|NCT00920699|Experimental|600 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day of CoQ10 in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
3239160|NCT00920699|Experimental|1200 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
3239161|NCT00920699|Experimental|2400 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
3239162|NCT00920686|Experimental|NXN-188|NXN-188, 600 mg, PRN
3239163|NCT00920686|Active Comparator|sumatriptan succinate 100 mg|Sumatriptan, 100 mg, PRN
3239164|NCT00920686|Placebo Comparator|placebo|matching, PRN
3239165|NCT00920660|Experimental|Treatment Group|"Subjects will be required to attend the research unit in a fasted state (at least 10 hours without food) on six separate occasions (treatment visits) during the study. At approximately the same time every morning, subjects will consume a standard, non-high-fat meal (approximately 650 kcal with 30% of calories derived from fat). Test material (per treatment) will be administered within 15-30 minutes following the meal. There will be at least a 7-day washout period between treatment visits.~During the first five treatment visits, subjects will receive one of the following treatments in the form of 8 capsules: 0.25g SRT2104, 0.5g SRT2104, 1g SRT2104, 2g SRT2104, or placebo.~During the last treatment visit, subjects will receive 30 mg of open-label prednisolone tablets."
3239166|NCT00920647|Other|Control|Untreated Patients
3239167|NCT00920647|Experimental|Idursulfase -IT (1 mg)|monthly using an intrathecal drug delivery device (IDDD)
3239168|NCT00920647|Experimental|Idursulfase-IT (10 mg)|monthly using an intrathecal drug delivery device (IDDD)
3239169|NCT00920647|Experimental|Idursulfase -IT (30 mg)|monthly using an intrathecal drug delivery device (IDDD)
3239170|NCT00920634||1|Patients with anovulation and oligoovulation due to hypothalamus-pituitary dysfunction (amenorrhea first grade, anovulatory cycle, polycystic ovary syndrome, oligoamenorrhea) who underwent ovulation induction
3239171|NCT00920621|Experimental|Vitamin D treatment|vitamin D treatment plus prenatal multivitamins
3239172|NCT00920621|Placebo Comparator|placebo|placebo plus prenatal multivitamins
3239173|NCT00920608|Experimental|A|AZD9056 400 mg and Methotrexate
3239174|NCT00920595|Experimental|1|CEP-9722 alone and in combination therapy with temozolomide.
3239175|NCT00920582|Experimental|1|
3239176|NCT00920582|Experimental|2|
3239177|NCT00920582|Experimental|3|
3239178|NCT00920582|Placebo Comparator|4|
3239179|NCT00920556|Experimental|Treatment|"5.0 g SRT501 will be administered for 20 consecutive days in a 21 day cycle for a maximum of 12 cycles. SRT501 will be administered at the same time each morning (approximately 15-30 minutes after breakfast) on all dosing days. No SRT501 administration will occur on Day 21 of each cycle.~After the first two cycles of SRT501, any subject who exhibits stable disease or better with SRT501 monotherapy (5.0 g/day) will continue for an additional two cycles. If, after the first two cycles, a subject exhibits PD, that subject will receive bortezomib (1.3 mg/m2 on Day 1, Day 4, Day 8, and Day 11 in a 21 day cycle) in conjunction with SRT501. Bortezomib will be administered prior to breakfast and SRT501 administration.~If after two additional cycles of SRT501 monotherapy (4 cycles total), the subject exhibits a MR or better, they they will remain on SRT501 therapy. If PD or SD are exibited, they are to undergo bortezomib regiment listed above."
3239180|NCT00920543|Active Comparator|Fluticasone propionate|
3239181|NCT00920543|Active Comparator|Fluticasone propionate/salmeterol combination|
3239182|NCT00920530||Real time PCR monitoring|Women giving birth at the St Etienne Teaching Hospital
3239183|NCT00920517|Active Comparator|1|Participants will receive 1 injection of rDEN2/4delta30(ME) or placebo vaccine on Days 0 and 180
3239184|NCT00920517|Active Comparator|2|Participants will receive 1 injection of rDEN2/4delta30(ME) or placebo vaccine on Days 0 and 120
3239185|NCT00920504|Experimental|German PRO-SELF(c) Plus PCP|Group receives 10 weeks German PRO-SELF(c) Plus PCP intervention program
3239186|NCT00920504|Active Comparator|Standard Care|control group receives attention control and standard care
3239187|NCT00920491||patients with non-specific complaints|patients who do not have specific presenting symptoms (e.g. dyspnea, chest pain etc.)
3239188|NCT00920478|Active Comparator|Control Group|Inflammatory disease activity assessed using DAS28
3239189|NCT00920478|Experimental|Ultrasound Group|Inflammatory disease activity assessed using musculoskeletal ultrasound (gray scale and power doppler)
3239190|NCT00920465|Experimental|one-visit|
3239191|NCT00920465|Active Comparator|two-visit|
3239192|NCT00920439|Experimental|POLIORIX GROUP|Healthy male or female subjects between, and including, 18 and 24 months of age, received a single booster dose of Poliorix™ vaccine that was administrated into the upper right thigh by intramuscular injection (IM).
3239193|NCT00920426|Experimental|GSK1265744 30 mg|GSK1265744 30 mg
3239194|NCT00920426|Experimental|Placebo|Placebo to match GSK1265744
3239195|NCT00920426|Experimental|GSK1265744 5 mg|GSK1265744 5 mg
3239196|NCT00920413|Active Comparator|vitamin C|vitamin C 500mg orally once a day
3239197|NCT00920413|Placebo Comparator|placebo|
3239198|NCT00920387|Experimental|Experimental 200 mcg lysergic acid diethylamide|Administering 200 mcg LSD once during each of two LSD-assisted psychotherapy sessions scheduled two to four weeks apart.
3239199|NCT00920387|Active Comparator|Active Comparator 20 mcg Lysergic acid diethylamide|Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session
3239200|NCT00920374|Experimental|Fluarix Adult Group|Subjects who are 18-60 years of age received one dose of Fluarix™
3239201|NCT00920374|Experimental|Fluarix Elderly Group|Subjects who are > 60 years of age received one dose of Fluarix™
3239202|NCT00920361||1|Patients who underwent IVF
3239203|NCT00920348||Group 1|COPD moderate-severe(GOLD2-4)(post-BD FEV1/FVC<0.70 and FEV1<80% of pred.)
3239204|NCT00920348||Group 2|COPD mild (GOLD1)(post-BD FEV1/FVC<0.70 AND FEV1>=80% of pred.)
3239205|NCT00920348||Group 3|COPD at risk (ever smoker with post-BD FEV1/FVC>=0.70)
3239206|NCT00920348||Group 4|"Healthy control never smokers without respiratory disease (post-BD FEV1/FVC>=0.70."
3239207|NCT00920322|Active Comparator|five times weekly|Patients will receive rTMS on each weekday for 4 weeks (5 x weekly)
3239208|NCT00920322|Experimental|three times weekly|Patients will receive rTMS three times weekly for four weeks
3239209|NCT00920309|Experimental|Rapamycin|"Drug: Rapamycin~Other Names:~sirolimus The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml."
3239210|NCT00920309|Placebo Comparator|Standard of Care-Placebo|Standard of Care
3239211|NCT00920296|Experimental|Cohort 1|All subjects
3239212|NCT00920283|Experimental|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
3239213|NCT00920283|Active Comparator|Driver, Cobalt Alloy Coronary Stent|
3239214|NCT00920270|Active Comparator|antibiotic|conventional antibiotics
3239215|NCT00920270|Experimental|colistin group|nebulized colistin
3239216|NCT00920257|Experimental|GSK2141795|Oral GSK214179 given daily to patients with cancer. Groups of approximately three patients will receive GSK2141795 at increasing doses until a maximum tolerated dose is identified.
3239217|NCT00920231|Experimental|Arm 1 initial system|"8 blind subjects are asked to use a prototype computer vision system to determine the challenges facing computer vision based indoor navigation.~Subjects are asked to travel through the hallways of a large hospital from the front entrance to a side entrance. The pathway consists of 9 segments including corners, four-way intersections, and doorways, and the total length of the route was approximately 200 meters. This challenging route was designed to stress the capabilities of the navigation system. It is a route that even sighted persons may find difficult to follow without practice. Pedestrian traffic was present throughout the route and lighting conditions could change in two of the segments where there were windows and doors."
3239218|NCT00920231|Experimental|Arm 2 modified system|The system is redesigned in response to problems identified from the first phase of the study. The redesigned system is tested by a second set of 8 blind subjects in the same indoor path as used in Arm 1.
3239219|NCT00920218|Experimental|GSK 1437173A F1 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 1 (F1) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
3239220|NCT00920218|Experimental|GSK 1437173A F2 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 2 (F2) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
3239221|NCT00920218|Experimental|Placebo-GSK 1437173A F1 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 1 dose of the placebo followed by 2 doses of GSK 1437173A F1 vaccine. For some safety analyses, this Group was split into Placebo 1D Group (results following placebo administration) and GSK 1437173A 2D Group (results following HZV administration). All vaccines were administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
3239222|NCT00920218|Placebo Comparator|Placebo Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of placebo, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
3239223|NCT00920192|Experimental|Foretinib|Phase I starting dose of 30 mg/day escalated to 45 mg/day, de-escalated to 30 mg/day; MTD for Phase II was 30 mg/day
3239224|NCT00920179||Dry eye group|Dry eye patients with Primary Sjogren's syndrome
3239225|NCT00920179||Controls|Healthy subjects without dry eyes
3239226|NCT00920166|Experimental|Modilac Pétunia 1|Formula with reduced total protein concentration, enriched in alpha-lactalbumin and containing a symbiotic
3239227|NCT00920166|Active Comparator|Modilac 1|Regular milk
3239228|NCT00920153|Experimental|Group 1 (favorable prognosis)|Patients receive ABVD and VABEM chemotherapy.
3239229|NCT00920153|Experimental|Group 2 (intermediate prognosis)|Patients receive ABVD and VABEM chemotherapy.
3239230|NCT00920153|Experimental|Group 3 (poor prognosis)|Patients receive VABEM, CEO, BEAM, and MINE chemotherapy. Patients also undergo allogeneic or autologous stem cell transplantation.
3239231|NCT00920140|Experimental|Phase I|"The proposed treatment schedule of GSK1120212 is continuous daily dosing. At the initiation of dosing, a loading dose will be given prior to starting continuous dosing (maintenance dose).~Alterations to the dose and schedule will be based on emerging PK, PD, and tolerability data. The goal will be to define a regimen that is well tolerated and provides adequate PK and PD. This will be the recommended Phase II schedule."
3239232|NCT00920140|Experimental|Phase II|A dose determined by Phase I to further evaulate the safety profile, PK, PD, and clinical activity of GSK1120212.
3239233|NCT00920127|Placebo Comparator|Placebo|
3239234|NCT00920127|Active Comparator|AKL1|
3239235|NCT00920114|Experimental|Lupus disease|
3239236|NCT00920114|Active Comparator|Healthy witnesses|
3239237|NCT00920114|Active Comparator|Healthy witnesses with an other auto-immune disease|
3239238|NCT00920101|Active Comparator|Atorvastatin|
3239239|NCT00920101|Placebo Comparator|Lifestyle counseling|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
3239240|NCT00920088|Experimental|Cohort 1|GSK2248761 with LPV/RTV arm and probes
3239241|NCT00920088|Experimental|Cohort 2|GSK2248761 with DRV/RTV
3239291|NCT00919620|Active Comparator|case management (2 yrs) and standard care (2 yrs)|2-year case management and standard care
3239292|NCT00919620|No Intervention|standard care (4 yrs)|standard care for 4 years
3239293|NCT00919607|Active Comparator|1|quetiapine fumarate extended-release 300mg,administered once-daily Day1~5
3239242|NCT00920075||1 Alendronate for 12 months, post study|Participants earlier were treated with alendronate for 12 months either in an open label study (without control) or double blind study with placebo control. These studies were completed. In this post study evaluation, available participants will be scheduled for one clinic visit to assess their current status of the bone density and no treatment is involved.
3239243|NCT00920036|Experimental|Arm 1|Eight subjects were trained to utilize a handheld biofeedback device
3239244|NCT00920036|No Intervention|Arm 2|usual care
3239245|NCT00920023|Experimental|SPIO MRI|
3239246|NCT00919997||Specimen collection|Single group study. Blood, saliva, anal cytology, and penile cytology samples, and questionnaire responses will be collected from participants at a single study visit.
3239247|NCT00919984|Experimental|IP Chemotherapy|Patients with optimally debulked advanced (stage 3 or 4) epithelial ovarian cancer; IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
3239248|NCT00919958|Experimental|PLX-PAD low dose|
3239249|NCT00919958|Experimental|PLX-PAD intermediate dose|
3239250|NCT00919958|Experimental|PLX-PAD high dose|
3239251|NCT00919945|Experimental|1|The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed. Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms. Patients in arm 1 will receive continuous nasogastric formula feeding at time 1 and NPO at time 2 (12 hours later).
3239252|NCT00919945|Experimental|2|The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed. Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms. Patients in arm 2 will receive NPO at time 1 and crossover to continuous nasogastric formula feeding at time 2.
3239253|NCT00919932|Active Comparator|Paper and pen homework|Treatment as usual: therapy homework is completed by paper and pen.
3239254|NCT00919932|Experimental|Text-message homework|Experimental treatment: therapy homework is completed by text messaging.
3239255|NCT00919919|Experimental|Progesterone vaginal tablet|Group A - Daily use of Endometrin 100 mg progesterone vaginal tablet, and Estrofem orally.
3239256|NCT00919919|Other|Activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
3239257|NCT00919906|No Intervention|Handwriting without Tears|Standard practice
3239258|NCT00919906|Experimental|Haptic guidance|
3239259|NCT00919893|Active Comparator|Cernilton|Men with inflammatory chronic prostatitis-chronic pelvic pain syndrome (CP-CPPS)
3239260|NCT00919893|Placebo Comparator|Placebo|Men with inflammatory chronic prostatitis-chronic pelvic pain syndrome (CP-CPPS)
3239261|NCT00919880|Experimental|Experimental|
3239262|NCT00919880|Active Comparator|Active Comparator|
3239263|NCT00919867|Active Comparator|A: SPD503 (4mg)|
3239264|NCT00919867|Active Comparator|B: VYVANSE (50mg)|
3239265|NCT00919867|Active Comparator|C: SPD503 (4mg) + VYVANSE (50mg)|
3239266|NCT00919854|Experimental|Darunavir (DRV)+Ritonavir (rtv)|Before dose adjustment, oral darunavir suspension (100 mg/mL): 20 mg per kg body weight twice daily for children weighing between 10 and <20 kg. After dose adjustment, 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg twice daily if weight more than or equal to 15 kg. Before dose adjustment, oral ritonavir solution (80 mg/mL): 3 mg per kg body weight twice daily and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
3239267|NCT00919841||Postpartum women|Women who deliver a singleton vaginally
3239268|NCT00919815|Experimental|ciclosporin arm|ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)
3239269|NCT00919815|Active Comparator|prednisolone|standard course of prednisolone given in a reducing regimen over 24 weeks
3239270|NCT00919802|Active Comparator|Oxytocin|Oxytocin, 40 IU intranasally, once
3239271|NCT00919802|Placebo Comparator|Saline as a nasal spray|Saline, 4ml intranasally, once
3239272|NCT00919776|Experimental|ciclosporin|ciclosporin reducing regimen lasting 16 weeks (additional prednisolone given for the first four weeks)
3239273|NCT00919776|Active Comparator|Prednisolone|standard course of prednisolone given in a reducing regimen over 16 weeks
3239274|NCT00919763|Experimental|CD 2027|Topical Ointment
3239275|NCT00919763|Placebo Comparator|CD 2027 Vehicle|Topical Ointment
3239276|NCT00919750||Ancillary-Correlative (tissue and blood sample collection)|Brain tumor tissue and blood specimens are collected from patients and banked for future study.
3239277|NCT00919737|Experimental|NPC-08|
3239278|NCT00919724||HIV-Infected|HIV-infected participants who are not currently receiving antiretroviral medications
3239279|NCT00919724||HIV-Uninfected|HIV-uninfected participants matched in age, sex, smoking status, and height to the HIV-infected participants
3239280|NCT00919711|Experimental|Denosumab 60 mg|
3239281|NCT00919711|Active Comparator|Risedronate 150 mg QM|
3239282|NCT00919698||Sedated mechanically ventilated patients|
3239283|NCT00919672|Active Comparator|Sacral nerve stimulation ON-OFF|As previously described the patients will be randomized in a blinded design to receive either ON-OFF or OFF-ON stimulation in a 2 month period.
3239284|NCT00919672|Active Comparator|Sacral nerve stimulation OFF-ON|As previously described the patients will be randomized in a blinded design to receive either ON-OFF or OFF-ON stimulation in a 2 month period.
3239285|NCT00919659|Experimental|parenteral nutrition|25kcal/kg/bw /day via parenteral support
3239286|NCT00919633|Experimental|Group 1: interferon alfa-2b (dose 1)|continuous subcutaneous infusion for 48 weeks
3239287|NCT00919633|Experimental|Group 2: interferon alfa-2b (dose 2)|continuous subcutaneous infusion for 48 weeks
3239288|NCT00919633|Experimental|Group 3: interferon alfa-2b (dose 3)|continuous subcutaneous infusion for 48 weeks
3239289|NCT00919633|Active Comparator|Group 4: peginterferon alfa-2b (1.5 μg/kg)|subcutaneous weekly for 48 weeks
3239290|NCT00919620|Experimental|case management (4 yrs)|4-year case management and standard care
3239294|NCT00919607|Experimental|2|quetiapine fumarate extended-release 300mg/Day1,600mg/Day2~6,administered once-daily
3239295|NCT00919607|Experimental|3|quetiapine fumarate extended-release 300mg/Day1,600mg/Day2,800mg/Day3~7,administered once-daily
3239296|NCT00919594|Experimental|Interpersonal Psychotherapy for Mothers|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.
3239297|NCT00919594|Active Comparator|Brief Supportive Psychotherapy|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
3239298|NCT00919581||Healthy controls|
3239299|NCT00919581||Subjects with spinal cord injury|
3239300|NCT00919555|Active Comparator|Tretionoin and Pioglitazone HCL|20 patients will be randomized blindedly to Tretinoin and Pioglitazone HCL
3239301|NCT00919555|Placebo Comparator|Sugar Pill|10 Patients will randomly receive placebo
3239302|NCT00919542|Active Comparator|prednisolone|standard course of prednisolone given in a reducing regimen over 16 weeks
3239303|NCT00919542|Experimental|Ciclosporin|ciclosporin reducing regimen lasting 16 weeks (additional prednisolone given for the first four weeks)
3239304|NCT00919516|Experimental|Stem Cell Implantation|
3239305|NCT00919503|Experimental|Group I (PBSCT and BMT)|See Detailed Description. Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.
3239306|NCT00919503|Experimental|Group II (UBCT)|See Detailed Description. Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.
3239307|NCT00919490|Experimental|Group 1|Single dose of 400 mg
3239308|NCT00919490|Experimental|Group 2|Single dose of 800 mg after safety evolution of Group I
3239309|NCT00919490|Experimental|Group 3|Single dose of 1200 mg after safety evolution of Group 2
3239310|NCT00919490|Experimental|Group 4|Single dose of 1600 mg after safety evolution of Group 3
3239311|NCT00919490|Placebo Comparator|Group 5|Single dose of placebo
3239312|NCT00919451|Experimental|Ciclosporin|ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)
3239313|NCT00919438||Dialysis|
3239314|NCT00919412||Preterm delivery (< 37 weeks)|
3239315|NCT00919412||Term delivery (>=37 weeks)|
3239316|NCT00919386||1 Direct ureteric measurement|This is determined by using a 5 French Pollack Open-Ended Flexi-Tip Ureteral catheter (Cook, Spencer, Indiana) to cannulate the ureteral orifice. A retrograde pyelogram will be done at the conclusion of the procedure and the Pollack will be advanced to the pyeloureteral junction (PUJ) under fluoroscopy. At this point the length of the distance between the PUJ and vesicoureteral junction (VUJ) will be recorded and stent length determined based on this measurement.
3239317|NCT00919386||2 Based on patient height|"We will use the height measurement criteria used by Lee et al in their study. Patients less than 5'2 will receive a 22 cm stent, 5'3-5'7 will get a 24 cm stent, 5'8-5'10 will get a 26 cm stent, 5'11 to 6'1 will get a 28 cm stent, and all patients greater than 6'2 will receive a 30 cm stent."
3239318|NCT00919386||3 Based on a predetermined formula|We will use the formula described by Wieder. Stent length in cm= patients height in inches - 42.
3239319|NCT00919373|Active Comparator|ICD-Implantation|Implantation of an Implantable Cardioverter Defibrillator (ICD) alone.
3239320|NCT00919373|Active Comparator|ICD + Ablation|Stratified Catheter Ablation of Ventricular Tachycardia and ICD Implantation
3239321|NCT00919360||Controls|Gravidas without history of hypertension of any kind, and matched to cases for parity, gestational age, labor status, mode of delivery, maternal age, and race.
3239322|NCT00919360||Preeclamptics|Gravidas at 32-42 weeks gestation, delivered by Caesarean Section, who have preeclampsia as defined by Sibai et al, 1997.
3239323|NCT00919334|No Intervention|single vision soft contact lens|Single vision soft contact lenses with same materials of the DISC lens
3239324|NCT00919334|Experimental|Defocus Incorporated Soft Contact (DISC) lens|The use of DISC lens to slow down the progression of myopia
3239325|NCT00919321|Other|PPV|
3239326|NCT00919308||Control, traditional bedside training|Postgraduate year 1 and 2 residents who are trained in central venous catheter insertion according to the traditional, bedside apprenticeship model.
3239327|NCT00919308||Simulation training|Postgraduate year 1 and 2 residents who complete a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by: the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous cannulator on a partial task training simulator with no technical errors.
3239328|NCT00919295|Placebo Comparator|placebo|placebo
3239329|NCT00919295|Placebo Comparator|mirtazapine 15|mirtazapine 15 mg
3239330|NCT00919295|Placebo Comparator|mirtazapine 30|mirtazapine 30mg
3239331|NCT00919282|Experimental|Gemcitabine/folinic acid/5-FU|Gemcitabine 1g/m² 5-FU 750mg/m² FS 500 mg/m²
3239332|NCT00919269||Ancillary-Correlative (specimen collection)|Surgical tissue, bone marrow, and blood specimens are collected at diagnosis (initial or relapse) and, if applicable, at the development of a second primary tumor. Specimens are used for research purposes. A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute.
3239333|NCT00919243|Experimental|prednisone|
3239334|NCT00919243|Active Comparator|allopurinol|
3239335|NCT00919230|No Intervention|no treatment|no iron given
3239336|NCT00919230|Experimental|ferrous sulphate|iron given
3239337|NCT00919217||Relapsing-remitting multiple sclerosis|Females with relapsing-remitting multiple sclerosis
3239338|NCT00919204|Experimental|Cohort 1|
3239339|NCT00919191|Experimental|Two interventions in split-face model|"Once daily use in a split face model:~Tretinoin gel~Adapalene Benzoyl peroxide"
3239340|NCT00919178|Experimental|1|Participants will receive a single immunization for Dengue virus serotype 4 (DEN4)
3239341|NCT00919178|Placebo Comparator|2|Participants will receive a single immunization in the form of placebo resembling vaccine for DEN 4
3239342|NCT00919165||control and study group|severe carotid artery stenosis in asymptomatic patients defined as greater than 80% stenosis angiographically or greater than 400 cm/sec peak systolic velocity on carotid doppler evaluation
3239343|NCT00919126|Experimental|Group A|Xenon 50% (45%-55%) in Oxygen (45%-55%),
3239344|NCT00919126|Experimental|Group B|Xenon 70% (65%-75%) in Oxygen (25%-35%)
3239345|NCT00919126|Active Comparator|Group C|Medical Air in Oxygen (45%-55%)
3239346|NCT00919113|Experimental|8 weekly bladder instillations of Uracyst|20 mL Uracyst (2% sodium chondroitin sulfate) per instillation; 8 instillations over a 7-week period
3239347|NCT00919113|Placebo Comparator|8 weekly bladder instillations of inactive control|20 mL inactive control buffer (phosphate-buffered saline); 8 instillations over a 7-week period
3239348|NCT00919100|Other|Standard Care|venipuncture with vapocoolant spray offered
3239349|NCT00919100|Experimental|Buzzy|Vibrating device with cold pack held to arm with tourniquet proximal to venipuncture site, optional distraction cards.
3239350|NCT00919074|Active Comparator|Pancreatic duct stent|Placement of a pancreatic duct stent to facilitate bile duct cannulation
3239351|NCT00919074|Active Comparator|Pancreatic wire|Placement of a guidewire into the pancreatic duct to facilitate bile duct cannulation.
3239352|NCT00919061|Experimental|Gemcitabine and Cisplatin plus Sorafenib|This is a non-randomized, open label, single institution, phase II study of gemcitabine and cisplatin plus sorafenib for the treatment of patients with advanced or biliary tract carcinomas naïve to systemic therapy.
3239353|NCT00919048||Urodynamic patients|Uroflow studies of patients who underwent urodynamics as part of an incontinence work-up.
3239354|NCT00919035|Experimental|Torisel|Single Agent Temsirolimus (Torisel®)
3239355|NCT00919022||Group 1|
3239356|NCT00919009|Experimental|Sorafeinb|Oral sorafenib (400 mg BID) will be start the 3 day after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination.
3239357|NCT00918996|Experimental|No Bladder Flap Group|Uterine incision made 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
3239358|NCT00918996|No Intervention|Bladder Flap Group|Standard cesarean section technique with incision and dissection of a bladder flap prior to uterine incision.
3239359|NCT00918983|Experimental|NX-1207|
3239360|NCT00918983|Placebo Comparator|Placebo|
3239361|NCT00918970||SNA group|This group will have a real-time analysis of autonomic nervous system activity during its intensive care hospitalisation
3239362|NCT00918970||Clinical group|This group will have a conventional clinical analysis during its intensive care hospitalisation
3239363|NCT00918957|Experimental|TIP (Tobramycin Inhalation Powder)|Tobramycin 28 mg powder. The TIP dose of 112 mg twice a day (bis in diem = b.i.d.), given in a cycle of 28 days on treatment followed by 28 days off treatment.
3239364|NCT00918957|Placebo Comparator|Placebo|Placebo 20 mg powder ﻿capsules. The dose regimen for the reference product was inhaling the contents of four capsules twice a day (bis in diem = b.i.d.), in the morning and in the evening for 28 days (on treatment), followed by 28 days of no study treatment (off treatment).
3239365|NCT00918944|Other|Control arm|Practices with the EHR implemented will be randomized have the asthma disease management tools available passively (the control group).
3239366|NCT00918944|Other|Intervention arm|The intervention sites will have decision support alerts and reminders activated to guide providers toward these tools in the appropriate situations.
3239367|NCT00918931|Experimental|Obatoclax Mesylate|30 mg by vein over 3 hours Days 1-3, 14-day cycle
3239368|NCT00918918|Experimental|Treatment B|Vodka + orange juice
3239369|NCT00918918|Placebo Comparator|Treatment A|Orange juice
3239370|NCT00918905|Experimental|1 Telemonitor|Within 24 hours after the patient was discharged the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with a doctor. The patient was planned to have the equipment for approximately one week and had at least one follow-up phone call within the four weeks period. Telemonitoring video conferences could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period of time (hot-line).
3239371|NCT00918905|No Intervention|Control group|No tele-monitor at home. The COPD patients discharged after an acute exacerbation living outside Svendborg or Faaborg-Midtfyn municipalities in the recruiting area were included in the control group and assigned to conventional care.
3239372|NCT00918879|Experimental|1|Saxagliptin
3239373|NCT00918879|Placebo Comparator|2|
3239374|NCT00918866|Experimental|Low Pulmonary Arterial Pressure|Subjects with pulmonary arterial pressure (PAP) of < or = to 35 mmHg.
3239375|NCT00918866|Experimental|Elevated Pulmonary Arterial Pressure|Subjects with a PAP of > or = to 35 mmHg.
3239376|NCT00918853|Experimental|resection for adenocarcinoma|quality standard resection for adenocarcinoma of the head of the pancreas
3239377|NCT00918840||DermaVir + HAART|"Dosage: 0.4 mg DNA~Dosage form: 3.2 mL DNA/PEIm nanomedicine~Administration with 4 DermaPrep patches~Frequency: every 4 weeks~Duration: 8 weeks (3 DermaVir treatments)"
3239378|NCT00918840||Placebo + HAART|"Dosage form: 3.2 mL Placebo~Administration with 4 DermaPrep patches~Frequency: every four weeks~Duration: 8 weeks (3 Placebo treatments)"
3239379|NCT00918814|Experimental|LIPO-102|LIPO-102
3239380|NCT00918814|Experimental|Placebo|Placebo
3239381|NCT00918801||Type 1 Diabetes Mellitus|Adolescents ages 13-18 with T1DM
3239382|NCT00918801||Non Controls|Healthy adolescents ages 13-18 without T1DM
3239383|NCT00918775||Metastasectomy|Kidney cancer patients being considered for surgery
3239384|NCT00918762|Experimental|daVinci® Robotic Surgical System|Participants will undergo a planned surgical procedures via the robotic approach.
3239385|NCT00918749|Active Comparator|150 mg|150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.
3239386|NCT00918749|Experimental|75 mg|75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast
3239387|NCT00918749|Experimental|100 mg|100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast
3239388|NCT00918736|Experimental|hyaluronate injection|All patients with unilateral ankle OA received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
3239389|NCT00918723|Experimental|Treatment (induction and maintenance chemotherapy)|"INDUCTION THERAPY: Patients receive vorinostat PO once daily on days 1-5 and 8-12; cyclophosphamide IV over 30-60 minutes and fludarabine phosphate IV over 30-60 minutes on days 1-3; and rituximab IV on day 1, 2, 3, 4, or 5. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 3 months after the completion of induction therapy, patients receive vorinostat PO on days 1-14 and rituximab IV on day 1. Treatment repeats every 3 months for 2 years in the absence of disease progression or unacceptable toxicity."
3239390|NCT00918710||1|Patients with oropharyngeal squamous cell carcinomas
3239391|NCT00918697|Active Comparator|Mechanical debridment|In this arm, corneal epithelium was removed during PRK using conventional mechanical method.
3239392|NCT00918697|Experimental|Alcohol-asstisted debridement|In this arm, corneal epithelium was removed using ethanol 20% during PRK.
3239393|NCT00918684|Experimental|Escitalopram|12-week open label with 2 week placebo period (14 weeks total)
3239394|NCT00918671||Medication-overuse headache|Chronic daily headache combined with medication overuse
3239395|NCT00918658||Patients with hematologic cancer|Patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma
3239396|NCT00918658||Patients without cancer|Patients who do not have cancer.
3239397|NCT00918645|Experimental|41 Ca|
3239398|NCT00918632|Other|Sequence 1 (ABC)|"The following treatments will be administered in the following order A -> B-> C~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
3239399|NCT00918632|Other|Sequence 2 (ACB)|"The following treatments will be administered in the following order A -> C -> B~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
3239400|NCT00918632|Other|Sequence 3 (BCA)|"The following treatments will be administered in the following order B -> C -> A~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
3239401|NCT00918632|Other|Sequence 4 (BAC)|"The following treatments will be administered in the following order B -> A -> C~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
3239402|NCT00918632|Other|Sequence 5 (CAB)|"The following treatments will be administered in the following order C -> A -> B~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
3239403|NCT00918632|Other|Sequence 6 (CBA)|"The following treatments will be administered in the following order C -> B -> A~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
3239404|NCT00918619|Experimental|Sangustop|
3239405|NCT00918619|Active Comparator|Tachosil|
3239406|NCT00918606|Experimental|LIPO-102|
3239407|NCT00918593|Experimental|Electrochemotherapy|
3239408|NCT00918593|Active Comparator|radiotherapy|
3239409|NCT00918580|Experimental|1|
3239410|NCT00918567|Experimental|Combined therapy|atomoxetine plus behavior therapy
3239411|NCT00918567|Active Comparator|Drug therapy|atomoxetine alone
3239412|NCT00918554|Experimental|Methotrexate|
3239413|NCT00918554|Placebo Comparator|Placebo|
3239414|NCT00918541||A|asymptomatic patients with mild to moderate carotid artery stenosis
3239415|NCT00918528|Active Comparator|1. Internal urethrotomy|
3239416|NCT00918528|Experimental|2. Internal urethrotomy + mitomycin C|
3239417|NCT00918515|Experimental|AZD3043|Intravenous solution
3239418|NCT00918489|Experimental|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
3239419|NCT00918476|Experimental|1. filibuvir + Oral Contraceptives|
3239420|NCT00918463|Experimental|all patients|
3239421|NCT00918450|Experimental|1|
3239422|NCT00918437||RAUP treatment|Patients referred to the hospital for a snoring problem
3239423|NCT00918411|Experimental|Ramosetron group|oral
3239424|NCT00918411|Placebo Comparator|Placebo group|oral
3239425|NCT00918398|Experimental|1|AZD1981, 100 mg iv infusion
3239426|NCT00918398|Experimental|2|AZD1981, 514 mg oral solution
3239427|NCT00918398|Experimental|3|AZD1981, 500 mg oral tablet A
3239430|NCT00918385|Active Comparator|2|Low Androgen Receptor (AR) activity
3239431|NCT00918372||Extreme fitness|Female competitive long distance runners
3239432|NCT00918372||Control|Age and Risk matched controls
3239433|NCT00918359||HI|Subjects who experienced heat exhaustion or heat stroke in their past and will be identified by heat tolerance test (HTT) as Heat Intolerance .
3239434|NCT00918359||HT|Subjects who experienced heat exhaustion or heat stroke in their past and will be identified by heat tolerance test (HTT) as Heat Tolerance .
3239435|NCT00918346|Experimental|Tafluprost 0.0015% preserved formulation|
3239436|NCT00918346|Experimental|Tafluprost 0.0015% unpreserved formulation|
3239437|NCT00918333|Experimental|Treatment (panobinostat and everolimus)|Patients receive panobinostat PO QD or on days 1, 3, 5, 15, 17, and 19 and everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3239438|NCT00918320|Experimental|Toptecan + temozolomide|
3239439|NCT00918307|Experimental|Varenicline|Varenicline titrated to 2 x 0.5 mg twice daily for 12 weeks
3239440|NCT00918307|Placebo Comparator|Placebo|placebo titrated to 2 pills twice daily for 12 weeks
3239441|NCT00918294|Experimental|QuickOpt|QuickOpt is an optimization algorithm to program the AV, PV and VV delays
3239442|NCT00918281|Experimental|Fluciclatide Injection|Fluciclatide Injection
3239443|NCT00918268|Experimental|Influenza vaccine|
3239444|NCT00918255|Experimental|Adalimumab 40 mg qwk|Initial dose of adalimumab 160 mg at Week 0, adalimumab 80 mg at Week 2, followed by 40 mg weekly (qwk) starting at Week 4 through Week 15.
3239445|NCT00918255|Experimental|Adalimumab 40 mg eow|Initial dose of adalimumab 80 mg at Week 0, followed by adalimumab 40 mg eow (every other week) starting at Week 1 through Week 15.
3239446|NCT00918255|Placebo Comparator|Placebo|Matching placebo for adalimumab, administered weekly starting at Week 0 through Week 15.
3239447|NCT00918229|Other|balloon implantation|implantation of an absorbable perirectal spacer balloon
3239448|NCT00918203|Active Comparator|Paclitaxel + Carboplatin|"(Initial 4-6 cycles) Paclitaxel 200 milligram/square meter (mg/m2) over 3 hrs (Day 1) Carboplatin Area Under Concentration (AUC)=6 (Day 1) of each 21-day cycle (Initial 4-6 cycles) Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle~Participants who experience progressive disease may cross over to olaratumab monotherapy."
3239449|NCT00918203|Experimental|Olaratumab + Paclitaxel + Carboplatin|"(Initial 4-6 cycles)~Olaratumab 15 milligrams/kilogram (mg/kg) over 30 mins (Days 1 and 8) plus Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle~Participants can remain on study after completing chemotherapy and receive olaratumab monotherapy on Days 1 and 8, provided there is ongoing evidence of clinical benefit."
3239450|NCT00918190|Active Comparator|Ondansetron-Dexa group|Use 2 different antiemetics
3239451|NCT00918190|Active Comparator|Midazolam, Dexa group|use of midazolam and dexamethasone
3239452|NCT00918190|Placebo Comparator|Placebo|Saline will be given
3239453|NCT00918177|Experimental|Early patients|
3239454|NCT00918177|Experimental|Moderate Patients|
3239455|NCT00918164|Experimental|Healthy adult volunteers|Standard Phase 1 normal healthy adult volunteers, age range 21-55 years and of either sex
3239456|NCT00918151||A|
3239457|NCT00918138|Experimental|Saxagliptin + Metformin XR + matching Metformin XR placebo|(Saxagliptin 5 mg plus Metformin XR 1500 plus matching Metformin XR 500 mg placebo)
3239458|NCT00918138|Active Comparator|Metformin XR + Metformin XR + matching Saxagliptin placebo|(Metformin XR 500 mg plus Metformin XR 1500 mg plus matching Saxagliptin 5 mg placebo)
3239459|NCT00918125||White educational video|Patients will view an educational video that contains White physicians and patients.
3239460|NCT00918125||African-American educational video|Patients will view an educational video that contains African-American physicians and patients.
3239461|NCT00918125||Usual care|Patients will receive counseling about their condition and treatment options.
3239462|NCT00918112||Parkinson's Disease|Meets criteria for definite Parkinson's Disease
3239463|NCT00918112||Healthy Controls|- Must be in good health
3239464|NCT00918099|Active Comparator|Avaulta mesh|Avaulta mesh
3239465|NCT00918099|Active Comparator|Anterior repair|Anterior repair
3239466|NCT00918086|Experimental|Vitamin D pill|
3239467|NCT00918086|Placebo Comparator|Placebo|
3239468|NCT00918073||HIV positive smokers|50 HIV infected patients who enroll in a parent protocol to quit smoking and elect to participate in this sub-study.
3239469|NCT00918060|Experimental|gel a|
3239470|NCT00918060|Placebo Comparator|gel b|
3239471|NCT00918047|Experimental|SPN-804O 150mg/Day|Subjects who weighed 15.0 to 29.9 kg dosed with SPN-804O 150mg/Day
3239472|NCT00918047|Experimental|SPN-8040 300mg/Day|Subjects who weighed 30.0 to 44.9 kg dosed with SPN-8040 300mg/Day
3239473|NCT00918047|Experimental|SPN-8040 450mg/Day|Subjects who weighed 45.0 to 59.9 kg dosed with SPN-8040 450mg/Day
3239474|NCT00918047|Experimental|SPN-8040 600mg/Day|Subjects who weighed 60.0 kg and above dosed with SPN-8040 600mg/Day
3239475|NCT00918034|Experimental|LS11 (talaporfin sodium)|
3239476|NCT00918021|Active Comparator|olanzapine (B)|Group B: In addition to clozapine, the participants receive their normal dosage of olanzapine (=the same as on the hospital ward) for 12 weeks, next the decreasing dosage of olanzapine for four weeks and subsequently placebo for 8 weeks.
3239477|NCT00918021|Placebo Comparator|placebo (A)|Group A: : In addition to clozapine the participants receive the decreasing dosage of olanzapine for four weeks, next placebo for 8 weeks, after that the increasing dosage of olanzapine for four weeks and subsequently the normal dosage of olanzapine for 8 weeks.
3239478|NCT00918008||Blood sample|the blood sample only collected prior to surgery
3239479|NCT00917995|Experimental|Colostomy with a prophylactic mesh|
3239480|NCT00917995|No Intervention|Colostomy without a prophylactic mesh|
3239481|NCT00917982|Other|Vision therapy|
3239482|NCT00917943|Experimental|Tailored Counseling Intervention Arm|Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
3239483|NCT00917943|No Intervention|Control Arm|Women randomized to the control arm receive the booklet, Forever Free for Baby and Me: A Guide to Remaining Smoke Free and usual prenatal and postpartum care.
3239484|NCT00917930||physical training|
3239485|NCT00917904|Placebo Comparator|vehicle placebo gel|
3239486|NCT00917904|Experimental|dapivirine gel|
3239487|NCT00917891|Placebo Comparator|vehicle placebo gel|
3239488|NCT00917891|Experimental|dapivirine gel|
3239489|NCT00917878|Experimental|Milk|500 mL low-fat milk added to high-fat meal
3239490|NCT00917878|Experimental|Protein|Milk protein in 500 mL water added to high-fat meal
3239491|NCT00917878|Experimental|Calcium|Milk calcium in 500 mL water added to high-fat meal
3239492|NCT00917878|Experimental|Control|Lactose in 500 mL water added to high-fat meal (control condition)
3239493|NCT00917865|Experimental|FACBC Imaging|Dynamic FACBC PET of primary prostate carcinoma.
3239494|NCT00917852|Experimental|GORE Conformable TAG® Thoracic Endoprosthesis|
3239495|NCT00917839|Experimental|lamotrigine|7 weeks initial phase with increasing dose beginning with 25 mg oral 12 months treatment phase with fixed dose of 100 mg oral
3239496|NCT00917839|Placebo Comparator|Placebo|300mg Mannitol with 2% Aerosil
3239497|NCT00917826|Experimental|Arginine Butyrate + Ganciclovir/Valganciclovir|
3239498|NCT00917813|Experimental|KD-247|
3239499|NCT00917813|Placebo Comparator|Placebo|
3239500|NCT00917800||suspected coronary artery disease|patients referred to angiography because of suspected coronary artery disease
3239501|NCT00917787||Healthy, Non-asthmatic|
3239502|NCT00917787||Asthma|
3239503|NCT00917774|Active Comparator|Standard LPS Flex|Nexgen LPS-Flex total knee design used for TKA
3239504|NCT00917774|Experimental|Gender specific LPS-Flex|Gender specific LPS flex design used for TKA in female patients
3239505|NCT00917761|Experimental|Entecavir and peginterferon (52 weeks)|Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
3239506|NCT00917761|Experimental|Peginterferon (96 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-96
3239507|NCT00917761|Active Comparator|Peginterferon (48 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-48
3239508|NCT00917748|Experimental|1|docetaxel chemotherapy + modafinil 100 mg capsules
3239509|NCT00917748|Placebo Comparator|2|docetaxel chemotherapy + placebo (lactose) capsules (matched to modafinil drug)
3239510|NCT00917735|Experimental|Green tea extract|Green tea extract capsules containing 80.7 % total catechins (51.7 % EGCG)
3239511|NCT00917735|Placebo Comparator|Sugar pill|Placebo capsules containing 50% maltodextrin, 49.5 % cellulose, and 0.5 % magnesium stearate
3239512|NCT00917709|Experimental|DLB with extrapyramidal syndrome|patients dementia with Lewy bodies with extrapyramidal syndrome
3239513|NCT00917709|Other|DLB without extrapyramidal syndrome|patients dementia with Lewy bodies without extrapyramidal syndrome
3239514|NCT00917709|Sham Comparator|healthy volunteers|healthy volunteers
3239515|NCT00917696|Active Comparator|1|ATP
3239516|NCT00917696|Placebo Comparator|2|Saline
3239517|NCT00917683||1|Autistic patients.
3239518|NCT00917683||2|Matched controls
3239519|NCT00917644|Other|Reference|80 mg atorvastatin tablets
3239520|NCT00917644|Experimental|Test|New 80 mg atorvastatin tablets
3239521|NCT00917631|Experimental|Co-bedding|"Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.~Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.~Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes)."
3239522|NCT00917631|No Intervention|Standard care|For infants who are randomized to receive standard care, the twin pair will remain in separate incubators as per current NICU policy. The infant will be nested in boundaries consistent with neonatal care practices. The heelstick may occur at any time following randomization (within 10 days) to maintain consistency between groups.
3239523|NCT00917618|Active Comparator|Exercise intervention|Patients began the exercise intervention after randomization for 12 weeks
3239524|NCT00917618|Placebo Comparator|Control|Patients were asked not to change their baseline exercise program
3239525|NCT00917592|Experimental|Short intravenous amoxicillin plus clavulanic acid|Intravenous antibiotic 48 hours followed by oral antibiotic for 10 days
3239526|NCT00917592|Active Comparator|Long intravenous amoxicillin plus clavulanic acid|Intravenous antibiotic for 7 days followed by oral antibiotic for 5 days
3239527|NCT00917579|Other|Reference|10 mg atorvastatin
3239528|NCT00917579|Experimental|Test|New 10 mg atorvastatin tablet
3239529|NCT00917566|Active Comparator|Airtraq group|Use Airtraq for intubation
3239530|NCT00917566|Active Comparator|Macintoch gorup|Use Macintoch laryngoscope for intubation
3239531|NCT00917553|Experimental|doxycycline monohydrate|
3239532|NCT00917553|Placebo Comparator|Placebo|Placebo
3239533|NCT00917527|Placebo Comparator|Control|
3239534|NCT00917527|Experimental|Atorvastatin|
3239535|NCT00917501|Placebo Comparator|Placebo|Placebo to the Omega-3 given in other group taken twice a day.
3239536|NCT00917501|Active Comparator|Omega 3|Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA & will be taken twice a day.
3239537|NCT00917488|Experimental|A|Four concentrations of Glycyphagus domesticus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, was tested in every patient in duplicate on the volar surface of the forearm.
3239538|NCT00917475||Preterm infants|birth weight<1500 grams and gestational age<30 weeks
3239539|NCT00917462|Experimental|Sorafenib|Sorafenib for patients with metastatic or recurrent esophageal and gastroesophageal junction cancer.
3239656|NCT00916656|Other|Historical Control|
3239540|NCT00917449|Active Comparator|L-arginine|L-arginine (3.2 gr bid) plus lifestyle counselling vs placebo plus lifestyle counselling
3239541|NCT00917449|Placebo Comparator|placebo|placebo plus lifestyle counselling for 18 months
3239542|NCT00917423||Inpatients with anorexia nervosa|Hospital inpatients with anorexia nervosa
3239543|NCT00917423||Normal weight controls|Healthy, normal-weight volunteers
3239544|NCT00917410|Experimental|SMS intervention|
3239545|NCT00917397|Experimental|psychotherapy|Trauma-focused cognitive behavioral therapy
3239546|NCT00917397|Experimental|Drug|drug treatment and psychoeducation
3239547|NCT00917397|No Intervention|Waiting list|subjects randomized to waiting list
3239548|NCT00917397|Experimental|Combination|Both drug and psychotherapy
3239549|NCT00917384|Experimental|ramucirumab|Participants receive ramucirumab, administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), and best supportive care (BSC) as determined appropriate by the investigator(s). Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
3239550|NCT00917384|Placebo Comparator|Placebo|Participants receive injection for intravenous infusion every 2 weeks plus BSC as determined appropriate by the investigator(s). Because investigators and ancillary medical personnel will be blinded as to assignment to active therapy versus placebo, the volume of placebo to be administered will be calculated as if it were active product with a dose of 8 mg/kg. Treatment will continue until there is evidence of PD, the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
3239551|NCT00917371||atomoxetine group|
3239552|NCT00917371||methylphenidate group|
3239553|NCT00917371||psychological counseling group|
3239554|NCT00917358|Experimental|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
3239555|NCT00917358|No Intervention|Observation|Retrospectively chart review of dialysis patients with acute hepatitis C who did not receive any intervention
3239556|NCT00917345||aldosteronism, hypertension|
3239557|NCT00917345||hypertension|
3239558|NCT00917332|Experimental|intervention|"55 third trimester women will receive a CD of relaxation and guided imagery (of safe place), to practice daily at home until childbirth"
3239559|NCT00917332|No Intervention|control|55 third trimester women who does not receive the relaxation and guided imagery CD.
3239560|NCT00917319|Experimental|Infection control measure|Bundling Infection Control Interventions
3239561|NCT00917306|Experimental|PEP005 gel|PEP005 gel, 0.05% administered once daily for 2 consecutive days
3239562|NCT00917293|Experimental|Pyridoxal 5'-Phosphate|Pyridoxal 5'-Phosphate, enteric-coated 2x 250mgs po bid.
3239563|NCT00917293|Placebo Comparator|Placebo|Placebo 2 pills, po bid.
3239564|NCT00917280||Parkinson's Disease|Parkinson Disease participants without dementia
3239565|NCT00917280||Control|Non-PD participants, matched for age, education and gender.
3239566|NCT00917267|Experimental|1|
3239567|NCT00917267|Active Comparator|2|
3239568|NCT00917254|Experimental|YM150 group-1|YM150 low dose group
3239569|NCT00917254|Experimental|YM150 group-2|YM150 high dose group
3239570|NCT00917254|Placebo Comparator|Placebo group|
3239571|NCT00917254|Active Comparator|Enoxaparin group|
3239572|NCT00917241|Experimental|MMI+IID group|MMI,methimazole；IID,intrathyroid injection of dexamethasone
3239573|NCT00917241|Active Comparator|MMI Group|MMI,methimazole
3239574|NCT00917228||Feedback|Subjects of this group are equipped with the biofeedback system
3239575|NCT00917228||Control|Subjects of this group are not equipped with the biofeedback system
3239576|NCT00917215|Experimental|Active acupuncture|
3239577|NCT00917215|Sham Comparator|Sham acupuncture|
3239578|NCT00917215|No Intervention|Waiting list control|
3239579|NCT00917202|Experimental|MB3|3 days
3239580|NCT00917202|Experimental|MB5|5 days
3239581|NCT00917202|Experimental|MB7|
3239582|NCT00917189|Experimental|Computerized Cognitive Skills Training|Participants will receive the Challenging Our Minds intervention, delivered in-person in Phase 1 and remotely in Phases 2 and 3.
3239583|NCT00917176|Experimental|Effective stimulation|Effective stimulation at sub-threshold level
3239584|NCT00917176|Placebo Comparator|Placebo stimulation|Stimulation at non-effective strength
3239585|NCT00917163|Experimental|Supralimus(R) Sirolimus Eluting Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
3239586|NCT00917163|Active Comparator|Xience V™ Everolimus Eluting Stent|The XIENCE V™ Everolimus Eluting Coronary Stent System consisting of the MULTI-LINK VISION® Coronary Stent System coated with a formulation containing everolimus, the active ingredient, embedded in a non-erodible polymer., Drug Load: 100 µg/cm2
3239587|NCT00917150|Experimental|OPC-6535 12.5mg|
3239588|NCT00917150|Experimental|OPC-6535 25mg|
3239589|NCT00917150|Experimental|OPC-6535 50mg|
3239590|NCT00917150|Placebo Comparator|placebo|
3239591|NCT00917137||Peripheral pulmonary lesions|
3239592|NCT00917124|Active Comparator|INVOS|INVOS : Cerebral oxygenation (rSO2) monitoring with INVOS. If rSO2 decreased for more than 20% from patient's baseline value, simple interventions were performed to prevent brain injury. These interventions included: repositioning of head or perfusion cannulae, increasing arterial carbon dioxide tension, increasing oxygen inspiration concentration, increasing arterial blood pressure, adjusting pump flow rate, temperature decreasing, increasing of anesthetic depth and blood transfusion.
3239593|NCT00917124|No Intervention|CONTROL|The CONTROL arm did not have INVOS or any other cerebral oxygenation monitoring, so interventions to control cerebral oxygenation were not performed.
3239594|NCT00917111|Experimental|CO2 Gas|
3239595|NCT00917111|Placebo Comparator|Inactive Placebo Gas|
3239596|NCT00917098|Experimental|Behavior Therapy|Participants will receive behavior therapy during Phases 1 and 2.
3239597|NCT00917098|Placebo Comparator|Supportive Counseling|Participants will receive supportive counseling during Phase 1 and will not participate in Phase 2.
3240089|NCT00913627|Placebo Comparator|4|1 x placebo caplet
3239598|NCT00917085|No Intervention|Control group|Control infants received the same standard care as infants who were not in the study. Infants were kept warm in incubators or warmer beds and were wrapped in blankets when held by their mothers. Hospital staff was responsible for providing standard care.
3239599|NCT00917085|Experimental|Skin-to-Skin group|
3239600|NCT00917072|Experimental|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
3239601|NCT00917072|Experimental|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center.
3239602|NCT00917072|Placebo Comparator|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
3239603|NCT00917059|Active Comparator|1|Participants will receive a 1-week treatment of escitalopram and then an 8-week treatment with escitalopram.
3239604|NCT00917059|Active Comparator|2|Participants will receive a 1-week treatment with escitalopram and then an 8-week treatment with bupropion XL.
3239605|NCT00917046|Experimental|1 Interval training|high-intensity Interval Training
3239606|NCT00917046|Experimental|2 Moderate Training|Moderate continuous training
3239607|NCT00917046|Active Comparator|3 Recommendation of exercise|Recommendation of regular exercise at moderate intensity at individual choice
3239608|NCT00917033|Experimental|GlideScope|Orotracheal intubation using the GlideScope videolaryngoscope
3239609|NCT00917033|Active Comparator|Macintosh|Orotracheal intubation using the Macintosh direct laryngoscope
3239610|NCT00917020|Experimental|Active: CO2 Gas|
3239611|NCT00917020|Placebo Comparator|Inactive Placebo Gas|
3239612|NCT00917007||ABO compatible|
3239613|NCT00917007||ABO incompatible, antiglobulin positive|
3239614|NCT00917007||ABO incompatible, antiglobulin negative|
3239615|NCT00916994|Experimental|SpaceGuard Balloon implantation|
3239616|NCT00916968|Active Comparator|Standard CR-Flex|
3239617|NCT00916968|Experimental|Gender specific CR-Flex|
3239618|NCT00916955||Individuals with 22q11.2 deletions|Individuals confirmed with the diagnosis of velo-cardio-facial syndrome by positive FISH or CGH microarray confirming the diagnosis and deletion of 22q11.2
3239619|NCT00916942|Experimental|NGX-4010 patch|
3239620|NCT00916942|Experimental|Lidocaine (2.5%)/Prilocaine (2.5%) Cream|Pre-treatment for NGX-4010
3239621|NCT00916929|Other|Implantable Cardioverter Defibrillator (ICD)|Impedance Monitoring Feature in an Implantable Cardioverter Defibrillator (ICD).
3239622|NCT00916929|Other|Cardiac Resynchronization Therapy (CRT-D)|Impedance Monitoring Feature in a Cardiac Resynchronization Therapy (CRT-D) device.
3239623|NCT00916916||Lanreotide|Patients taking lanreotide for the treatment of acromegaly.
3239624|NCT00916903||1|Patients with genetic condition being studied.
3239625|NCT00916903||2|Matched controls
3239626|NCT00916890|Active Comparator|Oral extended-release morphine|
3239627|NCT00916890|Active Comparator|Oral extended-release oxycodone|
3239628|NCT00916890|Active Comparator|Transdermal fentanyl|
3239629|NCT00916890|Active Comparator|Transdermal buprenorphine|
3239630|NCT00916851||Control group|Normally developing children and adolescents
3239631|NCT00916851||ADHD group|Children and adolescents with ADHD
3239632|NCT00916851||ASD group|Children and adolescents with ASD
3239633|NCT00916838||Type 1 Diabetes Mellitis|Children with Type 1 Diabetes Mellitis (T1DM) between 4 and 16 were recruited.
3239634|NCT00916838||Non diabetic Control|62 healthy siblings also enrolled in the study between the ages of 4 and 17.
3239635|NCT00916825|Experimental|3-week family oriented rehabprogramme|waiting control group
3239636|NCT00916799|Experimental|Oximeter arm and non-oximetry arm|
3239637|NCT00916786||OROS-methylphenidate|The patients will be randomly assigned to two treatment groups, the OROS-methylphenidate group (n=80) and the atomoxetine group (n=80), respectively.
3239638|NCT00916786||Atomoxetine group|The patients will be randomly assigned to two treatment groups, the OROS-methylphenidate group (n=80) and the atomoxetine group (n=80), respectively.
3239639|NCT00916786||Control group|Healthy controls matching for the distribution of age and sex of the case groups
3239640|NCT00916760|Experimental|1|A Subcutaneous Depigmented and Polymerized Allergen extract of Parietaria Judaica 1000 DPP/ml. Depigoid Parietaria judaica 1000 DPP/ml.
3239641|NCT00916760|Placebo Comparator|2|
3239642|NCT00916747|Experimental|Treatment arm|All patients will receive zoledronic acid, pravastatin and lonafarnib
3239643|NCT00916734|Experimental|Spinal Manipulation Group|Subjects who received spinal thrust manipulation as an intervention.
3239644|NCT00916734|Active Comparator|McKenzie MDT Group|
3239645|NCT00916721|Active Comparator|Propranolol|propranolol
3239646|NCT00916721|Placebo Comparator|Placebo|sugar pill
3239647|NCT00916708|Experimental|Intensive follow up|Intensive follow up in low-risk patients Intensive follow up in high-risk patients
3239648|NCT00916708|Experimental|Minimalist follow up|Minimalist follow up in low-risk patients Minimalist follow up in high-risk patients
3239649|NCT00916695|Active Comparator|Complex PCI strategy for bifurcation coronary lesions|Stenting main vessel and T-stenting for the side branch
3239650|NCT00916695|Active Comparator|Simple PCI strategies for bifurcation coronary lesions|Stenting main vessel, with provisional stenting for the side branch.
3239651|NCT00916682||Cystic Fibrosis|
3239652|NCT00916669|Active Comparator|Group A|Cisplatin and Etoposide
3239653|NCT00916669|Experimental|Group B|Cisplatin and etoposide, plus low-dose enoxaparin sodium
3239654|NCT00916669|Experimental|Group C|Cisplatin and etoposide, plus high-dose enoxaparin sodium
3239655|NCT00916656|Experimental|Prospective Arm|
3239657|NCT00916643|Experimental|H.E.L.P. Secura|"The H.E.L.P. System is a device composed of multiple modules and their associated disposables which can selectively and continuously remove LDL-cholesterol from plasma by precipitating the LDL-cholesterol with high concentrations of heparin in an acidic buffer and returning the plasma to the patient. Procedure steps:~Flushing the system with normal saline.~Filtering whole blood through a 0.2 micron plasma filter for continuous plasma removal.~Mixing the plasma with an equal volume of acetate buffer containing heparin.~Precipitation of LDL as a complex with heparin.~Removing the LDL-heparin precipitate by continuous circulation through a filter.~Removing heparin with use of a heparin adsorber.~Bicarbonate dialysis and ultrafiltration to produce an LDL-free plasma without excess heparin.~Re-mixing the LDL-free plasma with blood coming from the plasma filter and returning the reconstituted blood to the patient."
3239658|NCT00916630|Other|Single-arm treatment|Dose finding study
3239659|NCT00916617|Experimental|1|5 mg/week
3239660|NCT00916604|Experimental|A|3 gradually increasing repeated oral doses of AZD1656 given to 3 groups (6 on active substance in each group)
3239661|NCT00916604|Placebo Comparator|B|Placebo oral suspension given to 3 groups (2 on placebo in each group)
3239662|NCT00916578|Experimental|Radiation Therapy + Capecitabine|"Capecitabine 825 mg/m2 twice a day. One of the two daily doses of capecitabine should be taken approximately 2 hours before receiving radiotherapy. The first day of Capecitabine is same day that radiotherapy is started, and last day that Capecitabine is given is last day of radiotherapy. Capecitabine administered only on days patient receives radiation therapy.~Radiation therapy dose 50-57 Gy to initial clinical target volume (CTV, gross disease + tissue at risk for micrometastatic disease including margin around gross disease and draining regional lymphatics)."
3239663|NCT00916565||Experimental milk-based infant formula|
3239664|NCT00916565||Control milk-based infant formula|
3239665|NCT00916565||Breastfed Reference Group|
3239666|NCT00916552|Experimental|Erythropoeitin|40.000 IU, epoetin alfa; Janssen-Cilag
3239667|NCT00916539|Experimental|Cast that immobilizes the thumb|Cast that immobilizes the thumb
3239668|NCT00916539|Active Comparator|Cast that does not immobilize the thumb|Cast that does not immobilize the thumb
3239669|NCT00916526|Experimental|bronchial provocation test with mannitol|"Patients referred for evaluation of a chronic cough (without treatment or after stopping inhaled corticosteroids for 2 weeks) will perform a measure of FeNO, a bronchial provocation test with mannitol, will fill out a questionnaire of quality of life for the cough (Leicester Cough Questionnaire) and the intensity of coughing on a 10-cm visual scale.~After 6 weeks after treatment with inhaled corticosteroids patients will perform the same tests."
3239670|NCT00916513||1|Patients ³ 40 years old, with T2DM diagnosed and followed up in the participating site at least 1 year prior to entry in the study, treated with diet, OADs and/or insulin for at least the past three months
3239671|NCT00916500|Experimental|CISPLATIN|Patients With Locally Advanced Cervical Cancer Who Underwent Concurrent Chemoradiation; Cisplatin 75mg/m2 IV Every 3 Week For 3 Cycles; External Pelvic Radiation 40 Gy; Brachytherapy Up to 85-90 Gy To Point A
3239672|NCT00916487|Experimental|Arm1|single arm of study in cross-over design
3239673|NCT00916474||Cohort A|Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time
3239674|NCT00916474||Cohort B|Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time
3239675|NCT00916461|Active Comparator|Minocycline|
3239676|NCT00916461|Placebo Comparator|Sugar Pill|
3239677|NCT00916448|Placebo Comparator|Placebo|placebo medication: 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously
3239678|NCT00916448|Active Comparator|Atazanavir|Atazanavir 150 mg, 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously
3239679|NCT00916422|Experimental|Depigoid Phleum pratense 1000DPP/Ml|Depigmented and Polymerized Allergen extract of Phleum Pratense.Subcutaneous Immunotherapy in an up-dosing cluster regimen for 4 weeks, followed by monthly injections for 2 years.
3239680|NCT00916422|Placebo Comparator|2|Placebo. Dosing regimen: An up-dosing cluster regimen for 4 weeks, followed by monthly injections for 2 years
3239681|NCT00916409|Experimental|NovoTTF-100A device in combination with Temozolomide|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
3239682|NCT00916409|Active Comparator|Temozolomide alone, as the best known standard of care|Patients will be treated with Temozolomide, as the best known standard of care for Glioblastoma Multiforme patients.
3239683|NCT00916396|Active Comparator|real drug|
3239684|NCT00916396|Placebo Comparator|placebo|
3239685|NCT00916383|Experimental|Upper Back|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of the upper back.
3239686|NCT00916383|Experimental|Upper Arm|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite arms.
3239687|NCT00916383|Experimental|Side of Torso|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of torso.
3239688|NCT00916370|Experimental|Core size registry (CSR)|Core size indicates the range of diameters of the stents used.
3239689|NCT00916370|Experimental|Long lesion registry (LLR)|Use of long lesion stents.
3239690|NCT00916357|Active Comparator|Humalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20|A subcutaneous (SC) injection of 0.3- to 0.5-units per kilogram (U/kg) of Humalog alone for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout period), followed by a SC injection of the appropriate dose of Humalog. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog + 3.75 nanograms/kilogram (ng/kg) recombinant human hyaluronidase PH20 (rHuPH20). The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 ng/kg rHuPH20 following a 3 to 14 day washout period.
3239725|NCT00916175|Experimental|TA (concentrated 5:1 aloe vera gel)|Food product TA contains concentrated 5:1 aloe vera gel by total process30 ml and purified water 200 ml.
3239726|NCT00916175|Placebo Comparator|P3|Food product Placebo 3 contains stabilizers and preservative used for TA 30 ml and purified water 200 ml.
3239691|NCT00916357|Active Comparator|Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog alone for up to 3 dose finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 nanograms/kilogram (ng/kg) recombinant human hyaluronidase PH20 (rHuPH20). The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
3239692|NCT00916357|Active Comparator|Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog + 3.75 nanograms per kilogram (ng/kg) recombinant human hyaluronidase PH20(rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog alone. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
3239693|NCT00916357|Active Comparator|Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then Humalog|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humulin-R + rHuPH20. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog following a 3- to 14-day washout period.
3239694|NCT00916357|Active Comparator|Humulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humulin-R + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humulin-R + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog alone. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
3239695|NCT00916357|Active Comparator|Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog|A subcutaneous (SC) injection of 0.3- to 0.5-units per kilogram (U/kg) of Humulin-R + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humulin-R + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog alone following a 3- to 14-day washout period.
3239696|NCT00916344|Experimental|Pacemaker therapy|
3239697|NCT00916331|Experimental|subcutaneous group|Vacuum drainage is indwelled in subcutaneous layer
3239698|NCT00916331|Experimental|intraarticular group|Vacuum drainage is indwelled in intraarticular space
3239699|NCT00916318|Experimental|A: experimental|"(A) internet based information and communication tool Sundabarn.se("
3239700|NCT00916318|Experimental|(B): experimental|(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A
3239701|NCT00916318|Experimental|(c): experimental|(C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A
3239702|NCT00916318|Active Comparator|(D): control group|
3239703|NCT00916305|Experimental|Modified Audio video|Participants will listen to an audio video modified to mimic noise induced hearing loss after one night at a loud club
3239704|NCT00916305|Active Comparator|Unmodified Audio video|Participants will listen to the same music as the other arm, but only the track with unaltered music.
3239705|NCT00916292|Experimental|Low dose|Four subjects will receive low dose FGF-1
3239706|NCT00916292|Experimental|High Dose|Four subjects will receive high dose FGF-1
3239707|NCT00916279|Experimental|Lutonix Catheter|
3239708|NCT00916266|Experimental|stem cell transplantation|Patients with refractory temporal lobe epilepsy that are transplanted with autologous bone marrow stem cells in order to provide seizure control.
3239709|NCT00916253|Experimental|Modafinil First|Treatment by Modafinil during first condition then placebo during second condition
3239710|NCT00916253|Experimental|Placebo First|Treatment by Placebo during first condition then Modafinil during second condition
3239711|NCT00916253|No Intervention|H|Healthy Volunteers
3239712|NCT00916240|Experimental|1|Participants will receive Multisystemic Therapy (MST).
3239713|NCT00916240|Active Comparator|2|Participants will receive home-based, non-directive family support.
3239714|NCT00916227|Experimental|ARRY-614|
3239715|NCT00916214|Experimental|Intervention|
3239716|NCT00916201|Experimental|Intranasal Insulin|Intranasal administered insulin
3239717|NCT00916201|Experimental|Cannabidiol CR|Cannabidiol is the main non psychoactive compound of the Cannabis sativa plant.
3239718|NCT00916201|Experimental|URB597|URB597 is a selective inhibitor of the Fatty acid amide hydrolase enzyme.
3239719|NCT00916188|Experimental|Black Tea-Four Doses|One, 2, 3 and 4 cups (150 ml/cup) of Black tea/day for week 1, 2, 3, and 4, respectively.
3239720|NCT00916188|Active Comparator|Black Tea-One Dose|One cup (150 ml) of Black tea/day during study.
3239721|NCT00916175|Placebo Comparator|P1&P2|Food product P1&P2 is composed of: placebo1(mimic aloe vera gel) 30ml and placebo2 (mimic Cnidoscolus chayamansa infusion) 200ml;
3239722|NCT00916175|Experimental|P1&CC|Food Product P1&CC contains: placebo1 (mimics liquified aloe vera gel) 30ml and Cnidoscolus Chayamansa infusion 200ml;
3239723|NCT00916175|Experimental|AG&P2|Food product AG&P2 contains (liquified aloe vera gel) 30ml and placebo2 (mimic CC infusion) 200ml.
3239724|NCT00916175|Experimental|AG&CC|Food product AG&CC is composed of: liquified aloe vera gel 30ml and Cnidoscolus Chayamansa infusion 200ml
3239776|NCT00915863|Active Comparator|Billroth-II-type|Billroth-II-type reconstruction after pancreaticoduodenectomy
3239727|NCT00916149|Active Comparator|Levetiracetam|12 individuals with epilepsy, 6 of whom experience infrequent focal epileptiform discharges and 6 of whom experience frequent focal discharges. These individuals will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.
3239728|NCT00916149|Active Comparator|Lamotrigine|12 individuals with epilepsy, 6 of whom experience infrequent generalized discharges and 6 of whom experience frequent generalized discharges. These individuals will be treated with lamotrigine (LMT). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LMT on discharge frequency, discharge duration, and cognitive task performance.
3239729|NCT00916149|No Intervention|No treatment|15 healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.
3239730|NCT00916136|Active Comparator|Cutaneous Traction|Applied by using a strap on boot that attaches to the leg. A rope is attached to the boot. Weight is attached to the rope to use gravity to pull traction. The traction is left in place until patient is taken to surgery for reduction of the femur fracture.
3239731|NCT00916136|Active Comparator|Skeletal Traction|A small incision is made on the inside of the knee and a pin is surgically inserted through the bone. Weights are then attached that will pull traction on the broken femur. This traction pin will stay in until patient is taken to surgery for reduction of the femur fracture.
3239732|NCT00916123|Experimental|Dose Level 1|177Lu-J591 at 20 mCi/dose
3239733|NCT00916123|Experimental|Dose Level 2|177Lu-J591 at 25 mCi/dose
3239734|NCT00916123|Experimental|Dose Level 3|177Lu-J591 at 30 mCi/dose
3239735|NCT00916123|Experimental|Dose Level 4|177Lu-J591 at 35 mCi/dose
3239736|NCT00916123|Experimental|Dose Level 5|177Lu-J591 at 40 mCi/dose
3239737|NCT00916110|Experimental|1.5mgSC|ATN-103
3239738|NCT00916110|Experimental|4mgSC|ATN-103
3239739|NCT00916110|Experimental|10mgSC|ATN-103
3239740|NCT00916110|Experimental|25mgSC|ATN-103
3239741|NCT00916110|Experimental|25mgIV|ATN-103
3239742|NCT00916110|Experimental|50mgSC|ATN-103
3239743|NCT00916110|Experimental|100mgSC|ATN-103
3239744|NCT00916110|Experimental|200mgSC|ATN-103
3239745|NCT00916110|Experimental|200mgIV|ATN-103
3239746|NCT00916097|Experimental|1|docetaxel 75mg/m2 in combination with cisplatin 75mg/m2 given every 3 weeks for 3 cycles
3239747|NCT00916084|Experimental|Group A|
3239748|NCT00916084|Experimental|Group B|
3239749|NCT00916071||Eating Disorders|Study subjects will be individuals with a history of eating disorder(s) diagnosis
3239750|NCT00916058|Experimental|1|Dose Level 1
3239751|NCT00916058|Experimental|2|Dose Level 2
3239752|NCT00916058|Experimental|3|Dose Level 3
3239753|NCT00916058|Experimental|4|Dose Level 4
3239754|NCT00916058|Experimental|5|Dose Level 5
3239755|NCT00916045|Other|Myeloblative conditioning regimen|
3239756|NCT00916045|Other|Reduced intensity conditioning regimen - FluCyTBI|
3239757|NCT00916045|Other|Reduced intensity conditioning regimen - FluMel|
3239758|NCT00916032|Active Comparator|1|One infusion using a 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent followed by a second infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total)
3239759|NCT00916032|Active Comparator|2|One infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total) followed by a second infusion of one 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent
3239760|NCT00916019|Experimental|exercise|mild exercise training
3239761|NCT00916006|Experimental|PEP005 gel|PEP005 gel, 0.015% applied once daily for three consecutive days
3239762|NCT00916006|Placebo Comparator|Vehicle gel|Vehicle gel applied once daily for three consecutive days
3239763|NCT00915980||Patients without diabetes undergoing gastric bypass|
3239764|NCT00915967|Experimental|Vancomycin|Subjects in the experimental group will receive Vancomycin injected directly into the wound pocket.
3239765|NCT00915967|Placebo Comparator|Saline|Subjects in the saline group will receive a Saline injection directly into the wound pocket.
3239766|NCT00915928|Active Comparator|ACE inhibitor|
3239767|NCT00915928|Placebo Comparator|Placebo|
3239768|NCT00915915|Experimental|Arm 1|
3239769|NCT00915915|Experimental|Arm 2|
3239770|NCT00915902|Experimental|Omega-3-acid ethyl esters (Lovaza)|This randomized, double-blind, placebo, crossover trial consisted of two 8-week treatment periods, separated by a 4-week washout. Eligible patients were randomized to receive either fish oil 4 g daily or corn oil placebo during the first 8-week treatment period; patients received the alternate treatment during the next treatment period. GlaxoSmithKline supplied the study drug and the placebo. The study drug, Omega-3-acid ethyl esters (Lovaza) was given to patients PO daily as two, 1 g capsules taken twice daily during the duration of their 8-week treatment period. The study drug contained minimally 1.5 g DHA (docosahexaenoic acid) and 1.86 g EPA (eicosapentaenoic acid).
3239771|NCT00915902|Placebo Comparator|Placebo|This randomized, double-blind, placebo, crossover trial consisted of two 8-week treatment periods, separated by a 4-week washout. Eligible patients were randomized to receive either fish oil 4 g daily or corn oil placebo during the first 8-week treatment period; patients received the alternate treatment during the next treatment period. The corn oil placebo was given to patients PO daily as two, 1 g capsules taken twice daily during the duration of their 8-week non-treatment (placebo) period.
3239772|NCT00915889|Active Comparator|Group I|Patients receive a survivorship booklet in the mail that contains information about cervical cancer. Patients then receive a follow-up telephone call at 3 months to clarify any issues relevant to the survivorship booklet.
3239773|NCT00915889|Experimental|Group II|Patients are randomly assigned to receive either 6 or 8 weekly telephone sessions that address managing medical issues, health education, and cancer resources; balancing emotions and managing stress; coping skills and problem solving; family and social concerns; relational, intimacy, and sexual concerns; and financial and employment concerns. Patients also receive a survivorship booklet as in group I.
3239774|NCT00915876|Active Comparator|Paricalcitol|
3239775|NCT00915876|Placebo Comparator|Placebo|
3239777|NCT00915863|Experimental|Isolated Roux-en-Y|Isolated Roux-en-Y type reconstruction after pancreaticoduodenectomy
3239778|NCT00915850|Experimental|Anticancer drug|docetaxel, cisplatin and 5-FU
3239779|NCT00915837|Experimental|Slow release formulation|Slow release formulation, helical intravitreal triamcinolone implant
3239780|NCT00915837|Experimental|fast release formulation|fast release formulation, helical intravitreal triamcinolone implant
3239781|NCT00915824|Experimental|STOPP/START intervention|STOPP/START intervention group
3239782|NCT00915811|Experimental|FBATG|Haematopoietic stem cell transplantation utilising conditioning with Fludarabine, Busulphan and Thymoglobuline
3239783|NCT00915798||Smokers with ADHD|Smokers with ADHD participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
3239784|NCT00915798||Nonsmokers with ADHD|Nonsmokers with ADHD participated in one condition.
3239785|NCT00915798||Control smokers|Control smokers participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
3239786|NCT00915798||Control nonsmokers|Control nonsmokers participated in one condition.
3239787|NCT00915785|Experimental|5 azacytidine|
3239788|NCT00915772|Experimental|Linagliptin + metformin bid|Linagliptin low dose + metformin 500 mg, bid
3239789|NCT00915772|Experimental|Linagliptin+ metformin bid|Linagliptin low dose + metformin 1000 mg bid
3239790|NCT00915772|Active Comparator|Metformin bid|Metformin 1000 mg bid
3239791|NCT00915759|Active Comparator|ProKera|
3239792|NCT00915759|Placebo Comparator|Bandage contact lens|
3239793|NCT00915733|Active Comparator|triple group|"Additive cilostazol to dual antiplatelet therapy (triple antiplatelet therapy) in patients with acute myocardial infarction (AMI).~Received cilostazol 100 mg twice daily in addition to aspirin 100 mg and clopidogrel 75 mg once daily."
3239794|NCT00915733|Active Comparator|high maintenance dose group|"High maintenance dose dual antiplatelet therapy in patients with acute myocardial infarction (AMI).~Received clopidogrel 150 mg/day with aspirin 100 mg once daily."
3239795|NCT00915707|Experimental|Baseline|Subjects are tested under normal sleep conditions for carbohydrate metabolism and appetite regulation.
3239796|NCT00915707|Experimental|Sleep restriction|Subjects are tested under sleep restriction for carbohydrate metabolism and appetite regulation.
3239797|NCT00915707|Experimental|Reduced sleep quality|Subjects are tested under a poor sleep quality condition for carbohydrate metabolism and appetite regulation.
3239798|NCT00915681|Experimental|Legalon SIL|Silibinin: loading dose of one hour infusion of 5 mg/kg, followed by 20 mg/kg/day infused continuously via pump
3239799|NCT00915655|Experimental|DRV/rtv (darunavir/ritonavir)|Patients will receive darunavir tablets 2 x 400 mg in combination with ritonavir capsule 100 mg once daily for 48 weeks along with 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) ie, either zidovudine/lamivudine or abacavir/lamivudine
3239800|NCT00915642||Normal volunteers|Volunteers, body mass index 17 to 25
3239801|NCT00915642||Obese volunteers|Volunteers body mass index higher than 30
3239802|NCT00915629|Experimental|Probiotic|Dietary supplement
3239803|NCT00915616|No Intervention|control|9 healthy normal subjects.
3239804|NCT00915616|Active Comparator|Group II|Included 9 patients suffering from GERD; receiving melatonin alone for treatment of GERD in a dose of 3 mg once daily at the bed time.
3239805|NCT00915616|No Intervention|Group III, combined group|Included 9 patients suffering from GERD; receiving omeprazole alone for treatment of GERD in a dose of 20 mg twice daily.
3239806|NCT00915616|Active Comparator|Group IV|Included 9 patients suffering from GERD receiving omeprazole and melatonin for treatment of GERD in the same dose of each of them.
3239807|NCT00915603|Active Comparator|paclitaxel/bevacizumab/everolimus|Systemic Therapy
3239808|NCT00915603|Placebo Comparator|paclitaxel/bevacizumab/placebo|Systemic Therapy
3239809|NCT00915590|Experimental|Placebo first, then IL-1RA|It is our intent that 10 patients will complete a course of treatment with placebo, followed by a course of treatment with 5% custom made topical IL-1Ra.
3239810|NCT00915590|Experimental|IL-1RA first, then Placebo|It is our intent that 10 patients will complete a course of treatment with 5% custom made topical IL-1Ra, followed by a course of treatment with placebo
3239811|NCT00915577|Experimental|1st Injection|Manual injection with pre-filled syringe.
3239812|NCT00915577|Experimental|Single-use autoinjector|Single-use autoinjector with Avonex pre-filled syringe
3239813|NCT00915564|Experimental|TMC435 + methadone|Supervised intake of individualized methadone dose (range, 30 to 150 mg once daily) from Day -14 to Day -1; followed by addition of 150 mg dose of TMC435 once daily from Day 1 to Day 7 along with methadone; and later followed by continued intake of individualized methadone 30 to 32 days follow-up.
3239814|NCT00915551|Experimental|PEP005 (Ingenol Mebutate) gel|
3239815|NCT00915551|Placebo Comparator|Vehicle gel|
3239816|NCT00915538|Experimental|Conventional First|This group will use pMDI in usual fashion first and cross over to pMDI and valved holding chamber
3239817|NCT00915538|Experimental|Spacer First|This arm will receive pMDI and Valved holding chamber on fist day. On anther day will receive pMDI in usual fashion. Pulmonary functions wil be measured over 12 hours
3239818|NCT00915525|Experimental|botulinum toxin Type A 100U|Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
3239819|NCT00915525|Experimental|botulinum toxin Type A 150U|Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
3239820|NCT00915512|Experimental|Paliperidone extended-release (ER)|
3239821|NCT00915499|Active Comparator|ASV mode|
3239822|NCT00915499|Active Comparator|CPAP mode|
3239823|NCT00915486|Experimental|Good Standard of Care (GSoC)|Twice per week
3239824|NCT00915486|Experimental|GSoC + vehicle|Twice per week
3239825|NCT00915486|Experimental|GSoC + I-020201 (33microg)|Twice per week
3239826|NCT00915486|Experimental|GSoC + I-020201 (100microg)|Twice per week
3239827|NCT00915486|Experimental|GSoC + I-020201 (300microg)|Twice per week
3240031|NCT00913991|Active Comparator|Stress Management #2|8 weeks of individual stress management training sessions
3239828|NCT00915473|Experimental|Active Injection|Subjects randomized to this arm will receive 2.5 mL 0.5% bupivicaine plus 0.5 mL 20 mg methylprednisolone injected over the ipsilateral (unilateral headache) or bilateral (bilateral headache) occipital nerve.
3239829|NCT00915473|Placebo Comparator|Placebo Injection|Subjects randomized to this arm will receive 2.75 mL normal saline plus 0.25 mL 1% lidocaine injected over the ipsilateral (unilateral headache) or bilateral (bilateral headache) occipital nerve.
3239830|NCT00915460|Experimental|1|Patients previously enrolled in BIogen Idec study C95-812.
3239831|NCT00915460|Experimental|2|Patients previously enrolled in Biogen Idec study C96-823.
3239832|NCT00915460|Experimental|3|Patients previously enrolled in Biogen Idec study C97-830.
3239833|NCT00915447||Cat Allergic Rhinitis|Individuals with cat allergic rhinitis, yet without routine cat exposure
3239834|NCT00915421||Prehospital hypothermia group|All patients included to the study
3239835|NCT00915408|Experimental|CRD|
3239836|NCT00915382|Active Comparator|3 weekly regimen of S-1 and cisplatin|
3239837|NCT00915382|Active Comparator|5 weekly regimen of S-1 and cisplatin|
3239838|NCT00915356|Experimental|1|AZD1305 iv infusion
3239839|NCT00915356|Placebo Comparator|2|Placebo iv infusion
3239840|NCT00915343|Experimental|Novel once daily modified release|"Test drug: hydrocortisone (modified release), oral tablet, available as 20 mg and 5 mg.~The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state"
3239841|NCT00915343|Active Comparator|Conventional TID hydrocortisone|Reference drug: hydrocortisone, oral tablet, 10 mg. The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM)in the same total daily dose as the experimental drug. The morning dose was administered in the fasting state.
3239842|NCT00915330|Active Comparator|TBNA alone|Arm A: TBNA alone.
3239843|NCT00915330|Experimental|TBNA with ROSE|Arm B: TBNA with ROSE.
3239844|NCT00915291|No Intervention|Usual education|"Participants randomized into the no intervention arm were not exposed to the web-based educational modules"
3239845|NCT00915291|Experimental|Web-based educational modules|Participants randomized into the intervention arm were exposed to the web-based educational modules
3239846|NCT00915278|Experimental|PF-04605412|
3239847|NCT00915252|Experimental|5-azacytidine|Patients enrolled in this arm will receive standard induction and consolidation chemotherapy preceded by 5-azacytidine. These patients will additionally receive maintenance therapy with 5-azacytidine for one year after start of induction therapy.
3239848|NCT00915252|Active Comparator|standard chemotherapy|Patients enrolled in this arm will receive standard chemotherapy treatment.
3239849|NCT00915239|Active Comparator|Pantoprazole|
3239850|NCT00915239|Placebo Comparator|Placebo|
3239851|NCT00915213||Repeat Prostate Biopsy|Men who undergo repeat prostate biopsy
3239852|NCT00915200|Placebo Comparator|Placebo|N-acetylcysteine placebo + silibin placebo
3239853|NCT00915200|Experimental|N-acetylcysteine|N-acetylcysteine active + silibin placebo
3239854|NCT00915200|Experimental|silibin|N-acetylcysteine placebo + silibin active
3239855|NCT00915200|Experimental|N-acetycysteine + silibin|N-acetylcysteine active + silibin active
3239856|NCT00915200|Experimental|N-acetylcysteine + high-dose silibin|N-acetylcysteine active + high-dose silibin active
3239857|NCT00915187|Active Comparator|Control|
3239858|NCT00915187|Experimental|CCS/C (Adjuvant Formulation)|
3239859|NCT00915148||Ultrasound examination|Women with prolonged Labour; Primi gravidae, single pregnancy, >37 weeks, fetus alive, cephalic presentation.
3239860|NCT00915135|Experimental|Ramelteon QD and Placebo QD (25 possible combinations total)|
3239861|NCT00915122|Experimental|IMRT in prostate cancer|
3239862|NCT00915109||vascular|People with a unilateral below-knee amputations due to a vascular reason
3239863|NCT00915109||nonvascular|People with a below-knee amputation due to nonvascular reasons
3239864|NCT00915109||Control|People with no gait impairments.
3239865|NCT00915096||High Tumor Burden Follicular Lymphoma|
3239866|NCT00915083|Experimental|Amrubicin 40mg/m^2|Amrubicin 40mg/m^2 given as a 5 minute IV infusion on Days 1, 2 & 3 of a 21 day cycle
3239867|NCT00915070|Active Comparator|BQ-123|
3239868|NCT00915070|Placebo Comparator|Physiological saline solution|
3239869|NCT00915057|Experimental|NRL972|Single 2mg intravenous dose of NRL972, administered on up to seven occasions
3239870|NCT00915044||IBD patients|Approximately 40 patients (adults and children) suffering from IBD will be enrolled.
3239871|NCT00915044||Controls|Approximately 100 healthy controls
3239872|NCT00915031|Active Comparator|Hypothermia Only OR|Use of Hypothermia Cooling device only in the operating room
3239873|NCT00915031|Active Comparator|Hypothermia in OR + Recovery|Use of hypothermia cooling device in the operating room and up to five hours after surgery.
3239874|NCT00915018|Experimental|neratinib plus paclitaxel|
3239875|NCT00915018|Active Comparator|trastuzumab plus paclitaxel|
3239876|NCT00915005|Experimental|Group 1|"Group 1: Photon Therapy - 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
3239877|NCT00915005|Experimental|Group 2|"Group 2: Proton Therapy - 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
3239878|NCT00915005|Experimental|Group 3|"Group 3: Receives either photon or proton therapy, whichever participant's doctor decides is better, for for 6-7 1/2 weeks.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
3239879|NCT00915005|Experimental|Group 4|"Photon Therapy - Highest practical dose (74 CGE, 66 CGE) radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
3239880|NCT00914979|Experimental|1|Single Arm - Interventional
3239932|NCT00914602|Experimental|Single Arm (Treatment Period A and B)|"Treatment Period A: Sinemet® 25-100 treatment~Treatment Period B: Multiple-Dose XP21279 (with Lodosyn®) treatment"
3239881|NCT00914966|Experimental|CINRYZE|"There were 3 potential dose escalation steps:~Step 1: 1500 Units of CINRYZE (C1 inhibitor [human]) administered by IV infusion twice per week for 12 weeks~Step 2: 2000 Units of CINRYZE (C1 inhibitor [human]) administered by IV infusion twice per week for 12 weeks~Step 3: 2500 Units of CINRYZE (C1 inhibitor [human]) administered by IV infusion twice per week for 12 weeks"
3239882|NCT00914953|Experimental|oxytocin|
3239883|NCT00914940|Experimental|Arm 1|"CONDITIONING: Patients undergo total-body irradiation twice daily on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine IV over 30 minutes on days -6 to -2. TRANSPLANTATION: Patients undergo infusion of CD34+ enriched allogeneic peripheral blood stem cells (PBSC) followed by CD45RA+ T-cell-depleted allogeneic PBSC on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Cohort A: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -1 and continuing until day 50 followed by standard taper in the absence of grade II-IV acute GVHD. Cohort B: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -1 and continuing until day 30 followed by rapid taper in the absence of grade II-IV acute GVHD."
3239884|NCT00914927|Experimental|1|
3239885|NCT00914927|Experimental|2|
3239886|NCT00914927|Placebo Comparator|3|
3239887|NCT00914914|Experimental|p28 Phase I Safety|A total of 15 patients were administered p28 i.v. as a short infusion three times per week for 4 weeks followed by a 2-week rest under an accelerated titration 3þ3 dose escalation design.
3239888|NCT00914901|Other|Healthy|10 healthy men
3239889|NCT00914901|Other|Asthmatics|10 male asthmatic subjects
3239890|NCT00914901|Other|Elite athletes with asthma|10 male elite athletes with asthma
3239891|NCT00914888|Experimental|A|Tigecycline
3239892|NCT00914888|Active Comparator|B|Ceftriaxone regimen
3239893|NCT00914875||group tramadol plus ketorolac|
3239894|NCT00914875||group tramadol plus dypirone|
3239895|NCT00914862|Experimental|Children Ramelteon 4 mg|Children 6 to 11 years of age who had insomnia associated with ADHD received a single 4 mg oral dose of ramelteon.
3239896|NCT00914862|Experimental|Children Ramelteon 8 mg|Children 6 to 11 years of age who had insomnia associated with ADHD received a single oral 8 mg dose of ramelteon.
3239897|NCT00914862|Experimental|Adolescents Ramelteon 4 mg|Adolescents 12 to 17 years of age with insomnia received a single oral dose of 4 mg ramelteon.
3239898|NCT00914862|Experimental|Adolescents Ramelteon 8 mg|Adolescents 12 to 17 years of age with insomnia received a single oral dose of 8 mg ramelteon.
3239899|NCT00914862|Active Comparator|Healthy Adult Ramelteon 8 mg|Healthy adults (18 to 50 years old) received a single oral dose of 8 mg ramelteon.
3239900|NCT00914849|Experimental|Arm 1 - Donor|"Day 1~AMD3100 320 ug/kg IV~Leukopheresis~Day 2 (if peripheral blood stem cell (PBSC) collected is not sufficient)~AMD3100 320 ug/kg IV~Leukopheresis"
3239901|NCT00914849|Experimental|Arm 2 - Recipient|"Standard of care and physician choice myeloablative or non-myeloablative chemotherapy with or without total body irradiation (permitted = cyclophosphamide and single dose total body irradiation (TBI) / fludarabine and busulfan / fractionated TBI and cyclophosphamide / fractionated TBI, etoposide, and cyclophosphamide / busulfan and cyclophosphamide / fludarabine, busulfan, and ATGAM~Day 0 = Stem Cell Transplant"
3239902|NCT00914836|Active Comparator|1 cc - Betamethasone Sodium Phosphate|1 cc - Betamethasone Sodium Phosphate
3239903|NCT00914836|Active Comparator|2 cc - Betamethasone Sodium Phosphate|2 cc - Betamethasone Sodium Phosphate
3239904|NCT00914823|Experimental|kisspeptin, GnRH|intravenous administration of kisspeptin 112-121 and/or GnRH
3239905|NCT00914810|Experimental|Vitamin D|Cholecalciferol (2000 I.U. daily)
3239906|NCT00914810|Placebo Comparator|Placebo|Placebo capsule (sugar pill daily)
3239907|NCT00914797|Active Comparator|asthmatics|10 male asthmatic subjects
3239908|NCT00914797|Active Comparator|healthy|10 male healthy volunteers
3239909|NCT00914797|Active Comparator|elite athletes with asthma|10 elite athletes with asthma.
3239910|NCT00914771|Active Comparator|H5N1 pandemic Influenza vaccine 3.75µg|
3239911|NCT00914771|Active Comparator|H5N1 pandemic Influenza vaccine 7.5µg|
3239912|NCT00914758||MS patients on Campath®|This group is comprised of patients diagnosed with relapsing remitting multiple sclerosis who were assigned to the Campath® treatment arm of the Care-MS II trial, for which this study is a sub-study
3239913|NCT00914758||MS patients on Rebif®|This group is comprised of patients diagnosed with relapsing remitting multiple sclerosis who were assigned to the Rebif® treatment arm of the Care-MS II trial, for which this study is a sub-study
3239914|NCT00914758||Control group|This group is comprised of non-MS, non-CNS compromised control participants matched in age, education level, and socioeconomic status to the participants in the 2 MS treatment groups
3239915|NCT00914732|Experimental|Group B, liquid, subcutaneous|Group B: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (1x10^8 TCID50/0.5 mL per dose) liquid formulation by the subcutaneous route on Day 0 and 28.
3239916|NCT00914732|Experimental|Group C, liquid, intradermal|Group C: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (2x10^7 TCID50/0.1mL per dose) liquid formulation by the intradermal route on Day 0 and 28.
3239917|NCT00914732|Experimental|Group A, lyophilized, subcutaneous|Group A: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (1x10^8 TCID50/0.5 mL per dose) lyophilized formulation by the subcutaneous route on Day 0 and 28.
3239918|NCT00914719|Active Comparator|Information only|
3239919|NCT00914719|Active Comparator|sexual risk reduction intervention|
3239920|NCT00914719|Experimental|SRRI+ETOH|
3239921|NCT00914693|Experimental|Arm 1|
3239922|NCT00914680|Experimental|MST|
3239923|NCT00914667|Experimental|Warfarin Alone|Reference treatment
3239924|NCT00914667|Experimental|Warfarin Concomitantly With Fesoterodine|Test treatment
3239925|NCT00914654|Other|Healthty|10 healthy men
3239926|NCT00914654|Other|Asthmatics|10 male asthmatic subjects
3239927|NCT00914654|Other|Elite asthmatics|10 male elite athletes with asthma
3239928|NCT00914641|Other|Apixaban Cross-over|
3239929|NCT00914628|Experimental|A|HSV-TK engineering donor Lymphocytes
3239930|NCT00914628|Active Comparator|B|T-cell depleted or T-cell replete strategies
3239931|NCT00914615|Experimental|SBRT for liver mets from colorectal cancer|
3240215|NCT00912834||5|basketball athletes
3239933|NCT00914589|Experimental|FXIII17.5IU/Kg|Recombinant factor XIII at a single dose of 17.5 IU/kg lean body mass (LBM) was administered via slow i.v. push at a rate not exceeding two mL per minute.
3239934|NCT00914589|Experimental|FXIII35IU/Kg|Recombinant factor XIII at a single dose of 35 IU/kg lean body mass (LBM) was administered via slow i.v. push at a rate not exceeding two mL per minute.
3239935|NCT00914589|Placebo Comparator|Placebo|Recombinant factor XIII placebo was administered as a single dose via slow i.v. push at a rate not exceeding two mL per minute.
3239936|NCT00914576|Active Comparator|1|
3239937|NCT00914576|Placebo Comparator|2|
3239938|NCT00914563|Experimental|LIDCO|The extensively burnt patients (age range 18-75 years) with second and the third degree burns, with TBSA above 15%, with or without inhalation injury will be included to the study. We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. We will use in the LIDCO group the continuous real-time hemodynamic monitoring through transpulmonal lithium dilution additionally. The monitor Lithium Dilution Cardiac Output (LIDCO) Plus permits, through analysis of the arterial blood pressure trace, to acquire items about CO, SVR and DO2. In fluid resuscitation, we will use a combination of the balanced crystalloids and synthetic colloids (of the middle molecular weight) in the ratio 2 ml/kg/% TBSA: 1 ml/kg/% TBSA.
3239939|NCT00914563|No Intervention|Standard care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
3239940|NCT00914550||Procalcitonin level, caregiver informed|Procalcitonin level for patients with lung infiltrates:caregivers know/ do not know results
3239941|NCT00914524|Experimental|Treatment|16 weeks of treatment starting with 5 mg of olmesartan medoxomil. If tolerated, the dose was increased to the next higher dose at weeks 4, 8, and 12.
3239942|NCT00914511|Experimental|Healthy young males|Healthy young males age 18-45, inclusive
3239943|NCT00914511|Experimental|Elderly males|Elderly males 65 years of age and older
3239944|NCT00914498|Experimental|Xylocaine|Participants will receive local injection of 20 ml 1% Xylocaine to the skin incision site
3239945|NCT00914498|Placebo Comparator|Controls|Participants will receive injection of 0.9% NaCl 20 ml to the incision site
3239946|NCT00914485|Other|Provider Communication Skills Training|Provider clinical communication training intervention
3239947|NCT00914472|Experimental|Test|Heparin - Hipolabor
3239948|NCT00914472|Active Comparator|Ative comparator|Heparin - APP
3239949|NCT00914459|Other|Moroctocog alfa (AF-CC)|Open Label
3239950|NCT00914446|Other|morbid obese subject|
3239951|NCT00914446|Other|overweight and NASH subjects|
3239952|NCT00914446|Other|control subjects|
3239953|NCT00914433|Experimental|TPI 1100|Drug to be given by inhalation.
3239954|NCT00914420|Experimental|Intrepide|Group A- Primary stenting with Intrepide trapidil eluting stent
3239955|NCT00914420|Experimental|Taxus|Group B Stenting with Taxus DES
3239956|NCT00914407|Experimental|Healthy subjects|
3239957|NCT00914394|Active Comparator|NG-monomethyl-L-arginine (L-NMMA)|
3239958|NCT00914394|Active Comparator|Phenylephrine|
3239959|NCT00914394|Placebo Comparator|Physiological saline solution|
3239960|NCT00914381|Active Comparator|CRA + CM|Community Reinforcement Approach (CRA) combined with Contingency Management (CM)
3239961|NCT00914381|Active Comparator|TSF + CM|Twelve-Step Facilitation (TSF) combined with Contingency Management (CM)
3239962|NCT00914381|Active Comparator|CRA + VC|Community Reinforcement Approach (CRA) combined with Voucher Control (VC)
3239963|NCT00914381|Active Comparator|TSF + VC|Twelve-Step Facilitation (TSF) combined with Voucher Control (VC)
3239964|NCT00914368|Active Comparator|1|Patients with previously experienced stent thrombosis while on dual antiplatelet treatment within 6 months after coronary stenting for coronary artery disease
3239965|NCT00914368|Active Comparator|2|Patients with previously experienced myocardial infarction while on dual antiplatelet treatment within 6 months after coronary stenting for coronary artery disease
3239966|NCT00914368|Active Comparator|3|Patients without previously experienced myocardial infarction or stent thrombosis 6 within months after coronary stenting for coronary artery disease(matched controls for group 1 and 2)
3239967|NCT00914355|Experimental|SBRT for Hepatocellular Carcinoma|
3239968|NCT00914342||Upper-GI symptoms in primary-care patients|
3239969|NCT00914329|Experimental|Gelsemium 5CH|Globules of Gelsemium sempervirens 5CH
3239970|NCT00914329|Experimental|Gelsemium 15CH|Globules of Gelsemium Sempervirens 15CH
3239971|NCT00914329|Placebo Comparator|Placebo|Globules of placebo
3239972|NCT00914316|Active Comparator|Phase 1-Ranolazine, Phase 2-Ranolazine|This group will participate in the Phase 1 -12 week supervised exercise program and will additionally receive ranolazine 1000 mg orally, twice daily, by mouth. In Phase 2, the group will exercise independently and also receive ranolazine 1000 mg orally twice daily by mouth.
3239973|NCT00914316|Active Comparator|Phase 1 -Ranolazine, Phase 2 -Placebo|This group will participate in the Phase 1 -12 week supervised exercise program and will additionally receive ranolazine 1000 mg orally, twice daily, by mouth. In Phase 2, the group will exercise independently and will receive a sugar pill in place of the study drug.
3239974|NCT00914316|Active Comparator|Phase 1 -Placebo, Phase 2 -Ranolazine|This group will participate in the Phase 1 -12 week supervised exercise regimen and will receive a sugar pill in place of the study drug. In Phase 2, the group will exercise independently and also receive ranolazine 1000 mg orally twice daily by mouth.
3239975|NCT00914316|Placebo Comparator|Phase 1 -Placebo, Phase 2 -Placebo|This group will participate in the Phase 1 -12 week supervised exercise regimen and will receive a sugar pill in place of the study drug. In Phase 2, the group will exercise independently and will receive a sugar pill in place of the study drug.
3239976|NCT00914303|Experimental|AZD3241|AZD3241 Tablets
3239977|NCT00914303|Experimental|Placebo|Placebo Tablets
3239978|NCT00914290|Other|IPX056-Baclofen IR-IPX056|Following 2 weeks of run-in period, subjects were randomized to IPX056 and Placebo IR for 2 weeks and then to Baclofen IR and Placebo IPX056 for 2 weeks.
3240030|NCT00913991|Experimental|Stress Management #1|8 weeks of individual stress management training sessions
3239979|NCT00914290|Active Comparator|IPX056-IPX056-Baclofen IR|Following 2 weeks of run-in period, subjects were randomized to Baclofen IR and Placebo IPX056 for 2 weeks and then to IPX056 and Placebo IR for 2 weeks.
3239980|NCT00914277|Experimental|Sequence 1|"Period 1: placebo~Period 2: sildenafil~Period 3: SAR407899 dose level 2~Period 4: SAR407899 dose level 1"
3239981|NCT00914277|Experimental|Sequence 2|"Period 1: sildenafil~Period 2: SAR407899 dose level 1~Period 3: placebo~Period 4: SAR407899 dose level 2"
3239982|NCT00914277|Experimental|Sequence 3|"Period 1: SAR407899 dose level 1~Period 2: SAR407899 dose level 2~Period 3: sildenafil~Period 4: placebo"
3239983|NCT00914277|Experimental|Sequence 4|"Period 1: SAR407899 dose level 2~Period 2: placebo~Period 3: SAR407899 dose level 1~Period 4: sildenafil"
3239984|NCT00914264||COPD with OSA with CPAP treatment|COPD with OSA: CPAP treatment
3239985|NCT00914264||COPD without OSA|COPD without OSA, not treat with CPAP
3239986|NCT00914264||COPD with OSA but without CPAP treatment|COPD with OSA but patient refused CPAP treatment
3239987|NCT00914251|Active Comparator|Hesperidin, 500 mg per day|500 mg daily of oral Hesperidin for 3 weeks
3239988|NCT00914251|Placebo Comparator|Placebo|
3239989|NCT00914238|Experimental|5 year|5 years OPUS treatment
3239990|NCT00914238|Active Comparator|2 years of OPUS treatment|2 years OPUS treatment and 3 years of treatment as usual
3239991|NCT00914225||Intervention|Cohort 1 is the intervention group who received long-lasting insecticide treated bednets and a water filtration device
3239992|NCT00914225||Comparison|"Cohort 2 is the comparison group included from the control arm of the study, Empiric therapy of helminth coinfection to reduce HIV-1 disease progression ClinicalTrials.gov identifier: NCT00507221~As part of the RCT (NCT00507221), we have enrolled 948 HIV infected ART naïve individuals to compare HIV disease progression in those receiving standard of care versus empiric deworming. Subjects are followed for 24 months and have serial measurements of HIV disease progression, and are evaluated serially for evidence of malaria, diarrhea and other co-morbidities. Participants in this study will have been consented for the collection of data on the frequency of malaria and diarrheal disease, their use of a bednet and water filtration and their compliance with TMP/SMX."
3239993|NCT00914212|Active Comparator|1|Sibutramine
3239994|NCT00914212|Placebo Comparator|2|Placebo
3239995|NCT00914199|Experimental|Kissing balloon post-dilatation|Percutaneous coronary intervention with implantation of stent using kissing balloon dilatation
3239996|NCT00914199|Experimental|No kissing balloon post-dilatation|Percutaneous coronary intervention with implantation of stent and not using kissing balloon postdilatation
3239997|NCT00914186|Placebo Comparator|Vehicle|
3239998|NCT00914186|Experimental|TS-022 0.005% lotion|
3239999|NCT00914186|Experimental|TS-022 0.010% lotion|
3240000|NCT00914186|Experimental|TS-022 0.020% lotion|
3240001|NCT00914173|Experimental|Pain/No Pain Stimuli|One Arm is used in this trial. The comparator is within the arm. The different types of stimuli levels and types are compared.
3240002|NCT00914160|Experimental|1|Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)
3240003|NCT00914160|Experimental|2|Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)
3240004|NCT00914160|Active Comparator|3|Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
3240005|NCT00914147|Other|Pulmonary Function Test (PFT)|After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization. PFT measurements will be reported as absolute values (e.g. liters) and percentage of predicted. The predicted normal values will be calculated according to sex, age, height and race using the Third National Health and Nutrition Examination Survey (NHANES III) reference equation. Predicted values for diffusion capacity will be calculated using the Morris/Polgar equation. DLCO values will be adjusted to anemia (hemoglobin levels)
3240006|NCT00914134|Experimental|Levodopa Infusion|Patients with advanced Parkinson's disease and motor fluctuations that cannot be adequately controlled with oral medication.
3240007|NCT00914121|Experimental|1|SKI-606 alone
3240008|NCT00914121|Placebo Comparator|2|Placebo
3240009|NCT00914121|Active Comparator|3|Moxifloxacin
3240010|NCT00914121|Experimental|4|SKI-606 plus ketoconazole
3240011|NCT00914121|Placebo Comparator|5|Placebo plus ketoconazole
3240012|NCT00914095|Active Comparator|methylphenidate|methylphenidate 10 mg tablets (1 mg /kg /day) 3 time a day
3240013|NCT00914095|Placebo Comparator|placebo|tablets of placebo 3 time a day
3240014|NCT00914082|Experimental|antenatal classes in self hypnosis|3 antenatal classes in self hypnosis. 3 audio compact discs for homework in self hypnosis and 1 audio compact disc for birth
3240015|NCT00914082|Active Comparator|relaxation and awareness|3 antenatal classes including training in relaxation methods and mindfulness.3 audio compact discs for homework and 1 for birth.
3240016|NCT00914082|Other|Control|Only receive ordinary antenatal care and no additional interventions
3240017|NCT00914069|Experimental|RIVS vascular access|RIVS vascular access
3240018|NCT00914069|Active Comparator|Conventional vascular access|Conventional vascular access
3240019|NCT00914056|Experimental|Lactulose withdrawal|Patients who were started on lactulose as a result of a precipitated HE episode underwent analysis while they were on lactulose; after this they underwent a controlled lactulose withdrawal with 3 visits post-withdrawal at 2 days, 14 days and 30 days after lactulose withdrawal
3240020|NCT00914030||A1|Patients with schizophrenia
3240021|NCT00914030||A2|Control subjects matched individually with patients with schizophrenia
3240022|NCT00914030||B1|Adult subjects with autism
3240023|NCT00914030||B2|Control subjects matched individually with adult subjects with autism
3240024|NCT00914030||C1|Children with autism
3240025|NCT00914030||C2|Control subjects matched individually with children with autism
3240026|NCT00914017|Experimental|Atorvastatin|40 mg of Lipitor (atorvastatin) daily for 1 year
3240027|NCT00914017|Placebo Comparator|Sugar Pill|Sugar pill daily for 1 year
3240028|NCT00914004|Experimental|1|Desipramine HCl 50 mg Tablets Cord Laboratories
3240029|NCT00914004|Active Comparator|2|Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc
3240032|NCT00913978|Active Comparator|Group 1: VitaHeat|Patients in group one will be warmed perioperatively with the VitaHeat mattress and IV fluid warmers once they are in the operating room.
3240033|NCT00913978|Active Comparator|Group 2: Bair Hugger|Patients in group two will be warmed perioperatively with the upper body bair hugger and IV fluid warmers once they are in the operating room.
3240034|NCT00913965|Experimental|1|Atenolol Tablets 100 mg (Cord Laboratories)
3240035|NCT00913965|Active Comparator|2|Atenolol Tablets 100 mg (Stuart Pharmaceutical)
3240036|NCT00913952|Experimental|1|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions.
3240037|NCT00913952|Experimental|2|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.
3240038|NCT00913952|Active Comparator|3|Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.
3240039|NCT00913939|Active Comparator|1: Salvage After EBRT|Patients with locally recurrent prostate cancer after radiotherapy will receive tumor-targeted salvage HDR brachytherapy. Arm 1 of the study will be coordinated and closely integrated with a separate concurrent study of MRI-guided prostate biopsy, which will be performed prior to accrual to Arm 1 of this trial (UHN 05-0641-C).
3240040|NCT00913939|Active Comparator|2: Boost to EBRT|Patients with locally advanced prostate cancer will receive a boost of prostate-targeted HDR brachytherapy during external beam radiotherapy.
3240041|NCT00913926||Group 1|
3240042|NCT00913913|Experimental|bevacizumab,IL-2, IFN, DC vaccine|Patients will be dosed with bevacizumab (10mg/kg) intravenously every two weeks beginning four weeks prior to the first vaccine. Each treatment week includes ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of continuous intravenous infusion of IL-2 (18 MiU/m2), and three subcutaneous injections of IFNa-2b (6 MiU) (every other day)
3240043|NCT00913900|Active Comparator|Autologous Stem cells (CD133+)|Intramuscular injection
3240044|NCT00913900|Placebo Comparator|Control|Intramuscular Injection
3240045|NCT00913887|Experimental|1|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)
3240046|NCT00913887|Experimental|2|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)
3240047|NCT00913887|Active Comparator|3|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
3240048|NCT00913874|Experimental|1|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
3240049|NCT00913874|Active Comparator|2|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
3240050|NCT00913861|Active Comparator|standard sedation|propofol and fentanyl
3240051|NCT00913861|Active Comparator|structured attention-standard sedation|structured attention
3240052|NCT00913861|Experimental|hypnosis-standard sedation|hypnosis
3240053|NCT00913848|Experimental|1|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
3240054|NCT00913848|Active Comparator|2|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
3240055|NCT00913835|Experimental|Olaratumab and Liposomal Doxorubicin|Olaratumab and Liposomal Doxorubicin
3240056|NCT00913835|Active Comparator|Liposomal Doxorubicin: Optional Olaratumab Monotherapy|Liposomal Doxorubicin Monotherapy until disease progression. Upon disease progression the participant had the option to receive Olaratumab monotherapy.
3240057|NCT00913822|Experimental|1|Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)
3240058|NCT00913822|Active Comparator|2|Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)
3240059|NCT00913809|Experimental|1|Desipramine HCL 100 mg Tablets Cord Laboratories
3240060|NCT00913809|Active Comparator|2|Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc
3240061|NCT00913796|Experimental|Postassium citrate|Aim: correction of metabolic acidosis
3240062|NCT00913796|Active Comparator|Potassium chloride|Potassium chloride is given to compensate for any possible effects of potassium in potassium citrate (primary treatment).
3240063|NCT00913783|Experimental|1|Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)
3240064|NCT00913783|Active Comparator|2|Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)
3240065|NCT00913770|No Intervention|SC|Standard Care
3240066|NCT00913770|Experimental|SBIRT|Screening, Brief Intervention and Facilitated Referral to Treatment
3240067|NCT00913770|Experimental|SBI+Bup|Screening, Brief Intervention and Buprenorphine initiation
3240068|NCT00913757||Group 1|400 patients with primary HCC (Hepatocellular carcinoma)
3240069|NCT00913757||Group 2|800 patients with chronic liver disease (high risk non-cancer cases)
3240070|NCT00913757||Group 3|800 population-based controls, identified through a OMV database that will match cases by age, gender, race, and county of residency
3240071|NCT00913744|Experimental|Ocriplasmin|
3240072|NCT00913744|Sham Comparator|Sham injection|
3240073|NCT00913731||psychotic patients|psychotic patients, acute ward, symptom rating scale.
3240074|NCT00913718|Experimental|1|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)
3240075|NCT00913718|Active Comparator|2|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
3240076|NCT00913705|Experimental|1|The patients will be randomized to receive taxol (Paclitaxel) and carboplatin as adjuvant or as neoadjuvant regimen or to surgery alone
3240077|NCT00913679|Active Comparator|Posterior approach|Posterior surgical approach in hip resurfacing arthroplasty
3240078|NCT00913679|Active Comparator|Anterolateral approach|Anterolateral surgical approach in hip resurfacing arthroplasty
3240079|NCT00913666|No Intervention|Group 1|Healthy Volunteers
3240080|NCT00913666|Experimental|Group 2|MS patients previously naïve to interferon therapy
3240081|NCT00913666|Experimental|Group 3|MS patients on Interferon beta-1a treatment with no history of breakthrough disease (clinically stable)
3240082|NCT00913666|Experimental|Group 4|MS patients on interferon beta-1a treatment with a history of breakthrough disease.
3240083|NCT00913653|Experimental|Stable heart failure patients|
3240084|NCT00913640||PD Group|
3240085|NCT00913640||Control Group|
3240086|NCT00913627|Experimental|1|1 x 600 mg ibuprofen IR/ER-roller compaction caplet
3240087|NCT00913627|Experimental|2|1 x 600 mg ibuprofen IR/ER-Wet granulation caplet
3240088|NCT00913627|Active Comparator|3|1x 220 mg naproxen sodium (Aleve caplet)
3240090|NCT00913614|Experimental|Age Group 6-11 year old - Dose level 1|
3240091|NCT00913614|Experimental|Age Group 6-11 year old - Dose Level 2|
3240092|NCT00913614|Experimental|Age Group 6-11 year old - Dose Level 3|
3240093|NCT00913614|Experimental|Age Group 12-17 year old - Dose level 1|
3240094|NCT00913614|Experimental|Age Group 12-17 year old - Dose level 2|
3240095|NCT00913614|Experimental|Age Group 12-17 year old - Dose level 3|
3240096|NCT00913601|Experimental|Dextra|Unilateral sacral nerve stimulation dextra for 4 weeks
3240097|NCT00913601|Experimental|Sinistra|Unilateral sacral nerve stimulation sinistra 4 weeks
3240098|NCT00913601|Experimental|Bilateral|Bilateral sacral nerve stimulation 4 weeks
3240099|NCT00913588|Experimental|1|Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)
3240100|NCT00913588|Experimental|2|Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)
3240101|NCT00913588|Active Comparator|3|Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)
3240102|NCT00913575|Experimental|preoperative neuromuscular training|preoperative neuromuscular training
3240103|NCT00913575|Placebo Comparator|education|knee school
3240104|NCT00913562|Active Comparator|Patients with diabetes|Rosuvastatin
3240105|NCT00913562|Active Comparator|Patients with glaucoma|Rosuvastatin
3240106|NCT00913562|Placebo Comparator|Control patients with diabetes|Placebo
3240107|NCT00913562|Placebo Comparator|Control patients with glaucoma|Placebo
3240108|NCT00913549|Experimental|1|Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)
3240109|NCT00913549|Experimental|2|Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)
3240110|NCT00913536|Experimental|Cone beam CT in Bladder Cancer|
3240111|NCT00913523|Experimental|Tampon with GML|Regular and Super Tampon with GML added to the cover
3240112|NCT00913523|Sham Comparator|Tampon without GML|Regular and Super Tampon without GML
3240113|NCT00913523|Sham Comparator|Tampon Normally Used|Type and Size of Tampon Normally Used by Subjects
3240114|NCT00913510|Experimental|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
3240115|NCT00913510|Active Comparator|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, i.e. Drug.
3240116|NCT00913497|Active Comparator|insulin glulisine|
3240117|NCT00913497|Active Comparator|insulin aspart|
3240118|NCT00913484|Experimental|Disulfiram|Disulfiram 250 mg per day
3240119|NCT00913484|Placebo Comparator|Placebo|Placebo
3240120|NCT00913471||Acute-Longitudinal SCI|
3240121|NCT00913471||Chronic SCI|
3240122|NCT00913471||Healthy volunteers|
3240123|NCT00913458|Experimental|1|etanercept + methotrexate; etanercept + methotrexate
3240124|NCT00913445|Active Comparator|surgery, absorbable stitches|wound healing after absorbable and nonabsorbable stitches are compared
3240125|NCT00913445|Active Comparator|surgery, nonabsorbable stitches|
3240126|NCT00913432|Experimental|masitinib 3 mg|masitinib 3 mg/kg/day
3240127|NCT00913432|Experimental|masitinib 6 mg|masitinib 6 mg/kg/day
3240128|NCT00913419|Experimental|1|Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories
3240129|NCT00913419|Active Comparator|2|Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme
3240130|NCT00913406|Experimental|1|Experimental=Standard formula with lutein added to the formula
3240131|NCT00913406|Active Comparator|2|Active Comparator=Standard formula
3240132|NCT00913393|Placebo Comparator|1|Placebo IV
3240133|NCT00913393|Experimental|2|3 mg/kg FG-3019 IV
3240134|NCT00913393|Experimental|3|10 mg/kg FG-3019 IV
3240135|NCT00913380|Experimental|Low-dose CT|
3240136|NCT00913380|Active Comparator|Standard-dose CT|
3240137|NCT00913367|Active Comparator|Amaryl group|
3240138|NCT00913367|Experimental|Amaryl M group|
3240139|NCT00913354|Experimental|1|30 minutes of acupuncture just before and just after embryo replacement
3240140|NCT00913354|Placebo Comparator|2|Sham acupuncture for 30 minutes just before and just after embryo transfer
3240141|NCT00913341|Experimental|1|Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
3240142|NCT00913341|Active Comparator|2|Alprazolam Tablets, 1 mg (The Upjohn Company)
3240143|NCT00913328|Active Comparator|Montelukast|Oral montelukast 10 mg once daily for 12 weeks
3240144|NCT00913328|Placebo Comparator|Placebo|Oral placebo once daily for 12 weeks
3240145|NCT00913315|Experimental|tolterodine + tamsulosin|
3240146|NCT00913315|Active Comparator|tamsulosin + placebo|
3240147|NCT00913302|Experimental|Training|cardiovascular training
3240148|NCT00913289|Other|adipose tissue derived stromal cells|
3240149|NCT00913276|Other|Sevoflurane anesthesia|
3240150|NCT00913276|Other|Propofol anesthesia|
3240151|NCT00913263|Experimental|2-Hydroxyflutamide|Single injection of 2-Hydroxyflutamide (2-8mL ready-made paste)in one prostate lobe
3240152|NCT00913250|Experimental|Sequence 1|Serum containing Avonex followed by serum free Avonex
3240153|NCT00913250|Experimental|Sequence 2|Serum free Avonex followed by serum containing Avonex
3240154|NCT00913237|Experimental|1|Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)
3240155|NCT00913237|Active Comparator|2|Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)
3240156|NCT00913224|Experimental|1|Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)
3240157|NCT00913224|Active Comparator|2|Voltaren 50 mg Tablets (Geigy Pharmaceuticals)
3240158|NCT00913211|Experimental|rTMS only|brain stimulation to non-stroke primary motor area
3240159|NCT00913211|Experimental|Finger tracking training|Motor learning training using finger flexion/extension tracking movements toward a target.
3240160|NCT00913211|Experimental|rTMS and finger tracking|Combination of rTMS and tracking
3240161|NCT00913211|Placebo Comparator|Sham|Sham rTMS treatment
3240162|NCT00913198|Experimental|IV CP-4126|
3240216|NCT00912834||6|Badminton athletes
3240163|NCT00913172||Intervention group|Directly Observed Treatment under Health Extension Workers
3240164|NCT00913172||Control group|Directly observed treatment under general health workers
3240165|NCT00913159|Active Comparator|Using HM3 lithotripter|This is an older generation lithotripter
3240166|NCT00913159|Active Comparator|F2 lithotripter|This is a newer generation lithotripter
3240167|NCT00913146||index|child with fever and a negative malaria RDT
3240168|NCT00913146||control|apparently healthy child with a negative RDT
3240169|NCT00913133|Experimental|Desirudin|desirudin 15 mg twice daily for a minimum of 5 days
3240170|NCT00913120|Experimental|YM150 group-1|YM150 low dose group
3240171|NCT00913120|Experimental|YM150 group-2|YM150 high dose group
3240172|NCT00913120|Placebo Comparator|Placebo group|
3240173|NCT00913120|Active Comparator|Enoxaparin group|
3240174|NCT00913107|Experimental|Lamictal®|"Lamictal® was used as the active medication in this study."
3240175|NCT00913107|Active Comparator|Tegretol®|"Tegretol® was employed as the control for comparative purposes in order to check and evaluate the efficacy (pain-relief) and occurrence of side- effects of Lamictal®."
3240176|NCT00913094||ICG|Group will have results blinded during observational phase of study. Results will be revealed at time of testing during the validation phase of the study.
3240177|NCT00913081|Experimental|Quercetin 500 mg|Quercetin 500 mg once, administered one hour before 500 mg immediate-release niacin
3240178|NCT00913081|Experimental|Quercetin 1000 mg|Quercetin 1000 mg once, administered one hour before 500 mg immediate-release niacin
3240179|NCT00913081|Experimental|Quercetin 2000 mg|Quercetin 2000 mg once, administered one hour before 500 mg immediate-release niacin
3240180|NCT00913081|Placebo Comparator|Placebo|Placebo once, administered one hour before 500 mg immediate-release niacin
3240181|NCT00913068|Experimental|TAP arm|in the experimental arm, the procedure will consist of the staff urologist injecting local anesthetic into the anterior abdominal wall bilaterally from the inside of the abdomen at the end of their surgery
3240182|NCT00913068|Active Comparator|standard post operative pain control|Our current post operative analgesic strategy involves a multi-modal approach, using local injectable anesthetic around the incision and systemic medications (i.e. non-steroidal anti-inflammatories, acetaminophen and break-through doses of opiates). Some of the more common adverse reactions are reparatory depression, sedation, confusion, delirium, nausea, pruritis, constipation, hypotension and bradycardia. Often it is these resulting side effects that extend the length of in hospital rehabilitation, and decrease a patient's overall satisfaction.
3240183|NCT00913055|Experimental|One hydrated 84mg Octreotide implant|hydrated implant
3240184|NCT00913055|Experimental|One non-hydrated 84mg Octreotide implant|
3240185|NCT00913042||1|febrile neutropenia patient
3240186|NCT00913029|Active Comparator|Stent|One hundred patients will be randomized to implantation of two G2 stents in at least one eye.
3240187|NCT00913029|Active Comparator|Medication|One hundred patients will be randomized to receive a fixed combination ocular hypotensive medication.
3240188|NCT00913016||letrozole (Femara)|
3240189|NCT00913003|Placebo Comparator|Placebo|Group B using saline as a placebo.
3240190|NCT00913003|Active Comparator|Lidocaine|Group A lidocaine infusion and bolus.
3240191|NCT00912990|Active Comparator|Cisatracurium|
3240192|NCT00912990|Placebo Comparator|Placebo|
3240193|NCT00912977||Group 1|Groups are defined by another study
3240194|NCT00912977||Group 2|Groups are defined by another study
3240195|NCT00912977||Group 3|Groups are defined by another study
3240196|NCT00912964|Placebo Comparator|Placebo|Participants received matching mirabegron placebo tablets orally once a day for 12 weeks.
3240197|NCT00912964|Experimental|Mirabegron 25 mg|Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.
3240198|NCT00912964|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.
3240199|NCT00912938|Experimental|Zoledronic acid|Patients with advanced breast cancer with radiographic confirmation of bone metastases. This arm will be receiving zoledronic acid administration. The primary endpoint is to find the correlation between bone turnover markers and the frequency of skeletal-related-events for one year. Skeletal related events are defined as pathologic fractures, the need for radiation therapy, orthopaedic surgery, hypercalcemia of malignancy and spinal cord compression. A total of 237 patients will be included.
3240200|NCT00912925|Placebo Comparator|Placebo|Patients in the placebo-control group were administered a solution of 100 millimolar (mM) sodium phosphate, 150 mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over approximately 4 hours once weekly for 26 weeks.
3240201|NCT00912925|Active Comparator|Aldurazyme treatment|Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 Units/kg (approximately 0.58 mg/kg = labeled dose) administered intravenously over approximately 4 hours once weekly for 26 weeks.
3240202|NCT00912912|Experimental|Sunitinib Malate|Sunitinib Malate 50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
3240203|NCT00912899|Experimental|One|Noscapine HCl
3240204|NCT00912886||1: Case|Patients with early and moderate AD
3240205|NCT00912886||2: Controls|AD free volunteer-controls matched for gender and age
3240206|NCT00912873|Active Comparator|1. 0.1% Ropivicaine|Patients will be given 0.1% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.
3240207|NCT00912873|Experimental|2. 0.4% Ropivicaine|Patients will be given 0.4% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.
3240208|NCT00912860|Experimental|1|serum-free avonex given IM
3240209|NCT00912847||JHC|AFP > 20 ng/ml and USG positive
3240210|NCT00912847||Non JHC|patient without AFP > 20 or USG negative
3240211|NCT00912834||1|tract and field athletes
3240212|NCT00912834||2|swimming athletes
3240213|NCT00912834||3|tennis athletes
3240214|NCT00912834||4|football athletes
3240218|NCT00912821|Active Comparator|8 L dialysate|8 L peritoneal dialysis solution
3240219|NCT00912821|Experimental|6 L dialysate|6 L peritoneal dialysis solution
3240220|NCT00912808|Experimental|Donepezil|
3240221|NCT00912808|Placebo Comparator|Sugar Pill|
3240222|NCT00912795|Experimental|SMS Turkey|6-week smoking cessation program delivered via daily text messages
3240223|NCT00912795|No Intervention|Brochure control|7-page brochure that provided general information and tips on how to quit smoking
3240224|NCT00912782|Placebo Comparator|Placebo|Placebo one time per week for 3 weeks
3240225|NCT00912782|Experimental|Cholecalciferol|Vitamin D 200,000 IU per week for 3 weeks
3240226|NCT00912769||subvastus approach/ midvastus approach|subvastus: vastus medialis oblique was not cut during operation midvastus: vastus medialis oblique was cut during operation
3240227|NCT00912769||Cybex|Knee extension/ flexion isometric and isokinetic performance of all cases were tested using Cybex
3240228|NCT00912756|Experimental|1cilostazol|Cilostazol group: Treatment with cilostazol 200 mg/day BID (morning and evening) and aspirin at 100 mg/day will be started 3 to 7 days prior to EVT and continued until the end of the 2-year follow-up period.
3240229|NCT00912756|Active Comparator|2aspirin|Non-cilostazol group: Treatment with aspirin 100 mg/day will be started 3 to 7 days prior to EVT and continued until the end of the 2-year follow-up period.
3240230|NCT00912743|Experimental|1|MSI - H arm
3240231|NCT00912717||Pancreatic Cancer|individuals who have been diagnosed with pancreatic cancer
3240232|NCT00912717||Unaffected|individuals who have not been diagnosed with pancreatic cancer
3240233|NCT00912691|Experimental|1|CM-AT
3240234|NCT00912678|Active Comparator|MMF and Steroid Group|Group of Patients randomized to MMF and Steroid maintenance immunosuppression after 3 months (Tacrolimus withdrawal)
3240235|NCT00912678|Active Comparator|Low-Dose Tacrolimus Group|Patients randomized to withdrawal of MMF after 3 months and maintenance immunosuppression with low-dose tacrolimus and Steroids
3240236|NCT00912665|Experimental|Healthy Volunteer|
3240237|NCT00912652|Experimental|High Intensity Lifestyle Intervention|High intensity group will receive 48 sessions of lifestyle intervention over a two-year period
3240238|NCT00912652|Experimental|Mod. Intensity Lifestyle Intervention|Moderate intensity group will receive 32 sessions of lifestyle intervention over a two-year period.
3240239|NCT00912652|Experimental|Low Intensity Lifestyle Intervention|Low intensity group will receive 16 sessions of lifestyle intervention over a two-year period.
3240240|NCT00912652|Active Comparator|Health Education Control|Health education control group will receive 16 sessions of health education related to diet and exercise over a two-year period.
3240241|NCT00912639|Experimental|Genexol-PM|"All the patients are recurrent breast cancer after taxane treatment. Patients with a measurable lesion (at least 1 measurable lesion)~Spiral CT : lesion ≥ 10mm (unidimension)~X-ray, MRI, ultrasound : lesion ≥ 20 mm (unidimension)"
3240242|NCT00912626|Experimental|FU-1 feedback|
3240243|NCT00912626|No Intervention|control group|
3240244|NCT00912613|No Intervention|Discussion with nurse|Brief discussion with ICU follow-up nurse about the patients' critical illness
3240245|NCT00912613|Experimental|ICU Diary|Receipt of ICU Diary at 1 month post critical illness
3240246|NCT00912600||1|Elderly individuals presenting to one of 15 emergency departments and possibly qualifying for admission to an ICU
3240247|NCT00912574|Active Comparator|Saline|first of 4 arms: injection: 1 ml saline
3240248|NCT00912574|Active Comparator|GM-CSF|Second of 4 arms: injection: specified dose of GM-CSF in 1 ml saline
3240249|NCT00912574|Active Comparator|0.5 ml Montanide ISA-51 adjuvant and 0.5 ml saline|Third of 4 arms: injection: 0.5 ml Montanide ISA-51 adjuvant and 0.5 ml saline
3240250|NCT00912574|Active Comparator|GM-CSF in 0.5 ml slaine plus 0.5 ml Montanide ISA-51 adjuvant|Fourth of 4 arms: injection: specified dose of GM-CSF in 0.5 ml slaine plus 0.5 ml Montanide ISA-51 adjuvant
3240251|NCT00912561|No Intervention|Sedentary|patients who train after an 8 week observational period
3240252|NCT00912561|Active Comparator|patients who train immediately after enrollment|patients who train immediately after enrollment
3240253|NCT00912548|Experimental|TAM+OFS(E) group|"Patients should be premenopausal women ,prior to the start of chemotherapy, less than or equal to 45 years of age with oestrogen receptor positive ± progesterone receptor positive who have undergone a primary mass excision, received an neo-/adjuvant chemotherapy ± radiotherapy for their stage I, II or III breast cancer. This arm is ovarian suppression group which have a various starting time of ovarian function suppression after neo-/adjuvant chemotherapy.~Ovarian function suppression will be done by administration of LHRH agonist (ZOLADEXTM) for 2 years. After that, the patients will complete taking tamoxifen 20mg/day for 5 years."
3240254|NCT00912548|Active Comparator|TAM(D) group|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 0, 6, 12, 18 and 24 months since the baseline asTsessment(0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized into the additional ovarian function suppression group or tamoxifen only group. The latter will complete taking tamoxifen 20mg/day for 5 years.
3240255|NCT00912548|No Intervention|Permanent postmenopausal(A) group|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. Eligible patients except for premenopausal status at the baseline will be followed up until 2 years after the baseline assessment for evaluating the menopausal status. This group still remains to postmenopausal status and will taking tamoxifen 20mg/day for 5 years if they remain in the study.
3240308|NCT00912184|Active Comparator|2|CVVH using standard high flux membrane with standard CVVH settings
3240309|NCT00912171|Active Comparator|Nasal steroid|
3240310|NCT00912171|Active Comparator|Anti-leukotrienes|
3240311|NCT00912171|Active Comparator|Nasal steroid + anti-leukotrienes|
3240312|NCT00912158|Active Comparator|CPAP + ST|Continuous positive airway pressure (CPAP) and Standard medical therapy (ST)
3240313|NCT00912158|Active Comparator|BiPAP + ST|Bilevel positive airway pressure (BiPAP) and standard medical therapy (ST)
3240256|NCT00912548|Active Comparator|TAM(B)|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 6, 12, 18 and 24 months since the baseline assessment (0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized into the additional ovarian function suppression group or tamoxifen only group. This group, patients are premenopausal women, they will be randomized into tamoxifen only group, complete taking tamoxifen 20mg/day for 5 years.
3240257|NCT00912548|Experimental|TAM+OFS (C)|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 6, 12, 18 and 24 months since the baseline assessment (0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized. This group, patients are premenopausal women, they will be randomized into the additional ovarian function suppression group. Ovarian function suppression will be done by administration of LHRH agonist (ZOLADEXTM) for 2 years. Then, Patients will complete taking tamoxifen 20mg/day for 5 years.
3240258|NCT00912535|Active Comparator|Quetiapine extended release tablet|Quetiapine orally at a flexible dose fo 50-300mg/day according to the judgment by the investigator for 8 weeks, as adjunct to the same antidepressant at the same dose.
3240259|NCT00912535|Placebo Comparator|Placebo|Placebo orally, as adjunct to the same antidepressant at the same dose.
3240260|NCT00912522|Active Comparator|LT PFC HIGH FREQ TMS|
3240261|NCT00912522|Active Comparator|LT PFC LOW FREQ TMS|
3240262|NCT00912522|Active Comparator|RT PFC HIGH FREQ TMS|
3240263|NCT00912522|Active Comparator|RT PFC LOW FREQ TMS|
3240264|NCT00912522|Sham Comparator|SHAM STIMULATION|
3240265|NCT00912509|Active Comparator|30 minute light duration|30 minute treatment with UVX light
3240266|NCT00912509|Active Comparator|45 minute light duration|45 minute treatment with UVX light
3240267|NCT00912496|Experimental|Group 9: 2 dose prime|Received two doses of A/Vietnam/1203/04 90mcg vaccine as prime (on Days 0, 28 in DMID 07-0019), will receive a booster dose of A/Anhui/05 vaccine (A) with or without MF59 adjuvant in DMID 08-0013 on Day 0.
3240268|NCT00912496|Experimental|Group 8: 1 dose prime|Received A/Vietnam/1203/04 90mcg vaccine as prime (Day 0 in DMID 07-0019), will receive a booster dose of A/Anhui/05 vaccine (A) with or without MF59 adjuvant in DMID 08-0013 on Day 0.
3240269|NCT00912496|Experimental|Group 10: unprimed control/dose response group|Unprimed control and dose response group of H5 vaccine naive volunteers will be added in DMID 08-0013 to receive two doses of A/Anhui/05 vaccine (A) with or without MF59 adjuvant or placebo on Day 0 and Day 28.
3240270|NCT00912483|Experimental|Test|Heparin Sodium 5.000UI/0.25mL
3240271|NCT00912483|Active Comparator|Ative comparator|Heparin Sodium 5.000USP/mL
3240272|NCT00912457|Experimental|Donepezil|Donepezil-treated sleep apnea patients
3240273|NCT00912457|Placebo Comparator|Placebo|Placebo-treated sleep apnea patients
3240274|NCT00912444|Experimental|TAC Arm|six cycles of neoadjuvant Docetaxel, Anthracycline and Cyclophosphamide
3240275|NCT00912444|Experimental|TC Arm|six cycles of neoadjuvant Docetaxel and Cyclophosphamide
3240276|NCT00912431|Experimental|1|
3240277|NCT00912431|Placebo Comparator|2|
3240278|NCT00912405|Experimental|Sinexus Intranasal Splint|Patient receives a drug-coated intranasal splint
3240279|NCT00912392|Experimental|Etoposide-Carboplatin with Endostar|Endostar® 7.5mg/m2 on day 1 to day 14, etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
3240280|NCT00912392|Active Comparator|Etoposide-Carboplatin|Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
3240281|NCT00912379||hemoglobin determination|ICU and emergency unit patients
3240282|NCT00912366||Group A|VATS
3240283|NCT00912366||Group B|Open Surgery
3240284|NCT00912353|Experimental|AZD7268|
3240285|NCT00912353|Placebo Comparator|Placebo|
3240286|NCT00912340|Experimental|Everolimus, trastuzumab|Patients receive 10 mg everolimus PO daily and continue to receive their most recent hormone therapy. Patients achieving disease progression receive 8 mg/kg trastuzumab IV over 30-90 minutes once every 3 weeks in combination with everolimus and hormone therapy.
3240287|NCT00912327||Stage 1|
3240288|NCT00912327||Stage 2|
3240289|NCT00912314|Active Comparator|Monthly Maintenance PTNS|After 12 weeks of PTNS, patients will be randomized to either the monthly PTNS arm, or the no maintenance PTNS arm.
3240290|NCT00912314|No Intervention|No maintenance PTNS|After 12 weeks of PTNS, patients will either be randomized to the Monthly PTNS arm or the No maintenance PTNS arm.
3240291|NCT00912301|Experimental|NaCDC 500 mg|Participants randomized to this arm received 500 mg NaCDC per day for 4 days.
3240292|NCT00912301|Experimental|NaCDC 1000 mg|Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.
3240293|NCT00912301|Placebo Comparator|Placebo|Participants randomized to this arm received a placebo capsule each day for 4 days.
3240294|NCT00912288|Experimental|Dimebon|
3240295|NCT00912288|Placebo Comparator|Placebo|
3240296|NCT00912275|Experimental|Lapatinib plus Oral Vinorelbine|Oral vinorelbine on day 1 and day 8 q3w plus lapatinib 1000mg/day.
3240297|NCT00912262|Active Comparator|Low and High Concentration Capsaicin Topical Liquids|
3240298|NCT00912249|Experimental|Horticultural Therapy|
3240299|NCT00912236||1|BMI 20-25 kg/m2
3240300|NCT00912236||2|BMI > 30 kg/m2 with low TG (<150) and normal HDL (>50 for females, >40 for males)
3240301|NCT00912236||3|BMI > 30 kg/m2 with high TG (>150) and low HDL (<50 for females, <40 for males)
3240302|NCT00912223|Experimental|Hematopoietic Stem Cell Transplant|Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
3240303|NCT00912210|Active Comparator|Higher protein|
3240304|NCT00912210|Placebo Comparator|Higher carbohydrate|
3240305|NCT00912197|Experimental|Oligofructose|
3240306|NCT00912197|Placebo Comparator|Cellulose and maltodextrin|
3240307|NCT00912184|Experimental|1|CVVH with high cut-off polyamide membrane (P2SH) using standard continuous veno-venous hemofiltration (CVVH) settings
3240314|NCT00912158|Active Comparator|ST|Standard Medical therapy (ST)
3240315|NCT00912145|Experimental|1|Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)
3240316|NCT00912145|Active Comparator|2|Alprazolam Tablets, 2 mg, Xanax (The Upjohn Company)
3240317|NCT00912132||Low risk singleton cohort|Women with singleton gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2009-2013) in this prospective cohort study. A sub-set of women with and without gestational diabetes were followed up to 6 weeks postpartum. Enrollment was based upon a predefined set of criteria including medical/reproductive history and pre-pregnancy body mass index. Women with a body mass index between 19.0-29.9 kg/m2 were in the low-risk cohort.
3240318|NCT00912132||Obese cohort|Women with singleton gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2009-2013) in this prospective cohort study. A sub-set of women with and without gestational diabetes were followed up to 6 weeks postpartum. Enrollment was based upon a predefined set of criteria including medical/reproductive history and pre-pregnancy body mass index. Women with a body mass index between 30.0-44.9 kg/m2 were in the obese cohort.
3240319|NCT00912119|Experimental|Group A|Group A - Low Dose
3240320|NCT00912119|Experimental|Group B|Group B - Intermediate Dose
3240321|NCT00912119|Experimental|Group C|Group C - High Dose
3240322|NCT00912119|Experimental|Group D|Group D - Extra Low
3240323|NCT00912106||HA injection|Patients with osteoarthritis of knee. They are going to received HA injection 1 vial per week for 5 weeks.
3240324|NCT00912093|Placebo Comparator|Placebo|Single subcutaneous injection of matching placebo
3240325|NCT00912093|Experimental|Icatibant|Single subcutaneous injection of icatibant, 30 mg
3240326|NCT00912080|Experimental|good signature|"Patients who have a good signature for the genomic analysis. They will receive the standard chemotherapy."
3240327|NCT00912067||hematopoietic stem cell transplantation|
3240328|NCT00912054|Experimental|1|DuoTrav APS
3240329|NCT00912054|Active Comparator|2|Xalacom
3240330|NCT00912041|Other|BrainGate|BrainGate Neural Interface System
3240331|NCT00912028|Active Comparator|senofilcon A|contact lens
3240332|NCT00912028|Active Comparator|lotrafilcon B|contact lens
3240333|NCT00912028|Active Comparator|balafilcon A|contact lens
3240334|NCT00912028|Active Comparator|methafilcon A|contact lens
3240335|NCT00912028|Active Comparator|vifilcon A|contact lens
3240336|NCT00912015|Experimental|Tramadol OAD 200mg|
3240337|NCT00912015|Experimental|Tramadol OAD 300mg|
3240338|NCT00912015|Experimental|Tramadol OAD 400mg|
3240339|NCT00912015|Other|Tramadol OAD 100mg|Despite provision in the protocol that the minimum daily dose was 200 mg, 2 patients took 100 mg against instructions.
3240340|NCT00912002|Experimental|MK-0941|MK-0941
3240341|NCT00911989|Other|Transvaginal Sleeve Gastrectomy|Transvaginal Sleeve Gastrectomy using Steerable Flex Trocar (SFT) for transvaginal endoscope placement (endoscopic visualization)
3240342|NCT00911976|Experimental|Xience V|Implantation of the Xience V stent in saphenous vein graft lesions
3240343|NCT00911963|Experimental|Part A|This will be a 4 dose escalation study comparing VCH-222 to placebo treatment.
3240344|NCT00911963|Experimental|Part B|VCH-222 + peginterferon alfa-2a + ribavirin (12 weeks) followed by peginterferon alfa-2a + ribavirin for 36 weeks
3240345|NCT00911937|Experimental|Fesoterodine|
3240346|NCT00911937|Placebo Comparator|Placebo|
3240347|NCT00911924|Experimental|iStent|
3240348|NCT00911911|Experimental|FEC 100 + TAXOTERE|"FEC 100 = Fluoro-uracile + Epirubicin + Cyclophosphamide Fluoro-uracile : 500 mg/m²/cycle Epirubicin : 100 mg/m²/cycle Cyclophosphamide : 500 mg/m²/cyle 1 cycle = 21 days. For a total of 6 cycles or 3 cycles followed by 3 cycles of TAXOTERE~TAXOTERE 100 mg/m²/cycle~1 cycle = 21 days. For a total of 3 cycles following 3 FEC 100"
3240349|NCT00911898|Experimental|MM-111|
3240350|NCT00911885|Experimental|High Fiber Diet|A single dietary change condition that focuses exclusively on increasing fiber.
3240351|NCT00911885|Active Comparator|AHA Diet|The AHA Diet is the current recommendation for patients with the metabolic syndrome.
3240352|NCT00911872|Experimental|aging|
3240353|NCT00911859|Experimental|Part 1: VMP+Siltuximab 11 mg/kg|Siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP (Velcade+Melphalan+Prednisone). Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally (by mouth).
3240354|NCT00911859|Experimental|Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg|Siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP. Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally
3240355|NCT00911859|Active Comparator|Part 2, Arm B: VMP|Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally
3240356|NCT00911846||Buprenorphine|opioid-dependent patients with buprenorphine substitution
3240357|NCT00911846||methadone|opioid-dependent patients substituted with methadone
3240358|NCT00911846||no substitution|opioid-dependent patients without substitution
3240359|NCT00911846||therapists|therapists of the patients
3240360|NCT00911820|Active Comparator|Arm A: PCA|Patients first received bevacizumab 10 mg/kg IV on day 1 of every cycle (cycle length=21 days) at approximately 0.5 mg/kg/minute. Additionally, on days 1 and 8 of each cycle, patients received cisplatin 30 mg/m2 IV over 30 minutes and then irinotecan 65 mg/m2 IV over 30 minutes of each 3-week cycle. Treatment could continue until disease progression or unacceptable toxicity.
3240361|NCT00911820|Active Comparator|Arm B: TPCA|Patients first received bevacizumab 10 mg/kg IV on day 1 of every cycle (cycle length=21 days) at approximately 0.5 mg/kg/minute. Additionally on days 1 and 8 of each cycle, patients received docetaxel 30 mg/m2 IV over 30 minutes followed by cisplatin 25 mg/m2 IV over 30 minutes and then irinotecan 50 mg/m2 IV over 30 minutes of each 3-week cycle.
3240362|NCT00911807|Experimental|Cerebrolysin + donepezil|
3240363|NCT00911807|Experimental|Cerebrolysin + placebo|
3240364|NCT00911807|Active Comparator|Donepezil + placebo|
3240365|NCT00911794|Experimental|Written Disclosure Therapy|
3240366|NCT00911794|Sham Comparator|Controls|
3240367|NCT00911781||Infants with infantile hemangiomas|
3240368|NCT00911768|Experimental|Korean Red Ginseng group|The brand name of experimental drug is 'Capsule of Korean Red Ginseng Powder'. It consists of the powder of steamed root of Panax ginseng made by Korean Ginseng Corp.
3240369|NCT00911768|Placebo Comparator|Corn-starch powder with ginseng flavor|The placebo of this study is corn-starch powder with Korean Red Ginseng flavor. It has the same shape, color and flavor like experimental drug.
3240370|NCT00911755|Other|Laryngoscopy|
3240371|NCT00911755|Other|Videolaryngoscopy|
3240372|NCT00911742|Experimental|1 Tramadol Contramid Once A Day|
3240373|NCT00911742|Active Comparator|2 Zytram (R)|
3240374|NCT00911716|Experimental|cyclophosphamide, Docetaxel, bevacizumab|
3240375|NCT00911703||Acute heart failure|Subjects with an ED diagnosis of acute decompensated heart failure .
3240376|NCT00911690||Cognitively Impaired|Patients in this cohort with be diagnosed with mild to moderate cognitive impairment, Alzheimers disease, Dementia, or any other form of cognitive impairment.
3240377|NCT00911690||Non-cognitively impaired|Patients in this cohort will be normal healthy adults over the age of 60 years that have no cognitive impairment.
3240378|NCT00911677||Open Aortic Repair|Patients 60 years of age and older undergoing open repair of the abdominal aorta
3240379|NCT00911664|Placebo Comparator|1|
3240380|NCT00911664|Experimental|2|
3240381|NCT00911664|Experimental|3|
3240382|NCT00911651|Active Comparator|salbutamol|6 patients with moderate (GOLD 2) and severe (GOLD 3) COPD
3240383|NCT00911651|Active Comparator|ipratropium bromide|COPD patients GOLD stage II and III
3240384|NCT00911638|Experimental|1: Patient decision aid|Patient decision aid focused on treatment options for osteoarthritis of the hip or knee and preference report for surgeons. The patient decision aid used is from the Informed Medical Decisions Foundation
3240385|NCT00911638|Active Comparator|2: Usual care|Usual patient educational resources for patients undergoing hip or knee replacement surgery.
3240386|NCT00911625|Active Comparator|0.5 units/kg|Participants randomized to this arm will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
3240387|NCT00911625|Experimental|0.25 units/kg|Participants randomized to this arm will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
3240388|NCT00911612|Experimental|Colesevelam|Participants received colesevelam 1.875 g twice daily
3240389|NCT00911612|Placebo Comparator|Placebo|Participants received an inert capsule matching the study drug twice daily, as prepared by the Mayo Clinic research pharmacy
3240390|NCT00911599|Active Comparator|BFH|BFH
3240391|NCT00911599|Active Comparator|Metal with Polyethylene Liner|Metal with Polyethylene Liner
3240392|NCT00911573|Experimental|A|Tigecycline
3240393|NCT00911573|Active Comparator|B|Clindamycin (or Vancomycin if needed)
3240394|NCT00911560|Experimental|vaccine|This phase I/II trial in patients with high-risk neuroblastoma (NB) will in phase I assess the toxicity of escalating doses and in phase II the anti-NB activity of, and immune responses to, a vaccine comprised of the immunological adjuvant OPT-821 plus GD2L and GD3L covalently attached to the immunological carrier protein keyhole limpet hemocyanin (KLH) and each abundantly expressed on NB. The patients will take oral β-glucan, which augments neutrophil cytotoxicity
3240395|NCT00911547|Experimental|1|Montelukast + Beclomethasone
3240396|NCT00911547|Experimental|2|Montelukast + Placebo inhaler
3240397|NCT00911547|Experimental|3|Placebo tablet + Beclomethasone
3240398|NCT00911547|Placebo Comparator|4|Placebo tablet + Placebo inhaler
3240399|NCT00911534|Experimental|1|
3240400|NCT00911534|Placebo Comparator|2|
3240401|NCT00911521|Active Comparator|Vaccine arm|subjects receiving vaccination
3240402|NCT00911508|Active Comparator|Left Atrial Ablation|Pulmonary vein isolation using a circumferential ablative approach in the left atrium. Ablation may be performed using circular mapping catheter-guided ablation, antral isolation using a circular guided approach, or wide area circumferential ablation.
3240403|NCT00911508|Active Comparator|Rate or Rhythm Control Therapy|Current state-of-the-art drug therapy for atrial fibrillation (rate control or rhythm control). Treating physicians will be encouraged to follow the American College of Cardiology / American Heart Association / European Society of Cardiology Atrial Fibrillation Guidelines with regard to drug therapy for atrial fibrillation. The specific choice of rate control versus rhythm control drug therapy and the specific drugs to be used will ultimately be left to the discretion of the treating physician.
3240404|NCT00911495|Experimental|GMI-1070|
3240405|NCT00911482||Diabetes/weight loss|12 individuals with type 2 diabetes and hypertriglyceridemia
3240406|NCT00911482||Nondiabetic/hypertriglyceridemic|10 insulin resistant nondiabetic individuals with dyslipidemia
3240407|NCT00911482||Normotensive/nondiabetic|10 insulin resistant, normotensive, nondiabetic individuals
3240408|NCT00911482||Insulin resistant/dyslipidemic|14 insulin resistant nondiabetic individuals with dyslipidemia
3240409|NCT00911469|Experimental|1|
3240410|NCT00911469|Placebo Comparator|2|
3240411|NCT00911443|Experimental|Dacarbazine + Interferon alpha + thymosin-alpha-1 1.6 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
3240412|NCT00911443|Experimental|Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
3240413|NCT00911443|Experimental|Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
3240414|NCT00911443|Experimental|Dacarbazine + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
3240415|NCT00911443|Active Comparator|Dacarbazine + Interferon alpha|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
3240416|NCT00911404|Experimental|Low CHO|Diet with 40% total calories from carbohydrates.
3240417|NCT00911404|Active Comparator|High CHO|Diet with 55% total calories from carbohydrates.
3240418|NCT00911391|Active Comparator|Fluid restriction|Current best practice of intraoperative fluid restriction
3240419|NCT00911391|Experimental|Oesophageal Doppler|Oesophageal Doppler-guided fluid administration
3240420|NCT00911378|Active Comparator|Pressure support ventilation|Patients in this arm are weaned by gradual reduction of pressure support
3240421|NCT00911378|Active Comparator|Spontaneous breathing trials|Patients in this arm are weaned by T piece trials
3240422|NCT00911365|Placebo Comparator|normal saline|
3240423|NCT00911365|Experimental|autologous mesenchymal stem cells|
3240424|NCT00911352|Experimental|Frozen gel glove (Elasto-Gel Mitten)|Cryotherapy hand
3240425|NCT00911352|No Intervention|No frozen glove therapy|Usual care
3240426|NCT00911339|Active Comparator|Atorvastatin 10 mg|
3240427|NCT00911339|Active Comparator|Atorvastatin 80 mg|
3240428|NCT00911313|Experimental|Letrozole|
3240429|NCT00911313|Active Comparator|Metformin-CC|
3240430|NCT00911300|Active Comparator|Arm 1: fondaparinux|
3240431|NCT00911300|Active Comparator|Arm 2: unfractionated heparin + Vitamin-K-Antagonist|
3240432|NCT00911287|Experimental|Single Arm|
3240433|NCT00911274|Experimental|Test (mycophenolate mofetil) First|Mycophenolate Mofetil 250 mg Capsule dosed in first period followed by CellCept® 250 mg Capsule dosed in second period.
3240434|NCT00911274|Active Comparator|Reference (CellCept®) First|CellCept® 250 mg Capsule dosed in first period followed by Mycophenolate Mofetil 250 mg Capsule dosed in second period.
3240435|NCT00911261|Experimental|Single Arm|
3240436|NCT00911248|Experimental|PTC299|PTC299 administered at 100 mg/dose twice per day
3240437|NCT00911235|Experimental|Fesoterodine Alone|Reference treatment
3240438|NCT00911235|Other|fesoterodine plus fluconazole|Test treatment
3240439|NCT00911222||antiemetic treatment|epidemiological registry
3240440|NCT00911209|Experimental|Intervention|The Intervention group at each session will receive information on Heart healthy diet, lifestyle recommendations and diet and exercise counseling with a dietitian in order to achieve at least 7% weight loss (for example a person weighing 200 pounds will be encourage to lose at least 14 pounds).
3240441|NCT00911209|No Intervention|No Intervention|The standard of care group will receive information on Heart healthy diet at baseline visit and will return to a final visit about 28 weeks later.
3240442|NCT00911196||Group A|
3240443|NCT00911183|Experimental|Arm I (R-COP regimen)|Patients receive rituximab IV, cyclophosphamide IV, and vincristine sulfate IV on day 1. Patients also receive oral prednisone on days 1-5 and filgrastim subcutaneously (SC) on days 8-14 or pegfilgrastim SC on day 2. Treatment repeats every 21 days for at least 3 courses.
3240444|NCT00911183|Experimental|Arm II (R-COPY regimen)|Patients receive rituximab, cyclophosphamide, vincristine sulfate, prednisone, and filgrastim or pegfilgrastim as in arm I. Patients also receive liposome-encapsulated doxorubicin citrate IV on day 1. Treatment repeats every 21 days for at least 3 courses.
3240445|NCT00911170|Placebo Comparator|Placebo|Participants received standard chemotherapy (FOLFOX or FOLFIRI) on Days 1-2, and bevacizumab 5 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle plus placebo subcutaneous injection once per cycle, for a maximum of 4 cycles, 24 hours after chemotherapy (Day 4).
3240446|NCT00911170|Placebo Comparator|Pegfilgrastim|Participants received standard chemotherapy (FOLFOX or FOLFIRI) on Days 1-2 and bevacizumab 5 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle plus pegfilgrastim 6 mg administered as a single subcutaneous injection once per cycle, for a maximum of 4 cycles, 24 hours after chemotherapy (Day 4).
3240447|NCT00911157|Experimental|Fondaparinux|
3240448|NCT00911157|Other|unfractionated heparin|
3240449|NCT00911144|Experimental|Synflorix Group|Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.
3240450|NCT00911144|Active Comparator|Prevenar Group|Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.
3240451|NCT00911131|Active Comparator|Screening esophagoduodenoscopy (EGD)|"EGD will be performed utilizing conscious sedation. During EGD, the endoscopist will capture pictures of the esophageal body, Z-line, lower esophagus and proximal gastric folds. Grading of esophageal varices will be performed by all investigators using the Italian Liver cirrhosis project.~Patients who are found to have small grade varices and meet the inclusion and exclusion criteria will be enrolled in the study."
3240452|NCT00911131|Active Comparator|Capsule Endoscopy|The capsule endoscope will be swallowed by the participant with 100cc of water and simethicone in the supine position. Recording is done for 2 minute in this position and then the head will be elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient will sip10cc of water and after 15 seconds, they will sit upright and sip water again. They can then walk and resume normal activity for 15 minutes. The videos will be reviewed and graded by a gastroenterologist experienced with capsule endoscopy and will be blinded to the patient's clinical and procedural history as well as the most recent EGD. The varices will be graded using the Given Imaging software that grades varices as no varices (C0), small varices or < 25% of esophageal circumference (C1), and large varices or > 25% of esophageal circumference (C2).
3240453|NCT00911131|Active Comparator|Capsule Endoscopy with abdominal binder|Before swallowing the capsule endoscope, an inflatable girdle is wrapped around the waist above the umbilicus and held in place by a an abdominal binder. The pressure is increased by 10mmHg for 10 minutes. The PillCam ESO is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.
3240454|NCT00911118|Experimental|Radiation|Patients enrolled in the study will undergo image-guided, intensity-modulated radiotherapy using the same equipment, techniques, and treatment-planning procedures as currently practiced as MSKCC. MSKCC patients will have the option of continued follow-up through MSKCC's established Prostate Survivorship Clinic for an indefinite period of time, meaning patients enrolled in the protocol will be encouraged to remain at MSKCC for life-long follow-up after their treatment. The standard assessments obtained in the Survivorship Clinic will not be altered. All protocol relevant data collected at these visits through month 60 will be used for protocol analysis.
3240455|NCT00911105||Patients with multiple myeloma|Patients with multiple myeloma receiving second line therapy or higher.
3240456|NCT00911079|Experimental|Hyperthermia with HDR brachytherapy|Hyperthermia will be delivered within approximately 2 hours of (HDR) brachytherapy associated with the implant session
3240457|NCT00911066|Experimental|MLN4924|
3240458|NCT00911066|Experimental|Azacitidine|
3240459|NCT00911053|No Intervention|Baseline|
3240460|NCT00911053|Experimental|Melatonin|Subjects will be administered melatonin.
3240461|NCT00911053|Experimental|Light|
3240462|NCT00911053|Experimental|Regular Sleep Schedule|
3240463|NCT00911053|No Intervention|Longitudinal Monitoring|Optional longitudinal study, an extension of the first study stage, for subjects whose rhythms are not clearly free-running.
3240464|NCT00911027|Experimental|SonoVue guided biopsy|
3240465|NCT00911027|Other|Systematic biopsy|
3240466|NCT00911014||Vesicovaginal fistula repair|Women undergoing repair of vesicovaginal fistula
3240467|NCT00911001||Group 1|
3240468|NCT00910988|Active Comparator|olanzapine|olanzapine injection in healthy control
3240469|NCT00910988|Active Comparator|ziprasidone|ziprasidone injection in healthy control
3240470|NCT00910988|Placebo Comparator|saline|saline injection in healthy control
3240471|NCT00910975|Active Comparator|Standard of care|Treatment with Pegasys 180 µg/week and ribavirin 1000/1200 mg per day. Treatment is given for 24, 48 or 72 weeks depending on the time point (week 4, 12 or 24) when HCV RNA becomes undetectable by the Cobas Taqman assay. If HCV RNA has not declined 2 logs by week 12 or is detectable at week 24, treatment is stopped.
3240472|NCT00910975|Experimental|Tailored treatment|Treatment with Pegasys 180 µg/week and ribavirin 1000/1200 mg per day. Treatment duration is flexible, 24-72 weeks, depending on the time point when the HCV RNA level is calculated to be 1 copy/mL. If the decline between day 14 and 28 is poor, treatment is stopped after 5 weeks.
3240473|NCT00910962|Experimental|Treatment A|7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg twice daily for 12 weeks
3240474|NCT00910962|Experimental|Treatment B|15 mg GW856553 starting dose, followed 12 hours later by 7.5mg twice daily for 12 weeks
3240475|NCT00910962|Placebo Comparator|Treatment C|Placebo twice daily for 12 weeks
3240476|NCT00910949||Painfree|Thoracotomy patients without chronic pain
3240477|NCT00910949||With Pain|Thoracotomy patients with chronic pain
3240478|NCT00910936|Experimental|Intervention|
3240479|NCT00910936|No Intervention|Control|
3240480|NCT00910910|Experimental|1 - Lenalidomide|1 - Lenalidomide
3240481|NCT00910910|Active Comparator|2- Chlorambucil|2- Chlorambucil
3240482|NCT00910897|Active Comparator|Velcade-Dexamethasone|
3240483|NCT00910897|Active Comparator|Velcade-Thalidomide-Dexamethasone|
3240484|NCT00910884||Arm I|Patients receive oral natural supplements comprising indole-3-carbinol, perillyl alcohol, glucuronic acid, and flavonoids daily for 12 months. Patients also consume whole foods comprising indole-3-carbinol and a diet that eliminates exogenous growth hormones.
3240485|NCT00910884||Arm II|Patients do not receive natural supplements or consume whole foods or a special diet.
3240486|NCT00910871|Experimental|TMC207|TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks in addition to Background Regimen (BR) for the treatment of multi-drug resistant tuberculosis (MDR-TB).
3240487|NCT00910858|Experimental|10 mg Lenalidomide|"Participants in the Pharmacokinetic Phase received a single 10 mg oral dose of lenalidomide on Day -7. During the Monotherapy Phase participants received 10 mg oral lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or erythroid failure.~During the Combined Treatment Phase participants who were erythroid nonresponders and erythroid responders who had developed an erythroid relapse continued treatment with 10 mg lenalidomide in conjunction with recombinant human erythropoietin (rhu EPO) 40,000 units administered weekly by subcutaneous injection for 8 weeks. Responding patients could continue combined treatment."
3240488|NCT00910858|Experimental|15 mg Lenalidomide Non-del 5q|Following the enrollment of the first 25 patients into the Monotherapy Phase, a second group of 15 patients with low- or intermediate-1-risk MDS not associated with a del 5q (non-del 5q) cytogenetic abnormality were enrolled to receive 15 mg of lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or erythroid failure. During the Combined Treatment Phase participants who were erythroid nonresponders and erythroid responders who had developed an erythroid relapse continued treatment with 15 mg lenalidomide in conjunction with recombinant human erythropoietin (rhu EPO) 40,000 units administered weekly by subcutaneous injection for 8 weeks. Responding patients could continue combined treatment.
3240489|NCT00910845|Experimental|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
3240490|NCT00910845|Other|placebo/onabotulinumtoxinA|Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).
3240491|NCT00910832|Experimental|Eductyl suppository|
3240492|NCT00910832|Placebo Comparator|Placebo suppository|
3240493|NCT00910806|Experimental|TMC207, nevirapine|
3240494|NCT00910793|Other|Inuvair|
3240495|NCT00910780|Active Comparator|Staying on Risperdal|
3240496|NCT00910780|Active Comparator|Risperdal switched to Abilify|
3240497|NCT00910780|Active Comparator|Staying on Zyprexa|
3240498|NCT00910780|Active Comparator|Zyprexa switched to Abilify|
3240499|NCT00910767|Experimental|Closed loop (algorithm)|
3240500|NCT00910767|Placebo Comparator|Open loop|
3240501|NCT00910754|Experimental|Abiraterone acetate|Patients will take 1000 mg of abiraterone acetate once daily plus prednisone 5 mg twice daily orally (by mouth) until disease progression.
3240502|NCT00910741|Experimental|Nanoplatin|"Nanoplatin (NC-6004) had to be administered once every 3 weeks, on Day 1, Day 22 and Day 43 etc.~Gemcitabine had to be administered to every patient 2 times on Day 1 and Day 8 every 3 weeks after the infusion of Nanoplatin (NC-6004)."
3240503|NCT00910728|Experimental|1|AZD1480
3240504|NCT00910715|Active Comparator|EM-10 days doxycycline|
3240505|NCT00910715|Active Comparator|EM-doxycycline 15 days|
3240506|NCT00910715|Placebo Comparator|controls|
3240507|NCT00910702|Experimental|FCVB team|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB)
3240508|NCT00910689|Placebo Comparator|1|Optimal Acute Therapy plus Beta Blocker Placebo
3240509|NCT00910689|Active Comparator|2|Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)
3240510|NCT00910689|Active Comparator|3|Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker placebo
3240511|NCT00910689|Active Comparator|4|Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)
3240512|NCT00910676|Experimental|DIPROSONE|
3240513|NCT00910663|Experimental|Test (mycophenolate mofetil) First|Mycophenolate Mofetil 250 mg Capsule dosed in first period followed by Cellcept® 250 mg Capsule dosed in second period.
3240514|NCT00910663|Active Comparator|Reference (CellCept®) First|CellCept® 250 mg Capsule dosed in first period followed by Mycophenolate Mofetil 250 mg Capsule dosed in second period.
3240515|NCT00910650|Experimental|F5 TCR transgenic cells|F5 TCR transgenic cell adoptive transfer therapy
3240516|NCT00910637|Experimental|Arm 1|
3240517|NCT00910624|Experimental|BOC + PEG/RBV|Participants who enrolled within 2 weeks after the last dose of PEG/RBV in previous protocol received boceprevir (BOC) + peginterferon/ribavirin (PEG/RBV) for up to 44 weeks followed by 24 weeks post-treatment follow-up. Participants who did not enroll within 2 weeks after the last dose of PEG/RBV in previous protocol received PEG/RBV for 4 weeks followed by BOC + PEG/RBV for up to 44 weeks, with 24 weeks post-treatment follow-up.
3240518|NCT00910611|No Intervention|Standard Care|Immunizations given with standard care of no pain control
3240519|NCT00910611|Experimental|Buzzy|Vibrating device with cold pack held to arm proximal to injections
3240520|NCT00910598|Experimental|glatiramer acetate|glatiramer acetate 20 mg s.c. daily for 1 year
3240521|NCT00910598|No Intervention|no treatment|No disease modifying treatment allowed
3240522|NCT00910585|Experimental|Active coaching|Telephone and in person coaching
3240523|NCT00910585|Active Comparator|Usual care|Return to PCP for usual care
3240524|NCT00910546|Experimental|Implantation of gold marker|CT guided implantation of gold marker into early stage lung tumors. Extra 4DCT scans and fluoroscopies during planning and the 3 fraction radiotherapy course.
3240525|NCT00910533|Active Comparator|Early Lyme neuroborreliosis patients|
3240526|NCT00910533|No Intervention|control subjects|Control subjects without a history of Lyme borreliosis.
3240527|NCT00910520|Experimental|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
3240528|NCT00910520|Other|placebo/onabotulinumtoxinA|Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).
3240529|NCT00910507|Experimental|Exercise counseling|Each participant in the experimental group receives exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
3240530|NCT00910507|Active Comparator|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
3240531|NCT00910494|Experimental|12 Gray IORT|
3240532|NCT00910494|Experimental|15 Gray IORT|
3240533|NCT00910481|Experimental|Elective IABP Insertion|
3240534|NCT00910481|No Intervention|No Planned IABP Insertion|
3240535|NCT00910468||Robot Assisted Laparoscopic Myomectomy|
3240536|NCT00910468||Myomectomy via Laparotomy|
3240537|NCT00910455|Experimental|Active|Single oral dose of SRX246 capsule
3240538|NCT00910455|Placebo Comparator|Placebo|Single oral dose of placebo capsule
3240539|NCT00910442|Experimental|Patient Group|Dietary supplement:N-acetylcysteine 1g/day and Glutamine 20g/day for 7 consecutive days. The dietary supplements were intermediated by 7 days of washout with usual diet.
3240540|NCT00910442|Active Comparator|Control Group|Healthy HIV negative subjects submitted to the same dietary supplement than experimental group: N-acetylcysteine 1g/day and Glutamine 20g/day for 7 consecutive days. The dietary supplements were intermediated by 7 days of washout with usual diet.
3240541|NCT00910429|Experimental|Arm 1|
3240542|NCT00910416||patients receiving iv anesthesia|
3240543|NCT00910416||patients receiving balanced anesthesia|
3240544|NCT00910390|Placebo Comparator|Slow Freezing|Standard freezing protocol (slow freezing) of preimplantation embryos
3240545|NCT00910390|Experimental|VIT-Irvine|Vitrification with Irvine solution (rapid freezing) of preimplantation embryos
3240546|NCT00910390|Experimental|VIT-Vitrolife|Vitrification (rapid freezing) with Vitrolife solution
3240547|NCT00910377|Experimental|visit with grandmother|Teenagers mothers and their grandmothers receive counseling sessions about breastfeeding and complementary feeding.
3240548|NCT00910377|Experimental|visit without grandmother|Teenagers mothers don´t live with their grandmothers and receive counseling sessions about breastfeeding and complementary feeding.
3240631|NCT00909766|Placebo Comparator|Panel H|
3240549|NCT00910377|No Intervention|no visit with grandmother|Teenagers mothers live with their grandmothers and don´t receive counseling sessions about breastfeeding and complementary feeding.
3240550|NCT00910377|No Intervention|no visit without grandmother|Teenagers mothers don´t live with their grandmothers and don´t receive counseling sessions about breastfeeding and complementary feeding.
3240551|NCT00910364|Experimental|Exercise testing|Feasibility study; all participants receive intervention
3240552|NCT00910351|Experimental|Arm 1|
3240553|NCT00910338|Experimental|PFMT with Extracorporeal Biobeedback|
3240554|NCT00910312|Experimental|Breast Fibroadenoma|
3240555|NCT00910299|Experimental|Prasugrel|
3240556|NCT00910299|Active Comparator|Clopidogrel|
3240557|NCT00910286|Other|VENTILATOR WEANING|Two ventilators with different flow termination criteria (TC) were compared: Servo 300 (Siemens-Elema, Sweden) with fixed TC (5% of peak inspiratory flow) and Newport E500 (Newport Medical Instruments, CA) with automatic TC (varies between 5% to 55%). Each patient remained three hours in the protocol, one hour in each ventilator, after been randomized to one of two sequences of 3 steps: Fixed 5% / Automatic / Fixed 5% or Automatic / Fixed 5% / Automatic . The PS, the positive end expiratory pressure (PEEP), the inspiratory oxygen fraction (FiO2) and the pressure trigger sensitivity levels were unchanged during the protocol.
3240558|NCT00910273|Experimental|1|etanercept 50 mg/week
3240559|NCT00910247|Experimental|eslicarbazepine acetate|Open-label treatment with eslicarbazepine acetate will be at doses between 800 and 2400 mg QD
3240560|NCT00910234|Active Comparator|Drug: rhEpo, low dose|rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
3240561|NCT00910234|Active Comparator|Drug: rhEpo, high dose|rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
3240562|NCT00910234|Placebo Comparator|Control Normal saline|normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
3240563|NCT00910221|Active Comparator|1|
3240564|NCT00910221|Placebo Comparator|2|
3240565|NCT00910208|Experimental|PCA 1 mg demand dose|0.1 mg/kg morphine loading dose followed by PCA with 1.0 mg morphine demand dosing every 6 minutes
3240566|NCT00910208|Experimental|PCA 1.5 mg demand dose|0.1 mg/kg morphine loading dose followed by PCA with 1.5 mg morphine demand dosing every 6 minutes
3240567|NCT00910208|Active Comparator|Non-PCA comparison group|0.1 mg/kg morphine loading dose followed by additional analgesia supplemented as needed at the discretion of the treating physician, using usual procedures for monitoring and treating pain.
3240568|NCT00910195|Experimental|CPAP before Bi-Level-APAP|receiving CPAP treatment during the first night and then Bi-level-APAP treatment during second night
3240569|NCT00910195|Experimental|Bi-Level-APAP before CPAP|receiving Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
3240570|NCT00910182||1|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 and treated non-operatively
3240571|NCT00910182||2|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 who underwent emergency surgical treatment
3240572|NCT00910182||3|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 treated non-operatively plus transcatheter arterial embolisation
3240573|NCT00910169||inpatient treatment|naturalistic treatment no modification: observational study
3240574|NCT00910156|Active Comparator|Airtraq|
3240575|NCT00910156|Active Comparator|Glidescope|
3240576|NCT00910156|Active Comparator|Macintosh|
3240577|NCT00910143||1|patients operated before summer 1995, that is before the introduction of TME
3240578|NCT00910143||2|patients operated after summer 1995, that is after the introduction of TME.
3240579|NCT00910130||End Stage Renal Disease|Patients suffering from End Stage Renal Disease on Hemodialysis, without Diabetes
3240580|NCT00910130||Control|"Healthy people, with normal Renal Function and without Diabetes, matched with ESRD group for age, gender, BMI"
3240581|NCT00910117|Experimental|nimotuzumab|nimotuzumab plus PF regimen
3240582|NCT00910104|Experimental|Omegaven|1g/kg/day for duration of study participation for all participants
3240583|NCT00910091|Experimental|A- BN 83495- 40mg|After eligibility is confirmed, subjects will be randomised at baseline. The randomisation number and associated treatment for the total study will be allocated by an Interactive Voice Response System (IVRS) service
3240584|NCT00910091|Active Comparator|B- MA - 160mg|After eligibility is confirmed, subjects will be randomised at baseline. The randomisation number and associated treatment for the total study will be allocated by an Interactive Voice Response System (IVRS) service
3240585|NCT00910065|Experimental|Arm 1|
3240586|NCT00910065|Experimental|Arm 2|
3240587|NCT00910065|Active Comparator|Arm 3|
3240588|NCT00910052|Experimental|Fibrin sealant|received intraoperative fibrin sealant
3240589|NCT00910052|No Intervention|Control|No fibrin sealant
3240590|NCT00910039|Experimental|Sunitinib malate|"Oral sunitinib malate once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.~Patients undergo neuropsychological battery testing at baseline and periodically during study to assess cognitive function (memory, verbal fluency, visual-motor speed, executive function, and motor dexterity), activities of daily living, and quality of life."
3240591|NCT00910026|Experimental|low tidal volume ventilation|6 ml/kg tidal volume ventilation
3240592|NCT00910026|Experimental|high tidal volume ventilation|12 ml/kg tidal volume ventilation
3240593|NCT00910013|Experimental|Ropivacaine + femoral block|After the surgery is proceeded and after the closure of the joint capsule, 20 cc of ropivacaine 0.5% is inserted intra-articular through a catheter.
3240594|NCT00910000|Experimental|Dose Level 1A|"Vorinostat: 200 mg taken orally once a day for the first two weeks of each three-week cycle~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle~Gemcitabine: 100 mg/m2, given intravenously on day 1 and day 8 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
3240595|NCT00910000|Experimental|Dose Level 2A|"Vorinostat: 300mg, taken orally once a day for the first two weeks of each three-week cycle~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 1 and day 8 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
3240596|NCT00910000|Experimental|Dose Level 1B|"Vorinostat: 200mg, taken orally twice a day for days 1-3 and days 8-10 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 1 and day 8 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
3240597|NCT00910000|Experimental|Dose Level 1C|"Vorinostat: 200mg, taken orally twice a day for days 1, 2, 8 and 9 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
3240598|NCT00910000|Experimental|Dose Level 1D|"Vorinostat: 300mg, taken orally once a day for days 1 and 2 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
3240599|NCT00910000|Experimental|Dose Level 2D|"Vorinostat: 400mg, taken orally once a day for days 1 and 2 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
3240600|NCT00909987|Experimental|Single arm|"Neoadyuvant chemotherapy with XELOX: Xeloda 1000mg/m2/12h dayly, day one in the afternoon until day 15 in the morning; plus oxaliplatin 130mg/m2 (day 1); and Bevacizumab 7.5 mg/kg (day 1)during 3 cycles (each cycle of 3 weeks).~Followed by a selective use of chemoradiotherapy with radiotherapy (50.4Gy, 28 sesions of 1.8Gy during 5 weeks) plus Xeloda 825mg/m2/12h dayly."
3240601|NCT00909974|Experimental|Food supplement (FS)|Recipe of food supplement: 33% peanut butter, 32% soy flour, 15% vegetable oil, 20% sugar, UNIMMAP in powdered form Nutritional composition (per dose of 72g) Energy 1.56 MJ, protein 14.7 g, vitamin A 881 µg, vitamin E 13 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 21 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 461 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
3240602|NCT00909974|Active Comparator|UNIMMAP|UNIMMAPin tablet form: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
3240603|NCT00909961|Experimental|Zoledronic acid|
3240604|NCT00909948|Active Comparator|Fludarabine|The patients in this cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
3240605|NCT00909948|Active Comparator|TBI only|Patients will be given 200 centiGray (cGy) total body irradiation (TBI) in one fraction. TBI will be given on day 0, 4 to 6 hours prior to HCT.
3240606|NCT00909922||Lower Limb Amputees|Unilateral Above knee amputees
3240607|NCT00909909|Active Comparator|A|3DCRT/IMRT lumpectomy bed boost followed by accelerated whole breast irradiation (AWBI)
3240608|NCT00909909|Active Comparator|B|Accelerated whole breast irradiation (AWBI) followed by 3DCRT/IMRT lumpectomy bed boost
3240609|NCT00909896||Robotic Surgery candidates|Group of patients receive Robotic approach for endometrial cancer staging
3240610|NCT00909896||Open Laparotomy Surgical Candidates|Patients receiving open laparotomy for endometrial cancer surgical staging
3240611|NCT00909870|Experimental|1|Weekly applications of Dermagraft and compression dressings, in combination with systematic surgical wound debridement.
3240612|NCT00909870|Active Comparator|2|Weekly application of compression dressings only, in combination with systematic surgical wound debridement.
3240613|NCT00909857|Experimental|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one tablet SH T00658ID (BAY86-5027) plus one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles
3240614|NCT00909857|Active Comparator|Ethinyl estradiol, Levonorgestrel (Miranova)|Daily oral administration of one tablet placebo plus one tablet SH D593B (Miranova) for 28 days without tablet-free interval for 3 treatment cycles
3240615|NCT00909844|Experimental|Triptorelin|
3240616|NCT00909818|Active Comparator|standard fractionated radiotherapy|50 Gy/25 fractions, 2.00 Gy/fraction, 5 fractions per week
3240617|NCT00909818|Experimental|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
3240618|NCT00909805|Experimental|Cutaneous suture with glue|Inguinal surgical incision closing using Dermabond® glue instead of cutaneous suture with surjet
3240619|NCT00909805|Active Comparator|Conventional suture|Inguinal surgical incision closing with conventional cutaneous suture (surjet)
3240620|NCT00909792|Other|Lotrafilcon B / Senofilcon A|Lotrafilcon B, followed by Senofilcon A
3240621|NCT00909792|Other|Senofilcon A / Lotrafilcon B|Senofilcon A, followed by Lotrafilcon B
3240622|NCT00909779|Experimental|Arformoterol 15 mcg twice daily|Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.
3240623|NCT00909779|Placebo Comparator|Placebo twice daily|Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.
3240624|NCT00909766|Active Comparator|Panel A|
3240625|NCT00909766|Active Comparator|Panel B|
3240626|NCT00909766|Active Comparator|Panel C|
3240627|NCT00909766|Active Comparator|Panel D|
3240628|NCT00909766|Active Comparator|Panel E|
3240629|NCT00909766|Active Comparator|Panel F|Low Dose
3240630|NCT00909766|Active Comparator|Panel G|High Dose
3240632|NCT00909753|Experimental|Ursodiol (test) First|Ursodiol Tablets, 500 mg
3240633|NCT00909753|Active Comparator|Urso Forte™ (reference) First|Urso Forte™ Tablets, 500 mg
3240634|NCT00909740|Experimental|1|
3240635|NCT00909727|Placebo Comparator|Placebo|Subjects who received placebo every 12 hours (q12h) for up to 48 weeks.
3240636|NCT00909727|Experimental|150 mg Ivacaftor q12h|Subjects who received 150 mg of ivacaftor q12h for up to 48 weeks.
3240637|NCT00909714|Experimental|Anodal tDCS|Direct Current (DC)-Stimulator to apply tDCS + Training
3240638|NCT00909714|Sham Comparator|Sham tDCS|Direct Current (DC)-Stimulator to apply Sham tDCS (Placebo) + Training
3240639|NCT00909701|Experimental|Test|PreOP Booster (Fresenius Kabi, Bad Homburg, Germany)
3240640|NCT00909701|Active Comparator|Comparator|PreOP (Nutricia Clinical Care, Trowbridge, UK)
3240641|NCT00909688|Experimental|1|BLI-489
3240642|NCT00909688|Placebo Comparator|2|placebo
3240643|NCT00909662||Patients|Female patients with operable breast cancer intending to undergo adjuvant chemotherapy
3240644|NCT00909662||Participants|Female control subjects will be recruited, consisting predominantly of age-matched (i.e.+/- 10 years of age) friends or family members of the patients.
3240645|NCT00909649|Active Comparator|1 fibrin glue|8 ml of fibrin glue was sprayed on the surgical area with Y canula ( doubleject application system).One milliliter of fibrin glue contains 70-100 mg. fibrinogen, 10-50 u factor 8 aprotinin 3000k iu/ml, 2-9 mg fibronectin,40-120 ug plasminogen ,4 Iu/ml thrombin, 40 mmol cocl2/L (immuno AG/austrial)
3240646|NCT00909649|No Intervention|2 non fibrin glue|after good haemostasis the same sized drain was applied in axillary and breast area and incision was closed. Followed by external compression for 10 minutes in both groups. Drains were left in places until the drainage for the preceding 24 h was less than 20 ml.
3240647|NCT00909636|Active Comparator|1. ABT-333 Tablet|Three 400mg ABT-333 Tablets, BID
3240648|NCT00909636|Active Comparator|2. ABT-333 Tablet|Four 400mg ABT-333 Tablets, BID
3240649|NCT00909636|Placebo Comparator|3. Placebo|Three or four placebo tablets, BID
3240650|NCT00909610|Experimental|Ursodiol (test) First|Ursodiol Tablets, 500 mg (test) dosed in first period followed by Urso Forte™ Tablets, 500 mg dosed in second period.
3240651|NCT00909610|Active Comparator|Urso Forte™ (reference) First|Urso Forte™ Tablets, 500 mg (reference) dosed in first period followed by Ursodiol Tablets, 500 mg (test) dosed in second period.
3240652|NCT00909597|Active Comparator|pioglitazone|
3240653|NCT00909597|Experimental|taspoglutide 10mg|taspoglutide 10mg sc weekly
3240654|NCT00909597|Experimental|taspoglutide 10mg/20mg|taspoglutide 20mg sc weekly after 4 weeks of taspoglutide 10mg sc weekly
3240655|NCT00909584|Experimental|1|4-Week dose equilibration period with Telintra followed by 4 month treatment period
3240656|NCT00909584|No Intervention|2|4 Month observation period with standard of care treatment and option to crossover to Telintra treatment for 4 week dose equilibration followed by 4 week treatment period
3240657|NCT00909571|Experimental|1. FK506E high dose group|
3240658|NCT00909571|Experimental|2. FK506E low dose group|
3240659|NCT00909545|Active Comparator|Isradipine CR 5mg|Isradipine CR 5mg/day
3240660|NCT00909545|Active Comparator|Isradipine CR 10mg|Isradipine CR 10mg/day
3240661|NCT00909545|Active Comparator|Isradipine CR 20mg|Isradipine CR 20mg/day
3240662|NCT00909545|Placebo Comparator|Placebo|Placebo
3240663|NCT00909532|Placebo Comparator|Placebo|Subjects who received placebo every 12 hours (q12h) for up to 48 weeks.
3240664|NCT00909532|Experimental|150 mg Ivacaftor q12h|Subjects who received 150 mg of ivacaftor q12h for up to 48 weeks.
3240665|NCT00909519|Active Comparator|naproxen|
3240666|NCT00909519|Experimental|naproxcinod|
3240667|NCT00909519|Placebo Comparator|placebo|
3240668|NCT00909506|Placebo Comparator|Placebo|Placebo
3240669|NCT00909506|Active Comparator|Metformin 500 mg/d|Metformin 500 mg/d
3240670|NCT00909506|Active Comparator|Metformin 1000 mg/d|Metformin 1000 mg/d
3240671|NCT00909493|Experimental|Access to Pain Specialist|Network
3240672|NCT00909480|Experimental|IDet|Individually adjusted insulin detemir once daily + metformin at least 1500 mg/day
3240673|NCT00909480|Active Comparator|IGlar|Individually adjusted insulin glargine once daily + metformin at least 1500 mg/day
3240674|NCT00909467||myeloproliferative, -dysplastic disease|
3240675|NCT00909454|Experimental|Daily 2000 IU vitamin D supplement|
3240676|NCT00909454|Active Comparator|Daily Vitamin D supplement 400 IU|
3240677|NCT00909441|Experimental|SNB + ALND|Intervention: Sentinel Lymph Node Biopsy followed by Axillary Node Dissection.
3240678|NCT00909428|Experimental|Solifenacin Succinate|The intervention for this study is 10mg daily solifenacin. Patients with overactive bladder syndrome will take this study drug for 30 days.
3240679|NCT00909402|Experimental|All Subjects|
3240680|NCT00909389||Filipino Patients with Hypercholesterolemia|
3240681|NCT00909376||1 - transabdominal sonography|Women who will have a transabdominal sonography done in the early second trimester.
3240682|NCT00909376||2 - transvaginal sonography|Women who will have a transvaginal sonography done in the early second trimester.
3240683|NCT00909363|Experimental|Promacta|Promacta® is commercially available in 12.5 mg, 25 mg, 50 mg, and 75 mg tablets. For this study, for young children unable to swallow a tablet, eltrombopag powder for oral suspension (Eltrombopag PfOS) will be used. PfOS is only available for investigational use at 20mg. Each sachet contains eltrombopag equivalent to 20mg per gm of powder and is reconstituted to a total of 10 ml so that the concentration is 2 mg/ml.
3240684|NCT00909350||No treatment|genetic research project; to meet inclusion criteria, participants must have normal upper GI tract upon upper endoscopy, for study biopsies to be taken
3240685|NCT00909337|Other|Bosentan|"In this study, all participants have normal pulmonary arterial pressure at rest and elevated pulmonary arterial pressure during exercise. First, they were followed up for a year and were controlled after 1 year without specific therapy for pulmonary hypertension. Then Bosentan was introduced. A second control showing the effects of the therapy was done after 6 months. The changes in the therapy period can be compared with the changes in the follow up period."
3240686|NCT00909324|Experimental|Pre-LASIK 0.3% hypromellose|
3240687|NCT00909324|Active Comparator|Post-LASIK 0.3% hypromellose|
3240688|NCT00909311|Active Comparator|1|Non-fasting
3240689|NCT00909311|Active Comparator|2|Fasting
3240690|NCT00909298|Experimental|1|TTP889 300 mg
3240691|NCT00909298|Placebo Comparator|2|TTP889 Placebo
3240692|NCT00909285|Experimental|Treatment Group (#1)|
3240693|NCT00909285|Sham Comparator|Control group (#2)|
3240694|NCT00909272||US-guided lumbar medial branch block|Patients who have low back pain and/or leg pain due to possible lumbar facet joint disease .
3240695|NCT00909272||Cadavers for Ultrasound landmarks|Cadavers donated to the Department of Anatomy in McMaster University will be used to determine the landmarks for ultrasound.
3240696|NCT00909259|Experimental|Phrenic Stimulation|
3240697|NCT00909233||Group 1|
3240698|NCT00909220||Current Major Depressive Disorder|Forty-one participants with a primary diagnosis of major depression using the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV) and scores > 24 on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-C; Rush et al., 1986) were enrolled into a treatment study at Northwestern University's Feinberg School of Medicine in Chicago, Illinois. This group will receive Behavioral Activation psychotherapy.
3240699|NCT00909220||Healthy Participants|Another 36 participants with no lifetime psychiatric symptoms and scores < 11 on the IDS-C were tracked prospectively, naturalistically, for 16 weeks.
3240700|NCT00909207||Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
3240701|NCT00909194|Experimental|Intervention|Educational Seminar on Juvenile Primary Fibromyalgia Syndrome and CD-guided total body relaxation technique
3240702|NCT00909194|No Intervention|Control|Control Arm consisted of an educational seminar on skin care
3240703|NCT00909181|Experimental|Oxybutynin Gel 56 mg/day|
3240704|NCT00909181|Experimental|Oxybutynin Gel 84 mg/day|
3240705|NCT00909181|Placebo Comparator|Placebo Gel|
3240706|NCT00909168|Experimental|Efficacy of FLAIMy|
3240707|NCT00909155|Active Comparator|Depressed; Venlafaxine treatment|Currently depressed subjects; Randomized medication treatment with Venlafaxine extended release tablets (Venlafaxine ERT). Dosage 75-300mg/day for up to 6 months.
3240708|NCT00909155|Active Comparator|Depressed; Fluoxetine treatment|Currently depressed subjects; Randomized medication treatment with Fluoxetine tablets. Dosage 20-80mg/day for up to 6 months.
3240709|NCT00909155|No Intervention|Control|Non-psychiatric subjects with no past or current history of depression. Subjects will receive no medication
3240710|NCT00909142||Group1|
3240711|NCT00909129|Experimental|HIV-1 HCV coinfected patients|HIV-1 HCV coinfected patients undergoing HCV therapy
3240712|NCT00909116||Chronic constipation - ODS|Adult Patients with ODS
3240713|NCT00909103||Pancreatic adenocarcinoma|Patients diagnosed with solid pancreatic adenocarcinoma masses, with cytological / histological confirmation
3240714|NCT00909103||Chronic pancreatitis|Patients diagnosed with solid pancreatic tumor masses with all the criteria fulfilled to exclude pancreatic cancer
3240715|NCT00909090|Active Comparator|LZ supplement|Lutein and zeaxanthin supplementation (12mg/day) will be compared to a placebo control for a one year duration.
3240716|NCT00909090|Placebo Comparator|Placebo|Lutein and zeaxanthin supplementation (12mg/day) will be compared to a placebo control for a one year duration.
3240717|NCT00909077|Active Comparator|1|Combination therapy with Dexamethasone and Rituximab
3240718|NCT00909077|Active Comparator|2|Dexamethasone as monotherapy
3240719|NCT00909064|Experimental|Arixtra|Effect of Arixtra on would drainage and length of stay for the patients with hip and knee replacement
3240720|NCT00909051||Group 1|
3240721|NCT00909025|Experimental|Claudiximab|
3240722|NCT00909012|Placebo Comparator|1|
3240723|NCT00909012|Experimental|2|
3240724|NCT00909012|Experimental|3|
3240725|NCT00909012|Experimental|4|
3240726|NCT00909012|Experimental|5|
3240727|NCT00908999||Controls|The control group have to be medically and cognitively healthy(MMSE ≥ 28; Hopkins Verbal Memory Test-Revised raw score within 1.5 SD of normative values for age and gender). These individuals are recruited from the community and all attempts will be made to match them on age and education to individuals recruited for groups of AD and aMCI.
3240728|NCT00908999||amnestic Mild Cognitive Impairment|Participants who have expressed interest to take part in the study. A consensus from the study clinicians regarding the diagnosis will be required before a subject is enrolled. The criteria for MCI include 1) observation of memory decline by informant, 2) Mini Mental Status Exam (MMSE) score between 24 and 30, 3) objective memory impairment on neuropsychological tests, 3) intact functional abilities, and 4) no diagnosis of dementia.
3240729|NCT00908999||Alzheimer's disease|Patients with probable Alzheimer's disease according with the NINDS-ADRDA and DSM-IV diagnostic criteria. An additional criterion is a MMSE score between 16 and 27. All AD patients must have capacity to provide informed consent as judged by the referring physician.
3240730|NCT00908986|Experimental|Rituximab|Subjects receive rituximab in an open label manner
3240731|NCT00908973||Good responders|Excess weight loss of > 60% 1 year after gastric bypass surgery
3240732|NCT00908973||Poor responders|Excess weight loss of =< 50% 1 year after gastric bypass surgery
3240733|NCT00908973||Lean controls|Non-gastric bypass operated lean individuals, matched for age and sex
3240734|NCT00908960|Experimental|High TFMP: Enoxaparin|Patients received enoxaparin 40 mg subcutaneously once daily for 2 months (60 days).Only patients with high TFMP status at baseline were randomized to treatment or observation.
3240735|NCT00908960|No Intervention|High TFMP: Observation|Patients undergo observation until evaluation with a lower extremity ultrasound at 2 months (day 60). Only patients with high TFMP status at baseline were randomized to treatment or observation.
3240736|NCT00908960|No Intervention|Low TFMP: Observation|Patients undergo observation until evaluation with a lower extremity ultrasound at 2 months (day 60). Patients with low TFMP status at baseline were directly assigned to observation.
3240737|NCT00908947|Experimental|Overall Study|PTA plus stenting with the LifeStent® Vascular Stent System
3240738|NCT00908934|Experimental|1|50 or 400 mg AZD9056, Test formulation
3240739|NCT00908934|Experimental|2|50 or 400 mg AZD9056, Reference formulation
3240740|NCT00908921|Experimental|1|"The treatment period is 16 weeks with 5 visits: at weeks 2, 4, 8, 12, 16. At every visit if Fasting Blood Glucose (FBG) >7.0mmol/L the Glimepiride dosage is increased from 1mg to 2mg or 2mg to 4mg.~At every visit if FBG<3.9mmol/L the Glimepiride dosage is decreased from 4mg to 2mg or 2mg to 1mg.~Patients who have been on 4mg for 4 weeks and FBG>11.0mmol/L at visit, another treatment can be added at the physician's discretion."
3240741|NCT00908908|Experimental|1|
3240742|NCT00908895|Experimental|Radio-radial fixator|Patients are operated on using a radio-radial fixator (Distal radius fixator, Synthes)
3240743|NCT00908895|Active Comparator|Percutaneous pinning|Two K-wires inserted on a percutaneous way (dorsally and from the styloid), with a cast for 6 weeks
3240744|NCT00908882|Experimental|Enhanced PTSD Health Buddy and Motivational Interviewing|Veterans with PTSD who smoke are exposed to an intervention which included a 90-day smoking cessation curriculum that is integrated into the PTSD Health Buddy Program and weekly motivational interviewing counseling by a nurse plus usual smoking cessation care
3240745|NCT00908882|No Intervention|Usual PTSD Health Buddy Care|Veteran with PTSD who smoke randomly assigned to this arm received standard of care for smoking cessation and used the standard PTSD Health Buddy
3240746|NCT00908856|Placebo Comparator|Placebo|Placebo
3240747|NCT00908856|Active Comparator|autologous mononuclear cells|a single intravenous autologous bone marrow mononuclear cell transfusion
3240748|NCT00908856|Active Comparator|autologous marrow stromal cells|a single intravenous autologous marrow stromal cell transfusion
3240749|NCT00908843|Experimental|(I) BICARBONATE INTRAVENOUS INFUSION|Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
3240750|NCT00908843|Active Comparator|(II) ORAL SODIUM SOLUTION|Oral hydration with Sodium solution (Casen solution of rehydratation) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
3240751|NCT00908830||Cystic fibrosis|Lung transplant patients with cystic fibrosis. Measuring MPA levels in cystic fibrosis lung transplant patients for pharmacokinetic parameters.
3240752|NCT00908830||Non-cystic fibrosis lung transplant|Non-cystic fibrosis lung transplant patients. Non-cystic fibrosis lung transplant patients will have MPA levels drawn after their dose to determine pharmacokinetic parameters.
3240753|NCT00908817|Active Comparator|triamcinolone|
3240754|NCT00908817|Placebo Comparator|chlorhexidine|
3240755|NCT00908804|Active Comparator|open appendectomy|
3240756|NCT00908804|Active Comparator|laparoscopic appendectomy|
3240757|NCT00908778|Experimental|Vitreosolve I|Intravitreal injection
3240758|NCT00908778|Experimental|Vitreosolve|Intravitreal injection
3240759|NCT00908765|Active Comparator|Aerobe Interval Training|High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.
3240760|NCT00908765|Active Comparator|Moderate Continous Training|Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks
3240761|NCT00908752|Active Comparator|Brivanib|Adjuvant treatment with TACE Therapy
3240762|NCT00908752|Placebo Comparator|Brivanib Placebo|Placebo adjuvant treatment with TACE Therapy
3240763|NCT00908726|Experimental|Microemulsion propofol|
3240764|NCT00908726|Active Comparator|Lipid emulsion propofol|
3240765|NCT00908713|Experimental|methylprednisolone|methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
3240766|NCT00908713|Placebo Comparator|Placebo|
3240767|NCT00908700|Experimental|Occlusion arm|Surgical intervention: Occlusion of the left atrial appendage (LAA) using 'cut-and-sew' technique appendage occlusion.
3240768|NCT00908700|Active Comparator|Medical arm|Medical arm: The comparator is best medical practice for atrial fibrillation related stroke prevention as per guidelines.
3240769|NCT00908687|Experimental|Group 1: 30 µg HA, no LT patch|A/H5N1 Vaccine 30 µg HA i.m. on Day 0
3240770|NCT00908687|Experimental|Group 2: 30 µg HA + 50 µg LT patch|A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
3240771|NCT00908687|Experimental|Group 3: 30 µg HA + 100 µg LT patch|A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
3240772|NCT00908687|Experimental|Group 4: 45 µg HA, no LT patch|A/H5N1 Vaccine 45 µg HA i.m. on Day 0
3240773|NCT00908687|Experimental|Group 5: 45 µg HA + 50 µg LT patch|A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
3240774|NCT00908687|Experimental|Group 6: 45 µg HA + 100 µg LT patch|A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
3240775|NCT00908674||Group 1|
3240776|NCT00908661|Active Comparator|Prophylactic mesh|All patients will have a permanent ostomy and a randomisation with prophylactic mesh
3240777|NCT00908661|No Intervention|without prophylactic mesh|All patients will have a permanent ostomy and a randomisation without prophylactic mesh
3240778|NCT00908648|No Intervention|1|standard white light
3240779|NCT00908648|Experimental|2|Narrow Band Imaging
3240780|NCT00908635||survivor|survivors of patients
3240781|NCT00908635||fatalities|non-survivors of patients
3240782|NCT00908622|Experimental|Skeletal myoblasts|Percutaneous autologous myoblast implantation
3240783|NCT00908622|Placebo Comparator|No cells|Percutaneous culture medium without cells implantation
3240784|NCT00908609||1|Patients who undergo routine ultrasound guided biopsy will be studied by optical imaging technique.
3240785|NCT00908609||2|Patients who have advanced breast cancers and are under neoadjuvant chemotherapy treatment will be studied by optical technique.
3240786|NCT00908596|Experimental|Gadoxetic acid disodium (Primovist/Eovist, BAY86-4873)|Participants received Primovist at a dose of 0.025 mmol/kg body weight (BW) intravenously.
3240817|NCT00908414|Experimental|Panel 4: Multiple dosing|BB mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589354 (n=6) b.i.d. during 7 days (Session Vb) ) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session VIIIb).
3241867|NCT00901017|Active Comparator|Straumann BoneCeramic|Straumann BoneCeramic
3240787|NCT00908583|Experimental|Phase 1, two stages|Patients will receive 1 dose of rituximab, 4 doses of bortezomib and plasmapheresis. Rituximab will be given at a dose of 375 mg/m2 on day 32. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 32, 35, 39, 42. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
3240788|NCT00908583|Experimental|Phase 2, two stages|Patients will receive 1 dose of rituximab, 4 doses of bortezomib and plasmapheresis. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 32, 35, 39, 42. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
3240789|NCT00908583|Experimental|Phase 3, two stages|Patients will receive 1 dose of rituximab and 4 doses of bortezomib. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 23, 26, 30 and 33. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
3240790|NCT00908583|Experimental|Phase 4, single stage|Patients will receive 1 dose of rituximab and 6 doses of bortezomib. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered during the pre-transplant period on days 1, 4, 8, and 11, 14, and 17. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
3240791|NCT00908583|Experimental|Phase 5, single stage|Phase 5 evaluated even greater bortezomib dosing density by eliminating the inter-cycle dosing interval. Phase 5 evaluated eight consecutive doses of bortezomib with one dose of rituximab. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patient will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, 11, 14, 17, 20, and 23. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
3240792|NCT00908570|Experimental|1Topical estriol cream|
3240793|NCT00908570|Placebo Comparator|2Placebo cream|
3240794|NCT00908557|Experimental|1|Patients receiving an information and consent form that has been modified using the LISYCOM methods.
3240795|NCT00908557|Active Comparator|2|Patients receiving a standard information and consent form.
3240796|NCT00908544|Experimental|PHI-patients|"Patients with primary HIV infection (PHI) (see also Eligibility) are immediately treated with 2 NRTI + 1 PI/r + Maraviroc + Raltegravir"
3240797|NCT00908544|Experimental|CHI-patients|"Patients with chronic HIV infection (CHI) and with suppressed plasma viral load for at least three years under continuous HAART (2 NRTI + 1 PI/r see also Eligibility) intensified by Maraviroc + Raltegravir"
3240798|NCT00908531|Active Comparator|Postoperative letrozole|Definitive surgery without preoperative AI treatment followed post-operatively by 5 AI for years.
3240799|NCT00908531|Experimental|Preoperative letrozole|Treatment with letrozole for 4 months before definitive surgery. Post-operatively patients with responsive or stationary tumors continue letrozole to a total of 5 years. Patients with endocrine resistant tumors are re-considered for chemotherapy.
3240800|NCT00908518||Total Intravenous Anesthesia|Propofol based anesthesia
3240801|NCT00908518||Inhaled anesthesia|Isoflurane based anesthesia
3240802|NCT00908505|Experimental|physiotherapy|
3240803|NCT00908492|Active Comparator|Education Control|
3240804|NCT00908492|Experimental|Environmental Skill Building|
3240805|NCT00908479|Experimental|LE|Leg Exercise group
3240806|NCT00908479|Experimental|LM|Leg Management (Control group)
3240807|NCT00908466|Experimental|Intravitreal Injection|Will receive intravitreal injections of sirolimus 352 µg in study eye on Days 0, 60, and 120.
3240808|NCT00908466|Experimental|Subconjunctival Injection|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
3240809|NCT00908453|Experimental|15mg/kg of loading dose|
3240810|NCT00908453|Experimental|18mg/kg of loading dose|
3240811|NCT00908453|Experimental|22.5mg/kg of loading dose|
3240812|NCT00908427|Active Comparator|1|PVP group
3240813|NCT00908427|Active Comparator|2|TURP group
3240814|NCT00908414|Experimental|Panel 1: Single Dose Escalation|Panel 1 will receive doses of 40 milligram (mg) (Session Ia), 100 mg (Session IIa), 200 mg (Session IIIa) and 400 mg (Session IVa) of TMC589337 or placebo.
3240815|NCT00908414|Experimental|Panel 2: Single Dose Escalation|Panel 2 will receive doses of 40 mg (Session Ib), 100 mg (Session IIb), 200 mg (Session IIIb) and 400 mg (Session IVb) of TMC589354 or placebo.
3240816|NCT00908414|Experimental|Panel 3: Multiple dosing|AA mg (Final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) b.i.d. (twice daily) during 7 days (Session Va) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session VIIIa).
3240857|NCT00908115||Infanrix Group|Subjects received one dose of Infanrix™ at 2, 4 and 6 months of age (primary vaccination), one dose at 15-18 months of age (booster vaccination) and one dose at 4-6 years of age (booster vaccination).
3240818|NCT00908414|Experimental|Panel 5: Multiple dosing|CC mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) b.i.d. during 7 days (Session VIa) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session IXa).
3240819|NCT00908414|Experimental|Panel 6: Multiple dosing|DD mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589354 (n=6) b.i.d. during 7 days (Session VIb) ) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session IXb).
3240820|NCT00908414|Experimental|Panel 7: Multiple dosing|EE mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) or YY mg TMC589354 (n=6) b.i.d. or q.d. during 7 days (Session VII) ) plus a single oral dose of 300 mg or 600mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg or 600 mg TMC310911, single dose (Session X).
3240821|NCT00908401|Active Comparator|sucrose|This group will receive oral sucrose for procedural pain
3240822|NCT00908401|Experimental|breastmilk|this group will receive breastmilk as analgesic product to avoid procedural pain
3240823|NCT00908388|Experimental|GORE Conformable TAG® Device Surgical Implant|
3240824|NCT00908375|Active Comparator|Pregabalin|A 75mg pregabalin capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
3240825|NCT00908375|Placebo Comparator|Surgar Pill|One Sugar pill capsule will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 Sugar pill capsules twice a day. The total duration of the treatment will be 3 weeks.
3240826|NCT00908362|Active Comparator|A|Inhalation of Fluticasone (via discus) twice daily for 28 days
3240827|NCT00908362|Active Comparator|B|Inhalation of Fluticasone and Salmeterol (via discus) twice daily for 28 days
3240828|NCT00908362|Placebo Comparator|C|Inhalation of Placebo (via discus) twice daily for 28 days.
3240829|NCT00908349|Other|Oxcarbazepine XR|Open Label Study
3240830|NCT00908336|Experimental|Docetaxel and Erlotinib|"Patients in the experimental arm will receive sequential treatment of intermittent erlotinib and docetaxel up to 4 cycles in the absence of disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.~After 4 cycles, participants will receive 150 mg of erlotinib per day until disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment."
3240831|NCT00908336|Active Comparator|Erlotinib|Erlotinib (Tarceva®) 150 mg/day po daily until disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.
3240832|NCT00908323||A|Participants receiving the JS7 DNA and MVA/HIV62 vaccinations in HVTN 205
3240833|NCT00908323||B|Participants receiving the placebos of the JS7 DNA and MVA/HIV62 vaccines in HVTN 205
3240834|NCT00908310|Other|Omniscan|
3240835|NCT00908284|Active Comparator|Control Group|Participants will take part in a 12-week control group.
3240836|NCT00908284|Experimental|Exercise Program|Participants will take part in a 12-week exercise program.
3240837|NCT00908271|Other|Dapagliflozin|PO and IV
3240838|NCT00908245|Experimental|Preconditioning|Surgery with ischemic preconditioning
3240839|NCT00908245|Active Comparator|Control|Surgery without preconditioning ischemia
3240840|NCT00908232|Experimental|Stable Disease: VD|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8
3240841|NCT00908232|Experimental|Stable Disease: VDC|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and cyclophosphamide 500 mg, orally daily, days 1, 8 and 15 for cycle 5 to 8
3240842|NCT00908232|Experimental|Stable Disease: VDL|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and lenalidomide 10 mg orally daily from day 1 to day 14 for cycle 5 to 8
3240843|NCT00908232|Experimental|Complete to Partial Response: VD|Complete, very good partial or partial response after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8
3240844|NCT00908219|Experimental|Bevacizumab IV|All subjects will be treated with an intravenous infusion of the experimental drug (Bevacizumab 15 mg/kg) every 3 weeks for a total of twelve (12) weeks on study.
3240845|NCT00908206|Placebo Comparator|Placebo|Placebo to match GSK598809.
3240846|NCT00908193|Experimental|1|robot-assisted coelioscopy
3240847|NCT00908193|Active Comparator|2|conventional coelioscopy
3240848|NCT00908167|Other|Research Participants|Participants treated with sorafenib, cytarabine and clofarabine.
3240849|NCT00908154|Other|Cohort 1|
3240850|NCT00908154|Other|Cohort 4|
3240851|NCT00908154|Other|Cohort 3|
3240852|NCT00908154|Other|Cohort 2|
3240853|NCT00908141|Experimental|Arm I: sargramostim (days1-14)|Patients receive sargramostim (GM-CSF) subcutaneously (SC) on days 1-14. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3240854|NCT00908141|Experimental|Arm II: sargramostim (3xweek)|Patients receive GM-CSF SC three times weekly for 4 weeks. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3240855|NCT00908128|Experimental|Mycophenolate Mofetil (test) First|Mycophenolate Mofetil Tablets, 500 mg dosed in first period followed by CellCept® Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
3240856|NCT00908128|Active Comparator|CellCept® (reference) First|CellCept® Tablets, 500 mg dosed in first period followed by Mycophenolate Mofetil Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
3241031|NCT00907010||Group IV|66 - 82 years - composed of 12 aged with six women and six men
3240858|NCT00908102|Active Comparator|BB|"Subjects received the back book booklet, which is an self-information booklet about managing low back symptoms.~Included in the Mild and Mild vs. NC interventions."
3240859|NCT00908102|Experimental|BB+A|"Subjects received a back book booklet and also oral advice based on the back book by the occupational health professional (OH Nurse or OH Physician in mild or moderate intervention, respectively).~Included in the Mild and Mild vs. NC interventions. Arm was also used as a control at the Moderate and Moderate vs. NC interventions."
3240860|NCT00908102|Experimental|DBC|A graded activity back school program was carried out in a physiotherapy out-patient clinic that consisted of one-hour session twice or three times per week, lasting for 12 weeks, supervised by a specially trained physiotherapist. Arm is included in the MOderate and Moderate vs. NC interventions.
3240861|NCT00908102|Experimental|PMU|An intensive, multidisciplinary LBP rehabilitation program was carried out in a physical medicine out-patient unit at the local Central Hospital. The program included a 3-week pre-course of 1,5 hour session at 3 days per week, closely followed by a 3-week intensive rehabilitation course of 6.5 hours per day for 5 days per week. A personal graded activity training program was made for each subject and patients were later called for follow-up visit within 1 year of the initial course. Arm is included in the MOderate and Moderate vs. NC interventions.
3240862|NCT00908102|Placebo Comparator|NC|Natural course of low back pain
3240863|NCT00908089|Active Comparator|Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab|Combination therapy with 3 DMARDs (starting with methotrexate 10-25 mg/week, sulphasalazine 1-2 g/day and hydroxychloroquine 35 mg/kg/week)+ Prednisolon 7.5 mg/day + infliximab 3 mg/kg at weeks 4, 6, 10, 18, 26
3240864|NCT00908089|Placebo Comparator|Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo|Combination therapy with 3 DMARDs (starting with methotrexate 10-25 mg/week, sulphasalazine 1-2 g/day and hydroxychloroquine 25 mg/kg/week)+ Prednisolon 7.5 mg/day + placebo at weeks 4, 6, 10, 18, 26
3240865|NCT00908076|Active Comparator|amitiza|Amitiza
3240866|NCT00908076|Placebo Comparator|Placebo|Matching Placebo
3240867|NCT00908063|Experimental|Oxycyte|"Single intravenous infusion of Oxycyte (Perfluoro(t-butylcyclohexane) Intravenous Emulsion 60% w/v)~One of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury."
3240868|NCT00908063|Placebo Comparator|Normal Saline|"Single intravenous infusion of Normal Saline~One of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury."
3240869|NCT00908050|Placebo Comparator|Placebo|Placebo arm
3240870|NCT00908050|Active Comparator|botulinum toxin type A|Active arm
3240871|NCT00908037|Experimental|eltrombopag plus standard of care|eltrombopag
3240872|NCT00908037|Placebo Comparator|placebo plus standard of care|placebo
3240873|NCT00908024|Experimental|BMS-754807 + cetuximab|Combination
3240874|NCT00908011|Active Comparator|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)
3240875|NCT00908011|Active Comparator|Standard Care|Increased dose of rosuvastatin to 20mg/day
3240876|NCT00907998|Experimental|APL180 (first dose level)|
3240877|NCT00907998|Experimental|APL180 (second dose level)|
3240878|NCT00907998|Placebo Comparator|Placebo|
3240879|NCT00907985|Experimental|Treatment sequence A|Subjects on sequence A will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
3240880|NCT00907985|Experimental|Treatment sequence B|Subjects on sequence B will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
3240881|NCT00907985|Experimental|Treatment sequence C|Subjects on sequence C will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
3240882|NCT00907985|Experimental|Treatment sequence D|Subjects on sequence D will receive single dose of placebo in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
3240883|NCT00907985|Experimental|Treatment sequence E|Subjects on sequence E will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + placebo in session B of part 2.
3240884|NCT00907985|Experimental|Treatment sequence F|Subjects on sequence F will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
3240885|NCT00907985|Experimental|Treatment sequence G|Subjects on sequence G will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + placebo in session B of part 2.
3240886|NCT00907985|Experimental|Treatment sequence H|Subjects on sequence H will receive single dose of placebo part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
3240887|NCT00907985|Experimental|Treatment sequence I|Subjects on sequence I will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
3240888|NCT00907985|Experimental|Treatment sequence J|Subjects on sequence J will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
3240889|NCT00907985|Experimental|Treatment sequence K|Subjects on sequence K will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
3241032|NCT00906997|Active Comparator|Fecal occult blood testing|
3241033|NCT00906997|Active Comparator|Colonoscopy|
3240890|NCT00907985|Experimental|Treatment sequence L|Subjects on sequence L will receive single dose of placebo in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
3240891|NCT00907985|Experimental|Treatment sequence M|Subjects on sequence M will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + placebo in session B of part 2.
3240892|NCT00907985|Experimental|Treatment sequence N|Subjects on sequence N will receive single dose of vofopitant 10 milligrams capsule in part 1, placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
3240893|NCT00907985|Experimental|Treatment sequence O|Subjects on sequence O will receive placebo in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + placebo in session B of part 2.
3240894|NCT00907985|Experimental|Treatment sequence P|Subjects on sequence P will receive placebo in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
3240895|NCT00907985|Experimental|Treatment sequence Q|Subjects on sequence Q will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session A of part 2 and placebo + placebo in session B of part 2.
3240896|NCT00907985|Experimental|Treatment sequence R|Subjects on sequence R will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session B of part 2.
3240897|NCT00907985|Experimental|Treatment sequence S|Subjects on sequence S will receive placebo in part 1, single doses of lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session A of part 2 and placebo + placebo in session B of part 2.
3240898|NCT00907985|Experimental|Treatment sequence T|Subjects on sequence T will receive placebo in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session B of part 2.
3240899|NCT00907972|Experimental|Vitamin D3 supplementation|1000 IU/day of Vitamin D3
3240900|NCT00907972|Placebo Comparator|Placebo|Placebo
3240901|NCT00907946|No Intervention|NT at the time of PCNL|
3240902|NCT00907946|Active Comparator|NT prior to PCNL|"A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one week prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol."
3240903|NCT00907933|Experimental|Part 1 - Arm 1|HVTs
3240904|NCT00907933|Placebo Comparator|Part 2 - Arm 3|HVTs
3240905|NCT00907933|Experimental|Part 1 - Arm 2|HVTs
3240906|NCT00907933|Experimental|Part 1 - Arm 3|HVTs
3240907|NCT00907933|Experimental|Part 1 - Arm 4|HVTs
3240908|NCT00907933|Experimental|Part 1 - Arm 5|HVTs
3240909|NCT00907933|Placebo Comparator|Part 1 - Arm 6|HVTs
3240910|NCT00907933|Experimental|Part 2 - Arm 1|HVTs
3240911|NCT00907933|Experimental|Part 2 - Arm 2|HVTs
3240912|NCT00907920||Correlative studies|"Tumor DNA samples are examined by mutation analysis for germline and somatic mutations in the ALK tyrosine kinase domain. Samples are analyzed by whole genome amplification using polymerase chain reaction and then sequenced for DNA alterations in the entire ALK coding sequence. Samples are also examined for SNPs by polymorphism analysis. Exploratory multivariable analysis is performed to test for the prognostic ability of ALK mutations in the presence of other known prognostic variables (i.e., age, International Neuroblastoma Staging System stage, MYCN status, International Neuroblastoma Pathology Classification, and diploidy).~A subset of tumor DNA samples from high-risk patients will be resequenced for DNA alterations to determine whether or not additional regions in ALK, outside of the tyrosine kinase domain, are prone to mutations and should be sequenced in a larger panel."
3240913|NCT00907907|Experimental|Mycophenolate Mofetil (test) First|Mycophenolate Mofetil Tablets, 500 mg dosed in first period followed by CellCept® Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
3240914|NCT00907907|Active Comparator|Cellcept® (reference) First|CellCept® Tablets, 500 mg dosed in first period followed by Mycophenolate Mofetil Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
3240915|NCT00907894|Experimental|Stratum 1|
3240916|NCT00907894|Experimental|Stratum 2|
3240917|NCT00907894|Experimental|Stratum 3|
3240918|NCT00907881||All participants|Participants with type 2 diabetes mellitus (T2DM) who had sulfonylurea treatment added to an on-going regime of oral hypoglycemic agent(s).
3240919|NCT00907868|Active Comparator|Arm I|Patients undergo whole breast irradiation (WBI) once daily for 5 weeks (weekdays only).
3240920|NCT00907868|Experimental|Arm II|Patients undergo WBI as in arm I and a radiation tumor bed boost once daily for 8 days (weekdays only).
3240921|NCT00907842|Experimental|mesh placement|
3240922|NCT00907829|Active Comparator|Arm 1|persons with severe hand impairment following hemiparetic stroke
3240923|NCT00907829|Active Comparator|Arm 2|persons with severe hand impairment following hemiparetic stroke
3240924|NCT00907816||intervention|PCPs at MGH who receive display of utilization and quality during computer order entry
3240925|NCT00907816||control|
3240926|NCT00907803|Experimental|ST-246 400 mg|ST-246 400mg (2 x 200 mg Capsules) Orally Once Daily for 14 days
3240927|NCT00907803|Experimental|ST-246 600 mg|ST-246 600 mg (3 x 200 mg Capsules) Orally Once Daily for 14 days
3240928|NCT00907803|Placebo Comparator|Placebo|Matching Placebo capsules, Orally Once Daily for 14 days
3241868|NCT00901017|Active Comparator|Bio-Oss|Geistlich Bio-Oss
3240929|NCT00907790|Experimental|Comprehensive Self-Management (CSM)|Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS
3240930|NCT00907790|Other|Usual Care (Control Group)|Includes the usual care provided by the person and their health care provider.
3240931|NCT00907777|Experimental|Pn Group|Subjects receiving GSK 1024850A vaccine.
3240932|NCT00907777|Active Comparator|Prev Group|Subjects receiving Prevenar™ vaccine.
3240933|NCT00907764|Experimental|Regadenoson alone|
3240934|NCT00907764|Experimental|Regadenoson with exercise|
3240935|NCT00907764|Experimental|Regadenoson with contrast agent|
3240936|NCT00907764|Experimental|Regadenoson with contrast agent (perfusion)|
3240937|NCT00907751|Experimental|1|Microangiopathic hemolytic anemia (< 12 g/dL) with thrombocytopenia (<50 G/L)
3240938|NCT00907738|Experimental|Vorinostat|
3240939|NCT00907725|Other|1|serum BhCG follow-up
3240940|NCT00907725|Other|2|ultrasonographic follow-up
3240941|NCT00907712|No Intervention|cardiovascular|cardiac echo
3240942|NCT00907686||LBWIs of CMV-positive mother|LBWIs born to CMV-positive mothers
3240943|NCT00907686||CMV Sero-negative & Sero-postive LBWIs|LBWIs of CMV sero-negative & sero-positive mothers
3240944|NCT00907673|Active Comparator|Patient condition pre-implant|
3240945|NCT00907660|Active Comparator|Full Dose|Provision of 8 weight loss counseling sessions, calorie guide, pedometer, meal plan, and 2 meals per day of portion-controlled foods (shakes and entrees)
3240946|NCT00907660|Experimental|Half dose|Provision of 8 weight loss counseling sessions, calorie guide, pedometer, meal plan, and 1 meal per day of portion-controlled foods (shakes and entrees)
3240947|NCT00907621|Experimental|Acupuncture|"Acupuncture with Seirin 020x15 mm sterile acupuncture needle:~Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36 on infants born after 36th week of gestation and weighing over 2500 grams at birth, and who qualify according to Wessels definition:~Paroxystical, uncontrolled crying in an otherwise healthy child under 3 months of age, and with more than 3 hours of crying 3 days per week for 3 weeks."
3240948|NCT00907621|No Intervention|Control|"Infants born after 36th week of gestation and weighing over 2500 grams at birth, and who qualify according to Wessels definition:~Paroxystical, uncontrolled crying in an otherwise healthy child under 3 months of age, and with more than 3 hours of crying 3 days per week for 3 weeks.~The Control group will have no intervention."
3240949|NCT00907608|Experimental|1|Receive Darbepoetin alfa
3240950|NCT00907608|No Intervention|2|
3240951|NCT00907595|Active Comparator|Ramelteon|Subjects randomized to Ramelteon
3240952|NCT00907595|Placebo Comparator|Placebo|Subjects randomized to placebo
3240953|NCT00907582|Experimental|ASCT in relapsed APL|autologous hematopoietic cell transplantation for patients with relapsed APL after achieving molecular remission
3240954|NCT00907543|Other|Neoadjuvant Treatment|Preoperative chemotherapy/radiotherapy treatment
3240955|NCT00907543|Experimental|Adjuvant Treatment|Postoperative chemotherapy/radiotherapy treatment
3240956|NCT00907530|Active Comparator|MULTIHANCE|gadobenate dimeglumine
3240957|NCT00907530|Active Comparator|GADOVIST|gadobutrol
3240958|NCT00907517|Experimental|MK-8776 10 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 10 mg/m^2 intravenously (IV) on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour continuous intravenous infusion (CIV) on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
3240959|NCT00907517|Experimental|MK-8776 20 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 20 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
3240960|NCT00907517|Experimental|MK-8776 40 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 40 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
3240961|NCT00907517|Experimental|MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 56 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
3240962|NCT00907517|Experimental|MK-8776 140 mg + Cytarabine 2 g/m^2|Participants received MK-8776 140 mg flat dose IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
3240963|NCT00907504|Experimental|CP-751,871 + Gemcitabine + Cisplatin|investigational arm
3240964|NCT00907504|Active Comparator|Gemcitabine + Cisplatin|standard of care
3240965|NCT00907491||A|
3240966|NCT00907478|Experimental|Romiplostim|"Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years.~The starting dose of romiplostim was 1 μg/kg; weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L."
3240967|NCT00907465||Calibration study|These individuals were used to develop cut points for sedentary behavior using accelerometers and a metabolic chamber.
3240968|NCT00907452|Active Comparator|melphalan-prednisone-thalidomide|
3240969|NCT00907452|Active Comparator|lenalidomide-dexamethasone|
3240970|NCT00907426|Experimental|Bimatoprost 0.03% Followed by Bimatoprost 0.03%|Treatment period one (0-6 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin.
3241079|NCT00906659||diabetic macular edema|type 2 patients who had been treated with selective photocoagulation for clinically significant macular edema
3240971|NCT00907426|Other|Bimatoprost 0.03% Followed by Vehicle|Treatment period one (0-6 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin.
3240972|NCT00907426|Other|Vehicle Followed by Bimatoprost 0.03%|Treatment period one (0-6 months), once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin.
3240973|NCT00907413|Experimental|ERCP and PDT|Endoscopic Retrograde Cholangio Pancreatography (ERCP) and stenting combined with Photodynamic Dynamic Therapy ERCP and PDT
3240974|NCT00907413|Active Comparator|ERCP alone|Endoscopic Retrograde Cholangio Pancreatography (ERCP) with stenting alone
3240975|NCT00907400|Experimental|1|PN400
3240976|NCT00907400|Active Comparator|2|Naprosyn E
3240977|NCT00907387|Active Comparator|Dose A|Dose A RT001
3240978|NCT00907387|Active Comparator|Dose B|Dose B RT001
3240979|NCT00907387|Placebo Comparator|Dose C|Dose C Placebo
3240980|NCT00907374|Active Comparator|Low dose inhibition of RAS|Standard low dose inhibition of the RAS with 10 mg of benazepril orally daily to treat microalbuminuria
3240981|NCT00907374|Experimental|Agressive inhibition of the RAS|40-80 mg benazepril plus 25-100 mg losartan both orally once or twice daily
3240982|NCT00907348|Experimental|Cohorts 1 - 2 - 3 - 4|Chemiotherapy
3240983|NCT00907335|Experimental|Retin-A Micro|Retin-A Micro 0.04% facial acne treatment used once daily
3240984|NCT00907335|Placebo Comparator|Vehicle Control|Color matched facial gel vehicle control used once daily
3240985|NCT00907322|Experimental|Dimbeon 20 mg|
3240986|NCT00907322|Experimental|Dimebon 40 mg|
3240987|NCT00907322|Experimental|Dimebon 60 mg|
3240988|NCT00907322|Experimental|Placebo|
3240989|NCT00907309|No Intervention|Treatment as usual|Participants will receive treatment as usual from their provider.
3240990|NCT00907309|Experimental|iMET|Participants will receive the iMET intervention.
3240991|NCT00907309|Experimental|iMET/TE|Participants will receive the iMET intervention and Technological Extenders (TEs).
3240992|NCT00907296|Experimental|AMG 785 dose group 5|Three doses of 140mg AMG 785
3240993|NCT00907296|Experimental|AMG 785 dose group 3|Two doses of 70mg AMG 785
3240994|NCT00907296|Experimental|AMG 785 dose group 6|Two doses of 140mg AMG 785
3240995|NCT00907296|Experimental|AMG 785 dose group 8|Three doses of 210mg AMG 785
3240996|NCT00907296|Experimental|AMG 785 dose group 7|Four doses of 210mg AMG 785
3240997|NCT00907296|Experimental|AMG 785 dose group 1|Four doses of 70mg AMG 785
3240998|NCT00907296|Experimental|AMG 785 dose group 2|Three doses of 70mg AMG 785
3240999|NCT00907296|Experimental|AMG 785 dose group 4|Four doses of 140mg AMG 785
3241000|NCT00907296|Experimental|AMG 785 dose group 9|Two doses of 210mg AMG 785
3241001|NCT00907296|Placebo Comparator|Placebo arm|Four doses of placebo
3241002|NCT00907283|Experimental|deferiprone|15 mg/Kg/twice for 1 year
3241003|NCT00907270|Active Comparator|Cholecalciferol: 400 IU/day|Control: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D (Cholecalciferol: 400 IU/day)
3241004|NCT00907270|Experimental|Cholecalciferol 4000 IU/day|Experimental: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D
3241005|NCT00907257|Experimental|Same time of day|5% benzoyl peroxide wash and 0.04% tretinoin gel used at same time of day
3241006|NCT00907257|Active Comparator|Different times of day|5% benzoyl peroxide wash used in the morning and 0.04% tretinoin gel used in the evening
3241007|NCT00907218|Experimental|1|Adults who meet DSM-IV-TR criteria for ADHD and smoke cigarettes.
3241008|NCT00907205|Experimental|SF1126|Twice weekly IV infusion
3241009|NCT00907192||Opioids|Personal Interview and Questionnaire of Advanced cancer patients, taking narcotic pain drugs (opioids).
3241010|NCT00907179|Experimental|Dose escalation|"Phase I: Determine the highest and safest dosage of LBH589 (15 mg, 20 mg, and 30 mg). If the 15 mg dosage causes too many side effects, a back-up dosage of 10 mg will be used instead of the 15 mg.~Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given"
3241011|NCT00907166|Experimental|Phase I, Arm A|CPI-613 + Gemcitabine
3241012|NCT00907166|Experimental|Phase II, Arm A|CPI-613 + Gemcitabine
3241013|NCT00907166|Active Comparator|Phase II, Arm B|Gemcitabine
3241014|NCT00907153|Experimental|Vitamin D|
3241015|NCT00907153|Placebo Comparator|Placebo|
3241016|NCT00907140|Other|Chemoradiation therapy|
3241017|NCT00907127|Active Comparator|Mediterranean Diet and Exercise|Mediterranean Diet and Exercise
3241018|NCT00907114|Active Comparator|Ketorolac tromethamine|ocular topic ketorolac used 4 times a day during a week after panphotocoagulation
3241019|NCT00907114|Placebo Comparator|Polivynilic alcohol|ocular lubricant drops 4 times a day during one week after panphotocoagulation
3241020|NCT00907101|Experimental|Study Treatment|"Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)~Other Names:~Epiduo® Gel Apply once daily"
3241021|NCT00907088|Active Comparator|1|
3241022|NCT00907088|Experimental|2|
3241023|NCT00907075|Active Comparator|NES With Energy Restriction|
3241024|NCT00907075|Active Comparator|NES Without Energy Restriction|
3241025|NCT00907062|Experimental|Gingko biloba|60 mg of Ginkgo biloba (standardized to 15 mg ginkgofavonglycosides) given 2 times per day, with food, for 12 weeks.
3241026|NCT00907049||Subacute neck pain; chronic neck pain|Patients with subacute or chronic neck pain seen in the Primary Care Centers participating in the study.
3241027|NCT00907023||SOT|Patients that have had a solid organ transplant
3241028|NCT00907010||Group I|11 to 18 years - composed of 12 adolescent with six women and six men
3241029|NCT00907010||Group II|20 to 26 years - composed of 12 young with six women and six men
3241030|NCT00907010||Group III|45 to 60 years - composed of 12 adult with six women and six men
3241034|NCT00906984|Other|TheraSphere® treatment|TheraSphere® treatment will be performed in the outpatient setting. The effect on the tumor and any side effects of TheraSphere® HUD treatment will be examined. This is not a research study and there are no comparison or experimental treatments being used. Within 14 days of initial treatment, reverification of eligibility will be confirmed. If review of eligibility indicates an uncorrectable risk of flow to the gastrointestinal organs or risk of shunting to the lungs, treatment will not be administered. In this event, the patient will receive alternative treatment (chemoembolization) or no treatment. If the patient remains eligible, TheraSphere® will be administered within 14 days. All patients will be evaluated at 30 days post-treatment to assess clinical experience and adverse effects. Subsequently, patient status will be followed via communication with the referring oncologist to determine disease status and survival. Survival surveillance will continue up to 24 months.
3241035|NCT00906971|Active Comparator|Laxatives|Magnesium hydroxide for which the dosage varied according to individual needs (a minimum of 2 ml/kg), and received guidance regarding fiber-rich foods, water and toilet training. Patients attended weekly consultations with a pediatric gastroenterologist.
3241036|NCT00906945|Experimental|Dose Level 1|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 240 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
3241037|NCT00906945|Experimental|Dose Level 2|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 320 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
3241038|NCT00906945|Experimental|Dose Level 3|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 420 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
3241039|NCT00906945|Experimental|Dose Level 4|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 560 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
3241040|NCT00906945|Experimental|Dose Level 5|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 750 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
3241041|NCT00906945|Experimental|MTD - Phase II|"G-CSF MTD determined in Phase 1 SQ on Days 1-8~Plerixafor MTD determined in Phase 1 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
3241042|NCT00906932||Trachview videoscope, direct laryngoscopy|Each subject served as their own control - the Trachview videoscope and direct laryngoscopy was performed on by all subjects in a sequential fashion.
3241043|NCT00906932||See above|See above
3241044|NCT00906919|Active Comparator|Regular diabetes patient education|Regular professionally-led diabetes patient education
3241045|NCT00906919|Experimental|Augmented Diabetes Patient Education|Regular professionally-led diabetes patient education augmented by participation in the Stanford Chronic Disease Self-Management Program
3241046|NCT00906906||1|Patient to receive CPB
3241047|NCT00906893|Experimental|1|
3241048|NCT00906867||Vocal cord dysfunction|Patients with suspicion of VCD
3241049|NCT00906854||Group I|practice of weight training exercises
3241050|NCT00906854||Group II|aerobic exercises as part of lessons jump, step and dance classes
3241051|NCT00906854||Group III|swimming (crawl mode)
3241052|NCT00906841|Experimental|90Y-DOTA-hLL2|Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)
3241053|NCT00906828|Active Comparator|1. Duodopa, optimised dose|
3241054|NCT00906828|Experimental|2. 80% Duodopa + entacapone|80% of optimised Duodopa dose + two tablets of entacapone at t=0 hours and at t= 6 hours
3241055|NCT00906828|Experimental|3. 80% Duodopa + tolcapone|80% of optimised Duodopa dose + two tablets of tolcapone at t=0 hours and at t= 6 hours
3241056|NCT00906802|Experimental|R-Y reconstruction|the reconstruction was performed by R-Y anastomosis
3241057|NCT00906802|No Intervention|conventional reconstruction|the anastomosis was performed by B-II
3241058|NCT00906789||Radiologists|Radiologists who have certification by the American Board of Radiology
3241059|NCT00906776|Active Comparator|Emdogain PLUS|Straumann Emdogain in combination with Straumann BoneCeramic
3241060|NCT00906776|Active Comparator|Autogenous bone|Autogenous bone from the patient
3241061|NCT00906763|Active Comparator|Dark Chocolate (85% cocoa)|Oral Intake of dark chocolate (85% cocoa) over 15 minutes.
3241062|NCT00906763|Active Comparator|White chocolate (0% cocoa)|Oral intake of 200 grams of white chocolate (0% cocoa) over 15 Minutes.
3241063|NCT00906750|Experimental|1|
3241064|NCT00906750|Active Comparator|2|
3241065|NCT00906737|Experimental|Ankle-Bot Training|Subjects in this group receive focused ankle training using the ankle-bot device.
3241066|NCT00906737|Active Comparator|Conventional Therapy|Subjects in this group will receive conventional focused ankle physical therapy.
3241067|NCT00906737|No Intervention|Control|Subjects in this group will not receive treatment; they will continue their usual care.
3241068|NCT00906724||aerobic exercise|Aerobic exercise in Insulin Resistant Minority Adolescents
3241069|NCT00906711||Group I|(G1): 10 - 18 years old
3241070|NCT00906711||Group II|(G2): 20 - 35 years old
3241071|NCT00906711||Group III|(G3): 45 - 60 years old
3241072|NCT00906711||Group IV|(G4): 65 - 85 years old
3241073|NCT00906698|Experimental|BIBW 2992 and vinorelbine i.v|Daily low (20mg), medium (40mg) and high (50mg) dosages of BIBW 2992 with standard dosage of vinorelbine i.v.
3241074|NCT00906698|Experimental|BIBW 2992 and vinorelbine per os|Daily low (20mg), medium (40mg) and high (50mg) dosages of BIBW 2992 with standard dosage of vinorelbine per os.
3241075|NCT00906685|Active Comparator|Intravitreal bevacizumab|
3241076|NCT00906685|Sham Comparator|Sham injection|
3241077|NCT00906672|Experimental|INTEGRA®|
3241078|NCT00906672|Active Comparator|Flap technique|
3241080|NCT00906646|Experimental|Metabolic therapy|Metabolic therapy with antioxidants and cellular energisers
3241081|NCT00906646|Placebo Comparator|Placebo|Placebo tablets
3241082|NCT00906633||Outcome of combination antifungal therapy|
3241083|NCT00906620|Experimental|QPR intervention|"QPR intervention (Question, Persuade & Refer): The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
3241084|NCT00906620|Experimental|Awareness program|The awareness programme is comprised of a leaflet, six posters and four seminars. The seminars are made up of one introductory lesson, and two interactive follow-up lessons with role play and one final meeting as a closing/debriefing lesson.
3241085|NCT00906620|Experimental|ProfScreen|The program's primary objective is to help young people and their parents through the early identification of mental health problems, such as anxiety, depression, substance abuse, and suicide. Screening strategies are based on the valid premise that suicidal adolescents are under-identified, suffer from an active, often treatable mental illness such as depression and exhibit identifiable risk factors (Gould et al. 2003). A potential shortcoming of screening programs is that asking about suicide could increase suicidal ideation and behaviour. About this issue a recent study (Gould et al . 2005) on over 2300 students reported no evidence of iatrogenic effects of suicide screening and that screening in high schools is a safe component of youth suicide prevention efforts.
3241086|NCT00906620|Experimental|Control group|The control group will comprise 250 subjects. After the baseline assessment, subjects will be randomized in one of the three intervention arms or in the control group. Individuals in the control group will undergo the same baseline and follow-up evaluations as subjects in the intervention arms and will receive the same leaflet about healthy lifestyles with information about the possibility to seek help for unhealthy, suicidal behaviour and mental health problems. In this arm, no additional intervention will be performed although the possibility of seeking help from mental health resources will be available.
3241087|NCT00906607||Group I|10-18 years
3241088|NCT00906607||Group II|20-35 years
3241089|NCT00906607||Group III|45-60 years
3241090|NCT00906607||Group IV|65-75 years
3241091|NCT00906594|Active Comparator|Latanoprost|Latanoprost mono therapy
3241092|NCT00906594|Experimental|Latanoprost + Fixed combination|Latnoprost + Fixed combination
3241093|NCT00906581|Experimental|Behavioral|Behavioral
3241094|NCT00906581|No Intervention|Waitlist control|Waitlist control
3241095|NCT00906568||Sensitized vs non-sensitized|CF with and without SAD defined by MEF25 <50%
3241096|NCT00906555|No Intervention|1|hemodialysis patients with baseline Kt/V between 1.2 and 1.7 (1.2 ≤ Kt/V ＜ 1.7)
3241097|NCT00906555|Experimental|2|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
3241098|NCT00906542||Acute ischemic stroke patients|Acute ischemic stroke patients admitted to the neurological intensive care unit or stroke unit within 24 hours after stroke onset in whom ischemic brain lesion was clearly assessed on CT and/or MRI
3241099|NCT00906529|Active Comparator|Conservative Blood Glucose Control|Goal Pre-prandial blood glucose <180 mg/dl.
3241100|NCT00906529|Active Comparator|Aggressive Blood Glucose Control|Pre-prandial goal blood glucose <110 mg/dl
3241101|NCT00906516|Experimental|Neuradiab in combination with Avastin|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
3241102|NCT00906503|Experimental|PET/Computed Tomography (CT)|Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan; Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
3241103|NCT00906477|Experimental|Early intervention|Modified CI therapy starting between 7 and 28 days post stroke.
3241104|NCT00906477|Active Comparator|Delayed intervention|Modified CI Therapy starting 6 months post stroke
3241105|NCT00906451|No Intervention|No lipid-lowering|No lipid-lowering treatment during the first 7 days and then simvastatin 20 mg/day for three additional weeks, till the endothelial function assessment
3241106|NCT00906451|Experimental|Simvastatin 20 mg|Simvastatin 20 mg/day for 30 days, till the endothelial function assessment
3241107|NCT00906451|Experimental|Simvastatin 40 mg|Simvastatin 40 mg/day for 7 days and then switched to simvastatin 20mg/day for additional 3 weeks, till the endothelial function assessment
3241108|NCT00906451|Experimental|Simvastatin 80 mg|Simvastatin 80 mg/day for 7 days and then switched to simvastatin 20 mg/day for additional 3 weeks, till the endothelial function assessment
3241109|NCT00906438|Placebo Comparator|Control|
3241110|NCT00906438|Experimental|Treated|
3241111|NCT00906425|Active Comparator|Submerged healing|The Straumann Bone Level Implant(s) will be placed using a submerged healing treatment
3241112|NCT00906425|Active Comparator|Trans-mucosal healing|The Straumann Bone Level Implant(s) will be placed using a trans-mucosal healing treatment
3241113|NCT00906412||ET Group|Total of 25 participants with ET
3241114|NCT00906412||Controls|25 controls without ET
3241115|NCT00906399|Placebo Comparator|Placebo|Placebo every 2 weeks for 48 weeks followed by 125 µg peginterferon beta-1a subcutaneously every 2 or 4 weeks for 48 weeks.
3241116|NCT00906399|Experimental|Peginterferon Beta-1a Q2W|125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 96 weeks.
3241117|NCT00906399|Experimental|Peginterferon Beta-1a Q4W|125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 96 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).
3241118|NCT00906386|Experimental|1|
3241119|NCT00906386|Placebo Comparator|placebo|
3241307|NCT00905047|Other|UFT|
3241308|NCT00905034|Experimental|MOAD|Chemotherapy regimen of methotrexate, rituximab, vincristine, pegylated L-asparaginase and dexamethasone (MOAD).
3241120|NCT00906373|Active Comparator|Cohort 1, IMC A12 - 10 mg/kg|Treatment cycles will repeat until there is evidence of progressive disease (PD), toxicity, or withdrawal. If any participant experiences a dose-limiting toxicity (DLT), an additional 3 participants will be enrolled at this dose level (for a total of 6). If no further DLTs, enrollment into Cohort 2 will occur.
3241121|NCT00906373|Active Comparator|Cohort 2, IMC A12 20 - mg/kg|Treatment cycles will repeat until there is evidence of PD, toxicity, or withdrawal.
3241122|NCT00906360|Experimental|Treatment (enzyme inhibitor and monoclonal antibody therapy)|Patients receive sunitinib malate orally or by percutaneous gastrostomy tube once daily, cetuximab IV over 60-120 minutes once weekly, and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 7-9 weeks in the absence of disease progression or unacceptable toxicity. Patients with persistent disease undergo surgical resection.
3241123|NCT00906347|Active Comparator|Oxytocin augmentation|Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
3241124|NCT00906347|Active Comparator|Misoprostol augmentation|Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
3241125|NCT00906334|Experimental|800 mg/m^2 ON 01910.Na|800 mg/m^2 ON 01910.Na administered as a continuous intravenous infusion (CIV) over 24 hours for 48 hours (i.e. 2 consecutive 24-hour infusions) every week for the first 3 weeks of 4-week cycle.
3241126|NCT00906334|Experimental|1800 mg ON 01910.Na|1800 mg ON 01910.Na administered as a continuous intravenous infusion (CIV) over 24 hours for 72 hours (i.e., 3 consecutive 24-hour infusions) every 2 weeks for the first four 2-week cycles and every 4 weeks afterwards.
3241127|NCT00906308|Placebo Comparator|Placebo|
3241128|NCT00906308|Experimental|MF101 5 g/day|
3241129|NCT00906308|Experimental|MF101 10 g/day|
3241130|NCT00906295|Active Comparator|Allowed drop in hemoglobin to 4.5-5.5 mmol/L|Transfusion with red blood cells to level between 4.5-5.5 mmol/L
3241131|NCT00906295|Experimental|Allowed drop in hemoglobin to 5.6-6.5 mmol/L|Transfusion with red blood cells to level between 5.6-6.5 mmol/L
3241132|NCT00906282|Experimental|Pemetrexed/Carboplatin|"4 cycles of preoperative treatment (1 Cycle = 21 days):~Pemetrexed: 500 mg/m2 intravenously (IV) for 10 minutes on Day 1 each cycle; Carboplatin: AUC 6.0 by IV on Day 1 each cycle."
3241133|NCT00906269|Active Comparator|1|
3241134|NCT00906269|Sham Comparator|2|
3241135|NCT00906256|Active Comparator|AZD7295|AZD7295
3241136|NCT00906256|Placebo Comparator|Placebo capsule|Placebo
3241137|NCT00906243|Experimental|CV9103|CV9103 will be applied intradermally on three (3) or five (5) time points. Treatment with CV9103 is administered over a period of either seven (7) or twenty-three (23) weeks.
3241138|NCT00906217||elderly patients|patients older than 70 years with normal renal function
3241139|NCT00906204|Experimental|Single-dose Thymoglobulin|Biological/Vaccine Single-dose rabbit Anti-thymocyte Globulin induction, 6 mg/kg IV infusion
3241140|NCT00906204|Active Comparator|Divided-dose Thymoglobulin|Biological/Vaccine Divided-dose rabbit Anti-thymocyte Globulin induction, 1.5 mg/kg IV infusion QD x 4
3241141|NCT00906191|Experimental|1|Single oral dose
3241142|NCT00906178|Experimental|CyberSenga|6-module HIV prevention program tailored for adolescents in Uganda
3241143|NCT00906178|No Intervention|Control|"treatment as usual - the sexual health education adolescents currently receive in secondary school"
3241144|NCT00906165|Active Comparator|1- Immediately provisionalized|The Straumann® Bone Level SLActive Implant (4.1mm diameter) will be immediately provisionalized upon placement, i.e. impressions will be taken directly after implant installation in order to fabricate screw-retained resin crowns within 48 hours after implant placement. At 16 weeks, the final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration.
3241145|NCT00906165|Active Comparator|2- Delayed Loading|The Straumann® Bone Level SLActive Implant (4.1mm diameter) will not be immediately provisionalized, instead there will be delayed implant loading. i.e. the patient will receive a removable prosthesis if necessary and the impressions for the final restoration will be taken 12-14 weeks after implant installation. At 16 weeks, the final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration.
3241146|NCT00906152||Subacute low back pain; chronic low back pain|Patients with subacute or chronic low back pain seen in the Primary Care Centers participating in the study.
3241147|NCT00906139|Active Comparator|Propofol|To receive propofol (0.5 mg/kg up to 400 mg) and fentanyl (0.05 mg);
3241148|NCT00906139|Active Comparator|Midazolam|To receive midazolam (0.1 mg/kg) and fentanyl (0.05 mg).
3241149|NCT00906126|Experimental|Oral Misoprostol 1|Oral misoprostol 25 micrograms every 4 hours for up to two doses.
3241150|NCT00906126|Experimental|Oral Misoprostol 2|Oral misoprostol 50 micrograms every 4 hours for up to two doses.
3241151|NCT00906126|Experimental|Oral Misoprostol 3|Oral misoprostol 100 micrograms every 4 hours for up to two doses.
3241152|NCT00906126|Experimental|Oral Misoprostol 4|Oral Misoprostol 50 micrograms every 2 hours for up to two doses.
3241153|NCT00906126|Experimental|Oral Misoprostol 5|Oral Misoprostol 75 micrograms every 4 hours for up to two doses.
3241154|NCT00906113|Experimental|Intra-arterial melphalan|The patients will be treated by injection of chemotherapy (melphalan) into the ophthalmic artery of an eye affected by retinoblastoma
3241155|NCT00906087|Other|Cosopt|Intraocular pressure and blood pressure measurements will be compared under the following conditions: 1) after washout of clinical treatment, 2) after treatment with Cosopt, and 3) after another washout of Cosopt.
3241156|NCT00906074||Case|Cases will be defined as patients with elective or emergency abdominal surgery who develop severe surgical site infection (deep incisional or organ cavity type; see Center for Disease Control (CDC) criteria for definition in the Appendix), within 0-30 days of surgery.
3241157|NCT00906074||Control|Surgeon-matched controls will be patients with elective or emergency abdominal surgery who are free of surgical site infection (SSI) after 30 days from the surgery.
3241158|NCT00906061|Experimental|Gemcitabine and Docetaxel|Patients received biweekly docetaxel 50 mg/m2 iv, Gemcitabine 2000 mg/m2 iv days 1 and 14.
3241159|NCT00906048|Experimental|1|Levofloxacin and Rifampicin
3241310|NCT00905008||DES|Patients underwent percutaneous coronary intervention and received at least one drug-eluting stent during their index hospitalisation.
3241160|NCT00906035|Active Comparator|Dipyridamole 200mg and Aspirin 25mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy. (NIRS) of the legs.
3241161|NCT00906035|Active Comparator|Dipyridamole 200 mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy. (NIRS) of the legs.
3241162|NCT00906035|Active Comparator|Aspirin 25 mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy (NIRS) of the legs.
3241163|NCT00906022|Experimental|Astron Pulsar Stent|Device: Astron Pulsar Stent
3241164|NCT00906022|Active Comparator|PTA alone|Device: Balloon angioplasty alone
3241165|NCT00905996|Active Comparator|Endoscopic Cyanoacrylate injection|Endoscopic injection of cyanoacrylate in the gastric varix until obturation
3241166|NCT00905996|No Intervention|No Intervention|No treatment offered for gastric varix
3241167|NCT00905996|Other|Beta-blocker (propranolol)|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was > 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure < 90 mm Hg or pulse rate < 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
3241168|NCT00905983|Experimental|Gemcitabine and Docetaxel|Patients received biweekly docetaxel 50 mg/m2 iv, Gemcitabine 2000 mg/m2 iv days 1 and 14.
3241169|NCT00905970||1|Patients with LTBI recently diagnosed under prophylactic chemotherapy treatment.
3241170|NCT00905970||2|Patients with LTBI recently diagnosed not following any prophylactic chemotherapy treatment.
3241171|NCT00905970||3|Patients with LTBI diagnosed time ago.
3241172|NCT00905970||4|Positive control for the Exhaled Breath condensate assay only. Patients with active TB will conform this group. The n of this group is determined, as it will only be used as a positive control to prove the bacilli's DNA can be detected in the exhaled breath condensate.
3241173|NCT00905957|Active Comparator|Transversus abdominis plane (TAP) Group|Patients will receive a TAP block using a local anaesthetic agent after induction of anaesthesia
3241174|NCT00905957|Placebo Comparator|Control Group|Patients will receive a TAP block using a placebo after induction of anaesthesia
3241175|NCT00905944|No Intervention|Control|
3241176|NCT00905944|Experimental|Intervention|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
3241177|NCT00905931|Experimental|Active|
3241178|NCT00905931|Placebo Comparator|Placebo|
3241179|NCT00905918|No Intervention|Arm I|Patients receive no intervention before undergoing planned surgery.
3241180|NCT00905918|Experimental|Arm II|Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 1 week before undergoing planned surgery.
3241181|NCT00905918|Experimental|Arm III|Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 2 weeks before undergoing planned surgery.
3241182|NCT00905905|Experimental|Ezetimibe-Simvastatin 10/40 mg|
3241183|NCT00905905|Active Comparator|Simvastatin 40 mg|
3241184|NCT00905879||Group 1|
3241185|NCT00905866||Quality of life|All participants undergoing parathyroidectomy
3241186|NCT00905853|Active Comparator|Ventricular Tachycardia Ablation|Catheter ablation for Ventricular tachycardia will be performed within 14 days of randomization.
3241187|NCT00905853|Active Comparator|Escalated Antiarrhythmic Drug Therapy|Patients are prescribed a loading dose of amiodarone or the addition of mexiletine to their current anti-arrhythmic medication which is stratified by the dose and type of antiarrhymic medication at the time of the index arrhythmic event.
3241188|NCT00905840|Active Comparator|Titanium Zircon implant|Intervention: each subject will receive two Straumann bone level implants, one implant is fabricated with Titanium Zircon and the other is a grade IV Titanium implant. Both implants will be randomly placed in the interforaminal region of the edentulous mandible, one on the right half and the other in the left part. Both implants will be treated the same way.
3241189|NCT00905840|Placebo Comparator|Titanium Grade IV implant|Intervention: each subject will receive two Straumann bone level implants, one implant is fabricated with Titanium Zircon and the other is a grade IV Titanium implant. Both implants will be randomly placed in the interforaminal region of the edentulous mandible, one on the right half and the other in the left part. Both implants will be treated the same way.
3241190|NCT00905827|Experimental|Intervention 1: in person CAMS|In person Collaborative Assessment and Management of Suicidality (CAMS) training for providers
3241191|NCT00905827|Experimental|Intervention 2: e-learning CAMS|Online Collaborative Assessment and Management of Suicidality (CAMS) training for providers
3241192|NCT00905827|No Intervention|Control: no training|Control Group: no training
3241193|NCT00905814|Other|Sequence 1 (BABA)|Treatment A: One 5-mg FCIR tablet Treatment B: Five 1-mg FCIR tablets Subjects in this sequence will participate in 4 periods in the following order: B -> A -> B -> A
3241194|NCT00905814|Other|Sequence 2 (ABAB)|Treatment A: One 5-mg FCIR tablet Treatment B: Five 1-mg FCIR tablets Subjects in this sequence will participate in 4 periods in the following order: A -> B -> A -> B
3241586|NCT00902902||2|
3241195|NCT00905801|Other|Arm A CT Perfusion|"Arm A Procedure~On the first required study visit, subject will undergo one SOC CT scan followed by the research component:~CTP imaging: Single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from clinical scan~Subject will stand up and walk around, and then lay back down~CT Perfusion imaging: Second single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from their clinical scan~Procedures will be repeated at optional second study visit ~6-8 weeks later."
3241196|NCT00905801|Other|Arm B CT Perfusion|"Arm B Procedure~On the first required study visit, subject will undergo one SOC CT scan followed by the research component:~- CT Perfusion imaging: Single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from clinical scan~Procedures will be repeated at optional second study visit ~6-8 weeks later."
3241197|NCT00905788|No Intervention|Control Group|Embryo transfer without any intervention
3241198|NCT00905788|Experimental|Embryo Expulsion|
3241199|NCT00905775||1 Isoflurane|The first group (G1) will be submitted to inhalational general anesthesia with isoflurane (1 CAM, evaluated by expired concentration of isoflurane)
3241200|NCT00905775||2 Propofol|The second group (G2) to targeted venous general anesthesia controlled with propofol. The targeted concentration of propofol will be kept at the predicted plasma concentration from 1 to 2 µg.ml-1 by means of a Diprifusor® infusion pump. During the interval from 10 minutes preceding ECC initiation to 10 minutes after ECC, the propofol concentration will be increased to 2 or 3 µg.ml-
3241201|NCT00905762|Experimental|Besifloxacin|Besifloxacin one drop instilled into study eye.
3241202|NCT00905762|Active Comparator|Gatifloxacin|Gatifloxacin one drop instilled into study eye.
3241203|NCT00905762|Active Comparator|Moxifloxacin|Moxifloxacin one drop instilled into study eye.
3241204|NCT00905736|Experimental|current controlled|a current controlled microcurent device providing a primarily monophasic waveform of typical amplitude 40 microamps
3241205|NCT00905736|Experimental|voltage controlled|constant voltage amplitude delivering high frequency AC waveform
3241206|NCT00905723|Experimental|Estrogen|Women randomized to this group will receive daily pills containing 1 mg of estradiol
3241207|NCT00905723|Experimental|Isoflavone|Women randomized to this group will receive daily pills of 150 mg isoflavone
3241208|NCT00905723|Placebo Comparator|Placebo|Women randomized to this group will be administered daily placebo pills
3241209|NCT00905710|No Intervention|1|Conventional colonoscopy
3241210|NCT00905710|Experimental|2|Colonoscopy using chromoendoscopy
3241211|NCT00905697||Living donor lung transplantation|Living lung transplantation donors
3241212|NCT00905684||Group 1|
3241213|NCT00905684||Group 2|
3241214|NCT00905671|Experimental|LCP+ Bifurcation Lesion|Bifurcating lesions that are positive for lipid core plaque, as detected by LipiScan Coronary Imaging, prior to angioplasty.
3241215|NCT00905671|Experimental|LCP- Bifurcation Lesion|Bifurcating lesions that are not positive for lipid core plaque, as detected by LipiScan Coronary Imaging, prior to angioplasty.
3241216|NCT00905658|No Intervention|Arm I|Patients are monitored via standard follow-up assessments every 3 weeks.
3241217|NCT00905658|Experimental|Arm II|Patients receive nutritional supplements and are monitored via standard follow-up assessments every 3 weeks.
3241218|NCT00905658|Experimental|Arm III|Patients receive nutritional supplements and are monitored via standard follow-up assessments every 3 weeks with additional biweekly assessments completed at home by a service provider.
3241219|NCT00905645|Experimental|Primary Augmentation|Silimed Gel-Filled Mammary Implant
3241220|NCT00905645|Experimental|Primary Reconstruction|Silimed Gel-Filled Mammary Implant
3241221|NCT00905645|Experimental|Revison|Silimed Gel-Filled Mammary Implant
3241222|NCT00905632|Experimental|BI 207127 low dose + SOC|BI 207127 low dose tid + SOC
3241223|NCT00905632|Experimental|BI 207127 middle dose +SOC|BI 207127 middle dose tid + SOC
3241224|NCT00905632|Experimental|BI 207127 high dose+SOC|BI 207127 high dose tid +SOC
3241225|NCT00905632|Placebo Comparator|Placebo + SOC|Placebo tid +SOC
3241226|NCT00905619||Control|No kidney disease
3241227|NCT00905619||PreHD kidney disease|Kidney disease stage 4 or below
3241228|NCT00905619||Hemodialysis|Kidney disease receiving hemodialysis
3241229|NCT00905606|Experimental|1|Topiramate Tablets, 25 mg
3241230|NCT00905606|Active Comparator|2|Topamax® Tablets, 25 mg
3241231|NCT00905580|Placebo Comparator|Placebo|Patients receive oral Placebo 150 mg 1 hour prior to surgery, and 12 hours later
3241232|NCT00905580|Experimental|Pregabalin|Patients receive oral pregabalin 150 mg 1 hour prior to surgery, and 12 hours later
3241233|NCT00905567|Experimental|Test First|Topiramate 2 x 25 mg Tablet
3241234|NCT00905567|Active Comparator|Reference First|Topamax® Tablet 2 x 25 mg
3241235|NCT00905554|Experimental|warm water|warm water irrigation during the insertion phase of colonoscopy
3241236|NCT00905554|Active Comparator|air|air insufflation during the insertion phase of colonoscopy
3241237|NCT00905541|No Intervention|No treatment|Phase A: No treatment
3241238|NCT00905541|Experimental|simvastatin chronic|Phase B: 40 mg/day simvastatin
3241239|NCT00905541|Experimental|simvastatin acute-on-chronic|Phase C: 80 mg simvastatin acute-on-chronic
3241240|NCT00905528||A|Subjects with type 2 diabetes mellitus, eGFR > 80, hypertension, no overt proteinuria
3241241|NCT00905528||B|Subjects with type 2 diabetes mellitus, eGFR > 80, hypertension, no overt proteinuria
3241242|NCT00905515|Active Comparator|1|Maintain on Cyclosporine (CsA) at target trough level of 50-250 ng/mL.
3241243|NCT00905515|Active Comparator|2|Convert to Prograf (TAC) at target trough levels of 3.0-5.9 ng/mL.
3241244|NCT00905515|Active Comparator|3|Convert to TAC at target trough levels of 6.0-8.9 ng/mL.
3241245|NCT00905502|Experimental|1: Restricted protocol (RG) group|Received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period.
3241246|NCT00905502|Active Comparator|2: Liberal protocol (LG) group|Received 10 ml/kg•hr of RL solution intraoperatively.
3241309|NCT00905021|Experimental|Exemestane plus Sutent|"All patients enrolled on the study will receive treatment as follows:~Exemestane 25 mg by mouth every day.~Sunitinib 37.5 mg by mouth every day."
3241247|NCT00905489|Experimental|Nevirapine IR / Nevirapine XR|In this pharmaco-kinetic (PK) cross-over design trial, all patients initially receive nevirapine immediate release and then all patients are switched to nevirapine extended release 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).
3241248|NCT00905476||NPPV|Patients with chronic respiratory failure receiving domiciliary NPPV
3241249|NCT00905463||Transplantation|Lung transplantation candidates
3241250|NCT00905450|Experimental|BOL-303242-X|BOL-303242-X (Mapracorat)
3241251|NCT00905450|Placebo Comparator|Vehicle|Vehicle for BOL-303242-X (Mapracorat)
3241252|NCT00905437|Placebo Comparator|Placebo|Placebo as an adjunct to standard of care
3241253|NCT00905437|Active Comparator|Pregabalin|Pregabalin as an adjunct to standard of care
3241254|NCT00905424|Experimental|Active|Antidepressant + SPD489
3241255|NCT00905424|Placebo Comparator|Placebo|Antidepressant + placebo
3241256|NCT00905411|No Intervention|Attention Control / Usual Care|
3241257|NCT00905411|Experimental|Intervention|
3241258|NCT00905398|Experimental|nilotinib|single arm study
3241259|NCT00905385|Experimental|Low Dose: 3,200 CFU|5 subjects inoculated with 3,200 colony forming units (CFU).
3241260|NCT00905385|Experimental|High Dose: 32,000 CFU|5 subjects inoculated with 32,000 colony forming units (CFU).
3241261|NCT00905372|Experimental|LY2062430|
3241262|NCT00905372|Placebo Comparator|Placebo|
3241263|NCT00905359|Active Comparator|Aperius™ PercLID™ System|Aperius™ PercLID™ System arm. Patients randomized to this arm will undergo treatment with the Aperius™ PercLID™ System.
3241264|NCT00905359|Active Comparator|Standalone Decompressive Surgery|Patients randomized to this arm will receive Standalone Decompressive Surgery, defined as decompressive surgery without instrumentation or fusion.
3241265|NCT00905346|Experimental|Test First|Topiramate Capsules 25 mg
3241266|NCT00905346|Active Comparator|Reference First|Topamax® 25 mg Capsule
3241267|NCT00905333|Other|Single-arm|3 treatments, 6 sequences, 3 periods, cross-over, single dose arm (Willians' Plan)
3241268|NCT00905320|Active Comparator|Metallic Fasteners and Sutures|Laparoscopic ventral hernia repair with mesh fixation using both metallic fasteners and transabdominal sutures
3241269|NCT00905320|Experimental|Metallic Fasteners Alone|Laparoscopic ventral hernia repair with mesh fixation using metallic fasteners alone
3241270|NCT00905307|Experimental|1|OPC-34712 0.25 mg arm
3241271|NCT00905307|Experimental|2|OPC-34712 low-dose arm
3241272|NCT00905307|Experimental|3|OPC-34712 mid-dose arm
3241273|NCT00905307|Experimental|4|OPC-34712 high-dose arm
3241274|NCT00905307|Placebo Comparator|5|
3241275|NCT00905307|Active Comparator|6|Aripiprazole arm
3241276|NCT00905294||coronary artery disease|Subjects with coronary artery disease undergoing percutaneous coronary intervention
3241277|NCT00905281|Experimental|Action Group|
3241278|NCT00905281|Other|Standard care|
3241279|NCT00905268|Experimental|Group A: Idebenone|Patients under/equal 45 kg: idebenone 180 mg/day Patients over 45 kg: idebenone 360 mg/day
3241280|NCT00905268|Experimental|Group B: Idebenone|Patients under/equal 45 kg: idebenone 450 mg/day Patients over 45 kg: idebenone 900 mg/day
3241281|NCT00905268|Experimental|C: Idebenone|Patients under/equal 45 kg: idebenone 1350 mg/day Patients over 45 kg: idebenone 2250 mg/day
3241282|NCT00905268|Placebo Comparator|D: Placebo|placebo
3241283|NCT00905255|Experimental|Lixisenatide (Two-step Titration)|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
3241284|NCT00905255|Experimental|Lixisenatide (One-step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to end of treatment.
3241285|NCT00905229|Active Comparator|PO (by mouth)|2.5 mg P.O Vitamin K
3241286|NCT00905229|Active Comparator|IV (intravenous )|0.5 mg IV Vitamin K
3241287|NCT00905216|Experimental|Test|Heparin sodium - Bergamo
3241288|NCT00905216|Active Comparator|Comparator|Heparin APP
3241289|NCT00905203|Experimental|1|moderate exercise training (three times/ week including one home-based training and two supervised training)
3241290|NCT00905203|Experimental|2|intensive exercise training (four times/ week including one home-based training and three supervised training)
3241291|NCT00905190|Experimental|Fed|A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast
3241292|NCT00905190|Experimental|Fasting|A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.
3241293|NCT00905164|Experimental|Test First|Topiramate Capsules, 25 mg
3241294|NCT00905164|Active Comparator|Reference First|Topamax® Capsules, 25 mg
3241295|NCT00905151||HIV Positive|Across-sectional analysis of 200 HIV+ patients with varying levels of kidney function
3241296|NCT00905138|Experimental|1|single ascending doses
3241297|NCT00905138|Placebo Comparator|2|single dose placebo
3241298|NCT00905138|Experimental|3|multiple dose, 5 days, oral solution
3241299|NCT00905138|Placebo Comparator|4|multiple dose, 5 days, oral solution
3241300|NCT00905125|Experimental|Arm 2, Fluarix®|Single 0.5 mL intramuscular injection of Fluarix®.
3241301|NCT00905125|Experimental|Arm 1, Fluzone®|Single 0.5 mL intramuscular injection of Fluzone®.
3241302|NCT00905112|Experimental|MOMS|Receives manual therapy, stabilization exercise and patient education
3241303|NCT00905112|Active Comparator|STOB|Receive standard obstetrical care
3241304|NCT00905073|Experimental|cyclosporin+Methotrexate|cyclosporin treatment at 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for on year and methotrexate 5 mg/kg/day for one year.
3241305|NCT00905060|Experimental|protein peptide-complex (HSPPC-96)|autologous tumor-derived heat shock protein peptide-complex (HSPPC-96) administered at 25 μg per dose injected intradermally once weekly for 4 consecutive weeks and monthly following standard treatment with radiation and temozolomide.
3241306|NCT00905047|Other|XELODA|
3241311|NCT00905008||BMS|Patients underwent percutaneous coronary intervention and received at least one uncoated stent during their index hospitalisation.
3241312|NCT00904995|Experimental|Group 1 - Oral|Voriconazole Starting oral dose of 400 mg pills twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
3241313|NCT00904995|Experimental|Group 2 - IV + Oral|Voriconazole 6 mg/kg by vein (IV) first dose then 200 mg pills two times a day thereafter.
3241314|NCT00904982|Other|1 Usual Care Group/Control|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication. The MM can display messages to the participant and can confirm when medication is taken correctly.
3241315|NCT00904982|Experimental|2Med-eMonitor/Reminder|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication and will be set on active mode for this group. The MM will display messages of encouragement to participants and education on the importance of taking their warfarin medication. The Med-eMonitor also features an alarm that will sound to remind participants to take their medication as scheduled.
3241316|NCT00904982|Experimental|3 Incentive Group/Lottery|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication. The MM can display messages to the participant. This group will also be entered into a daily lottery in which he/she can win money. On any given study day, participants have a 1 in 10 chance of winning $10 and 1 in 100 chance of winning $100 when taking their warfarin as prescribed. Participants must take their dose correctly in order to be eligible for the daily lottery.
3241317|NCT00904982|Experimental|4 Combined Group/Lottery and Reminder|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication and will be set on active mode for this group. The MM will display messages of encouragement to participants and education on the importance of taking their warfarin medication. The Med-eMonitor also features an alarm that will sound to remind participants to take their medication as scheduled. Participants in this group will also be entered into a daily lottery. On any given study day, participants have a 1 in 10 chance of winning $10 and 1 in 100 chance of winning $100 when taking their warfarin medication as prescribed. Participants must take their dose correctly in order to be eligible for the daily lottery.
3241318|NCT00904969|Experimental|AMS Transobturator Male Sling System|
3241319|NCT00904943|Experimental|Test First|Topiramate Capsules, 25 mg
3241320|NCT00904943|Active Comparator|Reference First|Topamax® Capsules, 25 mg
3241321|NCT00904930||no periodontal disease|33 dental students (13 male, 20 female) with a mean age of 24.7 years (min. 19.8; max. 36.5) with no periodontal disease or dental trauma
3241322|NCT00904917|Experimental|Adapted PIP|"Participants (both mother and children) participated in an adapted cognitive family prevention program for the families of children with a depressed African American mother.~The intervention was the Prevention Intervention Project."
3241323|NCT00904917|Active Comparator|Lecture|"Mothers received psychoeducation about depression.~The intervention was psychoeducation."
3241324|NCT00904904|Experimental|Indomethacin|Indomethacin ophthalmic solution 0.1% for post-surgical inflammation
3241325|NCT00904904|Active Comparator|Ketorolac|Ketorolac ophthalmic solution 0.5% for post-surgical inflammation
3241326|NCT00904891|Experimental|1|Participants will receive a cognitive-behavioral group intervention.
3241327|NCT00904891|Active Comparator|2|Participants will receive cognitive-behavioral bibliotherapy.
3241328|NCT00904891|No Intervention|3|Participants will only complete study assessments.
3241329|NCT00904865|Other|1|SPA cholecystectomy
3241330|NCT00904865|Other|2|laparoscopic cholecystectomy
3241331|NCT00904852|Experimental|Tandutinib, bevacizumab, and temozolomide|tandutinib in combination with temozolomide and bevacizumab following concurrent radiation therapy and temozolomide treatment.
3241332|NCT00904839|Experimental|BIBF 1120 + mFolfox6|BIBF1120 medium dose twice daily
3241333|NCT00904839|Active Comparator|Bevacizumab + mFolfox6|Bevacizumab 5mg/kg once daily every other week
3241334|NCT00904826|Experimental|Eculizumab|The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks. Subjects will receive therapy for a total of 12 months.
3241335|NCT00904813|Active Comparator|1. RT 5x5 Gy + surgery within 1 week|RT=Preoperative radiotherapy Gy=Gray
3241336|NCT00904813|Active Comparator|2.RT 5x5 Gy + surgery after 4-8 weeks|RT=radiotherapy Gy= Gray
3241337|NCT00904813|Active Comparator|3.RT 25x2 Gy + surgery after 4-8 weeks|RT= radiotherapy Gy= Gray
3241338|NCT00904800|Experimental|1|Low dose
3241339|NCT00904800|Experimental|2|Middle dose
3241340|NCT00904800|Experimental|3|High dose
3241341|NCT00904800|Placebo Comparator|4|placebo
3241342|NCT00904787|Experimental|1|
3241343|NCT00904774||premature neonates|gestational age less than 28 weeks
3241344|NCT00904761|Experimental|exercise|arm: intervention
3241345|NCT00904748|Experimental|Test 1|
3241346|NCT00904748|Experimental|Test 2|
3241347|NCT00904748|Active Comparator|Reference|
3241348|NCT00904735|Experimental|Arm I|Patients receive oral hydroxyurea twice daily and oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
3241349|NCT00904735|Experimental|Arm II|Patients receive oral hydroxyurea twice daily in the absence of disease progression or unacceptable toxicity.
3241350|NCT00904722|Experimental|CT-011 in combination with Rituximab|Combination of the immunotherapy drugs, CT-011 and rituximab.
3241351|NCT00904709|Experimental|Tranexamic acid, Menorrhagia, Bleeding|Tranexamic acid with titrated doses. All women with menorrhagia will take .
3241352|NCT00904683|Experimental|LY2062430|
3241353|NCT00904683|Placebo Comparator|Placebo|
3241354|NCT00904670|Experimental|Active|
3241355|NCT00904670|Placebo Comparator|Comparator|
3241633|NCT00902590||2|unrelated adults accompanying patients to clinic
3241870|NCT00900991|Experimental|10 ug|10 microgram per dose
3241356|NCT00904644||Salvage group|In this group patients are enrolled that have failed previous antiretroviral drug regimens and qualify for Raltegravir treatment according to the approved indication of this drug in Switzerland.
3241357|NCT00904644||Switch group|In this group, patients are enrolled which have to switch to Raltegravir due to drug toxicity or adverse events caused by other antiretroviral drugs.
3241358|NCT00904631|Experimental|Treatment|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
3241359|NCT00904618|Experimental|TVT-SECUR|This study arm consisted of 48 women operated from January 2007 to October 2008. All patients underwent the implantation of the TVT-SECUR for the treatment of stress urinary incontinence or stress predominant mixed urinary incontinence. The surgery was done under local anesthesia by one high-volume surgeon.
3241360|NCT00904605|Experimental|1- Lidoderm®|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
3241361|NCT00904605|Active Comparator|2-Celecoxib 200mg|Celecoxib (Celebrex®, G.D. Searle & Co., Chicago, IL), one 200 mg oral capsule QD
3241362|NCT00904592|Experimental|Qi ming granula|"Study group(combined therapy with Intervention of TCM): Basic therapy ＆ treating both on deficiency and stasis of blood.~Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management, exercise and education.~Qi ming granula, Usage: 4.5g，po，tid."
3241363|NCT00904592|Placebo Comparator|placebo comparator|"Control group: Basic therapy ＆ placebo~Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~placebo,Usage: 4.5g，po，tid"
3241364|NCT00904553||Novalis Shaped Beam Surgery|Patients with limited brain metastases (mostly solitary brain metastasis) treated with Novalis Shaped Beam Surgery followed by planned craniotomy and resection of the metastases.
3241365|NCT00904540|Experimental|Lidoderm®|Commercially available Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain
3241366|NCT00904527|Experimental|Relaxation|Relaxation (Schultz)+ medical treatment (beta-bloquant or Oxetorone)+ patient's education
3241367|NCT00904527|No Intervention|without relaxation|Patients have no relaxation (only medical treatment+ education)
3241368|NCT00904501|Placebo Comparator|A|A bone marrow harvest (500 mL under general anaesthesia) is performed and BM-MNC are separated and concentrated (30mL). A placebo cell-product (30 mL saline with 4 ml peripheral blood) is implanted and the BM-MNC are cryo-conserved. Only the cell therapy unit, neither the patient, nor the clinician, know whether BM-MNC or placebo is implanted. After 6 months, it is possible to use previously cryo-conserved BM-MNC.
3241369|NCT00904501|Experimental|B|A bone marrow harvest (500 mL under general anaesthesia) is performed and BM-MNC are separated and concentrated (30mL) . The BM-MNC are implanted on the same day. Only the cell therapy unit, neither the patient, nor the clinician, know whether BM-MNC or placebo is implanted
3241370|NCT00904488|Active Comparator|Addition of PO Thiazide Diuretic|Addition of oral metolazone 5 mg daily to current intravenous bolus furosemide. All subjects will continue their current dose of intravenous bolus furosemide.
3241371|NCT00904488|Active Comparator|IV furosemide dose escalation|Current IV furosemide dose will be escalated to 2-2.5 x current dose, given as either IV bolus or continuous infusion over 24 hours.
3241372|NCT00904475|Experimental|1- Lidoderm®|Lidoderm (lidocaine patch 5%), up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain
3241373|NCT00904475|Placebo Comparator|2-Placebo|Matching placebo, up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain
3241374|NCT00904462|Experimental|Lidocaine 5% patch|Lidocaine 5% patch (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied on each affected knee once every 24 hours
3241375|NCT00904462|Placebo Comparator|Placebo patch|Matching placebo patch, 1⅓ patches applied on each affected knee once every 24 hours
3241376|NCT00904449|Experimental|Open Label|
3241377|NCT00904436|Experimental|1|Spinal Cord Injury: subjects who have cervical spinal cord injury and complaints of dyspnea
3241378|NCT00904436|No Intervention|2|Controls
3241379|NCT00904423|Experimental|Vitamin D|
3241380|NCT00904410|Experimental|1|
3241381|NCT00904397|Experimental|Lidoderm|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 2 patches applied once daily (q24h) directly to the most painful area of the low back
3241382|NCT00904397|Active Comparator|Celecoxib|Celecoxib (Celebrex®, G.D. Searle & Co., Chicago, IL), one 200 mg oral capsule QD
3241383|NCT00904384||HIV+|Patients with HIV infection living in the Autonomous Community of the Balearic Islands (CAIB), Spain
3241384|NCT00904384||Reference group|Same determinations as in HIV+ cases will be obtained in the control group of COPD patients without HIV infection as part of the study PAC-EPOC (FIS 05/2082)
3241385|NCT00904371||Patients with arterial hypertention|
3241386|NCT00904358||cross sectional area|internal jugular cross sectional area measured by ultrasound
3241387|NCT00904345|Experimental|Treatment|
3241388|NCT00904319|Experimental|Aquatic|Aquatic Power Training
3241389|NCT00904306|Placebo Comparator|Sugar pill|6 months treatment with placebo
3241390|NCT00904306|Active Comparator|low dose|600ug/day chromium picolinate for 6 months
3241391|NCT00904306|Active Comparator|high dose chromium picolinate|1000 ug/day
3241392|NCT00904293|Experimental|Genotype-guided warfarin dosing|A dosing algorithm including clinical factors and genotype information (VKORC1 and CYP2C9) will be used to determine initial warfarin doses.
3241393|NCT00904293|Active Comparator|Non-genotype guided warfarin dosing|Initial warfarin dosing will be determined using the same algorithm as in the experimental group, but only including the clinical factors and not including the genotype information
3241394|NCT00904280|Experimental|Oxymorphone ER|
3241395|NCT00904254|Experimental|1, diagnostic comparison|EP 1645/Solution For Injection
3241869|NCT00901004||1|Reflux esophageal minimal change in the endoscopic finding
3241396|NCT00904241||Ancillary-Correlative (cytology specimen collection)|Patients undergo collection of blood, tissue, and bone marrow samples for analysis via RT-PCR, quantitative PCR, flow cytometry, and FISH.
3241397|NCT00904202|Placebo Comparator|placebo capsules + placebo patch|Placebo to match lidocaine patch; up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing
3241398|NCT00904202|Experimental|placebo capsules + Lidoderm patch (Lidocaine Group)|Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing
3241399|NCT00904202|Active Comparator|Gabapentin capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules for oral dosing at a dose of 1800 mg/day AND Placebo patch to match lidocaine patch; up to four patches applied topically daily (q24h) to the area of maximal peripheral pain
3241400|NCT00904202|Other|Gabapentin capsules 1800 mg/day + Lidoderm patch|Gabapentin 1800 mg/day AND Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain
3241401|NCT00904189|No Intervention|Standard of care radiation therapy|Standard of care given for treatment of cancer. Subjects receiving incidental radiation dose to fingernails.
3241402|NCT00904176|Active Comparator|Dapagliflozin + Warfarin|
3241403|NCT00904176|Active Comparator|Warfarin|
3241404|NCT00904176|Active Comparator|Dapagliflozin + Digoxin|
3241405|NCT00904176|Active Comparator|Digoxin|
3241406|NCT00904150||1 Menstrual migraine|Caucasian women with a current or past history of menstrual migraine (MM = pure menstrual migraine or menstrually-related migraine) attending the City of London Migraine Clinic
3241407|NCT00904150||2 No migraine|Caucasian women with no personal history of migraine
3241408|NCT00904137|Active Comparator|Cast|Above elbow fiberglass cast with a collar-and-cuff
3241409|NCT00904137|Active Comparator|Splint|Long arm posterior plaster splint with a collar-and-cuff
3241410|NCT00904137|Active Comparator|Tape|Elastoplast tape applied to keep the elbow in flexion, with a collar-and-cuff
3241411|NCT00904124|Placebo Comparator|Control|No regular flour replaced
3241412|NCT00904124|Experimental|5% Cellulose|5% regular flour is replaced by cellulose
3241413|NCT00904124|Experimental|2.5% Alginate|2.5% regular flour is replaced by Alginate
3241414|NCT00904124|Experimental|5% Alginate|5% regular flour is replaced by Alginate
3241415|NCT00904124|Experimental|2.5% Guar gum|2.5% regular flour is replaced by Guar gum
3241416|NCT00904124|Experimental|1.25% Guar gum|1.25% regular flour is replaced by Guar gum
3241417|NCT00904111|Experimental|Lidocaine 5% Patch|Lidocaine 5% patch (Lidoderm®,Endo Pharmaceuticals Inc.), 2 patches applied directly to the most painful area of the low back once daily (q24h)
3241418|NCT00904111|Placebo Comparator|Placebo Topical Patch|Matching placebo patch, 2 patches applied directly to the most painful area of the low back once daily (q24h)
3241419|NCT00904098|Experimental|Frovatriptan|Frovatriptan 2.5 mg oral tablet
3241420|NCT00904098|Active Comparator|Usual Care|Usual care includes the current treatment used to treat all episodes of migraine headache
3241421|NCT00904085|Active Comparator|Oxymorphone|
3241422|NCT00904085|Placebo Comparator|Placebo|
3241423|NCT00904072||accepted|The suggestions provided by the CDSS which were accepted by the physicians.
3241424|NCT00904072||denied|The suggestions provided by the CDSS which were denied by the physicians.
3241425|NCT00904059|Experimental|Treatment Group A|
3241426|NCT00904059|Experimental|Treatment Group B|
3241427|NCT00904059|Experimental|Treatment Group C|Treatment Groups A and B are followed by Treatment Group C: A combination of BMS-650032 (200 mg) and BMS-790052 (30 mg)
3241428|NCT00904046|Experimental|Pioglitazone|For 60 Aim 2 Subjects Only - Pioglitazone (Actos)
3241429|NCT00904046|Placebo Comparator|Placebo|For 60 Subjects in Aim 2 Only - Placebo for Pioglitazone
3241430|NCT00904033|Experimental|1Calcitriol|Calcitriol
3241431|NCT00904033|Experimental|2 Exericse|Home based walking and resistance band training
3241432|NCT00904033|Experimental|3 Calcitriol and Exericse|
3241433|NCT00904033|Active Comparator|4 Multivitamin|
3241434|NCT00904020|Experimental|(1) Lidoderm|(1) Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
3241435|NCT00904007|Experimental|SE Game Cohort|Will receive ISE intervention.
3241436|NCT00904007|No Intervention|Control Cohort|The control cohort will receive identical content online (with no ISE)
3241437|NCT00903994|Other|Single Arm|Single Arm
3241438|NCT00903981|Experimental|Avanafil 100mg|
3241439|NCT00903981|Experimental|Avanafil 200mg|
3241440|NCT00903981|Placebo Comparator|Placebo|
3241441|NCT00903968|Experimental|Phase I Dose Level 1|Phase I Dose Level 1 patients received plerixafor 160ug/kg by injection on days 1-6 and bortezomib 1.0 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
3241442|NCT00903968|Experimental|Phase I Dose Level 2|Phase I Dose Level 2 patients received plerixafor 160ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
3241443|NCT00903968|Experimental|Phase I Dose Level 3|Phase I Dose Level 3 patients received plerixafor 240ug/kg by injection on days 1-6 and bortezomib 1.0 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
3241444|NCT00903968|Experimental|Phase I Dose Level 4|Phase I Dose Level 4 patients received plerixafor 240ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
3241445|NCT00903968|Experimental|Phase I Dose Level 5|Phase I Dose Level 5 patients received plerixafor 320ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
3241446|NCT00903968|Experimental|Phase I Dose Level 5B|Phase I Dose Level 5B patients received plerixafor 320ug/kg by injection on days 1, 2, 3, 6, 10, and 13 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
3241447|NCT00903968|Experimental|Phase I Dose Level 6|Phase I Dose Level 6 patients received plerixafor 400ug/kg by injection on days 1, 2, 3, 6, 10, and 13 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
3241448|NCT00903968|Experimental|All Phase I Participants|All Phase I participants received plerixafor by injection and bortezomib intravenously according to the established dose escalation schedule. Participants were treated until disease progression or unacceptable toxicity.
3241449|NCT00903968|Experimental|All Phase II Participants|All Phase I participants received plerixafor 320ug/kg by injection on days 1, 2, 3, 6, 10, and 13, bortezomib 1.3 mg/m2 intravenously or subcutaneously days 3, 6, 10, and 13, and dexamethasone 40mg orally days 3, 6, 10, and 13 of each 21 day cycle during induction. In maintenance, participants received plerixafor, bortezomib, and dexamethasone days 1, 8, 15, and 22 of each 35 day cycle. Participants were treated until disease progression or unacceptable toxicity.
3241450|NCT00903955||Chronic Obstructive Pulmonary Disease|Subjects diagnosed with COPD are classified according to standards set forth by the Global Initiative on Obstructive Lung Disease. This study recruits subjects in each of three GOLD categories.
3241451|NCT00903929|Experimental|Eltrombopag|
3241452|NCT00903903||1|RA patients with at least one active synovitis
3241453|NCT00903903||2|Non-RA patients with at least one active synovitis
3241454|NCT00903890||A|Individuals who have previously received radiation therapy and anthracycline chemotherapy for their Hodgkin's or non-Hodgkin's lymphoma.
3241455|NCT00903877|Experimental|Placebo followed by T3|Participants receive placebo for 4 weeks. Following placebo, participants begin T3 treatment at 25 mcg per day, for 4 weeks. Following this, participants begin T3 treatment at 50 mcg per day, for 4 more weeks.
3241456|NCT00903864||stethoscopy|
3241457|NCT00903864||BPM|blood pressure monitor
3241458|NCT00903851|Experimental|(1) Lidoderm|(1)Commercially available Lidoderm® (lidocaine patch 5%), up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain
3241459|NCT00903838|Experimental|1|
3241460|NCT00903838|Active Comparator|2|
3241461|NCT00903825|Active Comparator|Manual palpation|Local anesthetic before femoral artery puncture will be injected with the classic manual palpation technique
3241462|NCT00903825|Experimental|Ultrasound guidance|Local anesthetic before femoral artery puncture will be performed with the use of duplex ultrasound guidance
3241463|NCT00903812||A|No intervention - observational study
3241464|NCT00903799|Other|1|"Gastric electrical stimulation using Enterra Therapy. Device activated during 4 months then device in 'OFF' position the 4 following months.~After the cross-over period, device activated until the end of the trial"
3241465|NCT00903799|Other|2|"Gastric electrical stimulation using Enterra Therapy. Device in 'OFF' position during 4 months then device activated the 4 following months.~After the cross-over period, device activated until the end of the trial"
3241466|NCT00903786|Experimental|Perampanel|"Participants were treated with the perampanel dose that was administered in maintenance period of Study E2007-J081-231 (Study 231) [NCT00849212]. In some instances, a 1-step down-titration from the viewpoint of safety and up-titration to the maintenance dose of Study 231 was allowed. In general, 1 to 6 tablets of perampanel was administered orally as a 2-milligram (mg) tablet (2 mg to 12 mg) once daily before bedtime (under fed conditions as much as possible).~The investigator, or subinvestigator, was allowed to complete the treatment by tapering the study drug after end of treatment or discontinuation (Follow-up Period), as appropriate. The taper period was 4 weeks at the longest."
3241467|NCT00903760|Experimental|Decitabine + Clofarabine|"Decitabine + Clofarabine~Receive drugs in alternating series of cycles (decitabine for first 3 cycles, then clofarabine for next 3 cycles), pattern repeats for up to 24 cycles."
3241468|NCT00903760|Experimental|Decitabine|Decitabine 20 mg/m2 by vein daily for 5 days for a total of 24 courses.
3241469|NCT00903747|Experimental|1|Prucalopride
3241470|NCT00903747|Placebo Comparator|2|Placebo/moxifloxacin
3241471|NCT00903734|Experimental|Erlotinib Hydrochloride|Those eligible for umbrella of studies and have not received Erlotinib hydrochloride in past, will first receive Erlotinib hydrochloride alone.
3241472|NCT00903721||1|Patients with perennial allergic rhinitis
3241473|NCT00903721||2|Patients with seasonal allergic rhinitis (including patients who also have perennial allergic rhinitis)
3241474|NCT00903708|Experimental|LY2275796|
3241475|NCT00903695|Experimental|Memory XL|"Subjects will take 2 Memory XL pills daily for 12 months (a vitamin nutriceutical developed by Thomas Shea, Ph.D.).~Mild Cognitive Impairment (MCI) patients, who met inclusion/exclusion criteria, were assessed initially using 3 cognitive tests and 4 behavioral questionnaires, before they began ingesting pills assigned to them by VAMC Research Pharmacist. Each 3 months thereafter, they returned to lab to be reassessed using same instruments, and to receive the next batch of study pills from the Pharmacist. The last assessment was when the patient had just finished 12 months of pill ingestion."
3241476|NCT00903695|Placebo Comparator|placebo|"Subjects diagnosed with MCI took two placebo pills daily for 12 months; these pills are formulated to look and taste the same as the nutriceutical being studied, Memory XL, so study was double-blind. Procedures for this arm are exactly the same as the MEMORY XL arm.~MCI subjects were assessed using 3 cognitive tests and 4 behavioral questionnaires, before they began ingesting the pills assigned to them by the Research Pharmacist at VAMC. Each 3 months thereafter, they returned to lab to be reassessed using the same instruments, and to receive next batch of study pills. Last assessment was when patient had completed 12 months of pill ingestion."
3241477|NCT00903682|Experimental|etravirine|etravirine (ETR TMC125) 400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
3241478|NCT00903682|Active Comparator|efavirenz|efavirenz (EFV) 600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
3241479|NCT00903669||Peripheral Facial Paralysis (PFP)|Patients who are diagnosed with peripheral facial paralysis.
3241480|NCT00903656|Experimental|Caelyx/Lapatinib|
3241481|NCT00903643||Healthy subjects|
3241482|NCT00903643||PBS subjects|
3241483|NCT00903630|Experimental|Phase 1 - Dose Level 1|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: 10 mg daily on Days 1-28 every 28 days
3241484|NCT00903630|Experimental|Phase I - Dose Level 2|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: 15 mg daily on Days 1-28 every 28 days
3241485|NCT00903630|Experimental|Phase 2|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: maximum tolerated dose from Phase I portion of the study (10mg) daily on Days 1-28 every 28 days
3241486|NCT00903617|Experimental|Part A Treatment A|5 mg of GSK256073
3241487|NCT00903617|Experimental|Part A Treatment B|50 mg of GSK256073
3241488|NCT00903617|Experimental|Part A Treatment C|150 mg of GSK256073
3241489|NCT00903617|Placebo Comparator|Part A Treatment D|placebo
3241490|NCT00903617|Placebo Comparator|Part B Treatment A|placebo
3241491|NCT00903617|Active Comparator|Part B Treatment B|1500 mg Niaspan
3241492|NCT00903617|Experimental|Part B Treatment C|x mg dose of GSK256073 based on data from Part A
3241493|NCT00903617|Experimental|Part B Treatment D|optional dose of GSK256073 based on data from Part A
3241494|NCT00903604|Experimental|AP214|Infusions of sequential ascending dosages of AP214
3241495|NCT00903604|Placebo Comparator|Placebo|Infusions of saline solution
3241496|NCT00903591||1|All women will be interviewed by telephone using the a similar questionnaire as used in the parent study. DNA samples will be obtained either via blood samples drawn during a home or clinic visits, or an Oragene Saliva DNA Self-Collection Kit sent to the participant's home.
3241497|NCT00903578||Kidney transplant recipients|
3241498|NCT00903552|Experimental|Low Dose|
3241499|NCT00903552|Placebo Comparator|PBS|
3241500|NCT00903552|Experimental|High Dose|
3241501|NCT00903526||candidemia|
3241502|NCT00903500|Experimental|1|Daily physical activity
3241503|NCT00903500|No Intervention|2|Usual care
3241504|NCT00903461|Experimental|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Subjects will receive a total of up to 7 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive a total EGFR AS dose of 1.92 milligrams in 1.78 milliliters on each weekly treatment. This dose may be delivered equally in the same tumor site per weekly session, the primary tumor or cervical lymph nodes.
3241505|NCT00903448|Experimental|A|Prilosec OTC
3241506|NCT00903448|Active Comparator|B|Prevacid
3241507|NCT00903422|Active Comparator|Eltrombopag|Eltrombopag
3241508|NCT00903422|Placebo Comparator|Placebo|Placebo
3241509|NCT00903409|Experimental|"Simvastatin + Lovaza® (Non-switchers)"|"Open label Simvastatin + Lovaza® (omega-3-acid ethyl esters) NOTE: this group was originally assigned to Simvastatin + Lovaza® in the double-blind trial, hence in this open-label extension, they are termed Non-switchers"
3241510|NCT00903409|Experimental|"Simvastatin + Lovaza® (Switchers)"|"Open label Simvastatin + Lovaza® (omega-3-acid ethyl esters) NOTE: this group was originally assigned to Simvastatin + placebo in the double-blind trial, hence in this open-label extension, they are termed Switchers"
3241511|NCT00903396|Experimental|Arm I|Patients receive palonosetron hydrochloride IV on day 1.
3241512|NCT00903396|Experimental|Arm II|Patients receive palonosetron hydrochloride IV on days 1 and 4.
3241513|NCT00903396|Placebo Comparator|Arm III|Patients receive placebo IV on day 1.
3241514|NCT00903396|Placebo Comparator|Arm IV|Patients receive placebo IV on days 1 and 4.
3241515|NCT00903383|Experimental|Low Dose|A low dose of LX3305; daily oral intake for 12 weeks
3241516|NCT00903383|Experimental|Mid Dose|A mid dose of LX3305; daily oral intake for 12 weeks
3241517|NCT00903383|Experimental|High Dose|A high dose of LX3305; daily oral intake for 12 weeks
3241518|NCT00903383|Placebo Comparator|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
3241519|NCT00903370|Active Comparator|MVS|All participants will undergo mitral valve surgery with ligation/excision of left atrial appendage.
3241520|NCT00903370|Experimental|Ablation|Participants will undergo mitral valve surgery with ligation/excision of left atrial appendage plus surgical ablation with pulmonary vein isolation or biatrial lesion set.
3241521|NCT00903357|Experimental|Montelukast first, then placebo|The group received active medication (montelukast 4 mg or 5mg once daily) for 8 weeks followed by a crossover to 8 weeks of placebo after 2-weeks washout period.
3241522|NCT00903357|Experimental|Placebo first, then Montelukast|The group received placebo medication (ascorbic acid) for 8 weeks followed by a crossover to 8 weeks of active medication (montelukast 4 mg or 5mg once daily) after 2-weeks washout period.
3241523|NCT00903344|Experimental|Vitamin D|4000IU Vitamin D3 in tablet taken daily with multivitamin
3241524|NCT00903344|Active Comparator|Multivitamin|Multivitamin with 400IU vitamin D tablet
3241525|NCT00903331|Experimental|ACT-064922|ACT-064922 tablet (macitentan), 10 mg, once daily
3241526|NCT00903331|Placebo Comparator|Placebo|Matching placebo, once daily
3241527|NCT00903318||Mexican American Men and Women|Rural and urban Mexican American men and women , aged 18 to 40, in urban Baytown, TX and rural Rio Grande Valley (Hidalgo County) communities along the Texas-Mexico border
3241528|NCT00903305|Experimental|Group II (SNIP)|Patients undergo SNIP comprising four visits over 2 months and four monthly telephone calls from the APN. The APN will provide 24 hour access during the study. Patients complete questionnaires about satisfaction with care, perceived preparedness with self-care, and helpfulness of patient teaching at baseline, 3 months and 6 months.
3241529|NCT00903305|Active Comparator|Group I (usual care intervention)|Patients undergo usual care and complete questionnaires about satisfaction with care, perceived preparedness with self-care, and helpfulness of patient teaching at baseline, 3 months and 6 months.
3241530|NCT00903292|Active Comparator|A, erlotinib|If EGFR mutation found then assigned to thyrosine kinase inhibitor (erlotinib)
3241531|NCT00903292|Active Comparator|B, pemetrexed|If EGFR wild type found then assigned to chemotherapy (pemetrexed)
3241532|NCT00903279|Placebo Comparator|Placebo|
3241533|NCT00903279|Experimental|Altabax|
3241534|NCT00903266|Experimental|MIT|Melodic Intonation Therapy
3241535|NCT00903266|Active Comparator|SRT|Speech-Repetition-Therapy
3241536|NCT00903266|No Intervention|NTC|No-Therapy Control; Patients in this arm will be re-randomized to the two active arms at the end of the NTC period.
3241764|NCT00901836|Active Comparator|Surgery|Standard of care surgery will be performed 4-6 weeks after the completion of radiation.
3241537|NCT00903227|Experimental|Low Dose|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg) and 1 puff of inhaled Placebo twice a day with placebo intranasal spray 2 squirts each nostril once a day.
3241538|NCT00903227|Experimental|Combined|One puff of inhaled fluticasone propionate Evohaler pMDI 50 µg twice a day (Total daily FP dose 100 µg) and 1 puffs of Placebo twice a day with intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts each nostril once a day (i.e. total intranasal FP daily dose 200ug).
3241539|NCT00903227|Experimental|High dose|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg) and 1 puff of inhaled placebo twice a day with placebo intranasal spray 2 squirts each nostril once a day.
3241540|NCT00903201|Experimental|Treatment A|20 mg of SB656933
3241541|NCT00903201|Experimental|Treatment B|50 mg of SB656933
3241542|NCT00903201|Experimental|Placebo|Placebo
3241543|NCT00903188|Active Comparator|Cyclosporine|Simulect + cyclosporine + Myfortic + steroid stop at 3 months
3241544|NCT00903188|Active Comparator|Everolimus|Simulect + cyclosporine (decrease dose in one week at month 3 and replace by Everolimus (Certican)) + Myfortic + steroid maintenance
3241545|NCT00903175|Experimental|everolimus 1L/sunitinib 2L|everolimus First Line: 10 mg orally, once daily, (two 5 mg tablets), continuous treatment. sunitinib Second Line: 50 mg orally, once daily, 4 weeks on treatment followed by 2 weeks off (4/2)
3241546|NCT00903175|Active Comparator|sunitinib 1L/everolimus 2L|sunitinib First Line: 50 mg orally, once daily, 4 weeks on treatment followed by 2 weeks off (4/2) everolimus Second Line: 10 mg orally, once daily (two 5 mg tablets), continuous treatment
3241547|NCT00903162|Experimental|Letrozole-Leuprolide|Patients will receive 2.5mg oral letrozole daily and either 7.5mg monthly of Leuprolide IM or 22.5mg every three months of Leuprolide IM. Zoledronic acid 4mg IV every 6 months x 4 will also be offered optionally.
3241548|NCT00903149||MITP exposure or not|Mothers of children born preterm and term.
3241549|NCT00903084|Active Comparator|1|Participants will receive 7 doses per week, then 4 doses per week, then 2 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
3241550|NCT00903084|Active Comparator|2|Participants will receive 7 doses per week, then 2 doses per week, then 4 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
3241551|NCT00903084|Active Comparator|3|Participants will receive 4 doses per week, then 7 doses per week, then 2 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
3241552|NCT00903084|Active Comparator|4|Participants will receive 4 doses per week, then 2 doses per week, then 7 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
3241553|NCT00903084|Active Comparator|5|Participants will receive 2 doses per week, then 7 doses per week, then 4 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
3241554|NCT00903084|Active Comparator|6|Participants will receive 2 doses per week, then 4 doses per week, then 7 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
3241555|NCT00903071|Active Comparator|REAL PPL|REAL+PPL profiles PCP performance using real electronic medical record derived data to identify each PCP's specific failures of decision making in HT care antecedent to the personalized learning intervention.
3241556|NCT00903071|Active Comparator|SIM PPL|SIM+PPL, profiles PCP performance using simulated cases to identify each PCP's specific failures of decision making in HT care antecedent to the personalized learning intervention.
3241557|NCT00903071|No Intervention|Control|No intervention -control group
3241558|NCT00903045|Experimental|1|
3241559|NCT00903045|Placebo Comparator|2|
3241560|NCT00903032|Experimental|Arm 1|The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
3241561|NCT00903032|Active Comparator|Arm 2|Patients will receive usual care following ACS hospital discharge
3241562|NCT00903019|Experimental|1|Participants will receive problem-solving therapy (PST) delivered via teleconferencing (tele-PST).
3241563|NCT00903019|Active Comparator|2|Participants will receive problem-solving therapy (PST) delivered in-person.
3241564|NCT00903019|Placebo Comparator|3|Participants will receive monitoring phone calls.
3241565|NCT00903006|Active Comparator|Group 1: Fulvestrant|Group 1 will receive Fulvestrant only.
3241566|NCT00903006|Active Comparator|Group 2: Fulvestrant + Dasatinib|Group 2 will receive Fulvestrant and Dasatinib.
3241567|NCT00903006|Active Comparator|Group 3: Fulvestrant + MK-0646|Group 3 will receive Fulvestrant and MK-0646.
3241568|NCT00903006|Active Comparator|Group 4: Fulvestrant, MK-0646 + Dasatinib|Group 4 will receive Fulvestrant, MK-0646, and Dasatinib.
3241569|NCT00902993|Experimental|1|Part A single and multiple dose and part B fractionated dose
3241570|NCT00902993|Placebo Comparator|2|
3241571|NCT00902980||1. Community Based Clinics|Patient charts from community based nephrology clinics
3241572|NCT00902980||2. Regional Clinics|Patient charts from regional transplant clinics
3241573|NCT00902967|Active Comparator|1|Tablet Atorvastatin 10 mg once daily for 5 weeks (1 week before operation till 2 weeks after the operation)
3241574|NCT00902967|Placebo Comparator|2|Placebo tablets of similar shape and color given at night time dosing
3241575|NCT00902954|Experimental|A|anastrozole/letrozole 2-3 years switching to exemestane 3-2 years
3241576|NCT00902954|Active Comparator|B|anastrozole/letrozole 5 years
3241577|NCT00902941|Experimental|Rasagiline|
3241578|NCT00902941|Placebo Comparator|Placebo|
3241579|NCT00902928|Experimental|1. YM150, Dose X, twice daily|
3241580|NCT00902928|Experimental|2, YM150, Dose X, once daily|
3241581|NCT00902928|Experimental|3. YM150, Dose Y, twice daily|
3241582|NCT00902928|Experimental|4. YM150, Dose Y, once daily|
3241583|NCT00902928|Active Comparator|5. Enoxaparin|
3241584|NCT00902915|Experimental|Lenalidomide - Dexamethasone|
3241585|NCT00902902||1|
3241587|NCT00902889|Experimental|1|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation with GPE (upper cranial two contacts).
3241588|NCT00902889|Experimental|2|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
3241589|NCT00902876|Experimental|Mucograft + CAF|Mucograft in combination with coronally advanced flap (CAF)
3241590|NCT00902863|Experimental|YOGA patients|Patients assessed for chronic pain at our Pain Management Centre
3241591|NCT00902850|Experimental|SofLens Daily Disposable|SofLens Daily Disposable Lenses
3241592|NCT00902850|Active Comparator|Marketed 1 Day Contact Lens|Marketed 1 Day Contact Lens
3241593|NCT00902837|Active Comparator|oxycodone Tablet|OxyCodone Prolonged release tablets
3241594|NCT00902837|Experimental|oxycodone naloxone tablet|Oxycodone naloxone prolonged release tablets (OXN)
3241595|NCT00902824|Active Comparator|Group A|"ADVAX at 0,1 and 2 months followed by TBC-M4 at 6 months~Number of volunteers: 12"
3241596|NCT00902824|Active Comparator|Group B|"TBC-M4 at 0,1,6 months~Number of volunteers: 12"
3241597|NCT00902824|Placebo Comparator|Placebo|Both Groups A and B will have 4 volunteers each (8 total) that will receive a placebo.
3241598|NCT00902811|Active Comparator|AM(LT)|Artesunate (Arsumax®, Sanofi)
3241599|NCT00902811|Experimental|AM(FDC)|Artesunate-mefloquine fixed dose combination
3241600|NCT00902811|Experimental|AL|artemether 20 mg - lumefantrine 120 mg co-formulated tabs
3241601|NCT00902811|Experimental|DP|40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/Piperaquine 160 mg tablets
3241602|NCT00902811|Experimental|AA (FDC)|Artesunate-amodiaquine fixed dose combination
3241603|NCT00902798|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
3241604|NCT00902798|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.~Time commitment: about 1 hour per week; Location: Pittsburgh, PA only"
3241605|NCT00902785||no drug|no drug
3241606|NCT00902772|Placebo Comparator|A|Placebo
3241607|NCT00902772|Active Comparator|B|Lorazepam
3241608|NCT00902772|Active Comparator|C|Lorazepam
3241609|NCT00902772|Active Comparator|D|Lorazepam
3241610|NCT00902772|Experimental|E|AZD7325
3241611|NCT00902772|Experimental|F|AZD7325
3241612|NCT00902772|Experimental|G|AZD7325
3241613|NCT00902759|No Intervention|Usual Care Group|"Participants randomized to the usual care group will be encouraged to return to their usual or pre-surgical levels of activity. Usual care of post-surgical PC and peri-ampullary patients typically includes encouragement to walk and be active as they can be by the surgeons, surgical nurses and the nurse practitioners. Participants in the usual care group will not receive an individual Exercise Prescription at the time of entry. The usual care group will perform a baseline walk. Participants in the usual care group will not receive an individual Exercise Prescription at the time of entry nor will they will a telephone call every month. Repeat questionnaires will be performed at 6 months."
3241614|NCT00902759|Experimental|Walking Program|Participants in the intervention arm will participate in a walking program consisting of a 6 week graduated walking program. There are three phases to the walking program, Phase 1 is Warm-up, Phase 2 is Brisk Walking and Phase 3 is Cool Down. Phase 1 is the same for all 6 weeks, and consists of a slow 5 minute walk. In Months 1 and 2, Phase 2 is a 10 minute brisk walk. In Months 3 and 4, Phase 2 is a 20 minute brisk walk. In Months 5 and 6, Phase 2 is a 25 - 30 minute brisk walk. Phase 3 is the same for all 6 weeks and consists of a 5 minute rest/cool down period.
3241615|NCT00902746|Experimental|NPC-01|Norethisterone, Ethinyl Estradiol
3241616|NCT00902720|Experimental|Cryopreservation|The ovarian tissue is frozen and banked at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
3241617|NCT00902707|Experimental|Mucinex 1200mg|Pill
3241618|NCT00902707|Placebo Comparator|Placebo|Pill
3241619|NCT00902694|Experimental|ACHIEVE Intervention|Group and individual weight counseling and group physical activity classes for 18 months.
3241620|NCT00902694|Other|Control|Control arm receives group health classes quarterly with topics not related to weight
3241621|NCT00902681|Other|Reference|a single dose of 8 mg fesoterodine (Toviaz™ 8 mg) tablet manufactured at Zwickau
3241622|NCT00902681|Other|Test|a single dose of 8 mg fesoterodine (Toviaz™ 8 mg) tablet manufactured at Vega Baja (Test)
3241623|NCT00902668|Experimental|Supportive care (lovastatin)|Patients undergo 25-28 fractions of standard whole-breast irradiation followed by a boost to the tumor bed or 10 fractions of accelerated partial-breast irradiation with balloon brachytherapy BID over 5-10 days. Patients also receive lovastatin PO QD for 12 months beginning on day 1 of radiation therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
3241624|NCT00902655|Experimental|Desmopressin|
3241625|NCT00902642|No Intervention|control group|
3241626|NCT00902642|Active Comparator|Course on psychosocial factors|an eight day university training course for physical therapists designed to integrating psychosocial factors in clinical practice on a patient level
3241627|NCT00902629|Experimental|Intervention|Intervention group contains the patients randomized for early treatment of their epiretinal fibrosis.
3241628|NCT00902629|No Intervention|Control|Control contains patients not randomized for early surgery.
3241629|NCT00902616|Active Comparator|1. L-arginine|3 gm TDS for 3 months
3241630|NCT00902616|Placebo Comparator|2. Placebo - Lactose powder|3 gm TDS for 3 months
3241631|NCT00902603||1|Patients with WHO Group I pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3 months.
3241632|NCT00902590||1|Patients with urothelial cancer
3241634|NCT00902577|Experimental|Diagnostic (MRI and PET using FMISO)|Two weeks before initiation of chemoradiotherapy with temozolomide, patients undergo MRI and PET scan using FMISO. A subset of 15 patients undergo FMISO PET scans approximately 1 week before chemoradiotherapy.
3241635|NCT00902564|Experimental|Escitalopram|
3241636|NCT00902551||1|Subjects underwent cervical sample DNA image cytometry
3241637|NCT00902551||2|Subjects underwent cervical sample conventional cytology
3241638|NCT00902538|Experimental|Olmesartan (OLM) 40mg-Amlodipine (AML) 10mg|The participants in this arm received these 2 drugs for the 8-week, single-blind, run-in Period 1. Participants could then randomized to this same combination for an additional 8 weeks in the double-blind, Period 2.
3241639|NCT00902538|Experimental|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg|Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3.
3241640|NCT00902538|Experimental|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg|Participants could start receiving this combination in randomized, double-blind, 8- week Period 2.
3241641|NCT00902538|Experimental|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg (Responders)|Participants who meet their blood pressure goals in Period 3 and continued into the 8-week, double-blind Period 4 continued to receive this combination.
3241642|NCT00902538|Experimental|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg (Non-responders)|Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4
3241643|NCT00902538|Experimental|OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg (Non-responders)|Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4
3241644|NCT00902525|Experimental|90Y-Ibritumomab Tiuxetan double dose|90Y-Ibritumomab Tiuxetan administered at 0.4 mCi/kg at phase 2 and then at 0.2 mCi/kg at phase 3
3241645|NCT00902512|Active Comparator|Treatment A|Viagra® 100 mg tablet, administered with water
3241646|NCT00902512|Active Comparator|Treatment B|Sildenafil 100 mg CT administered with water
3241647|NCT00902512|Active Comparator|Treatment C|Sildenafil 100 mg CT administered without water
3241648|NCT00902499||NC|Normal older controls, not cognitively impaired; MMSE 27-30 and performance above education adjusted cutoff scores on the Logical Memory II subscale (LM-II Delayed Paragraph Recall) of the Wechsler Memory Scale
3241649|NCT00902499||vMCI|Very mild cognitive impairment; less severe objective memory deficit, scoring .5 to 1.5 S.D. (standard deviation) below education adjusted norms on the LM-II
3241650|NCT00902499||sMCI|significant mild cognitive impairment; objective cut off of 1.5 S.D. level below education adjusted norms on the LM-II
3241651|NCT00902499||AD|Mild Alzheimer's disease; meet NINCDS/ADRDA criteria for probable AD with mild dementia severity (CDR Total = 1), MMSE 20-26
3241652|NCT00902486|Experimental|1|INCB028050 4mg QD
3241653|NCT00902486|Experimental|2|INCB028050 7mg QD
3241654|NCT00902486|Experimental|3|INCB028050 10mg QD
3241655|NCT00902486|Placebo Comparator|4|Placebo group may 'cross-over' following 3 months of treatment to receive either active arm #2 (7mg QD) or active arm #3 (10mg QD) of INCB028050 capsules.
3241656|NCT00902473|Experimental|1|25 mg Topiramate tablets of Ranbaxy Laboratories, Ltd
3241657|NCT00902473|Active Comparator|2|(Topamax®) 25 mg Topiramate tablets of Ortho-McNeil Pharmaceutical, Inc. New jersey 08869
3241658|NCT00902460|Experimental|Treatment Sequence 1|
3241659|NCT00902460|Experimental|Treatment Sequence 2|
3241660|NCT00902447||Human Blood Cell Disorders|Human Blood Cell Disorders Tissue Bank
3241661|NCT00902421|Active Comparator|Antimuscarinics|
3241662|NCT00902421|Experimental|Selective serotonin reuptake inhibitors|Selective serotonin reuptake inhibitor
3241663|NCT00902408|Experimental|Lutein|Lutein enriched eggs
3241664|NCT00902408|Placebo Comparator|Placebo|Non enriched
3241665|NCT00902395|Active Comparator|Midazolam|Oral midazolam
3241666|NCT00902395|Experimental|Midazolam/ketamine|Combined midazolam and ketamine
3241667|NCT00902395|Other|Protective stabilization|No drug or placebo administered
3241668|NCT00902382||1|Infertile women who conceive spontaneously
3241669|NCT00902382||2|Infertile women who conceive on various ovulation stimulation medications
3241670|NCT00902369|Experimental|AK106-001616|
3241671|NCT00902369|Placebo Comparator|Placebo|Part1: AK106-001616 and Placebo
3241672|NCT00902369|Active Comparator|Active comparator|Part2: AK106-001616 and Active comparator
3241673|NCT00902356|Active Comparator|B|Six female subjects in each of cohorts 1 to 5 will receive AMG 167; six male subjects in each of cohorts 6 and 8; three female subjects in each of cohorts 7 and 9.
3241674|NCT00902356|Placebo Comparator|A|Two female subjects in each of cohorts 1 to 5 will receive placebo; two male subjects in each of cohorts 6 and 8; and 1 female subject in each of cohorts 7 and 9.
3241675|NCT00902343|Experimental|1|nomogram-based selection for acute normovolemic hemodilution
3241676|NCT00902343|Active Comparator|2|standard selection for ANH based on a planned resection of 3 or more segments.
3241677|NCT00902330|Experimental|Arm I (cranial microcurrent electrical stimulation [CES])|Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level), modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz, and to automatically turn off at the end of 1 hour. Patients use their CES unit once daily in weeks 1-18.
3241678|NCT00902330|Sham Comparator|Arm II (sham CES)|Patients receive a CES unit as in arm I, but the ear-lobe electrodes do not pass electrical current. Patients use their CES unit once daily in weeks 1-18.
3241679|NCT00902317|Active Comparator|Boston Scientific|The PolarCath peripheral balloon catheter (CryoVascular Systems, Inc., Los Gatos, CA) is a novel angioplasty system that simultaneously dilates and cools the plaque and vessel wall in the area of treatment. Cooling is achieved by inflating the balloon with nitrous oxide rather than the usual saline/contrast mixture.
3241710|NCT00902148|Active Comparator|Test Group|Colorectal Surgery with use of SurgiWrapTM film secured directly below the abdominal incision
3241711|NCT00902135||Group 1|
3241680|NCT00902317|Active Comparator|Spectranetics|The excimer laser has unique properties that make it ideally suited to debulk atheromatous and thrombotic arterial blockages. LASER is an acronym for Light Amplification by Stimulated Emission of Radiation. However, there are many types of lasers, each distinguished by the wavelength of the emitted light, the effective power of the light beam, and whether the light is pulsed (like a flashbulb) or continuous (like a light bulb). The effectiveness of a given laser for intraarterial applications depends on how the light interacts with tissue inside an artery.
3241681|NCT00902317|Active Comparator|Fox Hollow|"The SilverHawk peripheral catheter system and cutter driver (FoxHollow Technologies, Redwood City, CA) are designed for the treatment of de novo and restenotic atherosclerotic lesions located in the native peripheral arteries. The catheter consists of a flexible shaft designed to track over a 0.014 guidewire. At the distal end of the catheter is a small cutting assembly comprised of a rotating inner blade contained within a tubular housing. The proximal end of the catheter contains a connector and Positioning Lever designed to fit into a small, disposable, battery-driven Cutter Driver which powers the device."
3241682|NCT00902317|Active Comparator|WL Gore|Viabahn Endoprosthesis (W.L. Gore & Associates, Flagstaff, AZ) is a flexible self-expanding endoluminal device consisting of expanded polytetrafluoroethylene (ePTFE) lining with an external Nitinol (NiTi=Nickel:Titanium) support extending along its entire length. The device is compressed and attached to a catheter delivery system. The Gore Viabahn Endoprosthesis is available in a wide range of diameters and lengths.
3241683|NCT00902317|Placebo Comparator|Control Group, Guidant|Balloon angioplasty is a treatment that uses a catheter with a tiny balloon mounted on the end. The balloon is positioned through the narrowing/blockage in your leg artery, and then it is inflated to push the narrowing apart and restore a channel for blood flow. The balloon is then deflated and removed from your body. A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface. The FDA has approved the use of certain stents for the treatment of narrowing in the leg arteries. Stents have been widely used in various parts of the body, including blocked blood vessels in the arms, legs, heart (coronary arteries), and kidneys (renal arteries).
3241684|NCT00902304|Active Comparator|Usual care|Physicians applied their usual pattern of patient visits and treatment strategies to achieve individualized blood pressure target
3241685|NCT00902304|Experimental|Monotherapy (initial monotherapy arm)|Physicians utilized valsartan 160mg per day for 6 weeks, followed by (if required) dose titrations every 4 weeks thereafter until week 14 (valsartan 320mg per day, then valsartan 320mg plus hydrochlorothiazide (HCTZ) 12.5mg per day, then valsartan 320mg plus HCTZ 25mg per day (maximal dose)). For patients not at blood pressure target at week 18, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
3241686|NCT00902304|Experimental|Combination (initial combination therapy arm)|Physicians initially utilized single tablet combination products of either valsartan plus hydrochlorothiazide (HCTZ) or valsartan plus amlodipine for an initial 6 weeks of therapy (based on the treating physician's preference), with dose titrations (if required) every 4 weeks thereafter until week 10. The maximum dose for the HCTZ combination was valsartan 160mg plus HCTZ 25mg per day. The maximum dose for the amlodipine combination was valsartan 160mg plus amlodipine 10mg per day. For patients who were not at blood pressure target at week 14, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
3241687|NCT00902291|Active Comparator|1. Gemcitabine monotherapy|
3241688|NCT00902291|Experimental|2. Gemcitabine plus AGS-1C4D4|
3241689|NCT00902278|Active Comparator|Flulaval|
3241690|NCT00902278|Active Comparator|Fluvirin|
3241691|NCT00902278|Active Comparator|Fluzone|
3241692|NCT00902278|Active Comparator|Fluarix|
3241693|NCT00902278|Active Comparator|Affluria|
3241694|NCT00902265||desmopressin|"Participants with benign prostate syndrome suffering from nocturia associated with nocturnal polyuria.~Drug given by prescription."
3241695|NCT00902252|Experimental|Usual/Natura®/Vitala™|All subjects will wear usual product for 21 days, followed by Natura® for 14 days and followed by Vitala™ for 159 days.
3241696|NCT00902226|Experimental|Escitalopram|
3241697|NCT00902213|No Intervention|Minimal movement|Minimal movement group with usual care non-intervention.
3241698|NCT00902213|Active Comparator|Physical Therapy|
3241699|NCT00902200|Placebo Comparator|Vehicle|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
3241700|NCT00902200|Experimental|AR-12286 0.05%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
3241701|NCT00902200|Experimental|AR-12286 0.1%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
3241702|NCT00902200|Experimental|AR-12286 0.25%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
3241703|NCT00902187|Other|Reference|fesoterodine (Toviaz™ 4 mg) tablet manufactured at Zwickau (Reference)
3241704|NCT00902187|Other|Test|fesoterodine (Toviaz™ 4 mg) tablet manufactured at Vega Baja (Test)
3241705|NCT00902174|Experimental|imatinib mesylate|Imatinib mesylate (QTI571) 200 mg once daily for two weeks, increased to 400 mg once daily if well tolerated. If 400 mg dose was not well tolerated, a down titration to 200 mg once daily was permitted.
3241706|NCT00902174|Placebo Comparator|Placebo|Placebo to imatinib mesylate taken once daily. Participants receiving placebo were allowed to receive already approved PAH treatments.
3241707|NCT00902161|Experimental|Propanolol + Placebo > Propanolol + MK0893|Participants received propanolol for 7 weeks. On Day -1 of Period 1 (Study Visit 6), single dose MK0893-matched placebo was added and propanolol was continued. After Period 1, participants underwent a 3-week wash-out while continuing to receive propanolol. Following the washout, participants were treated with a single dose of MK0893 on Day 21 (Visit 8).
3241708|NCT00902161|Placebo Comparator|Propanolol + MK0893 > Propanolol + Placebo|Participants received propanolol for 7 weeks. On Day -1 of Period 1 (Study Visit 6), single dose MK0893 was added and propanolol was continued. After Period 1, participants underwent a 3-week wash-out while continuing to receive propanolol. Following the washout, participants were treated with a single dose of MK0893-matched placebo on Day 21 (Visit 8).
3241709|NCT00902148|No Intervention|Control Group|Colorectal Surgery without use of SurgiWrapTM
3241714|NCT00902122|Experimental|1|Five times of p53 gene intratumoral injection are given before surgery,then radical surgery will be conducted.
3241715|NCT00902122|Active Comparator|2|surgery
3241716|NCT00902122|Experimental|3|p53 gene therapy
3241717|NCT00902122|Active Comparator|4|p53 gene therapy plus radioactive iodine
3241718|NCT00902109||perimetry, HRT, OCT|perimetry, HRT, OCT
3241719|NCT00902096||Prenatal factors|Prenatal factors to predict cord blood IgE
3241720|NCT00902083|Experimental|surgery plus p53 gene|using p53 gene therapy before surgery
3241721|NCT00902083|Active Comparator|surgery alone|Surgery without pre-p53 gene therapy
3241722|NCT00902083|Experimental|p53 plus chemotherapy|p53 gene therapy with concurrent chemotherapy
3241723|NCT00902083|Experimental|p53 gene therapy alone|Intra-tumor injectio of rAd-p53 gene with no concurrent treatment
3241724|NCT00902070||1|Patients to whom Eslax has been administered to relax muscles at the time of anesthesia or tracheal intubation
3241725|NCT00902057|Active Comparator|desmopressin 1.5|
3241726|NCT00902057|Active Comparator|desmopressin 3|
3241727|NCT00902057|Active Comparator|desmopressin 15|
3241728|NCT00902057|Placebo Comparator|placebo|
3241729|NCT00902044|Experimental|Autologous HER2-specific T cells|"THIS ARM IS CLOSED~Dose Level 1: 1x10^4 cells/m2~Dose Level 2: 3x10^4 cells/m2~Dose Level 3: 1x10^5 cells/m2 (NOT BEING USED)~Dose Level 4: 3x10^5 cells/m2 (NOT BEING USED)~Dose Level 5: 1x10^6 cells/m2~Dose Level 6: 3x10^6 cells/m2~Dose Level 7: 1x10^7 cells/m2~Dose Level 8: 3x10^7 cells/m2~Dose Level 9: 1x10^8 cells/m2"
3241730|NCT00902044|Experimental|HER2-specific T cells+fludarabine|"Autologous HER2-specific T cells+fludarabine:~Dose Level 9A: fludarabine followed by 1x10^8 cells/m^2"
3241731|NCT00902044|Experimental|HER2-specific T cells+fludarab.+cycloph.|"Autologous HER2-specific T cells+fludarabine+cyclophosphamide:~Dose Level 9B: fludarabine + cyclophosphamide followed by 1x10^8 cells/m^2"
3241732|NCT00902031|Experimental|Docusate + Sennoside|
3241733|NCT00902031|Placebo Comparator|Sennoside + Placebo|
3241734|NCT00902018|Other|no arm|No Arm
3241735|NCT00902005||Rheumatic patients|"Three groups:~RA patients: 30 starting on Methotrexate, 30 starting on combination of Methotrexate and TNFalpha inhibitor.~PSA patients: 20 starting on Methotrexate, 20 starting on combination of Methotrexate and TNFalpha inhibitor.~AS patients: 20 starting on TNFalpha inhibitor"
3241736|NCT00901992|Experimental|MEDIAS 2 ICT|MEDIAS 2 ICT - education program for the initiation of intensive conventional insulin treatment (ICT) in type 2 diabetic patients
3241737|NCT00901992|Active Comparator|Current ICT program (ACC)|This education program consists of 10 lessons combining an insulin education program with an hypertension program
3241738|NCT00901979|Experimental|LCQ908 Dose 1|
3241739|NCT00901979|Experimental|LCQ908 Dose 2|
3241740|NCT00901979|Experimental|LCQ908 Dose 3|
3241741|NCT00901979|Experimental|LCQ908 Dose 4|
3241742|NCT00901979|Experimental|LCQ908 Dose 5|
3241743|NCT00901979|Placebo Comparator|Placebo|
3241744|NCT00901979|Active Comparator|Sitagliptin|
3241745|NCT00901953||1|migrainous vertigo
3241746|NCT00901953||2|migraine without vertigo
3241747|NCT00901940|Active Comparator|MenACWY Plain Polysaccharide (ACWY Vax)|The MenACWY Plain Polysaccharide Vaccine, which is already licensed and is used as a travel vaccine, is known as the MenACWY plain polysaccharide (ACWY Vax). Participants in this arm will receive 1 dose of the MenACWY plain polysaccharide (ACWY Vax) and 1 dose of the MenACWY conjugate (MenACWY).
3241748|NCT00901940|Active Comparator|MenACWY conjugate|The MenACWY conjugate vaccine was licensed in the UK in March 2010, and is known as the MenACWY conjugate vaccine (Menveo). Participants in this arm will receive 2 doses of the MenACWY conjugate vaccine.
3241749|NCT00901927|Experimental|Bendamustine + Mitoxantrone + Rituximab|Bendamustine starting dose 90 mg/m^2 by vein over 30-60 minutes on Days 1 and 2 of each cycle. Mitoxantrone 10 mg/m^2 by vein over 15 minutes on Day 2 of each cycle. Rituximab 375 mg/m^2 by vein over several hours on Day 1 of each cycle.
3241750|NCT00901914|Placebo Comparator|1|Placebo
3241751|NCT00901914|Experimental|2|12.5 µg rBet v 1
3241752|NCT00901914|Experimental|3|25 µg rBet v 1
3241753|NCT00901914|Experimental|4|50 µg rBet v 1
3241754|NCT00901901|Experimental|Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)|Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)
3241755|NCT00901901|Active Comparator|Sorafenib (Nexavar, BAY43-9006) + Placebo|Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)
3241756|NCT00901888|Experimental|Angiotensin II infusion|Using forearm venous occlusion plethysmography angiotensin II will be infused to cause reduction in forearm blood flow. Infusion of apelin and sodium nitroprusside will given and vasodilatation will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
3241757|NCT00901888|Active Comparator|Noradrenaline|Using forearm venous occlusion plethysmography noradrenaline will be infused to cause reduction in forearm blood flow. Infusion of apelin and sodium nitroprusside will given and vasodilatation will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
3241758|NCT00901875|Experimental|Suboxone, maximum 8mg|
3241759|NCT00901875|Experimental|Buprenorphine + naloxone|
3241760|NCT00901875|Experimental|Buprenorphine + naloxone (Suboxone)|
3241761|NCT00901862|Active Comparator|1 Active PEFs|The pulsed electromagnetic fields were directed to the wrist. The model used has the form of a bracelet called Quantum MH-2MR which uses, as a source of power, an alkaline battery of 1.5 volts connected to an electronic circuit formed by two hybrid circuits of magnetic oscillation and a control system of all the generating frequency system.
3241762|NCT00901862|Sham Comparator|2 Sham|The sham machines were identical to the machines in actual operation in both phases of the study. The only difference was that the hybrid circuits crucial for the generation of the electromagnetic field had been removed.
3241763|NCT00901836|Experimental|Preoperative Proton Therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
3241865|NCT00901043|Active Comparator|Ad lib diet|Eight weeks ad lib diet without walnut supplementation
3241765|NCT00901823|Experimental|Sequence 1|Single dose of low dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
3241766|NCT00901823|Experimental|Sequence 2|Single dose of high dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
3241767|NCT00901810|Active Comparator|Apex Locator|Working length for cleaning and shaping of the canal is measured by Electronic Apex Locator in this group.
3241768|NCT00901810|Active Comparator|Radiography|Working length for cleaning and shaping of the canal is measured by Radiography in this group.
3241769|NCT00901797|Active Comparator|Arthroscopic Bankart repair|
3241770|NCT00901797|Active Comparator|ABR+ARIC|
3241771|NCT00901784|Experimental|1|25 mg Topiramate tablets of Ranbaxy Laboratories, Ltd
3241772|NCT00901784|Active Comparator|2|(Topamax®) 25 mg Topiramate tablets of Ortho-McNeil Pharmaceutical, Inc. New jersey 08869
3241773|NCT00901758|Placebo Comparator|2|Placebo solution was normal saline. After an initial 1mL dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL.
3241774|NCT00901758|Active Comparator|1|Treatment solution consisted of 100micrograms/mL of nitroglycerin. After an initial 1mL dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL.
3241775|NCT00901745|Experimental|Infusion of apelin|Using forearm venous occlusion plethysmography apelin will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
3241776|NCT00901745|Active Comparator|Sodium nitroprusside infusion|Using forearm venous occlusion plethysmography sodium nitroprusside will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
3241777|NCT00901719|Experimental|Sodium depletion|Subjects will be randomised to normal diet or sodium depleted diet. The sodium depletion protocol comprises of a single oral dose of 40 mg of furosemide followed by an out-patient diet containing >2000 kcal of energy, >60 g of protein, <12 mmol of sodium and <70 mmol of potassium per day for 3 days prior to study. This diet is know to increase the activity of the renin-angiotensin system.
3241778|NCT00901719|Placebo Comparator|Normal diet|Subjects will be randomised to a normal diet, with no restriction on sodium intake during the three days prior to the study.
3241779|NCT00901706|Experimental|CGA plus APS Usual Care|Comprehensive geriatric assessment coupled with Adult Protective Services (APS) usual care for elders with self-neglect.
3241780|NCT00901706|Active Comparator|APS Usual Care|APS usual care consisting of social, medical, and legal interventions.
3241781|NCT00901693|Experimental|AL-46383A|AL-46383A Ophthalmic Solution, 1 drop in each eye, 8 times a day for 10 days
3241782|NCT00901693|Placebo Comparator|Vehicle|AL-46383A Ophthalmic Solution Vehicle, 1 drop in each eye, 8 times a day, for 10 days
3241783|NCT00901654|Experimental|ACE527|
3241784|NCT00901654|Placebo Comparator|Placebo comparator|
3241785|NCT00901641|Experimental|cognitive training|CogniFit Personal Coach® computer cognitive training program. The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®). The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
3241786|NCT00901628|Experimental|Periarticular Injection group|Periarticular injection with ropivacaine, morphine, ketorolac, epinephrine, cefuroxime
3241787|NCT00901628|No Intervention|No Injection group|usual postoperative care without periarticular injection
3241788|NCT00901615|Experimental|Lenalidomide and R-CHOP|Escalating Lenalidomide dose from 2.5 to 25 mg Lenalidomide and R-CHOP
3241789|NCT00901589|Active Comparator|Premenopausal women-fishoil|
3241790|NCT00901589|Placebo Comparator|Premenopausal-placebo|
3241791|NCT00901589|Active Comparator|Postmenopausal women-fishoil|
3241792|NCT00901589|Placebo Comparator|Postmenopausal-placebo|
3241793|NCT00901576|Experimental|SPD503|
3241794|NCT00901576|Active Comparator|Concerta|
3241795|NCT00901576|Active Comparator|SPD503 + Concerta|
3241796|NCT00901563|Active Comparator|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
3241797|NCT00901563|Placebo Comparator|Saline|Saline will be infused through-out the study.
3241798|NCT00901550|Active Comparator|Methotrexate|A drug for RA patient
3241799|NCT00901550|Active Comparator|Infliximab|for RA treatment
3241800|NCT00901537|Experimental|Azacitidine and Cisplatin|Every 4 weeks, azacitidine is given daily as subcutaneous injection for 5 days from day 1 to day 5, and cisplatin is given as intravenous injection on day 8. The dose of azacitidine will be dose escalated among each group of 3-6 patients, and the dose of cisplatin is fixed.
3241801|NCT00901524|No Intervention|PegIFN- alpha 2a + RBV|
3241802|NCT00901511|Experimental|WLL/GM-CSF|Whole lung lavage followed by inhaled GM-CSF
3241803|NCT00901511|Active Comparator|WLL alone|
3241804|NCT00901498|Experimental|Treatment A (Reference)|
3241805|NCT00901498|Active Comparator|Treatment B|
3241806|NCT00901498|Active Comparator|Treatment C|
3241807|NCT00901498|Active Comparator|Treatment D|
3241808|NCT00901498|Active Comparator|Treatment E|
3241809|NCT00901485|Experimental|autotitrating NIV|approximately 6 weeks using domiciliary nocturnal autotitrating non-invasive ventilation
3241810|NCT00901485|Active Comparator|Standard non-invasive ventilation|approximately 6 weeks using domiciliary nocturnal standard non-invasive ventilation
3241811|NCT00901472||Stable type 2 Diabetes (ST2D)|Adults with Type 2 diabetes who receive medical care at the University of Chicago
3241866|NCT00901030||Patients with PCI on blood thinners|Patients have a coronary stent and are taking anti-clotting (anti-platelet) drug and are having non-cardiac surgery.
3241812|NCT00901459|Active Comparator|rTMS 90% MT - Low frequency rTMS|Intervention type: device. Intervention description: low frequency rTMS was administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues using 90% MT (Motor Threshold) 1 Hz rTMS Dose on Superior Frontal Gyrus
3241813|NCT00901459|Active Comparator|Location Control|rTMS Dosing: 90% MT (Motor Threshold) 1 Hz rTNS Location: Motor Cortex
3241814|NCT00901459|Active Comparator|Frequency Control|rTMS Dosing: 90% MT (Motor Threshold) 10 Hz rTNS Location: Superior Frontal Gyrus
3241815|NCT00901446||Imaging|Subjects who receive intracoronary imaging with the investigative device.
3241816|NCT00901433||A|Usability study of the Personal Wheezometer
3241817|NCT00901420||Prostatectomy|
3241818|NCT00901420||Prostatectomy After Radiation Therapy|
3241819|NCT00901407|Experimental|1|lamotrigine
3241820|NCT00901407|Placebo Comparator|2|placebo
3241821|NCT00901394|Experimental|Treatment 1|B12-Folic acid, nitrous oxide
3241822|NCT00901394|Active Comparator|Treatment 2|Nitrous oxide (NO) and placebo
3241823|NCT00901394|Placebo Comparator|Control group|oxygen nitrogen
3241824|NCT00901381|Experimental|G-CSF|
3241825|NCT00901381|No Intervention|Control|
3241826|NCT00901368|Experimental|1|CHF1535 (beclometasone dipropionate plus formoterol, 400/24 µg daily)
3241827|NCT00901368|Active Comparator|2|Seretide® Diskus® (fluticasone plus salmeterol, 500/100 µg /daily)
3241828|NCT00901342|Experimental|Sipuleucel-T|Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
3241829|NCT00901329|Experimental|1: Gender prosthesis|
3241830|NCT00901329|Active Comparator|2: LPS flex prosthesis|
3241831|NCT00901316|Experimental|Routine Measures|
3241832|NCT00901316|Experimental|Bleach Baths|
3241833|NCT00901303|Other|Early Stage Disease|Group A
3241834|NCT00901303|Other|Advance Stage Disease|Group B
3241835|NCT00901290|Experimental|1|monophasic oral contraceptive
3241836|NCT00901290|Experimental|2|AZD7325
3241837|NCT00901277|No Intervention|Control|Usual Care
3241838|NCT00901277|Experimental|Web Intervention|Web-based: interactive web-based tool based on Microsoft's HealthVault technology for data transmission, tracking and communication of cardiac risk factors (e.g. home BP monitors for all in this intervention arm)
3241839|NCT00901277|Experimental|Nurse Intervention|Nurse: an interactive web-based tool based on Microsoft's HealthVault technology for data transmission, tracking and communication of cardiac risk factors (e.g. home BP monitors for all in this intervention arm)
3241840|NCT00901264||1|Patients with pathological diagnoses of cancer or leukemia
3241841|NCT00901264||2|3.1.3 Patients for whom chemotherapy is planned.
3241842|NCT00901251||1|
3241843|NCT00901225|Experimental|G-CSF plus Plerixafor|Patients who were unable to mobilize a minimum number of cells (CD34+ cell count <20 cells/ul)following 5 days of G-CSF mobilization.
3241844|NCT00901212|Active Comparator|LV Pacing|left univentricular pacing
3241845|NCT00901212|Active Comparator|BV Pacing|biventricular pacing
3241846|NCT00901199|Other|Child Cohort|This is the cohort in the study for children ages 8-18 years old. All subjects in this arm must have Liver Iron by SQUID of between 5-15mg/g dry liver and have a documented endocrinopathy or cardiac finding (low T2* or decreased cardiac function). All subjects in this arm will receive 7 days per week of Exjade and 3-5 days per week of Desferal.
3241847|NCT00901199|Other|Moderate Adult Cohort|Adults in this arm will have moderate iron overload,defined as SQUID of 5-15mg/g dry weight. They will also have to have a documented endocrinopathy or cardiac finding (low T2*). All subjects in this cohort will receive 7 days per week of Exjade (20-30mg/kg) and Desferal (50mg/kg)3-5 days per week.
3241848|NCT00901199|Other|Adults cohort with high iron overload|Adults with high iron overload defined as over 15mg/g dry liver. No cardiac finding or endocrinopathy necessary. Subjects in this cohort will receive Exjade 20-30mg/kg 7 days per week and Desferal (50mg/kg)5-7 days per week.
3241849|NCT00901186|Experimental|RFB002|RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.
3241850|NCT00901186|Active Comparator|Laser photocoagulation|At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.
3241851|NCT00901160||Surgical patients|Blood will be taken from patients who are on anti-platelet medication and are having surgery that requires an overnight stay. This is a pilot study to see if Thromboelastography® and Platelet Mapping Assay™ will be able to predict if a patient is at risk for a bleeding or a clotting problem after surgery.
3241852|NCT00901147|Experimental|panobinostat and bortezomib|Oral Panobinostat and intravenous bortezomib
3241853|NCT00901134||hypothermia|Patients with therapeutic hypothermia after cardiac arrest in hospitals
3241854|NCT00901121|Experimental|BoneCeramic|Straumann BoneCeramic is a fully synthetic bone graft substitute of medical grade purity in particulate form composed of biphasic calcium phosphate - a mixture of 60% hydroxylapatite and of 40% of the beta form of tricalcium phosphate (beta-TCP).
3241855|NCT00901121|Active Comparator|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
3241856|NCT00901108|Active Comparator|Trabectome-IOL|Combined Trabectome and cataract extraction with intraocular lens insertion
3241857|NCT00901108|Active Comparator|Trab-IOL|Combined Trabeculetomy with Mitomycin C and cataract extraction with intraocular lens insertion
3241858|NCT00901095|No Intervention|Control|Usual Care
3241859|NCT00901095|Experimental|Lifestyle intervention|The Lifestyle intervention group consists of in-person meetings co-led by an exercise specialist and dietician as well as follow-ups with an interventionist by phone.
3241860|NCT00901082|Active Comparator|information and relaxation|will receive the intervention that consist of information and relaxation
3241861|NCT00901082|No Intervention|No intervention|No specific intervention before the medial branch block.
3241862|NCT00901069|Other|Azacitidine|
3241863|NCT00901056|Active Comparator|Treated Group|This group will receive actual shockwave treatment
3241864|NCT00901043|Experimental|Walnut supplementation|Eight weeks with walnut supplementation to an ad lib diet
3241871|NCT00900991|Experimental|15 ug|15 microgram per dose
3241872|NCT00900978|Experimental|7v-PCV (Prevenar)|Biological/vaccine
3241873|NCT00900965|Active Comparator|Electroacupuncture treatment|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
3241874|NCT00900965|Sham Comparator|Sham acupunture treatment|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
3241875|NCT00900952||1|Infected elderly patients
3241876|NCT00900939|Experimental|Low-fat, vegan diet|
3241877|NCT00900939|Placebo Comparator|Control|
3241878|NCT00900900|Experimental|Dehydroepiandrosterone (DHEA)|
3241879|NCT00900900|Experimental|Pregnenolone|
3241880|NCT00900900|Placebo Comparator|Placebo|
3241881|NCT00900887|Active Comparator|Ketorolac|ocular topic ketorolac used 3 times a day for a week after the selective photocoagulation
3241882|NCT00900887|Active Comparator|Nepafenac|ocular topic nepafenac 3 times a day during one week after selective photocoagulation
3241883|NCT00900887|Placebo Comparator|Polietilenglicol 400, propilenglicol|ocular lubricant drops 3 times a day for a week after selective photocoagulation
3241884|NCT00900874|Active Comparator|1|Salbutamol + steroid
3241885|NCT00900874|Active Comparator|2|Formoterol + steroid
3241886|NCT00900861||1|Asthmatic patients above 18 y, treated with ICS or bronchodilators
3241887|NCT00900848||8|8 patients
3241888|NCT00900822|Experimental|Straumann Bone Ceramic|StraumannBone Ceramic is used as bone grafting material in sinus augmentation procedures
3241889|NCT00900822|Active Comparator|BioOss|BioOss is used as a bone grafting material in sinus augmentation procedure
3241890|NCT00900809|Experimental|Neukoplast™ (NK-92)|Neukoplast™ will be infused in three doses.1 x 10e9 cells/m2 dose, 3 x 10e9 cells/m2 dose, 5 x 10e9 cells/m2 dose.
3241891|NCT00900796||1|Patients diagnosed with active AS who start anti-TNF therapy according to standard clinical practice.
3241892|NCT00900783|Experimental|2|FV-100, 400 mg once daily AND valacyclovir placebo, three times a day, for seven days
3241893|NCT00900783|Active Comparator|3|Valacyclovir, 1 gram, three times a day AND FV-100 placebo, once daily, for seven days
3241894|NCT00900783|Experimental|1|FV-100, 200 mg once daily AND valacyclovir placebo, three times a day, for seven days
3241895|NCT00900770||PIB+ NC|PIB positive, cognitively normal individuals with foci of elevated PIB retention in cortical regions typically affected in AD
3241896|NCT00900770||PIB- NC|PIB negative, cognitively normal individuals without amyloid deposition
3241897|NCT00900757|Experimental|Palonosetron|Single Arm trial of Palonosetron for the prevention of RINV in primary malignant glioma patients receiving radiation therapy (RT) and concomitant temozolomide (TMZ)
3241898|NCT00900744||Tamoxifen|20mg daily
3241899|NCT00900731|Experimental|Indacaterol 150 µg|Participants received indacaterol 150 μg delivered via a single-dose dry-powder inhaler (SDDPI) plus placebo to tiotropium delivered via the manufacturer's proprietary inhalation device (HandiHaler®) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.
3241900|NCT00900731|Active Comparator|Tiotropium 18 µg|Participants received tiotropium 18 μg delivered via the manufacturer's proprietary inhalation device (HandiHaler®) plus placebo to indacaterol delivered via a single-dose dry-powder inhaler (SDDPI) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.
3241901|NCT00900718|Experimental|Straumann Bone Ceramic|Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
3241902|NCT00900718|Active Comparator|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
3241903|NCT00900692|Experimental|Dynasplint Group|Along with the standard of care Botox and manual therapy, patients will use the Supination Dynasplint every day
3241904|NCT00900692|No Intervention|Standard of care|Patients in the standard of care group will have the standard Botox treatments and manual therapy with no additional interventions.
3241905|NCT00900666|Placebo Comparator|Saline injection|
3241906|NCT00900666|Experimental|Botulinum toxin injection|
3241907|NCT00900653|Experimental|Gynoflor|
3241908|NCT00900653|No Intervention|Control|
3241909|NCT00900640||ERCP group|All patients who have been scheduled for an ERCP due to medical necessity will be considered for this study.
3241910|NCT00900627|Experimental|1|AZD8931 plus Paclitaxel
3241911|NCT00900627|Placebo Comparator|2|Placebo plus Paclitaxel
3241912|NCT00900601|Experimental|Sacroilliac fusion|Pastient are treated with sacroiliac joint arthrodesis to the sacroiliac joint and symphysis
3241913|NCT00900588|Experimental|10 ug|10 microgram split-virion vaccine per dose
3241914|NCT00900588|Experimental|15 ug|15 microgram split-virion vaccine per dose
3241915|NCT00900588|Experimental|30 ug|30 microgram split-virion vaccine per dose
3241916|NCT00900588|Active Comparator|5 ug|5 microgram whole-virion vaccine per dose
3241917|NCT00900575|Experimental|Duke Arm|patients referred for colposcopically directed biopsy or LEEP. The intervention for this arm is the use of the bench-top, miniature optical spectrometer or trans-vaginal colposcope
3241918|NCT00900562|Experimental|Arm 1|Zalypsis (PM00104)
3241919|NCT00900549|Experimental|CRT|
3241920|NCT00900549|Sham Comparator|No CRT|
3241921|NCT00900523||Known or suspected ovarian cancer|Women who have a diagnosis of ovarian cancer or who are suspected of having ovarian cancer
3241922|NCT00900510|Experimental|Drainage and placebo|Incision and drainage with placebo.
3241923|NCT00900510|Active Comparator|Drainage with TMP/SX|Drainage with Bactrim
3241924|NCT00900497|Experimental|White Blood Cells/Granulocytes|Fresh, non-irradiated granulocytes from ABO-Rh compatible, HLA-mismatched donors
3241925|NCT00900458|Active Comparator|1|formerly preeclamptic women with low plasma volume
3241926|NCT00900458|Active Comparator|2|formerly preeclamptic women with normal plasma volume
3241927|NCT00900458|Other|3|Healthy controls
3241928|NCT00900445||Basic science (pharmacokinetics)|Patients receive anticancer therapy as prescribed by their treating clinicians. Patients receive prednisone/prednisolone orally twice on either day 1 or day 8. Patients also receive daunorubicin hydrochloride IV over 30 minutes and vincristine IV once on the same day.
3241929|NCT00900406||Recipients of stem cells with graft versus host disease|
3241930|NCT00900406||Recipients of stem cells at risk of graft versus host disease|
3241931|NCT00900406||Donator of stem cells|
3241932|NCT00900328||Ancillary-Correlative (biomarkers in resected AC specimens)|Previously collected tissue samples from patients enrolled in CALGB 140202 are assessed for mutation analysis of c-Met, EGFR, Kras, p53, and c-CBL via standard PCR and sequencing; gene amplification of c-Met via real time quantitative PCR; LOH analysis of c-CBL; expression levels of met/HGF protein in serum via ELISA; and expression levels of c-Met, EGFR, p53, c-CBL, DUB3, ALK, and EMT via IHC.
3241933|NCT00900250||Ancillary-correlative (specimen collection and baking)|"Patients enrolled on HL therapeutic clinical trials undergo collection of tumor tissue samples at baseline and at relapse or disease progression. Serum and anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year after diagnosis, and at relapse or disease progression.~Patients with relapsed or progressive disease who plan to enroll on HL relapse/retrieval clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral blood samples at relapse or disease progression.~Patients enrolled more than 1 year after completion of treatment undergo collection of tumor specimens, serum, and anticoagulated peripheral blood samples at time of clinical evaluation."
3241934|NCT00900237|Active Comparator|Eslicarbazepine acetate|Eslicarbazepine acetate (ESL) 600 mg QD morning from Day 1-3 and 1200 mg ESL QD morning from Day 4-9
3241935|NCT00900237|Active Comparator|Oxcarbazepine|Oxcarbazepine 300 mg BID from Day 1-3 and oxcarbazepine 600mg BID from Day 4-9
3241936|NCT00900224||Group 1|Previously procured and archived bone marrow aspirate samples, blood and buccal cell samples, and bone marrow biopsy slides are analyzed for FLT3 ITD, MLL PTD, NPM1, KIT, KRAS, NRAS, CEBPA, WT1, JAK2, RUNX1, TET2, ASXL1, IDH1 and IDH2, CBL, and DNMT3A mutations, CBF fusion genes, levels of BAALC, ERG, EVI1, MN1, and APP microarray gene-expression, microRNA gene-expression signature, levels of methylation of genes silenced in AML, and genomic DNA by PCR amplification, RT-PCR, and denaturing high-performance liquid chromatography.
3241937|NCT00900159|Experimental|eszopiclone|Treatment with eszopiclone
3241938|NCT00900159|Placebo Comparator|matching placebo|Treatment with matching placebo
3241939|NCT00900146|Experimental|Canakinumab 5 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 5 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
3241940|NCT00900146|Experimental|Canakinumab 15 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 15 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
3241941|NCT00900146|Experimental|Canakinumab 50 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 50 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
3241942|NCT00900146|Experimental|Canakinumab 150 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 150 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
3241943|NCT00900146|Placebo Comparator|Placebo + Metformin|In 4 month dose finding period as well as during intermediate period, patients received one injection of canakinumab matching placebo monthly and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations).
3241944|NCT00900029||No HP802 Treatment|Treatment received in Study 802-247-09-015 was HP802
3241945|NCT00900029||No HP802 Vehicle Treatment|Treatment received in Study 802-247-09-015 was HP802 Vehicle
3241946|NCT00900003||pancreatic cancer patients|pancreatic cancer patients with excess tissue collected at the time of standard of care surgery
3241947|NCT00899990||Observational (biomarker sampling)|Patients undergo collection of tumor specimens, bone marrow, and peripheral blood at diagnosis. Associated demographic and clinical data are collected and archived. Patients who are not enrolled on a therapeutic clinical trial are followed annually.
3241948|NCT00899977|Placebo Comparator|Placebo|Subjects may receive a single, oral dose of placebo (capsule) in one of 4 crossover periods. Also, subjects may receive placebo orally, twice daily for 14 days in the last phase of the study.
3241949|NCT00899977|Experimental|1 mg TC-5214|Subjects may receive a single, oral capsule of 1 mg TC-5214 in one of 4 crossover periods.
3241950|NCT00899977|Experimental|2 mg TC-5214|Subjects may receive a single, oral capsule of 2 mg TC-5214 in one of 4 crossover periods.
3241951|NCT00899977|Experimental|4 mg TC-5214|Subjects may receive a single, oral capsule of 4 mg TC-5214 in one of 4 crossover periods. Also, subjects may receive 4 mg TC-5214 orally, twice daily for 14 days in the last phase of the study.
3241952|NCT00899977|Experimental|8 mg TC-5214|Subjects may receive a single, oral capsule of 8 mg TC-5214 in one of 4 crossover periods.
3241953|NCT00899964|Active Comparator|1|automated tailored feedback per E-mail
3241954|NCT00899964|Active Comparator|2|1 + active contact per E-mail possible
3241955|NCT00899964|Active Comparator|3|2 + active contact by trainer in case of exercise-related problems
3241956|NCT00899964|Active Comparator|4|3 + regular active contact by trainer
3241957|NCT00899951||Cohort 1|receiving fentaly citrate
3241958|NCT00899860||patients with renal cell cancer|
3241959|NCT00899847|Experimental|Autologous-Allogeneic Peripheral Blood Stem Cell Transplant|Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.
3241960|NCT00899834||Tumor Samples|fresh-frozen and fixed tumor samples and correspondent normal tissue from patients affected with this tumor.(peripheral blood is applicable only to patients with focal brainstem gliomas and patients who undergo biopsy of a diffuse brainstem glioma at diagnosis)
3241961|NCT00899782||Ancillary-Correlative (lung cancer tissue bank)|Grossly viable tumor and grossly normal lung tissue are identified and removed from patient surgical specimens and cryopreserved until shipment to the CALGB Lung Cancer Tissue Bank for future use in research. Blood specimens are also collected prior to surgery and at 4-12 weeks post-surgery (before the start of adjuvant therapy) and shipped immediately to the Tissue Bank.
3241962|NCT00899717|Experimental|A|
3241963|NCT00899717|Placebo Comparator|B|
3241964|NCT00899704||Group 1|Patient tissue samples are screened using polymerase chain reaction (PCR) for human papilloma virus-specific primers. Samples are analyzed to identify a nodal-metastasis signature for oral squamous cell carcinoma. Samples also undergo microarray analysis to quantify expression levels for targeted genes. Initial data analysis is performed using Affymetrix® Microarray Suite 5.0 to quantify expression levels for targeted genes.
3241965|NCT00899678|Active Comparator|Maintenance High-Dose|Maintenance High-Dose group: 400 mg Certolizumab Pegol for subjects ≥ 40 kg or 200 mg Certolizumab Pegol for subjects 20 to < 40 kg
3241966|NCT00899678|Active Comparator|Maintenance Low-Dose|Maintenance Low-Dose group: 200 mg Certolizumab Pegol for subjects ≥ 40 kg or 100 mg Certolizumab Pegol for subjects 20 to < 40 kg
3241967|NCT00899652||All Patients|Completion of Telephone Study Entry Form, Additional On Study Form, and Specimen Transmittal Form.
3241968|NCT00899600|Placebo Comparator|Normal saline|
3241969|NCT00899600|Experimental|Ketamine|
3241970|NCT00899587|Experimental|Oxygen|
3241971|NCT00899587|Experimental|Enalapril|
3241972|NCT00899587|Placebo Comparator|Control|
3241973|NCT00899574|Experimental|Imiquimod|"Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
3241974|NCT00899548||Metastatic breast cancer patients|
3241975|NCT00899548||Normals/Controls|
3241976|NCT00899535||Group 1|This research study is looking at the cancer genome using tumor samples from patients with stage I or stage II non-small cell lung cancer treated on clinical trial ACOSOG-Z0030. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
3241977|NCT00899483|Active Comparator|1|Administered with glucose potassium insulin solution to achieve euglycaemia 4.0-6.0 mmol/L
3241978|NCT00899483|No Intervention|2|Normal departmental practice using dextrose insulin infusion
3241979|NCT00899470|Experimental|S+ M, (fasted)> S/M (fed)> S/M (fasted)>S+M (fed)|Participants were randomized to receive oral co-administration of a 2.5 mg tablet of saxagliptin plus a 500 mg tablet of metformin immediate release (IR) under fasted conditions (S + M [fasted]) followed by a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions (S/M [fed]) followed by S/M under fasting conditions (S/M [fasted]) followed by S + M under fed conditions (S + M [fed])
3241980|NCT00899470|Experimental|S/M (fasted)> S+M (fasted)> S+M (fed)> S/M (fed)|Participants were randomized to receive S/M (fasted) followed by S + M (fasted) followed by S + M (fed) followed by S/M (fed)
3241981|NCT00899470|Experimental|S+M (fed)> S/M (fasted) >S/M (fed)> S+M (fasted)|Participants were randomized to receive S + M (fed) followed by S/M (fasted) followed by S/M (fed) followed by S+M (fasted)
3241982|NCT00899470|Experimental|S/M (fed)> S+M (fed)> S+M (fasted)> S/M (fasted)|Participants were randomized to receive S/M (fed) followed by S+M (fed) followed by S+M (fasted) followed by S/M (fasted)
3241983|NCT00899457||Healthy, non-smokers|
3242017|NCT00898885||Bone Marrow Transplantation|
3242018|NCT00898859||1|Healthy, non-smoking
3242019|NCT00898859||2|healthy, ex-smoking
3242020|NCT00898859||3|healthy, current-smokers
3242021|NCT00898859||4|COPD, ex-smokers
3241984|NCT00899431|Active Comparator|Group 1: Lenalidomide|Chemotherapy, Plus Lenalidomide - Lenalidomide starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months. Fludarabine 30 mg/m^2 intravenously daily on days -5, -4, -3. Rituximab 375 mg/m2 intravenously on day -13, and 1000 mg/m^2 on days -6, +1 and +8. Thymoglobulin 1.0 mg/kg intravenously over 4 hours (day -2 and -1). On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes. Bendamustine 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine). Allopurinol 300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
3241985|NCT00899431|Active Comparator|Group 2: No Lenalidomide|Chemotherapy Treatment, No Lenalidomide - Fludarabine 30 mg/m^2 intravenously daily on days -5, -4, -3. Rituximab 375 mg/m2 intravenously on day -13, and 1000 mg/m^2 on days -6, +1 and +8. Thymoglobulin 1.0 mg/kg intravenously over 4 hours (day -2 and -1). On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes. Bendamustine 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
3241986|NCT00899405||Patients with lung cancer|Collection of archival tumor specimen at the beginning of the study and collection of blood samples at the beginning of the study and then at regular intervals
3241987|NCT00899392|Experimental|Electronic Assisted Consent|Standard procedural consent performed by pediatric gastroenterologist plus assistance from computerized emmi module.
3241988|NCT00899392|No Intervention|Control Consent|Standard procedural consent as performed by pediatric gastroenterologists
3241989|NCT00899379|Experimental|Treatment Sequence 1|Placebo-Rizatriptan-Rizatriptan-Rizatriptan
3241990|NCT00899379|Experimental|Treatment Sequence 2|Rizatriptan-Placebo-Rizatriptan-Rizatriptan
3241991|NCT00899379|Experimental|Treatment Sequence 3|Rizatriptan-Rizatriptan-Placebo-Rizatriptan
3241992|NCT00899379|Experimental|Treatment Sequence 4|Rizatriptan-Rizatriptan-Rizatriptan-Placebo
3241993|NCT00899379|Experimental|Treatment Sequence 5|Rizatriptan-Rizatriptan-Rizatriptan-Rizatriptan
3241994|NCT00899353|Experimental|Omega 3 supplement|Omega 3 supplement will be added to diet, 3 capsules per day for one month then 6 capsules per day for one month then 9 capsules per day as tolerated
3241995|NCT00899301||Patients with Breast Cancer|
3241996|NCT00899301||Patients without breast cancer|
3241997|NCT00899288|Experimental|tamoxifen and no bone fracture|Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have not had a bone fracture.
3241998|NCT00899288|Experimental|Letrozole and no bone fracture|Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have not had a bone fracture.
3241999|NCT00899288|Experimental|Tamoxifen and bone fracture|Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have had a bone fracture.
3242000|NCT00899288|Experimental|Letrozole and bone fracture|Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have had a bone fracture.
3242001|NCT00899275||Ancillary-correlative|After the initial submission of blood samples, patients may undergo open or closed biopsy in order to obtain fresh and frozen tissue samples as well as paraffin embedded material. Patients who are enrolled at the time of initial diagnosis but then have a definitive surgery or develop recurrent disease may submit additional samples (paraffin block, frozen and fresh tumor tissue, or slides together with blood samples). Autopsy tumor samples may also be submitted.
3242002|NCT00899223||Group 1|Previously untreated patients on a CALGB treatment protocol for leukemia (acute or chronic) or myelodysplasia are eligible. Patients must be registered to CALGB 9665 prior to receiving any therapy for their disease.
3242003|NCT00899145||Ancillary-Correlative (biomarker sampling and analysis)|Previously collected DNA samples and associated clinical information obtained from BRCA mutation-positive participants enrolled on GOG-0199 are studied. DNA samples are analyzed by mutation testing for variants (i.e., SNPs) in candidate genes of interest. Once genetic testing for a given set of variants has been completed, the coded laboratory data file is merged with selected demographic, clinical, and epidemiological data obtained from the GOG-0199 baseline questionnaire and submitted to the CIMBA Central Database to analyze and publish the data. The epidemiological and SNP data contributed to the central database are then distributed to the investigators responsible for analysis of a particular SNP or set of SNPs from a candidate gene or genetic pathway.
3242004|NCT00899093||Ancillary-Correlative (serum collection for YKL-40 and CA125)|Patients undergo collection of serum samples for analysis of YKL-40 via ELISA and CA125 via chemiluminometric sandwich immunoassay at the following time-points: at baseline; prior to beginning each course of chemotherapy (courses 1-6); at completion of chemotherapy; every 3 months during years 1-2 post-chemotherapy; every 6 months during years 3-5 post-chemotherapy; every year during years 6-10 post-chemotherapy; and at time of disease recurrence or progression.
3242005|NCT00899054|Experimental|P276-00 plus Radiation|"P276-00:~Level 1:100 mg/m2/day x 5 q 3 weeks, level 2:140 mg/m2/day x 5 q 3 weeks, level 3: 185 mg/m2/day x 5 q 3 weeks.~External beam radiotherapy (EBRT):~2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 2 cycles (6 weeks)followed by upto 10 additional Gy if required"
3242006|NCT00899041|Active Comparator|Standard knee prosthesis|'standard' knee prosthesis (Sigma FB, J&J, UK).
3242007|NCT00899041|Active Comparator|High flexion knee prosthesis|'high flexion' knee prosthesis (Sigma RP-F, J&J, UK).
3242008|NCT00898989||Inclusion Body Myositis|
3242009|NCT00898989||Control|
3242010|NCT00898976||Group I|Immunohistochemistry is performed on tumor samples to analyze the following molecular markers: estrogen receptor, progesterone receptor, c-erbB2, p53, Ki-67, Bcl-2, Bax, cyclin D-1, and insulin-like growth factor-1R. PROJECTED ACCRUAL: A total of 300 tissue samples (150 from Native American women and 150 from Caucasian women) will be accrued for this study.
3242011|NCT00898950|Experimental|Aspirin low dose|Effects of using aspirin 75 mgs/day for 2 weeks.
3242012|NCT00898950|Experimental|Aspirin medium dose|Effects of using aspirin 300 mgs/day
3242013|NCT00898950|Experimental|aspirin high dose|aspirin 900mgs QID orally for 2 weeks
3242014|NCT00898950|Placebo Comparator|placebo|
3242015|NCT00898924||Group 1|Tissue samples were collected from patients on Day 1, Cycle 1. Whole blood and serum samples were collected on Day 1 (Cycle 1), Day 1 (Cycle 3), post-radiotherapy ZD1839 and at progression.
3242016|NCT00898898||Arm I|Tissue samples from protocol NCCTG-N9831 are obtained for immunohistochemistry and fluorescence in situ hybridization analysis of MYC, IGF- 1R, PTEN, and TOP2A genes. Exons 9 and 20 of PIK3CA gene are amplified via polymerase chain reaction; mutations in exons 9 and 20 of PIK3CA gene are identified.
3242023|NCT00898846||UFT adjuvant therapy group|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year. During protocol treatment, clinical findings and laboratory values are evaluated every month. After the completion of protocol treatment, patients are followed-up, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
3242024|NCT00898846||Observation group|Patients are followed-up without adjuvant treatment, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
3242025|NCT00898833||Group 1|Previously collected plasma and urine samples are analyzed for VEGF via ELISA, plasma samples are analyzed for CgA and IL-6 via ELISA, hK2 via immunometric assay, plasma samples are analyzed for PSA via Tandem-R PSA kit, plasma samples are analyzed for TNF-alpha, sTNF-R1, and IL-8 via quantikine IL-8 immunoassay.
3242026|NCT00898807|Experimental|Citalopram and psychosocial intervention|Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention
3242027|NCT00898807|Placebo Comparator|Placebo and psychosocial intervention|Matching placebo, oral, and psychosocial intervention
3242028|NCT00898781||Metastatic Breast Cancer|
3242029|NCT00898781||Metastatic Ovarian Cancer|
3242030|NCT00898781||Metastatic Pancreatic Cancer|
3242031|NCT00898781||Metastatic Colon Cancer|
3242032|NCT00898781||Stage 3 Ovarian Cancer|
3242033|NCT00898781||Locally Advanced Pancreatic Cancer|
3242034|NCT00898768|Other|capsule endoscopy|capsule endoscopie at baseline and after 2 years
3242035|NCT00898755||Ancillary-Correlative (tissue sample collection)|"Leftover tissue from diagnostic procedures and/or surgery is cryopreserved and banked. Blood and/or bone marrow are also collected and banked. Cell lines are established and characterized via reverse-transcriptase polymerase chain reaction and/or flow cytometry for biomarkers and by DNA fingerprinting. Markers to be identified may include the following:~NEUROBLASTOMA: tyrosine hydroxylase, protein gene product (PGP) 9.5, GD2, HLA class I, and HSAN 1.2 antigens EWING FAMILY OF TUMORS: EWS-FLI1, EWS-ERG, and PGP 9.5 RETINOBLASTOMA: interphotoreceptor retinoid-binding protein ACUTE LYMPHOBLASTIC LEUKEMIA: immunophenotype ALVEOLOR RHADOMYOSARCOMA: PAX3-FKHR, PAX7-FKHR, and MyoD1 ALL CELL TYPES: telomerase expression including hTR and hTERTMutations of TP53 gene are detected by flow cytometry and/or immunocytochemistry"
3242036|NCT00898742||head and neck cancer patients|
3242037|NCT00898716|Experimental|BMS-754807|
3242038|NCT00898677|Experimental|1|rizatriptan 5 mg
3242039|NCT00898677|Experimental|2|rizatriptan 10 mg
3242040|NCT00898677|Active Comparator|3|sumatriptan 100 mg
3242041|NCT00898677|Placebo Comparator|4|placebo
3242042|NCT00898638||Healthy Volunteers|Non-tumor volunteers will be asked to participate at the time that they are attending a head and neck cancer screening clinic or at the time they are accompanying a patient to their appointment at the head and neck clinic. Intake sheets and biological specimens contributed by volunteers will be coded at the time of collection so that no identifiers are obtained. These specimens will not be linked to identifiers.
3242043|NCT00898638||Head and Neck Tumor patients|Eligible patients will be identified at the Vanderbilt Head & Neck Clinic by clinical and research staff. An appropriately trained staff member will discuss the protocol with the patient (including, risks, benefits, alternatives, etc.).
3242044|NCT00898599|Placebo Comparator|Maltodextrin|
3242045|NCT00898599|Experimental|Prebiotic|Inulin type fructooligosaccharides
3242046|NCT00898560|Other|Microginon®|A single oral dose of a combined oral contraceptive containing 30ug ethinyloestradiol and 150ug levonorgestrel (Microginon ®).
3242047|NCT00898560|Experimental|ESL and Microginon®|15-day treatment with ESL 800 mg once daily, with co administration of a single oral dose of Microginin® on Day 14 of the relevant dosing period, to assess impact of ESL on pharmacokinetics of the combined oral contraceptive.
3242048|NCT00898547||Group 1|Serum samples previously obtained from patients on protocol CALGB-30107 are tested for levels of thrombospondin I serum, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked immunosorbent assays (ELISA).
3242049|NCT00898534|Experimental|Immediate Feedback|Subjects receive point-of-care hemoglobin A1c testing prior to their diabetes clinic visit, with results made available to the provider during the visit.
3242050|NCT00898534|No Intervention|Conventional Feedback|Subjects receive laboratory hemoglobin A1c testing at the clinic visit, with results made available to the provider several days later.
3242051|NCT00898521|Experimental|DGD|
3242052|NCT00898508||Normal benign breast disease or ductal carcinoma in situ|
3242053|NCT00898508||Invasive breast cancer|
3242054|NCT00898482||Healthy individuals|
3242055|NCT00898482||At risk individuals|
3242056|NCT00898482||Cancer patients|
3242057|NCT00898456||Group 1|Leukemia blast cells obtained from bone marrow aspirate or peripheral blood at diagnosis are used to study polymorphisms and haplotypes of ATP-binding cassette (ABC) B1, ABCC1, ABCG2, and other candidate genes. Multidrug resistance (MDR) protein expression and function are also analyzed using leukemia blast cells from patients enrolled on CALGB-9760.
3242058|NCT00898443|Other|Spinal Anesthetic Group|This group will receive spinal anesthetic for the surgical procedure and will serve as the control group for this study.
3242059|NCT00898443|Experimental|Epidural Anesthetic Group|This is the experimental group for this study.
3242060|NCT00898430||Head and neck squamous cell carcinoma patients (HNSCC)|
3242061|NCT00898404||Arm I|Tumor diagnostic specimens from patients who subsequently failed therapy within 4 years of diagnosis or who did not fail therapy within 4 years of diagnosis (control patients) are obtained from the Children's Oncology Group cellbank. Specimens are studied for molecular determinants of human reduced folate carrier (hRFC) gene expression and gene sequence alterations using reverse transcriptase-polymerase chain reaction (RT-PCR), thymidylate synthase inhibition assay, Rnase protection assay, or 5'RACE. Multidrug resistance proteins are also studied by RT-PCR.
3242062|NCT00898391||Ancillary-Correlative|Circulating DNA is extracted from serum. PCR amplification of MYCN is performed and analyzed by agarose gel electrophoresis. Real-time quantitative PCR is also performed.
3242063|NCT00898378||Colorectal Cancer Patients|Patients with stages I/II, III and IV colorectal cancer
3242151|NCT00896636||Menopause|Women who have entered menopause.
3242064|NCT00898378||Colorectal Polyps Patients|Patients with adenomatous polyp(s) after colonoscopy.
3242065|NCT00898378||Healthy Controls|No abnormalities after colonoscopy.
3242066|NCT00898365||Ancillary-correlative (renal tumor classification, biology)|Tumor tissue, blood, and urine samples are collected for research studies, including immunohistochemistry. CT scans and MRIs are also performed. Loss of heterozygosity analyses (chromosome 1p and 16q) are performed by extraction of DNA. DNA polymorphisms are assayed by polymerase chain reaction using standard methodology. Leftover specimens are archived for future studies. (LOH and INI1 testing discontinued as of April 2014)
3242067|NCT00898326||Biopsy 36 month after breacchytherapy|Biopsy 36 month after breacchytherapy on protocol JUSMH-BRI-GU05-01.
3242068|NCT00898313||Sample Collection|
3242069|NCT00898300||Patients with confirmed or suspected head and neck cancer|
3242070|NCT00898287|Experimental|P276-00 plus Gemcitabine|"Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/m2/day x 5 q 3 weeks Level 2 - 140 mg/m2/day x 5 q 3 weeks Level 3 - 185 mg/m2/day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.~Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity."
3242071|NCT00898274||High risk for developing prostate cancer|Male subjects age 45-65 at high risk for developing prostate cancer.
3242072|NCT00898274||Healthy participants|Aged matched healthy participants
3242073|NCT00898222|Experimental|aspirin|Low dose daily aspirin in healthy volunteers for two weeks
3242074|NCT00898209||Health Volunteers|Blood and exhaled breath condensate will be collected.
3242075|NCT00898209||Patients at risk or already identified as having lung cancer|Blood and exhaled breath condensate will be collected.
3242076|NCT00898170|Experimental|myoma, with or without hypertension|those with myoma with or without hypertension in holter monitoring
3242077|NCT00898092||Group 1|Peripheral blood and bone marrow samples are analyzed to assess gene expression using polymerase chain reaction (PCR) or reverse transcriptase-PCR assays and microarray assays. Genes to be studied include BAALC, ERB, EVI1, MLL, FLT3, NPM1, and CEBPA.
3242078|NCT00898079||Observational|Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.
3242079|NCT00898053||Correlative studies|Previously archived tumor samples are analyzed for p53 mutations and p16 deletion by immunohistochemistry, FISH, PCR, and DNA sequencing.
3242080|NCT00897975|Experimental|red yeast rice (RYR) plus phytosterol|arm will take red yeast rice and phytosterol supplement
3242081|NCT00897975|Placebo Comparator|red yeast rice plus placebo|
3242082|NCT00897975|Active Comparator|TLC plus red yeast rice plus placebo|subjects attend 12 week therapeutic lifestyle program and take above supplement
3242083|NCT00897975|Experimental|TLC plus RYR plus phytosterol|Therapeutic lifestyle program for 12 weeks plus red yeast rice plus phytosterol
3242084|NCT00897962||Metastatic Breast Cancer|Patients with metastatic breast cancer receiving treatment with chemotherapy, endocrine therapy or targeted therapy
3242085|NCT00897962||Non-cancer medical illness|Patients with non-cancer medical condition
3242086|NCT00897962||Healthy Controls|Healthy patients being seen for an annual exam
3242087|NCT00897949|Experimental|Rizatriptan 10 mg|
3242088|NCT00897949|Experimental|Rizatriptan 5 mg|
3242089|NCT00897949|Placebo Comparator|Placebo|
3242090|NCT00897897|Other|Treated leiomyomas|Pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure receive a treatment with the Philips MRI-guided HIFU system. Patients must have completed child bearing prior to enrolling in this study.
3242091|NCT00897884|Experimental|Metformin|Patients will take metformin three times a day for two to three weeks prior surgery.
3242092|NCT00897858||Pediatric CNS tumor patients|Newly diagnosed pediatric patients with CNS tumor and no prior irradiation or chemotherapy
3242093|NCT00897832||pancreatic cancer|Patients with pancreatic cancer
3242094|NCT00897806||Genetic Markers|
3242095|NCT00897793||patients with epithelial cancers|Patients with head and neck cancer, and lung, breast, colorectal, and prostate cancers who are to undergo radiation therapy
3242096|NCT00897715|Active Comparator|Interleukin-1 receptor antagonist|active drug
3242097|NCT00897715|Placebo Comparator|Placebo|matching placebo
3242098|NCT00897676|Other|Vehicle first, then Exendin-(9-39)|An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). At time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. The following day, at time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, GLP-1, and glucagon will be measured every 30 minutes.
3242099|NCT00897676|Other|Exendin-(9-39) first then Vehicle.|An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). . At time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. The following day, at time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, GLP-1, and glucagon will be measured every 30 minutes.
3242100|NCT00897663||Single group|Tissue samples from patients enrolled on clinical trials NCCTG-N0177 or NCCTG-N0074 are analyzed by microarray analysis and immunohistochemistry for biological markers predicting progression-free survival and overall survival. Biological markers include epidermal growth factor expression, vIII mutant p53 gene, P-AKT, p7056k, S6, 4EBP1, STAT-3, PLC-g, Erk, ErbB2, ErbB3, ErbB4, platelet-derived growth factor receptor, IGF1R, interleukin-6, FADD, and MGMT.
3242101|NCT00897650||Lung cancer|Patients with a diagnosis of invasive lung cancer.
3242102|NCT00897637||Observational|Three hundred tumor specimens are analyzed for genetic expression profiles using Affymetrix assays. Specific genes are identified as classifiers and analyzed using tissue arrays. An additional 300 specimens are examined for gene expression and categorized according to the classifiers.
3242103|NCT00897468||breast cancer patients|
3242538|NCT00893841|Experimental|3|Quetiapine XR 300mg + Pramipexole 0.50mg
3242104|NCT00897442||Ancillary-Correlative (biomarker sampling and analysis)|Snap frozen tumor tissue, OCT molds of tumor tissue, formalin-preserved tumor tissue, buffy coat-prepared tumor tissue, and blood samples are collected and stored in the repository. Patient information is kept confidential, and patients are not informed of any research/test results from use of their tissues.
3242105|NCT00897429||Ancillary-Correlative (laboratory biomarker analysis)|Previously collected tissue samples are analyzed for K-ras mutations; COX-2, phospho-AKT, and VEGF overexpression; microvessel density; association of genomic instability with microsatellite instability and p53 mutations; and methylation status of MLH1, MGMT, and WRN and to identify prognostic biomarkers by LINE-1 hypomethylation, PIK3CA mutation, BRAF mutation, FASN expression, and VDR expression via immunohistochemistry, PCR, RT-PCR, and microarray.
3242106|NCT00897390|Other|Arm A|Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fasted conditions
3242107|NCT00897390|Other|Arm B|Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fasted conditions
3242108|NCT00897390|Other|Arm C|Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fed conditions with a standard meal
3242109|NCT00897390|Other|Arm D|Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fed conditions with a standard meal
3242110|NCT00897377|Experimental|Total resection with early radiation|Total resected LGGs treated with early radiation
3242111|NCT00897377|No Intervention|Total resection without radiation|Total resected LGGs treated without radiation
3242112|NCT00897377|Experimental|Residual LGGs with radiation|Residual LGGs treated with early radiation
3242113|NCT00897377|Experimental|Residual LGGs with chemo|Residual LGGS treated with temozolomide
3242114|NCT00897325||Ancillary-Correlative (Collecting and banking ALL specimens)|Patients undergo collection of bone marrow and peripheral blood at diagnosis of relapse and/or at the end of the first month of treatment.
3242115|NCT00897286||Tumor/Tissue Sample|Tumor material collected prospectively from a clinically well characterized patient cohort
3242116|NCT00897260|Experimental|1|
3242117|NCT00897234||Healthy Volunteers|Non-smoking healthy volunteers
3242118|NCT00897234||Non-Small Cell Lung Cancer|Patients with non-small cell lung cancer.
3242119|NCT00897221|Experimental|Dose 1|Deferiprone oral solution 20 mg/kg/day
3242120|NCT00897221|Experimental|Dose 2|Deferiprone oral solution 40 mg/kg/day
3242121|NCT00897182||Group 1|This is a CALGB Leukemia Tissue Bank project makes use of tissue from patients who have previously provided their consent. Diagnostic samples from patients enrolled on CALGB AML treatment studies (eg, CALGB 9621, 9710, and 19808) and who have been registered on the companion Leukemia Tissue Bank Protocol CALGB 9665 were used.
3242122|NCT00897169|Experimental|A|
3242123|NCT00897169|Experimental|B|
3242124|NCT00897130|Experimental|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted.
3242125|NCT00897117||Resectable non-small cell lung cancer|Patients with clinical stage I or II invasive lung cancer that can be completely removed by surgery and who have not undergone chemotherapy or radiotherapy before surgery
3242126|NCT00897104|Experimental|1|Rizatriptan
3242127|NCT00897104|Experimental|2|Sumatriptan
3242128|NCT00897104|Placebo Comparator|3|Placebo
3242129|NCT00897026||Group 1|Tissue samples are collected from patients. Tissue samples are analyzed by immunohistochemistry (Ki67, CK5/6, EGFR, ER) and fluorescence in situ hybridization (FISH).
3242130|NCT00896987|Experimental|1|lamotrigine
3242131|NCT00896987|Active Comparator|2|carbamazepine
3242132|NCT00896974|Experimental|Arm I|Participants receive a single dose of oral 9cUAB30 on day 1.
3242133|NCT00896961|Experimental|Observational (EF5)|Approximately 24-48 hours prior to surgical resection or biopsy, patients receive EF5 IV over no more than 2½ hours. Tissue samples are analyzed by immunohistochemistry for EF5 binding. Blood samples are analyzed for genetic markers and cytokines associated with hypoxia and EF5 concentration.
3242134|NCT00896883|Experimental|Middle Turbinate Implant|Subjects to receive Middle Turbinate Implant
3242135|NCT00896844|Experimental|emotional disclosure|writing about emotional events from the past
3242136|NCT00896844|Placebo Comparator|placebo writing|writing about how they spent their time the previous day
3242137|NCT00896831|Active Comparator|L-ornithine-L-aspartate|5 g L-ornithine-L-aspartate (1 sachet) three times per day for 60 days
3242138|NCT00896831|Placebo Comparator|placebo|5 g (1 sachet) of placebo comparator three times per day for 60 days
3242139|NCT00896779|Other|ranibizumab Group 1|Group 1: 3 monthly injections of 0.5mg then prn
3242140|NCT00896779|Other|ranibizumab Group 2|Group 2: 6 monthly injections of 0.5 mg then prn
3242141|NCT00896753||patients with metastatic colon cancer|
3242142|NCT00896714|Experimental|Closed loop anesthesia|
3242143|NCT00896701||Patient samples from C9621, C9720 and C19808|This is a CALGB Leukemia Tissue Bank project that makes use of tissue from patients who have previously provided their consent. Diagnostic and follow-up samples from acute myeloid leukemia (AML) patients treated on CALGB protocols 9621, 9720 and 19808, and who have been registered on the mandatory companion Leukemia Tissue Bank Protocol CALGB 9665 will be used.
3242144|NCT00896688||Healthy Volunteers|It will involve 5 volunteers and they will undergo C arm fluoroscopic guided cervical medial branch blocks (C2-C7) on unilateral position and then followed by the 3D ultrasound machine for visualization of needle position.
3242145|NCT00896688||Candidates for upper and lower cervial medical branch blocks|This will involve 25 patients and they will follow the same procedures as the healthy volunteers.
3242146|NCT00896675||patients treated with EGFR inhibitors and/or VEGF inhibitor|
3242147|NCT00896675||NOT treated with EGFR inhibitors and/or VEGF inhibitor|
3242148|NCT00896649|Experimental|positron emission mammography|questionnaire administration digital mammography positron emission mammography
3242149|NCT00896636||Luteal|Pre-menopausal women who undergo rFNA procedure during the luteal phase of their menstrual cycle.
3242150|NCT00896636||Follicular|Pre-menopausal women who undergo rFNA procedure during the follicular phase of their menstrual cycle.
3242152|NCT00896597|Experimental|NRL972|A single dose of 2 mg NRL972 will be administered on four occasions over a period of up to 6 weeks.
3242153|NCT00896571|Experimental|Arm 1|
3242154|NCT00896558|Experimental|Cohort A|A single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
3242155|NCT00896558|Experimental|Cohort B|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
3242156|NCT00896558|Experimental|Cohort C|Subjects in the probe cohort will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12. All subjects will receive a single dose of midazolam alone on Day -1, and co-administered with the morning dose of GSK1322322/placebo on Day 1 and Day 12.
3242157|NCT00896558|Experimental|Cohort D|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
3242158|NCT00896558|Experimental|Cohort E|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
3242159|NCT00896545|Experimental|5-keys feeding program|Counseling in small groups aimed at enhancing children's self control over eating
3242160|NCT00896545|Active Comparator|Healthy lifestyle counseling|Counseling in small groups aimed at achieving healthy eating patterns aimed at both the family and young children
3242161|NCT00896532|Placebo Comparator|Placebo|"Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously (SC) for up to 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
3242162|NCT00896532|Active Comparator|Alendronate|"Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. At month 36 participants ended study participation."
3242163|NCT00896532|Active Comparator|Teriparatide|Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
3242164|NCT00896532|Experimental|Romosozumab 70 mg QM|"Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
3242165|NCT00896532|Experimental|Romosozumab 140 mg Q3M|"Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
3242166|NCT00896532|Experimental|Romosozumab 140 mg QM|"Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
3242167|NCT00896532|Experimental|Romosozumab 210 mg Q3M|"Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
3242168|NCT00896532|Experimental|Romosozumab 210 mg QM|"Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
3242169|NCT00896493|Experimental|Total lymphoid irradiation & anti-thymocyte immunoglobulin|
3242170|NCT00896480|Experimental|Single group|Patients will receive a treatment consisting of 24 injections of the experimental GSK2132231A immunotherapeutic
3242171|NCT00896454|Experimental|denosumab|Eligible subjects will receive denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
3242172|NCT00896441|Experimental|Depressed patients|Depressed patients assigned in an open-label study of citalopram
3242173|NCT00896441|No Intervention|Controls|Healthy controls used as a comparison (no intervention) group for change in resting-state fMRI over time
3242174|NCT00896428|Experimental|1|16 patients with a diagnosis of severe asthma under gallopamil treatment
3242175|NCT00896428|Placebo Comparator|2|16 patients with a diagnosis of severe asthma under placebo treatment
3242176|NCT00896402|Active Comparator|Chlorhexidine|skin antisepsis with chlorhexidine
3242177|NCT00896402|Active Comparator|Povidone-iodine|skin antisepsis with povidone-iodine
3242178|NCT00896389|Other|Salt-loading and thiazide diuretic (HCTZ)|Salt loading:2 L of 0.9% NaCl. HCTZ:12.5/ 25 mg of HCTZ for 1 week
3242179|NCT00896376|Experimental|trastuzumab|
3242180|NCT00896363|Active Comparator|Active|Parallel Group - High Dose Arm, Low Dose Arm
3242181|NCT00896363|Placebo Comparator|Placebo|Parallel Group
3242182|NCT00896337|Experimental|ORION|All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with iliac artery stenting with the Epic™ Nitinol Stent System.
3242183|NCT00896324|Active Comparator|Cognitive Rehabilitation|Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
3242184|NCT00896324|Experimental|Active Neurofeedback|Neurofeedback training: 2-3, 30 min training sessions.
3242185|NCT00896324|Sham Comparator|Sham Neurofeedback|Neurofeedback training: 2-3, 30 min training sessions.
3242186|NCT00896311|Active Comparator|1|Treatment solution consisted of 100 micrograms/mL of nitroglycerin. After an initial 1ml dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL
3242187|NCT00896311|Placebo Comparator|2|Placebo solution was saline. After an initial 1ml dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL
3242188|NCT00896298|Active Comparator|1 Leptin|Active Comparator for 4 months, then for 8 months.
3242189|NCT00896298|Placebo Comparator|2 Sugar pill|Placebo for 4 months, then active comparator for 8 months.
3242190|NCT00896285|Active Comparator|1|
3242191|NCT00896285|Active Comparator|2|
3242192|NCT00896285|Active Comparator|3|
3242193|NCT00896285|Active Comparator|4|
3242194|NCT00896259||THA control|those with THA not participating in exercise and education program
3242195|NCT00896259||THA exercise|those with THA and participating in exercise and education program
3242196|NCT00896259||healthy control|Healthy control, people with no lower limb gait abnormalities
3242197|NCT00896246|Active Comparator|Klean-Prep®|1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Klean-Prep® (4 L) containing 99mTc-DTPA administered as a divided dose.
3242198|NCT00896246|Experimental|Moviprep®|1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Moviprep® (2 L) containing radiolabelled 99mTc-DTPA administered as a divided dose.
3242199|NCT00896233|Experimental|MRE|
3242200|NCT00896220||ICU Survivors and Their Family Caregiver|ICU Survivors who required one week or more of mechanical ventilation during their critical illness and their primary family caregiver
3242201|NCT00896207|Experimental|Arm I|Participants complete an overnight fast of ≥ 10 hours, eat a high-fat (approximately 50% of total caloric content of the meal) and high-calorie (approximately 800-1,000 calories) meal, and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.
3242202|NCT00896207|Experimental|Arm II|Participants complete an overnight fast of ≥ 10 hours and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.
3242203|NCT00896207|Experimental|Arm III|Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol® self-emulsifying solid dispersion capsule formulation.
3242204|NCT00896207|Experimental|Arm IV|Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol®/vitamin E TGPS self-emulsifying solid dispersion capsule formulation.
3242205|NCT00896207|Experimental|Arm V|Participants receive a single dose of oral Akt inhibitor SR13668 in a vitamin E TGPS self-emulsifying solid dispersion capsule formulation.
3242206|NCT00896207|Experimental|Arm VI|Participants receive a single dose of oral Akt inhibitor SR13668 in a Myrj 53 self-emulsifying solid dispersion capsule formulation.
3242207|NCT00896194|Active Comparator|1: Standard Behavioral Treatment (SBT)|This group receives standard behavioral treatment for weight loss as described below.
3242208|NCT00896194|Experimental|2: Modified SBT + Self-Efficacy|This group receives modified SBT with an additional self-efficacy component as described below.
3242209|NCT00896181|Experimental|Arm I|"INDUCTION THERAPY: Patients receive docetaxel IV over 60 minutes on day 1; cisplatin IV over 1-3 hours (or carboplatin IV over 30 minutes) on day 1; and fluorouracil IV continuously over 24 hours on days 1-5. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~CONCURRENT CHEMORADIOTHERAPY: Beginning within 3-6 weeks after initiating the last course of induction chemotherapy, patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily for 6.5-7 weeks. Patients also receive cisplatin IV over 1 hour (or carboplatin IV over 30 minutes) once weekly in weeks 1-6 in the absence of disease progression or unacceptable toxicity."
3242210|NCT00896168|Experimental|Infliximab + Methotrexate (Moderate RA)|Participants with moderate RA (score greater than 3.2, but less than 5.1 on the disease activity score [DAS] 28) received infliximab 3 milligram per kilogram (mg/kg) intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) at Week 0, 2, 6, 14 and 22 along with oral MTX IN a stable dose of 7.5 to 20 mg per week (equal to the dose used before participation in the study) for 22 weeks.
3242211|NCT00896168|Experimental|Infliximab + Methotrexate (Severe RA)|Participants with severe RA (score greater than 5.1 on the DAS 28) received infliximab 3 mg/kg intravenous infusion at Week 0, 2, 6, 14 and 22 along with oral MTX in a stable dose of 7.5 to 20 mg per week (mg/week) equal to the dose used before participation in the study) for 22 weeks.
3242212|NCT00896155|Experimental|Concurrent Tamoxifen and Radiotherapy|ARM 1 will receive Tamoxifen given concurrently with radiotherapy. Tamoxifen will continue for a period of 5 years.
3242213|NCT00896155|Active Comparator|Sequential radiotherapy and tamoxifen|ARM-2 shall receive radiotherapy followed by tamoxifen sequentially. Again tamoxifen will continue for a period of 5 years.
3242214|NCT00896129||Study population|
3242215|NCT00896090||Depressed|
3242216|NCT00896090||Healthy Controls|
3242217|NCT00896077|Active Comparator|Subcutaneous|Subcutaneous administration of LSF
3242218|NCT00896077|Active Comparator|IV|IV administration arm
3242219|NCT00896064|Experimental|Formulation 1|
3242220|NCT00896064|Experimental|Formulation 2|
3242221|NCT00896051|Experimental|ATV/rtv 300/100 mg (Treatment A)|Treatment-experienced human immunodeficiency virus - type 1 (HIV-1) infected participants will take by mouth atazanavir (ATV)/low-dose ritonavir (rtv) 300/100 mg once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 2 weeks pre-treatment followed by ATV/rtv 300/100 mg once daily + etravirine (ETR) 200 mg twice daily + 1 NRTI for 48 weeks. If particpating in an optional substudy to assess the effect of adding tenofovir disoproxil fumarate (TDF) for 7 days on ATV and ETR pharmacokinetics, participants will receive TDF 300 mg once daily for 7 days in addition to their antiretroviral regimen (ETR+ATV/rtv+NRTI).
3242270|NCT00895752|Experimental|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
3242271|NCT00895726|Experimental|APD209|
3242272|NCT00895713|Experimental|im HBIG Grifols|
3242273|NCT00895700|Experimental|Web-based behavioral intervention|
3242274|NCT00895700|No Intervention|Usual care|
3242222|NCT00896051|Experimental|ATV/rtv 400/100 mg (Treatment B)|Treatment-experienced human immunodeficiency virus - type 1 (HIV-1) infected participants will take by mouth atazanavir (ATV)/low-dose ritonavir (rtv) 300/100 mg once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 2 weeks pretreatment followed by ATV/rtv 400/100 mg once daily + etravirine (ETR) 200 mg twice daily + 1 NRTI for 48 weeks. If particpating in an optional substudy to assess the effect of adding tenofovir disoproxil fumarate (TDF) for 7 days on ATV and ETR pharmacokinetics, participants will take TDF 300 mg once daily for 7 days in addition to their antiretroviral regimen (ETR+ATV/rtv+NRTI).
3242223|NCT00896038|Experimental|Aprepitant|Following a 1-week placebo lead-in period subjects were given 125 mg of Aprepitant orally daily for 21 days
3242224|NCT00896038|Placebo Comparator|Placebo|Subjects received oral placebo during the 1-week placebo lead-in and then daily for 21 days
3242225|NCT00896025|Other|N-acetycylcysteine|Each eligible Acute Liver Failure patient will be given N-acetylcysteine (NAC), beginning at a dose of 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour, followed by 50 mg/kg in 500 ml 5% dextrose over four hours, and 125 mg/kg in 1000 ml 5% dextrose over 19 hours, then 150 mg/kg in 1000 ml 5% dextrose per 24 hours for an additional 48 hours. The patient will be on continuous NAC infusion for a total of 72 hours.
3242226|NCT00896012|Experimental|1. Low-dose tacrolimus arm|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months). All patients will undergo a second protocol biopsy at 12 months.
3242227|NCT00896012|Experimental|2. Rapamune conversion arm:|Patients in this group will undergo a gradual conversion from tacrolimus to Rapamune therapy. Tacrolimus will be withdrawn progressively over a period of 7-10 days. Dosage adjustments will be made with the aim of reducing the blood levels of tacrolimus by 25% every other day until tacrolimus is discontinued. Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
3242228|NCT00895999|Experimental|1|Female patients (n=30) who meet criteria for major depression and chronic pelvic pain will be randomly assigned to 8 individual sessions of IPT adapted for depression and pain.
3242229|NCT00895999|Other|2|Female patients (n=30) who meet criteria for major depression and chronic pelvic pain will be randomly assigned to Enhanced Support and Connection to Counseling (ESCC).
3242230|NCT00895986|Experimental|1|Conversation Maps Diabetes Education
3242231|NCT00895986|Experimental|2|Heart Healthy Living Diabetes Education
3242232|NCT00895973|Experimental|Stirrups delivery|Mom will be assigned to deliver with legs positioned in stirrups
3242233|NCT00895973|Experimental|Bed delivery|Mom will be assigned to deliver with the legs positioned in bed in the supine position
3242234|NCT00895960|Experimental|Dasatinib Plus RT + TMZ|Dasatinib (Sprycel) with Radiotherapy (RT) and 6 weeks of concomitant Temozolomide (TMZ)
3242235|NCT00895947|Experimental|Interferon-alpha|150 international units of interferon-alpha
3242236|NCT00895947|Placebo Comparator|placebo|placebo lozenges
3242237|NCT00895934|Experimental|Phase 1 - Dose Finding|Varying schedules and dose levels of vorinostat, azacitidine and gemtuzumab ozogamicin. Includes cohorts 1-3.
3242238|NCT00895934|Experimental|Phase 2 - Treatment at Selected Dose|Vorinostat 400 mg/day on days 1-9, azacitidine 75 mg/m2/day on days 1-7, gemtuzumab ozogamicin 3 mg/m2/day on days 4 and 8.
3242239|NCT00895921|Active Comparator|1|Participants will receive an injection of aripiprazole during the trace-clamp study.
3242240|NCT00895921|Active Comparator|2|Participants will receive an injection of olanzapine during the trace-clamp study.
3242241|NCT00895908|Experimental|Friendship Group Intervention|"Participants will receive the Friendship Groups intervention."
3242242|NCT00895908|Active Comparator|Individual Tutoring|Participants will receive individual academic tutoring.
3242243|NCT00895895|Placebo Comparator|1|Placebo
3242244|NCT00895895|Experimental|2|SAM-531 1.5 mg
3242245|NCT00895895|Experimental|3|SAM-531 3.0 mg
3242246|NCT00895895|Experimental|4|SAM-531 5.0 mg
3242247|NCT00895895|Active Comparator|5|Donepezil
3242248|NCT00895882|Experimental|1|vaniprevir 300 mg b.i.d. + peg-IFN + RBV for 12 weeks, followed by placebo to vaniprevir + peg-IFN + RBV for 12 weeks
3242249|NCT00895882|Experimental|2|vaniprevir 300 mg b.i.d. + peg-IFN + RBV for 24 weeks
3242250|NCT00895882|Experimental|3|vaniprevir 600 mg b.i.d. + peg-IFN + RBV for 12 weeks, followed by placebo to vaniprevir + peg-IFN + RBV for 12 weeks
3242251|NCT00895882|Experimental|4|vaniprevir 600 mg b.i.d. + peg-IFN + RBV for 24 weeks
3242252|NCT00895882|Experimental|5|vaniprevir 600 mg q.d. + peg-IFN + RBV for 24 weeks
3242253|NCT00895882|Placebo Comparator|6|Placebo to vaniprevir + peg-IFN + RBV for 24 weeks, followed by peg-IFN + RBV for 24 weeks
3242254|NCT00895856||Old-aged people|
3242255|NCT00895843|Active Comparator|Conventional ibuprofen|
3242256|NCT00895843|Experimental|Brufen retard|
3242257|NCT00895830|Placebo Comparator|1|
3242258|NCT00895830|Experimental|2|0.3mg dose level
3242259|NCT00895830|Experimental|3|1mg dose level
3242260|NCT00895830|Experimental|4|2mg dose level
3242261|NCT00895830|Experimental|5|3mg dose level
3242262|NCT00895817|Active Comparator|Swallowed fluticasone|
3242263|NCT00895817|Active Comparator|Esomeprazole|
3242264|NCT00895804|Other|Pindolol, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
3242265|NCT00895804|Other|MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
3242266|NCT00895791|Active Comparator|1|AXXESS Biolimus A9-eluting bifurcation stent
3242267|NCT00895791|Active Comparator|2|culotte stenting with use of 2 drug eluting stents
3242268|NCT00895778|Experimental|NMB|muscle relaxation (neuromuscular block) during laparoscopic cholecystectomy
3242269|NCT00895778|Placebo Comparator|no NMB|no muscle relaxation (neuromuscular block) during laparoscopic cholecystectomy
3242275|NCT00895687|Experimental|Erlotinib + Bortezomib|Up to 4 dose levels of study drug combination tested with 3-6 participants enrolled at each dose level. Erlotinib beginning dose of 150 mg taken by mouth daily for 21-day cycle. Bortezomib beginning dose of 1. mg/m^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
3242276|NCT00895674||Group 1|
3242277|NCT00895661|Other|rituximab|single-arm, open-label, interventional
3242278|NCT00895648|Experimental|Alimta plus Cisplatin|
3242279|NCT00895635|Experimental|Treadmill Exercise Training|Participants will take part in a 12-week supervised treadmill exercise training program.
3242280|NCT00895635|Experimental|Arm Ergometry Exercise Training|Participants will take part in a 12-week supervised aerobic arm ergometry exercise training program.
3242281|NCT00895635|Active Comparator|Usual Care Control Group|Participants will receive usual care for PAD from their doctor.
3242282|NCT00895622|No Intervention|Low Risk|No treatment given.
3242283|NCT00895622|Experimental|Intermediate Risk|54 Gy radiotherapy
3242284|NCT00895622|Experimental|High Risk|60 Gy radiotherapy
3242285|NCT00895609|Experimental|Sugammadex|Sugammadex in doses: 0 (placebo), 0.0625, 0.125, 0.25, 0.5 and 1 mg/kg
3242286|NCT00895609|Active Comparator|Neostigmine|Neostigmine in doses: 0 (placebo), 5, 8, 15, 25, 40 mg/kg
3242287|NCT00895596|Experimental|LB80380 30mg|LB80380 30mg
3242288|NCT00895596|Experimental|LB80380 60mg|LB80380 60mg
3242289|NCT00895596|Experimental|LB80380 90mg,|LB80380 90mg
3242290|NCT00895596|Experimental|LB80380 150mg|LB80380 150mg
3242291|NCT00895596|Experimental|LB80380 240mg|LB80380 240mg
3242292|NCT00895583|Experimental|Group I - Planned transition to sirolimus from tacrolimus|
3242293|NCT00895583|Active Comparator|Group II - Continuation of tacrolimus|
3242294|NCT00895570|Experimental|Modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
3242295|NCT00895570|Placebo Comparator|Placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
3242296|NCT00895557|Active Comparator|chantix|
3242297|NCT00895544|Experimental|1|Day 0: Single priming vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Vietnam strain) - Day 360: Randomization to booster vaccination with Dose B of whole virion, Vero cell-derived influenza vaccine (Indonesia strain)
3242298|NCT00895544|Experimental|2|Day 0: Single priming vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Vietnam strain) - Day 360: Randomization to booster vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Indonesia strain)
3242299|NCT00895531|Active Comparator|Peripheral Nerve group|Group will receive sciatic catheter placed before or after surgery by subgluteal approach with the use of ultrasound. The ischial tuberosity will be identified with the ultrasound probe and its midpoint marked. A catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
3242300|NCT00895531|Experimental|Depodur Group|patients will have an L2-L3 epidural placed while they are in the sitting position before or after femoral catheter placement. They will receive 7.5 mg Depodur via the epidural catheter. All of these patients will receive Singular 10 mg and Claritin 10 mg before the epidural Depodur is placed, as per our protocol of patients receiving EREM.
3242301|NCT00895518|No Intervention|1|Participants will receive assessments only.
3242302|NCT00895518|Experimental|2|Participants will receive prolonged exposure therapy.
3242303|NCT00895505|Active Comparator|oral anticoagulants|Experimental intervention: Extension of OAT in VTE patients showing high plasma levels of D-Dimer after end of routine secondary prophylaxis.
3242304|NCT00895505|No Intervention|2|Control: Withdrawal of OAT in VTE patients after end of routine secondary prophylaxis and receiving low molecular weight heparin in risk situations.
3242305|NCT00895492||Sotero del Rio|Emergency Room and Hospital based surveillance
3242306|NCT00895492||Van Buren|Emergency Room and Hospital based surveillance
3242307|NCT00895479|Experimental|Trinam|Graft placement plus Trinam therapy
3242308|NCT00895479|No Intervention|Control|Graft placement surgery alone
3242309|NCT00895453|Active Comparator|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid).
3242310|NCT00895453|Active Comparator|itraconazole + lactobacilli agent|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid). Additionally, Lactobacillus vaginal tablets monthly given through 6 days.
3242311|NCT00895453|Active Comparator|classic homeopathy (CH)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
3242312|NCT00895440||1|Diabetic patients without neuropathy
3242313|NCT00895440||2|Diabetic patients with painless neuropathy
3242314|NCT00895440||3|Diabetic patients with painful neuropathy
3242315|NCT00895440||4|Diabetic patients with Charcot neuroarthropathy
3242316|NCT00895440||5|Control non-diabetic subjects
3242317|NCT00895427||1|Male ages 45-54, without diabetes, CAC score from 0 to >1000
3242318|NCT00895427||2|Male ages 55-64, without diabetes, CAC score from 0 to >1000
3242319|NCT00895427||3|Male ages 65+, without diabetes, CAC score from 0 to >1000
3242320|NCT00895427||4|Male ages 45-54, with diabetes and CAC score from 0 to >1000
3242321|NCT00895427||5|Male ages 55-64, with diabetes, CAC score from 0 to >1000
3242322|NCT00895427||6|Male ages 65+, with diabetes, CAC score from 0 to >1000
3242323|NCT00895427||7|Female ages 50-59, without diabetes, CAC score from 0 to >1000
3242324|NCT00895427||8|Females ages 60-69, without diabetes and CAC score from 0 to >1000
3242325|NCT00895427||9|Females ages 70 +, without diabetes, CAC score from 0 to >1000
3242326|NCT00895427||10|Female ages 50- 59, with diabetes, CAC score from 0 to >1000
3242327|NCT00895427||11|Female ages 60-69, with diabetes, CAC score from 0 to >1000
3242328|NCT00895427||12|Female age 70+, with diabetes, CAC score from 0 to >1000
3242329|NCT00895414|Experimental|Arm I|Patients receive doxorubicin hydrochloride IV over 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2.
3242330|NCT00895414|Experimental|Arm II|Patients receive doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
3242331|NCT00895401|Active Comparator|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
3242332|NCT00895401|Experimental|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available nutritional supplement designed to meet the nutritional needs of malnourished hemodialysis patients. The serving size is 8 oz which provides 425 kcal and 19 g protein
3242333|NCT00895388|Other|Structured Rehabilitation program|
3242334|NCT00895388|No Intervention|Controls|
3242335|NCT00895375||Psoriasis patients|40 subjects (male or female) age 18 or older with psoriasis covering >10% BSA and without a diagnosis of depression.
3242336|NCT00895375||Patients without psoriasis|40 subjects without psoriasis matched for age, sex and BMI, as a control population.
3242337|NCT00895362|Experimental|Erlotinib + Cetuximab|Erlotinib in Combination with Cetuximab
3242338|NCT00895349|Experimental|1|CT Abdomen and Pelvis + whole body PET-CT
3242339|NCT00895349|Active Comparator|2|CT Abdomen and Pelvis
3242340|NCT00895310|Experimental|Ketoconazole and Hydrocortisone|Ketoconazole 200mg PO TID + Hydrocortisone 20mg PO Qam, 10mg PO Qpm
3242341|NCT00895284|Experimental|Robot|Robotic hysterectomy
3242342|NCT00895284|Active Comparator|Standard|Standard hysterectomy
3242343|NCT00895258|Experimental|IPS-CT|Participants will receive individual placement and support (IPS) plus cognitive training (CT).
3242344|NCT00895258|Active Comparator|IPS-ES|Participants will receive individual placement and support (IPS) plus enhanced support (ES).
3242345|NCT00895245|Experimental|Arm I|"Patients receive cisplatin IV on day 1. Treatment repeats every 21 days for up to 3 courses. Patients also undergo radiotherapy once daily 5 days a week for up to 7 weeks.~Patients receive fosaprepitant dimeglumine IV, palonosetron hydrochloride IV, and dexamethasone IV on day 1.Patients then receive oral dexamethasone on days 2-4. Patients with no emesis or requirement for rescue anti-emetics in the first 120 hours after cisplatin infusion continue to receive the anti-emetic regimen as above with the second and third courses of cisplatin.~Patients complete an emesis diary daily for 5 days after each cisplatin infusion. Patients also complete a Functional Living Index-Emesis Questionnaire on day 8 after each cisplatin infusion."
3242346|NCT00895232|Experimental|Cohort I|500 mg dose Venofer over 4 hours
3242347|NCT00895232|Experimental|Cohort II|500 mg Venofer infusion over 4-6 hours on Day 0 and repeated on Day 2 to 7
3242348|NCT00895232|Experimental|Cohort III|500 mg Venofer over 6 hours, followed within 24 hours by 500 mg Venofer over 6 hours
3242349|NCT00895219|Active Comparator|1|Breathing re-training
3242350|NCT00895219|Active Comparator|2|Breathing re-training and musculoskeletal physiotherapy techniques
3242351|NCT00895206|Experimental|1|individual adapted immunosuppression
3242352|NCT00895206|Active Comparator|2|golden standard therapy
3242353|NCT00895193|Active Comparator|Apple-pectin 2000mg|Participant receives Apple pectin 2000mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
3242354|NCT00895193|Active Comparator|Regular Non-enteric coated aspirin 325mg|Participant receives aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
3242355|NCT00895193|Active Comparator|Apple pectin + aspirin|Participant receives apple pectin 2000mg and aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
3242356|NCT00895193|Placebo Comparator|Placebo Comparator|Participant receives placebo 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
3242357|NCT00895180|Experimental|Group 1|Patients receive ramucirumab IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3242358|NCT00895180|Experimental|Group 2|Patients receive olaratumab IV over 60-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3242359|NCT00895167|Experimental|curcumin|every subject receives 12 g of oral curcumin
3242360|NCT00895154|Active Comparator|1|Participants will receive general tutoring in the subject of his/her choice.
3242361|NCT00895154|Experimental|2|Participants will receive tutoring and memory training.
3242362|NCT00895141|Experimental|Low saturated fat diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 8%E saturated fat
3242363|NCT00895141|Experimental|High saturated fat diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
3242364|NCT00895128|Experimental|Erlotinib + Dasatinib|Erlotinib starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients. Dasatinib starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
3242365|NCT00895115|Sham Comparator|Arm I|Patients receive no supplementation.
3242366|NCT00895115|Experimental|Arm II|Patients receive oral high γ-tocopherol vitamin E supplementation once daily for 1 week.
3242367|NCT00895115|Experimental|Arm III|Patients receive oral high γ-tocopherol vitamin E supplementation once daily for 2 weeks.
3242368|NCT00895102|Active Comparator|1. ABT-333 Capsule vs ABT-333 Tablet|400mg ABT-333 Tablet, QD, single dose vs eight 50mg ABT-333 Capsules, QD, single dose
3242369|NCT00895102|Active Comparator|2. ABT-333 Tablet|ABT-333 400mg Tablet, QD, single ascending doses (1200mg, 1600mg, 2400mg)
3242370|NCT00895102|Placebo Comparator|3. Placebo|Placebo tablets, QD, single ascending doses
3242371|NCT00895089|Experimental|A: Moxifloxacin|Moxifloxacin 400mg IV once daily for 14 days, then 400mg PO once daily for 7 days.
3242372|NCT00895089|Active Comparator|B: Ceftriaxone|Ceftriaxone 2gm IV every 12 hours for 14 days, then cephalexin 1gm PO every 6 hours for 7 days.
3242373|NCT00895076|Experimental|1|dexamethasone iontophoretic patch
3242374|NCT00895076|Active Comparator|2|dexamethasone intramuscular injection
3242375|NCT00895063|Experimental|Vocal Exercise|Subject will speak continually for one hour following injection of botulinum toxin.
3242376|NCT00895063|Placebo Comparator|Silence|Subject will remain silent for one hour following injection of botulinum toxin.
3242377|NCT00895050||1|Patients diagnosed with RA
3242378|NCT00895037||1|Patients treated with Refacto AF
3242379|NCT00895024||Caregivers|
3242380|NCT00895011|Placebo Comparator|Placebo|
3242381|NCT00895011|Experimental|Avanafil 100 mg|
3242382|NCT00895011|Experimental|Avanafil 200 mg|
3242383|NCT00894998|Experimental|1|Heparin sodium 5.000 UI - Cristália
3242384|NCT00894998|Active Comparator|2|Heparin Sodium 5.000 USP - APP
3242385|NCT00894985|Experimental|1|Heparin 5.000UI
3242386|NCT00894985|Active Comparator|2|Heparin 5.000USP - APP
3242387|NCT00894972|Active Comparator|1|General exercise. Participants in this group will perform aerobic exercise, range of motion exercise and general strengthening exercise.
3242388|NCT00894972|Experimental|2|Specific exercise. Participants in this group will perform aerobic exercise, range of motion exercise, and specific motor control exercises.
3242389|NCT00894959|Experimental|1|Heparin Sodium Blausiegel 1
3242390|NCT00894959|Experimental|Active Comparator|heparin sodium - APP 5.000 USP
3242391|NCT00894946|Experimental|Recurrent IVF implantation failure|
3242392|NCT00894946|Experimental|Endometriosis|
3242393|NCT00894933|Experimental|Continuum|Verify the consistency of performance of the AMS CONTINUUM device in facilitating a sustainable anastomosis following a radical prostatectomy using updated Device design elements and Physician training materials on Device implant technique.
3242394|NCT00894920|Placebo Comparator|placebo|
3242395|NCT00894920|Active Comparator|biotin|
3242396|NCT00894907|Experimental|PiCCO-group|Insertion of an arterial PiCCO catheter. Resuscitation using crystalloids and/or colloids according to PiCCO-parameter-guided algorithm
3242397|NCT00894907|Other|2|Control: Haemodynamic management without ITBI and ELWI using any other haemodynamic monitoring tool, with the exception of the PiCCO-system.
3242398|NCT00894881||1 group|patients before colonoscopy
3242399|NCT00894868|Experimental|Vildagliptin|
3242400|NCT00894868|Placebo Comparator|Placebo|
3242401|NCT00894855|Active Comparator|education only|This comprehensive education program included a health educator visit, on the education van, who gave education about sun safety.
3242402|NCT00894855|Experimental|education plus dermatologist skin exam|"In addition to the education program, participants received free skin exams by board certified dermatologists from Brigham and Women's Hospital. The van was equipped with a private clinical setting conducive to carry out such examinations. Based on the recommendations of the American Academy of Dermatology (AAD), a visual full body exam was provided to participants. At the end of each skin exam the dermatologist provided a presumptive diagnosis to the participant, and made appropriate recommendations and referrals for follow up with the participants' physician/dermatologist (if and when necessary). All participants undergoing the skin exam were required to complete an AAD Skin Cancer Screening Registration and Report form."
3242403|NCT00894855|Experimental|educ, biometric fb, and derm skin exam|Participants received the active components of the other three conditions.
3242404|NCT00894855|Experimental|education plus biometric feedback|In addition to the educational program, participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
3242405|NCT00894842|Active Comparator|Pregnenolone|
3242406|NCT00894842|Placebo Comparator|Sugar pill|
3242407|NCT00894829|Experimental|1|Heparin sodium - Eurofarma
3242408|NCT00894829|Active Comparator|2|Heparin APP
3242409|NCT00894816|Active Comparator|1|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19) 10E8 CFU per serving
3242410|NCT00894816|Placebo Comparator|2|Placebo (infant cereals without any additions)
3242411|NCT00894803|Active Comparator|rt-PA only|Subject will receive the standard dose (0.9mg/kg) of IV rt-PA given over 60 minutes. One out of 6 subjects will be in this group.
3242412|NCT00894803|Experimental|rt-PA and Eptifibatide|Subject will receive the standard dose (0.9mg/kg) of IV rt-PA. This IV dose will be discontinued at 40 minutes. The subject will immediately receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours. Five out of six subjects will be in this group.
3242413|NCT00894790|Experimental|1|
3242414|NCT00894790|Active Comparator|2|
3242415|NCT00894777||1|Patients with moderate and severe psoriasis under treatment with topical and/or systemic drugs
3242416|NCT00894764||Routine Follow Up|Monthly nasopharyngeal swab for infant. Seen during acute illness.
3242417|NCT00894764||Immunology|Monthly nasopharyngeal swab for mother and infant. Serum sample taken from Infant. Seen during acute illness.
3242418|NCT00894751|Active Comparator|dexmedetomidine|Determine if there is a significant difference in the quality of care between our two standard anesthesia techniques for children undergoing a MRI of the body and/or extremity MRI.
3242419|NCT00894751|Active Comparator|propofol|Determine if there is a significant difference in the quality of care between our two standard anesthesia techniques for children undergoing a MRI of the body and/or extremity MRI.
3242420|NCT00894738|Active Comparator|antipsychotic treated|Children with psychiatric diagnoses who are currently treated with antipsychotic medications.
3242421|NCT00894738|Placebo Comparator|healthy control|Age- and gender-matched children who do not have a psychiatric diagnosis, are not taking antipsychotic medications, and are otherwise healthy.
3242422|NCT00894725|Experimental|LPS|laparoscopic left colonic resection
3242423|NCT00894725|Active Comparator|Open|open left colonic resection
3242424|NCT00894699|Active Comparator|1|single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
3242534|NCT00893854|Experimental|Diclophenac|
3242425|NCT00894699|Placebo Comparator|2|single dose of sublingual Placebo NanoTab™
3242426|NCT00894686|Experimental|All subjects|Assessment of seropersistence of TBE antibodies at yearly intervals from approximately 3 years (38 months) to 10 years (118 months) after the first booster vaccination (in Study 700401), as well as antibody response to a second booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5 mL, depending on the subject´s age. Timing of the second booster vaccination will depend on the level of serum TBE antibodies detected at the defined assessment time points. Subjects who are not protected against TBE for an entire further season (NT titer <= 20 and/or ELISA value < 126 VIE U/mL) will be invited to receive the second booster vaccination at either the 40, 48, 60, 72, 84, 96, 108, or 120-month time point.
3242427|NCT00894673|Experimental|1|Heparin sodium Hipolabor
3242428|NCT00894673|Active Comparator|2|Heparim Sodium APP 5.000 USP
3242429|NCT00894660|Experimental|Amodiaquine (Pfizer)|
3242430|NCT00894660|Active Comparator|Amodiaquine tablets (Arsuamoon-Guilin China)|
3242431|NCT00894647|Placebo Comparator|2|placebo cream in 250mg/packet, up to 2 packets applied daily
3242432|NCT00894647|Active Comparator|imiquimod cream|Imiquimod 3.75% cream, 250 mg single-use packets, up to 2 packets applied daily
3242433|NCT00894634|Experimental|Brompheniramine maleate|Brompheniramine maleate oral solution 1 mg/5 mL, single dose
3242434|NCT00894621|Experimental|Norepinephrine|
3242435|NCT00894621|Placebo Comparator|Placebo|
3242436|NCT00894608|Experimental|letrozole protocol|patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
3242437|NCT00894608|Experimental|long GnRHa protocol|patients in long GnRHa protocol for ovarian stimulation with Gnrha and gonadotropins
3242438|NCT00894595|Experimental|Intervention group|The clubs in the intervention group are instructed to perform a warm-up program at two training sessions per week throughout the entire 2009 competitive season.
3242439|NCT00894595|Active Comparator|Control group|The clubs in the control group are instructed to train and play as usual throughout the 2009 season
3242440|NCT00894569|Active Comparator|A|6 cycles of carboplatin/paclitaxel
3242441|NCT00894569|Experimental|B|carboplatin/paclitaxel plus cetuximab until disease progression
3242442|NCT00894556|Experimental|Treatment Sequence A|Rizatriptan - Rizatriptan - Placebo
3242443|NCT00894556|Experimental|Treatment Sequence B|Rizatriptan - Placebo - Rizatriptan
3242444|NCT00894556|Experimental|Treatment Sequence C|Placebo - Rizatriptan - Rizatriptan
3242445|NCT00894556|Other|Baseline Phase|Sumatriptan
3242446|NCT00894543|Active Comparator|Escitalopram|Escitalopram is a selective serotonin reuptake inhibitor (SSRI)
3242447|NCT00894543|Placebo Comparator|Placebo|Inactive pill
3242448|NCT00894530|Experimental|1|
3242449|NCT00894530|Placebo Comparator|2|
3242450|NCT00894517|Experimental|Botulinum Toxin Type A|OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
3242451|NCT00894517|Placebo Comparator|Placebo (saline)|Placebo (saline) injected into the prostate on Day 1.
3242452|NCT00894504|Experimental|Panitumumab/Gemcitabine/Carboplatin|Systemic therapy
3242453|NCT00894478||1|12 children with MRI-negative partial epilepsy who are being worked-up for epilepsy surgery
3242454|NCT00894478||2|12 children with MRI-visible FCD who are being worked-up for epilepsy surgery
3242455|NCT00894478||3|Control Group- Healthy Volunteers
3242456|NCT00894465|Experimental|Versed|Both patients who are VCUG naive and patients who have had a previous VCUG are given oral midazolam prior to undergoing the VCUG.
3242457|NCT00894465|Placebo Comparator|Placebo|Both patients who are VCUG naive and patients who have had a previous VCUG are given an oral placebo prior to undergoing the VCUG.
3242458|NCT00894439|Experimental|1|
3242459|NCT00894426||1|Morning Symptoms (+)
3242460|NCT00894426||2|Morning Symptoms (-)
3242461|NCT00894413|Placebo Comparator|Placebo|
3242462|NCT00894413|Experimental|Drug|Tadalafil 20 mg once per day
3242463|NCT00894400|Experimental|Targeting of most fractionated electrograms first|During catheter ablation of AF patients will have fractionated electrograms targeted. In the experimental group the fractionated electrograms believed to be most critical will be targeted first.
3242464|NCT00894400|Active Comparator|Targeting least fractionated electrograms first|During catheter ablation of AF fractionated electrograms are targeted. In this arm the least fractionated electrograms will be targeted first.
3242465|NCT00894387|Experimental|Aliskiren|Randomized patients in this arm received, Aliskiren 150 mg once daily for 2 weeks. From week 2 upto 6 months , patients who could tolerate study medication were up-titrated to aliskiren 300 mg once daliy.
3242466|NCT00894387|Placebo Comparator|Placebo|Randomized patients in this arm received matching placebo of Aliskiren. At week 2, Patients who could tolerate study medication were up-titrated to matching placebo of 300 mg aliskiren.
3242467|NCT00894374|Experimental|Artesunate (Pfizer)|
3242468|NCT00894374|Active Comparator|Artesunate (Arsuamoon® Tablets Guilin-China)|
3242469|NCT00894361|Active Comparator|rotating-platform design TKA|patients who were randomized to receive the rotating platform mobile-bearing TKA design
3242470|NCT00894361|Active Comparator|all-polyethylene tibia design TKA|patients who were randomized to receive the all-polyethylene tibial component design
3242471|NCT00894335||1|Pheochromocytoma
3242472|NCT00894335||2|Conn-Syndrome
3242473|NCT00894335||3|Cushing disease
3242474|NCT00894335||4|Metastasis
3242475|NCT00894335||5|Non-functional tumor
3242476|NCT00894322|Experimental|Cohort 1: Healthy Participants|A single 10-mg dose of exenatide once weekly suspension given to healthy participants via 3 subcutaneous (SC) injections at Day 1.
3242477|NCT00894322|Experimental|Cohort 2: Diabetes Participants|On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, thiazolidinedione (TZD), or a combination of metformin or TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks.
3242535|NCT00893854|Experimental|Triamcinolone|
3242536|NCT00893841|Placebo Comparator|1|Quetiapine XR 300mg + Placebo
3242537|NCT00893841|Experimental|2|Quetiapine XR 300mg + Pramipexole 0.25mg
3242478|NCT00894322|Placebo Comparator|Cohort 2: Diabetes Participants Placebo|On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, thiazolidinedione (TZD), or a combination of metformin or TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks.
3242479|NCT00894296||1|schizophrenia patients
3242480|NCT00894296||2|healthy control
3242481|NCT00894283|Active Comparator|Enoxaparin|Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.
3242482|NCT00894283|Active Comparator|Fondaparinux|Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.
3242483|NCT00894257||HCV/HIV infected pregnant women|
3242484|NCT00894244|Experimental|Treatment|Treatment using a non-invasive skin tightening radiofrequency device to observe skin shrinkage in the arms
3242485|NCT00894231|Placebo Comparator|placebo|Sugar tablet
3242486|NCT00894231|Active Comparator|Xyzal|
3242487|NCT00894218|Active Comparator|Conventional arthroplasty|Total hip or knee conventional arthroplasty
3242488|NCT00894218|Experimental|Mini-invasive arthroplasty|Total hip or knee mini-invasive arthroplasty
3242489|NCT00894218|Experimental|Mini-invasive and computer-assisted arthroplasty|Mini-invasive and computer-assisted total hip or knee arthroplasty
3242490|NCT00894205|Experimental|strengthening exercise|"A low intensity strengthening exercise program based on the Tufts University Strong Bones program. Utilizes small free weights and chair exercises."
3242491|NCT00894192|Active Comparator|Wavefront guided lenses|
3242492|NCT00894192|Placebo Comparator|Conventional lenses|
3242493|NCT00894166|Active Comparator|Nicotine Replacement Therapy Responder|Nicotine Responders
3242494|NCT00894166|Active Comparator|Pre-Quit Rescue to Bupropion & Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 2 to use of Zyban (bupropion) in combination with nicotine patches
3242495|NCT00894166|Active Comparator|Pre-Quit Rescue to Varenicline|Participants not responsive to nicotine patches who are randomly assigned at week 2 to use of Chantix (varenicline)
3242496|NCT00894166|Active Comparator|Pre-Quit Rescue to Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 2 to continued use of nicotine patches
3242497|NCT00894166|Active Comparator|Post-Quit Rescue to Bupropion & Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 4 to use of Zyban (bupropion) in combination with nicotine patches
3242498|NCT00894166|Active Comparator|Post-Quit Rescue to Varenicline|Participants not responsive to nicotine patches who are randomly assigned at week 4 to use of Chantix (varenicline)
3242499|NCT00894166|Active Comparator|Post-Quit Rescue to Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 4 to continued use of nicotine patches
3242500|NCT00894153|Experimental|chemo plus p53|chemotherapy plus p53
3242501|NCT00894153|Active Comparator|chemo only|chemotherapy group
3242502|NCT00894153|Active Comparator|radio|radiotherapy
3242503|NCT00894140|Other|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
3242504|NCT00894127|Experimental|CyPath Assay of Deep-Lung Sputum Sample|Deep-lung sputum was obtained from two cohorts, including (1) high-risk control group comprised of individuals not diagnosed but at high risk for lung cancer (n=102) and, (2) cancer group comprised of individuals with confirmed lung cancer diagnosis (n=26), was labeled in exact manner with TCPP and evaluated to detect red fluorescent [ie, cancer] cells (RFCs) from deep-lung sputum samples.
3242505|NCT00894114|Other|Stratum 1|Placebo recipients in the parent protocol (Merck V520 Protocols 007 or 012) will receive ALVAC-HIV Vaccine
3242506|NCT00894114|Experimental|Stratum 2|Nonresponders who received active vaccine in parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
3242507|NCT00894114|Experimental|Stratum 3|Low responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
3242508|NCT00894114|Experimental|Stratum 4|High responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
3242509|NCT00894101|Experimental|[F-18] FLT and FDG|
3242510|NCT00894062|Active Comparator|1|ZES resolute (Endeavor® resolute)
3242511|NCT00894062|Active Comparator|2|EES (Xience®)
3242512|NCT00894049|Experimental|Flu-Bu-ATG|Fludarabine (30mg/m²/5 days) Oral Busulfan (8 mg/kg over 2 days) Thymoglobuline (2.5 mg/m²/1day).
3242513|NCT00894049|Experimental|Fluda-TBI|Fludarabine (25mg/m²/ 3 days) 2 Gy TBI
3242514|NCT00894023|Experimental|Abciximab|IC bolus of abciximab
3242515|NCT00894023|Active Comparator|IV Abciximab|IV abciximab + infusion
3242516|NCT00893997|Experimental|PR-1 vaccine|4 injections of 0.5 mg PR1 peptide vaccine every 3 weeks.
3242517|NCT00893984|Experimental|Nebivolol|
3242518|NCT00893971|Experimental|1|Inhaled PT001 18 μg
3242519|NCT00893971|Experimental|2|Inhaled PT005 2.4 μg
3242520|NCT00893971|Experimental|3|Inhaled PT003 (PT001 18 μg / 2.4 μg PT005)
3242521|NCT00893971|Experimental|4|PT001 18 μg + PT005 2.4 μg
3242522|NCT00893945|Experimental|DC/AAT vaccine|Intradermal injection of 3 Autologous dendritic cell vaccines (DC/AAT, DC/AAT-flu, DC/KLH) that have been co-cultured with autologous apoptotic tumor specimens.
3242523|NCT00893932||SIRS|
3242524|NCT00893906|Experimental|TIV|Children living in villages randomized to influenza vaccine
3242525|NCT00893906|Experimental|IPV|Children living in villages randomized to polio vaccine
3242526|NCT00893893||1|Lean premenopausal women
3242527|NCT00893893||2|Visceral obese premenopausal women
3242528|NCT00893880|Experimental|1|(1) 30min treatment
3242529|NCT00893880|Experimental|2|(1) 60min treatment
3242530|NCT00893880|Experimental|3|(2) 30min treatments over two consecutive days.
3242531|NCT00893880|Experimental|4|(2) 60min treatments over two consecutive days.
3242532|NCT00893867|Experimental|DP-b99|
3242533|NCT00893867|Placebo Comparator|Mannitol|
3242539|NCT00893815||1|HIV-Positive and Early HIV infection
3242540|NCT00893815||2|HIV-Positive and Late HIV-infection
3242541|NCT00893815||3|HIV-negative
3242542|NCT00893802|Experimental|Periodontal treatment|Scaling and root planning
3242543|NCT00893802|No Intervention|Control|
3242544|NCT00893789|Experimental|1|Armodafinil 50 mg/day
3242545|NCT00893789|Experimental|2|Armodafinil 150 mg/day
3242546|NCT00893789|Experimental|3|Armodafinil 250 mg/day
3242547|NCT00893789|Placebo Comparator|4|Placebo
3242548|NCT00893776|Active Comparator|1 Unilateral Group|This group will wear the SaeboFlex orthosis on their affected extremity and do exercises with that extremity only. SaeboFlex exercises include moving the ball in high repetition of grasp and release while wearing the SaeboFlex orthosis to various positions individualized to each participant based on movement deficits, as well as Task Training (using the affected arm during specific functional activities to use newly acquired movement patterns)
3242549|NCT00893776|Experimental|2 Bilateral training|Members of this group will wear the SaeboFlex orthosis on the affected extremity and do exercises with the affected extremity and the non-affected extremity at the same time. SaeboFlex exercises include moving the ball in high repetition of grasp and release while wearing the SaeboFlex orthosis to various positions individualized to each participant based on movement deficits, as well as Task Training (using the affected arm during specific functional activities to use newly acquired movement patterns)
3242550|NCT00893763|Experimental|Pre-intubation CHX|Chlorhexidine applied to oral cavity prior to intubation
3242551|NCT00893763|Active Comparator|Control|No chlorhexidine applied to oral cavity prior to intubation
3242552|NCT00893750|Experimental|NET Truth Education|
3242553|NCT00893750|Experimental|Conflict Resolution Trainings|
3242554|NCT00893750|Experimental|Traditional Methods|
3242555|NCT00893737|Experimental|Treximet|Treximet (a combination of sumatriptan 85 mg and naproxen sodium 500 mg) 1 tablet to be administered as soon as patient has headache indicative of migraine. Patient may treat up to 16 migraine attacks in 2 month study period.
3242556|NCT00893724|Placebo Comparator|P (Placebo)|
3242557|NCT00893724|Active Comparator|S (Supplement)|
3242558|NCT00893724|Active Comparator|SM (Supplement with Minocycline)|
3242559|NCT00893711|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938 is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops of a commercially available oil suspension, 30 min before feeding, once a day for 30 days.
3242560|NCT00893711|Placebo Comparator|Placebo|Placebo is administered in V drops once a day for 30 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
3242561|NCT00893711|Active Comparator|L.reuteri + vit D|L. reuteri DSM 17938 (10^8 CFU) plus vitamin D3 (400 UI) five drops/day for 3 months
3242562|NCT00893711|Placebo Comparator|Vit D Placebo|vitamin D3 (400 UI) five drops/day for 3 months
3242563|NCT00893685|Experimental|Home telemonitoring|
3242564|NCT00893685|No Intervention|Usual care (control group)|
3242565|NCT00893672||1|Routine strategy of chest radiograph prescription
3242566|NCT00893672||2|On-demand strategy of chest radiograph prescription
3242567|NCT00893659|Experimental|wheat bread with beta-glucan supplementation|
3242568|NCT00893659|Placebo Comparator|wheat bread without beta-glucan|
3242569|NCT00893646|Experimental|weight loss counseling|individual monthly counseling on diet, physical activity and sleep
3242570|NCT00893646|No Intervention|control|no lifestyle advice, yearly assessments
3242571|NCT00893620|Other|1|Treatment
3242572|NCT00893607|Experimental|Intra-anal|The first 12 subjects were administered 10mg NRL001 as a slow release suppository into the anal canal.
3242573|NCT00893607|Experimental|Rectal|The second 12 subjects were administered 10mg NRL001 as a slow release rectal suppository.
3242574|NCT00893594|Placebo Comparator|1|Placebo taken at onset of aura associated with migraine.
3242575|NCT00893594|Active Comparator|2|Sumatriptan with naprosyn taken at onset of aura associated with migraine.
3242576|NCT00893581|Active Comparator|1--Quetiapine & Placebo|Quetiapine & Placebo in the place of Lithium
3242577|NCT00893581|Active Comparator|2-- Lithium & Placebo|Lithium & Placebo in the place of Quetiapine
3242578|NCT00893581|Placebo Comparator|Placebo|Sugar Pill (Placebo) given to mimic drug
3242579|NCT00893568|Active Comparator|Healthy volunteers|Healthy volunteers without treatment
3242580|NCT00893568|Experimental|CBT|Psychotraumatized patients treated by Cognitive and Behavioral Therapies (CBT)
3242581|NCT00893568|Experimental|EMDR|Psychotraumatized patients treated by Eye Movement Desensitization and Reprocessing (EMDR)
3242582|NCT00893555|Active Comparator|control|Voriconazole dosing based on SPC
3242583|NCT00893555|Experimental|TDM|Voriconazole serum concentration based dosing
3242584|NCT00893529|Experimental|dietary intervention 1|
3242585|NCT00893529|Experimental|dietary intervention 2|
3242586|NCT00893516|Experimental|1|CHOP chemo therapy + CD4 therapy
3242587|NCT00893516|Active Comparator|2|CHOP chemotherapy
3242588|NCT00893490|Experimental|Ahmed Glaucoma Valve (AGV) alone|
3242589|NCT00893490|Experimental|AGV plus MMC|
3242590|NCT00893490|Experimental|AGV plus amniotic membrane coverage|
3242591|NCT00893464|Experimental|IXAZOMIB|
3242592|NCT00893451|Active Comparator|A|Vitamin D3 1600 IU orally twice daily
3242593|NCT00893451|Placebo Comparator|B|Placebo orally twice daily
3242594|NCT00893438|Experimental|FitNet treatment|FitNet treatment: web-based cognitive behaviour therapy
3242595|NCT00893438|Active Comparator|Usual care|waiting list for FitNet intervention (usual care allowed)
3242596|NCT00893412|Active Comparator|Tramadol + Metal cannula|Fast-release Orodispersible Tramadol Tablet + Metal cannula
3242597|NCT00893412|Placebo Comparator|Placebo + Metal cannula|Placebo + Metal cannula
3242598|NCT00893412|Active Comparator|Tramadol + Balloon|Fast-release Orodispersible Tramadol Tablet + balloon catheter
3242599|NCT00893412|Placebo Comparator|Placebo + Balloon|Placebo + balloon catheter
3242600|NCT00893399|Experimental|1|chemotherapy in combination with ATRA with gemtuzumab ozogamicin
3242601|NCT00893399|Active Comparator|2|chemotherapy in combination with ATRA without gemtuzumab ozogamicin
3242602|NCT00893386||Non-4195 Lead, 181 days|Patients with a Medtronic LV Lead, other than Model 4195, implanted at least 181 days
3242603|NCT00893386||4195 Lead, 181 days|Patients with a Medtronic Model 4195 LV Lead implanted at least 181 days
3242604|NCT00893386||4195 Lead, 90-180 days|Patients with Medtronic Model 4195 LV Lead implanted for 90-180 days
3242605|NCT00893373|Experimental|Sorafenib|Induction, Consolidation and Maintenance plus Sorafenib 2x 400 mg/d
3242606|NCT00893373|Placebo Comparator|Placebo|Induction, Consolidation and Maintenance plus Placebo
3242607|NCT00893360|Experimental|Cardiac Stem Cell Treatment - Group 1|Autologous stem cell infusion of 12.5 MIL CDCs via intracoronary infusion.
3242608|NCT00893360|Experimental|Cardiac Stem Cell Treatment -Group 2|Autologous stem cell infusion of 25 MIL CDCs via intracoronary infusion.
3242609|NCT00893360|No Intervention|Observation (Control Group)|Observation of myocardial recovery after usual medical management.
3242610|NCT00893347|Active Comparator|I|Treatment as usual
3242611|NCT00893347|Experimental|II|Treatment as usual + cognitive-behavioural therapy
3242612|NCT00893334||BMD:|Patients diagnosed with Becker Muscular Dystrophy
3242613|NCT00893334||LGMD2A|patient diagnosed with Limb-Girdle Muscular Dystrophy, type 2A Calpain-3 deficiency
3242614|NCT00893334||LGMD2B|Patients diagnosed with Limb-Girdle Muscular Dystrophy, type 2B Miyoshi myopathy Dysferlin deficiency
3242615|NCT00893334||LGMD2I|Patients diagnosed with Limb-Girdle Muscular Dystrophy, type 2I FKRP-deficiency
3242616|NCT00893334||Control|Healthy Controls
3242617|NCT00893321|Other|Inferior Oblique Muscle Recession and Myectomy|
3242618|NCT00893282|Experimental|BackStop|Intracorporeal lithotripsy with the use of an anti-retropulsion device.
3242619|NCT00893282|Active Comparator|Control|No anti-retropulsion device will be used during lithotripsy.
3242620|NCT00893269|Experimental|Active Medication|Participants receive active hypnotic medication prior to sleep
3242621|NCT00893269|Placebo Comparator|Placebo|Participants receive placebo prior to sleep
3242622|NCT00893256|Experimental|Risperidone and citalopram|24 patients were randomized to receive add-on citalopram (20 mg/day) in a double-blind fashion to open-label risperidone (4-8 mg/day)
3242623|NCT00893256|Placebo Comparator|Risperidone and placebo|24 patients were randomized to receive add-on placebo in a double-blind fashion to open-label treatment with risperidone (4-8 mg/day)
3242624|NCT00893243||1Tears Again/Control|
3242625|NCT00893243||2Opticol/Control|
3242626|NCT00893243||3Optive/Control|
3242627|NCT00893243||4Tears Again/Opticol|
3242628|NCT00893243||5Tears Again/Optive|
3242629|NCT00893243||6Opticol/Optive|
3242630|NCT00893230|Experimental|Lactobacillus sakei KCTC 10755BP|
3242631|NCT00893230|Placebo Comparator|microcrystalline cellulose|
3242632|NCT00893217|Active Comparator|Arm 1|
3242633|NCT00893217|Experimental|Arm 2|
3242634|NCT00893191||Sildenafil|Treated with 50 mg of Sildenafil at night
3242635|NCT00893191||Placebo|Treated with placebo at night
3242636|NCT00893178||CHF with elevated PAP|CHF patients (LVEF > 35%) with elevated mean pulmonary pressure( > 20 mmHg ) measured by pa catheter
3242637|NCT00893178||CHF patient without elevated PAP|CHF patients (LVEF > 35%) with normal mean pulmonary pressure
3242638|NCT00893178||Normal EF with elevated PAP|Patients with normal LVEF < 60% with elevated mean pulmonary pressure
3242639|NCT00893165||hemodialysis patients|chronic hemodialysis patients with elevated inflammation markers
3242640|NCT00893152||Group 1|Male veterans (focus groups and individual interviews)
3242641|NCT00893152||Group 2|Female veterans (focus groups and individual interviews)
3242642|NCT00893152||Group 3|Family members of participating veterans (focus groups and individual interviews)
3242643|NCT00893139|Experimental|AL-38583 0.05%|AL-38583 ophthalmic solution 0.05%, 1 drop per eye, 3 times a day, for 35 days
3242644|NCT00893139|Experimental|AL-38583 0.10%|AL-38583 ophthalmic solution 0.10%, 1 drop per eye, 3 times a day, for 35 days
3242645|NCT00893139|Placebo Comparator|AL-38583 vehicle|Inactive ingredients used as a placebo comparator, 1 drop per eye, 3 times a day, for 35 days
3242646|NCT00893126||Subjects with severe psoriasis|Subjects 18 to 55 with severe psoriasis. Subject will undergo a CCTA (Coronary CT Angiogram) scan.
3242647|NCT00893126||Subjects without psoriasis|Subjects 18 to 55 who do not have psoriasis or rheumatologic conditions, including rheumatoid arthritis and systemic lupus erythematosus. This group of subjects will complete a CCTA (Coronary CT Angiogram)scan.
3242648|NCT00893113|Placebo Comparator|Placebo, Then Alfuzosin|Participants first received 1 Placebo tablet once daily for 12 weeks. Participants then received a 10 mg tablet of Alfuzosin daily for 12 weeks.
3242649|NCT00893113|Experimental|Alfuzosin, Then Placebo|Participants first received a 10 mg tablet of Alfuzosin once daily for 12 weeks. Participants then received 1 Placebo tablet once daily for 12 weeks.
3242650|NCT00893100|Experimental|Diltiazem|
3242651|NCT00893087|Active Comparator|1|Flow triggering
3242652|NCT00893087|Active Comparator|2|Pressure triggering
3242653|NCT00893087|Active Comparator|3|NAVA triggering
3242654|NCT00893074|Other|0, 30, 60, and 120mg dronabinol|0, 30, 60, and 120mf dronabinol was administered in a randomized within-subjects crossover study to compare the medication dose effects of cannabis withdrawal, cognitive performance, and response to acute cannabis dosing
3242655|NCT00893061|Experimental|Arm I|Patients receive oral tamoxifen citrate once daily for 1 year in the absence of disease progression or unacceptable toxicity.
3242656|NCT00893061|Experimental|Arm II|Patients receive an oral aromatase inhibitor (letrozole, anastrozole, or exemestane) once daily for 1 year in the absence of disease progression or unacceptable toxicity.
3242657|NCT00893048|Experimental|Prednisone|Use of prednisone to decrease LOS and overall treatment time of cellulitis
3242658|NCT00893048|Experimental|Placebo|
3242659|NCT00893035||Intermediate prognosis prostate cancer|Intermediate prognosis prostate cancer
3242660|NCT00893035||Breast cancer|conservative treatment and age<60 Boost irradiation and age>60
3242661|NCT00893009|Placebo Comparator|Placebo|
3242662|NCT00893009|Active Comparator|Theophylline|100 twice a day
3242663|NCT00892996|No Intervention|1|Metoclopramide 10 mg intravenous
3242664|NCT00892996|No Intervention|2|Ondansetron 8 mg intravenous
3242665|NCT00892996|Active Comparator|3|dexamethasone 5 mg and metoclopramide 10 mg
3242666|NCT00892996|Active Comparator|4|dexamethasone 5 mg and ondansetron 8 mg IV
3242667|NCT00892983|No Intervention|Standard well child care|Standard Well Child Care (SWCC) - 8 Core visits at 2-4 weeks, 6 weeks, 3, 5, 8-10 and 15 months, 2 and 3 years.
3242668|NCT00892983|Experimental|Food Activity Breast feeding support|FAB (Food Activity Breast feeding support) 8 extra parent contacts for augmented education and support around breast feeding, food and activity
3242669|NCT00892983|Experimental|Sleep|Prevention of sleep problems in first 6 months and then active early intervention for sleep problems from 6 months to 24 months
3242670|NCT00892983|Experimental|FAB + Sleep|combination of interventions used in arms 2 and 3
3242671|NCT00892970|Experimental|1|
3242672|NCT00892970|Placebo Comparator|2|
3242673|NCT00892957|Experimental|FS VH S/D 500 s-apr|FS VH S/D 500 s-apr will be applied to the study suture line.
3242674|NCT00892957|Active Comparator|Manual compression with surgical gauze pads|Dry gauze pads will be positioned to cover the complete study suture line.
3242675|NCT00892944|Experimental|1|AZD2516
3242676|NCT00892918|Active Comparator|Moxifloxacin|About 20 patients treated by Moxifloxacin ophthalmic solution 0.5% (Vigamox) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.
3242677|NCT00892918|Active Comparator|Gatifloxacin|About 20 patients treated by Gatifloxacin ophthalmic solution 0.3% (Zymar) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.
3242678|NCT00892905||POC INR and APTT Hemochron|Adult patients undergoing elective on pump coronary artery bypass grafting surgery who have not received anticoagulants or clopidogrel within 5 days preoperatively.
3242679|NCT00892892|Experimental|Arm 1|Rilmenidine as a sympatholytic agent for three months
3242680|NCT00892892|Active Comparator|Arm 2|Nitrendipine as a non-sympatholytic agent for three months
3242681|NCT00892879|Experimental|1|Single port laparoscopic device
3242682|NCT00892879|Active Comparator|2|Four-port laparoscopic device
3242683|NCT00892866||Ancillary-Correlative (biomarkers in cervical cancer)|Patients undergo liquid-based cytology specimen sample collection for analysis of CA-IX, p16, Ki-67, and MCM2 expression via IHC and for the presence of high risk HPV DNA and HPV genotyping.
3242684|NCT00892853|Other|Bone Density Scanning|To acquire high resolution images of the bones and aid in determining bone density.
3242685|NCT00892840|Experimental|Panels 1 to 7 (BMS-820836 or Placebo)|
3242686|NCT00892827|Experimental|Single Arm Study|Rituximab
3242687|NCT00892814|Experimental|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
3242688|NCT00892814|Active Comparator|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
3242689|NCT00892801|Experimental|Treatment|RAD001 + radiation therapy
3242690|NCT00892788|Active Comparator|A|Participants assigned to Group A will receive the LEARN (Lifestyle, Exercise, Attitudes, Relationships, Nutrition) Program weight loss manual and will be instructed to read a section of the manual each week and complete suggested activities. They will also meet with the research staff once a week for weigh-in and supportive counseling.
3242691|NCT00892788|Experimental|B|Participants assigned to Group B will receive the LEARN manual and will meet with research staff each week for weigh-in and supportive counseling. They will also receive contingency management or the opportunity to earn draws with the chance of winning prizes for losing weight and completing healthy activities.
3242692|NCT00892775|Experimental|Priorix-Tetra new WS Group|Subjects received 2 doses of Priorix-Tetra™ vaccine formulated with new measles and rubella working seeds at Day 0 and Week 12.
3242693|NCT00892775|Experimental|Priorix-Tetra current WS Group|Subjects received 2 doses of Priorix-Tetra™ vaccine manufactured with current working seed virus or new measles and rubella working seeds at Day 0 and Week 12.
3242694|NCT00892762|Experimental|Travoprost APS|Travoprost APS 40 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days
3242695|NCT00892762|Active Comparator|XALATAN|Latanoprost 50 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days
3242696|NCT00892749|Experimental|1. ASP1585|
3242697|NCT00892736|Experimental|Treatment (veliparib)|"Patients receive veliparib PO BID* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients receive veliparib once on day 1 of course 1 for pharmacokinetic and pharmacodynamic studies."
3242698|NCT00892723|Experimental|Low Dose|
3242699|NCT00892723|Experimental|High Dose|
3242700|NCT00892723|Placebo Comparator|Placebo|
3242701|NCT00892710|Experimental|Pemetrexed/Bevacizumab|"Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days~Bevacizumab 15 mg/kg IV every 21 days"
3242702|NCT00892710|Experimental|Pemetrexed/Bevacizumab/Carboplatin|"Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days~Bevacizumab 15 mg/kg IV every 21 days~Carboplatin AUC=5 IV every 21 days"
3242703|NCT00892710|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days
3242704|NCT00892697|Experimental|Arm|15 subjects will receive Telaprevir in combination with pegylated interferon alfa-2a and ribavirin
3242705|NCT00892671||medical students|
3242706|NCT00892658|Experimental|Sorafenib + RT|
3242707|NCT00892632|Experimental|1|1. To compare confocal image characteristics of benign vs. malignant biliary strictures
3242708|NCT00892619|Experimental|ILM forceps|Using ILM forceps to initiate and complete peel
3242709|NCT00892619|Active Comparator|Other|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
3242710|NCT00892606|Experimental|Methadone|Patients received 2 µg/kg fentanyl, 0.2 mg/kg ketamine and 0.2 mg/kg of methadone IV with induction of general anesthesia.
3242711|NCT00892606|Active Comparator|Control|Patients received 2 µg/kg fentanyl, 0.2 mg/kg ketamine, and 0.2 mg/kg morphine (standard of care)
3242712|NCT00892593|Experimental|1 Fecal Immunochemical Testing-Surveillance|Fecal Immunochemical Testing performed at yearly intervals.
3242713|NCT00892593|No Intervention|2 Usual Care - Surveillance|
3242714|NCT00892593|No Intervention|3 Usual Care - Screening|
3242715|NCT00892593|Experimental|4 Fecal Immunochemical Testing-Screening|Fecal Immunochemical Testing yearly, beginning at year 6.
3242716|NCT00892567|Experimental|9 Peptide Vaccine|
3242717|NCT00892554|Experimental|DHA supplementation|
3242718|NCT00892554|Placebo Comparator|corn/soy capsule, no DHA|
3242719|NCT00892502|Active Comparator|1|Bismuth tablets
3242720|NCT00892502|Placebo Comparator|2|Placebo tablets, containing no active substance
3242721|NCT00892476|Experimental|1|Infants receive supplemental calcium in their 24 cal/oz formula or fortified breast milk.
3242722|NCT00892476|Active Comparator|2|Infants will receive fortified breast milk or 24 cal/oz formula
3242723|NCT00892450|Experimental|Arm 1|crossover design
3242724|NCT00892437|Experimental|ATV+COBI+FTC/TDF|COBI + RTV placebo +ATV+FTC/TDF for 48 weeks
3242725|NCT00892437|Active Comparator|ATV+RTV+FTC/TDF|RTV + COBI placebo +ATV+FTC/TDF for 48 weeks
3242726|NCT00892424|Experimental|Sorafenib + RT|
3242727|NCT00892411||All study participants|Patients With Acute Low Back Pain
3242728|NCT00892398|Experimental|ranibizumab|Trabeculectomy with mitomycin C associated with 2 subconjunctival injections of ranibizumab: 1 intraoperatively and 1 at 2 weeks post-operatively
3242729|NCT00892398|Active Comparator|standard care|Trabeculectomy with mitomycin C and standard post-operative care
3242730|NCT00892385|Experimental|methoxyamine and temozolomide|
3242731|NCT00892372||1 (type 2 diabetes, body weight, HbA1c)|The investigators analyzed the recorded data (body weight and glycohemoglobin) of 70 type 2 diabetic patients treated with the diet therapy. Recorded values at 0, 2 and 4 months for body weight (BW) and glycohemoglobin (HbA1c) were used. And changes from baseline (0 month) in BW (ΔBW) were plotted against those of HbA1c (ΔHbA1c).
3242732|NCT00892372||2 (type 2 diabetes, pioglitazone, HbA1c)|The investigators analyzed the recorded data (body weight and glycohemoglobin) of 23 type 2 diabetic patients treated with pioglitazone. Recorded values at 0, 2 and 4 months for body weight (BW)and glycohemoglobin (HbA1c) were used. And changes from baseline (0 month) in BW (ΔBW) were plotted against those of HbA1c (ΔHbA1c).
3242733|NCT00892359|Experimental|Anidulafungin|
3242734|NCT00892346|Experimental|Single ASCT with Thalidomide maintenance|"Single ASCT followed by Thalidomide maintenance:~patients recieved 4-6 cycles of standard VAD chemotherapy or Thalidomide/dexamethasone as induction therapy~CTX+G-SCF mobilization to collecetd PBSC~Patiens recieved Mel 200 as conditioning followed by Thalidomide 100mg maintenance"
3242735|NCT00892281|Other|Oracea® as monotherapy|Oracea as monotherapy
3242736|NCT00892281|Other|Oracea® as add-on therapy|Oracea® as add-on Therapy (Oracea® + Metronidazoles and/or Azelaic Acids and/or Sodium Sulfacetamides
3242737|NCT00892268|Experimental|Arm I|Patients undergo acupuncture for 20-30 minutes, on the appropriate pain points on the anterior portion of the body alternating with posterior portion of the body, thrice weekly for 2 weeks and then twice weekly for 3 weeks.
3242738|NCT00892268|Active Comparator|Arm II|Patients receive standard-of-care analgesics (i.e., NSAIDs, narcotics, acetaminophen, or other) for 5 weeks. Patients not responding to analgesia may cross over to arm I.
3242739|NCT00892242|Experimental|Neoadjuvant Zoledronic Acid|"Zoledronic acid 4 mg IV prior to pancreatic resection (approximately 2 weeks prior to resection)~Pancreatic resection~Zoledronic acid 4 mg IV monthly for two additional doses"
3242740|NCT00892229|Active Comparator|Buccal Misoprostol|Group one: 50 patients with first trimester missed abortion received buccal misoprostol
3242741|NCT00892229|Active Comparator|Vaginal Misoprostol|Group two: 5 patients received vaginal misoprostol
3242742|NCT00892229|Active Comparator|Buccal and Vaginal Misoprostol|"50 primiparous and 50 multiparous women: one hundred patients have been administered the medication buccally (25 primigravida and 25 multigravida), and vaginally (25 primigravida and 25 multigravida), three hours before dilation and curettage. They were admitted to the hospital one day before the surgical evacuation, and preparation of cross matched blood done for all recruited subjects.~Each group was randomly allocated (1,3,5,... for the buccal group & 2,4,6,... for the vaginal group) to receive 400 microgram misoprostol."
3242743|NCT00892216|Experimental|Acupressure Band|A band with bead attachment will be used to produce Acupressure and applied to the P6 (three fingers breath from the wrist crease on th ventral surface of the upper limb). The application will be done 20 minutes prior to anesthesia and explanation as to usage after surgery will be given. The patient of caregiver will apply pressure on the bead for three minutes and repeat this four times a day for the next five days. None of the protocol for prevention of PONV in this group of patients will be changed. The postoperative therapy for nausea and vomiting will be on a PRN (as required) basis. Nausea and vomiting scores and VAS scores for pain estimation will be carried out according to hospital protocol in the PACU amd twice a day thereafter for their period of stay in the hospital. The amount of analgesics and antiemetics used and the number of days spent in the hospital will be registered.
3242744|NCT00892216|Sham Comparator|Sham Acupressure|The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
3242745|NCT00892203|Experimental|Active|
3242746|NCT00892203|Active Comparator|Comparator|
3242747|NCT00892203|Placebo Comparator|Placebo|
3242748|NCT00892190|Experimental|dasatinib (SPRYCEL) and all trans retinoic acid (VESANOID)|"Dasatinib DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours~ATRA 22.5mg/m2 every 12 hours"
3242749|NCT00892177|Experimental|Arm I|Patients receive bevacizumab on Day 1 and dasatinib on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3242750|NCT00892177|Active Comparator|Arm II|Patients receive bevacizumab on Day 1 and placebo on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3242751|NCT00892164|Active Comparator|FOCUS (Group A)|Patients submitted to total thyroidectomy with the use of the FOCUS harmonic scalpel device
3242752|NCT00892164|Active Comparator|LIGASURE (Group Β)|Patients submitted to total thyroidectomy with the use of the electrothermal bipolar vessel sealing device
3242753|NCT00892151|Experimental|Intended Users of the Software|10 Healthcare Professionals and 40 persons with diabetes (of which 6 were parents/legal guardians of children with diabetes) using a diabetes data management program.
3242754|NCT00892138|Experimental|Mindfulness training|Mindfulness training
3242755|NCT00892138|No Intervention|Control|Study program as usual
3242756|NCT00892112|Active Comparator|intravenous immunoglobulins|IV, 40 ml/kg over 4 days
3242757|NCT00892112|Placebo Comparator|plasma volume expander Albuman|IV, 40 ml/kg over 4 days
3242758|NCT00892099|Experimental|High Dose Ergocalciferol|Receives 50,000 IU of ergocalciferol weekly
3242759|NCT00892099|Experimental|Low Dose Ergocalciferol|Receives 50,000 IU of ergocalciferol per month
3242760|NCT00892099|Placebo Comparator|Placebo|Receives no ergocalciferol
3242761|NCT00892073|Experimental|Diazoxide and Metformin Therapy|
3242762|NCT00892047|Experimental|1: venlafaxine plus aripiprazole|antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
3242763|NCT00892047|Experimental|2: Placebo Comparator|antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
3242764|NCT00892021|Experimental|NSA-789|Active study drug
3242765|NCT00892021|Placebo Comparator|Placebo|Inactive study drug
3242766|NCT00892008||Open-Label|This study was open-label with only one treatment group. Pregabalin was prescribed in accordance with usual clinical practice.
3242767|NCT00891995|Experimental|Intensive Treatment|closed loop therapy (4-6 days), insulin pump (2 years), continuous glucose monitoring (2 years), home glucose monitoring (2 years)
3242768|NCT00891995|Active Comparator|Standard Treatment|home glucose monitoring (2 years)
3242769|NCT00891982|Experimental|CTGel plus BPO wash|Benzoyl peroxide (BPO) Wash in the morning and CTGel in the evening
3242770|NCT00891982|Active Comparator|CTGel|Soap Free Cleanser in the morning and CTGel in the evening
3242771|NCT00891943|Other|Structured lifestyle support|Intervention group-structured lifestyle support.
3242772|NCT00891943|No Intervention|Usual care for weight management|"This is the control group, and they will receive usual care for weight management at their GP practice."
3242773|NCT00891930|Experimental|Panitumumab|Participants received panitumumab (6 mg/kg starting dose) with irinotecan (starting dose of 180 mg/m²) every 2 weeks (Q2W) during Part 1. Upon radiographically confirmed disease progression, participants proceeded to Part 2 of the study and received treatment with panitumumab (6 mg/kg starting dose) and ganitumab (12 mg/kg starting dose) Q2W.
3242774|NCT00891917|Placebo Comparator|Syrup|
3242775|NCT00891917|Active Comparator|Ubiquinol-10 Syrup|
3242776|NCT00891904|Experimental|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once weekly in weeks 1-5
3242777|NCT00891891||Spina Bifida|140 children with spina bifida (ages 8-15)
3242778|NCT00891878|Experimental|Arm I|Patients receive oral capecitabine twice daily on days 1-14. Patients experiencing disease progression may crossover to arm II at the physician's discretion.
3242779|NCT00891878|Experimental|Arm II|Patients receive oral capecitabine as in arm 1 and oral sunitinib malate once daily on days 1-21.
3242780|NCT00891865||Pediatric lung transplantation|
3242781|NCT00891839|Experimental|Bendamustine+Rituximab|Patients receive bendamustine at 90 mg/m^2 intravenously (iv) on days 1 and 2, and 375 mg/m^2 of rituximab by iv on day 1 of each 28-day cycle. Six 28-day cycles were planned and up to 8 cycles permitted for patients who do not have progressive disease and who have not achieved a complete response (CR).
3242782|NCT00891826|Placebo Comparator|Corn oil|
3242783|NCT00891826|Experimental|Omega-3 fatty acids|
3242784|NCT00891813|Experimental|Zemplar (paracalcitol)|
3242785|NCT00891800|Experimental|1|All patients will be treated with SIR-Sphere therapy.
3242786|NCT00891774|Experimental|Device|Treatment with EVOLENCE®
3242787|NCT00891761|Active Comparator|Active Comparator|Patients receive IV casopitant (active), IV ondansetron and oral dexamethasone on Day 1 as well as oral dexamethasone on Days 2-4 of each cycle of cisplatin-based highly emetogenic chemotherapy for the prevention of chemotherapy induced nausea and vomiting.
3242788|NCT00891761|Placebo Comparator|Placebo Comparator|Patients receive IV casopitant (placebo), IV ondansetron and oral dexamethasone on Day 1 as well as oral dexamethasone on Days 2-4 of each cycle of cisplatin-based highly emetogenic chemotherapy for the prevention of chemotherapy induced nausea and vomiting.
3242789|NCT00891748|Experimental|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter.
3242790|NCT00891735|Experimental|Ranibizumab 0.5 mg monthly|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 24 months.
3242791|NCT00891735|Experimental|Ranibizumab 2.0 mg monthly|Patients received ranibizumab 2.0 mg monthly administered intravitreally for 24 months.
3242792|NCT00891735|Experimental|Ranibizumab 0.5 mg as-needed (pro re nata [PRN])|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.
3242793|NCT00891735|Experimental|Ranibizumab 2.0 mg as-needed (pro re nata [PRN])|Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.
3242794|NCT00891709|Experimental|1|LEO 29102 2.5 mg/g cream
3242795|NCT00891709|Placebo Comparator|2|LEO 29102 cream vehicle
3242796|NCT00891696|Active Comparator|Exp 1: AA + Rap|Participants will receive amino acid supplementation and rapamycin.
3242797|NCT00891696|Placebo Comparator|Exp 1: AA|Participants will receive amino acid supplementation and placebo rapamycin.
3242798|NCT00891696|Active Comparator|Exp 1: HEx + Rap|Participants will receive rapamycin and placebo amino acid supplementation, and they will undergo high-intensity resistance exercise.
3242799|NCT00891696|Placebo Comparator|Exp 1: HEx|Participants will receive placebo amino acid supplementation and placebo rapamycin, and they will undergo high-intensity resistance exercise.
3242800|NCT00891696|Active Comparator|Exp 1: HEx + AA + Rap|Participants will receive amino acid supplementation and rapamycin, and they will undergo high-intensity resistance exercise.
3242801|NCT00891696|Placebo Comparator|Exp 1: HEx + AA|Participants will receive amino acid supplementation and placebo rapamycin, and they will undergo high-intensity resistance exercise.
3242802|NCT00891696|Active Comparator|Exp 2: LExFR + Rap|Participants will receive rapamycin and will undergo low-intensity resistance exercise with blood flow restriction.
3242803|NCT00891696|Placebo Comparator|Exp 2 and 3: LExFR|Participants will receive placebo rapamycin and will undergo low-intensity resistance exercise with blood flow restriction.
3242804|NCT00891696|Active Comparator|Exp 2: SNP|Participants will receive sodium nitroprusside in a resting state.
3242805|NCT00891696|Active Comparator|Exp 2: FR|Participants will undergo blood flow restriction in a resting state.
3242806|NCT00891696|Active Comparator|Exp 2: LEx + SNP|Participants will receive sodium nitroprusside and undergo low-intensity resistance exercise.
3242807|NCT00891696|Placebo Comparator|Exp 3: LEx|Participants will undergo low-intensity resistance exercise.
3242808|NCT00891696|Active Comparator|Exp 3: HEx|Participants will undergo high-intensity resistance exercise.
3242809|NCT00891696|Active Comparator|Exp 3: HEx + AA|Participants will receive amino acid supplementation and will undergo high-intensity resistance exercise.
3242810|NCT00891683|Placebo Comparator|Placebo|4 Capsules of Placebo
3242811|NCT00891683|Active Comparator|100 mg|One 100 mg capsule and 3 placebo capsules of AEG33773
3242812|NCT00891683|Active Comparator|200 mg|Two 100 mg capsules and two placebo capsules
3242813|NCT00891683|Active Comparator|400 mg|Four 100 mg AEG33773 capsules
3242814|NCT00891670|Active Comparator|triple group|received cilostazol 100 mg twice daily in addition to aspirin 100mg and clopidogrel 75mg once daily
3242815|NCT00891670|Active Comparator|high maintenance dose group|received clopidogrel 150 mg/day with aspirin 100mg once daily
3242816|NCT00891657|Experimental|SprayShield™|SprayShield™
3242817|NCT00891657|No Intervention|Control|No adhesion barrier administered.
3242818|NCT00891644||1|HIV positive adolescents who never initiated care within 6 months of receipt of HIV positive results.
3242819|NCT00891644||2|HIV positive adolescents who initiated care, but did not follow up with care within 12 months of the initial care visit. Also included in this group are those who initiated and followed-up with care, but have dropped out of care for 12 or more months.
3242820|NCT00891644||3|HIV positive adolescents who initiated care and maintained care. These youth are currently in care.
3242821|NCT00891631|Experimental|iSBIRT|Participants will complete the iSBIRT system.
3242822|NCT00891631|Experimental|iSBIRT/TE|Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system and technological extenders
3242823|NCT00891631|No Intervention|TAU|Participants will receive Treatment as Usual from their primary care provider.
3242824|NCT00891618|Experimental|Acupuncture|3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
3242825|NCT00891605|Experimental|Paclitaxel and ABT-263|
3242826|NCT00891592|Experimental|Dose Escalation Arm|Subjects with cord blood stored in more than one fraction will be enrolled into Dose Escalation Arm. Subjects will receive Cord Blood Stem Cell Transplant followed by expanded Cord Blood T cells on Day 0.
3242827|NCT00891592|Active Comparator|Observation Arm|Subjects with cord blood stored in one fraction will be enrolled into the Observation Arm. Subjects will receive Cord Blood Stem Cell Transplant on Day 0.
3242828|NCT00891579|Active Comparator|Alimta|Treatment of Alimta
3242829|NCT00891579|Active Comparator|IRESSA|Treatment of IRESSA
3242830|NCT00891553||Ronacaleret|Subjects receiving ronacaleret (200mg,300mg or 400mg) in study CR9108963 will be enrolled into this study.
3242831|NCT00891553||Placebo|Subjects receiving placebo in study CR9108963 will be enrolled into this study.
3242832|NCT00891540|Active Comparator|1|Local infiltration with Ropivacaine
3242833|NCT00891540|Active Comparator|2|Local infiltration with Ropivacaine
3242834|NCT00891540|Placebo Comparator|3|Local infiltration with NaCl
3242835|NCT00891527|Experimental|Avastin and/or Gleevec|Patients were all treated with Gleevec (imatinib mesylate) and those without congenital heart disease and those who progressed were also treated with Avastin (bevacizumab).
3242836|NCT00891514|Experimental|Aerobic Exercise|Treadmill training
3242837|NCT00891514|Active Comparator|Stretch Control|Stretching exercises
3242838|NCT00891501|Experimental|Single|Clinical case series
3242839|NCT00891488||Fit|
3242840|NCT00891488||Unfit|
3242841|NCT00891475|Experimental|Arm 1|38 patients
3242842|NCT00891475|Experimental|Arm 2|38 patients
3242843|NCT00891475|Experimental|Arm 3|38 patients
3242844|NCT00891462|Experimental|1|Aclidinium bromide dose, inhaled, for 12 weeks of treatment
3242845|NCT00891462|Experimental|2|Aclidinium bromide dose, inhaled, for 12 weeks of treatment
3242846|NCT00891462|Placebo Comparator|3|Inhaled placebo for 12 weeks
3242847|NCT00891436|Placebo Comparator|Placebo nasal spray|
3242848|NCT00891436|Active Comparator|Fluticasone furoate nasal spray|
3242849|NCT00891423|Active Comparator|Meropenem short infusion|"Meropenem 1g infused over 30 minutes~every 8 hours if calculated CrCL greater than or equal to 50 mL/min OR~every 12 hours if calculated CrCL less than 50 mL/min or hemofiltration"
3242850|NCT00891423|Experimental|Meropenem extended infusion|"Meropenem 500mg infused over 3 hours~every 8 hours if calculated CrCL greater than or equal to 50 mL/min OR~every 12 hours if calculated CrCL less than 50 mL/min or hemofiltration"
3242851|NCT00891397|Experimental|1|Pregabalin group is made up of 20 patients. Patients will receive 150mg/day in two divided does. The patients will be assessed weekly and the dose can be increased to 300mg/day, if the patient does not report any decrease in pain. The following week the dose may be increased to 600mg/day if once again the patient reports no decrease in pain. This is also the maximum permissible does that will be given to the patient. If patient reports any side effects then the dose can be decreased once. The time period of 2 to 5 weeks will be the dose adjustment period. After which the drug maintenance period extends from week 5 to 12. All doses will be given in two divided doses/day.
3242852|NCT00891397|Placebo Comparator|2|Ten patients will be be in the placebo group.
3242853|NCT00891384|Experimental|1|25 mg lenalidomide
3242854|NCT00891384|Experimental|2|5 mg lenalidomide
3243079|NCT00889642|Placebo Comparator|Placebo|Contains Epinephrine
3242855|NCT00891371|Experimental|lanreotide (Autogel formulation) Autogel 120mg|lanreotide (Autogel formulation) Autogel 120mg
3242856|NCT00891358|Experimental|Focus Group|Participants in focus groups will meet and discuss their intervention needs.
3242857|NCT00891332|Experimental|1|S-1 plus LV
3242858|NCT00891319|Experimental|CCFES|"CCFES - Contralaterally Controlled Functional Electrical Stimulation~Electrical stimulator~Stimulation to finger and thumb extensors only in response to, and with an intensity proportional to, opening of the contralateral unimpaired hand.~A glove instrumented with sensors and worn on the unimpaired hand detects the degree of hand opening and determines stimulation intensity.~Therapy sessions are done with the subject being assisted by the CCFES system."
3242859|NCT00891319|Active Comparator|cNMES|"cNMES - Cyclic NeuroMuscular Electrical Stimulation~Electrical stimulator~Preprogrammed cycles of finger and thumb extensor stimulation repeatedly and automatically open the hand.~Subject instructed to not move the contralateral arm/hand during stimulation.~Therapy sessions are done without the stimulation system."
3242860|NCT00891306|Experimental|Treatment arm|Gene Therapy
3242861|NCT00891293|Experimental|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
3242862|NCT00891267|Experimental|Olmesartan medoxomil low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
3242863|NCT00891267|Experimental|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
3242864|NCT00891267|Active Comparator|Amlodipine|Amlodipine taken once daily for 6 weeks
3242865|NCT00891254|Active Comparator|1. Intraperitoneal repair|Patients with incisional hernia, 5 cm in diameter or with an area of 25 cm2, submitted to elective surgery
3242866|NCT00891254|Active Comparator|2. On-Lay repair|Patients with incisional hernia, with a diameter of 5 cm or an area of 25 cm2, submitted to elective surgery
3242867|NCT00891241|Experimental|Cohort 1|Healthy Population
3242868|NCT00891241|Experimental|Cohort 2|Heart Failure Subjects with a documented ejection fraction of 35% or less, and a diagnosis of NYHA Class II-III heart failure, history of ventricular arrhythmia and ICD placement
3242869|NCT00891228|Placebo Comparator|Testosterone Gel 10 g and Nestorone® 0 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
3242870|NCT00891228|Experimental|Testosterone Gel 10 g and Nestorone® 8 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg NES mL gel) by pressing two times with 2 mL dispenser head.
3242871|NCT00891228|Experimental|Testosterone Gel 10 g plus Nestorone® Gel 12 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
3242872|NCT00891202|Experimental|Active|Eliglustat
3242873|NCT00891202|Placebo Comparator|Placebo|Placebo
3242874|NCT00891189||1 Control|Healthy participants without asthma
3242875|NCT00891189||2 Non-nocturnal asthma|Participants with non-nocturnal asthma
3242876|NCT00891189||3 Nocturnal asthma|Participants with nocturnal asthma
3242877|NCT00891176|Experimental|Synflorix-Meningitec Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age. 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.
3242878|NCT00891176|Experimental|Synflorix-NeisVac-C Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age and 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.
3242879|NCT00891176|Experimental|Synflorix-Menitorix Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.
3242880|NCT00891176|Active Comparator|Prevenar-Menitorix Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.
3242881|NCT00891163|Experimental|Synera|
3242882|NCT00891163|Placebo Comparator|Placebo|
3242883|NCT00891150|Active Comparator|oxytocin|group 1 will receive oxytocin solutions with 20U/500ml during cesarean section
3242884|NCT00891150|Active Comparator|oxytocin2|group 2 will receive oxytocin solutions with 30U/500ml during cesarean section
3242885|NCT00891150|Active Comparator|oxytocin3|group 3 will receive oxytocin solutions with 40U/500ml during cesarean section
3242886|NCT00891137|Experimental|Group A|Low dose, single donor CLT-008 (human myeloid progenitor cells)
3242887|NCT00891137|Experimental|Group B|Low dose, multiple donor CLT-008 (human myeloid progenitor cells)
3242888|NCT00891137|Experimental|Group C|Intermediate dose, multiple donor CLT-008 (human myeloid progenitor cells)
3242889|NCT00891137|Experimental|Group D|High dose, multiple donor CLT-008 (human myeloid progenitor cells)
3242890|NCT00891124||1|Type II DM and Hypertension and/or Hyperlipidemia
3242891|NCT00891111|Experimental|Direct Payment|Direct Payment: Employees receive a $25 gift card upon completion of a Health Risk Assessment
3242892|NCT00891111|Experimental|Regret Lottery|Regret Lottery: Employees are divided into work units of about 5 employees. Employees in the lottery-linked incentive condition will be eligible for a weekly lottery drawing only if they have already completed their health risk assessment. The lotteries will work as follows. Participants will be assigned to work units of about 10 people. Each week, one work group is drawn at random. If a participants group was drawn and that participant already completed the health risk assessment, then that person will win a $100 cash prize. If all of the members of his or her work group also filled out the health risk assessment, then the prize will be boosted.
3242893|NCT00891098|Active Comparator|Imaginal exposure|
3242894|NCT00891098|Experimental|Imagery rescripting|
3242895|NCT00891085||Open Lung Ventilation|within 24 hours of arrival trauma patients with ISS >25 will be randomized to BiVent (APRV)
3242896|NCT00891085||SIMV|within 24 hours of arrival trauma patients with ISS >25 will be randomized to either SIMV or BiVent
3242897|NCT00891072|Experimental|Treatment|Patients receive oral R-(-)-gossypol acetic acid twice daily on days 1-3. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3242898|NCT00891059||Placebo Diskus Inhaler|
3242899|NCT00891046|Experimental|Canakinumab|Canakinumab
3242900|NCT00891033|Experimental|Cohort 1|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 5 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
3242901|NCT00891033|Experimental|Cohort 2|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 10 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
3242902|NCT00891033|Experimental|Cohort 3|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 15 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
3242903|NCT00891033|Experimental|Cohort 4|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 20 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
3242904|NCT00891020|Experimental|Tocilizumab 8 mg/kg Monotherapy|Participants received Tocilizumab 8 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions for 24 weeks. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
3242905|NCT00891020|Experimental|Tocilizumab 4 mg/kg + DMARD|Participants received Tocilizumab (TCZ) 4 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions plus non-biologic disease-modifying antirheumatic drug (DMARD) of the investigator's choice for 24 weeks. Participants not achieving a 20% improvement from baseline in tender and swollen joint counts at Week 8 were to have their dosage increased to 8 mg/kg, per protocol. Beginning at Week 12 dosage increase to 8 mg/kg was at the discretion of the investigator. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
3242906|NCT00891020|Experimental|Tocilizumab 8 mg/kg + DMARD|Participants received Tocilizumab (TCZ) 8 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions plus non-biologic disease-modifying antirheumatic drug (DMARD) of the investigator's choice for 24 weeks. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
3242907|NCT00891007|Experimental|Group 1|
3242908|NCT00891007|Experimental|Group 2|
3242909|NCT00891007|Active Comparator|Group 3|
3242910|NCT00890994||Suspected breast cancer|
3242911|NCT00890981|Other|Arm 1|Participants who were randomized to either denosumab or placebo in Study 20050179 and at least 12 months had elapsed from their 20050179 end-of-study visit had dual energy X-ray absorptiometry (DXA) of the forearm and HR-pQCT of the tibia and radius on Day 1 of this study. No study drug was administered.
3242912|NCT00890968|Experimental|Triamcinolone Acetonide (TAC) DuraPeel|
3242913|NCT00890968|Placebo Comparator|Placebo|
3242914|NCT00890955|Experimental|1|"Amrubicin + Cyclophosphamide 3+3 design with the following dose levels:~Dose Level -1: Amrubicin 20mg/m2, Cyclophosphamide 500mg/m2~Dose Level 1: Amrubicin 25mg/m2, Cyclophosphamide 500mg/m2~Dose Level 2: Amrubicin 30mg/m2, Cyclophosphamide 500mg/m2~Dose Level 3: Amrubicin 35mg/m2, Cyclophosphamide 500mg/m2~Dose Level 4: Amrubicin 40mg/m2, Cyclophosphamide 500mg/m2"
3242915|NCT00890942|Experimental|naloxone|
3242916|NCT00890942|Placebo Comparator|normal saline|
3242917|NCT00890929|Experimental|Azacitidine followed by lenalidomide|Dose escalation then dose expansion
3242918|NCT00890916|Experimental|Neuroprosthesis System|Receives implanted device for hand function.
3242919|NCT00890903||NSCLC|Patients with advanced non-small cell lung cancer
3242920|NCT00890903||MBC|Female patients with metastatic, Anthracycline-resistent breast cancer
3242921|NCT00890890|Experimental|Avagacestat (50 mg)|
3242922|NCT00890890|Placebo Comparator|Placebo|
3242923|NCT00890877|Experimental|1|
3242924|NCT00890877|Experimental|2|
3242925|NCT00890877|Experimental|3|
3242926|NCT00890877|Experimental|4|
3242927|NCT00890864|Active Comparator|1|Women aged 47-49 invited for breast screening
3242928|NCT00890864|Active Comparator|2|Women aged 71-73 invited for breast screening
3242929|NCT00890851|Other|Procedure TUNA|
3242930|NCT00890838|Active Comparator|Omegaven|will receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperatively
3242931|NCT00890838|No Intervention|Without Omegaven|will not receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperativel
3242932|NCT00890825|Active Comparator|AZD6244 + Docetaxel|AZD6244 75 mg bd + Docetaxel 75 mg/m^2
3242933|NCT00890825|Placebo Comparator|Placebo + Docetaxel|Placebo + Docetaxel 75 mg/m^2
3242934|NCT00890812||Factors VIII, IX and XI levels measured|Case group
3242935|NCT00890812||Non Stroke patients|This is the control group. This group represents patients who were initially evaluated for stroke.
3242936|NCT00890799|Experimental|occluders|Shanghai pmVSD occluder (LEPU Medical Tech-nology Co, Ltd, Beijing, China) was used in this study.
3242937|NCT00890786|Experimental|HGG|Temozolomide, Bevacizumab, and Irinotecan according to the treatment schedule in the intervention section.
3242938|NCT00890786|Experimental|DIPG|Temozolomide, Bevacizumab, and Irinotecan according to the treatment schedule in the interventions section.
3242939|NCT00890760|Experimental|Group 1|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 3 weeks after boost
3242940|NCT00890760|Experimental|Group 2|AdCh63 ME-TRAP alone followed by sporozoite challenge 3 weeks later
3242941|NCT00890760|Experimental|Group 3|Non-vaccinated Control for Groups 1 and 2 challenged with sporozoite
3242942|NCT00890760|Experimental|Group 4|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 11 weeks after boost
3242943|NCT00890760|Experimental|Group 5|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 3 weeks after boost
3242944|NCT00890760|Experimental|Group 6|Protected volunteers from Group 1 re-challenged with sporozoite after 6 months
3242945|NCT00890760|Experimental|Group 7|Non vaccinated control for Groups 4-6, 8-10 challenged with sporozoite
3242946|NCT00890760|Experimental|Group 8|3 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 8 weeks interval each followed by sporozoite challenge 3 weeks after last vaccination
3242947|NCT00890760|Experimental|Group 9|2 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 8 weeks interval followed by sporozoite challenge 3 weeks after last vaccination
3242948|NCT00890760|Experimental|Group 10|3 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 4 weeks interval each followed by sporozoite challenge 3 weeks after last vaccination
3242949|NCT00890747|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3242950|NCT00890734|Experimental|1|
3242951|NCT00890734|Placebo Comparator|2|
3242952|NCT00890721|Experimental|SKY0402|During the hemorrhoidectomy, 30cc of SKY0402 is injected into the wound.
3242953|NCT00890721|Placebo Comparator|Placebo|During the hemorrhoidectomy, 30cc Placebo injected into the wound.
3242954|NCT00890708|No Intervention|non-TDM of voriconazole|conventional dose
3242955|NCT00890708|Experimental|TDM of voriconazole|
3242956|NCT00890695|Active Comparator|Ready to use supplementary food (RUSF)|The RUSF intervention consists of a food paste made of maize, soya, sorghum, vegetable oil, sugar, dried skim milk and vitamin/mineral premix, prepared by VALID Nutrition in collaboration with Insta Products, Kenya in accordance with composition specified by the latest WHO expert consultation in 2008. Children in the intervention arm receive 4 weeks supply of RUSF. The amount supplied is based on the child's weight to give energy supplement of 100kcal per kg per day, equivalent to 25g RUSF per kg per day.
3242957|NCT00890695|No Intervention|Normal diet (standard of care)|For equity, parents or guardians of children in the usual diet arm will be given 2 bags of maize meal(4Kg) for family consumption instead of RUSF. All parents and carers in both arms will also receive standard nutritional advice as specified in the current WHO IMCI handbook.
3242958|NCT00890682|Experimental|Sky0402|Injection of Study Drug
3242959|NCT00890682|Placebo Comparator|Placebo|Injection of study drug
3242960|NCT00890669|Experimental|PD Group|Nine subjects with idiopathic PD, previously diagnosed by one specialist physician participated in this study.
3242961|NCT00890656|Experimental|Augmented Hyper-CVAD|Hyper-CVAD (courses 1, 3, 5, and 7) alternated with high-dose methotrexate/ara-C (courses 2, 4, 6, and 8) administered on day 21; Hyper-CVAD = Cyclophosphamide, Vincristine, Doxorubicin, Decadron + Pegaspargase.
3242962|NCT00890643|Experimental|Arm 1|Persons with PTSD
3242963|NCT00890643|Placebo Comparator|Arm 2|Persons with PTSD
3242964|NCT00890630|Active Comparator|Oxytocin|Induction of Labour with Oxytocin Alone
3242965|NCT00890630|Experimental|Intracervical Catheter|Insertion of an Intracervical Balloon Catheter plus administration of oxytocin for labour induction.
3242966|NCT00890617|Experimental|Prednisone & Cryotherapy|"Prednisone taken:~20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure"
3242967|NCT00890604|Other|1|Usual Care
3242968|NCT00890604|Experimental|2|Normothermia Protocol
3242969|NCT00890591|Experimental|Treatment|
3242970|NCT00890578||1-abdominal|half abdominal surgeries (20 patients out of 40)
3242971|NCT00890578||2-breast|half breast surgeries (20 out of 40)
3242972|NCT00890565|Experimental|Treatment A: Sancuso® patch|Treatment A: Sancuso® patch (Day 1) and placebo IV (Day 3)
3242973|NCT00890565|Experimental|Treatment B: IV Granisetron 10 mcg/kg|Treatment B: placebo patch (Day 1) and granisetron IV (Day 3)
3242974|NCT00890565|Placebo Comparator|Treatment C: Matching placebo patch|Treatment C: placebo patch (Day 1) and placebo IV (Day 3)
3242975|NCT00890565|Active Comparator|Treatment D: Oral Moxifloxacin 400 mg|Treatment D: placebo patch (Day 1) and oral moxifloxacin (Day 3).
3242976|NCT00890552|Experimental|Lenalidomide+Melphalan+Dexamethasone|Patients received lenalidomide 10 mg/day orally on days 1-21, melphalan 0.18 mg/kg orally on days 1-4, and dexamethasone 40 mg orally once weekly of a 28-day cycle (MDR treatment).
3242977|NCT00890539|Experimental|Quadrupling|methacholine challenge using quadrupling concentrations
3242978|NCT00890539|Active Comparator|doubling|doubling concentrations of methacholine
3242979|NCT00890526|Experimental|1|Full treatment = Counseling + sound therapy.
3242980|NCT00890526|Experimental|2|Counseling + placebo sound therapy.
3242981|NCT00890526|Experimental|3|No Counseling + Sound Therapy
3242982|NCT00890526|Placebo Comparator|4|No counseling + Placebo sound therapy.
3242983|NCT00890500|Active Comparator|Group 1|2 umbilical cord units: Second cord blood unit modulated with ProHema
3242984|NCT00890500|Active Comparator|Group 2|2 umbilical cord units: First cord blood unit modulated with ProHema
3242985|NCT00890487|Other|hyaluroni acid pill|
3242986|NCT00890474|Experimental|Moxibustion|
3242987|NCT00890474|No Intervention|Control|
3242988|NCT00890461||Defibrillator|The subject population will be obtained by approaching the Principal and Co- Investigators' patients who have been referred for ICD implantation or who already have an ICD. This population ranges in age from 18 years on, and includes both males and females. A maximum of 50 subjects will be enrolled in this study.
3242989|NCT00890448||Lapaquistat acetate participants|
3242990|NCT00890422|Experimental|1FSME vaccination|2 vaccination on day 0
3242991|NCT00890422|Experimental|2 FSME vaccination|1 vaccination on day 0 and one vaccination on day 4
3242992|NCT00890422|Experimental|3 FSME vaccination|2 vaccinations on day 0 and 1 vaccination on day 4
3242993|NCT00890409|No Intervention|Normothermia|Rectal temperature was maintained at 36.0-37.5 degree C.
3242994|NCT00890409|Experimental|Hypothermia|The group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
3242995|NCT00890396||1|Participants in the active follow-up group.
3242996|NCT00890396||2|Participants in the passive follow-up group.
3242997|NCT00890383|No Intervention|Crystalloid only|patients will receive crystalloid fluids only for volume therapy of severe trauma
3242998|NCT00890383|Active Comparator|Colloid + Crystalloid arm|Goal directed volume therapy for severe trauma resuscitation
3242999|NCT00890370|Other|1|Active cycle of breathing techniques
3243000|NCT00890370|Other|2|Autogenic drainage
3243001|NCT00890370|Other|3|R-C Cornet
3243002|NCT00890370|Other|4|Flutter
3243003|NCT00890370|Other|5|PEP
3243004|NCT00890357||Triptan User|
3243005|NCT00890357||Triptan Discontinued|
3243006|NCT00890331|Active Comparator|Diabetes Education|
3243007|NCT00890331|Experimental|TeamWork CS Sessions|
3243008|NCT00890318|Other|1|Healthy volunteers, receiving daily dose of 80 mg ABT-072 or placebo, QD for 10 days; and on Study Day 11 receiving a single dose of 80 mg ABT-072 or placebo + 400 mg ketoconazole
3243009|NCT00890318|Other|2|Healthy volunteers, receiving 160 mg ABT-072 or placebo, QD for 10 days.
3243010|NCT00890318|Other|3|Healthy volunteers, receiving 320 mg ABT-072 or placebo, QD for 10 days.
3243011|NCT00890305|Experimental|CT-011 in combination with FOLFOX|"CT-011 (3 mg/kg) administered intravenously every 4 weeks for 4 weeks and every 12 weeks thereafter until disease progression or maximum tolerance.~FOLFOX (FOLFOX4 or mFOLFOX6) administered 7 days after the first administration of CT-011 and repeated every 14 days for up to 24 cycles. At the end of FOLFOX therapy, patients who have not progressed will be eligible for maintenance chemotherapy with 5-FU/leucovorin at the same dose and schedule until disease progression or study drug discontinuation."
3243012|NCT00890305|Active Comparator|FOLFOX|FOLFOX (FOLFOX-4 or mFOLFOX6) administered every 14 days for up to 24 cycles. At the end of FOLFOX therapy, patients who have not progressed will be eligible for maintenance chemotherapy with 5-FU/leucovorin at the same dose and schedule until disease progression or study drug discontinuation.
3243013|NCT00890279|Experimental|Cilnidipine|The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group A, blood pressure is controlled by Candesartan plus Cilnidipine.
3243014|NCT00890279|Active Comparator|Imidapril|The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group B, blood pressure is controlled by Candesartan plus Imidapril.
3243015|NCT00890253|Experimental|CNI-free Immunosuppression|Immunosuppression after OLT including basiliximab, enteric-coated mycophenolate sodium (EC-MPS), and everolimus.
3243016|NCT00890227|Active Comparator|Traditional technique|All level open instrumented posterior spinal fusions
3243017|NCT00890227|Active Comparator|Minimally invasive technique|Open surgery for all the levels except the proximal segment (most proximal instrumented level) where minimally invasive technique will be used.
3243018|NCT00890214|Active Comparator|1 prostacyclin group|prostacyclin analogue (PGIA) used as circuit anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in acute kidney failure patients
3243019|NCT00890214|Active Comparator|2 heparin group|unfractionated heparin used as circuit anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in acute kidney failure patients
3243020|NCT00890201||Normal Gallbladder|"Patients with normal gallbladder (without gallstones) evidenced by preoperative ultrasonography (and postoperative biopsy) submitted to elective gastroesophageal surgery (gastrectomy for gastric cancer, bariatric surgery or esophageal surgery such as Nissen plicature or miotomy for achalasia).~The pancreaticobiliary junction must be normal as evidenced by intraoperative cholangiography. Preoperative values of amylase and lipase must be normal."
3243021|NCT00890201||Gallbladder with gallstones|"Patients submitted to elective cholecystectomy for diseased gallbladders (gallbladder with gallstones evidenced by preoperative ultrasound).~The pancreaticobiliary junction must be normal as evidenced by intraoperative cholangiography and the preoperative amylase and lipase levels must also be normal."
3243022|NCT00890188|Experimental|THALIDOMIDE and UFUR|
3243023|NCT00890175|Experimental|Inhaled loxapine @ 0 & 10 h|Inhalation of 10 mg of loxapine at 0 and 10 hours
3243024|NCT00890175|Placebo Comparator|Inhaled placebo @ 2 & 10 hours|Inhalation of 0 mg of loxapine (placebo) at 0 and 10 hours
3243025|NCT00890149|Experimental|Ondansetron|Ondansetron + BASICS Plus
3243026|NCT00890149|Placebo Comparator|Placebo|Placebo + BASICS Plus
3243027|NCT00890123|Active Comparator|Omegaven|Patients in this arm will receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperatively.
3243028|NCT00890123|No Intervention|Without Omegaven|Patients will not receive IV Omega 3 fatty acids
3243029|NCT00890110|Experimental|Autologus vaccination with suntinib|Combination of autologous dnp irradiated modified cells with sunitinib treatments
3243030|NCT00890097|Experimental|AL-8309B 1.0%|AL-8309B 1.0% Ophthalmic Solution, 1 drop in each eye twice daily for 30 months, up to a maximum of 36 months
3243031|NCT00890097|Experimental|AL-8309B 1.75%|AL-8309B 1.75% Ophthalmic Solution, 1 drop in each eye twice daily, for 30 months up to a maximum of 36 months
3243032|NCT00890097|Placebo Comparator|Vehicle|AL-8309B Vehicle, 1 drop in each eye twice daily, for 30 months up to a maximum of 36 months
3243033|NCT00890084||Group1|
3243034|NCT00890071||Acute circulatory failure|Patients for whom the decision to give fluids was taken because the presence of one or more clinical signs of acute circulatory failure.
3243035|NCT00890058||Cases|Postmenopausal breast cancer patients with hand pain receiving aromatase inhibitors
3243036|NCT00890058||Controls|Postmenopausal breast cancer patients with hand pain not receiving aromatase inhibitors
3243037|NCT00890045|Active Comparator|Control graft|Conventional ePTFE hemodialysis graft
3243038|NCT00890045|Experimental|HeRO Vascular Access Device|HeRO Vascular Access Device
3243039|NCT00890032|Experimental|BTSC mRNA-loaded DCs|BTSC mRNA-loaded DCs administered intradermally weekly for first 3 vaccines, then monthly until progression or withdrawal.
3243040|NCT00890019|Experimental|1A, 2A, 3A, 4A, 5A, 6A, 7A|AdCh63 ME-TRAP
3243041|NCT00890019|Experimental|1B, 2B, 3B, 4B, 6B, 7B, 7C|AdCh63 ME-TRAP; MVA ME-TRAP
3243042|NCT00890006|Experimental|MRI + CBCT in prostate cancer|
3243043|NCT00889980||Melanoma|Patients with primary melanoma
3243044|NCT00889967|Experimental|1|Ciprofloxacin for Inhalation 100 mg/day by inhalation
3243045|NCT00889967|Experimental|2|Ciprofloxacin for inhalation 150 mg/day by inhalation
3243046|NCT00889967|Placebo Comparator|Placebo|Placebo by inhalation
3243047|NCT00889954|Experimental|TGFBeta resistant HER2/EBV-CTLs|"The following dose levels will be evaluated:~Dose Level 1: 1 x 10^4 cells/m^2~Dose Level 2: 3 x 10^4 cells/m^2~Dose Level 5: 1 x 10^6 cells/m^2~Dose Level 6: 3 x 10^6 cells/m^2~Dose Level 7: 1 x 10^7 cells/m^2~Dose Level 8: 3 x 10^7 cells/m^2~Dose Level 9:1 x 10^8 cells/m^2"
3243048|NCT00889941|Active Comparator|small|
3243049|NCT00889941|Active Comparator|medium|
3243050|NCT00889941|Active Comparator|large|
3243051|NCT00889928|Experimental|cholecystectomy|transvaginal cholecystectomy
3243052|NCT00889915|Active Comparator|1|Participants will receive methylphenidate transdermal system.
3243053|NCT00889915|Active Comparator|2|Participants will receive lisdexamfetamine dimesylate.
3243054|NCT00889915|Active Comparator|3|Participants will receive osmotic-release oral system methylphenidate (OROS MPH).
3243055|NCT00889915|Active Comparator|4|Participants will receive mixed amphetamine salts extended release.
3243056|NCT00889889|Experimental|1|
3243057|NCT00889889|Placebo Comparator|2|
3243058|NCT00889876|Experimental|Metformin|
3243059|NCT00889876|Experimental|Exercise|
3243060|NCT00889863|Experimental|Canakinumab|In Part I participants received open label 4 mg/kg canakinumab subcutaneous injection every 4 weeks for up to 32 weeks. For the first 8 weeks Part Ia (4 weeks) and Ib (4 weeks) patients maintained a stable oral steroid dose (prednisone or equivalent) followed by Ic an up to 20 week steroid tapering period and then Id a 4 week stable steroid dose period. Participants were then randomized to receive either 4 mg/kg canakinumab subcutaneous injection or placebo comparator in Part II and remained on the stable oral steroid dose for 24 weeks. At 24 weeks in Part II participants with a >0.2 mg/kg and ≤ 0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤ 0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.
3243061|NCT00889863|Placebo Comparator|Placebo|Participants in Part II received placebo matching canakinumab subcutaneous injection every 4 weeks. At 24 weeks in Part II participants with a >0.2 mg/kg and ≤0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.
3243062|NCT00889850|Active Comparator|1|Oral fasted administration of one capsule of 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
3243063|NCT00889850|Active Comparator|2|Oral fasted administration of one tablet of INexium 40 mg MUPS tablets (AstraZeneca, France)
3243064|NCT00889850|Active Comparator|3|Oral fed administration of one capsule of 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
3243065|NCT00889850|Active Comparator|4|Oral fed administration of one tablet of INexium 40 mg MUPS tablets (AstraZeneca, France)
3243066|NCT00889837|Experimental|Inhaled Loxapine|Staccato Loxapine, 10 mg doses x 2, 10 hours apart
3243067|NCT00889837|Placebo Comparator|Inhaled Placebo|Staccato Placebo,inhalations x 2, 10 hours apart
3243068|NCT00889824|Experimental|prosthesis group|balance prosthesis
3243069|NCT00889785|Active Comparator|1 (Usual Care)|Patients will continue to review usual care in the diabetes clinic. Patients will receive monthly phone calls as an active control condition.
3243070|NCT00889785|Experimental|Intervention|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
3243071|NCT00889720|Other|Smoking cessation tratment including varenicline|
3243072|NCT00889707|Experimental|Active Drug|PRX302
3243073|NCT00889707|Placebo Comparator|Placebo|Placebo
3243074|NCT00889681|Experimental|Ablation|All study subjects will be receive cryo ablation with the experimental devices and, optionally, an Atrial Fibrillation Drug.
3243075|NCT00889668|Experimental|Experimental|subjects with a diagnosis of type 1 or 2 diabetes; GlucoTrack results will be compared with the readings from approved invasive glucose meter device.
3243076|NCT00889655|Active Comparator|Golytely|216 patients at random will provided a prescription for the standard 4 L golytely preparation as the bowel cleanser for their colonoscopy
3243077|NCT00889655|Experimental|MiraLax|216 patients will be randomized to take 238 gm of miralax mixed with 64 oz of gatorade for their bowel cleanser
3243078|NCT00889642|Active Comparator|Active|Contains Lidocaine and Epinephrine
3243080|NCT00889629|Experimental|1|Hectorol plus 25-OH Vitamin D3
3243081|NCT00889629|Placebo Comparator|2|placebo plus 25-OH Vitamin D3
3243082|NCT00889603||1|
3243083|NCT00889590|Experimental|Zoledronic acid|Adjuvant zoledronic acid
3243084|NCT00889590|No Intervention|Control|Standard care
3243085|NCT00889538|Placebo Comparator|Placebo|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
3243086|NCT00889538|Active Comparator|Glutathione|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
3243087|NCT00889538|Active Comparator|Glutathione, Vit C and NAC|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
3243088|NCT00889525|Experimental|Cabergoline|
3243089|NCT00889512|Active Comparator|Luveris Fixed dose|Participants in this arm will take Gonal F® and the same dose of Luveris® throughout the cycle. Their dose of Gonal F® will be adjusted throughout the cycle based on their response to the medication. The Luveris® dose will remain constant throughout.
3243090|NCT00889512|Experimental|Luveris increasing dose|Patients assigned to this group will gradually reduce the Gonal F® dose while increasing the Luveris® dose during the cycle, which more closely mimics the natural menstrual cycle.
3243091|NCT00889499|Placebo Comparator|Crossover study|Crossover study
3243092|NCT00889499|Placebo Comparator|2|Crossover Study
3243093|NCT00889499|Placebo Comparator|3|Crossover Study
3243094|NCT00889486|Placebo Comparator|Placebo|Four placebo capsules taken orally once per day for 28 days
3243095|NCT00889486|Experimental|10 mg TZP-102|One 10 mg TZP-102 Capsule and three placebo capsules taken orally once per day for 28 days
3243096|NCT00889486|Experimental|20 mg TZP-102|Two 10 mg TZP-102 Capsules and two placebo capsules taken orally once per day for 28 days
3243097|NCT00889486|Experimental|40 mg TZP-102|Four 10 mg TZP-102 Capsules taken orally once per day for 28 days
3243098|NCT00889473|Experimental|Larazotide acetate 1 mg|larazotide acetate 1 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
3243099|NCT00889473|Placebo Comparator|Placebo|placebo capsules TID + 900 mg gluten capsules TID for 6 weeks
3243100|NCT00889460|Placebo Comparator|1|Placebo group
3243101|NCT00889460|Experimental|2|rBet v 1 tablets
3243102|NCT00889434|Active Comparator|EGCG|Two cycles comprising 28 days of continuous daily treatment with EGCGgiven 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
3243103|NCT00889434|Active Comparator|Tocotrienol|
3243104|NCT00889434|Other|EGCG + Tocotrienol|Combination of both arms
3243105|NCT00889421|Experimental|Treatment|Patients receiving apremilast.
3243106|NCT00889408|Experimental|Treatment|DT2219ARL at assigned dose IV over 4 hours in the outpatient setting on day 1, 3, 5, and 8
3243107|NCT00889395|No Intervention|Home visit|Patients will have monthly home visits during which health educational talks will be given
3243108|NCT00889382|Experimental|Phase 1 Arm A|Intermittent OSI-906 Once Daily (QD) on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15 (except Treatment Period 1 (TP 1); in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22)
3243109|NCT00889382|Experimental|Phase 1 Arm B1|Continuous OSI-906 Twice Daily (BID) (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15;(except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15 and 22)
3243110|NCT00889382|Experimental|Phase 1 Arm B2|Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 (except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 5 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22); (additional PK sampling on Days 9 or 13 0r 14 for TP 1)
3243111|NCT00889382|Experimental|Phase 1 Arm B3|Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 with no separation in OSI-906 and paclitaxel dosing (except TP 1; in TP 1 continuous OSI-906 dosing 2 hours prior to the initiation of paclitaxel infusion on Day 8 only, with paclitaxel on Days 8, 15, and 22, and additional PK sampling on Day 9 or 13 or 14)
3243112|NCT00889382|Experimental|Phase 2 Arm A|Intermittent OSI-906 QD on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15
3243113|NCT00889382|Experimental|Phase 2 Arm B|Continuous OSI-906 BID from Day 1 onwards with paclitaxel on Days 1, 8, and 15
3243114|NCT00889382|Experimental|Phase 2 Arm C|Paclitaxel on Days 1, 8, and 15
3243115|NCT00889382|Experimental|Phase 2 Arm C Roll-over|Continuous OSI-906 BID from Day 1 onwards
3243116|NCT00889369|Experimental|A|Use of duloxetine, flexible dose (60-120mg/day) for 8 weeks, following a 2-week placebo lead-in phase
3243117|NCT00889356|Experimental|Clindamycin 100mg and Ketoconazole 400mg|
3243118|NCT00889356|Active Comparator|Tetracycline 100mg and Amphotericin B 50mg|
3243119|NCT00889343|Experimental|1|
3243120|NCT00889343|Placebo Comparator|2|
3243121|NCT00889330|Experimental|alcaftadine ophthalmic solution|active treatment: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).
3243122|NCT00889330|Placebo Comparator|inactive ophthalmic solution vehicle|Placebo, vehicle: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).
3243123|NCT00889317||healthy adults|
3243124|NCT00889304||A|HTO cohort
3243125|NCT00889265|Experimental|CopiOs Pericardium Membrane|Subject's study site must exhibit a partially edentulous ridge of the maxilla or mandible with at least one tooth-span in length and less than 5.5mm in its smallest buccolingual dimension as measured by ridge-mapping calipers.
3243126|NCT00889252|Experimental|K-Lens|Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug
3243127|NCT00889252|Placebo Comparator|Placebo Lens|Placebo lens
3243128|NCT00889239|Experimental|A|ceramic crown
3243129|NCT00889226|Experimental|Pitavastatin Group|
3243130|NCT00889226|Active Comparator|Atorvastatin Group|
3243131|NCT00889213|Experimental|Patch and glue arm|Randomized patients to the patch and glue arm will undergo placement of a falciform ligament tissue patch and fibrin glue to the resection margin of the remnant pancreas following distal pancreatectomy
3243132|NCT00889213|Active Comparator|stapled /sutured pancreatic closure|
3243133|NCT00889200|Experimental|Open-label Eszopiclone|Standard dosing of drug for 6 weeks for insomnia
3243134|NCT00889187|Experimental|Phase 1 Cohort 1: Photon Rad (30 Gy/12 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~At dose level 1, a total dose of 30 Gy in 10 fractions (3 Gy/day) was prescribed to the 95% isodose and administered 5 days per week over 12 days.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
3243135|NCT00889187|Experimental|Phase I Cohort 2: Photon Rad (25 Gy/11 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~At dose level 2, a total dose of 25 Gy in 5 fractions was prescribed to the 95% isodose and administered at 5 Gy per fraction over 11 days.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
3243136|NCT00889187|Experimental|Phase I Cohort 3: Photon Rad (25 Gy/5 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~At dose level 3, a total dose of 25 Gy in 5 fractions was prescribed to the 95% isodose and administered at 5 Gy per fraction over 5 days.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
3243137|NCT00889187|Experimental|All Phase I: Photon Rad+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~All Phase I participants received the radiation regimen according to the established dose escalation schedule.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
3243138|NCT00889187|Experimental|Phase II: Photon Rad (MTD)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~Phase II participants received the radiation regimen established in the Phase I study (MTD).~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
3243139|NCT00889148|Experimental|Gabapentin|600mg of gabapentin will be given orally two hours preoperatively and 200mg for 3 times a day after surgery for three days.
3243140|NCT00889148|Placebo Comparator|Placebo|
3243141|NCT00889122|Experimental|Lifestyle Counseling|
3243142|NCT00889109||1|Open Capsular Shift
3243143|NCT00889109||2|Arthroscopic Bankart Repair
3243144|NCT00889109||3|Healthy controls
3243145|NCT00889096|Active Comparator|study day 1 propanolol|Oral administration of 80 mg propranolol (1 capsule containing two Obsidan® tablets: 2 x 40 mg propranolol) according to randomization list with 240 ml. Determination of blood pressure, heart rate over 4 hours and until return to the initial baseline values.
3243146|NCT00889096|Placebo Comparator|study day 1 placebo|Oral administration of placebo (1 capsule containing two placebo tablets) according to randomization list with 240 ml. Determination of blood pressure, heart rate over 4 hours and until return to the initial baseline values.
3243147|NCT00889083||Control|Non septic patients needing hepatic surgery
3243148|NCT00889083||Sepsis|Septic patients needing surgery for peritonitis
3243149|NCT00889070||1|Stage 1 (Pilot Study) All infants enrolled in the pilot stage and completing baseline screening will be evaluated as the analyzable set.
3243150|NCT00889057|Experimental|sorafenib|
3243151|NCT00889044|Experimental|clopidogrel by chewing|
3243152|NCT00889044|Placebo Comparator|Placebo|
3243153|NCT00889031||No Treatment|
3243154|NCT00889018|Active Comparator|group 1|chemotherapy using carboplatin 560mg/m2
3243155|NCT00889018|Experimental|group 2|chemotherapy using 750mg/m2 carboplatin
3243156|NCT00889005|Experimental|Cognitive Behavioral Therapy|Five sessions of trauma-focused, telephone based cognitive behavioral therapy, followed by assessment and referral to clinical treatment if needed.
3243157|NCT00889005|No Intervention|Waitlist control group|Five weeks without active intervention, followed by assessment and referral to clinical treatment if needed.
3243158|NCT00888992|No Intervention|Group A|Receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls.
3243159|NCT00888992|Experimental|Group B|
3243160|NCT00888992|Experimental|Group C|
3243161|NCT00888979|Experimental|Nicotrol with Behavioral Counseling|Nicotrol Inhaler: 10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
3243162|NCT00888966||Out of hospital cardiac arrest|Out of hospital cardiac patients successfully resuscitated and admitted to ICU
3243163|NCT00888953|Experimental|Intervention|Residents living in nursing homes allocated to intervention group. Assessment of risk factors. Implementation of a multifactorial tailored program to prevent falls.
3243164|NCT00888953|Other|Control|Residents living in nursing homes allocated to control group. Assessment of risk factors. Receive the usual attention.
3243165|NCT00888940|Experimental|ecallantide|
3243166|NCT00888940|Active Comparator|Cyklokapron(R)|
3243167|NCT00888927|Experimental|KW-0761|open label, dose escalation(0.1, 0.3, 1.0 mg/kg)
3243168|NCT00888914|Active Comparator|Dose A|RT001 Dose A; Active Comparator
3243169|NCT00888914|Active Comparator|Dose B|RT001 Dose B; Active Comparator
3243170|NCT00888914|Active Comparator|Dose C|RT001 Dose C; Active Comparator
3243171|NCT00888914|Active Comparator|Dose D|RT001 Dose D; Active Comparator
3243172|NCT00888914|Placebo Comparator|Dose E|RT001 Dose E; Vehicle Comparator
3243173|NCT00888901|Experimental|1|Patients on eltrombopag
3243174|NCT00888901|Active Comparator|2|Patients on corticosteroids
3243175|NCT00888901|No Intervention|3|Untreated patients
3243176|NCT00888888||Cohort: Patients with colonic resections|Colonic resections in patients submitted to appendicectomy for suspected acute appendicitis
3243177|NCT00888875|Experimental|1|Computer randomized insertion of the i-gel. Intubation fiberoptically of a tracheal tube
3243178|NCT00888875|Active Comparator|2|Computer randomized insertion of the i-gel. Intubation fiberoptically of a tracheal tube
3243179|NCT00888862|Experimental|A|Use of desvenlafaxine succinate, flexible dose (50-100mg/day)
3243180|NCT00888849|Experimental|Stapling|
3243181|NCT00888849|Active Comparator|Suturing|4 layered hand-sutured anastomosis
3243182|NCT00888836|Active Comparator|GBP|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 years undergo gastric bypass
3243183|NCT00888836|Active Comparator|BPD 2|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 years undergo bilio-pancreatic diversion
3243184|NCT00888836|Active Comparator|Med Ter3|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 yearsundergo medical therapy
3243185|NCT00888797|Active Comparator|1|Perioperative Propranolol and Etodolac
3243186|NCT00888797|Placebo Comparator|2|Placebo
3243187|NCT00888784|Active Comparator|1. Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in the gastric varix
3243188|NCT00888784|Placebo Comparator|2. Beta-blocker|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
3243189|NCT00888771||1|
3243190|NCT00888771||2|
3243191|NCT00888771||3|
3243192|NCT00888771||4|
3243193|NCT00888758|Experimental|1|
3243194|NCT00888758|Active Comparator|2|
3243195|NCT00888745|Experimental|1|
3243196|NCT00888745|Placebo Comparator|2|
3243197|NCT00888732|Experimental|Insulin therapy|Insulin Aspart, Biphasic Insulin Aspart 70 and 50 & Fast-acting Human Insulin
3243198|NCT00888719|Experimental|CWP-0403 50mg|
3243199|NCT00888719|Experimental|CWP-0403 100mg|
3243200|NCT00888719|Placebo Comparator|placebo|
3243201|NCT00888706|Active Comparator|1|
3243202|NCT00888706|Active Comparator|2|
3243203|NCT00888706|Active Comparator|3|
3243204|NCT00888706|Experimental|4|
3243205|NCT00888693|Experimental|1|ABT-288 vs placebo capsules administered orally once daily for 14 days
3243206|NCT00888693|Experimental|2|ABT-288 vs placebo capsules administered orally once daily for 14 days
3243207|NCT00888693|Experimental|3|ABT-288 vs placebo capsules administered orally once daily for 14 days
3243208|NCT00888693|Experimental|4|ABT288 vs placebo administered orally once daily for 14 days
3243209|NCT00888693|Experimental|5|ABT-288 vs placebo administered orally once daily for 14 days
3243210|NCT00888693|Experimental|6|ABT-288 vs placebo administered orally once daily for 14 days
3243211|NCT00888693|Experimental|7|ABT-288 vs placebo administered orally once daily for 14 days
3243212|NCT00888693|Experimental|8|ABT-288 vs placebo administered orally once daily for 14 days
3243213|NCT00888693|Experimental|9|ABT-288 vs placebo administered orally once daily for 14 days
3243214|NCT00888680|Experimental|BGC20-1531 200 mg|
3243215|NCT00888680|Experimental|BGC20-1531 400mg|
3243216|NCT00888680|Placebo Comparator|Lactose|
3243217|NCT00888667||ICD patient with frequent PVCs|
3243218|NCT00888654|Experimental|B-Dim, Radical Prosatectomy|"B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)~Radical Prostatectomy"
3243219|NCT00888641|No Intervention|Normothermia|After arterial clamping, no ice slush will be used
3243220|NCT00888641|Experimental|Hypothermia|After arterial clamping, the kidney will be surrounded in ice slush for 10 minutes
3243221|NCT00888628|Experimental|Islet transplant|"Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.~For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.~Induction therapy for subsequent transplants will be 2 doses of basiliximab.~All patients will receive Etanercept to promote engraftment."
3243222|NCT00888615|Experimental|Treatment (paclitaxel, elesclomol sodium)|Patients receive paclitaxel IV over 1 hour and elesclomol sodium IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients who are currently on treatment must not be dosed with elesclomol sodium after 12/31/2015. All other study procedures, with the exception of elesclomol sodium administration and paclitaxel administration, should continue in accordance with protocol requirements. Any treatment given after 12/31/2015, including continuation of paclitaxel, will be considered off study.
3243223|NCT00888602|Experimental|MM1 - Meal|3.4g psyllium served with a meal
3243224|NCT00888602|Experimental|MM2 - Meal|6.8 g psyllium served with a meal
3243225|NCT00888602|Experimental|MM2 (no Meal)|6.8 g psyllium consumed with no meal
3243226|NCT00888602|Sham Comparator|Meal Only|meal only
3243227|NCT00888576||1|Non-intervention
3243228|NCT00888550|Experimental|1. Splinting|
3243229|NCT00888550|Active Comparator|2. No Splinting|
3243230|NCT00888537|Experimental|Decision Aid|Patients in this arm will discuss medications to help the heart heal after a heart attack with the clinician and the help of the acute myocardial infarction (AMI) Choice Decision Aid.
3243231|NCT00888537|Active Comparator|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
3243232|NCT00888524|Experimental|General Practice (GP) in Physio plus Deep water running|A supplementation of Deep Water running exercises of 20 minutes in high intensity around aerobic thresholds estimated in individual land and water test
3243233|NCT00888524|Experimental|General Practice in Physio|A procedure of evidence-based physiotherapy is usual care in pragmatic trial
3243234|NCT00888511|Experimental|1|
3243235|NCT00888498|Placebo Comparator|Hands-On Control|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the experimental groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
3243236|NCT00888498|Experimental|Fast Stretching|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
3243237|NCT00888498|Experimental|Slow Stretching|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
3243238|NCT00888485|Experimental|Behavioral intervention|Group exposed to behavioral intervention program
3243239|NCT00888485|Active Comparator|Standard treatment|
3243240|NCT00888472|Experimental|1|
3243241|NCT00888459|Active Comparator|active|Self-help counseling material and 4 mg nicotine lozenges
3243242|NCT00888459|Placebo Comparator|2|self help counseling material and placebo nicotine lozenges
3243243|NCT00888446|Experimental|Group A|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^10 DRP~Month 0 + 6"
3243244|NCT00888446|Experimental|Group B|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^10 DRP~Month 0+12"
3243245|NCT00888446|Experimental|Group C|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^11 DRP~Month 0+6"
3243246|NCT00888446|Experimental|Group D|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^11 DRP~Month 0+12"
3243247|NCT00888446|Experimental|Group E|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^12 DRP~Month 0+6"
3243248|NCT00888446|Experimental|Group F|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^12 DRP~Month 0+12"
3243249|NCT00888446|Experimental|Group G|"Number of Vaccine Recipients: 10~Preselected for baseline AAV neutralization titers of <1/8~Dosage level 3 x 10^12 DRP~Month 0+6"
3243250|NCT00888446|Placebo Comparator|Placebo|3 volunteers will receive placebo matched to each experimental group.
3243251|NCT00888433|Experimental|Renal Denervation|Renal Denervation and maintenance of anti-hypertensive medications
3243252|NCT00888433|No Intervention|Control|Maintenance of anti-hypertensive medications with option for cross-over treatment after 6-months
3243253|NCT00888420||Medical Management|Patient satisfaction under current operational conditions
3243254|NCT00888420||Interventional Management|Patient satisfaction under the PSDA (Plan, do, study, act) performance improvement measures
3243255|NCT00888407|Experimental|HBV Screening|Small group educational session with HBV screening resources provided.
3243256|NCT00888407|Sham Comparator|Nutrition|Small group educational discussion, diet & nutrition resources provided.
3243257|NCT00888394|Experimental|1|
3243258|NCT00888394|Experimental|2|
3243259|NCT00888394|Experimental|3|
3243260|NCT00888394|Experimental|4|
3243261|NCT00888381|Experimental|Adults|Healthy volunteers aged 18 to 59 years
3243262|NCT00888381|Experimental|Older Adults|Healthy volunteers aged 60 years or older
3243263|NCT00888368|Experimental|Transpatellar Approach|
3243264|NCT00888368|Active Comparator|Suprapatellar Approach|
3243265|NCT00888355|Placebo Comparator|1|Placebo
3243266|NCT00888355|Experimental|2|Losartan 50 q.a.m.
3243267|NCT00888355|Experimental|3|Losartan 25 b.i.d.
3243268|NCT00888355|Experimental|4|Losartan 25 q.a.m.
3243269|NCT00888342|Active Comparator|1 supplementary oxygen|participant receives supplementary oxygen one night, polysomnography with capnography will be compared to no treatment another night
3243270|NCT00888342|Active Comparator|2 Zopiclone|participant receives 5 mg zopiclone one night, polysomnography with capnography will be compared to no treatment another night
3243271|NCT00888342|Active Comparator|3 Alcohol|participant receives 0,5 mg alcohol /kg body weight before sleep one night, polysomnography with capnography will be compared to no intervention another night
3243272|NCT00888329|Experimental|Aprepitant|40 mg aprepitant
3243273|NCT00888329|Placebo Comparator|Placebo|Placebo
3243274|NCT00888316||Without Iron Overload|Patients entering study without pre-HSCT iron-overload. Iron overload will be defined as liver ion concentration (LIC above normal (>1.8 mg/g) on R2 magnetic resonance imaging (MRI) of the liver.
3243275|NCT00888316||With Iron-Overload|Patients entering study with pre-HSCT iron-overload. Iron overload will be defined as liver ion concentration (LIC above normal (>1.8 mg/g) on R2 magnetic resonance imaging (MRI) of the liver.
3243276|NCT00888303|Active Comparator|A (dexamethasone)|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
3243277|NCT00888303|Placebo Comparator|B (Control)|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
3243370|NCT00887523|Active Comparator|2|supine intensity-modulated radiotherapy
3243278|NCT00888290|Experimental|Single arm|Crossover design. Participants will be getting either placebo or different doses of sodium bicarbonate during the study.
3243279|NCT00888251||Comprehensive weight management program|
3243280|NCT00888238|Experimental|Sitagliptin/Sitagliptin/Placebo|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
3243281|NCT00888238|Experimental|Sitagliptin/Placebo/Sitaglipitin|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
3243282|NCT00888238|Experimental|Placebo/Sitagliptin/Sitagliptin|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
3243283|NCT00888225|Experimental|Eccentric exercise|Group exposed to eccentric exercise treatment
3243284|NCT00888225|Active Comparator|Concentric exercise|Group exposed to concentric exercise treatment
3243285|NCT00888212|Experimental|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
3243286|NCT00888199|Experimental|Congenital/Traumatic|Individuals who were born with a limb deficiency or who have had a traumatic amputation.
3243287|NCT00888199|Experimental|Dysvascular/Diabetic|Individuals who have had an amputation as a result of vascular disease.
3243288|NCT00888186|Active Comparator|1. Duodopa optimal dose|
3243289|NCT00888186|Experimental|2. Duodopa 20% too high dose|
3243290|NCT00888186|Experimental|3. Duodopa 10% too low dose|
3243291|NCT00888186|Experimental|4. Duodopa 20% too low dose|
3243292|NCT00888186|Experimental|5. Duodopa 10% too high dose|
3243293|NCT00888173|Experimental|Treatment (brivanib alaninate)|Patients receive brivanib alaninate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3243294|NCT00888147||Fiber formula|This group will receive tube feeding formula that contains fiber.
3243295|NCT00888134|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID for 3 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3243296|NCT00888108|Experimental|docetaxel +ABT-263|
3243297|NCT00888095|Experimental|1|caudal Zona incerta (cZI)
3243298|NCT00888095|Experimental|2|Nucleus subthalamicus (STN)
3243299|NCT00888082|No Intervention|A|Patients receiving only adjuvant chemotherapy
3243300|NCT00888082|Experimental|B|Patient receiving goserelin acetate along with adjuvant chemotherapy
3243301|NCT00888069|Experimental|Low Dose CTAP101 Capsules|CTAP101 Capsules, 450 mcg dose
3243302|NCT00888069|Experimental|High Dose CTAP101 Capsules|CTAP101 Capsules, 900 mcg dose
3243303|NCT00888069|Experimental|CTAP101 Injection|IV injection, 448 mcg dose
3243304|NCT00888056|Experimental|ARM A|Bilateral chronic electrical stimulation of the hypothalamus/fornix
3243305|NCT00888043|Other|I|CNTO 95 and avastin
3243306|NCT00888030||2|CKD patients with normal p-cresol
3243307|NCT00888030||3|CKD patient with normal indoxyl sulfate
3243308|NCT00888030||4|CKD patients with high indoxyl sulfate
3243309|NCT00888030||1|CKD patients with high p cresol
3243310|NCT00888017||PPI group|This group of infants have received treatment with a PPI as ordered by their neonatologist during their hospital stay.
3243311|NCT00888017||non-PPI group|These infants did not receive PPIs during their hospital stay.
3243312|NCT00888004|Experimental|Active|
3243313|NCT00888004|Placebo Comparator|Placebo|
3243314|NCT00887991||Electric Pump 1 (ISIS Duo iQ Electric Breast Pump)|This is a parallel trial where subjects (mother of preterm infants) will be allocated to use one of two electric breast pumps to express milk. The use of electric breast pumps is routine practice on neonatal units in the UK.
3243315|NCT00887991||Electric Pump 2 (Medela Symphony Electric Breast Pump)|This is a parallel trial where subjects (mother of preterm infants) will be allocated to use one of two electric breast pumps to express milk. The use of electric breast pumps is routine practice on neonatal units in the UK.
3243316|NCT00887978|Placebo Comparator|Placebo|Identical placebo tablets to UT-15C, doses were titrated in the same manner
3243317|NCT00887978|Experimental|UT-15C SR|Doses were initiated at 0.25 mg BID and increased by 0.25 mg BID every three days (as clinically indicated based on tolerability and symptoms of PAH), to a max dose of 16 mg BID.
3243318|NCT00887965|Other|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
3243319|NCT00887952|Experimental|1|Partial removal of carious dentine. Carious dentine partial removal plus restoration in one session. The group is divided according to the filling material: amalgam or resin.
3243320|NCT00887952|Active Comparator|2|Stepwise excavation: Carious dentine removal performed in 2 steps: partial removal of carious dentine, indirect pulp capping (calcium hydroxide cement); temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling (amalgam or resin).
3243321|NCT00887926|Experimental|IMC-EB10 5 mg/kg|All patients will receive intravenous infusions of IMC-EB10, with the dose depending on which cohort they are enrolled into.
3243322|NCT00887900|Experimental|1|Submitted to deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
3243323|NCT00887900|Active Comparator|2|Submitted to regular penetrating keratoplasty
3243324|NCT00887887||liver surgery|patients with benign or malignant hepatobiliary disease requiring partial hepatic resection
3243325|NCT00887874||A|
3243326|NCT00887861|Experimental|BGG492|
3243327|NCT00887861|Placebo Comparator|Placebo|
3243328|NCT00887848|Experimental|Lokomat training|Lokomat training
3243329|NCT00887848|Other|Waiting list|Lokomat training after waiting phase of 5 weeks
3243330|NCT00887835|Experimental|PERPOS™ PLS|Minimally invasive transfacet fixation with PERPOS™ PLS as an aid to fusion
3243366|NCT00887536|Active Comparator|Group 1: TAC then pegfilgrastim|docetaxel, doxorubicin, cyclophosphamide, and pegfilgrastim/filgrastim
3243367|NCT00887536|Active Comparator|Group 2: TC|docetaxel and cyclophosphamide
3243368|NCT00887536|Experimental|Group 3: TC + bevacizumab|docetaxel, cyclophosphamide, and bevacizumab
3243369|NCT00887523|Experimental|1|prone intensity-modulated radiotherapy
3243331|NCT00887822|Experimental|Bevacizumab, Capecitabine and Cisplatin|Participants will receive bevacizumab 7.5 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every 3-week cycle in combination with capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily (total daily dose 2000 mg/m^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
3243332|NCT00887822|Placebo Comparator|Placebo, Capecitabine and Cisplatin|Participants will receive placebo matched to bevacizumab on Day 1 of every 3-week cycle in combination with capecitabine 1000 mg/m^2 orally twice daily (total daily dose 2000 mg/m^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
3243333|NCT00887809|Experimental|gemcitabine and docetaxel with bevacizumab|Patients will receive bevacizumab at 15 mg/kg on day 1 of each 21-day cycle intravenously over 30 minutes followed by a one hour (+30/-15 min) break. For cycles 1 through 6, gemcitabine will be administered at 900 mg/m2 over 90 minutes on day 1 and 8 of a 21-day cycle. Docetaxel will be administered at 75 mg/m2, over 60 minutes, on day 8. This will be followed by either 5 days of filgrastim or a single injection of pegfilgrastim. For cycles 7 and beyond, gemcitabine will be given at 800 mg/m2 over 30 minutes on day 1 and 8; docetaxel will be given at 35 mg/m2 over 30 minutes, also on days 1 and 8.
3243334|NCT00887783|Experimental|B|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)
3243335|NCT00887783|Active Comparator|A|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)
3243336|NCT00887770|Experimental|A|600mg AZD5672 + Moxifloxacin placebo
3243337|NCT00887770|Experimental|B|100mg AZD5672 + Moxifloxacin placebo
3243338|NCT00887770|Active Comparator|C|AZD5672 placebo + Moxifloxacin 400mg
3243339|NCT00887770|Placebo Comparator|D|AZD5672 placebo + Moxifloxacin placebo
3243340|NCT00887757|Experimental|gemcitabine +ABT-263|
3243341|NCT00887744|Other|Aperius Treatment Arm|Single Arm
3243342|NCT00887731||Part 1 group|Observational study with a convenience sample of ten (10) patients. PART 1 will end when at least 3 of 4 consecutive patients achieve the goal of less than six (6) operator required interruptions per hour for oxygen saturation deviations from study guidelines, or at ten (10) patients.
3243343|NCT00887731||Part 2 group|(After successful completion of PART 1) Within patient cross-over study with a randomized cross-over sequence. Sequential data analysis methods will be used to help minimize the patient sample size which will be no more than twenty (20) patients plus up to a maximum of seven (7) who might be eligible from PART 1.
3243344|NCT00887731||Part 3 Group|(After successful completion of PART 2) Within patient cross-over study with a randomized cross-over sequence. Studies will last 4 to 12 hours divided in two (2) equal time blocks with one cross-over to either automatic or manual control modes.
3243345|NCT00887718|Experimental|PET scan for lymphoma assessment|
3243346|NCT00887705|No Intervention|1: Standard rehabilitation programme|
3243347|NCT00887705|Experimental|2. Additional ADL training|
3243348|NCT00887679|Experimental|Escitalopram|Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Open label, rater-blinded, prospective, 6-week trial of escitalopram.Subjects received escitalopram 10-20mg. Escitalopram was started at 10mg per day and augmented weekly in 10mg per day increments, the maximum dose being 20mg per day.
3243349|NCT00887653|Experimental|Raltegravir|This is a single arm study where HIV-infected individuals virologically suppressed on current regimen will be switched to raltegravir +optimized back ground regimen for 6 months
3243350|NCT00887640|Experimental|Temsirolimus 25 mg|Temsirolimus 25mg was administered by IV infusion each week (days 1, 8, 15, and 22 of each 28 day cycle). The infusion was to be administered over a period not less than 30 minutes and was to be completed within 60 minutes. Subjects were premedicated with 25 to 50 mg IV or PO diphenhydramine (or an alternative antihistamine in case of allergies) 30 minutes prior to the infusion.
3243351|NCT00887627|Experimental|1. Mild Renal Function Impaired Subjects|
3243352|NCT00887627|Experimental|2. Moderate Renal Function Impaired Subjects|
3243353|NCT00887627|Experimental|3. Subjects with Normal Renal Function|
3243354|NCT00887614|Experimental|MBSR|Participation will involve online completion of a questionnaire survey before and after the Mindfulness-Based Stress Reduction (MBSR) intervention. Specifically, research study participants will complete validated self-report measures to assess mindfulness, cognitive-emotional processes, sleep quality, symptoms of stress, sense of spirituality, and quality of life before and after the MBSR intervention.
3243355|NCT00887601|Experimental|Part I|Subjects will receive placebo, MK3134, and donepezil in one of four treatment sequences.
3243356|NCT00887601|Experimental|Part II|Subjects will receive placebo and three different doses of MK3134 (1 mg, 5 mg, and 25 mg) in one of four treatment sequences.
3243357|NCT00887588|Experimental|LCZ696|During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid.
3243358|NCT00887588|Active Comparator|Valsartan|During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid.
3243359|NCT00887575|Experimental|Dose Level I|"Neoadjuvant - Paclitaxel IV (70 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 5) day 1 of every cycle and Sunitinib PO (25mg) daily.~Maintenance - Sunitinib PO (25mg) daily"
3243360|NCT00887575|Experimental|Dose Level II|Paclitaxel IV (80 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 5) day 1 of every cycle and Sunitinib PO (25mg) daily.
3243361|NCT00887575|Experimental|Dose Level III|Paclitaxel IV (80 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 6) day 1 of every cycle and Sunitinib PO (25mg) daily.
3243362|NCT00887562|Experimental|Idebenone 900 mg/day|Idebenone 900 mg/day
3243363|NCT00887562|Experimental|Idebenone 2250 mg/day|Idebenone 2250 mg/day
3243364|NCT00887562|Placebo Comparator|placebo|Placebo
3243365|NCT00887549|Experimental|Pemetrexed|
3243371|NCT00887510|Active Comparator|Thiazide First|Participants will receive 25 mg of hydrochlorothiazide (HCTZ) each day for 6 weeks, followed by 25 mg of HCTZ every day plus 4 mg of trandolapril each day for 6 weeks, followed by 4 mg trandolapril each day for 6 weeks.
3243372|NCT00887510|Active Comparator|Trandolapril First|Participants will receive 4 mg of trandolapril each day for 6 weeks, followed by 4 mg of trandolapril for 6 weeks plus 25 mg of HCTZ each day for 6 weeks, followed by 25 mg of HCTZ each day for 6 weeks.
3243373|NCT00887497|Experimental|Catheterization|Patients receive angioembolization prior to surgery
3243374|NCT00887484|Experimental|Clindoxyl Gel|Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.
3243375|NCT00887484|Active Comparator|Epiduo gel|Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.
3243376|NCT00887471||Children who underwent PITA|Children who underwent partial intracapsular tonsillectomy and adenoidectomy between July 2003 and January 2008 for treatment of pediatric sleep-disordered breathing documented by positive preoperative polysomnography.
3243377|NCT00887471||Children who underwent T&A|Children who underwent total tonsillectomy and adenoidectomy between July 2003 and January 2008 for treatment of pediatric sleep-disordered breathing documented by positive preoperative polysomnography.
3243378|NCT00887458|Active Comparator|Low Dose|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
3243379|NCT00887458|Active Comparator|High Dose|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
3243380|NCT00887445|Experimental|A|
3243381|NCT00887445|Placebo Comparator|B|
3243382|NCT00887432|Experimental|Arm I (cholecalciferol and placebo)|Patients receive cholecalciferol PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm II.
3243383|NCT00887432|Experimental|Arm II (placebo and cholecalciferol)|Patients receive placebo PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm I.
3243384|NCT00887419|Experimental|Coping Skills Training|Coping Skills Training in pain management
3243385|NCT00887419|Active Comparator|Education|Chronic Pain Education
3243386|NCT00887419|No Intervention|Usual Care|Patients receive no study intervention, continue with usual medical care.
3243387|NCT00887406|Experimental|Cohort 1, Period 2|GSK961081 3mcg, Placebo, GSK961081 15mcg, GSK961081 50mcg
3243388|NCT00887406|Experimental|Cohort 1, period 1|Placebo, GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg
3243389|NCT00887406|Experimental|Cohort 1, period 3|GSK961081 3mcg, GSK961081 15mcg, Placebo, GSK961081 50mcg
3243390|NCT00887406|Experimental|Cohort 1, period 4|GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg, Placebo
3243391|NCT00887406|Experimental|Cohort 2, period 1|Placebo, GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg,
3243392|NCT00887406|Experimental|Cohort 2, period 2|GSK961081 100mcg, Placebo, GSK961081 200mcg, GSK961081 300mcg
3243393|NCT00887406|Experimental|Cohort 2, period 3|GSK961081 100mcg, GSK961081 200mcg, Placebo, GSK961081 300mcg
3243394|NCT00887406|Experimental|Cohort 2, period 4|GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg, Placebo
3243395|NCT00887406|Experimental|Cohort 3|GSK961081 100mcg or Placebo
3243396|NCT00887406|Experimental|Cohort 4|GSK961081 300mcg or Placebo
3243397|NCT00887393|Other|Low carbohydrate|Low carbohydrate pre-bariatric surgery diet
3243398|NCT00887393|Other|Low fat|Low fat pre-bariatric surgery diet
3243399|NCT00887380|Active Comparator|Arm A: Concurrent|Investigational treatment: Anastrozole commenced before (Pre-radiotherapy commencement of anastrozole) and continued during radiotherapy.
3243400|NCT00887380|Active Comparator|Arm B: Sequential|Standard Treatment: Anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy (Post radiotherapy commencement of anastrozole)
3243401|NCT00887367|Placebo Comparator|Placebo to match GSK598809|Placebo to match GSK598809.
3243402|NCT00887367|Placebo Comparator|Placebo to match ethanol infusion|Glucose solution to be given in the same way as ethanol.
3243403|NCT00887354|Experimental|Teriparatide|"20 micrograms (mcg) a day by subcutaneous injection throughout study.~Placebo oral tablets once a week, to match the active comparator weekly dose, during the double-blind, double-dummy phase only."
3243404|NCT00887354|Active Comparator|Risedronate|"35 milligrams (mg) risedronate sodium orally once weekly throughout study.~Daily placebo injection, to match the daily experimental drug dose, during the double-blind, double-dummy phase only."
3243405|NCT00887341|Experimental|1|
3243406|NCT00887341|Active Comparator|2|
3243407|NCT00887328|Experimental|IV tPA|intravenous tissue plasminogen activator
3243408|NCT00887328|Placebo Comparator|Placebo|
3243409|NCT00887315|Active Comparator|Group 1|Chemotherapy only
3243410|NCT00887315|Active Comparator|2|Chemotherapy and hypofractionated image guided radiotherapy
3243411|NCT00887302||1|Gastric Band
3243412|NCT00887302||2|Gastric Sleeve
3243413|NCT00887302||3|Gastric Bypass with PEG tube
3243414|NCT00887276|Active Comparator|Moxifloxacin|
3243415|NCT00887276|Active Comparator|Ampicillin; Amoxicillin|
3243416|NCT00887263|Experimental|A|
3243417|NCT00887263|Placebo Comparator|B|
3243418|NCT00887250|Placebo Comparator|1|Placebo
3243419|NCT00887250|Experimental|2|Losartan 50 mg for 12 weeks
3243420|NCT00887250|Experimental|3|Losartan 50 mg titrated to 100 mg after 6 weeks
3243421|NCT00887237|Experimental|TRIV|Cardiac resynchronization with triple site ventricular stimulation (2 RV leads and 1 LV lead)
3243422|NCT00887237|Active Comparator|BIV|Conventional cardiac resynchronization
3243423|NCT00887224|Experimental|Desvenlafaxine succinate sustained release 50 mg|
3243424|NCT00887224|Placebo Comparator|Placebo|
3243425|NCT00887211|Active Comparator|ProStent|implant ProStent drug-eluting stents
3243426|NCT00887211|Active Comparator|Firebird|implant Firebird drug-eluting stents
3243427|NCT00887198|Placebo Comparator|Placebo + prednisone|Placebo plus prednisone
3243428|NCT00887198|Experimental|Abiraterone + prednisone|Abiraterone acetate plus prednisone
3243429|NCT00887185|Active Comparator|1 - Traditional training|Temporal bone dissection training in cadaveric laboratory. Subjects are provided 2 cadaveric temporal bones and asked to spend 2 weeks practicing the surgical technique of complete mastoidectomy with facial recess approach.
3243430|NCT00887185|Experimental|2 Simulator training|Subjects perform temporal bone surgical dissection training on a simulator.
3243431|NCT00887172|Experimental|1|Wind-cold syndrome group were patients classified by Chinese Medicine practitioner of Wind-cold syndrome and took treatment of Jing Fang Bai Du san.
3243432|NCT00887172|Placebo Comparator|2|Wind-cold syndrome group were patients classified by Chinese Medicine practitioner of Wind-cold syndrome and took placebo of Jing Fang Bai Du san.
3243433|NCT00887172|Experimental|3|Wind-heat syndrome group were patients classified by Chinese Medicine practitioner of Wind-heat syndrome and took treatment of Ying Qiao san.
3243434|NCT00887172|Placebo Comparator|4|Wind-heat syndrome group were patients classified by Chinese Medicine practitioner of Wind-heat syndrome and took placebo of Ying Qiao san.
3243435|NCT00887159|Active Comparator|Arm A (CE)|Patients receive cisplatin IV over 1-2 hours on day 1 and etoposide IV over 1-2 hours on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3243436|NCT00887159|Experimental|Arm B (CE + GDC-0449)|Patients receive cisplatin and etoposide as in Arm A and vismodegib PO QD on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive vismodegib alone QD in the absence of disease progression or unacceptable toxicity.
3243437|NCT00887159|Experimental|Arm C (CE + IMC-A12)|Patients receive cisplatin and etoposide as in Arm A and cixutumumab IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cixutumumab alone once weekly in the absence of disease progression or unacceptable toxicity.
3243438|NCT00887146|Experimental|Arm A (RT, procarbazine, lomustine, vincristine)|Patients undergo 3D-CRT or IMRT on days 1-5 for 5-7 weeks. Patients also receive procarbazine hydrochloride PO on days 8-21, lomustine PO on day 1 and vincristine sulfate IV on days 8 and 29 of courses 3-8. Treatment repeats every 6-7 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3243439|NCT00887146|Experimental|Arm B (RT, temozolomide)|Patients undergo RT as in arm I and receive temozolomide PO QD on days 1-5 for 5-7 weeks. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients receive adjuvant temozolomide PO QD days 1-5. Treatment with adjuvant temozolomide repeats every 4 weeks for 6-12 courses in the absence of disease progression and unacceptable toxicity.
3243440|NCT00887133||1|Patients consulting Western Medicine outpatient clinics for a new episode of illness
3243441|NCT00887120|Active Comparator|1|Lopinavir/ritonavir standard dose + zidovudine and lamivudine
3243442|NCT00887120|Active Comparator|2|Lopinavir/ritonavir low dose (70% of standard dose) + zidovudine and lamivudine
3243443|NCT00887107|Experimental|sorafenib|30 patients with non-radioiodine avid differentiated thyroid carcinoma
3243444|NCT00887094|Experimental|Aerobic exercise|One bout of aerobic physical training will be performed on a cycle ergometer for 50 min
3243445|NCT00887094|Experimental|Aerobic-resistance exercise|One bout of aerobic-resistance physical training will be performed on a cycle ergometer added by a strenght training for 50 min (total)
3243446|NCT00887081|Experimental|Interferon and Ribavirin|Patients with hemoglobinopathy will receive Interferon and Ribavirin
3243447|NCT00887068|Experimental|Azacitidine|Azacitidine 32 mg/m^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
3243448|NCT00887068|No Intervention|No Azacitidine|Standard treatment post allogeneic transplant is supportive care only.
3243449|NCT00887042|Experimental|Fludarabine|
3243450|NCT00887029|Active Comparator|DuoTrav|
3243451|NCT00887029|Active Comparator|Xalacom|
3243452|NCT00887003|Experimental|LV/LD 1|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
3243453|NCT00887003|Experimental|LV/HD 2|Low Volume, High Dose (5cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
3243454|NCT00887003|Experimental|HV/LD 3|High Volume, Low Dose (10cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
3243455|NCT00887003|Experimental|HV/HD 4|High Volume, High Dose (10cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
3243456|NCT00886990||1|Receiving a single PI boosted by low dose ritonavir
3243457|NCT00886990||2|Receiving two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
3243458|NCT00886964|Active Comparator|1|HBV ID
3243459|NCT00886964|Active Comparator|2|HBV IM
3243460|NCT00886951|Experimental|Access I123MNI388/I123MNI390 and brain imaging|
3243461|NCT00886938|Experimental|rTMS to DLPF, pilot study|rTMS to the dorsolateral prefrontal cortex for patients with tinnitus
3243462|NCT00886925|Active Comparator|Albumin|
3243463|NCT00886925|Placebo Comparator|Saline|
3243464|NCT00886912|Active Comparator|Hypoxia|training in simulated altitude
3243465|NCT00886912|Placebo Comparator|Normoxia|training under normoxic conditions
3243466|NCT00886899|Experimental|BridgePoint Medical System|Attempt to cross CTO with the BridgePoint Medical System after an attempt to cross the CTO with a currently marketed guidewire
3243467|NCT00886886|Other|Reboxetine, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
3243468|NCT00886873|Experimental|Group 1|Oral administration of mifepristone 5 mg daily for six months.
3243469|NCT00886873|Experimental|Group 2|Oral administration of mifepristone 10 mg daily for six months.
3243470|NCT00886860|Active Comparator|conventional oral misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 centimeters
3243471|NCT00886860|Experimental|titrated oral misoprostol|misoprostol 20 micrograms oral every hour until cervical dilatation 3 centimeters
3243472|NCT00886847|Experimental|EBUS FNA vs FNC|
3243473|NCT00886834|Experimental|Misoprostol|Misoprostol 400 micrograms inserted vaginally or buccally, per the participants desire.
3243474|NCT00886834|Placebo Comparator|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
3243475|NCT00886821|Experimental|1|
3243476|NCT00886808|Experimental|1|110 microgram dose of iCo-007 Intravitreal Injection
3243477|NCT00886808|Experimental|2|350microgram dose of iCo-007 Intravitreal Injection
3243478|NCT00886808|Experimental|3|700microgram dose of iCo-007 Intravitreal Injection
3243479|NCT00886808|Experimental|4|1,000microgram dose of iCo-007 Intravitreal Injection
3243480|NCT00886795|Experimental|Abatacept|4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 weeks, and 8 weeks.
3243481|NCT00886782|Experimental|Cdc7-inhibitor|
3243482|NCT00886769|Experimental|Canakinumab|Patients received a single dose of subcutaneous(sc) injection of canakinumab (4 mg/kg) on Day 1. Maximal total single dose of canakinumab allowed was 300 mg. Any patient who required a dose greater than 150 mg (patients>37.5 kg) received two sc injections.
3243483|NCT00886769|Placebo Comparator|Placebo|Patients received a single dose matching placebo of canakinumab on day 1.
3243484|NCT00886756|Experimental|1|
3243485|NCT00886756|Placebo Comparator|2|
3243486|NCT00886743|Other|Oprelvekin as subcutaneous injection (50 mg/kg once daily)|Open label treatment with oprelvekin
3243487|NCT00886730|Experimental|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
3243488|NCT00886730|Experimental|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
3243489|NCT00886730|Experimental|Physicians endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
3243490|NCT00886704|Active Comparator|Convenience drink with EPA and DHA|Daily consumption of 200 ml convenience drink, containing 0.5 g EPA and DHA (Omega-3 Fatty Acids)
3243491|NCT00886704|Placebo Comparator|Convenience drink without EPA and DHA|Daily consumption of 200 ml convenience drink, not containing 0.5 g EPA and DHA (Omega-3 Fatty Acids), but containing 1.0 g of Omega-6 Fatty Acids (e.g. corn oil)
3243492|NCT00886691|Experimental|Arm I (bevacizumab and everolimus)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and everolimus PO QD on days 1-28.
3243493|NCT00886691|Experimental|Arm II (bevacizumab and placebo)|Patients receive bevacizumab as in Arm I and placebo PO QD on days 1-28.
3243494|NCT00886678|Experimental|1|patients receiving pemetrexed, carboplatin and radiation therapy.
3243495|NCT00886665|Placebo Comparator|Placebo|
3243496|NCT00886665|Experimental|JWHGWT|
3243497|NCT00886652|Experimental|Exercise|"The patients of the Exercise group were submitted to a four-month physiotherapy protocol, with three weekly sessions of 60 minutes each, accompanied by a physiotherapist, and consisting of warm-up, aerobic exercise on an electric treadmill, and then winding down and relaxation.~Each patient in this group was therefore submitted to an average of 48 sessions of exercises, always carried out at the same physiotherapy center."
3243498|NCT00886652|No Intervention|2|The patients of the control group were not submitted to any type of physical exercises. Like the patients submitted to the protocol, they were evaluated at the beginning, and again after four months.
3243499|NCT00886639|Other|First of 2 6-minute-walking test with oxygen|Continuous flow of 2 liters per minute First with oxygen, second with medical air
3243500|NCT00886639|Other|First of 2 6-minute-walking tests with medical air|Medical air is compressed room air. First test with medical air, second with oxygen
3243501|NCT00886626|Experimental|Exenatide|Exenatide
3243502|NCT00886626|No Intervention|Control|Control - no intervention
3243503|NCT00886613|Experimental|V212|Participants randomized to receive V212 (heat treated VZV Vaccine)
3243504|NCT00886613|Active Comparator|Zostavax™|Participants randomized to receive Zostavax™ (Zoster Vaccine, live)
3243505|NCT00886613|Placebo Comparator|Placebo|Participants randomized to receive placebo
3243506|NCT00886600|Placebo Comparator|1|Placebo
3243507|NCT00886600|Experimental|2|losartan 50 mg q.d.
3243508|NCT00886600|Experimental|3|losartan 100 mg q.d.
3243509|NCT00886600|Experimental|4|losartan 50 mg b.i.d.
3243510|NCT00886587|Experimental|11054-010|F# 11054-010 Investigational Device
3243511|NCT00886587|Active Comparator|10495-053|F# 10495-053 Atopiclair
3243512|NCT00886574|Active Comparator|Aspirin|Aspirin 100 mg once a day
3243513|NCT00886574|Active Comparator|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
3243514|NCT00886561|Experimental|HIV risk reduction intervention|Behavioral intervention designed to reduce HIV risk behaviors and enhance enhance HIV-preventive behaviors among female sex workers (FSWs) in Armenia
3243515|NCT00886561|Active Comparator|Wait list control|Will receive behavioral intervention after completion of study upon request.
3243516|NCT00886548||Ultrasound performed|Single arm study.
3243517|NCT00886522|Experimental|Intrabone cord blood infusion|All adults patients with hematological malignancies, lacking a HLA matched donor but with a HLA compatible CB unit, fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
3243518|NCT00886509|Experimental|Collateral promotion; PCI after 6 months|First pegGCSF or placebo; PCI after 6 months
3243519|NCT00886509|Experimental|Collateral promotion after PCI at baseline|Collateral promotion with pegGCSF after PCI at baseline
3243572|NCT00886119|Other|Omafilcon A / Lotrafilcon B|Omafilcon A, followed by Lotrafilcon B
3243573|NCT00886106|Experimental|1|Remifentanil
3243574|NCT00886106|Active Comparator|2|Midazolam
3243575|NCT00886093|Experimental|Sequence 1|
3243520|NCT00886483|Active Comparator|Active neurofeedback|In the active neurofeedback condition, the intervention is active neurofeedback (actual neurofeedback) either twice weekly or three times a week (randomized to frequency), with the same amount of total treatment over 40 sessions, varying only in frequency. Neurofeedback will be via the CyberLearning technology, using videogame race car speed and steering as feedback governed by EEG theta-beta ratio through the interface. the game controller is used in the usual fashion, but maximal speed is capped by the threshold theta-beta ratio, which changes from minute-to-minute by fuzzy logic based on the previous minute's ratio. If theta power exceeds a threshold, the rumble function of the controller comes on as a warning. The feedback is transparent to the patient, who just plays the videogame.
3243521|NCT00886483|Sham Comparator|Sham Neurofeedback|The sham condition will appear identical to the neurofeedback in all aspects: equipment, duration, frequency, and videogame choices. The only difference is that the interface module will be pre-programmed to give random feedback rather than contingent on the participant's brainwave power spectrum.
3243522|NCT00886470|Experimental|ACCS 1|Topical treatment every other day
3243523|NCT00886470|Experimental|ACCS 2|Topical treatment every 4th day
3243524|NCT00886470|Experimental|ACCS 3|Topical treatment every 7th day
3243525|NCT00886457|Experimental|Decitabine plus PEG Interferon-alfa 2B|3.7 mg/m**2 decitabine plus 0, 0.5, 1.5, 3, or 6 mcg/kg PET-Intron
3243526|NCT00886444|Experimental|Ferucarbotran|
3243527|NCT00886431|Experimental|Vitrification|The embryos of patients allocated to this arm will be cryopreserved by vitrification.
3243528|NCT00886431|No Intervention|Slow cooling|The embryos of patients allocated to this arm will be cryopreserved by the slow cooling method, which is the standard method (=no intervention)
3243529|NCT00886418|Active Comparator|1|Total intravenous anesthesia (propofol and remifentanil) is provided using the close-loop system. A muscle relaxant is used to facilitate tracheal intubation; its administration is continued throughout anesthesia.
3243530|NCT00886418|Experimental|2|Total intravenous anesthesia (propofol and remifentanil) is provided using the close-loop system. No muscle relaxant is used and a placebo is infused throughout anesthesia.
3243531|NCT00886405|Experimental|Nytroglicerin|
3243532|NCT00886392||diabetic macular edema|Type 2 diabetes patients who had clinically significant macular edema by the criterion of the ETDRS
3243533|NCT00886379|Active Comparator|1|Mongolian milk without D
3243534|NCT00886379|Experimental|2|Mongolian milk with vitamin D
3243535|NCT00886379|Experimental|3|UHT milk
3243536|NCT00886379|Experimental|4|Milk Substitute
3243537|NCT00886379|Experimental|5|Seasonal D
3243538|NCT00886379|Experimental|6|Daily D
3243539|NCT00886366|Experimental|1|AZD6714 in 8 increasing oral single doses a-h given to 8 groups (3 on active and 1 on placebo in each group)
3243540|NCT00886366|Experimental|2|2 oral single doses d and g suspensions of AZD6714 given to 2 groups (3+1) together with food
3243541|NCT00886366|Experimental|3|Two increasing oral doses of AZD6714 and one placebo given to 2 groups with 3 type 2 diabetic patients.
3243542|NCT00886353|Active Comparator|APN01|Healthy volunteers will receive APN01
3243543|NCT00886353|Placebo Comparator|Placebo|Physiological saline administrated i.v.
3243544|NCT00886340|Active Comparator|Enhanced standard care|
3243545|NCT00886340|Experimental|Lifestyle counseling|
3243546|NCT00886327||Postoperative patients|Patients with CD who recently underwent bowel resection
3243547|NCT00886314|Active Comparator|midazolam|
3243548|NCT00886314|Active Comparator|clown doctor|
3243549|NCT00886301|Other|1|obese or overweight patients with fatty liver or ectopic fat
3243550|NCT00886288||Telmisartan|
3243551|NCT00886288||Telmisartan + hydrochlorothiazide|
3243552|NCT00886275|Experimental|Dexmedetomidine|
3243553|NCT00886275|Active Comparator|Midazolam|
3243554|NCT00886275|Experimental|Dexmedetomidine, Midazolam|Combination
3243555|NCT00886262|Experimental|Vasopressin|
3243556|NCT00886262|Placebo Comparator|Normal saline placebo|
3243557|NCT00886236|Active Comparator|1 Preoperative Gabapentin Liquid|Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)
3243558|NCT00886236|Experimental|2 Preoperative and Postoperative Gabapentin Liquid|Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Gabapentin Elixir (300 mg x 6 doses)
3243559|NCT00886236|Placebo Comparator|3 Preoperative and Postoperative Placebo Liquid|Preoperative Placebo Liquid (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)
3243560|NCT00886223|Experimental|1|
3243561|NCT00886210|Active Comparator|1LC with drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
3243562|NCT00886210|Active Comparator|2LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. no drain at the end of operation.
3243563|NCT00886197||GERD|"Symptomatic reflux subjects who receive esophagogastroscopy, aged from 20 to 70 years old.~Patients with typical reflux symptoms (heartburn and/or acid regurgitation) at least 3 times per week in recent 4 months."
3243564|NCT00886184|Experimental|1|Induction of pre hospital early hypothermia in patients having a cardiac .
3243565|NCT00886184|Active Comparator|2|Induction of hypothermia only at hospital arrival.
3243566|NCT00886171|Experimental|Social Skills Training|
3243567|NCT00886171|Experimental|Physical Activity Training|
3243568|NCT00886158||Solid Organ Transplant Recipients|Solid organ transplant recipients receiving their care at Seattle Children's Hospital
3243569|NCT00886145|Other|Vibration and No Vibration|Vibration: Right Leg and No Vibration: Left Leg.
3243570|NCT00886132|Experimental|Sunitinib|Patients with progressive, recurrent and/or metastatic ACC treated with sunitinib 37.5 mg daily in this single-arm, two-stage phase II trial.
3243571|NCT00886119|Other|Lotrafilcon B / Omafilcon A|Lotrafilcon B, followed by Omafilcon A
3243576|NCT00886093|Experimental|Sequence 2|
3243577|NCT00886080|Experimental|Add-on arrhythmia surgery|"Adjuvant anti-arrhythmic surgery consists of a beating heart epicardial box isolation of all pulmonary veins using microwave energy (Flex 4 or Flex 10 ablation probes and Microwave generator by Guidant/Afix, Fremont, CA, USA). The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. In addition excision or exclusion of the left atrial appendage is performed in both the treated as the control group."
3243578|NCT00886067|Experimental|2-[18F]-F-A85380|Single microdose
3243579|NCT00886067|Experimental|AZD1446|Single oral administration
3243580|NCT00886054||Neurocritical patients|Neurocritical patients including those sustaining head injury, cerebrovascular events (such as intracerebral hemorrhage, subarachnoid hemorrhage, etc.), brain tumor, or hydrocephalus.
3243581|NCT00886041|Other|laparoscopy group|laparoscopy
3243582|NCT00886041|Active Comparator|ovarian stimulation group|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
3243583|NCT00886028|Experimental|Liposomal doxorubicin|Thirty patients with MPM who received liposomal doxorubicin 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles.
3243584|NCT00886015|Experimental|TT Clamp|The TT clamp will be used in trichiasis surgery.
3243585|NCT00886015|Active Comparator|Standard BLTR Technique|Standard BLTR technique will be used in trichiasis surgery.
3243586|NCT00885989|Experimental|1|
3243587|NCT00885989|Placebo Comparator|2|
3243588|NCT00885963|Experimental|sapacitabine|
3243589|NCT00885950||Colorectal liver metastases|Patients with colorectal liver metastases undergoing partial hepatic resection who were preoperatively treated with either neoadjuvant chemotherapy or not and/or anticoagulants or not
3243590|NCT00885937|Experimental|Arm 1|
3243591|NCT00885937|Active Comparator|Arm 2|
3243592|NCT00885937|Placebo Comparator|Arm 3|
3243593|NCT00885924|Active Comparator|Active treatment|Desmopressin 0.3 microgram/kg
3243594|NCT00885924|Placebo Comparator|Placebo|NaCl 0.9%
3243595|NCT00885911||Extraglottic device|The laryngeal mask airway (LMA) used during pediatric anesthesia for routine and difficult airway management.
3243596|NCT00885898|Active Comparator|1|"Non-invasive ventilation"
3243597|NCT00885898|Active Comparator|2|"Conventional"
3243598|NCT00885885|Experimental|1|Panitumumab+FOLFOX 4
3243599|NCT00885885|Experimental|2|Panitumumab+FOLFIRI
3243600|NCT00885872|Experimental|Treat|At visit 2 each eligible subject will be allocated to rosuvastatin. Subjects who reach the criteria at visit 3, dosage of rosuvastatin will be titrated. The subjects will be encouraged to take the study drug at the same time each day for 104 weeks.
3243601|NCT00885859||1|responders: patients who have a pain reduction of 30% or more after two weeks TENS-treatment
3243602|NCT00885859||2|non-responders: patient who have a pain reduction smaller than 15% after two weeks TENS-treatment
3243603|NCT00885846|Active Comparator|Qigong Therapy|
3243604|NCT00885846|Active Comparator|PRT|
3243605|NCT00885846|No Intervention|Control|
3243606|NCT00885833|Experimental|Fludarabine|
3243607|NCT00885820|Experimental|1|Protocol biopsies at 1, 2 and 3 months
3243608|NCT00885820|Active Comparator|2|No protocol biopsies
3243609|NCT00885794|Experimental|0.5 mg Ranibizumab|3 intravitreal injections of 0.5 mg Ranibizumab every 5 weeks
3243610|NCT00885794|Experimental|1.0 mg of Ranibizumab|3 intravitreal injections of 1.0mg Ranibizumab every 5 weeks
3243611|NCT00885781|Experimental|SMOFlipid|
3243612|NCT00885781|Active Comparator|Lipovenoes MCT|
3243613|NCT00885768||A|patients with renal artery stenosis
3243614|NCT00885755|Experimental|1|
3243615|NCT00885742|Experimental|FXIII|All subjects who received a dose of Factor XIII (FXIII) Concentrate (Human).
3243616|NCT00885729|Experimental|Stem cells|Cartilage defect are treated surgical either with chondrocytes or stem cells
3243617|NCT00885729|Active Comparator|Rehabilitation|Active rehabilitation program
3243618|NCT00885716|Experimental|communication skills training|group training in shared decision making.
3243619|NCT00885716|Active Comparator|cognitive training|standard group training of cognitive skills (Konzentrationstraining)
3243620|NCT00885703|Experimental|Stage 1, Fluconazole 1200mg|Participants receive Fluconazole 1200mg induction dose in Stage 1
3243621|NCT00885703|Experimental|Stage 1, Fluconazole 1600mg|Participants receive Fluconazole 1600mg induction dose in Stage 1
3243622|NCT00885703|Experimental|Stage 1, Fluconazole 2000mg|Participants receive Fluconazole 2000mg induction dose in Stage 1
3243623|NCT00885703|Active Comparator|Stage 1, Ampho B|Participants receive Amphotericin B followed by Fluconazole in Stage 1
3243624|NCT00885703|Experimental|Stage 2, Fluconazole 1600mg|Participants receive Fluconazole 1600mg induction dose in Stage 2
3243625|NCT00885703|Experimental|Stage 2, Fluconazole 2000mg|Participants receive Fluconazole 2000mg induction dose in Stage 2
3243626|NCT00885703|Active Comparator|Stage 2, Ampho B|Participants receive Amphotericin B followed by Fluconazole in Stage 2
3243627|NCT00885690|Active Comparator|Sertindole|Sertindole 16-24 mg
3243628|NCT00885690|Active Comparator|Olanzapine|Olanzapine 10-20 mg
3243629|NCT00885677|Active Comparator|Study Group|Patients of the study arm are CRT-D patients followed-up by means of a remote disease management system (Medtronic Carelink® Network), for which an automatic alerting system is enabled for fluid accumulation, AT/AF episodes and system integrity.
3243630|NCT00885677|No Intervention|Control Group|Patients are CRT-D patients managed according to current standard clinical practice, based on routinely performed in-office visits.
3243631|NCT00885664|Active Comparator|Truvada|
3243632|NCT00885664|Active Comparator|Kaletra|
3243633|NCT00885651|Experimental|1|Metoprolol for 10 days followed by placebo for 7 days.
3243634|NCT00885651|Placebo Comparator|2|Placebo for 7 days followed by Metoprolol for 10 days
3243635|NCT00885638|Placebo Comparator|Placebo|A placebo tablet is given before ingestion of macronutrients
3243636|NCT00885638|Active Comparator|Sitagliptin|Sitagliptin is given before ingestion of macronutrients
3243637|NCT00885599|Experimental|PERIORINSE|naturopathic remedy
3243638|NCT00885599|Active Comparator|CPC|Cepacol, standard anti-bacterial mouthwash
3243639|NCT00885599|Active Comparator|Listerine|standard anti-bacterial mouthwash
3243640|NCT00885599|Placebo Comparator|placebo|colored water
3243641|NCT00885586|Sham Comparator|Sham-laser acupuncture|Sham laser acupuncture (c) is applied at equivalent points as needle acupuncture. Laser irradiation is faked.
3243642|NCT00885586|Active Comparator|gabapentine|standard analgesic treatment
3243643|NCT00885586|Active Comparator|Acupuncture|Acupuncture treatment is semi-standardized, i.e. beside a scheme of basic points, individual points can be chosen according to the TCM diagnostic pattern.
3243644|NCT00885573|Other|Sleep apnea subjects|"Patients with suspected sleep apnea syndrome will have nocturnal polysomnography. According to the number of respiratory events per hour of sleep, patients will be classified as sleep apnea or controls. All the patients will be blindly assessed for pharyngeal sensitivity the morning following the nocturnal recording."
3243645|NCT00885547|Experimental|immunosuppressor|
3243646|NCT00885534|Experimental|Chemotherapy|This is a single institution phase II trial in stage III or IV melanoma patients with measurable disease but no prior cytotoxic chemotherapy and not thought to be curable by surgery.Before starting the chemotherapy, you may need to have a fresh biopsy of your tumor. If you have already had a tumor biopsy that we can use, you may not need another biopsy. Your study doctor will review with you the biopsies you have had. We will try to obtain biopsy material that already exists but if we cannot, you will need another biopsy.
3243647|NCT00885521|Experimental|Exercise|8 week, twice weekly exercise program with both endurance and upper and lower limb strength training
3243648|NCT00885521|No Intervention|2|No exercise, twice weekly phone calls
3243649|NCT00885508|Experimental|Aracytidine, Daunaurubicine, Lenalidomide|
3243650|NCT00885495|Active Comparator|B|Darunavir+ritonavir x 7 days; Rosuvastatin x 7 days; Combination x 7 days
3243651|NCT00885495|Active Comparator|A|Rosuvastatin x 7 days; darunavir+ritonavir x 7 days; Combination x 7 days
3243652|NCT00885482|Experimental|Single arm|"Treatment simplification from a standard combined antiretroviral therapy including 2 NRTIs and Atazanavir with Ritonavir to Lamivudine plus Atazanavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy."
3243653|NCT00885469||1|Patients with known Barrett's Esophagus or chronic GERD
3243654|NCT00885456|Experimental|PREVENT program|12-week program of exercise and education to induce physiological and behavioral changes needed to reduce vascular risk factors.
3243655|NCT00885456|Active Comparator|Usual Care|Average of three visits to the Neurovascular Clinic for a neurological and health assessment, counseling regarding stroke/TIA and diagnostic test results, and assessment, modification and education of secondary prevention factors
3243656|NCT00885443|Active Comparator|1|
3243657|NCT00885443|Active Comparator|2|
3243658|NCT00885430|Experimental|Pico-Salax|
3243659|NCT00885417|Experimental|Cravit-based sequential therapy|Cravit-based sequential therapy Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
3243660|NCT00885404|Other|Intravenous fluids|
3243661|NCT00885378|Active Comparator|Saxagliptin plus metformin IR|
3243662|NCT00885378|Placebo Comparator|Placebo plus metformin IR|
3243663|NCT00885365|Experimental|Bramitob|tobramycin / Bramitob administered 300mg twice a day for 4 weeks
3243664|NCT00885365|Active Comparator|TOBI|tobramycin / TOBI administered 300mg twice a day for 4 weeks
3243665|NCT00885352|Experimental|Sitagliptin|Sitagliptin 100 mg tablet orally once daily for 26 weeks.
3243666|NCT00885352|Placebo Comparator|Placebo|Placebo to sitagliptin orally once daily for 26 weeks.
3243667|NCT00885339||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases.
3243668|NCT00885326|Other|Treatment|"Bevacizumab: Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.~Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).~Zoledronic acid will be administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first."
3243669|NCT00885313|Experimental|DHA250|DHA 250 mg/kg/d plus lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
3243670|NCT00885313|Experimental|DHA500|DHA 250 mg/kg/d plus lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
3243671|NCT00885313|Placebo Comparator|PLA|placebo and lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
3243672|NCT00885300|Experimental|1|cloxacillin 100 mg/ml + heparin 1000iu/ml as catheter lock at the end of hemodialysis
3243673|NCT00885300|Active Comparator|2|heparin 1000iu/ml as catheter lock at the end of hemodialysis
3243674|NCT00885287|Active Comparator|HIV-positives on ARVs receiving AL for malaria|HIV-positive patients on first-line ARVs receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
3243675|NCT00885287|Active Comparator|HIV-positives receiving AL for malaria|HIV-positive patients not receiving antiretrovirals but receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
3243676|NCT00885287|Active Comparator|HIV-negatives receiving AL for malaria|HIV-negative patients receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
3243677|NCT00885274|Experimental|Split Dose|Doses of Pico-Salax split: one dose administered the night prior to colonoscopy and the other dose administered the day of the procedure.
3243678|NCT00885274|Active Comparator|Traditional Dose|Both doses of Pico-Salax taken the evening prior to colonoscopy.
3243679|NCT00885235||A|Subjects that are indicated for colonoscopy who are suspected or known to suffer from large bowel diseases.
3243680|NCT00885222|Active Comparator|1|PD patient that were treated with STN DBS and developed depression after the surgery (n=5).
3243681|NCT00885222|Active Comparator|2|PD patients with depression that are candidates for STN DBS (n=5).
3243682|NCT00885222|Active Comparator|3|PD patients without depression that are candidates for STN DBS (n=10).
3243683|NCT00885209||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases.
3243684|NCT00885196|Experimental|AEB071 200 mg BID|
3243685|NCT00885196|Experimental|AEB071 400 mg OD|
3243686|NCT00885196|Experimental|AEB071 300 mg BID|
3243687|NCT00885196|Placebo Comparator|Placebo BID|
3243688|NCT00885183|Experimental|acupuncture therapy|Breast cancer patients are randomised to additional 12 acupuncture treatment sessions while undergoing standard chemotherapy Control group receive standard chemotherapy alone
3243689|NCT00885170|Experimental|Odanacatib 50 mg|Odanacatib 50 mg tablets once weekly for 24 months. Vitamin D3 (dietary supplement), two 2800 IU tablets, taken once weekly for 24 months. Participants received calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
3243690|NCT00885170|Placebo Comparator|Placebo|Placebo to odanacatib 50 mg tablets once weekly for 24 months. Vitamin D3 (dietary supplement), two 2800 IU tablets, taken once weekly for 24 months. Participants received calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
3243691|NCT00885157|Experimental|Group A|Will receive fractional doses of IPV Intradermally
3243692|NCT00885157|Active Comparator|Group B|Will receive full doses of IPV Intramuscularly
3243693|NCT00885118|Experimental|BI 10773 low dose quaque die (QD)|patient to receive a BI 10773 low dose tablet and a placebo tablet once daily
3243694|NCT00885118|Experimental|BI 10773 mid-low dose QD|patient to receive a BI 10773 middle dose tablet and a placebo tablet once daily
3243695|NCT00885118|Experimental|BI 10773 mid-high dose QD|patient to receive two tablets of BI 10773 middle dose once daily
3243696|NCT00885118|Experimental|BI 10773 high dose QD|patient to receive a BI 10773 high dose tablet and a placebo tablet once daily
3243697|NCT00885118|Placebo Comparator|Placebo|patient to receive two tablets of placebo once daily
3243698|NCT00885105|Experimental|Fluzone® Vaccine-Primed Group|Participants received 2 doses of Fluzone® vaccine at 2 months (in Study GRC 27)
3243699|NCT00885105|Active Comparator|Influenza Vaccine-Naive Group|Participants who have never received influenza vaccine (and not in Study GRC27)
3243700|NCT00885092|Other|FID 114675A / RepleniSH|FID 114675A in Period 1; RepleniSH in Period 2. Each solution was used for 7 days for cleaning, rinsing, conditioning, disinfecting, and storing silicone hydrogel contact lenses, per protocol-specified instructions. A new pair of silicone hydrogel contact lenses was dispensed at the start of each period and worn bilaterally on a daily wear basis.
3243701|NCT00885092|Other|RepleniSH / FID 114675A|RepleniSH in Period 1; FID 114675A in Period 2. Each solution was used for 7 days for cleaning, rinsing, conditioning, disinfecting, and storing silicone hydrogel contact lenses, per protocol-specified instructions. A new pair of silicone hydrogel contact lenses was dispensed at the start of each period and worn bilaterally on a daily wear basis.
3243702|NCT00885079|Experimental|Rebamipide|Instillation,4 times/day for 4 weeks
3243703|NCT00885079|Active Comparator|Hyaluronate|Instillation,6 times/day for 4 weeks
3243704|NCT00885066|Experimental|gemcitabine, capecitabine, erlotinib|
3243705|NCT00885053|Experimental|Fish oil|
3243706|NCT00885053|Placebo Comparator|Olive oil|
3243707|NCT00885014|Experimental|CBT|Telephone cognitive-behavioral therapy
3243708|NCT00885014|Active Comparator|TAU|Treatment as usual through the Employees Assistance Program
3243709|NCT00885001|Experimental|Short Arc Banding Group|Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
3243710|NCT00884988|Active Comparator|Lymphomyosot|homeopathic remedy
3243711|NCT00884988|Placebo Comparator|Placebo remedy|identical in color, constituency and taste to true remedy
3243712|NCT00884962|Experimental|PLVR|
3243713|NCT00884949|Experimental|BMN 110|Within-patient Dose-Escalation
3243714|NCT00884936||Group 1|Young age: 20 to 30 years old
3243715|NCT00884936||Group 2|Middle Age: 38 to 48 years old (pre-menopausal only)
3243716|NCT00884936||Group 3|Elderly Age: 60 to 75 years old (Post-menopausal only)
3243717|NCT00884897|Experimental|Oxytocin|We will purchase OT from PharmaWorld, an international pharmacy located in Switzerland; the preparation of intranasal OT is manufactured by Novartis and sold under the trade name: Syntocinon. We have obtained an IND (number 78,246) for Syntocinon (intranasal oxytocin) manufactured by Novartis.
3243718|NCT00884897|Placebo Comparator|Placebo|We will be purchasing oxytocin placebo nasal spray through LABOSWISS located in Davos, Switzerland and distributed through PharmaWorld. LABOSWISS will manufacture the matching the placebo under GDP guidelines. The placebo will be in every way identical to the oxytocin formulation but will not contain OT.
3243719|NCT00884884|Placebo Comparator|Double Placebo|Placebo, Placebo
3243720|NCT00884884|Experimental|Aripiprazole 15, Placebo|15 mg Aripiprazole, Placebo
3243721|NCT00884884|Experimental|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
3243722|NCT00884884|Experimental|Topiramate 100mg, Placebo|Topiramate 100 mg daily plus Placebo daily
3243723|NCT00884884|Experimental|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
3243724|NCT00884884|Experimental|Topiramate 100, Aripiprazole 5|Topiramate 100 daily plus, Aripiprazole 5mg daily
3243725|NCT00884884|Experimental|Topiramate 200, Aripiprazole 15|Topiramate 200 mg daily plus Aripiprazole 15mg daily
3243726|NCT00884884|Experimental|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily, Aripiprazole 7.5 mg daily
3243727|NCT00884884|Experimental|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
3243728|NCT00884871||Laparoscopic adjustable gastric banding|100 obese women undergoing laparoscopic adjustable gastric banding
3243729|NCT00884858|Experimental|Maraviroc|Subjects in this group will add Maraviroc to their current HAART.
3243730|NCT00884858|No Intervention|2|Subjects in this group will continue their current HAART without adding Maraviroc.
3243731|NCT00884845|Experimental|Arm 1|Administration of i.v. infusions of PM02734 (on Days 1, 8 and 15) every three weeks and a daily oral dose of erlotinib
3243824|NCT00884026|Active Comparator|1|Subjects that experience hypotension after spinal anesthesia.
3243732|NCT00884832|Experimental|Oral Clonidine|Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
3243733|NCT00884832|Placebo Comparator|Oral Placebo|Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
3243734|NCT00884819|Experimental|1|fenofibrate 200mg/daily for 6 months
3243735|NCT00884819|Placebo Comparator|2|Placebo match for 6 months
3243736|NCT00884806|Experimental|FID 114675A|FID 114675A used for 7 days, per protocol-specified instructions. Silicone hydrogel or hydrogel contact lenses worn bilaterally on a daily wear basis, one brand only.
3243737|NCT00884793|Experimental|intensification with raltegravir +/- NNRTI or PI|Intensification with raltegravir 400mg PO BID +/- a study PI or NNRTI
3243738|NCT00884780||Pediatric Pain|Children between the ages of 8 and 17 experiencing pain.
3243739|NCT00884754|Experimental|rigid GlideScope Specific Stylet|
3243740|NCT00884754|Active Comparator|90º curvature, malleable stylet|
3243741|NCT00884741|Active Comparator|Arm I (radiation therapy, temozolomide, placebo)|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks and receive temozolomide PO QD for up to 7 weeks. Beginning 4 weeks after completion of chemotherapy and radiation therapy, patients receive temozolomide PO QD on days 1-5. Treatment with temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients also receive placebo IV over 30-90 minutes once every 2 weeks beginning in week 4 of chemotherapy and radiation therapy and continuing until the completion of temozolomide.
3243742|NCT00884741|Experimental|Arm II (radiation therapy, temozolomide, bevacizumab)|Patients undergo radiation therapy and receive temozolomide as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes once every 2 weeks beginning in week 4 of chemoradiotherapy and continuing until the completion of adjuvant temozolomide.
3243743|NCT00884728||Indigenous children aged <15 years|Indigenous children aged <15 years within participating communities of the Northern Territory
3243744|NCT00884715|Experimental|1 implant|117 mg Octreotide implant
3243745|NCT00884715|Experimental|2 implants|234 mg Octreotide implant
3243746|NCT00884689||1|Asthma patient with specific treatment
3243747|NCT00884689||2|Asthma patient on different specific treatment compared to the other group
3243748|NCT00884676|Experimental|Schedule A|Schedule A: Ixabepilone - Weekly for 3 weeks each cycle (Days 1, 8 and 15) For both Schedules A and B, Sunitinib daily, orally, starting on Day 8 of Cycle 1
3243749|NCT00884676|Experimental|Schedule B|Ixabepilone - Day 1 of each 3-week cycle For both Schedules A and B, Sunitinib daily, orally, starting on Day 8 of Cycle 1.
3243750|NCT00884663|Experimental|1 Candesartan|
3243751|NCT00884663|Active Comparator|2 propranolol|
3243752|NCT00884663|Placebo Comparator|3 Placebo|
3243753|NCT00884650|Active Comparator|Group 1|Group 1 will receive oral analgesia only
3243754|NCT00884650|Active Comparator|Group 2|Group 2 will have an anesthetic continuous-infusion device with supplemental oral analgesia
3243755|NCT00884637||CNV subjects|
3243756|NCT00884624||A|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
3243757|NCT00884611|Experimental|Predictive Low Glucose Suspend|The pump suspension system consists of the Revel CGM device communicating with a laptop computer that contains the hypoglycemia prediction algorithm. During the 21 night study period, the laptop is placed at the bedside and turned on by the participant at bedtime and off on arising in the morning.The laptop contains a randomization schedule (2:1) that indicats whether the hypoglycemia prediction algorithm will be in operation that night (Predictive Low Glucose Suspend Algorithm ON) or will not be activated (Predictive Low Glucose Suspend Algorithm OFF), to which the participant is blinded.
3243758|NCT00884585|Experimental|Cyclosporine Ophthalmic Solution (COS) followed by COS|Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
3243759|NCT00884585|Other|Placebo followed by COS|Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months followed by cyclosporine ophthalmic solution 0.010% up to 9 additional months; at Month 9 the dose may be adjusted to 2 times a day.
3243760|NCT00884559|Active Comparator|Technical|Technical Instructions
3243761|NCT00884559|Experimental|Leadership|Leadership-Instructions
3243762|NCT00884546|Experimental|Arm 1|BMS-833923 (Starting dose is a loading dose of 60 mg for 7 days with a 30 mg daily dose thereafter)
3243763|NCT00884546|Active Comparator|Arm 2|"BMS-833923 (MTD or below)~Lenalidomide (at or below the recommended prescribing dose)~Dexamethasone (40 mg)"
3243764|NCT00884546|Active Comparator|Arm 3|"BMS-833923 (MTD or below)~Bortezomib (at or below the recommended prescribing dose)"
3243765|NCT00884533|Experimental|Group 1|Group 1 - placebo on Day -1, rosi XR 8mg from Days 1-20, rosi XR 20mg on Day 21
3243766|NCT00884533|Placebo Comparator|Group 3|Placebo on Day -1, Days 1-20 and Day 21
3243767|NCT00884533|Active Comparator|Group 2|Placebo for Day -1, placebo on Days 1-20 and moxifloxacin active comparator 400 mg on Day 21
3243768|NCT00884520|Experimental|VM4-037|Approximately sixteen (16) adult subjects including four (4) healthy volunteers and twelve (12) cancer subjects who have confirmed or highly suspected diagnosis of head & neck, lung, large solitary hepatic and renal cell cancer, as defined by protocol criteria
3243769|NCT00884507|Placebo Comparator|Placebo|
3243770|NCT00884507|Experimental|RO5313534 15mg|
3243771|NCT00884507|Experimental|RO5313534 1mg|
3243772|NCT00884507|Experimental|RO5313534 5mg|
3243773|NCT00884494|Experimental|Roux-en-Y gastric bypass|
3243774|NCT00884494|Experimental|Lean|
3243775|NCT00884481||Natalizumab|Participants with MS treated with Tysabri over 12 months
3243776|NCT00884468||1|Patients with PsA that fulfill the eligibility criteria of the study
3243777|NCT00884442|Active Comparator|1|One tablet of Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL, fasted state
3243778|NCT00884442|Active Comparator|2|One tablet of Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL, fed state
3243779|NCT00884442|Active Comparator|3|One tablet of Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, fasted state
3243780|NCT00884442|Active Comparator|4|One tablet of Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, fed state
3243781|NCT00884429|Active Comparator|1- Conventional Chest Physiotherapy|Percussion , thorax compression and Postural Drainage/suction if necessary
3243782|NCT00884429|Active Comparator|2- Chest physiotherapy- Actual techniques|slow prolonged expiration and clearance rhinopharynx and suction if necessary
3243783|NCT00884429|Active Comparator|3- Airway Suction|Suction superior airways. Only in admission.
3243784|NCT00884416|Experimental|Sorafenib dose titration|
3243785|NCT00884390|Experimental|ReFacto AF|
3243786|NCT00884377|Active Comparator|Sodium stibogluconate intravenous|20 mg/kg/day Sodium stibogluconate intravenous
3243787|NCT00884377|Experimental|ThermoMed device|ThermoMed device, single heat treatment at 50 degrees Celsius
3243788|NCT00884364|Active Comparator|Control|
3243789|NCT00884364|Experimental|Exercise|
3243790|NCT00884338|Experimental|Exercise|
3243791|NCT00884338|Active Comparator|Control group|
3243792|NCT00884325|Experimental|Xyzal|
3243793|NCT00884325|Placebo Comparator|Placebo|
3243794|NCT00884312|Experimental|Carfilzomib|Participants received carfilzomib administered intravenously, using the same method, frequency, and dose level as in the last cycle of the participant's previous carfilzomib study. Treatment was continued until confirmation of disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or commercial availability of carfilzomib.
3243795|NCT00884299|No Intervention|1|Free diet
3243796|NCT00884299|Experimental|Diet rich in antioxidants|Diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients in this arm will be seen regularly in the outpatient clinic where there will be informed for the potential beneficial effects of fruits and vegetables in health status by two members of the study team (attending physician and specialist nurse). At baseline and at each visit it is clearly explained to them that the dietary goal is to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the 3-year study period.
3243797|NCT00884286|Experimental|Arm One|Aplidin® given as a 1-hour weekly IV infusion
3243798|NCT00884273|Experimental|Degarelix 240 mg/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
3243799|NCT00884273|Active Comparator|Goserelin (3.6 mg) + bicalutamide (50 mg)|"Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.~On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin."
3243800|NCT00884260|Experimental|Arm 1|
3243801|NCT00884234|Experimental|1|RT001 (Botulinum Toxin Type A Topical Gel)
3243802|NCT00884234|Placebo Comparator|2|Vehicle Control
3243803|NCT00884221|Experimental|Highly Purified Menotrophin|
3243804|NCT00884221|Active Comparator|Recombinant FSH|
3243805|NCT00884208||Group 1|Recommend assistive device
3243806|NCT00884208||Group 2|Consultation for PT assessment
3243807|NCT00884195|Experimental|1|Gratitude Journaling
3243808|NCT00884195|Placebo Comparator|2|Neutral Journaling
3243809|NCT00884182|Experimental|Group 1|Participants on vaccination schedule 1 (Day 0 and Day 21)
3243810|NCT00884182|Experimental|Group 2|Participants on vaccination schedule 2 (Day 0 and Day 14)
3243811|NCT00884182|Experimental|Group 3|Participants on vaccination schedule 3 (Day 0 and Day 42)
3243812|NCT00884130||Laparoscopic|Patients having a laparoscopic colorectal resection
3243813|NCT00884130||Open|Patients having an open colorectal resection
3243814|NCT00884117||Participants Infected with Influenza|Participants with a positive diagnostic test of influenza and/or displaying symptoms suggestive of influenza-like illness will be enrolled and followed for up to 10 days after informed consent for virological surveillance and assessment of clinical outcomes. Participants may receive treatment including oseltamivir, other treatment/medication, or no treatment.
3243815|NCT00884104|Experimental|1.tamsulosin + solifenacin|
3243816|NCT00884091||Healthy Adults|"Chinese in origin~Healthy~No medication at least two weeks before the study"
3243817|NCT00884078|Experimental|1|C-MAPS (Culturally adapted manualized problem solving training) will be a brief problem focused therapy comprising of 8 sessions within three months after a self-harm episode. We will have two engagement sessions before the actual therapy. The adapted therapy/training will be delivered by therapists/trained counselors in the patient's home/GP practice depending upon patient's choice. Sessions will be offered weekly in the first month and than fortnightly and will last 50 minutes.
3243818|NCT00884078|No Intervention|2 Control group|"Patients who will be randomized to the treatment as usual arm will receive routine care. In most cases this consists of an assessment by a casualty doctor or a junior psychiatrist in the emergency department, on the basis of which about one third patients are referred for follow up as a psychiatry outpatient, a small number are referred to addiction services, and the remainder are advised to consult their own general practitioner (Kapur 1998) this is particularly so in case of Asian females (Cooper et al, 2006). No patients are routinely referred to psychotherapy or psychology services. Participants will receive an initial assessment along with treatment as usual (TAU) as ascertained by the general practitioner or mental health professional any type of treatment apart from C-MAPS will be permitted. We will record the degree of patient adherence to standard care."
3243819|NCT00884065|Experimental|Intervention Group|The intervention group was treated with a single session of DF following the procedure as described by the authors.
3243820|NCT00884065|Placebo Comparator|Control Group|The control group was treated with a single placebo session of DF.
3243821|NCT00884052|Experimental|levetiracetam dose escalation|Escalation of dose after 6 patients treated to 40 mg/kg IV load and 10mg/kg/day maintenance
3243822|NCT00884039|Active Comparator|30 mg anecortave acetate|
3243823|NCT00884039|Active Comparator|15 mg anecortave acetate|
3243825|NCT00884026|Active Comparator|2|Subjects that do not experience hypotension after spinal anesthesia.
3243826|NCT00884013||1|Quality Payment and all clinical reminders turned on
3243827|NCT00884013||2|Quality Payment and ABCS measures reminders turned on
3243828|NCT00884013||3|Quality Payment and non-ABCS measures reminders turned on
3243829|NCT00884013||4|Quality Reporting and Recognition with all clinical reminders turned on
3243830|NCT00884013||5|Quality Reporting and Recognition with ABCS measures reminders turned on
3243831|NCT00884013||6|Quality Reporting and Recognition with non-ABCS measures reminders turned on
3243832|NCT00884000|Active Comparator|1|
3243833|NCT00884000|Experimental|2|
3243834|NCT00883987||Back Pain|"Patients with chronic mechanical low back pain (Chronic low back pain is defined as having pain between the lower ribs and gluteal folds, with minimal radiation to the thigh and never below the knee, present for a minimum of seven weeks)"
3243835|NCT00883974|Experimental|1|
3243836|NCT00883974|No Intervention|2|Standard Neonatal Intensive Care Unit (NICU) procedures for the care of pre-term infants
3243837|NCT00883961|Experimental|Supervised exercise|
3243838|NCT00883961|No Intervention|Control group|The patients will not carry out a structured exercise program.
3243839|NCT00883948|Experimental|1|Participants will receive initial minimal (trophic) enteral feeding.
3243840|NCT00883948|Experimental|2|Participants will receive initial full-calorie enteral feeding.
3243841|NCT00883935|Experimental|Sequence 2|In the first treatment period, all subjects will receive GSK1349572 30mg q24h for 5 days (treatment A). In period two, subjects will receive GSK1349572 30mg q24h in combination with ATV 400mg q24h (treatment C) for 14 days. There will be no washout between treatment periods. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
3243842|NCT00883935|Experimental|Sequence 1|In the first treatment period, all subjects will receive GSK1349572 30mg q24h for 5 days (treatment A). In period two, subjects will receive GSK1349572 30mg q24h in combination with ATV/RTV 300/100mg q24h (treatment B) for 14 days. There will be no washout between treatment periods. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
3243843|NCT00883909||observational|A follow-up study in adult male subjects who have received investigational
3243844|NCT00883896|Placebo Comparator|Arm 1|Part 1: Placebo
3243845|NCT00883896|Experimental|Arm 2|Part 1: 100 mg ILV-094 SC Q4W
3243846|NCT00883896|Experimental|Arm 3|Part 1: 100 mg ILV-094 SC Q2W
3243847|NCT00883896|Placebo Comparator|Arm 4|
3243848|NCT00883896|Experimental|Arm 5|Part 2: 200 mg ILV-094 SC Q2W
3243849|NCT00883883|Experimental|1|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)
3243850|NCT00883883|Active Comparator|2|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)
3243851|NCT00883870|Experimental|mesenchymal stem cells|Intramuscular injection
3243852|NCT00883870|Experimental|Placebo|Intramuscular injection
3243853|NCT00883844|Experimental|1|Continuation of any Nucleos(t)ide analogue treatment and add-on of peginterferon for 24 weeks
3243854|NCT00883844|Active Comparator|2|Continuation of Nucleos(t)ide analogue mono-therapy
3243855|NCT00883831|Experimental|Individualized manual acupuncture|
3243856|NCT00883818|Experimental|Antibiotics therapy|
3243857|NCT00883805||Metal-on-Metal Articulations|Subjects will be people who have had metal-on-metal total hip arthroplasties
3243858|NCT00883805||Ceramic-on-Metal Articulations|Subjects will be people who have had ceramic-on-metal total hip arthroplasties
3243859|NCT00883792|Experimental|Colonoscopy screening|One-time colonoscopy is the screening tool used in this trial. All individuals in the screening group will be offered a full colonoscopy. At colonoscopy, all detected CRC precursor lesions will be removed, whenever possible.
3243860|NCT00883792|No Intervention|Control|"The control group will not be offered any screening or intervention within the trial, but follow usual care in the participating countries. Individuals assigned to the control group will not be informed about their status as controls in the trial. This approach facilitates a truly population-based study, which will be used to estimate the effect of the screening intervention in the general population, mimicking national CRC screening programs.~All ethics committees at the participating centres have approved the study protocol before recruiting individuals to the trial. In Sweden, the national ethics committee particularly reviewed the non-information of the control group and found it ethically acceptable."
3243861|NCT00883779|Experimental|1|
3243862|NCT00883779|Placebo Comparator|2|
3243863|NCT00883766|Active Comparator|Long agonist protocol|
3243864|NCT00883766|Experimental|Antagonist protocol|
3243865|NCT00883753|Experimental|tocilizumab|Participants received tocilizumab 8 mg/kg intravenous (IV), maximum dose not exceeding 800 mg in a single infusion, every 4 weeks for up to 104 weeks or up to 4 weeks after tocilizumab became commercially available in the respective country whichever occurred first.
3243866|NCT00883740|Experimental|Lyrica|flexible dosing Lyrica 300-450mg/day
3243867|NCT00883740|Placebo Comparator|Placebo|Placebo
3243868|NCT00883727|Experimental|stem cells|
3243869|NCT00883727|Placebo Comparator|Placebo|
3243870|NCT00883714|Experimental|Supervised exercise|
3243871|NCT00883714|Active Comparator|Control group|
3243872|NCT00883701||COPD patients|COPD patients who undergo exacerbation
3243873|NCT00883701||Non COPD patients (controls)|Subjects who undergo respiratory infection (acute bronchitis) without COPD or other respiratory illness
3243874|NCT00883688|Experimental|Bevacizumab + Lapatinib|"Bevacizumab 10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week study cycle). Lapatinib Pills of 700 mg/m^2/dose given orally 2 times each day."
3243875|NCT00883675|Experimental|Treatment|Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin Area Under the Curve 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
3243876|NCT00883662||Group 1|
3243877|NCT00883649|Placebo Comparator|1|
3243879|NCT00883636||Focal Segmental Glomerulosclerosis|
3243880|NCT00883636||Non-Focal Segmental Glomerulosclerosis|
3243881|NCT00883623|Experimental|Treatment Arm|Treatment Arm
3243882|NCT00883597||Controls|Patients with ileostomy.
3243883|NCT00883597||Standard Sepsis Treatment|Patients with ileostomy and sepsis
3243884|NCT00883584|Active Comparator|1|IMD-1041
3243885|NCT00883584|Placebo Comparator|2|
3243886|NCT00883571|Active Comparator|house advancement flap|house advancement flap
3243887|NCT00883571|Active Comparator|Rhomboid flap|rhomboid flapa was incised in the ischiorectal fossa. Without undermining of its fatty base, the flap was then mobilized into the anal canal so that the tip could be sutured to the top of the strictured area using Vicryl 3/0 sutures
3243888|NCT00883571|Active Comparator|Y-V anoplasty|Y-V anoplasty
3243889|NCT00883558|Experimental|INSULIN-PH20 NP / Insulin Lispro|"All enrolled participants underwent a 1-month dose titration period and received 100 units per milliliter (U/mL) insulin lispro, injected subcutaneously (SC) pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.~INSULIN-PH20 NP (Treatment A): 100 U/mL non-preserved (NP) formulation of regular human insulin with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, doses titrated to each participant individually.~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, doses titrated to each participant individually.~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine or maintained their usual regimen through an insulin pump."
3243890|NCT00883545|Experimental|Woman endoscopist|
3243891|NCT00883545|Active Comparator|Usual care|
3243892|NCT00883532|Experimental|budesonide|The treatment group will receive surfactant and budesonide.
3243893|NCT00883532|Placebo Comparator|surfactant and air|The placebo group will receive surfactant and air as control.
3243894|NCT00883519|Active Comparator|IPT-A|
3243895|NCT00883519|Active Comparator|IPT-AP|
3243896|NCT00883506|Experimental|1|Lisinopril 40 mg Tablet under fed conditions.
3243897|NCT00883506|Active Comparator|2|Lisinopril 40 mg Tablet (Zestril)
3243898|NCT00883506|Experimental|3|Lisinopril 40 mg Tablet under fasting conditions.
3243899|NCT00883493|Experimental|Quetiapin fumarate XR|Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
3243900|NCT00883493|Experimental|Quetiapin fumarate XR+Lithium carbonate|Quetiapine XR will be administered like monotherapy arm. Lithium will be administered twice daily from Day 1 to Day 56.
3243901|NCT00883480|Experimental|1|
3243902|NCT00883467|Other|1|baseline MR signal prior to, during and 30 minutes after an ischemic period of 20 minutes
3243903|NCT00883467|Other|2|baseline MR signal prior to, during and 30 minutes after an ischemic period of 20 minutes with additional 5 minutes of cuff stenosis directly after cuff release
3243904|NCT00883467|Other|3|short time preconditioning, other details according arm 2
3243905|NCT00883467|Other|4|long time preconditioning, other details according arm 2
3243906|NCT00883441|Experimental|VM|implementation of new vector control tools (insecticide treated curtains and jar covers) through the existing routine vector control programme
3243907|NCT00883441|Experimental|PM|implementation of new vector control tools (insecticide treated covers and curtains) through partnerships
3243908|NCT00883428||Pergnant women|Pregnant women, of 28 weeks or more of gestation, who are seen in the Health Centers participating in the study.
3243909|NCT00883402|Active Comparator|CEA|Carotid endarterectomy
3243910|NCT00883402|Active Comparator|CAS|Carotid Artery Stenting
3243911|NCT00883389||Safe Kidney Care|Patients with Chronic Kidney Disease (eGFR < 60 ml/min/1.732)and not expected to need dialysis within 6 months of enrollment
3243912|NCT00883376||1|OSAS patients
3243913|NCT00883376||2|no OSAS patients
3243914|NCT00883363|Experimental|Precondition|Induction of precondition at start of operation on a arm
3243915|NCT00883363|No Intervention|Control|No precondition
3243916|NCT00883350|Experimental|RIDE|Participants randomized to utilize the RIDE e-health application for the duration of the 12 week intervention.
3243917|NCT00883350|No Intervention|Control|Participants assigned to the Health-Ed (control) group will receive health information via the cell phone throughout the 84-day study. We have generated numerous health information tips for other studies on a variety of topics, including stress management, the benefits of eating fruits and vegetables, etc. [6-9]. These lessons will be modified for delivery via cell phone. We have found that participants assigned to these health information control groups report being satisfied with the information and their assignment. Importantly, our data also indicate that such health information results in very little behavior change or weight loss, e.g., [6].
3243918|NCT00883337|Experimental|Teriflunomide 7 mg / 14 mg|Teriflunomide 7 mg once daily (core treatment period) and teriflunomide 14 mg once daily (extended treatment period).
3243919|NCT00883337|Experimental|Teriflunomide 14 mg / 14 mg|Teriflunomide 14 mg once daily (core treatment period) and teriflunomide 14 mg once daily (extension treatment period).
3243920|NCT00883337|Active Comparator|IFN-β-1a / 14 mg|Interferon β-1a 3 times a week (core treatment period) and teriflunomide 14 mg once daily (extended treatment period).
3243921|NCT00883324||1|fetal fibronectin specimens collected with a speculum
3243922|NCT00883324||2|fetal fibronectin specimens collected without a speculum
3243923|NCT00883298|Experimental|Open Label|temozolomide plus bevacizumab administered as open label single arm treatment
3243924|NCT00883285||1|conventional aortic valve replacement
3243925|NCT00883285||2|transfemoral aortic valve replacement
3243926|NCT00883285||3|transapical aortic valve replacement
3243927|NCT00883272||Normal Controls|25 women with CADP-CT > 66 seconds were treated with Femarelle
3243928|NCT00883272||Thrombophilic|Seven women in cohort of a previous study were found to have shortened closure times (CADP-CT < 61s) at time of enrollment. They all underwent genetic testing for a hypercoagulable state.
3243929|NCT00883259|Experimental|Experimental|Metformin treatment
3243930|NCT00883259|Placebo Comparator|Placebo|Placebo tablets
3243931|NCT00883246|Other|Atherectomy|All patients enrolled in this single-arm study were treated with directional atherectomy.
3243932|NCT00883233|Experimental|1|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks
3243933|NCT00883233|Experimental|2|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks
3243934|NCT00883233|Experimental|3|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
3243935|NCT00883233|Active Comparator|4|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week
3243936|NCT00883220|Experimental|Self-management of urinary catheter|Intervention: Self-management group--teaching behavioral approaches(awareness, self-monitoring, and self-management) to prevent or minimize urinary catheter complications.
3243937|NCT00883220|No Intervention|Usual care 2|Usual care for urinary catheter. Home care and/or clinic care is the usual care for people with long-term urinary catheters.
3243938|NCT00883194|Experimental|1|PRF-108 Gel, 4%
3243939|NCT00883194|Placebo Comparator|2|PRF-108 Gel, Vehicle
3243940|NCT00883194|Active Comparator|3|Ropivacaine Solution 0.5%
3243941|NCT00883194|Experimental|PRF-110, 4%|PRF-110, 4%
3243942|NCT00883168|Placebo Comparator|placebo|
3243943|NCT00883168|Active Comparator|azelastine Hcl|
3243944|NCT00883168|Active Comparator|fluticasone propionate|
3243945|NCT00883168|Experimental|azelastine Hcl /fluticasone propionate|
3243946|NCT00883155|Experimental|1|Bupropion HCl 100 mg Tablets (Invamed Inc.)
3243947|NCT00883155|Active Comparator|2|Wellbutrin 100 mg Tablets (Glaxo Wellcome)
3243948|NCT00883142||Group 1|
3243949|NCT00883129|Experimental|Mycophenolate Arm|Participants will receive oral mycophenolate mofetil for 2 years.
3243950|NCT00883129|Experimental|Cyclophosphamide Arm|Participants will receive oral cyclophosphamide for 1 year, followed by placebo for 1 year.
3243951|NCT00883116|Experimental|Ixabepilone, 40 mg/m^2, intravenously (IV)|Participants received ixabepilone, 40 mg/m^2, given IV over 3 hours every 21 days until unacceptable toxicity or disease progression
3243952|NCT00883116|Active Comparator|Control chemotherapy (Paclitaxel or Doxorubicin)|Participants received either paclitaxel, 175 mg/m^2 given IV over 3 hours, or per institutional guidelines but not exceeding 3 hours, every 21 days until disease progression or unacceptable toxicity or doxorubicin, 60 mg/m^2 given IV per institutional guidelines every 21 days, depending on the prior therapy received, until disease progression, unacceptable toxicity, or cumulative dose of 500 mg/m^2.
3243953|NCT00883103|Active Comparator|Lidocaine|2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
3243954|NCT00883103|Placebo Comparator|Aqueous gel|Plain aqueous gel as placebo will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
3243955|NCT00883090|Experimental|FXIII|All subjects treated with Factor XIII Concentrate (Human) (FXIII)
3243956|NCT00883077||Inflammation|Patients with long standing history or short onset of ulcerative colitis.
3243957|NCT00883077||Healthy controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
3243958|NCT00883077||Irritable bowel syndrome|Patients admitted to outpatient department with symptoms meeting ROME III criteria of irritable bowel syndrome.
3243959|NCT00883064|Experimental|1|Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)
3243960|NCT00883064|Active Comparator|2|Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)
3243961|NCT00883051|Experimental|1|COL-144 50 mg
3243962|NCT00883051|Experimental|2|COL-144 100 mg
3243963|NCT00883051|Experimental|3|COL-144 200 mg
3243964|NCT00883051|Experimental|4|COL-144 400 mg
3243965|NCT00883051|Placebo Comparator|5|Placebo
3243966|NCT00883038|Active Comparator|Active Comparator|Diabetic diet following the DNSG guidelines
3243967|NCT00883038|Experimental|Experimental|Low-fat vegetarian diet
3243968|NCT00883025||1|OSAS patients
3243969|NCT00883025||2|no OSAS Patient
3243970|NCT00883012|Experimental|Influenza vaccine|Two doses of trivalent sub-unit influenza vaccine (2009) to be administered one month apart
3243971|NCT00883012|Placebo Comparator|Placebo|Two doses of saline administered one month apart
3243972|NCT00882999|Placebo Comparator|Placebo|
3243973|NCT00882999|Experimental|4 mg LY2127399 / 4 weeks|
3243974|NCT00882999|Experimental|40 mg LY2127399 / 4 weeks|
3243975|NCT00882999|Experimental|120 mg LY2127399 / 4 weeks|
3243976|NCT00882999|Experimental|4 mg LY2127399 / 12 weeks|
3243977|NCT00882999|Experimental|120 mg LY2127399 / 12 weeks|
3243978|NCT00882999|Experimental|12 mg LY2127399 / 4 weeks|
3243979|NCT00882986||1|Men with high fitness (above VO2max of 60)
3243980|NCT00882986||2|Men with average fitness (below VO2max of 50)
3243981|NCT00882973|Experimental|Cohort 1|Genexol-PM 220 mg/m2 + Gemcitabine 1,250 mg/m2
3243982|NCT00882973|Experimental|Cohort 2|Genexol-PM 260 mg/m2 + Gemcitabine 1,250 mg/m2
3243983|NCT00882973|Experimental|Cohort 3|Genexol-PM 300 mg/m2 + Gemcitabine 1,250 mg/m2
3243984|NCT00882960|Active Comparator|1|patients who are randomized to receive intravenous fentanyl for control of their pain
3243985|NCT00882960|Active Comparator|2|patients who are randomized to receive intra-nasal fentanyl for control of their pain
3243986|NCT00882947||Group 1|
3243987|NCT00882934|Experimental|A1|Arm 1 received an informative letter explaining that they were allocated to receive a substance for Erectile Dysfunction treatment.
3243988|NCT00882934|Placebo Comparator|A2|Arm 2 (A2) was written informed that they could or could not receive an active drug for ED treatment.
3243989|NCT00882934|Experimental|A3|Arm 3 (A3) was properly written informed to be using no effective drug for ED treatment.
3243990|NCT00882921||Elaprase|Idursulfase 0.5 mg/kg Weekly
3243991|NCT00882908|Experimental|TMC435 75 mg 12 Wks + PR 24/48|Participants will receive TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
3243992|NCT00882908|Experimental|TMC435 75 mg 24 Wks + PR 24/48|Participants will receive TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
3243993|NCT00882908|Experimental|TMC435 150 mg 12 Wks + PR 24/48|Participants will receive TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
3243994|NCT00882908|Experimental|TMC435 150 mg 24 Wks + PR 24/48|Participants will receive TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
3243995|NCT00882908|Placebo Comparator|Placebo 24 Wks + PR48|Participants will receive Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.
3243996|NCT00882895|Experimental|Allogeneic Transplant|"TLI - 80 cGy on days -14, -11, -10, -9, -8, -7, -4, -3, -2, -1~Anti-thymocyte globulin (ATG) 1.5 mg/kg on days -11, -10, -8, -7~Solumedrol - 1 mg/kg on days -11, -10, -9, -8, -7~Tacrolimus - beginning on day -3 with starting dose of 0.3 mg/kg PO BID. Will be continued per institutional guidelines.~Stem cell infusion - day 0~Mycophenolate mofetil (MMF) - beginning on day 0 with dose of 15 mg/kg PO (5-10 hours after transplant)"
3243997|NCT00882882|Experimental|1|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
3243998|NCT00882882|Experimental|2|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
3243999|NCT00882882|Active Comparator|3|GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb
3244000|NCT00882882|Active Comparator|4|GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb
3244001|NCT00882856|Active Comparator|Bisoprolol-washout -placebo|Bisoprolol - wash out - placebo
3244002|NCT00882856|Active Comparator|Placebo - wash out - bisoprolol|Placebo - wash out - bisoprolol
3244003|NCT00882843||Group 1|Healthy Able bodied Control
3244004|NCT00882843||Group 2|Spinal Cord Injury
3244005|NCT00882830|Experimental|EMS group|
3244006|NCT00882830|No Intervention|control group|
3244007|NCT00882817|Active Comparator|1|Pulmonary Rehabilitation
3244008|NCT00882817|No Intervention|2|
3244009|NCT00882804|Experimental|Hemin|
3244010|NCT00882804|Placebo Comparator|placebo|
3244011|NCT00882791||Historical Arm|266 cases of BCC treated with Mohs surgery approximately 2-5 years ago will be assessed for recurrence.
3244012|NCT00882791||Prospective Arm|300 cases of BCC will be followed annually for 3 years after Mohs surgery to assess for recurrence.
3244013|NCT00882778||activated recombinant human factor VII|Male patients diagnosed with haemophilia A or B with inhibitors, who were prescribed activated recombinant human factor VII (rFVIIa) for at least 30 days. All direction for rFVIIa medication usage was at the sole discretion of the physician in accordance within their usual practice. Data was collected for approximately 6 months of pre-prophylaxis, while the prophylaxis period had no limits.
3244014|NCT00882765|Experimental|Arm I|Patients receive neoadjuvant oral genistein once daily for 2 weeks in the absence of disease progression or unacceptable toxicity.
3244015|NCT00882765|No Intervention|No intervention|Patients receive no specific neoadjuvant therapy.
3244016|NCT00882752||Ulcerative colitius|The method used to identify the microbes in the sample was chosen because it had the potential to provide more exhaustive identification of the bacteria present in the sample as compared to culturing methodology.
3244017|NCT00882739|Other|no pre-treatment|No pre-treatment at first medical contact - Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
3244018|NCT00882739|Experimental|600 mg loading dose|600 mg clopidogrel loading dose at first medical contact
3244019|NCT00882739|Experimental|900 mg loading dose|900 mg clopidogrel loading dose at first medical contact
3244020|NCT00882726|Experimental|CNTO 3649 IV (Healthy participants)|
3244021|NCT00882726|Experimental|CNTO 3649 SC (Healthy participants)|
3244022|NCT00882726|Experimental|CNTO 3649 SC (Diabetic patients)|
3244023|NCT00882713|Experimental|C.E.R.A.|Eligible participants will be administered continuous erythropoietin receptor activator (C.E.R.A.[Mircera]) intravenously (IV) every 4 weeks for 44 weeks. The starting dose of 120, 200, or 360 micrograms (mcg) will be based on the dose of epoetin alfa or beta administered in the week preceding the switch to C.E.R.A. Subsequent doses will be adjusted to maintain the individual participant's hemoglobin (Hb) within a range of +/- 1.0 grams per deciliter (g/dL) of the reference hemoglobin (Hb) concentration and between 10.50 and 12.50 g/dL.
3244024|NCT00882700|Experimental|1|Cefdinir 300 mg Capsule (Sandoz, Austria)
3244025|NCT00882700|Active Comparator|2|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
3244026|NCT00882687|Experimental|0.1% Lifitegrast|
3244027|NCT00882687|Experimental|1.0% Lifitegrast|
3244028|NCT00882687|Experimental|5.0% Lifitegrast|
3244029|NCT00882687|Placebo Comparator|Placebo|
3244030|NCT00882674|Experimental|1|
3244031|NCT00882661|Experimental|SECURE-C Cervical Artificial Disc|Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc
3244032|NCT00882661|Active Comparator|ASSURE Cervical plate and an allograft interbody spacer|Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
3244033|NCT00882648||Drug dependent women|All drug dependent women enrolled in comprehensive substance abuse treatment at the Center for Addiction and Pregnancy of Johns Hopkins University between 2004 and 2009; retrospective chart review.
3244034|NCT00882635|Experimental|Enoxaparin|
3244035|NCT00882635|Active Comparator|Unfractionated heparin|
3244036|NCT00882622|Active Comparator|RIPC|
3244037|NCT00882622|Sham Comparator|CONTROL|
3244038|NCT00882609|Active Comparator|TC-MDP Bone Scan|Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan
3244039|NCT00882609|Experimental|F18-Fluoride PET/CT|Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan
3244040|NCT00882596|Experimental|1|Contura accelerated partial breast irradiation. Following a lumpectomy, a Contura balloon catheter is placed in the lumpectomy cavity. Later that morning, accelerated partial breast irradiation begins.
3244041|NCT00882583|Other|A|"In both Cohort A and B, there will be an initial run-in period of single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8 and oral dasatinib from day 8-14.~Cohort A will consist of patients with AJCC stage II (T2N0) and III (T1-2N1) SCCHN of oral cavity, oropharynx, T2N0 hypopharynx, T2N0-1 supraglottic larynx. Treatment will be dasatinib in combination with cetuximab and radiation therapy (RT)."
3244042|NCT00882583|Other|B|"In both Cohort A and B, there will be an initial run-in period of single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8 and oral dasatinib from day 8-14.~Cohort B will include patients with AJCC stage III (T3N0-1) and IV (T1-4N2-3M0, T4N0-1M0) squamous cell carcinoma of Oral Cavity, Oropharynx, Hypopharynx, and Larynx. Treatment will be daily dasatinib, in combination with q 3 week cisplatin, weekly cetuximab and RT."
3244043|NCT00882570|Experimental|1|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)
3244044|NCT00882570|Active Comparator|2|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)
3244045|NCT00882557|Experimental|A|9 mg/kg of daptomycin administered during the last 30 minutes of a hemodialysis session.
3244046|NCT00882557|Experimental|B|Post dialysis dosing
3244047|NCT00882544||Diagnosed Pediatric Hydronephrosis|Children diagnosed with hydronephrosis who are to receive robotic pyeloplasty surgery
3244048|NCT00882531|Experimental|Isotretinoin|
3244049|NCT00882531|Placebo Comparator|placebo|
3244050|NCT00882518|Experimental|1-Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)|Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) extended-release (300 mg/1st day, 600 mg/2nd day, 400 or 600 or 800 mg/3-42 day)
3244051|NCT00882518|Active Comparator|2-Chlorpromazine|Chlorpromazine (50 or 100 mg/1st day; 100-200 mg/2nd day; 150-300 mg/3rd day; 200-400 mg/4th day; 300 or 400 or 500 or 600 mg/5-42 days)
3244052|NCT00882505|Experimental|Vitamin D supplement|Receive vitamin D supplements.
3244053|NCT00882505|Placebo Comparator|Placebo|Receive placebo pills
3244054|NCT00882505|No Intervention|Tanning bed user|Regular tanning bed users will be assessed for their vitamin D levels.
3244055|NCT00882492|Active Comparator|1|This active arm is a continuous infusion of GLP-1 during cardiac surgery
3244056|NCT00882492|Placebo Comparator|2|This is a continuous infusion of normal saline solution infusion as placebo at (1.5 pmol/kg/min)
3244057|NCT00882466|No Intervention|PCI only|primary PCI only
3244058|NCT00882466|Experimental|EPO|
3244059|NCT00882453||Group 1|
3244060|NCT00882440|Placebo Comparator|1|Placebo
3244061|NCT00882440|Experimental|2|Losartan 10 mg
3244062|NCT00882440|Experimental|3|Losartan 25 mg
3244063|NCT00882440|Experimental|4|Losartan 50 mg
3244064|NCT00882440|Experimental|5|Losartan 100 mg
3244065|NCT00882440|Experimental|6|Losartan 150 mg
3244066|NCT00882440|Active Comparator|7|Enalapril 20 mg
3244067|NCT00882427|Experimental|eMPC|improved model predictive control algorithm (eMPC) for glycaemic control in ICU patients
3244068|NCT00882414|Placebo Comparator|ThromboVIT Placebo|Patients will receive 1 placebo infusion of 100ml 0.9% sodium chloride every 7 days for a total of 3 infusions.
3244069|NCT00882414|Experimental|ThromboVIT 1000|ThromboVIT 1000: Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride every 7 days for a total of 2 infusions (1000 mg) followed by 1 placebo infusion of 100ml 0.9% sodium chloride.
3244070|NCT00882414|Experimental|ThromboVIT 1500|Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride every 7 days for a total of 3 infusions (1500 mg).
3244071|NCT00882414|Experimental|ThromboVIT 500|ThromboVIT 500: Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride (500 mg) followed by 2 placebo infusions of 100ml 0.9% sodium chloride every 7 days.
3244072|NCT00882401|Active Comparator|Ergocalciferol (oral)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
3244073|NCT00882401|Placebo Comparator|Placebo|Matching placebo at same dose schedule as ergocalciferol
3244074|NCT00882388|Active Comparator|ASA|aspirin only
3244075|NCT00882388|Active Comparator|Cele|
3244076|NCT00882388|Experimental|ASA + Cele|
3244077|NCT00882388|Active Comparator|ASA + Clo|
3244078|NCT00882388|Experimental|ASA + Clo + Cele|
3244079|NCT00882375|Experimental|Nicotine|Nicotine
3244080|NCT00882375|Placebo Comparator|Placebo|Placebo
3244081|NCT00882362|Experimental|1|
3244082|NCT00882336||1|Patients 50+ years old, with at least one additional CV risk factor (with no previous CV event or hospitalization for a CV event)
3244083|NCT00882323|Experimental|Fludarabine|
3244084|NCT00882310|Experimental|Gemcitabine, Docetaxel, Capecitabine GTX|GTX - A two week regimen of Gemcitabine at 600 mg/m2 on days 4 and 1, infused over 60 minutes, Docetaxel at 30 mg/m2 on days 4 and 11, infused over 60 minutes and Capecitabine at 1000 mg/m2 (capped at 1000 mg BID days 1-14) followed by one week off for a total of a 21 day cycle. This is repeated for a total of 6 months.
3244085|NCT00882297|Active Comparator|1|Transversal approach guided placement
3244086|NCT00882297|Active Comparator|2|Longitudinal approach guided placement
3244087|NCT00882271|Experimental|1|Traditional Chinese Acupuncture
3244088|NCT00882271|Placebo Comparator|2|Placebo Acupuncture
3244089|NCT00882258|Experimental|12.5 mg Proellex|Proellex 12.5 mg daily
3244090|NCT00882258|Experimental|25 mg Proellex daily|Proellex 25 mg
3244091|NCT00882258|Placebo Comparator|Placebo|Placebo daily
3244092|NCT00882245|Placebo Comparator|Vehicle ointment|
3244093|NCT00882245|Experimental|SRD441 Ointment|
3244094|NCT00882232|Experimental|1|Cross-linked hyaluronan gel and radiotherapy. Cross-linked hyaluronan gel is injected under anesthesia between the prostate and rectum prior to the start of radiotherapy. The gel pushes the prostate away from the rectum over several months, thereby reducing the dose of radiation delivered to the rectum. Hyaluronic acid is a naturally-occurring substance that is gradually absorbed by the body.
3244095|NCT00882219|Experimental|Xience V®|
3244096|NCT00882206|Experimental|Decitabine / Vorinostat|This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.
3244097|NCT00882167||1|Patients with laparotomy in history
3244098|NCT00882154|Experimental|1|Cefdinir 300 mg Capsule (Sandoz, Austria)
3244099|NCT00882154|Active Comparator|2|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
3244100|NCT00882141|Experimental|1|Weight loss
3244101|NCT00882141|Experimental|2|Exercise plus weight loss
3244102|NCT00882128||1|
3244103|NCT00882115|Experimental|Participants w/wo DEP sensitivity|BSE Extract will be ingested by drinking a liquid formula in a volume equaling less than 1 cup at study Visits 6,7,8, and 9 for subjects with and without DEP sensitivity
3244104|NCT00882102|Experimental|Decitabine + Gemtuzumab Ozogamicin|Decitabine 20 mg/m^2 by vein (IV) over 1-1/2 hours daily for 5 days. Gemtuzumab ozogamicin 3 mg/m^2 by vein on day 5.
3244105|NCT00882089|Experimental|1|A Contura balloon catheter is placed in the lumpectomy cavity. Later that morning, accelerated partial irradiation begins.
3244106|NCT00882076|Experimental|Treatment Plan|Three patients will be enrolled at a given dose level. If one of these patients experiences a dose limiting toxicity (DLT), an additional three patients will be enrolled at the given dose level. Dose escalation may proceed if < 2/6 patients at a given dose level experience a DLT. If > 2/6 patients experience a DLT at a given dose level, the next lower dose level (dose given prior to toxicity) will be considered the recommended phase 2 dose.
3244107|NCT00882076|Experimental|Retreatment|Once a maximum tolerated dose is established, an expanded cohort will be enrolled at that dose for a total of 15 patients to determine a recommended phase 2 dose.
3244108|NCT00882063|Experimental|P276-00|Starting dose level of P276-00 is 50 mg/m2/day. The drug will be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min. Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.
3244109|NCT00882050|Active Comparator|1|Exenatide to be infused by intravenous method at 0.27 ng/kg/min (0.066 pmol/kg/min)
3244110|NCT00882050|Active Comparator|2|IV Exenatide to be infused by intravenous method at0.41 ng/kg/min (0.099 pmol/kg/min)
3244111|NCT00882050|Placebo Comparator|3|Placebo of normal saline solution
3244112|NCT00882037||Meth Dependence|Methamphetamine Dependence in residential Substance Abuse Treatment Program
3244113|NCT00882024|Experimental|1 Tranilast|Tranilast, 300 mg/day
3244114|NCT00882024|Experimental|2 Tranilast|Tranilast, 150 mg/day
3244115|NCT00882024|Placebo Comparator|3|Placebo
3244116|NCT00882011||Arm 1|Adult patients with T-lymphoblastic lymphoma treated with intensive chemo/radiotherapy or intensive chemotherapy followed by transplant.
3244117|NCT00881998|Active Comparator|1|Minimally invasive total hip arthroplasty
3244118|NCT00881998|Active Comparator|2|
3244119|NCT00881985|Active Comparator|continuous positive airway pressure|
3244120|NCT00881985|No Intervention|observation|
3244121|NCT00881972|Experimental|exercise|
3244122|NCT00881959|Experimental|Group 1: Puros Dermis|Experimental treatment group of subjects who each have a single non-adjacent Miller's Class I or II gingival recession defect, greater than or equal to 2 mm, located on the buccal aspect of the maxillary incisor, canine, or premolar.
3244123|NCT00881959|Active Comparator|Group 2: Alloderm|Control group of subjects who each have a single non-adjacent Miller's Class I or II gingival recession defect, greater than or equal to 2 mm, located on the buccal aspect of the maxillary incisor, canine, or premolar.
3244124|NCT00881946|Experimental|GSK2119183|
3244125|NCT00881933|Experimental|Fludarabine|
3244126|NCT00881920|Experimental|Kappa CD28 T cells for B-CLL|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
3244127|NCT00881920|Experimental|Kappa CD28 T cells for B-cell lymphoma|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
3244128|NCT00881920|Experimental|Kappa CD28 T cells for myeloma|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
3244129|NCT00881907|Experimental|Group A|Group A subjects will be asked to attend a recall visit 2 months following completion of the treatment visits.
3244130|NCT00881907|Experimental|Group B|Group B subjects will be asked to attend a recall visit at 4 months following completion of the treatment visits.
3244131|NCT00881907|Experimental|Group C|Group C subjects will be asked to attend a recall visit at 6 months following completion of the treatment visits.
3244132|NCT00881894|Experimental|Sequence A-B (Test: PR2.1.1 - Reference: PR1.0)|Two single applications of rotigotine patches from two different manufacturing processes in the order A-B separated by a washout phase of at least 5 days
3244133|NCT00881894|Experimental|Sequence B-A (Reference: PR1.0 - Test: PR2.1.1)|Two single applications of rotigotine patches from two different manufacturing processes in the order B-A separated by a washout phase of at least 5 days
3244134|NCT00881881||1|Patients with early RA
3244135|NCT00881868|Active Comparator|Clobex Spray|
3244136|NCT00881868|Placebo Comparator|Vehicle spray|
3244137|NCT00881855|Experimental|1|Cefprozil 500 mg Tablets (Sandoz, GmbH)
3244138|NCT00881855|Active Comparator|2|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)
3244140|NCT00881829||Healthy volunteer|Smoker or non-smoker
3244141|NCT00881816|Experimental|Liposomal paclitaxel plus capecitabine|
3244142|NCT00881803||Group 1|Ascorbic Acid Supplementation Only
3244143|NCT00881803||Group 2|Iron Supplementation Only
3244144|NCT00881803||Group 3|Concurrent Ascorbic Acid & Iron Supplementation
3244145|NCT00881790||Fluoride application|
3244146|NCT00881777|Experimental|RF Heating + CABG|Radiofrequency heating of the myocardial infarct scar plus Coronary Artery Bypass Grafting (CABG) surgery
3244147|NCT00881777|Active Comparator|CABG Alone|Coronary Artery Bypass Grafting (CABG) surgery only, without radiofrequency heating of the myocardial infarct scar
3244148|NCT00881764||Exposed Cohort|Children who had inguinal hernia surgery and general anesthesia before 36 months of age (n=500). These children should be ages 8 yr, 0 mo to 15 yr, 0 mo at the time of the study period.
3244149|NCT00881764||Unexposed Cohort|Children who are siblings of the exposed children (inguinal hernia surgery and general anesthesia) and differ in age from the exposed children by less than 36 months and have no history of surgery or exposure to volatile and intravenous anesthetics or sedatives including barbiturates, benzodiazepines and chloral hydrate less than 36 months of age. These children should also be ages 8 yr, 0 mo to 15 yr, 0 mo at the time of the study period.
3244150|NCT00881751|Experimental|Arm 1: bevacizumab and erlotinib|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28.
3244151|NCT00881751|Active Comparator|Arm 2: sorafenib tosylate|Patients receive oral sorafenib tosylate twice daily on days 1-28.
3244152|NCT00881738|Experimental|1|Clarithromycin 250 mg Tablets (Geneva, USA)
3244153|NCT00881738|Active Comparator|2|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)
3244154|NCT00881725|Experimental|Metformin|500mg t.i.d. for 4-12 weeks prior to Radical Prostatectomy
3244155|NCT00881712|Experimental|PET positive nodal disease measuring 15 mm or greater|Proton radiation with concomitant chemotherapy
3244156|NCT00881712|Experimental|PET positive nodal disease measuring less than 15 mm|Proton radiation
3244157|NCT00881712|Experimental|Patients considered resectable|Proton radiation plus surgery
3244158|NCT00881699|Experimental|1|Participants will complete HIV risk reduction group meetings.
3244159|NCT00881699|Active Comparator|2|Participants will complete health promotion group meetings.
3244160|NCT00881686|Experimental|adenosine|Adenosine will be administered intravenously before surgery
3244161|NCT00881673|Experimental|1|
3244162|NCT00881673|Active Comparator|2|
3244163|NCT00881673|Placebo Comparator|3|
3244164|NCT00881660|Experimental|Fetal Endotracheal Occlusion|Placement and retrieval of the GoldBAL4 or GoldBal2 Detachable balloon using the plug/unplug method, using BALTACCIDBPE100 Delivery Catheter.
3244165|NCT00881647|Experimental|1|Participants will receive an 8-week course of cognitive behavioral therapy for insomnia.
3244166|NCT00881647|No Intervention|2|Participants will be placed on a waitlist for 8 weeks.
3244167|NCT00881634|Experimental|1|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)
3244168|NCT00881634|Active Comparator|2|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
3244169|NCT00881621|Experimental|Lapatinib and Capecitabine|Treatment
3244170|NCT00881608|Placebo Comparator|Placebo|Initiation-Placebo Cycle-Five (5) placebo capsules will be dispensed to subjects to self-administer for five days starting on cycle day 18.
3244171|NCT00881608|Experimental|3 mg Proellex|First Cycle (3 mg)- Five (5) 3 mg capsules of Proellex will be dispensed to subjects to self-administer for five days starting on cycle day 18.
3244172|NCT00881608|Experimental|6 mg Proellex|Second Cycle (6 mg)-Subjects, who have not experienced menses, will have their dose of Proellex escalated, and be dispensed ten (10) 3 mg capsules of Proellex to self-administer 2, 3 mg capsules each day for five days starting on cycle day 18.
3244173|NCT00881608|Experimental|12 mg Proellex|Third Cycle (12 mg)-Subjects, who have not experienced menses, will have their dose of Proellex escalated, and be dispensed twenty (20) 3 mg capsules of Proellex to self-administer 4, 3 mg capsules for five days starting on cycle day 18.
3244174|NCT00881608|Experimental|25 mg Proellex|Fourth Cycle (25 mg)-Subjects, who have not experienced menses, will be dispensed five (5) 25 mg capsules of Proellex to self-administer for five days starting on cycle day 18.
3244175|NCT00881595|Other|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Temozolomide five days per week during radiotherapy for 5 weeks. Proton radiation five days per week for 5 weeks Standard surgery will take place 4-6 weeks after completion of chemoradiation.
3244176|NCT00881595|Active Comparator|Chemoradiotherapy Temozolomide|Chemoradiotherapy Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
3244177|NCT00881595|Active Comparator|Proton Therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
3244178|NCT00881582|Experimental|Pegylated interferon alfa-2a plus ribavarin|Pegylated interferon alfa-2a plus ribavarin for 48 weeks
3244179|NCT00881569|Experimental|1|Cs-7017 tablets twice daily at strength 0.25mg
3244180|NCT00881556|Experimental|group 1|Reduced Intensity
3244181|NCT00881543|Placebo Comparator|1|This arm will begin taking the placebo by a month, after a month will be tested the diets (the same caloric amount with different composition on fat, protein and carbohydrates)making curves of insulin, glucagon, C peptide and glp 1 and lipid when diets are tested (three acute tests with diets). After that, the patient will begin the drug by month (Januvia, 100 mg a day)and repeat all the three curves using the prepared diets to compare with the first month.
3244182|NCT00881543|Active Comparator|2|Since the beginning they will use the drug. Then will make the three tests and after will stop the drug by 1 month and come back to do the tests. We objective to demonstrate the washout of the drug clinically.
3244183|NCT00881530|Active Comparator|Sitagliptin|100 mg
3244184|NCT00881530|Active Comparator|Metformin|2000 mg
3244185|NCT00881530|Experimental|BI 10773 X mg|lower dose
3244186|NCT00881530|Experimental|BI 10773 Y mg|higher dose
3244187|NCT00881517|Experimental|Cytotect|
3244188|NCT00881517|Placebo Comparator|placebo|
3244189|NCT00881504|Experimental|"FOLFOX6 and Bevacizumab"|"Intervention = bevacizumab in combination with chemotherapy~Treatment of biliary system carcinoma using Bevacizumab in combination with modified FOLFOX6."
3244190|NCT00881491|Experimental|Group A|Group A - Double antibiotic paste: intracanal medicament consisting of ciprofloxacin and metronidazole
3244191|NCT00881491|Experimental|Group B|Group B - Triple Antibiotic Paste: intracanal medicament consisting of ciprofloxacin, metronidazole, minocycline
3244192|NCT00881491|Active Comparator|Group C|Group C - Mineral trioxide aggregate: used as an apical barrier
3244193|NCT00881478|Active Comparator|Nutrition counselling alone|Nutrition counseling session with registered dietician
3244194|NCT00881478|Experimental|Nutrition counselling + portion control|Nutrition counseling with registered dietician in addition to teaching about use of a portion control tool
3244195|NCT00881465|Experimental|Cognitive-behavioral therapy|Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks. The first session will be held face-to-face to foster rapport. Sessions 1-4 will be held twice weekly; thereafter sessions will be held weekly. Sessions 1-3 are devoted to psychoeducation, treatment discussion, and hierarchy development. Sessions 4-10 involve CBT exercises specific to each youth.
3244196|NCT00881465|Placebo Comparator|Waitlist|Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
3244197|NCT00881452|Active Comparator|CM-AT|CM-AT (Luminenz-AT)- 900mg CM-AT, pancreatic enzyme concentrate (720mg)
3244198|NCT00881452|Placebo Comparator|Placebo|Placebo 900mg (Sucanate (98% w/w), Citric Acid (2% w/w)
3244199|NCT00881439|Placebo Comparator|Placebo|
3244200|NCT00881439|Active Comparator|Aliskiren|
3244201|NCT00881426|Experimental|1|Cefprozil 500 mg Tablets (Sandoz GmbH)
3244202|NCT00881426|Active Comparator|2|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)
3244203|NCT00881413|Experimental|Esomeprazole|High-dose esomeprazole
3244204|NCT00881413|Active Comparator|Pantoprazole|High-dose pantoprazole
3244205|NCT00881400|Experimental|1|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)
3244206|NCT00881400|Active Comparator|2|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)
3244207|NCT00881387|Experimental|Group 1 (eligible for SCT)|Patients receive rituximab IV, vinorelbine ditartrate IV over 6-10 minutes, and gemcitabine hydrochloride IV over 30 minutes on day 1 and pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response (CR) or partial response (PR) undergo SCT.
3244208|NCT00881387|Experimental|Group 2 (ineligible for SCT)|Patients receive rituximab, vinorelbine ditartrate, gemcitabine hydrochloride, and pegfilgrastim as in group 1. Patients with CR, PR, or stable disease after 3 courses continue to receive therapy in the absence of disease progression or unacceptable toxicity.
3244209|NCT00881374|Experimental|Dermacyd Infantile (Lactic Acid)|six weeks treatment
3244210|NCT00881361|Other|Study cohort|Patients who plan to receive or have received neoadjuvant chemotherapy are eligible. Patients undergo examination for breast and axilla lymph adenopathy and then undergo ultrasound of the axillary nodes at baseline and after completion of neoadjuvant chemotherapy. Within 12 weeks of completing neoadjuvant chemotherapy, patients undergo a mastectomy or lumpectomy (per surgeon discretion) including both sentinel lymph node surgery and axillary lymph node dissection.
3244211|NCT00881348|Experimental|Dermacyd infantile (Lactic Acid)|5 weeks treatment
3244212|NCT00881335|No Intervention|control group|
3244213|NCT00881335|Experimental|intervention|Intervention group were given flutter valve mucus clearance devices to do pulmonary function exercise
3244214|NCT00881322|Experimental|BC-130|Active Arm
3244215|NCT00881322|Placebo Comparator|Sugar Pill|Placebo
3244216|NCT00881309|Experimental|immunosuppressor|
3244217|NCT00881296|Experimental|1|"Gemcitabine 1000mg/m2 Day 1,15~Carboplatin AUC=3 Day 1, 15 every 4 weeks"
3244218|NCT00881296|Active Comparator|2|Gemcitabine 1000mg/m2 Day 1, 8, 15
3244219|NCT00881283||cured Cushing's disease|
3244220|NCT00881270|Experimental|Dermacyd infantile (Lactic Acid)|treatment duration 21 consecutive days
3244221|NCT00881257|Experimental|1|GRST Peripheral Catheter System
3244222|NCT00881244|Experimental|1|AS1411
3244223|NCT00881231|Experimental|1|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)
3244224|NCT00881231|Active Comparator|2|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)
3244225|NCT00881218|Experimental|Regadenoson CMR|Images in the cardiac short axis will be obtained using a gradient recalled echo sequence, TR 2.3 msec/TE 1.1 msec, 80*256 matrix, slice thickness 10 mm. Images will be obtained during power injection of 0.075 mmol/Kg of a conventional gadolinium based MR contrast agent at a rate of 5 mL/sec followed by a 15 mL saline flush into an antecubital vein. Perfusion imaging will be performed at stress and rest. Stress: Regadenoson 400 mcg will be administered IV bolus via an antecubital cannula. Immediately after injection, MR scanning will begin and contrast will be given. Rest: After 10 minutes, rest imaging will be performed identically, but without regadenoson injection. To identify late enhancement of myocardial tissue inversion recovery prepared images will be obtained.
3244226|NCT00881205|Experimental|Rivastigmine|Rivastigmine patch arm with the application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size.
3244227|NCT00881205|Placebo Comparator|Placebo|Placebo patch arm with the application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size.
3244228|NCT00881192|No Intervention|Control|No preoperative IABP; if needed, postoperative IABP placement
3244229|NCT00881192|Active Comparator|IABP|Preoperative IABP placement
3244230|NCT00881179|Experimental|1|Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)
3244231|NCT00881179|Active Comparator|2|Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)
3244232|NCT00881166|Experimental|1|oral MP-470 + paclitaxel/carboplatin
3244233|NCT00881166|Experimental|2|oral MP-470 + carboplatin/etoposide
3244234|NCT00881166|Experimental|3|oral MP-470 + topotecan
3244235|NCT00881166|Experimental|4|oral MP-470 + docetaxel
3244236|NCT00881166|Experimental|5|oral MP-470 + Erlotinib
3244237|NCT00881153|Experimental|1|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)
3244238|NCT00881153|Active Comparator|2|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)
3244239|NCT00881140|Experimental|antiprogestin|Daily use of 10 mg administrated per vagina
3244240|NCT00881127|Experimental|1|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)
3244241|NCT00881127|Active Comparator|2|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
3244242|NCT00881114|Experimental|Cetuximab|patients with 2 or fewer genetic variants will receive cetuximab
3244243|NCT00881114|Experimental|Cisplatin|Subjects with 3 to 8 genetic variants will receive cisplatin
3244244|NCT00881101|Experimental|1|Liposomal paclitaxel
3244245|NCT00881088|No Intervention|1|Patients randomized to the no intervention group
3244246|NCT00881088|Experimental|Nadroparin|Subjects randomized to group receiving nadroparin 0,3 cc daily during immobilization
3244247|NCT00881088|Experimental|Fondaparinux|Subjects randomized to fondaparinux 2,5 mg daily group during immobilization
3244248|NCT00881075|Experimental|SeeMore(TM)|intravenous imaging agent for enhanced magnetic resonance imaging.
3244249|NCT00881062|Experimental|25 mg Proellex|25 mg (100 µCi) [14C]-Proellex
3244250|NCT00881023|Active Comparator|1|Randomized to Microfracture
3244251|NCT00881023|Experimental|2|Randomized to Device
3244252|NCT00881023|Experimental|3|Non-randomized with lesion greater than 6cmˆ2
3244253|NCT00881010||Telephone Intervention|
3244254|NCT00881010||Usual Care|
3244255|NCT00880997|Experimental|Doxazosin|The starting dose will be 1 mg once daily at week 1 of the overall 17 week study, then 2 mg at week 2, with 1mg/week induction rate for 8 weeks. The target dose of 8 mg daily will probably not be attained by some patients over a 8 week induction period. We will try to increase their dose up to a minimum of 4 mg and optimum of 8 mg daily as daily dosing.
3244256|NCT00880997|Placebo Comparator|placebo|
3244257|NCT00880971|Experimental|1|
3244258|NCT00880971|No Intervention|2|
3244259|NCT00880958|Experimental|1|
3244260|NCT00880958|Placebo Comparator|2|
3244261|NCT00880945||36-40 patients|patients with small peripheral lesions who need bronchoscopy for diagnostic purposes
3244262|NCT00880932|Experimental|customized electronic alert|"This intervention was not targeted to patients with a disease but to the providers. The intervention was not a drug but a customized electronic alert, requesting the prescriber to specify a reason for override whenever the combination drugs of warfarin and NSAID were ordered together."
3244263|NCT00880932|No Intervention|Standard practice|The control group was not patients but the providers. Providers in the control group continued with the standard practice of receiving passive alerts in the form of message boxes warning the provider not to prescribe the combination drugs warfarin and NSAID.
3244264|NCT00880919|Active Comparator|1|Seroquel XR 150mg oral tablets taken daily for 8 weeks.
3244265|NCT00880919|Active Comparator|2|Seroquel XR 300mg oral tablets taken daily for 8 weeks.
3244266|NCT00880919|Placebo Comparator|3|Equivalent number of placebo oral tablets taken daily for 8 weeks.
3244267|NCT00880906|Active Comparator|A|Group A receives steroids and PPI, (SOC) and esophageal dilation.
3244268|NCT00880906|Sham Comparator|B|Receives steroids and PPI only- Does not have esophageal dilation.
3244269|NCT00880893|Experimental|CYD Dengue Vaccine Group|Participants will receive Sanofi Pasteur's CYD Dengue Vaccine at Day 0, Months 6 and 12, respectively.
3244270|NCT00880893|Sham Comparator|Control Group|Participants will receive a NaCl (placebo) vaccine followed by either 2 Hepatitis A or 2 Influenza vaccines at Months 6 and 12, respectively.
3244271|NCT00880880|Experimental|pre-visit e-PAQ-PF|Participants assigned to fill out the e-PAQ-PF prior to their clinic visit. Participants will arrive early to clinic appointment and fill out e-PAQ-PF. Results will be given to clinician and participant. After their visit they will complete the post visit questionnaire.
3244272|NCT00880880|No Intervention|post-visit e-PAQ-PF|Participants assigned to complete the e-PAQ-PF after their clinic visit. Pre-visit participants will sign consent form - but otherwise will receive no study interventions. Post-visit they will fill out e-PAQ-PF and post visit questionnaire.
3244273|NCT00880867|Experimental|Poly-ICLC|Poly-ICLC plus low dose local radiation.
3244274|NCT00880854|Experimental|1|BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 in combination with CP-675,206 I.V. week 3, week 1
3244275|NCT00880841||no treatment|phase 1a study for healthy normals
3244276|NCT00880828|Experimental|A|FIR cervical collar plus Acetaminophen
3244277|NCT00880828|Active Comparator|B|Conservative cervical collar plus Acetaminophen
3244278|NCT00880828|Placebo Comparator|C|Acetaminophen only
3244279|NCT00880815|Experimental|Bendamustine + Chemotherapy + SCT|Bendamustine starting dose of 70 mg/m^2 by vein over 1 hour on Day -5 through Day -3. Rituximab dose of 375 mg/m^2 by vein over 5-7 hours on Day -13 and 1000 mg/m^2 on Day -6, Day +1 and Day +8 (1 time each week for four weeks). Fludarabine 30 mg/m^2 on Day -5 to Day -3. Infusion of donor blood stem cells - Stem Cell Transplant (SCT) - by vein over 30-45 minutes on Day 0.
3244280|NCT00880789|Experimental|Dose Level One: 5x10^6/m2|CTL Dose Given from Day +30 post SCT (stem cell transplant). For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs. A maximum 18 patients will be accrued into each group. The final MTD will be the dose with probability closest to the target toxicity rate at these termination points. The trial continues until a minimum of 12 patients have been treated. The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD. We therefore expect to enroll between 12-18 patients into this trial.
3244281|NCT00880763|Experimental|Vaniprevir 200 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 100 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
3244325|NCT00880516||case|Adults with chronic sinusitis and positive findings on imaging.
3244326|NCT00880490|Experimental|1|Inhaled PT005 2.4 mcg
3244282|NCT00880763|Experimental|Vaniprevir 600 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 300 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
3244283|NCT00880763|Experimental|Vaniprevir 1200 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 600 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
3244284|NCT00880763|Placebo Comparator|Placebo + peg-IFN + ribavirin|Participants will receive placebo twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
3244285|NCT00880750|Experimental|Lanthanum carbonate granules|Lanthanum carbonate granulated formulation crossover to chewable tablet formulation
3244286|NCT00880750|Experimental|Lanthanum carbonate chewable tablets (Fosrenol)|Lanthanum carbonate chewable table formulation crossover to granulated formulation
3244287|NCT00880737||Stable PE patients|Hemodynamically stable patients with acute symptomatic pulmonary embolism
3244288|NCT00880724|No Intervention|Medical management|
3244289|NCT00880711||1|Patient with advanced BC, already receiving Faslodex therapy
3244290|NCT00880698|Experimental|HIV-uninfected RotaTeq|HIV-1 uninfected participants receiving 3 doses of RotaTeq vaccine at intervals of 4-10 weeks with the third dose administered by 32 weeks of age.
3244291|NCT00880698|Placebo Comparator|HIV-uninfected Placebo|HIV-1 uninfected participants receiving 3 doses of placebo at intervals of 4-10 weeks with the third dose administered by 32 weeks of age
3244292|NCT00880698|Experimental|HIV-infected RotaTeq|HIV-1 infected participants receiving 3 doses of RotaTeq vaccine at intervals of 4-10 weeks with the third dose administered by 32 weeks of age.
3244293|NCT00880698|Placebo Comparator|HIV-1 infected Placebo|HIV-1 infected participants receiving 3 doses of placebo at intervals of 4-10 weeks with the third dose administered by 32 weeks of age
3244294|NCT00880685|Experimental|Memantine|Memantine 10-30mg
3244295|NCT00880672|Active Comparator|dutasteride|oral, 5mg, once per day, 2 weeks
3244296|NCT00880672|Placebo Comparator|placebo|oral, 5mg, once per day, 2 weeks
3244297|NCT00880659|Experimental|1|Promotion of handwashing with soap and maintenance of a fully stocked handwashing station.
3244298|NCT00880659|No Intervention|2|Practice of routine handwashing among the household members
3244299|NCT00880646|Experimental|1|
3244300|NCT00880646|Placebo Comparator|2|
3244301|NCT00880620|Placebo Comparator|Placebo|One Placebo capsule was given TID for the first 21 days. Two placebo capsules were given TID on days 22 till end of study (week 30).
3244302|NCT00880620|Experimental|IPX066 145 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-21. One IPX066 145 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).
3244303|NCT00880620|Experimental|IPX066 245 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. One IPX066 245 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).
3244304|NCT00880620|Experimental|IPX066 390 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. Two IPX066 195 mg LD capsules were given TID on days 22 till end of study (week 30).
3244305|NCT00880607|No Intervention|1|Usual care
3244306|NCT00880607|Experimental|2|Receives DepoDur (morphine) for pain management
3244307|NCT00880594|Experimental|Open label desipramine|
3244308|NCT00880581|Experimental|PF-3512676|Patients will be treated with 18 mg PF-3512676 by intratumoral injection on day 2 following local radiotherapy, then weekly for a total of 10 injections over 10 weeks.
3244309|NCT00880568|Experimental|MK-1496 20 mg (21-Day Cycle)|Participants receiving MK-1496 20 mg on Day 1 of each 21-day cycle
3244310|NCT00880568|Experimental|MK-1496 40 mg (21-Day Cycle)|Participants receiving MK-1496 40 mg on Day 1 of each 21-day cycle
3244311|NCT00880568|Experimental|MK-1496 80 mg (21-Day Cycle)|Participants receiving MK-1496 80 mg on Day 1 of each 21-day cycle
3244312|NCT00880568|Experimental|MK-1496 120 mg (21-Day Cycle)|Participants receiving MK-1496 120 mg on Day 1 of each 21-day cycle
3244313|NCT00880568|Experimental|MK-1496 20 mg (28-Day Cycle)|Participants receiving MK-1496 20 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
3244314|NCT00880568|Experimental|MK-1496 40 mg (28-Day Cycle)|Participants receiving MK-1496 40 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
3244315|NCT00880568|Experimental|MK-1496 80 mg (28-Day Cycle)|Participants receiving MK-1496 80 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
3244316|NCT00880568|Experimental|MK-1496 100 mg (28-Day Cycle)|Participants receiving MK-1496 100 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
3244317|NCT00880568|Experimental|MK-1496 120 mg (28-Day Cycle)|Participants receiving MK-1496 120 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
3244318|NCT00880555||Arm 1: Non-Dementia Memory Disorder|Elderly patients with non-dementia memory disorder (mild cognitive impairment)
3244319|NCT00880555||Arm 2: Control|Elderly controls without memory impairment
3244320|NCT00880555||Arm 3: Mild Alzheimer Disease|Patients with mild Alzheimer disease (but preserved routine activities of daily living)
3244321|NCT00880542|Experimental|Sorafenib + Ifosfamide|"* Neoadjuvant therapy: Patients receive oral sorafenib tosylate twice daily on days 1-14 in course 1. Patients then receive oral sorafenib tosylate twice daily on days 1-28 and ifosfamide IV continuously on days 1-7 in courses 2 and 3. Treatment repeats every 14-28 days* for 3 courses.~NOTE: *Course 1 is 14 days in duration; courses 2 and 3 are 28 days in duration.~Surgery: At least 1 week after the completion of neoadjuvant therapy, patients undergo surgery.~Adjuvant therapy: Beginning ≥ 3 weeks after surgery, patients who respond to neoadjuvant therapy receive oral sorafenib twice daily for 6 months. Patients also receive 2 courses of ifosfamide as in courses 2 and 3 of neoadjuvant therapy."
3244322|NCT00880529|Experimental|ON-Q|Subcutaneous bupivicaine administration and IV opioid medication if necessary
3244323|NCT00880529|Active Comparator|IV opioids alone|Standard therapy with IV opioid administration
3244324|NCT00880516||control|Adults with normal sinuses
3244327|NCT00880490|Experimental|2|Inhaled PT005 4.8 mcg
3244328|NCT00880490|Experimental|3|Inhaled PT005 9.6 mcg
3244329|NCT00880490|Placebo Comparator|4|Inhaled Placebo
3244330|NCT00880490|Active Comparator|5|Formoterol Fumarate 12 mcg (Foradil Aerolizer)
3244331|NCT00880477|Experimental|Group A|
3244332|NCT00880477|Experimental|Group B|
3244333|NCT00880464|Experimental|Vaccine|Biological/Vaccine: Autologous, Lethally Irradiated Breast Cancer Cells Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
3244334|NCT00880425||Participants with continuous headache|
3244335|NCT00880425||Participnts with non-continuous headache|
3244336|NCT00880412|Experimental|EHT 0202 40 mg bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
3244337|NCT00880412|Experimental|EHT 0202 80 mg bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
3244338|NCT00880412|Placebo Comparator|placebo bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
3244339|NCT00880399|Placebo Comparator|Placebo|inactive placebo to match orvepitant 30 and 60 mg dosage forms
3244340|NCT00880399|Experimental|Orvepitant 30 mg|30 mg/day (low dose)
3244341|NCT00880399|Experimental|Orvepitant 60 mg|60 mg/day (high dose)
3244342|NCT00880386|Experimental|Losartan Group|50 mg Losartan tablet taken daily for 24 weeks
3244343|NCT00880373|Active Comparator|1|Diamorphine or Morphine by PCA and oral ibuprofen
3244344|NCT00880373|Placebo Comparator|2|Diamorphine or Morphine by PCA and oral placebo
3244345|NCT00880360|Experimental|Ontak|Administration of Ontak IV for treatment of epithelial ovarian cancer
3244346|NCT00880347|Other|Alzheimer's Disease|Group of patients clinically diagnosed with probable AD
3244347|NCT00880347|Other|Non-AD dementia|Group of patients clinically diagnosed with one of the 5 most frequent non-AD dementia : vascular dementia, mixed dementia, frontotemporal dementia, Lewy bodies dementia, Parkinson's disease dementia.
3244348|NCT00880347|Other|control subjects|Group of control subjects without any clinical cognitive impairment.
3244349|NCT00880334|Experimental|vandetanib & Docetaxel|vandetanib orally and Docetaxel intravenously
3244350|NCT00880334|Active Comparator|Placebo and Docetaxel|Placebo orally and docetaxel intravenously
3244351|NCT00880321|Experimental|Part 1|Part 1 will identify the recommended Part 2 dose using a dose-escalation procedure. Escalation may proceed until either a maximum tolerated dose is established, or the toxicokinetic safety limit is reached. Subjects may dose up to three times a day.
3244352|NCT00880321|Experimental|Part 2|Part 2 will explore further the safety, tolerability, and clinical activity of GSK2118436 in subjects with BRAF mutation-positive tumors using the recommended part 2 dose identified during Part 1. Biologically active doses will be identified by measurement of pharmacodynamic markers in tumor tissue and blood across a range of doses and these doses may be explored in Part 2.
3244353|NCT00880308|Experimental|LDE225|
3244354|NCT00880295|Active Comparator|endoscopic surgery|
3244355|NCT00880295|Active Comparator|open surgery|
3244356|NCT00880282|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 60 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.
3244357|NCT00880269|Experimental|Stratum A|patients with refractory acute myelogenous leukemia (AML) initially diagnosed as de novo AML received 60 mg of panobinostat per day on three discontinuous days per week.
3244358|NCT00880269|Experimental|Stratum B|patients with refractory AML initially diagnosed as AML secondary to myelodysplastic syndrome (MDS)/antecedent hematologic disorder (AHD) received 60 mg of panobinostat per day on three discontinuous days per week.
3244359|NCT00880256|Experimental|MBSR|Patients who undergo mindfulness-based stress reduction will fill out measures of IBS severity before and after the mindfulness course.
3244360|NCT00880243|Experimental|EMA+GM-CSF|"Daunorubicine (CérubidineR) : 80 mg/m2/jour IV over 30 min from day 1 to day 3,~AraC (AracytineR) : 500 mg/m2/jour IV from day 1 to day 3,~Mitoxantrone (NovantroneR) : 12 mg/m2/jour IV over 30 min from day 8 to 9~AraC (AracytineR) : 500 mg/m2/12h IV over 3 hours from day 8 to day10.~GM-CSF (LeucomaxR): 5 µg/kg/jour IV over 6 hours from day 1 to day 10."
3244361|NCT00880243|Active Comparator|EMA without GM-CSF|"Daunorubicine (CérubidineR) : 80 mg/m2/jour IV over 30 min from day 1 to day 3,~AraC (AracytineR) : 500 mg/m2/jour IV from day 1 to day 3,~Mitoxantrone (NovantroneR) : 12 mg/m2/jour IV over 30 min from day 8 to 9~AraC (AracytineR) : 500 mg/m2/12h IV over 3 hours from day 8 to day10."
3244362|NCT00880243|Experimental|HD AraC+ GM-CSF|"AraC (Aracytine) : 3 g/m2/12h IV (3 hours) on days 1, 3 , 5~GM-CSF :5 µg/kg/d IV (6 hours) from day1 to day 5"
3244363|NCT00880243|Active Comparator|HD-AraC without GM-CSF|- AraC (Aracytine) : 3 g/m2/12h IV (3 hours) on days 1, 3 , 5
3244364|NCT00880230|Experimental|Scuba Iliac Stent System|Device: Scuba™ iliac stent
3244365|NCT00880217|Experimental|001|JNJ-31001074 1 mg/d 1-mg capsule once daily for 42 days
3244366|NCT00880217|Experimental|002|JNJ-31001074 3 mg/d 3-mg capsule once daily for 42 days
3244367|NCT00880217|Experimental|003|JNJ-31001074 10 mg/d 10-mg capsule once daily for 42 days
3244368|NCT00880217|Active Comparator|004|Atomoxetine 80 mg/d 40-mg capsule for 3 days followed by 80-mg capsule once daily for 39 days
3244369|NCT00880217|Active Comparator|005|OROS methylphenidate HCl 54 mg/d 36-mg capsule for 3 days followed by 54-mg capsule once daily for 39 days
3244370|NCT00880217|Placebo Comparator|006|Placebo capsule once daily for 42 days
3244371|NCT00880204|Experimental|Trained doctors|ESS-EMCH Training will be provided to doctors working in general emergency, pediatrics and obstetrics department in district hospitals.
3244372|NCT00880204|No Intervention|No Training|No training will be given to doctors (act as controls)
3244373|NCT00880191|Experimental|Arm I|Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral gabapentin once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral gabapentin either two or three times daily on days 2-5 of chemotherapy.
3244416|NCT00879892|Active Comparator|Hypothermia|
3244374|NCT00880191|Experimental|Arm II|Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral placebo once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral placebo either two or three times daily on days 2-5 of chemotherapy.
3244375|NCT00880178||Simvastatin|Participants in the main AIM-HIGH study who are receiving simvastatin.
3244376|NCT00880178||Simvastatin and Extended-Release Niacin|Participants in the main AIM-HIGH study who are receiving simvastatin and extended-release niacin.
3244377|NCT00880165|Active Comparator|Arm 1|In-laboratory testing followed by continuous positive airway pressure treatment
3244378|NCT00880165|Active Comparator|Arm 2|Home unattended testing followed by continuous positive airway pressure treatment
3244379|NCT00880152|Experimental|MBSR|An 8-week course in mindfulness-based stress reduction (MBSR)
3244380|NCT00880152|No Intervention|2|Treatment as usual
3244381|NCT00880126|Experimental|CDT|Community Development Teams bring together counties who are implementing a new practice
3244382|NCT00880113||Acute stroke|Patients over 18 years of age with acute stroke symptoms of less then 9 hours duration and no hemorrhage on non-contrast CT.
3244383|NCT00880100|Experimental|Ultrase® MT12|
3244384|NCT00880087|Experimental|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia after experiencing cardiac arrest.
3244385|NCT00880087|Active Comparator|Therapeutic Normothermia|Participants will receive therapeutic normothermia after experiencing cardiac arrest.
3244386|NCT00880074|Experimental|FLT-PET Scan|FLT solution is administered through a peripheral intravenous catheter approximately 60 minutes before the PET scan. 3 Positron Emission Tomography (PET) scans performed 60-90 minutes after intravenous injection of FLT: 1) within 2 weeks before day 1 of chemotherapy treatment; 2) day 6-7 of chemotherapy treatment; and,3) at end of chemotherapy treatment, day 19-20.
3244387|NCT00880048|Experimental|orvepitant 30 mg|orvepitant 30 mg (low dose)
3244388|NCT00880048|Experimental|orvepitant 60 mg|orvepitant 60 mg (high dose)
3244389|NCT00880048|Placebo Comparator|Placebo|inactive placebo to match orvepitant 30 mg and 60 mg dosage forms
3244390|NCT00880035|Experimental|Group A|Group A: day 1 = music, day 2 = washout, day 3 = headphone without music
3244391|NCT00880035|Experimental|Group B|Group B: day 1 = headphone without music, day 2 = washout, day 3 = music
3244392|NCT00880022|Active Comparator|arm compression only|Intervention of arm compression only by Flexitouch System
3244393|NCT00880022|Experimental|arm, trunk and chest compression|Intervention of arm, trunk and chest compression by Flexitouch System
3244394|NCT00880009|Experimental|1|Combination of Bosutinib and Letrozole
3244395|NCT00880009|Active Comparator|2|Letrozole
3244396|NCT00879996|Active Comparator|1|Methadone 10-60 mg per day in 2-4 divided doses for 6 months
3244397|NCT00879996|Experimental|2|Buprenorphine 4-16 mg per day in 2-4 divided doses for 6 months (using tablets of buprenorphine/naloxone:4/1 mg)
3244398|NCT00879983|Other|Group 1|Will accept azithromycin ER first, after at least 14 days washout, then accept azithromycin tablet.
3244399|NCT00879983|Other|Group 2|Will accept azithromycin tablet first, after at least 14 days washout, then accept azithromycin ER .
3244400|NCT00879970|Active Comparator|pioglitazone|PIO tablet was administered in the dose of 30 milligrams (mg) OD initially and could be titrated to a maximum dose of 45 mg at or after the 6-month visit. After 1 year of treatment, the dose of PIO was increased to 45 mg OD for the duration of 5.5 years.
3244401|NCT00879970|Active Comparator|rosiglitazone|RSG tablet was administered in the dose of 4 mg OD initially and could be titrated to a maximum dose of 8 mg at or after the 6-month visit. After 1 year of treatment, the dose of RSG was increased to 8 mg OD for the duration of 5.5 years.
3244402|NCT00879970|Placebo Comparator|TZD placebo|Matching placebo tablet was administered once a day (OD) for the duration of 5.5 years
3244403|NCT00879970|Active Comparator|Vitamin D|Active comparator
3244404|NCT00879970|Placebo Comparator|Vitamin D placebo|Placebo Comparator
3244405|NCT00879957|Active Comparator|Heparin group|The heparin group is the arm of the study in which all of the subjects will be treated according to current standard medical therapy. All fluids to be infused through their PICCs will have 0.5 units heparin per milliliter of intravenous fluid.
3244406|NCT00879957|Experimental|No heparin group|This group will only receive the prescribed fluids to infuse through their PICCs. No heparin will be added to the intravenous infusions.
3244407|NCT00879944||Psoriasis|Children ages 5-17 years old with moderate or severe plaque type psoriasis. Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
3244408|NCT00879944||Atopic Dermatitis Controls|Children ages 5 to 17 years old with moderate to severe atopic dermatitis. Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
3244409|NCT00879944||Healthy Controls|"Children 5-17 years of age who are healthy and seen in dermatology clinic for a non-systemic skin condition.~Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm"
3244410|NCT00879931|Experimental|1|methylprednisolone
3244411|NCT00879931|Placebo Comparator|2|Placebo (NaCl 0.9%)
3244412|NCT00879918|Experimental|Nicotine pharmacokinetics|circadian smoking protocol and IV pharmacokinetic protocol
3244413|NCT00879905|Experimental|once weekly dosing schedule|
3244414|NCT00879905|Experimental|twice weekly dosing schedule|
3244415|NCT00879892|Active Comparator|Hypothermia and xenon|
3244417|NCT00879879|Experimental|Losartan|50 mg tablets of losartan taken daily by mouth for 1 year
3244418|NCT00879866|Experimental|1|
3244419|NCT00879853|Experimental|Interpersonal Therapy|
3244420|NCT00879853|No Intervention|Wait List Control|
3244421|NCT00879827|Experimental|Single Group|
3244422|NCT00879814|Experimental|1|rLP2086 vaccine 60 mcg
3244423|NCT00879814|Experimental|2|rLP2086 vaccine 120 mcg
3244424|NCT00879814|Experimental|3|rLP2086 vaccine 200 mcg
3244425|NCT00879814|Active Comparator|4|Tdap vaccine - normal saline - normal saline
3244426|NCT00879801||Subjects with IGR|Subjects at high risk of diabetes, such as those with impaired glucose regulation (IFG and or IGT)
3244427|NCT00879788|Experimental|1|Ramipril capsules 10 mg (containing Ramipril 10 mg)of of OHM Laboratories Inc., USA (a subsidiary of Ranbaxy Pharmaceuticals Inc), USA
3244428|NCT00879788|Active Comparator|2|ALTACE® capsule 10 mg (containing Ramipril 10 mg)of King Pharmaceuticals Inc., Bristol, TN 37620, USA
3244429|NCT00879775|Experimental|Caffeine|Intravenous injections of 200mg of caffeine with 100ml of normal saline over 1 hour
3244430|NCT00879775|Placebo Comparator|Placebo|Intravenous injections of 100ml of normal saline over 1 hour
3244431|NCT00879762|Experimental|Group A: High Dose|Single high dose of IMVAMUNE® (5x10^8 TCID50, consisting of two 0.5 mL injections) vaccine on Day 0 and a single saline placebo dose (single 0.5 mL injection) on Day 28 to match the two dose regimen of Group B.
3244432|NCT00879762|Active Comparator|Group B: Standard Dose|Standard two dose regimen of IMVAMUNE® (1x10^8 TCID50) vaccine on Day 0 (consisting of 0.5 mL injection of vaccine and 0.5 mL injection of saline placebo) and Day 28 (single 0.5 mL injection of vaccine).
3244433|NCT00879749|Placebo Comparator|Saline|
3244434|NCT00879749|Experimental|Nexvax2|
3244435|NCT00879736|Active Comparator|THT PACE eLearning module|The PACE (prepare, ask, check, express) training methodology will be available to patients before their 2nd doctor visit
3244436|NCT00879736|Active Comparator|THT PACE eLearning module & nurse-led workshop training|THT PACE eLearning and then nurse-led workshop for training on PACE methodology
3244437|NCT00879736|Placebo Comparator|Usual care|Patients just go to their doctor as they normally would but get some disease specific information in the form of brochures as do intervention arms
3244438|NCT00879723|Experimental|Vitamin and mineral supplementation|Intravenous micronutrient solution or an oral micronutrient supplementation twice per day for 14 days. Treatment is determined by percent total body surface area burned.
3244439|NCT00879723|No Intervention|Control|current vitamin regimen as listed on the Memorial medical Center Order Set for burn unit admission.
3244440|NCT00879710|Other|Subjects with type 1 diabetes mellitus,|"Half the subjects will start with arm (i.e. every other subject in order)~Simvastatin 40 mg tablet by month daily for 6 weeks,~4 weeks washout period~Ezetimibe 10 mg by month for 6 weeks~Half the subjects will start with arm (i.e. every other subject in order)~Ezetimibe 10 mg by month for 6 weeks~4 weeks washout period~Simvastatin 40 mg tablet by month daily for 6 weeks"
3244441|NCT00879710|Other|Subjects with type 2 diabetes mellitus|"Half the subjects will start with arm (i.e. every other subject in order)~Simvastatin 40 mg tablet by month daily for 6 weeks,~4 weeks washout period~Ezetimibe 10 mg by month for 6 weeks~Half the subjects will start with arm (i.e. every other subject in order)~Ezetimibe 10 mg by month for 6 weeks~4 weeks washout period~Simvastatin 40 mg tablet by month daily for 6 weeks"
3244442|NCT00879697|Active Comparator|Strength training|Patients who performed strength training. The strength training program was composed by 8 exercises for whole body performed at sub-maximal intensity prescribed according to the patients self-perceived effort
3244443|NCT00879697|Active Comparator|Walking training|Patients who performed walking training. The walking training was performed in a treadmill using sub-maximal intensity prescribed based in patients self perceived effort
3244444|NCT00879684|Experimental|1|
3244445|NCT00879671|Active Comparator|1|Lutamax
3244446|NCT00879671|Placebo Comparator|2|Placebo
3244447|NCT00879658|Experimental|BAF312 10mg (period 1)|
3244448|NCT00879658|Experimental|BAF312 2 mg (period 1)|
3244449|NCT00879658|Experimental|BAF312 0.5 mg (period 1)|
3244450|NCT00879658|Experimental|BAF312 dose between 0.1 to 8 mg period 2|
3244451|NCT00879658|Experimental|BAF312 dose between 0.1 - 8 mg period 2|
3244452|NCT00879658|Placebo Comparator|Placebo (period 1, 2)|
3244453|NCT00879645|Experimental|Sodium Sulfide - Mild Cohort|Mild renal impairment (RI) Cohort administered 1.5 mg/kg/hr infusion of Sodium sulfide intravenously for 3 hours.
3244454|NCT00879645|Experimental|Sodium Sulfide - Healthy Cohort|Healthy subjects received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
3244455|NCT00879645|Experimental|Sodium Sulfide - Moderate Cohort|Moderate RI cohort received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
3244456|NCT00879645|Experimental|Sodium Sulfide - Severe Cohort|Severe RI cohort received sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
3244457|NCT00879632||1|TREATMENT AS USUAL
3244458|NCT00879632||2|CONTROLS
3244459|NCT00879619|Experimental|Chemotherapy and enzyme inhibitor|Patients receive docetaxel IV over 60 minutes on day 1, prednisone PO BID on days 1-21, and sunitinib malate PO QD on days 2-15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sunitinib malate PO QD on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3244460|NCT00879606|Experimental|1|Participants will be randomized to receive ALT-836.
3244461|NCT00879606|Placebo Comparator|2|Patients will be randomized to receive placebo.
3244462|NCT00879593|Experimental|PtcCO2|
3244463|NCT00879580||Non-ruptured aneurysms|Patients with intracranial aneurysm(s) requiring an endovascular treatment with a Codman ENTERPRISE stent who have one or more non-ruptured or late ruptured (>30days), intracranial aneurysm.
3244464|NCT00879580||Acute ruptured Aneurysms|Patients with intracranial aneurysm(s) requiring an endovascular treatment with a Codman ENTERPRISE stent who have a on or more acute ruptured (<30Days) aneurysms
3244465|NCT00879554|Experimental|1|
3244466|NCT00879541|Other|PK Biostate® [SP]|"Part 1: PK subjects are randomized to receive Biostate® [SP] either on Day 1 or Day 8.~Part 3: All PK subjects receive Biostate® [SP] on Day 180."
3244467|NCT00879541|Other|PK Biostate® [RP]|Part 1: PK subjects are randomized to receive Biostate® [RP] either on Day 1 or Day 8.
3244468|NCT00879541|Experimental|Efficacy|Part 2: This arm includes all subjects during the efficacy component of the study.
3244469|NCT00879515||1|Males and females with fragile X syndrome, ages 5 to 25 years old
3244470|NCT00879515||2|Males and females with the FMR1 premutation, ages 5 to 25 year old
3244471|NCT00879515||3|Males and females with Down syndrome, ages 5 to 25 years old
3244472|NCT00879515||4|Males and females with normal development, ages 5 to 25 years old
3244473|NCT00879502||1|Men with the fragile X premutation
3244474|NCT00879502||2|Healthy men
3244475|NCT00879502||3|Brothers of men with the fragile X premutation
3244476|NCT00879476|Experimental|1|Ramipril capsules 10 mg (containing Ramipril 10 mg)of of OHM Laboratories Inc., USA (a subsidiary of Ranbaxy Pharmaceuticals Inc), USA
3244477|NCT00879476|Active Comparator|2|ALTACE® capsule 10 mg (containing Ramipril 10 mg)of King Pharmaceuticals Inc., Bristol, TN 37620, USA
3244478|NCT00879463|Active Comparator|GROUP A|Brain tissue oxygen saturation monitoring
3244479|NCT00879463|Active Comparator|GROUP B|CONTROL GROUP
3244480|NCT00879450|Experimental|1 Booklet|
3244481|NCT00879450|Active Comparator|2 standard|
3244482|NCT00879437|Experimental|1|
3244483|NCT00879424|Experimental|1|
3244484|NCT00879424|Placebo Comparator|2|
3244485|NCT00879411||arterial hypertension|
3244486|NCT00879398||OAB-Toviaz|All patients who enrolled in this study
3244487|NCT00879385|Experimental|All patients|All participants enrolled.
3244488|NCT00879372|Placebo Comparator|1|Placebo
3244489|NCT00879372|Active Comparator|2|Tianeptine
3244490|NCT00879359|Experimental|I|
3244491|NCT00879346|Experimental|1|160mg oral dose of AZD8931
3244492|NCT00879333|Experimental|Everolimus + BSC|All patients were randomized to receive everolimus + BSC. All patients orally took two 5 mg tablets of everolimus once daily. Therefore, all patients in the everolimus arm took a total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
3244493|NCT00879333|Placebo Comparator|Placebo + BSC|All patients were randomized to receive placebo + BSC. All patients orally took two 5 mg tablets of matching placebo once daily. Therefore, all patients in the placebo receive matching tablets of total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
3244494|NCT00879320||1|Adults with ADHD
3244495|NCT00879320||2|Healthy adults without ADHD
3244496|NCT00879307|Experimental|1|Use of quetiapine
3244497|NCT00879294|Sham Comparator|1 Wristband|Some patients will be randomized to wear a motion sickness wristband which does not have any drug effect.
3244498|NCT00879294|Experimental|Chewing Gum|Patients will be randomized to use chewing gum after surgery.
3244499|NCT00879294|No Intervention|Control|Usual post-operative care.
3244500|NCT00879281|No Intervention|1 Care as usual|Regular care
3244501|NCT00879281|Experimental|2 Intervention|"Regular Care + individualized written action plan to enhance self-mananagement and early detection/treatment of an exacerbation."
3244502|NCT00879255|Experimental|Videoteleconferencing CPT|"The experimental arm is the group condition that received the CPT treatment via videoteleconferencing modality as compared to the experimental condition which is via face-to-face traditional modality.~Cognitive Processing Therapy Group Videoteleconference is delivered to male combat veterans who have been diagnosed with PTSD, through videoteleconference."
3244503|NCT00879255|Active Comparator|Face-to-Face CPT|"The control arm is the group condition that received the CPT treatment via face-to-face traditional modality as compared to the experimental condition which is via videoteleconferencing modality.~Cognitive Processing Therapy Group In-Person is delivered to male combat veterans who have been diagnosed with PTSD, in-person, rather than through videoteleconference."
3244504|NCT00879242|Experimental|Deferasirox|30 mg/kg/day. The daily dose can be increased to 40 mg/kg in case of unsatisfactory response after 12 weeks of treatment.
3244505|NCT00879229|Experimental|Ambrisentan|Participants were randomized to receive ambrisentan treatment at an initial dose of 5 mg for 4 weeks, followed by ambrisentan at the target dose of 10 mg for an additional 52 weeks
3244506|NCT00879229|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match ambrisentan for 48 weeks, then transition to ambrisentan treatment at the initial dose of 5 mg for 4 weeks, followed by ambrisentan at the target dose of 10 mg for an additional 4 weeks.
3244507|NCT00879216|Placebo Comparator|Sugar pill|
3244508|NCT00879216|Experimental|VA106483|
3244509|NCT00879203||Type 1 Diabetes (T1DM)|Youth and young adults with T1DM
3244510|NCT00879203||Non diabetic siblings|Non diabetic, young siblings of T1DM participants
3244511|NCT00879190|Active Comparator|Unasyn (ampicillin/sulbactam)|
3244512|NCT00879190|Active Comparator|Ampicillin/gentamicin|
3244513|NCT00879177|Active Comparator|Group A|Study drug (varenicline) for 12 weeks, brief smoking cessation counseling for 5 weeks, and ambulatory blood pressure monitoring at Weeks 6 and 24.
3244514|NCT00879177|Experimental|Group B|Study drug (varenicline) for 12 weeks, brief smoking cessation counseling for 5 weeks, ambulatory blood pressure monitoring at Weeks 6 and 24, and behavioral therapy for Weeks 2-5.
3244515|NCT00879151|Experimental|Psychotherapy|Patients are randomized to one of three different types of psychotherapy: Cognitive-Behavioral Therapy for adolescents, Family-Based Therapy for Bulimia Nervosa, and Supportive Psychotherapy. All treatments consist of 18 sessions over a period of approximately 6 months.
3244516|NCT00879138|Placebo Comparator|Sugar pill|
3244517|NCT00879138|Experimental|VA106483 2 mg|
3244518|NCT00879138|Experimental|VA106483 4 mg|
3244519|NCT00879138|Experimental|VA106483 8 mg|
3244520|NCT00879112|Experimental|1|MB07811 Cohort 1
3244521|NCT00879112|Experimental|2|MB07811 Cohort 2
3244522|NCT00879112|Experimental|3|MB07811 Cohort 3
3244523|NCT00879112|Placebo Comparator|4|Cohort 4
3244524|NCT00879099|Active Comparator|Paroxetine|
3244525|NCT00879099|Placebo Comparator|Gelatine capsule|
3244526|NCT00879099|Experimental|Timolol 0.5 % eye drops|The plasm levels of timolol will be measured after one drop of timolol has been administered into both eyes.
3244527|NCT00879099|Experimental|Timosan 0.1% eye gel|The plasm levels of timolol will be measured after one drop of timolol has been administered into both eyes.
3244528|NCT00879086|Active Comparator|1|
3244529|NCT00879086|Active Comparator|2|
3244530|NCT00879073|Experimental|A - Cohort 1 Treatment|Cohort 1: Bendamustine 60 mg/m² x 4 weeks
3244531|NCT00879073|Experimental|B - Cohort 2 Treatment|Cohort 2: Bendamustine 80 mg/m² x 4 weeks
3244532|NCT00879073|Experimental|C - Cohort 3 Treatment|Cohort 3: Bendamustine 100 mg/m² x 4 weeks
3244533|NCT00879060|Experimental|spironolactone|
3244534|NCT00879047|Experimental|HIV+, Ritonavir-regimen|10 subjects will be HIV+ and will begin receiving Ritonavir-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
3244535|NCT00879047|Experimental|HIV+/HCV+ Co-infected, Ritonavir-regimen|10 subjects will be HIV+/HCV+ co-infected and will begin receiving Ritonavir-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
3244536|NCT00879047|Experimental|HIV+, Efavirenz-regimen|10 subjects will be HIV+ and will begin receiving Efavirenz-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
3244537|NCT00879047|Experimental|HIV+/HCV+ Co-infected, Efavirenz-regimen|10 subjects will be HIV+/HCV+ co-infected and will begin receiving Efavirenz-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
3244538|NCT00879047|Experimental|Maraviroc in Healthy Subjects|10 healthy subjects will begin receiving maraviroc, and their PK interactions with alcohol/placebo will be evaluated.
3244539|NCT00879034|Experimental|Zoledronic Acid,Pravastatin,and Lonafarnib|Lonafarnib;Zoledronic acid;Pravastatin
3244540|NCT00879021|Placebo Comparator|Pregabalin, (other name) Lyrica|Study subjects wil be randomized to either the Pregabalin or Placebo group. There is a 5o ,50 chance of being in either group.
3244541|NCT00879021|Placebo Comparator|pregabalin, drug|study subjects that are randomized to the placebo group will receive matching placebo
3244542|NCT00879008||Group 1|
3244543|NCT00878995|Placebo Comparator|Standard of Care Therapy + Placebo Testosterone|Patients receive standard of care chemotherapy and/or radiation plus placebo testosterone intramuscularly (IM) weekly for 7 weeks.
3244544|NCT00878995|Active Comparator|Standard of Care Therapy + Testosterone|Patients receive standard of care chemotherapy and/or radiation plus testosterone (Testosterone Enanthate 100mg/ml) intramuscularly (IM) weekly for 7 weeks.
3244545|NCT00878969|Active Comparator|Valsartan|80 mg of valsartan (ARB) taken orally on a daily basis for 1 week followed by 160 mg of valsartan taken orally on a daily basis for 18 months
3244546|NCT00878969|Active Comparator|Ramipril|2.5 mg of ramipril (ACE inhibitor) taken orally on a daily basis for 1 week followed by 5 mg of ramipril taken orally on a daily basis for 18 months
3244547|NCT00878969|Placebo Comparator|Placebo|matching placebo taken orally on a daily basis for 1 week followed by matching placebo taken orally on a daily basis for 18 months
3244548|NCT00878956|Active Comparator|1|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
3244549|NCT00878956|Placebo Comparator|2|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
3244550|NCT00878917|Experimental|Dorzolamide|
3244551|NCT00878904|Experimental|treatment with Panobinostat and Epirubicin|
3244552|NCT00878891|Active Comparator|1. Conventional glucose monitoring|Discontinuous glucose monitoring - GlucoDay Device with Continue record blinded
3244553|NCT00878891|Experimental|2. Conventional glucose monitoring + Glucoday|Continuous glucose monitoring - GlucoDay device with Continue record displayed
3244554|NCT00878878|Experimental|Arm A|
3244555|NCT00878878|Experimental|Arm B|
3244556|NCT00878865|Experimental|Alprazolam 1 mg tablet|Alprazolam 1 mg tablet
3244557|NCT00878865|Active Comparator|Xanax 1 mg tablet|Xanax 1 mg tablet
3244558|NCT00878852|Active Comparator|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of a 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001)
3244559|NCT00878852|Experimental|Experimental|Participants randomly assigned to this group will received standard treatment (including 12 session therapy program) supplemented with an intervention with a contingency management program, designed to improve adherence and efficacy of the treatment program.
3244560|NCT00878839|Other|Toric|AcrySof Toric IOL to assess corneal aberration
3244561|NCT00878826|Active Comparator|Enoxaparin 40 mg per day|
3244562|NCT00878826|Active Comparator|Enoxaparin 1 mg per kg daily|
3244563|NCT00878826|Active Comparator|Pre prescribed regimen of Enoxaparin|Current enoxaparin dose at time of first prenatal visit.
3244564|NCT00878813||1|All consecutive stroke patients undergoing acute intra-arterial revascularisation therapy
3244565|NCT00878813||2|All consecutive stroke patients undergoing acute intra-venous revascularisation therapy
3244566|NCT00878813||3|All consecutive stroke patients treated conservatively
3244567|NCT00878813||4|All consecutive TIA patients
3244568|NCT00878800|Experimental|Experimental: PXD101 and doxorubicin (BelDox)|5-day PXD101 IV schedule with dose escalation combined with 1 day doxorubicin dose escalation IV
3244569|NCT00878787|Experimental|Theta-burst Trancranial Magnetic Stim|
3244570|NCT00878774|Experimental|Cohort 1|ToleroMune Ragweed, subjects to receive either active or placebo comparator
3244571|NCT00878774|Experimental|Cohort 2|ToleroMune Ragweed or placebo comparator
3244572|NCT00878774|Experimental|Cohort 3|ToleroMune Ragweed or placebo comparator
3244573|NCT00878774|Experimental|Cohort 4|ToleroMune Ragweed or placebo comparator
3244574|NCT00878774|Experimental|Cohort 5|ToleroMune Ragweed or placebo comparator
3244575|NCT00878761|Experimental|STX-100 (0.03mg/kg)|8 patients (6 active and 2 placebo)
3244576|NCT00878761|Experimental|STX-100 (0.1mg/kg)|8 patients (6 active and 2 placebo)
3244577|NCT00878761|Experimental|STX-100 (0.3mg/kg)|16 patients (12 active and 4 placebo)
3244578|NCT00878761|Experimental|STX-100 (1mg/kg)|16 patients (12 active and 4 placebo)
3244579|NCT00878748|Experimental|A|Effexor XR
3244580|NCT00878748|Other|B|Effexor XR discontinue
3244581|NCT00878735|Experimental|1|Zen meditation
3244582|NCT00878735|No Intervention|2|No meditation (no intervention; keep regular activities) or a resting group (this group stays at the same place of the retreat group, but only to rest)
3244583|NCT00878722|Experimental|Arm A|"PXD101 administered as a 30-minute intravenous (IV) infusion of 1000 mg/m²/d for five consecutive days every 3 weeks.~Idarubicin administered on day 5 (first steps) or days 4 and 5 (later steps). Patients will be treated in a 21-day cycle for a minimum of 2 cycles and a maximum of 6 cycles (depending on cumulated idarubicin dose)."
3244584|NCT00878722|Experimental|Arm B|PXD101 administered by continuous intravenous infusion over 24-48 hours and idarubicin (in the later steps) added after the first 24 hours. The second cycle will start on day 15 but under observation of possible toxicity. Further cycles will be administered q 14 d for up to 6 cycles. The first dose steps will be carried out with PXD101 alone for safety reasons.
3244585|NCT00878709|Experimental|Neratinib|240 mg orally daily for one year
3244586|NCT00878709|Placebo Comparator|Placebo|orally daily for one year
3244587|NCT00878696||Tinnitus|Tinnitus patients
3244588|NCT00878683|Experimental|1|Device and standard catheter
3244589|NCT00878683|No Intervention|2|Standard catheter
3244590|NCT00878657|Experimental|Radiotherapy plus gemcitabine|"Drug: gemcitabine hydrochloride~Radiation: intensity-modulated radiation therapy"
3244591|NCT00878644|Experimental|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia after experiencing cardiac arrest.
3244592|NCT00878644|Active Comparator|Therapeutic Normothermia|Participants will receive therapeutic normothermia after experiencing cardiac arrest.
3244593|NCT00878631|Active Comparator|1 Normal Saline|infusion of 250 ccs of Normal Saline within 4 hours of the accident
3244594|NCT00878631|Experimental|2 - hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 infused within 4 hours of the accident
3244595|NCT00878618|Experimental|HAB|AZD0837 test- (in session 1) and reference- (in session 2) formulation with heavy breakfast
3244596|NCT00878618|Experimental|HBA|AZD0837 reference- (in session 1) and test- (in session 2) formulation with heavy breakfast
3244597|NCT00878618|Experimental|LAB|AZD0837 test- (in session 1) and reference- (in session 2) formulation with light breakfast
3244598|NCT00878618|Experimental|LBA|AZD0837 reference- (in session 1) and test- (in session 2) formulation with light breakfast
3244599|NCT00878605|Experimental|Cyclo-Z (minimally effective)|3mg CHP plus 20mg zinc containing gel capsule;
3244600|NCT00878605|Experimental|Cyclo-Z (maximally effective)|9mg CHP plus 20mg zinc containing gel capsule;
3244601|NCT00878605|Experimental|Cyclo-Z (not additionally effective)|15mg CHP plus 20mg zinc containing gel capsule
3244602|NCT00878605|Placebo Comparator|Placebo (for CHP)|Placebo capsules containing no zinc or CHP
3244603|NCT00878592|No Intervention|Control group|The first group (Group 1) will include the control subjects. They will receive one session of dietary and behavioral education.
3244604|NCT00878592|Experimental|Dietary and Lifestyle counseling|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of ~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
3244605|NCT00878579|Experimental|PDS System|
3244606|NCT00878579|Active Comparator|Fusion|
3244607|NCT00878566|Active Comparator|Usual Care|
3244608|NCT00878566|Experimental|Enhanced pharmacist care|
3244609|NCT00878553|Placebo Comparator|Placebo|Two placebo tablets administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
3244610|NCT00878553|Experimental|10 mg SKP-1041|One 10 mg SKP-1041 controlled release zaleplon tablet plus one placebo tablet administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
3244611|NCT00878553|Experimental|15 mg SKP-1041|One 15 mg SKP-1041 controlled release zaleplon tablet plus one placebo tablet administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
3244612|NCT00878553|Experimental|20 mg SKP-1041|Two 10 mg SKP-1041 controlled release zaleplon tablets administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
3244613|NCT00878540|Experimental|mirtazapine|
3244614|NCT00878527|Experimental|Treatment with the pump|Treatment with the CircuLite Synergy Pocket Circulatory Assist Device
3244615|NCT00878514|Experimental|Alprazolam|Alprazolam 1 mg tablet
3244616|NCT00878514|Active Comparator|Xanax|Xanax 1 mg tablet
3244617|NCT00878501|Experimental|AZD1386, 90 mg|
3244618|NCT00878501|Experimental|AZD1386, 30 mg|
3244619|NCT00878501|Placebo Comparator|Placebo|
3244620|NCT00878475||Group with obstructive causes of dyspnea|Criteria for clinical assessment of severe asthma (diffuse polyphonic bilateral and particular expiratory wheezes, chest tightness, shortness of breath, using accessory muscles of breathing, signs of hyperinflation, atopic condition, personal or family history of asthma, tachypnea, previous asthma and asthma medications, and the value of modified Boston criteria for HF ≤ 5) and criteria for chronic obstructive pulmonary disease (COPD) exacerbation (history of COPD, COPD medications, cough, worsening dyspnea, increased sputum production and volume, increased sputum purulence, rhonchi and rales, modified Boston criteria for HF ≤ 5)
3244621|NCT00878475||Heart failure group|The investigators protocol for clinical assessment of HF-related acute dyspnea (the prehospital clinical assessment for HF) was designed based on Boston (13) and Framingham criteria for HF (14) (Table 1). The investigators did not use certain criteria from the original protocols, which were not available in the prehospital setting (e.g., chest radiography).
3244622|NCT00878462|Experimental|Sequence 1|Subjects randomly assigned to this sequence receive in order: Treatment A, C, B, A, C, B. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
3244623|NCT00878462|Experimental|Sequence 2|Subjects randomly assigned to this sequence receive in order: Treatment A, B, C, A, B, C. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
3244624|NCT00878462|Experimental|Sequence 3|Subjects randomly assigned to this sequence receive in order: Treatment B, C, A, B, C, A. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
3244625|NCT00878462|Experimental|Sequence 4|Subjects randomly assigned to this sequence receive in order: Treatment B, A, C, B, A, C. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
3244626|NCT00878462|Experimental|Sequence 5|Subjects randomly assigned to this sequence receive in order: Treatment C, B, A, C, B, A. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
3244627|NCT00878462|Experimental|Sequence 6|Subjects randomly assigned to this sequence receive in order: Treatment C, A, B, C, A, B. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
3244628|NCT00878449|Experimental|ABT-263 + etoposide/cisplatin|
3244629|NCT00878436|Experimental|Arm A (120 mg/week)|"Each treatment cycle has 21 days:~Bicalutamide (Casodex®) 50mg P.O. daily, continuously, with the addition of:~40 mg Panobinostat 3 times per week (120 mg per week) for 2 consecutive weeks with one week rest"
3244630|NCT00878436|Experimental|Arm B (60 mg/week)-Closed to accrual|"Each treatment cycle has 21 days:~Bicalutamide (Casodex®) 50mg P.O. daily, continuously, with the addition of:~20 mg Panobinostat 3 times per week (60 mg per week) for 2 consecutive weeks with one week rest"
3244631|NCT00878397|Experimental|1|Free distribution of long lasting insecticide nets to school children and their younger siblings
3244632|NCT00878397|Experimental|2|No school-based delivery of long lasting insecticide nets in the first year, followed by free delivery in the second year
3244633|NCT00878384|Active Comparator|Rate control|Strategy of 'rate-control': acceptance of atrial fibrillation, and dose-adjusted drug therapy as needed to control ventricular rate.
3244634|NCT00878384|Active Comparator|Catheter Ablation|Strategy of 'rhythm control' by catheter ablation: patients will undergo catheter ablation with the intention of restoring sinus rhythm.
3244635|NCT00878371|Other|morphine|All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
3244636|NCT00878358|Active Comparator|Physiotherapy|
3244637|NCT00878358|Experimental|Hydrotherapy|
3244638|NCT00878345|Active Comparator|1|Dexmedetomidine sedation protocol
3244639|NCT00878345|Active Comparator|2|Pentobarbital sedation protocol
3244640|NCT00878332||partially edentulous patients|"Adult (post growth period) patients who are interested in fixed dental rehabilitation (non- removable denture) by dental implants.~Partially edentulous patients with insufficient bone height for dental implant insertion."
3244641|NCT00878319|Active Comparator|Surgical|Surgical intervention: open reduction and internal fixation (ORIF)
3244642|NCT00878319|Active Comparator|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
3244643|NCT00878306|Active Comparator|Disulfiram|Disulfiram
3244644|NCT00878306|Experimental|Disulfiram + Efavirenz|Efavirenz alone, then in addition with Disulfiram
3244645|NCT00878306|Experimental|Disulfiram + Atazanavir|Atazanavir alone, then in addition with Disulfiram
3244646|NCT00878306|Experimental|Disulfiram + Ritonavir|Ritonavir alone, then in addition with Disulfiram
3244647|NCT00878293|Experimental|A|Dose 1, 40 µg
3244648|NCT00878293|Experimental|B|Dose 2, 120 µg
3244649|NCT00878293|Experimental|C|Dose 3
3244650|NCT00878293|Experimental|D|Dose 4
3244651|NCT00878293|Experimental|E|Dose 5
3244652|NCT00878293|Experimental|F|Dose 6
3244653|NCT00878293|Experimental|G|Dose 7
3244654|NCT00878293|Active Comparator|H|Morphin
3244655|NCT00878293|Placebo Comparator|I|Placebo
3244656|NCT00878280||1|1:control(healthy subjects)
3244657|NCT00878280||2|2:case(dementia patients)
3244658|NCT00878267||Interview|
3244659|NCT00878254|Experimental|R-MACLO/IVAM|"Four 21-day cycles, followed by Maintenance Therapy as follows:~Cycles 1 and 3: Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Methotrexate, Leucovorin, and G-CSF per study protocol.~Cycles 2 and 4: Rituximab, Cytarabine, Ifosfamide, Mesna, Etoposide, and G-CSF per study protocol.~Maintenance Therapy: Rituximab: For study participants in complete remission. Every 6 months for up to 3 years, per study protocol."
3244660|NCT00878228|Experimental|Study Group|The study group will receive intraoperative IV ondansetron and also postoperative oral ondansetron tablets (8 mg each day for two days).
3244661|NCT00878228|Placebo Comparator|Control Group|The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days).
3244662|NCT00878215|Experimental|Phase 1:Localize Anatomical Points on Liver Surface|-The surgeon will use image-guided surgery equipment to create the mapping with 3-D pictures of the participants liver. Laser range scanning will also be used to take 3-D pictures of the liver surface. The participant will then have planned standard surgery.
3244663|NCT00878215|Experimental|Phase 2: Ceramic bead|-The surgeon will use image-guided surgery to create the mapping with 3-D pictures of the liver. During the surgery, a ceramic bead will be placed in a pre-operatively determined target location within the tumor using image-guided surgery. Standard surgical procedures will then be used to remove the tumors. Magnetic resonance (MR) images of the resected liver will confirm targeting accuracy.
3244719|NCT00877877|Other|Cervarix Group|Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.
3244664|NCT00878215|Experimental|Phase 3: Ablative therapy|-The surgeon will use image-guided surgery to create the mapping with 3-D pictures of the liver. The liver tumors will be ablated using image-guided surgery. Standard surgical procedures will then be used to remove the portion of the liver that has the ablated tumors. The accuracy of the ablation will be confirmed via pathology sectioning.
3244665|NCT00878215|Experimental|Phase 4: Ablative therapy (not liver resection candidates)|-This phase is for patients who otherwise do not qualify to have a portion of their liver to be surgically removed. The surgeon will use image-guidance to create the mapping with 3-D pictures of the liver. The tumors will be ablated using image-guided therapy.
3244666|NCT00878202|No Intervention|Control|Optimal medical treatment of Heart failure and therapeutic education
3244667|NCT00878202|Experimental|Telemedicine|Optimal medical treatment of heart failure disease and therapeutic education
3244668|NCT00878189|Experimental|1|
3244669|NCT00878176|Experimental|1|(Crossover study)
3244670|NCT00878163|Experimental|Treatment (vismodegib, erlotinib hydrochloride, gemcitabine)|Patients receive Hedgehog antagonist GDC-0449 PO QD and erlotinib hydrochloride PO QD on days 1-28. Some patients also receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3244671|NCT00878150|Experimental|Telephone-based CBT|- 12 counseling sessions over 16 weeks over the telephone
3244672|NCT00878150|Experimental|In-person CBT|- 12 counseling sessions over 16 weeks at either Harborview Medical Center or the University of Washington Medical Center in Seattle, WA
3244673|NCT00878150|No Intervention|3: Usual care|- No counseling sessions as part of this study, however you are free to pursue regular medical care and counseling outside of this study
3244674|NCT00878137||APLA|Patients with antiphospholipid antibody syndrome.
3244675|NCT00878137||Control|Patients on warfarin therapy but without antiphosphilipid antibody syndrome.
3244676|NCT00878124|Experimental|CoQ10|Coenzyme Q10 co-treatment
3244677|NCT00878124|Placebo Comparator|Placebo control|Placebo Co-treatment
3244678|NCT00878111|Experimental|A: escalating dose levels of NGR-hTNF|NGR-hTNF administered at high doses
3244679|NCT00878085|Experimental|1|Robot Therapy with activities of daily living (ADLs)
3244680|NCT00878085|Active Comparator|2|Standard Occupational Therapy
3244681|NCT00878072|Experimental|Famciclovir|
3244682|NCT00878059||Proxies|A family member-caregiver (the medical decision-maker) for someone with Alzheimer's Disease. Must be the person who would be able to make decisions for someone with Alzheimer's disease about being in medical research.
3244683|NCT00878046|Experimental|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
3244684|NCT00878033||1|Diabetic Dialysis Patients
3244685|NCT00878033||2|Non-Diabetic Dialysis Patients
3244686|NCT00878033||3|Healthy Controls
3244687|NCT00878020|Active Comparator|Arm 1|BMS-830216 (10 mg)
3244688|NCT00878020|Active Comparator|Arm 2|BMS-830216 (30 mg)
3244689|NCT00878020|Active Comparator|Arm 3|BMS-830216 (100 mg)
3244690|NCT00878020|Active Comparator|Arm 4|BMS-830216 (300 mg)
3244691|NCT00878020|Active Comparator|Arm 5|BMS-830216 (600 mg)
3244692|NCT00878020|Active Comparator|Arm 6|BMS-830216 (1200 mg)
3244693|NCT00878007|Experimental|1|"Intermittent screening and treatment (IST) for malaria.~This intervention is a change from a previous intervention based on intermittent preventive treatment for malaria owning to the withdrawal of amodiaquine (one of the previous IPT drugs) in Kenya in 2009."
3244694|NCT00878007|Experimental|2|Enhanced teacher training on literacy instruction.
3244695|NCT00878007|Experimental|3|Intermittent screening and treatment (IST) for malaria and enhanced teacher training on literacy instruction
3244696|NCT00878007|No Intervention|4|
3244697|NCT00877994|Active Comparator|Immediate|This group will receive the nurture group therapy immediately after enrolling in the study.
3244698|NCT00877994|Active Comparator|Delayed|This group will receive the nurture group therapy 16 weeks after enrolling in the study.
3244699|NCT00877981|Active Comparator|Videoassited surgery|"In patients randomized to a video-assisted approach, the surgeon has the option to choose either the lateral- (VAPLA) or medial (MIVAP) techniques, both initiated with a 15 mm transverse skin incision. The lateral approach is performed as described by Henry.~The medial approach is performed using the gasless procedure developed by Miccoli."
3244700|NCT00877981|Active Comparator|Open surgery|Open surgery, a 15 mm transverse skin incision is made close to the site of the parathyroid adenoma indicated by sestamibi scintigraphy.
3244701|NCT00877968|Placebo Comparator|Whole wheat banana bread|Banana bread made with whole wheat flour
3244702|NCT00877968|Active Comparator|Whole pea flour banana bread|Banana bread made with whole pea flour
3244703|NCT00877968|Placebo Comparator|Whole wheat biscotti|Biscotti made with whole wheat flour
3244704|NCT00877968|Active Comparator|Whole pea biscotti|Biscotti made with whole pea flour
3244705|NCT00877968|Placebo Comparator|Whole wheat pasta|Pasta made with whole wheat durum
3244706|NCT00877968|Active Comparator|Whole pea flour|Pasta made with 30% whole pea flour and 70% white wheat durum
3244707|NCT00877968|Placebo Comparator|White bread|
3244708|NCT00877968|Placebo Comparator|Boiled yellow peas|
3244709|NCT00877955|Active Comparator|alprazolam sublingual tablet reference|
3244710|NCT00877955|Experimental|alprazolam sublingual tablet test|
3244711|NCT00877942||1|Typically developing children drawn from the general population
3244712|NCT00877942||2|Children with Turner Syndrome
3244713|NCT00877929|Experimental|Telmisartan 80 / Amlodipine 10|Telmisartan 80 / Amlodipine 5 for two weeks, then forced titration to Telmisartan 80 / Amlodipine 10 Fixed Dose Combination
3244714|NCT00877929|Active Comparator|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
3244715|NCT00877903|Experimental|Prochymal®|200M Mesenchymal Stem Cell (MSC) administered via IV infusion
3244716|NCT00877903|Placebo Comparator|Placebo|Placebo via IV infusion
3244717|NCT00877890|Experimental|1|
3244718|NCT00877890|Active Comparator|2|
3244720|NCT00877864|Active Comparator|High volume combined aerobic/resistance exercise|
3244721|NCT00877864|Active Comparator|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
3244722|NCT00877864|Active Comparator|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
3244723|NCT00877864|Active Comparator|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
3244724|NCT00877864|Active Comparator|Printed PA information, pedometers and step log group|Printed physical activity information, pedometers and step log group
3244725|NCT00877864|Placebo Comparator|Control|
3244726|NCT00877851|Experimental|1 CD-ROM|Use of CD-ROM for 12 weeks
3244727|NCT00877851|No Intervention|2 Control|Usual care and list of useful websites
3244728|NCT00877812|Experimental|Arm 1 glycine and leucine infusion|Determine in healthy, adequately pyridoxine nourished humans using a protocol based on amino acid glycine tracer methods: (a) the postprandial rates of in vivo glycine turnover, glycine-based generation of one-carbon units, thymidylate and purine synthesis, and the impact of vitamin B6 deficiency on the rates of these processes and (b) the effect of vitamin B6 deficiency on the postprandial rate of glutathione synthesis. 14 subjects will be chosen after screening is complete and will begin a B6 deficient diet for 30 days. At the beginning and end of the 30 days they will receive an infusion of leucine and glycine then they will begin the four week diet. At the end of four weeks the infusion will be repeated.
3244729|NCT00877812|Experimental|Arm 2 Intervention of Serine and methionine infusion|This arm will allow investigation of total Hcy remethylation and remethylation from serine-derived 1C units, kinetics of serine and the methionine cycle and kinetics of transsulfuration reactions. 14 healthy subjects will be selected and screened. Prior to starting a B6 deficient diet for four weeks an infusion of serine and methionine will commence. Following the first infusion the diet will begin and after four weeks another infusion will be done.
3244730|NCT00877799|Experimental|CR845|CR845 administered as a single 15-min i.v. infusion at doses of 0.008 or 0.024 mg/kg on the day after surgery (Cohort 1), or at a dose of 0.040 mg/kg immediately after surgery (Cohort 2)
3244731|NCT00877799|Placebo Comparator|Placebo|Matched placebo administered as a single 15-min i.v. infusion on the day after surgery (Cohort 1), or the immediately after surgery (Cohort 2)
3244732|NCT00877786|Active Comparator|Face-to-face group therapy|
3244733|NCT00877786|Active Comparator|Online chat group therapy|
3244734|NCT00877773|Experimental|Temsirolimus|Temsirolimus 25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
3244735|NCT00877760|Experimental|ETV + pegIFN|Patients receive Entecavir in a dosage of 0.5 mg once daily per os from day 0, up to week 48. From week 24 to week 48, they also receive pegylated-interferon a-2a in a dose of 180 μg per week s.c. At week 48, response will be assessed. Responders will continue to take Entecavir until week 72, and quit subsequently. Non-responders at week 48 will continue on Entecavir up to week 96.
3244736|NCT00877760|Active Comparator|ETV|Patients receive Entecavir in a dosage of 0.5 mg once daily per os from day 0, up to week 48. At week 48, response will be assessed. Responders will continue to take Entecavir until week 72, and quit subsequently. Non-responders at week 48 will continue on Entecavir up to week 96.
3244737|NCT00877747||PET2 negative|Patients with negative early interim PET after 2 courses of ABVD who continued therapy with ABVD
3244738|NCT00877747||PET2 positive|Patients with positive early interim PET after 2 courses of ABVD who changed their therapy to BEACOPP
3244739|NCT00877734|Experimental|1|Baclofen
3244740|NCT00877734|Placebo Comparator|2|Placebo
3244741|NCT00877721|Experimental|balance treatment|
3244742|NCT00877695|Experimental|Motive8 2 Change FtF|This arm of the motivational enhancement intervention (MEI) will be delivered face to face (FtF) using a real-time, dynamic implementation approach. The intervention consisted of 2 sessions lasting approximately 60 to 90 minutes. The sessions focused on increasing participants' awareness of the multiple influences on behaviors from self, family, culture and community and how these influences impact the way we think and behave including sexually. Through a series of exercises the participant develops strategies for understanding and managing his own triggers that helps them to make healthy life choices. Both Motiv8 2Change arms used the exact same intervention, with the exception that one was delivered face to face and the other through the internet.
3244743|NCT00877695|Experimental|Motive8 2Change -Internet|This arm of the motivational enhancement intervention (MEI) will be delivered via the Internet face to face (FtF) using a real-time, dynamic implementation approach.The intervention consisted of 2 sessions lasting approximately 60 to 90 minutes. The sessions focused on increasing participants' awareness of the multiple influences on behaviors from self, family, culture and community and how these influences impact the way we think and behave including sexually. Through a series of exercises the participant develops strategies for understanding and managing his own triggers that helps them to make healthy life choices. Both Motiv8 2Change arms used the exact same intervention, with the exception that one was delivered face to face and the other through the internet.
3244744|NCT00877695|No Intervention|delayed|
3244745|NCT00877695|Active Comparator|Motiv8 2Change Careers|Comparable in number of sessions and duration to the experimental arms, but focused on resume development and interviewing skills. This arm consisted of 2 sessions. In the first session participants reviewed different career choices and created a winning resume. The second session focused on job interviewing skills. It included role plays with feedback. It also contains ethically mandated information regarding HIV prevention. It was delivered on line by a trained facilitator.
3244746|NCT00877682|Experimental|Cryotherapy|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
3244747|NCT00877669|Active Comparator|Transurethral resection of the prostate|TURP group
3244748|NCT00877669|Experimental|Holmium Laser Enucleation of Prostate|HoLEP group
3244749|NCT00877656|Experimental|CD4|Open label treatment arm
3244750|NCT00877643|Experimental|Upstream rhythm control|
3244751|NCT00877643|Active Comparator|Conventional rhythm control|
3244752|NCT00877630||1:endoscopic group|patients underwent endoscopic thyroidectomy
3244753|NCT00877630||2:conventional group|patients underwent open thyroidectomy
3244754|NCT00877617||QOL Questionnaire|
3244755|NCT00877604|Experimental|TUDCA|tauroursodeoxycholic acid di-hydrate
3244756|NCT00877604|Placebo Comparator|placebo|excipient lactose
3244757|NCT00877591|Experimental|1|Buprenorphine + Fosamprenavir/Ritonavir
3244758|NCT00877591|Active Comparator|2|Control Fosamprenavir/Ritonavir
3244759|NCT00877591|Experimental|3|Buprenorphine + Darunavir/Ritonavir
3244760|NCT00877591|Active Comparator|4|Control Darunavir/Ritonavir
3244761|NCT00877591|Experimental|5|Buprenorphine + Rifampin
3244762|NCT00877591|Experimental|6|Buprenorphine + Rifabutin
3244763|NCT00877578|Experimental|1|Nutri-Energie ®, a cake of high caloric density and palatability, twice a day for 4 weeks, in addition to an enriched diet.
3244764|NCT00877578|Active Comparator|2|Clinutren 1.5 ® standard isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet.
3244765|NCT00877552||Control|Typically developing
3244766|NCT00877552||Mild ventriculomegaly (MVM)|Fetal isolated mild ventriculomegaly
3244767|NCT00877552||Schizophrenia High Risk|Offspring of mothers with schizophrenia
3244768|NCT00877552||Bipolar High Risk|Offspring of mothers with schizophrenia
3244769|NCT00877539|Experimental|PF-03526299|
3244770|NCT00877539|Placebo Comparator|Placebo|
3244771|NCT00877539|Active Comparator|Fluticasone propionate|
3244772|NCT00877526||A|
3244773|NCT00877513|Experimental|Smokers|Cigarette smokers wishing to quit
3244774|NCT00877500|Experimental|Group 1 Ixabepilone|Ixabepilone 40 mg/m^2 by vein over 3 hours on Day 1 of each 21-day study cycle for up to 6 cycles.
3244775|NCT00877500|No Intervention|Group 2 Observation|Standard of care treatments for disease.
3244776|NCT00877487|Experimental|SPD489|
3244777|NCT00877487|Placebo Comparator|Placebo|
3244778|NCT00877474|Experimental|Arm 1|PM01183 administered i.v. over one hour, on Day 1, every three weeks, at a starting dose of 20 µg/m2.
3244779|NCT00877448|Experimental|Multimeric-001 250 Mcg|Multimeric-001 250 Mcg in PBS
3244780|NCT00877448|Experimental|Adjuvanted Multimeric-001 250 Mcg|250 Mcg in montanide
3244781|NCT00877448|Placebo Comparator|Phosphate Buffered saline|Non-adjuvanted placebo
3244782|NCT00877448|Placebo Comparator|Adjuvanted PBS|Adjuvant was montanide
3244783|NCT00877448|Experimental|Multimeric-001 500 Mcg|Multimeric-001 in PBS
3244784|NCT00877448|Experimental|Adjuvanted Multimeric-001 500 Mcg|Adjuvant was montanide
3244785|NCT00877448|Experimental|Multimeric-001 125 Mcg|Multimeric-001 in PBS
3244786|NCT00877435|Experimental|1|Cognitive behavioral therapy (CBT) + prize-based contingency management (prizeCM)
3244787|NCT00877435|Active Comparator|2|Cognitive behavioral therapy (CBT)
3244788|NCT00877422|No Intervention|Group A|Group A is identified as serum vitamin D level more than 16 ng/dl.
3244789|NCT00877422|Active Comparator|Group B|Group B is identified as serum vitamin D level less than 16 ng/dl and is supplemented with vitamin D3.
3244790|NCT00877422|No Intervention|Group C|Group C is identified as serum vitamin D less than 16 ng/dl and is not supplemented with vitamin D3.
3244791|NCT00877409|Active Comparator|Acnase|
3244792|NCT00877409|Placebo Comparator|Vehicle|
3244793|NCT00877396|Experimental|Influenza|Inactivated Influenza vaccination
3244794|NCT00877396|Placebo Comparator|Control|Hepatitis A vaccine
3244795|NCT00877383|Experimental|Indacaterol 150 μg and tiotropium 18 μg|Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single-dose dry-powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3244796|NCT00877383|Active Comparator|Tiotropium 18 μg|Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single-dose dry-powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3244797|NCT00877370|Experimental|ertapenem|subjects will receive ertapenem while receiving CVVHD
3244798|NCT00877357|Experimental|Shan 5 Lot No 1|
3244799|NCT00877357|Experimental|Shan 5 Lot No 2|
3244800|NCT00877357|Experimental|Shan 5 Lot No 3|
3244801|NCT00877344|Experimental|1|Immediate insertion of either a LNG-IUC or a Copper T380 IUD after 12-24 week abortion
3244802|NCT00877344|Experimental|2|Interval insertion (two to four weeks post abortion) of either a LNG-IUC or a Copper T380 IUD after 12-24 abortion
3244803|NCT00877331|Experimental|1|Brief intervention using motivational interviewing. One in-person session (30-45 minutes) with a brief phone follow-up one week later.
3244804|NCT00877331|No Intervention|2|Enhanced care as usual.
3244805|NCT00877318|No Intervention|Control|Program of cardiac rehabilitation introduced in complete hospitalization pursued in day hospital during 3 months
3244806|NCT00877318|Experimental|telemedicine|Program of cardiac rehabilitation introduced in complete hospitalization pursued at home via a terminal during 3 months
3244807|NCT00877305|Active Comparator|RIPC|Remote Ischemic Preconditioning
3244808|NCT00877305|Placebo Comparator|CONTROL|Control
3244809|NCT00877292||Down syndrome|Women having CVS or amniocentesis who, as a group, have a high prevalence of Down syndrome.
3244810|NCT00877279|Experimental|Belotero® Soft|Comparator will be given into the opposite side of the face that Belotero® Soft was administered for facial wrinkles, such as nasolabial folds.
3244811|NCT00877279|Active Comparator|CosmoDerm1|
3244812|NCT00877266|Active Comparator|1. Ultrasound|Ultrasound is randomly chosen by use of a computer program. The time for catheter placement will begin with the ultrasound probe touches the patient. Patients will be asked their discomfort on a 0-10 scale (0=no discomfort and 10=worst discomfort imaginable) and will be called the next day by the research staff.
3244942|NCT00876265|Active Comparator|Zyplast|
3244943|NCT00876252|Active Comparator|IC43 100 mcg|IC43 100 mcg with Aluminum hydroxide
3244813|NCT00877266|Active Comparator|2. Electrical Stimulation|Nerve Stimulation (electrical stimulation) is randomly chosen using a computer program. Time of placement begins when the catheter-placement first touches the patient. After catheter placement patient is asked their discomfort on a 0-10 scale (0=no discomfort and 10=worst discomfort imaginable) and called the day after surgery by the research staff.
3244814|NCT00877253|Experimental|Dose Level One|
3244815|NCT00877253|Experimental|Dose Level Two|
3244816|NCT00877253|Experimental|Dose Level Three|
3244817|NCT00877240|Other|Lifestyle counseling|
3244818|NCT00877227|Experimental|folinic acid|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns
3244819|NCT00877227|No Intervention|2|control subjects admitted at the Neonatal Intensive Care Unit (NICU)
3244820|NCT00877214|Experimental|Rituximab|Follicular Lymphomas: Rituximab 375 mg/m² for additional 2 years after 2 years of standard maintainance All other lymphomas: Rituximab 375 mg/m² for 2 years as maintainance. From 2014 only Morbus Waldenstroem: Rituximab 1.400 mg absolute s. c. injection
3244821|NCT00877214|Active Comparator|Standard|Rituximab / Observation
3244822|NCT00877188|Experimental|exercise|supervised combined aerobic and resistance training for 12 weeks
3244823|NCT00877188|No Intervention|control|waist list control with usual care
3244824|NCT00877175|Experimental|1|Lower conjunctival fornix packing arm. For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix.
3244825|NCT00877175|Active Comparator|2|Conventional instillation arm. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
3244826|NCT00877162|Experimental|1|Providing parents with a group teaching intervention (2 hours long). The teaching session is followed by 2 weeks of phone calls twice a week to offer parents support for their use of the strategies described in the teaching session and to clarify any questions about the teaching session content. The arm will have baseline data collected one week prior to the teaching session. Follow-up data will be collected at 6 and 24 weeks post intervention. A pamphlet on infant safety will be distributed to the intervention arm following the 6 week data collection point. A pamphlet on managing behavioural sleep problems will distributed to the control group following the 6 week data collection point.
3244827|NCT00877149|Experimental|A|
3244828|NCT00877123|Experimental|Vitamin D|Intervention arm: Oral vitamin D 100,000 IU once a month for three consecutive months.
3244829|NCT00877123|Placebo Comparator|Placebo|
3244830|NCT00877110|Experimental|chemotherapy, allogeneic NK cells, 3F8|This is a phase I study to assess the safety and feasibility of combining HLA-mismatched (KIR ligand incompatible) NK cells with 3F8 in high-risk NB patients. Following chemotherapy, patients will be treated in sequential groups of 3 patients/dose of NK cells. Four dose levels of NK cells, starting at dose level I, will be evaluated in this treatment protocol. In the unlikely case toxicity is encountered at dose level I, patients will then be treated at the lower dose level 0. Patients can receive up to 3 cycles of treatment on protocol. For subsequent cycles, patients will be treated at either less than or at the same dose level of NK cells as their first cycle.
3244831|NCT00877097|Experimental|1|Clodronate 800 mg / day + estradiol 2 mg + norethisterone acetate 1 mg / day for five years.
3244832|NCT00877097|Placebo Comparator|2|Placebo 2 tablets/ day + estradiol 2 mg + norethisterone acetate 1 mg / day for five years.
3244833|NCT00877097|Active Comparator|3|Clodronate 800 mg / day for five years.
3244834|NCT00877084|Experimental|1|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
3244835|NCT00877084|Placebo Comparator|2|Usual care according to clinical pathway for COPD exacerbations + NO training
3244836|NCT00877071|Experimental|LC Drug Eluting Bead, Regional Chemoembolization|Use of LC Drug-Eluting Beads for chemoembolization will provide a method for downstaging patients with hepatocellular carcinoma which is not amenable to surgical resection or local ablative therapy to liver transplant eligibility
3244837|NCT00877058|Experimental|1.Preventive home visit|Preventive home visits: This intervention included a single home visit made by either a nurse, a physiotherapist, a qualified social worker or an occupational therapist. Participants received verbal and written information/advice about what the districts could provide. The preventive home visit was guided by a protocol, which included an opportunity for individuals to further elaborate on certain elements. The visit lasted between one and a half to two hours.
3244838|NCT00877058|Experimental|2. Senior meetings|The senior meetings comprised four weekly meetings with about six participants in each group. The main purpose was to focus on two different topics: 1) information about the ageing process and its consequences and 2) provision of tools and strategies for solving problems that can arise in the home environment. A follow-up home visit took place two to three weeks after the group sessions were completed. The group meetings were led either by an occupational therapist, a registered nurse, a physiotherapist or a qualified social worker, all of whom spoke about their particular dimension of aging.
3244839|NCT00877058|No Intervention|3. Control group|The control group had access to the ordinary range of services if requested from the urban districts for the aged. The aim of the municipal provision of care for the older persons is to ensure the ability to live as independently as possible. This includes remaining in their homes. When an older person in Sweden has difficulties managing independently, she or he can apply for assistance from the district. The extent of such support is subject to an assessment of needs and includes meals on wheels, help with cleaning and shopping, assistance with personal care, safety alarms and transportation service. The older person are also offered healthcare, provided either by municipal home help or home medical care services.
3244840|NCT00877032|Experimental|Arm 1|
3244841|NCT00877006|Experimental|Bendamustine and Rituximab (BR)|Participants received the investigational bendamustine and rituximab regimen for 6 to 8 28-day cycles: bendamustine 90 mg/m^2 intravenous (IV) on Days 1 and 2; rituximab 375 mg/m^2 IV on Day 1
3244842|NCT00877006|Active Comparator|R-CHOP/R-CVP|"Participants received the standard regimen (R-CHOP or R-CVP) for 6 to 8 21-days cycles.~R-CHOP: rituximab 375 mg/m^2 IV on Day 1; vincristine 1.4 mg/m^2 (up to 2 mg/m^2 maximum dose) IV on Day 1; doxorubicin 50 mg/m^2 IV Day 1; cyclophosphamide 750 mg/m^2 IV Day 1; prednisone 100 mg oral on Days 1 to 5~R-CVP: rituximab 375 mg/m^2 IV on Day 1; cyclophosphamide 750 mg/m^2 IV on Day 1 or cyclophosphamide 1000 mg/m^2 IV on Day 1; vincristine 1.4 mg/m^2 (up to 2 mg/m^2 maximum dose) IV on Day 1; prednisone 100 mg oral on Days 1 to 5"
3244843|NCT00876993|Experimental|Dose Level 0|Bevacizmuab 10 mg/kg Irinotecan 125 mg/m2 Temozolomide 75 mg/m2
3244844|NCT00876993|Experimental|Dose Level 1|Bevacizmuab 10 mg/kg Irinotecan 125 mg/m2 Temozolomide 125 mg/m2
3244845|NCT00876993|Experimental|Dose Level 2|Bevacizmuab 10 mg/kg Irinotecan 125 mg/m2 Temozolomide 175 mg/m2
3244846|NCT00876993|Experimental|Dose Level 3|Bevacizmuab 10 mg/kg Irinotecan 125 mg/m2 Temozolomide 200 mg/m2
3244847|NCT00876993|Experimental|Dose Level 4|Bevacizmuab 10 mg/kg Irinotecan 150 mg/m2 Temozolomide 200 mg/m2
3244848|NCT00876980|Active Comparator|1|nasal Continuous Positive Airway Pressure treatment for 3 months
3244849|NCT00876980|No Intervention|2|controls have no treatment, being observed for 3 months
3244850|NCT00876967|Experimental|1|metallic single use blade
3244851|NCT00876967|Experimental|2|plastic single use blade
3244852|NCT00876967|Active Comparator|3|metallic reusable blade
3244853|NCT00876954|Placebo Comparator|Placebo|Warming without increase in core temperature
3244854|NCT00876954|Active Comparator|Hyperthermia|Hyperthermia for 2,5 hours (39 °C core temperature)
3244855|NCT00876941|Experimental|Standard Brief Intervention|
3244856|NCT00876941|Experimental|Enhanced Brief Intervention|
3244857|NCT00876941|Active Comparator|Control|
3244858|NCT00876928|Placebo Comparator|Placebo|Subjects with low vitamin D levels and pre-diabetes
3244859|NCT00876928|Experimental|vitamin D|Subjects with low vitamin D levels and pre-diabetes
3244860|NCT00876915|Experimental|High Risk for VTE recieving dalteparin|Patients assigned at random to receive prophylactic dalteparin injections
3244861|NCT00876915|No Intervention|High Risk for VTE No therapy|No prophylactic therapy for VTE prevention given (Subjects receiving standard of care)
3244862|NCT00876915|No Intervention|Low Risk for VTE|Used as a control for the secondary outcome of evaluating tissue factor in collected blood samples
3244863|NCT00876902|Experimental|1|Active Group: (18 subjects) YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient PRIOR to arterial reperfusion of the liver. One extra IV dose of 1 mg/kg will be given at the end of the procedure only to patients that have experienced an intraoperative blood loss of greater than 10 units.
3244864|NCT00876902|Placebo Comparator|2|Placebo Control: (18 subjects) Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient PRIOR to arterial reperfusion of the liver. One additional infusion of 0.1 mL/kg placebo control (saline) will be given at the end of the procedure to patients that have experienced an intraoperative blood loss of greater than 10 units.
3244865|NCT00876876|Placebo Comparator|Placebo QD or BID|Placebo QD or BID
3244866|NCT00876876|Experimental|Lixivaptan QD or BID|Lixivaptan QD or BID
3244867|NCT00876863|Experimental|CERE-110|CERE-110: Adeno-Associated Virus Delivery of NGF
3244868|NCT00876863|Sham Comparator|Placebo|Placebo Surgery
3244869|NCT00876850|Experimental|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
3244870|NCT00876850|Active Comparator|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
3244871|NCT00876837||Adults with pediatric-onset SCI|
3244872|NCT00876824|Experimental|Amphotericin B lipid emulsion|Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A Drug: Amphotericin B lipid emulsion
3244873|NCT00876824|Active Comparator|Liposomal Amphotericin B|Liposomal Amphotericin B in visceral leishmaniasis - 15mg/kg on day 1 in Group B
3244874|NCT00876811|Experimental|one-cup|
3244875|NCT00876811|Experimental|two-cups|
3244876|NCT00876811|Experimental|four-cups|
3244877|NCT00876798|Experimental|1|Lixivaptan
3244878|NCT00876798|Placebo Comparator|2|Placebo
3244879|NCT00876785|Active Comparator|1|Reference wheat bread breakfast
3244880|NCT00876785|Experimental|2|Rye bread breakfast
3244881|NCT00876759|Active Comparator|WBRT|standard WBRT to a total dose of 30 Gy in 10 fractions
3244882|NCT00876759|Experimental|WBRT with simulatneous boost|The experimental group will be treated with helical tomotherapy giving 3 Gy per fraction to the whole brain up to a total dose of 30 Gy in 10 fractions and raising the prescribed dose to the brain metastases to 5 Gy per fraction. The dose fall off to the normal brain should be as steep as possible around each brain metastasis. The optic chiasm and the optic nerves should not receive more than 3.5 Gy per fraction.
3244883|NCT00876746|Active Comparator|1. Supraclavicular|Patients will be randomized to placement of a nerve block in the supraclavicular position. After the catheter has been placed, sensory and motor deficit will be assessed and following surgery, for the next three days, the patient will be contacted by research staff to assess pain scores and other outcome measures.
3244884|NCT00876746|Active Comparator|2. Infraclavicular|Patients will be randomized to placement of a nerve block in the infraclavicular position. After the catheter has been placed, sensory and motor deficit will be assessed and following surgery, for the next three days, the patient will be contacted by research staff to assess pain scores and other outcome measures.
3244885|NCT00876733||HIV treatment|
3244886|NCT00876720|Experimental|1|Combined frontal and temporal transcranial magnetic stimulation
3244887|NCT00876720|Experimental|2|Temporal transcranial magnetic stimulation
3244888|NCT00876707|Active Comparator|Tecnis|
3244889|NCT00876707|Active Comparator|ReSTOR|
3244890|NCT00876707|Active Comparator|ReZoom|
3244944|NCT00876252|Active Comparator|IC43 200 mcg|IC43 200 mcg with Aluminum hydroxide
3244945|NCT00876252|Active Comparator|IC43 100 mcg w/o|IC43 100 mcg without Aluminum hydroxide
3244891|NCT00876694|Experimental|Indacaterol 300 µg|Indacaterol 300 μg once a day (o.d.) delivered via single dose dry powder inhaler (SDDPI). Daily ICS monotherapy, if needed, was allowed to remain stable throughout study. Salbutamol was available for rescue use throughout study.
3244892|NCT00876694|Active Comparator|Salmeterol 50 µg|Salmeterol 50 μg twice a day (b.i.d.) delivered via Diskus®. Daily ICS monotherapy, if needed, was allowed to remain stable throughout study. Salbutamol was available for rescue use throughout study.
3244893|NCT00876681|Active Comparator|1. Ultrasound|Ultrasound method of placement is selected randomly, using a computer program. The patient is asked their pain and discomfort using a 0-10 scale where 0=no pain/discomfort and 10=worst pain/discomfort imaginable. The patient is asked this question prior to surgery, but after catheter placement and then again the first day after surgery. Time of placement is also measured and begins when the ultrasound probe first touches the skin. Patients are also asked the numbness of their foot and toes based on a 0-10 scale where 0=no numbness and 10=completely numb.
3244894|NCT00876681|Active Comparator|2. Electrical Stimulation|Electrical stimulation (nerve stimulation) method of placement is selected randomly, using a computer program. The patient is asked their pain and discomfort using a 0-10 scale where 0=no pain/discomfort and 10=worst pain/discomfort imaginable. The patient is asked this question prior to surgery, but after catheter placement, and then again the first day after surgery. Time of placement is also measured and begins when the nerve stimulation needle first touches the skin. Patients are also asked the numbness of their foot and toes based on a 0-10 scale where 0=no numbness and 10=completely numb.
3244895|NCT00876655|Experimental|free acid|TR-701 free acid phosphate powder in capsule formulation (equivalent to 150 mg TR-700)
3244896|NCT00876655|Experimental|di-sodium phosphate salt|One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)
3244897|NCT00876642|Experimental|1|
3244898|NCT00876642|No Intervention|2|
3244899|NCT00876616|Experimental|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d+MMF 1.0g/d
3244900|NCT00876616|Active Comparator|Cyclophosphamide|CTX iv 0.75 g/m2 body surface area (BSA)
3244901|NCT00876603||1|
3244902|NCT00876603||2|
3244903|NCT00876603||CSM - ACDF|Cervical spondylotic myelopathy treated with anterior cervical decompression and fusion
3244904|NCT00876603||CSM - Cervical laminoplasty|Cervical spondylotic myelopathy treated with cervical laminoplasty
3244905|NCT00876577||Group 1|
3244906|NCT00876564|Other|Trauma patients|Included in trauma registry
3244907|NCT00876551|Experimental|E-V.A.C.|Patients that are treated with E-V.A.C.
3244908|NCT00876538|Experimental|TRO19622|2 capsules of TRO19622 (330mg) once day with the noon meal
3244909|NCT00876538|Placebo Comparator|Control|2 capsules of placebo once day with the noon meal
3244910|NCT00876525|Experimental|Freedom SOLO stentless valve|
3244911|NCT00876499||Questionnaire|
3244912|NCT00876486|Experimental|Genexol®-PM|This is a open-labeled, randomized, parallel, phase III Trial. Up to 106 elgible patients will be enrolled in each treatment arm(Total 212 subjects will recruited) according to the trial design. Patients will be randomly allocated to arm A (Genexol-PM) or arm B (Paclitaxel).
3244913|NCT00876486|Active Comparator|Genexol®|This is a open-labeled, randomized, parallel, phase III Trial. Up to 106 elgible patients will be enrolled in each treatment arm(Total 212 subjects will recruited) according to the trial design. Patients will be randomly allocated to arm A (Genexol-PM) or arm B (Paclitaxel).
3244914|NCT00876473||1|Acute Respiratory Failure patients
3244915|NCT00876460|Experimental|BIBF 1120 + docetaxel|Low, medium and high dose of BIBF 1120 and 60 mg/m2, 75 mg/m2 docetaxel every 3 weeks
3244916|NCT00876447|Experimental|Botulinum Toxin Type A 300U|Botulinum toxin Type A 300U injections into the detrusor > 12 weeks as needed for up to 3 years.
3244917|NCT00876447|Experimental|Botulinum Toxin Type A 200U|Botulinum toxin Type A 200U injections into the detrusor > 12 weeks as needed for up to 3 years.
3244918|NCT00876421|Placebo Comparator|P|
3244919|NCT00876421|Active Comparator|A|
3244920|NCT00876421|Experimental|E1|
3244921|NCT00876421|Experimental|E2|
3244922|NCT00876421|Experimental|E3|
3244923|NCT00876395|Experimental|Everolimus 10 mg daily|Everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22
3244924|NCT00876395|Placebo Comparator|Placebo of everolimus daily|Placebo of everolimus daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22
3244925|NCT00876369||Urticaria/Angioedema|Subjects with chronic urticaria and/or angioedema
3244926|NCT00876369||allergy control|Subjects with physician diagnosed allergic rhinitis
3244927|NCT00876356|Active Comparator|1|Conjugated Linoleic Acid 4.5g/day in three divided doses p.o. for 12 weeks
3244928|NCT00876356|Placebo Comparator|2|Olive oil 4.5g/day x 12 weeks.
3244929|NCT00876343|Experimental|1|Fixed dose
3244930|NCT00876343|Experimental|2|Titration dose
3244931|NCT00876343|Placebo Comparator|3|Placebo
3244932|NCT00876330|Experimental|1|Receives Hypertension and Hyperlipidemia Intervention using Clinical Decision Support.
3244933|NCT00876330|Experimental|2|Receives Hypertension and Hyperlipidemia Intervention with automated telephone outreach.
3244934|NCT00876317|Active Comparator|1|Etoricoxib 60 mg per oz for 14 days
3244935|NCT00876317|Active Comparator|2|Etoricoxib 90 mg per oz for 14 days
3244936|NCT00876304|Experimental|PF-04802540|
3244937|NCT00876304|Placebo Comparator|Placebo|
3244938|NCT00876291|Placebo Comparator|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
3244939|NCT00876291|Active Comparator|Probiotic|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
3244940|NCT00876278|Other|*AT.Smart 46LC|The *AT.Smart 46LC is indicated for primary implantation for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the *AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
3244941|NCT00876265|Experimental|Belotero|
3244946|NCT00876252|Placebo Comparator|Placebo|phosphate-buffered saline solution containing 0,9 % NaCl and 400 mcg Aluminum hydroxide as an adjuvant
3244947|NCT00876200|Experimental|Minoxidil|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
3244948|NCT00876200|Placebo Comparator|Placebo|Placebo = lactose
3244949|NCT00876187|Experimental|Tanezumab 20 mg IV|
3244950|NCT00876187|Experimental|Tanezumab 10 mg IV|
3244951|NCT00876187|Experimental|Tanezumab 5 mg IV|
3244952|NCT00876187|Active Comparator|Naproxen|
3244953|NCT00876187|Placebo Comparator|Placebo|
3244954|NCT00876174||Patients|20 patients with genotype 1, chronic hepatitis C who are to undergo standard antiviral therapy
3244955|NCT00876174||control|Group 2, (control): 10 healthy family members or significant others of patients who are to undergo standard antiviral therapy
3244956|NCT00876161|Experimental|DAS181|
3244957|NCT00876161|Placebo Comparator|Lactose|
3244958|NCT00876135|Placebo Comparator|Inhaled Bronchodilator|
3244959|NCT00876122|Experimental|1|
3244960|NCT00876109|Experimental|Group A: GDC-0941 QD Dose Escalation|Participants will receive GDC-0941 for up to 1 year, administered orally QD at a starting dose of 15 milligrams (mg).
3244961|NCT00876109|Experimental|Group B: GDC-0941 BID Dose Escalation|Participants will receive GDC-0941 for up to 1 year, administered orally BID at a starting dose determined from Group A assessments.
3244962|NCT00876109|Experimental|Group C: GDC-0941 QD or BID Expansion|Participants will receive GDC-0941 for up to 1 year, administered orally QD or BID. The dose/regimen will be determined on the basis of data from Groups A and B.
3244963|NCT00876096|Other|1|precocious diagnosis and taken care therapeutics of the systematic athlete's feet
3244964|NCT00876083||Group 1|
3244965|NCT00876057|Active Comparator|TH|Total hysterectomy
3244966|NCT00876057|Active Comparator|SH|Subtotal hysterectomy
3244967|NCT00876044|Experimental|1|4 mg/kg every 2 weeks
3244968|NCT00876044|Placebo Comparator|2|matching placebo
3244969|NCT00876031|Experimental|O-TIE|oral maintenance therapy with trofosfamide, idarubicin, and etoposide
3244970|NCT00876031|No Intervention|control|
3244971|NCT00876018|No Intervention|No intervention|No intervention
3244972|NCT00876018|Experimental|Nutritional supplement|Fortified nutritional powder
3244973|NCT00876018|Placebo Comparator|Placebo|Un-fortified nutritional powder
3244974|NCT00876005|Active Comparator|1|80% oxygen during cesarean section
3244975|NCT00876005|Active Comparator|2|30% oxygen during cesarean section
3244976|NCT00875992|Experimental|ETN with ASLS|Angle stable locking of the Expert Tibial Nail using ASLS
3244977|NCT00875992|Active Comparator|ETN with conventional locking|Conventional locking of the Expert Tibial Nail using conventional locking bolts
3244978|NCT00875979|Experimental|Trastuzumab emtansine 3.0 mg/kg + pertuzumab 420 mg|Patients received trastuzumab emtansine 3.0 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer therapy, or patient discontinuation. Patients also received a loading dose of 840 mg of pertuzumab IV on Day 1 of Cycle 1 followed by pertuzumab 420 mg IV on Day 1 of every subsequent 3 week cycle.
3244979|NCT00875979|Experimental|Trastuzumab emtansine 3.6 mg/kg + pertuzumab 420 mg|Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer therapy, or patient discontinuation. Patients also received a loading dose of 840 mg of pertuzumab IV on Day 1 of Cycle 1 followed by pertuzumab 420 mg IV on Day 1 of every subsequent 3 week cycle.
3244980|NCT00875966|Experimental|1|Azithromycin for oral suspension 200mg/5mL
3244981|NCT00875966|Active Comparator|2|Zithromax (azithromycin for oral suspension) 200mg/5mL
3244982|NCT00875953|Active Comparator|Standard dissection|standard neck dissection technique: scalpel and cautery.
3244983|NCT00875953|Experimental|Harmonic Scalpel|Harmonic scalpel used in neck dissection.
3244984|NCT00875940||Group 1|Patients having both Tc-99m perfusion scan and echocardiogram.
3244985|NCT00875927|Active Comparator|1 - control|candy not including scraping microcapsules
3244986|NCT00875927|Active Comparator|2 - Scraping|candy including scraping TCP microcapsules
3244987|NCT00875927|Active Comparator|3 - Scraping plus Propolis|candy including scraping Propolis microcapsules
3244988|NCT00875927|Active Comparator|4 - Scraping plus Zinc|candy including scraping Zinc microcapsules
3244989|NCT00875927|Active Comparator|5 - Scraping plus Propolis and Zinc|candy including scraping Propolis and Zinc microcapsules
3244990|NCT00875914|Experimental|Manually guided|Treatment with manually guided RF-catheter
3244991|NCT00875914|Experimental|Magnetically navigated|Treatment with magnetically navigated RF-catheter.
3244992|NCT00875901|Experimental|Peripherally located lung tumor|12 cobalt gray equivalent per fraction to a total of 48 cobalt gray equivalent
3244993|NCT00875901|Experimental|Centrally located lung tumor|6 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent
3244994|NCT00875888|Experimental|HCO|High cut-off filters HCO1100
3244995|NCT00875888|Active Comparator|control|conventional high-flux filters
3244996|NCT00875875|Active Comparator|1|This is the approved treatment regimen for travelers' diarrhea (600 mg)
3244997|NCT00875875|Active Comparator|2|This is the same dose as the standard dose, given once daily (200 mg)
3244998|NCT00875862|Active Comparator|1. 0.2% Ropivicaine perinueral infusion|Patients will receive normal standard of care post-manipulation (single-injection brachial plexus nerve block, oral analgesics, and cold therapy). They will then be randomized to 0.2% Ropivicaine attached to the perineural catheter and an infusion will be initiated. The outcome measures will be assessed by study staff on the phone and at regular visits to the surgeon's office.
3245047|NCT00875485|Experimental|Twinrix Adult Group|Subjects received 2 doses of Twinrix™ Adult intramuscularly according to a 0, 6 month schedule in the primary study
3245109|NCT00874978|Experimental|lenalidomide|
3245110|NCT00874965|Active Comparator|ES|Electrostimulation
3244999|NCT00875862|Placebo Comparator|2. Normal Saline perineural infusion|Patients will receive normal standard of care post-manipulation (single-injection brachial plexus nerve block, oral analgesics, and cold therapy). They will then be randomized to normal saline attached to the perineural catheter and an infusion will be initiated. The outcome measures will be assessed by study staff on the phone and at regular visits to the surgeon's office.
3245000|NCT00875849|Experimental|Cetuximab|
3245001|NCT00875836|Experimental|Buspirone|Buspirone
3245002|NCT00875836|Placebo Comparator|Placebo|Placebo
3245003|NCT00875823||PH Patients|"Patients with:~Primary Hyperoxaluria Type I Primary Hyperoxaluria Type II Primary Hyperoxaluria NonI-NonII"
3245004|NCT00875797|Active Comparator|parentral glutamine|parenteral glutamine given in central venous line in dose up to 30 g par day
3245005|NCT00875797|Experimental|entral glutamine|enteral glutamine given through gastric tube in a dose up to 30 g per day
3245006|NCT00875784|Experimental|TREXIMA tablet followed by IMITREX injection (4mg)|TREXIMA™ (sumatriptan succinate / naproxen sodium) Tablet followed by IMITREX® (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System®
3245007|NCT00875784|Experimental|TREXIMA tablet followed by IMITREX injection (6mg)|TREXIMA tablet followed by IMITREX® (sumatriptan succinate) Injection 6mg administered using the IMITREX STATdose System®
3245008|NCT00875784|Active Comparator|IMITREX tablet (100mg)|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
3245009|NCT00875771|Experimental|1|"Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~Bevacizumab: 5 mg/kg day 1, every 2 Weeks"
3245010|NCT00875758|Active Comparator|Standard threshold|
3245011|NCT00875758|Experimental|Low-threshold|
3245012|NCT00875745|Experimental|Sorafenib-Vorinostat|This is a single-arm, non-randomized feasibility and safety Phase I trial of a combination of Sorafenib and Vorinostat, both administered orally.
3245013|NCT00875732|Experimental|1|Biventricular Pacing
3245014|NCT00875732|Active Comparator|2|Right Ventricular Pacing
3245015|NCT00875719|Active Comparator|continuous v intermittent Oxygen therapy|intermittent oxygen compared to constant flow oxygen as regards walking distance
3245016|NCT00875706|Other|Training Feasibility|"4 sites will receive the training intervention to determine the feasibility of the train-the trainer approach.~The educational intervention is included in this arm."
3245017|NCT00875706|Other|Data Collection - Survey|Survey data collection tools will be piloted to assess feasibility of survey administration and development of the survey for future studies. This tools were piloted in sites where the educational intervention was administered.
3245018|NCT00875706|Other|Data Collection - Interview|Interview data collection tools will be piloted to assess feasibility of interview administration and development of the interview protocol for future studies. This tools were piloted in sites where the educational intervention was administered.
3245019|NCT00875693|Experimental|Arm A dose of CPX - 351|Dose level 1A: 60 units/m2 days -28, -26 and -24 Dose level 2A: 80 units/m2 days -28, -26 and -24 Dose level 3A: 100 units/m2 days -28, -26 and -24 Dose level 4A: 120 units/m2 days -28, -26 and -24 Dose level 5A: 140 units/m2 days -28, -26 and -24 Dose level 6A: 160 units/m2 days -28, -26 and -24
3245020|NCT00875693|Experimental|Arm B dose of CPX-351|Dose level 1B: 60 units/m2 days -21, -19 and -17 Dose level 2B: 80 units/m2 days -21, -19 and -17 Dose level 3B: 100 units/m2 days -21, -19 and -17 Dose level 4B: 120 units/m2 days -21, -19 and -17 Dose level 5B: 140 units/m2 days -21, -19 and -17
3245021|NCT00875680|Experimental|autoPPC|
3245022|NCT00875667|Experimental|Lenalidomide|Lenalidomide
3245023|NCT00875667|Active Comparator|Investigators choice single agent|Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, Fludarabine
3245024|NCT00875654|No Intervention|1|Control group without intervention nor placebo
3245025|NCT00875654|Experimental|2|First dose of stem cells
3245026|NCT00875654|Experimental|3|Second dose of stem cells
3245027|NCT00875641||Exposed cohort|Infants aged less than 1 year who are eligible for rotavirus vaccination and receive at least one dose of Rotarix according to routine recommendations.
3245028|NCT00875641||Unexposed cohort A|Infants aged less than 1 year who receive at least one dose of IPV (but NO dose of Rotarix) after 1 August 2008. The infants may or may not receive RotaTeq. All vaccines are provided according to routine recommendations.
3245029|NCT00875641||Unexposed cohort B|Infants aged less than 1 year who receive at least one dose of IPV between 1 January 2006 and 31 July 2008. All vaccines are provided according to routine recommendations.
3245030|NCT00875628|Other|Cohort 1|PF-00868554 100 mg or placebo
3245031|NCT00875628|Other|Cohort 2|PF-00868554 300 mg or placebo
3245032|NCT00875628|Other|Cohort 3|PF-00868554 600 mg or placebo
3245033|NCT00875615|Experimental|Cisplatin or Carboplatin + Sorafenib|
3245034|NCT00875602|No Intervention|control|before-after (retrospective) and concurrent controls as comparators with a prospective intervention group
3245035|NCT00875602|Active Comparator|Study unit|Hospitalized patients in the study group will be continously monitored / supervised by the contact-free device
3245036|NCT00875589||Control|Control subjects with no Mild Traumatic Brain Injury (MTBI) and no Post-Traumatic Stress Disorder (PTSD)
3245037|NCT00875589||MTBI|Subject with a diagnosis for Mild Traumatic Brain Injury (MTBI)
3245038|NCT00875563|Experimental|1|Zenith(R) Fenestrated AAA Endovascular Graft
3245039|NCT00875550|Active Comparator|Dexmedetomidine Low Dose|
3245040|NCT00875550|Active Comparator|Dexmedetomidine High dose|
3245041|NCT00875537|Active Comparator|Capsaicin oral gel 0.01%|
3245042|NCT00875537|Active Comparator|Capsaicin oral gel 0.025%|
3245043|NCT00875524|Experimental|Dengue Group|Participants will receive ChimeriVax™ tetravalent dengue vaccine.
3245044|NCT00875524|Sham Comparator|Control Group|Participants will receive Meningococcal Polysaccharide Vaccine A + C, a placebo (NaCl containing human serum albumin), and Typhoid Vi polysaccharide vaccine (Typhim Vi®) as first, second, and third vaccinations, respectively.
3245045|NCT00875498|Active Comparator|active iTBS|iTBS active intensity = 80%MT during 6 minutes. 20 sessions, 2 per day
3245046|NCT00875498|Placebo Comparator|sham iTBS|iTBS placebo (placebo coil)with same parameters than active
3245048|NCT00875485|Experimental|Twinrix Junior Group|Subjects received 3 doses of Twinrix™ Junior (= half dose Twinrix™ Adult) intramuscularly according to a 0, 1, 6 month schedule in the primary study
3245049|NCT00875459|Experimental|VIAject™|Single injection
3245050|NCT00875446|Experimental|Subjects receiving GSK1223249|"Eligible subjects will receive sequential dose of intravenous infusion of GSK1223249 with a starting dose of 0.01 milligram per kilogram followed by 0.1, 0.5,~1, 2.5, 5, 7.5, and 15 milligrams per kilograms."
3245051|NCT00875446|Placebo Comparator|Subjects receiving placebo|Eligible subjects will receive intravenous infusion of placebo.
3245052|NCT00875433|Experimental|Monotherapy|BIBW 2992 high dose, once daily, continuous, monotherapy
3245053|NCT00875420|Experimental|RAD1901 10 mg|Oral once a day for 28 days
3245054|NCT00875420|Experimental|RAD1901 25 mg|Oral once a day for 28 days
3245055|NCT00875420|Experimental|RAD1901 50 mg|Oral once a day for 28 days
3245056|NCT00875420|Experimental|RAD1901 100 mg|Oral once a day for 28 days
3245057|NCT00875420|Placebo Comparator|Placebo|Oral once a day for 28 days
3245058|NCT00875394|Experimental|1|sitagliptin + metformin
3245059|NCT00875394|Active Comparator|2|metformin + any other oral antidiabetic drug
3245060|NCT00875394|Active Comparator|3|metformin
3245061|NCT00875368|Active Comparator|Maraviroc|
3245062|NCT00875368|Placebo Comparator|Placebo|Placebo drug
3245063|NCT00875355|Experimental|Arm I|Patients undergo isocentric radiotherapy to the brain 5 times a week for 2 weeks.
3245064|NCT00875355|Experimental|Arm II|Patients undergo radiotherapy as in arm I and receive oral temozolomide once daily for 2 weeks.
3245065|NCT00875342|Experimental|D-cycloserine|
3245066|NCT00875342|Placebo Comparator|Placebo|
3245067|NCT00875329||Group 1|A convenience sample of 97VHA patients who served during the OEF or OIF era, who are targeted in CPRS as requiring the TBI Clinical reminder will be included. This includes all ages, both sexes, and all races and ethnicities.
3245068|NCT00875316|Experimental|Cohort A|
3245069|NCT00875316|Experimental|Cohort B|
3245070|NCT00875316|Experimental|Cohort C|
3245071|NCT00875316|Experimental|Cohort D (Optional)|
3245072|NCT00875303|Placebo Comparator|Control|Routine primary care.
3245073|NCT00875303|Experimental|Multimedia intervention|
3245074|NCT00875290|No Intervention|Control|Observational arm
3245075|NCT00875290|Experimental|Real-time glucose sensor|Subjects wear real-time glucose sensor
3245076|NCT00875277|Experimental|LEO 29102 cream|
3245077|NCT00875264|Experimental|1|At least one 6-week (42-day) cycle in which patients will be treated daily with CEP-11981 for 28 days, followed by a treatment-free period of 14 days.
3245078|NCT00875251||term infants body composition|Term infants from 2 days of life to 7 days of life without IUGR
3245079|NCT00875251||preterm infants body composition|very low birth weight infants before discharge
3245080|NCT00875225|Active Comparator|Control DVD|Control DVD with usual care information
3245081|NCT00875225|Active Comparator|Intervention DVD|Intervention group will receive DVD with patient stories and information from health care professionals
3245082|NCT00875212|Experimental|dentifrice intervention|4 types of dentifrices were used in 4 different periods in a crossover study design.
3245083|NCT00875199|Active Comparator|A|Participants assigned to Group A will receive the DPP manual (Wing & Gillis, 1996), a behavioral weight-loss program with demonstrated efficacy in facilitating weight loss. Participants in Group A will be instructed to read a section of the manual each week and complete suggested activities. They will also meet with the research staff once a week for weigh-in and supportive counseling.
3245084|NCT00875199|Experimental|B|Participants assigned to Group B will receive the DPP manual and will meet with research staff each week for weigh-in and supportive counseling. They will also receive contingency management or the opportunity to earn draws with the chance of winning prizes for losing weight and completing healthy activities.
3245085|NCT00875186||multiple-exercise group (ME)|participants exercised 2 times weekly for 1 hour (aerobic endurance training)
3245086|NCT00875186||Low-exercise group (LE)|participants exercises 1 time weekly for 1 hour (aerobic endurance training)
3245087|NCT00875173|Experimental|Selenium|Sodium selenite 100 micrograms in capsugel by mouth diary for 365 consecutive days
3245088|NCT00875173|Active Comparator|Placebo|Capsugel for placebo (selenium 100 micrograms capsugel) by mouth diary for 365 consecutive days
3245089|NCT00875160|Experimental|AT2101|
3245090|NCT00875147||with bevacizumab|Neoadjuvant chemotherapy with bevacizumab
3245091|NCT00875147||without Bevacizumab|Neoadjuvant chemotherapy without Bevacizumab
3245092|NCT00875134|Experimental|Verbal prompt, cutaneous stimulation|Patient receives either or both a verbal stimulus or cutaneous stimulus
3245093|NCT00875108|Experimental|VIAject™|Single injection
3245094|NCT00875095||IUI patients|Patients undergoing routine semen analysis as part of their infertility treatment pertaining to success or failure with intrauterine insemination, based upon their sperm DNA integrity
3245095|NCT00875095||IVF patients|Couples undergoing routine screening prior to IVF retrievals to assess their reproductive treatment outcomes as compared to the sperm DNA integrity
3245096|NCT00875082|Active Comparator|Montelukast|Montelukast chewing tablets once daily per os, plus inhaled short acting beta2 agonist as needed
3245097|NCT00875082|Placebo Comparator|placebo|placebo chewing tablets per os once daily, plus inhaled short acting beta 2 agonist as needed
3245098|NCT00875069|Experimental|ethanol|
3245099|NCT00875069|Placebo Comparator|placebo|
3245100|NCT00875056|Experimental|1|vorinostat
3245101|NCT00875043||1. flat Jackson table|All measurements previously described will be done with the patient in the prone postion and Jackson table flat.
3245102|NCT00875043||2. Elevated Jackson tablet|All measurements previously described will be performed with subjects placed prone on the elevated Jackson table.
3245103|NCT00875030|Experimental|1.0|
3245104|NCT00875030|Active Comparator|2.0|
3245105|NCT00875017|Experimental|Meal + Lanthanum|
3245106|NCT00875017|Active Comparator|Meal + Sevelamer|
3245107|NCT00875017|No Intervention|Meal Only|
3245111|NCT00874965|Placebo Comparator|Sham ES|Sham stimulation
3245112|NCT00874939|Experimental|PBO→MK-7.5→DON→MK-25|Treatment by single oral dose with Placebo (PBO) in the first crossover period; MK-0249 7.5 mg (MK-7.5) in the second crossover period; Donepezil 5 mg (DON) in the third crossover period; and MK-0249 25 mg (MK-25) in the fourth crossover period.
3245113|NCT00874939|Experimental|MK-7.5→PBO→MK-25→DON|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; Placebo in the second crossover period; MK-0249 25 mg in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
3245114|NCT00874939|Experimental|DON→MK-25→PBO→MK-7.5|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; MK-0249 25 mg in the second crossover period; Placebo in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
3245115|NCT00874939|Experimental|MK-25→DON→MK-7.5→PBO|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; Donepezil 5 mg in the second crossover period; MK-0249 7.5 mg in the third crossover period; and Placebo in the fourth crossover period.
3245116|NCT00874939|Experimental|PBO→MK-25→MK-7.5→DON|Treatment by single oral dose with Placebo in the first crossover period; MK-0249 25 mg in the second crossover period; MK-0249 7.5 mg in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
3245117|NCT00874939|Experimental|MK-7.5→DON→PBO→MK-25|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; Donepezil 5 mg in the second crossover period; Placebo in the third crossover period; and MK-0249 25 mg in the fourth crossover period.
3245118|NCT00874939|Experimental|DON→MK-7.5→MK-25→PBO|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; MK-0249 7.5 mg in the second crossover period; MK-0249 25 mg in the third crossover period; and Placebo in the fourth crossover period.
3245119|NCT00874939|Experimental|MK-25→PBO→DON→MK-7.5|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; Placebo in the second crossover period; Donepezil 5 mg in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
3245120|NCT00874939|Experimental|PBO→DON→MK-25→MK-7.5|Treatment by single oral dose with Placebo in the first crossover period; Donepezil 5 mg in the second crossover period; MK-0249 25 mg in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
3245121|NCT00874939|Experimental|MK-7.5→MK-25→DON→PBO|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; MK-0249 25 mg in the second crossover period; Donepezil 5 mg in the third crossover period; and Placebo in the fourth crossover period.
3245122|NCT00874939|Experimental|DON→PBO→MK-7.5→MK-25|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; Placebo in the second crossover period; MK-0249 7.5 mg in the third crossover period; and MK-0249 25 mg in the fourth crossover period.
3245123|NCT00874939|Experimental|MK-25→MK-7.5→PBO→DON|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; MK-0249 7.5 mg in the second crossover period; Placebo in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
3245124|NCT00874926||Group 1|
3245125|NCT00874913|Experimental|Laser Doppler Flowmetry|
3245126|NCT00874900|Experimental|Game|
3245127|NCT00874900|Experimental|Game + Activation|
3245128|NCT00874900|No Intervention|Booklet|
3245129|NCT00874900|Experimental|Booklet + Activation|
3245130|NCT00874887|Active Comparator|Vigamox®|moxifloxacin 0.5% (m mg/mL), boric acid, sodium chloride, and purified water
3245131|NCT00874887|Active Comparator|Zymar®|gatifloxacin 0.3% (3 mg/mL), benzalkonium chloride 0.005%, edetate disodium; purified water and sodium chloride
3245132|NCT00874861|Experimental|Vaccine + Poly-ICLC|Peptide Vaccine + Poly-ICLC
3245133|NCT00874848|Experimental|Imprime PGG|Imprime PGG Injection + Cetuximab + Paclitaxel/Carboplatin
3245134|NCT00874848|Active Comparator|Control|Cetuximab + Paclitaxel/Carboplatin
3245135|NCT00874822||Berlin|Patients diagnosed with obstructive sleep apnea by polysomnography after being screened with the Berlin questionnaire.
3245136|NCT00874809|Other|Insulin Treatment|There is only one arm for this study using lispro insulin administered by insulin pump.
3245137|NCT00874796|Experimental|GS-9450 10 mg/day|GS-9450 taken as one 10 mg capsule by mouth once daily
3245138|NCT00874796|Experimental|GS-9450 40 mg/day|GS-9450 taken as one 40 mg capsule by mouth once daily
3245139|NCT00874796|Placebo Comparator|Placebo|Placebo taken as one placebo capsule by mouth once daily
3245140|NCT00874770|Experimental|Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A)|Active Comparator
3245141|NCT00874770|Experimental|Daclatasvir, Peginterferon alpha-2a, ribavirin (B)|Active Comparator
3245142|NCT00874770|Experimental|Daclatasvir, Peginterferon alpha-2a, ribavirin (C)|Active Comparator
3245143|NCT00874770|Active Comparator|Placebo, Peginterferon alpha-2a, ribavirin (D)|
3245144|NCT00874744|Experimental|bevacizumab|
3245145|NCT00874744|Experimental|Triamcinolone|
3245146|NCT00874731|Experimental|Ridaforolimus|"Part 1: Participants receive a single oral dose of placebo (10 tablets) on Day 1 and a single oral dose of 100 mg ridaforolimus (10 x 10 mg tablets) on Day 2. Each dose to be followed by 24 hours of Holter electrocardiogram (ECG) monitoring for QTc assessment.~Part 2 (optional): Participants receive a weekly regimen of daily oral doses of 40 mg ridaforolimus (4 x 10 mg tablets) for 5 consecutive days followed by 2 days off-drug."
3245147|NCT00874718|Active Comparator|Action group|
3245148|NCT00874718|Other|Control group|Non-specific educational program for general health.
3245149|NCT00874692|Experimental|BMS and sterilisation|BMS and sterilisation programme will be delivered
3245150|NCT00874692|No Intervention|BMS standard water heating|
3245151|NCT00874679||Group 1|
3245152|NCT00874666|Active Comparator|1|Positive control with 100% allicin bioavailability
3245153|NCT00874666|Experimental|2|garlic powder tablet
3245154|NCT00874653||Group 1|
3245155|NCT00874640||Group 1|
3245156|NCT00874627|Experimental|Experimental|Administration of Milk
3245157|NCT00874627|Placebo Comparator|Placebo|meals without milk
3245158|NCT00874614|Experimental|Ultratrace® Iobenguane I 131 Treatment|
3245328|NCT00873431|Experimental|IC47 150 mcg|150 mcg with Alum
3245329|NCT00873431|Experimental|IC47 150 mcg w/o|150 mcg without Alum
3245159|NCT00874601|Experimental|valsartan group|The valsartan group will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.
3245160|NCT00874601|No Intervention|control group|Patients on control group will not receive any other antihypertensive medication for first 7 days after stroke onset. However, rescue therapy with antihypertensive agents can be permitted for episodes with severely elevated blood pressures during acute periods.
3245161|NCT00874588|Experimental|Phase I study|
3245162|NCT00874575|Placebo Comparator|1|Control
3245163|NCT00874575|Experimental|2|Beta-hydroxy-Beta-methylbutyrate, 3 g/d
3245164|NCT00874575|Experimental|3|Vitamin D, 2000 IU/d
3245165|NCT00874575|Experimental|4|Beta-hydroxy-Beta-methylbutyrate (3 g/d) + Vitamin D (2000 IU/d)
3245166|NCT00874562|Active Comparator|Steroid Only|Corticosteroid Alone
3245167|NCT00874562|Active Comparator|Steroid plus Rapamycin|Corticosteroid plus Rapamycin
3245168|NCT00874549|Active Comparator|Group 1: Menomune Day 0|Participants received a single dose of Menomune® vaccine on Day 0.
3245169|NCT00874549|Experimental|Group 2: Menactra® Day 0 x 2|Participants received two single-dose injections of Menactra® vaccine on Day 0
3245170|NCT00874549|Experimental|Group 3: Menactra® Day 0 and 14|Participants received a single dose of Menactra® vaccine on Day 0 and on Day 14
3245171|NCT00874549|Experimental|Group 4: Menactra® Day 0 and 28|Participants received a single dose of Menactra® vaccine on Day 0 and on Day 28.
3245172|NCT00874536|Experimental|ALA|This group will receive the ALA supplement
3245173|NCT00874536|Placebo Comparator|Placebo|This group will receive the placebo supplement
3245174|NCT00874523|Active Comparator|Arm A|
3245175|NCT00874523|Active Comparator|Arm B|
3245176|NCT00874510|No Intervention|Standard Schedule|interns work standard schedule, being on duty for 30 continuous hours
3245177|NCT00874510|Experimental|Mandatory Naps|interns on overnight extended duty shifts have mandatory sign out of cell phones and cross-coverage responsibilities for 5 hours roughly between 12 and 5 am. For Year 2, this will be two 3 hour shifts, the first between 12am-3am and the 2nd between 3am-6am.
3245178|NCT00874497|Experimental|1 Tetomilast|
3245179|NCT00874497|Placebo Comparator|2 Placebo|
3245180|NCT00874484|Experimental|1|
3245181|NCT00874484|Placebo Comparator|2|
3245182|NCT00874471||sarcoidosis|
3245183|NCT00874471||ankylosing spondylitis|
3245184|NCT00874471||Behcet's disease|
3245185|NCT00874471||toxoplasmosis|
3245186|NCT00874471||herpetic acute retinal necrosis|
3245187|NCT00874471||idiopathic uveitis|
3245188|NCT00874471||ankylosing spondylitis (no uveitis)|
3245189|NCT00874471||sarcoidosis (no uveitis)|
3245190|NCT00874471||Behcet's disease (no uveitis)|
3245191|NCT00874471||normal control|
3245192|NCT00874458|Experimental|MRI|
3245193|NCT00874445||ICD shocks programmed to Tuned Waveform|ICD shocks programmed to Tuned Waveform
3245194|NCT00874445||ICD shocks programmed to Fixed Tilt Waveform|ICD shocks programmed to Fixed Tilt Waveform
3245195|NCT00874432|Active Comparator|Chronic Kidney Disease-ACE-I|ace inhibitor
3245196|NCT00874432|Placebo Comparator|Chronic Kidney Disease|
3245197|NCT00874432|Active Comparator|Age matched control-ACE-I|ace-inhibitor
3245198|NCT00874432|Placebo Comparator|Age matched control|Placebo
3245199|NCT00874419|Experimental|erlotinib|Arm 1 receive erlotinib 150 mg oral, once a day until progression or unacceptable toxicity
3245200|NCT00874419|Active Comparator|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
3245201|NCT00874406|Experimental|1|transhepatic arterial chemotherapy (TAC) were given 7 days before liver metastasis resection. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
3245202|NCT00874406|Active Comparator|2|Liver metastasis resection was done without TAC. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
3245203|NCT00874393|Active Comparator|Dopamine and hydrocortisone|Dopamine AND hydrocortisone
3245204|NCT00874393|Active Comparator|Dopamine and placebo|Dopamine AND normal saline placebo
3245205|NCT00874393|Active Comparator|Placebo and hydrocortisone|Dextrose (D5W) placebo AND hydrocortisone
3245206|NCT00874393|Placebo Comparator|Placebo and Placebo|Dextrose (D5W) placebo AND normal saline placebo
3245207|NCT00874380||1|First describe the diet of a cohort of dialysis patients with focus on fiber content.
3245208|NCT00874354|Experimental|Autologous bone marrow stem cells|Patients within 3 to 14 days from percutaneous coronary intervention (PCI) and stent implantation for Acute Myocardial Infarction (AMI) will receive either 50 cc's or 100 cc's of autologous bone marrow mononuclear cells through an intracoronary tranplantation of stem cells into the infarct-related coronary artery.
3245209|NCT00874341|No Intervention|1|
3245210|NCT00874341|Active Comparator|2|4 portions fruit and vegetables daily for 12 weeks
3245211|NCT00874341|Active Comparator|3|7 portions of fruit and vegetables daily for 12 weeks
3245212|NCT00874328|Experimental|study arm|Irinotecan /IV D1 Cisplatin 60mg/m2 iv D1 S-1 bid, P.o. D1 ~ 14 q 3 weeks until maximum 6 cycles
3245213|NCT00874302|Experimental|25 mg|25 mg Proellex
3245214|NCT00874302|Experimental|50 mg|50 mg Proellex
3245215|NCT00874289||Acute heart failure patients|
3245216|NCT00874289||Chronic heart failure patients|
3245217|NCT00874276|Experimental|No EGT Allele, slow metabolizers for DCA|Individuals were genotyped at the beginning of the study and their haplotypes were defined. Dichloroacetate 2.5.ug/kg (non-clinical dose) will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
3245408|NCT00872833||age 30+|People age groups 30+ years with transfusion-dependent thalassemia who have reported at least mild degrees of pain during the main Assessment of Pain study.
3245218|NCT00874276|Experimental|1+ EGT Allele, fast metabolizers for DCA|Individuals were genotyped at the beginning of the study and their haplotypes were defined. Dichloroacetate 2.5.ug/kg (non-clinical dose) will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
3245219|NCT00874250|Experimental|GORE CTAG Device|The primary endpoint of this study is freedom from a Major Device Event (MDE) through 1 month post-treatment in subjects treated with the GORE® Conformable TAG® Thoracic Endoprosthesis.
3245220|NCT00874237|Experimental|1|Staccato Loxapine
3245221|NCT00874237|Active Comparator|2|Oral moxifloxacin
3245222|NCT00874237|Placebo Comparator|3|Placebo
3245223|NCT00874224|Active Comparator|1|patients undergoing open left lateral hepatic sectionectomy
3245224|NCT00874224|Active Comparator|2|patients undergoing a laparoscopic left lateral hepatic sectionectomy
3245225|NCT00874224|Active Comparator|3|Prospective registry of patients that cannot be randomized (both open and laparoscopic left lateral hepatic sectionectomy)
3245226|NCT00874211||Observation|Patients will be observed and will undergo assessment of therapy complications.
3245227|NCT00874185||Questionnaire|filling in questionnaires
3245228|NCT00874172|Active Comparator|2|Combination of acetaminophen, morphine
3245229|NCT00874172|Experimental|1|Combination of acetaminophen, nitrous oxide, nefopam, morphine
3245230|NCT00874159||A|
3245231|NCT00874146||1|HER2-positive advanced breast cancer
3245232|NCT00874133|Active Comparator|Motillium|20 mg motilium thrice daily for 12 weeks.
3245233|NCT00874133|Active Comparator|Acupuncture|Acupuncture treatment.
3245234|NCT00874120|Experimental|Phenylephrine HCl Extended-Release tablets 30 mg|Phenylephrine HCl Extended Release tablets 30 mg
3245235|NCT00874120|Placebo Comparator|Placebo|Placebo
3245236|NCT00874107|Experimental|1|Imprime PGG + bevacizumab + paclitaxel/carboplatin
3245237|NCT00874107|Other|2|bevacizumab + paclitaxel/carboplatin
3245238|NCT00874094|Active Comparator|platelet rich fibrin matrix|Both nasolabial folds treated with 0-2 cc of autologous platelet rich fibrin matrix,sufficient to efface nasolabial fold
3245239|NCT00874068|Active Comparator|Standard vegetable oil formula|
3245240|NCT00874068|Active Comparator|InFat|
3245241|NCT00874068|No Intervention|Breast-fed|
3245242|NCT00874042|Experimental|ARQ 197 in combination with gemcitabine|
3245243|NCT00874029|Experimental|Halt Procedure|In this single-arm study, subjects who have symptomatic uterine fibroids will have the Halt Procedure in which intra-abdominal ultrasound will guide RF ablation of uterine fibroids using the Halt System.
3245244|NCT00874016|Active Comparator|Airtraq|Intubation with the use of the Airtraq
3245245|NCT00874016|Active Comparator|Direct Laryngoscopy|Intubation using direct laryngoscopy
3245246|NCT00874003|Experimental|mirtazapine, tablet, 30 mg|n=29
3245247|NCT00874003|Placebo Comparator|sugar pill|n=30
3245248|NCT00873990|Active Comparator|1|application of total etch bonding agent ( 5th generation) for placement of resing based pit and fissure sealants.
3245249|NCT00873990|Experimental|2|Self etch bonding agent (7th generation) application for placement of resin based pit and fissure sealant
3245250|NCT00873977|Active Comparator|C-flex|
3245251|NCT00873977|Active Comparator|A-flex|
3245252|NCT00873977|No Intervention|Auto-CPAP|
3245253|NCT00873951|Experimental|Intact casein|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as 15N-labelled intact casein
3245254|NCT00873951|Experimental|Hydrolyzed casein|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
3245255|NCT00873951|Experimental|AA|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
3245256|NCT00873938||1-supervised|
3245257|NCT00873938||2 -unsupervised|
3245258|NCT00873925|Experimental|Autologous UCB Plus Vit D Omega 3 FA|A single autologous (self) intravenous umbilical cord blood infusion followed by 1 year of daily Vitamin D and Omega 3 Fatty Acid supplementation give as liquid drops and gel capsules that can be swallowed or added to food
3245259|NCT00873925|No Intervention|Control|Subjects randomized to be controls will continue to use intensive insulin therapy in order to compare c-peptide production at 1 year in those receiving combination therapy vs those who do not
3245260|NCT00873912|Experimental|Monovalent influenza virus vaccine|Frozen monovalent vaccine containing new strain
3245261|NCT00873912|Placebo Comparator|Placebo|Placebo
3245262|NCT00873899||Remote Arm|The patients in Remote arm will receive a Medtronic CareLink Monitor to perform remote interrogation and transmission of ICD data. The remote arm ICD will be programmed to transmit over the CareLink Network.
3245263|NCT00873899||Implantable defibrillator patients|Heart failure patients implanted with a wireless-transmission-enabled ICD.
3245264|NCT00873886|Experimental|Oseltamivir (Tamiflu)|
3245265|NCT00873886|Other|Esterase|
3245266|NCT00873873||Persistent obstruction|(pattern of asthma progression)
3245267|NCT00873873||Late obstruction|(pattern of asthma progression)
3245268|NCT00873873||Late normal|(pattern of asthma progression)
3245269|NCT00873873||Persistent normal|(pattern of asthma progression)
3245270|NCT00873860|Placebo Comparator|Placebo|Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
3245271|NCT00873860|Experimental|CAT-354 150 mg|CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
3245272|NCT00873860|Experimental|CAT-354 300 mg|CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
3245273|NCT00873860|Experimental|CAT-354 600 mg|CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
3245596|NCT00871533|Experimental|2|No intervention / no injection control.
3245274|NCT00873834|Experimental|Fluoxetine arm|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
3245275|NCT00873834|Placebo Comparator|placebo arm|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
3245276|NCT00873821|Experimental|1|MK-0941
3245277|NCT00873821|Placebo Comparator|2|Placebo Comparator
3245278|NCT00873795|Experimental|aripiprazole and sertraline|The patients of this arm receive ten weeks of treatment with a combination of sertraline 50mg/day and aripiprazole 2.5mg/day.The effect of this arm is assessed for HAM-D17, CGI, SF-36 and BSRS-50.
3245279|NCT00873795|Placebo Comparator|sertraline and placebo|The patients of this arm receive ten weeks of treatment with a combination of sertraline 50mg/day and placebo.The effect of this arm is assessed for HAM-D17, CGI, SF-36 and BSRS-50.
3245280|NCT00873782|Experimental|1|Participants will undergo retrograde high pressure transvenous limb perfusion with normal saline.
3245281|NCT00873769|Experimental|Healthy smokers|Healthy smokers, male and female
3245282|NCT00873769|Experimental|Healthy nonsmokers|Healthy nonsmokers, Healthy smokers, male and female
3245283|NCT00873756|Experimental|A|
3245284|NCT00873743||1|60 women after elective cesarian section
3245285|NCT00873743||2|60 women after elective cesarian section
3245286|NCT00873730|Experimental|1|
3245287|NCT00873730|Active Comparator|2|
3245288|NCT00873717|Experimental|Dentary|Intervention: trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.
3245289|NCT00873717|Experimental|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
3245290|NCT00873717|Experimental|Dentary + nutrition|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed) associated with control of the administration of dietary prescriptions, incitement to eat.
3245291|NCT00873717|No Intervention|Control|usual care
3245292|NCT00873704|Active Comparator|1|recieves supplemental oxygen postoperatively
3245293|NCT00873704|No Intervention|2|treated as usual without supplemental oxygen
3245294|NCT00873691||1|ICD shocks programmed to Tuned Waveform
3245295|NCT00873691||2|ICD shocks programmed to 50% Tilt waveform
3245296|NCT00873678||1|Children or adult patients affected with JS/CORS
3245297|NCT00873665|Experimental|Aerobic exercise|"To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.~The test of the arm effect of incidence of ED will be made with the Wald chi-square test from the logistic regression model. A dichotomous variable indicating whether the patient received PDE-5 inhibitor therapy will be used as a covariate in the model. The arm effect will be summarized by giving arm-specific covariate-adjusted proportions and their 80% confidence intervals, and the p-value."
3245298|NCT00873665|Other|Wait-list control|"To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.~For the analyses of arm differences in erectile dysfunction (IIEF) score, sexual functioning, urinary incontinence, and QOL, the primary endpoints will be the change across time in these continuous variables. Specifically, change across time for LTF patients will be imputed to be zero for all these analyses."
3245299|NCT00873639||A|
3245300|NCT00873626|Active Comparator|1|fluoroquinolones 5 days
3245301|NCT00873626|Active Comparator|2|fluoroquinolones 10 days
3245302|NCT00873613|No Intervention|Direct ophthalmoscopy|
3245303|NCT00873613|Experimental|Non-dilated retinal photography|
3245304|NCT00873587|Other|Inspiration|
3245305|NCT00873587|Other|Expiration|
3245306|NCT00873574||1|2 patients with MPD for each family. One case for each family will be randomised ; the cohort will be of 120 patients.
3245307|NCT00873574||2|1 control for each family
3245308|NCT00873561|Active Comparator|1 Experimental|NBI-6024 0.1 mg
3245309|NCT00873561|Active Comparator|2 Experimental|NBI-6024 0.5 mg
3245310|NCT00873561|Active Comparator|3 Experimental|NBI-6024 1 mg
3245311|NCT00873561|No Intervention|4 placebo|Placebo injection
3245312|NCT00873548||PFNA_Asia treated|
3245313|NCT00873535|Active Comparator|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
3245314|NCT00873535|Placebo Comparator|Placebo|This group (N=40) will receive placebo in the same dosing regimen as for Varenicline. The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
3245315|NCT00873522||Community acquired pneumonia|
3245316|NCT00873522||Health-Care-Associated pneumonia|
3245317|NCT00873509|Experimental|1|Buspirone 2.5 mg
3245318|NCT00873509|Experimental|2|Buspirone 5.0 mg
3245319|NCT00873509|Placebo Comparator|3|Placebo match
3245320|NCT00873496||Sjögren|Pre and post treatment establishment of salivary flow rate, objective and subjective clinical oral complications' severity of the patients using hydroxychloroquine
3245321|NCT00873483|Experimental|Arm 1|
3245322|NCT00873470|Experimental|Stimulation|All patients included have the stimulation
3245323|NCT00873457|Experimental|Perifosine|Perifosine 50 mg twice a day for a total of six 28-day cycles.
3245324|NCT00873444|Active Comparator|1) Ceramic-on-Metal Bearing|A cementless acetabular cup with ceramic liner for use in total hip replacement
3245325|NCT00873444|Active Comparator|2) Metal-on-Metal Bearing|A cementless acetabular cup with metal liner for use in total hip replacement
3245326|NCT00873431|Experimental|IC47 30 mcg|30 mcg with Alum
3245327|NCT00873431|Experimental|IC47 30 mcg w/o|30 mcg without Alum
3245330|NCT00873418|Experimental|Coping Skills Training|16 week telephone intervention using coping skills training to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
3245331|NCT00873418|Active Comparator|Educational Control|16 weekly telephone calls for extended (standardized) care on heart failure education.
3245332|NCT00873405|Active Comparator|SRSG|Silastic® ring sleeve gastrectomy (SRSG).
3245333|NCT00873405|Other|SRGB|Silastic® ring gastric bypass.
3245334|NCT00873392|Experimental|1|Experimental drug
3245335|NCT00873392|Active Comparator|2|Usual treatment
3245336|NCT00873379|Active Comparator|melatonin|.5 mg (one half of a 1 mg tablet of GNC rapid dissolving Melatonin, natural product number (NPN) 80001380)
3245337|NCT00873379|Placebo Comparator|placebo|half a white placebo tablet
3245338|NCT00873353|Experimental|Unique arm|"6 cycles (3 weeks each one) of :~capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~erlotinib (Tarceva®) 150mg/day, oral. Days: every days"
3245339|NCT00873340||Group 1|
3245340|NCT00873327|Active Comparator|1|Open label -- 6 interval doses
3245341|NCT00873314|Experimental|Bed rest|
3245342|NCT00873314|Placebo Comparator|Activity restriction|
3245343|NCT00873301|Experimental|vulvodynia|
3245344|NCT00873275|Experimental|Treatment (ursodiol, combination chemotherapy, bevacizumab)|Patients receive oral ursodiol twice daily on days 1-28 (days -6 to 28 of course 1), leucovorin calcium IV over 2 hours on days 1 and 15, fluorouracil IV over 46 hours on days 1-2 and 15-16, and oxaliplatin IV over 2 hours and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3245345|NCT00873262|Active Comparator|Hormones|
3245346|NCT00873262|Placebo Comparator|Solvent|
3245347|NCT00873236|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks.
3245348|NCT00873236|Experimental|Arm II|Patients receive bevacizumab as in arm I and low-dose recombinant interferon alpha-2a subcutaneously (SC) 3 times weekly beginning on day 0.
3245349|NCT00873236|Experimental|Arm III|Patients receive bevacizumab as in arm I and standard-dose recombinant interferon alpha-2a SC 3 times weekly beginning on day 0.
3245350|NCT00873223|Experimental|A|
3245351|NCT00873210||Patients treated with Sutent|125 consecutive patients in outpatient care with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
3245352|NCT00873197|Experimental|Sancuso® patch/IV granisetron|Subjects will receive 1 Sancuso® patch worn for 7 days (168 hours). Immediately after the patch has been applied on Day 1, IV granisetron will be administered over 30 seconds. Following patch removal at 168 hours, a new patch will be immediately applied to the opposite arm and will remain in place for a further 7 days (168 to 336 hours).
3245353|NCT00873184|Other|1|A prospective, single-arm intervention study, potential participants will be identified and screened for eligibility via medical record review of patient scheduled for their post surgical primary adjuvant treatment consultation at DUMC.
3245354|NCT00873171||1. OMT|This procedure consist of Sacral rocking is performed by placing the heel of the practitioner's hand over the sacrum and by using the palpatory skills of an osteopathic physician; rock the sacrum into a position with no restriction. Myofascial release will utilize various physical motions to place the patients lumbosacral region in a position of maximal comfort and tissue release.
3245355|NCT00873171||2. Attention control OMT|The procedure consist of light pressure applied to certain painful areas of the body and back to decrease pain and help patient relax. The physician will look for areas of the body that hurt, lay his/her hands on the those places, and apply light pressure.
3245356|NCT00873171||3. Standard of Care|This procedure consists of various conservative treatments that can help reduce stress. Those include dietary modifications, pharmaceuticals, bladder training, and neuromodulation. If these treatments are not successful, minimally invasive surgical procedures is performed.
3245357|NCT00873158|No Intervention|Physical Therapy Group|Patient's in the Physical Therapy Group will have the standard manual treatments during their usual physical therapy visits with no additional intervention
3245358|NCT00873158|Experimental|Dynasplint Group|Along with standard manual physical therapy, patients will have a stretching device (Dynasplint) used in rehabilitation to regain ROM in stiff joints. Patients will use this device 20-30 minutes 2 times per day at home.
3245359|NCT00873145||1|Patients with major bone defects around the elbow.
3245360|NCT00873132||Data Collection|Collect data both retrospectively and prospectively on subjects seen at the Preston Robert Tisch Brain Tumor Center
3245361|NCT00873119|Experimental|Arm A - BelCaP|Group A: belinostat 1000 mg/m² administered as a 30 minute IV infusion once daily on days 1, 2 and 3, with at least 18 hours between infusions, followed by belinostat 2000 mg administered orally once daily on days 4 and 5, every 3-weeks, in combination with paclitaxel 175 mg/m² administered as an IV infusion following the infusion of belinostat on cycle day 3, and carboplatin (AUC 6) administered as a 30-60 minute IV infusion directly after the paclitaxel administration on cycle day 3.
3245362|NCT00873119|Active Comparator|Arm B - CaP|Group B: paclitaxel 175 mg/m² administered as an IV infusion directly followed by carboplatin (AUC 6) administered as a 30-60 minute IV infusion on cycle day 1 of a 3-weekly cycle.
3245363|NCT00873093|Experimental|Pre-B ALL Relapse<18 mths from diagnosis (chemo) age<=21 yrs|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
3245364|NCT00873093|Experimental|Pre-B ALL Relapse 18-36 mths from diagnosis (chemo) age<=21 yr|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
3245365|NCT00873093|Experimental|Pre-B ALL Relapse<36 mths from diagnosis (chemo) age>21 yrs|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
3245409|NCT00872820|Active Comparator|1|Participants will receive standard cognitive behavioral therapy.
3245410|NCT00872820|Experimental|2|Participants will receive acceptance- and commitment-based behavioral therapy.
3245366|NCT00873093|Experimental|T-cell ALL (Chemotherapy)|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
3245367|NCT00873093|Experimental|T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy)|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
3245368|NCT00873067|Active Comparator|ACVP plus roof line|Standard procedure for atrial fibrillation ablation, including pulmonary vein isolation plus roof line ablation. All ablation lines will be tested.
3245369|NCT00873067|Active Comparator|Additional CFAEs ablation|Atrial fibrillation ablation with pulmonary vein ablation and roof line. In addition, complex fractionated atrial electrograms ablation will be performed, lasting at most 30 minutes.
3245370|NCT00873054||1 ESWL|In this procedure,scope will be placed inside bladder and a plastic tube (stent) will be left to drain the kidney on the affected side in a routine manner. Next the patient will be transferred to a separate room and sound waves will be aimed at the center of the stone until the stone is broken into pieces.
3245371|NCT00873054||2 PCNL|In this procedure,scope will be placed inside bladder and a plastic tube (stent) will be left to drain the kidney on the affected side in a routine manner. Next, a small (1cm) cut will be made in the back and a tube will be placed into the kidney. Through this tube a small camera will be placed inside the kidney and break the stone into many pieces and remove them through the same tube. All fragments that can be seen will be removed. A different plastic tube (drain) will be placed through the cut and into the kidney and left in place for 5-7 days.
3245372|NCT00873041|Experimental|5 mg/kg/day deferasirox|Participants received a starting dose of 5 mg/kg/day deferasirox tablets orally each day in the morning for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
3245373|NCT00873041|Experimental|10 mg/kg/day deferasirox|Participants received a starting dose of 10 mg/kg/day deferasirox tablets orally each day in the morning for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
3245374|NCT00873041|Placebo Comparator|5 mg/kg/day placebo|Placebo tablet matching 5 mg/kg/day orally in the morning each day for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
3245375|NCT00873041|Placebo Comparator|10 mg/kg/day placebo|Placebo tablet matching 10 mg/kg/day orally in the morning each day for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
3245376|NCT00873028|Experimental|1|
3245377|NCT00873028|No Intervention|2|Those patients assigned to Control were followed by their own physicians, received routine nursing assistance, were visited daily by the one of the investigators (CPM), but were not exposed to any specific respiratory or motor physical intervention.
3245378|NCT00873015|Experimental|Nitrite|Continuous intravenous infusion of Sodium Nitrite
3245379|NCT00873015|Placebo Comparator|Vehicle control|Continuous intravenous infusion of saline
3245380|NCT00873002|Active Comparator|LBH589|This study utilizes a sequential dose-escalation design to define the MTD of LBH589 when combined with standard doses of sorafenib.
3245381|NCT00872989|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who progress also receive oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of a second disease progression or unacceptable toxicity.
3245382|NCT00872989|Experimental|Arm II|Patients receive docetaxel IV over 1 hour on day 1 and oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3245383|NCT00872976|Experimental|Cohort #1|
3245384|NCT00872976|Experimental|Cohort #2|
3245385|NCT00872963||RABIES VACCINE|Those subjects who received the active comparator
3245386|NCT00872963||RTS,S/AS01E|The subjects who received investigational product
3245387|NCT00872950|Other|Open label|
3245388|NCT00872924|Experimental|1|sumatriptan succinate 100 mg tablets (containing 140 mg of sumatriptan succinate equivalent to 100 mg sumatriptan) of OHM laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA).
3245389|NCT00872924|Active Comparator|2|IMITREX® 100 mg tablets (containing 140 mg of sumatriptan succinate equivalent to 100 mg sumatriptan)
3245390|NCT00872911|Experimental|Nutritional supplement|
3245391|NCT00872911|Experimental|Placebo + Exercise|
3245392|NCT00872911|Experimental|Nutritional Supplement + Exercise|
3245393|NCT00872911|No Intervention|Placebo|
3245394|NCT00872898|Experimental|1|Once daily oral administration of memantine for 12 weeks.
3245395|NCT00872898|Placebo Comparator|2|Once daily oral administration of placebo for 12 weeks.
3245396|NCT00872885|Experimental|A|Dose 1
3245397|NCT00872885|Experimental|B|Dose 2
3245398|NCT00872885|Experimental|C|Dose 3
3245399|NCT00872885|Active Comparator|D|Morphine
3245400|NCT00872885|Placebo Comparator|E|Placebo
3245401|NCT00872872|Active Comparator|AZT/3TC 1 week after delivery|AZT/3TC 1week after delivery
3245402|NCT00872872|Experimental|AZT/3TC 2 weeks after delivery|AZT/3TC 2 weeks after delivery
3245403|NCT00872859|Experimental|1|Dermamatrix with radiation
3245404|NCT00872859|Experimental|2|Dermamatrix without radiation
3245405|NCT00872859|Experimental|3|Alloderm with radiation
3245406|NCT00872859|Experimental|4|Alloderm without radiation
3245407|NCT00872833||age 18-29|People age groups 18-29 with transfusion-dependent thalassemia who have reported at least mild degrees of pain during the main Assessment of Pain study.
3245411|NCT00872820|No Intervention|3|Participants will be placed on a waitlist for 3 months before being offered treatment.
3245412|NCT00872807|Experimental|Group intervention|Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality. They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months.
3245413|NCT00872807|Active Comparator|Individual intervention|Lifestyle counseling for each separate family practiced by single health professionals both in hospital and municipality. A more conventional model.
3245414|NCT00872794|Other|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
3245415|NCT00872781|Experimental|1|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc (a subsidiary of Ranbaxy pharmaceuticals Inc)
3245416|NCT00872781|Active Comparator|2|ACCURETICTM tablets (containing fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg)
3245417|NCT00872755|Active Comparator|Nissen|Laparoscopic Nissen Fundoplication
3245418|NCT00872755|Active Comparator|Gastropexy|Procedure/Surgery Laparoscopic Nissen Fundoplication combined with posterior gastropexy
3245419|NCT00872742|Experimental|1|Participants will receive acceptance enhanced behavior therapy (AEBT) for trichotillomania (TTM).
3245420|NCT00872742|Active Comparator|2|Participants will receive psychoeducation and supportive therapy (PST) for TTM.
3245421|NCT00872729|Active Comparator|Cystagon®|Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg
3245422|NCT00872729|Experimental|RP103|Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg
3245423|NCT00872716|Experimental|Quetiapine XR|100 mg single-dose Quetiapine XR
3245424|NCT00872716|Placebo Comparator|Placebo|
3245425|NCT00872703||1|
3245426|NCT00872703||2|
3245427|NCT00872690||Group 1|OEF/OIF veterans with polytrauma who have been referred by the Tampa VA Polytrauma Rehabilitation Center (PRC) to the VA VR&E Regional Office in St. Petersburg, Florida for Chapter 31 (IL) services.
3245428|NCT00872690||Group 2|Caregivers of the veterans who enroll in the study
3245429|NCT00872677||Dietitian-led counseling and Weight Watchers|Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.
3245430|NCT00872677||Dietitian & Weight Watchers + Spirituality Counseling|Dietitian wkly for the 1st-3 months, every other week for the next 3 months and monthly thereafter; Spiritual counselor weekly in months 6-9, every other week in months 9-12 and monthly thereafter.
3245431|NCT00872664|Active Comparator|formula with added carotenoids|Both arms are double-blinded. Infant will be assigned to receive preterm formula with added carotenoids. If infant is receiving human milk then the study formula will only be used as a supplement.
3245432|NCT00872664|Active Comparator|formula without added carotenoids|Both arms are double-blinded. This arm will use preterm formula as it is currently available, which is without any carotenoids. If the infant is receiving human milk, then the formula will be used as a supplement as needed.
3245433|NCT00872651|Experimental|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
3245434|NCT00872651|Active Comparator|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
3245435|NCT00872638|Active Comparator|1|
3245436|NCT00872638|Active Comparator|2|
3245437|NCT00872625|Experimental|Cyberknife|
3245438|NCT00872612|Experimental|A|Endosonography arm
3245439|NCT00872612|Active Comparator|B|Conventional bronchoscopy arm
3245440|NCT00872599|Placebo Comparator|Placebo, then fenofibrate|Randomized study of fenofibrate versus placebo during high salt diet
3245441|NCT00872599|Placebo Comparator|Fenofibrate, then placebo|Randomized study of fenofibrate versus placebo during high salt intake.
3245442|NCT00872586|Experimental|1|Olmesartan medoxomil and hydrochlorothiazide
3245443|NCT00872586|Active Comparator|2|olmesartan medoxomil
3245444|NCT00872573|Other|C-Stem™ AMT Femoral Component|
3245445|NCT00872547|Active Comparator|1|Resurfacing system
3245446|NCT00872547|Active Comparator|2|Large Metal-on-Metal Total Hip Replacement
3245447|NCT00872534|Experimental|PL-2200|PL-2200 is an NSAID product containing 325mg of acetylsalicylic acid and phosphatidylcholine in a neutral lipid matrix.
3245448|NCT00872534|Active Comparator|Aspirin|Immediate release 325mg aspirin
3245449|NCT00872521|Experimental|bortezomib; doxorubicin; dexamethasone|PAD induction Open Label Treatment: Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1 4 8 & 11) Doxorubicin 20 mg/m2 i.v. (D1 & 4) Dexamethasone 20 mg p.o. (D1 2 4 5 8 9 11 & 12)
3245450|NCT00872495||1|"Bladder Cancer Group:~Patients scheduled to have a cystectomy or cystoscopy of their bladder with possible removal or biopsy of bladder tumor or tissue.~Two urine samples collected at the time of the scheduled procedure:~One sample collected through voiding. The other sample collected from atheterized urine in the operating room. Additional urine samples may be collected at each follow up visit over two years. These samples will be obtained via voiding, standard urine sample collection."
3245451|NCT00872495||2|Control Group: Patients with no known evidence of bladder cancer. One urine sample will be collected through voiding, as with standard urine sample collection at the time of clinic visit.
3245452|NCT00872482|Experimental|1|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT. Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
3245453|NCT00872482|Placebo Comparator|2|"A placebo will be administered by the intravenous route weekly during WBRT and following WBRT.~Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day."
3245454|NCT00872469|Active Comparator|Tranexamic acid|
3245455|NCT00872469|Placebo Comparator|placebo|
3245456|NCT00872443||FOP|Patients who already have an occlusion of POF secondary to a cryptogenic CVA and younger than 55 years old and without characterized thromboembolic events.
3245457|NCT00872430|Active Comparator|Placebo/Laxative tea crossover|This arm received placebo in the first period and laxative tea in the second period (after washout period of 9 days).
3245509|NCT00872027|Experimental|1|Participants will receive 8 weeks of escitalopram treatment.
3245759|NCT00870415|Experimental|Surgerie|
3245458|NCT00872430|Active Comparator|Laxative tea/Placebo crossover|This arm received laxative tea in the first intervention period and placebo in the second intervention period (after washout period of 9 days).
3245459|NCT00872417|Experimental|Treatment-naive|To explore the efficiency and safety of generic antiretroviral drugs for 520 treatment-naive HIV/AIDS patients
3245460|NCT00872417|No Intervention|TREATMENT-EXPERIENCED|To explore the long term ARV of treatment-experienced patients who have no sign of drug resistance; to explore the long term efficiency and safety and drug sife effects of ARV in HIV/AIDS patients. These patients have taken ARV for approximately 3 years already.
3245461|NCT00872417|Experimental|drug resistance|To explore the second line drugs for those drug resistance patients
3245462|NCT00872404|Experimental|1|CP-751,871 will be administered as an open-label intravenous solution. Patients will remain under clinical observation for one hour post-infusion
3245463|NCT00872391|Experimental|Hypofractionated LINAC radiotherapy|
3245464|NCT00872378|Active Comparator|Exenatide|Laparoscopic adjustable gastric banding group: twice daily exenatide therapy plus a standard diet and exercise program
3245465|NCT00872378|Placebo Comparator|Placebo|Laparoscopic adjustable gastric banding group: twice daily placebo therapy plus a standard diet and exercise program
3245466|NCT00872365|Other|1|Regular aerobic physical exercise + placebo
3245467|NCT00872365|Other|2|Activities of daily living + Micronutrients
3245468|NCT00872365|Other|3|Regular aerobic exercise + micronutrients
3245469|NCT00872365|Placebo Comparator|4|Activities of daily living + placebo
3245470|NCT00872339||transfusion-dependant|People with transfusion-dependant thalassemia who received at least 8 transfusions in the past year.
3245471|NCT00872339||non-transfusion-dependant|People with non-transfusion-dependant thalassemia who received no transfusions in the past year.
3245472|NCT00872339||intermittently transfused|Intermittently transfused patients- individuals who received at least one but fewer than eight transfusions in the last year
3245473|NCT00872326|Experimental|Autologous Bone Marrow Mononuclear Cells|Consecutive inclusion among diabetic patients with critical limb ischemia. Intraarterial infusion of autologous bone marrow mononuclear cells
3245474|NCT00872313||1|Psychoses within the first 3 months postpartum
3245475|NCT00872313||2|Psychoses > 3 months to 6 months postpartum
3245476|NCT00872300|Experimental|1|
3245477|NCT00872287|Active Comparator|Laparoscopic Cholecystectomy|Four ports classic laparoscopic cholecystectomy
3245478|NCT00872287|Active Comparator|SILS|Single transumbilical incision laparoscopic cholecystectomy
3245479|NCT00872274|Experimental|1|sumatriptan succinate tablets 100 mg (containing sumatriptan succinate equivalent to 100 mg of sumatriptan) manufactured by OHM Laboratories In
3245480|NCT00872274|Active Comparator|2|IMITREX® 100 mg tablets (containing sumatriptan succinate equivalent to 100 mg of sumatriptan)
3245481|NCT00872261||Proxy microbicide product|Use of vaginal lubricant as a proxy microbicide gel; use of multivitamin as proxy pre-exposure prophylaxis (PrEP) product
3245482|NCT00872248|Experimental|1|Parturients received spinal anesthesia
3245483|NCT00872248|Active Comparator|2|Parturients received epidural anesthesia
3245484|NCT00872235|Experimental|1|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc.(division of Ranbaxy Laboratories Limited)
3245485|NCT00872235|Active Comparator|2|Accuretic tablets (fixed dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg)
3245486|NCT00872235|Experimental|3|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc.(division of Ranbaxy Laboratories Limited)
3245487|NCT00872235|Active Comparator|4|Accuretic tablets (fixed dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg)
3245488|NCT00872222|Other|Ceramic-on-Ceramic|Pinnacle™ Acetabular System with ceramic liner
3245489|NCT00872209|Active Comparator|Ciloxan Ear Drops|Ciloxan (Alcon, Inc.) Sterile Ophthalmic and Ear Drops
3245490|NCT00872209|Experimental|Foam Otic Cipro|Patients randomized to this study arm will receive the experimental product
3245491|NCT00872196|Other|1 - Follow-up Study|This is a follow-up study with no treatment and only samples being collected.
3245492|NCT00872170|Active Comparator|Intervention|Participants with thalassemia who have pulmonary hypertension will receive sildenafil for 12 weeks.
3245493|NCT00872170|No Intervention|Control|Participants with thalassemia who do not have pulmonary hypertension will be part of a control group and will only be undergoing screening/baseline assessments.
3245494|NCT00872157|Experimental|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
3245495|NCT00872144|Active Comparator|Sativex|
3245496|NCT00872131||Generalized social anxiety disorder participants|Participants with generalized social anxiety disorder will undergo MRI scanning and sertraline treatment.
3245497|NCT00872131||Healthy control participants|Healthy control participants will undergo MRI scanning.
3245498|NCT00872118|Experimental|1|Brief Intervention for Socially Anxious Drinkers
3245499|NCT00872118|Active Comparator|2|Enhanced Alcohol Skills and Education Program
3245500|NCT00872105|Other|Non-operative treatment|The first treatment strategy will involve conservative (nonoperative) management of the clavicle fracture.
3245501|NCT00872105|Active Comparator|Operative treatment|The second treatment strategy will involve operative fixation (i.e. ORIF) of the fracture with a plate and screws.
3245502|NCT00872092||Breath test|Subjects with suspected SBBO
3245503|NCT00872079|Active Comparator|Genomics|"Aim 1: Collect historical data on warfarin dosing in subjects at the VA. Aim 2: Collect genotype information on up to 300 subjects receiving warfarin anticoagulation.~Aim 3: Develop a computer model incorporating the information from Aim 1 and 2. Aim 4: Conduct randomized clinical trial."
3245504|NCT00872066|Active Comparator|1) SmartSet® HV Bone Cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
3245505|NCT00872066|Active Comparator|2) SmartSet® GHV Bone Cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
3245506|NCT00872053|Experimental|Arm 1|Focused Ankle Training
3245507|NCT00872053|Experimental|Arm 2|Combination Therapy
3245508|NCT00872040||Nuliparous women and their husbands|Women in their first pregnancy with their husbands
3245510|NCT00872027|Placebo Comparator|2|Participants will receive 8 weeks of placebo pills.
3245511|NCT00872014|Experimental|15mg/ kg cohort|AMG 386 15mg/kg intravenously once weekly and Sorafenib 400mg orally twice daily in an every 4 weeks dosing schedule.
3245512|NCT00872014|Experimental|10 mg/kg cohort|AMG 386 10mg/kg intravenously once weekly and Sorafenib 400mg orally twice daily in an every 4 weeks dosing schedule.
3245513|NCT00872001|Active Comparator|Acadesine|Acadesine intravenous (IV) infusion, plus cardioplegia solution with acadesine, and priming solution with acadesine in the heart lung machine during cardiopulmonary bypass (CPB)
3245514|NCT00872001|Placebo Comparator|Placebo|Normal saline, IV infusion, plus cardioplegia solution with added normal saline, and priming solution with added normal saline in the heart lung machine during CPB
3245515|NCT00871975|Experimental|Urodynamics + Tetra|All patients were recruited to the same arm and receive Urodynamics testing as part of the routine diagnostic work-up, plus the Tetra-NIRS intervention.
3245516|NCT00871962||1|COPD patients on necessity of long-term oxygen therapy
3245517|NCT00871949|Experimental|Cohort 1, Sequence 1|Period 1- Placebo Period 2- 100 mg Period 3- 300 mg
3245518|NCT00871949|Experimental|Cohort 1, Sequence 2|Period 1- 35 mg Period 2- Placebo Period 3- 300 mg
3245519|NCT00871949|Experimental|Cohort 1, Sequence 3|Period 1- 35 mg Period 2- 100 mg Period 3- Placebo
3245520|NCT00871949|Experimental|Cohort 2, Sequence 1|Period 1- Placebo Period 2- 1000 mg Period 3- 1500 mg Period 4- 600 mg (Fed conditions)
3245521|NCT00871949|Experimental|Cohort 2, Sequence 2|Period 1- 600 mg Period 2- Placebo Period 3- 1500 mg Period 4- 600 mg (Fed conditions)
3245522|NCT00871949|Experimental|Cohort 2, Sequence 3|Period 1- 600 mg Period 2- 1000 mg Period 3- Placebo Period 4- 600 mg (Fed conditions)
3245523|NCT00871936|Experimental|1|SLx-4090 in combination with Metformin
3245524|NCT00871936|Other|2|Placebo
3245525|NCT00871923|Experimental|Tarceva + RT|Tarceva (Erlotinib hydrochloride) + Radiation Therapy. Tarceva 150 mg by mouth every day beginning Day 1. Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
3245526|NCT00871910|Experimental|2 Hour SCH 727965 infusion|Participants treated with 2 hour SCH 727965 IV infusion
3245527|NCT00871910|Experimental|8 Hour SCH 727965 infusion|Participants treated with 8 hour SCH 727965 IV infusion.
3245528|NCT00871910|Experimental|24 Hour SCH 727965 infusion|Participants treated with 24 hour SCH 727965 IV infusion.
3245529|NCT00871910|Experimental|2 Hour SCH 727965 infusions plus aprepitant in Cycle 1|Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 1 only.
3245530|NCT00871910|Experimental|2 Hour SCH 727965 infusion plus aprepitant in Cycle 2|Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 2 only.
3245531|NCT00871897||Cardiac Rehabilitation|People with heart failure who elect to participate in cardiac rehabilitation.
3245532|NCT00871897||No Cardiac Rehabiliation|People with heart failure who elect NOT to participate in cardiac rehabilitation.
3245533|NCT00871884|Active Comparator|Treatment As Usual|
3245534|NCT00871884|Experimental|Experimental|
3245535|NCT00871871|Experimental|Part I, Placebo-HCTZ|Placebo in Period 1 followed by HCTZ in Period 2
3245536|NCT00871871|Experimental|Part I, HCTZ-Placebo|HCTZ in Period 1, followed by placebo in Period 2
3245537|NCT00871871|Experimental|Part II, Placebo-ISMN|Placebo in Period 1, followed by ISMN in Period 2
3245538|NCT00871871|Experimental|Part II, ISMN-Placebo|ISMN in Period 1, followed by placebo in Period 2
3245539|NCT00871858|Active Comparator|Arm I|Patients receive oral anastrozole once daily for 6 months.
3245540|NCT00871858|Experimental|Arm II|Patients receive fulvestrant intramuscularly on days 1, 14, and 28 and then once a month at 2-6 months.
3245541|NCT00871845|No Intervention|1) non obese, naive|Patients naive to hepatitis C therapy with body mass index (BMI) <25
3245542|NCT00871845|No Intervention|2) obese, naive, control|Patients naive to hepatitis C therapy with BMI ≥ 30
3245543|NCT00871845|Active Comparator|3) obese, naive, orlistat|"Patients naive to hepatitis C therapy with BMI ≥ 30 as an interventional group, patients will receive up to 6 sessions of dietary and physical education after which they will start receiving their standard hepatitis C treatment. they will be encouraged to attend up to 12 monthly meetings (along side the monthly visits for their standard viral hepatitis therapy) at the health education room of center for liver diseases, to check dietary diaries. The dietary and physical education (given through up to 6 weekly sessions and subsequently up to 12 monthly follow-up meetings) will be presented.~Orlistat (60 mg capsules, three times daily, before meals) will be prescribed for a time frame starting 3 to 6 weeks prior to and during the 48 weeks of the standard anti-viral therapy."
3245544|NCT00871845|Placebo Comparator|4) obese, naive, Placebo|"Patients naive to hepatitis C therapy with BMI ≥ 30 as an interventional group, patients will receive up to 6 sessions of dietary and physical education after which they will start receiving their standard hepatitis C treatment. they will be encouraged to attend up to 12 monthly meetings (along side the monthly visits for their standard viral hepatitis therapy) at the health education room of center for liver diseases, to check dietary diaries. The dietary and physical education (given through up to 6 weekly sessions and subsequently up to 12 monthly follow-up meetings) will be presented.~Placebo will be prescribed for a time frame starting 3 to 6 weeks prior to and during the 48 weeks of the standard anti-viral therapy."
3245545|NCT00871845|Active Comparator|5) obese, non-naive, orlistat|"Patients non responder or relapser after previous course of Hepatitis C therapy, with BMI ≥ 25. Patients will receive up to 6 sessions of dietary and physical education after which they will start receiving their standard hepatitis C treatment. they will be encouraged to attend up to 12 monthly meetings (along side the monthly visits for their standard viral hepatitis therapy. The dietary and physical education.~Orlistat 60 mg capsules, three times daily, before meals) will be prescribed for a time frame starting 3 to 6 weeks prior to and during the 48 weeks of the standard anti-viral therapy."
3245594|NCT00871546|Experimental|B-CLL treated w/ SCH 727965 after progression on alemtuzumab|
3245595|NCT00871533|Experimental|1|"REGIONAL PEG IFN MAINTENANCE: Regional PEG IFN-a2b given subcutaneously at MAINTENANCE dose level. (This arm has completed enrollment; non-evaluable subjects as defined in section 9.5 may be replaced at any point during study."
3245546|NCT00871845|Placebo Comparator|6) obese, non-naive, Placebo|"Patients naive to hepatitis C therapy with BMI ≥ 30 as an interventional group, patients will receive up to 6 sessions of dietary and physical education after which they will start receiving their standard hepatitis C treatment. they will be encouraged to attend up to 12 monthly meetings (along side the monthly visits for their standard viral hepatitis therapy) at the health education room of center for liver diseases, to check dietary diaries. The dietary and physical education (given through up to 6 weekly sessions and subsequently up to 12 monthly follow-up meetings) will be presented.~Placebo will be prescribed for a time frame starting 3 to 6 weeks prior to and during the 48 weeks of the standard anti-viral therapy."
3245547|NCT00871819|Other|Spinal Cord Stimulation Group|Spinal Cord Stimulation (SCS) Treatment Group
3245548|NCT00871806|Active Comparator|Eletriptan commercial tablet with water|Eletriptan commercial tablet given with water
3245549|NCT00871806|Experimental|Eletriptan oral disintegrating tablet (ODT) #1 without water|Oral disintegrating tablet formulation #1 without water
3245550|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #2 without water|Oral disintegrating tablet formulation #2 without water
3245551|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #1 with water|Oral disintegrating tablet formulation (ODT) #1 with water
3245552|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #2 with water|Oral disintegrating tablet formulation (ODT) #2 with water
3245553|NCT00871793|Active Comparator|1|Occupational therapy
3245554|NCT00871793|No Intervention|2|watchful waiting
3245555|NCT00871780|Experimental|Natalizumab|natalizumab 300 mg IV every 4 weeks for 48 weeks
3245556|NCT00871767|Experimental|1|40 or 100mg AZD5672, Reference formulation
3245557|NCT00871767|Experimental|2|40 or 100mg AZD5672, Test formulation
3245558|NCT00871741|Experimental|GSK2202083A GROUP|Subjects in this group were to receive three doses of GSK2202083A vaccine at 3, 5 and 11 months of age, as an intramuscular injection in the anterolateral quadrant of the right thigh.
3245559|NCT00871741|Active Comparator|INFANRIX + MENJUGATE GROUP|Subjects in this group were to receive three doses of Infanrix™ hexa vaccine at 3, 5 and 11 months of age, and two doses of Menjugate® vaccine at 3 and 5 months of age, as an intramuscular injection in the anterolateral quadrant of the right thigh.
3245560|NCT00871728|Experimental|Itraconazole|
3245561|NCT00871715|Experimental|ASAP|A focused, intense, evidence-based, upper extremity rehabilitation program, administered during the early post-acute outpatient interval. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence.
3245562|NCT00871715|Active Comparator|DEUCC|Dose-equivalent usual and customary arm therapy administered early post-acutely in the outpatient setting. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
3245563|NCT00871715|Other|UCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group with treatment dose administered in accordance with usual and customary practices.
3245564|NCT00871702|Experimental|Donor lymphocyte infusion|CD34-TK75 transduced T lymphocytes from donors matched at a 5/6 or 6/6 antigen level at a dose of 1.0 x 105 cells/kg recipient weight.
3245565|NCT00871689|Experimental|UCBT With Post-Transplant IL-2|Patients receive cyclophosphamide, fludarabine phosphate, total-body irradiation, T cell depleted umbilical cord blood transplantation (UCBT), followed by interleukin-2 (IL-2, aldesleukin) every other day beginning day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
3245566|NCT00871676|Active Comparator|1|Overweight/obese individuals being treated with lifestyle modification to facilitate weight loss.
3245567|NCT00871676|Experimental|2|Lifestyle modification plus use of chewing gum to facilitate weight loss in overweight/obese persons.
3245568|NCT00871663|Experimental|Advanced solid tumors|Participants with advanced solid tumors treated with SCH 727965 in dose-escalation cohorts
3245569|NCT00871663|Experimental|Non-Hodgkin's lymphoma and multiple myeloma|Participants with non-Hodgkin's lymphoma or multiple myeloma treated with SCH 727965
3245570|NCT00871663|Experimental|B cell chronic lymphocytic leukemia|Participants with B-cell chronic lymphocytic leukemia treated with SCH 727965 in dose-escalation cohorts
3245571|NCT00871650||Combat Veterans with PTSD|Male Veterans of Operation Iraqi Freedom (OIF) and/or Operation Enduring Freedom (OEF), ages 18-50, with Combat Exposure Scale score > 17, who are not on medication and do not have trauma history before age 18.
3245572|NCT00871650||Combat Veterans without PTSD|Male Veterans of Operation Iraqi Freedom (OIF) and/or Operation Enduring Freedom (OEF), ages 18-50, with combat experience, who are not suffering from PTSD, and who are not on medication.
3245573|NCT00871637||Group One|Healthy non-smoking controls
3245574|NCT00871637||Group Two|Smoking adults with chronic bronchitis/chronic obstructive pulmonary disease
3245575|NCT00871637||Group Three|Non-smoking adults with chronic bronchitis/chronic obstructive pulmonary disease
3245576|NCT00871624|Active Comparator|Dexmedetomidine|Subjects received active dexmedetomidine 0.2 -0.7 mcg/kg/hr
3245577|NCT00871624|Placebo Comparator|Placebo|Subjects received placebo saline solution 0.2-0.7 mcg/kg/hr
3245578|NCT00871598|Placebo Comparator|Placebo|
3245579|NCT00871598|Experimental|Single 0.3|
3245580|NCT00871598|Experimental|Repeat 1.0|
3245581|NCT00871598|Experimental|Repeat 2.0|
3245582|NCT00871598|Experimental|Repeat 4.0|
3245583|NCT00871598|Experimental|Repeat 8.0|
3245584|NCT00871572|Placebo Comparator|Placebo|
3245585|NCT00871572|Experimental|LY2409021 10 milligrams (mg)|
3245586|NCT00871572|Experimental|LY2409021 30 mg|
3245587|NCT00871572|Experimental|LY2409021 60 mg|
3245588|NCT00871559|Experimental|Q2W|REGN421 (SAR153192) taken once every two weeks (Q2W)
3245589|NCT00871546|Experimental|Participants with MCL randomized to SCH 727965|
3245590|NCT00871546|Active Comparator|Participants with MCL randomized to bortezomib|
3245591|NCT00871546|Experimental|MCL treated w/SCH 727965 after progression on bortezomib|
3245592|NCT00871546|Experimental|Participants with B-CLL randomized to SCH 727965|
3245593|NCT00871546|Active Comparator|Participants with B-CLL randomized to alemtuzumab|
3245597|NCT00871533|Experimental|3|"PEG IFN INDUCTION: System PEG IFN-a2b given subcutaneously at INDUCTION dose level"
3245598|NCT00871533|Experimental|4|"REGIONAL HDI MAINTENANCE: Regional HDI given subcutaneously at MAINTENANCE dose level per standard HDI regimen"
3245599|NCT00871533|No Intervention|5|"HDI Induction: Systemic HDI given intravenously at INDUCTION dose level per the standard HDI regimen."
3245600|NCT00871520||Palliative Therapy|Patients referred to the oncology / radiation oncology departments for palliative therapy.
3245601|NCT00871507|Experimental|001|
3245602|NCT00871507|Experimental|002|
3245603|NCT00871507|Placebo Comparator|003|
3245604|NCT00871507|Active Comparator|004|
3245605|NCT00871494|Experimental|Azithromycin switch therapy (switch from intravenous to oral).|
3245606|NCT00871481|Experimental|Treatment (laboratory-treated T cells and ipilimumab)|Patients receive cyclophosphamide IV on day -2, therapeutic cytotoxic T lymphocytes IV over 30-60 minutes on day 0, low-dose aldesleukin SC BID on days 0-13, and ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
3245607|NCT00871468|Active Comparator|superior plate|Clavicle plate on the superior surface of the bone
3245608|NCT00871468|Experimental|anterior inferior plate|plate placed on anterior inferior surface of bone
3245609|NCT00871455|Experimental|1|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
3245610|NCT00871442|Active Comparator|No Basal Infusion|"PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml~Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)"
3245611|NCT00871442|Active Comparator|Basal Infusion|"PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml~Group 2: Basal Infusion: 10 ml/hr; Bolus 5 ml q 30min prn (5ml demand dose with 30min lockout)"
3245612|NCT00871403|Experimental|Arm 1|Investigational treatment (pazopanib and pemetrexed)
3245613|NCT00871403|Active Comparator|Arm 2|Standard treatment (pemetrexed and cisplatin)
3245614|NCT00871377|Placebo Comparator|Placebo|Corn Oil Placebo (n-6 fatty acids)
3245615|NCT00871377|Experimental|High Dose Fish Oil|2160 mg of EPA + DHA
3245616|NCT00871377|Experimental|Low Dose Fish Oil|1060 mg of EPA + DHA
3245617|NCT00871364|Experimental|A|VENLAFAXINE TABLETS 50 mg, single dose
3245618|NCT00871364|Active Comparator|B|Effexor® (venlafaxine HCl) Tablets equivalent to 50 mg venlafaxine, single dose
3245619|NCT00871351|Experimental|Ezetimibe + Atorvastatin|Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
3245620|NCT00871351|Active Comparator|Atorvastatin|Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
3245621|NCT00871351|Active Comparator|Rosuvastatin|Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
3245622|NCT00871338|Experimental|GSK2197870A Group|Subjects aged between and including 6 and 12 weeks of age at the time of first vaccination received 3 doses of GSK2197870A vaccine at Months 0, 1 and 2, 2 doses of Prevenar™ vaccine at Months 0 and 2 and a booster dose of Menitorix™ vaccine at Month 10. All vaccines were administered intramuscularly. GSK2197870A and Menitorix™ vaccines were administered in the right upper anterolateral thigh and Prevenar™ vaccine in the left upper anterolateral thigh.
3245623|NCT00871338|Active Comparator|Pediacel Group|Subjects aged between and including 6 and 12 weeks of age at the time of first vaccination received 3 doses of Pediacel™ vaccine at Months 0, 1 and 2, 2 doses of Prevenar™ vaccine at Months 0 and 2, 2 doses of Menjugate™ vaccine at Months 1 and 2 and a booster dose of Menitorix™ at Month 10. All vaccines were administered intramuscularly. Pediacel™ and Menitorix™ vaccines were administered in the right upper anterolateral thigh and Prevenar™ vaccine in the left upper anterolateral thigh and Menjugate™ vaccine in the left lower anterolateral thigh.
3245624|NCT00871325|Experimental|Daikenchuto (TU-100) 7.5g/day|Daikenchuto (TU-100) 2.5g TID (7.5g/day)
3245625|NCT00871325|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID (15g/day)
3245626|NCT00871325|Placebo Comparator|Placebo|Placebo TID
3245627|NCT00871312|Active Comparator|Topical Wound Oxygen Therapy|Subjects will receive four 90 minute treatments of two2 therapy per week
3245628|NCT00871312|Placebo Comparator|Placebo Therapy|Subjects will receive four 90 minute treatments of Placebo two2 therapy per week
3245629|NCT00871299|Experimental|1|Mindfulness Based Cognitive Therapy (MBCT) + medication management
3245630|NCT00871299|Active Comparator|2|The Health Enhancement Program (HEP) + medication management
3245631|NCT00871286|Experimental|CT scan (sinus) pre-tx|Sinus CT scan performed at initial otolaryngology (ear, nose, and throat)visit
3245632|NCT00871286|Other|CT scan (sinus) post-tx|Sinus CT scan performed after 3-4 weeks of antibiotic treatment and any other indicated medical treatment(s), per insurance company guidelines
3245633|NCT00871260|Other|Open Label|Approximately 25 healthy volunteers will be recruited as controls, and approximately 500 patients with suspected coronary artery disease be recruited. Scan will be done with regadenoson contrast.
3245634|NCT00871247|Experimental|A|Finasteride 5 mg single dose tablet, single dose
3245635|NCT00871247|Active Comparator|B|Proscar® 5 mg Tablet, single dose
3245636|NCT00871208|Experimental|1|Altabax (R) and Locoid Lipocream (R):Patients will apply both drugs sequentially to active lesions of atopic dermatitis. Physical examination, skin cultures, photos and quality of life scores will be performed at baseline, week 1, week 2 and week 4.
3245637|NCT00871208|Active Comparator|2|Vehicle and Locoid Lipocream (R):Patients will apply both drugs sequentially to active lesions of atopic dermatitis. Physical examination, skin cultures, photos and quality of life scores will be performed at baseline, week 1, week 2 and week 4.
3245638|NCT00871182|Experimental|PT001 18 mcg|Inhaled PT001 18 mcg
3245639|NCT00871182|Experimental|PT001 36 mcg|Inhaled PT001 36 mcg
3245640|NCT00871182|Experimental|PT001 72 mcg|Inhaled PT001 72 mcg
3245641|NCT00871182|Experimental|PT001 144 mcg|Inhaled PT001 144 mcg
3245642|NCT00871182|Placebo Comparator|Inhaled Placebo|Inhaled Placebo
3245643|NCT00871182|Active Comparator|Tiotropium Handihaler|Tiotropium 18 mcg administered via Handihaler
3245760|NCT00870402|Experimental|1|
3245644|NCT00871169|Experimental|Irinotecan, oxaliplatin, and cetuximab|The goal is to administer at least 4 cycles to each patient, but treatment may stop earlier if the treating physician deems stopping to be in the best interest of the patient. Repeated treatment may be given to patients who benefit (either complete or partial response or stabilization of disease)
3245645|NCT00871156|Active Comparator|Part 1|Tafenoquine + Chloroquine vs. Chloroquine alone
3245646|NCT00871156|Placebo Comparator|Part 2|Chloroquine alone, Tafenoquine alone or Chloroquine+Tafenoquine
3245647|NCT00871143|Experimental|CBT specific for BDD|This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.
3245648|NCT00871143|Active Comparator|Non Specific CBT|Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
3245649|NCT00871117|Experimental|Kinrix + M-M-R II + Varivax|Subjects received at Day 0 one dose of Kinrix, intramuscularly in the deltoid region of the left upper arm, co-administered with one dose of M-M-R II and Varivax each, subcutaneously in the deltoid of the right upper and lower arm, respectively.
3245650|NCT00871117|Active Comparator|Kinrix + M-M-R II -> Varivax|Subjects received at Day 0 one dose of Kinrix, intramuscularly in the deltoid region of the left upper arm, co-administered with one dose of M-M-R II, subcutaneously in the deltoid of the right upper arm. At Day 30 they received one dose of Varivax subcutaneously in the deltoid region of the right upper arm.
3245651|NCT00871104|Experimental|1|IV fosfomycin and imipenem adjusted to renal function
3245652|NCT00871104|Active Comparator|2|IV Vancomycin twice a day with valley leves higher than 15 mcg/kg
3245653|NCT00871091|Experimental|1|CAD/CAM group, customized archwires
3245654|NCT00871091|Active Comparator|2|prefabricated archwires (superelastic)
3245655|NCT00871091|Active Comparator|3|prefabricated archwires with manual adjustments
3245656|NCT00871078||A|HIV-positive patients with CD4 cell counts below 100 cells/mm³ at some point of time in their medical history lasting for at least 6 months
3245657|NCT00871078||B|HIV-positive patients with CD4 cell counts never below 100 cells/mm³ in their medical records
3245658|NCT00871078||C|HIV-negative patients (control group)
3245659|NCT00871065|Experimental|A|Trial Arm (single arm study)
3245660|NCT00871039|Experimental|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
3245661|NCT00871039|Experimental|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
3245662|NCT00871026|Experimental|1|CAD/CAM group, customized archwires
3245663|NCT00871026|Active Comparator|2|prefabricated archwires (superelastic)
3245664|NCT00871013|Experimental|MEL-VTD-PACE|Melphalan, Velcade, Thalidomide, Dexamethasone, CisPlatin, Adriamycin, Cyclophosphamide, Etoposide
3245665|NCT00871000|Experimental|BOOSTRIX POLIO GROUP|Healthy male or female children, between and including 5 to 6 years of age, who were primed with three doses of Infanrix™ vaccine according to the Italian 3-5-11 month vaccination schedule, additionally received a single booster dose of Boostrix Polio™ vaccine co-administered with a single dose of Priorix Tetra™ vaccine at Day 0. Boostrix Polio™ vaccine was administered intramuscularly in the deltoid region of the left upper arm, while the Priorix Tetra™ vaccine was administered subcutaneously in the deltoid region of the right upper arm.
3245666|NCT00871000|Active Comparator|TETRAVAC GROUP|Healthy male or female children, between and including 5 to 6 years of age, who were primed with three doses of Infanrix™ vaccine according to the Italian 3-5-11 month vaccination schedule, additionally received a single booster dose of Tetravac™ vaccine co-administered with a single dose of Priorix Tetra™ vaccine at Day 0. Tetravac™ vaccine was administered intramuscularly in the deltoid region of the left upper arm, while the Priorix Tetra™ vaccine was administered subcutaneously in the deltoid region of the right upper arm.
3245667|NCT00870987|Experimental|1|DNA vaccine prime
3245668|NCT00870987|Experimental|2|adenovirus type 5 vaccine boost
3245669|NCT00870974|Experimental|Assess [18F]FPEB and PET imaging|To assess [18F] FPEB and PET imaging in subjects with neuropsychiatric conditions.
3245670|NCT00870961|Experimental|Arm I|Patients receive oral cholecalciferol (vitamin D3) supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
3245671|NCT00870961|Placebo Comparator|Arm II|Patients receive oral placebo supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
3245672|NCT00870948|Experimental|Regimen A|One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
3245673|NCT00870948|Experimental|Regimen B|One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected IV in an arm vein
3245674|NCT00870948|Experimental|Regimen C|One 100 mg ABT 874 (reconstituted lyophilized powder from the 3000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
3245675|NCT00870948|Experimental|Regimen D|One 100 mg ABT-874 (reconstituted lyophilized powder from the 1000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
3245676|NCT00870948|Experimental|Regimen E|700 mg ABT-874 (reconstituted lyophilized powder from the 3000 L process) in 100 mL 5% dextrose solution IV infusion in an arm vein
3245677|NCT00870935|Active Comparator|Balloon catheter|Hysterosalpingography using intrauterine Balloon catheter
3245678|NCT00870935|Active Comparator|Cervical vacuum cup|Hysterosalpingography using cervical vacuum cup
3245679|NCT00870935|Experimental|Operator choice|Hysterosalpingography is performed using either balloon catheter or cervical vacuum cup on the basis of the operator's choice
3245680|NCT00870922|Experimental|TMD group|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
3245681|NCT00870909|Active Comparator|active tDCS|"tDCS active; - Intensity = 2 milliamps (mA) during 20 minutes. ramp up/ramp down 30sec anodal tDCS applied over the left DLPFC combined with cathodal tDCS applied over the left temporoparietal junction (TPJ).~10 sessions, 2 per day"
3245682|NCT00870909|Placebo Comparator|sham tDCS|tDCS placebo same electrode montage than in the active group. 30 sec of active tDCS in the beginning of the stimulation sessions; ramp up/ramp down 30 sec
3245683|NCT00870896|Experimental|Tiotropium|Cough reflex measured by capsaicin Inhalation Challenge will follow Dicpinigaitis performed at 1 and 3 months. Solutions prepared to make a stock solution of 0.01 Mol diluted with physiologic saline to yield 11 doubling concentrations from 0.98 to 1,000 uMol/L. Final diluted capsaicin concentrations are: 0.98, 1.95, 3.9, 7.8, 15.6, 31.2, 62.5, 125, 250, 500, and 1000 uMol/L. Then, place 1 ml of the first concentration into nebulizer. Subjects inhale single breath of capsaicin aerosol. Single breaths are delivered in ascending order, with normal saline randomly interspersed to increase blindness, until two or more coughs (C2) and five or more coughs (C5) are reached. The different concentrations are delivered at 2 minute intervals.
3245684|NCT00870883|Experimental|N-acetylcysteine plus deferoxamine|
3245685|NCT00870870|Experimental|GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)|"Cycles repeat every 3 weeks for first 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met~*Cisplatin will replace Carboplatin. Gemcitabine/Carboplatin/Cetuximab (GCC) plus cixutumumab will change to Gemcitabine/Cisplatin/Cetuximab (GCiC) plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)"
3245686|NCT00870870|Active Comparator|GCiC (Gemcitabine/Cisplatin/Cetuximab)|"Cycles repeat every 3 weeks for 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met~*Cisplatin will replace Carboplatin. GCC plus cixutumumab will change to GCiC plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)"
3245687|NCT00870857||1|Subjects will be 300 HIV+ subjects and 300 HIV- controls selected by random sampling stratified by age and smoking history. Subjects will be recruited from the University of Pittsburgh and the University of Washington (UW) MACS sites. The University of California San Francisco (UCSF) will serve as the recruiting center for the WIHS cohort
3245688|NCT00870844|Experimental|Lu AA24493 (CEPO): 0.5 mcg/kg|
3245689|NCT00870844|Experimental|Lu AA24493 (CEPO): 5.0 mcg/kg|
3245690|NCT00870844|Experimental|Lu AA24493 (CEPO): 50.0 mcg/kg|
3245691|NCT00870844|Placebo Comparator|Placebo|
3245692|NCT00870831||Islet Recipient|Subjects that have successfully received and maintained an Islet transplant at Washington University Center for Islet Transplantation
3245693|NCT00870831||Control|subjects that were similar in height, weight and age that did NOT have diabetes to act as the comparative group
3245694|NCT00870818|Experimental|1 Active|"Protege had 4 study arms, 3 were dosed with different doses of teplizumab, and 1 was a control group given placebo. This Extension study will continue to assess the subjects from these 4 arms.~In Protege: Experimental Drug: Teplizumab, IV dosing daily for 14 days times 2 courses"
3245695|NCT00870818|Experimental|2 Active|In Protege: Experimental Drug: Teplizumab, IV dosing daily for 14 days times 2 courses
3245696|NCT00870818|Experimental|3 Active|In Protege: Experimental Drug: Teplizumab, IV dosing daily for 14 days times 2 courses
3245697|NCT00870818|Placebo Comparator|1 controlled|In Protege: Placebo Comparator: IV dosing daily for 14 days times 2 courses
3245698|NCT00870805|Experimental|bilateral-ultrabrief ECT|Patients will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 3-4 times seizure threshold.
3245699|NCT00870805|Active Comparator|bilateral standard ECT|Patients will be treated with a standard (1.0ms) pulse with a bilateral placement at 1.5 times seizure threshold.
3245700|NCT00870805|Experimental|right-unilateral ultrabrief ECT|Patients will be treated with an ultrabrief (0.3ms) pulse with a right unilateral placement at 8 times seizure threshold.
3245701|NCT00870805|Active Comparator|right-unilateral standard ECT|Patients will be treated with a standard (1.0ms) pulse with a right unilateral placement at 5 times seizure threshold.
3245702|NCT00870792|Active Comparator|Received report|
3245703|NCT00870792|Placebo Comparator|Routine care|Patients receive usual, routine, care.
3245704|NCT00870779|Experimental|5-aminolevulinic acid|
3245705|NCT00870766|Active Comparator|CT|All patients in the CT arm undergo abdominal CT scanning within 24 hours of admission to the ER.
3245706|NCT00870766|No Intervention|Current practice|The patients in the current practice arm are referred to radiological examinations, such as US, plain radiography or CT, based on the clinical need only.
3245707|NCT00870753|Experimental|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
3245708|NCT00870753|No Intervention|Controls|Control group are offered the yoga intervention after finishing the study
3245709|NCT00870740|Experimental|Group 1: DAC HYP 150 mg|Participants who received placebo in 205MS201 receive DAC HYP 150 mg subcutaneous (SC) injection every 4 weeks for a total of 13 doses.
3245710|NCT00870740|Experimental|Group 1: DAC HYP 300 mg|Participants who received placebo in 205MS201 receive DAC HYP 300 mg SC injection every 4 weeks for a total of 13 doses.
3245711|NCT00870740|Experimental|Group 2: Washout then DAC HYP 150 mg|Participants who received DAC HYP 150 mg SC injection in 205MS201 undergo a washout period (placebo SC every 4 weeks for a total of 5 doses) and then receive DAC HYP 150 mg SC every 4 weeks for a total of 8 doses.
3245712|NCT00870740|Experimental|Group 2: DAC HYP 150 mg|Participants who received DAC HYP 150 mg SC injection in 205MS201 receive DAC HYP 150 mg SC every 4 weeks for a total of 13 doses.
3245713|NCT00870740|Experimental|Group 3: Washout then DAC HYP 300 mg|Participants who received DAC HYP 300 mg SC in 205MS201 undergo a washout period (placebo SC every 4 weeks for a total of 5 doses) and then receive DAC HYP 300 mg SC every 4 weeks for a total of 8 doses.
3245761|NCT00870402|Placebo Comparator|2|
3245762|NCT00870376||urodynamic studies|
3245714|NCT00870740|Experimental|Group 3: DAC HYP 300 mg|Participants who received DAC HYP 300 mg SC in 205MS201 receive DAC HYP 300 mg SC every 4 weeks for a total of 13 doses.
3245715|NCT00870727|Experimental|Arm 1. Aripiprazole oral product|Participants will receive Aripiprazole oral product with a minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.
3245716|NCT00870727|Placebo Comparator|Arm 2. Placebo oral capsule|Partipants will recieve matching (identical in size and appearance to study drug) placebo oral capsules over 8-weeks of treatment.
3245717|NCT00870714|Experimental|A|Eligible patients with high-risk prostate cancer who are scheduled to undergo radical prostatectomy will receive four cycles of therapy with ketoconazole and docetaxel prior to surgery resection
3245718|NCT00870701|Experimental|Absence of Radiotherapy|No Radiotherapy; Simple monitoring without active treatment
3245719|NCT00870701|Active Comparator|Radiotherapy|Radiotherapy
3245720|NCT00870688||1|epilepsy patients
3245721|NCT00870675||ventriculomegaly|Pregnant women carrying a fetus with the ultrasound finding of enlarged ventricles (ventriculomegaly).
3245722|NCT00870662|Experimental|Automatic Fluid Shunt|
3245723|NCT00870649|Experimental|Bilhvax vaccine (Sh28GST)|Arm 1 : S. haematobium infected children pretreated by two doses of PZQ (at Week-9 and W-8)receiving 3 injections of candidate vaccine at D0, W4, W8 and a boost at W52, and then treated by a third dose of PZQ at W44.
3245724|NCT00870649|Placebo Comparator|Placebo|Arm 2 : S. haematobium infected children pretreated by two doses of PZQ (at Week-9 and W-8)receiving 3 injections of placebo at D0, W4, W8 and a boost at W52, and then treated by a third dose of PZQ at W44.
3245725|NCT00870597|Experimental|1|Multifocal IOL implant associated with vitreous opacities that underwent 25-gauge vitrectomy were prospectively analyzed.
3245726|NCT00870597|Experimental|2|Multifocal IOL implantation without transconjunctival vitrectomy
3245727|NCT00870584|Experimental|Omalizumab|The determined dose (at least 0.016 mg/kg/IgE (IU/mL) was administered subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used.
3245728|NCT00870584|Placebo Comparator|Placebo|Placebo was administered subcutaneously every 2 weeks or every 4 weeks depending on the dosing schedule in the protocol.
3245729|NCT00870571|Experimental|A|AMLODIPINE (as BESILATE) TABLETS 10 mg, single dose
3245730|NCT00870571|Active Comparator|B|NorvasC® 10 mg Tablets, single dose
3245731|NCT00870558|Experimental|Arm I|Patients receive an intra-arterial infusion of iodine I 131 ethiodized oil.
3245732|NCT00870558|Placebo Comparator|Arm II|Patients receive an intra-arterial infusion of unlabeled ethiodized oil.
3245733|NCT00870545|Experimental|Telephone support|12 telephone support group sessions based on the letters of the word BATTLEMIND
3245734|NCT00870532|Experimental|1|60 mg/week of vinorelbine + sorafenib
3245735|NCT00870532|Experimental|2|90 mg/week of vinorelbine + sorafenib
3245736|NCT00870532|Experimental|3|120 mg/week of vinorelbine + sorafenib
3245737|NCT00870519|Experimental|I 123-MNI-168|
3245738|NCT00870519|Experimental|I123 MNI168|brain imaging using I123MNI168
3245739|NCT00870506|No Intervention|2|No intervention (control)
3245740|NCT00870506|Experimental|1|5-minute video on donation and transplantation
3245741|NCT00870493|Experimental|I|each subject will receive oral aliskiren 300 mg/day for 16 weeks, followed by a washout period of 4 weeks, then crossed over to placebo for another 16 weeks
3245742|NCT00870493|Active Comparator|II|each subject will receive placebo for 16 weeks, followed by a washout period of 4 weeks, then crossed over to oral aliskiren 300 mg/day for another 16 weeks
3245743|NCT00870480|Experimental|A|Finasteride 5 mg single dose tablet, single dose
3245744|NCT00870480|Active Comparator|B|Proscar® 5 mg Tablet, single dose
3245745|NCT00870467|Placebo Comparator|DB Placebo|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
3245746|NCT00870467|Experimental|DB adalimumab|Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
3245747|NCT00870467|Experimental|DB Adalimumab/OL Adalimumab|Participants received double-blind adalimumab administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
3245748|NCT00870467|Experimental|DB Placebo/OL Adalimumab|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
3245749|NCT00870467|Experimental|DB Adalimumab/RE OL Adalimumab|Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
3245750|NCT00870467|Experimental|DB Placebo/RE OL Adalimumab|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
3245751|NCT00870454|Experimental|001|Carisbamate 800 mg/d 200 mg/d twice daily titrated up to 400 mg twice daily as tolerated by Week 3
3245752|NCT00870454|Experimental|002|Carisbamate 1 200 mg/d 200 mg/d twice daily titrated up to 600 mg twice daily as tolerated by Week 3
3245753|NCT00870454|Active Comparator|003|Pregabalin 300 mg/d 75 mg/d twice daily for Week 1 followed by 150 mg twice daily for the remainder
3245754|NCT00870454|Placebo Comparator|004|Placebo Placebo capsules twice daily
3245755|NCT00870441|Experimental|1. ASP2151|
3245756|NCT00870441|Active Comparator|2. Valacyclovir|
3245757|NCT00870441|Placebo Comparator|3. Placebo|
3245758|NCT00870428||Preeclampsia Evaluation|Patients who are admitted for the evaluation of preeclampsia
3245763|NCT00870363|Active Comparator|1|maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
3245764|NCT00870363|Active Comparator|2|maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
3245765|NCT00870363|Active Comparator|3|efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
3245766|NCT00870363|No Intervention|4|HIV-negative
3245767|NCT00870350|Active Comparator|Td5ap|Group 1 receiving Td5ap as a single intramuscular injection.
3245768|NCT00870350|Active Comparator|Td1aP|Group 2 receiving Td1aP as a single intramuscular injection
3245769|NCT00870337|Experimental|Single arm|
3245770|NCT00870324||1. Control|Patients will receive the Tendril (wide-spaced) lead as part of their ICD implant
3245771|NCT00870324||2. Experimental|Patients will receive the OptiSense (narrow-spaced) lead as part of their ICD implant
3245772|NCT00870311|Experimental|Blinded Lithium|Bipolar Disorder patients
3245773|NCT00870298|Experimental|computerized alert|An automatic electronic stop of the tmp/sulfa or warfarin order whenever a resident or nurse practitioner places an order for tmp/sulfa with an already active warfarin order, or when ordering both simultaneously
3245774|NCT00870298|Other|2 Current practice|Current practice of the pharmacist recommending cessation of concurrent warfarin and tmp/sulfa orders
3245775|NCT00870272|Active Comparator|1|400mcg sublingual misoprostol
3245776|NCT00870272|Active Comparator|2|400mcg buccal misoprostol
3245777|NCT00870246||1|High mobility
3245778|NCT00870246||2|Lower mobility
3245779|NCT00870233||GYN pts undergoing surgery|This study will assess patient use of WEBCORE, an online system designed for cancer patients to self-record toxicity-related symptoms based on NCI Common Terminology Criteria for Adverse Events and global quality of life (QoL) by European Organization for Research and Treatment of Cancer (EORTC QLQ-C30).
3245780|NCT00870220|Experimental|GH alone, Low dose E2 patch, Very Low-dose E2 patch|"Group 1: Growth hormone alone, no E2. Group 2: Growth Hormone plus Estradiol patch dose A(14 mcg/d x 10 d) x 6 months then Estradiol patch dose B(25 mcg/d x 10 d) x 6 months.~Group 3: Growth Hormone plus Estradiol patch dose B(25 mcg/d x 10 d) x 6 months then Estradiol patch dose C(25 mcg/d x 3 w) x 6 months."
3245781|NCT00870207|Other|Immediate Intervention Group|The immediate intervention group will receive the TSSC pilot worksite intervention in the initial 12 week period from the pre-test/enrollment visit.
3245782|NCT00870207|Other|Delayed Intervention Group|The delayed intervention group will receive the TSSC pilot worksite intervention beginning in month 6 of the study (6 months from the enrollment/pre-test visit).
3245783|NCT00870194|Experimental|1|
3245784|NCT00870194|Placebo Comparator|2|
3245785|NCT00870181|Experimental|ADV-TK/GCV|ADV-TK was administered via intraarterial cerebral infusion. Systemic GCV therapy was delivered at a dose of 5mg/kg intravenous, every 12 h at 36 hours after ADV-TK therapy.
3245786|NCT00870181|Active Comparator|Control group|Patients received surgery or systemic chemotherapy or palliative care.
3245787|NCT00870155|Experimental|Dirucotide|
3245788|NCT00870142|Experimental|A|AMLODIPINE (as BESILATE) TABLETS 10 mg, single dose
3245789|NCT00870142|Active Comparator|B|Norvasc® 10 mg Tablets, single dose
3245790|NCT00870129|Experimental|MRI|The advanced MRI studies will be obtained at the time of the routinely scheduled preoperative planning MRI and/or the routinely scheduled pre-RT planning MRI at approximately 3±2 weeks after surgery. The routine sequences obtained for the planning MRI are standard of care. The advanced MRI sequences may or may not be additional as some have already been adopted into the standard of care imaging at MSKCC.
3245791|NCT00870116|Other|1 - SBRT using cyberknife|SBRT using cyberknife: treatment = 2x15 Gy during 2 weeks
3245792|NCT00870116|Other|2 - SBRT using linear accelerator|SBRT using linear accelerator: treatment = 2x15 Gy during 2 weeks
3245793|NCT00870116|Other|3 - Conformational radiotherapy|Conformational radiotherapy: treatment = 5x2 Gy during 7 weeks
3245794|NCT00870103|Experimental|Vigadexa eye drops|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
3245795|NCT00870077|Experimental|1|
3245796|NCT00870064|Other|Formal Operative Treatment|Children randomized to the formal operative management arm will be taken to the Operating Room within 24 hours for irrigation and debridement and appropriate bone management.
3245797|NCT00870064|Other|Emergency Department Treatment|Children in the Emergency Department Treatment arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
3245798|NCT00870051||AAA patients|Subjects diagnosed with an AAA who are considered candidates for endovascular repair with Endurant Stent Graft, and who meet the inclusion/exclusion criteria are intended to participate in this registry
3245799|NCT00870038|Experimental|1|Paclitaxel eluting balloon (Elutax) + Genous stent
3245800|NCT00870038|Experimental|2|Uncoated balloon + Genous stent
3245801|NCT00870038|Active Comparator|3|Drug eluting stent (Taxus stent)
3245802|NCT00870025|Active Comparator|hCG|200 IU rec hCG s.c./5 days, 4 doses prior to onset of COH
3245803|NCT00870025|Placebo Comparator|placebo|similar injection at same time points with similar diluent but no hCG
3245804|NCT00870012|Active Comparator|Lepicol probiotic & prebiotic formula+simple lifestyle advice|
3245805|NCT00870012|Placebo Comparator|Simple lifestyle advice alone|
3245806|NCT00869986|Experimental|Dirucotide|
3245807|NCT00869986|Placebo Comparator|Placebo|
3245808|NCT00869973|Experimental|1|Aprepitant
3245809|NCT00869973|Active Comparator|2|dexamethasone
3245810|NCT00869960|Experimental|Antiretroviral therapy|Healthy volunteers received two doses of Tenofovir, Emtricitabine, Atazanavir and Ritonavir administered twice (on day 6 - 10 and day 20 - 25 after day of Follicular phase); with pharmacokinetic measurements at 6 - 10 days after menses and then again at day 20 - 25 after menses.
3245811|NCT00869947|Experimental|Prosthesis|Powered ankle-foot prosthesis and passive-elastic prosthesis
3245812|NCT00869947|Experimental|Non-amputee|Non-amputee
3245813|NCT00869934|Active Comparator|1. Cognitive-Behavior Therapy|
3245814|NCT00869934|Experimental|2. Behavior Therapy|
3245815|NCT00869934|Experimental|3. Cognitive Therapy|
3245816|NCT00869908||A|
3245817|NCT00869895|Experimental|1|
3245818|NCT00869882|Experimental|1|Posterolateral fusion with instrumentation combined to transforaminal lumbar interbody fusion
3245819|NCT00869882|Active Comparator|2|Posterolateral fusion with instrumentation
3245820|NCT00869869|Experimental|melatonin|melatonin
3245821|NCT00869869|Placebo Comparator|placebo|placebo
3245822|NCT00869856|Experimental|1|HX575, EPO Hexal
3245823|NCT00869843|Other|Single group|
3245824|NCT00869830|Experimental|biofeedback|
3245825|NCT00869817||1|Mutation Positive
3245826|NCT00869817||2|Mutation Negative
3245827|NCT00869804|Experimental|Exercise|combination aerobic (walking) and resistance (strength training) exercise
3245828|NCT00869804|Sham Comparator|attention control|attention control with daily journal and cancer-related education
3245829|NCT00869791|Other|Sequence 1|"Treatment Period 1:~IPX066 - 7 days; Washout Period - 7 days;~Treatment Period 2:~IR CD-LD- 7 days"
3245830|NCT00869791|Other|Sequence 2|"Treatment Period 1:~IR CD-LD - 7 days; Washout period - 7 days;~Treatment Period 2:~IPX066- 7 days"
3245831|NCT00869778|Experimental|εPA-44 900μg|Inject εPA-44 900μg at week 0, 4, 8, 12, 20, 28.
3245832|NCT00869778|Experimental|εPA-44 600μg+Placebo 300μg|Inject εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.
3245833|NCT00869778|Placebo Comparator|Placebo 900μg|Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.
3245834|NCT00869765|Experimental|tDCS and D-CYC|Major Depression tDCS and D-cyc
3245835|NCT00869752|Experimental|Arm 1|MK-0646, a monoclonial antibody in combination with etoposide and cisplatin.
3245836|NCT00869726|Experimental|Dirucotide|
3245837|NCT00869726|Placebo Comparator|Placebo|
3245838|NCT00869713|Other|primary vaccination with boost|Inactivated, Dried (TSI-GSD 200), RVF Vaccine
3245839|NCT00869674|No Intervention|Routine pathologic method|Half of each sentinal lymph node will have rountine pathologic examination as normal practice.
3245840|NCT00869674|Experimental|GeneSearch BLN Assay|Half of each sentinal lymph node will have GeneSearch BLN testing.
3245841|NCT00869661|Experimental|Group 1|RO5024048 500 mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 12 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
3245842|NCT00869661|Experimental|Group 2|RO5024048 1000mg bid + Pegasys + Copegus for 8 weeks, followed by SOC for 16 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
3245843|NCT00869661|Experimental|Group 3|RO5024048 1000mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 12 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
3245844|NCT00869661|Experimental|Group 4|Group 4 will receive RO5024048 1000mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 36 weeks
3245845|NCT00869661|Active Comparator|Group 5|Group 5 will receive SOC for 48 weeks
3245846|NCT00869661|Experimental|Group 6|Group 6 provides retreatment on an open-label basis for patients of Group 5 who failed treatment. Patients will receive RO5024048 1000mg bid + Pegasys + Copegus for 24 weeks, followed by SOC for 24 weeks.
3245847|NCT00869648|Active Comparator|Neutralposition|Head placed in neutral position
3245848|NCT00869648|Active Comparator|Extension|Head placed in extension
3245849|NCT00869648|Active Comparator|Anaesthesiologist's position|Head placed in position deemed optimal by an anaesthesiologist
3245850|NCT00869635|Experimental|1|"Treatment by combination of photodynamic therapy and S-1~PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation~S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, <1.25m2: 80mg/day, 1.25~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment"
3245851|NCT00869635|Active Comparator|2|"Treatment by photodynamic therapy only~PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation~Other managements except systemic chemotherapy were added freely."
3245852|NCT00869635|Other|3|Treatment by photodynamic therapy only or combined chemotherapy with photodynamic therapy: Open label
3245853|NCT00869622|Active Comparator|Risedronate|Active drug
3245854|NCT00869622|Placebo Comparator|Placebo + Calcium and Vitamin D|All patients both on placebo and active bisphosphonate to receive calcium and vitamin D
3245855|NCT00869609|Active Comparator|GLB Traditional Maintenance (TM)|Group Lifestyle Balance (GLB) program Traditional Maintenance: After completion of the GLB 12 core sessions, participants who are randomly assigned to GLB program Traditional Maintenance (TM) will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions.
3245856|NCT00869609|Active Comparator|GLB-Carb-focused Maintenance (CF)|Group Lifestyle Balance (GLB) program Carb-focused Maintenance: After completion of the GLB 12 core sessions, participants randomly assigned to GLB Carb-focused Maintenance (CF) will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information regarding healthy carbohydrate intake and hunger management.
3245857|NCT00869596|Placebo Comparator|1|Placebo
3245858|NCT00869596|Active Comparator|2|Fluticasone 440 mcg
3245859|NCT00869596|Active Comparator|3|Fluticasone 1980 mcg
3245860|NCT00869583|Experimental|1|Participants will immediately take part in the physical activity program.
3245861|NCT00869583|No Intervention|2|
3245911|NCT00869258|Experimental|GTX and Radiation Therapy with Gemzar|"Chemotherapy Treatment with Gemcitabine, Docetaxel, and Capecitabine:~A cycle of chemotherapy is made up of 21 days. During each cycle patients will take Xeloda® twice a day for 14 days followed by a rest period of 7 days. On day 4 and 11 (+/- 2 days) of each 21-day cycle patients will also receive Gemzar and Taxotere.~Weekly Radiation Therapy with Low-Dose Gemzar Chemotherapy:~After completing a total of 3 cycles of GTX chemotherapy each patient will receive 5 weeks of standard radiation therapy in combination with low-dose Gemzar chemotherapy."
3245912|NCT00869245|Experimental|1|Cardiac MRI Protocol. Patients will be transferred to the observation unit and undergo a stress cardiac MRI evaluation.
3245862|NCT00869570|Experimental|Arm A: Sorafenib & Capecitabine & RT|"Sorafenib: day 1 to 33 (5 weeks, including Saturday and Sunday) every 24 hours, immediately or within two hours after RT according to the dose escalation table during phase I, and the recommended dose during phase IIa. The intake stops at the last day of RT. On nonradiotherapy days (e.g. Saturday, Sunday), the tablets have to be taken at the same time as during the week.~Capecitabine: day 1 to 33 (5 weeks, including Saturday and Sunday) according to dose escalation table during phase I, and at the recommended dose during phase IIa. The intake stops in the evening of the last day of RT.~External beam RT: Monday through Friday for 5 weeks starting on day 1 (daily fraction 1.8 Gy, final dose 45 Gy) each day at the same time (e.g. 11:00 a.m. daily).~Surgery: 6 weeks (± 1 week) after radiochemotherapy (RCT) has been completed"
3245863|NCT00869557|Experimental|Stribild|
3245864|NCT00869557|Active Comparator|Atripla|
3245865|NCT00869544||HIV|Those positive for HIV and those negative but at high risk for HIV. Both positive and negative for HIV who smoke and those who do not smoke. Both HIV positive and negative with and without asthma and/or COPD
3245866|NCT00869531|Experimental|WW|wholegrain wheat
3245867|NCT00869531|Active Comparator|RW|refined wheat
3245868|NCT00869518|Active Comparator|Rifabutin|Subjects will be assigned to 7 days of treatment with rifabutin plus trimethoprim-sulfamethoxazole
3245869|NCT00869518|Placebo Comparator|Placebo|Subjects will be assigned to 7 days of treatment with placebo plus trimethoprim-sulfamethoxazole
3245870|NCT00869505||Case Group|Intensive Residential Treatment with memantine augmentation
3245871|NCT00869505||Control Group|Intensive Residential Treatment without memantine augmentation
3245872|NCT00869492|Other|A|instructed nadifloxacine 1% cream twice dailly, and placebo for benzoyl peroxide 5% solution once dailly
3245873|NCT00869492|Other|B|instructed nadifloxacine 1% cream twice dailly, and active benzoyl peroxide 5% solution once dailly
3245874|NCT00869479||1|subjects with a histologically-proven diagnosis of NSF
3245875|NCT00869479||2|subjects with other fibrosing skin diseases
3245876|NCT00869479||3|subjects with non-fibrosing skin diseases
3245877|NCT00869479||4|subjects without skin diseases
3245878|NCT00869453||1|Healthy volunteers
3245879|NCT00869440|Experimental|1: CNS 7056 0.10 mg/kg|CNS 7056 0.10 mg/kg
3245880|NCT00869440|Experimental|2: CNS 7056 0.15 mg/kg|CNS 7056 0.15 mg/kg
3245881|NCT00869440|Experimental|3: CNS 7056 0.20 mg/kg|CNS 7056 0.20 mg/kg
3245882|NCT00869440|Experimental|4: Midazolam 0.075 mg/kg|Midazolam 0.075 mg/kg
3245883|NCT00869427|Active Comparator|1 vitamin C|Vitamin C 1g bid
3245884|NCT00869427|No Intervention|2|Usual Care
3245885|NCT00869414|Active Comparator|insulin glargine only in morning|Morning only administration of insulin glargine
3245886|NCT00869414|Active Comparator|insulin glargine only at evening|Evening only administration of insulin glargine
3245887|NCT00869414|Active Comparator|split dose insulin glargine|Split dose administration of insulin glargine, half dose in morning, half dose in evening
3245888|NCT00869401|Experimental|Group 1 (Phase II) dasatinib + radiation + temozolomide|Patients receive concomitant chemotherapy and radiation for cycle one for a total of 42 days, then patients receive adjuvant chemotherapy 28-42 days post cycle one treatment. Patients receive only dasatinib post cycle 8 until progressive disease, unacceptable adverse events or refusal.
3245889|NCT00869401|Active Comparator|Group 2 (Phase II) placebo + radiation + temozolomide|Patients receive concomitant chemotherapy and radiation for cycle one for a total of 42 days, then patients receive adjuvant chemotherapy 28-42 days post cycle one treatment. Patients receive only placebo post cycle 8 until progressive disease, unacceptable adverse events or refusal.
3245890|NCT00869388|Experimental|Arm 1|rBBX-01 1.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
3245891|NCT00869388|Experimental|Arm 2|rBBX-01 2.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
3245892|NCT00869388|Experimental|Arm 3|rBBX-01 4.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
3245893|NCT00869388|Experimental|Arm 4 (optional)|rBBX-01 8.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
3245894|NCT00869375|Active Comparator|CLEARWAY GROUP|Endovascular peripheral intervention - Percutaneous transluminal angioplasty with simultaneous in situ thrombolysis (local thrombolytic plus low pressure balloon angioplasty) with Clearway balloon
3245895|NCT00869375|Active Comparator|ANGIOJET GROUP|Endovascular peripheral intervention - Percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy with AngioJet Rheolytic Thrombectomy System
3245896|NCT00869362|Experimental|Diabetes Management Team|Evaluation and management by diabetes management team
3245897|NCT00869362|No Intervention|Control|Patients receive usual care for diabetes
3245898|NCT00869349|Experimental|IFS Intervention Group|
3245899|NCT00869349|Active Comparator|Education Group|
3245900|NCT00869336|Experimental|Luliconazole Cream 1% - 2 wks|Daily treatment with Luliconazole Cream 1% for 2 weeks
3245901|NCT00869336|Experimental|Luliconazole Cream 1% - 4 wks|Daily treatment with Luliconazole Cream 1% for 4 weeks
3245902|NCT00869336|Placebo Comparator|Placebo Comparator - 2 wks|Daily treatment with Vehicle Cream for 2 weeks
3245903|NCT00869336|Placebo Comparator|Placebo Comparator - 4 wks|Daily treatment with Vehicle Cream for 4 weeks
3245904|NCT00869323|Experimental|Treated Patients|This group includes patients receiving Bortezomib and Rituximab for post-transplant lymphoproliferative disorders (PTLD).
3245905|NCT00869310|Experimental|1|Dexamethasone plus Aprepitant
3245906|NCT00869310|Active Comparator|2|dexamethasone plus metoclopramide
3245907|NCT00869297|Active Comparator|Control|
3245908|NCT00869297|Experimental|Intervention|These patients receive fluid boluses based on measurements from the FloTrac
3245909|NCT00869271|Experimental|1|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.
3245910|NCT00869271|Active Comparator|2|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle.
3245913|NCT00869245|Experimental|2|Conventional care cardiac testing. Patients will be transferred to the observation unit and undergo cardiac testing as determined by their treating physician.
3245914|NCT00869232|Experimental|MEL--VTD-PACE|Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide and Etoposide
3245915|NCT00869219|Active Comparator|Nevanac|
3245916|NCT00869219|Active Comparator|Acular LS|
3245917|NCT00869206|Experimental|Arm I (zoledronic acid every 4 weeks)|Patients receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
3245918|NCT00869206|Experimental|Arm II (zoledronic acid every 12 weeks)|Patients receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
3245919|NCT00869193|Active Comparator|Grape seed|Grape seed extract
3245920|NCT00869193|Placebo Comparator|Placebo|Microcrystalline cellulose
3245921|NCT00869180|Experimental|Diclofenac Sodium Patch|
3245922|NCT00869180|Placebo Comparator|Topical Placebo Patch|
3245923|NCT00869167|Experimental|1: Ramelteon|
3245924|NCT00869167|Placebo Comparator|2: Placebo|
3245925|NCT00869154|Active Comparator|Primary care follow up|Multidisciplinary examination and follow up by the family doctor.
3245926|NCT00869154|Experimental|Multidisciplinary follow up|Multidisciplinary examination and follow up by a multidisciplinary outpatient team.
3245927|NCT00869141|Experimental|Research arm (postop IOP>10)|Receive glaucoma medications if the eye pressure more than 10 mmHg after AHmed valve implantation
3245928|NCT00869141|Active Comparator|Standard of care arm (postop IOP>17)|Receive glaucoma medication if eye pressure more than 17 mmHg after Ahmed valve implantation
3245929|NCT00869128|Other|Placebo First|Subjects were treated for 3 weeks with 1 tablet per night of Placebo and then with 2 mg melatonin (Circadin).
3245930|NCT00869128|Other|Circadin first|Subjects were treated for 3 weeks with 1 tablet per night of 2 mg melatonin (Circadin) and then with placebo.
3245931|NCT00869115|Experimental|1|TREATMENT 0.5 μg/kg/min
3245932|NCT00869115|Experimental|2|TREATMENT 1.0 μg/kg/min
3245933|NCT00869115|Experimental|3|TREATMENT 1.5 μg/kg/min
3245934|NCT00869115|Placebo Comparator|4|PLACEBO
3245935|NCT00869102|Experimental|GLP-1|
3245936|NCT00869089|Experimental|CC-10004|"CC-10004 treament:~30mg,oral medication, BID, for 24 weeks (60mg total DAILY)"
3245937|NCT00869076|Experimental|Pharmacist Management|In this arm the Pharmacist managed the Diabetes in collaboration with the primary care physician
3245938|NCT00869076|Active Comparator|Usual Care|The patient was managed by the primary care physician
3245939|NCT00869063|Experimental|Diclofenac Sodium Patch|
3245940|NCT00869063|Placebo Comparator|Placebo Patch|
3245941|NCT00869050|Experimental|Capecitabine and Temozolomide|Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg and Temozolomide 150-200 mg/m2/day (PO divided BID).
3245942|NCT00869037|Active Comparator|Periarticluar Multimodal Technique|
3245943|NCT00869037|Active Comparator|CFNB plus Posterior Capsular Injection|
3245944|NCT00869024|Experimental|Stem Cell therapy|Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells in Patients with Severe LV Dysfunction and LVAD Support
3245945|NCT00869024|Placebo Comparator|Placebo|Intramyocardial Delivery Placebo solution into Patients with Severe LV Dysfunction and LVAD Support
3245946|NCT00869011|Experimental|1|Exercise
3245947|NCT00869011|No Intervention|2|No structured exercise program
3245948|NCT00868998|Experimental|Treatment|Gemcitabine, docetaxel, and capecitabine
3245949|NCT00868985|Experimental|PEG 3350 plus electrolytes|Patients were dosed with PEG 3350 with electrolytes
3245950|NCT00868985|Experimental|PEG 3350 without electrolytes|Patients were dosed with PEG 3350 without electrolytes
3245951|NCT00868972|Active Comparator|Embolic protection|Percutaneous renal stenting using a distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
3245952|NCT00868972|Sham Comparator|No embolic protection|Percutaneous renal stenting intervention without embolic protection
3245953|NCT00868959|Experimental|lurasidone|
3245954|NCT00868946|Experimental|Treatment with IND Ribavirin|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with IND Virazole (Ribavirin) for 7 days with multiple dosing regime based on weight and dosage day.
3245955|NCT00868933|Active Comparator|Low glycemic index dietary intervention program|The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
3245956|NCT00868933|Placebo Comparator|Simple lifestyle advice|The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
3245957|NCT00868920|Experimental|1|"The Graseby 3300 PCA pump will be loaded with a mixture of propofol 10 mg/cc containing 10 µg/cc remifentanil. The loading and demand doses will be individualized based on patient weight, height, age, and gender.~The initial loading phase of sedation will be performed by the anesthesiologist to permit estimation of patient sensitivity. Following the initial loading dose, a series of button presses will be issued by the anesthesiologist to achieve a state of moderate sedation, as determined by a decrease in BIS to the range of 75-80. Once this state has been reached, the button will be transferred to the patient for Patient C0ntrolled Sedation."
3245958|NCT00868920|Experimental|2|"The Graseby 3300 PCA pump will be loaded with a mixture of propofol 10 mg/cc containing 10 µg/cc remifentanil. The loading and demand doses will be individualized based on patient weight, height, age, and gender.~The initial loading phase of sedation will be performed by the anesthesiologist to permit estimation of patient sensitivity. Following the initial loading dose, a series of button presses will be issued by the anesthesiologist to achieve a state of moderate sedation, as determined by a decrease in BIS to the range of 75-80. Once this state has been reached,the anesthesiologist will control the sedation."
3245959|NCT00868907|Experimental|Treatment A|35 mg risedronate DR tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
3245960|NCT00868907|Experimental|Treatment B|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
3245961|NCT00868907|Active Comparator|Treatment C|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
3245962|NCT00868894|Experimental|1|
3245963|NCT00868894|Experimental|2|
3245966|NCT00868881||1|Blood Pressure poorly controlled in the previous year and poorly controlled at the inclusion in the study
3245967|NCT00868881||2|Blood Pressure poorly controlled in the previous year and well controlled at the inclusion in the study.
3245968|NCT00868881||3|Blood Pressure well controlled in the previous year and well controlled at the inclusion in the study
3245969|NCT00868881||4|Blood Pressure well controlled in the previous year and poorly controlled at the inclusion in the study
3245970|NCT00868881||5|Blood Pressure well controlled in the previous year independently of the level of control at the inclusion.
3245971|NCT00868881||6|Blood Pressure poorly controlled in the previous year independently of the level of control at the inclusion.
3245972|NCT00868855|Experimental|1|Bradykinin
3245973|NCT00868829|Experimental|Firebird2|
3245974|NCT00868816|Experimental|1|12 cycles of oxaliplatine based adjuvant chemotherapy
3245975|NCT00868816|Active Comparator|2|8 cycles of oxaliplatine based adjuvant chemotherapy
3245976|NCT00868790|Experimental|PLA→MK-3577 QD AM→MK-3577 QD PM→MK-3577 BID (Arm 1)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
3245977|NCT00868790|Experimental|MK-3577 QD AM→PLA→MK-3577 BID→MK-3577 QD PM (Arm 2)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
3245978|NCT00868790|Experimental|MK-3577 QD PM→MK-3577 BID→PLA→MK-3577 QD AM (Arm 3)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed MK- 3577 25 mg BID for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4.
3245979|NCT00868790|Experimental|MK-3577 BID→MK-3577 QD PM→MK-3577 QD AM→PLA (Arm 4)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
3245980|NCT00868790|Experimental|PLA→MK-3577 BID→MK-3577 QD AM→MK-3577 QD PM (Arm 5)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 25 mg BID for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4.
3245981|NCT00868790|Experimental|MK-3577 QD AM→MK-3577 QD PM→PLA→MK-3577 BID (Arm 6)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4.
3245982|NCT00868790|Experimental|MK-3577 QD PM→MK-3577 QD AM→MK-3577 BID→PLA (Arm 7)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
3245983|NCT00868790|Experimental|MK-3577 BID→PLA→MK-3577 QD PM→MK-3577 QD AM (Arm 8)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4.
3245984|NCT00868790|Experimental|PLA→MK-3577 QD PM→MK-3577 BID→MK-3577 QD AM (Arm 9)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
3245985|NCT00868790|Experimental|MK-3577 QD AM→MK-3577 BID→MK-3577 QD PM→PLA (Arm 10)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by MK-3577 25 mg BID for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
3245986|NCT00868790|Experimental|MK-3577 QD PM→PLA→MK-3577 QD AM→MK-3577 BID (Arm 11)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
3245987|NCT00868790|Experimental|MK-3577 BID→MK-3577 QD AM→PLA→MK-3577 QD PM (Arm 12)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4.
3245988|NCT00868790|Experimental|PLA→METF→MK-3577 QD AM→MK-3577 QD PM (Arm 13)|Domiciled participants were to receive oral treatment with dose-matched placebo to metformin (METF) for 4 weeks during Period 1, followed by metformin 1000 mg BID for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4. Participants in this arm were administered metformin placebo during Period 1 and active metformin during Period 2.
3245989|NCT00868790|Experimental|METF→PLA→MK-3577 QD PM→MK-3577 QD AM (Arm 14)|Domiciled participants were to receive oral treatment with metformin 1000 mg BID for 4 weeks during Period 1, followed by dose-matched placebo to metformin for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4. Participants in this arm were administered active metformin during Period 1 and metformin placebo during Period 2.
3245990|NCT00868777|Experimental|Sinus grafting using allogenic bone|
3245991|NCT00868764|Experimental|Sancuso® patch|Subjects receiving 1 Sancuso® patch worn for 7 days
3245992|NCT00868751|Experimental|Tocilizumab|Single arm study - treatment only
3246040|NCT00868413|Active Comparator|A|FCR+ABT-263
3245993|NCT00868738|Active Comparator|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU), given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
3245994|NCT00868738|Placebo Comparator|Placebo|Subjects will be provided a placebo, given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
3245995|NCT00868725||possible oral cancer|Patients reporting for oral cavity examination with the possibility or certainty of oral lesions
3245996|NCT00868712||1|Warfarin use < 6 months
3245997|NCT00868712||2|Warfarin use 6-24 months
3245998|NCT00868712||3|Warfarin use >24 months
3245999|NCT00868699|Experimental|lurasidone low arm|
3246000|NCT00868699|Placebo Comparator|Placebo|
3246001|NCT00868699|Experimental|lurasidone high arm|
3246002|NCT00868686|Active Comparator|Volar aluminum splint|
3246003|NCT00868686|Active Comparator|Dorsal aluminum splint|
3246004|NCT00868686|Active Comparator|Custom thermoplastic|
3246005|NCT00868673|Active Comparator|Low fructose arm|"Overweighted or obese previously healthy adults (with no other comorbidities, defined as: Diabetes (DM1 or DM2), hypertension, chronic kidney disease (CKD), hepatic damage, dyslipidemia medication, anemia, malignancy or pregnancy), with a Body Mass Index (BMI) of >25 kilograms(weight)/ squared meters (height).~They will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and rest energy (without exercise).~This group will be assigned to a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of less than 20 grams/day fructose diet levels.~Total Time of intervention 6 weeks for each patient"
3246006|NCT00868673|Active Comparator|Normal fructose arm|"Overweighted or obese previously healthy adults (with no other comorbidities; defined as: Diabetes Mellitus (DM1 or DM2), hypertension, chronic kidney disease (CKD), hepatic damage, dyslipidemia medication, anemia, malignancy or pregnancy), with a Body Mass Index (BMI) of >25 kilograms(weight)/ squared meters (height).~Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet (of 15% proteins, 30% lipids and 55% carbohydrates); calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise).~This group will receive a controlled fructose diet between 50 and 70 grams/day of fructose intake.~Total time of intervention:6 weeks for each patient"
3246007|NCT00868660|Experimental|ZP1848|Healthy Subjects or Crohn's Disease patients
3246008|NCT00868660|Placebo Comparator|Placebo|Healthy subjects or Crohn's Disease patients
3246009|NCT00868647|Other|Radiofrequency Ablation|
3246010|NCT00868634|Active Comparator|A|Capecitabine / Bevacizumab
3246011|NCT00868634|Experimental|B|Capecitabine / Bevacizumab / Vinorelbine
3246012|NCT00868621||1|Control
3246013|NCT00868621||2|Overactive Bladder Patients
3246014|NCT00868621||3|Urinary Tract Infection
3246015|NCT00868608|Experimental|inotuzumab ozogamicin|inotuzumab ozogamicin
3246016|NCT00868595|Experimental|Dose escalation|"Cohort 1: BPX-101, 4 x 10*6 cells administered every other week for 6 cycles Cohort 2: BPX-101, 12.5 x 10*6 cells administered every other week for 6 cycles Cohort 3: BPX-101, 25 x 10*6 cells administered every other week for 6 cycles Cohort 4: BPX-101, 25 x 10*6 cells administered every 4 weeks for 3 cycles~At 24 hours after each vaccination, a single dose of the activating agent, AP1903 for Injection, will be administered at a fixed dose of 0.4 mg/kg via intravenous (IV) infusion over 2 hours."
3246017|NCT00868582||FDG-PET|F-18 fluorodeoxyglucose (FDG-PET)
3246018|NCT00868582||NaF-18 PET|F-18 sodum-fluoride (NaF-18 PET)
3246019|NCT00868569|Experimental|1|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemoembolision (TACE) using oxaliplatin, fudr, mmc and iodine. Then begin folfox4 again.
3246020|NCT00868569|Active Comparator|2|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy (TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.
3246021|NCT00868556||1 episodic migraine sufferers|
3246022|NCT00868556||2 chronic migraine sufferers|
3246023|NCT00868556||3 non migraine sufferers (controls)|
3246024|NCT00868543|Active Comparator|Long limb|Hospitalized male or female subjects 18-65 years of age,obese with body mass index (BMI= kg/m²)>50.Patients without mental or nervous disorders interfering with adequate evaluation of one's health condition, who read the informed consent form and gave a written consent to participate in the study. Gastric bypass was performed with long (150 cm) alimentary Roux limb
3246025|NCT00868543|Active Comparator|Very long limb|Hospitalized male or female subjects 18-65 years of age,obese with body mass index (BMI= kg/m²)>50.Patients without mental or nervous disorders interfering with adequate evaluation of one's health condition, who read the informed consent form and gave a written consent to participate in the study. Gastric bypass was performed with very long (250 cm) alimentary Roux limb
3246026|NCT00868530|Experimental|Xyntha|This trial was an open-label and included assessments of safety, clinical efficacy, and Factor VIII (FVIII) recovery in Chinese subjects with hemophilia A. Subjects received on-demand treatments with Xyntha over a 6-month (calendar day) period.
3246027|NCT00868517|Experimental|True Group Auricular Acupuncture|Received true group auricular acupuncture twice weekly for a period of two months.
3246028|NCT00868517|Sham Comparator|Sham Group Auricular Acupuncture|Received sham group auricular acupuncture twice weekly for a period of two months.
3246029|NCT00868517|Other|Wait-List Control Group|Served as wait list control. Did not receive any acupuncture during the study period.
3246030|NCT00868504||examined by endoscopy|Patients, examined by endoscopy, being screened for GI tract tumors
3246031|NCT00868465|Active Comparator|1|Artemether-lumefantrine; currently the first line treatment in Tanzania
3246032|NCT00868465|Experimental|2|Dihydroartemisinin-piperaquine, alternative ACT
3246033|NCT00868452|Experimental|Lurasidone|
3246034|NCT00868452|Placebo Comparator|Placebo|
3246035|NCT00868439|Active Comparator|patiromer|
3246036|NCT00868439|Placebo Comparator|placebo|
3246037|NCT00868426|Experimental|1|Budesonide/Formoterol Batch 1
3246038|NCT00868426|Experimental|2|Budesonide/Formoterol Batch 2
3246039|NCT00868426|Experimental|3|Budesonide/Formoterol Batch 1 and charcoal
3246041|NCT00868413|Active Comparator|B|BR+ABT-263
3246042|NCT00868400|Experimental|1|High-carbohydrate
3246043|NCT00868400|Placebo Comparator|2|Placebo
3246044|NCT00868400|No Intervention|3|Control
3246045|NCT00868387|Experimental|energy-restricted, CHO-restricted diet|Interventions: carbohydrate restriction of diet: 40% Frequency: daily Duration: 12 months
3246046|NCT00868387|Active Comparator|energy-restricted, CHO-rich diet|Comparator: carbohydrate content of diet: > 55% Frequency: daily Duration: 12 months
3246047|NCT00868374|Experimental|1|Quetiapine XR
3246048|NCT00868374|Placebo Comparator|2|
3246049|NCT00868361|Experimental|Slow and rapid N-acetyl transferase genotypes|
3246050|NCT00868348|Placebo Comparator|Saline|
3246051|NCT00868348|Active Comparator|Ketorolac|
3246052|NCT00868335|Active Comparator|1|Anterior cervical discectomy, no disc prosthesis
3246053|NCT00868335|Experimental|2|Anterior cervical discectomy, with disc prosthesis
3246054|NCT00868309|Experimental|Anavip|The initial dose of study drug was administered in a total volume of 500 mL (initial doses only) IV over 30 minutes for Anavip
3246055|NCT00868309|Active Comparator|CroFab|The initial dose of study drug was administered in a total volume of 500 mL (initial doses only) IV over 60 minutes for CroFab, or as permitted by IV access.
3246056|NCT00868296|Active Comparator|Low dose|
3246057|NCT00868296|Active Comparator|High dose|
3246058|NCT00868283|Experimental|Cerebrolysin|
3246059|NCT00868283|Placebo Comparator|0.9% Saline Solution|
3246060|NCT00868270||Children with UTIs|
3246061|NCT00868257||CHARTA study cohort|Primarily 5- to 10-year-old Ugandan children with HIV or AIDS who are taking ART, with some 1- to 4-year-olds included because of recent trends in treating younger children
3246062|NCT00868231|Experimental|Aclidinium 400 μg bid|Aclidinium bromide 400 μg twice-daily by inhalation
3246063|NCT00868231|Active Comparator|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily by inhalation
3246064|NCT00868231|Placebo Comparator|Placebo|Placebo
3246065|NCT00868218|Active Comparator|1|30µg HA vaccine Intramuscularly administered
3246066|NCT00868218|Active Comparator|2|1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
3246067|NCT00868218|Active Comparator|3|7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
3246068|NCT00868218|Active Comparator|4|30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
3246069|NCT00868205|Experimental|low coffee dose|3 cups of coffee daily for 8 weeks
3246070|NCT00868205|Experimental|high coffee dose|5 cups of coffee daily for eight weeks
3246071|NCT00868205|No Intervention|Control|Consumption of water instead of coffee daily for eight weeks
3246072|NCT00868192|Experimental|Pemetrexed and bevacizumab|"Pemetrexed 500 mg/m2 IV on Day 1 of each 21 day cycle~Bevacizumab 15 mg/kg IV on Day 1 of each 21 day cycle"
3246073|NCT00868179|Experimental|Pradax|This is the only arm in the study and all will follow the same protocol for the study which is taking the pradax after total knee replacement
3246074|NCT00868166|Experimental|TRO19622|2 Capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzole 50mg bid
3246075|NCT00868166|Placebo Comparator|Control|2 Capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
3246076|NCT00868153||Group 1|
3246077|NCT00868140|Experimental|1/Pioglitazone|Pioglitazone in pill form at 45mg twice per day for 6 months
3246078|NCT00868140|Placebo Comparator|2/Placebo|Placebo control to arm 1 in pill form identical to treatment form also twice per day for 6 months
3246079|NCT00868127|Experimental|Lapaquistat Acetate 100 mg QD|
3246080|NCT00868127|Experimental|Lapaquistat Acetate 100 mg QD + Added Therapy|
3246081|NCT00868114|Experimental|1|3 weekly injections of intratumoral TNFerade plus radiation and 3 weekly intratumoral injections of dendritic cell vaccine
3246082|NCT00868114|Experimental|2|Radiation Only with 3 weekly intratumoral injections of dendritic cell vaccine
3246083|NCT00868101|Experimental|Preconditioning|Children who received the preconditioning stimulus
3246084|NCT00868101|No Intervention|Control|Children who did not receive the preconditioning stimulus
3246085|NCT00868088|Active Comparator|ALA + PDT|Topical ALA will be applied to the entire lip surface and allowed to incubate for 60 minutes plus or minus 30 minutes. Blue light at a wavelength of 405-420 nm will be used for treatment at a dose of 1000 seconds.
3246086|NCT00868088|Placebo Comparator|placebo + PDT|Topical placebo will be applied to the entire lip surface and allowed to incubate for 60 minutes plus or minus 30 minutes. Blue light at a wavelength of 405-420 nm will be used for treatment at a dose of 1000 seconds.
3246087|NCT00868075|Experimental|Chest Physiotherapy|Twice daily chest physiotherapy
3246088|NCT00868075|Experimental|Chest Physiotherapy + Exercise Program|Chest Physiotherapy + Exercise Program
3246089|NCT00868062|Experimental|1|
3246090|NCT00868049||1|Obese subjects
3246091|NCT00868049||2|Normal-weight subjects
3246092|NCT00868036|Active Comparator|Patch testing|Patch testing on patients with chronic idiopathic dermatitis.
3246093|NCT00868023|Experimental|1|CHF 1535 DPI : BDP/Formo 400/24 µg
3246094|NCT00868023|Active Comparator|2|CHF 1535 pMDI HFA : BDP/Formo 400/24 µg
3246095|NCT00868023|Experimental|3|CHF 1535 DPI : BDP/Formo 100/6 µg
3246096|NCT00868023|Active Comparator|4|CHF 1535 pMDI HFA : BDP/Formo 100/6 µg
3246097|NCT00868023|Placebo Comparator|5|Placebo
3246098|NCT00868010|Experimental|1: donepezil|Participants will receive treatment for 12 weeks on donepezil 10 mg (or 5 mg if unable to tolerate 10 mg). Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
3246099|NCT00868010|Placebo Comparator|2. placebo|Participants will receive treatment for 12 weeks with placebo pill. Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
3246100|NCT00867997|Active Comparator|Dentifrice|Chemoactive (remineralizing, neuroactive) dentifrice treatment
3246101|NCT00867997|Active Comparator|Sealant|DBA/sealant application
3246156|NCT00867620||1|case group: patients with urothelial carcinoma
3246102|NCT00867997|Active Comparator|Resin-based composite|Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
3246103|NCT00867984|Experimental|1|Torsion-guided VV optimization plus AV optimization.
3246104|NCT00867984|Active Comparator|2|AV optimization only.
3246105|NCT00867971||RGH treated|
3246106|NCT00867971||Starting treatment with RGH|
3246107|NCT00867945||1. Pregnant Women|
3246108|NCT00867945||2. Non-Pregnant Controls|
3246109|NCT00867945||3. IVF controls|
3246110|NCT00867932|Experimental|Eculizumab|"Eculizumab administered intravenously for 12 weeks. Dosing regimen based on body weight as follows:~≥30 kg: induction/loading = 600 mg weekly x 4; maintenance = 900 mg Wk5; 900 mg Q2 wks 20 - <30 kg: induction/loading = 600 mg weekly x 2; maintenance = 600 mg Wk3; 600 mg Q2 wks 10 - <20 kg: induction/loading = 600 mg weekly x 1; maintenance = 300 mg Wk2; 300 mg Q2 wks 5 - <10 kg: induction/loading = 300 mg weekly for 1 week; maintenance = 300 mg Wk2; 300 mg Q3 wks"
3246111|NCT00867919|Experimental|1|Participants will receive a cognitive behavioral family therapy for adolescent depression to be developed in this study.
3246112|NCT00867919|Active Comparator|2|Participants will receive treatment as usual 1 year prior to the experimental treatment group.
3246113|NCT00867906|Other|Cohort 1|Asthmatics using salbutamol only, subjects to receive either Cat-PAD or placebo comparator
3246114|NCT00867906|Other|Cohort 2|Asthmatics using inhaled corticosteroid, subjects to receive either Cat-PAD or placebo comparator
3246115|NCT00867906|Other|Cohort 3|Asthmatics using inhaled corticosteroid and LABA, subjects to receive either Cat-PAD or placebo comparator
3246116|NCT00867893||DA group|RLS patients started treatment on dopamine agonists within the past year
3246117|NCT00867893||NonDA|RLS patients started treatment on medication other than dopamine agonists within the past year
3246118|NCT00867880|Experimental|1|
3246119|NCT00867880|Active Comparator|2|
3246120|NCT00867867|Active Comparator|1|Ferrous Fumarate with Ferrous Sulphate
3246121|NCT00867867|Active Comparator|2|Ferric pyrophosphate with ferrous sulphate
3246122|NCT00867867|Placebo Comparator|3|Ferrous sulphate
3246123|NCT00867854||Experimental|25 evaluable subjects from the experimental arm of ATN 061 who undergo de-intensification to boosted atazanavir (ATV) with VL suppression of < 100 copies/ml and CD4+ T cells > 350 cells/mm3 at week 48 and maintain VL suppression to < 400 copies/ml with stable CD4+ T cell counts after week 48.
3246124|NCT00867854||Control|25 evaluable subjects from ATN 071 will also be enrolled. These subjects will have initiated HAART according to current DHHS guidelines (CD4+ T cells < 350 cells/mm3), had viral load suppression to < 100 copies/ml at 24 through 48 weeks on HAART and maintained suppression to < 400 copies/ml through week 80.
3246125|NCT00867841||Pneumonia|Children diagnosed with community-acquired pneumonia by the emergency department physician
3246126|NCT00867828|Experimental|1|Neptune Krill Oil(TM)softgels (1g QD). Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
3246127|NCT00867828|Active Comparator|2|Fish oil softgels (1g QD). Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
3246128|NCT00867828|Placebo Comparator|3|Placebo (soy oil) softgels (1g QD. The soy oil placebo will provide neither EPA nor DHA.
3246129|NCT00867815|Other|Arm 1|
3246130|NCT00867802|Experimental|Mindfulness- Based Stress Reduction: Active Comparator|Mindfulness-Based Stress Reduction program
3246131|NCT00867789|Experimental|Trimethoprim-sulfamethaxazole|Incision and drainage of the abscess and treatment with oral TMP-SMX (100 patients)
3246132|NCT00867789|Placebo Comparator|Sugar pill|Incision and drainage of the abscess and treatment with oral placebo (100 patients)
3246133|NCT00867776|Experimental|AAHC Excercise Program Support Group|Participants taking part in the AAHC Exercise Program Support Group (the intervention).
3246134|NCT00867763|Experimental|IVM|Early egg retrieval, in vitro maturation, then IVF
3246135|NCT00867763|Active Comparator|Mild IVF|Mild gonadotropin and conventional IVF
3246136|NCT00867750|Experimental|RE|Device: Radioembolisation with yttrium-90 labelled SIR-Spheres microspheres
3246137|NCT00867750|Active Comparator|TACE|Transarterial Chemoembolisation with embolising agent Embospheres and chemotherapeutic agent epirubicin
3246138|NCT00867737|Experimental|Advair 115/21 MDI|Advair HFA 115/21 MDI Intervention = initiate intervention after screening
3246139|NCT00867737|Active Comparator|2 = Symbicort 160/4.5|Symbicort initiated after screening
3246140|NCT00867724|Experimental|Aer-O-Scope Colonoscopy|Screening Colonoscopy
3246141|NCT00867698|Experimental|AST-120 (6g)|2 grams TID
3246142|NCT00867698|Placebo Comparator|Placebo A|2 grams TID
3246143|NCT00867698|Experimental|AST-120 (12g)|4 grams TID
3246144|NCT00867698|Placebo Comparator|Placebo B|4 grams TID
3246145|NCT00867685|Experimental|Treatment A|Single oral dose of 40 mg AZD2624 liquid suspension in a fasted state.
3246146|NCT00867685|Experimental|Treatment B|Single oral dose of 40 mg (2x20mg tablets)AZD2624 in a fasted state.
3246147|NCT00867685|Experimental|Treatment C|Single oral dose of 40 mg (2x20mg tablets) in a fed state.
3246148|NCT00867672|Experimental|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
3246149|NCT00867672|Experimental|Decitabine+VPA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks, and VPA (p.o.) from day 6 of first cycle continuously throughout all treatment cycles
3246150|NCT00867672|Experimental|Decitabine+ATRA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
3246151|NCT00867672|Experimental|Decitabine+VPA+ATRA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and VPA (p.o.) from day 6 continuously throughout all treatment cycles and ATRA (45 mg/m² p.o.), from day 6 to day 28 of each treatment cycle
3246152|NCT00867659|Experimental|Cetrotide acetate|oocyte donors will receive cetrotide acetate on the day of oocyte retrieval. The incidence of OHSS will be assessed.
3246153|NCT00867633||Urothelial carcinoma|The DNA samples extracted from the urothelial carcinoma tissue
3246154|NCT00867633||RCC|the DNA sample extracted from RCC
3246155|NCT00867633||Non-cancer|The DNA sample extracted from the non-cancerous kidney tissue
3246157|NCT00867620||2|control group: those without previous history of any malignancy
3246158|NCT00867607|Experimental|MRX-6 (2%)|
3246159|NCT00867607|Experimental|MRX-6 (1%)|
3246160|NCT00867607|Experimental|MRX-6 (0.2%)|
3246161|NCT00867607|Active Comparator|Steroid|
3246162|NCT00867581||1|chronic-stage patients after infarction in the territory of unilateral middle cerebral artery
3246163|NCT00867581||2|age, sex and risk factor matched volunteers without ischemic stroke
3246164|NCT00867568|Experimental|TPI 287|
3246165|NCT00867555|Experimental|EGCG|"Double blind randomized, placebo-controlled cross-over design with two arms:~the green tea extract TEAVIGO, high in EGCG and~placebo"
3246166|NCT00867555|Placebo Comparator|placebo|
3246167|NCT00867542||past IUGR|3-4 y old children with past IUGR
3246168|NCT00867542||control|3-4 y old healthy children
3246169|NCT00867529|Experimental|Treatment (rituximab pre- and post-transplant)|Patients receive rituximab IV, pre- and post-transplant, on days -3, 10, 24, and 38. Patients undergo donor peripheral blood stem cell transplant on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity.
3246170|NCT00867516|Experimental|1|ALD518 80 mg
3246171|NCT00867516|Experimental|2|ALD518 160 mg
3246172|NCT00867516|Experimental|3|ALD518 320 mg
3246173|NCT00867516|Placebo Comparator|4|No ALD518
3246174|NCT00867503|Experimental|bendamustine|bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
3246175|NCT00867490|Experimental|Candesartan+HCTZ, aliskiren+HCTZ, aliskiren+HCTZ+amlodipine|
3246176|NCT00867477|Experimental|Cohort 1: Esophagus Cancer|Breathing Test + Respiratory Symptoms Questionnaire
3246177|NCT00867477|Experimental|Cohort 2: Lung Cancer|Breathing Test + Respiratory Symptoms Questionnaire
3246178|NCT00867451|Experimental|Immediate Treatment|Children will receive behavioral sleep interventions and, if needed, melatonin, to improve sleep functions.
3246179|NCT00867451|Experimental|Delayed Treatment|Children will only receive sleep behavior interventions for the first four weeks of the trial. Treatment with study drug will be delayed to the 5th week.
3246180|NCT00867438|Placebo Comparator|1|
3246181|NCT00867438|Experimental|2|
3246182|NCT00867425|Experimental|Intervention|
3246183|NCT00867412||Conventional staging|Staging with CT, mediastinoscopy and bronchoscopy
3246184|NCT00867412||Conventional staging and PET/CT|Staging with CT, mediastinoscopy and bronchoscopy, and PET/CT performed prior to mediastinoscopy
3246185|NCT00867399|Active Comparator|20mg of ABT-126 QD|20 mg of ABT-126 QD for 10 days
3246186|NCT00867399|Active Comparator|30mg and 45mg ABT-126 QD|30 mg and 45mg of ABT-126 QD for 21 days
3246187|NCT00867373|Experimental|Education Intervention|"The intervention used in the randomized controlled trial consists of 1) measuring the parents' height and weight and 2) providing the parents with feedback on their calculated BMI on an educational handout (included in Appendix V). The purpose of the handout is to convey the following 5 messages:~Definition of BMI~How BMI is calculated~What the parent's BMI is based on the measurements taken~What weight category the parent is in (underweight, normal weight, overweight, or obese)~Children with overweight or obese parents are at higher risk of becoming overweight themselves.~The Research Assistant will verbally review the educational handout with the parent. The handout will be available in both English and Spanish."
3246188|NCT00867373|No Intervention|Control Group|Parents assigned to the control group will proceed to their child's well child visit after their baseline data are collected.
3246189|NCT00867360|Experimental|Mifepristone|Receive mifepristone for 8 days
3246190|NCT00867360|Placebo Comparator|Placebo|Receive placebo rather than mifepristone
3246191|NCT00867347|Active Comparator|Arm I|"Patients undergo a radical cystectomy, including pelvic lymphadenectomy,~between 4 and 6 weeks after initiating course 4 of chemotherapy."
3246192|NCT00867347|Experimental|Arm II|Patients with no visible residual tumor (cT0 or pT0) or residual but superficial tumor (pTa, pT1) undergo radiotherapy beginning within 4-6 weeks of day 1 of course 4 and continuing for 6.5 weeks.
3246193|NCT00867334|Experimental|1|Subjects whose initial liver biopsy samples meet certain lab values will be placed in Arm 1. Each participant assigned to Arm 1 will receive imatinib mesylate for 28 days, followed by a combination of imatinib mesylate and panitumumab.
3246194|NCT00867334|Active Comparator|2|Subjects whose initial liver biopsy samples meet certain lab values will be placed in Arm 2. Participants in Arm 2 will receive standard-of-care treatment with panitumumab.
3246195|NCT00867321|Experimental|Arm I (Phase II)|Patients receive oral sorafenib tosylate on days 1-28 twice daily and bevacizumab IV on days 1 and 15.
3246196|NCT00867321|Experimental|Arm II (Phase II)|Patients receive oral sorafenib tosylate twice daily on days 1-28.
3246197|NCT00867308|Experimental|Lenalidomide in high risk MDS patients|"Patients diagnosed with high risk Myelodysplastic syndrome (MDS), regardless of 5q deletion status, will receive lenalidomide, 50mg/day orally, on days 1-28 of a 42 day cycle for 2 cycles. At this point, patients meeting protocol specified response criteria will proceed to Continuing Therapy on a reduced dose of lenalidomide until progression.~Patients not achieving response will receive 2 additional cycles of treatment, whereupon response will again be assessed. Patients achieving response at this point will proceed to Continuing Therapy as described.~Patients without evidence of response after 4 cycles will be taken off-study."
3246198|NCT00867295|Placebo Comparator|placebo|no antibiotic is used
3246199|NCT00867295|Active Comparator|drug|cefazolin Sodium 1g i.v. before the operation
3246200|NCT00867282|Experimental|Treatment A|
3246201|NCT00867282|Active Comparator|Treatment B|
3246202|NCT00867243||Group 1: HCV Positive|50 patients whom are HCV positive
3246203|NCT00867243||Group 2: HCV Negative|50 patients whom are HCV negative.
3246204|NCT00867230|Experimental|FTS (S-trans, trans-farnesylthiosalicylic acid)|
3246205|NCT00867217|Experimental|High Dose Vitamin D|High Dose Vitamin D3 capsule (3 x 10,000 IU capsules weekly). All subjects also received standard dose vitamin D3 (600 IU daily) and letrozole (2.5 mg daily).
3246299|NCT00866502|Experimental|sNN0031|Continuous ICV infusion for two weeks at one of three dose levels
3246206|NCT00867217|Placebo Comparator|Placebo|Placebo matched for High Dose Vitamin D3 capsules. All subjects also received standard dose vitamin D3 (600 IU daily) and letrozole (2.5 mg daily).
3246207|NCT00867204||Short-wire device|The Fusion Short-wire ERCP device was used
3246208|NCT00867204||Long-wire device|The traditional Long-wire ERCP device was used
3246209|NCT00867191|Placebo Comparator|1|Placebo, 1 tablet daily, per os
3246210|NCT00867191|Active Comparator|2|Desloratadine, one 5 mg tablet daily, per os
3246211|NCT00867178|Experimental|Treatment (vorinostat, isotretinoin, chemotherapy)|See Detailed Description
3246212|NCT00867165|Experimental|Ezetimibe|Ezetimibe 10-mg tablet once daily for 12 weeks
3246213|NCT00867165|Placebo Comparator|Placebo|Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks
3246214|NCT00867152|Experimental|Cohort 2|All subjects will receive GSK1349572 50mg q24h (Treatment A) from Day 1 to Day 5 in Period 1. There will be no washout between treatment Periods 1 and 2. Subjects will receive GSK1349572 50mg q24h and ETV/DRV/RTV 200/600/100mg q12h from Day 1 to Day 14 in Period 2. Day 1 of Period 3 will be approximately 3 weeks after the last dose in Period 2. Subjects will receive GSK1349572 50mg q12h and ETV/DRV/RTV 200/600/100mg q12h from Day 1 to Day 14. Period 3 will not be performed if there is no significant interaction in Period 2.
3246215|NCT00867152|Experimental|Cohort 1|All subjects will receive GSK1349572 50mg q24h (Treatment A) from Day 1 to Day 5 in Period 1. There will be no washout between treatment Periods 1 and 2. Subjects will receive GSK1349572 50mg q24h and ETV/LPV/RTV 200/400/100mg q12h from Day 1 to Day 14 in Period 2. Day 1 of Period 3 will be approximately 3 weeks after the last dose in Period 2. Subjects will receive GSK1349572 50mg q12h and ETV/LPV/RTV 200/400/100mg q12h from Day 1 to Day 14. Period 3 will not be performed if there is no significant interaction in Period 2.
3246216|NCT00867139|Experimental|TCAD-Randomized Arm|TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
3246217|NCT00867139|Active Comparator|Neuraminidase Monotherapy Arm|Zanamivir or Oseltamivir
3246218|NCT00867139|Other|TCAD Open Label Arm|TCAD for subjects who cannot tolerate or are ineligible to receive zanamivir
3246219|NCT00867113|Experimental|Imatinib|All subjects received in tablet form imatinib (STI571) 400 mg once daily.
3246220|NCT00867100|Experimental|1|
3246221|NCT00867087|Experimental|Rituximab 375 mg/m^2 + Inotuzumab Ozogamicin 1.8 mg/m^2|Inotuzumab ozogamicin, in combination with rituximab, will be administered to patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma prior to an autologous stem cell transplant (aSCT).
3246222|NCT00867048|Experimental|Early ART|Initiate ART immediately following randomization
3246223|NCT00867048|Active Comparator|Deferred ART|Defer ART until the CD4+ count declines to <350 cells/cu mm or AIDS develops
3246224|NCT00867035|Active Comparator|Chlorhexidine gluconate and scraper|The intervention was accomplished by subject after instructions from investigator: twice a day a tongue scraper was used with 4 or more strokes, followed by 20ml of 0.12% chlorhexidine gluconate mouthwash used for 30 sec, for one week.
3246225|NCT00867035|Experimental|Chlorine dioxide and scraper|The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.1% stabilized chlor8ine dioxide rinse for 30sec, for one week.
3246226|NCT00867022||1|Women with gestational diabetes
3246227|NCT00867022||2|Pregnant women without gestational daibetes
3246228|NCT00867022||3|Women with gestational diabetes and hypertension
3246229|NCT00867022||4|Non pregnant women
3246230|NCT00867009|Experimental|Induction/maintenance Therapy|pemetrexed, cisplatin and cetuximab followed by pemetrexed and cetuximab
3246231|NCT00866970|Experimental|1|ALD518
3246232|NCT00866970|Experimental|2|ALD518
3246233|NCT00866970|Experimental|3|ALD518
3246234|NCT00866970|Placebo Comparator|4|No ALD518
3246235|NCT00866957||Patients with liver cancer|Patients diagnosed with liver cancer
3246236|NCT00866944|Experimental|1|Adecatumumab alone
3246237|NCT00866944|Experimental|2|FOLFOX 4 followed by Adecatumumab
3246238|NCT00866944|Active Comparator|3|FOLFOX 4 alone
3246239|NCT00866918|Experimental|Standard Risk (WBC < 10000/uL)|See Detailed Description
3246240|NCT00866918|Active Comparator|High Risk (WBC > 10000/uL)|See Detailed Description
3246241|NCT00866905|Experimental|Ixabepilone/Cyclophosphamide|Systemic Therapy followed by surgery and possible radiation therapy
3246242|NCT00866892|Active Comparator|irrigation|
3246243|NCT00866892|Experimental|no irrigation|
3246244|NCT00866879|Active Comparator|Control|Group 1 will continue immunosuppression medication per standard of care (SOC) at Northwestern by taking mycophenolate mofetil and tacrolimus.
3246245|NCT00866879|Experimental|Transition to Sirolimus Group|Group 2 will switch immunosuppression medication to taking mycophenolate mofetil and sirolimus
3246246|NCT00866879|Other|Donors|Data and blood samples from the donors are collected in this study to contribute to the general knowledge to be used in assessing the two donor recipient groups, which are the target of this study.
3246247|NCT00866866|Experimental|N-Acetyl Cysteine|
3246248|NCT00866866|Placebo Comparator|Placebo|
3246249|NCT00866840|Experimental|Riluzole|100 mg orally twice daily
3246250|NCT00866814||Ventrio Group|Patients diagnosed with a ventral hernia requiring an open surgery for repair.
3246251|NCT00866801||Healthy|Healthy subjects scheduled for general anesthesia
3246252|NCT00866801||Healthy with thoracic epidural anelgesia|Healthy subjects scheduled for general anesthesia and thoracic epidural analgesia
3246253|NCT00866801||Diabetes|Subjects with diabetes scheduled for general anesthesia
3246254|NCT00866801||Diabetes with autonomic neuropathy|Subjects with diabetes and cardiovascular autonomic neuropathy scheduled for general anesthesia
3246255|NCT00866788|Experimental|Omalizumab 75 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.).
3246300|NCT00866502|Placebo Comparator|Placebo|Continuous ICV infusion
3246301|NCT00866489|No Intervention|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min.
3246256|NCT00866788|Experimental|Omalizumab 300 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
3246257|NCT00866788|Experimental|Omalizumab 600 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
3246258|NCT00866788|Placebo Comparator|Placebo|Participants received a single subcutaneous placebo injection on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
3246259|NCT00866775|Experimental|Eslicarbazepine 1600 mg QD|"Subjects randomized to 1600 mg QD of eslicarbazepine acetate will titrate from 600 mg QD (Day 0) to 1200 mg QD (Week 1) to 1600 mg QD (Weeks 2-18)~Subjects may continue in an open-label extension study with a starting dose of 1600 mg QD, or taper off study drug at the completion of this study The treatment period for subjects entering the open label extension study is up to 9 study visits over 18 weeks. The treatment period for subjects not entering the open-label extension study is up to 10 study visits over 19 weeks."
3246260|NCT00866775|Experimental|Eslicarbazepine 1200 mg QD|"Subjects randomized to 1200 mg QD eslicarbazepine acetate will titrate from 400 mg QD (Day 0) to 800 mg QD (week 1) to 1200 mg QD (weeks 2-18)~Subjects may continue in an open-label extension study with a starting dose of 1600 mg QD, or taper off study drug at the completion of this study The treatment period for subjects entering the open label extension study is up to 9 study visits over 18 weeks. The treatment period for subjects not entering the open-label extension study is up to 10 study visits over 19 weeks."
3246261|NCT00866762|Experimental|1|Treatment with study drug approximately 6 months and follow-up for 3 months
3246262|NCT00866749|Experimental|Augmented BFM Therapy|Induction + Maintenance: Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Doxorubicin, Thioguanine
3246263|NCT00866736|Experimental|dasatinib|
3246264|NCT00866723|Experimental|bevacizumab|Bevacizumab was administered at 15 mg/kg intravenously every 3 weeks. Treatment continued until disease progression or unacceptable toxicity.
3246265|NCT00866697|Experimental|Arm A|Pazopanib 800 mg daily for 104 weeks (24 months)
3246266|NCT00866697|Placebo Comparator|Arm B|Matching placebo 800 mg daily, for 104 weeks (24 months).
3246267|NCT00866684|Experimental|1|Patients will receive Sirolimus in addition to their previous immunosuppressive therapy.
3246268|NCT00866684|Active Comparator|2|Patients will stay on their previous immunosuppressive regimen.
3246269|NCT00866671||Nelarabine|nelarabine 650mg/m2 IV daily for 5 days. repeat every 21 days.
3246270|NCT00866658|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
3246271|NCT00866658|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
3246272|NCT00866645|Experimental|1|Intramuscular Levosulpiride
3246273|NCT00866645|Active Comparator|2|Intramuscular Haloperidol
3246274|NCT00866632|Experimental|Group Cognitive Behavioural Therapy|
3246275|NCT00866632|Experimental|Telephone Cognitive Behavioural Therapy|
3246276|NCT00866632|No Intervention|Group Education|
3246277|NCT00866632|No Intervention|Telephone Education|
3246278|NCT00866619|Experimental|Group R3R (children)|Children enrolled to this group will receive 3 doses of experimental malaria vaccine, and a booster dose of experimental malaria vaccine
3246279|NCT00866619|Active Comparator|Group R3C (children)|Children enrolled to this group will receive 3 doses of experimental malaria vaccine, and a booster dose of comparator vaccine
3246280|NCT00866619|Active Comparator|Group C3C (children)|Children enrolled to this group will receive 3 doses of comparator vaccine, and a booster dose of comparator vaccine
3246281|NCT00866619|Experimental|Group R3R (infants)|Infants enrolled to this group will receive 3 doses of experimental malaria vaccine, and a booster dose of experimental malaria vaccine
3246282|NCT00866619|Experimental|Group R3C (infants)|Infants enrolled to this group will receive 3 doses of experimental malaria vaccine, and a booster dose of comparator vaccine
3246283|NCT00866619|Active Comparator|Group C3C (infants)|Infants enrolled to this group will receive 3 doses of comparator vaccine, and a booster dose of comparator vaccine
3246284|NCT00866606|Experimental|Benefix|Subjects received on-demand treatments with BeneFIX over a 6-month (calendar day) period.
3246285|NCT00866593|Experimental|1|Generic Escitalopram Oxalate Tablets
3246286|NCT00866593|Active Comparator|2|Innovator Escitalopram(Lexapro®)
3246287|NCT00866580|Experimental|Group A|
3246288|NCT00866580|Experimental|Group B|
3246289|NCT00866567||1|Premature infants of less than 28 weeks of gestational age
3246290|NCT00866567||2|Premature infants of more than 28 weeks and less than 32 weeks of gestational age
3246291|NCT00866567||3|Term newborns
3246292|NCT00866567||4|Adults
3246293|NCT00866554|Active Comparator|LHRH agonist|Administration of a 3-month treatment with an LHRH agonist (chosen by the treating radiation oncologist) and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
3246294|NCT00866554|Experimental|Dutasteride, Bicalutamide, Tamoxifen|"Administration of Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."
3246295|NCT00866541|Experimental|volunteers|artificial increased respiratory resistance
3246296|NCT00866528|Experimental|Phase I|oral pazopanib once daily (Phase I starting dose 800 mg) and paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
3246297|NCT00866515|Experimental|Active|Ketoconazole 400mg OD days 1-6
3246298|NCT00866515|Placebo Comparator|Placebo|Placebo OD for 1 to 6 days
3246302|NCT00866489|Experimental|RIPC|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
3246303|NCT00866476|Experimental|Vaccine-recipients|
3246304|NCT00866476|Placebo Comparator|Placebo|
3246305|NCT00866463|Active Comparator|Conventional Oral Tablet With Water|
3246306|NCT00866463|Experimental|Experimental Tablet With Water|
3246307|NCT00866463|Experimental|Experimental Tablet Without Water|
3246308|NCT00866450|Active Comparator|Western style diet|high-fat, low-calcium diet
3246309|NCT00866450|Active Comparator|Prudent diet|low-fat, calcium-sufficient diet
3246310|NCT00866437|Experimental|Healthy Control group|
3246311|NCT00866437|Experimental|PMS|
3246312|NCT00866424|Experimental|A,2, II|
3246313|NCT00866398||1 DES|Patients receiving drug-eluting stent
3246314|NCT00866398||2 BMS|Patients receiving bare metal stent
3246315|NCT00866359|Active Comparator|A. Apremilast|
3246316|NCT00866359|Placebo Comparator|B. Placebo Comparator|
3246317|NCT00866346|Experimental|PR1-CTL|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg."
3246318|NCT00866333|Experimental|treatment|entinostat, oral, once weekly for 3 weeks followed by a 1-week break in a 4-week cycle
3246319|NCT00866320|Experimental|Sorafenib|Chemotherapy single agent systemic. Sorafenib given up to 600mg orally every 12 hours for up to 10 months (40 weeks).
3246320|NCT00866307|Experimental|High Risk - Average (Day 29 MRD < 0.01%)|Cyclophosphamide IV days 1 & 29; cytarabine IV subcutaneously (SC) days 1-4, 8-11, 29-32, & 36-39; mercaptopurine PO once daily (QD) days 1-14 & 29-42; vincristine sulfate IV days 15, 22, 43, & 50; methotrexate IT days 1, 8, 15, & 22; & pegaspargase IV days 15 & 43. Int. Maint.: Vincristine sulfate IV days 1, 11, 21, 31, & 41; methotrexate IV days 1, 11, 21, 31, & 41; methotrexate IT days 1 & 31; and pegaspargase IV days 2 & 22. Delayed Intensification: Vincristine sulfate IV days 1, 8, 15, 43, & 50; dexamethasone IV or PO days 1-7 & 15-21; doxorubicin hydrochloride IV days 1, 8, & 15; cyclophosphamide IV day 29; cytarabine IV or SC days 29-32 & 36-39; thioguanine PO days 29-42; methotrexate IT days 1, 29, & 36; and pegaspargase IV days 4 & 43. Maint. begins day 57 of DI: Vincristine sulfate IV days 1, 29, & 57; prednisone PO days 1-5, 29-33, & 57-61; mercaptopurine PO days 1-84; methotrexate IT day 1; and methotrexate PO days 8, 15, 22, 29*, 36, 43, 50, 57, 64, 71, & 78.
3246321|NCT00866307|Experimental|High Risk - High (Day 29 MRD ≥ 0.01%) or other factors|Cyclophosphamide, cytarabine, mercaptopurine, vincristine sulfate, and methotrexate as in group A. Beginning on day 1, pegaspargase IV every 2 weeks. Patients with CNS3 disease undergo cranial radiotherapy QD for 10 days and patients with testicular disease undergo testicular radiotherapy QD for 12 days, beginning on day 1 of consolidation. Interim Maintenance: Patients receive vincristine sulfate and methotrexate as in group A. Beginning on day 1, pegaspargase IV every 2 weeks. Delayed Intensification: Vincristine sulfate, dexamethasone, doxorubicin hydrochloride, cyclophosphamide, cytarabine, thioguanine, and methotrexate as in group A. Beginning on day 1, pegaspargase IV over 1-2 hours every 2 weeks. Maint. begins day 57 of DI: Vincristine sulfate IV days 1, 29, & 57; prednisone PO days 1-5, 29-33, & 57-61; mercaptopurine PO days 1-84; methotrexate IT day 1; and methotrexate PO days 8, 15, 22, 29*, 36, 43, 50, 57, 64, 71, & 78.
3246322|NCT00866294|Experimental|paroxetine CR group|controlled-release (CR) of paroxetine 12.5 to 50mg/day
3246323|NCT00866294|Other|paroxetine IR group|Immediate-release (IR) of paroxetine 10 to 40mg/day as a reference arm
3246324|NCT00866294|Placebo Comparator|placebo group|matched placebo to both paroxetine CR and paroxetine IR
3246325|NCT00866281|Experimental|30 mg/m^2 bid|Participants received bodyweight and body surface area (BSA) stratified dose of midostaurin 30 mg/m^2 twice daily (bid) through oral route. The total daily dose in 30 mg/m^2 bid cohort was 60 mg/m^2.
3246326|NCT00866281|Experimental|60 mg/m^2 bid|Participants received bodyweight and BSA stratified dose of midostaurin 60 mg/m^2 bid through oral route. The total daily dose in 60 mg/m^2 bid cohort was 120 mg/m^2.
3246327|NCT00866268|Experimental|Low suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter.
3246328|NCT00866268|Active Comparator|High suction drainage|The standard DRENOFAST® system was used in the control group, and the initial negative pressure was 700 mmHg.
3246329|NCT00866242|Experimental|Challenge-recipients|
3246330|NCT00866216|Experimental|1|Azithromycin Monohydrate 600mg Tablets
3246331|NCT00866216|Active Comparator|2|Zithromax (Azithromycin Dihydrate) 600mg Tablets
3246332|NCT00866203|Experimental|HDS|modified high dose sequential therapy
3246333|NCT00866203|Active Comparator|ProMECE/CytaBOM|four additional courses of standard ProMECE/CytaBOM
3246334|NCT00866190|Experimental|Cohort 1|SQ109 dose 75 mg or placebo once daily for 14 days.
3246335|NCT00866190|Experimental|Cohort 3|SQ109 dose 150 mg or placebo once daily for 14 days.
3246336|NCT00866190|Experimental|Cohort 2|SQ109 dose 150 mg or placebo once daily on Days 1-5, 9, and 14.
3246337|NCT00866177|Experimental|Arm I|Patients receive oral MEK inhibitor AZD6244 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3246338|NCT00866151||1|"Previously enrolled subjects in the Benefits and Risks of Alternative Weight Loss Strategies - a Clinical Trial, which was run at Stanford 2003-2005. (A to Z Study)"
3246339|NCT00866138|Experimental|1|masitinib (AB1010)
3246340|NCT00866112|Experimental|1|Intervention group to promote physical activity
3246341|NCT00866112|Other|2|Minimal contact control group
3246342|NCT00866099|No Intervention|"Normal Care"|Primary care practices randomly allocated will be given a summary of the NICE/SCIE dementia guidelines (2006) and offered workshop training and software at the end of the study.
3246449|NCT00865293||Obesity|Subjects with obesity, defined as BMI > 30, aged 25-60
3246450|NCT00865293||Control|Subjects with a BMI 18,5-25, aged 25-60
3246343|NCT00866099|Experimental|Training|Practices randomly allocated to the intervention arm will be asked to participate in tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.
3246344|NCT00866073|Experimental|A|Decitabine 15 mg/m2 i.v. - single arm
3246345|NCT00866060|Active Comparator|1|"10mg donepezil plus 20mg memantine~Participants in this arm will continue with their current donepezil 10mg/day regimen and immediately commence active memantine at a dose of 5mg per day, increasing in 5mg increments weekly until 20mg per day is achieved from week 4 onwards"
3246346|NCT00866060|Placebo Comparator|2|"Placebo donepezil plus 20mg memantine~Participants in this arm will immediately commence active memantine at a dose of 5mg per day, increasing in 5mg increments weekly until 20mg per day is achieved from week 4 onwards. Donepezil dose will be reduced to 5mg daily in weeks 1 to 4 and replaced with placebo donepezil in week 5."
3246347|NCT00866060|Placebo Comparator|3|"10mg donepezil plus placebo memantine~Participants in this arm will continue with their current donepezil 10mg/day regimen and immediately commence placebo memantine."
3246348|NCT00866060|Placebo Comparator|4|"Placebo donepezil plus placebo memantine~Participants in this arm will immediately commence placebo memantine dose escalation and will switch to donepezil 5mg daily in weeks 1 to 4, and replaced with placebo donepezil in week 5."
3246349|NCT00866047|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion
3246350|NCT00866034|Experimental|CD2|Early fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2, together with the initiation of daily treatment with exogenous gonadotropins.
3246351|NCT00866034|Experimental|CD6|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6. As in the other arm of the study, exogenous gonadotropins will commence on cycle day 2.
3246352|NCT00866021|Experimental|1|Lopinavir/ritonavir (LPV/r) as single antiretroviral administered concomitantly with peg-interferon and ribavirin
3246353|NCT00866021|Active Comparator|2|Lopinavir/ritonavir (LPV/r) with 2 NRTIs, administered concomitantly with peg-interferon and ribavirin
3246354|NCT00866008|Experimental|1|Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment.
3246355|NCT00866008|Experimental|2|Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG.
3246356|NCT00865995||1|patients undergoing elective procedures with intubation and no known respiratory pathology
3246357|NCT00865995||2|patients with tracheostomy
3246358|NCT00865995||3|patients with chronic lung disease or respiratory symptoms undergoing bronchoscopy
3246359|NCT00865969|Experimental|Belinostat|Belinostat (PXD101) 1000 mg/m²administered as a 30 minute IV infusion
3246360|NCT00865956|Experimental|Care Management|Care Management plus voucher incentives for adherence to primary care appointments.
3246361|NCT00865956|No Intervention|Usual care|Usual care
3246362|NCT00865943|Experimental|A|Citalopram HBr eq. 10 mg tablets, single dose
3246363|NCT00865943|Active Comparator|B|CELEXATM 10 mg tablets, single dose
3246364|NCT00865917|Active Comparator|1|beta-blocker
3246365|NCT00865917|Experimental|2|I(f)-blocker
3246366|NCT00865917|Placebo Comparator|3|Placebo
3246367|NCT00865904|Placebo Comparator|Placebo|Placebo matched to VX-809 capsule orally once daily for 28 days.
3246368|NCT00865904|Experimental|VX-809, 25 mg|VX-809, 25 milligram (mg) capsule orally once daily for 28 days.
3246369|NCT00865904|Experimental|VX-809, 50 mg|VX-809, 50 mg capsule orally once daily for 28 days.
3246370|NCT00865904|Experimental|VX-809, 100 mg|VX-809, 100 mg capsule orally once daily for 28 days.
3246371|NCT00865904|Experimental|VX-809, 200 mg|VX-809, 200 mg capsule orally once daily for 28 days.
3246372|NCT00865891|Experimental|A|Nifedipine Extended Release tablets 60 mg, single dose
3246373|NCT00865891|Active Comparator|B|ADALAT® CC Extended Release Tablets 60 mg
3246374|NCT00865878|Active Comparator|1|Topical Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA) will be applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to blue light treatment for 16 minutes and 40 seconds.
3246375|NCT00865878|Placebo Comparator|2|Kerastick containing vehicle ingredients only (VEH) will be applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to blue light treatment for 16 minutes 40 seconds.
3246376|NCT00865865|Other|1|Conventional total knee arthroplasty
3246377|NCT00865865|Active Comparator|2|Computer aided total knee arthroplasty
3246378|NCT00865852|Experimental|A|Metformin HCl 750 mg Extender Release tablets, single dose
3246379|NCT00865852|Active Comparator|B|GLUCOPHAGE® XR 750 mg tablets, single dose
3246380|NCT00865839|Experimental|A|Metformin HCl 500 mg tablets, single dose
3246381|NCT00865839|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
3246382|NCT00865826||1|HIV-infected males and females who are not currently receiving ART
3246383|NCT00865813|Experimental|Punch Biopsy|
3246384|NCT00865787||Olive Oil A|
3246385|NCT00865787||Olive Oil B|
3246386|NCT00865774|Experimental|1|Arm number 1 focuses on the traditional quantity frequency model.
3246387|NCT00865774|Experimental|2|Arm number 2 targets subjective drunkenness.
3246388|NCT00865761|Experimental|A|Alprazolam 3 mg Extended Release Tablets, single dose
3246389|NCT00865761|Active Comparator|B|XANAX XR® 3 mg tablets, single dose
3246390|NCT00865748|Experimental|A|Metformin HCl 500 mg tablets, single dose
3246391|NCT00865748|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
3246392|NCT00865722|Active Comparator|RemotePostConditioning|Patients will receive pPCI and treatments according to guidelines for STEMI PLUS extrinsic cuff compression to the lower limb for 5 ' followed by 5' reperfusion for three cycles (30' in total) starting with myocardial reperfusion
3246393|NCT00865722|Sham Comparator|Controls|pPCI and treatments according to guidelines for STEMI
3246451|NCT00865280|Experimental|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet, 150 mg
3246394|NCT00865709|Experimental|Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6|Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease (PD)
3246395|NCT00865709|Placebo Comparator|Matching placebo + mFOLFOX6|Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease
3246396|NCT00865696|Experimental|A|Mirtazapine 15 mg tablets, single dose
3246397|NCT00865696|Active Comparator|B|REMERON® 15 mg tablets, single dose
3246398|NCT00865683|Active Comparator|1|Participants will receive DHA supplements.
3246399|NCT00865683|Placebo Comparator|2|Participants will receive placebo capsules of corn oil.
3246400|NCT00865670|Experimental|1|Azithromycin Monohydrate 600mg Tablets
3246401|NCT00865670|Active Comparator|2|Zithromax (azithromycin dihydrate)600mg Tablets
3246402|NCT00865657|Experimental|A|Alprazolam 3 mg Extended Release Tablets, single dose
3246403|NCT00865657|Active Comparator|B|XANAX XR® 3 mg tablets, single dose
3246404|NCT00865644|Experimental|Imiquimod|
3246405|NCT00865631|Experimental|A|Gabapentin 800 mg tablets, single dose (1 tablet)
3246406|NCT00865631|Active Comparator|B|NEURONTIN® 400 mg capsules, single dose (2 capsules)
3246407|NCT00865618|Experimental|1|Eplerenone 50mg Tablets
3246408|NCT00865618|Active Comparator|2|INSPRA 50mg Tablets
3246409|NCT00865605|Experimental|A|Halobetasol Propionate 0.05% Ointment, single exposure
3246410|NCT00865605|Active Comparator|B|Ultravate® 0.05% ointment, single exposure
3246411|NCT00865579|Experimental|1|All subjects to receive first 50mg/d Safinamide with an increase of target dose of 100mg/d after 14 days of taper period until end of treatment visit. In case of any intolerance the daily dose of 100mg might be decreased to 50mg/d. Patients permanently discontinuing treatment will enter a 7day taper phase before treatment discontinuation at a dose of 50mg/day. Subjects already taking 50mg/d may stop Safinamide immediately.
3246412|NCT00865566|Experimental|1|Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
3246413|NCT00865566|Placebo Comparator|2|Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
3246414|NCT00865540|Experimental|prednisolone acetate 1%|one drop every 8h two days before surgery
3246415|NCT00865540|Experimental|ketorolac tromethamine 0.4%|one drop every 8h two days before surgery
3246416|NCT00865540|Experimental|nepafenac 0.1%|one drop every 8h two days before surgery
3246417|NCT00865540|Placebo Comparator|placebo|one drop every 8h two days before surgery
3246418|NCT00865527|Active Comparator|Fecal Occult Blood Test|fecal occult blood test
3246419|NCT00865527|Active Comparator|Virtual Colonoscopy|virtual colonoscopy
3246420|NCT00865527|Active Comparator|Optical Colonoscopy|optical (conventional / endoscopic) colonoscopy
3246421|NCT00865514|Experimental|Haplotypes and DCA metabolism|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
3246422|NCT00865501|Experimental|1|spironolactone
3246423|NCT00865501|Placebo Comparator|2|placebo
3246424|NCT00865488|No Intervention|1|patients who will be treated in accordance with standard of care
3246425|NCT00865488|Experimental|2|patients for which Adhexil will be applied to prevent/reduce adhesions
3246426|NCT00865475|No Intervention|TZV (Trizivir)|Keeping on TZV in patients with viral suppression
3246427|NCT00865475|Experimental|2|Switching to LPV/r monotherapy
3246428|NCT00865462|Experimental|A|Abrika Bupropion 150 mg XL Tablet, single dose
3246429|NCT00865462|Active Comparator|B|Wellbutrin XL® 150 mg Tablet, single dose
3246430|NCT00865449|Active Comparator|1|Peritoneal Dialysis patients on aldactone for 6 months
3246431|NCT00865449|Placebo Comparator|2|Peritoneal dialysis Patients on the placebo arm for 6 months
3246432|NCT00865436|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
3246433|NCT00865436|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
3246434|NCT00865423|Experimental|A|Gabapentin 800 mg Tablets, single dose
3246435|NCT00865423|Active Comparator|B|NEURONTIN® 800 mg Tablets, single dose
3246436|NCT00865410|Experimental|A|Abrika Bupropion 150 mg Extended-Released Tablet, single dose
3246437|NCT00865410|Active Comparator|B|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
3246438|NCT00865397||A|
3246439|NCT00865384|Experimental|A|Mirtazapine 15 mg tablets, single dose
3246440|NCT00865384|Active Comparator|B|REMERON® 15 mg tablets, single dose
3246441|NCT00865371|Experimental|A|Abrika Bupropion 150 mg Extended-Released Tablet, single dose
3246442|NCT00865371|Active Comparator|B|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
3246443|NCT00865358|Experimental|Yoga Group|A standardized hatha yoga protocol delivered in 12 weekly classes.
3246444|NCT00865358|No Intervention|Usual care|Participants continue to receive their usual medical care for their back pain
3246445|NCT00865319|Experimental|99 m Tc-EC-DG|99m Tc-Ec-DG injection followed by SPECT/CT imaging (range 20-30 mCi) 1mg EC-DG
3246446|NCT00865319|Active Comparator|18F-FDG|18 F FDG injection followed by PET/CT imaging
3246447|NCT00865306|Experimental|Active CBT|"Seven parent-only and 8-13 child-only sessions focusing on CBT for anxiety disorders using the Being Brave protocol."
3246448|NCT00865306|No Intervention|No intervention (wait-list controls)|Control children received no intervention.
3246452|NCT00865280|Active Comparator|Linezolid|Gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; Gram negative treatment: moxifloxacin 400 mg tablet and moxifloxacin 400 mg IV infusion solution
3246453|NCT00865267|Experimental|A|Ultravate® 0.05% ointment, single exposure
3246454|NCT00865254|Experimental|Traditional Contingency Management|Standard treatment plus prize based contingency management.
3246455|NCT00865254|Experimental|Early Enhanced Contingency Management|Prize based contingency management with enhanced magnitude early in treatment and reduced magnitude later in treatment.
3246456|NCT00865254|Active Comparator|Standard Treatment|Counseling and monitoring of smoking cessation.
3246457|NCT00865241|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
3246458|NCT00865241|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
3246459|NCT00865228|Experimental|Lapaquistat Acetate 100 mg QD (morning)|
3246460|NCT00865228|Experimental|Lapaquistat Acetate 100 mg QD (evening)|
3246461|NCT00865228|Experimental|Lapaquistat Acetate 50 mg BID|
3246462|NCT00865228|Placebo Comparator|Placebo BID|
3246463|NCT00865215|Experimental|A|Propranolol Hydrochloride Extended Release Capsules 160 mg, single dose
3246464|NCT00865215|Active Comparator|B|INDERAL® LA 160 mg Capsules, single dose
3246465|NCT00865202|Experimental|L-Tryptophan|L-tryptophan supplementation (1 gram enterally three times per day) starting post-operatively and continuing for a maximum of 9 doses or the time of discharge from ICU (whichever occurs first)
3246466|NCT00865202|Placebo Comparator|Placebo|Similar appearing placebo administered post-operatively (1 enterally three times per day) for a total of nine doses or discharge from ICU (whichever occurs first)
3246467|NCT00865189|Experimental|Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)|In this arm, participants will undergo 3 phases of treatment. During the Phase 1, participants will receive induction chemotherapy with 6 two-week cycles of bevacizumab + Folfox-4 (5-FU + oxaliplatin + folinic acid) for 12 weeks followed by a treatment-free interval of 3 to 4 weeks. The Phase 2 will include 7 weeks of bevacizumab + chemoradiotherapy (intravenous [IV] infusion of bevacizumab alone, 2 weeks before administration of the first cycle of chemoradiotherapy, then 5 one-week cycles of chemoradiotherapy [5-FU + radiotherapy], with administration of bevacizumab every two weeks [Cycles 1, 3 and 5]) followed by a treatment-free interval of 6 to 8 weeks. The Phase 3 will be surgery involving a radical rectal excision using the total mesorectal excision (TME) technique.
3246468|NCT00865189|Experimental|Arm B (Bevacizumab, Chemoradiotherapy)|In this arm, participants will receive the Phase 2 and Phase 3 treatments only. The phase 2 will include 7 weeks of bevacizumab + chemoradiotherapy (IV infusion of bevacizumab alone, 2 weeks before administration of the first cycle of chemoradiotherapy, then 5 one-week cycles of chemoradiotherapy [5-FU + radiotherapy], with administration of bevacizumab every two weeks [Cycles 1, 3 and 5]) followed by a treatment-free interval of 6 to 8 weeks. The phase 3 will be surgery involving a radical rectal excision using the TME technique.
3246469|NCT00865176|Experimental|1|Eplerenone 50mg Tablets
3246470|NCT00865176|Active Comparator|2|INSPRA 50mg Tablets
3246471|NCT00865137|Experimental|1 FK506E|
3246472|NCT00865124|Experimental|Spironolactone (mineralocorticoid receptor [MR] blockade)|
3246473|NCT00865124|Active Comparator|Hydrochlorothiazide + potassium|
3246474|NCT00865124|Placebo Comparator|Placebo capsule|
3246475|NCT00865111|Experimental|A|Bupropion 150 mg Extended-Released Tablet, single dose
3246476|NCT00865111|Active Comparator|B|Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
3246477|NCT00865098|Experimental|Cetuximab With Radiotherapy|
3246478|NCT00865085|Experimental|A|Citalopram HBr 40 mg tablets, single dose
3246479|NCT00865085|Active Comparator|B|CelexaTM 40 mg tablets, single dose
3246480|NCT00865072|Experimental|A|Metformin HCl 750 mg Extender Release tablets, single dose
3246481|NCT00865072|Active Comparator|B|GLUCOPHAGE® XR 750 mg tablets, single dose
3246482|NCT00865059|Experimental|A|Gabapentin 800 mg Tablets, single dose
3246483|NCT00865059|Active Comparator|B|NEURONTIN® 800 mg Tablets, single dose
3246484|NCT00865046|Experimental|PST + PST boosters|PST once a week for 10 weeks, then tapering over 6 months
3246485|NCT00865046|Active Comparator|PST + control-PST boosters|PST once a week for 10 weeks, then control-PST tapering over 6 months
3246486|NCT00865046|Placebo Comparator|Control-PST|control-PST for 10 weeks
3246487|NCT00865033|Experimental|1|Metformin HCL Tablets, 1000 mg
3246488|NCT00865033|Active Comparator|2|Glucophage 1000 mg Tablets
3246489|NCT00865020|Experimental|Aliskiren 300 mg|Aliskiren tablets starting at a dose of 150 mg taken orally daily for 2 weeks followed by a dose of 300 mg taken orally for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Aliskiren: 1 tablet for the first 2 weeks and 2 tablets during the one week withdrawal period.
3246490|NCT00865020|Active Comparator|Telmisartan 80 mg|Telmisartan capsules starting at a dose of 40 mg taken orally daily for 2 weeks followed by a dose of 80 mg taken orally daily for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Telmisartan: 1 capsule for the first 2 weeks and 2 capsules during the one week withdrawal period.
3246491|NCT00865007|Experimental|Monotherapy group|Lopinavir/ritonavir (LPV/r).
3246492|NCT00865007|Active Comparator|Triple arm|Lopinavir/ritonavir (LPV/r)+ ABC/3TC
3246493|NCT00864994||1|• 30 healthy subjects with 20 pack years smoking who have no signs of COPD (age 40-75 years)
3246494|NCT00864994||2|• 30 COPD patients with GOLD stage II (age 40-75 years)
3246495|NCT00864981|Experimental|1|Bupropion HCI ER Tablets, 150 mg
3246496|NCT00864981|Active Comparator|2|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg
3246497|NCT00864968|Experimental|A|Nabumetone 750 mg tablets, single dose
3246498|NCT00864968|Active Comparator|B|Nabumetone 750 mg tablets, single dose
3246499|NCT00864955|Experimental|phototype 2|Volunteers with cutaneous phototype 2
3246500|NCT00864955|Experimental|phototype 4|Volunteers with cutaneous phototype 4
3246501|NCT00864942|Experimental|BL-NHL|Bendamustine and lenalidomide for NHL
3246502|NCT00864942|Experimental|BLR-CLL|Bendamustine, lenalidomide, rituximab for CLL
3246503|NCT00864942|Experimental|BLR-NHL|Bendamustine, lenalidomide, and rituximab for NHL
3246504|NCT00864942|Experimental|BL-CLL|bendamustine and lenalidomide in patients with CLL
3246505|NCT00864929||1|Appropriate antimicrobial treatment
3246506|NCT00864929||2|Inappropriate antimicrobial treatment
3246507|NCT00864916|Experimental|1|Participants will receive pentoxifylline and combination antiretroviral therapy (cART).
3246508|NCT00864916|Active Comparator|2|Participants will receive placebo and cART.
3246509|NCT00864903||pediatric ER|any child undergoing a spinal tap due to suspected meningitis
3246510|NCT00864890|Experimental|A|Citalopram HBr 40 mg tablets, single dose
3246511|NCT00864890|Active Comparator|B|CelexaTM 40 mg tablets, single dose
3246512|NCT00864864|Experimental|Sunitinib|
3246513|NCT00864851|Active Comparator|Replagal 0.2 mg/kg, IV, every other week|Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every other week for 52 weeks.
3246514|NCT00864851|Active Comparator|Replagal 0.2 mg/kg, IV, weekly|Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every week for 52 weeks.
3246515|NCT00864851|Active Comparator|Replagal 0.4 mg/kg, IV, weekly|Patients randomized to receive Replagal 0.4 mg/kg via intravenous infusion every week for 52 weeks.
3246516|NCT00864838|No Intervention|1|Patients submitted to 1,5 mg/0,06 ml intravitreal injection of bevacizumab and no treatment for intraocular pressure elevation
3246517|NCT00864838|Experimental|2|Acetazolamide: 250 mg of oral acetazolamide 1 hour before intravitreal bevacizumab injection
3246518|NCT00864838|Experimental|3|topic brimonidine tartarate: one drop of brimonidine tartarate 1 hour before intravitreal bevacizumab injection
3246519|NCT00864838|Experimental|4|anterior chamber paracentesis: anterior chamber paracentesis immediately after intravitreal bevacizumab
3246520|NCT00864825|Experimental|Allopurinol|
3246521|NCT00864825|Placebo Comparator|Placebo|
3246522|NCT00864812|Experimental|1|tiotropium with fluticasone propionate/salmeterol (FSC)
3246523|NCT00864812|Active Comparator|2|tiotropium
3246524|NCT00864799|Active Comparator|Vaginal misoprostol|"Women allocated to the vaginal misoprostol management protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 4 hours by 400 mcg vaginal misoprostol, the latter repeated every 4 hours for a maximum of 4 doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
3246525|NCT00864799|Active Comparator|Oral misoprostol|"Women allocated to the standard management protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 3 hours by 400 mcg misoprostol orally, the latter repeated every 3-hours to a maximum of 4 oral doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
3246526|NCT00864799|Active Comparator|Sublingual misoprostol|"Women allocated to the sublingual misoprostol protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 3 hours by 400 mcg sublingual misoprostol, the latter repeated every 3 hours for a maximum of 4 doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
3246527|NCT00864786|Experimental|Cohort 1|200 mcg
3246528|NCT00864786|Experimental|Cohort 2|600 mcg
3246529|NCT00864786|Experimental|Cohort 3|1000 mcg
3246530|NCT00864786|Experimental|Cohort 4|Dose to be decided
3246531|NCT00864786|Experimental|Cohort 5|Dose to be decided
3246532|NCT00864760|Experimental|A|Gabapentin 800 mg tablets, single dose (1 tablet)
3246533|NCT00864760|Active Comparator|B|NEURONTIN® 400 mg capsules, single dose (2 capsules)
3246534|NCT00864747|Experimental|A|Propranolol Hydrochloride Extended Release Capsules 160 mg, single dose
3246535|NCT00864747|Active Comparator|B|INDERAL® LA 160 mg Capsules, single dose
3246536|NCT00864734|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
3246537|NCT00864734|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
3246538|NCT00864721|Experimental|Sunitinib Malate|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
3246539|NCT00864708|Experimental|Arm 1|radio frequency-controlled (RF) Microstimulator (RFM) Gait System
3246540|NCT00864695||Surgical patients|Individuals who were hospitalized in the Botucatu Medical School Hospital to undergo surgery under anesthesia administered by the Anesthesiology Service of BMS Department of Anesthesiology.
3246541|NCT00864682|Placebo Comparator|Placebo|Saline pretreatment, saline admixture
3246542|NCT00864682|Active Comparator|Lidocaine pretreatment|Lidocaine pretreatment / saline-propofol admixture
3246543|NCT00864682|Active Comparator|Lidocaine-Propofol admixture|saline pretreatment / Lidocaine-propofol admixture
3246544|NCT00864669|Experimental|A|Metformin HCl 500 mg tablets, single dose
3246545|NCT00864669|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
3246546|NCT00864656||1|Patients submitted to application of 1 drop of 10% phenylephrine
3246547|NCT00864656||2|Patients submitted to application of 2 drops of 10% phenylephrine
3246548|NCT00864656||3|Patients submitted to application of 4 drops of 10% phenylephrine
3246549|NCT00864643|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin QD|
3246550|NCT00864643|Active Comparator|Atorvastatin QD|
3246551|NCT00864630|No Intervention|Wait list|
3246552|NCT00864630|Experimental|Computer-based problem solving therapy|
3246553|NCT00864617|Experimental|A|Nifedipine Extended Release tablets 60 mg, single dose
3246554|NCT00864617|Active Comparator|B|ADALAT® CC Extended Release Tablets 60 mg
3246555|NCT00864604|Experimental|A|Nabumetone 750 mg tablets, single dose
3246556|NCT00864604|Active Comparator|B|Nabumetone 750 mg tablets, single dose
3246557|NCT00864591||SPECT and stress CMR patients|"patients undergoing SPECT stress imaging, for the evaluation of myocardial ischemia.~The study group will include patients with either normal undergoing SPECT stress imaging or with mild to severe ischemia, to include the entire spectrum of coronary artery disease.~Patients will be pre selected and evaluated by a non-dependent cardiologist in order to verify that patients in whom the repeat stress might pose a serious risk will be excluded from the study."
3246558|NCT00864565|Experimental|A|Fentanyl 25 μg/h transdermal system, single application
3246559|NCT00864565|Active Comparator|B|Duragesic 25 μg/h transdermal system single application
3246560|NCT00864552||Group 1|
3246561|NCT00864539|Experimental|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 mL
3246562|NCT00864539|Active Comparator|plain milk|daily intake of 200 mL plain milk
3246563|NCT00864539|Experimental|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium
3246564|NCT00864539|Active Comparator|plane juice|subjects receiving plain orange juice
3246565|NCT00864539|Experimental|vitamin D-Ca supplement|Subjects receiving daily supplement containing 500 mg + 200 IU vitamin D
3246566|NCT00864539|Placebo Comparator|Placebo|Subjects receiving daily placebo containing 1g starch
3246567|NCT00864526|Experimental|A|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
3246568|NCT00864526|Active Comparator|B|COMBONOX® tablets, single dose
3246569|NCT00864513|Experimental|chemotherapy|pemetrexed
3246570|NCT00864500|Experimental|A|Clobetasol Propionate 0.05% lotion, single exposure
3246571|NCT00864500|Active Comparator|B|Clobex TM 0.05% Lotion, single exposure
3246572|NCT00864487|Experimental|1|Neratinib alone
3246573|NCT00864487|Experimental|2|Neratinib plus rifampin
3246574|NCT00864474||Maraviroc Tablets|Patients administered.
3246575|NCT00864461||Case|Patients with clinical and cytogenetics diagnosis of Down syndrome, between 7 - 24 years old.
3246576|NCT00864461||Control|Siblings of the same gender of the case, between 7-24 years old.
3246577|NCT00864448|Experimental|A|Ramipril10 mg Capsules, single dose
3246578|NCT00864448|Active Comparator|B|Atlace® 10 mg capsules, single dose
3246579|NCT00864435|Experimental|A|Carvedilol 12.5 mg Tablets, single dose
3246580|NCT00864435|Active Comparator|B|Coreg® 12.5 mg Tablets , single dose
3246581|NCT00864422|Experimental|1|
3246582|NCT00864422|Active Comparator|2|
3246583|NCT00864409|Active Comparator|Hip 1|high volume local anesthetic infiltration
3246584|NCT00864409|Placebo Comparator|Hip 2|
3246585|NCT00864396|Experimental|Prevacid|
3246586|NCT00864383|Placebo Comparator|Regimen 1 - 2EHRZ/4HR (control regimen)|"Eight weeks of chemotherapy with Ethambutol, Isoniazid, Rifampicin and Pyrazinamide plus the Moxifloxacin placebo, followed by~Nine weeks of Isoniazid and Rifampicin plus the Moxifloxacin placebo, followed by~Nine weeks of Isoniazid and Rifampicin only."
3246587|NCT00864383|Experimental|Regimen 2 - 2MHRZ/2MHR|"Eight weeks of chemotherapy with Moxifloxacin, Isoniazid, Rifampicin and Pyrazinamide plus the Ethambutol placebo, followed by~Nine weeks of Moxifloxacin, Isoniazid and Rifampicin, followed by~Nine weeks of the Isoniazid placebo and the Rifampicin placebo."
3246588|NCT00864383|Experimental|Regimen 3 - 2EMRZ/2MR|"Eight weeks of chemotherapy with Ethambutol, Moxifloxacin, Rifampicin and Pyrazinamide plus the Isoniazid placebo, followed by~Nine weeks of Moxifloxacin and Rifampicin plus the Isoniazid placebo, followed by~Nine weeks of the Isoniazid placebo and the Rifampicin placebo"
3246589|NCT00864357|Experimental|A|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
3246590|NCT00864357|Active Comparator|B|COMBONOX® tablets, single dose
3246591|NCT00864344|Experimental|A|Sertraline HCl 100 mg tablets, single dose
3246592|NCT00864344|Active Comparator|B|Zoloft® 100 mg tablets, single dose
3246593|NCT00864331|Active Comparator|Radiotherapy|For patients in Group A (Stage IIIA or IIIB), EBRT 39 Gy in 13 daily fractions over, with no chemotherapy.
3246594|NCT00864331|Experimental|Chemotherapy and radiotherapy|For patients in Group A (either stage IIIA or IIIB) receive a course of up to 3 cycles of chemotherapy followed by EBRT of 10 Gy in a single fraction or 16 Gy in 2 fractions 1 week apart.
3246595|NCT00864331|Active Comparator|Chemotherapy|For patients in Group B (either stage IIIB (wet) or IV) receive up to 3 cycles of chemotherapy, and no radiotherapy.
3246596|NCT00864331|Experimental|Palliative radiotherapy and chemotherapy|For patients in Group B (either stage IIIB (wet) or IV) receive EBRT of 10 Gy in a single fraction or 16 Gy in two fractions 1 week apart, followed by up to 3 cycles of chemotherapy.
3246597|NCT00864305|Experimental|A|Gabapentin 400 mg capsules
3246598|NCT00864305|Active Comparator|B|Neurontin 400 mg capsules
3246599|NCT00864292||HIV-infected, no dementia|Patients with HIV-infection but no dementia
3246600|NCT00864292||HIV-infected, dementia|Patients with HIV-infection and dementia
3246601|NCT00864279|Experimental|A|Cetirizine Hydrochloride 10 mg tablets, single dose
3246602|NCT00864279|Active Comparator|B|Zyrtec® 10 mg tablets, single dose
3246603|NCT00864266|Experimental|1|After obtaining the biopsy, patients will be treated by standard chemotherapy (the regimen has to be in agreement with the ELCWP guidelines, available on the website www.elcwp.org)
3246604|NCT00864253|Experimental|ABI-007|Treatment Arm A (ABI-007): Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
3246605|NCT00864253|Active Comparator|Dacarbazine|Treatment Arm B (dacarbazine): Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
3246606|NCT00864240|Experimental|A|Clobex TM 0.05% Lotion, single exposure
3246607|NCT00864227|Experimental|Umbilical Cord Blood Transplantation|Participants will receive a double unit Hematopoietic Umbilical Cord Blood Stem Cell Transplantation using a non-myeloablative preparative regimen, GVHD prophylaxis.
3246608|NCT00864214|Experimental|1|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
3246609|NCT00864214|Experimental|2|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
3246610|NCT00864214|Experimental|3|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
3246611|NCT00864214|Experimental|4|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
3246612|NCT00864201|Experimental|bosentan|
3246613|NCT00864188|Placebo Comparator|1|Glucono-Delta-Lactone acidified milk containing no bacterial strains
3246614|NCT00864188|Experimental|2|Glucono-Delta-Lactone acidified milk containing one probiotic strain called Lactobacillus paracasei NCC2461.
3246615|NCT00864188|Placebo Comparator|3|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii subsp.bulgaricus.
3246616|NCT00864188|Experimental|4|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii and one probiotic strain called Lactobacillus paracasei NCC2461.
3246617|NCT00864188|Experimental|5|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii, one probiotic strain called Lactobacillus paracasei NCC2461 and Vitamin B2,B3, C and E, Beta Carotene and an Oil.
3246618|NCT00864175|Experimental|Treatment A - INCB007839 and Trastuzumab|"INCB007839 100 mg BID and trastuzumab~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
3246619|NCT00864175|Experimental|Treatment B - INCB007839 and Trastuzumab|"INCB007839 200 mg BID and trastuzumab~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
3246620|NCT00864175|Experimental|Treatment C - INCB007839 and Trastuzumab|"INCB007839 300 mg BID and trastuzumab~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
3246621|NCT00864175|Experimental|Treatment D - INCB007839 and Docetaxel|INCB007839 300mg BID with docetaxel
3246622|NCT00864162|Experimental|A|Ramipril10 mg Capsules, single dose
3246623|NCT00864162|Active Comparator|B|Atlace® 10 mg capsules, single dose
3246624|NCT00864149|Experimental|A|Carvedilol 12.5 mg Tablets, single dose
3246625|NCT00864149|Active Comparator|B|Coreg® 12.5 mg Tablets , single dose
3246626|NCT00864136||Group 1|
3246627|NCT00864136||Group 2|
3246628|NCT00864136||Group 3|
3246629|NCT00864123|Active Comparator|Cognitive-behavioral therapy + placebo|Involves receiving cognitive-behavioral treatment of OCD symptoms for 10 sessions. One hour prior to sessions 4-10, the child will take either 1 or 2 pills containing 25mg of placebo. The number of pills depends on the child's weight (e.g., about 46kgs takes 2 capsules).
3246630|NCT00864123|Experimental|Cognitive-behavioral therapy + D-cycloserine|Involves receiving cognitive-behavioral treatment of OCD symptoms for 10 sessions. One hour prior to sessions 4-10, the child will take either 1 or 2 pills containing 25mg of D-cycloserine. The number of pills depends on the child's weight (e.g., about 46kgs takes 2 capsules).
3246631|NCT00864110|Experimental|99mTc EC-DG|99mTc-EC-DG with SPECT/CT imaging
3246632|NCT00864110|Active Comparator|18F FDG|18F FDG with PET/CT imaging
3246633|NCT00864097|Experimental|Tanezumab 10 mg + diclofenac|IV tanezumab 10 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
3246634|NCT00864097|Experimental|Tanezumab 5 mg + diclofenac|IV tanezumab 5 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
3246635|NCT00864097|Experimental|Tanezumab 2.5 mg + diclofenac|IV tanezumab 2.5 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
3246636|NCT00864097|Placebo Comparator|IV placebo + diclofenac|IV placebo to match tanezumab every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
3246637|NCT00864084|Experimental|Pulmonary rehabilitation|People with respiratory disease
3246638|NCT00864071|Experimental|A|Griseofulvin 125 mg/5 mL Suspension, single dose
3246639|NCT00864071|Active Comparator|B|Grifulvin V® 125 mg/5 mL Suspension, single dose
3246640|NCT00864058|Experimental|A|Gabapentin 400 mg capsules
3246641|NCT00864058|Active Comparator|B|Neurontin 400 mg capsules
3246642|NCT00864045|Experimental|Sertindole|
3246643|NCT00864045|Active Comparator|Olanzapine|
3246644|NCT00864032|Experimental|Phase I|
3246645|NCT00864019|Experimental|A|Sertraline HCl 100 mg tablets, single dose
3246646|NCT00864019|Active Comparator|B|Zoloft® 100 mg tablets, single dose
3246647|NCT00864006|Experimental|1|Divalproex Sodium 125 MG Delayed Release Tablets Sandoz
3246648|NCT00864006|Active Comparator|2|Depakote 125 MG DR Tablets Abbott Laboratories USA
3246649|NCT00863980|Experimental|Telmisartan|Treatment with Telmisartan
3246650|NCT00863980|Active Comparator|Candesartan|Treatment with Candesartan
3246651|NCT00863967||1|no cardiovascular events
3246652|NCT00863967||2|proven cardiovascular events
3246653|NCT00863967||3|possible cardiovascular events
3246654|NCT00863954|Active Comparator|Output A|
3246655|NCT00863954|Active Comparator|Output B|
3246656|NCT00863954|Active Comparator|Output C|
3246657|NCT00863954|Active Comparator|Output D|
3246658|NCT00863954|Active Comparator|Output E|
3246659|NCT00863954|Active Comparator|Output F|
3246660|NCT00863941|Experimental|A|Abrika Bupropion 150 mg XL Tablet, single dose
3246661|NCT00863941|Active Comparator|B|Wellbutrin XL® 150 mg Tablet, single dose
3246662|NCT00863915|Experimental|A|Ramipril10 mg Capsules, single dose
3246663|NCT00863915|Active Comparator|B|Atlace® 10 mg capsules, single dose
3246664|NCT00863902|Experimental|Cetirizine Hydrochloride|Cetirizine Hydrochloride 10 mg tablets, single dose
3246929|NCT00862095|Placebo Comparator|Placebo|Placebo group
3246665|NCT00863902|Active Comparator|Zyrtec|Zyrtec® 10 mg tablets, single dose
3246666|NCT00863889|Experimental|1|1cc Depomedrol, 4 cc 1% Lidocaine, 4 cc 0.25% Marcaine
3246667|NCT00863889|Placebo Comparator|2|4 cc 1% Lidocaine, 4 cc 0.25% Marcaine
3246668|NCT00863876||1|non-operated healthy eyes
3246669|NCT00863876||2|eyes 1 months following LASIK
3246670|NCT00863876||3|eyes 3-6 months following LASIK
3246671|NCT00863876||4|eyes with spherical monofocal IOLs more than 3 months postop
3246672|NCT00863876||5|eyes with aspherical monofocal IOLs more than 3 months postop
3246673|NCT00863876||6|eyes with toric monofocal IOLs more than 3 months postop
3246674|NCT00863876||7|eyes with diffractive multifocal IOLs more than 3 months postop
3246675|NCT00863876||8|eyes with phakic IOLs more than 3 months postop
3246676|NCT00863876||9|eyes with keratoconus
3246677|NCT00863863|Experimental|A|Griseofulvin 125 mg/5 mL Suspension, single dose
3246678|NCT00863863|Active Comparator|B|Grifulvin V® 125 mg/5 mL Suspension, single dose
3246679|NCT00863850|Experimental|1|
3246680|NCT00863837|Active Comparator|Arm A|add pantoloc to reduce ulcer bleeding after banding ligation
3246681|NCT00863837|Placebo Comparator|Arm B: ligation + terlipressin 1mg q6h|Arm B, intervention: ligation + terlipressin 1mg q6h
3246682|NCT00863811||2|POAG patients with IOP under control by prostaglandins eye drops treatment and assuming two tablets per day of the food supplement KRONEK
3246683|NCT00863811||1|POAG patients compensated by the treatment of betablockers eye drops and taking two tablets per day of KRONEK
3246684|NCT00863798|Experimental|Desvenlafaxine succinate sustained release 10 mg|
3246685|NCT00863798|Experimental|Desvenlafaxine succinate sustained release 50 mg|
3246686|NCT00863798|Placebo Comparator|Placebo|
3246687|NCT00863785|Experimental|Corticoids plus N Acetyl Cysteine|40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
3246688|NCT00863772|Experimental|Tanezumab 5 mg|
3246689|NCT00863772|Experimental|Tanezumab 10 mg|
3246690|NCT00863772|Placebo Comparator|Placebo|
3246691|NCT00863759|Active Comparator|1|Patients will receive an aspheric intraocular lenses (IOL) Akreos AO in the right eye and an spheric IOL Akreos Fit in the left eye, during cataract surgery.
3246692|NCT00863759|Active Comparator|2|Patients will receive an spheric intraocular lens (IOL) Akreos Fit in the right eye and an aspheric IOL Akreos AO in the left eye, during cataract surgery.
3246693|NCT00863746|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (BID)
3246694|NCT00863746|Placebo Comparator|Placebo|Participants received 2 tablets of placebo orally twice daily (BID)
3246695|NCT00863707|Placebo Comparator|Placebo|Matching intravenous (IV) bolus injection
3246696|NCT00863707|Experimental|Regadenoson|0.4 mg/5 mL intravenous bolus injection
3246697|NCT00863681|Experimental|Arm 1|
3246698|NCT00863668|Active Comparator|Efavirenz|
3246699|NCT00863668|Experimental|Raltegravir|
3246700|NCT00863655|Experimental|Everolimus + Exemestane|Everolimus 10 mg daily in combination with exemestane 25 mg daily
3246701|NCT00863655|Active Comparator|Placebo + Exemestane|Placebo of everolimus in combination with exemestane 25 mg daily
3246702|NCT00863642|Experimental|Early|In patients who present with mild to moderate gallstone pancreatitis, those randomized to the early arm will undergo laparoscopic cholecystectomy within 48 hours of admission, regardless of laboratory values normalization and resolution of abdominal pain.
3246703|NCT00863642|Other|Control|In patients in the control arm, laparoscopic cholecystectomy is delayed until laboratory values normalize and abdominal pain resolves.
3246704|NCT00863629|No Intervention|1|25 normoglycemic patients as control group
3246705|NCT00863629|Active Comparator|2|20 hyperglycemic patients (glucose >140 mg/dl) randomized to conventional glycemic control by insulin (CGC group; glucose goal 180-200 mg/dl)
3246706|NCT00863629|Experimental|3|20 hyperglycemic patients (glucose >140 mg/dl) were randomized to intensive glycemic control by insunin (IGC group; glucose goal 80-140 mg/dl)
3246707|NCT00863616|Experimental|HFCWO|HFCWO twice a day delivered by SmartVest device at 13Hz FOR 20min x2. Duration 4 weeks in each phase with a 2week washout.
3246708|NCT00863616|No Intervention|Placebo/Control|Self-administered breathing exercises
3246709|NCT00863603|No Intervention|1|No exposure to supplemental oxygen
3246710|NCT00863603|Other|Oxygen, treatment, supplement|6 weeks of supplemental oxygen delivered by nasal cannula post hemodialysis graft placement
3246711|NCT00863590|Experimental|A|Panel A
3246712|NCT00863590|Experimental|B|Panel B
3246713|NCT00863590|Experimental|C|Panel C
3246714|NCT00863590|Experimental|D|Panel D
3246715|NCT00863564|Active Comparator|Whey Isolate|
3246716|NCT00863564|Active Comparator|Caseine|
3246717|NCT00863564|Active Comparator|Cod|
3246718|NCT00863564|Active Comparator|Gluten|
3246719|NCT00863551|Experimental|Trospium Chloride Extended Release, 60 mg|Trospium Chloride Extended Release, 60 mg
3246720|NCT00863538|Experimental|1|
3246721|NCT00863525|Experimental|1|Odanacatib
3246722|NCT00863525|Placebo Comparator|2|Placebo
3246723|NCT00863512|Experimental|Arm I|Patients receive cisplatin IV on day 1 and vinorelbine ditartrate IV on days 1 and 8 OR docetaxel IV and cytarabine IV on day 1 OR gemcitabine hydrochloride IV on days 1 and 8 and cytarabine IV on day 1 OR pemetrexed disodium IV and cisplatin IV on day 1.. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3246724|NCT00863512|Experimental|Arm II|Patients receive standard care (observation).
3246725|NCT00863499|Active Comparator|A|Short Acting methylphenidate
3246726|NCT00863499|Active Comparator|B|Long Acting Methylphenidate
3246727|NCT00863499|No Intervention|C|Healthy Controls
3246728|NCT00863473|No Intervention|Conservative /Physiotherapy|Active training protocol with instructed physiotherapy and self excercises
3246729|NCT00863473|Active Comparator|Surgery with LCP T plate|Surgical treatment with interlocking plate
3247089|NCT00860873|Experimental|Test 2|Hard Capsules EMS
3246730|NCT00863460|Active Comparator|A|MTX-based chemotherapy followed by WBRT
3246731|NCT00863460|Experimental|B|MTX-based chemotherapy followed by intensive chemotherapy and hematopoietic stem cell rescue
3246732|NCT00863434|Experimental|Treatment (colony stimulating factor and chemotherapy)|Patients receive G-CSF SC QD on days 1-5 and clofarabine IV over 1 hour and cytarabine IV on days 2-5. Beginning approximately 1 month later, patients may receive one additional course of treatment in the absence of disease progression or unacceptable toxicity.
3246733|NCT00863395|Experimental|Skin Biopsy|
3246734|NCT00863382|Active Comparator|1|Standard Event Monitor
3246735|NCT00863382|Active Comparator|2|Sleuth recorder
3246736|NCT00863369|Experimental|Treatment (bortezomib, gemcitabine hydrochloride, rituximab)|Patients receive bortezomib IV, gemcitabine hydrochloride IV over 3-4 hours, and rituximab IV on days 1 and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
3246737|NCT00863356|Experimental|Epistaxis Group|"Subjects presenting with epistaxis that have not been controlled by traditional nasal packing, or that recurred immediately upon removal of the nasal packing will be included in this study. Subject will be evaluated during the packing period to determine the effect of hemostasis. Chitosan coated packing will be removed after 48 hours. Subjects' nasal cavities will be examined endoscopically to evaluate bleeding control, morphological changes induced by the chitosan coated packing.~One week after the removal of the packing, the patients will be endoscopically examined to assess the healing of the packed area, to monitor control of bleeding, and observe any potential delayed reaction to the packing material."
3246738|NCT00863343||All|Anyone presenting with influenza-like-illness
3246739|NCT00863330|Experimental|Determine toxicity of treatment regimen.|
3246740|NCT00863317|Experimental|montelukast sodium|4mg granules PO QD for 14 days
3246741|NCT00863317|Placebo Comparator|Placebo|Sucrose granules PO QD for 14 days
3246742|NCT00863304|Experimental|1|
3246743|NCT00863304|Experimental|2|
3246744|NCT00863304|Active Comparator|3|
3246745|NCT00863304|Placebo Comparator|4|
3246746|NCT00863291|Active Comparator|1|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
3246747|NCT00863291|Placebo Comparator|2|Placebo given in a manner similar to he active comparator
3246748|NCT00863278|Active Comparator|Arm A|"All patients will be treated by stabilized Kligman's trio with daily application during 4 months.~After one month, the left side of the face will be treated with pulsed dye laser at the rate of 3 sessions (one every weeks).~Applications of cream will be stopped on both side of the face for the 3 days following each laser session. Final visit will be scheduled 1 month after the end of applications of stabilized Kligman's trio.~All the patients will used a sunscreen indication 50 + for the duration of the entire study.~The patient is her own witness. They compare the hemiface treated without laser and the hemiface treated with the laser."
3246749|NCT00863278|Active Comparator|Arm B|"All patients will be treated by stabilized Kligman's trio at the rate of application in the evening during 4 months.~After one month, the side of the right face will be treated by pulsed dye laser at the rase of 3 sessions spaced out by 3 weeks each.~Applications will be stopped in the 3 days which will follow every session by laser with blown colouring agent. The patients will be seen again 1 month after the stopping of applications of stabilized Kligman's trio~All patients will be used a sunscreen indication 50 + for the duration of study.~The patient is her own witness. They compare the cheek treated without laser and the cheek treated with the laser."
3246750|NCT00863265|Experimental|Crossover order ABC|The order of treatments is A (phytosterols + ezetimibe), B (double placebo), and C (active ezetimibe and phytosterol placebo).
3246751|NCT00863265|Experimental|Crossover order BCA|The order of treatments is B (double placebo), C (active ezetimibe and phytosterol placebo), and A (phytosterols + ezetimibe).
3246752|NCT00863265|Experimental|Crossover order BAC|The order of treatments is B (double placebo), A (phytosterols + ezetimibe), and C (active ezetimibe and phytosterol placebo)
3246753|NCT00863265|Experimental|Crossover order ACB|The order of treatments is A (phytosterols + ezetimibe), C (active ezetimibe and placebo phytosterols, and B (double placebo).
3246754|NCT00863265|Experimental|Crossover order CAB|The order of treatments is C (active ezetimibe and placebo phytosterols), A (phytosterols + ezetimibe), and B (double placebo).
3246755|NCT00863265|Experimental|Crossover order CBA|The order of treatments is C (active ezetimibe and placebo phytosterols), B (double placebo), and A (phytosterols and ezetimibe).
3246756|NCT00863252|Experimental|1|MMF
3246757|NCT00863252|Active Comparator|2|Control
3246758|NCT00863239|Experimental|1|Locteron™ (controlled-release interferon alpha 2b) 320 µg as biweekly subcutaneous injection
3246759|NCT00863239|Experimental|2|Locteron™ (controlled-release interferon alpha 2b) 480 µg as biweekly subcutaneous injection
3246760|NCT00863239|Experimental|3|Locteron™ (controlled-release interferon alpha 2b) 640 µg as biweekly subcutaneous injection
3246761|NCT00863239|Active Comparator|4|PEG-Intron™ (12 kDalton pegylated interferon alpha 2b) 1.5 µg/kg body weight weekly subcutaneous injection
3246762|NCT00863213|Experimental|Atrial Fibrillation Ablation|
3246763|NCT00863213|Active Comparator|Drug therapy|
3246764|NCT00863200||Telephone Intervention Group|
3246765|NCT00863200||Standard Care Group|
3246766|NCT00863187|Experimental|rituximab|b cell depletion drug
3246767|NCT00863174|Experimental|1|SPARC147709
3246768|NCT00863174|Active Comparator|2|Reference147709
3246769|NCT00863161|Experimental|1|AZD3355 65 + 65 mg capsule
3246770|NCT00863135|Experimental|Continuous Positive Airway Pressure|nocturnal continuous positive airways pressure
3246771|NCT00863135|Other|Control|Waiting list,3 months without any change in their treatment, come into the CPAP procedure after that time
3246772|NCT00863122|Experimental|lapatinib|Subjects will receive lapatinib for 10 days prior to surgery for vestibular schwannoma resection.
3246773|NCT00863122|No Intervention|control|Control subjects will not receive any intervention prior to surgery for vestibular schwannoma resection.
3246774|NCT00863109||PEG + RBV (Standard Clinical Practice)|Participants receive peginterferon alfa-2b (PEG) and ribavirin (RBV) in combination therapy for 48 weeks according to standard clinical practice followed by 24 weeks of observation.
3246775|NCT00863096||Gardasil|
3246776|NCT00863083|Active Comparator|1|Multifamily group weight management intervention plus rewards for program attendance
3246777|NCT00863083|Active Comparator|2|Multifamily group weight management intervention plus rewards for attendance and goal attainment
3246778|NCT00863070||Bladder Exstrophy Patients|Patients who receive follow-up care at Connecticut CMC urology clinic for bladder exstrophy.
3246779|NCT00863057|Experimental|1|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine and methadone placebo, (Period 2, Weeks 6 to 9) duloxetine placebo and methadone, (Period 3, Weeks 11 to 14) duloxetine and methadone, (Period 4, Weeks 16 to 19) duloxetine placebo and methadone placebo
3246780|NCT00863057|Experimental|2|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine placebo and methadone, (Period 2, Weeks 6 to 9) duloxetine placebo and methadone placebo, (Period 3, Weeks 11 to 14) duloxetine and methadone placebo, (Period 4, Weeks 16 to 19) duloxetine and methadone
3246781|NCT00863057|Experimental|3|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine and methadone, (Period 2, Weeks 6 to 9) duloxetine and methadone placebo, (Period 3, Weeks 11 to 14) duloxetine placebo and methadone placebo, (Period 4, Weeks 16 to 19) duloxetine placebo and methadone
3246782|NCT00863057|Experimental|4|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine placebo and methadone placebo, (Period 2, Weeks 6 to 9) duloxetine and methadone, (Period 3, Weeks 11 to 14) duloxetine placebo and methadone, (Period 4, Weeks 16 to 19) duloxetine and methadone placebo
3246783|NCT00863044|Active Comparator|High frequency ventilation|high frequency ventilation
3246784|NCT00863044|Placebo Comparator|Apnea|lung ventilation will be stopped during distal anastomosis as is commonly done
3246785|NCT00863031|Experimental|problem-solving therapy|Three sessions of brief problem-solving counselling at week 1, 3 and 5 by a family doctor.
3246786|NCT00863031|Placebo Comparator|viewing video|Three sessions of health education viewing video in groups of 3 to 5 people
3246787|NCT00863018||Control|Eyes with glaucoma and on anti-glaucoma medication but without glaucoma surgery
3246788|NCT00863018||Implant surgery|Eyes underwent Ahmed glaucoma valve implantation
3246789|NCT00863018||Trabeculectomy|Eyes underwent conventional trabeculectomy with mitomycin-C
3246790|NCT00863005|Experimental|1. K201|
3246791|NCT00863005|Active Comparator|2.|
3246792|NCT00862992|Experimental|1|
3246793|NCT00862992|Experimental|2|
3246794|NCT00862992|Experimental|3|
3246795|NCT00862979|Active Comparator|CNI-regimen|CNI-regimen: cyclosporine A (CyA) or tacrolimus (TAC) with everolimus (EVR) with corticosteroids
3246796|NCT00862979|Experimental|CNI-free-regimen|CNI-free regimen: everolimus (EVR) with MPA (either MMF or enteric coated mycophenolate sodium (EC-MPS)) and corticosteroids
3246797|NCT00862966|Experimental|citrate|
3246798|NCT00862966|Active Comparator|heparin|
3246799|NCT00862953|Active Comparator|Normal protein normal carbohydrate|Normal protein normal carbohydrate calory restricted nutrition
3246800|NCT00862953|Experimental|Normal protein low carbohydrates|Normal protein low carbohydrate energy-restricted diet
3246801|NCT00862953|Experimental|High protein normal carbohydrates|High protein normal carbohydrates
3246802|NCT00862953|Experimental|High protein low carbohydrate|High protein low carbohydrate nutrition
3246803|NCT00862940|Experimental|Memantine|
3246804|NCT00862940|Placebo Comparator|Placebo|
3246805|NCT00862927||Cue reactivity in virtual reality|Breath Scan + Saliva Sample + Questionnaires + View Virtual Reality Scenes
3246806|NCT00862914||1|benign melanocytic naevi
3246807|NCT00862914||2|dysplastic melanocytic naevi
3246808|NCT00862914||3|cutaneous malignant melanoma
3246809|NCT00862901|Experimental|1|100 J / cm2 over 24 hours
3246810|NCT00862901|Experimental|2|200 J / cm2 over 24 hours
3246811|NCT00862901|Experimental|3|400 J / cm2 over 24 hours
3246812|NCT00862901|Experimental|4|800 J / cm2 over 24 hours
3246813|NCT00862888|Placebo Comparator|Cohort 1; Study Period 1, 2, 3 or 4|Cohort 1: Exploring two single doses of PF-00446687 200 mg as well as sildenafil 100mg and placebo (double dummy design)
3246814|NCT00862888|Placebo Comparator|Cohort 2; study periods 1, 2, 3 or 4|Cohort 2: Exploring single doses of PF-00446687 20 mg - 175 mg. Subjects to receive two of 3 possible doses of PF-00446687 as well as a single dose of sildenafil 100mg and placebo (double dummy design).
3246815|NCT00862875|Experimental|1:Insulin detemir|Insulin detemir (Levemir® - Novolin® 4 pen)
3246816|NCT00862875|Active Comparator|2:Insulin Glargin|Insulin glargine (Lantus® - Solostar®)
3246817|NCT00862849|Experimental|Insulin Lispro, Regular Human Insulin, rHuPH20|"All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C).~Intervention A: a single, subcutaneous (SC) injection of 0.15 units per kilogram (U/kg) insulin lispro with 3.75 nanograms per kilogram (ng/kg) recombinant human hyaluronidase (rHuPH20)~Intervention B: a single, SC injection of 0.15 U/kg regular human insulin (RHI) with 3.75 ng/kg rHuPH20~Intervention C: a single, SC injection of 0.15 U/kg insulin lispro alone~There was a washout period of 3 to 14 days between interventions.~The treatment sequence (ABC, ACB, BAC, BCA, CAB, or CBA) was repeated once so that each participant received up to 6 injections."
3246818|NCT00862836|Experimental|1|Vandetanib added to standard therapy (pegliposomal doxorubicin)
3246819|NCT00862823|Active Comparator|Atripla Tablet|Drug exposure after administration of Atripla Tablet
3246820|NCT00862823|Experimental|Atripla Liquid|Drug exposure after administration of an extemporaneously prepared liquid formulation of Atripla
3246821|NCT00862810|Other|Received HPV vaccine first|
3246822|NCT00862810|Other|Received concomitant vaccines first|
3246823|NCT00862797||endotracheal tube|Patients intubated with cuffed endotracheal tubes
3246824|NCT00862784|Experimental|IMC-1121B (ramucirumab) + mFOLFOX-6|This regimen will be repeated every 2 weeks until disease progression, unacceptable toxicity, or withdrawal.
3246825|NCT00862745|Experimental|Active|fesoterodine 4 mg (1 tablet) for 2 weeks with the option to increase to fesoterodine 8 mg or stay at fesoterodine 4 mg for 10 weeks for a total of 12 weeks of study medication.
3246875|NCT00862420|Experimental|Clopidogrel|75 mg clopidogrel once daily from Day 1 to Week 12
3246826|NCT00862745|Placebo Comparator|Control|placebo (an identical pill that contains no medication) 1 tablet daily for 2 weeks followed by the option to increase the placebo pill daily for 10 weeks for a total of 12 weeks of study placebo medication.
3246827|NCT00862732|Active Comparator|1 Cognitive Behavioural Therapy|Intervention group will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
3246828|NCT00862732|Active Comparator|2 Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
3246829|NCT00862719|Experimental|Sitagliptin once per day|600 mg sitagliptin once per day orally starting on Day -1 for a total of 4 doses
3246830|NCT00862719|Experimental|Sitagliptin twice per day|600 mg sitagliptin twice per day orally starting on Day -1 for a total of 8 doses
3246831|NCT00862719|Experimental|Sitagliptin three times per day|600 mg sitagliptin three times per day orally starting on Day -1 for a total of 12 doses
3246832|NCT00862706|Experimental|A|
3246833|NCT00862693|Experimental|1 calcitriol|calcitriol 0.5ug/BIW for 12 months
3246834|NCT00862693|No Intervention|2|no intervention
3246835|NCT00862680|Experimental|PET/CT Scan|Routine PET/CT scan with small plastic box (weighing less than 1 oz) placed on abdominal area to track breathing motion.
3246836|NCT00862667|Experimental|Treatment A|PF-00241939 300ug using Inhaler A
3246837|NCT00862667|Active Comparator|Treatment B|PF-00241939 300ug using Inhaler B
3246838|NCT00862667|Active Comparator|Treatment C|PF-00241939 300ug using Inhaler C
3246839|NCT00862654|Experimental|C propionate 4/week + Ketoconasole 2/week|Clobetasol propionate shampoo 0.05% (4/week) + Ketoconazole shampoo 2% (2/week)
3246840|NCT00862654|Experimental|C propionate 2/week + Ketoconasole 2/week|Clobetasol propionate shampoo 0.05% (2/week) + Ketoconazole shampoo 2% (2/week)
3246841|NCT00862654|Experimental|C propionate 2/week|Clobetasol propionate shampoo 0.05% (2/week)
3246842|NCT00862654|Active Comparator|Ketoconazole 2/week|Ketoconazole shampoo 2% (2/week)
3246843|NCT00862641|Placebo Comparator|Placebo - Asthma|Matching intravenous (IV) bolus injection, subjects with Asthma
3246844|NCT00862641|Experimental|Regadenoson - Asthma|0.4mg / 5mL intravenous bolus injection, subjects with Asthma
3246845|NCT00862641|Placebo Comparator|Placebo - COPD|Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)
3246846|NCT00862641|Experimental|Regadenoson - COPD|0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)
3246847|NCT00862628|Experimental|Rebamipide|
3246848|NCT00862602|Experimental|1|Stepping Up to Health
3246849|NCT00862602|No Intervention|2|Usual care group
3246850|NCT00862576||1|Burning Mouth Syndrome Group
3246851|NCT00862576||2|Control Group
3246852|NCT00862563|Experimental|Zonisamide|Encapsulated zonisamide with a target maintenance doses of 400 mg/day administered as 4 capsules per day.
3246853|NCT00862563|Experimental|Levetiracetam|Encapsulated levetiracetam with a target maintenance doses of 2000 mg/day administered as 4 capsules per day .
3246854|NCT00862563|Active Comparator|Topiramate|Encapsulated topiramate with a target maintenance doses of 300 mg/day administered as 4 capsules per day .
3246855|NCT00862563|Placebo Comparator|Sugar Pill|Encapsulated sugar pill with a target maintenance dose administered as 4 capsules per day.
3246856|NCT00862550|Experimental|Group 1|Acupuncture (Areas known to help dry mouth)
3246857|NCT00862550|Experimental|Group 2|Acupuncture (Areas not known to help dry mouth)
3246858|NCT00862537||Active Resonator magnetic field therapy|Administration of active magnetic fields with the Resonator Device
3246859|NCT00862524|Experimental|ARRY-334543 + gemcitabine|
3246860|NCT00862511|Experimental|Coated Total Knee Arthroplasty|allergy coated TKA
3246861|NCT00862511|Active Comparator|Standard Total Knee Arthroplasty|normal TKA
3246862|NCT00862498|Experimental|Group 1 Treatment in Clinic|Participants will complete the written disclosure treatment in a clinic setting.
3246863|NCT00862498|Experimental|Group 2 Treatment via telephone|Participants will complete the written disclosure treatment in their homes via telephone.
3246864|NCT00862498|No Intervention|Group 3 Waitlist|Individuals will be placed on a waitlist for a period of 4 months, during which they will receive a phone call every other week to assess their suicidal ideation and post-traumatic stress disorder symptom severity.
3246865|NCT00862485||StudyGroup|
3246866|NCT00862472|Experimental|DuoTrav APS|DuoTrav APS QD AM
3246867|NCT00862472|Active Comparator|DuoTrav|DuoTrav QD AM
3246868|NCT00862459|Experimental|Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.03 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg body weight (BW) of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
3246869|NCT00862459|Experimental|Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.1 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
3246870|NCT00862459|Experimental|Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.3 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
3246871|NCT00862446|Experimental|Treatment|All infants will receive Omegaven
3246872|NCT00862433|Experimental|Arm 1|Description: Determine optimal fat content of meal for optimal absorption of vitamin E
3246873|NCT00862433|Experimental|Arm 2|Determine optimal dose of vitamin E.
3246874|NCT00862433|Experimental|Arm 3|Investigate the relationship between vitamin C status and vitamin E turnover
3246928|NCT00862108|Experimental|Methylphenidate|
3246876|NCT00862420|Active Comparator|Ticlopidine|200 mg ticlopidine once daily from Day 1 to Week 12
3246877|NCT00862407||1|Non-pulsatile Group (conventional)
3246878|NCT00862407||2|Pulsatile group (Alternate)
3246879|NCT00862394|Experimental|1|CHF 1535 Next DPI : BDP/Formoterol : 200/12 µg
3246880|NCT00862394|Active Comparator|2|CHF 1535 HFA pMDI : BDP/Formoterol : 200/12 µg
3246881|NCT00862394|Experimental|3|CHF 1535 Next DPI : BDP/Formoterol : 400/24 µg
3246882|NCT00862394|Active Comparator|4|CHF 1535 HFA pMDI : BDP/Formoterol : 400/24 µg
3246883|NCT00862381|Experimental|1|Hydrocortisone
3246884|NCT00862381|Placebo Comparator|2|Placebo
3246885|NCT00862368|Experimental|PAM -Enhanced/Asthma|The PAM-Enhanced/Asthma group: 2 in-home visits that included asthma education consistent with NIH recommendations (NIH, NAEPP, 1997) and smoking cessation counseling. Consistent with Motivational Interviewing (MI), smoking was broached in a non-judgmental manner and as another trigger for asthma. Feedback was given on expired air Carbon Monoxide (CO) levels of the smoker (to increase personal perception of risk) and the amount of smoke exposure to the child (to increase risk perception to the child). 6 phone calls were then provided over the next 4 months that focused on asthma education, a second round of feedback on the child's ETS exposure, and smoking cessation counseling. MI was used at all contacts. Free nicotine patch tx was given if they were ready to quit within 30 days.
3246886|NCT00862368|Active Comparator|PAM-Asthma|The PAM-Asthma arm received the same in-home counseling visits as PAM-Enhanced/Asthma. The 6 counseling phone calls were different from those received by PAM-Enhanced/Asthma, and included only an asthma follow-up and discussion of a child wellness topic. Smoking cessation was not discussed and additional feedback on ETS samplers was not provided. Motivational Interviewing approaches were used in all in-home and phone counseling. Free nicotine patch tx was given if they were ready to quit within 30 days.
3246887|NCT00862368|Active Comparator|PAM-Healthy|The PAM-Healthy arm received the same in-home counseling visits as PAM and PAM Enhanced but asthma information was replaced with child wellness topics. The 6 counseling phone calls were the same timing and duration as the other two groups (six, 15 minutes calls, over four months) focused on a child wellness topic. Smoking cessation or sampler feedback was not discussed. Motivational Interviewing approaches were used in all in-home and phone counseling. Free nicotine patch tx was given if they were ready to quit within 30 days.
3246888|NCT00862355|Experimental|1|SPARC147609
3246889|NCT00862355|Active Comparator|2|Reference147609
3246890|NCT00862342|Experimental|Bevacizumab|Bevacizumab continuation plus chemotherapy in patients who have failed previous bevacizumab plus other chemotherapy
3246891|NCT00862329|Experimental|Casein|
3246892|NCT00862329|Experimental|MSP|
3246893|NCT00862329|Experimental|Casein/MSP|
3246894|NCT00862329|Experimental|Soy protein|
3246895|NCT00862316|Experimental|Computer Navigational Unit Assistance|Oxford Unicompartmental Knee arthroplasty will be performed with the assistance of a computer navigational unit.
3246896|NCT00862316|Active Comparator|Non- Computer Navigational Unit Assisted|Oxford Unicompartmental Knee arthroplasty will be performed traditionally (without the assistance of a computer navigational unit).
3246897|NCT00862303|Placebo Comparator|IL-2/IFN-α|
3246898|NCT00862303|Experimental|DC-CIK|
3246899|NCT00862290||sepsis group|Patients who develop sepsis in the ICU
3246900|NCT00862290||SIRS group|Patients who develop SIRS after cardiac surgery with cardiopulmonary bypass
3246901|NCT00862290||control group|normal healthy volunteers
3246902|NCT00862277||Group 1: Menactra® from Previous Studies|Subjects previously received only one dose of meningococcal vaccine, Menactra® in Study MTA04, MTA12, MTA19, or MTA21.
3246903|NCT00862277||Group 2: Menomune® from Previous Study|Subjects previously received only one dose of meningococcal vaccine, Menomune® in Study MTA04
3246904|NCT00862277||Group 3: Control|Meningococcal vaccine-naive age matched subjects
3246905|NCT00862264|Experimental|CHF 1535 pMDI|CHF 1535 HFA pMDI aerosol (100 µg/unit dose of beclomethasone dipropionate plus 6 µg of formoterol/unit dose
3246906|NCT00862264|Active Comparator|BDP pMDI|Beclomethasone dipropionate-CFC pMDI, 250 µg/unit dose
3246907|NCT00862251|Experimental|Ezetimibe/simvastatin|
3246908|NCT00862251|Active Comparator|Doubling statin dose|
3246909|NCT00862251|Active Comparator|Rosuvastatin|
3246910|NCT00862238|Experimental|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, & C
3246911|NCT00862238|Other|Health Promotion|4-session education offering basic information about the prevention of hepatitis A, B & C
3246912|NCT00862225|Placebo Comparator|1|
3246913|NCT00862225|Active Comparator|2|
3246914|NCT00862225|Experimental|3|
3246915|NCT00862212|Experimental|Brief Alcohol Intervention|Half of the subjects will be randomly assigned to receive a brief physician-delivered alcohol intervention designed by the NIAAA to be delivered by primary care and mental health providers.
3246916|NCT00862212|No Intervention|Control Group|
3246917|NCT00862186|Other|Self-Management Arm|Behavioral: 'Fatigue Facts & Fixes'
3246918|NCT00862173||Patients with NSCLC with CNS Metastasis|Patients who developed CNS metastasis of NSCLC during the treatment.
3246919|NCT00862173||Patients with NSCLC without CNS Metastasis|Patients with NSCLC that does not develop CNS metastasis during the treatment.
3246920|NCT00862160|Active Comparator|1|using minimized cardiopulmonary bypass circuit ROCsafeTM
3246921|NCT00862160|No Intervention|2|using standard cardiopulmonary bypass circuit
3246922|NCT00862147|Experimental|ICDP|International Child Development Program
3246923|NCT00862147|Active Comparator|Treatment as usual|Treatment as usual
3246924|NCT00862134|Active Comparator|Docetaxel 75 mg/m^2|Subjects randomized to the docetaxel arm will be administered 75 mg/m^2, IV, every 21 days (an approved dose and schedule)
3246925|NCT00862134|Experimental|PR104 + 60 mg/m^2 docetaxel|Subjects randomized to the PR104/docetaxel arm will be administered 60 mg/m^2 docetaxel, IV, every 21 days plus 770 mg/m^2 PR104, IV, every 21 days and prophylactic G-CSF.
3246926|NCT00862121|Experimental|Mesalazine|Mesalazine (Mesalamine) 2 g sachet; 6 g daily
3246927|NCT00862121|Placebo Comparator|Placebo|Placebo to Mesalazine (Mesalamine) 2 g sachet; 6 g daily
3246930|NCT00862095|Experimental|Propranolol|Propranolol (target dose 80 mg a day)
3246931|NCT00862095|Experimental|Topiramate|Topiramate (target dose 100 mg a day)
3246932|NCT00862095|Experimental|Amitriptyline|Amitriptyline (target dose 50 mg a day)
3246933|NCT00862082|Experimental|PR104 + Sorafenib|PR104 will be administered IV once every four weeks, in addition to 400mg sorafenib PO twice daily
3246934|NCT00862056||Cardiac CT|All participants will undergo a coronary artery CT angiogram
3246935|NCT00862043|Experimental|Sildenafil Citrate|Sildenafil Citrate 40 mg t.i.d. oral
3246936|NCT00862043|Placebo Comparator|Placebo|Sildenafil-matched oral placebo 40 mg t.i.d
3246937|NCT00862030||1|Study Cohort
3246938|NCT00862017|Experimental|MSG|Subjects receive a 6-d supplementation of MSG and are studied on the 7th day in the postprandial period following a standard meal ingestion with 2g MSG
3246939|NCT00862017|Placebo Comparator|Control|
3246940|NCT00861991|Experimental|Perspective taking intervention|Students were given an instruction to take the perspectives of their standardized patients
3246941|NCT00861991|Active Comparator|Control|Students given standard instructions
3246942|NCT00861978|Placebo Comparator|1|
3246943|NCT00861978|Experimental|2|
3246944|NCT00861965|Experimental|Treatment|AlloStim-8
3246945|NCT00861952|Experimental|Neuragen|Ad lib use of Neuragen (a natural health product) applied topically 2-3 times per day in 2-3 drops per application
3246946|NCT00861952|Sham Comparator|Mineral oil|Mineral oil, scent and color matched to intervention
3246947|NCT00861939|Experimental|1|Bupropion HCl 300mg Extended Release Tablet
3246948|NCT00861939|Active Comparator|2|WELLBUTRIN XL 300mg Tablets
3246949|NCT00861926|Experimental|Beclometasone/formoterol (100/6 µg)|Foster : fixed combination of BDP extrafine 100 µg plus formoterol fumarate 6 µg administered via a pMDI standard actuator
3246950|NCT00861926|Active Comparator|salbutamol|Ventolin : salbutamol sulphate 100 µg per metered dose
3246951|NCT00861913|Experimental|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3246952|NCT00861887|Active Comparator|Vancomycin|Vancomycin 125 mg every 6 hours x 4 weeks
3246953|NCT00861887|Placebo Comparator|Placebo|Vancomycin 125 mg every 6 hours x 2 weeks, followed by placebo every 6 hours x 2 weeks
3246954|NCT00861874|Experimental|Treatment|
3246955|NCT00861861|Active Comparator|1|pitavastatin group
3246956|NCT00861861|Active Comparator|2|atorvastatin group
3246957|NCT00861848||13-40 with heart disease|
3246958|NCT00861835|Experimental|ROSE for TBNA|
3246959|NCT00861835|No Intervention|NR|no on-site cytopathology assessment (NR)
3246960|NCT00861822|Active Comparator|RBC|Advance RBC transfusion' (ART) group
3246961|NCT00861822|Other|Standard Care|Standard-of-care RBC transfusion (SRT) group
3246962|NCT00861809|Experimental|Cohort 1 Period 1|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
3246963|NCT00861809|Experimental|Cohort 1 Period 2|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
3246964|NCT00861809|Experimental|Cohort 1 Period 3|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
3246965|NCT00861796|Experimental|1|
3246966|NCT00861796|Placebo Comparator|2|
3246967|NCT00861783|Experimental|Group A - irinotecan|"Note: As of Amendment 2 (March 2009), treatment in the irinotecan arm of the study (Group A) is closed to enrollment.~Treatment with escalating doses of ON 01910.Na in combination with irinotecan."
3246968|NCT00861783|Experimental|Group B - oxaliplatin|Treatment with escalating doses of ON 01910.Na in combination with oxaliplatin.
3246969|NCT00861770|Other|1 - Control|All subjects will receive blood volume measurement immediately before and 30 minutes after ultrafiltration is completed. In the control group, the treating physician will not see the blood volume measurement results and treat according to standard of care.
3246970|NCT00861770|Experimental|2 - BVM|Ultrafiltration will be guided by blood volume measurement results.
3246971|NCT00861757|Placebo Comparator|Placebo|
3246972|NCT00861757|Experimental|2.5 mg Tadalafil|
3246973|NCT00861757|Experimental|5.0 mg Tadalafil|
3246974|NCT00861757|Active Comparator|0.2 mg Tamsulosin|
3246975|NCT00861744|Experimental|Priorix 1 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 1) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
3246976|NCT00861744|Experimental|Priorix 2 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 2) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
3246977|NCT00861744|Experimental|Priorix 3 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 3) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
3247090|NCT00860873|Active Comparator|Comparator 1|Oral Powder Zodiac
3246978|NCT00861744|Active Comparator|MMR-II Group|Subjects between 12 and 15 months of age at the time of study vaccination who randomly received one dose of one of three different commercially-available lot of M-M-R II (Merck and Co.) vaccine subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
3246979|NCT00861731|Active Comparator|1|hypolipidemic treatment
3246980|NCT00861731|Sham Comparator|2|hypolipidemic treatment
3246981|NCT00861731|Sham Comparator|3|hypolipidemic treatment
3246982|NCT00861718|Experimental|AZD7268|
3246983|NCT00861718|Placebo Comparator|Placebo|
3246984|NCT00861705|Active Comparator|Arm I (paclitaxel, doxorubicin, cyclophosphamide)|Patients receive paclitaxel IV over 60 minutes once weekly in weeks 1-12. Patients then receive dose-dense doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 5-30 minutes (ddAC) once in weeks 13, 15, 17, and 19.
3246985|NCT00861705|Experimental|Arm II (paclitaxel, ddAC, bevacizumab)|Patients receive paclitaxel and ddAC as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes in weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17.
3246986|NCT00861705|Experimental|Arm III (paclitaxel, ddAC, carboplatin)|Patients receive paclitaxel and ddAC as in Arm I. Patients also receive carboplatin IV over 30 minutes once in weeks 1, 4, 7, and 10.
3246987|NCT00861705|Experimental|Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin)|Patients receive paclitaxel and ddAC as in Arm I, bevacizumab as in Arm II, and carboplatin as in Arm III.
3246988|NCT00861692|Experimental|Argatroban|
3246989|NCT00861666|Other|Forgiveness-based Writing|
3246990|NCT00861640|Experimental|Intravenous Omeprazole|100 cases of Intravenous Omeprazole
3246991|NCT00861640|Experimental|Oral Rabeprazole|100 cases of oral rabeprazole
3246992|NCT00861614|Active Comparator|Ipilimumab|
3246993|NCT00861614|Placebo Comparator|Placebo|
3246994|NCT00861601|Experimental|low dose|eltrombopag 12.5 mg/day
3246995|NCT00861601|Experimental|middle dose|eltrombopag 25 mg/day
3246996|NCT00861601|Experimental|high dose|eltrombopag 37.5 mg/day
3246997|NCT00861588|Experimental|isoflavones|Subjects who met the inclusion and exclusion criteria would be randomly assigned (concealment of allocation) to receive isoflavones
3246998|NCT00861588|Placebo Comparator|starch|Subjects who met the inclusion and exclusion criteria would be randomly assigned (concealment of allocation) to receive placebo
3246999|NCT00861562|Active Comparator|Imescard pills/Placebo crossover|Patients received Imescard water smartweed composed pills during the first intervention period and placebo during the second, after a 10-day washout period.
3247000|NCT00861562|Active Comparator|Placebo/Imescard pills crossover|Patients received placebo during the first intervention period and Imescard water smartweed composed pills during the second, after a 10-day washout period.
3247001|NCT00861549|Experimental|cohort 1|1mg / 0.5 tablet
3247002|NCT00861549|Experimental|cohort 2|2mg / 1 tablet; crossover with Phencynonate hydrochloride (2mg/1 tablet) made in China
3247003|NCT00861549|Experimental|cohort 3|4mg / 2 tablets
3247004|NCT00861536|Experimental|ATG Fresenius|
3247005|NCT00861536|Active Comparator|Thymoglobuline Genzyme|
3247006|NCT00861523|Active Comparator|1. thiamine|Pregnant women until 12 week of gestation who refer to the ER because of nausea and vomiting and didn't improve after hydration, will receive thiamine IV
3247007|NCT00861523|Active Comparator|2. promethazine|Pregnant women until 12 week of gestation who refer to the ER because of nausea and vomiting and didn't improve after hydration, will receive promethazine IV
3247008|NCT00861497|Experimental|Bifeprunox|
3247009|NCT00861484|Experimental|GSK958108 3 mg|Experimental
3247010|NCT00861484|Placebo Comparator|Placebo of GSK958108|Placebo
3247011|NCT00861471|Experimental|Docetaxel +Gleevec|
3247012|NCT00861458|Experimental|PF-00868554|
3247013|NCT00861445|Experimental|1|
3247014|NCT00861445|Placebo Comparator|2|
3247015|NCT00861432|Active Comparator|additive homeopathic treatment|These patients receive additive homeopathic treatment during conventional cancer treatment.
3247016|NCT00861432|No Intervention|no additive homeopathic treatment|These patients do not receive additive homeopathic treatment during conventional cancer treatment.
3247017|NCT00861419|Experimental|D|3 mg/kg AMG 386 IV (QW) / 125 mg AMG 706 PO (QD)
3247018|NCT00861419|Experimental|A|3 mg/kg AMG 386 IV (QW) / 15 mg/kg bevacizumab IV (Q3W)
3247019|NCT00861419|Experimental|B|3 mg/kg AMG 386 IV (QW) / 75 mg AMG 706 PO (QD)
3247020|NCT00861419|Experimental|E|3 mg/kg AMG 386 IV (QW) / 400 mg sorafenib PO (BID)
3247021|NCT00861419|Experimental|H|10 mg/kg AMG 386 IV (QW) / 50 mg sunitinib PO (QD - 4 weeks on/2 weeks off)
3247022|NCT00861419|Experimental|G|3 mg/kg AMG 386 IV (QW) / 50 mg sunitinib PO (QD - 4 weeks on/2 weeks off)
3247023|NCT00861419|Experimental|C|10 mg/kg AMG 386 IV (QW) / 15 mg/kg bevacizumab IV (Q3W)
3247024|NCT00861419|Experimental|F|10 mg/kg AMG 386 IV (QW) / 400 mg sorafenib PO (BID)
3247025|NCT00861406|Experimental|Group 1|Pegylated Interferon alfa-2b (Once week x 4 weeks) + GP-100 Peptide
3247026|NCT00861406|Experimental|Group 2|Pegylated Interferon alfa-2b (Once week x 8 weeks) + GP-100 Peptide
3247027|NCT00861406|Experimental|Group 3|Pegylated Interferon alfa-2b (Once week x 12 weeks) + GP-100 Peptide
3247028|NCT00861393|Other|CBT|
3247029|NCT00861393|Other|Waitlist|
3247030|NCT00861380|Experimental|Pn 3+1|Children receiving the Pneumococcal conjugate vaccine GSK1024850A. Children within the first 7 months of life enrolled in this group will receive a 3-dose primary vaccination schedule.
3247031|NCT00861380|Experimental|Pn 2+1|Children receiving the Pneumococcal conjugate vaccine GSK1024850A. Children within the first 7 months of life enrolled in this group will receive a 2-dose primary vaccination schedule.
3247087|NCT00860899|Active Comparator|levobupivacaine|Levobupivacaine is long-acting local anesthetic, S-enantiomer of bupivacaine, with identical anesthetic potency.
3247088|NCT00860873|Experimental|Test 1|Oral Powder EMS
3247032|NCT00861380|Active Comparator|Control 3+1|Children receiving the control vaccine: Engerix TM (Hepatitis B vaccine) for children < 12 months of age at the time of first vaccination or Havrix TM (Hepatitis A vaccine) for children >= 12 months of age at the time of first vaccination. Children within the first 7 months of life enrolled in this group will receive a 3-dose primary vaccination schedule.
3247033|NCT00861380|Active Comparator|Control 2+1|Children receiving the control vaccine: Engerix TM (Hepatitis B vaccine) for children < 12 months of age at the time of first vaccination or Havrix TM (Hepatitis A vaccine) for children >= 12 months of age at the time of first vaccination. Children within the first 7 months of life enrolled in this group will receive a 2-dose primary vaccination schedule.
3247034|NCT00861367|Active Comparator|1|aspirin 100mg
3247035|NCT00861367|Placebo Comparator|2|empty capsule
3247036|NCT00861341|Experimental|Pioglitazone with or without Aspirin|Blood samples will be taken at time 0 to measure platelet aggregation. 30mg Pioglitazone will be ingested and another blood sample will be obtained 90-180 minutes later for platelet aggregation. After 6-9 days, subjects will ingest 81mg of aspirin. Another blood sample will be obtained 2-24 hours later for baseline determination of platelet aggregation and activation after taking aspirin. Subjects will then ingest 30mg pioglitazone and a final blood sample will be obtained 90-180 minutes later to measure platelet aggregation.
3247037|NCT00861328|Experimental|A|Treatment of escalating doses of ON 01910.Na in combination with irinotecan
3247038|NCT00861328|Experimental|B|Treatment of escalating doses of ON 01910.Na in combination with oxaliplatin
3247039|NCT00861315|Experimental|Nebulized amikacin|Patients receive nebulized amikacin once a day during three days. Placebo is administered intravenousely
3247040|NCT00861315|Active Comparator|Intravenous amikacin|
3247041|NCT00861302|Experimental|Treatment group|This is the only group in the study. It consists of patients with chronic musculoskeletal pain who are receiving the treatment program
3247042|NCT00861276|Experimental|1|Arm instructed to use spray at least once an hour when awake.
3247043|NCT00861276|Active Comparator|2|Ad libitum: patients were instructed to use NNS when craving appears.
3247044|NCT00861263|Other|spiral overtube|Any subject that has been referred for spiral enteroscopy will be asked to participate in this study. The purpose is to gather data about the technical aspects of the procedure,diagnostic capability and treatment as well as long term follow up.
3247045|NCT00861250|Experimental|Vel/Dex|
3247046|NCT00861237|Placebo Comparator|Placebo globules group|Patients receive Placebo globules made out of sugar and looking similar to active drug sublingually before surgery.
3247047|NCT00861237|Active Comparator|Nux vomica group|Patients receive Nux vomica globules made out of sugar sublingually before surgery.
3247048|NCT00861224||Observed Subjects|Subjects that submitted bone marrow biopsy and aspirates.
3247049|NCT00861211|Experimental|Active treatment arm|
3247050|NCT00861211|Placebo Comparator|Placebo|
3247051|NCT00861198||ERCP|Patients who have a medical indication for ERCP with cholangioscopy and/or pancreatoscopy and are referred for the procedure as part of their standard medical care will be considered for the study.
3247052|NCT00861185|Experimental|Senicapoc|
3247053|NCT00861185|Placebo Comparator|Placebo|
3247054|NCT00861172|Experimental|1|
3247055|NCT00861159||1|
3247056|NCT00861146|Experimental|1 concurrent smoking cessation|smoking cessation delivered concurrent with intensive alcohol treatment
3247057|NCT00861146|Active Comparator|2 deferred smoking cessation|smoking cessation delivered 12 weeks after intensive alcohol treatment
3247058|NCT00861094|Experimental|FOLFOX and radiotherapy|Oxaliplatin (85mg/m2); Folinic Acid (200mg/m2); 5-FU (400mg/m2-Bolus and 1600mg/m2 over 46h)- once every two weeks for six cycles
3247059|NCT00861094|Experimental|5-FU / cisplatin and radiotherapy|5-FU (100mg/m2); Cisplatin (75mg/m2)
3247060|NCT00861081|Experimental|1: Care management|
3247061|NCT00861081|Active Comparator|2: Written Materials|
3247062|NCT00861068|Experimental|1|
3247063|NCT00861068|Placebo Comparator|2|
3247064|NCT00861055||Infants|Infants less than 7 days of age with clinical signs of sepsis
3247065|NCT00861055||Mothers|Mothers following antenatal care at SMRU antenatal clinic, Maela camp who are 28 - 30 weeks gestation
3247066|NCT00861042|Experimental|1|
3247067|NCT00861029|Experimental|Pazopanib|Subjects will receive pazopanib during study
3247068|NCT00861029|Other|Placebo|Placebo as a comparator to pazopanib
3247069|NCT00861016|Experimental|1|The patients with mild to moderate essential hypertension
3247070|NCT00861003||Schizophrenia, antipsychotics|Stable outpatient status of schizophrenia or schizoaffective disorder currently taking a single oral antipsychotic
3247071|NCT00860990||1|SCI or disabled
3247072|NCT00860990||2|Able-bodied
3247073|NCT00860977|Placebo Comparator|Placebo|Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
3247074|NCT00860977|Experimental|Valacyclovir|oral valacyclovir 500mg twice daily
3247075|NCT00860964|Placebo Comparator|Placebo|
3247076|NCT00860964|Experimental|estradiol valerate|
3247077|NCT00860951|Other|Brain Computer Interface Keyboard|What effect does the environment (BCI, AT device, Computer) have on the accuracy of typing using a BCI keyboard?
3247078|NCT00860938|Active Comparator|Budesonide|
3247079|NCT00860938|Placebo Comparator|Placebo|
3247080|NCT00860925|Experimental|active clonidine and active ASA|
3247081|NCT00860925|Experimental|active clonidine and ASA placebo|
3247082|NCT00860925|Experimental|Clonidine placebo and active ASA|
3247083|NCT00860925|Placebo Comparator|Clonidine placebo and ASA placebo|
3247084|NCT00860912|Experimental|Intervention: Collagen matrix|Cystocele repair: Veritas reinforcing material implanted for reinforcement of cystocele repair with collagen matrix
3247085|NCT00860912|Other|Native tissue repair|Intervention: Cystocele repair performed: No reinforcing material used and routine performance of a cystocele repair using native tissues.
3247086|NCT00860899|Active Comparator|clonidine|Clonidine is an alpha2-adrenergic agonist with sedative, analgesic and hemodynamic properties. It inhibits transmission of nociceptive stimuli in the dorsal horn of the spinal cord, acting on the inhibitory descending pathways.
3247091|NCT00860873|Active Comparator|Comparator 2|Hard capsules - Zodiac
3247092|NCT00860847|Active Comparator|Aged Garlic Extract and Coenzyme Q10|"AGE (1200 mg) and CoQ10 (120 mg)~This is a combination of aged garlic extract and co-enzyme Q10"
3247093|NCT00860847|No Intervention|Placebo|placebo pills will be given
3247094|NCT00860834|Experimental|1|Pediatricians and parents of children with asthma will participate in the asthma coaching program.
3247095|NCT00860834|Active Comparator|2|Children of parents enrolled in the study will receive usual asthma care from their pediatrician.
3247096|NCT00860821|Experimental|1|AZD8309
3247097|NCT00860821|Placebo Comparator|2|Placebo
3247098|NCT00860808|Experimental|1 AM-101|low dose
3247099|NCT00860808|Experimental|2 AM-101|high dose
3247100|NCT00860808|Placebo Comparator|3 Placebo|
3247101|NCT00860795|Active Comparator|Echinacea|
3247102|NCT00860795|Placebo Comparator|placebo|
3247103|NCT00860782|Experimental|Low Frequency Support|Parent Educational Support (once/year for 2 years)
3247104|NCT00860782|Experimental|High Frequency Support|Parent Educational Support (4 times/year for 2 years)
3247105|NCT00860769|Experimental|ASHA Life|6-session educational group discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills.
3247106|NCT00860769|Active Comparator|Usual Care|3-session educational group focusing on HIV prevention, anti-retroviral therapy (ART) and parenting.
3247107|NCT00860756|Experimental|1|Intervention Group
3247108|NCT00860743|No Intervention|Arm 1|"We plan to study 10 males and 10 females with moderate obstructive sleep apnea (OSA), and 10 healthy males and 10 healthy females. The males and the females will be matched based on age, race, sex and body mass index. The OSA and control participants will be exposed to intermittent hypoxia and sham intermittent hypoxia during wakefulness and sleep."
3247109|NCT00860743|Experimental|ANTIOXIDANT COCKTAIL|We plan to study 10 male participants with moderate obstructive sleep apnea (OSA) and 10 male control participants matched for age, race and body mass index. The OSA and control participants will be exposed to intermittent hypoxia during wakefulness and sleep following administration of an antioxidant or a placebo cocktail that will be presented in a randomized fashion.
3247110|NCT00860730|Experimental|Perceval S|
3247111|NCT00860717|Active Comparator|1|Subjects from the arm number 1 received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
3247112|NCT00860717|Experimental|2|Subjects from the arm number 2 received low level laser therapy 3 times per week for 12 weeks, in addition to the same treatment as patients from the arm number 1.
3247113|NCT00860704|Active Comparator|crystalloids lean|fluidotherapy with crystalloids in lean patients
3247114|NCT00860704|Active Comparator|crystalloids obese|fluidotherapy with crystalloids in obese patients
3247115|NCT00860691|Active Comparator|ARM I - Open colorectal surgery|Open colorectal surgery
3247116|NCT00860691|Experimental|ARM II - Laparoscopic colorectal surgery|Laparoscopic colorectal surgery
3247117|NCT00860691|Other|Control - reference value|Blood samples from healthy volunteers will be obtained at one time point.Peripheral blood samples will be obtained into tubes with no additive (BD Vacutainer System, Plymouth, UK).Samples will be processed to serum. Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA)using specific anti-Fas MoAbs, Human sFas Immunoassay. Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay. Serum concentration of IL - 17 will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using Human IL-17 Immunoassay. . Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube. burst neutrophil production will be determined quantitatively by flow cytometry as described by Rothe using a commercial kit Bursttest Kit.
3247118|NCT00860678|Active Comparator|A|Training group
3247119|NCT00860678|Other|B|Controls
3247120|NCT00860665||1|Observational study on consecutive persons over the age of 55 years presenting for screening colonoscopy
3247121|NCT00860652|Experimental|Adjuvant Radiotherapy (RT)|Adjuvant Radiotherapy (64Gy in 32 Fractions to the prostate bed)
3247122|NCT00860652|Experimental|Active Surveillance with Early SalvageRT|Active Surveillance with Early Salvage Radiotherapy
3247123|NCT00860639|Active Comparator|gemtuzumab ozogamycin|Initial randomization will be completed upon receipt of karyotype results and will determine the administration of gemtuzumab ozogamycin (MYLOTARG ®) in combination with chemotherapy during the induction course and the first intensive consolidation course.
3247124|NCT00860639|No Intervention|without Mylotarg|
3247125|NCT00860626|Experimental|1|At the twelfth week of interferon α treatment, HBV DNA is detectable(>1000 copies/ml), or HBeAg is still positive. And nucleoside analogue is added for 12 weeks.
3247126|NCT00860626|Active Comparator|2|At the twelfth week of interferon α treatment, HBV DNA is detectable (>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
3247127|NCT00860626|Active Comparator|3|At the twelfth week of interferon α treatment, HBV DNA is undetectable (<1000 copies/ml), or HBeAg is negative. And interferon is continued for another 9 months.
3247128|NCT00860613|Experimental|1|women in this group received usual medical treatment and counseling from a nutritionist and diabetes educator. They received a specific diet using carbohydrate counting (40-45% of carbohydrates)and a moderate energy restriction. Weight gain, adequacy of diet, results of the self glucose monitoring, and ketonuria were evaluated every two weeks. They also received education on diabetes, diet and glucose monitoring.
3247129|NCT00860613|Experimental|2|Women in this group received usual medical treatment and counseling from a nutritionist and diabetes educator. The diet they received was based on carbohydrate counting (40-45% of carbohydrates), but recommended only low-moderate glycemic index foods. Weight gain, adequacy of diet, results of the self glucose monitoring, and ketonuria were evaluated every two weeks. They also received education on diabetes, diet and glucose monitoring.
3247287|NCT00859573|Active Comparator|1. Modafinil|
3247130|NCT00860613|No Intervention|3|women in this group received the current hospital treatment. They did not receive any intervention except for the self glucose monitoring that they did every two weeks. Weight gain and the results of the self glucose monitoring, were evaluated every two weeks.
3247131|NCT00860600|Experimental|1. PG2 Treatment: 5 days/week|Powder for Injection, 500 mg PG2/500 ml normal saline, 5 days/week, 2 to 4 weeks
3247132|NCT00860600|Experimental|2. PG2 Treatment: 3 days/week|Powder for Injection, 500 mg PG2/500 ml normal saline, 3 days/week, 2 to 4 weeks
3247133|NCT00860574|Experimental|Treatment (allogeneic transplantation)|CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.
3247134|NCT00860561||1|Postmenopausal women with locally advanced or metastatic breast cancer who have failed 2 or more prior hormone therapies, or were intolerant to prior hormone therapy and have no endocrine therapeutic options.
3247135|NCT00860535|Experimental|Ph+ CML or Ph+ ALL|GFS biomarker evaluation
3247136|NCT00860522|Experimental|Phase I|Three patients will be enrolled at dose Level 1. If the patient does not completed the three infusion of JVRS-100 during cycle 1 for reason other than toxicity, another patient will be accrued at the same dose level.
3247137|NCT00860522|Experimental|Phase II|3 patients will be enrolled at a given dose level. If one of these patients experiences a dose limiting toxicity, an additional 3 patients will be enrolled at the given dose level. If the 1st 2 subjects enrolled and treated at a given dose experience dose limiting toxicities, no additional subjects will be enrolled at that dose. Dose escalation may proceed if < 2/6 patients at a given dose level experience a LDT. If ≥ 2/6 patients experience a DLT at a given dose level, the next lower dose level will be considered the RP2D. If a patient does not complete the 3 infusions of JVRS-100 during Cycle 1 for reasons other than toxicity, another patient will be accrued at the same dose level. Once the RP2D is established, the cohort will be expanded to a total of 12 patients.
3247138|NCT00860509|Placebo Comparator|Low Phytosterol Diet|Diet with 100 mg of daily phytosterols
3247139|NCT00860509|Active Comparator|High Phytosterol Diet|Diet with 600 mg of daily phytosterols
3247140|NCT00860496|Other|1|Treatment Arm 1 will receive one single dose of CP-690,550 on Day 1, Tacrolimus on Days 1-8, and one single dose of CP-690,550 on Day 8.
3247141|NCT00860496|Other|2|Treatment Arm 2 will receive one single dose of CP-690,550 on Day 1, Cyclosporine on Days 1-6, and one single dose of CP-690,550 on Day 6.
3247142|NCT00860483|No Intervention|observational|This is an observational study. no intervention occurs in subjects. their performance in a laparoscopic trainer is observed and correlated with brain activity
3247143|NCT00860470|Active Comparator|1|Iron (27 mg) and folic acid (600 ug)
3247144|NCT00860470|Experimental|2|Multiple micronutrient
3247145|NCT00860457|Experimental|Chemotherapy|Fludarabine/Rituximab followed by Lenalidomide
3247146|NCT00860444|Active Comparator|1|Participants will take part in the basic educational and counseling program through their community health care center.
3247147|NCT00860444|Experimental|2|Participants will take part in the comprehensive educational and counseling program through their community health care center.
3247148|NCT00860431|No Intervention|1|Standard-of-care (conservative treatment)
3247149|NCT00860431|Experimental|2|AST-120 6g/day (3 times a day)
3247150|NCT00860418|Active Comparator|1|Standard asthma education delivered during 2 home visits by a nurse.
3247151|NCT00860418|Experimental|2 PAAL|PAAL
3247152|NCT00860405|Experimental|1|Investigational drug: HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion)
3247153|NCT00860405|Active Comparator|2|Control drug: Human serum albumin (HSA 50g/L)
3247154|NCT00860392|Experimental|1|Biomarker evaluation
3247155|NCT00860379|Placebo Comparator|Placebo|Placebo
3247156|NCT00860379|Experimental|Selenium1|Subject will receive 2 ug/kg of IV selenium per day
3247157|NCT00860379|Experimental|Selenium2|Subject will receive 4 ug/kg of IV selenium per day
3247158|NCT00860366|Experimental|Uric Acid|Single intravenous infusion of 1 gram of Uric Acid dissolved in vehicle (500 ml of 0'1% Lithium Carbonate and 5% Mannitol).
3247159|NCT00860366|Placebo Comparator|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
3247160|NCT00860353|Experimental|1|
3247161|NCT00860353|Placebo Comparator|2|
3247162|NCT00860340|Experimental|1|Study patient will take 100mg tablet of Spironolactone
3247163|NCT00860327||Newborns|Newborns with hypoplastic left heart syndrome who are receiving a right ventricle to pulmonary artery shunt as first stage palliation.
3247164|NCT00860327||Infants|Infants who are undergoing complete repair for tetralogy of Fallot or similar pathology.
3247165|NCT00860314|Active Comparator|AP Position|Cardioversion with antero-posterior electrode position
3247166|NCT00860314|Active Comparator|AL Position|Cardioversion with antero-lateral electrode position
3247167|NCT00860301|Experimental|Acupuncture group|
3247168|NCT00860301|No Intervention|Control group|Infants come to the clinic six times, are left alone for five minutes with the acupuncture nurse who hold its hand and talks to it.
3247169|NCT00860288|Experimental|Vildagliptin Dose 1|
3247170|NCT00860288|Experimental|Vildagliptin Dose 2|
3247171|NCT00860288|Placebo Comparator|Placebo|
3247172|NCT00860288|Active Comparator|Sitagliptin|
3247173|NCT00860275|Active Comparator|BMS-708163 / Ketoconazole|
3247174|NCT00860275|Active Comparator|BMS-708163 / Fluconazole|
3247175|NCT00860262|Experimental|telmisartan and amlodipine|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
3247176|NCT00860262|Active Comparator|amlodipine|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
3247177|NCT00860262|Active Comparator|telmisartan|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
3247288|NCT00859573|Placebo Comparator|2: Placebo|Placebo
3247178|NCT00860249|No Intervention|Usual Care|Usual Care. Participants in this arm will receive Usual care until outcome assessment is performed at 6 months following randomization. At that time, they will be sent a letter reminding them to obtain the ordered preventative service test, however no further outcomes will be assessed. Thus, during the course of the study, all participants in this arm will have solely received usual care.
3247179|NCT00860249|Experimental|Behavioral: Letter Only|Behavioral: Letter Only Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
3247180|NCT00860249|Experimental|Behavioral: Letter and Educational DVD|Behavioral: Letter and Educational DVD Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
3247181|NCT00860236|Active Comparator|Psycoeducation/counseling|
3247182|NCT00860236|Active Comparator|Cognitive behavioural therapy|
3247183|NCT00860223|Experimental|1|Digoxin alone
3247184|NCT00860223|Experimental|2|Digoxin plus neratinib
3247185|NCT00860197|No Intervention|Control|No coffee
3247186|NCT00860197|Experimental|Group 1|Fully torrefied coffee
3247187|NCT00860197|Experimental|Group 2|Partially torrefied coffee
3247188|NCT00860184||50-79% stenosis|Subjects with 50-79% stenosis of the carotid artery Absence of prior ischemic neurological symptoms Age 18 or older
3247189|NCT00860171|Experimental|Treatment (iodine I 131 monoclonal antibody B, autologous HCT)|Patients receive a dosimetric dose of iodine I 131 monoclonal antibody BC8 IV on day -20 and a therapeutic dose on day -11. Before day -20, patients may also receive up to 2 additional dosimetric doses of iodine I 131 monoclonal antibody BC8 IV approximately 1-2 weeks apart. Patients then undergo autologous stem cell transplantation on day 0.
3247190|NCT00860158|Experimental|Single Arm Assignment|Neoadjuvant dasatinib plus leuprolide acetate followed by radical prostatectomy
3247191|NCT00860145|Experimental|radiosurgery|Radiosurgical treatment of the medial temporal lobe
3247192|NCT00860145|Active Comparator|temporal lobectomy|Resection of medial temporal lobe
3247193|NCT00860132||2|a group of consecutive hip fracture patients admitted to a dedicated comprehensive orthogeriatric ward and a group of similar patients admitted to an orthopedic ward and later on transferred to geriatric rehab center
3247194|NCT00860119|Experimental|Sublingual tablet|Test treatment
3247195|NCT00860119|Experimental|Oral tablet|Reference treatment
3247196|NCT00860106|Other|Follow up|"ED score and DDimer level of patients who have stopped their VKA treatment (after the first or the second previous proximal VTE).~Phone follow up for 2 years."
3247197|NCT00860093|Experimental|1|MPC-5971
3247198|NCT00860093|Placebo Comparator|2|placebo identical in appearance to study drug
3247199|NCT00860080|Experimental|PXL01|Four Subjects per cohort will receive 10, 20, or 40 mg PXL01 respectively.
3247200|NCT00860080|Placebo Comparator|Placebo|One subject per cohort will receive 10, 20, or 40 mg Placebo respectively.
3247201|NCT00860067|Experimental|Q/LAIV (MEDI3250)|Q/LAIV (quadrivalent influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson (BD) Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 temperature-sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], B/Victoria [B/Malaysia/2506/2004], and B/Yamagata [B/Florida/4/2006]).
3247202|NCT00860067|Active Comparator|FluMist/B/Yamagata|FluMist/B/Yamagata (trivalent influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature-sensitive, cold-adapted, attentuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Yamagata [B/Florida/4/2006])a B strain of the Yamagata lineage.
3247203|NCT00860067|Active Comparator|FluMist/B/Victoria|FluMist/B/Victoria(trivalent influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature-sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Victoria [B/Malaysia/2506/2004])a B strain of the Victoria lineage.
3247204|NCT00860054|Experimental|Medium Phytosterols|Diets with daily 400 mg of phytosterols
3247205|NCT00860054|Experimental|High Phytosterols Diet|Diet with 2000 mg of daily phytosterols
3247206|NCT00860054|Placebo Comparator|Low Phyto Diet|Diet with less than 100 mg of daily phytosterols
3247207|NCT00860041||Group I|Patients complete pain questionnaires at baseline, 2-8 days after each weekly paclitaxel treatment given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
3247208|NCT00860041||Group II|Patients complete pain questionnaires at baseline, 2-8 days after each weekly paclitaxel treatment not given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
3247209|NCT00860041||Group III|Patients complete pain questionnaires at baseline, 2-8 days after each 2-4 week paclitaxel treatment given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
3247210|NCT00860041||Group IV|Patients complete pain questionnaires at baseline, 2-8 days after each 2-4 week paclitaxel treatment not given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
3247289|NCT00859547|Experimental|Recombinant thrombin (rThrombin), 1000 IU/mL|
3247293|NCT00859508|Active Comparator|other FDA cleared dura replacements|
3247211|NCT00860028|Experimental|Extended Varenicline Pretreatment|Arm 1 (Experimental) = 4 weeks varenicline (Chantix) titrated to 1 mg oral tablet twice per day before the smoking quit date followed by 4 weeks varenicline (Chantix) 1 mg oral tablet twice per day treatment.
3247212|NCT00860028|Experimental|Short-term Varenicline Pretreatment|Arm 2 (Experimental) = 3 weeks placebo + 1 week varenicline (Chantix)pretreatment + 4 weeks varenicline 1 mg oral tablet twice per day treatment following the smoking quit date.
3247213|NCT00860015|Experimental|Alimta/Gemcitabine|IV administration of drugs for 14 days for up to 4 cycles
3247214|NCT00860002||1|Ultramini laparotomy (UMLT) myomectomy (UMLT-M) versus laparoscopic myomectomy (LM)
3247215|NCT00860002||2|Laparoscopically aided myomectomy (LAM) versus LM
3247216|NCT00860002||3|LAM versus UMLT-M
3247217|NCT00860002||4|Mini laparotomy myomectomy (ML-M) versus UMLT-M
3247218|NCT00860002||5|Laparoscopic uterine artery occlusion with blockage of anastomosis between the uterine and ovarian vessels (LUVO) versus laparoscopic uterine artery occlusion without blockage of anastomosis between the uterine and ovarian vessels (LUAO)
3247219|NCT00860002||6|LUVO+LAM versus LUAO+LAM
3247220|NCT00860002||7|LUVO+LM versus LUAO+LM
3247221|NCT00860002||8|LUVO+UMLT-M versus LUAO+UMLT-M
3247222|NCT00860002||9|LUVO versus UMLT-UVO
3247223|NCT00860002||10|UMLT-UVO versus UMLT-UAO
3247224|NCT00860002||11|LUAO versus UMLT-UAO
3247225|NCT00860002||12|UMLT-UVO+UMLT-M versus UMLT-UAO+UMLT-M
3247226|NCT00860002||13|LUVO versus LM
3247227|NCT00860002||14|LUVO versus LAM
3247228|NCT00860002||15|LUVO versus LUAO+LM
3247229|NCT00860002||16|LUVO versus LUAO+UMLT-M
3247230|NCT00860002||17|LUVO versus LUAO+LAM
3247231|NCT00859976|Active Comparator|Plasma-sprayed shell|Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
3247232|NCT00859976|Experimental|BoneMaster coated shell|Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
3247233|NCT00859950|Active Comparator|Sleep Apnea|Subjects found to have Obstructive Sleep Apnea (OSA) with Intermittent Hypoxemia (IH). This arm will undergo a pre-treatment blood draw, one month of Continuous Positive Airway Pressure (CPAP) to treat OSA, and a post-treatment blood draw.
3247234|NCT00859950|No Intervention|Normal Control|Subject found to have no evidence of Obstructive Sleep Apnea (OSA) after Nocturnal Polysomnography (NPSG). These subjects will only undergo a blood draw and will not have the Continuous Positive Airway Pressure (CPAP) treatment.
3247235|NCT00859937|Experimental|Arm I|Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3247236|NCT00859911|Active Comparator|2|Thiamine Mononitrate 5mg, Riboflavin 2 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg
3247237|NCT00859911|Experimental|1|Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocobalamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
3247238|NCT00859898|Experimental|Dapagliflozin + Metformin XR|"Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks~Metformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"
3247239|NCT00859898|Experimental|Dapagliflozin + Placebo|"Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks.~Placebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks."
3247240|NCT00859898|Active Comparator|Metformin XR + Placebo|"Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks~Placebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"
3247241|NCT00859885||1|Patients who receive antithrombotic treatment only
3247242|NCT00859885||2|Patients who undergo percutaneous device closure
3247243|NCT00859872|Experimental|oral group|risperidone oral solution combination clonazepam oral
3247244|NCT00859872|Active Comparator|IM group|haloperidol IM injection
3247245|NCT00859846|Experimental|Long Axis arterial line placement|Twenty four patients will undergo arterial line placements using long axis arterial line placement under ultrasound.
3247246|NCT00859846|Experimental|Short Axis arterial line placement|Twenty four patients will undergo arterial line placements using short axis arterial line placement under ultrasound.
3247247|NCT00859846|Active Comparator|Palpation arterial line placement|Twenty four patients will undergo arterial line placements using Traditional palpation arterial line placement.
3247248|NCT00859833|Experimental|myocardial perfusion reserve|Myocardial perfusion reserve will be measured by quantifying myocardial blood flow using MRI at rest and then with each of 2 coronary vasodilators. Measurements are performed with first pass gadolinium perfusion (i.v. bolus injection of 0.02 or 0.03 mmol/kg of gadolinium). Each of the 2 drugs is given sequentially (30 minutes apart) in the same sequence in every patient. The shorter acting drug (adenosine) is given first so it has time to wear off before giving the second drug. It is ideal to measure MPR with each drug during the same imaging session so that there are no other clinical variables that change between the administration of the 2 agents. See below.
3247249|NCT00859807|Experimental|Sequence 1 (19 subjects)|"Period 1: treatment A (15.3 mL (50 mg/5 mL) AQ suspension (Pfizer); test treatment.~Period 2: treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis); reference treatment)."
3247250|NCT00859807|Experimental|Sequence 2 (19 subjects)|Period 1: treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis Period 2: treatment A (15.3 mL (50 mg/5 mL) AQ suspension (Pfizer); test treatment
3247251|NCT00859781|Experimental|1. 177Lu-J591+Ketoconzole|Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 177Lu-J591 Infusion, continue ketoconazole and hydrocortisone
3247252|NCT00859781|Placebo Comparator|2. 111In-J591 + ketoconazole|Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 111In-J591 (placebo) Infusion, continue ketoconazole and hydrocortisone
3247290|NCT00859521|Experimental|Levetiracetam|Levetiracetam 1000 mg Tablet (test) dosed in first period followed by Keppra® 1000 mg Tablet (reference) dosed in second period
3247291|NCT00859521|Active Comparator|Keppra®|Keppra® 1000 mg Tablet (reference) dosed in first period followed by Levetiracetam 1000 mg Tablet (test) dosed in second period
3247292|NCT00859508|Experimental|SyntheCel|
3247656|NCT00856895||Hispanic|
3247253|NCT00859768|Experimental|Intervention group 1|Pre-test measures are assessed. The patient receives the SIPP twice during their RT period. The first time is before the first consultation with the radiotherapist and the second time is before the last consultation at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
3247254|NCT00859768|Experimental|Intervention group 2|No pre-test measures are assessed. The patient receives the SIPP twice during their RT period. The first time is before the first consultation with the radiotherapist and the second time is before the last consultation at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
3247255|NCT00859768|No Intervention|Control group 1|Pre-test measures are assessed. Enhanced usual care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
3247256|NCT00859768|No Intervention|Control group 2|No pre-test measures are assessed. Enhanced usual care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
3247257|NCT00859755|Experimental|ARRY-403|
3247258|NCT00859755|Placebo Comparator|Placebo|
3247259|NCT00859742|Experimental|EBUS-TBNA|
3247260|NCT00859729|Experimental|Cohort I|50 µg DNA/dose, 3 patients
3247261|NCT00859729|Experimental|Cohort II|150 µg DNA/dose, 3 patients
3247262|NCT00859729|Experimental|Cohort III|400 µg DNA/dose, 3 patients
3247263|NCT00859729|Experimental|Cohort IV|1000 µg DNA/dose, 3 patients
3247264|NCT00859729|Experimental|Cohort V|Optimal dose to be determined, 6 patients
3247265|NCT00859716|Experimental|1|vaccination with ACE393 followed by challenge with campylobacter jejuni
3247266|NCT00859716|Placebo Comparator|2|Placebo vaccination followed by challenge with campylobacter jejuni
3247267|NCT00859703|Placebo Comparator|2|"Patients receive placebo 35 mg once a week plus a calcium and vitamin D supplementation.~Measure of bone density, bone markers, clinical examination and questionnaire regarding fractures will be assessed at 12 and 24 months of treatment"
3247268|NCT00859703|Active Comparator|1|"Patients receive risedronate 35 mg once a week plus a calcium and vitamin D supplementation.~Measure of bone density, bone markers, clinical examination and questionnaire regarding fractures will be assessed at 12 and 24 months of treatment"
3247269|NCT00859690||Sleep Disorder - Sleep Apnea|Subjects determined by a clinically indicated overnight sleep study (Nocturnal Polysomnography) to have Obstructive Sleep Apnea (OSA).
3247270|NCT00859690||Sleep Disorder - Not Sleep Apnea|Subjects determined by a clinically indicated overnight sleep study (Nocturnal Polysomnography) to have a sleep disorder other than Obstructive Sleep Apnea (OSA).
3247271|NCT00859677||1|HIV-positive and MRSA negative
3247272|NCT00859677||2|HIV-positive and MRSA infected (skin/soft tissue)
3247273|NCT00859677||3|HIV-positive and MRSA colonized
3247274|NCT00859677||4|HIV-negative and MRSA negative
3247275|NCT00859677||5|HIV-negative and MRSA infected (skin/soft tissue)
3247276|NCT00859677||6|HIV-negative and MRSA colonized
3247277|NCT00859664||Neuroleptics|Children with autistic spectrum disorder, treated with neuroleptics
3247278|NCT00859651|Active Comparator|20,000 IU weekly|"Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 20,000 IU weekly, for one year.~Cholecalciferol 20,000 IU (2 active capsules + 1 matching placebo capsule)"
3247279|NCT00859651|Active Comparator|30,000 IU weekly|"Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 30,000 IU weekly, for one year.~Cholecalciferol 30,000 IU (3 active capsules)"
3247280|NCT00859638|Experimental|Intervention Group|Rehabilitation self-management group, on-line self monitoring of physical function, and organizational capacity building.
3247281|NCT00859638|No Intervention|Case matched controls|Usual care in primary health care.
3247282|NCT00859625|Experimental|1|Nurse participation during colonoscope withdrawal
3247283|NCT00859625|No Intervention|2|usual colonoscopy practice
3247284|NCT00859599|Active Comparator|1|"At the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A & B, E & F, X & Y) the randomised patient shall receive.~Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed."
3247285|NCT00859599|Placebo Comparator|2|"At the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A & B, E & F, X & Y) the randomised patient shall receive.~Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed."
3247286|NCT00859586|Experimental|Miltenyi Magnetic cell sorter for CD3|"Miltenyi Magnetic cell sorter device will be used for CD3 selection of granulocyte colony stimulating factor mobilized allogeneic PBSCT. In stage 1, subjects will receive 1 x 10 to the eight power CD3 cells/kg. In stage II, the dose of CD3+ cells will be increased to 2 x 10 to the eight power cells/kg.~This phase II clinical trial is designed to evaluate a novel non-myeloablative but highly immunosuppressive disease specific conditioning regimen and infusion of unmanipulated lymphocytes from a haplo-identical familial donor in subjects with relapsed disease following matched sibling stem cell transplantation who are not candidates for alternative treatment options. The clinical trial will evaluate recipient survival at six months post-relapse of disease."
3247294|NCT00859495|Experimental|Multimodal lung sparing regimen|Intrapleural chemotherapy plus systemic chemotherapy
3247295|NCT00859469|Experimental|Oxaliplatin and Gemcitabine|
3247296|NCT00859456|Experimental|Sunitinib|Drug administered PO daily for 42 days
3247297|NCT00859430|Experimental|Levetiracetam|Levetiracetam 1000 mg Tablet (test) dosed in first period followed by Keppra® 1000 mg Tablet (reference) dosed in second period
3247298|NCT00859430|Active Comparator|Keppra®|Keppra® 1000 mg Tablet (reference) dosed in first period followed by Levetiracetam 1000 mg Tablet (test) dosed in second period
3247299|NCT00859417|Active Comparator|1|Traditional surgical method without prosthesis
3247300|NCT00859417|Experimental|2|Surgical method with Perigee prosthesis
3247301|NCT00859404|Experimental|1. oglemilast|
3247302|NCT00859404|Experimental|2. oglemilast|
3247303|NCT00859404|Experimental|3. oglemilast|
3247304|NCT00859404|Placebo Comparator|4. placebo|
3247305|NCT00859391||1 - Active|This group received gluten pre-treated with ALV003
3247306|NCT00859391||2 - Placebo|This group received Gluten pre-treated with placebo.
3247307|NCT00859378|Active Comparator|1 - cemented|Patients are treated with a cemented semiendoprosthesis
3247308|NCT00859378|Active Comparator|2 - non-cemented|Patients are treated with a non-cemented semiendoprosthesis
3247309|NCT00859365|Experimental|Acupuncture|Real Acupuncture
3247310|NCT00859365|Placebo Comparator|2 Placebo acupuncture|
3247311|NCT00859365|No Intervention|3 No treatment|No treatment performed
3247312|NCT00859352|Experimental|1|AZD1981 100mg and Midazolam
3247313|NCT00859352|Experimental|2|AZD1981 500mg and Midazolam
3247314|NCT00859339|Experimental|Experimental Treatment|Neoadjuvant cisplatin, gemcitabine and sunitinib malate followed by radical cystectomy
3247315|NCT00859313|Experimental|Sufentanil NanoTab PCA System/15 mcg|
3247316|NCT00859300||1|500 patients with ventricular fibrillation at the acute phase of myocardial infarct
3247317|NCT00859300||2|500 patients without ventricular fibrillation at the acute phase of myocardial infarct.
3247318|NCT00859274|Experimental|Budesonide|All patients receive this treatment to induce a change in asthma control
3247319|NCT00859261|Experimental|Breast imaging using Ultrasound and Photoacoustic|Evaluating 3D ultrasound for breast abnormalities/masses/cysts. This includes ultrasound imaging and possibly photoacoustic imaging.
3247320|NCT00859235|Active Comparator|1|
3247321|NCT00859235|Placebo Comparator|2. Plain water|
3247322|NCT00859222|Experimental|Phase I Cohort 1: Bevacizumab +LBH589 20 mg every week|Phase I Cohort 1 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the original starting LBH589 dose of 20 mg/day orally, 3x per week, every week (days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26). Participants were treated until disease progression or unacceptable toxicity.
3247323|NCT00859222|Experimental|Phase I Cohort 2: Bevacizumab + LBH589 20 mg every other week|Phase I Cohort 2 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the amended starting LBH589 dose of 20 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
3247324|NCT00859222|Experimental|Phase I Cohort 3: Bevacizumab + LBH589 30 mg every other week|Phase I Cohort 3 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
3247325|NCT00859222|Experimental|All Phase I Participants|All phase I participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 according to the established dose escalation schedule. Participants were treated until disease progression or unacceptable toxicity.
3247326|NCT00859222|Experimental|Phase II GBM: Bevacizumab + LBH589 30 mg every other week|Phase II glioblastoma (GBM) participants received the regimen established in the Phase I study (Feb 2011). Phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
3247327|NCT00859222|Experimental|Phase II AG: Bevacizumab + LBH589 30 mg every other week|Phase II Anaplastic Glioma (AG) participants received the regimen established in the Phase I study (Feb 2011). Phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
3247328|NCT00859222|Experimental|All Phase II Participants|All phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
3247329|NCT00859196|Experimental|Arm 1|
3247330|NCT00859196|Placebo Comparator|Arm 2|
3247331|NCT00859183|Active Comparator|1|cumulative loading dose of 8 mg of sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
3247332|NCT00859183|Active Comparator|2|cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
3247333|NCT00859183|Placebo Comparator|3|oral placebo
3247334|NCT00859170|Experimental|Accordion use|Use of an Accordion device during the lithotripsy.
3247335|NCT00859170|No Intervention|Control Group|Patients who will not have an Accordion device used during lithotripsy.
3247336|NCT00859157||Group 1|Patients undergo standard mastectomy.
3247337|NCT00859157||Group 2|Patients undergo tumescent mastectomy.
3247338|NCT00859144|Experimental|BART|Participants will complete the Becoming a Responsible Teen (BART) program.
3247339|NCT00859144|Experimental|Reducing the Risk|Participants will complete the Reducing the Risk program.
3247340|NCT00859144|Active Comparator|Be Proud Be Responsible|Participants will complete the Be Proud! Be Responsible! program.
3247341|NCT00859131|Active Comparator|Thymoglobulin|Subjects receiving Thymoglobulin as induction agent in renal transplantation
3247657|NCT00856895||Non-Hispanic|
3247342|NCT00859131|Active Comparator|Zenapax|subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
3247343|NCT00859118|Experimental|Schedule A Cohort 1|"Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.~Scan#1: Baseline (days -3 to 0) Scan#2: Week 2 (between days 12-14) Scan#3: Week 3 (7 days after axitinib held) Up to 10 patients will receive 2 DCE-CT scans at week 2 and 3, coinciding with the FLT-PET scans."
3247344|NCT00859118|Experimental|Schedule A: Cohort 2|"Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.~Scan#1: Week 2 (between days 12-14) Scan#2: Week 3 (2 days after axitinib held) Scan#3: Week 3 (7 days after axitinib held) Up to 10 patients will receive 2 DCE-CT scans at week 2 and 3, coinciding with the FLT-PET scans."
3247345|NCT00859105|Experimental|Imiquimod 5%|Manufactured by Apotex
3247346|NCT00859105|Active Comparator|Adara 5 % Cream US|Manufactured by 3M, US.
3247347|NCT00859105|Active Comparator|Adara 5% Cream Canada|Manufactured by 3M, Canada
3247348|NCT00859105|Placebo Comparator|Vehicle|Manufactured by Apotex
3247349|NCT00859092|Experimental|Thickening of feeds|
3247350|NCT00859092|No Intervention|Removal of thickener|
3247351|NCT00859079|Active Comparator|GLP-1|Intravenously administered GLP-1
3247352|NCT00859079|Active Comparator|Insulin intravenously|Insulin intravenously according to the Munich registry
3247353|NCT00859066||Control Group|"First year University of Michigan Radiology residents will take call as scheduled without a buddy call experience.~(Enrollment completed for the control group)"
3247354|NCT00859066||Experimental Group|2009 class of first year Radiology residents who will be assigned two 5 hour shifts working side by side with a more senior resident (who has experience taking call).
3247355|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh A|
3247356|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh B|
3247357|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh C|
3247358|NCT00859053|Active Comparator|BMS-790052 in Healthy Subjects|
3247359|NCT00859040|Experimental|SOM230C|Monthly SOM230C (pasireotide LAR) - 60 mg intramuscularly (Single-Arm Trial)
3247360|NCT00859027|Experimental|Risedronate|35 mg by mouth every week as directed
3247361|NCT00859027|Placebo Comparator|risedronate placebo tablet|Calcium and vitamin D
3247362|NCT00859014|Experimental|Autologous Bone Marrow Mononuclear Cells|Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg.
3247363|NCT00859001|Experimental|FM+R|4 cycles of FM+R plus Zevalin
3247364|NCT00858988|Experimental|Rifaximin|
3247365|NCT00858988|Placebo Comparator|Placebo|
3247366|NCT00858975|Experimental|Cryotherapy|The patients who receive cryotherapy for their renal tumors
3247367|NCT00858962|Experimental|Bup/Ral|Buprenorphine and Raltegravir co-administration
3247368|NCT00858949||Post surgery monitored group|Outpatients undergoing elective surgery with anesthesia that is expected to last one hour and to require significant postoperative opioids
3247369|NCT00858936|Experimental|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
3247370|NCT00858936|Placebo Comparator|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
3247371|NCT00858910|Experimental|EG1: embedded MI|"Experimental group 1:~Participants receive motor imagery (MI) training included in 45min physiotherapy, 3 times per week for 2 weeks."
3247372|NCT00858910|Experimental|EG2: added MI|"Experimental group 2:~Participants receive a 15 minutes motor imagery (MI) training added to a 30 min physiotherapy session, 3 times a week for two weeks."
3247373|NCT00858910|Placebo Comparator|CG|"Control group:~Participants receive a 15 min control intervention added to their 30 min physiotherapy session, 3 times a week for two weeks."
3247374|NCT00858897|Experimental|1|Normoglycemia (80-140 mg/dL)
3247375|NCT00858897|Experimental|2|Hyperglycemia (200-250 mg/dL)
3247376|NCT00858884|No Intervention|No intevention|No intervention
3247377|NCT00858871|Active Comparator|Brivanib|
3247378|NCT00858871|Active Comparator|Sorafenib|
3247379|NCT00858858|Experimental|Arm 1|All patients are treated with DCA and UDCA perfusion of the esophagus, one year apart, followed by 8 weeks of treatment with oral ursodeoxycholic acid 10 mg/kg qd. Then a final DCA perfusion of the esophagus.
3247380|NCT00858845|Experimental|Clonidine patch|Participants assigned to wear a clonidine patch.
3247381|NCT00858845|Placebo Comparator|Placebo|Participants assigned to wear a matching placebo patch.
3247382|NCT00858832|Experimental|Methergine|Methergine group received Methergine 0.2mg po every 6 hours for two days, plus routine postpartum care.
3247383|NCT00858832|No Intervention|No treatment|No treatment group received only routine postpartum care.
3247384|NCT00858819||AS|Patients with AS attending three different rheumatology clinics in Western Sweden have been invited to participate.
3247385|NCT00858806|Experimental|Intermittent Imatinib|"Imatinib will be given with the following schedule:~1 week on / 1 week off for the 1st month(weeks 1-4)~2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)~1 month on / 1 month off from the 4th month thereafter (weeks 13 on)"
3247386|NCT00858793|Experimental|A|
3247387|NCT00858780|Active Comparator|1|50mg once weekly + methotrexate
3247388|NCT00858780|Active Comparator|2|25mg once weekly + methotrexate
3247389|NCT00858780|Placebo Comparator|3|once weekly + methotrexate
3247390|NCT00858767|Active Comparator|1|2 casein capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks
3247391|NCT00858767|Active Comparator|2|2 arabic gum capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks
3247392|NCT00858767|Active Comparator|3|2 linseed capsules existing of 90 µg menaquinone-7 per day for 8 weeks
3247393|NCT00858754|Experimental|Group 1 Active Drug|Methylnaltrexone
3247394|NCT00858754|Placebo Comparator|Group 2 Non-Active Drug|Placebo
3247395|NCT00858741|Experimental|8 Gy arm|8.0 Gy in 1 fraction to 8.0 Gy total dose.
3247396|NCT00858741|Active Comparator|30 Gy arm|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
3247397|NCT00858728|Experimental|1|5 portions fruit and vegetables/day
3247398|NCT00858728|Other|2|2 portions fruit and vegetables/day
3247399|NCT00858715|Active Comparator|1|75 mg clopidogrel + 100 mg aspirin
3247400|NCT00858715|Active Comparator|2|150 mg clopidogrel + 100 mg aspirin
3247401|NCT00858702|Experimental|1|olmesartan medoxomil tablets and a CCB tablet (of the dihydropyridine class), once daily for 8 weeks
3247402|NCT00858702|Experimental|2|olmesartan medoxomil and a diuretic tablet (of the thiazide class)
3247403|NCT00858689|Experimental|minocyline 50 mg or 100 mg PO BID|open label treatment with minocycline low or high dose, 50 mg or 100 mg PO (by mouth) BID (twice a day), added to existing medication regimen for 8 weeks
3247404|NCT00858676|Active Comparator|Acarbose|
3247405|NCT00858663|Experimental|Chemoradiation|"IMRT, 1 fraction/day, over approximately 33 treatment days~RAD001 per oral or PEG, per dose escalation scheme (Days 1 - 42)~Cisplatin IV weekly, per dose escalation scheme (Days 1, 8, 15, 22, 29, 36)"
3247406|NCT00858650||Standard of Care|Hypogonadal males treated by standard of care, with or without testosterone replacement therapy
3247407|NCT00858637|Experimental|1 MCI-196|
3247408|NCT00858637|Placebo Comparator|2 Placebo of MCI-196|
3247409|NCT00858637|Active Comparator|3 Simvastatin|
3247410|NCT00858637|Placebo Comparator|4 Placebo of Simvastatin|
3247411|NCT00858624|Active Comparator|Chronic Cough Patients|
3247412|NCT00858624|Active Comparator|Healthy Volunteers|
3247413|NCT00858598||Pro Osteon|All patients in this pilot study will receive pro osteon as a bone void filler and will be enrolled according to the same inclusion / exclusion criteria.
3247414|NCT00858572|Experimental|Cohort|
3247415|NCT00858559|Experimental|1|Home Monitoring
3247416|NCT00858559|Active Comparator|2|Home Monitoring not used
3247417|NCT00858546|Experimental|Active repetitive transcranial Stimulation|Active repetitive transcranial Stimulation
3247418|NCT00858533|Other|workplace health advice|The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances.
3247419|NCT00858533|No Intervention|GP sickness absence consultation|Routine general practitioner care for workplace sickness absence.
3247420|NCT00858520||Smoking controls|Smokers without lung cancer and without COPD
3247421|NCT00858520||COPD patients|Smokers with COPD but without lung cancer
3247422|NCT00858520||Lung cancer patients|smokers - never smokers with lung cancer
3247423|NCT00858507|Experimental|Personal Health Assessment/RN Brief Intervention|RN-based medical outreach, administration of a personal health assessment and brief intervention
3247424|NCT00858507|Placebo Comparator|Social Work-Administered Outreach|Social work based outreach (usual care)
3247425|NCT00858494|Experimental|homeopathic cold remedy|
3247426|NCT00858481|Placebo Comparator|1|Vehicle control
3247427|NCT00858481|Active Comparator|2|0.5% Spinosad creme rinse
3247428|NCT00858481|Active Comparator|3|1.0% Spinosad Creme Rinse
3247429|NCT00858481|Active Comparator|4|2.0% Spinosad Creme Rinse
3247430|NCT00858468|Experimental|Group 1|Participants aged 6 to 12 Weeks at enrollment
3247431|NCT00858468|Experimental|Group 2|Participants aged 24 to 36 Weeks at enrollment
3247432|NCT00858455|Experimental|Healthy Volunteers|4 period cross over
3247433|NCT00858442|Experimental|With PRP|Each patient received a single dose of 5cc PRP before the graft.
3247434|NCT00858442|No Intervention|Without PRP|Control patients did not receive any intervention before the graft.
3247435|NCT00858429|Experimental|Cohort 1 (capecitabine, Y90)|2,000mg/m2 capecitabine +110 Y90
3247436|NCT00858429|Experimental|Cohort 2 (capecitabine , Y90)|2,000mg/m2 capecitabine + 130 Y90
3247437|NCT00858429|Experimental|Cohort 3 (capecitabine, Y90)|2,000mg/m2 Capecitabine + 150 Y90
3247438|NCT00858429|Experimental|Cohort 4 (capecitabine, Y90)|2,000 mg/m2 capecitabine = 170 Y90
3247439|NCT00858416|Experimental|AB|First active then Sham
3247440|NCT00858416|Sham Comparator|BA|First sham then active
3247441|NCT00858403|Experimental|Treatment with Dasatinib|Dasatinib 140 mg orally (po) every day starting Day #1, continuous dosing. This dose was chosen based on the current experience in patients with solids tumors who have had prior chemotherapy.
3247442|NCT00858390|No Intervention|1 standard care|organ donors receiving standard care
3247443|NCT00858390|Experimental|2 Enteral Feeding|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
3247444|NCT00858377|Experimental|Arm 1- Dose Expansion|The dose expansion part of the study will begin after completion of the dose escalation phase and will consist of 3 cohorts of 14 subjects each. One taxane-resistant tumor type will be evaluated in each cohort.
3247445|NCT00858377|Experimental|Arm 1- Dose Escalation|The dose escalation part of the study is aimed at determining the maximum tolerated dose (MTD) of AMG 900 and if necessary, the MTD with prophylactic GCSF support (MTD-G).
3247446|NCT00858364|Placebo Comparator|Placebo|Participants received placebo once every 3 weeks (Q3W) administered subcutaneously until 3 weeks after the completion of chemotherapy or upon determination of disease progression, whichever occurred first.
3247447|NCT00858364|Experimental|Darbepoetin alfa|Participants received darbepoetin alfa 500 µg once every 3 weeks (Q3W) administered subcutaneously until 3 weeks after the completion of chemotherapy or upon determination of disease progression, whichever occurred first.
3247448|NCT00858351|Experimental|Thermal Biofeedback Assisted Relaxation|
3247449|NCT00858351|Active Comparator|Discussion|
3247450|NCT00858312|Experimental|1|Diet with 3-4 servings of dairy-rich foods/day
3247451|NCT00858312|Placebo Comparator|2|Low Dairy < 1 serving of dairy food/day
3247452|NCT00858299|Experimental|valsartan|
3247453|NCT00858286|Experimental|Stable dosing with SERETIDE, short acting B-2agonist as needed|Regular treatment with SERETIDE in a stable dosing with short acting beta-2 agonists as needed
3247658|NCT00856882|Experimental|soy protein and isoflavones|
3247454|NCT00858286|Experimental|Maintenance treatment with SYMBICORT and SYMBICORT as needed|Maintenance treatment with SYMBICORT and using the same inhaler with SYMBICORT as needed
3247455|NCT00858273|Active Comparator|Antioxidant Supplement|Vitamin C 250 mg; beta-carotene 6 mg; vitamin E 30 mg; selenium 100 mcg; zinc 20 mg
3247456|NCT00858273|Placebo Comparator|Placebo|
3247457|NCT00858260||hemodialysis patients|Adult patients undergoing maintenance dialysis since at leat three months
3247458|NCT00858247|Experimental|Vitamin D3-low dose|Vitamin D3 400 IU capsule, one capsule daily for 12 weeks.
3247459|NCT00858247|Experimental|Vitamin D3-high dose|Vitamin D3 2000 IU capsule, one capsule daily for 12 weeks.
3247460|NCT00858234|Experimental|1|MK0683
3247461|NCT00858208||Patients with neovascular Age-Related Macula Degeneration|
3247462|NCT00858195|Experimental|1|Indomethacin 75mg ER Capsules
3247463|NCT00858195|Active Comparator|2|Indocin 75mg SR Capsules
3247464|NCT00858182|Experimental|Group A|
3247465|NCT00858182|Experimental|Group B|
3247466|NCT00858143||1|
3247467|NCT00858130|Experimental|Veinoplus|Every subject enrolled in study will be in this experimental arm. VeinoPlus device will be used by all enrolled subjects.
3247468|NCT00858117|Experimental|Alemtuzumab and Rituximab|Administration of Alemtuzumab combined with Rituximab to test the feasibility of combining these two monoclonal antibodies as a first line therapy in patients with B-cell chronic lymphocytic leukemia.
3247469|NCT00858104|Active Comparator|1|Laser thermal ablation
3247470|NCT00858104|No Intervention|2|Follow-up
3247471|NCT00858065|Active Comparator|RCT FM|Random control trial- Family Matters. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to Family Matters program.
3247472|NCT00858065|Active Comparator|Choice SFP|Half the families were assigned to the choice condition in which they can choose between two prevention programs. This arm chose the Strengthening Families Program (SFP).
3247473|NCT00858065|Active Comparator|RCT SFP|Random control trial- Strengthening Families Program. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to Strengthening Families Program.
3247474|NCT00858065|No Intervention|RCT Control|Random control trial- Control Group. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to the control group and received no prevention program. However, this group and all groups received an informational pamphlet about youth alcohol and other drug use.
3247475|NCT00858065|Active Comparator|Choice FM|Half the families were assigned to the choice condition in which they can choose between two prevention programs. This arm chose the Family Matters (FM) program.
3247476|NCT00858052|Experimental|breast augmentation|breast implant
3247477|NCT00858039||Her-2 positive ESBC|
3247478|NCT00858026|Other|1|Breastfed babies
3247479|NCT00858026|Active Comparator|2|Weaning with the standard milk
3247480|NCT00858026|Experimental|3|Weaning with the fermented milk
3247481|NCT00858013|Active Comparator|Nateglinide|Nateglinide 90~120mg three times a day
3247482|NCT00858013|Active Comparator|Glimepiride|Glimepiride 1~2mg once a day
3247483|NCT00858000||Group A|No intervention
3247484|NCT00857987|Experimental|1|Guaifenesin, doxylamine succinate and hydrochloride etafedrine syrup
3247485|NCT00857987|Placebo Comparator|2|Vehicle
3247486|NCT00857974|No Intervention|Usual Care|No physical activity intervention will be prescribed for the Usual Care Arm.
3247487|NCT00857974|Active Comparator|Physical Activity|
3247488|NCT00857961|Experimental|3 mL (30 mg) of 1% Testosterone MD-Lotion|Applied once daily for 7 days to both axilla (1.5 mL to each axilla). All study participants are randomized to each of the 4 study treatments.
3247489|NCT00857961|Experimental|1.5 mL (30 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days to one axilla. All study participants are randomized to each of the 4 study treatments.
3247490|NCT00857961|Experimental|3 mL (60 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days to both axilla (1.5 mL to each axilla). All study participants are randomized to each of the 4 study treatments.
3247491|NCT00857961|Experimental|4.5 mL (90 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days by three doses to both axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla). All study participants are randomized to each of the 4 study treatments.
3247492|NCT00857948|Experimental|0.15% ivermectin|Participant on 0.15% ivermectin treatment conditioner
3247493|NCT00857948|Experimental|0.25% ivermectin|Participants on 0.25% ivermectin treatment conditioner
3247494|NCT00857948|Experimental|0.50% ivermectin|Participants on 0.50% ivermectin treatment conditioner
3247495|NCT00857948|Placebo Comparator|Placebo|participants on Placebo (Vehicle control)
3247496|NCT00857935|Experimental|1|NatrOVA Creme Rinse - 1%
3247497|NCT00857935|Active Comparator|2|NIX Creme Rinse
3247498|NCT00857922||Neurosurgical patient|Neurosurgical patient of the Mischer Neuroscience Institute, 18 years and over
3247499|NCT00857922||Family members|Family members of specific vascular, trauma, brain tumor and functional disorder cohorts
3247500|NCT00857909|Active Comparator|Randomisation 1|Amiloride 5 mg twice daily for 28 days, later compared with spironolactone and placebo
3247501|NCT00857909|Active Comparator|Randomisation 2|Spironolactone 25 mg twice daily, to be compared with placebo and amiloride
3247502|NCT00857909|Placebo Comparator|Placebo|calcium tablet
3247503|NCT00857896|Experimental|Fesoterodine once daily|
3247504|NCT00857883|Placebo Comparator|Part A|Part A: This part of the study will start with a very low dose of study drug, which will then be gradually increased in subsequent doses. This is known as dose-rising and is the way to assess safety and tolerability (i.e. possible presence of any side effects that make taking the drug unpleasant) of increasing doses of the study drug. Effects will be compared to those seen when a placebo is taken. Up to 4 groups of 6-9 healthy male or female volunteers will be enrolled.
3247659|NCT00856882|Experimental|milk protein and isoflavones|
3247660|NCT00856882|Placebo Comparator|milk protein only|
3247661|NCT00856869|Experimental|1 YM|Healthy young males
3247505|NCT00857883|Active Comparator|Part B|Part B: A dose selected from Part A that was well tolerated will be used to check if there is a difference in the pharmacokinetics (blood levels) of the study drug when taken without food in liquid form, or as a capsule, or as a capsule together with a high fat meal to assess the effect of food. One group of 12 healthy male or female volunteers will be enrolled.
3247506|NCT00857883|Placebo Comparator|Part C|Part C: A well tolerated dose selected from Parts A & B will be used to test whether the drug has an effect on individual preferences for sugary and high fat food, when compared to placebo. Up to 32 healthy overweight male volunteers will be enrolled.
3247507|NCT00857870|Active Comparator|Metformin|
3247508|NCT00857870|Active Comparator|Insulin glargine|
3247509|NCT00857857|Experimental|13 day repeat dose|
3247510|NCT00857844||Group 1|Normal GFR (>90ml/min/1.73m2). Stage I CKD
3247511|NCT00857844||Group 2|GFR between 30-59ml/min/1.73m2. Stage III CKD
3247512|NCT00857844||Group 3|GFR between 15-29ml/min/1.72m2. Stage IV CKD
3247513|NCT00857831|Experimental|Arm 1|Vitamin D & Calcium supplementation in FES
3247514|NCT00857818|Experimental|Aripiprazole|
3247515|NCT00857818|Active Comparator|Control group (Oanzapine, risperidone, or quetiapine)|
3247516|NCT00857805|Active Comparator|Transarterial Chemoembolization|Transarterial Chemoembolization
3247517|NCT00857805|Active Comparator|Proton Beam Radiotherapy|Proton Beam Radiotherapy
3247518|NCT00857792|Other|Open Label|
3247519|NCT00857779|Active Comparator|subcutaneous immunotherapy|subcutaneous immunotherapy using a slow updosing schedule
3247520|NCT00857779|Active Comparator|subcutaneous injections|subcutaneous immunotherapy using a fast updosing schedule
3247521|NCT00857766|Active Comparator|ADVAIR DISKUS|Subjects receive blinded Fluticasone Propionate/Salmeterol. At 4 months subjects will receive open label SPIRIVA HANDIHALER
3247522|NCT00857766|Placebo Comparator|Placebo|Subjects will receive placebo ADVAIR DISKUS. At 4 months subjects will receive open label SPIRIVA HANDIHALER
3247523|NCT00857753|Experimental|1|Fentanyl patch 25 ug/hr Sandoz
3247524|NCT00857753|Active Comparator|2|Duragesic Patch 25 ug/hr
3247525|NCT00857727|Experimental|Drug|Dexmedetomidine
3247526|NCT00857727|Placebo Comparator|Control|Normal Saline IV solution
3247527|NCT00857701|No Intervention|1|Patient will receive post-surgical standard of care treatment with standard Physical therapy and NSAIDs.
3247528|NCT00857701|Experimental|2|Patients will be treated with the Standard of Care physical therapy and NSAIDs as well as a Knee Extension Dynasplint that includes tension chambers.
3247529|NCT00857688|Experimental|1 - Test|Patients will recieve the association.
3247530|NCT00857688|Placebo Comparator|2|Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
3247531|NCT00857675|Experimental|Adefovir Dipivoxil|ADV 10mg tablets once daily
3247532|NCT00857675|Placebo Comparator|Adefovir Dipivoxil matched placebo|Adefovir Dipivoxil matched placebo one tablet once daily
3247533|NCT00857662|Experimental|Onyx|
3247534|NCT00857662|Active Comparator|TRUFILL|
3247535|NCT00857649|Experimental|Memantine|
3247536|NCT00857649|Placebo Comparator|Placebo|
3247537|NCT00857636|Experimental|Health Literacy|
3247538|NCT00857623|Experimental|1|
3247539|NCT00857623|Placebo Comparator|2|
3247540|NCT00857610||1|Subjects using 0.1% retinol one day per week
3247541|NCT00857610||2|Subjects using 0.1% retinol three days per week
3247542|NCT00857610||3|Subjects using 0.1% retinol seven days per week
3247543|NCT00857610||4|Subjects using 0.5% retinol one day per week
3247544|NCT00857610||5|Subjects using 0.5% retinol three days per week
3247545|NCT00857610||6|Subjects using 0.5% retinol seven times per week
3247546|NCT00857597|Experimental|EsophyX|
3247547|NCT00857597|Active Comparator|Proton Pump Inhibitors|
3247548|NCT00857584|Experimental|Quetiapine Extended Release|Lithium or valproate at stable doses within seric therapeutic levels
3247549|NCT00857584|Active Comparator|Sertraline|Lithium or valproate at stable doses within seric therapeutic levels
3247550|NCT00857571|Experimental|Suspension|PF-02413873 suspension
3247551|NCT00857571|Experimental|Tablet|PF-02413873 Phase 2 Tablets
3247552|NCT00857558|Experimental|1|OPC-262 1mg
3247553|NCT00857558|Experimental|2|OPC-262 2.5mg
3247554|NCT00857558|Experimental|3|OPC-262 5mg
3247555|NCT00857558|Placebo Comparator|4|
3247556|NCT00857545|Experimental|Arm I (vaccine therapy and adjuvant)|Patients receive polyvalent antigen-KLH conjugate vaccine and immunological adjuvant OPT-821 subcutaneously (SC) once in weeks 1, 2, 3, 7, 11, 23, 35, 47, 59, 71, and 83 in the absence of disease progression or unacceptable toxicity.
3247557|NCT00857545|Experimental|Arm II (adjuvant)|Patients receive immunological adjuvant OPT-821 SC as in arm I.
3247558|NCT00857532|Experimental|Normal cognitive performance|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores of ≥9, indicating normal cognitive performance.
3247559|NCT00857532|Experimental|Mild cognitive deficits|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores between 6 and 8, inclusive, indicating mild cognitive deficits.
3247560|NCT00857532|Experimental|Severe cognitive impairment|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores below 5, indicating moderate to severe cognitive impairment.
3247561|NCT00857519|Experimental|Chemotherapy|Chemotherapy using Melphalan, Carboplatin.
3247562|NCT00857493|Experimental|Group 1|
3247563|NCT00857493|Experimental|Group 2|
3247564|NCT00857480|Experimental|Reference|No pre-treatment
3247565|NCT00857480|Experimental|T1|Cloxacillin pre- and co-treatment
3247566|NCT00857480|Experimental|T2|UDCA pre-treatment
3247567|NCT00857467|Experimental|1 g suppository|Subjects receive 5 mg NRL001, 10 mg NRL001 and placebo in a 1g rectal suppository
3247568|NCT00857467|Experimental|2 g suppository|Subjects receive 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository.
3247662|NCT00856869|Experimental|2 EM|Healthy elderly males
3247663|NCT00856869|Experimental|3 YF|Healthy young females
3247569|NCT00857454|Experimental|Testosterone MD-lotion|"In this open-label extension of the MTE08 trial, participants received Testosterone Metered Dose (MD)-Lotion for 60 days (dosing from Day 121 of the MTE08 trial to Day 180 of the MTE09 trial). Participants in MTE08 initially received 3.0 milliliters (mL) (60 micrograms [mg]) of 2% Testosterone MD-Lotion, and may have had their dose of testosterone adjusted upwards or downwards.~Doses could be titrated to one of the following:~1.5 mL (30 mg) of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to one axilla).~3.0 mL (60 mg)of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to each axilla).~4.5 mL (90 mg)of 2% Testosterone MD-Lotion applied daily by 3 doses to the axilla (2 x 1.5 mL to one axilla and 2 x 1.5 mL to the other axilla).~6.0 (120 mg)of 2% Testosterone MD-Lotion applied daily by 4 doses to the axilla (2 x 1.5 mL to each axilla)."
3247570|NCT00857441|Experimental|1|Use of Dior balloon and implant of Liberté Bare Metal Stent
3247571|NCT00857441|Active Comparator|2|Use of standard balloon and implant of Liberté Bare Metal Stent
3247572|NCT00857441|Active Comparator|3|Use of standard balloon and implant of Taxus Liberté Drug Eluting Stent
3247573|NCT00857428|Experimental|1|Oxymorphone ER 40 mg tablets Sandoz
3247574|NCT00857428|Active Comparator|2|Opana ER 40 mg tablets Eon Pharmaceuticals
3247575|NCT00857415|Experimental|Autopsy Cohort|End-of-life subjects (life expectancy < 6 months) consenting to brain donation at autopsy.
3247576|NCT00857415|Experimental|Specificity Cohort|Younger healthy controls presumed to be devoid of beta-amyloid plaques.
3247577|NCT00857402|Active Comparator|Peanuts|
3247578|NCT00857402|Active Comparator|Daboqolo|
3247579|NCT00857389|Experimental|Thio-Clo-Bu with Allo SCT|"Pre-transplant conditioning regimen:~Thiotepa (Thio) + Clofarabine (Clo) + Busulfan (Blu) + Allogeneic Stem Cell Transplantation (Allo SCT) + ATG + G-CSF~Post haploidentical stem cell transplant participants:~Cyclophosphamide 50 mg/kg by vein on Days + 3 and + 4. Mesna 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses."
3247580|NCT00857376|Placebo Comparator|placebo|Placebo 2 tabs three times daily
3247581|NCT00857376|Experimental|Alpha lipoic acid 1|Alpha lipoic acid 600 mg daily
3247582|NCT00857376|Experimental|Alpha lipoic acid 2|Alpha Lipoic acid 1200 mg daily
3247583|NCT00857376|Experimental|Alpha lipoic acid 3|Alpha lipoic acid 1800 mg daily
3247584|NCT00857363||Constipated|Adult subjects with functional constipation as define by Rome II criteria
3247585|NCT00857350||HIV+, opiod dependent|
3247586|NCT00857324|Experimental|ZMP|Combination with Vorinostat, Melphalan and Prednisone
3247587|NCT00857311|Experimental|MRKAd5 HIV-1 gag vaccine 1x10^9 vp/dose|Participants administered MRKAd5 HIV-1 gag vaccine 1x10^9 viral particles (vp)/dose (V520), on Day 1, Week 4, and Week 26.
3247588|NCT00857311|Experimental|MRKAd5 HIV-1 gag vaccine 1x10^10 vp/dose|"Participants were to be administered MRKAd5 HIV-1 gag 1x10^10 vp/dose (V520) on Day 1, Week 4, and Week 26.~Per a letter dated 30-Aug-2005 all sites were notified that due to recruitment challenges enrollment would be halted as of 01-Oct-2005. Consequently, no participants were enrolled in the group MRKAd5 HIV-1 gag 1x10^10 vp/dose."
3247589|NCT00857311|Experimental|Placebo|Participants administered placebo to MRKAd5 HIV-1 gag vaccine (V520) on Day 1, Week 4, and Week 26.
3247590|NCT00857311|Sham Comparator|Open Label Tetanus and Diptheria Toxoids Adsorbed|"Participants were to be administered open label tetanus and diptheria toxoids adsorbed (Td) at Day 1 only.~Per a letter dated 30-Aug-2005 all sites were notified that due to recruitment challenges enrollment would be halted as of 01-Oct-2005. Consequently, no participants were enrolled in this group."
3247591|NCT00857298|Active Comparator|HIV-MS|HIV-positive obese women with metabolic syndrome will be studied before and after losing 6-8% of body weight
3247592|NCT00857298|Active Comparator|MS only|HIV-negative obese women with metabolic syndrome will be studied before and after losing 6-8% of body weight
3247593|NCT00857285|Experimental|1|olmesartan medoxomil
3247594|NCT00857285|Active Comparator|2|losartan potassium
3247595|NCT00857272|Active Comparator|HalfLytely with 10mg bisacodyl|Active control
3247596|NCT00857272|Experimental|HalfLytely with 5mg bisacodyl|Investigational dose
3247597|NCT00857259|Experimental|Everolimus 5 mg|5 mg orally once daily plus sham ocular injection on Day 1 (Baseline) until Day 28
3247598|NCT00857259|Active Comparator|Ranibizumab 0.5 mg|Ranibizumab intra-vitreal therapy (IVT) 0.5 mg on Day 1 (baseline)
3247599|NCT00857259|Active Comparator|Oral Everolimus (5mg) and Ranibizumab (0.5mg)|Everolimus orally 5 mg once daily plus Ranibizumab Intra-vitreal therapy (IVT) 0.5 mg on day 1 (baseline)
3247600|NCT00857246|Experimental|Induction/ surgery/ chemoRT|"Induction treatment (3 weeks/cycle x 4 cycles): Cisplatin and Irinotecan on days 1 and 8; Cetuximab on days 1, 8, and 15.~Surgery (starts 3-4 weeks after induction treatment).~Chemoradiation treatment (starts 4-6 weeks after surgery):~weeks 1-19: Cetuximab on day 1 of every week; week 1: 5-FU and Leucovorin (LV) x 5 days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU+ LV on days 1-4; week 9: 5-FU+ LV on days 1-3; weeks 14 and 19: 5-FU+LV x 5days"
3247601|NCT00857233|Experimental|Memantine|
3247602|NCT00857220|Experimental|2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs)|
3247603|NCT00857207|Experimental|Arm 1: Treatment Goal Management Training|Treatment Goal Management Training
3247604|NCT00857207|No Intervention|Arm 2: Control-Brain Health Workshop|Control-Brain Health Workshop
3247605|NCT00857194||Group 2|Chronic, stable spinal cord injury
3247606|NCT00857181||Liver Cirrhosis|Single cohort of patients with liver cirrhosis to be investigated in the study. Two-monthly measurements of serum cytokines.
3247607|NCT00857168|Active Comparator|Group 1|
3247608|NCT00857168|Active Comparator|Group 2|
3247609|NCT00857168|Active Comparator|Group 3|
3247610|NCT00857168|Active Comparator|Group 4|
3247611|NCT00857168|Active Comparator|Group 5|
3247612|NCT00857168|Active Comparator|Group 6|
3247613|NCT00857155|No Intervention|Aspirin only|Continue aspirin until surgery
3247614|NCT00857155|Other|Clopidogrel and Aspirin|
3247615|NCT00857142|Experimental|1|Oxymorphone hydrochloride 40 mg extended release tablets (Sandoz)
3247616|NCT00857142|Active Comparator|2|Opana 40 mg extended release tablets
3247664|NCT00856869|Experimental|4 EF|Healthy elderly females
3247617|NCT00857129|No Intervention|1|Low risk women with expected normal birth are being Randomized to The Midwife-led Unit, with low amount of intervention, No epidural is offered, no medical augmentation available, unless for the active phase of the second stage. If extended surveillance is necessary or if the birth no longer is considered to be normal and needs to be taken over by a doctor, the woman will be transferred to either the Normal Unit or the Special Unit
3247618|NCT00857129|Experimental|2|Low-risk women are randomised to this Low-risk maternal unit, The Normal Unit.The unit is organised for low-risk women with expected normal birth. The unit has access to extended surveillance, epidural and operative vaginal deliveries. If extended surveillance is necessary for a woman randomised to this unit, she does not have to be transferred to a higher level of care. Instrumental vaginal deliveries can be carried out at this unit.
3247619|NCT00857129|Experimental|3|Women with expected normal births are being randomised to this Special birth unit designed to take care of women before, under and after birth. The Special Unit cares for women with extended need for surveillance, but does also handle low-risk women.
3247620|NCT00857116|Active Comparator|Albendazole|Albendazole 400mg per os once daily for three consecutive days
3247621|NCT00857116|Placebo Comparator|Placebo|Placebo 400mg per os for three consecutive days
3247622|NCT00857103|No Intervention|1|Standard care
3247623|NCT00857103|Experimental|2|Use of Choice intervention to support consultations
3247624|NCT00857090|Experimental|1|Drug
3247625|NCT00857090|Placebo Comparator|2|Vehicle
3247626|NCT00857077|Placebo Comparator|1 Placebo|
3247627|NCT00857077|Active Comparator|2 Sulfadoxine-pyrimethamine (SP)|
3247628|NCT00857051|Experimental|1|A 22 minute DVD that discusses common stressor in the early postpartum.
3247629|NCT00857051|Experimental|2|A 24 hour hotline available for the first 3 months postpartum.
3247630|NCT00857051|Experimental|3|Both the film and the hotline will be given to this arm.
3247631|NCT00857051|No Intervention|4|A CD of children's music will be given to mothers in this arm.
3247632|NCT00857038|Experimental|1|Doxycycline 100mg daily
3247633|NCT00857038|Placebo Comparator|2|Placebo
3247634|NCT00857025|Experimental|Treatment (beta-glucan MM-10-001)|Patients receive oral beta-glucan MM-10-001 once or twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3247635|NCT00857012||All patients|treated with Anastrozole as per SPC
3247636|NCT00856999|Experimental|Botox|Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
3247637|NCT00856986|Experimental|Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%
3247638|NCT00856986|Experimental|Insulin detemir + Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%
3247639|NCT00856986|Experimental|Non-Randomised Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%
3247640|NCT00856986|Other|Early Withdrawals Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial
3247641|NCT00856986|Other|Intensified group|Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c ≥ 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group.
3247642|NCT00856973|Experimental|Low dose eszopiclone|1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
3247643|NCT00856973|Experimental|High dose eszopiclone|2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
3247644|NCT00856973|Placebo Comparator|Placebo|Placebo 6-17 years
3247645|NCT00856960|Active Comparator|1|Aliskiren 600 mg
3247646|NCT00856960|Active Comparator|2|Aliskiren 150 mg
3247647|NCT00856960|Active Comparator|3|Losartan 100 mg
3247648|NCT00856960|Placebo Comparator|4|Placebo
3247649|NCT00856947|Active Comparator|Vitamin D|Dietary supplement: 2400 IU Vitamin D3 (2 tablets of 1200 IU) from week 24 of gestation to 1 week after delivery
3247650|NCT00856947|Placebo Comparator|Placebo|Placebo: 2 placebo tablets with no active substance, identical to the active tablets, from week 24 of gestation to 1 week after delivery
3247651|NCT00856934|No Intervention|Control|Wounds covered with standard dressings: three layers of paraffin gauze, standard bandages, elastic bandage.
3247652|NCT00856934|Experimental|PRP|PRP sprayed onto the wound bed with Calcium Choride. Wounds covered with same standard dressings used in control group.
3247653|NCT00856934|Experimental|PRP+K|Keratinocytes suspended in PRP sprayed onto the wound bed with Calcium Choride. Wounds covered with same standard dressings used in control group.
3247654|NCT00856908|Experimental|1|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
3247655|NCT00856908|Placebo Comparator|2|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
3247665|NCT00856869|Experimental|5 NASH|Patients with presumed NASH
3247666|NCT00856869|Experimental|6 CTP-A|Patients with hepatic cirrhosis CTP-class A
3247667|NCT00856869|Experimental|7 CTP-BC|Patients with hepatic cirrhosis CTP-class B and C
3247668|NCT00856856|Experimental|ABSORB stent|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)
3247669|NCT00856843|Active Comparator|Polyethylene glycol 3350 based bowel preparation|Polyethylene glycol 3350 based bowel preparation
3247670|NCT00856843|Experimental|BLI800|BLI800
3247671|NCT00856830|Experimental|Novel Drug Combination|"This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin.~This study has only one arm but it incorporates two phases. Phase I utilizes a combination of bendamustine and irinotecan for Regimen A followed by etoposide and carboplatin for Regimen B."
3247672|NCT00856817|Experimental|1|L-arginine treatment first, heme arginate treatment second
3247673|NCT00856817|Experimental|2|Heme arginate treatment first, L-arginine treatment second
3247674|NCT00856804|Experimental|1|thalidomide added to peg-interferon + ribavirina
3247675|NCT00856791|Experimental|ON 01910.Na|3200 mg ON 01910.Na administered intravenously over 2 hours on days 1, 4, 8, 11, 15, and 18 of 28-day cycle
3247676|NCT00856778|Other|Virtue® Male Sling|Subjects implanted with Virtue® Male Sling
3247677|NCT00856765|Experimental|1|Drug eluting balloon followed immediately by implantation of bare metal stent
3247678|NCT00856765|Active Comparator|2|Drug eluting stent
3247679|NCT00856765|Active Comparator|3|Bare metal stent
3247680|NCT00856752|Experimental|T1|Pre-treatment with rifampicin
3247681|NCT00856752|Experimental|T2|Pre-treatment with cyclosporin
3247682|NCT00856752|Experimental|Reference|Administration of NRL001 alone: no pre-treatment
3247683|NCT00856739||Group 1|
3247684|NCT00856726|Experimental|PTH infusion|(1-34) PTH infusion at a rate of 0.055 ug/kg/hour for six hours
3247685|NCT00856713|Experimental|1 YM|Healthy young males
3247686|NCT00856713|Experimental|2 EM|Healthy elderly males
3247687|NCT00856713|Experimental|3 YF|Healthy young females
3247688|NCT00856713|Experimental|4 EF|Healthy elderly females
3247689|NCT00856713|Experimental|5 CTP-A|Patients with hepatic cirrhosis CTP-class A
3247690|NCT00856713|Experimental|6 CTP-BC|Patients with hepatic cirrhosis CTP-class B and C
3247691|NCT00856700|Experimental|GLP-1 infusion|Patients with metabolic syndrome
3247692|NCT00856687|Experimental|PF-03893787|
3247693|NCT00856687|Placebo Comparator|Placebo|
3247694|NCT00856687|Active Comparator|Montelukast|
3247695|NCT00856661|Experimental|Desmoteplase|
3247696|NCT00856661|Placebo Comparator|Placebo|
3247697|NCT00856648||Group 1|SCI
3247698|NCT00856648||Group 2|Able-bodied
3247699|NCT00856635|Experimental|Glatiramer acetate|Participants received glatiramer acetate 20 mg subcutaneous injection once a day for up to 6 months.
3247700|NCT00856635|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once a day for up to 6 months.
3247701|NCT00856622|Experimental|Fixed combination of latanoprost 0.005% and timolol 0.5%|
3247702|NCT00856622|Active Comparator|timolol 0.5% ophthalmic solution|one drop in the morning and evening
3247703|NCT00856622|Active Comparator|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
3247704|NCT00856609|Active Comparator|Exenatide|10 micrograms subcutaneously twice
3247705|NCT00856609|Placebo Comparator|Placebo|Twice daily
3247706|NCT00856596|Other|Males and females with athlete's foot|Male and female subjects with athlete's foot inbetween their toes without nail involvement
3247707|NCT00856583|Experimental|Sertindole|Normally in the range of 4 to 20 mg/day
3247708|NCT00856583|Active Comparator|Risperidone|Normally in the range of 2 to 8 mg/day
3247709|NCT00856557|Experimental|Seminar and Practicum|Seminar and practicum that occurs over 4 week period for internal medicine residents, designed to provide a systematic approach to identifying and addressing contextual factors essential to planning patient care.
3247710|NCT00856557|No Intervention|No intervention|No educational intervention.
3247711|NCT00856544|Experimental|Active 5 mg|
3247712|NCT00856544|Experimental|Active 10 mg|
3247713|NCT00856544|Placebo Comparator|Placebo Sequence 1|Placebo non-responders advance to 5 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 5 mg CP-690,550 at Month 6 visit.
3247714|NCT00856544|Placebo Comparator|Placebo Sequence 2|Placebo non-responders advance to 10 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 10 mg CP-690,550 at Month 6 visit.
3247715|NCT00856531||1|
3247716|NCT00856531||2|
3247717|NCT00856531||3|
3247718|NCT00856531||4|
3247719|NCT00856531||5|
3247720|NCT00856531||6|
3247721|NCT00856531||7|
3247722|NCT00856531||8|
3247723|NCT00856531||9|
3247724|NCT00856531||10|
3247725|NCT00856531||11|
3247726|NCT00856531||12|
3247727|NCT00856531||13|
3247728|NCT00856531||14|
3247729|NCT00856531||15|
3247730|NCT00856518|Active Comparator|Arm 1: EMST|The experimental group receives five weeks of expiratory muscle strength training (EMST) using a positive pressure threshold device
3247731|NCT00856518|Sham Comparator|Arm 2: Sham group|The Sham group undergoes the same 5-week EMST exercise as the experimental group using the same device but without a spring for minimal pressure load
3247732|NCT00856505|Experimental|Everolimus and mycophenolate sodium|Combination of experimental immunosuppressants for GvHD prophylaxis
3247733|NCT00856492|Experimental|Arm 1|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 and bevacizumab IV over 30- to 90-minutes on day 1 of weeks 1-12. Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 14, 16, 18, 20, 22, and 24.
3247778|NCT00856219|Active Comparator|Parenteral|Parenteral continuously for 72 hours
3248102|NCT00853593|Experimental|Model 4396 LV Lead|Non-randomized study.
3247734|NCT00856492|Active Comparator|Arm 2|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 of weeks 1-12, and then receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 14, 16, 18, 20, 22, and 24.
3247735|NCT00856492|Active Comparator|Arm 3|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 1, 3, 5, 7, 9, and 11, and then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 of weeks 14-25.
3247736|NCT00856479|Active Comparator|1 Infuse|The patient will receive BMP 2 with allograft
3247737|NCT00856479|Active Comparator|2 Iliac crest autograft|Autograft from Patients Iliac Crest and allograft
3247738|NCT00856453|Experimental|Yoga classes plus home yoga practic|
3247739|NCT00856453|Experimental|home yoga practice alone|
3247740|NCT00856440||1|SCI
3247741|NCT00856440||2|Able-bodied
3247742|NCT00856427|Experimental|Diagnostic|Patients undergo implantation of radio-opaque markers into the primary lesion and affected lymph nodes by bronchoscopy. Patients then undergo routine 4D CT, 4D CBCT, fluoroscopy, and x-ray imaging during standard stereotactic radiation therapy (early stage tumors) or conventionally fractionated radiation therapy (advanced stage tumors).
3247743|NCT00856414|Experimental|1|botulinum toxin Type A 20U
3247744|NCT00856401|Experimental|PTH1-84 in parent study|In the RELAY, RACE, and HEXT study participants utilize PTH1-84. In the REPLACE Study participants utilize PTH1-84 or placebo of PTH1-84.
3247745|NCT00856388|Experimental|Treatment (Reduced intensity allogeneic stem cell transplant)|"Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.~Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan."
3247746|NCT00856375|Experimental|NKTR-102|NKTR-102
3247747|NCT00856375|Active Comparator|irinotecan|IV every 3 weeks
3247748|NCT00856362|Experimental|1|
3247749|NCT00856349||Analysis cohort|Enrolled subjects who met study eligibility criteria and contributed data toward study endpoints.
3247750|NCT00856323|Experimental|PEP/CM|Participants are provided contingency management vouchers for methamphetamine abstinence, and can initiate postexposure prophylaxis (Truvada; 1 pill daily for 28 days) after non-occupational exposure to HIV.
3247751|NCT00856310|Active Comparator|Cohort 1|Dose 1 REGN475
3247752|NCT00856310|Active Comparator|Cohort 2|Dose 2 of REGN475
3247753|NCT00856310|Active Comparator|Cohort 3|Dose 2 of REGN475
3247754|NCT00856310|Active Comparator|Cohort 4|Dose 1 of REGN475
3247755|NCT00856310|Active Comparator|Cohort 5|Dose 2 of REGN475
3247756|NCT00856310|Active Comparator|Cohort 6|Dose 1 REGN475 subcutaneous administration
3247757|NCT00856310|Active Comparator|Cohort 7|Dose 2 REGN475 subcutaneous administration
3247758|NCT00856297|Experimental|MenACWY-CRM|Subjects received one primary dose of MenACWY-CRM conjugate vaccine in the parent study and were followed for persistence in the present study.
3247759|NCT00856297|Active Comparator|Licensed comparator|Subjects received one primary dose of a quadrivalent meningococcal conjugate vaccine with diphtheria toxoid as the protein carrier in the parent study and were followed for persistence in the present study at 5 years postvaccination.
3247760|NCT00856297|Other|Naive|Subjects who were age-matched to the other study groups and had not received any previous meningococcal vaccinations.
3247761|NCT00856297|Experimental|MenACWY-CRM/MenACWY-CRM|Subjects received one primary dose of the MenACWY-CRM conjugate vaccine in the parent study and one booster dose of MenACWY-CRM conjugate vaccine at 3 years after primary vaccination.
3247762|NCT00856297|Experimental|Licensed comparator/MenACWY-CRM|Subjects received one primary dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine in the parent study and one booster dose of MenACWY-CRM conjugate vaccine at 3 years after primary vaccination.
3247763|NCT00856284|Experimental|Metformin + Alogliptin 12.5 mg|Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.
3247764|NCT00856284|Experimental|Metformin + Alogliptin 25 mg|Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.
3247765|NCT00856284|Active Comparator|Metformin + Glipizide|Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.
3247766|NCT00856271|Experimental|1|olmesartan medoxomil
3247767|NCT00856271|Active Comparator|2|losartan potassium
3247768|NCT00856258|Placebo Comparator|Cohort 1|Cohort 1 completed.
3247769|NCT00856258|Placebo Comparator|Cohort 2|Cohort 2 not studied
3247770|NCT00856258|Placebo Comparator|Cohort 3|Cohort 3 not studied
3247771|NCT00856258|Placebo Comparator|Cohort 4|Cohort 4 not studied
3247772|NCT00856245|Other|Rituximab|Patients will be treated IV with rituximab at the rate of 50 milligrams per hour (mg/hour) for 1 hour. If patient tolerates the infusion, the rate is increased by increments of 50 mg/hour every 30 minutes to a maximum of 400 mg/hour. If patient has a severe reaction, the infusion is stopped temporarily and the infusion rate is decreased by 50%. Subsequent infusions are started at the rate of 100 mg/hour, increased by 100 mg/hour every 30 minutes to a maximum of 400 mg/hour if tolerated. Vital signs are monitored every 15 minutes for 2 hours and every 30 minutes thereafter.
3247773|NCT00856232|No Intervention|Standard therapy|Standard emergency department evaluation and treatment for headache
3247774|NCT00856232|Placebo Comparator|Medical Air|Air inhalation at 15L / min x 15 minutes followed by standard emergency department evaluation and treatment for headache
3247775|NCT00856232|Experimental|Oxygen|Oxygen inhalation at 15 L/min for 15 minutes followed by standard emergency department evaluation and treatment for headache
3247776|NCT00856219|Active Comparator|Enteral Continuous|Continuous tube feeding for 72 hours.
3247777|NCT00856219|Active Comparator|Enteral Intermittent|Intermittent tube feedings for 72 hours
3248248|NCT00852683|Placebo Comparator|B|
3247779|NCT00856206|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
3247780|NCT00856206|Experimental|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
3247781|NCT00856193|Placebo Comparator|Placebo then NVA237 50μg|Placebo 50 μg capsules followed by NVA237 50 μg capsules for inhalation once daily with Concept 1 device.
3247782|NCT00856193|Experimental|NVA237 50μg then placebo|NVA237 50 μg capsules followed by matching placebo 50 μg capsules for inhalation once daily with Concept 1 device.
3247783|NCT00856180|Experimental|Bevacizumab then Cyclophosphamide with Bevacizumab|Patients were given a regimen of sequential antiangiogenic blockade and disease assessed serologically and radiologically every 2 cycles/6 weeks. Patients started with bevacizumab 15 mg/kg IV every 3 weeks until they experienced progressive disease (PD) [RECIST 1.0 or Rustin criteria] or significant toxicity. If clinically stable as assessed by their treating physician, patients then received cyclophosphamide 50 mg orally (PO) daily continuously with bevacizumab treatment. If second PD occurred, patients discontinued the combination treatment.
3247784|NCT00856167|Active Comparator|TCM|Whole systems traditional Chinese medicine, including individually tailored herbal formulas, acupuncture, tuna (Chinese massage), lifestyle recommendations
3247785|NCT00856167|Active Comparator|Self-care|Self-care for TMD developed by Dworkin, LeResche et al.
3247786|NCT00856141|Experimental|1. High fluidic parameters|Bottle height varied from 90-110cms, fixed aspiration flow rate 40cc/min, vacuum upto 650mmHg depending on the grade of cataract
3247787|NCT00856141|Active Comparator|2. Low fluidic parameters|Bottle height varied from 70-90cms, fixed aspiration flow rate of 25cc/min, vacuum upto 400mmHg, depending on the grade of cataract
3247788|NCT00856115||African American Female|
3247789|NCT00856115||African American Male|
3247790|NCT00856115||Caucasian Female|
3247791|NCT00856115||Caucasian Male|
3247792|NCT00856102|Experimental|Exercise|
3247793|NCT00856102|No Intervention|Control|
3247794|NCT00856089|Experimental|Retapamulin|
3247795|NCT00856076||VTE case group 1/2|Women with first time venous thromboembolism in pregnancy. VTE data validated from medical records.
3247796|NCT00856076||VTE control group 1|All pregnancies of source population - clinical data from the Norwegian Birth Registry and the Norwegian Patient Registry.
3247797|NCT00856076||VTE control group 2|Randomly drawn from group 1 (using the Norwegian Birth Registry), but matched for time of delivery. Without history of venous thromboembolism, and with validated data from medical records.
3247798|NCT00856076||VTE case group 3|Subjects from VTE case group 1/2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
3247799|NCT00856076||VTE control group 3|Subjects from VTE control group 2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
3247800|NCT00856076||IUFD group 1|Women who have experienced IUFD - data verified from medical records.
3247801|NCT00856076||IUFD group 2|Subjects from IUFD group 2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
3247802|NCT00856076||IUFD control group 1|All pregnancies of source population - clinical data from the Norwegian Birth Registry and the Norwegian Patient Registry.
3247803|NCT00856076||IUFD control group 2|Subjects from VTE control group 1/2 with validated data from medical records.
3247804|NCT00856076||IUFD control group 3|Subjects from VTE control group 3 invited to answer a disease specific questionnaire for IUFD.
3247805|NCT00856050|Experimental|letrozole|single arm trial - all patients received letrozole 2.5mg by mouth per day
3247806|NCT00856037|Experimental|Treatment (doxorubicin hydrochloride, topotecan hydrochloride)|Patients receive doxorubicin hydrochloride IV over 3-5 minutes on day 6 of course 1 and on days 6, 13, and 20 of courses 2-5. Patients also receive topotecan hydrochloride PO on days 1-5. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
3247807|NCT00856024||Group 1: Naïve patients|Patients, from Brazil, with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin and who previous to this treatment had not been treated with peginterferon alfa-2b.
3247808|NCT00856024||Group 2: Re-treatment|Patients, from Brazil, with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin and who previous to this treatment had been considered nonresponders or relapsing to prior treatment for chronic hepatitis C.
3247809|NCT00856024||Group 3: HIV/HCV co-infected patients|Patients, from Brazil, with confirmed chronic hepatitis C and infected with Humman Immunodeficiency Virus (HIV) who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin.
3247810|NCT00856011||1|Diabetic patients with carpal tunnel syndrome
3247811|NCT00856011||2|Non-diabetic patients with carpal tunnel syndrome
3247812|NCT00855998||1|With BRCA1 or BRCA2 mutations
3247813|NCT00855998||2|Without BRCA1 or BRCA2 mutations
3247814|NCT00855985|Active Comparator|1|Pancreaticojejunostomy for reconstruction after pancreaticoduodenectomy
3247815|NCT00855985|Active Comparator|2|Pancreaticogastrostomy for reconstruction after pancreaticoduodenectomy
3247816|NCT00855959|Experimental|1|Four weeks treatment with either Pulmicort Turbuhaler at a dose of 400 μg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily
3247817|NCT00855959|Experimental|2|Pulmicort Turbuhaler at a dose of 200 μg twice daily and Pulmicort Respules at a dose of 0.5 mg twice daily or 1.0 mg once daily (low dose)
3247818|NCT00855933|No Intervention|Control - no flossing|Subjects brushed thoroughly for one minute with Crest® Cavity Protection toothpaste and an Oral-B® Indicator soft, manual toothbrush once daily.
3247819|NCT00855933|Experimental|Experimental Floss|Subjects brushed thoroughly for one minute with Crest® Cavity Protection toothpaste and an Oral-B® Indicator soft, manual toothbrush once daily. Subjects flossed once daily with the experimental floss.
3247820|NCT00855920|Active Comparator|Placebo (for Rilonacept) and Indomethacin|Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 with Indomethacin orally thrice a day (TID) for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
3247821|NCT00855920|Active Comparator|Rilonacept and Indomethacin|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 with Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
3247822|NCT00855920|Active Comparator|Rilonacept and Placebo (for Indomethacin)|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 with Placebo (for Indomethacin) orally TID for 12 days.
3247823|NCT00855907||cases|IBD patients above the age of 18 years old, suffering from the disease for at least one year.
3247824|NCT00855894|Experimental|Pertuzumab + erlotinib|Patients received pertuzumab 840 mg intravenously (IV) 1 time (loading dose) followed by 420 mg IV (maintenance dose) every 3 weeks (q3w) plus erlotinib 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.
3247825|NCT00855881|Experimental|Treatment arm|Treated with tegafur-uracil for 1 year
3247826|NCT00855855||Hib vaccine|Participants has received at least one dose of an Hib vaccine
3247827|NCT00855842|Experimental|osmotic dilator|osmotic dilator
3247828|NCT00855829|Active Comparator|Miniature Actilady device active|one miniature Actilady device tested for all patients during a 4 months period. The device is active in 3 months out of the 4, and the patients are blinded to the action of the device (sham comparator).
3247829|NCT00855829|Sham Comparator|Miniature Actilady device not active|Sham Comparator: one miniature Actilady device tested for all patients during a 4 months period. The device is active in 3 months out of the 4, and the patients are blinded to the action of the device (sham comparator).
3247830|NCT00855816|Experimental|Breathing training|relaxation training
3247831|NCT00855816|No Intervention|Treatment as usual|treatment as usual
3247832|NCT00855803|Experimental|Group 1 radiation|"Intervention:~Patients had prior radiotherapy will undergo 5 fractions of stereotactic body radiotherapy (SBRT) over 30-90 minutes each."
3247833|NCT00855803|Experimental|Group 2 radiation|"Intervention:~Patients has no prior radiotherapy will undergo 1 fraction of SBRT over 30-90 minutes."
3247834|NCT00855790|Active Comparator|RJ3 Biopsy Forcep|use of RJ3 Biopsy forcep for the polypectomy
3247835|NCT00855790|Active Comparator|RJ4 Biopsey Forcep|Use of RJ$ biopsy forcep for polypectomy
3247836|NCT00855777|Experimental|Etoricoxib|Etoricoxib 120 mg/day x 3 days
3247837|NCT00855777|Active Comparator|Ibuprofen|Ibuprofen 1800 mg/day x 3 days
3247838|NCT00855764|Experimental|Paclitaxel|
3247839|NCT00855738|Other|1.0|
3247840|NCT00855712|Experimental|Organ Care System|
3247841|NCT00855712|Active Comparator|Cold cardioplegia solution|
3247842|NCT00855686|Experimental|Memantine|
3247843|NCT00855686|Placebo Comparator|Placebo|
3247844|NCT00855673|Experimental|Active|Active group receiving intermittent compression
3247845|NCT00855673|Active Comparator|Control|Standard Medical Treatment
3247846|NCT00855660|Active Comparator|Riociguat|Subjects received multiple doses of riociguat (thrice a day) with concomitant administration of ranitidine (once daily) for 14 days
3247847|NCT00855660|Placebo Comparator|Placebo|Subjects received placebo (thrice a day) with concomitant administration of ranitidine (once daily) for 14 days
3247848|NCT00855634|Active Comparator|1|"COHORT 1 (minimal metastatic disease):~Arm 1 (intervention): resection of the primary tumor, followed by resection of the liver metastasis/metastases~Arm 2 (control): exploration and/or gastroenterostomy and/or hepaticojejunostomy/choledochojejunostomy"
3247849|NCT00855634|Active Comparator|2|"COHORT 2 (venous infiltration):~Arm 1 (intervention): resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV)~Arm 2 (control): resection of the primary tumor with dissection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV) plus tumor masses adjacent to these veins; no venous resection"
3247850|NCT00855621|Active Comparator|Single microelectrode|Surgical procedure performed using single microelectrode recording guidance intraoperatively
3247851|NCT00855621|Active Comparator|Multiple microelectrode|Surgical procedure performed using multiple microelectrode recording guidance intraoperatively
3247852|NCT00855608|Experimental|adalimumab arm|intravitreal mode of delivery
3247853|NCT00855595|Experimental|Azelaic acid (Finacea, BAY39-6251) plus Doxycycline (Oracea)|Participants received topical azelaic acid gel 15% twice daily and doxycycline 40 mg once daily for 12 weeks
3247854|NCT00855595|Active Comparator|Metronidazole (Metrogel) plus Doxycycline (Oracea)|Participants received topical metronidazole 1% gel once daily and doxycycline 40 mg once daily for 12 weeks
3247855|NCT00855582|Experimental|Tadalafil 2.5 mg|
3247856|NCT00855582|Experimental|Tadalafil 5 mg|
3247857|NCT00855582|Placebo Comparator|Placebo|
3247858|NCT00855569||1|Each donor site will act as it own control - both dressings will be applied to the donor site and assessments will be made
3247859|NCT00855530|Experimental|1|
3247860|NCT00855517|Experimental|Punctal Plug|
3247861|NCT00855504||Subjects|All the consecutive primigravidae who register in the antenatal clinic before 20 weeks of gestation
3247862|NCT00855491|Experimental|1. MYOPIA|axial length > 26.00 mm
3247863|NCT00855491|Active Comparator|2. Emmetropia|emmetropic eyes- eyes with an axial length of 21.00 to 23.99 mm
3247864|NCT00855478|Experimental|1|Cypher drug-eluting stent
3247865|NCT00855465|Experimental|Riociguat (Adempas, BAY63-2521)_individual dose titration|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 16 weeks
3247866|NCT00855465|Placebo Comparator|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 16 weeks
3247867|NCT00855439|Experimental|Exenatide|Subjects will take exenatide by subcutaneous injection twice daily for 18 months
3247868|NCT00855439|Active Comparator|glargine|Subjects will take 1 daily injection of insulin glargine for 18 months.
3247869|NCT00855413|Other|Darunavir/Ritonavir and Etravirine|"Darunavir/Ritonavir 800 mg/100 mg orally once daily.~ETR will be given 200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen."
3247870|NCT00855400|Experimental|Transplant|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
3247871|NCT00855387||Costs|Patients collected consecutively for undergoing major surgical procedures(liver, bile duct, pancreas, small bowel, colo-rectal, gastric bypass resections).
3247872|NCT00855361|Experimental|Rabeprazole sodium|
3247873|NCT00855348||Adults > 50 Years Scheduled for Colonscopy|Average to increased risk adults older than 50 years without symptoms indicative of CRC and designated for colonoscopy.
3247874|NCT00855335|Experimental|Group 1: Darunavir 600 /Ritonavir 100|TMC114 (darunavir) Two 300 milligram (mg) or one 600 mg tablet twice daily up to 12 weeks postpartum / ritonavir one 100 mg tablet twice daily with darunavir up to 12 weeks postpartum.
3247875|NCT00855335|Experimental|Group 2: Darunavir 800/Ritonavir 100|TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum/ ritonavir one 100 mg tablet once daily with darunavir up to 12 weeks postpartum.
3247876|NCT00855335|Experimental|Group 3: Etravirine|TMC125 (etravirine) 200 mg (1*200 mg/2*100 mg) tablets twice daily up to 12 weeks postpartum.
3247877|NCT00855335|Experimental|Group 4: Rilpivirine|TMC278 (rilpivirine) One 25 mg tablet once daily up to 12 weeks postpartum.
3247878|NCT00855335|Experimental|Group 5: Darunavir 800/Cobicistat 150|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
3247879|NCT00855322|Experimental|1|Gym group exercise intervention
3247880|NCT00855322|Experimental|2|Hydrotherapy group exercise intervention
3247881|NCT00855322|No Intervention|3|Control group
3247882|NCT00855309|Experimental|Arm I|Patients receive weight-based IV acyclovir sodium every 8 or 12 hours.
3247883|NCT00855309|Experimental|Arm II|Patients receive low-dose IV acyclovir sodium every 8 or 12 hours.
3247884|NCT00855283|Experimental|Arm 1|SCI
3247885|NCT00855270|Placebo Comparator|saline|An IV injection of saline will be administered to the control group in a double blind, randomized manner.
3247886|NCT00855270|Experimental|Hydrocortisone|IV hydrocortisone will be given in a double blind random manner as the active treatment group
3247887|NCT00855257|Experimental|1|treatment by acid nicotinique
3247888|NCT00855257|Placebo Comparator|2|Treatment by placebo
3247889|NCT00855244|Other|BMT survivors|Diagnostic exams
3247890|NCT00855218|Experimental|Sorafenib (Nexavar, BAY43-9006) + TACE|Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Patients were then also treated with Transarterial Chemoembolization (TACE) performed with DC Bead (300 to 500 microns) and doxorubicin (150 mg) between 3 to 7 days after the first dose of sorafenib, TACE was also performed on Days 1 (+ 4 days) of cycle 1, 3, 7, 13 and then every 6 cycles thereafter (an optional TACE procedure could be performed between Day 1 of Cycle 7 and Cycle 13 and between Day 1 of Cycles 13 and 19, if deemed necessary by the Investigator.)
3247891|NCT00855218|Placebo Comparator|Placebo + TACE|Placebo was to be orally administered as 2 tablets bid (twice daily). Patients were then also treated with TACE performed with DC Bead (300 to 500 microns) and doxorubicin (150 mg) between 3 to 7 days after the first dose of placebo, TACE was also performed on Days 1 (+ 4 days) of cycle 1, 3, 7, 13 and then every 6 cycles thereafter (an optional TACE procedure could be performed between Day 1 of Cycle 7 and Cycle 13 and between Day 1 of Cycles 13 and 19, if deemed necessary by the Investigator.)
3247892|NCT00855205|Experimental|Treatment|Treatment with rituximab
3247893|NCT00855192|Experimental|mindfulness-based therapy|mindfulness-based meditation
3247894|NCT00855192|Experimental|interpersonal therapy|psycho-educational
3247895|NCT00855179|Active Comparator|Antistax film-coated tablets 360 mg|Patient to receive 2 tablets daily as a morning dose, each containing 360 mg Antistax
3247896|NCT00855179|Placebo Comparator|Placebo|Patient to receive 2 tablets identical to those containing 360 mg Antistax daily as a morning dose
3247897|NCT00855166|Experimental|A|Dapagliflozin 10 mg plus Metformin
3247898|NCT00855166|Placebo Comparator|B|Placebo plus Metformin
3247899|NCT00855153|Experimental|treatment|Subjects receive 50mg DCS prior to 90 min session with graded VRE treatment
3247900|NCT00855140|Placebo Comparator|Sham acupuncture|Sham acupuncture at non-active acupuncture points, using the Park Sham Device
3247901|NCT00855140|Experimental|Verum Acupuncture|Acupuncture following a specific TCM-based protocol
3247902|NCT00855127||Liver transplant recipients|
3247903|NCT00855114|Experimental|Patients Treated with Everolimus|Breast cancer patients treated with Everolimus by mouth, 5 mgs/day x 7 days, followed by surgery.
3247904|NCT00855101|Experimental|voriconazole|
3247905|NCT00855088|Experimental|Darunavir, ritonavir, etravirine|Single arm trial looking at the pharmacokinetics of darunavir, ritonavir, etravirine in healthy volunteers.
3247906|NCT00855075||Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
3247907|NCT00855062|Active Comparator|Minocycline|Minocycline 100 mg orally every 12 hours
3247908|NCT00855062|Placebo Comparator|Placebo|Placebo minocycline capsules every 12 hours
3247909|NCT00855049|Experimental|1|Intranasal acetaminophen administration
3247910|NCT00855049|Active Comparator|2|Oral acetaminophen administration
3247911|NCT00855036||Renal Injury|All patients who have a discernable injury to the renal parenchyma on CT scan from blunt trauma
3247912|NCT00855023||Asymptomatic Volunteers|healthy volunteer athletes and excluded those who had any of the following criteria: 1) counter-indications to magnetic resonance imaging (e.g., pregnancy or postsurgical hardware [plates, screws, aneurysm clip, implanted cardiac pacemaker, etc.]); (2) relevant medical problems (e.g., connective tissue problems, paralyzed hemidiaphragm, morbid obesity, claustrophobia, etc.); (3) clinical signs of an impairment or abnormality in the knee (e.g., abnormal range of motion, muscle weakness, or malalignment); (4) injury to the knee that required medical attention; (5) previous surgery on the knee; or (6) current pain in the knee.
3247913|NCT00855010|Experimental|pioglitazone|pioglitazone tablet 45 mg once daily
3247914|NCT00855010|Placebo Comparator|placebo pill|placebo pill once daily (look-alike pill which contains no active ingredients)
3247915|NCT00854997||1|AMI with OSA
3247916|NCT00854997||2|AMI without OSA
3247917|NCT00854984|Experimental|Self-help CBT|A nurse supported self-help CBT intervention in addition to usual care.
3247918|NCT00854984|No Intervention|Usual care|
3247919|NCT00854971|No Intervention|control|Oxaliplatin infusion (85mg/m2) on days 1 and 15 (every 2 weeks) 5-FU bolus + infusions (400 mg/m2) on days 1, 2, 15 and 16 LV infusions (200 mg/m2) on days 1, 2, 15 and 16
3247920|NCT00854971|Active Comparator|Active|FOLFOX-4 regimen + Infusion of TKCell(autologous activated lymphocyte) over 2x10^9 cells, IV route, 7 times
3247921|NCT00854945|Experimental|ON 01910.Na|1800 mg/day of ON 01910.Na administered as a 24-hour continuous intravenous infusion on days 1, 2 and 3 of 14-day cycle.
3247922|NCT00854932|Experimental|PCT group|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PCT values are within the normal range.Antibiotic therapy can be continued despite fulfilled criteria at the discretion of the attending physician. These divesions from the stopping rules will be reported for further analysis.
3247923|NCT00854932|No Intervention|Standard group|The duration of antibiotic treatment in the standard group is based on the attending physician's assessment of the risk of classification: infection unlikely for 36-72 hours, infection possible for 5-7 days, infection probable of proven for 7-21 days depending on clinical course, laboratory values and positive cultures.
3247924|NCT00854919|Experimental|CBT|All subjects received cognitive-behavioral therapy (CBT) during the study period.
3247925|NCT00854919|Experimental|1|Drug; Paroxetine (30-50mg/D)or Fluvoxamine (150-250mg/D), 1-year administration
3247926|NCT00854919|Active Comparator|2|Either risperidone (1-5mg/D), olanzapine (1-5mg/D) or quetiapine (25-100mg/D) was added to ongoing SSRI, the combination trial was continued at least for half a year.
3247927|NCT00854906||Keratometric Tear Breakup Time|These are the study participants whose tear break up times were measured with a keratometer.
3247928|NCT00854906||Fluorescein Break Up Time|These are the study participants whose tear break up times were measured with with fluorescein dye.
3247929|NCT00854893|Experimental|anodal|anodal stimulation: 20 min during language learning, intensity: 1 mV, anodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
3247930|NCT00854893|Experimental|cathodal|anodal stimulation: 20 min during language learning, intensity: 1 mV, cathodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
3247931|NCT00854893|Experimental|sham (placebo)|sham stimulation (placebo condition): 30 seconds during language learning, intensity: 1 mV, anodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
3247932|NCT00854867|Experimental|Whole brain radiotherapy (WBRT) with concomitant Depocyte|Subjects will receive a total of 38.4 Gray (Gy) WBRT given over 4 weeks. Subjects will receive 3 GyWBRT on Days 1 and 2 and then 1.8 Gy on the third fourth and fifth days of WBRT treatment during Week 1. Subjects will then receive 1.8 Gy WBRT per day; 5 days out of seven, each week for the next 3 weeks. A total of 4 doses of DepoCyte (50 mg of liposomal ARA-C) will be administered intrathecally. The first dose will be administered on Day 3 (or Day 4 or 5) of Week 1, i.e. the third day of radiotherapy treatment when the dosage is reduced to 1.8 Gy. The second dose will be administered on Day 17(+2 days); the third dose will be administered on Day 31 (+2 days); the fourth dose will be administered on Day 45 (+2 days) to complete the induction phase of the protocol. Subjects will continue to receive an additional 6 doses of DepoCyte one dose every 28 days (+2 days) during the maintenance period. The first dose will be given 28 days after the last dose in the induction phase.
3247933|NCT00854867|Active Comparator|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|Subjects will receive a total of 38.4 Gy WBRT given over 4 weeks. Subjects will receive 3 Gy (WBRT on Day 1 and Day 2) and then 1.8 Gy on the third fourth and fifth days of WBRT treatment during Week 1. Subjects will then receive 1.8 Gy WBRT per day; 5 days out of seven, each week for the next 3 weeks. A total of 4 doses of DepoCyte (50 mg of liposomal ARA-C) will be administered intrathecally. The first dose will be administered on Day 29 (+2 days); the second dose will be administered on Day 43(+2 days); the third dose will be administered on Day 57 (+2 days); the fourth dose will be administered on Day 71 (+2 days) to complete the induction phase of the protocol. DepoCyte should never be administered more frequently than every 14th day. Subjects will continue to receive an additional 6 doses of DepoCyte one dose every 28 days (+2 days) during the maintenance period. The first dose will be given 28 days after the last dose in the induction phase.
3247934|NCT00854854|No Intervention|Control|"Oxaliplatin infusion (100mg/m2) on days 1 and 15 (every 2 weeks)~5-FU bolus + infusions (400 mg/m2) on days 1, 2, 15 and 16~LV infusions (200 mg/m2) on days 1, 2, 15 and 16"
3247935|NCT00854854|Active Comparator|Active|"Infusion of TKCell(autologous activated lymphocyte) over 2x10^9 cells, IV route, 7 times~and chemotherapy schedule"
3247936|NCT00854828|Active Comparator|Surgical Intervention|
3247937|NCT00854828|Active Comparator|Non-Operative Intervention|
3247938|NCT00854815|Active Comparator|Irrigation|Irrigation of the area with at least 500ml normal saline using the power suction/irrigator
3247939|NCT00854815|Active Comparator|No Irrigation|Only suction with the power suction/irrigator without saline attached
3247940|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 48 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 47 weeks + peg-IFNα2a 180 µg subcutaneously (sc) once weekly for 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 48 weeks.
3247941|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 24 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 23 weeks + peg-IFNα2a 180 µg sc once weekly for 24 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 24 weeks.
3247942|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 24 or 48 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 23 or 47 weeks + peg-IFNα2a 180 µg sc once weekly for 24 or 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 24 or 48 weeks. Participants who achieve a rapid viral response, defined as having undetectable hepatitis C virus RNA at week 4, are treated for 24 weeks; other patients are treated for 48 weeks.
3247943|NCT00854802|Placebo Comparator|Debio 025 placebo + peg-IFNα2a + ribavirin - 48 weeks|Participants receive Debio 025 placebo orally twice daily for 7 days followed by Debio 025 placebo orally once daily for 47 weeks + peg-IFNα2a 180 µg subcutaneously (sc) once weekly for 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 48 weeks.
3248249|NCT00852670|Experimental|A|
3247944|NCT00854789|Experimental|Vaccine|HLA-A2+ and HLA-A3+ patients are administered the E75+GM-CSF vaccine.
3247945|NCT00854789|No Intervention|Control/observation|HLA-A2- and HLA-A3- patients are prospectively followed for disease recurrence. Control patients are not vaccinated.
3247946|NCT00854776|Active Comparator|1|Upper GI tract symptoms are evaluated. Patients are asked to report to gastroenterologist if they have persistent ulcer symptoms and to report to the emergency room if they have evidence of GI bleeding or ulcer complications (melena, hematemesis, or sudden onset of severe epigastric pain). Endoscopy will be undergone to document any gastroduodenal ulcers with or without ulcer complications. If the hemoglobin level has decreased by 2g/dL or more, or stool check shows occult blood at each visit, endoscopy will be undergone to check the presence of gastroduodenal ulcers with or without bleeding. Patients without persistent ulcer symptoms or without evidence of ulcer complications will be invited to undergone scheduled endoscopy at the 3-month end of follow-up in each subjective.
3247947|NCT00854776|Placebo Comparator|2|Upper GI tract symptoms are evaluated at each visit. Patients are asked to report to gastroenterologist if they have persistent ulcer symptoms and to report to the emergency room if they have evidence of GI bleeding or ulcer complications (melena, hematemesis, or sudden onset of severe epigastric pain). Endoscopy will be undergone to document any gastroduodenal ulcers with or without ulcer complications. An ulcer is defined as a circumscribed mucosal break at least 3 mm in diameter. If the hemoglobin level has decreased by 2g/dL or more, or stool check shows occult blood at each visit, endoscopy will be undergone to check the presence of gastroduodenal ulcers with or without bleeding. Patients without persistent ulcer symptoms or without evidence of ulcer complications will be invited to undergone scheduled endoscopy at the 3-month end of follow-up in each subjective.
3247948|NCT00854763||Hypertension|
3247949|NCT00854750|Experimental|ACTHAR- placebo first|Placebo, 20 mg, 40 mg, 80 mg
3247950|NCT00854750|Experimental|ACTHAR- placebo second|20mg, Placebo, 40 mg, 80mg
3247951|NCT00854750|Experimental|ACTHAR- placebo third|20 mg, 40 mg, Placebo, 80 mg
3247952|NCT00854750|Experimental|ACTHAR- placebo fourth|20 mg, 40 mg, 80 mg, Placebo
3247953|NCT00854737|Active Comparator|1|Omega-3 fatty acid and cytidine supplementation
3247954|NCT00854737|Active Comparator|2|omega-3 fatty acid supplementation
3247955|NCT00854737|Placebo Comparator|placebo|placeno or sugar pill
3247956|NCT00854724|Active Comparator|Puerarin|
3247957|NCT00854724|Placebo Comparator|Placebo|Sugar beet filler in capsule
3247958|NCT00854711|Experimental|nitric oxide|inhaled nitric oxide 80 ppm and oxygen
3247959|NCT00854711|Placebo Comparator|standart of care|no intervention
3247960|NCT00854698|Experimental|Group with MVA|
3247961|NCT00854698|Other|group without MVA|
3247962|NCT00854685|Experimental|1|
3247963|NCT00854685|Experimental|2|
3247964|NCT00854685|Experimental|3|
3247965|NCT00854685|Experimental|4|
3247966|NCT00854685|Placebo Comparator|5|
3247967|NCT00854685|Placebo Comparator|6|
3247968|NCT00854672||sarcoidosis patients|Sarcoidosis patients referred to the ild care team of the outpatient clinic of the department of Respiratory Medicine of the MUMC and also participated in the baseline study between November 2008 and September 2009 will be included in this study
3247969|NCT00854659|Active Comparator|1|ABT-102 Tablets, 4 mg BID
3247970|NCT00854659|Active Comparator|2|ABT-102 Tablets BID, escalating dose
3247971|NCT00854659|Active Comparator|3|ABT-102 Tablets BID, escalating dose
3247972|NCT00854659|Placebo Comparator|4|Placebo Tablets, BID
3247973|NCT00854646|Experimental|ON 01910.Na|The starting dose is 650 mg/m2 per day for 3 continuous days every 2 weeks. In successive courses, infusion time may be increased by 1 day up to 7 days every two weeks and/or drug dose may be increased (650, 1050, 1700 mg/m2/day, etc.). After 4 2-week cycles, cycle length may be extended to 3 or 4 weeks. Treatment continues until evidence of disease progression, intolerable adverse events or withdraw of consent.
3247974|NCT00854633|Experimental|1|Talactoferrin
3247975|NCT00854633|Placebo Comparator|2|Placebo
3247976|NCT00854620|Experimental|Sorafenib|"Cycle 1: 400 mg BID sorafenib~Cycle 2: 600 mg BID sorafenib~Cycle 3+: 800 mg BID sorafenib"
3247977|NCT00854607||Invasive Aspergillosis|Observational
3247978|NCT00854594|No Intervention|Control|Control sites will receive the baseline measures pre and post. These sites will receive traditional diabetes education, which includes teleconsultation.
3247979|NCT00854594|Experimental|ReSPECT Intervention|Intervention sites will receive baseline measures pre and post, but also in-depth Shared Medical Appointments (SMA)(The Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT) intervention) and at 15 months SMA video conferences. At the end of the 18 months the randomly selected patients and providers will be asked to take part in a qualitative interview.
3247980|NCT00854581|Experimental|Induction (Up to Day 21)|"For one cycle, up to Day 21. All participants are enrolled to induction therapy phase, then move to the maintenance therapy phase if they achieve complete response (PR) or partial response (PR). Participants who achieve a clinical CR at Day 14 response assessment will go on to Part 1 maintenance therapy. Patients who achieve a PR will receive 7 more days of induction therapy and then go on to Part 1 Maintenance Therapy.:~Zidovudine:~Days 1-2: 1.5 grams intravenously (IV) twice daily~Days 3-21: 1.5 grams IV twice daily~Interferon alfa-2b (IFN):~5 10 million units (mu) intravenously twice daily"
3247981|NCT00854581|Experimental|Part 1 Maintenance (Up to Day 60)|"From Treatment Day 14 or 21 to start of Month 3 (Day 60). Study participants move on to Part 1 Maintenance Therapy only if they achieve complete response (CR) or partial response (PR) after induction therapy. Restaging and molecular evaluation of disease at start of Month 3:~Zidovudine: 600 mg orally twice daily in all phases of Maintenance Therapy~PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly~Participants then proceed to Part 2 maintenance."
3247982|NCT00854581|Experimental|Part 2A Maintenance (Up to 12 Months)|"Participants achieving a CR with undetectable clonal disease. Participants will receive therapy for as long as response is maintained:~Zidovudine: 600 mg orally twice daily~PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly"
3248041|NCT00854022||Healthy|Healthy adults, of any ethnicity, or sex, and with no previous history of cancer, except for non-melanoma skin cancer
3248100|NCT00853619|Active Comparator|Normal CDS interventions at PHS and RI|Normal CDS intervention at both PHS and RI hospitals
3247983|NCT00854581|Experimental|Part 2B Maintenance (Up to 12 Months)|"Participants achieving a CR with minimal residual disease (by multiplex PCR) or PR in Part 1:~Zidovudine: 600 mg or 300 mg orally twice daily, per protocol~PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly, per protocol~Valproic acid, 250 mg orally twice daily, per protocol"
3247984|NCT00854568|Experimental|CEOP regimen|CEOP regimen
3247985|NCT00854568|Active Comparator|CHOP regimen|CHOP regimen
3247986|NCT00854555|Experimental|robot|30 persons with incomplete SCI who live within driving distance to Oslo and who meet the inclusion/exclusion criteria will be selected for randomization to robotic assisted training or control (conventional treatment). Intervention consists of locomotor training with robot for 60 days during 6 months period in an out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
3247987|NCT00854555|Experimental|manual assistance|30 persons with incomplete SCI who live outside driving distance to Oslo and who meet inclusion/exclusion criteria will be selected for manually assisted training in Tromsø or control (conventional treatment). Intervention consists of 60 days locomotor training with manual assistance during 6 months period in an in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
3247988|NCT00854542|Active Comparator|TCSCT|
3247989|NCT00854542|Placebo Comparator|Usual Care|
3247990|NCT00854529|Experimental|1|20 patients who had an uneventful trabeculectomy with usage of mitomycin C, will receive subconjunctival bevacizumab 1 week after the surgery
3247991|NCT00854529|Active Comparator|2|20 patients who had an uneventful trabeculectomy with usage of mitomycin C, will receive subconjunctival bevacizumab 2 weeks after the surgery
3247992|NCT00854529|No Intervention|3|20 patients after an uneventful trabeculectomy with usage of mitomycin C, will not receive any bevacizumab injection.
3247993|NCT00854503|Active Comparator|Simvastatin|Simvastatin 20 mg/day
3247994|NCT00854503|Active Comparator|Rosuvastatin|Rosuvastatin 20 mg/day
3247995|NCT00854451|Active Comparator|1 omeprazole plus amoxicillin|omeprazole 20mg bid 2wk + amoxicillin 500mg qid 2wk
3247996|NCT00854451|Active Comparator|2 omeprazole plus amoxicillin|omeprazole 20mg bid 2wk + amoxicillin 250mg qid 2wk
3247997|NCT00854451|Active Comparator|3 omeprazole plus amoxicillin|omeprazole 20mg qd 2wk + amoxicillin 500mg qid 2wk
3247998|NCT00854451|Active Comparator|4 omeprazole plus amoxicillin|omeprazole 20mg qd 2wk + amoxicillin 250mg qid 2wk
3247999|NCT00854438|Experimental|Active treatment arm|Reduction of anticholinergic drug effects by pharmacist review
3248000|NCT00854438|No Intervention|Control|No intervention
3248001|NCT00854425|Experimental|L-asp|
3248002|NCT00854386|Active Comparator|1|liberal fluid administration group
3248003|NCT00854386|Experimental|2|Restrictive fluid administration group
3248004|NCT00854373|Experimental|1|Bravelle
3248005|NCT00854373|Placebo Comparator|2|Saline
3248006|NCT00854360|Experimental|BDP HFA 80 µg/day|During the 2-week double-blind Treatment Period participants self-administered two actuations (one per nostril) of 40 micrograms (µg) BDP HFA and two actuations of placebo HFA once daily.
3248007|NCT00854360|Experimental|BDP HFA 160 µg/day|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of 40 µg BDP HFA once daily.
3248008|NCT00854360|Experimental|BDP HFA 320 µg/day|During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.
3248009|NCT00854360|Placebo Comparator|Placebo|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.
3248010|NCT00854334||1.|Children with both obesity and obstructive sleep apnea
3248011|NCT00854334||2|Children without the presence of both obesity and obstructive sleep apnea
3248012|NCT00854321||patients with active RA|drug, follow-up
3248013|NCT00854308|Experimental|MetMAb + Erlotinib|MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity.
3248014|NCT00854308|Placebo Comparator|Placebo + Erlotinib|Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity.
3248015|NCT00854295|Other|1|Follow-up of existing IDE study subjects
3248016|NCT00854295|Other|2|Newly enrolled study subjects
3248017|NCT00854256|Experimental|Canaloplasty|
3248018|NCT00854256|Active Comparator|Trabeculectomy with mitomycin C|
3248019|NCT00854230|Experimental|1|Naltrexone
3248020|NCT00854230|Placebo Comparator|2|
3248021|NCT00854217|Placebo Comparator|placebo, hemodilution|
3248022|NCT00854191|Experimental|1|4 half-day of simulator ERCP practice and usual training
3248023|NCT00854191|Active Comparator|2|Usual training
3248024|NCT00854178|Experimental|2|
3248025|NCT00854152|Experimental|1|
3248026|NCT00854139|Experimental|Bone marrow and renal transplant|Cyclophosphamide, anti-thymocyte globulin, thymic irradiation conditioning and kidney transplant and bone marrow transplant from a related donor for patients with multiple myeloma and end stage renal disease with cyclosporine for graft versus host disease prophylaxis
3248027|NCT00854126|Experimental|1|
3248028|NCT00854113|Experimental|EGT0001474|Ascending doses of EGT0001474
3248029|NCT00854113|Placebo Comparator|Placebo|Placebo
3248030|NCT00854100|Placebo Comparator|1|Drug: Antidepressant + Placebo
3248031|NCT00854100|Experimental|2|Drug: Antidepressant + cariprazine low dose
3248032|NCT00854100|Experimental|3|Drug: Antidepressant + cariprazine high dose
3248033|NCT00854087|Active Comparator|Fuzheng Huayu|Pill with Fuzheng Huayu
3248034|NCT00854087|Placebo Comparator|Placebo|Pill without Fuzheng Huayu (sugar pill)
3248035|NCT00854074|No Intervention|2|Subject will be observed until recovery of normal GI function
3248036|NCT00854074|Experimental|1|Spinal neurostimulation
3248037|NCT00854061|Experimental|T-Pred|Tobramycin prednisolone acetate combination
3248038|NCT00854061|Active Comparator|Pred Forte|Prednisolone acetate
3248039|NCT00854035|Experimental|E|
3248040|NCT00854035|Placebo Comparator|P|
3248101|NCT00853606|Experimental|avanafil|
3248042|NCT00854022||RCC|Adult patients with newly diagnosed (diagnosed within the year of enrollment) renal carcinoma (RCC) any ethnicity, or sex, who have not received prior chemotherapy or radiotherapy.
3248043|NCT00854009|Experimental|1|BLI-489
3248044|NCT00854009|Placebo Comparator|2|Placebo
3248045|NCT00853996|Experimental|Prevention (acolbifene hydrochloride)|Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
3248046|NCT00853970|Experimental|Bromfenac ophthalmic solution 0.09%|dosed 1 drop daily in study eye for 2 weeks
3248047|NCT00853970|Placebo Comparator|Placebo|dosed 1 drop daily in study eye for 2 weeks
3248048|NCT00853957|Experimental|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
3248049|NCT00853957|Active Comparator|Amlodipine|Amlodipine 5mg titrated to 10 mg
3248050|NCT00853944|No Intervention|P|subjects take 1 tablet of placebo daily
3248051|NCT00853944|Experimental|S|subjects take 1 tablet of sitagliptin 100 mg daily
3248052|NCT00853931|Experimental|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 [i.e. Cycles 1, 2, 3, etc.]) until disease progression or intolerance panitumumab as determined by the investigator.
3248053|NCT00853918|Experimental|$20 Cash|
3248054|NCT00853918|Experimental|$50 Cash|
3248055|NCT00853918|Experimental|$50 Check|
3248056|NCT00853918|Experimental|$100 Check|
3248057|NCT00853905|Experimental|Treatment 1(Triesence)|glaucoma surgery with 0.2cc Triesence adjunct.
3248058|NCT00853905|Active Comparator|Treatment 2 (balanced salt solution BSS)|glaucoma surgery with balanced salt solution, the standard technique.
3248059|NCT00853892|Experimental|A|Controlled-Release Oxycodone Hydrochloride 40 mg tablet
3248060|NCT00853892|Active Comparator|B|OxyContin® 40 mg tablet
3248061|NCT00853879|Active Comparator|Arm 1. B6, B12, folate|Triple therapy with folate. Intervention #1.
3248062|NCT00853879|Active Comparator|Arm 2. B6, B12, L-methylfolate|Triple therapy with L-methylfolate. Intervention #2
3248063|NCT00853879|Placebo Comparator|Arm 3. B6, B12, Placebo|Triple therapy with placebo. Intervention #3.
3248064|NCT00853866|Experimental|1|reboxetine + tDCS verum
3248065|NCT00853866|Experimental|2|reboxetine + sham tDCS
3248066|NCT00853866|Experimental|3|placebo drug + verum tDCS
3248067|NCT00853866|Experimental|4|placebo drug + sham tDCS
3248068|NCT00853853|Active Comparator|1. EnSeal Device|The EnSeal device cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding. The device is able to seal blood vessels up to 7mm and hemorrhoidal vessels are much smaller than this size.
3248069|NCT00853853|Active Comparator|2. Ferguson Hemorrhoidectomy|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced.
3248070|NCT00853840|Experimental|1.|Maraviroc + Vardenafil
3248071|NCT00853840|Placebo Comparator|2.|Maraviroc + Placebo
3248072|NCT00853827|Placebo Comparator|1|
3248073|NCT00853827|Experimental|2|Aliskiren 300 mg
3248074|NCT00853814|Experimental|Reduced access to sedentary behaviors, High park access|
3248075|NCT00853814|Experimental|Usual access to sedentary behaviors, High park access|
3248076|NCT00853814|Experimental|Reduced access to sedentary behaviors, Low park access|
3248077|NCT00853814|Experimental|Usual access to sedentary behaviors, Low park access|
3248078|NCT00853801|Experimental|1|Lifestyle modification education and counseling for intervention patients. Diagnosis and treatment education and feedback on performance for providers of intervention patients.
3248079|NCT00853775||African American Families|Families with 2 parents and 2 children - no intervention, observational study
3248080|NCT00853775||Caucasian Families|Families with 2 parents and 2 children - no intervention, observational study
3248081|NCT00853762|Experimental|Atacicept 25 mg (With Loading)|
3248082|NCT00853762|Experimental|Atacicept 75 mg (With Loading)|
3248083|NCT00853762|Experimental|Atacicept 150 mg (With Loading)|
3248084|NCT00853762|Experimental|Atacicept 150 mg (Without Loading)|
3248085|NCT00853749|Other|Single|All subjects will receive a single dose of 13vPnC
3248086|NCT00853736|Experimental|A|Oxycodone hydrochloride tablet 30 mg
3248087|NCT00853736|Active Comparator|B|Roxicodone™ tablet 30 mg
3248088|NCT00853723|Experimental|PTHrP 400 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months.
3248089|NCT00853723|Experimental|PTHrP 600 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months.
3248090|NCT00853723|Active Comparator|PTH 20 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months.
3248091|NCT00853710|Experimental|rapid PSA assay on whole blood|
3248092|NCT00853697|Experimental|testosterone with the 5α-reductase inhibitor dutast|This trial is a multi-center, open-label, phase II trial of the combination of exogenous testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride in patients with castration-resistant metastatic prostate cancer.
3248093|NCT00853684|Experimental|oxaliplatin, capecitabine plus endostar|
3248094|NCT00853658|Experimental|Combination Aliskiren / Enalapril|Aliskiren / Enalapril combination therapy-150 mg/10 mg titrated to 300 mg/ 10 mg film-coated tablets and administered orally.
3248095|NCT00853658|Experimental|Aliskiren|Aliskiren monotherapy - 150 mg titrated to 300 mg film-coated tablets and administered orally.
3248096|NCT00853658|Active Comparator|Enalapril|Enalapril monotherapy -10 mg film-coated tablet and administered orally.
3248097|NCT00853645|Experimental|S-ICD System|Single-arm with 6 patients implanted with an S-ICD System
3248098|NCT00853632|Other|Device - CEP Mitral Valve|
3248099|NCT00853619|Experimental|Services Demo at PHS and RI|Service based CDS intervention at PHS.
3248103|NCT00853580|Placebo Comparator|2|This is a prospective multi-centre randomized, placebo-controlled Phase II study to determine the efficacy of Lovastatin ™ on visual spatial learning and/or attention abilities of children with NF1 aged between 8 and less than 16 years. In addition, the effect of Lovastatin ™ on secondary measures of executive function, visual spatial skills, behavior and quality of life will be assessed. Participants will be randomized to 16-weeks of treatment with Lovastatin ™ or a matched placebo.
3248104|NCT00853580|Experimental|1|This is a prospective multi-centre randomized, placebo-controlled Phase II study to determine the efficacy of Lovastatin ™ on visual spatial learning and/or attention abilities of children with NF1 aged between 8 and less than 16 years. In addition, the effect of Lovastatin ™ on secondary measures of executive function, visual spatial skills, behavior and quality of life will be assessed. Participants will be randomized to 16-weeks of treatment with Lovastatin ™ or a matched placebo.
3248105|NCT00853567|Active Comparator|25 g Proellex|25 mg oral daily dose of Proellex
3248106|NCT00853567|Active Comparator|50 mg Proellex|50 mg oral daily dose of Proellex
3248107|NCT00853567|Placebo Comparator|Placebo|Placebo treatment
3248108|NCT00853554|Experimental|A|Hydromorphone Hydrochloride tablet 8 mg
3248109|NCT00853554|Active Comparator|B|Dilaudid® tablet 8 mg
3248110|NCT00853541||heart failure with renal impairment|Heart Failure patients with renal impairment
3248111|NCT00853528|Experimental|Single-fraction radiosurgery; 16 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 16 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
3248112|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 21 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 21 Gray
3248113|NCT00853528|Experimental|Single-fraction radiosurgery; 18 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 18 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
3248114|NCT00853528|Experimental|Single-fraction radiosurgery; 20 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 20 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
3248115|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 24 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 24 Gray
3248116|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 27 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 27 Gray
3248117|NCT00853515|Experimental|1|Goal-directed fluid resuscitation with lactated Ringer's solution
3248118|NCT00853515|Experimental|2|Goal-directed fluid resuscitation with normal saline
3248119|NCT00853515|No Intervention|3|Standard fluid resuscitation with lactated Ringer's solution
3248120|NCT00853515|No Intervention|4|Standard fluid resuscitation with normal saline
3248121|NCT00853502|Active Comparator|testosterone cypionate|
3248122|NCT00853502|No Intervention|bone monitoring|
3248123|NCT00853489|Experimental|recombinant bone morphogenetic protein 2|The patient will receive rhBMP-2 plus allograft chips in the bone defect site. Intervention type: surgical
3248124|NCT00853489|Active Comparator|Autogenous iliac crest bone graft|Bone will be harvested from the iliac crest and placed in the bone defect.
3248125|NCT00853463|No Intervention|No Alert|The responsible physician of a patient randomized to the control arm will not be contacted regarding the increased VTE risk of the patient.
3248126|NCT00853463|Other|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
3248127|NCT00853450|Experimental|1|AZD6482 on top of ASA
3248128|NCT00853450|Active Comparator|2|Clopidogrel on top of ASA
3248129|NCT00853424|Active Comparator|M|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
3248130|NCT00853424|Experimental|I|subjects receive an islet cell transplant in addition to all recommended medical treatment for diabetes and diabetic eye disease
3248131|NCT00853398|Experimental|Minimal Invasive Surgery,|
3248132|NCT00853398|Active Comparator|Standard Surgical Technique|
3248133|NCT00853385|Experimental|5mg|
3248134|NCT00853385|Experimental|10 mg|
3248135|NCT00853385|Placebo Comparator|Placebo Sequence 1|
3248136|NCT00853385|Placebo Comparator|Placebo Sequence 2|
3248137|NCT00853385|Active Comparator|adalimumab|
3248138|NCT00853372|Experimental|AMG 386 10mg/kg (Cohort A)|Cohort A: AMG 386 10mg/kg IV QW plus Sunitinib 50 mg PO QD 4 wks on/2 wks off
3248139|NCT00853372|Experimental|AMG 386 15mg/kg (Cohort B)|Cohort B: AMG 386 15mg/kg IV QW plus Sunitinib 50 mg PO QD 4 wks on/2 wks off
3248140|NCT00853346|Experimental|1|Patients randomized to the immediate arm will be given 12 weeks of CBT starting one week after randomization
3248141|NCT00853346|Active Comparator|2|Patients in the delayed arm will receive 12 weeks of CBT, starting 12 weeks after randomization.
3248142|NCT00853333|Active Comparator|Propofol|Administration via an IV
3248143|NCT00853333|Active Comparator|Midazolam|Administration via an IV
3248144|NCT00853333|Active Comparator|Dexmedetomidine|Administration via an IV
3248145|NCT00853320|Experimental|A|Oxycodone hydrochloride tablet 15 mg
3248146|NCT00853320|Active Comparator|B|Roxicodone™ tablet 15 mg
3248147|NCT00853307|Experimental|Alisertib 50 mg|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).
3248148|NCT00853294|Active Comparator|B|Tussionex® Pennkinetic® Extended Release Oral Suspension
3248149|NCT00853294|Experimental|A|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule
3248150|NCT00853281|Experimental|Hammocks with LLIN|Locally-made hammocks covered with long-lasting insecticidal net (LLIN)- Olyset(R), used in addition to the standard vector control measures
3248151|NCT00853281|Active Comparator|ITN|Standard vector control measures (insectice-treated net or ITN)
3248152|NCT00853268|Experimental|A|Controlled-Release Oxycodone Hydrochloride 40 mg tablet
3248153|NCT00853268|Active Comparator|B|OxyContin® 40 mg tablet
3248154|NCT00853255|Experimental|1|Participants will receive 0.5 mL of vaccine intranasally via an Accuspray device (0.25 mL in each nostril)
3248155|NCT00853242|Placebo Comparator|Placebo|Placebo matched to Genz-644470 tablet orally three times a day (TID) with meals for 3 weeks.
3248156|NCT00853242|Experimental|Genz-644470 2.4 Grams Per Day (g/day)|Genz-644470 2.4 g/day tablets dosed orally TID with meals for 3 weeks.
3248157|NCT00853242|Experimental|Genz-644470 4.8 g/day|Genz-644470 4.8 g/day tablets dosed orally TID with meals for 3 weeks.
3248158|NCT00853242|Experimental|Genz-644470 7.2 g/day|Genz-644470 7.2 g/day tablets dosed orally TID with meals for 3 weeks.
3248159|NCT00853242|Active Comparator|Sevelamer Carbonate 2.4 g/day|Sevelamer Carbonate 2.4 g/day tablets dosed orally TID with meals for 3 weeks.
3248160|NCT00853242|Active Comparator|Sevelamer Carbonate 4.8 g/day|Sevelamer Carbonate 4.8 g/day tablets dosed orally TID with meals for 3 weeks.
3248161|NCT00853242|Active Comparator|Sevelamer Carbonate 7.2 g/day|Sevelamer Carbonate 7.2 g/day tablets dosed orally TID with meals for 3 weeks.
3248162|NCT00853229|Experimental|pregabalin/placebo|pregabalin and placebo given using a cross-over design
3248163|NCT00853229|Experimental|placebo/pregabalin|placebo and pregabalin given using a cross-over design
3248164|NCT00853216|Experimental|A|Oxycodone hydrochloride tablet 30 mg
3248165|NCT00853216|Active Comparator|B|Roxicodone™ tablet 30 mg
3248166|NCT00853203||Part 1|Interviews + Questionnaire + Electronically Activated Recorder (EAR)
3248167|NCT00853203||Part 2, Expressive Disclosure Group|Group Meetings + Written Materials
3248168|NCT00853203||Part 2, Standard Care Control Group|Written Materials
3248169|NCT00853190|Experimental|A|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule
3248170|NCT00853190|Active Comparator|B|Tussionex® Pennkinetic® Extended Release Oral Suspension
3248171|NCT00853177|Experimental|nitrous oxide|"N2O of 50% and 50% O2~MEOPA"
3248172|NCT00853177|Active Comparator|lidocaine|Injection solution 1%
3248173|NCT00853164|Experimental|aerobic exercise|Subjects who are randomly assigned to this arm will be assigned a walking program to participate in 3 times a week for eight weeks
3248174|NCT00853164|Experimental|resistence training|Subjects who are randomly assigned to this arm will be assigned a weight training program to participate in 3 times a week for eight weeks
3248175|NCT00853164|Active Comparator|Usual Care|Subjects who are randomly assigned to this arm will not participate in any exercise program and will continue with usual care treatment
3248176|NCT00853151|Experimental|LY2428757 plus TT223 3 milligrams (mg)|Weekly LY2428757 plus 3 milligrams (mg) daily TT223
3248177|NCT00853151|Experimental|LY2428757 plus TT223 2mg|Weekly LY2428757 plus 2 mg daily TT223
3248178|NCT00853151|Experimental|LY2428757 plus placebo|Weekly LY2428757 plus daily TT223 placebo
3248179|NCT00853151|Placebo Comparator|Placebo plus Placebo|Weekly LY2428757 placebo plus daily TT223 placebo
3248180|NCT00853138|Experimental|CBT|Cognitive-behavioral therapy delivered via the internet in eight treatment modules for children (education, stress and negative emotions, deep breathing and relaxation, distraction, cognitive skills, sleep hygiene and lifestyle, staying active, relapse prevention) and eight treatment modules for parents (education, stress and negative emotions, operant strategies I, operant strategies II, modeling, sleep hygiene and lifestyle, communication, relapse prevention).
3248181|NCT00853138|No Intervention|SMC|The standard medical care wait-list control group continued with the treatment recommendations proscribed by their pain care team.
3248182|NCT00853125|Experimental|Sunitinib plus Irradiated Allogeneic Lymphocytes|
3248183|NCT00853112|Experimental|PF-00489791 1 mg|
3248184|NCT00853112|Experimental|PF-00489791 2 mg|
3248185|NCT00853112|Experimental|PF-00489791 4 mg|
3248186|NCT00853112|Experimental|PF-00489791 10 mg|
3248187|NCT00853112|Experimental|PF-00489791 20 mg|
3248188|NCT00853112|Placebo Comparator|Placebo|
3248189|NCT00853112|Active Comparator|Sildenafil|Observational comparator arm
3248190|NCT00853099|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections every 2 weeks for 52 weeks. From Week 8, participants with an inadequate response could switch to rescue therapy, where they initially received adalimumab 160 mg, 80 mg 2 weeks later, and then 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
3248191|NCT00853099|Experimental|Adalimumab 80 mg/40 mg|Participants received adalimumab 80 mg on Day 1, 40 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
3248192|NCT00853099|Experimental|Adalimumab 160 mg/80 mg|Participants received adalimumab 160 mg on Day 1, 80 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
3248193|NCT00853086||A|
3248194|NCT00853073|Active Comparator|Bevacizumab|subjects will receive 1.0mg (0.04cc of 25 mg/ml) subconjunctival bevacizumab either temporal or nasal to the bleb following bleb needling procedure in addition to 0.1 cc mitomycin C.
3248195|NCT00853073|Placebo Comparator|balanced salt solution|patients randomized to treatment B are given 0.04cc of balanced salt solution injected in identical fashion either temporal or nasal to the bleb following bleb needling procedure in addition to 0.1 cc mitomycin C.
3248196|NCT00853047|Experimental|Low Dose LX1606 Part 1|A low dose of LX1606; daily oral intake for 28 days.
3248197|NCT00853047|Experimental|Mid-Low Dose LX1606 Part 1|A mid-low dose of LX1606; daily oral intake for 28 days
3248198|NCT00853047|Experimental|Mid-High Dose LX1606 Part 1|A mid-high dose of LX1606; daily oral intake for 28 days
3248199|NCT00853047|Experimental|High Dose LX1606 Part 1|A high dose of LX1606; daily oral intake for 28 days
3248200|NCT00853047|Experimental|Part 2 LX1606 Expanded Cohort|A dose of LX1606 to an expanded cohort based upon Part 1; daily oral intake for 28 days
3248201|NCT00853047|Experimental|LX1606 Open Label Extension|
3248202|NCT00853034|Active Comparator|FOS-IN|prebiotic fructo-oligosaccharide enriched inulin
3248203|NCT00853034|Experimental|AXOS|arabinoxylan-oligosaccharides (AXOS)
3248204|NCT00853021|Experimental|Bevacizumab and Aldesleukin|
3248205|NCT00852995|Experimental|A - Low Q7D|Low dose HP802-247, applied at each visit
3248206|NCT00852995|Experimental|B - Low Q14D|Low dose HP802-247 applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
3248207|NCT00852995|Experimental|C - High Q7D|High dose HP802-247, applied at each visit
3248208|NCT00852995|Experimental|D - High Q14D|High dose HP802-247, applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
3248209|NCT00852995|Placebo Comparator|E - Vehicle|Placebo (Vehicle), applied at each visit
3248210|NCT00852982|Experimental|Exercise|Five hours of Nordic walking per week, during four months
3248211|NCT00852982|No Intervention|Control|Control group asked not to alter lifestyle during study
3248212|NCT00852969|Active Comparator|Niacin|
3248213|NCT00852969|Placebo Comparator|Placebo|
3248214|NCT00852956|Experimental|Treatment|Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total)and Olanzapine (10 mg/day)
3248215|NCT00852956|Active Comparator|Control|Matching placebo TID; 08:00, 13:00 and 18:00 and Olanzapine (10 mg/day).
3248216|NCT00852930|Experimental|laser alone|The intervention was therapist administered low level laser therapy using low level laser, number of sessions based upon patient response
3248217|NCT00852930|Active Comparator|mld alone|The intervention was therapist administered manual lymphatic drainage (mld) using standard massage techniques,number of sessions based upon patient response
3248218|NCT00852930|Experimental|laser and mld combined|The intervention was therapist administered low level laser and mld using low level laser and standard massage techniques, number of sessions based upon patient response
3248219|NCT00852917|Experimental|1: Tramadol Once A Day 100mg|
3248220|NCT00852917|Experimental|2: Tramadol Once A Day 200mg|
3248221|NCT00852917|Experimental|3: Tramadol Once A Day 300mg|
3248222|NCT00852917|Placebo Comparator|4: Placebo|
3248223|NCT00852878|Active Comparator|Biofeedback|heart rate variability biofeedback
3248224|NCT00852878|Active Comparator|Behavioral|Behavioral intervention will provide parent and child with a variety of pain management techniques such as relaxation, distraction, contingency management, and coping statements
3248225|NCT00852865|Experimental|1|24 healthy volunteers consuming L.farciminis during three weeks
3248226|NCT00852865|Placebo Comparator|2|24 healthy volunteers consuming placebo during three weeks
3248227|NCT00852852|Experimental|Intervention|Patient participants in the intervention arm can access educational information about self-care strategies, track and share reports of their symptoms and quality of life issues over time, and receive coaching on how to discuss these issues with their care team.
3248228|NCT00852852|No Intervention|Control|Participants in the control arm access the ESRA-C from home or clinic to self-assess only.
3248229|NCT00852839|Experimental|552-02|
3248230|NCT00852839|Placebo Comparator|Placebo|
3248231|NCT00852826|Sham Comparator|1|Standard axillary lymphadenectomy
3248232|NCT00852826|Experimental|2|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
3248233|NCT00852800|Active Comparator|Standard regimen|Albumin in standard regimen (1.5 g/Kg IV on day 1 and 1 g/kg IV on day 3)with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3
3248234|NCT00852800|Experimental|Dose reduced regimen|Albumin in dose reduced regimen (1 g/kg IV on day 1 and 0.5 g/kg IV on day 3) with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3
3248235|NCT00852787|Experimental|Low|0.1mg/kg
3248236|NCT00852787|Experimental|Medium|0.4mg/kg
3248237|NCT00852787|Experimental|High|1.6 mg/kg
3248238|NCT00852787|Placebo Comparator|Placebo|
3248239|NCT00852774||1|Endometrial Cancer Patients Hysterectomy Robotic Surgery
3248240|NCT00852774||2|Endometrial Cancer Patient Hysterectomy Laparotomy Surgery
3248241|NCT00852761|Experimental|Olux-E Foam|Olux-E (clobetasol propionate 0.05%) foam
3248242|NCT00852761|Active Comparator|Clobex lotion|Clobex (clobetasol propionate 0.05%) lotion.
3248243|NCT00852722|Experimental|1. Low fat study diet|The low fat study diet arm will receive low fat diet training and followed for 12 months on the diet.
3248244|NCT00852722|No Intervention|2. Regular diet group|The regular diet arm will be a wait-listed group that will receive no training in diet and will be advised to continue their regular (usual) diet as was prior to entry into the study, for the duration of the study. They will have a similar clinic follow up schedule as the treatment group. The regular diet group will be given identical instructions to exercise regularly similar to the treatment group.
3248245|NCT00852696|Placebo Comparator|Placebo Group|Placebo Orally 9 weeks once daily.
3248246|NCT00852696|Experimental|Solifenacin Group|Solifenacin Orally 9 weeks once daily.
3248247|NCT00852683|Active Comparator|A|
3248251|NCT00852657|Active Comparator|Surgical treatment|Open or mini-open tendon repair with acromioplasty
3248252|NCT00852657|Active Comparator|Physiotherapy|Physiotherapy by exercises
3248253|NCT00852644|Experimental|56 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
3248254|NCT00852644|Experimental|62 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
3248255|NCT00852644|Experimental|68 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
3248256|NCT00852644|Experimental|56 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
3248257|NCT00852644|Experimental|62 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
3248258|NCT00852644|Experimental|68 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
3248259|NCT00852618||A|Participants undergoing treatment with raltegravir (RAL) in the main study
3248260|NCT00852618||B|Participants undergoing treatment with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in the main study
3248261|NCT00852605|No Intervention|Oxygen|Conventional Treatment including Oxygen-support
3248262|NCT00852605|Experimental|NIV|Conventional Treatment plus intermittent Non-Invasive-Ventilation
3248263|NCT00852592|Active Comparator|Active Comparator|7000lux broad-spectrum light
3248264|NCT00852592|Placebo Comparator|Inactive Comparator|50lux dim red light
3248265|NCT00852579|Experimental|1|Active treatment.
3248266|NCT00852579|Placebo Comparator|2|Placebo control group.
3248267|NCT00852566|Active Comparator|Imatinib|Standard treatment Imatinib 400mg OD
3248268|NCT00852566|Experimental|dasatinib|Dasatinib 100mg OD
3248269|NCT00852540|Experimental|Retapamulin|
3248270|NCT00852540|Active Comparator|Linezolid|
3248271|NCT00852527||Subjects with mild TBI|Presence of mild TBI defined by positive reference test
3248272|NCT00852527||Subjects without mild TBI|Absence of mild TBI defined by negative reference test
3248273|NCT00852514|Experimental|Monthly BIA|monthly BIA to monitor fluid status
3248274|NCT00852501||Non-functioning pituitary macroadenoma|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
3248275|NCT00852488|Experimental|Catheter|Cohort undergoing catheter placement using the new technique being studied
3248276|NCT00852475|Placebo Comparator|MUFA|Assignment to monounsaturated enriched diet with exercise. This represents the MUFA MOVE! program
3248277|NCT00852475|Active Comparator|PUFA|Assignment to polyunsaturated enriched diet with exercise. This represents the PUFA MOVE! program
3248278|NCT00852462|Experimental|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
3248279|NCT00852462|No Intervention|Usual Care|Symptom assessment and management follows customary procedures in each study site.
3248280|NCT00852449|Experimental|restrictive fluid|Restrictive fluid administration: 6 ml kg-1 h-1 of crystalloids (lactated Ringer's solution)
3248281|NCT00852449|Experimental|liberal fluid|Liberal fluid administration: 12 ml kg-1 h-1 of crystalloids (lactated Ringer's solution)
3248282|NCT00852436|Active Comparator|1|Pregabalin capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.
3248283|NCT00852436|Placebo Comparator|2|Placebo capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.
3248284|NCT00852423|Experimental|DHAPQ|Three-day treatment with dihydroartemisinin-piperaquine
3248285|NCT00852423|Experimental|MQAS|Three-day treatment with mefloquine artesunate
3248286|NCT00852423|Active Comparator|AQAS|Three-day treatment with artesunate-amodiaquine
3248287|NCT00852423|Active Comparator|AL|Three day treatment with artemether-lumefantrine (Coartem(R)
3248288|NCT00852410|Active Comparator|1% lidocaine with 1:100000 adrenaline|high dose adrenaline
3248289|NCT00852410|Active Comparator|1% lidocaine with 1:200,000 adrenaline|low dose
3248290|NCT00852397|Experimental|Apixaban 2.5 mg|
3248291|NCT00852397|Experimental|Apixaban 5.0 mg|
3248292|NCT00852397|Placebo Comparator|Placebo|
3248293|NCT00852371|Active Comparator|2|Amodiaquine + sulfadoxine-pyrimethamine
3248294|NCT00852371|Active Comparator|3|Dihydroartemisinin-piperaquine
3248295|NCT00852371|Placebo Comparator|4|Placebo
3248296|NCT00852371|Active Comparator|1|sulfadoxine-pyrimethamine
3248297|NCT00852358|Experimental|intrathecal laronidase|The Experimental treatment group will receive study assessments and intrathecal laronidase (1.74 mg laronidase) treatments every 1-3 months beginning at start of study.
3248560|NCT00850603|Experimental|Group 5|0.15 mL Intradermal arm (Menomune®)
3248298|NCT00852358|Other|Control Group|During the first 11 months, the control group will receive study assessments but will be unblinded with no intrathecal treatment or placebo administered. Beginning at month 12, the control group will receive intrathecal laronidase (1.74 mg) treatment every 3 months (months 12, 15, 18, and 21).
3248299|NCT00852332|Experimental|Curcumine|With curcumin capsules
3248300|NCT00852332|Active Comparator|Drug taxotere only|Without curcumin
3248301|NCT00852319|Experimental|Central Mississippi group|Participants from central Mississippi are provided with 24 months of interpregnancy care. The results from this arm are compared to a historical control group (who were not given interpregnancy care) from the same geographical area in Mississippi.
3248302|NCT00852319|Experimental|Mississippi Delta group|Participants from 18 counties of the Mississippi delta are provided with 24 months of interpregnancy care. The results from this arm are compared to a historical control group (who were not given interpregnancy care) from the same geographical area in Mississippi.
3248303|NCT00852306|Experimental|slow freeze|these recipients will have their first embryo transfer with oocytes frozen via the slow freeze method.
3248304|NCT00852306|Experimental|vitrification|these recipients will have their first attempt at an embryo transfer with oocytes frozen via the vitrification method.
3248305|NCT00852293||study group|Patients with liver disease followed at the liver unit at Hadassah Medical Center.
3248306|NCT00852267|Active Comparator|High CHO, High SatFat Diet|
3248307|NCT00852267|Experimental|Low CHO, High SatFat Diet|
3248308|NCT00852267|Experimental|Low CHO, Low SatFat Diet|
3248309|NCT00852241|Experimental|Restalyne and Perlane|One syringe of Perlane® (1.0cc) and one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
3248310|NCT00852228|Experimental|chronomodulated HAI chemotherapy|
3248311|NCT00852228|Experimental|conventional HAI chemotherapy|
3248312|NCT00852215|Active Comparator|1|Taxus stent group
3248313|NCT00852215|Active Comparator|2|Vision stent group
3248314|NCT00852202|Experimental|1|0.25 - 0.75 mg/day cariprazine capsules, oral administration, once daily dosing.
3248315|NCT00852202|Experimental|2|1.5 - 3.0 mg/day cariprazine capsules, oral administration, once daily dosing.
3248316|NCT00852202|Placebo Comparator|3|Matching placebo capsules, oral administration, once daily dosing.
3248317|NCT00852176||On-label treatment|"Patients treated in routine clinical practice following FDA Pre-Market Approval of the Beta-Cath(TM) 3.5F System within the parameters of the approved indications for use for the System (on-label)."
3248318|NCT00852163|Experimental|Clofarabine with Busulfan|Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days
3248319|NCT00852137|Experimental|PEP005 (ingenol mebutate) Gel, 0.05%|
3248320|NCT00852137|Placebo Comparator|Vehicle Gel|
3248321|NCT00852124|Placebo Comparator|Placebo|Packets similar to VSL#3 will be taken 2 X daily but not containing active bacteria
3248322|NCT00852124|Active Comparator|VSL#3|Packets of VSL#3 (powder containing 8 bacteria believed to be beneficial) will be taken 2 x daily in food or a cool beverage.
3248323|NCT00852098|Active Comparator|1|dividing short gastric vessels
3248324|NCT00852098|Active Comparator|2|non-dividing short gastric vessels
3248325|NCT00852085|Experimental|Group MI|Four group counseling sessions and a directed observational visit to the emergency department of a busy urban hospital
3248326|NCT00852085|Active Comparator|Enhanced community service|
3248327|NCT00852072|Active Comparator|Mechanical lithotripsy|Ability to clear the bile duct of all stones within 20 minutes in one ERCP session using mechanical lithotripsy.
3248328|NCT00852072|Active Comparator|Balloon sphincteroplasty|Ability to clear the bile duct of all stones within 20 minutes in one ERCP session using balloon sphincteroplasty.
3248329|NCT00852059|Experimental|Immediate release|Treatment with immediate release (IR) methylphenidate (Medikinet®) in the morning and 3-4 h later (twice a day)
3248330|NCT00852059|Active Comparator|Extended release|Treatment with extended release (ER) methylphenidate (Medikinet reatard®) applied with breakfast(once daily)
3248331|NCT00852046|Experimental|1. Low dose dexmedetomidine|Dexmedetomidine 0.2 mcg/kg/hr added to fentanyl & propofol.
3248332|NCT00852046|Experimental|2. High dose dexmedetomidine|Dexmedetomidine 0.6 mcg/kg/hr added to fentanyl & propofol.
3248333|NCT00852046|Placebo Comparator|3. Placebo|Placebo added to fentanyl & propofol.
3248334|NCT00852033|No Intervention|1|Assessment Group (no intervention)
3248335|NCT00852033|Active Comparator|2|Brief Motivational Intervention (BMI)
3248336|NCT00852033|Active Comparator|3|Parent Based Intervention (PBI)
3248337|NCT00852033|Active Comparator|4|BMI and TBI
3248338|NCT00852020|Experimental|1|oral nutritional supplement containing n-3-fatty acids, amino acids and antioxidants
3248339|NCT00852020|Placebo Comparator|2|oral nutritional supplement (isocaloric, isonitrogenous)
3248340|NCT00852007|Experimental|DC-Tn-MUC|DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1. 1.2 x 10e7 dendritic cells per dose. 5 administrations (doses)may be given in total.
3248341|NCT00851994||1|Patients having surgery
3248342|NCT00851981|Placebo Comparator|1|
3248343|NCT00851981|Active Comparator|SAMe|
3248344|NCT00851968|Active Comparator|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
3248345|NCT00851968|Experimental|Hemihepatic vascular Clamping|Patients with HCC received Hemihepatic vascular Clamping in hepatectomy
3248346|NCT00851968|Experimental|portal vein occlusion|Patients with HCC received portal vein occlusion in hepatectomy
3248347|NCT00851955||1. Normal pancreas patients|Patients with no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test (EUS, CT scan or MRI).
3248348|NCT00851955||2. Chronic pancreatitis patients|Patients with documented diagnosis of moderate to advanced chronic pancreatitis supported by at least 1 positive imaging test (EUS,CT scan or MRI).
3248349|NCT00851955||3. Pancreatic cancer patients|Patients with documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.
3248350|NCT00851942|Experimental|Synacthen 250 micrograms|IV injection of 250 micrograms of Synacthen in 1m
3248351|NCT00851929|Experimental|sarcoidosis associated pulmonary hypertension|sarcoidosis associated pulmonary hypertension
3248352|NCT00851916|Other|CyberKnife Radiosurgery|Single arm study using CyberKnife radiosurgery to treat recurrent prostate cancer patients that have already received external beam radiotherapy.
3248353|NCT00851903|Experimental|Combination insulin glargine and sitagliptin|"Insulin glargine administered once a day, in the evening, at dinner or at bedtime. Starting dose: - last dose administered in the core study for patients previously treated with insulin glargine, - 0.2 U/Kg of body weight for patients previously treated with sitagliptin. Monitoring of blood glucose and titration: all patients, irrespective of their previous treatment group in the core study were empowered to adjust their insulin doses, under strict investigator's supervision. The goal was to achieve through a force titration 70 < Fasting Plasma Glucose (FPG) ≤ 100 mg/dL (3.9 <FPG ≤ 5.5 mmol/L).~Sitagliptin: stable dose of 100 mg once a day administered with or without food."
3248354|NCT00851890|Experimental|ABT-333 (300 mg) twice daily (BID) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 300 mg ABT-333 BID for 2 days followed by 300 mg ABT-333 BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3248355|NCT00851890|Experimental|ABT-333 (600 mg) twice daily (BID) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 600 mg ABT-333 BID for 2 days followed by 600 mg ABT-333 BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3248356|NCT00851890|Experimental|ABT-333 (1200 mg) once daily (QD) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 1200 mg ABT-333 QD for 2 days followed by 1200 mg ABT-333 QD with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3248357|NCT00851890|Placebo Comparator|Placebo + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naïve participants received matching placebo once daily (QD) or twice daily (BID) for 2 days followed by placebo QD or BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3248358|NCT00851877|Experimental|arm one|Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy
3248359|NCT00851864|Experimental|A|Women requiring therapeutic anticoagulation, singleton pregnancy,<30weeks
3248360|NCT00851838|Experimental|PD solution|
3248361|NCT00851812|Other|Arm 1|Usual Care: Standard care monitoring
3248362|NCT00851812|Experimental|Arm 2|Progressive walking and resistance exercise treatment
3248363|NCT00851799||Cohort A|"ATV/RTV + FTC/TDF~Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily."
3248364|NCT00851799||Cohort B|"RAL + FTC/TDF~FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily."
3248365|NCT00851799||Cohort C|"DRV/RTV + FTC/TDF~FTC/TDF, darunavir (DRV), and RTV, orally, once daily."
3248366|NCT00851786|Experimental|1|Participants with CD4 cell counts of 200 cells/uL or greater in Stages 1 and 2, stratified by CD4 cell counts (200-349 cells/uL vs. >=350 cells/uL), will be given one dose of ZOSTAVAX (Zoster Vaccine Live) at Day 0 and Week 6 and will be followed for at least 42 days after each vaccination after which a safety assessment will be conducted.
3248367|NCT00851786|Placebo Comparator|2|Participants with CD4 cell counts of 200 cells/uL or greater in Stages 1 and 2, stratified by CD4 cell counts (200-349 cells/uL vs. >=350 cells/uL), will be given one dose of placebo at Day 0 and Week 6 and will be followed for at least 42 days after each vaccination after which a safety assessment will be conducted
3248368|NCT00851773|Experimental|A|
3248369|NCT00851773|Experimental|B|
3248370|NCT00851773|Experimental|C|
3248371|NCT00851773|Experimental|D|
3248372|NCT00851773|Experimental|E|
3248373|NCT00851773|Placebo Comparator|F1|
3248374|NCT00851773|Placebo Comparator|F2|
3248375|NCT00851773|Placebo Comparator|F3|
3248376|NCT00851773|Placebo Comparator|F4|
3248377|NCT00851773|Placebo Comparator|F5|
3248378|NCT00851760|Experimental|1 Combined Surgery|
3248379|NCT00851760|Active Comparator|2 consecutive surgery|
3248380|NCT00851747|Experimental|C Phosphatidylcholine Deoxycholate|Phosphatidylcholine Deoxycholate Injections. Group C will receive only study drug injections
3248381|NCT00851747|Placebo Comparator|A Saline|Group A will serve as a control and will receive only injections of saline as a placebo.
3248382|NCT00851747|Active Comparator|B PhosphatidylcholineDeoxycholate/Saline|Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side.
3248383|NCT00851734|Experimental|LX214 0.02%|LX214 ophthalmic solution 0.02%
3248384|NCT00851734|Experimental|LX214 0.2%|
3248385|NCT00851734|Placebo Comparator|placebo|placebo
3248386|NCT00851721|Experimental|Prophylaxis arm|
3248387|NCT00851721|Active Comparator|On-demand arm|
3248388|NCT00851708|Active Comparator|NAC|treatment
3248389|NCT00851708|No Intervention|control|
3248390|NCT00851695||Asthma|All 1024 participants of the Childhood Asthma Management Program, who provided blood samples.
3248391|NCT00851695||Asthma in Hispanics|All 616 subjects in the Genetic Epidemiology of Asthma in Costa Rica who have serum.
3248392|NCT00851695||Lung function and lung function decline|626 subjects from the Normative Aging Study who have serum and lung function.
3248393|NCT00851682|Other|Radical prostatectomy patients|Patients who have been diagnosed with prostate cancer and are scheduled to undergo radical prostatectomy and have not received any preoperative treatment for prostate cancer.
3248394|NCT00851682|Other|Brachytherapy patients|Patients who have been diagnosed with prostate cancer and are scheduled to undergo brachytherapy and have not received any preoperative treatment for prostate cancer.
3248395|NCT00851669|Experimental|IPT|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
3248396|NCT00851669|Active Comparator|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
3248397|NCT00851643|Active Comparator|qHPV (GARDASIL™) - Phase A Control|Quadrivalent Human Papillomavirus (qHPV) (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™). This is the control for the Octavalent HPV with 15 mcg ISCOMATRIX™ (IMX) / Aluminum Hydroxyphosphate Sulfate (AAHS) and Octavalent HPV with 30 mcg IMX / AAHS during Phase A.
3248398|NCT00851643|Experimental|Octavalent HPV with 15 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg AAHS and 15 mcg IMX.
3248399|NCT00851643|Experimental|Octavalent HPV with 30 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 30 mcg IMX.
3248400|NCT00851643|Active Comparator|qHPV (GARDASIL™) - Phase B Control|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™). This is the control for the Octavalent HPV with 60 mcg IMX / AAHS and Octavalent HPV with 120 mcg IMX / AAHS during Phase B.
3248401|NCT00851643|Experimental|Octavalent HPV with 60 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 60 mcg IMX.
3248402|NCT00851643|Experimental|Octavalent HPV with 120 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 120 mcg IMX.
3248403|NCT00851630|Experimental|Early|Initiation of fixed dose combination zidovudine/lamivudine/abacavir 2 weeks after commencing antituberculous therapy
3248404|NCT00851630|Experimental|Delayed|Initiation of fixed dose combination zidovudine/lamivudine/abacavir 8 weeks after commencing antituberculous therapy
3248405|NCT00851617|Experimental|IMT Group|The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
3248406|NCT00851617|No Intervention|Control Group|Patients were evaluated until weaning without interventions
3248407|NCT00851604||1|Patients with malignant neuroendocrine tumors
3248408|NCT00851591|Experimental|Fenugreek category 1|receive fenugreek
3248409|NCT00851591|Placebo Comparator|Placebo Category 2|receive placebo
3248410|NCT00851578|Experimental|WATCHMAN|non-valvular atrial fibrillation patients contraindicated to warfarin
3248411|NCT00851565|Active Comparator|1|Patients with Crohn's disease with secondary loss of response to infliximab.
3248412|NCT00851565|Active Comparator|2|Patients with Crohn's disease with secondary loss of response to infliximab.
3248413|NCT00851539|No Intervention|Control|Participants received counseling from a live counselor.
3248414|NCT00851539|Experimental|Video|Behavioral Intervention Video
3248415|NCT00851526||Coronary bifurcation lesion|
3248416|NCT00851513|Experimental|Group B|local anesthetics (lidocaine) associated with local steroids (depo-medrol)
3248417|NCT00851513|Experimental|Group C|local anesthetics (lidocaine) associated with local steroids (depomedrol) and important volumes of physiological serum
3248418|NCT00851513|Active Comparator|Group A|only local anesthetic (lidocaine)
3248419|NCT00851500|Experimental|low dose K-604|
3248420|NCT00851500|Experimental|high dose K-604|
3248421|NCT00851500|Placebo Comparator|placebo|
3248422|NCT00851487|Experimental|Amoxicillin|Oral amoxicillin in the dose of 15 mg/kg/dose 8 hourly was given as an active drug
3248423|NCT00851487|Placebo Comparator|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
3248424|NCT00851448|Experimental|1|Oral nutritional supplement containing n-3 fatty acids, amino acids, antioxidants
3248425|NCT00851448|Placebo Comparator|2|isocaloric, isonitrogenous
3248426|NCT00851435|Experimental|KBPA-101, a monoclonal antibody|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
3248427|NCT00851409|Other|Recombinant Human C1 Inhibitor|Weekly administration of 50 IU/kg Recombinant Human C1 Inhibitor
3248428|NCT00851396||Obese female adolescents|Obese adolescents will be screened for vitamin D deficiency through an existing study. Those found to be vitamin D deficient will be given standard treatment of vitamin D deficiency. In this study, patients who self report that they had taken the treatment for vitamin D will be screened for serum 25 OH D level and will undergo OGTT. The OGTT results as well as insulin resistance indices will be compared to their initial values.
3248429|NCT00851383|Experimental|Group A|Ad35-GRIN/ENV: 2x10^9 vp
3248430|NCT00851383|Experimental|Group B|Ad35-GRIN/ENV: 2x10^10 vp
3248431|NCT00851383|Experimental|Group C|Ad35-GRIN/ENV: 2x10^11 vp
3248432|NCT00851383|Experimental|Group D|Ad35-GRIN at 1x10^10 vp
3248433|NCT00851370|Experimental|Omalizumab|
3248434|NCT00851370|Placebo Comparator|Placebo|
3248435|NCT00851357|Experimental|Active patches and telephone counseling|Proactive Telephone Counseling and 8-weeks of nicotine patches
3248436|NCT00851357|Placebo Comparator|Placebo patches and telephone counseling|Proactive Telephone Counseling and 8-weeks of placebo patches
3248437|NCT00851357|Active Comparator|Telephone counseling|Proactive Telephone Counseling
3248438|NCT00851357|Active Comparator|Active patches and materials|8-weeks of nicotine patches and materials
3248439|NCT00851357|Active Comparator|Placebo patches and materials|8-weeks placebo patches and materials
3248440|NCT00851357|Active Comparator|Materials|Self-help materials
3248441|NCT00851344|Active Comparator|GSK835726 (10mg)|10mg oral dose
3248442|NCT00851344|Active Comparator|GSK835726 (50mg)|50mg oral dose
3248443|NCT00851344|Active Comparator|GSK835726 (100mg)|50mg oral dose
3248444|NCT00851344|Active Comparator|Cetirizine 10mg|10mg cetirizine as active comparator
3248445|NCT00851344|Placebo Comparator|placebo|placebo tablet
3248446|NCT00851318|Experimental|Certolizumab pegol 200 mg|Participants received 200 mg certolizumab pegol by subcutaneous injection once every 2 weeks in combination with methotrexate for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
3248447|NCT00851318|Experimental|Certolizumab pegol 400 mg|Participants received 400 mg certolizumab pegol by subcutaneous injection once every 4 weeks in combination with methotrexate for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
3248448|NCT00851305|Experimental|1 confocal laser endomicroscopy|Targeted biopsies are performed when the lesion was considered as IM, dysplasia or carcinoma by confocal laser endomicroscopy.
3248449|NCT00851305|Active Comparator|2 Conventional endoscopy|Routine biopsies are performed when the lesion was considered as IM, dysplasia or carcinoma by conventional endoscopy.
3248450|NCT00851292|Active Comparator|Side-firing|prostate biopsies obtained with side-firing probe
3248451|NCT00851292|Active Comparator|End-firing|
3248452|NCT00851279|Experimental|Magnetic irrigated ablation catheter|Patients with documented VT and prior MI, in whom an ICD was implanted either for primary or secondary prevention, were recruited for endocardial mapping/ablation during VT (entrainment mapping, activation mapping) and/or substrate mapping in sinus rhythm (elimination of fractionated/late potentials, endocardial scar homogenization) with remote magnetic navigation (Niobe, Stereotaxis Inc.,St Louis, USA) and irrigated RF ablation (NaviStar RMT ThermoCool, Biosense Webster,California, USA).
3248453|NCT00851266|Experimental|1|V512
3248454|NCT00851266|Placebo Comparator|2|Placebo to V512
3248455|NCT00851253|Experimental|Group 1 (CK SRS boost therapy)|Radiation: CyberKnife Stereotactic Radiosurgery boost (2 fractionated doses) beginning 4-8 weeks after completion of standard therapy.
3248456|NCT00851253|Experimental|Group 2 (CK SRS salvage therapy)|Radiation : CyberKnife® stereotactic radiosurgery salvage therapy (5 fractions) 3 times weekly.
3248457|NCT00851240|Experimental|BTT1023|
3248458|NCT00851240|Placebo Comparator|Placebo|
3248459|NCT00851227|Experimental|1. Mildly Hepatic Impaired Subjects|
3248460|NCT00851227|Experimental|2. Moderately Hepatic Impaired Subjects|
3248461|NCT00851227|Experimental|3. Subjects with Normal Hepatic Function|
3248462|NCT00851214||Acute CHF/COPD|Patients presenting with shortness of breath secondary to acute exacerbation of CHF/COPD
3248463|NCT00851214||Acute Trauma|Acute trauma patients with a trauma ISS>15
3248464|NCT00851214||Sepsis|Patients presenting with a suspicion of acute sepsis (fever, tachycardia, tachypnea)
3248465|NCT00851214||Stroke|Patients presenting with symptoms and signs of acute stroke (thrombotic or hemorrhagic)
3248466|NCT00851201|Active Comparator|Standard Intervention|
3248467|NCT00851201|Experimental|Intensive lifestyle|
3248468|NCT00851188|Experimental|internet CBT self-help|CBT via the internet
3248469|NCT00851188|Experimental|CBT self-help booklet|
3248470|NCT00851188|Active Comparator|Waiting list|
3248471|NCT00851175|No Intervention|1|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia
3248472|NCT00851175|Active Comparator|2|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia with concommitant administration of caffeine (90 ug/min/100ml forearm volume) into the brachial artery of the experimental (=non dominant) arm
3248473|NCT00851175|Experimental|3|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia after 7 days oral treatment with rosuvastatin 1dd 20mg
3248474|NCT00851175|Active Comparator|4|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia after 7 days oral treatment with rosuvastatin 1dd 20mg with concommitant administration of caffeine (90 ug/min/100ml forearm volume) into the brachial artery of the experimental (=non dominant) arm
3248475|NCT00851162|Experimental|Trinity|Trinity multipotent stem cells
3248476|NCT00851162|Active Comparator|Demineralized bone matrix|Demineralized bone matrix
3248477|NCT00851149||1/10|Abdominal aortic surgery patients
3248478|NCT00851149||2/10|Total hip replacement patients
3248479|NCT00851136|Experimental|1|
3248480|NCT00851123|Experimental|1. Modified Constraint-Induced Movement therapy|Modified Constraint-Induced Movement Therapy at the rehabilitation unit or in an outpatient clinic.
3248481|NCT00851123|Experimental|2.Task-specific bimanual training|Task-specific bimanual training at the rehabilitation unit or in an outpatient clinic.
3248482|NCT00851084|Active Comparator|mFOLFOX6 only|modified FOLFOX6 chemotherapy regimen
3248483|NCT00851084|Experimental|mFOLFOX6 + aflibercept|modified FOLFOX6 chemotherapy regimen in combination with aflibercept
3248484|NCT00851071|Active Comparator|Cognitive Behavioral Therapy|Three individual 45 minute cognitive behavioral therapy sessions over a 3 month period
3248485|NCT00851071|No Intervention|Usual Care Arm|The Usual Care Arm will be the control arm. These patients will not be scheduled with any CBT sessions.
3248486|NCT00851058|Experimental|Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
3248487|NCT00851058|Active Comparator|Community Counseling|Four session of group counseling and six hours of volunteering in a local not for profit community agency.
3248488|NCT00851058|Placebo Comparator|Prototypic Community Service|Four hours of education about road safety and 16 hours volunteering at a local not for profit community service.
3248489|NCT00851045|Active Comparator|Arm 1|Irinotecan/5-Fluorouracil (bolus)/5-Fluorouracil (infusional)/Leucovorin calcium/CT-322
3248490|NCT00851045|Active Comparator|Arm 2|Irinotecan/5-Fluorouracil(bolus)/5-Fluorouracil(infusional)/Leucovorin calcium /Bevacizumab/Bevacizumab Placebo(saline solution)
3248491|NCT00851032||Molecular Profiling Analyses|Participants seen in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center in Houston, Texas
3248492|NCT00851019|Experimental|DDR|"Dance Dance Revolution (DDR) Exergaming"
3248493|NCT00851019|Active Comparator|Treadmill|Treadmill exercise
3248494|NCT00851006|Experimental|Open-Label Creatine|Creatine Monohydrate 4 grams daily by mouth
3248495|NCT00850993|Experimental|Stannsoporfin|3 sequential cohorts of approximately 24 subjects will be recruited. Subjects in the first cohort who are randomized to receive active drug treatment will receive a single dose of 1.5 mg/kg by IM injection. Subjects in the second and third cohorts will receive 3.0 and 4.5 mg/kg, respectively.
3248496|NCT00850993|Placebo Comparator|Placebo (Saline)|Cohort of approximately 24 subjects will be recruited.
3248497|NCT00850954||Intervention Tools + Materials for Smokers|
3248498|NCT00850954||Intervention Tools + Materials for Non-Smokers|
3248499|NCT00850941||Questionnaire|Prognostic factors and outcome for patients treated with radiation with curative intent for rising Prostate Specific Antigen (PSA) post-prostatectomy.
3248500|NCT00850928||Subjects|65 years and older scheduled for spine surgery will be undergoing serial assessments preoperatively and postoperatively over 6 time-points.
3248606|NCT00850161|Experimental|Nasulin™|Intranasal insulin spray
3248501|NCT00850915|Other|1|in this arm contacts of enrolled TB-HIV index cases were actively approached and screened for TB and offered HIV testing by CHW at their homes
3248502|NCT00850915|Other|2|no interventation was done in this group, they received the regulare care and follow up following NTP guidelines
3248503|NCT00850902|Active Comparator|Moderate Humidity (MH)|
3248504|NCT00850902|Experimental|High Humidity|
3248505|NCT00850889|Active Comparator|1|Juvederm Ultra Injectable Gel with Lidocaine
3248506|NCT00850889|Active Comparator|2|Restylane Injectable Gel
3248507|NCT00850863||A|20 healthy individuals not susceptible for COPD (age 18-40 years, 0 < pack years > 10, FEV1/FVC >70% , FEV1 >85% predicted)
3248508|NCT00850863||B|30 healthy individuals susceptible for COPD (age 40-75years, pack years >20, FEV1/FVC > 70%, FEV1 > 85% predicted)
3248509|NCT00850863||C|20 healthy individuals very susceptible for COPD (age 18-40 year, 0 < pack years > 10, FEV1/FVC > 70%, FEV1 > 85% predicted)and high prevalance of COPD in smoking family members older than 45 years
3248510|NCT00850863||D1|30 COPD patients with GOLD stage I (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 > 80% predicted)
3248511|NCT00850863||D2|30 COPD patients with GOLD stage II (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 50-80 predicted)
3248512|NCT00850863||D3|30 COPD patients with GOLD stage III (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 30-50% predicted)
3248513|NCT00850863||D4|30 COPD patients with GOLD stage IV (age 40-75 years,Pack years > 10, FEV1/FVC ≤ 70%, FEV1 30% predicted)
3248514|NCT00850863||E|20 healthy individuels very susceptible for COPD ( Age 18-40 years,0 < Pack years > 10, FEV1/FVC >70%, FEV1 > 85% predicted, and one of the smoking family members has severe early onset COPD or mild COPD with very low smoke exposure
3248515|NCT00850863||F|30 COPD patients who are highly susceptible (age > 53 years with Pack years > 10 , FEV1/FVC ≤ 70% and FEV1 < 40% predicted) or (age >18 years with 0 < pack years > 5, FEV1/FVC ≤ 70% and FEV1 < 80% predicted)
3248516|NCT00850850|Active Comparator|Physostigmine|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 mg of physostigmine.
3248517|NCT00850850|Placebo Comparator|NaCl|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo).
3248518|NCT00850837|Experimental|1|Participants will apply Acidform lubricant twice daily for 14 consecutive days between menses
3248519|NCT00850837|Placebo Comparator|2|Participants will apply HEC gel twice daily for 14 consecutive days between menses
3248520|NCT00850824|Experimental|Behavioral|Community Health Worker home visits
3248521|NCT00850824|Active Comparator|Usual Care|Usual Care, Wait List Control
3248522|NCT00850811|Experimental|1|
3248523|NCT00850798|Experimental|1|Fasting plasma glucose (mg/dL) 90 to 130 Glycated hemoglobin (%) 6.0 to 7.0
3248524|NCT00850798|Active Comparator|2|Fasting plasma glucose (mg/dL) 90 to 180 Glycated hemoglobin (%) 7.0 to 9.0
3248525|NCT00850772|Experimental|Early post-operative enteral feeding|Standard post-operative care and diet together with early post-operative enteral feeding
3248526|NCT00850772|No Intervention|Standard post-operative care and diet|Standard post-operative care and diet only
3248527|NCT00850759|Experimental|virtual reality|street-crossing training in a virtual pedestrian environment
3248528|NCT00850759|Active Comparator|computer and video|exposure to training in pedestrian safety via computer software, internet games, and television videos
3248529|NCT00850759|Active Comparator|streetside training|one-on-one training in street-crossing skills by an adult, at a streetside location
3248530|NCT00850759|No Intervention|no-contact control|no-contact control group.
3248531|NCT00850746|Placebo Comparator|A. Placebo|
3248532|NCT00850746|Experimental|B. Ym443 Lower Dose|
3248533|NCT00850746|Experimental|C. YM443 Higher Dose|
3248534|NCT00850746|Active Comparator|D. Moxiflocxacin|
3248535|NCT00850720||Cardiac Surgery|Infants with congenital defects.
3248536|NCT00850707||1|220 hemodialysis patients with Arterovenous fistula (AVF group)
3248537|NCT00850707||2|58 hemodialysis patients with Arterovenous graft (AVG group)
3248538|NCT00850707||3|180 hemodialysis patients with Tunneled cuffed catheters (TCC group)
3248539|NCT00850707||4|60 healthy subjects as controls
3248540|NCT00850694||1|Obese female adolescents
3248541|NCT00850681|Experimental|1|PEP005 (ingenol mebutate) Gel
3248542|NCT00850668|Active Comparator|EMP-123|Participants who are not allergic to peanuts will receive four escalating doses of study product on a weekly basis
3248543|NCT00850668|Experimental|EMP-123 in Peanut Allergics|Participants who are allergic to peanuts will receive weekly dose escalation of the study product for 10 weeks followed by administration every 2 weeks for 6 weeks
3248544|NCT00850642|Placebo Comparator|Placebo|12 day repeat dosing with placebo
3248545|NCT00850642|Experimental|GSK2190915 100mg|12 day repeat dosing treatment phase with 100mg GSK2190915.
3248546|NCT00850629|Placebo Comparator|placebo|Placebo
3248547|NCT00850629|Experimental|lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
3248548|NCT00850616|Experimental|1|MRKAd6 Trigene 0.5x10^9 Ad6 vg
3248549|NCT00850616|Experimental|2|MRKAd6 Trigene 0.5x10^10 Ad6 vg
3248550|NCT00850616|Experimental|3|MRKAd6 Trigene 0.5x10^11 Ad6 vg
3248551|NCT00850616|Experimental|4|MRKAd5 Trigene 0.5x10^10 Ad5 vg
3248552|NCT00850616|Experimental|5|MRKAd5 Trivalent 1.5x10^10 Ad5 vg
3248553|NCT00850616|Experimental|6|MRKAd5+6 Trigene 1x10^9 Ad vg
3248554|NCT00850616|Experimental|7|MRKAd5+6 Trigene 1x10^10 Ad vg
3248555|NCT00850616|Placebo Comparator|8|Placebo
3248556|NCT00850603|Active Comparator|Group 1|0.5 mL Subcutaneous arm (Menomune® )
3248557|NCT00850603|Experimental|Group 2|0.1 mL Subcutaneous arm (Menomune®)
3248558|NCT00850603|Experimental|Group 3|0.05 mL Intradermal arm (Menomune®)
3248559|NCT00850603|Experimental|Group 4|0.1 mL Intradermal arm (Menomune®)
3248607|NCT00850161|Active Comparator|aspart|Subcutaneous administration
3248561|NCT00850590|Experimental|Low Dose|NRL001 at 5, 7.5, and 10 mg administered in a dose escalating manner with placebo in a random position in the sequence. NRL001 is contained in either a 1 g or a 2 g slow release rectal suppository.
3248562|NCT00850590|Experimental|High Dose|NRL001 at 10, 12.5, and 15 mg administered in a dose escalating manner with placebo in a random position in the sequence. NRL001 is contained in either a 1 g or a 2 g slow release rectal suppository.
3248563|NCT00850577|Active Comparator|Paclitaxel/Carboplatin/CT-322|
3248564|NCT00850577|Active Comparator|Paclitaxel/Carboplatin/Bevacizumab/Placebo|
3248565|NCT00850564|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone (Tesamorelin) 2mg by subcutaneous injection once daily
3248566|NCT00850551|Active Comparator|Usual Care|Usual Care
3248567|NCT00850551|Other|Intervention|Twice weekly home spirometry and symptom assessment
3248568|NCT00850512|Experimental|CHOP21|4 cycles CHOP21-R plus Zevalin
3248569|NCT00850499|Experimental|VELCADE and fludarabine (Group A)|VELCADE 1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 and fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
3248570|NCT00850499|Active Comparator|fludarabine and rituximab (Group B)|fludarabine 40mg/m2/day orally on Days 1 to 5 and rituximab 375mg/m2 on Day 1 of every 35-day cycle
3248571|NCT00850473|Experimental|Positron Emitting Image|Patient will have a PET/CT imaging study to determine cardiac stenosis, F-18 FDG and heparin/intralipid infusion and Contrast Dye.will be administered.
3248572|NCT00850460|Placebo Comparator|Placebo|Lactose placebo pill
3248573|NCT00850460|Active Comparator|Statins|Statin medications
3248574|NCT00850447|Experimental|Cognitive Remediation Therapy|
3248575|NCT00850447|Placebo Comparator|Videogames|
3248576|NCT00850421|Other|Botulinum Toxin Type A|
3248577|NCT00850408|Experimental|Real rTMS|Real rTMS - subjects receiving real repetitive TMS - 1Hz over unaffected hemisphere
3248578|NCT00850408|Sham Comparator|Sham rTMS|Sham rTMS
3248579|NCT00850395||1|Non-Interventional
3248580|NCT00850382|Experimental|Dasatinib|"Induction cycle(s):~Patients will receive in cycle 1 induction therapy with daunorubicin 60 mg/m2/day administered on days 1 through 3 and cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7). Patients will receive dasatinib 100 mg QD on days 8-21. Patients not achieving CR or CRi at the end of cycle 1 will be evaluable to receive a second induction cycle identical in schedule and dosage to the first induction cycle.~Consolidation Cycles 1, 2, 3, 4:~Patients achieving CR or CRi at the end of cycle 1 will receive consolidation therapy for 4 cy-cles. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours. Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
3248581|NCT00850369|Experimental|1|All subjects wil receive monthly RBC transfusions for 6 months
3248582|NCT00850356||Bariatric Surgery Patient (Sx)|Participants who are patients in an Adult Weight Management Clinic (AWMC) and undergo bariatric surgery.
3248583|NCT00850356||Medical Treamtent (Mx)|Participants who are patients in the same AWMC as above and are currently undergoing a medical treatment program that includes intensive lifestyle counseling (diets, exercise, behavioral modification).
3248584|NCT00850356||Wait-List (Wx)|Participants who are on the Wait-List for the AWMC, and waiting to undergo medical treatment program and/or bariatric surgery.
3248585|NCT00850343|Experimental|Certolizumab pegol 200 mg|Participants received 200 mg certolizumab pegol by subcutaneous injection once every 2 weeks for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
3248586|NCT00850343|Experimental|Certolizumab pegol 400 mg|Participants received 400 mg certolizumab pegol by subcutaneous injection once every 4 weeks for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
3248587|NCT00850330||Hospitalized patients|Patients elder than 65 years old hospitalized for any reason.
3248588|NCT00850304|Experimental|Arm one|
3248589|NCT00850291||1|Electrosurgical vessel sealing device
3248590|NCT00850291||2|traditional surgical methods:stitches and ligations
3248591|NCT00850278|Experimental|FLT-PET imaging|Prior to surgical resection, patient will undergo [11C]MET PET imaging, [18F]FLT PET imaging, MRI, and spectroscopy imaging.
3248592|NCT00850265|Experimental|Spacer|Extrafine formoterol plus beclomethasone with spacer
3248593|NCT00850265|No Intervention|No Spacer|Extrafine formoterol plus beclomethasone without spacer
3248594|NCT00850252|Experimental|Lifeline blood vessel|
3248595|NCT00850239|Experimental|1|dutogliptin/PHX1149T
3248596|NCT00850239|Placebo Comparator|2|Plabeco
3248597|NCT00850226|Experimental|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
3248598|NCT00850226|Experimental|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
3248599|NCT00850213||Endeavor Resolute Stent|Patients implanted with the Medtronic Endeavor Resolute stent
3248600|NCT00850200|Experimental|Proton Radiation Plan|
3248601|NCT00850200|Active Comparator|Conventional Photon Radiation Plan|
3248602|NCT00850200|Active Comparator|Intensity Modulated Radiation Plan|
3248603|NCT00850187|Experimental|Bone marrow mesenchymal stem cells|
3248604|NCT00850174|Experimental|Oxcarbazepine|Oxcarbazepine 600 mg Tablet (test) dosed in first period followed by Trileptal® 600 mg Tablet (reference) dosed in second period
3248605|NCT00850174|Active Comparator|Trileptal®|Trileptal® 600 mg Tablet (reference) dosed in first period followed by Oxcarbazepine 600 mg Tablet (test) dosed in second period
3248610|NCT00850135|Other|Continuous Glucose Monitor in pregnancy|The Seven Continuous Glucose Monitoring System: Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
3248611|NCT00850122|Experimental|Cefazolin|"Dosage Number of Infants~≤28 days of age 25 mg/kg IV q12 6 29-120 days of age 25 mg/kg IV q8 6"
3248612|NCT00850096|Placebo Comparator|Placebo for Nasulin|Placebo for Nasulin Spray
3248613|NCT00850096|Active Comparator|Nasulin|Nasulin (intranasal insulin spray 1%)
3248614|NCT00850083||Children in the ED|
3248615|NCT00850070|Experimental|sapropterin, 100 mg capsules|Sapropterin was supplied as a 100 mg tablet and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks.
3248616|NCT00850070|Placebo Comparator|Placebo, matching active drug|The placebo was supplied as a 100 mg tablet, and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks.
3248617|NCT00850044|Active Comparator|1|ABT-450
3248618|NCT00850044|Placebo Comparator|2|Placebo for ABT-450
3248619|NCT00850044|Active Comparator|3|ABT-450/ritonavir
3248620|NCT00850044|Placebo Comparator|4|Placebo for ABT-450/placebo for ritonavir
3248621|NCT00850031|Experimental|AcuFocus Corneal Inlay|Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.
3248622|NCT00850018|Experimental|1|Participants will receive monthly blood transfusions.
3248623|NCT00850018|Active Comparator|2|Participants will receive usual care.
3248624|NCT00850005|Experimental|IVIG|Active treatment will be intravenous immunoglobulin G (Gamunex, immune globulin intravenous [human], 10%), at a dose of 2 g/kg divided over five days (0.4 g/kg/day).
3248625|NCT00850005|Placebo Comparator|Placebo|The placebo treatment will be intravenous normal saline and will be infused in a similar manner.
3248626|NCT00849992|Other|Imiquimod 5%|Patients randomized to this arm will receive treatment with imiquimod 5%
3248627|NCT00849992|Other|Photodynamic therapy|Patients will be randomized to receive photodynamic therapy twice at a 2 week interval to the affected area.
3248628|NCT00849979|Other|Questionnaire|
3248629|NCT00849979|Other|Questionnaire + Interview|
3248630|NCT00849966|Experimental|A|Celebrex suspension
3248631|NCT00849966|Placebo Comparator|B|Placebo
3248632|NCT00849953||FinESS Treatment|Subjects undergoing treatment with the FinESS Sinus Treatment System
3248633|NCT00849940|Experimental|CAS NIRS FORE-SIGHT oximeter|Pediatric patients presenting for cardiac catheterization.
3248634|NCT00849914||1|Patients with actinic keratoses of the skin
3248635|NCT00849914||2|Patients with basal cell carcinoma of the skin
3248636|NCT00849914||3|Patients with squamous cell carcinoma of the skin
3248637|NCT00849901|Placebo Comparator|Placebo|
3248638|NCT00849901|Active Comparator|Fluoxetine|
3248639|NCT00849901|Experimental|Duloxetine|
3248640|NCT00849888|Experimental|Atypical Complete DiGeorge|Thymus Transplantation with Immunosuppression
3248641|NCT00849888|Experimental|Typical Complete DiGeorge|Thymus Transplantation without Immunosuppression
3248642|NCT00849875|Experimental|Group A|All patients are to receive the same treatment consisting of 24 injections of the immunotherapeutic GSK2132231A combined with a course of 8 cycles of dacarbazine given at the beginning of the treatment
3248643|NCT00849862|Experimental|Levetiracetam|Levetiracetam 750 mg Tablet (test) dosed in first period followed by Keppra 750 mg Tablet (reference) dosed in second period
3248644|NCT00849862|Active Comparator|Keppra®|Keppra® 750 mg Tablet (reference) dosed in first period followed by Levetiracetam 750 mg Tablet (test) dosed in second period
3248645|NCT00849849||Postpartum GDM OGTT|200 women with prior GDM in their index pregnancies will undergo postpartum screening assessment. This program will follow these women who are at a high risk of developing DM2 after delivery for 1 year.
3248646|NCT00849836||Acute exacerbation|
3248647|NCT00849836||Stable disease|
3248648|NCT00849836||Healthy control|
3248649|NCT00849823|Active Comparator|Male Sexual Health Program|
3248650|NCT00849823|Experimental|Focus on the Future Program|
3248651|NCT00849810|Experimental|Metoprolol to nebivolol|metoprolol 25-200mg at a stable daily dose for 4 weeks, then change to nebivolol at a comparable stable dose (5-20 mg) for 4 -5 weeks.
3248652|NCT00849797|Experimental|Oxcarbazepine|Oxcarbazepine 600 mg Tablet (test) dosed in first period followed by Trileptal® 600 mg Tablet (reference) dosed in second period
3248653|NCT00849797|Active Comparator|Trileptal®|Trileptal® 600 mg Tablet (reference) dosed in first period followed by Oxcarbazepine 600 mg Tablet (test) dosed in second period
3248654|NCT00849771||1|Operative Treatment (Open Reduction Internal Fixation)
3248655|NCT00849771||2|Non-operative/Conservative Care
3248656|NCT00849758||1|chemotherapy: elderly patients receiving 4x adjuvant taxotere cyclophosphamide adjuvant for breast cancer
3248657|NCT00849758||2|adjuvant hormone therapy: 40 patients receiving adjuvant aromatase inhibitor without chemotherapy
3248658|NCT00849745|Experimental|Systemic Lupus Erythematosus|"Nonmyeloablative allogeneic stem cell transplant~Patients must:~Satisfy the American College of Rheumatology (ACR) criteria for the diagnosis of SLE~Have Lupus nephritis, refractory and severe seizures or encephalopathy, severe pulmonary involvement, transfusion-dependent cytopenias, catastrophic antiphospholipid syndrome or vasculitis and/or immune complex deposition causing end-organ signs or symptoms.~Have received a trial of corticosteroids equivalent to prednisone greater than or equal to 0.5 mg/kg/d for at least one month~Have received a trial of IV cyclophosphamide pulse greater than 500 mg/square meter at least once within the previous 6 months, unless contraindicated because of severe cytopenias or intolerance."
3248746|NCT00849056|Experimental|albiglutide + pioglitazone (with or without metformin)|albiglutide weekly injection + pioglitazone (with or without meformin)
3248659|NCT00849745|Experimental|Systemic Sclerosis|"Nonmyeloablative allogeneic stem cell transplant~Patients must:~Have diagnosis of SSc as defined by American College of Rheumatology and at high-risk for fatal outcome.~Have (1) both a and b below and (2) at least one of c, d, or e.~Diffuse cutaneous scleroderma with skin score of >= 16~Duration of systemic sclerosis <= 3 years from the onset of first non-Raynaud's symptom.~Presence of interstitial or pulmonary vascular lung involvement (FVC or DLCO <70% of predicted) especially with evidence of alveolitis (abnormal bronchoalveolar lavage or high-resolution chest CT scan).~Presence of myocardial disease~History or presence of proteinuria > 500 mg/24 hrs or serum creatinine > the upper limit of normal."
3248660|NCT00849732|Experimental|1|V520 (1x10^9 vp/d)
3248661|NCT00849732|Experimental|2|V520 (1x10^10 vp/d)
3248662|NCT00849732|Placebo Comparator|3|Placebo to V520
3248663|NCT00849719|Experimental|1|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient.
3248664|NCT00849719|Active Comparator|2|Patients in this arm will be administered with only boluses of 1.5 mg/bolus of MO, by request.
3248665|NCT00849706||Study group|Medical staff personal, doctors and nurses, working night shifts.
3248666|NCT00849693|Placebo Comparator|Placebo|
3248667|NCT00849693|Active Comparator|Fluoxetine|
3248668|NCT00849693|Experimental|Duloxetine 60 mg|
3248669|NCT00849693|Experimental|Duloxetine 30 mg|
3248670|NCT00849680|Placebo Comparator|Placebo|Participants receiving 1.0 ml of placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine or the placebo to the MRKAd5 HIV-1 gag vaccine injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26 or a 2-dose regimen at Day 1 and Week 26 or Day 1 and Week 4.
3248671|NCT00849680|Experimental|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)|Participants receiving 1.0 ml of the Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
3248672|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
3248673|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
3248674|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
3248675|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
3248676|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26, or in a 2-dose regimen at Day 1 and Week 4 (with no vaccine administered at Week 26) or Day 1 and Week 26 (with placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine administered at Week 4)
3248677|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
3248678|NCT00849667|Active Comparator|1|Carboplatin and taxane with MORAb-003 1.25 mg/kg
3248679|NCT00849667|Active Comparator|2|Carboplatin and taxane with MORAb-003 2.5 mg/kg
3248680|NCT00849667|Placebo Comparator|3|Carboplatin and taxane with Placebo
3248681|NCT00849654|Experimental|PCI-32765|
3248682|NCT00849641||1|patients with decompensated liver cirrhosis admitted to the medical ICU
3248683|NCT00849641||2|critically ill patients without liver cirrhosis, matched to group 1
3248684|NCT00849641||3|healthy control group
3248685|NCT00849628||1|Constipation
3248686|NCT00849615|Experimental|FLOT|
3248687|NCT00849602|Placebo Comparator|1|
3248688|NCT00849602|Active Comparator|2|
3248689|NCT00849589|No Intervention|1|Treatment as Usual (TAU)
3248690|NCT00849589|Experimental|2|Computerized Screening and Brief Physician Advice (SBA)
3248691|NCT00849589|Experimental|3|Computerized screening and brief physician advice with technological extenders (SBA/TE)
3248692|NCT00849576|Active Comparator|Regular Human Insulin|Single Injection
3248693|NCT00849576|Active Comparator|Inuslin Lispro (90%)|Single Injection
3248694|NCT00849576|Experimental|Insulin VIAject™ (75%)|Single Injection
3248695|NCT00849576|Experimental|Insulin VIAject™ (90%)|Single injection
3248696|NCT00849563|Active Comparator|SRA+genetic test|patients randomized to receive genetic test for type 2 diabetes risk will be followed and surveyed and will be counseled based on SAR and genetic risk for type 2 diabetes
3248697|NCT00849563|No Intervention|SRA only|Patients randomized to not get genetic testing will be followed and surveyed and will be counseled based on SRA only
3248698|NCT00849563|No Intervention|no testing control|Patients not interested in genetic testing will be followed and surveyed. Counseling will be based on SRA only
3248699|NCT00849550|Experimental|XELOX-A-Ev|
3248700|NCT00849537|Experimental|Triamcinolone|Injection of intravitreal Triamcinolone
3248701|NCT00849524|Experimental|Ad-ISF35|Ad-ISF35, intranodal injection, 3.3 x 10^10 ISF35 viral particles, every 2-4 weeks up to six total injections.
3248702|NCT00849511|Active Comparator|Placebo first|Placebo 8 weeks, 6 weeks washout, extended-release melatonin 2 mg vesper for 8 weeks
3248703|NCT00849511|Active Comparator|Melatonin first|Extended-release melatonin 2 mg vesper for 8 weeks, 6 weeks washout, placebo 8 weeks
3248704|NCT00849485|Experimental|Levetiracetam|Levetiracetam 750 mg Tablet (test) dosed in first period followed by Keppra® 750 mg Tablet (reference) dosed in second period
3248705|NCT00849485|Active Comparator|Keppra®|Keppra® 750 mg Tablet (reference) dosed in first period followed by Levetiracetam 750 mg Tablet (test) dosed in second period
3248747|NCT00849043||Provent|Provent Professional Sleep Apnea Therapy device
3248706|NCT00849472|Experimental|Treatment Arm|"Preoperative~Cycles 1-4 Doxorubicin 60 mg/m2 IV over 15 minutes + Cyclophosphamide 600 mg/m2 IV over 30 minutes of Day 1 every 21 days~followed by:~Cycles 5-8 Paclitaxel 80 mg/m2 IV over 60 minutes (Days 1, 8, and 15) every 28 days in combination with pazopanib (800 mg) PO once daily (2 tablets taken at the same time each day either 1 hour before or 2 hours after a meal) Daily beginning on Day 1 of the first paclitaxel cycle Until 7 days before surgery~Followed by Surgery~Postoperative Pazopanib 800 mg PO once daily (2 tablets taken at the same time each day either 1 hour before or 2 hours after a meal) Daily beginning 4-6 weeks after surgery 6 months from first postoperative dose"
3248707|NCT00849459|Experimental|adenovirus-mediated human interleukin-12|starting dose of ADV-hIL12 - 1 x 10 to the 10th power vp (virus particles) per patient, escalating in half-log increments up to 1 x 10 to the 13th power vp per patient, after which dose escalation will be at lower increments of 2 x 10 to the 13th power vp, to a maximum of 3.0 x 10 to the 13th power vp per patient.
3248708|NCT00849446||Activity monitoring in CVA patients|
3248709|NCT00849446||Activity monitoring in healthy persons|
3248710|NCT00849433||1|30 patients with asthma
3248711|NCT00849433||2|30 patients with COPD
3248712|NCT00849407||1|melanoma patients
3248713|NCT00849407||2|controls
3248714|NCT00849394||1|Shortened infusions of bevacizumab
3248715|NCT00849381|Experimental|Cervarix Compliance Issue Centre Group|Subjects from one centre where compliance issues were discovered, who received the Hepatitis A control vaccine in the primary study (NCT00122681) and the Cervarix vaccine in the current study
3248716|NCT00849381|Experimental|Cervarix All Centres Group|Subjects from all study centres who received the Hepatitis A control vaccine in the primary study (NCT00122681) and the Cervarix vaccine in the current study.
3248717|NCT00849368|Experimental|Azathioprine / Allopurinol|Single arm study: Dose escalations as described.
3248718|NCT00849355|Experimental|unique|RCOMP-14 with Rituximab
3248719|NCT00849342||A|
3248720|NCT00849329|Experimental|Period 1|1250mg lapatinib once daily in the morning
3248721|NCT00849329|Experimental|Period 2|1250mg lapatinib once daily in the morning in combination with esomeprazole 40mg once daily at bedtime.
3248722|NCT00849316||A|
3248723|NCT00849303|Experimental|earlier gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.
3248724|NCT00849303|Active Comparator|later gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.
3248725|NCT00849290|Experimental|APC8015F|
3248726|NCT00849264|Experimental|A|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with endostar
3248727|NCT00849264|Active Comparator|B|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with CBP and 5-FU
3248728|NCT00849264|Experimental|C|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with endostar, CBP and 5-FU
3248729|NCT00849251|Experimental|Treatment (chemotherapy and enzyme inhibitor)|Patients receive cyclophosphamide IV or PO over 1 hour, bortezomib IV over 3 minutes, and dexamethasone IV or PO on days 1, 8, and 15. Patients also receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3248730|NCT00849212|Experimental|1|
3248731|NCT00849199||High risk of breast or ovarian cancer|
3248732|NCT00849186|Experimental|Arm 1|
3248733|NCT00849160|Experimental|Darunavir/r|
3248734|NCT00849147|Experimental|Haploidentical Bone Marrow Transplant|Participants will receive a human leucocyte antigen (HLA) haploidentical bone marrow transplantation using a non-myeloablative preparative regimen, GVHD prophylaxis.
3248735|NCT00849134|Placebo Comparator|Cohort 1,2 & 3|This part of the study will start with a very low dose of study drug, which will then be gradually increased in subsequent doses. This is known as dose-rising and is the way to assess safety and tolerability (i.e. possible presence of any side effects that make taking the drug unpleasant) of increasing the study drug. Effects will be compared to those seen when a placebo is taken. Up to 3 groups of 8 healthy male and female volunteers may be enrolled.
3248736|NCT00849134|Active Comparator|Cohort 4|If an investigation of food effect is not possible in Cohorts 2 or 3, this Cohort will be used to check if there is a difference in the blood levels of the study drug when taken with or without a high fat meal.
3248737|NCT00849121|Experimental|1|Intradermal vaccinations of a DNA vaccine encoding PAP, with GM-CSF as an adjuvant given every 2 weeks for the first 12 weeks, then every 12 weeks until disease progression.
3248738|NCT00849121|Experimental|2|Intradermal vaccinations of a DNA vaccine encoding PAP, with GM-CSF as an adjuvant given every 2 weeks for the first 12 weeks, then given every 2-week, 4-week, or 3-month intervals as dictated by cellular immune response measurement.
3248739|NCT00849108|Experimental|Cohort 1: dose range and dose interval|Patients to receive either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during pharmacological or exercise stress, over a 1-day or 2-day period.
3248740|NCT00849108|Experimental|Cohort 2: Pharm&exercise stress Efficacy|"Patients to receive 2 IV bolus injections of BMS747158:1 at rest and 1 at stress~For the Pharmacologic (Adenosine) Stress:~Doses at rest to range between 2.9 and 3.4 mCi.~Doses under stress to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~Doses at rest were to range between 1.7 and 2.0 mCi.~Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi."
3248741|NCT00849095|Experimental|as needed medication|patients assigned to this arm will take bid inhaled placebo plus prn inhaled 160/4.5 mcg budesonide/formoterol combination
3248742|NCT00849095|Active Comparator|guideline treatment|bid inhaled 160/4.5 mcg budesonide/formoterol combination plus prn 500 mcg terbutaline
3248743|NCT00849069|Experimental|Group A|
3248744|NCT00849069|Active Comparator|Group B|
3248745|NCT00849056|Placebo Comparator|placebo + pioglitazone (with or without metformin)|Placebo albiglutide weekly injection + pioglitazone (with or without metformin)
3248748|NCT00849030|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
3248749|NCT00849030|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
3248750|NCT00849030|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
3248751|NCT00849017|Experimental|albiglutide|albiglutide weekly injection
3248752|NCT00849017|Placebo Comparator|placebo|albiglutide matching placebo
3248753|NCT00849017|Experimental|albiglutide up-titration|albiglutide weekly injection uptitration at week 12
3248754|NCT00849004|Active Comparator|Gel vs. Sheet|One group will act to compare the effectiveness between silicone gel and silicone sheet.
3248755|NCT00849004|Active Comparator|sheet vs. paper tape|The second group between silicone sheet and paper tape.
3248756|NCT00849004|Active Comparator|gel vs. paper tape|One group will act to compare the effectiveness between silicone gel and paper tape.
3248757|NCT00848991|Active Comparator|Precedex|In the operating room routine anesthesia monitors will be placed and vital signs will be recorded continuously using data collection software. A routine propofol anesthetic will be administered to subjects randomized to the control group or a Precedex infusion with propofol for subjects randomized to the treatment group. Precedex infusion will be started after induction of general anesthesia. Vital signs (SBP, DBP, MAP) will be recorded continuously throughout the surgery. At the end of the case subjects will be extubated and the blinded observer will assess emergence from anesthesia based on hemodynamic stability and tolerance of the endotracheal tube. Videotaping of emergence will be used to assist in the evaluation of emergence of anesthesia and extubation.
3248758|NCT00848991|Active Comparator|Propofol|Propofol for emergence from anesthesia
3248759|NCT00848978|Experimental|2|The experimental group will participate in the aerobic and strength training program.
3248760|NCT00848978|No Intervention|1|The usual care group will receive general physical activity guidelines.
3248761|NCT00848965|Placebo Comparator|Placebo|
3248762|NCT00848965|Experimental|Fluticasone propionate 25ug|
3248763|NCT00848965|Experimental|Fluticason propionate 50ug|
3248764|NCT00848965|Experimental|Fluticasone propionate 100ug|
3248765|NCT00848965|Experimental|Flutciasone propionate 200ug|
3248766|NCT00848939|Experimental|treprostinil diethanolamine|
3248767|NCT00848926|Experimental|Brentuximab vedotin|
3248768|NCT00848913|Active Comparator|Rehabilitation without strength training|Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
3248769|NCT00848913|Experimental|Rehabilitation with strength training|Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of fractured limb every day during admission.
3248770|NCT00848900|No Intervention|Control|
3248771|NCT00848900|Experimental|Outdoor activity|Adding 1 hour outdoor time into school curricula
3248772|NCT00848887|Experimental|1|
3248773|NCT00848874|Experimental|PVGS User|
3248774|NCT00848861|Active Comparator|1 propofol|
3248775|NCT00848861|Active Comparator|2 midazolam plus meperidine|
3248776|NCT00848848|Active Comparator|1|
3248777|NCT00848848|Active Comparator|2|
3248778|NCT00848848|Active Comparator|3|
3248779|NCT00848848|Active Comparator|4|
3248780|NCT00848848|Active Comparator|5|
3248781|NCT00848848|Active Comparator|6|
3248782|NCT00848848|Active Comparator|7|
3248783|NCT00848848|Active Comparator|8|
3248784|NCT00848848|Active Comparator|9|
3248785|NCT00848848|Active Comparator|10|
3248786|NCT00848835||control|all patients in the control group
3248787|NCT00848809||1|Slow-low efficiency daily dialysis group
3248788|NCT00848809||2|Intermittent Hemodialysis group
3248789|NCT00848796|Other|Heparin|Compare two market brands of Heparin
3248790|NCT00848783|Experimental|A-with IP Floxuridine|"Induction treatment:~Cisplatin 25 mg/m^2 and Irinotecan 75 mg/m^2 once a week for 4 weeks, both intravenous; Two weeks without treatment; Repeat the course once.~Re-evaluation, surgery if complete response, partial response or stable disease, or off the protocol if progression of disease.~Randomization~Surgery.~Postoperative IP treatment:~Day 1,2,3: Floxuridine 3 gm/day, IP; Day 3: Cisplatin 60 mg/m^2, IP; 2 weeks without treatment; repeat the course once~Postoperative systemic treatment: courses 1-9: Capecitabine 2,000 mg/m^2/day x14 every 3 weeks/course, Oral"
3248791|NCT00848783|Experimental|B-Without IP Floxuridine|Same as Arm A except no postoperative IP treatment.
3248792|NCT00848770|Active Comparator|1, 140 to 160 mmHg|Esmolol, NPS or NOR
3248793|NCT00848770|Active Comparator|2, 161 to 180 mmHg|Esmolol, NPS or NOR
3248794|NCT00848770|Active Comparator|3, 181 to 200 mmHg|Esmolol, NPS or NOR
3248795|NCT00848757|Experimental|Lifestyle Counseling|"Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the DPP Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population."
3248796|NCT00848757|No Intervention|Usual Care Control|Women with pre-diabetes randomized to usual care will be offered 30 minute appointments with a medical provider to review their diagnosis, risk for diabetes, and stress the importance of lifestyle changes to prevent diabetes, including weight loss and exercise and setting individual goals for these. Usual care participants will be encouraged to achieve goals equivalent to the ILI group: to reduce their weight by 7%, and to increase their physical activity to approximately 150 minutes moderate intensity exercise per week. They will be offered a consultation with an FHCHC nutritionist to achieve dietary/weight loss objectives. Participants are offered printed educational materials which are language and literacy-appropriate.
3248797|NCT00848744|Experimental|topical salicylic acid 1.0% cream|
3248798|NCT00848731|Experimental|iNO|gaseous NO is delivered by facemask
3248799|NCT00848718|Experimental|MK-2206 + carboplatin + paclitaxel|MK-2206 combined with carboplatin and paclitaxel
3248800|NCT00848718|Experimental|MK-2206 + docetaxel|MK-2206 combined with docetaxel
3248801|NCT00848718|Experimental|MK-2206 + erlotinib|MK-2206 combined with erlotinib
3248802|NCT00848705|Active Comparator|Measurement Only|
3248803|NCT00848705|Experimental|Internet Intervention|
3248804|NCT00848692|Experimental|1|Rituximab
3248805|NCT00848692|Placebo Comparator|2|Placebo (saline)
3248806|NCT00848679|Active Comparator|Epidural lidocaine|30 women to receive 5 x 5mL boluses of epidural lidocaine 2%. 10 pre-eclampsia, 10 term pregnancy, 10 non-pregnant.
3248807|NCT00848679|Placebo Comparator|Epidural saline|30 women to receive 5 x 5 mL boluses of epidural saline. 10 pre-eclamptics, 10 normal term pregnancy, 10 non-pregnant
3248808|NCT00848666|Experimental|I|Patients with tinea pedis
3248809|NCT00848640|Experimental|Sorafenib|
3248810|NCT00848627||Males|60 years of age or older Smokers or history of smoking
3248811|NCT00848588||1|Full and part-time 9-1-1 call takers employed at Ambulance Communication Centres in the Canadian provinces of Ontario, Nova Scotia, New Brunswick, as well as the city of Montreal, Quebec, Canada.
3248812|NCT00848575||Group 1 - Device|The principal Investigator and sub-investigators of this study will identify potential participants that attend the gynecologic oncology or gynecology clinics of UAMS. These subjects will have been scheduled for diagnostic or therapeutic laparoscopy. Based on the Inclusion Criteria and Exclusion Criteria of this study, women who are eligible for the study will be approached to participate.
3248813|NCT00848562|Experimental|Nicorandil|
3248814|NCT00848549|Active Comparator|ZNS|
3248815|NCT00848549|Active Comparator|CBZ|
3248816|NCT00848536|Experimental|TRAVATAN APS|One drop once daily in the evening for 3 months
3248817|NCT00848536|Active Comparator|TRAVATAN|One drop once daily in the evening for 3 months
3248818|NCT00848510|Experimental|EMD 525797|
3248819|NCT00848497|Active Comparator|Testim® + Viagra®|Testim® gel (50 mg of testosterone) once daily + Viagra® 25 mg tablet every night
3248820|NCT00848497|Placebo Comparator|Placebo Testim® + Viagra®|Placebo Testim® gel once daily + Viagra® 25 mg tablet every night
3248821|NCT00848484|Experimental|1|MK5757
3248822|NCT00848484|Placebo Comparator|2|Placebo
3248823|NCT00848471|Experimental|1|Quark RMR calorimeter (Cosmed)
3248824|NCT00848471|Active Comparator|2|Deltatrac II (GE health Care Clinical Systems)
3248825|NCT00848458|Experimental|Azelaic Acid Iontophoresis|
3248826|NCT00848458|Active Comparator|Azelaic acid topical|
3248827|NCT00848445|Experimental|APP and VRR on|APP and VRR turned on at 2 week visit
3248828|NCT00848445|Active Comparator|APP and VRR off|APP and VRR turned off
3248829|NCT00848432|Experimental|1|Optimal therapeutic doses of risperidone continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months in clinically stable schizophrenia patients
3248830|NCT00848432|Experimental|2|Optimal therapeutic doses of risperidone continued for 26 weeks followed by a 50% dose reduction for at least another 6 months in clinically stable schizophrenia patients
3248831|NCT00848432|Experimental|3|Optimal therapeutic doses of risperidone continued for at least 1 year in clinically stable schizophrenia patients
3248832|NCT00848419|Active Comparator|Methadone|Epidural methadone bolus 4mg
3248833|NCT00848419|Active Comparator|Morphine|Epidural morphine 4mg bolus
3248834|NCT00848419|Active Comparator|Fentanyl|Epidural fentanyl 200 microgram bolus
3248835|NCT00848419|Placebo Comparator|Saline|Epidural saline bolus
3248836|NCT00848406||1|30 individuals ≤ 40 years, who currently smoke ≥ 10 cigarettes/day and > 10 packyears
3248837|NCT00848406||2|30 individuals ≤ 40 years, who have not smoked during the last year, have never smoked for as long as a year (i.e. at least one cigarette per day or one cigar per week, AND have < 0.5 packyear.
3248838|NCT00848406||3|30 individuals above 40 years, who currently smoke ≥ 10 cigarettes per day, and > 20 packyears.
3248839|NCT00848406||4|30 individuals above 40 years, who have not smoked during the last year, have never smoked for as long as a year, and have < 0.5 packyear.
3248840|NCT00848393|Active Comparator|Fentanyl (High Dose)|This arm will receive a total of 25 mcg/kg of Fentanyl (High Dose) in two divided doses. First half-dose given at induction and second half-dose given before incision.
3248841|NCT00848393|Active Comparator|Fentanyl (Low Dose)|This arm will receive a total of 10 mcg/kg of Fentanyl (Low Dose). First half-dose will be given at induction and second half -dose given before incision.
3248842|NCT00848393|Active Comparator|Fentanyl (Low Dose) + Dexmedetomidine|This arm will receive10 mcg/kg of Fentanyl (Low Dose) -2 divided doses. Dexmedetomidine (Dex) loading dose-1 mcg/kg over 10 min, then Dex infusion at 0.5mcg/kg/hr.
3248843|NCT00848380||1|Patients with hypertension and hyperlipidemia and other CV risk factors
3248844|NCT00848367|Experimental|High attachment anxiety condition|16 weeks of Group Psychodynamic Interpersonal Psychotherapy for patients with Binge Eating Disorder, matching them by attachment anxiety dimensions in order to enhance the impact of the therapy. It is hypothesized that by optimally matching patients to groups, they will have better clinical and health outcomes.
3248845|NCT00848367|Experimental|Low attachment anxiety condition|16 weeks of Group Psychodynamic Interpersonal Psychotherapy for patients with Binge Eating Disorder, matching them by attachment anxiety dimensions in order to enhance the impact of the therapy. It is hypothesized that by optimally matching patients to groups, they will have better clinical and health outcomes.
3248846|NCT00848354|Experimental|Phase 1 Etanercept + methotrexate|Phase 1: Etanercept + methotrexate
3248847|NCT00848354|Active Comparator|Phase 1 Conventional DMARD (SSZ or HCQ) + MTX|Phase 1: Sulfasalazine (SSZ) + methotrexate (MTX) OR Phase 1: Hydrocholoquine (HCQ) + methotrexate
3248848|NCT00848341||Control|
3248849|NCT00848328|Experimental|Lenalidomide and Rituximab|Rituximab 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15. Lenalidomide 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
3248850|NCT00848315|No Intervention|1|Usual Care that the Type 2 Diabetes Patients usually receive at the health centers.
3248851|NCT00848315|Experimental|2|Cognitive Behavioral Intervention
3248852|NCT00848302|Experimental|L-arginine|Assess the effects of regional L-arginine supplementation in patients with chronic lower extremity occlusive disease undergoing angiography
3248853|NCT00848289||Participants with Bladder Cancer|Patients diagnosed with superficial or muscle-invasive bladder cancer. Specimens, personal and follow-up telephone interviews will be collected and conducted.
3248854|NCT00848276||1|Hypogonadal Men before and after starting testosterone replacement therapy
3248855|NCT00848276||2|Post-menopausal women before and after starting Estrogen Replacement Therapy
3248856|NCT00848263|Active Comparator|DVR|Volar plate
3248857|NCT00848263|Active Comparator|DNP|Dorsal nail plate
3248858|NCT00848250|Experimental|ACE inhibitor|Patients already on an ACE inhibitor will continue it until the day of surgery
3248859|NCT00848250|Experimental|No ACE inhibitor|Patients on ACE inhibitors who are randomized to stop their ACE inhibitor 48 hours prior to surgery
3248860|NCT00848237|Experimental|Treatment|All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
3248861|NCT00848224|Experimental|2|
3248862|NCT00848211|Placebo Comparator|Placebo|
3248863|NCT00848211|Experimental|TUTI-16 0.03 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
3248864|NCT00848211|Experimental|TUTI-16 0.1 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
3248865|NCT00848211|Experimental|TUTI-16 0.6 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
3248866|NCT00848198||Normal|Subjects with no objective signs of Dry Eye Disease
3248867|NCT00848198||Dry Eye Disease|Subjects with objective signs of Dry Eye Disease
3248868|NCT00848185||Antagonist-hCG for triggering|Protocol with antagonist and hCG to trigger oocyte maturation
3248869|NCT00848185||Antagonist-aGnRH for triggering|Protocol with antagonist and 0,2 mg triptorelin to trigger oocyte maturation
3248870|NCT00848185||Long protocol-hCG for triggering|Long Protocol and hCG to trigger oocyte maturation
3248871|NCT00848172|Active Comparator|Octanoic Acid|
3248872|NCT00848172|Placebo Comparator|Placebo|
3248873|NCT00848159||1|Group 1 was composed of six women with a densitometric diagnosis of osteoporosis in column (DP =- 2.70 to -4.97), with an average weight of 57.5 (+6.9) kg, mean height of 1 , 4 (+ 0.07) my body mass index (BMI) of 26.1 (+1.8) Kg/m2
3248874|NCT00848159||2|Group 2 consists of six women with a densitometric diagnosis of osteopenia in column (DP =- 1.07 to -2.09), with an average weight of 62.1 (+9.9) kg, mean height of 1, 5 (+0.03) I BMI 25.3 (3.3) kg/m2, both compared with young adults
3248875|NCT00848146|Experimental|NOTES-Assisted Lap Chole|These patients will undergo an experimental surgical procedure that uses a combination of laparoscopic instruments (i.e., inserted through the skin into the abdominal cavity) and flexible endoscopic instruments (i.e., inserted through the mouth).
3248876|NCT00848133|Active Comparator|mini-midvastus|
3248877|NCT00848133|Active Comparator|mini-subvastus|
3248878|NCT00848120|Experimental|1|
3248879|NCT00848107|Experimental|Treprostinil|Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose (MTD).
3248880|NCT00848094|Other|arm 1|Arm I: tumor diameter more than 5 cm and less than 10 cm.
3248881|NCT00848094|Other|arm 2|Arm II: tumor diameter no less than 10 cm.
3248882|NCT00848081|Placebo Comparator|Placebo|
3248883|NCT00848081|Experimental|Tadalafil|
3248884|NCT00848068|Other|OD (Right Eye)|FID 114657 or OPTIVE
3248885|NCT00848068|Other|OS (Left eye)|FID 114657 or OPTIVE
3248886|NCT00848055|Experimental|arm 1|AbGn168 cohort 1
3248887|NCT00848055|Experimental|arm 2|AbGn168 cohort 2
3248888|NCT00848055|Experimental|arm 3|AbGn168 cohort 3
3248889|NCT00848055|Experimental|arm 4|AbGn168 cohort 4
3248890|NCT00848055|Experimental|arm 5|AbGn168 cohort 5
3248891|NCT00848055|Experimental|arm 6|AbGn168 cohort 6
3248892|NCT00848055|Experimental|arm 7|AbGn168 cohort 7
3248893|NCT00848055|Experimental|arm 8|AbGn168 cohort 8
3248894|NCT00848042|Active Comparator|AuroShell-3.5|Group treated with the lowest treatment level with 4.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 3.5 watts. Device: AuroLase Therapy
3248895|NCT00848042|Active Comparator|AuroShell-4.5|Group treated with up to 7.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 4.5 watts. Device: AuroLase Therapy
3248896|NCT00848042|Active Comparator|AuroShell-5.0|Group treated with up to 7.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 5.0 watts. Device: AuroLase Therapy
3248897|NCT00848029|Experimental|1|
3248898|NCT00848016|Experimental|Treatment (R-(-)-gossypol acetic acid)|Patients receive 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3248899|NCT00848003|Active Comparator|1. Active|"Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12)~Probiotic, BB-12, supplemented yogurt, 4 ounces taken orally for 10 days"
3248900|NCT00848003|Placebo Comparator|2. Placebo|Strawberry flavored yogurt
3248901|NCT00847990||Pregnant women|Pregnant women who are scheduled to undergo an amniocentesis or CVS procedure and will receive the fetal FISH and/or karyotype results from the procedure.
3248902|NCT00847977|Active Comparator|1|Heafusine - Physiologic serum
3248903|NCT00847977|Experimental|2|Isofundine - Tetraspan
3248904|NCT00847964|Experimental|Algisyl-LVR implants|Algisyl-LVR implants to the left ventricular wall
3248905|NCT00847951|Other|Renal perfusion in Neonates|Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys.
3248906|NCT00847938|Active Comparator|1|neostigmine 0.04 mg.kg associated with atropine 0.02 mg/kg
3248907|NCT00847938|Active Comparator|2|neostigmine 0.02 mg.kg associated with atropine 0.01 mg/kg
3248908|NCT00847938|Active Comparator|3|neostigmine 0.1 mg.kg associated with atropine 0.05 mg/kg
3248909|NCT00847938|No Intervention|4|no injection of neostigmine
3248910|NCT00847925|Other|A|50ng Avotermin/100ul
3248911|NCT00847925|Other|B|20ng Avotermin/100ul
3248912|NCT00847925|Other|C|5ng Avotermin/100ul
3248913|NCT00847925|Other|D|100ng Avotermin/100ul
3248914|NCT00847925|Other|E|500ng Avotermin/100ul
3248915|NCT00847925|Other|F|0.25ng Avotermin/100ul
3248916|NCT00847925|Other|G|1ng Avotermin/100ul
3248917|NCT00847925|Other|H|20ng Avotermin/100ul
3248918|NCT00847925|Other|I|50ng Avotermin/100ul
3248919|NCT00847912|Experimental|Arm 1: 5-fluorouracil|Group assigned to blinded 5-FU (5-fluorouracil) cream applied to face and ears twice daily for maximum of 56 doses
3248920|NCT00847912|Placebo Comparator|Arm 2: Placebo|Group assigned to blinded placebo, vehicle control cream applied to face and ears twice daily for maximum of 56 doses
3248921|NCT00847899|Active Comparator|1|AR9281
3248922|NCT00847899|Active Comparator|2|AR9281
3248923|NCT00847899|Placebo Comparator|3|Placebo
3248924|NCT00847899|Placebo Comparator|4|Placebo
3248925|NCT00847886|Experimental|LX3305|Daily oral intake of LX3305 for 14 days.
3248926|NCT00847886|Placebo Comparator|LX3305 Placebo|Matching placebo dosing with daily oral intake for 14 days.
3248927|NCT00847873|Experimental|Combined SU/IPV treatment|A combined treatment containing cognitive behavioral therapy addressing partner violence and cognitive behavioral therapy addressing substance abuse
3248928|NCT00847873|Active Comparator|control condition|Cognitive behavioral therapy addressing substance abuse
3248929|NCT00847860|Experimental|1|Cilostazol
3248930|NCT00847860|Active Comparator|2|Asprin
3248931|NCT00847847|Other|2|control subjects with muscle biopsy
3248932|NCT00847847|Other|1|ALS patients with muscle biopsy
3248933|NCT00847834|Experimental|1|"4 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg followed by:~If DBP<85mmHg: 4 weeks of one tablet of Irbesartan 150mg / Hydrochlorothiazide 12.5mg~If DBP≥85mmHg: 4 weeks of one tablet of Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet of Irbesartan 150mg"
3248934|NCT00847834|Experimental|2|"2 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg followed by 2 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet Irbesartan 150mg followed by:~If DBP<85mmHg: 4 weeks of of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet Irbesartan 150mg~If DBP≥85mmHg: 4 weeks of two tablets Irbesartan 150mg / Hydrochlorothiazide 12.5mg"
3248935|NCT00847821||Bazedoxifene 10 mg/CE 0.625 mg|
3248936|NCT00847821||Bazedoxifene 20 mg/CE 0.625 mg|
3248937|NCT00847821||Bazedoxifene 40 mg/CE 0.625 mg|
3248938|NCT00847821||Bazedoxifene 10 mg/CE 0.45 mg|
3248939|NCT00847821||Bazedoxifene 20 mg/CE 0.45 mg|
3248940|NCT00847821||Bazedoxifene 40 mg/CE 0.45 mg|
3248941|NCT00847821||Raloxifene 60 mg|
3248942|NCT00847821||Placebo|
3248943|NCT00847808|Experimental|1|
3248944|NCT00847795|Experimental|1|5ng Avotermin
3248945|NCT00847795|Experimental|2|50ng Avotermin
3248946|NCT00847795|Experimental|3|100ng Avotermin
3248947|NCT00847795|Placebo Comparator|4|Placebo
3248948|NCT00847795|No Intervention|5|Standard Care
3248949|NCT00847782|Other|Blood draw (Group 1)|"Normocholesterolemic Subjects~Normal Healthy Volunteers"
3248950|NCT00847782|Other|Blood draw (Group 2)|Hypercholesterolemic Subjects
3248951|NCT00847782|Other|Blood draw (Group 3)|Hypercholesterolemic Subjects with Statin Treatment
3248952|NCT00847769|Experimental|High velocity, low amplitude stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
3248953|NCT00847769|Active Comparator|Slow, mobilization stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
3248954|NCT00847769|Sham Comparator|Passive positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
3248955|NCT00847756||rAOM|Children 0-5 years of age suffering from recurrent acute otitis media and waiting for tympanostomy tube insertion.
3248956|NCT00847756||COME|Children 0-5 years of age suffering from chronic otitis media with effusion and waiting for tympanostomy tube insertion.
3248957|NCT00847756||CSOM|Children 0-5 years of age suffering from chronic suppurative otitis media and waiting for tympanostomy tube insertion. Note: Only 3 patients with CSOM were recruited and therefore not suitable for publication.
3248958|NCT00847717|Experimental|1|IIb preserving neck dissection
3248959|NCT00847717|Other|2|Conventional neck dissection
3248960|NCT00847704|Experimental|Test treatment group|Device: Assisted movement and enhanced sensation
3248961|NCT00847691||Sarcoma|patients with biopsy or excision of sarcoma (suspected or diagnosed)
3248962|NCT00847678|Experimental|1|Mycograb + Amphotericin B + 5 flucytosine
3248963|NCT00847678|Placebo Comparator|2|Placebo + Amphotericin B + 5 flucytosine
3248964|NCT00847678|Experimental|3|Mycograb + Amphotericin B
3248965|NCT00847665|Active Comparator|Turning every 4 hours|The four-hours repositioning group patients were turned every four hours following the next sequence: left side, back with a 30º elevation of the head end and the foot end of the bed, right side using the 30º tilt, back.
3248966|NCT00847665|Experimental|Turning every 2 hours|The two-hours repositioning group patients, were turned every two hours following the next sequence: left side, back with a 30º elevation of the head end and the foot end of the bed, right side using the 30º tilt, back.
3248967|NCT00847639|Experimental|Lenalidomide|Lenalidomide maintenance therapy will start within 60 to 180 days after allogeneic HCT at a starting dose of 10mg PO once daily. Dose escalation and de-escalation are performed depending on tolerability of lenalidomide. The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days).
3248968|NCT00847626|Experimental|Azilsartan medoxomil 20 mg/chlorthalidone 12.5 mg QD|
3248969|NCT00847626|Experimental|Azilsartan medoxomil 20 mg/chlorthalidone 25 mg QD|
3248970|NCT00847626|Experimental|Azilsartan medoxomil 40 mg/chlorthalidone 12.5 mg QD|
3248971|NCT00847626|Experimental|Azilsartan medoxomil 40 mg/chlorthalidone 25 mg QD|
3248972|NCT00847626|Experimental|Azilsartan medoxomil 80 mg/chlorthalidone 12.5 mg QD|
3248973|NCT00847626|Experimental|Azilsartan medoxomil 80 mg/chlorthalidone 25 mg QD|
3248974|NCT00847626|Active Comparator|Chlorthalidone 12.5 mg QD|
3248975|NCT00847626|Active Comparator|Chlorthalidone 25 mg QD|
3248976|NCT00847626|Experimental|Azilsartan medoxomil 20 mg QD|
3248977|NCT00847626|Experimental|Azilsartan medoxomil 40 mg QD|
3248978|NCT00847626|Experimental|Azilsartan medoxomil 80 mg QD|
3248979|NCT00847613|Experimental|Sequence 1|
3248980|NCT00847613|Experimental|Sequence 2|
3248981|NCT00847613|Placebo Comparator|Sequence 3|
3248982|NCT00847613|Placebo Comparator|Sequence 4|
3248983|NCT00847600|Experimental|1 Pregnenolone|50 mg/day
3248984|NCT00847600|Placebo Comparator|2 Placebo|1 caps.
3248985|NCT00847587|Experimental|1|Early postpartum insertion
3248986|NCT00847587|Active Comparator|2|Standard postpartum insertion
3248987|NCT00847574|Experimental|Moderate-fat|35% of calories from fat
3248988|NCT00847574|Experimental|Lower-fat|20% of calories from fat
3248989|NCT00847561|Experimental|Family-based CBT|Family-based CBT. Participants will receive family-based cognitive behavioral therapy. Families in this group will learn about how to identify the signs and symptoms of anxiety, ways to cope with anxiety, relaxation techniques, and problem-solving skills. They will participate in 8, one-hour sessions, once/week with trained clinicians and 3 monthly booster sessions to reinforce what they learned.
3248990|NCT00847561|Placebo Comparator|Information Monitoring|Information Monitoring. Participants will receive a packet of information about anxiety. Participants in this group will be called monthly to monitor symptoms of anxiety.
3248991|NCT00847548|Experimental|combined treatment|A combined treatment containing cognitive behavioral therapy addressing partner violence and cognitive behavioral therapy addressing substance abuse
3248992|NCT00847548|Active Comparator|control condition|Cognitive behavioral therapy addressing partner violence
3248993|NCT00847535|Other|1|Transurethral dose escalation
3248994|NCT00847535|Other|2|Periurethral dose escalation
3248995|NCT00847522|Experimental|All patients|All participants enrolled.
3248996|NCT00847509|Experimental|FLT PET scan|Open label, nonrandomized, uncontrolled, single group assignment, multi-center clinical trial to evaluate [F-18] FLT as a PET imaging tool in cancer patients clinically scheduled for treatment with radiation or radiation - chemotherapy. Standard [F-18] FDG PET will be the active comparator.
3248997|NCT00847496|Experimental|1|AWBAT
3248998|NCT00847496|Active Comparator|2|BIOBRANE(R)
3248999|NCT00847483|Active Comparator|Latanoprost|
3249000|NCT00847483|Active Comparator|Travoprost|
3249001|NCT00847483|Active Comparator|Bimatoprost|
3249002|NCT00847457|Experimental|Aerobic exercise|Participants will perform aerobic exercise regularly for 12 weeks.
3249003|NCT00847457|Active Comparator|Stretch|Participants will stretch regularly for 12 weeks.
3249004|NCT00847444|Active Comparator|AA|Drug intervention
3249005|NCT00847444|Active Comparator|BA|Lifestyle intervention
3249006|NCT00847444|No Intervention|BB|No individualized lifestyle intervention program.
3249007|NCT00847431||STN DBS Group|PD patients with deep brain stimulators in the subthalamic nucleus. Subjects within this group will be placed into either a 1 contact group, or 2 contact group, depending on contact location requirements for this study.
3249008|NCT00847431||Control Group|PD patients without deep brain stimulator surgery, with similar symptoms to the study group.
3249009|NCT00847418|Experimental|Esketamine|
3249010|NCT00847405|Experimental|1|
3249011|NCT00847405|Active Comparator|2|
3249012|NCT00847392|Experimental|Ultrasound|Bladder ultrasound prior to catheterization
3249013|NCT00847392|No Intervention|Standard catheterization|No ultrasound prior to bladder catheterization
3249014|NCT00847379|Experimental|Ataluren (PTC124)|Ataluren (PTC124)
3249015|NCT00847366|Experimental|Perifosine 201|"Perifosine 201: A Phase 1/2 trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer.~Perifosine dosage:~Arm A: 50 mg p.o. 3 times daily with meals. Arm B: 150 mg p.o. daily at bedtime. Arm C: 300 mg p.o. 3 times a day (900 mg) once a week."
3249016|NCT00847366|Experimental|Perifosine 206|"Perifosine 206: A Randomized Phase II Trial of Three Doses of Perifosine in Combination with Trastuzumab.~Arm A: Perifosine 50 mg p.o. daily + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle.~Arm B: Perifosine 50 mg p.o three times a day + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle.~Arm C: Perifosine 300 mg three times on one day + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle."
3249017|NCT00847366|Experimental|Perifosine 207|Perifosine 207: a Phase IIA Trial of Two Schedules of Perifosine Arm A: 50 mg daily with food. Arm B: 50 mg twice daily with food.
3249018|NCT00847366|Experimental|Perifosine 208|Perifosine 208: A Phase II Trial of Two Schedules of Perifosine in Combination with Endocrine Therapy (Tamoxifen) for Patients with Estrogen Receptor or Progesterone Receptor Positive Metastatic Breast Cancer Dosage: Arm A: 50 mg Perifosine /day p.o. .Endocrine therapy continued at same dose and schedule. Arm B: 900 Perifosine weekly. Endocrine therapy continued at same dose and schedule.
3249019|NCT00847366|Experimental|Perifosine 209|Perifosine 209: A Phase II Trial of Perifosine in Patients with Sarcomas. Perifosine 900 mg weekly (This dose should be divided so that the maximum dose rate is 300 mg in any 4-hour interval).
3249020|NCT00847327|Experimental|Parental Support|
3249021|NCT00847327|Active Comparator|Diabetes Education|
3249022|NCT00847314||Group 1|
3249023|NCT00847301||Renal Impairment|
3249024|NCT00847288|Experimental|Monthly Review Arm|Patients enrolled at centers that are assigned to the monthly review arm will have their device data reviewed monthly
3249025|NCT00847288|Active Comparator|Quarterly Review Arm|Patients enrolled at centers that are assigned to the quarterly review arm will have their device data reviewed every 3 months
3249026|NCT00847275|Placebo Comparator|1|"Exclusive nephrology follow-up arm"
3249027|NCT00847275|Experimental|2|"Geriatric follow-up arm"
3249028|NCT00847262|Experimental|Telmisartan Group|Telmisartan intervention group
3249029|NCT00847262|Active Comparator|Amlodipine Group|Amlodipine intervention group
3249030|NCT00847249|Experimental|1|Solution for nebulisation, inhaled
3249031|NCT00847249|Placebo Comparator|2|Solution for nebulisation, inhaled
3249032|NCT00847236||Subjects with Polymyalgia Rheumatica|50 subjects with Polymyalgia Rheumatica, both acute and chronic
3249033|NCT00847236||Subjects w/o Polymyalgia Rheumatica|50 subjects with Rheumatic Disease other than polymyalgia Rheumatica
3249034|NCT00847236||Subjects w/o Rheumatic Disease|50-Non Rheumatic disease subjects
3249035|NCT00847223|Experimental|ZARNESTRA (Tipifarnib)|
3249036|NCT00847210|Experimental|Dexlansoprazole MR 30 mg QD|
3249037|NCT00847210|Experimental|Dexlansoprazole MR 60 mg QD|
3249038|NCT00847197|Experimental|1|MK1903
3249039|NCT00847197|Placebo Comparator|2|Placebo to MK1903
3249040|NCT00847184|Active Comparator|1. Airtraq|Intubation with the use of the Airtraq technique
3249041|NCT00847184|Active Comparator|2. MacIntosh|Intubation using the standard MacIntosh blade
3249042|NCT00847158|Active Comparator|1|phacoemulsification alone
3249043|NCT00847158|Active Comparator|2|phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
3249044|NCT00847145|Experimental|12B12M (1a)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age,respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
3249045|NCT00847145|Experimental|12B13M (1b)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.
3249046|NCT00847145|Experimental|12M13B15B (2a)|Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.
3249047|NCT00847145|Experimental|12M12B14B (2b)|Previously in the parent study subjects ahd received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.
3249048|NCT00847145|Experimental|12B12M (3a)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ at 2, 4 and 6 months of age respectively. These subjects had received one booster (fourth) dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
3249049|NCT00847145|Experimental|12B13M (3b)|Previously in the present study subjects had received three doses of rMenB+OMV NZ at 12 months of age respectively. These subjects one booster (fourth) dose of rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.
3249050|NCT00847145|Experimental|12B12M_C (4a)|Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age respectively. These subjects had received one single dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
3249051|NCT00847145|Experimental|12B13M_C (4b)|Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age. These subjects received one single dose o rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.
3249052|NCT00847132|Experimental|Collaborative Care|Collaborative Care Treatment: A study care manager provides depression education, consults with study psychiatrist to develop individualized treatment recommendations, and collaborates with patient and medical team to implement those recommendations
3249053|NCT00847132|Active Comparator|Usual Care|Usual Care Treatment: Primary medical providers are informed that the patient has depression and that treatment is recommended.
3249054|NCT00847119|Experimental|Bevacizumab & capecitabine & radiotheraphy|"Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.~Radiotherapy 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.~Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period."
3249055|NCT00847093|Experimental|Cream|Experimental group receiving either medicated topical cream or placebo cream
3249056|NCT00847080|Experimental|Sitagliptin|
3249057|NCT00847080|Placebo Comparator|Placebo|
3249058|NCT00847067|Active Comparator|Block|
3249059|NCT00847067|Sham Comparator|Sham injection|Skin injections with Normal Saline
3249060|NCT00847054|Experimental|MORAb-004|
3249061|NCT00847028|Experimental|1|glucose 10%
3249062|NCT00847028|Experimental|2|glucose 20%
3249063|NCT00847028|Experimental|3|glucose 30%
3249064|NCT00847028|Placebo Comparator|4|placebo: sterile water
3249065|NCT00847015|Experimental|Gemcitabine, Cisplatin, and Sunitinib|This is a phase II study of GCS (Gemcitabine, Cisplatin, and Sunitinib) as neoadjuvant chemotherapy in patients with muscle-invasive urothelial carcinoma of the bladder. Patients with muscle invasive urothelial carcinoma who are candidates for radical cystectomy will be enrolled.
3249066|NCT00847002|Active Comparator|1|Standard Wound Care
3249067|NCT00847002|Active Comparator|2|Flexitouch system with Standard Wound Care
3249068|NCT00846989|Experimental|1|
3249069|NCT00846989|Experimental|2|
3249070|NCT00846989|Active Comparator|3|
3249071|NCT00846976|Experimental|200 mg Casodex|
3249072|NCT00846963|Experimental|Ursodiol|Participants assigned in this arm receive an ursodiol suspension at 20mg/ml.
3249073|NCT00846963|Placebo Comparator|placebo|A placebo suspension that looks like the ursodiol suspension used.
3249074|NCT00846950|Experimental|healthy volunteers|
3249075|NCT00846924|Active Comparator|repeat 24-hour Holter monitor|
3249076|NCT00846924|Experimental|30-day ambulatory cardiac event monitor|
3249077|NCT00846911||Group 1|
3249145|NCT00846365|Experimental|Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD|(dependant on blood pressure)
3249078|NCT00846898|Experimental|cinnamon|Subjects in this group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
3249079|NCT00846898|Placebo Comparator|Control|Subjects in this group will receive placebo capsules (starch flour) for 12 weeks period. The 2 g dose of starch capsules will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
3249080|NCT00846885|Experimental|1|
3249081|NCT00846885|Active Comparator|2|
3249082|NCT00846872|Active Comparator|Low dose GHRP-3|Subjects will receive the infusion for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
3249083|NCT00846872|Active Comparator|High dose GHRP -3|Subjects will receive the infusion for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
3249084|NCT00846872|Placebo Comparator|Saline Infusion|Subjects will receive Placebo for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
3249085|NCT00846859|Experimental|varenicline|
3249086|NCT00846859|Placebo Comparator|placebo|
3249087|NCT00846846|Experimental|Endeavor® Zotarolimus Eluting Coronary Stent|Endeavor® Zotarolimus Eluting Coronary Stent System
3249088|NCT00846833|Experimental|Cyclophosphamide, high-dose interleukin-2, NK cell|
3249089|NCT00846807||Patients 75 years or younger|
3249090|NCT00846794||1 Asymptomatic|students with conditions being studied
3249091|NCT00846794||2 Symptomatic|students without conditions being studied
3249092|NCT00846781|Experimental|Denufosol tetrasodium Inhalation Solution|
3249093|NCT00846755|Active Comparator|Levothyroxine, Propylthiouracil|Drugs for the treatment of thyroid disease, are administered, when necessary, in high risk women, either in case finding, or in Universal Screening Group
3249094|NCT00846755|No Intervention|clinical checks|Low risk women whose sera are tested postpartum. Then patients with undiagnosed thyroid disease, are not treated
3249095|NCT00846742|Experimental|Treatment|Participants receive Stanford V Chemotherapy with or without radiation therapy. Patients receive doxorubicin hydrochloride IV and vinblastine IV on day 1 of weeks 1, 3, 5, and 7; mechlorethamine hydrochloride IV on day 1 of weeks 1 and 5; vincristine sulfate IV and bleomycin IV on day 1 of weeks 2, 4, 6, and 8; etoposide IV on day 1 of weeks 3 and 7; and prednisone PO three times 2-3 weeks after completion of chemotherapy, patients not achieving complete response undergo radiation therapy to individual nodal sites (tailored fields)
3249096|NCT00846716|Experimental|Pioglitazone add on to SU or biguanide|
3249097|NCT00846716|Active Comparator|SU or Biguanide|
3249098|NCT00846703|Active Comparator|Protocol A (MM)|
3249099|NCT00846703|Experimental|Protocol B (MM/VD)|
3249100|NCT00846690|Active Comparator|Benzocaine|"serves as active control"
3249101|NCT00846690|Experimental|TAC|serves as comparator
3249102|NCT00846677|Experimental|1|Vitamin D quick dissolve strip
3249103|NCT00846677|Active Comparator|2|Vitamin D syrup
3249104|NCT00846664|Experimental|Group 1|Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
3249105|NCT00846651|Experimental|colloid, then phenylephrine infusion|colloid administration; with 0.5 L Hydroxyethylstarch solution at a rate of 17 ml/min and completed over 30 min. A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
3249106|NCT00846651|Active Comparator|crystalloid, then phenylephrine infusion|crystalloid administration; The patients received 1.5 L Ringer's lactate infusion at a rate of 50 ml/min and completed over 30 min prior to spinal anesthesia for cesarean section. A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
3249107|NCT00846638|Experimental|1|Diagnostic assessment with brief intervention and 3, 6, and 12 month follow-up
3249108|NCT00846638|Active Comparator|2|Diagnostic assessment with 12 month follow-up
3249109|NCT00846625|Experimental|1|Ranibizumab (0.5 mg)
3249110|NCT00846625|Active Comparator|2|Triamcinolone (4 mg/0.1 ml)
3249111|NCT00846612|Experimental|Avastin-Doxil|
3249112|NCT00846599||1|High omega-3
3249113|NCT00846599||2|High saturated fat
3249146|NCT00846365|Active Comparator|Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD|(dependant on blood pressure)
3249147|NCT00846352|Active Comparator|Early Bronch|This group will receive bronchoscopy within 36 hours of enrollment into the study.
3249114|NCT00846586|Experimental|Indacaterol 150 μg and tiotropium 18 μg|Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3249115|NCT00846586|Active Comparator|Tiotropium 18 μg|Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3249116|NCT00846573|Experimental|Asthmatic Participants|This population is made up of only confirmed asthmatics. Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
3249117|NCT00846573|Experimental|Healthy|"This population is made up of subjects who are considered clinically healthy. This means that there are no records of any chronic disorders or pulmonary history.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
3249118|NCT00846573|Experimental|COPD Patients|"This population is made up of only confirmed COPD patients. Diagnosis must be confirmed through their doctor prior to enrollment.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
3249119|NCT00846573|Experimental|Cystic Fibrosis Patients|"This population is made up entirely of confirmed cystic fibrosis patients. Diagnosis must be confirmed through their physician.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
3249120|NCT00846560||1 ALS patients|
3249121|NCT00846560||2 Healthy subjects|
3249122|NCT00846547|Experimental|Arbaclofen|
3249123|NCT00846534||Post operative atrial fibrillation|To evaluate the ability of oxidative stress markers to predict postoperative atrial fibrillation in subjects undergoing cardiac surgery.
3249124|NCT00846521|Experimental|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
3249125|NCT00846508|Experimental|ciaplantin,cancer,survival|
3249126|NCT00846495|Active Comparator|topiramate|Subjects randomized to Group A at Visit 2 were provided with topiramate, titrated over 4 weeks to a maximum dose of 100 mg daily. One dosage adjustment was allowed with a minimum dose of 50 mg daily.
3249127|NCT00846495|Active Comparator|frovatriptan|Subjects randomized to Group B at Visit 2 were provided with frovatriptan 5 mg to treat during prodrome at the point they were confident a disabling migraine would occur (before the onset of headache).
3249128|NCT00846482||1|All patients with advanced or stage II or III colorectal cancer being treated with oxaliplatin
3249129|NCT00846469|Experimental|chest pain|CCTA (Coronary computed tomography angiography)
3249130|NCT00846443|Experimental|1|pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
3249131|NCT00846443|Experimental|2|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
3249132|NCT00846443|Experimental|3|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions
3249133|NCT00846443|Experimental|4|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
3249134|NCT00846430|Experimental|Open-Label Intervention|This is a phase II single arm study with sequential treatments available by response where all participants begin therapy with a combination of celecoxib and interferon alpha-2b (CI, treatment-1). Response to CI therapy will be assessed at six months by clinical and radiographic evaluations. Those patients who have achieved a partial response (improvement in pain, improvement in functioning, or ≥50% reduction in tumor size) or complete response (resolution of pain, and normalization of functioning with a ≥ 90% reduction in tumor size) will continue with the same CI therapy for up-to two years on study.
3249135|NCT00846417||Case|Patients with ICDs who attend the ICD Support Groups.
3249136|NCT00846417||Control|Patients with ICDs who do not attend the ICD support groups.
3249137|NCT00846404||Case|Patients with Diastolic Dysfunction
3249138|NCT00846404||Control|Patients without Diastolic Dysfunction
3249139|NCT00846391|Experimental|MK8245 5 mg b.i.d.|MK8245
3249140|NCT00846391|Experimental|MK8245 50 mg b.i.d.|MK8245
3249141|NCT00846391|Placebo Comparator|Placebo|Placebo
3249142|NCT00846378|Experimental|Post conditioning|After 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. The balloon should be inflated to only occlude the coronary artery. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.
3249143|NCT00846378|Active Comparator|Usual Care|Usual care for treatment of thrombolysis in myocardial infarction (TIMI) 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
3249144|NCT00846365|Experimental|Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD|(dependant on blood pressure)
3249675|NCT00842283||dermatologic diseases|skin tissue sample
3249148|NCT00846352|Active Comparator|Late bronch|This group will receive bronchoscopy within 5 days of enrollment.
3249149|NCT00846339|Experimental|1|DRD2 Taq1A1 allele
3249150|NCT00846339|Experimental|2|DRD Taq1 A2 homozygote2
3249151|NCT00846326|Experimental|Oxymetazoline-Fluticasone Propionate|Combination nasal spray with oxymetazoline 0.05% and fluticasone propionate 0.05%
3249152|NCT00846326|Placebo Comparator|Oxymetazoline-placebo|oxymetazoline 0.05% w/v and placebo fluticasone propionate
3249153|NCT00846313|Active Comparator|Dietary counseling|Patients receive dietary advice at an individual level and are offered contact with clinical dietitian every second week if necessary.
3249154|NCT00846313|No Intervention|Control|
3249155|NCT00846287|Active Comparator|Drug Subjects|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. BROVANA (arformoterol tartrate) Inhalation Solution is supplied as 2 mL of arformoterol tartrate solution packaged in 2.1 mL unit-dose, low-density polyethylene (LDPE) unit-dose vials. Each unit-dose vial contains 15 mcg of arformoterol (equivalent to 22 mcg of arformoterol tartrate) in a sterile, isotonic saline solution, pH-adjusted to 5.0 with citric acid and sodium citrate. After administration of the drug, three additional bags of hyperpolarized helium-3 will be administered, again with five to ten minutes between each bag.
3249156|NCT00846287|Placebo Comparator|Saline|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the placebo (nebulized saline solution) will be administered (2.1 mL). After administration of the placebo, three additional bags of hyperpolarized helium-3 will be administered, again with five to ten minutes between each bag.
3249157|NCT00846274|Active Comparator|Antithrombin III|
3249158|NCT00846274|Experimental|SK Antithrombin III|
3249159|NCT00846261|Experimental|Ilzarov|
3249160|NCT00846248|Active Comparator|1|Chromium picolinate
3249161|NCT00846248|Placebo Comparator|2|2 sugar pills taken twice daily
3249162|NCT00846235|Experimental|Moisturising cream|
3249163|NCT00846222|Experimental|Mild theraputic hypothermia|
3249164|NCT00846196|Experimental|2|one commercial risedronate 35 mg DR tablet
3249165|NCT00846196|Active Comparator|1|one Phase III risedronate 35 mg DR tablet
3249166|NCT00846183|Active Comparator|local ingury|In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed.
3249167|NCT00846183|No Intervention|control|in 60 patients routine IVF are performed
3249168|NCT00846170|Active Comparator|probiotics|patients with IBS that will receive investigational treatment for 4 weeks
3249169|NCT00846170|Placebo Comparator|Placebo|cross over of patients from arm 1
3249170|NCT00846157|No Intervention|control|Rituximab 375mg/m2 IV administered on day 1. Cyclophosphamide 750mg/m2 IV for 2hours,Adriamycin 50mg/m2 ,Vincristine 1.4mg/m2 IV respectively. Prednisone 60mg P.O. per day for 5 days.
3249171|NCT00846157|Active Comparator|Active|R-CHOP plus Natural Killer Cell therapy
3249172|NCT00846131|Active Comparator|A: Y-90 alone|Patients randomized to Arm A will proceed to Y-90 treatment alone in the Northwestern standard of care procedure
3249173|NCT00846131|Experimental|B: Sorafenib + Y-90|Patients randomized to Arm B will start sorafenib at a dose of 400 mg twice daily for bilirubin ≤ 1.5 x ULN and 200 mg twice daily for bilirubin > 1.5 x ULN to ≤ 3 x ULN. After 14 days of sorafenib therapy (+/- 3 days) patients will proceed to Y-90 in the Northwestern standard of care procedure
3249174|NCT00846118|Active Comparator|Pitavastatin|Pitavastatin in addition to optimal standard care
3249175|NCT00846118|No Intervention|optimal standard care|
3249176|NCT00846105|Experimental|Rapid PCR screen|Rapid PCR screen test for detection of MRSA carriers upon hospital admission
3249177|NCT00846105|Active Comparator|Conventional culture|Conventional culture screen for detection of MRSA carriers upon hospital admission
3249178|NCT00846092|Experimental|Device|"The study will require 20 subjects.~Each subject will have one study eye that will be designated for treatment.~Subjects will be exposed to light emitted from Warp 10 LED's (Quantum Devices, Barneveld, WI) at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.~Treatments involve application of the LED-generated light for 80 seconds, twice daily.~Primary efficacy and toxicity outcomes are determined by measuring excess retinal thickness via Ocular Coherence Tomography at 1 month, 3 months, and 6 months, prior to conclusion of the study.~• This protocol will be stopped if, at any point in the study, a 50% increase in excess retinal thickness is demonstrated via OCT in 25% of subjects in the experimental group."
3249179|NCT00846066|Experimental|Hands on Training|Hands on Training by a pediatric dentist
3249180|NCT00846066|Active Comparator|Web Based Training|Web Based Training for all residents before randomization
3249181|NCT00846053|Other|Stable lung function|* Group S (n = 14) will consist of CF patients, aged 12-21 years old, who underwent FDG-PET with stable lung function during the past 4 years, defined as less than 2% decline per year. There is no therapeutic intervention and FDG-PET scan will be performed in both cohorts.
3249182|NCT00846053|Other|Rapidly deteriorating lung function|* Group R (n = 14) will contain CF patients, aged 12-21 years old, who underwent FDG-PET with rapidly deteriorating lung function during the past 4 years with greater than 4% per year decline. There is no therapeutic intervention and FDG-PET scan will be performed in both cohorts.
3249183|NCT00846027|Experimental|Bevacizumab + paclitaxel + gemcitabine|Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m^2 IV, and gemcitabine 2000 mg/m^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
3249184|NCT00846014|Experimental|Asthmatics|All subjects will be asthmatics that have had an exacerbation (asthma attack) no more than 48 hours before the imaging session.
3249185|NCT00846001|Active Comparator|CABG alone|Standard coronary artery bypass grafting according guidelines
3249468|NCT00843843|Active Comparator|3 hour nap and 6 hour sleep, then 9 hour sleep|
3249186|NCT00846001|Experimental|CABG+CRT|Standard coronary artery bypass grafting according guidelines with concomitant three bipolar epicardial leads implantation for cardiac resynchronization therapy
3249187|NCT00845988|Active Comparator|treatment as usual|patients showing weight gain while receiving treatment with risperidone, olanzapine, quetiapine, or clozapine
3249188|NCT00845988|Experimental|switch to aripiprazole|aripiprazole
3249189|NCT00845975|Active Comparator|Erchonia Hearing Lasers #1 & #2|"Erchonia Hearing Laser #1 is a dual laser system composed of a pulsed red 7.5 milliwatts (mW) laser of 635 nm +/- 5 nm and a pulsed green 7.5 mW laser of 532 nm, both lasers in simultaneous operation when the laser is activated.~Erchonia Hearing Laser #2 is a single diode laser that in pulsed mode emits 4.9 mW of red 635 nm +/- 5 nm light."
3249190|NCT00845975|Placebo Comparator|Placebo Lasers|Inactive lasers that do not emit any therapeutic light.
3249191|NCT00845962|Active Comparator|Chloroprocaine|
3249192|NCT00845962|Active Comparator|Bupivacaine|
3249193|NCT00845936|Experimental|1|850 mg of Metformin bid
3249194|NCT00845936|Placebo Comparator|placebo|Tablets Identical to Metformin, bid
3249195|NCT00845923|Other|Civamide Patch 0.015%|All subjects in study will receive the Civamide Patch 0.015%
3249196|NCT00845910|Experimental|1|
3249197|NCT00845897|Placebo Comparator|1|Placebo (saline) injections into 6 sites in the calf muscle
3249198|NCT00845897|Active Comparator|2|Total 200 units of Botulinum Toxin injected into 6 sites into the calf muscles.
3249199|NCT00845897|Active Comparator|3|300 units of botulinum toxin injected into 6 sites in the calf muscle
3249200|NCT00845884|Experimental|AVDCF|Drug: Docetaxel, Cisplatin, Capecitabine, Bevacizumab
3249201|NCT00845871|Experimental|deferasirox|Patients will have five general options for taking Deferasirox including with or without meals, crushed and added to a soft food or mixed in a liquid of choice.
3249202|NCT00845858|Active Comparator|Metoclopramide Nasal Spray 10 mg|
3249203|NCT00845858|Active Comparator|Metoclopramide Nasal Spray 14 mg|
3249204|NCT00845858|Placebo Comparator|Placebo Nasal Spray|
3249205|NCT00845845|Active Comparator|Omega-3-acid ethyl esters (Lovaza)|Participants receive 4 milligrams (mg) daily of omega-3-acid ethyl esters (Lovaza) and dietary counseling for 24 weeks
3249206|NCT00845845|Placebo Comparator|Placebo|Participants receive daily placebo and dietary counseling for 24 weeks
3249207|NCT00845832|Experimental|1|
3249208|NCT00845832|Active Comparator|2|
3249209|NCT00845819|Active Comparator|EGF|rhEGF + povidone iodine, chlorhexidine, & nystatin
3249210|NCT00845819|Placebo Comparator|Placebo|Placebo + povidone iodine, chlorhexidine, & nystatin
3249211|NCT00845806||Arabic Speakers|All subjects must be male native arabic speakers who can read and speak english.
3249212|NCT00845780|Experimental|withdrawal amiodarone|withdrawal amiodarone afer at least 6 months of sinus rhythm maintenance on amiodarone therapy
3249213|NCT00845780|Active Comparator|continuation amiodarone|continuation of amiodarone after 6 months of sinus rhythm maintenance on amiodarone therapy
3249214|NCT00845767|Experimental|Diesel Exposure|1 hour exposure to dilute diesel exhaust at a concentration of 300 µg/m3 with intermittent exercise
3249215|NCT00845767|Experimental|Air Exposure|1 hour exposure to filtered air during intermittent exercise
3249216|NCT00845754|Placebo Comparator|1|Placebo
3249217|NCT00845754|Active Comparator|2|Ketorolac
3249218|NCT00845728|Experimental|Indacaterol|Indacaterol 150 µg o.d. delivered via single-dose dry powder inhaler (SDDPI)
3249219|NCT00845728|Active Comparator|Tiotropium|Tiotropium 18 µg o.d. delivered via the handihaler®
3249220|NCT00845715|Other|Early motion|
3249221|NCT00845715|Other|Standard motion|
3249222|NCT00845702|Experimental|Dotarem|Each subject will receive one injection of Dotarem 0.2 ml/kg.
3249223|NCT00845702|Other|Time Of Flight Magnetic Resonance Angiography|Each subject undergo a TOF MRA
3249224|NCT00845689|Placebo Comparator|1|liver resection with Pringle + placebo
3249225|NCT00845689|Active Comparator|2|liver resection with Pringle + adenosine preconditiong
3249226|NCT00845689|Active Comparator|3|liver resection with Pringle + adenosine pre- and postconditioning
3249227|NCT00845676|Experimental|Pegylated interferon alfa-2a + Ribavirin|Pegylated interferon alfa-2a + Ribavirin
3249228|NCT00845663|Active Comparator|Pre-filled Syringe|pre-filled syringe (reference)
3249229|NCT00845663|Experimental|Auto-injection Device|Auto-injection device (test)
3249230|NCT00845650|Experimental|AIGIV 3.5 mg/kg (Cohort A)|AIGIV containing 3.5 mg/kg anti-PA IgG as a single intravenous infusion.
3249231|NCT00845650|Other|Gamunex 90 mg/kg (Cohort A)|Gamunex 90 mg/kg total IgG as a single intravenous infusion.
3249232|NCT00845650|Experimental|AIGIV 7.0 mg/kg (Cohort B)|AIGIV containing 7.0 mg/kg anti-PA IgG as a single intravenous infusion.
3249233|NCT00845650|Other|Gamunex 180 mg/kg (Cohort B)|Gamunex 180 mg/kg total IgG as a single intravenous infusion.
3249234|NCT00845650|Experimental|AIGIV 14.0 mg/kg (Cohort C)|AIGIV containing 14.0 mg/kg anti-PA IgG as a single intravenous infusion.
3249235|NCT00845650|Other|Gamunex 360 mg/kg (Cohort C)|Gamunex 360 mg/kg total IgG as a single intravenous infusion.
3249236|NCT00845637|Active Comparator|Eggplant extract|
3249237|NCT00845637|Placebo Comparator|Placebo|
3249238|NCT00845624||1|Preterm infants <1500 grams or 32 weeks gestation.
3249239|NCT00845598|Experimental|Azelastine Fluticasone|
3249240|NCT00845598|Active Comparator|Fluticasone propionate|
3249241|NCT00845585|Active Comparator|Owniflow II|
3249242|NCT00845585|Active Comparator|PTFE|
3249243|NCT00845572|Experimental|Consta Club|
3249244|NCT00845559|Experimental|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide.
3249245|NCT00845559|No Intervention|No Treatment|
3249246|NCT00845546|Experimental|1|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets of Ranbaxy
3249247|NCT00845546|Active Comparator|2|(Claritin_D® 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets
3249248|NCT00845520|Experimental|Lens implantation +1.00 diopter (D) postop target|Lens implant power calculated for postoperative MRSE target of +1.00 D
3249249|NCT00845520|Experimental|Lens implantation -1.00 D postop target|Lens implant power calculated for postoperative MRSE target of -1.00 D
3249250|NCT00845520|Experimental|Lens implantation 0.00 D postop target|Lens implant power calculated for postoperative MRSE target of 0.00 D
3249251|NCT00845507|Experimental|Exenatide Group|Exenatide dstarted at 5 mcg subcutaneously twice daily within one hour before the morning and evening meals, and increased (as tolerated) to 10 mcg.
3249252|NCT00845507|Placebo Comparator|Placebo Group|Placebo: Sterile solution in equivalent doses as Exenatide
3249253|NCT00845494|Other|medication history education|Four hospital unit nurses asked to participate in the study. Two nursing units will receive the cognitive behavioral intervention.
3249254|NCT00845481|Experimental|all patients apply all products|
3249255|NCT00845468||No treatment|
3249256|NCT00845455||1. Harm Avoidance|Personality type
3249257|NCT00845455||2. Reward Dependence|Personality type
3249258|NCT00845455||3. Novelty Seeking|Personality type
3249259|NCT00845429|Experimental|Group 1: Standard-dose Cell-based Influenza Vaccine|Participants will receive a single dose of standard-dose cell-based influenza virus vaccine.
3249260|NCT00845429|Experimental|Group 2: High-dose Cell-based Influenza Vaccine|Participants will receive a single dose of high-dose cell-based influenza virus vaccine.
3249261|NCT00845429|Active Comparator|Group 3: Licensed Fluzone® Influenza Vaccine|Participants will receive a single dose of licensed Fluzone® influenza vaccine.
3249262|NCT00845390||ICD Patients|ICD patients
3249263|NCT00845377|Experimental|Counseling|
3249264|NCT00845364|Experimental|Perhexiline|Pre-operative administration of Perhexiline tablets according to dosing schedule
3249265|NCT00845364|Placebo Comparator|Placebo|Pre-operative administration of placebo tablets according to dosing schedule
3249266|NCT00845351|Experimental|Bexarotene|Bexarotene 300 mg/m2/day times 5 days
3249267|NCT00845338|Experimental|Arm 1|
3249268|NCT00845325|Active Comparator|Group One|"The first group (early motion) will have a bulky dressing placed at the time of surgery. They will be instructed to remove the dressing on the first postoperative day and to place a band-aid over the incision. A set of non-weight bearing stretching exercises will be explained on the day of surgery and instructions with diagrams sent home with the patient. They will begin these exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work."
3249269|NCT00845325|Other|Behavorial Control Group Two|The second group will have wrist immobilization splints placed at the time surgery. The thumb and fingers will not have limited motion in this splint. Due to the splint placement, the patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
3249270|NCT00845312||Complicated hospitalization|"Patients 60 years old or younger, who were diagnosed with community acquired pneumonia (CAP) between March 1, 2005 and December 31, 2008 were retrospectively analyzed for risk factors for severe morbidity or mortality.~was defined as at least one of the following parameters: hospitalization longer than ten days, admission to intensive care unit and in- hospital mortality. Otherwise, the hospitalization was defined uncomplicated .The Rambam hospital Institutional Review Board approved the study."
3249271|NCT00845299|Experimental|1|Latanoprost punctal plug and use of artificial tears containing Benzalkonium Chloride
3249272|NCT00845299|Experimental|2|Latanoprost punctal plug only
3249273|NCT00845273||Pegaptanib sodium|Patients administered Pegaptanib sodium.
3249274|NCT00845260|Experimental|Internet CBT|Internet-based cognitive behavior therapy (CBT).
3249275|NCT00845260|Experimental|Group CBT|Group cognitive behavior therapy (CBT).
3249276|NCT00845247|Placebo Comparator|Control|Control group patients will receive usual medical plus usual supportive treatment.
3249277|NCT00845247|Active Comparator|Case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
3249278|NCT00845234|No Intervention|Standard of Care Group|Received the current standard of care as operationally defined by the investigators- Q&A session + Video
3249279|NCT00845234|Experimental|Intervention Group|Intervention group- Patients will receive the brief educational CBT intervention + video and Q&A session
3249280|NCT00845221|Experimental|Imatinib|
3249281|NCT00845208|Active Comparator|Case Management|
3249282|NCT00845208|Experimental|Network Support|12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
3249283|NCT00845208|Experimental|Network Support + Contingency Mgmnt|12 weekly sessions intended to help patients change their social networks to be more supportive of abstinence. Contingency management component added to reinforce efforts to make network changes.
3249284|NCT00845195|Experimental|Olopatadine HCl Nasal Spray, 0.6%|
3249285|NCT00845195|Active Comparator|Azelastine HCl Nasal Spray, 0.1%|
3249286|NCT00845182|Active Comparator|Pioglitazone|Pioglitazone: 15 Patients will be randomized to Pioglitazone only arm
3249287|NCT00845182|Experimental|Exenatide|Exenatide: 15 subjects will be randomized to receive Exenatide
3249288|NCT00845182|Experimental|Drug Pioglitazone and Drug Exentatide|Pioglitazone and Exenatide: 15 subjects will be randomized to Pioglitazone and Exenatide
3249289|NCT00845169|Experimental|Diesel Exposure|1 hour exposure to diesel exhaust at 300 µg/m3 during intermittent exercise
3249290|NCT00845169|Experimental|Air Exposure|1 hour exposure to filtered air during intermittent exercise
3249291|NCT00845156|Active Comparator|Anti-Oxidant|Alpha Lipoic Acid
3249292|NCT00845156|Placebo Comparator|Placebo|Placebo
3249293|NCT00845130|Experimental|Diabetic Type II Subjects|Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm
3249294|NCT00845130|Experimental|Healthy Subjects|Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm
3249295|NCT00845117|Experimental|Limbal Stem Cell Transplant|The cornea is debrided of all superficial fibrovascular tissue and the cultivated stem cell graft is glued onto the cornea.
3249296|NCT00845104|Experimental|Arm I|See Detailed Description
3249297|NCT00845091|Experimental|Exercise|moderate-intensity, low-impact, supervised, aerobic exercise
3249618|NCT00842673|Experimental|3|180 mg ST101
3249298|NCT00845091|Active Comparator|Heart Healthy Education|Educational topics on heart health (e.g., nutrition, smoking, sleep)
3249299|NCT00845078||1|Immediate reconstruction followed by radiation therapy
3249300|NCT00845078||2|Radiation therapy followed by delayed reconstruction
3249301|NCT00845065|Placebo Comparator|Arm 1 (Control Arm)|Peginterferon alfa-2a (180 μg/week subcutaneously [SC]) plus ribavirin (1000 to 1200 mg/day orally [PO]) for 4 weeks followed by placebo (800 mg three times a day [TID] PO, using placebo matching SCH 503034 200-mg capsules) + peginterferon alfa-2a 180 μg/week SC plus ribavirin 1000 to 1200 mg/day PO divided twice daily (BID) for 48 weeks with 24 weeks post-treatment follow-up.
3249302|NCT00845065|Experimental|Arm 2 (Boceprevir Arm)|"Peginterferon alfa-2a (180 μg/week subcutaneously [SC]) plus ribavirin (1000 to 1200 mg/day orally [PO]) for 4 weeks followed by boceprevir (800 mg three times a day [TID] PO, using SCH 503034 200-mg capsules) + peginterferon alfa-2a 180 μg/week SC plus ribavirin 1000 to 1200 mg/day PO divided twice daily (BID) for 48 weeks~with 24 weeks post-treatment follow-up."
3249303|NCT00845052||First group of house staff|First group of house staff to be surveyed
3249304|NCT00845052||Second group of house staff|Second group of house staff to be surveyed
3249305|NCT00845052||Thirst group of house staff|Third group of house staff to be surveyed
3249306|NCT00845039|Active Comparator|Cetuximab + Irinotecan|Participants in Treatment Group 1 will receive intravenous infusions of Cetuximab 500 milligrams per square meter (mg/m²) and Irinotecan 180 mg/m².
3249307|NCT00845039|Experimental|Cetuximab + IMC-A12 + Irinotecan|Participants in Treatment Group 2 will receive intravenous infusions of Cetuximab 500 mg/m², IMC-A12 10 milligrams/kilogram (mg/kg) and Irinotecan 180 mg/m².
3249308|NCT00845026|Experimental|LY2140023|
3249309|NCT00845026|Active Comparator|aripiprazole|
3249310|NCT00845026|Active Comparator|olanzapine|
3249311|NCT00845026|Active Comparator|risperidone|
3249312|NCT00845013||HIV Infection|HIV-infected individuals with the clinical diagnosis of pulmonary hypertension or HIV-infected individuals who have mildly elevated pulmonary arterial pressures
3249313|NCT00845000|Experimental|SCH 420814 10 mg→SCH 420814 100 mg→Placebo|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
3249314|NCT00845000|Experimental|SCH 420814 100 mg→Placebo→ SCH 420814 10 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
3249315|NCT00845000|Experimental|Placebo→SCH 420814 10 mg→SCH 420814 100 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
3249316|NCT00845000|Experimental|SCH 420814 10 mg→ Placebo→ SCH 420814 100 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
3249317|NCT00845000|Experimental|SCH 420814 100 mg→ SCH 420814 10 mg→Placebo|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
3249318|NCT00845000|Experimental|Placebo→ SCH 420814 100 mg→SCH 420814 10 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
3249319|NCT00844974|Other|1|
3249320|NCT00844961|Experimental|Internet CBT|10 weeks of internet delivered cognitive behaviour therapy
3249321|NCT00844961|No Intervention|Waiting list|Waiting list which is offered treatment after completion of post intervention assessments
3249322|NCT00844948||Young adults (18-25 years old)|Young adults (18-25 years old). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started treatment or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
3249367|NCT00844597|Experimental|Cohort 2 - 1.0 mg/kg/wk|Subjects in this group will receive a 1.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
3249368|NCT00844597|Experimental|Cohort 3 - 2.0 mg/kg/wk|Subjects in this group will receive a 2.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
3249323|NCT00844948||Elderly (60-80 years old)|Elderly (60-80 years old). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started treatment or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
3249324|NCT00844948||Chinese speakers|Chinese speakers (Mandarin or Cantonese). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
3249325|NCT00844922|Experimental|Org 34517|Org 34517 titrated to 900 mg daily for 2 weeks
3249326|NCT00844922|Placebo Comparator|Placebo|
3249327|NCT00844896|Active Comparator|DEF-only|Distress Emotional Support and Family Assessment Treatment
3249328|NCT00844896|Experimental|DEF + COPE|Distress Emotional Support and Family Assessment Treatment and Creating Opportunities for Parent Empowerment Treatment
3249329|NCT00844883|Experimental|sorafenib and drug eluting beads|single arm
3249330|NCT00844870|Active Comparator|1|stabilization training group
3249331|NCT00844870|Experimental|2|auditory response training group
3249332|NCT00844857|Experimental|Olanzapine/Fluoxetine Combination|
3249333|NCT00844857|Placebo Comparator|Placebo|
3249334|NCT00844844|Experimental|Eculizumab|
3249335|NCT00844831|Experimental|Treatment with lubiprostone|Subjects receive lubiprostone and bacteria is measured before and after
3249336|NCT00844818|No Intervention|Control|Moms and dads who were current smokers (1 cigarette, even a puff, in past 30 days) or recent quitters (smoked since one month prior to conception)
3249337|NCT00844818|Experimental|Intervention Group|Moms and dads who were current smokers (1 cigarette, even a puff, in past 30 days) or recent quitters (smoked since one month prior to conception)
3249338|NCT00844805|Experimental|Infliximab + Naproxen|Infliximab administered at a dose of 5 mg/kg intravenously on Day 1 of Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks during the 28-week treatment phase.
3249339|NCT00844805|Placebo Comparator|Placebo + Naproxen|Placebo administered intravenously on Day 1 at Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks, during the 28-week treatment phase.
3249340|NCT00844805|Experimental|Naproxen Only (Follow-Up)|For participants who achieved partial remission during 28-week treatment phase, naproxen was continued at a daily dose of 1000 mg administered orally for an additional 24 weeks in the follow-up phase.
3249341|NCT00844805|No Intervention|No Treatment (Follow-Up)|For participants who achieved partial remission during Treatment phase, no treatment was administered for an additional 24 weeks in the follow-up phase.
3249342|NCT00844792|Experimental|1|This group of men will be on active treatment (antioxidants)for 6-8 weeks prior to their radical prostatectomy.
3249343|NCT00844792|Placebo Comparator|2|This group of men will be on placebo for 6-8 weeks prior to their radical prostatectomy.
3249344|NCT00844779||T|(n=30): without central adiposity, without insulin resistance, operated for cholecystectomy or a benign liver tumor.
3249345|NCT00844779||A|(n=30): with central adiposity, insulin resistance and hepatic steatosis (histology).
3249346|NCT00844779||B|(n=30): with central adiposity, insulin resistance and steatohepatitis ± hepatic fibrosis (histology).
3249347|NCT00844753|Active Comparator|1|Atomoxetine + Parent Management Training
3249348|NCT00844753|Active Comparator|2|Atomoxetine without Parent Management Training
3249349|NCT00844753|Placebo Comparator|3|Placebo + Parent Management Training
3249350|NCT00844753|Placebo Comparator|4|Placebo without Parent Management Training
3249351|NCT00844740|Experimental|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood and urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
3249352|NCT00844727|Active Comparator|1|Rofexocib 25 mg OD, 1 year treatment
3249353|NCT00844727|Placebo Comparator|2|Placebo
3249354|NCT00844714|Experimental|Rituxan|
3249355|NCT00844701||Non-smoker|Non-smoking control
3249356|NCT00844701||Nicotine Dependent Smoking Group|current smokers
3249357|NCT00844688|Other|sorafenib/gemcitabine|
3249358|NCT00844675|Experimental|rabeprazole|rabeprazole
3249359|NCT00844675|Experimental|placebo|placebo
3249360|NCT00844662|Experimental|1|
3249361|NCT00844662|Active Comparator|2|
3249362|NCT00844649|Experimental|Albumin-bound paclitaxel (ABI-007)/Gemcitabine|ABI-007 125 mg/m2 administered in combination with gemcitabine 1000 mg/m2 weekly for 3 weeks followed by one week of rest.
3249363|NCT00844649|Active Comparator|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks followed by a week of rest (Cycle 2 onward).
3249364|NCT00844636|Active Comparator|Sharp Needles|Sharp needles to close uterus, fascia and skin during cesarean section
3249365|NCT00844636|Active Comparator|Blunt Needles|Assignment to blunt needles to close uterus, fascia and skin during cesarean section
3249366|NCT00844597|Experimental|Cohort 1 - 0.5 mg/kg/wk|Subjects in this group will receive a 0.5 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
3249465|NCT00843856|Active Comparator|tacrolimus|Intervention type -drug tacrolimus therapy 2mg bd adjust to obtain levels of 5-12ng/L
3249369|NCT00844597|Experimental|Cohort 4 - 4.0 mg/kg/wk|Subjects in this group will receive a 4.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
3249370|NCT00844597|Experimental|Cohort 5 - 10.0 mg/kg/wk|Subjects in this group will receive a 10.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
3249371|NCT00844597|Experimental|Cohort 6 - 20.0 mg/kg/wk|Subjects in this group will receive a 20.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
3249372|NCT00844584|Other|ablation|patients with atrial fibrillation underwent radiofrequency ablation with totally thoracoscope.
3249373|NCT00844571||E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
3249374|NCT00844571||control group|
3249375|NCT00844558|Experimental|Gait Training|Gait Training Intervention Group Participants
3249376|NCT00844558|Placebo Comparator|Control|Gait Training Control Group Participants
3249377|NCT00844545|Experimental|Eculizumab|
3249378|NCT00844532|Experimental|Absolute Pro™ Peripheral Self-Expanding Stent System|Arm includes both Absolute Pro™ and Absolute Pro™ Long Lesion (LL) Peripheral Self-Expanding Stent Systems
3249379|NCT00844519|Active Comparator|Maraviroc|For subjects assigned to the maraviroc group, subjects will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medication. For subjects on ritonavir, the dose of maraviroc will be 150mg by mouth twice daily.
3249380|NCT00844519|Placebo Comparator|Placebo|
3249381|NCT00844493|Experimental|H10407 challenge 1|7 or 8 logs of E. coli strain H10407 with CeraVacx buffer
3249382|NCT00844493|Experimental|H10407 challenge 2|7 or 8 logs of E. coli strain H10407 with bicarbonate buffer
3249383|NCT00844493|Experimental|H10407 challenge 3|6 logs of E. coli H10407 with bicarbonate buffer
3249384|NCT00844493|Experimental|H10407 challenge 4|5 logs of E. coli H10407 with bicarbonate buffer
3249385|NCT00844480|Experimental|zoledronic acid|
3249386|NCT00844480|Placebo Comparator|placebo|
3249387|NCT00844454|Experimental|QFEA|multi-pronged ethanol ablation
3249388|NCT00844454|Active Comparator|RFA|radiofrequency ablation
3249389|NCT00844428|Experimental|Eculizumab|
3249390|NCT00844415|Experimental|dabigatran etexilate|open label; patient to receive dabigatran etexilate BID for three days
3249391|NCT00844402|Experimental|Atorvastatin|Atorvastatin 10 mg per day for 48 weeks
3249392|NCT00844389|Active Comparator|NIR light|Group of patients stimulated with near to infrared light daily stimulation
3249393|NCT00844389|Placebo Comparator|Green light|Group of patients stimulated with green light.
3249394|NCT00844376|Other|Test|Extemporaneous preparation suspension Atorvastatin prototype formulation
3249395|NCT00844376|Other|Reference|Commercial atorvastatin tablet (Lipitor®)
3249396|NCT00844363|Other|NB-UVB|Regular, monitored NB-UVB treatment. Patients will be treated 3 times per week, and a full course of therapy is 12 weeks. NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
3249397|NCT00844350|No Intervention|letrozole+hCG|
3249398|NCT00844350|No Intervention|letrozole+oxytocin|
3249399|NCT00844350|No Intervention|letrozole+oxytocin+hCG|
3249400|NCT00844350|No Intervention|clomiphene citrate +oxytocin|
3249401|NCT00844350|No Intervention|clomiphene citrate +oxytocin+hCG|
3249402|NCT00844337|Active Comparator|1|One study arm will receive injectable gentamicin once daily and oral amoxicillin twice daily for seven days by comparison to other study arms.
3249403|NCT00844337|Active Comparator|2|Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days
3249404|NCT00844337|Active Comparator|3|Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days (COMPARISON ARM)
3249405|NCT00844324|Experimental|A|Candesartan cilexetil 1mg/mL
3249406|NCT00844324|Experimental|B|Candesartan cilexetil 1.6mg/mL
3249407|NCT00844311|Active Comparator|Control arm|150 iu/day of rFSH alone
3249408|NCT00844311|Experimental|hCG low dose|150 iu/day of rFSH + 50 iu/day of hCG from stimulation day 1
3249409|NCT00844311|Experimental|hCG medium dose|150 iu/day of rFSH + 100 iu/day of hCG from stimulation day 1
3249410|NCT00844311|Experimental|hCG high dose|150 iu/day of rFSH + 150 iu/day of hCG from stimulation day 1
3249411|NCT00844298|Experimental|Nilotinib+mVPD|Patients who were Philadelphia-positive, newly-diagnosed adult ALL and treated with nilotinib + mVPD treatment plan
3249412|NCT00844285||Cimzia Cohort:|Patients about to receive treatment with Cimzia® as part of pre-existing management plan for Crohn's disease or has already been receiving treatment with Cimzia® for ≤12 months. Patients must also receive a Cimzia dose within 2 months following enrollment.
3249413|NCT00844285||Comparison cohort|Patient must be about to receive treatment with any other medication as part of a pre-existing management plan for Crohn's disease or has already been receiving treatment (previous Cimzia® treatment is prohibited).
3249414|NCT00844272|Experimental|Psychoeducation|"PE group sessions lasted 60 minutes and were carried out under continuous supervision. The manualised program was especially tailored to (former) IDUs in HCV treatment, containing the following aspects:~Module 1: HCV infection and symptoms, course of illness, interaction with opioid dependence, further problems and risk factors~Module 2: HCV treatment, side effects, psychiatric and somatic comorbidities, reinfection and drug use, risk behaviour~Module 3: Coping strategies, resources and self-help, effective use of health-care support, the role of social environment, healthy living & nutrition"
3249415|NCT00844272|No Intervention|Treatment as usual|Control group did not received no intervention.
3249416|NCT00844259||Research Group|15 children with Down syndrome, observed in two interaction conditions: playing with their therapist (A) and playing with their caregiver (B).
3249466|NCT00843856|Active Comparator|tacrolimus and mycophenolate mofetil|tacrolimus 2mgs bd (adjusted to obtain levels 5-12mg/L and mycophenolate mofetil 500mg bd adjusted to obtain levels 1.5-3mg/L
3249467|NCT00843843|Active Comparator|9 hour sleep, then 3 hour nap and 6 hour sleep|
3249619|NCT00842673|Placebo Comparator|4|Placebo
3249417|NCT00844246|Experimental|SRS|School Readiness Specialist (SRS) will administer the screening questionnaire to the subject during the intervention period, at the subject's 9, 18, 24 and 30 month visits. They will then see their PCP for a well child visit in which the results of the test will be interpreted, developmental counseling and/or anticipatory guidance provided as per usual care. EI (Early intervention) referral will be completed, at the discretion of the providers, if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
3249418|NCT00844246|Experimental|Provider|Primary Care Physician (PCP) will do the developmental screening at the subject's 9, 18, 24 and 30 month well child visits. Once the screening questionnaire is complete the PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI (Early intervention) referral will be completed, at the discretion of the providers, if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
3249419|NCT00844246|No Intervention|Routine|Subjects randomized to routine surveillance will receive routine preventive care as well as developmental surveillance at all well child visits, including the 9, 18, 24 and 30 month visits. EI referral will be completed, at the discretion of the provider, if the PCP observes a developmental delay during surveillance or the caregivers raise a specific concern about the child's development.
3249420|NCT00844233|Experimental|1|Irinotecan Bead
3249421|NCT00844220|Experimental|CT/MR|CT/MRI-directed clinical management strategy
3249422|NCT00844220|Active Comparator|Catheterization|Standard clinical management
3249423|NCT00844207|Experimental|Treatment A|Two of the fixed combination tablets each containing 250 mg of azithromycin and 155 mg of chloroquine base.
3249424|NCT00844207|Active Comparator|Treatment B|A single tablet containing 500 mg of azithromycin and a single tablet containing 300 mg of chloroquine base.
3249425|NCT00844194|Other|DPNP with depression (1)|Patients that have diabetic polyneuropathy and depression and are responder to 60 mg duloxetine QD (>30% pain reduction after week 6)
3249426|NCT00844194|Other|DPNP with depression (2)|Patients that have diabetic polyneuropathy and depression and are non-responder to 60 mg duloxetine QD (<30% pain reduction after week 6)
3249427|NCT00844194|Other|DPNP without depression (1)|Patients that have diabetic polyneuropathy and no depression and are responder to 60 mg duloxetine QD (>30% pain reduction after week 6)
3249428|NCT00844194|Other|DPNP without depression (2)|Patients that have diabetic polyneuropathy and no depression and are non-responder to 60 mg duloxetine QD (<30% pain reduction after week 6)
3249429|NCT00844181||0|white women
3249430|NCT00844181||1|Black women
3249431|NCT00844168|Experimental|Treatment (adjuvant sorafenib tosylate after liver transplant)|Patients receive sorafenib tosylate PO twice daily on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3249432|NCT00844155|Active Comparator|A.Oseltamivir 75 mg dose|Patients will be randomized to two groups (group A) to receive oseltamivir at 75 mg, or (group B) to receive the drug at 150 mg in the fasting or fed state.
3249433|NCT00844155|Active Comparator|B. Oseltamivir 150mg|Patients will be randomized to groups (group A) to receive oseltamivir at 75 mg, or group B to receive the drug at 150 mg in the fasting or fed state.
3249434|NCT00844142|Other|1|etanercept 25mg twice weekly
3249435|NCT00844142|Active Comparator|2|Sulfasalazine 2000- 3000mg daily
3249436|NCT00844129||Neurofibromatosis Type 1|Children with Neurofibromatosis Type 1
3249437|NCT00844116|Active Comparator|Conventional Spirometry|personal spirometry
3249438|NCT00844116|Experimental|Telematic Spirometry|"performed remotely on line"
3249439|NCT00844103|Experimental|1|
3249440|NCT00844103|Placebo Comparator|2|
3249441|NCT00844090|Placebo Comparator|Arm 1|placebo tablets
3249442|NCT00844090|Experimental|Arm 2|methylphenidate tablets
3249443|NCT00844077||Barrett's metaplasia|Barrett's intestinal metaplasia, confirmed via pathology, undergoing standard of care endoscopic screening.
3249444|NCT00844064|Experimental|AP 12009|
3249445|NCT00844051|No Intervention|No Intervention|No school-based influenza vaccination program
3249446|NCT00844051|Active Comparator|Intervention|School-based Influenza Vaccination Program
3249447|NCT00844038||1|Sick
3249448|NCT00844025|Experimental|Pharmacist intervention|Patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including medication review, medication reconciliation, patient education and recommended actions.
3249449|NCT00844025|No Intervention|Usual care|Patients randomized to usual care group will receive routine review of medication by ward-based pharmacist and nurse.
3249450|NCT00844012|Experimental|Experimental group|
3249451|NCT00844012|Active Comparator|Control|
3249452|NCT00843986|Placebo Comparator|Placebo|Matching loading dose and continuous intravenous infusion for 48 hours
3249453|NCT00843986|Experimental|Conivaptan|20mg loading dose followed by a 20mg/ day continuous intravenous infusion for 48 hours
3249454|NCT00843973||iliac crest bone graft|Bone graft harvested via iliac crest bone graft procedure
3249455|NCT00843973||Reamer Irrigator Aspirator|Bone graft harvested via the Reamer Irrigator Aspirator (RIA) Procedure
3249456|NCT00843960|Active Comparator|1|intervention group
3249457|NCT00843960|No Intervention|2|control group
3249458|NCT00843934|Experimental|anti-cancer agent|
3249459|NCT00843921|Experimental|Carbaglu|Investigate whether a 3-day treatment with NCG can improve or restore urea genesis capacity in patients with NAGS, CPSI, or OTC deficiency or PA or MMA using surrogate markers: [13C] label incorporation into urea and plasma levels of ammonia, urea nitrogen (BUN) and amino acids
3249460|NCT00843908|Active Comparator|TVT|Women in this arm will undergo the Tension Free Vaginal Tape procedure
3249461|NCT00843908|Experimental|Miniarc|Women in this group will undergo the Miniarc suburethral sling procedure
3249462|NCT00843882|Active Comparator|Arm A (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21.
3249463|NCT00843882|Experimental|Arm B (lenalidomide, epoetin alfa)|Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa SC once weekly.
3249464|NCT00843869||Chronic Rhinosinusitis|Participants with chronic rhinosinusitis
3249722|NCT00841893|Experimental|1|Mustard
3249469|NCT00843830|Experimental|Treatment Arm|Participants will receive tumoral irradiation and dendritic cell vaccination.
3249470|NCT00843817|Experimental|DRUG|PULMOZYME
3249471|NCT00843791|Placebo Comparator|Placebo|Treatment with placebo for 3 months before spectroscopy, hyperinsulinemic-euglycemic clamp, control diet, blood sampling.
3249472|NCT00843791|Active Comparator|2|Treatment with pioglitazone for 3 months before hyperinsulinemic-euglycemic clamp, control diet with blood sampling and spectroscopy.
3249473|NCT00843778|Experimental|Certolizumab Pegol|Certolizumab Pegol 200 mg every two weeks at the hospital by a nurse. Certolizumab Pegol 200 mg every two weeks at the patient's home done by patient (self-injection).
3249474|NCT00843765|Active Comparator|TCM integrated group|800 patients with acupuncture, massage and basic Chinese medicine treatment
3249475|NCT00843765|Active Comparator|Western Medicine group|400 patients with modern rehabilitation techniques and Western Medicine basic treatment
3249476|NCT00843739|Experimental|EMST|Four week device driven strength training program
3249477|NCT00843739|Sham Comparator|sham|Four week sham device driven training program
3249478|NCT00843739|No Intervention|Control|Four weeks of no intervention
3249479|NCT00843726|Experimental|Arm I|Patients undergo 1 high-dose fraction of stereotactic body radiotherapy (SBRT).
3249480|NCT00843726|Experimental|Arm II|Patients undergo 3 high-dose fractions (approximately 1 week apart) of SBRT.
3249481|NCT00843713|Placebo Comparator|Placebo|For subjects assigned to the placebo group, patients will take a matching placebo pill of 400 mg by mouth twice daily for 24 weeks in addition to taking their current HIV medication
3249482|NCT00843713|Active Comparator|Raltegravir|For subjects assigned to the active comparator group, they will receive raltegravir at 400 mg by mouth twice daily for 24 weeks in addition to continuing to take their current HIV medication
3249483|NCT00843700|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy, 16 individual sessions within 32 weeks
3249484|NCT00843700|Active Comparator|Individual Psychotherapy|Individual Psychotherapy, 16 individual sessions within 32 weeks
3249485|NCT00843661|Experimental|Ezetimibe and fenofibrate|
3249486|NCT00843661|Active Comparator|Pravastatin|
3249487|NCT00843648||preterms|mother and preterm babies
3249488|NCT00843648||term-bfing|term breastfed babies and mothers
3249489|NCT00843648||term-PIF|term non breastfed babies and mothers
3249490|NCT00843648||c-section|c-section babies and their mothers
3249491|NCT00843635|Experimental|Arm A - Tadalafil 10mg|Patients will receive 10mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
3249492|NCT00843635|Experimental|Arm B - Tadalafil 20mg|Patients will receive 20mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
3249493|NCT00843635|Placebo Comparator|Arm C - Placebo|Patients receive oral placebo once daily on days 1-20 in the absence of unacceptable toxicity.
3249494|NCT00843622|Experimental|1|Tobacco-based, smokefree product in pouch format for oral use, pouch size 1.0 or 0.5 g to be used ad libitum by participants
3249495|NCT00843622|Placebo Comparator|2|Non-tobacco, non-nicotine placebo product in pouch format for oral use, pouch size 1.0 g or 0.5 g, to be used ad libitum by the participants
3249496|NCT00843609|Experimental|Continuous glucose monitoring|Continuously wearing the FreeStyle Navigator continuous glucose monitor, displaying real-time glucose values and sounding alarms
3249497|NCT00843609|No Intervention|Control|Using SMBG with standard routine instructions
3249498|NCT00843596|Experimental|vacuum device - suction cup|
3249499|NCT00843583||resistant hypertension subjects|subjects with resistant hypertension
3249500|NCT00843570|No Intervention|1|Natural FER (frozen embryo replacement)
3249501|NCT00843570|Active Comparator|2|HRT-FER (Down regulated frozen embryo replacement)
3249502|NCT00843557||all ICU admissions|patients admitted to the ICU for greater then 72hrs
3249503|NCT00843544|Experimental|Integrative Medicine|
3249504|NCT00843544|No Intervention|Control|
3249505|NCT00843531|Experimental|RAD001 and erlotinib|"Each 28 day cycle:~RAD001: 5 mg per day by mouth (self-administered) Erlotinib: 100 mg per day by mouth (self-administered)"
3249506|NCT00843518|Experimental|LY451395|3 milligram (mg) LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate
3249507|NCT00843518|Placebo Comparator|Placebo|Placebo orally twice daily for 12 weeks
3249508|NCT00843505|Experimental|1|Participants will take part in a telemedicine smoking cessation program.
3249509|NCT00843505|Active Comparator|2|Participants will take part in a telephone quitline smoking cessation program.
3249510|NCT00843492|Active Comparator|Nadroparin|After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days. Patients will then be followed up to five weeks (± one week) after the cast or brace removal.
3249511|NCT00843492|Experimental|Fondaparinux|After randomization (Day 1), subjects will receive subcutaneously, once daily, fondaparinux 2.5 mg (1.5 mg in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days. Patients will then be followed up to five weeks (± one week) after the cast or brace removal.
3249512|NCT00843479||Elderly NGT|Normoglycemic subjects 65-80 years old
3249513|NCT00843479||Middle-age NGT|Middle-age normoglycemic subjects 35 to 50 years old.
3249514|NCT00843466|Active Comparator|Mild moisturizing Hand Cleanser|The test group will be provided with a mild moisturizing hand cleanser for all hand cleansing needs during the duration of the study.
3249515|NCT00843466|No Intervention|Current Hand Cleanser|The control group will continue to use their current cleanser for all hand washing.
3249516|NCT00843453|Other|1|Comparison of serum vitamin and B12 concentrations of PPI and non-PPI groups
3249517|NCT00843453|Experimental|2|Comparison of baseline and end of treatment serum vitamin B12 and MMA concentrations.
3249518|NCT00843440|Experimental|Bevacizumab|Study using a Gehan design, 7 patients will be included in the first phase and 18 additional patients will enter the second phase.
3249620|NCT00842660|Experimental|Gemzar,survival|
3249519|NCT00843427|Experimental|Aphasia - CIAT|Patients with aphasia >1 year after left MCA stroke who will be randomized to receive CIAT
3249520|NCT00843427|No Intervention|Aphasia - observation|Patients with aphasia >1 year after left MCA stroke who will be randomized to no intervention (observation)
3249521|NCT00843388|Active Comparator|1|60 days treatment with tablet hexalacton 25 mg OD.
3249522|NCT00843388|Placebo Comparator|2|Inactive drug of 25 mg OD
3249523|NCT00843375||Normal|Subjects who have had a colonoscopy and no adenomas or cancer was found.
3249524|NCT00843375||Adenomas|Subjects who had an adenoma found on colonoscopy. All samples must be collected before the adenoma is removed.
3249525|NCT00843375||Colorectal Adenocarcinoma|Subjects who have confirmed colorectal carcinoma. All samples must be collected before the cancer is removed.
3249526|NCT00843375||High Risk Normals|Subjects who had a colonoscopy without adenomas or cancer AND have a history of adenomas, colorectal cancer (greater than 3 years ago) or a family history of cancer or adenomas.
3249527|NCT00843362|Experimental|1|24-hours vaginal dinoprostone pessary
3249528|NCT00843362|Active Comparator|2|Vaginal dinoprostone gel
3249529|NCT00843349|Active Comparator|900 mg Phosphate Diet-LC|dietary phosphorus restriction (900 mg/day of phosphorus) + phosphorus binder (Lanthanum Carbonate)
3249530|NCT00843349|Active Comparator|Ad Libitum Diet-LC|no dietary intervention + phosphorus binder (Lanthanum Carbonate)
3249531|NCT00843349|Active Comparator|900 mg Phosphate Diet-LC Placebo|dietary phosphorus restriction (900 mg/day of phosphorus) + placebo
3249532|NCT00843349|Placebo Comparator|Ad Libitum Diet-LC Placebo|no dietary intervention + placebo
3249533|NCT00843336|Experimental|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that measures urinary estrogen and LH and provides users with low, high, or peak fertility readings.
3249534|NCT00843336|Active Comparator|Cervical mucus monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
3249535|NCT00843310|Experimental|ReMeDex|"Treatment phase (28 days/cycle x 6 cycles):~Lenalidomide: 10 mg/day orally on days 1-21, followed by 7 days of rest. Melphalan: 4 mg/m2 daily on days 1-4. Dexamethasone: 40 mg daily on days 1, 8, 15 and 22.~Maintenance Phase (for subjects who achieve partial response or better at the end of the treatment phase):~lenalidomide: 10 mg/day orally on days 1-21 followed by 7 days of rest (28 days/cycle) for a maximum of 24 cycles."
3249536|NCT00843297|Active Comparator|CG|Coolgard: invasive Cooling
3249537|NCT00843297|Active Comparator|AS|ArcticSun: Surface-Cooling
3249538|NCT00843297|Sham Comparator|UnCOOL|No Cooling-Therapy due to non-operational cooling-devices
3249539|NCT00843284||Patients with neuropathic pain|
3249540|NCT00843271||MESA Lung|MESA-Lung is an ancillary study of the Multi-Ethnic Study of Atherosclerosis (MESA). MESA, established in 1999, is well characterized, multi-ethnic (white, Black, Hispanic and Chinese), and multi-center (Columbia, Johns Hopkins, Northwestern, UCLA, Minnesota,and Wake Forest) prospective cohort study. MESA-Lung included a 60% random sample of the MESA cohort at the six Field Centers in Exam 3 and Exam 4, stratified on race/ethnicity.
3249541|NCT00843258|No Intervention|Active Sonographic surveillance|Follow-up at 1.5 and 3 months (Ultrasound,Clinical examination), at 6 and 12 months (clinical examination, pelvic X-ray)
3249542|NCT00843258|Experimental|Abduction treatment|Treatment (abduction splint) from 0-6 weeks, follow-up at 1.5 and 3 months (clinical examination and ultrasound) and at 6 and 12 months (clinical examination and pelvic x-ray)
3249543|NCT00843245||heart failure|Heart failure attending a HF clinic with or without clinical decompensation
3249544|NCT00843232||Elderly T2DM|Elderly T2DM subjects 65 to 80 years old
3249545|NCT00843232||Middle-age T2DM|Middle-age T2DM subjects 35 to 50 years old
3249546|NCT00843219||PET/CT Scan|
3249547|NCT00843193|Experimental|GSK679586|Subjects will receive three, once monthly intravenous administration of 10 mg/kg of GSK679586, according to randomization
3249548|NCT00843193|Placebo Comparator|PLACEBO|Subjects will receive three, once monthly intravenous administration of saline, according to randomization
3249549|NCT00843180|Experimental|massage|
3249550|NCT00843180|No Intervention|control|usual care only as control arm
3249551|NCT00843167|Experimental|Sulforaphane Supplement|Patients receive oral broccoli sprout extract supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.
3249552|NCT00843167|Placebo Comparator|Placebo|Patients receive oral placebo supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.
3249553|NCT00843154|Experimental|Candesartan QD|
3249554|NCT00843154|Active Comparator|Standard chronic heart disease therapy|
3249555|NCT00843141|Experimental|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
3249556|NCT00843141|Active Comparator|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
3249557|NCT00843128|Experimental|1: RAGT|Following randomization, 20 patients will be treated with RAGT, 12 sessions over three weeks
3249558|NCT00843128|Active Comparator|2: Control|The control group will be treated by CWT, 12 sessions in three weeks.
3249559|NCT00843115||Observational|This study was non-interventional and simply followed for 3 months patients initiating a treatment with donepezil
3249560|NCT00843089|No Intervention|1|Standard care
3249561|NCT00843089|Experimental|2|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
3249562|NCT00843063|Active Comparator|pantoprazole|pantoprazole 20 mg om and matching placebo nocte
3249563|NCT00843063|Active Comparator|famotidine|Famotidine 40 mg om and nocte
3249564|NCT00843050|Experimental|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
3249565|NCT00843037|Experimental|Open label - Sunitinib|Sunitinib, 50mg daily, once daily for 4 weeks followed by a 2-week break
3249566|NCT00843024|Experimental|Sumatriptan and Naproxen 1|Sumatriptan succinate and naproxen sodium combination 10mg/60mg
3249567|NCT00843024|Experimental|Sumatriptan and Naproxen 2|Sumatriptan succinate and naproxen sodium combination 30mg/180mg
3249723|NCT00841893|Experimental|2|Placebo
3249568|NCT00843024|Experimental|Sumatriptan and Naproxen 3|Sumatriptan succinate and naproxen sodium combination 85mg/500mg
3249569|NCT00843024|Placebo Comparator|Placebo|Placebo to match
3249570|NCT00843011|Experimental|Arm 1|Orvepitant 60 mg
3249571|NCT00842998|Experimental|1 - Trastuzumab|Day1 Week1: 8 mg/kg iv in 90 min. Following 1st week: 2 mg/kg once/weekly for 8 weeks
3249572|NCT00842998|Experimental|2 - Lapatinib|1500 mg/die orally
3249573|NCT00842985|Other|drug condition|Participants received each drug condition in sequential order across 4 test days. Not all participants received the interventions in the same order.
3249574|NCT00842959|Other|ZO|XL Stabi ZO or Invent ZO
3249575|NCT00842946|Experimental|Exposure w/ Acceptance-Based Rationale|Behavioral exposure within the context of psychological acceptance.
3249576|NCT00842946|Active Comparator|Exposure w/ Habituation-Based Rationale|Behavioral exposure within the context of habituation.
3249577|NCT00842933|Experimental|Experimental group|Corticosteroids discontinued 24 hours after cessation of vasopressor therapy or 7 days, which ever comes first.
3249578|NCT00842933|Active Comparator|Standard of care group|Standard corticosteroid therapy given for 7 days as treatment for adrenal insufficiency during septic shock.
3249579|NCT00842920|Placebo Comparator|Placebo|Placebo or 20 mg Simvastatin (stratified by prior use of statins)
3249580|NCT00842920|Experimental|Simvastatin|Simvastatin 60 mg once daily
3249581|NCT00842907|Active Comparator|oral isotretinoin|Twelve subjects will be treated with oral isotretinoin 20.0 mg, once a day, every other day, for 24 weeks.
3249582|NCT00842907|Active Comparator|tretinoin|Twelve patients will be treated with 0,05% tretinoin cream applied on face and forearms at night and moisturizer broad-spectrum sunscreen twice a day.
3249583|NCT00842894||Insulin detemir|
3249584|NCT00842894||Biphasic insulin aspart 30|
3249585|NCT00842881|No Intervention|a|healingstone
3249586|NCT00842881|No Intervention|b|stone powder
3249587|NCT00842855||1|274 GERD patients, partial responders to PPI treatment
3249588|NCT00842842|Active Comparator|1: tacks|mesh fixation with tacks
3249589|NCT00842842|Experimental|2: glue|mesh fixation with glue
3249590|NCT00842829|Experimental|FBT 100 mcg|During the Titration Period, participants took fentanyl buccal tables (FBT) with a starting dose of 100 mcg until they reached an effective dose, with a maximum dose of 800 mcg and a maximum timeframe of 7 days. Participants who reached an effective dose entered the Open-label Treatment Period, whose length depended on how long was needed to treat up to 8 episodes of breakthrough pain (BTP) with FBT (maximum of 8 days). The length of the Continuation Period (when applicable) varied from country to country, up to until FBT was commercially available in that country.
3249591|NCT00842829|Active Comparator|FBT 200 mcg|During the Titration Period, participants took fentanyl buccal tables (FBT) with a starting dose of 200 mcg until they reached an effective dose, with a maximum dose of 800 mcg and a maximum timeframe of 7 days. Participants who reached an effective dose entered the Open-label Treatment Period, whose length depended on how long was needed to treat up to 8 episodes of breakthrough pain (BTP) with FBT (maximum of 8 days). The length of the Continuation Period (when applicable) varied from country to country, up to until FBT was commercially available in that country.
3249592|NCT00842816|Experimental|1|10 mg ST101
3249593|NCT00842816|Experimental|2|60 mg ST101
3249594|NCT00842816|Experimental|3|120 mg ST101
3249595|NCT00842816|Placebo Comparator|4|Placebo
3249596|NCT00842803|No Intervention|Control Group|Patients in this group will not be allowed albumin or any other colloids fluid for the first 7 days post-operative
3249597|NCT00842803|Experimental|Albumin group|Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
3249598|NCT00842777|Experimental|Parent group treatment|Manualized group treatment of parents. Allocation of 4-6 parental couples of children with similar age.
3249599|NCT00842777|Active Comparator|Parent self-help groups|Professionals initiate and organize the self-help groups initially. The groups will not receive any teaching or counseling concerning eating and physical activity.
3249600|NCT00842764|Experimental|eyelid|eyelid
3249601|NCT00842751|Placebo Comparator|Testosterone Undecanoate + placebo finasteride|Acyline 300mcg/kg subcutaneous on days 1, 15 and 29 + Testosterone Undecanoate (TU)200mg twice daily, orally for 7 days + placebo finasteride twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)
3249602|NCT00842751|Experimental|Testosterone Undecanoate + Finasteride 0.5mg|Acyline 300mcg/kg subcutaneous on days 1, 15 & 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 0.5mg twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)
3249603|NCT00842751|Experimental|Testosterone Undecanoate + Finasteride 1mg|Acyline 300mcg/kg subcutaneous on days 1, 15 & 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 1mg twice daily, orally for 7 days during one of the three intervention periods ((First Intervention, Second Intervention or Third Intervention)
3249604|NCT00842738|Active Comparator|Mindfulness meditation|Women with mild dysplasia offered mindfulness meditation
3249605|NCT00842738|Other|No meditation|Women with mild dysplasia offered health care services as usual
3249606|NCT00842738|Other|Controls|Women with normal cervical cells
3249607|NCT00842712|Experimental|Safety run-in part: Cil (1000 mg) + Cetuximab + Cis + Gem|
3249608|NCT00842712|Experimental|Safety run-in part: Cil (1000 mg) + Cetuximab + Cis + Vin|
3249609|NCT00842712|Experimental|Safety run-in part: Cil (2000 mg) + Cetuximab + Cis + Gem|
3249610|NCT00842712|Experimental|Safety run-in part: Cil (2000 mg) + Cetuximab + Cis + Vin|
3249611|NCT00842712|Experimental|Randomized part: Cil (Once Weekly) + Cetuximab + Chemotherapy|
3249612|NCT00842712|Experimental|Randomized part: Cil (Twice Weekly) + Cetuximab + Chemotherapy|
3249613|NCT00842712|Active Comparator|Randomized part: Cetuximab + Chemotherapy|
3249614|NCT00842699||1|patients receiving IL-2 receptor antagonist (Simulect) as induction treatment
3249615|NCT00842699||2|patients receiving Thymoglobulin as induction treatment
3249616|NCT00842673|Experimental|1|30 mg ST101
3249617|NCT00842673|Experimental|2|90 mg ST101
3249621|NCT00842634|Experimental|Cohort 1|Patients who have failed two more HAART regimens
3249622|NCT00842634|Experimental|Cohort 2|Patients doing well on a stable antiretroviral medication
3249623|NCT00842634|Experimental|Cohort 3|Patients who have an undetectable viral load on HAART who have exhibited suboptimal CD4+ T cell gains during long term antiretroviral therapy. This group will not participate in the structured treatment interruption.
3249624|NCT00842621||1|Pediatric participants with severe sickle cell disease (HbSS or Hb S/β°-thalassemia) who are not receiving treatment, e.g., hydroxyurea or chronic transfusions
3249625|NCT00842621||2|Pediatric participants with other forms of SCD or severe sickle cell disease patients (HbSS or Hb S/β°-thalassemia) being treated with hydroxyurea or chronic transfusions
3249626|NCT00842621||3|Pediatric and adult participants with other non-sickling hematological disorders
3249627|NCT00842608|Experimental|Haloperidol Eligible Intervention|0.5-1mg Haloperidol Q8h for 7 days, reduced exposure to anticholinergics, reduced exposure to benzodiazepines
3249628|NCT00842608|Active Comparator|Haloperidol Eligible Usual Care|Usual care
3249629|NCT00842608|Experimental|Haldol-Ineligible Arm|"Haldol-Ineligible arm for patients with contraindications for Haldol, unresolvable prolonged QTc, history of torsades de pointes, or history of seizures.~Patients are randomized and will still receive:~reduced exposure to anticholinergics, reduced exposure to benzodiazepines"
3249630|NCT00842608|Active Comparator|Haldol Ineligible Usual Care|Usual Care
3249631|NCT00842595|Experimental|R NIMP|(Mabthera®) Rituximab IV 375 mg/m²day 1 (Navelbine ®)Vinorelbine IV 25mg/m² day 1 and day 5 (Novantrone®)Mitoxantrone IV 10 mg/m² day 1 (Holoxan®)Ifostamide IV 1000 mg/m²day 1 to day 5 (Cortancyl®)prednisone oral day 1 to day 5
3249632|NCT00842582|Experimental|Single group assignment|Patients will receive Azacitidine at 20, 40, or 75 milligrams per meter squared subcutaneous once daily for 7 days.
3249633|NCT00842569||Normal weighted|BMI<25
3249634|NCT00842569||Obese|BMI>30
3249635|NCT00842556|Active Comparator|Dapagliflozin|
3249636|NCT00842556|Active Comparator|Glimepiride|
3249637|NCT00842556|Active Comparator|Dapagliflozin + Glimepiride|
3249638|NCT00842556|Active Comparator|Sitagliptin|
3249639|NCT00842556|Active Comparator|Dapagliflozin + Sitagliptin|
3249640|NCT00842543|Experimental|Overweight|Overweight Boys receiving either Fruit and Vegetable Juice Concentrate (FVJC) or Placebo, 1 capsule, twice a day, for 6 months
3249641|NCT00842543|Experimental|Lean|Lean Boys receiving either Fruit and Vegetable Juice Concentrate (FVJC) or Placebo, 1 capsule, twice a day, for 6 months
3249642|NCT00842530|Experimental|Dengue Vaccine Group|
3249643|NCT00842530|Sham Comparator|Control Vaccine Group|
3249644|NCT00842517|Experimental|Extended|36-week duration contingency management program
3249645|NCT00842517|Active Comparator|Standard|12-week duration contingency management program
3249646|NCT00842504|Other|Micafungin|3 mg/kg given once
3249647|NCT00842491|Experimental|endostar+chemotherapy|
3249648|NCT00842478|Experimental|Raspall|
3249649|NCT00842478|No Intervention|Control|
3249650|NCT00842465||1|benign breast diseases
3249651|NCT00842465||2|breast cancer
3249652|NCT00842465||3|control
3249653|NCT00842452|Experimental|Oral Topotecan|
3249654|NCT00842439|Experimental|Cognitive Behavioral Intervention (CBI)|Participants will meet with an interventionist once a week for 12 weeks. They will discuss the child's behavior, will learn coping skills and how to deal with other people.
3249655|NCT00842439|Experimental|Nutritional Supplements (NUT)|Participants will be asked to take omega-3 supplements, multivitamin tablets, and calcium tablets every day for 12 weeks.
3249656|NCT00842439|Experimental|CBI + NUT|Participants will receive both the cognitive behavioral intervention and the nutritional supplements.
3249657|NCT00842439|No Intervention|No intervention|Participants will not be asked to come for sessions or any other intervention. They will receive a list of the types of help that are available if they are interested in following up on their own.
3249658|NCT00842426|No Intervention|Usual Care|Usual Care
3249659|NCT00842426|Experimental|Self-Management Program|Online Self-Management.
3249660|NCT00842426|Experimental|Care Management Program|Care management lifestyle modification program with intensive intervention phase with exercise and nutrition specialist. Followed by a online self-management phase.
3249661|NCT00842413||1|The study compares brain-damaged patients with healthy ones on two psychophysical tasks.
3249662|NCT00842413||2|The study does not intervene on the brain-damaged patients, it merely compares their behaviour with that of healthy patients on a range of psychophysical tasks.
3249663|NCT00842387||1|Patients with symptoms suggestive of GERD, managed according to a new structured and implemented pathway
3249664|NCT00842387||2|Patients with symptoms suggestive of GERD, managed according to usual clinical practice.
3249665|NCT00842374||Non-STEMI ACS|
3249666|NCT00842361|Active Comparator|Mix30|
3249667|NCT00842361|Experimental|SIAC|
3249668|NCT00842348|Experimental|Lanreotide (Autogel formulation)|Patients from the preceding DB study (Study 726) were treated with open label lanreotide Autogel 120 mg by deep subcutaneous injections every 28 days. Patients were included if they had been treated with lanreotide (Autogel formulation) or placebo in DB Study 726 and had stable disease at the end of the 96-week treatment period, or if they had received placebo and had disease progression at any time during Study 726. Safety data were based on the safety population patients who received lanreotide in Study 729). The main efficacy analysis was based on the ITT population (patients randomised in Study 726 regardless of whether they continued into Study 729).
3249669|NCT00842335|Experimental|JI-101|
3249670|NCT00842322|Experimental|High fluid intake|fluid intake of 4 litres per day
3249671|NCT00842322|Experimental|normal fluid intake|Fluid intake of 2 litres per day
3249672|NCT00842309|Active Comparator|D-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
3249673|NCT00842309|Placebo Comparator|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
3249674|NCT00842296|Experimental|Seg. RF Ablation with CLF catheter|Single Arm with CLF Catheter
3249873|NCT00840866|Experimental|1|
3249676|NCT00842270|Experimental|2|4,5 mg/kg/day
3249677|NCT00842270|Experimental|3|6 mg/kg/day
3249678|NCT00842270|Placebo Comparator|4|matching placebo for AB1010 3, 4,5 and 6 mg/kg/day
3249679|NCT00842270|Experimental|1|AB1010 3 mg/kg/day
3249680|NCT00842257|Experimental|Panitumumab|Panitumumab administered by a central line infusion on days 1 and 15 of each 4 week cycle.
3249681|NCT00842244|Experimental|A|
3249682|NCT00842231||Visual performance measures|Collection of visual performance measures in subjects with low levels of astigmatism.
3249683|NCT00842205|Active Comparator|1 HCV positive pts|"Patients with chronic HCV infection undergoing liver biopsy followed by antiviral treatment.~peg-IFN alfa 2a 180ug s.c. QW + ribavirin 1000-1200mg p.o. daily 48weeks or peg-IFN alfa 2b 1.5 ug/kg s.c. QW + ribavirin 100-1200mg p.o. daily 48 weeks"
3249684|NCT00842205|No Intervention|2 Other liver disease|pts. with NASH (or other liver disease) undergoing liver biopsy.
3249685|NCT00842192||A|
3249686|NCT00842179||Manual Closure|Patients who received vascular closure with manual compression after percutaneous coronary intervention (PCI)
3249687|NCT00842179||Perclose Device|Patients who received vascular closure with the Perclose VCD after percutaneous coronary intervention (PCI)
3249688|NCT00842153|Experimental|Clobetasol Propionate Foam|Topical foam formulation that includes clobetasol propionate (Steroid)
3249689|NCT00842153|Placebo Comparator|Vehicle Foam|Vehicle foam is the same as the clobetasol propionate foam except it does not include the active drug.
3249690|NCT00842140|Active Comparator|1|This group will receive an oral contraceptive containing 0,03mg ethynylestradiol and 2mg chlormadinone acetate
3249691|NCT00842140|Experimental|2|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
3249692|NCT00842140|Experimental|3|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg metformin.
3249693|NCT00842114|Experimental|R+CVP+IFN|8 cycles of Rituximab plus CVP chemotherapy (Bagley's et al) associated with Interferon for 12 weeks
3249694|NCT00842101||pressure monitor|Tibial Fracture
3249695|NCT00842088|Experimental|Active|
3249696|NCT00842088|Placebo Comparator|Placebo|
3249697|NCT00842075|Experimental|1 Symlin|Subcutaneous injection of pramlintide prior to each meal with reduction of mealtime bolus insulin
3249698|NCT00842075|No Intervention|2 Usual Regimen|Usual bolus insulin dose at each meal
3249699|NCT00842062|Experimental|MyoScience Tissue Remodeling Device|
3249700|NCT00842049|Experimental|Study|Insertion of lumbar drain
3249701|NCT00842049|Other|Control|Normal clinical management without lumbar drain
3249702|NCT00842036|Active Comparator|ANft|12- step Al/Nar-Anon Facilitation
3249703|NCT00842036|Experimental|TEnT|Treatment Entry Training
3249704|NCT00842036|Experimental|CRAFT|Community Reinforcement and Family Training
3249705|NCT00842023|Experimental|Nesiritide Infusion|Nesiritide: 2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours.
3249706|NCT00842023|Active Comparator|Nitroglycerin Infusion|Nitroglycerin was initiated at 10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP<or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment.
3249707|NCT00842010||HND|Patients with hyperglycemia, without previous diagnosis of diabetes
3249708|NCT00842010||DH|Patients that have previous diagnosis of Diabetes Mellitus
3249709|NCT00842010||NHND|Patient with NO previous diagnosis of diabetes, and no hyperglycemia
3249710|NCT00841984||1|patients with complex neurological disease of unknown cause
3249711|NCT00841984||2|positive controls : patients with already known metabolic disease for whom we already have CSF or urines
3249712|NCT00841984||3|negative controls: patients with non metabolic neurological disorders of known cause hospitalized for a lumbar puncture
3249713|NCT00841971|Experimental|anidulafungin|anti-fungal agent
3249714|NCT00841971|Active Comparator|Fluconazole|anti-fungal agent
3249715|NCT00841945|Active Comparator|1|"Chemotherapy + Radiotherapy~- 4 or 6 R CHOP courses regimen every 14 days R CHOP = Rituximab, Doxorubicin, Vincristine and prednisone~Radiotherapy 40 gray on initial nodes"
3249716|NCT00841945|Experimental|2|"Chemotherapy~- 4 or 6 R CHOP courses regimen every 14 days R CHOP = Rituximab, Doxorubicin, Vincristine and prednisone"
3249717|NCT00841932||Fractional Flow Reserve|Patients with suspected coronary artery disease undergoing FFR to assess physiological significance of stenosis
3249718|NCT00841919|Active Comparator|2|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
3249719|NCT00841919|Experimental|1|"The study group will receive Insulin Glargine as basal insulin and bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff"
3249720|NCT00841906|Other|Alice PDx with only written instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device.
3249721|NCT00841906|Other|Alice PDx with written and verbal instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device.
3249724|NCT00841880|Experimental|1|2 weeks run-in of Ramipril 5 mg followed by 8 weeks of Ramipril + Felodipine
3249725|NCT00841880|Active Comparator|2|2 weeks run-in of Ramipril 5 mg followed by 8 weeks of Ramipril 10 mg
3249726|NCT00841867||1|Subjects 18-80 years of age who have previously undergone partial pancreatectomy due to a benign lesion
3249727|NCT00841867||2|Healthy control subjects, 18-80 years of age, who have not had partial pancreatectomy.
3249728|NCT00841854|Active Comparator|PBMT7|pantoprazole 40mg bid, bismuth 300mg qid, metronidazole 500mg tid,tetracycline 500mg qid for 7 days
3249729|NCT00841854|Active Comparator|PBMT14|pantoprazole 40mg bid, bismuth 300mg qid, metronidazole 500mg tid,tetracycline 500mg qid for 14 days
3249730|NCT00841841|Experimental|Dipyrone|"Analgesic affectiveness using Dipyrone (500mg) as a postoperative drug for pain relief.~Intervention: Drug: dipyrone and acetaminophen"
3249731|NCT00841841|Experimental|Acetaminophen|"Analgesic affectiveness using Acetaminophen (750mg) as a postoperative drug for pain relief.~Intervention: Drug: dipyrone and acetaminophen"
3249732|NCT00841828|Experimental|1|"EC -> T + Lapatinib~Drugs plus Biological"
3249733|NCT00841828|Active Comparator|2|"EC -> T + Trastuzumab~Drug plus Biological"
3249734|NCT00841815|Experimental|Amlodipine Besylate|Amlodipine Besylate 10 mg tablet (test) dosed in first period followed by Norvasc® 10 mg tablet (reference) dosed in second period
3249735|NCT00841815|Active Comparator|Norvasc®|Norvasc® 10 mg tablet (reference) dosed in first period followed by Amlodipine Besylate 10 mg tablet (test) dosed in second period
3249736|NCT00841802|Experimental|Prednisone|Steroid medication
3249737|NCT00841802|No Intervention|No Intervention|No Intervention
3249738|NCT00841789|Experimental|Arm 1 -Etanercept|Drug - Treatment with Etanercept as adjunct to standard treatment with IVIG and aspirin
3249739|NCT00841789|Placebo Comparator|2|Placebo
3249740|NCT00841776|Active Comparator|Duac gel|Clindamycin and benzoyl peroxide gel
3249741|NCT00841776|Active Comparator|Ziana gel|Clindamycin and tretinoin gel
3249742|NCT00841763|Experimental|TIV + aH5N1|First dose of the non-adjuvanted trivalent influenza virus vaccine(TIV) followed by two doses of the adjuvanted monovalent influenza virus vaccine (aH5N1)
3249743|NCT00841763|Active Comparator|PL + aTIV|First dose of placebo (PL-saline) followed by two doses of the adjuvanted trivalent influenza virus vaccine (aTIV)
3249744|NCT00841750|Experimental|No chest tube|No chest tube left in the pleural cavity at the end of a VATS pulmonary wedge resection.
3249745|NCT00841750|Active Comparator|Chest tube|Chest tube left in the pleural cavity at the end of a VATS pulmonary wedge resection.
3249746|NCT00841737|Experimental|Psychoeducational group intervention|Psychoeducational group received weekly a psychoeducational intervention during a period of 12 weeks run by a nurses.
3249747|NCT00841737|Active Comparator|Control group|Individual conventional care
3249748|NCT00841724|Active Comparator|Busilvex, Fludara, Thymoglobuline|D-6: Fludara D-5: Fludara + Busilvex D-4: Fludara + Busilvex D-3: Fludara + Busilvex D-2: Fludara + Thymoglobuline D-1: Thymoglobuline D0: graft infusion
3249749|NCT00841711|Other|Behavioral counseling|
3249750|NCT00841698|Experimental|Paroxetine|Paroxetine HCl 40 mg Tablet (test) dosed in first period followed by Paxil® 40 mg Tablet (reference) dosed in second period
3249751|NCT00841698|Active Comparator|Paxil®|Paxil 40 mg Tablet (reference) dosed in first period followed by Paroxetine HCl 40 mg Tablet (test) dosed in second period
3249752|NCT00841685|Experimental|1|Goldlock
3249753|NCT00841685|Active Comparator|2|Visicoil smallest size
3249754|NCT00841685|Active Comparator|3|Visicoil larger size
3249755|NCT00841685|Active Comparator|4|Bard goldmarker smallest size
3249756|NCT00841685|Active Comparator|5|Bard goldmarker larger size
3249757|NCT00841672|Experimental|Aliskiren/amlodipine 300/10 mg tablet|Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg.
3249758|NCT00841672|Active Comparator|Amlodipine 10 mg capsule|Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg.
3249759|NCT00841659|Experimental|Paroxetine|Paroxetine HCl 40 mg Tablet (test) dosed in first period followed by Paxil® 40 mg Tablet (reference) dosed in second period
3249760|NCT00841659|Active Comparator|Paxil®|Paxil® 40 mg Tablet (reference) dosed in first period followed by Paroxetine HCl 40 mg Tablet (test) dosed in second period
3249761|NCT00841646|Other|1|
3249762|NCT00841633|No Intervention|1|No induced hypertension (reference group)
3249763|NCT00841633|Experimental|2|Induced hypertension with a MAP of 30 mmHg above the average MAP on the previous day; during 24-36 hours, until a perfusion CT scan has been performed
3249764|NCT00841620|Active Comparator|1|Haemorrhoidectomy a.m. Milligan for grade 3-4 haemorrhoids
3249765|NCT00841620|Active Comparator|2|Stapled anopexy for grade 3-4 haemorrhoids
3249766|NCT00841607|Experimental|Pancreaticojejunostomy|Pancreaticojejunostomy reconstruction used following Whipple surgery.
3249767|NCT00841607|Active Comparator|Pancreaticogastomy|Pancreaticogastomy reconstruction used following Whipple surgery.
3249768|NCT00841594|Active Comparator|1|"MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.~Applied to the hand."
3249769|NCT00841594|Active Comparator|2|"MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.~Applied to the chest."
3249770|NCT00841581|Experimental|Lucentis|"All patients receive iL for for first 6 months of study. At 6 months - patients are classified as responders or non-responders. Responders receive iL PRN based on OCT,clinical exam etc. Non-responders are seen again at 12 months for repeat investigations."
3249771|NCT00841568|Experimental|1|
3249772|NCT00841555|Experimental|Hypofractionation Radiotherapy+Temozolomide|Patients will receive temozolomide PO daily for 5 weeks. Beginning week 1 after initiation of temozolomide therapy, patients undergo HIMRT times a week for a total of 15 fractions.
3249773|NCT00841542|Experimental|Amlodipine Besylate|Amlodipine Besylate 10 mg tablet (test) dosed in first period followed by Norvasc® 10 mg tablet (reference) dosed in second period
3249874|NCT00840866|Active Comparator|2|
3249774|NCT00841542|Active Comparator|Norvasc®|Norvasc® 10 mg tablet (reference) dosed in first period followed by Amlodipine Besylate 10 mg tablet (test) dosed in second period
3249775|NCT00841516|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
3249776|NCT00841516|Experimental|80 µg rBet v1-FV Immunotherapy|All randomized patients were treated with either placebo or 80 µg rBet v1-FV (maintenance dose) for 2 years.
3249777|NCT00841503||12 healthy volunteers|Healthy volunteers are randomized to 1 of 4 products over 4 weekly visits: i)buckwheat crackers;ii)crackers without buckwheat; iii)oral glucose; iv) oral sugar substitute, followed by 7 days of buckwheat crackers.
3249778|NCT00841503||12 Participants with Type 2 diabetes|Volunteers with type 2 diabetes are randomized to 1 of 4 products over 4 weekly visits: i)buckwheat crackers;ii)crackers without buckwheat; iii)oral glucose; iv) oral sugar substitute, followed by 7 days of buckwheat crackers.
3249779|NCT00841490||1|Intellectually & Developmentally Disabled Adults
3249780|NCT00841490||2|Control Group of Adults without Intellectual & Developmental Disabilities
3249781|NCT00841477|No Intervention|A1|standard behavioral intervention, standard HB vaccine schedule (0,1,6month)
3249782|NCT00841477|Active Comparator|A2|standard behavioral intervention, accelerated HB vaccine schedule (0,1,2month)
3249783|NCT00841477|Active Comparator|B1|enhanced behavioral intervention, standard vaccine schedule
3249784|NCT00841477|Active Comparator|B2|enhanced behavioral intervention, accelerated vaccine schedule (0,1,2MONTH)
3249785|NCT00841438|Active Comparator|Provisional use of Clotinab|Provisional use of clotinab
3249786|NCT00841438|Experimental|Upstream use of clotinab|early upstream use of clotinab
3249787|NCT00841425||Swimmers|
3249788|NCT00841412|Experimental|Immediate Intervention Group|Immediate Intervention: Long term care units assigned to the Immediate Intervention group were first to receive the staff training and management intervention to improve nutritional care processes.
3249789|NCT00841412|Active Comparator|Delayed Intervention Group|Delayed Intervention: Long term care units assigned to the Delayed Intervention group were monitored under usual care conditions to serve as a control for the Immediate Intervention group. Then, these units received the staff training and management intervention at a later date.
3249790|NCT00841399|Experimental|E75 + GM-CSF vaccine|The dose escalation scheme is for three patients to receive each of the doses, 100, 500, and 1,000 mcg of peptide + 250 mcg GM-CSF each month for 6 months until the maximum tolerated dose is determined. Patients who receive the vaccine are HLA-A2+ and/or HLA-A3+. Responses to the vaccine are measured via immunologic assays.
3249791|NCT00841399|No Intervention|Control/observation|HLA-A2- and HLA-A3- patients do not receive the E37 + GM-CSF vaccine, but are instead enrolled to the control arm for observation.
3249792|NCT00841386|Experimental|Cross-linking treatment|Topical anesthesia (lidocaine jelly 2%) will be used. The central 9 mm of corneal epithelium will be removed cautiously with an Amoils brush. Riboflavin 0.1% solution will be applied (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) to the cornea every 2-3 minutes for 15 minutes and then every 5 minutes thereafter. The UV source will be from the CBM VEGA X-linker (CSO, Florence, Italy). A wavelength of 370 nm will be used to direct 5.4 J/cm2 to the area of cornea debrided for 30 minutes. The distance from the UV source to the cornea will be 1.5 to 5.4 cm.
3249793|NCT00841386|Sham Comparator|Sham treatment group|Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and a 2% methylcellulose solution combined with 1% fluorescein dye will be applied to the cornea every 5 minutes for 30 minutes. The patient will be placed under the UV device, but instead of the UV light, the LED aiming beam will be applied for 30 minutes.
3249794|NCT00841373|Active Comparator|1|Panretinal Photocoagulation
3249795|NCT00841373|Active Comparator|2|Ranibizumab Supplementing Panretinal Laser Photocoagulation
3249796|NCT00841360||HIV Positive|"Participant self-discloses as HIV positive.~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
3249797|NCT00841360||HIV Negative|"Participant self-discloses as HIV negative (based on receiving a negative HIV test within 12 months prior to study consent).~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
3249798|NCT00841360||HIV Status Unknown|"Participant self-discloses as HIV negative (no history of prior HIV testing, or HIV screening more than 12 months prior to date of study consent).~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
3249799|NCT00841360||Friendship Network Members|Friendship network members will also consist of sexually experienced females, aged 13 years and older. Although most members are expected to be of African American race and/or Hispanic/Latina ethnicity, all races and ethnicities will be included.
3249800|NCT00841347|No Intervention|1|Study of habitual sleep length on non obese teen group
3249801|NCT00841347|Experimental|2|Study of habitual sleep length period followed by extended sleep length period on obese teen group
3249802|NCT00841347|Experimental|3|Study of extended sleep length period followed by habitual sleep length period on obese teen group
3249803|NCT00841334|Experimental|1|ACTION
3249804|NCT00841334|Active Comparator|2|Usual care
3249805|NCT00841321|Active Comparator|Arm 1|Subjects with multiple sclerosis and documented cognitive impairment will be randomized to take the intervention or placebo.
3249806|NCT00841321|Placebo Comparator|Arm 2|Subjects with multiple sclerosis and documented cognitive impairment will be randomized to receive the placebo.
3249807|NCT00841308|Active Comparator|Usual care|
3249808|NCT00841308|Active Comparator|Home blood pressure monitoring|
3249809|NCT00841295|Experimental|Carnitine|Intervention 'Parenteral L-carnitine supplementation' Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
3249810|NCT00841295|Placebo Comparator|Controle|Intervention 'Parenteral supplementation with sterile water'
3249811|NCT00841282|Active Comparator|1|Water Infusion in lieu of Air Insufflation Colonoscopy
3249812|NCT00841282|Placebo Comparator|2|Air Insufflation Colonoscopy
3249813|NCT00841269|Experimental|Uridine|Uridine 500 mg by mouth twice daily for 6 weeks
3249814|NCT00841269|No Intervention|Healthy Comparison|Healthy comparison participants were seen for baseline and week 6 MRI scans. No treatment was administered to participants enrolled as healthy comparisons.
3249815|NCT00841256|Experimental|Immunotherapy|Grass pollen allergens in a water/glycerol solution
3249816|NCT00841256|Placebo Comparator|Placebo|Water/glycerol solution with phosphate buffered saline
3249817|NCT00841243|Active Comparator|nutritional advise/support|Nutritional advise and support
3249818|NCT00841243|No Intervention|control|Control
3249819|NCT00841230|Placebo Comparator|Lactose placebo|1x/day
3249820|NCT00841230|Experimental|Deanxit|
3249821|NCT00841217|Placebo Comparator|1|placebo group
3249822|NCT00841217|Active Comparator|2|GW501516, 2.5mg
3249823|NCT00841204|Experimental|Arm I|Participants receive oral sulindac twice daily for 8 weeks
3249824|NCT00841204|Placebo Comparator|Arm II|Participants receive oral placebo twice daily for 8 weeks
3249825|NCT00841191|Experimental|Siltuximab 2.8 mg/kg (Cohort 1)|
3249826|NCT00841191|Experimental|Siltuximab 5.5 mg/kg (Cohort 2)|
3249827|NCT00841191|Experimental|Siltuximab 11 mg/kg (Cohort 3)|
3249828|NCT00841191|Experimental|Siltuximab 15 mg/kg (Cohort 4)|
3249829|NCT00841191|Experimental|Siltuximab 15 mg/kg (Expansion Cohort 5)|
3249830|NCT00841191|Experimental|Siltuximab 15 mg/kg (Ovarian Cancer Cohort 6)|
3249831|NCT00841191|Experimental|Siltuximab 15 mg/kg (KRAS Mutant Tumors Cohort 7)|
3249832|NCT00841178|Active Comparator|Surgery|Patients undergo Surgery under a general anaesthetic.
3249833|NCT00841178|Experimental|EVLT|Patients undergo EVLT under a local anaesthetic.
3249834|NCT00841165|Experimental|1|Participants in this arm are treated with Continuous Positive Airway Pressure at 5cm H2O and 100% oxygen
3249835|NCT00841165|Active Comparator|2|Participants in this arm receive standard of care therapy- oxygen via a non-rebreather mask
3249836|NCT00841152||Hand lesions|Stratum I: comparison of three interventions (autograft, bioactive glass and beta-tricalcium phosphate)
3249837|NCT00841152||Long-bone lesions|Stratum II: comparison of three interventions (bioactive glass, beta-tricalcium phosphate, allograft)
3249838|NCT00841139|Experimental|Perhexiline|perhexiline 100mg bd for 1 month duration
3249839|NCT00841139|Placebo Comparator|Placebo|placebo one tablet bd for 1 month duration
3249840|NCT00841126|Experimental|Magnesium iron hydroxycarbonate|
3249841|NCT00841126|Active Comparator|Lanthanum carbonate|
3249842|NCT00841126|Placebo Comparator|Placebo|
3249843|NCT00841113|Experimental|1 Abarelix|Investigative drug
3249844|NCT00841113|Active Comparator|2 Goserelin plus bicalutamide|Standard therapy
3249845|NCT00841100|Experimental|Kuvan and nutrition couseling|
3249846|NCT00841087|Experimental|SIBA|
3249847|NCT00841087|Active Comparator|Insulin Detemir|
3249848|NCT00841074|Experimental|1|Peridex mouthwash
3249849|NCT00841074|Placebo Comparator|2|Placebo mouthwash
3249850|NCT00841061|Active Comparator|Cereal L|Rice cereal with electrolytic iron
3249851|NCT00841061|Active Comparator|Cereal M|Rice cereal with ferrous fumarate
3249852|NCT00841048|Experimental|1|AZD4017 in ascending doses (start dose 75mg od)
3249853|NCT00841048|Placebo Comparator|2|Placebo
3249854|NCT00841035|Experimental|Eroltinib added to standard of care|150 mg of erlotinib for 7 days prior to surgery,then in the adjuvant stage the subject will receive 100mg of erlotinib and gemcitabine 1000mg/2 for 6 cycles
3249855|NCT00841022|Experimental|1|Information of children with comic leaflet
3249856|NCT00841022|No Intervention|2|
3249857|NCT00840996|Placebo Comparator|Placebo|Perioperative placebo IV infusion besides the standard anesthesia care, including general anesthesia and postoperative patient controlled analgesia.
3249858|NCT00840996|Active Comparator|Lidocaine|Perioperative intravenous lidocaine infusion besides the standard anesthesia care, including general anesthesia plus and post operative patient controlled analgesia.
3249859|NCT00840983|No Intervention|1-Immediate Cord Clamping|infants received the routine care of immediate clamping of the umbilical cord
3249860|NCT00840983|Experimental|2-Delayed Cord Clamping|after birth, cord clamping was delayed 30 to 45 seconds while infant was held lower than the level of the placenta.
3249861|NCT00840957||A|Rhumatoid arthritis patient currently receiving infliximab
3249862|NCT00840944|Experimental|ZOMATRIP|GnRH agonist triptorelin plus somatropin
3249863|NCT00840931|Experimental|Immunotherapy|Participants will take two 5 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Participants will receive 4 treatment cycles with 28 days in each cycle. Those participants showing a clinical response after 4 cycles of treatment may continue to receive lenalidomide as a single agent for additional cycles at the treating Physicians discretion. During each 28 day cycle participants will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
3249864|NCT00840918|Active Comparator|1|Intravenous Lidocaine group
3249865|NCT00840918|Placebo Comparator|Placebo|Intravenous placebo Group - Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
3249866|NCT00840905||1|HIV seropositive women from an HIV Antiretroviral therapy clinic in Johannesburg South Africa
3249867|NCT00840905||2|A cohort of HIV seropositive women from Gabarone Botswana
3249868|NCT00840905||3|A cohort of HIV seropositive women from Rio De Janeiro Brasil
3249869|NCT00840892|Experimental|Intercom|INTERdisciplinary COMmunity-based COPD management (INTERCOM)
3249870|NCT00840892|No Intervention|Usual Care|
3249871|NCT00840879|Experimental|Meloxicam|Meloxicam 15 mg Tablet (test) dosed in first period followed by Mobic® 15 mg Tablet (reference) dosed in second period
3249872|NCT00840879|Active Comparator|Mobic®|Mobic® 15 mg Tablet (reference) dosed in first period followed by Meloxicam 15 mg Tablet (test) dosed in second period
3249875|NCT00840853|Experimental|Group A with disease|"CD19+ B-ALL undergoing allogeneic HSCT, with minimal residual disease or relapse post-HSCT~Patients will receive one of the following dose levels of CD19CAR/virus specific T cells:~Dose Level 1: 1.5 x 10^7/m2~Dose Level 2: 4.5 x 10^7/m2~Dose Level 3: 1.2 x 10^8/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~If patients with relapse have a partial response or have stable disease they will be eligible to receive up to 6 further doses of CTLs, each of which will consist of the same number or less than as their first injection."
3249876|NCT00840853|Experimental|Group A without disease|"CD19+ B-ALL undergoing allogeneic HSCT, without detectable disease post-HSCT .~Patients will receive CD19CAR/virus specific T cells - Dose Level 1: 1.5 x 10^7/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT."
3249877|NCT00840853|Experimental|Group B with disease|"CD19+ B cell CLL or NHL undergoing allogeneic HSCT, with minimal residual disease or relapse post-HSCT~Patients will receive one of the following dose levels of CD19CAR/virus specific T cells:~Dose Level 1: 1.5 x 10^7/m2~Dose Level 2: 4.5 x 10^7/m2~Dose Level 3: 1.2 x 10^8/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~If patients with relapse have a partial response or have stable disease they will be eligible to receive up to 6 further doses of CTLs, each of which will consist of the same number or less than as their first injection."
3249878|NCT00840853|Experimental|Group B without disease|"CD19+ B cell CLL or NHL undergoing allogeneic HSCT, without detectable disease post-HSCT~Patients will receive CD19CAR/virus specific T cells -~Dose Level 1: 1.5 x 10^7/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT."
3249879|NCT00840840|Experimental|1|
3249880|NCT00840840|Active Comparator|2|
3249881|NCT00840827|Experimental|all patients|Lenalidomide 10mg po daily/ CSA 250mg orally twice daily
3249882|NCT00840801|Experimental|1|Subjects receive three vaccinations with a paediatric TBE vaccine according to the conventional vaccination schedule.
3249883|NCT00840801|Experimental|2|Subjects receive three vaccinations with a paediatric TBE vaccine according to the conventional vaccination schedule.
3249884|NCT00840788|Experimental|Skin adhesive|perineal skin repair with octyl-2-cyanoacrylate skin adhesive
3249885|NCT00840788|Active Comparator|subcuticular suture|continuous subcuticular suture of perineal skin using rapidly absorbable polyglactin 910
3249886|NCT00840775|Other|Presillion™ Stent System|
3249887|NCT00840762|Experimental|VircoType HIV-1|Genotypic HIV resistance testing results interpreted by VircoType HIV-1 algorithm
3249888|NCT00840762|Active Comparator|Local Expert review|Local Expert HIV genotypic review, as per Badri, S. et al CID 2003
3249889|NCT00840749|Experimental|CyberKnife Stereotactic Radiotherapy|
3249890|NCT00840749|Active Comparator|Surgery|
3249891|NCT00840736|Active Comparator|1|Laparoscopic adjustable gastric banding
3249892|NCT00840736|Active Comparator|2|vertical banded gastroplasty
3249893|NCT00840723||Current smokers|Current cigarette smokers with no other illness
3249894|NCT00840723||Healthy controls|Healthy non smokers
3249895|NCT00840697|Active Comparator|Work related rehabilitation|"work related rehabilitation and exercises~The workplace intervention includes two steps:~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks.~Exercises comprises of treatment in groups. The treatment includes exercises, both strength and fitness, in addition to cognitive intervention of how to manage pain and work."
3249896|NCT00840697|Active Comparator|Brief intervention|1 consultation at the physiotherapist, which give advise and a summary talk with the physician
3249897|NCT00840697|Active Comparator|Multidisciplinary exercise group|10 days of exercise and cognitive treatment group
3249898|NCT00840671|Experimental|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
3249899|NCT00840671|Placebo Comparator|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
3249900|NCT00840658|Placebo Comparator|Group A|Didactic safer injection & sexual activity education: In each city, 75 women will participate in a 60 minute lecture-format presentation and printed materials on safer sex and safer injection based on CDC guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). In this component, there will be no theory-driven active skill building elements oriented towards safer sex or safer injection.
3249901|NCT00840658|Active Comparator|Group B|"Interactive injection risk intervention and didactic safer sex education: In each city, 75 women will participate in the 60 minute Di No a las Jeringas Contaminadas ['Say No to Contaminated Syringes'] counseling session. This one-on-one intervention incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared. In addition, participants will be provided a lecture-format presentation on safer sex. However, in this component, there will be no theory-driven active skill building elements oriented towards safer sex."
3249902|NCT00840658|Active Comparator|Group C|"Interactive sexual risk intervention and didactic safer injection education: In each city, 75 women will participate in the 60 minute Di No Al Sexo Inseguro [Say No to Unsafe Sex'] counseling session. This one on one intervention incorporates elements of MI and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of unsafe sex and condom use with clients. In addition, participants will be provided a lecture format presentation on safer injection sharing. However, in this component, there will be no theory-driven active skill building elements oriented towards safer injection behavior."
3249951|NCT00840242|Placebo Comparator|Placebo gum|Placebo gum
3249952|NCT00840242|Active Comparator|Nicotine inhaler|Nicotine inhaler
3249953|NCT00840242|Placebo Comparator|Placebo inhaler|Placebo inhaler
3250793|NCT00834418|Active Comparator|Arava™|Arava™ 20 mg Tablet
3249903|NCT00840658|Experimental|Group D|"Interactive injection and sexual risk intervention: In each city, 75 women will participate in the 60 minute Di No a las Jeringas Contaminadas ['Say No to Contaminated Syringes'] and Di No Al Sexo Inseguro [Say No to Unsafe Sex'] counseling session. This one-on-one intervention incorporates elements of MI and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy)."
3249904|NCT00840645|Experimental|1. YM178|
3249905|NCT00840632|Experimental|Trandolapril|Trandolapril 4 mg Tablet (test) dosed in first period followed by Mavik® 4 mg Tablet (reference) dosed in second period
3249906|NCT00840632|Active Comparator|Mavik®|Mavik® 4 mg Tablet (reference) dosed in first period followed by Trandolapril 4 mg Tablet (test) dosed in second period
3249907|NCT00840606|Experimental|1|
3249908|NCT00840606|Active Comparator|2|
3249909|NCT00840593|Active Comparator|1. Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
3249910|NCT00840593|Active Comparator|2 Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
3249911|NCT00840580|Experimental|Vigamox|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
3249912|NCT00840580|Active Comparator|Cravit|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
3249913|NCT00840567|Other|Healthy Volunteers|To obtain a one time skin sample (4 ml skin punch biopsy) and one time blood sample (1 teaspoon)
3249914|NCT00840567|Other|Patients with benign, inherited hematologic disease|To obtain a one time skin sample (4 ml skin punch biopsy) and one time blood sample (1 teaspoon)
3249915|NCT00840554|Active Comparator|Physical Therapy|
3249916|NCT00840554|Experimental|Home Exercise|
3249917|NCT00840541||DR|Type-2 diabetic subjects diagnosed with diabetic retinopathy (DR).
3249918|NCT00840528|Experimental|Ozone exposure|Exposure to ozone at 0.4ppm
3249919|NCT00840515||Emulsion|
3249920|NCT00840502||Pregnant women|Pregnant women who present at the SMRU antenatal clinics on the Thai Burmese border.
3249921|NCT00840489|Experimental|Ribavirin|Ribavirin 1000-1200 mg qd
3249922|NCT00840489|Active Comparator|Colchicine|Colchicine 0.5 mg bd
3249923|NCT00840476|Experimental|Meloxicam|Meloxicam 15 mg Tablet (test) dosed in first period followed by Mobic® 15 mg Tablet (reference) dosed in second period
3249924|NCT00840476|Active Comparator|Mobic®|Mobic® 15 mg Tablet (reference) dosed in first period followed by Meloxicam 15 mg Tablet (test) dosed in second period
3249925|NCT00840463|Active Comparator|1|
3249926|NCT00840463|Placebo Comparator|2|
3249927|NCT00840450|Experimental|Paclitaxel + Imatinib Mesylate (Gleevec)|
3249928|NCT00840411|Experimental|Clarithromycin (test) First|
3249929|NCT00840411|Active Comparator|Biaxin® XL (reference) First|
3249930|NCT00840398|Experimental|1|
3249931|NCT00840398|Active Comparator|2|
3249932|NCT00840385|Experimental|A|
3249933|NCT00840372||1|Chronic hemodialysis patients, native arterio-venous fistula
3249934|NCT00840372||2|Chronic hemodialysis patients, native arterio-venous fistula
3249935|NCT00840359|Experimental|1 PDT|Leishmania lesion
3249936|NCT00840359|Active Comparator|Cryo|Leishmania lesion
3249937|NCT00840346|Experimental|1|The first patients enrolled in the trial will be successively distributed into three cohorts of patients for each dose level of panobinostat (20 mg, 30 mg, 40 mg) in combination with idarubicin and cytarabine, according to the classical 3+3 schedule
3249938|NCT00840333|Experimental|1|CF PATIENTS 6-11 YEARS OF AGE
3249939|NCT00840333|Experimental|2|CF PATIENTS 12-16 YEARS OF AGE
3249940|NCT00840320|Experimental|1|Repeat doses of active at escalating doses
3249941|NCT00840320|Placebo Comparator|2|Repeat doses of placebo
3249942|NCT00840294|No Intervention|Observation|Observation only for 2 weeks
3249943|NCT00840294|Active Comparator|Antibiotic|Ciprofloxacin 500 mg twice daily for 2 weeks
3249944|NCT00840281|Experimental|1|
3249945|NCT00840281|Active Comparator|2|
3249946|NCT00840268|Experimental|HPGG 0.25%|Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel, 1 drop per eye twice daily (BID) (in the morning upon awakening and in the evening prior to bedtime) for 21 days (Treatment phase).
3249947|NCT00840268|Placebo Comparator|HPGG Vehicle|Hydroxypropyl Guar Galactomannan Vehicle, 1 drop per eye twice daily (BID) (in the morning upon awakening and in the evening prior to bedtime) for 21 days (Treatment phase).
3249948|NCT00840255|Active Comparator|Breif Behavioral Treatment of Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
3249949|NCT00840255|Other|Information Control|This arm of the study does not receive the Brief Behavioral Treatment for Insomnia. This arm will act as the control arm.
3249950|NCT00840242|Experimental|Nicotine gum|Nicotine gum
3249954|NCT00840229|Experimental|1 capsular & intra-articular|corticosteroid injection (Triamcinolone) in capsule/rotator interval and intra-articular
3249955|NCT00840229|Active Comparator|2 intra-articular|corticosteroid injection (Triamcinolone) intra-articular placebo injection (Lidocaine) in capsule
3249956|NCT00840229|Placebo Comparator|3 placebo|placebo injections (Lidocaine) in capsule and intra-articular
3249957|NCT00840216|Experimental|1|
3249958|NCT00840216|Active Comparator|2|
3249959|NCT00840203|Experimental|Mesalamine|Mesalamine 4gm/60mL Rectal Enema (test) dosed in first period followed by Rowasa® 4gm/60mL Rectal Enema (reference) dosed in second period
3249960|NCT00840203|Active Comparator|Rowasa®|Rowasa® 4gm/60mL Rectal Enema (reference) dosed in first period followed by Mesalamine 4gm/60mL Rectal Enema (test) dosed in second period
3249961|NCT00840190|Experimental|P1446A-05|
3249962|NCT00840177|Experimental|treatment|"Induction (1 cycle):~pravastatin 1280 mg/d PO D 1-8 idarubicin 12 mg/m2/d IV D 4-6 AraC 1.5 g/m2/d contIV D 4-7~Consolidation (up to 2 cycles):~pravastatin 1280 mg/d PO D 1-6 idarubicin 12 mg/m2/d IV D 4-5 AraC 1.5 g/m2/d contIV D 4-5"
3249963|NCT00840151|No Intervention|Treatment Group A|Individuals randomized to Treatment Group A will receive standard treatment for study weeks 1-6.
3249964|NCT00840151|Experimental|Treatment Group B|Individuals randomized to Treatment Group B will receive contingency management plus standard treatment for study weeks 1-6.
3249965|NCT00840151|No Intervention|Aftercare Group A|All participants will be re-randomized after study week 6. Those participants assigned to Aftercare Group A will receive standard treatment for study weeks 7-12.
3249966|NCT00840151|Experimental|Aftercare Group B|All participants will be re-randomized after study week 6. Those participants assigned to Aftercare Group B will receive contingency management treatment plus standard treatment for weeks 7-12.
3249967|NCT00840138||1|Patients with common bile duct injury after open cholecystectomy
3249968|NCT00840138||2|Patients with common bile duct injury after laparoscopic cholecystectomy
3249969|NCT00840125|Experimental|1|docetaxel + erlotinib
3249970|NCT00840112|Experimental|LCHAD/TFP with peripheral neuropathy|Subjects diagnosed with LCHAD or TFP and with documented peripheral neuropathy
3249971|NCT00840099|Experimental|1|
3249972|NCT00840099|Active Comparator|2|
3249973|NCT00840086|Experimental|rFVIII|
3249974|NCT00840073|Experimental|Trandolapril|Trandolapril 4 mg Tablet (test) dosed in first period followed by Mavik® 4 mg Tablet (reference) dosed in second period
3249975|NCT00840073|Active Comparator|Mavik®|Mavik® 4 mg Tablet (reference) dosed in first period followed by Trandolapril 4 mg Tablet (test) dosed in second period
3249976|NCT00840060|Experimental|AMALS|Addressing multiple aspects of language simultaneously
3249977|NCT00840060|Experimental|DTA|Discrete Trial Approach
3249978|NCT00840047|Experimental|Participants|Participants who meet the eligibility criteria in the study will receive methionine.
3249979|NCT00840034|Experimental|LY2216684|
3249980|NCT00840034|Placebo Comparator|Placebo|
3249981|NCT00840008|Experimental|Educational intervention|see protocol
3249982|NCT00840008|No Intervention|Standard care|distribution of guidelines and a published algorithm
3249983|NCT00839995||Patients undergoing multi-level spine surgery|
3249984|NCT00839982|Experimental|Treatment (chemotherapy)|Patients receive clofarabine PO QD on days 1-5 and low-dose cytarabine SC BID on days 1-10 or SC QD on days 1-14. Treatment repeats every 21-28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3249985|NCT00839969|Sham Comparator|Cystoscopy alone|Women in this arm will undergo saline cystoscopy under general anaesthesia only.
3249986|NCT00839969|Active Comparator|Cystoscopy and urethral dilatation|Women in this group will undergo cystoscopy and urethral dilatation under general anaesthesia
3249987|NCT00839956|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive bortezomib IV on days 2 and 5 and vorinostat PO QD on days 1-14. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3249988|NCT00839943|Active Comparator|ozone|obese vs non-obese women
3249989|NCT00839943|Active Comparator|air|obese vs non obese women
3249990|NCT00839930|Experimental|Cilostazol (test)|Cilostazol 50 mg Tablet (test) dosed in first period followed by Pletal® 50 mg Tablet (reference) dosed in second period
3249991|NCT00839930|Active Comparator|Pletal® (reference)|Pletal® 50 mg Tablet (reference) dosed in first period followed by Cilostazol 50 mg Tablet (test) dosed in second period.
3249992|NCT00839917|Experimental|ProQuad™|
3249993|NCT00839917|Active Comparator|M-M-R™ II and Varivax™|
3249994|NCT00839904|Experimental|exercise|two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
3249995|NCT00839904|No Intervention|control|no intervention
3249996|NCT00839891|Placebo Comparator|3|"Group 1: 56 subjects to receive active study drug (VI-0521) at steady state, PHEN/TPM 7.5/46 (a potential therapeutic dose), escalating to PHEN/TPM 22.5/138 (a supra-therapeutic dose);~Group 2: 28 subjects to receive placebo preceded by a single oral dose of moxifloxacin on Day 2;~Group 3: 28 subjects to receive placebo followed by a single oral dose of moxifloxacin on Day 24;"
3249997|NCT00839878||A|
3249998|NCT00839865|Experimental|herb ointment dressing change group|This group of patients in the ointment dressing every 2 days until Wound Healing or 6 months
3249999|NCT00839865|No Intervention|Conventional dressing change group|This group of patients in the Conventional dressing every 2 days until Wound Healing or 6 months
3250000|NCT00839839|Experimental|Oocyte Vitrification|
3250001|NCT00839826|Active Comparator|Arm 2|
3250002|NCT00839826|Experimental|Arm 1|
3250003|NCT00839813|Experimental|Yoga|10 week trauma-sensitive yoga classes
3250004|NCT00839813|No Intervention|Women's Health Education|10 weeks of women's health education classes as an attentional control group
3250005|NCT00839800|Experimental|1|Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + Symbicort Turbuhaler 160/4.5 µg as needed
3250006|NCT00839800|Active Comparator|2|Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + terbutaline Turbuhaler 0.4 mg as needed
3250247|NCT00838227|Experimental|One arm|
3250007|NCT00839787|Experimental|Morphine|Morphine Sulfate: If weight is <50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given.
3250008|NCT00839787|Placebo Comparator|Placebo|Normal saline
3250009|NCT00839774|Experimental|1|Whole yellow pea flour
3250010|NCT00839774|Experimental|2|Fractionated yellow pea flour
3250011|NCT00839774|Experimental|3|White wheat flour
3250012|NCT00839761|Experimental|iron fortified rice group|
3250013|NCT00839761|Placebo Comparator|iron drop group|
3250014|NCT00839748||asthmatics|asthmatics registry for those interested in future asthma studies
3250015|NCT00839735||COPD|Chronic obstructive pulmonary disease
3250016|NCT00839735||Asthma|
3250017|NCT00839735||Healthy controls|
3250018|NCT00839722|Experimental|1|fertility after embolization
3250019|NCT00839709||depletion immunosuppression|
3250020|NCT00839709||no depletion immunosuppression|
3250021|NCT00839683|Active Comparator|simvastatin|
3250022|NCT00839683|Active Comparator|Dapagliflozin + simvastatin|
3250023|NCT00839683|Active Comparator|Dapagliflozin|
3250024|NCT00839683|Active Comparator|valsartan|
3250025|NCT00839683|Active Comparator|Dapagliflozin + valsartan|
3250026|NCT00839670|Active Comparator|Modified Therapy|
3250027|NCT00839670|Active Comparator|Standard Therapy|
3250028|NCT00839657|Experimental|1|Genotype-guided dosing algorithm for warfarin
3250029|NCT00839657|Active Comparator|2|Clinical-guided dosing algorithm for warfarin
3250030|NCT00839644|Active Comparator|2|
3250031|NCT00839644|Active Comparator|3|
3250032|NCT00839644|Active Comparator|1|
3250033|NCT00839605||Dexmedetomidine|Those requiring thoracic surgery and receiving dex
3250034|NCT00839605||placebo|Group having thoracic surgery and not receiving dex drug
3250035|NCT00839592|Experimental|Electroacupuncture|"Acupoints will be treated at bilateral Ear Shenmen, Sishencong (EX-HN1), Anmian, and unilateral Yintang (EX-HN3) and Baihui (GV20).~Acupuncture will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (CEFAR Acus II, Lund, Sweden) will be connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.45 ms square wave pulses and constant current. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
3250036|NCT00839592|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the same acupoints as stated in the electroacupuncture group. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
3250037|NCT00839579|Experimental|4x4min|4x4minutes interval group
3250038|NCT00839579|Experimental|1x4min|
3250039|NCT00839566|Experimental|AV ablation|
3250040|NCT00839566|Active Comparator|Rate control|Rate control by drugs
3250041|NCT00839566|No Intervention|Sinus rhythm|
3250042|NCT00839540|Active Comparator|micafungin 100|Patients receive Micafungin 100 mg qd
3250043|NCT00839540|Active Comparator|micafungin 200|Patients receive 200 mg Micafungin qd
3250044|NCT00839540|Active Comparator|Caspofungin|Patients receive caspofungin 70 mg LD followed by 50 mg qd
3250045|NCT00839527|Active Comparator|metformin + glimepiride + pioglitazone + albiglutide placebo|Metformin + glimepiride + pioglitazone + matching albiglutide placebo
3250046|NCT00839527|Experimental|metformin + glimepiride + pioglitazone placebo + albiglutide|Metformin + open-label glimepiride + pioglitazone matching placebo + albiglutide
3250047|NCT00839527|Active Comparator|met + glimepiride + pioglitazone placebo + albiglutide placebo|metformin + open-label glimepiride + pioglitazone placebo + albiglutide placebo
3250048|NCT00839501|Experimental|1|Participants will receive either potassium or placebo during six 3-week-long treatments, as randomly determined. Participants will then continue to receive potassium, if tolerated, and also either acetazolamide or placebo during another six 3-week-long treatments, as randomly determined.
3250049|NCT00839488|Active Comparator|I|pantoprazole 40 mg iv qd
3250050|NCT00839488|Active Comparator|II|famotidine 20 mg q12h
3250051|NCT00839462|Experimental|Arm 1|
3250052|NCT00839462|Active Comparator|Arm 2|
3250053|NCT00839449|Experimental|A|Patients in the group A are orally administered eicosapentaenoic acid ethyl ester.
3250054|NCT00839449|No Intervention|B|Patients in the group B (control) are not administered eicosapentaenoic acid ethyl ester.
3250055|NCT00839436|Experimental|3 microgram/kg CYT107|3 microgram/kg CYT107
3250056|NCT00839436|Experimental|10 microgram/kg CYT107|10 microgram/kg CYT107
3250057|NCT00839436|Experimental|20 microgram/kg CYT107|20 microgram/kg CYT107
3250058|NCT00839423|Placebo Comparator|Placebo|
3250059|NCT00839423|Experimental|Vortioxetine (Lu AA21004) 5 mg|
3250060|NCT00839423|Experimental|Vortioxetine (Lu AA21004) 10 mg|
3250061|NCT00839423|Other|Venlafaxine XL 225 mg|Active Reference
3250062|NCT00839397|Other|Paroxetine|A 52-week, non-comparative, uncontrolled study (However, the baseline phase is single blind)
3250063|NCT00839384|Experimental|Implant Advisa IPG|Advisa IPG implant
3250064|NCT00839371|Active Comparator|Midazolam|i.v. midazolam titration until adequate depth of sedation
3250065|NCT00839371|Active Comparator|Propofol|i.v. propofol titration until adequate depth of sedation
3250066|NCT00839358|Active Comparator|Albumin plus midodrine|Albumin 40 g every 15 days during 1 year or until liver transplantation. Midodrine 5mg/8h. It can be increased according the value of mean arterial pressure. If there is no increase (defined as at least 10mmHGin MAP)midodrine can be increased at a dose of 10mg/8h. This treatment will be given during 1 year or until liver transplantation.
3250067|NCT00839358|Placebo Comparator|salin solution plus pills|Placebo of albumin in the same schedule thats in arm 1; placebo of midodrine in the same schedule thats in arm 1.
3250068|NCT00839332|Experimental|LY2603618 + Gemcitabine|"Participants participated in Phase 1 or 2.~LY2603618 (Phase 1): 70 to 250 milligrams/meter squared (mg/m^2) LY2603618 as a 1-hour continuous intravenous (IV) infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until disease progression (DP). Participants received LY2603618 as part of the dose escalation cohort (dose of 70, 105, 150, 200, or 250 mg/m^2) or the expansion cohort (flat dose of 200 mg or 230 mg).~LY2603618 (Phase 2): 230 mg LY2603618 as a 1-hour continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until DP.~Gemcitabine (Phase 1 and 2): 1000 mg/m^2 gemcitabine as a 30-minute continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until DP. Participants received gemcitabine 24 hours prior to LY2603618 administration."
3250069|NCT00839332|Active Comparator|Gemcitabine|"Participants participated in Phase 2 only.~Gemcitabine (Phase 2): 1000 mg/m^2 gemcitabine as a 30-minute continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until disease progression."
3250070|NCT00839319|Experimental|Acyline plus Placebo|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous placebo hCG injection (inj) every other day (5 doses) for 10 days
3250071|NCT00839319|Experimental|Acyline plus 15 IU hCG|Acyline 300 ug/kg (SQ) inj(s) on Day 1 plus subcutaneous 15 IU hCG injection (inj) every other day (5 doses) for 10 days
3250072|NCT00839319|Experimental|Acyline plus 60 IU hCG|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 60 IU hCG injection (inj) every other day (5 doses) for 10 days
3250073|NCT00839319|Experimental|Acyline plus 125 IU hCG|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 125 IU hCG injection (inj) every other day (5 doses) for 10 days
3250074|NCT00839319|Experimental|Acyline plus Testosterone gel|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus Testosterone gel 75 mg/day daily for 10 days
3250075|NCT00839306|Experimental|1|
3250076|NCT00839306|Active Comparator|2|
3250077|NCT00839293|Experimental|A|ABT -335 capsules 135mg
3250078|NCT00839293|Experimental|B|ABT-335 capsules 45mg
3250079|NCT00839280|Experimental|Arm 1|
3250080|NCT00839280|Active Comparator|Arm 2|
3250081|NCT00839267||Unstable|Patient with acute myocardial infarction plus severe hemodynamical instability. It means, on mechanical ventilation and catecholamine support
3250082|NCT00839267||Stable|Patients with myocardial infarction hemodynamically completely (Killip I)stable.
3250083|NCT00839254|Experimental|Pn 3+1|Children receiving the pneumococcal conjugate vaccine 1024850A. Children within the first 7 months of life enrolled in this group of clusters receive a 3-dose primary vaccination schedule.
3250084|NCT00839254|Experimental|Pn 2+1|Children receiving the pneumococcal conjugate vaccine 1024850A. Children within the first 7 months of life enrolled in this group of clusters receive a 2-dose primary vaccination schedule.
3250085|NCT00839254|Active Comparator|Control 3+1|Children receiving the control vaccine: Hepatitis B vaccine for children < 12 months of age at the time of first vaccination or Hepatitis A vaccine for children >= 12 months of age at the time of first study vaccination. Children within the first 7 months of life enrolled in this group of clusters receive a 3-dose primary vaccination schedule.
3250086|NCT00839254|Active Comparator|Control 2+1|Children receiving the control vaccine: Hepatitis B vaccine for children < 12 months of age at the time of first vaccination or Hepatitis A vaccine for children >= 12 months of age at the time of first study vaccination. Children within the first 7 months of life enrolled in this group of clusters receive a 2-dose primary vaccination schedule.
3250087|NCT00839241|Experimental|Autologous Blood Transfusion|
3250088|NCT00839241|Active Comparator|Allogenic Blood Transfusion|
3250089|NCT00839228|Experimental|Perhexiline|perhexiline 100mg o bd for 3 months
3250090|NCT00839228|Placebo Comparator|Placebo|Placebo one tablet bd for 3 months
3250091|NCT00839202|Experimental|FVIII immuno-assay|The study is not designed as a therapeutic evaluation, but an assessment of clotting factor VIII timed responses after the infusion of specified doses of licensed clotting factor VIII concentrates. The purpose of the study is to measure the levels of infused licensed clotting factor VIII by standard assay techniques and comparing these standard assays with an experimental assay. Measurements of possible co-factors that might impact the results were also carried out.
3250092|NCT00839176|Placebo Comparator|Placebo|Placebo (w/o API)
3250093|NCT00839176|Experimental|2|5mg dose of RX-10100
3250094|NCT00839176|Experimental|3|10mg dose of RX-10100
3250095|NCT00839176|Experimental|4|15 mg dose of RX-10100
3250096|NCT00839163|Experimental|Arm 1|
3250097|NCT00839163|Experimental|Arm 2|
3250098|NCT00839163|Experimental|Arm 3|
3250099|NCT00839163|Experimental|Arm 4|
3250100|NCT00839163|Active Comparator|Arm 5|
3250101|NCT00839150||1|Diabetic patients without diabetic retinopathy : No intervention
3250102|NCT00839150||2|Sex and age-matched control subjects : No intervention
3250103|NCT00839137||no exercise program group|group will continue with current level of activity and will be asked not to start an exercise program. They will be seen in the clinic three times a week for 12 weeks. These visits will be very brief; blood pressure, heart rate, oxygen level and peak flow will be measured at each visit
3250104|NCT00839137||exercise group|will meet three times a week for 12 weeks, following specific exercise program
3250105|NCT00839124|Active Comparator|Allergic asthma|subjects with allergic asthma will undergo challenge with 20,000 EU CCRE
3250106|NCT00839124|Active Comparator|healthy control|Healthy volunteers will undergo challenge with 20,000 EU CCRE
3250107|NCT00839111|Experimental|A|Sorafenib plus FOLFIRI regimen
3250108|NCT00839098|No Intervention|Control Group|Control Group
3250109|NCT00839098|Experimental|Instruction Group|Instruction Group
3250110|NCT00839098|Experimental|Instruction and Virtual Coach Group|Instruction and Virtual Coach Group
3250111|NCT00839085|No Intervention|1|normal procedure of CABG
3250248|NCT00838214|Experimental|budesonide|3mg capsules 3x/day for 6 months
3250112|NCT00839085|Active Comparator|2: GSE|100 mg GSE every 6h /Po, starting one day before surgery (4 doses in 24h)
3250113|NCT00839085|Active Comparator|3: Vit C|25 mg/kg through pump
3250114|NCT00839072|Experimental|Trazodone Contramid OAD|
3250115|NCT00839072|Active Comparator|Desyrel|
3250116|NCT00839059|Experimental|Lenalidomide|
3250117|NCT00839046|Active Comparator|1 Community Health Worker Intervention|This is the active control group, which all 150 participants will receive. It consists of visits from trained community health workers, who will provide asthma education, as well as provision of equipment and supplies to reduce indoor environmental exposures for asthma. These will include: vacuum cleaners, mattress and pillow covers, cleaning supplies.
3250118|NCT00839046|Experimental|2 Air Filter|The 50 families in the Air Filter Arm will receive an air filter in addition to the standard community health worker intervention. The Air Filter will be installed right after baseline measurements in the home.
3250119|NCT00839046|Experimental|3 Air Filter and Air Conditioner|"Fifty families will be assigned to the Air Filter and Air Conditioner Arm. In addition to the standard community health worker intervention, they will receive an air filter and an air conditioner (for the warmer months)."
3250120|NCT00839033|Experimental|1|patients treated with standard treatment and a mechanical insufflation-exsufflation
3250121|NCT00839033|Active Comparator|2|Patients with standard treatment and standard respiratory physiotherapy
3250122|NCT00839020|Active Comparator|1|Navigated total knee arthroplasty with a minimally invasive approach
3250123|NCT00839020|Active Comparator|2|Navigated total knee arthroplasty with a conventional approach
3250124|NCT00839007|Experimental|A|Dose 1 of CD-NP
3250125|NCT00839007|Experimental|B|Dose 2 of CD-NP
3250126|NCT00839007|Experimental|C|Dose 3 of CD-NP
3250127|NCT00839007|Experimental|D|Dose 4 of CD-NP
3250128|NCT00839007|Experimental|E|Dose 5 of CD-NP
3250129|NCT00839007|Experimental|F|Dose 6 of CD-NP
3250130|NCT00839007|Placebo Comparator|G|Placebo
3250131|NCT00838994|Experimental|Traditional Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (CEFAR Acus II, Lund, Sweden) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.45 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
3250132|NCT00838994|Active Comparator|Minimal Acupuncture|"Patients will be treated superficially at points away from classic acupoints. The points include bilateral Deltoideus [in the middle of the line insertion of Binao LI 14 and acromion], Forearm [1 inch laterally of the middle point between Shaohai HE3 and Shenmen HE7], Upper arm [1 inch laterally of Tianfu LU 3] and Lower leg [0.5 inch dorsally of Xuanzhong GB39]. De qi is avoided during needling. The treatment procedure, electric-stimulation, frequency, duration and number of treatment sessions will be the same for the Traditional Acupuncture group."
3250133|NCT00838994|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the site 1 inch beside the acupoints in order to avoid the acupressure effect. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
3250134|NCT00838981|Active Comparator|Modafinil Plus Contingency Magagement|Modafinil from 200mg up to 400mg plus Contingency Management
3250135|NCT00838981|Placebo Comparator|Sugar Pill Plus Contingency Management|Placebo: sugar pill
3250136|NCT00838981|Active Comparator|Modafinil Plus Voucher Control|
3250137|NCT00838981|Placebo Comparator|Sugar Pill Plus Voucher Control|
3250138|NCT00838968|Active Comparator|interferon-alpha (IFN-alpha)|the interferon-alpha is intramuscular injected 3,000,000U three times a week for 18 months
3250139|NCT00838968|No Intervention|control|no interventions were assigned
3250140|NCT00838955|Experimental|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
3250141|NCT00838942||1|Patients suffering from both Alzheimer's disease and low vision due to a bilateral impeding cataract.
3250142|NCT00838929|Experimental|Vorinostat (200 mg) and radiation|Cohort 1: Patients receive 200 mg of Vorinostat and radiation
3250143|NCT00838929|Experimental|Vorinostat (300 mg) and radiation|Cohort 2: Patients receive 300 mg of vorinostat and radiation
3250144|NCT00838929|Experimental|Vorinostat (400 mg) and radiation|Cohort 3: Patients receive 400 mg of vorinostat and radiation
3250145|NCT00838916|Experimental|albiglutide weekly injection|albiglutide weekly subcutaneous injection
3250146|NCT00838916|Active Comparator|insulin glargine|insulin glargine daily injection
3250147|NCT00838903|Experimental|albiglutide + metformin|Albiglutide + metformin + placebo sitagliptin + placebo glimepiride
3250148|NCT00838903|Active Comparator|sitagliptin + metformin|Sitagliptin + metformin + placebo albiglutide + placebo glimepiride
3250149|NCT00838903|Active Comparator|glimepiride + metformin|Glimepiride + metformin + placebo albiglutide + placebo sitagliptin
3250150|NCT00838903|Active Comparator|metformin + placebo|Metformin + placebo albiglutide + placebo sitagliptin + placebo glimepiride
3250151|NCT00838890|Active Comparator|Cdc7-inhibitor (A)|
3250152|NCT00838890|Active Comparator|Cdc7-inhibitor (B)|
3250153|NCT00838877|Experimental|1|
3250154|NCT00838864|Active Comparator|1|ceftrioxone 500mg q12h for 3 days
3250155|NCT00838864|Active Comparator|2|ceftrioxone 500 mg q12h for 7 days
3250156|NCT00838851|Experimental|CCRE|
3250157|NCT00838838||Group 1|
3250249|NCT00838214|Active Comparator|prednisone|5mg tablet, 40mg starting dose titrated to 10mg over 3 months
3250250|NCT00838201|Experimental|Arm 1|
3250158|NCT00838825|No Intervention|traditional|The traditional arm is composed of primary care physicians who continue the health care delivery model existing for the 5 years prior to the study. The traditional includes the physician, a pool of resources including random assignment of diabetic educators and includes the entire panel of patients assigned to the PCP.
3250159|NCT00838825|Experimental|care management|The care management group is composed of primary care physicians who have been assigned a specific physician extender, the care manager, and an additional medical assistant and form a care manager team working together with registry support, team meetings and instruction in self-management and includes the entire panel of patients assigned to the PCP.
3250160|NCT00838812|Other|clindamicin and tretinoin gel|
3250161|NCT00838799|Experimental|1|
3250162|NCT00838799|Experimental|2|
3250163|NCT00838799|Experimental|3|
3250164|NCT00838799|Active Comparator|4|
3250165|NCT00838799|Placebo Comparator|5|
3250166|NCT00838773|Experimental|YMSM|Young Men Who Have Sex with Men
3250167|NCT00838773|Experimental|YHA|Young Heterosexual Adults
3250168|NCT00838773|Experimental|ROMA|Gypsies (Bulgarian)
3250169|NCT00838773|No Intervention|Control|All study participants (including those in control condition networks) receive HIV/AIDS/STD risk reduction counseling at baseline, as well as testing and treatment or treatment referral for STDs and HIV infection. STD/HIV testing and treatment or treatment referral are provided at each followup point. This constitutes the control intervention.
3250170|NCT00838747||Gynaecological Cancer|Gynaecological Cancer
3250171|NCT00838734||1|Pre-LASIK
3250172|NCT00838734||2|Post-LASIK
3250173|NCT00838708|Placebo Comparator|Vehicle cream|
3250174|NCT00838708|Experimental|SRD174 Cream|
3250175|NCT00838695|Experimental|Vascular sensitivity|Subjects undergo hand vein testing with phenylephrine and nitroglycerin and then mental stress and cold pressor testing
3250176|NCT00838682|Experimental|rabeprazole sodium|Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
3250177|NCT00838682|Active Comparator|Omeprazole|Intravenous Omeprazole 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
3250178|NCT00838656|Experimental|Arm I|Patients receive carboplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo treatment with paclitaxel and may also receive 6 more courses of neoadjuvant chemotherapy. Patients may then undergo surgery. After surgery, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3250179|NCT00838656|Experimental|Arm II|Patients receive carboplatin IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo treatment with paclitaxel and may also receive 6 more courses of neoadjuvant chemotherapy. Patients may then undergo surgery. After surgery, patients receive paclitaxel IV over 3 hours and gemcitabine hydrochloride IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3250180|NCT00838643||Allogeneic pts|Adult allogeneic HSCT recipients
3250181|NCT00838630|Experimental|1|
3250182|NCT00838630|Active Comparator|2|
3250183|NCT00838617||Participants with ALS|Participants diagnosed with ALS.
3250184|NCT00838591|Experimental|1|MN-221 given i.v. 1-hour infusion a total dose of 1200 μg (40 μg/min for 15 min [600 μg] + 13.3 μg/min for 45 min [600 μg]) as an adjunct to the standard of care for acute exacerbation of asthma.
3250185|NCT00838591|Placebo Comparator|Placebo|Placebo (Lot #CLO-095) was packaged in identical vials containing only excipients and administered as an i.v. 1-hour infusion with a regimen as described for MN-221.
3250186|NCT00838578|Experimental|KRN330 + Irinotecan|open label, single arm
3250187|NCT00838565|Placebo Comparator|Placebo|
3250188|NCT00838565|Experimental|PF-04236921|
3250189|NCT00838552||1 Asthma subjects|Children with asthma undergoing clinically indicated bronchoscopy at National Jewish Health.
3250190|NCT00838552||2 Non-asthma subjects|Children with other respiratory diseases than asthma undergoing clinically indicated bronchoscopy at National Jewish Health.
3250191|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 1)|Neratinib 120 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3250192|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 2)|Neratinib 120 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3250193|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 3)|Neratinib 120 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3250194|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 4)|Neratinib 120 mg and Temsirolimus 75 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3250195|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 5)|Neratinib 160 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3250196|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 6)|Neratinib 160 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3250251|NCT00838188||1|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
3250197|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 7)|Neratinib 160 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3250198|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 8)|Neratinib 160 mg and Temsirolimus 75 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3250199|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 9)|Neratinib 200 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3250200|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 10)|Neratinib 200 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3250201|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 11)|Neratinib 200 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3250202|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 12)|Neratinib 240 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3250203|NCT00838526|Experimental|1|
3250204|NCT00838526|Active Comparator|2|
3250205|NCT00838513|Experimental|eculizumab|
3250206|NCT00838500|Active Comparator|Immediate SPA treatment|Immediate spa treatment during 18 days soon after randomization (1 year)
3250207|NCT00838500|Sham Comparator|Late SPA treatment|Late spa treatment during 18 days soon after 12 months visit (2nd year)
3250208|NCT00838487|Active Comparator|condroflex and exercise|assent arm
3250209|NCT00838487|Placebo Comparator|sugar pill and exercise|sugar pill arm
3250210|NCT00838474|Other|music therapy|Each infant was randomized to receive music therapy or no music over 2 consecutive days
3250211|NCT00838461|Active Comparator|1|HSD-016
3250212|NCT00838461|Placebo Comparator|2|placebo
3250213|NCT00838448|Experimental|Cannabis users|Cannabis users
3250214|NCT00838448|Experimental|Cannabis no-users|Cannabis no-users
3250215|NCT00838435|Experimental|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
3250216|NCT00838422||FD-OCT, ORA, USP|
3250217|NCT00838409||1|
3250218|NCT00838396|Experimental|XP19986 CR|On either study Day 1 or study Day 5 (after completion of the minimum 3-day washout period), participants received a single dose of XP19986 10, 20, 40 or 60 mg.
3250219|NCT00838396|Placebo Comparator|Placebo for XP19986 CR|On either study Day 1 or study Day 5 (after completion of the minimum 3-day washout period), participants received a single dose of placebo.
3250220|NCT00838383|Experimental|sitaxsentan (1.0 mg/kg)|
3250221|NCT00838383|Experimental|sitaxsentan (2.0 mg/kg)|
3250222|NCT00838383|Placebo Comparator|Placebo|
3250223|NCT00838370|Experimental|DPYD*2A|Patients are screened for a DPD-deficiency. Patients with a DPYD*2A mutation are eligible for intervention with capecitabine/5-FU .
3250224|NCT00838357|Experimental|Plerixafor|Plerixafor added to a G-CSF Mobilisation regimen
3250225|NCT00838344|No Intervention|Usual care|Usual prescription refill system and pharmacy care.
3250226|NCT00838344|Experimental|Intervention|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
3250227|NCT00838331|Experimental|Fresh blood, then aged blood|
3250228|NCT00838318||Arm 1 Hispanic CRC Patients|
3250229|NCT00838318||Arm 2 FDRs of Hispancic CRC Patients|First-Degree Relatives (FDRs) of Hispanic CRC Patients
3250230|NCT00838318||Arm 3 Key Informants|Key informants from Houston Hispanic Health Coalition.
3250231|NCT00838305|Placebo Comparator|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
3250232|NCT00838305|Experimental|mdma|drug: mdma subjects also get citalopram and placebo in a 2x2 crossover design
3250233|NCT00838292|Active Comparator|ART: food|ART + food supplementation + nutrition counseling
3250234|NCT00838292|Active Comparator|ART: no food|ART + nutrition counseling
3250235|NCT00838292|Active Comparator|pre-ART: food|no ART (cotrimoxazole provided) + food supplementation + nutrition counseling
3250236|NCT00838292|Active Comparator|pre-ART: no food|no ART (cotrimoxazole provided) + nutrition counseling
3250237|NCT00838279|Experimental|Lamotrigine|Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in first period followed by Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in second period
3250238|NCT00838279|Active Comparator|Lamictal®|Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in first period followed by Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in second period
3250239|NCT00838266|Experimental|1|Antiplaque mouthrinse containing active component (Grape Seed Extract + nicométhanol fluorhydrate)
3250240|NCT00838266|Placebo Comparator|2|Antiplaque mouthrinse containing non-active component
3250241|NCT00838253|Experimental|1|
3250242|NCT00838253|Experimental|2|
3250243|NCT00838253|Experimental|3|
3250244|NCT00838253|Placebo Comparator|4|
3250245|NCT00838240|Experimental|Arm I|Patients receive idarubicin IV over 5 minutes on days 1, 3, and 5, cytarabine IV continuously on days 1-10, and clofarabine IV over 1 hour on days 2, 4, 6, 8, and 10.
3250246|NCT00838240|Experimental|Arm II|Patients receive idarubicin IV and cytarabine IV as in arm I. Patients also receive clofarabine IV by push injection over 10 minutes on days 2, 4, 6, 8, and 10.
3250252|NCT00838188||2|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
3250253|NCT00838188||Breast - feeding first|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
3250254|NCT00838188||Bottle first|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
3250255|NCT00838188||Way of feeding|Each infant is evaluated twice, once after breastfeeding and once after bottle feeding of breast milk using a Premature Nipple & Ring (Ross Products Division, Columbus OH, USA). In this way, each infant serves as its own control. REE is recorded for 20 minutes after each meal
3250256|NCT00838175||1|All pts. who have undergone percutaneous intervention who received a suture-mediated closure of the venous access site will be screened for eligibility for this research trial.
3250257|NCT00838162|Experimental|TMC310911/rtv 75/100 mg twice daily|TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14
3250258|NCT00838162|Experimental|TMC310911/rtv 150/100 mg twice daily|TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14
3250259|NCT00838162|Experimental|TMC310911/rtv 300/100 mg twice daily|TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14
3250260|NCT00838162|Experimental|TMC310911/rtv 300/100 mg once daily|TMC310911 300 mg + ritonavir 100 mg once daily on Days 1 to 14
3250261|NCT00838149|Active Comparator|Glutamine|Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
3250262|NCT00838149|Placebo Comparator|Whey Protein|"Whey Protein:~Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
3250263|NCT00838136|Experimental|Lamotrigine|Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in first period followed by Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in second period
3250264|NCT00838136|Active Comparator|Lamictal®|Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in first period followed by Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in second period
3250265|NCT00838110|Experimental|Dimebon 20 mg TID (Cohort 1)|
3250266|NCT00838110|Placebo Comparator|Placebo TID (Cohort 1)|
3250267|NCT00838110|Experimental|Dimebon 20 mg TID (Cohort 2)|
3250268|NCT00838110|Placebo Comparator|Placebo TID (Cohort 2)|
3250269|NCT00838097||Darbepoetin alfa|Participants with chronic kidney disease who received darbepoetin alfa for the treatment of anaemia as part of routine clinical practice.
3250270|NCT00838084|Experimental|LY2811376 Part 1|LY2811376 (5 mg up to 500 mg); once a day or twice a day for 1 day in up to 3 periods.
3250271|NCT00838084|Placebo Comparator|Placebo Part 1|once a day or twice a day for 1 day in up to 3 periods.
3250272|NCT00838084|Experimental|LY2811376 - Part 2 low dose|Single dose of LY2811376, dose determined by part 1
3250273|NCT00838084|Experimental|LY2811376 - Part 2 high dose|Single dose of LY2811376, dose determined by part 1
3250274|NCT00838084|Placebo Comparator|Placebo Part 2|single dose
3250275|NCT00838071|Experimental|IGIV-HB Grifols|
3250276|NCT00838058|Experimental|Part1; controlled release formulation 4; 250 mg|one 250 mg controlled release tablet, once in the morning, in fasted state
3250277|NCT00838058|Experimental|Part1; controlled release formulation 4; 500 mg|2x250 mg, once in the morning, in fasted state
3250278|NCT00838058|Experimental|Part 1; controlled release formula 4; 1000 mg|4x250 mg tabs, once in the morning, in fasted state
3250279|NCT00838058|Experimental|Part 1; controlled release formulation 4; 500 mg FED|2x250 mg, once in the morning , in fed state
3250280|NCT00838058|Experimental|Part 2; IR formulation 500mg|4x125 mg tab of current formulation , once in the morning in the fasted state. This arm will occur as Part 2, only as needed, pending results of Part 1
3250281|NCT00838058|Experimental|Part 2; IR formulation, 500 mg FED|4x125 mg once in the morning in the fed state. This arm will occur as part of Part 2,only as needed, pending results of Part 1.
3250282|NCT00838058|Experimental|Part 2; controlled release formulation 5;500 mg, FASTED|2x250 controlled release formulation 5 tabs once in the morning in the fasted state. This arm will only occur as part of Part 2, pending results of Part 1.
3250283|NCT00838058|Experimental|Part 2; controlled release formulation 5;500 mg, FED|2x250 mg controlled release formulation 5 tabs once in the morning in the fed state. This arm will only occur as part of Part 2 pending results of Part 1
3250284|NCT00838045|Experimental|Akreos TL intraocular lens|Bausch & Lomb Akreos TL intraocular lens
3250285|NCT00838032|Experimental|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
3250286|NCT00838032|Active Comparator|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
3250287|NCT00838019|Experimental|Cord blood|
3250288|NCT00838006|Experimental|Biofeedback training|Heart rate variability biofeedback training and iPod with Breath Pacer app
3250289|NCT00838006|Experimental|Cognitive bias modification training|Cognitive bias modification training and iPod with cognitive bias training app
3250290|NCT00838006|Sham Comparator|Control Group|No additional resilience training and iPod with no resilience training apps
3250291|NCT00837993||Survival Analysis|Survival Analysis Based on Reclassification to a Two-tier Grading System: Review of Pathology Slides for Patients participating on Protocol COG 158.
3250292|NCT00837967|Experimental|First Symbicort, then Terbutaline|Symbicort Turbuhaler 160/4.5μg for 3 days First , then Terbutaline Turbuhaler 0.4 mg for 3 days
3250293|NCT00837967|Experimental|First Turbuhaler, then Symbicort|Terbutaline Turbuhaler 0.4 mg for 3 days First, then Symbicort Turbuhaler 160/4.5μg for 3 days,
3250294|NCT00837954|Active Comparator|1|distal Anastomosis Lyostypt®, proximal Anastomosis Surgicel®
3250295|NCT00837954|Active Comparator|2|distal Anastomosis Surgicel®, proximal Anastomosis Lyostypt®
3250296|NCT00837954|Active Comparator|3|distal and proximal Anastomosis Lyostypt®
3250297|NCT00837954|Active Comparator|4|distal and proximal Anastomosis Surgicel®
3250298|NCT00837941|Experimental|1|sequence 1 - Pregabalin, Duloxetine hydrochloride, Diphenhydramine hydrochloride
3250299|NCT00837941|Experimental|2|sequence 2 - Duloxetine hydrochloride, Pregabalin, Diphenhydramine hydrochloride
3250300|NCT00837941|Experimental|3|sequence 3 - Diphenhydramine hydrochloride, Duloxetine hydrochloride, Pregabalin
3250301|NCT00837941|Experimental|4|sequence 4 - Pregabalin, Diphenhydramine hydrochloride, Duloxetine hydrochloride
3250302|NCT00837941|Experimental|5|sequence 5 - Duloxetine hydrochloride, Diphenhydramine hydrochloride, Pregabalin
3250303|NCT00837941|Experimental|6|sequence 6 - Diphenhydramine hydrochloride, Pregabalin, Duloxetine hydrochloride
3250304|NCT00837928|Experimental|Bendamustine and Fractionated stereotactic radiotherapy|Bendamustine 40 mg/m2 and will be administered IV on days 1,2,and 3 prior to surgery on each day of SRT (Sterotactic radiation therapy). Laboratory biomarker analysis will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. Pharmacokinetic samples will not be collected from patients who begin SRT on day 1). Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine) Stereotactic fractionated radiation therapy starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri). Concurrent Bendamustine is administered on Days of Stereotactic Radiotherapy (Arm 1: 40 mg/m2/ Day; Arm 2: 50 mg/m2/day).
3250305|NCT00837915|Experimental|1|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets of Ranbaxy
3250306|NCT00837915|Active Comparator|2|(Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets
3250307|NCT00837902|Experimental|Atenolol|There is only 1 arm to this study. Intervention: administration of atenolol. Pharmacodynamic measures will be obtained in subjects before administration of atenonol and after administration of atenolol
3250308|NCT00837889||decompensated heart failure patients|
3250309|NCT00837889||chronic heart failure patients|
3250310|NCT00837889||healthy controls|
3250311|NCT00837876|Experimental|Treatment|Sorafenib + Erlotinib
3250312|NCT00837863|Experimental|1|ALTU-238
3250313|NCT00837863|Experimental|2|ALTU-238
3250314|NCT00837863|Experimental|3|ALTU-238
3250315|NCT00837863|Active Comparator|4|Nutropin AQ
3250316|NCT00837850|Active Comparator|1|
3250317|NCT00837850|Active Comparator|2|
3250318|NCT00837837|Experimental|Chlorpheniramine|Chlorpheniramine dose by body weight.
3250319|NCT00837824|Experimental|Fabrazyme 1mg/kg every 2 weeks|Fabrazyme 1.0 mg/kg every 2 weeks
3250320|NCT00837824|Experimental|Fabrazyme 3mg/kg every 2 weeks|Fabrazyme 3.0 mg/kg every 2 weeks
3250321|NCT00837811|Experimental|LY2127399|
3250322|NCT00837798||No history of AF|Patient should not have had a documented history of AF for a period of 3 months prior to enrollment.
3250323|NCT00837785|Experimental|1|240 mg (two 120 mg capsules) twice a day
3250324|NCT00837785|Experimental|2|240 mg (two 120 mg capsules) three times a day
3250325|NCT00837772|Active Comparator|Arm 1|Usual standard cutting guide for TKA (Total Knee Arthroscopy)
3250326|NCT00837772|Experimental|Arm 2|Otismed MRI generated cutting guide for TKA
3250327|NCT00837759|Other|T1D group|This study was terminated prior to full subject accrual because of changes to study personnel. The original study design was changed from a double-blind, placebo-controlled study to an open-label pilot study in order to collect safety data on enrolled subjects prior to study termination.
3250328|NCT00837746||1|Women taking risedronate for 5 years
3250329|NCT00837733|Experimental|Biopsy catheter|Biopsy catheter (Pipelle de Cornier, Prodimed, Neuilly-en-Thelle, France
3250330|NCT00837694||1|Non-obese/0 kcal
3250331|NCT00837694||2|Non-obese/100 kcal
3250332|NCT00837694||3|Non-obese/300 kcal
3250333|NCT00837694||4|Obese/0 kcal
3250334|NCT00837694||5|Obese/100 kcal
3250335|NCT00837694||6|Obese/300 kcal
3250336|NCT00837681||lung disease|hematopoietic stem cell transplantation (HSCT)
3250337|NCT00837668||sarcoidosis|sarcoidosis patients undergoing clinical bronchoscopy
3250338|NCT00837655|Experimental|1|Sevelamer intervention
3250339|NCT00837655|Active Comparator|2|Calcium carbonate
3250340|NCT00837616|Active Comparator|Group A|Group A will receive the oral estradiol for 12 months
3250341|NCT00837616|Active Comparator|Group B|Group B will receive the transdermal estradiol for 12 months
3250342|NCT00837603|Active Comparator|Training|Ergometer Training
3250343|NCT00837603|No Intervention|2|Counseling
3250344|NCT00837590|Experimental|1|Nondiabetic lean and obese subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months of treatment with salsalate.
3250345|NCT00837590|Experimental|Metformin|Obese subjects will be pre-treated with metformin 1000mg bid for 4 weeks prior to baseline measurements and will continue metformin in addition to salsalate for an additional 2 months.
3250346|NCT00837590|Experimental|Lisinopril|Obese subjects will be pre-treated with lisinopril 20mg qd for 4 weeks prior to baseline measurements and continue lisinopril in addition to salsalate for an additional 2 months.
3250347|NCT00837577|Experimental|Sitagliptin/Sitagliptin|
3250348|NCT00837577|Experimental|Placebo/Sitagliptin|
3250349|NCT00837564|Experimental|CBASP|CBASP psychotherapy
3250350|NCT00837564|Experimental|Escitalopram|Escitalopram pharmacotherapy and clinical management
3250351|NCT00837551|Placebo Comparator|1 Placebo cream|0% cream 12 patients
3250352|NCT00837551|Active Comparator|2. Cream|0.5% WBI-1001 cream 12 patients
3250353|NCT00837551|Active Comparator|3. Cream|1.0% WBI-1001 cream 12 patients
3250354|NCT00837538||Back pain|Persons with back pain and supposed instability of lumbar spine
3250355|NCT00837512|Experimental|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
3250459|NCT00836667|Active Comparator|2|
3250794|NCT00834405|Experimental|Leflunomide|Leflunomide 20 mg Tablet
3250356|NCT00837512|Active Comparator|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
3250357|NCT00837499||Mexican Women from Mexico|
3250358|NCT00837499||Mexican-American Women in U.S.|
3250359|NCT00837499||African-American Women in U.S.|
3250360|NCT00837486|Active Comparator|Active Group - Active Stimulation|Receive active stimulation with Reclaim™ DBS System
3250361|NCT00837486|Sham Comparator|Control Group - Sham Stimulation|Receive sham stimulation with Reclaim™ DBS System
3250362|NCT00837473|Other|Plexur-P Bone Void Filler|Single arm. Open Label.
3250363|NCT00837460|Experimental|rehabilitation|Bilateral and unilateral prehension oriented rehabilitation to enhance prehension.
3250364|NCT00837447|Active Comparator|NexGen CR knee prosthesis|side of knee operated with total knee replacement with Nexgen CR prosthesis
3250365|NCT00837447|Active Comparator|NexGen CR-Flex knee prosthesis|side of knee operated with total knee arthroplasty using Nexgen CR-flex prosthesis
3250366|NCT00837434|Experimental|Etanercept|Participants receive a subcutaneous injection of etanercept once every week for 24 weeks
3250367|NCT00837434|Experimental|Adalimumab|Participants receive a subcutaneous injection of adalimumab once every 2 weeks for 24 weeks
3250368|NCT00837421||sepsis|sepsis survivors
3250369|NCT00837395||premenstual asthma|women with asthma have an increase in asthma symptoms during the premenstrual or menstrual period
3250370|NCT00837382|Experimental|1|MEDVAMC Nightmare Treatment
3250371|NCT00837382|Experimental|2|Videoconferencing nightmare Treatment
3250372|NCT00837369|Experimental|1|RTPE studies (resting and following Regadenoson 400 ug IV bolus injection) will be performed during a continuous infusion of lipid encapsulated microbubbles (Definity, Lantheus Medical Imaging) to qualitatively and quantitatively examine wall motion and myocardial contrast enhancement.
3250373|NCT00837356|Experimental|Advate®/turoctocog alfa|
3250374|NCT00837343|Experimental|Quetiapine Fumarate arm|Quetiapine Fumarate arm
3250375|NCT00837330|Experimental|Ranibizumab 0.5 mg/ 0.05 cc|Intraocular injection of 0.5 mg/ 0.05 cc ranibizumab
3250376|NCT00837330|Experimental|Ranibizumab 0.3 mg/ 0.05 cc|Intraocular injection of 0.3 mg/ 0.05 cc ranibizumab
3250377|NCT00837317|Experimental|1|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
3250378|NCT00837304||UC|Patients with known ulcerative colitis
3250379|NCT00837291|Experimental|CF101 1 mg BID|
3250380|NCT00837291|Placebo Comparator|Placebo|Placebo tablets BID
3250381|NCT00837278||1 IVF|Pregnancies conceived with the use of assisted reproductive technologies. This is defined as a pregnancy conceived with all gametes being handled outside of the body.
3250382|NCT00837278||2 Control|Spontaneously conceived pregnancies.
3250383|NCT00837265|Experimental|Neugranin Dose Level 1|
3250384|NCT00837265|Experimental|Neugranin Dose Level 2|
3250385|NCT00837265|Active Comparator|Pegfilgrastim|
3250386|NCT00837252|Experimental|Finasteride|
3250387|NCT00837239|Experimental|Gemcitabine + HuaChanSu|Gemcitabine 1,000 mg/m2 once a week for 3 weeks then 1 week off + HuaChanSu 20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
3250388|NCT00837239|Experimental|Gemcitabine + Placebo|Gemcitabine 1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle) + Placebo 500 ml saline only administered as a 2 hour infusion by central line.
3250389|NCT00837226||Study group-Bariatric procedure performed|
3250390|NCT00837226||Control group: No bariatric procedures|
3250391|NCT00837213|Active Comparator|BPO with clindamycin foam|Benzoyl peroxide (BPO) wash with clindamycin foam
3250392|NCT00837213|Active Comparator|BPO + clindamycin foam + doxycycline|Benzoyl peroxide (BPO) wash with clindamycin foam and doxycycline capsules
3250393|NCT00837200|Experimental|Oncaspar, Doxil, Decadron Regimen|Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
3250394|NCT00837187|Active Comparator|Intravenous dexmedetomidine|Dexmedetomidine is administered intravenously
3250395|NCT00837187|Experimental|Intranasal administration|Dexmedetomidine is administered intranasally
3250396|NCT00837174|Experimental|Combination Vorinostat + Bortezomib|Six cycle combination therapy with vorinostat and bortezomib.
3250397|NCT00837161|Experimental|Philips MR guided HIFU system|Patient receiving HIFU treatment
3250398|NCT00837148|Experimental|Sorafenib and Dacarbazine|This study is an open label, single arm, Simon two stage, phase 2 trial of continuous, daily oral sorafenib, with intravenous dacarbazine administered every three weeks for patients with synovial sarcoma, leiomyosarcoma and malignant peripheral nerve sheath tumor.
3250399|NCT00837135|Experimental|All Subjects|Screening for Eligibility into Trial
3250400|NCT00837135|Experimental|ARM A|GI-4000 Vaccine
3250401|NCT00837135|Experimental|ARM B|GI-4000 Vaccine + Activated T Cells
3250402|NCT00837135|Experimental|After GI-4000 Vaccine #4|GI-4000 Monthly - For those with incomplete removal of tumor GI-4000 Monthly + Chemotherapy - For those with complete removal of tumor
3250403|NCT00837109|Experimental|1|Imagery Rescripting Nightmare Treatment
3250404|NCT00837109|Active Comparator|2|Treatment-as-usual in the Trauma Recovery Program
3250405|NCT00837096|Experimental|V.A.C. Therapy|Negative Pressure Wound Therapy (NPWT) distrubtes negative pressre across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
3250406|NCT00837096|Active Comparator|Moist Wound Therapy (MWT)|t wound therapy (MWT) is a widely used treatment modality that demonstrates benefit through the facilitation of a moist wound environment, which is known to promote faster relative wound healing compared to wounds exposed to air.
3250407|NCT00837070|Experimental|1|Percutaneous zygapophyseal cyst rupture
3250408|NCT00837057|Other|early crrt, late crrt|
3250409|NCT00837044|Active Comparator|1|Treximet, cognitive testing
3250410|NCT00837044|Placebo Comparator|2|Placebo, Cognitive testing
3250790|NCT00834431|Experimental|1|
3250411|NCT00837031|Experimental|Intervention|"The study began with a lead-in portion to confirm the tolerability of lenalidomide (25mg PO days 1-21) in combination with gemcitabine (1000mg/m2 IV days 1, 8, and 15).~After completion of the lead-in phase, all subsequent patients received lenalidomide 25mg PO on days 1-21 and gemcitabine 1000mg/m2 IV days 1, 8, and 15 of 28-day treatment cycles. Patients were instructed to take lenalidomide at approximately the same time each morning. Patients were permitted to continue treatment until disease progression or intolerable toxicity occurred."
3250412|NCT00837018|Experimental|Physical exercise program|45 min, 3 times a week
3250413|NCT00837005||1|Patients with suspected CAD
3250414|NCT00837005||2|Patients with known CAD and suspected ischemia.
3250415|NCT00836992||Control|Patient's QOL assessments data is not shared with the physician, nurse, and/or nurse practitioner and the patient
3250416|NCT00836992||Active|Patient's QOL assessments data is shared with the physician, nurse, and/or nurse practitioner and the patient immediately prior to the on-treatment visit.
3250417|NCT00836953|Experimental|Study Group|Participants received 2 doses of Fluzone® vaccine
3250418|NCT00836940|Placebo Comparator|1|
3250419|NCT00836940|Experimental|2|GRC 8200-25mg OD
3250420|NCT00836940|Experimental|3|GRC 8200-50mg OD
3250421|NCT00836940|Experimental|4|GRC 8200-50mg BD
3250422|NCT00836940|Experimental|5|GRC 8200-100mg OD
3250423|NCT00836927|Experimental|Ridaforolimus 10 mg Days 1-5|Ridaforolimus 10 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus intravenous (IV) infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
3250424|NCT00836927|Experimental|Ridaforolimus 10 mg Days 1-6|Ridaforolimus 10 mg administered orally once daily on Days 1-6 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
3250425|NCT00836927|Experimental|Ridaforolimus 20 mg Days 1-5|Ridaforolimus 20 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
3250426|NCT00836927|Experimental|Ridaforolimus 30 mg Days 1-5|Ridaforolimus 30 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
3250427|NCT00836927|Experimental|Ridaforolimus 40 mg Days 1-5|Ridaforolimus 40 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
3250428|NCT00836914|Active Comparator|CAL-101|
3250429|NCT00836914|Placebo Comparator|Placebo|
3250430|NCT00836901|Experimental|Amoxicillin Calvulanic Acid|Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in first period followed by Augmentin® 40-57 mg Chewable Tablet (reference) dosed in second period
3250431|NCT00836901|Active Comparator|Augmentin®|Augmentin® 400-57 mg Chewable Tablet (test) dosed in first period followed by Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (reference) dosed in second period
3250432|NCT00836888|Experimental|Cohort|
3250433|NCT00836875|Experimental|1|Children from 2 to 17 years who have possible, probable or proven invasive aspergillosis, or other rare mold infection (eg, Scedosporium and Fusarium).
3250434|NCT00836862||Arteriovenous Fistula|
3250435|NCT00836849|Experimental|1|
3250436|NCT00836849|Active Comparator|2|
3250437|NCT00836836|Experimental|1|Modified Atkins diet arm-In this arm, the children will start the modified Atkins diet after a 4-week baseline period, during which daily seizure log will be maintained. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided.
3250438|NCT00836836|No Intervention|2|"No Intervention arm- After the 4-week baseline period, this group will receive their normal diet with no dietetic input, and remain on the same on-going antiepileptic medication for the 3 months. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided.~At the end of three months, patients in this arm will be offered the option of the modified Atkins diet treatment.~This group will not receive any dietetic input"
3250439|NCT00836823|Experimental|Alpha blocker|Alfuzosin 10mg
3250440|NCT00836810|Experimental|Timed Release Tablet Prednisone|12 patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
3250441|NCT00836810|Active Comparator|Standard Prednisolone|12 patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.
3250442|NCT00836797||1 Case with scaffold|This group of patients will be having a placement of PLGA bioscaffold in the alveolar socket after teeth extraction
3250443|NCT00836797||2 Control without scaffold|The Alveolar socket will be left to heal and no treatment/scaffold placement will be done
3250444|NCT00836784|Experimental|1|
3250445|NCT00836784|Experimental|2|
3250446|NCT00836771|Placebo Comparator|Materna infant formula 1|milk based infant formula powder
3250447|NCT00836771|Experimental|Materna infant formula 2|Probiotic supplemented infant formula
3250448|NCT00836771|Experimental|Materna infant formula 3|Prebiotic supplemented infant formula
3250449|NCT00836771|Experimental|Materna infant formula 4|Prebiotic+ Probiotic supplemented infant formula
3250450|NCT00836771|Other|Human milk|Human Milk
3250451|NCT00836758|Experimental|CPAP Device|Breathing event detection by the CPAP device will be compared to breathing event detection by a simultaneous PSG.
3250452|NCT00836745||1|Non Interventional
3250453|NCT00836719|Experimental|Polyphenon E|Standarized green tea extract containing 50% EGCG
3250454|NCT00836706|Experimental|Clarithromycin (test)|Clarithromycin 500 mg Tablet (test) dosed in first period followed by Biaxin® 500 mg Tablet (reference) dosed in second period
3250455|NCT00836706|Active Comparator|Biaxin®|Biaxin® 500 mg Tablet (reference) dosed in first period followed by Clarithromycin 500 mg Tablet (test) dosed in second period
3250456|NCT00836693|Experimental|Tadalafil|
3250457|NCT00836693|Placebo Comparator|Placebo|
3250458|NCT00836667|Experimental|1|
3250460|NCT00836654|Active Comparator|1 Catumaxomab|Patient received Catumaxomab and paracentesis
3250461|NCT00836654|No Intervention|2:|Patient treated by paracentesis alone, but after the second paracentesis the patient is able to cross-over in the Catumaxomab-arm
3250462|NCT00836641|Active Comparator|pneumococcal immunization (2 mo)|one dose of pneumococcal conjugate vaccine (prevenar) followed after 2 months by one dose of pneumococcal polysaccharide vaccine (pneumovax)
3250463|NCT00836641|Active Comparator|pneumococcal immunization (10 mo)|one dose of pneumococcal conjugate vaccine (prevenar) followed after 10 months by one dose of pneumococcal polysaccharide vaccine (pneumovax)
3250464|NCT00836628|Experimental|experimental|
3250465|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 1)|
3250466|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 2)|
3250467|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 3)|
3250468|NCT00836589||Data Collection Group|
3250469|NCT00836576|Experimental|1|
3250470|NCT00836576|Active Comparator|2|
3250471|NCT00836563||Forearm Arteriovenous Loop Graft|
3250472|NCT00836550|Active Comparator|Control|The participants spoke with a live counselor prior to answering the knowledge measure
3250473|NCT00836550|Experimental|Video|
3250474|NCT00836537|Experimental|1|
3250475|NCT00836537|Active Comparator|2|
3250476|NCT00836524||1|Pregnant women are included when they attend nuchal transcluency examination and will during their pregnancy be examined 4 times with ultrasound
3250477|NCT00836498|Experimental|Part I, RotaTeq|3 doses of RotaTeq
3250478|NCT00836498|Placebo Comparator|Part I, placebo|3 doses of placebo
3250479|NCT00836498|Experimental|Part II, RotaTeq|3 doses of RotaTeq
3250480|NCT00836498|Experimental|Part II, RotaTeq and placebo|1 dose of RotaTeq and 2 doses of placebo
3250481|NCT00836498|Placebo Comparator|Part II, placebo|3 doses of placebo
3250482|NCT00836485|Experimental|1|Ketotifen 4.0% Patch
3250483|NCT00836485|Placebo Comparator|2|Placebo Patch
3250484|NCT00836485|Active Comparator|3|Pataday(TM)
3250485|NCT00836485|Placebo Comparator|4|Placebo eye drops
3250486|NCT00836472|Experimental|Glyburide Metformin|Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in first period followed by Glucovance® 5/500 mg Tablet (reference) dosed in second period
3250487|NCT00836472|Active Comparator|Glucovance®|Glucovance® 5/500 mg Tablet (reference) dosed in first period followed by Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in second period
3250488|NCT00836459|No Intervention|Control|
3250489|NCT00836459|Experimental|Mini Booster|
3250490|NCT00836459|Experimental|Full Booster|
3250491|NCT00836446|Active Comparator|Group 1|20 min. physical activity routine
3250492|NCT00836446|Experimental|Group 2|40 min. aerobic physical activity routine
3250493|NCT00836433|Active Comparator|FALLS only|Traditional falls educational intervention, including self-study modules, audit and feedback, falls team training, academic detailing, and toolkit.
3250494|NCT00836433|Experimental|CONNECT and FALLS|CONNECT educational intervention is designed to improve relationship-building and communication. The intervention includes 2 in-class session, group mapping exercise, individual relationship mapping exercises, Self-monitoring of interactions, individual staff coaching sessions. FALLS is a traditional falls educational intervention, including self-study modules, audit and feedback, falls team training, academic detailing, and toolkit.
3250495|NCT00836420||liver|patients with acute liver failure
3250496|NCT00836407|Experimental|Arm 1: Ipilimumab Alone|Ipilimumab alone
3250497|NCT00836407|Experimental|Arm 2: Ipilimumab + Pancreatic Cancer Vaccine|Ipilimumab + Pancreatic Cancer Vaccine
3250498|NCT00836394|Experimental|Intervention Group|Will undergo whole body vibration (WBV) therapy (6 minutes of training on 5 days a week for 3 months)
3250499|NCT00836394|No Intervention|Control|Will follow daily habitual activities
3250500|NCT00836381|Experimental|Tolterodine ER|Tolterodine ER 4mg once daily
3250501|NCT00836381|Placebo Comparator|Placebo|Placebo once daily
3250502|NCT00836368|Experimental|MaxiGamma|
3250503|NCT00836355|Experimental|Enoxaparin|
3250504|NCT00836355|Experimental|Minocycline|Minocycline 200 mg orally once daily for 5 days
3250505|NCT00836355|Experimental|Enoxaparin and minocycline|
3250506|NCT00836355|No Intervention|Control|
3250507|NCT00836342||Previous history of SCC|Participants had previous history of SCC
3250508|NCT00836342||Previous history of BCC|Participants had previous history of BCC
3250509|NCT00836342||Control|Participants had no previous history of squamous cell carcinoma or basal cell carcinoma
3250510|NCT00836329|Experimental|Intensive Glucose Management|Participants will receive intensive glucose management.
3250511|NCT00836329|Active Comparator|Traditional Glucose Management|Participants will receive a traditional method of glucose management.
3250512|NCT00836303|No Intervention|Control|Patients of physicians randomly assigned to the control group received usual care
3250513|NCT00836303|Experimental|Intervention Group|This group will receive the behavioral intervention.
3250514|NCT00836290|Experimental|Pre-release|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
3250515|NCT00836290|Experimental|Post-release|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
3250516|NCT00836290|No Intervention|Control|Participants in the control group do not receive education sessions during their term in the study. However, these sessions are available to them after completing the study.
3250517|NCT00836277|Experimental|Irinotecan plus panitumumab|"Irinotecan 100 mg/m2 IV Day 1 and Day 8~+ Panitumumab 9mg/kg IV Day 1 Cycle = 21 days"
3250518|NCT00836264||Morphine T & A|"Subjects ages 4-18 years of age who have a Tonsillectomy and Adenoidectomy and receive morphine for pain control and who have also enrolled in the CAG study at CHOP, A Study of the Genetic Causes of Complex Pediatric Disorders (GCPD study), as approved by the CHOP IRB, 2006-7-4886."
3250519|NCT00836251||H218O and 2H2O|schizophrenia
3250520|NCT00836238||Questionnaire + Fall Risk Assessment|Physical Function Interview + Physical Function Tests + Symptom Assessment Interview
3250521|NCT00836225|Experimental|A|50 mg ISIS 388626 vs Placebo, s.c. injection
3250522|NCT00836225|Experimental|B|100 mg ISIS 388626 vs Placebo, s.c. injection
3250523|NCT00836225|Experimental|C|200 mg ISIS 388626 vs Placebo, s.c. injection
3250524|NCT00836225|Experimental|D|400 mg ISIS 388626 vs Placebo, s.c. injection
3250525|NCT00836225|Experimental|AA|50 mg ISIS 388626, 3x over 1 week s.c. injection, weekly s.c. injection for 5 weeks vs Placebo
3250526|NCT00836225|Experimental|BB|100 mg ISIS 388626, 3x over 1 week s.c. injection, weekly s.c. injection for 5 weeks vs Placebo
3250527|NCT00836225|Experimental|AAA|50 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
3250528|NCT00836225|Experimental|BBB|100 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
3250529|NCT00836225|Experimental|CCC|200 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
3250530|NCT00836225|Experimental|FFF|50 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
3250531|NCT00836212|Experimental|LPV|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
3250532|NCT00836212|Experimental|EFV|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
3250533|NCT00836199|Placebo Comparator|Placebo vaccine|
3250534|NCT00836199|Experimental|NicVAX vaccine|
3250535|NCT00836173|Experimental|RICE followed by GARD|"RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, for 3 cycles.~GaRD treatment: After RICE treatment, gallium nitrate will be given continuously over a 7 day period. In addition rituximab will be given on day 1 of each cycle. Dexamethasone will be given for the first 4 days of each cycle. The length of each cycle is 21 days."
3250536|NCT00836160||1|
3250537|NCT00836160||2|
3250538|NCT00836147|Placebo Comparator|1|250 ng dose
3250539|NCT00836147|Active Comparator|2|250 ng dose
3250540|NCT00836134|Experimental|1|rectus sheath block
3250541|NCT00836134|Active Comparator|2|local anesthetic infiltration
3250542|NCT00836121||tumor|
3250543|NCT00836108|Sham Comparator|1|spontaneous
3250544|NCT00836108|Experimental|2|coordinating arm elevation with inspiration
3250545|NCT00836108|Experimental|3|coordinating arm elevation with expiration
3250546|NCT00836095|Other|Supreme LMA|"Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant.~The choice of the airway device will be randomized by opening a sealed envelope immediately before induction. The airway device will be blindly inserted by an experienced attending anesthesiologist."
3250547|NCT00836095|Active Comparator|Proseal LMA|"Proseal is a multiple use, variant of the laryngeal mask airway.~The choice of the airway device will be randomized by opening a sealed envelope immediately before induction. The airway device will be blindly inserted by an experienced attending anesthesiologist."
3250548|NCT00836082|Experimental|Cohort 1 (N=10)|Placebo-controlled, escalating multiple doses of 0.5mg per day for 14 days.
3250549|NCT00836082|Experimental|Cohort 2 (N=10)|Placebo-controlled, escalating multiple doses of 1mg per day for 14 days.
3250550|NCT00836082|Experimental|Cohort 3 (N=10)|Placebo-controlled, escalating multiple doses of 4mg per day for 14 days.
3250551|NCT00836082|Experimental|Cohort 4 (N=10)|Placebo-controlled, escalating multiple doses of 8mg per day for 14 days.
3250552|NCT00836069|Experimental|1|PD 0332334, 450mg/day
3250553|NCT00836069|Experimental|2|PD 0332334, 600mg/day
3250554|NCT00836069|Active Comparator|3|Paroxetine, 20mg/day
3250555|NCT00836069|Placebo Comparator|4|Inactive Substance (placebo)
3250556|NCT00836056|Experimental|Clindamycin (test)|Clindamycin 300 mg Capsule (test) dosed in first period followed by Cleocin® 300 mg Capsule (reference) dosed in second period
3250557|NCT00836056|Active Comparator|Cleocin® (reference)|Cleocin® 300 mg Capsule (reference) dosed in first period followed by Clindamycin 300 mg Capsule (test) dosed in second period
3250558|NCT00836043||Group 1|
3250559|NCT00836030||A|
3250560|NCT00836017||BOTOX®|Patients received BOTOX® (onabotulinumtoxinA) treatment as standard of care in clinical practice as prescribed by the physician. No intervention was administered as part of the study.
3250561|NCT00836004|Experimental|Clindamycin (test)|Clindamycin 300 mg Capsule (test) dosed in first period followed by Cleocin® 300 mg Capsule (reference) dosed in second period
3250562|NCT00836004|Active Comparator|Cleocin® (reference)|Cleocin® 300 mg Capsule (reference) dosed in first period followed by Clindamycin 300 mg Capsule (test) dosed in second period
3250563|NCT00835991|Experimental|Glyburide Metformin|Glyburide Metformin 5/500 Film-Coated Tablet (test) dosed in first period followed by Glucovance® 5/500 mg Tablet (reference) dosed in second period
3250564|NCT00835991|Active Comparator|Glucovance®|Glucovance® 5/500 mg Tablet (reference) dosed in first period followed by Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in second period
3250565|NCT00835978|Other|A|Randomized arm
3250566|NCT00835978|Other|B|Randomized arm
3250567|NCT00835978|Other|C|Non-randomized arm
3250568|NCT00835965|Active Comparator|Active Comparator|Patients receive aprepitant and dexamethasone for prevention of postoperative nausea and vomiting
3250569|NCT00835965|Placebo Comparator|Placebo Comparator|Patients receiving aprepitant and placebo dexamethasone for prevention of postoperative nausea and vomiting
3250570|NCT00835952|Experimental|ATX-101|
3250571|NCT00835939|Active Comparator|25% Dextrose and 1% Lidocaine|
3250572|NCT00835939|Placebo Comparator|Lidocaine|
3250573|NCT00835926|Experimental|Fluzone® Vaccine Group 1|Participants aged 18 to 59 years at enrollment - Fluzone® Group
3250574|NCT00835926|Experimental|Fluzone® Vaccine Group 2|Participants aged 60 years and older at enrollment - Fluzone® Group
3250575|NCT00835900|Experimental|varenicline|drug plus counseling.
3250576|NCT00835900|Active Comparator|placebo|placebo plus counseling
3250577|NCT00835887|Experimental|1|Treatment with low dose flavanoids
3250578|NCT00835887|Experimental|2|Treatment with high dose flavanoids
3250579|NCT00835861|Experimental|Metformin|Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation. After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.
3250580|NCT00835861|Active Comparator|Insulin|Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation. After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.
3250581|NCT00835848|Active Comparator|Exenatide|25 μg Byetta (Lilly, Exenatide) is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
3250582|NCT00835848|Placebo Comparator|Saline|Isotonic saline infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
3250583|NCT00835835|Placebo Comparator|Control group|The placebo group did not receive treatment during the matched period yet did undergo all assessments. The MS Placebo group received equal treatment following the study intervention period.
3250584|NCT00835835|Experimental|Combination Treadmill training group|Subjects randomized to Combination therapy received 20 minutes of Lokomat assisted treadmill training followed by up to 20 minutes of BWS treadmill training (without robotic assistance) twice a week.
3250585|NCT00835822|Experimental|A|Arm treated with Investigational product.
3250586|NCT00835822|Placebo Comparator|B|Arm treated with placebo.
3250587|NCT00835809||Acute respiratory diseases.|Patient admit in emergency or intensive care unite with acute respiratory insufficiency.
3250588|NCT00835796|Experimental|Finasteride|Finasteride 5 mg Tablet (test) dosed in first period followed by Proscar® 5 mg Tablet (reference) dosed in second period
3250589|NCT00835796|Active Comparator|Proscar®|Proscar® 5 mg Tablet (reference) dosed in first period followed by Finasteride 5 mg Tablet (test) dosed in second period
3250590|NCT00835783||FUO|Patients with fever of unknown origin undergoing FDG-PET/CT as part of work-up.
3250591|NCT00835783||BUO|Patients with bacteremia of unknown origin undergoing FDG-PET/CT as part of work-up.
3250592|NCT00835783||VGI|Patients with vascular graft infections undergoing FDG-PET/CT as part of work-up.
3250593|NCT00835770|Experimental|BG00012 plus placebo|In the first phase, participants will receive BG00012 240 mg (two 120 mg capsules) twice a day (BID) and 2 placebo capsules once a day. In the second phase participants will receive open-label BG00012 240 mg BID, for atleast 8 years.
3250594|NCT00835770|Experimental|BG00012|In the first phase participants will receive BG00012 240 mg (two 120 mg capsules) three times a day (TID). In the second phase participants will receive open-label BG00012 240 mg BID for atleast 8 years.
3250595|NCT00835757||1|Diabetic peripheral neuropathy
3250596|NCT00835757||2|Healthy controls
3250597|NCT00835744|Placebo Comparator|A|Patients undergo a standard treatment with clomiphene citrate from day 3 until day 7 of the cycle at a dose of 50 mg daily. If no reaction on day 13 of the cycle, an increased dose of 100 mg of clomiphene citrate is administered from day 13 until day 17 of the cycle.
3250598|NCT00835744|Active Comparator|B|Patients undergo a standard treatment with clomiphene citrate from day 3 until day 7 of the cycle at a dose of 50 mg daily. If no reaction on day 13 of the cycle, gonadotropins (75IU) are administered from day 13 until day 17 of the cycle.
3250599|NCT00835731|Experimental|1|400mcg buccal misoprostol
3250600|NCT00835731|Experimental|2|Dilapan-S, control: vitamin B-12 administered sublingually
3250601|NCT00835718|Experimental|Stage I, Arm 1|MK0594 5 mg/day
3250602|NCT00835718|Placebo Comparator|Stage I, Arm 2|Placebo
3250603|NCT00835718|Experimental|Stage II, Arm 2|MK0594 1 mg/day
3250604|NCT00835718|Experimental|Stage II, Arm 3|MK0594 1 mg/week
3250605|NCT00835718|Placebo Comparator|Stage II, Arm 4|Placebo
3250606|NCT00835705|Experimental|Amoxicillin Clavulanic Acid|Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in first period followed by Augmentin® 400-57 mg Chewable Tablet (reference) dosed in second period
3250607|NCT00835705|Active Comparator|Augmentin®|Augmentin® 400-57 mg Chewable Tablet (reference) dosed in first period followed by Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in second period
3250608|NCT00835692|Experimental|Clarithromycin Tablets|Clarithromycin 500 mg Tablet (test) dosed in first period followed by Biaxin® 500 mg Tablet (reference) dosed in second period
3250609|NCT00835692|Active Comparator|Biaxin® Tablets|Biaxin® 500 mg Tablet (reference) dosed in first period followed by Clarithromycin 500 mg Tablet (test) dosed in second period
3250610|NCT00835679|Experimental|Cohort A (no systemic neoadjuvant therapy)|Patients receive no systemic neoadjuvant therapy between enrollment and the time of definitive surgical resection of liver metastases. Liver biopsies were performed at surgery since this cohort received no systemic therapy.
3250611|NCT00835679|Experimental|Cohort B (cetuximab)|Patients receive 400 mg/m^2 cetuximab IV over 120 minutes on day 1 and 250 mg/m^2 cetuximab IV over 60-120 minutes on day 8. Definitive surgical resection of liver metastases will take place on day 15.
3250612|NCT00835679|Experimental|Cohort C (dasatinib)|Patients receive dasatinib 100 mg orally once daily on days 1-14. Definitive surgical resection of liver metastases will take place on day 15.
3250613|NCT00835679|Experimental|Cohort D (cetuximab, dasatinib)|Patients receive 400 mg/m^2 cetuximab IV over 120 minutes on day 1 and 250 mg/m^2 cetuximab IV over 60-120 minutes on day 8 AND dasatinib 100 mg orally once daily on days 1-14. Definitive surgical resection of liver metastases will take place on day 15.
3250614|NCT00835666|Experimental|Finasteride|Finasteride 5 mg Tablet (test) dosed in first period followed by Proscar® 5 mg Tablet (reference) dosed in second period
3250615|NCT00835666|Active Comparator|Proscar®|Proscar® 5 mg Tablet (reference) dosed in first period followed by Finasteride 5 mg Tablet (test) dosed in second period
3250616|NCT00835653||1|patients with a carpal tunnel syndrome
3250617|NCT00835653||2|patients without a carpal tunnel syndrome
3250618|NCT00835640|Experimental|1|
3250619|NCT00835640|Active Comparator|2|
3250620|NCT00835627|Active Comparator|sertraline|flexible dose sertraline
3250621|NCT00835627|Active Comparator|CBT-ip|cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual, 1 hour therapy sessions
3250622|NCT00835627|Active Comparator|Combined (sertraline + CBT-ip)|flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12 individual, 1 hour therapy sessions
3250623|NCT00835627|Active Comparator|Standard care|community care / treatment as usual: routine follow up with existing providers
3250624|NCT00835614|Experimental|1|
3250625|NCT00835614|Active Comparator|2|
3250626|NCT00835588|Experimental|Pantoprazole|Pantoprazole Sodium 40 mg DR Tablet (test) dosed in first period followed by Protonix® 40 mg DR Tablet (reference) dosed in second period
3250627|NCT00835588|Active Comparator|Protonix®|Protonix 40 mg DR Tablet (reference) dosed in first period followed by Pantoprazole Sodium 40 mg DR Tablet (test) dosed in second period
3250628|NCT00835575|Experimental|1|
3250629|NCT00835575|Active Comparator|2|
3250630|NCT00835562|Experimental|Osteosynthesis|
3250631|NCT00835562|Experimental|Non-surgical|
3250632|NCT00835562|Experimental|Hemiarthroplasty|
3250633|NCT00835549|Experimental|1|
3250634|NCT00835549|Active Comparator|2|
3250635|NCT00835536|Experimental|1|
3250636|NCT00835536|Active Comparator|2|
3250637|NCT00835523||OHSS risk|
3250638|NCT00835510|Experimental|Butenafine cream 1% (Taro)|Butenafine cream manufactured by Taro applied for 7 days
3250639|NCT00835510|Active Comparator|Lotrimin Ultra (butenafine) 1%|Lotrimin Ultra (butenafine) applied for 7 days
3250640|NCT00835510|Placebo Comparator|Vehicle|Butenafine vehicle applied for 7 days
3250641|NCT00835497|Experimental|Glipizide Metformin|Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in first period followed by Metaglip® 5/500 mg Tablet (reference) dosed in second period
3250642|NCT00835497|Active Comparator|Metaglip®|Metaglip® 5/500 mg Tablet (reference) dosed in first period followed by Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in second period
3250643|NCT00835484|Experimental|1|
3250644|NCT00835484|Active Comparator|2|
3250645|NCT00835471|Experimental|1|Erlotinib plus docetaxel (squamous cell NSCLC) or pemetrexed (non-squamous cell NSCLC)
3250646|NCT00835471|Active Comparator|2|Erlotinib
3250647|NCT00835445||1|Asthmatics with polyps
3250648|NCT00835445||2|Non-asthmatics with polyps
3250649|NCT00835419|Experimental|1|P276-00 investigational product (small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor)
3250650|NCT00835406|Experimental|Alendronate Sodium First|70 mg Alendronate Sodium Tablets test product dosed in first period followed by 70 mg Fosamax® Tablets reference product dosed in second period
3250651|NCT00835406|Active Comparator|Fosamax® First|70 mg Fosamax® Tablets reference product dosed in first period followed by 70 mg Alendronate Sodium Tablets test product dosed in second period.
3250652|NCT00835393|Experimental|1|
3250653|NCT00835393|Active Comparator|2|
3250654|NCT00835380|Experimental|1|VAQTA™
3250655|NCT00835367|Experimental|Amlodipine Benazepril|Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period
3250656|NCT00835367|Active Comparator|Lotrel®|Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in second period
3250657|NCT00835354|Experimental|1|
3250658|NCT00835354|Active Comparator|2|
3250659|NCT00835341||p16-methylated|patients with mild or moderate oral epithelial dysplasia containing methylated p16 CpG island.
3250660|NCT00835341||p16-unmethylated|patients with mild or moderate oral epithelial dysplasia NOT containing methylated p16 CpG island.
3250661|NCT00835328|Experimental|exendin-(9-39)|exendin-(9-39) 1000-30000pmol/kg/min (0.2-6mg/kg/hr) Intravenous infusion over 9 hours
3250662|NCT00835328|Placebo Comparator|placebo|intravenous infusion of normal saline over 9 hours
3250663|NCT00835315||3|patients with psoriasis , patients with atopic dermatitis and healthy patients.
3250664|NCT00835302|Experimental|Manipulation + Exercise Group|Cervicothoracic manipulation and ROM exercises
3250665|NCT00835289|Placebo Comparator|Placebo|Each participant will be taking 3 capsules of a matching placebo (corn oil).
3250666|NCT00835289|Experimental|PUFA|Omax3[TM] (Cenestra Health) is a 1 gram softgel capsule containing 94.5% omega-3 fatty acids. Each participant will be taking 3 capsules of Omax3[TM].
3250667|NCT00835276|Experimental|1|
3250668|NCT00835276|Active Comparator|2|
3250669|NCT00835263|Experimental|Lamotrigine|Lamotrigine 200 mg Tablet (test) dosed in first period followed by Lamictal® 200 mg Tablet (reference) dosed in second period
3250670|NCT00835263|Active Comparator|Lamictal®|Lamictal® 200 mg Tablet (reference) dosed in first period followed by Lamotrigine 200 mg Tablet (test) dosed in second period
3250671|NCT00835250|Active Comparator|Laparoscopy|Laparoscopic cholecystectomy
3250672|NCT00835250|Experimental|Transumbilical|Transumbilical endoscopic cholecystectomy
3250673|NCT00835250|Experimental|Transvaginal|Transvaginal endoscopic cholecystectomy
3250674|NCT00835237|Experimental|Boostrix Group|Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)
3250675|NCT00835237|Active Comparator|Decavac Group|Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)
3250676|NCT00835224|Experimental|Midodrine|A drug to treat low blood pressure.
3250677|NCT00835224|Experimental|L-Name|L-Name: A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
3250791|NCT00834431|Active Comparator|2|
3250678|NCT00835224|Placebo Comparator|Placebo|Placebo: A pill with an inactive substance that looks like the study drug.
3250679|NCT00835211|Experimental|1|
3250680|NCT00835211|Active Comparator|2|
3250681|NCT00835198|Active Comparator|1|Dapsone gel 5% and Tretinoin gel 0.025%
3250682|NCT00835198|Active Comparator|2|Tretinoin gel 0.025%
3250683|NCT00835185|Experimental|IMC-11F8 (necitumumab) /mFOLFOX-6 regimen|Participants will receive IMC-11F8 (necitumumab) once every 2 weeks in combination with the mFOLFOX-6 regimen (oxaliplatin/5-FU/FA)
3250684|NCT00835172|Experimental|Glimepiride|Glimepiride 4 mg Tablet (test) dosed in first period followed by Amaryl® 4 mg Tablet (reference) dosed in second period
3250685|NCT00835172|Active Comparator|Amaryl®|Amaryl® 4 mg Tablet (reference) dosed in first period followed by Glimepiride 4 mg Tablet (test) dosed in second period
3250686|NCT00835159|Experimental|Rivastigmine Patch|Group receiving Rivastigmine Patch
3250687|NCT00835159|Placebo Comparator|Placebo Patch|A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
3250688|NCT00835146|Experimental|1|
3250689|NCT00835146|Active Comparator|2|
3250690|NCT00835120|Experimental|Pioglitazone|Pioglitazone has been approved by the U.S. Food and Drug Administration (FDA) to help people who are diagnosed with diabetes
3250691|NCT00835107|Experimental|Ziprasidone|
3250692|NCT00835107|Placebo Comparator|Sugar pill|
3250693|NCT00835094|Experimental|Morning|
3250694|NCT00835094|Experimental|Evening|
3250695|NCT00835081|Experimental|1|
3250696|NCT00835081|Active Comparator|2|
3250697|NCT00835068||BeneFIX|
3250698|NCT00835042|Experimental|1|
3250699|NCT00835042|Active Comparator|2|
3250700|NCT00835029|Active Comparator|Clotrimazole varnish|Clotrimazole in a slow release varnish treatment
3250701|NCT00835029|Active Comparator|Clotrimazole troches|Clotrimazole troches 10 mgx5 day for treatment of denture associated candiad infection
3250702|NCT00835016|Experimental|Early psychosocial stimulation (LTP)|The 10 session of Early psychosocial stimulation (LTP)will be delivered to depressed mothers in the intervention group
3250703|NCT00835016|Active Comparator|Waiting group|Waiting group will receive standard follow-up by their own LHWs. This group intervention will be documented at baseline, 3 months (end of the trial) and at 6 months. Similar training of Learning through Play will be provided to the mothers in this group at the end of the study.
3250704|NCT00835003|Active Comparator|1|Elective caesarean section at 38 weeks and 3 days of gestation
3250705|NCT00835003|Active Comparator|2|Elective caesarean section at 39 weeks and 3 days of gestation
3250706|NCT00834990|Experimental|1|
3250707|NCT00834990|Active Comparator|2|
3250708|NCT00834977|Experimental|Amlodipine Benazepril|Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period
3250709|NCT00834977|Active Comparator|Lotrel®|Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsules (test) dosed in second period
3250710|NCT00834964|Experimental|Venlafaxine|Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period
3250711|NCT00834964|Active Comparator|Effexor®|Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period
3250712|NCT00834938||1|Patients with DM2 undergoing RYGB with remission of DM2
3250713|NCT00834938||2|Patients with DM2 undergoing RYGB without remission of DM2
3250714|NCT00834925|No Intervention|standard dose diltiazem|
3250715|NCT00834925|Experimental|low dose diltiazem|
3250716|NCT00834912|Experimental|1: Tramadol HCl (Confab Laboratories) fasting|
3250717|NCT00834912|Experimental|2: Tramadol HCl (Confab Laboratories) fed|
3250718|NCT00834912|Experimental|3: Tramadol HCl (Trillium Healthcare) fasting|
3250719|NCT00834899|Experimental|1|As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the eptifibatide arm will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
3250720|NCT00834899|Placebo Comparator|2|As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
3250721|NCT00834886|Active Comparator|Combination|Bright light 10.000 lux + melatonin 3 mg
3250722|NCT00834886|Active Comparator|Melatonin|Melatonin 3 mg + placebo red light 400 lux
3250723|NCT00834886|Active Comparator|Bright light|Bright light 10.000 lux + placebo capsule 3 mg rice flour
3250724|NCT00834886|Placebo Comparator|Placebo|Placebo Red light 400 lux + placebo capsule 3 mg rice flour
3250725|NCT00834873|Experimental|Carvedilol|Carvedilol 25 mg Tablet (test) dosed in first period followed by Coreg® 25 mg Tablet (reference) dosed in second period
3250726|NCT00834873|Active Comparator|Coreg®|Coreg® 25 mg Tablet (reference) dosed in first period followed by Carvedilol 25 mg Tablet (test) dosed in second period
3250727|NCT00834860|Active Comparator|CHC, HCC|100 naïve CHC patients concomitant with hepatocellular carcinoma without clinical evidence of HCC recurrence more than 3 months after curative treatments.
3250728|NCT00834860|Active Comparator|CHC, LC|100 naïve CHC patients without malignancy
3250729|NCT00834847|Experimental|1|Test product under fasting conditions
3250730|NCT00834847|Experimental|2|Test product under fed conditions
3250731|NCT00834847|Active Comparator|3|Reference product under fed conditions
3250732|NCT00834834|Active Comparator|Fluoxetine|Participants will receive fluoxetine with clinical management, which may involve switching medication to citalopram, another SSRI.
3250733|NCT00834834|Active Comparator|Dialectical behavior therapy|Participants will receive dialectical behavioral therapy (DBT).
3250734|NCT00834821|Experimental|1|Participants will undergo the Child Life and Attention Skills (CLAS) Program.
3250735|NCT00834821|Active Comparator|2|Participants will undergo parent focused training (PFT).
3250792|NCT00834418|Experimental|Leflunomide|Leflunomide 20 mg Tablet
3250736|NCT00834821|No Intervention|3|Participants will receive a list of referrals for clinical services as needed, including professional organizations, support groups, and the community mental health system.
3250737|NCT00834808|Experimental|1: Tramadol HCl 100mg|
3250738|NCT00834808|Experimental|2: Tramadol HCl 200mg|
3250739|NCT00834808|Experimental|3: Tramadol HCl 300mg|
3250740|NCT00834795|Experimental|Carvedilol|Carvedilol 25 mg Tablet (test) dosed in first period followed by Coreg® 25 mg Tablet (reference) dosed in second period
3250741|NCT00834795|Active Comparator|Coreg®|Coreg® 25 mg Tablet (reference) dosed in first period followed by Carvedilol 25 mg Tablet (test) dosed in second period
3250742|NCT00834782||IOP|Measuring IOP
3250743|NCT00834756|Experimental|Azithromycin|Azithromycin 600 mg tablet (test) dosed in first period followed by Zithromax® 600 mg tablet (reference) dosed in second period
3250744|NCT00834756|Active Comparator|Zithromax®|Zithromax® 600 mg tablet (reference) dosed in first period followed by Azithromycin 600 mg tablet (test) dosed in second period
3250745|NCT00834743|Experimental|1|
3250746|NCT00834743|Active Comparator|2|
3250747|NCT00834730|Active Comparator|Ketamine|Ketamine 2mg/kg IV
3250748|NCT00834730|Experimental|N2O gas|50%-70% N2O gas inhalation
3250749|NCT00834717|Experimental|Granisetron|Granisetron 1 mg Tablet (test) dosed in first period followed by Kytril® 1 mg Tablet (reference) dosed in second period
3250750|NCT00834717|Active Comparator|Kytril®|Kytril 1 mg Tablet (reference) dosed in first period followed by Granisetron 1 mg Tablet (test) dosed in second period
3250751|NCT00834704|Other|1|Dose determination
3250752|NCT00834691||1|Patients with anemia and systolic heart failure
3250753|NCT00834691||2|Patients with systolic heart failure but without anemia
3250754|NCT00834691||3|Patients with at least moderate chronic renal failure, with or without anemia and without systolic heart failure.
3250755|NCT00834678|Experimental|Bendamustine and Erlotinib|Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 - 21 of each 28 day cycle.
3250756|NCT00834665|Experimental|ARM A|"ARM A Injection 1 and 2 the telomerase vaccination, followed by GM-CSF, which will also be injected at the same site in order to make the vaccinations work better.~Injection 3 and 4 (deep part of the skin in the left thigh)- the survivin and CMV vaccination, followed by GM-CSF.~Injection 5 - the PCV vaccination."
3250757|NCT00834665|Active Comparator|ARM B|ARM B Injection 1: PCV vaccination Injection 2 GM-CSF injection Injection 3 : GM-CSF injection
3250758|NCT00834652|Experimental|1|Participants will receive sertraline and metformin.
3250759|NCT00834652|Placebo Comparator|2|Participants will receive sertraline and placebo.
3250760|NCT00834639|Experimental|1|
3250761|NCT00834639|Active Comparator|2|
3250762|NCT00834626|Other|Surgery group|Interventional study of the effects of a novel metabolic procedure of Ileal Interposition with Sleeve Gastrectomy
3250763|NCT00834613|Experimental|1|
3250764|NCT00834613|Active Comparator|2|
3250765|NCT00834600|Experimental|HCTZ , ARB|Patients randomized to the Experimental Arm have initial drug choice determined by Plasma Renin Activity level. Low renin subjects are assigned to the diuretic hydrochlorothothiazide. Those with PRA >.65 ng/hr are assigned to the angiotensin receptor blocker, olmesartan.
3250766|NCT00834600|Active Comparator|Conventional antihypertensive therapy|All patients randomized to Active Comparator Arm received hydrochlorothiazide 25 mg, which is increased to 50 mg at 3-4 weeks. At 6 weeks, olmesartan may be added if BP > 140 mmHg
3250767|NCT00834587|Experimental|Glipizide Metformin|Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in first period followed by Metaglip™ 5/500 mg Tablet (reference) dosed in second period
3250768|NCT00834587|Active Comparator|Metaglip™|Metaglip™ 5/500 mg Tablet (reference) dosed in first period followed by Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in second period
3250769|NCT00834574|Experimental|1|
3250770|NCT00834574|Active Comparator|2|
3250771|NCT00834561|Experimental|Lamotrigine|Lamotrigine 200 mg Tablet (test) dosed in first period followed by Lamictal® 200 mg Tablet (reference) dosed in second period
3250772|NCT00834561|Active Comparator|Lamictal®|Lamictal® 200 mg Tablet (reference) dosed in first period followed by Lamotrigine 200 mg Tablet (test) dosed in second period
3250773|NCT00834548||1|WB-MRA standard protocol
3250774|NCT00834548||2|WB-MRA hybrid protocol
3250775|NCT00834535|Experimental|1|
3250776|NCT00834535|Active Comparator|2|
3250777|NCT00834522|Experimental|Granisetron|Granisetron 2 x 1 mg Tablet (test) dosed in first period followed by Kytril® 2 x 1 mg Tablet (reference) dosed in second period
3250778|NCT00834522|Active Comparator|Kytril®|Kytril® 2 x 1 mg Tablet (reference) dosed in first period followed by Granisetron 2 x 1 mg Tablet (test) dosed in second period
3250779|NCT00834509||Obstructive Sleep Apnea (OSA)|OSA participants will be treated with a CPAP/APAP treatment, per standard clinical care.
3250780|NCT00834509||Control|Control participants will not receive APAP/CPAP treatment, if not diagnosed with OSA.
3250781|NCT00834496||1|"Our experience with the use of Sirolimus is delineated below. About 15% to 20% of our patients are currently switched to Sirolimus.Indications for conversion from calcinurin inhibitors (CNIs) to Sirolimus more than 90 days post liver transplantation include:~CNI renal toxicity.~Hepatic fibrosis on biopsy.~CNI neurologic toxicity.~Post transplant diabetes. Any of the above 4 indications makes a patient a candidate for conversion from CNIs to Sirolimus at or > 90 days after liver transplantation."
3250782|NCT00834483|Experimental|1|Knotless suture for wound closure
3250783|NCT00834483|Active Comparator|2|Layered traditional wound closure (monocryl)
3250784|NCT00834470|Experimental|Atropine|Atropine 0.01mg/kg IV
3250785|NCT00834470|Placebo Comparator|Normal saline|Same volume of atropine
3250786|NCT00834457|Active Comparator|2A|co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg po(Trizivir)one tablet twice daily(BID)for 96 weeks
3250787|NCT00834457|Active Comparator|2B|co-formulated abacavir 600mg/3TC 300mg orally (as Kivexa) one tablet daily plus fixed dose lopinavir 133.3mg/ritonavir 33.3mg orally (as Aluvia) four tablets daily for 96 weeks
3250788|NCT00834444|Experimental|1|
3250789|NCT00834444|Active Comparator|2|
3250795|NCT00834405|Active Comparator|Arava®|Arava® 20 mg Tablet
3250796|NCT00834392|No Intervention|Control|
3250797|NCT00834392|Experimental|Exercise|
3250798|NCT00834379|Experimental|1|
3250799|NCT00834379|Active Comparator|2|
3250800|NCT00834366|Experimental|Tramadol HCl 200 mg Film-coated Tablets|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet based on randomization schedule.
3250801|NCT00834366|Experimental|Tramadol HCl 200 mg Uncoated Tablets|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Uncoated Tablet based on randomization schedule.
3250802|NCT00834353||Pulmonary tuberculosis patients|Freshly diagnosed pulmonary tuberculosis patients who are started with antituberculosis drugs
3250803|NCT00834340|Experimental|Glimepiride|Glimepiride 4 mg Tablet (test) dosed in first period followed by Amaryl® 4 mg Tablet (reference) dosed in second period
3250804|NCT00834340|Active Comparator|Amaryl®|Amaryl® 4 mg Tablet (reference) dosed in first period followed by Glimepiride 4 mg Tablet (test) dosed in second period
3250805|NCT00834327|Experimental|1|aplindore 0.05 mg MR total daily dose
3250806|NCT00834327|Experimental|2|aplindore 0.1 mg MR total daily dose
3250807|NCT00834327|Experimental|3|aplindore 0.25 mg MR total daily dose (to include short titration)
3250808|NCT00834327|Experimental|4|aplindore 0.5 mg MR total daily dose (to include short titration)
3250809|NCT00834327|Placebo Comparator|5|Placebo
3250810|NCT00834314|Experimental|Vacuum-pack|see Interventions
3250811|NCT00834314|Active Comparator|Abdominal dressing|see Interventions
3250812|NCT00834301|Experimental|Treatment Arm|
3250813|NCT00834288|Experimental|1: 1x200 mg Tramadol HCl OAD tablet daily|
3250814|NCT00834288|Active Comparator|2: 1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly|
3250815|NCT00834275|Experimental|1|
3250816|NCT00834275|Active Comparator|2|
3250817|NCT00834262||A|
3250818|NCT00834249|Experimental|Venlafaxine|Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period
3250819|NCT00834249|Active Comparator|Effexor®|Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period
3250820|NCT00834236|Experimental|gastric cancer|gastric cancer patients
3250821|NCT00834236|Active Comparator|normal subject|healthy subject
3250822|NCT00834223|Other|Aquashunt|Open label, all subjects receive device.
3250823|NCT00834210|Active Comparator|1|Dapsone Gel 5% and Tazarotene Cream 0.1%
3250824|NCT00834210|Active Comparator|2|Tazarotene Cream 0.1%
3250825|NCT00834197|Experimental|1|
3250826|NCT00834197|Active Comparator|2|
3250827|NCT00834184|Experimental|A|nikkomycin Z 250 mg BID versus placebo BID x 14 days
3250828|NCT00834184|Experimental|B|nikkomycin Z 500 mg BID versus placebo BID x 14 days
3250829|NCT00834184|Experimental|C|nikkomycin Z 750 mg BID versus placebo BID x 14 days
3250830|NCT00834184|Experimental|D|nikkomycin Z 750 mg TID versus placebo TID x 14 days
3250831|NCT00834171||1|Loteprednol etabonate ophthalmic suspension 0.5%
3250832|NCT00834171||2|Loteprednol etabonate (0.5%) and tobramycin (0.3%)
3250833|NCT00834158|Active Comparator|TACE|perform TACE only
3250834|NCT00834158|Experimental|TACE+PVE|perform TACE and PVE sequentially
3250835|NCT00834145|Experimental|1|Patients will receive a NormaTec pump and perform active pumping twice daily during hospitalization and thereafter once daily in addition to routine medical therapy.
3250836|NCT00834145|No Intervention|2|Routine medical treatment
3250837|NCT00834132|Experimental|Azithromycin|Azithromycin 600 mg tablet (test) dosed in first period followed by Zithromax® 600 mg tablet (reference) dosed in second period
3250838|NCT00834132|Active Comparator|Zithromax®|Zithromax® 600 mg tablet (reference) dosed in first period followed by Azithromycin 600 mg tablet (test) dosed in second period
3250839|NCT00834119|Experimental|Mometasone furoate|
3250840|NCT00834119|Experimental|Mometasone furoate plus an oral antihistamine|
3250841|NCT00834106|Experimental|qHPV|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6
3250842|NCT00834106|Placebo Comparator|Placebo|Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6
3250843|NCT00834093|Experimental|Biological/Vaccine|'Epstein-Barr Virus Specific Immunotherapy' given intravenously on Days 1 and 14
3250844|NCT00834080|Experimental|Medisorb naltrexone 380 mg (VIVITROL)|
3250845|NCT00834067|Experimental|1|
3250846|NCT00834067|Active Comparator|2|
3250847|NCT00834054||Double-lung transplanted patients|
3250848|NCT00834041|Experimental|Aliskiren 2 mg/kg|Oral mini-tablets (3.125 mg) of aliskiren dosed at 2 mg/kg body weight once each morning
3250849|NCT00834041|Experimental|Aliskiren 6 mg/kg|Oral mini-tablets (3.125 mg) of aliskiren dosed at 6 mg/kg body weight once each morning
3250850|NCT00834028||1|patients with hepatocellular carcinoma receive transcatheter arterial chemoembolization
3250851|NCT00834015|Other|Experimental|combined strength and aerobic training
3250852|NCT00833989|Placebo Comparator|PLACEBO|
3250853|NCT00833989|Experimental|ACTIVE|
3250854|NCT00833976|Experimental|open-label Lovaza (omega-3 fatty acids)|4g per day (4g once a day or 2g two times a day) for 16 weeks
3250855|NCT00833963||Participants Treated With Trastuzumab|Participants who are being treated with trastuzumab during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
3250856|NCT00833963||Participants Treated With Trastuzumab and Pertuzumab|Participants who are being treated with the combination of trastuzumab and pertuzumab during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
3250977|NCT00833092|Placebo Comparator|Sugar pill|Sugar Pill
3250978|NCT00833092|Active Comparator|magnesium|300 milligrams of magnesium daily
3250857|NCT00833963||Participants Treated With Ado-Trastuzumab Emtansine|Participants who are being treated with ado-trastuzumab emtansine during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
3250858|NCT00833950|Experimental|narrow band noise|Phase out in narrow band noise tinnitus patients
3250859|NCT00833937|Experimental|Zolpidem|Zolpidem Tartrate 10 mg Tablet (test) dosed in first period followed by Ambien® 10 mg Tablet (reference) dosed in second period
3250860|NCT00833937|Active Comparator|Ambien®|Ambien® 10 mg Tablet (reference) dosed in first period followed by Zolpidem Tartrate 10 mg Tablet (test) dosed in second period
3250861|NCT00833924|Other|1|Treatment with Endovascular Graft
3250862|NCT00833911|Experimental|Tramadol Contramid® OAD|
3250863|NCT00833898|No Intervention|Caregiver Control|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care.
3250864|NCT00833898|Experimental|Caregiver Intervention|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation Paced Respiration and Relaxation (PEPRR), which included one-on-one psychoeducation, stress management intervention, with paced respiration.
3250865|NCT00833885|Other|1|Control
3250866|NCT00833885|Other|2|Masks
3250867|NCT00833885|Other|3|Masks and Hygiene
3250868|NCT00833872|Experimental|LEO 22811 solution|
3250869|NCT00833872|Placebo Comparator|placebo solution|
3250870|NCT00833859|Experimental|Chemotherapy followed by Radiation Treatment|GTX-SRS: Gemcitabine, Taxotere, Xeloda (GTX)-Stereotactic Radiosurgery (SRS)
3250871|NCT00833833|Experimental|Phase 1: 2 mg pomalidomide|Pomalidomide 2 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
3250872|NCT00833833|Experimental|Phase 1: 3 mg pomalidomide|Pomalidomide 3 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
3250873|NCT00833833|Experimental|Phase 1: 4 mg pomalidomide|Pomalidomide 4 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
3250874|NCT00833833|Experimental|Phase 1: 5 mg pomalidomide|Pomalidomide 5 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
3250875|NCT00833833|Experimental|Phase 2: pomalidomide + dexamethasone|Combination therapy of 4 mg pomalidomide given once per day on Days 1-21 of each 28-day cycle and the starting dose of dexamethasone (determined by age) on days 1, 8, 15, and 22 of each 28-day cycle. The starting dose of dexamethasone was 40 mg for participants who were ≤ 75 years of age and 20 mg for participants who were > 75 years of age. Dose reduction steps for dexamethasone were provided for drug-related toxicities.
3250876|NCT00833833|Experimental|Phase 2: pomalidomide|4 mg pomalidomide was given once per day on Days 1-21 of each 28-day cycle until PD. Participants in the single agent pomalidomide treatment arm who developed confirmed PD at any time had the option to receive oral dexamethasone on days 1, 8, 15, and 22 of each 28-day cycle at the starting dose of 20 or 40 mg depending on age in addition to their current dose of pomalidomide, or to discontinue treatment.
3250877|NCT00833820|Active Comparator|A|Patients receiving real rTMS
3250878|NCT00833820|Sham Comparator|B|patients receiving sham stimulation
3250879|NCT00833807|Experimental|Nab-paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
3250880|NCT00833794|Experimental|1 Tramadol Once A Day|
3250881|NCT00833794|Placebo Comparator|2 Placebo|
3250882|NCT00833781|Active Comparator|mRNA-transfected dendritic cells|Participants in this arm/group received mRNA-transfected autologous dendritic cells
3250883|NCT00833781|Placebo Comparator|Dendritic cells without mRNA|Participants in this arm/group received autologous dendritic cells with no mRNA transfection
3250884|NCT00833768|Active Comparator|Sevelamer carbonate|
3250885|NCT00833768|Placebo Comparator|Placebo|
3250886|NCT00833755|Active Comparator|Opioid - Ketamine|This group consists of 16 subjects who have chronic pain conditions treated with an opioid regimen. Subjects were randomized to receive a ketamine treatment during the study. They were given an intravenous infusion of ketamine (0.05mg/kg) diluted in 50 ml normal saline over 30 minutes.
3250887|NCT00833755|Active Comparator|Non-opioid - Ketamine|This group consists of 22 subjects who have chronic pain conditions but were not on an opioid regimen over the last 3 months. Subjects were randomized to receive a ketamine treatment during the study. They were given an intravenous infusion of ketamine (0.05mg/kg) diluted in 50 ml normal saline over 30 minutes.
3250888|NCT00833755|Placebo Comparator|Opioid - Placebos|This group consists of 18 subjects who have chronic pain conditions treated with an opioid regimen. Subjects were randomized to receive a placebo treatment during the study. They were given an intravenous infusion of 50 ml normal saline over 30 minutes.
3250889|NCT00833755|Placebo Comparator|Non-opioid - Placebos|This group consists of 23 subjects who have chronic pain conditions but were not on an opioid regimen over the last 3 months. Subjects were randomized to receive a placebo treatment during the study. They were given an intravenous infusion of 50 ml normal saline over 30 minutes.
3250890|NCT00833742|Experimental|1|ISTDP therapy was provided
3250891|NCT00833742|No Intervention|2|People referred but never seen
3250892|NCT00833729|Experimental|etanercept|Single armed study
3250893|NCT00833716|Experimental|A|
3250894|NCT00833703|Placebo Comparator|Placebo|0.2 mL/kg/day matching placebo solution once daily.
3250895|NCT00833703|Experimental|Clopidogrel 0.2 mg/kg/day|0.2 mL/kg/day Clopidogrel reconstituted solution at 1mg/mL once daily.
3250896|NCT00833690|Placebo Comparator|[A:]|Placebo to produce no urate elevation
3250982|NCT00833066|Placebo Comparator|Placebo|
3250897|NCT00833690|Experimental|[B:]|"Inosine to produce a mild urate elevation~500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL"
3250898|NCT00833690|Experimental|[C.]|"Inosine to produce a moderate urate elevation~500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL"
3250899|NCT00833664|Experimental|Terbinafine|Terbinafine 250 mg Tablet (test) dosed in first period followed by Lamisil® 250 mg Tablet (reference) dosed in second period
3250900|NCT00833664|Active Comparator|Lamisil®|Lamisil® 250 mg Tablet (reference) dosed in first period followed by Terbinafine 250 mg Tablet (test) dosed in second period
3250901|NCT00833651||tacrolimus|Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus
3250902|NCT00833651||sirolimus|Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing sirolimus
3250903|NCT00833651||Healthy controls|Age, gender- and race-matched individuals, not on immunosuppressive medications
3250904|NCT00833638|Experimental|Tadalafil 2.5 mg|No drug during baseline period, 2.5 mg for 14 days, then will continue at 5 mg for 14 days.
3250905|NCT00833638|Experimental|Tadalafil 5 mg|No drug during baseline period, 5 mg for 14 days, then will continue at 5 mg for 14 days.
3250906|NCT00833638|Placebo Comparator|Placebo|No drug during baseline period, placebo for 14 days, then will continue tadalafil at 5 mg for 14 days.
3250907|NCT00833625|Experimental|PET/CT Scan + Biomarkers Testing|"PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).~Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis."
3250908|NCT00833612|No Intervention|Control arm of study|
3250909|NCT00833599||1: NIRFLI with ICG|1) Persons affected with lymphatic or lympho-vascular disorders, 2) Family members (affected or unaffected) of persons affected with lymphatic or lympho-vascular disorders and 3) Health, normal persons (Controls) that participate at one of the clinical sites in both the lymphatic function imaging with indocyanine green and the Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) system, as well, as the genetic analysis portion of the study.
3250910|NCT00833599||2: Genetic Analysis Only|Family members of an affected subject from Group 1. Subjects in Group 2 can be either affected or unaffected and will provide a blood or saliva sample for the genetic analysis portion of the study, but will not undergo lymphatic function imaging with ICG and the NIRFLI system. Group 2 individuals are not required to travel to one of the clinical sites in order to participate in the study.
3250911|NCT00833586|Experimental|Terbinafine|Terbinafine HCl 250 mg Tablet (test) dosed in first period followed by Lamisil® 250 mg Tablet (reference) dosed in second period
3250912|NCT00833586|Active Comparator|Lamisil®|Lamisil® 250 mg Tablet (reference) dosed in first period followed by Terbinafine 250 mg Tablet (test) dosed in second period
3250913|NCT00833573||1|For GP : the first 3 consecutive adult patients and the first children seen during the GP's visit with a diagnosis of GERD.
3250914|NCT00833573||2|For Paediatrics : the first 2 consecutive children seen during the Paediatric's visit with a diagnosis of GERD.
3250915|NCT00833560|Experimental|Cyclophosphamide + Bortezomib + Dexamethasone|Part 1 will be the dose titration part for cyclophosphamide. Participants will receive cyclophosphamide, bortezomib, and dexamethasone for 3 cycles. In Part 2, participants will receive cyclophosphamide (dose determined in Part 1) with pre-defined dose of bortezomib and dexamethasone for 3 cycles.
3250916|NCT00833547|Experimental|Eszopiclone|3mg of eszopiclone on two consecutive nights
3250917|NCT00833547|Placebo Comparator|placebo|placebo capsule that looks identical to eszopiclone capsule on two consecutive nights
3250918|NCT00833534|Experimental|Group I (consolidation phase)|Patients receive oral lenalidomide once daily on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
3250919|NCT00833534|Experimental|Group II (consolidation phase)|Patients receive lenalidomide as in group I. Patients also receive rituximab IV once on the day before the start of lenalidomide and then once between days 25-30, 50-55, and 75-80 for a total of 4 doses in the absence of disease progression or unacceptable toxicity.
3250920|NCT00833521|Experimental|Zolpidem|Zolpidem Tartrate 10 mg Tablet (test) dosed in first period followed by Ambien® 10 mg Tablet (reference) dosed in second period
3250921|NCT00833521|Active Comparator|Ambien®|Ambien® 10 mg Tablet (reference) dosed in first period followed by Zolpidem Tartrate 10 mg Tablet (test) dosed in second period
3250922|NCT00833508|Experimental|Test arm|Patients undergoing preoperative chemoradiotherapy will have their exercise capacity measured before and after chemoradiotherapy.
3250923|NCT00833495|Experimental|1|FOV1101-00 concentration 1 and Prednisolone Acetate 0.12% (Pred Mild®)
3250924|NCT00833495|Experimental|2|FOV1101-00 concentration 2 and Prednisolone Acetate 0.12% (Pred Mild®)
3250925|NCT00833495|Experimental|3|Vehicle of FOV1101-00 and Prednisolone Acetate 1% (Pred Forte®)
3250926|NCT00833495|Placebo Comparator|4|Vehicle of FOV1101-00 and vehicle of FOV1101-00
3250927|NCT00833482|Active Comparator|Voriconazole, 200 mg BID (EM)|
3250928|NCT00833482|Active Comparator|Atazanavir/Ritonavir, 300/100 QD (EM & PM)|
3250929|NCT00833482|Active Comparator|Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)|
3250930|NCT00833482|Active Comparator|Voriconazole, 50 mg BID (PM)|
3250931|NCT00833482|Active Comparator|Atazanavir/ritonavir, 300/100mgQD+voriconazole, 50mgBID (PM)|
3250932|NCT00833469|Experimental|Escitalopram|Flexible dose escitalopram 10mg
3250933|NCT00833456||1|Seroquel SR: Patients whose symptoms are controlled with Seroquel SR and started with the therapy up to 1 month before the inclusion
3250934|NCT00833456||2|Atypical antipsychotics: Patients whose symptoms are controlled with atypical antipsychotic in once daily formulation (excluding Seroquel SR) and started with the therapy up to 1 month before the inclusion
3250979|NCT00833079|Experimental|Tacrolimus 0.1% Taro|Tacrolimus 0.1% manufactured by Taro applied for 14 days
3250980|NCT00833079|Active Comparator|Protopic - Tacrolimus 0.1%|Protopic, Tacrolimus 0.1% applied for 14 days
3250981|NCT00833079|Placebo Comparator|Vehicle|Tacrolimus vehicle applied for 14 days
3250935|NCT00833443|Active Comparator|Bupropion|Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days.
3250936|NCT00833443|Placebo Comparator|Sugar Pill|
3250937|NCT00833417|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.
3250938|NCT00833404|Experimental|Smoking Cessation|8-week nicotine patch regimen
3250939|NCT00833404|No Intervention|Wait List Control|Smoking as usual
3250940|NCT00833391|Experimental|GSK1838262 arm|Each subject will participate in five dosing sessions separated by at least seven days. Subjects will receive a single dose of current formulation of GSK1838262 or one of the four new formulations of GSK1838262 at each dosing session in random sequence.
3250941|NCT00833378|Active Comparator|Period 2|Treatment B
3250942|NCT00833378|Active Comparator|Period 1|Treatment A
3250943|NCT00833378|Active Comparator|Period 3|Treatment C
3250944|NCT00833365|Active Comparator|Early treatment|Infants randomized to this group will receive their initial dose of ibuprofen prior to reaching 96 hrs old
3250945|NCT00833365|Active Comparator|Late treatment|Infants randomized to this group will receive their initial dose of ibuprofen after infant has reached 96 hrs old but before the infant reaches 10 days old.
3250946|NCT00833352|Experimental|1|Right ventricular lead located in Mid Septum
3250947|NCT00833352|Active Comparator|2|Right ventricular lead located in Apex
3250948|NCT00833339|Experimental|1|mifepristone
3250949|NCT00833339|Placebo Comparator|2|
3250950|NCT00833326|Experimental|ARRY-334543 + docetaxel + prophylactic growth factors|
3250951|NCT00833300|Active Comparator|1|Haloperidol
3250952|NCT00833300|Active Comparator|2|Olanzapine
3250953|NCT00833274|Experimental|1|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
3250954|NCT00833261|Experimental|chemo radiation|Cetuximab, Cisplatin, and Radiation Therapy intensity-modulated radiation therapy
3250955|NCT00833248|Experimental|Degarelix 240 mg/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
3250956|NCT00833248|Active Comparator|Goserelin (3.6 mg) + bicalutamide (50 mg)|"On Day 0, the participants began once-daily oral (p.o.) treatment with bicalutamide as anti-androgen flare protection. This treatment continued for 2 weeks after the first dose of goserelin (i.e. 17 days in total).~On Day 3, the first goserelin implant was inserted s.c. into the abdominal wall. The second and third doses of goserelin were administered on Days 31 and 59, respectively."
3250957|NCT00833235||Patients with dry eye|No treatment is prescribed for the study. Patient dry eye progression will be followed for up to 60 months. Patients may use artificial tears to treat their dry eye symptoms.
3250958|NCT00833235||Patients with no history of dry eye|No treatment is prescribed for this control group. Patients will be followed for up to 60 months. If needed, patients may use artificial tears.
3250959|NCT00833222||Full Term Infants|Infants born between 37 4/7 weeks and 42 3/7 weeks gestation.
3250960|NCT00833222||Preterm Infants|Infants born between 32 4/7 weeks and 35 3/7 weeks gestation.
3250961|NCT00833209|Experimental|1|Patients with Medication Overuse Headache (MOH)
3250962|NCT00833209|Sham Comparator|2|controls suffering from migraine
3250963|NCT00833209|Sham Comparator|3|controls without any neurological disease
3250964|NCT00833183|Active Comparator|25 J/cm2, with occlusion on right side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to either 25 J/cm2 of red light starting with the occluded side first.
3250965|NCT00833183|Active Comparator|37 J/cm2, with occlusion on right side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to 37 J/cm2 of red light starting with the occluded side first.
3250966|NCT00833183|Active Comparator|25 J/cm2 , with occlusion on left side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to either 25 J/cm2 of red light starting with the occluded side first.
3250967|NCT00833183|Active Comparator|37 J/cm2 , with occlusion on left side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to 37 J/cm2 of red light starting with the occluded side first.
3250968|NCT00833157|Experimental|Glucosamine|
3250969|NCT00833157|Experimental|Ibuprofen|
3250970|NCT00833157|Placebo Comparator|Placebo|
3250971|NCT00833144||1|Congestive Heart Failure
3250972|NCT00833144||2|Patients without congestive heart failure
3250973|NCT00833131|Experimental|1|25 Gy in 5 fractions of 5 Gy over 5 days. One week interval. Consolidating chemotherapy of 3 courses of FOLFOX4. Surgery 10-11 weeks from beginning of radiation and at least 4 weeks from the last dose of fluorouracil.
3250974|NCT00833131|Active Comparator|2|Conventionally fractionated chemoradiation with 50.4 Gy total dose in 28 fractions of 1.8 Gy over 5.5 weeks. Surgery 10-11 weeks from beginning of radiation and at least 4 weeks from the last dose of radiation.
3250975|NCT00833118||Intubation|
3250976|NCT00833105|Experimental|AMES treatment|The subject will receive 25 treatment sessions, conducted 2-3 times per week on the AMES device. Each session will consist of testing followed by 30 minutes of wrist and finger rehabilitation using the AMES device.
3250986|NCT00833053|Experimental|IFX q 6 weeks|
3250987|NCT00833053|Experimental|IFX + MTX|
3250988|NCT00833040|Experimental|Titration of sufentanil, the DBL sufentanil & PBO|"During the Titration Phase, patients titrated to the effective dosage of sublingual sufentanil NanoTab™(20, 30, 40, 60 or 80 mcg). One sublingual sufentanil NanoTab™ was taken as needed for breakthrough pain.~During the Double-Blind Phase, patients were then randomized to one of six treatment sequences, each of which included seven active doses of sublingual sufentanil (dosage determined in Titration Phase) and three placebo doses taken in random order. One NanoTab™ was taken as needed for breakthrough pain."
3250989|NCT00833027|Experimental|1|Sitagliptin
3250990|NCT00833014|Experimental|I|
3250991|NCT00833001||1|GYNECARE PROLIFT+M* Pelvic Floor Repair System
3250992|NCT00832988||Pacemaker patients|Patients who are implanted with a SJM Zephyr™ DR device for a standard pacing indication will be eligible
3250993|NCT00832962||1|Adult Rh negative pregnant patients from 7 selected centers (SAINT ANTOINE hospital, CHU Marseille, CHU Nantes, CHU Lille, LOUIS MOURIER Hospital, SAINT VINCENT-PAUL Hospital, CH POISSY)
3250994|NCT00832962||2|Adult Rh negative pregnant patients from 6 selected centers (Tenon hospital, Jean VERDIER Hospital, La Pitie-Salpetriere Hospital, Cochin Hospital, Robert Debre Hospital, BICHAT Hospital)
3250995|NCT00832923|No Intervention|Routine IMPACT DC care|Participants receive standard asthma education as routine for IMPACT DC
3250996|NCT00832923|Experimental|Enhanced care PEPAC Intervention|
3250997|NCT00832910||Rheumatoid Arthritis group1|This group had patients with rheumatoid arthritis
3250998|NCT00832910||2|
3250999|NCT00832897|Sham Comparator|Eyedrop|
3251000|NCT00832897|Active Comparator|Crosslinking|The patients will be submitted to corneal collagen crosslinking, by use riboflavin eyedrop with UVA light.
3251001|NCT00832884|Active Comparator|Group 1A|Lacosamide, IV, 50 mg, once, 30 minutes
3251002|NCT00832884|Active Comparator|Group 2A|Lacosamide, IV, 100 mg, once, 30 min
3251003|NCT00832884|Active Comparator|Group 3A|Lacosamide, IV, 150 mg, once, 30 min
3251004|NCT00832884|Active Comparator|Group 4A|Lacosamide, IV, 200 mg, once, 30 min
3251005|NCT00832884|Active Comparator|Group 1B|Lacosamide, IV, 50 mg, once, 15 min
3251006|NCT00832884|Active Comparator|Group 2B|Lacosamide, IV, 100 mg, once, 15 min
3251007|NCT00832884|Active Comparator|Group 3B|Lacosamide, IV, 150 mg, once, 15 min
3251008|NCT00832884|Active Comparator|Group 4B|Lacosamide, IV, 200 mg, once, 15 min
3251009|NCT00832871|Experimental|Mifepristone|200 mg RU-486 (Mifepristone) daily
3251010|NCT00832845|Experimental|CBSST plus treatment as usual|Subject randomized to the CBSST Group arm will attend 2 hour weekly Cognitive Behavioural Social Skills therapy sessions for 9 months. They will also be attending follow-up assessments q 4 months.
3251011|NCT00832845|Active Comparator|Treatment as Usual Group|Subjects randomized to the Treatment as Usual Group Arm will continue with their regular psychiatric treatment for 1 year. Like the CBSST Group Arm, they will have follow up assessments q 4 months. After completing the Treatment as Usual Group arm, they will automatically continue on with the CBSST Group Arm.
3251012|NCT00832832|Experimental|Eyelid closure|Eyelids will be closed after administration of eye drop
3251013|NCT00832832|Active Comparator|No eyelid closure|Eyelids will not be closed after eye drop instillation
3251014|NCT00832819|Experimental|E7080 (Dose Escalation Cohort)|This will be a dose-escalation evaluation of 12-18 participants to determine the maximum tolerated dose of E7080 in combination with paclitaxel and carboplatin.
3251015|NCT00832819|Experimental|E7080 (Expansion Cohort)|Dosage of E7080 for Expansion Cohort will be determined based on the maximum tolerated dose in the Dose-Escalation Cohort.
3251016|NCT00832806|Active Comparator|1|Extended IVR (integrated voice response technology) vs. no extended IVR
3251017|NCT00832806|Active Comparator|2|Extended IVR (integrated voice response technology) vs. no extended IVR
3251018|NCT00832780|Experimental|Stereotactic Body Radiation (SBRT)|60 Gy using 12 Gy per fraction over 5 fractions, to be given within 10 calendar days
3251019|NCT00832767|Active Comparator|SILS Port|SILS™ Port Laparoscopic Cholecystectomy
3251020|NCT00832767|Active Comparator|Four Port|Four Port Laparoscopic Cholecystectomy
3251021|NCT00832754|Experimental|RDT+ACT group|RDT+ACT group (ACT offered to RDT positive cases only)
3251022|NCT00832754|Active Comparator|Clinical judgement+ACT group|Clinical judgement+ACT group (ACT offered to all suspected cases of malaria by clinical judgement)
3251023|NCT00832728|Active Comparator|ELAD|ELAD Therapy + Standard of Care
3251024|NCT00832728|Other|Standard of Care|Hospital based standard of care for acute liver failure
3251025|NCT00832715|Experimental|EBUS-TBNA|Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA)
3251026|NCT00832689|Experimental|1|
3251027|NCT00832663|Experimental|NSAID|receive NSAID
3251028|NCT00832663|Placebo Comparator|Placebo|receive placebo
3251029|NCT00832650|Experimental|Fesoterodine|Tablets
3251030|NCT00832650|Placebo Comparator|Placebo|Tablets
3251031|NCT00832650|Active Comparator|Solifenacin|Tablets
3251032|NCT00832637|Experimental|Gemcitabine, Cisplatin, Erlotinib|A combination of Cisplatin at 40 mg/m2 + Gemcitabine at 1000 mg/m2, every 28 days + Erlotinib 100 mg daily, orally. Cycles will be repeated every four weeks.
3251033|NCT00832624|Experimental|1|sitagliptin
3251034|NCT00832611|Experimental|Experimental: Group A Anastomotic Coupler|Device: ROX Anastomotic Coupler System (ACS). The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
3251035|NCT00832598|Experimental|PET imaging|We will perform [18F]FACBC PET and [18F]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc.
3251036|NCT00832585|Experimental|Alefacept|"Amevive® has been shown to be a safe and effective agent in the treatment of psoriasis but may prove useful in treating atopic dermatitis at a dose of 15mg IM every week for 12 weeks. Unlike other biologics for the treatment of skin diseases, the use of alefacept is not associated with increased infection, congestive heart failure, demyelinating disorders or lupus- like syndromes."
3251371|NCT00830154|Experimental|2|0.60 mg pagoclone BID
3251037|NCT00832572|Experimental|Placebo-Ranolazine|Participants were randomized to receive placebo to match ranolazine during Weeks 1 to 6, then ranolazine during Weeks 7 to 12.
3251038|NCT00832572|Experimental|Ranolazine-Placebo|Participants were randomized to receive ranolazine during Weeks 1 to 6, then placebo to match ranolazine during Weeks 7 to 12.
3251039|NCT00832559|Experimental|CVA21|CVA21
3251040|NCT00832546|Placebo Comparator|1|Placebo
3251041|NCT00832546|Experimental|2|Powder in solution
3251042|NCT00832546|Experimental|3|
3251043|NCT00832520|Experimental|Remeron (Mirtazapine)|Mirtazapine 15 mg orally at bed time for 8 weeks
3251044|NCT00832507|Experimental|Cicletanine 150 mg QD|Cicletanine 150 mg administered once daily (QD)
3251045|NCT00832507|Experimental|Cicletanine 150 mg BID|Cicletanine 150 mg administered twice daily (BID)
3251046|NCT00832507|Experimental|Cicletanine 300 mg QD|Cicletanine 300 mg administered once daily (QD)
3251047|NCT00832507|Placebo Comparator|Placebo|Placebo to match cicletanine administered once daily
3251048|NCT00832481|Active Comparator|Repaglinide,tablet|
3251049|NCT00832481|Active Comparator|Metformin, tablet|
3251050|NCT00832468|Placebo Comparator|sham ear acupressure|
3251051|NCT00832468|Experimental|ear acupressure|
3251052|NCT00832455|Experimental|Montelukast|
3251053|NCT00832442||Beta blocker|
3251054|NCT00832442||Placebo|
3251055|NCT00832429|Experimental|Lymphatic Mapping + SLN Mapping/Biopsy|SLN mapping and biopsy done in OR under general anesthesia. Injection of Tc99m-Sulfur colloid again around eyelid tumor(s) or removed tumor site(s). Lymph nodes visible from injection removed and tested for signs of metastatic disease.
3251056|NCT00832416|Experimental|1 Tramadol Once A Day 100mg|
3251057|NCT00832416|Experimental|2: Tramadol Once A Day 200mg|
3251058|NCT00832416|Experimental|3: Tramadol Once A Day 300mg|
3251059|NCT00832416|Experimental|4: Placebo|
3251060|NCT00832403||polytetrafluoroethylene|
3251061|NCT00832390|Experimental|1|sitagliptin
3251062|NCT00832377|Experimental|Timolol/Dorzolamide|Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks
3251063|NCT00832364|Experimental|1|U0279 and Injectable Biologic
3251064|NCT00832364|Placebo Comparator|2|Placebo and Injectable Biologic
3251065|NCT00832351|Experimental|1|Early mobilisation within 24 hours after admittance to hospital
3251066|NCT00832351|No Intervention|2|Mobilisation after 24 but within 48 hours from admittance to hospital
3251067|NCT00832338|Experimental|Docetaxel with Cytoxan|Patients will be treated with docetaxel at 75 mg/m² concomitantly with cytoxan 600 mg/m² (TC) IV D1 every 3 weeks for 6 cycles. Due to known toxicity of docetaxel, all patients require dexamethasone 4 mg twice daily (BID) PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel to minimize hypersensitivity reactions and fluid retention.
3251068|NCT00832325||1 individual interviews|The patient will be asked to come in to the Counseling Center at MSKCC (641 Lexington Avenue, 7th Floor) and participate in an individual interview at their convenience.
3251069|NCT00832325||2 Focus Groups|The patient will be asked to come in to the Counseling Center at MSKCC (641 Lexington Avenue, 7th Floor) and participate in a focus group at their convenience.
3251070|NCT00832325||3 Questionnaire|The patient will be asked to participate in three 60-90 minute telephone interviews scheduled at their convenience.
3251071|NCT00832312|Experimental|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml) injected into the knee joint
3251072|NCT00832312|Placebo Comparator|Saline|Injection of 1cc of saline into the knee joint
3251073|NCT00832299|Experimental|6 cycles of FOLFOX pre and post TME|
3251074|NCT00832286|Experimental|Cipro|At Week 12, subjects will receive a 3-day course of oral Ciprofloxacin 500 mg every 12h.
3251075|NCT00832234|Experimental|BDR|
3251076|NCT00832221|Active Comparator|1|
3251077|NCT00832221|Active Comparator|2|
3251078|NCT00832208|Active Comparator|Ambisome control:|Ambisome, Total dose 21.0 mg given as 7 x 3mg on days 1,2,3,4,5, and 14 and 21
3251079|NCT00832208|Experimental|Ambisome test|Single dose Ambisome in sequence(7.5 / 10.0/ 12.5 / 15.0mg)
3251080|NCT00832195|Experimental|1|Footwear with motion controlling elements built into construction in order to reduce pronation of the foot and ankle during running.
3251081|NCT00832195|Active Comparator|2|Footwear with standard neutral stabilization elements for the foot and ankle during running.
3251082|NCT00832182|Experimental|Insulin aspart and neutral protamine Hagedorn insulin|
3251083|NCT00832169|Experimental|1|
3251084|NCT00832156|Experimental|1|wound 1: the placement of keratinocytes onto a collagen/elastin support after the application of the meshed split skin autograft.
3251085|NCT00832156|Other|2|control wound site; application of mesh graft alone
3251086|NCT00832143|No Intervention|1|Usual Care
3251087|NCT00832143|Experimental|2|Referral Card with one-to-one counseling
3251088|NCT00832130|Experimental|Manual Mini System|Treatment with experimental Manual Mini System
3251089|NCT00832130|Active Comparator|Warm Compress Therapy|Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase
3251090|NCT00832117|Experimental|Escalation and Expansion|
3251091|NCT00832091|Active Comparator|1|There are 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were 3 concentrations used for topical administration to the active drug groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
3251092|NCT00832091|Placebo Comparator|2|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
3251093|NCT00832078|Other|Group A|SCCM (SpeediCath Compact Male catheter) then SC (SpeediCath cathter) on test day 1. SC then SCCM on test day 2
3251094|NCT00832078|Other|Group B|SC (SpeediCath cathter)then SCCM (SpeediCath Compact Male catheter) on test day 1. SCCM then SC on test day 2
3251372|NCT00830154|Placebo Comparator|3|placebo
3251095|NCT00832065||Patients With Sleep Apnea and Low Testosterone|Adult male patients between 18-70 years of age with nely diagnosed OSAS documented by all night polysomnography(PSG)
3251096|NCT00832052|Experimental|Cohort 1|Subjects will be randomized to receive either experimental drug (n=6) or placebo (n=2).
3251097|NCT00832052|Experimental|Cohort 2|Subjects will be randomized to receive either experimental drug (n=6) or placebo (n=2).
3251098|NCT00832052|Experimental|Cohort 3a|Subjects will be randomized to receive either experimental drug (n=3) or placebo (n=1).
3251099|NCT00832052|Experimental|Cohort 3b|Subjects will be randomized to receive either experimental drug (n=3) or placebo (n=1).
3251100|NCT00832052|Experimental|Cohort 4|
3251101|NCT00832039|Active Comparator|SelPCT|Patient receives sodium-selenite; causal therapy is guided by a PCT based algorithm.
3251102|NCT00832039|Active Comparator|SelKon|Patient receives sodium-selenite; causal therapy is not guided by a PCT based algorithm.
3251103|NCT00832039|Placebo Comparator|PlacPCT|Patient receives placebo; causal therapy is guided by a PCT based algorithm.
3251104|NCT00832039|Placebo Comparator|PlacKon|Patient receives placebo; causal therapy is not guided by a PCT based algorithm.
3251105|NCT00832026||Sleep apnea|Patients with diagnosed obstructive sleep apnea
3251106|NCT00832013|Active Comparator|1|"Propofol 1 % at a dose of 4mg/kg will be administered intravenously via a standard Medex Protégé® 3010 (Medex-A Furon. Healthcare Company, Duluth, GA, USA) infusion pump at a constant rate determined by the randomization schedule. Fresh gas flow will be maintained at 6 l/min throughout the induction procedure with the FiO2 increased to 0.5. Full cardiovascular, respiratory and EEG monitoring will continue during induction of anesthesia.~Once the loading dose of propofol has been delivered the propofol infusion will be maintained at a rate of 200mcg/kg/min or as determined by the attending anesthesiologist whilst the end-point respiratory responses are observed."
3251107|NCT00832013|Active Comparator|2|Same procedure as above. These subjects will be stratified by age and randomized, using the Biased Coin Design (BCD) principle to determine the infusion rate of propofol for delivery of the induction dose.
3251108|NCT00832000|Experimental|1|Participants will receive mexiletine for 4 weeks, then no intervention for 1 week, and finally placebo for 4 weeks.
3251109|NCT00832000|Experimental|2|Participants will receive placebo for 4 weeks, then no intervention for 1 week, and finally mexiletine for 4 weeks.
3251110|NCT00831987|Experimental|Fluzone® Vaccine Group - Age 18-59 Years|Participants aged 18 to 59 years at enrollment and received 1 dose of Fluzone® Vaccine
3251111|NCT00831987|Experimental|Fluzone® Vaccine Group - Age ≥ 60 Years|Participants aged at least 60 years or older at enrollment and received 1 dose of Fluzone® Vaccine
3251112|NCT00831974|Experimental|2|masitinib (AB1010) 6 mg/kg/day
3251113|NCT00831974|Experimental|1|masitinib (AB1010) 3 mg/kg/day
3251114|NCT00831961||1|Patients randomized to gatifloxacin (Zymar)
3251115|NCT00831961||2|Patients randomized to moxifloxacin (Vigamox)
3251116|NCT00831961||3|Patients randomized to ofloxacin (Ocuflox)
3251117|NCT00831961||4|Patients randomized to azithromycin (AzaSite)
3251118|NCT00831948||Mitochondrial disease|Patients already diagnosed for mitochondrial pathology without mtDNA mutations yet detected by current diagnostic techniques
3251119|NCT00831935||Depressed|Depressed individuals, as identified by their referring physician.
3251120|NCT00831935||Non-depressed|Non-depressed individuals, confirmed to be non-depressed by the Centers for Epidemiological Studies Depression Scale (CES-D).
3251121|NCT00831922|Experimental|1|masitinib (AB1010) 3 mg/kg/day
3251122|NCT00831922|Experimental|2|masitinib (AB1010) 6 mg/kg/day
3251123|NCT00831909||1|All NSCLC patients attending the responsible department of treating this type of patients (e.g. Oncology Department, Pneumology Department) for the first time (regardless of whether the patient is diagnosed with locally, advanced or metastatic disease) at the participating sites from the first of January 2009 to the end of March 2009. Patients diagnosed, or even treated, in other departments within the same hospital or in another hospital are susceptible to be included in the study if full access to the patient's medical record is made available.
3251124|NCT00831896|Experimental|1|TAK-701
3251125|NCT00831883|Experimental|Partner Specific IMB|partner-specific HIV risk reduction intervention
3251126|NCT00831883|Placebo Comparator|HLS|5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
3251127|NCT00831857||Group A|Treatment with sunitinib.
3251128|NCT00831857||Group B|Treatment with bevacizumab and interferon
3251129|NCT00831844|Experimental|Group 1 - Recurrent or Refractory Hepatoblastoma|Group 1 - Recurrent or Refractory Hepatoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3251130|NCT00831844|Experimental|Group 2 - Recurrent or Refractory Synovial Sarcoma|Group 2 - Recurrent or Refractory Synovial Sarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3251131|NCT00831844|Experimental|Group 3 - Recurrent or Refractory Rhabdomyosarcoma|Group 3 - Recurrent or Refractory Rhabdomyosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3251132|NCT00831844|Experimental|Grp 4-Recurrent or Refractory Adrenocortical Carcinoma|Group 4 - Recurrent or Refractory Adrenocortical Carcinoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3251133|NCT00831844|Experimental|Grp 5-Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Group 5 - Recurrent or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3251134|NCT00831844|Experimental|Grp 6 - Neuroblastoma-MIBG Positive Without Measurable Disease|Group 6 - Recurrent or Refractory Neuroblastoma -meta-iodobenzylguanidine (MIBG) Positive Without Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3251135|NCT00831844|Experimental|Grp 7-Neuroblastoma with measurable disease|Group 7 - Recurrent or Refractory Neuroblastoma -With Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3251136|NCT00831844|Experimental|Group 8 - Recurrent Osteosarcoma|Group 8 - Recurrent Osteosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3251137|NCT00831844|Experimental|Group 9 - Recurrent or Refractory Wilms Tumor|Group 9 - Recurrent or Refractory Wilms Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3251138|NCT00831844|Experimental|Group 10 - Recurrent or Refractory Retinoblastoma|Group 10 - Recurrent or Refractory Retinoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3251139|NCT00831818||1|Mothers of healthy infants who breastfeed on demand
3251140|NCT00831818||2|Mothers of healthy infants who do not breastfeed
3251141|NCT00831792|Experimental|TK1258|4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day). Following an initial 4-week cycle at a starting dose of 400 mg 5 days- on and 2 days off, TKI258 may be escalated to 500 mg/day 5 days-on/2 days off if no significant Grade3/4 AEs or laboratory abnormalities are observed.
3251142|NCT00831779|Experimental|Dapagliflozin|
3251143|NCT00831779|Placebo Comparator|Placebo|
3251144|NCT00831766|Experimental|Phase I: Dose Escalation|"Induction: A dose escalation plan for induction therapy using a standard 3x3 design with dose escalation of Lenalidomide only, to determine maximum tolerated dose (MTD). Idarubicin and cytarabine doses will be fixed.~Idarubicin: 12 mg/m^2.~Cytarabine: 200 mg/m^2.~Lenalidomide: According to dose escalation levels. Level 1: 5 mg/d; Level 2: 10 mg/d; Level 3: 15 mg/d; Level 4: 20 mg/d; Level 5: 25 mg/d."
3251145|NCT00831766|Experimental|Phase II: Treatment at MTD|"Idarubicin: 12 mg/m^2.~Cytarabine: 200 mg/m^2.~Lenalidomide: Maximum Tolerated Dose (MTD)."
3251146|NCT00831753|Experimental|Group 1|DTaP-IPV-Hep B-PRP~T vaccine group
3251147|NCT00831753|Active Comparator|Group 2|Infanrix® Hexa vaccine group
3251148|NCT00831740|Experimental|Speech Therapy|
3251149|NCT00831740|Active Comparator|ACT NoW Visitor|
3251150|NCT00831727|Experimental|Expressive Writing|
3251151|NCT00831727|Placebo Comparator|Control|
3251152|NCT00831714||Group 1|
3251153|NCT00831714||Group 2|
3251154|NCT00831701|Active Comparator|Tamsulosin|Tamsulosin treatment
3251155|NCT00831701|Placebo Comparator|Placebo|Placebo treatment
3251156|NCT00831688|Active Comparator|1|Local overpressure treatment
3251157|NCT00831688|Placebo Comparator|2|Placebo treatment
3251158|NCT00831675|Experimental|Infants <12 Months|Participants aged ≥ 6 to < 12 months at enrollment and received 2 doses of Fluzone® Vaccine
3251159|NCT00831675|Experimental|Toddlers ≥12 Months|Participants aged ≥ 12 to < 36 months at enrollment and received 2 doses of Fluzone® vaccine
3251160|NCT00831662|Placebo Comparator|Arm 2|
3251161|NCT00831662|Experimental|Arm 1|
3251162|NCT00831649|Experimental|natalizumab|
3251163|NCT00831636|Experimental|Open label CP-4055|Phase I: Dose escalation Phase II: Fixed dose
3251164|NCT00831623|Experimental|Proton radiation therapy|Single arm
3251165|NCT00831610|Other|STUDY|"Female healthy volunteers (25 to 55 years old) with normal weight.~Morbid Obese women waiting for bariatric surgery.~Post-bariatric female patients, 25 to 55 years old, MORE than 12 months of weight stability, pendular abdominal wall, clinical conditions to anchor-line abdominoplasty without flap undermining. Skin Evaluation before the abdominoplasty.~Group 3, submitted to anchor-line abdominoplasty without flap undermining."
3251166|NCT00831610|Other|CONTROL|Group 3: Post-bariatric female patients, 25 to 55 years old, LESS than 12 months of weight stability, pendular abdominal wall, clinical conditions to anchor-line abdominoplasty without flap undermining. Who will be submitted to abdominoplasty after the study period.
3251167|NCT00831597|Experimental|Bendamustine with rituximab|All patients received combination bendamustine with rituximab
3251168|NCT00831571||All Participants|Patients receiving Oxaliplatin
3251169|NCT00831571||Desensitization|Patients that have experienced a moderate to severe hypersensitivity reaction to oxaliplatin
3251170|NCT00831545|Experimental|Subjects with melanoma|
3251171|NCT00831545|Experimental|Subjects with breast cancer|
3251172|NCT00831545|Experimental|Subjects with non-small cell lung cancer|
3251173|NCT00831532|Experimental|Normal|Healthy Volunteers
3251174|NCT00831532|Experimental|Mild Hepatic Impairment|Mild hepatic impairment patients
3251175|NCT00831532|Experimental|Moderate hepatic Impairment|Moderate Hepatic Impairment Patients
3251176|NCT00831532|Experimental|Severe Hepatic Impairment|Severe Hepatic Impairment Patients
3251177|NCT00831519||Macrosomial, GD|
3251178|NCT00831519||Macrosomial, control|
3251179|NCT00831506|Experimental|A|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
3251180|NCT00831506|Experimental|B|digoxin once daily (0.125 mg QD) plus Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
3251181|NCT00831493|Experimental|Vorinostat + Radiation Therapy|Vorinostat starting dose 200 mg orally once daily, Monday to Friday, Weeks 1 to 6; Radiation Therapy Dose of 50.4 Gray (Gy) in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.
3251182|NCT00831480|Experimental|1|All subjects will take everolimus
3251183|NCT00831467|Experimental|CV9103|CV9103 is applied intradermally into the thigh and upper arm of either side of the body at week 1, week 3, week 7, week 15, week 23
3251184|NCT00831441|Active Comparator|Apixaban|
3251185|NCT00831441|Placebo Comparator|Placebo|
3251186|NCT00831428||Scottish swimming team|
3251187|NCT00831415|Experimental|1|DVS SR
3251373|NCT00830141||1|50 children with GH deficiency
3251374|NCT00830141||2|50 children with ISS
3251375|NCT00830141||3|50 children with FTT
3251188|NCT00831402|No Intervention|Arm without iodized vitamin (VITAMIN OLIGOBS PREGNANCY)|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
3251189|NCT00831402|Active Comparator|Arm with iodized vitamin|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
3251190|NCT00831389|Experimental|Closed Loop (CL) Phase|Closed Loop (CL) Phase
3251191|NCT00831389|No Intervention|Standard of Care (OL) Phase|Standard of Care (OL) Phase or Open Loop Phase
3251192|NCT00831376|Experimental|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
3251193|NCT00831376|Active Comparator|2: racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
3251194|NCT00831376|Placebo Comparator|3: Placebo|Patients will be asked to take two puffs four times a day for 2 weeks
3251195|NCT00831363||1|minimal invasive approach
3251196|NCT00831363||2|traditional transgluteal approach
3251197|NCT00831350|Experimental|ranibizumab|
3251198|NCT00831337|Experimental|Liver cirrhosis compensated|VSL3 supplemented twice daily for 28 days
3251199|NCT00831337|Experimental|Liver cirrhosis decompensated|VSL3 supplemented twice daily for 28 days
3251200|NCT00831337|Experimental|Control group|VSL3 supplemented twice daily for 28 days
3251201|NCT00831311|Experimental|1|DTaP IPV HB-PRP~T vaccine group
3251202|NCT00831311|Active Comparator|2|PENTAXIM™ and ENGERIX B® vaccines group
3251203|NCT00831298|Other|1|Behavioral Questionnaire Sleep Recordings Genetic analysis
3251204|NCT00831285|Experimental|tortilla with high amylose flour|
3251205|NCT00831285|Experimental|barley tortilla with low amylose flour|
3251206|NCT00831285|Experimental|barley tortilla with low amylose flour and soluble fibre|
3251207|NCT00831285|Experimental|barley tortilla with low amylose flour and insoluble fibre|
3251208|NCT00831285|Active Comparator|glucose|
3251209|NCT00831285|Experimental|barley tortilla with low amylose flour and low soluble fibre|
3251210|NCT00831272|Experimental|Naltrexone|50mg/day of naltrexone
3251211|NCT00831272|Placebo Comparator|Placebo|Placebo
3251212|NCT00831259||1|Incidence of silent stroke in patients with PFO
3251213|NCT00831259||2|Incidence of silent stroke in patients without PFO
3251214|NCT00831246|Experimental|1|Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
3251215|NCT00831246|Sham Comparator|2|Patients are given standard post-op care with clear liquid diet as tolerated .
3251216|NCT00831233|Experimental|Degarelix 240 mg/80 mg|Degarelix 240 mg (40 mg/mL) + 80 mg (20 mg/mL)
3251217|NCT00831233|Active Comparator|Goserelin (3.6 mg) + bicalutamide (50 mg)|Goserelin (3.6 mg) + bicalutamide (50 mg)
3251218|NCT00831220||1|Patients with a COPD exacerbation
3251219|NCT00831220||2|Patients with stable COPD
3251220|NCT00831220||3|Smokers or former smokers
3251221|NCT00831220||4|Never smokers
3251222|NCT00831207||G1|15 HIV-1+ individuals, previously untreated or without HAART for at least six months and CD4+ < 350 cells/mm3.
3251223|NCT00831207||G2|31 HIV-1+ individuals undergoing HAART without virological therapeutic failure (TF).
3251224|NCT00831207||G3|43 HIV-1+ individuals undergoing HAART with TF.
3251225|NCT00831207||G4|20 normal individuals who served as controls for serum cytokines.
3251226|NCT00831194|Experimental|Diet plan and PDA|
3251227|NCT00831181|Experimental|Preoperative Chemoradiation|Preoperative Chemoradiation with oxaliplatin/5-FU followed by mesorectal excision and 5-FU / leucovorin (FOLFOX 6)
3251228|NCT00831155|Active Comparator|1|Extinction Based Group (EBT): switch to smoking denicotinized cigarettes while wearing a 21mg/day nicotine patch for one month prior to their quit date.
3251229|NCT00831155|No Intervention|2|Nicotine Replacement Group (NRT): smoke their usual brand of cigarettes up to the quit date.
3251230|NCT00831142||Prostate Cancer|Males with prostate cancer, referred for biopsy or radical prostatectomy
3251231|NCT00831129|Active Comparator|Simvastatin + Placebo Rosiglitazone|Subjects will receive 40 mg Simvastatin + 1 tab Placebo Rosiglitazone daily
3251232|NCT00831129|Active Comparator|Simvastatin + rosiglitazone|Subjects will receive 40 mg Simvastatin + 4 mg Rosiglitazone once daily
3251233|NCT00831116||LipiScan|Subjects who have at least one native coronary artery imaged with the LipiScan CIS.
3251234|NCT00831103|Experimental|EPB-348 1000 mg|EPB-348 1000 mg dosed once daily for seven days
3251235|NCT00831103|Experimental|EPB-348 2000 mg|EPB-348 2000 mg dosed once daily for seven days
3251236|NCT00831103|Experimental|EPB-348 3000 mg|EPB-348 3000 mg dosed once daily for seven days
3251237|NCT00831103|Active Comparator|Valacyclovir|Valacyclovir 1000 mg dosed three times daily for seven days
3251238|NCT00831077|Active Comparator|14C-ORM-14540|
3251239|NCT00831077|Active Comparator|14C-ORM-12741|
3251240|NCT00831064|Active Comparator|1. 4L PEG only|4L PEG PO
3251241|NCT00831064|Active Comparator|2. 2L PEG plus bisacodyl|2L PEG PO + 4 tablets bisacodyl PO
3251242|NCT00831064|Active Comparator|3. NaP|90 cc NaP PO
3251243|NCT00831064|Active Comparator|4. PSMC plus Mg-citrate|PSMC plus 300 cc Mg-citrate PO
3251244|NCT00831051|Experimental|Q8003 12mg/8mg|Combination
3251245|NCT00831051|Active Comparator|Morphine sulfate 12 mg|Single component
3251246|NCT00831051|Active Comparator|Oxycodone HCl 8mg|Single component
3251247|NCT00831051|Experimental|Q8003 6mg/4mg|Combination
3251248|NCT00831051|Active Comparator|Morphine sulfate 6mg|Single component
3251249|NCT00831051|Active Comparator|Oxycodone HCl 4mg|Single component
3251250|NCT00831025|Experimental|1|Depigmented and polymerized allergen extract of Olea europaea pollen for subcutaneous injection.
3251251|NCT00831025|Placebo Comparator|2|Placebo for subcutaneous injection.
3251252|NCT00831012|Experimental|Group 1|Group 1 will consist of healthy participants receiving an immunization of 10^3 PFU rDEN3delta30/31‐7164
3251376|NCT00830141||4|50 children with obesity
3251253|NCT00831012|Experimental|Group 2|"Group 2A will consist of healthy participants who will receive an immunization of 10^5 PFU of rDEN3delta30/31‐7164 vaccine or placebo. Group 2A participants will be enrolled if less that 90% of Group 1 participants seroconvert to DEN3 by Study Day 42.~Group 2B will consist of healthy participants who will receive an immunization of 10^1 PFU of rDEN3delta30/31‐7164 vaccine or placebo. Group 2B participants will be enrolled if more that 90% of Group 1 participants seroconvert to DEN3 by Study Day 42."
3251254|NCT00830999|Experimental|Positive energy balance|Comparison between isocaloric and hypercaloric diets with no exercise performed in any trials
3251255|NCT00830999|Experimental|Energy balance with exercise|Comparison between an isocaloric diet without exercise and a hypercaloric diet with a sufficient amount of exercise performed to match the excess calories consumed resulting in both trials being in net energy balance.
3251256|NCT00830999|Experimental|Negative energy balance|Comparison between isocaloric and hypocaloric diets with no exercise performed in any trials
3251257|NCT00830999|Experimental|Negative energy balance with exercise|Comparison between consuming an isocaloric diet without exercise and consuming the same amount of calories as in the isocaloric trial but with exercise performed resulting in net negative energy balance in the exercise trial.
3251258|NCT00830986||1|Computer Assisted Total Knee Arthroplasty
3251259|NCT00830986||2|Conventional Instrumented Total Knee Arthroplasty
3251260|NCT00830973||Active Study Group|The active study group consists of 50 year or older postmenopausal women taking tamoxifen for the prevention of reoccurrence of breast cancer, do not meet exclusion criteria, meet all inclusion criteria, and are enrolled members for Medco clients agreeing to participate.
3251261|NCT00830960|Experimental|Prasugrel 60/10 Primary|Loading dose 60 mg followed by maintenance dose 10 mg/day
3251262|NCT00830960|Experimental|Prasugrel 30/7.5 Primary|Loading dose 30 mg followed by maintenance dose 7.5 mg/day
3251263|NCT00830960|Experimental|Prasugrel 30/5 Primary|Loading dose 30 mg followed by maintenance dose 5 mg/day
3251264|NCT00830960|Active Comparator|Clopidogrel 300/75 Primary|Loading dose 300 mg followed by maintenance dose 75 mg/day
3251265|NCT00830960|Experimental|Prasugrel 30/5 Low Weight/Elderly|Loading dose 30 mg followed by maintenance dose 5 mg/day
3251266|NCT00830960|Active Comparator|Clopidogrel 300/75 Low Weight/Elderly|Loading dose 300 mg followed by maintenance dose 75 mg/day
3251267|NCT00830947|Experimental|OrthoAccel Device|Device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
3251268|NCT00830947|Sham Comparator|Sham Device (inactive device)|Sham device will look identical to active devices but will not deliver vibration to the patient.
3251269|NCT00830934|Active Comparator|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
3251270|NCT00830934|Experimental|Group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
3251271|NCT00830921||1|"Patients will be identified from the Oxford Pleural Clinic and from referrals within the multi-disciplinary team including palliative care and oncology services.~Screening criteria are based on normal practice and consecutive eligible patients will be offered trial entry. The principal investigator or a nominated member of staff will approach participants who fulfil the criteria for inclusion in the study. Screening logs will be kept."
3251272|NCT00830908|Experimental|LaserComb|Patients aged 18 years and older with a diagnosis of seborrheic dermatitis of the scalp
3251273|NCT00830895|Experimental|RAD001|RAD001 10mg/day
3251274|NCT00830882|Experimental|1:levosalbutamol|2 puffs four times a day for 2 weeks
3251275|NCT00830882|Active Comparator|2: racemic salbutamol|2 puffs four times a day for 2 weeks
3251276|NCT00830882|Placebo Comparator|3: Placebo|2 puffs four times a day for 2 weeks
3251277|NCT00830869|Experimental|1|IXAZOMIB (MLN9708)
3251278|NCT00830856|Experimental|1|Early initiation of antiretroviral therapy. Patients in this treatment group were started on Fluconazole 800mg by mouth every day for Cryptococcal Meningitis, and within 72hrs of diagnosis were started on First line antiretroviral therapy per Zimbabwe treatment guidelines which is Stavudine, Lamivudine and Nevirapine.
3251279|NCT00830856|Experimental|2|Delayed initiation of antiretroviral therapy. Patients in this treatment group were started on Fluconazole 800mg by mouth every day for Cryptococcal Meningitis, and after completion of high dose fluconazole for 10 weeks, the patients in this group were started on First line antiretroviral therapy per Zimbabwe treatment guidelines which is Stavudine, Lamivudine and Nevirapine.
3251280|NCT00830843|Active Comparator|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
3251281|NCT00830843|Experimental|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
3251282|NCT00830804|Experimental|RAL + DRV/RTV|Raltegravir (400 mg BID) plus Darunavir/Ritonavir (800 mg/100 mg QD) for 52 weeks
3251283|NCT00830791|Experimental|MK-0941 20 mg Mild Renal Insufficiency|MK-0941 20 mg administered to participants with mild renal insufficiency and type 2 diabetes.
3251284|NCT00830791|Experimental|MK-0941 20 mg Moderate Renal Insufficiency|MK-0941 20 mg administered to participants with moderate renal insufficiency and type 2 diabetes.
3251285|NCT00830791|Experimental|MK-0941 5 mg Severe Renal Insufficiency|MK-0941 5 mg administered to participants with severe renal insufficiency and type 2 diabetes.
3251286|NCT00830791|Experimental|MK-0941 20 mg Matched Controls|MK-0941 20 mg administered to age-, gender-, race-, body mass index (BMI)-, and hemoglobin A1C (HbAIc)-matched control subjects with normal renal function and type 2 diabetes.
3251287|NCT00830791|Experimental|MK-0941 5 mg Matched Controls|MK-0941 5 mg administered to age-, gender-, race-, body mass index (BMI)-, and HbAIc-matched control subjects with normal renal function and type 2 diabetes.
3251288|NCT00830778|Experimental|PG anastomosis|Pancreaticogastrostomy (PG) reconstruction/anastomosis after pancreaticoduodenectomy (PD)
3251289|NCT00830778|Active Comparator|PJ anastomosis|Pancreaticojejunostomy (PJ) reconstruction/anastomosis after pancreaticoduodenectomy (PD)
3251290|NCT00830765|Placebo Comparator|1 Placebo|The participant will receive a weekly injection of placebo from the time of enrollment up until 34 weeks' gestation or delivery, whichever occurs first.
3251291|NCT00830765|Active Comparator|Progesterone|The participant will receive weekly injections of 100mg of OHP17 from the time of enrollment until 34 weeks' gestation or delivery, whichever occurs first.
3251292|NCT00830726||1|Healthy volunteers
3251293|NCT00830726||2|Patients with symptomatic heart failure and EF < 40%
3251294|NCT00830726||3|Patients with symptomatic aortic valve stenosis
3251295|NCT00830726||4|Patients with Acute Coronary syndromes prior to surgical intervention
3251296|NCT00830726||5|Patients with refractory stable angina requiring surgical intervention.
3251297|NCT00830726||6|Patients with pulmonary hypertension and preserved systolic left ventricular function.
3251298|NCT00830713|Experimental|MKTP treatment|subject will undergo MKTP
3251299|NCT00830700|Experimental|CATMH intervention|Child telemental health service delivery intervention
3251300|NCT00830700|No Intervention|augmented TAU/PCP|Augmented treatment as usual with primary care physician
3251301|NCT00830687|Other|Targon FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
3251302|NCT00830674|Experimental|KRN23|Single IV or SC administration on day 1
3251303|NCT00830674|Placebo Comparator|Placebo|Single IV or SC administration on day 1
3251304|NCT00830661|Active Comparator|LIFT|those subjects receiving the Ligation of Intersphincteric Fistula Track procedure
3251305|NCT00830661|Active Comparator|Plug|those subjects randomized to the receive the placement of the porcine anal fistula plug
3251306|NCT00830648|Experimental|1|
3251307|NCT00830622|Experimental|1|Cell Phone Intervention: participant receives weekly SMS text message from the health care worker.
3251308|NCT00830622|No Intervention|2|SOC: Participant receives standard of care support but not weekly SMS text messages from the health care worker.
3251309|NCT00830609|Active Comparator|A|Patients in this arm will receive standard of care (Peginterferon alfa 2A 180 mcg/weeks SC plus ribavirin 800 mg/day for 24 weeks).
3251310|NCT00830609|Experimental|B1|After a period of 4 weeks with peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day (Induction phase), these patients will be allocated according to negativity or positivity of RNA-HCV at week 4. If RNA-HCV negative, treatment with peginterferon alfa 2 a 180 mcg/week plus RBV 800 mg/day (SOC) will be continued over 20 additional weeks (Arm B1). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin > 12g/dL.
3251311|NCT00830609|Experimental|B2|If RNA-HCV at week 4 remains positive after the induction phase, then peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day will be continued for 20 additional weeks (Arm B2). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin > 12g/dL.
3251312|NCT00830596|Active Comparator|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
3251313|NCT00830596|Active Comparator|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
3251314|NCT00830596|Placebo Comparator|Sham Intervention|Light effleurage and a sham mechanically-assisted chiropractic treatment for 2 weeks followed by full spine manipulation for 4 weeks
3251315|NCT00830583|Other|1|pompe's disease suspected patient
3251316|NCT00830570||1|Historical control group. Patients in this group are drawn from the same plan populations as the intervention group, but they are identified during the 1-year period prior to the start of patient enrollment in the intervention group. The historical control group is closely matched with the intervention group on demographic characteristics, practice patterns, and benefit plan features that may affect resource utilization.
3251317|NCT00830570||2|Concurrent control group. Patients in this group are drawn from different set of plan populations, but they initiate warfarin treatment during the same time period as patients in the intervention group. Outcomes data for the concurrent control group will be used to evaluate whether any differences between the intervention group and the historical control group can be attributed to changes in clinical practice over time. Baseline data for the concurrent control group will help validate the incidence assumptions used in the calculation of statistical power. This use of baseline population norms is an effective means of limiting bias in quasi-experimental studies.
3251318|NCT00830570||3|Active study group. For plans participating in the active arm of the study, enrollment is offered to every patient who initiates warfarin therapy during the enrollment period (beginning in July 2007) and who meets the eligibility criteria. Patients are identified for the active study group if they have a warfarin pharmacy claim and no prior warfarin claims during the preceding 180 days. Only patients who remain eligible for the pharmacy benefit throughout the study period are included in the final sample.
3251319|NCT00830544|Experimental|1|Experimental chemotherapy using neoadjuvant approach
3251320|NCT00830531|Experimental|1|Standard phenobarbital combined with either 0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the status of the dose escalation design.
3251321|NCT00830531|Placebo Comparator|2|Standard phenobarbital therapy combined with normal saline as placebo for bumetanide
3251322|NCT00830518|Experimental|Alisertib|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period, in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).
3251323|NCT00830505|Experimental|1: fluticasone/salmeterol|2 puffs twice a day for 2 weeks
3251324|NCT00830505|Active Comparator|2: fluticasone|2 puffs twice a day for 2 weeks
3251325|NCT00830492|Active Comparator|2|In group A (n=100), the patients were stimulated conventional. They desensitized with buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg and ovarian stimulation would commence with 150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
3251377|NCT00830141||5|50 children without short stature or obesity will serve as controls
3251378|NCT00830128|Experimental|pregabalin (Lyrica)|
3251379|NCT00830115||Pantoprazole|All patients enrolled
3251326|NCT00830492|Experimental|clomiphen/gonadotropin/GnRH antagonist|Patients in group B ( n=100 ) were stimulated clomiphene citrate ( ) 100 mg from cycle day three through seven and continuous gonadotropin stimulation with of r_FSH 75 IU daily from cycle day 5. Ultrasound in two group was performed on 8 cycle day. In group B 0.25 mg GnRH antagonist (Ganirelix , Organon ,Netherland ) daily was started with dominant follicle ≥14mm and in this day 75 IU human menopoasl gonadotropin (HMG) (Menogon, ferring, pharmacenticals , Germany ) increased to the initial gonadotropin . LH assessment on the day of starting antagonist was performed and if LH was >15 IU/L , cycle was cancelled. Human chorionic gonadotropin 10000 IU ((pregnyl, Organon, Oss, the Netherlands ) was given when 1 to 3 follicles reached 18 mm
3251327|NCT00830479|Active Comparator|Open Surgery|
3251328|NCT00830479|Active Comparator|Endoscopic Surgery|
3251329|NCT00830466|Experimental|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
3251330|NCT00830440|Experimental|EndoBarrier Device|EndoBarrier Device and Diet & Lifestyle Counseling
3251331|NCT00830440|Active Comparator|Control|Diet & Lifestyle Counseling
3251332|NCT00830427|Experimental|PF-00610355|
3251333|NCT00830427|Experimental|PF - 00610355|
3251334|NCT00830427|Placebo Comparator|Placebo|
3251335|NCT00830414|Experimental|1|
3251336|NCT00830414|Active Comparator|2|DEPO-PROVERA®
3251337|NCT00830401|No Intervention|1|One or more of the predefined minor intra-uterine abnormalities have been detected, but not treated during hysteroscopy.
3251338|NCT00830401|Active Comparator|2|One or more of the predefined minor intra-uterine abnormalities have been detected and treated during hysteroscopy.
3251339|NCT00830388|Experimental|Ketoconazole 2% Foam|Open-label study
3251340|NCT00830375|Experimental|Memantine|10-30mg, memantine
3251341|NCT00830362|Active Comparator|Propranolol 40mg|
3251342|NCT00830362|Placebo Comparator|Placebo|
3251343|NCT00830349|Experimental|1|Risperidone 1 mg Tablets
3251344|NCT00830349|Active Comparator|2|Risperdal® 1 mg Tablets
3251345|NCT00830336|Experimental|Azithromycin (test)|Azithromycin for Oral Suspension 200 mg/5 mL (test) dosed in first period followed by Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in second period
3251346|NCT00830336|Active Comparator|Zithromax® (reference)|Zithromax® for Oral Suspension 200 mg/5 mL (reference) dosed in first period followed by Azithromycin for Oral Suspension 200 mg/5 mL (test) dosed in second period
3251347|NCT00830323|Experimental|1|
3251348|NCT00830323|Experimental|Arm 2|
3251349|NCT00830323|Active Comparator|Arm 3|
3251350|NCT00830310|Experimental|Customized Adherence Enhancement (CAE)|"Participants will be assigned to receive one or more of the study interventions based upon the participant's responses on the Attitudes toward Mood Stabilizers Questionnaire (AMSQ) and reasons for non-adherence on the Rating of Medication Influences (ROMI).~Individuals will participate in a series of 4 60-minute sessions over a 4-week period, with the study therapist who will implement the module-based intervention. The number of modules may differ depending on the baseline adherence profile of the participant.~An intervention manual developed by the investigators will provide explicit guidelines regarding how modules may be co-administered in single or multiple sessions to minimize redundancy as well as time and effort burden on study participants. The manual for each module will specifically address how any module could be combined with the other modules."
3251351|NCT00830297|Active Comparator|1 Insulatard (long-acting insulin)|
3251352|NCT00830297|Active Comparator|2 Conventional treatment|
3251353|NCT00830284|Experimental|Recruitment|Patients with hypoxic respiratory failure
3251354|NCT00830271|Experimental|Vicryl plus/Monocryl plus|"Vicryl plus and Monocryl plus is the active comparator arm. These are the active sutures, coated with triclosan antiseptic, being used in the closure of skin and subcutaneous tissues after breast cancer surgery."
3251355|NCT00830271|Placebo Comparator|vicryl/monocryl|"Plain Vicryl or Monocryl suture currently the standard which are not coated with triclosan, serve as the control."
3251356|NCT00830258|Experimental|Pravastatin|Pravastatin 80 mg Tablet (test) dosed in first period followed by Pravachol® 80 mg Tablet (reference) dosed in second period
3251357|NCT00830258|Active Comparator|Pravachol®|Pravachol® 80 mg Tablet (reference) dosed in first period followed by Pravastatin 80 mg Tablet (test) dosed in second period
3251358|NCT00830245|Experimental|Erlotinib|Erlotinib 150mg/day (if no negative conversion --> increment to 250mg/day)
3251359|NCT00830232|Active Comparator|Closed-cell stent|For patients randomized to the closed-cell stent group, the Xact closed-cell stents were used. The Xact stent is a FDA approved device.
3251360|NCT00830232|Active Comparator|Open-cell stent|For patients randomized to the open-cell stent group, the Acculink carotid stent was used. The Acculink stent is a FDA approved device.
3251361|NCT00830219|Experimental|1|
3251362|NCT00830219|Active Comparator|2|
3251363|NCT00830206|Experimental|Azithromycin (test)|Azithromycin Oral Suspension 200 mg/5 mL (test) dosed in first period followed by Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in second period
3251364|NCT00830206|Active Comparator|Zithromax® (reference)|Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in first period followed by Azithromycin Oral Suspension 200 mg/5 mL (test) dosed in second period
3251365|NCT00830193|Active Comparator|N-acetylcysteine|Intravenous fluid administration was administered as soon as possible following randomization (not to exceed 12 hours prior to anticipated contrast exposure) and continued for 12 hours post CT. Patients randomized to the experimental arm received intravenous normal saline plus NAC 10 grams IV (5 g pre and 2.5 g at 6 and 12 hours post-exposure) for a total of 3 doses.
3251366|NCT00830193|Placebo Comparator|Placebo|Intravenous fluid administration was administered as soon as possible following randomization (not to exceed 12 hours prior to anticipated contrast exposure) and continued for 12 hours post CT. Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g in 100 cc D5W (pre-CT dose) or 2.5 g in 50 cc D5W (post-CT doses). The placebo was D5W and was colour and consistency matched by pharmacy. Patients randomized to placebo received intravenous normal saline plus 3 doses of placebo.
3251367|NCT00830180|Experimental|Anti-NGF AB|
3251368|NCT00830167|Placebo Comparator|Placebo|
3251369|NCT00830167|Experimental|Pregabalin|
3251370|NCT00830154|Experimental|1|0.30 mg pagoclone BID
3251380|NCT00830102|Active Comparator|1|"Period 1 Treatment Regimen A: FlutiForm 100/10 ug~Period 2 Treatment Regimen B: FlutiForm 250/10 ug~Period 3 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug~Period 4 Treatment Regimen D: Flixotide Evohaler 250 ug"
3251381|NCT00830102|Active Comparator|2|"Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug~Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug~Period 3 Treatment Regimen B: FlutiForm 250/10 ug~Period 4 Treatment Regimen A: FlutiForm 100/10 ug"
3251382|NCT00830102|Active Comparator|3|"Period 1 Treatment Regimen B: FlutiForm 250/10 ug~Period 2 Treatment Regimen A: FlutiForm 100/10 ug~Period 3 Treatment Regimen F: Placebo~Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug"
3251383|NCT00830102|Active Comparator|4|"Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug~Period 2 Treatment Regimen F: Placebo~Period 3 Treatment Regimen A: FlutiForm 100/10 ug~Period 4 Treatment Regimen B: FlutiForm 250/10 ug"
3251384|NCT00830102|Active Comparator|5|"Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug~Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug~Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug~Period 4 Treatment Regimen F: Placebo"
3251385|NCT00830102|Active Comparator|6|"Period 1 Treatment Regimen F: Placebo~Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug~Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug~Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug"
3251386|NCT00830089|Experimental|TAP block|40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
3251387|NCT00830089|No Intervention|Standard care|No TAP block is given. Care is otherwise identical to arm 1
3251388|NCT00830076|Experimental|Sitagliptin + placebo metformin|
3251389|NCT00830076|Experimental|Metformin + placebo sitagliptin|
3251390|NCT00830076|Experimental|Sitagliptin + metformin|Co-administration of sitagliptin and metformin
3251391|NCT00830076|Placebo Comparator|Placebo sitagliptin + placebo metformin|Co-administration of placebo to sitagliptin and placebo to metformin
3251392|NCT00830063|Experimental|1|
3251393|NCT00830063|Experimental|2|
3251394|NCT00830063|Active Comparator|3|
3251395|NCT00830063|Placebo Comparator|4|
3251396|NCT00830050|Experimental|Arm 1|
3251397|NCT00830050|Placebo Comparator|Arm 2|
3251398|NCT00830037|Experimental|IV Iron|
3251399|NCT00830037|Active Comparator|Oral Iron|
3251400|NCT00830024|Experimental|Alprazolam (test)|Alprazolam 3 mg ER Tablet (test) dosed in first period followed by Xanax XR® 3 mg Tablet (reference) dosed in second period
3251401|NCT00830024|Active Comparator|Xanax XR®|Xanax XR® 3 mg Tablet (test) dosed in first period followed by Alprazolam 3 mg ER Tablet (test) dosed in second period
3251402|NCT00830011|Active Comparator|standard care|Medical care including medication for neuropathic pain
3251403|NCT00830011|Active Comparator|CBT|
3251404|NCT00829998|Experimental|Zaleplon|Zaleplon 10 mg Capsule (test) dosed in first period followed by Sonata® 10 mg Capsule (reference) dosed in second period
3251405|NCT00829998|Active Comparator|Sonata®|Sonata® 10 mg Capsule (reference) dosed in first period followed by Zaleplon 10 mg Capsule (test) dosed in second period
3251406|NCT00829985|Experimental|Glycerinated German Cockroach Allergenic Extract|Participants with German cockroach allergy and mild to moderate asthma, rhinitis, or both self-administered concentrated (1:20 weight per volume [w/v]) daily doses of glycerinated German cockroach allergenic extract (50% glycerin) placed under the tongue (sublingually) to dissolve. The treatment course and study duration was 6 months. Note: The extract was also administered during the preliminary dosing visits, up to five escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
3251407|NCT00829985|Placebo Comparator|Placebo|Participants with German cockroach allergy and mild to moderate asthma, rhinitis, or both self-administered daily doses of placebo placed under the tongue (sublingually) to dissolve. The treatment course and study duration was 6 months. Note: The placebo was also administered during the preliminary dosing visits, up to five escalating doses, or until the maximum study dose (420 microliters, 1:20 weight per volume [w/v]) was achieved.
3251408|NCT00829972||1|children undergoing adenotonsillectomy
3251409|NCT00829972||2|children undergoing elective procedures other than adenotonsillectomy
3251410|NCT00829959||Genetic Counseling|Women referred to the Clinical Cancer Genetics Program for discussion of Hereditary Breast And Ovarian Syndrome (HBOC).
3251411|NCT00829946|Experimental|2|
3251412|NCT00829933|Experimental|1|DU-176b low dose
3251413|NCT00829933|Experimental|2|DU-176b intermediate dose
3251414|NCT00829933|Experimental|3|DU-176b high dose
3251415|NCT00829933|Active Comparator|4|Warfarin
3251416|NCT00829920||Bladder cancer|Patients with muscle invasive or metastatic bladder cancer who will be planning for treatment with surgery or chemotherapy.
3251417|NCT00829907|Experimental|1|Orm-12741
3251418|NCT00829894|Experimental|1|Risperidone 1 mg Tablet
3251419|NCT00829894|Active Comparator|2|Risperdal® 1 mg Tablet
3251420|NCT00829881|Placebo Comparator|1|Participants will receive a placebo capsule, administered orally, once per study visit.
3251421|NCT00829881|Experimental|2|Participants will receive a betahistine capsule, administered orally, once per study visit.
3251422|NCT00829868|Experimental|Zaleplon|Zaleplon 10 mg Capsule (test) dosed in first period followed by Sonata® 10 mg Capsule (reference) dosed in second period
3251423|NCT00829868|Active Comparator|Sonata®|Sonata® 10 mg Capsule (reference) dosed in first period followed by Zaleplon 10 mg Capsule (test) dosed in second period
3251424|NCT00829855||1|Patients with hypertensive (systolic blood pressure ≥160 mmHg) acute pulmonary edema, evaluated within 120 minutes after admittance.
3251425|NCT00829855||2|The same patients from group 1 followed-up at 48 to 96 hours.
3251426|NCT00829842|Placebo Comparator|1|Placebo
3251427|NCT00829842|Experimental|2|
3251428|NCT00829829|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
3251429|NCT00829829|Active Comparator|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.
3251430|NCT00829829|Active Comparator|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
3251431|NCT00829816|Experimental|Dimebon|20 mg dimebon by mouth 3 times per day
3251432|NCT00829816|Placebo Comparator|Placebo|20 mg placebo by mouth 3 times per day
3251433|NCT00829803|Experimental|SNAP Monitor EEG signals|
3251434|NCT00829803|Active Comparator|BIS Monitor EEG signals (VISTA)|
3251435|NCT00829790|Experimental|1|Doxycycline Monohydrate
3251436|NCT00829790|Active Comparator|2|Vibramycin Monohydrate®
3251437|NCT00829764|Experimental|1|Doxycycline Monohydrate
3251438|NCT00829764|Active Comparator|2|Vibramycin Monohydrate®
3251439|NCT00829751|Active Comparator|ReNu Multiplus|Purevision lenses will be soaked in ReNu Multiplus
3251440|NCT00829751|Active Comparator|OptiFree RePlenish|PureVision lenses will be soaked in OptiFree RePlenish
3251441|NCT00829738||Group 1|All patients enrolled
3251442|NCT00829725|Active Comparator|screws-internal fixation|3-4-screws-internal fixation
3251443|NCT00829725|Experimental|TARGON FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
3251444|NCT00829712|Experimental|1|
3251445|NCT00829712|Active Comparator|2|Focalin®
3251446|NCT00829699|Experimental|1|Euinsulinemic (low insulin infusion) Euglycemic (normal blood glucose levels) glucose clamp with lipid (fat) infusion
3251447|NCT00829699|Experimental|2|Euinsulinemic Hyperglycemic (high glucose levels) glucose clamp with lipid infusion
3251448|NCT00829699|Experimental|3|Hyperinsulinemic (High dose insulin) euglycemic glucose clamp with lipid infusion
3251449|NCT00829699|Experimental|4|Hyperinsulinemic hyperglycemic (high glucose level) glucose clamp with lipid infusion
3251450|NCT00829686|No Intervention|No intervention|No antibiotic
3251451|NCT00829686|Active Comparator|Septra DS|Septra DS (800/160) two pills PO BID x 7 days
3251452|NCT00829673|Experimental|1|
3251453|NCT00829673|Active Comparator|2|Focalin®
3251454|NCT00829660|Active Comparator|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
3251455|NCT00829660|Placebo Comparator|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
3251456|NCT00829647|Experimental|combination dasatinib plus lenalidomide|dasatinib 70 mg po daily plus lenalidomide 2.5 md po daily
3251457|NCT00829634|Other|l-methamphetamine|
3251458|NCT00829621|Active Comparator|75 mmHg suction|IVAC suction 75 mmHg
3251459|NCT00829621|Experimental|125 mmHg suction|IVAC suction 125 mmHg
3251460|NCT00829608|Experimental|Human Papillomavirus Vaccine|There are 9 participants currently being followed in the faculty sponsor's clinic that carry the clinical and histologic diagnosis of RRP. The 9 participants meet one or more of the following criteria: Surgery requirement of more than 4 procedures per year, distal multisite spread of disease, and rapid regrowth of papilloma disease with airway compromise.
3251461|NCT00829595|Experimental|1|IBD, on both an anti-TNF agent and an immunomodulator
3251462|NCT00829595|Experimental|2|IBD, not on any immunosuppressive medications
3251463|NCT00829595|Active Comparator|3|Healthy, non-IBD, not on immunosuppressive medications (control arm)
3251464|NCT00829582|Experimental|ETI-204|ETI-204, Anthim
3251465|NCT00829582|Sham Comparator|placebo|
3251466|NCT00829569|Experimental|Intralipid with/without Omegaven|Lipid infusion with/without marine n-3 fatty acids
3251467|NCT00829556|Experimental|1|
3251468|NCT00829556|No Intervention|2|Standard Surgical skin preparation
3251469|NCT00829543|Experimental|sacroiliac injection|an open label study designed to evaluate the efficacy and safety of guide-free sacroiliac injection in refractory sacroiliac pain due to spondyloarthropathies
3251470|NCT00829530|Experimental|1|
3251471|NCT00829530|Active Comparator|2|
3251472|NCT00829517|Active Comparator|STI kiosk|computer-assisted provision of screening for chlamydia
3251473|NCT00829517|Experimental|contraceptive kiosk|computer-assisted provision of hormonal contraception
3251474|NCT00829504|Experimental|1|
3251475|NCT00829504|Active Comparator|2|
3251476|NCT00829478|Placebo Comparator|1|Usual Care
3251477|NCT00829478|Experimental|2|Intervention
3251478|NCT00829465|Active Comparator|control|
3251479|NCT00829465|Experimental|therapy|
3251480|NCT00829452|Experimental|1|
3251481|NCT00829452|Active Comparator|2|
3251482|NCT00829439|Experimental|Levodopa/Carbidopa|"Other Names:~Sinemet L-dopa~Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
3251483|NCT00829426|Experimental|Alprazolam|Alprazolam 3mg ER Tablet (test) dosed in first period followed by Xanax XR® 3 mg Tablet (reference) dosed in second period
3251484|NCT00829426|Active Comparator|Xanax XR®|Xanax XR® 3 mg Tablet (reference) dosed in first period followed by Alprazolam 3 mg ER Tablet (test) dosed in second period
3251550|NCT00828932|Experimental|Lorcaserin 10mg|
3251551|NCT00828919|Other|axitinib|
3251552|NCT00828906|Experimental|1|DuoTrav
3251553|NCT00828880||DRX9000|
3251485|NCT00829413|Other|Patients who received SonoVue|"Patients with at least one target lesions requiring work-up for characterization to undergo~Unenhanced ultrasound of the target lesion (UE-US): gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion using commercially available ultrasound equipment and standard techniques (B-mode or Harmonic imaging) to study the anatomy of the target lesion and surrounding parenchyma;~SonoVue-enhanced ultrasound of the target lesion (CE-US):procedures described in protocol Section 7.5.1.2, to study the lesion vascularity in comparison to the surrounding parenchyma; and~Truth standard~2.4 mL of sulfur hexafluoride microbubbles (SonoVue®) will be administered as a bolus injection in a peripheral vein."
3251486|NCT00829400|Experimental|Posit Science|Brain Fitness, Insight, and Aristotle Cognitive Software Training Suites Targeting 100 hours of training
3251487|NCT00829400|Active Comparator|Nintendo Brain Age|Brain Age 2 Nintendo DS Portable Device for home or office use, targeting 100 hours of training
3251488|NCT00829387|Experimental|Behavioral|Cognitive behavioral therapy - Ten sessions of individual treatment delivered by a doctoral level psychologist.
3251489|NCT00829387|Active Comparator|Educational|Diabetes Education - Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator
3251490|NCT00829374|Experimental|1|Dimebon, 5 mg orally three times daily
3251491|NCT00829374|Experimental|2|Dimebon, 20 mg orally three times daily
3251492|NCT00829374|Placebo Comparator|3|Placebo orally three times daily
3251493|NCT00829361|Other|Telemedicine|
3251494|NCT00829348|No Intervention|Statins, counseling|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
3251495|NCT00829348|Experimental|Statins, Counselling, SMS|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
3251496|NCT00829335||HCC patients|According with the investigators previously reported selection flow-chart , patients suitable for surgical approach were those with HCC without ascites, without or with esophageal varices for which preoperative endoscopic eradication could be carried out successfully, and with serum bilirubin level lower than 1.5 mg/dl. Potential candidates to systematic segmental or subsegmental resection by IOUS-guided finger compression were considered patients with single HCC located in one or 2 adjacent segments without portal thrombosis, and anyway not demanding for its complete removal a sectional resection or wider.
3251497|NCT00829322|Experimental|Treatment group|
3251498|NCT00829322|Placebo Comparator|Control group|
3251499|NCT00829309|Experimental|Pravastatin|Pravastatin 80 mg Tablet (test) dosed in first period followed by Pravachol® 80 mg Tablet (reference) dosed in second period
3251500|NCT00829309|Active Comparator|Pravachol®|Pravachol® 80 mg Tablet (reference) dosed in first period followed by Pravastatin 80 mg Tablet (test) dosed in second period
3251501|NCT00829296|Experimental|nebivolol|Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
3251502|NCT00829296|Active Comparator|Metoprolol|Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
3251503|NCT00829283|Active Comparator|1|Standard Care
3251504|NCT00829283|Experimental|2|Stepped-care
3251505|NCT00829270||mitochondrial diseases diagnosis|
3251506|NCT00829257|Experimental|Fine particle steroid inhaler|HFA-BDP plus Fluticasone/Salmeterol Combination
3251507|NCT00829257|Active Comparator|Coarse Particle Inhaler|FP plus Fluticasone/Salmeterol combination
3251508|NCT00829244|Experimental|CONSORT Dosing|GONAL-f® dose based on subject baseline characteristics determined according to the CONSORT calculator
3251509|NCT00829244|Active Comparator|Standard Dosing|GONAL-f® at a standard dose of 150 IU per day
3251510|NCT00829231|Experimental|Arm 1|
3251511|NCT00829231|Experimental|Arm 2|
3251512|NCT00829231|Experimental|Arm 3|
3251513|NCT00829218|Active Comparator|1 - Glutamate challenge|Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 1 is the 5 grams of glutamate which will be given in a mixed juice.
3251514|NCT00829218|Placebo Comparator|2- Placebo|Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 2 is the placebo arm, which will be juice with nothing added.
3251515|NCT00829192|Experimental|1|Afamelanotide (CUV1647) implant administered subcutaneously every 60 days for 24 months
3251516|NCT00829192|Placebo Comparator|2|Placebo implant administered subcutaneously every 60 days for 24 months
3251517|NCT00829166|Experimental|Trastuzumab emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
3251518|NCT00829166|Active Comparator|Lapatinib + Capecitabine|Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.
3251519|NCT00829153|Experimental|U clip|Anastomosis with U clips
3251520|NCT00829153|Active Comparator|2|Prolene anastomosis
3251521|NCT00829140|Placebo Comparator|Placebo BID|
3251522|NCT00829140|Experimental|Lorcaserin 10mg BID|
3251523|NCT00829127|Experimental|1|
3251524|NCT00829127|Placebo Comparator|2|
3251525|NCT00829114|Active Comparator|1|ART/COC group
3251526|NCT00829114|Active Comparator|2|COC group
3251527|NCT00829101||1 One-stage repair|A consecutive group of children born with unilateral cleft lip and palate from the south region of Sweden, in all 10 children, who have had a primary palatal surgery at 12 months of age.
3251554|NCT00828867|Experimental|Cohort 1|100mg
3251555|NCT00828867|Experimental|Cohort 2|200mg
3251556|NCT00828867|Experimental|Cohort 3|400mg
3251557|NCT00828867|Experimental|Cohort 4|800mg
3251528|NCT00829101||2 Two-stage repair, early closure|A consecutive group of children born with unilateral cleft lip and palate from the western region of Sweden, in all 10 children, who have had a two-stage palatal surgery, with soft palate closure at 4-6 months and repair of the hard palate at 12 months of age.
3251529|NCT00829101||3 Two-stage repair, delayed closure|A consecutive group of children born with unilateral cleft lip and palate from the western region of Sweden, in all 10 children, who have have had a two-stage palatal surgery, with soft palate closure at 4-6 months and repair of the hard palate at 36 months of age.
3251530|NCT00829075|Experimental|I|only r-FSH TREATMENT
3251531|NCT00829075|Experimental|II|only HP-hMG TREATMENT
3251532|NCT00829075|Experimental|III|r-FSH plus HP-hMG TREATMENT
3251533|NCT00829062|No Intervention|Glucose sensor|Children who have assented to wear a 72 hour physician ordered continuous glucose monitor.
3251534|NCT00829049|Active Comparator|Tazarotene Cream 0.1%|1 pea-size amount, QD x 16 weeks
3251535|NCT00829049|Active Comparator|Adapalene Gel 0.3%|1 pea-size amount, QD x 16 weeks
3251536|NCT00829036|Experimental|Wayfinding Prototype|A Wayfinding Prototype is evaluated in terms of the time it takes subjects to use this device to walk to specific indoor locations versus baseline walking time.
3251537|NCT00829023|Experimental|betadine, DuraPrep, ChloraPrep|surgical skin preparation solution
3251538|NCT00829010|Experimental|HIV+/+ Group|Infants born from a HIV positive mother and confirmed as HIV infected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered intramuscularly in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
3251539|NCT00829010|Experimental|HIV+/- Group|Infants born from a HIV positive mother and confirmed as HIV exposed uninfected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
3251540|NCT00829010|Experimental|HIV- (3+1) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
3251541|NCT00829010|Experimental|HIV- (EPI) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected.Subjects received 3 primary doses of Synflorix™ vaccine (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
3251542|NCT00829010|Experimental|HIV- (2+1) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected.Subjects received 2 primary doses (at 6 & 14 weeks of age at study Months 0 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
3251543|NCT00828997|Active Comparator|Prevenar vaccine|
3251544|NCT00828984|Experimental|Arm A (high-dose PEG 3350)|Patients receive high-dose macrogol 3350-based oral osmotic laxative PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
3251545|NCT00828984|Experimental|Arm B (low-dose polyethylene glycol)|Patients receive low-dose macrogol 3350-based oral osmotic laxative PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
3251546|NCT00828984|Placebo Comparator|Arm C (placebo)|Patients receive placebo PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
3251547|NCT00828971|Experimental|Arm 1|
3251548|NCT00828971|Active Comparator|Arm 2|
3251549|NCT00828945||Hyperlipidemic Patients|
3251558|NCT00828867|Experimental|Cohort 5|1500mg
3251559|NCT00828867|Experimental|Cohort 6|2000mg
3251560|NCT00828867|Experimental|Cohort 7|800mg with food
3251561|NCT00828867|Experimental|Cohort 8|3000mg
3251562|NCT00828867|Experimental|Cohort 9|4000mg
3251563|NCT00828854|Experimental|treatment|Continued treatment with same AI at labeled dose and schedule, plus Entinostat (5mg PO every week)
3251564|NCT00828841|Active Comparator|Paclitaxel, Carboplatin, Cetuximab (Arm A)|Patients with squamous or non-squamous histologies will receive carboplatin and paclitaxel for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion.
3251565|NCT00828841|Active Comparator|Platinum, Gemcitabine, Cetuximab (Arm B)|Patients with squamous or non-squamous histologies will receive gemcitabine with either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion.
3251566|NCT00828841|Active Comparator|Platinum, Pemetrexed, Cetuximab (Arm C)|Patients with squamous histology will receive pemetrexed and either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion. Patients with non-squamous histology are not eligible for this arm.
3251567|NCT00828828||Sarcoidosis|Sarcoidosis patients who are assigned to receive influenza vaccine
3251568|NCT00828828||Healthy Controls|Healthy controls who are assigned to receive influenza vaccine
3251569|NCT00828802|Experimental|Cohort 1|Lenalidomide (5mg) and Decitabine
3251570|NCT00828802|Experimental|Cohort 2|Lenalidomide (10 mg) and Decitabine
3251571|NCT00828802|Experimental|Cohort 3|Lenalidomide (15 mg) and Decitabine
3251572|NCT00828802|Experimental|Cohort 4|Lenalidomide (20 mg) and Decitabine
3251573|NCT00828802|Experimental|Cohort 5|Lenalidomide (25 mg) and Decitabine
3251574|NCT00828776|Experimental|1|Heparin Cristália
3251575|NCT00828776|Active Comparator|2|Heparin - Roche
3251576|NCT00828763|Experimental|1|[14C]-GSK1349572 administered as a single oral dose
3251577|NCT00828750|Experimental|Treatment|Eltrombopag oral tablets once daily
3251578|NCT00828737|Experimental|Arm 1|
3251579|NCT00828724|Experimental|Lorcaserin 10mg|
3251580|NCT00828711|Experimental|MVI 100|MVI 100 mcg vaginal insert
3251581|NCT00828711|Experimental|MVI 150|MVI 150 mcg vaginal insert
3251582|NCT00828711|Experimental|MVI 200|MVI 200 mcg vaginal insert
3251583|NCT00828698||Acute Myocardial Infarction patients|
3251584|NCT00828685|Active Comparator|Operative (CRPP)|If indicated, the wrist fracture would be treated with surgery-the specific operative procedure would be randomized.
3251585|NCT00828685|Active Comparator|Operative (ORIF)|If indicated, the wrist fracture would be treated with surgery-the specific operative procedure would be randomized
3251586|NCT00828672|Active Comparator|AXE (ARM 1)|Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.
3251587|NCT00828672|Active Comparator|AX (ARM 2)|Bevacizumab and Capecitabine concurrently with radiotherapy
3251588|NCT00828659|Placebo Comparator|Placebo|
3251589|NCT00828659|Active Comparator|Active Comparator #1|
3251590|NCT00828659|Active Comparator|Active Comparator #2|
3251591|NCT00828659|Active Comparator|Active Comparator #3|
3251592|NCT00828659|Experimental|Lorcaserin Dose #1|
3251593|NCT00828659|Experimental|Lorcaserin Dose #2|
3251594|NCT00828659|Experimental|Lorcaserin Dose #3|
3251595|NCT00828646|Experimental|BMS-708163 - Panel 1|(Age 20-45 years)
3251596|NCT00828646|Experimental|BMS-708163 - Panel 2|(Age 20-45 years)
3251597|NCT00828646|Experimental|BMS-708163 - Panel 3|(age 65 or above)
3251598|NCT00828646|Experimental|BMS-708163 - Panel 4|(age 65 or above)
3251599|NCT00828620||PET-CT|Patients with Unresectable stage IV colorectal cancer; eligible for 3rd line Irinotecan and Cetuximab
3251600|NCT00828607||liver mass|The group will comprise any patients with an unknown liver mass at the time of diagnostic imaging.
3251601|NCT00828594|Experimental|Phase 1: RAD001 plus sorafenib|
3251602|NCT00828581|Experimental|Lorcaserin|
3251603|NCT00828568|Experimental|Imiquimod 5% Taro|Imiquimod 5% manufactured by Taro applied for 16 weeks
3251604|NCT00828568|Active Comparator|Aldara - Imiquimod 5%|Aldara, Imiquimod 5% applied for 16 weeks
3251605|NCT00828568|Placebo Comparator|Vehicle|Imiquimod vehicle applied for 16 weeks
3251606|NCT00828542|Experimental|etonogestrel implant|Etonogestrel releasing contraceptive implant (Implanon®, NV Organon, Oss, The Netherlands) inserted 24-48 h after delivery. It is compounded by 68mg of etonogestrel, 3years of duration.
3251607|NCT00828542|Active Comparator|depot medroxyprogesterone acetate|At the 6th week postpartum, this group received intramuscular 150 mg of depot medroxyprogesterone acetate (Contracept®, EMS Sigma Pharma, Hortolandia, Brazil).
3251608|NCT00828516|Experimental|Usual treatment plus acupuncture|Acupuncture and moxibustion, individualised according to participant priorities, delivered once weekly for 7 treatments (Series 1) followed by 6 treatments (Series 2) if participant wishes to continue treatment
3251609|NCT00828503|Active Comparator|1 Certican + Valganciclovir|Valganciclovir will be administered and Certican (everolimus) will be added as immunosuppression
3251610|NCT00828503|Active Comparator|2 Valganciclovir alone|Valganciclovir will be added alone.
3251611|NCT00828490||Pediatric Asthmatics|Medicaid beneficiaries ≤21 years of age who meet the HEDIS criteria for persistent asthma
3253003|NCT00818493|Experimental|1|Q8003, flexible ascending dose
3251612|NCT00828490||Antipsychotic Therapy|Medicaid beneficiaries ≥18 years of age and enrolled ≥6 months of the past 12 months with enrollment in at least one of the past 3 months and ≥3 antipsychotic Rx within past 12 months
3251613|NCT00828490||Bipolar Therapy|Medicaid beneficiaries ≥18 years of age and enrolled ≥6 months of the past 12 months with enrollment in at least one of the past 3 months and a diagnosis of Bipolar in past 3 years, and ≥ 1 antidepressant Rx in past 6 months, and no mood stabilizer in past 6 months.
3251614|NCT00828490||Opioid Therapy|"Medicaid beneficiaries ≥18 years and enrolled ≥6 of prior 12 months with enrollment in ≥1 of prior 3 months and ≥1 opioid fill in prior 3 months and none of the following in prior 12 months:~Hospice CPT code or Primary diagnosis of cancer or Oncology CPT code"
3251615|NCT00828490||Fraud and Abuse|Medicaid beneficiaries who filled at least 3 opioid Rx in the last 12 months
3251616|NCT00828490||Pediatric Antipsychtotic Therapy|Medicaid beneficiaries <18 years of age with at least 3 antipsychotic Rx's in the past year.
3251617|NCT00828477|Active Comparator|1|Xibrom (bromfenac)
3251618|NCT00828477|Active Comparator|2|Nevanac (nepafenac)
3251619|NCT00828464|Experimental|clobetasol propionate foam|All subjects receive clobetasol propionate
3251620|NCT00828451|Experimental|Preterm Infants for EGF Profiles|Premature infants born at < 32 weeks gestation who are 7 days old or less. Infants received and intravenous infusion of [5,5,5-2H3]leucine (stable isotope labeled leucine) with sampling of blood, urine and saliva.
3251621|NCT00828438|Experimental|Lorcaserin 10mg|
3251622|NCT00828425||1|Diabetic patients with retinopathy
3251623|NCT00828412|Active Comparator|1|EpiCeram Skin Barrier Emulsion
3251624|NCT00828412|Active Comparator|2|Desonide Cream 0.05%
3251625|NCT00828399|Experimental|Glutamine|
3251626|NCT00828399|Placebo Comparator|Whole protein|
3251627|NCT00828386|Experimental|Induction chemotherapy + concurrent chemoradiotherapy|"Induction chemotherapy (Docetaxel + Cisplatin + 5-FU):~Docetaxel 75 mg/m² administered on D1 of each course, every 3 weeks, via one-hour IV infusion~Cisplatin 75 mg/m² administered on D1 via one-hour infusion followed by~5-Fluorouracil (as a continuous infusion): 750 mg/m²/d administered as a continuous infusion from D1 to D5.~The cycles will be repeated every 3 weeks up to a total of 3 courses. Followed by concurrent chemoradiotherapy with Cisplatin : weekly Cisplatin 40 mg/m2 starting on D1 of the radiation therapy (70 Gy/7 weeks)."
3251628|NCT00828386|Active Comparator|Concurrent radiochemotherapy alone|Concurrent chemoradiotherapy with Cisplatin : weekly Cisplatin 40 mg/m2 starting on D1 of the radiation therapy (70 Gy/7 weeks).
3251629|NCT00828373|Placebo Comparator|Placebo|
3251630|NCT00828373|Active Comparator|Lidocaine|
3251631|NCT00828347|Other|1.0 μg/day Alfacalcidol|Alfacalcidol 1.0 μg capsule by mouth, every day for 6 months
3251632|NCT00828347|Other|0.25 μg/day Alfacalcidol|Alfacalcidol 0.25 μg capsule by mouth, every day for 6 months
3251633|NCT00828334|Experimental|Transcatheter PDA Coil|Transcatheter occlusion of Patent Ductus Arteriosus (PDA) with the flex and medium Nit-Occlud PDA.
3251634|NCT00828321|Experimental|1|
3251635|NCT00828321|Active Comparator|2|
3251636|NCT00828308|Experimental|Ixabepilone|"Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.~Prostatectomy 2-8 weeks after completion ***this was standard of care and not a part of the study***"
3251637|NCT00828295|Experimental|1 mcg/kg arm|Single dose IV Palonosetron 1 mcg/kg (up to a maximum total dose of 0.075 mg)
3251638|NCT00828295|Experimental|3 mcg/kg arm|Single dose IV Palonosetron 3 mcg/kg (up to a maximum total dose of 0.25 mg)
3251639|NCT00828282|Experimental|1|
3251640|NCT00828269|No Intervention|1|Liver tissue biopsy
3251641|NCT00828243||Case-control|Infants with varying degrees of neonatal respiratory distress syndrome
3251642|NCT00828243||Nutrient|Infants up to 6 months of age with varying severity of respiratory distress receive stable isotopically labeled nutrients (precursors of surfactant phospholipids or proteins) to permit mass spectrometry-based measurement of surfactant kinetics.
3251643|NCT00828230|Experimental|1|2mg rectal budesonide per day for 8 weeks
3251644|NCT00828230|Placebo Comparator|2|One application of placebo foam once daily for 8 weeks
3251645|NCT00828217|Experimental|with APA|Children have adapted physical activity during their hospitalization
3251646|NCT00828217|No Intervention|without APA|Children don't have adapted physical activity during their hospitalization
3251647|NCT00828204|Experimental|Avonex Single-Use Autoinjector|"Participants received open label weekly treatment with Avonex 30 mcg intramuscular (IM) injections, provided in Avonex prefilled syringes.~In the Main Study, injection #1: administration of Avonex prefilled syringe via manual IM injection on Day 1. Injections #2, #3, and #4: administration of Avonex prefilled syringe using the single-use autoinjector on Days 8, 15, and 22, respectively. In the Extension Study, participants were to continue treatment with the Avonex single-use autoinjector for up to an additional 12 weeks."
3251648|NCT00828191|Experimental|Progesterone SC|
3251649|NCT00828191|Active Comparator|Progesterone Tablets|
3251650|NCT00828178|Active Comparator|Omega-3|3 g of Omega-3 (1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid ethyl esters); flow-mediated dilation of the brachial artery
3251651|NCT00828178|Placebo Comparator|corn starch|corn starch; flow-mediated dilation of the brachial artery
3251652|NCT00828165|Experimental|ARRY-300|
3251653|NCT00828165|Placebo Comparator|Placebo|Placebo
3251654|NCT00828152|Experimental|1|Internet-delivered CBT. Contact with therapist thru an e-mail system. 12 weeks.
3251655|NCT00828152|Placebo Comparator|2|On line discussion group.
3251656|NCT00828139|Experimental|Arm I (ziv-aflibercept, topotecan hydrochloride)|Patients receive ziv-aflibercept IV over 1 hour on day 1 and topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after 4 courses may then receive ziv-aflibercept IV on day 1 and topotecan hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3251704|NCT00827736|Experimental|Botox injection|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline. In addition, a placebo ointment has to be applied to the anoderm six times a day
3253004|NCT00818493|Experimental|2|Low dose Q8003
3251657|NCT00828139|Active Comparator|Arm II (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after 4 courses may then receive topotecan hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3251658|NCT00828126||PET-CT Scan|
3251659|NCT00828113|Experimental|Extended treatment|52-week varenicline therapy + individual smoking cessation counseling
3251660|NCT00828113|Active Comparator|Standard treatment|13 weeks of varenicline therapy + individual smoking cessation counseling
3251661|NCT00828087|Experimental|Everolimus Arm|Everolimus Eluting Coronary Stent System
3251662|NCT00828087|Active Comparator|non drug eluting stent Arm|cobalt chromium balloon expandable stent
3251663|NCT00828074|Experimental|Treatment (vinorelbine tartrate and sorafenib tosylate)|Patients receive sorafenib tosylate PO twice daily on days 1-28 and vinorelbine ditartrate IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3251664|NCT00828061|Placebo Comparator|A|placebo
3251665|NCT00828061|Active Comparator|B|10 mg prednisone
3251666|NCT00828061|Active Comparator|C|25 mg prednisone
3251667|NCT00828048||Pancreatic Cyst|Pancreatic Cyst
3251668|NCT00828035|Other|1, REL|rel group : patients with light endoscopic robot
3251669|NCT00828035|Active Comparator|2, AO|AO group : Patients with surgery assistant
3251670|NCT00827983|Experimental|Progesterone SC|
3251671|NCT00827983|Active Comparator|Progesterone Vaginal gel|
3251672|NCT00827970|Experimental|1 Screening|Individuals receiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
3251673|NCT00827970|No Intervention|2 Control|Control group receiving usual care
3251674|NCT00827957|Active Comparator|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
3251675|NCT00827957|Active Comparator|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
3251676|NCT00827944|Active Comparator|1|Parietex ProGrip
3251677|NCT00827944|Active Comparator|2|Low weight polypropylene mesh
3251678|NCT00827931|Experimental|A|end of the operation and on the mornings of the first, second, fourth and seventh postoperative days.
3251679|NCT00827931|Other|B|Standard of Care
3251680|NCT00827918|Experimental|MK-8998|MK-8998, 6 mg twice a day (BID) for Days 1 to 7, and 8 mg BID thereafter for a 4-week total treatment period
3251681|NCT00827918|Active Comparator|Olanzapine|Olanzapine, 5 mg BID for Day 1 to 7, and 15 mg (5 mg in the morning and 10 mg in the evening) thereafter for a 4-week total treatment period
3251682|NCT00827918|Placebo Comparator|Placebo|Placebo Comparator to MK-8998 or olanzapine
3251683|NCT00827905||Hospitalized|Patients admitted to the hospital
3251684|NCT00827892|Experimental|1|
3251685|NCT00827892|Placebo Comparator|2|
3251686|NCT00827879|Experimental|Strength at Home Couples Group|PTSD-Focused Cognitive Behavioral Therapy for Couples
3251687|NCT00827879|Placebo Comparator|Supportive Group Therapy|Supportive therapy for couples
3251688|NCT00827866|Other|1|Counselor-Initiated Tobacco Quit Line Group QL where the counselor contacts the client with a standardized intervention protocol)
3251689|NCT00827866|Other|2|Self-Paced Tobacco Quit Line Group which leaves the calling up to participants
3251690|NCT00827853|Experimental|1|Conventional angioplasty balloon post-dilation of nitinol self expanding stents
3251691|NCT00827853|Experimental|2|Cryoplasty balloon post-dilation
3251692|NCT00827840|Experimental|1. Paliperidone ER|New antipsychotics
3251693|NCT00827840|Active Comparator|2 Risperidone|
3251694|NCT00827827|Experimental|Arm 1|Participants in this group undergo lower-extremity strength training on three pneumatic resistance machines (Keiser Leg Press, Keiser Leg Extension, and Keiser Leg Curl). Training sessions happen 3 times per week (M,W,F) and last approximately 45 minutes to 1 hour. Participants in this group exercise each limb individually to account for the large discrepancies in strength between legs in stroke survivors.
3251695|NCT00827827|Active Comparator|Arm 2|Participants in this group receive equal exposure to study staff compared with the experimental ST group (approximately 45 minutes to 1 hour 3 times per week). Exercise sessions for this group involve a full battery of active and passive...upper and lower body...stretching and range of motion exercises performed on raised padded tables.
3251696|NCT00827814|Experimental|Dutasteride|
3251697|NCT00827801||Group 1|MDASI-HF questionnaire provided to Doctor for symptom management.
3251698|NCT00827801||Group 2|MDASI-HF questionnaire collected not provided to Doctor.
3251699|NCT00827788|Active Comparator|iodixanol|Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
3251700|NCT00827788|Active Comparator|iopromide|Low-osmolar contrast medium (Iopromide) will be administered during PCI
3251701|NCT00827775|No Intervention|Control|Patients without intradialytic hypertension defined as average pre to post hemodialysis SBP falling >10 mmhg for more than 4/6 of the last dialysis treatment sessions
3251702|NCT00827775|Active Comparator|Intervention|Patients with intradialytic hypertension defined as average pre to post hemodialysis SBP elevation of >10 mmhg for more than 4/6 of the last dialysis treatment sessions
3251703|NCT00827762||Phenylketonuria|Individuals with mild phenylketonuria/hyperphenylalanemia who are beginning treatment with Kuvan.
3251705|NCT00827736|Active Comparator|ISDN ointment|application of ISDN 1% ointment 6 times a day. injection of placebo into internal anal sphincter
3251706|NCT00827723||Alcoholic|Alcoholic cirrhotic patient with resectable hepatocellular carcinoma
3251707|NCT00827723||Viral|Viral cirrhotic patient with resectable hepatocellular carcinoma
3251708|NCT00827710|Active Comparator|1|patients who received point-of-care report cards and were listed on provider performance report card
3251709|NCT00827710|Active Comparator|2|Patients who received point-of-care diabetes report cards but were not listed on provider performance report card
3251710|NCT00827710|Active Comparator|3|Patients who did not receive point-of-care report card but who were listed on provider performance report card
3251711|NCT00827710|No Intervention|4|Patients who did not receive point of care report card and who did were not listed on provider performance report card
3251712|NCT00827684|Active Comparator|Response or stable disease|will receive Temsirolimus
3251713|NCT00827684|Experimental|Progression|Will receive a combination of Temsirolimus and Irinotecan
3251714|NCT00827671|Other|Pre-operative chemotherapy|
3251715|NCT00827658|Active Comparator|Hypothenar Palm block|Hypothenar Palmar block group. Local anesthetic is placed at this location in this study group. The same local composition (Intervention) is used for both study groups. The trial is a comparison of location not the Intervention.
3251716|NCT00827658|Active Comparator|Volar Wrist Block|Volar Wrist block group. Local anesthetic is placed at this location in this study group. The same local composition (Intervention) is used for both study groups. The trial is a comparison of location not the Intervention.
3251717|NCT00827645||Uterine artery embolization|Women with symptomatic uterine fibroids scheduled for uterine artery embolization
3251718|NCT00827632|Active Comparator|Normal Weight group|Participants with a BMI of 19-24.9 kg/m^2
3251719|NCT00827632|Active Comparator|Obese group|Participants with a BMI of 30-39.9 kg/m^2
3251720|NCT00827619|Other|1|single arm non-randomized post-market study
3251721|NCT00827606|Experimental|Atorvastatin|All subjects will be treated with atorvastatin
3251722|NCT00827593|Active Comparator|Standard behavioral weight loss|University-based behavioral weight loss treatment
3251723|NCT00827593|Active Comparator|Weight Watchers|Weight Watchers program
3251724|NCT00827593|Active Comparator|Combined Treatment|University-based behavioral weight loss treatment followed by Weight Watchers
3251725|NCT00827580|Experimental|Eniluracil|
3251726|NCT00827567|Experimental|RAD 001|RAD001-10 mg by mouth once everyday
3251727|NCT00827554|Experimental|LMWH plus TACE|50 HCC patients will be allocated to receive Nadroparin 4100 AXa iu twice daily 3 days after TACE which lasted for 6 weeks
3251728|NCT00827554|Active Comparator|TACE alone|50 HCC patients randomly assigned to receive TACE without LMWH
3251729|NCT00827541||1|Patients hospitalized because of cIAI or cSSTI
3251730|NCT00827528|Experimental|SIS graft|this group will use a biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.
3251731|NCT00827528|Active Comparator|2|this group will use a traditional repair on correction of anterior vaginal wall prolapse.
3251732|NCT00827515|Experimental|One|
3251733|NCT00827515|Experimental|Two|
3251734|NCT00827515|Experimental|Three|
3251735|NCT00827515|Experimental|Four|
3251736|NCT00827489|Experimental|HTC-867|
3251737|NCT00827489|Placebo Comparator|Placebo|
3251738|NCT00827476|Experimental|ovarian transplantation|tissue will be used for xenotransplantation or in vitro culture
3251739|NCT00827463|Experimental|NFS and iron in the first quater|first arm: dosage NFS and iron during the beginning of the pregnancy then in the sixth month of pregnancy then in th delivery.
3251740|NCT00827463|Experimental|No NFS and iron in the first quater|second arm: dosage NFS and iron during the sixth month of pregnancy then in th delivery. No dosage of NFS and iron during the beginning of the pregnancy
3251741|NCT00827450|Placebo Comparator|Ctl|control isocaloric diet; no coffee
3251742|NCT00827450|Placebo Comparator|HF|Hypercaloric. high fructose diet; no coffee
3251743|NCT00827450|Experimental|C1|Hypercaloric, high fructose diet; caffeine-free, torrefied coffee
3251744|NCT00827450|Experimental|C2|Hypercaloric, high fructose diet; caffeine-free, partially torrefied coffee
3251745|NCT00827450|Experimental|C3|Hypercaloric, high fructose diet; caffeinated, partially torrefied coffee
3251746|NCT00827437|Other|1|
3251747|NCT00827424|Experimental|1|This arm will receive Lifestyle counseling by applying a modified PACE protocol
3251748|NCT00827424|No Intervention|2|Subject in this arm will be recruited but will receive no intervention
3251749|NCT00827411|Experimental|1: Monitoring Arm|"First randomization:~Monitoring Arm: dose adjustment of both aspirin and clopidogrel in suboptimal responders identified based on a point of care assay (VerifyNow)."
3251750|NCT00827411|Active Comparator|2: Conventional Arm|"First randomization:~Conventional Arm: fixed dose regiment of both aspirin and clopidogrel in all patients following DES implantation according to international guidelines"
3251751|NCT00827411|Experimental|3: Pursuit Arm|"Second randomization after one year of follow-up:~Pursuit Arm: Pursuit of a dual oral antiplatelet therapy (aspirin and clopidogrel) beyond one year"
3251752|NCT00827411|Active Comparator|4: Interruption Arm|"Second randomization after one year of follow-up:~Interruption Arm: Interruption of clopidogrel therapy."
3251753|NCT00827385||hypertensive|
3251754|NCT00827385||normotensive|
3251755|NCT00827372|Experimental|Pazopanib Treatment|Pazopanib 800 mg orally once each day (maximum total duration of treatment = 24 weeks)
3251756|NCT00827359|Experimental|Treatment|This is a single-arm study. All patients will receive everolimus.
3251757|NCT00827346|Active Comparator|Group 1|600-mg double dose
3251758|NCT00827346|Active Comparator|Group 2|600/600-mg double loading dose (first dose 600 mg given immediately upon arrival at the hospital and the second dose 600 mg, 3 hours after the first loading dose for a total of 900 mg
3251759|NCT00827346|Active Comparator|Group 3|Clopidogrel 900mg
3251760|NCT00827346|Active Comparator|Group 4|First dose 600 mg given immediately upon arrival at the hospital and the second dose 300 mg, 3 hours after the first loading dose for a total of 900 mg
3251761|NCT00827333|No Intervention|Phase I-Usual Care|
3251762|NCT00827333|Active Comparator|Phase 2 - Intervention|
3251763|NCT00827307|Experimental|Combination|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg.
3251764|NCT00827307|Active Comparator|Conctrol|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
3251765|NCT00827281|Experimental|1|DCS-augmented CBT for smoking cessation
3251766|NCT00827281|Placebo Comparator|2|Placebo-augmented CBT for smoking cessation
3251767|NCT00827268|Other|Arm 1|Repeated probes every 8 hours of treatment (1/week)
3251768|NCT00827255||Patients who received Restasis®|Patients who received Restasis® (cyclosporine ophthalmic emulsion 0.05%)
3251769|NCT00827242|Experimental|Tadalafil|
3251770|NCT00827242|Placebo Comparator|Placebo|
3251771|NCT00827229|Other|LaborPro, active Labor, Vaginal Examination|
3251772|NCT00827216|Placebo Comparator|Physiologic saline|
3251773|NCT00827216|Active Comparator|Erythromycine|
3251774|NCT00827203|Experimental|Cohort|
3251775|NCT00827190|Experimental|1|ILS-920
3251776|NCT00827177|Experimental|ARQ 197 in combination with sorafenib|
3251777|NCT00827164|Experimental|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
3251778|NCT00827164|Other|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
3251779|NCT00827151|Active Comparator|Estrogen and lifestyle|
3251780|NCT00827151|No Intervention|Lifestyle|
3251781|NCT00827138|Experimental|DCC-2036|This is a single arm study
3251782|NCT00827112|Experimental|Arm A|maraviroc (Selzentry, Celsentri) 150 mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100mg QD Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, but expressing cosmetic concerns because of the jaundice or scleral icterus (associated with bilirubin elevations) and wish to discontinue atazanavir (Reyataz) in spite of reassurances by the investigator, will be permitted on a single occasion only to switch to another protease inhibitor either darunavir (Prezista)/ritonavir (Norvir)((800/100 mg) QD or lopinavir/ritonavir (Kaletra, Aluvia)(400/100mg) BID and remain in the study. If the investigator decides to switch to a protease inhibitor other than darunavir (Prezista)/ritonavir (Norvir) or lopinavir/ritonavir (Kaletra, Aluvia)(, then the subject must be discontinued from the study.
3251783|NCT00827112|Experimental|Arm B|"emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD~Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, but expressing cosmetic concerns because of the jaundice or scleral icterus (associated with bilirubin elevations) and wish to discontinue atazanavir in spite of reassurances by the investigator, will be permitted on a single occasion only to switch to another protease inhibitor either darunavir/ritonavir (800/100 mg) QD or lopinavir/ritonavir (400/100mg) BID and remain in the study. If the investigator decides to switch to a protease inhibitor other than darunavir/ritonavir or lopinavir/ritonavir, then the subject must be discontinued from the study."
3251784|NCT00827086||1|Patients with non-infectious Uveitis
3251785|NCT00827086||2|Patients with scleritis
3251786|NCT00827073|Active Comparator|Tetracaine 0.5% drop|Tetracaine 0.5% drop of betadine will be used on the operative eye after Tetracaine has been administered
3251787|NCT00827073|Active Comparator|Lidocaine 2% Jelly|Lidocaine 2% Jelly drop of betadine will be used on the operative eye after Lidocaine 2% Jelly has been administered
3251788|NCT00827047|Active Comparator|Total Hemihepatic Vascular Exclusion|Patients with HCC received Total Hemihepatic Vascular Exclusion in hepatectomy.
3251789|NCT00827047|Experimental|Hemihepatic vascular Clamping|Patients with HCC received Hemihepatic vascular Clamping in hepatectomy.
3251790|NCT00827047|Experimental|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
3251791|NCT00827034|Other|A|A: Warfarin alone
3251792|NCT00827034|Other|B|B: Dimebon and Warfarin co-administration
3251793|NCT00827021|Experimental|ESAs 1 low dose|
3251794|NCT00827021|Active Comparator|ESAs 2 high dose|
3251795|NCT00827008|Experimental|1, verum|
3251796|NCT00826995|Experimental|Video-based education arm:|Subjects receiving the video-based educational material
3251797|NCT00826995|Active Comparator|Written education arm:|Subjects receiving the written educational material
3251798|NCT00826982||Pancreatic Cancer|
3251799|NCT00826969|Active Comparator|1|Ciclesonide 320µg
3251800|NCT00826969|Placebo Comparator|2|Placebo
3251801|NCT00826943|Active Comparator|Levocetirzine|5 mg daily x 7 days (note = cross over = all participants receive active comparators and placebo)
3251802|NCT00826943|Active Comparator|cetirizine|10 mg daily x 7 days. Note = crossover study, so all participants recieve all active comparators and placebo.
3251803|NCT00826943|Placebo Comparator|placebo|one tablet daily x 7 days; note that this is a crossover study so all participants receive all active comparators and placebo
3251804|NCT00826930|Experimental|1A|0.5 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
3251805|NCT00826930|Experimental|2A|0.75 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
3251806|NCT00826930|Experimental|3A|1.0 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
3251807|NCT00826930|Experimental|4A|Dose of TSC either 0.5 mg/kg, 0.75 mg/kg, or 1.0 mg/kg based on the Data Monitoring Committee decision, anticonvulsants at Baseline - phenytoin only or none
3251808|NCT00826930|Experimental|1B|0.5 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
3251809|NCT00826930|Experimental|2B|0.75 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
3251810|NCT00826930|Experimental|3B|1.0 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
3251862|NCT00826501|Active Comparator|1|Endoscopic cyst-gastrostomy with a neurolytic block along with oral/transdermal analgesic therapy
3251811|NCT00826930|Experimental|4B|Dose of TSC either 0.5 mg/kg, 0.75 mg/kg, or 1.0 mg/kg based on the Data Monitoring Committee decision, anticonvulsants at Baseline - any except phenytoin-only or none
3251812|NCT00826917||Objective 1: XI VOCALTM in 3D fetal volumetry measurement|group 1: multiplanar; group 2: VOCALTM; group 3: XI VOCALTM
3251813|NCT00826917||Objective 2: XI VOCALTM in 3D placental volumetry measurement|group 1: multiplanar; group 2: VOCALTM; group 3: XI VOCALTM
3251814|NCT00826917||Objective 3: Comparison between 2 ultrasound machine|"intramachine reliability for (i)fetal, (ii)gestational sac and (iii)placenta volumetry measurement for (a)multiplanar and (b)VOCALTM:- group 1:Accuvix; group 2:Voluson 730~intermachine reliability for fetal, gestational sac and placenta volumetry measurement for (a)multiplanar and (b)VOCALTM for Accuvix and Voluson 730"
3251815|NCT00826917||Objective 4:3D volumetry in fetuses at risk of Hb Bart's|Measurement of fetal, gestational sac and placenta volume per CRL quotient using multiplanar technique:- group 1: affected; group 2: unaffected
3251816|NCT00826904||Lean|Healthy, pregnant women with BMI of 20 - 26 kg/m2
3251817|NCT00826904||Obese|Healthy, obese pregnant women with BMI 30 - 38 kg/m2
3251818|NCT00826878|Experimental|Tivozanib (AV-951)|
3251819|NCT00826839|Experimental|OCP/MDL|Oral contraceptive pills/microdose lupron
3251820|NCT00826839|Experimental|E2/antagonist|Estradiol patch/gonadotropin-releasing hormone antagonist
3251821|NCT00826826|Active Comparator|Amiodarone|
3251822|NCT00826826|Placebo Comparator|Placebo|
3251823|NCT00826813|Experimental|stenting|The conventional esophageal stent or 125I radiation stent is placed in the patients with dysphagia who are enrolled to the study.
3251824|NCT00826800|Experimental|Neoadjuvant FOLFOX Plus Bevacizumab|FOLFOX and bevacizumab will be given to colon cancer patients for 4 cycles over 8 weeks; an additional 2 cycles of FOLFOX without bevacizumab will be given for a total of 12 weeks of pre-operative chemotherapy.Restaging will be performed within 3 weeks of the 6th chemotherapy cycle. Colon surgery will be performed between weeks 3 and 6 subsequent to the 6th cycle of FOLFOX. Patients receiving preoperative chemotherapy without radiation will wait a minimum of 3 weeks from their last dose of chemotherapy, and 6 weeks from their last dose of bevacizumab, before proceeding to surgery. Specifically, it is intended that patients will undergo surgery between 3-6 weeks from completion of their neoadjuvant therapy as deemed clinically appropriate by their surgeon and medical oncologist. This permits a 7-10 week interval between the 4th bevacizumab administration and colon surgery.
3251825|NCT00826774|Active Comparator|Ususal Care|
3251826|NCT00826774|Experimental|Breif Lifestyle Counseling|
3251827|NCT00826774|Experimental|Enhanced Brief Lifestyle Counseling|
3251828|NCT00826761|Active Comparator|1|High dose Lb. casei
3251829|NCT00826761|Active Comparator|2|Low dose Lb. Casei
3251830|NCT00826761|Placebo Comparator|3|
3251831|NCT00826748|Experimental|Treated Smokers|The treatment with inhaled beclomethasone will be administered to this cohort from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days.
3251832|NCT00826748|No Intervention|Non-Treated Smokers|This cohort will act as control and include healthy smokers who receive no treatment.
3251833|NCT00826748|No Intervention|Non-Smokers|This cohort will act as control and include healthy non-smokers who receive no treatment.
3251834|NCT00826735|Experimental|Guided imagery|The experimental group received a relaxation focused guided imagery intervention to use through the remainder of pregnancy plus a physiologic guided imagery intervention during the third stage of labor. These interventions were scripted and prerecorded on CDs.
3251835|NCT00826709|Experimental|Arm 1|2 Nasal swabs
3251836|NCT00826709|Experimental|Arm 2|2 Nasopharyngeal swabs
3251837|NCT00826709|Experimental|Arm 3|Nasal wash or aspirate
3251838|NCT00826683|Other|Control group of healthy subjects|Control group of healthy subjects : simple blood analysis of EPCs
3251839|NCT00826683|Active Comparator|COPD|COPD: one initial blood sample and simple clinical follow-up
3251840|NCT00826683|Active Comparator|NSCLC|NSCLC: one initial blood sample and usual clinical follow-up
3251841|NCT00826670|Experimental|Topical decolonization|
3251842|NCT00826670|Placebo Comparator|Placebo|
3251843|NCT00826657|Placebo Comparator|placebo|Receive placebo (sugar pill) during the intervention. Received a 1000 mg vitamin B12 injection at the end of the study.
3251844|NCT00826657|Active Comparator|Vitamin B12|Received 500 micrograms vitamin B12 per day during the study Received a 1000 mg vitamin B12 injection at the start of the study
3251845|NCT00826644|Experimental|Belotecan|
3251846|NCT00826644|Active Comparator|Etoposide|
3251847|NCT00826631|Active Comparator|1|Fast food intake, doubling of caloric intake, in combination with sedentary behavior (no exercise)
3251848|NCT00826631|No Intervention|2|Control group, parallel
3251849|NCT00826618|Experimental|Ranibizumab|
3251850|NCT00826605||Urobilinogen increase|Increase in urobilinogen increase on routine dipstick test at prenatal appointment after 37 weeks gestation
3251851|NCT00826605||Weight Loss at Term|Weight loss since previous prenatal appointment after 37 weeks gestation
3251852|NCT00826592|Experimental|Video-based education arm|Subjects receiving the video-based educational material
3251853|NCT00826592|Active Comparator|Written education arm:|Subjects receiving the written educational material
3251854|NCT00826579|Experimental|Colon cancer|Colon cancer patients of all stages
3251855|NCT00826566|Active Comparator|1|500 mg caffeine capsules per day
3251856|NCT00826566|Placebo Comparator|2|500 mg placebo capsules
3251857|NCT00826553|Experimental|GABA agonist|
3251858|NCT00826553|Experimental|Alpha 2 agonist|
3251859|NCT00826540|Experimental|Treatment (sorafenib tosylate and bevacizumab)|Patients receive sorafenib tosylate orally twice daily on days 1-5 and 8-12 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Blood samples are collected at baseline and then periodically during study treatment for laboratory biomarker and pharmacogenetic studies
3251860|NCT00826514|Experimental|Tanezumab|
3251861|NCT00826514|Placebo Comparator|Placebo|
3251863|NCT00826501|Active Comparator|2|Surgical cyst-gastrostomy with neurolytic block and pain managed by only oral/transdermal analgesic
3251864|NCT00826488|Other|observational|Observational
3251865|NCT00826475|Experimental|Mindfulness|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
3251866|NCT00826475|Active Comparator|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
3251867|NCT00826462|Experimental|1|"Corticosteroid injection in combination with physical therapy~Injection with triamcinolone 10 mg and 10 mg of lidocaine at start and at 3 weeks in combination with physiotherapy for 6 weeks (12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises) Naprosyn Entero 500 mg bid for 14 days"
3251868|NCT00826462|Placebo Comparator|2|"Placebo injection in combination with physical therapy~Injection with sodium chloride and 10 mg of lidocaine at start and at 3 weeks in combination with physiotherapy for 6 weeks (12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises) Naprosyn entero 500 mg bid for 14 days"
3251869|NCT00826462|Active Comparator|3|Control group: wait-and-see treatment Naprosyn entero 500 mg bid for 14 days
3251870|NCT00826449|Experimental|Phase I|Dasatinib + Erlotinib
3251871|NCT00826436||8 subjects for Cohort 1|
3251872|NCT00826436||8 subjects for Cohort 2|
3251873|NCT00826410|Experimental|subcutaneous drain|"Use of subcutaneus suction drain (Redon) after laparotomy"
3251874|NCT00826397|Experimental|Acupuncture Arm|Patients in the treatment arm will receive acupuncture administered twice weekly for six weeks and will be allowed to take pain medication as necessary.
3251875|NCT00826397|Sham Comparator|Control Arm|The control patients will receive a form of sham acupuncture, which will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks.
3251876|NCT00826371|Experimental|1|
3251877|NCT00826358|Experimental|A|ABT-143 capsules 5/45mg
3251878|NCT00826358|Active Comparator|B|ABT-335 45mg and rosuvastatin 5mg
3251879|NCT00826345|Experimental|Acupuncture/Moxibustion|Diagnostic Acupuncturists assessments will inform acupuncture/moxibustion treatment prescriptions for persons with HIV/AIDS experiencing distal peripheral neuropathy. This protocol is tailored specifically for the subject's unique diagnosis according to the symptoms being reported at each diagnostic acupuncture (DA) session.
3251880|NCT00826345|Placebo Comparator|Placebo Acupuncture / Moxibustion|Sham/placebo Arm: Points will be administered away from the classic/traditional true point location.
3251881|NCT00826332|Active Comparator|Abdominal|Transabdominal ultrasound guided embryo transfer
3251882|NCT00826332|Active Comparator|Vaginal|Transvaginal ultrasound guided embryo transfer
3251883|NCT00826319||Bioimpedance sub-study cohort|Funded by a grant from Kidney Foundation of Canada, Dr. Catherine Clase initiated a bioimpedance sub-study across 7 centres and recruited n=416 within the CANPREDDICT population. The study uses bioimpedance measurements to assess volume status to determine the multivariable relationship between baseline volume overload and subsequent cardiovascular events. Subjects are followed at 6 months intervals for 2 years.
3251884|NCT00826319||Ethnic enrichment cohort|Additional recruitment initiated and funded by the Principal Investigator, Adeera Levin for enriching the ethnic representation within the Canadian cohort on South Asian and Oriental Asian was completed from Sept 2012 to June 2013, n=53.
3251885|NCT00826319||Original CanPreddict cohort|The original CanPreddict cohort was recruited from Jun 2008 - Oct 2009 has 2544 CKD patients across Canada.
3251886|NCT00826306|Experimental|Video-based education arm|Subjects receiving the video-based educational material
3251887|NCT00826306|Active Comparator|Written education arm|Subjects receiving the written educational material
3251888|NCT00826293|Active Comparator|True Stabilization Group|Patients will be randomized to one of the two treatment groups (true stabilization vs. sham stabilization). Patients will be exercising with a belt that is expected to reduce impingement of the rotator cuff tendons.
3251889|NCT00826293|Sham Comparator|Sham Stabilization|Patients receive sham stabilization. The sham procedure imitates the treatment without any true effect.
3251890|NCT00826280|Placebo Comparator|Placebo plus Regadenoson|Two placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection
3251891|NCT00826280|Experimental|Caffeine 200 mg plus Regadenoson|One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection
3251892|NCT00826280|Experimental|Caffeine 400 mg plus Regadenoson|Two 200 mg Caffeine capsules plus 0.4 mg regadenoson per 5mL intravenous bolus injection
3251893|NCT00826267|Experimental|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
3251894|NCT00826267|Active Comparator|Lapatinib|Lapatinib tablets 1500 mg daily.
3251895|NCT00826267|Active Comparator|Trastuzumab|Trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly.
3251896|NCT00826241|Experimental|Temozolomide + Lapatinib|Temozolomide starting dose 125 mg/m2 daily by mouth on days 1-7 & 15-21 of a 28 day cycle. Lapatinib starting dose 1250 mg daily by mouth.
3251897|NCT00826228|Experimental|PTH/Weight-Bearing|
3251898|NCT00826215|Experimental|1|Electroacupuncture treatment
3251899|NCT00826215|Sham Comparator|2|Sham laser acupuncture
3251900|NCT00826202|Experimental|D serine|60 mg/kg/day
3251901|NCT00826202|Placebo Comparator|Placebo|
3251902|NCT00826176|Experimental|Sugammadex in Caucasian Subjects|At 1-2 post-tetanic counts (PTC) after the last dose of rocuronium, 4.0 mg.kg-1 sugammadex was to be administered. Caucasian subjects living in Europe.
3251903|NCT00826176|Experimental|Sugammadex in Chinese Subjects|At 1-2 post-tetanic counts (PTC) after the last dose of rocuronium, 4.0 mg.kg-1 sugammadex was to be administered. Chinese subjects living in China.
3251904|NCT00826163|Active Comparator|stable COPD|Postbronchodilator FEV1> or = 50% predicted
3251905|NCT00826163|Sham Comparator|Asthma|Postbronchodilator FEV1 > or = 50% predicted
3251906|NCT00826150|Experimental|BC-819|BC-819 60, 120 and 240 mg IP administration
3251907|NCT00826137|Experimental|A|Treated with prebiotics.
3251908|NCT00826137|Placebo Comparator|B|Placebo treated.
3251909|NCT00826124|Active Comparator|I|Two epidural steroid injections two weeks apart based on history and physical exam alone
3251910|NCT00826124|Active Comparator|II|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
3251911|NCT00826111|Active Comparator|Eszopiclone|Lexapro for 10 weeks together with eszopiclone.
3251912|NCT00826111|Placebo Comparator|Placebo|Lexapro for 10 weeks together with placebo.
3251913|NCT00826098|Experimental|1 (PRP)|Total knee replacement with PRP
3251914|NCT00826098|No Intervention|2 (non-PRP)|Total knee replacement without PRP
3251915|NCT00826085|Experimental|Thermodox in combination with hyperthermia|Single arm study
3251916|NCT00826072||ALI|patients with acute lung injury at 24h after cardiac surgery
3251917|NCT00826072||Control|patients without acute lung injury 24h after cardiac surgery
3251918|NCT00826059|Experimental|Active Stimulation|Implantation and ISS Stimulation during five consecutive days & Standard of Care
3251919|NCT00826059|Sham Comparator|Sham Stimulation|Sham Implantation and Sham Stimulation during five consecutive days & Standard of Care
3251920|NCT00826033||Therapy monitoring|
3251921|NCT00826020|Experimental|Omegaven™|This study will be a prospective, non-randomized, open-label study of Omegaven™ for provision of parenteral lipid calories. The study cohort, receiving the PN lipid at 1g/kg/day, will be compared to historical controls at UNMC where parenteral lipid calories were provided exclusively through soybean-based formulations. The study is planned to enroll 100 patients. The Intestinal Rehabilitation Program at UNMC sees between 20 and 30 new pediatric patients per year, with almost all being PN-dependent and over 75% presenting with a bilirubin ≥ 2mg/dL. Based on these calculations, we estimate 4-5 years to enroll 100 patients.
3251922|NCT00825994|Experimental|Omega-3|omega-3 fatty acids, 2grams qd [every day] (2 x 1 gram tablets), PO [by mouth]
3251923|NCT00825981||coronary artery bypass graft|patients undergoing elective coronary artery bypass graft with or without cardiopulmonary bypass
3251924|NCT00825968||Data collection group|Patients having procedures done at the electrophysiology Laboratories at the Ross Heart Hospital at The Ohio State University Medical Center.
3251925|NCT00825955|Experimental|Brivanib|
3251926|NCT00825955|Placebo Comparator|Placebo|
3251927|NCT00825942|Experimental|C-KAD Ophthalmic Solution|
3251928|NCT00825929||1|Treated with one of the antiretroviral agents under study, PK parameters during pregnancy will be compared with PK parameters after pregnancy (within the same woman)
3251929|NCT00825916|Experimental|High Dose|
3251930|NCT00825916|Placebo Comparator|Placebo|
3251931|NCT00825916|Experimental|Low Dose|
3251932|NCT00825903|Experimental|1|Aquatic based exercise
3251933|NCT00825864|Active Comparator|1diclofenac drops treatment|four times a day for 3 months
3251934|NCT00825864|Active Comparator|2dexamethasone drops|
3251935|NCT00825851|Active Comparator|continuous smoking|subjects smoke 20 cigarettes per day
3251936|NCT00825851|Active Comparator|smoking cessation and NRT|subjects quit smoking and use transdermal nicotine patch
3251937|NCT00825851|Placebo Comparator|smoking cessation and placebo patch|subjects quit smoking and use placebo patch
3251938|NCT00825851|No Intervention|never smokers|subjects being never smokers and who refrain from smoking
3251939|NCT00825838|Experimental|1|Oral ingestion of 6mg chili pepper extract
3251940|NCT00825838|Placebo Comparator|2|Oral ingestion of 0 mg chili pepper extract (matching placebo)
3251941|NCT00825825|Active Comparator|Escitalopram|One week of escitalopram at 10 mg followed by one week at 20 mg in healthy volunteers.
3251942|NCT00825825|Active Comparator|Citalopram|One week of citalopram at 20 mg followed by one week at 40 mg in healthy volunteers.
3251943|NCT00825825|Placebo Comparator|Placebo|Two weeks of placebo in healthy volunteers.
3251944|NCT00825812|Experimental|Sugammadex in Caucasian Subjects|At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
3251945|NCT00825812|Active Comparator|Neostigmine in Caucasian Subjects|At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
3251946|NCT00825812|Experimental|Sugammadex in Chinese Subjects|At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
3251947|NCT00825812|Active Comparator|Neostigmine in Chinese Subjects|At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
3251948|NCT00825799||Major Depressive Disorder|Adults with major depressive disorder who are experiencing a current depressive episode.
3251949|NCT00825799||Healthy controls|Individuals without any Axis I psychiatric diagnosis who are matched to depressed subjects by age and sex.
3251950|NCT00825786|Active Comparator|Group 1|combined group: ropivacaine and mepivacaine mixture: 1:1 volume mixture of 1.5% mepivacaine and 0.5% ropivacaine in 2 syringes (labeled 1 and 2) with 15 mL in each (total, 30 mL) injected in immediate sequence;
3251951|NCT00825786|Active Comparator|Group 2|sequential group: mepivacaine followed by ropivacaine: syringe 1 containing 15 mL of 1.5% mepivacaine, syringe 2 containing 15 mL of 0.5% ropivacaine (total, 30 mL); syringe 2 was injected with a 90-sec delay after injection of syringe 1.
3251952|NCT00825773|Active Comparator|Excel|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
3251953|NCT00825773|Sham Comparator|Cypher|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
3251954|NCT00825760|Other|1|Single treatment
3251955|NCT00825760|Other|2|12 treatments, once weekly
3251956|NCT00825734|Experimental|Dose Level 1|Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (40mg/m^2)
3251957|NCT00825734|Experimental|Dose Level -1|Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (32mg/m^2)
3251958|NCT00825734|Experimental|Dose Level 1a|Sorafenib PO BID (400mg), Ixabepilone IV every 21 days (32mg/m^2)
3251959|NCT00825721|Active Comparator|1.3% (low dose)|
3251960|NCT00825721|Active Comparator|2% (medium dose)|
3251961|NCT00825721|Active Comparator|2.6% (high dose)|
3251962|NCT00825721|Placebo Comparator|Placebo|
3251963|NCT00825708|Active Comparator|rTMS|rTMS session
3251964|NCT00825708|Sham Comparator|SHAM|sham session
3251965|NCT00825695|Active Comparator|flavanol-rich cocoa|
3251966|NCT00825695|Placebo Comparator|flavanol-poor cocoa|
3251967|NCT00825682|Experimental|1|20 breast cancer patients scheduled for adjunctive radiation treatment will be recruited for this study to receive reflexology treatment initiated at the beginning of radiation therapy, once a week, for 10 weeks.
3251968|NCT00825682|No Intervention|2|20 breast cancer patients, scheduled for adjunctive radiation treatment, matched by age to the intervention group will receive treatment as usual, and will be evaluated by the same measures as the intervention group.
3251969|NCT00825669|Active Comparator|survival rate (TACE)|to compare the effects of TACE and TACE plus laser ablation for treating patients with PVTT
3251970|NCT00825669|Active Comparator|survival rate (TACE plus laser ablation)|to compare the effects of TACE and TACE plus laser ablation for treating patients with PVTT
3251971|NCT00825656|Experimental|1|Sinol-M
3251972|NCT00825656|Active Comparator|2|Sinol
3251973|NCT00825643||Insulin detemir|
3251974|NCT00825630|Active Comparator|Lansoprazole (Lanton)|Patients with H.pylori infection will take one tablet a day of 20 mg Lansoprazole for 14 days orally in the morning
3251975|NCT00825630|Active Comparator|Omeprazole (Losec)|Patients with H.pylori infection will take one tablet of 30 mg a day of Omeprazole for 14 days orally in the morning
3251976|NCT00825630|Active Comparator|Pantoprazole (Controloc)|Patients with H.pylori infection will take one tablet a day of 40 mg of Pantoprazole for 14 days orally in the morning
3251977|NCT00825630|Active Comparator|Esomeprazole(Nexium)|Patients with H.pylori infection will take one tablet a day of 20 mg Esomeprazole for 14 days orally on the morning
3251978|NCT00825617|Experimental|HRT|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
3251979|NCT00825604|No Intervention|Without PCI|Optimized medical treatment, physical training and smoking cessation
3251980|NCT00825604|Active Comparator|With PCI|optimized medical treatment, physical training and smoking cessation with complimentary treatment with percutaneous coronary intervention(PCI)
3251981|NCT00825591|Active Comparator|1|Individuals with abnormal rhythmicity will be treated with melatonin to assess if sleep patterns are improved.
3251982|NCT00825591|Placebo Comparator|2|
3251983|NCT00825578|Active Comparator|1|Upper-lobe predominant emphysema
3251984|NCT00825578|Active Comparator|2|Non-upper lobe predominant emphysema
3251985|NCT00825565|Experimental|Alwextin cream|8 subjects enrolled in this single study arm. All 8 subjects completed the study.
3251986|NCT00825539|Placebo Comparator|Placebo|
3251987|NCT00825539|Experimental|AQW051|
3251988|NCT00825526|Experimental|Early Intervention, MBSR therapy|Group that receives Mindfulness Based Stress Reduction Therapy immediately after randomization
3251989|NCT00825526|Active Comparator|Delayed Treatment Arm, MBSR Therapy|Group that receives Mindfulness Based Stress Reduction Therapy within 3 months of randomization
3251990|NCT00825513|Experimental|Akreos Toric|Akreos Toric Intraocular Lens
3251991|NCT00825513|Active Comparator|Akreos Advanced|Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)
3251992|NCT00825500|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo (0 mg)
3251993|NCT00825500|Active Comparator|Inhaled Loxapine 1.25 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
3251994|NCT00825500|Experimental|Inhaled Loxapine 2.5 mg|Inhaled Staccato Loxapine 2.5 mg, single dose
3251995|NCT00825487|Experimental|ARQ 621 treatment|
3251996|NCT00825474|Experimental|survival rate|therapeutic effect of partial hepatectomy or TACE plus PEI for small hepatocellular carcinoma
3251997|NCT00825461||1|Anorexia with tube feeding
3251998|NCT00825461||2|Anorexia without tube feeding
3251999|NCT00825461||3|Control
3252000|NCT00825448|Experimental|2|patient in hospital a week before the date of surgery for the treatment of his addiction alcohol
3252001|NCT00825448|No Intervention|1|no treatment of his addiction alcohol during a week before the date of surgery
3252002|NCT00825435|Experimental|1|Coronary CT angiogram plus Standard of care (CTA+SOC)
3252003|NCT00825435|No Intervention|2|Standard of Care (SOC)
3252004|NCT00825422|Experimental|A|first bolus of 20 ml of ropivacaine(5mg/ml) and continuous infiltration (8ml/h)of ropivacaine (2mg/ml)
3252005|NCT00825422|Placebo Comparator|B|first bolus of 20 ml of physiological saline solution(9%) and continuous infiltration (8ml/h)of physiological saline solution(9%)
3252006|NCT00825396|Experimental|C-KAD Ophthalmic Solution|
3252007|NCT00825383|Active Comparator|1|High Fiber Diet
3252008|NCT00825383|Active Comparator|2|Moderate Fiber Diet
3252009|NCT00825370|Experimental|Protocolized|"1 mg IV hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
3252010|NCT00825370|Active Comparator|Discretionary Care|Patients receive an IV opioid the type and dose of which is determined by the treating physician
3252011|NCT00825344|Experimental|1|Etanercept 50 mg preoperatively
3252012|NCT00825344|Placebo Comparator|2|Subcutaneous saline preoperatively
3252013|NCT00825331||1|patients for elective catheterization without special risks
3252014|NCT00825331||2|patients for elective catheterization with special risks
3252015|NCT00825331||3|patients for PCI without GP IIb/IIIa
3252016|NCT00825331||4|Patients for PCI with GPIIb/IIIa and emergencies
3252017|NCT00825318|Experimental|Daily ultrafiltration|During the treatment phase of the study, the subject will undergo ultrafiltration 6 times a week and hemodialysis 2 times a week.
3252018|NCT00825305|Experimental|Zagreb (2-1-1)|Rabies PCEC vaccine was applied according Zagreb schedule with 2 vaccinations on day 0, 1 vaccination on day 7 and day 21, respectively
3252019|NCT00825305|Active Comparator|Essen (1-1-1-1-1)|Rabies PCEC vaccine was applied according Essen schedule, i.e. 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.
3252020|NCT00825292|Active Comparator|2|HDNBI colonoscopy followed by standard white light colonoscopy
3252021|NCT00825292|Active Comparator|1|standard white light colonoscopy followed by HDNBI colonoscopy
3252022|NCT00825279|Active Comparator|1-BMS|Bare Metal Stent (Euca STS Flex)
3252023|NCT00825279|Experimental|2-DES|Drug Eluting Stent (Euca STS Flex DE), Paclitaxel Eluting stent with biodegradable polymer
3252024|NCT00825266|Active Comparator|bosentan|Bosentan 62.5 twice daily for 4 weeks, then 125 mg twice daily.
3252025|NCT00825266|Active Comparator|Pioglitazone|Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration of the study.
3252026|NCT00825240||Cancer Survivorship Study|Survey of colorectal cancer patients within one year from treatment end.
3252027|NCT00825227|Active Comparator|Patient responses to 150 mg/day armodafinil|"150 mg/day armodafinil~taxane chemotherapy treatment alone or in combination with other agents"
3252028|NCT00825227|Placebo Comparator|Patient responses to placebo|"placebo~taxane chemotherapy treatment alone or in combination with other agents"
3252029|NCT00825214|Active Comparator|1|Use of zapperclick on mosquito bite
3252030|NCT00825214|Placebo Comparator|2|use of inactivated zapperclick on mosquito bite
3252031|NCT00825201|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation given IP on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3252032|NCT00825188|Active Comparator|eplerenone|
3252033|NCT00825188|Active Comparator|amlodipine|Amlodipine 5-10mg daily times 8 weeks
3252034|NCT00825175|Active Comparator|1|Treadmill Training in infants with Down syndrome only
3252035|NCT00825175|Experimental|2|Treadmill Training and supramalleolar orthoses use for infants with Down syndrome
3252036|NCT00825162|Experimental|Cohort A|Participants aged 6 months to less than 3 years
3252037|NCT00825162|Experimental|Cohort B|Participants aged 3 years to less than 9 years
3252038|NCT00825162|Experimental|Cohort C|Participants aged 9 years to less than 18 years
3252039|NCT00825149|Experimental|A: R/R FL: Obinutuzumab Low Dose + CHOP|Participants with Relapsed/Refractory (R/R) FL will receive obinutuzumab 400 milligrams (mg) intravenous (IV) infusion on Days 1 and 8 of Cycle 1 and every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 milligrams per square-meter (mg/m^2), vincristine 1.4 mg/m^2 capped at 2 mg, and cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 400 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
3252040|NCT00825149|Experimental|B: R/R FL: Obinutuzumab High Dose + CHOP|Participants with R/R FL will receive obinutuzumab 1600 mg IV infusion on Days 1 and 8 of Cycle 1 and 800 mg IV infusion every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 capped at 2 mg, and cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 800 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
3252041|NCT00825149|Experimental|C: R/R FL: Obinutuzumab Low Dose + FC|Participants with R/R FL will receive obinutuzumab 400 mg IV infusion on Days 1 and 8 of Cycle 1 and every 4 weeks on Day 1 of subsequent cycles (for 46 cycles) in the induction period; Fludarabine 25 mg/m^2/day and cyclophosphamide 250 mg/m^2/day IV infusion every 4 weeks on Days 13 of each cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 400 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
3252042|NCT00825149|Experimental|D: R/R FL: Obinutuzumab High Dose + FC|Participants with R/R FL will receive obinutuzumab 1600 mg IV infusion on Days 1 and 8 of Cycle 1 and 800 mg IV infusion every 4 weeks on Days 1 of subsequent cycles (for 46 cycles) in the induction period; Fludarabine 25 mg/m^2/day and cyclophosphamide 250 mg/m^2/day IV infusion every 4 weeks on Days 13 of each cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 800 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
3252043|NCT00825149|Experimental|E: First-Line FL: Obinutuzumab + Bendamustine|Participants with first-line FL will receive obinutuzumab 1000 mg IV infusion on Days 1 and 8 of Cycle 1 and every 4 weeks on Day 1 of subsequent cycles (for 46 cycles) in the induction period; Bendamustine 90 mg/m^2 IV infusion on Days 2 and 3 of Cycle 1 and every 4 weeks on Days 1 and 2 of each subsequent cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 1000 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
3252044|NCT00825149|Experimental|F: First-Line FL: Obinutuzumab + CHOP|Participants with first-line FL will receive obinutuzumab 1000 mg IV infusion on Days 1 and 8 of Cycle 1 and every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 capped at 2 mg, cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 1000 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
3252045|NCT00825136|Active Comparator|relaxation|The patients of this arm practice on-line muscle relaxation for 8 weeks.
3252046|NCT00825136|Experimental|relaxation & biofeedback|The patients of this arm practice on-line muscle relaxation plus finger temperature biofeedback for 8 weeks.
3252047|NCT00825123|Experimental|Ivabradine|
3252048|NCT00825123|Active Comparator|Metoprolol|
3252049|NCT00825123|Placebo Comparator|Placebo|
3252050|NCT00825110||No treatment|confirmed diagnosis of colorectal carcinoma
3252051|NCT00825097|Experimental|Neurotomy Group|8 patients undergoing a selective tibial neurotomy under general anesthesia
3252052|NCT00825097|Active Comparator|BTX Group|8 patients undergoing a botulinum toxin injection in the calf muscles under EMG-control
3252053|NCT00825084|Experimental|single dose cohort-Japanese group|Japanese healthy subjects
3252054|NCT00825084|Experimental|single dose cohort-Western group|Western healthy subjects
3252055|NCT00825084|Experimental|multiple dose cohort-Japanese group|Japanese healthy subjects
3252056|NCT00825084|Experimental|multiple dose cohort-Western group|Western healthy subjects
3252057|NCT00825071|Active Comparator|Group D|Dexamethasone group : This group received 8 mg dexamethasone
3252058|NCT00825071|Active Comparator|Group O|Ondansetron Group: received 4 mg ondansetron
3252059|NCT00825071|Placebo Comparator|Group P|(Group P) received normal saline (Placebo)
3252060|NCT00825058|Experimental|1|
3252061|NCT00825058|Placebo Comparator|2|
3252062|NCT00825058|Active Comparator|3|
3252063|NCT00825045|Experimental|Treatment with risperidone|Gradual titration of risperidone according to clinical response
3252064|NCT00825032|Active Comparator|1: comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
3252065|NCT00825032|Experimental|2: UEET + PR|Experimental program consisting in additional 15 daily sessions of unsupported UEET over and above the same PR program used for control patients.
3252066|NCT00825019|Experimental|1|
3252067|NCT00825019|Placebo Comparator|2|
3252068|NCT00825019|Active Comparator|3|paroxetine
3252069|NCT00825006|No Intervention|Control|Dual site pacing (LV tip electrode and RV tip electrode)
3252070|NCT00825006|Experimental|Triple site pacing|Triple site pacing(LV tip electrode,RV tip electrode and RV ring electrode)
3252071|NCT00824993|Experimental|Ibandronate + Calcium + Vitamin D|Ibandronate infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant. Calcium 500 mg by mouth everyday for 12 months. Vitamin D 400 units by mouth 2 times a day for 12 months.
3252072|NCT00824993|Experimental|Calcium + Viatmin D|Calcium 500 mg by mouth everyday for 12 months. Vitamin D 400 units by mouth 2 times a day for 12 months.
3252073|NCT00824980|Experimental|IP10.C8 Gel|
3252074|NCT00824980|Placebo Comparator|Placebo Gel|
3252075|NCT00824967|No Intervention|1- The reference group|one will take care of the patient in a habitual way: no consultation additional, step of exam on top of that...
3252076|NCT00824967|Other|2- The intervention group|Training and valuation of the treating personnel
3252077|NCT00824928||Observational|Patients with locally recurrent prostate cancer that have chosen salvage cryotherapy
3252078|NCT00824902|Experimental|Tissue Elastography Imaging|Using special elastography software, probe pressed gently against prostate during routine ultrasound before prostate surgery, 10-15 minutes process.
3252079|NCT00824889|Other|1|Healthy volunteer
3252080|NCT00824889|Other|2|atopic dermatitis patient
3252081|NCT00824889|Other|3|contact dermatitis patient
3252082|NCT00824889|Other|4|psoriasis patient
3252083|NCT00824889|Other|5|lichen planus patient
3252084|NCT00824889|Other|6|GVH patient
3252085|NCT00824889|Other|7|melanoma patient
3252086|NCT00824863|Experimental|one arm|All 10 patients receive ketoconazole 2% foam in the uncontrolled study.
3252087|NCT00824850|Experimental|1|Subjects received Prevnar in study D118-P8
3252088|NCT00824850|Experimental|2|Subjects received MnCC in study D118-P8
3252089|NCT00824837|Experimental|A|New larger pore membrane
3252090|NCT00824837|Active Comparator|B|Standard haemodialysis membrane
3252091|NCT00824824|Experimental|Brimonidine 0.2%-timolol 0.5% arm|Patients using timolol were switched to brimonidine tartrate / timolol maleate 0.2%/05% 1 get BID OU for six weeks.
3252092|NCT00824824|Active Comparator|Dorzolamide 2%-timolol 0.5% arm|Patients using timolol were switched ti dorzolamide hydrochloride / timolol 0.5% 2%/0.5% bid OU for six weeks
3252093|NCT00824811|Experimental|Group 1: Cyclosporine eye drops|Cyclosporine Eye Drops (Restasis) 1 drop twice/day for 84 days to both eyes + Fluorometholone Eye Drops (FML Forte) on declining dose schedule.
3252094|NCT00824811|Experimental|Group 2: Lubricant Eye Drops|Lubricant Eye Drops (Refresh Endura) 1 drop twice/day for 84 days to both eyes + Fluorometholone Eye Drops (FML Forte) on declining dose schedule.
3252095|NCT00824798||haemophiliacs A and B|haemophiliacs A and B mild, moderate or severe from 4 to 80 years old, with or without inhibitors.
3252096|NCT00824785|Active Comparator|Arm A EOX|EOX chemotherapy (epirubicin, oxaliplatin and capecitabine)
3252097|NCT00824785|Active Comparator|Arm B EOX + panitumumab.|EOX chemotherapy with the addition of panitumumab 9mg/kg every 21 days
3252098|NCT00824759|Placebo Comparator|placebo|
3252099|NCT00824759|Active Comparator|oxygen|
3252100|NCT00824746|Experimental|Gefitinib retreatment group|Gefitinib retreatment
3252101|NCT00824733|Experimental|Arm I: Treatment (PF03512676 in combination with Trastuzumab)|12 weekly treatments. Week 1-12 patients will receive Trastuzumab 2mg/kg IV(intervenous infusion). Patients who have not been treated wih Trastuzumab within 4 weeks will receive a loading dose of 4 mg/kg on week 1 and PF-03512676-0.16 mg/kg subcutaneous injection.Correlative studies will be drawn on week 1, 2, 6, 12 and 18.
3252102|NCT00824720|Experimental|High Dose Device|device worn continuously for 14 days
3252103|NCT00824720|Experimental|Low Dose Device|device worn continuously for 14 days
3252104|NCT00824720|Placebo Comparator|Placebo Device|device worn continuously for 14 days
3252105|NCT00824707|Experimental|anti-virus therapy|100 HCC patients will be allocated to receive anti-virus therapy.
3252106|NCT00824707|Active Comparator|conventional therapy|100 patients will undergo conventional therapy
3252167|NCT00824304||Fe, Zn, Fe+Zn, Placebo|placebo comparator
3252168|NCT00824291|Placebo Comparator|1|
3252169|NCT00824291|Experimental|2|
3252396|NCT00822523|Placebo Comparator|Placebo|Saline, Single dose, Intramuscular injection into right EDB
3252107|NCT00824694|Active Comparator|Intervention|The intervention will consist of targeted SMBG, provider training and patient education-all of which are focused on normalizing the most significant glucose abnormalities at any given time. SMBG will alternate between 2 strategies: glucose profiling and target monitoring. Intervention PCP's will use 380 View to identify a patient's most significant glucose elevations(s) and devise a treatment plan that includes drug type, dose increases, monitoring times, goal for the target, and stop criteria.
3252108|NCT00824694|Active Comparator|Control Arms|Subjects will repeat the dose titration cycle under the guidance of a case manager until the target is reached, maximal recommended doses of medications are used, or a stop criterion is met. They will then resume glucose profiling to identify the next target. This process is repeated until all targets reach their optimal value. Control patients will monitor and be treated in the customary manner.
3252109|NCT00824681|Experimental|1|Sound Of Family Together (S.O.F.T.) Music Program
3252110|NCT00824681|Active Comparator|2|Non-Therapy Related Activities (NTRA)
3252111|NCT00824655|Experimental|Group 1|
3252112|NCT00824655|Experimental|Group 2|
3252113|NCT00824642|Experimental|Group 1|Applied Acu-TENS prior to exercise
3252114|NCT00824642|Experimental|Group 2|Applied Acu-TENS prior to and during exercise
3252115|NCT00824642|Placebo Comparator|Group 3|Applied placebo TENS prior to exercise
3252116|NCT00824629|Experimental|1|Afterloading embryo transfer procedure
3252117|NCT00824629|Active Comparator|2|Direct embryo transfer procedure
3252118|NCT00824616|Placebo Comparator|Placebo|Participants receiving placebo tablets three times daily plus insulin injection once daily
3252119|NCT00824616|Experimental|MK-0941|Participants receiving MK-0941 tablets three times daily plus insulin injection once daily
3252120|NCT00824603||primary care provider|attending insulin CME Training
3252121|NCT00824590|Experimental|Severe renal impairment group|Subjects with severe renal impairment defined by creatinine clearance of less than 30 mL/min but not yet on dialysis
3252122|NCT00824590|Experimental|normal renal function|Subjects with normal renal function defined by creatinine clearance of greater than 80 mL/min and demographically comparable to subjects with impaired renal function
3252123|NCT00824577||250~300 patients|heart rate variability, heart function and Kt/V
3252124|NCT00824564|Experimental|A|Tranexamic Acid plus standard of care
3252125|NCT00824564|Other|B|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss.
3252126|NCT00824551|Experimental|Hyperbaric Oxygen Therapy|2 HBOT treatments
3252127|NCT00824551|Active Comparator|2|Standard care and treatment
3252128|NCT00824538|Experimental|sunitinib|Study to evaluate the effect of sunitinib (37.5 mg/day orally for 6 months) on occult tumor cells in the bone marrow of patients with high risk early stage breast cancer
3252129|NCT00824512|Experimental|EGb 761® 120 mg|
3252130|NCT00824512|Placebo Comparator|Placebo|
3252131|NCT00824499|Experimental|DPA|Regional complex intervention based on the Chronic Care Model
3252132|NCT00824499|No Intervention|VR|
3252133|NCT00824486|Active Comparator|TIPP|Injury prevention education using TIPP materials
3252134|NCT00824486|Experimental|Safe Home Model|Injury prevention education using safe home model
3252135|NCT00824473|Placebo Comparator|1|Placebo
3252136|NCT00824473|Active Comparator|2|0.15% azelastine hydrochloride
3252137|NCT00824460|Experimental|1.25 g PA21|
3252138|NCT00824460|Experimental|5.0 g PA21|
3252139|NCT00824460|Experimental|7.5 g PA21|
3252140|NCT00824460|Experimental|10.0 g PA21|
3252141|NCT00824460|Experimental|12.5 g PA21|
3252142|NCT00824460|Experimental|Sevelamer hydrochloride - active control|
3252143|NCT00824447|Placebo Comparator|Placebo control|Placebo control
3252144|NCT00824447|Active Comparator|Grass pollen extract, twice weekly|Grass pollen extract, 9,500 BU, given twice weekly
3252145|NCT00824447|Active Comparator|Grass pollen extract daily|Grass pollen extract, 9,500 BU, given daily
3252146|NCT00824447|Active Comparator|Increased dose of grass pollen extract|Increased dose of grass pollen extract, 19,000 BU, given daily
3252147|NCT00824434|Experimental|Experimental Stent|
3252148|NCT00824421|Experimental|UK- 453,061 Dose One|UK 453,061 Dose One plus Truvada
3252149|NCT00824421|Experimental|UK-453,061 Dose Two|UK 453,061 Dose Two plus Truvada
3252150|NCT00824421|Active Comparator|Efavirenz + Truvada|Efavirenz + Truvada
3252151|NCT00824408|Experimental|BI 6727 +pemetrexed|BI 6727 plus 500 mg/^m2 pemetrexed i.v. on day 1 of 21 day cycle
3252152|NCT00824408|Active Comparator|pemetrexed|500 mg/m^2 i.v. on day 1 of a 21 day cycle
3252153|NCT00824395||1|Individuals with diabetes
3252154|NCT00824395||2|Individuals without diabetes
3252155|NCT00824382|Experimental|BI 1744 CL 5 Âµg|2 puffs of 2.5 Âµg/actuation
3252156|NCT00824382|Experimental|BI 1744 CL 10 Âµg|2 puffs of 5 Âµg/actuation
3252157|NCT00824382|Placebo Comparator|Placebo|2 puffs
3252158|NCT00824382|Experimental|BI 1744 CL 2 Âµg|2 puffs of 1 Âµg/actuation
3252159|NCT00824369|No Intervention|Anti-retroviral therapy|Anti-retroviral therapy
3252160|NCT00824356|Active Comparator|GSK1004726 (1000mg)|1000mg aqueous suspension
3252161|NCT00824356|Placebo Comparator|Placebo|Intranasal spray
3252162|NCT00824356|Active Comparator|GSK1004723 (200mg)|200 mg aqueous suspension
3252163|NCT00824343|Experimental|Single P276-00 arm|This is a single experimental arm study
3252164|NCT00824330|Other|Control Phase; Exercise Phase|"Participants act as their own control.~Control Phase:~Participants will not change their activity during the 3 month control phase (defined as no strength training and less than 30 minutes brisk walking/moderate exercise per week, no vigorous exercise) Baseline measures will be obtained.~Exercise Phase:~This phase will consist of a Titration phase followed by an Intervention Phase. During the Titration phase, under the guidance of a trainer, subjects will increase their number of steps by 20% per week until they have reached 10,000 steps or 3 months have passed. During the Intervention Phase subjects will continue to walk 10,000 steps (or the number of steps they reached in the Titration phase)."
3252165|NCT00824317|Placebo Comparator|1|Placebo
3252166|NCT00824317|Experimental|2|methylphenidate
3252170|NCT00824265|Experimental|Ofatumumab, Fludarabine, Cyclophosphamide|Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
3252171|NCT00824265|Active Comparator|Fludarabine, Cyclophosphamide|Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
3252172|NCT00824252||Spousal Support|Questionnaire for Head and Neck Cancer Patients + Spouses
3252173|NCT00824239|Active Comparator|1. Intermittent sedation|
3252174|NCT00824239|Active Comparator|2. Daily interruption of sedation|
3252175|NCT00824200|Experimental|Behavioral and Exercise Therapy (M-BET)|Multicomponent behavior and exercise therapy program (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene & non-pharmacological management of peripheral edema. M-BET alone will be given with placebo capsules.
3252176|NCT00824200|Active Comparator|Drug Therapy w/ Behavioral Placebo|alpha-adrenergic antagonist medication with a placebo behavioral intervention
3252177|NCT00824200|Active Comparator|Combination Therapy|Combination therapy: MBET and alpha-adrenergic antagonist medication
3252178|NCT00824187|Experimental|Arm 1|
3252179|NCT00824187|Placebo Comparator|Arm 2|
3252180|NCT00824174||Questionnaire|1 questionnaire, about 15-20 minutes.
3252181|NCT00824161|Experimental|1|TAS-109
3252182|NCT00824148|Experimental|Real-time glucose monitoring|Use of Guardian REAL-Time Continuous Glucose Monitoring System, (Medtronic Minimed, Northridge, CA) for 1 month, followed by observation for 2 months.
3252183|NCT00824148|Active Comparator|Self-monitoring of plasma glucose|Conventional self-monitoring of plasma glucose by finger-prick sampling for 1 month, followed by 1 month observation.
3252184|NCT00824135|Experimental|1|
3252185|NCT00824122||1|Children greater than 6 months receiving at least one dose of Vancomycin and Red Man Syndrome
3252186|NCT00824122||2|Children greater than 6 months receiving at least one dose of Vancomycin and has not had Red Man Syndrome
3252187|NCT00824109|Other|Single Arm Study|Consecutive patients meeting the selection criteria
3252188|NCT00824083||1|sarcoma survivors
3252189|NCT00824083||2|healthy subjects
3252190|NCT00824070|Experimental|Besifloxacin|Besifloxacin ophthalmic suspension
3252191|NCT00824070|Active Comparator|Moxifloxacin|Vigamox (moxifloxacin ophthalmic solution, 0.5%)
3252192|NCT00824070|Active Comparator|Gatifloxacin|Zymar (gatifloxacin ophthalmic solution, 0.3%)
3252193|NCT00824057|Experimental|1|
3252194|NCT00824044|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a manualized therapeutic treatment for depression based on principles of cognitive restructuring and behavioral changes.
3252195|NCT00824044|Active Comparator|Escitalopram|Escitalopram or Lexapro is a Selective Serotonin Reuptake Inhibitor (SSRI) used to treat depression
3252196|NCT00824005|Placebo Comparator|Placebo Injections|Participants will receive placebo injections.
3252197|NCT00824005|Experimental|Active Stem Cell Injections|Participants will receive active stem cell injections.
3252198|NCT00823992|Placebo Comparator|placebo|
3252199|NCT00823992|Experimental|taspoglutide|
3252200|NCT00823979|Experimental|UK- 453,061 Dose One|
3252201|NCT00823979|Experimental|UK- 453,061 Dose Two|
3252202|NCT00823979|Active Comparator|Comparator|
3252203|NCT00823966||Delavirdine Mesilate|Patients administered.
3252204|NCT00823953|Placebo Comparator|Placebo|placebo powder (wheat flour) The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
3252205|NCT00823953|Active Comparator|Momordica charantia|"Thirty patients will be assigned to each arm in a double blind manner. The active arm will be administered capsules containing a total of 500 mg of Momordica charantia freeze dried powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.~The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3."
3252206|NCT00823940|Placebo Comparator|Cohort A1|Dose escalation: 5 - 100mg and placebo in 4 planned doses
3252207|NCT00823940|Placebo Comparator|Cohort A2|Dose escalation: 100-600mg and placebo in 4 planned doses
3252208|NCT00823940|Other|Cohort B1|Glucagon challenge test
3252209|NCT00823940|Active Comparator|Cohort B3|Glucagon challenge test + selected dose of GSK1362885
3252210|NCT00823927||1|HIV smokers with emphysema
3252211|NCT00823927||2|HIV smokers without emphysema
3252212|NCT00823901|Experimental|Clindamycin/Tretinoin Gel|Participants applied Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel on entire face (forehead, nose, chin, cheeks) once daily at night for 12 weeks
3252213|NCT00823901|Placebo Comparator|Placebo gel|Participants applied Placebo gel with no active medication on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks.
3252214|NCT00823875|Experimental|1|
3252215|NCT00823875|Experimental|2|
3252216|NCT00823875|Experimental|3|
3252217|NCT00823875|Other|4|Control Group
3252218|NCT00823862|Experimental|Active (SD-101)|SD-101 in cohorts of escalating doses
3252219|NCT00823849|Experimental|1|
3252220|NCT00823849|Experimental|2|
3252221|NCT00823849|Experimental|3|
3252222|NCT00823849|No Intervention|4|Control Group
3252223|NCT00823836|Experimental|ropinirolePR-PR group|
3252224|NCT00823836|Active Comparator|ropiniroleIR-PR group|
3252225|NCT00823823|Active Comparator|Bivalved cast|Patients with a displaced distal radius or mid-diaphyseal forearm fracture requiring closed reduction will be immobilized in a bivalved cast
3252226|NCT00823823|Active Comparator|Circumferential cast|Patients with a displaced distal radius or mid-diaphyseal forearm fracture requiring closed reduction will be immobilized in a circumferential cast
3252227|NCT00823810|Experimental|Colorectal cancer|
3252228|NCT00823797|Experimental|Treatment (bendamustine hydrochloride)|Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
3252563|NCT00821236|Active Comparator|LADARVision 4000 excimer laser|LADARVision 4000 excimer laser
3252229|NCT00823784|Experimental|1THD group|Series of 135 patients with 3rd degree Hemorrhoids treated by THD device under spinal anaesthesia
3252230|NCT00823784|Active Comparator|2 stapler group|135 patients with 3rd degree hemorrhoids will be treated by staple hemorrhoidopexy
3252231|NCT00823771||Reviewed by radiation oncologist|
3252232|NCT00823771||Reviewed by general practitioner|
3252233|NCT00823758||1|Parents of children under 8 years of age who have ever given their children an over- the-counter medication.
3252234|NCT00823758||2|Adolescents who are 13 to 20 years of age who have ever heard of over-the-counter medication.
3252235|NCT00823758||3|Adults (21 years of age or older) who have used over-the-counter medication in the past 2 years.
3252236|NCT00823758||4|Primary care physicians will be Family Practitioners or General Internist, with an active Texas license, who devote at least 50% of their time to clinical practice.
3252237|NCT00823758||5|Pharmacists holding a PharmD degree and licensure in the state of Texas and work at least half-time in a community pharmacy setting.
3252238|NCT00823745|Experimental|1|[14C]-PF-00868554
3252239|NCT00823732|Active Comparator|Phase 2 Intervention|GROUP II (palliative care intervention): Patients receive an individualized interdisciplinary palliative care intervention comprising learner-centered, knowledge-centered, assessment-centered, and community-centered concepts. Patients undergo 4 teaching sessions, focused on physical, psychological, social, and spiritual well-being, once weekly in weeks 3-6. Patients then receive 4 follow-up phone calls in weeks 9, 13, 17, and 21.
3252240|NCT00823732|No Intervention|Phase I Usual Care|GROUP I (usual care): Patients receive standard care.
3252241|NCT00823719|Experimental|ofatumumab + DHAP or ICE chemotherapy regimen|This study is a single arm study, but the Investigators are required to prospectively choose to treat all of their subjects with either ICE or DHAP chemotherapy regimens in combination with ofatumumab. Regardless of whether the subject receives ICE or DHAP chemotherapy, all subjects will receive the same ofatumumab regimen and dose.
3252242|NCT00823693|Active Comparator|Bimosiamose Cream|
3252243|NCT00823693|Placebo Comparator|Placebo Cream|
3252244|NCT00823680|Placebo Comparator|Placebo|
3252245|NCT00823680|Experimental|RO5027838 200mg|
3252246|NCT00823680|Experimental|RO5027838 50mg|
3252247|NCT00823680|Experimental|RO5093151 10mg|
3252248|NCT00823680|Experimental|RO5093151 400mg|
3252249|NCT00823667|Active Comparator|Phase 1 Usual care|
3252250|NCT00823667|Active Comparator|Phase 2 Intervention|
3252251|NCT00823654||Premenopausal Women with Early Stage Breast Cancer|
3252252|NCT00823654||Unaffected High Risk Women with BRCA mutations|
3252253|NCT00823641|Experimental|Infliximab|Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
3252254|NCT00823628|Active Comparator|iopromide|
3252255|NCT00823628|Experimental|iodixanol|
3252256|NCT00823615|Other|Lotrafilcon B / Senofilcon A|Lotrafilcon B, followed by Senofilcon A
3252257|NCT00823615|Other|Senofilcon A / Lotrafilcon B|Senofilcon A, followed by Lotrafilcon B
3252258|NCT00823602|Experimental|1|"GnRH antagonist ganirelix 0.25 mg fromm 6th ovarian stimulation"
3252259|NCT00823602|Active Comparator|2|GnRH agonist, suprefact, stimulation with a standard long protocol
3252260|NCT00823589|Experimental|pathological group|pathological group
3252261|NCT00823589|Experimental|healthy aged|healthy aged
3252262|NCT00823576|Active Comparator|1|"Group witness: one receiving a single bolus of analgesic~Seepage simple person the end of intervention of 200mg of ropivacaïne 0,5 % at the level of zones it"
3252263|NCT00823576|Active Comparator|2|Group catheter: receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.
3252264|NCT00823550|Experimental|A|entecavir 0.5 mg QD
3252265|NCT00823550|Active Comparator|B|lamivudine 100 mg QD
3252266|NCT00823524|Experimental|donor NK cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
3252267|NCT00823511||Female Partners|Female partners of HIM Study participants
3252268|NCT00823498||African American Parents|
3252269|NCT00823498||African American Youth|African American Youth between ages of 12-15 Years Old
3252270|NCT00823485|Active Comparator|2|drainage of hemorraghia
3252271|NCT00823485|Experimental|1|Actylise
3252272|NCT00823472|Experimental|Start rFSH cycle day 2|
3252273|NCT00823472|Experimental|Start rFSH on cycle day 5|
3252274|NCT00823459|Experimental|Daily Intervention with RAD001|RAD001 will be administered orally as once daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day. RAD001 may be taken with or without food.
3252275|NCT00823446|Experimental|Revera Wound Care|
3252276|NCT00823446|Placebo Comparator|Normal Saline|
3252277|NCT00823433|Experimental|Oral Penicillin|2 grams of oral penicillin V given within 4 hours of delivery
3252278|NCT00823420|Experimental|in-vitro maturation of oocytes|
3252279|NCT00823407|Other|MDA|
3252280|NCT00823394||Windsor Village United Methodist Church|Questionnaire + Body Measurements + Self-help Materials
3252281|NCT00823381|Experimental|Resveratrol|
3252282|NCT00823381|Placebo Comparator|Placebo|
3252283|NCT00823381|Active Comparator|Calorie Restriction|
3252284|NCT00823368||Arbaclofen followed by Placebo|
3252285|NCT00823368||Placebo followed by Arbaclofen|
3252286|NCT00823355|Experimental|BCX1777|
3252287|NCT00823342|Placebo Comparator|Group A|CLEVUDINE 30 mg qd + TENOFOVIR Placebo
3252288|NCT00823342|Active Comparator|Group B|TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
3252289|NCT00823342|Placebo Comparator|Group C|TENOFOVIR 300 mg qd + CLEVUDINE Placebo
3252290|NCT00823316|Experimental|1|at a dose of 1x1,000,000 hMSC/kg
3252291|NCT00823316|Experimental|2|at a dose of 5x1,000,000 hMSC/kg
3252292|NCT00823303|Experimental|Paricalcitol|titrated to achieve 40-60% PTH suppression
3252293|NCT00823303|Active Comparator|Calcitriol|titrated to achieve 40-60% PTH suppression
3252294|NCT00823277||1|Overweight and obese Children (BMI SDS > 90th percentile according to Danish BMI sheets) 5-20 Years of age. Recruited from the Paediatric department, University Hospital Holbaek, Region Zealand, Denmark, University of Copenhagen
3252295|NCT00823264|Experimental|Multiple Doses of Activated Charcoal|Patients will receive 50 grams of activated charcoal by mouth every 4 hours until phenytoin levels drop below 25 ug/cc
3252296|NCT00823264|No Intervention|Control|Will not receive activated charcoal. Serum levels will be followed.
3252297|NCT00823251|Experimental|IlluminOss device|IlluminOss bone-pin device
3252298|NCT00823238|Active Comparator|systemic|
3252299|NCT00823238|Active Comparator|inhaled|
3252300|NCT00823225|Other|A: Standard therapy|
3252301|NCT00823225|Experimental|B: Urokinase|
3252302|NCT00823212|Active Comparator|PROMUS|Patients who received the PROMUS (XIENCE V) Everolimus-Eluting Coronary Stent
3252303|NCT00823212|Experimental|PROMUS Element|Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent
3252304|NCT00823199|Experimental|Allopurinal treatment|Allopurinal 300mg once daily by mouth for four weeks
3252305|NCT00823186|Experimental|Phyxol,cancer,intra vascular flow|weekly cisplatin plus paclitaxel for 3 cycles as neoadjuvant chemotherapy (NAC) for FIGO IB2 and bulky IIA, squamous cell cervical cancer followed by radical hysterectomy and pelvic lymphedectomy
3252306|NCT00823173|Experimental|Topical ESBA105|ESBA105 applied as eye drops
3252307|NCT00823160|Active Comparator|1: Sternotomy|Patients who are randomized to a sternotomy after the finding of blood in the pericardial sac.
3252308|NCT00823160|Active Comparator|2: Subxyphoid window|Patients who receive a subxyphoid window after the finding of blood in the pericardial sac.
3252309|NCT00823147||Pain Catastrophizing Induction Group|"Collect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest.~Catastrophizing group: 10-minute catastrophizing induction. Participants self-rate their level of emotional distress.~Subsequent blood draws occur per protocol time points:~25 minutes following IV placement (BASELINE)~15 minutes post catastrophizing induction (stress experiment)~90 minutes (1.5 hours) post-induction~150 minutes (2.5 hours) post-induction~210 minutes (3.5 hours) post-induction~270 minutes (4.5 hours) post-induction"
3252310|NCT00823147||Control Group|"Collect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest.~Control group: Persons in this group will rest, complete puzzles, read emotionally-neutral material or watch videos provided to them.~Blood draws and saliva samples gathered per protocol time points:~25 minutes following IV placement (BASELINE- T1)~25 minutes following baseline T2~115 minutes (1 hour 55 min) post baseline T3~175 minutes (2 hours 55 min) post baseline T4~235 minutes (3 hours 55 min) post baseline T5~295 minutes (4 hours 55 min) post baseline T6"
3252311|NCT00823121|Active Comparator|frozen-embryo transfer|In this group all embryos are cryopreserved and two months later embryo transfer will perform.
3252312|NCT00823121|Active Comparator|fresh embryo transfer|In this arm fresh embryo transfers are performed on day 2 or 3.
3252313|NCT00823108|Experimental|1|Glucose-insulin-potassium
3252314|NCT00823108|No Intervention|2|Control
3252315|NCT00823095|Experimental|Topically applied Nitric Oxide|Topically applied Nitric Oxide for 8 hours daily for 2 weeks.
3252316|NCT00823082|Experimental|Antithrombin III treatment group|Preoperative ATIII supplementation administered immediately after anesthesia induction
3252317|NCT00823082|No Intervention|Control group|No preoperative ATIII supplementation administered
3252318|NCT00823069|Other|Perlane and Perlane-L|This is a split-face design injecting both Perlane and Perlane-L injectable gels, administered once. Each subject received Perlane-L on one side of the face, and Perlane on the other. Subjects were blinded to which side of their face receive Perlane or Perlane-L. The study was randomized and treatments successive.
3252319|NCT00823056|Placebo Comparator|1|
3252320|NCT00823056|Active Comparator|2|
3252321|NCT00823043||Timolol hemihydrate|Subjects currently prescribed timolol hemihydrate 0.5% solution.
3252322|NCT00823043||Timolol maleate|Subjects currently prescribed timolol maleate in sorbate.
3252323|NCT00823030|Placebo Comparator|Placebo|Placebo instillation: 20 ml of normal saline instilled intravesically
3252324|NCT00823030|Experimental|experimental arm|The experimental instillation will include 8 ml of 2% lidocaine, 3 ml of sodium bicarbonate, and 9 ml of normal saline.
3252325|NCT00823017|Experimental|1|Patient-preferred music
3252326|NCT00823017|Experimental|2|Relaxation Music
3252327|NCT00823017|Placebo Comparator|3|Standard of Care
3252328|NCT00823004|Active Comparator|1|A/L: Poor responders who will receive letrozole and GnRH antagonist for ovarian stimulation
3252329|NCT00823004|Active Comparator|2|MF: In this arm poor responders are treated by microdose GnRH agonist flare protocol
3252330|NCT00822991|Active Comparator|Group of CE-US|screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
3252331|NCT00822991|Active Comparator|Group of B-mode US|screening by conventional B-mode US every 3-5 months
3252332|NCT00822978|Active Comparator|ACHN-490 Injection|ACHN-490 Injection in escalating doses
3252333|NCT00822978|Placebo Comparator|2|Placebo is normal saline
3252334|NCT00822965||Patient Knowledge Assessments|Questionnaires + Phone Interview
3252335|NCT00822926|Experimental|Placebo then Botox|Injection 1: Saline- Subcutaneous injection of saline into scar tissue Injection 2: Botulinum Toxin Type A- Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue
3252336|NCT00822926|Experimental|Botox then Placebo|Injection 1: Botulinum Toxin Type A- Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue Injection 2: Saline- Subcutaneous injection of saline into scar tissue
3252337|NCT00822913|Experimental|Botulinum A toxin|Botulinum A toxin intravesical injection
3252394|NCT00822523|Experimental|Botulinum toxin type A, 20 units|Single intramuscular (into extensor digitorum brevis muscle of the foot) dose of Botulinum toxin type A, 20 units
3252395|NCT00822523|Experimental|Botulinum toxin, type A, 2 units|Single intramuscular (into extensor digitorum brevis muscle of the foot) dose of Botulinum toxin type A, 2 units
3252338|NCT00822900|Experimental|Progesterone|Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 72 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone will be combined with a 20% Intralipid mixture for infusion.
3252339|NCT00822900|Placebo Comparator|Placebo|"Placebo stock solution was the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid was based on the same mg/kg/hr volume that would be required if PROG had been in the vial. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid was administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table was used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 72 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The placebo will be combined with a 20% Intralipid mixture for infusion."
3252340|NCT00822887|Experimental|Vandetanib|Dose level 1:100 mg qd, 2:200 mg qd, 3:300 mg qd. Fractionated Stereotactic Radiotherapy: all patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
3252341|NCT00822874|Experimental|in-vitro maturation of oocytes|
3252342|NCT00822861|Experimental|Dose level No.1|TPI ASM8 1 mg BID
3252343|NCT00822861|Experimental|Dose level No.2|TPI ASM8 2 mg BID
3252344|NCT00822861|Experimental|Dose level No.3|TPI ASM8 4mg BID
3252345|NCT00822861|Experimental|Dose level No.4|TPI ASM8 8 mg Die
3252346|NCT00822848|Experimental|Sorafenib, Epirubicin, Ifosfamide|
3252347|NCT00822835|Active Comparator|ILV-095|6 SC single dose injections
3252348|NCT00822835|Placebo Comparator|Placebo|Placebo
3252349|NCT00822822||A|Health History Process
3252350|NCT00822809|Experimental|A|"Patients will receive premedication of 25 mg (i.v.) prednisolone 30 minutes prior start of infusion of catumaxomab.~Catumaxomab will be infused i.p. with 3 hour constant rate infusions via an indwelling catheter."
3252351|NCT00822809|Other|B|Catumaxomab will be administered in a dosage identical to Arm A but without the prednisolone premedication.
3252352|NCT00822796|Experimental|A|Burn patients with >20% TBSA burns scheduled to undergo debridement and grafting who will have placed the Thermogard™ central venous warming catheter by Alsius
3252353|NCT00822796|Active Comparator|B|Burn patients with >20% TBSA burns scheduled to undergo debridement and grafting who will have placed a central venous catheter as a part of their routine burn management
3252354|NCT00822783|Active Comparator|Omalizumab|
3252355|NCT00822783|Placebo Comparator|Placebo|
3252356|NCT00822770|Experimental|Phase I|ATG + Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant
3252357|NCT00822770|Experimental|Phase II|ATG + MTD Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant
3252358|NCT00822757|Experimental|1|V710
3252359|NCT00822757|Placebo Comparator|2|Placebo
3252360|NCT00822744|Experimental|SSR411298 10 mg|SSR411298 10 mg, one capsule once daily for 8 weeks
3252361|NCT00822744|Experimental|SSR411298 50 mg|SSR411298 50 mg, one capsule once daily for 8 weeks
3252362|NCT00822744|Experimental|SSR411298 200 mg|SSR411298 200 mg, one capsule once daily for 8 weeks
3252363|NCT00822744|Active Comparator|Escitalopram 10 mg|Escitalopram 10 mg, one capsule once daily for 8 weeks
3252364|NCT00822744|Placebo Comparator|Placebo|Placebo (for SSR411298), one capsule once daily for 8 weeks
3252365|NCT00822731|Experimental|Lymphoma|patients diagnosed as lymphoma
3252366|NCT00822705|Active Comparator|ORAL GLP-1, TABLET|
3252367|NCT00822705|Active Comparator|Oral PYY3-36|
3252368|NCT00822705|Active Comparator|Oral GLP-1 plus oral PYY3-36|
3252369|NCT00822705|Placebo Comparator|4|
3252370|NCT00822692|Active Comparator|Bactrim DS|Trim/sulfa (800/160) two tablets orally (PO) twice a day (BID) x 7 days
3252371|NCT00822692|Placebo Comparator|matched placebo|matched placebo 2 pills orally (PO) twice a day (BID) x 7 days
3252372|NCT00822679|Experimental|1: Eszopiclone|Subjects receive Eszopiclone for three consecutive nights to observe changes in sleep measures, and inflammatory and coagulation factors
3252373|NCT00822679|Placebo Comparator|2: Placebo|Subjects given placebo for 3 consecutive nights to observe changes in sleep measures, and inflammatory and coagulation factors
3252374|NCT00822666|Active Comparator|1|patients homozygous for the 2C19*1 genetic variant
3252375|NCT00822666|Experimental|2|carriers of the 2C19*2 genetic variant (homozygous or heterozygous)
3252376|NCT00822653|Experimental|Calf Muscle Pump Stimulation|Subjects serve as self-control. Six weeks of dialysis data without intervention will be compared to six weeks post intervention
3252377|NCT00822640|Experimental|1|Columbus Knee Prosthesis with rotating Platform
3252378|NCT00822640|Active Comparator|2|Columbus Knee Prosthesis with fixed platform
3252379|NCT00822627|Experimental|Vaccination group|Vaccination group
3252380|NCT00822627|Experimental|Education/referral|Education/referral
3252381|NCT00822614|Active Comparator|Active Comparator|Current BTP Medication
3252382|NCT00822614|Experimental|Fentanyl TAIFUN|Titration for dose confirmation followed by observation period
3252383|NCT00822601|Experimental|1|
3252384|NCT00822601|Placebo Comparator|2|
3252385|NCT00822588|Experimental|1|
3252386|NCT00822588|No Intervention|2|
3252387|NCT00822575|Active Comparator|A|
3252388|NCT00822575|Sham Comparator|B|
3252389|NCT00822562|Active Comparator|Procedure/Surgery|surgery
3252390|NCT00822562|Experimental|Procedure|PRFA or PMCT
3252391|NCT00822549||1|all the patients included in the study received intravenous morphine in PACU and in the wards
3252392|NCT00822536|Active Comparator|1|Bi therapy : aspirin/ clopidogrel
3252393|NCT00822536|Active Comparator|2|Monotherapy: aspirin
3252397|NCT00822510|Experimental|Telephone Interpersonal Counseling|Telephone delivered interpersonal counseling support intervention. Intervention was for 8 weeks. Participants were called on the telephone each week for about 30 minutes.
3252398|NCT00822510|Active Comparator|Telephone delivered education only|Telephone delivered education only. Educational topics included prostate cancer health, side effects, physical activity, diet. Participants were called on the telephone each week for about 30 minutes.
3252399|NCT00822497|Experimental|1|Music-Based Imagery
3252400|NCT00822497|Experimental|2|Music Alternate Engagement
3252401|NCT00822497|No Intervention|Control|Debridement under standard care with no music therapy interventions
3252402|NCT00822484|Active Comparator|ILV-095|6 SC single dose injections
3252403|NCT00822484|Placebo Comparator|Placebo|Placebo
3252404|NCT00822471|Other|Diabetes Self-Management Education|Education intervention with historic self-controls.
3252405|NCT00822458|Experimental|Arm I|"Patients receive oral hedgehog antagonist GDC-0449 once daily on days 1 and 4-28 in course 1 and on days 1-28 in all subsequent courses. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.~Blood samples are collected periodically for pharmacokinetic studies. Archival tumor tissue samples are collected and analyzed for the expression of genes that activate the SHH (e.g., Gli1, Gli2, SFRP1, ATOH1, and PTCH2) or WNT (e.g., DKK2 and DKK4) cell signal pathways by in situ hybridization and reverse transcriptase real time-PCR."
3252406|NCT00822432||1|
3252407|NCT00822419|Active Comparator|lidocaine|Lidocaine 5% cream 5 gr will be double blindly put on the skin preoperatively
3252408|NCT00822419|Experimental|ketamine|ketamine cream 5% 5gr will be put on the skin preoperatively
3252409|NCT00822419|Sham Comparator|placebo|non-drug similar cream will be put on the skin preoperatively
3252410|NCT00822406|Active Comparator|1|This arm received individualized homeopathic medicine during 6 months (initial phase), and completed three years (second phase)
3252411|NCT00822406|Placebo Comparator|2|This arm received placebo during 6 months. After this period, all patients received individualized homeopathic medicine for three years.
3252412|NCT00822393|Active Comparator|1|Busulfan
3252413|NCT00822393|Experimental|2|Treosulfan
3252414|NCT00822380|Experimental|Anemic children|
3252415|NCT00822367|Experimental|Nutritional suplements|
3252416|NCT00822354|Experimental|1|Subjects will receive tadalafil 20mg every other day for the first month, and then placebo for the second month.
3252417|NCT00822354|Experimental|2|Subjects will receive placebo for the first month, and tadalafil 20mg orally every other day for the second month.
3252418|NCT00822328|Experimental|1|Fermented milk with Lactobacillus casei strain Shirota 100ml per day
3252419|NCT00822328|Placebo Comparator|2|Unfermented milk without Lactobacillus casei strain Shirota 100ml per day
3252420|NCT00822315|Active Comparator|1|efavirenz
3252421|NCT00822315|Experimental|2|raltegravir 400 mg
3252422|NCT00822315|Experimental|3|raltegravir 800 mg
3252423|NCT00822302|Placebo Comparator|1.Saline Infusion|Patients randomised to this arm will receive an infusion of saline
3252424|NCT00822302|Active Comparator|2.recHDL|Patients randomised to the active comparator arm of the study will receive 40mg/kg reconstituted High density lipoproteins (lot nos 05422-00006) over a period of 4 hours, 24 hours prior to carotid endarterectomy.
3252425|NCT00822276||ADEH+ participants colonized with MSSA|
3252426|NCT00822276||ADEH+ participants colonized with MRSA|
3252427|NCT00822276||Uncolonized ADEH+ participants|
3252428|NCT00822276||ADEH- participants colonized with MSSA|
3252429|NCT00822276||ADEH- participants colonized with MRSA|
3252430|NCT00822276||Uncolonized ADEH- subjects|
3252431|NCT00822276||Non-atopic uncolonized S. aureus participants|
3252432|NCT00822263|Placebo Comparator|2|control
3252433|NCT00822263|Experimental|1|Active medicine
3252434|NCT00822250|Other|1|cutting hair, skin phenotype description
3252435|NCT00822237|Experimental|VARIVAX 2007 process + M-M-R II|
3252436|NCT00822237|Active Comparator|VARIVAX 1999 process + M-M-R II|
3252437|NCT00822224|Experimental|1|Use of MEOPA during the painful care
3252438|NCT00822211|Experimental|Vildagliptin Dose 1|
3252439|NCT00822211|Experimental|Vildagliptin Dose 2|
3252440|NCT00822211|Placebo Comparator|Placebo|
3252441|NCT00822198|Experimental|plantar vibration|Subject will use Juvent plantar vibration device daily in the home or office for six months.
3252442|NCT00822185|Experimental|vatreptacog alfa, 5 mcg/kg|
3252443|NCT00822185|Experimental|vatreptacog alfa, 10 mcg/kg|
3252444|NCT00822185|Experimental|vatreptacog alfa, 20 mcg/kg|
3252445|NCT00822185|Experimental|vatreptacog alfa, 30 mcg/kg|
3252446|NCT00822172|Active Comparator|Cilostazol + L-Carnitine|
3252447|NCT00822172|Placebo Comparator|Cilostazol + Placebo|
3252448|NCT00822146|Experimental|1|
3252449|NCT00822133|Active Comparator|lodocaine|lidocaine 5% cream will be put on the skin
3252450|NCT00822133|Experimental|ketamine|ketamine 5% will be put on the skin
3252451|NCT00822133|Placebo Comparator|placebo|non-active cream will be put on the skin
3252452|NCT00822120|Experimental|HIV Positive, PET Positive: BEACOPP standard|Etoposide 100 mg/m2 IV Days 1, 2, 3 Dox 25 mg/m2 IV Day 1 Cyclo 650mg/m2 IV Day 1 Procarb 100 mg/m2 PO Days 1-7 Pred 40 mg/m2 PO Days 1-14 Bleo 10u/m2 IV Day 8 Vincristine 1.4 mg/m2 IV Day 8 Q 21 Days x 6 cycles
3252453|NCT00822120|Experimental|HIV Negative, PET Positive: BEACOPP escalated|Etoposide 200 mg/m2 IV Days 1, 2, 3 Dox 35 mg/m2 IV Day 1 Cyclo 1,250 mg/m2 IV Day 1 Procarb 100 mg/m2 PO Days 1-7 Pred 40 mg/m2 PO Days 1-14 Bleo 10u/m2 IV Day 8 Vincristine 1.4 mg/m2 IV Day 8 G-CSF 5mcg/kg/day SQ Days 8-14 Q 21 Days x 6 cycles
3252454|NCT00822120|Active Comparator|HIV Positive, PET Negative: ABVD|Doxorubicin 25 mg/m2 IV Bleomycin 10u/m2 IV Vinblastine 6mg/m2 IV Dacarbazine 375 mg/m2 IV Days 1, 15 Q 28 Days x 2
3252455|NCT00822120|Active Comparator|HIV Negative, PET Negative: ABVD|Doxorubicin 25 mg/m2 IV Bleomycin 10u/m2 IV Vinblastine 6mg/m2 IV Dacarbazine 375 mg/m2 IV Days 1, 15 Q 28 Days x 2
3252456|NCT00822107|Experimental|Thiazide Response|The response to a single dose of a thiazide diuretic will be tested.
3252457|NCT00822094|Experimental|CPX-351 (Arm A)|First induction: 100 units/m2 on Days 1, 3, and 5 by 90-minute IV infusion Second induction: 100 units/m2 on Days 1 and 3 by 90-minute IV infusion Consolidation(s): 100 units/m2 on Days 1 and 3 by 90-minute IV infusion
3252458|NCT00822094|Active Comparator|Salvage Therapy (Arm B)|First induction: Investigator's choice salvage therapy administered according to local practice Second induction: Investigator's choice salvage therapy administered according to local practice Consolidation(s): Investigator's choice consolidation therapy administered according to local practice
3252459|NCT00822081|Active Comparator|1|brimonidine/timolol. Fixed-combination monotherapy.
3252460|NCT00822081|Active Comparator|2|dorzolamide/timolol. Fixed-combination monotherapy.
3252461|NCT00822081|Active Comparator|3|prostaglandin analogue+ brimonidine/timolol fixed combination.
3252462|NCT00822081|Active Comparator|4|prostaglandin analogue+dorzolamide/timolol fixed combination.
3252463|NCT00822068|Experimental|anodal tDCS|
3252464|NCT00822068|Active Comparator|2|cathodal tDCS
3252465|NCT00822068|Placebo Comparator|3|sham stimulation
3252466|NCT00822055|Active Comparator|1|brimonidine/timolol Fixed-combination monotherapy
3252467|NCT00822055|Active Comparator|2|dorzolamide/timolol fixed-combination monotherapy
3252468|NCT00822055|Active Comparator|3|prostaglandin analogue + brimonidine/timolol fixed combination
3252469|NCT00822055|Active Comparator|4|prostaglandin analogue + dorzolamide/timolol fixed combination
3252470|NCT00822042||1|Patients with corticotherapy lasting more than 3 months
3252471|NCT00822029|Experimental|1|FOSAMAX (oral bisphosphonate)
3252472|NCT00822029|Placebo Comparator|2|PLACEBO
3252473|NCT00822003|Active Comparator|1|Human GLP-1
3252474|NCT00822003|Placebo Comparator|2|Placebo tablet
3252475|NCT00821990|Active Comparator|Chemotherapy|Eligible patients will be first offered randomization. If willing to participate RCT, the patient will be randomized to chemotherapy or best supportive care. If patients refuse to participate in RCT, but nevertheless agree to receive treatment of their preferences, they are offered their treatment of choice (chemotherapy or supportive care).
3252476|NCT00821990|Active Comparator|Supportive care|Eligible patients will be first offered randomization. If willing to participate RCT, the patient will be randomized to chemotherapy or best supportive care. If patients refuse to participate in RCT, but nevertheless agree to receive treatment of their preferences, they are offered their treatment of choice (chemotherapy or supportive care).
3252477|NCT00821977|Experimental|Vildagliptin Dose 1|
3252478|NCT00821977|Experimental|Vildagliptin Dose 2|
3252479|NCT00821977|Placebo Comparator|Placebo|
3252480|NCT00821964|Experimental|Treatment (biological therapy, chemo)|Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
3252481|NCT00821951|Experimental|Vorinostat and Radiotherapy|
3252482|NCT00821938|Active Comparator|CRT-ICD|
3252483|NCT00821938|Placebo Comparator|DDD-ICD|
3252484|NCT00821912|Experimental|Taxotere Xeloda|"Taxotere i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule.~Xeloda orally day 1-14 every 3 weeks."
3252485|NCT00821886|Experimental|Ixabepilone/Trastuzumab/Carboplatin|Neoadjuvant treatment with Ixabepilone, Trastuzumab and Carboplatin, followed by surgery, peri-operative treatment and post-operative (adjuvant) treatment if patient deemed to be a surgical candidate
3252486|NCT00821873|Experimental|CR Plug BackFill|Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site
3252487|NCT00821860|Experimental|Arm I|Patients undergo video-assisted thoracoscopic cytoreductive pleurectomy either at the time of biopsy or after confirmation of biopsy results.
3252488|NCT00821860|Active Comparator|Arm II|Patients undergo talc pleurodesis via an indwelling intercostal chest drain or via thoracoscopy either at the time of biopsy or after confirmation of biopsy results.
3252489|NCT00821847||1:experimental|male, caucasian, HIV infected patients with glomerular filtration rate between 60 and 30 ml/min (estimated with cockcroft and Gault formulae)
3252490|NCT00821834|Experimental|Clopidogrel|"Patients received:~clopidogrel 300 mg as a loading dose, then 75 mg once daily as a maintenance dose,~ticlopidine matching placebo twice daily."
3252491|NCT00821834|Active Comparator|Ticlopidine|"Patients received:~ticlopidine 100 mg twice daily,~clopidogrel matching placebo once daily."
3252492|NCT00821821|Experimental|MCI-186|
3252493|NCT00821821|Placebo Comparator|Placebo Group|
3252494|NCT00821795|Active Comparator|NPH/Regular 70/30 mix|transition insulin therapy with NPH/Regular 70/30 mix for outpatient glycemic control following a hospitalization for non-critical acute illness
3252495|NCT00821795|Active Comparator|Aspart insulin analog biphasic mix|transition insulin therapy with Aspart insulin analog 70/30 mix for outpatient glycemic control following a hospitalization for non-critical acute illness
3252496|NCT00821756|Experimental|1|Assertive intervention in OPAC-style: Outreach,problem solving,adherence,continuity
3252497|NCT00821756|No Intervention|2|Control arm: Treatment as usual
3252498|NCT00821743|Other|1|The DBS electrodes (model 3389, Medtronic) will be stereotactically implanted bilaterally in the PPN, according to the technique usually used for STN-DBS, and connected to the subcutaneously implanted stimulator (Kinetra, Medtronic).
3252499|NCT00821717|Experimental|1:|
3252500|NCT00821717|Placebo Comparator|2|
3252501|NCT00821691|Other|1|"Amantadin - Placebo: 5 amantadin caps - 4 days wash out - 5 placebo caps~5 amantadin caps (100mg); 2 caps a day during 3 days; after wash out period (4 days): 5 placebo caps (2 caps a day during 3 days)"
3252502|NCT00821691|Other|2|"Placebo - Amantadin: 5 placebo caps - 4 days wash out - 5 amantadin caps~5 placebo caps: 2 caps a day during 3 days after wash out period (4 days): 5 amantadin caps(100mg) (2 caps a day during 3 days)"
3252503|NCT00821678|Experimental|Arm 1 Telemedicine Outreach for PTSD|Telemedicine-Based Collaborative Care
3252504|NCT00821678|No Intervention|Arm 2 Treatment as usual|Usual Care
3252505|NCT00821665|Experimental|Sucrose|Sucrose
3252506|NCT00821665|Placebo Comparator|Water|Water
3253153|NCT00817479|Placebo Comparator|Placebo [Saline]|Saline
3252507|NCT00821652|Other|Dose-esclation|Part I represents a dose-escalation part with topical resiquimod in an open-label fashion.
3252508|NCT00821652|Experimental|2|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I.
3252509|NCT00821626|Active Comparator|Rapid test|Returning travelers with fever will have a rapid flu test
3252510|NCT00821626|Sham Comparator|Comparator|Returning travelers with fever will benefit of the usual medical care, without rapid flu test
3252511|NCT00821600|Experimental|001|risperidone IR and LAI formulation 1 mg risperidone IR single injection followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
3252512|NCT00821587|Active Comparator|Tacrolimus|Tacrolimus
3252513|NCT00821587|Active Comparator|Cyclosporine|Cyclosporine
3252514|NCT00821574|Experimental|1|Fluvastatin: daily 80 mg, oral
3252515|NCT00821574|Experimental|2|Valsartan
3252516|NCT00821574|Experimental|3|Hydrochlorothiazide
3252517|NCT00821548|Experimental|1|Electrostimulation of the muscles of the scapular belt and the femoris quadristocks
3252518|NCT00821535|Other|Active group|maraviroc dosing group
3252519|NCT00821522|Active Comparator|Preconditioning|
3252520|NCT00821522|No Intervention|Control|Standard clinical management during cardiac surgery.
3252521|NCT00821509|Active Comparator|Hand washing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent hand washing in office and at home
3252522|NCT00821509|Active Comparator|Disinfectant rubbing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
3252523|NCT00821509|No Intervention|Control|No change in hygiene behaviour
3252524|NCT00821496|Experimental|Oral Contraceptive|
3252525|NCT00821483|Placebo Comparator|1: placebo|
3252526|NCT00821483|Active Comparator|2 Frovatriptan|
3252527|NCT00821470|Experimental|bone marrow graft group|core decompression + bone marrow implantation into the necrotic lesion
3252528|NCT00821470|Active Comparator|control|core decompression
3252529|NCT00821457|Active Comparator|Group 1|250ng Juvista vs placebo
3252530|NCT00821457|Active Comparator|Group 2|500 ng Juvista vs placebo
3252531|NCT00821444|Active Comparator|Geodon fed|Commercial Geodon (ziprasidone) capsules given with food
3252532|NCT00821444|Experimental|B16 Fasted|Experimental reduced food effect formulation given without food
3252533|NCT00821444|Experimental|B16 Fed|Experimental reduced food effect formulation given with food
3252534|NCT00821431|Experimental|Compression device|The electrical compression device is operated from battery or a main adaptor. It is based upon the use of inflatable pneumatic cuffs that apply controlled compression to the foot, ankle and calf.
3252535|NCT00821431|Active Comparator|Profore, 4-layer bandage|A high compression 4-layer bandage (Profore, Trademark of Smith and Nephew). This is a four-layer system that can be purchased either separately or as a package: a wound contact layer (Knitted viscose), a sub-compression wadding bandage, two layers of elastane bandage plus a top cohesive layer.
3252536|NCT00821418|Experimental|PulsHaler first|
3252537|NCT00821418|Placebo Comparator|Placebo first|
3252538|NCT00821405||peritoneal dialysis|peritoneal dialysis patient lasting for more than 3 months
3252539|NCT00821392|Active Comparator|1 Febuxostat 40mg|
3252540|NCT00821392|Active Comparator|2 Febuxostat 80mg|
3252541|NCT00821392|Active Comparator|3 Febuxostat 120mg|
3252542|NCT00821392|Sham Comparator|4 Allopurinol 300mg|
3252543|NCT00821392|Placebo Comparator|5 Placebo|
3252544|NCT00821366|Active Comparator|1|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment only group
3252545|NCT00821366|Active Comparator|2|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment and ARV peer adherence support group
3252546|NCT00821366|Active Comparator|3|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment, ARV peer adherence support and nutritional support group
3252547|NCT00821366|No Intervention|4|Randomly selected households from the general community served by the selected health facility, excluding households where someone is known to receive ARV treatment - comparison/control group
3252548|NCT00821353|Active Comparator|RFCA|
3252549|NCT00821353|Active Comparator|Drug|
3252550|NCT00821340|Experimental|rAAV2-hRPE65|
3252551|NCT00821327|Experimental|Study Arm|Gemcitabine, Cisplatin, Sunitinib
3252552|NCT00821288|Experimental|Survivorship Intervention|Latina and Caucasian breast cancer survivors treated in an urban academic medical center receiving Survivorship Intervention
3252553|NCT00821288|Active Comparator|Facing Forward|Latina and Caucasian breast cancer survivors treated in an urban academic medical center receiving Survivorship Intervention Facing Forward: Life after Cancer Treatment manual
3252554|NCT00821275|Active Comparator|pregnancy expectation|The patients who desire for future pregnancy will enroll into this arm , and will be divided into UAE group and SURGERY group.
3252555|NCT00821275|Active Comparator|No pregnancy expectation|The patients who don't desire for reserving uterus and/ or future pregnancy will enroll into this arm , and will be divided into UAE group and SURGERY group.
3252556|NCT00821262|Experimental|sevoflurane|The study group will receive Sevoflurane for a 4-6 hours period (from anesthesia induction to transfer to ICU).
3252557|NCT00821262|Active Comparator|propofol|The control group will receive propofol for the same 4-6 hours period.
3252558|NCT00821249|Experimental|ARRY-520|
3252559|NCT00821249|Experimental|ARRY-520 + G-CSF support|
3252560|NCT00821249|Experimental|ARRY-520 + dexamethasone + G-CSF support|
3252561|NCT00821236|Active Comparator|Wavelight|WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment
3252562|NCT00821236|Active Comparator|AMO/VISX CustomVue|AMO/VISX CustomVue™
3252564|NCT00821223|Active Comparator|manual small incision cataract surgery|surgical intervention by small incision cataract surgery
3252565|NCT00821223|Other|phacoemulsification|surgical intervention by phacoemulsification
3252566|NCT00821210|Sham Comparator|2|
3252567|NCT00821210|Active Comparator|1|
3252568|NCT00821197|Active Comparator|long-limb bypass|Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)
3252569|NCT00821197|Active Comparator|Distal gastric bypass|Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)
3252570|NCT00821184|Active Comparator|Vesicare|Vesicare alone
3252571|NCT00821184|Active Comparator|Vesicare/behavioral modification|Vesicare plus behavioral modification
3252572|NCT00821158|Placebo Comparator|1|Placebo tablet and iv
3252573|NCT00821158|Experimental|2|Placebo tablet and intervention iv
3252574|NCT00821158|Experimental|3|Intervention tablet and placebo iv
3252575|NCT00821145|Active Comparator|1|50 patients operated using a conventional open surgery to exclude an abdominal aortic aneurysm
3252576|NCT00821145|Experimental|2|50 patients operated using a total laparoscopic aortic aneurysm resection
3252577|NCT00821145|Active Comparator|3|25 patients using a laparoscopic approach for AAA resection with a stapled proximal anastomosis
3252578|NCT00821132||ALS families|Patients with either inherited or sporadic ALS or PLS and selected family members
3252579|NCT00821119|Active Comparator|NCPAP|preterm infants with nasal positive pressure ventilation as a primary mode of respiratory support in preterm infants with respiratory distress syndrome will be compared to preterm infants with nasal intermittent positive pressure ventilation
3252580|NCT00821119|Experimental|NIPPV|preterm with nasal intermittent positive pressure ventilation as a primary mode of respiratory support in preterm infants with respiratory distress syndrome
3252581|NCT00821106|Experimental|Right transradial approach|Coronary diagnostic or interventional procedures performed through right radial approach
3252582|NCT00821106|Experimental|Left transradial approach|Diagnostic or interventional procedures performed through left radial approach
3252583|NCT00821093|Experimental|Indacaterol 150 µg|Patients inhaled indacaterol 150 μg once daily in the morning between 8:00 and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Patients also inhaled placebo to salmeterol twice daily, once in the morning between 8:00 and 11:00 AM and once in the evening between 8:00 and 11:00 PM via the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3252584|NCT00821093|Active Comparator|Salmeterol 50 µg|Patients inhaled salmeterol 50 μg twice daily, once in the morning between 8:00 and 11:00 AM and once in the evening between 8:00 and 11:00 PM via the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]) for 12 weeks. Patients also inhaled placebo to indacaterol once daily in the morning between 8:00 and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3252585|NCT00821080|Experimental|Vandetanib and Sirolimus|Single arm study
3252586|NCT00821067|Active Comparator|1|A 6 gm/day (3 gm/bid) dose of D-ribose
3252587|NCT00821067|Placebo Comparator|2|A 6 gm/day (3 gm/bid) dose of dextrose.
3252588|NCT00821054|Experimental|Period 1|Treatment A, B or C
3252589|NCT00821054|Experimental|Period 2|Treatment A, B or C
3252590|NCT00821054|Experimental|Period 3|Treatment A, B or C
3252591|NCT00821041|No Intervention|Waiting list control|
3252592|NCT00821041|Experimental|CBT|A 6 weeks online course. Each week participants log on to view videos and read information that focus on a variety of intervention techniques. These include relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training. Participants also monitor their sleep using an online sleep diary and respond to questions regarding their adherence to the program.
3252593|NCT00821028|Experimental|Paclitaxel|Participants will receive Paclitaxel.
3252594|NCT00821015|Experimental|Experimental|All study subjects will undergo cryoablation. This is a non-randomized trial.
3252595|NCT00821002|Experimental|Plug placement|
3252596|NCT00820989|Experimental|A|Time points after IV Endotoxin administration compared to baseline (immediately before Endotoxin administration).
3252597|NCT00820976|No Intervention|control|remission induction with cytosine arabinoside amd idarubicine
3252598|NCT00820976|Experimental|G-CSF|G-CSF was administered starting on Day 8 until neutrophil recovery
3252599|NCT00820963|Experimental|Arm I|Patients undergo standard radiotherapy 5 days a week for 6 weeks.
3252600|NCT00820963|Experimental|Arm II|Patients undergo hypofractionated radiotherapy 5 days a week for 2 weeks.
3252601|NCT00820963|Experimental|Arm III|Patients receive oral temozolomide on days 1-5. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3252602|NCT00820950|Experimental|Treatment 1: INCB018424|INCB018424 -- 0.5%
3252603|NCT00820950|Experimental|Treatment 2: INCB018424|INCB018424 -- 1.0%
3252604|NCT00820950|Experimental|Treatment 3: INCB018424|INCB018424 -- 1.5%
3252605|NCT00820950|Placebo Comparator|Treatment 4: Placebo|Placebo Cream
3252606|NCT00820950|Active Comparator|Treatment 5: Dovonex® calcipotriene|Dovonex® calcipotriene 0.005% cream
3252607|NCT00820950|Active Comparator|Treatment 6: Diprolene® AF betamethasone diproprionate|
3252608|NCT00820924|Experimental|LAPATINIB|LAPATINIB 1500MG ORAL ONCE DAILY
3252609|NCT00820911|Active Comparator|cyclosporine (reduced exposure) / everolimus|
3252610|NCT00820911|Experimental|AEB071 300 mg b.i.d. / everolimus|
3252611|NCT00820911|Experimental|AEB071 200 mg b.i.d. / everolimus|
3252612|NCT00820898|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3252613|NCT00820885|Other|cohort A|20 mg dose 20 mg/ML concentration and placebo
3252614|NCT00820885|Other|Cohort AR|20 mg in 50 mg/ml concentration and placebo
3252615|NCT00820885|Other|Cohort C|25 mg in 50mg/ml concentration and placebo
3252616|NCT00820885|Other|Cohort D|15 mg in 50mg/ml concentration and placebo
3252617|NCT00820885|Other|Cohort E|10 mg in 50mg/ml concentration and placebo
3252618|NCT00820885|Other|Cohort F|30mg in 50mg/ml concentration and placebo
3252619|NCT00820885|Other|Cohort H|50mg in 50mg/ml concentration and placebo
3252620|NCT00820885|Other|cohort I|80mg in 50mg/ml concentration and placebo
3252621|NCT00820872|Experimental|docetaxel + carboplatin + trastuzumab + lapatinib|"Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes on day 1, trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15, and oral lapatinib ditosylate on days 1-21 (TCHL). Treatment with TCHL repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30-90 minutes on day 1 and oral lapatinib ditosylate on days 1-21 (days 1-7 of course 12 only) (LT). Treatment with LT repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 6 months for 2 years and then annually for up to 8 years."
3252622|NCT00820859|Experimental|1|
3252623|NCT00820859|Active Comparator|2|
3252624|NCT00820846|Experimental|Part A, Group 1|Participants will receive two injections of the pGA2/JS7 DNA vaccine and then two injections of the MVA/HIV62 vaccine
3252625|NCT00820846|Placebo Comparator|Part A, Group 2|Participants will receive four placebo injections
3252626|NCT00820846|Experimental|Part B, Group 3|Participants will receive two injections of the pGA2/JS7 DNA vaccine and then two injections of the MVA/HIV62 vaccine
3252627|NCT00820846|Experimental|Part B, Group 4|Participants will receive three injections of the MVA/HIV62 vaccine and one injection of the placebo
3252628|NCT00820846|Placebo Comparator|Part B, Group 5|Participants will receive four placebo injections
3252629|NCT00820833|Placebo Comparator|1|Standard infant formula
3252630|NCT00820833|Experimental|2|Test formula
3252631|NCT00820833|No Intervention|3|Breastfeeding reference group
3252632|NCT00820820|Active Comparator|Rouvax|
3252633|NCT00820820|Placebo Comparator|Placebo|Sub cutaneous injection of vehicle
3252634|NCT00820807|Experimental|1|3g/day
3252635|NCT00820807|Experimental|2|6g/day
3252636|NCT00820807|Placebo Comparator|Placebo beverage|0g/day
3252637|NCT00820794|Experimental|Cohort 1a|Subjects are treated with single dose lithium first. Then after at least 7 day washout, the subjects start PD 0332334 treatment from day 1 to day 9. At day 4 of PD 0332334 treatment, single dose lithium is given to subjects.
3252638|NCT00820794|Experimental|Cohort 1b|Subjects are treated with PD 0332334 from day 1 to 9 and a single dose of lithium is given at day 4. After at least 7 day washout, the subjects are treated with single dose of lithium.
3252639|NCT00820781|Active Comparator|Portacaval shunt|Undergo portacaval shunt surgery
3252640|NCT00820781|Active Comparator|Sclerotherapy|Undergo endoscopic sclerotherapy
3252641|NCT00820768|Experimental|ABI-010|
3252642|NCT00820755|Active Comparator|Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy|
3252643|NCT00820755|Active Comparator|Cetuximab 500 mg/m^2 every 2 weeks|
3252644|NCT00820755|Active Comparator|Cetuximab 250 mg/m^2 weekly|
3252645|NCT00820742||Phase IV Post Marketing Surveillance Study|Open-label, observational study
3252646|NCT00820729||1|Patients with interstitial pulmonary disease
3252647|NCT00820716|Experimental|CA|Exercise training with alternate load
3252648|NCT00820716|Active Comparator|CC|Exercise training with constant load
3252649|NCT00820690||Clinical stage III|Women with invasive breast cancer; clinical stage III, condition to receive neoadjuvant chemotherapy based in doxorubicin/ cyclophosphamide and paclitaxel followed by surgery (mastectomy and axillary lymph node dissection)
3252650|NCT00820677|Experimental|DVD/Video|Parents of newborns in the experimental group attending their first baby visit will be shown a video about newborn care.
3252651|NCT00820664|Active Comparator|17β-estradiol 2.0 milligrams|Estrace 2.0 mg tablet
3252652|NCT00820664|Active Comparator|17β-estradiol 0.5 milligrams|Estrace 0.5 mg tablet
3252653|NCT00820664|Placebo Comparator|3|Placebo
3252654|NCT00820651|Placebo Comparator|Placebo|
3252655|NCT00820651|Experimental|Diamel|
3252656|NCT00820638|Experimental|1|observational
3252657|NCT00820625|Active Comparator|1|ablation: pulmonary vein isolation
3252658|NCT00820625|Active Comparator|2|ablation: pulmonary vein isolation with additional ablation of fragmented potentials
3252659|NCT00820612|Active Comparator|1|Indomethacin suppository
3252660|NCT00820612|Placebo Comparator|2|Placebo suppository
3252661|NCT00820599|Experimental|TAVR|Transaortic Valve Replacement
3252662|NCT00820586|Experimental|Mononuclear bone marrow derived cells|Intramyocardial injection of total mononuclear bone marrow derived cells
3252663|NCT00820586|Experimental|Selected CD34+ bone marrow derived cells|Intramyocardial injection of selected CD34+ bone marrow derived cells
3252664|NCT00820573|Placebo Comparator|Placebo|Placebo to be provided for 6 weeks
3252665|NCT00820573|Experimental|Sitagliptin|Sitagliptin to be provided for 6 weeks
3252666|NCT00820573|Experimental|Metformin|Metformin to be provided for 6 weeks
3252667|NCT00820573|Experimental|Sitagliptin+Metfromin|Sitagliptin + Metformin combined will be provided for 6 weeks
3252668|NCT00820560|Experimental|INCB07839 100mg, immediate release (IR) capsules|
3252669|NCT00820560|Experimental|INCB07839 200 mg IR capsules|
3252670|NCT00820547|Experimental|(FEC / Docetaxel) + Bevacizumab|Neoadjuvant treatment: 4 cycles FEC + Bevacizumab followed by 4 cycles Docetaxel + Bevacizumab Adjuvant: Bevacizumab for 1 year
3252671|NCT00820534|Experimental|Penciclovir|Penciclovir
3252672|NCT00820534|Placebo Comparator|Placebo|Placebo
3252673|NCT00820521|Experimental|active|
3252674|NCT00820521|Placebo Comparator|placebo|
3252675|NCT00820508|Experimental|1|Oral, once daily administration of CHR-2845 to determine safety and tolerability
3252676|NCT00820495|Experimental|Web + Phone|Highly interactive tailored Web-based smokeless tobacco cessation program plus phone counseling
3252677|NCT00820495|Experimental|Web Only|Highly interactive tailored Web-based smokeless tobacco cessation program
3252678|NCT00820495|Experimental|Phone Only|Phone counseling intervention for smokeless tobacco cessation
3252679|NCT00820495|Experimental|Control|Usual care (initial call plus self-help materials)
3252680|NCT00820482|Active Comparator|Group A|Group A: 75 UI/day of Hp-hMG (Menopur®, Ferring, Copenhaghen, Dinamarca)
3252681|NCT00820482|Experimental|Group B|75UI/day of rFSH (Gonal®, Serono, Ginebra, Suiza) + 75UI/day of rLH (Luveris®, Serono, Ginebra, Suiza)
3252682|NCT00820469|Experimental|1|Patients treated by rituximab
3252683|NCT00820469|Experimental|2|Patients treated by rituximab and plasma exchange
3252684|NCT00820456||Colorectal Cancer, Hepatic Metastasis|Eligible participants in Arm A enrolled in this imaging study will: be older than 18, have metastatic colorectal cancer with at least one hepatic lesion, and be treated with FOLFOX in combination with bevacizumab.
3252685|NCT00820456||Primary Tumor Undefined, Hepatic Metastasis|Eligible participants in Arm B enrolled in this imaging study will: be older than 18, must have prior histological documentation of any types of cancer with metastasis to the liver, and must be in stable treatment conditions prior to and between scans.
3252686|NCT00820443|Experimental|Ceramic on metal prosthesis|Ceramic on metal prosthesis
3252687|NCT00820430||Control--Non-Osteoporotic Knee|Kellgren-Lawrence (KL) scale score of 0, Age: 18-35 years
3252688|NCT00820430||Minimal Osteoarthritis, Knee|Kellgren-Lawrence (KL) scale score of 1 or 2, Age: Older than 18; no upper limit
3252689|NCT00820430||Moderate Osteoarthritis, Knee|Kellgren-Lawrence (KL) scale score of 3, Age: Older than 18; no upper limit
3252690|NCT00820417|Experimental|a|Dose-escalation
3252691|NCT00820417|Experimental|B|Maximum tolerated dose (MTD)
3252692|NCT00820404|Experimental|1|BLI-489
3252693|NCT00820404|Placebo Comparator|2|Placebo
3252694|NCT00820391|Experimental|KIDNET|Narrative Exposure Therapy for Children
3252695|NCT00820391|Experimental|Meditation/Relaxation|
3252696|NCT00820378||atherosclerosis|Patients With Clinically Evident Arterial Disease or Cardiovascular Risk Factors
3252697|NCT00820352|Active Comparator|bosentan|Patients in this arm receive bosentan twice a day for 12 weeks
3252698|NCT00820352|Placebo Comparator|placebo|patients in this arm receive 12 placebo twice a day for 12 weeks
3252699|NCT00820339|Active Comparator|Selective Hepatic Vascular Exclusion|Patients with HCC received Selective Hepatic Vascular Exclusion in hepatectomy.
3252700|NCT00820339|Experimental|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
3252701|NCT00820326|Active Comparator|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
3252702|NCT00820326|Placebo Comparator|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
3252703|NCT00820313|Other|Lifestyle Intervention|Comprehensive lifestyle intervention for reversal of heart disease
3252704|NCT00820300|Experimental|Punctal plug|
3252705|NCT00820274|Experimental|amniotic membranes|
3252706|NCT00820261||Diarrhea|children and infants (less than 5 years of age) presenting with severe diarrhea will be enrolled
3252707|NCT00820248|Active Comparator|Arm I|Patients undergo standard fractionation radiotherapy (IMRT or 3D CRT) once daily, 5 days a week, for 7 weeks. Patients receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
3252708|NCT00820248|Experimental|Arm II|Patients undergo accelerated fractionation radiotherapy (IMRT or 3D CRT) once or twice daily, 5 days a week, for 6 weeks. Patients receive panitumumab IV over 30-90 minutes 1 week prior to and on days 15 and 36 of radiotherapy.
3252709|NCT00820235|Experimental|A|
3252710|NCT00820235|Active Comparator|B|
3252711|NCT00820235|Active Comparator|C|
3252712|NCT00820222|Experimental|Lapatinib plus capecitabine|Lapatinib 1250 mg once daily and capecitabine 2000mg/m2/day, days 1-14, every 21 days
3252713|NCT00820222|Active Comparator|Trastuzumab plus capecitabine|trastuzumab loading dose of 8mg/kg followed by 6mg/kg q3weekly infusions, and capecitabine 2500mg/m2/day, days 1-14, every 21 days
3252714|NCT00820183|Experimental|quality improvement plan|It will be the group of primary health care teams who will undertake the quality improvement plan for hypertensive patients
3252715|NCT00820183|No Intervention|non intervention|It will be the group of primary health care teams that will not undertake the quality improvement plan for hypertension control
3252716|NCT00820170|Experimental|dasatinib and paclitaxel|"The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel.~The phase II portion of this trial has a Simon two-stage design to determine the efficacy of dasatinib when administered in combination with paclitaxel."
3252717|NCT00820157|Active Comparator|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE
3252718|NCT00820157|Experimental|TACE|TACE alone
3252719|NCT00820144|Experimental|1|voie nasale 0.25 mg
3252720|NCT00820144|Experimental|2|0.5mg of CTB by oral way
3252721|NCT00820144|Experimental|3|1mg of dukoral by oral way
3252722|NCT00820144|Experimental|4|0.25mg of CTB by sublingual way
3252723|NCT00820144|Experimental|5|1mg of CTB by sublingual way
3252724|NCT00820131|Experimental|1|
3252725|NCT00820131|Active Comparator|2|
3252726|NCT00820118|Experimental|Intermittent treatment|6 months on antiretroviral treatment and 6 months off treatment
3252727|NCT00820105|Experimental|ADX10059 25 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
3252728|NCT00820105|Experimental|ADX10059 50 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
3252729|NCT00820105|Experimental|ADX10059 100 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
3252730|NCT00820105|Placebo Comparator|ADX10059 Matching Placebo|Weeks 1-2: once daily Weeks 3-12: twice daily
3252731|NCT00820092|Active Comparator|Xerecept 1.0|1.0 ug/kg/hr hCRF -24 hour IV infusion
3252732|NCT00820092|Active Comparator|Xerecept 2.0|2.0 ug/kg/hr-24 hour IV infusion
3252733|NCT00820092|Active Comparator|Xerecept 3.0|3.0 ug/kg/hr-24 hour infusion
3252734|NCT00820079|Experimental|ADX10059 120 mg|Twice-daily
3252735|NCT00820079|Placebo Comparator|ADX10059 Matching Placebo|twice-daily
3252736|NCT00820053|No Intervention|no adjuvant TACE|controll group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive adjuvant TACE after liver resection
3252737|NCT00820053|Experimental|adjuvant TACE|patients who adjuvant TACE after liver resection
3252738|NCT00820027|Experimental|Etoricoxib 90 mg|
3252739|NCT00820027|Experimental|Etoricoxib 120 mg|
3252740|NCT00820027|Active Comparator|Ibuprofen 1800 mg|
3252741|NCT00820027|Placebo Comparator|Placebo|
3252742|NCT00820014|Experimental|1|ESBA105 eye drops
3252743|NCT00820014|Placebo Comparator|2|Placebo control (vehicle)
3252744|NCT00820001|Experimental|Acute Treatment Protocol Booster|Child participants in this arm were initial participants enrolled in the parent study and randomized to receive the specialty treatment from study clinicians in either the clinic or community setting. In this continuation study, the participants were enrolled at the 36 month assessment and randomized to participate in the booster dose of treatment. The treatment provided in this arm includes specific booster treatment based on the 8 modules of the initial treatment study. Saliva samples were also collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
3252745|NCT00820001|Experimental|Acute Treatment Protocol No-Booster|Child participants in this arm were initial participants enrolled in the parent study and randomized to receive the specialty treatment from study clinicians in either the clinic or community setting. In this continuation study, the participants were enrolled at the 36 month assessment and randomized to participate in assessments only thus not receiving any additional booster treatment. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
3252746|NCT00820001|Active Comparator|Treatment As Usual|Child participants in this arm were initial participants enrolled in the parent study in the clinically referred Treatment As Usual comparison group. These participants were initially enrolled in treatment services with identified providers and received treatment services as provided in that community agency. In this continuation study, the participants were enrolled at the 36 month assessment and participated in the ongoing follow-up assessments only. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
3252747|NCT00820001|Other|No Intervention Healthy Comparison|The Healthy Control subjects enrolled initially in the parent study are incorporated in a related project designed to evaluate the role of biological measures in differentiating antisocial and normal children. All Healthy Control participants were initially matched to cases in the clinical sample (both the acute treatment and the clinically referred Treatment as Usual).
3252748|NCT00819988|Placebo Comparator|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
3252749|NCT00819988|Experimental|Pregabalin|Single dose of 75 mg given 30-60 minutes preoperatively, then 50 mg every 8 hours for 3 days postoperatively if creatinine clearance > 60 ml/min OR 25 mg every 8 hours for 3 days postoperatively if creatinine clearance 30-60 ml/min
3252750|NCT00819975|Active Comparator|Casein|
3252751|NCT00819975|Active Comparator|Whey Isolate|
3252752|NCT00819975|Active Comparator|Whey Hydrolysate|
3252753|NCT00819975|Active Comparator|Alphalact-Albumin|
3252754|NCT00819962|Other|TAP|ksu
3252755|NCT00819949|Experimental|Arm 1|Potential eligible subjects for the trial will be individuals between ages 18-85, with a confirmed diagnosis of PD that experience freezing.
3252756|NCT00819936|Experimental|2|Backward walking,
3252757|NCT00819936|Active Comparator|1|Forward walking
3252758|NCT00819923|Experimental|1|Patients receiving bio-active stent during the intervention
3252759|NCT00819923|Active Comparator|2|Patients receiving everolimus-eluting stent during the intervention
3252760|NCT00819910|Active Comparator|Rosiglitazone + Placebo|Rosiglitazone 8 mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks
3252761|NCT00819910|Active Comparator|Fenofibrate + Placebo|Fenofibrate 145mg daily + Placebo (Rosiglitazone) 8mg daily for 12weeks
3252762|NCT00819910|Experimental|Rosiglitazone +Fenofibrate|Rosiglitazone 8mg daily + Fenofibrate 145mg daily for 12 weeks
3252763|NCT00819910|Placebo Comparator|Placebo Therapy Daily|Placebo (Rosiglitazone) 8mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks
3252764|NCT00819884|Experimental|1|twice daily during 4 days
3252765|NCT00819884|Experimental|2|once daily during 4 days
3252766|NCT00819871||PLI|patients with postoperative lung injury
3252767|NCT00819871||without PLI|patients without postoperative lung injury
3252768|NCT00819871||PLI/PKI|patients with at least one organ injury of lung or kidney after surgery
3252769|NCT00819871||without PLI/PKI|patients without lung or kidney injury after surgery
3252770|NCT00819858|Experimental|RUTF|RUTF supplement (Plumpynut®) of 500 kcal/day for 2 weeks
3252771|NCT00819858|No Intervention|control|no supplement given
3252772|NCT00819845|Experimental|Ramipril|
3252773|NCT00819845|Experimental|Carvedilol|
3252774|NCT00819832|Experimental|Phase 1 Group 1 Vertebroplasty|Vertebroplasty
3252775|NCT00819832|Experimental|Phase 1 Group 2 Kyphoplasty|Kyphoplasty
3252776|NCT00819832|Active Comparator|Phase 2 Group 1 Vertebroplasty|Vertebroplasty
3252777|NCT00819832|Active Comparator|Phase 2 Group 2 Vertebroplasty + Cavity SpineWand|Vertebroplasty with Cavity SpineWand
3252778|NCT00819832|Active Comparator|Phase 2 Group 3 Kyphoplasty|Kyphoplasty
3252779|NCT00819832|Active Comparator|Phase 2 Group 4 Kyphoplasty + Cavity SpineWand|Kyphoplasty with Cavity SpineWand
3252780|NCT00819819|Active Comparator|1 Gluten containing diet|Gluten added to diet at 6 months per American Academy of Pediatrics recommendations
3252781|NCT00819819|Active Comparator|2 Gluten free diet|Non gluten containing food starch added to diet from 6-12 months
3252782|NCT00819806|Experimental|A|PF-3512676, and three MHC class I Montanide ISA 720 VG and the peptides NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102 will be administered in three separate subcutaneous (under the skin) injections.
3252783|NCT00819806|Experimental|B|This vaccine injection contains all the same components of Arm A and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm). Cyclophosphamide is an agent that is thought to increase the anti-tumor response of vaccines.
3252784|NCT00819806|Experimental|C|PF-3512676, Montanide ISA 720 VG and the peptides NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102, NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-1 157-170 will be administered in three separate subcutaneous injections.
3252785|NCT00819806|Experimental|D|This vaccine injection contains all the same components of Arm C and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm).
3252786|NCT00819806|Experimental|E|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein will be administered in three separate subcutaneous injections.
3252787|NCT00819806|Experimental|F|This vaccine injection contains all the same components of Arm E and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm).
3252788|NCT00819793|Experimental|CentriMag Ventricular Assist System|All patients meeting the patient selection criteria will be treated with the CentriMag Ventricular Assist System.
3252789|NCT00819780|Experimental|Panitumumab Plus mFOLFOX6|Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and modified FOLFOX6 (mFOLFOX6) chemotherapy regimen consisting of oxaliplatin (85 mg/m^2), leucovorin (400 mg/m^2) and 5-fluorouracil (5-FU) (2400 mg/m^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
3252790|NCT00819780|Active Comparator|Bevacizumab Plus mFOLFOX6|Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 regimen consisting of oxaliplatin (85 mg/m^2), leucovorin (400 mg/m^2), followed by 5-FU (2400 mg/m^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
3252791|NCT00819767|Experimental|Aliskiren|For the first week of the 8 week treatment period, patients received aliskiren 150 mg, placebo to aliskiren, and 2 capsules of placebo to valsartan. For the remaining 7 weeks of the study, patients received aliskiren 300 mg (two 150 mg tablets) and 2 capsules of placebo to valsartan. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
3252792|NCT00819767|Active Comparator|Valsartan|For the first week of the 8 week treatment period, patients received valsartan 160 mg, placebo to valsartan, and 2 tablets of placebo to aliskiren. For the remaining 7 weeks of the study, patients received valsartan 320 mg (two 160 mg capsules) and 2 tablets of placebo to aliskiren. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
3252793|NCT00819754|Experimental|IXO regimen + bevacizumab|This is phase I/II safety and efficacy study. There is only one arm of Irinotecan, Xeloda and Oxaliplatin (IXO) regimen with Avastin (bevacizumab)
3252794|NCT00819741|Experimental|Repaglinide + metformin|Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily.
3252795|NCT00819741|Active Comparator|Repaglinide|Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily.
3252796|NCT00819728|Experimental|Taxotere/Irinotecan|
3252797|NCT00819715||1|Small for gestational age preterm infants
3252798|NCT00819715||2|Appropriate for gestational preterm infants
3252799|NCT00819702|Experimental|Model Care|The Model Care approach was implemented in 7 practices, where PCPs were trained to address major risk factors for CM, including maternal depression, alcohol/substance abuse, intimate partner violence, food insecurity, harsh punishment and major stress. We taught how they can be briefly assessed and initially addressed. The initial training consisted of one 4-hour in-person session. Use of the Parent Screening Questionnaire (PSQ) was discussed, as was the importance of applying it universally during regular checkups. PCPs SEEK Parent Handouts on each targeted problem. We held 1-hour booster sessions every 6 months over the subsequent 2.5 years.
3252800|NCT00819702|No Intervention|Standard Care|PCPs in Standard Care group served as the controls. They continued to practice as usual.
3252801|NCT00819676||subjects with asthma|
3252802|NCT00819676||healthy subjects|
3252803|NCT00819663||Crohns patients|Established Crohn's disease patients who underwent CTE imaging before and after initiating infliximab therapy
3252804|NCT00819650|Experimental|Licartin|patients who receive Licartin therapy after liver resection
3252805|NCT00819650|No Intervention|placebo|control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive Licartin therapy after liver resection
3252806|NCT00819637|Experimental|Arformoterol 3 doses|
3252807|NCT00819637|Experimental|Arformoterol 1 dose, placebo 2 doses|
3252808|NCT00819637|Active Comparator|Levalbuterol 3 doses|
3252809|NCT00819624|Other|Interactive Voice Response System|
3252810|NCT00819624|Other|Personal Digital Assisstant|
3252811|NCT00819611|Experimental|Working memory training|
3252812|NCT00819611|Sham Comparator|Control version of working memory training|
3252813|NCT00819598||SUSPECTED ARTERIAL DISEASE|
3252814|NCT00819585|Experimental|Core study: Canakinumab 25 mg|Canakinumab 25 mg subcutaneously (sc) once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
3252815|NCT00819585|Experimental|Core study: Canakinumab 50 mg|Canakinumab 50 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
3252816|NCT00819585|Experimental|Core study: Canakinumab 100 mg|Canakinumab 100 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
3252817|NCT00819585|Experimental|Core study: Canakinumab 200 mg|Canakinumab 100 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
3252818|NCT00819585|Experimental|Core study: Canakinumab 300 mg|Canakinumab 300 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
3252819|NCT00819585|Experimental|Core study: Canakinumab q4wk|Canakinumab 50 mg sc at Days 1, and 29 followed by canakinumab 25 mg sc on Days 57, and 85 plus daily placebo capsules for 16 weeks, repeated every 4 week (q4wk). Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
3252820|NCT00819585|Active Comparator|Core study: Colchicine 0.5 mg|Colchicine 0.5 mg capsule orally once daily throughout the whole treatment phase of 16 weeks plus placebo matching canakinumab s.c. at Days 1, 29, 57, and 85. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
3252821|NCT00819585|Experimental|Extension study: Group A|Participants who were randomized to canakinumab in the core study and were treated with canakinumab for at least 1 flare in the extension study.
3252822|NCT00819585|Experimental|Extension study: Group B|Patients who were randomized to canakinumab in the core study but did not receive treatment with canakinumab in the extension study.
3252823|NCT00819585|Experimental|Extension study: Group C|Patients who were randomized to colchicine in the core study and were treated with canakinumab for at least 1 flare in the extension study.
3252824|NCT00819585|Experimental|Extension study: Group D|Patients who were randomized to colchicine in the core study but did not receive treatment with canakinumab in the extension study.
3252825|NCT00819572|Experimental|1|DLX105 low dose
3252826|NCT00819572|Experimental|2|DLX105 high dose
3252827|NCT00819572|Placebo Comparator|3|
3252828|NCT00819559|Active Comparator|Open PCRT group|Patients who underwent preoperative chemoradiotherapy and open resection
3252829|NCT00819559|Experimental|Open no PCRT group|Patients who did not undergo preoperative chemoradiotherapy and open resection
3252830|NCT00819559|Active Comparator|LAP PCRT group|Patients who underwent preoperative chemoradiotherapy and laparoscopic resection
3252831|NCT00819559|Experimental|LAP no PCRT group|Patients who did not undergo preoperative chemoradiotherapy and laparoscopic resection
3252832|NCT00819546|Other|Only one arm on this study.|
3252833|NCT00819533|Experimental|sensor|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
3252834|NCT00819520|Experimental|Ivermectin|ivermectin Stromectol®)
3252835|NCT00819520|Active Comparator|Malathion|malathion(Prioderm®)
3252836|NCT00819507|Experimental|Vanos Cream|glucocorticoid cream
3252837|NCT00819494|Sham Comparator|Healthy controls|
3252838|NCT00819494|Active Comparator|Patients with immediate reactions|
3252839|NCT00819481||3DKnee|Post Market Study
3252840|NCT00819468|Active Comparator|1|Subjects with moderate hepatic impairment (Child-Pugh score of 7-9)
3252841|NCT00819468|Active Comparator|2|Healthy volunteers with normal hepatic function matched to hepatic impaired subjects by age, gender, BMI, and renal function as measured by creatinine
3252842|NCT00819455|Active Comparator|2|In person lifestyle advice at baseline, 6, 12, 18 months.
3252843|NCT00819455|Experimental|1|In person lifestyle advice at baseline, 6, 12, 18 months. Receive reminders by internet based, mobile phone text messaging (Frequency, time and number(s) of messages according to participants requirement)
3252844|NCT00819442|Placebo Comparator|1|patients without heart failure, with cardiobiopsy
3252845|NCT00819442|Experimental|2|patients with heart failure in NYHA class I, II
3252846|NCT00819442|Experimental|3|Patients with heart failure in NYHA class III, IV
3252847|NCT00819429|Experimental|1|"Omega-3 + Standard treatment~Children in this group will be given 400 mg of DHA and 600 mg of EPA. Caregivers will be instructed to give two 500mg Omega-3 capsules twice a day, at breakfast and at the evening meal for 6 months. Parents will be seen by the attending on a monthly basis for standard treatment procedure."
3252848|NCT00819429|Experimental|2|"Social skills + Omega-3 placebo + Standard treatment~Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months. They will also undergo a manualised group social problem solving skills training protocol of 12 weekly 1-hour sessions (Ang & Ooi, 2003a, 2003b). There will be booster sessions scheduled at 3-week intervals after the initial treatment period of 12 weeks, for a total of 4 booster sessions."
3252849|NCT00819429|Experimental|3|"Omega-3 + Social skills + Standard treatment~Children in this group will receive omega-3 supplement and social skills training on top of standard treatment. Procedures for administration of Omega-3 supplement are similar to those stated in (1) and (2)."
3252943|NCT00818805|Experimental|Tranilast 0.5% one eye|Patients received one drop Tranilast ophthalmic solution 0.5% in one eye and 1 drop tranilast placebo in contralateral eye
3252850|NCT00819429|Placebo Comparator|4|"Omega-3 placebo + Standard treatment.~Children in this group will receive placebo as well as a course of the standard treatment. Procedure for administering the placebo capsules is similar to that outlined in (2)."
3252851|NCT00819416|Experimental|1|5% albumin
3252852|NCT00819416|Other|2|Normal saline
3252853|NCT00819403|Active Comparator|simvastatin|Simvastatin 40 mg daily
3252854|NCT00819403|Active Comparator|simvastatin/ezetimibe|Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
3252855|NCT00819390|Experimental|A: Chloroquine then Placebo for Off-ART Participants|Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
3252856|NCT00819390|Experimental|B: Placebo then Chloroquine for Off-ART Participants|Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
3252857|NCT00819390|Experimental|C: Chloroquine then Placebo for On-ART Participants|Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
3252858|NCT00819390|Experimental|D: Placebo then Chloroquine for On-ART Participants|Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
3252859|NCT00819377|Placebo Comparator|Normal saline|Normal saline by inhalation over 15 min
3252860|NCT00819377|Active Comparator|Milrinone|Inhaled milrinone 5 mg(as for the injectable solution)
3252861|NCT00819364|Experimental|1|Participants with autism will receive BCRI intervention program.
3252862|NCT00819364|Active Comparator|2|Participants with autism will receive standard care available in the community.
3252863|NCT00819351|Experimental|PEG-asparaginase 6 weeks intervals|"PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (from week 13 after diagnosis to week 33).~All additional therapy (High Dose Methotrexate, Vincristin, Dexamethasone, 6-Mercaptopurine, doxorubicin, intrathecal chemotherapy) is the same in both arms."
3252864|NCT00819351|Active Comparator|PEG-Asparaginase 2 weeks intervals|"PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (from week 13 after diagnosis to week 33).~All additional therapy (High Dose Methotrexate, Vincristin, Dexamethasone, 6-Mercaptopurine, doxorubicin, intrathecal chemotherapy) is the same in both arms."
3252865|NCT00819338|Active Comparator|polyunsaturated|5g per day of polyunsaturated fatty acids (3.5g EPA and DHA).
3252866|NCT00819338|Placebo Comparator|monounsaturated|5g a day of oleic enriched sunflower oil
3252867|NCT00819325|Experimental|Intensive glycemic control|Included routine use of pioglitazone (30 mg/d) for 6 months in addition to titration of their other oral hypoglycemic agents in order to get the HbA1c<6%.
3252868|NCT00819325|Active Comparator|conservative glycemic control|Included titration of oral hypoglycemic agents to get HbA1c<7% without the use of a thiazolidinedione.
3252869|NCT00819312|Active Comparator|Arm 1|
3252870|NCT00819299|Experimental|AcuFocus Corneal Inlay|Implantation of the AcuFocus Corneal Inlay ACI 7000PDT in emmetropic presbyopic patients.
3252871|NCT00819286|Active Comparator|wire (control)|patients will have their sternum closed using wire (stainless steel surgical wire).
3252872|NCT00819286|Experimental|SternaLock Rigid Fixation Plates|patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates.
3252873|NCT00819273||1|patients who have records of clinic visit with circulatory and endocrine internal medicines of nationwide tertiary hospitals within the last one year.
3252874|NCT00819260|Experimental|Harmonic Reduced Breast|harmonic scalpel used to reduce breast on that side
3252875|NCT00819260|Active Comparator|Electrocautery Reduced Breast|Electrocautery (current practice = control) used to reduce breast on that side
3252876|NCT00819247|Experimental|Degarelix 80/80 + 40|Loading doses of Degarelix 80 mg (20 mg/mL) on Days 0 and 3. Maintenance doses of 40 mg (20 mg/mL) given on days 28, 56, 84, 112 and 140.
3252877|NCT00819247|Experimental|Degarelix 40/40 + 40|Loading doses of Degarelix 40 mg (20 mg/mL) on Days 0 and 3. Maintenance doses of 40 mg (20 mg/mL) given on days 28, 56, 84, 112 and 140.
3252878|NCT00819247|Experimental|Degarelix 80 + 20|Loading dose of Degarelix 80 mg (20 mg/mL) on Day 0. Maintenance doses of 20 mg (10 mg/mL) given on days 28, 56, 84, 112 and 140.
3252879|NCT00819234|Placebo Comparator|1|
3252880|NCT00819234|Experimental|2|Pramlintide and 1.25mg Metreleptin
3252881|NCT00819234|Experimental|3|Pramlintide and 2.5mg Metreleptin
3252882|NCT00819234|Experimental|4|Pramlintide and 5.0mg Metreleptin
3252883|NCT00819221|Experimental|1|
3252884|NCT00819208|Active Comparator|Physical Activity Program + General Health Education Materials|Intervention Arm
3252885|NCT00819208|Active Comparator|General Health Education Materials|Control Arm
3252886|NCT00819195||RRMS|Relapsing-remitting multiple sclerosis patients who have not yet received glatiramer acetate (Copaxone) therapy recommended as part of clinical care
3252887|NCT00819195||HC|Healthy control volunteers
3252888|NCT00819182|Experimental|Paced respiration|The paced respiration intervention group received a compact disc with paper booklet. The booklet reinforced instructions on the first audio track for how to accomplish a target breath rate of 6-8 breaths per minute, practice twice per day for 15 minutes, and apply the breathing at the onset of each hot flash. Women were instructed to do slow, deep, abdominal breathing in through the nose and out through the mouth as per international recommendations (4). They were also instructed to practice twice per day for 15 minutes as per the small, laboratory-based studies (5, 6). The second and third tracks contained specially composed, digitally recorded music to help entrain the breath rate and structure the length of practice.
3252889|NCT00819182|Sham Comparator|Sham comparator: Fast, shallow breathing|The sham comparator group received a digital videodisc with paper booklet. The booklet reinforced voice-over and video demonstration to practice twice per day and apply the fast shallow breathing at the onset of each flash. A previously published report provides additional details and data indicating this program was a suitable attention control.
3252944|NCT00818805|Placebo Comparator|Placebo (Olopatadine)|Patients received one drop Olopatadine 0.1% in one eye and 1 drop Olopatadine placebo in contralateral eye
3252890|NCT00819182|No Intervention|Control: Usual Care|The usual care group received an investigator-signed letter explaining they were not selected to receive any study materials during the 16-week follow-up. These participants received paced respiration materials by mail after study completion.
3252891|NCT00819169|Experimental|Part 1 Cohort 3|AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg IV (day 1 of each Q3W cycle)
3252892|NCT00819169|Experimental|Part 1 Cohort 1|AMG 479 18 mg/kg IV plus AMG 655 1 mg/kg IV (day 1 of each Q3W cycle)
3252893|NCT00819169|Experimental|Part 1 Cohort 2|AMG 479 18 mg/kg IV plus AMG 655 3 mg/kg IV (day 1 of each Q3W cycle)
3252894|NCT00819169|Experimental|Part 2|AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg Q3W, or the MTD, as determined in Part 1 of the study
3252895|NCT00819156|Experimental|Degarelix 200/80|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.
3252896|NCT00819156|Experimental|Degarelix 200/120|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.
3252897|NCT00819156|Experimental|Degarelix 200/160|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.
3252898|NCT00819156|Experimental|Degarelix 240/80|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.
3252899|NCT00819156|Experimental|Degarelix 240/120|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.
3252900|NCT00819156|Experimental|Degarelix 240/160|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.
3252901|NCT00819117|Active Comparator|Transvenous Lead (TVN CRT)|Control group: resynchronization via a transvenous left ventricular lead (TVN CRT)
3252902|NCT00819117|Experimental|Epicardial Lead (EPI CRT)|Treatment group: resynchronization via an epicardial left ventricular lead (EPI CRT)
3252903|NCT00819104|Experimental|1|FDC of Metoprolol XL 50mg + Amlodipine 5mg
3252904|NCT00819104|Experimental|2|FDC of Metoprolol XL 25mg + Amlodipine 2.5mg
3252905|NCT00819104|Active Comparator|3|Extended release Metoprolol succinate
3252906|NCT00819104|Active Comparator|4|Extended release Metoprolol succinate
3252907|NCT00819104|Active Comparator|5|Amlodipine 5mg in immediate release formulation
3252908|NCT00819091|Active Comparator|BI 1356|5 mg orally (po) once daily
3252909|NCT00819091|Placebo Comparator|Placebo|one tablet once daily
3252910|NCT00819078|Active Comparator|Bupropion Sr|40 adolescent patients
3252911|NCT00819078|Placebo Comparator|Placebo (sugar pill)|40 adolescent patients will receive placebo
3252912|NCT00819065|Active Comparator|1-BTA Lanzhou/Allergan|Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Lanzhou at allocation and after twelve weeks will receive the same drug from laboratory Allergan.
3252913|NCT00819065|Active Comparator|2. BTA Allergan/Lanzhou|Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Allergan at allocation and after twelve weeks will receive the same drug from laboratory Lanzhou.
3252914|NCT00819052|Active Comparator|NVP IR|200 mg orally twice a day (po BID)
3252915|NCT00819052|Experimental|NVP XR|400 mg orally once a day (po QD)
3252916|NCT00819039|Experimental|Part 1: Oral Aprepitant|In Study Part 1, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.
3252917|NCT00819039|Experimental|Part 2: Oral Aprepitant|In Study Part 2, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.
3252918|NCT00819039|Active Comparator|Part 2: Intravenous Ondansetron|In Study Part 2, participants aged 6 months to 17 years received a single intravenous dose of ondansetron on Day 1.
3252919|NCT00819013|Experimental|Study Group 1|ACAM-FLU-A low dose + Adjuvant 1
3252920|NCT00819013|Experimental|Study Group 2|ACAM-FLU-A low dose + Adjuvant 2
3252921|NCT00819013|Experimental|Study Group 3|ACAM-FLU-A low dose
3252922|NCT00819013|Placebo Comparator|Study Group 4|Saline placebo
3252923|NCT00819000||Treated MS Subjects|Subjects who are treated with Glatiramer Acetate or Interferon (IFN)-β and receive their therapy from one of the participating Specialty Pharmacies
3252924|NCT00818987|Other|Operative|Treatment arm - intervention = Open Reduction Internal Fixation or Reduction & Immobilization
3252925|NCT00818987|No Intervention|Non Operative|Placebo arm
3252926|NCT00818961|Other|Hematopoietic Stem Cell Transplantation|All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on donor type
3252927|NCT00818948|Placebo Comparator|Placebo|2 subjects of each cohort (cohort 1 to 6) will receive placebo
3252928|NCT00818948|Other|AMG811|Six subjects in each cohort (cohort 1 to 6) will receive AMG 811
3252929|NCT00818935|Experimental|Low-Intermediate-Glycemic Index diets|
3252930|NCT00818935|Active Comparator|High GI diet|
3252931|NCT00818909|Experimental|Systane|Systane ocular product
3252932|NCT00818883|Experimental|Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD|
3252933|NCT00818883|Experimental|Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD|
3252934|NCT00818870|Active Comparator|Omeprazole 20 mg|
3252935|NCT00818870|Experimental|Vecam 20/300|
3252936|NCT00818870|Experimental|Vecam 40/300|
3252937|NCT00818857|Active Comparator|1|Early intervention.
3252938|NCT00818857|Active Comparator|2|Delayed intervention
3252939|NCT00818844|Experimental|Nepafenac|Nepafenac 0.1% dosed topically TID for 3 months after Epiretinal Membrane (ERM) Surgery
3252940|NCT00818844|Placebo Comparator|BSS|BSS dosed topically TID for 3 months after Epiretinal Membrane (ERM) Surgery
3252941|NCT00818818|Experimental|Meglumine antimoniate|Treated with 5mg/kg/d of pentavalent antimony (meglumine antimoniate) intravenously for 20 consecutive days.
3252942|NCT00818805|Experimental|Olopatadine 0.1% one eye|Patients received one drop Olopatadine 0.1% in one eye and 1 drop Olopatadine placebo in contralateral eye
3253002|NCT00818506||Controls|Healthy controls (matched for age, sex, and tobacco use status)
3252945|NCT00818805|Placebo Comparator|Placebo (Tranilast)|Patients received one drop Tranilast ophthalmic solution 0.5% in one eye and 1 drop tranilast placebo in contralateral eye
3252946|NCT00818792|Active Comparator|Drug-eluting stent Xience V|
3252947|NCT00818792|Active Comparator|Bare-metal stent Vision|
3252948|NCT00818779|Experimental|Aliskiren|Aliskiren 150-300 mg once daily
3252949|NCT00818779|Active Comparator|Amlodipine|5-10 mg amlodipine once daily
3252950|NCT00818766|Active Comparator|Antibiotic|Participants received intravenous (IV) cefazolin or vancomycin (for participants allergic to cephalosporin) immediately following surgery for 48 hours or until all chest tubes were removed, whichever occurred first.
3252951|NCT00818766|Placebo Comparator|Placebo|Participants received IV placebo-matching antibiotics immediately following surgery for 48 hours or until all chest tubes were removed, whichever occurred first.
3252952|NCT00818753|Experimental|Dabigatran 110 mg|experimental drug therapy in this indication
3252953|NCT00818753|Experimental|Dabigatran 150 mg|experimental drug therapy in this indication
3252954|NCT00818753|Active Comparator|Unfractionated Heparin|standard therapy in this indication as comparator
3252955|NCT00818740|Experimental|ORM-12741 i.v.|
3252956|NCT00818740|Experimental|ORM-12741 oral solution|
3252957|NCT00818740|Experimental|ORM-12741 oral capsule with food|
3252958|NCT00818740|Experimental|ORM-12741 oral capsule without food|
3252959|NCT00818714|Experimental|1|Dose escalation study to define the maximum tolerated boost dose of stereotactic body radiation therapy (SBRT) to the residual primary tumor after definitive therapy with concurrent chemotherapy and external beam radiation.
3252960|NCT00818701|Placebo Comparator|1: low dose BNP alone|low dose BNP with placebo
3252961|NCT00818701|Active Comparator|2: low dose BNP + PDEVI|low dose BNpo + PDEVI
3252962|NCT00818688||1|Patients eligible for enrolment were all consecutive patients aged 18 years or over, with a symptomatic ST of the lower limbs at least 5 cm long on compression ultrasonography. Patients who had undergone surgery under general or loco-regional anaesthesia in the previous 10 days, those in whom ST had occurred after sclerotherapy within the previous 30 days and those whose follow-up was not considered to be feasible were ineligible.
3252963|NCT00818688||2|Patients eligible for enrolment were all consecutive patients aged 18 years or over, with a symptomatic ST of the lower limbs at least 5 cm long on compression ultrasonography. Patients who had undergone surgery under general or loco-regional anaesthesia in the previous 10 days, those in whom ST had occurred after sclerotherapy within the previous 30 days and those whose follow-up was not considered to be feasible were ineligible.
3252964|NCT00818675|Experimental|Ridaforolimus|
3252965|NCT00818675|Placebo Comparator|Placebo|
3252966|NCT00818662|Experimental|IGIV, 10% 400mg/kg|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
3252967|NCT00818662|Experimental|IGIV, 10% 200mg/kg|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
3252968|NCT00818662|Placebo Comparator|Human Albumin 0.25% Solution - 4 mL/kg|0.25% human albumin solution infused at 4 mL/kg/2weeks
3252969|NCT00818662|Placebo Comparator|Human Albumin 0.25% Solution - 2 mL/kg|0.25% human albumin solution infused at 2 mL/kg/2weeks
3252970|NCT00818649|Experimental|Velcade + Vorinostat|This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.
3252971|NCT00818636|Experimental|Expressive Writing|In addition to attending group therapy as usual, participants write about their feelings about an issue of their choosing three times during a two week period for at least 20 minutes each time.
3252972|NCT00818636|Active Comparator|Treatment as Usual|Participants attend group therapy as usual only.
3252973|NCT00818623|Experimental|Degarelix 120 mg (20 mg/mL)|Degarelix 120 mg (20 mg/mL)
3252974|NCT00818623|Experimental|Degarelix 120 mg (40 mg/mL)|Degarelix 120 mg (40 mg/mL)
3252975|NCT00818623|Experimental|Degarelix 160 mg (40 mg/mL)|Degarelix 160 mg (40 mg/mL)
3252976|NCT00818623|Experimental|Degarelix 200 mg (40 mg/mL)|Degarelix 200 mg (40 mg/mL)
3252977|NCT00818623|Experimental|Degarelix 200 mg (60 mg/mL)|Degarelix 200 mg (60 mg/mL)
3252978|NCT00818623|Experimental|Degarelix 240 mg (40 mg/mL)|Degarelix 240 mg (40 mg/mL)
3252979|NCT00818623|Experimental|Degarelix 240 mg (60 mg/mL)|Degarelix 240 mg (60 mg/mL)
3252980|NCT00818623|Experimental|Degarelix 320 mg (60 mg/mL)|Degarelix 320 mg (60 mg/mL)
3252981|NCT00818610|Experimental|Monotherapy|
3252982|NCT00818610|Active Comparator|Bi-therapy|
3252983|NCT00818597|Experimental|EISS-treatment|In this arm patients receive additional treatment with the EISS-bioreactor
3252984|NCT00818584|Experimental|1. micafungin lower dose|
3252985|NCT00818584|Experimental|2. micafungin higher dose|
3252986|NCT00818571|Experimental|Vildagliptin 25 mg qd in Renal Impaired (RI) patients|
3252987|NCT00818571|Experimental|Vildagliptin 50 mg qd in RI Patients|
3252988|NCT00818571|Experimental|Vildagliptin 25 mg qd in matched Healthy Volunteer (HV)|
3252989|NCT00818571|Experimental|Vildagliptin 50 mg qd in matched HV|
3252990|NCT00818558|Experimental|1|stade IA [pT1 N0M0]
3252991|NCT00818558|Experimental|2|stade IB [pT2 N0M0]
3252992|NCT00818558|Experimental|3|stade IIA [pTI N1M0]
3252993|NCT00818558|Experimental|4|stade IIB [pT2 N1 et T3N0M0]
3252994|NCT00818558|Experimental|5|control groupe [tabagic subject]
3252995|NCT00818558|Experimental|6|Control group B [intervention for a pulmonaire non tumoral pulmonary lesion]
3252996|NCT00818545|Placebo Comparator|2|
3252997|NCT00818545|Experimental|hydroxypropyltetrahydropyrantriol|
3252998|NCT00818532||1|Measurement device
3252999|NCT00818519|Experimental|EE20/Drospirenone (YAZ, BAY86-5300)|In the active treatment group, participants received 24 consecutive days of active tablets followed by 4 consecutive days of inactive tablets. The active tablet contained 3 mg DRSP (Drospirenone) and 20µg EE (Ethinyl estradiol).
3253000|NCT00818519|Placebo Comparator|Placebo|The participants of the placebo group received inert but identical-appearing, color-matched tablets.
3253001|NCT00818506||Late onset MDD|Patients with major depressive disorder between 50 and 70 years of age that did not suffer from depression before the age of 50.
3253005|NCT00818493|Active Comparator|3|Percocet (oxycodone and acetaminophen)
3253006|NCT00818480|Experimental|1. YM155|
3253007|NCT00818467|Experimental|Tanning spray|To characterize the 25(OH)D response to 4 weeks of thrice weekly 40 mJ of UV-B light in a group of normal subjects with skin types I and II while using multiple applications of 3% DHA for five weeks.
3253008|NCT00818467|Active Comparator|UVB|To characterize the 25(OH)D response to 4 weeks of thrice weekly 40 mJ of UV-B light in a control group of normal subjects with skin types I and II who are not using 3% DHA applications.
3253009|NCT00818441|Experimental|Cohort A|Dacomitinib (PF-00299804) in patients with EGFR mutated NSCLC or clinical characteristics defined above to enhance for EGFR mutated NSCLC
3253010|NCT00818441|Experimental|Cohort B|Dacomitinib in patients with HER2 mutated or amplified NSCLC
3253011|NCT00818428|Active Comparator|1|Speech Production Intervention + Articulation Parent Group
3253012|NCT00818428|Experimental|2|Speech Production Intervention + Dialogic Reading Parent Group
3253013|NCT00818428|Experimental|3|Speech Perception Intervention + Articulation Parent Group
3253014|NCT00818428|Experimental|4|Speech Perception Intervention + Dialogical Reading Parent Group
3253015|NCT00818415|Experimental|Arm 1|
3253016|NCT00818415|Active Comparator|Arm 2|
3253017|NCT00818402||Non-small cell lung cancer patients|
3253018|NCT00818389|Active Comparator|1|Participants randomized to lithium/riluzole (randomization is 1:1 lithium/riluzole to placebo/riluzole, i.e., participants have an equal chance of getting randomized to lithium vs. placebo).
3253019|NCT00818389|Placebo Comparator|2|Participants randomized to placebo/riluzole (randomization is 1:1 lithium/riluzole to placebo/riluzole, i.e., participants have an equal chance of getting randomized to lithium vs. placebo).
3253020|NCT00818363|Experimental|Group 1: SABER™-Bupivacaine|5.0 mL SABER™-Bupivacaine/Once
3253021|NCT00818363|Placebo Comparator|Group 2: SABER™-Placebo|5.0 mL SABER™-Placebo/Once
3253022|NCT00818350|Experimental|SUNITINIB|
3253023|NCT00818337|Active Comparator|Aspirin 81mg|Resistant
3253024|NCT00818324|Experimental|OPC-12759 Ophthalmic suspension|Instillation, 4times/day
3253025|NCT00818311|Other|5|
3253026|NCT00818298|Experimental|1|ziprasidone
3253027|NCT00818285|No Intervention|1|Physicians in this arm will be using the standard electronic prescription interface.
3253028|NCT00818285|Experimental|2|In addition to the standard electronic prescription module, physicians in this arm will receive targeted drugs alert and decision support for psychotropic drug management
3253029|NCT00818272||Remicade (infliximab)|Participants with confirmed diagnosis of active Crohn's disease.
3253030|NCT00818259|Experimental|Part IA-fosaprepitant 115 mg/aprepitant|Day 1, fosaprepitant intravenous (IV) at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg orally (PO), prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
3253031|NCT00818259|Experimental|Part IB-fosaprepitant 150 mg|Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
3253032|NCT00818259|Experimental|Part IIA-aprepitant 80 mg equiv.|Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to <12 years of age - 47 mg/m^2; 4 months to <6 months of age - 2.0 mg/kg; 1 month to <4 months of age - 1.0 mg/kg; birth to <1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
3253033|NCT00818259|Experimental|Part IIB-aprepitant 125 mg equiv.|Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to <12 years of age - 74 mg/m^2; 6 months to <2 years of age - 1.3 mg/kg; 4 months to <6 months of age - 3.0 mg/kg; 1 month to <4 months of age - 1.5 mg/kg; birth to <1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
3253034|NCT00818259|Active Comparator|Part III-ondansetron|Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to <12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.
3253035|NCT00818259|Experimental|Part IV-aprepitant regimen|Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to <12 years of age - 3.0 mg/kg; 1 month to <4 months of age - 1.5 mg/kg; Birth to <1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to <12 years of age - 2.0 mg/kg; 1 month to <4 months of age - 1.0 mg/kg; Birth to <1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.
3253036|NCT00818259|Experimental|Part V-fosaprepitant regimen|Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to <12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
3253037|NCT00818246|Sham Comparator|Sham light|one side of the face was treated three times weekly for four consecutive weeks (12 treatments) with a Sham light on the experimental periorbital area
3253038|NCT00818246|Experimental|LED-treated|one side of the face was treated three times weekly for four consecutive weeks (12 treatments) with 660 nm Light emitting diode (LED) on the experimental periorbital area
3253039|NCT00818233||Observation|Variability will be assessed between each examiner.
3253040|NCT00818220|Experimental|1-Delayed Cord Clamping (DCC)|Immediately after birth, the infant is placed in a warm blanket and held lower than the placenta. The research nurse counts out 30 to 45 seconds for the obstetrician. The cord is milked once and then clamped at 30 to 45 seconds after birth.
3253041|NCT00818220|Active Comparator|2-Immediate Cord Clamping (ICC)|Routine care which is immediate cord clamping
3253042|NCT00818207|Other|Full Smoking Cessation Treatment Coverage (100%)|A subject randomized to the intervention group will be eligible for smoking cessation treatment (SCT) reimbursement during the 26-week period following the randomization.
3253043|NCT00818207|Other|No Smoking Cessation Treatment Coverage (0%)|Subjects in the control group choosing to quit using an SCT method will not be eligible for smoking cessation treatment (SCT) reimbursement and, thus, will have to purchase their treatment out of pocket.
3253044|NCT00818194|Experimental|A. tacrolimus first|Subjects receive extended release tacrolimus in first dosing interval then cross over to cyclosporine A for second dosing interval
3253045|NCT00818194|Experimental|B. cyclosporine first|Subjects receive cyclosporine A in first dosing interval then cross over to extended release tacrolimus for second dosing interval
3253046|NCT00818181|Experimental|Solution of birch pollen allergen extract|In total up to 4 drops (dose for maintainace therapy)are administered under the tongue.
3253047|NCT00818168||Infliximab|Subjects with ankylosing spondylitis who were treated with infliximab. The dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC)
3253048|NCT00818155|Experimental|desvenlafaxine succinate SR|desvenlafaxine succinate SR
3253049|NCT00818155|Placebo Comparator|Placebo|
3253050|NCT00818142||eating disorder, type 1 diabetes|Individuals diagnosed with type 1 diabetes and an eating disorder who withhold their insulin.
3253051|NCT00818129|Experimental|1|
3253052|NCT00818129|Placebo Comparator|2|
3253053|NCT00818116|Experimental|ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL)
3253054|NCT00818103|Experimental|Atorvastatin, β-interferon, EPO|
3253055|NCT00818090|Experimental|TP|paclitaxel and cisplatin every 3 weeks
3253056|NCT00818077||Metformin, Type 2 Diabetes|
3253057|NCT00818064|Experimental|A, HV|Dose cohort 1 (3 subjects active, 1 placebo)
3253058|NCT00818064|Experimental|B, HV|Dose cohort 2 (3 subjects active, 1 placebo)
3253059|NCT00818064|Experimental|C, HV|Dose cohort 3 (3 subjects active, 1 placebo)
3253060|NCT00818064|Experimental|D, HV|Dose cohort 4 (3 subjects active, 1 placebo)
3253061|NCT00818064|Experimental|E, HV|Dose cohort 5 (3 subjects active, 1 placebo)
3253062|NCT00818064|Experimental|A, RA|Dose cohort 1 (3 subjects active, 1 placebo)
3253063|NCT00818064|Experimental|B, RA|Dose cohort 2 (3 subjects active, 1 placebo)
3253064|NCT00818064|Experimental|C, RA|Dose cohort 3 (3 subjects active, 1 placebo)
3253065|NCT00818051|Active Comparator|Arm I (control)|Patients undergo sequential boost dose intensity-modulated radiotherapy (IMRT) 5 days a week for 4.6 weeks (23 fractions; 56 Gy).
3253066|NCT00818051|Experimental|Arm II|Patients undergo concurrent boost dose IMRT 5 days a week for 3 weeks (15 fractions; 48 Gy).
3253067|NCT00818051|Experimental|Arm III|Patients undergo concurrent boost dose IMRT 5 days a week for 3 weeks (15 fractions; 53 Gy).
3253068|NCT00818038||TYSABRI|Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
3253069|NCT00818025|No Intervention|Standard of Care|All subjects will receive standard care to prepare for discharge that consists of a one-on-one, pre-discharge educational session delivered by the transplant coordinator prior to hospital discharge and provision of a reference binder for each lung transplant recipient to take home.
3253070|NCT00818025|Experimental|Pocket PATH hand-held device|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
3253071|NCT00817999|Experimental|Loading Dose|Participants received a 300 mg dose of clopidogrel with or without GFJ.
3253072|NCT00817999|Experimental|Maintenance Dose|Participants received clopidogrel 75 mg/day for 7 days with or without GFJ
3253073|NCT00817986|Experimental|Arbaclofen placarbil 20 mg|Arbaclofen placarbil 20 mg, BID, for 14 days including the taper period.
3253074|NCT00817986|Placebo Comparator|Placebo for Arbaclofen placarbil|Placebo for 14 days
3253075|NCT00817986|Experimental|Arbaclofen placarbil 30 mg|Arbaclofen placarbil 30 mg, BID, for 14 days including the taper period.
3253076|NCT00817986|Experimental|Arbaclofen placarbil 40 mg|Arbaclofen placarbil 40 mg, BID, for 14 days including the taper period.
3253077|NCT00817973|Active Comparator|Casein|
3253078|NCT00817973|Active Comparator|Whey|
3253079|NCT00817973|Active Comparator|Cod|
3253080|NCT00817973|Active Comparator|Gluten|
3253081|NCT00817960|Experimental|Methylphenidate|
3253082|NCT00817947|Active Comparator|Usual airway clearance technique|Airway clearance using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure or oscillating positive expiratory pressure
3253083|NCT00817947|Other|HFCWO|High frequency chest wall oscillation
3253084|NCT00817934||PREVENTION AND TREATMENT|PATIENTS 50 YEARS AND OLDER REQUIRE SCREENING COLONOSCOPY. PATIENTS WITH FAMILY HISTORY OF COLON CANCER WILL REQUIRE IT BEFORE THE AGE OF 50.
3253085|NCT00817921||1|former premature children treated by ibuprofen
3253086|NCT00817921||2|former premature children not treated by ibuprofen
3253087|NCT00817921||3|former term children (control)
3253088|NCT00817908||1|Patients at high risk for CMV infection (CMV serostatus: D+/R-) who are expected to receive three months of antiviral prophylaxis.
3253089|NCT00817895|Experimental|5-FU+Cisplatin|50 HCC patients will be implanted 600mg sustained released 5-FU and 60mg sustained released cisplatin into liver incisal margin after tumor is resected.
3253090|NCT00817895|Active Comparator|5-FU|50 HCC patients will be implanted 600mg sustained released 5-FU into liver incisal margin after tumor is resected.
3253091|NCT00817895|Experimental|control|
3253092|NCT00817882|Experimental|1|individually targeted vocational rehabilitation
3253093|NCT00817882|Active Comparator|2|routine back pain rehabilitation
3253094|NCT00817869|Experimental|New Flooring|Will receive 8.3mm thick floor covering (Omnisports EXCEL) to replace previous floor covering.
3253095|NCT00817869|No Intervention|Standard Flooring|Ward will remain with standard floor covering. The overlay will have a comparable slip resistance rating to the new flooring. The sub-floor will also be comparable.
3253096|NCT00817843|Experimental|First Simva 80mg then Simvai/Eze10/10mg|First 6 weeks of Simvastatin 80mg, then 6 weeks of Simvastatin/Ezetimibe 10/10mg after 6 weeks of placebo washout
3253097|NCT00817843|Experimental|First Simva/Eze 10/10mg then Simva 80mg|First 6 weeks of Simvastatin/Ezetimibe 10/10mg, then 6 weeks of Simvastatin 80mg after 6 weeks of placebo washout
3253154|NCT00817466|Experimental|Racemic adrenaline, fixed intervals|Active drug with fixed intervals of inhalation, adjusted at least every 24h.
3253098|NCT00817830|Experimental|lodenafil carbonate|Evaluate cardiovascular safety of lodenafil carbonate in patients with coronary artery disease undergoing physical effort, before and after using lodenafil carbonate.
3253099|NCT00817817|Experimental|Group 1|
3253100|NCT00817817|Experimental|Group 2|
3253101|NCT00817804|Experimental|V60 then Conventional|Study device first
3253102|NCT00817804|Experimental|Conventional then V60|Conventional device first
3253103|NCT00817791|Experimental|HBO|
3253104|NCT00817778|Experimental|AZD1656|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
3253105|NCT00817778|Placebo Comparator|Placebo|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
3253106|NCT00817765|Active Comparator|Posaconazole alone|400mg posaconazole BID for 10 days (start on day 1 with 200mg QD, day 2 200mg BID; from day 3 onwards 400mg BID)
3253107|NCT00817765|Active Comparator|Fosamprenavir ritonavir|Fosamprenavir 700mg / ritonavir 100mg BID for 10 days
3253108|NCT00817765|Experimental|Fosamprenavir posaconazole|Fosamprenavir 700mg / posaconazole 400mg BID for 10 days (start on day 1 with 200mg QD, day 2 200mg BID; from day 3 onwards 400mg BID)
3253109|NCT00817752|Experimental|1|Receives Ashwagandha herb.
3253110|NCT00817739|Active Comparator|Continuous Therapy|Continuous complete androgen suppression therapy with leuprorelin 3.75 mg sustained release (SR), injection, subcutaneously once every 28 days and flutamide, 250 mg, tablet, orally thrice daily until there are signs of disease progression.
3253111|NCT00817739|Experimental|Intermittent therapy|Intermittent complete androgen suppression therapy starting at randomization with interruption of treatment given in the induction period until PSA levels reach >=10 ng/mL or other signs of progression appear. Upon treatment resumption, leuproreline 3.75 mg SR, injection, subcutaneously once every 28 days and flutamide 250 mg, tablet, orally thrice daily, until PSA levels are <normal (that is, <4 ng/mL) and no signs of disease progression appear. The intermittent therapy will be continued similarly until the study end or the appearance of signs of disease progression under treatment.
3253112|NCT00817726||1- RBD|polysomnographically diagnosed RBD patients. RBD is a sleep disorder diagnosed by a sleep lab in which the individual has muscle movements during the phase of deep sleep during which the muscles should be relaxed. Suspicion of RBD by history will be confirmed during screening.
3253113|NCT00817726||2 - control|"control:~must not have any neurological degenerative diagnosis.~must NOT have RBD.~must be able to age and/or gender-match to RBD and PD subjects already enrolled."
3253114|NCT00817713|Active Comparator|anthelminthic treatment|Albendazol plus fix-dose Praziquantel plus Ivermectin
3253115|NCT00817713|No Intervention|HIV care, no anthelminthic treatment|HIV care as per Tanzanian National AIDS Control Program (NACP) guidelines
3253116|NCT00817700|No Intervention|Normal (8 hours) sleep time|Subjects are studied under normal sleep time conditions.
3253117|NCT00817700|Experimental|Sleep restriction|"Sleep restriction to 4 hours of sleep per night.~Overnight sleep recording, measures of endocrine and metabolic (from blood), cardiovascular (measures of blood pressure and heart rate), performance ( before and after sleep restriction and after sleep recovery."
3253118|NCT00817687|Experimental|1|
3253119|NCT00817687|No Intervention|2|
3253120|NCT00817674||1|CKD subjects
3253121|NCT00817674||2|Healthy Controls
3253122|NCT00817661|Experimental|1|Vitamin A group
3253123|NCT00817661|Placebo Comparator|2|Placebo group
3253124|NCT00817648|Experimental|1|Quetiapine fumarate, flexible doses(600-750 mg/d)
3253125|NCT00817648|Active Comparator|2|risperidone, flexible doses(3-6 mg/d)
3253126|NCT00817635|Placebo Comparator|Placebo|
3253127|NCT00817635|Experimental|LCI699 dosing regimen 1|
3253128|NCT00817635|Experimental|LCI699 dosing regimen 2|
3253129|NCT00817635|Experimental|LCI699 dosing regimen 3|
3253130|NCT00817635|Active Comparator|Eplerenone 50 mg BID|
3253131|NCT00817622|Placebo Comparator|A|"Placebo, Placebo :~Placebo pearls,500 mg QID for 12 Weeks (2000 mg corn oil per day) Placebo pearl + corn oil 400 mg per day for 12 weeks"
3253132|NCT00817622|Active Comparator|B|"EPA, Placebo :~EPA pearls,500 mg QID for 12 Weeks (2000 mg per day),From MINAMINUTRITION Company(Belgium)+ Placebo pearl ,corn oil 400 mg per day for 12 weeks"
3253133|NCT00817622|Placebo Comparator|C|"Placebo ,Vitamin E :~Placebo pearls,500 mg QID for 12 Weeks (2000 mg corn oil per day)+ Vitamin E pearls, 400 mg from DANA Company(IRAN) per day for 12 weeks"
3253134|NCT00817622|Active Comparator|D|"EPA, Vitamin E :~EPA pearls,500 mg QID From MINAMINUTRITION Company(Belgium) for 12 Weeks (2000 mg EPA per day)+ Vitamin E pearls, 400 mg from DANA Company ( IRAN) per day for 12 weeks"
3253135|NCT00817609|Experimental|A|
3253136|NCT00817609|Placebo Comparator|B|
3253137|NCT00817583|Experimental|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous intravenous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of two cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.The radiation dose is 66-76Gy to the GTV, 60Gy to CTV1, and 54Gy to CTV2.
3253138|NCT00817570||1|Transfemoral Amputees using the C- Leg knee.
3253139|NCT00817570||2|Transfemoral Amputees using a Multiaxial Knee.
3253140|NCT00817570||3|Able bodied.
3253141|NCT00817557|Active Comparator|Loteprednol|Loteprednol BID
3253142|NCT00817557|Placebo Comparator|Rewetter|Rewetter BID
3253143|NCT00817544|Experimental|ORM-12741|ORM-12741
3253144|NCT00817531|Experimental|All subjects take open label Dasatinib|Dasatinib / Sprycel 100 mg
3253145|NCT00817518|Experimental|1|
3253146|NCT00817518|Experimental|2|
3253147|NCT00817505|Active Comparator|1|AZD1656 tablet + food
3253148|NCT00817505|Active Comparator|2|AZD1656 susp. without food
3253149|NCT00817505|Active Comparator|3|AZD1656 tablet
3253150|NCT00817492||1|Subjects with mild to moderate kidney disease
3253151|NCT00817492||2|Healthy Control Subjects
3253152|NCT00817479|Active Comparator|Dexamethasone|20 mg of dexamethasone
3253155|NCT00817466|Experimental|Racemic adrenalin, on demand|Racemic adrenaline, inhalations on demand (max every 2 hrs)
3253156|NCT00817466|Active Comparator|Saline, fixed intervals|Saline inhalation fixed intervals, adjusted at least every 24 hrs
3253157|NCT00817466|Active Comparator|saline on demand|Saline inhalations on demand, max every 2 hrs, adjusted every 12 hrs
3253158|NCT00817453||1|Clinically diagnosed Early iPD
3253159|NCT00817453||2|Age/gender matched controls without neurodegenerative diagnosis
3253160|NCT00817453||atypical or late Parkinsonian Syndromes|Includes subjects facing or having undergone DBS, diagnoses of MSA, PSP or other atypical syndromes.
3253161|NCT00817440|No Intervention|Control|control: muscle and fat biopsies and basal aminoacid and glucose turnover
3253162|NCT00817440|Experimental|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
3253163|NCT00817440|Experimental|Fasting|3 days of fasting and then the same as arm 1
3253164|NCT00817427|No Intervention|Baseline|CKD subjects and healthy, matched controls will have measures of cardiovascular function (BP, HR) measure of hormonal fluid balance (renin/aldosterone) measure and measures of glucose metabolism (response to glucose load and over 24 hr profile) with 3 days of habitual sleep time
3253165|NCT00817427|Experimental|CKD- Sleep extension|Measures as in baseline but with bed time increased by 2 hours
3253166|NCT00817427|Experimental|Controls short sleep|Measures as in baseline but with sleep disruption
3253167|NCT00817414|Placebo Comparator|Cohort A, Placebo|
3253168|NCT00817414|Experimental|Cohort A, LCI699 dosing regimen 1|
3253169|NCT00817414|Experimental|Cohort A, LCI699 dosing regimen 2|
3253170|NCT00817414|Placebo Comparator|Cohort B, Placebo|
3253171|NCT00817414|Experimental|Cohort B, LCI699 dosing regimen 3|
3253172|NCT00817414|Experimental|Cohort B, LCI699 dosing regimen 4|
3253173|NCT00817388||1|patients will be asked to provide a urine specimen and complete a questionnaire.
3253174|NCT00817375|Experimental|SSRI treated group|SSRI treated group is depressive patients treated with fluoxetine, paroxetine, or sertraline
3253175|NCT00817375|Active Comparator|non-SSRI treated group|non-SSRI treated group is depressive patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine
3253176|NCT00817362|Experimental|IPI-504 and Trastuzumab|"IPI-504 IV infusion 300 mg/m2 once weekly in combination with trastuzumab infusion every 3 weeks. (Continuous schedule)~Three week cycle with IPI-504 twice per week for 2 weeks and trastuzumab once per cycle followed by one week without treatment.~Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was <4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.~IPI-504 and trastuzumab will be administered for all cycles. Until progression or unacceptable toxicity develops."
3253177|NCT00817336|Experimental|D-serine|60 mg/kg/day
3253178|NCT00817336|Placebo Comparator|Placebo|
3253179|NCT00817323|Experimental|Quetiapine fumurate (Seroquel)|See Detailed description
3253180|NCT00817310||Severe IVH|Infants born at less than 1500g with diagnosis of Grade II or IV IVH
3253181|NCT00817310||control|infants born at less than 1500g without IVH on HUS
3253182|NCT00817297|Other|V60 Mask, Then Conventional Mask|Experimental V60 Mask Ventilator for treating adult patients with COPD, then Comparator Conventional Mask Ventilator for treating adult patients with COPD
3253183|NCT00817297|Other|Conventional Mask, Then V60 Mask|Comparator Conventional Mask noninvasive Ventilator for treating adult patients with COPD, then Experimental V60 Mask noninvasive Ventilator for treating adult patients with COPD.
3253184|NCT00817284|Experimental|arm I|Bevacizumab + Irinotecan and concomitant radiotherapy
3253185|NCT00817284|Experimental|Arm II|Bevacizumab and Temozolomide and concomitant radiotherapy
3253186|NCT00817271|Experimental|1|
3253187|NCT00817271|Experimental|2|
3253188|NCT00817258|Other|1|All patients will receive radical radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
3253189|NCT00817245|Active Comparator|1|Oral Amoxicillin Capsule Metronidazole Tablet Omeprazole Capsule
3253190|NCT00817245|No Intervention|2|No medical treatment
3253191|NCT00817232|Experimental|Treatment 1|50 microamp amplitude
3253192|NCT00817232|Experimental|Treatment 2|500 microamp amplitude
3253193|NCT00817219|Experimental|TACLONEX ointment|
3253194|NCT00817206|Experimental|LCP-Tacro|LCP-Tacro tablets™, once daily (LifeCycle Pharma A/S, Hoersholm DK)
3253195|NCT00817206|Active Comparator|Prograf (tacrolimus)|Prograf® capsules, twice daily (Astellas Pharma US, Deerfield IL)
3253196|NCT00817193|Experimental|Physical Activity|Participants will begin to participate in walking sessions and strength building classes that will be offered at each location. Participants will be asked to attend a minimum of 1 strength class per week, with a target of doing 150 minutes of moderate exercise each week. The exercise classes will include stretching and counseling to help participants understand and address the barriers to becoming and staying involved in regular exercise.
3253197|NCT00817193|Active Comparator|Wellness|Participants will begin to participate in a wellness program that will meet at each site twice per month. The first meeting will involve a lecture or presentation on a wellness-related topic. The second meeting will follow-up on concepts that were introduced in the first meeting, and will also to provide participants an opportunity to share experiences. Participants will be asked to attend both wellness sessions each month for whole year that the program is running.
3253198|NCT00817180|Active Comparator|A|Positive Expiratory Pressure (PEP) - an airway clearance technique
3253199|NCT00817180|Active Comparator|B|High Frequency Chest Wall Oscillation (HFCWO) also known as the 'Vest technique' - an airway clearance technique.
3253200|NCT00817167|Experimental|inReach (A)|Bronchoscopy procedure is planned using inReach planning software
3253201|NCT00817167|Active Comparator|Control (B)|Bronchoscopy procedure is planned using standard CT viewer software
3253247|NCT00816868|Experimental|non-small cell lung cancer (NSCLC)|erlotinib in combination with capecitabine as first-line treatment in elderly patients with stage IIIB/IV adenocarcinoma non-small cell lung cancer (NSCLC)
3253440|NCT00815373|Active Comparator|2|Xalacom* q.d.(dosed bedtime) and placebo vehicle q.d. (dosed morning) topically in the other group
3253202|NCT00817154|Experimental|Hopes-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
3253203|NCT00817141||Without urinary catheter|
3253204|NCT00817128|Experimental|1|PEPT after randomization
3253205|NCT00817128|Experimental|2|CBO after randomization
3253206|NCT00817115|No Intervention|1|Subjects undergoing routine cardiac catheterization or interventional procedures using the standard fluoroscopy system.
3253207|NCT00817115|Experimental|2|Subjects undergoing routine cardiac catheterization or interventional procedures using the region-of-interest fluoroscopy (x-ray fovea imaging) system.
3253208|NCT00817102|Other|CorCTA|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures
3253209|NCT00817089|Experimental|P1A|Phase 1: Placebo then naltrexone prior to alcohol challenge sessions
3253210|NCT00817089|Placebo Comparator|P1B|Phase 1: placebo prior to alcohol challenge sessions
3253211|NCT00817089|Experimental|P2A|Phase 2: naltrexone treatment
3253212|NCT00817089|Placebo Comparator|P2B|Phase 2: placebo
3253213|NCT00817076|Experimental|1|
3253214|NCT00817063|Experimental|Alitretinoin|Patients will receive alitretinoin 30mg capsule for up to 24 weeks
3253215|NCT00817063|Experimental|Placebo|Patients will receive placebo 30mg capsule for up to 24 weeks
3253216|NCT00817050|Active Comparator|Nasonex Followed by Flonase|
3253217|NCT00817050|Active Comparator|Flonase Followed by Nasonex|
3253218|NCT00817037|Experimental|Sitaxsentan|"Once daily oral sitaxsentan 100mg given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
3253219|NCT00817037|Placebo Comparator|Placebo|"Once daily oral placebo tablet given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
3253220|NCT00817037|Active Comparator|Nifedipine|"Open labeled active comparator~Once daily oral nifedipine 30mg given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
3253221|NCT00817024|Experimental|Xuefu Zhuyu Capsules|
3253222|NCT00817024|Active Comparator|Sheng Mai Capsules|
3253223|NCT00817024|Placebo Comparator|Placebo|
3253224|NCT00817011|Experimental|SSRI treated group|SSRI treated group are depressive patients treated with fluoxetine, paroxetine, citalopram or sertraline
3253225|NCT00817011|Active Comparator|non-SSRI treated group|non-SSRI treated group are depressive patients treated with venlafaxine, nortriptyline, bupropion, duloxetine, trazodone or mirtazapine
3253226|NCT00816998|Other|Early|Participants randomized to this arm will begin physical therapy of their fractured wrist approximately one week following surgery
3253227|NCT00816998|Other|Delayed|Participants randomized to this group will begin physical therapy of their fractured wrist approximately 6 weeks from their surgery. This is the approximate time frame in which therapy begins for patients not involved in the study. The term Delayed refers to therapy being delayed in starting from those in the study who begin therapy at one week post-operatively, not a delay in current care practice.
3253228|NCT00816985|Experimental|Liposuction + Questionnaires|Liposuction, followed by Quality of Life Questionnaires and extended follow-up period.
3253229|NCT00816972|Active Comparator|DL 2.5 mg|Desloratadine 2.5 mg twice daily (BID) + Placebo for Oxybutynin 2.5 mg BID for 7 days
3253230|NCT00816972|Active Comparator|OXY 5 mg|Placebo for Desloratadine 2.5 mg BID + Oxybutynin 5 mg BID for 7 days
3253231|NCT00816972|Experimental|DL 2.5 mg + OXY 2.5 mg|Desloratadine 2.5 mg BID + Oxybutynin 2.5 mg BID + Placebo for Oxybutynin 2.5 mg BID for 7 days
3253232|NCT00816972|Experimental|DL 2.5 mg + OXY 5 mg|Desloratadine 2.5 mg BID + Oxybutynin 5 mg BID for 7 days
3253233|NCT00816972|Placebo Comparator|Placebo|Placebo for Desloratadine 2.5 mg BID + Placebo for Oxybutynin 2.5 mg BID for 7 days
3253234|NCT00816959|Active Comparator|Arm I: R-mabHDI and ABVD|
3253235|NCT00816959|Active Comparator|Arm II: ABVD|
3253236|NCT00816946|No Intervention|Routine LHW Advice|Arm receiving routine advice by their local Lady Health Workers (LHWs)
3253237|NCT00816946|Active Comparator|Enhanced LHW Advice|Arm receiving enhanced nutrition and health advice from the local Lady Health Workers (LHWs)during their routine community visits.
3253238|NCT00816933|Experimental|one port|Patients undergo one port appectomy. Skin incision about 2cm size is made upon umbilicus and dissection is performed to make opening. Then, wound retractcor(Alexis) is iserted on opening site and wound is extended. Rubber glove built-in three 5mm trocars is applied over wound retractor. Pneumoperitoneum is achieved via trocar and appendectomy is performed. After appendectomy, wound is repaired.
3253239|NCT00816933|Active Comparator|Three ports|"Paitents will undergo three port appendectomy. 10 mm trocar is inserted on umbilicus, and two 5mm trocas is inserted low abdomen, left flank respectively.~Appendectomy is performed vis these trocas. After operation, wounds are repaired."
3253240|NCT00816920||1|Outpatients with suspected leg DVT after exclusion of proximal DVT
3253241|NCT00816907|Experimental|Metformin|Encapsulated metformin 1000-2000 mg/day
3253242|NCT00816907|Placebo Comparator|Placebo|Matching placebo capsules 2-4 daily
3253243|NCT00816894|Experimental|D-serine arm|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes.
3253244|NCT00816894|Active Comparator|Olanzapine arm|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
3253245|NCT00816881|Experimental|1|flutter mucus clearance device
3253246|NCT00816881|No Intervention|2|Observation
3253301|NCT00816465|Placebo Comparator|2|Patients receiving placebo
3253248|NCT00816855|Other|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of three cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
3253249|NCT00816829|Placebo Comparator|1|Fenofibrate-matching placebo tablet
3253250|NCT00816829|Experimental|2|145 mg NanoCrystal fenofibrate tablet
3253251|NCT00816816|Other|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of three cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
3253252|NCT00816803|Experimental|BM transplant with physiotherapy|Autologous BM transplant
3253253|NCT00816803|Active Comparator|Physiotherapy only|conventional physical therapy for chronic spinal cord injury.
3253254|NCT00816790|Active Comparator|Dose Adjusted|This arm will receive their broad spectrum antibiotic as an adjusted dose based on their renal function as measured when sepsis is diagnosed and antimicrobials are initiated
3253255|NCT00816790|Experimental|Unadjusted Dose|This arm will receive their broad spectrum antibiotic as an unadjusted dose regardless of their renal function
3253256|NCT00816777|Experimental|Chemoembolization|Chemoembolization with Irinotecan Bead in combination with Intravenous Chemotherapy Group (test arm)
3253257|NCT00816777|Active Comparator|Chemotherapy|Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks
3253258|NCT00816764|Experimental|1. AGS-8M4 Dose 1|
3253259|NCT00816764|Experimental|2. AGS-8M4 Dose 2|
3253260|NCT00816764|Experimental|3. AGS-8M4 Dose 3|
3253261|NCT00816764|Experimental|4. AGS-8M4 Dose 4|
3253262|NCT00816751|Active Comparator|1|
3253263|NCT00816751|Experimental|2|
3253264|NCT00816725|Experimental|Self-help course and information|
3253265|NCT00816712|Active Comparator|A|Testosterone - 300 mg IM
3253266|NCT00816712|Active Comparator|B|Testosterone - 100 mg IM
3253267|NCT00816712|Placebo Comparator|C|Placebo - IM
3253268|NCT00816699|Placebo Comparator|1|Routine anesthetic risk information
3253269|NCT00816699|Active Comparator|2|Preprint preoperative risk information
3253270|NCT00816686|Experimental|1. AGS-16M18 Dose 1|
3253271|NCT00816686|Experimental|2. AGS-16M18 Dose 2|
3253272|NCT00816686|Experimental|3. AGS-16M18 Dose 3|
3253273|NCT00816686|Experimental|4. AGS-16M18 Dose 4|
3253274|NCT00816686|Experimental|5. AGS-16M18 Dose 5|
3253275|NCT00816673|Placebo Comparator|placebo|
3253276|NCT00816673|Experimental|Circadin|
3253277|NCT00816660|Experimental|1|
3253278|NCT00816660|Active Comparator|2|
3253279|NCT00816647|Active Comparator|1|Medial patellofemoral ligament reconstruction
3253280|NCT00816647|Active Comparator|2|Medial reefing
3253281|NCT00816634|Active Comparator|1|"Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr repeat every 3 weeks"
3253282|NCT00816634|Active Comparator|2|"XT Regimen:~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs Repeat every 3 weeks"
3253283|NCT00816621|Experimental|ABC for Children Adopted Internationally|ABC for Children Adopted Internationally: 10 session in home intervention that targets parent nurturance, synchrony, pseudo-autistic behaviors, and indiscriminate sociability
3253284|NCT00816621|Active Comparator|DEF for Children Adopted Internationally|DEF for Children Adopted Internationally: 10 session in home intervention that targets cognitive and motor delays
3253285|NCT00816608||type 2 diabetes|
3253286|NCT00816595|Experimental|Arm A: Pentostatin, Cyclophosphamide, Rituximab, and Avastin|Patients receive 15 mg/kg bevacizumab IV over 30-90 minutes on day 1 of courses 1-5 and on days 1, 22, and 43 of course 6; 375 mg/m^2 rituximab IV over 2-4 hours on days 2 and 3 of course 1 and on day 1 of courses 2-6; and 2 mg/m^3 pentostatin IV over 30 minutes and 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 2 of course 1 and on day 1 of courses 2-6. Patients also receive 6 mg pegfilgrastim subcutaneously (SC) on day 3 of course 1 and on day 2 of courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3253287|NCT00816595|Experimental|Arm B: Pentostatin, Cyclophosphamide, and Rituximab|Patients receive 100 mg rituximab IV over 2-4 hours on day 1 and 375 mg/m^2 on day 2 of course 1 and 375 mg/m^2 on day 1 of courses 2-6. They receive 2 mg/m^2 pentostatin IV over 30 minutes and 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1. Patients also receive 6 mg pegfilgrastim SC on day 2. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3253288|NCT00816582|Experimental|PET/CT Guided FES Therapy|All subjects will be seen at baseline and then monthly until month 6 of fulvestrant therapy unless clinical or radiological progression or unacceptable toxicity earlier than month 6.
3253289|NCT00816569|Experimental|Keratoconus|One eye of Keratoconus patient
3253290|NCT00816556|Active Comparator|Estriol|Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
3253291|NCT00816556|Active Comparator|Estradiol|Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
3253292|NCT00816556|Placebo Comparator|Vanicream Lite|Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
3253293|NCT00816543|Experimental|1|3 cycles of neoadjuvant chemotherapy of Docetaxel, Oxaliplatin and S-1. Surgery 5 to 6 weeks after completion of the chemotherapy.
3253294|NCT00816530||Asymptomatic Women who have Dense Breast Tissue|Women who have no signs or symptoms of breast cancer who have > 50% parenchymal density on mammography.
3253295|NCT00816517|Experimental|botulinum toxin|injection of botulinum toxin type A
3253296|NCT00816504|Experimental|1|Galactose
3253297|NCT00816491|Active Comparator|A|Conventional white light colonoscopy
3253298|NCT00816491|Experimental|B|Chromoendoscopy
3253299|NCT00816478|Experimental|1|Galactose
3253300|NCT00816465|Experimental|1|Patients receiving Hoodia
3253302|NCT00816426|Other|1|Dosing 2 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
3253303|NCT00816426|Other|2|Dosing 4 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
3253304|NCT00816426|Other|3|Dosing 8 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
3253305|NCT00816426|Other|4|Dosing 12 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
3253306|NCT00816426|Other|5|Dosing 24 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
3253307|NCT00816400|Experimental|MEDI-575, 3.0 mg/kg QWk Escalation Phase (Cohort 1)|Single lead-in dose of MEDI-575 at 0.5 mg/kg as a 60-minute intravenous (IV) infusion administered 7 days prior to first dose at 3.0 mg/kg; MEDI-575 administered at 3.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (once every 7 days [QWk]) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3253308|NCT00816400|Experimental|MEDI-575, 6.0 mg/kg QWk Escalation Phase (Cohort 2)|MEDI-575 administered at 6.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3253309|NCT00816400|Experimental|MEDI-575, 9.0 mg/kg QWk Escalation Phase (Cohort 3)|MEDI-575 administered at 9.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3253310|NCT00816400|Experimental|MEDI-575, 12 mg/kg QWk Escalation Phase (Cohort 4)|MEDI-575 administered at 12.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3253311|NCT00816400|Experimental|MEDI-575, 15 mg/kg QWk Escalation Phase (Cohort 5)|MEDI-575 administered at 15.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3253312|NCT00816400|Experimental|MEDI-575, 25 mg/kg Q3Wk Escalation Phase (Cohort 6)|MEDI-575 administered at 25.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (once every 21 days [Q3Wk]) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3253313|NCT00816400|Experimental|MEDI-575, 35 mg/kg Q3Wk Escalation Phase (Cohort 7)|MEDI-575 administered at 35.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (Q3Wk) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3253314|NCT00816400|Experimental|MEDI-575, 9.0 mg/kg QWk Expansion Phase|MEDI-575 administered at 9.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3253315|NCT00816400|Experimental|MEDI-575, 25 mg/kg Q3Wk Expansion Phase|MEDI-575 administered at 25.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (Q3Wk) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3253316|NCT00816387|Active Comparator|IUI|Intrauterine insemination using standard catheter
3253317|NCT00816387|Experimental|FSP|Fallopian tube sperm perfusion using a commercial device for hysterosalpingography and tubal hydropertubation
3253318|NCT00816374|Other|1|Group I
3253319|NCT00816374|Other|2|Group II
3253320|NCT00816361|Experimental|1|MEDI-573 - (Dose escalation Cohort)
3253321|NCT00816348|Other|Omegaven|All subjects will receive Omegaven
3253322|NCT00816335|Experimental|Arm 1|F-FDG-directed surgery for known or suspected malignancy using gamma detection probes.
3253323|NCT00816322|Active Comparator|omega-3 fatty acids|EPA 2.1 g/d+DHA 1.1 g/d
3253324|NCT00816322|Placebo Comparator|Placebo|high oleic oil
3253325|NCT00816309|Experimental|Acapella Physiotherapy|Physiotherapy with acapella versus no physiotherapy
3253326|NCT00816309|No Intervention|No physiotherapy|Physiotherapy with acapella versus no physiotherapy
3253327|NCT00816296||Controls|Obese (BMI>30) and normal AST and ALT. Between the ages of 5 and 18 years old.
3253328|NCT00816296||Liver Disease|Obese (BMI>30) and elevated AST and/or ALT (evidence of NAFLD). Between the ages of 5 and 18 years old.
3253329|NCT00816270|Experimental|1|Experimental operatory wound closure with liquid bandage (Johnson & Johnson, Skillman, NJ, USA).
3253330|NCT00816244|Experimental|Atorvastatin|
3253331|NCT00816231|Experimental|Alcohol and Nicotine Group|Alcohol and Nicotine Drug/Cue Interactions
3253332|NCT00816231|Active Comparator|Alcohol Only Group|Alcohol Only Drug/Cue Interactions
3253333|NCT00816231|Active Comparator|Nicotine Only Group|Nicotine Only Drug/Cue Interactions
3253334|NCT00816231|Placebo Comparator|Placebo and Placebo Group|Placebo Only Drug/Cue Interactions
3253435|NCT00815412|Placebo Comparator|Contol group|
3253436|NCT00815399|Experimental|1|
3253437|NCT00815399|Active Comparator|2|
3253438|NCT00815386|Experimental|PTMA implanted|Enrolled patients receiving a PTMA implant
3253335|NCT00816218|Experimental|Pioglitazone|Fifty type 2 diabetic patients (25 diet-treated and 25 treated with diet plus sulfonylurea) will have pioglitazone, 45 mg daily; added to their therapeutic regimen. All patients will be closely monitored and, in addition to periodic contacts and clinical visits, metabolic and vascular parameters will be assessed at the beginning and after 3 and 6 months of therapy. Euglycemic hyperinsulinemic clamp with muscle biopsies will be performed at the beginning and after 6 months of treatment.
3253336|NCT00816205|Experimental|Single Arm|This is an open label, dose-finding study. After detrminig baseline resting anal pressure with a manometric test, coated Suppositories will be administered intra rectally. Subjects will take rectally a total of 3 Coated Suppositories per study.
3253337|NCT00816192|Active Comparator|1|"The externally irrigated-tip catheter is an open system in which saline is continuously infused and empties into the blood pool. For the externally irrigated-tip catheter, RF energy delivery settings were: power ≤ 35 watts and temperature ≤ 43°C with a variable flow-rate to obtain a temperature around 40°C."
3253338|NCT00816192|Experimental|2|"For the internally irrigated tip catheter (reference catheter), radiofrequency (RF) energy delivery settings will be: power ≤ 35 watts, temperature ≤ 47◦C and a fixed flow rate of 0.6 ml/s.~The advantage of the Chili thermo-cooled tip system is that no saline solution leaves the catheter system and flows into the patient."
3253339|NCT00816166|Experimental|Stent Group|"Medical therapy + PHAROS Vitesse neurovascular stent (Stent Group)"
3253340|NCT00816166|Active Comparator|Medical Therapy Group|"Medical therapy alone (Medical Therapy Group)"
3253341|NCT00816153|Experimental|PVI|PVI guided fluid management
3253342|NCT00816153|No Intervention|Control|
3253343|NCT00816140|Active Comparator|Klaricid, triple therapy|Klaricid based triple therapy
3253344|NCT00816140|Experimental|Cravit, triple therapy|Cravit based triple therapy
3253345|NCT00816127|Experimental|1|DDAVP
3253346|NCT00816127|Active Comparator|2|Standard Treatment
3253347|NCT00816114||Chronic Myelogenous Leukemia|All CML patients in any phase of the disease that received imatinib treatment outside of MDACC clinical trials and has had at least one MDACC clinic visit.
3253348|NCT00816101|Experimental|PROCELLERA™Antimicrobial Dressing|Dressing changes every 3 days, more frequently if needed
3253349|NCT00816101|Active Comparator|Mepilex® Border Lite|Dressing changes every 2-3 days, more frequently if needed
3253350|NCT00816101|Active Comparator|Band-Aid® Adhesive Bandage|Dressing changes every 2-3 days, more frequently if needed.
3253351|NCT00816088||neutropenia|Patients undergoing stem cell transplantation or chemotherapy likely to lead to prolonged neutropenia.
3253352|NCT00816075|Experimental|1, Distilled water|the group of patients with superficial bladder cancer in the intermediate risk group who had their first recurrence after 6 months from the initial TUR. We plan to administer 200 ml of distilled water as immediate instillation for 2 hours
3253353|NCT00816062|Experimental|Treatment|Patients diagnosed with an abdominal aortic or aorto-iliac aneurysm that are considered candidates for endovascular repair, per the FDA approved IFU.
3253354|NCT00816049|Active Comparator|6MPfixed|Fixed dose 6-mercaptopurine days 30-85
3253355|NCT00816049|Experimental|6MPindividualized|Individualized dose increments of 6-mercaptopurine days 30-85
3253356|NCT00816036|No Intervention|Arm 1|Baseline Period
3253357|NCT00816036|Experimental|Arm 2|Intervention Period
3253358|NCT00816023|Experimental|Ecallantide Low Dose|target steady state concentration of 0.15 mg/L
3253359|NCT00816023|Experimental|Ecallantide Medium Dose|target steady state concentration of 0.75 mg/L
3253360|NCT00816023|Experimental|Ecallantide High Dose|target steady state concentration of 2.25 mg/L
3253361|NCT00816023|Placebo Comparator|Placebo|placebo
3253362|NCT00816010|Experimental|1|Lifestyle and compliance counseling via telephone contact with structured set of questions and reinforcements provided
3253363|NCT00816010|No Intervention|2|Control arm with usual care as per local hospital practice
3253364|NCT00815997|No Intervention|6 Fr TRI|TRI will be performed using a 6-Fr guiding catheter.
3253365|NCT00815997|Active Comparator|4-Fr TRI|TRI will be performed using a 4-Fr guiding catheter.
3253366|NCT00815984||Schoolchildren with asthma.|Schoolchildren with asthma.
3253367|NCT00815971||NSCLC|Patients with non-small cell lung cancer carcinoma treated with erlotinib
3253368|NCT00815958|Experimental|A|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)
3253369|NCT00815958|Active Comparator|B|Reaming with conventional reamer
3253370|NCT00815945|Experimental|PegLiposomal Doxorubicin + Carboplatin|Subjects will receive PegLiposomal Doxorubicin (40mg/m²) and Carboplatin (AUC6) every 28 days. Treatment period up to 6 months (therapy can be continued in case of tumor response and benefit for the patient)
3253371|NCT00815932|Experimental|1-CRPS|10 tDCS naïve patients with CRPS-related neuropathic pain in upper limb
3253372|NCT00815932|Experimental|2-DN|20 tDCS naïve patients with diabetic neuropathy
3253373|NCT00815932|Experimental|3-RPNP|20 tDCS naïve patients with resistant peripheral neuropathic pain
3253374|NCT00815932|Experimental|4-CIPN|10 tDCS naïve patients with CIPN-Chemotherapy Induced Pain Neuropathy patients
3253375|NCT00815919|Experimental|Velcade (bortezomib)|
3253376|NCT00815906|Experimental|SBI-087 0.15 mg IV|
3253377|NCT00815906|Experimental|SBI-087 0.5 mg IV|
3253378|NCT00815906|Experimental|SBI-087 100 mg SC|
3253379|NCT00815906|Experimental|SBI-087 200 mg SC|
3253380|NCT00815893|Experimental|1 dex group|received dexmedetomidine (1.0 mcg/kg) infusion
3253381|NCT00815893|Placebo Comparator|2 control group|received 0.9% saline
3253382|NCT00815893|Active Comparator|3 Propofol group|received 1% propofol using effect-site TCI(Base Primea, Fresenius, France)
3253383|NCT00815880|Active Comparator|Implantable Counterpulsation Therapy|The study is a single arm study with 20 patients being treated with implantable counterpulsation. Patients that meet eligibility will be enrolled and implanted into the treatment arm of the study. These patients will receive the C-Pulse System Implant as intervention therapy. There is not a control arm in this feasibility study.
3253384|NCT00815867|Experimental|A|Patient will receive Epoetin Beta
3253385|NCT00815867|No Intervention|B|
3253439|NCT00815373|Active Comparator|1|Cosopt* b. i. d. (dosed morning and bedtime) will be administered topically
3253386|NCT00815854|Experimental|Folate|"During Phase 1, participants will undergo screening for metabolic syndrome and have genetic makeup, body size, and endothelial functioning measured. During Phase 2, participants will receive daily folic acid as a treatment for metabolic syndrome.~Phase 2B participants will receive either daily folic acid or placebo as a treatment for metabolic syndrome."
3253387|NCT00815854|Placebo Comparator|Placebo|"During Phase 1, participants will undergo screening for metabolic syndrome and have genetic makeup, body size, and endothelial functioning measured. During Phase 2, participants will receive daily folic acid as a treatment for metabolic syndrome.~Phase 2B participants will receive either daily folic acid or placebo as a treatment for metabolic syndrome."
3253388|NCT00815828|Other|1|Group that don't do the resistance exercises
3253389|NCT00815815|Active Comparator|Continued inpatient treatment|Participants will undergo inpatient hospital treatment until they have gained enough weight to be discharged.
3253390|NCT00815815|Experimental|Sequenced treatment|Participants will begin with inpatient treatment, transition to day patient treatment, and then transition to outpatient treatment.
3253391|NCT00815789|Experimental|Intervention|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
3253392|NCT00815789|No Intervention|Control|Receive educational material about CVD reduction at baseline
3253393|NCT00815776|Experimental|1|Treatment group receiving the CID
3253394|NCT00815776|Active Comparator|2|Group assigned a mouth splint
3253395|NCT00815776|Active Comparator|Exercise Control Group|Group who received no device but were instead assigned a study-specified jaw exercise program
3253396|NCT00815763|Experimental|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg once a day and continued for 14 days
3253397|NCT00815763|Placebo Comparator|placebo|infusion placebo (group B)once a day and continued for 14 days
3253398|NCT00815750|Other|Phase I - Information Gathering|
3253399|NCT00815750|Other|Phase 2 - Decision Aid|
3253400|NCT00815737|Experimental|A|
3253401|NCT00815737|Placebo Comparator|B|
3253402|NCT00815724|Experimental|1|Participants will take part in a distance learning group.
3253403|NCT00815724|No Intervention|2|Participants in the control group will not receive any study materials or take part in any study activities.
3253404|NCT00815698|Active Comparator|no suture|self-adhesive mesh, i.e. no suture for mesh fixation
3253405|NCT00815698|Experimental|Suture|Suture for mesh fixation
3253406|NCT00815685|Experimental|Eicosapentaenoic Acid|
3253407|NCT00815672|No Intervention|Treatment Arm 1|Usual Care: Standard care monitoring
3253408|NCT00815672|Experimental|Treatment arm 2|Home-based Exercise: Progressive walking and resistance exercise treatment.
3253409|NCT00815659|Experimental|Rosuvastatin|medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
3253410|NCT00815646|Experimental|Sildenafil|Measurements of pulmonary and systemic pressures during cold water immersion before and after sildenafil 50 mg orally.
3253411|NCT00815633|Experimental|Alefacept|Treatment Group (only one group)
3253412|NCT00815620||1|patients undergoing local ablative therapy such as transcatheter-arterial chemoembolization or selective interal radiotherapy
3253413|NCT00815620||2|patients undergoing surgery or radiofrequency ablation
3253414|NCT00815620||3|patients undergoing peptide receptor radiotherapy
3253415|NCT00815581|Other|photorefraction|
3253416|NCT00815568|Experimental|Regimen|Conditioning regimen for AML with FLT3 mutation, AML/MDS unfavorable cytogenetic risk group, chemorefractory NHL or HD, or ALL/CML
3253417|NCT00815555||1|Women diagnosed with receptor positive breast cancer, treated with Tamoxifen
3253418|NCT00815542|Active Comparator|double balloon catheter|Cervical ripening by double balloon catheter
3253419|NCT00815542|Placebo Comparator|prostaglandins E2|cervical ripening using prostaglandins E2
3253420|NCT00815516|Experimental|Micafungin|Infants received micafungin at a dose of 10 mg/kg per day by intravenous infusion for a minimum of 21 days to a maximum of 28 days for infants without end-organ dissemination or for a maximum of 42 days for infants with end-organ dissemination.
3253421|NCT00815516|Active Comparator|Amphotericin B deoxycholate|Infants received amphotericin B deoxycholate (CAB) at a dose of 1.0 mg/kg per day by intravenous infusion for a minimum of 21 days to a maximum of 28 days for infants without end-organ dissemination or for a maximum of 42 days for infants with end-organ dissemination.
3253422|NCT00815503|Active Comparator|Ropivacaine|
3253423|NCT00815503|Placebo Comparator|Saline|
3253424|NCT00815490|Experimental|Desaturation|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
3253425|NCT00815477|Active Comparator|1|Waitlist control with generic Information about lifestyle and hypertension
3253426|NCT00815477|Experimental|2|Web-based intervention of lifestyle counseling messages based on the transtheoretical model of readiness for change.
3253427|NCT00815464|Experimental|Antiviral Therapy|Liquid Acupuncture(Herb Acupoints Injection) Therapeutics was researched and developed by Herbalist Yu Ru Lin in early of 1950s and used by Yu Medical Garden till now. It is an integrated therapeutics,according to individual condition, select the Acupoints(not limit to current used common acupoints) and proper herbs made individually.It is a special medical treatment conception, which theory is utilizing patients' condition, mobilizing their individual internal curability,therefore the final efficacy can be retrieved.
3253428|NCT00815451|Placebo Comparator|placebo dark chocolate|polyphenol-poor dark chocolate
3253429|NCT00815451|Experimental|polyphenol-rich dark chocolate|
3253430|NCT00815438|Experimental|Surgical Procedure|Laparoscopic transvaginal cholecystectomy with endoscopic assistance.
3253431|NCT00815425||African Americans with RA|1063 participants with RA
3253432|NCT00815425||African-Americans without RA|550 participants without RA
3253433|NCT00815412|Active Comparator|Counseling in use of health care|
3253434|NCT00815412|Active Comparator|Counseling in diet, exercise|
3253441|NCT00815360|Experimental|Treatment group|"single intravitreal injection of ranibizumab (0.5 mg in 0.1 cc)~peripheral laser to areas of retinal nonperfusion on ultra-widefield fluorescein angiography"
3253442|NCT00815360|Active Comparator|Control Group|"single intravitreal injection of triamcinolone acetonide (4.0 mg in 0.1 cc)~macular laser per treatment criteria"
3253443|NCT00815347|Other|1 Crossover|
3253444|NCT00815334|Experimental|Patients with decreased bladder compliance|Patients who have decreased bladder compliance
3253445|NCT00815334|Active Comparator|Patients with normal bladder compliance|Patients who have normal bladder compliance
3253446|NCT00815308|Experimental|cetuximab, concurrent chemo-radiotherapy|Cetuximab, injection, loading dose400 mg/m^2,(Day1 in Week1) followed by 250 mg/m^2(Day1, every week for Weeks 2-8) Paclitaxel, injection,45 mg/m^2 (Day 1, every week for Weeks 2-8) Cisplatin, injection,20 mg/m^2 (Day 1, every week for Weeks 2-8) radiation therapy, 59.4 Gy, 1.8 Gy/33 fractions,1 fraction daily, Days 1-5 every week for Weeks 2-7, and Days 1-3 for Week 8
3253447|NCT00815295|Experimental|Cetuximab + sorafenib|Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly. Sorafenib will be given at 200mg/m2 twice daily.
3253448|NCT00815282|Other|Patients|patients were girls aged 15 to 18 immunised with the HPV vaccine according to dutch vaccination guidelines
3253449|NCT00815269|Active Comparator|1|Halothane anesthesia: induction and maintenance with different doses
3253450|NCT00815269|Experimental|2|Isoflurane anesthesia: induction and maintenance with different doses
3253451|NCT00815269|Experimental|3|Sevoflurane anesthesia: induction and maintenance with different doses
3253452|NCT00815269|Experimental|4|Desflurane anesthesia: induction and maintenance with different doses
3253453|NCT00815269|Experimental|5|Enflurane anesthesia: induction and maintenance with different doses
3253454|NCT00815256|Experimental|Cross linking (CXL)|Patients with progressive mild and moderate grades of ketatoconus are randomized and allocated to this group and submitted to the treatment with riboflavin and ultraviolet -A light. They do not match any of the exclusion criterion: pregnancy, corneal thickness less than 400 μm, history of corneal surgery, herpes ocular infection, other corneal disease or scarring, chemical injuries and riboflavin allergy.
3253455|NCT00815243|Experimental|Telemed|Group of trauma&orthopedic patients - for determination of clinical strategy and treatment plan telemedicine will be used
3253456|NCT00815243|Active Comparator|InternalControl|Group of trauma&orthopedic patients from 3rd level trauma center - for determination of clinical strategy and treatment plan usual clinical approaches will be used
3253457|NCT00815243|Active Comparator|ExternalControl|Group of trauma&orthopedic patients from 1-2rd level trauma centers (in rural and small municipal hospitals) - for determination of clinical strategy and treatment plan personal arriving of the expert by the car (so-called Urgent Expert Care) will be used
3253458|NCT00815217|Experimental|1 lipoaspirate|wounds which have received the lipoaspirate
3253459|NCT00815217|Placebo Comparator|2 control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
3253460|NCT00815204||posttraumatic stress disorder|
3253461|NCT00815204||history of trauma exposure but no PTSD|
3253462|NCT00815204||healthy controls|
3253463|NCT00815191|Active Comparator|Vital Heat|Vital HEAT (vH2) Temperature Management System
3253464|NCT00815191|Active Comparator|Forced air|Forced-air warming
3253465|NCT00815178|Experimental|Inspiratory muscle training|
3253466|NCT00815178|Placebo Comparator|Placebo|
3253467|NCT00815165||Protocol 04-039 subjects|At least 50 and maximum of 100 healthy adolescent female subjects aged 12-17 years who were vaccinated in protocol 04-039 will be enrolled.
3253468|NCT00815165||Positive and Negative Controls|Approximately 100 screened subjects will be enrolled to serve as positive and negative controls.
3253469|NCT00815152|Experimental|1|Twenty five caregivers will randomly be assigned to receive active coping skills training and 25 caregivers will randomly receive usual care at The Preston Robert Tisch Brain Tumor Center at Duke.
3253470|NCT00815152|Placebo Comparator|2|Caregivers that will receive ususal care.
3253471|NCT00815139||ZES group|Groups who were treated with zotarolimus eluting stent
3253472|NCT00815126|Active Comparator|Mucocutaneous symptoms from NSAIDs|
3253473|NCT00815126|Active Comparator|Respiratory symptoms from NSAIDs|
3253474|NCT00815126|Active Comparator|NSAIDs tolerant individuals|
3253475|NCT00815113||1|First degree relative of gastric cancer patient
3253476|NCT00815113||2|Consecutive gastro-esophageal reflux patients
3253477|NCT00815100|Placebo Comparator|Placebo|
3253478|NCT00815100|Active Comparator|Ivabradine|
3253479|NCT00815087|Experimental|Functional Electrical Stimulation (FES)|Functional electrical stimulation: Experimental
3253480|NCT00815087|Active Comparator|Home Rehabilitation Program (HRP)|Exercise home program
3253481|NCT00815074||1|Women in the military who have returned from deployment within the past 12 months.
3253482|NCT00815048|Active Comparator|Remifentanil|"Atropine~Remifentanil"
3253483|NCT00815048|Placebo Comparator|Fentanyl|"Atropine~Fentanyl~Succinylcholine"
3253484|NCT00815035|Active Comparator|Peanut OIT|Subjects randomized to receive active treatment with peanut protein flour.
3253485|NCT00815035|Placebo Comparator|Placebo|Subjects randomized to receive placebo in the form of oat flour.
3253486|NCT00815022|Active Comparator|1|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 20 degree celsius
3253487|NCT00815022|Experimental|2|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 10 degree celsius
3253488|NCT00815022|Experimental|3|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 15 degree celsius
3253489|NCT00815022|Experimental|4|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 25 degree celsius
3253575|NCT00814502|Placebo Comparator|Placebo|Subjects randomized to Placebo
3253490|NCT00815022|Experimental|5|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 30 degree celsius
3253491|NCT00815022|Experimental|6|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 35 degree celsius
3253492|NCT00815009|No Intervention|A (Std of Care)|Standard of Care/Control, including Lifestyle Advice (attend a basic healthy nutrition class as well as follow up appointments with GI MD).
3253493|NCT00815009|Experimental|B (Low Fat)|Standard of Care, plus Low Fat Diet and Moderate Exercise
3253494|NCT00815009|Experimental|C (Mod Fat)|Standard of Care, plus Moderate Fat/Low Processed Carbohydrate Diet and Moderate Exercise
3253495|NCT00815009|Experimental|D (Exercise only)|Standard of Care plus Moderate Exercise only
3253496|NCT00814996||1: employment|
3253497|NCT00814996||2: unemployment|
3253498|NCT00814983|Experimental|Naive T-cell Depleted Stem Cell Transplant|Experimental: Cohort 2 will receive a T-cell depleted peripheral blood stem cell graft. All other aspects of this stem cell transplantation are in line with the standard of care.
3253499|NCT00814983|Active Comparator|Stem Cell Transplant No Manipulation|Control: Cohort 1 Stem Cell Transplant No Manipulation will receive the currently accepted standard approach to myeloablative allogeneic stem cell transplantation
3253500|NCT00814970|Experimental|Complete SE Vascular Stent System|COMPLETE SE Vascular Stent System - implantation of study device in native SFA and/or PPA for subjects with symptomatic ischemic peripheral arterial disease in the superficial femoral artery or proximal popliteal arteries with an occlusion or lesion greater or equal to 50 percent with lesions located above the knee and amenable to percutaneous treatment with angioplasty and vascular stent implantation.
3253501|NCT00814957|Experimental|Open-label|D3 receptor antagonist
3253502|NCT00814944|Experimental|Dose Group 1|
3253503|NCT00814944|Experimental|Dose Group 2|
3253504|NCT00814944|Experimental|Dose Group 3|
3253505|NCT00814944|Placebo Comparator|Dose Group 4|
3253506|NCT00814931|Experimental|1|Treatment Group
3253507|NCT00814931|Placebo Comparator|2|
3253508|NCT00814918|Experimental|1|5-ALA Application and exposure using Blu-U light to 1/2 of face.
3253509|NCT00814918|Experimental|2|5-ALA Application and exposure using Candela V-beam Pulse Dye Laser to 1/2 of face.
3253510|NCT00814905|Placebo Comparator|vaginal delivery 1|no further antibiotics after delivery (the patient will receive a saline infusion instead of antibiotics)
3253511|NCT00814905|Active Comparator|vaginal delivery antibotics2|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following vaginal delivery
3253512|NCT00814905|Other|cesarean delivery one dose3|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
3253513|NCT00814905|Other|cesarean multiple antibiotics 4|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
3253514|NCT00814892|Experimental|DC-APCC|Patients undergo standard leukapheresis to harvest peripheral blood mononuclear cells for dendritic cell vaccine preparation. Patients receive the APCC vaccine and autologous dendritic cells derived from CD14-positive myeloid peripheral blood cells ID on days 0, 14, and 28 and then every 28 days for up to 14 courses in the absence of disease progression or unacceptable toxicity.
3253515|NCT00814879|Active Comparator|a.|N(t)RTI(s) based backbone & PI/r
3253516|NCT00814879|Experimental|b.|Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID
3253517|NCT00814866|Other|Adalimumab|Open label
3253518|NCT00814853||Extubation readiness testing|Patients who pass the ERT.
3253519|NCT00814840|Active Comparator|Triple-site group|Triple-site resynchronization group
3253520|NCT00814840|Active Comparator|Standard resynchronization group|Standard (double-site) resynchronization group
3253521|NCT00814814||Cardiopulmonary arrest|
3253522|NCT00814801|Placebo Comparator|Placebo|
3253523|NCT00814801|Experimental|Galantamine 16 mg/day|
3253524|NCT00814801|Experimental|Galantamine 24 mg/day|
3253525|NCT00814788|Experimental|Bicalutamide + Everolimus|Patients receive oral bicalutamide and oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3253526|NCT00814775|Active Comparator|Group 1|Fastrach Laryngeal Mask Airway intubation
3253527|NCT00814775|Active Comparator|Group 2|Intubation of difficult airway using CTrach Laryngeal Mask
3253528|NCT00814762|Experimental|HIV 732462 Group|Subjects received 2 doses of the HIV Vaccine 732462 into the deltoid muscle of the dominant arm, on a 0, 1 Month schedule.
3253529|NCT00814762|Placebo Comparator|Placebo Group|Subjects received 2 doses of the placebo vaccine into the deltoid muscle of the dominant arm, on a 0, 1 Month schedule.
3253530|NCT00814749|Active Comparator|surgical therapy|
3253531|NCT00814749|Active Comparator|individual management|
3253532|NCT00814736|Experimental|UK369,003 + Placebo or sildenafil|All subjects will receive 17 days daily dosing of UK-369,003 100 mg MR Subjects will receive single oral doses of the following interactant treatments in a randomized order On Day 14, a single dose of sildenafil-matching placebo or 100 mg sildenafil and on Day 17 a single dose of 100 mg sildenafil or a sildenafil matching placebo
3253533|NCT00814723|Active Comparator|Fluvastatin|Fluvastatin 80 mg MR
3253534|NCT00814723|Active Comparator|Fluvastatin + Ezetimibe|Fluvastatin MR 80 mg plus Ezetimibe 10 mg
3253535|NCT00814710|Experimental|Synflorix & Tritanrix-HebB/Hib Group|Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
3253536|NCT00814710|Active Comparator|Hiberix group & Tritanrix-HebB Group|Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
3253576|NCT00814489|Experimental|GSK2254233A Group|Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3253537|NCT00814697|Experimental|Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Coil Stimulation (rTMS) treatment in Alzheimer's disease. The Magstim Rapid2 stimulator with a peak magnetic field of 0.5-3.5 Tesla at 100% output was used over the right and left dorsolateral prefrontal cortex. Patients received 4 sessions of rTMS over 2 weeks, lasting approximately 30 minutes, 2 consecutive days a week for 2 weeks.
3253538|NCT00814671|Experimental|RPT450|Rifapentine 450mg daily
3253539|NCT00814671|Active Comparator|RIF 600|Rifampin 600mg daily
3253540|NCT00814671|Experimental|RPT 600|Rifapentine 600mg daily
3253541|NCT00814658|Experimental|Galantamine + Nimodipine|
3253542|NCT00814658|Experimental|Galantamine + Placebo|
3253543|NCT00814645|Active Comparator|Dose level 1|a single dose (5 mg sodium nitrite)of AIR001 Inhalation Solution administered by inhalation following nebulization
3253544|NCT00814645|Active Comparator|Dose level 2|a single dose(15 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
3253545|NCT00814645|Active Comparator|Dose level 3|a single dose(45 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
3253546|NCT00814645|Active Comparator|Dose level 4|a single dose(113 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
3253547|NCT00814645|Placebo Comparator|Expansion arm|On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
3253548|NCT00814632|Experimental|Study Drug CC 10004|Study drug CC-10004 20mg taken orally twice a day.
3253549|NCT00814619|Experimental|Arm I|Patients receive panitumumab IV over 30-90 minutes on days 1, 15, 29, 43, and 57 and oral capecitabine twice daily on days 8-40. Beginning on day 8, patients undergo daily fractions of 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning approximately 6 weeks after completion of panitumumab and chemoradiotherapy, patients undergo surgery.
3253550|NCT00814619|Active Comparator|Arm II|Patients receive oral capecitabine twice daily on days 1-33. Patients undergo concurrent 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning 6 weeks after completion of chemoradiotherapy, patients undergo surgery.
3253551|NCT00814606|Experimental|Single Group|8 weeks period of escalating doses of fluvastatin to a goal dose of 80mg daily, then patients will start treatment of HCV at week 9 with the usual standard of care protocol for medication dose, office visits and laboratories. Peginterferon alfa2a 180 mcg/ml SQ injection once a week for 48 weeks and ribavirin 1000-1200 mg daily orally in two divided doses for 48 weeks. Patients weighing < 75 kg will receive 1000mg per day (400mg in the morning and 600mg in the evening). Patients weighing ≥ 75 kg will receive 1200 mg per day (600mg in the morning and 600 mg in the evening).
3253552|NCT00814593|Experimental|Arm I|Patients undergo intracranial placement of polifeprosan 20 with carmustine implant (Gliadel® wafer) at the time of therapeutic craniotomy.
3253553|NCT00814593|Experimental|Arm II|Patients undergo leukapheresis to obtain autologous lymphokine-activated killer (LAK) cells, followed 3-7 days later by therapeutic craniotomy. The autologous LAK cells are then instilled into the tumor bed cavity at the time of therapeutic craniotomy.
3253554|NCT00814580|Experimental|001|Tapentadol IR First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1 if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
3253555|NCT00814580|Active Comparator|002|Oxycodone IR First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1 if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
3253556|NCT00814567|Active Comparator|Arm I (control)|Patients undergo standard whole breast radiotherapy once daily on days 1-5 for 3 weeks.
3253557|NCT00814567|Experimental|Arm II|Patients undergo reduced whole breast radiotherapy and standard partial breast radiotherapy once daily on days 1-5 for 3 weeks.
3253558|NCT00814567|Experimental|Arm III|Patients undergo standard partial breast radiotherapy once daily on days 1-5 for 3 weeks.
3253559|NCT00814554|No Intervention|control|no intervention was carried out in high school
3253560|NCT00814554|Experimental|Educational strategy|Educational strategy was carried out in high school.
3253561|NCT00814554|Experimental|Screening strategy|Screening strategy was carried out in high school.
3253562|NCT00814554|Experimental|Environmental strategy|Environmental strategy was carried out in high school.
3253563|NCT00814554|Experimental|Educational and Screening strategies|Educational strategy and Screening strategy were carried out in high school
3253564|NCT00814554|Experimental|Screening and Environmental strategies|Screening strategy and Environmental strategy were carried out in high school
3253565|NCT00814554|Experimental|Educational and Environmental strategies|Educational strategy and Environmental strategy were carried out in high school
3253566|NCT00814554|Experimental|the three strategies|Educational strategy, Screening strategy and Environmental strategy were carried out in high school.
3253567|NCT00814541|Experimental|1|Relapsed patients, previously treated with VAD or VAD like regimen (VAMP, C-VAMP and Z-Dex are examples of VAD like therapy) and who have had autologous transplants at least 1 year previously.Patients may proceed directly to PAD therapy or have had a maximum of one other line of therapy before PAD.
3253568|NCT00814541|Experimental|2|Relapsed patients, previously treated with VAD or VAD-like regimen who have not had autologous transplantation and achieved at least PR (Appendix A). Patients may proceed directly to PAD therapy or have had a maximum of two other lines of therapy before PAD.
3253569|NCT00814541|Experimental|3|Patients refractory (MR, NC or PD) to VAD or VAD-like therapy. Patients should proceed directly to PAD therapy. Patients with NC or PD may proceed to PAD after a minimum of two cycles of VAD or VAD-like therapy or a minimum of 4 cycles, if MR.
3253570|NCT00814528|Experimental|1|"Application of 5-ALA PDT to some lesions on skin with Blue U light source (417 nm)."
3253571|NCT00814528|Experimental|2|5-FU, Imiquimod or treatment with cryotherapy to lesions on the skin.
3253572|NCT00814515|Active Comparator|1|Ciclosporin 0.1%
3253573|NCT00814515|Placebo Comparator|2|Vehicle
3253574|NCT00814502|Active Comparator|Zolpidem CR|Subjects randomized to Zolpidem CR
3253577|NCT00814489|Experimental|GSK2254232A Group|Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3253578|NCT00814489|Active Comparator|Engerix Group|Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3253579|NCT00814476|Active Comparator|2|Regular treated group in the first segment and CareLink treated group in the second segment
3253580|NCT00814476|Experimental|1. CareLink team supported group|CareLink team supported group
3253581|NCT00814463|Active Comparator|Post-operative SRS|All patients will undergo SRS with the planned target volume (PTV) defined as the resection cavity plus a 3-mm margin after surgical resection of a single brain metastasis. Dose will be prescribed to the maximum isodose line completely encompassing the PTV using the guidelines established in RTOG 9005. All patients will be evaluated for neurocognitive function via Mini-Mental State Examination (MMSE), Quality of Life (QOL) via FACT-Br, and for local recurrence via MRI every 3 months over the course of the study.
3253582|NCT00814437||Donors|Oocyte donor
3253583|NCT00814424|Active Comparator|1|ERCP patients monitored using currently marketed smart biteblock o2
3253584|NCT00814424|Experimental|2|ERCP patients monitored using experimental biteblock delivering up to 10 lit/min oxygen
3253585|NCT00814411|Experimental|Group Counseling|Group family planning counseling
3253586|NCT00814411|Active Comparator|Individual Counseling|Individual family planning counseling with gynecological patients who have unmet need
3253587|NCT00814398|Experimental|SET on day 3|Single embryo transfer on day 3 of embryo development
3253588|NCT00814398|Experimental|DET on day 3|Double embryo transfer on day 3 of embryo development
3253589|NCT00814398|Experimental|SET on day 5|Single embryo transfer on day 5 of embryo development
3253590|NCT00814398|Experimental|DET on day 5|Double embryo transfer on day 5 of embryo development
3253591|NCT00814385|Active Comparator|Vaccine arm 1|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by non-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
3253592|NCT00814385|Active Comparator|Vaccine arm 2|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
3253593|NCT00814385|Active Comparator|Vaccine arm 3|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by non-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
3253594|NCT00814385|Active Comparator|Vaccine arm 4|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
3253595|NCT00814385|Active Comparator|Vaccine arm 5|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by non-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
3253596|NCT00814385|Active Comparator|vaccine arm 6|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
3253597|NCT00814385|Active Comparator|Vaccine arm 7|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by non-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
3253598|NCT00814385|Active Comparator|Vaccine arm 8|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
3253599|NCT00814385|Active Comparator|Vaccine arm 9|No priming dose and single dose MF59 adjuvanted H5N1 vaccine at 52 weeks
3253600|NCT00814372|Experimental|MBX-102 400|
3253601|NCT00814372|Experimental|MBX-102 600|
3253602|NCT00814372|Placebo Comparator|Placebo|
3253603|NCT00814372|Active Comparator|Actos|30-45 mg
3253604|NCT00814359|Experimental|Magic Mouthwash Plus Sucralfate|
3253605|NCT00814359|Active Comparator|Benzydamine HCl|
3253606|NCT00814346|Active Comparator|EGb 120 mg|
3253607|NCT00814346|Placebo Comparator|Placebo|
3253608|NCT00814333|Experimental|1|Thrombin-JMI
3253609|NCT00814333|Active Comparator|2|Merocel pack
3253610|NCT00814320|Experimental|1|Efficacy and tolerability of subcutaneous (SC) infusions of immune globulin intravenous (IGIV), 10% with hyaluronidase (rHuPH20) after ramp-up
3253611|NCT00814320|Experimental|2|Pharmacokinetics of intravenous (IV) infusions of immune globulin intravenous (IGIV), 10% and efficacy and tolerability of subcutaneous (SC) infusions of immune globulin intravenous (IGIV), 10% with hyaluronidase (rHuPH20) after ramp-up
3253612|NCT00814307|Experimental|Active 5mg|
3253613|NCT00814307|Experimental|Active 10 mg|
3253614|NCT00814307|Placebo Comparator|Placebo Sequence 1|
3253615|NCT00814307|Placebo Comparator|Placebo Sequence 2|
3253616|NCT00814294|Placebo Comparator|1|Patients on metformin will remain on their stable dose and receive a sugar pill.
3253617|NCT00814294|Experimental|2; Oral HDV-Insulin|Patients on a stable dose of metformin will receive Oral HDV-I.
3253618|NCT00814294|Experimental|3; Oral HDV-Insulin|Patients on a stable dose of metformin will receive Oral HDV-I.
3253619|NCT00814281|Placebo Comparator|1|Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.
3253620|NCT00814281|Placebo Comparator|2|Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.
3253621|NCT00814281|Experimental|3|Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.
3253622|NCT00814281|Experimental|4|Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.
3253623|NCT00814268|Experimental|Combination therapy|Administration of Aspirin + Clopidogrel for 30 days
3253624|NCT00814268|Active Comparator|Monotherapy|Administration of Aspirin + Clopidogrel placebo for 30 days
3253625|NCT00814255|Experimental|2|Conservative medical therapy plus adalimumab
3253729|NCT00813670|Experimental|Cohort 3: Single dose of XPF-001|
3253626|NCT00814255|Active Comparator|1|Conservative medical therapy (lisinopril, losartan, atorvastatin)
3253627|NCT00814255|Experimental|conservative medical therapy plus galactose|drug: galactose 0.2 g /kg/dose (maximum dose 15g) po BID
3253628|NCT00814242|Active Comparator|hepatectomy|Patients with HCC adjacent to major blood vessels recieved radical resection.
3253629|NCT00814242|Experimental|percutaneous radiationfrequency ablation|CT or Ultrasound-guided percutaneous radiofrequency ablation
3253630|NCT00814229|Active Comparator|Vaccine 1|influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
3253631|NCT00814229|Active Comparator|vaccine 2|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
3253632|NCT00814229|Active Comparator|Vaccine 3|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
3253633|NCT00814229|Active Comparator|Vaccine 4|influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
3253634|NCT00814229|Active Comparator|Vaccine 5|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
3253635|NCT00814229|Active Comparator|Vaccine 6|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
3253636|NCT00814229|Active Comparator|Vaccine 7|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
3253637|NCT00814229|Active Comparator|Vaccine 8|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
3253638|NCT00814229|Active Comparator|Vaccine 9|influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
3253639|NCT00814229|Active Comparator|Vaccine 10|influenza H9N2 vaccine virosomal containing 5microg haemagglutinin by intramuscular injection
3253640|NCT00814229|Active Comparator|Vaccine 11|influenza H9N2 vaccine virosomal containing 15microg haemagglutinin by intramuscular injection
3253641|NCT00814229|Active Comparator|Vaccine 12|influenza H9N2 vaccine virosomal containing 45microg haemagglutinin by intramuscular injection
3253642|NCT00814229|Active Comparator|Vaccine 13|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
3253643|NCT00814229|Active Comparator|Vaccine 14|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
3253644|NCT00814216|Experimental|QAV680|
3253645|NCT00814216|Placebo Comparator|Placebo|
3253646|NCT00814216|Active Comparator|Fluticasone Propionate Inhaler|
3253647|NCT00814203||Chronic obstructive lung disease|those with a condition
3253648|NCT00814190|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
3253649|NCT00814190|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
3253650|NCT00814177|Experimental|No change|Intervention Drug warfarin no change in the dose is performed
3253651|NCT00814177|Active Comparator|Change|Intervention Drug Warfarin One dose increased if subtherapeutic level; one dose deleted or reduced if supratherapeutic level
3253652|NCT00814164|Experimental|Clorafarbine with daunorubicin|Patients receive clofarabine IV over 1 hour on days 1-5 and daunorubicin hydrochloride IV over 5 minutes on days 1, 3, and 5.
3253653|NCT00814151||MicroPhage|Blood Culture positive specimens available within 24 hours of alarm.
3253654|NCT00814151||Standard of Care|Blood Culture positive specimens.
3253655|NCT00814138|Active Comparator|1|Methotrexate
3253656|NCT00814138|Placebo Comparator|2|Placebo
3253657|NCT00814125|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
3253658|NCT00814125|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
3253659|NCT00814125|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
3253660|NCT00814112||1 septic shock|septic shock, ICU
3253661|NCT00814112||2 controls|matched controls
3253662|NCT00814099|Active Comparator|1|Participants will receive care at a pediatric ICU that is continuing the usual approach to sedation management.
3253663|NCT00814099|Experimental|2|Participants will receive care at a pediatric ICU that is implementing the team approach to sedation management.
3253664|NCT00814086|Experimental|Treatment (paclitaxel, cisplatin)|Patients receive paclitaxel IV over 3 hours and cisplatin intraperitoneally (IP) on day 1 and paclitaxel IP on day 8. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3253665|NCT00814073|Experimental|1|masitinib (AB1010) 6 mg/kg/day per os
3253666|NCT00814073|Placebo Comparator|2|placebo
3253667|NCT00814060|Experimental|1|40-mg tablet
3253668|NCT00814060|Experimental|2|240-mg tablet
3253669|NCT00814060|Experimental|3|80-mg capsule
3253670|NCT00814034||1:Tamoxifen|
3253671|NCT00814034||2:Steroidal Aromatase Inhibitor|
3253672|NCT00814034||3:Non-steroidal Aromatase Inhibitor|
3253673|NCT00814021|Experimental|sunitinib,|
3253674|NCT00813995|Experimental|Sitagliptin|
3253675|NCT00813995|Placebo Comparator|Placebo|
3253676|NCT00813982|Experimental|Experimental Lotrafilcon A Contact Lens|Lotrafilcon A experimental contact lens randomly assigned to one eye
3253677|NCT00813982|Active Comparator|Commercial Lotrafilcon A Contact Lens|Lotrafilcon A commercial contact lens randomly assigned to one eye
3253678|NCT00813969|Experimental|Autologous MSC transplantation|
3253679|NCT00813956|Experimental|1|standard chemotherapy plus BSI-201
3253680|NCT00813943|Experimental|Cilengitide (2-times weekly) + Temozolomide + Radiotherapy|
3253681|NCT00813943|Experimental|Cilengitide (5-times weekly) + Temozolomide + Radiotherapy|
3253682|NCT00813943|Active Comparator|Temozolomide + Radiotherapy|
3253730|NCT00813670|Experimental|Cohort 4: Single dose of XPF-001|
3253731|NCT00813670|Experimental|Cohort 5: Single dose of XPF-001|
3253683|NCT00813930|Experimental|INTERxVENT Program|Participants in INTERxVENT will complete a 'Baseline Assessment' and 'Follow-up' questionnaire, and will have a health professional visit his/her home for an initial assessment (BP,height,weight,waist measurement) and blood collection (blood glucose and cholesterol levels). As part of the program, each participant will also complete a self-reported 'Health History Questionnaire' (HHQ); a follow-up HHQ will be completed about 12 weeks into the program to monitor progress. Each participant randomized to INTERxVENT receives educational articles which address diabetes management issues. A structured, individualized program, consisting of educational materials and 12 live mentoring/coaching telephone calls will take place over 6 months. The mentors consist of allied health professionals. The sequence by which educational content is administered will be both self-directed and guided by the mentors using an algorithmic approach according to the participant's readiness-to-change scores.
3253684|NCT00813930|No Intervention|Usual medical care|Each participant randomized to this group will not receive any formal intervention but will receive the same care over the 6-month period as he/she usually receives from his/her health care team. Participants in this group will undergo the same baseline and outcome assessment as those in the intervention group, including blood pressure (BP) measurement, physical assessment (height, weight, waist measurement) and blood collection (blood glucose and cholesterol levels), as well as completion of the 'Baseline Assessment' and 'Follow-up' questionnaires.
3253685|NCT00813917|Active Comparator|varenicline|
3253686|NCT00813917|Placebo Comparator|Placebo|
3253687|NCT00813904|Experimental|rThrombin, 1000 IU/mL|
3253688|NCT00813891|Active Comparator|Pre-PDT|Participants in this group will receive an intraocular Ranibizumab injection one week prior to the first PDT with verteporfin.
3253689|NCT00813891|Active Comparator|Post-PDT|Participants in this group will receive an intraocular Ranibizumab injection one week post the first PDT with verteporfin.
3253690|NCT00813891|Active Comparator|No PDT|Participants in this group will receive an intraocular Ranibizumab injection with no accompanying PDT with verteporfin.
3253691|NCT00813878||Normal participants|
3253692|NCT00813878||Breast Cancer Patients|
3253693|NCT00813865|Experimental|Afegostat Tartrate Treatment Regimen 1|Afegostat tartrate was administered orally at a dose of 225 mg QD for 3 or 7 consecutive days followed by no study medication for 4 or 7 consecutive days (consecutive 3-days-on/4-days-off or 7-days-on/7-days-off, respectively). Amendment 2 added a MWF 3-days-on/4-days-off regimen. After Amendment 2 was implemented, all participants were assigned to one of the two 3-days-on/4-days-off regimens. Amendment 4 removed the consecutive 3-days-on/4-days-off regimen, and all participants were assigned to the MWF 3-days-on/4-days-off regimen. Participants were to receive afegostat tartrate for 30 months and be followed for 6 months after EOT.
3253694|NCT00813852|Experimental|2|exercise training, CPAP, and inspiratory muscle strengthening program
3253695|NCT00813839|Experimental|1 SmartCare|automated ventilator controlled adjustment of pressure support
3253696|NCT00813839|Active Comparator|2 spontaneous breathing Trial|daily SBT on minimum pressure support
3253697|NCT00813826|Experimental|SLC022|300mg TID
3253698|NCT00813826|Placebo Comparator|Placebo|Matching placebo capsule
3253699|NCT00813813|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
3253700|NCT00813800|Experimental|Varenicline|Open-label; subjects will receive a behavioral intervention in addition to Varenicline.
3253701|NCT00813787||A. glioma|A. glioma population
3253702|NCT00813787||B. Normal brain|B. Normal brain
3253703|NCT00813774|Active Comparator|Reference|Lyophilized formulation (reference)
3253704|NCT00813774|Experimental|Liquid|Liquid Formulation (test)
3253705|NCT00813774|Experimental|Pre-filled Syringe|Pre-filled syringe (test)
3253706|NCT00813761|Other|02Optix CL and ReNu MPS with SICS|O2Optix contact lens and ReNu MultiPlus Multi-Purpose Solution
3253707|NCT00813761|Other|Proclear CL and ReNu MPS with SICS|Proclear contact lens and ReNu MultiPlus Multi-Purpose Solution
3253708|NCT00813761|Other|02Optix CL and Clear Care LCS with SICS|O2Optix contact lens and Clear Care lens care solution subject
3253709|NCT00813761|Other|Proclear CL and Clear Care LCS with SICS|Proclear contact lens and Clear Care lens care solution
3253710|NCT00813761|Other|02Optix CL and ReNu MPS without SICS|O2Optix contact lens and ReNu MultiPlus Multi-Purpose Solution
3253711|NCT00813761|Other|Proclear CL and ReNu MPS without SICS|Proclear contact lens and ReNu MultiPlus Multi-Purpose Solution
3253712|NCT00813761|Other|02Optix CL and Clear Care LCS without SICS|O2Optix contact lens and Clear Care lens care solution
3253713|NCT00813761|Other|Proclear CL and Clear Care LCS without SICS|Proclear contact lens and Clear Care lens care solution
3253714|NCT00813735|Experimental|Eszopiclone|Drug: Eszopiclone 2mg, Drug: Escitalopram 10mg or 20mg
3253715|NCT00813735|Placebo Comparator|Placebo|Drug: Placebo, Drug: Escitalopram 10mg or 20mg
3253716|NCT00813722|Active Comparator|phone calls|patients received phone calls
3253717|NCT00813722|Placebo Comparator|no phone calls|patients received no phone calls
3253718|NCT00813722|Active Comparator|current treatment|calcium chanel blocker and at1 antagonist
3253719|NCT00813722|Active Comparator|tradittional treatment|beta blocker and diuretic
3253720|NCT00813709|Active Comparator|RNF 44 mcg thrice weekly|
3253721|NCT00813709|Active Comparator|RNF 44 mcg once weekly and placebo|
3253722|NCT00813709|Active Comparator|Placebo/RNF 44 mcg thrice weekly|
3253723|NCT00813696|Experimental|A|cisplatin + gemcitabine
3253724|NCT00813696|Active Comparator|B|gemcitabine
3253725|NCT00813683|Experimental|1|"Stimulation of 67 Bladder point"
3253726|NCT00813683|Sham Comparator|2|"Stimulation of 45 Stomach point (sham)"
3253727|NCT00813670|Experimental|Cohort 1: Single dose of XPF-001|
3253728|NCT00813670|Experimental|Cohort 2: Single dose of XPF-001|
3253732|NCT00813670|Experimental|Cohort A: Repeated doses of XPF-001|
3253733|NCT00813670|Experimental|Cohort B: Repeated doses of XPF-001|
3253734|NCT00813670|Experimental|Cohort C: Repeated doses of XPF-001|
3253735|NCT00813657|Experimental|Lifestyle counseling|
3253736|NCT00813644||1|uromentor training
3253737|NCT00813644||2|non uromentor training
3253738|NCT00813631|Experimental|silver-releasing dressings|Silver, in its common ionic (active) form (Ag+), is particularly attractive as an antibacterial agent because it can be readily incorporated into dressing materials. Silver-dressing are wound products designed to control infection and provide a wound environment conducive to management exudates, pain, and malodour.
3253739|NCT00813618|Experimental|1|MEDI-507
3253740|NCT00813618|Experimental|2|MEDI-507
3253741|NCT00813618|Experimental|3|MEDI-507
3253742|NCT00813605|Experimental|Arm A|AMG 655 10 mg/kg plus AMG 479 placebo in combination with FOLFIRI every 14 days
3253743|NCT00813605|Active Comparator|Arm C|AMG 479 Placebo plus AMG 655 Placebo in combination with FOLFIRI every 14 days
3253744|NCT00813605|Experimental|Arm B|AMG 479 12 mg/kg plus AMG 655 placebo in combination with FOLFIRI every 14 days
3253745|NCT00813592|Experimental|All participants|
3253746|NCT00813566||Diagnostic|
3253747|NCT00813553|Placebo Comparator|beta-alanine 0|
3253748|NCT00813553|Experimental|beta-alanine 1|
3253749|NCT00813553|Experimental|beta-alanine 2|
3253750|NCT00813540|Experimental|1|Exercise
3253751|NCT00813540|Other|2|Usual Care, no intervention
3253752|NCT00813527|Experimental|Lapaquistat Acetate 100 mg QD + Fenofibrate 145 mg QD|
3253753|NCT00813527|Active Comparator|Fenofibrate 145 mg QD|
3253754|NCT00813514|Experimental|1|Open longitudinal study with observer masked analysis
3253755|NCT00813488|Experimental|Fentanyl buccal tablet first then immediate release oxycodone|This crossover study includes a screening period, two titration periods, two double-blind treatment periods during which subjects will be randomized to receive fentanyl buccal tablet (FBT) plus placebo during the first treatment period and then immediate release oxycodone plus placebo during the second treatment period or vice versa, then followed by a 12-week open-label treatment period with FBT or an alternative short acting opioid.
3253756|NCT00813488|Experimental|Immediate Release Oxycodone first then FBT|This crossover study includes a screening period, two titration periods, two double-blind treatment periods during which subjects will be randomized to receive fentanyl buccal tablet (FBT) plus placebo during the first treatment period and then immediate release oxycodone plus placebo during the second treatment period or vice versa, then followed by a 12-week open-label treatment period with FBT or an alternative short acting opioid.
3253757|NCT00813475|Experimental|tight control|
3253758|NCT00813475|Experimental|standard control|basal bolus insulin regimen
3253759|NCT00813449|Experimental|A|Experimental group : Endostar combined with dacarbazine
3253760|NCT00813449|Placebo Comparator|2|Control group : Dacarbazine combined with placebo
3253761|NCT00813436|Experimental|1|Oxytocin
3253762|NCT00813436|Placebo Comparator|2|Placebo
3253763|NCT00813423|Experimental|Treatment (sunitinib malate, hydroxychloroquine)|Patients receive sunitinib malate PO QD on days 1-28 and hydroxychloroquine PO QD or BID on days 1-42 (beginning day 4 of course 1). Treatment repeats every 42 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3253764|NCT00813397|Experimental|Sepraspray|Receive Sepraspray
3253765|NCT00813397|No Intervention|Control|No Treatment, No Placebo
3253766|NCT00813384|Experimental|Dose Escalation|The dose escalation part of the study is aimed at determining the maximum tolerated dose (MTD), if feasible, and evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 208.
3253767|NCT00813384|Experimental|Dose Expansion|The dose expansion will consist of up to 30 subjects and the dose level of AMG 208 will be dependent upon emerging safety and PK data from the dose escalation part of the study.
3253768|NCT00813371|Active Comparator|1|Airway Pressure Release Ventilation Arm
3253769|NCT00813371|Active Comparator|2|ARDSnet protocol
3253770|NCT00813358|Experimental|Endovascular repair|treatment
3253771|NCT00813345|Experimental|A - Light therapy|Light therapy (1500 lux)
3253772|NCT00813345|Placebo Comparator|B - identical control lamp|identical control lamp
3253773|NCT00813332|Experimental|1|Endostar combined with Docetaxel for Advanced NSCLC: All eligible patients will receive Endostar in combination with Docetaxel chemotherapy for 2 cycles (21 days for each cycle) and cases of good response(CR+PR+SD) will continue treatment for 2 cycles. Endostar treatment will continue after completion of first 4 cycles until disease progression.
3253774|NCT00813332|Placebo Comparator|2|Docetaxel combined with placebo for Advanced NSCLC: All eligible patients will receive placebo in combination with Docetaxel chemotherapy for 2 cycles (21 days for each cycle) and cases of good response(CR+PR+SD) will continue treatment for 2 cycles. Placebo will continue after completion of first 4 cycles until disease progression.
3253775|NCT00813319|Experimental|1 - Girls OnGuard/HPV awareness|Adolescents will watch a short (10 min), interactive DVD designed to promote HPV awareness and initial GARDASIL vaccination and receive a keepsake to help them remember to return to the clinic for their second and third vaccine doses.
3253776|NCT00813319|No Intervention|2 - General health promotion|Adolescents will watch an equally short (10 min) DVD on healthy lifestyles and behaviors. HPV awareness and vaccination will not be addressed.
3253777|NCT00813306|Experimental|A|AZD2066
3253778|NCT00813306|Placebo Comparator|B|Placebo
3253779|NCT00813306|Experimental|C|AZD2066
3253780|NCT00813306|Experimental|D|AZD2066
3253781|NCT00813306|Placebo Comparator|E|Placebo
3253782|NCT00813293|Experimental|Intervention Arm|Sorafenib treatment given prior to radiofrequency ablation
3253783|NCT00813293|Placebo Comparator|Placebo Arm|Placebo pills given prior to radiofrequency ablation
3253784|NCT00813280||hyperglycemia|hospitalized patients with BG >300 ml/dL
3253785|NCT00813267|Experimental|stem cell|mesenchymal stem cell infusion and bone marrow mononuclear cell infusion
3253837|NCT00812903|No Intervention|Control|Control group
3253838|NCT00812903|Experimental|Exercise|Intervention group
3253786|NCT00813254||Questionnaire|Longitudinal measure of QOL, sexual functioning and symptoms in women with recurrent, platinum-resistant ovarian cancer receiving multiple second-line treatment regimens
3253787|NCT00813241|Active Comparator|A|A single dose of 200 mg celecoxib capsule administered as 1 x 200 mg celecoxib capsule, (Reference Formulation)
3253788|NCT00813241|Experimental|B|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet formulation containing granule type A1
3253789|NCT00813241|Experimental|C|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet containing granule type B2
3253790|NCT00813241|Experimental|D|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet containing granule type C1
3253791|NCT00813215|Experimental|1|Relatives to patients with type 2 diabetes.
3253792|NCT00813215|Active Comparator|2|Controls with no family history of type 2 diabetes.
3253793|NCT00813202|Experimental|Nesiritide|
3253794|NCT00813189|Experimental|1 : early start (GH treatment) group|in the early start group, patients were treated with growth hormone for one year immediately after randomisation
3253795|NCT00813189|No Intervention|2 :delayed start (GH treatment) group|in the delayed start group patients took GH treatment for 1 year , 6 months after randomisation
3253796|NCT00813176|Active Comparator|Double Lumen Endotracheal Tube|We used a device called a double lumen tube ( DLT Broncho-Cath®). It is a bifurcated endotracheal tube designed to independently collapse the operated lung.
3253797|NCT00813176|Active Comparator|Arndt Bronchial Blocker|We used a device called a bronchial blocker (9 Fr Arndt® blocker) along with a standard single-lumen tracheal tube (8.0-9.0 mm ID). The Arndt bronchial blocker is a single device, with a distal balloon that is passed thru the single lumen endotracheal once the patient is intubated. The Arndt bronchial blocker is designed to collapse the operated lung.
3253798|NCT00813163|Experimental|PEP02|Liposome Irinotecan
3253799|NCT00813150|Experimental|Vd (bortezomib + dexamethasone)|"Participants received bortezomib at a dose of 1.3 mg/m² body surface area (BSA) for eight 3-week cycles. Within each cycle it was administered twice weekly (on Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 through 21). They received single oral doses of 20 mg dexamethasone on Days~1 and 2, 4 and 5, 8 and 9, and 11 and 12 of each cycle."
3253800|NCT00813150|Active Comparator|Vcd (bortezomib + low-dose dexamethasone + cyclophosphamide)|Participants received bortezomib at a dose of 1.3 mg/m² body surface area (BSA) for eight 3-week cycles. Within each cycle it was administered twice weekly (on Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 through 21). They received single oral doses of 20 mg dexamethasone on Days 1 and 2, 4 and 5, 8 and 9, and 11 and 12 of each cycle and single oral doses of 50 mg cyclophosphamide on a once daily basis from Day 1, Cycle 1 continuously until Day 21, Cycle 8.
3253801|NCT00813137|Experimental|Folfox4 plus Endostar|
3253802|NCT00813124|Experimental|Azacytidine Maintenance after allotx|Busulfan + Fludarabine + ATG + Azacytidine after allogeneic stem cell transplantation (allotx)
3253803|NCT00813111|Experimental|SKY0402|A single local administration of 300 mg in a 20-mL volume into each breast implant pocket for a total dose of 600 mg (i.e., a total of 40 mL)
3253804|NCT00813111|Active Comparator|Bupivacaine HCl|A single local administration of 100 mg in a 20-mL volume into each breast implant pocket for a total dose of 200 mg (i.e., a total of 40 mL)
3253805|NCT00813098|Experimental|High dose|A high dose of LX1031; daily oral intake for 28 days
3253806|NCT00813098|Experimental|Low Dose|A low dose of LX1031; daily oral intake for 28 days
3253807|NCT00813098|Placebo Comparator|Placebo|Matching placebo dosing with daily oral intake
3253808|NCT00813085|Other|Electronic disease management decision support|An electronic Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS).
3253809|NCT00813085|No Intervention|2|Usual care by Family Physician
3253810|NCT00813072|Experimental|1. PEP02|liposome irinotecan
3253811|NCT00813072|Active Comparator|2. irinotecan|
3253812|NCT00813072|Active Comparator|3. docetaxel|
3253813|NCT00813059|Experimental|1|
3253814|NCT00813046|Experimental|gpASIT+TM|
3253815|NCT00813033|Other|patient decision aid|
3253816|NCT00813020|Experimental|A|
3253817|NCT00813020|Experimental|B|
3253818|NCT00813020|Experimental|C|
3253819|NCT00813007||Questionnaire|Radical trachelectomy outcomes for cervical cancer
3253820|NCT00812994|Placebo Comparator|Placebo|
3253821|NCT00812994|Experimental|Escitalopram|
3253822|NCT00812981|Experimental|1562902A NP GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the new-processed (NP) 1562902A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Days 0 and 21.
3253823|NCT00812981|Experimental|1562902A CP GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the comparative-processed (CP) 1562902A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Days 0 and 21.
3253824|NCT00812968|Experimental|Lenalidomide|Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
3253825|NCT00812955|Experimental|A - ABT-143 capsules 5/135 mg|ABT-143 capsules 5/135 mg - ABT-143 (rosuvastatin 5 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
3253826|NCT00812955|Experimental|B - ABT-143 capsules 10/135 mg|ABT-143 capsules 10/135 mg - ABT-143 (rosuvastatin 10 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
3253827|NCT00812955|Experimental|C - ABT-143 capsules 20/135 mg|ABT-143 capsules 20/135 mg - ABT-143 (rosuvastatin 20 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
3253828|NCT00812955|Active Comparator|D - Simvastatin capsules 40 mg|Simvastatin capsules 40 mg daily for 8 weeks
3253829|NCT00812942|Active Comparator|fobt|faecal occult blood test
3253830|NCT00812942|Active Comparator|colonoscopy|colonoscopy screening
3253831|NCT00812929|Placebo Comparator|Placebo|
3253832|NCT00812929|Experimental|GSK2190915 10 mg|
3253833|NCT00812929|Experimental|GSK2190915 50 mg|
3253834|NCT00812929|Experimental|GSK2190915 100 mg|
3253835|NCT00812929|Experimental|GSK2190915 200 mg|
3253836|NCT00812916||RF ablation|RF Ablation using specialized CFAE software
3253839|NCT00812877|Active Comparator|Mineral Trioxide Aggregate|Pulp capping agent, Mineral Trioxide Aggregate used as a direct pulp cap
3253840|NCT00812877|Active Comparator|Calcium Hydroxide|Pulp capping agent, Calcium Hydroxide used as a direct pulp cap
3253841|NCT00812864|Experimental|Capecitabine|
3253842|NCT00812838|Experimental|100 units of Botulinum Toxin Type A|Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline
3253843|NCT00812838|Placebo Comparator|Normal saline|Injection solution will consist of 10 cc preservative free normal saline
3253844|NCT00812825|Experimental|PF-04173127|
3253845|NCT00812825|Active Comparator|Prednisolone|
3253846|NCT00812825|Placebo Comparator|Placebo|
3253847|NCT00812825|Sham Comparator|Solution Placebo|
3253848|NCT00812825|Experimental|PF-04171327 Tablet|
3253849|NCT00812812|Experimental|paroxetine group|paroxetine 10-40mg/day
3253850|NCT00812812|Placebo Comparator|placebo group|matched placebo to paroxetine
3253851|NCT00812799|Active Comparator|Grass pollen extract|Subjects will receive 19.000 BU grass pollen extract daily sublingually
3253852|NCT00812799|Placebo Comparator|Placebo control|Subjects will receive matching placebo control daily sublingually
3253853|NCT00812773|Experimental|3 day repeat dose|
3253854|NCT00812760|Experimental|1|
3253855|NCT00812747||1|
3253856|NCT00812734||surgery|
3253857|NCT00812721|Placebo Comparator|1|Preservative Free Saline
3253858|NCT00812721|Active Comparator|2|Optive (TM)
3253859|NCT00812721|Active Comparator|3|Refresh Moderate/Severe (TM)
3253860|NCT00812721|Active Comparator|4|Systane (TM)
3253861|NCT00812721|Active Comparator|5|Systane Ultra (TM)
3253862|NCT00812708|Experimental|Morcher iris diaphragm implantation|This is a non-randomized, non-comparative interventional surgical series. Patients will undergo Morcher iris diaphragm implantation in their affected eye(s). After surgery, patients will complete 5 postoperative examinations. At each examination, they will be evaluated for changes in light and glare sensitivity and visual acuity. They will also be monitored for adverse reactions.
3253863|NCT00812695|No Intervention|1|
3253864|NCT00812695|Active Comparator|2|CPAP
3253865|NCT00812669|Experimental|Fludarabine, Cylophosphamide and Rituximab|
3253866|NCT00812656||Stroke Panel group|Patients undergoing cardiac surgery with the use of cardiopulmonary bypass
3253867|NCT00812630|Experimental|1|In the second part of the trial, subjects will apply MENT or placebo gel transdermally for 12 weeks and will have 24-hour blood pressure monitoring at baseline, Week 6 and Week 12.
3253868|NCT00812617|Experimental|Mineral water 1|
3253869|NCT00812617|Experimental|Mineral water 2|
3253870|NCT00812604|Experimental|Ping On Ointment|Ping On Ointment
3253871|NCT00812604|Placebo Comparator|Vaseline|Vaseline with minor trace of Ping On ointment to give medicinal smell
3253872|NCT00812578|Active Comparator|Cholecalciferol|
3253873|NCT00812578|Placebo Comparator|Placebo pill|
3253874|NCT00812565|Placebo Comparator|Placebo every 2 weeks|Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).
3253875|NCT00812565|Experimental|0.1 g/kg octagam 10% every 2 weeks|Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).
3253876|NCT00812565|Experimental|0.25 g/kg octagam 10% every 2 weeks|Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).
3253877|NCT00812565|Experimental|0.4 g/kg octagam 10% every 2 weeks|Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).
3253878|NCT00812565|Placebo Comparator|Placebo every 4 weeks|Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).
3253879|NCT00812565|Experimental|0.2 g/kg octagam 10% every 4 weeks|Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).
3253880|NCT00812565|Experimental|0.5 g/kg octagam 10% every 4 weeks|Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).
3253881|NCT00812565|Experimental|0.8 g/kg octagam 10% every 4 weeks|Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).
3253882|NCT00812552||Case|Late or very late drug-eluting stent thrombosis
3253883|NCT00812552||Control|No drug-eluting stent thrombosis
3253884|NCT00812539|Experimental|"Diabetes Connected Health Tool Deluxe"|Subjects enrolled into the intervention arm will measure their glucose levels by using a glucometer. An iMetrikus modem will upload the blood glucose readings to a secure, web-based portal. Participants will be given login information to access this portal, where they can view their glucose readings and detailed graphical representation of their blood glucose levels over time, read educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to these subjects' information on the web portal).
3253885|NCT00812539|Active Comparator|"Diabetes Connected Health Tool Basic"|Control group will measure their glucose levels by using a glucometer. An iMetrikus modem will upload the blood glucose readings to a secure, web-based portal. Participants will be given login information to access this portal. where they can view their glucose readings in tabular form. Their physicians will not have access to this information.
3253886|NCT00812500|Experimental|1|Young men, age 21-46 years.
3253887|NCT00812500|Experimental|2|Old Men, age 63-81 years.
3253888|NCT00812500|Experimental|3|Young women, age 21-46 years.
3253889|NCT00812500|Experimental|4|Old women, age 63-81 years.
3253890|NCT00812487|Experimental|Intravenous insulin|
3253891|NCT00812487|Active Comparator|Subcutaneous Insulin|4 injections of insulin/day
3253892|NCT00812461|Placebo Comparator|Placebo|
3253893|NCT00812461|Experimental|Nalmefene|
3253894|NCT00812448|Experimental|tea catechin extracts containing mask|wearing the tea catechin extracts containing mask
3253895|NCT00812435|Experimental|Eptifibatide|PCI with administration of eptifibatide
3253896|NCT00812422|Experimental|Dexibuprofen 1|Dexibuprofen 2.5 or 5 mg/kg
3253897|NCT00812422|Experimental|Dexibuprofen 2|Dexibuprofen 3.5 or 7 mg/kg
3253898|NCT00812422|Active Comparator|Ibuprofen|Ibuprofen 5 or 10 mg/kg
3253899|NCT00812409|Experimental|1|Control group: non-protein supplement with resistance and aerobic exercise.
3253900|NCT00812409|Experimental|2|Low protein supplement with resistance and aerobic exercise.
3253901|NCT00812409|Experimental|3|Moderate protein supplement with resistance and aerobic exercise.
3253902|NCT00812409|Experimental|4|High protein supplement with resistance and aerobic exercise.
3253903|NCT00812396|Active Comparator|1|Low dose testosterone
3253904|NCT00812396|Active Comparator|2|High dose testosterone
3253905|NCT00812396|Placebo Comparator|3|Placebo
3253906|NCT00812383|Experimental|Bivalirudin|
3253907|NCT00812383|Active Comparator|Heparin|
3253908|NCT00812370|Experimental|open label|
3253909|NCT00812357||1|Patients treated with Symbicort basic treatment
3253910|NCT00812357||2|Patients treated with Symbicort basic treatment + treatment of symptoms as needed
3253911|NCT00812344|Experimental|1|
3253912|NCT00812344|Active Comparator|2|AZD0837 + Ketoconazole
3253913|NCT00812331|Experimental|Genotype 2|Participants with chronic genotype 2 hepatitis C virus (HCV) infection
3253914|NCT00812331|Experimental|Genotype 3|Participants with chronic genotype 3 HCV infection
3253915|NCT00812331|Experimental|Genotype 4|Participants with chronic genotype 4 HCV infection
3253916|NCT00812331|Experimental|Genotype 5|Participants with chronic genotype 5 HCV infection
3253917|NCT00812331|Experimental|Genotype 6|Participants with chronic genotype 6 HCV infection
3253918|NCT00812318|Experimental|Treatment A|GSK1265744 10mg oral solution
3253919|NCT00812318|Experimental|Treatment B|GSK1265744 5mg tablet, fasted
3253920|NCT00812318|Experimental|Treatment C|GSK1265744 5mg tablet, fed
3253921|NCT00812305|Experimental|Low dose in healthy patients|
3253922|NCT00812305|Experimental|Low dose in hepatically impaired patients|
3253923|NCT00812279|Experimental|1. SMAR|Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times.
3253924|NCT00812279|Active Comparator|2 Conventional cigarette (CC)|Subjects will be allowed to smoke without any limit on consumption during the designated smoking times.
3253925|NCT00812279|Active Comparator|3. smoking cessation (SC)|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
3253926|NCT00812266|Experimental|A|Topotecan + cisplatin
3253927|NCT00812266|Active Comparator|B|Etoposide + carboplatin
3253928|NCT00812253|Experimental|Intravenous Insulin|
3253929|NCT00812253|Active Comparator|Subcutaneous Insulin|Basal bolus insulin (4 injections per day)
3253930|NCT00812240|Experimental|1|masitinib 7.5 mg/kg/day, per os
3253931|NCT00812240|Active Comparator|2|imatinib 400 mg or 600 mg per day, per os
3253932|NCT00812227|Experimental|Psychodynamic psychotherapy|
3253933|NCT00812214|Experimental|1|
3253934|NCT00812214|Placebo Comparator|2|
3253935|NCT00812201||1|
3253936|NCT00812188|Active Comparator|Medium Dose UVA-1|Medium dose (60 J/cm2) UVA-1 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream to another morphea plaque twice daily for twelve weeks.
3253937|NCT00812188|Active Comparator|High Dose UVA-1|High dose UVA-1 treatment 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream twice daily for 12 weeks to another morphea plaque.
3253938|NCT00812175||Group 1|
3253939|NCT00812162|Experimental|1|High protein diet.
3253940|NCT00812162|Experimental|2|Lower protein diet.
3253941|NCT00812123|Experimental|Calcineurin free|Immunosuppression with Sirolimus, Mycophenolate and Steroids
3253942|NCT00812123|Active Comparator|Calcineurin|Immunosuppressive therapy with Cyclosporin A, Mycophenolate and Steroids
3253943|NCT00812097|Other|Primary Augmentation|The Primary Augmentation cohort will include patients who wish general breast enlargement receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants.
3253944|NCT00812097|Other|Primary Reconstruction|The Primary Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants.
3253945|NCT00812097|Other|Revision Augmentation|The Revision Augmentation cohort will include patients receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants during a revision surgery to correct or improve the result of a primary breast augmentation surgery.
3253946|NCT00812097|Other|Revision Reconstruction|The Revision Reconstruction cohort will include patients receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants during a revision surgery to correct or improve the result of a primary breast reconstruction surgery.
3253947|NCT00812084||CAP cohort|Includes cases that were hospitalized because of a community-acquired pneumonia during the study period, and for which we had a baseline EQ-5D score from the start of the study period. These CAP cases are prospectively followed for up to one year using questionnaires for health status and (health) resources.
3253948|NCT00812084||Controls cohort|For each CAP cases, two controls are matched based on age, sex and baseline EQ-5D score measured at the start of the study. These controls are prospectively followed for up to one year using questionnaires for health status and (health) resources.
3253949|NCT00812058|Experimental|RG2417|Oral RG2417 taken twice daily for 8 weeks
3253950|NCT00812058|Placebo Comparator|Placebo|Oral placebo taken twice daily for 8 weeks
3253951|NCT00812045|Experimental|1|
3253952|NCT00812045|Placebo Comparator|2|
3253953|NCT00812019|Experimental|3.75_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
3253954|NCT00812019|Experimental|3.75_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
3253955|NCT00812019|Experimental|3.75_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
3254018|NCT00811720|Placebo Comparator|Placebo|
3254019|NCT00811720|Experimental|Nalmefene|
3253956|NCT00812019|Experimental|3.75_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
3253957|NCT00812019|Experimental|7.5_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
3253958|NCT00812019|Experimental|7.5_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
3253959|NCT00812019|Experimental|7.5_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
3253960|NCT00812019|Experimental|7.5_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
3253961|NCT00812019|Experimental|15_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
3253962|NCT00812019|Experimental|15_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
3253963|NCT00812019|Experimental|15_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
3253964|NCT00812019|Experimental|15_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
3253965|NCT00812006|Experimental|A|Treatment Sequence A: rizatriptan, rizatriptan, placebo
3253966|NCT00812006|Experimental|B|Sequence B: rizatriptan, placebo, rizatriptan
3253967|NCT00812006|Experimental|C|Sequence C: placebo, rizatriptan, rizatriptan
3253968|NCT00811993|Experimental|1|
3253969|NCT00811993|Experimental|10|
3253970|NCT00811993|Experimental|11|
3253971|NCT00811993|Experimental|12|
3253972|NCT00811993|Experimental|13|
3253973|NCT00811993|Experimental|2|
3253974|NCT00811993|Experimental|3|
3253975|NCT00811993|Experimental|4|
3253976|NCT00811993|Experimental|5|
3253977|NCT00811993|Experimental|6|
3253978|NCT00811993|Experimental|7|
3253979|NCT00811993|Experimental|8|
3253980|NCT00811993|Experimental|9|
3253981|NCT00811980||Heathy Subjects|
3253982|NCT00811967|Experimental|Treatment Arm|
3253983|NCT00811967|No Intervention|Control Arm|
3253984|NCT00811954|Experimental|Arm A: ATV/RTV + FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
3253985|NCT00811954|Experimental|Arm B: RAL + FTC/TDF|FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
3253986|NCT00811954|Experimental|Arm C: DRV/RTV + FTC/TDF|FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
3253987|NCT00811941|Placebo Comparator|Placebo|
3253988|NCT00811941|Experimental|Nalmefene|
3253989|NCT00811928|Active Comparator|Posaconazole|Posaconazole oral suspension 200 mg three times a day (TID)
3253990|NCT00811928|Active Comparator|Fluconazole|Fluconazole 400 mg once daily (QD)
3253991|NCT00811915|Experimental|Sirolimus|"Group A : Sirolimus introduction and tacrolimus withdrawal~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14.~Sirolimus daily dose according to CYP3A5 genotype CYP3A5*1/*1 or *1/*3: 4 mg/d CYPY3A5*3/*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml"
3253992|NCT00811915|Active Comparator|B|Tacrolimus (Advagraf) dose to obtain a trough level between 4 and 10 ng/ml
3253993|NCT00811902|Experimental|Nerispirdine 50mg|Nerispirdine 50mg once daily for 14 weeks
3253994|NCT00811902|Experimental|Nerispirdine 100mg|Nerispirdine 100mg once daily for 14 weeks
3253995|NCT00811902|Experimental|Nerispirdine 200mg|Nerispirdine 200mg once daily for 14 weeks
3253996|NCT00811902|Placebo Comparator|Placebo|Placebo for Nerispirdine once daily for 14 weeks
3253997|NCT00811889|Placebo Comparator|Placebo|
3253998|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 75mg|
3253999|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 150mg|
3254000|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 25mg|
3254001|NCT00811863||1|Subjects with moderate renal insufficiency defined as an eGFR 30-60 mL/min/1.73 m2
3254002|NCT00811863||2|Subjects with severe renal insufficiency defined as an eGFR <30 mL/min/1.73 m2 and ESRD defined as requiring dialysis
3254003|NCT00811850|Active Comparator|Combigan®|Combigan® (fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution). One drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks.
3254004|NCT00811850|Active Comparator|Cosopt®|Cosopt® (fixed combination of dorzolamide hydrochloride - timolol maleate ophthalmic solution). One drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks.
3254005|NCT00811837|Experimental|Remifentail|Remifentanil Infusion
3254006|NCT00811837|Active Comparator|Midazolam|Active Placebo
3254007|NCT00811824|Active Comparator|1|Immediate physical activity and dietary change intervention
3254008|NCT00811824|Other|2|Delayed physical activity and dietary change intervention
3254009|NCT00811811|Experimental|1|Behavioral neurocardiac training
3254010|NCT00811811|Active Comparator|2|Autogenic relaxation training
3254011|NCT00811798|Experimental|Cervarix Group|
3254012|NCT00811772|Active Comparator|Bare metal stent|Implantation of one or more bare metal stent(s) to to treat coronary artery stenosis
3254013|NCT00811772|Experimental|Drug eluting stent|Implantation of one or more drug eluting stent(s) to treat coronary artery stenosis
3254014|NCT00811746|Experimental|1|Rozerem (Ramelteon) 8 mg taken orally 30 minutes before a split-night PSG
3254015|NCT00811746|Active Comparator|2|Lunesta (Eszopiclone) 3 mg taken 30 minutes before the start of split-night PSG
3254016|NCT00811746|Other|3|Historical controls (chart review) matched for demographics and comorbidities of the study drug groups.
3254017|NCT00811733|Experimental|Ofatumumab|Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.
3254020|NCT00811707||1: volunteers|non-pregnant female
3254021|NCT00811707||2: parturients|parturients was scheduled to receive lumbar epidurals for elective cesaeran delivery labor analgesia
3254022|NCT00811694||a|15 male and 15 female patients with glaucoma
3254023|NCT00811694||b|30 sex matched healthy volunteers
3254024|NCT00811681|Experimental|Pioglitazone|pioglitazone
3254025|NCT00811681|Placebo Comparator|Control|placebo
3254026|NCT00811668|Experimental|CPAP before SOMNOVentCR|started with CPAP and continued with SOMNOvent CR
3254027|NCT00811668|Experimental|SOMNOVentCR before CPAP|began with SOMNOvent CR and ended with CPAP
3254028|NCT00811655|Experimental|Pre-Operative SRS|SRS pre-operatively with the planned target volume defined as the tumor plus a 3-mm margin.
3254029|NCT00811642|Experimental|Posaconazole|Posaconazole 400 mg twice a day (BID) oral suspension for 12 weeks
3254030|NCT00811629||control group|
3254031|NCT00811603|Active Comparator|1|Patients who receive antibiotic prophylaxis after clamping of the umbilical cord
3254032|NCT00811603|Experimental|2|Patients who receive antibiotic prophylaxis prior to skin incision
3254033|NCT00811590|Experimental|All patients|All participants enrolled.
3254034|NCT00811577|Experimental|AZX100-placebo|Three trocar sites designated as anterior, lateral and posterior were randomized on each patient to receive one low dose of AZX100 3 mg/linear cm, one high dose of AZX100 10 mg/linear cm, or placebo (saline).
3254035|NCT00811577|Placebo Comparator|Placebo-only|Three trocar sites on each patient received one dose of placebo (saline).
3254036|NCT00811564|Active Comparator|1|Fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution
3254037|NCT00811564|Active Comparator|2|Latanoprost 0.005% ophthalmic solution
3254038|NCT00811538||1 1 (Liv*)|i.v. thrombolysis with rtPA
3254039|NCT00811538||2 (L*)|intraarterial thrombolysis
3254040|NCT00811499|Experimental|ARRY-371797 (Schedule 1)|
3254041|NCT00811499|Experimental|ARRY-371797 (Schedule 2)|
3254042|NCT00811499|Placebo Comparator|Placebo|
3254043|NCT00811486|No Intervention|Usual care|Group II
3254044|NCT00811486|Experimental|Spironolactone and conivaptan|Group I
3254045|NCT00811473|Experimental|Quetiapine XR|
3254046|NCT00811473|Placebo Comparator|Placebo|
3254047|NCT00811460|Experimental|1|
3254048|NCT00811447|Experimental|1|Administration of docetaxel 60 mg/m² on Day 1, Cisplatin 60 mg/m² after the end of the docetaxel infusion and 5-fluorouracil (5-FU) 600 mg/m²/day from Day 1 after the end of the cisplatin infusion to Day 5.
3254049|NCT00811447|Active Comparator|2|Cisplatin 75 mg/m² on Day 1, 5-FU 600 mg/m²/day from Day 1 after the end of the cisplatin infusion to Day 5.
3254050|NCT00811434|Active Comparator|Lactulose|3 months of Lactulose therapy based on pt. weight
3254051|NCT00811434|Placebo Comparator|placebo|1.5 ml/kg day po of sugar water placebo for three months
3254052|NCT00811421|Active Comparator|Trial 1: IPTp-SP+LLITNs|HIV-negative pregnant women receiving 2 doses of IPTp (500mg of sulfadoxine and 25 mg of pyrimethamine) in the context of long lasting Insecticide Treated Nets (LLITNs)
3254053|NCT00811421|Experimental|Trial 1: IPTp-MQ (full dose) + LLITNs|HIV-negative pregnant women receiving 2 full doses of IPTp (15 mg/Kg) in the context of long lasting Insecticide Treated Nets (LLITNs)
3254054|NCT00811421|Experimental|Trial 1: IPTp-MQ (split dose)+LLITNs|HIV-negative pregnant women receiving 2 doses of MQ as IPTp split dose over 2 days (15mg/kg) in the context of long lasting Insecticide Treated Nets (LLITNs
3254055|NCT00811421|Experimental|Trial 2: CTX+IPTp-Placebo+LLITNs|HIV-positive pregnant women receiving 3 doses of IPTp (placebo) in the context of long lasting Insecticide Treated Nets (LLITNs)
3254056|NCT00811421|Experimental|Trial 2: CTX + IPTp-MQ+ LLITNs|HIV-positive pregnant women receiving 3 doses of IPTp (15 mg/Kg) in the context of long lasting Insecticide Treated Nets (LLITNs)
3254057|NCT00811395|Placebo Comparator|Placebo + IFN-β|Placebo (for teriflunomide) once daily concomitantly with interferon-β [IFN-β] for 24 additional weeks
3254058|NCT00811395|Experimental|Teriflunomide 7 mg + IFN-β|Teriflunomide 7 mg once daily concomitantly with interferon-β [IFN-β] for 24 additional weeks
3254059|NCT00811395|Experimental|Teriflunomide 14 mg + IFN-β|Teriflunomide 14 mg once daily concomitantly with interferon-β [IFN-β] for 24 additional weeks
3254060|NCT00811395|Placebo Comparator|Placebo + GA|Placebo (for teriflunomide) once daily concomitantly with glatiramer acetate [GA] for 24 additional weeks
3254061|NCT00811395|Experimental|Teriflunomide 7 mg + GA|Teriflunomide 7 mg once daily concomitantly with glatiramer acetate [GA] for 24 additional weeks
3254062|NCT00811395|Experimental|Teriflunomide 14 mg + GA|Teriflunomide 14 mg once daily concomitantly with glatiramer acetate [GA] for 24 additional weeks
3254063|NCT00811382|Experimental|1: Access to HMSC (Home Monitoring Service Center)|Full functionality of the Home Monitoring System for an early optimization of CRT and management of AF with a full access for the treating physician to the HMSC
3254064|NCT00811382|Active Comparator|2: No access to HMSC|Limited access of the treating physician to the HMSC where only events regarding implant and lead status will be generated and sent to the physician.
3254065|NCT00811369|Experimental|1|Fulvestrant + ZACTIMA Group
3254066|NCT00811369|Placebo Comparator|2|Fulvestrant + Placebo Group
3254067|NCT00811356|Experimental|Single Dose, Repeat Dose, Drug-Drug Interaction|"GSK932121 or placebo will be administered as a single dose with or without food in a dose escalation manner. Once the results from the single dose is obtained and reviewed, GSK932121 or placebo will be administered as a repeat dose. The results from each repeat dose level will be reviewed prior to determining the next repeat dose level.~To better understand the effect of GSK932121 on rosiglitazone and rosuvastatin, a drug-drug interaction arm will also be investigated in this study. Rosiglitazone and rosuvastatin will be administered alone, then GSK932121 will be given as a repeat dose. Rosiglitazone and rosuvastatin will then be administered in combination with GSK932121."
3254068|NCT00811343|Experimental|1|
3254069|NCT00811330|Experimental|1: Atorvastatin 80 mg.|Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
3254070|NCT00811330|No Intervention|2: No Atrovastatine|
3254071|NCT00811317|Experimental|Closed-loop|Type 1 diabetic subjects under closed-loop blood glucose control
3254072|NCT00811304||US group|All patients admitted to the labor and delivery suite who request an epidural for labor analgesia.
3254073|NCT00811291|Placebo Comparator|1|
3254074|NCT00811291|Active Comparator|2|folic acid and B-vitamin supplement
3254075|NCT00811278||step1|asthma patients on step 1 therapy
3254076|NCT00811278||step 2|asthma patients on step 2 therapy
3254077|NCT00811278||healthy|non-asthmatics
3254078|NCT00811265|Experimental|Simulated ExAblate MRgFUS|Patients undergoing simulated ExAblate MRgFUS device use
3254079|NCT00811252|Placebo Comparator|Placebo|
3254080|NCT00811252|Experimental|Vortioxetine 5 mg|
3254081|NCT00811252|Other|Duloxetine 60 mg|Active reference
3254082|NCT00811239|Other|control group|As the antivenom was not yet clinically available until 2006, all patients included during the first two years (2004-2005) received supportive therapy only.
3254083|NCT00811239|Active Comparator|antivenom group|The patients included during the third year (2006) were treated with antivenom therapy and supportive care.
3254084|NCT00811226||Patients|Patients with arterial hypertension Stade I or Stade II
3254085|NCT00811213|Experimental|1|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
3254086|NCT00811213|Active Comparator|2|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
3254087|NCT00811200|Active Comparator|1: Lucentis|
3254088|NCT00811200|Active Comparator|2: Kenalog|
3254089|NCT00811200|Sham Comparator|3: No treatment|
3254090|NCT00811187|Experimental|1|Lidocaine paracervical block
3254091|NCT00811187|Placebo Comparator|2|Saline placebo injection
3254092|NCT00811174|Experimental|Octagam 10%|
3254093|NCT00811161|Experimental|needle free injector of HA|
3254094|NCT00811148||Tissue Bank|Collection of clinical data and tumor tissue removed during brain surgeries for future research.
3254095|NCT00811135|Experimental|1|
3254096|NCT00811109|No Intervention|Standard|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity
3254097|NCT00811109|Active Comparator|2|With Blood Volume on-line monitoring only
3254098|NCT00811109|Active Comparator|3|With Blood volume and Blood temperature on-line monitoring
3254099|NCT00811096|Experimental|Treatment Arm|
3254100|NCT00811096|Active Comparator|Comparator Arm|Comparator Arm
3254101|NCT00811083|Active Comparator|DMSA- 1 round|Subjects receive 1 round of DMSA (10 mg/kg-dose, 9 doses over 3 days), followed by 3 months of placebo
3254102|NCT00811083|Active Comparator|DMSA-7 rounds|Participants receive 7 rounds of DMSA over 4 months; each round consists of 3 days of DMSA (10 mg/kg-dose, 9 doses over 3 days), followed by 11 days off (no treatment), and then repeating.
3254103|NCT00811070|Experimental|1|
3254104|NCT00811057|Active Comparator|1 Magnesium Sulfate|
3254105|NCT00811057|Active Comparator|2 Nifedipine|Participants randomized to this group will receive the medication nifedipine orally.
3254106|NCT00811057|Active Comparator|3 Indomethacin|Participants randomized to this arm will receive the medication indomethacin per rectum and orally.
3254107|NCT00811044||Entry|This group is just entering the study and will need to be genotyped.
3254108|NCT00811044||Affected|This group has been genotyped and has the gene undergoing study at that time.
3254109|NCT00811044||Control|This group has been genotyped and does not have the gene currently under study.
3254110|NCT00811031|Experimental|Taxotere + Prednisone|
3254111|NCT00811018|Experimental|Sitaxsentan|Sitaxsentan
3254112|NCT00811005|Active Comparator|Acitretin-PUVA combination|"Acitretin-PUVA combination:~Acitretin monotherapy: Patients randomized to the acitretin group will receive acitretin in a dose of 1mg /kg daily two weeks prior to additional PUVA treatment.~PUVA treatment (see below) will be applied thrice weekly in addition to acitretin until (near) complete clearance or over a maximum period of 12 weeks. (Near) complete clearance is defined by improvement of the clinical baseline score (see below) by ≥90%.~PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation."
3254113|NCT00811005|Experimental|Fumaric acid ester -PUVA combination|"FAE monotherapy:~Patients randomized to this group will receive FAE in weekly incremental doses (initial daily dose: 30 mg dimethylfumarate (DMF), highest daily dose: 720 mg DMF) starting two weeks prior to additional PUVA treatment.~FAE-PUVA combination:~PUVA treatment will be applied thrice weekly in addition to FAE until (near) complete clearance or over a maximum period of 12 weeks. (Near) complete clearance is defined by improvement of the clinical baseline score (see below) by ≥90%.~PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation."
3254114|NCT00810992|Active Comparator|1 Program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
3254115|NCT00810992|Experimental|2 Program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
3254116|NCT00810979|Experimental|1|SLx-4090 dose #1 in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
3254117|NCT00810979|Experimental|2|SLx-4090 dose #2 in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
3254118|NCT00810979|Other|3|Placebo in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
3254119|NCT00810953|Experimental|single arm|Use of pentamidine in locally advanced or metastatic pancreatic cancer
3254120|NCT00810940|Active Comparator|1|Control: Standard treatment for severe head trauma including mannitol
3254121|NCT00810940|Experimental|2|Study drug plus standard treatment
3254122|NCT00810927|Active Comparator|1|Phenylephrine (Neosynephrine®, Abbott Laboratories, North Chicago, IL, USA) dose: 1µg/(kg.min), infusion period 20 minutes
3254170|NCT00810641|Active Comparator|Headshaking maneuver|headshaking maneuver for apogeotropic HC BPPV
3254123|NCT00810927|Active Comparator|2|NG-monomethyl-L-arginine (L-NMMA, Clinalfa, Läufelfingen, Switzerland) dose: bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/(kg.min) over 15 minutes
3254124|NCT00810927|Placebo Comparator|3|Physiologic saline solution
3254125|NCT00810914|Experimental|1|Continuous epidural infusion of medication for method of pain relief
3254126|NCT00810914|Experimental|2|continuous epidural infusion in conjuction with patient controlled anesthesia (PCA)
3254127|NCT00810914|Experimental|3|patient controlled anesthesia only this arm has pt controlled medication delivery. (PCA)
3254128|NCT00810901|Experimental|Organ Donor|Intervention used a DVD, text messaging, emails, a website, US Mail, and telephone calls to educate teens about their choice to become a designated organ donor on their first driver's license application.
3254129|NCT00810901|Active Comparator|Alcohol Prevention|Intervention used a DVD and text messages, to educate teens about the laws that prohibit underage minors purchasing and consuming alcohol
3254130|NCT00810888|Active Comparator|Group 1-Recombinant activated factor VII|"Participants with ICH determined by CTA to be high risk for hemorrhage growth (spot sign positive for contrast leakage within the brain hematoma) randomized to receive rFVIIa at 80 mcg/kg (max dose 21.3 mL)."
3254131|NCT00810888|Placebo Comparator|Group 2 - Placebo|"Participants with ICH determined by CTA to be high risk for hemorrhage growth (spot sign positive for contrast leakage within the brain hematoma) will be randomized to receive placebo."
3254132|NCT00810888|No Intervention|Group 3 - Observation Only Arm|"Participants with ICHdetermined by CTA not to be at high risk for hemorrhage growth (CTA spot sign negative) enrolled into a prospective observational group."
3254133|NCT00810875||hepatitis C|pregnant women with hepatitis C virus infection and their infants
3254134|NCT00810875||controls|pregnant women without hepatitis C infection and their infants
3254135|NCT00810862|Experimental|Pimecrolimus|Pimecrolimus 1% cream
3254136|NCT00810862|Placebo Comparator|2|Placebo cream over affected study area
3254137|NCT00810849|Placebo Comparator|Prednisolone|Six-week tapering course of prednisolone and those assigned to the prednisolone control arm will receive the same number of identically-coated placebo tablets.
3254138|NCT00810849|Placebo Comparator|Mycobacterium w|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months).
3254139|NCT00810836|Active Comparator|1|BG00012 480 mg/day
3254140|NCT00810836|Active Comparator|2|BG00012 720 mg/day
3254141|NCT00810836|Placebo Comparator|3|
3254142|NCT00810823||1:Gastric bypass/diabetes|Patients undergoing gastric bypass surgery, and who are diagnosed with type 2 diabetes.
3254143|NCT00810823||2:Gastric bypass/not Diabetic|Patients undergoing gastric bypass surgery, not diagnosed with diabetes.
3254144|NCT00810810|Active Comparator|1|Blood components with no additional treatment
3254145|NCT00810810|Experimental|2|Blood components leukoreduced
3254146|NCT00810810|Experimental|3|Blood components leukoreduced and irradiated
3254147|NCT00810797|Experimental|Treatment (exemestane)|Patients receive oral exemestane once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3254148|NCT00810784||1|Patients cared for before our intervention.
3254149|NCT00810784||2|Patients cared for after our intervention.
3254150|NCT00810771|Experimental|Preference-tailored (PT) intervention|"Intervention:~Behavioral: Standard Information Behavioral: Preference-tailored Information"
3254151|NCT00810771|Active Comparator|Standard information (SI) intervention|Behavioral: Standard Information
3254152|NCT00810771|No Intervention|Usual Care|Due to budget and time constraints this group was not powered as a true study arm but was used to assess the impact of our baseline physician information letter and to control for any other interventions of system-wide initiatives that may occur during the study timeframe and impact rated of CRC screening. Data was not collected on every participant in this arm.
3254153|NCT00810758|Experimental|PF-04878691|
3254154|NCT00810745|Experimental|rectal resection|
3254155|NCT00810732|Experimental|Sitaxsentan|Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
3254156|NCT00810732|Active Comparator|Nifedipine|Nifedipine 30 mg extended release tablets, orally administered once daily (open label arm)
3254157|NCT00810732|Placebo Comparator|Placebo|Placebo for sitaxsentan, orally administered once daily (double blind arm)
3254158|NCT00810719|Experimental|Gemcitabine and Erlotinib|The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.Erlotinib will be dosed at 150mg orally (tablets) on days 2-5, 9-12, and 16-26 of a 28 day cycle.
3254159|NCT00810706|No Intervention|1: observation only|Patients have completed at least 5 years and not more than 7 years of continued treatment with tamoxifen (20 mg/day). Tamoxifen could have been discontinued up to 6 months prior to study entry.
3254160|NCT00810706|Active Comparator|2: Exemestane|Patients randomised to receive exemestane (25 mg/day) for 5 years, following completion of 5-7 years of Tamoxifen treatment
3254161|NCT00810693|Experimental|Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks
3254162|NCT00810693|Experimental|Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 1.5mg three times daily (tid) (titration between 1.0 mg and 1.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks
3254163|NCT00810693|Placebo Comparator|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 12 weeks
3254164|NCT00810680|Experimental|Valproic acid|
3254165|NCT00810667|Experimental|Lu AE58054|
3254166|NCT00810667|Placebo Comparator|Placebo|
3254167|NCT00810654|Experimental|ANPEP|Aspergillus niger prolyl endoprotease (AN-PEP), a microbial-derived prolyl endoprotease which cleaves gluten
3254168|NCT00810654|Placebo Comparator|Placebo|
3254169|NCT00810641|Active Comparator|Gufoni maneuver|Gufoni maneuver for apogeotropic HC-BPPV
3254171|NCT00810641|Sham Comparator|sham maneuver|sham maneuver for apogeotropic HC BPPV
3254172|NCT00810628|Experimental|1|All subjects in same investigative group with same CBT intervention.
3254173|NCT00810615|Sham Comparator|Sham treatment|Subject will breathe air at less than 1.3 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at less that 1.3 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
3254174|NCT00810615|Experimental|Hyperbaric oxygen 2.4 ATA|Subject will breathe 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
3254175|NCT00810602|Experimental|Vorinostat prophylaxis|Vorinostat,combined with standard GVHD prevention medications(tacrolimus, mycophenolate) for adults who received a reduced intensity, related donor stem cell transplant
3254176|NCT00810589|Experimental|1|
3254177|NCT00810589|Active Comparator|2|
3254178|NCT00810576|Experimental|Vorinostat + Bortezomib|Vorinostat 200 mg orally twice on Days 1-14 + Bortezomib 1.3 mg/m^2 intravenous (IV) on Days 1, 4, 8, 11.
3254179|NCT00810563|Placebo Comparator|1|Saline solution 0.9% 5mL in each portal
3254180|NCT00810563|Active Comparator|2|Bupivacaine 0.5% 5mL in each portal
3254181|NCT00810550|Other|LV systolic dysfunction|Diagnostic Testing
3254182|NCT00810524|Experimental|A|120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).
3254183|NCT00810524|Active Comparator|B|120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).
3254184|NCT00810524|Experimental|C|180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).
3254185|NCT00810524|Active Comparator|D|180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).
3254186|NCT00810511|Experimental|Lotrafilcon A|Investigational, spherical, silicone hydrogel contact lenses
3254187|NCT00810511|Active Comparator|Comfilcon A|Commercially marketed, spherical, silicone hydrogel contact lenses
3254188|NCT00810485|Experimental|ADX10059 50 mg|twice-daily
3254189|NCT00810485|Experimental|ADX10059 100 mg|twice-daily
3254190|NCT00810485|Experimental|ADX10059 150 mg|twice-daily
3254191|NCT00810485|Placebo Comparator|ADX10059 Matching Placebo|twice-daily
3254192|NCT00810472|Experimental|HLA Matching|HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial [8]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method [6]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
3254193|NCT00810472|Placebo Comparator|Random graft assignment|
3254194|NCT00810446||rifabutin|Patients administered Rifabutin.
3254195|NCT00810433|Experimental|Arm 1|
3254196|NCT00810407||rifabutin|Patients administered Rifabutin.
3254197|NCT00810394|Experimental|Sorafenib|Dose Re-Escalation Following a Dose Reduction
3254198|NCT00810381|Active Comparator|1|"Nitroglycerin: (Perlinganit, Nycomet Heilmittelwerke, Vienna, Austria):~0, 0.25, 0.5, 1, 1.5 and 2 µg/kg/min, each infusion step for 20 minutes"
3254199|NCT00810381|Active Comparator|2|"Isosorbide-Dinitrate: (Isoket 0,1 %, Gebro Broschek, Fieberbrunn, Austria):~0, 0.5, 1, 2, 4 and 6 µg/kg/min , each infusion step for 20 minutes"
3254200|NCT00810381|Active Comparator|3|"Sodium-Nitroprusside: (Nipruss, Sanol-Schwarz, Monheim, Germany):~0, 0.25, 0.5, 1, 2 and 4 µg/kg/min, each infusion step for 20 minutes"
3254201|NCT00810381|Placebo Comparator|4|Physiologic saline solution
3254202|NCT00810368|Active Comparator|Carnosine treatment group|Carnosine treatment group
3254203|NCT00810368|Placebo Comparator|Placebo control group|Placebo control group
3254204|NCT00810355|Active Comparator|Arm 1|Support group
3254205|NCT00810355|Experimental|Arm 2|Cognitive Behavior Therapy
3254206|NCT00810355|Experimental|Arm 3|Cognitive Behavior Therapy and Cognitive Remediation
3254207|NCT00810342|Experimental|1- physical activity tailored|Tailored telephone counseling about how to become more physically active and goal setting. Email feedback on physical activity progress. Website listing resources new mothers can use to become more active.
3254208|NCT00810342|Active Comparator|2 - physical activity standard|Standard Website resources / information on physical activity
3254209|NCT00810329||1|This group consists of patients with Chronic fatigue syndrome, Fibromyalgia and other conditions like Multiple chemical sensitivity, Irritable bowel syndrome, Interstitial Cystitis, Gulf War Illness.
3254210|NCT00810329||2|The healthy control group
3254211|NCT00810316|Other|Treatment A|
3254212|NCT00810316|Other|Treatment B|
3254213|NCT00810316|Other|Treatment C|
3254214|NCT00810303|Experimental|whole study group|A study with a duration of 34 days with 4 periods (= 4 pharmakokinetics) on 12 healthy subjects.
3254215|NCT00810277|Experimental|1|
3254216|NCT00810264||Data Collection Group|
3254217|NCT00810251||MatrixRIB|
3254218|NCT00810238|Experimental|1|Optimal standard of care + C-Cure
3254219|NCT00810238|No Intervention|2|Optimal standard of care
3254220|NCT00810225||1|GWI: veterans of the 1990-1991 Persian Gulf War who have autonomic, neurological and other symptoms
3254221|NCT00810225||2|HC: healthy veterans of the 1990-1991 Persian Gulf War
3254222|NCT00810212|Active Comparator|1|Autograft
3254223|NCT00810212|Experimental|2|Low Dose MPCs
3254224|NCT00810212|Experimental|3|Medium Dose MPCs
3254225|NCT00810212|Experimental|4|High Dose MPCs
3254265|NCT00809939|Active Comparator|2|previous preterm delivery, treatment with daily vaginal natural progesterone
3254226|NCT00810199|Experimental|Tocilizumab + Methotrexate|Tocilizumab 8 mg/kg (up to 800 mg) intravenous (IV) once every 4 weeks + weekly oral methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drugs (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded methotrexate if a flare occurred.
3254227|NCT00810199|Placebo Comparator|Tocilizumab + Placebo|Tocilizumab 8 mg/kg (up to 800 mg) IV once every 4 weeks + weekly oral placebo to methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and placebo to methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drug (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded placebo to methotrexate if a flare occurred.
3254228|NCT00810186||Newborns needing respiratory monitoring|Premature and term newborn infants (male/female)
3254229|NCT00810173|Experimental|1|This group received call phone support to incentive the increase of the number of steps during 6 weeks
3254230|NCT00810173|No Intervention|2|This group just received a pedometer to register the number of steps for 6 weeks but this group don´t received a phone call.
3254231|NCT00810160|Active Comparator|1|Permeate
3254232|NCT00810160|Active Comparator|2|GOS
3254233|NCT00810160|Active Comparator|3|Bifidobacterium infantis
3254234|NCT00810160|Active Comparator|4|Bifidobacterium animalis
3254235|NCT00810147|Active Comparator|A1|
3254236|NCT00810147|Active Comparator|A2|
3254237|NCT00810147|Active Comparator|A3|
3254238|NCT00810147|Active Comparator|A4|
3254239|NCT00810147|Placebo Comparator|A5|
3254240|NCT00810134|Other|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
3254241|NCT00810134|Other|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
3254242|NCT00810121|Experimental|1|Ketoprofen 100 mg b.i.d. for 5 days
3254243|NCT00810121|Experimental|2|Ketoprofen 150 mg b.i.d. for 5 days
3254244|NCT00810108|Experimental|Whole Then Crushed Tablets|These subjects will take whole lopinavir tablets at Study Visit 1, and crushed tablets at Study Visit 2.
3254245|NCT00810108|Experimental|Crushed Then Whole Tablets|These subjects will take crushed tablets at Study Visit 1, and whole tablets at Study Visit 2.
3254246|NCT00810095|Experimental|Treatment Arm|
3254247|NCT00810082|Active Comparator|Group A|Standard physical therapy for fall prevention
3254248|NCT00810082|Experimental|Group B|Physical therapy for fall prevention that includes ActiveStep
3254249|NCT00810069|Experimental|Early Intervention|Escitalopram 10 milligrams per day for 4 weeks (one 10 milligram [mg]-capsule) followed by Duloxetine flexible dose (60 or 120 mg daily) for 12 weeks.
3254250|NCT00810069|Experimental|Delayed Intervention|Escitalopram 10 mg per day for 4 weeks (one 10 mg-capsule) followed by Escitalopram 10 to 20 mg per day for 4 weeks (one or two 10 mg capsule[s]). Then, non-responders switched to Duloxetine 60 or 120 mg per day for 8 weeks , and responders continued on Escitalopram 10 to 20 mg per day for 8 weeks.
3254251|NCT00810056|Active Comparator|Assessment only|Cognitive, academic achievement and mental health screening assessment and report.
3254252|NCT00810056|Experimental|Assessment + FHF|Cognitive, academic achievement and mental health screening assessment and report. Fostering Healthy Futures program (FHF) including weekly therapeutic skill groups and mentoring over a 9-month period.
3254253|NCT00810043|Active Comparator|Curette-First|All of patients in the study were treated with Balloon Kyphoplasty. During Balloon Kyphoplasty, two inflatable bone tamps (IBTs) are placed into the vertebral body bilaterally via a transpedicular or extrapedicular approach under fluoroscopic guidance. In this arm, curettage was performed prior to use of inflatable bone tamps.
3254254|NCT00810043|Active Comparator|IBT-First|All of patients in the study were treated with Balloon Kyphoplasty. During Balloon Kyphoplasty, two inflatable bone tamps (IBTs) are placed into the vertebral body bilaterally via a transpedicular or extrapedicular approach under fluoroscopic guidance. In this arm, inflatable bone tamps were used prior to curettage, then followed by a second inflation of the bone tamps.
3254255|NCT00810030|Experimental|FERINJECT® (Ferric carboxymaltose)|
3254256|NCT00810030|Active Comparator|VENOFER® (Iron Sucrose)|
3254257|NCT00810004|Experimental|Ferinject|Intravenous infusion of iron
3254258|NCT00810004|Placebo Comparator|Placebo|NaCL 0,9%
3254259|NCT00809991|Experimental|Arm 1|This will be a Phase II study evaluating the effectiveness and toxicity of a regimen of 3.6 Gy per day to a total dose of 57.6 Gy (16 fractions). This choice of daily dose is based on the prior published experience showing safety and efficacy of hypofractionated regimens of 2.5 Gy, 2.7 Gy, and 3.0 Gy daily fractions. The total dose is calculated to be iso-effective for late effects to a conventionally fractionated total dose of 81 Gy, which has been shown to be effective and safe in a large prospective Phase II study. If the alpha/beta ratio for prostate is between 1.5-3.0, then this regimen should be at least as effective or more effective for tumor control than 81 Gy given in conventional fractions.
3254260|NCT00809965|Experimental|Rivaroxaban 2.5 mg bid|One 2.5 mg rivaroxaban tablet twice daily for up to 6 months
3254261|NCT00809965|Experimental|Rivaroxaban 5 mg bid|One 5 mg rivaroxaban tablet twice daily for up to 6 months
3254262|NCT00809965|Placebo Comparator|Placebo|One placebo tablet twice daily for up to 6 months
3254263|NCT00809952||Recombinat FSH|
3254264|NCT00809939|Active Comparator|1|previous preterm delivery, treatment with weekly injections of 17 alfa hydroxyprogesterone caproate.
3254322|NCT00809601|Experimental|1|
3254266|NCT00809939|Active Comparator|3|short cervical length, treatment with weekly injections of 17 alfa hydroxyprogesterone caproate.
3254267|NCT00809939|Active Comparator|4|short cervical length, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
3254268|NCT00809926|Experimental|Valsartan/aliskiren|
3254269|NCT00809926|Active Comparator|Valsartan|
3254270|NCT00809913|Experimental|Short treatment|7 days of standard antibiotic treatment (preferably ciprofloxacin) followed by 7 days of placebo
3254271|NCT00809913|Active Comparator|Standard treatment|14 days of standard antibiotic treatment (initial b-lactam or fluoroquinolone followed by ciprofloxacin through the 8th till 14th day)
3254272|NCT00809900||Dietary Supplement|Cranberry Juice Consumption
3254273|NCT00809887|Placebo Comparator|1|ALT with placebo with systemic Micafungin therapy
3254274|NCT00809887|Experimental|2|ALT with Micafungin and heparin with systemic Micafungin therapy
3254275|NCT00809874|Active Comparator|Casein|
3254276|NCT00809874|Active Comparator|Whey Isolate|
3254277|NCT00809874|Active Comparator|Whey Hydrolysate|
3254278|NCT00809874|Active Comparator|Alphalact-Albumin|
3254279|NCT00809861|Active Comparator|1|volar locking plating of distal radius fractures
3254280|NCT00809861|Active Comparator|2|
3254281|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
3254282|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
3254283|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
3254284|NCT00809848|Active Comparator|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
3254285|NCT00809848|Placebo Comparator|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
3254286|NCT00809835|No Intervention|Standard Treatment As Usual (TAU)|Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals. This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment. The counseling program's theoretical orientation is described as client-centered.
3254287|NCT00809835|Experimental|TAU Plus Galantamine|Standard treatment plus Galantamine. In this study, we will use 8 mg galantamine extended release (ER). Galantamine ER is used once daily. The recommended initial dose is 8 mg/day and the maintenance dose is 16-24 mg/day.
3254288|NCT00809835|Experimental|TAU plus Computer Assisted Cognitive Behavioral Therapy (CBT)|TAU plus computer assisted CBT plus placebo. All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project. Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.
3254289|NCT00809835|Experimental|TAU plus CBT plus galantamine|Standard treatment, plus computer assisted cognitive behavioral therapy, plus galantamine.
3254290|NCT00809822|Active Comparator|1|Intravenous immunoglobulin
3254291|NCT00809822|Placebo Comparator|2|Physiological saline
3254292|NCT00809809|Active Comparator|Zinc gluconate|Oral swabs containing homeopathic Zinc gluconate
3254293|NCT00809809|Placebo Comparator|Placebo|placebo
3254294|NCT00809796|Experimental|single arm|Use of pentamidine in second and/or third line metastatic colon cancer
3254295|NCT00809783|Experimental|Tanezumab 10 mg|Tanezumab 10 mg
3254296|NCT00809783|Experimental|Tanezumab 5 mg|Tanezumab 5 mg
3254297|NCT00809783|Experimental|Tanezumab 2.5 mg|Tanezumab 2.5 mg
3254298|NCT00809770|Experimental|1|Contingency management
3254299|NCT00809770|Other|2|Non Contingent Control Condition
3254300|NCT00809757|Experimental|1|90 ug Levalbuterol (2 actuations)
3254301|NCT00809757|Active Comparator|2|0.31 ug Levalbuterol UDV TID
3254302|NCT00809757|Placebo Comparator|3|Placebo
3254303|NCT00809731||Observational Group|All commercially available 2nd-generation antipsychotic with an indication of treating schizophrenia will be prescribed by the physician according to normal practices
3254304|NCT00809718|Other|raltegravir and rifapentine|Concomitant administration of raltegravir and rifapentine in healthy volunteers
3254305|NCT00809705|Experimental|1|
3254306|NCT00809705|Experimental|2|
3254307|NCT00809705|Placebo Comparator|3|
3254308|NCT00809692|Active Comparator|1|50 subjects with allergic disease receiving histamine challenges by the prick test and iontophoresis technique (serial assessment of blood flow using validated Doppler technique)
3254309|NCT00809692|Experimental|2|150 additional subjects with allergic disease; undergo genotyping; laser Dopper assessment
3254310|NCT00809679|Experimental|T-62 100 mg bid|
3254311|NCT00809679|Experimental|T-62 200 mg bid|
3254312|NCT00809679|Placebo Comparator|Placebo|
3254313|NCT00809666|No Intervention|Mercury|All subsequent blood pressure recording done using mercury sphygmomanometry
3254314|NCT00809653|Experimental|Visit 1|2 hour walk in city centre location in Beijing China
3254315|NCT00809653|Experimental|Visit 2|2 hour walk in city centre location in Beijing China
3254316|NCT00809640|Active Comparator|1|The intervention group will receive prevention of low back pain education through a Back Comic-Book, and their beliefs/knowledge will be tested twice after intervention.
3254317|NCT00809640|No Intervention|2|The control group will receive no intervention, and their beliefs/knowledge on low back pain will be tested twice after the first assessment.
3254318|NCT00809627|Experimental|1|IV caffeine with saline and opiate
3254319|NCT00809627|Placebo Comparator|2|IV saline with opiate
3254320|NCT00809614|Experimental|AIN457 (2x 10mg/kg)|Each patient received 10 mg/kg AIN457 intravenously, on Day 1 and Day 22.
3254321|NCT00809614|Placebo Comparator|Placebo|Each patient received 10 mg/kg of matching placebo intravenously, on Day 1 and Day 22.
3254323|NCT00809588|Experimental|Melanoma Vaccine|GM-CSF Vaccine
3254324|NCT00809562|Experimental|1|
3254325|NCT00809562|Placebo Comparator|2|
3254326|NCT00809549|Placebo Comparator|Normal Saline|
3254327|NCT00809549|Experimental|Filgrastim|
3254328|NCT00809536|Other|Cohort 1|This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults
3254329|NCT00809536|Other|Cohort 2|This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults
3254330|NCT00809523|Experimental|Inactivated negative ion generator|Equivalent exposure to inactivated Negative Ion Generator
3254331|NCT00809523|Experimental|LED light treatment device|Light-emitting photodiode light treatment device, used for 30 min before 8 am
3254332|NCT00809510|Experimental|1|
3254333|NCT00809484||1: Low risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily
3254334|NCT00809484||2:Moderate risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, +/- Risedronate 35mg orally once a week
3254335|NCT00809484||3:High risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, Risedronate 35mg orally once a week
3254336|NCT00809471|Placebo Comparator|placebo|
3254337|NCT00809471|Experimental|avanafil 100 mg|
3254338|NCT00809471|Experimental|avanafil 200 mg|
3254339|NCT00809458|Experimental|Arm 1 (Vitamin E)|Vitamin E
3254340|NCT00809458|Placebo Comparator|Arm 2|Placebo (same vehicle as used for vitamin E)
3254341|NCT00809445|Experimental|HIV rapid test & counseling|Participants will be offered an oral fluid HIV rapid test (via oral swab) and brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach (Project RESPECT-2 counseling). Prior to receiving testing, study participants must first provide consent for HIV testing. Consent for testing will be obtained through a second consent form required of all participants who wish to proceed with the HIV test.
3254342|NCT00809445|Experimental|HIV rapid test and info|Participants will be offered an oral fluid HIV rapid test (via oral swab). Prior to receiving testing, study participants must first provide consent for HIV testing. Again, consent for testing will be obtained through a second consent form required of all participants who wish to proceed with the HIV test. Participants will receive rapid HIV testing and test results after signing the consent to be tested. In both Groups 1 and 2, participants who test reactive (preliminary positive) will be counseled on the sexual risk behaviors associated with transmission of HIV and the acquisition of STDs, as is current clinical practice with those testing HIV positive. Confirmed positives will be linked to HIV primary care.
3254343|NCT00809445|Active Comparator|HIV testing referral|Participants randomized to group 3 will receive a referral list for HIV community-testing agencies. Each CTP site will have previously prepared an extensive referral list of testing sites in the surrounding geographic area. By virtue of their status as patients in the CTPs, they will receive whatever HIV testing and HIV education referrals the CTPs normally provide to their patients. This is the standard of care at CTPs that do not provide on-site testing.
3254344|NCT00809432|Experimental|Visit 1|2 hour city centre kerbside walk in Beijing China
3254345|NCT00809432|Experimental|Visit 2|2 hour city centre kerbside walk in Beijing China
3254346|NCT00809419|Experimental|A|NeoVista Ophthalmic System procedure + Lucentis
3254347|NCT00809393|Active Comparator|low dose|low dose tranexamic acid
3254348|NCT00809393|Experimental|high dose|
3254349|NCT00809380|Experimental|Parental presence|Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
3254350|NCT00809380|Active Comparator|Control|One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
3254351|NCT00809367|Other|Collection of Leukemia Cells|Other: Collection of Leukemia Cells Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
3254352|NCT00809354|Active Comparator|IV Placebo + NSAID|Oral NSAID
3254353|NCT00809354|Experimental|Tanezumab 5 mg|IV tanezumab 5 mg every 8 weeks (through Week 48)
3254354|NCT00809354|Experimental|Tanezumab 10 mg|IV tanezumab 10 mg every 8 weeks (through Week 48)
3254355|NCT00809354|Experimental|Tanezumab 5 mg + NSAID|IV doses of tanezumab 5 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
3254356|NCT00809354|Experimental|Tanezumab 10 mg + NSAID|IV doses of tanezumab 10 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
3254357|NCT00809341|Active Comparator|PET Negative|PET negative patients will complete conventional therapy under a treatment plan formulated by their primary oncologist. Decisions regarding subsequent therapy, including BMT for disease relapse, will also be at the discretion of the primary oncologist.
3254358|NCT00809341|Active Comparator|PET Positive|R-ICE x 2 cycles (outpatient regimen; Pre-high dose therapy evaluations during R-ICE cycles; Cyclophosphamide 50mg/kg/day day2-5; rituximab d1, 30, 37
3254359|NCT00809328|Experimental|Azithromycin|Azithromycin switch therapy (switch from intravenous to oral)
3254360|NCT00809315|Active Comparator|Assessment only|Cognitive, academic achievement and mental health screening assessment and report.
3254361|NCT00809315|Experimental|Fostering Healthy Futures (FHF) Assessment + FHF|Cognitive, academic achievement and mental health screening assessment and report. Weekly therapeutic skill groups and mentoring over a 9-month period.
3254362|NCT00809302|Experimental|1|aplindore 2 mg MR total daily dose
3254363|NCT00809302|Experimental|2|aplindore 6 mg MR total daily dose
3254364|NCT00809302|Experimental|3|aplindore 12 mg MR total daily dose
3254365|NCT00809302|Placebo Comparator|4|Placebo
3254366|NCT00809289|Experimental|One|
3254368|NCT00809289|Active Comparator|Three|Administration of a single oral dse of 400mg moxifloxacin
3254369|NCT00809250|Experimental|GM-K562/leukemia cell vaccine|Biological/Vaccine: GM-K562/leukemia cell vaccine Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
3254370|NCT00809237|Experimental|Gefitinib, Hydroxychloroquine|"For the lead in phase I study, recruited patients will receive one week of 250 mg of Gefitinib, before HCQ at the assigned dose is introduced in addition to Gefitinib 250 mg om.~After the MTD of HCQ is determined, the phase II study will proceed with the combination of 250 mg of Gefitinib and the MTD dose of HCQ."
3254371|NCT00809224||ALS|ALS group should have ALS.
3254372|NCT00809224||Control|The control group should not have ALS or any other neurological/psychiatric disorder, and must be over the age of 40.
3254373|NCT00809211|Experimental|Nilotinib|
3254374|NCT00809198|Experimental|Sodium Hyaluronate|Sodium Hyaluronate (Kynex)
3254375|NCT00809198|Active Comparator|Carboxymethylcellulose sodium|Carboxymethylcellulose sodium (Refresh Plus)
3254376|NCT00809185|Experimental|RAD001 (everolimus)|RAD001 (everolimus) at 10mg/day with Bone marrow aspirate/biopsy and other laboratory biomarker analysis
3254377|NCT00809172|Active Comparator|1|Ciclosporin
3254378|NCT00809172|Experimental|2|Methotrexate
3254379|NCT00809159|Experimental|Part 1 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as a single dose.
3254380|NCT00809159|Placebo Comparator|Part 1 - Placebo|Placebo to AIN457A was administered intravenously as a single dose
3254381|NCT00809159|Experimental|Parts 1 and 2 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
3254382|NCT00809159|Experimental|Part 1 and 2 - AIN457 0.1 mg/kg|AIN457A 0.1 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
3254383|NCT00809159|Experimental|Part 1 and 2 - AIN457 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
3254384|NCT00809146|Active Comparator|Intramuscular (IM) anticonvulsant|This group gets active treatment with an anticonvulsant by the intramuscular route of administration.
3254385|NCT00809146|Active Comparator|Intravenous (IV) anticonvulsant|This group gets active treatment with an anticonvulsant by the intravenous route of administration.
3254386|NCT00809133|Experimental|Part A|BIBW2992 + Paclitaxel
3254387|NCT00809133|Experimental|Part B|BIBW2992 + Paclitaxel + Bevacizumab
3254388|NCT00809133|Experimental|Part C|BIBW2992 + Carboplatin
3254389|NCT00809133|Experimental|Part D|BIBW2992 +Paclitaxel + Carboplatin
3254390|NCT00809107|Experimental|1|HCG GROUP
3254391|NCT00809107|No Intervention|2|LH pick
3254392|NCT00809094|Placebo Comparator|Placebo|Placebo was administered oral tablet TID for 24 weeks.
3254393|NCT00809094|Active Comparator|N-Acetylcysteine|Participants received 900 mg of oral N-acetylcysteine TID for 24 weeks.
3254394|NCT00809081|Other|1|1. Enteral Feeding
3254395|NCT00809081|No Intervention|2|Total Parental support
3254396|NCT00809068|Active Comparator|1|fenofibrate and tibolone
3254397|NCT00809068|Sham Comparator|2|tibolone
3254398|NCT00809055|Experimental|High dose caffeine|Loading dose 40mg/kg IV caffeine citrate, followed 12 hours later by 20mg/kg IV caffeine citrate, followed 12 hours later by 10mg/kg IV caffeine citrate, followed 12 hours later by 10mg/kg IV caffeine citrate.
3254399|NCT00809055|Active Comparator|Standard dose caffeine|Loading dose 20mg/kg IV caffeine citrate, followed 12 hours later with D5W placebo, followed 12 hours later with 10mg/kg IV caffeine citrate, followed 12 hours later with D5W placebo.
3254400|NCT00809042|Experimental|1|Hydroxyurea
3254401|NCT00809042|Active Comparator|2|L-carnitine and hydroxyurea
3254402|NCT00809042|Active Comparator|4|L-carnitine , magnesium chloride and hydroxyurea
3254403|NCT00809042|Active Comparator|3|magnesium chloride and hydroxyurea
3254404|NCT00809003||Sjogren's group|
3254405|NCT00809003||Dry eye|
3254406|NCT00809003||Normals|
3254407|NCT00808990|Experimental|OSA and NAFLD patients using CPAP|OSA and NAFLD patients using CPAP being followed for 6 months.
3254408|NCT00808990|No Intervention|control|OSA and NAFLD patients not using CPAP being followed for 6 months.
3254409|NCT00808977|Experimental|Dersalazine|
3254410|NCT00808977|Active Comparator|Mesalazine|
3254411|NCT00808977|Placebo Comparator|Placebo|
3254412|NCT00808951|Experimental|Artemether -lumefantrine|Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso
3254413|NCT00808951|Experimental|Artesunate-amodiaquine|Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso
3254414|NCT00808938|Experimental|Active Treatment|
3254415|NCT00808925|Experimental|research arm|
3254416|NCT00808912|Active Comparator|1|Subjects will exercise in a high air pollutant environment after ingesting a standard dose of sildenafil.
3254417|NCT00808912|Active Comparator|2|Subjects will exercise in a low pollutant environment after ingesting a standard dose of sildenafil.
3254418|NCT00808912|Placebo Comparator|3|Subjects will exercise in a high pollutant environment after ingesting a placebo.
3254419|NCT00808912|Placebo Comparator|4|Subjects will exercise in a low pollutant environment after ingesting a placebo.
3254472|NCT00808509|Active Comparator|Adalimumab + MTX|Participants continued treatment with adalimumab 40 mg subcutaneously every other week plus methotrexate (at least 10 mg/week orally or subcutaneously) for 52 weeks. After Week 52 an observational extension period ensued where participants were treated at the discretion of the investigator.
3254473|NCT00808509|Experimental|Methotrexate|Participants discontinued adalimumab and continued to receive methotrexate (at least 10 mg/week orally or subcutaneously) for 52 weeks. Participants with a significant increase in RA disease activity were re-instituted to adalimumab 40 mg every other week (rescue arm). After Week 52 an observational extension period ensued where participants were treated at the discretion of the investigator.
3254420|NCT00808899|Experimental|1|Fixed doses of IV temsirolimus concomitantly with two courses of fixed dosages of irinotecan, 2 days off, repeated daily 5 times.If initial dosages are not tolerable, subsequent patients will be given a reduced dosage of temsirolimus with irinotecan.If this dosage combination is not tolerable,irinotecan dosage will be decreased.If this dosage combination is not tolerable.Further enrollment to initial six week treatment will be terminated.Second course of irinotecan will begin on day 22, response will be determined after six weeks. Resection of primary tumor will be attempted after initial therapy.Following initial treatment children will undergo alternating courses of induction chemotherapy with cyclophosphamide,doxorubicin,etoposide,topotecan, and cisplatin.First cohort of 17 patients will receive Block 2 with temsirolimus for all three courses, weekly 2 times.If this is not tolerated subsequent patients will receive Block 2 chemotherapy with reduced dosages of temsirolimus.
3254421|NCT00808873|Experimental|1|brief education and 6 follow-up visits
3254422|NCT00808873|No Intervention|2|treatment-as-usual
3254423|NCT00808860|Placebo Comparator|Placebo group|Gliclazide + Placebo tea
3254424|NCT00808860|Active Comparator|GP group|Gliclazide + Gynostemma pentaphyllum tea
3254425|NCT00808834|Other|Senofilcon A / Lotrafilcon A|Senofilcon A, followed by Lotrafilcon A
3254426|NCT00808834|Other|Lotrafilcon A / Senofilcon A|Lotrafilcon A, followed by Senofilcon A
3254427|NCT00808808||Arm A (Control)|A control arm of usual care offering TIV with baseline advertisement
3254428|NCT00808808||Arm B (Choice)|An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
3254429|NCT00808808||Arm C (Choice Plus)|An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
3254430|NCT00808795|Experimental|N-acetylcysteine|
3254431|NCT00808795|Placebo Comparator|Placebo|
3254432|NCT00808782|Sham Comparator|Sham rTMS|Sham 5Hz rTMS.
3254433|NCT00808782|Experimental|rTMS|Active 5Hz deep TMS.
3254434|NCT00808769|Active Comparator|1|Zegerid®
3254435|NCT00808769|Experimental|2|Prilosec OTC®
3254436|NCT00808756|Experimental|1: Intervention|This group will be fed a diet enriched with fermentable carbohydrates.
3254437|NCT00808756|Placebo Comparator|2: Placebo.|The placebo group will be fed a diet without addition of fermentable carbohydrates. This placebo formula will have the same nutritional values than the intervention (energy, proteins, carbohydrates, fat, vitamins & minerals).
3254438|NCT00808756|No Intervention|BF|The 2 intervention groups will be compared with a breast-fed infants control group.
3254439|NCT00808743|Active Comparator|Group 1|Patients receive oral celecoxib twice daily and oral placebo twice daily
3254440|NCT00808743|Experimental|Group 2|Patients receive oral celecoxib twice daily and oral ursodeoxycholic acid twice daily
3254441|NCT00808730|Experimental|1|fiberoptic fibroscopy
3254442|NCT00808717|Experimental|High dose Atorvastatin 80 mg|Administered Atorvastatin 80 mg before intervention
3254443|NCT00808717|Active Comparator|Control|Administered Atorvastatin 10 mg before intervention
3254444|NCT00808691||1|Patients with sepsis
3254445|NCT00808691||2|Patient admitted for postoperative care
3254446|NCT00808691||3|Patients with ARDS
3254447|NCT00808691||4|Patients with ARF
3254448|NCT00808691||5|Patients who receive liver support treatment
3254449|NCT00808691||6|Patients wiht brain death
3254450|NCT00808678|Experimental|1|ABT-143 capsules 20/135 mg
3254451|NCT00808678|Active Comparator|2|ABT-335 135 mg and rosuvastatin 20 mg
3254452|NCT00808665|Experimental|Dexmedetomidine|At the beginning of spinal surgery, patients will receive 1 hour dexmedetomidine intravenous bolus of 0.7 mcg/kg, followed by infusion of dexmedetomidine at a rate of 0.5 mcg/kg/hour for 2 hours, followed by an infusion of dexmedetomidine at a rate of 0.2 mcg/kg/hour for the duration of the procedure and for 4 hours after the procedure.
3254453|NCT00808665|Placebo Comparator|Saline|Since this is a blinded study, at the beginning of spinal surgery, patients will receive a 1 hour 0.9% saline intravenous bolus at a rate and volume commensurate with a 0.7 mcg/kg/hour bolus of dexmedetomidine. Similarly, this will be followed with a saline infusion at a rate of 0.5 mcg/kg/hour for 2 hours, followed by an infusion of saline at a rate of 0.2 mcg/kg/hour for the duration of the procedure and for 4 hours after the procedure.
3254454|NCT00808639|Experimental|Dose Dense MVAC|Chemo therapy with methotrexate, vinblastine, Adriamycin, Cisplatin
3254455|NCT00808626|Experimental|99mTc-rBitistatin|
3254456|NCT00808613|Active Comparator|1|Optetrak Posterior Stabilized
3254457|NCT00808613|Active Comparator|2|Optetrak Hi-Flex
3254458|NCT00808600|Other|resource-activating training, intensified exercise training|combination of the two interventions: resource-activating behavioural training and intensified exercise training
3254459|NCT00808600|Other|resource-activating training, moderate exercise training|combination of the two interventions: resource-activating training and moderate exercise training
3254460|NCT00808600|Other|relaxation training, intensified exercise training|combination of the two interventions: relaxation training and intensified exercise training
3254461|NCT00808600|Other|relaxation training, moderate exercise training|combination of the two interventions: relaxation training and moderate exercise training
3254462|NCT00808587||No Treatment|
3254463|NCT00808574|Experimental|Intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
3254464|NCT00808574|No Intervention|Control|No risk assessment or presentation
3254465|NCT00808561|Active Comparator|1 Alternative Fistula|
3254466|NCT00808561|Active Comparator|2 Forearm AV Graft|
3254467|NCT00808548||Lifestyle counseling|
3254468|NCT00808535||diabetics|
3254469|NCT00808535||healthy controls|
3254470|NCT00808522|Experimental|hCG|Patients at high risk for breast cancer will be treated with hCG
3254471|NCT00808522|No Intervention|routine care|Patients receiving routine care will be followed
3254474|NCT00808496|Experimental|MRI|Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline.
3254525|NCT00808184|Active Comparator|CPT-11|
3254475|NCT00808496|Active Comparator|Radiography|Biannual disease progression monitoring with radiography of both hands and wrists.
3254476|NCT00808496|Placebo Comparator|Standard of Care|Diagnostic imaging results (MRI or radiography) reported to upon requisition.
3254477|NCT00808483|Experimental|Walking skill training group|Participation in the supervised walking skill training program.
3254478|NCT00808483|No Intervention|Control group|No participation in the supervised walking skill training program
3254479|NCT00808470|Experimental|Nutrients|Subjects in University of Florida music player study who are assigned to nutrient condition(beta-carotene, vitamins C and E, magnesium). Nutrient tablets are consumed for 4 days.
3254480|NCT00808470|Placebo Comparator|Placebo for nutrients|Subjects in University of Florida music player study who are assigned to control (placebo) condition. Placebo tablets are consumed for 4 days.
3254481|NCT00808457||patients with suspected pneumonia|
3254482|NCT00808444|Experimental|Synflorix Clinical Lot & Infanrix Group|Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).
3254483|NCT00808444|Experimental|Synflorix Commercial Lot Infanrix Group|Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).
3254484|NCT00808431|Experimental|Lifestyle counseling|Lifestyle counseling
3254485|NCT00808418|Experimental|Cohort|
3254486|NCT00808405|Active Comparator|acyclovir|
3254487|NCT00808405|Placebo Comparator|placebo|
3254488|NCT00808392|Experimental|1|
3254489|NCT00808392|Active Comparator|2|
3254490|NCT00808379|Other|Arm 2 (Radiation + boost )|"Radiation dose to pelvis will be delivered at 1.8 Gy per day, five days per week, to give a total of 25 fractions over a period of five weeks for a total of 45 Gy.~Boost Field - Will be given to all the patients in the radiotherapy alone followed by surgery arm.~The boost will be given with by 3dimensional conformal radiotherapy to a dose of 15-20 Gy. After 45Gy the boost will be planned on the original tumor volume."
3254491|NCT00808379|Active Comparator|Arm 1 (standard) Chemoradiation|"The Radiation dose will be delivered at 1.8 Gy per day, five days per week, to give a total of 25 fractions over a period of five weeks for a total of 45 Gy.~Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles."
3254492|NCT00808366|Experimental|RV4104A ointment|
3254493|NCT00808366|Active Comparator|bifonazole-urea ointment|
3254494|NCT00808340|Active Comparator|senofilA test/senofilA prod/balafilconA|Subjects wear 3 multifocal contact lenses: senofilcon A test worn first, senofilcon A production worn second, and balafilcon A worn third.
3254495|NCT00808340|Active Comparator|senofilcon A test/balafilcon A/senofilcon A prod|Subjects wear 3 multifocal contact lenses: senofilcon A test worn first, balafilcon A worn second, and senofilcon A production worn third.
3254496|NCT00808340|Active Comparator|senofilcon A prod/senofilcon A test/balafilcon A|Subjects wear 3 multifocal contact lenses: senofilcon A production worn first, senofilcon A test worn second, and balafilcon A worn third.
3254497|NCT00808340|Active Comparator|senofilcon A prod/ balifilcon A/ senofilcon A test|Subjects wear 3 multifocal contact lenses: senofilcon A production worn first, balafilcon A worn second, and senofilcon A test worn third.
3254498|NCT00808340|Active Comparator|balafilcon A/senofilcon A test/senofilcon A prod|Subjects wear 3 multifocal contact lenses: balafilcon A worn first, senofilcon A test worn second, and senofilcon A production worn third.
3254499|NCT00808340|Active Comparator|balafilcon A/senofilcon A prod/senofilcon A test|Subjects wear 3 multifocal contact lenses: balafilcon A worn first, senofilcon A production worn second, senofilcon A test worn third.
3254500|NCT00808327|Active Comparator|1|Bupivacaine alone
3254501|NCT00808327|Active Comparator|2|Bupivacaine plus Fentanyl
3254502|NCT00808314|Active Comparator|LL for CAD|Subjects with <5% pre-test low likelihood for CAD based on Diamond and Forrester criteria will be recruited to undergo both rest/stress dipyridamole PET followed by a rest/stress Lexiscan(TM) PET with 30 days.
3254503|NCT00808314|Active Comparator|CAD|Subjects with existing mild-moderate ishemia demonstrated by a recent (< 1 month) rest/stress dipyridamole PET will undergo a rest/stress Lexiscan(TM) PET.
3254504|NCT00808301|Other|A/B|This is a cross-over design, i.e. each patient is treated with either oat or control products in different times.
3254505|NCT00808288|Experimental|PF-00610355|
3254506|NCT00808288|Experimental|PF- 00610355|
3254507|NCT00808288|Experimental|PF - 00610355|
3254508|NCT00808288|Placebo Comparator|Placebo|
3254509|NCT00808288|Active Comparator|Salmeterol|
3254510|NCT00808275|Experimental|Dairy calcium|Diet with dairy calcium sources
3254511|NCT00808275|Experimental|Non-dairy calcium|Diet with non-dairy calcium sources
3254512|NCT00808262|Experimental|TNFa Kinoid dose 1|
3254513|NCT00808262|Experimental|TNFa Kinoid dose 2|
3254514|NCT00808262|Experimental|TNFa Kinoid dose 3|
3254515|NCT00808249|Experimental|A-AZD7325 2mg|AZD7325 2mg BID
3254516|NCT00808249|Experimental|B-AZD7325 5mg|AZD7325 5mg BID
3254517|NCT00808249|Experimental|C-AZD7325 10mg|AZD7325 10mg QD
3254518|NCT00808249|Experimental|D-Placebo|Placebo
3254519|NCT00808236|Experimental|RhinoChill|Intra-arrest cooling with the RhinoChill during advanced cardiac life support
3254520|NCT00808236|Other|Control|Advanced cardiac life support, only
3254521|NCT00808223|Experimental|1. alefacept|
3254522|NCT00808210|Experimental|A|
3254523|NCT00808210|Active Comparator|B|
3254524|NCT00808197|Experimental|1|Observatory, longitudinal, 3-years follow up study
3254526|NCT00808171|Experimental|EMLA and Livopan|Administered EMLA and Livopan
3254527|NCT00808171|Experimental|EMLA and gas placebo|Administered EMLA and oxygen
3254528|NCT00808171|Experimental|Livopan and placebo cream|Administered Livopan and placebo cream
3254529|NCT00808158||1|Children ages 9 to 10 years old, with a body mass index (BMI) in the 50th to 98th percentile range
3254530|NCT00808145|Experimental|Gemcitabine/Cisiplatin/Sorafenib|All eligible patients will receive intravenous gemcitabine/cisplatin + daily oral sorafenib until disease progression occurs
3254531|NCT00808132|Experimental|1|bazedoxifene 20 mg/conjugated estrogens 0.45 mg
3254532|NCT00808132|Experimental|2|bazedoxifene 20 mg/conjugated estrogens 0.625 mg
3254533|NCT00808132|Experimental|3|bazedoxifene 20 mg
3254534|NCT00808132|Active Comparator|4|Prempro
3254535|NCT00808132|Placebo Comparator|5|Placebo
3254536|NCT00808093|Other|fixed sequence|fixed sequence (14 days fasted followed by 14 days either high fat or standard meal
3254537|NCT00808080|Experimental|Biologic|AML_CTL cells
3254538|NCT00808067|Experimental|dabigatran dose 1|dabigatran high dose twice daily
3254539|NCT00808067|Experimental|dabigatran dose 2|dabigatran low dose twice daily
3254540|NCT00808054|Experimental|Glucose and EMLA|Received glucose oral and topical EMLA
3254541|NCT00808054|Experimental|Glucose and placebo|Received glucose and no EMLA
3254542|NCT00808054|Experimental|Oral placebo and EMLA|Received oral placebo and EMLA
3254543|NCT00808041||Treatment|Breast cancer patients undergoing hormonal therapy before surgery.
3254544|NCT00808028|Experimental|1|dose level 1 rLP2086 vaccine
3254545|NCT00808028|Experimental|2|dose level 2 rLP2086 vaccine
3254546|NCT00808028|Experimental|3|dose level 3 rLP2086 vaccine
3254547|NCT00808028|Placebo Comparator|4|normal saline (placebo)
3254548|NCT00808015||Patients in routine practice|Patients prescribed Champix by treating physician and then entered into trial
3254549|NCT00808002|Experimental|1|From Baseline to Week48: Raltegravir BID + Tenofovir/Emtricitabine QD + Maraviroc BID From W48 to W72: Raltegravir BID + Tenofovir/Emtricitabine QD
3254550|NCT00808002|Active Comparator|2|Start ARV treatment with : Raltegravir BID + Tenofovir/Emtricitabine
3254551|NCT00807989|Active Comparator|Carbamazepine|Carbamazepine
3254552|NCT00807989|Experimental|Lamotrigine/Valproate|Lamotrigine and Valproate combination therapy
3254553|NCT00807976||Study group|Type 2 diabetic patients aged 70 years and older.
3254554|NCT00807976||Control group|Patients aged 70 years and older, with no history of type 2 diabetes mellitus.
3254555|NCT00807963|Experimental|Stage 1: rHuPH20 plus ZA|Participants will receive one of several dose/concentrations of recombinant human hyaluronidase PH20 (rHuPH20) with zoledronic acid (ZA).
3254556|NCT00807963|Experimental|Stage 2: ZA|Participants will receive a dose/concentration of ZA administered without rHuPH20.
3254557|NCT00807963|Experimental|Stage 3: rHuPH20 plus ZA|Participants will receive one of several dose/concentrations of rHuPH20 with ZA.
3254558|NCT00807963|Experimental|Stage 4: ZA|Participants will receive an intravenous (IV) dose of 5 milligrams (mg) ZA.
3254559|NCT00807963|Experimental|Stage 4: ZA with rHuPH20|Participants will receive a subcutaneous (SC) dose of ZA with rHuPH20.
3254560|NCT00807937|Experimental|A|AZD7325 5mg twice daily
3254561|NCT00807937|Experimental|B|AZD7325 15mg twice daily
3254562|NCT00807937|Active Comparator|C|Lorazepam 2mg twice daily
3254563|NCT00807937|Placebo Comparator|D|Placebo
3254564|NCT00807911|Active Comparator|Adjuvant FL|FL (5-FU 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles)
3254565|NCT00807911|Experimental|Adjuvant FOLFOX|FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-FU bolus 400 mg/m2 on D1, 5-FU infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles)
3254566|NCT00807885|Experimental|Tegaderm-secured 24 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, Teflon angiocatheter secured with Tegaderm
3254567|NCT00807885|Experimental|Tape-secured 24 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, Teflon angiocatheter secured with a tape double chevron
3254568|NCT00807885|Experimental|Tegaderm-secured 24 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, polyurethane angiocatheter secured with Tegaderm
3254569|NCT00807885|Experimental|Tape-secured 24 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, polyurethane angiocatheter secured with a tape double chevron
3254570|NCT00807885|Experimental|Tegaderm-secured 20 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, Teflon angiocatheter secured with Tegaderm
3254571|NCT00807885|Experimental|Tape-secured 20 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, Teflon angiocatheter secured with a tape double chevron
3254572|NCT00807885|Experimental|Tegaderm-secured 20 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, polyurethane angiocatheter secured with Tegaderm
3254573|NCT00807885|Experimental|Tape-secured 20 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, polyurethane angiocatheter secured with a tape double chevron
3254666|NCT00807209|Experimental|High Dose SKY0402|
3254574|NCT00807885|Experimental|SC button with 27 ga X 9 mm needle|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a button-type subcutaneous delivery system (with a 27-gauge, 9 mm long metal needle)
3254575|NCT00807872|Other|I-124 Mu 11-1F4 sterile injection|Single arm study
3254576|NCT00807859|Experimental|Cohort A1|
3254577|NCT00807859|Experimental|Cohort A3|
3254578|NCT00807859|Experimental|Cohort B1|
3254579|NCT00807859|Experimental|Cohort B3|
3254580|NCT00807846|Experimental|Celecoxib|
3254581|NCT00807846|Experimental|Naproxen|
3254582|NCT00807833||CBF measurement|"It is a proof of concept study, aimed to evaluate whether the optimal CPP, defined by the best PRx, corresponds to the acceptable CBF values.~Patients admitted with the diagnosis of TBI and SAH in for whom ICP and CPP needs to be monitored on clinical ground will be also monitored with a TD probe and routinely tested for cerebral autoregulation, thus obtaining the CBF corresponding at a given the best CPP and autoregulation status."
3254583|NCT00807807|Placebo Comparator|1|Participants will receive placebo folic acid.
3254584|NCT00807807|Experimental|2|Participants will receive 100 mcg of folic acid.
3254585|NCT00807807|Experimental|3|Participants will receive 400 mcg of folic acid.
3254586|NCT00807807|Experimental|4|Participants will receive 1000 mcg of folic acid.
3254587|NCT00807807|Experimental|5|Participants will receive 2000 mcg of folic acid.
3254588|NCT00807794|Experimental|1|MEDI-507
3254589|NCT00807794|Experimental|2|MEDI-507
3254590|NCT00807794|Experimental|3|MEDI-507
3254591|NCT00807794|Experimental|4|MEDI-507
3254592|NCT00807794|Experimental|5|MEDI-507
3254593|NCT00807781|Experimental|Mammaglobin-A DNA vaccine|"Patients will receive vaccine day 1 (week 1), week 4 (day 29 +/- 7), week 8 (day 57 +/- 7) with at least 21 days between injection days.~All injections will be given intramuscularly using a jet delivery device.~Patients will be administered the vaccine in lateral shoulder and buttocks positions that will be rotated with each administration in the above order."
3254594|NCT00807768|Active Comparator|Arm I (pelvic radiation therapy)|Patients undergo conventional or intensity-modulated pelvic radiation therapy once daily, 5 days a week, for 5-6 weeks (total of 25-28 fractions) in the absence of disease progression or unacceptable toxicity. Patients with stage II disease or stage I disease with a confirmed diagnosis of clear cell and/or papillary serous histology may also undergo 1 or 2 intravaginal (i.e., vaginal cuff) brachytherapy boost treatments.
3254595|NCT00807768|Experimental|Arm II (brachytherapy, paclitaxel, carboplatin)|Patients undergo vaginal cuff brachytherapy comprising 3-5 high-dose rate brachytherapy treatments over approximately 2 weeks or 1 or 2 low-dose rate brachytherapy treatments over 1-2 days. Beginning within 3 weeks after initiating brachytherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Chemotherapy repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3254596|NCT00807755|Experimental|Phase I Dose-Escalation|This is a phase I dose escalation study of RAD001 and carboplatin/etoposide. Patients will be accrued in a standard 3 + 3 design based on toxicities experienced during the first cycle. Ten additional chemotherapy naive extensive stage small cell lung cancer (ES-SCLC) patients will be accrued at the Maximum Tolerated Dose (MTD) for further toxicity and response assessment.
3254597|NCT00807742|Experimental|Contingency Management (CM)|Condition provides contingent monetary reinforcement for smoking reductions (first 5 days) then for smoking abstinence (subsequent 14 days). Expired carbon monoxide (CO) levels will be the basis for determining reductions and abstinence. A system of laptop recording, vouchers and certificates, will be used.
3254598|NCT00807742|Other|Noncontingent Reinforcement (NR)|Controls for effects of receiving payments, providing daily breath samples for CO level, and degree of interaction between patient and research staff. NR will allow them to earn an amount which is matched in amount to the expected average earned in CM contingent only on providing breath samples independent of the CO level attained.
3254599|NCT00807729|Active Comparator|ERCP|All ERCP's were performed by one of the authors (JPC), a fulltime faculty member and gastroenterology fellowship instructor in the presence and concurrence of the principal author/ surgeon (SJR). Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
3254600|NCT00807729|Active Comparator|Lap CBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
3254601|NCT00807716|Experimental|walking skill group|weight-bearing 12 times, 70 minutes
3254602|NCT00807716|Active Comparator|usual physiotherapy care|partial weight-bearing, 12 times, 40 minutes
3254603|NCT00807703|Experimental|1|Select Stim: see summary
3254604|NCT00807677|Experimental|1|TAK-901
3254605|NCT00807664|Experimental|1|Biatain Ag dressing
3254606|NCT00807664|Active Comparator|2|Biatain dressing
3254607|NCT00807651|Active Comparator|insulin therapy|The participants not accepted written informed consent will receive insulin therapy
3254608|NCT00807651|Experimental|AHSCT|The participants accepted written informed consent will receive the therapy of autologous hematopoietic stem cell transplantation(AHSCT)
3254609|NCT00807625|Active Comparator|IUCD|Assigned to use a copper intrauterine device
3254610|NCT00807625|Active Comparator|DMPA|Assigned to use Depo Provera
3254664|NCT00807222|Active Comparator|lisdexamfetamine dimesylate|30, 50, or 70 mg
3254665|NCT00807222|Placebo Comparator|placebo|
3254611|NCT00807612|Experimental|Part 1 Cohort 1|AMG 479 at 18 mg/kg in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 at 18 mg/kg monotherapy for 24 months from study day 1
3254612|NCT00807612|Experimental|Part 1 Cohort 2|AMG 479 at 12 mg/kg in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 at 12 mg/kg monotherapy for 24 months from study day 1
3254613|NCT00807612|Experimental|Part 2|"AMG 479 in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 monotherapy for 24 months from study day 1~(AMG 479 dose in Part 2 will be the final AMG 479 dose from Part 1)"
3254614|NCT00807599|Experimental|Stem cell transplant x 1 or x 2|"All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :~stem cell transplant right after collection~continue lenalidomide and dexamethasone, saving stem cell transplant for a later time."
3254615|NCT00807599|Experimental|Continue lenalidomide and dexamethasone|"All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :~stem cell transplant right after collection~continue lenalidomide and dexamethasone~saving stem cell transplant for a later time."
3254616|NCT00807586|Experimental|Steroid|
3254617|NCT00807586|Placebo Comparator|Placebo|
3254618|NCT00807573|Experimental|Paclitaxel, Bevacizumab & Pemetrexed|During each 28-day cycle, paclitaxel, pemetrexed and bevacizumab will be given intravenously on days 1 and 15. Paclitaxel will be administered at 90mg/m^2 over 60 minutes on days 1 and 15. Pemetrexed 500mg/m^2 will be administered over 10 minutes on days 1 and 15. Bevacizumab will be given at 10mg/kg over 20 minutes on days 1 and 15
3254619|NCT00807560|Experimental|FBT-PO|Family Based Therapy for Pediatric Overweight.
3254620|NCT00807560|Active Comparator|NEC-control|Nutritional Educational Control Condition (NEC).
3254621|NCT00807547|Active Comparator|Allergy vaccination|Allergy vaccination by 6 subcutaneous injections to 10,000 SQ-U with 1-3 days intervals, continuation by 2 injections with 10,000 SQ-U with 2-4 weeks intervals
3254622|NCT00807547|Placebo Comparator|Subcutaneous injections|Placebo injections
3254623|NCT00807534|Active Comparator|ipratropium bromide|acute bronchodilation: ipratropium bromide
3254624|NCT00807534|Placebo Comparator|placebo|placebo nebulization
3254625|NCT00807521|Active Comparator|1|High dose bolus of dexamethasone before surgery
3254626|NCT00807521|Placebo Comparator|2|Placebo control
3254627|NCT00807508|Experimental|1|daily leucine supplementation
3254628|NCT00807508|Placebo Comparator|2|daily placebo supplementation
3254629|NCT00807495|Experimental|Alisertib 50 mg|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 24 months or longer with Sponsor approval).
3254630|NCT00807482||1|People who have been definitively diagnosed with primary ciliary dyskinesia (PCD).
3254631|NCT00807469||1|20 healthy individuals not susceptible for COPD (age 18-40 years, >0>10 packyears, FEV1/VC >70%, FEV1 >85% predicted)
3254632|NCT00807469||2|20 healthy individuals susceptible for COPD (age 18-40 years >20 packyears, FEV1/VC >70%, FEV1 >85% predicted) and high prevalence of COPD in smoking family members older than 45 years
3254633|NCT00807469||3|20 healthy individuals very susceptible for COPD (age 18-40 years, > 0 > 10 packyears, FEV1/VC >70%, FEV1 >85% predicted), and one of the smoking family members has severe early onset COPD or mild COPD with very low smoke exposure
3254634|NCT00807469||4|30 healthy individuals not susceptible for COPD (age 40-75 years, >20 packyears, FEV1/VC >70%, FEV1 >85% predicted)
3254635|NCT00807469||5|30 COPD patients with GOLD stage II (age 40-75 years, >10 packyears, FEV1/VC <_70%, FEV1 50-80% predicted)
3254636|NCT00807456|Experimental|ASTRA TECH Implant System, OsseoSpeed™|
3254637|NCT00807443|Experimental|Raltegravir|
3254638|NCT00807430|Experimental|1|24 patients receiving active treatment
3254639|NCT00807430|Placebo Comparator|2|Placebo treatment
3254640|NCT00807391|Other|TBCA/TBNA|Under fluoroscopy first transbronchial forceps biopsy is performed, afterwards in random order transbronchial catheter aspiration(TBCA) and transbronchial needle aspiration (TBNA).
3254641|NCT00807378||1|AIDS PATIENTS
3254642|NCT00807378||2|NON-AIDS PATIENTS
3254643|NCT00807365|Experimental|GHRH|Growth Hormone-Releasing Hormone
3254644|NCT00807352||level 2|Patients triaged level 2
3254645|NCT00807352||level 3|patients triaged level 3
3254646|NCT00807352||level 4|patients triaged level 4
3254647|NCT00807352||level 5|patients triaged level 5
3254648|NCT00807339|Experimental|1|Phase I dose escalation
3254649|NCT00807326|Experimental|Loperamide/simeticone Caplets|Drug (including placebo)
3254650|NCT00807326|Active Comparator|Loperamide/simeticone Chewable Tablets|Drug (including placebo)
3254651|NCT00807326|Active Comparator|Probiotic Capsules|Drug (including placebo)
3254652|NCT00807313||At best response|Patients with oligometastatic colorectal cancer, who presents at best response under chemotherapy, will receive stereotactic body radiotherapy on their residual disease
3254653|NCT00807313||No indication for chemotherapy|Patients with oligometastatic colorectal cancer, who are progressive under chemotherapy or who are no candidates for (further) chemotherapy, will receive stereotactic body radiotherapy on the sites of disease.
3254654|NCT00807300|Active Comparator|brachytherapy|
3254655|NCT00807300|Other|TACE|transarterial chemoembolization
3254656|NCT00807287|Experimental|1|Placement of jejunal feeding tube using the unguided frictional method
3254657|NCT00807287|Active Comparator|2|Jejunal tube placement using the endoscopic method
3254658|NCT00807248|Placebo Comparator|Escitalopram placebo and gaboxadol placebo|
3254659|NCT00807248|Active Comparator|Escitalopram 20 mg and gaboxadol placebo|
3254660|NCT00807248|Experimental|Escitalopram 20 mg and gaboxadol 5 mg|
3254661|NCT00807248|Experimental|Escitalopram 20 mg and gaboxadol 10 mg|
3254662|NCT00807235|Experimental|Regimen 1|
3254663|NCT00807235|Experimental|Regimen 2|
3254667|NCT00807209|Active Comparator|Standard of Care|
3254668|NCT00807209|Experimental|Low Dose SKY0402|
3254669|NCT00807196|Experimental|T|
3254670|NCT00807183|Placebo Comparator|Tx1|Inactive air filter
3254671|NCT00807183|Experimental|Tx2|New EPA-certified woodstove
3254672|NCT00807183|Experimental|Tx3|Active air filter
3254673|NCT00807170|Experimental|ZACTIMA TM|
3254674|NCT00807157|Placebo Comparator|2|Every morning subjects will consume a stick of placebo during 30 days
3254675|NCT00807157|Experimental|1|Every morning subjects will consume a stick of PROBIOSTICK® during 30 days
3254676|NCT00807144|Experimental|Prolonged-Release Tacrolimus|Transplant maintenance immunosuppression with Prolonged-release Tacrolimus monotherapy
3254677|NCT00807144|Active Comparator|Standard-Release tacrolimus|Transplant maintenance immunosuppression with Standard-release Tacrolimus monotherapy
3254678|NCT00807131|Experimental|1|Patient follow-up
3254679|NCT00807131|Experimental|2|Counseling
3254680|NCT00807131|Experimental|3|Drug dispensing
3254681|NCT00807131|Active Comparator|4|pharmacy usual care
3254682|NCT00807118|Experimental|A (Cohort I)|
3254683|NCT00807118|Experimental|B (Cohort I)|
3254684|NCT00807118|Experimental|C (Cohort I)|
3254685|NCT00807118|Experimental|B (Cohort II)|
3254686|NCT00807118|Experimental|D (Cohort II)|
3254687|NCT00807118|Experimental|E (Cohort II)|
3254688|NCT00807105|Experimental|depressive patients|patients suffering from deppresion
3254689|NCT00807092|Experimental|BIAsp 30|BIAsp 30 (biphasic insulin aspart 30) administered subcutaneously (under the skin) twice daily (before breakfast and dinner) + metformin. Initial total daily dose of 0.3 U or IU/kg body weight followed by individual dose adjustment for BIAsp 30 was performed over the first 4 weeks (titration period) to achieve the pre-meal blood glucose target of 4.4-6.1 mmol/l. The achieved dose was maintained for the last 2 weeks of treatment unless hypoglycaemia occurred.
3254690|NCT00807092|Experimental|BHI 30|BHI 30 (biphasic human insulin 30) administered subcutaneously (under the skin) twice daily (30 minutes before breakfast and dinner) + metformin. Initial total daily dose of 0.3 U or IU/kg body weight followed by individual dose adjustment for BHI 30 was performed over the first 4 weeks (titration period) to achieve the pre-meal blood glucose target of 4.4-6.1 mmol/l. The achieved dose was maintained for the last 2 weeks of treatment unless hypoglycaemia occurred.
3254691|NCT00807079|Experimental|single arm|
3254692|NCT00807066|Experimental|A|Gefitinib
3254693|NCT00807066|Active Comparator|B|Platinum based chemotherapy
3254694|NCT00807053|Active Comparator|1|Ciclesonide HFA 75 mcg (37,5 mcg / actuation, 1 actuation/nostril), once daily
3254695|NCT00807053|Active Comparator|2|Ciclesonide HFA 150 mcg (75 mcg / actuation, 1 actuation/nostril), once daily
3254696|NCT00807053|Active Comparator|3|Ciclesonide HFA 300 mcg (150 mcg / actuation, 1 actuation/nostril), once daily
3254697|NCT00807053|Placebo Comparator|4|Placebo
3254698|NCT00807040|Active Comparator|Mitral Valve Repair with Annuloplasty|Participants will undergo mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.
3254699|NCT00807040|Active Comparator|Mitral Valve Replacement|Participants will undergo mitral valve replacement and complete preservation of the sub-valvular apparatus.
3254700|NCT00807027|No Intervention|Control Group|The study subjects randomly assigned to the control group is given Temozolomide chemotherapy and radiation therapy for 6 weeks according to the clinical test plans, and then administers Temozolomide only for 6 weeks.
3254701|NCT00807027|Experimental|Test Group|The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after surgery by administering Temozolomide chemotherapy and radiation therapy same as control group with Immuncell-LC (14 times).
3254702|NCT00807014|Experimental|Duac Gel|Duac Gel
3254703|NCT00807014|Active Comparator|Differin gel|Differin gel
3254704|NCT00807001|Experimental|Cohort A|Subjects randomized 8:2 (active:placebo) to receive one 25 milligrams (mg) capsule of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
3254705|NCT00807001|Experimental|Cohort B|Subjects randomized 8:2 (active:placebo) to receive two 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
3254706|NCT00807001|Experimental|Cohort C|Subjects randomized 8:2 (active:placebo) to receive three 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
3254707|NCT00807001|Experimental|Cohort D|Subjects randomized 8:2 (active:placebo) to receive four 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
3254708|NCT00806988|Active Comparator|Mitral Valve Repair|Participants will undergo CABG and a mitral valve repair procedure.
3254709|NCT00806988|Active Comparator|CABG|Participants will undergo CABG.
3254710|NCT00806975|Other|usability and preference|
3254711|NCT00806962|Experimental|Vaccine Arm 1|50 µg Norwalk VLP Vaccine + Adjuvant/Excipients
3254712|NCT00806962|Experimental|Vaccine Arm 2|100 µg Norwalk VLP Vaccine + Adjuvant/Excipients
3254713|NCT00806962|Active Comparator|Adjuvant/Excipients (MPL)|14 mg chitosan, 3 mg mannitol, 3 mg sucrose, and 50 mcg MPL
3254714|NCT00806962|Sham Comparator|Empty device|Empty device that contains no dry powder formulation. Actuation of the empty intranasal delivery device will deliver a puff of air per device.
3254715|NCT00806936||A|
3254716|NCT00806936||B|
3254717|NCT00806923|Experimental|1|
3254718|NCT00806923|Experimental|2|
3254719|NCT00806923|Placebo Comparator|3|
3254720|NCT00806910|Active Comparator|Treatment|Subjects will be treated with Intravenous Vaprisol along with Nesiritide infusion and intravenous Furosemide (either continuous infusion or bolus injections - total dose of Furosemide received will be calculated at the end of the study).
3254818|NCT00806208|Active Comparator|2|MEDI-507 and Methylprednisolone
3254721|NCT00806910|Placebo Comparator|Placebo|Subjects will be given Placebo (at the same rate of Vaprisol given in the treatment arm) along with Nesiritide infusion and intravenous Furosemide (either continuous infusion or bolus injections - total dose of Furosemide received will be calculated at the end of the study).
3254722|NCT00806897||A|
3254723|NCT00806884|Other|Control Arm1|Normal optimal medical and physiotherapy treatment
3254724|NCT00806884|Experimental|Treatment Arm 2|Physiotherapy musculoskeletal interventions in addition to normal optimal medical and physiotherapy care
3254725|NCT00806871|Active Comparator|A|
3254726|NCT00806871|Active Comparator|B|
3254727|NCT00806871|Placebo Comparator|C|
3254728|NCT00806858||A|
3254729|NCT00806845||HIV infected individuals, HIV controllers|CD4+ T cell count > 350/µl, HIV load < 1000 copies/ml
3254730|NCT00806845||HIV infected individuals, early progressors|CD4+ T cell count > 350/µl, HIV load > 1000 copies/ml
3254731|NCT00806845||HIV infected individuals, late progressors|CD4+ T cell count < 200/µl
3254732|NCT00806845||HIV infected individuals, late progressors with therapy|CD4+ T cell count < 200/µl, under ART
3254733|NCT00806845||Healthy individuals|Uninfected
3254734|NCT00806832||Medical clowns treatment|Patients scheduled for an elective cataract surgery will receive pre-operative conventional treatment and in addition will be exposed to medical clowns effect
3254735|NCT00806832||Conventional treatment only|Patients scheduled for elective cataract surgery will receive only conventional pre-operative treatment
3254736|NCT00806819|Experimental|nintedanib (BIBF1120) plus pemetrexed|nintedanib (BIBF1120) along with standard therapy of pemetrexed
3254737|NCT00806819|Placebo Comparator|Placebo plus pemetrexed|Pemetrexed standard therapy
3254738|NCT00806819|Experimental|nintedanib (BIBF1120) monotherapy|nintedanib (BIBF1120) monotherapy only for patients who discontinue pemetrexed
3254739|NCT00806819|Active Comparator|pemetrexed monotherapy|pemetrexed monotherapy only for patients who discontinue nintedanib (BIBF1120) or placebo
3254740|NCT00806819|Placebo Comparator|placebo monotherapy|placebo monotherapy only for patients who discontinue pemetrexed
3254741|NCT00806806|Placebo Comparator|Placebo|
3254742|NCT00806806|Experimental|SKY0402|
3254743|NCT00806780|No Intervention|1|routine surgery with cholangiography
3254744|NCT00806780|Experimental|2|routine cholangiography
3254745|NCT00806754|Active Comparator|1|Ciclesonide nasal spray (50 mcg/spray, one spray per nostril) and placebo azelastine nasal spray ( two sprays per nostril) administered twice daily approximately 1 minute apart, once in the morning and 12 hours later, in the evening.
3254746|NCT00806754|Active Comparator|2|Ciclesonide nasal spray (50 mcg/spray, one spray per nostril) and azelastine nasal spray (137 mcg/spray, two sprays per nostril) administered twice daily approximately 1 minute apart, once in the morning and 12 hours later, in the evening.
3254747|NCT00806741|Active Comparator|1|NG-monomethyl-L-arginine (L-NMMA)
3254748|NCT00806741|Active Comparator|2|Phenylephrine
3254749|NCT00806741|Placebo Comparator|3|Physiological saline solution
3254750|NCT00806728|Experimental|1|MEDI-507
3254751|NCT00806728|Experimental|2|MEDI-507
3254752|NCT00806689||Cardiac surgery patients|Patients in atrial fibrillation being scheduled for cardiac surgery and concomitant ablation procedure
3254753|NCT00806676|Other|1. Chronic Kidney Disease, NKF Stage 1-4|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with chronic kidney disease will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
3254754|NCT00806676|Other|2. ESRD (dialysis)|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with ESRD will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
3254755|NCT00806676|Other|3. Kidney Transplant Recipient|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with a kidney transplant will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
3254756|NCT00806650||Blood draw for diagnosis testing|
3254757|NCT00806637|Experimental|1|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
3254758|NCT00806637|Active Comparator|2|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
3254759|NCT00806624|Experimental|2|DU-176b tablets: high-dose
3254760|NCT00806624|Active Comparator|3|Warfarin tablets
3254761|NCT00806624|Experimental|1|DU-176b tablets: low-dose
3254762|NCT00806611|Experimental|50% Ethanol|Operating surgeon injects 20 ml of 50% ethanol on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
3254763|NCT00806611|Placebo Comparator|Placebo|Operating surgeon injects 20 ml of saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
3254819|NCT00806208|Active Comparator|3|MEDI-507 and Methylprednisolone
3254764|NCT00806598|Experimental|Thymoglobulin + Cyclosporin|Combination of Thymoglobulin 3.5 or 2.5 mg/kg/day intravenous (IV) for 5 days + Methylprednisone 1 mg/kg/day IV for 5 days, before each dose Thymoglobulin + Cyclosporin 5 mg/kg orally for 6 months following Thymoglobulin + Granulocyte - Colony Stimulating Factor (G-CSF) 5 microgram/kg subcutaneously daily up to 3 months
3254765|NCT00806585|Experimental|MK-0736 0.5 mg|One MK-0736 0.5 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will then be switched to MK-0736 8.0 mg, once daily for an additional 52 weeks (Phase B).
3254766|NCT00806585|Experimental|MK-0736 2.0 mg|One MK-0736 2.0 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will then be switched to MK-0736 8.0 mg, once daily for 52 weeks (Phase B).
3254767|NCT00806585|Experimental|MK-0736 8.0 mg|One MK-0736 8.0 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will continue to receive MK-0736 8.0 mg, once daily for 52 weeks (Phase B).
3254768|NCT00806585|Active Comparator|HCTZ 12.5 mg → MK-0736 8.0 mg|one 12.5 mg hydrochlorothiazide (HCTZ) tablet daily, orally, for 12 weeks. Participant then switched to MK-0736 8.0 mg for 12 weeks (Phase A). Participant will continue to receive MK-0736 8.0 mg, once daily for an additional 52 weeks (Phase B).
3254769|NCT00806585|Placebo Comparator|Placebo|One placebo tablet daily, orally, for 24 weeks (Phase A). Participant will continue to receive placebo, once daily for 52 weeks (Phase B)
3254770|NCT00806572|Experimental|Treatment|
3254771|NCT00806572|No Intervention|Control|
3254772|NCT00806559|Active Comparator|Usual room|Patients in this arm will see their clinician in the usual clinical exam room
3254773|NCT00806559|Experimental|Re-designed room|Patients assigned to this arm will see the physician in a redesigned clinical exam room
3254774|NCT00806546|Experimental|NP101|sumatriptan iontophoretic transdermal patch
3254775|NCT00806533||HES 130 / 0.42|paediatric patients aged up to 12 years requiring non-emergency volume replacement therapy with HES 130/0.42
3254776|NCT00806507||Echocardiogram + Blood Test|Additional Echocardiogram views performed in 5-10 minutes of regularly scheduled echocardiograms plus blood tests measuring of hormones and metabolic proteins (such as sugars and acids).
3254777|NCT00806494|Experimental|Treatment Arm|Fesoterodine 4mg, escalating to 8mg as required
3254778|NCT00806481|Active Comparator|1|Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
3254779|NCT00806481|Placebo Comparator|2|Treatment group: treatment with tablets of placebo three times daily for 36 weeks
3254780|NCT00806468|Experimental|Desmopressin|Desmopressin 0,2 mg once daily and Desmopressin 0,2 mg bid for one week each.
3254781|NCT00806442|Experimental|1: Borage Seed Oil and Echium Seed Oil|Borage/Echium plant seed oils: 2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
3254782|NCT00806442|Placebo Comparator|2: Placebo Comparator|Placebo comparator: 9 g/day corn oil
3254783|NCT00806429|Experimental|1|transvaginal appendectomy
3254784|NCT00806429|No Intervention|2|
3254785|NCT00806416|Experimental|Sequence 1|alendronate/vitamin D combination then alendronate
3254786|NCT00806416|Experimental|Sequence 2|alendronate then alendronate/vitamin D combination
3254787|NCT00806416|Experimental|Sequence 3|alendronate/vitamin D combination then vitamin D
3254788|NCT00806416|Experimental|Sequence 4|vitamin D then alendronate/vitamin D combination
3254789|NCT00806403|Active Comparator|thrombolysis|
3254790|NCT00806403|Active Comparator|invasive|
3254791|NCT00806390|Active Comparator|Metoprolol|Receiving metoprolol
3254792|NCT00806390|No Intervention|Control|Not receiving metoprolol
3254793|NCT00806351|Experimental|Anidulafungin Arm|Subjects were randomized 2:1 (anidulafungin:caspofunin).
3254794|NCT00806351|Experimental|Caspofungin Arm|Subjects were randomized 2:1 (anidulafungin:caspofunin).
3254795|NCT00806338|Experimental|Trodusquemine (MSI-1436) 3mg/m2|
3254796|NCT00806338|Experimental|Trodusquemine (MSI-1436) 6mg/m2|
3254797|NCT00806338|Experimental|Trodusquemine (MSI-1436) 10mg/m2|
3254798|NCT00806338|Placebo Comparator|Placebo|
3254799|NCT00806325||AML|Adult patients with AML admitted for treatment of the same
3254800|NCT00806312||1 PAH|Patients who are ≥ 18 years of age, not pregnant, and undergoing right heart catheterization for PAH diagnosis as part of their clinical care will be approached for consent and participation in this study.
3254801|NCT00806312||2. Control|Patients who present with symptoms of PAH and whose clinical right heart catheterization doesn't support this diagnosis will be enrolled as control subjects.
3254802|NCT00806299|Experimental|1|Drug (including placebo)
3254803|NCT00806299|Experimental|2|Drug (including placebo)
3254804|NCT00806299|Experimental|3|Drug (including placebo)
3254805|NCT00806286|Experimental|CS-7017 with Paclitaxel and Carboplatin|
3254806|NCT00806286|Placebo Comparator|Paclitaxel and Carboplatin|
3254807|NCT00806273|Active Comparator|Group 2|For Group II, the ultrasonic irrigation system involves using an initial irrigation with a conventional syringe followed by ultrasonic irrigation.
3254808|NCT00806273|Active Comparator|Group 1|For Group I, needle irrigation will be delivered into the pulp chamber using a syringe tip placed above the access opening and removed with high volume suction.
3254809|NCT00806260|Experimental|Treatment 1|Dosed first with alcohol, then active VI-0521, and last, VI-0521 placebo
3254810|NCT00806260|Experimental|Treatment 2|First dosed with alcohol placebo (fruit juice), then active VI-0521, and last, placebo VI-0521
3254811|NCT00806260|Experimental|Treatment 3|First dosed with alcohol, then VI-0521 placebo, and last, active VI-0521
3254812|NCT00806260|Experimental|Treatment 4|First dosed with alcohol placebo, then VI-0521 placebo, and last, active VI-0521
3254813|NCT00806234|Active Comparator|1|Participants will continue on current antipsychotic medication.
3254814|NCT00806234|Experimental|2|Participants will undergo a staggered switch from current antipsychotic medication to aripiprazole or perphenazine.
3254815|NCT00806234|Experimental|3|Participants will add metformin to current antipsychotic medication treatment.
3254816|NCT00806221|Experimental|Emollient|Skin barrier protection from birth
3254817|NCT00806208|Active Comparator|1|MEDI 507 and Methylprednisolone
3254857|NCT00806000||Athletes|
3254820|NCT00806208|Active Comparator|4|MEDI-507 and Methylprednisolone
3254821|NCT00806208|Placebo Comparator|5|Placebo
3254822|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (Non-Detailed)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR: 12 months.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Non-Detailed - infants who only provided SAEs (Serious Adverse Events) and medically attended AEs (Adverse Events)."
3254823|NCT00806195|Active Comparator|Routine Vaccines (Non-Detailed)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6 months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR: 12 months.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Non-Detailed - subjects who only provided SAEs and medically attended AEs."
3254824|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (Detailed)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs."
3254825|NCT00806195|Active Comparator|Routine Vaccines (Detailed)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6 months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, and Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs."
3254826|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (All)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~All (Detailed and Non-Detailed subjects): Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs; Non-Detailed - subjects who only provided SAEs and medically attended AEs."
3254827|NCT00806195|Active Comparator|Routine Vaccines (All)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, and Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~All (Detailed and Non-Detailed subjects): Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs; Non-Detailed - subjects who only provided SAEs and medically attended AEs."
3254828|NCT00806182||Pediatric case-controls|These are children who underwent lumbar puncture and blood drawing for diagnostic testing for non-inflammatory neurological or non-neurological disorders, and whose samples were retrieved from the clinical lab under a linked Institutional Review Board (IRB) protocol.
3254829|NCT00806182||Pediatric OMS|These are patients treated by the P.I. based on clinical decision making, not a clinical trial (this is an observational study). The types of treatments are varied, and, on the initial evaluation, the patients may be untreated or already tried on various immunotherapies. They range from monotherapy with steroids, ACTH, or IVIg, to disease modifying agents, such as rituximab, cyclophosphamide, and other chemotherapy, typically adjunctively or as combination therapy.
3254830|NCT00806169|Experimental|1|group I (n=17) nonproliferative DR and ischemic maculopathy
3254831|NCT00806169|Experimental|2|group II (n=38) nonproliferative DR without ischemic maculopathy
3254832|NCT00806169|Experimental|3|group III (n=18) proliferative DR with or without ischemic maculopathy
3254833|NCT00806156|Experimental|1|NKTR-102
3254834|NCT00806156|Experimental|2|NKTR-102
3254835|NCT00806143|Active Comparator|1|patients will undergo sequential bilateral rTMS treatment
3254836|NCT00806143|Active Comparator|2|patients will undergo unilateral low frequency right sided DLPFC rTMS
3254837|NCT00806117|Active Comparator|Radiotherapy (RT)|Radiotherapy
3254838|NCT00806117|Experimental|Concurrent chemoirradiation (CCRT)|"Concurrent chemoirradiation:~External beam radiation with concurrent weekly platinum chemotherapy"
3254839|NCT00806117|Experimental|Sequence chemo and radiation (SCRT)|"Sequence chemotherapy and radiotherapy:~2 cycles chemotherapy of Paclitaxel and Cisplatin before and after the irradiation"
3254840|NCT00806104|Experimental|1|Fructo-oligosaccharides
3254841|NCT00806104|Placebo Comparator|2|Maltodextrins
3254842|NCT00806091||COPD subjects|healthy subjects
3254843|NCT00806078|Experimental|1|Single dose intact capsules 2 x 324 mg
3254844|NCT00806078|Experimental|2|Single dose contents of two capsules (2 x 324 mg) opened and mixed in 120 mL of chocolate pudding
3254845|NCT00806065|Experimental|1|
3254846|NCT00806039|Other|1|Early renal involvement
3254847|NCT00806039|No Intervention|2|control
3254848|NCT00806026|Experimental|PBO/PGB 300 mg|
3254849|NCT00806026|Active Comparator|PBO/PPX 0.25 mg|
3254850|NCT00806026|Active Comparator|PBO/PPX 0.5 mg|
3254851|NCT00806026|Experimental|PGB 300 mg|
3254852|NCT00806026|Active Comparator|PPX 0.25 mg|
3254853|NCT00806026|Active Comparator|PPX 0.5 mg|
3254854|NCT00806013||1|CYP2C9*1/*1 and CYP2C19*1/*1 alleles carrier
3254855|NCT00806013||2|CYP2C19 PMs (CYP2C19*2/*2, CYP2C19*2/*3 or CYP2C19*3/*3)
3254856|NCT00806013||3|CYP2C9*1/*3 and CYP2C19*1/*1 alleles carrier
3254858|NCT00805961|Experimental|Intervention|"Combined Modality Treatment and Systemic Therapy~Combined Modality Therapy - Radiation Therapy: 2 Gy/fraction, single daily fractions Monday-Friday, to total of 60 Gy Temozolomide: 75 mg/m2 by mouth daily Bevacizumab: 10 mg/kg IV every 2 weeks (Weeks 1, 3, 5, and 7)~After the last dose of radiation, patients exhibiting an objective response, stable disease on MRI scan, or have stable/improved tumor-related symptoms will begin systemic therapy~Systemic Therapy - Bevacizumab: 10 mg/kg IV every 2 weeks Everolimus: 10 mg by mouth daily"
3254859|NCT00805948|Experimental|Test Group|Patients diagnosed with a descending thoracic aortic aneurysm are considered candidates for the endovascular repair. The Talent Thoracic Stent Graft System is compressed and pre-loaded into the delivery system,which is inserted endoluminally via the femoral or iliac artery and tracked through the patient's vasculature to deliver the stent graft to the target site.
3254860|NCT00805935|Experimental|Menotropin/Progesterone vaginal insert|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone vaginal insert (Endometrin®) 100 mg starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
3254861|NCT00805935|Experimental|Menotropin/Progesterone in oil|"Menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in oil 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
3254862|NCT00805935|Active Comparator|Follitropin beta/Progesterone vaginal insert|"Follitropin beta (Follistim Pen®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone vaginal insert (Endometrin®) 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
3254863|NCT00805935|Active Comparator|Follitropin beta/Progesterone in oil|"Follitropin beta (Follistim Pen®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in oil 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
3254864|NCT00805922||A|
3254865|NCT00805909|Experimental|NI-0401|5 daily infusions of escalating doses of NI-0401
3254866|NCT00805896|Experimental|1|Songyou Granule
3254867|NCT00805896|Placebo Comparator|2|
3254868|NCT00805883|Experimental|1|
3254869|NCT00805870|Experimental|Fish Oil|Lovaza, 3 grams/day for 65 days
3254870|NCT00805870|Placebo Comparator|Control|Wheat Germ Oil, 3 grams/day for 65 days
3254871|NCT00805844||1|Spine surgery with Motor Evoked Potential monitoring without SedLine monitoring visible.
3254872|NCT00805844||2|Spine surgery with Motor Evoked Potential Monitoring with SedLine monitoring visible.
3254873|NCT00805831|Experimental|A|Aortic anastomosis surgery will be conducted using HDH device.
3254874|NCT00805818|Experimental|NNZ-2566|20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1 mg/kg/h (Cohort 1, n=20), 3 mg/kg/h (Cohort 2, n=20) or 6 mg/kg/h (Cohort 3, n=133) intravenous infusion for a total of 72 consecutive hours.
3254875|NCT00805818|Placebo Comparator|Sodium Chloride (0.9%) for Injection|Intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion (Cohort 1, n=10), (Cohort 2, n=10) or (Cohort 3, n=67) intravenous infusion for a total of 72 consecutive hours.
3254876|NCT00805805|Experimental|1|Tetrathiomolybdate with ursodiol
3254877|NCT00805805|Placebo Comparator|2|Placebo with ursodiol
3254878|NCT00805792|Experimental|Donepezil|Participants received treatment with donepezil within 24 hours after the onset of ischemic stroke symptoms. Participants received donepezil 5 mg/day for 30 days, followed by an increase to 10 mg/day for 60 days.
3254879|NCT00805766|Experimental|TA-650|
3254880|NCT00805753|Active Comparator|Arm 1 ACTH 40 units|Receive ACTH at the dose of 40 units sub-cutaneously for up to 12 weeks. If at day 91 no response has been shown, you will have the option to increase the dose of ACTH to 80 units for up to an additional 120 days.
3254881|NCT00805753|Active Comparator|Arm 2 ACTH 80 units|Receive ACTH at the dose of 80 units sub-cutaneously for up to 12 weeks.
3254882|NCT00805740|Experimental|Anidulafungin arm|
3254883|NCT00805740|Experimental|Caspofungin arm|
3254884|NCT00805714||Acute myocardial infarction|AMI patients who are in need to be treated by statins
3254885|NCT00805701|Active Comparator|0.5mg Avodart|.5mg avodart capsule orally once a day during 13 months
3254886|NCT00805701|Placebo Comparator|Placebo|placebo capsule orally daily for 13 months
3254887|NCT00805688||Symptom Study|Questionnaires + Blood Draw + Pedometer used to learn about symptoms related to chemotherapy and the disease, in patients with advanced pancreatic cancer.
3254888|NCT00805675|Experimental|Telbivudine 600 mg monotherapy|All patients in this arm were randomized to receive Telbivudine (LDT) 600 mg QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
3254889|NCT00805675|Active Comparator|Tenofovir disproxil fumarate 300 mg monotherapy|All patients in this arm were randomized to receive Tenofovir disoproxil fumarate 300 mg(equivalent to tenofovir disoproxil 245 mg)QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
3254890|NCT00805675|Active Comparator|Telbivudine 600 mg and Tenofovir 300 mg|All patients in this arm were randomized to receive Telbivudine (LDT) 600 mg QD and Tenofovir (TDF) 300 mg (equivalent to Tenofovir disoproxil 245 mg)QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
3254891|NCT00805662|Experimental|Oxytocin|Intranasal oxytocin during IUI
3254892|NCT00805649|Experimental|1|eyes with predominately classic lesions
3254893|NCT00805649|Experimental|2|eyes with occult lesions
3254894|NCT00805623|No Intervention|AW|no pacifier , no sucrose
3254895|NCT00805623|Active Comparator|AS|sucrose without pacifier
3254896|NCT00805623|No Intervention|PW|
3254897|NCT00805623|Experimental|PS|Pacifier and sucrose interventional
3254898|NCT00805610|Experimental|Hepatocyte Transplantation|Hepatocyte Transplantation through single donor will be transplanted into the liver via intraportal or intrasplenic routes.
3254899|NCT00805597|Experimental|radiotherapy|radiotherapy of 50Gy/25/f/5w to the ipsilateral chest wall and supraclavicular region
3254900|NCT00805597|Active Comparator|no radiotherapy|no radiotherapy
3254901|NCT00805584|Experimental|Arm 1|
3254902|NCT00805571||Adult|Adult patients with end-stage kidney disease awaiting kidney transplantation.
3254903|NCT00805571||Pediatric|Children with end-stage kidney disease awaiting kidney transplantation.
3254904|NCT00805558|Experimental|Moxifloxacin|Scaling and root planing plus 400 mg moxifloxacin once daily for 7 days.
3254905|NCT00805558|Active Comparator|Ciprofloxacin plus metronidazole|Scaling and root planing plus ciprofloxacin 1000 mg once daily for 7 days and metronidazole 500 mg twice daily for 7 days
3254906|NCT00805545|Experimental|A|Group of patients that will receive antibiotics 30-60 minutes prior to incision
3254907|NCT00805545|Active Comparator|B|Group of patients that will receive antibiotics immediately after clamping the umbilical cord
3254908|NCT00805532|Experimental|Arm 1|Behavioral Activation (BA)- modified to be delivered in 6-8, 60 minute sessions in a primary care setting by skilled psychotherapists. BA has also been modified to better address PTSD concerns.
3254909|NCT00805532|Active Comparator|Arm 2|Usual Care for PTSD (UC)-that is provided in the VA PTSD Specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system. Subjects assigned to Usual Care will be permitted to receive medical intervention (i.e., pharmacotherapy) and any additional psychotherapy deemed appropriate by the provider. They will also be offered a minimum of 6 sessions of individual therapy.
3254910|NCT00805519|Active Comparator|Glucosamine and chondroitin sulfate|in this group patients will receive Glucosamine and chondroitin sulfate oral dietary supplementation
3254911|NCT00805519|Experimental|P :glucosa, chondroitin, Prednis|in this group patients will receive glucosamine and chondroitin sulfate plus Prednisolone oral administration
3254912|NCT00805519|Experimental|Glucosa, Chondroitin, Chloroquine|in this group pateints will orally receive Glucosamine and Chondroitin sulfate plus Chloroquine.
3254913|NCT00805519|Experimental|Glucosa, Chondro, Prednis,Chloroq|in this group patients will receive Glucosamine and Chondroitin sulfate plus Prednisolone and Chloroquine
3254914|NCT00805506||Diabetes Insulin Treated|People with type 1 or type 2 diabetes on insulin.
3254915|NCT00805493|No Intervention|Medication Taper|All participants begin with gradual tapering to the point of discontinuing medication
3254916|NCT00805493|No Intervention|Random assignment to placebo|Once they are medication-free, 50% of participants are randomized to placebo
3254917|NCT00805493|Active Comparator|Random assignment to riluzole|One they are medication-free, 50% of participants are randomized to riluzole
3254918|NCT00805480|Experimental|AIN457 3 mg/kg|Participants randomized to this arm received AIN457 3 mg/kg on day 1, and then matching placebo on days 15 and 29.
3254919|NCT00805480|Experimental|AIN457 10 mg/kg|Participants randomized to this arm received AIN457 10 mg/kg on day 1, and then matching placebo on days 15 and 29.
3254920|NCT00805480|Experimental|AIN457 10 mg/kg x3|Participants randomized to this arm received AIN457 3 mg/kg on days 1, 15 and 29.
3254921|NCT00805480|Placebo Comparator|Placebo|Participants randomized to this arm received matching placebo to AIN457 on days 1, 15 and 29
3254922|NCT00805467|Experimental|1|R935788 50 mg tablet, orally, twice-a-day
3254923|NCT00805467|Experimental|2|R935788 100 mg tablet, orally, twice-a-day
3254924|NCT00805467|Experimental|3|R935788 100 mg tablet, orally, once-a-day
3254925|NCT00805467|Experimental|4|R935788 150 mg tablet, orally, once-a-day
3254926|NCT00805441|Placebo Comparator|Placebo|
3254927|NCT00805441|Experimental|LY686017|
3254928|NCT00805428||2|control group
3254929|NCT00805428||patients with UC|patients with UC, without corticosteroid or immunosuppressive therapy
3254930|NCT00805415|Experimental|Arm 1|
3254931|NCT00805415|Experimental|Arm 2|
3254932|NCT00805402|Experimental|1 flow cytometry|flow cytometry
3254933|NCT00805389|Experimental|GSK223192A 1 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
3254934|NCT00805389|Experimental|GSK223192A 2 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
3254935|NCT00805389|Experimental|GSK223192A 3 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
3255012|NCT00804908|Active Comparator|ABT-888 40 mg BID + TMZ QD|ABT-888 40 mg twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
3255013|NCT00804895|Experimental|1|subcutaneous injection of Cortivazol ALTIM, 3,375mg
3254936|NCT00805389|Experimental|Fendrix Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
3254937|NCT00805389|Active Comparator|Engerix-B Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
3254938|NCT00805376|Experimental|Group A: DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
3254939|NCT00805376|Experimental|Group B: DNX-2401 + Surgery|DNX-2401 injection + Tumor removal
3254940|NCT00805350|Experimental|Eplivanserin|Eplivanserin 5 mg/day
3254941|NCT00805350|Placebo Comparator|Placebo|Placebo of Eplivanserin 5 mg/day
3254942|NCT00805324|Experimental|Arm 1|
3254943|NCT00805311|Experimental|CEA Group|Patients will undergo carotid endarterectomy (CEA) and receive medical treatment including medical therapy with statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.
3254944|NCT00805311|Active Comparator|OMT Group|Patients will receive conservative therapy - optimal medical treatment (OMT) including statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.
3254945|NCT00805298|Active Comparator|methylprednisolone|
3254946|NCT00805298|Placebo Comparator|placebo|
3254947|NCT00805298|Active Comparator|lidocaine|
3254948|NCT00805298|Active Comparator|bupivacaine|
3254949|NCT00805285|Experimental|Combination Oral Budesonide and Rectal Hydrocortisone|See intervention
3254950|NCT00805272|Experimental|1|
3254951|NCT00805259|Active Comparator|1. Atomistic|payment for own work
3254952|NCT00805259|Active Comparator|2. Altruistic|payment for partner's work
3254953|NCT00805259|Active Comparator|3. Team-based|payment for relative performance of combined effort of each team
3254954|NCT00805259|No Intervention|4. Control|access to software but no financial incentives
3254955|NCT00805246||Pulmonary Embolism (PE)|Subjects diagnosed with PE by CT will be recruited.
3254956|NCT00805233|Experimental|1|Combination Ranibizumab intravitreal injection plus bromfenac ophthalmic drops
3254957|NCT00805233|Active Comparator|2|ranibizumab injection alone.
3254958|NCT00805220|Active Comparator|1|Regular overground walking without poles
3254959|NCT00805220|Experimental|2|Nordic Walking
3254960|NCT00805207|Experimental|Progesterone - PCOS|Women with obesity and polycystic ovary syndrome
3254961|NCT00805207|Experimental|Testosterone - premenopausal women|Healthy premenopausal women.
3254962|NCT00805207|Experimental|Continuous positive airway pressure|Women and men with obesity and obstructive sleep apnea
3254963|NCT00805207|Experimental|Glucocorticoid|Lean and obese healthy women, and obese men
3254964|NCT00805207|Experimental|Estrogen|Postmenopausal women
3254965|NCT00805207|Other|control|Postmenopausal women - tested before and after no treatment. Duration between before and after testing ranged from 31 to 78 days with an average of 46 days between visits
3254966|NCT00805207|No Intervention|control - baseline testing only|Healthy men and women
3254967|NCT00805207|Experimental|Progesterone - Postmenopausal women|Postmenopausal women
3254968|NCT00805207|Experimental|Testosterone - Postmenopausal women|Postmenopausal women
3254969|NCT00805194|Experimental|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
3254970|NCT00805194|Placebo Comparator|Placebo plus docetaxel|Placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
3254971|NCT00805181||Acute uncomplicated pyelonephritis|
3254972|NCT00805155||Cohort Group 1|Subjects number 1 to 20
3254973|NCT00805155||Cohort Group 2|Subjects number 21 to 50
3254974|NCT00805155||Cohort Group 3|Subject Numbers 51 to 80
3254975|NCT00805142|Experimental|Opioid-Naive Participants (Tapentadol PR)|Opioid-naive participants are defined as those who had moderate to severe cancer pain that is not controlled sufficiently with non-opioid medications. Treatment period comprises of Titration and Maintenance period. Titration period (3-14 days) is duration between start of treatment to day before initial dose in the maintenance period. Treatment will be initiated with tapentadol prolonged release (JNS024PR, PR) 25 milligram (mg) oral tablet twice daily. Dose will be increased or decreased as per Investigator's discretion up to Day 14. Maximum dose limit will be 500 mg per day. Participants will then be assigned to the treatment in the maintenance period (15-19 days). The maintenance period is duration between the first dose and the final assessment in the maintenance period. Participants will receive tapentadol PR oral tablet twice daily for 5 days at the same dose used on last day of titration period.
3255014|NCT00804895|Placebo Comparator|2|PROAMP, subcutaneous serum physiological saline
3255015|NCT00804882||1|Mexican Americans with heart failure and metabolic syndrome
3255016|NCT00804882||2|Mexican Americans with heart failure without metabolic syndrome
3255017|NCT00804882||3|Non-Hispanic White Americans with heart failure and metabolic syndrome
3255018|NCT00804882||4|Non-Hispanic White Americans with heart failure without metabolic syndrome
3255019|NCT00804869||1|PalmScan biometric group
3255020|NCT00804869||2|A-mode ultrasonography biometric group
3254976|NCT00805142|Experimental|Opioid-Switch Participants (Tapentadol PR)|Opioid-switching participants are defined as those who had moderate to severe cancer pain that is controlled sufficiently with opioid therapy. Treatment period comprises of Titration and Maintenance period. Titration period (3-14 days) is duration between start of treatment to day before initial dose in maintenance period. Initial dose of tapentadol PR is selected according to daily dose of opioid (morphine sustained release [SR] preparation, oxycodone hydrochloride [HCl] SR tablet or fentanyl patch). Equivalent dose of tapentadol PR oral tablet twice daily is given depending on daily dose of opioid at completion of Screening period. Maximum dose limit is 500 mg per day. Participants will then be assigned to treatment in maintenance period (15-19 days). Maintenance period is defined as duration between first dose and final assessment in maintenance period. Participants will receive tapentadol PR oral tablet twice daily for 5 days at same dose used on last day of titration period.
3254977|NCT00805129|Experimental|Everolimus|Everolimus will be administered at a dose of 10 mg orally once daily continuously.
3254978|NCT00805116|Experimental|1|Whale blubber oil
3254979|NCT00805116|Active Comparator|2|Cod liver oil
3254980|NCT00805103|Experimental|(HFA-SRT) in Large-Volume Brain Metastases|
3254981|NCT00805090|Active Comparator|Sporanox|Active arm approved as an anti-fungal being used to compare HPβCD when administered in DIC075V compared to Sporanox.
3254982|NCT00805090|Experimental|Dyloject|Diclofenac Sodium
3254983|NCT00805077|Experimental|1|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
3254984|NCT00805077|Other|2|tidal volume of 10 ml/kg of ideal body weight without PEEP
3254985|NCT00805064|Active Comparator|ischemic CRVO|treatment was applied to this entity
3254986|NCT00805064|Active Comparator|non ischemic CRVO|treatment was applied to this entity
3254987|NCT00805064|Active Comparator|BRVO|treatment was applied to this entity
3254988|NCT00805051||Severe aortic stenosis|Patients undergoing aortic valve replacement because of severe aortic stenosis
3254989|NCT00805038|Placebo Comparator|Control|Usual care
3254990|NCT00805038|Experimental|Intervention|Navigator will assist patients in completing steps in transplant process
3254991|NCT00805025|Experimental|AZLI|Participants were evaluated beginning 14 days prior to starting a 28-day course of AZLI (Day 0 to Day 28), followed by post-treatment assessments every 14 days through Day 56, for a total of 70 days of participation in the study.
3254992|NCT00805012|Active Comparator|1|docetaxel+CDDP
3254993|NCT00805012|Experimental|2|docetaxel+S-1
3254994|NCT00804999|Placebo Comparator|Placebo 1|Subjects that have never worn contacts with no ocular problems were selected. A baseline HRT was performed. Trial contact lenses were soaked in clear care solution for 10 hours. After 10 hours of the lenses soaking in clear care the subject returned. The contacts lenses that were soaked in clear care were inserted onto the patients eyes. The patient then wore the contacts for two hours. After two hours the contact lenses were removed. An HRT was performed immediately after removing the contact lenses. The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
3254995|NCT00804999|Active Comparator|Renu|Subjects that had worn contacts for at least two weeks without incident were selected. A baseline HRT was performed.Trial contacts lenses were soaked in ReNu contact solution for 10 hours. After 10 hours of the lenses soaking in ReNu the subject returned. The contacts were inserted onto the patients eyes. The patient then wore the contacts for two hours. After two hours the contacts lenses were removed. An HRT both with and without sodium fluorescein was performed immediately after removing the contact lenses.The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
3254996|NCT00804999|Active Comparator|Optifree|Subjects that had worn contacts for at least two weeks without incident were selected. A baseline HRT was performed.Trial contacts lenses were soaked in Optifree Replenish contact solution for 10 hours. After 10 hours of the lenses soaking in Optifree Replenish the subject returned. The contacts were inserted onto the patients eyes. The patient wore contacts the for two hours. After two hours the contacts were removed. An HRT both with and without sodium fluorescein was performed immediately after removing the contact lenses.The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
3254997|NCT00804986|Experimental|0.5 mg LY2428757|Once weekly, subcutaneous injection of 0.5 milligram (mg) LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
3254998|NCT00804986|Experimental|2.0 mg LY2428757|Once weekly, subcutaneous injection of 2.0 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
3254999|NCT00804986|Experimental|6.2 mg LY2428757|Once weekly, subcutaneous injection of 6.2 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
3255000|NCT00804986|Experimental|12.0 mg LY2428757|Once weekly, subcutaneous injection of 12.0 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
3255001|NCT00804986|Experimental|17.6 mg LY2428757|Once weekly, subcutaneous injection of 17.6 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
3255002|NCT00804986|Placebo Comparator|Placebo|Once weekly, subcutaneous injection of placebo for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
3255003|NCT00804973|Experimental|1|
3255004|NCT00804973|Placebo Comparator|2|
3255005|NCT00804973|Active Comparator|3|
3255006|NCT00804960|Experimental|Letrozole|1) Letrozole/ Recombinant FSH
3255007|NCT00804960|Active Comparator|Standard IVF|luteal phase GnRHa suppression/gonadotropin
3255008|NCT00804947|Experimental|Intravenous busulfan and melphalan|
3255009|NCT00804934||0|
3255010|NCT00804908|Placebo Comparator|Placebo for ABT-888 BID + TMZ QD|Placebo for ABT-888 twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
3255011|NCT00804908|Active Comparator|ABT-888 20 mg BID + TMZ QD|ABT-888 20 mg twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
3255021|NCT00804856|Experimental|Schedule A|BI 6727 (d1 and 15 - one hour iv.) + LD ARA C 2x20 mg/d s.c.
3255022|NCT00804856|Experimental|Schedule B|BI 6727 (d1 and 15 - one hour iv.)
3255023|NCT00804856|Active Comparator|Schedule C|LD-ARA C monotherapy (2 x 20 mg/d s.c.)
3255024|NCT00804843|Experimental|Statin 80 mg + Niacin extended-release (ER)|Participants in Russia and Brasil will receive 80 mg Simvastatin + niacin. All other participants will receive 80 mg Atorvastatin + niacin.
3255025|NCT00804843|Active Comparator|Statin 10 mg|Participants in Russia and Brasil will receive 10 mg Simvastatin. All other participants will receive 10 mg Atorvastatin.
3255026|NCT00804830|Experimental|chemotherapy|Treatment with Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w for 6 months.
3255027|NCT00804817|Active Comparator|Care as usual|Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
3255028|NCT00804817|Experimental|SCION-HSCT program|"Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.~The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects."
3255029|NCT00804804|Experimental|Y1|young volunteers (20-30 years), morningness chronotype
3255030|NCT00804804|Experimental|Y2|young volunteers (20-30 years), eveningness chronotype
3255031|NCT00804804|Experimental|O1|Aged volunteers (65-75 years), morningness chronotype
3255032|NCT00804804|Experimental|O 2|aged volunteers (65-75 years), eveningness chronotype
3255033|NCT00804791|Active Comparator|Systane|One drop dispensed into each eye
3255034|NCT00804791|Active Comparator|Unisol|One drop dispensed into each eye
3255035|NCT00804778||CABG,general anesthesia|their CO and CI was measured with USCOM and Swan-ganz cco respectively.
3255036|NCT00804778||group 1|co measured with swan-ganz cco combined with vigilance
3255037|NCT00804765|Experimental|1|Therapeutic education
3255038|NCT00804765|Placebo Comparator|2|
3255039|NCT00804752|Experimental|Vitamin D|An addition of Vitamin D to the standard treatment
3255040|NCT00804739|Experimental|MITT|Mothers will be assigned to the Mother-Infant Treatment Team (MITT)and will receive either psychotherapy or sertraline or both as well as outreach.
3255041|NCT00804726|Experimental|Akreos MI Five-O|Accommodating intraocular lens
3255042|NCT00804713|Experimental|All study participants|Subjects administered the TB skin test, Battey skin test, QFT-GIT, and T-Spot
3255043|NCT00804700|Active Comparator|Control Group|Subjects will be given a 60 minute lecture on the benefits of regular exercise and how music can enhance the exercise experience. Subjects will be individually instructed how to use the Precor elliptical trainer at the Yates fitness center while listening to music. Subjects are instructed to exercise using the elliptical trainer for periods of 45 -55 minutes at a time as frequently as they like with a minimum frequency of once per week. Subjects will also be encouraged to exercise regularly by walking, jogging or engaging in other forms of physical activity during the intervention period. A fitness attendant will be on hand to supervise their exercise activity, but will not give specific advice how to exercise, other than to make sure they are exercising safely.
3255044|NCT00804700|Experimental|Intervention Arm|Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
3255045|NCT00804687|Experimental|JNJ-39220675 then Pseudoephedrine then Placebo|Single-dose of JNJ-39220675 will be administered as 1 milliliter (ml) of 10 milligram/milliliter (mg/ml) solution orally along with placebo tablet in first treatment period; after that in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with 60 milligram (mg) pseudoephedrine tablet; and then single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
3255046|NCT00804687|Experimental|JNJ-39220675 then Placebo then Pseudoephedrine|Single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
3255047|NCT00804687|Experimental|Placebo then JNJ-39220675 then Pseudoephedrine|Single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
3255048|NCT00804687|Experimental|Placebo then Pseudoephedrine then JNJ-39220675|Single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet; and then single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
3255049|NCT00804687|Experimental|Pseudoephedrine then JNJ-39220675 then Placebo|Single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in first treatment period; after that, in second treatment period, single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
3255343|NCT00802698|Experimental|Group 1|
3255479|NCT00801853|Experimental|Aerovant 1|Aerovant 1mg bid
3255050|NCT00804687|Experimental|Pseudoephedrine then Placebo then JNJ-39220675|Single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with placebo tablet; and then single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
3255051|NCT00804674|Active Comparator|1 bupivacain|
3255052|NCT00804674|Placebo Comparator|2 placebo|
3255053|NCT00804661||1|Children and adults with cystic fibrosis
3255054|NCT00804648|Active Comparator|hemihydrate/maleate/maleate gel|Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate 0.5% Period three - Timolol maleate gel forming solution 0.5%
3255055|NCT00804648|Active Comparator|maleate/maleate gel/hemihydrate|Period one - Timolol maleate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol hemihydrate 0.5%
3255056|NCT00804648|Active Comparator|maleate gel/hemihydrate/maleate|Period one - Timolol maleate gel forming solution 0.5% Period two - Timolol hemihydrate 0.5% Period three - Timolol maleate 0.5%
3255057|NCT00804648|Active Comparator|hemihydrate/maleate gel/maleate|Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol maleate 0.5%
3255058|NCT00804648|Active Comparator|maleate/hemihydrate/maleate gel|Period 1 - Timolol maleate 0.5% Period 2 - Timolol hemihydrate 0.5% Period 3 - Timolol maleate gel forming solution 0.5%
3255059|NCT00804648|Active Comparator|maleate gel, maleate, hemihydrate|Period 1 - Timolol maleate gel forming solution 0.5% Period 2 - Timolol maleate 0.5% Period 3 - Timolol hemihydrate 0.5%
3255060|NCT00804622|Active Comparator|1|tenofovir disproxil fumarate 300 mg monotherapy
3255061|NCT00804622|Active Comparator|2|telbivudine 600 mg monotherapy
3255062|NCT00804622|Active Comparator|3|telbivudine 600 mg and tenofovir disproxil fumarate 300 mg
3255063|NCT00804609|Active Comparator|DepoDur following epidural lidocaine|Epidural DepoDur was administered 60 minutes after an epidural Lidocaine top-up for surgical anesthetic in cesarean section patients.
3255064|NCT00804609|Active Comparator|DepoDur following spinal anesthetic|Epidural DepoDur was administered 60 minutes after a standard spinal anesthetic. No prior epidural local anesthetic was used prior to DepoDur in this group assignment.
3255065|NCT00804596|Other|Subjects with diabetes|Subjects with diabetes use a new blood glucose monitoring system with subject capillary blood.
3255066|NCT00804570|Experimental|LY2196044|
3255067|NCT00804570|Placebo Comparator|Placebo|
3255068|NCT00804557||Uro-Ease Spirus Catheter|10 patients randomized to the Uro-Ease Catheter group for 1 week. In clinic, patients will be instructed in the use of the Uro-Ease Catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to a standard, non-helical urinary catheter. Patients will be followed up to 1 month.
3255069|NCT00804557||Standard Urinary Catheter|10 patients randomized to a Standard Urinary Catheter group for 1 week. In clinic, patients will be instructed in the use of the catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to the UroEase Spirus Catheter. All patients will be followed up to 1 month.
3255070|NCT00804544|Experimental|1|Mammoscintigraphy with SPECT-CT optimized 99mTc-MIBI imaging (experimental arm) will be compared to conventional planar imaging. Mammoscintigraphy results before and after chemotherapy and radiation therapy, will be compared to the histopathological results after surgery.
3255071|NCT00804531|Experimental|Visipaque - Hydrocortancyl|Administration of two treatments for the experimental arm
3255072|NCT00804531|Placebo Comparator|Visipaque|Administration of only one treatment in intra discal of visipaque
3255073|NCT00804518|Experimental|Exercise intervention|
3255074|NCT00804505|Experimental|1|Test arm daily wear hybrid contact lens.
3255075|NCT00804505|Other|2|Control: SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Hybrid Contact Lens
3255076|NCT00804492|Experimental|1|To establish an integrated intervention model for prevention of elderly fall
3255077|NCT00804492|Experimental|2|To perform a RCT to investigate the effectiveness of the multicenter, multifaceted intervention program
3255078|NCT00804479||no treatment|Available 301 subjects enrolled in CALM-PD Available 82 subjects enrolled in CALM-PD imaging substudy
3255079|NCT00804466|Experimental|Women referred to colposcopy clinic|Triage tests for diagnosis of cervical pre-cancer amongHPV positive women
3255080|NCT00804453|Active Comparator|1|Standard blood line
3255081|NCT00804453|Experimental|2|Cartridge blood line
3255082|NCT00804440|Active Comparator|Test Product|
3255083|NCT00804440|Active Comparator|Reference Product|
3255084|NCT00804427|Experimental|Fish oil (90% triglycerides)|Fish oil (4 grams/day of combined EPA and DHA) as 90% triglyceride formulation, taken in two divided doses with main meals.
3255085|NCT00804427|Experimental|Fish oil (60% triglycerides)|Fish oil (4 grams/day of combined EPA and DHA) as 60% triglyceride formulation, taken in two divided doses with main meals.
3255086|NCT00804427|Experimental|Fish oil (ethyl esters)|Fish oil (4 grams/day of combined EPA and DHA) as ethyl esters formulation (0% triglycerides), taken in two divided doses with main meals.
3255087|NCT00804427|Placebo Comparator|Soy oil|Soy oil supplement with identical total fat content, taken in two divided doses with main meals.
3255088|NCT00804414|Experimental|1|
3255089|NCT00804414|Placebo Comparator|2|
3255090|NCT00804401|Active Comparator|Test Product|
3255091|NCT00804401|Active Comparator|Reference Product|
3255092|NCT00804388|Active Comparator|1|Uncemented total hip replacement, 32 mm caput
3255093|NCT00804388|Active Comparator|2|Uncemented total hip replacement, 36 mm caput
3255094|NCT00804375|Experimental|2PX|Pain medication
3255095|NCT00804375|Placebo Comparator|placebo|placebo
3255096|NCT00804349|No Intervention|Control|Patients will receive standard medical therapy for heart failure only and will not receive Autotitrating Positive Airway Pressure therapy.
3255097|NCT00804349|Active Comparator|Autotitrating Positive Airway Pressure|Patients will receive Autotitrating Positive Airway Pressure therapy in addition to standard medical care for heart failure.
3255098|NCT00804336|Experimental|Pasireotide and RAD001|RAD001 was administered orally as a once-daily dose. Pasireotide s.c. was self-administered s.c. twice daily for 4 weeks. If pasireotide s.c. was tolerated, patients received pasireotide LAR i.m. at the corresponding dose level. Pasireotide s.c. was continued for an additional 2 weeks after administration of pasireotide LAR until anticipated steady-state levels of pasireotide LAR were achieved. Pasireotide LAR was administered every 28 days. Cycles for everolimus and pasireotide LAR were repeated every 28 days.
3255099|NCT00804323|Experimental|Group 1|Patients with open-angle glaucoma
3255100|NCT00804310|Experimental|Lapatinib and Ixabepilone|
3255101|NCT00804284||Pentacel Group|Infants initiated on PENTACEL® vaccine
3255102|NCT00804284||Other DTap vaccines Group|Infants initiated on other DTaP vaccines
3255103|NCT00804271|Other|Memantine|
3255104|NCT00804245|Experimental|radiolabeled choline tracer scans|PET-CT scans supplemented with Choline 11 tracer
3255105|NCT00804232|Experimental|1|effects on child health of family-based home care compared to traditional hospital-based care,
3255106|NCT00804232|Experimental|2|effects on child health of family-based psychological treatment compared to traditional hospital-based treatment
3255107|NCT00804219|Experimental|TBE low responder|
3255108|NCT00804219|Experimental|FSME responder|
3255109|NCT00804219|Experimental|hepatitis B non-responder|
3255110|NCT00804206|Experimental|Group A|Bevacizumab before panretinal photocoagulation.
3255111|NCT00804206|Experimental|Group B|Bevacizumab after panretinal photocoagulation
3255112|NCT00804193|Experimental|Test Product|Ciclopirox Olamine Topical Suspension
3255113|NCT00804193|Active Comparator|Reference Product|Loprox® Topical Suspension 0.77%
3255114|NCT00804193|Placebo Comparator|Vehicle Product|placebo of test product
3255115|NCT00804180|Other|Coping skills intervention|Self-Injection Anxiety Counseling: Evaluation of a group treatment for injection-related anxiety. The intention of the study is to obtain basic evaluation of a clinical treatment offered in a natural clinic setting, and does not include a control group, or procedure for random assignment of participants.
3255116|NCT00804141|Experimental|1|open-label
3255117|NCT00804115|No Intervention|1|Latanoprost in combination with Pilocarpine
3255118|NCT00804115|No Intervention|2|Timolol or Cosopt
3255119|NCT00804102|Active Comparator|Retinitis pigmentosa|
3255120|NCT00804102|Active Comparator|Macula off|condition after treatment of retinal detachment
3255121|NCT00804102|Active Comparator|Primary open angle Glaucoma|
3255122|NCT00804102|Active Comparator|Hereditary Macular Degeneration|
3255123|NCT00804102|Active Comparator|Treated Retina detachment|
3255124|NCT00804102|Active Comparator|Retinal Artery Occlusion|
3255125|NCT00804102|Active Comparator|Retinal Vein Occlusion|
3255126|NCT00804102|Active Comparator|Non-Arteriitic-Anterior-Ischemic Optic-Neuropathy|
3255127|NCT00804102|Active Comparator|Hereditary autosomal dominant Optic atrophy|
3255128|NCT00804102|Active Comparator|dry Age-related Macular Degeneration|
3255129|NCT00804102|Active Comparator|Ischemic Macula edema|
3255130|NCT00804102|Sham Comparator|Non-stimulated|
3255131|NCT00804089|Experimental|1|Traditional needle acupuncture
3255132|NCT00804089|Active Comparator|2|Myofascial trigger point dry needling
3255133|NCT00804089|Active Comparator|3|Myofascial trigger point acupressure
3255134|NCT00804076|Experimental|NP2|Intradermal injection
3255135|NCT00804063||1|glaucoma patients
3255136|NCT00804063||2|non-glaucoma controls
3255137|NCT00804050|Experimental|Infusion A: rEPO|rEPO for 4 mounths consequently
3255138|NCT00804050|Experimental|Infusion B combined r-EPO|rEPO in association with acid 13-cis-retinoic acid and Dihydroxyvitamin D3 for 4 mounths consequently
3255139|NCT00804037|Active Comparator|Ethanol|
3255140|NCT00804037|Active Comparator|Ethanolamine Oleate|
3255141|NCT00804024||ClearWay™ RX|
3255142|NCT00804011|Experimental|1|Automatic tube compensation plus pressure support
3255143|NCT00804011|Active Comparator|2|Pressure support alone
3255144|NCT00803985|Active Comparator|Lichtenstein|Open operation with onlay light weight polypropylene mesh
3255145|NCT00803985|Active Comparator|TEP|Laparoscopic operation with preperitoneal nonfixated mesh
3255146|NCT00803972|Experimental|Stage 1: 3 U insulin plus rHuPH20|Participants will receive 3 Units (U) of regular insulin (100 U/milliliter [mL]), coadministered with sequential concentrations of 0, 1.25, 5, 10, 20, and 80 micrograms (μg)/mL recombinant human hyaluronidase (rHuPH20).
3255147|NCT00803972|Experimental|Stage 1: 12 U insulin plus rHuPH20|Participants will receive 12 U of regular insulin (100 U/mL), coadministered with sequential concentrations of 0, 1.25, 5, 10, 20, and 80 μg/mL rHuPH20.
3255148|NCT00803972|Experimental|Stage 2: insulin plus rHuPH20|Participants will receive 6, 12, and 24 U regular insulin (100 U/mL) in a randomly assigned order, with each insulin dose administered once with and once without 5 μg/mL rHuPH20.
3255149|NCT00803972|Experimental|Stage 3: 1.5 U insulin lispro plus rHuPH20|Participants will receive 1.5 U of insulin lispro (50 U/mL), coadministered with sequential concentrations of 0, 0.0625, 0.3125, 1.25, 5, and 20 μg/mL rHuPH20.
3255150|NCT00803972|Experimental|Stage 3: 6 U insulin lispro plus rHuPH20|Participants will receive 6 U of insulin lispro (50 U/mL), coadministered with sequential concentrations of 0, 0.0625, 0.3125, 1.25, 5, and 20 μg/mL rHuPH20.
3255151|NCT00803972|Experimental|Stage 4: 95 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 95 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
3255152|NCT00803972|Experimental|Stage 4: 50 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 50 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
3255473|NCT00801892|Active Comparator|1 subjects treated with CPAP|Continuous Positive Airway Pressure treatment (CPAP)
3255480|NCT00801853|Experimental|Aerovant 2|Aerovant 3mg bid
3255153|NCT00803972|Experimental|Stage 4: 25 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 25 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
3255154|NCT00803959|Active Comparator|No UDS|Women desiring surgery for diagnosed, uncomplicated predominant stress urinary incontinence (UI) who receive a basic office evaluation only.
3255155|NCT00803959|Active Comparator|UDS|Women desiring surgery for diagnosed, uncomplicated predominant stress urinary incontinence (UI) who receive a basic office evaluation with preoperative urodynamic studies prior to surgery.
3255156|NCT00803946|Active Comparator|Test Product|
3255157|NCT00803946|Active Comparator|Reference Product|
3255158|NCT00803933|Experimental|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
3255159|NCT00803933|Active Comparator|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
3255160|NCT00803920||Exenatide|
3255161|NCT00803920||Exenatide LAR|
3255162|NCT00803907|Experimental|nodular BCC of the eyelid|Patients with nodular BCC of the eyelid
3255163|NCT00803894|Active Comparator|A|MK0752 1000 mg
3255164|NCT00803894|Active Comparator|B|MK0752 350 mg
3255165|NCT00803894|Placebo Comparator|C|Placebo
3255166|NCT00803881||CF patients of all age groups|Longitudinal prospective assessment of upper and lower airway colonization in all patients attended in the Jena University CF centre
3255167|NCT00803868|Experimental|1|Varenicline
3255168|NCT00803868|Placebo Comparator|2|Placebo
3255169|NCT00803855|Experimental|AZD1446 Oral or placebo|Single oral administration of AZD1446 or placebo
3255170|NCT00803855|Experimental|AZD1446 Oral, with or without food|Single oral administration of AZD1446 with or without food
3255171|NCT00803816|Other|Addition of everolimus to standard care|refractive to cyclosporine A (CsA) received additional everolimus.
3255172|NCT00803803|Experimental|Pilocarpine Concentration|Varying concentration 0.5 to 8% - 22 patients were examined regarding: visual acuity, iris color, pupil size, chamber angle, C/D ratio, visual field (VF), coefficient of aqueous outflow and Goldmann tonometry. After a one month washout period, pilocarpine was used 4 times daily, in concentrations from 0.5 to 8%. The amount of IOP change was compared with various clinical findings
3255173|NCT00803803|Experimental|Pilocarpine Frequency|Varying frequency, once to four times daily - 15 patients were included in a crossover study: IOP was checked daily for 3 days and for 9 hours on fourth day. Pilocarpine was started on day 5 once daily OD and BID OS; on day 9 once daily OD and QID OS; on day 12 QID OD and once daily OS; on day 16 once daily OD and QID OS; and on day 19 QID OD and once daily OS. No medications were used on days 23-25. IOP was measured on days 4, 8, 11, 15, 18, 22 and 25.
3255174|NCT00803790|Experimental|Sequence 1- alendronate+vitamin D combination then alendronate|Participants in Part 1 received 70mg alendronate+5600 International Units (IU) vitamin D combination tablet in Period 1 followed by 70mg alendronate tablet in Period 2. A washout of at least 12 days separated each treatment period.
3255175|NCT00803790|Experimental|Sequence 2 alendronate then alendronate+vitamin D combination|Participants in Part 1 received 70mg alendronate tablet in Period 1 followed by 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.
3255176|NCT00803790|Experimental|Sequence 3 alendronate+vitamin D combination then vitamin D|Participants in Part 2 received 70mg alendronate+5600 IU vitamin D combination tablet in Period 1 followed by a single dose of 5600 IU vitamin D, administered as two 2800 IU tablets in Period 2. A washout of at least 12 days separated each treatment period.
3255177|NCT00803790|Experimental|Sequence 4- vitamin D then alendronate+vitamin D combination|Participants in Part 2 received a single dose of 5600 IU vitamin D, administered as two 2800 IU tablets in Period 1 followed by a 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.
3255178|NCT00803777|Experimental|Intended Users of the Monitoring System|Subjects with type 1 diabetes and healthcare professionals (HCP) used a new blood glucose monitoring system (BGMS) with subject capillary blood. Any subject under age 18 was accompanied by a parent or guardian, who assisted subject if applicable.
3255179|NCT00803764|Active Comparator|Test Product|
3255180|NCT00803764|Active Comparator|Reference Product|
3255181|NCT00803751|Experimental|Truview intubation|Receive laryngoscopy with Truview first and is immediately followed by laryngoscopy and intubation with Macintosh
3255182|NCT00803751|Active Comparator|Macintosh intubation|Macintosh blade will be used first followed by laryngoscopy and intubation with the truview
3255183|NCT00803738|Experimental|Test Product|Terconazole Vaginal Suppository
3255184|NCT00803738|Active Comparator|Reference Product|Terazol Vaginal Suppository
3255185|NCT00803725|Active Comparator|1|Mepivicaine for spinal anesthesia
3255186|NCT00803725|Experimental|2|Mepivacaine with Fentanyl for spinal anesthesia
3255187|NCT00803712|Experimental|Cinacalcet Group|Cinacalcet plus low dose active Vitamin D (if prescribed)
3255188|NCT00803712|Active Comparator|Control Group|Flexible active vitamin D dosing
3255189|NCT00803699|Placebo Comparator|Placebo|Capsule contains no selenium
3255190|NCT00803699|Active Comparator|Selenium as L-selenomethionine|50, 100, or 200 micrograms of selenium
3255191|NCT00803686|Experimental|Part 1 Double Blind Oral rsCT Tablet|Intervention: Oral rsCT tablet given once 4 hours after evening meal.
3255192|NCT00803686|Placebo Comparator|Part 1, Double-blind Oral Placebo Tablet|Intervention: Oral placebo tablet matching the oral rsCT tablet, given once 4 hours after evening meal
3255193|NCT00803686|Experimental|Part 2 Open label, Oral rsCT tablet|Intervention: Oral rsCT tablet given once 2 hours after evening meal.
3255194|NCT00803686|Active Comparator|Part 2, Open Label Fortical Nasal Spray|Intervention: Part 2 Open label. Fortical (rsCT) nasal spray given once 2 hours after evening meal
3255195|NCT00803673|Experimental|Active|100mcg 719
3255196|NCT00803673|Experimental|Active 2|500mcg '719
3255197|NCT00803673|Experimental|Active 3|1000mcg '719
3255198|NCT00803673|Placebo Comparator|Placebo|Placebo '719
3255199|NCT00803647|Experimental|treatment|mFOLFOX7 (5-FU, leucovorin, oxaliplatin) + cetuximab
3255481|NCT00801853|Experimental|Aerovant 3|Aerovant 10mg bid
3255200|NCT00803634|Experimental|Clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was administered intravenously via a single dedicated line to all patients randomized to the clevidipine arm. Clevidipine was infused at an initial rate of 2 mg/h for the first 3 minutes. If blood pressure was not in the target range at 3 minutes, clevidipine was titrated to effect thereafter by doubling the dose every 3 min, per physician discretion and as tolerated by the patient until the desired effect until the SBP target range was attained. Once target range was achieved, the infusion rate could be increased or decreased as needed to maintain blood pressure for minimum of 30 minutes and a maximum duration of 96 hours. The minimum infusion rate was 1 mg/h and maximum infusion rate was 32 mg/h.
3255201|NCT00803634|Active Comparator|Standard of Care IV antihypertensive|For patients randomized to standard of care (SOC) IV antihypertensive treatment, a continuous infusion of an intravenous antihypertensive agent represented standard of care. The selection of treatment was at the discretion of the investigator. The infusion was to be administered according to the institution's treatment practice.
3255202|NCT00803608|Active Comparator|02|Current standard of care insole
3255203|NCT00803608|Experimental|01|TrueContour® insole
3255204|NCT00803595|Experimental|CS-8958 Low Dose|CS-8958 powder to be inhaled - low-dose arm
3255205|NCT00803595|Experimental|CS-8958 High Dose|CS-8958 powder to be inhaled - high-dose arm
3255206|NCT00803595|Active Comparator|Oseltamivir phosphate|oseltamivir phosphate oral capsules
3255207|NCT00803582|Experimental|Experimental|Traditional acupuncture
3255208|NCT00803582|Sham Comparator|Placebo|Placebo acupuncture
3255209|NCT00803582|No Intervention|No-treatment|no treatment
3255210|NCT00803556|Experimental|Arm 1|"Patients whose last dose is > 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin~Patients whose last dose is < 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin"
3255211|NCT00803556|Experimental|Arm 2|"Patients whose last dose is > 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of paclitaxel and 60 min of infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin~Patients whose last dose is < 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin"
3255212|NCT00803543|Active Comparator|Valacyclovir|This is the arm taking Valacyclovir
3255213|NCT00803543|Placebo Comparator|Placebo|This is the arm taking the placebo
3255214|NCT00803530|Experimental|1|"Loading phase (week 1): ATO 0.3 mg/Kg/die for 5 consecutive days.~Subsequent phase (from week 2 to week 16): ATO 0.25 mg/kg twice a week (day 2 and 5 of every week).~Ascorbic acid 1000 mg IV within 30 minutes after each arsenic trioxide infusion for 16 consecutive weeks."
3255215|NCT00803517||Photodynamic therapy (PDT)|
3255216|NCT00803517||Focal laser photocoagulation (focal)|
3255217|NCT00803491|Experimental|Problem based learning program|PBL intervention - a self-promoting PBL program for patients with rheumatic diseases.
3255218|NCT00803491|Active Comparator|Control group|Traditional rheumatological care.
3255219|NCT00803478|Active Comparator|Hinge position|superior vs. temporal
3255220|NCT00803478|Active Comparator|Hinge width|45 vs 90 degrees
3255221|NCT00803478|Active Comparator|Flap Thickness|110 vs 130 microns
3255222|NCT00803465||Cohort Group 1|Subjects number 1 to 24
3255223|NCT00803465||Cohort Group 2|Subjects number 25 to 44
3255224|NCT00803465||Cohort Group 3|Subjects number 45 to 68
3255225|NCT00803465||Cohort Group 4|Subjects number 69 to 91
3255226|NCT00803465||Cohort Group 5|Subjects Number 92 to 115
3255227|NCT00803452|Active Comparator|Doxycycline|Oral doxycycline
3255228|NCT00803452|Active Comparator|azithromycin|Topical azithromycin daily to the conjunctival culdesac
3255229|NCT00803439||Cohort Group 1|Subjects number 1 to 20
3255230|NCT00803439||Cohort Group 2|Subjects number 21 to 40
3255231|NCT00803439||Cohort Group 3|Subjects number 41 to 60
3255232|NCT00803439||Cohort Group 4|Subjects number 61 to 80
3255233|NCT00803426|Active Comparator|1|Local anesthetic will be injected above the division of the sciatic nerve.
3255234|NCT00803426|Experimental|2|Local anesthetic will be injected below the division of the sciatic nerve, around the common peroneal and tibial nerves.
3255235|NCT00803413|Other|Back School|Participants received weekly sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)
3255236|NCT00803413|Other|Supervised Walking|Participants received weekly sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group
3255237|NCT00803413|Other|Back School and Walking|Participants received weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening); 30 minutes of on-place supervised walking in group
3255238|NCT00803413|Other|Control Group|Participants received weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
3255239|NCT00803400|Active Comparator|Alprazolam|
3255240|NCT00803400|Active Comparator|Alprazolam + Aerobic exercise|
3255482|NCT00801853|Placebo Comparator|Placebo Control|Placebo Control
3255241|NCT00803387||Patients taking Xalatan with ocular dryness or irritation|"patient must already be using xalatan for at least 1 month prior to study enrollment in both eyes and have complaints of dry eye and/or irritation.~any race and of either sex, diagnosed with open angle glaucoma (OAG) (with or without pseudoexfoliation or pigment dispersion components) or ocular hypertension (OHT)"
3255242|NCT00803374|Experimental|0.1 mg/kg|
3255243|NCT00803374|Experimental|0.3 mg/kg|
3255244|NCT00803374|Experimental|1.0 mg/kg|
3255245|NCT00803374|Experimental|3.0 mg/kg|
3255246|NCT00803374|Experimental|10 mg/kg|
3255247|NCT00803361|Experimental|Duloxetine|
3255248|NCT00803361|Placebo Comparator|Placebo|
3255249|NCT00803348|Active Comparator|1|Initial Bolus dose of 0.2% ropivicaine followed by 0.2% ropivicaine infusion until day 2 post-op
3255250|NCT00803348|Experimental|2|Initial Bolus dose of 0.2% ropivicaine followed by 0.1% ropivicaine infusion until day 2 post-op
3255251|NCT00803348|Placebo Comparator|3|Initial Bolus dose of 0.375% ropivicaine followed by saline infusion until day 2 post-op
3255252|NCT00803335|Active Comparator|Premarin cream 0.5gm|Application of 0.5gm of vaginal estrogen cream nightly until surgery.
3255253|NCT00803335|Active Comparator|Premarin cream 1.0gm|Application of 1.0gm of vaginal estrogen cream nightly until surgery.
3255254|NCT00803335|No Intervention|No intervention|Women in this arm will not apply any cream or moisturizers to the vagina until surgery, ie no intervention.
3255255|NCT00803322||1|communities where tuberculosis patients followed the conventional health facility based tuberculosis case finding and treatment
3255256|NCT00803322||2|community where suspects of pulmonary tuberculosis were identified by community health workers and received treatment in the community
3255257|NCT00803309|Active Comparator|A|PegIntron® 1.5 µg/kg once weekly (QW) subcutaneous (sc) plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 24 weeks beyond standard treatment with 24 weeks follow-up
3255258|NCT00803309|Active Comparator|B|PegIntron® 1.5 µg/kg QW sc plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 12 weeks beyond standard treatment with 24 weeks follow-up
3255259|NCT00803296||Obese patients with type 2 diabetes|Patients with type 2 diabetes and BMI>33
3255260|NCT00803296||Obese subjects with normal glucose tolerance|Subjects with normal glucose tolerance and BMI>33
3255261|NCT00803296||Lean subjects with type 2 diabetes|Patients with type 2 diabetes and BM<25
3255262|NCT00803296||Lean subjects with normal glucose tolerance|Subjects with normal glucose tolerance and BM<25
3255263|NCT00803283|Experimental|Hydromprphone Hydrochloride (HCl) OROS|Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
3255264|NCT00803283|Active Comparator|Morphine Sustain Release (SR)|Participants will receive morphine SR 8 mg every 24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
3255265|NCT00803270|Active Comparator|Surgical Treatment|Surgical treatment will consist of the following evidence-based stress incontinence procedures: mid-urethral slings (TVT, TOT, TVT-O), fascial slings, and Burch colposuspension.
3255266|NCT00803270|Active Comparator|Non Surgical Treatment|"The non-surgical treatment will include two components:~Pharmacological therapy with any FDA approved overactive bladder (OAB) drug in approved doses; and~Behavioral therapy."
3255267|NCT00803257|Experimental|1|Lumbrical splint and lumbrical stretches
3255268|NCT00803257|Active Comparator|2|Lumbrical Splint and regular exercises
3255269|NCT00803257|Active Comparator|3|Regular splint and lumbrical exercises
3255270|NCT00803257|Active Comparator|4|Regular splint and regular exercises
3255271|NCT00803244|Experimental|300 IR|300 IR grass pollen allergen extract tablet
3255272|NCT00803244|Placebo Comparator|Placebo|Placebo tablet
3255273|NCT00803231||Retrospective cohort|Patient treated with Xigris between January 2006 and November 2008.
3255274|NCT00803231||Prospective cohort|Patient treated with Xigris between November 2008 and November 2009.
3255275|NCT00803218||Cohort Group 1|Subjects number 1 to 26
3255276|NCT00803218||Cohort Group 2|Subjects number 27 to 56
3255277|NCT00803205|Experimental|Ataluren (PTC124)|10-,10-,20-mg/kg TID at morning, midday and evening doses for 48 weeks.
3255278|NCT00803205|Placebo Comparator|Placebo|10-,10-,20-mg/kg TID at morning, midday and evening doses for 48 weeks.
3255279|NCT00803192|Active Comparator|Test Drug|
3255280|NCT00803192|Active Comparator|Reference Drug|
3255281|NCT00803179|Experimental|Growth Hormone Therapy|"Nutropin Aqueous (AQ):~Initiation treatment for adult males is 0.2mg/d and for women 0.4mg/d"
3255282|NCT00803166||Cohort Group 1|Subjects number 1 to 30
3255283|NCT00803166||Cohort Group 2|Subjects number 31 to 60
3255284|NCT00803140|Active Comparator|Cautery Arm|Cautery to make skin incision
3255285|NCT00803140|Active Comparator|Scalpel Incision|Scalpel to make skin incision
3255286|NCT00803127||no treament|
3255287|NCT00803114|Experimental|Epidural Morphine|2.5 mg dose of epidural morphine given within one hour following vaginal delivery
3255288|NCT00803114|Placebo Comparator|Placebo|5 ml of epidural preservative-free saline given within one hour following vaginal delivery
3255289|NCT00803101|Experimental|Beriplex® P/N|
3255290|NCT00803101|Active Comparator|Fresh frozen plasma|
3255291|NCT00803088|Experimental|1|Treatment of airways with the Alair System
3255292|NCT00803062|Active Comparator|Arm I (paclitaxel and cisplatin)|Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV on day 1 or 2.
3255293|NCT00803062|Experimental|Arm II (paclitaxel, cisplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV and bevacizumab IV over 30-90 minutes on day 1 or 2.
3255294|NCT00803062|Experimental|Arm III (topotecan hydrochloride and paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
3255295|NCT00803062|Experimental|Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab)|Patients receive paclitaxel IV over 3 hours and bevacizumab IV over 30-90 minutes on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
3255296|NCT00803049|Experimental|Placebo/Teriflunomide 7 mg|Participants who completed treatment of placebo (for teriflunomide) tablet once daily (QD) for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.
3255297|NCT00803049|Experimental|Teriflunomide 7 mg/7 mg|Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.
3255298|NCT00803049|Experimental|Placebo/Teriflunomide 14 mg|Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.
3255299|NCT00803049|Experimental|Teriflunomide 14 mg/14 mg|Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.
3255300|NCT00803023|Experimental|1|Sodium Oxybate Oral Solution (4.5 grams)
3255301|NCT00803023|Experimental|2|Sodium Oxybate taken as a combination of an Oral Solution and Placebo Tablets (4.5 grams)
3255302|NCT00803023|Experimental|3|Sodium Oxybate Oral Solution (6 grams)
3255303|NCT00803023|Experimental|4|Sodium Oxybate taken as a combination of an Oral Solution and Placebo Tablets (6 grams)
3255304|NCT00803010|Active Comparator|Tacrolimus / Rapamycin (TAC/RAPA)|"Tacrolimus: beginning 3 days before transplant and given for at least 50 days.~Rapamycin: given the day before transplant and continued daily for at least one year."
3255305|NCT00803010|Active Comparator|Tacrolimus / Methotrexate (TAC/MTX)|"Tacrolimus: beginning 3 days before transplant and given for at least 50 days.~Methotrexate: given on days 1, 3, 6 and 11, after transplant."
3255306|NCT00802997|Active Comparator|1|Treatment with Sinergy system
3255307|NCT00802997|Placebo Comparator|2|placebo controlled
3255308|NCT00802971|Experimental|1: FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
3255309|NCT00802971|No Intervention|2: Control|
3255310|NCT00802958||Cohort Group 1|Subjects number 1 to 30
3255311|NCT00802958||Cohort Group 2|Subjects number 31 to 56
3255312|NCT00802958||Cohort Group 3|Subject Numbers 57 to 76
3255313|NCT00802945|Experimental|NKTR-102 q14d|NKTR-102
3255314|NCT00802945|Experimental|NKTR-102 q21d|NKTR-102
3255315|NCT00802932||Partial Breast Radiation|1. Patients receiving Partial breast radiation
3255316|NCT00802932||Whole Breast Radiation|2. Patients receiving whole breast radiation
3255317|NCT00802919|Experimental|Varenicline|Varenciline 1-2 mg/day
3255318|NCT00802919|Placebo Comparator|Matched Placebo|placebo for varenicline
3255319|NCT00802906|Active Comparator|1|1.5 mg bevacizumab single injection and on demand if leakage is persistent or recurs
3255320|NCT00802906|Active Comparator|2|initial selective subthreshold micropulselasercoagulation and on demand if leakage is persistent or recurs
3255321|NCT00802906|No Intervention|3|control
3255322|NCT00802893|Experimental|Experimental Drug|
3255323|NCT00802893|Placebo Comparator|Placebo Comparator|
3255324|NCT00802880|Experimental|Dacarbazine|Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.
3255325|NCT00802867|Experimental|1|Subjects in Study 494-01 and Study 494-03 who had received 4 doses of Pentacel™ vaccine.
3255326|NCT00802841|Experimental|Nilotinib|Participants received 400 mg nilotinib twice daily (BID).
3255327|NCT00802841|Active Comparator|Imatinib|Participants received 600 mg imatinib once daily (QD).
3255328|NCT00802828|Active Comparator|Test Product|
3255329|NCT00802828|Active Comparator|Reference Product|
3255330|NCT00802815|Experimental|Etanercept|
3255331|NCT00802802|Experimental|Cohort I, Step 1|HIV-infected children 3 months to 36 months of age, receiving EFV and two NRTIs
3255332|NCT00802802|Experimental|Cohort II|HIV/TB-coinfected children 3 months to 36 months of age, receiving EFV, two NRTIs, and rifampin-containing anti-tuberculosis (anti-TB) therapy
3255333|NCT00802802|Experimental|Cohort I, Step 2|HIV-infected children from Cohort I who become coinfected with TB during the study. They will receive EFV, two NRTIs, and rifampin-containing anti-TB therapy
3255334|NCT00802789||1|Mild to moderate adult asthmatics (≥18years of age) insufficiently treated with ICS or ICS + LABA.
3255335|NCT00802776|Active Comparator|FLAK|Femtosecond laser assisted keratoplasty
3255336|NCT00802776|Active Comparator|PKP|Penetrating Keratoplasty
3255337|NCT00802763||vaginitis|
3255338|NCT00802737|Experimental|Ofatumumab|Eight once weekly infusions (1 x 300 mg + 7 x 2000 mg), then 2000 mg once monthly for two years
3255339|NCT00802724|Experimental|1 Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
3255340|NCT00802724|Active Comparator|2 Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
3255341|NCT00802711|Experimental|Arm I|Patients undergo accelerated partial breast irradiation (APBI) using 3-dimensional conformal radiation therapy twice daily over 5-10 days (total of 10 fractions) in the absence of disease progression or unacceptable toxicity.
3255342|NCT00802711|Experimental|Arm II|Patients undergo APBI using multi-catheter interstitial brachytherapy twice daily over 5-10 days (total of 10 fractions) in the absence of disease progression or unacceptable toxicity.
3255344|NCT00802685|Experimental|early ibuprofen|"Drug: Early ibuprofen~IBUPROFEN DOSING SCHEDULE: At the diagnosis of PDA, infants randomized to early treatment will receive blinded ibuprofen initial dose 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy will be blinded. This group will then be eligible to receive unblinded, open label ibuprofen for a hemodynamically significant PDA include: SIGNS OF PDA + Presence of significant pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (not due to something other than PDA) defined as at least two of the following respirator settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV."
3255345|NCT00802685|Other|Late Ibuprofen expectant group (placebo)|"Late ibuprofen expectant group (placebo): Ibuprofen schedule: At PDA diagnosis, infants randomized to late expectant group will receive blinded placebo. If hemo-dynamically significant PDA develops, infants now receive open label ibuprofen, initial dose of 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA: Signs of PDA + pulmonary hemorrhage alone or Signs of PDA + Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following respirator settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV. Infants who had received placebo will ibuprofen for the first time (thus, late ibuprofen or expectant)."
3255346|NCT00802672|Experimental|Test Product|Ciclopirox Olamine Cream 0.77%
3255347|NCT00802672|Active Comparator|Reference Product|Loprox Cream 0.77%
3255348|NCT00802672|Placebo Comparator|Vehicle Product|placebo of test product
3255349|NCT00802659|Experimental|Group -1|1000 cGY radiation
3255350|NCT00802659|Experimental|Group 1|1200 cGY radiation
3255351|NCT00802659|Experimental|Group 2|1400 cGY radiation
3255352|NCT00802659|Experimental|Group 3|1600 cGY radiation
3255353|NCT00802646|Experimental|1|When it is time for the epidural catheter, the mother will receive 2.5 mcg fentanyl spinally and then a bag of preservative-free normal saline will be administered through the epidural pump. When additional pain medication is requested, the mother will receive a known combined spinal epidural solution.
3255354|NCT00802646|Active Comparator|2|When it is time for the epidural catheter, the mother will receive 2.5 mcg fentanyl spinally and then a bag of combined spinal epidural anesthetic through the epidural pump. When additional pain medication is requested, the mother will receive a known combined spinal epidural solution.
3255355|NCT00802633|Active Comparator|Stapling device|Efficacy of stapling device during radical cystectomy
3255356|NCT00802633|Active Comparator|Ligasure Device|Efficacy of ligasure tissue sealing device during radical cystectomy
3255357|NCT00802594|Experimental|DB289|
3255358|NCT00802581|Experimental|1|Ensuring circumferential spread of local anesthetic around the sciatic nerve.
3255359|NCT00802581|Active Comparator|2|Single shot injection of local anesthetic near the sciatic nerve will be performed, without ensuring circumferential spread.
3255360|NCT00802555|Experimental|ARQ 197|
3255361|NCT00802542||1|Adult patients with mild or moderate essential hypertension who do not tolerate ACE inhibitors because of cough, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal and the doctor has decided to increase the Atacand dose to 16mg as per SmPC.
3255362|NCT00802529|Experimental|Steroid (Methylprednisolone)|
3255363|NCT00802529|Active Comparator|Gentamicin|
3255364|NCT00802516|Placebo Comparator|1. placebo|placebo margarine
3255365|NCT00802516|Experimental|2. stanol ester|margarine with plant stanol ester
3255366|NCT00802516|Experimental|3. sterol ester|margarine with plant sterol ester
3255367|NCT00802503|Experimental|SPN group|"experimental arm: Supplemental Parenteral Nutrition (SPN) is added to enteral nutrition (EN) to reach 100% of their predicted energy needs from ICU day 4.~In the treated group, SPN is started if at day 4 energy input by EN is < 60% of energy target in order to reach 100% of energy target by peripheral or central line. Nutritional products as currently used in our institution. SPN is composed of EN and PN, both techniques being currently used in our institution."
3255368|NCT00802503|No Intervention|Control gr|EN : start EN at 20-30 ml/h per day up to maximal 150 ml/h per day; or day1: 500 ml, day2: 1000 ml, day3: 1500 ml of EN dependant on gastrointestinal tolerance (gastric residue volume more than 500ml). Nutritional products as currently used in our institution.
3255369|NCT00802490|Active Comparator|Intervention|20 sessions of EEG biofeedback training
3255370|NCT00802490|Placebo Comparator|Control|Only 1 session of EEG biofeedback training
3255371|NCT00802477|Experimental|1|Application of Autologous Blood Products to surgical site during mastectomy.
3255372|NCT00802477|Active Comparator|2|Standard Modified Radical Mastectomy
3255373|NCT00802464|Experimental|GSK1437173A formulation 1 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
3255374|NCT00802464|Experimental|GSK1437173A formulation 2 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) GSK1437173A formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
3255375|NCT00802464|Experimental|GSK1437173A formulation 3 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
3255376|NCT00802464|Placebo Comparator|Control Group|Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
3255377|NCT00802451|Active Comparator|Test Drug|
3255378|NCT00802451|Active Comparator|Reference Drug|
3255379|NCT00802438|Experimental|Mepolizumab|up to 3 monthly doses of 750mg i.v. mepolizumab
3255380|NCT00802425|Experimental|2|AM-111 low dose
3255381|NCT00802425|Placebo Comparator|1|
3255382|NCT00802425|Experimental|3|AM-111 high dose
3255474|NCT00801892|Sham Comparator|2 subjects treated with sham-CPAP|Sham Continuous Positive Airway Pressure treatment (sham-CPAP)
3255688|NCT00800293||Cohort Group 3|Subject Numbers 60 to 89
3255383|NCT00802412|Other|Topiramate|The subjects for the proposed study will be 180 currently smoking, treatment-seeking male veterans with alcohol and nicotine dependence. Ninety subjects will be randomized to the topiramate arm and 90 subjects will be randomized to the placebo group.
3255384|NCT00802412|Placebo Comparator|Placebo|90 participants, will receive matching placebo
3255385|NCT00802399|Other|Partial Lacrimal Punctual Occlusion|Cauterization of the edge of all lacrimal punctum was carried out in all patients
3255386|NCT00802373|Experimental|I|Solifenacin succinate 5/10mg
3255387|NCT00802373|Experimental|II|Tolterodine 4mg
3255388|NCT00802360|Experimental|Menopur/Endometrin|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progestrone vaginal insert (Endometrin®) starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
3255389|NCT00802360|Experimental|Menopur/Progesterone in Oil|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in Oil injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
3255390|NCT00802360|Active Comparator|Follistim/Endometrin|"Follitropin beta (Follistim®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progestrone vaginal insert (Endometrin®) starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
3255391|NCT00802360|Active Comparator|Follistim/Progesterone in Oil|"Follitropin beta (Follistim®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in Oil injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
3255392|NCT00802347|Experimental|I5NP|
3255393|NCT00802347|Placebo Comparator|Saline|
3255394|NCT00802334|Experimental|1|
3255395|NCT00802321|Experimental|dutasteride|
3255396|NCT00802308|Experimental|Treatment A|Single dose administration of Egalet® morphine with alcohol
3255397|NCT00802308|Experimental|Treatment B|Single dose administration of Egalet® morphine with alcohol
3255398|NCT00802308|Experimental|Treatment C|Single dose administration of Egalet® morphine with alcohol
3255399|NCT00802308|Placebo Comparator|Treatment D|Single dose administration of Egalet® morphine with water
3255400|NCT00802295|Active Comparator|standard dosis protocol|Administration of standard dosis of gonadotrophins for ovarian stimulation.
3255401|NCT00802295|Experimental|2|Administration of low dosis of Gonadotrophins for ovarian stimulation
3255402|NCT00802282|Experimental|1|First of 5 groups, as described in the protocol and to which volunteers are blinded
3255403|NCT00802282|Experimental|2|Second of 5 groups, as described in the protocol and to which volunteers are blinded
3255404|NCT00802282|Experimental|3|Third of 5 groups, as described in the protocol and to which volunteers are blinded
3255405|NCT00802282|Experimental|4|Fourth of 5 groups, as described in the protocol and to which volunteers are blinded
3255406|NCT00802282|Experimental|5|Fifth of 5 groups as described in the protocol and to which volunteers are blinded
3255407|NCT00802269|Experimental|Reduced Fluence Parameters|Eyes receiving retinal photocoagulation with reduced fluence parameters (time 20-50 msec, power 400-700 mW)
3255408|NCT00802269|Active Comparator|Traditional parameters|Eyes receiving retinal photocoagulation with traditional parameters (time 100-200 msec, power 200-400 mW)
3255409|NCT00802256|Experimental|A|teeth which are treated with Mineral Trioxide Aggregate (MTA) material
3255410|NCT00802256|Experimental|B|teeth which are treated with new Endodontic Cement (NEC) material
3255411|NCT00802230|Active Comparator|1|Carvedilol IR
3255412|NCT00802230|Active Comparator|2|Metoprolol Succinate
3255413|NCT00802217|Active Comparator|Cohort 1|Civamide liquid filled softgel capsule 5 mg
3255414|NCT00802217|Active Comparator|Cohort 2|Civamide liquid filled soft gel capsules 2 x 5 mg
3255415|NCT00802204|Active Comparator|Lean controls|Lean complete baseline outcome measures only
3255416|NCT00802204|Experimental|Obese|Obese completing baseline and post-VLCD outcome measures
3255417|NCT00802191||Control Group|Participants with no movement disorders.
3255418|NCT00802191||Movement Disorders Participants|Participants have a movement disorder
3255419|NCT00802165|Experimental|Electroacupuncture Treatment Group|Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness
3255420|NCT00802165|Sham Comparator|Sham Treatment Group|Sham electroacupuncture treatment gives comparison to the experimental group
3255421|NCT00802152|Experimental|Home Monitoring|100 eligible subjects identified as (HbA1c >= 8% OR SBP > 130 mm Hg)
3255422|NCT00802152|No Intervention|Usual Care|100 eligible subjects identified as (HbA1c >= 8% OR SBP > 130 mm Hg)
3255423|NCT00802139|Experimental|venoferrum group|
3255424|NCT00802139|Active Comparator|Bolgre group|
3255425|NCT00802126|Experimental|Bevacizumab and verteporfin|
3255426|NCT00802113|Experimental|Arm A|Fludarabine and Busulfan: Patients who have a matched family (allogeneic) donor will go on to receive non-ablative therapy, followed by an infusion of donor stem cells; this is called an allogeneic peripheral blood stem cell transplant. The non-ablative therapy will be busulfan and ﬂudarabine, Usually large (myeloablative) doses of these drugs are used for an allogeneic transplant. However, in this study lower doses (non-ablative) of chemotherapy will be given. In patients who still have evidence of disease after allogeneic transplant, additional donor immune cells (donor lymphocyte infusion) (DLI) will be given twice to further treat the lymphoma.
3255475|NCT00801879|Active Comparator|Mupirocin ointment|0.25g mupirocin calcium ointment, 2% in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
3255476|NCT00801879|Placebo Comparator|Placebo ointment|0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
3255477|NCT00801866|Experimental|Group 1|Panretinal Photocoagulation + Bevacizumab
3255478|NCT00801866|Experimental|Group 2|Panretinal Photocoagulation
3255427|NCT00802113|Experimental|Arm B|Fludarabine, Busulfan and ATG: For patients who don't have a matched family donor, a cord blood search and unrelated adult search will be done at all of the cord blood banks and adult donor registries in the world. If a closely matched cord blood donor or unrelated adult donor is found, non-ablative chemotherapy with busulfan, ﬂudarabine and antithymocyte globulin followed by the infusion of matched unrelated cord blood cells or adult donor stem cells or bone marrow to restore the bone marrow will be given.
3255428|NCT00802100|Experimental|Olanzapine|Participants will receive treatment with olanzapine and metformin, with the possible addition of simvastatin or benztropine, depending on side effects.
3255429|NCT00802100|Experimental|Perphenazine|Participants will receive treatment with perphenazine and benztropine, with the possible addition of simvastatin or metformin, depending on side effects.
3255430|NCT00802100|Experimental|Aripiprazole|Participants will receive treatment with aripiprazole, with the possible addition of simvastatin, metformin, or benztropine, depending on side effects.
3255431|NCT00802087|Experimental|Egalet® hydrocodone treatment A|Single Dose administration
3255432|NCT00802087|Experimental|Egalet® hydrocodone Treatment B|Single Dose Administration
3255433|NCT00802087|Experimental|Egalet® hydrocodone Treatment C|Single Dose Administration
3255434|NCT00802087|Experimental|Egalet® hydrocodone Treatment D|Single Dose Administration
3255435|NCT00802087|Active Comparator|Active Comparator|Single Dose Administration
3255436|NCT00802074|Active Comparator|Group A|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 1400mg BID Period 3- Fosamprenavir 1400mg BID + Raltegravir 400mg BID
3255437|NCT00802074|Active Comparator|Group B|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg BID + Raltegravir 400mg BID Period 3 Fosamprenavir 1400mg BID
3255438|NCT00802074|Active Comparator|Group C|Period 1-Raltegravir 400mg BID Period2- Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3- Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID
3255439|NCT00802074|Active Comparator|Group D|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID
3255440|NCT00802074|Active Comparator|Group E|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3- Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID
3255441|NCT00802074|Active Comparator|Group F|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
3255442|NCT00802048|Experimental|1|48h postoperative infusion of ropivacaine
3255443|NCT00802048|Placebo Comparator|2|48h postoperative infusion of NaCl.
3255444|NCT00802035|Active Comparator|IR am|30 mg, single dose, morning administration (immediate release [IR])
3255445|NCT00802035|Experimental|ER am|30 mg; single dose; morning administration (extended release [ER])
3255446|NCT00802035|Experimental|ER pm|30 mg; single dose; evening administration
3255447|NCT00802035|Active Comparator|IR pm|30 mg; single dose; evening administration
3255448|NCT00802009|Experimental|1|Dexamethasone 8mg added to routine local anesthetic during brachial plexus blockade.
3255449|NCT00802009|Active Comparator|2|Routine anesthetic solution (30 cc 1.5% mepivicaine) used during brachial plexus blockade.
3255450|NCT00801996||1. Prostate Cancer|"Inclusion Criteria:~All study subjects should be able to provide informed consent~Males ages 40 years or older~Individuals from the Qatari Peninsula whose ancestors up to three generations back were natives of Qatar.~Individuals undergoing Trans Rectal Ultrasound (TRUS) biopsy as dictated by their standard clinical care~Ultrasound OR digital rectal examination consistent with prostate disease OR A level of PSA (Prostatic Specific Antigen) greater than 3.0~Exclusion Criteria:~• Patient refuses consent"
3255451|NCT00801996||2. Normal Healthy Controls|"Inclusion Criteria:~All study subjects should be able to provide informed consent~Males or females ages 40 years or older (see section A8 for the rationale for the inclusion of females)~Individuals of Arab descent from Qatari peninsula without any personal or family history of prostate cancer~Exclusion Criteria:~Individuals with family history of prostate cancer~Individuals not deemed in good overall health by the investigator will not be accepted into the study"
3255452|NCT00801983|Experimental|A|Subject receives typical keyboard first for 6 months and alternative keyboard second for 6 months
3255453|NCT00801983|Experimental|B|Subject receives alternative keyboard first for 6 months and typical keyboard second for 6 months
3255454|NCT00801970|Experimental|1 - Pregnant - Tokophobic|Psychoanalysis treatment.
3255455|NCT00801970|Experimental|2 - Pregnant - Tokophobic|Cognitive-Behavioral treatment.
3255456|NCT00801970|Experimental|3 - Non-pregnant - Tokophobic|Group Therapy
3255457|NCT00801970|No Intervention|4 - Control|Pregnant and non-pregnant non-tokophobic women will answer questionnaires. Won't receive therapy.
3255458|NCT00801957|Experimental|1|tacrolimus ointment 0.03%
3255459|NCT00801957|Active Comparator|2|hydrocortisone acetate 1% and butyrate 0.1%
3255460|NCT00801957|Other|3|Control group vaccination and challenge dose only
3255461|NCT00801944|Experimental|I|Solifenacin succinate 5/10mg
3255462|NCT00801944|Experimental|II|Placebo
3255463|NCT00801931|Experimental|A|
3255464|NCT00801931|Experimental|B|
3255465|NCT00801931|Experimental|C|
3255466|NCT00801931|Experimental|D|
3255467|NCT00801931|Experimental|E|
3255468|NCT00801931|Experimental|F|
3255469|NCT00801918|Other|DD Alone|Patients will get Denileukin Diftitox for 5 days every 3 weeks for a total of 4 cycles.
3255470|NCT00801918|Experimental|DD with ICE Chemotherapy|For patients who show a response to DD alone after 4 cycles or for patients who show progressive disease after 2 cycles, DD will be given with ICE chemotherapy for 2 cycles.
3255471|NCT00801905|Active Comparator|1: Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
3255472|NCT00801905|Placebo Comparator|2: placebo|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
3255483|NCT00801827|Experimental|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET) scans of their brains using F-18 (fallypride), a dopamine type 2/3 (DA D2/3) receptor radioligand whose binding is sensitive to competition with endogenous dopamine, before and after the operation.
3255484|NCT00801814|Placebo Comparator|1|White Bread
3255485|NCT00801814|Placebo Comparator|2|White Bread and Margarine Control
3255486|NCT00801814|Placebo Comparator|3|Glucose drink control
3255487|NCT00801814|Experimental|4|"White bread and margarine~or~Glucose drink"
3255488|NCT00801814|Experimental|5|"White bread and margarine~or~Glucose drink"
3255489|NCT00801814|Experimental|6|"White bread and margarine~or~Glucose drink"
3255490|NCT00801801|Experimental|Metronomic Docetaxel + Sorafenib|"Subjects with advanced non-squamous cell non-small cell lung cancer with poor performance status will receive treatment in this non-randomized, open-label Phase II Study of Metronomic Chemotherapy (docetaxel) plus sorafenib as first-line therapy.~Subjects will be treated with metronomic chemotherapy with low dose docetaxel weekly for 3 out of 4 weeks, and sorafenib will be administered continuously 400 mg bid on a 28 day cycle. Treatment with metronomic chemotherapy will be expressed as a 4-week cycle."
3255491|NCT00801788|Experimental|Egalet® oxycodone Treatment A|Single Dose Administration
3255492|NCT00801788|Experimental|Egalet® oxycodone Treatment B|Single Dose Administration
3255493|NCT00801788|Experimental|Egalet® oxycodone Treatment C|Single Dose Administration
3255494|NCT00801788|Active Comparator|Active comparator|Single Dose Administration
3255495|NCT00801736|Experimental|Platinum Arm|Cisplatin (IMP) / Pemetrexed (IMP)
3255496|NCT00801736|Experimental|Non Platinum Arm|Paclitaxel (IMP) / Pemetrexed (IMP)
3255497|NCT00801723|Experimental|1: Budesonide MMX® 6 mg|One Budesonide-MMX® 6 mg tablet self-administered by the patients with a glass of water, in the morning after breakfast.
3255498|NCT00801723|Placebo Comparator|2: Placebo|One placebo tablet self-administered by the patients with a glass of water, in the morning after breakfast.
3255499|NCT00801710|Experimental|BridgePoint Medial System|
3255500|NCT00801697|Experimental|1A|rAD5-naive participants will receive rAd35 intramuscularly at study entry and rAd5 intramuscularly at Month 6
3255501|NCT00801697|Placebo Comparator|1B|Participants will receive rAd35 placebo intramuscularly at study entry and rAd5 placebo intramuscularly at Month 6
3255502|NCT00801697|Experimental|2A|rAD5-naive participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd5 intramuscularly at Month 6
3255503|NCT00801697|Placebo Comparator|2B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd5 placebo intramuscularly at Month 6
3255504|NCT00801697|Experimental|3A|Participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd35 intramuscularly at Month 6
3255505|NCT00801697|Placebo Comparator|3B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd35 placebo intramuscularly at Month 6
3255506|NCT00801697|Experimental|4A|Participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd35 intramuscularly at Month 6
3255507|NCT00801697|Placebo Comparator|4B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd35 placebo intramuscularly at Month 6
3255508|NCT00801684|Placebo Comparator|Placebo|Represents Dose A in the Dosing Sequence assignments.
3255509|NCT00801684|Experimental|TrIP-2D (100mcg)|Represents Dose B
3255510|NCT00801684|Experimental|TrIP-2SS (100mcg)|Represents Dose C
3255511|NCT00801684|Experimental|TrIP-2D (400mcg)|Represents Dose D
3255512|NCT00801684|Experimental|TrIP-2SS (100mcg) + Foradil (12mcg)|Represents Dose E. All subjects received Dose E as their final (5th) dose, after completing their initial 4 single doses according to their sequence assignment.
3255513|NCT00801671|Active Comparator|1|
3255514|NCT00801671|Sham Comparator|2|
3255515|NCT00801645|Experimental|Obese exercise|
3255516|NCT00801645|No Intervention|Obese Control|
3255517|NCT00801645|Experimental|Lean Exercise|
3255518|NCT00801645|No Intervention|Lean Control|
3255519|NCT00801632|Experimental|Kidney and Marrow Recipients|Combined kidney and bone marrow transplant
3255520|NCT00801619||Intervention|Receive decision support when reviewing bilirubin results in the clinical information systems/electronic health record
3255521|NCT00801619||Control|No decision support
3255522|NCT00801606|Experimental|Study drug containing zinc alone|Zinc 20 mg daily
3255523|NCT00801606|Experimental|Study drug Micronutrient without zinc|micronutrients (vitamin A, thiamine, riboflavin, vitamins B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, and copper) without zinc.
3255524|NCT00801606|Experimental|Study drug Micronutrient with zinc|micronutrients in combination with zinc (vitamin A, thiamine, riboflavin, vitamin B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, copper, and 20 mg elemental zinc).
3255525|NCT00801606|Placebo Comparator|Placebo|Placebo only
3255526|NCT00801593||Children with JIA|
3255527|NCT00801580|Experimental|1|The patient receive 2 different drug combinations on this study. The first combination will consist of an intensive chemotherapy regimen (cyclophosphamide, mesna, methotrexate, doxorubicin liposomal or doxorubicin, vincristine, ARA-C (cytarabine) and dexamethasone). The second combination will consist of another intensive chemotherapy regimen (methotrexate and Ara-C [cytarabine]).
3255528|NCT00801567|Experimental|1|All subjects will receive the intervention (MRS scan).
3255529|NCT00801554||ASD|Children and adults with Autism Spectrum Disorders.
3255530|NCT00801554||Non-ASD|Healthy volunteers who have never been diagnosed with an Autism Spectrum Disorder in their lifetime.
3255531|NCT00801541||AMD|Patients with wet AMD in one eye and dry AMD in the other eye (study eye).
3255532|NCT00801528|Active Comparator|Ropivacaine|Continuous wound instillation of ropivacaine 0.2 % at a rate set of 10 mL/hr
3255533|NCT00801528|Active Comparator|Diclofenac|Continuous wound instillation of diclofenac (300 mg/240 ml water for injection) at a rate set of 10 mL/hr
3255534|NCT00801528|Placebo Comparator|Water for injection|Continuous wound instillation of water for injection at a rate set of 10 mL/hr
3255535|NCT00801502|Other|Control|No change in diet
3255536|NCT00801502|Active Comparator|Oily fish|Two portions of salmon per week from week 20 of pregnancy until giving birth
3255537|NCT00801489|Experimental|Remission Induction Group|Fludarabine by vein on Days 1, 2, 3, 4, and 5. Cytarabine by vein on Days 1, 2, 3, 4, and 5 infusion starting 3.5 hours after the completion of Fludarabine. Gemtuzumab ozogamicin by vein over on Day 1.Idarubicin by vein given immediately after Fludarabine administration on Days 3 and 4. Filgrastim starting Day -1 till recovery of absolute neutrophil count (ANC) to 1.0 X 10^9/L or above. (Filgrastim started after WBC count is < 5 X 10^9/L for patients with presenting WBC count > 10 X 10^9/L).
3255538|NCT00801489|Experimental|Post-Remission Therapy Group|Fludarabine, Cytarabine, and Filgrastim as during induction except that Fludarabine and Cytarabine given for 3, rather than 5 days. Idarubicin administered as in induction cycle, in one post-remission cycle (from cycle 3-6). Idarubicin given immediately after Fludarabine administration on Days 2 and 3. Filgrastim given on Day -1 of each post-remission cycle irrespective of WBC count. Gemtuzumab ozogamicin as in induction cycle, in post-remission cycle 1 or 2 and cycle 5 or 6.
3255539|NCT00801463|Experimental|Large pred|Prednisone 60mg/d*8 wks
3255540|NCT00801463|Experimental|small pred|Pred 30mg/d*8wks
3255541|NCT00801450|Experimental|Intravitreal (IVI)|
3255542|NCT00801450|Experimental|SubTenon´s (STI)|
3255543|NCT00801437||Xalacom treatment|patients with primary glaucoma
3255544|NCT00801424|Experimental|standard heating|Standard intraoperative warming measures including heated sheets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
3255545|NCT00801411|Experimental|Arm I|Patients receive cyclophosphamide IV and docetaxel IV over 1 hour on day 1.
3255546|NCT00801411|Active Comparator|Arm II|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1.
3255547|NCT00801398|Experimental|Oxymorphone IR|Open-Label, 2 part ascending-dose multicenter study
3255548|NCT00801372||Pre-existing Fibroblast MCB|Pre-existing fibroblast donors for hESC derivation project
3255549|NCT00801359|Active Comparator|BSSplus|
3255550|NCT00801359|Experimental|Ringer|
3255551|NCT00801320|Experimental|Cohort 1|Patients with either primary ovarian carcinoma or ovarian carcinoma in first relapse treated with DC/Ovarian tumor cells + GM-CSF
3255552|NCT00801320|Experimental|Cohort 2|Patients with either primary ovarian carcinoma or ovarian carcinoma in first relapse treated with DC/Ovarian tumor cells + GM-CSF and topical Imiquimod at site of vaccination
3255553|NCT00801307|Experimental|1|He/O2 78:22
3255554|NCT00801307|Experimental|2|He/O2 65:35
3255555|NCT00801307|Active Comparator|3|Medical Air
3255556|NCT00801281|Active Comparator|R-CVP|Standard arm 1. R-CVP - Rituximab, Cyclophosphamide, Vincristine, Prednisone 2
3255557|NCT00801281|Experimental|R-CHOP|Study arm 2. R-CHOP - Rituximab, Cyclophosphamide, Hydroxyldaunorubicine (doxorubicin), Oncovin (vincristine), Prednisone 1
3255558|NCT00801268|Active Comparator|emodin|
3255559|NCT00801268|Experimental|Triptolide Woldifii|TW60mg/d
3255560|NCT00801255|Experimental|Cohort A|
3255561|NCT00801255|Experimental|Cohort B|
3255562|NCT00801255|Experimental|Cohort C|
3255563|NCT00801255|Experimental|Cohort D|
3255564|NCT00801255|Experimental|Cohort E|
3255565|NCT00801255|Experimental|Cohort F|
3255566|NCT00801255|Experimental|Cohort G|
3255567|NCT00801242|Experimental|Degarelix 240 mg / 80 mg|
3255568|NCT00801229|Active Comparator|Vyvanse|Patients may be randomized to the active comparator arm. Participants randomized to this arm will receive 30, 50, or 70mg Vyvanse daily.
3255569|NCT00801229|Placebo Comparator|Placebo|Patients may be randomized to the placebo comparator arm. Those randomized to this arm will receive 30, 50, or 70mg placebo daily.
3255570|NCT00801216|Experimental|High-dose sequential chemoimmunotherapy|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 & 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
3255571|NCT00801203|Experimental|1|Induced Reflex Cough Test (IRCT) followed by Voluntary Cough Test (VCT)
3255572|NCT00801203|Experimental|2|Voluntary Cough Test (VCT) followed by Induced Reflex Cough Test (IRCT)
3255573|NCT00801190|Active Comparator|HES (130/0.4)|33 ml/kg i.v. HES (130/0.4)
3255574|NCT00801190|Placebo Comparator|Ringer's Lactate|33 ml/kg i.v. Rigner's Lactate
3255575|NCT00801177|Experimental|IMC-11F8 (Every week)|Cycle of therapy administered intravenously, once a week for 6 weeks, for a total of six doses per cycle.
3255576|NCT00801177|Experimental|IMC-11F8 (Every other week)|Cycle of therapy administered intravenously, every other week for 6 weeks, for a total of three doses per cycle.
3255577|NCT00801164|Experimental|Frio Oral Rinse|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
3255578|NCT00801164|Experimental|Placebo|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
3255579|NCT00801151|Experimental|Vorinostat, vinorelbine|Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.
3255580|NCT00801138|Placebo Comparator|Group 1|Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block
3255581|NCT00801138|Placebo Comparator|Group 2|Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline
3255582|NCT00801138|Active Comparator|Group 3|Group 3 Ropivacaine and dexamethasone: 30 ml 0.5% ropivacaine mixed with dexamethasone 8 mg (2 ml)
3255583|NCT00801138|Active Comparator|Group 4|Group 4 Bupivacaine and steroid: 30 ml 0.5% bupivacaine mixed with dexamethasone 8 mg (2 ml).
3255584|NCT00801112||1|PD patients with residual renal function >200ml with BIA monitor.
3255585|NCT00801112||2|PD patients with residual renal function <200ml with BIA monitor.
3255586|NCT00801112||3|PD patients with residual renal function >200ml without BIA monitor
3255587|NCT00801112||4|PD patients with residual renal function <200ml without BIA monitor
3255588|NCT00801099|Experimental|Abx|single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
3255589|NCT00801086|Experimental|1|MTS-01 (7% Tempol gel)
3255590|NCT00801086|Placebo Comparator|2|Vehicle
3255591|NCT00801073|Experimental|Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
3255592|NCT00801060|Experimental|Treatment Group A|"FCR + Lumiliximab (L)~L (Lumiliximab): Day 2 50 mg/m2, Day 4 450 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks.~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
3255593|NCT00801060|Active Comparator|Treatment Group B|"FCR~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
3255594|NCT00801047|Experimental|1|Epidural group
3255595|NCT00801047|Active Comparator|2|Remifentanil iv PCA
3255596|NCT00801034|Placebo Comparator|1|Calcium tablets
3255597|NCT00801034|Active Comparator|2|Potassium tablets
3255598|NCT00801021|Experimental|Frio Oral Rinse|Prescription Mouth Rinse
3255599|NCT00801008|Experimental|Exercise and Relaxation Intervention|Participants in this arm will receive a 12 week exercise and relaxation intervention
3255600|NCT00801008|No Intervention|Wait List Control Condition|Participants in this arm will be offered the exercise and relaxation intervention after a 12 week delay.
3255601|NCT00800995|Sham Comparator|Control|
3255602|NCT00800995|Experimental|SOD|
3255603|NCT00800982|Active Comparator|1 (Etanercept only)|Subjects will only be treated with etanercept. This is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months. No UVB will be given. Sham UVB will not be used because the subjects are not blinded because they often know they are receiving sham UVB due to differences in light intensity and heat.
3255604|NCT00800982|Experimental|2 (Etanercept + nb-UVB)|"Subjects will receive etanercept. This is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.~In addition, for months 3-6, subjects will receive Narrow Band Ultraviolet B phototherapy three times a week for 12 weeks in addition to the etanercept maintenance dose. The safety and efficacy of the combination therapy will be evaluated by the registered phototherapy nurses at each phototherapy visit and by the study investigator at monthly visits. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff."
3255605|NCT00800969|Other|all patients|all patients with Adenocarcinoma
3255606|NCT00800956|Experimental|Single oral dose of [14C]-esreboxetine|
3255607|NCT00800943|Experimental|Campath-1H|
3255608|NCT00800930|Active Comparator|1|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
3255609|NCT00800930|Placebo Comparator|2|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
3255610|NCT00800865|Other|Biomarker Evaluation Group I|Biomarker evaluation before and after dosing with cytotoxic agent(s)
3255611|NCT00800865|Other|Biomarker Evaluation Group II|Biomarker evaluation before and after dosing with cytotoxic agent(s)
3255612|NCT00800839|Experimental|Busulfan + Fludarabine + Cyclophosphamide|Busulfan starting dose of 32 mg/m^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3. Fludarabine dose of 40 mg/m^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan. Cyclophosphamide dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
3255613|NCT00800813||open, laparoscopic, or robotic-assisted lap|Patients will also be assessed for penile length and the presence of Peyronie's Disease at these specified times.
3255614|NCT00800800|Active Comparator|1|Rosuvastatin 40 mg
3255615|NCT00800800|Placebo Comparator|2|placebo
3255616|NCT00800787|Experimental|Arm One: Nabi-HB|All subjects will be administered Nabi HB Subcutaneously
3255617|NCT00800774|Experimental|1|Nine eyes of nine patients (3 male and 6 female) with high anisometropia (>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
3255618|NCT00800761|Active Comparator|Deferoxamine alone|comparison of deferoxamine subcutaneous 40mg/kg/die alone versus combined therapy deferoxamine-deferiprone
3255619|NCT00800761|Active Comparator|Deferoxamine plus Deferiprone|comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
3255620|NCT00800748|Experimental|Group A|Participants with genotype 1, 4, 5 or 6 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 1000-1200 mg PO daily (dependent on body weight) for 48 weeks.
3255621|NCT00800748|Experimental|Group B|Participants with genotype 2 or 3 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 24 weeks.
3255622|NCT00800748|Experimental|Group C|Participants with HIV co-infection received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 48 weeks.
3255623|NCT00800735|Experimental|Pegylated-interferon alfa-2a plus ribavirin|Participants received pegylated-interferon alfa-2a 180 µg/week subcutaneously plus ribavirin 1000 mg/day orally for patients weighing < 75 kg or 1200 mg/day for patients weighing ≥ 75 kg for 48 weeks.
3255624|NCT00800722|Experimental|Treatment of Port Wine Stain|Rapamycin Treatment of Port Wine Stain
3255625|NCT00800709|Experimental|Memantine|
3255626|NCT00800696|Experimental|oral care|intervention: The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx.
3255627|NCT00800696|No Intervention|control|continue to receive oral care as performed today.
3255628|NCT00800683|Experimental|BI 1356|patient to receive a tablet containing BI 1356 once daily
3255629|NCT00800683|Placebo Comparator|placebo|patient to receive a tablet identical to BI 1356 once daily
3255630|NCT00800670|Experimental|Lower dose|Lower dose of Ad5Ag85A: 10^8pfu
3255631|NCT00800670|Experimental|Higher dose|Higher dose of vaccine Ad5Ag85A: 10^9pfu
3255632|NCT00800644||Evaluation Group|Bone Mineral Density Test + MRI or CT + Blood Test
3255633|NCT00800618|Experimental|PF-02413873|PF-2413873 active treatment
3255634|NCT00800618|Placebo Comparator|Placebo|Placebo
3255635|NCT00800605|Experimental|1|Vero cell-derived, trivalent, seasonal influenza vaccine
3255636|NCT00800605|Placebo Comparator|2|Phosphate-buffered saline
3255637|NCT00800592|Active Comparator|10 mg sildenafil bolus|10 mg sildenafil bolus
3255638|NCT00800579|Experimental|1|GS-9411 0.6 mg
3255639|NCT00800579|Experimental|2|GS-9411 1.2 mg
3255640|NCT00800579|Experimental|3|GS-9411 2.4 mg
3255641|NCT00800579|Placebo Comparator|4|Inhaled volume-matched sterile saline placebo
3255642|NCT00800566|Experimental|Oral Clofarabine|
3255643|NCT00800553|Experimental|donepezil|donepezil, 5 mg p.o. for approx 2 weeks
3255644|NCT00800553|Placebo Comparator|placebo|placebo
3255645|NCT00800540|Other|AZARGA/COMBIGAN|AZARGA, followed by COMBIGAN, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
3255646|NCT00800540|Other|COMBIGAN/AZARGA|COMBIGAN, followed by AZARGA, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
3255647|NCT00800527|Active Comparator|1|Gabapentin
3255648|NCT00800527|Active Comparator|2|Diclofenac
3255649|NCT00800514|Experimental|active|
3255650|NCT00800501|Experimental|sNN0029|
3255651|NCT00800501|Placebo Comparator|Placebo|
3255652|NCT00800475|Active Comparator|Test Drug|
3255653|NCT00800475|Active Comparator|Reference Drug|
3255654|NCT00800462|Active Comparator|Oxybutynin Cl|
3255655|NCT00800462|Active Comparator|Trospium Cl|
3255656|NCT00800462|Active Comparator|Darifenacin Hydrogren Bromide (HBr)|
3255657|NCT00800436|Experimental|Part 1: Cohort 1|Healthy male participants will receive Herceptin 6 mg/kg IV on Day 1.
3255658|NCT00800436|Experimental|Part 1: Cohort 2|Female participants with HER2-positive breast cancer will receive Herceptin 6 mg/kg IV on Day 1.
3255659|NCT00800436|Experimental|Part 1: Cohort 3|Healthy male participants will receive Herceptin 6 mg/kg SC on Day 1.
3255660|NCT00800436|Experimental|Part 1: Cohort 4|Healthy male participants will receive Herceptin 10 mg/kg SC on Day 1.
3255661|NCT00800436|Experimental|Part 1: Cohort 5|Healthy male participants will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohorts 1, 2, 3, and 4.
3255662|NCT00800436|Experimental|Part 2: Cohort A|Female participants with HER2-positive breast cancer will receive Herceptin SC at the dose level determined in Part 1.
3255663|NCT00800436|Experimental|Part 2: Cohort B|Female participants with HER2-positive breast cancer will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohort A.
3255664|NCT00800423|Experimental|brimonidine|"50 patients receiving Brimonidine Tartrate drops in the operated eye: 1 drop X2 a day for 1 month.~they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)"
3255665|NCT00800423|Active Comparator|2 tmolol|"50 patients receiving timolol maleate 0.5% drops in the operated eye~1 drop X2 a day for 1 month. they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)"
3255666|NCT00800423|No Intervention|3|50 patients will not receive any additional drug to the usual medications after cataract surgery (corticosteroids and antibiotics drops)
3255667|NCT00800410|No Intervention|Information on community resources|Participants received information about free and publicly available community resources on healthy lifestyle activities
3255668|NCT00800410|Experimental|Community Health Worker services|
3255669|NCT00800384|Experimental|1|ICD implant without defibrillation testing
3255670|NCT00800384|Active Comparator|2|ICD implant with defibrillation testing
3255671|NCT00800371||JIA|Patients with JIA
3255672|NCT00800358|Experimental|1|Oral Paricalcitol in varying doses
3255673|NCT00800358|Active Comparator|2|Calcitriol
3255674|NCT00800345|Experimental|Experimenal|Metronomic oral topotecan and oral pazopanib will be administered by mouth beginning on Cycle 1 Day 1. Patients will be enrolled and observed for dose limiting toxicity (DLT) for 1 cycle of treatment. Dose modification of the combination will depend on the number of patients experiencing DLT(s) at each dose level.
3255675|NCT00800332|Experimental|1|
3255676|NCT00800332|Experimental|2|
3255677|NCT00800332|Placebo Comparator|3|
3255678|NCT00800319|Experimental|RDC-0313, 5mg|5 mg of RDC-0313; single dose
3255679|NCT00800319|Experimental|RDC-0313, 15 mg|15 mg RDC-0313; single dose
3255680|NCT00800319|Experimental|RDC-0313, 25mg|25 mg RDC-0313; single dose
3255681|NCT00800319|Experimental|RDC-0313, 50 mg|50 mg RDC-0313; single dose
3255682|NCT00800319|Experimental|RDC-0313, 75 mg|75 mg RDC-0313; single dose
3255683|NCT00800319|Placebo Comparator|Placebo|volume-match placebo; single dose
3255684|NCT00800306|Experimental|levosimendan|
3255685|NCT00800306|Active Comparator|Control|
3255686|NCT00800293||Cohort Group 1|Subject Numbers 1 to 29
3255687|NCT00800293||Cohort Group 2|Subject Numbers 20 to 59
3255689|NCT00800293||Cohort Group 4|Subject Numbers 90 to 116
3255690|NCT00800280|Experimental|Single dose PD 0332334|
3255691|NCT00800280|Experimental|Single dose PD 0332334 with steady-state cimetidine|
3255692|NCT00800267|Experimental|Fixed combination of latanoprost 0.005% and timolol 0.5%|
3255693|NCT00800267|Active Comparator|latanoprost 0.005%|
3255694|NCT00800267|Active Comparator|Timolol - 0.5%|
3255695|NCT00800254|Experimental|Neuromuscular Electrical Stimulation (NMES)|
3255696|NCT00800254|Active Comparator|Standard Rehabilitation Protocol|
3255697|NCT00800228||1|Eight men and eight women to define the time course of changes in MBG \ and OLC accompanying sodium loading
3255698|NCT00800228||2|32 additional women to determine whether breathing pattern is predictive of sodium sensitivity in that gender. Women are being studied in the second experiment because they, but not men, have been shown to have an association of breathing pattern with high perceived stress11 and an association of high resting end tidal CO2 with high resting blood pressure.
3255699|NCT00800215|Experimental|1|
3255700|NCT00800215|Placebo Comparator|2|
3255701|NCT00800215|Experimental|3|
3255702|NCT00800215|Placebo Comparator|4|
3255703|NCT00800202|Experimental|1|
3255704|NCT00800202|Experimental|2|
3255705|NCT00800176|Placebo Comparator|Placebo|
3255706|NCT00800176|Experimental|RO4998452 10mg|
3255707|NCT00800176|Experimental|RO4998452 2.5mg|
3255708|NCT00800176|Experimental|RO4998452 20mg|
3255709|NCT00800176|Experimental|RO4998452 40mg|
3255710|NCT00800176|Experimental|RO4998452 5mg|
3255711|NCT00800163|Experimental|ED Physician Activation/Immediate Transfer|
3255712|NCT00800137|Active Comparator|Bridging anti-coagulation|Low Molecular Weight Heparin or IV unfractionated Heparin
3255713|NCT00800137|Experimental|Continued oral anti-coagulation|Coumadin
3255714|NCT00800124|No Intervention|1|Cemented hemiprosthesis
3255715|NCT00800124|Active Comparator|2|Non-cemented hemiprosthesis
3255716|NCT00800111|Other|Treatment|Endothelial keratoplasty procedure is performed.
3255717|NCT00800098|Placebo Comparator|Placebo|Placebo cream matched on consistency, color, and smell
3255718|NCT00800098|Active Comparator|Active|AARP active arthritis cream
3255719|NCT00800085|No Intervention|FDR of type 1 diabetes patients receiving glucose 20%|First Degree Relatives of diabetes type 1 patient with a high, intermedian or low risk (accoring to the criteria of the protocol), for developing diabetes type 1.
3255720|NCT00800072|Experimental|oxygen therapy|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
3255721|NCT00800059|Experimental|Treatment|Treatment with TMI and autologous Stem Cell transplant
3255722|NCT00800046|Experimental|AccuCinch® Ventriculoplasty System|Patients meeting the enrollment criteria will be treated with the AccuCinch® Ventriculoplasty System.
3255723|NCT00800033|Experimental|Aerobic exercise training|
3255724|NCT00800033|Placebo Comparator|Resistance exercise training|
3255725|NCT00800033|Experimental|pulse diet|Pulse based diet containing peas, lentils, and beans
3255726|NCT00800033|No Intervention|Regular diet|
3255727|NCT00800007|Active Comparator|ANZ-521|
3255728|NCT00800007|Placebo Comparator|Placebo|
3255729|NCT00799994||1|Patients that have medical intervention in an attempt to lower intraocular pressure (oral or topical)
3255730|NCT00799994||2|Patients who have received no intervention
3255731|NCT00799968|Active Comparator|Group 1|UK-12h group
3255732|NCT00799968|Experimental|Group 2|UK-2h group
3255733|NCT00799955|Placebo Comparator|1|Subjects will receive 100 micrograms of spinal morphine, at the time of spinal needle insertion (standard care at BCW). At the end of the case, one of two investigators, using ultrasound, will visualize the transversus abdominis plane. A capped needle will be pushed against the skin to mimic the pressure sensation of the TAP block. The needle will not break the skin and nothing will be injected in this control group. The procedure will then be repeated on the other side. A dressing will be applied on each side to blind the subject and researcher to which group she is in.
3255734|NCT00799955|Active Comparator|2|No additional spinal medications will be given. At the end of the case, one of the two investigators, under sterile conditions, and using ultrasound, will visualize the tip of a blunt regional anaesthesia needle entering the transversus abdominis plane. After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected, under vision, into the transversus abdominis plane, on each side. The subjects will still have spinal anesthesia of the abdomen and therefore will not feel needle insertion as sharp although most will have a sensation of pressure. A dressing will be applied over the needle's entry points.
3255735|NCT00799929|Active Comparator|ARM A - Mini IVF|The Mini IVF method entails pre-treatment with oral contraceptive pills. Ovarian stimulation is achieved using an oral anti-estrogen in conjunction with injections of gonadotropin (225IU-600IU per cycle), with initial dose of 75IU-150IU per injection. Ovulation is induced by a GnRH (gonadotropin-releasing hormone) agonist nasal spray/hCG (human chorionic gonadotropin) injection. Retrieved oocytes following in vitro fertilization (IVF/ICSI) are cultured to the blastocyst stage. Blastocyst stage embryos are vitrified using the CryoTop method. No fresh embryo transfer is conducted. Subsequently, SET of a thawed blastocyst is performed in a natural cycle/HRT that does not involve ovarian stimulation. SETs are conducted until pregnancy is achieved or all vitrified blastocysts have been used.
3255736|NCT00799929|Active Comparator|Arm B - Conventional IVF|The standard IVF method entails pre-treatment with a GnRH analog injections in the midluteal phase. Controlled ovarian hyperstimulation is achieved with injections of gonadotropin (150IU-300IU/day). Ovulation is induced by hCG injection and retrieved oocytes following in vitro fertilization (IVF/ICSI) are cultured to the blastocyst stage. If this occurs on day 5, then fresh SET/DET (single embryo transfer/double embryo transfer) is performed. Remaining blastocysts are cryopreserved and transferred in subsequent natural cycles/HRT (hormone replacement therapy) that does not involve ovarian stimulation.
3255737|NCT00799916|Active Comparator|Voluven|Resuscitation fluid: Voluven (R)
3255738|NCT00799916|Active Comparator|Saline|Resuscitation fluid: Saline solution
3255739|NCT00799903|Experimental|Darapladib|Single daily oral tablet
3255740|NCT00799903|Placebo Comparator|Placebo|Single daily oral tablet
3255741|NCT00799890|Experimental|Sunphenon|
3255742|NCT00799890|Placebo Comparator|Placebo|
3255743|NCT00799877||1|This registry will evaluate the long-term safety and effectiveness of HUMIRA® as used in routine clinical practice.
3255744|NCT00799864|Experimental|Rilpivirine (TMC278)|The patients will receive rilpivirine with 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) as a background regimen in Cohort 1 [Aged greater than or equal to (> =) 12 to less than (<) 18 years] and Cohort 2 (children aged > = 6 to < 12 years). The NRTIs includes zidovudine, abacavir, or tenofovir disoproxil fumarate in combination with lamivudine or emtricitabine.
3255745|NCT00799851|Active Comparator|Variceal band ligation|VBL was performed with a multiband ligation device (Euroligator System®). The first band was placed at or close to the gastroesophageal junction, with subsequent bands being placed proximally in a slightly spiral pattern. All visible varices within the distal esophagus were treated, with a maximum of 10 bands being placed in each session. There was a 3-week interval between each treatment session. When VBL was technically impossible due to scarring, sclerotherapy with ethanolamine oleate was performed on thin vessels.
3255746|NCT00799851|Active Comparator|cyanoacrylate injection|"CI group received intravariceal injections of 0.5 ml of N-butyl-2-cyanoacrylate (Histoacryl®) diluted in 0.5 ml of Lipiodol (Lipiodol®). Before injection of the Histoacryl-Lipiodol mixture, the catheter was filled up with 1 ml of Lipiodol. After puncturing the EV, the mixture was injected inside it and followed by injection of 1 ml of distilled water. Finally the catheter was retracted. To minimize the risk of embolism, a maximum of two medium or large vessels, in opposite walls, were treated in each session and not more than 0.5 ml of Histoacryl® was injected into each vessel.~A second injection was performed in any EV that maintained blood flow (medium or large size, blue, depressive at palpation with the catheter), in a bi-weekly interval basis. A chest x-ray was performed to evaluate the location of the Histoacryl-Lipiodol solution. Small vessels were treated with ethanolamine oleate sclerotherapy."
3255747|NCT00799838|Experimental|Ketoprofen + Amoxicillin|Ketoprofen + Amoxicillin for 3 days, then Amoxicillin alone for 7 days
3255748|NCT00799838|Placebo Comparator|Amoxicillin|Placebo (for ketoprofen) + Amoxicillin for 3 days, then Amoxicillin alone for 7 days
3255749|NCT00799825|Experimental|Cervarix group|Female subjects who previously received the active control i.e. Hepatitis A vaccine in the primary study (NCT00122681) and who received the Cervarix vaccine in the current study. The Cervarix vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1 and 6 months schedule.
3255750|NCT00799812|Experimental|CHG Swabstick (3 @ once)|Chlorhexidine(CHG)2% CHG/isopropyl alcohol (IPA)70%-3 swabsticks applied @ same time
3255751|NCT00799812|Experimental|CHG Swabstick sequential|Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v--3 swabsticks applied one-at-a-time
3255752|NCT00799812|Active Comparator|Hibiclens|Chlorhexidine gluconate 4% w/v in an aqueous base
3255753|NCT00799812|Placebo Comparator|Sterile water swab (3 @ once)|Sterile swabstick wetted with sterile water--3 swabsticks applied at the same time.
3255754|NCT00799812|Placebo Comparator|Sterile water swabstick (sequential)|Sterile swabstick wetted with sterile water--3 swabsticks applied one-at-a-time.
3255755|NCT00799799|Experimental|NK|patient treated as per protocol
3255756|NCT00799773|Experimental|1|Participants will receive rituximab in addition to plasma exchange and corticosteroids.
3255757|NCT00799773|Active Comparator|2|Participants will receive plasma exchange and corticosteroids.
3255758|NCT00799760|Experimental|1|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
3255759|NCT00799760|Active Comparator|2|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 days
3255760|NCT00799760|Active Comparator|3|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
3255761|NCT00799747|Experimental|1|AZD4017 in ascending doses (start dose 2mg)
3255762|NCT00799747|Placebo Comparator|2|Placebo
3255763|NCT00799734|Active Comparator|alternative medicine|Intake of prepacked Chinese herbal medicine (EXD), one sachet of granules (15g extracted granules) twice a day
3255764|NCT00799734|Placebo Comparator|placebo|placebo therapy of 15g granules with similar colour and taste.
3255765|NCT00799721||1|VLBW infants with erythropoietin therapy
3255766|NCT00799721||2|VLBW infants without erythropoietin therapy.
3255767|NCT00799708|Placebo Comparator|1|Placebo
3255768|NCT00799708|Active Comparator|2|Estrace 0.5 mg
3255769|NCT00799708|Active Comparator|3|Estrace 2 mg
3255770|NCT00799682|Active Comparator|Xalatan®|
3255771|NCT00799682|Active Comparator|Travatan Z®|
3255772|NCT00799669||MAPS+|"MAPS+ (Motivation and Problem-Solving Plus):~Counseling using specific treatment approach that focuses on combined smoking cessation and the reduction of at-risk alcohol use."
3255773|NCT00799669||MAPS|"MAPS (Motivation and Problem-Solving):~Counseling treatment approach with a focus on smoking cessation."
3255774|NCT00799656|Experimental|1|First period: Ataciguat - Second period: Placebo
3255775|NCT00799656|Experimental|2|First period: Placebo - Second period: Ataciguat
3255776|NCT00799643|Active Comparator|1|Salsalate, 3.5 g/d orally, divided dosing
3255777|NCT00799643|Placebo Comparator|2|Salsalate Placebo, orally, divided dosing
3255778|NCT00799617|Active Comparator|AndroGel® (testosterone gel)|The initial dose of AndroGel will be 5.0 g (containing 50 mg of testosterone) once a day. Participants will apply AndroGel once daily to the shoulders, abdomen or upper arms. The serum testosterone concentration will be measured monthly for the first three months, then at months 6, 9 and 12. If the testosterone concentration is not between 500 and 800 ng/dL at any time point, the dose will be either increased by increments of 1.25-2.5 g/day, up to a maximum of 15 g/day or decreased by increments of 1.25-3.75 ng/day. Participants will be taught how to apply the gel and they will be provided with written instructions and precautions. This information will be reviewed at each contact and visit.
3255779|NCT00799617|Placebo Comparator|Placebo gel|Placebo gel is identical to the testosterone gel and is supplied in an identical pump bottle container. It is applied to the shoulders, abdomen or upper arms once a day. Participants will be taught how to apply the gel and they will be provided with written instructions and precautions. This information will be reviewed at each contact and visit.
3255872|NCT00798824|Active Comparator|Indwelling nasogastric tube placement|
3255780|NCT00799604|Experimental|clevidipine|"Patients were sequentially assigned to one of following three planned dose cohorts for Bolus 1 within the clevidipine arm:~Cohort 1: clevidipine 250 µg (0.5 mL)~Cohort 2: clevidipine 500 µg (1 mL)~Cohort 3: clevidipine 125 µg (0.25 mL or 0.5 mL of a 1:1 solution)"
3255781|NCT00799591||1|Intensive Care
3255782|NCT00799578|Experimental|Cystagon-EC|
3255783|NCT00799565|Experimental|1|Subject with a Mitral Valvular Prolapse
3255784|NCT00799565|Experimental|2|Healthy Volunteers
3255785|NCT00799552|Placebo Comparator|Placebo|
3255786|NCT00799552|Experimental|RX-10045|
3255787|NCT00799526|Experimental|Ex Vivo Transplantation|Autologous Ex Vivo Conjunctival Epithelial Cell Expansion for Symblepharon Transplantation
3255788|NCT00799513|Experimental|Lenalidomide|single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
3255789|NCT00799500|Experimental|Weekly screening|Screening and treatment of bacterial vaginosis during pregnancy through self-administered weekly vaginal pH determination.
3255790|NCT00799500|No Intervention|Observation|Usual care
3255791|NCT00799487|Experimental|1|CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
3255792|NCT00799487|Experimental|2|CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
3255793|NCT00799461|Experimental|Arm I (full website access w/ PST; first study only)|Patients receive full access to INSPIRE website for 6 months, which offers an individually tailored greeting home page with links to information on each of the target areas identified as being elevated on baseline assessment and how to manage the complications; a bulletin board with input from other survivors that is solicited, edited, and posted weekly; resource pages; and an opportunity to send secure messages with questions or comments. Patients also undergo 4-8 phone-based PST sessions with a behavioral health specialist.
3255794|NCT00799461|Experimental|Arm II (full website access without PST)|Patients receive full access to INSPIRE website for 6 months as in arm I.
3255795|NCT00799461|Sham Comparator|Arm III (delayed website access)|Patients do not have access to INSPIRE website for 6 months. After 6 months, patients receive full access to INSPIRE website for 3 months.
3255796|NCT00799435|No Intervention|1|Participants will receive usual care for 12 weeks. The care will be dictated by the primary physician and/or diabetologist caring for the participant. Efforts will be made to ensure that all participants receive standard measures as indicated by guidelines, with a particular emphasis on blood pressure control and glucose control.
3255797|NCT00799435|Experimental|2|Participants will receive exenatide for 12 weeks.
3255798|NCT00799422|Active Comparator|ReNu MultiPlus|ReNu MultiPlus used as specified in the protocol for contact lens care. In this crossover study, ReNu MultiPlus was dispensed in randomized order with Complete Easy Rub and Clear Care. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
3255799|NCT00799422|Active Comparator|Complete Easy Rub|Complete Easy Rub used as specified in the protocol for contact lens care. In this crossover study, Complete Easy Rub was dispensed in randomized order with ReNu MultiPlus and Clear Care. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
3255800|NCT00799422|Active Comparator|Clear Care|Clear Care used as specified in the protocol for contact lens care. In this crossover study, Clear Care was dispensed in randomized order with Complete Easy Rub and ReNu MultiPlus. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
3255801|NCT00799409|Experimental|1|CONCERTA (methylphenidate HCl) / Placebo Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
3255802|NCT00799409|Experimental|2|Placebo/ CONCERTA (methylphenidate HCl) Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
3255803|NCT00799396|Experimental|Overall Study|Participants will receive clopidogrel treatment alone, followed by clopidogrel plus aspirin treatment on the last day of treatment.
3255804|NCT00799383|Experimental|Calcium and Vitamin D|Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
3255805|NCT00799383|Placebo Comparator|Placebo|Placebo
3255806|NCT00799370|Experimental|1|Early weight bearing: immediate in postoperative
3255807|NCT00799370|Experimental|2|Delayed weight bearing: 2 months after surgery
3255808|NCT00799344||Stent|Catania Stent
3255809|NCT00799331|Experimental|A|AZD5985
3255810|NCT00799331|Experimental|B|placebo
3255811|NCT00799305||COPD patients|
3255812|NCT00799292|No Intervention|No injection|Patients did not receive an injection at cervix prior to beginning the procedure
3255813|NCT00799292|Experimental|Injection of vasopressin|Patients will be randomized to receive 20cc of dilute vasopressin (20units in 50cc normal saline)injected at cervix at beginning of the hysterectomy
3255814|NCT00799279|Experimental|Follow-up Counseling Arm|smoking cessation training for providers,practice tools for providers, patient quit plan, and follow-up telephone counselling for smokers
3255815|NCT00799279|Active Comparator|Practice Support Arm|smoking cessation training for providers,practice tools for providers, patient quit plan for smokers.
3255816|NCT00799266|Experimental|1|Arm 1
3255817|NCT00799266|Placebo Comparator|2|Arm 2
3255818|NCT00799240|Active Comparator|Arm A Pemetrexed Cisplatin|Arm A: Pemetrexed, cisplatin: pemetrexed and cisplatin chemotherapy at standard doses given IV every 21 days. Patients will be treated for a maximum of 6 cycles.
3255819|NCT00799240|Experimental|Arm B Permetrexed, Cisplatin, MK-0646|Pemetrexed and cisplatin chemotherapy at standard doses given IV every 21 days in combination with MK-0646 given IV, 10 mg/Kg, Days 1, 8 and 15 weekly
3255820|NCT00799227|Experimental|700 µg Dexamethasone Implant|700 µg dexamethasone implant in the study eye at Day 1
3255821|NCT00799214|Placebo Comparator|1|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
3255873|NCT00798824|Active Comparator|Intermittent orogastric tube placement|
3255969|NCT00798252|Experimental|Arm D (Docetaxel + Brivanib alaninate)|
3255822|NCT00799214|Experimental|2|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
3255823|NCT00799214|Active Comparator|3|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
3255824|NCT00799201|Experimental|Control|Sennosides liquid 5mL (8.8mg) every 6 hours plus docusate sodium liquid 10mL (100mg) every 12 hours
3255825|NCT00799188|No Intervention|1|reduction of immunosuppression
3255826|NCT00799188|Experimental|2|switch to Everolimus : 50% reduction of calcineurin inhibitors (ciclosporine or tacrolimus)
3255827|NCT00799175|Active Comparator|1 Group A(Active)|Group A (Active) receives a multimodal injection intra- and postoperatively
3255828|NCT00799175|Placebo Comparator|2 Group P (Placebo)|Group P (Placebo) receives no injection intraoperatively and a saline injection postoperatively
3255829|NCT00799162||Women with a scheduled cesarean section|
3255830|NCT00799149|Active Comparator|Gabapentin|Gabapentin (1200 mg) administered 30-90 min before the patient entered the operating room; Subsequent doses of Gabapentin (1200 mg)were administered on the mornings (08H00) of the first, second, and third postoperative days.
3255831|NCT00799149|Active Comparator|Etoricoxib|Etoricoxib (120 mg)administered 30-90 min before the patient entered the operating room; Subsequent doses of etoricoxib (120 mg)were administered on the mornings (08H00) of the first, second, and third postoperative days.
3255832|NCT00799149|Placebo Comparator|Sugar pill|Sugar pill administered 30-90 min before the patient entered the operating room. Subsequent doses of Sugar pill were administered on the mornings (08H00) of the first, second, and third postoperative days.
3255833|NCT00799136|Other|One|Rituxan with EPOCH and Antiretrovirals
3255834|NCT00799110|Experimental|Group 2|Vaccine, GM-CSF and imiquimod,
3255835|NCT00799110|Experimental|Group 1|Vaccination plus GM-CSF
3255836|NCT00799097||Endoscopic Sinus Surgery|Subjects who have failed maximum medical management and have elected for endoscopic sinus surgery
3255837|NCT00799084|Experimental|Nurse|Receives symptom management assistance from an oncology nurse via the telephone
3255838|NCT00799084|Experimental|AVR|Receives symptom management assistance from an Automated telephone system
3255839|NCT00799071|Experimental|posaconazole|posaconazole as antifungal prophylaxis
3255840|NCT00799058|Active Comparator|dapivirine gel 4789|will be applied by participants once daily for 12-weeks treatment period
3255841|NCT00799058|Active Comparator|dapivirine gel 4759|Will be applied by participants once daily for12-weeks treatment period
3255842|NCT00799058|Placebo Comparator|HEC-based placebo gel, 2.5g containing no Dapivirine|Will be applied once daily for 12-weeks treatment period
3255843|NCT00799045|Experimental|Aspirin + clopidogrel|Aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
3255844|NCT00799045|Active Comparator|Aspirin|Aspirin (80 mg/day) for 3 months following ASD closure.
3255845|NCT00799032|Other|Stent|Catania Stent
3255846|NCT00799006|Placebo Comparator|Placebo|
3255847|NCT00799006|Experimental|PF-04620110|
3255848|NCT00798993|Active Comparator|Structured exercise program|Participants will be randomised at 3 months into either this group or the comparator of usual exercise.
3255849|NCT00798993|Experimental|Vitamin D|Cholecalciferol 2000U per day will be given to all participants for the duration of the study
3255850|NCT00798993|Placebo Comparator|Usual exercise|Participants randomised to this arm, at 3 months, will continue on their usual exercise routine
3255851|NCT00798980||Arm 1|
3255852|NCT00798967|Experimental|Teduglutide|0.05 mg/kg/day sc dose of teduglutide
3255853|NCT00798967|Placebo Comparator|Placebo|Matching subcutaneous dose of placebo to teduglutide
3255854|NCT00798954|Active Comparator|TAXUS|
3255855|NCT00798954|Active Comparator|Cypher|
3255856|NCT00798941|Experimental|pain intervention|music and massage for 30 minutes
3255857|NCT00798941|Experimental|thirst intervention|sterile water mouth spray, lip moisturizer,mouth swab
3255858|NCT00798941|No Intervention|control|
3255859|NCT00798915|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
3255860|NCT00798915|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
3255861|NCT00798915|Experimental|Type 2 diabetes mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
3255862|NCT00798902|Active Comparator|Control|Iliac Crest Autograft
3255863|NCT00798902|Experimental|Prefix 150|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
3255864|NCT00798889|Experimental|Sunitinib|
3255865|NCT00798876|Placebo Comparator|Standard Western Diet|Subjects will be asked to consume a standard Western Diet for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages. Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
3255866|NCT00798876|Experimental|Low-Fat Diet|Subjects will be asked to consume a low fat diet with fish oil and vitamin E supplements for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages. Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
3255867|NCT00798863|Experimental|operative group|The patients of the group will have the operation of two step video assisted submandibular sialadenectomy.
3255868|NCT00798850|Active Comparator|PTA|
3255869|NCT00798850|Active Comparator|SEP|
3255870|NCT00798850|Active Comparator|PTA+SEP|
3255871|NCT00798837|Other|IMAX|"There is only one arm in this study.~Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~The prescription dose will be 73.7 Gy in 28 fractions.~A simultaneous intraprostatic maximal simultaneous boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
3256051|NCT00797706|Experimental|High dose|
3255874|NCT00798811|Other|KSPNO-S-081|Reduced-dose Craniospinal Radiotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Rescue in Children with Newly Diagnosed High-risk Brain Tumor
3255875|NCT00798811|Other|KSPNO-S-082|High-dose Chemotherapy and Autologous Stem Cell Rescue in Infants and Young Children with Newly Diagnosed High-risk Brain Tumor To Avoid or Reduce Craniospinal Radiation
3255876|NCT00798811|Other|KSPNO-S-083|High-dose Chemotherapy and Autologous Stem Cell Rescue in Children with Recurrent Brain Tumor or Non-germinomatous Germ Cell Tumor with Inadequate Response to Conventional Treatment
3255877|NCT00798798|Experimental|Implantable Tissue Expansion Device|Will apply externally implantable tissue expansion device for 2 days
3255878|NCT00798785|Experimental|group I ATG-MMF-TAC|"Two clinical implants in the liver:~First implant: ATG-fresenium Maintained immunosuppression: MMF-TAC n=30"
3255879|NCT00798785|Experimental|group II ATG-Rituximab-MMF-TAC|"Two clinical implants in the liver:~First Implant: ATG fresenium + Rituximab Maintained immunosuppression: MMF-TAC n=5"
3255880|NCT00798785|Experimental|group III ATG-Basilixumab-MMF-TAC|"Two clinical implants in the liver:~First implant: ATG-fresenium Second implant: basilixumab Maintained immunosuppression: MMF-TAC n=5"
3255881|NCT00798785|Experimental|group IV omentum|"Two clinical implants: first in the omentum followed by a clinical implant in the liver:~First implant: ATG-fresenium Maintained immunosuppression: MMF-TAC n=10"
3255882|NCT00798772|Experimental|A: Broad spectrum micronutrients|"The experimental treatment medications (micronutrients and antioxidants) will be taken as one packet (8 capsules) twice a day with meals. Because of the presence of calcium, iron and zinc in the study medication, any other medication must be taken at least two hours before or after taking it. Participants may initiate the intervention at half dose (one packet of 8 capsules once a day) and increase to full dose after one week.~The intervention will last for two years."
3255883|NCT00798772|Active Comparator|B: Identical appearing multivitamins|"The active comparator/control medications (identical appearing RDA multivitamins and minerals) will be taken as one packet (8 capsules) twice a day with meals. Because of the presence of calcium, iron and zinc in the study medication, any other medication must be taken at least two hours before or after taking it. Participants may initiate the intervention at half dose (one packet of 8 capsules once a day) and increase to full dose after one week.~The intervention will last for two years."
3255884|NCT00798759|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
3255885|NCT00798759|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
3255886|NCT00798746||Pyloric Drainage Procedure|Esophagectomy with pyloric drainage procedure
3255887|NCT00798746||No Pyloric Drainage Procedure|Esophagectomy without pyloric drainage procedure
3255888|NCT00798733||Non-Operative|Surgeon treated the patient non-operatively
3255889|NCT00798733||Operative|Surgeon treated the patient operatively
3255890|NCT00798720|Experimental|Vorinostat + Bortezomib|Vorinostat 400 mg + Bortezomib 1.3 mg/m2
3255891|NCT00798707|Experimental|Desvenlafaxine succinate sustained-release 25 mg|
3255892|NCT00798707|Experimental|Desvenlafaxine succinate sustained-release 50 mg|
3255893|NCT00798707|Placebo Comparator|Placebo|
3255894|NCT00798694|Other|New to Meds|Naive to glaucoma therapy medical or surgical. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
3255895|NCT00798694|Other|Currently on Xalatan|Patients currently on Xalatan at least one month. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
3255896|NCT00798681|Experimental|1|Patients will receive RTU TPN with olive-oil as the primary source of lipids
3255897|NCT00798681|Active Comparator|2|CNF parenteral nutrition made with olive oil as the primary source of lipids
3255898|NCT00798681|Active Comparator|3|CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
3255899|NCT00798668|Experimental|1|participants continue current exercise and take liquid supplement
3255900|NCT00798668|Experimental|2|Participants continue current exercise and take solid supplement
3255901|NCT00798668|Experimental|3|Participants continue current sedentary behavior and take liquid supplements
3255902|NCT00798668|Experimental|4|Participants continue current sedentary behavior and take solid supplements
3255903|NCT00798655|Experimental|Panitumumab, Cisplatin plus radiation|Standard radiation 60-66 Gy with 200 cGy daily fractions in 6-7 weeks Cisplatin* 30 mg/m2 IV, weekly during radiation (total of 6-7 doses based upon radiation therapy dose requirements) Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses based upon radiation therapy dose requirements)
3255904|NCT00798642|Active Comparator|Hypnotherapy|
3255905|NCT00798642|Placebo Comparator|Standard care|
3255906|NCT00798642|Placebo Comparator|Mind Body Therapy|
3255907|NCT00798629|Experimental|Vaccine Dose Escalation|Dose Escalation: Intradermal DC Injection. Level 1: Cell Dose: 2 x 10^6 Level 2: Cell Dose: 1 x 10^7 Level 3: Cell Dose: 2 x 10^7
3255908|NCT00798616|Placebo Comparator|Responders/Placebo|Albuterol responders being given placebo
3255909|NCT00798616|Active Comparator|Responders/Steroids|albuterol responders being given steroids
3255910|NCT00798616|Placebo Comparator|Non-responders/placebo|non-albuterol responders being given placebo
3255911|NCT00798616|Active Comparator|non-responders/steroids|non-albuterol responders being given steroids
3255912|NCT00798603|Experimental|pemetrexed + carboplatin + bevacizumab|Patients receive pemetrexed disodium IV over 10 minutes, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease or partial or complete response after 6 courses may continue to receive pemetrexed disodium and bevacizumab every 21 days in the absence of disease progression or unacceptable toxicity.
3255913|NCT00798590|Experimental|GLP-1|
3255914|NCT00798590|Placebo Comparator|Saline|
3255915|NCT00798577|Experimental|Vigamox|Vigamox Ophthalmic Solution (Moxifloxacin 5mg/mL)
3255916|NCT00798577|Placebo Comparator|BSS Placebo|Balanced Salt Solution
3255917|NCT00798551|Other|Risk counseling|Risk counseling regarding elevated blood pressure
3255918|NCT00798538|Active Comparator|Integrated|Provision of buprenorphine induction and management, substance abuse counseling and HIV care at one clinic.
3255919|NCT00798538|Placebo Comparator|Non-integrated|Buprenorphine induction, substance abuse counseling and HIV care will be managed at multiple locations, respectively: the Community Health Care Van, the Yale AIDS Program, and individuals' HIV clinics.
3255920|NCT00798525|Active Comparator|PR1|Patients treated with Argatroban (Argatra®), a direct thrombin inhibitor
3255921|NCT00798525|Active Comparator|PR2|Patients treated with Lepirudin (Refludan®), a direct thrombin inhibitor
3255922|NCT00798512|Experimental|1|Single arm Study in which 120 patients fulfilling eligibility criteria will be screened and undergo carotid stenting with the Cristallo ideale™ carotid stent after placement of the Mo.Ma device as cerebral protection system. The technique of diffusion-weighted magnetic resonance imaging (DW-MRI) will be used to identify new ischemic lesions.
3255923|NCT00798499||1|Laboratory variables
3255924|NCT00798486|Other|Subjects with and without Diabetes|Subjects participating in this study included 93 who had diabetes and 17 who did not have diabetes.
3255925|NCT00798473|Experimental|1|Zoledronic acid, 0.06 mg/kg IV in a single infusion, maximum of 4 mg
3255926|NCT00798473|Placebo Comparator|2|IV saline infusion
3255927|NCT00798460|Active Comparator|Lamivudine plus adefovir|
3255928|NCT00798460|Active Comparator|Clevudine plus adefovir|
3255929|NCT00798447|Experimental|lipid emulsion with n-3 FA|
3255930|NCT00798447|Active Comparator|lipid emulsion without n-3 FA|
3255931|NCT00798434|Active Comparator|Placebo|Flexible dose regimen of placebo once daily. The dose can be increased after 4 weeks if clinically indicated. Subsequently the dose can be reduced to the original dose if clinically indicated.
3255932|NCT00798434|Active Comparator|Fesoterodine|Flexible dose regimen of fesoterodine fumarate 4mg once daily. The dose can be increased to 8mg once daily after 4 weeks if clinically indicated. Subsequently the dose can be reduced to 4mg if clinically indicated.
3255933|NCT00798421||Heathcare worker|health care worker exposed to patient with influenza
3255934|NCT00798408|Experimental|1|Participants will maintain current physical activity and take a fluid supplement.
3255935|NCT00798408|Experimental|2|Participants will maintain current physical activity and take a solid supplement.
3255936|NCT00798395|Experimental|Treatment 1|
3255937|NCT00798395|Experimental|Treatment 2|
3255938|NCT00798395|Placebo Comparator|Treatment 3|
3255939|NCT00798395|Active Comparator|Treatment 4|
3255940|NCT00798382|Experimental|1: Soy formula|experimental soy formula #1
3255941|NCT00798382|Active Comparator|2: Soy Formula|Commercially available soy formula
3255942|NCT00798382|Experimental|3: Soy formula|experimental soy formula #2
3255943|NCT00798369|Experimental|Canakinumab 10 mg|Canakinumab 10 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
3255944|NCT00798369|Experimental|Canakinumab 25 mg|Canakinumab 25 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
3255945|NCT00798369|Experimental|Canakinumab 50 mg|Canakinumab 50 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
3255946|NCT00798369|Experimental|Canakinumab 90 mg|Canakinumab 90 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
3255947|NCT00798369|Experimental|Canakinumab 150 mg|Canakinumab 150 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
3255948|NCT00798369|Active Comparator|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg intramuscularly (i.m) once. The i.m. injection was recommended to be administered deeply into the gluteal muscle. Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
3255949|NCT00798356|Other|1|Yoga training
3255950|NCT00798343|Active Comparator|Seasonal vaccine|Seasonal influenza vaccination
3255951|NCT00798343|Experimental|Pandemic vaccine|MF59-adjuvanted H5N1 monovalent vaccine
3255952|NCT00798317|Experimental|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
3255953|NCT00798317|Placebo Comparator|Placebo|Intravitreal injection of placebo
3255954|NCT00798304|Experimental|1|Dose level 1 of meningococcal B rLP2086 vaccine and routine childhood vaccines
3255955|NCT00798304|Experimental|2|Dose level 2 of meningococcal B rLP2086 vaccine and routine childhood vaccines
3255956|NCT00798304|Experimental|3|Control group
3255957|NCT00798291|Placebo Comparator|Ad lib diet/placebo|Ad lib diet and control product placebo
3255958|NCT00798291|Experimental|Ad lib diet/AN 777|Ad lib diet and AN 777
3255959|NCT00798291|Active Comparator|Ad lib diet/placebo/exercise|Diet ad lib; exercise; and placebo
3255960|NCT00798291|Experimental|Ad lib diet/ AN 777/ exercise|Diet ad lib; AN 777; exercise
3255961|NCT00798278|Experimental|Urokinase|urokinase infusion for 3 days
3255962|NCT00798278|Active Comparator|Thoracoscopic|Video-Assisted Thoracoscopic
3255963|NCT00798265|Experimental|1|HIV(+) on HAART
3255964|NCT00798265|Experimental|2|HIV(+) not on HAART
3255965|NCT00798265|Active Comparator|3|HIV(-)
3255966|NCT00798252|Experimental|Arm A (Capecitabine + Brivanib alaninate)|
3255967|NCT00798252|Experimental|Arm B (Doxorubicin + Brivanib alaninate)|
3255968|NCT00798252|Experimental|Arm C (Ixabepilone + Brivanib alaninate)|
3255970|NCT00798252|Experimental|Arm E (Paclitaxel + Brivanib alaninate)|
3255971|NCT00798239|Active Comparator|Control|The control arm is Iliac Crest Autograft
3255972|NCT00798239|Experimental|Prefix 150|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
3255973|NCT00798239|Experimental|Prefix 750|Prefix (AMPLEX) B2A Enhanced Ceramic Granules
3255974|NCT00798226|Active Comparator|1|n-3 fatty acid
3255975|NCT00798226|Placebo Comparator|2|Olive oil
3255976|NCT00798213|Experimental|Participants with AML randomized to SCH 727965|
3255977|NCT00798213|Active Comparator|Participants with AML randomized to gemtuzumab ozogamicin|
3255978|NCT00798213|Experimental|AML treated w/ SCH 727965 after prog. on gemtuzumab ozogamicin|
3255979|NCT00798213|Experimental|Participants with ALL treated with SCH 727965|
3255980|NCT00798200|Other|Exercise|All participants will take part in a supervised, structured, exercise program
3255981|NCT00798187||Homogeneous Support Group|
3255982|NCT00798187||Heterogeneous Support Group One|
3255983|NCT00798187||Heterogeneous Support Group Two|
3255984|NCT00798174|No Intervention|Standard|The DFT with the standard SVC coil.
3255985|NCT00798174|Experimental|Azygos coil|DFT with the azygos vein coil in place.
3255986|NCT00798161|Experimental|BI 1356 + metformin|BI 1356 low dose + metformin 500 mg, twice daily
3255987|NCT00798161|Placebo Comparator|matching placebo|matching placebo
3255988|NCT00798161|Experimental|BI 1356+ Metformin|BI 1356 low dose + metformin 1000 mg, twice daily
3255989|NCT00798161|Active Comparator|Metformin|Metformin 500 mg, twice daily
3255990|NCT00798161|Active Comparator|metformin|Metformin 1000 mg, twice daily
3255991|NCT00798161|Experimental|BI 1356|BI 1356 high dose, once daily
3255992|NCT00798148|Experimental|MIBG|
3255993|NCT00798135|Experimental|itraconazole|Patients will receive oral itraconazole 200mg a day until disease progression.
3255994|NCT00798122|Experimental|Women|IVUS and MRI performed in women with no obstructive CAD at angiography
3255995|NCT00798109|Experimental|Motivational Therapy|Four motivational interview for cannabis abuse in schizophrenia population during one month
3255996|NCT00798109|Other|Usual Care|Usual care with intensive psychotherapy
3255997|NCT00798096|Experimental|1|
3255998|NCT00798070|Experimental|Arm A: dtEC→dtT|Individually tailored and two weekly dosed epirubicin + cyclophosphamide followed by a three weeks break followed by biweekly and tailored docetaxel (dtEC→dtT) given every second week
3255999|NCT00798070|Active Comparator|Arm B: FEC→T|Fixed dosed and three weekly epirubicin, cyclophosphamide and 5-fluorouracil, followed by fixed dosed and three weekly docetaxel
3256000|NCT00798057||Proton Radiation|
3256001|NCT00798044|Experimental|Feedback to counselors|substance abuse counselors received feedback reports on their average performance and on the average performance of the clinic as a whole. Feedback reports contained information on average alliance, treatment satisfaction, and drug/alcohol use.
3256002|NCT00798044|No Intervention|Treatment as Usual|No feedback reports were provided in this arm.
3256003|NCT00798031|Other|1|a minimum of two dental implants, but up to 3 dental implants, will be placed in each of 20 subjects. All surgical procedures will be performed as outpatient procedures at the College of Dentistry and implant placement will follow a one-stage procedure under local anesthesia. Placement of the 2-3 dental implants is the only intervention.
3256004|NCT00798018|Placebo Comparator|Air|air was used to inflate the cuff.
3256005|NCT00798018|Placebo Comparator|Normal Saline|Normal saline was used to inflate the cuff.
3256006|NCT00798018|Active Comparator|lidocaine|2% lidocaine was used to inflate the cuff.
3256007|NCT00798018|Experimental|tetracaine|1% tetracaine was used to inflate the cuff.
3256008|NCT00797992|Experimental|1|Myopic eyes with retinal neovascularization
3256009|NCT00797979|Experimental|1|Skull Grip bone fixation
3256010|NCT00797979|Active Comparator|2|Standard skull bon flap fixation, sutures
3256011|NCT00797966|Experimental|1|OPC-34712 + ADT
3256012|NCT00797966|Placebo Comparator|2|Placebo + ADT
3256013|NCT00797953|Experimental|Low dose|2 capsules of T89 with 1 placebo capsule each time, twice daily. The daily dose is 250 mg.
3256014|NCT00797953|Experimental|High dose|3 capsules of T89 each time, twice daily. The daily dose is 375 mg
3256015|NCT00797953|Placebo Comparator|Placebo|3 placebo capsules (PC) each time, twice per day. The daily dose is 0 mg.
3256016|NCT00797940|Experimental|Single Arm|Up to 42 subjects with first recurrence or progression of GBM
3256017|NCT00797927|Experimental|1. quetiapine|quetiapine would replace the original conventional antipsychotic agent
3256018|NCT00797927|No Intervention|2. conventional antipsychotics|
3256019|NCT00797914||Patients undergoing colonoscopy|Patients who are undergoing outpatient colonoscopy for colorectal cancer screening or for symptoms suggestive of colonic diseases.
3256020|NCT00797901|Experimental|Collaborative Care, Treatment as Usual|
3256021|NCT00797888|Experimental|Telephonic|Tailored telephonic intervention to improve HbA1c for participants in the diabetes registry
3256022|NCT00797888|Active Comparator|Standard registry|People with diabetes who are in the A1c registry may receive letters from the DOHMH to promote improved A1c and also give lists of bronx resources for healther foof and activites
3256023|NCT00797875|Experimental|1|PNF stretching x 5 repetitions for 3 days
3256024|NCT00797875|Active Comparator|2|passive stretching
3256025|NCT00797862|Experimental|Aliskiren + Amlodipine|Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.
3256052|NCT00797693|Experimental|Vaginal Misoprostol|A drug is given vaginally and to compare this with an oral administration of the same drug to find it is effect on it is effect on the cervix
3256026|NCT00797862|Experimental|Aliskiren Start - Amlodipine Add-On|Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.
3256027|NCT00797862|Experimental|Amlodipine Start- Aliskiren Add-On|Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks.
3256028|NCT00797849|Active Comparator|1|Wear prosthetics laminated with Farabloc surrounding the liner. If not wearing prosthetics, subject needs to wear Farabloc sock or glove over shrinker.
3256029|NCT00797849|Sham Comparator|2|Wear prosthetics laminated with sham material surrounding the liner. If not wearing prosthetics, subject needs to wear sock or glove over shrinker.
3256030|NCT00797836|Experimental|Quantiferon Gold|
3256031|NCT00797823|Placebo Comparator|Insulin + Placebo|Glycemic control of subject participants was managed by the closed-loop system which delivered insulin and normal saline (instead of glucagon) as a placebo, based upon algorithm calculations.
3256032|NCT00797823|Active Comparator|Insulin + Glucagon|Glycemic control of subject participants was managed by the system which delivered insulin and glucagon based upon algorithm calculations.
3256033|NCT00797823|Experimental|Pilot Study|Pilot studies designed to assess safety of the system. Includes 6 participants undergoing 7 studies.
3256034|NCT00797810|Experimental|therapy|
3256035|NCT00797797|Experimental|Milnacipran Added|
3256036|NCT00797797|Experimental|No Treatment Added|
3256037|NCT00797771|Experimental|A|"Adi insulin pump users"
3256038|NCT00797758|Experimental|1|Umbilical cord blood transplantation after reduced intensity conditioning
3256039|NCT00797745|Active Comparator|Standard of Care|"PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily for 48 weeks.~Subjects with >= 1 log decrease from baseline in HCV-RNA levels after 12 weeks, but still above the lower limit of quantitation, have the option of crossing over to PegIntron, ribavirin plus SCH 900518 400 mg and ritonavir 100 mg daily for 12 weeks. This is followed by standard of care, PegIntron and ribavirin, for a total treatment duration of up to 48 weeks."
3256040|NCT00797745|Experimental|2|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
3256041|NCT00797745|Experimental|3|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 400 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
3256042|NCT00797745|Experimental|4|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
3256043|NCT00797745|Experimental|5|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 400 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
3256044|NCT00797745|Experimental|6|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 100 mg twice daily plus ritonavir 100 mg twice daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
3256045|NCT00797745|Experimental|7|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 600 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
3256046|NCT00797732|Active Comparator|Active Acupuncture|The active intervention used a three-phase step-up protocol to gradually increase the body areas treated and needling intensity. Acupuncture needles (0.20x25mm) were inserted with a depth of 5-10 mm into predefined points based on a systematic literature review following the STRICTA guideline. Needles were stimulated to obtain the de qi sensation. An electroacupuncture (EA) device was connected at two acupoints. All needles remained in place for 30 minutes. The active acupuncture was administered once every 2 weeks for 24 weeks, starting 2 weeks into CRT and ending at 20 weeks after CRT. [Refs: Lu W, Wayne PM et al. Contemp Clin Trials 2012; 33; 700-711; MacPherson H, Altman DG et al. PLoS Med 2010;7:e1000261]
3256047|NCT00797732|Sham Comparator|Sham Acupuncture|The sham intervention was designed to be maximally inert and minimally invasive, while simulating most aspects of the active protocol. Sham needles (0.12x30mm) were inserted at 14 locations paralleling the same body regions needled in the active group; however, all sham point locations were off the pathways of traditional Chinese medicine acupuncture meridians and points. An identical but deactivated EA device was used following sham protocols previously used. The sham acupuncture was administered once every 2 weeks for 24 weeks, starting 2 weeks into CRT and ending at 20 weeks after CRT. [Refs: Lu W, Wayne PM et al. Contemp Clin Trials 2012; 33; 700-711; Wayne PA, Krebs DE et al. Arch Phys Med Rehabil 2005;86:2248-2255]
3256048|NCT00797719|Experimental|All|This is a single arm study. All patients enrolled will be in this arm.
3256049|NCT00797706|Placebo Comparator|Vehicle|
3256050|NCT00797706|Experimental|Low dose|
3256053|NCT00797693|Experimental|Oral Misoprostol|A drug is given vaginally and to compare this with an oral administration of the same drug to find it is effect on it is effect on the cervix
3256054|NCT00797680|Experimental|72 hours hypothermia|72 hours hypothermia
3256055|NCT00797680|Experimental|24 hours hypothermia|24 hours hypothermia
3256056|NCT00797667|Experimental|Telcagepant 140 mg|Participants receive one telcagepant 140 mg tablet and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks
3256057|NCT00797667|Experimental|Telcagepant 280 mg|Participants receive one telcagepant 280 mg tablet and one 140 mg telcagepant placebo, orally, twice daily for 12 weeks
3256058|NCT00797667|Placebo Comparator|Placebo|Participants receive one 140 mg telcagepant placebo and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks
3256059|NCT00797654|Experimental|1|Participants will receive pre and post HIV-test counseling and an information-motivation-behavior skills training combined with cognitive processing therapy
3256060|NCT00797654|Active Comparator|2|Participants will receive pre and post HIV-test counseling
3256061|NCT00797641||1|Patients admitted to the hospital, or inpatients admitted for another reason, presenting with overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia, as well as other clinical or laboratory evidence of acute blood loss from the upper gastrointestinal tract
3256062|NCT00797628|Experimental|Information Prescription|"Providers will give usual care to patients who smoke and a paper prescription with the name and url of the Smoking Coach website. The smoking coach website is a tailored, public health intervention for smoking cessation."
3256063|NCT00797628|Experimental|QUIT-PRIMO|Providers will give usual care to patients who smoke and then refer patients to the online smoking cessation system electronically.
3256064|NCT00797615|Placebo Comparator|Alternative Intervention|12-week alternate intervention program focused on building self-esteem and social self-efficacy
3256065|NCT00797615|Active Comparator|Active Intervention|12-week intervention program focused on dietary intake and physical activity
3256066|NCT00797602||Proton Radiation|
3256067|NCT00797589|Experimental|Ringer lactate|Crystalloid solution
3256068|NCT00797589|Experimental|HES solution (Tetraspan®)|Balanced colloid solution
3256069|NCT00797576||1/Cases|Subjects whom had cardioversion aborted due to LAA thrombus or suspicion of LAA thrombus on TEE.
3256070|NCT00797576||2/Controls|Subjects with underlying atrial fibrillation undergoing elective TEE as clinically indicated for any reason.
3256071|NCT00797563|Other|Subjects with diabetes|Subjects with diabetes use a new blood glucose monitoring system (BGMS) Apollo Blood Glucose Monitoring System with capillary blood; healthcare professionals use the new BGMS with subject capillary and venous blood.
3256072|NCT00797550|Active Comparator|Control|The Control arm of the study will receive bone autograft.
3256073|NCT00797550|Experimental|Treatment|The Treatment arm of the study will receive single level posterolateral spinal fusion between L1 to S1 levels with implantation of BRC product.
3256074|NCT00797524||DR|Diabetic Retinopathy
3256075|NCT00797524||ARMD|Age-Related Macular Degeneration
3256076|NCT00797524||ME|Macular Edema
3256077|NCT00797511|Experimental|Study Group|Participants will receive one dose of Tetanus, diphtheria (reduced antigen content), pertussis (acellular components) vaccine (TdcP-IPV, ADACEL Polio) on Day 0
3256078|NCT00797498||Xerostomia Questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
3256079|NCT00797485|Active Comparator|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive FOLFIRI chemotherapy comprising irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3256080|NCT00797485|Experimental|Arm II|Patients receive bevacizumab and FOLFIRI chemotherapy (B-FOLFIRI) as in arm I. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes on day 1 and oral capecitabine once every 12 hours on days 1-14. Treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3256081|NCT00797472|Active Comparator|Arm I: R-mabHD|Anti-hodgkin disease agent
3256082|NCT00797472|Active Comparator|Arm II: ABVD|
3256083|NCT00797459|Experimental|Restylane and Restylane with Lidocaine|This is a split-face design injecting both Restylane and Restylane-L injectable gels, administered once. Each subject received Restylane on one side of the face, and Restylane-L on the other. Subjects were blinded to which side of their face received Restylane or Restylane-L. The study was randomized and treatments successive.
3256084|NCT00797446||Photon/Proton Radiation Therapy|Data collection will be obtained from the patient's medical records including initial evaluation, pathology report, dosimetry information, radiotherapy completion records and follow-up.
3256085|NCT00797433||Mechanical ventilation|All male patients with acute respiratory failure requiring mechanical ventilation
3256086|NCT00797420|Other|Loading Dose|Loading Dose
3256087|NCT00797420|Other|Loading & high dose|Loading dose & high dose Fluconazole
3256088|NCT00797394|Experimental|Treated|
3256089|NCT00797394|Active Comparator|Control|
3256090|NCT00797381||1|
3256091|NCT00797381||2|
3256092|NCT00797368|Experimental|Manual Therapy and Exercise|Manual Therapy and Exercise
3256093|NCT00797368|Active Comparator|Home Exercise|Home Exercise
3256094|NCT00797342|Other|first of three dosing cohorts|
3256095|NCT00797342|Other|second of three dosing cohorts|
3256096|NCT00797342|Other|third of three dosing cohorts|
3256097|NCT00797329||observation|adult men with alcohol and polydrug use according to DSM-IV criteria, hospitalized in maximum security department between 2002 - 2008
3256098|NCT00797316|Experimental|Aliskiren plus Hydrochlorothiazide|Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.
3256099|NCT00797316|Active Comparator|Aliskiren|Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.
3256100|NCT00797303|Experimental|1|A single intraoperative subconjunctival application of bevacizumab and 2 months follow-up
3256101|NCT00797290||Photon/Proton Radiation Therapy|Photon/Proton Radiation Therapy
3256102|NCT00797277|Experimental|IM olanzapine|Patients of this arm received 10 mg IM olanzapine after randomization
3256103|NCT00797277|Active Comparator|IM haloperidol plus lorazepam|Patients of this arm received 5 mg IM haloperidol plus 2 mg IM lorazepam after randomization
3256104|NCT00797264|Experimental|A|Ketamine pre and per operative, and morphine postoperative
3256105|NCT00797264|Active Comparator|B|NaCl pre and per operative, and morphine postoperative
3256106|NCT00797264|Experimental|C|Ketamine and morphine postoperative
3256107|NCT00797251||Right posterior section group|Patients with tumors in the right posterior section of the liver (segments 6-7)
3256108|NCT00797238||NSCLC stage III|Taiwanese NSCLC patients with stage III
3256109|NCT00797225|Experimental|1|NBI-56418 sodium or placebo
3256110|NCT00797225|Experimental|2|NBI-56418 sodium or placebo
3256111|NCT00797225|Other|3|Leuprorelin or placebo
3256112|NCT00797225|Placebo Comparator|4|placebo
3256113|NCT00797212|Other|Subjects with diabetes|Subjects with diabetes use a new Apollo Blood Glucose Monitoring System with blood obtained from the palm and forearm
3256114|NCT00797199||1-Treatment Group 1|Women receiving HRT treatment of Premarin.
3256115|NCT00797199||2-Treatment Group 2|Women receiving combination HRT treatment of Premarin + Provera.
3256116|NCT00797199||3- Treatment Group 3|Women receiving combination HRT treatment of Premarin + Prometrium.
3256117|NCT00797199||4- Controls|Women not on HRT or healthy controls.
3256118|NCT00797186|Other|Intensive therapy|There is one arm in this trial. All patients receive the same therapy. The goal is to compare a noninvasive and invasive imaging technique in the same population.
3256119|NCT00797134||DR|Diabetic Retinopathy
3256120|NCT00797121|Experimental|Preoperative biliary drainage|
3256121|NCT00797121|No Intervention|Controlled group|
3256122|NCT00797108|Experimental|1|Loading dose of IV sulopenem with switch to oral PF-03709270
3256123|NCT00797108|Experimental|2|IV sulopenem with switch to oral PF-03709270
3256124|NCT00797108|Active Comparator|3|IV ceftriaxone with switch to oral amoxicillin/clavulanate potassium comparator
3256125|NCT00797082|Experimental|1|"MRI = Myocardial Perfusion Stress and MPS = Myocardial Perfusion Scintigraphy~Diabetic patients~Coronary insufficiency"
3256126|NCT00797069|Active Comparator|standard nutritional product|Standard nutritional product not specific for diabetes
3256127|NCT00797069|Active Comparator|diabetes specific product|Diabetes specific nutritional product
3256128|NCT00797069|Experimental|Experimental diabetes specific product|Diabetes specific experimental nutritional product
3256129|NCT00797056|Experimental|G-CSF|
3256130|NCT00797056|Placebo Comparator|Placebo|
3256131|NCT00797043||Photon/Proton Radiation Therapy|Data consolidation and analysis
3256132|NCT00797030|Active Comparator|1|Ten HIV-positive-patients with dry eye diagnosis received sodium carboxymethylcellulose 0.5% drops (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) for six months.
3256133|NCT00797030|Other|2|Ten HIV-positive-patients with dry eye received sodium carboximethylcelullose 0.5% (1 drop 4 times per day) during six months
3256134|NCT00797017||001|
3256135|NCT00797017||002|
3256136|NCT00797017||003|
3256137|NCT00797017||004|
3256138|NCT00797017||005|
3256139|NCT00797017||006|
3256140|NCT00797017||007|
3256141|NCT00797004||endoscopic sinus procedure candidates|
3256142|NCT00796991|Active Comparator|Arm A|
3256143|NCT00796991|Active Comparator|Arm B|
3256144|NCT00796991|Active Comparator|Arm C|
3256145|NCT00796978|Experimental|trastuzumab|
3256146|NCT00796965|Experimental|1|
3256147|NCT00796965|Placebo Comparator|2|
3256148|NCT00796952|Active Comparator|Usual Care|"Patient management by the attending Radiation oncologist as usual."
3256149|NCT00796952|Experimental|Pharyngocise|Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their chemo-radiation treatment (up to a maximum of 6 weeks)
3256150|NCT00796952|Sham Comparator|Valchuff|"Standardised sham swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of chemo-radiation treatment."
3256151|NCT00796939|Active Comparator|Green Light Mask|
3256152|NCT00796939|Placebo Comparator|Red light mask|
3256153|NCT00796926|Experimental|Systane Ultra|Used four times a day topically to each eye
3256154|NCT00796926|Active Comparator|Refresh|Used four times a day topically to each eye
3256155|NCT00796913|Active Comparator|Stop of medication after remission|"After enetering remission patients are randomised to continue low dose medication or to stop medication: Overview of study described in:~Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487."
3256156|NCT00796913|No Intervention|Medication for 2 yrs after remission|See Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.
3256157|NCT00796913|Experimental|Se-yeast 200 Microgr/day + arm A|Additional arm where patients have been taking Se supplements during RISG1 therapy, and for 2 years after ATD withdrawal.
3256158|NCT00796900|Experimental|Dantrolene|
3256159|NCT00796900|Placebo Comparator|Placebo|
3256160|NCT00796887|Experimental|Niaspan® 500mg|
3256161|NCT00796887|Experimental|Niaspan® 1000mg|
3256162|NCT00796887|Placebo Comparator|Placebo|
3256163|NCT00796861|Experimental|Single Arm|Sunitinib (50mg PO daily x 4 wks + 2 wks rest x 3 cycles if able to tolerate tx
3256164|NCT00796822|Experimental|1|Participants will receive pentoxifylline.
3256165|NCT00796822|Placebo Comparator|2|Participants will receive placebo.
3256166|NCT00796809||Biologics|Patients receiving TNF inhibitors or biologic agents
3256167|NCT00796809||DMARD|Patients receiving methotrexate without any biologic
3256168|NCT00796796|Experimental|Cohort 1 (Starting Dose)|"Temsirolimus 20 mg IV weekly for 4 weeks~Radiation therapy will begin on Day 2, one day after the initial dose of temsirolimus. Treatment will consist of daily fractions of 250 cGy, 5 days per week to a total cumulative dose of 3500 cGy for a total of 14 days."
3256169|NCT00796796|Experimental|Cohort 2|"Temsirolimus 25 mg IV weekly for 4 weeks~Radiation therapy will begin on Day 2, one day after the initial dose of temsirolimus. Treatment will consist of daily fractions of 250 cGy, 5 days per week to a total cumulative dose of 3500 cGy for a total of 14 days."
3256170|NCT00796783||1|Patients with presumed Cushing's disease who have failed pituitary surgery and/or radiation and require medical treatment for recurrent or persistent Cushing's syndrome.
3256171|NCT00796770|Experimental|Dendritic Cell Vaccine|Autologous dendritic cells generated using GM-CSF and interferon alpha, loaded with HIV lipopeptides and activated with lipopolysaccharide
3256172|NCT00796757|Experimental|1|
3256173|NCT00796744|Placebo Comparator|Placebo Vehicle Control|control placebo vehicle gel
3256174|NCT00796744|Active Comparator|0.03% DSC127|0.03 % DSC127 in Vehicle Control
3256175|NCT00796744|Active Comparator|0.01% DSC127|0.01% DSC127 in Vehicle Control
3256176|NCT00796718|Experimental|Capecitabine|Capecitabine orally twice daily plus standard radiotherapy for 5 weeks, followed by surgery within 6 weeks after completion of treatment.
3256177|NCT00796705|Experimental|Adalimumab / Adalimumab Placebo|1 sub-cutaneous (SQ) injection of adalimumab or 1 SQ injection of placebo will be given in a blinded and alternating fashion for a total of 12 weeks
3256178|NCT00796705|Experimental|Etanercept|Participants will receive 1 SQ injection of etanercept each week for 12 weeks
3256179|NCT00796692|Experimental|Group 2|Low molecular weight heparin
3256180|NCT00796692|Active Comparator|Group 1|Unfractionated heparin(UFH)
3256181|NCT00796679|Experimental|1|paricalcitol
3256182|NCT00796679|Placebo Comparator|2|placebo
3256183|NCT00796666|Experimental|Sitaxsentan and Placebo|Monotherapy arm
3256184|NCT00796666|Experimental|Sitaxsentan and Sildenafil|Combination treatment
3256185|NCT00796653|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
3256186|NCT00796653|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
3256187|NCT00796653|Active Comparator|Formoterol 12mcg|12mcg inhaled twice daily from the Aerolizer inhaler
3256188|NCT00796653|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
3256189|NCT00796627|Sham Comparator|Healthy volunteers|"Healthy volunteers with no burn wounds Volunteers donate blood that will be studied in comparison to patients who have sustained burns. The circulating bone marrow stem cells will be counted and compared to the levels in burn patients. Six 12 ml tubes will be taken for the study. You will not be compensated. But you will be helping to advance science if you join the study."
3256190|NCT00796627|Active Comparator|Burn volunteer|To recruit burn wound patients with defined clinical criteria for study. A second-degree burn of at least 10 cm2 to up to 95% BSA; age = 14-75 years; BP > 100 mm Hg systolic; heart rate < 100 beats/minute; urine output > 30 ml/hour; area of burn < 20% of BSA; body temperature = 98.5-101 degrees Fahrenheit; serum albumin > 3 mg/ml; and informed consent. We will also obtain a history regarding the presence or absence of risk factors that may affect CAC numbers: hypertension > 1 year; smoking > 2 pack-years or within the last year; diabetes mellitus; and family history of premature coronary artery disease (men < 55 and women < 65 years of age).Six 12 ml tubes will be taken at 5 time points
3256191|NCT00796614|Placebo Comparator|Placebo|Participants received matching placebo to tamsulosin hydrochloride via opened capsules every day for 14 weeks
3256192|NCT00796614|Experimental|Low dose|Participants received 0.001 - 0.002 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
3256193|NCT00796614|Experimental|Medium dose|Participants received 0.002 - 0.004 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
3256194|NCT00796614|Experimental|High dose|Participants received 0.004 - 0.008 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
3256195|NCT00796601|Experimental|Esreboxetine|
3256196|NCT00796601|Placebo Comparator|Placebo|
3256197|NCT00796588|No Intervention|Control group|Patients undergoing liver surgery without the designated intervention
3256198|NCT00796588|Other|RIPC|application of pneumatic tourniquet in patients undergoing liver surgery
3256199|NCT00796575|Experimental|CS-8080|3 mg CS-8080, 10mg CS-8080, 20 mg CS-8080
3256200|NCT00796575|Placebo Comparator|placebo|placebo
3256201|NCT00796562|Active Comparator|Arm A|All patients except those with acute lymphoblastic leukemias and lymphoblastic lymphomas. Busulfan will be administered 1 mg/kg oral (or 0.8 mg/kg IV) four times per day for four days, followed by cyclophosphamide 50 mg/kg once per day for two days.
3256202|NCT00796562|Active Comparator|Arm B|Patients with acute lymphocytic leukemia or lymphoblastic lymphoma. Cyclophosphamide will be administered 50 mg/kg once per day for two days, followed by total body irradiation at 300 cGy per day for four days.
3256203|NCT00796549|Experimental|BIBW 2992|BIBW 2992 in EGFR FISH positive NSCLC patients
3256204|NCT00796536|Experimental|1|Participants will undergo 12 weeks of group cognitive behavioral therapy (CBT) and a pre- and post-intervention MRI brain scan.
3256205|NCT00796536|Active Comparator|2|Participants will received 12 weeks of pain education and a pre- and post-intervention MRI brain scan.
3256206|NCT00796523|Experimental|Happiest Baby videotape|videotape describing the Happiest Baby on the Block technique
3256207|NCT00796523|Placebo Comparator|control videotape|videotape with normal newborn instruction
3256208|NCT00796510|Experimental|Sitaxsentan|Monotherapy arm
3256209|NCT00796510|Experimental|Sitaxsentan and Sildenafil|Combination treatment
3256210|NCT00796497|Experimental|ondansetron|
3256211|NCT00796484|Experimental|1|
3256212|NCT00796458|Active Comparator|Arm I|Patients continue to receive LHRH-A therapy until disease progression.
3256213|NCT00796458|Experimental|Arm II|Patients receive LHRH-A therapy as in arm I. Patients also receive docetaxel IV on day 1. Treatment with docetaxel repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3256214|NCT00796445|Experimental|MAGE-A3 Group|Patients who received up to 13 doses of recMAGE-A3 + AS15 ASCI.
3256215|NCT00796445|Placebo Comparator|Placebo Group|Patients who received up to 13 doses of placebo.
3256216|NCT00796419|Experimental|1|Intravenous 5% human albumin
3256217|NCT00796419|Experimental|2|Intravenous 6% hetastarch
3256218|NCT00796393|Experimental|2|Subject with active product, not vaccinated against influenza.
3256219|NCT00796393|Placebo Comparator|3|Subject with placebo, vaccinated against influenza.
3256220|NCT00796393|Placebo Comparator|4|Subject with placebo, not vaccinated against influenza.
3256221|NCT00796393|Experimental|1|Subject with active product, vaccinated against influenza
3256222|NCT00796367|Placebo Comparator|Placebo|Placebo
3256223|NCT00796367|Experimental|VI-0521 Mid|7.5 mg phentermine and 46 mg topiramate
3256224|NCT00796367|Experimental|VI-0521 Top|15 mg phentermine and 92 mg topiramate
3256225|NCT00796354|Active Comparator|NRL920|
3256226|NCT00796354|Placebo Comparator|Placebo|
3256227|NCT00796341|Experimental|1|
3256228|NCT00796341|No Intervention|2|
3256229|NCT00796328|Experimental|1|
3256230|NCT00796315|Experimental|Doxylamine Succinate (USP)|Doxylamine Succinate United States Pharmacopeia (USP)
3256231|NCT00796302|Experimental|1|Children will receive active methylphenidate HCl and active risperidone. Parents will receive parent management training.
3256232|NCT00796302|Active Comparator|2|Children will receive methylphenidate HCl and placebo instead of the active risperidone. Parents will receive parent management training.
3256233|NCT00796289|Experimental|GnRH High Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
3256234|NCT00796289|Experimental|GnRH Medium Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a medium target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
3256235|NCT00796289|Experimental|GnRH Low Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a low target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
3256236|NCT00796289|Active Comparator|Clomiphene Citrate|Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral 50 mg clomiphene citrate for 5 days
3256237|NCT00796289|Placebo Comparator|Placebo|Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
3256238|NCT00796263|Other|HAART|"The proposed HAART regimen consists of:~2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications~Dolutegravir(DTG) 50 mg orally once daily"
3256239|NCT00796250|Experimental|Group A|
3256240|NCT00796250|Active Comparator|Group B|
3256241|NCT00796237|Experimental|WBV|In their regular physiotherapy sessions, the subjects in the experimental group will receive whole body vibration therapy for a duration of 4 weeks during their stay in the Tung Wah Hospital.
3256242|NCT00796237|Active Comparator|CON|The subjects in this group will not receive whole body vibration therapy.
3256243|NCT00796224|Active Comparator|1.|60 mg/kg azithromycin ER (Extended Release)arm
3256244|NCT00796224|Active Comparator|2.|30 mg/kg azithromycin IR (Immediate Release) arm
3256245|NCT00796211|Experimental|1|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
3256246|NCT00796211|Experimental|2|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
3256247|NCT00796211|Active Comparator|3|0.1% nortriptyline HCl topical cream
3256248|NCT00796211|Active Comparator|4|0.005% calcipotriol topical cream
3256249|NCT00796211|Placebo Comparator|5|Vehicle of CRx-197 topical cream (placebo)
3256250|NCT00796198|Active Comparator|Xalatan+Cosopt|Cosopt will be added to Xalatan when Xalatan is effective but not sufficient to reach the target pressure (Add group) (n = 25)
3256251|NCT00796198|Active Comparator|Xalatan|when Xalatan is effective and sufficient to reach the target pressure no other medication will be added (control group) (n = 25)
3256252|NCT00796172|Experimental|1|Medication adherence system (MAS) plus counseling from doctors
3256253|NCT00796172|Active Comparator|2|Usual care
3256254|NCT00796159||Olmesartan medoxomil + HCTZ|
3256255|NCT00796133|Active Comparator|1|0.5 ml of NES/E2 equaling 0.45 g and contains 1.5 mg NES/0.5 mg E2
3256256|NCT00796133|Active Comparator|2|1.0 ml of NES/E2 gel equaling 0.9 g and contains 3.0 mg NES/1.0 mg E2
3256257|NCT00796133|Active Comparator|3|1.5 ml of NES/E2 gel equaling 4.5 mg NES/1.5 mg E2
3256258|NCT00796120|Experimental|Trabectedin|Trabectedin 1.5 milligram per square meter (mg/m^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
3256259|NCT00796120|Active Comparator|Doxorubicin plus Ifosfamide|Doxorubicin (as a monotherapy) 75 mg per m^2 will be given intravenously every 3 weeks or Doxorubicin 60 mg per m^2 will be given intravenously every 3 weeks followed by ifosfamide 6 to 9 gram (g)/m^2 every 3 weeks until disease progression.
3256260|NCT00796107|Experimental|R1507 in Combination With Letrozole|
3256261|NCT00796094||Evaluation of tissue elasticity|Evaluate the potential importance of tissue elasticity in the assessment soft tissue structures.
3256262|NCT00796068|Experimental|Arm I (low risk for graft failure)|"Patients receive a conditioning regimen comprising fludarabine phosphate IV over 1 hour QD on days -6 to -2 and treosulfan IV over 120 minutes on days - 6 to -4. Patients undergo TBI on day -1. Patients then undergo donor UCBT on day 0.~Patients receive GVHD prophylaxis comprising cyclosporine IV or PO 2-3 times daily on days -3 to 100, followed by a taper in the absence of GVHD. Patients also receive mycophenolate mofetil IV 3 times daily on days 0 to 40, followed by a taper in the absence of GVHD."
3256263|NCT00796068|Experimental|Arm II (high risk for graft failure)|Patients receive a conditioning regimen, TBI, donor UCBT, GVHD prophylaxis, and mycophenolate mofetil as in Arm I.
3256264|NCT00796055|Experimental|1|MEDI-547
3256265|NCT00796042|Active Comparator|1|Usual Care
3256266|NCT00796042|Experimental|2|Individualized, Community-based, Pressure management and Mobility program:
3256267|NCT00796003|Experimental|Phase I: JNJ-30979754 15 mg/m2|JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
3256268|NCT00796003|Experimental|Phase I: JNJ-30979754 20 mg/m2|JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
3256269|NCT00796003|Experimental|Phase II: JNJ-30979754 20 mg/m2|JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles
3256270|NCT00795977|Experimental|dendritic cells|
3256271|NCT00795964|Experimental|1|intraoperative mechanical ventilation with 6 ml/kg predicted body weight
3256272|NCT00795964|Active Comparator|2|intraoperative mechanical ventilation with 12 ml/kg predicted body weight
3256273|NCT00795951|Experimental|TRUE Test panels 1.1, 2,1, 3,1|All subjects were patched with TRUE Test panels 1.1, 2,1 and 3.1
3256274|NCT00795938|Active Comparator|Conventional Oral Tablet With Water|
3256275|NCT00795938|Experimental|Experimental Tablet With Water|
3256276|NCT00795938|Experimental|Experimental Tablet Without Water|
3256277|NCT00795925|Experimental|propiverine hydrochloride|
3256278|NCT00795912|Active Comparator|1|Atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
3256279|NCT00795912|No Intervention|2|Usual medical care of heart failure
3256280|NCT00795899|Experimental|1|Epirubicin/Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab in patients with HER-2 overexpression
3256281|NCT00795886|Experimental|All participants|
3256282|NCT00795860|Active Comparator|Weight loss - diet only|
3256283|NCT00795860|Experimental|Weight loss plus exercise|
3256284|NCT00795847|Experimental|1. Preminent|Patients with blood pressure self-measurement-proven morning hypertension are treated with Preminent 1T qd for 3 months.
3256285|NCT00795847|Active Comparator|2. High-dose losartan|Patients with blood pressure self-measurement-proven morning hypertension are treated with losartan 100 mg qd for 3 months.
3256286|NCT00795834|Placebo Comparator|Beverage|
3256287|NCT00795834|Active Comparator|High Polyphenol Beverage|
3256288|NCT00795821|Experimental|LY2216684|"10-week Acute Treatment Phase: Day after Week 0=start of 6 milligram (mg) once daily (QD) dosing; Week 1=all participants titrated to 9 mg QD; After Week 1=dose increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.~1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of acute treatment phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62)."
3256289|NCT00795821|Placebo Comparator|Placebo|"10-week Acute Treatment Phase: 3 tablets QD for 10 weeks~1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684 dose; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62)."
3256290|NCT00795808|Experimental|BMI > 32|Women with BMI > 32
3256291|NCT00795808|Experimental|BMI </= 32|Women with BMI </= 32
3256292|NCT00795795|Active Comparator|with PGS|IVF cycles with Preimplantation Genetic Screening (PGS)
3256293|NCT00795795|Active Comparator|Without PGS|IVF cycle without Preimplantation Genetic Screening
3256294|NCT00795782|Experimental|UniCND|Limited/ipsilateral central lymph node dissection
3256295|NCT00795782|Active Comparator|BiCND|Comprehensive/bilateral central lymph node dissection
3256296|NCT00795782|No Intervention|NoCND|No central lymph node dissection
3256297|NCT00795769|Experimental|Ondansetron therapy|Patients receive ondansetron IV once 30-60 minutes before undergoing autologous peripheral blood stem cell transplantation.
3256298|NCT00795756|Experimental|Intrathecal DepoCyte|I.t. DepoCyte 50 mg admninistered x6-8 (depending on immunophenotypic disease subset) during induction/consolidation/eraly maintenance phases
3256299|NCT00795756|Active Comparator|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg injected intrathecally x12 during indiction/consolidation phases
3256300|NCT00795730|Placebo Comparator|placebo|
3256301|NCT00795730|Experimental|NSA-789|
3256302|NCT00795717|Active Comparator|Lovaza|Lovaza, dietary counseling
3256303|NCT00795717|Placebo Comparator|Placebo|Placebo, dietary counseling
3256304|NCT00795704|Placebo Comparator|Placebo|Control Group
3256305|NCT00795704|Active Comparator|Mulberry Leaf Extract|
3256306|NCT00795691|Experimental|1|low-carbohydrate diet
3256307|NCT00795691|Active Comparator|2|low-fat diet
3256308|NCT00795665|Experimental|Bevacizumab and Carmustine|
3256309|NCT00795652|Experimental|Distance Treatment|50% randomized to receive Distance Treatment for postpartum depression
3256310|NCT00795652|No Intervention|Usual Care Services|50% randomized to receive usual care services for postpartum depression
3256311|NCT00795639|Experimental|Sitaxsentan|Monotherapy
3256312|NCT00795639|Placebo Comparator|Sitaxsentan Placebo|Monotherapy
3256313|NCT00795626|Experimental|Lifestyle counseling|"Two groups:~control - conventional care~intervention - systematic education in the reduction of the risk estimate to cardiovascular events"
3256314|NCT00795613|Experimental|PET pos|Patients With Interim Pet Positive Proceed To Escalated Beacopp Regimen
3256315|NCT00795613|Other|PET negative|Patients With Interim-Pet Negative Continue The Conventional ABVD Regimen
3256316|NCT00795600|Experimental|insulin detemir|Insulin detemir injected subcutaneously (s.c.) in the evening in combination with insulin aspart injected s.c. as mealtime insulin for 26 weeks
3256426|NCT00794807|Experimental|Alefacept|
3256511|NCT00794079|Experimental|A|omega-3 fatty acids
3256317|NCT00795600|Active Comparator|insulin NPH|Insulin isophane (Neutral Protamine Hagedorn, NPH) injected subcutaneously (s.c.) in the evening in combination with insulin aspart injected s.c. as mealtime insulin for 26 weeks
3256318|NCT00795587|Active Comparator|mannitol high dose|mannitol 20% 0,8 g/ kg on minutes
3256319|NCT00795587|Active Comparator|mannitol low dose|mannitol 20% 0,4 g/ kg on minutes
3256320|NCT00795574|Experimental|infliximab|Double blind placebo cross-over
3256321|NCT00795574|Placebo Comparator|Placebo|Double blind placebo controlled cross-over
3256322|NCT00795561|Experimental|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
3256323|NCT00795561|Active Comparator|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
3256324|NCT00795548|Experimental|5-Azacitidine|5-Azacitidine in addition to standard donor lymphocyte infusions.
3256325|NCT00795522|Experimental|Arm 1|Desloratadine
3256326|NCT00795509||Tolterodine tartrate.|Patients taking Tolterodine tartrate.
3256327|NCT00795496||AD patients|AD patients who fulfill the inclusion criteria for the study
3256328|NCT00795483|Experimental|1-ANNUAL|1. Zoledronic acid + Lifestyle modifications (experimental)
3256329|NCT00795483|Other|2-CONTROL|2. Lifestyle modifications (control)
3256330|NCT00795483|Experimental|3-BIENNIAL|3. Zoledronic acid + Lifestyle modifications (experimental)
3256331|NCT00795470|No Intervention|No catheter change no antimicrobial|Urinary catheter will not be changed and no antimicrobials will be prescribed
3256332|NCT00795470|Active Comparator|Antimicrobial and catheter change|
3256333|NCT00795470|Active Comparator|Catheter change and NO antimicrobial|
3256334|NCT00795470|Active Comparator|Antimicrobial and NO catheter change|
3256335|NCT00795457|Experimental|1|Patients must have undergone surgery or biopsy alone ≤16 weeks prior to study entry (no postoperative radiation or chemotherapy).
3256336|NCT00795457|Experimental|2|Patients received surgery or biopsy and radiation therapy (RT) (including fractionated external beam radiation therapy and/or stereotactic radiosurgery), which was completed ≥6 months prior to enrollment, and have a baseline MRI scan (within 4 weeks of the first vaccine) that shows stable disease or regression.
3256337|NCT00795444|Experimental|Maraviroc|Adult patients with HIV infection and a viral load that has been suppressed for a long period (less than 50 copies/mL for at least 2 years) while on antiretroviral therapy.The treatment group will maintain the habitual antiretroviral therapy combined with maraviroc.
3256338|NCT00795418|Experimental|CAD106|
3256339|NCT00795418|Placebo Comparator|Placebo|
3256340|NCT00795405|Sham Comparator|1|No exposure to sporting events
3256341|NCT00795405|Experimental|2|Exposure to sporting events
3256342|NCT00795392||1|Patients assessed with ASA physical status scale
3256343|NCT00795392||2|Patients assessed with full-scale psychological factors
3256344|NCT00795379|Experimental|IE|Participants will complete an at home four-week, intervention targeting their negative cognitions triggered by physical sensations. The goal of IE is to purposefully induce bodily sensations related to autonomic arousal so that participants can learn that those sensations are not harmful. IE and Cognitive restructuring have been found to be superior to progressive muscle relaxation as a way to avoid aversive autonomic sensations.
3256345|NCT00795379|No Intervention|2|waitlist control
3256346|NCT00795366|Active Comparator|AVP, arginine vasopressin|Vasopressin
3256347|NCT00795366|Active Comparator|Standard Catecholamine|levophed, dopamine, phenylephrine)
3256348|NCT00795353||1. Amevive Exposure|Canadian subjects with moderate to severe chronic plaque psoriasis
3256349|NCT00795340|Experimental|Arm I Cediranib|Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
3256350|NCT00795340|Placebo Comparator|Arm II Placebo|Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.
3256351|NCT00795327|Experimental|1|single arm study
3256352|NCT00795314|Active Comparator|1|Propofol-fentanyl combined anesthesia
3256353|NCT00795314|Experimental|2|Propofol-butorphanol combined anesthesia
3256354|NCT00795288|Experimental|Simvastatin, 80 mg/day|Simvastatin, 80 mg/day for 21 days
3256355|NCT00795288|Placebo Comparator|Placebo|Placebo
3256356|NCT00795275|Experimental|IFG|people with impaired fasting glucose
3256357|NCT00795275|Experimental|NGT|people with normal glucose tolerance
3256358|NCT00795262|Placebo Comparator|placebo comparator|Quinapril 40 mg (Accupril)plus placebo will be given for 8 weeks.
3256359|NCT00795262|Active Comparator|Active comparator|Quinapril 40 mg plus Alpha Lipoic Acid (ALA)on vascular effects of patients with diabetes and hypertension
3256360|NCT00795249|Experimental|smoker|Individuals who have a habit of chronic smoking without any coronary risk factors
3256361|NCT00795249|No Intervention|non-smoker|the age-matched healthy volunteers
3256362|NCT00795236|No Intervention|Observational|Observe to determine free-running versus entrained status.
3256363|NCT00795236|Experimental|Melatonin|Subjects with free-running rhythms will take melatonin.
3256364|NCT00795223|Active Comparator|1|Injection of 0.3 mg morphine with spinal block and perform femoral nerve block with 0.5% bupivacaine
3256365|NCT00795223|Active Comparator|2|Injection of 0.3 mg morphine with spinal block and perform femoral nerve block with 0.25% bupivacaine
3256366|NCT00795223|Active Comparator|3|Injection of 0.2 mg morphine with spinal block and perform femoral nerve block with 0.5% bupivacaine
3256367|NCT00795223|Active Comparator|4|Injection of 0.2 mg morphine with spinal block and perform femoral nerve block with 0.25% bupivacaine
3256368|NCT00795210|Experimental|GH 6mcg/kg/d|Recombinant human growth hormone 6mcg/kg SC once daily
3256369|NCT00795210|Experimental|GH 2mg daily|Recombinant human growth hormone 2mg SC once daily
3256370|NCT00795210|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks
3256371|NCT00795197||Screening Group|Screening Group
3256469|NCT00794443|Active Comparator|3. Daily|Daily administration
3256372|NCT00795184|Other|Imaging Procedures HDWLE first NBI second and pCLE|All patients undergo both endoscopic imaging procedures and then the endomicroscopy procedure; the endoscopic imaging procedures being performed back to back by two endoscopists, blinded to each other.
3256373|NCT00795184|Other|Imaging Procedures NBI first HDWLE second and pCLE|All patients undergo both endoscopic imaging procedures and then the endomicroscopy procedure; the endoscopic imaging procedures being performed back to back by two endoscopists, blinded to each other.
3256374|NCT00795171|Experimental|Docetaxel + Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
3256375|NCT00795171|Active Comparator|Taxotere|docetaxel 75mg/m2 day1 q 21d x 4 cycles
3256376|NCT00795158|Experimental|Arm 1|
3256377|NCT00795145|Placebo Comparator|Cohort 1: Placebo|
3256378|NCT00795145|Experimental|Cohort 1: 900 mg linezolid|
3256379|NCT00795145|Experimental|Cohort 1: 1200 mg linezolid|
3256380|NCT00795145|Placebo Comparator|Cohort 2: Placebo|
3256381|NCT00795145|Experimental|Cohort 2: 600 mg linezolid|
3256382|NCT00795145|Experimental|Cohort 2: 1200 mg linezolid|
3256383|NCT00795145|Active Comparator|Cohort 2: 400 mg Moxifloxacin|
3256384|NCT00795132|Active Comparator|Related BM PBSC|Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor related to the participant/recipient
3256385|NCT00795132|Active Comparator|Unrelated BM PBSC|Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor unrelated to the participant/recipient
3256386|NCT00795132|Active Comparator|Unrelated Blood Cord|Blood Cord donated from a donor unrelated to the participant/recipient
3256387|NCT00795119|Experimental|NIRS|Children who undergo NIRS
3256388|NCT00795106|Active Comparator|Capsaicin patch|Patches will contain capsaicin 0.1% (500 mcg)
3256389|NCT00795106|Placebo Comparator|Placebo patch|Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing.
3256390|NCT00795093||1|552 GERD patients, partial responders to PPI treatment
3256391|NCT00795080||1|Normal volunteers who do not have malformations in their cerebral spinal fluid (CSF)
3256392|NCT00795080||2|Patients with incidentally discovered Chiari 1 DVS malformation of the cerebral spinal fluid (CSF)
3256393|NCT00795080||3|Patients with known Chiari or any other CVJ malformations undergoing a workup prior to surgery. Research images will be added to the clinically ordered exams ordered at 3 months and 1 year after surgery.
3256394|NCT00795067||Carotid atherosclerosis group|Patients who undergo carotid ultrasound examination for carotid atherosclerosis screening
3256395|NCT00795054||allogeneic stem cell recipients|Pediatric and adult allogeneic stem cell transplant recipients and their care givers.
3256396|NCT00795041||1|10 women with indication for ART with ICSI or IVF
3256397|NCT00795028|Active Comparator|1|Standard Care for people after a hip fracture
3256398|NCT00795028|Experimental|2|Standard Care + exercise intervention
3256399|NCT00795015|Active Comparator|leuven|these patients had their IV insulin controlled by using the protocol adapted from van den Berghe et al. University of Leuven, Belgium, NEJM Nov. 2001
3256400|NCT00795015|Active Comparator|glucommander|these subjects had IV insulin controlled by a computer program called the glucommander described by Davidson, P et al Diabetes Care Oct. 2005
3256401|NCT00795002|Experimental|Arm I|Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 60-120 minutes on day 9.
3256402|NCT00795002|Experimental|Arm II|Patients receive alvocidib IV over 30 minutes followed by alvocidib IV over 4 hours on days 1-3. Patients also receive cytarabine and mitoxantrone hydrochloride as in arm I.
3256403|NCT00794989|Experimental|Arm 1: Intervention|Patients ingest ground flaxseed daily, with already prepared foods, for 6 months.
3256404|NCT00794989|Other|Arm 2: Observational|Patients do not receive ground flaxseed.
3256405|NCT00794976|Experimental|1|Dexamethasone Iontophoretic Patch (low dose)
3256406|NCT00794976|Experimental|2|Dexamethasone Iontophoretic Patch (high dose)
3256407|NCT00794976|Experimental|3|Dexamethasone Passive Patch
3256408|NCT00794976|Placebo Comparator|4|Placebo Patch
3256409|NCT00794963|Experimental|Integrated care|Provide on-site internal medicine evaluation, treatment and follow up of metabolic syndrome for patients in Clozapine Clinic
3256410|NCT00794963|Other|Usual Care|Follow the 8-month outcome of schizophrenia patients with metabolic syndrome treated in the community
3256411|NCT00794950|Experimental|Sunitinib treatment|Intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma.
3256412|NCT00794924|Experimental|Probiotics, VSL#3|Acutely hospitalized elderly patients in a geriatric orthopedic rehabilitation department received commercially available probiotics (VSL#3) for 45 days.
3256413|NCT00794924|Placebo Comparator|Placebo|Acutely hospitalized elderly patients in a geriatric orthopedic rehabilitation department received placebo sachets for 45 days.
3256414|NCT00794911|Experimental|QOLT|Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions.
3256415|NCT00794911|Active Comparator|ST|Supportive Therapy (ST) 8 weekly individual counseling sessions
3256416|NCT00794911|No Intervention|Standard Care|
3256417|NCT00794898|Experimental|Arm 1|Remicade in the treatment of patients with active RA despite treatment with MTX.
3256418|NCT00794885|Experimental|Enalapril/folic acid|A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
3256419|NCT00794885|Active Comparator|Enalapril|Enalapril maleate 10 mg per day is given
3256420|NCT00794872||1|Patients with stage 3 CKD
3256421|NCT00794872||2|Patients with stage 4 CKD
3256422|NCT00794872||3|Patients without evidence for CDK
3256423|NCT00794846|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3256424|NCT00794846|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3256425|NCT00794820|Experimental|FCR-Multiple Dose Rituximab|Fludarabine phosphate + Cyclophosphamide + Rituximab
3256427|NCT00794794|Experimental|Desloratadine and Cetirizine Crossover|To compare the preference in taste between desloratadine and cetirizine.
3256428|NCT00794781|Experimental|1|
3256429|NCT00794768|Experimental|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3256430|NCT00794768|Experimental|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3256431|NCT00794755|Active Comparator|Vitamin K|
3256432|NCT00794755|Placebo Comparator|Placebo|
3256433|NCT00794742||Burn Wounds|Patients with burn wounds
3256434|NCT00794716|Experimental|NRL972|
3256435|NCT00794703|Experimental|1. Micafungin|
3256436|NCT00794703|Active Comparator|2. Itraconazole|
3256437|NCT00794690|Experimental|black cohosh extract, liver|100 postmenopausal women
3256438|NCT00794677|Placebo Comparator|Sugar Pill|Placebo medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
3256439|NCT00794677|Experimental|ezetimibe|10 mg medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
3256440|NCT00794664|Placebo Comparator|Placebo|Weekly subcutaneous injections for 26 weeks
3256441|NCT00794664|Experimental|Mipomersen|200 mg weekly subcutaneous injections for 26 weeks
3256442|NCT00794651||OA|moderate to severe osteoarthritis of the knee
3256443|NCT00794625|Experimental|1|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add valproate and behavioral family counseling to their treatment during Phase 2. If they do not respond to valproate, they will be switched to risperidone.
3256444|NCT00794625|Experimental|2|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add risperidone and behavioral family counseling to their treatment during Phase 2. If they do not respond to risperidone, they will switch to valproate.
3256445|NCT00794625|Placebo Comparator|3|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add placebo and behavioral family counseling to their treatment during Phase 2.
3256446|NCT00794612|Experimental|1|Dermacyd Femina Pocket BR (Lactic Acid)
3256447|NCT00794599|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3256448|NCT00794599|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3256449|NCT00794586|Experimental|FTI 80mg/20mg BID|Fosfomycin/Tobramycin combination 80mg/20 mg inhaled twice daily
3256450|NCT00794586|Experimental|FTI 160mg/40mg BID|Fosfomycin/Tobramycin combination 160 mg/40 mg inhaled twice daily
3256451|NCT00794586|Placebo Comparator|Placebo A BID|Placebo A inhaled twice daily
3256452|NCT00794586|Placebo Comparator|Placebo B BID|Placebo B inhaled twice daily
3256453|NCT00794573|Experimental|Varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
3256454|NCT00794573|Placebo Comparator|Sugar pill|placebo for 0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
3256455|NCT00794560|Experimental|clinical setting: intervention|"Recruitment of patients in the hospital into the randomized intervention group. Intervention is done by a trained pharmacist/Doctor of Philosophy-student in the study center (a pharmacy) or at patient's bedside in the hospital.~Intervention: patient education"
3256456|NCT00794560|No Intervention|clinical setting: standard care|Recruitment of patients in the hospital into the randomized control group (standard care in community pharmacy)
3256457|NCT00794560|Experimental|daily life setting: intervention|"Recruitment of patients in trained community pharmacies into the intervention group. Intervention is done by trained pharmacists.~Intervention: patient education"
3256458|NCT00794560|No Intervention|daily life setting: standard care|Recruitment of patients in community pharmacies into control group (standard care in community pharmacy)
3256459|NCT00794547|Experimental|1|In the Phase I part of the study, we will test the safety of calcitriol along with standard chemotherapy. In addition, the goal is to see what effects (good and bad) it has on you and your type of Non-Small Cell Lung Cancer. This study is ongoing. In this portion of the study, we are testing increasing doses of calcitriol in combination with standard chemotherapy. If 2/3 patients at any dose level experience side effects that are limiting, we will call the dose level below that dose the maximum tolerated dose.
3256460|NCT00794547|Experimental|2|In the Phase II part of the study, we will find out the response of subjects' cancer has to the combination of a fixed dose of calcitriol (determined in the phase I study) with standard chemotherapy.
3256461|NCT00794508|Experimental|Retroviral-mediated ADA gene transfer|Transfer of the human ADA gene to isolated CD34+ cells from the bone marrow.
3256462|NCT00794495|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3256463|NCT00794495|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3256464|NCT00794469||Water|obese children (body mass index > 95th percentile for age and sex) that will drink cold water
3256465|NCT00794456|Experimental|1|Association of Passiflora incarnata L; Crataegus Oxyacantha L and Salix alba L.
3256466|NCT00794456|Active Comparator|2|Valeriana officinalis 50 mg
3256467|NCT00794443|Experimental|1. Monthly - Dose 1|Monthly intermittent administration, dose 1
3256468|NCT00794443|Experimental|2. Monthly - Dose 2|Monthly intermittent administration, dose 2
3256570|NCT00793676|Other|A= Asthma|
3256470|NCT00794430|Experimental|V3381|V3381: titrated from 100 mg bid to maximum 400 mg bid over 4 weeks followed by maintenance phase at highest tolerated dose. Total duration of treatment 13 weeks.
3256471|NCT00794430|Placebo Comparator|Placebo|Placebo to match V3381, 100 mg, given according to the same regimen.
3256472|NCT00794417|Experimental|1|
3256473|NCT00794391|Experimental|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller & Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
3256474|NCT00794391|Active Comparator|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
3256475|NCT00794378|Experimental|Desloratadine and Cetirizine Crossover|To compare the preference in taste between desloratadine and cetirizine.
3256476|NCT00794365||Open-label|
3256477|NCT00794339|Experimental|Copper ATSM|pre-therapy pelvic 64Cu-ATSM-PET/CT with Pre- and post- therapy FDG PET/CT
3256478|NCT00794326|Experimental|PDsol 12|Treatment with a peritoneal dialysis solution containing a low concentration of sodium.
3256479|NCT00794326|Active Comparator|Gambrosol trio 40|Treatment with the peritoneal dialysis solution Gambrosol trio 40 isotonic bag (1.5%)
3256480|NCT00794313|Experimental|Amantadine|
3256481|NCT00794313|Experimental|Amantadine plus Topiramate|
3256482|NCT00794313|Placebo Comparator|Sugar Pill|
3256483|NCT00794300||Acute myocardial infarction patients|
3256484|NCT00794287||1|Hymenoptera allergic patients before allergen specific immunotherapy
3256485|NCT00794287||2|Hymenoptera allergic patients after allergen specific immunotherapy
3256486|NCT00794274|Experimental|Open label drug|"Drug: CC-100004~After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis"
3256487|NCT00794261|Experimental|Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
3256488|NCT00794261|Active Comparator|Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN > 0.5 G/L)
3256489|NCT00794248|Experimental|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3256490|NCT00794248|Experimental|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3256491|NCT00794235|Other|Sorafenib and Dacarbacine|
3256492|NCT00794222|Experimental|Mood monitoring|The mobiletype monitoring intervention group will monitor their current activities, current mood, responses to negative mood, any recent stressors and coping strategies. Other activities monitored include eating patterns, exercise patterns, quantity and quality of sleep and alcohol and cannabis use.
3256493|NCT00794222|No Intervention|Comparison monitoring program|"The mobiletype monitoring comparison group will monitor their current activities, eating patterns, exercise patterns, quantity and quality of sleep and alcohol and cannabis use.~This program excludes questions about mood, stress and coping strategies."
3256494|NCT00794209|Experimental|1|
3256495|NCT00794196|No Intervention|Usual Care|The control group will be receiving usual medical and pharmaceutical care.
3256496|NCT00794196|Experimental|Intervention Group|Intervention group will be receiving usual medical and pharmaceutical care plus a pharmaceutical support program.
3256497|NCT00794183|Active Comparator|1|AVD set by taking the larger of 0.50ms or A-V interval 0.30
3256498|NCT00794183|Active Comparator|2|AVD set by taking the larger of 0.50ms or A-V interval 0.50
3256499|NCT00794183|Active Comparator|3|AVD set by taking the larger of 0.50ms or A-V interval 0.70
3256500|NCT00794170|Experimental|Telephone and print based intervention|The I-SIGHT intervention consists of twelve interactive voice recognition (IVR) phone calls over a nine-month period and accompanying printed materials that are mailed to participants following each call. The phone call messages and print materials are tailored to individuals' circumstances using data from the screening and baseline interviews. The intervention is based on theoretical constructs from Social Cognitive Theory and the Health Belief Model, and emphasizes self-efficacy, medication taking skills, outcome expectancies, facilitators and barriers to compliance, and social support. The treatment group receives the tailored telephone intervention and mailed, printed materials.
3256501|NCT00794170|No Intervention|Usual care|The control group received usual care at each clinical site and interacted with study personnel only for data collection.
3256502|NCT00794157|Experimental|Indacaterol 150 µg|Patients received indacaterol 150 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3256503|NCT00794157|Experimental|Indacaterol 300 µg|Patients received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3256504|NCT00794157|Placebo Comparator|Placebo|Patients received placebo delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3256505|NCT00794144|Experimental|1|Olopatadine Hydrochloride Nasal Spray 0.6%
3256506|NCT00794144|Placebo Comparator|2|Olopatadine Hydrochloride Nasal Spray Vehicle
3256507|NCT00794118||1.0|As per routinary clinical practice
3256508|NCT00794105||Normal ears|
3256509|NCT00794105||Otitis media ears.|
3256510|NCT00794092|Experimental|Sinerem|MRI scanning of patients with AAA before and 24hrs +/- 4hrs after administration of Sinerem
3256512|NCT00794079|Placebo Comparator|B|corn oil
3256513|NCT00794066||1|TIA
3256514|NCT00794066||2|Ischemic stroke
3256515|NCT00794066||3|Hemorrhagic stroke
3256516|NCT00794053|Experimental|study group|The members in this group will undergo intervention by having surgery and lymph node detection by dye staining
3256517|NCT00794027|Other|Yoga group|Patients with heart failure
3256518|NCT00794014|Experimental|Conservative strategy|
3256519|NCT00794014|Experimental|Aggressive strategy|
3256520|NCT00794001|Experimental|Data Feedback|The intervention is systematic feedback on performance (using predefined quality indicators) to cardiology, ED, and EMS-stakeholders and staff.
3256521|NCT00793988|Active Comparator|1|Group receiving vibration-assisted anaesthesia
3256522|NCT00793988|Placebo Comparator|2|Group receiving switched-off vibrating device
3256523|NCT00793975|Experimental|IMC-1121B|"All patients will receive intravenous infusions of IMC-1121B with the dose depending on which cohort they are enrolled into. A minimum of three patients will be enrolled in each cohort.~A completed patient will be either a patient who completes the 4-week treatment cycle and 2-week observation period (for a total of 6 weeks), or a patient who discontinues therapy for an IMC-1121B-related toxicity. Toxicity data for each cohort will be reviewed prior to dose escalation.~When all patients complete a cohort, dose escalation to the next cohort will occur."
3256524|NCT00793962|Experimental|hypofractionation radiotherapy|breast cancer women with mastectomy high-risk: T3-4 and/or 4 or more axillary nodes involvement postmastectomy hypofractionation radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
3256525|NCT00793962|Active Comparator|conventional fractionation radiotherapy|breast cancer women with mastectomy high-risk with T3-4 and/or 4 or more axillary nodes postmastectomy conventional fractionation radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
3256526|NCT00793923|Experimental|Combination Therapy|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
3256527|NCT00793923|Active Comparator|Monotherapy|intravitreal injection of 0.5 mg ranibizumab
3256528|NCT00793910|Active Comparator|Gabapentin|oral medication
3256529|NCT00793910|Placebo Comparator|placebo|
3256530|NCT00793897|Experimental|Sequential allocation of patients in two dosing schedules|
3256531|NCT00793884||Diabetes Education|Program participants attend an initial 2.5hr diabetes education class in Spanish. The class curriculum follows the American Association of Diabetes Educators (AADE) seven self-care behaviors: healthy eating, being active, monitoring, medication use, problem-solving and healthy coping. Participants are invited to return to a follow-up session within 6 months. Follow-sessions are held in the late afternoon. These sessions are discussion-based and include an activity such as salsa lessons and cooking demonstrations.
3256532|NCT00793871|Experimental|sunitinib|single agent sunitinib, single arm
3256533|NCT00793858|Active Comparator|1|placebo in left nostril, isotonic ciclesonide in right
3256534|NCT00793858|Active Comparator|2|hypotonic ciclesonide in left nostril, placebo in right
3256535|NCT00793858|Active Comparator|3|hypotonic ciclesonide in right and left nostrils
3256536|NCT00793858|Active Comparator|4|isotonic ciclesonide in both right and left nostrils
3256537|NCT00793858|Placebo Comparator|6|placebo in both right and left nostrils
3256538|NCT00793858|Active Comparator|5|isotonic ciclesonide in left nostril and hypotonic ciclesonide in right
3256539|NCT00793845|Experimental|High risk neuroblastoma|"Conventional chemotherapy (9 cycles)~Surgery conventional chemotherapy (after 6 cycles of chemotherapy)~Tandem HDCT/autoSCT~First HDCT (cyclophosphamide, etoposide, carboplatin)~Second HDCT (total body irradiation, thiotepa, melphalan)~Local radiotherapy~Retinoic acid, interleukin-2"
3256540|NCT00793832|Active Comparator|1|Supervised exercise.
3256541|NCT00793832|Active Comparator|2|Diet Advice
3256542|NCT00793819|Experimental|1 Silodosin|
3256543|NCT00793819|Placebo Comparator|2 Placebo|
3256544|NCT00793806||Medical Tool|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
3256545|NCT00793793|Experimental|20mg|patient to receive 20mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
3256546|NCT00793793|Experimental|48mg|patient to receive 48mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
3256547|NCT00793793|Experimental|120mg|patient to receive 120mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
3256548|NCT00793793|Experimental|240mg|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
3256549|NCT00793793|Placebo Comparator|Placebo|
3256550|NCT00793780|Active Comparator|Naltrexone 25mg|
3256551|NCT00793780|Placebo Comparator|Placebo|
3256552|NCT00793767|Placebo Comparator|placebo|placebo
3256553|NCT00793767|Experimental|Erythropoietin|acute administration of erythropoietin
3256554|NCT00793754|No Intervention|1|
3256555|NCT00793754|Experimental|2|Aspirin 100 mg / day
3256556|NCT00793754|Experimental|3|Atorvastatin 40 mg / day
3256557|NCT00793754|Experimental|4|Aspirin 100 mg / day + Atorvastatin 40 mg / day
3256558|NCT00793741||1|Type 1 Diabetes Hypoglycemia unawareness Islet transplant candidate
3256559|NCT00793741||2|Healthy control subjects
3256560|NCT00793728|Active Comparator|Antrectomy|
3256561|NCT00793728|Active Comparator|Without antrectomy|
3256562|NCT00793715|Active Comparator|1|Decompressive laparotomy with temporary abdominal closure
3256563|NCT00793715|Active Comparator|2|Patients who will receive percutaneous puncture with placement of abdominal catheter
3256564|NCT00793702|Experimental|A|two injections 0.01 µg rdESAT-6 + rCFP-10 (6 weeks interval)
3256565|NCT00793702|Experimental|B|two injections 0.01 µg rdESAT-6 + rCFP-10 (12 weeks interval)
3256566|NCT00793702|Experimental|C|two injections 0.1 µg rdESAT-6 + rCFP-10 (6 weeks interval)
3256567|NCT00793702|Experimental|D|two injections 0.1 µg rdESAT-6 + rCFP-10 (12 weeks interval)
3256568|NCT00793702|Experimental|E|one injection 1.0 µg rdESAT-6 + rCFP-10
3256569|NCT00793689||total thyroidectomy|patients undergoing total thyroidectomy
3256573|NCT00793663|Experimental|1|The effect of xenon as an anaesthetic on the depth of hypnosis.
3256574|NCT00793663|Active Comparator|2|The effect of sevoflurane as an anesthetic on the depth of hypnosis
3256575|NCT00793663|Experimental|3|Dexamethasone as prevention of postoperative nausea and vomiting after xenon or sevoflurane anesthesia
3256576|NCT00793663|Placebo Comparator|4|
3256577|NCT00793663|Experimental|5|Ondansetron, to determine the onset-time of ondansetron when used as rescue medication for postoperative nausea and vomiting
3256578|NCT00793663|Placebo Comparator|6|
3256579|NCT00793650|Active Comparator|Bortezomib before Melphalan|Enrolled patients were randomized to receive a single escalating dose of bortezomib (1.0, 1.3, or 1.6 mg/m2) 24 hours before melphalan.
3256580|NCT00793650|Active Comparator|Bortezomib after Melphalan|Enrolled patients were randomized to receive a single escalating dose of bortezomib (1.0, 1.3, or 1.6 mg/m2) 24 hours after melphalan.
3256581|NCT00793637||Surgical|Patients with proximal and/or distal tibial, femoral and/or humeral fractures treated with intramedullary nails and the Angular Stable Locking System(ASLS)
3256582|NCT00793624|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
3256583|NCT00793624|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
3256584|NCT00793624|Active Comparator|Formoterol 12mcg|12mcg inhaled twice daily from the Aerolizer inhaler
3256585|NCT00793624|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
3256586|NCT00793611|Active Comparator|Behavioral therapy|"Behavioral Therapy standard of care (which consists of bladder drills, voiding diaries, timed voiding and pelvic floor exercises)"
3256587|NCT00793611|Experimental|hypnotherapy|patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatments for overactive bladder
3256588|NCT00793598|Experimental|CMX001|Cohort 3A 40 mg of CMX001 given on Days 0, 7, 14, 21, and 28 Cohort 4A 100 mg of CMX001 given twice weekly for a total of 9 doses Cohort 4B 200 mg of CMX001 given once or twice weekly Cohort 4C 300 mg of CMX001 given once or twice weekly
3256589|NCT00793598|Placebo Comparator|Placebo|Cohort 3A once weekly for a total of 5 doses Cohort 4A twice weekly for a total of 9 doses Cohort 4B once or twice weekly Cohort 4C once or twice weekly
3256590|NCT00793585|Experimental|Allopurinol|Allopurinol group:allopurinol, 100-300mg/d according to the levels of Scr(serum creatinine) and UA(uric acid), for those Scr < 1.5mg/dl (133 umol/L) at the baseline, allopurinol was given 100 mg three times daily.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
3256591|NCT00793585|Other|Control group|Control group:(patient in this group were received health education and were encouraged to adhere to a low-purine diet and continue their usual therapy.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
3256592|NCT00793572|Experimental|Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy|See Detailed Description
3256593|NCT00793559|Active Comparator|terlipressin bolus|1 mg of terlipressin received one time only
3256594|NCT00793559|Experimental|terlipressin drip|
3256595|NCT00793546|Experimental|1|combination of bosutinib and exemestane
3256596|NCT00793546|Active Comparator|2|exemestane
3256597|NCT00793520|Experimental|1|Twice daily oral administration of milnacipran for 5 weeks, placebo for 2 weeks, and crossover to placebo for 5 weeks.
3256598|NCT00793520|Experimental|2|Twice daily oral administration of placebo for 5 weeks, placebo for 2 weeks, and crossover to milnacipran for 5 weeks.
3256599|NCT00793507|Experimental|1: Intervention Group|All participants in the intervention group will be receiving standard preventive dental care received by children in their dental providers' office. These intervention children will receive dental scaling, cleaning and fluoride varnish at visits every three to six months. All participants in the intervention group will receive active reminder/recall from the hygienist, encouraging the participants to return every three to six months for the oral exam, cleaning, scaling and fluoride application.
3256600|NCT00793507|Active Comparator|2: Control Group|The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist.
3256601|NCT00793494|Experimental|Probaclac|Administration of Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™) b.i.d.
3256602|NCT00793494|Placebo Comparator|Placebo|
3256603|NCT00793481||Diagnostic tool|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
3256604|NCT00793468|Placebo Comparator|Placebo Arm|Subjects in placebo arm will be taking placebo once daily for 12 weeks from week 5 to 16.
3256605|NCT00793468|Experimental|GSK598809 Arm|Subjects in GSK598809 arm will be taking GSK598809 once daily for 12 weeks from weeks 5 to 16.
3256606|NCT00793455|Experimental|Intervention Group|Received Educational Outreach
3256607|NCT00793455|No Intervention|Usual Care Control Group|Participants in this arm will receive normal care until outcome assessment is performed at 6 months following the placement of the order for the preventive service. They will be sent a letter reminding them to obtain the ordered preventive service test.
3256608|NCT00793442||Novel Endothelial Markers Derivation|"Our study participants will come from the Protocolized Care for Early Severe Sepsis (ProCESS) trial will be eligible participants.~From the ProCESS subjects, the researchers will include those who were: 1) recruited by participating centers who participated in other components of this ancillary study or 2) who were sequentially enrolled from periods derived from the beginning, middle, and end of the ProCESS study."
3256609|NCT00793442||Novel Endothelial Marker Validation|Our study participants will come from the Protocolized Care for Early Severe Sepsis (ProCESS) trial will be eligible participants; the researchers will recruit a sequential 300 patient validation set.
3256610|NCT00793416|Experimental|ShuntCheck measure|All patients will have ShuntCheck measurements along with radionuclide shunt patency testing.
3256611|NCT00793403||1|As per routine clinical care
3256721|NCT00792584|Experimental|2|patients treats with efavirenz for 6 weeks
3256612|NCT00793377|Experimental|ADOC x 4 + Tam 20|Adriamycin will be given at a dose of 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles. Adriamycin will be administered as a short i.v. infusion over 15 minutes, followed immediately by a 1-hour infusion of docetaxel diluted in 250 mL NaCl. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
3256613|NCT00793377|Experimental|AC x 4 - Doc x 4 + Tam 20|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy
3256614|NCT00793364|Active Comparator|Stanol ester|Stanol-ester administration group
3256615|NCT00793364|Placebo Comparator|Placebo spread|Placebo spread group
3256616|NCT00793364|Other|Mediterranean diet group|Mediterranean diet group
3256617|NCT00793338|Experimental|Sildenafil|All patients will receive open-label treatment with sildenafil.
3256618|NCT00793325||Somatropin|Patients administered Somatropin.
3256619|NCT00793299|Experimental|Video Illness Narrative|single arm pilot study
3256620|NCT00793286|Other|A|Mesh fixation by staples
3256621|NCT00793286|Other|B|Mesh fixation by glue
3256622|NCT00793273||A|
3256623|NCT00793260|Active Comparator|Usual Support Group|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
3256624|NCT00793260|Experimental|Enhanced Support Group|The Enhanced-Support Group intervention used more sophisticated predictive models, more extensive outreach to engage individuals, and provided tighter feedback loops to inform the care support process.
3256625|NCT00793234|Experimental|1|0.3 mg/kg TB-402
3256626|NCT00793234|Experimental|2|0.6 mg/kg TB-402
3256627|NCT00793234|Experimental|3|1.2 mg/kg TB-402
3256628|NCT00793234|Active Comparator|4|
3256629|NCT00793221|Other|Sirolimus-eluting stent|Implantation of sirolimus-eluting coronary stent
3256630|NCT00793221|Active Comparator|Everolimus-eluting stent|Implantation of everolimus-eluting coronary stent
3256631|NCT00793208|Experimental|Vaccine|vaccine composed of lethally irradiated semi-allogeneic human fibroblasts transfected with genomic tumor DNA from the patient's own tumor
3256632|NCT00793195|Active Comparator|1) Intralipid|Fat Emulsions for Intravenous Nutrition
3256633|NCT00793195|Experimental|2) SMOFlipid|Fat Emulsions for Intravenous Nutrition
3256634|NCT00793182|Active Comparator|1|Ioversol 320 mgI/mL
3256635|NCT00793182|Active Comparator|2|Iodixanol 320 mgI/mL
3256636|NCT00793169||lidocane|Patients undergoing Mohs micrographic surgery of the face or neck will have their blood drawn before, during, and after the procedure.
3256637|NCT00793156|Placebo Comparator|Placebo|Patients will be randomized into Placebo group
3256638|NCT00793156|Active Comparator|2|2.5 µg group randomized
3256639|NCT00793156|Active Comparator|3|5.0 µg group randomized
3256640|NCT00793143||Sleeve|
3256641|NCT00793143||Bypass|
3256642|NCT00793130|Other|Coltect|Coltect contains natural compounds: curcumin, green tea and selenium which are approved as food supplements by the Ministry of Health in Israel. Curcumin and green tea are widely used in the food industry.
3256643|NCT00793117|Experimental|1|poly vinil chloride packing
3256644|NCT00793104|Other|CR Plug|Placement of allograft CR Plug in primary injury site
3256645|NCT00793091|Active Comparator|1|
3256646|NCT00793091|Placebo Comparator|2|
3256647|NCT00793065||1|Physicians that are using paper-based medical charts and who are not receiving Medical Home redesign incentives.
3256648|NCT00793065||2|Physicians that are using Electronic Health Records (EHRs) and who are not undergoing Medical Home redesign.
3256649|NCT00793065||3|Physicians that are using Electronic Health Records (EHRs) and undergoing Medical Home redesign.
3256650|NCT00793052|Experimental|A|
3256651|NCT00793026|Experimental|1|Dermacyd Breeze Pocket BR (Lactic Acid)
3256652|NCT00793013|Experimental|ARDS Net Low Tidal Volume|
3256653|NCT00793013|Experimental|APRV Ventilation|
3256654|NCT00793000|Experimental|Cohort 1|
3256655|NCT00793000|Experimental|Cohort 2|
3256656|NCT00793000|Experimental|Cohort 3|
3256657|NCT00793000|Experimental|Cohort 4|
3256658|NCT00793000|Experimental|Cohort 5|
3256659|NCT00793000|Experimental|Cohort 6|
3256660|NCT00793000|Experimental|Cohort 7|
3256661|NCT00793000|Experimental|Cohort 8|Japanese volunteers, low dose previously tested (based on PK)
3256662|NCT00793000|Experimental|Cohort 9|Japanese volunteers, intermediate dose previously tested (based on PK)
3256663|NCT00793000|Experimental|Cohort 10|Japanese volunteers, high dose previously tested (based on safety)
3256664|NCT00792974||COPD by GOLD-criteria III and IV|
3256665|NCT00792961|Experimental|Endomicroscopy|Endomicroscopy is performed in addition to the patient's indicated robot-assisted prostate surgery
3256666|NCT00792948|Experimental|Treatment (chemotherapy, transplant, maintenance)|See Detailed Description
3256667|NCT00792935|Experimental|MK-0941|
3256668|NCT00792935|Active Comparator|Glimepiride|
3256669|NCT00792922|Active Comparator|≥90% coverage with azithromycin target|Selected communities will receive mass treatment annually for three years.
3256670|NCT00792922|Active Comparator|80%-89% coverage with azithromycin target|Selected communities will receive mass treatment annually for three years.
3256671|NCT00792922|Active Comparator|≥90% coverage with azithromycin , treatment based|"Treatment to be administered at baseline then continued yearly if trachoma prevalence is greater than 5%~In Niger, treatment will be every 6-months for children ages twelve and under."
3256672|NCT00792922|Active Comparator|80%-89% coverage with azithromycin : treatment based|"Treatment to be administered at baseline then continued yearly if trachoma prevalence is greater than 5%~In Niger, treatment will be every 6-months for children ages twelve and under."
3256673|NCT00792909|Experimental|Synflorix™ Group 1|Subjects previously vaccinated with the Synflorix™ vaccine according to a 2+1 schedule, receiving one dose of Synflorix™ at 36-46 months of age.
3256674|NCT00792909|Experimental|Synflorix™ Group 2|Subjects previously vaccinated with the Synflorix™ vaccine according to a 3+1 schedule, receiving one dose of Synflorix™ at 36-46 months of age.
3256675|NCT00792909|Active Comparator|Unprimed Group|Age-matched subjects not previously vaccinated with any pneumococcal vaccine receiving two doses of Synflorix™ at 36-46 and 38-48 months of age. Age-matching was ensured by the enrolment of subjects 36-46 months of age.
3256676|NCT00792896|Experimental|1|Family conference + education materials
3256677|NCT00792896|No Intervention|2|education materials
3256678|NCT00792883||patients ARDS|142 Patients in respiratory failure with a diagnosis of ARDS hospitalized at the ICU.
3256679|NCT00792883||Patients non ARDS|432 patients in respiratory failure from other causes (ARDS being formally excluded), hospitalized at the same ICU.
3256680|NCT00792883||Healthy controls|626 healthy patients undergoing elective surgery at the Pediatric Surgery Department or recruited from the pediatric ambulatory.
3256681|NCT00792870|Experimental|SURI Enhanced|
3256682|NCT00792870|Active Comparator|SURI Standard|
3256683|NCT00792857|Experimental|CTAP201 Injection at dose a|CTAP201 at dose a
3256684|NCT00792857|Experimental|CTAP201 Injection|CTAP201 at dose b or dose c
3256685|NCT00792857|Active Comparator|Doxercalciferol at dose a|Active at dose a
3256686|NCT00792857|Active Comparator|Doxercalciferol|Active at dose b or dose c
3256687|NCT00792844|Experimental|Bio-K capsule|1 capsule of lactobacillus acidophilus and lactobacillus casei (50 billion live bacteria) daily for duration of antibiotic therapy and 7 days after or until discharge, whichever comes first
3256688|NCT00792844|Active Comparator|Bio-K liquid|98 g of lactobacillus acidophilus and lactobacillus casei (50 billion live bacteria) daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever comes first
3256689|NCT00792844|No Intervention|no Bio-K|No lactobacillus product - standard infection control procedures (i.e. handwashing, etc.)
3256690|NCT00792831|Experimental|ITF2357|
3256691|NCT00792818|Experimental|curcuma domestica|1,500 mg/day (oral) divided into 3 times for 28 days
3256692|NCT00792818|Active Comparator|Ibuprofen|1,200 mg/day (oral) divided into 3 times for 28 days
3256693|NCT00792805|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3256694|NCT00792805|Experimental|Indacaterol 300 μg|Patients inhaled indacaterol 300 μg via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3256695|NCT00792805|Placebo Comparator|Placebo to indacaterol|Patients inhaled placebo to indacaterol via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3256696|NCT00792792||Tissue transfer skin flap|Modulated Imaging Spectroscopy
3256697|NCT00792766|Experimental|RAD001|
3256698|NCT00792753|Experimental|1. DESyne DES|Test arm: Intervention with DESyne Novolimus-Eluting Coronary Stent DESyne Novolimus Stent System
3256699|NCT00792753|Active Comparator|2. Medtronic Endeavor DES|Control arm: Intervention with Medtronic Endeavor Zotarolimus-Eluting Coronary Stent Medtronic Endeavor Coronary Stent System
3256700|NCT00792753|Experimental|3. DESyne BD DES|Test arm: Intervention with DESyne BD Novolimus-Eluting Coronary Stent DESyne BD Novolimus Stent System
3256701|NCT00792740|Placebo Comparator|Placebo capsules|"oral ITF2357 50 mg b.i.d.~matching placebo Two parallel groups (1:1)"
3256702|NCT00792740|Experimental|ITF2357|"oral ITF2357 50 mg b.i.d.~matching placebo Two parallel groups (1:1)."
3256703|NCT00792727|Experimental|Ketoprofen Patch|Treatment with experimental drug
3256704|NCT00792727|Placebo Comparator|Placebo Patch|Treatment with placebo drug
3256705|NCT00792701|Experimental|Arm II|Beginning within 84 days after surgery, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3256706|NCT00792688|Experimental|1|GLYC-101 Gel, 0.1% on one eyelid and Placebo Gel on the other eyelid
3256707|NCT00792688|Experimental|2|GLYC-101 Gel, 1.0% on one eyelid and Placebo Gel on the other eyelid
3256708|NCT00792688|Experimental|3|GLYC-101 Gel, 0.1% on one eyelid and GLYC-101 Gel, 1.0% on the other eyelid
3256709|NCT00792675|Experimental|Exercise|
3256710|NCT00792662|Experimental|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
3256711|NCT00792662|Placebo Comparator|Placebo|Standard inactive pill.
3256712|NCT00792649||1|screening colonoscopy with HD+ endoscopes
3256713|NCT00792649||2|screening colonoscopy with standardvideoendoscopes
3256714|NCT00792636|Experimental|sumatriptan and naproxen sodium combination|
3256715|NCT00792636|Active Comparator|sumatriptan|
3256716|NCT00792636|Active Comparator|naproxen sodium|
3256717|NCT00792623|Experimental|Varilrix Group|Subjects with autologous peripheral stem cell/bone marrow transplants, who received 2 doses of Varilrix vaccine subcutaneously in the deltiod region of the non-dominant upper arm, at 4.5 and 6.5 months post-transplantation.
3256718|NCT00792610|Experimental|Hepatitis B booster|They receive 3 doses of hepatitis B vaccine (Engerix-B Injection, recombinant HBsAg, 20mcg/ml/vial, GSK) at 0, 1st, 6th month during follow-up. Their anti-HBs status were checked at baseline, one week, one month, sixth month, and seven months later after the first dose of hepatitis B vaccine.
3256719|NCT00792597||spine or hip surgery|
3256720|NCT00792584|Experimental|1|patients treats with etravirine for 6 weeks
3256722|NCT00792571|Experimental|B.I.D|Beraprost Sodium Modified Release Tablets, 60mcg, b.i.d (twice a day dosing)
3256723|NCT00792571|Experimental|Q.I.D|Beraprost Sodium Modified Release Tablets, 60mcg, q.i.d (four times a day dosing)
3256724|NCT00792558|Experimental|Single Arm|
3256725|NCT00792532|Experimental|iMRI|
3256726|NCT00792519|Experimental|CBT|group cognitive behavioral treatment
3256727|NCT00792519|Active Comparator|HIV support group|group support
3256728|NCT00792506|Experimental|ITF2357|
3256729|NCT00792493|Experimental|ORM-12741|
3256730|NCT00792493|Placebo Comparator|Placebo|
3256731|NCT00792480|Experimental|Intensive Counseling Group|
3256732|NCT00792480|No Intervention|Routine care group|"The routine care group took part in an initial physical exam and history, routine labs, and routine visits per American College of Obstetrics & Gynecology (ACOG) standards. The only counseling on diet and exercise during pregnancy was that included in our standard prenatal booklet What to do When You're Having a Baby by Gloria Mayer (Institute for Health Advancement, 2003, La Habra, CA). At each routine obstetric appointment, the participant's weight was measured recorded in the medical chart. The healthcare provider did not counsel the participant regarding any changes in diet or lifestyle."
3256733|NCT00792467|Experimental|ITF2357|"Patients will receive the following therapy cycle~ITF2357, 50 mg every 6 hours, per os, days 1 - 3;~Mechlorethamine, 6 mg/sqm, intravenously , day 4. Therapy will be administered every 21 days as long as there is no evidence of progressive disease or unacceptable toxicity, but in any case for a maximum of 12 cycles."
3256734|NCT00792454|Experimental|exercise training/renal rehabilitation|Experimental arm will undergo 12 weeks of training in exercise, meditation, and nutrition education.
3256735|NCT00792454|No Intervention|control|Control co-hort will receive usual chronic kidney disease care and no exercise, meditation or dietary education intervention.
3256736|NCT00792441|No Intervention|intervention group|Patients with mechanical ventilated who met the criteria for weaning from medical doctor in Srinagarind hospital, Khon Kaen University
3256737|NCT00792428|Active Comparator|Real-tDCS + PT-OT|Each subject will receive up to 5 days of traditional physical-occupational therapy for at least 1 hour per day in the stroke recovery laboratory in combination with real transcranial direct current stimulation (tDCS) over the motor region for up to 30 min.
3256738|NCT00792428|Sham Comparator|Sham-tDCS + PT-OT|Each subject will receive up to 5 days of traditional physical-occupational therapy for at least 1 hour per day in the stroke recovery laboratory in combination with sham (pretend) tDCS for up to 30 min. over the motor region.
3256739|NCT00792415||1|Limited continuous opioid exposure (at least 120 and less than 156 hours)
3256740|NCT00792415||2|Extended continuous opioid exposure (156 hours or more)
3256741|NCT00792402||1 control group|Computerized data collection of outcome measures in usual care
3256742|NCT00792402||2 intervention group|Computerized data collection of outcome measures and interviews to clinicians which are using a computerized Heart Failure guideline in their daily practice.
3256743|NCT00792389|Experimental|1|Patients receiving warmed, humidified gas
3256744|NCT00792389|Active Comparator|2|Patients receiving cool, day gas
3256745|NCT00792376|Experimental|etoricoxib|etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
3256746|NCT00792376|Active Comparator|diclofenac|diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
3256747|NCT00792350||Group 1|
3256748|NCT00792337|Active Comparator|simvastatin|simvastatin in combination with budesonide
3256749|NCT00792337|Placebo Comparator|B1-6-12|Budesonide in combination with B1-6-12
3256750|NCT00792324|Active Comparator|Group 1|Four 100mg Etravirine tablets plus one Efavirenz (EFV) placebo tablet once daily
3256751|NCT00792324|Active Comparator|Group 2|One 600mg EFV tablet plus four Etravirine placebo tablet tablets once daily
3256752|NCT00792311|Experimental|Tsui test|Tsui test administration.
3256753|NCT00792298|Experimental|Suvorexant 10 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 10 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
3256754|NCT00792298|Experimental|Placebo → Suvorexant 10 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 10 mg suvorexant daily prior to bedtime during Treatment Period 2.
3256755|NCT00792298|Experimental|Suvorexant 20 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 20 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
3256756|NCT00792298|Experimental|Placebo → Suvorexant 20 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 20 mg suvorexant daily prior to bedtime during Treatment Period 2.
3256757|NCT00792298|Experimental|Suvorexant 40 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 40 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
3256758|NCT00792298|Experimental|Placebo → Suvorexant 40 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 40 mg suvorexant daily prior to bedtime during Treatment Period 2.
3256759|NCT00792298|Experimental|Suvorexant 80 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 80 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
3256812|NCT00791921|Placebo Comparator|Placebo|Placebo of CDP870
3257032|NCT00790296|Placebo Comparator|Saline|Placebo
3256760|NCT00792298|Experimental|Placebo → Suvorexant 80 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 80 mg suvorexant daily prior to bedtime during Treatment Period 2.
3256761|NCT00792285|Experimental|Automated Telephone Outreach|Automated Telephone Outreach with Speech Recognition
3256762|NCT00792285|No Intervention|Usual Care|Usual Care
3256763|NCT00792259||1|Patients with Retinal Disease
3256764|NCT00792259||2|Patients without Retinal Disease
3256765|NCT00792259||3|Normal Subjects
3256766|NCT00792246|Experimental|graft versus host disease|Patients receiving oral voriconazole will be switched to intravenous voriconazole. Pharmacokinetics will be determined after each formulation.
3256767|NCT00792246|Experimental|No graft versus host disease|Patients receiving oral voriconazole will be switched to intravenous voriconazole. Pharmacokinetics will be determined after each formulation.
3256768|NCT00792233|Experimental|1|Participants taking anti-TNF medications will be monitored for signs of their disease for 6 months. If, after 6 months, their disease has become inactive, they will stop taking anti-TNF medications for up to 8 months. If participants who are no longer taking anti-TNF medications have a disease flare-up, they will begin treatment again.
3256769|NCT00792220|Experimental|MSU|
3256770|NCT00792220|Active Comparator|OCCM|
3256771|NCT00792207|Experimental|Intervention|"Intervention Group:~The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data recorded by an activity monitor."
3256772|NCT00792207|Active Comparator|Control|The control group will use an activity monitor and will have access to a website to monitor activity, but will not receive the Virtual Coach program.
3256773|NCT00792194|Experimental|training group|supervised training program 3 times a week with coach.
3256774|NCT00792194|No Intervention|group without training|a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.
3256775|NCT00792181|Experimental|1|Medical intervention - with benzodiazepines (Midazolam).
3256776|NCT00792181|Experimental|2|Course intervention - a professional development course for caregivers.
3256777|NCT00792181|Experimental|3|Combination of both medical interventions and a professional development course for caregivers.
3256778|NCT00792181|No Intervention|4|No intervention at all = a control group
3256779|NCT00792168|Active Comparator|1. Venlafaxine|
3256780|NCT00792168|Placebo Comparator|2. Placebo|
3256781|NCT00792142|Experimental|Treatment (stem cell transplant, maintenance treatment)|Patients receive high-dose melphalan IV over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation on day 0. Patients receive filgrastim IV or SC beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive oral thalidomide once daily until disease progression.
3256782|NCT00792129||Control|Posterior unilateral interbody fusion using an open approach midline incision (TLIF)
3256783|NCT00792129||Experimental|MiLIF procedure with specialized Atavi instrumentation and minimally invasive visualization capabilities
3256784|NCT00792116|Experimental|Gum Chewing|
3256785|NCT00792116|No Intervention|Non-gum chewing|
3256786|NCT00792103|Experimental|NP101|sumatriptan iontophoretic transdermal patch
3256787|NCT00792090|Experimental|1|Fermented milk
3256788|NCT00792090|Active Comparator|2|Standard milk
3256789|NCT00792077|Experimental|Sleep time|"Assessment of patients with chronic lymphocytic leukemia (CLL) experience severe cancer related fatigue (CRF):~Lenalidomide + Actigraph + Questionnaire + Sleep Test"
3256790|NCT00792064||1|Kidney-Tx-recipients
3256791|NCT00792064||2|Liver-Tx-recipients
3256792|NCT00792064||3|Heart-Tx-recipients
3256793|NCT00792064||4|Lung-Tx-recipients
3256794|NCT00792051|Active Comparator|1|Influenza vaccine
3256795|NCT00792051|Placebo Comparator|2|
3256796|NCT00792038||1|OCD patients
3256797|NCT00792038||2|Normal Controls
3256798|NCT00792012|Experimental|Glioblastoma Multiforme Patients|Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining with Temozolomide (TMZ) Chemotherapy
3256799|NCT00791999|Experimental|CDP870 100mg|200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks
3256800|NCT00791999|Experimental|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks
3256801|NCT00791999|Experimental|CDP870 400mg|400mg CDP870 given every 2 weeks
3256802|NCT00791999|Placebo Comparator|Placebo|Placebo given every 2 weeks
3256803|NCT00791986|No Intervention|control|The patients in this control group do not conduct any breathing training.
3256804|NCT00791986|Experimental|ULB|The patients conduct controlled slow breathing training using the WPTB device without inspiratory resistance.
3256805|NCT00791986|Experimental|LB|The patients breath in against resistance using WPTB device.
3256806|NCT00791973|Active Comparator|Veramyst, then Placebo|fluticasone furoate (Veramyst) nasal spray once daily for a week, then one week washout period followed by placebo nasal spray once daily for a week
3256807|NCT00791973|Active Comparator|Placebo, then Veramyst|placebo nasal spray once daily for a week, then one week washout period followed by fluticasone furoate (veramyst) nasal spray once daily for a week
3256808|NCT00791960|Active Comparator|Dimenhydrinate|Dimenhydrinate
3256809|NCT00791960|Placebo Comparator|Placebo|Placebo
3256810|NCT00791934|Experimental|Stratus Microflow Ethmoid Spacer|Temporary implantation of Ethmoid spacer with Triamcinolone Acetonide for 28 days.
3256811|NCT00791921|Experimental|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks
3257033|NCT00790283|Experimental|Numen|
3256813|NCT00791908|Experimental|electrodessication (ED)|Treatment over 6 weeks using electrodessication (ED) to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
3256814|NCT00791908|Experimental|pulsed dye laser (PDL)|Treatment over 6 weeks using pulsed dye laser (PDL) to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
3256815|NCT00791908|Experimental|potassium titanyl phosphate (KTP) laser|Treatment over 6 weeks using potassium titanyl phosphate (KTP) laser to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
3256816|NCT00791895|Experimental|A|
3256817|NCT00791882|Experimental|1|"Group of behaviors by which someone express feelings, attitudes, wishes,opinions and rights , in an adequate manner regarding situation and context.~Social skills are the substrate for social competence, which is the ability to find and legitimate relevant and personal goals"
3256818|NCT00791882|No Intervention|2|Control group will attend the same number of sessions, but without intervention of the therapists
3256819|NCT00791856|Active Comparator|1|28 cm2 testosterone patch
3256820|NCT00791856|Experimental|2|14 cm2 testosterone patch
3256821|NCT00791843|Experimental|GHRH and placebo|Everyone will receive 12 weeks of GHRH and 12 weeks of Placebo
3256822|NCT00791830|Active Comparator|Irbesartan|
3256823|NCT00791830|Placebo Comparator|Placebo|
3256824|NCT00791817|Experimental|200 mg PG 760564, Subjects Fasted|200 mg PG 760564, Subjects Fasted, single dose
3256825|NCT00791817|Experimental|200 mg PG 760564, Subjects Fed|200 mg PG 760564, Subjects Fed high fat meal
3256826|NCT00791804|Experimental|Single Arm|
3256827|NCT00791791|Other|1|increasing remifentanil administration
3256828|NCT00791791|Other|2|decreasing remifentanil concentration
3256829|NCT00791778|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)
3256830|NCT00791778|Placebo Comparator|Placebo|Participants received 2 matching placebo tablets per oral twice daily
3256831|NCT00791765|Experimental|Placebo BIW/Etanercept 50 mg BIW|Participants received placebo subcutaneous injections twice per week (BIW) for the first 12 weeks of the study. From Week 12 to Week 24, participants received etanercept 50 mg BIW.
3256832|NCT00791765|Experimental|Etanercept 50 mg BIW/Etanercept 50 mg QW|Participants received etanercept 50 mg by subcutaneous injection twice per week (BIW) for the first 12 weeks of the study. From Week 12 to Week 24, participants received etanercept 50 mg once per week (QW) and placebo once per week.
3256833|NCT00791752|Experimental|1|AZD4017 in ascending doses (start dose 2mg)
3256834|NCT00791752|Placebo Comparator|2|Placebo
3256835|NCT00791739|Experimental|one arm study|
3256836|NCT00791726||1|Patients with noninfectious uveitis and macular edema
3256837|NCT00791700|Experimental|Maraviroc|"Subjects will be stratified by age and formulation into one of the following cohorts:~Cohort 1: ≥2-<6 years of age, maraviroc liquid formulation; Cohort 2: ≥6-<12 years of age, maraviroc tablet formulation; Cohort 3: ≥6-<12 years of age, maraviroc liquid formulation and Cohort 4: ≥12-<18 years of age, maraviroc tablet formulation."
3256838|NCT00791687||PRENATAL CORTICOSTEROIDS|Extremely low gestational age neonates (<28 weeks gestation) whose mothers received full course of betamethasone before delivery.
3256839|NCT00791687||NON PRENATAL CORTICOSTEROIDS|Extremely low gestational age neonates (<28 weeks gestation) whose mothers did not receive full course of betamethasone before delivery.
3256840|NCT00791661|Experimental|Panel A: MK-1006 15/30/45|Participants received a single rising dose of MK-1006 (dosed at 15 mg, 30 mg, and 45 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
3256841|NCT00791661|Experimental|Panel B: MK-1006 60/80/60 fed|Participants received a single rising dose of MK-1006 (dosed at 60 mg, 80 mg, and 60 mg fed state) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
3256842|NCT00791661|Experimental|Panel C: MK-1006 100/140/170|Participants received a single rising dose of MK-1006 (dosed at 100 mg, 140 mg, and 170 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
3256843|NCT00791648|Experimental|statin|
3256844|NCT00791648|Placebo Comparator|placebo|
3256845|NCT00791635||Prospective Group|Questionnaires Prior to Scheduled Pelvic Exenteration Surgery.
3256846|NCT00791635||Retrospective Group|Questionnaires Post Pelvic Exenteration Surgery.
3256847|NCT00791596|Experimental|1|The first Arm received the intervention between baseline and the first follow-up, whereas the second Arm was the Control group
3256848|NCT00791596|Experimental|2|The second Arm received the intervention between the third and the fourth follow-up, whereas the first Arm was the Control group
3256849|NCT00791570|Experimental|A|
3256850|NCT00791557|Experimental|Infliximab|Single arm open label IV Infliximab given at weeks 1,2,14,22
3256851|NCT00791544|Experimental|Dose Level -1|0.5 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
3256852|NCT00791544|Experimental|Dose Level 1|1 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
3256853|NCT00791544|Experimental|Dose Level 2|3 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
3256854|NCT00791544|Experimental|Dose Level 3|6 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
3256855|NCT00791544|Experimental|Dose Level 4|12 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
3256856|NCT00791544|Experimental|Dose Level 5|18 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
3256857|NCT00791544|Experimental|Combination cohort 1|AVE1642 selected dose in combination with sorafenib
3256858|NCT00791544|Experimental|Combination cohort 2|AVE1642 selected dose in combination with erlotinib
3256859|NCT00791531|Experimental|Methotrexate|Oral methotrexate 5mg once daily for 5 consecutive days
3256860|NCT00791518||No group|No group
3256861|NCT00791505|Active Comparator|Ciprofloxacin|750 mg a day during 10 days
3256862|NCT00791505|Active Comparator|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
3256863|NCT00791492|Experimental|Fx-1006A|
3256864|NCT00791479|Experimental|0.1 milligram (mg) LY2189265|LY2189265: 0.1 milligram (mg), subcutaneous (SC), once weekly (QW)
3256865|NCT00791479|Experimental|0.5 milligram (mg) LY2189265|LY2189265: 0.5 milligram (mg), subcutaneous (SC), once weekly (QW)
3256866|NCT00791479|Experimental|1.0 milligram (mg) LY2189265|LY2189265: 1.0 milligram (mg), subcutaneous (SC), once weekly (QW)
3256867|NCT00791479|Experimental|1.5 milligram (mg) LY2189265|LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
3256868|NCT00791479|Placebo Comparator|Placebo|Placebo: subcutaneous (SC) once weekly (QW)
3256869|NCT00791466|Experimental|1|
3256870|NCT00791466|Placebo Comparator|2|
3256871|NCT00791453||I|Established patients at the Clarksdale Diabetes and Metabolism Center
3256872|NCT00791440|Experimental|1|Up to 26 sessions (over a 30 week period) of weekly, individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
3256873|NCT00791440|Active Comparator|2|30 weeks of standard psychiatric treatment.
3256874|NCT00791427||AMD Patients|
3256875|NCT00791388|Placebo Comparator|placebo|placebo capsule
3256876|NCT00791388|Experimental|50 mg PG 760564|50 mg PG 760564 active
3256877|NCT00791388|Experimental|100 mg PG 760564|100 mg PG 760564 active
3256878|NCT00791388|Experimental|200 mg PG 760564|200 mg PG 760564 active
3256879|NCT00791388|Experimental|400 mg PG 760564|400 mg PG 760564 active
3256880|NCT00791375|Experimental|Physical Activity Intervention|Participants in this arm will be given access to a website designed to help them increase their levels of physical activity
3256881|NCT00791375|Placebo Comparator|Cancer Website Control Group|Participants in this arm will be given information on cancer-related websites (that do not provide information on physical activity)
3256882|NCT00791362|Other|improvement programme CVD|
3256883|NCT00791362|Other|improvement programme other conditions|
3256884|NCT00791336|Experimental|Nelfinavir|
3256885|NCT00791323|Active Comparator|1|Ketorolac 0.4%
3256886|NCT00791323|Active Comparator|2|Mineral Oil Emollient
3256887|NCT00791310|Experimental|TEP|Performance of of TEP coupled to scanner X
3256888|NCT00791297|Active Comparator|1|Contraceptive Vaginal Ring delivering a daily dose of 1500 μg of CDB-2914
3256889|NCT00791297|Active Comparator|2|Contraceptive Vaginal Ring delivering a daily dose of 2500 μg of CDB-2914
3256890|NCT00791271|Experimental|Decitabine + Peginterferon Alfa-2b|Decitabine starting dose of 10mg/m^2 given daily via intravenous infusion on days 1-5 of 28 day cycle. Peginterferon Alfa-2b starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
3256891|NCT00791258|Experimental|1|Azor tablets and hydrochlorothiazide tablets (if necessary) will be administered for up to 20 weeks
3256892|NCT00791245||1|DeNovo NT
3256893|NCT00791219|Experimental|1|100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
3256894|NCT00791219|Active Comparator|2|200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).
3256895|NCT00791219|Placebo Comparator|3|Two placebo capsules taken approximately 30 minutes prior to breakfast
3256896|NCT00791206|Experimental|1|
3256897|NCT00791206|Other|2|
3256898|NCT00791154|Active Comparator|ARM B|Blinded AMG 102 study drug and carboplatin or cisplatin and etoposide
3256899|NCT00791154|Placebo Comparator|ARM C|Blinded placebo and carboplatin or cisplatin and etoposide
3256900|NCT00791154|Active Comparator|ARM A|Blinded AMG 479 study drug and carboplatin or cisplatin and etoposide
3256901|NCT00791141|Experimental|Cetuximab|Cetuximab in combination with radiotherapy, cisplatin and 5-FU. After chemoradiotherapy all patients receive a cetuximab maintenance therapy.
3256902|NCT00791128|Experimental|EndoBarrier GI Liner|22 patients were implanted with the GI Liner for a 52-week duration. Assessments were performed during the 6 months post-explant period.
3256903|NCT00791115|Experimental|prostatectomy after radiotherapy|
3256904|NCT00791102|Active Comparator|1|Topical ASP-1001
3256905|NCT00791102|Placebo Comparator|2|Placebo for Topical ASP-1001
3256906|NCT00791089|Experimental|Fish Oil, Ablation, Sinus Rhythm|Patients in the treatment arm will receive omega-3 fatty acids (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
3256907|NCT00791089|Placebo Comparator|placebo, Ablation, sinus rhythm|Patients in the control arm will not receive any omega-3 fatty acids. However they will receive placebo.
3256908|NCT00791076|Placebo Comparator|Saline Placebo|Saline
3256909|NCT00791076|Active Comparator|Pancreatic Polypeptide|Pancreatic Polypeptide
3256910|NCT00791063|Experimental|18F ML-10|Intervention - 18F ML-10 PET/CT imaging for early detection of response of brain metastases to WBRT
3256911|NCT00791050|Experimental|1 Thermo|
3256912|NCT00791050|No Intervention|2 Control|
3256913|NCT00791037|Experimental|Treatment (vaccine therapy)|"Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2 weeks later, patients undergo leukapheresis to isolate and collect peripheral blood mononuclear cells for T-cell expansion.~Patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10 days for up to three immunizations. Patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion, followed by 2 additional booster vaccines at 2-month intervals."
3256914|NCT00791024|Experimental|single arm|
3256915|NCT00791011|Experimental|Cohort 4|AMG 655 (intermediate dose) with Vorinostat
3256916|NCT00791011|Experimental|Cohort 1|AMG 655 (low dose) with Bortezomib
3256917|NCT00791011|Experimental|Cohort 2|AMG 655 (low dose) with vorinostat
3256918|NCT00791011|Experimental|Cohort 5|AMG 655 (high dose) with Bortezomib
3256919|NCT00791011|Experimental|Cohort 6|AMG 655 (high dose) with Vorinostat
3256920|NCT00791011|Experimental|Cohort 7|Part 2 - Mantle Cell Lymphoma subjects only: AMG 655 at dose TBD with Bortezomib
3256921|NCT00791011|Experimental|Cohort 3|AMG 655 (intermediate dose) with Bortezomib
3256922|NCT00790998|Experimental|Moxidectin|Moxidectin 8mg
3256923|NCT00790998|Active Comparator|Ivermectin|Ivermectin 150 mcg/kg
3256924|NCT00790985|Experimental|flavocoxid 500 mg|flavonoid mixture
3256925|NCT00790985|Active Comparator|naproxen|nonsteroidal anti-inflammatory drug
3256926|NCT00790972|Placebo Comparator|2|Identical-appearing placebo
3256927|NCT00790972|Active Comparator|1|two sprays in each nostril three times daily for one week
3256928|NCT00790959|Experimental|SASA!|
3256929|NCT00790959|Active Comparator|Control|
3256930|NCT00790946|Active Comparator|Valsartan|Valsartan 80 to 160mg
3256931|NCT00790946|No Intervention|standard therapy|
3256932|NCT00790933|Experimental|Vedolizumab|Vedolizumab 300 mg, 30-minute intravenous (IV) infusion every 4 weeks, starting at Week 0 for up to 46 months.
3256933|NCT00790920|Experimental|Desmoteplase|
3256934|NCT00790920|Placebo Comparator|Placebo|
3256935|NCT00790907|Experimental|Open label fondaparinux background and standard dose UFH|Subjects indicated for PCI and randomized to receive standard dose UFH
3256936|NCT00790907|Experimental|Open label fondaparinux background and low dose UFH|Subjects indicated for PCI and randomized to receive low dose UFH
3256937|NCT00790907|Other|Open label fondapaparinux|Subjects not indicated for PCI and not randomized
3256938|NCT00790894|Active Comparator|1|
3256939|NCT00790894|Experimental|2|
3256940|NCT00790881|Other|Antiretroviral-naive|Antiretroviral-naive included as control group
3256941|NCT00790881|Active Comparator|Nevirapine-based antiretroviral therapy|Nevirapine-based antiretroviral therapy
3256942|NCT00790868|Experimental|D-cycloserine|DCS-augmented CBT
3256943|NCT00790868|Placebo Comparator|Placebo|placebo-augmented CBT
3256944|NCT00790855|Experimental|Bendamustine|Starting dose 50 mg/m^2 intravenously over 2 hours twice on Days 1-4 of every 4 week study cycle.
3256945|NCT00790842|Other|Group A=30-60 CrCl (mL/min)|Lenalidomide days 1-21 and Dexamethasone 40 mg days 1, 8, 15 and 22 every 28 days. Phase I will determine the dose of lenalidomide to be used in Phase II.
3256946|NCT00790842|Other|Group B=CrCL<30 mL/min not on dialysis|Lenalidomide days 1-21 and Dexamethasone 40 mg days 1, 8, 15 and 22 every 28 days. Phase I will determine the dose of lenalidomide to be used in Phase II.
3256947|NCT00790842|Other|Group C=CrCL<30 mL/min and on dialysis|Lenalidomide days 1-21 and Dexamethasone 40 mg days 1, 8, 15 and 22 every 28 days. Phase I will determine the dose of lenalidomide to be used in Phase II.
3256948|NCT00790829|Experimental|A, B|Group B received a seven-milligram transdermal patch and Group A received a placebo patch.
3256949|NCT00790816|Experimental|Group 1|Study Drug
3256950|NCT00790816|Experimental|Group 2|Study Drug
3256951|NCT00790803|Other|Pegaptanib (Macugen)|Open label, non randomized, interventional controlled injection of 0.3mg of Pegaptanib (Macugen) every 6weeks with max of 5 injections over 30weeks.
3256952|NCT00790790|Placebo Comparator|Placebo|Participants randomized to LY545694 placebo were given LY545694 placebo twice daily (BID) oral (po) for 5 weeks.
3256953|NCT00790790|Experimental|LY545694 49 mg|Participants randomized to LY545694 49 milligrams (mg) BID po were first administered LY545694 21 mg BID po at Visit 3. After 1 week of dosing, participants were escalated to LY545694 49 mg BID po at Visit 4. Participants who were intolerant of this dose were titrated back down to 21 mg BID po for the remainder of study treatment.
3256954|NCT00790790|Experimental|LY545694 105 mg|Participants randomized to LY545694 105 mg BID po were first administered LY545694 21 mg BID po at Visit 3. After 1 week of dosing, participants were escalated to LY545694 49 mg BID po at Visit 4. At Visit 5, participants were titrated to the final dose of LY545694 105 mg BID po. Participants who were intolerant of this dose were titrated back down to LY545694 49 mg BID po for the remainder of study treatment.
3256955|NCT00790764|Placebo Comparator|Placebo|20 individuals will receive placebo.
3256956|NCT00790764|Experimental|MESENDO|"Active combination autologous stem cell therapy. 40 individuals will receive MESENDO in either the high or low dose treatment groups."
3256957|NCT00790751|Placebo Comparator|placebo|
3256958|NCT00790751|Experimental|avanafil 50 mg|
3256959|NCT00790751|Experimental|avanafil 100 mg|
3256960|NCT00790751|Experimental|avanafil 200 mg|
3256961|NCT00790738|Experimental|1|liothyronine (T3)
3256962|NCT00790738|Placebo Comparator|2|placebo
3256963|NCT00790725|Other|PAV|Proportional Assist Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
3256964|NCT00790725|Other|PS|Pressure Support Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
3256965|NCT00790699|Active Comparator|I-PORT|
3256966|NCT00790699|Active Comparator|standard injections|
3256967|NCT00790686|Experimental|1|Memokath 051
3256968|NCT00790673|Experimental|1|CF102 1 mg qd
3256969|NCT00790673|Experimental|2|CF102 1 mg bid
3256970|NCT00790673|Experimental|3|CF102 1 mg bid; 16 weeks
3256971|NCT00790673|Placebo Comparator|5|
3256972|NCT00790660|Experimental|ASP1941 Lowest Dose|Oral
3256973|NCT00790660|Experimental|ASP1941 Low Dose|Oral
3256974|NCT00790660|Experimental|ASP1941 Medium Dose|Oral
3256975|NCT00790660|Experimental|ASP1941 High Dose|Oral
3256976|NCT00790660|Placebo Comparator|Placebo|Oral
3256977|NCT00790647|Experimental|Stem Cell Transplant with Bortezomib and Melphalan|Mobilization with Filgrastim Stem Cell Collection Bortezomib Melphalan Stem Cell infusion
3256978|NCT00790634||Parkinson's Disease|Patients with idiopathic Parkinson's disease
3256979|NCT00790634||Obsessive-compulsive disorder|Individuals with a diagnosis of obsessive-compulsive disorder
3256980|NCT00790634||OCD controls|Healthy controls, matched in age and number to obsessive-compulsive group
3256981|NCT00790634||PD controls|Healthy controls, matched in age and number to Parkinson's disease group
3256982|NCT00790595|Experimental|Group A|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
3256983|NCT00790595|Experimental|Group B|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
3256984|NCT00790595|Experimental|Group C|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
3256985|NCT00790595|Experimental|Group D|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
3256986|NCT00790595|Experimental|Group E|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
3256987|NCT00790582|Experimental|lithium carbonate|
3256988|NCT00790569|Experimental|Arm I|Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
3256989|NCT00790569|Placebo Comparator|Arm II|Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
3256990|NCT00790569|Active Comparator|Arm III|Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
3256991|NCT00790556|Experimental|1|MK8245
3256992|NCT00790556|Placebo Comparator|2|Placebo Comparator
3256993|NCT00790543||Observation|Children newly diagnosed with Crohn's disease.
3256994|NCT00790530|Experimental|ATO-SR|Automated Telephone Outreach with Speech Recognition
3256995|NCT00790530|No Intervention|Usual Care|Usual Care
3256996|NCT00790517|Experimental|1|Premier Lifestyle Intervention with Dash Diet, adapted for populations with mental illnesses
3256997|NCT00790517|No Intervention|2|Usual care
3256998|NCT00790504||1 study group|Women with multiple gestations recruited from the prenatal care or high risk pregnancy units
3256999|NCT00790504||2 control group|Women with singleton gestation recruited from the prenatal care or high risk pregnancy units
3257000|NCT00790491|Experimental|Lifestyle counseling|
3257001|NCT00790478|Placebo Comparator|Placebo|
3257002|NCT00790478|Active Comparator|Melatonin|
3257003|NCT00790465|Active Comparator|1|dark chocolate consumption during manometry and 2 weeks treatment with dark chocolate
3257004|NCT00790465|Other|2|placebo comparator: 7 grams of placebo-chocolate at day 1 during manometry, and than crossover to treatment with dark chocolate for 2 weeks.
3257005|NCT00790452|Active Comparator|Group 1 (Aspirin)|Aspirin 325 mg/day orally
3257006|NCT00790452|Placebo Comparator|Group 2 (Placebo)|Tablet/day orally
3257007|NCT00790439|Experimental|LMW-SD|18 participants randomized to immunosuppression with Low Molecular Weight Sulfated Dextran (LMW-SD)
3257008|NCT00790439|Active Comparator|Control Group, Standard of Care|18 participants randomized to immunosuppression without Low Molecular Weight Sulfated Dextran (LMW-SD)
3257009|NCT00790426|Experimental|FGFR3 wild type|
3257010|NCT00790426|Experimental|FGFR3 mutant|
3257011|NCT00790413|Experimental|High-dose MIBG with haploidentical stem cell transplantation|High-dose MIBG followed by Fludarabine, Thiotepa and Melfalan as conditioning Before haploidentical transplantation of T-cell depleted graft
3257012|NCT00790400|Experimental|Everolimus|Study drug was given by continuous oral daily dosing of two 5 mg tablets.
3257013|NCT00790400|Placebo Comparator|Placebo|Placebo was given by continuous oral daily dosing of two 5 mg tablets.
3257014|NCT00790387|Experimental|1 High dose tirofiban and enoxaparin|"Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg .~Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours."
3257015|NCT00790387|Active Comparator|2 tirofiban and unfractionated heparin|"Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours.~UFH heparin was administered as a bolus of 70 U/kg and additional heparin was given to maintain the activated clotting time (ACT) at 250"
3257016|NCT00790374|Experimental|Cohort 1|6 patients have been enrolled, the cohort has been completed.
3257017|NCT00790374|Experimental|Cohort 2|6 patients have been enrolled in cohort 2, the cohort has been completed.
3257018|NCT00790374|Experimental|Cohort 3|5 patients have been enrolled in cohort 3. The cohort was closed after the 5th patient enrolled.
3257019|NCT00790361||Control|"Controls (healthy volunteers) will have two scans (fMRI, MRS and DTI) six months apart to determine reproducibility.~A blinded investigator will administer JOA, ASIA/ISCOS, NDI and SF-36 prior to the scan at all time points."
3257020|NCT00790361||CCS Participants|"CCS participants will have three scans (fMRI, MRS and DTI), one acutely (up to 48 hours after injury), one subacutely (15 days after injury), and one late (6 months after injury).~A blinded investigator will administer JOA, ASIA/ISCOS, NDI and SF-36 prior to the scan at all time points."
3257021|NCT00790348||1|Patients who on Januvia
3257022|NCT00790348||2|Patients on Janumet (Combination of Januvia and Metformin)
3257023|NCT00790348||3|Patients on Metformin
3257024|NCT00790335|Experimental|A-Intervention|PCDT with intrathrombus delivery of recombinant tissue plasminogen activator (rt-PA, maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
3257025|NCT00790335|No Intervention|B-Control|Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target international normalized ratio 2.0 - 3.0). Elastic compression stockings will be prescribed
3257026|NCT00790322|Experimental|Active|
3257027|NCT00790322|Placebo Comparator|Placebo|
3257028|NCT00790309||Weight loss surgery|This group will be comprised of people having weight loss surgery: Roux-en Y gastric bypass, vertical sleeve gastrectomy, or adjustable gastric banding
3257029|NCT00790309||Abdominal surgery|This group will be comprised of people having abdominal surgeries such as nissen fundoplication or cholecystectomy.
3257030|NCT00790309||Lean|This group will be comprised of normal weight healthy volunteers.
3257031|NCT00790296|Experimental|Thyrotropin releasing hormone (TRH)|TRH
3257034|NCT00790283|Active Comparator|Vision/MiniVision|
3257035|NCT00790270|Active Comparator|Cyclobenzaprine|
3257036|NCT00790270|Active Comparator|Ibuprofen|
3257037|NCT00790270|Experimental|Ibuprophen plus Cyclobenzaprine|
3257038|NCT00790257|Experimental|Monolayer Cellular Device|Encapsulated human islets allotransplantation transplanted in subcutaneous tissue in Type 1 diabetes patient
3257039|NCT00790244|Experimental|Arm 2|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and 4.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
3257040|NCT00790244|Experimental|Arm 3|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 45Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and 4.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
3257041|NCT00790244|Experimental|Group B|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
3257042|NCT00790244|Experimental|Arm 1|<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle (>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)
3257043|NCT00790231||men|observation of the urinary function with and without thoracic epidural anesthesia
3257044|NCT00790231||women|observation of the urinary function with and without thoracic epidural anesthesia
3257045|NCT00790218|Experimental|CF102|An open-label trial (1, 5, and 25 mg BID) in 28-day cycles.
3257046|NCT00790205|Experimental|Sitagliptin|Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
3257047|NCT00790205|Placebo Comparator|Placebo|Placebo to sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
3257048|NCT00790192|Experimental|Lurasidone 80mg|
3257049|NCT00790192|Experimental|Lurasidone 160mg|
3257050|NCT00790192|Active Comparator|Quetiapine XR|
3257051|NCT00790192|Placebo Comparator|Placebo|
3257052|NCT00790179|Active Comparator|PCA;active comparator|Patients with intravenous PCA hydromorphone alone
3257053|NCT00790179|Active Comparator|CFB|Patients with a continuous femoral block (CFB) + PCA hydromorphone
3257054|NCT00790179|Active Comparator|CLPB|Patients with a continuous lumbar plexus block + PCA hydromorphone
3257055|NCT00790166|Active Comparator|CPAP + ThermoSmart™ humidity|
3257056|NCT00790166|Active Comparator|CPAP + Conventional humidity|
3257057|NCT00790166|Active Comparator|CPAP + No added humidity|
3257058|NCT00790153|Active Comparator|1|AZD1656
3257059|NCT00790153|Active Comparator|2|Insulin
3257060|NCT00790140|Active Comparator|Immunonutrition Prosure|This group of patients are to be given a tube feed enriched with 2.2 g Eicosapentaenoic Acid (EPA) per day for 5 days pre surgery and 21 days post surgery
3257061|NCT00790140|Placebo Comparator|Standard enteral nutrition Ensure Plus|This group are to be given a standard enteral tube feed without EPA for 5 days pre op and 21 days post surgery
3257062|NCT00790127|Placebo Comparator|Placebo|Placebo
3257063|NCT00790127|Experimental|HQK-1001|HQK-1001
3257064|NCT00790114|Experimental|1|
3257065|NCT00790101|Experimental|1|Risedronate 35mg once a week
3257066|NCT00790101|Active Comparator|2|Raloxifene 60mg daily
3257067|NCT00790101|Placebo Comparator|3|
3257068|NCT00790062|Active Comparator|Oxytocin 10 units/500cc|1 dose only for prophylaxis given over 1 hour
3257069|NCT00790062|Experimental|Oxytocin 40 units/500cc|One dose only given over 1 hour. Per DSMB recommendations, this intermediate arm was stopped Jan 2010.
3257070|NCT00790062|Experimental|Oxytocin 80U/500cc|1 dose only given over 1 hour
3257071|NCT00790049|Experimental|ARRY-371797|
3257072|NCT00790049|Placebo Comparator|Placebo|
3257073|NCT00790036|Experimental|Everolimus|Participants who received Everolimus 10 mg (two 5 mg tablets), daily for 12 months
3257074|NCT00790036|Placebo Comparator|Placebo|Participants who received Everolimus placebo 10 mg (two 5 mg tablets), daily for 12 months
3257075|NCT00790023|Experimental|80 mcg Ciclesonide|80 mcg Ciclesonide once daily
3257076|NCT00790023|Experimental|160 mcg Ciclesonide|160 mcg Ciclesonide once daily
3257077|NCT00790023|Placebo Comparator|Placebo|Placebo once daily
3257078|NCT00790010|Experimental|Bevacizumab Plus Ipilimumab Cohort 1|5 subjects for this cohort
3257079|NCT00790010|Experimental|Bevacizumab Plus Ipilimumab Cohort 2|17 subects for this cohort
3257080|NCT00790010|Experimental|Bevacizumab Plus Ipilimumab Cohort 3|12 subjects
3257081|NCT00790010|Experimental|Bevacizumab Plus Ipilimumab Cohort 4|12 subjects
3257082|NCT00789997|Experimental|Etanercept|etanercept 50 mg subcutaneous given on the day of randomization and one week later prednisone placebo po daily for 10 days Levofloxacin 750 mg po daily for 10 days.
3257083|NCT00789997|Active Comparator|Prednisone|prednisone 40 mg daily for 10 days etanercept placebo subcutaneous given on the day of randomization and one week later Levofloxacin 750 mg daily for 10 days.
3257084|NCT00789958|Experimental|Adjuvant Chemo+ Chemoradiotherapy|"Adjuvant Chemotherapy~Capecitabine, 1500 mg/m^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~Gemcitabine hydrochloride, 1000 mg/m^2, IV, Days 1 & 8 of each cycle~Chemoradiotherapy~-Capecitabine, 1330 mg/m^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT~Radiation (RT):~3-dimensional conformal radiation therapy - 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.~intensity-modulated radiation therapy: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions."
3257085|NCT00789945|Placebo Comparator|Study Arm A|Study Arm A will be the primary control arm.
3257086|NCT00789945|Experimental|Study Arm B|Study Arm B will serve as the intervention arm.
3257087|NCT00789932|Experimental|CBT|
3257088|NCT00789932|Active Comparator|Usual Care|
3257089|NCT00789919|No Intervention|1|Study participants (those diagnosed with mild preeclampsia) are admitted to hospital for standard inpatient management of their disease.
3257135|NCT00789594|Experimental|Both interventions|Both laboratory monitoring and result management interventions
3257136|NCT00789594|No Intervention|Usual care|Usual care
3257090|NCT00789919|Experimental|2|Study participants (those diagnosed with mild preeclampsia) are admitted to hospital and their infant is delivered as soon as possible after 34 weeks gestation. As there is no determined optimal time of delivery in these patients, delivery is the intervention.
3257091|NCT00789906||1|350 healthy women , aged from 18 to 89
3257092|NCT00789906||2|350 healthy men, aged from 18 to 89
3257093|NCT00789893||Women with cervical, endometrial, rectal or anal cancer|Women seen in the radiation oncology clinic with cervical, endometrial, rectal or anal cancer who will receive external beam pelvic radiation or brachytherapy
3257094|NCT00789880|Experimental|Vitamin D3|Subjects received a 21-day course of oral vitamin D3 (cholecalciferol, 4,000 international units [IU]
3257095|NCT00789880|Placebo Comparator|Placebo|Subjects received a 21-day course of oral vitamin D3-placebo
3257096|NCT00789867|Experimental|pGM169/GL67A|Single nebulised and nasal dose
3257097|NCT00789854|Active Comparator|Add-on Quetiapine XR+SSRI/Venlafaxine|"Selective serotonin reuptake inhibitors (SSRI) or Venlafaxine from previous therapy + add-on treatment with quetiapine XR, 300mg tablet once daily (od).~From previous anti-depressant treatment 64% of the patients had SSRI and 35% had Venlafaxine at baseline."
3257098|NCT00789854|Active Comparator|Add-on Lithium+SSRI/Venlafaxine|"Selective serotonin reuptake inhibitors (SSRI) or venlafaxine from previous therapy + add-on treatment with lithium, approximately 900mg tablet once daily (od).~From previous anti-depressant treatment 67% of the patients had SSRI and 33% had Venlafaxine at baseline."
3257099|NCT00789854|Active Comparator|Monotherapy Quetiapine XR|Switch from previous treatment with SSRI or venlafaxine to quetiapine XR monotherapy, 300mg tablet once daily (od)
3257100|NCT00789841||Patients with NET and diarrhea.|
3257101|NCT00789828|Experimental|Everolimus|Everolimus was administered orally at a starting dose of 4.5mg/m^2 daily and subsequently titrated to attain whole blood trough concentration of 5 to 15 ng/mL. Dose adjustments were permitted based on safety and whole blood trough concentrations.
3257102|NCT00789828|Placebo Comparator|Placebo|Matching Placebo administered orally.
3257103|NCT00789815|Active Comparator|BIS-guided propofol infusion|In the study group, induction was started using alfentanil 4~5μg/kg bolus following repeated propofol boluses (0.5~1.5 mg/kg) until the BIS level reached 70. During maintenance, propofol infusion (3~12 mg/kg/hour) was given using a syringe pump (Injectomat Agilia, Fresenius Kabi, France), which was titrated to keep the BIS level between 65 and 75.
3257104|NCT00789815|Active Comparator|Clinical-judged midazolam administration|In the control group, induction was started using alfentanil 4~5μg/kg bolus following 2 mg midazolam bolus. After 2 minutes, if the patient was not well sedated, midazolam boluses were repeat by increments of 2 mg/2min until conscious sedation was achieved
3257105|NCT00789802|Experimental|transdermal estradiol|participants will be randomized to transdermal estradiol
3257106|NCT00789802|Experimental|oral naproxen|participants will be randomized to oral naproxen
3257107|NCT00789802|Placebo Comparator|oral placebo|participants will be randomized to oral placebo
3257108|NCT00789789||1|
3257109|NCT00789776|Experimental|Treatment (non-myeloablative transplant)|"CONDITIONING: Patients receive fludarabine IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total-body irradiation on day -1.~DONOR BONE MARROW TRANSPLANTATION: Patients undergo donor bone marrow transplantation on day 0.~POST-TRANSPLANTATION IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3 and mycophenolate mofetil PO TID on days 4 to 40, followed by a taper until day 84 in the absence of GVHD. Patients also receive tacrolimus IV continuously or IV QD over 1-2 hours or PO BID on days 4 to 84, followed by a taper until day 180 in the absence of GVHD.~NK CELL INFUSION: Patients undergo donor lymphocyte infusion of NK cells on day 7."
3257110|NCT00789763|Experimental|Sorafenib + gemcitabine + radiotherapy|
3257111|NCT00789750|Experimental|Colesevelam|Participants receive six colesevelam tablets (3.8 grams/day) in addition to pioglitazone-based therapy (30 mg or 45 mg)
3257112|NCT00789750|Placebo Comparator|Placebo|Participants receive six placebo tablets in addition to pioglitazone-based therapy (30 mg or 45 mg)
3257113|NCT00789737|Experimental|Welchol|Welchol 625mg tablets
3257114|NCT00789737|Placebo Comparator|placebo|placebo
3257115|NCT00789724|Experimental|Anakinra|Anakinra 100 mg given daily by subcutaneous injection for 14 days
3257116|NCT00789724|Placebo Comparator|Placebo|0.67 ml of NaCl 0.9% solution
3257117|NCT00789711||A|
3257118|NCT00789711||B|
3257119|NCT00789698|Experimental|Lurasidone HC1|
3257120|NCT00789698|Active Comparator|Quetiapine|
3257121|NCT00789685|Experimental|Interferon Beta|Interferon Beta
3257122|NCT00789672|Active Comparator|Lower Dose (3-1) levodopa/carbidopa|Oral levodopa 0.51 mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation) combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam 9 weeks after starting medication.
3257123|NCT00789672|Active Comparator|Higher Dose (4.5-1) levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation) combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam 9 weeks after starting medication.
3257124|NCT00789659|Experimental|VAC dressing|The patients whose postoperative wound will be dressed with a negative pressure (V.A.C.) dressing.
3257125|NCT00789646|Other|1|First injection: Normal saline Second injection: 2% Lidocaine without adrenaline
3257126|NCT00789646|Other|2|First injection: 2% Lidocaine without adrenaline Second injection: Normal saline
3257127|NCT00789633|Experimental|1|masitinib (AB1010) in combination with gemcitabine
3257128|NCT00789633|Placebo Comparator|2|placebo in combination with gemcitabine
3257129|NCT00789620|Active Comparator|1|Lidocaine 1% administrated as a bolus of 1.5 mg/kg, then intraoperative 2mg/kg/h and postoperative 1.3mg/kg/h during 24 h
3257130|NCT00789620|Placebo Comparator|2|NaCl 0.9% as a bolus 1.5mg/kg, then intraoperative 2mg/kg/h and postoperative 1.3mg/kg/h during 24h
3257131|NCT00789607|Active Comparator|MRI-guided FM|
3257132|NCT00789607|Active Comparator|TRUS-guided FM|
3257133|NCT00789594|Experimental|Laboratory Monitoring|Laboratory Monitoring
3257134|NCT00789594|Experimental|Result management|Result management
3257340|NCT00788138|Placebo Comparator|2|Matching Placebo
3257137|NCT00789581|Experimental|Doxorubicin/cyclophosphamide, ixabepilone|Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by ixabepilone at 40 mg/m2 given for 4 cycles of 21 days each.
3257138|NCT00789581|Active Comparator|Doxorubicin/cyclophosphamide, paclitaxel|Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by paclitaxel at 80 mg/m2 weekly for 12 weeks.
3257139|NCT00789568|Experimental|Sapropterin Dihydrochloride 100mg/kg and placebo Moxifloxacin|A single dose of 100mg/kg of Sapropterin Dihydrochloride taken along with placebo Moxifloxacin.
3257140|NCT00789568|Experimental|Sapropterin Dihydrochloride 20mg/kg and placebo Moxifloxacin|A single dose of 20mg/kg of Sapropterin Dihydrochloride taken along with a placebo Moxifloxacin.
3257141|NCT00789568|Active Comparator|Sapropterin Dihydrochloride placebo and Moxifloxacin|No placebo tablets for Sapropterin Dihydrochloride will be administered, but instead will be apple juice only, taken along with 400mg of Moxifloxacin.
3257142|NCT00789568|Placebo Comparator|Sapropterin Dihydrocholide placebo and Moxifloxacin placebo|No placebo tablets for Sapropterin Dihydrochloride will be administered, but instead will be apple juice only, taken along with placebo of Moxifloxacin.
3257143|NCT00789555|Experimental|PATANASE|Olopatadine hydrochloride 0.6% nasal spray (PATANASE), two sprays in each nostril twice a day (morning and evening) for up to 12 months
3257144|NCT00789555|Placebo Comparator|Patanase Vehicle, pH 3.7|Olopatadine nasal spray vehicle, pH 3.7, two sprays in each nostril twice a day (morning and evening) for up to 12 months
3257145|NCT00789555|Placebo Comparator|Patanase Vehicle, pH 7.0|Olopatadine nasal spray vehicle, pH 7.0, two sprays in each nostril twice a day (morning and evening) for up to 12 months
3257146|NCT00789542|Experimental|Intermittent Pneumatic Compression|SCD Express device applied with thigh length sleeves for up to 30 days
3257147|NCT00789542|Other|Routine care|Routine care which might include: early mobilisation, adequate hydration, aspirin if ischaemic stroke and graduated compression stockings according to local protocols.
3257148|NCT00789529|Active Comparator|1|Opti-Free® RepleniSH® MPDS
3257149|NCT00789529|Active Comparator|2|Renu MultiPlus®
3257150|NCT00789516||1|Normal control
3257151|NCT00789516||2|B thalassemia regular transfusion
3257152|NCT00789516||3|B thalassemia post transplantation
3257153|NCT00789503|Experimental|Bread fortified with vitamin D3 and calcium|
3257154|NCT00789477|Experimental|Intravitreal Aflibercept Injection .5Q4|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) .5 mg every 4 weeks
3257155|NCT00789477|Experimental|Intravitreal Aflibercept Injection 2Q4|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2 mg every 4 weeks
3257156|NCT00789477|Experimental|Intravitreal Aflibercept Injection 2Q8|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2mg every 4 weeks for 3 visits followed by every 8 weeks
3257157|NCT00789477|Experimental|Intravitreal Aflibercept Injection 2PRN|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2mg every 4 weeks for 3 visits followed by PRN (as-needed) dosing according to the re-treatment criteria
3257158|NCT00789477|Active Comparator|Laser Photocoagulation|Focal laser at week 1, and one week after visits at which the participant met laser re-treatment criteria to the end of the study (week 52) starting at week 16; laser re- treatment was permitted no more than once every 16 weeks.
3257159|NCT00789464|Other|ARM A|Probiotics drops plus placebo elixir
3257160|NCT00789464|Other|ARM B|TMP/SMZ elixir plus placebo drops
3257161|NCT00789451|Sham Comparator|1|no ischaemia - only sham. Blood pressure cuff inflation up till 10 mmHg on the upper arm for 20 mins.
3257162|NCT00789451|Active Comparator|2|Ischaemia 20 minutes. Blood pressure cuff will be inflated around the upper arm for 20 minutes to induce ischaemia.
3257163|NCT00789438||General Anesthesia|Patients undergoing short-term surgery (30-90 min) under general anesthesia
3257164|NCT00789438||Spinal|Patients undergoing short-term surgery (30-90 min) under spinal anesthesia
3257165|NCT00789438||Spinal + Sedation|Patients undergoing short-term surgery (30-90 min) under spinal anesthesia with sedation
3257166|NCT00789425|Active Comparator|1|a standardized extract of olive polyphenols at 250 mg per day + 1000 mg of calcium per day.
3257167|NCT00789425|Placebo Comparator|2|Placebo (starch) + 1000 mg of calcium per day.
3257168|NCT00789412||Expected ICU|Patients with expected postoperative admission to the ICU. Baseline measurement of SSI. Exploration prior to weaning.
3257169|NCT00789412||Unexpected ICU|Patients with unexpected stay at the ICU. No baseline measurement of SSI. Exploration in `steady state` of analgosedation.
3257170|NCT00789399|Active Comparator|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
3257171|NCT00789399|Placebo Comparator|Placebo|
3257172|NCT00789386|Experimental|Remifentanil|
3257173|NCT00789386|Placebo Comparator|Midazolam|Active Placebo
3257174|NCT00789373|Experimental|pemetrexed + cisplatin followed by pemetrexed|pemetrexed plus cisplatin followed by pemetrexed plus best supportive care
3257175|NCT00789373|Placebo Comparator|pemetrexed + cisplatin followed by placebo|pemetrexed plus cisplatin followed by placebo plus best supportive care
3257176|NCT00789360|Experimental|1|Placebo -- Active
3257177|NCT00789360|Experimental|2|Active -- Placebo
3257178|NCT00789347||1|Healthy volunteers
3257179|NCT00789347||2|Patient with neuropathic pain
3257180|NCT00789347||3|patients without neuropathic pain
3257181|NCT00789321|Experimental|1|amlodipine
3257182|NCT00789321|Placebo Comparator|2|Placebo to amlodipine
3257183|NCT00789308|Active Comparator|Standard of Care|18 participants randomized to protocol immunosuppression (Daclizumab OR Basiliximab; Tacrolimus OR Cyclosporine; Mycophenolate Mofetil OR Sirolimus; and heparin) without LMW-DS
3257184|NCT00789308|Experimental|LMW-DS|18 participants randomized to protocol immunosuppression (Daclizumab OR Basiliximab; Tacrolimus OR Cyclosporine; Mycophenolate Mofetil OR Sirolimus; and heparin) and LMW-DS
3257185|NCT00789295|Active Comparator|Mediterranean diet|The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%)
3257341|NCT00788125|Experimental|Dasatinib with Ifosfamide, Carboplatin, Etoposide|
3257186|NCT00789295|Active Comparator|Low-Carbohydrates diet|Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)
3257187|NCT00789282|Active Comparator|Usual Care Group|The 'usual care' study arm (control) will reflect current patterns of care for patients with thpe 2 diabetes in the Capital Health region
3257188|NCT00789282|Experimental|Enhanced Care Group|In the enhanced care group(intervention arm) the participants will receive a multifactorial intervention with three main components that include: optimized medical management, 2) support for development of enhanced patient self management skills, and 3) organized proactive follow-up by chronic disease management teams to support improvement in care.
3257189|NCT00789269|Experimental|1|rhubarb
3257190|NCT00789269|Placebo Comparator|2|
3257191|NCT00789256|Experimental|Study treatment|All patients will receive the following regimen: 1) Melphalan 2 mg orally, once daily. 2) Bortezomib 1.0 mg/M2 IV on days 1, 4, 8, 11.
3257192|NCT00789243|Active Comparator|1|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, local ischaemic preconditioning will be induced by inflating a cuff around the non-dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
3257193|NCT00789243|Active Comparator|2|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
3257194|NCT00789243|Placebo Comparator|3|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, sham will be performed by inflating a cuff to 10 mmHg for 5 mins followed by 5 mins of deflation. This cycle will be repeated 3 times.
3257195|NCT00789230|Active Comparator|primary suture|
3257196|NCT00789230|Active Comparator|mesh enforced closure|
3257197|NCT00789217|Active Comparator|In-house penicillin testing preparation|In-house penicillin testing prepared from alkali-treated penicillin G
3257198|NCT00789217|Active Comparator|Commercial penicillin test kit|Commercial penicillin test kit order from Diater company
3257199|NCT00789217|Active Comparator|Penicillin G Sodium|Penicillin G Sodium from routine clinical use
3257200|NCT00789204|Experimental|GPR|Global Postural Re-Education
3257201|NCT00789204|Active Comparator|SEP|Standard Exercise Programm
3257202|NCT00789191|Experimental|Comb|Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment
3257203|NCT00789191|Active Comparator|Sita|Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment
3257204|NCT00789178||patients with fibromyalgia|
3257205|NCT00789178||patients with active RA|
3257206|NCT00789165|Experimental|Quinidine|Patients with type I Brugada electrocardiogram (either spontaneous or following a drug challenge with sodium channel blocker) who never experienced arrhythmia-related symptoms. Patients will receive quinidine therapy at the discretion of the attending physician.
3257207|NCT00789165|Active Comparator|no therapy|Patients with asymptomatic Brugada syndrome who opted to receive no therapy following the recommendation of their attending physician
3257208|NCT00789152|Experimental|desloratadine followed by levocetirizine|Subjects in this arm received desloratadine 5 mg daily for 8 days, followed by 10 day washout period, then followed by levocetirizine 5 mg daily for 8 days
3257209|NCT00789152|Experimental|levocetirizine followed by desloratadine|Subjects in this arm received levocetirizine 5 mg daily for 8 days, followed by 10 day washout period, then followed by desloratadine 5 mg daily for 8 days
3257210|NCT00789139|Other|AF monitoring by ICM|Only one arm
3257211|NCT00789113|Experimental|Extended Release Lamotrigine|Extended Release Lamotrigine
3257212|NCT00789100||1|Group provided with home-based monitor
3257213|NCT00789100||2|Group receives no home-based monitor
3257214|NCT00789087|Active Comparator|1. Videothoracoscopic talc poudrage (VT)|
3257215|NCT00789087|Active Comparator|2. Talc slurry through a chest tube (DT)|
3257216|NCT00789074|Experimental|Varenicline pre-treatmemt|Participants will use varenicline (1mg BD) 4-weeks prior to quitting
3257217|NCT00789074|Placebo Comparator|Placebo|Participants will use 3 weeks of placebo, followed by 1 week of varenicline, prior to quitting
3257218|NCT00789048|No Intervention|Surgeon doesn't see|The surgeon doesn't see the radiograph prior to surgery
3257219|NCT00789048|Experimental|Surgeon does see|The surgeon can see the radiograph prior to surgery
3257220|NCT00789022||1|40 subjects in a First Psychotic Episode
3257221|NCT00789022||2|20 First Degree relatives
3257222|NCT00789022||3|20 Healthy subjects
3257223|NCT00788996|Experimental|Lifestyle counseling|Usual care
3257224|NCT00788970|Experimental|Acupressure|Acupressure adjuvant therapy
3257225|NCT00788970|Placebo Comparator|Placebo acupressure|Sham acupressure adjuvant therapy
3257226|NCT00788970|No Intervention|No treatment|Wait list group (no treatment)
3257227|NCT00788957|Experimental|Part 1: Panitumumab + Rilotumumab|Participants received panitumumab 6 mg/kg and rilotumumab 10 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
3257228|NCT00788957|Active Comparator|Part 2: Panitumumab Alone|Participants received panitumumab 6 mg/kg and placebo by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
3257229|NCT00788957|Experimental|Part 2: Panitumumab + Rilotumumab|Participants received panitumumab 6 mg/kg and rilotumumab 10 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
3257230|NCT00788957|Experimental|Part 2: Panitumumab + Ganitumab|Participants received panitumumab 6 mg/kg and ganitumab 12 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
3257231|NCT00788944|Other|1|
3257232|NCT00788931|Experimental|IV LBH589 + trastuzumab + paclitaxel|i.v. panobinostat
3257233|NCT00788931|Experimental|Oral LBH589 + trastuzumab + paclitaxel|oral panobinostat
3257342|NCT00788112|Experimental|Vorinostat|
3257234|NCT00788918|Experimental|Chronic hepatitis C treatment|30 Chronic HCV patients with pending antiviral treatment. A majority will have pending treatment with interferon and ribavirin, and the treated patients will be assessed 8-12 weeks after starting treatment for interferon-induced depression.
3257235|NCT00788918|No Intervention|Healthy Controls|50 age, sex and education matched controls (matched 1:1 to participants in the HCV patient groups (+/- treatment)
3257236|NCT00788918|No Intervention|Former HCV infected|20 Subjects with prior HCV infection identified through positive HCV antibodies, but negative HCV RNA.
3257237|NCT00788918|No Intervention|Chronic HCV patient - no treatment|20 chronic HCV patients without pending antiviral treatment.
3257238|NCT00788905|Experimental|A|"Subject will continue conventional hemodialysis therapy for one week (no intervention phase) and then swtich to the Allient system for two weeks (active comparator phase)."
3257239|NCT00788892|Experimental|Arm A: CPX-351|First induction: CPX-351 at 100u/m2 administered on days 1, 3 and 5 Second induction: CPX-351 at 100u/m2 administered on days 1 and 3 Consolidation: CPX-351 at 100u/m2 administered on days 1 and 3
3257240|NCT00788892|Active Comparator|Arm B: Cytarabine + Daunorubicin|First induction: Cytarabine at a dose of 100mg/m2/day on days 1-7, Daunorubicin at dose of 45 or 60mg/m2 on days 1-3 Second induction: Cytarabine at a dose of 100mg/m2/day on days 1-5, Daunorubicin at a dose of 45 or 60 mg/m2/day on days 1 and 2 Consolidation: Investigator's Choice
3257241|NCT00788879|Experimental|1|This study arm is located in Brownsville, Texas. This community is exposed to the TSSC media messages as well as may be visited by the lay health workers and see the built environment changes
3257242|NCT00788879|No Intervention|2|The control group is located in Laredo. This community is not exposed to the TSSC messages nor does the campaign work to actively change the built environment or use lay health workers to share physical activity and nutrition information.
3257243|NCT00788866|Experimental|Pomegranate juice|This arm with receive 8oz of pomegranate juice per day.
3257244|NCT00788866|Placebo Comparator|Placebo|This group will take 8oz of placebo juice that lacks pomegranate daily
3257245|NCT00788853||A|
3257246|NCT00788840|Active Comparator|1. Insulatard|
3257247|NCT00788840|Active Comparator|2. Detemir|
3257248|NCT00788827|Experimental|Autologous CD34+ stem cells|Up to 5 x 10 log 8 of autologous stem cells on a single occasion
3257249|NCT00788814|Other|Control|Control group
3257250|NCT00788801|Experimental|Baseline|
3257251|NCT00788801|Experimental|ABT-614 Low Dose|
3257252|NCT00788801|Experimental|ABT-614 High Dose|
3257253|NCT00788788|Active Comparator|1|Study subjects where breathing Heliox with a fraction of Helium of 25% followed by 50% and 75% with larger external resistor in comparison to medical air
3257254|NCT00788788|Active Comparator|2|Study subjects where breathing Heliox with a fraction of Helium of 50% followed by 75% and 25% with larger external resistor in comparison to medical air
3257255|NCT00788788|Active Comparator|3|Study subjects where breathing Heliox with a fraction of Helium of 25% followed by 50% and 75% with larger external resistor in comparison to medical air
3257256|NCT00788775|Experimental|Nilotinib|Nilotinib was given at a dose of 400 mg orally daily (200 mg pills twice per day). Patients received treatment up to 12 months as long as they were receiving clinical benefit.
3257257|NCT00788762||Villagers in Taxiarchis|
3257258|NCT00788749|Placebo Comparator|Placebo|Placebo tablets for 2 weeks followed by fluticasone nasal drops 800mcg/d for 2 months followed by fluticasone nasal spray 400 mcg/d for 4 months
3257259|NCT00788749|Experimental|Prednisolone|25 mg Prednisolone OD for 2 weeks followed by Fluticasone nasal drops 800 mcg/d for 2 months, followed by fluticasone nasal spray 400mcg/day for 4 months
3257260|NCT00788723|Experimental|1|Patients with severe brain injury, awake, but have cognitive problems
3257261|NCT00788723|Experimental|2|Patients with severe brain injury and disorders of consciousness ( in minimally conscious or in vegetative state)
3257262|NCT00788723|Experimental|3|Healthy volunteers
3257263|NCT00788710|Experimental|Etoricoxib 120 mg|etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.
3257264|NCT00788710|Experimental|Etoricoxib 90 mg|etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.
3257265|NCT00788710|Placebo Comparator|Placebo|Placebo- 3 tablets once daily
3257266|NCT00788697|Other|Patients who received SonoVue|"Patients with at least 1 target lesion requiring work-up for characterization to undergo~Unenhanced ultrasound of the target lesion (UE-US): gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion using commercially available ultrasound equipment and standard techniques (B-mode or Harmonic imaging) to study the anatomy of the target lesion and surrounding parenchyma;~SonoVue-enhanced ultrasound of the target lesion (CE-US): procedures described in protocol Section 7.5.1.2, to study the lesion vascularity in comparison to the surrounding parenchyma; and~Truth standard"
3257267|NCT00788684|Experimental|ABT-263 + rituximab|
3257268|NCT00788671|Experimental|Levonorgestrel IUD|Intrauterine placement during surgery.
3257269|NCT00788658|Placebo Comparator|Diet modifications|Diet consultation and life style modifications for 6 sessions
3257270|NCT00788658|Active Comparator|Cognitive therapy|6 sessions of cognitive behavioral therapy
3257271|NCT00788645|Experimental|Forecast|COPD patients receiving advice and poor weather warning
3257272|NCT00788645|Experimental|No Forecast|COPD patients receiving advice and poor weather warning
3257273|NCT00788645|No Intervention|Control|Age matched non - COPD subjects
3257274|NCT00788632|Experimental|educational materials|Patient educational DVD and brochure
3257275|NCT00788632|Other|physician education|Physician web modules
3257276|NCT00788632|Experimental|System intervention|Self-referral letter with toll-free number provided
3257277|NCT00788619|Active Comparator|Day 3 transfer|Subjects in this arm will have two embryos transferred three days after fertilization. Embryos will be selected based on the concentration of nitric oxide metabolites in the culture medium.
3257278|NCT00788619|Active Comparator|Day 5 transfer|Subjects will have two embryos transferred on day 5 after fertilization with selection of embryos based on morphologic criteria.
3257343|NCT00788099|Experimental|1|Plitidepsin and Sorafenib
3257344|NCT00788099|Experimental|2|Gemcitabine and Plitidepsin
3257279|NCT00788606|Experimental|bevacizumab and Rituximab|This study evaluates the feasibility using the anti-VEGF drug, bevacizumab, in combination with the standard treatment Rituximab in patients with stage II, III and IV diffuse large B cell lymphoma (DLBCL)
3257280|NCT00788593|Placebo Comparator|Placebo|
3257281|NCT00788593|Experimental|EUR-1008 (APT-1008) High Dose|
3257282|NCT00788593|Experimental|EUR-1008 (APT-1008) Low Dose|
3257283|NCT00788567|Experimental|1|
3257284|NCT00788554|Active Comparator|1|
3257285|NCT00788554|Active Comparator|2|
3257286|NCT00788541|Experimental|3 mg Anecortave Acetate, low volume high dose|Anecortave Acetate Sterile Suspension, 6 mg/mL, one injection of 0.5 mL in the study eye monthly for 6 months.
3257287|NCT00788541|Experimental|3 mg Anecortave Acetate, high volume low dose|Anecortave Acetate Sterile Suspension, 3.75 mg/mL, one injection of 0.8 mL in the study eye monthly for 6 months.
3257288|NCT00788541|Experimental|48 mg Anecortave Acetate, low volume high dose|Anecortave Acetate Sterile Suspension, 96 mg/mL, one injection of 0.5 mL in the study eye monthly for 6 months.
3257289|NCT00788541|Experimental|48 mg Anecortave Acetate, high volume low dose|Anecortave Acetate Sterile Suspension, 60 mg/mL, one injection of 0.8 mL in the study eye monthly for 6 months.
3257290|NCT00788541|Placebo Comparator|Anecortave Acetate Vehicle, low volume|Anecortave Acetate Vehicle, one injection of 0.5 mL in the study eye monthly for 6 months.
3257291|NCT00788541|Placebo Comparator|Anecortave Acetate Vehicle, high volume|Anecortave Acetate Vehicle, one injection of 0.8 mL in the study eye monthly for 6 months.
3257292|NCT00788528|Experimental|Arm A|1600 mg S-2367 (velneperit)
3257293|NCT00788515|Experimental|1|
3257294|NCT00788515|Active Comparator|2|
3257295|NCT00788476||Childhood Cancer Survivors|
3257296|NCT00788476||Primary Caregivers|
3257297|NCT00788463|Experimental|Aerosol|
3257298|NCT00788463|Active Comparator|Spray|
3257299|NCT00788424|Experimental|AS101 Cream|Twice daily topical application of AS101 cream on the psoriatic lesions for approx. 12 weeks is expected to clear the treated area.
3257300|NCT00788424|Experimental|Placebo|Twice daily topical application on the psoriatic lesions for 8 weeks will serve as control group.
3257301|NCT00788398|Active Comparator|Saline, gravity flow|
3257302|NCT00788398|Active Comparator|Saline, Low Pressure|
3257303|NCT00788398|Active Comparator|Saline, High Pressure|
3257304|NCT00788398|Active Comparator|Soap, Gravity Flow|
3257305|NCT00788398|Active Comparator|Soap, low pressure|
3257306|NCT00788398|Active Comparator|Soap, high pressure|
3257307|NCT00788372|Experimental|Fentanyl|Fentanyl transdermal patch will be applied once daily up to 4 weeks in Treatment period 1, releasing at the rate of 12.5 microgram per hour (mcg/hr), maintained for 2 days and for another 48 weeks in Treatment period 2. The dose will be increased as per Investigators' discretion in both treatment periods and the maximum applied dose will be 300 mcg/hr. Total duration of treatment is 52 weeks.
3257308|NCT00788346|Experimental|Computerized Alerts|Computerized Clinical Decision Support to clinician at the time of prescribing
3257309|NCT00788346|Experimental|Alerts PLUS Detailing|Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
3257310|NCT00788346|No Intervention|Usual Care|Usual Care
3257311|NCT00788333|Experimental|A|Combination
3257312|NCT00788320|Placebo Comparator|Placebo|Placebo three times a week for 8 weeks
3257313|NCT00788320|Experimental|Cholecalciferol|Vitamin D3 50,000 IU three times a week for 8 weeks
3257314|NCT00788307|Experimental|Experimental Arm|
3257315|NCT00788294|Active Comparator|10 mg IV|
3257316|NCT00788294|Active Comparator|5 mg SC|
3257317|NCT00788294|Active Comparator|10 mg SC|
3257318|NCT00788294|Active Comparator|19 mg SC|
3257319|NCT00788281|Experimental|A|laparoscopic surgery plus postsurgery adjuvant chemotherapy of FOLFOX4
3257320|NCT00788281|Active Comparator|B|open surgery plus postsurgery adjuvant chemotherapy of FOLFOX4
3257321|NCT00788255||All participants|"For each patient, 1 solution with citrated whole blood (control) and 3 solutions with citrated whole blood and exogenous oxytocin were prepared in separate vials using micropipettes as follows:~Citrated whole blood 1mL + 23μU oxytocin: final exogenous oxytocin concentration=22.5 μU/mL Citrated whole blood 1mL + 31μU oxytocin: final exogenous oxytocin concentration=30.1μU/mL Citrated whole blood 1mL + 34μU oxytocin: final exogenous oxytocin concentration=32.9μU/mL~After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation."
3257322|NCT00788242|Experimental|1|Administration of glucose-insulin-potassium
3257323|NCT00788242|Placebo Comparator|2|
3257324|NCT00788229|Experimental|1. Study Drugs|
3257325|NCT00788229|Experimental|2. Study Drug|
3257326|NCT00788229|Experimental|3. Study Drug|
3257327|NCT00788229|Placebo Comparator|4. Placebo|
3257328|NCT00788216||Healthy Volunteers|Women over the age of 18 without the diagnosis of cervical cancer.
3257329|NCT00788216||Cervical Cancer Patients|Women over the age of 18 with a history of cervical cancer treated with surgery or chemoradiation.
3257330|NCT00788203||5-keys program|Counseling re family feeding behaviors.
3257331|NCT00788203||Lifestyle counseling|Counseling re healthy eating for child and family
3257332|NCT00788190|Other|Surgery|Surgical intervention to reduce Distal Radius Fracture
3257333|NCT00788190|Other|Conservative Treatment|Conservative treatment of Distal Radius Fractures
3257334|NCT00788164|Experimental|Groups 1-3|Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine intramuscularly (IM) on days 1 and 29 and TA-HPV vaccine IM on day 57.
3257335|NCT00788164|Experimental|Group 4|Patients receive topical imiquimod on days 1, 29, and 57.
3257336|NCT00788164|Experimental|Group 5|Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and TA-HPV vaccine as in groups 1-3, and imiquimod as in group 4.
3257337|NCT00788151|Experimental|1|
3257338|NCT00788151|Sham Comparator|2|
3257339|NCT00788138|Experimental|1|Vitamin D3 250,000 PO Once
3257345|NCT00788073|Active Comparator|STX209|STX209 variable dose from 1mg bid to 10mg tid, capsule, oral, 4 weeks
3257346|NCT00788073|Placebo Comparator|Placebo|variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
3257347|NCT00788060|Experimental|RAD001|
3257348|NCT00788047|Other|Regimen A (Reference)|
3257349|NCT00788047|Experimental|Regimen B (Test)|
3257350|NCT00788034|Experimental|Lu AA21004|
3257351|NCT00788034|Placebo Comparator|Placebo|
3257352|NCT00788021||Tacrolimus|Recipients of deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus
3257353|NCT00788021||Sirolimus|Recipients of deceased or living donor renal transplants maintained on immunosuppressive regimen using sirolimus
3257354|NCT00788021||Healthy controls|Age, race and gender-matched individuals not on immunosuppressive regimens. Whenever possible an transplant recipient's donor may be recruited to serve as healthy control
3257355|NCT00788008|Active Comparator|1|Inhalational anesthesia with isoflurane
3257356|NCT00788008|Active Comparator|2|total intravenous anesthesia with propofol
3257357|NCT00787995||MPS IVA|Subjects with mucopolysaccharidosis IVA (Morquio Syndrome)
3257358|NCT00787969|Experimental|Treatment (rituximab, cladribine, temsirolimus)|Patients receive rituximab IV on day 1 and cladribine IV over 2 hours on days 1-5. Patients then receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive filgrastim SC on days 6-15 or pegfilgrastim SC on day 6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3257359|NCT00787943|Experimental|Left side of face|Topical benzoyl peroxide 10.0% cream - Formulation 2 or Topical benzoyl peroxide 10.0% cream - Formulation 1 is to be applied to left side of the face.
3257360|NCT00787943|Experimental|Right side of face|Topical benzoyl peroxide 10.0% cream - Formulation 2 or Topical benzoyl peroxide 10.0% cream - Formulation 1 is to be applied to right side of the face.
3257361|NCT00787930||Manic Subject with DWM Hyperintensities >2|Subjects with acute mania who were treated with naturalistic protocol (starting with valproic acid) who had a BOYKO DWM Hyperintensity rating >2 and a YMRS <15 at week 3.
3257362|NCT00787930||Manic Subjects with DWM Hyperintensities <3|Subjects with acute mania who were treated with naturalistic protocol (starting with valproic acid)who had a BOYKO DWM Hyperintensity rating <3 and a YMRS <15 at week 3.
3257363|NCT00787917|Experimental|Omalizumab|"Eligible participants received a maximum dose of 600 mg omalizumab via subcutaneous injection for 6 months in the double-blind phase of the study. The study medication was to be administered at the same time of day. Study medication was injected subcutaneously into the upper arm in the area of the deltoid or to the thigh. A maximum 600 mg dose required 4 injections. All participants who entered the study received itraconazole twice daily, while receiving oral corticosteroids, with a maximum daily dose of 400 mg.~Participants who completed double-blinded phase, entered open-label treatment period of 6 months and continued the same regimen of omalizumab of double-blinded phase."
3257364|NCT00787917|Placebo Comparator|Placebo|Eligible participants received placebo comparator via subcutaneous injection for 6 months in the double-blind phase of the study. The study medication was to be administered at the same time of day. Study medication was injected subcutaneously into the upper arm in the area of the deltoid or to the thigh. All participants who entered the study received itraconazole twice daily, while on oral corticosteroids, with a maximum daily dose of 400 mg.
3257365|NCT00787904||Surgical Menopause|Pre-menopausal women undergoing total hysterectomy with oophorectomy rendering them post-menopausal
3257366|NCT00787904||Surgical Control|Pre-menopausal women undergoing abdominal surgery but without ovary removal
3257367|NCT00787904||Healthy|Healthy matched pre-menopausal controls
3257368|NCT00787891|Experimental|Rabeprazole 0.5 mg/kg|rabeprazole 0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
3257369|NCT00787891|Experimental|Rabeprazole 1.0 mg/kg|rabeprazole 1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
3257370|NCT00787878||A|
3257371|NCT00787878||B|
3257372|NCT00787878||C|
3257373|NCT00787865||Krabbe Disease|Children with infantile Krabbe disease
3257374|NCT00787865||Low Enzyme/No Krabbe Disease|Children without disease who have low enzyme levels
3257375|NCT00787865||Control|Children with no disease and normal enzyme levels
3257376|NCT00787865||Motor Disability|Children at risk of developing motor disability
3257377|NCT00787852|Experimental|Group 1: Radiation, Paclitaxel, Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily~Maintenance x 2 years*"
3257378|NCT00787852|Experimental|Group 2: Radiation, Paclitaxel, carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily Maintenance x 2 years*"
3257379|NCT00787839||Group 1|Atlanta VA Medical Center patients who meet criteria for screening for prediabetes and early diabetes based on standard guidelines of the VA, the American Diabetes Association, and the National Institutes of Health
3257380|NCT00787826|Experimental|Vaccination|Live Francisella Tularensis Vaccine
3257381|NCT00787813|Active Comparator|1|N-Acetyl Cysteine
3257382|NCT00787813|Placebo Comparator|2|placebo
3257383|NCT00787800|Active Comparator|Dual Chamber ICD|Dual chamber Implantable Cardioverter-Defibrillator (ICD): Atrial therapies and minimized ventricular pacing will be programmed on along with Ventricular Tachycardia/Ventricular Fibrillation (VT/VF) detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation.
3257474|NCT00787124||1|< 28 weeks gestation, < 30 days of age, < 3 previous transfusions
3257475|NCT00787124||2|< 28 weeks gestation, >=30 days of age, >= 3 previous transfusions
3257384|NCT00787800|Active Comparator|Single Chamber ICD|Single chamber Implantable Cardioverter-Defibrillator: Optimally programmed Ventricular Tachycardia/Ventricular Fibrillation (VT/VF) detection and therapies will be programmed on including use of detection enhancements.
3257385|NCT00787787|Experimental|Treatment (sunitinib malate and capecitabine)|Patients receive sunitinib malate PO QD on days 1-21 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence or disease progression or unacceptable toxicity.
3257386|NCT00787761|Experimental|ATG, Cytoxan, Bu/Flu based Allogeneic Transplant|All patients will receive an ATG, Cyclosphosphamide, Busulfan and Fludarabine based Allogeneic Transplant
3257387|NCT00787735|Experimental|Integrated Care|Integrated Substance Abuse and Psychiatric Care (ISAP). Subjects received both their substance abuse and psychiatric care within the ATS clinic. Counseling compliance will be measured over time.
3257388|NCT00787735|Active Comparator|Parallel Care|Parallel Substance Abuse and Psychiatric Care (PSAP). Subjects received their substance abuse treatment at the ATS clinic. Their psychiatric care was received at Community Psychiatry. Counseling compliance will be measured over time.
3257389|NCT00787722|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.
3257390|NCT00787709|Experimental|1|Receives Pathways universal school-based health promotion curriculum from 4th-6th grade
3257391|NCT00787709|No Intervention|2|Control group of students who do not receive the intervention
3257392|NCT00787696|Experimental|Skills Training|intervention group received information, motivation and skills training: condom application, assertive communication & problem solving
3257393|NCT00787696|Active Comparator|Health Education|Comparsion group received information and motivation
3257394|NCT00787683|Experimental|Home-monitoring|Patients receive an additional home-monitoring (remote-monitoring) device (CardioMessengerII) following Biotronik Lumax ICD implantation. The device enables regular transmission and examination of ICD information via home-monitoring. Follow-up appointments in outpatient clinic are changed compared to standard care. While follow-up 1, 12, and 24 months after ICD implantation consist of outpatient clinic appointments, follow-up 3, 6, and 18 months after ICD implantation are conducted remotely.
3257395|NCT00787683|No Intervention|Standard care|Patients randomised to the standard care group receive no home-monitoring device (CardioMessengerII) following Lumax ICD implantation. Patients have scheduled follow-up appointments at the ICD outpatient clinics at 1, 3, 6, 12, 18, and 24 months after ICD implantation.
3257396|NCT00787670|Experimental|Gastric Bypass Surgery|Gastric Bypass Surgery consists of a laparoscopic approach and includes the creation of an isolated 10-15-ml proximal gastric pouch, a retro-colic, retro-gastric Roux-en-Y gastrojejunostomy with linear stapler technique, a 100-cm Roux-limb, a 30-cm biliopancreatic limb, and a stapled end-side enteroenterostomy.
3257397|NCT00787670|Active Comparator|Diabetes Support and Education|Diabetes Support and Eduction. Subjects attend three educational/social support sessions for 1 year after enrollment. The educational sessions offered for diabetes support and education including informational sessions on diet/nutrition and exercise. These sessions are informational only and do not teach behavioral self-regulation skills. Different nutrition and exercise topics are covered each session. Education
3257398|NCT00787670|Active Comparator|Tissue Control Group|Tissue control group includes subjects who are undergoing other non-gastric bypass abdominal surgery. A pea size piece of omentum and subcutaneous fat will be collected.
3257399|NCT00787657||Arm 1|
3257400|NCT00787644|Active Comparator|1|
3257401|NCT00787644|Placebo Comparator|2|
3257402|NCT00787618|Active Comparator|50 mg Proellex Mild impairment|50 mg Proellex single dose Female subjects with mild renal impairment function.
3257403|NCT00787618|Active Comparator|50 mg Proellex Moderate|50 mg Proellex, Female subjects with moderate renal impairment function.
3257404|NCT00787618|Active Comparator|50 mg Proellex, Normal|50 mg Proellex, Female subjects with normal renal function.
3257405|NCT00787605|Active Comparator|Amlodipine|Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
3257406|NCT00787605|Experimental|Aliskiren / HCTZ|Aliskiren / HCTZ 150/12.5 mg for 1 week followed by 300/25 mg for 7 weeks
3257407|NCT00787592||1|"SSD:~Patients that receive SSD as the topical debriding agent"
3257408|NCT00787592||2|"Collagenase:~Patients that receive collagenase as the debriding agent."
3257409|NCT00787579|Active Comparator|Bifocal spectacles|
3257410|NCT00787579|Active Comparator|Prismatic bifocals|
3257411|NCT00787579|No Intervention|Single vision spectacles|
3257412|NCT00787566|Experimental|0.5 mg of TRG (intranasal granisetron)|0.5 mg dose, intranasal powder, single spray, administered once
3257413|NCT00787566|Experimental|1.0 mg of TRG (intranasal granisetron)|1.0 mg dose, intranasal powder, songle spray, administered once
3257414|NCT00787566|Experimental|2.0 mg of TRG (intranasal granisetron)|2.0 mg dose, intranasal powder, single spray, administered once
3257415|NCT00787553|Active Comparator|cefazolin|
3257416|NCT00787553|Active Comparator|tinidazole|
3257417|NCT00787553|Active Comparator|cefazolin plus tinidazole|
3257418|NCT00787540||I|Coronary Slow Flow Patients
3257419|NCT00787540||II|Coronary Artery Occlusion Patients
3257420|NCT00787527|Experimental|Zolinza + CHOP|Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
3257421|NCT00787501|Active Comparator|SSRIs|Selective Serotonin Reuptake Inhibitors
3257422|NCT00787501|Active Comparator|CBT|Cognitive Behavior Therapy
3257423|NCT00787488|Experimental|1|Chemotherapy plus Hyperthermia
3257424|NCT00787475|Experimental|1|CHW intervention
3257425|NCT00787475|No Intervention|2|Enhanced usual care (brochure mailings)
3257476|NCT00787111|Experimental|Fluoxetine ODT|Fluoxetine ODT ranging from 2mg to 54mg
3257531|NCT00786721||Diffuse Optical Spectroscopy|muscle properties scanning
3257532|NCT00786708||NGAL|Urine that would otherwise be discarded will be obtained from a convenience sample of patients admitted to the hospital through the emergency room who meet the inclusion / exclusion criteria for this study.
3257533|NCT00786695|Placebo Comparator|Placebo|Identical looking Placebo
3257534|NCT00786695|Experimental|esomeprazole|esomeprazole (40 mg o d) for 14 days
3257426|NCT00787462|Active Comparator|Active|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
3257427|NCT00787462|Placebo Comparator|Placebo|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
3257428|NCT00787436|No Intervention|1|Standard of care with normal treatment
3257429|NCT00787436|Active Comparator|Thalidomide|Standard of care and treatment using Thalidomide
3257430|NCT00787410|Experimental|1|
3257431|NCT00787397|Experimental|1. Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy-Sleep
3257432|NCT00787384|Experimental|Imatinib|Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib was discontinued after 12 total weeks of therapy.
3257433|NCT00787371|Experimental|0.25 Dose Group|PegIntron 0.25 mcg/kg SC QW for 12 weeks
3257434|NCT00787371|Experimental|0.5 Dose Group|PegIntron 0.5 mcg/kg SC QW for 12 weeks
3257435|NCT00787371|Experimental|1.0 Dose Group|PegIntron 1.0 mcg/kg SC QW for 12 weeks
3257436|NCT00787371|No Intervention|No-treatment Control|No treatment (no placebo)
3257437|NCT00787358|Active Comparator|ZT-031|
3257438|NCT00787358|Placebo Comparator|Placebo|
3257439|NCT00787345|Other|Surgery residents|general surgery residents undergoing evaluation and training in MBP during CVC placement as per department policy are eligible for the study.
3257440|NCT00787332|Experimental|Desirudin|Patients with suspected HIT without thrombosis syndrome (HIT/TS), randomized to SC Desirudin
3257441|NCT00787332|Active Comparator|Argatroban®|Patients randomized to IV Argatroban®
3257442|NCT00787319||AMD|
3257443|NCT00787306|Experimental|Multi-faceted Cardiovascular Decision Support|Risk factor active surveillance, multi-disciplinary disease management and decision aid intervention
3257444|NCT00787306|Other|Control Usual Care|Usual care in a wait-list control arm that receives the experimental intervention after 6 months.
3257445|NCT00787293|Experimental|1|Patient is screened for study and given baseline assessments. Pending fulfillment of study eligibility criteria, patient is implanted with PTMA system.
3257446|NCT00787280|Experimental|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
3257447|NCT00787280|Experimental|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
3257448|NCT00787267|Experimental|Dasatinib|"After a biopsy is done to obtain fresh frozen tumor tissue (Stage I), dasatinib is to be administered as an oral dose of 70 mg twice daily on a continuous basis for 6 weeks. Every 6 weeks radiologic exam will be done to assess response. Treatment will continue until progression of disease, intolerable toxicity or patient withdrawal.~For Stage II, a biopsy to obtain fresh frozen tumor tissue will also be done. Depending on results from Stage I and results of biopsy, treatment with dasatinib will be determined."
3257449|NCT00787254|Experimental|Lansoprazole 15 mg QD|
3257450|NCT00787254|Active Comparator|Gefarnate 50 mg BID|
3257451|NCT00787241||Mild preeclampsia|Preeclampsia without eclampsia or HELLP syndrome
3257452|NCT00787241||Severe preeclampsia|Severe preeclampsia with eclampsia and/or HELLP syndrome
3257453|NCT00787241||Mild preeclampsia superimposed on chronic hypertension|Mild preeclampsia in association with chronic hypertension
3257454|NCT00787215||no treatment|observational: no treatment involved
3257455|NCT00787202|Experimental|15 mg BID|
3257456|NCT00787202|Experimental|10 mg BID|
3257457|NCT00787202|Experimental|3 mg BID|
3257458|NCT00787202|Experimental|0.5 mg BID|
3257459|NCT00787202|Placebo Comparator|Placebo|
3257460|NCT00787189|Active Comparator|The Hearing Laser|Active low level laser light therapy of 635 nanometers (nm)
3257461|NCT00787189|Placebo Comparator|Placebo Laser|inactive low level laser light therapy with no therapeutic output
3257462|NCT00787176|Active Comparator|Group A|An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient was positioned for epidural placement. Oxytocin management continued as per protocol.
3257463|NCT00787176|Experimental|Group B|An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement was halved and not increased for 60 minutes until after placement.
3257464|NCT00787176|Active Comparator|Group C|The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. Oxytocin management continued per protocol.
3257465|NCT00787176|Experimental|Group D|The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement was halved and not increased for 60 minutes until after placement.
3257466|NCT00787163|Experimental|1|amnioinfusion
3257467|NCT00787163|No Intervention|2|expectant management
3257468|NCT00787150|Experimental|Apixaban 5mg BID|
3257469|NCT00787150|Experimental|Apixaban 2.5mg BID|
3257470|NCT00787150|Active Comparator|Warfarin|
3257471|NCT00787137|Experimental|PG102 0.3 mg/kg|Lowest dose PG102
3257472|NCT00787137|Experimental|PG102 1 mg/kg|Second dose PG102
3257473|NCT00787137|Placebo Comparator|Placebo (phosphate-buffered saline)|Control
3257477|NCT00787098|No Intervention|1|RA begins data collection with chart review for demographic and explanatory variables, collects data for baseline muscle strength. During standard care period, PM will obtain information about the plan for activity for enrolled patients (turning, complete or partial weight-bearing i.e., reverse Trendelenberg positioning, ROM, sitting and walking) through discussion with the direct providers. RA will interview one provider about factors which influence the decision to implement activity or provide bedrest, including the presence of orders for bedrest or physical therapy. If activity is planned, the PM will observe and record the type and duration of activity, drawing serum biomarkers 20 minutes before and 20 minutes after the activity. If no activity is planned or activity duration is less than 10 minutes, serum for only baseline inflammatory biomarkers will be drawn. The RA will collect outcomes data within 24 hours of discharge from the ICU.
3257478|NCT00787098|Experimental|2|Identical procedures for date recruitment, consent and data collection will occur. In this phase, the Project Manager will promote the use of the ETM protocol through coaching (e.g., reminding staff of benefits of mobility, identification of available resources, or suggesting cessation of bedrest orders) and by participating in planning at least one 20-minute activity.
3257479|NCT00787085||Case|Patients hospitalized with a urine or blood culture positive for fungi
3257480|NCT00787085||Control|Patients hospitalized with a urine culture negative for fungi
3257481|NCT00787072|Experimental|1|
3257482|NCT00787072|Placebo Comparator|2|
3257483|NCT00787059|Experimental|Ad5.hAC6|Will receive intracoronary adenovirus encoding human adenylyl cyclase type 6
3257484|NCT00787059|Placebo Comparator|sucrose solution|Will receive intracoronary sucrose solution
3257485|NCT00787033|Experimental|1|Dose escalation study with Expansion Cohorts at RP2D and Schedule
3257486|NCT00787020||Ventriculostomy Open|Subjects are treated with near continuous cerebrospinal fluid (CSF) diversion by positioning the stopcock in the open position and the intracranial pressure (ICP) is monitored once each hour: CSF drains into an external ventricular drainage bag.
3257487|NCT00787020||Ventriculostomy Monitored|Subjects are treated with intermittent cerebrospinal fluid (CSF) diversion. Intracranial pressure (ICP) is monitored and CSF is drained only when the ICP exceeds a threshold dictated by the attending physician.
3257488|NCT00787007|Experimental|1|10 mg
3257489|NCT00787007|Experimental|2|20 mg, fasted and fed
3257490|NCT00787007|Experimental|3|40 mg
3257491|NCT00787007|Experimental|4|80 mg
3257492|NCT00787007|Experimental|5|160 mg
3257493|NCT00787007|Experimental|6|320 mg
3257494|NCT00787007|Placebo Comparator|7|placebo capsule
3257495|NCT00786994|Experimental|1|Oleogel-S10 100 mg/g ointment for three months once a day (54 patients)
3257496|NCT00786994|Experimental|2|Oleogel-S10 100 mg/g ointment for three months twice a day (54 patients)
3257497|NCT00786994|Placebo Comparator|3|Placebo (petroleum jelly) for three months once a day (27 patients)
3257498|NCT00786994|Placebo Comparator|4|Placebo (petroleum jelly) for three months twice a day (27 patients)
3257499|NCT00786981|Other|Epidural steroid injection and physical therapy|
3257500|NCT00786981|Other|Epidural steroid injection|
3257501|NCT00786968|Experimental|intrathecal laronidase|drug laronidase, dose 1.74 mg, route intrathecal, frequency every 30-90 days, duration 1 year
3257502|NCT00786942|Active Comparator|1|autologous bone graft
3257503|NCT00786942|Experimental|2|without bone graft
3257504|NCT00786929|Experimental|drainage|
3257505|NCT00786929|Active Comparator|2|Conservative treatment
3257506|NCT00786916|Placebo Comparator|Group A|Saline
3257507|NCT00786916|Active Comparator|Group B|Lidocaine 0.25 mg/kg
3257508|NCT00786916|Active Comparator|Group C|Lidocaine 0.5 mg/kg
3257509|NCT00786890||no treatment|observational, no treatment needed
3257510|NCT00786877|Experimental|Improved biomass cookstove with exterior ventilation|"In phase 1, installation of an improved cookstove with ventilation to exterior is the active arm.~In phase 2, this improved biomass cookstove is the control arm."
3257511|NCT00786877|No Intervention|Traditional cookstove|In phase 1, the control arm is the traditional standard open burning cookstove in house.
3257512|NCT00786877|Experimental|Phase 2 invervention arm (LPG stove)|In phase 2 of this project, households are individually randomized to either continuation of the improved biomass stove from phase 1, or a new LPG stove and gas for 12 months.
3257513|NCT00786864|Experimental|1. Experimental Group|Exercise Intervention Group
3257514|NCT00786864|No Intervention|2. Control Group|Control group - no intervention
3257515|NCT00786851|Experimental|1|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
3257516|NCT00786838|Experimental|Trabectedin|3-hour placebo intravenous infusion on Day 1 and trabectedin 1.3 mg/m2 3-hour intravenous infusion on Day 2 (single-blind). Patients may continue treatment with trabectedin until clinical benefit or drug is commercially available (open-label).
3257517|NCT00786825|Experimental|somatostatin|Type 1 diabetes and Hypoglycemia unawareness
3257518|NCT00786825|No Intervention|2|Healthy control subjects
3257519|NCT00786812|Other|CAMN107A2109 Extension Patients|
3257520|NCT00786812|Other|AMN107 Naive|
3257521|NCT00786799|Active Comparator|Omega-3 Fatty Acids|
3257522|NCT00786799|Placebo Comparator|Placebo|
3257523|NCT00786786||1|Spinal Cord Injury
3257524|NCT00786773||1|GERD patients who will be treated for GERD with PPI, H2RA, antacid, prokinetics, combination therapy
3257525|NCT00786760||1. Men ages 18 - 44 years|
3257526|NCT00786760||2. Men ages 45 - 70 years|
3257527|NCT00786747|Experimental|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
3257528|NCT00786747|Active Comparator|Non-tailored control computer program|This program provides non-tailored, generic information about colorectal cancer screening, in the user's preferred language (English or Spanish).
3257529|NCT00786734|Experimental|Pitavastatin Group|
3257530|NCT00786734|Other|Usual Care Group|
3257535|NCT00786682|Experimental|Docetaxel and Hydroxychloroquine|"Drug: Docetaxel 75 mg/m2 intravenously every 21 days on Day 1 of the treatment cycle~Drug: hydroxychloroquine 200 mg twice daily~A cycle is defined as an interval of 21 days."
3257536|NCT00786669|Experimental|Bevacizumab+TEM/VCR/IRN/CEF|"Bevacizumab(IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles~Temozolomide (TEM) 100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.~Vincristine (VCR) 1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients <0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).~Irinotecan (IRN) 90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles~Cefexime (CEF) 8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity"
3257537|NCT00786643|Experimental|Stratum 1|Patients in stratum 1 have not received prior chemotherapy in the metastatic setting.
3257538|NCT00786643|Experimental|Stratum 2|Patients in stratum 2 have received 1-2 prior chemotherapy regimens in the metastatic setting.
3257539|NCT00786630|Experimental|Case Management|
3257540|NCT00786630|Experimental|Facilitated Treatment Alliance|
3257541|NCT00786617||Nurse-driven|Mechanically ventilated patients weaned by nurse-driven ventilator weaning protocol
3257542|NCT00786617||Physician-initated|Mechanically ventilated patients weaned by physician-initiated, non-protocol methods
3257543|NCT00786604||1|Those with a cervical spinal cord injury
3257544|NCT00786604||2|Those with a thoracic spinal cord injury
3257545|NCT00786604||3|Healthy, control group
3257546|NCT00786591||Acute Pancreatitis Patients|Patients presenting with clinical features compatible with acute pancreatitis
3257547|NCT00786591||Control|Preoperative patients going for elective cholecystectomy
3257548|NCT00786578||1|overweight runners (BMI>25)
3257549|NCT00786578||2|lean runners (BMI<24)
3257550|NCT00786565|Experimental|Advanced Akreos Adapt|Advanced Akreos Adapt Aspheric Intraocular Lens (IOL).
3257551|NCT00786565|Experimental|Akreos Adapt|Akreos Adapt Spherical Intraocular Lens (IOL).
3257552|NCT00786552|Experimental|chemotherapy|
3257553|NCT00786513|Active Comparator|Control Arm|
3257554|NCT00786513|Experimental|Intervention Arm|
3257555|NCT00786500|Active Comparator|Gynostemma pentaphyllum tea|
3257556|NCT00786500|Placebo Comparator|Placebo tea|
3257557|NCT00786487|Experimental|lipid trained|20% lipid infusion in trained subjects
3257558|NCT00786487|Active Comparator|glycerol trained|glycerol infusion into trained subjects
3257559|NCT00786487|Experimental|lipid untrained|lipid infusion into untrained subjects
3257560|NCT00786487|Active Comparator|glycerol untrained|glycerol infusion into untrained subjects
3257561|NCT00786474|Placebo Comparator|Placebo|
3257562|NCT00786474|Experimental|Dalteparin|
3257563|NCT00786448||Group 1|
3257564|NCT00786435||1|Those with a cervical spinal cord injury
3257565|NCT00786435||2|Those with a thoracic spinal cord injury
3257566|NCT00786435||3|Healthy, control group
3257567|NCT00786422|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|
3257568|NCT00786409|Other|Gardasil|30 patients will receive 0.5 ml Gardasil vaccine at months 0,2, and 6.
3257569|NCT00786396|Experimental|DAART|Group that will be observed daily taking their medications for a period of six months. Followed by the remaining six months of the intervention in which the subject will take medications on their own.
3257570|NCT00786396|No Intervention|2|SAT (standard of care) group will take their medications as directed by their physicians for the period of one year.
3257571|NCT00786383|Experimental|IMC-1121B|IMC-1121B injectable solution at a concentration of 5 mg/mL in single-use vials containing 100 mg/20 mL or 250 mg/50 mL of product, administered intravenously at an initial dose of 6 mg/kg.A minimum of three patients will be enrolled into each cohort. When all patients complete a cohort, dose escalation to the next cohort will occur.
3257572|NCT00786370|Active Comparator|Propofol|
3257573|NCT00786370|Experimental|Dexmedetomidine|
3257574|NCT00786357|Experimental|Intervention|
3257575|NCT00786344|Experimental|Lifestyle Redesign|
3257576|NCT00786344|No Intervention|No Treatment Control|The no treatment control arm did not receive the intervention during the first six-month period. However the intervention, which has been proven to be beneficial, was administered to the control arm immediately following the 6 month assessment.
3257577|NCT00786331|Active Comparator|A|Monochemotherapy
3257578|NCT00786331|Experimental|B|Combination chemotherapy
3257579|NCT00786318|Experimental|ziprasidone|
3257580|NCT00786318|Active Comparator|Standard therapy|
3257581|NCT00786305|Experimental|1: nebulized ceftazidime and amikacin|
3257582|NCT00786305|Active Comparator|2: intravenous ceftazidime and amikacin|
3257583|NCT00786292|Other|Noisy PSV|Assisted mechanical ventilation with noisy PSV
3257584|NCT00786292|Other|PSV|Assisted mechanical ventilation with PSV
3257585|NCT00786279|Placebo Comparator|1|150 cc daily of flavored, calorie-free beverage without alcohol
3257586|NCT00786279|Experimental|2|150 cc flavored, calorie-free beverage with 15 gm ethanol daily
3257587|NCT00786266|Active Comparator|NIOSH shiftwork booklet|
3257588|NCT00786266|Experimental|Sleep Enhancement Training System|
3257589|NCT00786253|Experimental|Arm 1|
3257590|NCT00786253|Experimental|Arm 2|
3257591|NCT00786240|Experimental|A|
3257592|NCT00786240|Experimental|B|
3257593|NCT00786227||Legacy HAQ-DI first, PROMIS 20-item short form first|To eliminate effects due to order of administration, patients with RA will be randomized to complete either the Legacy measure HAQ-DI first in the assessment battery or the PROMIS 20-item short forms first.
3257594|NCT00786214|Experimental|Acupuncture|Patients given acupuncture treatment
3257595|NCT00786214|Sham Comparator|Sham acupuncture|Patients given sham acupuncture treatment
3257596|NCT00786201|Placebo Comparator|Placebo|
3257597|NCT00786201|Experimental|CNTO 888 1 mg/kg|
3257598|NCT00786201|Experimental|CNTO 888 5 mg/kg|
3257599|NCT00786201|Experimental|CNTO 888 15 mg/kg|
3257600|NCT00786188|Experimental|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg.
3257601|NCT00786188|Placebo Comparator|Placebo - Sugar Pill|Eligible subjects will be randomized to receive a sugar pill.
3257602|NCT00786162|Experimental|Intervention|Internet-based hypertension self-management platform
3257603|NCT00786162|Active Comparator|Control|Installation of BP cuff for communal use at the worksite
3257604|NCT00786149|Experimental|1|Participants will receive NRT and Motivational Interviewing counseling
3257605|NCT00786149|Active Comparator|2|Varenicline plus brief advice
3257606|NCT00786136|Experimental|1|perioperative rosuvastatin administration for at least 5 dosages
3257607|NCT00786136|Placebo Comparator|control|blank control of perioperative statin administration
3257608|NCT00786123|Experimental|VSL#3|Patients taking probiotics (VSL#3)
3257609|NCT00786123|Placebo Comparator|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
3257610|NCT00786110|Experimental|1 arm only|"One arm only with Sorafenib plus Paclitaxel Patients enrolled will undergo strict follow-up~Intervention: Sorafenib plus Paclitaxel"
3257611|NCT00786097|Experimental|1|Dermacyd PH_DETINLYN (Lactic Acid)
3257612|NCT00786084||1|Phase I patients who had a paraesophageal hernia repair with synthetic mesh.
3257613|NCT00786084||2|Phase I patients who had a paraesophageal hernia repair with small intestine submucosa mesh.
3257614|NCT00786071||Rett syndrome girls|The study population consists of a well-defined group of Dutch RTT thirteen girls with complete clinical, molecular and neurophysiological work-up.
3257615|NCT00786045|Experimental|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
3257616|NCT00786045|No Intervention|Control|The investigators have devised a series of mobility-related tasks that can be easily and safely carried out at home without ongoing professional supervision
3257617|NCT00786032||BCI Device|All participants will use the BCI System as a means of communication.
3257618|NCT00786019|Experimental|Ascorbic acid|All study subjects have ascorbic acid infusion during one exercise visit as well as a three month exercise training intervention.
3257619|NCT00786006|Experimental|Arm 1|FOLFIRI.3
3257620|NCT00786006|Active Comparator|Arm 2|FOLFOX
3257621|NCT00785993|Active Comparator|Control Group|Fresh donor oocytes
3257622|NCT00785993|Experimental|Group I|vitrified donor oocytes
3257623|NCT00785980|Active Comparator|Quinine Sulfate|Baseline quinine sulfate pharmacokinetics
3257624|NCT00785980|Experimental|Quinine Sulfate with Ciprofloxacin|Quinine sulfate pharmacokinetics in the presence of steady state ciprofloxacin
3257625|NCT00785967|Experimental|1|raltegravir 400mg bid + Truvada 1 tab qd
3257626|NCT00785967|Active Comparator|2|efavirenz 600mg qhs + Truvada 1 tab qd (or Atripla 1 tab qhs)
3257627|NCT00785954|Experimental|A1: KAI-9803|
3257628|NCT00785954|Experimental|A2: KAI-9803|
3257629|NCT00785954|Experimental|A3: KAI-9803|
3257630|NCT00785954|Placebo Comparator|A4: Placebo|
3257631|NCT00785941|Experimental|IMC-A12|"All patients will receive intravenous infusions of IMC-A12, with the dose depending on which cohort they are enrolled into a minimum of three patients will be enrolled in each Cohort. When all patients complete a cohort, dose escalation to the next Cohort will occur.~A treatment cycle will consist of IMC-A12 administered intravenously, once every other week for 4 weeks, for a total of 2 doses; followed by a 2-week observation period."
3257632|NCT00785928|Experimental|Placebo|
3257633|NCT00785928|Experimental|1 mg LY2127399|
3257634|NCT00785928|Experimental|3 mg LY2127399|
3257635|NCT00785928|Experimental|10 mg LY2127399|
3257636|NCT00785928|Experimental|30 mg LY2127399|
3257637|NCT00785928|Experimental|60 mg LY2127399|
3257638|NCT00785928|Experimental|120 mg LY2127399|
3257639|NCT00785915|Experimental|1|
3257640|NCT00785915|Placebo Comparator|2|given (2 subjects in each ethnic/dose group)
3257641|NCT00785876|No Intervention|1|Control Sites
3257642|NCT00785876|Experimental|2|Intervention Sites
3257643|NCT00785863|Placebo Comparator|Placebo|
3257644|NCT00785863|Active Comparator|Remifentanil|
3257645|NCT00785863|Active Comparator|Ketorolac and remifentanil|
3257646|NCT00785863|Active Comparator|Parecoxib and remifentanil|
3257647|NCT00785850|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower
3257648|NCT00785837|No Intervention|Before Hidrotherapy|
3257649|NCT00785837|Experimental|Hidrotherapy|
3257650|NCT00785824||1 A-A Breastfeeding Mothers|Group 1: Postpartum African-American breastfeeding women at 6-8 weeks post childbirth, and again at 12-14 weeks post childbirth
3257651|NCT00785824||2 - AA Bottlefeeding Mothers|Group 2: Postpartum African-American bottlefeeding women at 6-8 weeks post childbirth and again at 12-14 weeks post childbirth.
3257652|NCT00785824||3 - AA Normal Controls|Group 3: Normal African-American non-pregnant controls who are age-matched to Group 1
3257653|NCT00785811|Experimental|1|L-arginine aspartate (Targifor)
3257654|NCT00785811|Placebo Comparator|2|Placebo
3257655|NCT00785798|Experimental|vorinostat doxil|Escalating doses of vorinostat 200mg to 400mg twice daily on days 1-7, and fixed-dose IV PLD 30mg/m2 on day 3 of a 21-day cycle
3257656|NCT00785785|Experimental|Nilotinib|nilotinib 400 mg twice a day
3257657|NCT00785785|Active Comparator|Imatinib|imatinib 400 mg once daily
3257658|NCT00785772|Experimental|1: Patients with Cleatinine Clearance (CLcr) 5-14 mL/min|
3257659|NCT00785772|Experimental|2: Patients with CLcr 15-29 mL/min|
3257660|NCT00785772|Experimental|3: Patients with CLcr 30-59 mL/min|
3257661|NCT00785746|Experimental|core|strength training of the core muscles.
3257662|NCT00785746|No Intervention|stretch and strength|This program consists of general stretching exercises and peripheral muscle strengthening exercises with a special emphasis on strengthening the upper extremity muscles because of their importance for ADL but not necessarily balance.
3257663|NCT00785733||1|Moderate and severe asthma patients stabilized on Symbicort SMART
3257664|NCT00785720|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid)
3257665|NCT00785707||cochlear implant|children less than 24 months at time of cochlear implantation
3257666|NCT00785694|Experimental|B|One instillation of mitomycin C after transurethral resection in white and blue fluorescence light with Hexvix.
3257667|NCT00785694|No Intervention|A|Multiple instillations of mitomycin C after transurethral resection in white light alone.
3257668|NCT00785681|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid)
3257669|NCT00785655|Experimental|1|Dermacyd PH_DETINLYN (Lactic Acid)
3257670|NCT00785642|Experimental|1|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)
3257671|NCT00785629|Active Comparator|Calcium Acetate|667 mg with meals
3257672|NCT00785629|Active Comparator|Lanthanum Carbonate|500 mg with meals
3257673|NCT00785629|Active Comparator|Sevelamer Carbonate|800 mg with meals
3257674|NCT00785629|Placebo Comparator|Placebo|with meals
3257675|NCT00785590|Experimental|1|Dermacyd PH_DETINLYN (Lactic Acid)
3257676|NCT00785577|Placebo Comparator|Placebo|LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules thrice daily (TID) po for 6 weeks
3257677|NCT00785577|Active Comparator|Pregabalin|"Pregabalin thrice daily (TID) oral for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6~LY545694 placebo BID po for 5 weeks"
3257678|NCT00785577|Experimental|LY545694 21 mg|"LY545694 21 milligrams (mg) BID po for 1 week~Pregabalin placebo TID po for 6 weeks"
3257679|NCT00785577|Experimental|LY545694 49 mg|"LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.~Pregabalin placebo TID po for 6 weeks"
3257680|NCT00785577|Experimental|LY545694 105 mg|"LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.~Pregabalin placebo TID po for 6 weeks"
3257681|NCT00785551|Experimental|1|quinine sulfate 648mg in subjects with normal renal function (CLcr > 80mL/min)
3257682|NCT00785551|Experimental|2|quinine sulfate 648mg in subjects with mildly impaired renal function (CLcr > 50 to 80 mL/min)
3257683|NCT00785551|Experimental|3|quinine sulfate 648mg in subjects with moderately impaired renal function (CLcr 30 to 50mL/min)
3257684|NCT00785538|Experimental|IMC-A12|All patients will receive intravenous infusions of IMC-A12, with the dose depending on which cohort they are enrolled into a minimum of three patients will be enrolled in each cohort. When all patients complete a cohort, dose escalation to the next cohort will occur.
3257685|NCT00785512|Active Comparator|1|Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
3257686|NCT00785512|Placebo Comparator|2|Matching placebo tablets, oral administration
3257687|NCT00785499|Experimental|skim milk|skim milk
3257688|NCT00785499|Experimental|whey|Whey milk drink
3257689|NCT00785499|Experimental|casein|casein milk drink
3257690|NCT00785499|Active Comparator|water|Danish mineral water
3257691|NCT00785486|Other|Midazolam alone|Baseline midazolam and 1-hydroxy-midazolam pharmacokinetics. One day 1 after a fast of at least 10 hours patients received a single oral dose of midazolam 2 mg. Blood was drawn at times sufficient to characterize the pharmacokinetics of midazolam and its main metabolite.
3257692|NCT00785486|Other|Qualaquin (quinine) alone steady state|On the morning of day 9 after taking Qualaquin (quinine) capsules 324 mg orally every 8 hours for the prior 5 days, and following a fast of at least 10 hours all study participants received their usual morning dose of Qualaquin (quinine) 324 mg. Blood was drawn at times sufficient to determine the steady state Cmax and AUC 0-tau for Qualaquin (quinine).
3257693|NCT00785486|Experimental|Midazolam with Qualaquin (quinine)|On day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen, all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg. Blood was drawn sufficient to characterize the steady state kinetics of quinine and the kinetics of midazolam and 1-hydroxy-midazolam in the presence of each other.
3257694|NCT00785473|Active Comparator|1|cholecalciferol, calcium carbonate
3257695|NCT00785473|Placebo Comparator|2|capsules not containing cholecalciferol, otherwise identical to Active comparator; calcium carbonate
3257696|NCT00785460|Experimental|Benfotiamine and Smoking|
3257697|NCT00785460|Placebo Comparator|Smoking alone|
3257698|NCT00785447|Other|1|Twenty healthy subjects between 18 to 59 years of age meeting ASA I-II criteria, undergoing elective surgery, requiring general anesthesia and being able to breathe through both their nose and mouth.
3257699|NCT00785434|Experimental|Active|Active escitalopram
3257700|NCT00785421|Experimental|A|"Patients with KPS > 80% and normal kidney function receive GFFC + LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.).~Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) + Enoxaparin 1mg/kg daily s.c.~After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) + Enoxaparin 40mg/d s.c."
3257701|NCT00785421|Active Comparator|B|"Patients with KPS > 80% and normal kidney function receive GFFC - LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w - Enoxaparin 1mg/kg daily s.c.).~Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) - Enoxaparin 1mg/kg daily s.c.~After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) - Enoxaparin 40mg/d s.c."
3257702|NCT00785408|Experimental|1|
3257703|NCT00785408|Experimental|2|
3257704|NCT00785408|Experimental|3|
3257711|NCT00785369|Other|1|Device: In vivo reflectance confocal microscopy of pigmented lesions in vivo
3257712|NCT00785356|Experimental|25 mg Proellex|Proellex 25 mg
3257713|NCT00785356|Experimental|Proellex 50 mg|Proellex 50 mg
3257714|NCT00785356|Placebo Comparator|Placebo|Placebo
3257715|NCT00785343|Active Comparator|Conventional Treatment|
3257716|NCT00785343|Experimental|Robotic and Conventional Therapy|
3257717|NCT00785330|No Intervention|A|Patients receiving no rituximab as GVHD prophylaxis after allogeneic SZT and only standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
3257718|NCT00785330|Experimental|B|rituximab in addition to standard GVHD prophylaxis
3257719|NCT00785317|Experimental|Angemin|1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP
3257720|NCT00785317|Active Comparator|Activelle|1 mg of oral E2 in continuous combination with 0.5 mg of NETA
3257721|NCT00785304||Traumatic Brain Injury|Active Duty military blast-related TBI patients
3257722|NCT00785304||Other Injury Control|Active duty military patients with other injuries but no TBI
3257723|NCT00785291|Active Comparator|Arm A (Paclitaxel)|Patients receive 90 mg/m^2 paclitaxel IV over 1 hour on days 1, 8, and 15. Patients may receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15.
3257724|NCT00785291|Experimental|Arm B (Nab-paclitaxel)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Patients may also receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15.
3257725|NCT00785291|Experimental|Arm C (Ixabepilone)|Patients receive ixabepilone IV over 60 minutes on days 1, 8, and 15. Patients may also receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. (closed to accrual as of 7/18/11)
3257726|NCT00785278||1|Able-bodied participants: Able-bodied individuals will be asked to propel a wheelchair at a self-selected speed for a period of time during which data will be collected on their propulsion biomechanics. It is assumed, for the purpose of the study, that un-learned able-bodied individuals learning to propel a wheelchair reflect newly injured individuals who are just getting accustomed to a new chair.
3257727|NCT00785278||2|Participants with paraplegia: Individuals who are at least 1-year post injury and have used a manual wheelchair as their primary means of locomotion during this time, will be assumed to be, for the purpose of this study, experienced wheelchair users.
3257728|NCT00785265|Experimental|Group Based|60-minute group session involving other study patients who have been assigned to this condition and their guests.
3257729|NCT00785265|Active Comparator|Home-Based|60-minute educational intervention in their home, which will be delivered by an African American health educator.
3257730|NCT00785265|No Intervention|Standard Care|60-minute individual session with an African American health educator.
3257731|NCT00785252|Experimental|1|EZIO
3257732|NCT00785252|Experimental|2|Central line
3257733|NCT00785226|Experimental|RDEA119 with Sorafenib|Total daily doses of RDEA119 from 10 mg/day to 100 mg/day and sorafenib from 400 mg/day to 800 mg/day.
3257734|NCT00785213|Active Comparator|Rosiglitazone Alone|Baseline rosiglitazone pharmacokinetics.
3257735|NCT00785213|Experimental|Rosiglitazone with Steady State Quinine Sulfate|Rosiglitazone pharmacokinetics in the presence of steady state quinine sulfate.
3257736|NCT00785200|Experimental|Chlorhexidine|Approximately 500 detainees housed in approximately 23 detention tanks will be enrolled and receive 2% chlorhexidine-soaked disposable wash cloths (Sage Products, Inc.) to clean their skin on Mondays, Wednesdays, and Fridays for 6 months. Newly arrived detainees in the tanks will be offered enrollment in the study on a biweekly schedule.
3257737|NCT00785200|Placebo Comparator|Water|Approximately 500 detainees in approximately 23 detention tanks will receive water-soaked wash cloths to clean their skin each Monday, Wednesday, and Friday for a 6-month period. If detainees newly arrive to these study tanks, they will be offered enrollment on a biweekly schedule.
3257738|NCT00785200|No Intervention|Usual care|Approximately 500 detainees in approximately 23 detention tanks will be enrolled. These detainees will not receive any intervention. They will be followed for 6 months, and newly arrived detainees will be offered enrollment on a biweekly schedule.
3257739|NCT00785174|Active Comparator|continuous positive airway pressure|respiratory assistance
3257740|NCT00785174|Active Comparator|NIPSV|respiratory assistance using face mak and ventilator to provide inspiratory pressure support and positive end expiratory pressure
3257741|NCT00785148|Experimental|1|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)
3257742|NCT00785135|Active Comparator|Standard (Treatment)|
3257743|NCT00785135|Sham Comparator|Placebo (control)|
3257744|NCT00785109|Experimental|1|100 patients daily additional intake of 2mg vitamin k1
3257745|NCT00785109|Placebo Comparator|2|100 patients no additional intake of vitamin K
3257746|NCT00785096||Patients|Patients who admit for a minor or major surgical intervention
3257747|NCT00785096||Nurses|Medical staff of the University Hospital of Zurich
3257748|NCT00785096||Physicians|Medical staff of the University Hospital of Zurich and other institutions
3257749|NCT00785083|Experimental|1|
3257750|NCT00785083|Placebo Comparator|2|
3257751|NCT00785070||1|Perioperative
3257752|NCT00785057||1|Hypertension patients with history of stroke
3257753|NCT00785057||2|Hypertension patients without history of stroke
3257754|NCT00785044||Group|No participants received any drug administration. No intervention conducted.
3257755|NCT00785031|Active Comparator|internet based intervention|
3257756|NCT00785031|No Intervention|usual care|Patients receive their usual care from their specialist or general practitioner.
3257757|NCT00785018|Active Comparator|C1-esterase inhibitor|Endotoxin 2ng/kg followed by C1- esterase inhibitor 100 U/kg infusion
3257758|NCT00785018|Placebo Comparator|Placebo|Endotoxin 2ng/kg followed by saline 0.9%(placebo) infusion
3257759|NCT00785005||1|Females with Type 2 Diabetes
3257760|NCT00785005||2|Females without Type 2 Diabetes
3257761|NCT00784992|No Intervention|1|Endonasal DCR with silicone tubes (this is the control group since it is the standard procedure / gold standard, although the evidence base for the use of tubes is lacking, hence the need for this trial)
3257816|NCT00784615||5|Women with out polycystic ovary syndrome
3257762|NCT00784992|Active Comparator|2|Endonasal DCR without silicone tubes (this is the 'intervention' arm)
3257763|NCT00784979|No Intervention|CMVIG followed by PP|MMF or rapamycin was given with CMVIG for 4 weeks followed by plasmapheresis
3257764|NCT00784966|Active Comparator|1|Two weeks etanercept post islet transplant
3257765|NCT00784966|Active Comparator|2|Two months etanercept treatment post islet transplant
3257766|NCT00784953||1|Asthma patients who were partly controlled or uncontrolled, need to step up, or adjust dose of the controller medications to ICS/LABA
3257767|NCT00784940|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
3257768|NCT00784940|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
3257769|NCT00784940|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
3257770|NCT00784927|Experimental|Treatment|"Participants with symptomatic untreated low grade NHL will be treated according to a 28 day schedule for up to a maximum of 12 consecutive cycles:~375 mg/m^2 Rituximab IV on day 1. 20 mg Lenalidomide taken orally on days 1-21. 250 mg/m^2 Cyclophosphamide orally on days 1, 8, 15. 40 mg Dexamethasone orally on days 1, 8, 15, 22."
3257771|NCT00784914|Active Comparator|Cohort 1|Patients do not receive temsirolimus.
3257772|NCT00784914|Experimental|Cohort 2|48 hours after surgery, patients receive one 200 mg dose of temsirolimus IV.
3257773|NCT00784888||Aromatase inhibitors|Early stage postmenopausal breast cancer patients under tamoxifen treatment who are switching to aromatase inhibitor treatment
3257774|NCT00784875|Experimental|Period A|2-week double-blind placebo lead-in period. Period A is the first of four 2-week treatment periods.
3257775|NCT00784875|Experimental|Period B|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period B is the second of four 2-week treatment periods.
3257776|NCT00784875|Experimental|Period C|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period C is the third of four 2-week treatment periods.
3257777|NCT00784875|Experimental|Period D|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period D is the fourth of four 2-week treatment periods.
3257778|NCT00784862|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
3257779|NCT00784862|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
3257780|NCT00784862|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
3257781|NCT00784849|Experimental|1|One arm diagnostic
3257782|NCT00784836|Experimental|Avonex|Avonex 30 mcg given subcutaneously, once weekly, for 18 months.
3257783|NCT00784823|Experimental|Combined dose intense Melphalan with bortezomib (MTD)|"The purpose of this study is to determine the tolerance and potential efficacy of combining dose intense melphalan with escalating doses of bortezomib in patients with multiple myeloma undergoing autologous stem cell transplantation.~Combined dose intense Melphalan with maximum tolerated dose of bortezomib (MTD)"
3257784|NCT00784810|Experimental|Oxycodone/Naloxone Tablets|Oxycodone/Naloxone combination
3257785|NCT00784810|Active Comparator|Codeine/Paracetamol Tablets|Codeine/Paracetamol combination
3257786|NCT00784797|Active Comparator|pitocin|high dose pitocin drip 48 hours after mifepristone preparation.
3257787|NCT00784797|Active Comparator|misopristol|vaginal and oral misopristol 48 hours after mifepristone preparation.
3257788|NCT00784784|Experimental|Influenza vaccine|Influenza vaccine, using Fluviral trivalent split virus vaccine
3257789|NCT00784784|Experimental|Antiviral prophylaxis|Zanamivir antiviral prophylaxis
3257790|NCT00784758|Experimental|Fenzian Device|Subjects randomized to this arm will receive treatment with the Fenzian Device
3257791|NCT00784758|Sham Comparator|Sham Device|Subjects randomized to this arm will receive treatment with the sham device.
3257792|NCT00784745|Experimental|Dexamethasone|
3257793|NCT00784732|Experimental|1|
3257794|NCT00784732|Experimental|2|
3257795|NCT00784732|Active Comparator|3|
3257796|NCT00784719|Experimental|Treatment 1|
3257797|NCT00784719|Experimental|Treatment 2|
3257798|NCT00784719|Experimental|Treatment 3|
3257799|NCT00784719|Experimental|Treatment 4|
3257800|NCT00784719|Active Comparator|Active comparator|
3257801|NCT00784719|Placebo Comparator|Placebo|
3257802|NCT00784706|Experimental|CIT with eye-patching|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log. Participants were also asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
3257803|NCT00784706|Experimental|constraint-induced therapy|The intervention in this group resembled the intervention of the CIT+EP group, except participants did not wear the EP glasses.
3257804|NCT00784706|Active Comparator|conventional therapy|traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
3257805|NCT00784693|Experimental|Tanezumab|
3257806|NCT00784693|Placebo Comparator|Placebo|
3257807|NCT00784680|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
3257808|NCT00784680|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
3257809|NCT00784680|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
3257810|NCT00784654|Experimental|Lisdexamfetamine dimesylate (LDX)|Open-label 30, 50, or 70mg
3257811|NCT00784654|Placebo Comparator|Placebo|
3257812|NCT00784615||1|Women with polycystic ovaries, oligo or anovulation and hyperandrogenism.
3257813|NCT00784615||2|Women with polycystic ovaries and oligo or anovulation without hyperandrogenism
3257814|NCT00784615||3|Women with normal ovaries, oligo or anovulation and hyperandrogenism
3257815|NCT00784615||4|Women with normal ovaries, oligo or anovulation and hyperandrogenism
3257818|NCT00784589|Active Comparator|Corticotherapy|General Corticotherapy
3257819|NCT00784576||Cardiac surgery patients|Individuals consecutively scheduled for cardiac surgery
3257820|NCT00784563|Active Comparator|Continuous training|Aerobic walking using continuous heart rate training.
3257821|NCT00784563|Active Comparator|Interval training|Aerobic walking using interval heart rate training
3257822|NCT00784550|Experimental|ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler|Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID Plus Tiotropium Bromide 18 mcg QD
3257823|NCT00784550|Active Comparator|SPIRIVA® HANDIHALER® inhaler|Tiotropium Bromide 18mcg QD plus Placebo DISKUS BID
3257824|NCT00784537|Other|Arm A|"Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)~The subsequent treatment will be as it follows:~PET-2 positive patients will be high-dose salvage treatment;~PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).~The following restaging procedures are planned as it follows:~Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.~Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).~PET-6 negative patients will be randomized to first arm:~No radiotherapy."
3257825|NCT00784537|Other|Arm B|"Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)~The subsequent treatment will be as it follows:~PET-2 positive patients will be high-dose salvage treatment;~PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).~The following restaging procedures are planned as it follows:~Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.~Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).~PET-6 negative patients will be randomized to second arm:~Adjuvant radiotherapy (30 Gy) on sites of initial bulky disease."
3257826|NCT00784524|Experimental|LMI Vaccination + IL-2|Patients receiving allogeneic large multivalent immunogen breast cancer vaccine and aldesleukin.
3257827|NCT00784511|Experimental|1 vitamin D3|vitamin D3, 4000 IU/d
3257828|NCT00784511|Placebo Comparator|2|placebo
3257829|NCT00784498|Active Comparator|midazolam/ketamine|Patients with orthopedic injuries requiring painful manipulation
3257830|NCT00784498|Active Comparator|propofol|Patients with orthopedic injuries requiring painful manipulation
3257831|NCT00784485|Experimental|Xolair injections|All subjects receive active drug (Xolair-see 'interventions').
3257832|NCT00784472|Active Comparator|oxycodone|
3257833|NCT00784472|Active Comparator|morphine|
3257834|NCT00784459|Experimental|Treatment with Abatacept|Administration of Abatacept intravenously 10 mg/kg every 2 weeks for 3 doses, followed by every 4 weeks for 2 doses.
3257835|NCT00784459|Placebo Comparator|Placebo|Administration of placebo (normal saline) intravenously 10 mg/kg every 2 weeks for 3 doses, followed by every 4 weeks for 2 doses.
3257836|NCT00784446|No Intervention|XELOX, Bevacizumab, Imatinib|
3257837|NCT00784433|Experimental|alcohol 1|
3257838|NCT00784433|Experimental|alcohol 2|
3257839|NCT00784433|Placebo Comparator|control|
3257840|NCT00784420|Active Comparator|UK-453,061|
3257841|NCT00784420|Active Comparator|Raltegravir|
3257842|NCT00784420|Experimental|UK-453,061 plus Raltegravir|
3257843|NCT00784407|Active Comparator|FOCUS (group A)|Patients submitted to total thyroidectomy with the use of the FOCUS harmonic scalpel device
3257844|NCT00784407|Active Comparator|HARMONIC ACE (group B)|Patients submitted to total thyroidectomy with the use of the HARMONIC ACE harmonic scalpel device
3257845|NCT00784394|Experimental|Arm I (diindolylmethane)|Participants receive a single dose of diindolylmethane PO on day 1.
3257846|NCT00784394|Placebo Comparator|Arm II (placebo)|Participants receive a single dose of placebo orally (PO) on day 1.
3257847|NCT00784381||1|
3257848|NCT00784381||2|These units use the same electronic prescribing system, but had no counselling software
3257849|NCT00784368|Experimental|SFI (ITCZ Oral Solution Monotherapy)|Participants with deep-seated mycosis (Systemic Fungal Infection [SFI]) received itraconazole (ITCZ) oral solution in the dose range of 20 milliliter (ml) per day to 40 ml per day for 12 weeks as per Investigator's discretion.
3257850|NCT00784368|Experimental|SFI (Switched Treatment)|Participants with SFI received 200 milligram (mg) twice daily itraconazole intravenous (into the vein) infusion (ITCZ-IV) for first 2 days followed by 200 mg per day ITCZ-IV up to 14 days. Participants then received ITCZ oral solution in the dose range of 20 ml per day to 40 ml per day for 12 weeks as per Investigator's discretion.
3257851|NCT00784368|Experimental|FN (Switched treatment)|Participants with febrile neutropenia (FN) with suspected fungal infection received 200 mg twice daily ITCZ-IV for first 2 days followed by 200 mg per day ITCZ-IV up to 14 days. Participants then received ITCZ oral solution in the dose range of 20 ml per day to 40 ml per day for 12 weeks as per Investigator's discretion.
3257852|NCT00784355|Experimental|1:Laparoscopic cholecystectomy|Surgery
3257853|NCT00784355|No Intervention|2:controls|non-surgical control group
3257854|NCT00784342||Stable|Patients who are stable have not had a COPD exacerbation in the past 2 months.
3257855|NCT00784342||Exacerbation|Patients with an exacerbation have been diagnosed and started on treatment for an exacerbation within the past 3 days.
3257856|NCT00784329|Experimental|Optical Frequency Domain Imaging|Optical Frequency Domain Imaging System used during Lung and Bronchial biopsies to detect cancerous tissue. Tissue imaging results will be compared to tissue biopsy results.
3257857|NCT00784316|Active Comparator|metoprolol|
3257858|NCT00784316|Active Comparator|amiodarone|
3257859|NCT00784303|Experimental|1|
3257860|NCT00784290|Experimental|1|Orantinib
3257861|NCT00784277|Experimental|001|Tapentadol IR (CG5503) 50mg for 14 days
3257862|NCT00784277|Experimental|002|Tapentadol IR (CG5503) 75mg for 14 days
3257863|NCT00784277|Active Comparator|003|oxycodone IR 10mg for 14 days
3257864|NCT00784277|Placebo Comparator|004|placebo 1 capsule for 14 days
3257865|NCT00784277|Experimental|005|Tapentadol ER (CG5503) flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
3257866|NCT00784277|Active Comparator|006|oxycodone CR flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
3257867|NCT00784277|Placebo Comparator|007|placebo Tablets and capsules 2 x a day for 28 days
3257868|NCT00784238|Experimental|Paliperidone|Paliperidone Extended-Release (ER) oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
3257869|NCT00784225|Experimental|Vitamin E + selenium placebo|vitamin E and selenium placebo daily for 7-12 years
3257870|NCT00784225|Experimental|Selenium + vitamin E placebo|selenium and vitamin E placebo daily for 7-12 years
3257871|NCT00784225|Experimental|Vitamin E + selenium|vitamin E and selenium placebo daily for 7-12 years
3257872|NCT00784225|Placebo Comparator|Vitamin E placebo + selenium placebo|vitamin E placebo and selenium placebo daily for 7-12 years
3257873|NCT00784212|Experimental|Cohort 1|
3257874|NCT00784212|Experimental|Cohort II|
3257875|NCT00784212|Experimental|Cohort III|
3257876|NCT00784186|Experimental|mifepristone+misoprostol|200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
3257877|NCT00784186|Experimental|misoprostol|800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
3257878|NCT00784160|Experimental|1|Lactic Acid
3257879|NCT00784147|Active Comparator|Ibalizumab 800 mg|every 2 weeks, combined with an Optimized Background Regimen
3257880|NCT00784147|Active Comparator|Ibalizumab 2000 mg|every 4 weeks, combined with an Optimized Background Regimen
3257881|NCT00784134|Experimental|Alteplase|administration of alteplase via the intraventricular catheter
3257882|NCT00784134|Placebo Comparator|Saline Placebo|1 ml of normal saline administered via the intraventricular catheter
3257883|NCT00784121|Experimental|1|Lactic Acid (Dermacyd Breeze)
3257884|NCT00784108|Other|Diagnostic tool|Modulated Imaging measure effect of Photodynamic therapy treatment
3257885|NCT00784108|Other|Photodynamic therapy|Modulated Imaging measure effect of Photodynamic therapy treatment
3257886|NCT00784095|Experimental|Preparation and Completion|"Subjects in the first group (treatment) met with the facilitator three times for a period of forty-five minutes to one hour to discuss issues of life completion and preparation. In the first session, subjects were asked to discuss issues related to life review. In session two, participants spoke about issues of regret and forgiveness. In the final session, subjects discussed issues of heritage and legacy."
3257887|NCT00784095|Active Comparator|Attention Control|"The subjects in the second group (attention control) met with a facilitator three times for 45 minutes and listened to a non-guided relaxation CD."
3257888|NCT00784095|No Intervention|True Control|"Subjects in the third group (true control) were exposed to no intervention or attention control."
3257889|NCT00784082||Homozygous SS sickle cell children|"Hydroxycarbamide, Hydroxyurea (drug):~Homozygous SS sickle cell children, aged > 3 years, of sub-Saharian Africa extraction, in a steady-state of disease , taken no drug except penicillin-V, folate or iron supplementation, hydroxyurea, divided into three groups :~children treated with hydroxyurea 20-25 mg/kg/day since at least 3 months with clinical efficacy on vaso-occlusive events~untreated children with major vaso-occlusive events~children > 5 year-old without a history of vaso-occlusive events~Controls : heterozygous AS parents or siblings of the patients, and AA siblings or healthy African unrelated subjects, aged > 3 years, taken no drug on the day of blood sampling."
3257890|NCT00784082||Homozygous SS children|"Hydroxycarbamide, Hydroxyurea (drug):~Homozygous SS children, aged > 3 years, of sub-Saharian Africa extraction, in a steady-state of disease, taken no drug except penicillin-V, folate or iron supplementation, hydroxyurea, divided into three groups :~children treated with hydroxyurea 20-25 mg/kg/day since at least 3 months with clinical efficacy on vaso-occlusive events~untreated children with major vaso-occlusive events~children > 5 year-old without a history of vaso-occlusive events~Controls : heterozygous AS parents or siblings of the patients, and AA siblings or healthy African unrelated subjects, aged > 3 years, taken no drug on the day of blood sampling."
3257891|NCT00784069|Experimental|1|Lactic Acid (Dermacyd Breeze)
3257892|NCT00784056|Experimental|1|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)
3257893|NCT00784043|Experimental|Bilateral|Bilaterally implanted simultaneously
3257894|NCT00784043|Experimental|Unilateral|Unilaterally implanted
3257895|NCT00784030|Other|Polycystic Kidney Disease Patients|Patients who present with polycystic kidney disease (PKD)
3257896|NCT00784030|Other|Healthy Patients|
3257897|NCT00784017|Active Comparator|asparaginase medac|
3257898|NCT00784017|Experimental|recombinant asparaginase|
3257899|NCT00784004|Other|Volunteers|Ten healthy volunteers
3257900|NCT00784004|Other|Patients|Sixteen patients with respiratory insufficiency
3257901|NCT00783991||IVR-PC|This group will have instruments administered through interactive voice response (IVR) and personal computer (PC).
3257902|NCT00783991||PP-PC|This group will have instruments administered through paper and pencil (PP) and PC.
3257903|NCT00783991||PDA-PC|This group will have instruments administered by personal digital assistant (PDA) and PC.
3257904|NCT00783991||PC-PC|This group will have all instruments administered through PC.
3257905|NCT00783978||1|Children with chronic lung disease
3257906|NCT00783965|Experimental|Arm I|Patients apply 0.1% tazarotene cream on months 0-12 and vehicle (placebo) on months 13-36 once daily to the chest.
3257907|NCT00783965|Experimental|Arm II|Patients apply, vehicle (placebo) on months 0-12 and 0.1% tazarotene cream on months 13-36 once daily to the chest.
3257908|NCT00783952|Other|1|Mixed venous oxygen saturation measurement obtained from blood drawn from a pulmonary artery catheter.Calculation of mixed venous oxygen saturation from the measurement of peripheral oxygen saturations using multiple Cerebral/Somatic Tissue Oximeter device probes
3257909|NCT00783939|Experimental|1|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
3257910|NCT00783926|Experimental|Cohort 1|60 subjects randomized in an equal number to six different vaccine doses
3257911|NCT00783926|Experimental|Cohort 2|Following review of safety data of Cohort 1, approximately 360 additional subjects randomized in an equal number to the six different vaccine doses
3257912|NCT00783900|Active Comparator|metoprolol|
3257913|NCT00783900|Active Comparator|biatrial pacing|
3257914|NCT00783887||1|Patients with suspected or confirmed primary ciliary dyskinesia after ciliary investigations who accepted to participate to the genetic studies
3257915|NCT00783861|Experimental|1|Lactic Acid (Dermacyd Femina)
3257916|NCT00783835|Experimental|Methylphenidate|
3257917|NCT00783822|Other|intervention|rapid genetic counseling and testing
3257918|NCT00783822|No Intervention|control|usual care
3257919|NCT00783796|Experimental|2.25mm XIENCE V®|Patients receiving the 2.25 mm XIENCE V® stent
3257920|NCT00783783||Poor metabolizers|Patients with CYP2D6 genotypes predictive of poor metabolizer phenotype
3257921|NCT00783783||Non poor metabolizers|Patients with CYP2D6 genotypes predictive of intermediate, extensive, or ultra-rapid metabolizer phenotypes
3257922|NCT00783770||30-33 weeks|mother infant pairs with gestation of 30-33 weeks
3257923|NCT00783770||34-37 weeks|mother infant pairs with gestation of 34-37 weeks
3257924|NCT00783770||38-42 weeks|mother infant pairs with gestation of 38-42 weeks
3257925|NCT00783757|Experimental|Optical Imaging|Tomographic Optical Imaging Arm
3257926|NCT00783744|Experimental|1|Insulin Glargine + Glimepiride + Metformin
3257927|NCT00783744|Active Comparator|2|Insulin monotherapy with premixed insulin NPH 30/70
3257928|NCT00783731|Experimental|Low dose midazolam|
3257929|NCT00783718|Experimental|Vedolizumab|"In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase."
3257930|NCT00783718|Placebo Comparator|Placebo|In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.
3257931|NCT00783705|Experimental|Arm I (inositol)|Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.
3257932|NCT00783705|Experimental|Arm II (placebo)|Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.
3257933|NCT00783692|Experimental|Vedolizumab|"In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase."
3257934|NCT00783692|Placebo Comparator|Placebo|In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.
3257935|NCT00783679|Other|1|Twenty adult spontaneously breathing patients without intubation and mechanical ventilation recruited from the cardiac catheterization laboratory. All will be post-heart-transplant patients coming for yearly evaluation.
3257936|NCT00783666|Experimental|1|Lactic Acid
3257937|NCT00783640|Experimental|1|Lactic Acid
3257938|NCT00783627||1|Patient with sickle cell disease
3257939|NCT00783627||2|Healthy volunteers
3257940|NCT00783614|Active Comparator|1|Start antiretroviral therapy (ART) immediately and initiate aspirin 325mg po daily
3257941|NCT00783614|Placebo Comparator|2|Start antiretroviral therapy (ART) immediately and initiate placebo pill daily
3257942|NCT00783614|Active Comparator|3|Defer antiretroviral therapy (ART) for 1 month and immediately initiate aspirin 325mg po daily
3257943|NCT00783614|Placebo Comparator|4|Defer antiretroviral therapy (ART) for 1 month and immediately initiate placebo pill daily
3257944|NCT00783601|Experimental|1|Treatment Sequence 1: MK0524 + placebo, MK0524 + montelukast, placebo, placebo, placebo + montelukast
3257945|NCT00783601|Experimental|2|Treatment sequence 2: Placebo, montelukast, placebo, MK0524, MK0524 + montelukast
3257946|NCT00783575||Inflammatory Bowel Disease|Crohn's disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel disease (IBD) are chronic, life-long, destructive inflammatory conditions of the gastrointestinal tract.
3257947|NCT00783562|Experimental|1|
3257948|NCT00783562|Active Comparator|2|
3257949|NCT00783549|Experimental|Cohort 1|6 active 2 placebo
3257950|NCT00783549|Experimental|Cohort 2|9 active 3 placebo
3257951|NCT00783549|Experimental|Cohort 3|Optional cohort
3257952|NCT00783549|Experimental|Cohort 4|12 active
3257953|NCT00783549|Experimental|Cohort 5|12 active
3257954|NCT00783536|Experimental|1|"Clinical and demographic information~Clinical and Laboratory information"
3257955|NCT00783536|Active Comparator|2|"Clinical and demographic information~Clinical and Laboratory information"
3257956|NCT00783523|Active Comparator|Doxycycline|Patients undergoing elective vascular malformation surgery will receive doxycycline100 mg twice a day, a dose shown to effectively decrease MMP or placebo, treatment for two weeks prior to surgery
3257957|NCT00783523|Placebo Comparator|Placebo|Patients undergoing elective vascular malformation surgery will receive doxycycline100 mg twice a day, a dose shown to effectively decrease MMP or placebo, treatment for two weeks prior to surgery
3257958|NCT00783510||HUMIRA® Treatment Arm|For patients taking HUMIRA®
3257959|NCT00783510||Methotrexate Treatment Arm|For patients taking Methotrexate
3257960|NCT00783497||1|Caucasian Americans
3257961|NCT00783497||2|African Americans
3257962|NCT00783484|Experimental|Cohort 1|PF-03716539 crossover, single dose escalation (doses subject to change).
3257963|NCT00783484|Experimental|Cohort 2|PF-03716539 crossover, single dose escalation (doses subject to change).
3257964|NCT00783484|Experimental|Cohort 3|Midazolam-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
3257965|NCT00783484|Experimental|Cohort 4|Darunavir-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
3257966|NCT00783484|Experimental|Cohort 5|Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
3257967|NCT00783484|Experimental|Cohort 6|Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 200 mg).
3257968|NCT00783471|Experimental|1|Erlotinib followed by Docetaxel
3257969|NCT00783471|Experimental|2|Docetaxel followed by Erlotinib
3257970|NCT00783458|Active Comparator|Nasonex Followed by Flonase|
3257971|NCT00783458|Active Comparator|Flonase Followed by Nasonex|
3257972|NCT00783445|Experimental|1|Exercise in a community setting while supervised by a coach
3257973|NCT00783445|Active Comparator|2|Self-exercise plan based on an individualized prescription after an initial fitness evaluation
3257974|NCT00783432|Experimental|1|Astepro Nasal Spray (0.1% azelastine hydrochloride)
3257975|NCT00783432|Active Comparator|2|Astelin Nasal Spray (0.1% azelastine hydrochloride)
3257976|NCT00783406|Experimental|PF- 00610355|
3257977|NCT00783406|Experimental|PF-00610355|
3257978|NCT00783406|Experimental|PF -00610355|
3257979|NCT00783406|Placebo Comparator|Placebo|
3257980|NCT00783393|Experimental|Single arm|"The study consists of two steps:~Step 1, the therapeutic study phase, comprising six cycles of treatment with temozolomide, and~Step 2, the long-term treatment phase, where subjects with at least disease stabilization at the end of Step 1 may continue temozolomide treatment until unacceptable toxicity or disease progression occur, up to a maximum of 2 years from the start of treatment in Cycle 1."
3257981|NCT00783380|Experimental|Virosomal influenza vaccine|
3257982|NCT00783380|Active Comparator|Subunit influenza vaccine|
3257983|NCT00783367|Experimental|lenalidomide-low dose dexamethasone plus rituximab|
3257984|NCT00783354|Active Comparator|Continuous Treatment|
3257985|NCT00783354|Experimental|PRN regimen|
3257986|NCT00783341|Experimental|GAP-134|
3257987|NCT00783341|Placebo Comparator|placebo|
3257988|NCT00783328|Experimental|1|Open label single arm trial
3257989|NCT00783315|Active Comparator|1|Self-Directed Weight Loss Program (Control Group)
3257990|NCT00783315|Experimental|2|Call-Center Directed (CCD) Weight Loss Program
3257991|NCT00783315|Experimental|3|In-Person Directed (IPD) Weight Loss Program
3257992|NCT00783289|Experimental|1|MEDI-563
3257993|NCT00783289|Placebo Comparator|2|Placebo
3257994|NCT00783276|Placebo Comparator|Sugar Pill|Placebo
3257995|NCT00783276|Active Comparator|SYN115|
3257996|NCT00783263|Experimental|Rosuvastatin 5 mg + Ezetimibe 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
3257997|NCT00783263|Active Comparator|Rosuvastatin 10 mg|Participants who received rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
3257998|NCT00783263|Experimental|Rosuvastatin 10 mg + Ezetimibe 10 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
3257999|NCT00783263|Active Comparator|Rosuvastatin 20 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
3258000|NCT00783250|Experimental|Salbutamol+Tiotropium|Salbutamol will be given at the dose of 400 micrograms and Tiotropium at the dose of 18 micrograms
3258001|NCT00783250|Placebo Comparator|placebo + Tiotropium|Placebo using MDI + administration of Tiotropium after 20 minutes
3258002|NCT00783237|Experimental|Mometasone Furoate Nasal Spray|
3258003|NCT00783237|Placebo Comparator|Placebo Nasal Spray|
3258004|NCT00783224|Placebo Comparator|Mometasone Furoate Placebo (PLAMF)|Placebo to mometasone furoate nasal spray, made to be indistinguishable from mometasone furoate nasal spray
3258005|NCT00783224|Placebo Comparator|Fluticasone Propionate Placebo (PLAFP)|Placebo to fluticasone propionate nasal spray, made to be indistinguishable from fluticasone propionate nasal spray
3258006|NCT00783224|Experimental|Mometasone Furoate (MF)|Mometasone furoate nasal spray 200 μg/day(QD)
3258007|NCT00783224|Active Comparator|Fluticasone Propionate (FP)|Fluticasone Propionate nasal spray 200 μg/day, twice per day (BID)
3258008|NCT00783211|Experimental|1|desloratadine
3258009|NCT00783211|Active Comparator|2|fexofenadine
3258010|NCT00783211|Placebo Comparator|3|placebo
3258011|NCT00783198|Experimental|SCH 39641 6 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 6 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
3258012|NCT00783198|Experimental|SCH 39641 12 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 12 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
3258013|NCT00783198|Placebo Comparator|Placebo|Participants receive placebo matching ambrosia artemisiifolia allergen extract, rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
3258014|NCT00783185|Experimental|ACT|Anti-Cannabis-Consumption-Training
3258015|NCT00783185|Active Comparator|CG|Control group
3258016|NCT00783172|Experimental|OGF & Gemcitabine|Opioid Growth factor 250 ug/kg IV once a week. Gemcitabine 1000 mg/m2 weekly for 7 out of 8 weeks induction then every 3 out of 4 week cycles.
3258017|NCT00783159|Experimental|A|Training I
3258018|NCT00783159|Experimental|B|Training II
3258019|NCT00783159|Active Comparator|C|Control
3258020|NCT00783146|Experimental|1|desloratadine
3258021|NCT00783146|Active Comparator|2|fexofenadine
3258022|NCT00783146|Placebo Comparator|3|placebo
3258023|NCT00783133|Experimental|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3258024|NCT00783133|Experimental|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3258025|NCT00783120|Experimental|1|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold).
3258073|NCT00782808||2 HIV DNA will be stratified by low|
3258026|NCT00783120|Sham Comparator|2|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session)
3258027|NCT00783107|Experimental|Cyclosporine|
3258028|NCT00783107|Placebo Comparator|Placebo|Subjects will be randomly assigned to Cyclosporine or placebo, in a ratio of 2:1.
3258029|NCT00783094|Experimental|Tadalafil 2.5 milligrams (mg)|2.5 mg tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.
3258030|NCT00783094|Experimental|Tadalafil 5 mg|5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.
3258031|NCT00783094|Placebo Comparator|Placebo|"Placebo tablet taken by mouth once a day for 12 weeks.~Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks."
3258032|NCT00783081|Experimental|low dose K-134|
3258033|NCT00783081|Experimental|mid dose K-134|
3258034|NCT00783081|Experimental|high dose K-134|
3258035|NCT00783081|Active Comparator|Comparator|
3258036|NCT00783081|Placebo Comparator|Placebo|
3258037|NCT00783068|Active Comparator|GTS-21|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0).
3258038|NCT00783068|Placebo Comparator|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
3258039|NCT00783055|Experimental|Treatment|12 weeks of individually tailored intervention programmes based on participants individual wishes for daily activities e.g.ADL, mobility, social, mental or creative that they want to improve, conserve - and/or to revive.
3258040|NCT00783042|Active Comparator|1|
3258041|NCT00783042|Placebo Comparator|2|
3258042|NCT00783029||Healthy Subjects|Healthy participants between the ages of 21 and 65 years old.
3258043|NCT00783016|Experimental|Morphine|
3258044|NCT00783016|No Intervention|Placebo|
3258045|NCT00783003|Experimental|Long acting muscarinic receptor antagonist (LAMA)|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
3258046|NCT00783003|Experimental|Long acting Beta 2 agonist (LABA)|Inhaled Long Acting Beta 2 agonist (LABA) which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
3258047|NCT00783003|Experimental|LAMA with LABA|Inhaled Long Acting Muscarinic receptor Antagonist (LAMA) and a inhaled Long Acting Beta 2 Agonist (LABA), both in development for treatment of Chronic Obstructive Pulmonary Disease and taken in combination.
3258048|NCT00783003|Placebo Comparator|Placebo|Matching placebo, no intervention.
3258049|NCT00782990|Active Comparator|tvt group|Surgical treatment for incontinence: TVT
3258050|NCT00782990|Active Comparator|Burch group|Surgical treatment for incontinence: Colposuspension
3258051|NCT00782977|Sham Comparator|1|Nasal cannulae with no oxygen flow
3258052|NCT00782977|Active Comparator|2|Nasal cannulae with oxygen flow at 5 L/minute
3258053|NCT00782977|Active Comparator|3|Nasal cannulae with oxygen flow at 10 L/minute
3258054|NCT00782964||1|Outpatient with major depressive disorder, who has a change in pharmacological therapeutical plan after an incomplete response or intolerance to a treatment with an adequate dosage of an antidepressant (SSRI/NSRI) (20-40 mg fluoxetine, 75-225 mg venlafaxine or equivalent) for at least 6 weeks.
3258055|NCT00782951|Experimental|Org 28611|
3258056|NCT00782951|Active Comparator|morphine sulfate|
3258057|NCT00782951|Placebo Comparator|Placebo|
3258058|NCT00782938||low SAA|
3258059|NCT00782938||high SAA|
3258060|NCT00782925|Experimental|1|"Study intervention:~A face/profile X-ray of their entire spine at baseline~Educational program~Exercise program~Self-led exercises~A follow-up at 12 and 24 months with their occupational therapist.~A follow-up at 18 months with a physical therapist.~Workers received also at the end of the educational program written standardized information about back pain (the back book, an information booklet) 1.~Coudeyre E., Tubach F., Rannou F. & all, Effect of simple information booklet on pain persistance after an acute episode of low back pain: a non- randomised trial in a primary care setting. PLoS ONE. 2007 ; 2 : e706"
3258061|NCT00782925|No Intervention|2|"Control intervention :~No intervention~A face/profile X-ray of their entire spine at baseline~A follow-up at 12 and 24 months with their occupational therapist,~A follow-up at 18 months with a physical therapist."
3258062|NCT00782899||1|Schizophrenic patients with a acute episode treated in outpatients clinics
3258063|NCT00782873||obese subjects|BMI > 35
3258064|NCT00782860||unsuccessful termination|unsuccessful termination of early pregnancy failure with Misoprostol
3258065|NCT00782860||successful termination|successful termination of early pregnancy failure with Misoprostol
3258066|NCT00782847|Active Comparator|with DiaNe program|study subjects which participated in the DiaNe consultation and support program
3258067|NCT00782847|No Intervention|without DiaNe program|study subjects which received standard care by diabetologist and/or nephrologist
3258068|NCT00782821|Active Comparator|Rabbit Antithymocyte Globulin (rATG)|Rabbit Antithymocyte Globulin (rATG) 1.5mg/kg per dose x 6 doses rATG was administered on post-op day 0, 2, 4, 6, 8 and 10.
3258069|NCT00782821|Experimental|RATG/Rituxan|Rabbit Antithymocyte Globulin (rATG)/Rituxan 1.5mg/kg per dose x 5 doses of rATG. 375mg/m2 x 1 dose of rituxan. rATG was administered on post-op day 0, 2, 4, 6 and 8. Rituxan was given on post-op day 1.
3258070|NCT00782821|Experimental|RATG/Velcade|Rabbit Antithymocyte Globulin (rATG) /Velcade 1.5mg/kg per dose x 5 doses of rATG. 1.3mg/m2 per dose x 4 doses of velcade. rATG was administered on post-op day 0, 2, 4, and 6. Velcade was administered on post-op day 0, 3, 7 and 10.
3258071|NCT00782821|Experimental|RATG/Rituxan/Velcade|"Rabbit Antithymocyte Globulin (RATG) / Rituxan / Velcade 1.5mg/kg per dose x 4 doses of rATG. 200mg/m2 for 1 dose of rituxan. 1.3mg/m2 per dose x 4 doses of velcade.~rATG was administered on post-op day 0, 2, 4, and 6. Velcade was administered on post-op day 0, 3, 7 and 10. Rituxan was given on post-op day 1."
3258072|NCT00782808||1 HIV DNA will be stratified by high|
3258074|NCT00782795|Active Comparator|Pioglitazone|30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
3258075|NCT00782795|Placebo Comparator|sugar pill (placebo)|1 sugar pill (placebo) taken once daily for 48 weeks.
3258076|NCT00782769|Experimental|Oxybutinyn Vaginal Ring 4mg|inserted daily and replaced every 4 weeks
3258077|NCT00782769|Experimental|Oxybutinyn Vaginal Ring 6mg|inserted daily and replaced every 4 weeks
3258078|NCT00782756|Experimental|RT, with temozolomide and bevacizumab|This treatment regimen is novel in that it delivers the initial course of RT over 2 weeks instead of 6 weeks; also, the addition of bevacizumab during and after RT is a new approach.
3258079|NCT00782743||1|patients with required new anticoagulation with phenprocoumon 1/2 of them with a GFR< 60 ml/min and >15 ml/min
3258080|NCT00782743||2|patients with required therapy with ASS, 1/2 of them with a GFR <60 ml/min and >15 ml/min
3258081|NCT00782730||Bladder Scan Group|Patients who agree to enroll in the trial and allow their known bladder volumes and residual bladder volumes to be measured by actual volumes retrograde instilled, and also by bladder scanner ultrasound.
3258082|NCT00782717|Experimental|NEVANAC|One drop three times a day starting on the day prior to cataract surgery (Day -1) and continuing on the day of surgery (Day 0) and for 90 days thereafter.
3258083|NCT00782717|Placebo Comparator|Nepafenac Vehicle|One drop three times a day starting on the day prior to cataract surgery (Day -1) and continuing on the day of surgery (Day 0) and for 90 days thereafter.
3258084|NCT00782704||1|questionnair for Patients
3258085|NCT00782704||2|questionnaire for Nurses
3258086|NCT00782704||3|questionnaire for Physicians
3258087|NCT00782691||Head-and-neck cancer patients.|Head-and-neck cancer patients eligible for therapeutic lymph node dissection of cervical nodes.
3258088|NCT00782665|Active Comparator|Group 1|Patients who have labored and subsequently delivered by cesarean section
3258089|NCT00782665|Placebo Comparator|2|Patients who electively select cesarean section
3258090|NCT00782652|Active Comparator|1|inhaled nitric oxide at 40 or 80ppm
3258091|NCT00782652|Placebo Comparator|2|inhaled nitrogen at either 40 or 80ppm
3258092|NCT00782639|Active Comparator|Iopamiro-370|
3258093|NCT00782639|Active Comparator|Visipaque 320|
3258094|NCT00782626|Experimental|everolimus|Patients rcvd oral everolimus 5.0 mg/m2/day for a 28-day treatment course up to a total of 12 courses (48 weeks) if a patient had stable disease except if toxicity was unacceptable. Two dose reductions were permitted (3.0 5.0 mg/m2/day and 2.0 mg/m2/day).
3258095|NCT00782613|Active Comparator|1|Two psoriatic plaques of similar surface area and severity will be identified for each subject. ALT-2074 will be applied topically twice daily to 1 of the 2 target plaques, and the placebo control to the other plaque for a period of 28 days in amounts sufficient to cover the entire surface area of the target plaque, extending to 1 cm outside of the plaque border.
3258096|NCT00782613|Placebo Comparator|2|Placebo
3258097|NCT00782600|Experimental|50 mg oral suspension|once daily for one day
3258098|NCT00782600|Experimental|50 mg CR Type 1|once daily for one day
3258099|NCT00782600|Experimental|50 mg CR Type 2|once daily for one day
3258100|NCT00782600|Experimental|50 mg SR Type 3|once daily for one day
3258101|NCT00782587|Experimental|Arm 1|Single arm, open label, single dose, intravesical instillation of Chemophase (combination of rHuPH20 and mitomycin) for appropriate superficial bladder cancer patients within 6 hours of TURBT.
3258102|NCT00782574|Experimental|1|AZD2281 + Cisplatin combination therapy
3258103|NCT00782561|Experimental|FG-3019|FG-3019 5 mg/kg
3258104|NCT00782548|Active Comparator|1|Test product A (1 x 30 mg KADIAN)
3258105|NCT00782548|Active Comparator|2|Test product B (1 x 30 mg Avinza)
3258106|NCT00782535|Experimental|Treatment A|Single therapeutic dose of CHF 4226 pMDI
3258107|NCT00782535|Experimental|Treatment B|Single therapeutic dose of CHF 4226 pMDI
3258108|NCT00782535|Experimental|Treatment C|Single supratherapeutic dose of CHF 4226 pMDI
3258109|NCT00782535|Experimental|Treatment D|Single supratherapeutic dose of CHF 4226 pMDI
3258110|NCT00782535|Placebo Comparator|Treatment E|Single dose of placebo
3258111|NCT00782522|Experimental|1|Eccentric training program
3258112|NCT00782522|Active Comparator|2|Traditional training program
3258113|NCT00782509|Experimental|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
3258114|NCT00782509|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
3258115|NCT00782509|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
3258116|NCT00782496|Experimental|Level1 Basic Meter Features|Adults with type 1 and type 2 diabetes use only basic features (Level 1) to test their blood. The CONTOUR meter has the basic features such as small meter size, easy to use , No Coding™ technology, 5-second test time, small sample size (0.6 µL), automatic control solution marking, 480 reading memory capacity.
3258117|NCT00782496|Experimental|Level 2 Advanced Meter Features|Adults with type 1 and type 2 diabetes additionally access and use more advanced meter features(Level 2)during blood glucose testing. The advanced features include ability to mark blood glucose values as obtained before or after meals or to set an audible reminder to test.
3258118|NCT00782470||Group 1|
3258119|NCT00782470||Group 2|
3258120|NCT00782470||Group 3|
3258121|NCT00782457|Active Comparator|OPEN SURGERY|
3258122|NCT00782457|Experimental|LAPAROSCOPIC SURGERY|
3258123|NCT00782444|Active Comparator|Computer navigated knee replacement|Computer navigation system from Brainlab, vector vision, kolibri.
3258124|NCT00782444|Placebo Comparator|Conventional knee replacement|Conventional total knee replacement is performed with intramedullary guides in the traditional way.
3258125|NCT00782431|Experimental|1|Vero cell-derived, trivalent, seasonal influenza vaccine
3258126|NCT00782431|Active Comparator|2|Licensed egg-derived, trivalent seasonal influenza vaccine
3258127|NCT00782418|Active Comparator|1|exenatide 5mcg
3258128|NCT00782418|Active Comparator|2|exenatide 1.5mcg
3258129|NCT00782418|Placebo Comparator|3|Placebo
3258130|NCT00782405|Experimental|1|quetiapine
3258131|NCT00782405|Active Comparator|2|mirtazapine
3258132|NCT00782379|Experimental|Myeloablative Haploidentical Transplant|All patients will receive treatment using Fludarabine, Busulfan and Cyclophosphamide prior to receiving a haploidentical transplant followed by post-transplant cyclosphosphamide.
3258133|NCT00782366||Genetic Testing Group|Those who will receive predictive genetic risk assessments
3258134|NCT00782366||Control|Those who will receive standard of care
3258135|NCT00782353|Experimental|Cohort 1|Subjects randomized 8:2 (active:placebo) to receive ANA598 200 mg bid
3258136|NCT00782353|Experimental|Cohort 2|Subjects randomized 8:2 (active:placebo) to receive ANA598 400 mg bid
3258137|NCT00782353|Experimental|Cohort 3|Subjects randomized 8:2 (active:placebo) to receive ANA598 800 mg bid
3258138|NCT00782340|Active Comparator|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
3258139|NCT00782340|Placebo Comparator|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
3258140|NCT00782327|Experimental|1|Losartan
3258141|NCT00782327|Placebo Comparator|2|Placebo
3258142|NCT00782314||1|patients with maintenance only treatment with Symbicort Turbuhaler for at least 1 month
3258143|NCT00782314||2|patients with SMART treatment with Symbicort Turbuhaler for at least 1 month
3258144|NCT00782301|Active Comparator|Maraviroc|
3258145|NCT00782301|Active Comparator|Etravirine|
3258146|NCT00782288|Active Comparator|1|low dose 0.05mg digitoxin given once daily for 28 days
3258147|NCT00782288|Active Comparator|2|higher dose 0.1mg digitoxin daily for 28 days
3258148|NCT00782288|Placebo Comparator|3|placebo given daily for 28 days
3258149|NCT00782275|Experimental|bevacizumab and temsirolimus|"bevacizumab: given intravenously at a dose of 10mg/kg every 2 weeks (days 1 and 15)~temsirolimus: given intravenously at a dose of 25mg weekly on days 1, 8, 15, and 22~1 cycle=28-days~There were no dose reductions for bevacizumab allowed. If bevacizumab was held, the same dose would be used if treatment were resumed. If temsirolimus was held, the same or a reduced dose (15mg IV weekly) could be used upon resumption of therapy. Treatment was continued until the development of unacceptable toxicity or progression."
3258150|NCT00782262|Other|Group 1 (n=20)|BP < 140/90, no diabetes mellitus and fasting glucose < 5.5
3258151|NCT00782262|Other|Group 2 (n=20)|BP > 140/100, no diabetes mellitus and fasting glucose < 5.5
3258152|NCT00782262|Other|Group 3 (n=20)|BP <140/100, no diabetes mellitus, fasting glucose 5.5 - 6.9
3258153|NCT00782249|Experimental|1|Vagus nerve stimulation paradigm #1
3258154|NCT00782249|Experimental|2|Vagus nerve stimulation paradigm #2
3258155|NCT00782249|Experimental|3|Vagus nerve stimulation paradigm #3
3258156|NCT00782236|Active Comparator|Straumann BoneCeramic|In the test group, the subjects will receive the Bone Graft Material Straumann BoneCeramic in combination with a collagen membrane for preservation of the alveolar ridge after tooth extraction.
3258157|NCT00782236|Active Comparator|Freeze Dried Allograft Bone|In the control group, the subjects will receive Bone Graft Material Freeze Dried Allograft Bone in combination with a collagen membrane for preservation of the alveolar ridge after tooth extraction.
3258158|NCT00782223||1|Hip X-rays DDH
3258159|NCT00782223||2|Hip X-rays, CP
3258160|NCT00782223||3|Long standing lower Limb X-rays
3258161|NCT00782223||4|Scoliosis, AP X-rays
3258162|NCT00782223||5|Scoliosis Lateral X-rays
3258163|NCT00782210|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
3258164|NCT00782210|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
3258165|NCT00782210|Placebo Comparator|Placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
3258166|NCT00782197|Experimental|1|PRGF
3258167|NCT00782197|Active Comparator|2|Hyaluronic Acid
3258168|NCT00782184|Experimental|ezetimibe/simvastatin 10/40|Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, ezetimibe/simvastatin 10/40 was administered once daily in tablet form during the 6-week double-blind treatment period
3258169|NCT00782184|Active Comparator|atorvastatin 40 mg|Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, 40 mg atorvastatin was administered once daily in tablet form during the 6-week double-blind treatment period
3258170|NCT00782171|Active Comparator|Immediate Loading|SLActive dental implant(s) will be restored with a temporary restoration on the day of surgery.
3258171|NCT00782171|Active Comparator|Early Loading|Healing caps will be placed on the SLActive dental implant(s) immediately after surgery. A provisional restoration will be placed between day 28 to day 34 post surgery
3258172|NCT00782145|Experimental|Arm I|"Each dyad receives institution-specific care for 6 months, which typically includes psychosocial support for the HSCT recipient and individualized or group education and support for the accompanying parent during the peri-transplant period. They also receive the Web-based Hematopoietic Stem Cell Transplantation (HSCT-) Comprehensive Health Enhancement Support System (HSCT-CHESS) intervention for 6 months. Accompanying parents also identify a companion to receive access to the HSCT-CHESS Web Site.~The HSCT-CHESS Web site provides ready access to accurate information and resources about pediatric HSCT, practical tips, organizational tools, and other supporting services for use during the transplant process. In addition to collecting data for later analysis, the Web site tracking system allows for further tailoring of information and support for the user, principally by time post transplant."
3258173|NCT00782145|Active Comparator|Arm II|Each dyad receives institution-specific usual care for 6 months as described in arm I. Accompanying parents also receive a book from the Blood and Marrow Transplant Information Network (BMT Infonet).
3258174|NCT00782106|Experimental|1|Tolerability of subcutaneous infusions
3258175|NCT00782106|Experimental|2|Tolerability of subcutaneous infusions and pharmacokinetics
3258176|NCT00782080|Experimental|Sedariston|Sedariston (100 mg St. John´s Wort and 50 mg Valerian extract) capsule given orally in capsules (size 1) twice daily for eight weeks in children (6-11): 1 - 0 -1 In Adolescents (12-17 years) two capsules (size 1) twice daily: 2 - 0 - 2.
3258177|NCT00782080|Placebo Comparator|Placebo campsule|Placebo provided by the company given orally in capsules (size 1 )twice daily
3258178|NCT00782067|Experimental|Midostaurin (PKC412)|Midostaurin was administered at a dose of 100 mg twice daily (bid) in continuous cycles of 28 days until disease progression, intolerable toxicity or withdrawal due to any cause, whichever occurred first.
3258179|NCT00782054|Active Comparator|Active|moisturizer with endopeptidases
3258180|NCT00782054|Placebo Comparator|Placebo|moisturizer without endopeptidases
3258181|NCT00782041|Experimental|1|Oxaliplatin 85 mg/m² over 3 hours at Day 1 and Day 15. 5-FU 2,000 mg/m² over 4 hours at Day 1. Folinic acid 20 mg/m² Bolus at Day 1.
3258182|NCT00782028|No Intervention|Standard Care|No intervention consists of routine well child care
3258183|NCT00782028|Other|Centering parenting/Group well child care|
3258184|NCT00782015|Active Comparator|almonds|3 oz/d almonds
3258185|NCT00782015|Placebo Comparator|Placebo|NCEP Step 2 diet
3258186|NCT00782002|Experimental|IMC-18F1|
3258187|NCT00781989||Rheumatoid Arthritis patients|Patients with seropositive Rheumatoid Arthritis with symptom onset of less than three years
3258188|NCT00781976|Placebo Comparator|1|
3258189|NCT00781976|Active Comparator|2|
3258190|NCT00781963|Experimental|Individual CBTI|Manual-based CBTI provided in 5 individual sessions by health educator.
3258191|NCT00781963|Experimental|Group CBTI|Manual-based CBTI provided in 5 group sessions by health educator.
3258192|NCT00781963|Experimental|Control|Sleep education control condition provided in 5 group sessions by health educator.
3258193|NCT00781950|Placebo Comparator|Placebo|Randomized, Blinded Controlled Arm of patients receiving placebo food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing a mixture of wheat and wheat bran to replace the flaxseed daily for one year.
3258194|NCT00781950|Experimental|Flaxseed|Randomized, Blinded group of patients that will be given food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing 30 g of milled flaxseed daily for one year
3258195|NCT00781937|Experimental|Lira 3.0 mg|A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liraglutide 3.0 mg, once daily, injected subcutaneously and instructed to follow a standard energy-restricted diet in the 56-week main trial period. Subjects discontinued treatment in the 12-week follow-up period. The starting dose of liraglutide was 0.6 mg, with weekly increments of 0.6 mg every 7 days until the target dose of 3.0 mg was reached
3258196|NCT00781937|Placebo Comparator|Placebo|A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liraglutide placebo, once daily, injected subcutaneously for 56 weeks and instructed to follow a standard energy-restricted diet in the 56-week main trial period. Subjects discontinued treatment in the 12-week follow-up period
3258197|NCT00781924||biopsy|
3258198|NCT00781911|Experimental|Carcinoid tumor|Participants with carcinoid tumor will receive cixutumumab 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
3258199|NCT00781911|Experimental|Islet cell carcinoma|Participants with islet cell carcinoma will receive cixutumumab 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
3258200|NCT00781898|Active Comparator|Depot Naltrexone|
3258201|NCT00781898|Placebo Comparator|Placebo|
3258202|NCT00781872|Experimental|open|a group of patients with active multiple sclerosis, failures to respond to other treatments
3258203|NCT00781859|Experimental|125µg Ocriplasmin|125µg intravitreal injection of ocriplasmin
3258204|NCT00781859|Placebo Comparator|Placebo|placebo intravitreal injection
3258205|NCT00781846|Experimental|1|30mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks
3258206|NCT00781846|Experimental|2|40mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks
3258207|NCT00781846|Experimental|3|40mg QDx5/wk ridaforolimus plus 15mg/kg Q3wks bevacizumab for 3 weeks
3258208|NCT00781833|Experimental|Treatment|Intramuscular Electrical Stimulation
3258209|NCT00781820|Placebo Comparator|Arm 2|
3258210|NCT00781820|Experimental|Arm 1|
3258211|NCT00781807|Experimental|1|The prospective intervention group with nutrition management, home-based bicycle ergometer training program and psychosocial support
3258212|NCT00781794|Experimental|1|Dose 1
3258213|NCT00781794|Experimental|2|Dose 2
3258214|NCT00781794|Placebo Comparator|3|
3258215|NCT00781781|Experimental|1|"High risk patients (at least one GVHD high risk criterion):~Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive)."
3258216|NCT00781781|Experimental|2|"Low Risk patients (no GVHD high risk criterion):~Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive)."
3258217|NCT00781768|Placebo Comparator|Standard PO (Zofran + Dexamethasone)|Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron (Zofran) 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion.
3258218|NCT00781768|Active Comparator|Aprepitant (MK-869) + Standard PO|Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO [blinded] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO [blinded] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
3258219|NCT00781755|Experimental|1|VAR-MI: This group will receive 1mg/day varenicline (titrated from .5mg/day) and two sessions of a motivational interviewing platform CBT treatment over the course of two weeks.
3258382|NCT00780429||1|MMF+cyclosporine
3258220|NCT00781755|Placebo Comparator|2|PLA-MI: VAR-MI: This group will receive a daily placebo pill and two sessions of a motivational interviewing platform CBT treatment over the course of two weeks.
3258221|NCT00781742|Experimental|1|100 mg iv once per dosing day
3258222|NCT00781742|Experimental|2|150 mg iv once per dosing day
3258223|NCT00781742|Placebo Comparator|3|
3258224|NCT00781729|Experimental|1|Yoga, one hour class, 3 times per week, for 24 weeks
3258225|NCT00781729|Placebo Comparator|2|Luncheon Seminar Series, once per month, for 24 weeks
3258226|NCT00781716|Active Comparator|Cypher Stent|Cypher Sirolimus-Eluting Coronary Stent System
3258227|NCT00781716|Active Comparator|Endeavor Stent|Endeavor Zotarolimus-Eluting Coronary Stent System
3258228|NCT00781703|Other|DIAMOND Care Model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the Patient Health Questionnaire-9 (PHQ9), treatment adjustment as indicated, psychiatric consultation, relapse prevention.
3258229|NCT00781690|Experimental|1|Treatment with Evodial with reduction of heparin across study period
3258230|NCT00781677||MDD|
3258231|NCT00781664|Experimental|A|AN2718 Cream SF Vehicle
3258232|NCT00781664|Experimental|B|AN2718 Cream SF, 0.3%
3258233|NCT00781664|Experimental|C|AN2718 Cream SF, 1%
3258234|NCT00781664|Experimental|D|AN2718 Gel Vehicle
3258235|NCT00781664|Experimental|E|AN2718 Gel, 1.5%
3258236|NCT00781664|Experimental|F|AN2718 Gel, 2.5%
3258237|NCT00781664|Experimental|G|AN2718 Gel, 5%
3258238|NCT00781664|Experimental|H|AN2718 Gel, 7.5%
3258239|NCT00781664|Active Comparator|I|Sodium Lauryl Sulfate, 0.5%
3258240|NCT00781625|Active Comparator|Probiotic vaginal capsules|Probiotic vaginal capsule, placebo oral capsule
3258241|NCT00781625|Placebo Comparator|placebo|placebo oral capsule, placebo vaginal capsule
3258242|NCT00781625|Active Comparator|Probiotic oral capsules|Probiotic oral capsules, placebo vaginal capsules
3258243|NCT00781612|Experimental|Trastuzumab Emtansine|Participants will receive trastuzumab emtansine either as a single agent or in combination with other anti-cancer therapy (pertuzumab, paclitaxel, trastuzumab and docetaxel). Participants will receive the same dose and schedule on Cycle 1, Day 1 at which it was given at the end of the parent study. Study drug will be administered in 21-day cycles or weekly, depending on the schedule used in the parent study. Participants will receive study treatment until disease progression or unacceptable toxicity.
3258244|NCT00781599|Active Comparator|1|Chantix for 3 months and Standard Counseling
3258245|NCT00781599|Experimental|2|Chantix for 3 months and Adherence Counseling
3258246|NCT00781586|Experimental|Arm 1|
3258247|NCT00781586|Active Comparator|Arm 2|
3258248|NCT00781586|Placebo Comparator|Arm 3|
3258249|NCT00781573|Experimental|1|Clopidogrel (75 mg/day) is continued for another year at the completion of the initial year of clopidogrel and aspirin administration post DES implantation
3258250|NCT00781573|No Intervention|2|Clopidogrel (75 mg/day) is stopped at the completion of the initial year of clopidogrel and aspirin administration post DES implantation
3258251|NCT00781560||1|patients being diagnosed as dyslipidemia but not receiving Crestor®
3258252|NCT00781560||2|hypercholesterolemia or mixed dyslipidemia and have been initiated treatment with Crestor®
3258253|NCT00781547|Experimental|Recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
3258254|NCT00781547|Placebo Comparator|Placebo|
3258255|NCT00781534|Active Comparator|1. Ginseng|Ginseng group
3258256|NCT00781534|Active Comparator|2. Ginsenosdie RE|Ginsenoside RE (a metabolite of ginseng) group
3258257|NCT00781534|Placebo Comparator|3. Placebo|"placebo (sugar pill) group"
3258258|NCT00781521|Experimental|1|Floxin otic solution twice a day for 7 days
3258259|NCT00781508|Experimental|sildenafil|Effect of oral administration of a single dose of sildenafil 50 mg on left ventricular filling pressures as evaluated 1 hr after sildenafil administration in patients with heart failure
3258260|NCT00781508|Placebo Comparator|placebo|Inactive placebo prepared to mimic the appearance of sildenafil.
3258261|NCT00781495||type 2 diabetes mellitus|
3258262|NCT00781482|Experimental|1|This is a crossover study. Each study drug will be administered (one at a time and in random order) to each subject on separate occasions over the course of the study.
3258263|NCT00781469||A|12 treatment naive patients who fulfil the American College of Rheumatology (ACR) criteria for RA with active disease defined by a Disease Activity Score (DAS)28 score of more than 3.2.
3258264|NCT00781469||B|6 RA patients in remission on a stable dose of methotrexate with a DAS28 score lower than 2.6
3258265|NCT00781469||C|12 patients who fulfill the ACR criteria for RA and are being treated with methotrexate but still have active disease, defined as a DAS28 score of more than 3.2
3258266|NCT00781456|Experimental|91-day Levonorgestrel Oral Contraceptive|Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10 µg EE monotherapy, for a total of 13 weeks.
3258267|NCT00781456|Placebo Comparator|Placebo|Participants received placebo, 12 weeks (84 consecutive days) of inactive tablets, followed by an additional 7 days of inactive tablets, for a total of 13 weeks.
3258268|NCT00781443|Experimental|A|
3258269|NCT00781443|Placebo Comparator|B|
3258270|NCT00781430|Experimental|1|
3258271|NCT00781417|Active Comparator|1|Cholecalciferol 50,000 IU once a week for 12 weeks then every other week for 40 weeks
3258272|NCT00781417|Placebo Comparator|Placebo|Placebo
3258273|NCT00781391|Active Comparator|Warfarin/placebo edoxaban|Warfarin tablets plus placebo Edoxaban tablets
3258274|NCT00781391|Experimental|high dose edoxaban/placebo warfarin|Edoxaban tablets (60mg) plus warfarin placebo tablets
3258275|NCT00781391|Experimental|low dose edoxaban/placebo warfarin|Edoxaban tablets (30mg) plus warfarin placebo tablets
3258276|NCT00781378|Active Comparator|Group 1|rt-PA 100 mg continuous intravenous infusion for 2 hours
3258277|NCT00781378|Experimental|group 2|rt-PA 50 mg continuous intravenous infusion for 2 hours
3258278|NCT00781365|No Intervention|Control|Patients in the control group will receive usual care from their primary care physicians at HealthPartners Medical Group clinics.
3258279|NCT00781365|Experimental|Telemonitors and pharmacy management|The telemonitoring intervention (TI) patients will receive a home blood pressure telemonitor and will work with a clinical pharmacist case manager to control elevated blood pressure. Patients will use their home telemonitors to read and send their blood pressures to their Pharmacist case manager, who will use phone meetings with the patient to make medication adjustments.
3258280|NCT00781352|Active Comparator|group 1|Colorectal surgery with 65% nitrous oxide administration
3258281|NCT00781352|Active Comparator|group 2|Colorectal surgery with nitrogen administration
3258282|NCT00781339|Experimental|Active|
3258283|NCT00781326|Other|Open Label Antidepressant|In Phase 1, all participants will be placed on antidepressant medication. In Phase 2, participants will continue with their antidepressant medication and also receive receive either nimodipine or placebo.
3258284|NCT00781300|Active Comparator|Loteprednol|
3258285|NCT00781300|Active Comparator|Dexamethasone|
3258286|NCT00781287|Experimental|Raltegravir + 3-drug anti-HIV therapy|
3258287|NCT00781287|Active Comparator|3-drug anti-HIV therapy|
3258288|NCT00781274|Experimental|MP-424|
3258289|NCT00781261|Placebo Comparator|Control|Subjects in the control group will receive a placebo drug for a 1 year period
3258290|NCT00781261|Active Comparator|Zoledronic Acid|Subjects in this intervention group will be given 5mg Zoledronic acid as a single injection
3258291|NCT00781248|Experimental|1|starting with active NG Shield
3258292|NCT00781248|Experimental|2|Starting with inactive NG Shield
3258293|NCT00781209|Experimental|Exp|Posterior Fossa Irradiation 37.5 Gy in 2.5 Gy fractions+Radiosurgical boost; Follow up:Contrast enhanced MRI & Mini Mental Status Examination
3258294|NCT00781196|Experimental|1|Oral folic acid
3258295|NCT00781196|Placebo Comparator|2|placebo
3258296|NCT00781183|Experimental|pulmonary rehabilitation|patients that are enrolled in pulmonary rehabilitation
3258297|NCT00781157|Experimental|1|
3258298|NCT00781144||1|first year osteopathic students
3258299|NCT00781144||2|fourth and fifth year osteopathic students
3258300|NCT00781144||3|experienced osteopathic clinicians
3258301|NCT00781131|Placebo Comparator|1|
3258302|NCT00781131|Experimental|2|Pregabalin 75 mg
3258303|NCT00781131|Experimental|3|Pregabalin 150 mg
3258304|NCT00781118|Experimental|Treatment|The Treatment arm has alerting enabled in their device during the 6-month randomization period. Treatment arm patients also have alerting enabled in the post-randomization period. Once a patient arrives at the ER, the standard of care triage process for MI is followed and that is outside of the ALERTS Study protocol. With Amendment the Treatment arm was re-defined as an ALARMS_ON group which included A) Control patients after the randomization period and until database lock (4/1/2014); and, b) Treatment patients both during the randomization period and after the randomization period until database lock (4/1/2014).
3258305|NCT00781118|Other|Control|The Control arm has alerting disabled in their device during the 6-month randomization period. Control arm patients also have alerting enabled in the post-randomization period. Once a patient arrives at the ER, the standard of care triage process for MI is followed and that is outside of the ALERTS Study protocol. With Amendment the Control arm was re-defined as an ALARMS_OFF group which included A) Control patients during the randomization period when the Guardian did not have alarms enabled.
3258306|NCT00781105|Experimental|1|
3258307|NCT00781092|Experimental|1|Systane Ultra
3258308|NCT00781092|Active Comparator|2|Bausch and Lomb Sensitive Eyes
3258309|NCT00781079|Experimental|Arm 1|Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
3258310|NCT00781079|No Intervention|Arm 2|Care as usual
3258311|NCT00781066|Experimental|1|Controlled cord traction (CCT)
3258312|NCT00781066|Active Comparator|2|No CCT
3258313|NCT00781053|Experimental|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months.
3258314|NCT00781040||Neutropenic patients|Adult AML and ASCT patients with neutropenic fever.
3258315|NCT00781027|Active Comparator|1|Torsional phacoemulsification
3258316|NCT00781027|Active Comparator|2|Longitudinal phacoemulsification
3258317|NCT00781001|Placebo Comparator|1|Placebo cannabis
3258318|NCT00781001|Experimental|2|Active cannabis - 1% THC by weight
3258319|NCT00781001|Experimental|3|Active cannabis - 4% THC by weight
3258320|NCT00781001|Experimental|4|Active cannabis - 7% THC by weight
3258321|NCT00780975|Experimental|Arm 1|Aplidin (Plitidepsin)
3258322|NCT00780962|Experimental|N-Acetylcysteine group|Subjects in this group will receive 3 grams of N-acetylcysteine in 500 cc normal saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, they will receive a continuous infusion of 200 mg N-acetylcysteine per hour. This dose will be administered as an infusion of 67 cc per hour of a solution of 3 grams of N-acetylcysteine in 1000 cc of normal saline. The infusion will be administered for a minimum of two hours and then stopped after 24 hours, or when the patient is discharged from the Emergency Department or the hospital, whichever comes first.
3258323|NCT00780962|Placebo Comparator|0.9% Sodium-chloride group|Subjects in this group will receive 500 cc Normal Saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, they will receive a continuous infusion of 67 cc per hour of normal saline. The infusion will be administered for a minimum of two hours and then stopped after 24 hours, or when the patient is discharged from the Emergency Department or the hospital, whichever comes first.
3258324|NCT00780949|Experimental|1: Crohn's disease patient|intestinal biopsies
3258325|NCT00780923|Experimental|CPAP|
3258326|NCT00780910|Experimental|MP-424|
3258327|NCT00780897||1|POF patients; 18 years <Age> 40 years; Hormonal sampling; FMR1 analysis; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy; Bone Mineral Density; Pelvic Ultrasonography;
3258328|NCT00780897||2|Control Group No POF patients; Benign ovarian pathology; 18 years <Age> 40 years; Hormonal sampling; FMR1 analyze; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy under specific conditions; Bone Mineral Density; Pelvic Ultrasonography
3258329|NCT00780884|Experimental|acupuncture needles|Acupuncture needles named acuzone needles. The acuzone needles are sterile and single use, manufactured by DONG BANG MEDICAL CO.,LTD.
3258330|NCT00780858||Ganirelix|Patients with premature lutenization (progesterone >1,2 ng/ml) who did not get pregnant during the first IUI underwent a second IUI.
3258331|NCT00780858||Control|Patients without premature lutenization (progesterone >1,2 ng/ml) underwent a only one IUI.
3258332|NCT00780845||AKI (-)|Patients without acute kidney injury after on-pump CABG
3258333|NCT00780845||AKI (+)|Patients with acute kidney injury after on-pump CABG
3258334|NCT00780832|Active Comparator|1|Caffeine reduction through diet and beverage counselling
3258335|NCT00780832|Active Comparator|2|Anticholinergic medication
3258336|NCT00780819|Experimental|PoleStar N20 intraoperative MRI|PoleStar N20 intraoperative MRI
3258337|NCT00780806|Experimental|1|Immunization with one dose of MnB rLP2086 vaccine at 0, 1 and 6 months
3258338|NCT00780793|Active Comparator|1-M : Maintenance|Usual care
3258339|NCT00780793|Experimental|2 -S : Spacing of TNF-blocker injections|Spacing of TNF-blocker injections
3258340|NCT00780780|Active Comparator|1|Triamcinolone intravitreal injection + Nepafenac eye drops
3258341|NCT00780780|Other|2|Triamcinolone intravitreal injection
3258342|NCT00780767|Experimental|Thrombectomy arm|
3258343|NCT00780754|Experimental|dutasteride|treatment group
3258344|NCT00780754|Active Comparator|watchful waiting strategy|
3258345|NCT00780741|Active Comparator|Immediate Office Probing|Probing to be performed in the office setting using topical anesthesia and infant restraint. Probing to be performed either the same day as randomization or within two weeks.
3258346|NCT00780741|Active Comparator|Deferred Facility Probing|Probing to be performed in a surgical facility under general anesthesia within four weeks after completion of the 26-week visit if any of the clinical signs persist.
3258347|NCT00780728|Active Comparator|Sildenafil|
3258348|NCT00780715|Active Comparator|Gliclazide MR|
3258349|NCT00780715|Active Comparator|Sitagliptin|
3258350|NCT00780715|Active Comparator|Pioglitazone|
3258351|NCT00780715|Experimental|Metformin|
3258352|NCT00780702|Experimental|Arm 1|
3258353|NCT00780702|Placebo Comparator|Arm 2|
3258354|NCT00780676|Experimental|Dasatinib sensitivity signature|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
3258355|NCT00780676|Experimental|SRC pathway activity signature|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
3258356|NCT00780676|Experimental|Dasatinib target index|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
3258357|NCT00780676|Experimental|Selumetinib pathway predictor|Participants predicted to respond to selumetinib/AZD6244 by predictive gene signature (either MEK pathway activity predictor positive or MEK pathway predictor negative) receive selumetinib 75 mg by mouth twice daily (BID).
3258358|NCT00780663|Experimental|Quarfloxin|Single arm study - open label.
3258359|NCT00780650|Experimental|1|
3258360|NCT00780650|Placebo Comparator|2|
3258361|NCT00780637|Experimental|Bradykinin|Patients receive 0, 10, 20, and 40 ng/min/100cc forearm volume of intrabrachial bradykinin, for 5 minutes at each dose. Forearm blood flow will be measured by strain gauge plethysmography, blood samples will be obtained to measure t-PA, PAI-1 at each dose. FMD and Radial artery tonometry will also be performed under resting conditions.
3258362|NCT00780624|Active Comparator|NIPPV|The NIPPV group receiving NIPPV treatment.
3258363|NCT00780624|Active Comparator|Control|The Control group receiving nCPAP treatment.
3258364|NCT00780598|Experimental|Tosedostat|oral, once daily administration of tosedostat to evaluate its efficacy, safety and tolerability
3258365|NCT00780585||1|Subjects who participated in previous Org 24448 trials
3258366|NCT00780572|Experimental|Arm 1: ADE Alerts|Arm 1 is a random intervention group in which half of the patients admitted to the VASLCHCS during study time period will be randomly selected. Providers will see ADE alerts for all patient in the randomly selected experimental group
3258367|NCT00780572|No Intervention|Arm 2: Control/No Alerts|The second arm is the control. Alerts will not be displayed for these patients.
3258368|NCT00780559|Other|Arm 1|Tailored Diet and Physical Activity
3258369|NCT00780559|Other|Arm 2|Standard of Care
3258370|NCT00780520|Experimental|1|
3258371|NCT00780520|Placebo Comparator|2|
3258372|NCT00780507||1|Patients are in a state of remission
3258373|NCT00780507||2|Patients are in a flare
3258374|NCT00780494|Experimental|bevacizumab in combination with carboplatin and capecitabine|
3258375|NCT00780481|Experimental|Bradykinin|Patients will have flow mediated vasodilation and radial artery tonometry performed. They will then receive 0, 10, 20, 40 ng/100cc/min of intrabrachial bradykinin. Strain gauge plethysmography and blood sampling at each dose will be done to evaluate t-PA release. Blood will also be drawn for other biomarkers.
3258376|NCT00780468|Active Comparator|1|Existing diet plan
3258377|NCT00780468|Experimental|2|New diet plan
3258378|NCT00780455|Experimental|Interferon beta-1b, FRP within 15 days after randomization|Interferon beta-1b (Betaseron, BAY86-5046) 250 microgram (8 MUI), sub-cutaneous, administration every other day, Participants starting the 6 weeks functional rehabilitation protocol (FRP) within 15 days after randomization
3258379|NCT00780455|Experimental|Interferon beta-1b, FRP about 6 weeks after randomization|Interferon beta-1b (Betaseron, BAY86-5046) 250 microgram (8 MUI), sub-cutaneous, administration every other day, Participants starting the 6 weeks functional rehabilitation protocol (FRP) about 6 weeks after randomization
3258380|NCT00780442|Experimental|DCS|D-Cycloserine 50 mg is a partial glutamate agonist. Participants received DCS prior to cocaine cue exposure sessions.
3258381|NCT00780442|Placebo Comparator|Placebo|Saline comparator. Participants received placebo prior to cocaine cue exposure sessions.
3258385|NCT00780416|Experimental|TRV/PEG/RBV|
3258386|NCT00780416|Active Comparator|PEG/RBV|
3258387|NCT00780403|Active Comparator|RediTab/Zyrtec|Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
3258388|NCT00780403|Active Comparator|Zyrtec/RediTab|Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.
3258389|NCT00780390|Placebo Comparator|CRPS patients without spinal cord stimulation|CRPS patients declining spinal cord stimulation therapy. Autonomic Function will be assessed at baseline and again within 2 years.
3258390|NCT00780390|Experimental|CRPS patients: candidates for spinal cord stimulator|CRPS patients who are candidates for spinal cord stimulator implant. These patients will have Autonomic Function assessments before and after the Standard of Care spinal cord stimulation implant
3258391|NCT00780377|Experimental|Bradykinin|Patients have holter monitoring. Patients receive intracoronary bradykinin (0.2, 0.6, 2.0 ug/min) and have coronary sinus and coronary artery blood sampling for t-PA and O2 content.
3258392|NCT00780351||SLEDD-f, vanco|Surgical ICU patients who is on slow low efficiency daily hemodiafiltration (SLEDD-f) and requires vancomycin therapy
3258393|NCT00780338|Experimental|1|Cohort 1: receives the Assets Getting To Outcomes intervention first. The AGTO intervention includes three types of assistance which are adapted to fit the needs and priorities of the individuals involved, as well as the inner and outer setting: (1) a manual of text and tools; (2) face-to-face training, and (3) onsite technical assistance (TA). These three types of assistance aim to improve the implementation process for each program. Two full-time, Maine-based staff, one with a master's and one with a bachelor's degree, provided AGTO tools, training, and TA to the intervention coalitions and programs during the two year intervention period. The tools are in the Search Institute-published manual, Getting To Outcomes with Developmental Assets: Ten steps to measuring success in youth programs and communities, which all intervention participants received.
3258394|NCT00780338|Active Comparator|2|Cohort 2: receives the Assets Getting To Outcomes intervention second, after Cohort 1 is done receiving the intervention.
3258395|NCT00780325|Experimental|1|CG100649, single oral dose of 2 mg
3258396|NCT00780325|Experimental|2|CG100649, single oral dose of 8 mg
3258397|NCT00780325|Active Comparator|3|Celecoxib, single oral dose of 200 mg
3258398|NCT00780325|Active Comparator|4|Naproxen, single oral dose of 500 mg
3258399|NCT00780325|Active Comparator|5|Acetazolamide, single oral dose of 250 mg
3258400|NCT00780325|Placebo Comparator|6|Placebo, single oral administration
3258401|NCT00780312|No Intervention|2|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse before onset of radiotherapy treatment.
3258402|NCT00780312|Experimental|1|physiotherapy
3258403|NCT00780299|Active Comparator|2|control
3258404|NCT00780299|Experimental|1|HDHP
3258405|NCT00780273|Experimental|Ankylos dental implants.|"3 Ankylos dental implants placed in platform switch configuration on one side of the mandible in support of a fixed restoration.~A total number of 19 subjects participated in this randomized, split mouth, masked, prospective, open, comparison, monocenter study. Participants were subjects with an edentulous mandible who recieved 3 implants on each side which were splinted for the delivery of a fixed prosthesis."
3258406|NCT00780273|Active Comparator|3i Prevail dental implants.|"Three 3i Prevail dental implants placed on the opposite side of the mandible from the Ankylos implants in support of fixed dental restoration.~After a baseline phase of 1 month the mandible sides of subjects were randomly assigned to one of the 2 parallel treatment groups: one side received ANKYLOS plus implants. The contralateral sde recieved Certain PREVAIL Implants. Abutments were installed and loaded immediately by a fixed temporary bridge. After 3 months the final prosthesis was incorporated."
3258407|NCT00780260|Experimental|1|5 session strengths-based case management intervention delivered by a professional case manager and a peer support specialist team
3258408|NCT00780260|Active Comparator|2|5 session strengths-based case management intervention delivered by a professional case manager.
3258409|NCT00780247||Alaska residents|"50 healthy community dwelling males or females."
3258410|NCT00780247||Hawaiian residents|"50 healthy community dwelling males or females at each site"
3258411|NCT00780234|Experimental|Arm 1: pioglitazone|Current or former smokers receive 6 months of treatment with pioglitazone
3258412|NCT00780234|Placebo Comparator|Arm 2: placebo|Current or former smokers receive 6 months of treatment with placebo
3258413|NCT00780221||control|patients without coronary artery disease
3258414|NCT00780221||case|patients with coronary artery disease
3258415|NCT00780208|Other|Daytrana (methylphenidate patch)|Methylphenidate patch
3258416|NCT00780195|Experimental|1|Single 2 hour hyperinsulinemic euglycemic clamp study at ~90 mg/dl.
3258417|NCT00780195|Experimental|2|Single 2 hour hyperinsulinemic hypoglycemic clamp study at ~70 mg/dl.
3258418|NCT00780195|Experimental|3|Single 2 hour hyperinsulinemic hypoglycemic clamp at ~60 mg/dl.
3258419|NCT00780195|Experimental|4|Single, 2 hour hyperinsulinemic hypoglycemic clamp at ~50 mg/dl.
3258420|NCT00780182|Experimental|1|All subjects will receive three 40mg doses of CMX001 as 1)solution fasted, 2)tablet fasted and 3)tablet following a high-fat breakfast. The order in which each subject receives each of the doses will be determined by a randomization code.
3258421|NCT00780169|Experimental|sorafenib +FOLFIRI|This is a Phase I safety study. There is only one arm of FOLFIRI administered every 14 days (2 week schedule) and sorafenib administered orally, twice daily continuously. First cycle sorafenib began at day +2 to FOLFIRI.
3258422|NCT00780143|Experimental|Arm 1|Plitidepsin in combination with Cytarabine
3258423|NCT00780130||Group 1|male & female college students ages 20 to 50, asymptomatic normals
3258424|NCT00780104|Experimental|Rapamycin + MEC|
3258425|NCT00780091||1|classical monitoring strategy
3258426|NCT00780091||2|optimized monitoring strategy
3258427|NCT00780078||1|Patients intubated orotracheally for over 6 days
3258428|NCT00780052|Experimental|1|c-myb AS ODN as a 24-hour continuous infusion over 7 days
3258591|NCT00778934|Experimental|1|Intimate Health Gel
3258429|NCT00780039|Experimental|Single Arm|Caelyx 30 mg/m2 in combination with carboplatin dosed to target AUC of 5 mg/mL.min.
3258430|NCT00780026|Experimental|Strict Glycemic Control|strict glycemic control (80 to 110 mg/dl)
3258431|NCT00780026|No Intervention|Standard of Care Control|standard of care insulin dosing
3258432|NCT00780013|Experimental|1|metformin hydrochloride (HCI) liquid 500 mg/5 mL of Ranbaxy
3258433|NCT00780013|Active Comparator|2|Glucophage® 1000 mg tablets
3258434|NCT00780000|Experimental|A1|
3258435|NCT00779987|Other|Autologous serum -Systane|Crossover arm starting with autologous serum for 2 weeks. After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using artificial tears (Systane)
3258436|NCT00779987|Other|Systane- Autologous serum|Crossover arm starting with artificial tears (Systane) for 2 weeks. After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using autologous serum.
3258437|NCT00779974||s/p Total Shoulder Arthroplasty|The subject population for this study consists of adult patients with a primary diagnosis of osteoarthritis who have had a total shoulder arthroplasty preformed by the PI between September 2003 through December 2007.
3258438|NCT00779961|Experimental|Group A|Early Cleft Palate Repair (Age group 6-10 months)
3258439|NCT00779961|Active Comparator|Group B|Sick Kids Routine cleft palate repair (age group 10-14 months)
3258440|NCT00779948||Targon FN|
3258441|NCT00779948||DHS|
3258442|NCT00779935|Experimental|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
3258443|NCT00779922|Experimental|group 1 to 5|
3258444|NCT00779909|Placebo Comparator|1- Placebo|placebo capsule once per day
3258445|NCT00779909|Experimental|2- Vitamin D3, 500 IU|vitamin D3, 500 IU capsule once per day
3258446|NCT00779909|Experimental|3- Vitamin D3, 2500 IU|vitamin D3, 2500 IU capsule once per day
3258447|NCT00779909|Experimental|4- Vitamin D3, 5000 IU|vitamin D3, 5000 IU capsule once per day
3258448|NCT00779870||1|health volunteers
3258449|NCT00779870||2|mild asthmatics
3258450|NCT00779870||3|moderately-severe asthmatics
3258451|NCT00779870||4|severe asthmatics
3258452|NCT00779857|Experimental|AtriCure LAA Exclusion System|AtriCure LAA Exclusion System
3258453|NCT00779844|Experimental|1|obese patients
3258454|NCT00779844|Active Comparator|2|lean patients
3258455|NCT00779831|Experimental|1|120 mg Pseudoephedrine hydrochloride extended release tablets of ranbaxy
3258456|NCT00779831|Active Comparator|2|(Sudafed ® 12 hour) 120 mg Pseudoephedrine hydrochloride extended - release tablets
3258457|NCT00779818|Experimental|Group 1|Treatment by electrical acupuncture
3258458|NCT00779818|Experimental|Group 2|Treatment by laser
3258459|NCT00779805|Experimental|1|Pseudoephedrine hydrochloride 120 mg ER tablets of Ranbaxy
3258460|NCT00779805|Active Comparator|2|Sudafed 120 mg ER tablets
3258461|NCT00779779||Rotarix Group|Subjects received 2 oral doses of Rotarix vaccine at an interval of at least 4 weeks between doses. The first dose was given from the age of 6 weeks and vaccination with both doses was to be completed by 24 weeks of age.
3258462|NCT00779766|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ vaccine. Cervarix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
3258463|NCT00779766|Placebo Comparator|Placebo Group|Subjects received 3 doses of placebo. Placebo was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
3258464|NCT00779753|Experimental|Neonates|Sixteen neonates admitted to the Neonatal Intensive Care Unit (NICU) at the Hospital for Sick Children (SickKids) will be required for this study. The diagnoses will include, but are not limited to, the following: Trachea-esophageal fistula and/or esophageal atresia, Congenital diaphragmatic hernia, imperforate anus, Hirschsprung's disease, Malrotation with or without volvulus, Intestinal atresias, Gastroschisis, Omphalocele, Necrotizing enterocolitis, Respiratory distress syndrome.
3258465|NCT00779740|Experimental|New Formulation Group|
3258466|NCT00779740|Active Comparator|Old Formulation Group|
3258467|NCT00779714|Experimental|A (individualized combined chemotherapy)|
3258468|NCT00779714|Active Comparator|B (DTIC monochemotherapy)|
3258469|NCT00779701|Other|A|All subjects placed on insulin infusion.
3258470|NCT00779675||Infliximab 5 mg/kg|
3258471|NCT00779649|Active Comparator|MoviPrep|
3258472|NCT00779649|Active Comparator|HalfLytely|
3258473|NCT00779636|Experimental|Desloratadine 10 mg|
3258474|NCT00779636|Placebo Comparator|Placebo|
3258475|NCT00779610|Experimental|Active|Vibration with forearm flexion (active contraction)
3258476|NCT00779610|Sham Comparator|Passive|Vibration without forearm flexion (passive)
3258477|NCT00779597|No Intervention|Care as usual|Care as usual, i.e. standard pain treatment and standard care
3258478|NCT00779597|Experimental|SCION-PAIN program|SCION-PAIN program - Additionally to standard pain treatment, patients from the intervention wards received, the SCION-PAIN program consisting of 3 modules: pharmacologic pain management, non-pharmacologic pain management and discharge management.
3258479|NCT00779584|Experimental|MK-8776 10mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 10 mg/m^2 given as monotherapy as an intravenous (IV) infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3258480|NCT00779584|Experimental|MK-8776 20mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 20 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3258481|NCT00779584|Experimental|MK-8776 40mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 40 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3258482|NCT00779584|Experimental|MK-8776 80mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 80 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3258592|NCT00778921|Experimental|Amlodipine 10 mg|Amlodipine 10 mg
3258483|NCT00779584|Experimental|MK-8776 112mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 112 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3258484|NCT00779584|Experimental|MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 80 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3258485|NCT00779584|Experimental|MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 112 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3258486|NCT00779584|Experimental|MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 150 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3258487|NCT00779584|Experimental|MK-8776 200mg+Gemcitabine 1000mg/m^2|Participants received MK-8776 200 mg given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3258488|NCT00779571|Experimental|Crispbread|Intervention: Crispbread LCD
3258489|NCT00779571|Active Comparator|Liquid meal replacement|Intervention: LMR LCD
3258490|NCT00779558|Active Comparator|Study drug|Heparin sulfate infusion at 10 units/kg/hour
3258491|NCT00779558|Placebo Comparator|Placebo|Placebo - normal saline infusion
3258492|NCT00779545|Placebo Comparator|Placebo|The placebo group was divided into 3 groups receiving 1, 2 or 4 sprays/nostril. The regimen of each placebo group was BID
3258493|NCT00779545|Experimental|Mometasone furoate nasal spray 100 mcg QD|
3258494|NCT00779545|Experimental|Mometasone furoate nasal spray 200 mcg QD|
3258495|NCT00779545|Experimental|Mometasone furoate nasal spray 400 mcg QD|
3258496|NCT00779545|Experimental|Mometasone furoate nasal spray 100 mcg BID|
3258497|NCT00779545|Experimental|Mometasone furoate nasal spray 200 mcg BID|
3258498|NCT00779532|Active Comparator|Group A|"Once daily intake (orally) of 5 NOMAC-E2 placebo tablets from Day -1 to Day 14.~Once daily intake (orally) of one moxifloxacin placebo capsule at Day -1.~Once daily intake (orally) of one moxifloxacin capsule of 400 mg at Day 14."
3258499|NCT00779532|Experimental|Group B|"Once daily intake (orally) of 4 NOMAC-E2 placebo tablets and 1 NOMAC-E2 (2.5/1.5 mg) tablet from Day 1 to Day 14.~Once daily intake (orally) of 5 NOMAC-E2 placebo tablets and 1 moxifloxacin placebo capsule at Day -1.~Once daily intake (orally) of 1 moxifloxacin placebo capsule at Day 14."
3258500|NCT00779532|Experimental|Group C|"Once daily intake (orally) of 5 NOMAC-E2 (2.5/1.5 mg) tablets from Day 1 to Day 14.~Once daily intake (orally) of 5 NOMAC-E2 placebo tablets and 1 moxifloxacin placebo capsule at Day -1.~Once daily intake (orally) of 1 moxifloxacin placebo capsule at Day 14"
3258501|NCT00779532|Placebo Comparator|Group D|"Once daily intake (orally) of 5 NOMAC-E2 placebo tablets from Day -1 to Day 14.~Once daily intake (orally) of 1 moxifloxacin placebo capsule at Days -1 and 14."
3258502|NCT00779519|Placebo Comparator|Placebo|
3258503|NCT00779519|Experimental|TTP435|
3258504|NCT00779506|Experimental|Quetiapine Fumarate XR|Seroquel XR 400-800mg
3258505|NCT00779493|Active Comparator|A|Curcumin 900mg twice daily by mouth
3258506|NCT00779493|Placebo Comparator|B|Placebo capsule to be made by Swanson Vitamins to simulate the capsule.
3258507|NCT00779480|Experimental|KW-2449|Sequential dose escalation in separate cohorts of 3+3 design from 450 mg/day to 800 mg/day total daily dose.
3258508|NCT00779467|Experimental|Bupivacaine with Neostimgine 8 mcg/ml|STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
3258509|NCT00779467|Experimental|Bupivacaine and Neostigmine 4 mcg/ml|STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
3258510|NCT00779467|Experimental|Bupivacaine with Neostigmine 2 mcg/ml|STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
3258511|NCT00779467|Active Comparator|BUPIVACAINE WITH FENTANYL 2 MCG/ML|Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
3258512|NCT00779454|Other|KRAS wildtype|
3258513|NCT00779454|Other|KRAS mutation|Inclusion has been completed in the KRAS mutation arm.
3258514|NCT00779441|Experimental|1|Zolpidem 10mg tablets of ranbaxy
3258515|NCT00779441|Active Comparator|2|AmbienÂ® 10mg tablets
3258516|NCT00779428|Experimental|A1|
3258517|NCT00779415||Partial Rotator Cuff Tear|Patients who presented from 1/1/02 to 12/31/06 to Hershey Medical Center with complaint of shoulder pain and were treated by the Orthopaedic Department
3258518|NCT00779402|Experimental|Sipuleucel-T|Subjects received infusion of Sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
3258519|NCT00779402|Placebo Comparator|Control|Subjects received infusion of control (autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen) at 2-week intervals, for a total of 3 infusions.
3258520|NCT00779389|Experimental|Arm A|Erlotinib 150 mg
3258521|NCT00779389|Experimental|Arm B|Dasatinib + placebo
3258522|NCT00779389|Experimental|Arm C|Erlotinib (150 mg) plus Dasatinib (100 mg) for 14-21 days.
3258523|NCT00779389|Placebo Comparator|Arm D|Placebo for 14-21 days
3258524|NCT00779376|Experimental|1|Zidovudine 300mg tablets of Ranbaxy
3258525|NCT00779376|Active Comparator|2|Retrovir ®) 300 mg Zidovudine tablets of Glaxosmithkline
3258526|NCT00779363|Experimental|Implanted Device|
3258527|NCT00779350|Experimental|1|sertraline 100 mg tablets of ranbaxy
3258528|NCT00779350|Active Comparator|2|Zoloft® 100 mg tablets
3258529|NCT00779337|Experimental|Single group study|Autologous AdE1- Latent Membrane Protein (LMP) Cytotoxic T Lymphocytes.
3258530|NCT00779324|Experimental|Amantadine|Amantadine 100 mg every morning and Noon
3258531|NCT00779324|Placebo Comparator|Placebo|Placebo tablets
3258532|NCT00779311|Experimental|Experimenal|All eligible patients will receive the mFOLFOX6 regimen at full dose followed by IV bevacizumab 5mg/kg on Day 1 of each treatment cycle. Sorafenib will be administered daily throughout treatment beginning on day 1
3258533|NCT00779298||Healthy subjects|Healthy subjects, without symptoms or a prior history of gastrointestinal disease, abdominal surgery or diabetes mellitus
3258757|NCT00777933|Active Comparator|cyclosporine|
3258534|NCT00779285|Experimental|Single-arm|Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles
3258535|NCT00779272||1|Without preoperative chemotherapy
3258536|NCT00779272||2|With preoperative chemotherapy
3258537|NCT00779259|Active Comparator|Theophylline alone|baseline theophylline pharmacokinetics
3258538|NCT00779259|Active Comparator|Quinine alone|baseline quinine pharmacokinetics at steady state
3258539|NCT00779259|Experimental|Theophylline with steady state quinine|Theophylline pharmacokinetics in the presence of steady state quinine and quinine pharmacokinetics in the presence of theophylline.
3258540|NCT00779246|Active Comparator|1|Active surveillance cultures (ASC) (via nasal swabs) will be performed for all patients admitted to the medical intensive care unit (ICU) during the designated study period. All patients will be placed in contact isolation until nasal swabs return negative; otherwise will remain in isolation.
3258541|NCT00779246|Active Comparator|2|Chlorhexidine gluconate (CHG) cloths will be used to bathe patients daily instead of standard soap and water. Active surveillance cultures (ASC) will also be used in this arm, but results will be blinded and not used to determine whether patients should be in contact isolation.
3258542|NCT00779233|Experimental|1|Zidovudine tablets 300 mg of Ranbaxy
3258543|NCT00779233|Active Comparator|2|RETROVIR ® 300 mg tablets (GlaxoSmithKline)
3258544|NCT00779220|Placebo Comparator|1|
3258545|NCT00779220|Experimental|2|
3258546|NCT00779220|Experimental|3|
3258547|NCT00779220|Experimental|4:|
3258548|NCT00779207|Experimental|1|weight loss
3258549|NCT00779207|Experimental|2|Weight loss and exercise
3258550|NCT00779194|Experimental|1|SLE subjects receiving the study drug, Rapamune.
3258551|NCT00779194|No Intervention|2|Healthy control group donating blood for the main study.
3258552|NCT00779194|No Intervention|3|SLE subjects donating blood for Genetic sub-study
3258553|NCT00779194|No Intervention|4|Healthy control subjects donating blood for the Genetic sub-study
3258554|NCT00779181|Experimental|ADX415 (high dose)|A high dose of ADX415
3258555|NCT00779181|Experimental|ADX415 (mid level dose)|A mid level dose of ADX415
3258556|NCT00779181|Experimental|ADX415 (low dose)|A low dose of ADX415
3258557|NCT00779181|Placebo Comparator|Placebo|
3258558|NCT00779168|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive white button mushroom extract PO twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
3258559|NCT00779155|Placebo Comparator|Inactive Resonator Therapy|Inactive magnetic resonance therapy
3258560|NCT00779155|Active Comparator|Active Resonator Therapy|active magnetic resonance therapy
3258561|NCT00779142|Other|Methotrexate 25mg/ml|Methotrexate intravenous 25mg/ml: Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose to subjects with diabetic macular edema resistant to conventional therapies.
3258562|NCT00779129|Experimental|Single Arm|Caelyx 35 mg/m2 and Cyclophosphamide 600 mg/m2
3258563|NCT00779116|Active Comparator|RediTab/Zyrtec|Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
3258564|NCT00779116|Active Comparator|Zyrtec/RediTab|Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.
3258565|NCT00779103|Experimental|Histrelin Subcutaneous Implant (50 mg)|Subcutaneous implant designed to deliver histrelin continously for 12 months.
3258566|NCT00779090|Experimental|Group A_RM|Patients with FRC after open endotracheal suctioning of more than 94% of baseline randomized to receive an alveolar recruitment manoeuvre.
3258567|NCT00779090|No Intervention|Group A_NRM|Patients with FRC after open endotracheal suctioning of more than 94% of baseline randomized to receive no alveolar recruitment manoeuvre.
3258568|NCT00779090|Experimental|Group B_RM|Patients with FRC after open endotracheal suctioning of less than 94% of baseline randomized to receive an alveolar recruitment manoeuvre.
3258569|NCT00779090|No Intervention|Group B_NRM|Patients with FRC after open endotracheal suctioning of less than 94% of baseline randomized to receive no alveolar recruitment manoeuvre.
3258570|NCT00779077||cystic fibrosis|adults and children with cystic fibrosis
3258571|NCT00779064|Experimental|Arm 1|
3258572|NCT00779064|Experimental|Arm 2|
3258573|NCT00779051|Experimental|1|Zolipidem 10mg tablets of Ranbaxy
3258574|NCT00779051|Active Comparator|2|Ambien® 10mg tablets
3258575|NCT00779038|Experimental|Fentanyl ITS|40 microgram (mcg) per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an Iontophoretic Transdermal System (ITS). Total duration of treatment will be 72 hours.
3258576|NCT00779025|Active Comparator|MINE Alone|Female Personal Lubricant (PD-F-5254)
3258577|NCT00779025|Experimental|YOURS and MINE|Male Personal Lubricant (10855-096) used in conjunction with Female Personal Lubricant (PD-F-5254)
3258578|NCT00779012|Experimental|Remicade|
3258579|NCT00778999|Active Comparator|Oral Contraceptive|Use of oral contraceptive pills prior to controlled ovarian stimulation
3258580|NCT00778999|No Intervention|Non-Oral Contraceptive|No use of oral contraceptive pills prior to controlled ovarian stimulation
3258581|NCT00778986|Experimental|remote monitoring|group of patients that will be using the heart failure remote patient monitoring system in addition to the usual care they receive at the University Health Network Heart Failure Clinic
3258582|NCT00778986|No Intervention|control|group of patients provided with usual care at the University Health Network Heart Failure Clinic
3258583|NCT00778973|Experimental|1|sertraline 100 mg tablets of Ranbaxy
3258584|NCT00778973|Active Comparator|2|Zoloft® 100 mg tablets
3258585|NCT00778960|Experimental|Slow Breathing Group|
3258586|NCT00778960|Experimental|Meditation Group|
3258587|NCT00778960|Experimental|Meditation and Slow Breathing Group|
3258588|NCT00778960|Placebo Comparator|Sitting Quietly Group|
3258589|NCT00778947|Active Comparator|1|
3258593|NCT00778921|Experimental|Aliskiren/Amlodipine 150/10 mg|Aliskiren/Amlodipine 150/10 mg
3258594|NCT00778921|Experimental|Aliskiren/Amlodipine 300/10 mg|Aliskiren/Amlodipine 300/10 mg
3258595|NCT00778908|Experimental|A|Late-course accelerated hyperfractionated IMRT with concomitant cisplatin chemotherapy
3258596|NCT00778908|Other|B|Conventionally fractionated IMRT with concomitant cisplatin chemotherapy
3258597|NCT00778895|Experimental|Fluviral F1 Group|Subjects 6 months to 3 years of age received if primed, 1 dose of formulation 1 of Fluviral vaccine at Day 0 and if unprimed, 2 doses of formulation 1 of Fluviral vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
3258598|NCT00778895|Experimental|Fluviral F2 Group|Subjects 6 months to 3 years of age received if primed, 1 dose of formulation 2 of Fluviral vaccine at Day 0 and if unprimed, 2 doses of formulation 1 of Fluviral vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
3258599|NCT00778895|Active Comparator|Vaxigrip Group|Subjects 6 months to 3 years of age received if primed, 1 dose of Vaxigrip vaccine at Day 0 and if unprimed, 2 doses of Vaxigrip vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
3258600|NCT00778882|Experimental|VM106|
3258601|NCT00778869|Experimental|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
3258602|NCT00778856|Experimental|Hand Transplant|
3258603|NCT00778843|Experimental|Viusid|
3258604|NCT00778843|Placebo Comparator|Placebo|Placebo three oral sachets daily during 24 weeks
3258605|NCT00778830|Experimental|Cetuximab plus FOLFIRI|
3258606|NCT00778830|Experimental|Cetuximab plus FOLFOX|
3258607|NCT00778817|Experimental|Arm II (Mitotane + IMC-A12)|Patients receive mitotane as in arm I and anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once every 2 weeks in the absence of disease progression or unacceptable toxicity.
3258608|NCT00778804|Experimental|telemedicine|Web-based monitoring in addition to usual clincial care with quarterly visits
3258609|NCT00778804|No Intervention|Control|Ususal care with quarterly visits
3258610|NCT00778791|Experimental|1|metformin HC1 750 mg extended-release tablets
3258611|NCT00778791|Experimental|2|Glucophage® XR 750 mg tablets
3258612|NCT00778778|Experimental|1|Cefprozil 500mg tablets of ranbaxy
3258613|NCT00778778|Active Comparator|2|CEFZIL ® 500 mg cefprozil tablets of BMS, USA
3258614|NCT00778778|Active Comparator|3|CEFZIL ® 500 mg tablets, BMS Canada
3258615|NCT00778765|Experimental|1|400 mg Gabapentin Capsules of Ranbaxy
3258616|NCT00778765|Active Comparator|2|Neurontin® 400 mg Gabapentin Capsules
3258617|NCT00778752|Experimental|A|"Lenalidomide-treatment starts between 100 and 180 days after allogeneic stem cell transplantation. Three dose-levels will be investigated.~Dose-level -1: 2.5 mg/d if 2.5mg capsules are available, day 1-21, otherwise 5 mg every other day, day 1-21~Dose-level 0: 5 mg/d, day 1-21~Dose-level 1: 10 mg/d, day 1-21~Dose-level 2: 15 mg/d, day 1-21"
3258618|NCT00778739|Experimental|1|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
3258619|NCT00778739|Active Comparator|2|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
3258620|NCT00778726|Experimental|1|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets of Ranbaxy
3258621|NCT00778726|Active Comparator|2|Lotensin® HCT tablets
3258622|NCT00778713|Experimental|1|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets of Ranbaxy laboratories Limited
3258623|NCT00778713|Active Comparator|2|Monopril ® - HCT 20-12.5 mg tablets by Bristol Meyers Squibb following a single oral dose (1 x 20/12.5 mg tablet)
3258624|NCT00778700|Experimental|Treatment 1: INCB018424|INCB018424 -- 0.5 percent phosphate cream
3258625|NCT00778700|Experimental|Treatment 2: INCB018424|INCB018424 -- 1.0 percent phosphate cream
3258626|NCT00778700|Experimental|Treatment 3: INCB018424|INCB018424 -- 1.5 percent phosphate cream
3258627|NCT00778700|Placebo Comparator|Treatment 4: Placebo|Placebo cream
3258628|NCT00778674|Experimental|1|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
3258629|NCT00778674|Active Comparator|2|Lotensin® HCT tablets
3258630|NCT00778661|Experimental|1|amoxicillin 400mg + clovalunic acid 57.5mg tablets of Ranbaxy
3258631|NCT00778661|Active Comparator|2|Augmentin® tablets of glaxosmithkline
3258632|NCT00778648|Experimental|Juice Plus|
3258633|NCT00778648|Placebo Comparator|Placebo|
3258634|NCT00778622|Experimental|A1|Normal Weight by Body Weight Index
3258635|NCT00778622|Experimental|A2|Overweight by Body Weight Index
3258636|NCT00778622|Experimental|A3|Obese by Body Weight Index
3258637|NCT00778609|Experimental|Arm 1|
3258638|NCT00778609|Active Comparator|Arm 2|
3258639|NCT00778596|Experimental|Prednisolone priming|Prednisolone priming 4 weeks, then treated with telbivudine.
3258640|NCT00778596|Placebo Comparator|Placebo priming|Placebo priming for 4 weeks, then followed a telbivudine treatment for 2 years.
3258641|NCT00778583|Experimental|1|Nitrofurantoin 100 mg capsules of Ranbaxy
3258642|NCT00778583|Active Comparator|2|Macrobid 100 mg capsules
3258643|NCT00778570||ASA|Participants treated for Excimer laser vision correction using Advanced Surface Ablation (ASA).
3258644|NCT00778570||LASIK|Participants treated for Excimer laser vision correction using Laser-Assisted In Situ Keratomileusis (LASIK)
3258645|NCT00778557|Experimental|1|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL (Ranbaxy Laboratories Limited, India)
3258646|NCT00778557|Active Comparator|2|Cefzil TM (CEFPROZIL) for oral suspension equivalent to 250mg/5mL anhydrous, cefprozil (Bristol-Myers Squibb Company, New Jersey USA)
3258647|NCT00778557|Active Comparator|3|Cefzil TM (CEFPROZIL) for oral suspension equivalent to 250mg/5mL anhydrous, cefprozil (Bristol-Myers Squibb Company, New Jersey USA)
3258648|NCT00778544|Experimental|1|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension of Ranbaxy
3258649|NCT00778544|Active Comparator|2|Augmentin ES-600
3258758|NCT00777933|Experimental|Tacrolimus|
3258650|NCT00778531|Other|single-arm study|This study was a multi-center, open-label, post-approval study
3258651|NCT00778518|Active Comparator|1|low dose
3258652|NCT00778518|Active Comparator|2|Medium dose
3258653|NCT00778518|Active Comparator|3|High Dose
3258654|NCT00778505|Experimental|1|closed-loop administration of propofol and remifentanil using bispectral index as the controller
3258655|NCT00778505|Active Comparator|2|manual administration of propofol and remifentanil according to bispectral index values
3258656|NCT00778492||No Treatment|Patients with the history of ingestion of aspirin and/or ADP receptor antagonist (clopidogrel or ticlopidine) for at least 7 days prior the surgery. All patients undergoing cardiac surgery with the use of cardiopulmonary bypass on elective and urgent basis.
3258657|NCT00778479|Experimental|Sepraspray|Receive Sepraspray
3258658|NCT00778479|No Intervention|Control|no treatment
3258659|NCT00778466|Experimental|1|metformin hydrochloride 1000 mg tablets of ranbaxy
3258660|NCT00778466|Active Comparator|2|GLUCOPHAGE® (metformin hydrochloride) 1000 mg tablets
3258661|NCT00778453|Experimental|Hospital-based mCIT|Hospital-based modified constraint-induced therapy(mCIT)
3258662|NCT00778453|Experimental|Hospital-based BIT|Hospital-based bilateral isokinematic training (BIT)
3258663|NCT00778453|Experimental|Hospital-based TR|Hospital-based traditional rehabilitation (TR)
3258664|NCT00778453|Experimental|Home-based BAT|Home-based bilateral arm training(BAT)
3258665|NCT00778453|Experimental|Home-based TR|Home-based traditional rehabilitation (TR)
3258666|NCT00778453|Experimental|Home-based mCIT|Home-based modified constraint-induced therapy (mCIT)
3258667|NCT00778427|Experimental|1|metformin hydrochloride 1000 mg tablets of Ranbaxy
3258668|NCT00778427|Active Comparator|2|GLUCOPHAGE® (metformin hydrochloride) 1000 mg tablets
3258669|NCT00778414|Experimental|1|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension of ranbaxy
3258670|NCT00778414|Active Comparator|2|Augmentin ES - 600
3258671|NCT00778401|Experimental|1|Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited
3258672|NCT00778401|Active Comparator|2|Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd.
3258673|NCT00778388|Active Comparator|IC43 50|IC43 50 mcg with AI(OH)3
3258674|NCT00778388|Active Comparator|IC43 100 with|IC43 100 mcg with AI(OH)3
3258675|NCT00778388|Active Comparator|IC43 100 w/o|IC43 100 mcg w/o AI(OH)3
3258676|NCT00778388|Active Comparator|IC43 200|IC43 200 mcg with AI(OH)3
3258677|NCT00778388|Placebo Comparator|Placebo|Placebo (0,9% NaCl)
3258678|NCT00778375|Experimental|Clofarabine + Cytarabine + Decitabine|Clofarabine 20 mg/m^2 by vein (IV) as a 1- to 2-hour intravenous infusion daily for 5 days. Cytarabine 20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions. Decitabine 20 mg/m^2 as a 1- to 2-hour infusion daily for 5 days.
3258679|NCT00778362||Splenectomy|all patients received splenectomy (patient list will be applied from Dept. of Pathology) at National Taiwan University Hospital in the last 20 years.
3258680|NCT00778349|Experimental|1|Metformin solution 100 mg/mL under fasting condition
3258681|NCT00778349|Experimental|2|Metformin solution 100 mg/mL, after low fat meal
3258682|NCT00778349|Experimental|3|Metformin solution 100 mg/mL, after high fat meal
3258683|NCT00778336||Limb Ischemia|Patients presenting with limb ischemia for treatment
3258684|NCT00778336||Deep Vein Thrombosis|Patients presenting with deep vein thrombosis for treatment
3258685|NCT00778336||Hemodialysis Access|Patients presenting with thrombosed hemodialysis access for treatment
3258686|NCT00778336||Other Thrombotic Conditions|Patients presenting with thrombosed conditions other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment.
3258687|NCT00778323|Experimental|A,2, II|
3258688|NCT00778310|Experimental|Concerta|The subject will be administered their usual dose of Concerta the morning of the FMRI scan in a double blind fashion
3258689|NCT00778310|Placebo Comparator|Placebo|The subject will be administered a placebo the morning of the FMRI scan in a double blind fashion
3258690|NCT00778297|Experimental|Group 1|
3258691|NCT00778297|Active Comparator|Group 2|
3258692|NCT00778284|Experimental|1|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets of Ranbaxy
3258693|NCT00778284|Active Comparator|2|Augumentin chewable tablets of Glaxosmithkline
3258694|NCT00778271|Experimental|1|Gabapentin 400mg capsules
3258695|NCT00778271|Active Comparator|2|Neurontin® 400 mg capsules
3258696|NCT00778258|Experimental|Milk-allergic; Non-consumption|Subjects in this arm reacted to the lowest baseline dose of baked milk (muffin) and will continue strict milk avoidance, returning for re-evaluation with laboratory tests at 12 and 24 months and baked milk challenge at 36 months. Individual participants may be challenged at 12 and or 24 months.
3258697|NCT00778258|Experimental|Tolerated Muffin, Reacted to Pizza|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin but react to ingesting the amount of baked milk in a standardized portion of pizza. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
3258698|NCT00778258|Experimental|Reacted to Rice Pudding|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin and a standardized portion of pizza but react to a standardized dose of baked milk in rice pudding. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
3258699|NCT00778258|Experimental|Reacted to Non-baked Milk|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin, pizza and rice pudding but react to a standardized dose of non-baked milk. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
3258756|NCT00777946|Active Comparator|Aliskiren 300 mg|Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.
3258700|NCT00778258|Experimental|Tolerant to Baked and Non-baked Milk|"Biological/Vaccine: Baked Milk At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.~Biological/Vaccine: Non-baked Milk Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk."
3258701|NCT00778258|No Intervention|Non-Interventional Comparison|Thirty subjects who fulfill inclusion criteria but are unwilling to participate in the full protocol will be enrolled as a comparison group to the active arms.
3258702|NCT00778245|Experimental|1|cefprozil 500mg tablets of Ranbaxy
3258703|NCT00778245|Active Comparator|2|CEFZIL ® 500 mg tablets of Bristol-Myers Squibb Company, USA
3258704|NCT00778232|Experimental|1|Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited
3258705|NCT00778232|Active Comparator|2|Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd
3258706|NCT00778219||A|Patients needing intubation of single lumen tracheal tube and performed using laryngoscope
3258707|NCT00778219||B|Patients needing intubation of single lumen tracheal tube and performed using lightwand
3258708|NCT00778219||C|Patients needing intubation of double lumen endobronchial cath and performed using laryngoscope
3258709|NCT00778206||1. PKUDOS Registry|Patients with a confirmed diagnosis of Phenylketonuria (PKU) with hyperphenylalaninemia who have either received Kuvan therapy, or currently receive Kuvan therapy, or intend to begin receiving Kuvan therapy within 90 days of entering the registry.
3258710|NCT00778206||2. PKU MOMS Subregistry|Patients with PKU who are pregnant at enrollment in the registry or who become pregnant while participating in the registry.
3258711|NCT00778193|Placebo Comparator|Placebo|
3258712|NCT00778193|Active Comparator|Naproxen|
3258713|NCT00778193|Experimental|Aspirin|
3258714|NCT00778193|Experimental|Clopidogrel|
3258715|NCT00778193|Experimental|Celecoxib|
3258716|NCT00778180|Experimental|1|furosemide 80 mg tablets of Ranbaxy
3258717|NCT00778180|Active Comparator|2|Lasix® (furosemide) 80 mg tablets
3258718|NCT00778167|Experimental|Arm I (Enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO once daily on days 1-21. Patients with documented disease progression may cross over and receive treatment on arm II.
3258719|NCT00778167|Experimental|Arm II (Enzyme inhibitor and monoclonal antibody therapy)|Patients receive erlotinib hydrochloride PO as in arm I and cixutumumab IV over 1 hour on days 1, 8, and 15.
3258720|NCT00778154||Alendronate 3 to < 5 years|Alendronate (any combination of 10 mg daily or 70 mg once weekly) 3- 5 years.
3258721|NCT00778154||Risedronate 3 to < 5 Years|Risedronate (any combination of 5 mg daily or 35 mg once weekly) 3-5 years.
3258722|NCT00778154||Alendronate ≥ 5 Years|Alendronate (any combination of 10 mg daily or 70 mg once weekly) for greater than or equal to 5 years.
3258723|NCT00778154||Risedronate ≥ 5 Years|Risedronate (any combination of 5 mg daily or 35 mg once weekly) for greater than or equal to 5 years.
3258724|NCT00778141|Experimental|1|metformin HC1 750 mg extended-release tablets
3258725|NCT00778141|Active Comparator|2|Glucophage® XR 750 mg tablets
3258726|NCT00778128|Experimental|1|"Step 1: Dose escalation - oral CP-4126~Step 2: Oral CP-4126 on day 1 and 15 in a 4 week schedule. One dose (only) gemcitabine IV on day 8."
3258727|NCT00778128|Experimental|2|"Step 1: Dose escalation - oral CP-4126~Step 2: Oral CP-4126 on day 8 and 15 in a 4 week schedule. One dose (only) gemcitabine IV on day 1."
3258728|NCT00778115|Experimental|1|Loperamide HCl 2 mg and simethicone 125 mg tablets of ranbaxy
3258729|NCT00778115|Active Comparator|2|Imodium® Advanced caplets
3258730|NCT00778102|Experimental|1|
3258731|NCT00778102|Active Comparator|2|
3258732|NCT00778076|Active Comparator|HAG|Patients that will receive a Hyaluronic acid treatment course consisting of 3 consecutive injections one week apart.
3258733|NCT00778076|Placebo Comparator|PG|Those patients that receive 3 consecutive placebo injections one week apart.
3258734|NCT00778063|Placebo Comparator|saline|intranasal saline will be given 30 minutes prior to surgery
3258735|NCT00778063|Experimental|dexmedetomidine|2 mcg/kg dexmedetomidine will be given intranasally 30 minutes prior to surgery
3258736|NCT00778050|Experimental|1|amoxicillin tablets for oral suspension 600 mg by Ranbaxy Laboratories Limited
3258737|NCT00778050|Active Comparator|2|Amoxil ® for oral suspension 400 mg/ 5 mL by SmithKline Beecham Pharmaceuticals (600mg dose)
3258738|NCT00778037|Experimental|1|Cyclobenzaprine hydrochloride 10 mg tablet of ranbaxy
3258739|NCT00778037|Active Comparator|2|Flexeril® 10 mg tablets
3258740|NCT00778024|Experimental|1|fluoxetine HCL 40 mg capsules of ranbaxy
3258741|NCT00778024|Active Comparator|2|PROZAC® 40 mg capsules
3258742|NCT00778011|Active Comparator|1|
3258743|NCT00778011|Active Comparator|2|
3258744|NCT00778011|Active Comparator|3|
3258745|NCT00777998|Experimental|A|Auto-Allo Tandem Stem cell Transplantation plus maintenance therapy with Thalidomide and DLI
3258746|NCT00777998|Active Comparator|B|Auto-Auto Tandem stem cell Transplantation plus maintenance therapy with Thalidomide
3258747|NCT00777985|Experimental|1|
3258748|NCT00777985|Active Comparator|2|
3258749|NCT00777972|Experimental|1|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets by Ranbaxy Laboratories Limited
3258750|NCT00777972|Active Comparator|2|Monopril ®.-HCT 20-12.5 mg tablets by Bristol-Meyers Squibb following a single oral dose (1 x 20-12.5 mg tablet
3258751|NCT00777959|Experimental|Open Label|ridaforolimus (MK8669)+ bicalutamide
3258752|NCT00777959|Experimental|Ridaforolimus|ridaforolimus (MK8669)+ bicalutamide
3258753|NCT00777959|Placebo Comparator|Placebo|Placebo + bicalutamide
3258754|NCT00777946|Experimental|Aliskiren 300 mg/Amlodipine 5 mg|Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.
3258755|NCT00777946|Experimental|Aliskiren 300 mg/Amlodipine 10 mg|Participants received 1 Aliskiren/Amlodipine 300/10 mg tablet + 1 Placebo to Aliskiren tablet orally once daily in the morning for 8 weeks.
3258759|NCT00777920|Experimental|Ambrisentan|Participants will receive ambrisentan 5 mg or 10 mg once daily.
3258760|NCT00777907|Active Comparator|Coil embolization|Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed. Stents are not allowed in this arm.
3258761|NCT00777907|Experimental|Pipeline|Placement of 1 or more Pipeline Embolization Device(s)(PED) into the parent artery at the target aneurysm.
3258762|NCT00777894|Experimental|Radiation: 3-dimensional conformal radiation therapy|
3258763|NCT00777868|Experimental|1|
3258764|NCT00777868|Experimental|2|
3258765|NCT00777868|Experimental|3|
3258766|NCT00777868|Placebo Comparator|4|
3258767|NCT00777855|Experimental|warfarin then warfarin plus rifampin|
3258768|NCT00777842|Experimental|1|Device
3258769|NCT00777829|Experimental|Low-dose sodium oxybate|
3258770|NCT00777829|Experimental|High-dose sodium oxybate|
3258771|NCT00777829|Experimental|Low-dose zolpidem|
3258772|NCT00777829|Experimental|High-dose zolpidem|
3258773|NCT00777829|Placebo Comparator|Placebo|
3258774|NCT00777816|Active Comparator|1|
3258775|NCT00777816|Placebo Comparator|2|
3258776|NCT00777803|Experimental|IncobotulinumtoxinA (Xeomin®/Bocouture®)|IncobotulinumtoxinA (Xeomin®/Bocouture®), 24 units; mode of administration: intramuscular injection.
3258777|NCT00777803|Active Comparator|OnabotulinumtoxinA (Vistabel®)|OnabotulinumtoxinA (Vistabel®), 24 units; mode of administration: intramuscular injection.
3258778|NCT00777790|Experimental|Menactra® Group|Received Menactra® vaccine in Study MTA02
3258779|NCT00777790|Experimental|Menomune® Group|Received Menomune® vaccine in Study MTA02
3258780|NCT00777790|Experimental|Control Group|Meningococcal vaccine-naïve Control Group.
3258781|NCT00777777|Experimental|1|Either the Circumflex Coronary Artery or the Right Coronary Artery will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
3258782|NCT00777764|Experimental|Healthy Volunteers|Healthy participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and 1:1000, 1:100, 1:10 dilution and full concentrations of both omalizumab and omalizumab excipients.
3258783|NCT00777764|Experimental|Allergic Asthma Participants|Allergic asthma participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and a succession of 1:1000, 1:100, 1:10 dilutions and full concentration of both omalizumab and omalizumab excipients.
3258784|NCT00777738|Experimental|bortezomib|bortezomib
3258785|NCT00777725||1|Chronic stable left sided HF patients
3258786|NCT00777725||2|Predominant right sided HF patients secondary to valvular heart disease, pulmonary artery hypertension (PAH), chronic obstructive pulmonary disease (COPD), or thrombotic disease and etc
3258787|NCT00777725||3|Acute decompensated left sided heart failure patients who have volume overload and have been admitted for diuresis
3258788|NCT00777725||4|Control subjects with no evidence of heart disease.
3258789|NCT00777712||Diabetics (HbA1c level >8%) with infection|Poorly controlled diabetes in patients with HbA1c level >8% who have wound (s) 4 weeks or longer with infection. N=50
3258790|NCT00777712||Normoglycemic- with infection|Non-Diabetic patients with wound(s) 4 weeks or longer with infection. N=50
3258791|NCT00777712||Diabetics (HbA1c level >8%) without infection|Poorly controlled diabetes in patients with HbA1c level >8% who have wound (s) 4 weeks or longer without infection. N=50
3258792|NCT00777712||Normoglycemic- without infection|Non-Diabetic patients with wound(s)4 weeks or longer without infection. N=50
3258793|NCT00777712||Diabetics (HbA1c level<8%) with infection|Patients with controlled diabetes with HbA1c level<8% who have wound (s) 4 weeks or longer and also with infection. N=50
3258794|NCT00777712||Diabetics (HbA1c level <8%) without infection|Patients with controlled diabetes with HbA1c level <8% who have wound (s) 4 weeks or longer and also without infection. N=50
3258795|NCT00777699|Experimental|1|
3258796|NCT00777686||MRI/MRS Scanning|Magnetic resonance imaging with magnetic resonance spectroscopy (MRI/MRS Scanning)
3258797|NCT00777647|Experimental|Sugar-sweetened soft drink|54g sugar/L, 180kJ/100mL
3258798|NCT00777647|Experimental|Aspartame-sweetened soft drink|1.5kJ/100mL
3258799|NCT00777647|Active Comparator|Semi-skimmed milk|202kJ/100mL
3258800|NCT00777647|Placebo Comparator|Water|0kJ/100mL
3258801|NCT00777634||Binge eating disorder (BED)|Individuals who meet criteria for binge eating disorder.
3258802|NCT00777634||Without BED|Individuals who do not meet criteria for binge eating disorder.
3258803|NCT00777621|Active Comparator|Calorie restriction|
3258804|NCT00777621|Active Comparator|Exercise|
3258805|NCT00777621|Experimental|Calorie restriction and exercise|
3258806|NCT00777608|Experimental|Donepezil 5-10 mg|There will be a 14 day period when all participants will receive placebo, followed by 5 mg donepezil, once daily for 14 days then titrated to 10 mg donepezil once daily for 70 days. Participants may then receive open-label donepezil for an additional 24 weeks.
3258807|NCT00777608|Placebo Comparator|Placebo|There will be a 14 day period when all participants will receive placebo. Participants will take placebo capsules orally, once daily for 84 days. Participants may then receive open-label donepezil for an additional 24 weeks.
3258808|NCT00777595|Experimental|Treatment A|Single therapeutic dose of CHF 4226 pMDI
3258809|NCT00777595|Experimental|Treatment B|Single supratherapeutic dose of CHF 4226 pMDI
3258810|NCT00777595|Placebo Comparator|Treatment C|Single dose of placebo
3258811|NCT00777595|Active Comparator|Treatment D|Single dose of moxifloxacin
3258812|NCT00777582|Experimental|Treatment A|300mg bid (twice daily) tablet dose
3258813|NCT00777582|Experimental|Treatment B|400 mg twice daily (bid) capsule dose
3258814|NCT00777582|Experimental|Treatment C|400mg bid (twice daily) tablet dose
3258815|NCT00777569|Experimental|Extra-low nicotine cigarettes|
3258816|NCT00777569|Experimental|Nicotine-free cigarettes|
3258817|NCT00777569|Active Comparator|Medicinal Nicotine|
3258818|NCT00777556|Experimental|DR-104|One tablet for emergency contraception
3258819|NCT00777543|Other|Control|The control is the wholegrain bread enriched with bran that has not been pretreated.
3258820|NCT00777543|Experimental|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
3258821|NCT00777530|Experimental|1|
3258822|NCT00777517|Other|Reference|Commercial 10 mg Lipitor formulation tablet
3258823|NCT00777517|Other|Test|Atorvastatin pediatric formulation
3258824|NCT00777504|Active Comparator|A|When PD is being determined the patient will continue with the oral angiogenesis inhibitors for 2 more weeks. After 2 weeks, an Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI). After evaluating these scans patients in group A now stop the orale angiogenesis inhibitor.
3258825|NCT00777504|Active Comparator|B|When PD is being determined the patient will continue with the oral angiogenesis inhibitors for 2 more weeks. After 2 weeks, an Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI). After evaluating these scans patients in group B continue with angiogenesis inhibitors for 2 more weeks. After these 2 weeks(so 4 weeks after inclusion) another Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI) and a FDG-PET-scan.
3258826|NCT00777491|Experimental|Arm I|Patients receive induction therapy comprising fluorouracil IV, cisplatin IV, and radiotherapy in weeks 1-4. Patients then undergo either radical cystectomy or receive consolidation therapy comprising fluorouracil IV, cisplatin IV, and radiotherapy in weeks 8-10.
3258827|NCT00777491|Experimental|Arm II|Patients receive induction therapy comprising gemcitabine hydrochloride IV and radiotherapy in weeks 1-4. Patients then undergo either radical cystectomy or receive consolidation therapy comprising gemcitabine hydrochloride IV and radiotherapy in weeks 8-10.
3258828|NCT00777465||KDIGO 0|Patients with no acute kidney injury after cardiac surgery
3258829|NCT00777465||KDIGO 1|Patients with acute kidney injury KDIGO stage 1 after cardiac surgery (Increase in SCr by ≥ 0.3 mg/dL (≥ 26.5 lmol/L) or 1.5 to 1.9 times baseline)
3258830|NCT00777465||KDIGO 2|Patients with acute kidney injury KDIGO stage 2 after cardiac surgery (2.0 to 2.9 times baseline SCr)
3258831|NCT00777465||KDIGO 3|Patients with acute kidney injury KDIGO stage 3 after cardiac surgery (3.0 times baseline or more; or increase in SCr to ≥ 4.0 mg/dL; or initiation of renal replacement therapy)
3258832|NCT00777452||1|active surveillance
3258833|NCT00777452||2|radical prostatectomy
3258834|NCT00777452||3|external beam radiotherapy
3258835|NCT00777452||4|high intensity focused ultrasound
3258836|NCT00777439|Other|Domperidone|All eligible subjects will receive domperidone in an open label, single group assignment.
3258837|NCT00777426||Thai HAD individuals (25 cases)|
3258838|NCT00777426||Thai Non-HAD individuals (25 cases)|
3258839|NCT00777426||Thai Non-infected individuals (10 cases)|
3258840|NCT00777413|Experimental|1|Minocycline 100 mg tablets of Ranbaxy
3258841|NCT00777413|Active Comparator|2|Minocin 100mg tablets
3258842|NCT00777400|Experimental|1|Efalizumab will be started on Day 0 until the end of the study at Week 24. At the end of the first week, after efalizumab is started, cyclosporine or tacrolimus will be decreased by 50% and at 2 weeks the dose of cyclosporine or tacrolimus will be completely discontinued. At 12 weeks Cellcept or myfortic will be discontinued and the patient will be converted to sirolimus for the remainder of the study.
3258843|NCT00777387|Active Comparator|1|slow-freeze
3258844|NCT00777387|Active Comparator|2|vitrification
3258845|NCT00777374|Experimental|1|Allergen containing patch
3258846|NCT00777374|Placebo Comparator|2|Placebo patch
3258847|NCT00777361|Experimental|AZD3480 iv|Single iv infusion AZD3480
3258848|NCT00777361|Experimental|Oral [14C] AZD3480|Single oral dose [14C]AZD3480
3258849|NCT00777348|Experimental|1|DSCG + Reproterol
3258850|NCT00777348|Active Comparator|2|DSCG
3258851|NCT00777348|Active Comparator|3|Reproterol
3258852|NCT00777348|Placebo Comparator|4|Placebo
3258853|NCT00777335|Experimental|Panobinostat i.v.|
3258854|NCT00777335|Experimental|Panobinostat oral|
3258855|NCT00777322|Experimental|Interventional study|Patients with known keratoconus or pellucid marginal degeneration will be invited to join the study. The study is partly a continuation in the management of patients who have had previous keratophakia, who will have near−normal or supra−physiological levels of corneal thickness. It is also intended for patients with relatively mild keratoconus who have sufficient corneal thickness to allow a limited laser ablation whilst still leaving a residual stromal bed of at least 350μ.
3258856|NCT00777309|Experimental|1|Erlotinib (150 mg) once daily plus ARQ 197 (360 mg) twice daily.
3258857|NCT00777309|Active Comparator|2|Erlotinib (150 mg) once daily plus ARQ 197 placebo twice daily
3258858|NCT00777296|Experimental|Cohort 1 - 280 mg Arikayce|Subjects in this cohort will receive 280 mg of Arikayce
3258859|NCT00777296|Placebo Comparator|Cohort 1 - Placebo|Subjects in this arm of cohort 1 will receive matching placebo
3258860|NCT00777296|Experimental|Cohort 2 - 560 mg Arikayce|Subjects in this cohort will receive 560 mg of Arikayce
3258861|NCT00777296|Placebo Comparator|Cohort 2 - Placebo|Subjects in this arm of cohort 2 will receive matching placebo
3258862|NCT00777270|Experimental|1 continuous|continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
3258863|NCT00777270|Experimental|2 interrupted|interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
3258864|NCT00777257|Experimental|Study Group A|Tdap vaccine + placebo concomitantly on Day 0; Menactra® vaccine 28 days later
3258865|NCT00777257|Experimental|Study Group B|Tdap vaccine + Menactra® vaccine concomitantly on Day 0; placebo 28 days later
3258866|NCT00777257|Experimental|Study Group C|Menactra® vaccine + placebo concomitantly on Day 0; Tdap vaccine 28 days later
3258867|NCT00777244|No Intervention|Follow-up|Arm B
3258868|NCT00777244|Experimental|Mitotane|Arm A
3258869|NCT00777231|Experimental|Sickle Cell Disease|Recipients treated with an enriched hematopoetic stem cell infusion
3258870|NCT00777231|Experimental|Non-Malignant Disorders|Recipients treated with an enriched hematopoetic stem cell infusion
3258871|NCT00777231|Experimental|Aplastic Anemia|Recipients treated with an enriched hematopoetic stem cell infusion
3258982|NCT00776438|Experimental|Study Group 2|Adult, age 18 to 40 years
3258872|NCT00777231|Experimental|Sickle Cell Disease : Extended Protocol|Recipients treated with an enriched hematopoetic stem cell infusion and Campath 1H conditioning
3258873|NCT00777218|Active Comparator|1|
3258874|NCT00777218|Active Comparator|2|
3258875|NCT00777218|Active Comparator|3|
3258876|NCT00777205|Active Comparator|Enhanced Usual Care|Patients in the enhanced usual care arm received their usual mental health care, a copy of the Depression Helpbook, and bi-weekly study mailings with depression management tips.
3258877|NCT00777205|Experimental|Telephone-based peer support|Participants in the intervention arm received usual mental health care and biweekly study mailings. In addition, they had access to a telephone platform over which they could make free calls to their peer partner for mutual peer support over a 6-month period of time.
3258878|NCT00777192||Symptoms in Colorectal Cancer|Colorectal Cancer Patients Receiving Oxaliplatin Chemotherapy
3258879|NCT00777179|Experimental|Vandetanib|
3258880|NCT00777179|Placebo Comparator|Placebo|
3258881|NCT00777166|Active Comparator|1|oxytocin 5 units
3258882|NCT00777166|Active Comparator|2|oxytocin, 10 units
3258883|NCT00777153|Experimental|Cediranib 30mg|Cediranib 30mg
3258884|NCT00777153|Other|Cediranib 20mg + lomustine|Cediranib 20mg + lomustine
3258885|NCT00777153|Active Comparator|Lomustine and Placebo Cediranib|Lomustine and Placebo Cediranib
3258886|NCT00777140|Active Comparator|1. Deferoxamine|Intravenous deferoxamine: bolus of 10mg/Kg (initiated during tPA infusion) and perfusion of 20/40/60 mg/Kg/day during 72h. Three different doses (3 steps), 15 patient in the active arm for each dose.
3258887|NCT00777140|Placebo Comparator|2. Placebo|Saline solution: Bolus and perfusion during 72h. 5 patients in the placebo arm in each step (randomization 3:1)
3258888|NCT00777127|Experimental|1|Aldara 5% Cream
3258889|NCT00777127|Active Comparator|2|Solaraze 3% Gel
3258890|NCT00777114|Experimental|All patients|
3258891|NCT00777101|Experimental|Neratinib|
3258892|NCT00777101|Active Comparator|Lapatinib plus Capecitabine|
3258893|NCT00777088|Experimental|Pipeline|Placement of Pipeline Embolization Device in the parent artery at the aneurysm location
3258894|NCT00777075|Active Comparator|L-arginine|
3258895|NCT00777075|Placebo Comparator|placebo|
3258896|NCT00777062|Experimental|1|VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6
3258897|NCT00777062|Placebo Comparator|2|Placebo injection, 380 mg injection at the start of weeks 2 and 6.
3258898|NCT00777049|Experimental|ER+ and/or PgR+ (Arm I)|Panobinostat oral 40 mg (3 times a week) given every other week as part of a 28 day cycle.
3258899|NCT00777049|Experimental|ER- and PgR- (Arm II)|Panobinostat oral 40 mg (3 times a week) given every other week as part of a 28 day cycle.
3258900|NCT00777036|Experimental|Cohort 1: Imatinib-resistant/intolerant CP-CML|"Dasatinib 60 mg/m² tablet every day (QD) [with a maximum dose of 100 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 72 mg/m² powder for oral suspension (PFSO) QD [with a maximum dose of 120 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
3258901|NCT00777036|Experimental|Cohort 2: Ph+ALL or AP- or BP-CML|"Dasatinib 80 mg/m² tablet QD [with a maximum dose of 140 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 96 mg/m² PFSO QD [with a maximum dose of 170 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
3258902|NCT00777036|Experimental|Cohort 3: Newly diagnosed, treatment naïve CP-CML|"Dasatinib 60 mg/m² tablet QD [with a maximum dose of 100 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 72 mg/m² PFSO QD [with a maximum dose of 120 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
3258903|NCT00777023|Experimental|G-ER 1200 mg|Gabapentin extended-release (G-ER) 1200 mg
3258904|NCT00777023|Experimental|G-ER 1800 mg|Gabapentin extended-release (G-ER) 1800 mg
3258905|NCT00777023|Placebo Comparator|Sugar Pill|Placebo 1200 mg or 1800 mg
3258906|NCT00777010|Active Comparator|Healthy high carbohydrate diet|Participants will follow a typical, higher carbohydrate dietary intervention with emphasis on lower glycemic carbohydrate foods and monounsaturated fatty acid consumption
3258907|NCT00777010|Experimental|Carbohydrate restricted, ketogenic diet|Paricipants will follow a carbohydrate restricted dietary intervention designed to induce ketone metabolism
3258908|NCT00776997|Other|Magnetic Sphincter Augmentation|Single-arm study: all subjects were treated with magnetic sphincter augmentation. A subject's baseline measurements prior to sphincter augmentation were compared to post-sphincter augmentation measurements. Subjects served as their own control.
3258909|NCT00776984|Experimental|tiotropium 5mcg/day|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
3258910|NCT00776984|Experimental|placebo|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
3258911|NCT00776971|Experimental|Sugar-sweetened soft drink|54g sugar/L, 180kJ/100mL
3258912|NCT00776971|Experimental|Aspartame-sweetened soft drink|1.5kJ/100mL
3258913|NCT00776971|Active Comparator|Semi-skimmed milk|202kJ/100mL
3258914|NCT00776971|Placebo Comparator|Water|0kJ/100mL
3258915|NCT00776958||Ovarian or Breast Cancer Study Registry|
3258916|NCT00776932||Knee OA|Those over the age of 50 who have frequent pain in their knee that has lasted for at least six months.
3258917|NCT00776919|Experimental|1|clindamycin / benzoyl peroxide gel
3258918|NCT00776919|Active Comparator|2|Clindamycin gel
3258919|NCT00776919|Active Comparator|3|BPO gel
3258920|NCT00776919|Placebo Comparator|4|vehicle gel
3258921|NCT00776906|Experimental|1|PTX-coated balloon
3258922|NCT00776906|Active Comparator|2|Bare balloon
3258923|NCT00776880||1|Patients assessed with ASA physical status scale
3258924|NCT00776880||2|Patients assessed with PPS scale
3258983|NCT00776438|Experimental|Study Group 3|Elderly, age 60 to 85 years
3258984|NCT00776438|Experimental|Study Group 4|Elderly, age 60 to 85 years
3258925|NCT00776867|Experimental|perifosine|This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level.
3258926|NCT00776841|Placebo Comparator|Placebo|Placebo control single dose
3258927|NCT00776841|Experimental|Dose 1|Dose 30 mg
3258928|NCT00776841|Experimental|Dose 2|Dose 100 mg
3258929|NCT00776841|Experimental|Dose 3|Dose 300 mg
3258930|NCT00776841|Experimental|Dose 4|Dose 900 mg
3258931|NCT00776841|Experimental|Dose 1 repeated|Dose 30 mg for 4 days
3258932|NCT00776841|Experimental|Dose 2 repeated|Dose high for 4 days
3258933|NCT00776828|Active Comparator|TAT|triple antiplatelet therapy : aspirin, clopidogrel and cilostazol
3258934|NCT00776828|Placebo Comparator|DAT|dual antiplatelet therapy : aspirin, clopidogrel
3258935|NCT00776802|Experimental|GCS-10|
3258936|NCT00776789|Experimental|skin to skin contact|Infants randomized to this group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. Mothers in both the groups received support for initiating breastfeeding, if required. All mothers, regardless of the group allocation, were advised to give exclusive breastfeeding to their infants during the hospital stay. They were discouraged from giving supplemental feeds to their infants unless indicated by the duty registrar. All the mothers were counseled regarding the duration of exclusive breastfeeding at the time of discharge.
3258937|NCT00776789|Experimental|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC. All mothers, regardless of the group allocation, were advised to give exclusive breastfeeding to their infants during the hospital stay. They were discouraged from giving supplemental feeds to their infants unless indicated by the duty registrar. All the mothers were counseled regarding the duration of exclusive breastfeeding at the time of discharge.
3258938|NCT00776763|Experimental|Avastin|
3258939|NCT00776750|Experimental|influenza vaccination|All participants received a standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection. The vaccine contained 15 μg hemagglutinin of each of the following influenza strains: A/ New Caledonia/20/99 (H1N1), A/ Panama/2007/99 (H3N2), and B/Shangdong/7/97, recommended by WHO as components of the influenza vaccine for the epidemic season 2003/2004.
3258940|NCT00776724|Active Comparator|1|docetaxel-epirubicin for 4 cycles before surgery
3258941|NCT00776724|Experimental|2|Tailored regimens, base on immunohistochemical study of the tumor biopsy tissue, for 4 cycles before surgery.
3258942|NCT00776698|Experimental|1|
3258943|NCT00776685|Experimental|learning to cope with your impulsivity|Cognitive-behavioural intervention targeting impulsive personality
3258944|NCT00776685|Experimental|learning to cope with your sensation seeking|cognitive behavioural intervention designed to help sensation seeking youth manage their need for stimulation and excitement.
3258945|NCT00776685|Experimental|learning to cope with your anxiety sensitivity|cognitive behavioural intervention teaching anxiety sensitive youth to manager their sensitivity to threat and anxiety.
3258946|NCT00776685|Experimental|learning to manage your negative thinking|cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
3258947|NCT00776672|Experimental|1|fosinopril sodium 40 mg tablets of Ranbaxy
3258948|NCT00776672|Active Comparator|2|Monopril® 40mg tablets
3258949|NCT00776659||Observational|
3258950|NCT00776646|Experimental|1|hydrochlorothiazide 50 mg tablet
3258951|NCT00776646|Active Comparator|2|hydrochlorothiazide 50 mg tablet
3258952|NCT00776633|Experimental|Short triple|6 weeks triple therapy
3258953|NCT00776633|Active Comparator|Long triple|6 months triple therapy
3258954|NCT00776620|Experimental|1|Glimepiride 1 MG Tablets of Ranbaxy
3258955|NCT00776620|Active Comparator|2|AMARYL® 1 mg tablets
3258956|NCT00776607|Experimental|Insulin|Insulin: NovoMix 30. Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal.
3258957|NCT00776607|Active Comparator|Tablet|Patients will progress from lifestyle modification to metformin, to metformin with Rosiglitazone and finally insulin depending on HbA1c levels.
3258958|NCT00776594|Experimental|Group 1|Androgen Deprivation Therapy Plus Bevacizumab
3258959|NCT00776594|Experimental|Group 2|Androgen Deprivation Therapy Alone
3258960|NCT00776581||1|Records regarding combined spinal-epidural analgesia (CSEA) with patient-controlled analgesia (PCA) pump
3258961|NCT00776581||2|Records regarding combined spinal-epidural analgesia with intermittent bolus injection (IBI)
3258962|NCT00776581||3|Records regarding epidural analgesia (EA) with patient-controlled pump
3258963|NCT00776581||4|Records regarding epidural analgesia with intermittent bolus injection
3258964|NCT00776568|Active Comparator|2|
3258965|NCT00776568|Experimental|1|
3258966|NCT00776555|Experimental|Vyvanse™|50mg capsule that has been emptied and made into solution
3258967|NCT00776555|Experimental|ADDERALL XR®|20mg capsule that has been emptied, crushed, and made into solution
3258968|NCT00776542|Experimental|1|Minocycline 100 mg tablets of ranbaxy
3258969|NCT00776542|Active Comparator|2|Minocin 100mg tablets
3258970|NCT00776529|Experimental|A Sensorimotor first|In each of nine sessions: first sensorimotor exercises, then strengthening exercises
3258971|NCT00776529|Experimental|B Sensorimotor & strength alternated|In each of nine sessions: Strength and sensorimotor exercises alternated
3258972|NCT00776516|Experimental|1|mirabegron alone
3258973|NCT00776516|Experimental|2|mirabegron and rifampin
3258974|NCT00776503|Experimental|B|Cytarabine 10mg/m2 day 1-14 Vorinostat 400mg/d day 1-(7 or 10 or 14)
3258975|NCT00776503|Experimental|A|Cytarabine 10mg/m2 day 1-14 Vorinostat 400mg/d day 15-(21 or 24 or 28)
3258976|NCT00776490|Experimental|1|Glimepiride 1 MG Tablets of ranbaxy
3258977|NCT00776490|Active Comparator|2|AMARYL® 1 mg tablets
3258978|NCT00776477|Experimental|1|
3258979|NCT00776477|Active Comparator|2|
3258980|NCT00776451||1|Subjects diagnosed with Dry AMD
3258981|NCT00776438|Experimental|Study Group 1|Adult, age 18 to 40 years
3258985|NCT00776425|Experimental|Epoetin Beta 150 IU/kg|Participants with solid and lymphoid malignancies will receive subcutaneous or intravenous epoetin beta at a dose of 150 IU per kg of body weight thrice weekly.
3258986|NCT00776425|Experimental|Epoetin Beta 30000 IU|Participants with lymphoid malignancies will receive subcutaneous or intravenous epoetin beta at a dose of 30000 IU once weekly.
3258987|NCT00776399|Experimental|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
3258988|NCT00776373|Experimental|Arm 1|Rapamycin in combination with High Dose Etoposide and Cytarabine (HiVAC)
3258989|NCT00776360|Experimental|oxytocin, gastric emptying|Oxytocin is given to study the gastric emptying rate
3258990|NCT00776360|Placebo Comparator|oxytocin|sodium chloride is given to study gastric emptying rate
3258991|NCT00776347|Experimental|donepezil|
3258992|NCT00776334|Experimental|1|fosinopril sodium 40 mg tablets of Ranbaxy
3258993|NCT00776334|Active Comparator|2|Monopril® 40mg tablets
3258994|NCT00776321|Placebo Comparator|1|
3258995|NCT00776321|Experimental|Eprotirome dose 1|
3258996|NCT00776321|Experimental|Eprotirome dose 2|
3258997|NCT00776295|Experimental|adeno virus vectored p53|Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes
3258998|NCT00776282|Experimental|1|loratadine 10 mg orally disintegrating tablets
3258999|NCT00776282|Active Comparator|2|loratadine 10 mg orally disintegrating tablets
3259000|NCT00776269|Experimental|argon laser|
3259001|NCT00776256|Active Comparator|1|effect of beta-glucan
3259002|NCT00776256|Active Comparator|2|effect of fructo-oligosaccharide
3259003|NCT00776256|Active Comparator|3|effect of beta-glucan and fructooligosaccharide
3259004|NCT00776256|Placebo Comparator|4|no beta-glucan nor fructooligosaccharide
3259005|NCT00776243||wDM|Early diabetes
3259006|NCT00776243||pDM|Poorly controlled diabetic patients
3259007|NCT00776230|Active Comparator|IC51 (~12 months post filling)|6 mcg (~12 months post filling)
3259008|NCT00776230|Active Comparator|IC51 (~18 months post filling)|6 mcg (~18 months post filling)
3259009|NCT00776230|Active Comparator|IC51 (~24 months post filling)|6 mcg (~24 months post filling)
3259010|NCT00776217|Experimental|1|loratadine 10 mg orally disintegrating tablets
3259011|NCT00776217|Active Comparator|2|loratadine 10 mg orally disintegrating tablets
3259012|NCT00776204|Active Comparator|1|Drug Eluting Stent
3259013|NCT00776204|Active Comparator|2|Drug Eluting Stent
3259014|NCT00776204|Active Comparator|3|Drug Eluting Stent
3259015|NCT00776191|Active Comparator|Physioneal 35 vs. 40|Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks, followed by Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks.
3259016|NCT00776191|Active Comparator|Physioneal 40 vs. 35|Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks followed by Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks
3259017|NCT00776165|Experimental|1|Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF)(Shantha) Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
3259018|NCT00776165|Active Comparator|2|Neupogen (rhG-CSF) Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
3259019|NCT00776139|Experimental|1|Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc.
3259020|NCT00776139|Experimental|2|Zyrtec® Cetirizine Hydrochloride, 10 mg tablet of Pfizer Labs
3259021|NCT00776126||1|All enrolled subjects will undergo digital breast tomosynthesis.
3259022|NCT00776113|Active Comparator|2|Carvedilol 12.5 mg tablets
3259023|NCT00776113|Experimental|1|Carvedilol 12.5 mg tablets
3259024|NCT00776100|Other|Arm I|Patients undergo observation for 6 weeks.
3259025|NCT00776100|Experimental|Arm II|Patients undergo radiotherapy 5 days a week for 6 weeks to all sites of gross disease.
3259026|NCT00776087|Experimental|1 = Home Monitoring|Remote monitoring of ICD and CRT-D function and patient status
3259027|NCT00776087|Active Comparator|2 = No Home Monitoring|Home Monitoring option is switched off
3259028|NCT00776074|Experimental|Leuprorelin (GF)|
3259029|NCT00776074|Experimental|Leuprorelin (GC)|
3259030|NCT00776048||ABI|Acquired brain injury with lower limb spasticity
3259031|NCT00776048||Healthy Controls|Age matched healthy controls
3259032|NCT00776035||heart failure|Obesity related Heart failure population
3259033|NCT00776022|Experimental|1|Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories
3259034|NCT00776022|Active Comparator|2|Cetirizine Hydrochloride 10 mg tablet of Pfizer Labs
3259035|NCT00776009|Experimental|Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg|Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg dose (one 20 mg capsule and one 10 mg capsule) orally once a day for 7 days.
3259036|NCT00776009|Active Comparator|Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg|Dex-Methylphenidate hydrochloride (Focalin® XR) one 20 mg capsule orally once a day for 7 days.
3259037|NCT00776009|Placebo Comparator|Placebo|Two Capsules taken orally once a day for 7 days
3259038|NCT00775996|Experimental|1|15 mg clorazepate dipotassium tablets of ranbaxy
3259039|NCT00775996|Active Comparator|2|(TranxeneeT-Tab®) 15 mg clorazepate dipotassium tablets
3259040|NCT00775983|Active Comparator|laminaria|laminaria placed for cervical dilation; usual standard of care in study clinic
3259041|NCT00775983|Experimental|Dilapan-S|experimental treatment
3259042|NCT00775957||1|FLT-PET Scan
3259043|NCT00775957||2|FDG-PET Scan
3259044|NCT00775944|Active Comparator|Standard support|Standard 'Together Programme' telephone support for smoking cessation & advice to obtain nicotine addiction treatment
3259102|NCT00775541|Experimental|Vitamin C|2 gms vitamin C
3259103|NCT00775528|Experimental|A|
3259045|NCT00775944|Active Comparator|Proactive telephone support|Proactive support & advice to obtain nicotine addiction treatment
3259046|NCT00775944|Active Comparator|Standard support & offer NRT|Reactive telephone support (i.e. Together Programme) and offer of voucher for cost free Nicotine Replacement Therapy
3259047|NCT00775944|Active Comparator|Proactive support & offer NRT|Proactive telephone support and offer of voucher for cost free NRT
3259048|NCT00775931|Active Comparator|marrow graft transplant conditioning|Pre-transplant conditioning using Campath-1H, Busulfan, Fludarabine monophosphate, and total lymphoid irradiation followed by unrelated or matched related donor marrow graft transplantation (both peripheral blood and marrow) and a second CD34 cell infusion on Day 42.
3259049|NCT00775931|Active Comparator|cord blood transplant conditioning|Pre-transplant conditioning using Campath-1H, Busulfan and Cyclophosphamide followed by unrelated umbilical cord blood transplantation and a second smaller portion cord blood graft infusion on Day 42.
3259050|NCT00775918|Experimental|1|Doxycycline monohydrate 100mg tablets of Ranbaxy
3259051|NCT00775918|Active Comparator|2|Adoxa ® 100 mg tablets of Bradley Pharmaceuticals Inc
3259052|NCT00775905|Experimental|1|amlodipine 10 mg tablets of Ranbaxy
3259053|NCT00775905|Active Comparator|2|Norvasc® 10 mg tablets
3259054|NCT00775879|Experimental|A|2.5% target concentration
3259055|NCT00775879|Active Comparator|B|2.5% manually selected
3259056|NCT00775866|Experimental|MRI guided prostate biopsy|
3259057|NCT00775840|Experimental|Candesartan QD + Heart Failure Therapy|(with angiotensin-converting enzyme-inhibitors/beta-blockers)
3259058|NCT00775840|Placebo Comparator|Placebo QD + Heart Failure Therapy|(with angiotensin-converting enzyme-inhibitors/beta-blockers)
3259059|NCT00775827|Experimental|1|fenofibrate 160 mg tablets of Ranbaxy Laboratories
3259060|NCT00775827|Active Comparator|2|Tricor 160 mg tablets
3259061|NCT00775814|Experimental|Candesartan + Hydrochlorothiazide QD|
3259062|NCT00775814|Active Comparator|Hydrochlorothiazide QD|
3259063|NCT00775801|Experimental|Treatment|FLD
3259064|NCT00775801|Active Comparator|Control|
3259065|NCT00775788|Experimental|Implant Failure|
3259066|NCT00775788|Experimental|Post mastectomy breast reconstruction|
3259067|NCT00775788|Experimental|Congenital malformations|
3259068|NCT00775788|Experimental|Breast Ptosis|
3259069|NCT00775788|Experimental|Micromastia|
3259070|NCT00775788|Experimental|Asymmetric Breasts|
3259071|NCT00775775||TBI|Patients with moderate to severe TBI
3259072|NCT00775762|Active Comparator|aspirin|
3259073|NCT00775762|Active Comparator|clopidogrel|
3259074|NCT00775762|Active Comparator|clopidogrel plus aspirin|
3259075|NCT00775749|Experimental|1|The nicotine patch will be applied prior to surgery and remain on the right upper back for 24 hours.
3259076|NCT00775749|Placebo Comparator|2|The placebo patch has no active ingredients and the same inactive ingredients as the nicotine patch. It will be administered the same fashion as the nicotine patch.
3259077|NCT00775736||A|
3259078|NCT00775710|Active Comparator|1|Non-invasive ventilation is maintained during three nights after recovery of an episode of hypercapnic respiratory failure.
3259079|NCT00775710|No Intervention|2|Discontinuation of NIV after the recovery of hypercapnic respiratory failure, without prolong it during night.
3259080|NCT00775697|Experimental|Montelukast|the single arm will receive montelukast
3259081|NCT00775684|Experimental|Exenatide|Exenatide (Byetta®)—5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
3259082|NCT00775684|Experimental|Sitagliptin|Sitagliptin (Januvia®)—100 mg by mouth every morning
3259083|NCT00775684|Active Comparator|Glimepiride|Glimepiride (Amaryl®)—0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose < 110mg/dl
3259084|NCT00775671|Active Comparator|Nebivolol|Nebivolol 5mg by mouth daily for 12 weeks.
3259085|NCT00775671|Active Comparator|Metoprolol|Metoprolol ER 100mg by mouth daily for 12 weeks.
3259086|NCT00775658|Active Comparator|olopatadine then placebo|participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
3259087|NCT00775658|Active Comparator|placebo then olopatadine|participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
3259088|NCT00775645|Experimental|Arm I|Patients receive oral acetyl-L-carnitine hydrochloride 3 times daily for 24 weeks.
3259089|NCT00775645|Placebo Comparator|Arm II|Patients receive oral placebo 3 times daily for 24 weeks.
3259090|NCT00775632|Active Comparator|Standard of Care|The current standard of care for GVHD prophylaxis at Princess Margaret Hospital is cyclosporine and Mycophenolate or cyclosporine and methotrexate.
3259091|NCT00775632|Experimental|Cyclosporine and Campath|The efficacy of experimental arm will be tested against standard of care for prevention of Chronic extensive GVHD.
3259092|NCT00775619|Active Comparator|2|Coreg® 12.5 mg tablets
3259093|NCT00775619|Experimental|1|Carvedilol 12.5 mg tablets
3259094|NCT00775606|Active Comparator|ARM A/Lopinar/ritonavir|Subjects randomized to Arm A initiated Lopinavir 400 mg/ritonavir 100 mg BID + emtricitabine 200 mg/tenofovir 300 mg QD
3259095|NCT00775606|Active Comparator|ARM B/Efavirenz|Subjects randomized to Arm B initiated Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg QD
3259096|NCT00775580|Experimental|1|atenolol 100 mg Capsules of Ranbaxy
3259097|NCT00775580|Active Comparator|2|Tenormin 100mg capsules
3259098|NCT00775567|Active Comparator|1|30g fructose dissolved in water twice a day
3259099|NCT00775567|No Intervention|No Intervention|
3259100|NCT00775554|Other|traditional hematoma block|people will receive traditional hematoma block for closed forearm fractures
3259101|NCT00775554|Other|ultrasound guided hematoma block|pts. will receive a hematoma block using bedside ultrasound to guide the placement
3259104|NCT00775515|Experimental|one|laparoscopic prostatectomy
3259105|NCT00775502|Experimental|BIW-8962, monoclonal antibody|
3259106|NCT00775489|Active Comparator|1|Steroid nasal spray (beclomethasone)
3259107|NCT00775489|Placebo Comparator|2|Normal saline nasal spray
3259108|NCT00775476|Active Comparator|NAC Group 1|1.2 g of NAC two times daily
3259109|NCT00775476|Active Comparator|NAC Group 2|2.4 g of NAC two times daily
3259110|NCT00775476|Placebo Comparator|Placebo|2.4 g of placebo 2 times per day
3259111|NCT00775463|Experimental|treprostinil diethanolamine|Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
3259112|NCT00775463|Placebo Comparator|placebo (sugar pill)|Matching placebo sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
3259113|NCT00775450|Experimental|Group 1a: Fluzone ID After Fluzone ID|
3259114|NCT00775450|Experimental|Group 1b: Fluzone IM After Fluzone ID|
3259115|NCT00775450|Active Comparator|Group 2a: Fluzone IM After Fluzone IM|
3259116|NCT00775450|Experimental|Group 2b: Fluzone ID After Fluzone IM|
3259117|NCT00775450|Active Comparator|Group 3: Fluzone HD After Fluzone HD|
3259118|NCT00775437|Experimental|Adalimumab|Adalimumab 24 mg/m^2 body surface area (BSA) up to a total dose of 20 mg administered every other week (eow) by parent or designee as a single dose via subcutaneous injection at approximately the same time of day, for a minimum of 24 weeks. Participants could continue in the study until age 4 and 15 kg (US and Puerto Rico) or for up to 1 additional year after reaching age 4 and 15 kg (EU). Visits beyond Week 24 occurred every 12 weeks for those participants who continued in the study.
3259119|NCT00775424|Experimental|PENNVAX-B alone|PENNVAX-B alone
3259120|NCT00775424|Experimental|PENNVAX-B+IL12|PENNVAX-B+IL12
3259121|NCT00775424|Experimental|PENNVAX-B+IL15|PENNVAX-B+IL15
3259122|NCT00775424|Placebo Comparator|PLACEBO|PLACEBO
3259123|NCT00775411|Experimental|700 µg dexamethasone and ranibizumab|700 µg dexamethasone intravitreal injection at Day 1 in the study eye. Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
3259124|NCT00775398||A|Subjects with anti-topical bovine thrombin antibodies pre-surgery, who received topical THROMBIN-JMI® during the study surgery.
3259125|NCT00775398||B|Subjects with anti-topical bovine thrombin antibodies pre-surgery, who did not received THROMBIN-JMI® during the study surgery.
3259126|NCT00775398||C|Subjects with no anti-topical bovine thrombin antibodies pre-surgery and who did receive THROMBIN-JMI® during the study surgery.
3259127|NCT00775398||D|Subjects with no anti-topical bovine thrombin antibodies pre-surgery and who did not receive THROMBIN-JMI® during the study surgery.
3259128|NCT00775385|Active Comparator|A|Standard chemotherapy
3259129|NCT00775385|Experimental|B|Customized treatment
3259130|NCT00775372|Experimental|1|clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories
3259131|NCT00775372|Active Comparator|2|Biaxin® granules 250 mg/5 mL oral suspension
3259132|NCT00775359|Experimental|1|Fenofibrate 160mg Tablets of Ranbaxy
3259133|NCT00775359|Active Comparator|2|TriCor® 160 mg Fenofibrate Tablets
3259134|NCT00775346||Polysomnography (PSG) Subjects|Subjects who have been prescribed with needing a polysomnography (PSG) will be enrolled into the study.
3259135|NCT00775333||1|Patients with diabetes and carpal tunnel syndrome
3259136|NCT00775333||2|Non-diabetic patients with carpal tunnel syndrome
3259137|NCT00775320||Brain tumor FLT-PET|Those diagnosed with a brain tumor and are to undergo surgery
3259138|NCT00775307|Placebo Comparator|B|Placebo 400 mg/day (24 weeks)
3259139|NCT00775307|Experimental|A|Pazopanib 400 mg/day (24 weeks)
3259140|NCT00775294|Experimental|maraviroc|Single arm trial looking at the pharmacokinetics of maraviroc in healthy volunteers.
3259141|NCT00775281||1|
3259142|NCT00775281||2|
3259143|NCT00775281||3|
3259144|NCT00775268|Experimental|Group A|Patients undergo 3'-deoxy-3'-[18F] fluorothymidine (FLT) and fludeoxyglucose F 18 (FDG) PET/CT scans at baseline, after 2 courses of chemotherapy, and after completion of chemotherapy. Patients with residual FDG-positive mass after completion of therapy may be enrolled in group B.
3259145|NCT00775268|Experimental|Group B|Patients undergo an FLT PET/CT scan within 2 weeks after completion of chemotherapy. Patients also undergo a biopsy or fine-needle aspiration, if clinically indicated.
3259146|NCT00775255|Experimental|1|clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories
3259147|NCT00775255|Active Comparator|2|Biaxin® granules 250 mg/5 mL oral suspension
3259148|NCT00775242|Experimental|Estradiol and progesterone injection|Comparison of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P
3259149|NCT00775229|Active Comparator|1|Naltrexone
3259150|NCT00775229|Placebo Comparator|2|Placebo
3259151|NCT00775216|No Intervention|Standard care|Standard behavioral counseling
3259152|NCT00775216|Experimental|Intervention|"Behavioral counseling intervention augmented with an interactive health promotion telephone helpline"
3259153|NCT00775203|Experimental|Trazodone Contramid Once A Day (OAD)|
3259154|NCT00775203|Placebo Comparator|Placebo|
3259155|NCT00775190|Active Comparator|Ortho tricyclen™|Participant Randomized to Ortho tricyclen 1 tablet by mouth Daily
3259156|NCT00775190|Active Comparator|Trinessa™|Participant Randomized to Trinessa 1 tablet by mouth Daily
3259157|NCT00775177|Experimental|1|Doxycycline monohydrate 100mg tablets of Ranbaxy
3259158|NCT00775177|Active Comparator|2|Adoxa ® 100mg tablets of Bradley Pharmaceuticals, Inc
3259159|NCT00775164|Experimental|pioglitazone|Pioglitazone: 15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
3259160|NCT00775164|Active Comparator|Metformin|Metformin XR; 1000 mg once daily for 16 weeks.
3259161|NCT00775151|Experimental|1|amlodipine 10 mg tablet of Ranbaxy
3259162|NCT00775151|Active Comparator|2|Norvasc® 10 mg tablets
3259195|NCT00774878|Experimental|Arm A|
3259196|NCT00774878|Active Comparator|Arm B|
3259163|NCT00775138|Experimental|Arikace at 280 mg|Subjects will be randomly assigned to study drug dose of 280mg or 560mg and then within dose group to either Arikace™ or placebo in accordance with a code provided by the Sponsor/CRO. At each dose of study drug, randomization will be made in a 2:1 allocation between Arikace™ and placebo. Thus, the final allocation among study drug levels and placebo will be 1:1:1 (Arikace™ 280mg: Arikace™ 560mg: placebo, both doses). Because of the mode of study drug delivery, study subjects will not be blinded to whether they have been assigned to the 280mg concentration or the 560mg concentration, however, they will be blinded to whether they will receive Arikace™ or placebo. Study subjects will receive Arikace™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
3259164|NCT00775138|Experimental|Arikace at 560 mg|Subjects will be randomly assigned to study drug dose of 280mg or 560mg and then within dose group to either Arikace™ or placebo in accordance with a code provided by the Sponsor/CRO. At each dose of study drug, randomization will be made in a 2:1 allocation between Arikace™ and placebo. Thus, the final allocation among study drug levels and placebo will be 1:1:1 (Arikace™ 280mg: Arikace™ 560mg: placebo, both doses). Because of the mode of study drug delivery, study subjects will not be blinded to whether they have been assigned to the 280mg concentration or the 560mg concentration, however, they will be blinded to whether they will receive Arikace™ or placebo. Study subjects will receive Arikace™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
3259165|NCT00775138|Placebo Comparator|Matching placebo (280mg or 560mg)|Subjects will be randomly assigned to study drug dose of 280mg or 560mg and then within dose group to either Arikace™ or placebo in accordance with a code provided by the Sponsor/CRO. At each dose of study drug, randomization will be made in a 2:1 allocation between Arikace™ and placebo. Thus, the final allocation among study drug levels and placebo will be 1:1:1 (Arikace™ 280mg: Arikace™ 560mg: placebo, both doses). Because of the mode of study drug delivery, study subjects will not be blinded to whether they have been assigned to the 280mg concentration or the 560mg concentration, however, they will be blinded to whether they will receive Arikace™ or placebo. Study subjects will receive Arikace™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
3259166|NCT00775112|Experimental|1|with pillow
3259167|NCT00775112|No Intervention|2|without pillow
3259168|NCT00775099|Experimental|Filtered Air Exposure|1 hour exposure to filtered air during intermittent exercise
3259169|NCT00775099|Experimental|Diesel Exhaust Exposure|1 hour exposure to dilute diesel exhaust at a concentration of 300 µg/m3 during intermittent exercise
3259170|NCT00775099|Experimental|Filtered Diesel Exposure|1 hour exposure to diesel exhaust with all particulates filtered out using teflon filter with intermittent exercise
3259171|NCT00775099|Experimental|PALAS Exposure|1 hour exposure to pure carbon particles produced by PALAS generator during intermittent exercise
3259172|NCT00775073|Experimental|Treatment|Bevacizumab (Avastin) & Everolimus (RAD001)
3259173|NCT00775047|Experimental|Pharmacy|Women receive their second and third depot-medroxyprogesterone acetate injections at the pharmacy by clinical pharmacists
3259174|NCT00775047|Active Comparator|Planned Parenthood clinic|Women receive their second and third depot-medroxyprogesterone acetate injections per usual care at their Planned Parenthood clinic.
3259175|NCT00775034|Experimental|1|Study group (Tisseel®)
3259176|NCT00775034|Other|2|Control group
3259177|NCT00775021|Active Comparator|etafilcon A/nelfilcon A|etafilcon A contact lens worn first and nelfilcon A contact lens worn second
3259178|NCT00775021|Active Comparator|nelfilcon A/etafilcon A|nelfilcon A contact lens worn first and etafilcon A contact lens second.
3259179|NCT00775008|Experimental|podcast|
3259180|NCT00775008|Active Comparator|Web group|
3259181|NCT00774995|Experimental|Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig)|Subjects who previously received HBV vaccine at 0, 1, 6 and 60 months (4 doses) and HBIg concomitantly at Month 0, and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
3259182|NCT00774995|Experimental|Engerix(3-dose)+HBIg|Subjects who previously received HBV vaccine at 0, 1, 6 months (3 doses) and HBIg concomitantly at Month 0, and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
3259183|NCT00774995|Experimental|Engerix(4-dose)|Subjects who previously received HBV vaccine at 0, 1, 6 and 60 months (4 doses) and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
3259184|NCT00774995|Experimental|Engerix(3-dose)|Subjects who previously received HBV vaccine at 0, 1, 6 months (3 doses) and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
3259185|NCT00774982|Experimental|1 6MP Test Formulation|1 x 40 mg Oral Tablet, 6 MP Delayed Release Test Formulation, for targeted ileal delivery
3259186|NCT00774982|Active Comparator|2. 6MP Reference Formulation|2 x 50 mg oral tablet, PURINETHOL
3259187|NCT00774969|Experimental|All|6 patients with Perianal Crohn's Disease and 10 healthy Volunteers
3259188|NCT00774956|Experimental|1|Subject with shoulder impingement
3259189|NCT00774956|Active Comparator|2|Healthy persons
3259190|NCT00774943|Active Comparator|AMG 557|
3259191|NCT00774943|Placebo Comparator|Placebo|
3259192|NCT00774930|Experimental|Lanreotide Autogel (Somatuline Depot) 120 mg|"Subjects received deep s.c. lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).~After completing the DB phase (or if they met criteria for early roll over [ERO]) the subjects entered the IOL phase during which they received lanreotide Autogel 120 mg deep s.c. every 4 weeks for 32 weeks. During the LTOLE phase, subjects continued treatment with lanreotide Autogel 120 mg deep s.c. every 4 weeks until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained [whichever occurred first])."
3259193|NCT00774930|Placebo Comparator|Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE|"Subjects received deep s.c. placebo every 4 weeks (±3 days) for 16 weeks (DB phase).~After completing the DB phase (or if they met criteria for ERO) the subjects entered the IOL phase during which they received lanreotide Autogel 120 mg deep s.c. every 4 weeks for 32 weeks. During the LTOLE phase, subjects continued treatment with lanreotide Autogel 120 mg deep s.c. every 4 weeks until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained [whichever occurred first])."
3259194|NCT00774917|Experimental|Numen|
3259197|NCT00774865||Surgical|Patients who have previously undergone robotic bypass surgery
3259198|NCT00774852|Experimental|Treatment|Abatacept plus Euro-lupus regimen
3259199|NCT00774852|Placebo Comparator|Control|Abatacept placebo plus Euro-lupus regimen
3259200|NCT00774839||Newly diagnosed stage II-III colon cancer 65 years or older|Medicare-eligible (≥ or = to 65 years) patients diagnosed with stage II - III colon cancer, are at least 4 months into chemotherapy and up to 7 months post-chemotherapy.
3259201|NCT00774826|Experimental|1|R-CVP x 3; Restaging if> RP then R-CVP x 5
3259202|NCT00774826|Experimental|2|R-CHOP x 3; Restaging if > RP then R-CHOP x 3 plus 2 Rituximab
3259203|NCT00774826|Experimental|3|R-FM x 3; Restaging if > RP then R-FM x 3 plus 2 Rituximab
3259204|NCT00774813|Active Comparator|A|Nexalin 1.3mA device + placebo antidepressant
3259205|NCT00774813|Active Comparator|B|Nexalin 15mA device + placebo antidepressant
3259206|NCT00774813|Placebo Comparator|C|Placebo device + SSRI (Citalopram or similar)
3259207|NCT00774800|Experimental|First Humalog+PH20, then Humalog, Humulin-R+PH20, Humulin-R|"Humalog + Recombinant human hyaluronidase PH20 (rHuPH20) (Intervention 1): 24 units (U) of rHuPH20 per unit of Humalog, injected subcutaneously (SC), for up to 3 visits until an appropriate dose was identified.~Humalog alone (Intervention 2): a single SC injection of the appropriate identified dose of Humalog, delivered before a liquid meal.~Humulin-R + rHuPH20 (Intervention 3): 24 U of rHuPH20 per unit of Humulin-R, injected SC, for up to 2 visits until an appropriate dose was identified.~Humulin-R alone (Intervention 4): a single SC injection of the appropriate identified dose of Humulin-R, delivered before a liquid meal.~Appropriate dose of either Humalog or Humulin-R was that at which blood glucose following a liquid meal was <160 milligrams per deciliter (mg/dL) for more than 30 minutes during the first 4 hours after injection and never fell below 60 mg/dL.~All dose finding visits and interventions were separated by 3-10 days."
3259208|NCT00774787|Experimental|Imiquimod, treatment, topical cream|Imiquimod 5% cream, 1 packet (250 mg cream), applied to left or right treatment area on the face and/or balding scalp
3259209|NCT00774787|No Intervention|Control, Untreated|No treatment of treatment area on the other half of the face and/or balding scalp
3259210|NCT00774774|Placebo Comparator|2|No intervention
3259211|NCT00774774|Experimental|1|Mask
3259212|NCT00774761|Experimental|1|
3259213|NCT00774761|Experimental|2|
3259214|NCT00774761|Active Comparator|3|
3259215|NCT00774761|Active Comparator|4|
3259216|NCT00774761|Active Comparator|5|
3259217|NCT00774748|Experimental|I|All participants in the study will use the subcutaneous catheter twice for a period of one week each to inject the enoxaparin. For the remainder of the study the participants will inject subcutaneously.
3259218|NCT00774735|Experimental|Sequence 1|
3259219|NCT00774735|Experimental|Sequence 2|
3259220|NCT00774722|Experimental|Metronidazole|
3259221|NCT00774722|Placebo Comparator|Placebo|
3259222|NCT00774709||1|
3259223|NCT00774696|Experimental|1|Clarithromycin 500 mg Tablets
3259224|NCT00774696|Active Comparator|2|BIAXIN® 500 mg tablets
3259225|NCT00774683||Sub-study Group A|Six HIV-positive African American women from the main study, CID 0706
3259226|NCT00774644|Experimental|1|clarithromycin 500 mg tablets of Ranbaxy Laboratories Limited
3259227|NCT00774644|Active Comparator|2|BIAXIN® 500 mg tablets containing clarithromycin 500mg tablets
3259228|NCT00774631|Experimental|Hypothermia|mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming
3259229|NCT00774631|Active Comparator|No hypothermia|no hypothermia, according to local recommendations and guidelines of medical societies and literature
3259230|NCT00774618|Experimental|Resection|Those subjects undergoing resection with or without plate fixation
3259231|NCT00774618|No Intervention|Nonoperative|These patients were not considered candidates for surgical intervention by the investigators, declined surgical intervention, or did not receive insurance approval for surgery
3259232|NCT00774605|Experimental|Varenicline free base solution|
3259233|NCT00774605|Experimental|Varenicline transdermal delivery system|
3259234|NCT00774592|Experimental|1|Focus on Youth in the Caribbean (FOYC) plus Caribbean Informed Parents and Children Together (CImPACT)
3259235|NCT00774592|Experimental|2|FOYC plus Goal For It (GFI)
3259236|NCT00774592|Active Comparator|3|Wonderous Wetlands plus GFI
3259237|NCT00774592|Experimental|Grade 10-BFOOY+CImPACT|Youth receives HIV intervention; parents receive parental monitoring intervention
3259238|NCT00774592|Experimental|Grade 10 BFOOY+GFI|Youth receive HIV prevention intervention and parents receive attention control intervention on career planning
3259239|NCT00774592|Experimental|BFOOYand no parent intervention|Youth receive HIV prevention intervention; parents receive no intervention
3259240|NCT00774592|Placebo Comparator|Health and FAmily life|Youth receive standard of care (current curriculum); parents receive no intervention
3259241|NCT00774579||1|Patients with growth hormone (GH) deficiency starting GH replacement.
3259242|NCT00774579||2|Patients with growth hormone (GH) deficiency not starting GH replacement.
3259243|NCT00774566|Active Comparator|1|segmental PVI using an irrigated tip catheter
3259244|NCT00774566|Active Comparator|2|PVI using the Cryo-Balloon
3259245|NCT00774553|Experimental|1|AZD1656
3259246|NCT00774553|Placebo Comparator|2|Placebo
3259247|NCT00774540|Experimental|1|Ketorolac
3259248|NCT00774540|Placebo Comparator|2|saline
3259249|NCT00774527|No Intervention|ArmI(CyATG)|•Conditioning therapy will start on day -5 in patients who are randomized to receive Cy+ATG. Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter
3259250|NCT00774514|Experimental|Air exposure|1 hour exposure to filtered air during intermittent exercise
3259251|NCT00774514|Experimental|NO2 exposure|1 hour exposure to nitrogen dioxide at 4ppm during intermittent exercise
3259252|NCT00774501|Experimental|treatment of metastatic liver disease|The intervention is the use of image guidance with general anesthesia and suspended ventilation during treatment delivery. This will allow precise localization and delivery of dose to the tumor.
3259396|NCT00773331|Active Comparator|2|
3259253|NCT00774475|Placebo Comparator|1: standard therapy|clopidogrel 75 mg/day
3259254|NCT00774475|Active Comparator|2: doubled therapy|clopidogrel 150 mg/day
3259255|NCT00774462|Experimental|1|
3259256|NCT00774449||1|individuals, who have undergone double (DLTx) or heart and lung transplantation (HLTx) at Hannover Medical School 6 months prior to inclusion
3259257|NCT00774436|Experimental|Patients scheduled to receive Focal Cryotherapy|After enrollment, patients will undergo a repeat transrectal ultrasound- guided prostate biopsy (minimum of 12 cores) to confirm the low-risk nature of their cancer. For study purposes, patients must meet the original entry crieteria on this repeat biopsy. If the patient meets the repeat-biopsy enrollment criteria, they will be treated with focal cryotherapy, meaning cryoablation of the regions of the prostate containing cancer. Efficacy is defined as all negative biopsy cores at the site of the focal ablation on a repeat transrectal biopsy 6 months after cryoablation. At baseline (prior to the re-staging biopsy), 3 months after focal cryotherapy, and at 6 months after focal cryotherapy (prior to the repeat prostate biopsy used to define efficacy), the patient will complete quality of life questionnaires as standard for all patients in the Urology Service.
3259258|NCT00774423|Placebo Comparator|Placebo|MAIN EXCIPIENT OF THE RILUTEK
3259259|NCT00774423|Active Comparator|Riluzole|RILUTEK
3259260|NCT00774397|Experimental|240 mg QD TN|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
3259261|NCT00774397|Experimental|240 mg QD / LI-TN|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
3259262|NCT00774397|Placebo Comparator|Placebo|Placebo once daily combined with PegIFN/RBV for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
3259263|NCT00774397|Experimental|120 mg QD / LI-TN|120 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in (LI) phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), followed by an additional 24 weeks of PegIFN/RBV in treatment naive (TN) patients
3259264|NCT00774397|Experimental|240 mg QD TE|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV in treatment experienced (TE) patients
3259265|NCT00774397|Experimental|240 mg QD / LI-TE|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-experienced (TE) patients
3259266|NCT00774397|Experimental|240 mg BID / LI-TE|240mg BI 201335 NA (Faldaprevir) twice daily combined with PegIFN/RBV for 24 or 48 weeks, with 3-day lead-in phase of PegIFN/RBV, in treatment-experienced patients
3259267|NCT00774384|Active Comparator|1|Immunisation with NZ MenB OMV vaccine (NZ98/254)
3259268|NCT00774384|No Intervention|2|No vaccine
3259269|NCT00774371|Experimental|1|The intervention program consists of group sessions provided according to the following schedule: weekly for 4 months, every other week for two months, and follow-up monthly sessions through 18 months of active subject participation. The time points for data collection from all subjects are baseline, 6 months, and 18 months. The group sessions offered to the treatment study arm are closed-group contingents with an average of 12-15 women assigned to each group.
3259270|NCT00774358|Experimental|Interleukin-2|We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
3259271|NCT00774345|Experimental|1|Lenalidomide po qd on days 1-28 of a 28 day cycle
3259272|NCT00774345|Placebo Comparator|2|Placebo capsules given orally on days 1-28 of a 28 day cycle
3259273|NCT00774319|Active Comparator|1|Induction Chemotherapy with TPF Then: cisplatin 100 mg/m2 on day 1, 22 and 43 combined with conventional radiotherapy
3259274|NCT00774319|Active Comparator|2|Induction chemotherapy with TPF Then cisplatin 40mg/m2 on day 1,8,15,22,29 and 35 combined with accelerated radiotherapy
3259275|NCT00774306|Active Comparator|1|Participants randomized to Group 1 will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
3259276|NCT00774306|Active Comparator|2|Participants randomized to Group 2 will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses or in a once-daily extended release formulation.
3259277|NCT00774306|Active Comparator|3|Participants randomized to Group 3 will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
3259278|NCT00774306|No Intervention|4|Participants randomized to Group 4 will receive no drug intervention.
3259279|NCT00774293|Experimental|1|Arnica 5CH and Bryonia 9CH (homeopathic drugs)
3259280|NCT00774293|Placebo Comparator|2|placebo Arnica 5CH and Bryonia 9CH
3259281|NCT00774280|No Intervention|ArmI(BuCy)|"Intravenous busulfan (Busulfex®; Orphan Medical, Minnetonka, MN) 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4~Cyclophosphamide 60 ㎎/㎏ in D5W 200 ㎖ i.v. over 1-2 hours on days -3 and -2"
3259282|NCT00774280|No Intervention|Arm II (BuFlu)|"Intravenous busulfan 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4.~Fludarabine (Fludara®, Schering AG, Berlin, Germany) 30 ㎎/㎡ i.v. over 30 minutes in D5W 100 ㎖ on days -6 to -2"
3259283|NCT00774267||1|
3259284|NCT00774267||2|
3259285|NCT00774267||3|
3259286|NCT00774267||4|
3259287|NCT00774241|Experimental|1|
3259288|NCT00774228|Experimental|I-ZIP Ocular Bandage|
3259289|NCT00774228|Active Comparator|Oasis 24 hour Soft Shield Collagen Corneal Shield|
3259290|NCT00774202|Active Comparator|Standard Dose of Rituxan and CVP|"'Standard Dose of Rituxan and CVP'~Interventions are as follows: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses. However, the schedule of the infusions will be different than the usual one: Rather than administrating the 4 doses once weekly, the first infusion will be given 5 days (± 3 days) prior to the first CVP, and the following 3 infusions will be given on the same day as the 3 cycles of CVP."
3259291|NCT00774202|Active Comparator|Higher Dose of Rituximab|In this arm, Rituximab will be administered at a dose of 750 mg/m2 once a week x 4 consecutive weeks (4 infusions in total). We will perform EKG monitor tracings before, during and after Rituxan infusions. This will be a single-lead tracing that will allow us to look at issues such as the Q-T interval.
3259292|NCT00774189|Experimental|1|clarithromycin 250 mg tablets of Ranbaxy Laboratories
3259293|NCT00774189|Active Comparator|2|Biaxin 250 mg tablets
3259294|NCT00774176||1|Phase 1 & Gene Expression:Hospitalized COPD exacerbators
3259295|NCT00774176||2|Phase 2: COPD group
3259296|NCT00774176||3|Genetic Association Studies: COPD and Healthy Controls
3259297|NCT00774163|Experimental|1|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
3259298|NCT00774163|Placebo Comparator|2|Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
3259299|NCT00774150|Experimental|1. Cognitive Behavioral Therapy|
3259300|NCT00774150|Active Comparator|2. Client Centered Therapy|
3259301|NCT00774124|Experimental|1 Telemedicine|Usual care plus telemonitoring
3259302|NCT00774124|Active Comparator|2 Standard of Care|Standard of care - women will monitor and record blood glucose levels four times a day.
3259303|NCT00774111|Experimental|Sequence 1|
3259304|NCT00774098|Placebo Comparator|Control Group|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
3259305|NCT00774098|Experimental|GICP|
3259306|NCT00774085||Patients with Schizophrenia|Patients with Schizophrenia are treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
3259307|NCT00774072|Active Comparator|Tobramycin 80 mg|applied once daily via Pari Sinus nebulizer
3259308|NCT00774072|Placebo Comparator|isotonic saline|applied once daily via Pari Sinus nebulizer
3259309|NCT00774046|Experimental|Induction chemotherapy followed by stem cell transplant|Ara-C Mitoxantrone Etoposide Stem cell mobilization Autologous transplant
3259310|NCT00774033|Experimental|1|Treatment of acute burn in adults and children by epidermal cell spray
3259311|NCT00774033|Active Comparator|2|Treatment of acute burn in adults and children by classic skin grafts
3259312|NCT00774020|Experimental|1|
3259313|NCT00774007|Placebo Comparator|Placebo|Placebo
3259314|NCT00774007|Active Comparator|Mesalazine|mesalazine 800 mg t.i.d.
3259315|NCT00773994|Other|Normal velopharyngeal mechanism|All participants in this study are normal healthy adults, who have agreed to undergo to a videofluoroscopic Televex. These participants are acceptable control subjects because they are not diagnosed with VPI and/or submucous cleft palate (SMCP) and the velopharyageal mechanism functions the same in adults as it does in children. This procedure will take approximately 3 minutes to 5 minutes.
3259316|NCT00773981|Active Comparator|1|Endoluminal vacuum therapy.
3259317|NCT00773981|No Intervention|2|Patients not receiving vacuum therapy should be treated with a catheter with daily rinsing for a minimum of 7 days.
3259318|NCT00773968|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants will receive methoxy polyethylene glycol-epoetin beta once monthly by subcutaneous (SC) injection for 28 weeks.
3259319|NCT00773955|Experimental|Treatment (R-(-)-gossypol)|Patients receive oral R-(-)-gossypol once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3259320|NCT00773942|No Intervention|Usual care|Study subjects receive usual care, without the intervention.
3259321|NCT00773942|Experimental|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
3259322|NCT00773942|Experimental|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and a brief chart synopsis including patient medical history, medication history, and relevant laboratory information.
3259323|NCT00773929|Experimental|1|3-6 subjects each cohort. Escalate dose after safety evaluation of subjects in cohort
3259324|NCT00773890|Experimental|TRF-1101|Daily treatment with TRF-1101
3259325|NCT00773890|Placebo Comparator|Placebo|Daily treatment with placebo
3259326|NCT00773877||1|Primary open angle glaucoma
3259327|NCT00773877||2|Normal Controls
3259328|NCT00773851|Other|A|transfacial sutures
3259329|NCT00773851|Other|B|staples
3259330|NCT00773838|Experimental|1|vorinostat and bortezomib
3259331|NCT00773825||1|Pregnancy after ICSI or IVF
3259332|NCT00773825||2|Pregnancy after ovarian stimulation
3259333|NCT00773825||3|natural pregnancy
3259334|NCT00773812|Experimental|Active Mecamylamine|There will be 12 children in this arm. These children will receive the active medication (mecamylamine).
3259335|NCT00773812|Placebo Comparator|Placebo|There will be 8 children in this arm. These children will receive placebo instead of the active medication.
3259336|NCT00773799||rehabilitation center's hospitalized patients|
3259337|NCT00773786|Experimental|Arformoterol|Arformoterol twice daily for 1 week via nebulizer
3259338|NCT00773786|Placebo Comparator|Placebo|Placebo twice daily for 1 week
3259339|NCT00773773|Experimental|Patients undergoing prostatic biopsy|This study will enroll two groups of 250 patients who are to undergo prostatic biopsy as part of their routine medical care because of suspicion of prostate cancer (elevated PSA between 2 and 10 ng/ml, abnormal rectal examination, or both). The first group will contain 250 patients of African-American descent and the second will contain 250 Caucasian men.
3259340|NCT00773760||dosing|
3259341|NCT00773747|Experimental|Vorinostat + bortezomib arm|
3259342|NCT00773747|Placebo Comparator|Placebo + bortezomib arm|
3259343|NCT00773734|Experimental|Apremilast 10mg|Apremilast 10 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 10 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
3259480|NCT00772603|Active Comparator|2400 mg SPN-804|2400mg OXC XR taken orally once daily as four identical tablets
3259344|NCT00773734|Experimental|Apremilast 20mg|Apremilast 20 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 20 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
3259345|NCT00773734|Experimental|Apremilast 30 mg|Apremilast 30 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
3259346|NCT00773734|Placebo Comparator|Placebo|Oral Placebo tablets administered twice daily (BID) for 16 weeks during the placebo-controlled phase.
3259347|NCT00773734|Experimental|Placebo/Apremilast 20 mg|Participants initially randomized to receive placebo twice daily during the 16 week placebo controlled phase are re-randomized to 20 mg apremilast BID during the 8 week active treatment phase
3259348|NCT00773734|Experimental|Placebo/Apremilast 30mg|Participants initially randomized to receive placebo twice daily during the 16 week placebo controlled phase are re-randomized to 30 mg apremilast BID during the 8 week active treatment phase
3259349|NCT00773708|Experimental|1|intensify their triple-drug therapy with Raltegravir (RAL)
3259350|NCT00773708|No Intervention|2|Continue with the same antiretroviral therapy
3259351|NCT00773695|Active Comparator|Chemotherapy|Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks.
3259352|NCT00773695|Experimental|Chemotherapy and Bevacizumab|Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks. Participants will also receive concurrent treatment with bevacizumab every 3 weeks for 24 weeks.
3259353|NCT00773695|Active Comparator|Endocrine Therapy|Participants will receive aromatase inhibitor therapy at discretion of the investigator for a period of 24 weeks.
3259354|NCT00773695|Experimental|Endocrine Therapy and Bevacizumab|Participants will receive aromatase inhibitor therapy at discretion of the investigator and concurrent treatment with bevacizumab for a period of 24 weeks.
3259355|NCT00773656||1|patients treated for a prostate adenocarcinoma
3259356|NCT00773643|Experimental|Tissue Sample|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
3259357|NCT00773630|Active Comparator|A|Intake of Pletal 100 mg tablets dose together with 200 ml water
3259358|NCT00773630|Experimental|B|Intake of Pletal 100 mg ODT dose without water
3259359|NCT00773630|Experimental|C|Intake of Pletal 100 mg ODT dose together with 200 ml water
3259360|NCT00773630|Active Comparator|D|Intake of Pletal 100 mg ODT dose without water
3259361|NCT00773617|Experimental|1|Integrative cognitive affective therapy (ICAT)
3259362|NCT00773617|Active Comparator|2|Cognitive behavioral therapy (CBT)
3259363|NCT00773591|Active Comparator|Botulinum Toxin Typ A|
3259364|NCT00773591|Placebo Comparator|Placebo|
3259365|NCT00773578||1|atopic asthmatic children exposed to environmental tobacco smoke
3259366|NCT00773578||2|atopic asthmatic children unexposed to environmental tobacco smoke
3259367|NCT00773565|Other|Optifast|Patients included take part at a weight reduction program over one year.
3259368|NCT00773552|Experimental|solifenacin succinate|Group randomized into solifenacin succinate treatment
3259369|NCT00773552|Placebo Comparator|placebo|Group randomized into placebo
3259370|NCT00773539|Active Comparator|1|
3259371|NCT00773539|Active Comparator|2|
3259372|NCT00773539|Active Comparator|3|
3259373|NCT00773526|Experimental|1|
3259374|NCT00773513|Active Comparator|Erythropoiesis Stimulating Agents|Participants will receive reference ESA according to approved label. The approved reference ESA compounds in the study will be darbepoetin alfa, epoetin alfa and epoetin beta.
3259375|NCT00773513|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants not currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta iv or sc once every 2 weeks for correction of renal anemia (target Hb 10-12 g/dL). Once corrected and in participants currently being treated with an ESA, methoxy polyethylene glycol-epoetin beta will be administered once monthly.
3259376|NCT00773500||1|Providers adopting electronic prescribing in New York City, New York
3259377|NCT00773500||2|Providers adopting electronic prescribing in the Taconic region of New York
3259378|NCT00773474|Experimental|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
3259379|NCT00773461|Experimental|1|
3259380|NCT00773461|Placebo Comparator|2|
3259381|NCT00773448|Active Comparator|Limited Malignancy Screening|
3259382|NCT00773448|Experimental|Extensive Malignancy Screening|Limited screen as described above in combination with comprehensive computed tomography of the abdomen/pelvis
3259383|NCT00773435|Active Comparator|1. Echinacea purpurea|
3259384|NCT00773435|Placebo Comparator|2. placebo|
3259385|NCT00773422|Experimental|naltrexone + varenicline|naltrexone (25mg) + varenicline (2mg)
3259386|NCT00773422|Experimental|varenicline|varenicline 2mg
3259387|NCT00773422|Placebo Comparator|placebo|placebo control
3259388|NCT00773383|Experimental|1|
3259389|NCT00773370|Experimental|APA-Stroke|The APA-stroke exercise program designed specifically for individuals with hemiparetic gait deficits due to stroke. These progressive exercises focus on walking, balance and weight shifting and include an exercise homework component.
3259390|NCT00773370|Active Comparator|Sittercise|Sittercise is not stroke specific. This less vigorous exercise program consists of seated exercise, focusing on stretching to improve general range of motion and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework associated with this group.
3259391|NCT00773357|Experimental|Guanfacine|guanfacine 3mg/day
3259392|NCT00773357|Placebo Comparator|Placebo|placebo control
3259393|NCT00773357|Experimental|Carvedilol|Carvedilol 50 mg/day
3259394|NCT00773344|Experimental|A1|
3259395|NCT00773331|Experimental|1|
3259397|NCT00773318|Experimental|A|"Patients with histologically proven AJCC stages I - II - III prostate cancer including men with clinical T3N0M0 disease, men with PSA > 10 mg/ml, and men with Gleason score of 8-10. Prostate cancer patients scheduled for prostatectomy and pelvic lymph node dissection (CLND).~Arm A = SPECT/CT guided LM/SL versus CLND"
3259398|NCT00773292|Experimental|ciclosporin|48 weeks treatment with ciclosporin
3259399|NCT00773279|Experimental|PDS290 --> FlexPen®|Subjects will receive trial drug with PDS290 for 12 weeks (treatment sequence 1) followed by FlexPen® for 12 weeks (treatment sequence 2)
3259400|NCT00773279|Experimental|FlexPen® --> PDS290|Subjects will receive trial drug with FlexPen® for 12 weeks (treatment sequence 1) followed by PDS290 for 12 weeks (treatment sequence 2)
3259401|NCT00773253|Active Comparator|standard EMG-guided Botox injection|All patients will undergo injection using conventional single channel EMG-guided technique. This will be used as a baseline for multi-channel mapping-based injections. Patients will be randomized to undergo single-channel vs. multi-channel assessment upon study entry and will then cross over to the alternate arm.
3259402|NCT00773253|Experimental|Multi-channel EMG-guided Botox injection|Patients will receive multi-channel EMG-guided Botox injection before or after they have been treated with single-channel EMG-guided Botox, depending on which group they are assigned in the cross-over design.
3259403|NCT00773240|Experimental|1|Grazax
3259404|NCT00773240|Placebo Comparator|2|
3259405|NCT00773227|Experimental|1|All patients included
3259406|NCT00773214|Experimental|exercise|
3259407|NCT00773201|Experimental|1|Healthy subjects
3259408|NCT00773188|Experimental|1|
3259409|NCT00773175|Active Comparator|Subcutaneous|Isotonic fluid rehydration by SC administration with hylenex (150 Units in 1 mL)
3259410|NCT00773175|Active Comparator|Intravenous|Isotonic fluid rehydration by IV
3259411|NCT00773162|Placebo Comparator|1|
3259412|NCT00773162|Active Comparator|2|
3259413|NCT00773149|Experimental|1|all included patients
3259414|NCT00773136|Active Comparator|Bimatoprost Suspension|Intervention to be administered: Each subject was given two suspensions, one mixed with Bimatoprost and one mixed with normal saline. They were instructed to use each suspension to a pre-determined eyelash (prepared prior to study enrollment in double blind fashion and marked after randomization with right and left). The intervention was the one eye with the Bimatoprost.
3259415|NCT00773123||1|Primary open angle glaucoma
3259416|NCT00773123||2|Normal controls
3259417|NCT00773110|Experimental|1 Albumin|Priming of the cardiopulmonary bypass circuit with 20% human albumin solution prior to surgery
3259418|NCT00773110|Placebo Comparator|2 Gelofusin|Priming of the cardiopulmonary bypass circuit with gelofusin prior to surgery
3259419|NCT00773097|Experimental|MUC1 Poly-ICLC|
3259420|NCT00773084|Active Comparator|Drug|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone
3259421|NCT00773071|Experimental|A|"Single photon emission computed tomography/computed tomography (SPECT/CT) guided lymphatic mapping and sentinel lymphadenectomy (LM/SL) vs. complete lymph node dissection (CLND)~All cervical cancer and vulvar cancer patients will undergo CLND according to the standard of care in gynecologic cancers as recommended by the International Federation of Gynecology and Obstetrics (FIGO).~Patients with FIGO IA2 and IB1 cervical cancers will be scheduled for radical hysterectomy and pelvic lymph node dissection.~Patients with FIGO IB and II vulvar cancers and those of patients with FIGO III with clinically negative regional lymph nodes will be scheduled for vulvectomy and inguinal lymph node dissection."
3259422|NCT00773058|Active Comparator|glucocorticoid+RAI|stress-dose glucocorticoid treatment, compared to placebo group and ACTH test hints RAI
3259423|NCT00773058|Placebo Comparator|placebo + RAI|no glucocorticoid But ATCH test hints RAI
3259424|NCT00773058|Active Comparator|glucocorticoid|stress-dose glucocorticoid treatment, compared to placebo group and ACTH test does not hint RAI
3259425|NCT00773058|Placebo Comparator|placebo|no glucocorticoid But ATCH test does not hint RAI
3259426|NCT00773045||pain training program|ICU Patients treated with or without pain management protocol
3259427|NCT00773032|Experimental|Sodium Oxybate|2.5g Sodium Oxybate administered during nap
3259428|NCT00773032|Experimental|Zolpidem|5mg Zolpidem administered during nap
3259429|NCT00773032|Placebo Comparator|Placebo|
3259430|NCT00773006||A|Stable/elective PCI patients
3259431|NCT00773006||B|NSTEMI PCI patients
3259432|NCT00773006||C|STEMI PCI patients
3259433|NCT00772993||1|Primary open angle glaucoma
3259434|NCT00772993||2|Normal Control
3259435|NCT00772993||3|Myopia with no evidence of glaucoma
3259436|NCT00772993||4|Myopia with evidence og glaucoma
3259437|NCT00772980|Experimental|1|Drug: Neramexa mesylate Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
3259438|NCT00772980|Placebo Comparator|2|Drug: Placebo Double-blind treatment period of 17 weeks placebo
3259439|NCT00772967|Experimental|Placebo, Naproxen, Ultracet|Participants were treated with Placebo for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
3259440|NCT00772967|Experimental|Naproxen, Ultracet, Placebo|Participants were treated with Naproxen for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
3259441|NCT00772967|Experimental|Ultracet, Placebo, Naproxen|Participants were treated with Ultracet for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
3259442|NCT00772967|Experimental|Placebo, Ultracet, Naproxen|Participants were treated with Placebo for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
3259443|NCT00772967|Experimental|Naproxen, Placebo, Ultracet|Participants were treated with Naproxen for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
3259481|NCT00772603|Active Comparator|1200mg SPN-804|1200mg OXC XR taken orally once daily as four identical tablets
3259444|NCT00772967|Experimental|Ultracet, Naproxen, Placebo|Participants were treated with Ultracet for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
3259445|NCT00772954|Placebo Comparator|Placebo vaccine group|Participants scheduled to receive a dose of placebo vaccine on Day 0, Day 28, and Day 56, respectively.
3259446|NCT00772954|Experimental|Clostridium Difficile Vaccine Group 1|Participants scheduled to receive a dose of 50 μg Clostridium Difficile vaccine on Day 0, Day 28, and Day 56, respectively.
3259447|NCT00772954|Experimental|Clostridium Difficile Vaccine Group 2|Participants scheduled to receive a dose of 100 μg Clostridium Difficile vaccine on Day 0, Day 28, and Day 56, respectively.
3259448|NCT00772941||Varenicline|Patients taking Varenicline.
3259449|NCT00772928|Experimental|Pentacel™ concurrently with Prevnar®|Participants had Pentacel™ concurrently administered with Prevnar®
3259450|NCT00772928|Experimental|Pentacel™ staggered schedule with Prevnar®|Participants had Pentacel™ given at different times from Prevnar® (using a standardized, staggered schedule).
3259451|NCT00772915|Experimental|Lenalidomide with On-Demand Dexamethasone|"Lenalidmoide: 25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.~Dexamethasone: 10-40 mg once weekly (days 1, 8, 15, & 22) orally with food until progression."
3259452|NCT00772902|Experimental|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg) once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
3259453|NCT00772902|Active Comparator|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
3259454|NCT00772889|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.
3259455|NCT00772889|Active Comparator|Fluarix elderly Group|Subjects aged ≥66 years received one dose of Fluarix vaccine.
3259456|NCT00772889|Active Comparator|Fluarix young Group|Subjects aged 19-43 years received one dose of Fluarix vaccine.
3259457|NCT00772876|Experimental|P1446A-05|Single arm of the study drug. This being a dose escalation study, patient will receive a dose depending on the stage of the trial.
3259458|NCT00772850||Antegrade nailing, humeral fractures|We included patient's age and gender, fracture location, fracture cause, presence of nail removal, post-operative period and comorbidity or associated disease as independent variables. Fracture location was either humeral neck or humeral shaft. Humeral neck fractures were defined as fractures above surgical neck of the humerus. Meanwhile, humeral shaft fractures were defined as fractures below surgical neck of the humerus and 5 cm above the olecarnon fossa. Humeral shaft fractures were separated into three groups: proximal third shaft fractures, middle third shaft fractures and distal third shaft fractures. Fracture causes included simple falls and traffic accidents.
3259459|NCT00772837|Experimental|1.H.Pylori Eradication Group|The eradication group will receive triple therapy (omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BID and Amoxycillin 1g BID) for 1 week for the eradication of H. pylori
3259460|NCT00772837|Placebo Comparator|2.Control Placebo Group|The control group will receive omeprazole 20 mg BID for 1 week along with placebo antibiotics for 1 week
3259461|NCT00772824|No Intervention|1|10 patients (30 cycles) of chemotherapy will receive placebo
3259462|NCT00772824|Active Comparator|2|Intravenous glutamine
3259463|NCT00772824|Experimental|3|Oral Glutamine
3259464|NCT00772811|No Intervention|Flu-Mel|Conditioning chemotherapy before infusion of allogeneic stem cells will include fludarabine 30 mg/m2/day for 5 consecutive days (days -6 to -2) and melphalan 100 mg/m2 at day -2.
3259465|NCT00772785|Experimental|Probuphine|buprenorphine implant
3259466|NCT00772772|Experimental|Vitamin D3|Vitamin D3 30,000 international units orally per week for 8 weeks
3259467|NCT00772759|Experimental|1|Dry powder for oral inhalation
3259468|NCT00772759|Placebo Comparator|2|Dry powder for oral inhalation
3259469|NCT00772746||exercise|Respiratory and cognitive exercises in panic disorder patients.
3259470|NCT00772707|Experimental|Opti-Free Replenish|Multi-purpose contact lens solution for cleaning and disinfecting study contact lenses used on a daily basis for 30 days.
3259471|NCT00772694|Experimental|sorafenib|drug
3259472|NCT00772681|Experimental|1|
3259473|NCT00772668|Experimental|RCVELP|"Rituximab, Cyclophosphamide, Bortezomib, Prednisone (RCVELP):~Rituximab~Induction: 375 mg/m2 IV infusion on Day 1 of every 21 days cycle for 8 cycles~Maintenance: 375/m2 Days 1, 8, 15, 22 every 6 months for up to 4 cycles~Cyclophosphamide: 750 mg/m2 intravenous piggyback (IVPB) on Day 1 of every 21 day cycle for 8 cycles~Bortezomib: 1.6 mg/m2 IV push on Days 1 and 8 of every 21 days cycle for 8 cycles~Prednisone: 100 mg PO daily on Days 1-5 of every 21 day cycle for 8 cycles"
3259474|NCT00772655|Experimental|Study Therapy|Induction therapy with a single course of 90Yttrium-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111Indium-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 up to a maximal dose of 12.000 MBq [if platelets are below 150000/µl only 11 MBq/kg are administered). Observation for patients achieving complete clinical and molecular response or partial clinical response. Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2 (t14;18)-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
3259475|NCT00772629|Experimental|Group 1|Subjects naïve to any meningococcal vaccination
3259476|NCT00772629|Experimental|Group 2|Subjects who previously received unconjugated polysaccharide vaccine (either bivalent A and C or tetravalent A, C, Y, and W 135)
3259477|NCT00772616|Experimental|1|Patients will receive propofol and remifentanil automatically administered (closed-loop administration using bispectral index as the single input for the controller).
3259478|NCT00772616|Active Comparator|2|Patients will receive propofol automatically administered (closed-loop administration using bispectral index as the single input for the controller) and sufentanil according to usual criteria
3259479|NCT00772603|Placebo Comparator|Placebo|Placebo - four identical tablets taken orally once daily
3259482|NCT00772590|Experimental|Raltegravir, bovine colostrum|Raltegravir and hyper-immune bovine colostrum
3259483|NCT00772590|Experimental|Hyper-immune bovine colostrum|Hyper-immune bovine colostrum and Raltegravir placebo
3259484|NCT00772590|Experimental|Raltegravir|Raltegravir and Hyper-immune Bovine Colostrum Placebo
3259485|NCT00772590|Placebo Comparator|Placebo|Raltegravir placebo and hyper-immune bovine colostrum placebo
3259486|NCT00772577|Experimental|1|Aliskiren Hydrochlorothiazide(HCTZ)
3259487|NCT00772577|Active Comparator|2|Ramipril
3259488|NCT00772564|Experimental|Atorvastatin 80 mg|
3259489|NCT00772564|Experimental|Atorvastatin 10 mg|
3259490|NCT00772551|Active Comparator|1|
3259491|NCT00772551|Active Comparator|2|
3259492|NCT00772538|Experimental|tiotropium 5mcg/day|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
3259493|NCT00772538|Experimental|placebo|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
3259494|NCT00772525|Experimental|Sequence 1|"placebo,1 day treatment period 1~50 mg Nerispirdine, 1 day treatment period 2~400 mg Nerispirdine, 1 day treatment period 3"
3259495|NCT00772525|Experimental|Sequence 2|"placebo,1 day treatment period 1~400 mg Nerispirdine, 1 day treatment period 2~50 mg Nerispirdine, 1 day treatment period 3"
3259496|NCT00772525|Experimental|Sequence 3|"50 mg Nerispirdine, 1 day treatment period 1~placebo, 1 day treatment period 2~400 mg Nerispirdine, 1 day treatment period 3"
3259497|NCT00772525|Experimental|Sequence 4|"50 mg Nerispirdine, 1 day treatment period 1~400 mg Nerispirdine, 1 day treatment period 2~placebo, 1 day treatment period 3"
3259498|NCT00772525|Experimental|Sequence 5|"400 mg Nerispirdine, 1 day treatment period 1~placebo, 1 day treatment period 2~50 mg Nerispirdine, 1 day treatment period 3"
3259499|NCT00772525|Experimental|Sequence 6|"400 mg Nerispirdine, 1 day treatment period 1~50 mg Nerispirdine, 1 day treatment period 2~placebo, 1 day treatment period 3"
3259500|NCT00772512|Experimental|A|
3259501|NCT00772512|Experimental|B|
3259502|NCT00772512|Placebo Comparator|C|
3259503|NCT00772499|Experimental|1|olmesartan medoxomil tablets with added doses of hydrochlorothiazide, amlodipine, or hydralazine, if required to maintain target blood pressure
3259504|NCT00772499|Active Comparator|2|Atenolol tablets with added doses of hydrochlorothiazide, amlodipine, or hydralazine, if required to maintain target blood pressure
3259505|NCT00772473||1 group, usual acute triptan treatment|
3259506|NCT00772460|Active Comparator|Forced Air|Warming with forced air (BairHugger)
3259507|NCT00772460|Experimental|Conductive Warming|Warming with the conductive device (HotDog)
3259508|NCT00772447|Experimental|AZ drug|Daptomycin
3259509|NCT00772447|Active Comparator|Comparator|Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin
3259510|NCT00772421||Responder|A subject having at least a 50% reduction in total seizure frequency compared to the SANTE study 3-month Baseline Phase
3259511|NCT00772421||Non-responder|A subject with a less than 50% reduction in total seizure frequency compared to the SANTE study 3-month Baseline Phase.
3259512|NCT00772408||TB|patients with pulmonary TB
3259513|NCT00772408||control|healthy controls
3259514|NCT00772395|Active Comparator|Risedronate|
3259515|NCT00772395|Placebo Comparator|Placebo|
3259516|NCT00772382|Experimental|MCI-196|
3259517|NCT00772356|Experimental|A|
3259518|NCT00772356|Active Comparator|B|
3259519|NCT00772343|Placebo Comparator|Placebo Vaccine|0.9% Normal saline
3259520|NCT00772343|Experimental|Low dose|Low dose vaccine with adjuvant
3259521|NCT00772343|Experimental|High dose 1|High-dose vaccine with adjuvant
3259522|NCT00772343|Experimental|High dose 2|High-dose vaccine without adjuvant
3259523|NCT00772330|Experimental|MIDI Arrow|Ab externo glaucoma drainage device with no reservoir
3259524|NCT00772317|Experimental|HIFU|High Intensity Focused Ultrasound
3259525|NCT00772304|Experimental|1|Olopatadine 0.6% / Azelastine 137 mcg
3259526|NCT00772291|Placebo Comparator|placebo|
3259527|NCT00772291|Active Comparator|pregabalin|
3259528|NCT00772278|Active Comparator|CAS|carotid artery stenting
3259529|NCT00772278|Active Comparator|CEA|carotid endarterectomy
3259530|NCT00772265|Experimental|Wosulin N|Wosulin N, Isophane insulin for injection (Recombinant Human Insulin)(100 IU/mL), cartridges 3.0 mL
3259531|NCT00772265|Active Comparator|Novolin N|Novolin N, Isophane insulin for injection (Recominant Human Insulin)(100IU/ml),cartridges 3.0ml.
3259532|NCT00772252||1|patient with hepatic failure undergoing liver support treatment in surgical intensive care unit
3259533|NCT00772239|Experimental|Rotem|ROTEM: Rotation thromboelastometry
3259534|NCT00772239|Active Comparator|S|Standard coagulation managment procedure
3259535|NCT00772226|Active Comparator|music|
3259536|NCT00772226|Placebo Comparator|Pillow without music|
3259537|NCT00772213|Experimental|MIGTS treatment|controlled trial (quasi-randomized) versus controls (=conventional treatment not in the MIGTS)
3259538|NCT00772213|No Intervention|controls (=conventional treatment not in the MIGTS)|
3259539|NCT00772200||Observational (neuropsychological and behavioral tests)|Parent and child participants complete the COG Standard Neuropsychological and Behavioral Battery testing at 9, 30, and 60 months post-diagnosis in a 1-hour session conducted by a neuropsychologist or psychologist. The Battery consists of tests of intelligence, processing speed/attention, memory, language preference, general developmental progress, attention and behavior/social/emotional function, executive function, adoptive function, and quality of life. Additionally, parents complete a parent-report questionnaire to gather information about patient's function in terms of attention, memory, executive abilities, and behavioral, social, and emotional adaption.
3259540|NCT00772187|Experimental|1|General anesthesia + I.V pca
3259541|NCT00772187|Experimental|2|General anesthesia + spinal analgesia + I.V pca
3259542|NCT00772174|Experimental|Pioglitazone + Metformin|
3259543|NCT00772174|Active Comparator|Metformin|
3259544|NCT00772161|Experimental|Sequence 1|First treatment week (day 1 to day 7) 20mg Ritalin LA; second treatment week (day 8 to day 14) 20mg Medikinet retard.
3259545|NCT00772161|Experimental|Sequence 2|First treatment week (day 1 to day 7) 20mg Medikinet retard; second treatment week (day 8 to day 14) 20mg Ritalin LA.
3259546|NCT00772148|Experimental|LCP-Tacro|LCP - Tacro™ tablets, once daily (LifeCycle Pharma A/S, Hørsholm DK)
3259547|NCT00772148|Active Comparator|Prograf (tacrolimus)|Prograf® capsules, twice daily (Astellas Pharma US, Deerfield IL)
3259548|NCT00772122|Experimental|Granulocyte colony stimulating factor|The G-CSF group of 35 women, underwent a daily sub-cutaneous administration of the filgrastim (Neupogen, Dompe', Italy), the recombinant G-CSF, at a dosage of 1 micro gram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
3259549|NCT00772122|Placebo Comparator|placebo (saline solution)|The placebo group consisting of 33 subjects, was given a treatment with saline solution at the 0.2ml/day subcutaneously/, from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
3259550|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 1|Participants will receive a dose of Influenza intradermal vaccine Lot 1
3259551|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 2|Participants will receive a dose of Influenza intradermal vaccine Lot 2
3259552|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 3|Participants will receive a dose of Influenza intradermal vaccine Lot 3
3259553|NCT00772109|Active Comparator|Fluzone Intramuscular Vaccine|Participants will receive a dose of influenza intramuscular vaccine
3259554|NCT00772096|Experimental|Verum|
3259555|NCT00772096|No Intervention|No treatment|
3259556|NCT00772083|Experimental|1|
3259557|NCT00772083|Active Comparator|2|standard approach currently being used
3259558|NCT00772070|Experimental|Previously received TetraMenD|Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.
3259559|NCT00772070|Experimental|Meningococcal vaccine-naїve|Participants have never received a Meningococcal vaccine in the past.
3259560|NCT00772057|Active Comparator|Propranolol group|
3259561|NCT00772057|Placebo Comparator|Placebo group|
3259562|NCT00772044|Active Comparator|Provent|Those receiving the active device
3259563|NCT00772044|Sham Comparator|Sham|Those receiving sham device
3259564|NCT00772031|Active Comparator|1|Participants will receive propranolol and topiramate.
3259565|NCT00772031|Placebo Comparator|2|Participants will receive a placebo and topiramate.
3259566|NCT00772005|Active Comparator|150 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
3259567|NCT00772005|Active Comparator|200 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
3259568|NCT00772005|Active Comparator|250 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
3259569|NCT00772005|Placebo Comparator|Matching Placebo|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
3259570|NCT00771979|Experimental|1|
3259571|NCT00771966|Placebo Comparator|Standard treatment|
3259572|NCT00771966|Active Comparator|SV maximization|
3259573|NCT00771953|Experimental|Apricoxib|Apricoxib 400mg once a day
3259574|NCT00771953|Placebo Comparator|Placebo|Placebo once a day
3259575|NCT00771940|Active Comparator|Ghrelin|
3259576|NCT00771927||Lacosamide|Epilepsy patients with partial-onset seizures who are uncontrolled on current therapy and are treated with add-on Vimpat
3259577|NCT00771927||Other AED|Epilepsy patients with partial-onset seizures who are uncontrolled on current therapy and are treated with other approved AED as add-on therapy
3259578|NCT00771914|Experimental|Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza|First Placebo, then 4 grams of Lovaza, then 81mg of Aspirin, then both 4 grams of Lovaza and 81 mg of Aspirin
3259579|NCT00771914|Experimental|Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo|First 81mg of Aspirin, then 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo
3259580|NCT00771914|Experimental|Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin|First 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 81mg of Aspirin
3259581|NCT00771914|Experimental|Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin|First both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 4 grams of Lovaza, then 81mg of Aspirin
3259582|NCT00771901|Placebo Comparator|Placebo|Subjects will be given a placebo rather than tauroursodeoxycholic acid.
3259583|NCT00771901|Experimental|tauroursodeoxycholic acid|Subjects will receive tauroursodeoxycholic acid for four weeks.
3259584|NCT00771901|Experimental|PBA|Subjects will receive sodium phenylbutyrate for four weeks.
3259585|NCT00771888|Other|1|lanreotide
3259586|NCT00771875|Active Comparator|Rabbit Antithymocyte Globulin (RATG)|Rabbit Antithymocyte Globulin (RATG) All patients will receive RATG (Thymoglobulin) dosed based on CD3 count. Patients will be redosed when the cluster of differentiation 3 (CD3) count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily. 1.5mg/kg/day over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels > 25 cells/mm3); Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
3259587|NCT00771875|Experimental|RATG/Rituximab|Rabbit Antithymocyte Globulin (RATG) + Rituximab Subjects will be given 1.5mg/kg/day of RATG over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels > 25 cells/mm3); Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
3259588|NCT00771875|Experimental|RATG/Bortezomib|Rabbit Antithymocyte Globulin (RATG) + Bortezomib -Subjects will be given 1.5mg/kg/day of RATG over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels > 25 cells/mm3). Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Bortezomib will be given at a dose of 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Methylprednisolone will be administered prior to each bortezomib dose. On days 2 and 5, administer methylprednisolone 100 mg intravenous push (IVP). On days 9 and 12, administer methylprednisolone 50 mg intravenous push (IVP). If thymoglobulin is administered the same day as bortezomib, the order of administration is- methylprednisolone, then bortezomib, then thymoglobulin.
3259589|NCT00771862|Placebo Comparator|1. standard care|1 day of perineural ropivacaine 0.2% infusion followed by 4-5 days of normal saline infusion.
3259590|NCT00771862|Active Comparator|2: experimental care|4-5 days of perineural ropivacaine 0.4% infusion.
3259591|NCT00771849|Experimental|Menactra® Vaccine Group|Participants receiving the tetravalent (A, C, Y, and W 135) meningococcal diphtheria toxoid conjugate vaccine
3259592|NCT00771849|Active Comparator|Hiberix® Vaccine Group|Participants receiving Haemophilus Influenzae Type b (Hib) vaccine
3259593|NCT00771823|Active Comparator|2|
3259594|NCT00771823|Active Comparator|1|"Maraviroc 300 mg twice daily for the first 14 days of the study.~Placebo twice daily for the last 14 days of the study"
3259595|NCT00771810|Placebo Comparator|Placebo|Combination gemcitabine and platinum-based chemotherapy with concurrent placebo
3259596|NCT00771810|Experimental|TXA127 100 ug/kg|Combination gemcitabine and platinum-based chemotherapy with concurrent 100 ug/kg/day TXA127
3259597|NCT00771810|Experimental|TXA127 300 ug/kg|Combination gemcitabine and platinum-based chemotherapy with concurrent 300 ug/kg/day TXA127
3259598|NCT00771797|Experimental|1|Treatement with low dose flavanoids over 60 days
3259599|NCT00771797|Experimental|2|Treatment with high dose flavanoids over 60 days
3259600|NCT00771784||1|Short term endotracheal intubation.
3259601|NCT00771784||2|Long term endotracheal intubation.
3259602|NCT00771771|Active Comparator|Day unit rehabilitation|Discharge from the hospital to the patients' homes as soon as possible, supported by an out-patient ambulatory coordinating multidisciplinary team. The patients will be offered rehabilitation in a day unit, and multidisciplinary policlinical follow-ups will be performed 3 and 6 months after inclusion.
3259603|NCT00771771|Active Comparator|Home rehabilitation|Discharge from the hospital to the patients' homes as soon as possible, supported by an out-patient ambulatory coordinating multidisciplinary team. The patients will be offered rehabilitation treatment in their homes, and multidisciplinary policlinical follow-ups will be performed 3 and 6 months after inclusion.
3259604|NCT00771771|No Intervention|Treatment as usual|Patients will receive rehabilitation treatment after today's principles and routines.
3259605|NCT00771758|Experimental|001|tapentadol IR 50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days maximum daily dose 450 mg
3259606|NCT00771758|Experimental|002|oxycodone IR 5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days maximum daily dose 60 mg
3259607|NCT00771758|Placebo Comparator|003|placebo 1 capsule every 4 - 6 hr as needed for up to 10 days
3259608|NCT00771745|Active Comparator|rATG 4 doses|Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
3259609|NCT00771745|Active Comparator|rATG 3 doses|Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
3259610|NCT00771732|Experimental|1|Light therapy
3259611|NCT00771732|Sham Comparator|2|"6 minute session given with machine off"
3259612|NCT00771719|Experimental|Ceftobiprole|Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
3259613|NCT00771706|Experimental|Proton Pump Inhibitor|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
3259614|NCT00771706|Placebo Comparator|Sugar Pill|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough
3259615|NCT00771680||A|
3259616|NCT00771667|Placebo Comparator|Placebo (IP)|
3259617|NCT00771667|Experimental|Ustekinumab 1mg/kg (IP)|
3259618|NCT00771667|Experimental|Ustekinumab 3 mg/kg (IP)|
3259619|NCT00771667|Experimental|Ustekinumab 6 mg/kg (IP)|
3259620|NCT00771667|Placebo Comparator|Placebo IV - Responder - Placebo SC (MP)|
3259621|NCT00771667|Placebo Comparator|Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC|
3259622|NCT00771667|Placebo Comparator|Ustekinumab IV - Responder - Placebo SC (MP)|
3259623|NCT00771667|Experimental|Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|
3259624|NCT00771667|Placebo Comparator|Ustekinumab IV - Nonresponder - Placebo SC (MP)|
3259625|NCT00771667|Experimental|Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|
3259805|NCT00770627|Active Comparator|Omega 3 caps|
3259626|NCT00771654|Placebo Comparator|Placebo|Subjects will be randomized to the daily dosing of either oral Phentermine 37.5mg or placebo to commence at their 2 week follow-up appointment following their gastric band procedure
3259627|NCT00771654|Experimental|Phentermine|Subjects will be randomized to the daily dosing of either oral Phentermine 37.5mg or placebo to commence at their 2 week follow-up appointment following their gastric band procedure
3259628|NCT00771641|Active Comparator|Standard Fractionation|Standard Fractionation: 2 Gy/Fx, Q.D. 5 Days/wk, Total Dose: 70 Gy/35 Fx x 7 wks
3259629|NCT00771641|Experimental|Hyperfractionation|Hyperfractionation: 1.2 Gy/Fx, b.i.d. (> 6 hours apart, 5 days/wk) Total Dose: 81.6 Gy/68 Fx/7 weeks
3259630|NCT00771641|Experimental|Accelerated Hyperfractionation with split|Accelerated Hyperfractionation with split: 1.6 Gy/Fx b.i.d. (> 6 hours apart), 5 days/wk, Total Dose: 67.2 Gy/42 Fx/6 wks with a 2 week rest after 38.4 Gy
3259631|NCT00771641|Experimental|Accelerated fractionation with concomitant boost|Accelerated fractionation with concomitant boost
3259632|NCT00771628|Experimental|Flex-It Stylet|Patients will be intubated using the GlideScope with an ETT fitted with a Flex-It stylet.
3259633|NCT00771628|Active Comparator|2 Malleable|
3259634|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation A Group|Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3259635|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation B1 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3259636|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation B2 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3259637|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation C1 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3259638|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation C2 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3259639|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation D1 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3259640|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation D2 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3259641|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation E1 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3259642|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation E2 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3259643|NCT00771602|Experimental|Rituximab|Group 1: 375 mg/m^2 IV Rituximab Alone
3259644|NCT00771602|Experimental|Alemtuzumab|Group 2: 30 mg SQ Alemtuzumab Alone
3259645|NCT00771602|Experimental|Rituximab + Alemtuzumab|Group 3: 375 mg/m^2 Rituximab + 30 mg SQ Alemtuzumab
3259646|NCT00771589|Experimental|Prosthesis|Motorized External Knee prosthesis for above knee amputees. Comprised of agonist and antagonist actuators to mimic behavior of knee joint during locomotion.
3259647|NCT00771576||A. Healthy Controls|subjects w/ predicted normal BCM (healthy, normalweight, nondiabetic individuals who have stimulated insulin and cpeptide levels within the normal range);
3259648|NCT00771576||B. Longstanding T1D|subjects with predicted reduced beta cell mass (subjects with established T1DM who have low or not measurable stimulated insulin and c peptide levels);
3259649|NCT00771576||C. Obese Subjects|subjects with predicted increased beta cell mass (euglycemic obese subjects with fasting hyperinsulinemia).
3259650|NCT00771563|Active Comparator|Arm A|Chemotherapy without LMWH
3259651|NCT00771563|Experimental|Arm B|Chemotherapy with LMWH
3259652|NCT00771537|No Intervention|Arm 1. Control PLUS Control|
3259653|NCT00771537|Experimental|Arm 2. Control PLUS 1-Sided|No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
3259654|NCT00771537|Experimental|Arm 3. Control PLUS 2-Sided Trivial|No message intervention control condition regarding HIV testing AND 2-Sided trivial message experimental intervention condition regarding HIV vaccine clinical trial participation.
3259655|NCT00771537|Experimental|Arm 4. Control PLUS 2-Sided Major|No message intervention control condition regarding HIV testing AND 2-Sided Major message experimental intervention condition regarding HIV vaccine clinical trial participation.
3259656|NCT00771537|Experimental|Arm 5. 1-Sided PLUS Control|1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
3259657|NCT00771537|Experimental|Arm 6. 1-Sided PLUS 1-Sided|1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
3259658|NCT00771537|Experimental|Arm 7. 1-Sided PLUS 2-Sided Trivial|1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
3259659|NCT00771537|Experimental|Aim 8. 1-Sided PLUS 2-Sided Major|1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Major message intervention experimental condition regarding HIV vaccine clinical trial participation.
3259660|NCT00771537|Experimental|Arm 9. 2-Sided Trivial PLUS Control|2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
3259661|NCT00771537|Experimental|Arm 10. 2-Sided Trivial PLUS 1-Sided|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
3259662|NCT00771537|Experimental|Arm 11. 2-Sided Trivial PLUS 2-Sided Trivial|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
3259663|NCT00771537|Experimental|Arm 12. 2-Sided Trivial PLUS 2-Sided Major|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
3259664|NCT00771537|Experimental|Arm 13. 2-Sided Major PLUS Control|2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
3259665|NCT00771537|Experimental|Arm 14. 2-Sided Major PLUS 1-Sided|2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
3259666|NCT00771537|Experimental|Arm 15. 2-Sided Major PLUS 2-Sided Trivial|2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
3259667|NCT00771537|Experimental|Arm 16. 2-Sided Major PLUS 2-Sided Major|2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
3259668|NCT00771524|Experimental|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
3259669|NCT00771524|No Intervention|Control|Standard of care antibiotics prior to hip replacement surgery
3259670|NCT00771511|Experimental|1|Capsaicin cream applied to cervix after lidocaine gel
3259671|NCT00771511|Placebo Comparator|2|only lidocaine applied to the cervix
3259672|NCT00771498|Other|lopinavir|Patients with HIV/TB co-infection will receive treatment for both infection, and PK of lopinavir 800mg + ritonavir 200mg (PO BID) during 5 months will be performed
3259673|NCT00771485|Experimental|1|
3259674|NCT00771485|Other|2|
3259675|NCT00771472|Experimental|Vorinostat|
3259676|NCT00771459|Active Comparator|Ropivacaine|
3259677|NCT00771459|Placebo Comparator|Placebo|
3259678|NCT00771446|Experimental|ELAD (plus Standard of Care)|Treatment with ELAD in addition to standard of care therapy Standard of care therapy defines uniform treatment for ascites, esophageal varices, dietary recommendations, etc.
3259679|NCT00771446|Other|Standard of Care (Control)|Standard of care treatment Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
3259680|NCT00771433|Experimental|Group 1|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 6-11 of each course of chemotherapy as primary prophylaxis. Chemotherapy courses repeat every three weeks for 3-6 courses.
3259681|NCT00771433|Experimental|Group 2|Patients receive G-CSF SC once daily on days 6-11 of each course of chemotherapy as primary prophylaxis. Chemotherapy courses repeat every three weeks for 3-6 courses. Patients may also receive secondary prophylaxis with G-CSF if they experience an episode of neutropenia.
3259682|NCT00771420|Active Comparator|1|0.01mg/kg and 0.03mg/kg CAM-3001
3259683|NCT00771420|Active Comparator|2|0.1mg/kg CAM-3001
3259684|NCT00771420|Active Comparator|3|0.3mg/kg CAM-3001
3259685|NCT00771420|Active Comparator|4|1.0mg/kg CAM-3001
3259686|NCT00771420|Active Comparator|5|3.0mg/kgCAM-3001
3259687|NCT00771420|Active Comparator|6|10.0mg/kg CAM-3001
3259688|NCT00771420|Placebo Comparator|7|Placebo
3259689|NCT00771407|Active Comparator|Strattice fascial inlay|Strattice will be placed as a fascial inlay to support the ostomy site
3259690|NCT00771407|Other|Standard ostomy construction|Ostomy will be created in the standard fashion
3259691|NCT00771394|Placebo Comparator|1. Tamsulosin alone|
3259692|NCT00771394|Experimental|2. Tamsulosin + solifenacin (low dose)|
3259693|NCT00771394|Active Comparator|3. Tamsulosin + solifenacin (high dose)|
3259694|NCT00771381|Experimental|1|18F-FAZA + FluGlucoScan Injection
3259695|NCT00771368|Experimental|Nitric Oxide|gaseous nitric oxide delivered topically for 30 minutes
3259696|NCT00771355||1|Subjects with vitiligo.
3259697|NCT00771355||2|Subjects with melasma.
3259698|NCT00771355||3|Subjects with post-inflammatory hyper-pigmentation.
3259699|NCT00771355||4|Subjects with post-inflammatory hypo-pigmentation.
3259700|NCT00771342|Experimental|1|1% gasoue nitric oxide, delivered topically for 40 minutes daily for three consecutive days
3259701|NCT00771342|Placebo Comparator|2|Nitrogen gas delivered topically for 40 minutes, daily, for 3 consecutive days
3259702|NCT00771329|Experimental|1|BIIB023
3259703|NCT00771329|Placebo Comparator|2|
3259704|NCT00771316|Experimental|Group 1|MK0826 (ertapenem)
3259705|NCT00771316|Active Comparator|Group 2|meropenem
3259706|NCT00771303||Ct scan|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer measurement, lower limb compression ultrasonography and multi-slice computed tomography.
3259707|NCT00771277|Experimental|Arm 1|Use of volunteer support teams to provide services
3259708|NCT00771264|Active Comparator|Urgent PC|
3259709|NCT00771264|No Intervention|Sham / Placebo|
3259710|NCT00771251|Experimental|CNTO 148 50 mg|
3259711|NCT00771251|Experimental|CNTO 148 100 mg|
3259712|NCT00771251|Experimental|Placebo|
3259713|NCT00771238|Experimental|P500 Mattress|The new P500 Low Air Loss mattress will be used to replace the standard mattress for this study arm.
3259714|NCT00771238|No Intervention|Standard of Care Mattress|Cardiovascular ICU patients that receive standard of care mattress (Total Care Treatment Mattress) and standard pressure ulcer prevention care. All patients had daily skin assessments, as per normal care.
3259715|NCT00771225|Other|prolapse surgery with fascial repair|
3259716|NCT00771225|Other|prolapse surgery with mesh repair|
3259717|NCT00771212||001|
3259718|NCT00771199|Experimental|Transdermal Therapeutic System (TTS)-Fentanyl|
3259719|NCT00771186||children with vocal fold immobility|
3259720|NCT00771173|Active Comparator|Study Medication Group|Participants that are randomized to the phenazopyridine HCl group will receive the study medication (200 mg of phenzopyridine HCl orally) after leaving the operating room. We anticipate the first dose to be given after the patient has left the recovery area. We will continue use of study medication until it has been given up to 24 hours after the first VAS collection or catheter removal, whichever occurs first
3259721|NCT00771173|Placebo Comparator|Placebo tablet Group|For participants randomized to the placebo group will follow the same dosing schedule for the study medication, although they will receive an inert placebo tablet.
3259722|NCT00771160|Experimental|1|MK0476 5mg
3259723|NCT00771160|Experimental|2|MK0476 10mg
3259724|NCT00771147||Group 1|
3259725|NCT00771134|Experimental|Lu AA39959|
3259726|NCT00771134|Placebo Comparator|Placebo|
3259727|NCT00771134|Active Comparator|Quetiapine|
3259728|NCT00771121|Active Comparator|new emulsion|
3259729|NCT00771121|Placebo Comparator|new emulsion placebo|
3259730|NCT00771108|No Intervention|control|Subjects will serve as controls, continuing current diet and activity levels. Subjects will get monthly weights by the investigator at the research center.
3259731|NCT00771108|Experimental|Exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
3259732|NCT00771095|Active Comparator|Control (available) podcast|
3259733|NCT00771095|Experimental|Enhanced podcast|
3259734|NCT00771069||1|Type II Diabetes Mellitus patients with Complication and Hypertension
3259735|NCT00771056|Experimental|Hydroxychloroquine|Hydroxychloroquine 400 mg po daily for up to one year.
3259736|NCT00771043|No Intervention|TYSABRI|
3259737|NCT00771043|No Intervention|AVONEX|
3259738|NCT00771030|Experimental|Rheumatoid Arthritis|"The arm will enroll sequentially in two parts:~Part A - Dose escalation at different dose levels with AMG 827 Part B - Dose expansion at selected dose level from part 1 with AMG 827"
3259739|NCT00771030|Placebo Comparator|Rheumatoid Arthritis (Placebo)|"The arm will enroll sequentially in two parts:~Part A - Dose escalation at different dose levels with placebo Part B - Dose expansion at selected dose level from part 1 with placebo"
3259740|NCT00771017|Active Comparator|Arm I|Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment comprising leuprolide acetate or goserelin intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
3259741|NCT00771017|Experimental|Arm II|Patients receive androgen ablation as in arm I. Patients receive GVAX prostate cancer vaccine (CG1940 and CG8711) intradermally (ID) on day 1. Beginning on day 1 of week 3, patients receive booster doses of CG1940 and CG8711 ID every 2 weeks for 24 weeks.
3259742|NCT00771004|Experimental|Pioglitazone 30 mg to 45 mg QD|
3259743|NCT00771004|Placebo Comparator|Placebo QD|
3259744|NCT00770991|Experimental|Black Raspberry (BRB) Slurry plus BRB suppositories|20 grams BRB Slurry BID plus two, 730 mg BRB suppositories HS
3259745|NCT00770991|Experimental|Black Raspberry (BRB) Placebo Slurry plus BRB suppositories|20 grams BRB Placebo Slurry BID plus two, 730 mg BRB suppositories HS
3259746|NCT00770978|Experimental|Ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
3259747|NCT00770978|Experimental|Ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
3259748|NCT00770965|Experimental|AIN457 0.3 mg/kg|Participants received AIN457 0.3 mg/kg IV on Day 1.
3259749|NCT00770965|Experimental|AIN457 1.0 mg/kg|Participants received AIN457 1.0 mg/kg IV on Day 1.
3259750|NCT00770965|Experimental|AIN457 3.0 mg/kg|Participants received AIN457 3.0 mg/kg IV on Day 1.
3259751|NCT00770965|Placebo Comparator|Placebo|Participants received placebo to AIN457A IV on day 1.
3259752|NCT00770952|Experimental|Pioglitazone 30 mg to 45 mg QD + Glimepiride 2 mg to 4 mg QD|
3259753|NCT00770952|Active Comparator|Glimepiride 4 mg to 6 mg QD|
3259754|NCT00770926|Experimental|Program immediately|Receives the lifestyle program as soon as possible after randomization
3259755|NCT00770926|No Intervention|Wait list control|Wait one year and at the end of the year, is offered the option of participating in the program
3259756|NCT00770913|Active Comparator|1|
3259757|NCT00770913|Experimental|2|
3259758|NCT00770913|Experimental|3|
3259759|NCT00770900|Experimental|Montelukast|Asthmatic children and teenagers took montelukast daily.
3259760|NCT00770900|Placebo Comparator|Placebo|Placebo to montelukast tablet daily.
3259761|NCT00770887||Study participants|This study will enroll 50 English-speaking/literate women at least 18 years of age of any race who have sought contraception with DMPA at the Planned Parenthood of Southwest and Central Florida clinics in Tampa and Fort Myers. Patients who choose to begin DMPA or who have already been using DMPA will be approached regarding voluntary participation in the study. Because DMPA is contraindicated in pregnancy, women with a positive urine pregnancy will not be eligible. Should a woman become pregnant during the study, she will receive no further DMPA injections
3259762|NCT00770874|Experimental|1|S-1 + Cisplatin (arm A)
3259763|NCT00770874|Active Comparator|2|Cisplatin (arm B)
3259764|NCT00770861|Active Comparator|Nebivolol|Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets, oral administration
3259765|NCT00770861|Placebo Comparator|Placebo|Matching placebo tablets, oral administration
3259766|NCT00770848|Other|Phase 1b - AMG 102|Phase 1b is an open-label study with AMG 102 at 15mg/kg de-escalating to 7.5mg/kg and 5mg/kg if needed, will be administered by IV Q3W in combination with MP.
3259767|NCT00770848|Experimental|Phase 2 Arm A - AMG 102 + MP|AMG 102 safe dose level in phase 1b in combination with MP, will be administered by IV Q3W.
3259768|NCT00770848|Placebo Comparator|Phase 2 Arm C- PLACEBO|Placebo in combination with MP, will be administered by IV Q3W.
3259769|NCT00770848|Experimental|Phase 2 Arm B - AMG 102 + MP|Safe dose level in phase 1b of AMG 102 + MP will be administered by Q3W
3259770|NCT00770835|Experimental|Pioglitazone and Metformin QD|(along with lifestyle modification)
3259771|NCT00770835|Active Comparator|Glibenclamide and Metformin QD|(along with lifestyle modification)
3259772|NCT00770822|Experimental|Device, HIFU|High Intensity Focused Ultrasound
3259773|NCT00770822|Active Comparator|Device, brachytherapy|Brachytherapy
3259774|NCT00770809|Experimental|Arm I (THL)|Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m^2 IV over 1 hour once weekly and lapatinib ditosylate 750 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity.
3259775|NCT00770809|Active Comparator|Arm II (TH)|Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m^2 IV over 1 hour once weekly for 16 weeks in the absence of disease progression or unacceptable toxicity.
3259776|NCT00770809|Experimental|Arm III (TL)|Patients receive paclitaxel 80 mg/m^2 IV over 1 hour once weekly and lapatinib ditosylate 15000 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity. (Discontinued as of 6-15-11)
3259777|NCT00770796|Placebo Comparator|Placebo|placebo
3259778|NCT00770796|Active Comparator|Atorvastatin|80 mg die of Atorvastatin given at least two days before elective angiography or angioplasty and continued for two days after.
3259779|NCT00770783|Experimental|Magnetic Seizure Therapy (MST)|
3259780|NCT00770783|Active Comparator|Electroconvulsive Therapy (ECT)|
3259781|NCT00770770|Experimental|Fluocinolone Acetonide 0.2 µg/day|0.2 µg/day
3259782|NCT00770770|Experimental|Fluocinolone Acetonide 0.5 µg/day|0.5 µg/day
3259783|NCT00770757|Experimental|CC-4047 Arm|CC-4047 2 mg orally every day for 1 course (12 weeks or 84 days). Every 28 days of treatment are considered as 1 cycle and every 3 cycles are are considered as 1 course of treatment. A total of 4 courses of treatment are planned (12 months).
3259784|NCT00770744|Experimental|Zicronapine|
3259785|NCT00770744|Active Comparator|Olanzapine|
3259786|NCT00770731|Experimental|Torisel + Hycamtin + Velcade|"Torisel starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle.~Hycamtin starting Dose 0.8 mg/m^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle.~Velcade starting Dose 0.3 mg/m^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle."
3259787|NCT00770731|Experimental|Expansion Group|"Torisel + Hycamtin + Velcade Expansion Group~Addition of 10 participants at highest tolerated dose level"
3259788|NCT00770718|Experimental|Recombinant Activated Factor VII|The first five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is >1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given. If a maximum total of 80mcg/kg has been administered without successful correction of INR, then FFP infusions will be utilized to complete correction.
3259789|NCT00770718|Experimental|Prothrombin Complex Concentrate (PCC)|5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is >1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered before FFP will be used to complete the correction.
3259790|NCT00770718|Active Comparator|Fresh Frozen Plasma (FFP)|The last five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is >4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to >1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
3259791|NCT00770705|Experimental|1|Group receiving phenoxybenzamine
3259792|NCT00770705|Other|2|Historical control
3259793|NCT00770692|Experimental|Eszopiclone 1 mg- Elderly|
3259794|NCT00770692|Experimental|Eszopiclone 2 mg- Elderly|
3259795|NCT00770692|Experimental|Eszopiclone 2 mg- Non-elderly|
3259796|NCT00770692|Experimental|Eszopiclone 3 mg- Non-elderly|
3259797|NCT00770679|Experimental|High-Dose Statin|80 mg atorvastatin daily for 3 weeks
3259798|NCT00770666|Experimental|1|Nicotine patch, nicotine inhaler, bupropion
3259799|NCT00770666|Active Comparator|2|Nicotine patch
3259800|NCT00770653|Experimental|Pioglitazone 15 mg and Metformin 850 mg BID|
3259801|NCT00770653|Active Comparator|Glimepiride 2 mg and Metformin 850 mg BID|
3259802|NCT00770640|Experimental|Pioglitazone 30mg QD|(and variable insulin therapy)
3259803|NCT00770640|Placebo Comparator|Placebo QD|(and variable insulin therapy)
3259804|NCT00770627|Placebo Comparator|Placebo caps|
3259806|NCT00770614|Active Comparator|1|Sodium Bicarbonate (154 mEq/L in dextrose and H2O) 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
3259807|NCT00770614|Active Comparator|2|Isotonic Saline (0.9% sodium chloride) 1 mL/kg/h for 12 hours after the procedure
3259808|NCT00770614|Placebo Comparator|3|Placebo
3259809|NCT00770601|Experimental|Canakinumab|
3259810|NCT00770588|Experimental|gefitinib|Gefitinib (Iressa® 250 mg) 1 tablet daily
3259811|NCT00770588|Placebo Comparator|placebo|placebo 1 tablet daily
3259812|NCT00770575|Experimental|Pioglitazone 30mg to 45 mg QD + Atorvastatin 20 mg to 40 mg QD|
3259813|NCT00770575|Active Comparator|Atorvastatin 20mg to 40 mg QD|
3259814|NCT00770562|Active Comparator|Dexamethasone|Participants received 40 milligrams (mg) dexamethasone, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4). Participants in this treatment arm who failed to achieve a sustained response and had a platelet count of less than or equal to (≤)20 x 10^9 platelets per liter (L; from Day 30 up to end of 6 months) were treated with salvage treatment of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg per square meter (mg/m^2), intravenously (IV), with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28.
3259815|NCT00770562|Experimental|Dexamethasone plus Rituximab|Participants received dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m^2, IV, with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28. Nonresponsive participants with platelets less than (<) 20 x10^9/L or with active bleeding could have also received an additional treatment course of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m^2, IV on Days 7, 14, 21, and 28 administered with immunoglobulin (IgG) IV (at investigator discretion) and/or low/medium dose steroids (at investigator discretion) on Days 7, 14, 21, and 28.
3259816|NCT00770536|Experimental|Part 1|In part 1, six subjects will be assigned to each cohort A or B. This is a dose escalation/de escalation study with a 6 + 3 design based on the incidence of DLTs (dose limiting toxicities) during the first 4 weeks of combined therapy [(cohort A: AMG 386 and pegylated liposomal doxorubicin) or (cohort B: AMG 386 and topotecan)].
3259817|NCT00770536|Experimental|Part 2|The decision on declaration of a safe and tolerable dose during part 1 will lead to part 2 (cohort A: liposomal doxorubicin + AMG 386 MTD (max tolerated dose) of part 1, cohort B: Topotecan + AMG 386 MTD (max tolerated dose) of part 1
3259818|NCT00770510|Experimental|Eszopiclone 1 mg|
3259819|NCT00770510|Experimental|Eszopiclone 2 mg|
3259820|NCT00770510|Experimental|Eszopiclone 3 mg|
3259821|NCT00770510|Placebo Comparator|Placebo|
3259822|NCT00770510|Active Comparator|Zolpidem Tartrate 10 mg|
3259823|NCT00770497|Experimental|Pioglitazone 15 mg to 30 mg QD|
3259824|NCT00770497|Active Comparator|Pioglitazone 15 mg to 30 mg QD + Ramipril 2.5 mg to 5 mg QD|
3259825|NCT00770497|Active Comparator|Ramipril 2.5 mg to 5 mg QD|
3259826|NCT00770484|Experimental|Propranolol then placebo|Active treatment
3259827|NCT00770484|Placebo Comparator|Placebo then propranolol|Placebo Treatment
3259828|NCT00770471|Experimental|Dose Escalation|
3259829|NCT00770458||Pregnant women|Pregnant women that will undergo standard of care procedures to evaluate fetus for Down Syndrome
3259830|NCT00770445|Experimental|Pioglitazone 15mg BID|Insulin therapy added
3259831|NCT00770445|Experimental|Pioglitazone 15mg + Metformin 850mg BID|Insulin Therapy Added
3259832|NCT00770445|Active Comparator|Metformin 850mg BID|Insulin therapy added
3259833|NCT00770432|Active Comparator|Polyethylene glycol 3350 powder for solution|MiraLAX® (polyethylene glycol 3350 powder for solution)
3259834|NCT00770432|Placebo Comparator|Placebo|MALTRIN 500® M500 (maltodextrin 500)
3259835|NCT00770393|Experimental|1|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging.
3259836|NCT00770393|Active Comparator|2|Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.
3259837|NCT00770380|Experimental|Hypnosis for relapse prevention|The hypnosis intervention was conducted in two face-to-face visits with hypnosis recorded for home practice. Learning, practicing, and employing hypnotic skills in resisting the urge to smoke are core components of this intervention.
3259838|NCT00770380|Active Comparator|Behavioral relapse prevention counseling|In the behavioral relapse prevention counseling, participants were taught coping strategies for resisting the urge to smoke. This intervention focused on relapse prevention (i.e., maintenance stage of change) and was based on the theoretical concepts and treatment procedures advocated by Marlatt and Gordon and recent smoking relapse data.
3259839|NCT00770367|Experimental|Pioglitazone then Placebo|18 volunteers that are Diabetic adults, 40-75 years that have higher ADMA levels as well as increased inflammation will take Pioglitazone for the first 12 week period of the study and then take the placebo for the final 12 weeks of the study.
3259840|NCT00770367|Experimental|Placebo then Pioglitazone|18 (other half of participants) volunteers that are Diabetic adults, 40-75 years that have higher ADMA levels as well as increased inflammation will take the placebo for the first 12 week period of the study and then take the Pioglitazone for the final 12 weeks of the study.
3259841|NCT00770354|Experimental|1|AS1402 plus letrozole
3259842|NCT00770354|Active Comparator|2|Letrozole
3259843|NCT00770341|Experimental|MK-3009 (daptomycin) 4 mg/kg|
3259844|NCT00770341|Active Comparator|Vancomycin|
3259845|NCT00770341|Experimental|MK-3009 (daptomycin) 6 mg/kg|
3259846|NCT00770328|Experimental|Pentoxifylline|Patients receive Pentoxifylline 400 mg po TID for 8 weeks.
3259847|NCT00770328|Placebo Comparator|Placebo|Patients take a placebo TID for 8 weeks.
3259848|NCT00770315|Experimental|SCH 39641 1.5 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
3259849|NCT00770315|Experimental|SCH 39641 6 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
3259850|NCT00770315|Experimental|SCH 39641 12 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
3259851|NCT00770315|Placebo Comparator|Placebo|Participants receive matching placebo rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
3259852|NCT00770289||Single group|
3259853|NCT00770276||Bariatric surgery|Bariatric surgery
3259854|NCT00770276||conservative Therapie|diet and exercise
3259855|NCT00770263|Experimental|Dose Level 1A|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 10 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 10 mg IV on days 8, 15, and 22 during subsequent cycles."
3259856|NCT00770263|Experimental|Dose Level 1|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 15 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 15 mg IV on days 8, 15, and 22 during subsequent cycles."
3259857|NCT00770263|Experimental|Dose Level 2|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 20 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 20 mg IV on days 8, 15, and 22 during subsequent cycles."
3259858|NCT00770263|Experimental|Dose Level 3|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 25 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 25 mg IV on days 8, 15, and 22 during subsequent cycles."
3259859|NCT00770263|Experimental|Dose Expansion Phase|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 25 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 25 mg IV on days 8, 15, and 22 during subsequent cycles."
3259860|NCT00770237|Experimental|Cues|Outcome Measures During cue trials, primary measures include craving (TCQ-SF, VAS), mood (mood form, VAS), and autonomic (heart rate, blood pressure, skin conductance and temperature) responsivity. During self-administration trials, primary measures include breakpoint (final ratio completed), total number of responses, and number of cigarette puffs earned and taken. Secondary measures include baseline smoking history, mood form, TCQ-SF, CO, FTND, and urinary cotinine and 3-hydroxycotinine (3-HC).
3259861|NCT00770224|Experimental|R-CHOP, tositumomab and rituximab|"Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 IV Day 1 Prednisone 100 mg PO Days 1-5 Rituximab 375 mg/m2 IV Day 1 Q 21 Days x 6 Cycles~Patients are restaged by CT scan. Unlabeled tositumomab antibody 450 mg IV within 12 after Cycle 6 of CHOP. Dosimetric dose 35 mg IV after infusion of unlabeled tositumomab antibody. Unlabeled tositumomab antibody 450 mg IV 7-14 days after dosimetric dose. Therapeutic dose 35 mg IV after infusion of unlabeled tositumomab antibody.~Rituximab 375 mg/m2 IV q 3 months x 4 years beginning 1 year after registration."
3259862|NCT00770211|Experimental|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
3259863|NCT00770211|Placebo Comparator|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
3259864|NCT00770198||alcoholic liver disease|alcoholic liver disease patients undergoing a transjugular liver biospy in our institution
3259865|NCT00770198||chronic HCV hepatitis|chronic HCV hepatitis patients undergoing a transjugular liver biopsy in our institution
3259866|NCT00770185|Experimental|Ridaforolimus|oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
3259867|NCT00770172|Experimental|Arm I|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily for 6 days beginning 1 week after the start of chemotherapy (days 7-12). If chemotherapy begins on day 8, patients receive G-CSF SC on days 9-14.
3259868|NCT00770172|Experimental|Arm II|Patients receive G-CSF SC every 2 days on days 10-20 for up to 6 injections.
3259869|NCT00770159|Experimental|1|MK0822
3259870|NCT00770159|Placebo Comparator|2|Placebo to MK0822
3259871|NCT00770146|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once a week for 26 weeks.
3259872|NCT00770146|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
3259873|NCT00770133|Experimental|Ketotifen/naphazoline|Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
3259874|NCT00770133|Placebo Comparator|Vehicle|Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
3259875|NCT00770133|Active Comparator|Naphazoline|Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
3259876|NCT00770133|Active Comparator|Ketotifen|Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
3259877|NCT00770120|Experimental|Everolimus|Daily oral Everolimus 10 mg/day
3259878|NCT00770107|Active Comparator|Thiamine|
3259879|NCT00770107|Placebo Comparator|Placebo|
3259880|NCT00770094|Active Comparator|Group 1|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment in one eye of the subject and the AMO/VISX CustomVue™ wavefront guided Excimer Laser System performed on the contralateral eye
3259952|NCT00769483|Experimental|Phase I, Arm B|MK-0646 + Gemcitabine + Erlotinib
3259953|NCT00769483|Experimental|Phase II, Arm A|Gemcitabine + Erlotinib
3259881|NCT00770094|Active Comparator|Group 2|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment in one eye of the subject and the Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System performed on the contralateral eye
3259882|NCT00770094|Active Comparator|Group 3|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment in one eye of the subject and the Bausch and Lomb Planoscan™ Excimer Laser System performed on the contralateral eye
3259883|NCT00770081|Experimental|1|50mg qd vildagliptin
3259884|NCT00770081|Active Comparator|2|sitagliptin (25mg qd)
3259885|NCT00770068||Experimental group|All participants testing positive for tree and ragweed pollen allergies, as determined by levels of immunoglobulin E (IgE) antibodies
3259886|NCT00770068||Control group|All participants testing negative for tree and ragweed pollen allergies, as determined by levels of IgE antibodies
3259887|NCT00770042|Experimental|Group 1|Ketoconazole 400 mg qd for 5 days (Days 2-6) plus a single dose of 50 mg avanafil on Days 1 and 6
3259888|NCT00770042|Experimental|Group 2|Erythromycin 500mg every 12 hours for 5 days (Days 2-6) plus a single dose of 200 mg Avanafil on Days 1 and 6.
3259889|NCT00770042|Experimental|Group 3|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8) plus a single dose of 50 mg avanafil on Days 1 and 8
3259890|NCT00770029|Experimental|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
3259891|NCT00770029|Placebo Comparator|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
3259892|NCT00770016|Experimental|1|the aim of the present study is to characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic - intramyocellular lipids in 12 adult patients, recently diagnosed with hypothyroidism
3259893|NCT00770003|Experimental|1|
3259894|NCT00770003|Placebo Comparator|2|
3259895|NCT00769990|Experimental|Genistein|Patients treated with Genistein who are going to undergo palliative radiation treatments for painful boney metastases.
3259896|NCT00769938|Active Comparator|Aspirin + clopidogrel + oral anticoagulation|
3259897|NCT00769938|Active Comparator|Oral anticoagulants + clopidogrel|
3259898|NCT00769925|Experimental|Therapist Assisted Bibliotherapy-Primary Care (TAB-PC)|
3259899|NCT00769925|Experimental|Cognitive Behavior Therapy-Primary Care (CBT-PC)|
3259900|NCT00769912|Experimental|1|50% N2O- 50%O2 mixture administration during the intervention
3259901|NCT00769912|Placebo Comparator|2|Placebo (air) during the intervention
3259902|NCT00769899|Experimental|1|
3259903|NCT00769899|Placebo Comparator|2|
3259904|NCT00769886|Experimental|KetoNaph|KetoNaph (ketotifen fumarate 0.025%, naphazoline HCl 0.05%) ophthalmic solution
3259905|NCT00769886|Active Comparator|Naphazoline|Naphazoline HCl 0.05% ophthalmic solution
3259906|NCT00769886|Active Comparator|Ketotifen|Ketotifen fumarate 0.025% ophthalmic solution
3259907|NCT00769886|Placebo Comparator|Vehicle|Vehicle of KetoNaph ophthalmic solution
3259908|NCT00769873|Active Comparator|Lovenox|Patients receive Lovenox 40mg SC daily (30mg SC daily if creatinine clearance < 30) for 21 days after laparoscopic splenectomy
3259909|NCT00769873|No Intervention|No Lovenox|Patients do NOT receive Lovenox post laparoscopic splenectomy
3259910|NCT00769860|Active Comparator|1|Arimoclomol
3259911|NCT00769860|Placebo Comparator|2|
3259912|NCT00769847||Sagittal synostosis|Male and female infants from 1-6 months of age with isolated, single suture sagittal craniosynostosis.
3259913|NCT00769834||CKD|The cohort comprises of patients who are diagnosed to have chronic kidney disease as defined by the K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease-2002.
3259914|NCT00769795|Experimental|Experimental|Bicalutamide 50 mg daily for 12 weeks Goserelin 10.8 mg SC once IMC-A12 10 mg/kg IV every three weeks for 12 weeks
3259915|NCT00769782|Experimental|therapeutic conventional surgery|All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
3259916|NCT00769769|Experimental|Telephone-based psychotherapy|
3259917|NCT00769769|Active Comparator|Face-to-face psychotherapy|
3259918|NCT00769756||2|"Financial incentive~For the parents the financial incentive was 5 euros for every kilogram of weight-loss. For children the weight loss was calculated differently, taking into account the individual need of each child to lose weight. Children with a body mass index between the 90th and 97th age-adjusted BMI-percentile were asked to maintain their weight, and were paid in dependence on how well they managed to achieve this goal. Children with age-adjusted BMI-percentiles between 97 and 99, or above the 99th age-adjusted BMI-percentile received 5 euros per weight losses of respectively 500 g or 1 kg."
3259919|NCT00769756||1|The telemedical equipment consisted of a weighing scale for each family, an accelerometer for each participant, and a Homebox for each family which received the data from the scale and the accelerometers via bluetooth and transfered them via a telephone link to a server in Munich.
3259954|NCT00769483|Experimental|Phase II, Arm B|MK-0646 + Gemcitabine + Erlotinib
3259955|NCT00769483|Experimental|Phase II, Arm C|Gemcitabine + Erlotinib
3260016|NCT00769041|Experimental|avanafil therapeutic|avanafil 100mg - therapeutic dose
3259920|NCT00769756||3|The basic diet for all participants was supported by a list giving the calorie contents of a large variety of food-stuffs. The dual diet group received a second list giving the glycemic index (GI) for a large variety of carbohy-drates. Emphasis was placed on a preference for low-GI carbohydrates but not on avoidance of carbohydrates as required by the Atkins diet.
3259921|NCT00769730||1|Patients with hepatocellular carcinoma caused by hepatitis B virus who will be treated by transcatheter arterial chemoembolization were included.
3259922|NCT00769717|Experimental|Wellness-Centered|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
3259923|NCT00769717|Active Comparator|Weight-Centered|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
3259924|NCT00769704|Active Comparator|GM-CSF|Granulocyte macrophage colony-stimulating factor (GM-CSF) was administered at a dose of 125 μg/m²/day subcutaneously for 14 days, followed by a 14-day rest period for 24 weeks. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, or lack of response by 12 months, for a maximum of 18 months.
3259925|NCT00769704|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec on Days 1 and 15 of each 28-day cycle for 24 weeks. The initial dose of talimogene laherparepvec was at a concentration of 10⁶ plaque forming units (PFU)/mL, injected into 1 or more skin, subcutaneous or nodal tumors. Subsequent doses began at least 3 weeks after the first dose and consisted of talimogene laherparepvec at a concentration of 10⁸ PFU/mL. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, lack of response by 12 months, or disappearance of all injectable lesions, for a maximum of 18 months.
3259926|NCT00769691||Group A|Adult patients undergoing cardiac surgery
3259927|NCT00769678|Active Comparator|Stimulation of diaphragm|
3259928|NCT00769665||Systane Ultra|Systane Ultra
3259929|NCT00769665||Sensitive Eyes|Sensitive Eyes
3259930|NCT00769652|Experimental|Medical nutrition therapy|Medical nutrition therapy
3259931|NCT00769652|Active Comparator|Standard care|Standard care
3259932|NCT00769626|Experimental|Early Treatment|
3259933|NCT00769626|Active Comparator|Usual Care|
3259934|NCT00769600|Active Comparator|Itraconazole Open Label added to standard of care pemetrexed|Subjects will receive standard dose pemetrexed day 1 of each 21-day cycle, IV. Participants will be randomized at the beginning of the study to receive either oral itraconazole 200 mg once daily during the period of chemotherapy (days 1-21).
3259935|NCT00769600|Active Comparator|Single agent pemetrexed|Subjects will receive standard dose pemetrexed day 1 of each 21-day cycle, IV. Participants will be randomized at the beginning of the study to receive pemetrexed alone.
3259936|NCT00769587|Experimental|Thalidomide|Use of thalidomide
3259937|NCT00769574|Experimental|1|Patients with coronary syndrome
3259938|NCT00769574|Other|2|Subjects without coronary syndrome
3259939|NCT00769561|Experimental|BFB-CBT|"Biofeedback-based cognitive-behavioral treatment:~The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits."
3259940|NCT00769561|Active Comparator|Occlusal Splint (OS)|"Dental treatment with occlusal splints:~Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment."
3259941|NCT00769548|Experimental|Arm 1|Neoadjuvant total androgen suppression (TAS) given 2 months before and during radiation therapy (RT) to the whole pelvis followed by a prostate boost.
3259942|NCT00769548|Experimental|Arm 2|Neoadjuvant TAS given 2 months before and during RT to the prostate only.
3259943|NCT00769548|Experimental|Arm 3|RT to the whole pelvis followed by a boost to the prostate followed by 4 months of TAS.
3259944|NCT00769548|Experimental|Arm 4|RT to the prostate only followed by 4 months of TAS.
3259945|NCT00769535|Experimental|HSP70 and TNF polymorphisms|
3259946|NCT00769522|Experimental|FCR|
3259947|NCT00769522|Experimental|BR|
3259948|NCT00769509|Experimental|preterm formula|Assessment of energy expenditure of preterm infant during fed with preterm formula
3259949|NCT00769509|Active Comparator|human milk with fortifier|Assessment of energy expenditure by indirect calorimetry during fed with human milk with fortifier
3259950|NCT00769496|Experimental|Arm 1|
3259951|NCT00769483|Experimental|Phase I, Arm A|MK-0646 + Gemcitabine
3259956|NCT00769470|Active Comparator|Arm I|Patients receive trastuzumab IV over 90 minutes on day in course 1. Patients receive docetaxel IV, carboplatin IV, and trastuzumab IV over 30 minutes on day 1 in course 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3259957|NCT00769470|Experimental|Arm II|Patients receive oral lapatinib ditosylate once daily on days 1-21 in course 1. Patients receive docetaxel IV and carboplatin IV on day 1 and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7.Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3259958|NCT00769470|Experimental|Arm III|Patients receive trastuzumab IV over 90 minutes on day 1 and oral lapatinib ditosylate daily on days 1-21. Starting on day 22, patients receive docetaxel IV, carboplatin IV, and trastuzumab IV three times a week and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3259959|NCT00769457|Experimental|1|Arm with activated OptiVol / Carelink-system, event-triggered physician alert and physician access to Cardiac Compass data
3259960|NCT00769457|No Intervention|2|Arm with standard ICD - CRT-D therapy, no OptiVol and no Carelink
3259961|NCT00769431|No Intervention|Focus group|
3259962|NCT00769418|Experimental|1|odanacatib (MK0822)
3259963|NCT00769418|Placebo Comparator|2|placebo to odanacatib (MK0822)
3259964|NCT00769405|Experimental|Arm I|Patients undergo surgery and receive standard systemic chemotherapy comprising leucovorin calcium IV followed by fluorouracil IV over 30 minutes. Systemic chemotherapy will continue for at least 6 months (before and after surgery). Patients also undergo CHIP comprising oxaliplatin intraperitoneally during surgery and hyperthermia for 30 minutes.
3259965|NCT00769405|Experimental|Arm II|Patients undergo surgery and receive standard systemic chemotherapy comprising leucovorin calcium IV followed by fluorouracil IV over 30 minutes. Systemic chemotherapy will continue for at least 6 months (before and after surgery).
3259966|NCT00769392|Active Comparator|1|Proparacaine Drops
3259967|NCT00769392|Active Comparator|2|Tetracaine Drops
3259968|NCT00769392|Active Comparator|3|Lidocaine 4% soaked cotton sponge
3259969|NCT00769392|Active Comparator|4|Lidocaine 2% subconjunctival injection
3259970|NCT00769379|Experimental|Arm I (standard WBI)|Patients undergo standard WBI over 5-6 weeks.
3259971|NCT00769379|Experimental|Arm II (WBI, trastuzumab)|Patients receive trastuzumab IV over 30-90 minutes once in weeks 1 and 4. Patients also undergo WBI as in Arm I.
3259972|NCT00769366|Experimental|Psychotherapy|Psychotherapy and medical therapy
3259973|NCT00769366|Active Comparator|Control|Optimal medical therapy
3259974|NCT00769353|Experimental|Cognitive Behavioral Therapy-PASCET|Primary and Secondary Coping Enhancement Training (PASCET)
3259975|NCT00769353|Active Comparator|Supportive Non-Directive Therapy (SNDT)|Supportive Non-Directive Therapy (SNDT)
3259976|NCT00769314|Experimental|1|Acyclovir Lauriad 50mg
3259977|NCT00769314|Placebo Comparator|2|
3259978|NCT00769301||1|Not hospitalized cancer patients under active treatment
3259979|NCT00769301||2|Caregivers of these cancer patients
3259980|NCT00769288|Experimental|I|Patients will receive a 1-hour infusion of FAU on days 1-5.
3259981|NCT00769275||1|Screening at start study with Adenosine vasodilator stress Tc-99m Sestamibi SPECT imaging
3259982|NCT00769275||2|No screening
3259983|NCT00769262|Active Comparator|Aggressive Weaning|Infants will be weaned from the isolette using our current NICU standard of care.
3259984|NCT00769262|Experimental|Conservative Weaning|Infants will be weaned from the isolette using a modified conservative weaning schedule.
3259985|NCT00769236|Other|1|Patients with crohn disease
3259986|NCT00769236|Other|2|Patients reached by hemorrhagic first side-colitis
3259987|NCT00769236|Other|3|Patients controls
3259988|NCT00769210|Experimental|A|
3259989|NCT00769197||1|Children with birth/time of neurologic insult less than 28 weeks of gestation
3259990|NCT00769197||2|Children with birth/time of neurologic insult at more than 28 weeks of gestation
3259991|NCT00769184|Experimental|Corticosteroid + LCD|corticosteroid and LCD treatment (2 weeks), LCD alone treatment (4 weeks)
3259992|NCT00769184|Placebo Comparator|Corticosteroid + Placebo|corticosteroid and placebo treatment (2 weeks), placebo alone treatment (4 weeks)
3259993|NCT00769171|Active Comparator|Arm 2|
3259994|NCT00769171|Experimental|Arm 1|
3259995|NCT00769158|Experimental|Topiramate + Naltrexone|Combination of Topiramate and Naltrexone
3259996|NCT00769158|Placebo Comparator|Placebo|
3259997|NCT00769145|Experimental|Ranibizumab|Patients to receive two injections of 0.5 mg ranibizumab subconjunctivally
3259998|NCT00769132|Experimental|A|ER niacin/laropiprant + Placebo to laropiprant
3259999|NCT00769132|Active Comparator|B|ER niacin + Placebo to laropiprant
3260000|NCT00769132|Experimental|C|laropiprant + Placebo to ER niacin/laropiprant
3260001|NCT00769132|Placebo Comparator|D|Placebo
3260002|NCT00769119|Experimental|AZD9668 active treatment|
3260003|NCT00769119|Placebo Comparator|AZD9668 placebo treatment|
3260004|NCT00769106|No Intervention|B (control group)|regular treatment and follow up
3260005|NCT00769106|Experimental|A (CIK group)|cytokine-induced killer cell treatment plus regular treatment and follow up
3260006|NCT00769093|Active Comparator|Group 1|Both groups will receive an intravenous chemotherapeutic drug (carboplatin). The first study group (n=6) will receive bevacizumab, the antiangiogenic agent for three weeks, then dexamethasone for three weeks.
3260007|NCT00769093|Active Comparator|Group 2|Both groups will receive an intravenous chemotherapeutic drug (carboplatin). The second study group (n=6) will receive dexamethasone for 3 weeks, then switch to bevacizumab, the antiangiogenic agent, for 3 weeks.
3260008|NCT00769080||1|Standard Treatment plus PSP
3260009|NCT00769080||2|Standard Treatment
3260010|NCT00769067|Active Comparator|A|
3260011|NCT00769067|Experimental|B|
3260012|NCT00769054|Active Comparator|1|Local Infiltration with Ropivacaine
3260013|NCT00769054|Placebo Comparator|2|Local Infiltration with Placebo
3260014|NCT00769041|Placebo Comparator|placebo|
3260015|NCT00769041|Active Comparator|moxifloxacin|
3260017|NCT00769041|Experimental|avanafil supratherapeutic|avanafil 800mg - supratherapeutic dose
3260018|NCT00769028|Experimental|AIMSPRO|
3260019|NCT00769028|Placebo Comparator|Placebo|
3260020|NCT00769015|Experimental|BA-LVR|In BA-LVR, a low vision occupational therapist (OT) will deliver Behavior Activation (BA), a psychological treatment to prevent depression. This will be administered in the context of the standard of low vision care for OTs as defined by the American Occupational Therapy Association (AOTA). The OTs will collaborate with low vision optometrists, who will deliver the standard of low vision care as defined by the American Optometric Association. The optometrists will evaluate remaining vision and magnification needs, prescribe optical devices, and provide the OTs with initial care plans. The OTs will subsequently meet with subjects in their homes 6 times over 12 weeks to enhance device use, home modifications, and compensatory strategies.
3260021|NCT00769015|Placebo Comparator|ST-LVR|Subjects randomized to ST-LVR will receive clinic-based low vision optometry, in addition to 6 in-home Supportive Therapy (ST) sessions. ST is a placebo condition that controls for the attention that subjects in the active treatment arm will receive.
3260022|NCT00769002|Active Comparator|1|Previous influenza positivity
3260023|NCT00769002|Active Comparator|2|No previous influenza positivity
3260024|NCT00768989|Experimental|Atazanavir + Raltegravir|Atazanavir 300 mg twice daily + Raltegravir 400 mg twice daily
3260025|NCT00768989|Active Comparator|Atazanavir + Ritonavir + Tenofovir /Emtricitabine|Atazanavir, 300 mg once daily, + Ritonavir, 100 mg once daily, + Tenofovir 300 mg/Emtricitabine, 200 mg once daily
3260026|NCT00768963|Experimental|1|Patients will receive one injection of ranibizumab 3 days prior to surgery
3260027|NCT00768963|Experimental|2|Patients will undergo one injection of ranibizumab at the time of surgery
3260028|NCT00768950||Spondyloarthropathies|Patients with spondyloarthropathies (ankylosing spondylitis, reactive arthritis, psoriatic arthritis and spondylitis, enteropathic arthritis and spondylitis, juvenile-onset spondyloarthritis, and undifferentiated spondyloarthritis) as defined by the AMOR criteria
3260029|NCT00768937|Experimental|Treatment arm|all patients will be treated with sorafenib
3260030|NCT00768924||1|Spinal fusion patients
3260031|NCT00768911|Experimental|1|
3260032|NCT00768898||2.5 microliters lissamine green|
3260033|NCT00768898||5.0 microliters lissamine green|
3260034|NCT00768898||10.0 microliters lissamine green|
3260035|NCT00768885|Active Comparator|PureVision 1|PureVision soft contact lens design #1.
3260036|NCT00768885|Experimental|PureVision 2|PureVision soft contact lens design #2
3260037|NCT00768859|Experimental|1|paclitaxel, trastuzumab and carboplatin
3260038|NCT00768846|Active Comparator|1|Endeavor Resolute Stent
3260039|NCT00768846|Active Comparator|2|Xience V Stent
3260040|NCT00768820|Experimental|1|
3260041|NCT00768807|Sham Comparator|Sham CPAP|Patients submitted to SHAM CPAP use for 06 months
3260042|NCT00768807|Active Comparator|CPAP|OSA patients submitted to 06 months of CPAP treatment
3260043|NCT00768794|Active Comparator|Acidolphilus|In the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.
3260044|NCT00768781|Active Comparator|Mindfulness-Based Stress Reduction|
3260045|NCT00768781|Active Comparator|Mindfulness-Based Therapy for Insomnia|
3260046|NCT00768781|Other|Behavioral Therapy for Insomnia (Delayed treatment condition)|
3260047|NCT00768768|Active Comparator|1|Iontophoretic Dose Level 1
3260048|NCT00768768|Active Comparator|2|Iontophoretic Dose Level 2
3260049|NCT00768768|Active Comparator|3|Iontophoretic Dose Level 3
3260050|NCT00768768|Active Comparator|4|Iontophoretic Dose Level 4
3260051|NCT00768768|Active Comparator|5|Iontophoretic Dose Level 5
3260052|NCT00768755|Experimental|I|Axitinib (continuous) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
3260053|NCT00768755|Experimental|II|Axitinib (modified) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
3260054|NCT00768755|Active Comparator|III|pemetrexed and cisplatin
3260055|NCT00768755|Experimental|IV|Axitinib interrupted before each chemo cycle (Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
3260056|NCT00768755|Active Comparator|V|pemetrexed and cisplatin
3260057|NCT00768729|Experimental|1|"Participants who have been maintained on MMF at study entry will start the study on 600 mg/m2 MMF orally daily. Participants who have been maintained on Azathioprine due to MMF intolerance will receive 1 mg/kg Azathioprine orally daily.~Participants will continue receiving sirolimus throughout the study. However, MMF or Azathioprine will be withdrawn gradually over a period of at least 6 months. Dosage will be reduced by 25% initially and by 25% every subsequent 2 months resulting in complete withdrawal by 6 months."
3260058|NCT00768716|Experimental|White subjects|2 x 500 mg acetaminophen by mouth once
3260059|NCT00768716|Experimental|Black subjects|2 x 500 mg acetaminophen by mouth once
3260060|NCT00768703|Experimental|Treatment|Percutaneous endoscopic fetal tracheal 'plug/unplug' using the Goldvalve balloon
3260061|NCT00768690|Other|1|Healthy volunteers, receiving daily doses of 200 mg ABT-333 or placebo, BID for 10 days; and on Study Day 11 receiving a single dose of 200 mg ABT-333 or placebo + 400 mg ketoconazole
3260062|NCT00768690|Other|2|Healthy volunteers, receiving 400 mg ABT-333 or placebo, BID
3260063|NCT00768690|Other|3|Healthy volunteers, receiving 600mg ABT-333 or placebo, BID
3260064|NCT00768690|Other|4|Healthy volunteers, receiving 1000mg ABT-333 or placebo, BID
3260065|NCT00768690|Other|5|"Healthy volunteers, receiving 1600mg ABT-333 or placebo, BID*~*After review of the data from previous groups, and in accordance with the protocol, this arm was not dosed."
3260066|NCT00768664|Experimental|A|
3260067|NCT00768651|Experimental|One arm: Sitagliptin + Pantoprazole|"Intervention Details:~Sitagliptin 100 mg daily and Pantoprazole 40 mg bid for 6 months, followed by a three-month washout."
3260068|NCT00768638|Active Comparator|Atorvastatin 10mg|
3260069|NCT00768638|Active Comparator|Atorvastatin 40mg|
3260070|NCT00768612|Experimental|1|Lowest dose
3260071|NCT00768612|Experimental|2|Middle dose
3260072|NCT00768612|Experimental|3|Highest dose
3260073|NCT00768612|Active Comparator|4|Positive Control
3260074|NCT00768599|Active Comparator|1|Econazole Nitrate Cream 1%
3260075|NCT00768599|Experimental|2|Econazole Nitrate Foam 1%
3260076|NCT00768599|Placebo Comparator|3|Vehicle Foam
3260077|NCT00768586||1|Extreme premature infants under the 28th week of gestation.
3260078|NCT00768573||1. Taste test|Not Specified
3260079|NCT00768560|Active Comparator|Nifedipine (Adalat CR, BAYA1040) 40 mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
3260080|NCT00768560|Experimental|Nifedipine (Adalat CR, BAYA1040) 40 mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
3260081|NCT00768560|Experimental|Nifedipine (Adalat CR, BAYA1040) 80 mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
3260082|NCT00768547||By protocol|Where the test are predefined
3260083|NCT00768547||By degression|The group where the doctor decided which test are to be taken.
3260084|NCT00768521|Experimental|1|Part I, Sequence 1: tolterodine tartrate crossing over to matching placebo
3260085|NCT00768521|Experimental|2|Part I, Sequence 2: placebo crossing over to study drug 4 mg once a Day (qd)
3260086|NCT00768521|Experimental|3|Part II, Sequence 1: study drug crossing over to placebo
3260087|NCT00768521|Experimental|4|Part II, Sequence 2: placebo crossing over to study drug
3260088|NCT00768508|Experimental|Ondansetron|Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy
3260089|NCT00768508|Experimental|Naltrexone|Naltrexone 50 mg/day + Cognitive Behavioral Therapy
3260090|NCT00768508|Experimental|Ondansetron + Naltrexone|Ondansetron 4 ug/kg b.i.d. + Naltrexone 50 mg/day + Cognitive Behavioral Therapy
3260091|NCT00768508|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy
3260092|NCT00768495||One Cohort|
3260093|NCT00768482|Experimental|Probuphine|Patients are first inducted on SL BPN, and then switched to 4 Probuphine implants
3260094|NCT00768469|Experimental|HKI-272 + Paclitaxel|HKI-272 + Paclitaxel
3260095|NCT00768456|Active Comparator|1|Local infiltration with Ropivacaine
3260096|NCT00768456|Placebo Comparator|2|Local infiltration with Placebo (NaCl)
3260097|NCT00768430|Experimental|1|Ketamine
3260098|NCT00768430|Active Comparator|2|Midazolam
3260099|NCT00768417||Participants|Participants completed all 3-arms of this cross-over design study.
3260100|NCT00768404|Experimental|A|
3260101|NCT00768391|Experimental|IMC-3G3|All patients will receive intravenous infusions of IMC-3G3, with the dose depending on which cohort they are enrolled into.
3260102|NCT00768378|Experimental|Perceived stimulation|When subjects assigned to the perceived stimulation group increase the intensity of the stimulus, they will feel a tingling sensation on the tongue. The tingling will move on the tongue in relation to where the head/body moves.
3260103|NCT00768378|Experimental|Subliminal stimulation|When subjects assigned to the subliminal stimulation group increase the intensity of the stimulus, the device provides a stimulus that is below their conscious awareness, so they will not be able to perceive it. The stimulus will move on the tongue in relation to where the head/body moves.
3260104|NCT00768365||group 1|patients with adrenal incidentaloma
3260105|NCT00768365||group 2|Thirty-five subjects comparable for sex, age, and BMI were enrolled as a control group (group 2).
3260106|NCT00768365||group 3|The other control group (group 3) of 35 healthy individuals matched for sex, age, BMI, metabolic syndrome criteria, cardiovascular risk parameters, menopausal status, smoking status, consumption of alcohol, usage of antihypertensive drugs, insulin or oral hypoglycaemic agents to perform a 1:1 case-control analysis.
3260107|NCT00768352|Other|Education Intervention|
3260108|NCT00768339|Experimental|1|Single agent AEG35156 as 2hr IV infusion, weekly dosing in Patients with relapsed or refractory chronic lymphocytic leukemia and indolent B-cell lymphomas
3260109|NCT00768326|Experimental|Zicronapine. Study Part A|
3260110|NCT00768326|Experimental|Zicronapine. Study Part B|
3260111|NCT00768326|Experimental|Zicronapine. Study Part C|
3260112|NCT00768326|Experimental|Zicronapine. Study Part D|
3260113|NCT00768326|Experimental|Zicronapine. Study Part E|
3260114|NCT00768326|Placebo Comparator|2A, 2B, 2C, 2D, 2E|
3260115|NCT00768313|Active Comparator|1|
3260116|NCT00768313|Experimental|2|
3260117|NCT00768300|Experimental|Ambrisentan|
3260118|NCT00768300|Placebo Comparator|Placebo|
3260119|NCT00768287|Experimental|IB1001|
3260120|NCT00768274|Experimental|Arm A|Low-dose apabetalone (RVX000222) or placebo
3260121|NCT00768274|Experimental|Arm B|apabetalone (RVX000222) Dose-escalation or placebo
3260122|NCT00768274|Experimental|Arm C|high-dose apabetalone (RVX000222) or placebo
3260123|NCT00768261|No Intervention|1|Group 1) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are untreated with either cholinesterase inhibitors or memantine
3260124|NCT00768261|Active Comparator|2|Group 2) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with donepezil.
3260125|NCT00768261|Active Comparator|3|Group 3) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with the combination of donepezil and memantine.
3260126|NCT00768261|No Intervention|4|Group 4) nondemented comparison subjects.
3260127|NCT00768248|Active Comparator|Active|3-7 days of perineural local anesthetic infusion
3260128|NCT00768248|Placebo Comparator|Placebo|3-7 days of perineural normal saline infusion
3260129|NCT00768235|Experimental|1: yoga group|Yoga group
3260130|NCT00768235|No Intervention|2: control group|
3260131|NCT00768222|Active Comparator|Chinese Silk Suture|Natural, non-absorbable silk suture made from entwined thread from silkworm larva, commercially available in China, used in a simple interrupted transdermal suture pattern
3260132|NCT00768222|Experimental|VICRYL* Plus Suture|Synthetic absorbable surgical suture composed of a copolymer of 90% glycolide and 10% L-lactide and containing triclosan antibacterial, used in a subcuticular closure technique
3260133|NCT00768209|Experimental|Treatment A|
3260134|NCT00768183|Experimental|1|KADIAN Capsule + alcohol (under fasting conditions)
3260135|NCT00768183|Experimental|2|KADIAN Capsule + alcohol (under fed conditions)
3260136|NCT00768183|Experimental|3|KADIAN Capsule + water (under fasting conditions)
3260137|NCT00768183|Experimental|4.|Morphine sulfate IR oral solution + water (under fasting conditions)
3260138|NCT00768170|Experimental|1|MK0633
3260139|NCT00768157|Experimental|antiviral group|Drug: antiviral treatment(lamivudine or entecavir) after the Procedure/Surgery (radical resection of HBV-related HCC)
3260140|NCT00768157|Active Comparator|control group|Procedure/Surgery (radical resection of HBV-related HCC) without Drug of antiviral treatment - close observation without antiviral treatment
3260141|NCT00768144|Experimental|Sunitinib|Patients received oral Sunitinib at the daily dose of 37.5 mg continuously over a 28- day treatment cycle. Treatment continued until clinical or radiological evidence of progressive disease or excessive toxicity.
3260142|NCT00768131|Experimental|A1 FISH (+)|
3260143|NCT00768131|Active Comparator|B1 FISH (+)|
3260144|NCT00768131|Experimental|A2 FISH (-)|
3260145|NCT00768131|Active Comparator|B2 FISH (-)|
3260146|NCT00768118|Experimental|Curcumin, Green Tea extract, Polygonum Cuspidatum & Soybean|Total number of visits: 2, pre-intervention blood draw and urine sample collection, post-intervention blood draw and urine sample collection and interview Length of each visit: 15-30 minutes Total expected duration of participants' involvement: 15 days During the two-week intervention, volunteers will take two 1/2g capsules of the combination capsule, twice daily immediately after morning and evening meals.
3260147|NCT00768105|Experimental|1|
3260148|NCT00768105|Placebo Comparator|2|
3260149|NCT00768079|Experimental|1|MEDI-563
3260150|NCT00768079|Experimental|2|MEDI-563
3260151|NCT00768079|Other|3|Placebo
3260152|NCT00768066|Experimental|1|Participants will receive an injection of 100 million or 200 million autologous human mesenchymal stem cells (hMSCs).
3260153|NCT00768066|Experimental|2|Participants will receive an injection of 100 million or 200 million autologous human bone marrow cells (hBMCs).
3260154|NCT00768066|Placebo Comparator|3|Participants will receive a placebo injection of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS).
3260155|NCT00768053|Experimental|1|
3260156|NCT00768040|Experimental|Aliskiren 300 mg|Aliskiren 300 mg once daily for 12 weeks
3260157|NCT00768040|Placebo Comparator|Placebo|Matching placebo once daily for 12 weeks
3260158|NCT00768014||1|Healthy term pregnant women in labor without any pain relief
3260159|NCT00768014||2|Healthy term pregnant women received TENS
3260160|NCT00768014||3|Healthy term pregnant women received epidural anesthesia
3260161|NCT00767988|Active Comparator|A|Urex-cap-5 capsules (2x10^9 cfu each of RC-14 and GR-1) 1:1 ratio
3260162|NCT00767988|Placebo Comparator|B|Capsule 1:1
3260163|NCT00767975|No Intervention|2|For patients who diagnosed with LTBI, they choose to receive LTBI treatment depends on their willingness; if they choose not, then they are in no intervention arm.
3260164|NCT00767975|Experimental|1|Provided INH 6m or RMP 4 m; whether enter treatment arm is determined by patient's willingness
3260165|NCT00767962|Other|1|talc pleurodesis under medical thoracoscopy
3260166|NCT00767962|Other|2|pleurodesis under video-assisted thoracoscopy surgery
3260167|NCT00767949|Experimental|1|iSONEP
3260168|NCT00767897||CKD stage 3 or 4|Girls and Boys age 9-18 with CKD stage 3 or 4
3260169|NCT00767897||On dialysis|Girls and Boys age 9-18 who are on dialysis
3260170|NCT00767897||Transplanted|Girls and Boys age 9-18 who have had a functioning kidney transplant for longer than 6 months and are on the same immunosuppression regimen.
3260171|NCT00767897||Healthy|Girls and Boys age 9-18
3260172|NCT00767871|Experimental|Escitalopram|escitalopram (10-20mg) to panic patients
3260173|NCT00767819|Experimental|Arm 1|Progressive or metastatic bone or soft tissue sarcomas
3260174|NCT00767819|Experimental|Arm 2|Progressive gastrointestinal stromal tumors (GIST) after failure of prior imatinib and sunitinib 1st and 2nd line
3260175|NCT00767819|Experimental|Arm 3|Progressive or metastatic alveolar soft part sarcoma (ASPS)
3260176|NCT00767806|Experimental|Duloxetine|Participants received duloxetine 60 milligram by mouth once daily for 12 weeks of double-blind treatment
3260177|NCT00767806|Placebo Comparator|Placebo|Patients received placebo by mouth once daily for 12 weeks of double-blind treatment
3260178|NCT00767793|Placebo Comparator|Arm 1|One drop in each eye every 12 hours for seven days
3260179|NCT00767793|Experimental|Arm 2|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
3260180|NCT00767793|Experimental|Arm 3|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
3260181|NCT00767793|Experimental|Arm 4|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
3260182|NCT00767780||3|Patients suffering from ankle fractures and instability
3260183|NCT00767780||4|Patients suffering from hip osteoarthritis
3260184|NCT00767780||5|Patients who underwent total knee replacement or total hip replacement
3260185|NCT00767780||1|Patients suffering from bilateral knee osteoarthritis
3260186|NCT00767780||2|Patients suffering fron non specific low back pain
3260187|NCT00767767|Placebo Comparator|Placebos|Saline Infusion
3260188|NCT00767767|Active Comparator|Propofol 0.45mcg/mL|Anesthetic Drug Infusion
3260189|NCT00767767|Active Comparator|Propofol 0.90mcg/mL|Anesthetic Drug Infusion
3260190|NCT00767767|Active Comparator|Thiopental 1.5mcg/mL|Anesthetic Drug Infusion
3260191|NCT00767767|Active Comparator|Thiopental 3mcg/mL|Anesthetic Drug Infusion
3260192|NCT00767754|Other|paroxetine cr|single arm
3260193|NCT00767741|Experimental|with treatment|
3260194|NCT00767728|Active Comparator|1|Mesalamine pellets
3260195|NCT00767728|Placebo Comparator|2|Placebo
3260196|NCT00767715|Experimental|A|Patients will be given olanzapine
3260197|NCT00767715|Active Comparator|B|Patients will be given either haloperidol or zuclopentixol
3260198|NCT00767689|Experimental|vitamin B6|patient receiving xeloda and vitamin B6
3260199|NCT00767689|Placebo Comparator|2 placebo|patient receiving xeloda and placebo
3260200|NCT00767676|Other|1|
3260201|NCT00767663|Experimental|1|dipyridamole
3260202|NCT00767663|Placebo Comparator|2|placebo
3260203|NCT00767637|Experimental|Arm 1|
3260204|NCT00767624|Other|antidepressant + desensitization|Combined antidepressant medication (determined by an algorithm) plus desensitization therapy
3260205|NCT00767624|Other|antidepressant + cognitive behavioral|Combined antidepressant medication (determined by algorithm) plus cognitive behavioral therapy
3260206|NCT00767598|Active Comparator|A|Vardenafil
3260207|NCT00767598|Active Comparator|B|Sildenafil
3260208|NCT00767598|Active Comparator|C|Udenafil
3260209|NCT00767585||A:|70 women with hormone-dependent or hormone-independent early breast cancer that have completed their chemo- and/or radiotherapy just recently (up to 6 months after completion of therapy)
3260210|NCT00767585||B|70 women with hormone-independent early breast cancer, 24-36 months after completion of chemo- and/or radiotherapy
3260211|NCT00767585||C|70 women with hormone-independent early breast cancer, 54-66 months after completion of chemo- and/or radiotherapy
3260212|NCT00767585||D|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of tamoxifen therapy
3260213|NCT00767585||E|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy
3260214|NCT00767585||F|70 women with hormone-dependent early breast cancer, 54-66 months after initiation of tamoxifen therapy
3260215|NCT00767585||G|70 women with hormone-dependent early breast cancer, 54-66 months after initiation of aromatase inhibitors therapy
3260216|NCT00767585||H|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy following 24-36 months of initial tamoxifen therapy
3260217|NCT00767572|Experimental|atorvastatin|Patients are randomized to either atorvastatin or placebo once daily for 12 weeks. There is a 4 week washout, and then the groups are switched for 12 weeks. Brachial artery assessment will be performed before and after each 12 week period on therapy.
3260218|NCT00767572|Placebo Comparator|sugar pill|See above. Patients will be randomized to atorvastatin vs. placebo for 12 weeks and after a 4 week washout period the groups will be switched.
3260219|NCT00767559|Active Comparator|1|"Variable dose warfarin: 5 mg beginning the night before surgery, followed by 5mg the PM of surgery*, and then variable daily dose,until day 30 follow-up.~(target INR 2.0-2.5)"
3260220|NCT00767559|Active Comparator|2|"Fondaparinux:~2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day*,or 6-8 hours after epidural catheter removal, and continued until follow-up (28 days +/-2) from day of surgery."
3260221|NCT00767559|Active Comparator|3|"Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily follow-up at Day 28 (+/-2 days from surgery)."
3260222|NCT00767520|Active Comparator|A|
3260223|NCT00767520|Placebo Comparator|B|
3260224|NCT00767507|Experimental|Cangrelor|Cangrelor was administered as a continuous IV infusion of 0.75µg/kg/min for a minimum of 48 hours and a maximum of 7 days.
3260225|NCT00767507|Placebo Comparator|Placebo|A placebo infusion was administered as a continuous IV infusion of 0.75µg/kg/min for a minimum of 48 hours and a maximum of 7 days, to maintain the blind.
3260226|NCT00767494|Experimental|1|Travoprost/Brinzolamide AM, Vehicle PM
3260227|NCT00767494|Experimental|2|Travoprost/Brinzolamide PM, Vehicle AM
3260228|NCT00767494|Active Comparator|3|AZOPT AM and PM
3260229|NCT00767494|Active Comparator|4|TRAVATAN PM, Vehicle AM
3260230|NCT00767481|Experimental|Travoprost/Brinzolamide PM, Vehicle AM|Travoprost/Brinzolamide PM, Vehicle AM
3260231|NCT00767481|Experimental|Travoprost/Brinzolamide AM, Vehicle PM|Travoprost/Brinzolamide AM, Vehicle PM
3260232|NCT00767481|Active Comparator|Cosopt|Cosopt BID
3260233|NCT00767468|Experimental|Bilirubin Normal to 3x Upper Limit of Normal|
3260234|NCT00767468|Experimental|Bilirubin >3x to 6x Upper Limit of Normal|
3260235|NCT00767455|Sham Comparator|Positive, Negative Controls|
3260236|NCT00767442||1|Health volunteer
3260237|NCT00767442||2|Patient with suspected oral mucosa lesion
3260238|NCT00767429|Experimental|1|subjects with fall risk
3260239|NCT00767416|Experimental|Cohort 1 MEDI-559|MEDI-559
3260240|NCT00767416|Placebo Comparator|Cohort 1 Placebo|Placebo
3260241|NCT00767403|Experimental|1|
3260242|NCT00767403|Active Comparator|2|
3260243|NCT00767403|Active Comparator|3|
3260244|NCT00767390||ACL Patch|
3260245|NCT00767377|Experimental|EOF5 Group|The regimen of 5-day Continuous infusion of FU combined with Epirubicin and Oxaliplatin will be used in the patients recruited in this trial.
3260246|NCT00767364|Experimental|Infants with bowel resection|Infants with bowel resection who will receive the oral rotavirus vaccine, RotaTeq(R).
3260247|NCT00767364|Active Comparator|Healthy Infants|Healthy infants that are gest. age and age-matched controls within 14 days will be given the oral rotavirus vaccine, RotaTeq(R).
3260248|NCT00767338|Active Comparator|No surgery + IUI|No microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with intrauterine insemination.
3260249|NCT00767338|Active Comparator|No Surgery + TI|No microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with timed intercourse.
3260250|NCT00767338|Active Comparator|Surgery + IUI|Microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with intrauterine insemination.
3260251|NCT00767338|Active Comparator|Surgery + TI|Microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with timed intercourse.
3260252|NCT00767325|Experimental|Abatacept, 10 mg/kg|
3260253|NCT00767299|Experimental|1|
3260254|NCT00767299|Placebo Comparator|2|
3260255|NCT00767260|Experimental|BM-MNC+HOT|Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
3260256|NCT00767260|Experimental|BM-MNC|Autologous Bone Marrow mononuclear cell Infusion
3260257|NCT00767260|Experimental|HOT|hyperbaric oxygen therapy
3260258|NCT00767260|Active Comparator|Control|stand medical therapy (enhanced hemoglucose monitor, health and diet counseling and insulin injection)
3260259|NCT00767247||1|Male or female with arterial hypertension
3260260|NCT00767221|Experimental|A|The patient is his own control. Endpoint variables are measured before, during and after treatment.
3260261|NCT00767208|Experimental|type 2 diabetic subjects|
3260262|NCT00767208|Experimental|overweight healthy subjects|
3260263|NCT00767195||1. Control group|Patients in the intensive care unit who have no pulmonary edema
3260264|NCT00767195||2. Study group 1|Patients with cardiogenic pulmonary edema in the intensive care unit
3260265|NCT00767195||3. Study group 2|Patients with non-cardiogenic pulmonary edema in the intensive care unit
3260266|NCT00767182||Pregnant patients with VPP antecedent|Pregnancy women consulting for an scan during their 12th week of amenorrhea at the University Hospital of Saint Etienne will be studied in this clinical trial. They have an history of VPP (Vascular Placental Pathology). They will have to give a blood sample.
3260267|NCT00767169|Experimental|coated implant and control|
3260268|NCT00767156|Active Comparator|SBA24 capsule plus Omega7 cream|the subjects took SBA24 sea buckthorn oil capsule and apply Omega7 cream
3260269|NCT00767156|Active Comparator|SBA24 capsule plus base cream|the subjects took SBA24 sea buckthorn oil capsule and apply a base cream
3260270|NCT00767156|Active Comparator|Omega7 Cream|The subjects Omega 7 Sea Buckthorn Oil Cream, twice per day
3260271|NCT00767156|Placebo Comparator|Base cream|The subjects use base cream on the face, twice per day
3260272|NCT00767130||1|receiving atorvastatin
3260273|NCT00767130||2|receiving simvastatin
3260274|NCT00767130||3|receiving rosuvastatin
3260275|NCT00767104|Experimental|Silk-Like Pillowcase|Silk- Like pillowcase-One-half of subjects will be assigned to sleep on the study product, which is a standard size pillowcase made of a silk-like fabric every night for 12 weeks. The study pillowcases are fabricated from a light-weight plain-weave fabric woven of 100 percent synthetic yarns. The fabric is comprised of approximately 50% polyester and 50% nylon. The yarns in the fabric are formed from continuous-filament fibers, with no fibers projecting beyond the planar surface of the fabric. The antimicrobial technology used in the fabric is incorporated into the fibers during the finishing process and does not migrate out of the fabric or cause adverse reactions with skin contact.
3260276|NCT00767104|Placebo Comparator|Cotton Pillowcase|Placebo Comparator-One-half of subjects will be assigned to sleep on the placebo pillow case every night for 12 weeks. Placebo pillowcase is made of 100% cotton
3260277|NCT00767091|Active Comparator|Active treatment|A: transdermal rivastigmine at 4.6 mg per day during one month then 9.5 mg per day during 5 months.
3260278|NCT00767091|Placebo Comparator|placebo|transdermal patch of placebo
3260279|NCT00767065|Active Comparator|Cardiac Computed Tomography (CCT)|Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. CCT will be available Monday to Friday from 9am until 5pm. Patients will be entered into the study provided CCT can be undertaken within 24 hours of troponin result. Therefore, the only period during which a patient will be ineligible for inclusion will be between 5pm on a Friday and 9am the following Sunday. Studies will be reported at CWH by one of 2 experienced radiologists trained in CCT and results passed to the referring team on the same day.
3260280|NCT00767065|Active Comparator|Standard Care Arm|Patients randomised to the standard care arm will undergo further care as dictated by the responsible clinician. Except for CCT, all standard investigations will be available to the responsible clinician and may be used at their discretion. CCT does not form part of current in-patient management at our hospital.
3260281|NCT00767052|Experimental|Active|AZD1236 tablet
3260282|NCT00767052|Placebo Comparator|Placebo|Placebo tablet
3260283|NCT00767052|Other|Relative bioavailability|AZD1236 Oral suspension
3260284|NCT00767052|Other|Relative bioavailability tablet|AZD1236 tablet
3260285|NCT00767039|Active Comparator|1|Surfactant (beractant, Survanta initial dose 100 mg/kg and subsequent doses 100 mg/kg phospholipids every 6-12 hours, as needed for up to 4 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation
3260286|NCT00767039|Experimental|2|Surfactant (poractant, Curosurf initial dose 200 mg/kg and subsequent doses 100 mg/kg phospholipids every 12-24 hours as needed for up to 3 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation
3260287|NCT00767026|Experimental|1|
3260288|NCT00767026|Active Comparator|2|
3260289|NCT00767013|Experimental|AVS, CAD|DSCT
3260290|NCT00767000|Experimental|MK-0941 10 mg|
3260291|NCT00767000|Experimental|MK-0941 20 mg|
3260292|NCT00767000|Experimental|MK-0941 30 mg|
3260293|NCT00767000|Experimental|MK-0941 40 mg|
3260294|NCT00767000|Placebo Comparator|Placebo|
3260295|NCT00766974|Active Comparator|1|Anti-embolism Knee High compression stocking
3260296|NCT00766974|Active Comparator|2|20-30mmHg Knee High Jobst Compression Stocking
3260297|NCT00766961|Active Comparator|TAE group|Trans-catheter arterial embolization
3260298|NCT00766961|Active Comparator|Surgery group|Surgery
3260299|NCT00766948||No Treatment|
3260300|NCT00766935||1|Females with previously diagnosed unilateral Lymphoedema of the arm, who have had a mastectomy or breast conservation surgery with axillary sampling or dissection, with or without adjuvant therapy.
3260301|NCT00766935||2|Healthy females aged between 18-75 years chosen randomly from the population of Queensland, Australia.
3260302|NCT00766909|Experimental|CsA|Cyclosporine
3260303|NCT00766909|Experimental|Tac|Tacrolimus
3260304|NCT00766909|Placebo Comparator|Placebo|placebo/saline
3260352|NCT00766506|Experimental|Fentanyl IONSYS|Participants will receive 40 microgram (mcg) of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
3260502|NCT00765362|Experimental|1|Subjects who are candidates for a total knee replacement and meet the inclusion/exclusion criteria of the study.
3260503|NCT00765349||All patients undergoing major surgery|
3260305|NCT00766896|Active Comparator|Aspirin Sensitive|"For PFA-100 using a cartridge with C-EPI (collagen-epinephrine): occlusion time >= 150 seconds~Chrono-Log Model 700 Whole-Blood: < 1Ω with 0.75 mM of arachidonic acid~Chrono-Log Model 700 Whole-Blood: with collagen at 1 mg/L and 5 mg/L, according to the formula 1 - (Rate of aggregation with 1 mg / Rate of aggregation with 5 mg) > 0.50~Chrono-Log Model 700 Whole-Blood: with collagen at 1 mg/L < 10Ω~Plateletworks: aggregation <60% with arachidonic acid will be considered sensitive~VerifyNow Aspirin Assay (Accumetrics): < 550 aspirin reaction units (ARUs)~Impact-R (Diamed) < 3.2% platelet aggregates on the surface of the plate after incubation with arachidonic acid"
3260306|NCT00766896|Active Comparator|Platelet with hyperreactivity to aspirin|"For PFA-100 using a cartridge with C-EPI (collagen-epinephrine): occlusion time < 150 s~Chrono-Log Whole-Blood: above or = 1Ω with 0.75 mM of AA~Chrono-Log Whole-Blood: with collagen at 1 mg/L and 5 mg/L, according to the formula 1 - (Rate of aggregation with 1 mg / Rate of aggregation with 5 mg) below 0.50~Chrono-Log Whole-Blood: with collagen 1 mg/L above or = 10Ω~Plateletworks: aggregation of more than 60% with arachidonic acid will be considered resistant~VerifyNow Aspirin Assay (Accumetrics): ≥ 550 aspirin reaction units (ARUs)~Impact-R (Diamed) > 3.2% platelet aggregates on the surface of the plate after incubation with arachidonic acid"
3260307|NCT00766870|Experimental|1|
3260308|NCT00766870|Experimental|2|
3260309|NCT00766870|Experimental|3|
3260310|NCT00766870|Other|4|
3260311|NCT00766870|Placebo Comparator|5|
3260312|NCT00766857|Experimental|1. Exenatide|
3260313|NCT00766857|Active Comparator|2. Insulin glargine|
3260314|NCT00766844|Experimental|Active|Spinal cord stimulation
3260315|NCT00766831|Experimental|Hydromorphone OROS|Participants will receive hydromorphone OROS (8 milligram [mg] up to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
3260316|NCT00766818|Experimental|1|Kaletra
3260317|NCT00766805|Active Comparator|EVL + Drugs|Patients randomized to the EVL plus drugs therapy received EVL plus beta-blocker (propranolol) and nitrate (ISMN).
3260318|NCT00766805|Placebo Comparator|EVL alone|Patients assigned to the EVL group underwent variceal band ligation alone till variceal obliteration.
3260319|NCT00766792|Experimental|1|Nocturnal dialysis
3260320|NCT00766792|Active Comparator|2|Standard dialysis
3260321|NCT00766779|Experimental|Transplant Arm|Hematopoietic cell transplantation after Reduced Intensity Conditioning
3260322|NCT00766779|Active Comparator|Conventional Chemotherapy|The non-transplant treatment approach for consolidation
3260323|NCT00766766|Experimental|1|Experimental Intervention Group
3260324|NCT00766766|No Intervention|2|Standard Care Control
3260325|NCT00766753|Experimental|Single|All consenting, eligible subjects receive the intervention
3260326|NCT00766740|Active Comparator|1|thrombectomy
3260327|NCT00766740|Active Comparator|2|Standard PCI
3260328|NCT00766714|Experimental|1|Cook K-SOFT-5100 catheter
3260329|NCT00766714|Active Comparator|2|Frydman classical catheter
3260330|NCT00766688|Experimental|25 mg/day AVE5530|
3260331|NCT00766688|Experimental|50 mg/day AVE5530|
3260332|NCT00766688|Placebo Comparator|Placebo|
3260333|NCT00766675|Experimental|Tramadol hydrochloride/acetaminophen|Tramadol hydrochloride/acetaminophen oral tablet will be administered as 37.5 /325 milligram respectively once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
3260334|NCT00766649|Experimental|Sirolimus|Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
3260335|NCT00766636|Experimental|Gemcitabine + Erlotinib Without Radiation|"Gemcitabine + Erlotinib without radiation - Arm A: Gemcitabine 1000 mg/M^2 given intravenously over 100 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day. Erlotinib 100 mg daily by mouth on days 1-42.~Surgical removal of the pancreas and duodenum."
3260336|NCT00766636|Experimental|Gemcitabine + Erlotinib With Radiation|Gemcitabine + Erlotinib with radiation - Arm B: Gemcitabine 400 mg/M^2 given intravenously over 40 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day. Erlotinib 100 mg daily by mouth on days 1-42. Radiation therapy 1 time each day for 5 days in a row for 5 1/2 weeks starting on Day 1 for a total of 50.4 Gy. Surgical removal of the pancreas and duodenum.
3260337|NCT00766623|Experimental|High fat meal|A high fat milkshake containing 95g of fat
3260338|NCT00766623|Experimental|Control meal|Milkshake comparable with a normal breakfast
3260339|NCT00766623|Experimental|High fat meal 2|A high fat milkshake containing 95g of fat
3260340|NCT00766623|Experimental|High fat meal 3|A high fat milkshake containing 95g of fat
3260341|NCT00766623|Experimental|Control meal 2|Milkshake comparable with a normal breakfast
3260342|NCT00766623|Experimental|Control meal 3|Milkshake comparable with a normal breakfast
3260343|NCT00766597|Experimental|Vicriviroc in tablet form (20/30 mg) or liquid form (1 mg/ml)|HIV-1 Infected Antiretroviral Therapy Experienced Participants with CCR5-tropic Virus
3260344|NCT00766584||PROOF cohort|This cohort is the same than the PROOF study (NCT00759304). Subjects were recruited amongst the inhabitants of the city of Saint-Etienne, France, and were eligible if aged 65 at the inclusion date in the PROOF study
3260345|NCT00766558||1 Disclosure|Traumatic writing prompts provided. Participant is assigned a potential stress-producing topic for written disclosure.
3260346|NCT00766558||2 control|Received nontraumatic writing prompts. Participant assigned a non-stressful writing condition
3260347|NCT00766545|Experimental|cilostazol|cilostazol oral tablet 100 mg, twice daily
3260348|NCT00766545|Placebo Comparator|placebo|placebo of cilostazol, twice daily
3260349|NCT00766532|Experimental|aromatase inhibitor therapy|aromatase inhibitor therapy for six weeks
3260350|NCT00766519|Experimental|Optimization|volume optimization: continuous monitoring of the respiratory-induced arterial pulse pressure variation during surgery and systematic minimization to 10% or less by volume loading
3260351|NCT00766519|Active Comparator|control; standard volume administration|standard volume administration
3260504|NCT00765336|Active Comparator|Minocycline Extended-Release Tablets|
3260353|NCT00766506|Active Comparator|Morphine IV PCA|Morphine sulphate solution will be administered intravenously (directly into the vein, IV) by a patient-controlled analgesia (PCA) pump using set bolus (a large amount) doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
3260354|NCT00766493|Experimental|GORE® Embolic Filter|Subjects treated with the GORE® Embolic Filter and an FDA-approved carotid stent.
3260355|NCT00766480|Experimental|Regimen 1|Patients receive low-dose cisplatin IV on days 1 and 29 and low-dose fluorouracil IV on days 1-4 and 29-32. Patients also undergo concurrent radiotherapy on days 1-4 and 29-32. Patients undergo salvage surgery if needed.
3260356|NCT00766480|Experimental|Regimen 2|Patients receive high-dose cisplatin IV on days 1 and 29 and high-dose fluorouracil IV on days 1-4 and 29-32. Patients also undergo concurrent radiotherapy and salvage surgery as in regimen 1.
3260357|NCT00766467|Experimental|Group 1|Armodafinil
3260358|NCT00766467|Placebo Comparator|Group 2|Placebo
3260359|NCT00766441|Active Comparator|1|Sitagliptin 100mg
3260360|NCT00766441|Active Comparator|2|Sulphonylurea
3260361|NCT00766415|Experimental|AZD1981|
3260362|NCT00766415|Placebo Comparator|Placebo|
3260363|NCT00766402|Experimental|Tramadol/Acetaminophen|Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
3260364|NCT00766402|Active Comparator|Diclofenac|Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
3260365|NCT00766389||1|Defined glaucoma patients
3260366|NCT00766389||2|Glaucoma suspects and normal controls
3260367|NCT00766363|Experimental|EVP-6124 (0.1 mg/day)|
3260368|NCT00766363|Experimental|EVP-6124 (0.3 mg/day)|
3260369|NCT00766363|Experimental|EVP-6124 (1.0 mg/day)|
3260370|NCT00766363|Placebo Comparator|Placebo|
3260371|NCT00766350|Active Comparator|amitriptyline|
3260372|NCT00766350|Experimental|quetiapine|
3260373|NCT00766337|Experimental|Dose Group 1|
3260374|NCT00766337|Experimental|Dose Group 2|
3260375|NCT00766337|Placebo Comparator|Dose Group 3|
3260376|NCT00766324|Experimental|A|
3260377|NCT00766324|Experimental|B|
3260378|NCT00766311|Other|1|This single-arm feasibility trial will evaluate the administration of an aggressive exercise regimen.
3260379|NCT00766298|Experimental|1|Weight Loss
3260380|NCT00766298|Experimental|2|Exercise
3260381|NCT00766298|Experimental|3|Exercise and Weight Loss
3260382|NCT00766285|Active Comparator|TIV|50 subjects to receive 45 mcg of TIV administered on Day 0 and Day 28.
3260383|NCT00766285|Experimental|rHAO|50 subjects to receive 405 mcg of rHAO administered on Day 0 and Day 28.
3260384|NCT00766272|Experimental|Arm 1|Body-weight supported treadmill training
3260385|NCT00766259||1|Hemodialysis
3260386|NCT00766259||2|Intensive care
3260387|NCT00766259||3|vascular patients with open wounds
3260388|NCT00766259||4|nursing home
3260389|NCT00766259||5|skin infections
3260390|NCT00766259||6|control- ambulatory care clinic patients with no infections
3260391|NCT00766246|Experimental|First-line|Carboplatin, docetaxel, bevacizumab Open-label, single arm with treatment period up to 6 cycles. Patients completing a total of 2 to 6 cycles of first-line without disease progression will be eligible for maintenance.
3260392|NCT00766246|Experimental|Maintenance|Bevacizumab Open-label, single arm with treatment period up to 18 cycles.
3260393|NCT00766233|Active Comparator|1|Hyperthermal treatment once per week
3260394|NCT00766233|Active Comparator|2|Hyperthermal treatment 3 times a week
3260395|NCT00766220|Active Comparator|SIR-Spheres + Therapy|SIR-Spheres with Cetuximab + Irinotecan Therapy
3260396|NCT00766220|Active Comparator|Therapy Only|Cetuximab + Irinotecan Therapy
3260397|NCT00766207|Experimental|multi-faceted decision support|Multi-faceted decision support
3260398|NCT00766207|Active Comparator|control|stream-lined clinical alert
3260399|NCT00766181||1: Lifestyle|Observatonal
3260400|NCT00766181||2: Lifestyle|Observational
3260401|NCT00766168|Active Comparator|Control|FluoroPerm 30 RGP lens daily wear
3260402|NCT00766168|Experimental|HDS HI 1.54|New rigid gas permeable contact lens material material
3260403|NCT00766155|Active Comparator|Arm I|Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients may receive additional chemoradiotherapy on days 36-38. Patients then undergo surgery. Beginning 4-8 weeks after surgery, patients receive capecitabine twice daily on day 1-15. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3260404|NCT00766155|Experimental|Arm II|Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients also receive oxaliplatin IV over 1 hour on days 1, 8, 15, 22, and 29 prior to radiotherapy followed by surgery. Patients may receive additional chemoradiotherapy on days 36-38. Beginning 4-8 weeks later, patients receive oxaliplatin IV over 2 hours on day 1, and oral capecitabine twice daily on days 1-15. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3260405|NCT00766129|Experimental|T|Implantation of Taxus stent into saphenous vein graft
3260406|NCT00766129|Experimental|C|Implantation of Luc-Chopin stent into saphenous vein graft
3260407|NCT00766116|Experimental|Treatment|5-Azacitidine, Gemtuzumab ozogamicin
3260408|NCT00766103|Other|crossover: hypo- and hypercarbia|
3260409|NCT00766090|Experimental|GW685698X|
3260410|NCT00766064|Experimental|Paliperidone Dosing|Paliperidone Dosing up to 6 weeks, with a maximum dosage of 6mg
3260411|NCT00766051|Experimental|Intervention Group|The infants in the intervention group were problem eaters with various diagnosis
3260412|NCT00766051|No Intervention|Matched Historical Comparison Group|The matched historical comparison group were also problem eaters and these infants did not receive the neurophysiologically based occupational therapy Intervention.
3260505|NCT00765336|Placebo Comparator|Placebo|
3260506|NCT00765323|Active Comparator|1|84 mg octreotide implant for 6 months
3260413|NCT00766038|Experimental|1|The GH treatment arm will receive a starting dose of 400 microgramsg/day, with increases (or decreases) in dose by 100-200 micrograms/day each month, monitoring for side effects, until goal IGF-1 (in the upper quartile of the range for age and body weight) is reached up to maximum dose of 1,000 microgramsg/day. Dose adjustments may be modified by the investigators for participants receiving oral estrogens or other circumstances know to influence GH dosing or atypical responses to treatment.
3260414|NCT00766038|Placebo Comparator|2|Doses for participants receiving placebo will also be adjusted monthly to maintain the blinding.
3260415|NCT00766025|Experimental|Rosuvastatin Calcium|
3260416|NCT00766012|Experimental|1|4 dose panels receiving a specified volume of AZD2066 oral solution once daily for 11 days
3260417|NCT00766012|Placebo Comparator|2|Included in each dose panel
3260418|NCT00765999|Experimental|1|Linaclotide 300 micrograms Open label starting dose for all patients, optional lower dose of 150 ug per protocol criteria
3260419|NCT00765986||1|Patients with inoperable NSCLC undergoing RT or Chemo-RT
3260420|NCT00765973|Experimental|A|Arm A: TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
3260421|NCT00765973|Experimental|B|Arm B: TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
3260422|NCT00765947|Experimental|Aliskiren-based regimen|All pts starting on aliskiren 150 mg (uptitrated to aliskiren 300 mg), followed by the addition of HCTZ 12.5 mg (uptitrated to 25 mg) and amlodipine 5 mg (uptitrated to 10 mg), as necessary to achieve the Blood Pressure goal.
3260423|NCT00765934|Other|Rapydan|Internal control. Blood from both arms will be drawn. Only one arm of the subject is treated with Rapydan.
3260424|NCT00765921|Experimental|1.0 mg ranibizumab|1.0 mg intravitreal injection given bi-monthly for 22 months
3260425|NCT00765921|Experimental|0.5 mg ranibizumab|0.5 mg intravitreal injection given bi-monthly for 22 months
3260426|NCT00765908|Experimental|A|Patients undergoing elective PCI will be randomised to 90 second balloon inflations rather than the standard less than 30 second inflations in order to induce peri-ischaemic conditioning.
3260427|NCT00765908|Active Comparator|B|Control group. These patients will have a standard procedure with balloon inflations of 30 seconds or less as per standard.
3260428|NCT00765895|Active Comparator|Nortriptyline|Nortriptyline Hydrochloride dose escalation from 10 mg to 75 mg
3260429|NCT00765895|Placebo Comparator|Placebo (for nortriptyline)|No treatment
3260430|NCT00765882|Experimental|1|Linaclotide 290 micrograms
3260431|NCT00765882|Experimental|2|Linaclotide 145 micrograms
3260432|NCT00765882|Placebo Comparator|3|Matching placebo
3260433|NCT00765869|Experimental|1|Bowel cancer screening decision aid, DVD and Question Prompt List (QPL)
3260434|NCT00765869|Experimental|2|Bowel cancer screening decision with DVD only
3260435|NCT00765869|Active Comparator|3|Australian Government Bowel Cancer Screening consumer information booklet
3260436|NCT00765856|Experimental|Opana® ER|Oxymorphone IR - Opioid
3260437|NCT00765843|Active Comparator|custom foot orthoses|Subjects will receive custom fabricated orthoses created from casts of the feet and according to individualized prescriptions. These orthoses are to be used in the standardized shoes provided to all subjects in the study.
3260438|NCT00765843|Active Comparator|pre-fabricated orthoses|Subjects will be provided pre-fabricated (non-customized) orthoses. These orthoses are to be used in the standardized shoes provided to all subjects in the study. for use in their shoes.
3260439|NCT00765843|Sham Comparator|sham insoles|Subjects will receive sham orthoses that are soft and pliable, but not designed to relieve pain. These orthoses are to be used in the standardized shoes provided to all subjects in the study.
3260440|NCT00765830|Experimental|1|50mg qd vildagliptin
3260441|NCT00765830|Placebo Comparator|2|Placebo
3260442|NCT00765817|Placebo Comparator|1|
3260443|NCT00765817|Experimental|2|
3260444|NCT00765804|Active Comparator|Low Dose: DP 7.5 mA-min at 2.5 mA|Ocular Iontophoresis with EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) 7.5 mA-min at 2.5 mA
3260445|NCT00765804|Active Comparator|High Dose: DP 10.5 mA-min at 3.5 mA|Ocular Iontophoresis with EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) 10.5 mA-min at 3.5 mA
3260446|NCT00765804|Placebo Comparator|Placebo: 10.5 mA-min at 3.5 mA|Ocular Iontophoresis with Placebo (sodium citrate buffer solution 100 mM at 10.5 mA-min at 3.5 mA)
3260447|NCT00765791|Active Comparator|1|Level IIB is dissected
3260448|NCT00765791|Active Comparator|2|Level IIB is not dissected
3260449|NCT00765765|Experimental|Ixabepilone and hydroxychloroquine|
3260450|NCT00765752||1 Primary Insomnia|Individuals with insomnia not related to another identified cause.
3260451|NCT00765752||3 Healthy comparison subjects|Healthy subjects with no history of insomnia
3260452|NCT00765739|Experimental|1|The group who will get neuromuscular electrical stimulation (NMES)
3260453|NCT00765739|Active Comparator|2|The group who will do the voluntary muscle contraction
3260454|NCT00765726|Other|Moroctocog alfa(AF-CC)|
3260455|NCT00765713|Experimental|CPAP|Continuous positive airway pressure
3260456|NCT00765713|No Intervention|Conventional|Hygienic-dietetic recommendations
3260457|NCT00765700|Active Comparator|Ketoprofen 10% Cream|"Topical Ketoprofen 10% Cream~1gram three times daily for 7 days"
3260458|NCT00765700|Placebo Comparator|Placebo|"Topical placebo cream~1gram three times daily for 7 days"
3260459|NCT00765687|No Intervention|Observation|
3260460|NCT00765674|Experimental|Aliskiren / amlodipine|Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
3260500|NCT00765388|Active Comparator|hollister Uro|The comparator product is CE-marked and non-sterile and produced for urostomy operated. It is a flat one-piece urostomy product, Hollister Moderma Flex Urostomy beige, Cut-to-Fit Bag, flat adhesive
3260501|NCT00765375|Experimental|Botox and Placebo on each side of face|Botulinum Neurotoxin Type A (Botox, 1.5-3 units/lesion); Bacteriostatic saline solution (0.11 cc/lesion)
3260461|NCT00765674|Experimental|Aliskiren / hydrochlorothiazide|Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
3260462|NCT00765674|Experimental|Amlodipine / hydrochlorothiazide|Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
3260463|NCT00765674|Experimental|Aliskiren / amlodipine / hydrochlorothiazide|Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
3260464|NCT00765661|Experimental|LCP-Tacro|The initial dose starting at 0.14 mg/kg (the starting daily dose for African-American patients was 0.17 mg/kg), will be administered orally in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.
3260465|NCT00765661|Active Comparator|Prograf (tacrolimus)|"Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other name: tacrolimus"
3260466|NCT00765648|Active Comparator|1|nicardipine intravenous
3260467|NCT00765648|Active Comparator|2|Labetalol
3260468|NCT00765635|Experimental|2|Taponoto ® (potassium carbonate 20 mg/1 ml, ethyl alcohol, glycerol 480, thymol 0.4; Teofarma Iberica S.A., Barcelona, Spain),
3260469|NCT00765635|Placebo Comparator|3|sterile saline solution (NaCl 0.9%, Braun Medical SA, Barcelona, Spain).
3260470|NCT00765635|Experimental|1: Chlorobutanol|ceruminolytic product, Otocerum® (Chlorobutanol 50 mg/1 ml, phenol 10 mg/1 ml, turpentine essence 0.15 ml/1 ml, ethyl alcohol; Reig Jofre laboratories, Barcelona, Spain),
3260471|NCT00765622||G2|G2 = control group (no incontinence)
3260472|NCT00765622||G1|G1 = urinary incontinence
3260473|NCT00765609||1|Using the information distributed with over−the−counter medication (The Patient Information Leaflet or PIL)
3260474|NCT00765609||2|Paediatric Analgesia Slide (the new device)
3260475|NCT00765596||1 RYGB|Subjects undergoing RYGB with gastric tube placement
3260476|NCT00765596||2 Matched controls|Subjects matched by BMI, age, gender to RYGB group
3260477|NCT00765583|Experimental|restylane|Restylane arm with different re-treatment schedules
3260478|NCT00765570|Active Comparator|Treatment Group 1|Treatment Group 1-one treatment of Grid therapy followed by 15 treatments with standard radiation
3260479|NCT00765570|Active Comparator|Treatment Group-2|Treatment Group 2-15 treatments with standard radiation
3260480|NCT00765544|Experimental|Arm 1|Anklebot
3260481|NCT00765544|Experimental|Arm 2|Body-weight supported treadmill training
3260482|NCT00765544|Experimental|Arm 3|Combination therapy (Anklebot and BWSTT)
3260483|NCT00765518|Experimental|Ixmyelocel-T|The treatment arm of the study will receive injections of the study cellular product.
3260484|NCT00765518|Other|Standard of Care|Standard of care therapy only.
3260485|NCT00765505|Experimental|1|Exercise Group
3260486|NCT00765505|Experimental|Health Education Group|
3260487|NCT00765492|Experimental|1|
3260488|NCT00765492|Placebo Comparator|2|
3260489|NCT00765479|Experimental|Arm I|Patients receive an oral soy protein isolate beverage once daily.
3260490|NCT00765479|Placebo Comparator|Arm II|Patients receive an oral casein placebo beverage once daily.
3260491|NCT00765453|Experimental|Intracoronary|Patients will be randomised in a 1:1 ratio to receive intracoronary injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
3260492|NCT00765453|Placebo Comparator|Placebo|Placebo infusion
3260493|NCT00765440|Placebo Comparator|Arm I|Patients receive standard oral or enteral nutrition (IMPACT® placebo) over 7 days prior to surgery and over 7 days after surgery.
3260494|NCT00765440|Experimental|Arm II|Patients receive oral or enteral neoadjuvant IMPACT® nutrition over 7 days prior to surgery and enteral adjuvant standard nutrition (IMPACT® placebo) over 7 days after surgery.
3260495|NCT00765440|Experimental|Arm III|Patients receive oral or enteral IMPACT® nutrition over 7 days prior to surgery and enteral adjuvant IMPACT® nutrition over 7 days after surgery.
3260496|NCT00765414|Experimental|1|
3260497|NCT00765401||Group A|The subject with positive breath Test for H.pylori and/or positive stool antigen test
3260498|NCT00765401||Group B|The subject with negative breath Test for H.pylori and negative stool antigen test
3260499|NCT00765388|Experimental|SenSura Uro|The test product is a CE-marked non-sterile one-piece urostomy multi-chamber bag with the SenSura adhesive.
3260734|NCT00763724||1|Duloxetine
3260507|NCT00765323|Active Comparator|2|Injections of Sandostatin LAR Depot(20, 30, 40 mg) every 4 weeks
3260508|NCT00765310|Active Comparator|Lipoic Acid|600 mg R-alpha lipoic acid in morning on empty stomach (two 300 mg capsules)
3260509|NCT00765310|Placebo Comparator|Placebo|Placebo two caps every morning on empty stomach
3260510|NCT00765297|Experimental|1|Healthy young 18-40years
3260511|NCT00765297|Experimental|2|Healthy elderly
3260512|NCT00765284||Treatment|Ten subjects will be low HDL-C male volunteers who will receive aspirin and Niaspan
3260513|NCT00765284||Placebo|Five subjects will be low HDL-C male volunteers who will receive only aspirin.
3260514|NCT00765271|Active Comparator|Group 2|Abacavir 600 mg (2 x 300mg tablet) once daily throughout the study (days 1- 30) Raltegravir 400 mg (2 x 200mg tablets) twice daily from days 2 to 15 Darunavir/ritonavir 900 (3 x 300mg tablets)/100 (1 x 100mg capsule) mg once daily from day 16 to day 29)
3260515|NCT00765271|Active Comparator|Group 1|Abacavir 600 mg (2 x 300mg tablet) once daily throughout the study (days 1- 30) Darunavir/ritonavir 900 (3 x 300mg tablets)/100 (1 x 100mg capsule) mg once daily from day 2 to day 15) Raltegravir 400 mg (2 x 200mg tablets) twice daily from day 16 to 29
3260516|NCT00765245|Experimental|Arm I: Lenalidomide|
3260517|NCT00765245|Experimental|Arm II: Lenalidomide and Rituximab IV|Patients receive lenalidomide as in arm I and rituximab IV on day 8 of courses 1, 3, 5, 7, 9, and 11 in the absence of disease progression or unacceptable toxicity.
3260518|NCT00765232|Experimental|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
3260519|NCT00765232|Placebo Comparator|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
3260520|NCT00765219|Experimental|1|CBT with ACS
3260521|NCT00765219|Experimental|2|CBT with Counselor
3260522|NCT00765219|Active Comparator|3|Usual Care
3260523|NCT00765206|Experimental|Zegerid|Omeprazole 20 mg /sodium bicarbonate 1100 mg over-the-counter (OTC) Capsule
3260524|NCT00765206|Active Comparator|Prilosec|Omeprazole magnesium 20 mg OTC tablet
3260525|NCT00765193|Other|Skin cancer screening|
3260526|NCT00765180|Active Comparator|2|The investigators evaluate beneficial effect of colonoscopy using narrow band imaging (NBI) for colorectal adenoma detection.
3260527|NCT00765180|Experimental|1|The investigators evaluate the beneficial effect of colonoscopy with a transparent retractable extension (TRE) device on colorectal adenoma detection rate.
3260528|NCT00765167|Placebo Comparator|A|
3260529|NCT00765167|Active Comparator|B|
3260530|NCT00765167|Active Comparator|C|
3260531|NCT00765154|Active Comparator|Group 1|Immediate switch from NNRTI/PI to DRV/r
3260532|NCT00765154|Active Comparator|Group 2|Switch after 10 weeks from NNRTI/PI to DRV/r
3260533|NCT00765141||No treatment|
3260534|NCT00765128|Experimental|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
3260535|NCT00765128|Placebo Comparator|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
3260536|NCT00765115|Experimental|1|100 mg LY 450139 oral
3260537|NCT00765115|Experimental|2|140 mg LY450139 oral
3260538|NCT00765115|Experimental|3|280 mg LY450139 oral
3260539|NCT00765115|Experimental|4|Placebo
3260540|NCT00765102|Experimental|Romidepsin + Bortezomib|"Romidepsin was given as an infusion on Days 1, 8 and 15 of each 28-day cycle. Bortezomib was administered twice a week for two consecutive weeks (Days 1, 4, 8 and 11) followed by a 17-day rest period.~Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles."
3260541|NCT00765089|Experimental|Pulmonary Vein isolation|Patients in this arm will receive pulmonary vein isolation during surgery
3260542|NCT00765089|No Intervention|Standard of care|Subjects in this arm will receive standard of care and no pulmonary vein isolation
3260543|NCT00765076|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0
3260544|NCT00765076|Active Comparator|Fluarix elderly Group|Subjects aged >= 65 years receiving 1 dose of Fluarix vaccine at Day 0
3260545|NCT00765076|Active Comparator|Fluarix young Group|Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0
3260546|NCT00765063|Experimental|Active|Active study treatment
3260547|NCT00765050|Experimental|CD133+ cells|CD133+ cells, obtained from peripheral blood in the treatment of diabetic patients with critic ischemia in lower limbs.
3260548|NCT00765037||Encore RSP|Subjects who need treatment for rotator cuff deficiency or glenohumeral arthritis, received the Encore Reverse Shoulder Prosthesis and are willing to participate in the study.
3260549|NCT00765024|Active Comparator|Albendazole|Albendazole for 7 days
3260550|NCT00765024|Experimental|ivermectin|ivermectin 200 mcg/kg single dose
3260551|NCT00765024|Experimental|ivermectin 2 doses|ivermectin 200 mcg/kg two doses in 2 weeks
3260552|NCT00765011|Experimental|Group A|TPF plus concomitant treatment with cetuximab and conventional radiotherapy
3260553|NCT00765011|Other|Grupo B|Surgery
3260554|NCT00764998|Active Comparator|Fluviral|
3260555|NCT00764998|Placebo Comparator|placebo|
3260556|NCT00764985||Syncope|
3260557|NCT00764972|Experimental|Sorafenib and Vinorelbine|
3260558|NCT00764959||Linear Hip|Encore Linear Hip System
3260559|NCT00764946|Experimental|1|raltegravir
3260560|NCT00764933|Experimental|1|Structured information
3260561|NCT00764933|Sham Comparator|2|Unspecific conversation
3260562|NCT00764920||Skin Imaging|non-invasive imaging modalities for assessment of skin
3260563|NCT00764907|Experimental|Arm I|During reinduction, patients receive 1 course of protocol II.
3260564|NCT00764907|Experimental|Arm II|During reinduction, patients receive 2-3 course of protocol III and interim maintenance therapy.
3260565|NCT00764907|Experimental|Arm III|During reinduction, patients are receive 2 courses of protocol II and interim maintenance therapy OR 3-block consolidation regimen and 1 course of protocol II.
3260566|NCT00764894||Foundation Knee|Retrospective data collection on 510(k) approved device
3260567|NCT00764881|Experimental|EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)|Daily oral administration of one capsule BAY86-5027 [estradiol valerate (EV) / dienogest (DNG)] for 28 days per cycle in the sequential 4-phasic regimen for 6 treatment cycles.
3260568|NCT00764881|Active Comparator|EE/LNG (Microgynon) + Placebo|Daily oral administration of one capsule ethinylestradiol (EE) / levonorgestrel (LNG) for 21 days, followed by 1 capsule placebo for 7 days (28 days total per cycle) for 6 treatment cycles.
3260569|NCT00764868|Experimental|LDX|Lisdexamfetamine Dimesylate (LDX)
3260570|NCT00764855||1|Patients undergoing a surgery with general anesthesia
3260571|NCT00764842||CLP Hip|
3260572|NCT00764816|Active Comparator|1 grain (soy) protein diet:|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
3260573|NCT00764816|Active Comparator|2 casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
3260574|NCT00764803||2|Subjects who meet the indications for use and are implanted with the Encore MJS™ Knee System.
3260575|NCT00764803||1|Subjects who meet the indications for and are implanted with the Encore 3DKnee™ system.
3260576|NCT00764790|Experimental|Fluarix Dose A Group|"Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
3260577|NCT00764790|Experimental|Fluarix Dose B Group|"Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
3260578|NCT00764790|Active Comparator|Fluzone Group|"Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
3260579|NCT00764777|Experimental|Stenting|
3260580|NCT00764764|Active Comparator|I|Group I - Shoulder treatment only
3260581|NCT00764764|Experimental|II|Cervical and shoulder treatment
3260582|NCT00764751|Experimental|1|
3260583|NCT00764751|Active Comparator|2|
3260584|NCT00764751|Placebo Comparator|3|
3260585|NCT00764738|Active Comparator|Monthly|Ranibizumab injections every month for 12 months.
3260586|NCT00764738|Active Comparator|As Needed|Ranibizumab injections monthly for 4 months then as needed thereafter.
3260587|NCT00764725|Active Comparator|A|MTX+SSZ+Plaquenil
3260588|NCT00764725|Active Comparator|B|MTX+Infliximab
3260589|NCT00764712|Active Comparator|Matias protocol|A protocol based on the absolute glucose value - Matias protocol (Matias)
3260590|NCT00764712|Active Comparator|Bath protocol|A protocol based on the relative glucose change - Bath protocol (Bath)
3260591|NCT00764712|Active Comparator|eMPC|a computer-based model predictive control algorithm with variable sampling rate (eMPC)
3260592|NCT00764699|Experimental|rhIGF|Treatment with rhIGF (Increlex)
3260593|NCT00764686|Experimental|1|Low disease severity group
3260594|NCT00764686|Experimental|2|Higher disease severity group
3260595|NCT00764673|Other|Primary|Post market study
3260596|NCT00764660|Experimental|SCH 900435|Participants received SCH 900435 12 mg (as three SCH 900435 4 mg tablets) by mouth twice daily for 12 weeks.
3260597|NCT00764660|Placebo Comparator|Placebo|Participants received matching placebo tablets by mouth twice daily for 12 weeks.
3260598|NCT00764647|Experimental|Single arm|Education program for family caregivers of frail elders.
3260599|NCT00764634|Placebo Comparator|1 Placebo|
3260600|NCT00764634|Active Comparator|2 rBV A/B Vaccine|
3260601|NCT00764634|Placebo Comparator|3 Placebo|
3260602|NCT00764634|Active Comparator|4 rBV A/B Vaccine|
3260603|NCT00764621|Experimental|Arm 1|
3260604|NCT00764621|Active Comparator|Arm 2|
3260605|NCT00764621|Active Comparator|Arm 3|
3260606|NCT00764608||No Treatment|
3260607|NCT00764595|Experimental|imatinib mesylate|All patients start imatinib mesylate as oral dose of 400 mg/d once daily after meal within 28 days after enrollment, and continue the treatment until 3 years after enrollment of the last patient.
3260608|NCT00764582|Experimental|1|
3260609|NCT00764582|Active Comparator|2|
3260610|NCT00764569||Oral Tissue measurement|Fluorescence/Elastic Scattering Spectroscopy Oral tissue measurement
3260611|NCT00764556|Experimental|Tight glycaemic control|Intravenous or subcutaneous insulin to control blood glucose to 4.4-6.5mM
3260612|NCT00764530|Experimental|Investigational|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell.
3260613|NCT00764530|Active Comparator|Control Device|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head.
3260614|NCT00764517|Experimental|Previously untreated|"Patients enrolled with untreated, newly diagnosed mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) [Group I].~Patients receive vorinostat PO on days 1-14, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 3 (weekly for the first course). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3260615|NCT00764517|Experimental|Relapsed|"Patients with relapsed disease including indolent Non-Hodgkins Lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL) [Group II].~Patients receive vorinostat PO on days 1-14, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 3 (weekly for the first course). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3260616|NCT00764504|Experimental|Primary|Primary shoulder
3260617|NCT00764504|Experimental|Revision|Revision shoulder
3260618|NCT00764504|Experimental|Continued Access|Primary shoulder subjects enrolled at a later date in order to collect more data.
3260619|NCT00764478|Experimental|Asenapine 5 mg BID|Participants were administered one 5 mg asenapine tablet, sublingually BID for 21 days
3260620|NCT00764478|Experimental|Asenapine 10 mg BID|Participants were administered one 10 mg asenapine tablet, sublingually BID for 21 days
3260621|NCT00764478|Placebo Comparator|Placebo BID|Participants were administered one asenapine-matched placebo tablet sublingually BID for 21 days
3260622|NCT00764465|Active Comparator|Group A|Period 1-Maraviroc 300mg BID Period 2- Fosamprenavir 1400mg BID Period 3- Fosamprenavir 1400mg BID + Maraviroc 300mg BID
3260623|NCT00764465|Active Comparator|Group B|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg BID + Maraviroc 300mg BID Period 3-Fosamprenavir 1400mg BID
3260624|NCT00764465|Active Comparator|Group C|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Maraviroc 300mg BID
3260625|NCT00764465|Active Comparator|Group D|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Maraviroc 300mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID
3260626|NCT00764465|Active Comparator|Group E|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3- Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Maraviroc 300mg BID
3260627|NCT00764465|Active Comparator|Group F|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Maraviroc 300mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
3260628|NCT00764439|Active Comparator|1|Standard NRT user direction
3260629|NCT00764439|Experimental|2|Novel NRT user direction
3260630|NCT00764426|Active Comparator|non-alcoholic beverages|dealcoholised red wine, de-alcoholised beer, water
3260631|NCT00764426|Active Comparator|alcoholic beverages|red wine, beer, ethanol
3260632|NCT00764413|Active Comparator|1|Both study arms receive both active treatment = methylprednisolone and an inactive treatment = Sodium chlorid (dummy)
3260633|NCT00764413|Active Comparator|2|Both arms receives both active treatment and inactive treatment = dummy. Active treatment is methylprednisolone, inactive treatment is sodium chlorid.
3260634|NCT00764400|Experimental|Errorless Naming Treatment|
3260635|NCT00764400|Experimental|Verbal+Gestural Facilitation|
3260636|NCT00764387|Experimental|Arm 1|
3260637|NCT00764387|Active Comparator|Arm 2|
3260638|NCT00764374|Experimental|1|
3260639|NCT00764361|Experimental|NanoDOX™ Hydrogel|1.0% doxycycline gel
3260640|NCT00764361|Placebo Comparator|Placebo|placebo gel
3260641|NCT00764348||no treatment|
3260642|NCT00764335||unilateral normal|total hip arthroplasty one side, normal offset of medial femoral head
3260643|NCT00764335||bilateral normal|total hip arthroplasty both sides, normal offset of medial femoral head
3260644|NCT00764335||bilateral abnormal offset|total hip arthroplasty both sides, abnormal offset of medial femoral head
3260645|NCT00764335||controls|Healthy, age-matched control group
3260646|NCT00764322|Experimental|Tamoxifen 20|One arm, containing the ultra-rapid and extensive metabolizer genotypes, continues treatment with tamoxifen at 20mg.
3260647|NCT00764322|Active Comparator|Tamoxifen 40|This arm, containing the intermediate and poor metabolizer genotypes, receives escalated treatment with tamoxifen at 40mg.
3260648|NCT00764309|Experimental|A1|
3260649|NCT00764296||no treatment|The information obtained by the evaluation of both acute and chronic wounds is pivotal to truly understanding the intercellular tactics used by wound biofilms which work to disrupt host tissue and to evade the host's immune system.
3260650|NCT00764283|Experimental|1|Tegaderm dressing
3260651|NCT00764283|Active Comparator|2|Epi-Fix dressing
3260652|NCT00764283|Active Comparator|3|Lockit-Plus dressing
3260653|NCT00764270|Active Comparator|Lipoic acid treatment|Participants take lipoic acid with a washout period before or after placebo.
3260654|NCT00764270|Placebo Comparator|Placebo treatment|Participants take placebo with a washout period before or after lipoic acid treatment
3260655|NCT00764257|Experimental|PREVELLE Shape|
3260656|NCT00764257|Active Comparator|Restylane|
3260657|NCT00764244|Active Comparator|1|Vitrectomy
3260658|NCT00764244|Active Comparator|2|Intravitreal triamcinolone injections
3260659|NCT00764244|Active Comparator|3|Laser photocoagulation
3260660|NCT00764231|Experimental|Exercise|This group will undergo a 12-week home-based exercise intervention with follow-up fitness assessments.
3260661|NCT00764231|Other|Wait list control|This group will go on a 12-week wait list, during which time they will be asked not to change their exercise habits. After 12 weeks, this group will participate in the exercise intervention.
3260662|NCT00764218|Experimental|SAS+HTA+|Obstructive sleep apnea syndrome and hypertension
3260663|NCT00764218|Experimental|SAS+HTA-|non hypertensive patients with obstructive sleep apnea syndrome
3260664|NCT00764218|Experimental|SAS-HTA+|hypertensive patients without obstructive sleep apnea syndrome
3260665|NCT00764218|Experimental|SAS-HTA-|non hypertensive patients without obstructive sleep apnea syndrome
3260666|NCT00764205||Study Group|Troponin measured prior to hospital arrival
3260667|NCT00764205||Control Group|Patients transported to hospital without troponin measurements enroute
3260668|NCT00764192|Experimental|1|14 HD patients are studied before and after a single HD using a polysulphone dialyser.
3260669|NCT00764179|Experimental|1|hyperproteinic milk
3260670|NCT00764179|Active Comparator|2|Normoproteinic milk
3260671|NCT00764166|Experimental|1|
3260672|NCT00764166|Active Comparator|2|
3260673|NCT00764153|Other|Internal fixation|Closed reduction and internal fixation with two parallel screws (Olmed)
3260674|NCT00764153|Other|Bipolar hemiarthroplasty|Hemiarthroplasty with Charnley/ Hastings prosthesis
3260675|NCT00764140||2|Specific tumor growth factors (IGFs, its binding proteins,receptors; transforming growth factor alpha and beta 1 and epidermal growth factor) in the urine and serum will be measured in patients with hepatocellular carcinoma and healthy controls
3260676|NCT00764140||1|Patients with hepatocellular carcinoma and Healthy controls
3260677|NCT00764127||Obese Control|
3260678|NCT00764127||Normal Control|
3260679|NCT00764127||OVERWEIGHT ADOLESCENT PATIENTS UNDERGOING BARIATRIC SURGERY|
3260680|NCT00764114|Active Comparator|1|- group A : during 6 weeks after the inclusion
3260735|NCT00763724||2|Venlafaxine
3260681|NCT00764114|Active Comparator|2|-group B : during 12 weeks after the inclusion
3260682|NCT00764101|Experimental|1|9 sessions of attentional bias modification (computerized training program)
3260683|NCT00764101|Placebo Comparator|2|Attentional control condition (placebo training program)
3260684|NCT00764088||Anaysis of Full Thickness wounds|To demonstrate the effectiveness or ineffectiveness of novel treating agents or agents used for compassionate rescue, subjects and their wounds will be analyzed retrospectively and their non-identifiable information will be compiled in the form of case studies. Subjects who demonstrated characteristics of interest (e.g. healing) as determined by the PI will be chosen for case studies.
3260685|NCT00764075|Experimental|1|guided implantation of the left ventricular lead
3260686|NCT00764075|Placebo Comparator|2|standard implantation of the left ventricular lead
3260687|NCT00764075|Experimental|Pilot Group|feasibility of guided placement of CRT-leads in 20 Patients
3260688|NCT00764062|Experimental|1|7-day amoxicillin treatment (1g per os twice daily)
3260689|NCT00764062|Active Comparator|2|3-day amoxicillin (1g per os twice daily) + 4-day placebo treatment (1g per os twice daily)
3260690|NCT00764049|Experimental|1: Single pass albumin dialysis|Patients entered in the pilot study.
3260691|NCT00764036|Experimental|experimental arm only|add-on therapy with 100, 150 or 200 mg oral artesunate once daily
3260692|NCT00764023||No treatment|
3260693|NCT00764023||human samples|
3260694|NCT00764010|No Intervention|1|No dietary counseling, placebo capsules for omega-3
3260695|NCT00764010|Active Comparator|2|Dietary counseling, placebo capsules for omega-3
3260696|NCT00764010|Active Comparator|3|No dietary counseling, omega-3 capsules
3260697|NCT00764010|Active Comparator|4|Dietary counseling and omega-3 capsules
3260698|NCT00763997|Experimental|1|Dipyrone
3260699|NCT00763997|Active Comparator|2|Ibuprofen
3260700|NCT00763997|Active Comparator|3|Acetaminophen
3260701|NCT00763997|Placebo Comparator|4|Parecoxib/Valdecoxib
3260702|NCT00763984|Active Comparator|1 Usual Care|This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT
3260703|NCT00763984|Experimental|2 Bladder Health Class|Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
3260704|NCT00763971|Experimental|Lisdexamfetamine Dimesylate (LDX)|Overencapsulated LDX 30, 50, or 70mg
3260705|NCT00763971|Active Comparator|Methylphenidate Hydrochloride|Overencapsulated Concerta 18, 36, or 54mg
3260706|NCT00763971|Placebo Comparator|Placebo|Overencapsulated Placebo
3260707|NCT00763958|Experimental|Buprenorphine|Active sublingual buprenorphine provided to participants; dose as clinically indicated up to 32 mg daily for up to 3 months
3260708|NCT00763958|Placebo Comparator|Placebo|Placebo sublingual medication provided to individuals randomized to control up to 3 months
3260709|NCT00763945||1|Patients representing to the hospital with acute coronary syndrome
3260710|NCT00763932|Experimental|1|
3260711|NCT00763919|Experimental|Customized Adherence Enhancement (CAE)|"Participants, all of whom have a history of medication nonadherence, will be assigned to one or more treatment modules based on their individual profiles.~Treatment Modules:~Psychoeducation module Substance abuse module Improved communication/rapport with provider module Medication routines management module"
3260712|NCT00763906|Placebo Comparator|1|Patients were assigned to norepinephrine infused at the clinician's discretion.
3260713|NCT00763906|Active Comparator|2|Patients were assigned to norepinephrine infused under computerized fuzzy logic control.
3260714|NCT00763893|Placebo Comparator|A: Placebo|placebo
3260715|NCT00763893|Active Comparator|B: Losartan|Losartan
3260716|NCT00763880|Experimental|Lidocaine|Subjects randomly assigned to this arm will receive 2% lidocaine by injection into their fracture site in the form of a hematoma block.
3260717|NCT00763880|Placebo Comparator|Normal Saline|Subjects randomly assigned to this arm will receive normal saline by injection into their fracture site
3260718|NCT00763867|Placebo Comparator|Placebo|Placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks
3260719|NCT00763867|Experimental|Sildenafil|Sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks
3260720|NCT00763841|Experimental|1|Stimulation will be given daily at a particular site for three days a week
3260721|NCT00763841|Sham Comparator|2|
3260722|NCT00763828|Experimental|ThermoSuit-Induced Patient Cooling|The Life Recovery Systems ThermoSuit System will be used to cool STEMI patients under conditions of conscious sedation.
3260723|NCT00763815|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3260724|NCT00763815|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3260725|NCT00763802||MNPDR|Type 2 diabetic patients with Mild non-prolipherative retinopathy.
3260726|NCT00763789|Experimental|1|Local anaesthesia and remifentanil sedation
3260727|NCT00763789|Other|2|Total intravenous anaesthesia
3260728|NCT00763776|Other|1|Liver transection by clamp crushing technique
3260729|NCT00763776|Other|2|Liver transection by the ultrasonic dissector
3260730|NCT00763763|Experimental|1|imatinib in combination with chemotherapy by vincristin and dexamethasone
3260731|NCT00763750|Experimental|PPX +TMZ+XRT|XRT 60Gy at 2 GY/fractions x 30 fractions TMZ 75mg/m2/day PPX 40mg/m2/week x 6 weeks Days 1,8,15,22,22,29,36
3260732|NCT00763737|Experimental|1|prenatal FETO at 30-31+6 weeks and removal at 34-34+6 wks, followed by standardized postnatal care
3260733|NCT00763737|No Intervention|2|expectant management during pregnancy followed by standardized neonatal care
3260738|NCT00763724||5|Multiple Antidepressants
3260739|NCT00763724||6|Depressed (not antidepressant treated)
3260740|NCT00763724||7|General population
3260741|NCT00763711|Experimental|Injection with Needle Guide|
3260742|NCT00763698|Experimental|QuickFlex micro 1258T left heart lead|
3260743|NCT00763685|Active Comparator|etoricoxib 120 mg|active control
3260744|NCT00763685|Placebo Comparator|2|Placebo
3260745|NCT00763685|Active Comparator|3|Paracetamol 1 g and etoricoxib 120 mg
3260746|NCT00763672|Other|A|sFlt-1 status known
3260747|NCT00763672|Other|B|sFlt-1 status unknown
3260748|NCT00763659|Active Comparator|1|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
3260749|NCT00763659|Active Comparator|2|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
3260750|NCT00763659|Placebo Comparator|3|Placebo
3260751|NCT00763633|Active Comparator|highB6|high vitamin B6
3260752|NCT00763633|Active Comparator|lowB6|low vitamin B6
3260753|NCT00763620|Experimental|1|Catheter for mini bronchoalveolar lavage
3260754|NCT00763607||1|Radically resected Non small cell lung cancer patients in stage I-III
3260755|NCT00763594|Active Comparator|IPT|Interpersonal Psychotherapy for Major Depressive Disorder
3260756|NCT00763594|Experimental|BRT|Brief Relational Therapy adapted for treatment of Major Depressive Disorder
3260757|NCT00763568|Experimental|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
3260758|NCT00763555|Experimental|1|CD 2027, 3 ug/g Oily Spray, twice a day for 8 weeks
3260759|NCT00763555|Placebo Comparator|2|
3260760|NCT00763542|Experimental|I|Combined treatment: CBT for SUD plus structured writing therapy for PTSD
3260761|NCT00763542|Active Comparator|II|CBT for SUD only
3260762|NCT00763529|Experimental|Arm 1|
3260763|NCT00763529|Active Comparator|Arm 2|
3260764|NCT00763516|Experimental|Proton radiation and chemotherapy|"Proton radiation~Capecitabine chemotherapy on radiation days~Surgery~Gemcitabine chemotherapy"
3260765|NCT00763503|Experimental|CD 2027|
3260766|NCT00763490|Experimental|Double cord blood transplant|'full intensity, double umbilical cord, stem cell transplant' with 'Flu/Bu4 conditioning regimen'
3260767|NCT00763477|Placebo Comparator|saline injections|
3260768|NCT00763451|Experimental|Lixisenatide (Two-Step Titration)|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3260769|NCT00763451|Experimental|Lixisenatide (One-Step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to the end of treatment.
3260770|NCT00763451|Placebo Comparator|Placebo (Two-Step Titration)|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3260771|NCT00763451|Placebo Comparator|Placebo (One-Step Titration)|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, then 20 mcg QD up to the end of treatment.
3260772|NCT00763438|Experimental|Sertindole|
3260773|NCT00763425|Experimental|1|
3260774|NCT00763425|Active Comparator|2|
3260775|NCT00763412|Placebo Comparator|1 Placebo|1 pill before each meal 3-4 times a day for 2 years. All subjects had abnormal glucose tolerance. Subjects were randomized to placebo or drug.
3260776|NCT00763412|Experimental|2. repaglinide|repaglinide 0.5 mg before each meal 3-4 times a day for 2 years. All subjects had abnormal glucose tolerance.Subjects were randomized to placebo or drug.
3260777|NCT00763399|Experimental|97-0549B|
3260778|NCT00763386|Active Comparator|1|Study arm will consist of patients that are treated with the NexGen LPS-Flex Fixed Bearing Knee.
3260779|NCT00763386|Active Comparator|2|Study arm will consist of patients that are treated with the NexGen Legacy Posterior Stabilized Knee.
3260780|NCT00763373||1|Observation group
3260781|NCT00763373||2|Intervention group
3260782|NCT00763360|Experimental|DisCoVisc®|DisCoVisc® Ophthalmic Viscosurgical Device
3260783|NCT00763360|Active Comparator|Healon|Healon
3260784|NCT00763360|Active Comparator|Amvisc Plus|Amvisc Plus
3260785|NCT00763347|Experimental|SYR-619 12.5 mg QD|
3260786|NCT00763347|Experimental|SYR-619 50 mg QD|
3260787|NCT00763347|Experimental|SYR-619 100 mg QD|
3260788|NCT00763347|Experimental|SYR-619 200 mg QD|
3260789|NCT00763347|Placebo Comparator|Placebo QD|
3260790|NCT00763347|Active Comparator|Alogliptin 25 mg QD|
3260791|NCT00763321|Experimental|Open-label ABT-712|2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks (open-label period).
3260792|NCT00763321|Experimental|Double-blind ABT-712|2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period).
3260793|NCT00763321|Placebo Comparator|Double-blind Placebo|2 placebo tablets, twice daily, for 4 weeks (double-blind period).
3260794|NCT00763308|Experimental|1|Participants will use the Web-based Heart Healthy program.
3260795|NCT00763308|No Intervention|2|Participants will receive treatment as usual.
3260796|NCT00763295||HIV infection|
3260797|NCT00763282|Experimental|SM+MI|Self Management (SM) + Motivational Interviewing (MI). Self Management and Motivational Interviewing (SM+MI) participants were assigned to both a self-management and motivational interview group. Motivational Interviewing (MI) is an evidence-based form of counseling to help individuals to engage in behavior change. Self Management (SM) consists of: 1) on-site decisional support to promote provider adherence to ulcer management guidelines, 2) enhanced, interactive PrU education, 3) chronic disease self-management skill building via telephone based groups, 4) proactive care management using MI to support ongoing self-management activities, and 5) distance technology.
3260861|NCT00762853|Active Comparator|B|fluoride/triclosan/copolymer toothpaste
3260862|NCT00762840|Experimental|Apexum|the tooth is treated by a standard root canal treatment, supplemented by Apexum Ablator protocol, in which the periapical lesion tissue is minced and removed through the root canal, in a minimally invasive fashion.
3261046|NCT00761553|Experimental|1|Solid dietary supplements with exercise
3260798|NCT00763282|Active Comparator|ED|Education (ED). An education control intervention (ED) designed to be a credible intervention that is comparable to the SM will control for potential effects of natural history/time, treatment dosing, measurement processes, attention, the non-specific effects of therapeutic alliance, social support, and of receiving a manualized treatment with specific therapist procedures. The ED intervention will differ only in that subjects will not be instructed in any specific problem solving, self-monitoring, or SM techniques, with the exception of encouraging them to become informed consumers of SCI care.
3260799|NCT00763269|Experimental|A|sensitive toothpaste
3260800|NCT00763269|Active Comparator|B|Triclosan control toothpaste
3260801|NCT00763256|Active Comparator|A|
3260802|NCT00763256|Placebo Comparator|B|
3260803|NCT00763243|Experimental|Cogmed Working Memory Training|Cogmed Working Memory Training Program
3260804|NCT00763230|Experimental|active|Full active tDCS treatment
3260805|NCT00763230|Sham Comparator|sham|Placebo tDCS will be give
3260806|NCT00763217||stroke patient cohort|Patients with an hemispheric ischemic or hemorrhage stroke hospitalized during the 48h following the beginning of stroke
3260807|NCT00763204|Experimental|1|AN2728 Cream, 2%
3260808|NCT00763204|Experimental|2|AN2728 Cream, 1%
3260809|NCT00763204|Experimental|3|AN2728 Cream, 0.3%
3260810|NCT00763204|Placebo Comparator|4|AN2728 Cream Vehicle
3260811|NCT00763204|Active Comparator|5|Betnesol®-V Creme (betamethasone 0.1 %)
3260812|NCT00763178|Experimental|PTSD|Duloxetine
3260813|NCT00763165|Active Comparator|A|
3260814|NCT00763165|Placebo Comparator|B|
3260815|NCT00763152||stability of Beacons in prostatic bed|Patients implanted with the Calypso transponders following radical prostatectomy for prostate cancer will be followed for observation of transponder stability.
3260816|NCT00763139|Experimental|Placebo First|Placebo for first 8 weeks, then washout period for 4 weeks, and finally pioglitazone for 8 weeks.
3260817|NCT00763139|Experimental|Pioglitazone First|Pioglitazone for first 8 weeks, then washout period for 4 weeks, and finally placebo for 8 weeks.
3260818|NCT00763126|Active Comparator|Spouse present,|
3260819|NCT00763126|Active Comparator|spouse absent|
3260820|NCT00763113|Experimental|1|Vanguard PS Knee
3260821|NCT00763113|Active Comparator|2|Vanguard CR Knee
3260822|NCT00763100||Breast cancer|Patients in treatment or post-treatment for breast cancer
3260823|NCT00763087|Active Comparator|nonweightbearing exercise|
3260824|NCT00763087|Placebo Comparator|nonexercising control|
3260825|NCT00763087|Experimental|weightbearing exercise|
3260826|NCT00763074|Placebo Comparator|Control|Conventional education of life style intervention for type 2 diabetes
3260827|NCT00763074|Active Comparator|Diet|Dietary calorie restriction
3260828|NCT00763074|Active Comparator|Exercise|Encourage to increase exercise amount: more than 60min's of exercise with moderate activity level two times per day
3260829|NCT00763074|Active Comparator|Diet and exercise|Intervention for both of exercise and diet
3260830|NCT00763061|Experimental|Travoprost 0.004%|Travoprost 0.004%
3260831|NCT00763061|Active Comparator|Timolol 0.5%|Timolol 0.5%
3260832|NCT00763048|Placebo Comparator|A -Control|Fluoride toothpaste (Colgate Great Regular Flavor) is the control for this study. All study toothpastes contain fluoride. The study is evaluating the additional ingredients in the other toothpastes.
3260833|NCT00763048|Active Comparator|B|fluoride/triclosan/copolymer toothpaste (Colgate Total Toothpaste)
3260834|NCT00763035|Active Comparator|A|Arm A will get Dobutamine Stress test with cardiac MR (CMR). Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.
3260835|NCT00763035|Active Comparator|B|Arm B will get Regadenoson stress test with CMR. Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.
3260836|NCT00763022|Experimental|TAK-559 16 mg QD|
3260837|NCT00763022|Experimental|TAK-559 32mg QD|
3260838|NCT00763022|Placebo Comparator|Placebo QD|
3260839|NCT00763009|Other|All subjects receive dipyridamole|Compare to baseline
3260840|NCT00762996|Active Comparator|etafilcon A/etafilcon A|Period 1: etafilcon A, Period 2: etafilcon A
3260841|NCT00762996|Active Comparator|etafilcon A/omafilcon A|Period 1: etafilcon A, Period 2: omafilcon A
3260842|NCT00762996|Active Comparator|omafilcon A/etafilcon A|Period 1: omafilcon A, Period 2: etafilcon A
3260843|NCT00762996|Active Comparator|omafilcon A/omafilcon A|Period 1: omafilcon A, Period 2: omafilcon A
3260844|NCT00762983||Group 1|Pediatric patients who are treated with Claritin for any of the following reasons: allergic rhinitis, urticaria, itching due to skin disease (eczema, dermatitis, or pruritus cutaneous)
3260845|NCT00762970|Experimental|Test Lens 1|Investigational soft contact lenses worn daily.
3260846|NCT00762970|Experimental|Test Lens 2|Investigational soft contact lenses worn daily.
3260847|NCT00762970|Active Comparator|Control lens|Spectacle lenses worn daily.
3260848|NCT00762957|Experimental|TAK-559 16 mg QD + Metformin QD|
3260849|NCT00762957|Experimental|TAK-559 32 mg QD + Metformin QD|
3260850|NCT00762957|Active Comparator|Metformin QD|
3260851|NCT00762931|Experimental|Resolve Stimulator and Proximity Lead|An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation, all subjects will receive active treatment
3260852|NCT00762905|Active Comparator|1|LiquiBand Laparoscopic
3260853|NCT00762905|Active Comparator|2|Dermabond
3260854|NCT00762892|Active Comparator|Raltegravir|Raltegravir in combination with truvada (tenofovir and emtricitabine)
3260855|NCT00762892|Active Comparator|Atazanavir|Atazanavir, low dose ritonavir, and truvada (tenofovir and emtricitabine)
3260856|NCT00762879||No treatment|
3260857|NCT00762866||MDD|Unipolar Major Depressive Disorder, any subtype
3260858|NCT00762866||Bipolar|Bipolar I or II Disorder or Bipolar Disorder NOS
3260859|NCT00762866||Psychosis|Psychotic Disorder including Schizophrenia, Schizoaffective, Schizophreniform, Brief Psychotic Disorder, and Psychotic Disorder NOS
3260860|NCT00762853|Placebo Comparator|A|fluoride toothpaste from Thailand
3260863|NCT00762840|Active Comparator|Control|the tooth is subject to conventional endodontic procedure alone, (standard root canal treatment)
3260864|NCT00762814|Experimental|Parkinson subjects with freezing|"Each subject will have been diagnosed with Parkinson disease and will serve as his/her own control. Inclusion criteria: history of consistent freezing with ambulation in a straight line and/or when turning, normal central and peripheral neurological function, at least grade 4 strength and normal joint ranges of motion in both legs, normal somatosensory function in the feet (joint position sense), except for their neurological diagnosis and use of levodopa, each must have had clear benefit from levodopa for at least some of his/her PD symptoms, and all subjects with PD must be able to walk independently for 10 feet.~Exclusion criteria include: serious medical problem that would impair the ability to undergo testing, use of neuroleptic or other dopamine-blocking drug, use of drugs that might affect balance, history or evidence of other neurological deficit that could interfere, such as previous stroke or muscle disease, or participants who are unable to provide informed consent."
3260865|NCT00762788|Active Comparator|senofilcon A contact lens|ACUVUE OASYS
3260866|NCT00762788|Active Comparator|lotrafilcon A contact lens|NIGHT&DAY
3260867|NCT00762788|Active Comparator|lotrafilcon B contact lens|O2Optix
3260868|NCT00762788|Active Comparator|balafilcon A contact lens|PureVision
3260869|NCT00762788|Active Comparator|comfilcon A contact lens|Biofinity
3260870|NCT00762788|Active Comparator|etafilcon A contact lens|ACUVUE 2
3260871|NCT00762775|Experimental|1|Calcium supplementation and placebo
3260872|NCT00762775|Experimental|2|Vitamin D supplementation and placebo
3260873|NCT00762775|Experimental|3|Calcium and Vitamin D supplementation
3260874|NCT00762775|Placebo Comparator|4|Placebos only
3260875|NCT00762762|Active Comparator|A|
3260876|NCT00762762|Placebo Comparator|B|
3260877|NCT00762749|Experimental|diphenhydramine HCl|diphenhydramine HCl / Children's Benadryl Allergy Liquid
3260878|NCT00762736|Experimental|Pioglitazone 15 mg QD + Azilsartan 5 mg QD|
3260879|NCT00762736|Experimental|Pioglitazone 15 mg QD + Azilsartan 40 mg QD|
3260880|NCT00762736|Active Comparator|Pioglitazone 15 mg QD|
3260881|NCT00762736|Experimental|Pioglitazone 45 mg QD + Azilsartan 5 mg QD|
3260882|NCT00762736|Experimental|Pioglitazone 45 mg QD + Azilsartan 40 mg QD|
3260883|NCT00762736|Active Comparator|Pioglitazone 45 mg QD|
3260884|NCT00762723|Experimental|Group 1|Trinica Anterior Lumbar Plate System with fixed screws only
3260885|NCT00762723|Experimental|Group 2|Trinica Anterior Lumbar Plate System with variable screws only
3260886|NCT00762723|Experimental|Group 3|Trinica Anterior Lumbar Plate with hybrid screw configuration (2 fixed-angle screws with 2 variable-angle screws).
3260887|NCT00762710|Experimental|1|Prazosin medication
3260888|NCT00762710|Placebo Comparator|2|Placebo medication
3260889|NCT00762684|Experimental|TAK-559 32 mg QD|
3260890|NCT00762684|Placebo Comparator|Placebo QD|
3260891|NCT00762671|Placebo Comparator|2|Placebo
3260892|NCT00762671|Active Comparator|1|Ebselen
3260893|NCT00762658|Experimental|1|AN2728 Ointment, 5%
3260894|NCT00762658|Experimental|2|AN2728 Ointment, 2%
3260895|NCT00762658|Experimental|3|AN2728 Ointment, 0.5%
3260896|NCT00762658|Placebo Comparator|4|AN2728 Ointment Vehicle
3260897|NCT00762658|Active Comparator|5|Betnesol®-V Creme (betamethasone 0.1 %)
3260898|NCT00762658|Active Comparator|6|Protopic® Ointment (tacrolimus 0.1 %)
3260899|NCT00762645|Experimental|Travoprost 0.004% (Travatan)|One drop in each eye, once daily at 9 AM
3260900|NCT00762645|Active Comparator|Pilocarpine 1%|One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
3260901|NCT00762619|Placebo Comparator|A -|fluoride toothpaste (Ultrabrite)
3260902|NCT00762619|Active Comparator|B - Postive control|fluoride/triclosan/copolymer toothpaste
3260903|NCT00762606|Active Comparator|Phaco|Cataract extraction surgery utilizing Phacoemulsification
3260904|NCT00762606|Active Comparator|SICS|Small incision cataract surgery (SICS)
3260905|NCT00762593|Experimental|1|transvaginal electrical stimulation with a home use programmable device used 30 minutes every day during 8 weeks
3260906|NCT00762593|Placebo Comparator|2|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
3260907|NCT00762580||Prospective|Patients with full thickness rotator cuff tears being treated with physical therapy
3260908|NCT00762567|Experimental|1|phenylephrine
3260909|NCT00762554|Active Comparator|1|Epidural Depodur after epidural lidocaine
3260910|NCT00762554|Active Comparator|2|Epidural Depodur after spinal bupivacaine
3260911|NCT00762554|Active Comparator|3|Epidural fentanyl infusion after epidural lidocaine or spinal bupivacaine
3260912|NCT00762528|Active Comparator|Total Toothpaste|Triclosan/Copolymer/fluoride toothpaste
3260913|NCT00762528|Placebo Comparator|Fluoride toothpaste|sodium monofluorophosphate toothpaste
3260914|NCT00762515|Placebo Comparator|A|commercially available Fluoride only toothpaste
3260915|NCT00762515|Active Comparator|B|Commercially available triclosan/copolymer/fluoride toothpaste
3260916|NCT00762502|Active Comparator|senofilcon A toric bilaterally|senofilcon A lenses worn daily bilaterally (in both eyes) for 3 months, replaced weekly.
3260917|NCT00762502|Active Comparator|balafilcon A toric bilaterally|balafilcon A lenses worn daily bilaterally (in both eyes) for 3 months, replaced weekly.
3260918|NCT00762502|Active Comparator|senofilcon A/balafilcon A contralaterally|senofilcon A lens worn in one eye and balafilcon A lens worn in the other eye (contralaterally), daily for 3 months, replaced weekly.
3260919|NCT00762489|Other|TAT vs. RT|This arm is comparing the Temporal Artery Thermometer (TAT) temperature to the Rectal Temperature (RT).
3260920|NCT00762489|Other|TAT vs. AT|This arm is comparing the Temporal Artery Thermometer (TAT) temperature to the Axillary Temperature (AT).
3260921|NCT00762476|Placebo Comparator|Placebo|
3260922|NCT00762476|Experimental|3804-250A|
3260923|NCT00762463|Experimental|Celecoxib 200 mg QD|
3260924|NCT00762463|Active Comparator|Diclofenac SR 75 mg QD|
3261045|NCT00761566|Experimental|2|
3260925|NCT00762450|Active Comparator|A- Positive Control|fluoride/triclosan/copolymer toothpaste
3260926|NCT00762450|Placebo Comparator|B - Silica control|fluoride only toothpaste
3260927|NCT00762450|Experimental|C- Experimental product|fluoride/triclosan/amino acid toothpaste
3260928|NCT00762437|Experimental|1|
3260929|NCT00762424|Active Comparator|Tamsulosin|
3260930|NCT00762424|Placebo Comparator|Placebo|
3260931|NCT00762411|Experimental|LY450139|Participants received 60 milligrams (mg) LY450139 orally once daily for 2 weeks followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.
3260932|NCT00762411|Placebo Comparator|Placebo|Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, participants in the placebo arm received LY450139 titrated up to 140 mg orally once daily until Week 88.
3260933|NCT00762398||Adult patient undergoing a surgery|Adult patient undergoing a surgery in the supine position and require an arterial line for anesthesia/surgery purposes
3260934|NCT00762385|Active Comparator|galyfilcon A/comfilcon A|galyfilcon A first, comfilcon A second
3260935|NCT00762385|Active Comparator|comfilcon A/galyfilcon A|comfilcon A first, galyfilcon A second
3260936|NCT00762372|Experimental|desflurane|
3260937|NCT00762372|Experimental|desflurane/N2O|
3260938|NCT00762372|Active Comparator|sevoflurane/N2O|
3260939|NCT00762359|Experimental|Lansoprazole 15 mg QD|
3260940|NCT00762359|Active Comparator|Gefarnate 50 mg BID|
3260941|NCT00762346|Experimental|1|
3260942|NCT00762333||Myocardial Infarction|
3260943|NCT00762320|Experimental|Low dose Kaletra tablets|Patients will serve as their own controls as they are switched from the baseline treatment with liquid Kaletra to the study intervention treatment with Low Dose Tablet Kaletra (100mg/25mg)
3260944|NCT00762307|Experimental|1|
3260945|NCT00762294||644-001|Women treated for breast cancer who will be starting Arimidex or Femara
3260946|NCT00762281|Other|Treatment of Hyperopic LASIK|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
3260947|NCT00762268|Experimental|SAMe|"SAMe: SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period."
3260948|NCT00762268|Placebo Comparator|placebo|"Placebo: Placebo SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral pills for only 3 days per week, followed by a 4 day rest-period, before the round. The apparent dosage will be progressively increased each week to mimic a maximum of 1600 mg per day over a 4-week period."
3260949|NCT00762255|Experimental|A - Phase I Dose Escalation|Dose Escalation - Irinotecan and bevacizumab are given IV on days 1 and 15 of each cycle. Vorinostat is given orally on days 1-7 and 15-21 of each cycle.
3260950|NCT00762255|Experimental|B - Treatment at Maximum Tolerated Dose (MTD)|MTD - Treatment at maximum tolerated dose
3260951|NCT00762242||1|Blood sampling and brachial artery ultrasound
3260952|NCT00762229|Active Comparator|Ezetimibe 10 mg|A whole ezetimibe 10 mg tablet
3260953|NCT00762229|Experimental|Ezetimibe 5 mg|"Ezetimibe 5 mg, formulated by splitting a 10 mg ezetimibe tablet in half"
3260954|NCT00762216|Other|Toric|Implantation with the AcrySof® Toric intraocular lens
3260955|NCT00762190|Experimental|TAK-559 32 mg QD + Insulin|
3260956|NCT00762190|Active Comparator|Insulin|
3260957|NCT00762177|Placebo Comparator|A -Control|fluoride toothpaste
3260958|NCT00762177|Experimental|B Experimental toothpaste|Stannous fluoride toothpaste
3260959|NCT00762177|Active Comparator|C- positive control|fluoride/triclosan/copolymer toothpaste
3260960|NCT00762164|Active Comparator|1Vytorin 10/80 divided into 4|Vytorin 10/80 divided into 4
3260961|NCT00762164|Active Comparator|Simvastatin|Simvastatin 20 milligrams
3260962|NCT00762151|Placebo Comparator|Negative Control|Regular Toothpaste
3260963|NCT00762151|Active Comparator|Positive Control|Standard anti-plaque and anti-bacterial toothpaste.
3260964|NCT00762151|Active Comparator|Prototype|AN0128 Toothpaste
3260965|NCT00762138|Other|Autologel System|Autologel System produces platelet rich plasma gel
3260966|NCT00762125|Experimental|Cognitive restructuring and coping skills training (CR+ST)|
3260967|NCT00762125|Experimental|Exposure therapy (ET)|
3260968|NCT00762125|Experimental|Combination (COMB) treatment|
3260969|NCT00762125|Active Comparator|Attention control (AC) treatment|
3260970|NCT00762112|Experimental|TAK-559 32 mg QD|
3260971|NCT00762099|Active Comparator|1|Pregabalin Group
3260972|NCT00762099|Placebo Comparator|2|Placebo group
3260973|NCT00762086|Active Comparator|Treatment Group|AngioPress Intermittent pneumatic compression (IPC) Device
3260974|NCT00762086|Other|Control Group|Aspirin/Clopidegrol and Standard walking exercises
3260975|NCT00762073|Placebo Comparator|1|
3260976|NCT00762073|Experimental|2|Low Dose Group
3260977|NCT00762073|Experimental|3|Medium Dose Group
3260978|NCT00762073|Experimental|4|High Dose Group
3260979|NCT00762060||Active|Surgical site continuous local anesthetic infusion with ONQ silver Soaker System
3260980|NCT00762060||Control|Hospital standard of care for pain management (Patient controlled analgesia or epidural)
3260981|NCT00762047|Experimental|Durasphere|
3260982|NCT00762047|Sham Comparator|Sham|
3260983|NCT00762034|Experimental|Pem/Carbo/Bev|Pemetrexed (Pem), carboplatin (Carbo) and bevacizumab (Bev) followed by pemetrexed and bevacizumab
3260984|NCT00762034|Active Comparator|Pac/Carbo/Bev|Paclitaxel (Pac), carboplatin (Carbo) and bevacizumab (Bev) followed by bevacizumab
3260985|NCT00762021|Experimental|SN60AT|Implantation with the AcrySof Intraocular Lens Model SN60AT
3260986|NCT00762021|Active Comparator|SN60WF|Implantation with the AcrySof Intraocular Lens Model SN60WF
3260987|NCT00762008||Heart Failure|
3260988|NCT00761995|Active Comparator|Azopt|topical eye drop dosed 1 drop 3 times daily
3260989|NCT00761995|Active Comparator|Cosopt|topical eye drop
3260990|NCT00761982|Other|bone marrow stem cells|Procedure: Infusion of autologous CD34+ stem cells into middle cerebral artery.
3260991|NCT00761969||PAB|Subjects with stable peripheral arterial disease; ankle-brachial pressure index on at least one leg =< 0.90.
3260992|NCT00761969||Control|Subjects without peripheral arterial disease (palpable pedal pulses and a normal ankle-brachial pressure index of 0.91-1.30), age- and sex-matched to the stuy group with PAD
3260993|NCT00761956|Active Comparator|1|Study arm will consist of patients that are treated with the NexGen CR-Flex Fixed Bearing Knee.
3260994|NCT00761956|Active Comparator|2|Study arm will consist of patients that are treated with the NexGen CR Knee.
3260995|NCT00761930|Placebo Comparator|A|commercially available Fluoride toothpaste
3260996|NCT00761930|Active Comparator|B|fluoride/triclosan/copolymer toothpaste
3260997|NCT00761930|Experimental|C|fluoride/herbal toothpaste
3260998|NCT00761917||1: Normal|Subjects without dry eye symptoms based on questionnaire.
3260999|NCT00761917||2: Dry Eye|Subjects with dry eye symptoms based on questionnaire.
3261000|NCT00761904|Experimental|receipt of free generic samples|
3261001|NCT00761904|No Intervention|usual prescribing|
3261002|NCT00761891|Experimental|Enteric-coated aspirin|81 mg daily for 2 weeks
3261003|NCT00761891|Active Comparator|Chewable aspirin|81 mg daily for 2 weeks
3261004|NCT00761878|Active Comparator|Skin treatment|
3261005|NCT00761865|Active Comparator|Air Cast Stirrup Brace|50 patients will be randomly assigned to receive the Air Cast Stirrup Brace.
3261006|NCT00761865|Active Comparator|High Tide Fracture Boot|50 patients will be randomly assigned to the High Tide Fracture Boot.
3261007|NCT00761852|Active Comparator|1|Ruboxistaurin
3261008|NCT00761852|Placebo Comparator|2|Placebo
3261009|NCT00761839|Experimental|Arm 1|These patients receive the experimental intervention--the after-care summary.
3261010|NCT00761839|Active Comparator|Arm 2|These patients are the control group and receive usual care.
3261011|NCT00761813|Experimental|Single Sliding Hip Screw|
3261012|NCT00761813|Experimental|Multiple Cancellous Screws|
3261013|NCT00761787||1|Heart transplanted subjects.
3261014|NCT00761774|Experimental|Brivaracetam|Brivaracetam at flexible dosing up to 200mg /day
3261015|NCT00761761|Experimental|1- Sensoril (Ashwagandha)|Sensoril (Ashwagandha) will be administered using random assignment at a dose of 250 mg/day, increasing to a dose of 500 mg/day by the second week.
3261016|NCT00761761|Placebo Comparator|2 - Placebo|Placebo will be administered using random assignment at a dose of 250 mg/day, increasing to a dose of 500 mg/day by the second week.
3261017|NCT00761748|Experimental|SenSura|SenSura Uro 2-piece. Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.
3261018|NCT00761748|Active Comparator|Convatec|Convatec Uro 2-piece Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.
3261019|NCT00761735|Other|PEG-IFN + RBV: LTFU|Pediatric participants who completed treatment with peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) in P02538 Part 1 of this study (NCT00104052) were enrolled in a 5-year Long Term Follow-Up (LTFU) during P02538 Part 2 (NCT00761735). No study treatment was administered in Part 2.
3261020|NCT00761722|Experimental|Arm 1|"subcutaneous and oral azacitidine~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle."
3261021|NCT00761722|Experimental|Arm 2|"Oral Azacitidine~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle."
3261022|NCT00761709|Experimental|AL-39256|AL-39256 Ophthalmic Suspension, 1%, 1 drop in the study eye(s) at 8 AM from the morning bottle and 1 drop in the study eye(s) at 8 PM from the evening bottle for 4 weeks.
3261023|NCT00761709|Active Comparator|XALATAN|Latanoprost Ophthalmic Solution, 0.005%, 1 drop in the study eye(s) at 8 PM from the evening bottle (morning bottle contained vehicle and was dosed 1 drop in the study eye(s) at 8 AM) for 4 weeks.
3261024|NCT00761709|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in the study eye(s) at 8 AM from the morning bottle and 1 drop in the study eye(s) at 8 PM from the evening bottle for 4 weeks.
3261025|NCT00761696|Experimental|IPI-926|Oral daily dosing
3261026|NCT00761683||1|Patients diagnosed with endometriosis
3261027|NCT00761670|Active Comparator|1|
3261028|NCT00761670|Active Comparator|2|
3261029|NCT00761657|Experimental|A|FG-4592 1.0 mg/kg
3261030|NCT00761657|Experimental|B|FG-4592 1.5 mg/kg
3261031|NCT00761657|Experimental|C|FG-4592 2.0 mg/kg
3261032|NCT00761657|Experimental|D|FG-4592 2.5 mg/kg
3261033|NCT00761657|Experimental|E|FG-4592 3.0 mg/kg
3261034|NCT00761657|Placebo Comparator|F|Placebo
3261035|NCT00761657|Experimental|G|FG-4592 0.7 mg/kg
3261036|NCT00761644|Experimental|Doxil, Bevacizumab + Temsirolimus|"Doxil day 1 of each 21 day cycle, beginning dose level 10 mg/m^2 by vein over 3 hours.~Bevacizumab day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.~Temsirolimus days 1, 8 & 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes."
3261037|NCT00761631|Experimental|Single|Open label
3261038|NCT00761618|Experimental|Arm 1 - Daily|Intrapleural Catheters (IPC) drained every day
3261039|NCT00761618|Experimental|Arm 2 - 3 Times a Week|IPC drained 3 times a week
3261040|NCT00761605|Experimental|Paliperidone|Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
3261041|NCT00761592|Active Comparator|1|
3261042|NCT00761592|Active Comparator|2|
3261043|NCT00761579|Experimental|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
3261044|NCT00761566|Experimental|1|
3261047|NCT00761553|Experimental|2|Solid dietary supplements without exercise
3261048|NCT00761553|Experimental|3|Liquid dietary supplements with exercise
3261049|NCT00761553|Experimental|4|Liquid supplements without exercise
3261050|NCT00761540|Experimental|A1|
3261051|NCT00761540|Placebo Comparator|A2|
3261052|NCT00761540|Experimental|B1|
3261053|NCT00761540|Placebo Comparator|B2|
3261054|NCT00761540|Experimental|C1|
3261055|NCT00761540|Placebo Comparator|C2|
3261056|NCT00761527||Participants with allergic rhinitis or idiopathic urticaria|Outpatient pediatric participants (ages 6 months-11 years) in the Philippines with a diagnosis of allergic rhinitis or chronic idiopathic urticaria.
3261057|NCT00761514|Experimental|1|All subjects will receive Adalimumab
3261058|NCT00761501|Experimental|1|
3261059|NCT00761501|Active Comparator|2|
3261060|NCT00761501|Active Comparator|3|
3261061|NCT00761488|Experimental|1|AcrySof® Toric IOL
3261062|NCT00761475|Placebo Comparator|1|primary closure of the midline
3261063|NCT00761475|Active Comparator|2|onlay mesh supported closure
3261064|NCT00761475|Active Comparator|3|sublay mesh supported closure
3261065|NCT00761462|Experimental|Ciprofloxacin|Subjects receiving Ciprofloxacin (group followed-up for 5 years)
3261066|NCT00761462|Active Comparator|Non-quinolone antibiotic|Subjects receiving non-quinolone antibiotic (group followed-up for 2 years)
3261067|NCT00761449|Experimental|1|1. lenalidomide
3261068|NCT00761436|Experimental|Arm 1|
3261069|NCT00761423|Experimental|1|Combination of eccentric exercises and injection of PRP
3261070|NCT00761423|Placebo Comparator|2|Combination of eccentric exercises and physiological saline injection
3261071|NCT00761410|Other|P.F.C. Sigma RP-F Total Knee Replacement|An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
3261072|NCT00761397||Study Program Group|
3261073|NCT00761397||Usual Care Group|
3261074|NCT00761384|Experimental|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
3261075|NCT00761371|Experimental|Imiquimod|Imiquimod 5% cream
3261076|NCT00761358|Experimental|Z-338|
3261077|NCT00761358|Placebo Comparator|placebo|
3261078|NCT00761345|Experimental|radiotherapy and chemotherapy|gemcitabine will be administered at 1000mg/m2 IV on days 1 and 8 of each 21 day cycle. erlotinib at either 100mg (cohort 1-3) or 150mg (cohort 4) PO daily. Low dose fractionated radiotherapy (LDRT) will be given BID on days 1 and 2 and 8 and 9 of each 21 day cycle
3261079|NCT00761332||Teriparatide|Patients treated with teriparatide
3261080|NCT00761332||Antiresorptive|Patients treated with antiresorptive therapy
3261081|NCT00761319|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily for 90 days
3261082|NCT00761319|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily for 90 days
3261083|NCT00761306|Experimental|Vortioxetine|
3261084|NCT00761280|Experimental|trabedersen 10 µM|10 µM trabedersen (AP 12009), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
3261085|NCT00761280|Active Comparator|Chemotherapy|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle, up to 26 cycles; carmustine: i.v. administration, up to 200 mg/sqm/day, 1 day per cycle, up to 8 cycles; lomustine: capsules, 110 mg/sqm/day, 1 day per cycle, up to 8 cycles. Only 1 of these 3 drugs/interventions is administered per patient in the comparator arm.
3261086|NCT00761267|Experimental|Anidulafungin IV|All subjects meeting screening criteria will receive IV anidulafungin.
3261087|NCT00761228|Active Comparator|Apomorphine|Patients will receive an ascending dosing schedule to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
3261088|NCT00761228|Placebo Comparator|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
3261089|NCT00761215|Experimental|TR-701 200 mg|
3261090|NCT00761215|Experimental|TR-701 300 mg|
3261091|NCT00761215|Experimental|TR-701 400 mg|
3261092|NCT00761202|Active Comparator|1|Optive Eyedrops
3261093|NCT00761202|Active Comparator|2|Hylocomod Eyedrops
3261094|NCT00761189|Experimental|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
3261095|NCT00761176|No Intervention|Standard of Care|Standard of Care will be utilized without the device.
3261096|NCT00761176|Other|The Provant Therapy System|Thirty minutes, twice daily treatment
3261097|NCT00761163|Experimental|1|
3261098|NCT00761163|Experimental|2|
3261099|NCT00761163|Experimental|3|
3261100|NCT00761150|Experimental|Open-label ABT-712|2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks (open-label period).
3261101|NCT00761150|Experimental|Double-blind ABT-712|2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period).
3261102|NCT00761150|Placebo Comparator|Double-blind Placebo|2 placebo tablets, twice daily, for 4 weeks (double-blind period).
3261103|NCT00761137|Experimental|Tropicamide placebo|subject received (blinded) each of the 4 drug doses at different visits - 0 mg tropicamide, 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide
3261104|NCT00761137|Experimental|Tropicamide 0.3 mg|subject received (blinded) each of the 4 drug doses at different visits - 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide, 0 mg tropicamide
3261105|NCT00761137|Experimental|Tropicamide 1 mg|subject received (blinded) each of the 4 drug doses at different visits - 1 mg tropicamide, 3 mg tropicamide, 0 mg tropicamide, 0.3 mg tropicamide
3261106|NCT00761137|Experimental|Tropicamide 3 mg|subject received (blinded) each of the 4 drug doses at different visits - 3 mg tropicamide, 0 mg tropicamide, 0.3 mg tropicamide, 1 mg tropicamide
3261107|NCT00761124|Experimental|1|Educational small group session regarding prostate cancer
3261108|NCT00761124|Other|2|Printed material regarding general prostate cancer information provided.
3261109|NCT00761098|Active Comparator|1|Standard Care (albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
3261324|NCT00759759|Other|1|Treatment A (test product) followed by Treatment B (reference product)
3261110|NCT00761098|Experimental|2|Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
3261111|NCT00761085|Active Comparator|Methadone|Methadone comparison to standard of care for pain management
3261112|NCT00761085|Active Comparator|Morphine|Mophine standard of Care pain management
3261113|NCT00761072||1|The source of data will be from spinal surgery procedures performed at CHOP from 4/1/07 to 3/31/08 using a TIVA anesthetic technique of propofol/remifentanil infusions
3261114|NCT00761059|Active Comparator|Glucose 20%|
3261115|NCT00761059|Placebo Comparator|placebo|
3261116|NCT00761033|Experimental|music|children will listen to music during procedure
3261117|NCT00761033|Other|Standard care|Standard care
3261118|NCT00761020|No Intervention|Mefloquine|Mefloquine 250 mg orally daily x 3 days beginning 2 days prior to challenge and then weekly for 4 weeks post challenge (n=19 to 25)
3261119|NCT00761020|No Intervention|Control|Sporozoite infectivity control; no prophylaxis (n=6). Infectivity controls will undergo primary sporozoite challenge in parallel with Cohort 1. Up to 9 individuals will be recruited (6, plus up to 3 alternates) to ensure that the goal of 6 enrollments is achieved.
3261120|NCT00761007|Experimental|Ibodutant 10 mg|
3261121|NCT00761007|Experimental|Ibodutant 30 mg|
3261122|NCT00761007|Experimental|Ibodutant 60 mg|
3261123|NCT00761007|Placebo Comparator|Placebo|
3261124|NCT00760994|Experimental|1|Experiential acceptance
3261125|NCT00760994|Active Comparator|2|Cognitive restructuring
3261126|NCT00760994|Placebo Comparator|3|No-intervention control: Nutrition information
3261127|NCT00760968|Experimental|TAK-783 100 mg QD + Methotrexate|
3261128|NCT00760968|Active Comparator|Methotrexate|
3261129|NCT00760955|Experimental|TAK-583 5 mg QD|
3261130|NCT00760955|Experimental|TAK-583 50 mg QD|
3261131|NCT00760955|Experimental|TAK-583 100 mg QD|
3261132|NCT00760955|Placebo Comparator|Placebo QD|
3261133|NCT00760942|Active Comparator|1|Liquid human milk fortifier
3261134|NCT00760942|Active Comparator|2|Powdered human milk fortifier
3261135|NCT00760929|Placebo Comparator|Placebo for R1507 (16mg/kg iv)|
3261136|NCT00760929|Placebo Comparator|Placebo for R1507 (9mg/kg iv)|
3261137|NCT00760929|Experimental|R1507 (16mg/kg iv)|
3261138|NCT00760929|Experimental|R1507 (9mg/kg iv)|
3261139|NCT00760916|Placebo Comparator|Placebo|placebo
3261140|NCT00760916|Active Comparator|UT-15C 0.25 mg|UT-15C 0.25 mg
3261141|NCT00760916|Active Comparator|UT-15C 1 mg|UT-15C 1 mg
3261142|NCT00760916|Active Comparator|UT-15C 5 mg|UT-15C 5 mg
3261143|NCT00760903||> 18 years moderate head trauma|Group I: (Pilot group): 5-10 patients > 18 years old, gender and race indifferent with moderate head trauma.
3261144|NCT00760903||> 18, gender and race indifferent|Group II: 30 patients > 18 years old, gender, and race indifferent with moderate head trauma
3261145|NCT00760903||Pediatric|Group III: 30 patients < 18 years old, gender and race indifferent with moderate head trauma (pediatric patient group)
3261146|NCT00760903||Pre-evaluated|Group IV: 10-20 patients age, gender and race indifferent with moderate head trauma that have been examined with conventional MRI of the brain, MRS and DTI as clinically requested. The images of these patients will be evaluated retrospectively for data- point collection.
3261147|NCT00760903||Control Group|Group V (control group): 20 volunteers without prior history of traumatic brain injury or neurological problems.
3261148|NCT00760890|Experimental|A|Medicinal Iron
3261149|NCT00760890|Experimental|B|Iron fortified wet pack cereal
3261150|NCT00760890|No Intervention|C|Control
3261151|NCT00760877|Experimental|Nilotinib|Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.
3261152|NCT00760877|Active Comparator|Imatinib|Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.
3261153|NCT00760864|Experimental|TAK-715 25 mg BID|
3261154|NCT00760864|Experimental|TAK-715 50 mg BID|
3261155|NCT00760864|Experimental|TAK-715 100 mg BID|
3261156|NCT00760864|Active Comparator|Methotrexate|
3261157|NCT00760851|Experimental|1|Bb-12 supplemented strawberry yogurt drink
3261158|NCT00760851|Placebo Comparator|2|Regular strawberry yogurt drink with no Bb-12 added
3261159|NCT00760838|Experimental|Azithromycin|"Azithromycin 250 mg~1x/day during 5 days 3x/week afterwards"
3261160|NCT00760838|Placebo Comparator|placebo|"Placebo~1x/day during 5 days 3x/week afterwards"
3261161|NCT00760825|Experimental|Vaccine|killed bivalent (O1 and O139)whole cell oral cholera vaccine(Shanchol™)
3261162|NCT00760812|Experimental|1|This group will first receive the Early Social Interaction Project parent-implemented intervention (PII) for 9 months, followed by the Early Social Interaction Project information, education, and support (IES) intervention for 9 months.
3261163|NCT00760812|Experimental|2|The group will first receive IES for 9 months, followed by PII for 9 months.
3261164|NCT00760799|Active Comparator|1|Standard discectomy without anular repair
3261165|NCT00760799|Experimental|2|Standard Discectomy with anular repair
3261166|NCT00760786|Active Comparator|1|Intensive lipid lowering plus Omega3-fatty acid
3261167|NCT00760786|Active Comparator|2|Moderate lipid lowering plus Omega3-fatty acid
3261168|NCT00760786|Active Comparator|3|Intensive lipid lowering plus placebo
3261169|NCT00760786|Active Comparator|4|Moderate lipid lowering plus placebo
3261170|NCT00760773|Experimental|1|
3261171|NCT00760773|Experimental|2|
3261172|NCT00760773|Placebo Comparator|3|
3261173|NCT00760760|Experimental|n-3 PUFA|
3261174|NCT00760760|Placebo Comparator|Control|
3261175|NCT00760747|Experimental|Slow Switching Group|Slow Switching Group (switch from full stimulant dose to atomoxetine, 1.2 mg/kg/day, orally (PO), during 10 weeks then continue treatment up to 1.8 mg/kg/day, PO to 14 weeks
3261176|NCT00760747|Experimental|Fast Switching Group|Fast Switching Group (switch from full stimulant dose to atomoxetine 1.2 mg/kg/day, PO, during 2 weeks then continue treatment up to 1.8 mg/kg/day, PO to 14 weeks
3261177|NCT00760734|Experimental|Hyperbaric oxygen therapy-TBI/PCS|Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT
3261178|NCT00760734|Experimental|Hyperbaric Oxygen Therapy-PCS/PTSD|Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT
3261179|NCT00760721|Experimental|1|Educational small group session with HBV screening resources provided
3261180|NCT00760721|Sham Comparator|2|Educational small group discussion, diet/physical activity resources provided
3261181|NCT00760708||undergoing persantine stress test|
3261182|NCT00760695|Active Comparator|A|the patients in this arm are receiving 2,5 mg dronabinol twice daily
3261183|NCT00760695|Placebo Comparator|B|the patients in this arm are receiving 2,5 mg placebo twice daily
3261184|NCT00760682|Experimental|1|30 preoperative HBO sessions, sequestrectomy and 10 postoperative HBO sessions. The duration of each session is 90 minutes. 100 % oxygen is inhaled during decompression to 2.4 ATA.
3261185|NCT00760682|No Intervention|2|Sequestrectomy without HBO treatment
3261186|NCT00760669||Participants Receiving Infiximab|Participants with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PA) receiving infliximab injection will be observed.
3261187|NCT00760656||Research Participants|Participants with a diagnosis of childhood malignancy treated or followed at SJCRH
3261188|NCT00760656||Control Participants|Siblings, parents, relatives or friends of St. Jude patients or former patients or SJCRH employees who are not SJLIFE study team members or supervised by a SJLIFE study team members
3261189|NCT00760630|Experimental|CDP LFC|all patients will have this calculation based upon diagnostic parameters with IVUS and FFR and/or CFR
3261190|NCT00760617|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A
3261191|NCT00760617|Active Comparator|Fluarix elderly Group|Subjects aged ≥65 years received 1 dose of Fluarix vaccine
3261192|NCT00760617|Active Comparator|Fluarix young Group|Subjects aged 18-40 years received 1 dose of Fluarix vaccine
3261193|NCT00760604|Active Comparator|A|En bloc esophagectomy is performed through a transthoracic approach by removing the tumor-bearing esophagus, the pericardium anteriorly, both pleural surfaces laterally, as well as the thoracic duct and all other lymphoareolar tissue wedged posteriorly between the esophagus and the spine, and en-bloc resection of all nodal groups in the middle and lower mediastinum as well as the upper abdomen.
3261194|NCT00760604|Active Comparator|B|Transhiatal esophagectomy is performed through an abdominal incision and a neck incision. The stomach is mobilized, and the left gastric vessels are transected at its origin. Celiac lymph nodes are dissected, and the intrathoracic esophagus is dissected bluntly through the hiatus and through the neck. The cervical esophagus is divided at the level of the neck. After the esophagogastrectomy is performed, a gastric tube is created. An esophagogastrostomy is then performed in the neck. If a transthoracic approach is used, dissection will be as described for the transhiatal approach.
3261195|NCT00760578|Placebo Comparator|Placebo|Microcrystaline cellulose once daily
3261196|NCT00760578|Active Comparator|Pioglitazone|Pioglitazone 45 mg once daily
3261197|NCT00760578|Experimental|MSDC-0160 90 mg|MSDC-0160 90 mg once daily
3261198|NCT00760578|Experimental|MSDC-0160 220 mg|MSDC-0160 220 mg once daily
3261199|NCT00760565|Experimental|1|
3261200|NCT00760565|Placebo Comparator|10|
3261201|NCT00760565|Experimental|11|
3261202|NCT00760565|Placebo Comparator|12|
3261203|NCT00760565|Placebo Comparator|2|
3261204|NCT00760565|Experimental|3|
3261205|NCT00760565|Placebo Comparator|4|
3261206|NCT00760565|Experimental|5|
3261207|NCT00760565|Placebo Comparator|6|
3261208|NCT00760565|Experimental|7|
3261209|NCT00760565|Placebo Comparator|8|
3261210|NCT00760565|Experimental|9|
3261211|NCT00760552|Active Comparator|Arm 1|VA patients with uncontrolled HTN.
3261212|NCT00760552|Active Comparator|Arm 2|VA patients with uncontrolled HTN.
3261213|NCT00760539|Experimental|Travoprost/Timolol BAC-free|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
3261214|NCT00760539|Active Comparator|Travoprost/Timolol|Travoprost 0.004%/Timolol 0.5% ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
3261215|NCT00760526|Active Comparator|1|continuous glucose monitoring
3261216|NCT00760526|Active Comparator|2|Standard glucose monitoring with a home glucose meter
3261217|NCT00760513|Active Comparator|Omega 3 fatty acid (fish oil)|OMACOR (alternative name: Lovaza) 4 grammes daily, oral capsule
3261218|NCT00760513|Placebo Comparator|dummy pill|4 grammes daily, oral capsule (olive oil)
3261219|NCT00760500||1|
3261220|NCT00760487|Experimental|AcrySof Toric IOL|AcrySof Toric Intraocular Lens (IOL)
3261221|NCT00760474|Experimental|Pregabalin, then placebo|
3261222|NCT00760474|Experimental|Placebo, then pregabalin|
3261223|NCT00760461|Other|Domperidone|
3261224|NCT00760435|Experimental|1|Infliximab plus Intravenous immunoglobulin (IVIG)
3261225|NCT00760435|Placebo Comparator|2|Placebo plus IVIG
3261226|NCT00760422||With fever|
3261227|NCT00760422||Without fever|
3261228|NCT00760409||Radiation Injury|Radiation Injury Recurrent symptoms after radiation therapy of a brain tumor are not always the result of tumor recurrence but may represent radiation necrosis of the brain.
3261229|NCT00760409||Tumor Recurrence|Symptoms are the result of actual tumor recurrence
3261230|NCT00760396|Experimental|Group 1|40mg QD dose group
3261231|NCT00760396|Experimental|Group 2|100mg QD dose group
3261232|NCT00760396|Experimental|Group 3|200mg QD dose group
3261233|NCT00760396|Experimental|Group 4|200mg BID dose group
3261234|NCT00760383|Experimental|EAA+PT|20 g EAA daily for 7 days prior to TKA surgery and for 14 days after surgery.
3261235|NCT00760383|Placebo Comparator|ALA+PT|20 g NEAA daily for 7 days prior to TKA surgery and for 14 days after surgery.
3261376|NCT00759369|Experimental|1|Water prescription
3261236|NCT00760357||Retrospective Anaylsis|Once the patients are identified that have a full thickness wound on a limb clearly identified as having critical limb ischemia, these patients will be evaluated
3261237|NCT00760344|Experimental|SYR-472 3.125 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
3261238|NCT00760344|Experimental|SYR-472 12.5 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
3261239|NCT00760344|Experimental|SYR-472 50 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
3261240|NCT00760344|Experimental|SYR-472 100 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
3261241|NCT00760344|Placebo Comparator|Placebo QD|(with lifestyle modification and/or metformin stable dose therapy)
3261242|NCT00760344|Active Comparator|Sitagliptin 100 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
3261243|NCT00760305|Experimental|1|Patients who received the Pro-Self psychoeducational intervention
3261244|NCT00760305|No Intervention|2|Patients who received standard care
3261245|NCT00760292||1|Type 2 Diabetic Patients
3261246|NCT00760292||2|Non-diabetic individuals
3261247|NCT00760266|Experimental|Aliskiren/HCTZ 300/25 mg|
3261248|NCT00760266|Active Comparator|HCTZ 25 mg|
3261249|NCT00760253||1|pure propofol by TCI pump with titration.
3261250|NCT00760253||2|10ug/kg alfentanyl bolus and propofol TCI pump infusion with titration
3261251|NCT00760253||3|20ug/kg alfentanyl bolus and propofol TCI pump infusion with titration
3261252|NCT00760240||Glaucoma patients|This is a group of patients with restricted visual fields or ETDRS visual acuity of 20/60 or worse
3261253|NCT00760240||Retina patients|A group of patients with retinal pathology(ARMD, CME, diabetic retinopathy) contributing to their decreased vision.
3261254|NCT00760227|Other|1: HPI-C|Child Intervention Only Group
3261255|NCT00760227|Other|2: HPI-CP|Parent and Child Intervention Group
3261256|NCT00760227|No Intervention|3: SC|Standard Care Control Group- No Intervention
3261257|NCT00760214|Experimental|Azilsartan Medoxomil 40 mg QD|
3261258|NCT00760214|Experimental|Azilsartan Medoxomil 80 mg QD|
3261259|NCT00760214|Active Comparator|Ramipril 10 mg QD|
3261260|NCT00760201||1|Hospital executives, physician administrators and hospital legal counsel
3261261|NCT00760175|Active Comparator|intradermal|
3261262|NCT00760175|Active Comparator|intramuscular|
3261263|NCT00760162||HSCB, Brooklyn, NY|State University of New York Brooklyn, NY 11203
3261264|NCT00760162||2. Nephrology Associates,|Scarborough, ON CANADA, LI H IC5
3261265|NCT00760162||3.New York Harbor VA Medical Center|NYU School of Medicine New York, NY.10010
3261266|NCT00760162||4.Hospital Juarez De Mexico|Madero, Mexico, D.FC.P. 07760
3261267|NCT00760162||5. Hospital Italiano de Buenos Aires|Buenos Aires, Argentina.
3261268|NCT00760162||6. National Hospital|Abuja, Nigeria
3261269|NCT00760149|Placebo Comparator|1|50 patients, treated with the standard anti-TB regimen, including rifampicin (600 mg), isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 2 placebo tablets resembling rifampicin 300 mg.
3261270|NCT00760149|Active Comparator|2|50 patients, treated with rifampicin (900 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 1 placebo tablet resembling rifampicin 300 mg.
3261271|NCT00760149|Active Comparator|3|50 patients, treated with rifampicin (1200 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment.
3261272|NCT00760123|Experimental|1|Early Physical Therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors, etc.
3261273|NCT00760123|Other|2|Educational Strategy: instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors, etc.
3261274|NCT00760110||1 Morning hypertension and normotension|Based on HBP, subjects were divided into MH and MN patients
3261275|NCT00760110||2 Clinic hypertension and normotension|Based on CBP, subjects were divided into CH and CN patients
3261276|NCT00760097|Experimental|AtCDS|Transcranial direct stimulation
3261277|NCT00760084|Experimental|A|Decitabine will be administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks.
3261278|NCT00760071||1CF-patients<6|Patients with diagnoses of cystic fibrosis from birth to the age of 6 years
3261279|NCT00760071||2 controls|age matched controls
3261280|NCT00760058|Experimental|1|AcrySof® IQ intraocular lens
3261281|NCT00760058|Active Comparator|2|Tecnis® Aspheric intraocular lens
3261282|NCT00760058|Active Comparator|3|Akreos® MI60 intraocular lens
3261283|NCT00760045|Experimental|1|AL-43546 0.15%
3261284|NCT00760045|Experimental|2|AL-43546 0.25%
3261285|NCT00760045|Active Comparator|3|AL-43546 0%(Vehicle)
3261286|NCT00760045|Active Comparator|4|0.1% sodium hyaluronate ophthalmic solutio
3261287|NCT00760032|Experimental|Active|Ciprofloxacin
3261288|NCT00760032|Placebo Comparator|Placebo|Placebo
3261289|NCT00760019|Active Comparator|Salsalate first, then Placebo|In this crossover study, this group was randomly allocated therapy with salsalate first, a 4 week washout, then 4 weeks of placebo therapy in a double-blinded fashion.
3261290|NCT00760019|Placebo Comparator|Placebo first, then Salsalate|In this crossover study, this group was randomly allocated therapy with placebo first, a 4 week washout, then 4 weeks of salsalate therapy in a double-blinded fashion.
3261325|NCT00759759|Other|2|Treatment B (reference product) followed by Treatment A (test product)
3261375|NCT00759382||I|Patients with non-small cell lung carcinoma treated with curative intent
3261291|NCT00760006|Active Comparator|Unasyn Antibiotic Arm|Unasyn® is a parenteral antibiotic that combines ampicillin with sulbactam, a beta-lactamase inhibitor. All subjects enrolled in the study will receive a single dose of antibiotic or saline solution (placebo control) intravenously, as the IV will already be in place as standard of care for surgery. The study aims to assess the efficacy of the prophylactic antibiotic in cleft surgery to: decrease the incidence of surgical site infections, speed the progression of postoperative healing, improve the final quality of wound healing achieved, and decrease the rate of palatal fistula formation.
3261292|NCT00760006|Placebo Comparator|Saline Placebo Arm|Saline Placebo. All subjects enrolled in the study will receive a single dose of antibiotic or saline solution (placebo control) intravenously, as the IV will already be in place as standard of care for surgery. This will act as the placebo control.
3261293|NCT00759993|Experimental|A,1|chromium piccolinate 1000mg
3261294|NCT00759993|Placebo Comparator|A,2|matching placebo
3261295|NCT00759980||Platelet Number|Infants randomized to this group will be transfused based on a specific set of transfusion guidelines pertaining to the total number of platelets
3261296|NCT00759980||Platelet Mass|Infants randomized to this group will be transfused based on a specific set of transfusion guidelines pertaining to a combination of platelet number and platelet size (mass)
3261297|NCT00759967|Active Comparator|Short daily hemodialysis|After a 3 month run-in period patients who are randomized to this arm will receive 3 months of short daily hemodialysis(2 hours/day,6 days/week)B/P will be monitored according to the Canadian hypertension guidelines both pre and post each dialysis session. Antihypertensive medication will be adjusted accordingly to maintain BP within the guidelines.At the end of this 3 month period extracellular fluid volume (bioimpedance) will be measured using bioimpedance as well as sympathetic nerve activity using microneurography. Additionally Catecholamines as well as markers of oxidative stress will be collected.
3261298|NCT00759967|Active Comparator|Conventional hemodialysis|After a 3 month run-in period patients who are randomized to this arm will receive 3 months of conventional hemodialysis 3 days/week 3.5-4 hours/ treatment. BP will be monitored according to the Canadian hypertension guidelines both pre and post each dialysis session. Antihypertensive medication will be adjusted accordingly to maintain BP within the guidelines.At the end of this 3 moth period extracellular fluid volume (bioimpedance) will be measured using bioimpedance as well as sympathetic nerve activity using microneurography. Additionally Catecholamines as well as markers of oxidative stress will be collected.
3261299|NCT00759954|Other|1|Treatment A (test product) followed by Treatment B (reference product)
3261300|NCT00759954|Other|2|Treatment B (reference product) followed by Treatment A (test product)
3261301|NCT00759941|Experimental|Xalatan + Azopt|Xalatan dosed once a day at 10 pm, with Azopt dosed three times a day at 8 AM, 2 PM, and 10:05 PM as an adjunctive therapy for 3 months.
3261302|NCT00759941|Active Comparator|Xalatan + Placebo|Xalatan dosed once a day at 10 pm, with placebo dosed three times a day at 8 AM, 2 PM, and 10:05 PM concomitantly for 3 months.
3261303|NCT00759928|Experimental|Erlotinib/Sorafenib|Patients will receive erlotinib 150 mg once daily by mouth and sorafenib 400 mg twice daily by mouth. The study will begin with a 2-week run-in period (which will begin on Day 14 of the study, and continue through Day 1 of the study), in which erlotinib will be dosed alone at 150 mg once daily. Patients will continue taking erlotinib as a single agent at 150 mg once daily through Day 1. After the 2-week run-in period, patients will receive continuous dosing of both agents (erlotinib 150 mg once daily and sorafenib 400 mg twice daily) in cycles of 28 days each. Toxicity will be assessed every cycle (every 4 weeks) for all patients. Because this is not an efficacy study, restaging tumor measurements will be at the discretion of the physician every 8 weeks during treatment. Patients with objective response or stable disease will continue therapy; patients with disease progression or unacceptable toxicity will be discontinued from the study.
3261304|NCT00759915|Other|1|Treatment A (test product) followed by Treatment B (reference product)
3261305|NCT00759915|Other|2|Treatment B (reference product) followed by Treatment A (test product)
3261306|NCT00759902|Other|1|Treatment A (test product) followed by Treatment B (reference product)
3261307|NCT00759902|Other|2|Treatment B (reference product) followed by Treatment A (test product)
3261308|NCT00759889||wound biopsy|diabetic foot,venous leg ulcer, decubitus ulcer
3261309|NCT00759876|Experimental|ataluren (ptc124)|Atalaluren (PTC124) 20-,20-,and 40-mg/kg TID PO for 96 weeks.
3261310|NCT00759863|Experimental|Lifezig|Subjects watch personalized reminiscence video channels developed by program staff with the help of family members/caregivers (using the LifeZig system)
3261311|NCT00759863|No Intervention|Usual Care|Subjects follow routine activities applied by nurses or caregivers, such as traditional reminiscence, crafts, singing, recreational activities, and other activities.
3261312|NCT00759850|Active Comparator|A|Patient with ST elevation myocardial infarction randomly assigned to receive a Bare Metal Stent n=90)
3261313|NCT00759850|Experimental|B|Patient with ST elevation myocardial infarction randomly assigned to receive a Paclitaxel Eluting Stent (n=90)
3261314|NCT00759850|Experimental|C|Patient with ST elevation myocardial infarction randomly assigned to receive a Sirolimus Eluting Stent (n=90)
3261315|NCT00759837|Experimental|1|
3261316|NCT00759824|Experimental|1|Chemotherapy regimen (adriamycin, cyclophosphamide, vindesine) plus valproic acid
3261317|NCT00759811|Experimental|Methotrexate|Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.
3261318|NCT00759811|Placebo Comparator|Placebo|Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.
3261319|NCT00759798|Experimental|Fludarabine, Cyclophosphamide, Rituximab|"Fludarabine 25 mg/m^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond. Cyclophosphamide 250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond. Rituximab 375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
3261320|NCT00759785|Experimental|ER-positive Luminal B|Single dose of dalotuzumab 20 mg/kg infused intravenously over 60-120 minutes.
3261321|NCT00759785|Experimental|Triple Negative|Single dose of dalotuzumab 20 mg/kg infused intravenously over 60-120 minutes.
3261322|NCT00759772|Active Comparator|Teriparatide|
3261323|NCT00759772|Placebo Comparator|Placebo|
3261326|NCT00759746|Active Comparator|Weight Maintenance Education|Participants assigned to this group will receive the Weight Maintenance Education intervention. They will meet every other week during the maintenance phase of the study for a total of 16 sessions over 8 months. During the visit, participants will participate in a series of interactive workshops within child and parent groups to learn general information about healthy eating and physical activity.
3261327|NCT00759746|Experimental|SFM+ Low Dose|Participants assigned to this group will receive the SFM+ Low Dose.
3261328|NCT00759746|Experimental|SFM+ High Dose|Participants assigned to this group will receive the SFM+ High Dose.
3261329|NCT00759733||1|Pregnant women with a history of cardiac disease (study group)
3261330|NCT00759733||2|Pregnant women with no history of heart disease (control group)
3261331|NCT00759720|Experimental|TAK-559 16 mg QD + Glyburide QD|
3261332|NCT00759720|Experimental|TAK-559 32 mg QD + Glyburide QD|
3261333|NCT00759720|Active Comparator|Glyburide QD|
3261334|NCT00759707|Experimental|1|ultrasound imaging of saphenous vein bypass graft following an ischemic stimulus, administration of sublingual nitroglycerin and intravenous administration of L-NMMA.
3261335|NCT00759681|Active Comparator|Control|Gelfoam and Thrombin
3261336|NCT00759681|Experimental|Investigational Device|ArterX Surgical Sealant
3261337|NCT00759668|Experimental|SN60D3|AcrySof Natural ReSTOR Intraocular Lens (IOL) Model SN60D3
3261338|NCT00759668|Active Comparator|SN60AT|AcrySof Natural Monofocal Intraocular Lens (IOL) Model SN60AT
3261339|NCT00759655|Other|open label|
3261340|NCT00759642|Experimental|Lapatinib|lapatinib
3261341|NCT00759629|Experimental|A|Interventional treatment group - Patients assigned to PCI will receive the loading dose of clopidogrel, aspirin plus a bolus of heparin and be transferred immediately for interventional treatment. They will receive abciximab as a bolus followed by a continuous infusion of for 12 hours.
3261342|NCT00759629|Active Comparator|B|Conservative treatment group - Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards.
3261343|NCT00759616|Experimental|1|
3261344|NCT00759603|Experimental|Lenalidomide + Rituximab|Oral Lenalidomide 10 mg/day started on Day 9 of cycle 1; Rituximab 375 mg/m^2 intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2. Treatment duration twelve cycles.
3261345|NCT00759590||1|ALI/ARDS patients
3261346|NCT00759577|Other|Home titration|Patients were given drug to self titrate
3261347|NCT00759564|Experimental|IV CP-70,429 and cross over to PF-03709270|
3261348|NCT00759551|Experimental|Azilsartan 2.5 mg QD|
3261349|NCT00759551|Experimental|Azilsartan 5 mg QD|
3261350|NCT00759551|Experimental|Azilsartan 10 mg QD|
3261351|NCT00759551|Experimental|Azilsartan 20 mg QD|
3261352|NCT00759551|Experimental|Azilsartan 40 mg QD|
3261353|NCT00759551|Placebo Comparator|Placebo QD|
3261354|NCT00759551|Active Comparator|Olmesartan 20 mg QD|
3261355|NCT00759538||1|lung transplant patients performing a three week lasting rehabilitation program
3261356|NCT00759525|Active Comparator|1|Glycyrrhetic Acid
3261357|NCT00759525|Placebo Comparator|2|Placebo
3261358|NCT00759512|Active Comparator|Arm 1|This arm received the Kreiger/Kunz method of Therapeutic Touch in addition to Standard of Care
3261359|NCT00759512|No Intervention|Arm 2|Standard of Care
3261360|NCT00759499||Debridement|The intent of this protocol is to salvage wound material that is normally destined for destruction, so it can be used in wound-related scientific studies. This clinical wound material can be studied in order to better understand the molecular, cellular, or ecological components of the wound system. These studies may be able to provide important insights into the keys of wound healing, wound persistence, or wound deterioration.
3261361|NCT00759473|Placebo Comparator|Placebo/Placebo/Placebo/Placebo|Participants were assigned to receive placebo for each of 3 cue exposure sessions and at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
3261362|NCT00759473|Experimental|DCS/DCS/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) for each of 3 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
3261363|NCT00759473|Other|DCS/Placebo/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) at the first and third cue exposure sessions and a placebo at the second cue exposure and the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
3261364|NCT00759473|Experimental|DCS/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) for each of 2 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities. Cue exposure sessions were accompanied by instructions on coping with craving.
3261365|NCT00759473|Active Comparator|Placebo/Placebo/Placebo|Participants were assigned to placebo for each of 2 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities. Cue exposure sessions were accompanied by instructions on coping with craving.
3261366|NCT00759460|Experimental|1|
3261367|NCT00759460|Active Comparator|2|
3261368|NCT00759434|Active Comparator|Surgery|
3261369|NCT00759434|Experimental|EVLT|
3261370|NCT00759421|Experimental|1|
3261371|NCT00759421|Active Comparator|2|
3261372|NCT00759408|Experimental|1|BQ-123
3261373|NCT00759395|Experimental|AZD2327|AZD2327 3mg BID
3261374|NCT00759395|Placebo Comparator|Placebo|Placebo BID
3261377|NCT00759356|Other|1|Treatment A (test product) followed by Treatment B (reference product)
3261378|NCT00759356|Other|2|Treatment B (reference product) followed by Treatment A (test product)
3261379|NCT00759343||Control Group|"The control subjects of this study will be asked to undergo renal ultrasound examination, if available, or will be asked to complete a disease history form to determine the presence or lack of a kidney stone. Urine and serum will then be taken for storage until further analysis.~Controls will be asked to undergo a screening renal ultrasound to ensure they are stone free, this will take approximately 45 minutes. If the controls are asked to complete the history form, this will not take more than 20 minutes. They will also give a blood and urine sample during this time to bring the total extra time up to at most 60 minutes for controls."
3261380|NCT00759343||Stone Group|"The stone group will undergo standard diagnostic procedures for their condition and recovery process. Serum and urine for storage and analysis will be taken prior to stone treatment and 6 weeks following stone treatment. This will allow for the determination of differences in a stone patient's protein profile while they have their stone and after they are stone free. All patients will be required to have a stone patient metabolic evaluation which includes serum and urine testing. The analysis will focus on the serum and urine sample that they provide.~The stone patient will be asked to undergo one extra tube of blood during their preoperative assessment which should only add a few seconds to their visit."
3261381|NCT00759330|Placebo Comparator|Placebo Tape (Arm 1)|Placebo tape remained on for 12 hours of continuous treatment per day.
3261382|NCT00759330|Experimental|Flurbiprofen Tape (Arm 2)|Flurbiprofen tape remained on for 12 hours of continuous treatment per day.
3261383|NCT00759330|Placebo Comparator|Placebo Tape (Arm 3)|Placebo tape remained on for 24 hours of continuous treatment per day.
3261384|NCT00759330|Experimental|Flurbiprofen Tape (Arm 4)|Flurbiprofen tape remained on for 24 hours of continuous treatment per day.
3261385|NCT00759317|Active Comparator|1|venlafaxine
3261386|NCT00759317|Placebo Comparator|2|
3261387|NCT00759304||PROOF cohort|Healthy inhabitants of the city of Saint-Etienne, France, and aged 65 years at the inclusion date.
3261388|NCT00759291|Active Comparator|Acipimox|Acipimox treatment QID for 7 days
3261389|NCT00759291|Placebo Comparator|Placebo|Placebo treatment QID for 7 days
3261390|NCT00759278||1|Group of 30 women who are pregnant as subjects that take antihypertensive medication
3261391|NCT00759278||2|Group of 30 women who are pregnant and do not take antihypertensive medications as a control group
3261392|NCT00759265|Experimental|resistance training|"During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).~During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home."
3261393|NCT00759265|No Intervention|control|No intervention was prescribed
3261394|NCT00759239|Experimental|1|One drop of Travoprost 0.004% / Timolol maleate 0.5% in each eye at 9 am and 1 drop of Timolol vehicle as placebo in each eye at 9 pm for 12 weeks.
3261395|NCT00759239|Experimental|2|One drop of Timolol vehicle as placebo in each eye at 9 am and one drop of Travoprost 0.004% / Timolol maleate 0.5% in each eye at 9 pm for 12 weeks.
3261396|NCT00759213||1|Any infant with a length of stay in the NICU of at least 7 days.
3261397|NCT00759200|Experimental|alb-interferon arm 1|
3261398|NCT00759200|Experimental|alb-interferon arm 2|
3261399|NCT00759200|Experimental|alb-interferon arm 3|
3261400|NCT00759200|Experimental|alb-interferon arm 4|
3261401|NCT00759200|Active Comparator|peg-interferon|
3261402|NCT00759187|Placebo Comparator|A|
3261403|NCT00759187|Active Comparator|B|
3261404|NCT00759187|Active Comparator|C|
3261405|NCT00759174||Case Group|
3261406|NCT00759161|Active Comparator|1|AN2728 Ointment, 5%
3261407|NCT00759161|Placebo Comparator|2|AN2728 Ointment Vehicle
3261408|NCT00759148|Experimental|Moxifloxacin AF|Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%, 1 drop in each eye twice daily for 3 days
3261409|NCT00759148|Placebo Comparator|Vehicle|Moxifloxacin AF vehicle, 1 drop in each eye twice daily for 3 days
3261410|NCT00759135|Experimental|1|Single therapeutic dose of 2.5 mg NX-1207
3261411|NCT00759135|Experimental|2|Single low dose of 0.125 mg NX-1207 for dose-response evaluation
3261412|NCT00759135|Active Comparator|3|5.0 mg finasteride q.d.
3261413|NCT00759122|Active Comparator|1|VENLAFAXINE
3261414|NCT00759122|Placebo Comparator|2|
3261415|NCT00759109|Experimental|Arm A - PegIntron|Participants randomized to Arm A received peginterferon α-2b (PegIntron), 50 μg, weekly, subcutaneously (SC), for a period of 3 years.
3261416|NCT00759109|Other|Arm B - Control|Participants randomized to Arm B were under observation and received no treatment.
3261417|NCT00759096|Experimental|Acrysof ReSTOR IOL|AcrySof ReSTOR Intraocular lens (IOL) implanted
3261418|NCT00759083|Experimental|1|Patients with HIT/HITTS who require anticoagulation for PCI
3261419|NCT00759070|Active Comparator|1|Tenofovir (TDF) + emtricitabine (FTC) + efavirenz (EFV)
3261420|NCT00759070|Active Comparator|2|Tenofovir (TDF) + emtricitabine (FTC) + lopinavir/ritonavir (LPV/RTV)
3261421|NCT00759057|Experimental|1 - Investigational|Dynesys Non-Fusion Spinal System
3261422|NCT00759057|Active Comparator|2 - Control|Silhouette Posterior Pedicle Screw System as an adjunct to Posterior Lateral Fusion with Autograft.
3261423|NCT00759044||AMD|Patients diagnosed with AMD
3261424|NCT00759044||DME|Patients diagnosed with DME
3261425|NCT00759031|Placebo Comparator|A - Marketed fluoride toothpaste|
3261426|NCT00759031|Active Comparator|B -Triclosan/NaF/CoPolymer toothpaste|
3261427|NCT00759005|Experimental|A, 4|
3261428|NCT00758992||Immunodeficient mice|Please see the Study Description for complete information.
3261429|NCT00758966|Experimental|NF (Naltrexone+Fluoxetine)|Naltrexone SR 32 mg and fluoxetine 60 mg
3261430|NCT00758966|Active Comparator|Fluoxetine|Fluoxetine 60 mg
3261431|NCT00758966|Active Comparator|Naltrexone|Naltrexone SR 32 mg
3261432|NCT00758953|Experimental|1|
3261433|NCT00758953|Experimental|2|
3261434|NCT00758953|Placebo Comparator|3|
3261435|NCT00758953|Placebo Comparator|4|
3261436|NCT00758940|Experimental|1|Acrysof ReSTOR multifocal IOL
3261437|NCT00758927|Placebo Comparator|2|Placebo administration for 10 weeks with exercise and diet therapy
3261438|NCT00758927|Experimental|1|Omacor 4 gram per day with exercise and diet therapy for 10 weeks
3261439|NCT00758901||1 ROCC Knee prosthesis|Consecutive series of patients with ROCC Knee prosthesis.
3261440|NCT00758888|Experimental|Treatment|Place the blocks under the pelvis for 2 minutes
3261441|NCT00758888|Active Comparator|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
3261442|NCT00758888|Sham Comparator|Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
3261443|NCT00758862|Experimental|1|
3261444|NCT00758849|Placebo Comparator|1|
3261445|NCT00758849|Active Comparator|2|
3261446|NCT00758836|Placebo Comparator|Placebo|Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine
3261447|NCT00758836|Experimental|Telcagepant 280 mg +Ibuprofen 400 mg|Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine
3261448|NCT00758836|Experimental|Telcagepant 280 mg +APAP 1000 mg|Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine
3261449|NCT00758836|Placebo Comparator|Telcagepant 280 mg|Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine
3261450|NCT00758810||1|Patients without cardiac rehabilitation
3261451|NCT00758810||2|Patients with cardiac rehabilitation
3261452|NCT00758797|Experimental|1|DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
3261453|NCT00758784|Experimental|1|
3261454|NCT00758771||Cystic Fibrosis|People who have been diagnosed with cystic fibrosis
3261455|NCT00758771||Healthy|People who do not have cystic fibrosis and who do not have any other lung conditions
3261456|NCT00758758|Experimental|Experimental Arm 1|Hedrocel 1 level - No plate
3261457|NCT00758758|Experimental|Experimental Arm 2|Hedrocel 1 level with plate
3261458|NCT00758758|Experimental|Experimental Arm 3|Hedrocel 2 levels with plate
3261459|NCT00758758|Active Comparator|Control Arm 1|Autograft alone - Illiac crest
3261460|NCT00758758|Active Comparator|Control Arm 2|Autograft 1 level with plate
3261461|NCT00758758|Active Comparator|Control Arm 3|Allograft 1 level with plate
3261462|NCT00758758|Active Comparator|Control Arm 4|Autograft 2 levels with plate
3261463|NCT00758758|Active Comparator|Control Arm 5|Allograft 2 levels with plate
3261464|NCT00758745|Active Comparator|Model SN60WF|Implantation with the AcrySof Model SN60WF Intraocular Lens (IOL)
3261465|NCT00758745|Active Comparator|Model MA60AC|Implantation with the AcrySof Model MA60AC Intraocular Lens (IOL)
3261466|NCT00758732|Experimental|1|Docetaxel/carboplatin
3261467|NCT00758732|Experimental|2|Docetaxel/Caelyx
3261468|NCT00758706|Experimental|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
3261469|NCT00758706|Placebo Comparator|Placebo|Dosing to match AZD1236
3261470|NCT00758693|Experimental|1|Bendamustine + Rituximab
3261471|NCT00758680|Experimental|MK-1006 20 mg Once Daily (Panel A)|After a 2-week run-in/wash-off period, participants received single daily doses (q.d.) of 20 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the Clinical Research Unit (CRU).
3261472|NCT00758680|Experimental|MK-1006 40 mg Once Daily (Panel B)|After a 2-week run-in/wash-off period, participants received single daily doses of 40 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
3261473|NCT00758680|Experimental|MK-1006 80 mg Once Daily (Panel C)|After a 2-week run-in/wash-off period, participants received single daily doses of 80 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
3261474|NCT00758680|Experimental|MK-1006 120 mg Once Daily (Panel D)|After a 2-week run-in/wash-off period, participants received single daily doses of 120 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
3261475|NCT00758680|Experimental|MK-1006 20 mg Twice Daily (Panel E)|After a 2-week run-in/wash-off period, participants received twice-daily doses (b.i.d.) of 120 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
3261476|NCT00758680|Experimental|MK-1006 30 mg Twice Daily (Panel F)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 30 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
3261477|NCT00758680|Experimental|MK-1006 50 mg Twice Daily (Panel G)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 50 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
3261478|NCT00758680|Experimental|MK-1006 120 mg Once Daily Outpatient (Panel H)|After a 2-week run-in/wash-off period, participants received single daily doses of 120 mg MK-1006 over a 7-day multiple-dosing period while remaining domiciled in the CRU. Participants were then discharged from the CRU and continued daily dosing of MK-1006 for an additional 21 days as outpatients.
3261479|NCT00758680|Experimental|MK-1006 50 mg Twice Daily Outpatient (Panel I)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 50 mg MK-1006 over a 7-day multiple-dosing period while remaining domiciled in the CRU. Participants were then discharged from the CRU and continued daily dosing of MK-1006 for an additional 21 days as outpatients.
3261480|NCT00758680|Placebo Comparator|Placebo|After a 2-week run-in/wash-off period, participants received dose-matched placebo to MK-1006 over a multiple-dosing period while remaining domiciled in the CRU.
3261481|NCT00758667|No Intervention|Standard treatment|Standard treatment
3261482|NCT00758667|Experimental|Use of Mesna|Standard surgical procedure with Mesna
3261483|NCT00758654||1|Patients with suspected or known stable coronary artery disease
3261484|NCT00758654||2|Healthy subjects as a control group
3261485|NCT00758641|Experimental|L-PRP Injection|L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
3261486|NCT00758641|Active Comparator|Steroid Injection|Corticosteroid injections
3261487|NCT00758628|Active Comparator|1|Bromfenac
3261488|NCT00758628|Placebo Comparator|2|Blink
3261489|NCT00758615|Experimental|I|Walking School Bus Intervention
3261490|NCT00758615|No Intervention|C|Usual school procedures for student transportation to school
3261491|NCT00758602|Active Comparator|MMF, Standard Dose Tacrolimus|Participants received mycophenolate mofetil (MMF) 0.75 to (-) 1 gram (g), orally (PO), twice daily (BID) from Day 0 through Month 12. Participants also received tacrolimus 0.1-0.15 milligrams per kilogram (mg/kg), PO, BID to reach a target trough dose of 8-10 nanograms per milliliter (ng/mL) from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12. Participants also received corticosteroids per center practice.
3261492|NCT00758602|Experimental|MMF, Low Dose Tacrolimus|Participants received MMF 0.75-1 g, PO, BID from Day 0 through Month 12. Participants also received tacrolimus 0.1-0.15 mg/kg, PO, BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to 0.05-0.08 mg/kg, PO, BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12. Participants also received corticosteroids per center practice.
3261493|NCT00758589|Experimental|AZD1981 50 mg|AZD1981 50 mg Twice Daily (Bid)
3261494|NCT00758589|Placebo Comparator|Placebo|Placebo
3261495|NCT00758589|Experimental|AZD1981 400 mg|AZD1981 400 mg Twice Daily (Bid)
3261496|NCT00758589|Experimental|AZD1981 1000 mg|AZD1981 1000 mg Twice Daily (Bid)
3261497|NCT00758576|Experimental|SN6AD1|AcrySof ReSTOR Model SN6AD1 Intraocular Lens
3261498|NCT00758563|Placebo Comparator|A|
3261499|NCT00758563|Active Comparator|B|
3261500|NCT00758550|Experimental|AcrySof Toric IOL|AcrySof Toric Intraocular Lens (IOL)
3261501|NCT00758550|Active Comparator|AcrySof Natural IOL|AcrySof Natural Intraocular Lens (IOL)
3261502|NCT00758537||Patients with chronic kidney disease stage 3|
3261503|NCT00758537||patients with chronic kidney disease stage 4|
3261504|NCT00758537||patients with chronic kidney disease stage 5 (ESRD)|
3261505|NCT00758537||Controls (no kidney disease)|
3261506|NCT00758524|Placebo Comparator|Placebo|
3261507|NCT00758524|Active Comparator|Eplerenone|
3261508|NCT00758524|Experimental|LCI699 1|
3261509|NCT00758524|Experimental|LCI699 2|
3261510|NCT00758524|Experimental|LCI699 3|
3261511|NCT00758524|Experimental|LCI699 4|
3261512|NCT00758511|Active Comparator|1|Orally administrated 25%sucrose before,during and after heel stick across 5 heel sticks during the first 14 days of postnatal life
3261513|NCT00758511|Active Comparator|2|facilitated tucking before, during and after heel stick across 5 heel stick during the first 14 days of postnatal life
3261514|NCT00758511|Active Comparator|3|orally administrated 25% sucrose AND facilitated tucking before, during and after heel stick across 5 heel sticks during the first 14 days of postnatal life
3261515|NCT00758498|Experimental|1|armodafinil - dosage of 50 mg/day
3261516|NCT00758498|Experimental|2|armodafinil - dosage of 150 mg/day
3261517|NCT00758498|Placebo Comparator|3|matching placebo
3261518|NCT00758485|Experimental|sugammadex|Participants receiving 4.0 mg.kg-1 Sugammadex at a target depth of NMB of 1-2 PTC after the last dose of rocuronium
3261519|NCT00758485|Placebo Comparator|Placebo|Participants receiving Placebo (0.9% NaCl) at a target depth of NMB of 1-2 PTC after the last dose of rocuronium
3261520|NCT00758472||Hip Resurfacing|
3261521|NCT00758459|Experimental|1|
3261522|NCT00758459|Placebo Comparator|2|
3261523|NCT00758446|Experimental|A|BLX-028914 50 mg
3261524|NCT00758446|Experimental|B|BLX-028914 15 mg
3261525|NCT00758446|Placebo Comparator|C|Placebo
3261526|NCT00758433|Active Comparator|1|Civamide patch 0.0075%
3261527|NCT00758433|Active Comparator|2|Civamide patch 0.0150%
3261528|NCT00758433|Placebo Comparator|3|Placebo patch
3261529|NCT00758420|Active Comparator|1|Varisolve (polidocanol endovenous mircofoam)
3261530|NCT00758420|Placebo Comparator|2|Agitated saline
3261531|NCT00758407|Active Comparator|1|
3261532|NCT00758407|Placebo Comparator|2|
3261533|NCT00758394|Placebo Comparator|Fluoride - A|Fluoride only toothpaste
3261534|NCT00758394|Active Comparator|Total + Whitening toothpaste - B|Triclosan/fluoride toothpaste
3261535|NCT00758394|Experimental|Triclosan/fluoride/Amino Acid - C|toothpaste containing amino acid #1
3261536|NCT00758394|Experimental|Triclosan/fluoride/Cavistat -D|toothpaste containing amino acid/bicarbonate
3261537|NCT00758381|Experimental|A|"Sorafenib 400 mg po bid, continuously~Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days."
3261538|NCT00758381|Active Comparator|B|Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days
3261539|NCT00758368|Experimental|Ambulatory Pump|Participants will receive apomorphine via a pump. Participants in the Continuous Delivery Arm will self-administer apomorphine continuously (12-14 hours a day) using a portable pump.
3261540|NCT00758368|Active Comparator|Subcutaneous Injections|Participants will receive apomorphine via an injection pen. Participants in the Intermittent Delivery Arm will self-administer apomorphine at intervals, via a injection, using pen injector.
3261541|NCT00758355||M2A magnum|Consecutive series of patients received Total Hip Resurfacing with ReCap/Magnum
3261542|NCT00758355||Recap Magnum|Consecutive series of patients received Total Hip Replacement with ReCap/Magnum
3261543|NCT00758342|Experimental|Travoprost 0.004% + Brinzolamide 1.0%|Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
3261544|NCT00758342|Active Comparator|Travoprost 0.004% + Tears Natural|Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
3261545|NCT00758329||1|
3261546|NCT00758316|Active Comparator|1|Thoracoscopy with pleurodesis Patients will then undergo standard medical thoracoscopy in the endoscopy center including the use of moderate sedation, prophylactic antibiotics for 1 week and 20F chest tube insertion at the end of the procedure.
3261715|NCT00756990|Experimental|Single group|Depot Naltrexone
3261547|NCT00758316|Experimental|2|Combined thoracoscopy with pleurodesis and pleurx catheter. In the combined procedure group, a PleurxTM tunnelled catheter will be inserted under ultrasound guidance. As this procedure will be done concurrently with thoracoscopy, there is no estimated increase in endoscopy time.
3261548|NCT00758303|Active Comparator|1|Low Dose TRIA-662
3261549|NCT00758303|Active Comparator|2|High Dose TRIA-662
3261550|NCT00758303|Placebo Comparator|3|Matching Placebo for TRIA-662
3261551|NCT00758290|Active Comparator|A|
3261552|NCT00758290|Experimental|B|
3261553|NCT00758277|Active Comparator|Levetiracetam|
3261554|NCT00758277|Placebo Comparator|Placebo|
3261555|NCT00758264|Experimental|Group A|Meningococcal vaccine GSK134612 co-administered with pneumococcal vaccine GSK1024850A.
3261556|NCT00758264|Active Comparator|Group B|Pneumococcal vaccine GSK1024850A followed one month later by meningococcal vaccine GSK134612.
3261557|NCT00758264|Active Comparator|Group C|Meningococcal vaccine GSK134612 followed one month later by pneumococcal vaccine GSK1024850A.
3261558|NCT00758251||1|Adult schizophrenia patients already on Seroquel XR therapy
3261559|NCT00758238|Experimental|myBP intervention|participants will receive access to hypertension self-management tools and support via a personal patient electronic health record
3261560|NCT00758238|No Intervention|usual care|participants allocated to usual care may still opt to use the personal patient electronic health record, but will not have access to the hypertension self-management tools until after the intervention period. The usual care group will be given a web-link for patient hypertension management resources
3261561|NCT00758225|Experimental|only one arm|
3261562|NCT00758212|Experimental|A|The experimental group will consist of HIV/AIDS patients(approx.50) who volunteer to receive a reduced dose Influenza vaccine using mesotherapy as a mode of injecting the vaccine intradermally.
3261563|NCT00758199|Active Comparator|2|Moxifloxacin
3261564|NCT00758199|Placebo Comparator|3|Prednisolone Acetate
3261565|NCT00758199|Active Comparator|1|Bromfenac
3261566|NCT00758186|Experimental|Colonic-stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction.
3261567|NCT00758186|Active Comparator|Emergency surgery|Emergency surgery: Patients underwent emergency surgery for acute left-sided malignant colonic obstruction.
3261568|NCT00758160|Experimental|OROS methylphenidate|Participants willl receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
3261569|NCT00758134|Experimental|A|Trastuzumab 6 mg/Kg
3261570|NCT00758121||Observation|Heart failure patients with an implanted CRT-D
3261571|NCT00758082|Active Comparator|1|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support
3261572|NCT00758082|Experimental|2|PDA-phone + phone consultations + standard visit at 3 months
3261573|NCT00758069|Placebo Comparator|1|Placebo
3261574|NCT00758069|Experimental|2|Sitagliptin 100 mg
3261575|NCT00758069|Experimental|3|Sitagliptin 50 mg
3261576|NCT00758043|Experimental|T12PR24 (eRVR+)|Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 12 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
3261577|NCT00758043|Experimental|T12PR48 (eRVR+)|Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
3261578|NCT00758043|Experimental|T12PR48 (eRVR-)|Assigned Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects did not achieve an extended rapid viral response and were assigned to this group
3261579|NCT00758043|Experimental|Other|Other Group: Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20, were not randomized or assigned to a treatment regimen.
3261580|NCT00758017|Experimental|Acupuncture 1|
3261581|NCT00758017|Active Comparator|Acupuncture 2|
3261582|NCT00758004|Other|Reference|Commercial 80 mg atorvastatin tablet
3261583|NCT00758004|Other|Test|Pediatric appropriate atorvastatin 40mg formulation
3261584|NCT00757978|Placebo Comparator|1|Clozapine plus placebo
3261585|NCT00757978|Active Comparator|2|Clozapine plus memantine
3261586|NCT00757939|Experimental|AD Participants|Participants with a diagnosis of mild-to-moderate AD
3261587|NCT00757939|Experimental|Cognitively Normal Elderly Participants|Elderly participants with no cognitive impairment
3261588|NCT00757926|Experimental|1|
3261589|NCT00757926|Placebo Comparator|2|
3261590|NCT00757913|Experimental|1|n-3 enriched nutrition
3261591|NCT00757913|Placebo Comparator|2|isocaloric nutrition without n-3 supplement
3261592|NCT00757900|Active Comparator|1|To receive a sub-unit influenza vaccine
3261593|NCT00757900|No Intervention|2|
3261594|NCT00757887|Experimental|EHMI8|Previously protected volunteers, N=10
3261595|NCT00757887|Active Comparator|control|5 malaria-naive volunteers
3261596|NCT00757874|Experimental|Tacrolimus cream|
3261597|NCT00757874|Active Comparator|Clobetasol cream|
3261598|NCT00757848|Experimental|AZD9668|
3261599|NCT00757848|Placebo Comparator|Placebo|
3261600|NCT00757835|Active Comparator|Travoprost/timolol therapy|treatment with travoprost/timolol fixed combination drops once in the evening for 3 months. 24-hour pressure monitoring.
3261601|NCT00757835|Active Comparator|Latanoprost/timolol therapy|Treatment with latanoprost/timolol fixed combination for 3 months. 24-hour pressure monitoring.
3261602|NCT00757822|Experimental|Arm 1|dronabinol
3261603|NCT00757822|Active Comparator|Arm 2|ondansetron
3261604|NCT00757809|Experimental|QD|Once daily
3261605|NCT00757809|Experimental|BID|Twice daily
3261606|NCT00757783|Experimental|darunavir|darunavir 800 mg tablet once daily for 48 weeks,emtricitabine [FTC]/tenofovir [TDF] 200/300 mg tablet once daily for 48 weeks,ritonavir 100 mg capsule or tablet once daily for 48 weeks
3261607|NCT00757783|Experimental|atazanavir|atazanavir 300 mg capsule once daily for 48 weeks,emtricitabine [FTC]/tenofovir [TDF] 200/300 mg once daily for 48 weeks,ritonavir 100 mg capsule or tablet once daily for 48 weeks
3261608|NCT00757770|Experimental|Group HRV Lot A|
3261609|NCT00757770|Experimental|Group HRV Lot B|
3261610|NCT00757770|Experimental|Group HRV Lot C|
3261611|NCT00757770|Active Comparator|Group Placebo|
3261612|NCT00757757|Experimental|MCS110|
3261613|NCT00757744|Experimental|A|Methadone maintenance treatment with Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
3261614|NCT00757744|Active Comparator|B|Methadone maintenance treatment with standard drug counseling
3261615|NCT00757731|Experimental|Minalcipran 100 mg|
3261616|NCT00757731|Experimental|Minalcipran 150 mg|
3261617|NCT00757731|Experimental|Minalcipran 200 mg|
3261618|NCT00757718|Active Comparator|CPAP treatment|Subjects will have repeat polysomnography on the second night, while wearing a continuous positive airway pressure (CPAP) device. Morning bloodwork will be drawn for inflammatory mediators.
3261619|NCT00757718|Experimental|Oral appliance|Subjects will have repeat polysomnography on the second night, while wearing an oral appliance, as well as a Breathe-Right nasal strip. Morning bloodwork will be drawn for inflammatory mediators.
3261620|NCT00757705|Experimental|Paliperidone Extended-Release (ER)|
3261621|NCT00757692|Experimental|A|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
3261622|NCT00757692|Active Comparator|B|Bicalutamide at 50 mg will be administered orally, daily and continuously.
3261623|NCT00757679|Experimental|Milnacipran|
3261624|NCT00757679|Placebo Comparator|Placebo|
3261625|NCT00757666|Active Comparator|Accelerometer|Patients implanted with a Boston Scientific ALTRUA 60 pacemaker with accelerometer (motion-based) sensor.
3261626|NCT00757666|Active Comparator|Minute Ventilation|Patients implanted with a Boston Scientific ALTRUA 60 pacemaker with minute ventilation sensor.
3261627|NCT00757653|Active Comparator|1|Stem with plasma sprayed porous Titanium 6Al4V alloy + Plasma sprayed HA
3261628|NCT00757653|Experimental|2|
3261629|NCT00757653|Active Comparator|3|
3261630|NCT00757640|No Intervention|B|no cholecystectomy
3261631|NCT00757640|Experimental|A|cholecystectomy
3261632|NCT00757627|Experimental|1|Etoricoxib
3261633|NCT00757601|Experimental|15 mg MK1006/Placebo/45 mg MK1006/60 mg MK1006/Placebo (Fed)|Participants received 15 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by placebo to MK1006 taken with food (Fed state) in Period 5.
3261634|NCT00757601|Experimental|Placebo/30mg MK1006/45mg MK1006/60mg MK1006/30mg MK1006 (Fed)|Participants received placebo to MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
3261635|NCT00757601|Experimental|15mg MK1006/30mg MK1006/Placebo/60mg MK1006/30mg MK1006 (Fed)|Participants received 15 mg MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
3261636|NCT00757601|Experimental|15mg MK1006/30mg MK1006/45mg MK1006/Placebo/30mg MK1006 (Fed)|Participants received 15 mg MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
3261637|NCT00757601|Experimental|60mg MK1006 / Placebo / 100mg MK1006 / 120mg MK1006 / Placebo|Participants received 60 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by placebo to MK1006 in Period 5.
3261638|NCT00757601|Experimental|Placebo/ 80mg MK1006/ 100mg MK1006/ 120mg MK1006/ 140mg MK1006|Participants received placebo to MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by 140 mg MK1006 in Period 5
3261639|NCT00757601|Experimental|60mg MK1006/ 80mg MK1006/ Placebo/ 120mg MK1006/ 140mg MK1006|Participants received 60 mg MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.
3261640|NCT00757601|Experimental|60mg MK1006/ 80mg MK1006/ 100mg MK1006/ Placebo/ 140mg MK1006|Participants received 60 mg MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.
3261641|NCT00757601|Experimental|140mg MK1006 / Placebo / 200mg MK1006 / 230mg MK1006 / Placebo|Participants received 140 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by placebo to MK1006 in Period 5.
3261642|NCT00757601|Experimental|Placebo/170mg MK1006/ 200mg MK1006/ 230mg MK1006/ 260mg MK1006|Participants received placebo to MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.
3261643|NCT00757601|Experimental|140mg MK1006/170mg MK1006/ Placebo/ 230mg MK1006/ 260mg MK1006|Participants received 140 mg MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by 260 mg MK1006 in Period 5
3261644|NCT00757601|Experimental|140mg MK1006/170mg MK1006/ 200mg MK1006/ Placebo/ 260mg MK1006|Participants received 140 mg MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.
3261645|NCT00757588|Experimental|Saxagliptin, 5 mg + insulin|Saxagliptin, 5 mg, plus insulin, administered to participants with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
3261646|NCT00757588|Placebo Comparator|Placebo + insulin|Placebo administered to participants with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
3261647|NCT00757575||1|
3261648|NCT00757562|Experimental|DL|Desloratadine syrup once daily
3261649|NCT00757562|Placebo Comparator|Placebo|placebo syrup once daily
3261650|NCT00757536|Active Comparator|Group 1|
3261651|NCT00757536|Active Comparator|Group 2|
3261652|NCT00757523|Active Comparator|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation).
3261653|NCT00757523|Experimental|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation).
3261654|NCT00757510||Congenital heart disease|All subjects will have known or suspected congenital heart disease
3261655|NCT00757471|Active Comparator|Group 1|Brillant Blue
3261656|NCT00757471|Active Comparator|Group 2|Indocyanine Green
3261657|NCT00757458|Active Comparator|1|TCI with EDTA
3261658|NCT00757458|Active Comparator|2|Re-filling of propofol syringe (Diprivan®-Astra Zeneca) with propofol containing EDTA
3261659|NCT00757458|Active Comparator|3|Re-filling of propofol syringe (Diprivan®-Astra Zeneca) with propofol without EDTA
3261660|NCT00757458|Active Comparator|4|Target controlled infusion of propofol without EDTA
3261661|NCT00757419|Experimental|1|
3261662|NCT00757419|Placebo Comparator|2|
3261663|NCT00757406||1|Test group - Lymphedema sufferers
3261664|NCT00757406||2|Control group - healthy volunteers
3261665|NCT00757393|Active Comparator|1|
3261666|NCT00757393|Experimental|2|
3261667|NCT00757380|Active Comparator|Group 1|Trypan Blue
3261668|NCT00757380|Active Comparator|Group 2|Brillant Blue
3261669|NCT00757367|Experimental|TI Inhalation Powder|TI Inhalation Powder, single dose, 60 units
3261670|NCT00757354|Experimental|Metal on Metal cementless hip|Metal on Metal cementless hip arthroplasty
3261671|NCT00757341|Experimental|SKI-606|
3261672|NCT00757328||1|Ambulatory bipolar I and II patients, clinically stabilized for at least the two months prior to recruitment and who had at least one acute episode (depressive, manic, hypomanic or mixed) within the year prior to recruitment.
3261673|NCT00757315|Experimental|1|
3261674|NCT00757315|Active Comparator|2|
3261675|NCT00757302|Experimental|I|For the first 10 patients, only a pre-operative procedure will be performed.
3261676|NCT00757302|Experimental|II|The last 100 patients will receive the complete procedure.
3261677|NCT00757289|Experimental|1|PRP injection
3261678|NCT00757289|Active Comparator|2|Corticosteroid Injection
3261679|NCT00757276||1|"All patients > 18 years who are tested for the diagnosis of DI because of a history of polyuria (> 40 ml/kg per 24 hours) in the presence of polydipsia Patients with known DI will be contacted whether they agree to participate in the study and to undergo again a water deprivation test to measure copeptin to confirm the diagnosis.~The investigators hypothesize that basal copeptin levels can reliably differentiate between the 5 groups(central, nephrogenic, psychogenic and partial forms) with a sensitivity and specificity >80%."
3261680|NCT00757250|Experimental|1|Dose Cohort 1: 50 mcg/kg/day of TXA127
3261681|NCT00757250|Experimental|2|Drug Cohort 2: 100 mcg/kg/day TXA127
3261682|NCT00757250|Experimental|3|Drug Cohort 3: 200 mcg/kg/day TXA127
3261683|NCT00757250|Experimental|4|Drug Cohort 4: 300 mcg/kg/day TXA127
3261684|NCT00757250|Experimental|5|Extended dosing cohort at 300mcg/kg TXA127 for 2 x 28-day treatment cycles, with an extended follow-up period to week 34.
3261685|NCT00757237|Experimental|AZLI 75 mg 3 times a day (TID)|
3261686|NCT00757237|Active Comparator|TIS 300 mg 2 times a day (BID)|
3261687|NCT00757224|No Intervention|non-smoking|
3261688|NCT00757224|No Intervention|smoking parents A|
3261689|NCT00757224|Experimental|smoking parents B|Parents will be educated on the hazards of passive smoke exposure and ways to reduce it
3261690|NCT00757198|Experimental|1|remifentanil o.1 mcg/kg/min
3261691|NCT00757198|Active Comparator|2|remifentanil 0.3 mcg/kg/min
3261692|NCT00757185|Experimental|1|GNRH antagonist alone
3261693|NCT00757185|Experimental|2|GnRH with Testosterone
3261694|NCT00757172|Other|Docetaxel + Cisplatin + Panitumumab + RT|Patients received docetaxel (40 mg/m^2), cisplatin (40 mg/m^2) and panitumumab (6 mg/kg) on weeks 1, 3, 5, 7, and 9 with radiotherapy (RT) (5040 cGy, 180 cGy/day x 28 days) beginning week 5. Resection was planned after completing chemotherapy (CRT).
3261695|NCT00757159|Experimental|1|
3261696|NCT00757159|Active Comparator|2|
3261697|NCT00757133|Experimental|1|Conventional laparotomy closure
3261698|NCT00757133|Active Comparator|2|Laparotomy closure with mesh augmentation
3261699|NCT00757120||1|This group will include current and former smokers who have emphysema.
3261700|NCT00757120||2|This group will include current and former smokers who do not have emphysema.
3261701|NCT00757107|Experimental|Taperloc Microplasty|Patients with primary osteoarthritis with Taperloc microplasty non inferiority
3261702|NCT00757107|Active Comparator|Taperloc Standard|Patients with primary osteoarthritis Taperloc standard
3261703|NCT00757094||I|Patients planning to observe fasting while receiving chemotherapy during the month of Ramadan
3261704|NCT00757081|Experimental|1|
3261705|NCT00757068|Active Comparator|SBT|Women assigned to SBT (blue) will receive a six month program that offers to help them stay quit after having a baby.
3261706|NCT00757068|Experimental|CBT|Women assigned to CBT (pink) will receive a six month treatment designed to provide support and address the concerns of women who have just had a baby and do not want to resume smoking.
3261707|NCT00757055|Active Comparator|1|Patients on ivabradine titrated to heart rate
3261708|NCT00757055|Placebo Comparator|2|No therapy given
3261709|NCT00757042|Active Comparator|AMG 157|Six subjects in each cohort (cohort 1 to 8) will receive AMG 157 in Part A 18 subjects in cohorts 9 and 10 (Part B) will receive AMG 157
3261710|NCT00757042|Placebo Comparator|placebo|2 subjects of each cohort (cohort 1 to 8) will receive placebo in Part A 6 subjects in cohorts 9 and 10 (Part B) will receive placebo
3261711|NCT00757029|Other|open label|
3261712|NCT00757016|Placebo Comparator|B|0.99 ml saline solution 9mg/ml and 0.01 ml fat emulsion will be given once to the sacrospinous ligament insertion.
3261713|NCT00757016|Active Comparator|A|1 ml triamcinolone 20mg/ml (Lederspan), Meda AB, Solna, Sweden) and 1 ml lidocaine hydrochloride 10mg/ml (Xylocain), Astra Zeneca, Södertälje, Sweden)
3261714|NCT00757003|Experimental|Treatment Arm - Placement of TAG device|A TAG device will be used to repair the pathology in the thoracic aorta
3261716|NCT00756977|Experimental|1|multi-dose preparation for oral administration prior to colonoscopy
3261717|NCT00756977|Active Comparator|2|multi-dose preparation for oral administration prior to colonoscopy
3261718|NCT00756964|Active Comparator|Rasburicase|patients receiving rasburicase to lower serum uric acid
3261719|NCT00756964|Placebo Comparator|Placebo|patients will receive a placebo
3261720|NCT00756951|Placebo Comparator|1|Placebo
3261721|NCT00756951|Active Comparator|2|SCV-07 at a dose of 0.02 mg/kg
3261722|NCT00756951|Active Comparator|3|SCV-07 at a dose of 0.10 mg/kg
3261723|NCT00756938|Experimental|Losartan potassium 0.1 to 1.4 mg/kg|Open-label losartan at starting dose of 0.1 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
3261724|NCT00756938|Experimental|Losartan potassium 0.3 to 1.4 mg/kg|Open-label losartan at starting dose of 0.3 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
3261725|NCT00756938|Experimental|Losartan potassium 0.7 to 1.4 mg/kg|Open-label losartan at starting dose of 0.7 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
3261726|NCT00756925||1|Cocaine dependent females
3261727|NCT00756925||2|Cocaine dependent males
3261728|NCT00756912|Experimental|1|
3261729|NCT00756899||Obese|Chilren with BMI of >95th percentile
3261730|NCT00756899||Non-obese|Children with BMI of <85th percentile
3261731|NCT00756886|Active Comparator|Atorvastatin|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
3261732|NCT00756886|Placebo Comparator|Placebo|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
3261733|NCT00756873|Placebo Comparator|1|
3261734|NCT00756873|Experimental|2|Etoricoxib 90 mg qd.
3261735|NCT00756873|Experimental|3|Etoricoxib 120 mg qd. (day 0-7) Etoricoxib 90 mg qd. (day 8-14)
3261736|NCT00756860|Active Comparator|2|30 subjects will be randomized on Day -1
3261737|NCT00756860|Experimental|1|30 subjects will be randomized on Day -1
3261738|NCT00756847|Experimental|1|
3261739|NCT00756821||SMA cohort|Subjects between the ages of 2-12 years diagnosed with SMA Type I, II, or III.
3261740|NCT00756821||Control cohort|Healthy children between the ages of 2-12 years. These children may be either genetically-related siblings of SMA children (genetically confirmed non-carriers of SMA),or unrelated children.
3261741|NCT00756795|Experimental|Attention Control|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Patient will be taught how to keep the Activity diary to record walking and physical activities.~Structured Interview will be conducted at baseline and post-intervention. All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis"
3261742|NCT00756782|Experimental|A|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days
3261743|NCT00756782|Placebo Comparator|B|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
3261744|NCT00756769||1|Patients with SLE
3261745|NCT00756769||2|Related unaffected controls
3261746|NCT00756769||3|Unrelated unaffected controls
3261747|NCT00756756|Experimental|1|post MI post PCI and G-CSF infusion
3261748|NCT00756756|Placebo Comparator|2|post MI and post PCI only placebo infused
3261749|NCT00756743|Experimental|PF-04802540|
3261750|NCT00756743|Placebo Comparator|Placebo|
3261751|NCT00756730|Other|Switch to DRV/r (800mg/100mg) QD|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this arm the sbject switched to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
3261752|NCT00756730|Other|Switch to ATV/r (300mg/100mg QD)|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this are the subject switched to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study
3261753|NCT00756717|Experimental|1|oral gamma-secretase inhibitor drug MK-0752, 350 mg for three days, four days off, then three days on, over a period of 10 days
3261754|NCT00756704|No Intervention|Baseline Period|
3261755|NCT00756704|Experimental|Intervention Period|
3261756|NCT00756691||1|First 5 consecutive 18F-FAZA avid subjects that undergo up to 5 PET scans, 13 blood and 2 urine samples over 4.5 hours
3261757|NCT00756691||2|Next 5 consecutive 18F-FAZA avid subjects that undergo up to 4 PET scans, 8 blood and 2 urine samples over 5.5 hours
3261758|NCT00756678|Active Comparator|1|Carboxymethylcellulose and Glycerin
3261759|NCT00756678|Active Comparator|2|Polyethylene glycol 400
3261760|NCT00756652||MemoryGel Breast Implant Participants|MemoryGel Breast Implant Participants received Mentor Silicone Gel-Filled Breast Implants (MemoryGel) during their Breast Augmentation, Breast Reconstruction, or Revision surgery
3261761|NCT00756652||Saline Breast Implant Control Participants|Saline Breast Implant Control Participants received Saline Filled Breast Implants during their Breast Augmentation, Breast Reconstruction, or Revision surgery
3261762|NCT00756639|Experimental|Radiation|Prophylactic cranial irradiation (PCI) treatments to be started within 4 months after the end of chemotherapy or surgery to a total dose of 30 Gy, given at 2 Gy per fraction, 5 days per week for 3 weeks. On the first day of each week of therapy, a brain X-ray will done to see if the radiation is being given to the best area.
3261763|NCT00756626|Experimental|1|Intervention group receives bottle weaning intervention from WIC nutritionist
3261764|NCT00756626|No Intervention|2|Control standard of care
3261765|NCT00756613||465 VADT partiticipants|The participants had previously participated in the VADT CSP #465 study
3261766|NCT00756600|Active Comparator|1|Regional Anesthesia
3261767|NCT00756600|Active Comparator|2|General Anesthesia
3261768|NCT00756587|Active Comparator|I|Group one received feeding by bottle as the standard method of feeding in the NICU
3261769|NCT00756587|Experimental|II|Group 2 received all feeding by cup
3261770|NCT00756574|Active Comparator|1. Surgical|surgical mask
3261771|NCT00756574|Active Comparator|2. N95 Respirator|N95 respirator
3261772|NCT00756548|Experimental|1|multi-dose preparation for oral administration prior to colonoscopy
3261773|NCT00756548|Active Comparator|2|multi-dose preparation for oral administration prior to colonoscopy
3261774|NCT00756535|Experimental|1|Group-based exercise training during hospitalization
3261775|NCT00756535|Active Comparator|2|Usual treatment and rehabilitation during hospitalization
3261776|NCT00756509|Experimental|nilotinib|nilotinib
3261777|NCT00756483||M, 1|Male patients that have undergone total knee replacement
3261778|NCT00756483||F, 1|Female patients that have undergone total knee replacement
3261779|NCT00756483||M, 2|Male patients that have undergone total hip replacement
3261780|NCT00756483||F, 2|Female patients that have undergone total hip replacement
3261781|NCT00756470|Experimental|Neoadjuvant Lapatinib plus Chemotherapy|"Four cycles of Lapatinib and Paclitaxel followed by 4 cycles of Lapatinib plus 5-Fluorouracil, Cyclophosphamide, Epirubicin (FEC75). Cycle is 21 days.~Lapatinib alone at 1,000 mg orally once daily for a 2-week run-in period, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each.~Week 3 Paclitaxel 80 mg/m^2 weekly for 4 cycles (12 weeks) administered on Day 1, Day 8, and Day 15) of each cycle combined with Lapatinib 750 mg orally once daily.~Week 15, second combination treatment consisting of Lapatinib (1,000 mg orally once daily) combined with FEC75 (5-FU 500 mg/m^2, Epirubicin 75 mg/m^2, and Cyclophosphamide 500 mg/m^2 every 3 weeks for 4 cycles)."
3261782|NCT00756457|Active Comparator|Active Treatment Group|Participants in Group A will undergo bracing and perform stretching exercises.
3261783|NCT00756457|Experimental|Passive Treatment Group|Participants in Group B will undergo bracing and perform stretching and strengthening exercises.
3261784|NCT00756444|Active Comparator|Panitumumab plus Chemotherapy|Subjects receiving cisplatin and 5/FU and receiving Panitumumab who have with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
3261785|NCT00756444|Active Comparator|Chemotherapy Alone|Subjects receiving cisplatin and 5/FU and not receiving Panitumumab who have with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
3261786|NCT00756431|Active Comparator|Screw without HA Coating (Hiploc)|
3261787|NCT00756431|Experimental|Screw with HA Coating (Hiploc)|
3261788|NCT00756418|Experimental|1|
3261789|NCT00756418|Active Comparator|2|
3261790|NCT00756405|Active Comparator|Diet Group|Increased antioxidant diet and placebo pill.
3261791|NCT00756405|Active Comparator|Supplement Group|Usual diet and antioxidant supplement.
3261792|NCT00756405|Placebo Comparator|Placebo|Usual diet and placebo pill.
3261793|NCT00756392|Other|1|
3261794|NCT00756379|Experimental|Intensive lifestyle modification|P.E.T. guided comprehensive therapy program. The study intervention is Comprehensive therapy program for risk factor modification. The Comprehensive program of atherosclerotic risk factor modification involves treatment to target lipid levels, blood pressure and diabetes control, smoking cessation, very low fat diet and aerobic exercise program. This is in addition to standard current medical therapy as provided by primary physician. No experimental medications or procedures will be used.
3261795|NCT00756379|No Intervention|Current standard of care|Current standard of care medical management as provided by primary physician.
3261796|NCT00756366|Active Comparator|1|Heart Failure-OSA Group, randomized to early CPAP
3261797|NCT00756366|Active Comparator|2|Heart Failure-OSA Group, randomized to late CPAP
3261798|NCT00756366|Other|3|Heart Failure- no OSA, no CPAP therapy, observational group
3261799|NCT00756353||Wave 1|
3261800|NCT00756353||Wave 2|
3261801|NCT00756340|Experimental|1|"Dose Level 0, Bevacizumab IV every 2 weeks 8 mg/kg, Everolimus 4 mg/m^2~Dose Level 1 (starting dose), Bevacizumab IV every 2 weeks 10 mg/kg, Everolimus 4 mg/m^2~Dose Level 2, Bevacizumab IV every 2 weeks 10 mg/kg, Everolimus 5 mg/m^2"
3261802|NCT00756314|Experimental|Personalized contraceptive counseling|All 123 allocated women for the intervention group received personalized counseling (face-to-face) and the contraceptive method chosen for free by a specialized trained doctor in family planning.
3261803|NCT00756314|No Intervention|Control|All 123 women allocated to control group received a standard care available at IMIP.Standard care is comprised of educational group counseling by specialized nursing staff in family planning discussing about contraceptive methods and side effects
3261804|NCT00756301|Active Comparator|Traditional Technique|Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
3261805|NCT00756301|Experimental|Alternative Technique|Local anesthetic (Lidocaine) injected using an alternative technique (inserting the numbing needle into the deeper tissues first and injecting numbing medication from there up to the skin).
3261806|NCT00756301|No Intervention|No Anesthetic|No local anesthetic is used.
3261807|NCT00756288|Experimental|1|Topical retinoid and Light therapy with photosensitizing agent
3261808|NCT00756288|Active Comparator|2|Light therapy with photosensitizing agent
3261809|NCT00756275|Active Comparator|Nicotine Replacement + PLA pill|Nicotine replacement treatment patch plus matched placebo pill
3261810|NCT00756275|Active Comparator|Varenicline + PLA patch|Varenicline plus matched placebo patches containing no nicotine
3261811|NCT00756262|Active Comparator|1|Lactobacillus rhamnosus LGG
3261812|NCT00756262|Placebo Comparator|2|Microcrystalline cellulose capsules
3261813|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.005 mcg/kg|
3261814|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.05 mcg/kg|
3261815|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.5 mcg/kg|
3261816|NCT00756249|Experimental|Lu AA24493 (CEPO): 5.0 mcg/kg|
3261817|NCT00756249|Experimental|Lu AA24493 (CEPO): 50.0 mcg/kg|
3261818|NCT00756249|Placebo Comparator|Placebo|
3261854|NCT00756015|Other|Immobilization|Immobilization following rotator cuff repair.
3261855|NCT00756002|Experimental|Ramelteon 4 mg QD|
3261819|NCT00756236|Experimental|M-Group|Patients were randomly assigned to Metoprolol Group. The drug was dispensed in 60ml & 5ml syringes of 0.9% NaCl and 1mg/ml Metoprolol. Investigators and patients were blinded to the group assignment.
3261820|NCT00756236|Experimental|E-Group|Patients were randomly assigned to Esmolol Group. The drug was dispensed in 60ml & 5ml syringes of 0.9% NaCl and 10mg/ml Esmolol. Investigators and patients were blinded to the group assignment.
3261821|NCT00756236|Placebo Comparator|P-Group|Patients were randomly assigned to this group. Patients received 0.9% NaCl only. To maintain the blind, 0.9% NaCl was also dispensed in 60ml & 5ml syringes.
3261822|NCT00756223|Experimental|Arm A|BI 831266 24h infusion on day 1 and day 15 every 4 weeks
3261823|NCT00756223|Experimental|Arm B|BI 831266 24h infusion on day 1 every 3 weeks
3261824|NCT00756197|Experimental|Cryo Spray Ablation Group 1|4 cycles of 10 seconds each
3261825|NCT00756197|Experimental|Cryo Spray Ablation Group 2|2 cycles of 20 seconds each
3261826|NCT00756184|Active Comparator|A|Intervention will consist of intensive teaching on the nature of glaucoma, value of IOP control, need to adhere to medical therapy and counseling on the proper use of travoprost eye drops.
3261827|NCT00756184|Placebo Comparator|B|"Intervention with travoprost therapy and TDA monitoring. Patients of this arm will also be prescribed travoprost and will be followed up in a standard clinical fashion. This group will receive a comparable amount of personal physician attention, but will not be given adherence, or glaucoma education and will not be told that their adherence will be monitored. Their attention placebo intervention will discuss the importance and techniques of good eye health (sunglasses, vitamins, cataract development, etc but no details, or discussion of either glaucoma or adherence) will insure that the study results are not a result of a change in physician attention to a patient, per se, rather than adherence training."
3261828|NCT00756171|Experimental|1|Verum; colesevelam
3261829|NCT00756171|Placebo Comparator|2|placebo
3261830|NCT00756145|Experimental|1|Injection of LMWH at the start of the hemodiafiltration session, at the inlet bloodline
3261831|NCT00756145|Experimental|2|Injection of LMWH 5 minutes after the start of the hemodiafiltration session, at the inlet bloodline
3261832|NCT00756145|Experimental|3|Injection of LMWH at the start of the hemodiafiltration session, at the outline bloodline
3261833|NCT00756132||Bloods Only (B)|Women aged 18-65 years with a newly diagnosed locally advanced or high risk operable breast cancer
3261834|NCT00756132||A-Cog|Women aged 18-65 years newly diagnosed with LABC/high risk who are willing and able to complete cognitive testing.
3261835|NCT00756132||Control (C)|Healthy women aged 18-65 years who are willing and able to complete cognitive testing.
3261836|NCT00756132||A1-Cog|Women newly diagnosed locally advanced or high risk breast cancer that qualify for cognitive testing but have a condition related to elevated serum levels of cytokines or other inflammatory markers.
3261837|NCT00756093|Experimental|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each one time
3261838|NCT00756093|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
3261839|NCT00756093|Active Comparator|Blink Tears|Blink Tears 1 drop each eye one time
3261840|NCT00756093|Active Comparator|GenTeal Moderate Lubricant Eye Drops|GenTeal Moderate Lubricant Eye Drops 1 drop each eye one time
3261841|NCT00756080|Experimental|1|After receiving a 7-day oral supplementation with citrulline, each subject will be admitted to the Clinical Investigation Unit for a half day, after an overnight fast,and will receive a 5-h intravenous infusion of L-[1-13C]leucine (i.e.; leucine labeled with 13C, a stable isotope of carbon) from 8 am to 1 pm. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, the keto acid of leucine, using gas chromatography-mas spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. The subject will then leave the hospital, take no treatment for13 days (wash-out period). The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with placebo, as a cross-over study design will be used.
3261842|NCT00756080|Placebo Comparator|2|After receiving a 7-day oral supplementation with placebo, each subject will be admitted to the Clinical Investigation Unit for a half day, after an overnight fast,and will receive a 5-h intravenous infusion of L-[1-13C]leucine (i.e.; leucine labeled with 13C, a stable isotope of carbon) from 8 am to 1 pm. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, the keto acid of leucine, using gas chromatography-mas spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. The subject will then leave the hospital, take no treatment for13 days (wash-out period). The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with citrulline, as a cross-over study design will be used.
3261843|NCT00756067|Experimental|Formulation 1|
3261844|NCT00756067|Experimental|Formulation 2|
3261845|NCT00756067|Experimental|Formulation 3|
3261846|NCT00756067|Experimental|Formulation 4|
3261847|NCT00756067|Experimental|Formulation 5|
3261848|NCT00756067|Experimental|Formulation 6|
3261849|NCT00756067|Active Comparator|23 valent pneumococcal vaccine|
3261850|NCT00756041|Experimental|TAK-128 100 mg QD|
3261851|NCT00756028|Experimental|1|Patients receiving short protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-antagonist (Orgalutran®: Ganirelix)
3261852|NCT00756028|Active Comparator|2|Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®: Nafarelin)
3261853|NCT00756015|Active Comparator|Early Motion|Other: Early range of motion post-operative therapy protocol.Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
3261856|NCT00756002|Placebo Comparator|Placebo QD|
3261857|NCT00755989|Placebo Comparator|1|group to receive topical gel without morphine
3261858|NCT00755989|Experimental|2|Morphine gel
3261859|NCT00755976|Experimental|Epirubicin hydrochloride (75mg/m2 i.v.) Sulindac: 600mg|
3261860|NCT00755963|Experimental|1|
3261861|NCT00755963|Experimental|2|
3261862|NCT00755963|Placebo Comparator|3|Placebo
3261863|NCT00755950|Experimental|1|280 mg of Silymarin administered three times daily for 4 weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
3261864|NCT00755950|Placebo Comparator|3|Placebo: Lactose monohydrate; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
3261865|NCT00755950|Experimental|2.|420 mg silymarin three times daily for four weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
3261866|NCT00755937||Subjects receiving Remicade|Crohn's disease subjects receiving Remicade® per Product Monograph.
3261867|NCT00755911|Experimental|Tissue Repair Cells (TRC)|Subjects will receive Tissue Repair Cell (TRC) therapy plus Gelfoam carrier
3261868|NCT00755911|Sham Comparator|Control|Subjects will receive the control treatment, consisting of Gelfoam carrier without Tissue Repair Cell (TRC) therapy.
3261869|NCT00755898|Active Comparator|1|Patients with a medical diagnosis of cancer appearing at outpatient clinics for treatment and/or monitoring of their disease status
3261870|NCT00755898|Active Comparator|2|Healthy adult volunteers
3261871|NCT00755872|Experimental|1|Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
3261872|NCT00755872|Experimental|2|Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
3261873|NCT00755872|Experimental|3|Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
3261874|NCT00755872|Experimental|4|Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
3261875|NCT00755859|Experimental|1|Six month steroid course plus azathioprine
3261876|NCT00755859|Active Comparator|2|six month steroid course
3261877|NCT00755846|Experimental|Alogliptin 6.25 mg QD|
3261878|NCT00755846|Experimental|Alogliptin 12.5 mg QD|
3261879|NCT00755846|Experimental|Alogliptin 25 mg QD|
3261880|NCT00755846|Experimental|Alogliptin 50 mg QD|
3261881|NCT00755846|Experimental|Alogliptin 100 mg QD|
3261882|NCT00755846|Placebo Comparator|Placebo QD|
3261883|NCT00755833||A|
3261884|NCT00755820||EXP-DCS/Exposure-D-cycloserine|Exposure Therapy + D-Cycloserine
3261885|NCT00755820||EXP-PBO|Exposure Therapy + Placebo
3261886|NCT00755820||SP|Supportive psychotherapy
3261887|NCT00755807|Placebo Comparator|Placebo|
3261888|NCT00755807|Experimental|Duloxetine|
3261889|NCT00755794|Experimental|1|Montelukast
3261890|NCT00755781|Active Comparator|CIS|CIS in addition to standard immunosuppressive regimen.
3261891|NCT00755781|No Intervention|SOC|Standard of care (SOC) therapy for lung transplant recipients
3261892|NCT00755755|Experimental|A (PGL4001 5mg)|PGL4001 5 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
3261893|NCT00755755|Experimental|B (PGL4001 10mg)|PGL4001 10 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
3261894|NCT00755755|Placebo Comparator|C (placebo)|PGL4001 matching placebo (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
3261895|NCT00755742|Experimental|Group 1 - Viremic / Non-cirrhotic|13 obese and insulin resistant, non-cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with chronic hepatitis C (HCV RNA positive) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who are naive to antiviral therapy, relapsed or not responded to antiviral therapy.
3261896|NCT00755742|Active Comparator|Group 2 - Non-viremic / Non-cirrhotic|13 obese and insulin resistant, non-cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with cured chronic hepatitis C (HCV RNA negative) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who have cleared hepatitis C virus with previous antiviral therapy.
3261897|NCT00755742|Experimental|Group 3 - Viremic / Cirrhotic|13 obese and insulin resistant, cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with chronic hepatitis C (HCV RNA positive) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who are naive to antiviral therapy, relapsed or not responded to antiviral therapy.
3261898|NCT00755742|Active Comparator|Group 4 - Non-viremic / Cirrhotic|13 obese and insulin resistant, cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with cured chronic hepatitis C (HCV RNA negative) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who have cleared hepatitis C virus with previous antiviral therapy
3261899|NCT00755729|Experimental|OCH|fast from midnight the night before surgery, and consume 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
3261900|NCT00755729|No Intervention|FSD|fast from midnight the night before surgery, and no preoperative oral carbohydrate loading
3261901|NCT00755716|Placebo Comparator|Placebo (sugar pill)|Person receives an inactive placebo
3261902|NCT00755716|Active Comparator|Topiramate|Subjects receive 10 weeks of topiramate with a dosage starting at 25 mg per day. At week two (quit date) subjects increase to 50 mg/day and gradually increase to 200 mg/day for a total time of 10 weeks.
3261964|NCT00755287|Active Comparator|insulin glargine|insulin glargine starting dose 10 IU daily in addition to continued prestudy metformin treatment
3261965|NCT00755287|Experimental|taspoglutide 10 mg|taspoglutide 10 mg once weekly in addition to continued prestudy metformin treatment
3261903|NCT00755716|Active Comparator|Topiramate and Nicotine patch|Subjects receive 10 weeks of topiramate with a dosage starting at 25 mg per day. At week two (quit date) subjects increase to 50 mg/day and gradually increase to 200 mg/day and one week taper for a total time of 10 weeks. On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
3261904|NCT00755703|Experimental|Group 1|There will be 12 subjects in Group 1 that will receive 10e8 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
3261905|NCT00755703|Experimental|Group 2|There will be 12 subjects in Group 2 that will receive 10e9 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
3261906|NCT00755703|Experimental|Group 3|There will be 12 subjects in Group 3 that will receive 10e10 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
3261907|NCT00755703|Placebo Comparator|Experimental: Group 4|There will be 12 subjects in Group 4 that will receive a placebo consisting of buffer administered via intranasal spray on day 0 and day 28 (+/- 4d).
3261908|NCT00755690|Active Comparator|1|"High/ Low Phosphate diet I. A five-day low phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder / A five-day high phosphate diet.~II. A five-day low phosphate diet / A five-day high phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder III. A five-day high phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder / A five-day low phosphate diet.~IV. A five-day high phosphate diet / A five-day low phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder.~V. A five-day low phosphate diet with the addition of a phosphate binder / A five-day low phosphate diet / A five-day high phosphate diet.~VI. A five-day low phosphate diet with the addition of a phosphate binder / A five-day high phosphate diet / A five-day low phosphate diet."
3261909|NCT00755690|Active Comparator|2|High/ Low Phosphate diet
3261910|NCT00755690|Active Comparator|3|High/ Low Phosphate diet
3261911|NCT00755677|Other|pulses|Interventional. Participants are registered sequentially to undergo daily consumption of pulses for eight weeks
3261912|NCT00755664|Active Comparator|Low-dose complex B-vitamins|Intervention group receives Low-dose complex B-vitamins every day. Low-dose complex B-vitamins contain 400µg of folic acid, 2mg of vitamin B6, 10µg of vitamin B12 and 50mg vitamin C. Daily supplementation lasts for 12 months
3261913|NCT00755664|Placebo Comparator|Vitamin C|Control group receives Vitamin C (50mg)every day. Daily supplementation lasts for 12 months.
3261914|NCT00755651|Experimental|H Pipelle|Endometrial sample obtained using the H Pipelle
3261915|NCT00755651|Active Comparator|Pipelle|Endometrial sample obtained with standard Pipelle
3261916|NCT00755638|Experimental|single|8 subjects (6 active and 2 placebo)
3261917|NCT00755599|Active Comparator|1|Vaginal speculum examinations done without stirrups.
3261918|NCT00755599|Active Comparator|2|Speculum examination with feet in stirrups.
3261919|NCT00755586|Experimental|A|
3261920|NCT00755586|Experimental|B|
3261921|NCT00755586|No Intervention|C|
3261922|NCT00755573|Active Comparator|Pregabalin|Pregabalin 300 mg - 600 mg BID
3261923|NCT00755573|Placebo Comparator|Placebo|Placebo arm
3261924|NCT00755560|Active Comparator|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
3261925|NCT00755560|Placebo Comparator|Placebo|Placebo BID for 15 days
3261926|NCT00755547|Experimental|High Intensity|70-85% of peak oxygen uptake for 30 min 3-5 days/week.
3261927|NCT00755547|Experimental|Low Intensity|40-55% of peak oxygen uptake for 60 min 3-5 days/week
3261928|NCT00755547|No Intervention|Sedentary Control|Regular activities of daily living for 6 months
3261929|NCT00755534|Experimental|1|Irinotecan+Erbitux -> XELOX+Erbitux
3261930|NCT00755534|Experimental|2|XELOX+Erbitux ->Irinotecan+Erbitux
3261931|NCT00755521|No Intervention|B|
3261932|NCT00755521|Experimental|A|adding Etoricoxib to the basic therapeutic regimen
3261933|NCT00755508|Experimental|Ramelteon 4 mg QD and Gabapentin 400 mg QD|
3261934|NCT00755508|Experimental|Ramelteon 8 mg QD and Gabapentin 800 mg QD|
3261935|NCT00755508|Experimental|Ramelteon 8 mg QD and Gabapentin Placebo QD|
3261936|NCT00755508|Active Comparator|Gabapentin 800 mg QD|
3261937|NCT00755508|Placebo Comparator|Placebo|
3261938|NCT00755495|Experimental|Ramelteon 8 mg QD and Doxepin 3 mg QD|
3261939|NCT00755495|Experimental|Ramelteon 8 mg QD and Doxepin Placebo QD|
3261940|NCT00755495|Active Comparator|Ramelteon Placebo QD and Doxepin 3 mg QD|
3261941|NCT00755495|Placebo Comparator|Placebo|
3261942|NCT00755482|Active Comparator|1|Subjects were given Aquamin F
3261943|NCT00755482|Placebo Comparator|2|Subjects were given a maltodextran placebo
3261944|NCT00755469|Experimental|1|
3261945|NCT00755456|Active Comparator|A|
3261946|NCT00755456|Experimental|B|
3261947|NCT00755443|Experimental|2|
3261948|NCT00755443|Placebo Comparator|1|Bare metal stent
3261949|NCT00755417|Experimental|G-ER 1200 mg|Gabapentin extended-release (G-ER) 1200 mg
3261950|NCT00755417|Experimental|G-ER 1800 mg|Gabapentin extended-release (G-ER) 1800 mg
3261951|NCT00755417|Placebo Comparator|Sugar Pill|Placebo 1200 mg or 1800 mg
3261952|NCT00755404|Active Comparator|A|
3261953|NCT00755404|Experimental|B|
3261954|NCT00755391|Placebo Comparator|supportive psychotherapy|supportive psychotherapy: 14 sessions
3261955|NCT00755391|Active Comparator|cognitive behavior therapy|cognitive behavior therapy: 14 sessions
3261956|NCT00755378|Experimental|1|
3261957|NCT00755378|Placebo Comparator|2|
3261958|NCT00755352|Experimental|1|pravastatin tablets and Welchol tablets
3261959|NCT00755352|Placebo Comparator|2|pravastatin tablets and Welchol placebo tablets
3261960|NCT00755326|Active Comparator|HLXL|Active herb
3261961|NCT00755326|Placebo Comparator|Placebo|Placebo HLXL
3261962|NCT00755300||1|Standard Total Knee Replacement
3261963|NCT00755300||2|Computer Guided Knee Replacement
3262079|NCT00754377||Comparison group|Received a different curriculum.
3261966|NCT00755287|Experimental|taspoglutide 10 mg/20 mg|taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued prestudy metformin treatment
3261967|NCT00755274|Experimental|Group 1: Primed|Have received 2 or more lifetime Flu Vaccinations Prior to Visit 1
3261968|NCT00755274|Experimental|Group 2: Naive/Inadequately Primed|Never Received or Received Only 1 Lifetime Flu Vaccination Prior to Visit 1
3261969|NCT00755261|Experimental|Avastin and Doxorubicin|Patients will be treated with Avastin 15 mg/kg IV infusion plus doxorubicin 60 mg/M2 (body surface area) IV 6-hour infusion on Day 1 of each 21-day treatment cycle. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
3261970|NCT00755248||1|Pts undergoing CABG or OPCAB
3261971|NCT00755235|Experimental|1|Participants will receive depression care management by secure messaging.
3261972|NCT00755235|No Intervention|2|Participants will receive their usual care, with no additional education or care management services.
3261973|NCT00755222|Experimental|AA4500|Clostridial collagenase for injection
3261974|NCT00755222|Placebo Comparator|Placebo|
3261975|NCT00755209|Placebo Comparator|Transamin|"Drug: tranexamic acid~Loading 1 gram (~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours"
3261976|NCT00755196|Active Comparator|1|AN2728 Ointment, 5%
3261977|NCT00755196|Placebo Comparator|2|AN2728 Ointment vehicle
3261978|NCT00755183|Experimental|testosterone ophthalmic solution|testosterone ophthalmic solution 0.03%
3261979|NCT00755183|Placebo Comparator|vehicle|vehicle of testosterone ophthalmic solution
3261980|NCT00755170|Experimental|1|Vinorelbine metronomic + bevacizumab
3261981|NCT00755157|Experimental|1|Docetaxel(metronomic)/Bevacizumab
3261982|NCT00755144|Experimental|1|ROCC
3261983|NCT00755144|Active Comparator|2|LCS
3261984|NCT00755131|Experimental|Training Group|Postinfarction patients undergo 6-month exercise-based Cardiac Rehabilitation Program
3261985|NCT00755131|No Intervention|Control Group|Postinfarction patients NOT undergoing 6-months exercise-based Cardiac Rehabilitation program
3261986|NCT00755118|Experimental|1|LoHP/AIO/Avastin->CPT-11/AIO/Erbitux
3261987|NCT00755092|Active Comparator|1|Doula for Nulliparous women
3261988|NCT00755092|Active Comparator|2|Doula for Multiparous women
3261989|NCT00755079|Placebo Comparator|Arm 1|group of persons with spinal cord injury will receive blinded placebo capsule
3261990|NCT00755079|Experimental|Arm 2|group of persons with spinal cord injury will receive blinded beta-2 adrenergic agonist capsule
3261991|NCT00755066|Experimental|F|Fluticasone propionate 200 µg intranasal
3261992|NCT00755066|Placebo Comparator|P|Placebo intranasal spray
3261993|NCT00755053|Active Comparator|Clotrimazole tablet (Canesten, BAY-B5097)|Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
3261994|NCT00755053|Experimental|Clotrimazole ovule (Canesten, BAY-B5097)|Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
3261995|NCT00755040|Experimental|Ocular Cyclosporine (Restasis)|Patients receive cyclosporine ophthalmic emulsion (Restasis®) drops in each eye twice daily for up to 1 year after transplant.
3261996|NCT00755040|Placebo Comparator|Placebo|Patients receive placebo ophthalmic drops in each eye twice daily for up to 1 year after transplant.
3261997|NCT00755014|Experimental|2|Forty subjects are randomized to a group (n=20) that consumed red wine (100 ml) or a group (n=20) that consumed beer (250 ml) daily for 3 weeks
3261998|NCT00755001||with Plasma HA|BiHapro Hip stem with PPS Ti + Plasma HA
3261999|NCT00755001||with BoneMaster HA|BiHapro Hip stem with PPS Ti + BoneMaster HA
3262000|NCT00754988|Placebo Comparator|Placebo|Once daily oral administration of placebo (matching sitagliptin). Once weekly sc injection of placebo (matching taspoglutide). Continued treatment with metformin at prescribed doses.
3262001|NCT00754988|Active Comparator|Sitagliptin|Once daily oral administration of 100 mg of sitagliptin. Once weekly sc injection of placebo (matching taspoglutide). Continued treatment with metformin at prescribed doses.
3262002|NCT00754988|Experimental|Taspoglutide 10 mg|Once weekly subcutaneous (sc) injection of 10 mg of taspoglutide. Once daily oral administration of placebo (matching sitagliptin). Continued treatment with metformin at prescribed doses.
3262003|NCT00754988|Experimental|Taspoglutide up-titrated to 20 mg|Once weekly sc injection of 10 mg of taspoglutide for the first 4 weeks, then up-titrated to once weekly sc injection of 20 mg of taspoglutide from week 5 onwards. Once daily oral administration of placebo (matching sitagliptin). Continued treatment with metformin at prescribed doses.
3262004|NCT00754975|Experimental|I|JACTAX LD DES
3262005|NCT00754975|Active Comparator|II|TAXUS™ Libertè™ DES
3262006|NCT00754949|Experimental|1|
3262007|NCT00754949|Active Comparator|2|
3262008|NCT00754949|Active Comparator|3|
3262009|NCT00754936|Experimental|Escitalopram|12 week open label with 2 week placebo period (14 weeks total)
3262010|NCT00754923|Experimental|Treatment: Sorafenib|Sorafenib will be administered at a dose of 400 mg taken twice daily, continuously on a 28 day cycle.
3262011|NCT00754910||Group 1|Patients receive porfimer sodium IV over 3-5 minutes and undergo irradiation with red light 48 hours later. Patients receive 2 more treatments at 2-day intervals.
3262012|NCT00754897||1|"We will do a database search to identify children less than 1 year of age that have undergone inguinal hernia surgery during the years of 1999-2007, and children who have had inguinal hernia surgery between the ages of 1 and 3 years during the years 1999-2007.~We will then do a telephone interview of the parents of these children to determine if there are siblings that are within three years of age and have not have any exposure to anesthetics agents or sedatives before their 3rd birthday."
3262013|NCT00754884|Experimental|A|200 U.I. of intranasal salmon calcitonin
3262014|NCT00754884|Placebo Comparator|B|intranasal saline solution and glycerol
3262015|NCT00754871|Experimental|Arm 1|
3262016|NCT00754871|Experimental|Arm 2|
3262017|NCT00754871|Experimental|Arm 3|
3262018|NCT00754871|Experimental|Arm 4|
3262019|NCT00754858|Experimental|belotecan and Cisplatin|belotecan 0.5 mg/m2 and Cisplatin 60mg/m2
3262078|NCT00754377||PBLI Curriculum group|To evaluate preliminary data on a PBLI curriculum grounded on QI system projects.
3262020|NCT00754845|Experimental|Arm I|Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
3262021|NCT00754845|Placebo Comparator|Arm II|Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
3262022|NCT00754832|Experimental|1|Period 1 with Ginseng therapy intervention; Washout Period with no drug; Period 2 with placebo
3262023|NCT00754832|Experimental|2|Period 1 with placebo; Washout period with no drug; Period 2 with ginseng therapy intervention
3262024|NCT00754819|Active Comparator|1|Colchicine 1mg daily oral
3262025|NCT00754819|Placebo Comparator|2|Placebo 1 capsule daily oral
3262026|NCT00754793|Active Comparator|1|escitalopram 10mg - 30mg daily
3262027|NCT00754793|Placebo Comparator|2|
3262028|NCT00754767|Experimental|Arm I|Patients receive oral L-carnitine L-tartrate twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.
3262029|NCT00754767|Placebo Comparator|Arm II|Patients receive oral placebo twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.
3262030|NCT00754754|Experimental|Brain Retraction Monitoring Sensor|
3262031|NCT00754741|No Intervention|Usual care|All Physicians are given limited training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software when they see patients assigned to this arm
3262032|NCT00754741|Active Comparator|Adherence|
3262033|NCT00754741|Active Comparator|Adherence Plus|
3262034|NCT00754728|Experimental|I|
3262035|NCT00754715|Experimental|AZD2516|
3262036|NCT00754715|Placebo Comparator|Placebo|
3262037|NCT00754702|Experimental|1|Vinorelbine metronomic/Lapatinib
3262038|NCT00754689|Active Comparator|Arm 1|Metformin 500mg twice daily (bid) + placebo
3262039|NCT00754689|Active Comparator|Arm 2|Metformin 1000mg bid + placebo
3262040|NCT00754689|Active Comparator|Arm 3|Rimonabant 20mg once daily (od) + placebo
3262041|NCT00754689|Experimental|Arm 4|Rimonabant 10mg bid (from week 2) in combination with metformin 500mg bid
3262042|NCT00754689|Experimental|Arm 5|Rimonabant 10mg bid (from week 2) in combination with metformin 1000mg bid
3262043|NCT00754663|Active Comparator|1|exercise training
3262044|NCT00754663|Placebo Comparator|2|control arm: normal behavior, no additional exercise will be advised
3262045|NCT00754650|Experimental|Bevacizumab 15 mg/kg|Participants received bevacizumab 15 mg/kg intravenously on Day 1 of each 3-week cycle for 8 cycles.
3262046|NCT00754637||510(k) Inclusion Criteria|Any person meeting the inclusion criteria for the device may be included in this study. These patients tend to be those seeking relief from painful or debilitating knee joint disease.
3262047|NCT00754624|Experimental|TI Inhalation Powder|Technosphere® Insulin Inhalation Powder
3262048|NCT00754585||I|"All participants will perform the five Chair Support tasks: (1) quiet standing, sitting, (2) upper back unsupported, (3) sitting, upper back unsupported with Logic Back in place, (4) sitting in a standard ergonomic chair, and (5) sitting in a standard ergonomic chair with Logic Back in place. Aside from the Quiet Standing trials which will be performed first, the order of Chair Support will be randomized. Participants will perform the Chair Support task for 30 minutes while quietly watching a movie DVD of their choice. The DVDs provided will the light in content without a lot of suspense or emotion. Data will be collected for the final two minutes of each 30-minute trial."
3262049|NCT00754572|Experimental|1|
3262050|NCT00754559|Experimental|Tocilizumab|
3262051|NCT00754546|Active Comparator|Arformoterol tartrate|Bronchodilator therapy with arformoterol solution 15 mcg
3262052|NCT00754546|Placebo Comparator|Normal saline|Placebo using normal saline
3262053|NCT00754533|Other|1|Continuous training
3262054|NCT00754533|Other|2|Interval training
3262055|NCT00754520|Experimental|Ceramic On Metal|This arm utilizes the ceramic on metal articulation using the M2a-38™ mm cup.
3262056|NCT00754520|Active Comparator|Metal on Metal|This arm utilizes the metal on metal articulation using M2a-38™ mm cup.
3262057|NCT00754507|Experimental|1|colesevelam tablets and atorvastatin tablets
3262058|NCT00754507|Placebo Comparator|2|colesevelam HCl placebo tablets and atorvastatin tablets
3262059|NCT00754494|Experimental|Erlotinib Hydrochloride (25 mg)|Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
3262060|NCT00754494|Experimental|Erlotinib Hydrochloride (50 mg)|Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
3262061|NCT00754494|Experimental|Erlotinib Hydrochloride (100 mg)|Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
3262062|NCT00754481|Active Comparator|1|
3262063|NCT00754481|Experimental|2|
3262064|NCT00754468|Experimental|Group 1: Cryo Spray Ablation|cryo spray ablation applied to healthy tissue 4 cycles x 10 seconds
3262065|NCT00754468|Experimental|Group 2: Cryo Spray Ablation|cryo spray ablation applied to healthy tissue 2 cycles x20 seconds
3262066|NCT00754455|Experimental|Low dose|
3262067|NCT00754455|Experimental|Mid dose|
3262068|NCT00754455|Experimental|High dose|
3262069|NCT00754455|Placebo Comparator|Placebo|
3262070|NCT00754442|Active Comparator|teriparatide control|control subject
3262071|NCT00754442|Experimental|Teriparatide Patient|Patient with secondary hyperparathyroidism
3262072|NCT00754429|Experimental|A|Losartan 50mg qd for 30 weeks, if blood pressure > 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.
3262073|NCT00754429|Active Comparator|B|Amlodipine 5 mg q.d for 30 weeks, if blood pressure > 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.
3262074|NCT00754416||S.E.S prosthesis|Consecutive series of patients with a S.E.S prosthesis.
3262075|NCT00754403|Experimental|Pioglitazone 30 mg QD + Metformin 1000 mg QD|
3262076|NCT00754403|Active Comparator|Metformin 1000 mg QD|
3262077|NCT00754390|Experimental|Overall Study|Participants consumed 4 experimental diets for 4 weeks each in randomized order
3262080|NCT00754364|Experimental|Pemetrexed/Carboplatin|Pemetrexed (500 mg/m2 infusion) plus Carboplatin (AUC5 infusion)
3262081|NCT00754364|Active Comparator|Gemcitabine|Gemcitabine 1250 mg/mq
3262082|NCT00754351|Experimental|1|Bevacizumab->Docetaxel->Gemcitabine
3262083|NCT00754338|Active Comparator|Phase1 - Arm 1|
3262084|NCT00754338|Active Comparator|Phase1 - Arm 2|
3262085|NCT00754338|Active Comparator|Phase 2 - Arm 1|
3262086|NCT00754338|Active Comparator|Phase 2 - Arm 2|
3262087|NCT00754325|Active Comparator|Arm 1 (Dasatinib +Fulvestrant)|
3262088|NCT00754325|Active Comparator|Arm 2 (Fulvestrant)|
3262089|NCT00754312|Experimental|1|ER positive
3262090|NCT00754312|Experimental|2|ER negative and/or PR negative histology
3262091|NCT00754312|Experimental|3|triple negative histology (for ER, PR, HER-2)
3262092|NCT00754286|Experimental|Aromatherapy|Participants will be given aromatherapy wand at the onset of their chemotherapy treatment.
3262093|NCT00754286|Placebo Comparator|Placebo|Participants will be given the placebo wand at the onset of their chemotherapy treatment. Placebo wands will look identical to the scented wands but will not contain a scent.
3262094|NCT00754273||1|PAL samples collected for pneumonia evaluation
3262095|NCT00754260|Experimental|Caffiene reduction group|Caffeine reduction group Intervention is to counseling to reduce caffeine intake
3262096|NCT00754260|No Intervention|No caffeine reduction group|No Caffeine reduction group Intervention is to not counsel regarding caffeine intake
3262097|NCT00754247|Experimental|Regimen A|0.5% hydrocortisone, silicone, vitamin E lotion
3262098|NCT00754247|Experimental|Regimen B|Onion extract gel
3262099|NCT00754247|Placebo Comparator|Regimen C|Cetearyl alcohol lotion
3262100|NCT00754234|Experimental|MyPyramid Menu Days 1-7|Iron absorption measured from one of the 7 different USDA MyPyramid menus for 1 day each, in randomized order for each subject, separated by 2 weeks
3262101|NCT00754221|Experimental|1|
3262102|NCT00754208|Other|methylpehnidate|open-label treatment with methylphenidate
3262103|NCT00754195|Active Comparator|1|Insertion distance of thoracic epidural catheter: 3 cm
3262104|NCT00754195|Active Comparator|2|Insertion distance of thoracic epidural catheter: 5 cm
3262105|NCT00754195|Active Comparator|3|Insertion distance of thoracic epidural catheter: 7 cm
3262106|NCT00754182|Experimental|A|Patients underwent thyroidectomy, emithyroidectomy, parathyroidectomy sutured with synthetic glue
3262107|NCT00754182|Active Comparator|B|Patients underwent thyroidectomy, emithyroidectomy, parathyroidectomy sutured with subcuticular suture
3262108|NCT00754156|Active Comparator|1 ABRA plus KCI ABThera or KCI VAC|ABRA Abdominal Wound Closure System in combination with KCI ABThera or KCI VAC
3262109|NCT00754156|Active Comparator|KCI V.A.C. Therapy or ABThera Alone|KCI V.A.C. Therapy ABThera Alone
3262110|NCT00754143|Placebo Comparator|A|Placebo
3262111|NCT00754143|Experimental|B|FG-3019 5 mg/kg
3262112|NCT00754143|Experimental|C|FG-3019 10 mg/kg
3262113|NCT00754130|Experimental|Placebo/MK-0941 20mg|Participants received Placebo during Period 1 and MK-0941 20 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
3262114|NCT00754130|Experimental|MK-0941 5mg/Placebo|Participants received MK-0941 5 mg during Period 1 and Placebo during Period 2. There was a washout period of at least 8 days between the two treatment periods.
3262115|NCT00754130|Experimental|MK-0941 5mg/MK-0941 20mg|Participants received MK-0941 5 mg during Period 1 and MK-0941 20 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
3262116|NCT00754130|Experimental|Placebo/MK-0941 40mg|Participants received Placebo during Period 1 and MK-0941 40 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
3262117|NCT00754130|Experimental|MK-0941 10mg/Placebo|Participants received MK-0941 10 mg during Period 1 and Placebo during Period 2. There was a washout period of at least 8 days between the two treatment periods.
3262118|NCT00754130|Experimental|MK-0941 10mg/MK-0941 40mg|Participants received MK-0941 10 mg during Period 1 and MK-0941 40 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
3262119|NCT00754117||All patients|All patients
3262120|NCT00754104|Experimental|A|
3262121|NCT00754078|Other|1|anal cancer patients treated with tomotherapy and chemotherapy
3262122|NCT00754065|Experimental|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one capsule BAY86-5027 [estradiol valerate (EV) / dienogest (DNG)] for 26 days, followed by one capsule placebo for 2 days (28 days total per cycle) for 13 treatment cycles (treatment encapsulated)
3262123|NCT00754065|Active Comparator|Ortho Tri-Cyclen Lo|Daily oral administration of one capsule Ortho Tri-Cyclen Lo [Ethinylestradiol (EE)/ Norgestimate (NGM)] for 21 days, followed by one capsule placebo for 7 days (28 days total per cycle) for 13 treatment cycles (treatment encapsulated)
3262124|NCT00754052|Active Comparator|1|
3262125|NCT00754052|Active Comparator|2|
3262126|NCT00754052|Placebo Comparator|3|
3262127|NCT00754039|Experimental|1|Welchol + TriCor
3262128|NCT00754039|Placebo Comparator|2|Welchol + placebo
3262129|NCT00754026|Active Comparator|1|
3262130|NCT00754026|Active Comparator|2|
3262131|NCT00754013|Active Comparator|Donepezil|
3262132|NCT00754013|Placebo Comparator|Placebo|
3262133|NCT00754000||Cohort 1|All patients in study
3262134|NCT00753987|Experimental|1|
3262135|NCT00753974||biological specimen|Biological specimen is taken from cardiovascular procedures that would have been discarded
3262136|NCT00753961|Active Comparator|1|fermented dairy product
3262137|NCT00753961|Placebo Comparator|2|non fermented acidified dairy product.
3262138|NCT00753948|Experimental|Arm 1|Individuals with chronic tetraplegia
3262139|NCT00753948|Active Comparator|Arm 2|Individuals with diagnosed mild asthma
3262140|NCT00753948|Placebo Comparator|Arm 3|Neurologically intact, otherwise healthy, age-matched control
3262141|NCT00753935|Experimental|Enteric-coated aspirin|patients received enteric-coated aspirin 81 mg qd for 2 weeks
3262220|NCT00753350|Experimental|1|Sensate™ anti-Obesity device
3262142|NCT00753935|Active Comparator|Chewable aspirin|Patients received chewable aspirin 81 mg qd for 2 weeks
3262143|NCT00753922|Other|Primary Augmentation|The Augmentation cohort will include patients who have post-lactational mammary involution or wish general breast enlargement.
3262144|NCT00753922|Other|Primary Reconstruction|"The Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity.~Congenital deformities will include deformities of the breast itself as well as skeletal abnormalities reflected in breast deformity or asymmetry."
3262145|NCT00753922|Other|Revison Augmentation|Patients in this cohort will have had previous breast augmentation with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast augmentation surgery.
3262146|NCT00753922|Other|Revision Reconstruction|Patients in this cohort will have had previous breast reconstruction with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast reconstruction surgery.
3262147|NCT00753909|Experimental|1|Paclitaxel/Carboplatin/Bevacizumab
3262148|NCT00753896|Experimental|1|
3262149|NCT00753883|Active Comparator|1|simvastatin 20 mg/qd for 8 weeks, and then add on ezetrol 10mg (if ldl-c . 160mg/dl) for another 8 weeks.
3262150|NCT00753883|Active Comparator|2|ezetrol 10 mg/qd for 8 weeks, and then add on simvastatin 20 mg qd (if ldl-c . 160mg/dl) for another 8 weeks
3262151|NCT00753870|Experimental|A|Otherwise healthy smokers
3262152|NCT00753857|Experimental|1|Participants received 2 ads for drugs to reduce cardiovascular risk with drug facts boxes second pages.
3262153|NCT00753857|Active Comparator|2|Participants receive the same 2 advertisements for drugs to reduce cardiovascular risk with the standard second page (i.e., brief summary)
3262154|NCT00753831|Experimental|1|Aurosling
3262155|NCT00753818|Experimental|1|
3262156|NCT00753818|Experimental|2|
3262157|NCT00753818|Experimental|3|
3262158|NCT00753818|Other|4|Control
3262159|NCT00753792|Active Comparator|1|methylprednisolone 1.000 mg/day intravenous administration during three days + placebo of methylprednisolone orally administered
3262160|NCT00753792|Experimental|2|methylprednisolone 1.250 mg/day orally administered during three days + placebo of methylprednisolone intravenous administered
3262161|NCT00753779|Experimental|1|colesevelam HCl Tablets and simvastatin tablets
3262162|NCT00753779|Placebo Comparator|2|simvastatin and Welchol placebo
3262163|NCT00753766|Experimental|Multifactorial intervention|Mulitfactorial intervention - addressing glucose, blood pressure, lipids, smoking, nutrition and exercise.
3262164|NCT00753766|No Intervention|Usual care|Control group
3262165|NCT00753740|Experimental|12mg/m2/dose|12mg per meter squared per dose
3262166|NCT00753740|Experimental|15mg/m2/dose|15mg per meter squared per dose
3262167|NCT00753740|Placebo Comparator|Placebo|5% dextrose infusion (placebo)
3262168|NCT00753714|Experimental|A|Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.
3262169|NCT00753714|Placebo Comparator|B|Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.
3262170|NCT00753688|Placebo Comparator|PLACEBO|matching placebo 800 mg once daily orally
3262171|NCT00753688|Experimental|PAZOPANIB|800 mg once daily orally
3262172|NCT00753675|Experimental|A|Vandetanib 300 mg as a once daily oral dose, from Day 1
3262173|NCT00753675|Experimental|B|Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy)
3262174|NCT00753675|Placebo Comparator|C|Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy).
3262175|NCT00753662|Active Comparator|1|15 patients in group 1 will be treated with 1Hz frequency
3262176|NCT00753662|Active Comparator|2|15 patients in group 2 will be treated with 1Hz frequency 10Hz
3262177|NCT00753662|Sham Comparator|3|15 patients in group 3 will be treated with SHAM (1Hz/10Hz)
3262178|NCT00753649|Experimental|Aboriginal infants group|
3262179|NCT00753649|Active Comparator|Other Non-Aboriginal infants|
3262180|NCT00753636|Experimental|Isradipine|
3262181|NCT00753623|Active Comparator|Ramelteon first, placebo second|"In a crossover design, a subject will be first assigned to the ramelteon arm and then switched over to the placebo arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night.The ramelteon and placebo will be blinded by the central pharmacy.~The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long."
3262214|NCT00753415|Experimental|Part B: V934 HD(5)+V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
3262215|NCT00753402|Placebo Comparator|A|IV Endotoxin plus saline vehicle (placebo)
3262216|NCT00753402|Active Comparator|B|IV Endotoxin plus IV epinephrine
3262217|NCT00753389||1|n.a.
3262182|NCT00753623|Placebo Comparator|Placebo first, ramelteon second|"In a crossover design, a subject will be first assigned to the placebo arm and then switched over to the ramelteon arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night. The ramelteon and placebo will be blinded by the central pharmacy.~The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long."
3262183|NCT00753597|Experimental|1|Receiving active treatment
3262184|NCT00753571|Active Comparator|1|1,CTG,po
3262185|NCT00753571|Placebo Comparator|2|
3262186|NCT00753558|Placebo Comparator|2|Oral solution of 0.45% saline and oral solution of H2O & saccharine. Oral gel composed of mineral oil, gelatine powder, pectin, sodium carboxymethylcellulose, polyethylene
3262187|NCT00753558|Active Comparator|1|Oral solution and buccal gel of gentamicin and polymyxin E
3262188|NCT00753545|Experimental|1|AZD2281
3262189|NCT00753545|Placebo Comparator|2|matching placebo
3262190|NCT00753532|Placebo Comparator|MRI(+ve),|121 volunteers in MRI(+ve) cohort were randomized into two groups to receive either 200mg palm vitamin E (tocotrienols) softgel capsules or a identical looking placebo twice daily. 62 volunteers received 200mg palm vitamin E (tocotrienols) and the remaining 59 received placebo. They were followed up every 3 months for a period of 2 years for their blood biochemistry profile and MRI of the brain was conducted at baseline, 12 months and 24 months..
3262191|NCT00753532|Placebo Comparator|MRI(-ve)|120 volunteers in MRI(-ve) cohort were randomized into two groups to receive either 200mg palm vitamin E (tocotrienols) softgel capsules or a identical looking placebo twice daily. 63 volunteers received 200mg palm vitamin E (tocotrienols) and the remaining 57 received placebo. They were followed up every 3 months for a period of 1 year for their blood biochemistry profile and MRI of the brain was conducted at baseline and 12 months.
3262192|NCT00753519|Experimental|Real iTBS|iTBS is a novel form of excitatory rTMS that may induce larger and longer lasting changes that standard rTMS. iTBS consists of bursts of 3 pulses at 50 Hz repeated at 200 msec intervals. The 2 sec trains were repeated 20 times every 10 sec. iTBS was applied to the primary motor and the dorsolateral prefrontal cortex bilaterally.
3262193|NCT00753519|Sham Comparator|Sham iTBS|The sham coil was placed in the same areas, and made a similar sound as the rTMS but was without a magnetic pulse.
3262194|NCT00753506|Active Comparator|Artemisinin|100 mg artemisinin capsule
3262195|NCT00753506|Placebo Comparator|Placebo|Identical looking placebo capsule
3262196|NCT00753493|Experimental|1|This is a one arm pharmacokinetic and safety study.
3262197|NCT00753467|Experimental|1|IFN-γ 1b monotherapy: 200 micro-grams daily for 30 days
3262198|NCT00753467|Experimental|2|IFN-γ 1b 200 micro-grams daily) combination therapy with Adefovir dipivoxil (10 mg daily) for 30 days
3262199|NCT00753467|Active Comparator|3|Adefovir dipivoxil monotherapy (10 mg QD) 30 days
3262200|NCT00753454|Experimental|CDP870|Patients having completed the week 34 assessment in C87077 (NCT00580840) or patients having been randomized at Week 18 and having met the pre-defined criteria for flare, will be given the option to enroll in C87084 and receive: 400 mg CZP at Entry, Week 2, and Week 4 followed by 200 mg every two weeks in combination with MTX until the drug is commercially available for the indication of RA in the patient's country or region (or until further notice from UCB).
3262201|NCT00753441|Experimental|A|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
3262202|NCT00753441|Active Comparator|B|Endoscopic biliary stenting using metal stent (completed by duodenal stent, if necessary)
3262203|NCT00753428||Baseline evaluation|Prior to the implementation of the pilot project of giving routine HAART as a method of PMTCT, a minimum of 387 households with children under the age of two will be sampled within each community, for a total of 1,548 households for the first round.
3262204|NCT00753428||Following implementation|Two years after full implementation of the pilot project of giving routine HAART for PMTCT across all sites, a minimum of 387 households with children under the age of two will be sampled within each community, for a total of 1,548 households. [Note: At time of implementation, we used the same sampling frame for each community. Because of the population increased observed in parts of Kafue, the final number of households significantly exceeded the minimum threshold.]
3262205|NCT00753415|Experimental|Part A: V935 LD|Two intramuscular (IM) injections of V935 low dose (LD), 1 given every other week over a 3-week period.
3262206|NCT00753415|Experimental|Part A: V934 LD(3)+V935 LD|Three electroporation (EP) injections of V934 (LD) , 1 given every other week over a 5-week period. Following a 4-week observation period, 2 IM injections of V935 (LD) will be administered, 1 given every other week over a 3-week period.
3262207|NCT00753415|Experimental|Part A: V935 HD|Two IM injections of V935 high dose (HD), 1 given very other week over a 3-week period.
3262208|NCT00753415|Experimental|Part A: V934 HD(3)+V935 HD|Three EP injections of V934 (HD), 1 given every other week over a 5-week period. Following a 4-week observation period, 2 IM injections of V935 (HD) will be administered, 1 given every other week over a 3-week period.
3262209|NCT00753415|Experimental|Part A: V934 HD(5)+V935 HD|Five EP injections of V934 (HD), 1 given every other week over a 9-week period. Following a 4-week observation period, 2 IM injections of V935 (HD) will be administered, 1 given every other week over a 3-week period.
3262210|NCT00753415|Experimental|Part B: V935 LD/V934 Booster|Participants who completed Part A could enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster were administered, 1 given every 2 weeks.
3262211|NCT00753415|Experimental|Part B: V934 LD(3)+V935 LD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
3262212|NCT00753415|Experimental|Part B: V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
3262213|NCT00753415|Experimental|Part B: V934 HD(3)+V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
3262218|NCT00753363|Experimental|Arm 1|6 months of aerobic exercise training
3262219|NCT00753363|Experimental|Arm 2|6 months of weight loss
3262221|NCT00753337|Experimental|Assurant Cobalt Iliac Stent|Assurant® Cobalt Iliac Stent System
3262222|NCT00753324|Experimental|Routine three-drug antiretroviral prophyalxis|Cohort of 160 HIV-infected women, approached at > 28 weeks gestation and initiated on routine HAART for the purposes of PMTCT.
3262223|NCT00753324|No Intervention|Control arm|A cohort of 160 women will be enrolled from the control clinics, from 28 weeks gestation onward. At these sites, the antenatal zidovudine will be offered, with provision of single-dose nevirapine for self-administration in labor. This practice is in accordance with the current standard of care recommended by the Zambian National Guidelines for PMTCT.
3262224|NCT00753311|Active Comparator|Rizatriptan|Patients with migraine with and without aura will be enrolled and randomly provided with study drug (rizatriptan 10 mg MLT or placebo, ratio 1:1). Patients were encouraged to take migraine medication as soon as their migraine headache became moderate or severe. If the moderate or severe migraine headache persisted 2 h after dosing, or recurred within 24 h, patients had the option of taking their own rescue medication but triptans and ergot derivatives were prohibited for 24 h after study medication intake.
3262225|NCT00753311|Placebo Comparator|placebo|Patients who met all the study entry criteria were enrolled and randomly allocated to receive either rizatriptan 10 mg wafer or placebo (ratio 1:1).Patients were encouraged to take migraine medication as soon as their migraine headache became moderate or severe. If the moderate or severe migraine headache persisted 2 h after dosing, or recurred within 24 h, patients had the option of taking their own rescue medication but triptans and ergot derivatives were prohibited for 24 h after study medication intake.
3262226|NCT00753298|Experimental|LoFric Primo (POBE) single-use urinary catheter|
3262227|NCT00753298|Active Comparator|LoFric Primo (PVC) single-use urinary catheter|
3262228|NCT00753285|Experimental|Renal Denervation|
3262229|NCT00753272|Experimental|FluNG Group|subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
3262230|NCT00753272|Active Comparator|Fluarix Group|subjects received 2 doses (1 dose per season) of Fluarix™ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
3262231|NCT00753259|Experimental|AF Clinic|
3262232|NCT00753259|Active Comparator|Care as Usual|
3262233|NCT00753246|Placebo Comparator|Arm B|adults with TMZ, RT
3262234|NCT00753246|Experimental|Arm A|adults with TMZ, RT, nimotuzumab
3262235|NCT00753220|Experimental|VDC2008|Cryoablation of prostate followed by dendritic cell injection (dose of 2.5 x 10^7, 7.5 x 10^7, or 1.0 x 10^8 cells depending on assigned cohort) into prostate and low dose cyclophosphamide therapy (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles [1 cycle = 4 weeks] starting Week 2 after cryoablation and going to Week 26)
3262236|NCT00753207|Experimental|Lapatinib and Epirubicin|Fixed dose of lapatinib in combination with escalating dose of epirubicin.
3262237|NCT00753194||1|"Newborns that show a Pass On the newborn hearing screening program before hospital discharge"
3262238|NCT00753194||2|"Newborns that show a fail and will be retested in 15 days."
3262239|NCT00753181|Experimental|A1|Diabetes Meal Plan with Experimental Diabetes-Specific nutritional shake
3262240|NCT00753181|Active Comparator|A2|Usual diet
3262241|NCT00753181|Experimental|A3|Diabetes Meal Plan with Experimental Diabetes-Specific Nutritional Shake, diabetes specific Cereal, and diabetes specific snack bars.
3262242|NCT00753168|Experimental|1|OT-730 ophthalmic solution
3262243|NCT00753168|Active Comparator|2|timolol maleate ophthalmic solution
3262244|NCT00753168|Placebo Comparator|3|placebo eye drops
3262245|NCT00753142|Active Comparator|Subjects with ketosis-prone diabetes|Obese African-Americans with type 2 diabetes with history of diabetic ketoacidosis (DKA)
3262246|NCT00753142|Active Comparator|Subjects with ketosis-resistant diabetes|Obese African-American with type 2 diabetes with hyperglycemia but without ketosis
3262247|NCT00753142|Active Comparator|Control|Obese African-American nondiabetic subjects
3262248|NCT00753129|Active Comparator|1|Start with turning to prone position without head elevation, after 2 hours 30° head elevation, after 2 hours back to PP without head elevation.
3262249|NCT00753129|Active Comparator|2|Start with turning to prone position with 30° head elevation, after 2 hours PP without head elevation, after 2 hours back to 0° PP.
3262250|NCT00753103|Experimental|1|Patients with active vasculitis who receive infliximab in addition to standard immunosuppressive therapy
3262251|NCT00753103|Active Comparator|2|Patients with active ANCA associated vasculitis who receive standard immunosuppression but no infliximab
3262252|NCT00753090|Experimental|VG DDRP|This arm utilizes the Vanguard™ Deep Dish Rotating Platform Knee.
3262253|NCT00753090|Active Comparator|VG CR|This arm utilizes the Vanguard™ Cruciate Retaining Knee.
3262254|NCT00753064|Active Comparator|AScVS|a clinical scoring system for dose requirement for AScVS is evolved based on sweating, pulse rate, respiratory rate, blood pressure, CNS effects and presence of priapism. Computed doses were given according to clinical grading as intravenous bolus slowly.
3262255|NCT00753064|Active Comparator|Prazosin.|Prazosin therapy Prazosin (30 micrograms/Kg/dose): 500 micrograms for pediatric patient, and 1mg for adult patients) will be given every 3 hourly orally till complete recovery.
3262256|NCT00753064|Active Comparator|AScVS + Prazosin|Combination AScVS and Prazosin therapy In this group, AScVS therapy will be given as mentioned in AScVS therapy group and in addition, prazosin (500 micrograms for pediatric patient and 1mg for adult patients,30 micrograms/Kg/dose) every 3 hourly will be given.
3262257|NCT00753051|Active Comparator|1.|clozapine as the main agent and it will be adjuncted by haloperidol
3262258|NCT00753051|Active Comparator|2.|clozapine as the main agent and it will be adjuncted by electroconvulsive therapy
3262259|NCT00753025|Experimental|CD133|
3262260|NCT00753025|Experimental|TNC|
3262261|NCT00753025|Placebo Comparator|Placebo|
3262262|NCT00753012|Experimental|Lisdexamfetamine|"Adults who meet DSM-IV-TR criteria for ADHD.~Group 1 is normotensive adults; Group 1 does not have high blood pressure. Group 2 is primary hypertensive adults; Group 2 does have high blood pressure and is being treated with stable doses of hypertensive medications achieving a blood pressure of <135/85."
3262263|NCT00752999|Experimental|A|150 mg tablet, oral, twice-a-day
3262264|NCT00752999|Placebo Comparator|B|Placebo tablet, oral, twice-a-day
3262265|NCT00752986|Experimental|Vandetanib at the dose of 100 mg|vandetanib at the dose of 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)
3262266|NCT00752986|Experimental|Vandetanib at the dose of 300 mg|vandetanib at the dose of 300 mg orally once-daily plus placebo to match vandetanib 100 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)
3262267|NCT00752986|Placebo Comparator|Placebo to match vandetanib 100 mg and 300 mg|placebo to match vandetanib 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3).
3262268|NCT00752973|Experimental|Treatment arm|MALG treatment
3262269|NCT00752960||A|Patients receiving olanzapine
3262270|NCT00752960||B|patients receiving risperidone
3262271|NCT00752960||C|Patients receiving quetiapine
3262272|NCT00752960||D|Patients receiving aripiprazole
3262273|NCT00752960||E|patients receiving ziprasidone
3262274|NCT00752947|Experimental|A|
3262275|NCT00752947|Active Comparator|B|
3262276|NCT00752934|Experimental|group a|Baclofen followed by Placebo
3262277|NCT00752934|Experimental|group b|Placebo followed by Baclofen
3262278|NCT00752921|Active Comparator|A|Healthy Patients, age 18-65, who typically suffer from a Headache while fasting
3262279|NCT00752921|Placebo Comparator|B|Healthy Patients, age 18-65, who typically suffer from a Headache while fasting
3262280|NCT00752908||1|
3262281|NCT00752908||2|
3262282|NCT00752895|Experimental|Arm I - Ginseng|Patients receive oral American ginseng extract twice daily.
3262283|NCT00752895|Placebo Comparator|Arm II - Placebo|Patients receive oral placebo twice daily.
3262284|NCT00752869|Placebo Comparator|B|This group will meet the same inclusion and exclusion criteria as the group receiving the study drug
3262285|NCT00752869|Active Comparator|A|This arm will receive the active medication dutasteride
3262286|NCT00752856|Experimental|1|Kaletra (lopinavir/ritonavir 400/100 mg) + Isentress (Raltegravir 400 mg) twice-daily
3262287|NCT00752856|Active Comparator|2|Sustiva (EFV 600 mg), Viread (TDF 300 mg) and Emtriva (FTC 200 mg) taken as Atripla® once-daily
3262288|NCT00752843|Experimental|1|
3262289|NCT00752830|Experimental|1|AZD0328 administration during fasting condition
3262290|NCT00752830|Experimental|2|AZD0328 administration after food intake
3262291|NCT00752817|Experimental|SC|Subjects (surgical trainees) randomised to train under a proficiency-based progression virtual reality simulation curriculum
3262292|NCT00752817|Active Comparator|CC|Subjects (surgical trainees) randomised to the current surgical training curriculum
3262293|NCT00752804|Experimental|1|Dialysis during 4 hours
3262294|NCT00752804|Active Comparator|2|Dialysis during 6 hours
3262295|NCT00752804|Active Comparator|3|Dialysis during 8 hours
3262296|NCT00752791|Experimental|Peginesatide|
3262297|NCT00752739|Placebo Comparator|Arm I|Patients receive oral placebo once daily for 48 months in the absence of disease progression or unacceptable toxicity.
3262298|NCT00752739|Experimental|Arm II|Patients receive low-dose oral selenium once daily for 48 months in the absence of disease progression or unacceptable toxicity.
3262299|NCT00752739|Experimental|Arm III|Patients receive high-dose oral selenium once daily for 48 months in the absence of disease progression or unacceptable toxicity.
3262300|NCT00752726|Active Comparator|Orlistat|Orlistat 60 milligram (mg) capsules to be consumed orally with each meal 3 times per day
3262301|NCT00752726|Placebo Comparator|Placebo|Placebo to match Orlistat 60 mg capsules to be consumed orally with each meal 3 times per day.
3262302|NCT00752713||1|Patients presenting to hospital with AMI
3262303|NCT00752713||2|healthy volunteers as control group
3262304|NCT00752700|No Intervention|1|Control group
3262305|NCT00752700|Active Comparator|2|Conventional resistance training program (CRT)
3262306|NCT00752700|Experimental|3|Whole body vibration resistance training (WBV) on the FITVIBE-platform
3262307|NCT00752687|Other|1|Single dose of ABT-072, dose escalation ranging from 10 mg to 320 mg or placebo in healthy volunteers
3262308|NCT00752687|Other|2|HCV positive subjects administered 160mg ABT-072 or placebo, multi-dose, QD
3262309|NCT00752674|Experimental|1|Neuromuscular balance
3262310|NCT00752622|Experimental|Shortened interval|Infliximab 5 mg/kg, then Infliximab 5 mg/kg every 6 weeks
3262311|NCT00752622|Experimental|Increased dose|Infliximab 5 mg/kg, then Infliximab 7 mg/kg every 8 weeks
3262312|NCT00752609|Experimental|Peginesatide|
3262313|NCT00752596|Experimental|1|1 tablet of 125 mg/day of azimilide 2HCl, oral
3262314|NCT00752583|Experimental|1|Peritoneal dialysis
3262315|NCT00752583|Active Comparator|2|Haemodialysis
3262316|NCT00752570|Placebo Comparator|2|AMG 386 placebo QW, FOLFIRI Q2W
3262317|NCT00752570|Active Comparator|1|Arm 1 : AMG 386 10 mg/kg QW, FOLFIRI Q2W
3262318|NCT00752557|Experimental|1|rhBMP-2/CPM , 1.0 mg/mL
3262319|NCT00752557|Experimental|2|rhBMP-2/CPM , 2.0 mg/mL
3262320|NCT00752557|Active Comparator|3|Oral bisphosphonate therapy (standard of care)
3262321|NCT00752531|Experimental|HAT|
3262322|NCT00752531|No Intervention|Control|
3262323|NCT00752505|Experimental|A|
3262324|NCT00752505|Experimental|B|
3262325|NCT00752492|Active Comparator|Study intervention|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. Ventilation will be assisted to maintain tidal volume of 8-10 mL/kg and respiratory rate of 20-25 breaths per minute to achieve minute ventilation of 15-20 L/min. Isocapnia manifold will maintain end-tidal PCO2 in range of 40-50 mm Hg.
3262326|NCT00752479|Experimental|1|
3262327|NCT00752479|Active Comparator|2|
3262328|NCT00752453|Experimental|1|Dialysis during 4 hours
3262329|NCT00752453|Experimental|2|Dialysis during 6 hours
3262330|NCT00752453|Experimental|3|Dialysis during 8 hours
3262331|NCT00752414|Experimental|1|MP-376 Inhalation Solution
3262332|NCT00752414|Placebo Comparator|2|Placebo
3262333|NCT00752401|Active Comparator|1|6800 IU/day of Cholecalciferol (Vitamin D3) orally for one year
3262334|NCT00752401|Placebo Comparator|2|Oral placebo solution daily for one year
3262335|NCT00752375|Active Comparator|A|Eligible children will be randomized to antibiotic prophylaxis. Children under 3 months will receive amoxicillin 10mg/kg once per day. Children >3months will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component). Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day.
3262336|NCT00752375|Placebo Comparator|B|Eligible children will then be randomized to placebo.
3262337|NCT00752362|Active Comparator|1|Percutaneous coronary intervention with bare metal stent
3262338|NCT00752362|Experimental|2|Percutaneous coronary intervention with paclitaxel-eluting stent
3262339|NCT00752362|Experimental|3|Percutaneous coronary intervention with sirolimus-eluting stent
3262340|NCT00752323|Experimental|Arm I: Newly diagnosed GBM 10mg/kg|Arm I: Newly diagnosed GBM patients receive oral aminolevulinic acid(10mg/kg)at 6 hours before the midpoint of surgery.
3262341|NCT00752323|Experimental|Arm II: Newly diagnosed GBM 20mg/kg|Arm II: Newly diagnosed GBM patients receive oral aminolevulinic acid (20mg/kg)at 6 hours before the midpoint of surgery.
3262342|NCT00752323|Experimental|Arm III: Recurrent GBM 10mg/kg|Arm III: Recurrent GBM patients receive oral aminolevulinic acid (10mg/kg)at 6 hours before the midpoint of surgery.
3262343|NCT00752323|Experimental|Arm IV: Recurrent GBM 20mg/kg|Arm IV: Recurrent GBM patients receive oral aminolevulinic acid (20mg/kg)at 6 hours before the midpoint of surgery.
3262344|NCT00752297|Active Comparator|1|Mentor Purified Toxin Botulinum Toxin Type A
3262345|NCT00752297|Placebo Comparator|2|Preservative-free Saline
3262346|NCT00752284|Experimental|A|Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure
3262347|NCT00752284|Active Comparator|B|"Control Group:~total excision of lower wisdom tooth"
3262348|NCT00752271||1|24 adults with meniscal damage for which arthroscopy is clinically indicated
3262349|NCT00752271||2|8 adults who have already undergone meniscal resection to serve as positive controls
3262350|NCT00752258|Experimental|1|Mentor Purified Toxin Botulinum Toxin Type A
3262351|NCT00752245|Experimental|1|Dialysis during 4 hours
3262352|NCT00752245|Active Comparator|2|Dialysis during 6 hours
3262353|NCT00752245|Active Comparator|3|Dialysis during 8 hours
3262354|NCT00752232|Experimental|ACC-001+QS-21|Active vaccine + adjuvant, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
3262355|NCT00752232|Experimental|ACC-001|Active vaccine, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
3262356|NCT00752232|Placebo Comparator|QS-21|Adjuvant, IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
3262357|NCT00752232|Placebo Comparator|PBS|Placebo, IM injection, Day 1, month 3, 6, 9, 12
3262358|NCT00752219|Experimental|NXL104/CAZ/MTZ|NXL104/ceftazidime + metronidazole
3262359|NCT00752219|Active Comparator|Meropenem|
3262360|NCT00752206|Active Comparator|1|
3262361|NCT00752206|Placebo Comparator|2|
3262362|NCT00752193|Experimental|1|Probiotic lactobacilli
3262363|NCT00752193|Placebo Comparator|2|Placebo
3262364|NCT00752180|Experimental|Wosulin R|Wosulin R,Regular insulin for injection(Recombinant Human Insulin)(600 nmol/ml, 100IU/ml)in vials 10.0 ml given subcutaneously.
3262365|NCT00752180|Active Comparator|Actrapid|Actrapid, Regular insulin for injection (Recombinant Human Insulin) (600nmol/ml,100IU/ml)in vials 10.0 ml given subcutaneously.
3262366|NCT00752167||Case|all Division I athletes, male and female, at the University of Arizona that are currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff
3262367|NCT00752167||Control|control athletes (ie, not currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff and/or not currently using asthma medications) from the same sport
3262368|NCT00752141|Experimental|1|oral oxybutynin
3262369|NCT00752141|Experimental|2|oxybutynin topical gel
3262370|NCT00752141|Placebo Comparator|3|placebo tablets plus placebo gel
3262371|NCT00752115|Active Comparator|A|Sildenafil plus carboplatin and weekly paclitaxel
3262372|NCT00752115|Placebo Comparator|P|carboplatin and weekly paclitaxel
3262373|NCT00752102|Active Comparator|Calcitriol|"Calcitriol is a synthetic vitamin D analog which is active in the regulation of the absorption of calcium from the gastrointestinal tract and its utilization in the body. Calcitriol is available as capsules containing 0.25 mcg or 0.5 mcg calcitriol and as an oral solution containing 1 mcg/ml of calcitriol. All dosage forms contain butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) as antioxidants.~Subjects taking calcitriol started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels."
3262374|NCT00752102|Active Comparator|Paricalcitol|"Paricalcitol, USP, the active ingredient in Zemplar® Capsules, is a synthetically manufactured analog of calcitriol, the metabolically active form of vitamin D indicated for the prevention and treatment of secondary hyperparathyroidism in chronic kidney disease. Zemplar is available as soft gelatin capsules for oral administration containing 1 mcg, 2 mcg or 4 mcg of paricalcitol. Each capsule also contains medium chain triglycerides, alcohol, and butylated hydroxytoluene.~Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels."
3262375|NCT00752089|Experimental|Sodium fluoride/potassium nitrate/Isopentane dentifrice|Participants to brush their teeth for one timed minute twice daily with a gel to foam dentifrice containing active ingredients: 1450 ppm F as sodium fluoride (NaF) and 5% potassium nitrate (KNO3) and isopentane as an excipient ingredient.
3262376|NCT00752089|Experimental|NaF/KNO3 Dentifrice|Participants to brush their teeth for one timed minute twice daily with a gel to foam dentifrice, containing as active ingredients: 1450 ppm NaF and 5% KNO3 but no isopentane.
3262377|NCT00752089|Active Comparator|NaF Dentifrice|Participants to brush their teeth for one timed minute twice daily with a dentifrice containing 1450 ppm F as NaF.
3262378|NCT00752089|Placebo Comparator|Placebo Dentifrice|Participants to brush their teeth for one timed minute twice daily with a fluoride free dentifrice (0 ppm F).
3262379|NCT00752076|Experimental|1|We collected malignant pleural effusion for NSCLC cell lines with different EGFR mutations development and then we can compare the difference responses and signal pathways in these cell lines. We can also explore the detailed mechanism of TKI responsive cancer cell and try to develop other agent to enhance the pathways.
3262380|NCT00752063|Experimental|A|All subjects will receive Sorafenib with Capecitabine and Oxaliplatin
3262381|NCT00752050|Active Comparator|1|Mentor Purified Toxin Botulinum Toxin Type A - Part II ONLY. (Part I is Single Group and all participants receive active drug and are not randomized)
3262382|NCT00752050|Placebo Comparator|2|Preservative-free Saline - Part II ONLY. (Part I is Single Group and all participants receive active drug and are not randomized)
3262383|NCT00752037|Other|1|open label single arm
3262384|NCT00752024|Experimental|1|To position haematoma's location, drills several millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
3262385|NCT00752024|Active Comparator|2|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
3262386|NCT00752011|Experimental|Carboplatin + TAS-106|Carboplatin starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle. TAS-106 starting dose 2.0 mg/m^2 by vein over 24 hours, Day 1 of 3 Week Cycle.
3262387|NCT00751998|Experimental|Arm 1|Test of SpyGlass device
3262388|NCT00751985|Experimental|1|Personalized normative feedback (PFI). The PFI was a single-session intervention; it was displayed in a single screenshot and addressed the participant by name. It consisted of a summary of the participant's weekly consumption, a comparison with maximum drinking limits and a graphical comparison of the participant's consumption to the average level in the municipality (gender-specific), followed by information about health and social risks of heavy drinking as well as links for further self-help material and a local alcohol treatment facility.
3262389|NCT00751985|Experimental|2|Self-help material (SHM). The SHM was a single-session intervention and was displayed in a single screenshot. It consisted of information about maximum drinking limits, followed by information about health and social risks of heavy drinking as well as links for further standardized self-help material and a local alcohol treatment facility.
3262390|NCT00751985|Placebo Comparator|3|Control
3262391|NCT00751972|Experimental|HeartWare® VAS|Ventricular Assist Device (HeartWare® VAS)
3262392|NCT00751959|Active Comparator|2|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
3262393|NCT00751959|Experimental|1|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
3262394|NCT00751946|Active Comparator|1|12 weekly sessions of one-to-one TARGET (psychotherapy)
3262395|NCT00751946|Active Comparator|2|12 weekly sessions of one-to-one ETAU (psychotherapy)
3262396|NCT00751933|Experimental|2|Vaccination with Vivotif and Dukoral
3262397|NCT00751933|Experimental|3|Dietary supplement with oats
3262398|NCT00751933|Placebo Comparator|4|Placebo instead of vaccines No dietary supplement
3262399|NCT00751933|Experimental|1|Vaccination with Vivotif and Dukoral + dietary supplement with oats.
3262400|NCT00751920|Experimental|1|
3262401|NCT00751907|Experimental|1|
3262402|NCT00751907|Placebo Comparator|2|
3262403|NCT00751881|Experimental|Teriflunomide 7 mg / 14 mg|Core treatment period: Teriflunomide 7 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
3262404|NCT00751881|Experimental|Teriflunomide 14 mg / 14 mg|Core treatment period: Teriflunomide 14 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
3262405|NCT00751881|Placebo Comparator|Placebo / Teriflunomide 14 mg|Core treatment period: Placebo (for teriflunomide) once daily. Extension treatment period: Teriflunomide 14 mg once daily.
3262406|NCT00751868|Experimental|ARM 1|FEC e Ixabepilone. A goal of 48 patients will be enrolled in this study by 16 Italian centres of the GIM (Gruppo Italiano Mammella) Group. Subjects must meet all of the inclusion criteria and none of the exclusion criteria to be enrolled in the study
3262407|NCT00751855|Active Comparator|1|Prolonged Exposure therapy with Hydrocortisone
3262408|NCT00751855|Placebo Comparator|2|Prolonged Exposure therapy with placebo
3262409|NCT00751842|Active Comparator|A|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on days 90 and 270.
3262410|NCT00751842|Active Comparator|B|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on days 90 and 270.
3262411|NCT00751842|Placebo Comparator|C|This arm will receive 4 injections of placebo, 1 each on days 1, 30, 90 and 270.
3262412|NCT00751829|Experimental|1|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to controll BP
3262413|NCT00751829|Active Comparator|2|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
3262414|NCT00751816||Supportive Care|head and neck cancer survivors who are undergoing chemotherapy and radiation therapy
3262415|NCT00751803|Experimental|BI 44370 TA Low Dose|
3262416|NCT00751803|Experimental|BI 44370 TA Medium Dose|
3262417|NCT00751803|Experimental|BI 44370 TA High Dose|
3262418|NCT00751803|Placebo Comparator|Placebo|
3262419|NCT00751803|Active Comparator|Eletriptan|
3262420|NCT00751790|Experimental|Triptorelin|
3262421|NCT00751777|Experimental|Group 1: 37.5 µg LT patch|80 subjects will receive a two vaccination regimen with a LT patch.
3262422|NCT00751777|Placebo Comparator|Group 2: 0 µg LT patch (placebo)|40 subjects will receive a two vaccination regimen with a placebo patch.
3262423|NCT00751764|Experimental|1|
3262424|NCT00751751|Experimental|1|oral olmesartan medoxomil tablets 20 or 40 mg taken once daily for 52 weeks + hydrochlorothiazide tablets 12.5 or 25 mg , if needed to control BP after 12 weeks
3262425|NCT00751751|Active Comparator|2|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tables, after 12 weeks, if needed to control BP.
3262426|NCT00751738|Experimental|1|125 mg azimilide
3262427|NCT00751712||Back of skull cerebral oximeter sensor|All patients enrolled will receive non-invasive oxygen perfusion monitoring on the back of the skull during their standard of care congenital heart surgery
3262428|NCT00751699|Experimental|1|Asacol 6x400 mg Q24h at 7 am for 7 days
3262429|NCT00751699|Experimental|2|Asacol 2x400 mg Q8h at 7 am, 3 pm, and 11 pm for 7 days
3262430|NCT00751699|Experimental|3|Lialda 2x1.2g Q24h at 7 am for 7 days
3262431|NCT00751686||RV GE Group|
3262432|NCT00751673||TESS prosthesis|Consecutive series of patients with a TESS prosthesis.
3262433|NCT00751647|Other|A1|Population receiving the CF specific outpatient PT services.
3262434|NCT00751634|Experimental|A|Application of the Gaymar Rapr-Round device per approved use
3262435|NCT00751621|Experimental|IgPro20|Subcutaneous (SC) administration by the subject/parent/guardian with the planned weekly dose of IgPro20 to be the same as the subject's last dose recommended by the investigator in study ZLB06_001CR (NCT00542997).
3262436|NCT00751608|Experimental|1|
3262437|NCT00751608|Active Comparator|2|
3262438|NCT00751608|Placebo Comparator|3|
3262439|NCT00751595|Experimental|ARM A (Tat Protein 7.5 or 30 microg 5X)|Group I: Subjects receiving 5 intradermal immunization with Tat (7.5 microg); Group II: Subjects receiving 5 intradermal immunization with Tat (30 microg).
3262440|NCT00751595|Experimental|ARM B (Tat Protein 7.5 or 30 microg, 3X)|Group I: Subjects receiving 3 intradermal immunization with Tat (7.5 microg); Group II: Subjects receiving 3 intradermal immunization with Tat (30 microg)
3262441|NCT00751582|Experimental|2|Food supplementation and nutrition education
3262442|NCT00751582|Experimental|1|Nutrition Education only
3262443|NCT00751569||A1|A group of 3 to 5 pregnant women as donors for umbilical cord blood
3262444|NCT00751556|Experimental|Arm 1|
3262445|NCT00751556|Active Comparator|Arm 2|
3262446|NCT00751530||Protease Inhibitor Group|Subjects who required a protease inhibitor in their new ART regimen
3262447|NCT00751530||Non-protease Inhibitor|Subjects who did not take a protease inhibitor in their regimen
3262448|NCT00751517|Active Comparator|A|Cyclophosphamide
3262449|NCT00751517|Experimental|B|Methotrexate
3262450|NCT00751491|Active Comparator|III|
3262451|NCT00751491|Active Comparator|A|
3262452|NCT00751491|Placebo Comparator|placebo|
3262453|NCT00751478|Experimental|A|2 Placebo capsules (whole) + ALO-01 2 x 60 mg capsules (crushed) in apple juice + apple juice (MSIR placebo)
3262454|NCT00751478|Experimental|B|2 x 60 mg ALO-01 (whole) + 2 x placebo capsules (crushed) in apple juice + apple juice (MSIR placebo)
3262455|NCT00751478|Active Comparator|C|2 x placebo capsules (whole) + 2 X placebo capsules (crushed) in apple juice + 120 mg MSIR in apple juice
3262456|NCT00751478|Placebo Comparator|D|2 x placebo capsules (whole) + 2 X placebo capsules (crushed) in apple juice + apple juice (MSIR placebo)
3262457|NCT00751465|Active Comparator|Task Concentration Training|Task Concentration Training TCT following Bögels et al. (1997)
3262458|NCT00751465|Active Comparator|Standard CBT|standard Cognitive Behavior Therapy, standard CBT following the model of Clark and Wells (1995).
3262459|NCT00751465|No Intervention|Wait list control|Wait list control group
3262460|NCT00751452||1|
3262461|NCT00751452||2|
3262462|NCT00751413|Experimental|1|MK0633
3262463|NCT00751400|Experimental|Naproxen Sodium ER (BAYH6689)|subjects take one tablet Naproxen Sodium ER (extended release) every 24 hours while symptoms last for no more than 10 consecutive days for pain and no more than 3 consecutive days for fever
3262464|NCT00751387||1|
3262465|NCT00751374|Other|group A|Topical gentamicin cream
3262466|NCT00751374|Active Comparator|Group B|topical gentamicin cream alternates with mupirocin cream at monthly basis
3262467|NCT00751361|Active Comparator|1|Treatment group: Patients receive 10 Rheopheresis treatments within 17 weeks
3262468|NCT00751361|No Intervention|2|No treatment control group
3262469|NCT00751348|Experimental|PRIORIX-TETRA GROUP|Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix-Tetra® vaccine at Day 0, administered subcutaneously in the deltoid region of the left upper arm.
3262470|NCT00751348|Active Comparator|PRIORIX + VARILRIX GROUP|Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix™ vaccine together with one dose of Varilrix™ vaccine at Day 0, administered subcutaneously in the deltoid regions of the left or right upper arm, respectively.
3262471|NCT00751335|Experimental|B|Heated breathing tube (CPAP with Thermosmart)
3262472|NCT00751335|Active Comparator|A|Non heated breathing tube (CPAP with conventional humidification)
3262473|NCT00751322|Active Comparator|1|RBC transfusion of 5 days or less storage age
3262474|NCT00751322|Active Comparator|2|RBC transfusion of conventional storage age
3262475|NCT00751309||1|Lung and heart-lung transplanted subjects.
3262476|NCT00751296|Experimental|Lenalidiomide|Lenalidomide target dose of 10 mg PO OD X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28-day cycle.
3262477|NCT00751283|Experimental|1|GRST Peripheral Catheter System
3262478|NCT00751270|Experimental|A|Arm A for unresectable malignant glioma was closed due to poor accrual.
3262479|NCT00751270|Experimental|B|Arm B for resectable malignant glioma completed the Phase I accrual and long term follow up continues. A follow on study at dose level 3 was opened as a Phase 2a study (see BrTK02).
3262480|NCT00751257|Experimental|1|2400mg N-acetylcysteine (1200mg b.i.d.) for 4 consecutive weeks
3262481|NCT00751257|Placebo Comparator|2|"Identically appearing placebo pills, packaged in an N-acetylcysteine slurry so that placebo will retain smell similar to active NAC capsules"
3262482|NCT00751244|Active Comparator|1|12 weekly sessions of one-to-one TARGET (psychotherapy)
3262483|NCT00751244|Active Comparator|2|12 weekly sessions of one-to-one PCT (psychotherapy)
3262484|NCT00751244|Other|3|90-day wait-list group
3262594|NCT00750412|No Intervention|Treatment As Usual|
3262485|NCT00751231|Active Comparator|Arm 1|300mg or 600mg loading dose of Clopidogrel followed by once daily dosing of 75 mg Clopidogrel for up to 120 days.
3262486|NCT00751231|Experimental|Arm 2|IV bolus of PRT060128 prior to PCI and twice daily administration of 50 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
3262487|NCT00751231|Experimental|Arm 3|IV bolus of PRT060128 prior to PCI and twice daily administration of 100 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
3262488|NCT00751231|Experimental|Arm 4|IV bolus of PRT060128 prior to PCI and twice daily administration of 150 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
3262489|NCT00751218|Active Comparator|Arm 1|desloratadine
3262490|NCT00751218|Placebo Comparator|Arm 2|Placebo
3262491|NCT00751218|Active Comparator|Arm 3|cetirizine
3262492|NCT00751205|Experimental|Arm 1|
3262493|NCT00751205|Placebo Comparator|Arm 2|
3262494|NCT00751192|Experimental|A|
3262495|NCT00751192|Active Comparator|B|
3262496|NCT00751179|Active Comparator|Rocuronium - Sugammadex|Rocuronium - Sugammadex 4.0 mg/kg
3262497|NCT00751179|Active Comparator|Succinylcholine|Succinylcholine 1.0 mg/kg
3262498|NCT00751166|Experimental|1|Desloratadine
3262499|NCT00751166|Active Comparator|2|Cetirizine
3262500|NCT00751166|Placebo Comparator|3|placebo
3262501|NCT00751140|Experimental|Lymph Node Dissection at Time of Nephroureterectomy|A prospective single-arm two-stage phase II study to allow for analysis of the treatment-specific outcomes and disease-specific survival of patients treated with open or laparoscopic nephroureterectomy and bladder cuff excision along with a lymph node dissection (modified template retroperitoneal lymph node dissection).
3262502|NCT00751127|Active Comparator|Timolol|
3262503|NCT00751127|Experimental|PhXA41|
3262504|NCT00751114|Experimental|Insulin Glargine|Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL<FPG≤100mg/dL (3.9mmol/L<FPG≤5.5mmol/L).
3262505|NCT00751114|Active Comparator|Sitagliptin|Dose of 100 mg once a day administered with or without food.
3262506|NCT00751101|Experimental|Arm I|Patients apply a transdermal nicotine patch once every 24 hours beginning 1 day prior to initiation of capecitabine and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.
3262507|NCT00751101|Experimental|Arm II|Patients apply a transdermal nicotine patch once every 24 hours beginning with the course of chemotherapy initiated after hand-foot syndrome symptoms appear and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.
3262508|NCT00751088|Active Comparator|1|Patients treated with Ajust positioning
3262509|NCT00751088|Active Comparator|2|Patients treated with MiniArc positioning
3262510|NCT00751088|Active Comparator|3|Patients treated with TVT secur system
3262511|NCT00751088|Active Comparator|4|Patients treated with tension free vaginal tape
3262512|NCT00751075|Active Comparator|1|MFNS once daily
3262513|NCT00751075|Experimental|2|MFNS twice daily
3262514|NCT00751075|Active Comparator|3|Amoxicillin
3262515|NCT00751075|Placebo Comparator|4|Placebo
3262516|NCT00751062|Active Comparator|Timolol|
3262517|NCT00751062|Experimental|PhXA41|
3262518|NCT00751049|Experimental|PhXA41|
3262519|NCT00751049|Active Comparator|timolol|
3262520|NCT00751036|Experimental|Nilotinib|Patients who were assigned to this treatment group received 400 mg. nilotinib bid.
3262521|NCT00751036|Active Comparator|Imatinib|Patients who were assigned to this treatment group received 400 mg. imatinib bid.
3262522|NCT00751023|Experimental|1|Modafinil 400 mg daily
3262523|NCT00751023|Placebo Comparator|2|Placebo
3262524|NCT00751010||1|In a mailed survey (Part 1 of this study), 127 women with a documented diagnosis of IC agreed to be contacted for an in-office examination.
3262525|NCT00750997||Hypertonic saline|Hypertonic resuscitation
3262526|NCT00750997||Control: normal saline|Normal saline resuscitation
3262527|NCT00750984|Experimental|1|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
3262528|NCT00750984|Active Comparator|2|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
3262529|NCT00750971|Experimental|1|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation
3262530|NCT00750971|Active Comparator|2|Best currently available immunosuppressive/immunomodulatory therapy
3262531|NCT00750958|No Intervention|1|ED patients that are not monitored with conventional therapy.
3262532|NCT00750945|Experimental|A|Treadmill with Music cueing group
3262533|NCT00750945|Active Comparator|B|Treadmill group
3262534|NCT00750945|Placebo Comparator|C|Home walking group
3262535|NCT00750932||T|Control
3262536|NCT00750932||M|Minor with cystic fibrosis
3262537|NCT00750932||A|Adult with cystic fibrosis
3262538|NCT00750919|Experimental|Esmirtazapine|Participants receive esmirtazapine 4.5 mg tablet, orally, once daily (QD) for up to 6 months.
3262539|NCT00750893||Rotarix Group|Subjects who received 2 doses of Rotarix™ or Rotarix™ liquid formulation (oral suspension or prefilled syringe ). The first dose was administered from the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.
3262540|NCT00750880|Experimental|1|
3262541|NCT00750867|Experimental|1|Interventions included monthly infusions of intravenous immunoglobulin.
3262542|NCT00750854|Experimental|NEM Treatment 1|NEM Formulation X (#0802), 500 mg, once daily, orally
3262543|NCT00750854|Experimental|NEM Treatment 2|NEM Formulation Y (#0505), 500 mg, once daily, orally
3262544|NCT00750841|Experimental|1|Cediranib alone, followed by cediranib plus rifampicin, followed by cediranib alone.
3262592|NCT00750425|Experimental|1|Cediranib alone, followed by cediranib plus ketoconazole, followed by cediranib alone
3262593|NCT00750412|Experimental|TeenScreen|
3262736|NCT00749541||1normal catheter.|
3262545|NCT00750815|Experimental|A. Phase I - Dose Escalation|"Dose of Cyclophosphamide to depend on how many patients we treated:~Dose Level 1: Cyclophosphamide 250 mg /m^2 IV Day 1; VELCADE, 1.0 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12~Dose Level 2: Cyclophosphamide 500 mg /m^2 IV Day 1; VELCADE, 1.0 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12~Dose Level 3: Cyclophosphamide 750 mg /m^2 IV Day 1; VELCADE, 1.0 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12~Dose Level 4: Cyclophosphamide 750 mg /m^2 IV Day 1; VELCADE, 1.3 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12"
3262546|NCT00750815|Experimental|B. Phase II - Maximum Planned Dose (MPD)|Participants received Cyclophosphamide and VELCADE at Level 4 (the MPD) at the same schedule of the Phase I study. Pegylated doxorubicin and Dexamethasone were given at the same doses and schedule as the Phase I part of study.
3262547|NCT00750802|Experimental|1|
3262548|NCT00750802|Experimental|2|
3262549|NCT00750802|Active Comparator|3|
3262550|NCT00750802|Placebo Comparator|4|
3262551|NCT00750763|Active Comparator|1|PEG (Colonlytely) - 4 litres
3262552|NCT00750763|Active Comparator|2|Picosulphate (Picolax/Picoprep) - 2 sachets
3262553|NCT00750763|Active Comparator|3|Sodium Phosphate (Fleet) - 2 bottles
3262554|NCT00750750|Active Comparator|1|MFNS once daily
3262555|NCT00750750|Experimental|2|MFNS twice daily
3262556|NCT00750750|Active Comparator|3|Amoxicillin
3262557|NCT00750750|Placebo Comparator|4|Placebo
3262558|NCT00750737|Experimental|Posaconazole|Posaconazole 200 mg three times daily by mouth up to 6 weeks (Days 1-42)
3262559|NCT00750737|Experimental|Amphotericin B Lipid Complex (ABLC)|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
3262560|NCT00750724|Placebo Comparator|B|2 ml of Normal saline intraarticular injection to the knee joint weekly for 5 weeks
3262561|NCT00750724|Experimental|A|2 ml of 25 mg sodium hyaluronate intraarticular injection to the knee joint weekly for 5 weeks
3262562|NCT00750711|Experimental|KT,2|There are two arms in this study: KT2 arm and KT4 arm. Patients in KT2 arm will be ablated with the 2 mm irrigated catheter and patients in KT4 mm will be ablated with the 4 mm irrigated catheter.
3262563|NCT00750698|Experimental|1|"Erlotinib-responsive patients are those who progressed following either a complete or partial response to erlotinib or a period of stable disease lasting at least 3 months."
3262564|NCT00750698|Experimental|2|"Erlotinib-nonresponsive patients are those who either progressed immediately during treatment with erlotinib (i.e. after at least 1 full cycle of erlotinib treatment) or had an objective response or period of stable disease lasting less than 3 months."
3262565|NCT00750685|Other|Reconstruction|"The study population will consist of women aged 18 or over who are undergoing primary breast reconstruction.~The Reconstruction cohort will include subjects with loss of breast tissue due to mastectomy, contralateral breast for post-reconstruction symmetry or subjects with deformities secondary to disease, malignancy, trauma, and congenital deformity. Subjects in this cohort cannot have been implanted with breast implants, but may have tissue expanders. A Becker implant is considered a tissue expander until the port and fill tube have been removed. Women who undergo surgery primarily for a mastopexy will not be part of the reconstruction cohort."
3262566|NCT00750659|Experimental|1|Nilotinib treatment
3262567|NCT00750646||A|Subject's adherence to prescribed therapy will be monitored with an electronic compliance device.
3262568|NCT00750633|Experimental|Moxidex|Moxidex otic solution
3262569|NCT00750633|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
3262570|NCT00750633|Active Comparator|Dexamethasone|Dexamethasone phosphate otic solution
3262571|NCT00750620|Experimental|1. Severe renal impairment|severe renal impairment
3262572|NCT00750620|Experimental|2. Moderate renal impairment|moderate renal impairment
3262573|NCT00750620|Experimental|3. Mild renal impairment|mild renal impairment
3262574|NCT00750620|Experimental|4. Normal renal function|normal renal function
3262575|NCT00750594||1|
3262576|NCT00750594||2|
3262577|NCT00750581|Placebo Comparator|Standard dose group|The infants randomized to the standard dose group will receive indomethacin (0.1 mg/kg) at 24 hr intervals for 5 days. These infants will also receive 5 extra doses of normal saline infusion of similar volume at 12 hrly intervals between the indomethacin schedules to match the Escalating dose Indomethacin Schedule
3262578|NCT00750581|Active Comparator|Escalating dose group|The infants randomized to the Escalating dose group will receive indomethacin started at 0.2 mg/kg/dose every 12 hours for 2 doses with stepwise increment in indomethacin dose by 0.1 mg/kg/dose every 24 hours upto maximum dose of 0.6 mg/kg/dose
3262579|NCT00750568||Group 1|"In-patient in the Pediatric Intensive Care Unit~Diagnosis of Status asthmaticus~Receiving a continuous infusion of terbutaline as part of their standard of care~Ages 2 years to 6 years"
3262580|NCT00750568||Group 2|"In-patient in the Pediatric Intensive Care Unit~Diagnosis of Status asthmaticus~Receiving a continuous infusion of terbutaline as part of their standard of care~Ages greater than 6 years to 12 years"
3262581|NCT00750568||Group 3|"In-patient in the Pediatric Intensive Care Unit~Diagnosis of Status asthmaticus~Receiving a continuous infusion of terbutaline as part of their standard of care~Ages greater than 12 years to 18 years"
3262582|NCT00750555|Other|1|
3262583|NCT00750529|Experimental|Galantamine|
3262584|NCT00750516||Lacid|Hypotensive, non pregnant by history, non comfort care Emergency Department patients.
3262585|NCT00750477|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 8 weeks
3262586|NCT00750477|Placebo Comparator|Placebo|Placebo, 500 mg, once daily, orally for 8 weeks
3262587|NCT00750451|Experimental|LMWH|Women in the LMWH arm are administered 1 mg/kg/day subcutaneously low molecular weight heparin after oocyte collection in addition to routine luteal phase support with vaginal progesterone
3262588|NCT00750451|Active Comparator|Control|Women in the control arm are administered routine luteal phase support without the addition of LMWH
3262589|NCT00750438|Experimental|Propionate ester|
3262590|NCT00750438|Placebo Comparator|Fermentable control|
3262591|NCT00750438|Placebo Comparator|Non fermentable control|
3262595|NCT00750399|Experimental|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab on a monthly basis depending on response to treatment
3262596|NCT00750386|Experimental|1|Paclitaxel/Carboplatin
3262597|NCT00750373|No Intervention|Conventional|Conventional Treatment based on current guidelines
3262598|NCT00750373|Active Comparator|Surgery|Early surgery within 48 hours of randomization
3262599|NCT00750360|Experimental|Unprimed, > 6 to < 72 Months|Subjects aged > 6 months to < 72 months who were previously not vaccinated against influenza (unprimed).
3262600|NCT00750360|Experimental|Unprimed, ≥ 72 to < 108 Months|Subjects aged ≥ 72 months to < 108 months who were previously not vaccinated against influenza (unprimed).
3262601|NCT00750360|Experimental|Primed, > 6 to < 72 Months|Subjects aged > 6 months to < 72 months who previously received a vaccination against influenza (primed).
3262602|NCT00750360|Experimental|Primed, ≥ 72 to < 108 Months|Subjects aged ≥ 72 months to < 108 months who previously received a vaccination against influenza (primed).
3262603|NCT00750360|Experimental|Primed, ≥ 108 to < 216 Months|Subjects aged ≥ 108 months to < 216 months who previously received a vaccination against influenza (primed).
3262604|NCT00750360|Experimental|Primed, ≥ 216 Months|Subjects aged ≥ 216 months who previously received a vaccination against influenza (primed).
3262605|NCT00750334|Experimental|Part A|clofarabine Dose Escalation
3262606|NCT00750334|Experimental|Part B|Part B is an open-label, replicated cross-over study in which 12 additional patients will be enrolled and treated at the MTD determined in part A to evaluate the effect of food on the PK disposition of oral clofarabine.
3262607|NCT00750308|Active Comparator|tadalafil, ramapril, combo, placebo|placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, ramipril + tadalafil, washout, placebo+placebo for three weeks
3262608|NCT00750308|Active Comparator|ramipril, tadalafil, placebo, combo|placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks
3262609|NCT00750308|Active Comparator|combo, placebo, tadalafil, ramipril|ramipril+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks
3262610|NCT00750308|Active Comparator|placebo, combo, ramipril, tadalafil|placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks, washout placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks
3262611|NCT00750308|Active Comparator|tadalafil, placebo, ramipril, combo|placebo+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+ramipril for three weeks, washout, ramipril+tadalafil for three weeks
3262612|NCT00750308|Active Comparator|ramipril, combo, tadalfil, placebo|placebo+ramipril for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo for three weeks
3262613|NCT00750308|Active Comparator|combo, ramipril, placebo, tadalafil|ramipril+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks
3262614|NCT00750308|Active Comparator|placebo, tadalafil, combo, ramipril|placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+ramipril for three weeks
3262615|NCT00750308|Active Comparator|tadalafil, combo, placebo, ramipril|placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+ramipril for three weeks
3262616|NCT00750308|Active Comparator|ramipril, placebo, combo, tadalafil|placebo+ramipril for three weeks, washout, placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks
3262617|NCT00750308|Active Comparator|combo, tadalafil, ramipril, placebo|ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+placebo for three weeks
3262618|NCT00750308|Active Comparator|placebo, ramipril, tadalafil, combo|placebo+placebo for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks
3262619|NCT00750295|Experimental|1|
3262620|NCT00750295|Experimental|2|
3262621|NCT00750295|Experimental|3|
3262622|NCT00750295|Experimental|4|
3262623|NCT00750295|Experimental|5|
3262624|NCT00750295|Experimental|6|
3262625|NCT00750295|Experimental|7|
3262626|NCT00750282|Experimental|Florbetaben (BAY94-9172)|
3262627|NCT00750269|Experimental|Level 1: 8.0 Gy/FX|SBRT 40.0 Gy
3262628|NCT00750269|Experimental|Level 2: 8.5 Gy/FX|SBRT 42.5 Gy
3262629|NCT00750269|Experimental|Level 3: 9.0 Gy/FX|SBRT 45.0 Gy
3262630|NCT00750269|Experimental|Level 4: 9.5 Gy/FX|SBRT 47.5 Gy
3262631|NCT00750269|Experimental|Level 5: 10.0 Gy/FX|SBRT 50.0 Gy
3262632|NCT00750269|Experimental|Level 6: 10.5 Gy/FX|SBRT 52.5 Gy
3262633|NCT00750269|Experimental|Level 7: 11.0 Gy/FX|SBRT 55.0 Gy
3262634|NCT00750269|Experimental|Level 8: 11.5 Gy/FX|SBRT 57.5 Gy
3262635|NCT00750269|Experimental|Level 9: 12.0 Gy/FX|SBRT 60.0 Gy
3262636|NCT00750256|Experimental|Cohorts|This study will be a single-blind, randomized, placebo-controlled, dose-rising, single dose, parallel group study with 6 proposed Cohorts from 2mg to 450mg.
3262637|NCT00750243|Experimental|A|
3262638|NCT00750243|Active Comparator|B|
3262639|NCT00750230|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 30 days.
3262640|NCT00750204|Experimental|APRV|Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.
3262641|NCT00750204|Active Comparator|Conventional MV|Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.
3262737|NCT00749541||abnormal catheter.|
3262738|NCT00749528||1|Children vith recurrent wheezing
3262739|NCT00749528||2|Healthy children
3262740|NCT00749502|Experimental|Part A-Dose escalation and confirmation|
3262741|NCT00749502|Experimental|Part B - Prostate/Ovarian Cancer Cohort|
3262642|NCT00750191|Active Comparator|Intradiscal Biacuplasty|"On the day of the procedure, patients were given midazolam for relaxation and, if needed, fentanyl IV during the procedure. For treatment subjects, two TransDiscal probes were positioned under fluoroscopic guidance in the posterior annulus of the intervertebral disc. The probes were attached to the Radiofrequency generator and Radiofrequency energy was delivered. Placement of the probes within the disc annulus was confirmed using oblique, lateral, and anterior-posterior fluoroscopic images.~Following completion of procedure the patient was transferred to recovery and monitored for 45 minutes then discharged home with instructions. It was expected that the patient limit their activities during the first week after the procedure."
3262643|NCT00750191|Placebo Comparator|Sham|"Sham procedures mimicked active treatment procedures, except that the probes were positioned just outside of the disc and no radiofrequency energy was delivered through the electrodes. Thus, sham patients were provided similar tactile, auditory and visual experiences as treatment patients, without receiving the active RF treatment.~Following completion of procedure the patient was transferred to recovery and monitored for 45 minutes then discharged home with instructions. It was expected that the patient limit their activities during the first week after the procedure.~The study will be unblinded at 6 months. If the patients in the IDB group show significant improvement compared to placebo they will be offered IDB."
3262644|NCT00750178|Experimental|A|MK0683
3262645|NCT00750165|Experimental|1|Treatment with the Fisher & Paykel Sleep Style 200 Auto CPAP device
3262646|NCT00750152|Placebo Comparator|2|placebo
3262647|NCT00750152|Experimental|1|NAFT-500
3262648|NCT00750139|Experimental|1|Naftin 2% cream applied daily for 2 weeks
3262649|NCT00750139|Placebo Comparator|2|Placebo cream applied daily for two weeks
3262650|NCT00750139|Active Comparator|3|Active comparator applied daily for 4 weeks
3262651|NCT00750139|Placebo Comparator|4|placebo cream applied daily for 4 weeks
3262652|NCT00750113|Experimental|Arm 1|
3262653|NCT00750113|Experimental|Arm 2|
3262654|NCT00750113|Experimental|Arm 3|
3262655|NCT00750100|Active Comparator|A|Patients undergo a standard antagonist protocol for in-vitro fertilisation, and are stimulated with recombinant gonadotropins.
3262656|NCT00750100|Experimental|B|Patients are undergo an antagonist protocol for in-vitro fertilisation and are stimulated with recombinant gonadotropins. When the patient has an estradiol value of 600 ng/L or more and when the patient has at least 6 follicles of 12 mm, the administration of gonadotropins is stopped and replaced by low dose human chorionic gonadotropins.
3262657|NCT00750087||1|Schizophrenia patients stabilized on Seroquel XR
3262658|NCT00750074||1|"During volume assist-control ventilation, a 0.4 second end-inspiratory pause will be set and the following pressures measured: peak pressure; plateau pressure; and PEEP. The following ventilator settings will be recorded: inspiratory flow; expired tidal volume; and rate. The presence or absence of autoPEEP will be noted.~During pressure-control ventilation, the flow versus time waveform will be printed from the ventilator using a conventional computer printer for later analysis. The following ventilator settings will be recorded: inspiratory pressure; PEEP; and expired tidal volume."
3262659|NCT00750061|Placebo Comparator|Placebo|Placebo tablet
3262660|NCT00750061|Experimental|Lithium carbonate|Lithium Carbonate tablet, 250mg
3262661|NCT00750035|Experimental|1|total abdominal hysterectomy and
3262662|NCT00750035|Experimental|2|Subtotal hysterectomy
3262663|NCT00750022|Experimental|E1|
3262664|NCT00750022|Active Comparator|A1|
3262665|NCT00750009|Experimental|Arm I (PRE-ACT)|Patients receive tailored feedback and video content to address clinical trial barriers following baseline assessment.
3262666|NCT00750009|Active Comparator|Arm II (control)|Patients receive generic clinical trials educational feedback taken from NCI publications following baseline assessment.
3262667|NCT00749996|Experimental|Investigational group|Single level herniectomy followed by placement of the DIAM™ Spinal Stabilization System
3262668|NCT00749996|Active Comparator|Control group|Single level herniectomy
3262669|NCT00749983|Experimental|1|creatine intake
3262670|NCT00749983|Placebo Comparator|2|placebo (dextrose) intake
3262671|NCT00749957|Experimental|1|Subjects at least 6 y/o treated with a lower dose of the vector by subretinal injection
3262672|NCT00749957|Experimental|2|Subjects at least 6 y/o treated with a higher dose of the vector by subretinal injection
3262673|NCT00749944|Experimental|varenicline|
3262674|NCT00749944|Placebo Comparator|placebo|
3262675|NCT00749931|Active Comparator|SOC|Standard of Care arm - standard of care lumpectomy procedure
3262676|NCT00749931|Experimental|Device + SOC|Use of the device in addition to the standard of care lumpectomy procedure.
3262677|NCT00749918|Experimental|1|Each subject was evaluated and data was collected before and after the intervention
3262678|NCT00749905|Experimental|1|Low fiber diet for 5 days prior to procedure
3262679|NCT00749905|Active Comparator|2|regular diet
3262680|NCT00749892|Experimental|Erlotinib Hydrochloride|Erlotinib Hydrochloride 150 mg (pill) by mouth daily for 3 to 5 weeks prior to surgery.
3262681|NCT00749879|Experimental|1|"25 mg Proellex capsule formulated with coarse microcrystalline cellulose~Fed State"
3262682|NCT00749879|Experimental|2|"25 mg Proellex capsule formulated with coarse microcrystalline cellulose~Fasting State"
3262683|NCT00749879|Experimental|3|"2, 25 mg Proellex capsules formulated with coarse microcrystalline cellulose~Fed State"
3262684|NCT00749879|Experimental|4|"2, 25 mg Proellex capsules formulated with coarse microcrystalline cellulose~Fasting State"
3262685|NCT00749879|Experimental|5|"2, 25 mg Proellex capsules formulated with microcrystalline cellulose~Fasting State"
3262686|NCT00749866|Active Comparator|1|Nebulised Gentamicin
3262687|NCT00749866|Placebo Comparator|2|Nebulised 0.9% Saline
3262742|NCT00749502|Experimental|Part C - T-PLL/CLL cohort|
3262743|NCT00749502|Experimental|Part D - CRC, endometrial, breast, and ovarian cancer cohort|
3262744|NCT00749489|Experimental|Femoral Nerve Block|Intervention patients will have a continuous fascia iliaca blocks placed by a regional anesthesiologist 24 hours after the initial single injection femoral nerve block or at the time of surgery.
3262745|NCT00749489|No Intervention|No Intervention|No intervention
3262746|NCT00749476|Experimental|1|
3262688|NCT00749853|Experimental|1|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
3262689|NCT00749853|Active Comparator|2|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
3262690|NCT00749840||HIV Care Questionnaire|Patients with a new diagnosis of HIV infection.
3262691|NCT00749827|Active Comparator|1|Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours
3262692|NCT00749827|Active Comparator|2|Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
3262693|NCT00749814|Experimental|A|Study group will receive melatonin.
3262694|NCT00749814|Placebo Comparator|B|Placebo
3262695|NCT00749814|No Intervention|C|No intervention control group.
3262696|NCT00749801|Active Comparator|A|nattokinase-mono formula (3500FU)
3262697|NCT00749801|Experimental|B|Nattokinase compound-multiple formulae
3262698|NCT00749801|Placebo Comparator|C|Placebo
3262699|NCT00749788|Experimental|1|JTT-302, 200 mg
3262700|NCT00749788|Experimental|2|JTT-302, 400 mg
3262701|NCT00749788|Placebo Comparator|3|Matching placebo tablets
3262702|NCT00749775||Eplerenone|Subjects who are treated with Eplerenone tablet for hypertension disease
3262703|NCT00749749|Experimental|Bupivacaine collagen sponge|Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.
3262704|NCT00749749|Active Comparator|ON-ON-Q PainBuster Post-op Pain relief SystemQ system|Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.
3262705|NCT00749736|Active Comparator|1|4000 IU of cholecalciferol per day
3262706|NCT00749736|Active Comparator|2|1 mcg of doxercalciferol per day.
3262707|NCT00749736|Placebo Comparator|3|placebo for six months
3262708|NCT00749723|Experimental|1: P-HIT-REZ 2005|"intravenous chemotherapy with carboplatin/etoposide,followed by~high dose chemotherapy with thiotepa, carboplatin, etoposide and autologous stem cell transplantation if patient have achieved a complete remission or~maintenance therapy with oral trofosfamide, etoposide"
3262709|NCT00749723|Experimental|2: P-HIT-REZ 2005|"oral chemotherapy with temozolomide, followed by~high dose chemotherapy with temozolomide, thiotepa and autologous stem cell transplantation if patient have achieved a complete remission~maintenance therapy with oral temozolomide or in case of progression with oral trofosfamide, etoposide"
3262710|NCT00749723|Experimental|3: E-HIT-REZ 2005|Phase II: oral chemotherapy with temozolomide after progression oral trofosfamide, etoposide
3262711|NCT00749723|Experimental|Intraventricular Etoposide|Phase II, intraventricular chemotherapy with etoposide
3262712|NCT00749710|Active Comparator|1|immediate operation - ORIF - of hip fracture in patient treated with clopidogrel
3262713|NCT00749710|Active Comparator|2|ORIF - surgical treatment patients not on antiaggregant therapy
3262714|NCT00749684||Adults with malignant melanoma at high risk of relapse|"Adults with malignant melanoma of the following stages:~II and III (>/= 1.5 mm Breslow thickness without distant metastases~melanoma with lymph node metastases"
3262715|NCT00749671|Active Comparator|ICD testing BIS|Bispectral Index Monitoring will be used to assess adequacy of moderate sedation during DFT.
3262716|NCT00749671|Active Comparator|ICD testing Ramsey|Ramsey Sedation Scale will be used to assess adequacy of moderate sedation during DFT
3262717|NCT00749658|Active Comparator|1|Order 1: Bupropion + Placebo Varenicline \Varenicline + Placebo Bupropion; Order 2: Varenicline + Placebo Bupropion \Bupropion + Placebo Varenicline
3262718|NCT00749658|Active Comparator|2|Order 1: Bupropion + Varenicline \Varenicline + Placebo Bupropion; Order 2: Varenicline + Placebo Bupropion \Bupropion + Varenicline
3262719|NCT00749658|Active Comparator|3|Order 1: Bupropion + Varenicline \Bupropion + Placebo Varenicline; Order 2: Bupropion+ Placebo Varenicline \Bupropion + Varenicline
3262720|NCT00749645|Active Comparator|1 - FANG(30)|1 - Active comparator, consisted of 30 adult patients with active Rheumatoid Arthritis, randomly assigned, taking the active product, in addition to base medication (Mtx + Pdn)
3262721|NCT00749645|Placebo Comparator|2 - Placebo|2 - Placebo comparator, consisted of 30 adult patients with active Rheumatoid Arthritis, randomly assigned, taking the placebo formulation, in addition to base medication (Mtx + Pdn)
3262722|NCT00749632|Active Comparator|1|
3262723|NCT00749632|Active Comparator|2|
3262724|NCT00749632|Active Comparator|3|
3262725|NCT00749619|Experimental|A|
3262726|NCT00749619|Experimental|B|
3262727|NCT00749619|No Intervention|C|
3262728|NCT00749606|Experimental|Individual Telephone Intervention|Individually administered weight loss intervention, based on the Diabetes Prevention Program, delivered by telephone in primary care practices.
3262729|NCT00749606|Active Comparator|Group Telephone Intervention|Group education conference calls to deliver the weight loss intervention, based upon the Diabetes Prevention Program, in primary care practices.
3262730|NCT00749593||CaHASE 1|Adults with CAH
3262731|NCT00749580|Experimental|1: Boosted PI+RAL|Group 1 Raltegravir 400 mg PO b.i.d. + their current boosted PI regimen Subjects in this study are HIV-Infected Patients who are on a stable boosted PI regimen; in this group are assigned to switched from their NRTIs as a Backbone to Raltegravir
3262732|NCT00749580|No Intervention|2: Boosted PI+NRTIs|Group 2 Continue the same regimen without change
3262733|NCT00749567|Experimental|1|Erlotinib/Bevacizumab
3262734|NCT00749554|Active Comparator|Disc biacuplasty|
3262735|NCT00749554|Placebo Comparator|Sham treatment.|
3262747|NCT00749463|Experimental|Gum 2|Nicotine Gum 2 mg for subjects smoking less than 20 cigarettes per day; 2 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
3262748|NCT00749463|Experimental|Gum 4|Nicotine Gum 4 mg for subjects smoking 20 or more cigarettes per day; 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
3262749|NCT00749463|Experimental|Patch|Nicotine Patch; Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
3262750|NCT00749450|Experimental|Arm I|Patients receive OxMdG or XELOX combination chemotherapy for a total of 12 courses for treatment lasting a total of 24 weeks.
3262751|NCT00749450|Experimental|Arm II|Patients receive OxMdG or XELOX combination chemotherapy for a total of 6 courses for treatment lasting a total of 12 weeks.
3262752|NCT00749424|Experimental|1|crushing technique
3262753|NCT00749424|Active Comparator|2|provisional T stenting technique
3262754|NCT00749411|Experimental|Arm 1|
3262755|NCT00749411|Placebo Comparator|Arm 2|
3262756|NCT00749398||Infliximab|Subjects with moderate-to-severe psoriasis who are treated with infliximab in daily clinics according to local country regulations and reimbursements.
3262757|NCT00749385|Experimental|1|PN 400
3262758|NCT00749385|Active Comparator|2|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule(20mg)
3262759|NCT00749385|Active Comparator|3|Enteric-coated naproxen tablet (500mg)
3262760|NCT00749385|Active Comparator|4|EC esomeprazole capsule (20mg)
3262761|NCT00749372|Other|1|Patients who meet eligibility will be sent for radiographic imaging to include T2* cardiac and liver MRI to ascertain quantification of organ-specific iron concentrations as well as cardiac left ventricular ejection fraction.
3262762|NCT00749359|Experimental|open label treatment|On each treatment period, subjects will receive controlled release paroxetine 37.5 milligram (mg) on Day 1.
3262763|NCT00749346|Experimental|A|Treatment with concomitant Alimta and NovoTTF-100L
3262764|NCT00749333|Experimental|1|
3262765|NCT00749333|Placebo Comparator|2|
3262766|NCT00749307|Experimental|1|
3262767|NCT00749307|Placebo Comparator|2|
3262768|NCT00749294||Observation|
3262769|NCT00749281||1|Patients with angiographically confirmed significant CAD
3262770|NCT00749281||2|Patients without significant CAD
3262771|NCT00749268|Active Comparator|A|
3262772|NCT00749268|Active Comparator|B|
3262773|NCT00749255||FFDM|a sum of at least 200 cancer cases, mammographically visible, on at least one image view (including masses and calcifications)
3262774|NCT00749242|Other|1|conventional orthopedic brace with antalgic treatment
3262775|NCT00749242|Other|2|balloon kyphoplasty introduction of balloon into the vertebral body, inflation of the balloon which creates a cavity, then balloon is deflated and removed , then introduction of the cement into the cavity.
3262776|NCT00749229|Other|1|Balloon kyphoplasty
3262777|NCT00749216|Experimental|QW|IV infusion of 400mg once each week for 2 months
3262778|NCT00749216|Experimental|Q4W|IV infusion of 400mg once every four weeks for 2 months
3262779|NCT00749216|Experimental|Q8W|IV infusion of 400mg once every eight weeks for 2 months
3262780|NCT00749203|Experimental|Ketamine|Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
3262781|NCT00749203|Active Comparator|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
3262782|NCT00749177|Active Comparator|2|Traditional Healing arm Provides Traditional Healing options only
3262783|NCT00749177|Active Comparator|3|Traditional Healing and usual standard of care arm Subjects will access both treatment options
3262784|NCT00749177|Active Comparator|1|Treatment as usual
3262785|NCT00749151|No Intervention|Literature|
3262786|NCT00749151|Experimental|Lit + Counseling|
3262787|NCT00749138|Experimental|tamoxifen|open label giving of tamoxifen
3262788|NCT00749125|Experimental|1 Lexapro|The depressed participants in this arm will be given Lexapro.
3262789|NCT00749125|No Intervention|2 Control|The nondepressed participants in this arm will not be given any intervention for depression.
3262790|NCT00749112|Experimental|A|
3262791|NCT00749099|Placebo Comparator|Phase I|All subject participate in Phase I
3262792|NCT00749099|Active Comparator|Phase II|All subject participate in Phase II
3262793|NCT00749086|Experimental|2|balloon kyphoplasty
3262794|NCT00749086|Active Comparator|1|vertebroplasty
3262795|NCT00749073|Other|Percutaneous Lumbar Decompression procedure|mild percutaneous lumbar decompression procedure
3262796|NCT00749060|Other|1|conventional treatment
3262797|NCT00749060|Other|2|kyphoplasty by balloons
3262798|NCT00749060|Other|3|vertebroplasty
3262799|NCT00749047|Experimental|1|Open label arm
3262800|NCT00749034|Experimental|1|VPM1002 in three dosages
3262801|NCT00749034|Active Comparator|2|BCG
3262802|NCT00749021|Active Comparator|Regimen 1|Intravitreal injection of Ranibizumab monthly for 12 months.
3262803|NCT00749021|Active Comparator|Regimen 2|Intravitreal injection of ranibizumab for 4 months (at Day 0, Month 1, Month 2, and Month 3) followed by by treatments on predefined re-treatment criteria.
3262804|NCT00749021|Active Comparator|Regimen 3|Intravitreal injection of Ranibizumab 2.0mg monthly for 12 months
3262805|NCT00749021|Active Comparator|Regimen 4|Intravitreal injection 2.0mg ranibizumab for 4 months (at Day 0, Month 1 and Month 2, and Month 3) followed by PRN treatments on pre-defined re-treatment criteria
3262806|NCT00749008||Term Infants|High risk infants with history of respiratory insufficiency requiring NICU care.
3262807|NCT00749008||Preterm Infants|Infants less than 37 weeks gestational age.
3262808|NCT00748995||Neurocognition Deployment Health Study (NDHS) participants|Surviving NDHS participants who returned from their initial deployment to Iraq or Afghanistan.
3262809|NCT00748982|Experimental|1|
3262810|NCT00748982|Placebo Comparator|2|
3262811|NCT00748969|Experimental|Growth hormone treatmen|Growth hormone treatment arm. Somatropin (DNA origin)
3262812|NCT00748969|No Intervention|No growth hormone treatment in year 1|No growth hormone treatment in year 1; option for treatment in year 2 open-label period.
3262813|NCT00748956|Experimental|Low dose NPY|Low dose, Receive 50 nmol dose of NPY
3262814|NCT00748956|Experimental|High dose NPY|High Dose, Receive 100 nmol dose of NPY
3262815|NCT00748956|Placebo Comparator|Placebo|Placebo comparator
3262816|NCT00748930||Cohort 1|Subjects previously enrolled in the ATTRACT trial from three Canadian sites.
3262817|NCT00748904|Experimental|A|35 patients receiving rifaximin
3262818|NCT00748904|Experimental|B|35 patients receiving lactulose
3262819|NCT00748891|Experimental|1|Open label 30mg Cediranib administered once daily during scanning phase and if tolerated by patient, until disease progression
3262820|NCT00748865|Experimental|Systane Ultra|Systane Ultra 1 drop each eye one time
3262821|NCT00748865|Active Comparator|Systane|Systane 1 drop each eye one time
3262822|NCT00748852|Experimental|1|JTT-302, 400 mg
3262823|NCT00748826||Infliximab -Rheumatoid Arthritis Participants|
3262824|NCT00748813|Other|1|
3262825|NCT00748800|Experimental|1|
3262826|NCT00748800|Active Comparator|2|
3262827|NCT00748787|Experimental|1|
3262828|NCT00748787|Placebo Comparator|2|
3262829|NCT00748774||MDASI-BT|MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) questionnaire given to patients with a primary brain tumor and their caregivers.
3262830|NCT00748761|Experimental|OCD Active CBT|Children with obsessive-compulsive disorder (OCD) will be treated with cognitive behavioral therapy (CBT) from the time of enrollment.
3262831|NCT00748761|Active Comparator|OCD Waitlist|Children with OCD will receive waitlist treatment at enrollment. Nonresponders will cross over to CBT.
3262832|NCT00748761|No Intervention|Healthy Controls|Healthy control children will be given no intervention.
3262833|NCT00748748|Experimental|1|Lactobacillus rhamnosus GG capsule three times per day while taking their antibiotic(s) and for 7 days following completion of the antibiotic.
3262834|NCT00748735||A1|heart failure patients undergoing CRT implantation
3262835|NCT00748722||1|Female patients, age 18-60 years, suitable for breast reconstruction using the lower abdominal tissue.
3262836|NCT00748709|Experimental|BIBW 2992 (Afatinib)|BIBW 2992 (Afatinib) for patients FISH positive for/or harboring EGFR or HER2 Mutation
3262837|NCT00748696|No Intervention|1|No intervention
3262838|NCT00748696|Experimental|2|patient receiving oral nutrition supplement
3262839|NCT00748696|Experimental|3|resistance training
3262840|NCT00748696|Experimental|4|patients receiving resistance training and oral nutritional supplement
3262841|NCT00748670|Experimental|A|
3262842|NCT00748657|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3262843|NCT00748644|Experimental|1|Experimental drug = rituximab for maintenance
3262844|NCT00748644|Active Comparator|2|Comparator drug = azathioprine for maintenance
3262845|NCT00748631|Experimental|1|balloon Kyphoplasty
3262846|NCT00748618|Other|1|Standard vitamin treatment
3262847|NCT00748618|Active Comparator|2|50,000 I.U. of vitamin D3
3262848|NCT00748605|Placebo Comparator|Placebo|S-2367 placebo + LCD (Low Calorie Diet) +RCD (Reduced Calorie Diet)
3262849|NCT00748605|Experimental|S-2367 1600 mg q.d. 54 weeks|S-2367 placebo + LCD for 6 weeks and 1600 mg S-2367 + RCD for 54 weeks
3262850|NCT00748605|Experimental|S-2367 1600 mg q.d. 60 weeks|S-23671600 mg q.d. + LCD for 6 weeks and S-2367 1600 mg q.d + RCD for 54 weeks
3262851|NCT00748592|Placebo Comparator|Placebo|
3262852|NCT00748592|Experimental|PD 0200390, 5 mg|
3262853|NCT00748592|Experimental|PD 0200390, 15 mg|
3262854|NCT00748592|Experimental|PD 0200390, 30 mg|
3262855|NCT00748579|Experimental|Cohort 1|0.5 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452
3262856|NCT00748579|Experimental|Cohort 2|≤ 1.0 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452
3262857|NCT00748566|Experimental|Active treatment (switch to oral Ziprasidone)|
3262858|NCT00748553|Experimental|All patients|All participants enrolled.
3262859|NCT00748540|Experimental|Implanted|Implanted with Vibrant Soundbridge
3262860|NCT00748527|Active Comparator|Arm I|Patients receive carboplatin IV over 30-60 minutes on day 1.
3262861|NCT00748527|Experimental|Arm II|Patients receive decitabine IV over 6 hours on day 1 and carboplatin IV over 30-60 minutes on day 8.
3262862|NCT00748501|Active Comparator|Cohort 1|SB-509 drug administration via IM injection of neck, arms, and legs
3262863|NCT00748501|Active Comparator|Cohort 2|SB-509 drug administration via IM injection of legs
3262864|NCT00748488|Experimental|A|Physical Therapy aimed to promote the level of physical activity
3262865|NCT00748488|Active Comparator|B|Physical Therapy aimed to move safely
3262866|NCT00748475|Experimental|Neurofeedback|
3262867|NCT00748462|Experimental|1|Fractional CO2 laser resurfacing
3262868|NCT00748449|Active Comparator|1|CT Colonography
3262869|NCT00748449|Active Comparator|2|Colonoscopy
3262870|NCT00748436|Placebo Comparator|A|Matching placebo twice a day
3262871|NCT00748436|Experimental|B|Betahistine 24 mg twice a day (48 mg/day total)
3262872|NCT00748436|Experimental|C|Betahistine 48 mg twice a day (96 mg/day total)
3262873|NCT00748423|Experimental|1|Nitric Oxide in nitrogen
3262874|NCT00748423|Placebo Comparator|2|Nitrogen
3262875|NCT00748410|Experimental|7 Days Repeat Dose|
3262876|NCT00748397|Experimental|A|
3262877|NCT00748384||1|Self trained subjects
3262878|NCT00748384||2|supervised trained subjects
3262879|NCT00748371|Experimental|1|ASA 40mg daily for 8 weeks followed by 3 weeks of observation
3262880|NCT00748371|Experimental|2|ASA 1300mg daily for 8 weeks followed by 3 weeks of observation
3262881|NCT00748371|Placebo Comparator|3|Placebo: one Avicel (cellulose) capsule by mouth twice daily
3262882|NCT00748358|Experimental|drug|drug
3262883|NCT00748345|Experimental|1|Caspofungin (drug)
3262884|NCT00748332|Active Comparator|1|Standard oral nutritional supplement
3262885|NCT00748332|Experimental|2|Omega-3-enriched oral nutritional supplement
3262886|NCT00748319|Other|1|Detection of KIR receptor
3262887|NCT00748306|Experimental|GSK2190915|Intervention
3262888|NCT00748306|Placebo Comparator|Placebo|
3262889|NCT00748293|No Intervention|A|PEG-ELS 2000 ml ingestion in the morning of colonoscopy
3262890|NCT00748293|Other|B|Low-reside diet on previous day (breakfast, lunch and dinner), PEG-ELS 1500 mL in the morning of colonoscopy
3262891|NCT00748280|Experimental|1|ORCT
3262892|NCT00748280|Experimental|2|PCEM/PMTA
3262893|NCT00748254||Rheumatoid Arthritis|Patients who have active disease affecting the joints in the hand will have Laser Based Photoacoustic Tomography (PAT), MRI, Ultrasound
3262894|NCT00748254||Normal controls|Healthy volunteers who do not have arthritis will also have Laser Based Photoacoustic Tomography (PAT), MRI, Ultrasound on the joints of their hand
3262895|NCT00748241|Experimental|Astra Tech Fixture ST|
3262896|NCT00748228|Experimental|A|10 mEq/day dietary sodium
3262897|NCT00748228|Experimental|B|150 mEq/day dietary sodium
3262898|NCT00748228|Experimental|C|300 mEq/day dietary sodium
3262899|NCT00748215|Experimental|Arm I: CASAD|Oral calcium aluminosilicate anti-diarrheal (CASAD) 4 times daily for 6 weeks in the absence of disease progression or unacceptable toxicity. Participants who develop grade 3 or 4 diarrhea may receive CASAD for an additional 6 weeks.
3262900|NCT00748215|Placebo Comparator|Arm II: Placebo|Oral placebo 4 times daily for 6 weeks in the absence of disease progression or unacceptable toxicity. Participants who develop grade 3 or 4 diarrhea may then receive CASAD for 6 weeks.
3262901|NCT00748202|Active Comparator|1|intravenous administration of C1-Inhibitor, after the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far
3262902|NCT00748202|Active Comparator|2|subcutaneous administration of C1-Inhibitor. After the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far.
3262903|NCT00748189|Experimental|ofatumumab + chlorambucil|ofatumumab dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days; chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
3262904|NCT00748189|Active Comparator|chlorambucil|chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
3262905|NCT00748176||A|
3262906|NCT00748163|Experimental|Stage IV Non-Small Cell Lung Cancer Patients|Patients with stage IV non-small cell lung cancer treated with paclitaxel albumin-stabilized nanoparticle formulation and sunitinib malate as first-line therapy.
3262907|NCT00748150|Experimental|1|
3262908|NCT00748137|Active Comparator|Fixed dose|Fixed meal size and fixed aspart insulin dose except for minor changes based on measured blood glucose. Detemir basal insulin.
3262909|NCT00748137|Experimental|ezy-BICC dose calculation card|variable meal size with variable aspart insulin dose determined with use of individualised dose calculation card. Detemir basal insulin.
3262910|NCT00748124|Experimental|PleuraSeal Sealant Device|
3262911|NCT00748124|Other|Control|
3262912|NCT00748111|Experimental|1|Sudden cardiac death hospitalized
3262913|NCT00748111|Experimental|2|Acute myocardial infarction
3262914|NCT00748111|Experimental|3|Angioplasty procedures programmed
3262915|NCT00748111|Experimental|4|Sudden cardiac death hospitalized without coronary syndrome
3262916|NCT00748098|Other|GSK1838262:placebo|GSK1838262 extended release tablets for Treatment Period 1 followed by Placebo for Treatment Period 2
3262917|NCT00748098|Other|Placebo:GSK1838262|Placebo for Treatment Period 1 followed by GSK1838262 for Treatment Period 2
3262918|NCT00748085|Experimental|Cryospray Ablation|Cryospray Ablation 4, 5-second spray cycles
3262919|NCT00748072|Placebo Comparator|Saline solution|patients treated with 1 ml of s.c. saline solution
3262920|NCT00748072|Experimental|DDAVP|treated with DDAVP (0.3 mcg/Kg s.c.) 1 hour before renal biopsy
3262921|NCT00748059|Experimental|A|Patients with Orthostatic Hypotension
3262922|NCT00748046|Experimental|Radium-223 chloride (Xofigo, BAY88-8223)|The patients will receive Radium-223 chloride as an escalating dose of either 50, 100 or 200 kBq/kg b.w. (0.0014, 0.0027 or 0.0054 mCi/kg).
3262923|NCT00748020|Active Comparator|group 1|Erythematogenic irradiation scheme
3262924|NCT00748020|Active Comparator|group 2|Suberythematogenic irradiation scheme
3262925|NCT00748007|Experimental|A|
3262926|NCT00748007|Placebo Comparator|Placebo|Placebo
3262927|NCT00747994||1|
3262928|NCT00747981|Experimental|A|Thoracic CT Scan
3262929|NCT00747968|Active Comparator|glp-1-analogue|During hyperglycemic clamp and GLP-1-analogue versus placebo infusion 15 patients will be heart OR CNS-PET scanned
3262930|NCT00747968|Placebo Comparator|placebo|During hyperglycemic clamp and GLP-1-analogue versus placebo infusion 15 patients will be CNS OR heart-PET scanned.
3262931|NCT00747942|No Intervention|A|exercise referral to lifestyle activities at the level of moderate intensity without support
3262932|NCT00747942|Active Comparator|B|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
3262933|NCT00747929|Placebo Comparator|S-2367 Placebo|Placebo + reduced calorie diet
3262934|NCT00747929|Experimental|S-2367 800 mg|S-2367 800 mg q.d. + reduced calorie diet
3262935|NCT00747929|Experimental|S-2367 1600 mg|S-2367 1600 mg q.d. + reduced calorie diet
3262936|NCT00747916|Experimental|CryoSpray Ablation (TM) System|subjects will receive cryotherapy using the CryoSpray Ablation (TM) System DOSE: up to 3 cycles of 10-40 second sprays
3262937|NCT00747890|Active Comparator|I|
3262938|NCT00747890|Other|II|
3262939|NCT00747877|Experimental|Arm I|Patients receive high-dose melphalan IV on day -1 followed by autologous stem cell transplantation (ASCT) on day 0.
3262940|NCT00747877|Experimental|Arm II|Patients receive low-dose cyclophosphamide IV or orally once a week for 12-20 weeks for a total of 12 courses.
3262941|NCT00747812|Experimental|1|Stimulation on from activation to 12 weeks post-activation. Stimulation off from 12 weeks post-activation to 16 weeks post-activation. Stimulation on from 16 weeks post-activation to end of study.
3262942|NCT00747812|Sham Comparator|2|Sham Stimulation from activation of device to 12 weeks post-activation. Stimulation on from 12 weeks post-activation on.
3262943|NCT00747799|Experimental|1|Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)
3262944|NCT00747760||1|Extended family members
3262945|NCT00747760||2|Control- subjects from the same town without known thyroid diseases
3262946|NCT00747747|No Intervention|Control|No coadiuvant treatment. The subject is treated with the antibiotic only and forbidden to take any coadiuvant medicine as a remedy for the symptoms during the period of the study.
3262947|NCT00747747|Active Comparator|Saline solution|Saline solution sprayed according to the product indication. Only one brand/specific product has been selected.
3262948|NCT00747747|Experimental|Sinuclean treatment|Sinuclean DM Spray.
3262949|NCT00747721|Experimental|1|Dexmedetomidine
3262950|NCT00747708|Experimental|Peripheral|Patients are randomised in a 1:1 ratio to receive granulocyte-colony stimulating factor (G-CSF) or placebo injection
3262951|NCT00747708|Experimental|Percutaneous intracoronary injection|All patients will receive granulocyte-colony stimulating factor injections followed by a bone marrow aspiration. Patients will be randomised in a 1:1 ratio to receive intracoronary injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
3262952|NCT00747708|Experimental|Percutaneous intramyocardial injection|All patients will receive granulocyte-colony stimulating factor injections followed by a bone marrow aspiration. Patients will be randomised in a 1:1 ratio to receive intramyocardial injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
3262953|NCT00747656||1|3 lead ECG subjects with chest pain and suspected ischemia transported to the nearest receiving ED and not eligible for bypass based on transport time
3262954|NCT00747656||2|3 lead ECG subjects with chest pain and suspected ischemia transported to the nearest receiving ED and eligible for bypass based on transport time, if 12 lead PHECG was possible
3262955|NCT00747656||3|12 lead ECG subjects with prehospital notification transported to nearest receiving ED adn not eligible for bypass to PCI center based on transport time
3262956|NCT00747656||4|12 lead PHECG subjects with prehospital notification bypassed past the nearest receiving ED to the PCI center.
3262957|NCT00747643|Active Comparator|Varenicline|For participants in the varenicline group, the medication doses followed the recommended dose schedule for the first 15 days of treatment: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day on days 8-15.
3262958|NCT00747643|Placebo Comparator|Placebo|Participants in this group received a placebo instead of medication. The placebo was taken once a day on days 1-3, twice a day on days 4-15.
3262959|NCT00747630|Experimental|Intervention|The group selected to watch the video.
3262960|NCT00747617|Active Comparator|PCOS group|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of recombinant human chorionic gonadotropin administered iv on 5 separate occasions.
3262961|NCT00747617|Active Comparator|Control group|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of recombinant human chorionic gonadotropin administered iv on 5 separate occasions.
3262962|NCT00747604||Increlex patients|Eligible patients will be patients beginning therapy with Increlex® or those previously treated with Increlex.
3262963|NCT00747578||1|"AS patients who fit the modified New York criteria (1984)~Exclusion criteria :~Patients who have cognitive impairment.~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~Patients who are less than 18 years old or older than 65 years old.~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
3262964|NCT00747578||2|"RA patients who fit the American College of Rheumatology (ACR) criteria (1987)~Exclusion criteria :~Patients who have cognitive impairment.~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~Patients who are less than 18 years old or older than 65 years old.~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
3262965|NCT00747578||3|"SLE patients who fit the ACR revised criteria for the classification of SLE (1997)~Exclusion criteria :~Patients who have cognitive impairment.~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~Patients who are less than 18 years old or older than 65 years old.~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
3262966|NCT00747565|Experimental|Tecnis Multifocal IOL group|Subjects implanted bilaterally with the Tecnis Multifocal IOL. Participants were enrolled in this arm in the original study and also in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.
3262967|NCT00747565|Active Comparator|CeeOn 911A monofocal control IOL group|Subjects implanted bilaterally with the CeeOn 911A monofocal IOL. Participants enrolled in this arm only in the original study; no control subjects were enrolled in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.
3262968|NCT00747539||1|This group will be composed of 165 HCV-infected people who are not also HIV infected.
3262969|NCT00747539||2|This group will be composed of 165 HCV-infected people who are also HIV infected.
3262970|NCT00747526|Experimental|Rabeprazole sodium 5 mg|
3262971|NCT00747526|Experimental|Rabeprazole sodium 10 mg|
3262972|NCT00747513|Experimental|I|intervention group
3262973|NCT00747487|Experimental|1|Idebenone
3262974|NCT00747487|Placebo Comparator|2|Placebo
3262975|NCT00747474|Experimental|Lipotecan|Intravenous Lipotecan (TLC388 HCl for Injection)
3262976|NCT00747461|Experimental|Cryospray Ablation|Experimental CSA (Cryospray Ablation)
3263036|NCT00747019|Active Comparator|PE|
3263086|NCT00746694||Caelyx|Participants with metastatic breast or ovarian cancer treated with Caelyx as part of standard treatment and according to data sheet approved indications.
3262977|NCT00747435|Experimental|Original Audiological Criteria|"Inclusion Criteria:~Pure-tone air-conduction threshold levels shall fall at or within the levels listed in the following chart.~Frequency (Hz): 250 500 750 1000 1500 2000 4000 8000 Lower Limit: 10 10 10 60 60 70 70 70 Upper Limit: 65 65 75 *110+ *110+*110+ *110+ *90+~Minimal benefit from optimally fit hearing aid/s, preferably bilateral, with monosyllabic word scores in quiet of ≤50% in the best-aided condition."
3262978|NCT00747435|Experimental|Expanded Audiological Criteria|"Pure-tone air-conduction threshold levels shall fall at or within the levels listed in the following chart.~Frequency (Hz): 250 500 750 1000 1500 2000 4000 8000 Lower Limit: 10 10 10 60 60 70 70 70 Upper Limit: 65 65 75 *110+ *110+*110+ *110+ *90+~Minimal benefit from optimally fit hearing aid/s, preferably bilateral, with monosyllabic word scores in quiet of ≤50% in the best-aided condition.~Study Arm 2 candidates are those who meet the inclusion criteria listed above with the exception that:~In the ear to be implanted, the pure-tone air conduction threshold(s) at 250, 500, and/or 750 Hz will be greater than or equal to 0 dB HL and less than 10 dB HL, and/or In the ear to be implanted, the pure-tone air conduction threshold(s) at 1000 and/or 1500 Hz will be greater than or equal to 0 dB HL and less than 60 dB HL and/or In their best-aided condition, they score 51-60% on monosyllabic word scores."
3262979|NCT00747422|Experimental|I|
3262980|NCT00747409|Active Comparator|Hum|use of human regular insulin and NPH insulin
3262981|NCT00747409|Active Comparator|Ana|use of insulin aspart and insulin detemir
3262982|NCT00747396|Experimental|Foster Care Group|Children randomized to this group were placed in high quality foster care developed for the study.
3262983|NCT00747396|No Intervention|Care As Usual Group|Children randomized to this group remained in institutional care.
3262984|NCT00747383|Active Comparator|1|
3262985|NCT00747383|Active Comparator|2|
3262986|NCT00747370|Other|1|16 healthy volunteers with no complaints of urinary symptoms and without urogenital prolapse of more than first degree.
3262987|NCT00747370|Other|2|Forty two stress urinary incontinence patients without prior urogenital prolapse or incontinence operation and without genital prolapse more than first degree
3262988|NCT00747370|Other|3|16 genital prolapse women without prior prolapse operations or any symptoms of incontinence
3262989|NCT00747357|Experimental|1|Balloon first
3262990|NCT00747357|Experimental|2|Stent First
3262991|NCT00747344|Placebo Comparator|Placebo - Controlled Period (CP)|
3262992|NCT00747344|Experimental|Ustekinumab 45 mg - CP|
3262993|NCT00747344|Experimental|Placebo to ustekinumab 45 mg - after CP|
3262994|NCT00747344|Experimental|Ustekinumab 45 mg - after CP|
3262995|NCT00747331|Experimental|A|
3262996|NCT00747331|Placebo Comparator|B|
3262997|NCT00747318|Experimental|1|
3262998|NCT00747305|Experimental|Sunitinib|Sunitinib will be administered for 8 weeks prior to sugery
3262999|NCT00747292|Active Comparator|Epidural|Epidural
3263000|NCT00747292|Active Comparator|2|Spinal
3263001|NCT00747292|Active Comparator|3|Patients in this limb receive a PCA
3263002|NCT00747279|Experimental|1|Carbohydrate restrictive strategy
3263003|NCT00747279|Active Comparator|2|Intensive insulin therapy
3263004|NCT00747253|Experimental|Single Active Arm|Only Arm. Patients treated using AutoLITT System.
3263005|NCT00747227|Experimental|ZV9003|modified light transmission intraocular lens
3263006|NCT00747227|Active Comparator|ZA9003|monofocal acrylic intraocular lens
3263007|NCT00747214|Experimental|CRx-102 plus DMARD therapy|
3263008|NCT00747214|Placebo Comparator|Placebo plus DMARD therapy|
3263009|NCT00747201|Active Comparator|2 Packaged intervention only|Patients will be seen by providers who receive the intervention package only.
3263010|NCT00747201|Experimental|1 Packaged intervention, training, and technical assistance|Patients will be seen by providers who receive the packaged intervention, along with provider training and ongoing technical assistance.
3263011|NCT00747188|Experimental|2|
3263012|NCT00747188|No Intervention|A, 2, III|
3263013|NCT00747175|Experimental|1|3 (alt.4) gradually increasing repeated oral doses of AZD1656 given to 3 (alt.4) groups (6 on active and 2 on placebo in each group)
3263014|NCT00747175|Experimental|2|Oral dose of AZD1656 titrated during 3 days to a tolerable dose (15 on active and 5 on placebo)
3263015|NCT00747162|Experimental|1|We will use The INVOS cerebral oximeter to determine oxygen content in the healthy muscle. In addition, we will use a the DermaSpectrometer to determine if there are differences in our readings according to skin color.
3263016|NCT00747149|Experimental|Rosuvastatin 1|titrated
3263017|NCT00747149|Experimental|Rosuvastatin 2|Non-titrated
3263018|NCT00747123|Placebo Comparator|Placebo|Subcutaneous injection on days 1, 29, 57 and 85.
3263019|NCT00747123|Experimental|ACE-011 0.1 mg/kg|Subcutaneous injection of ACE-011 0.1 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
3263020|NCT00747123|Experimental|ACE-011 0.3 mg/kg|Subcutaneous injection of ACE-011 0.3 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
3263021|NCT00747123|Experimental|ACE-011 0.5 mg/kg|Subcutaneous injection of ACE-011 0.5 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
3263022|NCT00747110|Experimental|A|9mg budesonide OD
3263023|NCT00747110|Active Comparator|B|3g mesalazine OD
3263024|NCT00747097|Experimental|1|gemcitabine+cetuximab
3263025|NCT00747084|Experimental|Arm 1: Study Treatment|Study Treatment: warm water loading of the sigmoid colon and warm water irrigation for dealing with colonic spasms.
3263026|NCT00747084|No Intervention|Arm 2: Control Treatment|Control Treatment: no water loading and waiting for spasms to subside.
3263027|NCT00747071|Experimental|1|Hospitalized patients with Clostridium difficile associated diarrhea.
3263028|NCT00747071|Experimental|2|Close hospital contacts of each index case
3263029|NCT00747058|Experimental|healthy volunteers|
3263030|NCT00747058|Placebo Comparator|Placebo|
3263031|NCT00747045|Experimental|Low tidal volume|Tidal volume of 6 mL/Kg ideal body weight
3263032|NCT00747045|Active Comparator|Usual care|Tidal volume of 10 mL/Kg ideal body weight
3263033|NCT00747032|Active Comparator|1|NYC 0462 Ointment
3263034|NCT00747032|Placebo Comparator|2|Placebo
3263035|NCT00747019|Experimental|PBPA|
3263037|NCT00747006|Experimental|TI Inhalation Powder (original protocol)|Under the original protocol, subjects with Type 1 and Type 2 diabetes will have TI Inhalation Powder administered prandially during dose optimization visits and meal challenge visits (with meals of varying carbohydrate contents). Subjects with Type 2 diabetes will also use TI Inhalation Powder daily at each meal between visits.
3263038|NCT00747006|Other|TI Inhalation Powder and Humalog (Amendment 1)|Under Amendment 1, TI Inhalation Powder will be administered prandially to a new subset of subjects with Type 2 diabetes during TI dose optimization visits and TI meal challenge visits (with meals of varying carbohydrate contents). Subjects will be crossed over to administration of Humalog 15 minutes before meals during Humalog dose optimization visits and Humalog meal challenge visits (with meals of varying carbohydrate contents). Subjects will also use TI Inhalation Powder daily at each meal between visits.
3263039|NCT00746993|Experimental|1|Structured contraceptive counseling and routine care.
3263040|NCT00746993|No Intervention|2|Routine care.
3263041|NCT00746980|Experimental|Treatment|Subjects receiving drug
3263042|NCT00746967|Other|Arm 1|
3263043|NCT00746954|Other|Arm 1 BUS to PLA to ACET|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=3
3263044|NCT00746954|Other|ARM 2 ACET to BUS to PLA|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=3
3263045|NCT00746954|Other|ARM 3 PLA to ACET to BUS|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=2
3263046|NCT00746941|No Intervention|Local standard of care|"All participants received local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.~Participants in this treatment arm had the option of adding 250 mg mefloquine by mouth at Week 4 (Day 28) or Week 8 (Day 56) daily for 3 days, and then weekly through Week 24."
3263047|NCT00746941|Experimental|Local standard of care plus mefloquine 250 mg|"All participants received local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.~Participants received 250 mg mefloquine by mouth on Days 0, 1, and 2 and then weekly through Week 24."
3263048|NCT00746902|Active Comparator|1|Arm 1: Active CPAP, a nasal continuous positive airway pressure
3263049|NCT00746902|Sham Comparator|2|Arm 2 : Sham CPAP :Placebo/CPAP
3263050|NCT00746889|Active Comparator|Corticosteroid Injection|40 mg of intraarticular triamcinolone acetonide
3263051|NCT00746889|Placebo Comparator|Placebo Injection|Intraarticular injection of 0.9% saline
3263052|NCT00746876|Active Comparator|Unipolar|15 patients randomized for treatment with a unipolar hip hemiarthroplasty
3263053|NCT00746876|Active Comparator|Bipolar|15 patients randomized for treatment with a bipolar hip hemiarthroplasty
3263054|NCT00746863|Experimental|1|Patients randomized to this arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
3263055|NCT00746863|No Intervention|2|Patients assigned to this arm will have the mid-urethral sling placed via the suprapubic approach in the standard fashion with no injection of Marcaine into the retropubic space.
3263056|NCT00746850|Experimental|H|early LC within 72 hours after the diagnosis with H (Harmonic)
3263057|NCT00746850|Active Comparator|MD|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)
3263058|NCT00746837|Experimental|1|Single ascending IV dose, 3 treatment periods separated by a minimum 14 day washout between doses
3263059|NCT00746837|Experimental|2|2 cohorts single IV dose + multiple oral dose period separated by a minimum of 14 days washout between IV and oral dose
3263060|NCT00746824|Experimental|1|"AM dose: 0.85 mg~PM dose: placebo"
3263061|NCT00746824|Experimental|2|"AM dose: 0.85 mg~PM dose: 0.85 mg"
3263062|NCT00746824|Experimental|3|"AM dose: 2.55 mg~PM dose: placebo"
3263063|NCT00746824|Experimental|4|"AM dose: placebo~PM dose: 2.55 mg"
3263064|NCT00746824|Experimental|5|"AM dose: 2.55 mg~PM dose: 2.55 mg"
3263065|NCT00746824|Experimental|6|"AM dose: placebo~PM dose: placebo"
3263066|NCT00746811|Other|1|P-OM3 for the first six weeks of treatment. Placebo for the second six weeks of treatment.
3263067|NCT00746811|Other|2|Placebo for the first six weeks of treatment. P-OM3 for the second six weeks of treatment.
3263068|NCT00746798|Experimental|ChimeriVax WN02 vaccine, low dose|Participants randomized to receive ChimeriVax WN02 vaccine, low dose
3263069|NCT00746798|Experimental|ChimeriVax-WN02 vaccine, medium dose|Participants randomized to receive ChimeriVax-WN02 vaccine, medium dose
3263070|NCT00746798|Experimental|ChimeriVax-WN02 vaccine, high dose|Participants randomized to receive ChimeriVax-WN02 vaccine, high dose
3263071|NCT00746798|Placebo Comparator|Placebo|Participants randomized to receive Placebo (Saline)
3263072|NCT00746785|Experimental|2.5 mg Olanzapine|"2.5 mg Olanzapine~1x per day for 12 weeks."
3263073|NCT00746785|Active Comparator|5mg Olanzapine|"5 mg Olanzapine~1x per day for 12 weeks."
3263074|NCT00746785|Placebo Comparator|Placebo|"Placebo~1x per day for 12 weeks."
3263075|NCT00746772|Active Comparator|1|Patients with oral lichen planus
3263076|NCT00746772|Placebo Comparator|2|Patients with oral lichen planus
3263077|NCT00746759||Standard of Care|
3263078|NCT00746733|Experimental|Vyvanse (LDX)|
3263079|NCT00746733|Experimental|Adderall XR (AXR)|
3263080|NCT00746720|Experimental|A, 1|Study part 1 (n = 8)
3263081|NCT00746720|Placebo Comparator|A, 2|Study part 1 (n = 4)
3263082|NCT00746720|Experimental|B, 1|Study part 2 (n = 20)
3263083|NCT00746720|Placebo Comparator|B, 2|Study part 2 (n = 20)
3263084|NCT00746707|Experimental|1|use of octyl-2-cyanoacrylate adhesive glue for perineal tear grade 1 in 80 women
3263085|NCT00746707|Active Comparator|3|use of traditional suturing for perineal tear grade 1 in 50 women
3263087|NCT00746681|Experimental|A|Tolterodine SR 2 mg once daily combined with pregabalin 75 mg twice daily
3263088|NCT00746681|Active Comparator|B|Tolterodine SR 4 mg once daily
3263089|NCT00746681|Placebo Comparator|C|Placebo
3263090|NCT00746681|Experimental|D|Tolterodine SR 4 mg once daily combined with pregabalin 150 mg twice daily
3263091|NCT00746681|Experimental|E|Pregabalin 150 mg twice daily
3263092|NCT00746668|Experimental|Control Group|Subjects randomly assigned to this group had their training delayed for 18 weeks. These subjects underwent four assessments: baseline and at three 6-week intervals' but, they were not given any training during this time. After this data collection period, these control subjects were given training on the three modules. However, their performance after each period of training was not assessed.
3263093|NCT00746668|Experimental|Group 1|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 2: Module 2 (Control of Reading Eye Movements) Training Session 3: Module 3 (Reading Practice with RSVP)"
3263094|NCT00746668|Experimental|Group 2|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 2 (Control of Reading Eye Movements) Training Session 2: Module 3 (Reading Practice with RSVP) Training Session 3: Module 1 (Visual Awareness and Eccentric Viewing)"
3263095|NCT00746668|Experimental|Group 3|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 3 (Reading Practice with RSVP) Training Session 2: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 3: Module 2 (Control of Reading Eye Movements)"
3263096|NCT00746668|Experimental|Group 4|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 2: Module 3 (Reading Practice with RSVP) Training Session 3: Module 2 (Control of Reading Eye Movements)"
3263097|NCT00746668|Experimental|Group 5|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 2 (Control of Reading Eye Movements) Training Session 2: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 3: Module 3 (Reading Practice with RSVP)"
3263098|NCT00746668|Experimental|Group 6|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 3 (Reading Practice with RSVP) Training Session 2: Module 2 (Control of Reading Eye Movements) Training Session 3: Module 1 (Visual Awareness and Eccentric Viewing)"
3263099|NCT00746655|Other|SBRT / TACE|
3263100|NCT00746642|Experimental|A|"Glucose measurements using Mellitor device."
3263101|NCT00746642|Active Comparator|B|"Glucose measurements conducted by using gold standard, Yellow Springs glucose analyzer"
3263102|NCT00746629|Active Comparator|Prescribed Skills|Behavioral skills are all prescribed and considered necessary tools expected to be used consistently, completely, and uniformly by all participants throughout treatment
3263103|NCT00746629|Experimental|Self-Directed Skills|Behavioral skills are considered a tool box from which families are encouraged to select skills that best apply to that family's situation in attempts to help their child make eating and activity change.
3263104|NCT00746616|Experimental|1|Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
3263105|NCT00746603|Experimental|1|Escalating dose of simvastatin
3263106|NCT00746590|Experimental|1|
3263107|NCT00746564|Experimental|Open Label|SJM Confirm Device
3263108|NCT00746551|Active Comparator|Ferrous fumarate, Ferri-6®, Oral tablet|In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
3263109|NCT00746551|Experimental|iron sucrose, Venofer®, intravenous drug|Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
3263110|NCT00746538|Experimental|1|metallic stent group
3263111|NCT00746538|Active Comparator|2|plastic stent group
3263112|NCT00746525|Experimental|Brain Computer Interface Training Stroke Experimental Group|Individuals in the stroke experimental group received treatment with BCI, FES, and motor learning targeted at their upper extremity motor deficits following stroke.
3263113|NCT00746512|Experimental|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days
3263114|NCT00746512|Placebo Comparator|Placebo 15 mg|Prednisone 15 mg placebo tablets once daily for 15 days
3263300|NCT00745108|Experimental|Tibolone 2.5 mg|
3263115|NCT00746512|Experimental|Prednisone 7.5 mg|"Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis."
3263116|NCT00746512|Placebo Comparator|Placebo 7.5 mg|"Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis."
3263117|NCT00746499|Experimental|1|No control group, only one active arm with subjects taking Raltegravir.
3263118|NCT00746486|Experimental|A|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d
3263119|NCT00746486|Active Comparator|B|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d
3263120|NCT00746473||1|15 HIV-1 infected individuals, with or without AIDS, who had never received ARV. These patients had not yet been indicated for ARV, or had had HIV-1 infection diagnosed a few days before inclusion in this study.
3263121|NCT00746473||2|"27 HIV-1 infected individuals, sick or not, on ARV treatment, five with two nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) and one nonnucleoside reverse transcriptase inhibitor (NNRTI), and 22 on HAART with two NRTI, or one NRTI and one NNRTI, and one protease inhibitor (PI), and VL equal to or greater than 50 copies of plasma RNA/mL.~Treatment duration in this group varied between three and 145 months (mean 53.62 months; median 42 months)."
3263122|NCT00746473||3|31 HIV-1 infected individuals on ARV treatment, 16 on HAART with two NRTI, or one NRTI and one NNRTI, and one PI, and 15 with two NRTI and one NNRTI. All G3 patients had undetectable VL for at least the past 6 months. Treatment in this group varied between five to 108 months (mean 48.13 months; median 42 months).
3263123|NCT00746473||4|20 blood donors without clinical complaints and negative for anti-HIV-1/2 antibodies. None of them showed any sign of disease.
3263124|NCT00746460|Experimental|A|Behavioral
3263125|NCT00746447|Experimental|3.0g OD|
3263126|NCT00746447|Experimental|1.5g OD|
3263127|NCT00746447|Active Comparator|0.5g TID|
3263128|NCT00746434|Active Comparator|1|Roflumilast cream 0.5%
3263129|NCT00746434|Placebo Comparator|2|Placebo cream
3263130|NCT00746421|Experimental|1|Quetiapine XR 200-400 mg/day
3263131|NCT00746421|Placebo Comparator|2|Placebo one pill per day matching 200, 300, or 400 mg
3263132|NCT00746408||Main 1|Insurants of the health insurance company BARMER using the prototype to receive expert system guided tailored internet information about the type of headache they suffer from.
3263133|NCT00746408||Main 2|Insurants of the health insurance company BARMER using search engines and portals to gather internet information about the type of headache they suffer from.
3263134|NCT00746408||Online 1|Internet users using the prototype to receive expert system guided tailored internet information about the type of headache they suffer from.
3263135|NCT00746408||Online 2|Internet users using search engines and portals to gather internet information about the type of headache they suffer from.
3263136|NCT00746395|Active Comparator|lubiprostone 24mcg single dose|lubiprostone 24mcg single dose po prior to capsule endoscopy
3263137|NCT00746395|Placebo Comparator|Sugar pill|Placebo (sugar pill) - matched single dose po prior to capsule endoscopy
3263138|NCT00746382|Active Comparator|1|Roflumilast cream 0.5%
3263139|NCT00746382|Placebo Comparator|2|Placebo cream
3263140|NCT00746369|No Intervention|2|
3263141|NCT00746369|Experimental|Intervention|IMARA HIV Prevention Intervention. Three individual sessions for incarcerated female teens.
3263142|NCT00746356|Experimental|Promote RF CRT-D|Patients with CRT-D device will have the autocapture features of the device tested.
3263143|NCT00746356|Experimental|Current RF ICD|Patients with ICD device will have the autocapture features of the device tested.
3263144|NCT00746343|Experimental|IRRI|"The integrated risk reduction intervention (IRRI) consists of three components:~psychiatric treatment by a study psychiatrist~assessment, referral, monitoring, and coordination by a certified registered nurse practitioner (CRNP) of medical treatment provided by the subject's own primary care physician~a healthy lifestyle behaviors program delivered by a lifestyle coach. The treating psychiatrist will work in collaboration with a CRNP and a lifestyle coach. The CRNP will assess and monitor the subject's medical needs and refer the subject to their primary care physician for care and will follow-up on adherence to the medical treatment recommendations. The CRNP will be responsible for coordinating the psychopharmacological care provided by the psychiatrist, the healthy lifestyle behaviors program that will be delivered by the lifestyle coach, and the medical care provided by the subject's PCP."
3263145|NCT00746343|Experimental|PCCM|"Psychiatric Care with Medical Monitoring (PCMM)~The psychiatric care with medical monitoring condition (PCMM) consists of two components:~psychiatric treatment by a study psychiatrist~assessment and referral by a psychiatric research nurse for medical treatment provided by the subject's own primary care physician.~The treating psychiatrist will be assisted by a psychiatric nurse clinician who will assess and monitor the subject's medical needs and refer the subject to their primary care physician for care."
3263146|NCT00746330|Experimental|F12M - PL - F12D - MFF|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 4: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
3263189|NCT00746070||B, essential hypertension|patients approved to be essential hypertension
3263190|NCT00746057|Other|1|Patients aged 18 to 65 years old receiving a first cadaveric renal graft.
3263191|NCT00746044||1|Healthy volunteers >18y, 20 male, 20 female
3263192|NCT00746031|Active Comparator|1|GnRH analogue-Zoladex
3263193|NCT00746031|Active Comparator|2|GnRH antagonist plus GnRH analogue
3263194|NCT00746031|No Intervention|3|
3263301|NCT00745108|Active Comparator|CE/MPA|
3263147|NCT00746330|Experimental|F12D - F12M - MFF - PL|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 2: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
3263148|NCT00746330|Experimental|MFF - F12D - PL - F12M|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 4: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
3263149|NCT00746330|Experimental|PL - MFF - F12M - F12D|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 2: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
3263150|NCT00746317|Experimental|1|
3263151|NCT00746304||1|infantile esotropia
3263152|NCT00746304||2|acquired esotropia
3263153|NCT00746291|Experimental|A|Traumatic brain injury
3263154|NCT00746291|Experimental|B|Cerebral palsy
3263155|NCT00746291|Experimental|C|Controls
3263156|NCT00746278|Experimental|1|Laparoscopic ovarian cystectomy using bipolar
3263157|NCT00746278|Experimental|2|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
3263158|NCT00746278|Active Comparator|3|Laparoscopic ovarian cystectomy using suture
3263159|NCT00746265|Active Comparator|SBT|Standard behavioral treatment based on the LEARN manual.
3263160|NCT00746265|Active Comparator|ABT|Acceptance-based group that is based on the behavioral interventions contained in LEARN manual
3263161|NCT00746252|Experimental|1|risperidone
3263162|NCT00746252|Experimental|2|aripiprazole
3263163|NCT00746239|Active Comparator|1|Subjects will be randomly assigned to receive either Ramelteon and Escitalopram OR Placebo and Escitalopram.
3263164|NCT00746239|Placebo Comparator|2|Subjects will be randomly assigned to receive either Ramelteon and Escitalopram OR Placebo and Escitalopram.
3263165|NCT00746226|Active Comparator|A|Numbers 509-513, 700-709 and 900-909 Probiotic combination of L. acidophilus and B. lactis
3263166|NCT00746226|Placebo Comparator|B|"Numbers 612-624 and 800-811~Microcrystalline cellulose"
3263167|NCT00746200|Experimental|A|
3263168|NCT00746200|Sham Comparator|S|
3263169|NCT00746187|Experimental|ASTRA TECH Implant System; Fixture ST|Ø 4.5 cm in lengths 9-13 mm
3263170|NCT00746187|Experimental|Biomet 3i; Osseotite® Implants|Ø 4.0 cm in lengths 8.5-13 mm
3263171|NCT00746174|Active Comparator|Rosiglitazone|Subjects in this arm will be randomly assigned to treatment with Rosiglitazone 4mg daily. After 4 weeks, we will assess changes in glucose levels and liver enzymes. The dose will then be increased to Rosiglitazone 8mg daily (if indicated). The patients will be reevaluated every 4 weeks, and at the end of 16 weeks, the participants will all be admitted to the research center at UTSW to measure changes in the following: 1) insulin sensitivity; 2) lipid content of heart, liver, & skeletal muscle; and 3) lipid oxidation using respiratory gas exchange. The patients will then switch to the alternative therapy for 16 additional weeks before the studies are repeated.
3263172|NCT00746174|Placebo Comparator|Placebo|Subjects in this arm will be randomly assigned to treatment with placebo. After 4 weeks, we will assess changes in glucose levels and liver enzymes. The patients will be reevaluated every 4 weeks, and at the end of 16 weeks, the participants will all be admitted to the research center at UTSW to measure changes in the following: 1) insulin sensitivity; 2) lipid content of heart, liver, & skeletal muscle; and 3) lipid oxidation using respiratory gas exchange. The patients will then switch to the alternative therapy for 16 additional weeks before the studies are repeated.
3263173|NCT00746161|Active Comparator|1|Roux-en-Y
3263174|NCT00746161|Experimental|2|double tract reconstruction
3263175|NCT00746148|Experimental|1|Reflexology
3263176|NCT00746148|No Intervention|2|No intervention
3263177|NCT00746135|Active Comparator|A|Conventional Biventricular Stimulation: RV Apex and LV Lead Tip
3263178|NCT00746135|Active Comparator|B|"Anodal-Cathodal Biventricular Stimulation: cathodal LV Stimulation und anodal RVHis Stimulation = Anodal-cathodal Bi-V."
3263179|NCT00746135|Active Comparator|C|Anodal-Cathodal Tri-V Stimulation: RV-apex and LV and RV-His
3263180|NCT00746122|Other|Open repair|Immediate Open Surgery
3263181|NCT00746122|Experimental|Endovascular strategy|Endovascular strategy involves immediate computed tomography (CT) and emergency EVAR, with open repair for patients anatomically unsuitable for EVAR
3263182|NCT00746109|Placebo Comparator|NOPACKING|The comparison group will undergo a routine incision and drainage procedure but will not have packing placed inside the abscess cavity.
3263183|NCT00746109|Experimental|PACKING|This group will receive wound packing as per usual protocol
3263184|NCT00746096|Experimental|IKH-01|ethinyl estradiol 0.035mg and norethisterone 1mg
3263185|NCT00746096|Placebo Comparator|Placebo|Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
3263186|NCT00746083|Experimental|Intervention group|
3263187|NCT00746083|No Intervention|Control group|
3263188|NCT00746070||A, primary aldosteronism|patients approved to be aldosteronism
3263195|NCT00746018|Experimental|1|The patients will already be undergoing a total hysterectomy with removal of the tubes and ovaries for a specific indication diagnosed or defined by their surgeon. If the patient is suitable to proceed by the surgeon, then he/she will perform a right salpingooophorectomy with the LigaSure devices.
3263196|NCT00746005|Experimental|1|3 g EPA-DHA
3263197|NCT00746005|Placebo Comparator|2|Placebo: sunflower oil
3263198|NCT00745992||Fungal infections|"Patients with invasive fungal infections; and~Patients who receive PO or IV voriconazole for more than 3 days"
3263199|NCT00745953|Active Comparator|Valsartan|This arm will determine if blockade of the renin-angiotensin system reduces myocardial fat levels and improves insulin sensitivity. It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month). Visits 1 & 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, & 24 hr ambulatory blood pressure monitoring. During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits. Visits 2 & 3 are needed for the adjustment of medication to the final dose level. During visits 4 & 5, Dr. Price will check subject's status as they continue the medication. In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.
3263200|NCT00745953|Active Comparator|Hydrochlorothiazide|This arm will determine if thiazide diuretics elevate myocardial triglyceride levels. It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month). Visits 1 & 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, & 24 hr ambulatory blood pressure monitoring. During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits. Visits 2 & 3 are needed for the adjustment of medication to the final dose level. During visits 4 & 5, Dr. Price will check subject's status as they continue the medication. In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.
3263201|NCT00745940|Experimental|MBCT Intervention Group|The curriculum of our mindfulness intervention draws upon elements from the mindfulness-based stress reduction program, and Segal and colleagues manual for mindfulness-based cognitive therapy. It was modified by one of the investigators to address issues associated with traumatic brain injury (e.g., problems with attention, concentration, memory, fatigue). The intervention was increased to ten weeks with one and a half hour weekly sessions, along with a 20-30 minute daily meditation home practice. Further adaptations included simplified language, the use of repetition to reinforce concepts, and visual aids. More attention was paid to fostering learning conditions to encourage an environment of trust and non-judgement. Connections between learning activities was also made more explicit.
3263202|NCT00745940|No Intervention|MBCT Control Group|Control group waited.
3263203|NCT00745927|No Intervention|Room air insufflations|Room air will be used for insufflations during colonoscopy
3263204|NCT00745927|Active Comparator|CO2 insufflations|CO2 will be used for insufflations during colonoscopy
3263205|NCT00745914|Experimental|1|Pioglitazone drug 15mg daily for 3 months then 30mg for 9 months (Peroxisome Proliferator-Activated Receptor-gamma agonist)
3263206|NCT00745914|Placebo Comparator|2|placebo comparator drug 15mg daily for 3months, then 30mg for 9 months
3263207|NCT00745888||1|age > 18 y/o Patients admitted to surgical ICU
3263208|NCT00745875|Experimental|1|ZD4054 + Pemetrexed
3263209|NCT00745875|Placebo Comparator|2|ZD4054 matched placebo + pemetrexed
3263210|NCT00745862||1|female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment
3263211|NCT00745849|Experimental|1|esomeprazole 40mg po bid
3263212|NCT00745849|Placebo Comparator|2|
3263213|NCT00745836|Experimental|atorvastatin 10 mg, 80 mg|
3263214|NCT00745823|Active Comparator|Raltegravir 400 mg b.i.d.|
3263215|NCT00745823|Experimental|Raltegravir 800 mg q.d.|
3263216|NCT00745810||1|sequential changes before and after cardiopulmonary bypass including ROS, antioxidant status, leukocyte elastase, complements, inflammatory cytokines
3263217|NCT00745797|Experimental|Prophylactic WBRT|Take the whole brain radiotherapy radiotherapy
3263218|NCT00745797|No Intervention|Observer Group|The first 14 days after randomization and patient follow-up after 1 month to complete the FACT-L questionnaire and the MMSE scale.
3263219|NCT00745784||1|Young spouses/domestic partners (20-49 years old) of cancer patients who have died from cancer.
3263220|NCT00745771|Active Comparator|1|200 mg Ketoprofen
3263221|NCT00745771|Active Comparator|2|100 mg Ketoprofen
3263222|NCT00745745|Active Comparator|1|Apical ICD lead placement
3263223|NCT00745745|Experimental|2|Mid-Septal ICD lead placement
3263224|NCT00745732|Experimental|Radiation Therapy + ZD6474|"Radiation Therapy - Phase I: 45 Gy at 3 Gy per fractions once a day.~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day.~ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth."
3263225|NCT00745719|Experimental|1|surgical total parathyroidectomy with forearm autografting
3263226|NCT00745706|Other|A|Implantable Loop Recorder (ILR) implant
3263227|NCT00745693|Experimental|1|1 hour exposure to filtered air, followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin-1 (5pmol/min)
3263228|NCT00745693|Experimental|2|1 hour exposure to filtered air, followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin receptor antagonists BQ-123 and BQ-788
3263229|NCT00745693|Experimental|3|1 hour exposure to dilute diesel exhaust (300mcg/m3), followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin-1 (5pmol/min)
3263230|NCT00745693|Experimental|4|1 hour exposure to dilute diesel exhaust (300mcg/m3), followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin receptor antagonists BQ-123 and BQ-788
3263231|NCT00745680||A|A: AMI patient
3263232|NCT00745667|Active Comparator|1|laparoscopic
3263233|NCT00745667|Active Comparator|2|open correction
3263234|NCT00745641||1|Sixty patients with abdominal illness and scheduled abdominal X-ray computed tomography examination will be included.
3263235|NCT00745615|Experimental|Laquinimod 0.3 mg|Double-blind period: participants who took laquinimod 0.3 mg in the previous study, plus participants who took placebo in the previous study and were randomized to laquinimod 0.3 mg in the double-blind extension.
3263236|NCT00745615|Experimental|Laquinimod 0.6 mg|"Double-blind period: Participants who took laquinimod 0.6 mg in the previous study, plus participants who took placebo in the previous study and were randomized to laquinimod 0.6 mg in the double-blind extension.~Open-label period: All study participants took laquinimod 0.6 mg once daily"
3263237|NCT00745602|Experimental|1|Patients referred for elective direct current cardioversion (DCCV) of atrial fibrillation.
3263238|NCT00745589|Active Comparator|1|first-line high dose sevelamer hydrochloride
3263239|NCT00745589|Active Comparator|2|second-line fixed low-dose sevelamer hydrochloride
3263240|NCT00745576|Experimental|1|
3263241|NCT00745563|Experimental|A|
3263242|NCT00745537|Experimental|Adolescent Mother|aged less than 17 years old and recently gave birth
3263243|NCT00745511|Active Comparator|1|
3263244|NCT00745511|Active Comparator|2|
3263245|NCT00745511|Placebo Comparator|3|
3263246|NCT00745498|Experimental|Preop IVB|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 1 to 14 days before vitrectomy
3263247|NCT00745498|Experimental|Intraop IVB|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
3263248|NCT00745498|No Intervention|No IVB|Patients will not receive bevacizumab before nor during vitrectomy
3263249|NCT00745485|Experimental|Zoldronic|
3263250|NCT00745472||1|
3263251|NCT00745472||2|
3263252|NCT00745459|Experimental|N|20 mL NPO-11
3263253|NCT00745446|Experimental|1|1 hour exposure to filtered air
3263254|NCT00745446|Experimental|2|1 hour exposure to diesel exhaust (300mcg/m3)
3263255|NCT00745446|Experimental|3|1 hour exposure to filtered diesel exhaust
3263256|NCT00745433||A|Repaglinide add-on to metformin.
3263257|NCT00745420|Experimental|Hematopoietic Stem Cell Transplantation|Bone Marrow Transplant with GVHD Prophylaxis Regimen
3263258|NCT00745407|Experimental|fenofibrate 160 mg, placebo|
3263259|NCT00745381||1|This registry will be open to all patients with GEPNET or NET of unknown primary.
3263260|NCT00745368|Experimental|Raltegravir|Raltegravir 400 mg tablets twice daily
3263261|NCT00745355||1|new patients with bladder cancer and/or are scheduled for radical cystectomy and urinary diversion
3263262|NCT00745342|Experimental|Teamwork Group|Families randomized to the Teamwork Group received the behavioral family teamwork intervention.
3263263|NCT00745342|No Intervention|Standard Care|Families in the Standard Care group received standard diabetes care and equal attention from study staff between visits to schedule appointments and encourage regular diabetes follow-up care.
3263264|NCT00745329||2|"patients~healthy volunteers"
3263265|NCT00745316|Experimental|1|oral Dose 1
3263266|NCT00745316|Experimental|2|oral Dose 2
3263267|NCT00745316|Experimental|3|oral Dose 3
3263268|NCT00745316|Experimental|4|oral Dose 4
3263269|NCT00745316|Experimental|5|oral Dose 5
3263270|NCT00745316|Placebo Comparator|6|Placebo - 2 capsules bid
3263271|NCT00745303||1|Subjects in this group received TCC training for 3 months
3263272|NCT00745303||2|Subjects in this group received no TCC training within 3 months
3263273|NCT00745290|Active Comparator|Bupivacaine HCl|Single dose of 200 mg bupivacaine HCl administered intraoperatively via local infiltration
3263274|NCT00745290|Other|SKY0402|Single dose of 600 mg SKY0402 (study drug) administered intraoperatively via local infiltration
3263275|NCT00745277|Active Comparator|1|Subjects will be randomly chosen to receive high dose carbidopa plus levodopa and take it for 4 weeks. After a hospital inpatient stay, the subject will then receive a low dose carbidopa plus levodopa for 4 weeks followed by one last hospital inpatient stay. The hospital stays include IV administration of the levodopa.
3263276|NCT00745277|Active Comparator|2|Subjects will be randomly chosen to receive low dose carbidopa plus levodopa and take it for 4 weeks. After a hospital inpatient stay, the subject will then receive high dose carbidopa plus levodopa for 4 weeks followed by one last hospital inpatient stay. The hospital stays will include IV administration of levodopa.
3263277|NCT00745264|Experimental|2|400 mg Ketoprofen from Diractin to 4 joints
3263278|NCT00745264|Experimental|3|100 and 400 mg Ketoprofen used concomittant with heat
3263279|NCT00745264|Experimental|4|100 and 400 mg Ketoprofen concomittant with moderate exercise
3263280|NCT00745264|Experimental|1|100 mg ketoprofen to 2 joints
3263281|NCT00745251|Experimental|VI-0521|15 mg Phentermine and 92 mg Topiramate
3263282|NCT00745251|Placebo Comparator|Placebo|
3263283|NCT00745238|Experimental|Myotonic Dystrophy 1|
3263284|NCT00745225|Experimental|Active intervention arm|Peroxisome proliferator activator receptor gamma treatment, Pioglitazone
3263285|NCT00745225|Placebo Comparator|placebo pill|placebo comparator
3263286|NCT00745199|Experimental|1|Patients on hemodialysis with pruritus, receiving cromolyn sodium
3263287|NCT00745199|Experimental|2|patients on hemodialysis with pruritus, receiving placebo
3263288|NCT00745199|No Intervention|3|Patients on hemodialysis but without pruritus who do not receive any treatment.
3263289|NCT00745186|Active Comparator|1|Glucagen
3263290|NCT00745186|Experimental|2|Mayne Glucagon
3263291|NCT00745173|Other|1|
3263292|NCT00745160||1|Never-smokers with lung cancer
3263293|NCT00745147|Experimental|A|Chinese herbal formula + Placebo of duphalac
3263294|NCT00745147|Active Comparator|B|Duphalac + Placebo of Chinese herbal formula
3263295|NCT00745134|Active Comparator|Radiotherapy + Capecitabine + Curcumin|Radiotherapy 45 Gy once a day, for 5 days in a row for 5-6 weeks (up to 28 treatments in all). Capecitabine 825 mg/m^2 by mouth twice a day only on days of radiation (Monday through Friday). Curcumin 4 gm tablets by mouth twice a day.
3263296|NCT00745134|Placebo Comparator|Radiotherapy + Capecitabine + Placebo|Radiotherapy 45 Gy once a day, for 5 days in a row for 5-6 weeks (up to 28 treatments in all). Capecitabine 825 mg/m^2 by mouth twice a day only on days of radiation (Monday through Friday). Placebo tablets by mouth twice a day.
3263297|NCT00745121|Experimental|A|Patients with osteoporosis/osteopenia.
3263298|NCT00745121|Experimental|B|Control (non-osteoporotic/-osteopenic patients).
3263299|NCT00745108|Experimental|Tibolone 1.25 mg|
3263302|NCT00745095|No Intervention|SCI MoviPrep® (without NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)<=50ml/min and SCI, GFR>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid [MoviPrep®] (without neostigmine plus glycopyrrolate [NG])
3263303|NCT00745095|No Intervention|SCI PIEE (without NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)>=50ml/min) pulsed irrigation enhanced evacuation [PIEE] (without neostigmine plus glycopyrrolate [NG])
3263304|NCT00745095|No Intervention|Control MoviPrep® only|(Control, glomerular filtration rate (GFR)>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid (MoviPrep®) only (no NG)
3263305|NCT00745095|No Intervention|Control PIEE only|(Control, glomerular filtration rate (GFR)>=50ml/min), pulsed irrigation enhanced evacuation (PIEE) only (no NG)
3263306|NCT00745095|Experimental|SCI MoviPrep® (with NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)<=50ml/min and SCI GFR>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid [MoviPrep®] (with neostigmine plus glycopyrrolate [NG])
3263307|NCT00745095|Experimental|SCI PIEE (with NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)>=50ml/min) pulsed irrigation enhanced evacuation (PIEE) (with neostigmine plus glycopyrrolate [NG])
3263308|NCT00745043|Placebo Comparator|R302|Daily placebo capsules
3263309|NCT00745043|Active Comparator|R303|Daily metoprolol 95mg capsules
3263310|NCT00745043|Active Comparator|R304|Daily propranolol 80mg capsules
3263311|NCT00745043|Active Comparator|Open Label|Daily Metoprolol 190mg capsules
3263312|NCT00745030|Experimental|1|Ramelteon (TAK-375) 8mg tablets
3263313|NCT00745030|Placebo Comparator|2|Placebo 8 mg tablets
3263314|NCT00745017|Experimental|1|
3263315|NCT00745017|Experimental|2|
3263316|NCT00745017|Experimental|3|
3263317|NCT00745004|Experimental|1|Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days.
3263318|NCT00745004|Placebo Comparator|2|Placebo 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days.
3263319|NCT00744991|Experimental|Arm A|Enzastaurin, Open Label
3263320|NCT00744978|Experimental|Varenicline|
3263321|NCT00744978|Placebo Comparator|Placebo|
3263322|NCT00744965|Active Comparator|1|Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
3263323|NCT00744965|Placebo Comparator|2|Women with mild gestational diabetes will be started ADA diet and placebo.
3263324|NCT00744939||Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Participants received Magnevist in accordance with its labeling
3263325|NCT00744926|Placebo Comparator|placebo|
3263326|NCT00744926|Experimental|taspoglutide 10mg sc|
3263327|NCT00744926|Experimental|taspoglutide 10mg/20mg sc|
3263328|NCT00744913|Experimental|1|
3263329|NCT00744913|Active Comparator|2|
3263330|NCT00744900|Experimental|A|
3263331|NCT00744874|Experimental|Ablated Patients|Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
3263332|NCT00744861|Active Comparator|Low Intensity Pulsed Ultrasound|Low Intensity Pulsed Ultrasound
3263333|NCT00744861|Sham Comparator|Sham|Sham (inactive) low intensity pulsed ultrasound device
3263334|NCT00744848|Active Comparator|Bupivacaine HCl|"100 mg Bupivacaine HCl (e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402.~A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration."
3263335|NCT00744848|Other|SKY0402|"300 mg SKY0402 in a 40-mL injection volume.~A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration."
3263336|NCT00744835|Experimental|1|Ablation Management
3263337|NCT00744796|Other|D|Not a comparative group. Assessing single group
3263338|NCT00744757|Experimental|Decitabine|Decitabine 20 milligram per square meter (mg per m^2) will be administered intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
3263339|NCT00744744||Survey|
3263340|NCT00744731|Experimental|001|placebo placebo for 1 week
3263341|NCT00744731|Experimental|002|carisbamate 400 mg/day to 1,200 mg per day
3263342|NCT00744705||1|Normal subjects who received routine health check-up in a comprehensive medical testing center
3263343|NCT00744692|Experimental|RIC Cord Blood Transplant|Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
3263344|NCT00744679|Experimental|Natalizumab 300 mg|Natalizumab infused at 300 mg every 28 days during the screening and assessment periods of the study which continues the therapy of the previous 12 months and maintains steady-state pharmacokinetics.
3263345|NCT00744666|Experimental|1|Patients receive Prednisolone 1% 1gtt qid x 4 weeks. If the intraocular pressure (IOP) after the 4 weeks is > or equal to 21 mmHg, then IVTA will be withheld. If the IOP < 21mmHg, then patients will receive an injection of IVTA.
3263346|NCT00744666|No Intervention|2|Patients will receive an injection of IVTA (no trial of Prednisolone gtts is given).
3263347|NCT00744653|Other|1|Patients with local-regional recurrence of breast cancer, lesion over 3 cm.
3263348|NCT00744640|Experimental|single|single arm study with triple combination chemotherapy
3263349|NCT00744627|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
3263350|NCT00744627|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
3263351|NCT00744614||1|Medical Intensive care unit patients with asthma, COPD, ILD or coronary disease who are at risk of intubation
3263352|NCT00744601||1|Patients with Cocaine Addiction
3263353|NCT00744601||2|Healthy Control Volunteers
3263354|NCT00744588||alcohol dependence|Alcohol-dependent subjects currently being treated in an inpatient treatment facility.
3263355|NCT00744575||1|Chronic Back Pain
3263356|NCT00744575||2|Healthy Sex & Age Matched Controls
3263357|NCT00744549|Experimental|A|This group of men will be on active treatment (antioxidants) for one year and placebo for the second year.
3263358|NCT00744549|Experimental|B|This group of men will be on placebo for one year and active treatment (antioxidants) for the second year.
3263359|NCT00744536|Experimental|Lenalidomide and Melphalan|Lenalidomide + Melphalan both given metronomically
3263360|NCT00744523|Experimental|Mo.ma cerebral protection device|Mo.Ma cerebral protection device
3263361|NCT00744510|Experimental|1|Reflexology
3263362|NCT00744510|No Intervention|2|
3263363|NCT00744497|Placebo Comparator|Placebo|Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
3263364|NCT00744497|Active Comparator|Dasatinib|Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
3263365|NCT00744484|Experimental|B1|B1 - training in water
3263366|NCT00744484|Experimental|S1|S1 - training on land
3263367|NCT00744471|Experimental|Tanezumab 10 mg|Tanezumab 10 mg IV every 8 weeks
3263368|NCT00744471|Experimental|Tanezumab 5 mg|Tanezumab 5mg IV every 8 weeks
3263369|NCT00744471|Experimental|Tanezumab 2.5 mg|Tanezumab 2.5 mg IV every 8 weeks.
3263370|NCT00744471|Experimental|Placebo|Placebo
3263371|NCT00744458|Active Comparator|1|
3263372|NCT00744458|Active Comparator|2|
3263373|NCT00744458|Active Comparator|3|
3263374|NCT00744445|Active Comparator|0800|r-HuEPO administered at 0800 hrs
3263375|NCT00744445|Active Comparator|1500|r-HuEPO administered at 1500 hrs
3263376|NCT00744445|Active Comparator|2200|r-HuEPO administered at 2200 hrs
3263377|NCT00744419|Experimental|3 age groups|Assigned to the arm based on age.
3263378|NCT00744406|Experimental|1|
3263379|NCT00744406|Experimental|2|
3263380|NCT00744406|Experimental|3|
3263381|NCT00744393|Active Comparator|A|Active drug
3263382|NCT00744393|Placebo Comparator|P|Placebo drug
3263383|NCT00744380|Active Comparator|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4) as other sedatives are down titrated. Daily awakenings are used.
3263384|NCT00744380|Experimental|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)as other sedatives are down titrated. Daily awakenings are used.
3263385|NCT00744367|Placebo Comparator|Placebo|Placebo in addition to continued stable metformin plus pioglitazone treatment. After the first 24 weeks patients on placebo will be switched to taspoglutide 10mg once weekly or taspoglutide 20mg once weekly (after 4 weeks of taspoglutide 10mg once weekly.
3263386|NCT00744367|Experimental|Taspoglutide 10mg|Taspoglutide 10mg once weekly in addition to continued stable metformin plus pioglitazone treatment
3263387|NCT00744367|Experimental|Taspoglutide 10mg/20mg|Taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued stable metformin plus pioglitazone treatment.
3263388|NCT00744354|Experimental|Non-Randomized Open Label Single Arm|Phase 1 dose escalation trial of vorinostat in combination with bortezomib and pegylated liposomal doxorubicin hydrochloride.
3263389|NCT00744341|Experimental|1|
3263390|NCT00744341|Experimental|2|
3263391|NCT00744341|Experimental|3|
3263392|NCT00744341|Experimental|4|
3263393|NCT00744341|Placebo Comparator|5|
3263394|NCT00744328|Experimental|Transdermal Estradiol|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The capsules for women in this arm do not contain any active ingredients. The skin patch contains transdermal estradiol ranging in dose from 50 to 200 mcg/day
3263395|NCT00744328|Active Comparator|Sertraline|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The skin patch contains no active ingredients, though packaging is designed to match active patches. The capsules contain sertraline ranging in dose from 25 to 200mg/day
3263396|NCT00744328|Placebo Comparator|Placebo|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The capsules for women in this arm do not contain any active ingredients. The skin patch contains no active ingredients, though packaging is designed to match active patches.
3263397|NCT00744315|Other|1|Controlled
3263398|NCT00744302|Experimental|PCD|Physiological calcium (1.25 mmol/L) dialysate therapy All subjects in the study phase will continue to take calcium carbonate and/or active vitamin D agents.
3263399|NCT00744302|Active Comparator|NCD|Normal calcium (1.5 mmol/L) dialysate therapy All subjects in the study phase will continue to take calcium carbonate and/or active vitamin D agents.
3263400|NCT00744289|No Intervention|Arm 1|Participants in Arm 1 will not receive any financial incentive after the second and third dose of hepatitis B vaccine have been administered.
3263401|NCT00744289|Other|Arm 2|Participants in Arm 2 will receive a small financial incentive after the second and third dose of the hepatitis B vaccine
3263402|NCT00744276|Active Comparator|1|
3263403|NCT00744276|Active Comparator|2|
3263404|NCT00744276|Active Comparator|3|
3263405|NCT00744276|Placebo Comparator|4|
3263406|NCT00744276|Placebo Comparator|5|
3263407|NCT00744276|Placebo Comparator|6|
3263408|NCT00744263|Placebo Comparator|Placebo|
3263409|NCT00744263|Experimental|13-valent pneumococcal conjugate vaccine|
3263410|NCT00744250|Other|1|"Pre-treatment vs. post-treatment-~In the first phase, before administration of the capsules and liquid diet, baseline gastric and duodenal secretions will be aspirated via the oro-enteric tube. Subjects will get 5 placebo capsules at Time=0 given orally with the liquid Lundh diet. Pancreato-biliary and duodenal secretions in the duodenal region will be aspirated continuously over the first 20 min. Gastric and duodenal fluids will be aspirated from 20-180 min at specified time points. Following a rest of 1 hour, the same process will be repeated with the drug capsules. At the end of the study the catheter will be removed and patient will be offered a meal."
3263411|NCT00744237|Experimental|1|"Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration~Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration~Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration~Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration~Open-label amlodipine may be given"
3263412|NCT00744237|Active Comparator|2|"Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration~Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration~Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration~Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration~Open-label amlodipine may be given"
3263413|NCT00744237|Active Comparator|3|"HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration~HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration~Open-label amlodipine may be given"
3263414|NCT00744224|Placebo Comparator|1|
3263415|NCT00744224|Active Comparator|2|
3263416|NCT00744224|Active Comparator|3|
3263417|NCT00744211|Placebo Comparator|Vehicle|Vehicle Group
3263418|NCT00744211|Experimental|ET-ARA 1mg/kg|ET-ARA 1 mg/kg
3263419|NCT00744211|Experimental|ET-ARA 2mg/kg|ET-ARA 2 mg/kg
3263420|NCT00744198|Active Comparator|1|Autologous sling
3263421|NCT00744198|Active Comparator|2|Synthetic sling
3263422|NCT00744198|Active Comparator|3|Biological sling
3263423|NCT00744185|Placebo Comparator|2|30-days placebo treatment
3263424|NCT00744185|Experimental|1|30-days propranolol treatment
3263425|NCT00744172|Active Comparator|I|laparoscopy
3263426|NCT00744172|Active Comparator|2|vaginal
3263427|NCT00744172|Active Comparator|3|abdominal
3263428|NCT00744159||OC|Open colorectal resection
3263429|NCT00744159||LC|Laparoscopic colorectal resection
3263430|NCT00744146|Experimental|1|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 50 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
3263431|NCT00744146|Experimental|2|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 100 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
3263432|NCT00744146|Experimental|3|"Eight volunteers total.~Randomized such that six volunteers will receive Protexia as a single 250 mg dose and two volunteers will receive saline placebo of the same volume on Study Days 1 and 72.~Volunteers to be followed for approximately 142 days total."
3263433|NCT00744146|Experimental|4|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 500 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
3263434|NCT00744146|Experimental|5|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 750 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
3263435|NCT00744133|Experimental|Group 1: 1, 3, or 5 bites|Part A: 18 subjects receive 1, 3, or 5 bites of Anopheles stephensi mosquitoes infected with the NF54 strain of Plasmodium falciparum.
3263436|NCT00744133|Experimental|Group 2: N bites|Part B: 20 subjects receive N bites of Anopheles stephensi mosquitoes infected with the NF54 strain of Plasmodium falciparum.
3263437|NCT00744094|Placebo Comparator|1|placebo drink
3263438|NCT00744094|Experimental|2|protein drink
3263439|NCT00744068|Experimental|1|Structured Directive Telephone Support Calls
3263440|NCT00744068|Experimental|2|Structured Non-Directive Telephone Continuing Care Support
3263441|NCT00744068|Experimental|3|Unstructured Directive Telephone Support
3263442|NCT00744068|Experimental|4|Unstructured Non-Directive Telephone Support
3263443|NCT00744068|No Intervention|5|
3263444|NCT00744055|Experimental|Prazosin|prazosin (16mg/day)
3263445|NCT00744055|Placebo Comparator|Placebo|Placebo in identical looking capsule blister packs
3263446|NCT00744042|Other|asfotase alfa|asfotase alfa
3263447|NCT00744029|Active Comparator|Intervention group|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
3263448|NCT00744029|No Intervention|Control group|No intervention was performed
3263449|NCT00744016|Placebo Comparator|2|Placebo
3263450|NCT00744016|Active Comparator|1|Granulated mesalamine
3263451|NCT00743990|Active Comparator|A|
3263452|NCT00743990|Placebo Comparator|B|
3263453|NCT00743990|No Intervention|3|no intervention
3263454|NCT00743977|Active Comparator|A|
3263455|NCT00743977|Experimental|B|
3263456|NCT00743964|Experimental|ECX|Epirubicin, cisplatin and capecitabine combination chemotherapy will be administered.
3263457|NCT00743964|Active Comparator|CX|Cisplatin and capecitabine combination chemotherapy will be administered.
3263458|NCT00743951|Experimental|1 Patient decision aid|Patient decision aid about treatment options for osteoarthritis
3263459|NCT00743951|Active Comparator|2 Usual care|Usual patient educational materials
3263460|NCT00743938|Experimental|A1|
3263461|NCT00743938|Active Comparator|B2|
3263462|NCT00743925|Active Comparator|1|A-002 (500 mg QD) plus Atorvastatin (80 mg QD)
3263463|NCT00743925|Placebo Comparator|2|Matching Placebo tablets plus Atorvastatin (80 mg QD)
3263464|NCT00743912|Experimental|1|open-label rifaximin 550 mg TID
3263465|NCT00743899|Experimental|1|The aggressive group
3263466|NCT00743899|Experimental|2|The conservative group
3263467|NCT00743886|Placebo Comparator|2|saline
3263468|NCT00743886|Experimental|1|Plasma Rich in Growth Factors (PRGF)
3263469|NCT00743873|Placebo Comparator|2|saline
3263470|NCT00743873|Experimental|1|Plasma Rich in Growth Factors (PRGF)
3263471|NCT00743860|Experimental|Single dose|single oral dose
3263472|NCT00743860|Experimental|Repeat Dose|28 day repeat dose
3263473|NCT00743847|Placebo Comparator|placebo|
3263474|NCT00743847|Active Comparator|varenicline 0.5 mg BID|
3263475|NCT00743847|Active Comparator|varenicline 1mg BID|
3263476|NCT00743834|Other|A|Effectiveness of Luvox CR plus Web-based CBT for OCD
3263477|NCT00743821||TBI Patients|Individuals who have suffered a mild traumatic brain injury and have persistent post-concussive symptoms (PCS)
3263478|NCT00743821||Normals|Individuals of comparable age and education who have not suffered a traumatic brain injury
3263479|NCT00743795|Placebo Comparator|1|Peginterferon and ribavirin + placebo BID for 48 weeks + 24 weeks treatment-free follow-up (n = 50)
3263480|NCT00743795|Experimental|2|Peginterferon and ribavirin + GS 9190 40 mg BID for 48 weeks + 24 weeks treatment-free follow-up (n = 100)
3263481|NCT00743795|Experimental|3|Peginterferon and ribavirin + GS 9190 40 mg BID for 48 weeks + 24 weeks treatment-free follow-up. However, subjects who achieve RVR (HCV RNA undetectable at Week 4) and maintain that response through Week 24 will stop all study drugs at Week 24 and be followed for an additional 48 weeks (n = 50).
3263482|NCT00743769|Active Comparator|2|"Thymosin Beta 4~A single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD (once a day)"
3263483|NCT00743769|Placebo Comparator|1|Placebo A single bolus injection of 0.0 mg QD of thymosin beta 4
3263484|NCT00743756|Experimental|1|A total of 20 African-American patients with type 2 diabetes will be randomized to receive home-delivered meals for twelve consecutive months. In addition, the subjects received diabetes education at every visit (8 clinic visits and 8 phone calls)
3263485|NCT00743756|Experimental|2|A total of 20 African-American patients with type 2 diabetes will be randomized to receive home-delivered meals for six consecutive months. In addition, the subjects received diabetes education for up to twelve months(8 clinic visits and 8 phone calls)
3263486|NCT00743756|Other|3|20 subjects received 12 months of diabetes education (8 clinic visits and 8 phone calls)
3263487|NCT00743743|Experimental|1|receive 1 Longevinex brand capsule daily containing 215 mg of resveratrol active ingredient
3263488|NCT00743743|Placebo Comparator|2|Receive 1 capsule daily for 52 weeks containing placebo for comparison to experimental arm
3263489|NCT00743730|Active Comparator|I|Parent and Nurse Controlled Analgesics with basal
3263490|NCT00743730|Active Comparator|II|Parent and Nurse Controlled Analgesics without basal
3263491|NCT00743730|Active Comparator|III|"Intermittent opioid administered IV on an as needed basis"
3263492|NCT00743717|Experimental|1|
3263493|NCT00743717|Active Comparator|2|
3263494|NCT00743691|No Intervention|Arm1|Make a diagnosis of Neonatal infections and refer patients according to IMNCI guideline
3263495|NCT00743691|Active Comparator|2|Health extension Workers will Make a diagnosis of Neonatal infections and treat with antibiotics when referal is not possible
3263496|NCT00743678|Experimental|NEO|NEO : Neoadjuvant therapy with FOLFOX6 plus cetuximab
3263497|NCT00743652|Experimental|Group1|Subjects 6 weeks to <10 months of age with 0 prior dose of Prevnar.
3263498|NCT00743652|Experimental|Group 2|Subjects <12 months of age with 1 prior dose of Prevnar.
3263499|NCT00743652|Experimental|Group 3|Subjects <12 months of age with 2 prior doses of Prevnar.
3263500|NCT00743652|Experimental|Group 4|Subjects ≥12 months to <2 years of age.
3263501|NCT00743652|Experimental|Group 5|Subjects ≥2 years to <5 years of age
3263502|NCT00743639|Other|1|Interventional
3263503|NCT00743626|Other|1|Healthy patients screened for cervical cancer
3263504|NCT00743600|Experimental|1|Patients with shoulder pain who were clinically referred to Ultrasound for evaluation
3263505|NCT00743600|Active Comparator|2|healthy volunteers who do not have shoulder pain
3263506|NCT00743587|Placebo Comparator|A|
3263507|NCT00743587|Active Comparator|B|
3263508|NCT00743587|Active Comparator|C|
3263509|NCT00743587|Active Comparator|D|
3263510|NCT00743574|Experimental|Vitamin D plus Calcium (Ca) supplementation|
3263511|NCT00743561|Other|1|
3263512|NCT00743548|Active Comparator|1|Interdental brush (IB), the intervention is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.
3263513|NCT00743548|Placebo Comparator|2|Dental floss (DF), the positive control, is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.
3263514|NCT00743535|Experimental|1|Transobturatory correction of anterior defect plus TOT
3263515|NCT00743535|Active Comparator|2|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
3263516|NCT00743522||Control|PROVE Trial settings
3263517|NCT00743522||Experimental|Pre-selected settings
3263518|NCT00743509|Experimental|Oral Cyclophosphamide and Sirolimus (OCR)|Sarcoma patients were given oral Cyclophosphamide and Sirolimus (OCR) in 28 day cycles.
3263519|NCT00743496|Experimental|Group 1|Participants who consent to the study will receive Anti-GD2 antibody.
3263520|NCT00743483|Experimental|rhBSSL|170 mg rhBSSL three times daily for 5 to 6 consecutive days
3263521|NCT00743470|Experimental|A, B|Group 1 receives regimen A and B. A: Healthy volunteers, receiving one 150 mg rifabutin QD alone. B: Healthy volunteers, receiving 150 mg rifabutin QD+ two lopinavir/ritonavir 200/50 mg tablets BID.
3263522|NCT00743470|Experimental|C|Group 2 receives regimen C. C: 150 mg rifabutin QD+ two lopinavir/ritonavir 200/50 mg tablets BID.
3263523|NCT00743457||VPS Patients|Children 6 months-18 years with VPS and symptoms of possible shunt failure
3263524|NCT00743444|Experimental|1|AZD3355
3263525|NCT00743444|Placebo Comparator|2|
3263526|NCT00743431||1|Women with advanced ovarian cancer
3263527|NCT00743418|Other|1|Healthy controls Mini Mental State evaluation score >28/30
3263528|NCT00743418|Other|2|Mild Cognitive Impairment: Mini Mental State Evaluation Score (MMSE)=26-28/30
3263529|NCT00743418|Other|3|Mild Dementia: Mini Mental State Evaluation Score (MMSE)=21-25/30
3263530|NCT00743405|Other|Cohort 1|Subjects will be receive GSK1034702 0.5 milligram (mg) following the dose escalation plan
3263531|NCT00743405|Other|Cohort 2|Subjects will be receive GSK1034702 5 mg following the dose escalation plan
3263532|NCT00743379|Experimental|A|TH-302 in combination with Gemcitabine. 1,000 mg/m2 of Gemcitabine is administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
3263533|NCT00743379|Experimental|B|TH-302 in combination with Docetaxel. 75 mg/m2 of Docetaxel is administered IV over 60 minutes on Day 1 of a 21-day cycle.
3263534|NCT00743379|Experimental|C|TH-302 in combination with Pemetrexed. 500 mg/m2 of Pemetrexed is administered IV over 10 minutes on Day 1 of a 21-day cycle.
3263535|NCT00743366|Experimental|Quetiapine (200mg/day), Marijuana (6.2%, 0.0%)|"Quetiapine (200mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (200 mg) were administered 2 times per day ((1100 and 2300 hours).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
3263536|NCT00743366|Placebo Comparator|Placebo, Marijuana (6.2%, 0.0%)|Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.
3263537|NCT00743353|Experimental|A|16 subjects to be enrolled; Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
3263538|NCT00743340|Experimental|Emtricitabine|Participants will receive emtricitabine for as long as they continue to meet specific virologic criteria and until either: (1) the participant chooses to discontinue treatment of emtricitabine and withdraw from the rollover protocol; (2) the participant experiences a toxicity that necessitates the permanent discontinuation of emtricitabine, or (3) emtricitabine is approved for market distribution in the participant's country of residence.
3263539|NCT00743327||1|Participants receiving ADT and pioglitazone
3263540|NCT00743327||2|Participants receiving ADT only
3263541|NCT00743327||3|Participants not receiving ADT and in remission from prostate cancer
3263542|NCT00743301|Active Comparator|Olive oil|
3263543|NCT00743301|Experimental|Palm olein|
3263544|NCT00743301|Active Comparator|Lard|
3263545|NCT00743288|Experimental|Melphalan and Panobinostat|"Schedule A: 10mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 of a 28-day cycle and melphalan PO at 0.05 mg/kg on days 1-5 of week 1.~Toxicity led to the following changes in dose and schedule Schedule B1: 10mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule B2: 20mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 and 0.05 mg/kg melphalan POon days 1, 3 and 5 of week 1.~Schedule C: 20mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1 and 2 and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1 Schedule D1: 15 mg/daily LBH589 PO and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule D2: 15 mg/daily LBH589 PO and 0.10 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule D3: 20 mg/daily LBH589 PO and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1."
3263546|NCT00743275|Experimental|Study Group|Participants received one dose of Fluzone® vaccine on Day 0.
3263547|NCT00743249|Experimental|Canalicular stent, 10 mm|MINI MONOKA canalicular stent (tube), 10 mm, inserted in the lower lacrimal canaliculus (tear duct) of one eye for up to 3 months
3263548|NCT00743249|Experimental|Canalicular stent, 20 mm|MINI MONOKA canalicular stent (tube), 20 mm, inserted in the lower lacrimal canaliculus (tear duct) of one eye for up to 3 months
3263549|NCT00743236|Experimental|Arm I|Patients undergo warm ischemia followed by partial nephrectomy.
3263550|NCT00743236|Experimental|Arm II|Patients undergo cold ischemia followed by partial nephrectomy.
3263551|NCT00743223||1|Study-group: The volunteers were selected on a randomized form among the individuals who went to the clinic of orofacial pain and temporomandibular disorders of São Paulo Hospital.
3263552|NCT00743223||2|Control-group: The volunteers were selected on a randomized form among the individuals who went to the dental offices of the researchers.
3263553|NCT00743210|Experimental|1|Oral L-citrulline, 3 grams once per day for 3 weeks.
3263554|NCT00743210|Placebo Comparator|2|Placebo, 3 grams once per day for 3 weeks.
3263555|NCT00743197|No Intervention|Usual Care Group|USUAL CARE GROUP—therapy in this group will be no dictated medical therapy, but usual care, as dictated by their referring physician.
3263556|NCT00743197|Active Comparator|Medical Treatment Group|TREATMENT GROUP—therapy in this group will be conventional treatment for CAD but targeting endothelial function, which will include aspirin, ACE-inhibitor and statin therapy, and therapeutic lifestyle changes.
3263557|NCT00743184|Placebo Comparator|1|Placebo + Placebo
3263558|NCT00743184|Experimental|2|15 mg Ozarelix + 15 mg Ozarelix
3263559|NCT00743184|Experimental|3|30 mg Ozarelix + 15 mg Ozarelix
3263560|NCT00743171||1|Good adherent patient: patient performed ≥ 80% of predicted HS within 24 months
3263561|NCT00743171||2|Moderate adherent patient: patient performed ≥ 50% of predicted HS within 24 months
3263562|NCT00743171||3|Non-adherent patient: patient performed < 50% of predicted HS within 24 months.
3263563|NCT00743145|Experimental|naltrexone, marijuana|naltrexone (0, 12, 25, 50, 100 mg) marijuana (active, placebo)
3263564|NCT00743145|Placebo Comparator|placebo, marijuana|
3263565|NCT00743132||1|Postoperative no renal dysfunction
3263566|NCT00743132||2|Postoperative renal dysfunction
3263567|NCT00743119|Placebo Comparator|Placebo + inactive marijuana (0% THC)|Participants received placebo capsules and smoked inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
3263568|NCT00743119|Experimental|Dronabinol 10 mg + Marijuana (0% THC)|Participants received low dose Dronabinol + inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
3263569|NCT00743119|Experimental|Dronabinol 20 mg + Marijuana (0% THC)|Participants received High dose Dronabinol + inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
3263570|NCT00743119|Experimental|Placebo + Marijuana (1.98% THC)|Participants received placebo + low THC marijuana (1.98% THC) on 1 of 5 outpatient sessions in randomized order.
3263571|NCT00743119|Experimental|Placebo + Marijuana (3.56% THC)|Participants received placebo + smoked high THC marijuana (3.56 % THC) on 1 of 5 outpatient sessions in randomized order.
3264004|NCT00740207|Active Comparator|Isovue 250|
3263572|NCT00743106|Placebo Comparator|Placebo Comparator|Placebo (0.9% Nacl)infusion beginning during surgery and lasting for up to 24 hours
3263573|NCT00743106|Active Comparator|Fenoldopam Comparator|Fenoldopam (0.1 ~g/kg/min)infusion will commence after placing the patient in a lateral/flex position during the operation. The infusion will continue for a total of 24 hours.
3263574|NCT00743093|Experimental|acetaminophen|acetaminophen, 4 grams/day (1 gram every 4 hours for 4 doses)
3263575|NCT00743093|Placebo Comparator|placebo|placebo for acetaminophen 4 grams/day (2 caplets every 4 hours for 4 doses)
3263576|NCT00743080|Experimental|1|Laparoscopic myomectomy and supracervical hysterectomy using GYNECARE MORCELLEX
3263577|NCT00743080|Active Comparator|2|Laparoscopic myomectomy and supracervical hysterectomy using ROTOCUT G1
3263578|NCT00743067|Experimental|Cohort 1|Cohort 1 will include 60 milligram (mg) of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
3263579|NCT00743067|Experimental|Cohort 2|Cohort 2 will include 120 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
3263580|NCT00743067|Experimental|Cohort 3|Cohort 3 will include 240 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
3263581|NCT00743067|Experimental|Cohort 4|Cohort 4 will include 480 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
3263582|NCT00743067|Experimental|Cohort 5|Cohort 5 will include 960 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
3263583|NCT00743041|Experimental|1|Standard of Care plus EFT (Emotional Freedom Techniques)
3263584|NCT00743041|No Intervention|2|Standard of Care (SOC)
3263585|NCT00743028|Experimental|1|
3263586|NCT00743028|Experimental|2|
3263587|NCT00743028|Experimental|3|
3263588|NCT00743028|Experimental|4|
3263589|NCT00743028|Experimental|5|
3263590|NCT00743028|Experimental|6|
3263591|NCT00743002|Experimental|TT223 with Metformin and/or TZD|TT223 as a treatment for Type 2 diabetes is administered by injection once daily at 1 mg, 2 mg and 3 mg patients currently treated with Metformin and/or Thiazolidinedione (TZD).
3263592|NCT00743002|Placebo Comparator|Placebo with Metformin and/or TZD|Placebo as a comparator is administered by injection once daily at 1 mg, 2 mg and 3 mg patients currently treated with Metformin and/or Thiazolidinedione (TZD).
3263593|NCT00742989|Experimental|A|OLT administration
3263594|NCT00742989|Sham Comparator|B|placebo-OLT
3263595|NCT00742976|Active Comparator|1|8 weeks of insulin Detemir, then cross over to 8 Weeks of Insulatard, then cross over to 1 week of Detemir
3263596|NCT00742976|Active Comparator|2|8 weeks of Insulin Insulatard, then cross over to 8 weeks of insulin Detemir, then crossover to 1 week of Insulin Insulatard
3263597|NCT00742963|Experimental|1|75 mg/m2 of Doxorubicin administered by bolus injection starting on Day 1 of a 21-day cycle.
3263598|NCT00742950|Active Comparator|I|Nasal 2.8-mm corneal incision
3263599|NCT00742950|Active Comparator|II|Temporal 2.8-mm corneal incision
3263600|NCT00742950|Active Comparator|III|Superior 2.8-mm corneal incision
3263601|NCT00742937|Placebo Comparator|A|After birth the women will receive one capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E and eight days after delivery the second capsule of vitamin E will be administer.
3263602|NCT00742937|Experimental|B|After birth the women will receive one capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E and eight days after delivery the second capsule of 200,000 UI of retinol palmitate (vitamin A)plus vitamin E will be administer.
3263603|NCT00742924|Experimental|Arm 1- Chemotherapy and 1.2 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery .~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
3263604|NCT00742924|Experimental|Arm 2 - Chemotherapy and 2.3 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
3263605|NCT00742924|Experimental|Arm 3 - Chemotherapy and 3.5 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
3264005|NCT00740207|Active Comparator|VISIPAQUE 270|
3264006|NCT00740194|Experimental|1|Aromatase inhibition
3263606|NCT00742924|Experimental|Chemotherapy and 2.3 mg/m2 Zoledronic Acid after MTD|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
3263607|NCT00742911|Experimental|1|
3263608|NCT00742898|Experimental|1|Non-targeted opt-out rapid HIV screening fully integrated into an urban, inner-city ED.
3263609|NCT00742898|Active Comparator|2|Diagnostic rapid HIV testing fully integrated into an urban, inner-city ED.
3263610|NCT00742885|Experimental|Influenza A (H5N1) 20-40 Years Group|Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.
3263611|NCT00742885|Experimental|Influenza A (H5N1) 41-64 Years Group|Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.
3263612|NCT00742872|Experimental|1|Mosapride
3263613|NCT00742872|Placebo Comparator|2|Placebo
3263614|NCT00742859|Experimental|Arm 1: Betrixaban|Betrixaban, 40 mg, orally, once daily for at least 3 months.
3263615|NCT00742859|Experimental|Arm 2: Betrixaban|Betrixaban, 60 mg, orally, once daily for at least 3 months
3263616|NCT00742859|Experimental|Arm 3: Betrixaban|Betrixaban, 80 mg, orally, once daily for at least 3 months
3263617|NCT00742859|Active Comparator|Arm 4: Warfarin|Warfarin will be prescribed by investigators according to the standard of care.
3263618|NCT00742846|Active Comparator|Group 1|The patient receives intra-articular steroid and local anesthetic injection under fluoroscopy.
3263619|NCT00742846|Active Comparator|Group 2|The patient receives subacromial steroid and local anesthetic injection under fluoroscopy.
3263620|NCT00742846|Active Comparator|Group 3|The patient receives intra-articular local anesthetic injection under fluoroscopy.
3263621|NCT00742846|Active Comparator|Group 4|The patient receives subacromial local anesthetic injection under fluoroscopy.
3263622|NCT00742833|Experimental|3|
3263623|NCT00742833|Placebo Comparator|1|
3263624|NCT00742820|Experimental|1|Calcium Acetate Oral Solution 667 mg per 5 mL
3263625|NCT00742820|Active Comparator|2|Calcium Acetate 667 mg Gelcaps
3263626|NCT00742820|Other|3|Calcium Citrate 950 mg Caplets
3263627|NCT00742807|Experimental|1|Administration of low dose of alfentanil hydrochloride before paracervical block
3263628|NCT00742807|Active Comparator|2|Administration of alfentanil hydrochloride dose after paracervical block
3263629|NCT00742794||1|Hymenoptera sting allergic patients under immunotherapy
3263630|NCT00742781|Experimental|Dietary supplement|Dietary supplement of vitamin D
3263631|NCT00742768|Active Comparator|1|softgel capsules
3263632|NCT00742768|Active Comparator|2|Gelpell capsules
3263633|NCT00742755|Experimental|Prospective Intervention|Peer navigator intervention
3263634|NCT00742742|Experimental|A|Nutrition advice (accroding to AHA recommendation) + 30 grams/day supplement of walnuts,walnuts were incorpatated into bread that provided to the participants
3263635|NCT00742742|Sham Comparator|B|Registed dietians give the advice for health lyfestyle
3263636|NCT00742729|Experimental|Arm 1|Educational small group session with free FOBT kit
3263637|NCT00742729|Experimental|Arm 2|Educational small group session with no FOBT kit
3263638|NCT00742729|Sham Comparator|Arm 3|Control
3263639|NCT00742716|Experimental|CTA018 Injection low dose|Low dose IV 3 times a week for 4 weeks
3263640|NCT00742716|Experimental|CTA018 Injection low to mid dose|low to mid dose IV 3 times a week for 4 weeks
3263641|NCT00742716|Experimental|CTA018 Injection mid to high dose|mid to high dose IV 3 times a week for 4 weeks
3263642|NCT00742716|Experimental|CTA018 Injection high dose|high dose IV 3 times a week for 4 weeks
3263643|NCT00742703|Experimental|1|
3263644|NCT00742703|Active Comparator|2|
3263645|NCT00742690|Active Comparator|1|35 patients with cirrhosis and type 1 HRS
3263646|NCT00742690|Experimental|2|35 patients with cirrhosis and type 1 HRS
3263647|NCT00742677|Experimental|Group 1 (early feeding)|Patients are offered a liquid diet on day 1 for 24 hours following surgery. Beginning on day 2, patients who tolerate a liquid diet are offered a light regular diet until hospital discharge.
3263648|NCT00742677|Active Comparator|Group 2 (traditional feeding)|Patients are offered nothing by mouth on days 1 and 2 following surgery. Beginning on day 3, patients are offered a liquid diet for 24 hours. Beginning on day 4, patients who tolerate a liquid diet (absence of nausea and vomiting) are offered a semi-solid diet for 24 hours. Beginning on day 5, patients who tolerate a semi-solid diet are offered a light regular diet until hospital discharge.
3263649|NCT00742664|Experimental|1|Will receive 12 sessions of twice weekly psychotherapy targeting obsessive-compulsive symptoms.
3263650|NCT00742664|Placebo Comparator|2|
3263651|NCT00742638|Experimental|The arm 1|Quetiapine fumarate tablet:25mg and 200mg
3263652|NCT00742638|Active Comparator|The arm 2|Sodium valproate tablet 200mg
3263653|NCT00742625|Experimental|Treatment (daunorubicin hydrochloride and bortezomib)|See Detailed Description
3263654|NCT00742612|Active Comparator|1|ARC1779 Injection
3263655|NCT00742612|Placebo Comparator|2|Placebo (normal saline)
3263656|NCT00742599|Active Comparator|N|
3263657|NCT00742599|Placebo Comparator|P|
3263658|NCT00742573|Active Comparator|1 Texas Medication Algorithm|Participants will receive medication treatment according to the Texas Medication Algorithm (TMA) for depression
3263659|NCT00742573|Experimental|2 Patient Choice|Participants will be offered brief interpersonal psychotherapy (IPT-B) alone or combined with the TMA for depression
3263660|NCT00742560|Experimental|Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 5 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
3263661|NCT00742560|Experimental|Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
3263662|NCT00742560|Experimental|Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
3263663|NCT00742560|Experimental|Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)|Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
3263664|NCT00742560|Experimental|Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)|Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
3263665|NCT00742547|No Intervention|Control group|No telephone counseling + usual care
3263666|NCT00742547|Experimental|Telephone Counseling|Telephone counseling + usual care
3263667|NCT00742521|Active Comparator|1|Euglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
3263668|NCT00742521|Active Comparator|2|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
3263669|NCT00742521|Active Comparator|3|Euglycemic glucose clamp procedure x 2 with cortisol infusion of 2ug/kg on Day 1 and hypoglycemic glucose clamp procedure on Day 2.
3263670|NCT00742521|Active Comparator|4|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
3263671|NCT00742508|Experimental|SK&F-105517-D group|SK&F-105517-D 10-80 mg/day
3263672|NCT00742508|Other|Carvedilol-IR group|Carvedilol-IR 5-20 mg/day
3263673|NCT00742469|Active Comparator|1|Rifaximin
3263674|NCT00742469|Placebo Comparator|2|Placebo
3263675|NCT00742456|Experimental|I|Glucose
3263676|NCT00742456|Placebo Comparator|II|Placebo
3263677|NCT00742443|Other|1|Active versus Placebo within patient
3263678|NCT00742443|Other|2|Active vs. Placebo within patient
3263679|NCT00742443|Other|3|Active vs. Active within patient
3263680|NCT00742430||Resistant|patients who are resistant to standard antithrombotic drugs
3263681|NCT00742430||Nonresistant|patients who are not resistant to standard dual antithrombotic drugs
3263682|NCT00742417|Experimental|Albutein 5%|Patients allocated to this arm underwent plasma exchange with Albutein 5%.
3263683|NCT00742417|Sham Comparator|Control|
3263684|NCT00742391|Active Comparator|1|PEP005 (ingenol mebutate) Gel
3263685|NCT00742391|Placebo Comparator|2|Vehicle gel
3263686|NCT00742378||C|Normal controls
3263687|NCT00742378||G|Glaucoma
3263688|NCT00742365||A|Participants will be given a 1-hour lab test of bright light treatment, then the bright light treatment for 6 weeks.
3263689|NCT00742365||B|Participants will be given a 1-hour treatment of the red light placebo, then the bright light treatment for 6 weeks.
3263690|NCT00742352||Breast cancer patients|
3263691|NCT00742352||Lung cancer patients|
3263692|NCT00742339|Active Comparator|1|Fifty patients with cirrhosis and HRS will be randomly assigned to arm 1.
3263693|NCT00742339|Experimental|2|Fifty patients with cirrhosis and HRS will be randomly assigned to arm 2.
3263694|NCT00742326|Experimental|Pioglitazone|pioglitazone 45 mg daily for 48 weeks
3263695|NCT00742326|Placebo Comparator|Placebo|one capsule daily for 48 weeks
3263696|NCT00742313|Experimental|Arm A|Arm A has FloSeal Matrix applied to EVH wound bed.
3263697|NCT00742313|No Intervention|Arm B|Arm B does not have FloSeal Matrix applied to EVH wound bed.
3263698|NCT00742300|Experimental|A|Treatment Group
3263699|NCT00742287|Placebo Comparator|1|placebo
3263700|NCT00742287|Active Comparator|2|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)
3263701|NCT00742274|Experimental|1|TAG+BMT
3263702|NCT00742274|Active Comparator|2|BMT alone
3263703|NCT00742261|Experimental|GSK1363089|Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
3263704|NCT00742248|Active Comparator|A|Formoterol pMDI
3263705|NCT00742248|Active Comparator|B|Formoterol dry powder
3263706|NCT00742248|Placebo Comparator|C|Placebo pMDI DPI
3263707|NCT00742235|Experimental|1|Vitamin D insufficient (treated with ergocalciferol 50,000 IU every other day x 5 doses)
3263708|NCT00742235|No Intervention|Vitamin D sufficient|Subjects who did not receive ergocalciferol and had a 25-OH vitamin D level >32 ng/ml
3263709|NCT00742222|Other|single arm, treatment with FDA cleared technology|Patients who have early stage breast cancer, and are candidate for intracavitary accelerated partial breast irradiation may be considered for this study.
3263710|NCT00742209|Placebo Comparator|Placebo|PBO
3263711|NCT00742209|Active Comparator|GSK 1838262 1200 mg/day|600 or 1200 mg/day
3263712|NCT00742209|Active Comparator|GSK 1838262 1800 mg/day|600 or 1200 or 1800 mg/day
3263713|NCT00742209|Active Comparator|GSK 1838262 2400 mg/day|600 or 1200 or 1800 or 2400 mg/day
3263714|NCT00742209|Active Comparator|GSK 1838262 3000 mg/day|600 or 1200 or 1800 or 2400 or 3000 mg/day
3263715|NCT00742196||1|No parapapillary atrophy
3263716|NCT00742196||2|Parapapillary atrophy
3263717|NCT00742183|Experimental|Mepilex® Ag|"Mepilex® Ag consists of a Safetac® soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film. Mepilex® Ag is an antimicrobial soft silicone foam dressing that absorbs exudate and maintains a moist wound environment.~Mepilex® Ag contains silver sulphate that releases silver ions to inactivate a wide range of wound related pathogens (bacteria and fungi), shown in vitro. By reducing the number of microorganisms, Mepilex® Ag may also reduce odour."
3263718|NCT00742183|Active Comparator|Silvadene® Cream 1%|Silvadene® Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second-and third-degree burns.
3263719|NCT00742170|Active Comparator|Active electroacupuncture|In the active electroacupuncture condition, the current is set at 2 times threshold (approximately 6-10 mA), which typically produces muscle twitching.
3263720|NCT00742170|Sham Comparator|Sham electroacupuncture|In the sham electroacupuncture condition, the current is set at 1 mA, the lowest intensity possible before the HANS device shuts off; this is undetectable stimulation.
3263721|NCT00742157|No Intervention|UNMC Group|Compare the low and high dose effects of Growth Hormone from previously pooled patients (high dose) and UNMC patients (low dose).
3263722|NCT00742144|Experimental|ofatumumab|Japanese patients with CD20 positive follicular lymphoma or chronic lymphocytic leukemia
3263723|NCT00742131|Experimental|Subjects receiving GSK1363089|Eligible subjects will receive GSK1363089 administered orally as a cinnamon-flavored liquid or as solid capsules with the starting dose for cohort 1 as 0.1 milligram/kilogram. Subjects in cohorts 1, 2, and 3A will receive GSK1363089 in the liquid formulation, while Cohorts 3B, 4, 5, 6, 7, and 8 will receive GSK1363089 in the solid capsule formulation.
3263724|NCT00742118|Experimental|2|patient with chronic inflammatory intestinal disease
3263725|NCT00742118|Other|3|patient having no symptoms
3263726|NCT00742118|Experimental|1|patient with irritable bowel syndrome
3263727|NCT00742105|Experimental|BGT226|
3263728|NCT00742092|Experimental|1|miglustat
3263729|NCT00742092|Placebo Comparator|2|placebo
3263730|NCT00742079|Experimental|1 D-cycloserine, placebo|Participants will receive D-cycloserine 1 hour before a cognitive behavioral therapy (CBT) session on Week 1, and they will receive placebo 1 hour before a CBT session on Week 2.
3263731|NCT00742079|Experimental|2 Placebo, D-cycloserine|Participants will receive placebo 1 hour before a CBT session on Week 1, and they will receive D-cycloserine 1 hour before a CBT session on Week 2.
3263732|NCT00742066|Experimental|I|Irbesartan
3263733|NCT00742066|Active Comparator|II|Felodipine
3263734|NCT00742066|Placebo Comparator|III|Placebo
3263735|NCT00742053|Experimental|1|Male or female inpatients, age ≥ 18 and ≤ 80 years, who are in normal sinus rhythm and do not have a pacemaker or other indwelling intracardiac device and require PICC insertion for their routine care will be studied. Intervention: ECG-guided Power PICC placement.
3263736|NCT00742040|Experimental|1|
3263737|NCT00742040|Active Comparator|2|
3263738|NCT00742027|Experimental|Panobinostat|
3263739|NCT00742014|Experimental|1|
3263740|NCT00742001|Experimental|Mirasol Illumination Dose #1|Whole blood units treated with Mirasol at Illumination dose #1.
3263741|NCT00742001|Experimental|Mirasol Illumination Dose #2|Whole Blood units treated with Mirasol at Illumination dose #2.
3263742|NCT00742001|Experimental|Mirasol Illumination Dose #3|Whole Blood units treated with Mirasol at Illumination dose #3.
3263743|NCT00741988|Experimental|Cohort A|ixabepilone 30 mg/m2 and carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
3263744|NCT00741988|Experimental|Cohort B|ixabepilone 30 mg/m2, carboplatin AUC = 6 intravenously (IV), and bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
3263745|NCT00741975|Experimental|1|Affect Management
3263746|NCT00741975|Active Comparator|2|General Health Promotion
3263747|NCT00741962|Experimental|1|
3263748|NCT00741962|Placebo Comparator|2|
3263749|NCT00741949|Experimental|1|
3263750|NCT00741949|Placebo Comparator|2|
3263751|NCT00741936|Experimental|MaZiRenWan (MZRW)|MZRW granule, 7.5g/sachet
3263752|NCT00741936|Placebo Comparator|Placebo|Placebo granule, 7.5g/sachet
3263753|NCT00741923|Experimental|Bean group|A group consuming 5 cups/week of navy beans for a month
3263754|NCT00741910|Experimental|1|Semapimod 60 mg IV q 6 - 10 weeks
3263755|NCT00741897|Experimental|1|Fexofenadine
3263756|NCT00741884|Experimental|Arm 1|
3263757|NCT00741884|Experimental|Arm 2|
3263758|NCT00741884|Experimental|Arm 3|
3263759|NCT00741884|Active Comparator|Arm 4|
3263760|NCT00741884|Placebo Comparator|Arm 5|
3263761|NCT00741858|Experimental|DuraGen (sutureless)|Duragen duraplasty - the Duragen patch is applied over the dural defect during Chiari decompression surgery. The Duragen represents sutureless technique of posterior fossa duraplasty. Rest of the treatment is as usual.
3263762|NCT00741858|Active Comparator|DuraGuard (suturable)|Duraguard duraplasty - the Duraguard patch is applied over the dural defect during Chiari decompression surgery and sutured to the dural edge. This represents suturable technique that theoretically provides better (water-tight) dural closure.
3263763|NCT00741845|Active Comparator|1|intravaginal metronidazole 750mg + 200mg miconazole
3263764|NCT00741845|Active Comparator|2|intravaginal metronidazole 750mg
3263765|NCT00741845|Active Comparator|3|intravaginal metronidazole 37.5mg
3263766|NCT00741832|Experimental|I|Patients breath while a conical positive expiratory pressure device during exercises
3263767|NCT00741832|Active Comparator|C|Patients (normal) breath during exercise
3263768|NCT00741819|Experimental|Inhaled treprostinil|Solution for oral inhalation treprostinil (0.6 mg/mL). Inhaled via an ultrasonic nebulizer which provides a dose of 6mcg of treprostinil per breath. Doses are titrated up to 12 breaths four times daily.
3263769|NCT00741806|Experimental|GHB04L1|Single dose, dose escalation
3263770|NCT00741806|Placebo Comparator|SPGN buffer|
3263771|NCT00741780||G-CSF plus plerixafor|Participants in AMD3100-3102 (NCT00103662) who underwent mobilization with granulocyte colony-stimulating factor (G-CSF) and received plerixafor prior to undergoing apheresis.
3263772|NCT00741780||G-CSF plus placebo|Participants in AMD3100-3102 (NCT00103662) who underwent mobilization with granulocyte colony-stimulating factor (G-CSF) and received placebo prior to undergoing apheresis.
3263773|NCT00741767|Other|Salmeterol-fluticasone|Patients randomized to receive salmeterol-fluticasone 250/50 twice daily for 4 weeks. Patients will cross-over and receive placebo medication for 4 weeks later in the study.
3264007|NCT00740194|Active Comparator|2|Estradiol
3263774|NCT00741767|Other|Placebo|Patients randomized to receive placebo medication twice daily for 4 weeks. Patients will cross-over and receive study medication later in the study.
3263775|NCT00741754|Experimental|I, II|compare the amount of salivary flow of the same patient at different times.
3263776|NCT00741728||general population|Observational study of 10000 adult men and women from the general population who benefited from a free extensive health check up in Paris, France
3263777|NCT00741715|Placebo Comparator|1|
3263778|NCT00741715|Experimental|2|AVE5530 25mg
3263779|NCT00741715|Experimental|3|AVE5530 50mg
3263780|NCT00741715|Active Comparator|4|atorvastatin 10mg
3263781|NCT00741715|Experimental|5|atorvastatin 10mg + AVE5530 25mg
3263782|NCT00741715|Experimental|6|atorvastatin 10mg + AVE5530 50mg
3263783|NCT00741715|Active Comparator|7|atorvastatin 20mg
3263784|NCT00741715|Experimental|8|atorvastatin 20mg + AVE5530 25mg
3263785|NCT00741715|Experimental|9|atorvastatin 20mg + AVE5530 50mg
3263786|NCT00741715|Active Comparator|10|atorvastatin 40mg
3263787|NCT00741715|Experimental|11|atorvastatin 40mg + AVE5530 25mg
3263788|NCT00741715|Experimental|12|atorvastatin 40mg + AVE5530 50mg
3263789|NCT00741715|Active Comparator|13|atorvastatin 80mg
3263790|NCT00741715|Experimental|14|atorvastatin 80mg + AVE5530 25mg
3263791|NCT00741715|Experimental|15|atorvastatin 80mg + AVE5530 50mg
3263792|NCT00741702|Experimental|Intervention group|A home care nurse followed a predefined treatment algorithm of pharmacologic antihypertensive therapy.
3263793|NCT00741702|No Intervention|Control group|Treatment decisions were made by each subject's primary care physician. Participants in this group received usual care.
3263794|NCT00741689|Experimental|1|AZD1656 in 6 increasing oral single doses given to 6 groups (5 on active and 1 on placebo in each group)
3263795|NCT00741676|Active Comparator|2|
3263796|NCT00741676|Experimental|1|
3263797|NCT00741663|Active Comparator|A|
3263798|NCT00741663|Experimental|B|
3263799|NCT00741650|Experimental|1|Information and peer advisor
3263800|NCT00741650|Experimental|2|Information, peer advisor and referral to further treatment
3263801|NCT00741650|No Intervention|3|Treatment as usual
3263802|NCT00741637|Experimental|Vaccine|Live attenuated oral CholeraGarde® (5x107 to 1x109 CFU) vaccine
3263803|NCT00741637|Placebo Comparator|Placebo|A buffer solution containing 2.5 g sodium bicarbonate, and 1.65 g ascorbic acid.
3263804|NCT00741624|Experimental|1|bilateral post refractive surgery subject
3263805|NCT00741611|Experimental|Mesh|Ablation with HD Mesh Ablation System
3263806|NCT00741611|Active Comparator|Drug|Treatment with anti-arrhythmic drugs
3263807|NCT00741598|Experimental|Galantamine-ER|Participants will receive treatment with extended release galantamine
3263808|NCT00741598|Placebo Comparator|Galantamine placebo|Participants will receive treatment with placebo.
3263809|NCT00741585|Active Comparator|1|Treatment with all prescribed hypertension medications on awakening
3263810|NCT00741585|Active Comparator|2|Treatment with at least one prescribed hypertension medication at bedtime
3263811|NCT00741572||1|
3263812|NCT00741572||2|
3263813|NCT00741559|Experimental|1|
3263814|NCT00741546||A|Patients referred for cardiac surgery intervention
3263815|NCT00741520|Placebo Comparator|1|Control group
3263816|NCT00741520|Active Comparator|2|CPAP
3263817|NCT00741507|Active Comparator|1|No alcohol drinking
3263818|NCT00741507|Active Comparator|2|Mild alcohol drinking
3263819|NCT00741507|Active Comparator|3|Moderate alcohol drinking
3263820|NCT00741507|Active Comparator|4|Severe over alcohol drinking
3263821|NCT00741507|Active Comparator|5|Alcohol-dependent
3263822|NCT00741494|No Intervention|1|HBA score over 65% control
3263823|NCT00741494|No Intervention|2|HBA score over 65%, non-participant (to even out the participation between patients with low HBA scores and those with high HBA scores)
3263824|NCT00741494|Active Comparator|3|HBA score over 65%. PICSI dish is used to select the sperm for ICSI.
3263825|NCT00741494|Experimental|4|HBA score less than 65%. PICSI dish used to select sperm for ICSI.
3263826|NCT00741494|No Intervention|5|HBA Score less than 65%. Control
3263827|NCT00741481||1|all study population
3263828|NCT00741468|Experimental|All subjects|Proellex 50 mg CYP1A2 probe CYP2C9 probe CYP2C19 probe CYP2D6 probe CYP3A4 probe
3263829|NCT00741455|Experimental|Study Treatment|Chemotherapy, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate
3263830|NCT00741442|Experimental|1|RDEA806 400 mg qd
3263831|NCT00741442|Experimental|3|RDEA806 400 mg bid
3263832|NCT00741442|Placebo Comparator|2|Placebo QD
3263833|NCT00741442|Placebo Comparator|4|Placebo BID
3263834|NCT00741429||Ex-TI|Ex-Technosphere® Insulin Inhalation Powder (subjects previously received TI Inhalation Powder)
3263835|NCT00741429||Non Ex-TI|Non Ex-Technosphere® Insulin Inhalation Powder (subjects previously received another anti-diabetic medication)
3263836|NCT00741416||Case|Those with a diagnosis of Coronary Artery Disease
3263837|NCT00741416||Control|Those who do not have Coronary Artery Disease (are healthy) but are matched to a Case participant by age, gender, and ethnicity.
3263838|NCT00741403|Experimental|A|IV Infusion of CPI-613 on Days 1,4,8,11,15,18 of 28 day cycle in patients with advanced malignancies
3263839|NCT00741390|Other|Arm A|In Visit 1 subjects tested BD/33G, OTM/33G, and OTM/28G devices. In Visit 2 subjects tested BD/33G and OTM/28G. See purpose for additional information.
3263840|NCT00741390|Other|Arm B|In Visit 1 subjects tested BD/33G, OTM/33G and OTU/28G devices. In Visit 2 subjects tested BD/33G and OTU/28G. See purpose for additional information.
3263841|NCT00741390|Other|Arm C|In Visit 1 subjects tested BD/33G, OTM/33G and ACC/28G devices. In Visit 2 subjects tested BD/33G and ACC/28G. See purpose for additional information.
3264014|NCT00740155|Active Comparator|Group 5|
3264052|NCT00739908|Experimental|CX157 (TriRima)|
3263842|NCT00741390|Other|Arm D|In Visit 1 subjects tested BD/33G, OTM/33G and OTM/28G devices. In Visit 2 subjects tested OTM/33G and OTM/28G. See purpose for additional information.
3263843|NCT00741377|Experimental|BHQ880 + zoledronic acid|BHQ880 3-40 mg/kg in combination with zoledronic acid 4 mg on day 1 of a 28-day cycle.
3263844|NCT00741364|Active Comparator|1|vitamin D3 (400 IU/d)
3263845|NCT00741364|Active Comparator|2|vitamin D3 (10,000 IU/d)
3263846|NCT00741364|Active Comparator|3|vitamin D3 (40,000 IU/d)
3263847|NCT00741351|Experimental|IF|Sevoflurane (Inhalation)+Fentanyl
3263848|NCT00741351|Experimental|IR|Sevoflurane (Inhalation)+Remifentanyl
3263849|NCT00741351|Experimental|ER|Propofol (Endovenous)+ Remifentanyl
3263850|NCT00741338|Experimental|Cohort 1|Tolerance Induction Period (TIP): Cyclosporine A (CsA) starting at 5 milligram per kilogram (mg/kg) orally three times daily until the target trough concentration of at least 350 nanogram per milliliter (ng/mL) (preferably 400 ng/mL) achieved along with azathioprine (Aza) 2.5 mg/kg/day orally. Once target CsA trough level achieved and maintained for at least 1 week, participants received laronidase 0.058 mg/kg (low-dose) once weekly intravenous (IV) infusion (starting from Day 1) up to Week 12. CsA and Aza were gradually discontinued. Immune Challenge Period (ICP): following TIP, laronidase dose increased to 0.12 mg/kg once weekly IV infusion for 1 week followed by 0.25 mg/kg once weekly IV infusion for 1 week and then 0.58 mg/kg (full-dose) once weekly IV infusion up to Week 39.
3263851|NCT00741338|Experimental|Cohort 2|TIP: CsA starting at 6.7 mg/kg orally three times daily until the target trough concentration of at least 350 ng/mL (preferably 400 ng/mL) achieved along with Aza 5 mg/kg orally every other day. Once target CsA trough level achieved and maintained for at least 1 week, participants received laronidase 0.058 mg/kg (low-dose) once weekly IV infusion (starting from Day 1) up to Week 18. CsA and Aza were gradually discontinued. ICP: following TIP, laronidase dose increased to 0.12 mg/kg once weekly IV infusion for 1 week followed by 0.25 mg/kg once weekly IV infusion for 1 week and then 0.58 mg/kg (full-dose) once weekly IV infusion up to Week 45.
3263852|NCT00741325||G-CSF plus plerixafor|Participants in Study AMD3100-3101 (NCT00103610)underwent mobilization with granulocyte colony-stimulating factor (G-CSF)and received plerixafor, prior to undergoing apheresis.
3263853|NCT00741325||G-CSF plus placebo|Participants in Study AMD3100-3101 (NCT00103610)underwent mobilization with granulocyte colony-stimulating factor (G-CSF)and received placebo, prior to undergoing apheresis.
3263854|NCT00741312|Experimental|I|
3263855|NCT00741312|Active Comparator|II|
3263856|NCT00741286|Placebo Comparator|Asprin (100mg) plus placebo|Asprin (100mg) plus placebo
3263857|NCT00741286|Active Comparator|Asprin (100mg) plus cilostazol (200mg)|Asprin (100mg) plus cilostazol (200mg)
3263858|NCT00741273|Experimental|Proellex 25 mg healthy|Proellex 25 mg in healthy females
3263859|NCT00741273|Experimental|Proellex 25 mg Impaired|Proellex 50 mg in hepatically impaired females
3263860|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Level 1)|Neratinib 160 mg and Capecitabine 1500 mg/m^2
3263861|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 2)|Neratinib 240 mg and Capecitabine 1500 mg/m^2
3263862|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 3)|Neratinib 240 mg and Capecitabine 2000 mg/m^2
3263863|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 4)|Neratinib 200 mg and Capecitabine 2000 mg/m^2
3263864|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 5)|Neratinib 160 mg and Capecitabine 2000 mg/m^2
3263865|NCT00741260|Experimental|Neratinib and Capecitabine MTD (Dose Group 6)|Neratinib and Capecitabine Maximum Tolerated Dose without prior lapatinib
3263866|NCT00741260|Experimental|Neratinib and Capecitabine MTD (Dose Group 7)|Neratinib and Capecitabine Maximum Tolerated Dose with prior lapatinib
3263867|NCT00741234|Experimental|A|Advanced solid tumors
3263868|NCT00741234|Experimental|B|Advanced hematologic malignancies
3263869|NCT00741234|Experimental|C|Myelodysplastic Syndrome
3263870|NCT00741221|Experimental|1|Pemetrexed/Bevacizumab
3263871|NCT00741208|Other|1|Patients randomized to receive soy isoflavone twice daily for 2 weeks. Patients will cross-over and receive placebo medication for 2 weeks later in the study
3263872|NCT00741208|Other|2|Patients randomized to receive placebo medication twice daily for 2 weeks. Patients will cross-over and receive soy isoflavone for 2 weeks later in the study
3263873|NCT00741195|Experimental|1|Docetaxel/Bevacizumab
3263874|NCT00741182|Experimental|Femur PTH(1-34)|24 participants with trochanteric fractures will be assigned to Forsteo (PTH(1-34)) treatment
3263875|NCT00741182|No Intervention|Femur Control|"24 participants with trochanteric fractures will be assigned to no treatment"
3263876|NCT00741182|Experimental|Humerus PTH(1-34)|24 participants with collum chirurgicum fracture will be assigned to Forsteo (PTH(1-34)) treatment
3263877|NCT00741182|No Intervention|Humerus Control|"24 participants with collum chirurgicum fracture will be assigned to no treatment."
3263878|NCT00741169|Experimental|Treatment Sequence ABC|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence will consist of Treatment A (TMC435350 200 mg once daily for 7 days), Treatment B (rifampin 600 mg once daily for 7 days), and Treatment C (TMC435350 200 mg once daily+rifampin 600 mg once daily for 7 days). Participants will receive 1 treatment (A, B, or C) during each treatment session. There will be 3 treatment sessions, each treatment session will be separated by 10 days.
3263879|NCT00741169|Experimental|Treatment Sequence BCA|
3263880|NCT00741169|Experimental|Treatment Sequence CAB|
3263881|NCT00741169|Experimental|Treatment sequence CBA|
3263882|NCT00741169|Experimental|Treatment Sequence BAC|
3263883|NCT00741169|Experimental|Treatment Sequence ACB|
3263884|NCT00741156|Experimental|Enalaprilat|enalaprilat 0.005-0.01 mg/kg intravenous x 1 dose
3263885|NCT00741143|Experimental|1|Group that receives NaFeEDTA fortified wheat flour
3263886|NCT00741143|Placebo Comparator|2|Unfortified wheat flour
3263887|NCT00741130||C|normal volunteers
3263888|NCT00741130||G|glaucoma patients
3263889|NCT00741117|Active Comparator|Low Bilirubin Group|Low Bilirubin Group: subjects with a bilirubin level less than or equal to 10 mg/dl
3263890|NCT00741117|Active Comparator|Medium Bilirubin Group|Medium Bilirubin Group: subjects with a bilirubin level from 11mg/dl to 30 mg/dl
3263891|NCT00741117|Active Comparator|High Bilirubin Group|High Bilirubin Group: subjects with a bilirubin level greater than or equal to 30 mg/dl
3263892|NCT00741104||RA patients|Patients on maintenance therapy for RA with infliximab for >= the past 12 months.
3263893|NCT00741091|Experimental|Registry|Registry to gather data on early clinical outcomes for the Carotid WALLSTENT Endoprosthesis and FilterWire EZ System in routine clinical practice.
3263894|NCT00741078|Experimental|atorvastatin, amlodipine|
3263895|NCT00741052|Experimental|1|Ciprofloxacin
3263896|NCT00741052|Active Comparator|2|Azithromycin
3263897|NCT00741039|Experimental|1,|Patients > or = to 65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23 valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly).
3263898|NCT00741039|Experimental|2|MSKCC employee volunteer controls > or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly).
3263899|NCT00741026|Placebo Comparator|Placebo|Placebo
3263900|NCT00741026|Experimental|Olanzapine|Olanzapine 10mg po daily x 3 days
3263901|NCT00741013|Placebo Comparator|Placebo pill and placebo IV|
3263902|NCT00741013|Experimental|Lovastatin pill and placebo IV|
3263903|NCT00741013|Experimental|Placebo pill and rhAPC IV|
3263904|NCT00741000|Experimental|Experimental|Cervical low force mobilization procedure.
3263905|NCT00740987|No Intervention|1|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
3263906|NCT00740987|Experimental|2|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
3263907|NCT00740961||Patients with cancer|Patients ≥ 65 years with new stage I-III breast or colon cancer seeking care. Patients will be matched on baseline scores, age and sex. Patients will be age and sex matched due to the known relation between inflammatory markers and demographic characteristics39,40, and will be matched on baseline VES scores to ensure similar baseline VES-13 scores between groups and which will then allow us to then assess effect of cancer treatment on outcomes.
3263908|NCT00740961||Patients without cancer|non-cancer patients, seeking care at out-patient clinics
3263909|NCT00740948|Experimental|1|Rituximab
3263910|NCT00740948|Placebo Comparator|2|Placebo
3263911|NCT00740935|Other|1|Cohort of vaccinated infants against rotavirus
3263912|NCT00740922||1|
3263913|NCT00740909|No Intervention|MAC|Minimal Attention Control
3263914|NCT00740909|Experimental|CBT|Cognitive Behavioral Therapy
3263915|NCT00740896|Active Comparator|1|Participants smoke 8 cigarettes in 4 hours.
3263916|NCT00740896|Sham Comparator|2|Participants are not allowed to smoke for 4 hours.
3263917|NCT00740883|Active Comparator|1|18 months of active warfarin therapy
3263918|NCT00740883|Placebo Comparator|2|18 months of placebo of warfarin
3263919|NCT00740870|Experimental|Melody TPV Implant|Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.
3263920|NCT00740857|Placebo Comparator|1|
3263921|NCT00740857|Active Comparator|2|
3263922|NCT00740857|Active Comparator|3|
3263923|NCT00740844|No Intervention|1|No intermittent pneumatic compression of the lower limbs during patient hospitalisation in réanimation unit
3263924|NCT00740844|Experimental|2|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
3263925|NCT00740831|Experimental|A (PGL4001 5 mg)|Drug: PGL4001 5mg (oral tablets) and leuproreline matching placebo (intramuscular injection)
3263926|NCT00740831|Experimental|B (PGL4001 10mg)|Drug: PGL4001 10 mg (oral tablets) and leuproreline matching placebo (intramuscular injection)
3263927|NCT00740831|Active Comparator|C (GnRH-agonist)|PGL4001 matching placebo (oral tablets) and leuprorelin 3.75 mg (intramuscular injection)
3263928|NCT00740818|No Intervention|A|The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.
3263929|NCT00740818|Sham Comparator|B|A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.
3263930|NCT00740818|Experimental|C|Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
3263931|NCT00740805|Experimental|Treatment (veliparib, cyclophosphamide, doxorubicin)|"GROUP I: Patients receive veliparib PO every 12 hours on days 1-4 and cyclophosphamide IV over 60 minutes on day 3.~GROUP II: Patients receive veliparib PO every 12 hours on days 1-4, cyclophosphamide IV over 60 minutes on day 3, and doxorubicin hydrochloride IV over 15 minutes on day 3.~GROUP III: Patients receive veliparib PO every 12 hours on days 1-7, cyclophosphamide IV over 60 minutes on day 1, and doxorubicin hydrochloride IV over 15 minutes on day 1.~GROUP IV: Patients receive veliparib PO every 12 hours on days 1-14, cyclophosphamide IV over 60 minutes on day 1, and doxorubicin hydrochloride over 15 minutes on day 1.~In all groups, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3263932|NCT00740792|Experimental|azelastine HCl/fluticasone propionate|nasal spray
3263933|NCT00740792|Active Comparator|azelastine HCL|nasal spray
3263934|NCT00740792|Active Comparator|fluticasone propionate|nasal spray
3263935|NCT00740792|Placebo Comparator|placebo|nasal spray
3263936|NCT00740779|Experimental|Silodosin 4 mg|4 mg daily
3263937|NCT00740779|Experimental|Silodosin 8 mg|Silodosin 8 mg daily
3263938|NCT00740779|Placebo Comparator|Placebo|1 placebo capsule daily
3263939|NCT00740766|Experimental|Monitored|
3263940|NCT00740766|No Intervention|Unmonitored|
3263941|NCT00740753|Other|Treatment|yttrium 90 (TheraSphere) administration
3263942|NCT00740740||1|Patients scheduled for elective conventional aneurysm repair
3263943|NCT00740740||2|Patients scheduled for emergent conventional aneurysm repair
3263944|NCT00740740||3|Patients scheduled for aortic bypass surgery
3264008|NCT00740181|Experimental|Chemotherapy|Decitabine 20 mg/m2 IV over 1 hr days 1-5 Cytarabine 20 mg/m2 subcut days 1-5 G-CSF 5mcg/kg subcut days 1-5
3264009|NCT00740168||TG|Bevacizumab treatment group with metastasized cancer
3263945|NCT00740727|Experimental|EASI|Subjects will undergo placement of EASI catheters. All subjects in whom EASI catheters are placed, will receive Human Recombinant Hyaluronidase (HRH) as part of the EASI placement. (No subject will receive HRH, other than as part of EASI catheter placement.)
3263946|NCT00740714|Experimental|A|Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)
3263947|NCT00740714|Experimental|B|Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)
3263948|NCT00740714|Placebo Comparator|C|Placebo (with vitamin E 1200 IU/day)
3263949|NCT00740701|Sham Comparator|Sham TMS|A Sham TMS coil, designed to elicit sham cerebellar transcranial magnetic stimulation, is used to administer sham TMS pulses after letters are presented.
3263950|NCT00740701|Experimental|TMS|A genuine TMS coil is used to administer cerebellar transcranial magnetic stimulation pulses after letter presentation.
3263951|NCT00740688|Experimental|Experimental Group|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
3263952|NCT00740688|Sham Comparator|Sham Group|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
3263953|NCT00740675|Experimental|1|"At post-discharge follow-up visit with PCP, PCP views:~Discharge medication reconciliation screen.~Prompts to perform post-discharge reconciliation at the first post-discharge visit."
3263954|NCT00740675|No Intervention|Uusual care|PCPs manage the patient's medications after hospital discharge as they normally would.
3263955|NCT00740662||1|Distal gastric bypass
3263956|NCT00740649|Experimental|1|HSD-016
3263957|NCT00740649|Other|2|placebo
3263958|NCT00740636|Experimental|75 mg/m2/day Temozolomide|75 mg/m2/day Temozolomide for 21 days (7 days off treatment). 28 day cycles.
3263959|NCT00740636|Experimental|200 mg/m2/day Temozolomide|200 mg/m2/day Temozolomide for 5 days (23 days off treatment). 28 day cycles.
3263960|NCT00740623|Experimental|001|Carisbamate 800 mg/day for 14 weeks
3263961|NCT00740623|Experimental|002|Carisbamate 1,200 mg/day for 14 weeks
3263962|NCT00740623|Placebo Comparator|003|placebo for 14 weeks
3263963|NCT00740610|Experimental|Cohort 1|22 subjects to receive 1 mg GS-9450 for 4 weeks
3263964|NCT00740610|Experimental|Cohort 2|22 subjects to receive 5 mg GS-9450 for 4 weeks
3263965|NCT00740610|Experimental|Cohort 3|22 subjects to receive 10 mg GS-9450 for 4 weeks
3263966|NCT00740610|Experimental|Cohort 4|22 subjects to receive 40 mg GS-9450 for 4 weeks
3263967|NCT00740610|Placebo Comparator|Cohort 5|22 subjects to receive placebo to match GS-9450 for 4 weeks
3263968|NCT00740597|Experimental|Arm 1|pre-operative radiation + surgery PTV will receive a total dose of 50 Gy in 25 fractions, 2 Gy per fraction, 5 fractions per week, over approximately 5 weeks. Concurrently, the GTV2, if present, will receive 54 Gy in 25 fraction. Dose will be prescribed to the isodose volume that encompasses the PTV. All patients will be treated by 6 MV photon beam.
3263969|NCT00740584|Experimental|Open Label, only arm|3%w/w SPL7013 vaginal gel (VivaGel)
3263970|NCT00740571|Active Comparator|1|Strategy in which patient starts with amitriptyline
3263971|NCT00740571|Active Comparator|2|Strategy in which patient starts with pregabalin
3263972|NCT00740558|Active Comparator|1|Two groups received a traditional chiropractic adjustment of the lumbar 5 and the other group received a manually assisted mechanical force adjustment of the lumbar 5.
3263973|NCT00740558|Sham Comparator|2|The investigators had two groups, one for each chiropractic technique used in the research project and we had a control group
3263974|NCT00740545|Placebo Comparator|2|
3263975|NCT00740545|Experimental|1|
3263976|NCT00740532||Observation|Breast cancer patients treated with Herceptin-based therapy
3263977|NCT00740519||A|
3263978|NCT00740493|Active Comparator|1|18 months of active warfarin therapy
3263979|NCT00740493|Placebo Comparator|2|18 months of placebo of warfarin
3263980|NCT00740480||Surgical|Adult population (ages 18-65) with clinically significant nasal septum deviation.
3263981|NCT00740454||A|Pregnant or post-partum women with a clinically suspected DVT and a negative distal and proximal leg veins compression ultrasonography
3263982|NCT00740441|Experimental|A|AS1411 treatment
3263983|NCT00740428|Experimental|G1|pregnants for the first time who will receive the physical therapy guide
3263984|NCT00740415|Experimental|ARM RiBVD|"RiBVD 6 cycles every 28 days day 1 :~Rituximab /Mabthera®, 375 mg/m2 en IV~Bendamustine, 90 mg/m2 en IVD~Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 2 : - Bendamustine, 90 mg/m2 en IVD~Dexamethasone, 40 mg IV day 4 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 8 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 11 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD"
3263985|NCT00740376|Experimental|1|Uniglide Mobile Bearing Unicondylar Knee System (MBK)
3263986|NCT00740376|Active Comparator|2|Uniglide Fixed Bearing Unicondylar Knee System (FBK)
3263987|NCT00740363|Experimental|A|Patients will receive 4 weeks of treatment with sitagliptin once daily
3263988|NCT00740363|Placebo Comparator|B|No treatment for 4 weeks
3263989|NCT00740350|Experimental|Experimental|Logan Basic chiropractic adjustments during pregnancy.
3263990|NCT00740337||COPD|Participants in this group will be people who have COPD and plan to undergo lung resection surgery at Barnes-Jewish Hospital (BJH).
3263991|NCT00740337||Control|Participants in this group will be people who do not have COPD and plan to undergo lung resection surgery at BJH.
3263992|NCT00740324|Active Comparator|N|
3263993|NCT00740324|Active Comparator|B|
3263994|NCT00740324|Active Comparator|G|
3263995|NCT00740311|Experimental|Filling|alveoli filling with an injectable calcium phosphate after extraction of mandibular molar or pre molar
3263996|NCT00740311|No Intervention|Without filling|
3263997|NCT00740298|Active Comparator|1|Sweet Taste
3263998|NCT00740298|Active Comparator|2|warmth
3263999|NCT00740285|Experimental|1|
3264000|NCT00740285|Placebo Comparator|2|
3264001|NCT00740272|Experimental|1|AF ablation + pacemaker
3264002|NCT00740272|Active Comparator|2|Pacemaker
3264003|NCT00740220||A|Each subject will be their own control. Each subject will perform three 6MWTs. Intra-subject reproducibility is being tested.
3264015|NCT00740142|Active Comparator|1|Interventional arm: oral L-ornithine-L-aspartate and oral lactulose
3264016|NCT00740142|Placebo Comparator|2|Oral lactulose
3264017|NCT00740129|Other|1|Open label, single arm treatment study
3264018|NCT00740116|Active Comparator|1|Tranexamic acid
3264019|NCT00740116|Placebo Comparator|2|0.9% NaCl solution
3264020|NCT00740103|Experimental|1|Semapimod 60 mg IV x 3 days q 6 - 8 weeks
3264021|NCT00740051|Experimental|Linagliptin|52 week treatment
3264022|NCT00740051|Placebo Comparator|Placebo|First 18 weeks of treatment
3264023|NCT00740051|Active Comparator|Glimepiride|Placebo patients switch to glimepiride week19-52
3264024|NCT00740038|Active Comparator|1|Active Control: Usual Care
3264025|NCT00740038|Experimental|2|Stress Management Intervention
3264026|NCT00740038|Experimental|3|Exercise Intervention
3264027|NCT00740038|Experimental|4|Combined Stress Management and Exercise Intervention
3264028|NCT00740025||QD|Women who received their meds as QD administration
3264029|NCT00740025||BID|Women who received their gonadotropins as a BID dose
3264030|NCT00740012|Active Comparator|Even, low numbers|They start with a alarm- clock night. No venous blood drawing.
3264031|NCT00740012|Active Comparator|Even, high numbers|They start with a nurse performing blood glucose determination. No venous blood drawing.
3264032|NCT00740012|Active Comparator|Uneven, low numbers|They start with an alarm- clock night and have venous blood drawing.
3264033|NCT00740012|Active Comparator|Uneven, high numbers|They start with a nurse performing blood glucose determination and have venous blood drawing.
3264034|NCT00739999|Other|1|6-10 years will be administered with atorvastatin tablet formulation with initial doses based on age cohort.
3264035|NCT00739999|Other|2|10-17 years will be administered 10-mg daily dose of atorvastatin tablet formulation.
3264036|NCT00739986|Experimental|1|Semapimod 60 mg IV x 1 day, placebo IV x 2 days
3264037|NCT00739986|Experimental|2|Semapimod 60 mg IV x 3 days
3264038|NCT00739986|Placebo Comparator|3|Placebo comparator IV x 3 days
3264039|NCT00739973|Placebo Comparator|Placebo|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 5 of the 5 pills taken were placebos.
3264040|NCT00739973|Experimental|Aliskiren 150 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
3264041|NCT00739973|Experimental|Aliskiren 300 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
3264042|NCT00739973|Experimental|Amlodipine 5 mg capsule|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
3264043|NCT00739973|Experimental|Amlodipine 10 mg capsule|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg
3264044|NCT00739973|Experimental|Aliskiren/amlodipine 150/5 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
3264045|NCT00739973|Experimental|Aliskiren/amlodipine 150/10 mg tablet|150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
3264046|NCT00739973|Experimental|Aliskiren/amlodipine 300/5 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
3264047|NCT00739973|Experimental|Aliskiren/amlodipine 300/10 mg tablet|300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
3264048|NCT00739960|Other|Abatacept|
3264049|NCT00739947||1|Standard of Care
3264050|NCT00739934|Experimental|Children aged 2 to <12 years|Immunocompromised children aged 2 to <12 years who are at high risk for systemic fungal infection.
3264051|NCT00739921|Experimental|1|"Patients with sinusitis compared to patients without.~To find out if any specific type of fungus or mold is correlated with chronic sinus disease. The study will add new information about the different types of fungus and mold found in the human nose."
3264053|NCT00739908|Placebo Comparator|Placebo|
3264054|NCT00739895||Athletes|high performing athletes
3264055|NCT00739882|Active Comparator|Efalizumab|
3264056|NCT00739882|Placebo Comparator|Placebo|
3264057|NCT00739869||1|Participants will include women who participated in the Women's Health Initiative Memory Study.
3264058|NCT00739830|Experimental|1|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
3264059|NCT00739830|Active Comparator|2|Investigator's choice of: oral medroxyprogesterone acetate tablets 200 mg daily or oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily) OR Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
3264060|NCT00739765|Experimental|1 Interpersonal Psychotherapy (IPT)|Participants will receive interpersonal psychotherapy.
3264061|NCT00739765|Active Comparator|2 Prolonged Exposure (PE)|Participants will receive prolonged exposure therapy.
3264062|NCT00739765|Active Comparator|3 Relaxation therapy|Participants will receive relaxation therapy.
3264063|NCT00739752|Experimental|Non-Framed-Offered|Non-Framed, Information Only Condition. Vaccine Offered.
3264064|NCT00739752|Experimental|Non-Framed-Recommended|Non-Framed, Information Only Condition. Vaccine Recommended.
3264065|NCT00739752|Experimental|Gain-Framed-Offered|Gain-Framed Intervention emphasizes the benefits associated with receiving HBV vaccine. Vaccine Offered.
3264066|NCT00739752|Experimental|Gain-Framed-Recommended|Gain-Framed Intervention emphasizes the benefits associated with receiving HBV vaccine. Vaccine Recommended.
3264067|NCT00739752|Experimental|Loss-Framed-Offered|Loss-Framed Intervention emphasizes the risks associated with not receiving HBV vaccine. Vaccine Offered.
3264068|NCT00739752|Experimental|Loss-Framed-Recommended|Loss-Framed Intervention emphasizes the risks associated with not receiving HBV vaccine. Vaccine Recommended.
3264069|NCT00739739|Experimental|PD 0299685 15mg|
3264070|NCT00739739|Experimental|PD 0299685 30mg|
3264071|NCT00739739|Placebo Comparator|Placebo|
3264072|NCT00739713|Experimental|SB|Sea buckthorn oil group
3264073|NCT00739713|Placebo Comparator|PL|Placebo group
3264074|NCT00739700||A|There is only one cohort of subjects, the critically ill. The NIBP will be correlated with the IABP in each subject.
3264075|NCT00739687|Experimental|ALT-711|Alagebrium 200 mg BID
3264076|NCT00739687|Experimental|Placebo|Placebo
3264077|NCT00739674|Active Comparator|Losartan-Based Regimen Alone (L Group)|Losartan-based regimen, with sequential titration including HCTZ and CCB as needed to achieve target blood pressure.
3264078|NCT00739674|Experimental|Diet Management and Losartan-Based Regimen (DML Group)|Losartan with sequential titration including HCTZ and CCB as needed to achieve target blood pressure combined with low-salt intake diet.
3264079|NCT00739661|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
3264080|NCT00739661|Placebo Comparator|Placebo to vismodegib|Patients received placebo to vismodegib orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
3264081|NCT00739648|Placebo Comparator|Placebo|Placebo inhaled twice daily via the PARI eFlow nebulizer for 5 consecutive days within a 28-day treatment cycle for up to 12 cycles
3264082|NCT00739648|Experimental|MP-376 240 mg Twice Daily (BID)|MP-376 240 mg BID inhaled via the PARI eFlow nebulizer for 5 consecutive days within a 28-day treatment cycle for up to 12 cycles
3264083|NCT00739635|Experimental|1|
3264084|NCT00739635|Placebo Comparator|2|
3264085|NCT00739609|Experimental|1|
3264086|NCT00739596|Experimental|Aliskiren Hydrochlorothiazide (HCTZ)|
3264087|NCT00739596|Active Comparator|Amlodipine|
3264088|NCT00739583|Active Comparator|1|Skin preparation for hip replacement with a Chlorhexidine based skin preparation solution, Chloraprep® (CHG 2% w/v and IPA 70% v/v; Enturia Inc., Leawood, KS, USA)
3264089|NCT00739583|Active Comparator|2|Skin preparation for hip replacement with an Iodine based skin preparation solution, Duraprep® (Iodophor 0.7% and IPA 74% w/w; 3M Healthcare, St. Paul, MN, USA.
3264090|NCT00739570|No Intervention|1|
3264091|NCT00739570|Active Comparator|2|Activator chiropractic technique basic scan protocol
3264092|NCT00739544|Other|1|Quantitative sensory testing (QST) of healthy women to create reference values for QST evaluation of women treated for breast cancer
3264093|NCT00739531||Asthmatics|Subjects with asthma
3264094|NCT00739518|Experimental|MRI scan - new technology|The patient's clinical MRI scan will also utilize some new technology, such as a change in software or additional MRI sequences
3264095|NCT00739505|Experimental|Cohort 1|3 HPP patients are to be enrolled in Cohort 1 and receive a single IV dose and three weekly SC doses of Asfotase Alfa . End of Study for patients in Cohort 1 is at 8 weeks.
3264096|NCT00739505|Experimental|Cohort 2|Cohort 2 will begin when the safety and PK data for Cohort 1 weeks 1-4 has been reviewed by the DSMB. Cohort 2 will enroll 3 HPP patients and will receive a higher dose level than Cohort 1. Cohort 2 patients will have a single IV dose and three weekly SC doses of Asfotase Alfa . End of Study for patients in Cohort 2 is at 8 weeks.
3264097|NCT00739492|Active Comparator|1|deposit based incentive
3264098|NCT00739492|Active Comparator|2|"deposit based incentive framed with maintenance period"
3264099|NCT00739492|No Intervention|3|Control arm, no financial incentive
3264100|NCT00739479|Active Comparator|1|Patients will be randomized to receive PHWP. Since sex and baseline weight can influence the response, randomization will be stratified according to these variables.
3264101|NCT00739479|Placebo Comparator|2|Patients will be randomized to receive PHG. Since sex and baseline weight can influence the response, randomization will be stratified according to these variables.
3264102|NCT00739466|Experimental|low dose|Liposomal Alendronate dose of 0.001 mg
3264103|NCT00739466|Experimental|high dose|Liposomal Alendronate dose of 0.01 mg
3264104|NCT00739466|Placebo Comparator|placebo|IV saline infusion
3264313|NCT00737932|Experimental|Laquinimod|Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day (sequential cohorts)
3264314|NCT00737932|Placebo Comparator|Placebo|Matching placebo
3264105|NCT00739453|Experimental|Schedule 1|OSI-906 is administered on Days 1-3 every 7 days. Erlotinib will be administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
3264106|NCT00739453|Experimental|Schedule 2|OSI-906 is administered daily starting on Day 1 and erlotinib is administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
3264107|NCT00739453|Experimental|Schedule 3|OSI-906 is administered continuously twice daily starting on Day 1 and erlotinib is administered daily starting on Day 2. The NSCLC expansion cohort will follow Schedule 3 with the exception that erlotinib is administered daily starting on Day 8.
3264108|NCT00739440|Experimental|I|Patients 15 to 60 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex
3264109|NCT00739440|Experimental|II|Patients 15 to 60 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)
3264110|NCT00739414|Experimental|LBH589 (Panobinostat)|
3264111|NCT00739401|Experimental|1|Test subjects requiring endovascular treatment of abdominal aortic or aorto-iliac aneurysms including a proximal cuff extension.
3264112|NCT00739388|Experimental|Arm: 5-azacytidine|5-azacytidine 100 mg/m2/day s.c. on days 1-5 of a 28-day cycle.
3264113|NCT00739362|Experimental|Active|Active TDCS stiumlation - Transcranial Direct
3264114|NCT00739362|Sham Comparator|Sham|Sham/no-stiimulation - Transcranial Direct
3264115|NCT00739349|Experimental|1|Cyclosporine 0.05%
3264116|NCT00739349|Experimental|2|Cyclosporine 0.1%
3264117|NCT00739349|Placebo Comparator|3|vehicle/placebo
3264118|NCT00739336|Experimental|A, 1|Intervention: Immediate 3 month program
3264119|NCT00739336|No Intervention|A, 2|Wait-List Control
3264120|NCT00739310|Experimental|Vest Treatment (HFCWO)|Patients will receive Vest treatments for airway clearance therapy 2 x daily for 12 months. These data will be compared to 12 months of data prior to Vest initiation.
3264121|NCT00739297|Placebo Comparator|1|montelukast Placebo
3264122|NCT00739297|Experimental|2|montelukast
3264123|NCT00739297|Experimental|3|montelukast
3264124|NCT00739297|Experimental|4|montelukast
3264125|NCT00739271|Active Comparator|Study arm|Early enteral feed 48 hours after abdominal surgery
3264126|NCT00739271|Active Comparator|Control arm|Traditional treatment where patient is kept on a nasogastric drainage for a few days after abdominal surgery, wait for bowel sounds to appear and then start enteral feeds.
3264127|NCT00739258||HIDU|intravenous drug user (IDU) with HIV infected
3264128|NCT00739258||IDU|intravenous drug user (IDU) without HIV
3264129|NCT00739258||MH|persons receiving methadone maintenance treatment
3264130|NCT00739232|Active Comparator|Active|Active
3264131|NCT00739232|Placebo Comparator|Placebo|Placebo
3264132|NCT00739219|Active Comparator|eNO group|eNO measurement is used to inform asthma management decisions
3264133|NCT00739219|No Intervention|control group|Asthma is managed according to existing standard of care
3264134|NCT00739206|Experimental|Cohort 1|Adult patients with uncomplicated malaria
3264135|NCT00739206|Experimental|Cohort 2|Pediatric patients with uncomplicated malaria
3264136|NCT00739206|Experimental|Cohort 3|Pediatric patients with severe malaria
3264137|NCT00739193|Placebo Comparator|Placebo|Placebo Control
3264138|NCT00739193|Experimental|PM101|PM101
3264139|NCT00739193|Active Comparator|Amiodarone IV|Amiodarone IV
3264140|NCT00739180|Other|Control|Standard care control
3264141|NCT00739180|Active Comparator|Aerobic Exercise|
3264142|NCT00739180|Active Comparator|Resistance Exercise|
3264143|NCT00739167||Y90 Group|Patients receiving treatment with radioembolization.
3264144|NCT00739167||TACE Group|Patients receiving treatment with transcatheter arterial embolization
3264145|NCT00739167||RFA Group|Patients receiving treatment with radiofrequency ablation.
3264146|NCT00739154||1|glaucoma patients who also suffer from epileptic disorder and receiving chronic oral Phenytoin treatment
3264147|NCT00739154||2|glaucoma patients who also suffer from epileptic disorder receiving anti-convulsant treatment other then Phenytoin
3264148|NCT00739154||3|glaucoma patients with no epileptic disorder and not receiving anti-convulsant treatment
3264149|NCT00739141|Experimental|1|There are three chemotherapy drugs involved. They are called fludarabine (5 doses), cyclophosphamide (1 dose), and thiotepa (2 doses). Also two days of radiation therapy. This is called Total Body Irradiation or TBI. The TBI if given for two days before, the transplant. On transplant day, the cord blood cells will be given through a catheter. The immune suppressing drugs given are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through the catheter. Later they can be given as tablets.
3264150|NCT00739128|Active Comparator|1|celiac patients who did not respond to initial hepatitis B vaccine series , will receive repeat hep B vaccine via intramuscular route
3264151|NCT00739128|Active Comparator|2|celiac patients who did not respond to initial hepatitis B vaccine series , will receive repeat hep B vaccine via intradermal route
3264152|NCT00739115|Experimental|1|Heliox gas added to nasal CPAP for the first 72 hours of life
3264153|NCT00739115|No Intervention|2|Conventional nasal CPAP for the first 72 hours of life
3264154|NCT00739102|Experimental|1|S.M.A.R.T.® Nitinol Self-Expandable Stent System
3264155|NCT00739076|Experimental|1|Virtual Reality Hypnosis
3264156|NCT00739076|Experimental|2|Virtual Reality Distraction
3264157|NCT00739076|Experimental|3|Standard treatment.
3264158|NCT00739063|Experimental|Tarceva daily|Tarceva oral 150 mg daily.
3264159|NCT00739050|Experimental|1|Arm 1: Drug
3264160|NCT00739050|Placebo Comparator|2|Arm 2: Placebo
3264161|NCT00739037|Placebo Comparator|A|
3264162|NCT00739037|Experimental|B|
3264163|NCT00739024|Active Comparator|Active Treatment|Ramelteon once daily (double-blind assignment)
3264164|NCT00739024|Placebo Comparator|Placebo|Placebo tablet, once daily (double-blind assignment)
3264165|NCT00739011|Experimental|1|
3264315|NCT00737919|Active Comparator|1|A group of subjects consuming daily 2 grams of plant stanols 4-6 weeks before the operation
3264166|NCT00738998|Experimental|Questionnaire and Telephone Assessments|Breast cancer patients assigned to one or two groups: Group 1) enrolled at beginning of anastrozole treatment; or Group 2) if beginning third year of anastrozole treatment.
3264167|NCT00738985|Placebo Comparator|ezetimibe/simvastatin 10/20 mg + placebo|The intervention consisted of an isocaloric diet, an exercise program (30 min/day of aerobic activity) and ezetimibe (+) simvastatin 10/20 mg + placebo for 12 weeks. Safety and efficacy parameters are measured at baseline and 12 weeks later
3264168|NCT00738985|Active Comparator|ezetimibe/simvastatin 10/20 mg + MK0524A|The intervention consisted of an isocaloric diet, an exercise program (30 min/day of aerobic activity) and ezetimibe/simvastatin 10/20 mg + MK0524A 1 gr for 6 weeks, if efficacy achieved will continue with ezetimibe (+) simvastatin 10/20 mg + MK0524A 1 gr + placebo; if not achieved, will receive ezetimibe (+) simvastatin 10/20 mg + MK0524A 2 gr for 6 weeks.
3264169|NCT00738972|Active Comparator|Valsartan 80 mg + Paravastin 40 mg|Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)
3264170|NCT00738972|Active Comparator|Valsartan 80 mg + Simvastatin 40 mg|Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)
3264171|NCT00738972|Experimental|Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg|Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)
3264172|NCT00738972|Active Comparator|Valsartan 80 mg|Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)
3264173|NCT00738959|Experimental|1|
3264174|NCT00738946|Experimental|2|Amodiaquine+pyrimethamine versus placebo
3264175|NCT00738933|Active Comparator|A|A group of patients consuming 2 grams plant stanols 4-8 weeks before the operation
3264176|NCT00738933|Active Comparator|E|A group of patients consuming daily 2 grams plant sterols 4-8 weeks before the operation.
3264177|NCT00738933|Placebo Comparator|C|
3264178|NCT00738920|Active Comparator|MC-CBT|Self Administered Cognitive Behavior Therapy
3264179|NCT00738920|Active Comparator|Standard-CBT|Therapist Administered Cognitive Behavior Therapy
3264180|NCT00738920|Active Comparator|Education/Support|Behavioral Patient Education/Counseling
3264181|NCT00738894|Active Comparator|Medical Management|Antiplatelet medical therapy alone
3264182|NCT00738894|Experimental|Device Closure|PFO closure with study septal occluder device plus antiplatelet medical therapy
3264183|NCT00738881|Experimental|Arm I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3264184|NCT00738881|Experimental|Arm II (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3264185|NCT00738855|Active Comparator|1|Gastrografin group
3264186|NCT00738855|Placebo Comparator|2|Control group
3264187|NCT00738842|Experimental|1|
3264188|NCT00738842|Placebo Comparator|2|
3264189|NCT00738829|Experimental|Treatment Arm|Lenalidomide Dose Escalation combined with Fludarabine/Rituximab followed by maximum tolerated lenalidomide dose/Rituximab maintenance therapy
3264190|NCT00738816|Other|Intervention|Systematic medication review
3264191|NCT00738803|Experimental|1|Leg Length and offset measurement arm
3264192|NCT00738790|Experimental|1|Preoperative radiotherapy with five fractions of 5 Gy during one week and boost 4 Gy after 1 week interval, total dose 29 Gy; after 6 weeks full-thickness local excision
3264193|NCT00738790|Active Comparator|2|"Radiochemotherapy with 28 fractions of 1,8 Gy plus boost 5,4 Gy in 3 fractions~+ simultaneous bolus 5-Fluorouracil and leucovorin; after 6 weeks full-thickness local excision"
3264194|NCT00738777|Active Comparator|1|Anastrozole
3264195|NCT00738777|Experimental|2|Anastrozole + Fulvestrant
3264196|NCT00738777|Active Comparator|3|Tamoxifen
3264197|NCT00738777|Other|4|Tamoxifen (pre-menopausal and male patients)
3264198|NCT00738764|Experimental|Cohort 1|PDL192 Dose Level 1
3264199|NCT00738764|Experimental|Cohort 2|PDL192 Dose Level 2
3264200|NCT00738764|Experimental|Cohort 3|PDL192 Dose Level 3
3264201|NCT00738764|Experimental|Cohort 4|PDL192 Dose Level 4
3264202|NCT00738764|Experimental|Cohort 5|PDL192 Dose Level 5
3264203|NCT00738764|Experimental|Cohort 6|PDL192 Dose Level 6
3264204|NCT00738751|Experimental|Dose Escalation Followed by Expansion|Eligible participants were enrolled in a 3+3 dose-escalation design to determine the maximum tolerated dose (MTD) of twice weekly panobinostat plus daily erlotinib at 4 planned dose levels (DLs).
3264205|NCT00738725||1|Survey only
3264206|NCT00738725||2|Imaging group
3264207|NCT00738725||3|Non-imaging group
3264208|NCT00738712|Experimental|New MRI techniques|New hardware or software technologies designed to improve MRI (Magnetic Resonance Imaging) exams.
3264209|NCT00738699|Active Comparator|1|MORAb-003 (Farletuzumab) Plus Paclitaxel
3264210|NCT00738699|Placebo Comparator|2|Placebo Plus Paclitaxel
3264211|NCT00738686|Experimental|1|Single-arm study, no placebo or control group
3264212|NCT00738673|Experimental|Degarelix|"Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0.~Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections."
3264213|NCT00738660|Experimental|A|single experimental arm cross over of patients, addition of Ramipril onto Telmisartan.
3264214|NCT00738647|Active Comparator|Ceram X|Fillings made with a traditional composite material (Ceram X)
3264215|NCT00738647|Experimental|Filtek Silorane|Fillings made with a new composite material (Filtek silorane)
3264216|NCT00738634|Experimental|Physical activity mediated|"Self-motivated physical activity intervention~Materials mailed to participants"
3264217|NCT00738634|Active Comparator|Nutrition control|"Nutrition attention-control arm.~Delivered by researcher."
3264218|NCT00738634|Experimental|Physical activity researcher contact|"Self-motivated physical activity intervention~Delivered by researcher."
3264219|NCT00738621|Active Comparator|1|Oral aprepitant 40 mg - given within 3 hours prior to induction dexamethasone (4mg intravenous) administered immediately after induction ondansetron (4mg (2ml) intravenous) administered at cessation of anesthesia
3264220|NCT00738621|Placebo Comparator|A,2|Oral aprepitant 40 mg- given within 3 hours prior to induction dexamethasone (4mg intravenous) administered immediately after induction Placebo ( intravenous saline 2ml) administered at cessation of anesthesia
3264221|NCT00738608||1|33 pat. with verum
3264222|NCT00738608||2|33 Pat. with placebo
3264223|NCT00738595|Experimental|1|EVT 302, 5 mg once Daily
3264224|NCT00738595|Placebo Comparator|2|Placebo once daily
3264225|NCT00738595|Experimental|3|EVT 302 plus open label Nicotine replacement
3264226|NCT00738595|Active Comparator|4|Placebo plus nicotine replacement therapy
3264227|NCT00738582|Experimental|Open Label|Pemetrexed, Cisplatin and MORAb-009 (Amatuximab)
3264228|NCT00738569|Experimental|Raltegravir|
3264229|NCT00738556|Active Comparator|1|Full cover stenting of coronary lesions
3264230|NCT00738556|Active Comparator|2|Spot-stenting of significantly stenotic parts of a coronary lesion
3264231|NCT00738543|Experimental|Whole group of 48 volunteers|The arm is composed of 48 human volunteers to test 10% povidone-iodine (Isodine Solucion ®, Boehringer-Ingelheim Promeco, Mexico City), Hypochlorite 10% of electrochemical production (Exsept 10% ®, Pisa, Guadalajara, Mexico), and control.
3264232|NCT00738530|Experimental|Bevacizumab + IFN-Alfa-2A|Bevacizumab infusions will be administered every 2 weeks at a dose of 10 milligram per kilogram (mg/kg) for 52 weeks or until disease progression or unacceptable toxicity. Interferon alfa-2a (IFN-Alfa-2A) will be administered 3 times per week as a subcutaneous injection at a dose of 9 million international units (MIU) for 52 weeks or until disease progression or major toxicity.
3264233|NCT00738530|Placebo Comparator|Placebo + IFN-Alfa-2A|Placebo matched with Bevacizumab infusions will be administered every 2 weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A will be administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
3264234|NCT00738517|Active Comparator|1|Immunoadsorption with subsequent immunoglobulin substitution
3264235|NCT00738517|No Intervention|2|
3264236|NCT00738504||1|
3264237|NCT00738504||2|
3264238|NCT00738504||Group 1|Group 1 (Carbohydrate Restrictive Strategy). Patients received intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16,7% proteins and 50% lipids (Glucerna, Abbott Laboratories). These patients received regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and, in stable patients, ideally below 150 mg/dl.
3264239|NCT00738504||Group 2|Group 2 (Intensive Insulin Therapy). Continuous intravenous insulin infusion was adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 to 120 mg/dl. Patients were submitted to capillary glycemic measurements every 2 hours. The insulin dose was adjusted according to an algorithm run by nurses and overseen by physicians. These patients received glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids (Diason, Nutricia Clinical Care Ltd).
3264240|NCT00738491||1|Patients with stable angina pectoris and documented coronary heart disease recruited in Edinburgh
3264241|NCT00738491||2|Patients with stable angina pectoris and documented coronary heart disease recruited in London
3264242|NCT00738478|Experimental|A|Arm A: with nasogastric tube
3264243|NCT00738478|Active Comparator|B|Arm B: without nasogastric tube
3264244|NCT00738452|Experimental|Treatment (chemo, monoclonal antibody therapy, radiation)|CHEMORADIOTHERAPY: Patients undergo external beam radiation therapy 5 days a week for 45 days. Beginning within 24 hours of the start of radiation therapy, patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36 OR cisplatin IV over 60 minutes on days 1, 8, 29, and 36 and etoposide IV over 60 minutes on days 1-5 and 29-33. CONSOLIDATION RADIOIMMUNOTHERAPY: Beginning 6-10 weeks after completion of chemoradiotherapy, patients with stable disease, partial response, or complete response receive a therapeutic dose of yttrium Y 90 anti-CEA monoclonal antibody cT84.66 IV. Treatment continues in the absence of disease progression or unacceptable toxicity.
3264245|NCT00738439||Operative|Diagnosis of adult degenerative or idiopathic scoliosis with a curvature of the spine measuring greater than or equal to 20 degrees requiring surgery.
3264246|NCT00738439||Nonoperative|Diagnosis of adult degenerative or idiopathic scoliosis with a curvature of the spine measuring greater than or equal to 20 degrees not requiring surgery.
3264247|NCT00738426|Active Comparator|Erchonia ML Scanner (MLS)|Red diode low level laser light energy
3264248|NCT00738426|Sham Comparator|Sham device|non-therapeutic sham light output
3264249|NCT00738413|Active Comparator|Arm 1|Subjects will be treated for 6 days with deferoxamine.
3264250|NCT00738413|Active Comparator|Arm 2|Subjects will be treated for 6 days with deferasirox.
3264251|NCT00738413|Experimental|Arm 3|Subjects will be treated for 6 days with a combination of deferoxamine and deferasirox.
3264252|NCT00738400|Experimental|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg tablets PRN (pro re nata) for 4 weeks, Vardenafil 5 mg/10 mg/20 mg tablets PRN for consecutive 4 weeks
3264253|NCT00738400|Placebo Comparator|Placebo|Matching placebo tablets PRN (pro re nata) for 4 weeks, placebo tablets PRN for consecutive 4 weeks
3264254|NCT00738387|Experimental|ASA404 + docetaxel|"1800 mg/m2 of ASA404 intravenous (IV) on day 1 of each 21 day cycle~75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days"
3264255|NCT00738387|Placebo Comparator|Placebo + docetaxel|"Placebo i.v. on day 1 of each 21 day cycle~75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days"
3264256|NCT00738374|Experimental|1|
3264257|NCT00738361|Experimental|nab-paclitaxel|Administered via intravenous bolus at a dose of 150 mg/m2 weekly for 3 of 4 weeks every 28 days.
3264258|NCT00738348|Active Comparator|2|250mL of 5% glucose plus 300mg of sivelstat was infected through the vein at 10mL per an hour
3264259|NCT00738348|Placebo Comparator|1|250mL of 5% glucose was injected though the vein at 10mL per an hour
3264260|NCT00738322|Experimental|1|
3264261|NCT00738322|Placebo Comparator|2|
3264316|NCT00737919|Active Comparator|2|A group of patients consuming daily 2 grams of plant sterols 4-6 weeks before the operation
3264317|NCT00737906|Experimental|I|Surgical turbinate reduction procedure
3264446|NCT00736879|Experimental|Dapagliflozin 5 mg|Dapagliflozin: 5 mg
3264262|NCT00738309||Operative|Diagnosis of classical Scheuermann's Kyphosis (3 successive vertebrae wedged 5 degrees or more, +/- end plate deformities) or idiopathic structural Kyphosis (rigid structural kyphosis without classic Scheuermann's Kyphosis findings) for which surgical treatment is recommended to prevent progression of the curvature or to correct trunk deformity (unacceptable cosmesis).
3264263|NCT00738309||Non-operative|Diagnosis of classical Scheuermann's Kyphosis (3 successive vertebrae wedged 5 degrees or more, +/- end plate deformities) or idiopathic structural Kyphosis (rigid structural kyphosis without classic Scheuermann's Kyphosis findings) for which surgical treatment was not undertaken.
3264264|NCT00738296|Active Comparator|A|Group A: Comparator
3264265|NCT00738296|Active Comparator|B|Group B: Comparator
3264266|NCT00738296|Experimental|C|Group C: Drug
3264267|NCT00738257|Experimental|Parmidronate|
3264268|NCT00738244||1|Normal hearing listeners
3264269|NCT00738244||2|Listeners with mild-to-moderate sensorineural hearing loss
3264270|NCT00738231|Active Comparator|I|"Group I's training material consisted of a brochure with the information we wanted the public to know about heart disease. The brochure had such titles as Cardiovascular Diseases, let us protect our hearts, the importance of cholesterol in preventing heart diseases, watch out for blood pressure, quit smoking for your health, weight watching, nutrition, food to avoid in cardiovascular disease, an easy method: exercise and exercise control, and an appropriate body weight vs. height chart for adults"
3264271|NCT00738231|Active Comparator|II|The Group II training material document was a letter in the form of a prescription in which the individual was addressed by name, the risk factors established at the first stage were explained, and the suggested measures for protection from such risk factors were indicated.
3264272|NCT00738218|Other|MDCT|Single Arm study. All patients underwent MDCT.
3264273|NCT00738205||1|
3264274|NCT00738205||2|
3264275|NCT00738192|Active Comparator|1|Fentanyl delivered for controlling awaking pain
3264276|NCT00738192|Active Comparator|2|Sufentanil delivered for controlling awaking pain
3264277|NCT00738192|Active Comparator|3|Butorphanol delivered for controlling awaking pain
3264278|NCT00738179|Experimental|1|CPAP plus standard care of cardiovascular risk factors
3264279|NCT00738179|Active Comparator|2|Standard care alone
3264280|NCT00738166|Experimental|II|organic animal manure
3264281|NCT00738166|Active Comparator|III|conventional
3264282|NCT00738166|Experimental|I|organic green manure
3264283|NCT00738153||A|
3264284|NCT00738140|Experimental|A|Intensive lifestyle intervention based on the Diabetes Prevention Program
3264285|NCT00738140|No Intervention|B|Will follow the guidelines for healthy living established by the Food Guide Pyramid and the National Cholesterol Education Program
3264286|NCT00738127|Experimental|1|Group I (treatment with our technique) Eighteen patients (18 wrists) were available for long-term follow-up at an average of 47.8 months after surgery. There were 11 men and seven women. Their mean age at the time of surgery was 35.4 years (range, 22 to 56 years). The dominant hand was involved in 12 patients and the nondominant hand, in six.
3264287|NCT00738127|Experimental|2|Group II (treatment with Inoue et al.'s technique) Fifteen patients (15 wrists) were evaluated at an average of 51 months. Nine patients were men and 6 were women. The mean age of the group at the time of surgery was 37.5 years (range, 24 to 58 years). The dominant hand was involved in 10 and nondominant hand, in seven.
3264288|NCT00738114||1|group without hyperglycemia (fasting blood glucose below 126mg/dl) approximately 1000 patients
3264289|NCT00738114||2|group with hyperglycemia (fasting blood glucose above 125 mg/dl) or history of diabetes approximately 500 patients
3264290|NCT00738101|Experimental|1|Drug: Omegaven
3264291|NCT00738088|Experimental|1|Withdrawal of sulphonylurea for 6 weeks, then re-introduction for 6 weeks, assessed by fasting glucose and HbA1c
3264292|NCT00738075||PD+FOG|Patients with Parkinson's disease prone to freezing
3264293|NCT00738062|Active Comparator|Droxidopa|Study medication
3264294|NCT00738062|Placebo Comparator|Placebo|Placebo
3264295|NCT00738049|Active Comparator|Group 1|Group 1 will receive oral darusentan 100mg for 2 weeks during Phase 1 then placebo for 2 weeks during Phase 2.
3264296|NCT00738049|Active Comparator|Group 2|Group 2 will receive placebo for 2 weeks during Phase 1 then oral darusentan 100 mg for two weeks during Phase 2
3264297|NCT00738036||Group P|Exposed to an acute painful phenomenon requiring an analgesic management
3264298|NCT00738036||Group C|Control, not exposed to acute pain
3264299|NCT00738023|Active Comparator|Diabetics|Obese, normotensive African-Americans with diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours, then normal saline 0.9% at 40 ml/hr intravenously for 48 hours, and then randomized to rosiglitazone for six weeks followed by Intralipid 20% at 40ml/hr intravenously for 48 hours
3264300|NCT00738023|Active Comparator|Non-Diabetic|Obese, normotensive African-Americans without diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours
3264301|NCT00738010|Experimental|KH|Kneehab is a garment integrated NMES device with multipath technology.
3264302|NCT00738010|Active Comparator|PS|Poli-Stim, a standard NMES device, used for 3 times per day, five days per week for 12 weeks.
3264303|NCT00738010|Active Comparator|CO|Control group performed voluntary muscle contractions for 20 minutes 3 times per day, 5 days per week for 12 weeks.
3264304|NCT00737997|Placebo Comparator|1|
3264305|NCT00737997|Experimental|2|
3264306|NCT00737984|No Intervention|1|Group 1 patients will receive standard superovulation-IUI treatment without endometrial sampling
3264307|NCT00737984|Active Comparator|2|Group 2 patients will receive standard superovulation-IUI treatment with endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
3264308|NCT00737971|Active Comparator|A|Avastin intravitreal injection D0, Week 4, Week 8
3264309|NCT00737971|Active Comparator|B|Triamcinolone intravitreal injection
3264310|NCT00737971|Active Comparator|C|Avastin + Triamcinolone intravitreal injection simultaneously
3264311|NCT00737958||1|Patients with documented stable coronary artery disease, symptoms of stable angina pectoris, and a positive standard BRUCE exercise stress test at 3 - 13 minutes.
3264312|NCT00737945||2|
3264318|NCT00737893|Experimental|Erythropoietin (EPO)|20,000 units of EPO given on the day before surgery, the day of surgery, and the day after surgery.
3264319|NCT00737893|Placebo Comparator|Placebo|Placebo doses given the day before surgery, the day of surgery, and the day after surgery.
3264320|NCT00737880|Active Comparator|1|In situ organ perfusion using HTK solution during pancreas procurement
3264321|NCT00737880|Active Comparator|2|In situ perfusion using UW solution during pancreas procurement
3264322|NCT00737867|Experimental|A|"Day 1: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Gemcitabine infusion 1000 mg/m2 Day 8: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Gemcitabine infusion 1000 mg/m2~All patients will receive a maximum of 3 courses with an interval of 3 weeks"
3264323|NCT00737867|Active Comparator|B|"Day 1: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Carboplatin infusion AUC = 5 (Calvert`s formula) Day 8: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2~All patients will receive a maximum of 3 courses with an interval of 3 weeks"
3264324|NCT00737854|Experimental|1 ARM|Otherwise healthy patients with oral lichen planus (precancerous/erosive OLP)
3264325|NCT00737841|Experimental|A|Bifidobacterium breve
3264326|NCT00737841|Placebo Comparator|B|Placebo
3264327|NCT00737828|Active Comparator|A|Control - Standard Perioperative Pathway, clinician decides post-operative care environment (usual care)
3264328|NCT00737828|Experimental|B|Intervention - Perioperative care pathway guided by CPX Results i.e.anaerobic threshold & ventilatory equivalents
3264329|NCT00737815|Active Comparator|A|Magnesium citrate: a total of 500 mg of elemental magnesium
3264330|NCT00737815|Placebo Comparator|B|Placebo pills
3264331|NCT00737802||Normal Control|Normal control subjects are the participants with no history of GERD, no signs and symptoms of GERD
3264332|NCT00737802||GERD Patients|GERD patients are those with history of GERD, signs and symptoms of GERD and selected signs and symptoms of GERD in the questionnaire.
3264333|NCT00737802||Barrett's patients|Barrett's patients are those participants who in addition to all the qualities of GERD patients have long standing history of GERD and mucosal changes in the esophagus.
3264334|NCT00737789|Experimental|Mesalazine once/day|Participants received 4g oral Mesalazine once a day (2 sachets of prolonged release granules) for 8 weeks during the induction period. In addition, participants received a liquid enema of 1g Mesalazine once a day at bedtime for the first 4 weeks. Participants who were in remission at Week 8 received oral mesalazine 2g once daily (1 sachet/day) for an additional 4 weeks (maintenance period).
3264335|NCT00737789|Active Comparator|Mesalazine twice/day|Participants received oral mesalazine 4 g per day in two divided doses (1 sachet prolonged release granules twice a day) for 8 weeks during the induction period. In addition, participants received a liquid enema of 1g Mesalazine once a day at bedtime for the first 4 weeks. Participants who were in remission at Week 8 received oral Mesalazine 2g (one sachet) once a day for an additional 4 weeks (maintenance period).
3264336|NCT00737776||A|
3264337|NCT00737763|Experimental|A|This group will receive weekly efalizumab injections for 6 months
3264338|NCT00737763|Placebo Comparator|B|This group will receive placebo injections for 6 months
3264339|NCT00737750|Experimental|KH|Kneehab is a garment integrated NMES device with multipath technology.
3264340|NCT00737750|Active Comparator|PS|Poli-Stim, a standard NMES device, used for 3 times per day, five days per week for 12 weeks.
3264341|NCT00737750|Active Comparator|CO|Control group performed voluntary muscle contractions for 20 minutes 3 times per day, 5 days per week for 12 weeks.
3264342|NCT00737737|Experimental|Opioid|Participants will receive MS Contin over a 4 week period starting at 15 mg bid. Doses will titrated upwards as tolerated by increments of 15-30 mg to a highest attained dose or a maximum dose of 90 mg
3264343|NCT00737737|Experimental|Placebo|Participants will receive a similar number of placebo tablets which match the study drug with regards to appearance over a period of 4 weeks
3264344|NCT00737724|Experimental|Group 1|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
3264345|NCT00737724|Experimental|Group 2|Receives only antituberculosis therapy, and 2 months afterwards antiretroviral therapy
3264346|NCT00737711|Experimental|Mircera|
3264347|NCT00737698|Experimental|1|Exercise
3264348|NCT00737698|Experimental|2|Repetitive magnetic stimulation
3264349|NCT00737698|No Intervention|3|No active treatment
3264350|NCT00737685|Experimental|Fludarabine|
3264351|NCT00737672|Experimental|VIABAHN Treatment Group|Use of GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Comparator Arm
3264352|NCT00737672|Active Comparator|PTA Treatment Group|Percutaneous Transluminal Angioplasty (PTA) in arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Experimental Arm
3264353|NCT00737659|Experimental|1|Concentration Controlled (CC)group will receive an individually adjusted MMF dosing regimen based on the plasma concentrations of mycophenolic acid (MPA,the active metabolite of mycophenolate mofetil).
3264354|NCT00737659|Active Comparator|2|Fixed dose (FD) group will receive an a priori set dose of 2mg\day MMF, the recommended dose, with a possible secondary adaptation by the clinician based on criteria of clinical efficacy, toxicity or interactions with other medications.
3264355|NCT00737646|Other|1|Usual care
3264356|NCT00737646|Experimental|2|Clinic-focused intervention: The clinicians and clinical staff in each of the clinics will be scheduled for training sessions. The provider trainings will be designed for clinicians and clinical staff and will be conducted in at least two separate sessions of approximately 3 hours total duration. The sessions will be scheduled to accommodate the clinic schedule, but will be held with no more than 1 month between them. Participants in clinic training sessions will receive continuing education credit.
3264404|NCT00737204|Experimental|Armodafinil|Participants will take armodafinil for 4 weeks. The dose will be titrated up from 50mg to 250mg per day as clinically indicated, using 50mg tablets. If responsive, participants will be offered 12 additional weeks of armodafinil.
3264447|NCT00736879|Placebo Comparator|Placebo|Placebo: 0 mg
3264448|NCT00736866|Experimental|Acetylcysteine|
3264449|NCT00736866|Placebo Comparator|Control|
3264357|NCT00737646|Experimental|3|"Clinic-focused and patient focused intervention: The clinic focused-intervention as described in Arm 2 will be combined with a patient-focused intervention.~Patient focused intervention: CRC education packets, based upon previously developed CDC CRC patient education materials, have been adapted for each study site. These CRC educational packets will be mailed to average-risk patients aged 50-80 years who are due for CRC screening (based on electronic records) and who schedule a non-acute ambulatory care visit in clinics assigned to the patient-focused intervention. A cover letter signed by the patient's physician will be included with each packet. The packets will be mailed approximately 1 week before the medical appointment."
3264358|NCT00737633|Experimental|16-Week population|Placebo subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)
3264359|NCT00737633|Experimental|72-Week population|Active treatment subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)
3264360|NCT00737620|Active Comparator|propaten graft|
3264361|NCT00737620|Active Comparator|Standard graft|
3264362|NCT00737594|Placebo Comparator|Placebo|Placebo
3264363|NCT00737594|Experimental|12 mcg TID|Cobiprostone 36 mcg
3264364|NCT00737594|Experimental|18 mcg TID|Cobiprostone 54 mcg
3264365|NCT00737568|Experimental|Tenofovir DF|TDF plus placebo to match FTC/TDF
3264366|NCT00737568|Experimental|FTC/TDF|FTC/TDF plus placebo to match TDF
3264367|NCT00737555|Experimental|1|Once daily oral administration of CHR-2797 ( escalating dose groups) in solid tumour patients receiving paclitaxel infusion every three weeks
3264368|NCT00737542|Placebo Comparator|A|
3264369|NCT00737542|Experimental|B|
3264370|NCT00737529|Experimental|Lenalidomide|"Single agent Lenalidomide~Lenalidomide: 10mg or 25 mg oral capsules on days 1 to 21 of each 28 day cycle and dependent on renal function; Participants with normal renal function (defined as Creatinine Clearance(CrCl)) of ≥ 60 mL/min in this study) received 25 mg of lenalidomide daily, and those with moderate renal insufficiency (CrCl) ≥ 30 mL/min but < 60 mL/min) were started at a 10-mg dose. Participants could continue to receive treatment until disease progression, development of unacceptable AEs, or voluntary withdrawal."
3264371|NCT00737516|Experimental|single arm|HPC, Cord Blood
3264372|NCT00737503|Experimental|1|All eligible children in the experimental arm will be vaccinated with the Rotavirus vaccine
3264373|NCT00737503|No Intervention|2|Children will not be vaccinated with rotavirus vaccine.
3264374|NCT00737490|Active Comparator|1|"Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm"
3264375|NCT00737490|Active Comparator|2|"Simultaneous BiV pacing. Simultaneous Arm"
3264376|NCT00737477|Experimental|Mircera in Renal Anemia|Participants will receive SC methoxy polyethylene glycol-epoetin beta (Mircera) every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 micrograms (mcg) will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
3264377|NCT00737464|Experimental|Mircera|Participant with chronic renal anemia will receive methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.
3264378|NCT00737451||skin itching|
3264379|NCT00737438|Experimental|1|"Initial chemo for ALL pts (ECX + BEV): Epirubicin 50 mg/m2 d1 every 21 days Cisplatin 60 mg/m2 d1 every 21 days, Capecitabine 625 mg/m2 po bid days 2-21 (held for 48 hours prior to FDG-PET/CT in week 3) Bev 15 mg/kg d1 every 21 days (cycle 1 & cycle 2 only) Salvage chemotherapy for metabolic non-responders (DI + BEV): Docetaxel 30 mg/m2 d1, d8 every 21 days, CPT-11 50 mg/m2 d1, d8 every 21 days, Bev 15 mg/kg d1, cycle 2 only 2 cycles are planned prior to resection.~Pts who aren't Cisplatin candidates (i.e. Creatinine clearance 40-60/cc, older age, marginal PS,etc.) may get oxaliplatin instead of cisplatin after discus with the PI. Oxaliplatin will be admin at 130 mg/m2 on day 1 every 21 days. Pts who aren't able to get Capecitabine (i.e. insurance restriction, unable to swallow, etc.) may get infusional fluorouracil instead of capecitabine after discus with the PI. Fluorouracil will be admin at 200 mg/m2/d x 21 days (held for 48 hours prior to FDGPET/ CT scan in week 3 of cycle 1)."
3264380|NCT00737425|Active Comparator|1|
3264381|NCT00737425|Sham Comparator|2|
3264382|NCT00737412|Active Comparator|1|The probiotic Bio-K+ CL1285 RX®
3264383|NCT00737412|Placebo Comparator|2|Placebo
3264384|NCT00737399|Experimental|1|Lifestyle Counseling with Emotional Freedom Techniques (EFT)
3264385|NCT00737373|Experimental|1|FLOT
3264386|NCT00737373|Active Comparator|2|FLO
3264387|NCT00737360|Experimental|1|
3264388|NCT00737347|No Intervention|1|usual care. Subjects had one 90 minute visit with registered dietitian
3264389|NCT00737347|Active Comparator|2.|Standard care. Subjects had 4 sessions with registered dietitian
3264390|NCT00737347|Active Comparator|3|Intensive care. subjects had 10 visits with registered dietitian
3264391|NCT00737334|Active Comparator|1|All patients will have continuous EEGo, BIS and FORE-SIGHT monitoring, which will be correlated with arterial to jugular venous lactate differences.
3264392|NCT00737321||2- Diabetics without wound (s)|These group of subject will be control arm, included who have good glycemic control diabetic with HbA1c 8.4 or lower and also without any open wounds. Samples will be collected.
3264393|NCT00737321||1-Subjects with diabetes with wound|This group of subjects will have wound and come for couple of follow up visits for saliva collection, biopsy collection and blood draw.
3264394|NCT00737308|Experimental|A|crown for clasp
3264395|NCT00737295|Experimental|US|There will be no experimental or control group, rather each individual will act as his/her own control.
3264396|NCT00737282|Active Comparator|25 mg Proellex|Proellex 25 mg once daily
3264397|NCT00737282|Active Comparator|Proellex 50 mg|Proellex 50 mg once daily
3264398|NCT00737256|Experimental|1|
3264399|NCT00737256|Active Comparator|2|
3264400|NCT00737243|Experimental|Paclitaxel, Carboplatin, Bevacizumab and Erlotinib|Paclitaxel, Carboplatin, Bevacizumab and Erlotinib
3264401|NCT00737243|Other|Treatment determined by physician|Other treatment determined by physician based on molecular profiling assay
3264402|NCT00737217||Parkinson's disease|
3264403|NCT00737217||Normal Controls|
3264445|NCT00736879|Experimental|Dapagliflozin 2.5 mg|Dapagliflozin: 2.5 mg
3264405|NCT00737204|Placebo Comparator|Placebo|Participants will receive placebo pills for 4 weeks. Placebo tablets that match the 50mg active medication tablets will given following the same dosing strategy as Arm 1. The dose will be titrated from 1 placebo tablet daily to 5 tablets daily as clinically indicated. Non-responders to placebo will then be offered 16 weeks of active medication.
3264406|NCT00737191|Active Comparator|Arm I|Patients receive oral opioid and oral placebo once daily for 4 weeks.
3264407|NCT00737191|Experimental|Arm II|Patients receive oral opioid and 2.5 mg oral olanzapine once daily for 4 weeks.
3264408|NCT00737191|Experimental|Arm III|Patients receive oral opioid and 5 mg oral olanzapine once daily for 4 weeks.
3264409|NCT00737178|Active Comparator|Immediate IUD insertion|Insertion of CuT380A at the routine medication abortion follow-up visit one week after initiation of a medication abortion
3264410|NCT00737178|Active Comparator|Delayed IUD insertion|Insertion of CuT380A four to six weeks after initiation of a medication abortion
3264411|NCT00737165|Experimental|Multimodal community intervention|Multimodal suicide prevention program
3264412|NCT00737165|Active Comparator|Community intervention as usual|Suicide prevention program as usual
3264413|NCT00737152|Experimental|1|All subjects will take RAS 130 administered orally in tablet form at a starting dose of 4 mg once a day or 2 mg tablets twice a day.
3264414|NCT00737139|Active Comparator|1|Intra-articular Injection of Marcaine/Epinephrine
3264415|NCT00737139|Active Comparator|2|Intra-articular Injection of Marcaine alone
3264416|NCT00737126|Placebo Comparator|1|Administration of an oral placebo pill
3264417|NCT00737126|Experimental|2|Administration of oral folic acid
3264418|NCT00737100|Experimental|Tiotropium Respimat 2.5 mcg|patient to receive low dose tiotropium once daily
3264419|NCT00737100|Experimental|Tiotropium Respimat 5 mcg|patient to receive high dose tiotropium once daily
3264420|NCT00737100|Placebo Comparator|Placebo Respimat|patient to receive placebo once daily
3264421|NCT00737087|Other|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
3264422|NCT00737061|Experimental|Adiana Transcervical Sterilization System|Single arm treatment
3264423|NCT00737048|Experimental|Tramadol plus Acetaminophen and Placebo|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively, along with two oral capsules of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed greater than or equal to (>=) 50.0 millimeter (mm) on the Visual Analog Scale (VAS), score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
3264424|NCT00737048|Experimental|Tramadol and Placebo|Tramadol hydrochloride will be administered as single oral dosing of two capsules once at a dose of 75 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed >= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
3264425|NCT00737048|Experimental|Acetaminophen and Placebo|Acetaminophen will be administered as single oral dosing of two capsules once at a dose of 650 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed >= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
3264426|NCT00737035|Experimental|1-Intervention|For 16 weeks, participants will have access to an interactive healthcare communication application (IHCA).
3264427|NCT00737035|Active Comparator|2- Control|For 16 weeks, participants will have access to generally available Internet-based information about parenting, trauma, and child development.
3264428|NCT00736996|Experimental|Pioglitazone|"Pioglitazone~30 - 45mg tablet daily for 6 months"
3264429|NCT00736996|Active Comparator|Endurance Exercise Training|Endurance Exercise Training (EET) Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
3264430|NCT00736996|Placebo Comparator|Placebo|Placebo matching tablet sugar pill daily for 6 months
3264431|NCT00736983|Active Comparator|1|Adalimumab
3264432|NCT00736983|Placebo Comparator|2|ciprofloxacin
3264433|NCT00736970|Experimental|1|10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus
3264434|NCT00736957|Experimental|Tramadol HCL plus Acetaminophen|
3264435|NCT00736944|Experimental|1|"Induction chemotherapy followed by Radiation therapy plus Cisplatin~Induction chemotherapy:~Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3.~Post-Induction:~Radiation - Monday-Friday weeks 1-7 with concurrent Cisplatin 100 mg/m2 IVPB on radiation day 1, 22, and 42."
3264436|NCT00736944|Experimental|2|"Induction chemotherapy followed by Radiation therapy plus Cetuximab~Induction chemotherapy:~Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3.~Post-Induction:~Radiation - Monday-Friday weeks 1-7 with concurrent Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB"
3264437|NCT00736931|Experimental|1|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
3264438|NCT00736931|Active Comparator|2|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
3264439|NCT00736931|Active Comparator|3|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
3264440|NCT00736931|Placebo Comparator|4|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
3264441|NCT00736918|Experimental|Case management|Case management
3264442|NCT00736918|Active Comparator|Enhanced usual care|Enhanced usual care
3264443|NCT00736892||A|All patients meeting the American European Consensus definition of acute lung injury will be included, regardless of etiology of respiratory failure. Specifically, all patients with rapid onset of acute lung injury not of cardiac origin (no indication of heart failure or a pulmonary capillary wedge pressure of greater than 18 mmHg, with pulmonary infiltrates in all four quadrants and a PaO2/FIO2 of > 200 to <300 mmHg or ≤ 200 mmHg.
3264444|NCT00736879|Experimental|Dapagliflozin 1 mg|Dapagliflozin: 1 mg
3264450|NCT00736853|Experimental|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|
3264451|NCT00736853|Experimental|Tramadol Hydrochloride Plus Acetaminophen (Double Blind)|
3264452|NCT00736853|Placebo Comparator|Placebo (Double-Blind)|
3264453|NCT00736840|Other|CLD (chronic liver disease)|Chronic liver disease subjects with recent biopsy will be tested with a breath tests using a 13C enriched substrate metabolized by their liver
3264454|NCT00736827||Patients with non-septic shock|Postoperative/posttraumatic surgical critically ill patients with non-septic shock with threatening acute renal failure
3264455|NCT00736827||Patients with septic shock|Postoperative/posttraumatic surgical critically ill patients with septic shock with threatening acute renal failure
3264456|NCT00736814|Active Comparator|Arm I|Patients receive standard chemotherapy of docetaxel and carboplatin.
3264457|NCT00736814|Experimental|Arm II, Genotype A1|Patients receive docetaxel and vinorelbine ditartrate.
3264458|NCT00736814|Experimental|Arm II, Genotype A2|Patients receive gemcitabine hydrochloride and vinorelbine ditartrate.
3264459|NCT00736814|Experimental|Arm II, Genotype B1|Patients receive docetaxel and carboplatin.
3264460|NCT00736814|Experimental|Arm II, Genotype B2|Patients receive gemcitabine hydrochloride and carboplatin.
3264461|NCT00736801|Experimental|A|Treatment with Salmeterol for 2 weeks, followed by a treatment with Salmeterol and Fluticasone for 2 weeks.
3264462|NCT00736788|Experimental|1|Four different oral dose levels of a suspension containing AZD1704
3264463|NCT00736788|Placebo Comparator|2|oral suspension
3264464|NCT00736762|Experimental|GPR|Global postural re-education intervention
3264465|NCT00736749||Observational (long-term follow-up)|Approximately 6 months after completion of therapy patients receive a mailed packet introducing the LTFC and containing information related to their individualized, protocol-specific follow-up guidelines. Patients are asked to complete a patient response form, verify information provided in packet, update contact information, and complete a Health Status Update Form. The Health Status Update Form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. Patients receive protocol-specific automatic reminders, and may respond by use of postage prepaid envelopes, email, or 24-hour toll-free telephone number.
3264466|NCT00736736|Active Comparator|Leg Press|Leg Press exercise for 3 times/week and sustain for 8 weeks.
3264467|NCT00736736|Experimental|Hip Exercise|Additional hip abductor and hip external rotator strength training to leg press exercise for people in this group. All participants received exercise for 3 times per week for 8 weeks.
3264468|NCT00736736|No Intervention|Control|Education was given during 8 weeks of study period. After 8 weeks of study, exercise was given as compensation.
3264469|NCT00736723||Patients non-septic shock|Postoperative/posttraumatic critically ill patients with non-septic shock
3264470|NCT00736723||Patients septic shock|Postoperative/posttraumatic critically ill patients with septic shock
3264471|NCT00736710|Experimental|1|
3264472|NCT00736710|Sham Comparator|2|
3264473|NCT00736697|Experimental|1|
3264474|NCT00736684|Active Comparator|1|Proximal Femoral Nail AntirotationTM (PFNA)
3264475|NCT00736684|Other|2|Gamma Nail 3TM (Gamma3)
3264476|NCT00736671||Observational Parkinson's Disease|Observational study of subjects with Parkinson disease
3264477|NCT00736671||Observational Normal Control aubjects|Observational study of normal control subjects
3264478|NCT00736658|Experimental|AZD1386|4 groups receiving a specified volume of the active component AZD1386 at different points of time.
3264479|NCT00736658|Placebo Comparator|Placebo|Included in each dose group
3264480|NCT00736645|Experimental|Arm I|Patients receive oral selenomethionine and oral finasteride once daily for 4-5 weeks.
3264481|NCT00736645|Experimental|Arm II|Patients receive oral placebo and oral finasteride once daily for 4-5 weeks.
3264482|NCT00736645|Experimental|Arm III|Patients receive oral selenomethionine and oral placebo once daily for 4-5 weeks.
3264483|NCT00736645|Placebo Comparator|Arm IV|Patients receive two oral placebos once daily for 4-5 weeks.
3264484|NCT00736632|Placebo Comparator|Placebo|Patients in the control group will receive placebo pills (instead of vitamin D) and calcium carbonate 500 mg twice daily.
3264485|NCT00736632|Active Comparator|Vitamin D|Patients in the vitamin D group will receive cholecalciferol 4000 units daily and calcium carbonate 500 mg twice daily.
3264486|NCT00736619|Experimental|1|"Cetuximab loading dose, 400 mg/m2 intravenously (IV) IMRT, 1 fraction/day, up to total of approximately 70 Gy, over approximately 33 treatment days~Cetuximab 250 mg/m2 weekly IV X 7 weeks~Albumin-bound paclitaxel (Abraxane®) weekly IV X 7 weeks, according to dose escalation scheme"
3264487|NCT00736606|Experimental|Period 1|simvastatin
3264488|NCT00736606|Experimental|Period 2|simvastatin + AZD9056
3264489|NCT00736593|Experimental|1|
3264490|NCT00736580|Active Comparator|Blunt Needles|Cesarean Delivery Performed with Blunt-tipped surgical Needles
3264491|NCT00736580|Placebo Comparator|Sharp Needles|Cesarean delivery performed with sharp surgical needles.
3264492|NCT00736541|Experimental|2|
3264493|NCT00736528|Experimental|PF-04447943 05 mg dose|
3264494|NCT00736528|Experimental|PF-04447943 15 mg dose|
3264495|NCT00736528|Experimental|PF-04447943 45 mg dose|
3264496|NCT00736528|Placebo Comparator|Placebo|
3264497|NCT00736515|Experimental|Combination therapy|The subjects allocated into this arm will receive the combination therapy of oral administration of 60~120mg Gliclazide MR (Diamicron MR) and subcutaneous injection of basal insulin (Insulin Glargine Injection, Lantus) once daily for 3 months
3264498|NCT00736515|Active Comparator|monotherapy|The patients allocated into this arm will receive the monotherapy of subcutaneous injection of premixed insulin (Biosynthetic Human Insulin Injection, Novolin 30R) twice daily for 3 months.
3264499|NCT00736502||Patients HIV-1 positive|
3264500|NCT00736489|Experimental|crossover dose 1|AZD3199 120 microgram
3264501|NCT00736489|Experimental|crossover dose 2|AZD3199 480 microgram
3264502|NCT00736489|Experimental|crossover dose 3|AZD3199 1920 microgram
3264503|NCT00736489|Placebo Comparator|crossover dose 4|Placebo
3264504|NCT00736489|Active Comparator|crossover dose 5|Formoterol 9 microgram
3264505|NCT00736489|Active Comparator|crossover dose 6|Formoterol 36 microgram
3264506|NCT00736476|Experimental|1|
3264507|NCT00736476|Placebo Comparator|2|
3264508|NCT00736463|Active Comparator|1|Aimvastatin 80 mg
3264509|NCT00736463|Active Comparator|2|Atorvastatin 80 mg
3264510|NCT00736450|Experimental|Arm I|See Detailed Description
3264511|NCT00736437|Experimental|1|ME-609
3264512|NCT00736437|Placebo Comparator|2|Vehicle
3264513|NCT00736424||1|Have received bilateral AN stimulation of the anterior nucleus (AN) of the thalamus for epilepsy or are receiving it at the time of enrollment
3264514|NCT00736411|Active Comparator|1|IVF
3264515|NCT00736411|Other|II|treatment
3264516|NCT00736398||Observation|Spinal fusion
3264517|NCT00736385|Active Comparator|Metformin|Metformin XR (extended-release) 2000 mg daily
3264518|NCT00736385|Placebo Comparator|Placebo|Placebo capsule
3264519|NCT00736372|Experimental|Investigational Drug|Dose Escalation
3264520|NCT00736346|Active Comparator|1|
3264521|NCT00736346|Active Comparator|2|
3264522|NCT00736346|Active Comparator|3|
3264523|NCT00736346|No Intervention|4|
3264524|NCT00736333||Pegylated Liposomal Doxorubicin|Subjects with metastatic breast cancer
3264525|NCT00736320|Active Comparator|A|2 cycles ABVD followed by 20 Gy IF-RT irrespective of FDG-PET results after chemotherapy
3264526|NCT00736320|Experimental|B|2 cycles ABVD followed by 20 Gy IF-RT if FDG-PET is positive after chemotherapy; 2 cycles ABVD and treatment stop if FDG-PET is negative after chemotherapy
3264527|NCT00736307|Experimental|1|Cultured limbal stem cells Transplantation
3264528|NCT00736294|Experimental|Ramipril|Inhibition Conversion Enzyme
3264529|NCT00736294|Placebo Comparator|Placebo|Placebo
3264530|NCT00736281|No Intervention|Placebo Food Drops|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
3264531|NCT00736281|Active Comparator|Food Drops|Group 2 (intervention group) will receive sublingual immunotherapy (escalation followed by maintenance) with vials containing glycerin and the previously diagnosed food allergens (peptides).
3264532|NCT00736268|Experimental|CST|Telephone-based Enhanced Coping Skills Training (CST)
3264533|NCT00736268|Other|UMC|Usual Medical Care and COPD education and symptom monitoring (UMC)
3264534|NCT00736255|Active Comparator|1|• The first group will receive LDX/SPD489 titrated up to 70 mg qd for 4 weeks after the identified quit date. Subjects will continue to receive NRT 21 mg at week 1 post quit date, then 14mg at week 2 post quit date and 7 at weeks 3 and 4 post quit date.
3264535|NCT00736255|Placebo Comparator|2|The second group will receive matching placebo and NRT after the quit date.
3264536|NCT00736242||PEG-IFN alfa-2b + RBV|Participants received a combination of PEG-IFN alfa-2b plus RBV according to routine clinical practice and locally-approved product recommendations for a minimum of 12 weeks. No investigational medicinal product was provided by the sponsor.
3264537|NCT00736229|Experimental|Exenatide|0.05 µg/min liquid bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
3264538|NCT00736203||A|non-smokers
3264539|NCT00736190|Experimental|TDF|300-mg tablet (marketed formulation) taken orally once daily
3264540|NCT00736177|Active Comparator|Control|Patients in the control group will undergo conventional IVF cycles with fresh blastocyst transfer.
3264541|NCT00736177|Experimental|Test group|Patients in the Test group will have their embryos cryopreserved for transfer in a second cycle.
3264542|NCT00736164|Experimental|Arm I|Patients receive oral selenomethionine once daily for 8-9 weeks.
3264543|NCT00736164|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 8-9 weeks.
3264544|NCT00736151|Experimental|1|Ralfinamide administered orally at rising doses of 80 - 320 mg/day
3264545|NCT00736151|Active Comparator|2|Placebo controlled with randomization of 2:1
3264546|NCT00736138|Active Comparator|1|training and pellots
3264547|NCT00736138|No Intervention|2|control
3264548|NCT00736125|Active Comparator|1|
3264549|NCT00736125|Active Comparator|2|
3264550|NCT00736112|Experimental|BMT and food allergy|trial subjects will receive food allergy testing and management in conjunction with BMT (Bilateral Myringotomy with Tympanostomy Tubes). Food allergy management involves parental education on how to avoid the specific offending foods.
3264551|NCT00736112|Experimental|BMT and adenoidectomy|"involves BMT (Bilateral Myringotomy with Tympanostomy Tubes), adenoidectomy, and food allergy testing and management.~Food allergy management involves parental education on how to avoid the specific offending foods."
3264552|NCT00736112|Active Comparator|BMT alone|The standard protocol for children presenting with initial Chronic OME is to perform a BMT (Bilateral Myringotomy with Tympanostomy Tubes).
3264553|NCT00736099|Experimental|linagliptin 5 mg|open label
3264554|NCT00736099|Experimental|linagliptin 5 mg and pioglitazone 30 mg|open label
3264555|NCT00736086||1|Subjects who are ambulated early post-percutaneous, cardiac or peripheral vascular, diagnostic catheterization procedures with the use of StarClose® Vascular Closure System in the femoral artery after diagnostic catheterization procedure.
3264556|NCT00736073|Active Comparator|1|aprepitant
3264557|NCT00736073|Placebo Comparator|2|Placebo
3264558|NCT00736060||1|Sickle cell anemia
3264559|NCT00736060||2|Sickle cell thalassemia
3264560|NCT00736047|Active Comparator|1|
3264561|NCT00736047|Placebo Comparator|2|
3264562|NCT00736021|Experimental|A|Single arm (open label study): Provide twelve weeks of treatment with high does (40 mg daily) of escitalopram to trauma survivors with chronic PTSD.
3264563|NCT00736008||A|Patients with thromboembolic events
3264564|NCT00735995|Experimental|A|Individual CBT
3264565|NCT00735995|Experimental|B|Group CBT
3264566|NCT00735995|No Intervention|C|Waiting-list control
3264567|NCT00735930|Experimental|Treatment (alvocidib, lenalidomide)|Patients receive alvocidib IV over 4.5 hours on days 1, 8, and 15 in course 1 followed by a week of rest. Beginning in course 2 and all subsequent courses, patients receive lenalidomide PO QD on days 1-21 and alvocidib IV over 4.5 hours on days 3, 10, and 17. Treatment repeats every 35 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3264568|NCT00735917|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO QD on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3264569|NCT00735904|Experimental|AG-013736/Cisplatin/Gemcitabine|
3264570|NCT00735865|Active Comparator|1|
3264571|NCT00735865|Active Comparator|2|
3264572|NCT00735865|Active Comparator|3|
3264573|NCT00735865|Active Comparator|4|
3264574|NCT00735839|Experimental|V710|V710 vaccination (60 mcg) single dose on Day 1
3264575|NCT00735839|Placebo Comparator|Placebo|Placebo single dose on Day 1
3264576|NCT00735813|Experimental|A|Tunneled central venous catheters locked with Taurolock
3264577|NCT00735813|Active Comparator|B|Tunneled central venous catheter locked with heparin
3264578|NCT00735800|Active Comparator|Supportive Counseling|
3264579|NCT00735800|Experimental|Problem-Solving|
3264580|NCT00735787|Placebo Comparator|Placebo/Adalimumab|"Loading dose of 2 placebo injections at Week 0 and placebo injections every other week (eow) from Week 1 through Week 15.~In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27."
3264581|NCT00735787|Active Comparator|Adalimumab|80 mg adalimumab loading dose at Week 0 and 40 mg adalimumab eow from Weeks 1 through 15. For subjects who continued in the second period of the study, subjects received 2 placebo injections at Week 16 to maintain the blind. Open-label 40 mg adalimumab eow was administered from Week 17 through Week 27.
3264582|NCT00735774|Experimental|11C-ORM-13070|
3264583|NCT00735761|Experimental|1|ME-609 (5% acyclovir and 1% hydrocortisone)
3264584|NCT00735761|Active Comparator|2|Acyclovir in ME-609 vehicle (5% acyclovir)
3264585|NCT00735748|Experimental|1|Tramadol per os (Tradonal Odis® orodispersible tablets)
3264586|NCT00735748|Active Comparator|2|Tramadol IV (Tradonal® IV)
3264587|NCT00735722|Active Comparator|Concomitant HIFU ablation|HIFU AF Ablation
3264588|NCT00735722|No Intervention|Best medical treatment|Best medical treatment
3264589|NCT00735709|Experimental|Vortioxetine 1 mg|Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks.
3264590|NCT00735709|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks.
3264591|NCT00735709|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up 8 weeks.
3264592|NCT00735709|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
3264593|NCT00735696|Experimental|ramucirumab + paclitaxel + carboplatin|"Participants will receive ramucirumab in combination with paclitaxel and carboplatin until disease progression, the development of an unacceptable toxicity, or other withdrawal criteria, for up to six cycles (3 weeks per cycle).~In the absence of any withdrawal criteria, participants will continue to receive ramucirumab monotherapy every 3 weeks, provided there is ongoing evidence of benefit upon review every 6 weeks."
3264594|NCT00735683|Placebo Comparator|1|
3264595|NCT00735683|Experimental|2|
3264596|NCT00735683|Experimental|3|
3264597|NCT00735683|Experimental|4|
3264598|NCT00735683|Experimental|5|
3264599|NCT00735683|Experimental|6|
3264600|NCT00735670|Experimental|Venlafaxine|Venlafaxine HCl is classified as a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) and has been approved by the FDA for the treatment of major depressive disorder. The treatment group will receive a sub-therapeutic dose over a two week period, with a two week titration, starting at 37.5 mg up to a maximum dose of 150 mg per day. At the end of the treatment period, dosage was tapered down in a step-wise fashion over a period of three weeks; 75 mg. for two weeks and 37.5 mg. for one week. While this was the standard protocol, study drug tapering was individualized based on side effects and the clinical judgment of the prescriber.
3264601|NCT00735670|Placebo Comparator|Placebo|Placebo capsules were compounded by filling a matching gelatin capsule with lactose. Titration up and down followed the same schedule as the treatment group.
3264602|NCT00735657|Active Comparator|Group 1|Control
3264603|NCT00735657|Active Comparator|Group 2|Block with short needle
3264604|NCT00735644|Experimental|JE-CV GPO MBP (Lot 1)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 1.
3264605|NCT00735644|Experimental|JE-CV GPO MBP (Lot 2)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 2.
3264606|NCT00735644|Experimental|JE-CV GPO MBP (Lot 3)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 3.
3264607|NCT00735644|Active Comparator|JE-CV WRAIR (Group 4)|Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)
3264608|NCT00735644|Sham Comparator|Hepatitis A (Group 5)|Participants 12 to 18 months of age randomized to receive Hepatitis A vaccine
3264609|NCT00735631|Experimental|1|The single-input-single-output (SISO) model-based predictive closed-loop system will be used to guide patient-individualized ICU sedation with propofol
3264610|NCT00735618|Experimental|Guided Relaxation|Heart rate variability (HRV) high frequency (HF) spectral analysis, before and after a 15 minute, one-time, guided relaxation program
3264611|NCT00735605|Active Comparator|1:BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
3264612|NCT00735605|Active Comparator|2 BTX A|Injected with BTX-A in the left lateral position; anesthesia was not required
3264613|NCT00735605|Active Comparator|3: PDPR|Inner half of puborectalis sling was divided on each side by using a scalpel NO
3264614|NCT00735592||A|Children discharged with the recommendation of performing a follow up X rays after lobar pneumonia
3264615|NCT00735579||Study group|Patients undergoing major abdominal surgery
3264616|NCT00735553|Active Comparator|25 mg Proellex|25 mg oral daily dose of Proellex
3264617|NCT00735553|Active Comparator|50 mg Proellex|50 mg oral daily dose of Proellex
3264618|NCT00735553|Placebo Comparator|placebo|oral daily dose of placebo
3264619|NCT00735540||A|Acute organic diseases
3264620|NCT00735540||B|Patients with chronic diseases
3264621|NCT00735540||C|Patients with psychiatric diagnosis
3264622|NCT00735527|Experimental|1|Intra-nasal lorazepam 0.1 mg/kg (max 4 mg)
3264623|NCT00735527|Active Comparator|2|Intra-venous lorazepam 0.1 mg/kg (max 4 mg)
3264624|NCT00735501||A|
3264625|NCT00735488||A|Thalassemia Minor carriers
3264626|NCT00735488||B|Sickle cell carriers
3264627|NCT00735475|Experimental|Afluria®|
3264628|NCT00735475|Active Comparator|Fluzone®|
3264629|NCT00735462|Experimental|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks
3264630|NCT00735462|Experimental|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
3264631|NCT00735462|Placebo Comparator|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks.
3264632|NCT00735449|Active Comparator|Combigan ®|Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%) adjunctive to Xalatan® (latanoprost 0.005%)
3264633|NCT00735449|Active Comparator|Timolol Maleate 0.5%|Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)
3264634|NCT00735436|Other|Gliadel/Avastin/CPT-11|Gliadel/Avastin/CPT-11
3264635|NCT00735423||No groups|IDE used for outcome measurement not intervention
3264636|NCT00735410|Experimental|1|
3264637|NCT00735397|Experimental|Perampanel|Participants previously receiving perampanel/placebo in the double blind-study, were titrated to receive perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years.
3264638|NCT00735384||Patients with critical illness myopathy|Patients with,e.g., sepsis, with secondary myopathy
3264639|NCT00735384||Patients with Primary Myopathies|Patients with primary myopathy, e.g., Duchenne Muscular Dystrophy, Myotonia
3264640|NCT00735371|Active Comparator|Lisdexamfetamine Dimesylate (LDX) 30 mg|
3264641|NCT00735371|Active Comparator|LDX 50 mg|
3264642|NCT00735371|Active Comparator|LDX 70 mg|
3264643|NCT00735371|Placebo Comparator|Placebo|
3264644|NCT00735358|Active Comparator|A|Single dose cyanoacrylate in one shot
3264645|NCT00735358|Experimental|B|Double doses cyanoacrylate in one shot
3264646|NCT00735345|Experimental|Treatment Arm|Chemo induction therapy followed by chemoradiotherapy and surgical resection or definitive radiotherapy
3264647|NCT00735332|Experimental|Single-Arm|
3264648|NCT00735319|No Intervention|A|In the 7 control Capital Health community health centers, babies will be followed up according to the current policy. Bilirubin determinations will be performed at the discretion of the visiting nurse if the infant is inappropriately jaundiced or at the request of the physician if risk factors are present. Transcutaneous Bilirubinometers will not be available in each of these 7 centers for all the duration of the study.
3264649|NCT00735319|Experimental|B|For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained.Depending on the level of bilirubin obtained and whether risk factors (gestational age < 38 weeks, blood group incompatibility with DAT positive) are present or not, a different management plan will apply. The algorithm is based on curves established by Bhutani et al to predict the risk of significant hyperbilirubinemia based on predischarge bilirubin measurements.
3264650|NCT00735306|Experimental|1|Avastin, Tarceva and Radiation Therapy
3264651|NCT00735293|Other|Treatment|There is only one arm to this study. All patients will receive treatment with the VASER for their axillary hyperhidrosis/bromidrosis
3264652|NCT00735280|Experimental|Reduced dose of unfractionated heparin|
3264653|NCT00735254|Active Comparator|Pulsed dye laser|PDL Patient will be have scar treated with pulsed dye laser.
3264654|NCT00735254|Active Comparator|Affirm laser|Patient will be have scar treated with Affirm Laser
3264655|NCT00735254|Active Comparator|combined PDL and Affirm Lasers|Patient will be have scar treated with combined Affirm + PDL
3264656|NCT00735254|Placebo Comparator|Placebo|Patient will be have scar treated with Placebo
3264657|NCT00735228|Active Comparator|1|Perioperative blood glucose was controlled within the normal levels (80-110 mg/dL) by artificial pancreas.
3264658|NCT00735228|Active Comparator|2|Perioperative blood glucose concentration was controlled within the range from 140 to 160 mg/dL by artificial pancreas.
3264659|NCT00735189|Experimental|1|Patient continues to receive anticoagulation care from the Anticoagulation Management Service
3264660|NCT00735189|Active Comparator|2|Patient receives anticoagulation care from their usual primary care physician
3264661|NCT00735176|Experimental|Artificial Cervical Disc|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
3264662|NCT00735176|Active Comparator|ACDF|Anterior cervical discectomy and fusion (ACDF)
3264663|NCT00735163|Experimental|A|improved model predictive control algorithm (eMPC) for glycaemic control in ICU patients
3264664|NCT00735150||1|25 female and 5 male BRCA carriers
3264665|NCT00735137|No Intervention|A|Expectant management in twin pregnancy
3264666|NCT00735137|Experimental|B|Vaginal pessary treatment in twin pregnancy
3264667|NCT00735137|No Intervention|C|Expectant management in singleton pregnancy with short cervix
3264668|NCT00735137|Experimental|D|Vaginal pessary treatment in singleton pregnancy with short cervix
3264669|NCT00735124|Active Comparator|Single pre-op dose of Gabapentine|Active treatment with the study drug
3264670|NCT00735124|Placebo Comparator|Placebo|Placebo arm for blinding the medication
3264671|NCT00735111|Experimental|Karnofsky Performance Status Score|
3264672|NCT00735098|Experimental|1|KBA exercise protocol
3264673|NCT00735098|Experimental|2|strength training exercise protocol
3264674|NCT00735098|Experimental|3|KBA and strength training protocol
3264675|NCT00735098|Sham Comparator|4|
3264676|NCT00735085|Experimental|SLV334|
3264677|NCT00735085|Placebo Comparator|Placebo|
3264678|NCT00735072|Experimental|Maraviroc|Maraviroc (dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).
3264679|NCT00735072|Placebo Comparator|Placebo|Placebo (dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).
3264680|NCT00735059|Experimental|1|treatment with dialyzer ELISIO 170H
3264681|NCT00735059|Active Comparator|2|treatment with dialyzer PES-170DS
3264682|NCT00735046||1|Intervention
3264683|NCT00735046||2|control
3264684|NCT00735020|Experimental|1|
3264685|NCT00735020|Active Comparator|2|
3264686|NCT00735007|Experimental|1|
3264687|NCT00734994|Experimental|Hyperthermia system, Mitomycin C|Pilot study single arm study to test the safety, tolerability and clinical benefit of regional hyperthermia and mitomycin-C intravesical chemotherapy to treat non-invasive Transitional Cell carcinoma (TCC) of the bladder that has recurred after standard resection and adjuvant therapy.
3264688|NCT00734968|Experimental|Treatment|Patients randomly assigned to be treated with nitrofurantoin 100mg PO BID x 3 days post-operatively
3264689|NCT00734968|Placebo Comparator|Placebo|Arm randomly assigned to receive placebo 1 tablet PO BID x 3 days post-operatively.The incidence of UTI in this group will be compared with group one (1)
3264690|NCT00734955|Experimental|Reduction Mammoplasty|Patients undergoing reduction mammoplasty
3264691|NCT00734955|Experimental|Mastectomy|Patients undergoing mastectomy
3264692|NCT00734955|Experimental|Lumpectomy|Patients undergoing a lumpectomy
3264693|NCT00734942|Experimental|1|intervention group
3264694|NCT00734942|No Intervention|2|waiting group
3264695|NCT00734929|Experimental|1|Aprepitant 40 mg preoperatively + dexamethasone 10 mg after induction of anesthesia
3264696|NCT00734929|Active Comparator|2|Ondansetron 4 mg within 30 min of the end of surgery + Dexamethasone 10 mg after induction of anesthesia
3264697|NCT00734916|Active Comparator|1|Omegaven 10%
3264698|NCT00734916|Active Comparator|2|Intralipid 10%
3264699|NCT00734916|Placebo Comparator|3|Placebo
3264700|NCT00734903|Experimental|Arm 1|Female participants randomly assigned to receive the experimental treatment model -- A Woman's Path to Recovery (WPR)
3264701|NCT00734903|Active Comparator|Arm 2|Female participants randomly assigned to receive the active behavioral treatment control -- Twelve-Step Facilitation (TSF)
3264702|NCT00734877|Active Comparator|ARM A|The standard TT3 Regimen (S-TT3) will consist of 2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
3264703|NCT00734877|Experimental|ARM B|The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD- PACE
3264704|NCT00734864|Other|1|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs).
3264705|NCT00734864|Other|2|Subjects NOT taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs).
3264706|NCT00734851|Experimental|Multimodality|4 cycles of 70 mg/m2 Docetaxel + 37.5 mg daily Sunitinib for 14 days followed by a 7 day break for 3 cycles + external beam radiotherapy to 66 Gray over 6-7 weeks
3264707|NCT00734838|Experimental|Core needle biopsy|Patients needing a needle biopsy of a breast mass
3264708|NCT00734838|Placebo Comparator|Reduction mammoplasty|Any patients scheduled for a reduction mammoplasty who would like to participate in a study to better understand breast cancer
3264709|NCT00734825|Active Comparator|1|IV contrast
3264710|NCT00734825|Active Comparator|2|IV contrast and oral contrast
3264711|NCT00734812|Active Comparator|1|Laparoscopic supracervical hysterectomy (LSH)
3264712|NCT00734812|Active Comparator|2|Total Laparoscopic Hysterectomy (TLH)
3264713|NCT00734799|No Intervention|2|Usual Care/Wait-List Control
3264714|NCT00734799|Experimental|1|Sleep Intervention for PTSD (SIP)
3264715|NCT00734786|Placebo Comparator|2|Volunteers will be their own control by randomly receiving the active on one face side and the placebo on the opposite one.
3264716|NCT00734760|Experimental|A|a tailored, face-to-face education and counseling intervention with a nurse lasting approximately 45 minutes, followed by a telephonic reinforcement in 30 days
3264717|NCT00734760|No Intervention|B|care-as-usual with data collection at the same time points as the experimental group
3264718|NCT00734747|Experimental|Medigus SRS Endoscopic Stapling System|Endoluminal fundoplication for the treatment of GERD
3264719|NCT00734734|Experimental|1|
3264720|NCT00734721|Active Comparator|A|Presentation of factual information video
3264721|NCT00734721|Active Comparator|B|Presentation of injection syringe/needle
3264722|NCT00734721|Active Comparator|C|Presentation of emotional information video
3264723|NCT00734721|Active Comparator|D|Stress relaxation music
3264724|NCT00734708|Experimental|A|positive drug (0.3% Trafermin contained)
3264725|NCT00734708|Placebo Comparator|P|control
3264726|NCT00734695|Experimental|1|Baruch Pade Medical Center
3264727|NCT00734695|Active Comparator|2|Rambam Medical Center
3264728|NCT00734695|Active Comparator|3|Soroka Medical Center
3264729|NCT00734682|Experimental|Nanoliposomal CPT-11|All patients are treated with nanoliposomal CPT-11
3264730|NCT00734669||1|Type 2 diabetic patients on glibenclamide at individual dosage up to 7 mg/day for more than one year prone to hypoglycemic events
3264731|NCT00734656|Placebo Comparator|Placebo medication + placebo alcohol|
3264732|NCT00734656|Experimental|Placebo Medication + 0.8 gr/kg Ethanol|
3264733|NCT00734656|Experimental|4 mg Dutasteride + Placebo Alcohol|
3264734|NCT00734656|Experimental|4 mg Dutasteride + 0.8 gr/kg Ethanol|
3264735|NCT00734630|Active Comparator|Nebivolol|Nebivolol 5 mg, 5 mg nontrade tablets, oral administration Nebivolol 10 mg, 10 mg nontrade tablets, oral administration Nebivolol 20 mg, 20 mg nontrade tablets, oral administration Nebivolol 40 mg (two 20 mg nontrade tablets), oral administration
3264736|NCT00734630|Placebo Comparator|Placebo|Matching placebo tablets, oral administration
3264737|NCT00734617|Experimental|Less Dependent Smokers|
3264738|NCT00734617|Experimental|More Dependent Smokers|
3264739|NCT00734604|Experimental|T(OaD)/S(PRN)/T(PRN)|Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks
3264740|NCT00734604|Experimental|T(OaD)/T(PRN)/S(PRN)|Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks
3264741|NCT00734604|Experimental|S(PRN)/T(OaD)/T(PRN)|Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks
3264742|NCT00734604|Experimental|S(PRN)/T(PRN)/T(OaD)|Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks
3264743|NCT00734604|Experimental|T(PRN)/T(OaD)/S(PRN)|Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks
3264744|NCT00734604|Experimental|T(PRN)/S(PRN)/T(OaD)|Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks
3264745|NCT00734591||Previously treated with Exubera|
3264746|NCT00734591||Previously treated with comparator|Subjects who had been treated with a comparator (other diabetes treatment such as injected insulin) in a prior Exubera controlled trial.
3264747|NCT00734578|Experimental|SPD503-AM|SPD503 (Guanfacine Extended Release)
3264748|NCT00734578|Experimental|SPD503-PM|SPD503 (Guanfacine Extended Release)
3264749|NCT00734578|Placebo Comparator|Placebo|
3264750|NCT00734565|Experimental|1|
3264751|NCT00734552|Active Comparator|1|α-Keto Acid plus low protein diet
3264752|NCT00734552|Other|2|Normal protein diet
3264753|NCT00734539|Experimental|1|fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
3264754|NCT00734539|Placebo Comparator|2|Placebo IV or PO twice weekly for 6 weeks
3264755|NCT00734526|Experimental|Dose Level 1|"Temozolomide + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle~Temozolomide 75mg/m^2 daily during radiation therapy, and 150mg/m^2 in the first cycle of adjuvant therapy. Dose Level 1 will receive sorafenib in the adjuvant phase (following radiation therapy) at the dose of 400mg BID in combination with standard dose temozolomide 150-200 mg/m^2 two days out of 28 day cycle. Radiotherapy 2.0 Grey (Gy)/day given daily 5 days per week for total of 60.0 Gy over 6 weeks."
3264756|NCT00734526|Experimental|2|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle + Higher Dose Sorafenib
3264757|NCT00734526|Experimental|3|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Lower Dose Sorafenib
3264758|NCT00734526|Experimental|4|Temozolomide + Higher Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Higher Dose Sorafenib
3264759|NCT00734513|Experimental|1|Partner-assisted Emotional Disclosure
3264760|NCT00734513|Active Comparator|2|Cancer Education
3264761|NCT00734500|Experimental|Treatment|Treatment
3264762|NCT00734487||1. AREDS2 subjects|Subjects enrolled in the AREDS2 clinical trial with a diagnosis of age-related macular degeneration.
3264763|NCT00734487||2. Controls|Age-matched subjects without retinal pathology
3264764|NCT00734474|Experimental|3.0 mg LY2189265|"LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
3264765|NCT00734474|Experimental|2.0 mg LY2189265|"LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
3264766|NCT00734474|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
3264767|NCT00734474|Experimental|1.0 mg LY2189265|"LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
3264768|NCT00734474|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
3264769|NCT00734474|Experimental|0.5 mg LY2189265|"LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
3264770|NCT00734474|Experimental|0.25 mg LY2189265|"LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
3264822|NCT00734240|Experimental|H|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
3264823|NCT00734240|Experimental|I|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
3264771|NCT00734474|Active Comparator|Sitagliptin|"Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks~Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks"
3264772|NCT00734474|Placebo Comparator|Placebo/Sitagliptin (Baseline Through 104 Weeks)|"Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks~Placebo: tablet, administered orally, once daily for 26 weeks~Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks"
3264773|NCT00734461|Placebo Comparator|Placebo|Placebo, single dose
3264774|NCT00734461|Active Comparator|Oxycodone 20 mg|Oxycodone 20 mg single dose tablet
3264775|NCT00734461|Active Comparator|Oxycodone 40 mg|Oxycodone 40 mg single dose tablet
3264776|NCT00734461|Experimental|PTI-801 20/.001 mg|Oxycodone 20 mg / Naltrexone 0.001 mg
3264777|NCT00734461|Experimental|PTI-801 40/.001 mg|Oxycodone 40 mg / Naltrexone 0.001 mg
3264778|NCT00734461|Experimental|PTI-801 20/.0001 mg|Oxycodone 40 mg / Naltrexone 0.0001 mg
3264779|NCT00734461|Experimental|PTI-801 40/.0001 mg|Oxycodone 40 mg / Naltrexone 0.0001 mg
3264780|NCT00734448|Experimental|A,1|Gestational diabetes patients who take myo-inositol
3264781|NCT00734435|Active Comparator|1|Zonisamide SR 360 mg and olanzapine 10-20 mg daily
3264782|NCT00734435|Placebo Comparator|2|Placebo and olanzapine 10-20 mg daily
3264783|NCT00734422|Experimental|VRET with yohimbine|Virtual Reality Exposure Therapy will be combined with the administration of yohimbine hydrochloride
3264784|NCT00734422|Placebo Comparator|VRET with placebo|Virtual Reality Exposure Therapy will be combined with an inactive placebo pill (Albochin).
3264785|NCT00734409|Experimental|RASS plus (BIS)|Participants in this arm will receive sedation assessment with the RASS scale augmented with Bispectral Index (BIS) Monitor
3264786|NCT00734409|No Intervention|RASS only|Participants will receive sedation assessment only using the RASS scale which is the standard of care at our institution
3264787|NCT00734383|Experimental|1|Propofol Cardioprotection
3264788|NCT00734383|Experimental|2|Volatile Anesthesia Preconditioning
3264789|NCT00734370|Experimental|VRET|Virtual Reality Exposure Therapy for agoraphobic participants
3264790|NCT00734370|Active Comparator|Exposure in vivo|Standard exposure in vivo for panic disorder
3264791|NCT00734370|No Intervention|Wait-list control|Wait-list control group. Participants from this arm are randomized to the two active conditions after 10 weeks of waiting.
3264792|NCT00734357|Experimental|Isovue Arm|Subjects with a clinically scheduled CT examination will be given the contrast Isovue. The investigators of this study will determine which contrast medication subjects will receive using randomization.
3264793|NCT00734357|Experimental|Omnipaque Arm|Subjects with a clinically scheduled CT examination will be given the contrast Omnipaque. The investigators of this study will determine which contrast medication subjects will receive using randomization
3264794|NCT00734344|Active Comparator|Arm 1|Raltegravir plus Truvada
3264795|NCT00734344|Active Comparator|Arm 2|Efavirenz plus Truvada
3264796|NCT00734331||IBD|Inflammatory bowel disease patients
3264797|NCT00734331||Control|Average risk patients undergoing screening colonoscopy
3264798|NCT00734318|Experimental|Flutiform 250/10 micrograms|Flutiform 250/10 micrograms (2 puffs bd)
3264799|NCT00734318|Experimental|Flutiform 50/5 micrograms|Flutiform 50/5 micrograms (2 puffs bd)
3264800|NCT00734318|Active Comparator|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|Flixotide pMDI 250 mcg (2 puffs bd) + foradil pMDI 24 50/5 mcg (bd)
3264801|NCT00734318|Active Comparator|Flixotide pMDI 250 micrograms|Flixatide pMDI 250 micrograms (2 puffs bd)
3264802|NCT00734305|Experimental|Dose Escalation|Cohorts of escalating doses of MM-121 administered IV QW to determine MTD or RP2D + expansion cohort at MTD/RP2D
3264803|NCT00734292|Placebo Comparator|I|"Period 1 Treatment Regimen A: FlutiForm 250/10 ug~Period 2 Treatment Regimen B: FlutiForm 100/10 ug~Period 3 Treatment Regimen C: placebo"
3264804|NCT00734292|Placebo Comparator|II|"Period 1 Treatment Regimen B: FlutiForm 100/10 ug~Period 2 Treatment Regimen C: placebo~Period 3 Treatment Regimen A: FlutiForm 250/10 ug"
3264805|NCT00734292|Placebo Comparator|III|"Period 1 Treatment Regimen C: placebo~Period 2 Treatment Regimen A: FlutiForm 250/10 ug~Period 3 Treatment Regimen B: FlutiForm 100/10 ug"
3264806|NCT00734279|Experimental|1|Girls with Early Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
3264807|NCT00734279|Experimental|2|Girls with Delayed Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
3264808|NCT00734279|Experimental|3|Boys with Early Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
3264809|NCT00734279|Experimental|4|Boys with Delayed Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
3264810|NCT00734266||1 Control|Patients with and without chronic obstructive pulmonary disease diagnosed before scheduling for cardiac surgery.
3264811|NCT00734266||2 COPD|Patients with and without chronic obstructive pulmonary disease diagnosed before scheduling for cardiac surgery.
3264812|NCT00734253|Experimental|1|Pyridorin 150 mg bid
3264813|NCT00734253|Experimental|2|Pyridorin 300 mg bid
3264814|NCT00734253|Placebo Comparator|3|Placebo bid
3264815|NCT00734240|Experimental|A|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 355312 or placebo
3264816|NCT00734240|Experimental|B|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
3264817|NCT00734240|Experimental|C|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
3264818|NCT00734240|Experimental|AA|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving 353512 or placebo
3264819|NCT00734240|Experimental|BB|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
3264820|NCT00734240|Experimental|CC|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
3264821|NCT00734240|Experimental|G|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
3264824|NCT00734240|Experimental|GG|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
3264825|NCT00734240|Experimental|HH|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
3264826|NCT00734240|Experimental|II|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
3264827|NCT00734240|Experimental|F (100 mg)|single-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
3264828|NCT00734240|Experimental|Dose-Titration 1|multiple-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
3264829|NCT00734240|Experimental|F (200 mg)|single-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
3264830|NCT00734240|Experimental|Dose-Titration 7|multiple-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
3264831|NCT00734227|Active Comparator|A|"Randomization: By the blind card method to TIPS or emergency portacaval shunt. Diagnostic Workup: Completed within 6hr. Rapidity of Therapy: Within 24 hr. Failure of Therapy: Bleeding requiring >6u PRBC in first 7 days, or 8 units PRBC during 12 months.~Rescue Crossover Therapy: When primary therapy has failed. Followup: Lifelong data collection on line, analysis by biostatistician Florin Vaida, PhD. External Advisory, Data Monitoring and Safety Committee by 3 senior academicians.~Procedure: Emergency portacaval shunt."
3264832|NCT00734227|Active Comparator|B|Procedure: Emergency TIPS.
3264833|NCT00734214|Experimental|0.9% NaCl|
3264834|NCT00734214|Active Comparator|0.45% NaCl|
3264835|NCT00734201|Experimental|1|Randomised to a parallel group comparison of either one of four doses of study drug (1mg, 2mg, 5mg, 25mg) or placebo. Dosed once daily for 28 days
3264836|NCT00734175|Experimental|1|Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
3264837|NCT00734162|Experimental|Tenofovir disoproxil fumarate (TDF)|
3264838|NCT00734162|Placebo Comparator|Placebo|
3264839|NCT00734149|Experimental|Bortezomib+Melphalan+Prednisone|Bortezomib 1.3 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 4, 8, and 11 of a 28 day cycle. Six cycles are planned. On days when both melphalan and bortezomib are given, melphalan is given at least one hour prior to bortezomib. Melphalan 6 mg/m2 is administered orally on an empty stomach daily on days 1-7 of each cycle. Prednisone 60 mg/m2 is administered orally daily on days 1-7 of each cycle.
3264840|NCT00734136|Other|1|50 surgical subjects undergoing either liver transplantation or hepatic resection
3264841|NCT00734136|Other|2|50 Subjects with Liver disease who are are not surgical candidates
3264842|NCT00734123|Experimental|1|Participants assigned to the intensive arm (1) will be targeted to specified therapeutic aims (concerning lipids, blood pressure and antiplatelets)according to the results of carotid ultrasound and ankle-brachial index.
3264843|NCT00734123|Active Comparator|2|Participants assigned to control group (2) will be followed according to the clinical standard of care.
3264844|NCT00734110|Experimental|P.F.C. Sigma Total Knee Replacement System|Primary total knee arthroplasty using the fixed bearing P.F.C. Sigma Total Knee Replacement System.
3264845|NCT00734097|Experimental|Nexium 40 mgs|
3264846|NCT00734084|Other|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
3264847|NCT00734071|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
3264848|NCT00734071|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
3264849|NCT00734058|Experimental|Persistent AF|Treatment arm to be compared with historical control.
3264850|NCT00734045||1|Subjects with diagnosed congestive heart failure
3264851|NCT00734045||2|Subjects not diagnosed with congestive heart failure
3264852|NCT00734032|Placebo Comparator|Placebo Group|Matched Placebo
3264853|NCT00734032|Experimental|SB480848 40mg Group|SB480848 40mg/day
3264854|NCT00734032|Experimental|SB480848 80mg Group|SB480848 80mg/day
3264855|NCT00734032|Experimental|SB480848 160mg Group|SB480848 160mg/day
3264856|NCT00734019|Other|P.F.C. Sigma Knee System|Orthopaedic implant for primary total knee replacement with a cobalt-chrome tibial tray and a moderately cross-linked polyethylene tibial insert
3264857|NCT00733993|Experimental|1 Caffeine 150 mg|Caffeine 150 mg
3264858|NCT00733993|Placebo Comparator|2 Placebo|Placebo
3264859|NCT00733993|Experimental|3 Amphetamine|Amphetamine
3264860|NCT00733993|Experimental|4 Caffeine 300 mg|Caffeine 300 mg
3264861|NCT00733980|Experimental|GSK561679 arm|Double blind GSK561679
3264862|NCT00733980|Placebo Comparator|placebo arm|Double blind placebo
3264863|NCT00733967|Placebo Comparator|Placebo|Matching oral placebo capsules as control.
3264864|NCT00733967|Active Comparator|Varenicline|See assigned interventions.
3264865|NCT00733954|Active Comparator|clobetasol propionate spray|clobetasol propionate spray 0.05%
3264866|NCT00733954|Active Comparator|clobetasol propionate ointment|clobetasol propionate ointment 0.05%
3264867|NCT00733941|Experimental|High frequency training|24 interval exercises performed 8 times per week
3264868|NCT00733941|Experimental|Normal frequency training|24 interval exercises performed 3 times per week
3264869|NCT00733928|Other|1 - All Polyethylene Tibia|Total knee replacement with an all polyethylene tibial tray
3264870|NCT00733928|Active Comparator|2 - Poly & Metal Tibia|Total knee replacement with a metal-backed tibial component
3264871|NCT00733915|Experimental|Single arm|Cohort of total knee replacements with LCS Complete knee implants
3264872|NCT00733902|Experimental|Tanezumab 10 mg|
3264873|NCT00733902|Experimental|Tanezumab 5 mg|
3264874|NCT00733902|Experimental|Tanezumab 2.5 mg|
3264875|NCT00733902|Placebo Comparator|Placebo|
3264876|NCT00733889|Experimental|1|
3264877|NCT00733876|Experimental|A|
3264878|NCT00733863|Experimental|1|
3264879|NCT00733863|Placebo Comparator|2|
3264880|NCT00733850|Experimental|1|Kanglaite Injection plus Gemcitabine
3264881|NCT00733850|Active Comparator|2|Gemcitabine
3264882|NCT00733837|Experimental|A|This is a repeated measures study. All participants experience the same conditions.
3264983|NCT00733083|Active Comparator|2|0,1 mg/kg of morphine
3264883|NCT00733824|Experimental|Cohort 1|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~160 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
3264884|NCT00733824|Experimental|Cohort 2|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~240 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
3264885|NCT00733824|Experimental|Cohort 3|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~320 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
3264886|NCT00733824|Experimental|Cohort 4|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~400 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
3264887|NCT00733824|Experimental|Phase II|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~MTD as determined in Phase I IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
3264888|NCT00733811|Experimental|1|Sequential treatment including DFP at 75 mg/kg, divided into three oral daily doses, for four days per week and DFO by subcutaneous infusions (8-12h) at 50 mg/kg/day for the remaining three days per week
3264889|NCT00733811|Active Comparator|2|Deferiprone alone at 75 mg/kg divided into three oral daily doses
3264890|NCT00733798|Experimental|1|
3264891|NCT00733785|Experimental|2mg tablet|2 mg tablet fasted
3264892|NCT00733785|Experimental|4 mg tablet|4 mg tablet fasted
3264893|NCT00733785|Experimental|8mg tablet|8 mg tablet fasted
3264894|NCT00733785|Experimental|2 x 4 mg tablets|2 x 4mg tablets fasting
3264895|NCT00733785|Experimental|2 x 2mg tablets|2 x 2mg tablets fasting
3264896|NCT00733785|Experimental|8 mg tablet fed|8 mg tablet fed
3264897|NCT00733785|Experimental|Repeat dose|8 mg once a day for 6 days
3264898|NCT00733772|Experimental|A|healthy lifestyle counseling + 30 grams/day supplement of Flaxseed
3264899|NCT00733772|Sham Comparator|B|TLC diet
3264900|NCT00733746|Experimental|Neoadjuvant therapy + Surgery + Adjuvant therapy|As part of neoadjuvant therapy, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 29, 36, and 43 and oral erlotinib hydrochloride once daily on days 1-43 in the absence of disease progression or unacceptable toxicity. Within 3-6 weeks after completion of neoadjuvant therapy, patients undergo pancreaticoduodenectomy and patients receive gemcitabine hydrochloride and erlotinib hydrochloride as in neoadjuvant therapy within 5-10 weeks post surgery.
3264901|NCT00733733|Active Comparator|ATG|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
3264902|NCT00733733|No Intervention|Control|Standard immunosuppressive treatment for renal transplantation including tacrolimus/MMF/prednisolone without ATG treatment.
3264903|NCT00733720|Active Comparator|1|Each subject will receive all 3 doses of suboxone and placebo
3264904|NCT00733707|Experimental|1|Text messaging reminders
3264905|NCT00733707|No Intervention|2|No text messaging reminder
3264906|NCT00733694|Other|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
3264907|NCT00733681|Experimental|PFC Sigma RP TC3 Revision Knee System|Revision knee surgery with the PFC Sigma RP TC3 Revision Knee System (mobile bearing).
3264908|NCT00733642|Experimental|PF-04360365 1 mg/kg|
3264909|NCT00733642|Experimental|PF-04360365 3 mg/kg|
3264910|NCT00733642|Experimental|PF-04360365 5 mg/kg|
3264911|NCT00733642|Experimental|PF-04360365 10 mg/kg|
3264912|NCT00733616|Experimental|1|
3264913|NCT00733603|Sham Comparator|1|Global Therapeutic Massage (GTM)
3264914|NCT00733603|Active Comparator|2|Myofascial Tissue Manipulation (MTM)
3264915|NCT00733577|Experimental|Cohort 1|15 mg SB756050 or placebo
3264916|NCT00733577|Experimental|Cohort 2|Planned dose for Cohorts 2 50mg SB756050 or placebo
3264917|NCT00733577|Experimental|Cohort 3|Planned dose for Cohort 3 150mg SB756050 or placebo
3264918|NCT00733577|Experimental|Cohort 4|Planned dose for Cohort 4 600mg SB756050 or placebo
3264919|NCT00733564|Active Comparator|1|Paracervical block will be performed
3264920|NCT00733564|Experimental|2|Propofol anesthesia will be performed
3264921|NCT00733564|Experimental|3|Sevoflurane anesthesia will be performed
3264922|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 1|Eligible subjects will receive repeat oral doses of GSK962040 given as 10 milligrams once daily tablet for 14 days.
3264923|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 2|Eligible subjects will receive repeat oral doses of GSK962040 given as 30 milligrams once daily tablet for 14 days.
3264924|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 3|Eligible subjects will receive repeat oral doses of GSK962040 given as 100 milligrams once daily tablet for 14 days.
3264925|NCT00733551|Placebo Comparator|Subjects receiving placebo in cohort 1, 2 and 3|Eligible subjects will receive repeat oral doses of placebo tablets given once daily for 14 days in cohort 1, 2 and 3.
3264926|NCT00733538|Active Comparator|1|patients receiving zometa treatment
3264927|NCT00733538|No Intervention|2|No treatment, just follow-up
3264928|NCT00733525|Experimental|Stepped Care|Participants will receive guided self-help with nine clinician checkups, followed by fluoxetine if nonresponsive, followed by cognitive behavioral therapy if still nonresponsive.
3264929|NCT00733525|Active Comparator|Cognitive Behavioral Therapy|Participants will receive 20 sessions of cognitive behavioral therapy with the addition of fluoxetine at interim points.
3264930|NCT00733512||ReSTOR|AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL)
3264931|NCT00733499|Other|LCS Complete Duofix|102 patients
3264932|NCT00733499|Active Comparator|LCS Complete Porocoat|104 patients
3264933|NCT00733486|Other|L.C.S. APG Knee Anterior Posterior Glide knee|Orthopaedic implant for primary knee replacement
3264984|NCT00733083|Active Comparator|3|0,5 mg/kg dexamethasone (max 24 mg
3264985|NCT00733083|Placebo Comparator|4|NaCl 0,9%
3264934|NCT00733473|Active Comparator|1 Budesonide|This arm consist 50 children with recurrent wheezing who are hospitalized for wheezing epizode. They received 1 mg nebulized budesonide 2 times a day upto 5 days
3264935|NCT00733473|Placebo Comparator|2 Placebo saline|This arm consist 50 children with recurrent wheezing who are hospitalized for wheezing epizode. They received 2ml of nebulized saline 2 times a day upto 5 days
3264936|NCT00733460|Experimental|BF-PET|
3264937|NCT00733434|Experimental|1|Patients receiving PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
3264938|NCT00733434|Placebo Comparator|2|Patients receiving 500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
3264939|NCT00733421|Experimental|1|"Active study drug:~Etoricoxib 90 mg once daily"
3264940|NCT00733421|Active Comparator|2|Tramadol 100 mg slow release twice daily
3264941|NCT00733408|Experimental|Treatment (chemo, monoclonal antibody, and enzyme inhibitor)|"INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients achieving complete response, partial response, or stable disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity."
3264942|NCT00733395|Experimental|1|Tart cherry juice
3264943|NCT00733395|Placebo Comparator|2|Fruit juice
3264944|NCT00733382|Experimental|1|
3264945|NCT00733382|Active Comparator|2|
3264946|NCT00733369|Other|PFC Sigma RP-F|125 patients to be allocated to this arm according to blinding envelopes
3264947|NCT00733369|Active Comparator|PFC Sigma RP|125 patients to be allocated to this arm according to blinding envelopes
3264948|NCT00733356|Experimental|Vyvanse Treatment|All subjects were tested at baseline before medication and then titrated to best dose and retested on Vyvanse Medication.
3264949|NCT00733343|Active Comparator|Treatment Group|treatment with Adaptive Servoventilation (Europe: AutoSet CS (USA: VPAP Adapt SV)) + standard medical therapy according to applicable guidelines (ESC, ACC/AHA)
3264950|NCT00733343|No Intervention|Control Group|standard medical therapy according to applicable guidelines (ESC, ACC/AHA)
3264951|NCT00733330|Other|Conventional TKR arm|Patients to receive treatment with either a P.F.C. Sigma or L.C.S. knee using the conventional manual surgical technique
3264952|NCT00733330|Active Comparator|MiTKR CAS arm|Patients to receive treatment with either a P.F.C. or L.C.S. knees in chronological order into the CAS group which will use minimally invasive surgery and computer navigation
3264953|NCT00733317|Active Comparator|1-Budesonide nebulized suspension|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times and will not give after 3 doses
3264954|NCT00733317|Placebo Comparator|2- 0.9% saline|Children will receive 2 ml of saline every 20 minutes for 3 times and will not give after 3 doses
3264955|NCT00733304|Experimental|5 mg/ml TID|eligible participants received 5 mg/ml Pazopanib eye drops three times daily (TID)
3264956|NCT00733304|Experimental|2 mg/ml TID|eligible participants received 2 mg/ml Pazopanib eye drops three times daily
3264957|NCT00733304|Experimental|5 mg/ml QD|eligible participants received 5 mg/ml Pazopanib eye drops once daily (QD)
3264958|NCT00733291|Active Comparator|Nelfilcon A soak / Nelfilcon A no-soak|Nelfilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution, followed by nelfilcon A contact lenses inserted directly from the blister package. Each pair of lenses worn for 2 hours.
3264959|NCT00733291|Active Comparator|Nelfilcon A no soak / nelfilcon A soak|Nelfilcon A contact lenses inserted directly from the blister package, followed by nelfilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution. Each pair of lenses worn for 2 hours.
3264960|NCT00733291|Active Comparator|Etafilcon A soak / etafilcon A no soak|Etafilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution, followed by etafilcon A contact lenses inserted directly from the blister package. Each pair of lenses worn for 2 hours.
3264961|NCT00733291|Active Comparator|Etafilcon A no soak / etafilcon A soak|Etafilcon A contact lenses inserted directly from the blister package, followed by etafilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution. Each pair of lenses worn for 2 hours.
3264962|NCT00733278|Experimental|Copper IUD|Copper IUD
3264963|NCT00733265|Experimental|AZD6140|
3264964|NCT00733239|Experimental|1|Receives 2-4 of the drugs listed under Intervention
3264965|NCT00733226|Active Comparator|1 Broncho-Vaxom|The children received one capsule per oral, OM-85 BV (3.5 mg) per day for the first 10 consecutive days of each month for 3 consecutive months.
3264966|NCT00733226|Placebo Comparator|2 (Placebo OM-85 BV)|The children received one capsule per oral, placebo per day for the first 10 consecutive days of each month for 3 consecutive months.
3264967|NCT00733200|No Intervention|Control group|
3264968|NCT00733187|Experimental|1|
3264969|NCT00733174|Experimental|1|Rosiglitazone
3264970|NCT00733174|Placebo Comparator|2|Placebo
3264971|NCT00733161|Active Comparator|1|Passive leg cycle exercise with stretching and resistance training
3264972|NCT00733161|Active Comparator|2|Stretching and resistance training
3264973|NCT00733148||1|Routine Care
3264974|NCT00733148||2|Insulin infusion based on model predictive algorithm (MPC)
3264975|NCT00733135|Other|Atherectomy with embolic protection|All subjects were treated with atherectomy (with SilverHawk or TurboHawk device) in conjunction with embolic protection (SpiderFX device).
3264976|NCT00733122|Experimental|A|GARDASIL, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
3264977|NCT00733109|Active Comparator|excision of the lesion|
3264978|NCT00733109|No Intervention|espontaneous regression|
3264979|NCT00733096|Experimental|1|Epidural etanercept 4 mg, two doses 2 weeks apart
3264980|NCT00733096|Active Comparator|2|Epidural methylprednisolone 60 mg, two doses 2 weeks apart
3264981|NCT00733096|Placebo Comparator|3|Epidural saline, two doses 2 weeks apart
3264982|NCT00733083|Active Comparator|1|0,1 mg/kg of oxycodone
3264986|NCT00733057|Experimental|1|Minocycline treatment
3264987|NCT00733057|Placebo Comparator|2|Placebo
3264988|NCT00733044|Experimental|Specialized Care|Stepped-care cognitive behavioural approach with elements from tinnitus retraining therapy
3264989|NCT00733044|Active Comparator|Usual Care|Audiological diagnostics and intervention and, if necessary, one or more consultations with a social worker with a maximum of ten one hour session
3264990|NCT00733031|Experimental|gemcitabine|gemcitabine administered in combination with AZD6918
3264991|NCT00733031|Experimental|pemetrexed|pemetrexed administered in combination with AZD6918
3264992|NCT00733031|Experimental|AZD6918|AZD6918 administered alone
3264993|NCT00733018|Active Comparator|A|Diet A - Western diet
3264994|NCT00733018|Active Comparator|B|Diet B - Balanced diet
3264995|NCT00733005|Experimental|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
3264996|NCT00733005|Placebo Comparator|Arm 2|Matching placebo nasal spray
3264997|NCT00732992|Experimental|CDD|
3264998|NCT00732992|Experimental|2/1|
3264999|NCT00732979|Experimental|A|Infrahepatic inferior vena cava clamping The inferior vena cava is circumferentially dissected below the liver and clamped with a vascular clamp. Patients in this study group will receive intravenous volume for maintenance of fluid hemostasis according to local standards.
3265000|NCT00732979|Active Comparator|B|Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below < 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
3265001|NCT00732966|Experimental|1|Hypertensive patients will be treated with losartan for one months
3265002|NCT00732966|Experimental|2|Hypertensive patients will be treated with valsartan
3265003|NCT00732953|Active Comparator|1|Genous stent implantation with paclitaxel-eluting balloon therapy
3265004|NCT00732953|Active Comparator|2|Genous stent implantation
3265005|NCT00732940|Experimental|Belimumab Q2WKS|Every other week: 100 mg of belimumab (1 injection) subcutaneous (under the skin) on days 0, 7, and 14, then every other week until final evaluation at Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.
3265006|NCT00732940|Experimental|Belimumab 3X/WK|Three times weekly: 200 mg of belimumab (2 injections of 100 mg each) subcutaneous (under the skin) on days 0, 2, and 4 then 100 mg three times a week until final evaluation at Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.
3265007|NCT00732927|Experimental|1|parnaparin, low molecular weight heparin
3265008|NCT00732927|Active Comparator|2|aspirin
3265009|NCT00732914|Active Comparator|1|Sunitinib (first-line) followed by Sorafenib (second-line)
3265010|NCT00732914|Experimental|2|Sorafenib (first-line) followed by Sunitinib (second-line)
3265011|NCT00732901|Experimental|A (escitalopram)|Escitalopram
3265012|NCT00732901|Experimental|B (placebo)|Placebo
3265013|NCT00732888|Other|1|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 15; and Tasigna® once daily on days 1 and 15 (i.e., Tasigna® alone on day 1, and combination of Tasigna® and calcium supplement on day 15).
3265014|NCT00732888|Other|2|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 1; and Tasigna® once daily on days 1 and 15 (i.e., combination of Tasigna® and calcium supplement on day 1, Tasigna® alone on day 15).
3265015|NCT00732875|Experimental|Open Label Infliximab + Methotrexate|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
3265016|NCT00732862|Experimental|1|Baseline clamp study before treatment phase.
3265017|NCT00732862|Active Comparator|2|Final clamp experiment after 6 months intensive therapy.
3265018|NCT00732849|No Intervention|1|Standard Enteral Nutrition - Peptisorb, Nutricia Ltd.
3265019|NCT00732849|No Intervention|2|Standard Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes
3265020|NCT00732849|Experimental|3|Immunomodulating Enteral Nutrition: Reconvan, Fresenius Kabi Poland
3265021|NCT00732849|Experimental|4|Immunomodulating Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes + Omegaven (Fresenius Kabi), Dipepitven (Fresenius Kabi)
3265022|NCT00732836|Experimental|HAI Abraxane MTD|Dose escalation beginning Day 1, Cycle 2 dose level 180 mg/m^2 for maximum tolerated dose (MTD) of Hepatic Arterial Infusion of Abraxane (HAI Abraxane) following same dose intravenous Abraxane in Cycle 1 of 21 day cycle.
3265023|NCT00732836|Experimental|HAI Abraxane Expansion|HAI Abraxane dose expansion at MTD or dose level 3 (260 mg/m^2) if MTD not defined.
3265024|NCT00732823|Placebo Comparator|Profile A|No device worn
3265025|NCT00732823|Active Comparator|Profile B|Foot 40 mmHg, ankle 40 mmHg, mid-calf 35 mmHg, upper calf 30 mmHg
3265026|NCT00732823|Active Comparator|Profile C|Foot 50 mmHg, ankle 50 mmHg, mid-calf 45 mmHg, upper calf 40 mmHg
3265027|NCT00732823|Active Comparator|Profile D|Foot 60 mmHg, ankle 60 mmHg, mid-calf 55 mmHg, upper calf 50 mmHg
3265028|NCT00732810|Experimental|Breast cancer randomized to SCH 727965|
3265029|NCT00732810|Active Comparator|Breast cancer randomized to capecitabine|
3265030|NCT00732810|Experimental|SCH 727965 in breast cancer after progression on capecitabine|
3265031|NCT00732810|Experimental|NSCLC randomized to SCH 727965|Note: Enrollment of participants with NSCLC was completed per protocol as of 26 JAN 2010
3265032|NCT00732810|Active Comparator|NSCLC randomized to erlotinib|Note: Enrollment of participants with NSCLC was completed per protocol as of 26 JAN 2010
3265033|NCT00732810|Experimental|SCH 727965 in NSCLC after progression on erlotinib|Note: Crossover to SCH 727965 after progression on erlotinib was completed per protocol as of 26 JAN 2010
3265034|NCT00732797|No Intervention|Routine Care|Participants will receive routine care.
3265035|NCT00732797|Active Comparator|Booklet|Participants will receive self-treatment booklets, but no expert telephone support.
3265036|NCT00732797|Active Comparator|Booklet &Therapist Support|Participants will receive self-treatment booklets, and up to an hour's expert telephone support.
3265117|NCT00732238|Experimental|Arm 1|Removal of Bladder Catheter. Urine Culture Post Catheter Removal. Shorter Duration of Antibiotic Therapy.
3265037|NCT00732784|Other|1|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 15; and Gleevec® once daily on days 1 and 15 (i.e., Gleevec® alone on day 1, and combination of Gleevec® and calcium supplement on day 15).
3265038|NCT00732784|Other|2|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 1; and Gleevec® once daily on days 1 and 15 (i.e., combination of Gleevec® and calcium supplement on day 1, Gleevec® alone on day 15).
3265039|NCT00732771|Experimental|LCI696 1mg bid|
3265040|NCT00732758|Experimental|Vitamin D3|Vitamin D3 1000 IU Tablet
3265041|NCT00732758|Placebo Comparator|Placebo|Placebo Tablet
3265042|NCT00732745|Experimental|Phase II arm I|Patients receive docetaxel IV over 1 hour on days 1 and 8, oxaliplatin IV over 2 hours on day 1, and oral vandetanib (at the maximum tolerated dose determined in phase I) once daily on days 1-21. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue to receive vandetanib beyond 8 courses in the absence of disease progression or unacceptable toxicity.
3265043|NCT00732745|Active Comparator|Phase II arm II|Patients receive docetaxel and oxaliplatin as in arm I. Patients also receive an oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue to receive vandetanib beyond 8 courses in the absence of disease progression or unacceptable toxicity.
3265044|NCT00732732|Experimental|Green banana|Subjects receiving green banana powder.
3265045|NCT00732732|Placebo Comparator|Placebo|Microcrystalline cellulose given as placebo
3265046|NCT00732719|Placebo Comparator|Profile A|Device worn; no pressure given (placebo)
3265047|NCT00732719|Active Comparator|Profile B|Foot at 30mm Hg, Gaiter at 40 mm Hg, mid-calf at 30 mm Hg and upper cuff at 20mm Hg
3265048|NCT00732719|Active Comparator|Profile C|Foot at 20mm Hg, Gaiter at 30 mm Hg, mid-calf at 20 mm Hg and upper cuff at 10mm Hg
3265049|NCT00732719|Active Comparator|Profile D|Foot at 10mm Hg, Gaiter at 20 mm Hg, mid-calf at 10 mm Hg and upper cuff at 0mm Hg
3265050|NCT00732719|Active Comparator|Profile E|Foot at 30mm Hg, Gaiter at 40 mm Hg, mid-calf at 40 mm Hg and upper cuff at 40mm Hg
3265051|NCT00732719|Active Comparator|Profile F|Foot at 20mm Hg, Gaiter at 30 mm Hg, mid-calf at 30 mm Hg and upper cuff at 30mm Hg
3265052|NCT00732719|Active Comparator|Profile G|Foot at 10mm Hg, Gaiter at 20 mm Hg, mid-calf at 20 mm Hg and upper cuff at 20mm Hg
3265053|NCT00732706|Other|Sartorius Twitch|Femoral Nerve detection using Sartorius Twitch
3265054|NCT00732706|Other|Quadriceps Twitch|Femoral Nerve detection using Quadriceps Twitch
3265055|NCT00732693|Experimental|1|Treatment with standard sex steroid replacement regimen
3265056|NCT00732693|Experimental|2|Treatment with physiologic sex steroid regimen
3265057|NCT00732680|Experimental|Botulinum Toxin Type A|Treatment will be in the form of 10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
3265058|NCT00732654|Experimental|Sublingual Immunotherapy (SLIT)|"These subjects will have a dose escalation of the milk protein extract given sublingually. After dose escalation, they will continue on the sublingual daily maintenance dose for approximately one year.~Milk Protein Extract Immunotherapy : Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years."
3265059|NCT00732654|Experimental|SLIT/ Oral Immunotherpay (OIT) B|"These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 1000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.~Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years."
3265060|NCT00732654|Experimental|SLIT/ OIT A|"These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 2000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.~Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.~Milk Protein Extract Immunotherapy : Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks."
3265061|NCT00732641|Experimental|Peginterferon α-2b|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
3265062|NCT00732641|No Intervention|No Treatment|Participants will be observed and will receive no treatment.
3265063|NCT00732628||Boomerang percutaneous closure unit|patients having a Boomerang percutaneous closure device after a Neurointerventional study
3265064|NCT00732615|Placebo Comparator|Placebo|Sterile water for injection
3265065|NCT00732615|Experimental|50, 75, 100 mcg NPSP558|Initial dose of 50mcg, to be titrated up to 75mcg and then 100mcg dependent upon response
3265066|NCT00732602|Active Comparator|B|GLP-2 infusion
3265067|NCT00732602|Placebo Comparator|C|Sodium-chloride infusion
3265068|NCT00732602|Active Comparator|A|GIP-infusion
3265069|NCT00732589|Experimental|A|Suprascapular nerve block
3265070|NCT00732589|Experimental|B|therapeutic ultrasound
3265071|NCT00732576|Active Comparator|1|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA)
3265072|NCT00732576|Active Comparator|2|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (10 µg)
3265073|NCT00732576|Active Comparator|3|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 2 capsules of menaquinone-7 per day (20 µg per day)
3265074|NCT00732576|Active Comparator|4|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (45 µg per day)
3265075|NCT00732576|Active Comparator|5|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA)
3265076|NCT00732576|Active Comparator|6|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (10 µg)
3265077|NCT00732576|Active Comparator|7|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 2 capsules of menaquinone-7 per day (20 µg per day)
3265078|NCT00732576|Active Comparator|8|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (45 µg per day)
3265079|NCT00732550|Experimental|Single trocar|Patients will undergo cholecystectomy by the single trocar approach
3265080|NCT00732550|Active Comparator|Standard lap cholecystectomy|Standard lap choly
3265081|NCT00732537|Experimental|Inhaled Nitric Oxide|iNO started at 20 ppm for 1 hour. The gas was then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off).
3265082|NCT00732537|Placebo Comparator|Placebo|The Oxygen at high concentration (>90%), which was standard therapy for PPHN, was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda).
3265083|NCT00732524|Active Comparator|Glipizide arm|Glipizide XL is an insulin secretagogue and is an extended release tablet designed to provide a controlled rate of delivery. Glipizide XL was chosen because it is the most frequently used discharge oral medication in our ED. It has a quick onset of action within a few hours after oral ingestion, lasts for 24 hours and has a powerful glucose lowering effect. In addition, there are very few contraindications to Glipizide XL and there is published literature regarding their use in subjects with severe hyperglycemia
3265084|NCT00732524|Active Comparator|Glipizide + Glargine|Insulin Glargine is a recombinant human basal insulin analog. It was chosen since it is a non-peaking insulin with cover for 24 hours. It can be injected subcutaneously only once a day and has a low incidence of hypoglycemia
3265085|NCT00732511|Experimental|1|Coreg Cr will be up-titrated as needed to achieve blood pressure <130/80
3265086|NCT00732511|Active Comparator|2|Toprol XL will be up-titrated at weekly intervals to achieve a blood pressure <130/80 mm Hg
3265087|NCT00732498|Experimental|ESHAP followed by Zevalin and Rituximab|Etoposide, Methylprednisolone, Cytarabine, Cisplatin (ESHAP) infusion X 2 Cycles followed by Rituximab and In-Zevalin or Y-Zevalin.
3265088|NCT00732485|Active Comparator|Fenofibrate|
3265089|NCT00732485|Placebo Comparator|Placebo|
3265090|NCT00732472|Experimental|7 day repeat dose|7 day repeat dose
3265091|NCT00732459||1|electro-acupuncture preconditioning group
3265092|NCT00732459||2|control group
3265093|NCT00732446|Active Comparator|2|antibiotic /steroid combination compared with individual administration of steroid and antibiotic
3265094|NCT00732446|Experimental|1|combination antibiotic steroid compared with individual administration of steroid and antibiotic - new therapeutic indication
3265095|NCT00732433|Experimental|digital mammogram|"Digital mammography is a non-invasive imaging technique to obtain an x-ray image of the breast.~Two-view digital mammogram of the breast with a lesion that has been recommended for biopsy during the subject's regular clinical care. The digital mammogram is then analyzed by a computer program."
3265096|NCT00732420|Experimental|Treatment Arm A|Daily oral pazopanib in combination with weekly oral topotecan. Initially rising dose to determine the maximum tolerated dose: finally an expanded cohort treated at the maximum tolerated dose.
3265097|NCT00732420|Experimental|Treatment Arm B|Daily oral pazopanib in combination with oral topotecan given for 5 consecutive days every 21 days. Initially rising dose to determine the maximum tolerated dose; finally an additional cohort of patients treated at the maximum tolerated dose.
3265098|NCT00732407|Experimental|1|Patients with diabetes melittus treated with an ACE inhibitor will be treated with aliskiren
3265099|NCT00732407|Experimental|2|Patients with diabetes melittus treated with an ACE inhibitor will be given losartan
3265100|NCT00732381|Experimental|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
3265101|NCT00732381|Placebo Comparator|Arm 2|Matching placebo nasal spray
3265102|NCT00732368|Experimental|Mometasone Nasal Spray|Open-label. Two sprays per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
3265103|NCT00732355||I|known syphilis infected patients
3265104|NCT00732355||U|presumed uninfected patients
3265105|NCT00732342|No Intervention|1|Standard Treatment
3265106|NCT00732342|Experimental|2|Standard Treatment with Contingency Management for 12 weeks with a 0.5 probability of winning prizes for each negative sample submitted
3265107|NCT00732342|Experimental|3|Standard Treatment with Contingency Management for 24 weeks with a 0.34 probability of winning prizes for each negative sample submitted
3265108|NCT00732342|Experimental|4|Standard Treatment with Contingency Management for 24 weeks with a 0.5 probability of winning prizes for each negative sample submitted
3265109|NCT00732329|Experimental|A|"optimized home based occupational therapy including:~diagnostic assessment~patient-centered definition of targets involving the care giver~occupational therapy"
3265110|NCT00732329|No Intervention|B|treatment according to guidelines of German Society for Psychiatry, Psychotherapy and Nervous Diseases (DGPPN) and German Society of Neurology (DGN) without optimized occupational therapy
3265111|NCT00732303|Experimental|1|"Pemetrexed (Alimta) 500mg/m^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles~Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.~The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks."
3265112|NCT00732290|Active Comparator|1|Clopidogrel then fluoxetine+clopidogrel
3265113|NCT00732290|Active Comparator|2|Fluoxetine+clopidogrel then clopidogrel
3265114|NCT00732277|Experimental|Treatment|Patients in this arm will be given the following IMP intraveneously at 6 hour intervals - hydrocortisone (100mg/m2/24 hours)
3265115|NCT00732277|No Intervention|Control|in each phase of study 15 patients will receive no IMP as control arm
3265116|NCT00732251|Experimental|Allopurinol|Using an open label, naturalistic design, subjects will continue with their current psychiatric medications during the study. Allopurinol will be given at a fixed dose of 300 mg/day for the first week and then 600mg/d for the remainder of the study. Subjects who cannot tolerate the 600mg dose will be given a dose of 300mg/d. Subjects will participate in monthly follow up visits for 24 months. Subjects who develop a substance abuse or substance dependence disorder during the study will be terminated from the study. Also, subjects who develop a medical condition which can affect their mood stability will be terminated from the study.
3265118|NCT00732238|Active Comparator|Arm 2|Urinary Catheter Is Not Exchanged. Antibiotic Therapy Is Based On Culture Obtained From Existing Catheter. Longer Duration of Antibiotic Therapy.
3265119|NCT00732225|Active Comparator|DisCoVisc|Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)
3265120|NCT00732225|Active Comparator|DuoVisc|Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)
3265121|NCT00732225|Active Comparator|BioVisc|Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)
3265122|NCT00732225|Active Comparator|Healon5|AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)
3265123|NCT00732225|Active Comparator|Amvisc Plus|Bausch & Lomb Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)
3265124|NCT00732212|Experimental|Doppler endoscopic probe hemostasis|In addition to stigmata of hemorrhage and visual cues, Doppler endoscopic probe will be used for detection of blood flow before and after standard endoscopic hemostasis. If residual blood flow in the lesion is found after standard treatment, further endoscopic treatment will be applied as deemed safe by the investigator-endoscopist.
3265125|NCT00732212|Active Comparator|Standard Endoscopic Hemostasis|Standard, visually guided endoscopic hemostasis based on visual cues of stigmata of hemorrhage and endoscopic control of bleeding or treatment of the stigmata according to current guidelines
3265126|NCT00732199|Other|Arm 1|Determine the apneic threshold and carbon- dioxide reserve using noninvasive positive pressure ventilation during NREM sleep and determine the effect effect of episodic hypoxia on ventilatory long-term facilitation during NREM sleep in Young adults.
3265127|NCT00732199|Experimental|Arm 2|Determine the apneic threshold and carbon- dioxide reserve using noninvasive positive pressure ventilation during NREM sleep and determine the effect of episodic hypoxia on ventilatory long-term facilitation during NREM sleep in Older adults.
3265128|NCT00732186|Experimental|Group 1 and Group 2|
3265129|NCT00732173|Experimental|Arm I|"Patients receive a lifestyle intervention, Survivors of Uterine Cancer Empowered by Exercise and Healthy Diet (SUCCEED), on a group and individual basis consisting of nutrition, exercise, and behavioral modification counseling from a physician, psychologist, registered dietitian, and physical therapist. Sixteen group sessions will be conducted (10 weekly, 6 bi-weekly) for 6 months. Weight and body mass index, satisfaction with study treatment, and exercise/activity logs are assessed weekly and biweekly. Patients receive additional feedback and support during the weeks not met in a group, including newsletters and telephone and e-mail contact."
3265130|NCT00732173|Active Comparator|Arm II|Patients receive usual care informational brochures but no lifestyle counseling related to weight loss, physical activity, and nutrition.
3265131|NCT00732160|Experimental|HS-V/A; LS-V/A|High Sodium diet- Vehicle infusion then Aldosterone infusion Low Sodium diet- Vehicle infusion then Aldosterone infusion
3265132|NCT00732160|Experimental|HS-A/V; LS-A/V|High Sodium diet- Aldosterone infusion then Vehicle infusion Low Sodium diet- Aldosterone infusion then Vehicle infusion
3265133|NCT00732160|Experimental|LS-V/A; HS-V/A|Low Sodium diet- Vehicle infusion then Aldosterone infusion High Sodium diet- Vehicle infusion then Aldosterone infusion
3265134|NCT00732160|Experimental|LS-A/V; HS-A/V|Low Sodium diet- Aldosterone infusion then Vehicle infusion High Sodium diet- Aldosterone infusion then Vehicle infusion
3265135|NCT00732147|Placebo Comparator|2|Type 2 diabetes patients will receive placebo with 3 meals in experimental period.
3265136|NCT00732147|Experimental|1|Type 2 Diabetes patient will receive Pramlintide with 3 meals in experimental period.
3265137|NCT00732121|Active Comparator|1|Sitagliptin
3265138|NCT00732121|Placebo Comparator|2|Placebo arm
3265139|NCT00732108|Experimental|topiramate|topiramate 50mg orally for 2 weeks, then 100mg orally for 6 weeks
3265140|NCT00732108|Placebo Comparator|2|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
3265141|NCT00732095|Experimental|Experimental|Immediate Ad
3265142|NCT00732082|Active Comparator|Dose Level 0|Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.
3265143|NCT00732082|Experimental|Dose Level 1|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 3 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free period."
3265144|NCT00732082|Experimental|Dose Level 2|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 6.5 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free perio"
3265145|NCT00732082|Experimental|Dose Level 3|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 13 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free perio"
3265146|NCT00732082|Experimental|Dose Level 4|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 26 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free perio"
3265147|NCT00732069|Active Comparator|Placebo, then ramipril, then valsartan|placebo, ramipril, valsartan: Subjects were treated sequentially with placebo, ramipril (5mg/day by mouth), then valsartan (160mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
3265148|NCT00732069|Active Comparator|Placebo, then valsartan, then ramipril|placebo, ramipril, valsartan: Subjects were treated sequentially with placebo, valsartan (160mg/day by mouth), then ramipril (5mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
3265149|NCT00732069|Active Comparator|Ramipril, then placebo, then valsartan|placebo, ramipril, valsartan: Subjects were treated sequentially with ramipril (5mg/day by mouth), then placebo (once a day by mouth), then valsartan (160mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
3265200|NCT00731679|Experimental|Rifaximin|Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
3265201|NCT00731666|Other|Titan® IPP|Subjects implanted with Titan® IPP
3265150|NCT00732069|Active Comparator|Valsartan, then placebo, then ramipril|placebo, ramipril, valsartan: Subjects were treated sequentially with valsartan (160mg/day by mouth), then placebo (once a day by mouth), then ramipril (5mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
3265151|NCT00732069|Active Comparator|Ramipril, then valsartan, then placebo|placebo, ramipril, valsartan: Subjects were treated sequentially with ramipril (5mg/day by mouth), then valsartan (160mg/day by mouth), then placebo (once a day by mouth). Each drug was given for 7 days after a 3-week washout.
3265152|NCT00732069|Active Comparator|Valsartan, then ramipril, then placebo|placebo, ramipril, valsartan: Subjects were treated sequentially with then valsartan (160mg/day by mouth), then ramipril (5mg/day by mouth), then placebo (once a day by mouth). Each drug was given for 7 days after a 3-week washout.
3265153|NCT00732056|Experimental|1|3+3 cohort dose escalation
3265154|NCT00732043|Experimental|1|
3265155|NCT00732043|Experimental|2|
3265156|NCT00732043|Placebo Comparator|3|
3265157|NCT00732030|Experimental|AcrySof Toric T3|Each enrolled eye receives AcrySof Toric Model SN60T3 Intraocular Lens (IOL)
3265158|NCT00732017|Experimental|HVPC-|This group received standard physical therapy treatment and HVPC with negative polarity.
3265159|NCT00732017|Active Comparator|CG|The control group received only standard physical therapy treatment.
3265160|NCT00732017|Experimental|HVPC+|This group received standard physical therapy treatment and HVPC using active electrodes with positive polarity.
3265161|NCT00732004|Experimental|1|Group 1
3265162|NCT00732004|Experimental|2|Group 2
3265163|NCT00732004|Experimental|3|Group 3
3265164|NCT00731991|Active Comparator|ART|ART to the levator scapulae.
3265165|NCT00731991|Active Comparator|PNF|PNF to the levator scapulae.
3265166|NCT00731991|Placebo Comparator|Control|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
3265167|NCT00731978|No Intervention|Standard|Standard intraoperative fluid management
3265168|NCT00731978|Experimental|Restricted|Restricted intraoperative fluid management
3265169|NCT00731965|Experimental|1|Measles, mumps, rubella booster vaccination within 3 months after randomisation
3265170|NCT00731965|No Intervention|2|Booster vaccination performed by regular health authorities at age 9; at least 1 year after randomisation
3265171|NCT00731952|Experimental|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
3265172|NCT00731939|Other|Titan® OTR IPP|Subjects implanted with Titan® One Touch Release (OTR) Inflatable Penile Prosthesis (IPP)
3265173|NCT00731926|Experimental|1|
3265174|NCT00731926|Active Comparator|2|
3265175|NCT00731926|Placebo Comparator|3|
3265176|NCT00731913||1|Subjects with skin lesions requiring surgical excision and repair. One half of the each wound received Monocryl suture and the other half received Monosyn suture.
3265177|NCT00731913||2|Subjects with skin lesions requiring surgical excision and repair. One half of the each wound received Monocryl suture and the other half received Monosyn suture.
3265178|NCT00731874|Active Comparator|Arm 1 (6 to 8 ng/mL)|Target tacrolimus trough concentration of 6 to 8 ng/mL
3265179|NCT00731874|Active Comparator|Arm 2 (3 to 5 ng.mL)|Target tacrolimus trough concentration of 3 to 5 ng/mL
3265180|NCT00731861|Experimental|1|Paclitaxel plus PTK787
3265181|NCT00731848|Experimental|1|Intervention 1
3265182|NCT00731835|No Intervention|Group I|1. Wound Care (group 1)--Best standard wound care with aggressive debridement
3265183|NCT00731835|Active Comparator|Group 2|"2. Endovascular Intervention + Wound Care (group 2)--Best standard wound care in combination with endovascular revascularization~Endovascular revascularization is the intervention"
3265184|NCT00731809|Other|1|PET CT
3265185|NCT00731796||1|Stroke victims with a visual field deficit that undergo vision restoration therapy
3265186|NCT00731796||2|Stroke victims with a visual field deficit who do not undergo any rehabilitation intervention
3265187|NCT00731796||3|Stroke victims that do not have a visual field deficit
3265188|NCT00731796||4|Normal individuals who have not had a stroke and do not have a visual field deficit
3265189|NCT00731783|Active Comparator|Index patient only|Only the child recently treated for a skin or soft tissue infection will undergo the decolonization regimen.
3265190|NCT00731783|Active Comparator|Household|All members of the household (over the age of 6 months) will be asked to follow the study protocol.
3265191|NCT00731770|Placebo Comparator|placebo|placebo diskus 1 puff bid
3265192|NCT00731770|Active Comparator|active|advair 250 1 puff bid
3265193|NCT00731757|Experimental|1|Patients being treated with Humira.
3265194|NCT00731731|Experimental|Treatment (radiation therapy, vorinostat, temozolomide)|Patients undergo radiotherapy and receive vorinostat PO QD on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Patients also receive temozolomide PO QD on days 1-42. Beginning 4-6 weeks later, patients receive vorinostat PO QD on days 1-7 and 15-21 and temozolomide PO QD on days 1-5. Treatment with vorinostat and temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3265195|NCT00731705||1|Patients with hematological malignancies who are undergoing evaluation for autologous or allogeneic stem cell transplants OR First-degree relatives of patients evaluated for stem cell transplantation
3265196|NCT00731692|Experimental|FTY720D 0.5 mg|Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment
3265197|NCT00731692|Placebo Comparator|Placebo|Cohort 1 and 2: Patients randomized to placebo continued on placebo after re-randomization
3265198|NCT00731692|Experimental|FTY720D 1.25 mg switch to 0.5 mg|Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment on Nov 2009
3265199|NCT00731679|Placebo Comparator|Placebo|Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
3265202|NCT00731653|Experimental|1|BCI-024 and BCI-049
3265302|NCT00730951|Experimental|5|6g Corn Starch Control (12 capsules)
3265203|NCT00731640|Active Comparator|Monofocal|Patients unilaterally implanted with ReSTOR lens in one eye and previously implanted with monofocal Intraocular lens (IOL) (unspecified) in other eye
3265204|NCT00731640|Active Comparator|Phakic|Patients unilaterally implanted with ReSTOR lens in one eye and phakic in the other eye with no necessary cataract removal impending
3265205|NCT00731627|Placebo Comparator|1|placebo
3265206|NCT00731627|Active Comparator|11|simvastatin
3265207|NCT00731614|Experimental|Arm 1|Cognitive Behavior Therapy + mirror retraining
3265208|NCT00731614|Active Comparator|Arm 2|Supportive psychotherapy
3265209|NCT00731601|Experimental|1|pantoprazole 40mg/q6h IV infusion for three days
3265210|NCT00731601|Active Comparator|2|pantoprazole 8mg/h for three days
3265211|NCT00731588|Experimental|PPG1A - Adults|Phase I completed: Healthy male and post-menopausal female volunteers between the ages of 18 and 65. Volunteers must not have donated blood in the previous 8 weeks.
3265212|NCT00731588|Experimental|PPG1B - Infants|Phase II in progress: Newborns >= 24 weeks gestation who are patients in the Neonatal Intensive Care Unit at the University of Iowa Hospitals and Clinics that are being treated with the expectation of survival.
3265213|NCT00731562|Experimental|Varenicline Controlled Release, Fasted|
3265214|NCT00731562|Experimental|Varenicline Controlled Release, Fed|
3265215|NCT00731549|Experimental|1|Active Treatment of aripiprazole IM depot (300mg or 400mg)
3265216|NCT00731536||Patients with Hepatosplenic T-cell Lymphoma (HSTCL)|
3265217|NCT00731523|Experimental|1|
3265218|NCT00731510|Experimental|1|Carbohydrate supplements (drinks and gels)
3265219|NCT00731510|Placebo Comparator|2|Primarily Aspartame plus natural flavourings. Powder dissolved in water to provide non-distinguishable placebo drink.
3265220|NCT00731497|Active Comparator|1|children in households/villages using Solar Water Disinfection (SODIS) method of disinfecting household drinking water
3265221|NCT00731497|No Intervention|2|children in households/villages where Solar Water Disinfection (SODIS) has not been implemented
3265222|NCT00731484||Volunteer Patients/Subjects|These subjects should present the general population.
3265223|NCT00731471|Experimental|1|12 Healthy adults infected with HIV
3265224|NCT00731471|Experimental|2|12 HIV+ adults on antiretroviral therapy
3265225|NCT00731432|Experimental|A|Transmucosal Herbal Periodontal Patch (THPP)
3265226|NCT00731432|Placebo Comparator|B|Placebo Patch
3265227|NCT00731419|Active Comparator|SEMS|Self expanding metal stent compared to plastic stent. Both recognised forms of treatment for condition
3265228|NCT00731419|Active Comparator|Plastic stent|
3265229|NCT00731393|Experimental|Group A|Subjects aged between 6 months and 3 years.
3265230|NCT00731393|Experimental|Group B|Subjects aged 3 to 6 years.
3265231|NCT00731393|Active Comparator|Group C|Subjects aged between 6 months and 3 years.
3265232|NCT00731393|Active Comparator|Group D|Subjects aged 3 to 6 years.
3265233|NCT00731380|Experimental|ABI-007 escalation; then radiation + AUC|Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-FU 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
3265234|NCT00731367|Active Comparator|Gelled|Aquacel Ag gelled.
3265235|NCT00731367|Active Comparator|Adherent|Aquacel Ag adherent
3265236|NCT00731354|Active Comparator|SAL|Each patient will have Suction Assisted Lipoplasty procedure on one side of the body (this will be considered the control side)
3265237|NCT00731354|Active Comparator|VAL|Each patient will have VASER- assisted lipoplasty on the opposite side of the body. This will be the comparison side.
3265238|NCT00731341|Experimental|Hysteroscopic cryoablation|Women undergoing hysteroscopic ultrasound guided cryoablation for the treatment of uterine fibroids.
3265239|NCT00731315|Experimental|Treatment Group 1 - uncomplicated UTI|Would receive computer-assisted treatment for a uncomplicated UTI.
3265240|NCT00731315|Active Comparator|Control Group 1|Qualified for expedited treatment for uncomplicated cystitis but would receive usual care in the Emergency Department of Community Health Center.
3265241|NCT00731315|Experimental|Treatment Group 2 - Complicated Cystitis|Would receive expedited treatment for complicated cystitis with longer antibiotic course than the simple UTI patients.
3265242|NCT00731315|Active Comparator|Control Group 2|Qualified for expedited treatment for complicated cystitis treatment but would receive usual care in the clinic or emergency department.
3265243|NCT00731302|Experimental|Aspirin and Meloxicam|Arm: Aspirin and Meloxicam Each participant will receive 81 mg aspirin per day for 7 days, followed by meloxicam 7.5 mg daily plus aspirin 81 mg daily for 5 days
3265244|NCT00731289|Experimental|1|single intraarticular injection of hyaluronan 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
3265245|NCT00731289|Active Comparator|2|single intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)
3265246|NCT00731276|Other|Four Regimens|"The study has four type of regimens, and dosing of irinotecan depends on genotype of patient.~Four Regimens are:~Weekly Irinotecan (Irinotecan given at day 1, 8 and 15) every four weekly~Weekly Xeliri ( Irinotecan given at day 1, 8 and 15)+ (Xeloda tabs 2000mg/m2 consumed over 14 days) every three weekly~Three-weekly Xeliri (Irinotecan given at day 1 only) + (Xeloda tabs 2000mg/m2 consumed over 14 days) every three weekly~Two-weekly FOLFIRI (Irinotecan given at day 1 only) + (CI Fluorouracil 600mg/m2 over 22hrs, IV Folinic Acid 200mg/m2 over 2hrs and IVP Fluorouracil 400mg/m2) every two weekly"
3265247|NCT00731263|Experimental|1|The study will start with AZD8055 formulated in a liquid solution prior to the tablet formulation becoming available. The tablet formulation will be introduced in Part A at the beginning of a new cohort at an appropriate dose, no higher than the dose of the liquid formulation in the last completed evaluated cohort. Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
3265248|NCT00731250|Placebo Comparator|PART 1-Visit 1-Placebo|Eligible subjects will receive matching placebo tablets
3265301|NCT00730951|Experimental|4|6g Korean Red Ginseng (12 capsules)
3265249|NCT00731250|Experimental|PART 1-Visit 1-Capsaicin|Eligible subjects will receive incremental capsaicin doses
3265250|NCT00731250|Placebo Comparator|PART 1-Visit 2-Placebo|Eligible subjects will receive matching placebo tablets
3265251|NCT00731250|Experimental|PART 1-Visit 2-Capsaicin|Eligible subjects will receive maximum capsaicin dose
3265252|NCT00731250|Placebo Comparator|PART 1-Visit 3-Placebo|Eligible subjects will receive matching placebo tablets
3265253|NCT00731250|Experimental|PART 1-Visit 3-Capsaicin|Eligible subjects will receive matching placebo tablets incremental capsaicin doses
3265254|NCT00731250|Placebo Comparator|PART 2-Visit 1-Placebo|Eligible subjects will receive matching placebo tablets
3265255|NCT00731250|Experimental|PART 2-Visit 1-SB-705498|Eligible subjects will receive SB-705498 tablets
3265256|NCT00731250|Experimental|PART 2-Visit 2-Capsaicin|Eligible subjects will receive matching placebo tablets incremental capsaicin doses
3265257|NCT00731237||1|The procedures undergone by this group will be evaluated for: Acute performance, deliverability and resource utilization during the procedure in the catheterization lab during commercial use by various physicians with a range of coronary stenting experience.
3265258|NCT00731224|Experimental|1|
3265259|NCT00731211|Experimental|Pazopanib|800 mg of pazopanib orally each day continuously
3265260|NCT00731198|Experimental|1|Drotaverine hydrochloride
3265261|NCT00731198|Active Comparator|2|Hyoscine-N-butylbromide
3265262|NCT00731185|Experimental|Mometasone Furoate Nasal Spray (MFNS)|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning
3265263|NCT00731185|Placebo Comparator|Placebo|Placebo nasal spray (2 sprays of 50 mcg in each nostril) once daily in the morning
3265264|NCT00731172|Experimental|1|20 mg copaxone(glatiramer acetate)subcutaneous injection(daily through week 12)
3265265|NCT00731172|Placebo Comparator|2|placebo subcutaneous injection(daily through week 12)
3265266|NCT00731159||A|"Sperm capacitation:~Sperm capacitation is measured in a sample of the same ejaculated sperm unit given for fertilizing human oocytes in an IVF treatment cycle"
3265267|NCT00731146|Active Comparator|1 - Ultrasound|Participants will receive an ultrasound guided interscalene brachial plexus block
3265268|NCT00731146|Active Comparator|2 - Nerve Stimulator|Participants will receive a nerve stimulator guided interscalene brachial plexus block
3265269|NCT00731133|Other|Disulfiram|Disulfiram at 250 mg daily
3265270|NCT00731120|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
3265271|NCT00731120|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg encapsulated tablets, orally, once daily for up to 8 weeks.
3265272|NCT00731120|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg encapsulated tablets, orally, once daily for up to 8 weeks.
3265273|NCT00731107|Active Comparator|1|Veress Needle laparoscopic entry
3265274|NCT00731107|Active Comparator|2|XCEL bladeless trocar laparoscopic entry
3265275|NCT00731094|Experimental|Physical Activity Intervention|Expert system-based physical activity counseling: Individualized baseline counseling and guided goal setting to increase physical activity gradually to at least 150 minutes/week of moderate intensity, with a 12-month follow-up via postal mail of 14 additional counseling contacts generated by responses to a physical activity questionnaire and individually tailored computer-generated expert system feedback messages for physical activity based on stages of the motivational readiness for change model
3265276|NCT00731094|No Intervention|Attention Control|Generalized baseline healthy lifestyle education and suggestion to increase physical activity, with a 12-month follow-up via postal mail of 14 wellness newsletters focused on health issues other than physical activity
3265277|NCT00731068|Experimental|1|PRGF
3265278|NCT00731068|Placebo Comparator|2|
3265279|NCT00731055|Experimental|Intervention 1|"Each participant participates in 4 consecutive interventions in random order.~Placebo, 1 capsule before the session~0.5 mg varenicline, 1 capsule before the session 3.1 mg varenicline, 1 capsule before the session~4. 2 mg varenicline, 1 capsule before the session"
3265280|NCT00731055|Experimental|Intervention 2|Each participant participates in 4 consecutive interventions in random order. 1.0.5 mg varenicline, 1 capsule before the session 2. 1 mg varenicline, 1 capsule before the session 3.2 mg varenicline, 1 capsule before the session 4. Placebo, 1 capsule before the session
3265281|NCT00731055|Experimental|Intervention 3|Each participant participates in 4 consecutive interventions in random order. 1.1 mg varenicline, 1 capsule before the session 2. 2 mg varenicline, 1 capsule before the session 3.Placebo, 1 capsule before the session 4. 0.5 mg varenicline, 1 capsule before the session
3265282|NCT00731055|Experimental|Intervention 4|Each participant participates in 4 consecutive interventions in random order. 1.2 mg varenicline, 1 capsule before the session 2. Placebo, 1 capsule before the session 3. 0.5 mg varenicline, 1 capsule before the session 4. 1 mg varenicline, 1 capsule before the session
3265283|NCT00731042|Experimental|Avagard|3M Avagard Surgical and healthcare Personnel Hand Antiseptic with Moisturizers
3265284|NCT00731042|Active Comparator|Purell|Purell Surgical Scrub with Moisturizers
3265285|NCT00731029|Experimental|Group A|The subjects in this group will be 18-60 years.
3265286|NCT00731029|Experimental|Group B|The subjects in this group will be > 60 years.
3265287|NCT00731029|Active Comparator|Group C|The subjects in this group will be 18-60 years.
3265288|NCT00731029|Active Comparator|Group D|The subjects in this group will be > 60 years.
3265289|NCT00731016|Other|1|Zoledronic acid, pravastatin
3265290|NCT00731003|Experimental|I|ATD procedure
3265291|NCT00731003|Experimental|II|Oxitriptan
3265292|NCT00731003|Placebo Comparator|III|Amino acid mixture with tryptophan
3265293|NCT00731003|Placebo Comparator|IV|Placebo capsule
3265294|NCT00730990|Experimental|Cohort 1|This arm will have no active treatment.
3265295|NCT00730990|Experimental|Cohort 2|
3265296|NCT00730977|Experimental|single|single arm, open label, 4 doses tested.
3265297|NCT00730964|Other|Phase 4|Open Label
3265298|NCT00730951|Experimental|1|0.5g Korean Red Ginseng (1 capsule) 5.5g Corn Starch (11 capsules)
3265299|NCT00730951|Experimental|2|1g Korean Red Ginseng (2 capsules) 5g Corn Starch (10 capsules)
3265300|NCT00730951|Experimental|3|3g Korean Red Ginseng (6 capsules) 3g Corn Starch (6 capsules)
3265304|NCT00730938|Placebo Comparator|2|Saline placebo
3265305|NCT00730925|Experimental|BIBW 2992|patient to receive tablets of BIBW 2992 once a day, starting at high dose until progression of the disease
3265306|NCT00730925|Experimental|BIBW 2992 + paclitaxel|patient whose disease progressed on treatment with BIBW 2992 monotherapy to receive tablet of BIBW 2992 once a day in combination with i.v. paclitaxel 3 weekly
3265307|NCT00730912|Experimental|Pediatrics 3 to 6 years|Pediatrics 3 to 6 years
3265308|NCT00730912|Experimental|Pediatrics 7 to 15 years|Pediatrics 7 to 15 years
3265309|NCT00730912|Experimental|Adults 16 to 64 years|Adults 16 to 64 years
3265310|NCT00730886|Experimental|1|Non-invasive procedure for fertility enhancement (i.e., ExAblate treatment)
3265311|NCT00730886|Active Comparator|2|Invasive surgical procedure for fertility enhancement (i.e., myomectomy)
3265312|NCT00730873|Experimental|A|continuous positive airway pressure
3265313|NCT00730860|Experimental|RFA+TACE|treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
3265314|NCT00730860|Active Comparator|RFA only|treatment of hepatocellular carcinoma by radiofrequency ablation only
3265315|NCT00730847|Experimental|Cervarix Group|Healthy female subjects who received three doses of the Cervarix vaccine, administered intramuscularly in the deltoid region according to a 0, 1 and 6-month schedule.
3265316|NCT00730821|Experimental|1|
3265317|NCT00730808|Experimental|Test|Oral nutritional supplement: assignment according to consecutive random numbers.
3265318|NCT00730808|Placebo Comparator|Control|Assignment according to consecutive random numbers.
3265319|NCT00730795|Experimental|Group A|Subjects receiving the low-dose antigen candidate TB vaccine
3265320|NCT00730795|Experimental|Group B|Subjects receiving the high-dose antigen candidate TB vaccine
3265321|NCT00730782|Active Comparator|1|The experimental vaccine PfAMA1 formulated in Alhydrogel
3265322|NCT00730782|Active Comparator|2|The experimental vaccine PfAMA1 formulated in Montanide ISA720
3265323|NCT00730782|Active Comparator|3|The experimental vaccine PfAMA1 formulated in ASO2A
3265324|NCT00730769|Experimental|Single arm|Patients received a short induction of IV ganciclovir (Cymevene®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir (Valcyte®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 900 mg bid (after meals) for 16 days up to complete 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockcroft-Gault equation)
3265325|NCT00730756|Active Comparator|Arm A|Fluticasone Furoate Nasal Spray 110mcg intranasally once daily
3265326|NCT00730756|Placebo Comparator|Arm B|Matching placebo nasal spray intranasally once daily
3265327|NCT00730743|Experimental|1|Intermittent clamp group
3265328|NCT00730743|No Intervention|2|No clamp group
3265329|NCT00730730|Experimental|Complete SE Iliac Stent|Complete SE Iliac Stent
3265330|NCT00730717|Experimental|1|Patients who are not concurrently receiving methotrexate treatment for pyoderma gangrenosum
3265331|NCT00730717|Experimental|2|Patients who are receiving concurrent methotrexate for pyoderma gangrenosum
3265332|NCT00730691|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
3265333|NCT00730691|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
3265334|NCT00730691|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
3265335|NCT00730691|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
3265336|NCT00730691|Active Comparator|Duloxetine 60 mg|Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week.
3265337|NCT00730678||All Participants|All participants enrolled on this study will have blood drawn for genetic testing.
3265338|NCT00730665|Experimental|100ug|
3265339|NCT00730665|Experimental|300ug|
3265340|NCT00730665|Experimental|1mg|
3265341|NCT00730665|Experimental|3mg|
3265342|NCT00730665|Placebo Comparator|Placebo|
3265343|NCT00730652|Experimental|MDX1411|An accelerated titration design (ATD) will be utilized and subjects will be assigned to a dose level in the order they enter the study.
3265344|NCT00730639|Experimental|Melanoma - BMS-936558 (MDX-1106)|
3265345|NCT00730639|Experimental|RCC - BMS-936558 (MDX-1106)|
3265346|NCT00730639|Experimental|mCRPC - BMS-936558 (MDX-1106)|
3265347|NCT00730639|Experimental|NSCLC - BMS-936558 (MDX-1106)|
3265348|NCT00730639|Experimental|CRC - BMS-936558 (MDX-1106)|
3265349|NCT00730626|Experimental|1|L.acidophilus and B.lactis (1x10E9 of each probiotics) with 40 mg of green the extract
3265350|NCT00730626|Experimental|2|L.acidophilus and B.lactis (1x 10E10 of each probiotics) with 40 mg of green tea extract
3265351|NCT00730626|Placebo Comparator|3|Placebo
3265352|NCT00730613|Experimental|Treatment (therapeutic autologous lymphocytes)|Patients receive an infusion of autologous antigen-specific CD8+ cytotoxic T-lymphocyte clones over 5-10 minutes on days 1, 3, and 5 of weeks 1 and 2. Treatment repeats every 3 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity.
3265353|NCT00730600|Experimental|1|1= THAI traditional massage
3265354|NCT00730587||1|Full-term healthy infants ages 5 months to 3 years.
3265355|NCT00730574|No Intervention|B|The control group, marked B, gets only B12 vitamin 1mg/day treatment to comply with ethics regulations seeing as they do suffer from B12 deficiency .
3265356|NCT00730574|Experimental|A|The trial group which receives daily treatment of 1mg Vitamin B12 (sublingual tablets) combined with 5 mg Folic acid (tablets)
3265357|NCT00730561|No Intervention|1|
3265358|NCT00730561|Experimental|2|Hematopoietic stem cell transplantation
3265359|NCT00730548|Experimental|1|Remote Arm (OptiVol plus Connexus Telemetry plus CareLink plus Intervention Algorithm), Clinical Management Alerts ON
3265360|NCT00730548|No Intervention|2|No Care Alerts available, standard treatment of the patient
3265361|NCT00730535|Experimental|Tolterodine 1|
3265362|NCT00730535|Experimental|Toterodine 3|
3265363|NCT00730535|Experimental|Tolterodine 6|
3265364|NCT00730522|Active Comparator|1|CPP-109 vigabatrin tablets
3265365|NCT00730522|Placebo Comparator|2|Matching Placebo Tablets
3265366|NCT00730496|Experimental|1|the study group, 45 women
3265367|NCT00730496|No Intervention|2|the control group, 45 women
3265368|NCT00730483|Experimental|DEB-TACE|PVA microporous hydrospheres loaded with doxorubicin hydrochloride used for the treatment of unresectable liver metastases from neuroendocrine tumors.
3265369|NCT00730470|Experimental|1|
3265370|NCT00730457|Experimental|A|Intramuscular (i.m.) vaccination of a single dose of 0.1 µg, 0.3 µg, 1 µg, 2 µg, 3 µg, 5 µg and 8 µg of STF2.HA1 (SI) (VAX125).
3265371|NCT00730431|Experimental|IDX184 5 mg|Healthy participants will be administered a single 5 mg dose of IDX184.
3265372|NCT00730431|Experimental|IDX184 10 mg|Healthy participants will be administered a single 10 mg dose of IDX184.
3265373|NCT00730431|Experimental|IDX184 25 mg|Healthy participants will be administered a single 25 mg dose of IDX184.
3265374|NCT00730431|Experimental|IDX184 50 mg|Healthy participants will be administered a single 50 mg dose of IDX184.
3265375|NCT00730431|Experimental|IDX184 75 mg|Healthy participants will be administered a single 75 mg dose of IDX184.
3265376|NCT00730431|Experimental|IDX184 100 mg|Healthy participants will be administered a single 100 mg dose of IDX184.
3265377|NCT00730431|Placebo Comparator|Placebo|Healthy participants will be administered placebo matching IDX184.
3265378|NCT00730418|Experimental|doxazosin 4mg|doxazosin 4mg group
3265379|NCT00730418|Experimental|doxazosin 8mg|doxazosin 8mg group
3265380|NCT00730405|Active Comparator|Albaconazole 100mg|Albaconazole for 36 weeks
3265381|NCT00730405|Active Comparator|Albaconazole 200mg|Albaconazole for 36 weeks
3265382|NCT00730405|Active Comparator|Albaconazole 400mg|Albaconazole for 36 weeks
3265383|NCT00730405|Active Comparator|Albaconazole 400mg 24 weeks, Placebo 12 weeks|Albaconazole for 24 weeks, Placebo for 12 weeks
3265384|NCT00730405|Placebo Comparator|Placebo 400 mg|Placebo for 36 weeks
3265385|NCT00730392|Experimental|1 drug, 2 placebo|"Etanercept~Placebo"
3265386|NCT00730379|Experimental|1|ridaforolimus (MK8669) + dalotuzumab (MK0646)
3265387|NCT00730366|Experimental|1|Experimental: IPTp-SP + promotion: Active Comparator
3265388|NCT00730366|Experimental|2|IPTp-SP alone (without promotion)
3265389|NCT00730366|Active Comparator|3|Weekly CQ prophylaxis
3265390|NCT00730353|Experimental|1|"Treatment will be administered on an outpatient basis. Chemotherapy will be administered in a 28-day treatment cycle. The 28 days of treatment with paclitaxel and sunitinib malate (plus the time required to recover if toxicity is encountered) is defined as a cycle.~Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.~Sunitinib malate 37.5 mg orally, daily. After 4 cycles, paclitaxel will be discontinued and patients will continue on sunitinib malate until disease progression, unacceptable toxicity, or physician discretion."
3265391|NCT00730340|Active Comparator|1|Patients will receive closure of the tonsillar fossae following tonsillectomy.
3265392|NCT00730340|Active Comparator|2|Patients will not receive closure to one or both tonsillar fossa following a tonsillectomy
3265393|NCT00730327|Experimental|BIB®|Receives BioEnterics® Intragastric Balloon Intervention as well as diet and exercise counseling with the Behavioral Modification Intervention.
3265394|NCT00730327|Other|Control|Control arm receives the Behavioral modification intervention only.
3265395|NCT00730314|Experimental|1|Unrelated donor
3265396|NCT00730314|Experimental|2|Cord Blood
3265397|NCT00730288|Experimental|1|Received monovalent Vero dengue vaccine in Study DIV12
3265398|NCT00730288|Experimental|2|Received Yellow fever vaccine in Study DIV12
3265399|NCT00730288|Experimental|3|Flavivirus-naive subjects
3265400|NCT00730275|Experimental|Sitagliptin 50 mg|Participants were randomized to sitagliptin 50 mg
3265401|NCT00730275|Experimental|Sitagliptin 100 mg|Participants were randomized to sitagliptin 100 mg
3265402|NCT00730275|Experimental|Sitagliptin 200 mg|Participants were randomized to a single dose of sitagliptin 200 mg
3265403|NCT00730275|Placebo Comparator|Placebo to sitagliptin|Participants were randomized to matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg
3265404|NCT00730262|Experimental|Single-Arm|
3265405|NCT00730249|Active Comparator|1|
3265406|NCT00730249|Placebo Comparator|2|
3265407|NCT00730236|Experimental|AEGR-733|
3265408|NCT00730210|Active Comparator|a: PTH (1-84) 100 ug s.c.inj. once a day|PTH (1-84) 100 ug subcutaneous injections once a day
3265409|NCT00730210|Placebo Comparator|b: placebo 100 ug s.c. inj. once a day|placebo 100 ug sub cutaneous injection once a day
3265410|NCT00730197|Experimental|1|NISOLDIPINE EXTENDED-RELEASE TABLETS, 40 MG
3265411|NCT00730197|Active Comparator|2|Sular® Extended Release 40 mg tablets
3265412|NCT00730184|Active Comparator|1|Participants receive potassium bicarbonate in dosage of 90 mmol/d. This compound has no other name.
3265413|NCT00730184|Placebo Comparator|2|Participants receive placebo as microcrystalline cellulose. This compound has no other name.
3265414|NCT00730171|Experimental|Linaclotide|Linaclotide 290 μg/day capsules, administered orally once daily for up to 78 weeks. Dose reduction to 145 μg/day was permitted at the discretion of the Investigator.
3265415|NCT00730158|Experimental|Arm A|irinotecan+ KD018
3265416|NCT00730158|Experimental|Arm B|irinotecan + placebo
3265417|NCT00730145|Experimental|PD-0332334|
3265418|NCT00730132||New Statin|Group 1 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) whose lipid-lowering therapy was modified by transition to a new statin treatment
3265469|NCT00729859|Experimental|Group 3|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
3265763|NCT00727857|Active Comparator|Metformin 850 mg BID|
3265419|NCT00730132||Statin Dose Titration|Group 2 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) whose lipid-lowering therapy was modified by increasing the dose of ongoing statin treatment
3265420|NCT00730132||Ezetimibe added to existing statin|Group 3 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) and whose lipid-lowering therapy was modified by the addition of ezetimibe to ongoing statin treatment
3265421|NCT00730119||Neonates|Subjects ages birth to 30 days
3265422|NCT00730119||Infants|Subjects aged >30 days to 2 years
3265423|NCT00730119||Adults|Subjects aged 18 years of age or older
3265424|NCT00730106||1|Patients with pre-defined alarm symptoms
3265425|NCT00730106||2|Patients without pre-defined alarm symptoms
3265426|NCT00730093|Other|A|
3265427|NCT00730080||Sapropterin (Kuvan)|Individuals with phenylketonuria (PKU) who are beginning treatment with sapropterin.
3265428|NCT00730080||Control|Healthy individuals without phenylketonuria (PKU).
3265429|NCT00730067|Experimental|1|Sildenafil treatment
3265430|NCT00730067|Placebo Comparator|2|placebo
3265431|NCT00730054|Active Comparator|1|Clonidine
3265432|NCT00730054|Active Comparator|2|Remifentanil
3265433|NCT00730054|Experimental|4|Remifentanil+clonidine
3265434|NCT00730054|Placebo Comparator|3|Placebo
3265435|NCT00730041|Active Comparator|Palatal Implants|Pillar(R) Palatal Implants in combination with continuous positive airway pressure (CPAP) in subjects diagnosed with obstructive sleep apnea (OSA)
3265436|NCT00730041|Sham Comparator|Sham procedure|Sham (procedure but no implants inserted) in combination with continuous positive airway pressure (CPAP) in subjects diagnosed with obstructive sleep apnea (OSA)
3265437|NCT00730028|Experimental|Limited Abscess|Limited abscess with or without cellulitis less than or equal to 5 cm in diameter will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA 300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children; or c) placebo two capsules three times daily.
3265438|NCT00730028|Experimental|Cellulitis or Larger Abscess|Subjects with cellulitis only or abscess > 5 cm in diameter, or with 2 or more sites of skin infection will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children.
3265439|NCT00730015|Experimental|145 μg linaclotide|
3265440|NCT00730015|Experimental|290 μg linaclotide|
3265441|NCT00730015|Placebo Comparator|Matching Placebo|
3265442|NCT00730002|Active Comparator|1- Healthy Subjects|Healthy Subjects- receive MRA
3265443|NCT00730002|Active Comparator|2 - patients with SLE, no neuropsych|Systemic Lupus Erythematosus(SLE) patients without neuropsychiatric symptoms - receive MRA
3265444|NCT00730002|Active Comparator|3 - patients with SLE with neuropsych|20 symptomatic neuropsychiatric systemic lupus erythematosus(NPSLE) patients.
3265445|NCT00730002|Active Comparator|4- healthy patients from other cohort|10 Healthy Controls (HC) from an existing cohort as part of another sponsored study.
3265446|NCT00729989|No Intervention|1|
3265447|NCT00729989|Experimental|2|
3265448|NCT00729976|Experimental|1|Ibuprofen Suppository
3265449|NCT00729976|Active Comparator|2|Ibuprofen suspension
3265450|NCT00729963|Experimental|1|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (< 1.8 kg) over the first month of treatment.
3265451|NCT00729963|Active Comparator|2|A standard reference group, which was paired according to age and BMI, received CPAP as a treatment for OSA.
3265452|NCT00729937|Experimental|TMP/SMX vs. Placebo|Subjects with an acute uncomplicated cutaneous abscess will be randomized to receive either Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day) or 4 placebo pills (twice per day).
3265453|NCT00729937|Experimental|TMP/SMX vs. Clindamycin|Subjects with an acute uncomplicated wound infection will be randomized to receive Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day, with alternating 1 identical placebo pill, twice per day) or clindamycin (300 mg, four times per day, with 3 placebo pills on alternating doses).
3265454|NCT00729937|Experimental|Cephalexin and TMP/SMX vs. Cephalexin|Subjects with acute uncomplicated cellulitis will be randomized to receive cephalexin (500 mg, four times per day) and Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day) or cephalexin (500 mg, four times per day) and placebo (4 pills, twice per day).
3265455|NCT00729924|Experimental|Open label oral raltegravir|Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days.
3265456|NCT00729911|Active Comparator|AF ablation|"Subjects assigned to the catheter ablation strategy will undergo catheter based AF ablation. The goal of the procedure is to achieve isolation of all 4 pulmonary veins.~Subjects assigned to receive Amiodarone will have the oral medication initiated in an clinic setting."
3265457|NCT00729911|Active Comparator|Amiodarone|Amiodarone is taken orally on a daily basis.
3265458|NCT00729898||A|
3265459|NCT00729885|Experimental|1 Goggle I|Optimized Goggle
3265460|NCT00729885|Sham Comparator|2 Google II|Goggle with 20 Degree error
3265461|NCT00729872|Experimental|1|AG011: low dose
3265462|NCT00729872|Placebo Comparator|2|Placebo: low dose
3265463|NCT00729872|Experimental|3|AG011: mid dose
3265464|NCT00729872|Placebo Comparator|4|Placebo: mid dose
3265465|NCT00729872|Experimental|5|AG011: high dose
3265466|NCT00729872|Placebo Comparator|6|Placebo: high dose
3265467|NCT00729859|Experimental|Group 1|Acyline 300 µg/kg injections every two weeks (2 doses) + placebo (no active ingredients) gel daily for 28 days + oral placebo pill daily for 28 days
3265468|NCT00729859|Experimental|Group 2|Acyline 300 µg/kg injections every two weeks (2 doses) + Testosterone gel 100 mg daily for 28 days + oral placebo pill daily for 28 days
3265470|NCT00729846|Experimental|A|Patients will receive combination verteporfin with photodynamic therapy at reduced fluence [300mw/cm2] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
3265471|NCT00729846|Experimental|B|Patients will receive combination verteporfin with photodynamic therapy at standard fluence [600mw/cm2] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
3265472|NCT00729833|Experimental|CP-751,871 + Sunitinib|Escalating cohorts of CP-751,871 + Sunitinib
3265473|NCT00729807|Experimental|Pentamidine|4 mg/kg/day IV pentamidine isethionate infused slowly over 2 hours. Each treatment cycle will consist of 2 weeks of therapy, five days per week, followed by 2 weeks of observation.
3265474|NCT00729794|Experimental|Study Group|Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.
3265475|NCT00729794|Placebo Comparator|Control Group|Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.
3265476|NCT00729781|Experimental|Polyester Implants|There is one arm for this study. All subjects in this study will receive the investigational nasal implants. See the detailed description for procedure information.
3265477|NCT00729768|Experimental|1|
3265478|NCT00729768|Active Comparator|2|
3265479|NCT00729755|Experimental|Creatine|The subjects with major depressive disorder, treated with creatine in addition to escitalopram
3265480|NCT00729755|Placebo Comparator|Placebo|The subjects with major depressive disorder, treated with placebo in addition to escitalopram
3265481|NCT00729742|Experimental|Part 1|erlotinib
3265482|NCT00729742|Experimental|Part 2|erlotinib + dalotuzumab
3265483|NCT00729729|Placebo Comparator|1|Placebo
3265484|NCT00729729|Experimental|2|Slow release PCA derivative
3265485|NCT00729729|Experimental|3|Slow release PCA derivative higher dose
3265486|NCT00729716|Experimental|A|BioCart™II treatment
3265487|NCT00729716|Active Comparator|B|Microfracture procedure
3265488|NCT00729703|Experimental|1|Dual-chamber detection and activated treatment (at least ATP) in the slow VT-zone plus activated AAIsafeR pacing (basic rate 60 bpm).
3265489|NCT00729703|Experimental|2|Single-chamber ICD following clinical practice but with a monitoring zone active to allow the documentation of all occurring ventricular arrhythmias
3265490|NCT00729690|Experimental|1 Multi-Dose Pregabalin|Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.
3265491|NCT00729690|Experimental|2 single-dose pregabalin|Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
3265492|NCT00729690|Placebo Comparator|3 Placebo|Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
3265493|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 1)|BMS-936559 (MDX-1105)
3265494|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 2)|BMS-936559 (MDX-1105)
3265495|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 3)|BMS-936559 (MDX-1105)
3265496|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 4)|BMS-936559 (MDX-1105)
3265497|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 5)|BMS-936559 (MDX-1105)
3265498|NCT00729651|Experimental|1|Alendronate sodium/Cholecalciferol
3265499|NCT00729651|Active Comparator|2|Alendronate sodium
3265500|NCT00729638|Experimental|Single arm|Single arm phase I study
3265501|NCT00729612|Experimental|Treatment (nab-paclitaxel, carboplatin)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and carboplatin IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3265502|NCT00729599|Experimental|1|Cetylpyridinium chloride during 21 consecutive days.
3265503|NCT00729586|Experimental|Arm I (temsirolimus)|Patients receive temsirolimus IV over 30 minutes once weekly for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3265504|NCT00729586|Experimental|Arm II (temsirolimus, megestrol acetate, tamoxifen citrate)|Patients receive temsirolimus as in Arm I and megestrol acetate PO BID for 3 weeks alternating with tamoxifen citrate PO BID for 3 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3265505|NCT00729573||1|Participants in MTN-003. Participants will remain a part of their assigned MTN-003 study groups.
3265506|NCT00729560|Experimental|1|Flutamide
3265507|NCT00729560|Placebo Comparator|2|control to arm 1
3265508|NCT00729547|Placebo Comparator|2|Psychotherapy placebo session
3265509|NCT00729547|Experimental|1|Neurofeedback training which enhance left frontal alpha wave.
3265510|NCT00729521|No Intervention|Control|a control group receiving no special resources or guidance related to fall injury prevention or the community health improvement process;
3265511|NCT00729521|Active Comparator|Standard Program|"a Standard Program group receiving modest funding to implement an evidence-based fall prevention program in their local community;"
3265512|NCT00729521|Experimental|Facilitative System|"a Facilitative System group receiving facilitative system support in addition to the resources provided the Standard Program group"
3265513|NCT00729508|Experimental|1|
3265514|NCT00729508|Experimental|2|
3265515|NCT00729508|Experimental|3|
3265516|NCT00729508|Experimental|4|
3265517|NCT00729508|Placebo Comparator|5|
3265518|NCT00729495|Active Comparator|1|marketed celecoxib
3265519|NCT00729495|Experimental|2|overencapsulated celecoxib
3265520|NCT00729482|Experimental|1|Treatment Arm (RAD001)
3265521|NCT00729469|Experimental|Ospemifene 60 mg/day and K-Y® lubricant|Subjects will receive a single, oral dose (1 tablet) of ospemifene 60 mg each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.
3265568|NCT00729131||B|Case Group: subjects are homozygotic or heterozygotic for minor allele of TNF-308 promoter polymorphism.
3265807|NCT00727506|Active Comparator|TMZ|TMZ 21/28 days
3265522|NCT00729469|Placebo Comparator|Placebo and K-Y® lubricant|Subjects will receive a single, oral dose (1 tablet) of Placebo each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.
3265523|NCT00729456|No Intervention|1|
3265524|NCT00729456|Other|2|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
3265525|NCT00729443|Experimental|1|
3265526|NCT00729443|Placebo Comparator|2|
3265527|NCT00729430|Experimental|Omega-3 Fatty Acids|Participants will receive a highly purified form of omega-3 fatty acids for 6 months.
3265528|NCT00729430|Placebo Comparator|Placebo|Participants will receive placebo for 6 months.
3265529|NCT00729404|Experimental|Arm 1|
3265530|NCT00729404|Experimental|Arm 2|
3265531|NCT00729391|Experimental|1|Women's CoOp
3265532|NCT00729391|Active Comparator|2|Nutrition (Attention-Control)
3265533|NCT00729391|Active Comparator|3|Voluntary Counseling and Testing
3265534|NCT00729378|Experimental|Exercise Intervention|Implementation of intervention program designed to provide skeletal loading through high impact activities. All activities performed by subjects in exercise intervention arm will be assessed by physical activity questionnaire and use of pedometer. Have baseline anthropometric measurements, total body DXA scans and peripheral quantitative computed tomography (pQCT) scans of the tibia and femur.
3265535|NCT00729378|No Intervention|Control|Participants in this arm will not take part in exercise intervention. All activities performed by subjects in control arm will be assessed by physical activity questionnaire and use of pedometer. Have baseline anthropometric measurements, total body DXA scans and peripheral quantitative computed tomography (pQCT) scans of the tibia and femur.
3265536|NCT00729365|Placebo Comparator|Dippers - Placebo Treated|Subjects with normal nighttime blood pressure profile that decreases at night (Dippers). This group are all given placebo.
3265537|NCT00729365|Placebo Comparator|NonDippers - Placebo Treated|Subjects with nighttime blood pressure that does not drop during the night (non-dippers). This group will be given placebo.
3265538|NCT00729365|Active Comparator|NonDippers - Ramipril Treated|Subjects with nighttime blood pressure that does not drop during the night (non-dippers). This group will be given ACE inhibitor (study medication).
3265539|NCT00729352||Control group|18-35 yr old healthy subjects with wild type genotype for NQO1.
3265540|NCT00729352||Case group|18-35 yr old healthy subjects who are homozygotic for minor allele of NQO1 Pro187Ser polymorphism
3265541|NCT00729339|Active Comparator|1|lansoprazole plus mosapride for the first month, and followed by lansoprazole plus placebo for the second month
3265542|NCT00729339|Active Comparator|2|lansoprazole plus placebo for the first month, and lansoprazole plus mosapride for the second month
3265543|NCT00729326|Experimental|Sequence A|
3265544|NCT00729326|Experimental|Sequence B|
3265545|NCT00729313|Experimental|1|"Drug: Lanreotide 30 mg microparticle formulation~One intra-muscular injection.~A (maximum) 60 day treatment period (6 intra-muscular injections of lanreotide 30 mg microparticle formulation every 10 days): according to the patient's treatment response at 72h~For non-responders patients lanreotide will be stopped."
3265546|NCT00729313|Placebo Comparator|2|"One intra-muscular injection.~A (maximum) 60 day treatment period (6 intra-muscular injections of placebo every 10 days): according to the patient's treatment response at 72h.~Non-responder patients having received placebo on the first injection should receive an open-labelled lanreotide treatment."
3265547|NCT00729300|Placebo Comparator|1|Placebo
3265548|NCT00729300|Experimental|2|disulfiram
3265549|NCT00729287|Placebo Comparator|Arm I|Patients receive oral placebo daily in addition to standard care.
3265550|NCT00729287|Experimental|Arm II|Patients receive oral selenium daily in addition to standard care.
3265551|NCT00729274|Active Comparator|hypertonic saline solution|Hypertonic Saline 3% solution alone.
3265552|NCT00729274|Placebo Comparator|nebulized normal saline solution|2 nebulisation with 30 minute interval (max 4ml)
3265553|NCT00729261|Experimental|armA I|Patients remain intubated until the patients Glasgow coma score improves to greater than 8.
3265554|NCT00729261|Experimental|arm 2|Patients that meet standard airway and ventilatory criteria for extubation but have a Glasgow coma score of less than or equal to 8 are immediately extubated.
3265555|NCT00729235|Experimental|1|"Slow VT zone programmed as a Monitoring zone (Monitoring arm)"
3265556|NCT00729235|Experimental|2|Slow VT zone programmed with ATP therapies (therapy arm).
3265557|NCT00729222|Placebo Comparator|1|Placebo
3265558|NCT00729222|Experimental|2|rolofylline
3265559|NCT00729209|Experimental|ARRY-371797 (Schedule 1)|
3265560|NCT00729209|Experimental|ARRY-371797 (Schedule 2)|
3265561|NCT00729209|Placebo Comparator|Placebo|
3265562|NCT00729196|Experimental|1|Low-Glycemic Load Diet
3265563|NCT00729196|Active Comparator|2|Low-Fat Diet
3265564|NCT00729183|Experimental|Odanacatib 50 mg|Participants receive 50 mg odanacatib and open-label 5600 IU vitamin D3 tablets once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
3265565|NCT00729183|Placebo Comparator|Placebo|Participants receive matching placebo to odanacatib and open-label 5600 IU vitamin D3 once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
3265566|NCT00729157|Experimental|Treatment (ziv-aflibercept and fludeoxyglucose F 18)|Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients experiencing clear clinical benefit with aflibercept may continue treatment beyond 12 months, at the discretion of the study sponsor. Patients undergo FDG-PET scans at baseline and after 8 weeks of study therapy to evaluate changes in FDG avidity on FDG-PET scan. Blood samples are obtained at baseline and periodically during study for laboratory correlative studies. Samples are examined for pretreatment serum VEGF concentration, thyroglobulin levels (when elevated), serum pharmacokinetics of aflibercept by ELISA, and anti-aflibercept antibodies.
3265567|NCT00729131||A|Control group: subjects are homozygotic for major allele for TNF-308 promoter polymorphism.
3265569|NCT00729118|Experimental|Lenalidomide + Vorinostat|Maintenance post autologous transplant
3265570|NCT00729079|Active Comparator|1|Subject will be randomly assigned to work with providers at Clinton Medical Associates
3265571|NCT00729079|Active Comparator|2|Subjects will be randomly assigned to work with providers at 1655 Elmwood AVe, Suite 125
3265572|NCT00729053|Active Comparator|Previous treatment, 0.16mg/kg|Patients will have clear cell renal carcinoma with previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.16mg/kg
3265573|NCT00729053|Active Comparator|Previous treatment, 0.64mg/kg|Patients will have clear cell renal carcinoma with previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.64mg/kg
3265574|NCT00729053|Active Comparator|Treatment Naive, 0.16mg/kg|Patients will have clear cell renal carcinoma without previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.16mg/kg
3265575|NCT00729053|Active Comparator|Treatment Naive, 0.64mg/kg|Patients will have clear cell renal carcinoma without previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.64mg/kg
3265576|NCT00729040|Active Comparator|1|Stepping Up to Health only
3265577|NCT00729040|Experimental|2|Stepping up to Health PLUS online message boards to talk with other participants
3265578|NCT00729027|Experimental|25 mg/day AVE5530|
3265579|NCT00729027|Experimental|50 mg/day AVE5530|
3265580|NCT00729027|Placebo Comparator|Placebo|
3265581|NCT00729001|Experimental|Group A|Human Rotavirus Vaccine - Formulation 1
3265582|NCT00729001|Experimental|Group B|Human Rotavirus Vaccine - Formulation 2
3265583|NCT00729001|Placebo Comparator|Group C|
3265584|NCT00728988|Experimental|Atorvastatin Group|
3265585|NCT00728988|Other|Usual Care Group|
3265586|NCT00728975||1|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Vancouver Centre,
3265587|NCT00728975||2|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Centre for Southern Interior
3265588|NCT00728975||3|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Fraser Valley Centre
3265589|NCT00728975||4|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Vancouver Island Centre
3265590|NCT00728975||5|Vancouver Coastal Cottage Hospice inpatients
3265591|NCT00728975||6|Vancouver Coastal Richmond Palliative Care Program patients
3265592|NCT00728975||7|Vancouver Coastal Lions Gate Palliative Care Unit inpatients
3265593|NCT00728975||8|Providence Health St Paul's Hospital Palliative Care Unit inpatients
3265594|NCT00728975||9|Providence Health Marion Hospice inpatients
3265595|NCT00728975||10|Vancouver Island Health Authority Victoria Hospice inpatients
3265596|NCT00728975||11|Fraser Health Burnaby Hospital Tertiary Palliative Care Unit inpatients
3265597|NCT00728975||12|Fraser Health Mission Hospice inpatients
3265598|NCT00728975||13|Fraser Health Langley Hospice inpatients
3265599|NCT00728949|Active Comparator|IMC-A12 (cixutumumab) + antiestrogen therapy|Participants will receive intravenous IMC-A12 10 mg/kg over 1 hour every 2 weeks, as well as the same dose and schedule of the last antiestrogen therapy to which their disease became refractory.
3265600|NCT00728949|Experimental|IMC-A12 (cixutumumab)|Participants will receive only IMC-A12 (10 mg/kg over 1 hour every 2 weeks).
3265601|NCT00728936|Experimental|1|IMO-2125, with 4 dose levels
3265602|NCT00728936|Placebo Comparator|2|
3265603|NCT00728923|Experimental|1|Minocycline (NPL-2003)
3265604|NCT00728910|Active Comparator|Atorvastatin|atorvastatin 10 mg/day by mouth for a total duration of 4 weeks
3265605|NCT00728910|Active Comparator|ABT335|ABT335 135 mg/day by mouth added to atorvastatin for a total duration of at least 8
3265606|NCT00728910|Active Comparator|ER niacin|ER niacin titrated up to 2 g/day with aspirin 325 mg/day by mouth added to atorvastatin and ABT335 for 10 weeks
3265607|NCT00728897|Experimental|Subjects receiving treatment sequence ABC|Eligible subjects will receive treatment sequence ABC; A= 4x25 milligrams GSK598809 capsule given in fasted state, B= 100 milligrams GSK598809 capsule in given fasted state and C= 100 milligrams GSK598809 capsule given in fed state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
3265608|NCT00728897|Experimental|Subjects receiving treatment sequence ACB|Eligible subjects will receive treatment sequence ACB; A= 4x25 milligrams GSK598809 capsule given in fasted state, C= 100 milligrams GSK598809 capsule given in fed state and B= 100 milligrams GSK598809 capsule in given fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
3265609|NCT00728897|Experimental|Subjects receiving treatment sequence BAC|Eligible subjects will receive treatment sequence BAC; B= 100 milligrams GSK598809 capsule in given fasted state, A= 4x25 milligrams GSK598809 capsule given in fasted state and C= 100 milligrams GSK598809 capsule given in fed state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
3265610|NCT00728897|Experimental|Subjects receiving treatment sequence BCA|Eligible subjects will receive treatment sequence BCA; B= 100 milligrams GSK598809 capsule in given fasted state, C= 100 milligrams GSK598809 capsule given in fed state and A= 4x25 milligrams GSK598809 capsule given in fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
3265611|NCT00728897|Experimental|Subjects receiving treatment sequence CAB|Eligible subjects will receive treatment sequence CAB; C= 100 milligrams GSK598809 capsule given in fed state, A= 4x25 milligrams GSK598809 capsule given in fasted state and B= 100 milligrams GSK598809 capsule in given fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
3265612|NCT00728897|Experimental|Subjects receiving treatment sequence CBA|Eligible subjects will receive treatment sequence CBA; C= 100 milligrams GSK598809 capsule given in fed state, B= 100 milligrams GSK598809 capsule in given fasted state and A= 4x25 milligrams GSK598809 capsule given in fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
3265613|NCT00728845|Experimental|Hydroxychloroquine, Carboplatin, Paclitaxel, Bevacizumab|Cohort 1: Bevacizumab Eligible Patients All on Day 1 Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Bevacizumab 15 mg/kg IV over 90 min for PLUS Hydroxychloroquine 200 mg PO BID Cycles every 3 weeks for 4-6 Cycles
3265660|NCT00728468|Experimental|Treatment arm|
3265661|NCT00728455|Experimental|A|
3265662|NCT00728455|Experimental|B|
3265614|NCT00728845|Experimental|Hydroxychloroquine, Carboplatin, Paclitaxel|Cohort 2: Bevacizumab Ineligible Patients All on Day 1 Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min PLUS Hydroxychloroquine 200 mg PO BID Cycles every 3 weeks for 4-6 Cycles
3265615|NCT00728832|Active Comparator|1|No test dose + DepoDur + flush with 1 mL normal saline
3265616|NCT00728832|Experimental|2|Test dose + flush with 1 mL normal saline + 3-minute wait + DepoDur + flush with 1 mL normal saline
3265617|NCT00728832|Experimental|3|Test dose + flush with 1 mL normal saline + 10-minute wait + DepoDur + flush with 1 mL normal saline
3265618|NCT00728832|Experimental|4|Test dose + flush with 1 mL normal saline + 15-minute wait + DepoDur + flush with 1 mL normal saline
3265619|NCT00728832|Experimental|5|Test dose + No flush + 3-minute wait + DepoDur + flush with 1 mL normal saline
3265620|NCT00728819|Active Comparator|1|Tapered PICC
3265621|NCT00728819|Active Comparator|2|Non-tapered PICC
3265622|NCT00728780|Experimental|A|ABT-143 15/135mg
3265623|NCT00728780|Active Comparator|B|ABT-335 135mg and rosuvastatin 15mg
3265624|NCT00728767|Experimental|1|
3265625|NCT00728767|Placebo Comparator|2|
3265626|NCT00728754|Experimental|Dental implant Osseotite Prevail|Dental implant with lateralized design
3265627|NCT00728754|Active Comparator|Dental implant Osseotite|Dental implant without the lateralized design
3265628|NCT00728728|Active Comparator|Arm 1: Pregnenolone|Pregnenolone
3265629|NCT00728728|Placebo Comparator|Arm 2: Placebo|Placebo
3265630|NCT00728715|Experimental|A|Medium Dose of budesonide-formoterol
3265631|NCT00728715|Active Comparator|B|High dose of inhaled budesonide (1600 mcg/day)
3265632|NCT00728689|Active Comparator|Group ST-246 Form I (followed by Form V)|Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.
3265633|NCT00728689|Active Comparator|Group ST-246 Form V (followed by Form I)|Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.
3265634|NCT00728663|Experimental|Arm: Cetuximab and Docetaxel|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8 and Docetaxel: 75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
3265635|NCT00728650||Observation|Patients with primary or metastatic hepatic malignancies
3265636|NCT00728637|Experimental|1|Participants took part in the Family Passport to Heart Health Program.
3265637|NCT00728637|Active Comparator|2|Participants took part in a control group.
3265638|NCT00728611|Experimental|1|
3265639|NCT00728611|Active Comparator|2|
3265640|NCT00728611|Placebo Comparator|3|
3265641|NCT00728598||1|Proliferative diabetic retinopathy, active.
3265642|NCT00728598||2|Proliferative diabetic retinopathy, quiescent.
3265643|NCT00728598||3|Control group. Patients with macular hole or idiopathic epiretinal membrane receiving vitrectomy for their disease.
3265644|NCT00728585|Experimental|Arm I (palifermin)|Patients receive palifermin IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity. Patients then receive palifermin IV on days 0, 1, and 2 after autologous or allogeneic hematopoietic stem cell transplantation.
3265645|NCT00728585|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity. Patients then receive placebo IV on days 0, 1, and 2 after autologous or allogeneic hematopoietic stem cell transplantation.
3265646|NCT00728572|Experimental|Experimental|Participant will receive a brief exam, a Basic Technique apex contact adjustment and Surface EMG.
3265647|NCT00728572|Sham Comparator|Sham|Participants will receive a sham Basic Technique adjustment (an adjacent contact not indicated by examination)and surface EMG.
3265648|NCT00728559|Experimental|1|preemptive trocar site analgesia
3265649|NCT00728559|Experimental|2|trocar site pre skin closure analgesia
3265650|NCT00728559|No Intervention|3|control
3265651|NCT00728546|Experimental|INA dose adjustment, NAT2|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
3265652|NCT00728533|Experimental|1|"Starting dose of 240 mg (40 mg/mL) will be given on Day 0.~Maintenance doses of 360 mg (60 mg/mL) will be given after 1, 4, 7, and 10 months"
3265653|NCT00728533|Experimental|2|"Starting dose of 240 mg (40 mg/mL) will be given on Day 0.~Maintenance doses of 480 mg (60 mg/mL) will be given after 1, 4, 7, and 10 months."
3265654|NCT00728507|Experimental|1|Two months of isoniazid, rifapentine, pyrazinamide and moxifloxacin (HPZM) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
3265655|NCT00728507|Active Comparator|2|Two months of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
3265656|NCT00728494||Treatment and Patient Assistance Program|Patient assistance program was provided to the participants treated with PegIntron/Rebetol. The support program consisted of training by physicians or specialized nurses on the significance of treatment compliance, methods for managing adverse events, and correct drug administration, as well as informational materials and assistance in the management of adverse events.
3265657|NCT00728494||Treatment Alone|PegIntron/Rebetol treatment only.
3265658|NCT00728481|Active Comparator|Esomeprazole|Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks for subjects with positive 24 hour pH study (GERD)
3265659|NCT00728481|Active Comparator|Budesonide|Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose [Splenda-registered trademark]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
3265666|NCT00728442|Experimental|1|medical decision based on computerized guideline-based decision support system
3265667|NCT00728442|No Intervention|2|
3265668|NCT00728429|No Intervention|standard of care|normal anthracycline therapy
3265669|NCT00728429|Experimental|exercise program|
3265670|NCT00728416|Experimental|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
3265671|NCT00728416|Placebo Comparator|Arm 2|Matching placebo nasal spray
3265672|NCT00728403|Experimental|1|American Ginseng and American Red Ginseng Capsules
3265673|NCT00728403|Experimental|2|American Ginseng Capsules
3265674|NCT00728403|Placebo Comparator|3|Placebo Capsules
3265675|NCT00728390|Experimental|1|
3265676|NCT00728377|Active Comparator|Heath & Wellness|
3265677|NCT00728377|Experimental|Exercise|
3265678|NCT00728351|Experimental|vildagliptin + metformin|
3265679|NCT00728351|Active Comparator|metformin|
3265680|NCT00728338|Experimental|1|Martek Biosciences Corporation Neuromins Capsules 7.5 g DHA oil/day
3265681|NCT00728338|Placebo Comparator|2|7.5 g/ day olive oil
3265682|NCT00728325|Active Comparator|1|Standard Vocational Rehabilitation (VRP)
3265683|NCT00728325|Experimental|2|Supported Employment (SE)
3265684|NCT00728312|Active Comparator|1|Aripiprazole (Abilify), flexible dosing 5-15 mg per day
3265685|NCT00728312|Placebo Comparator|2|Placebo look-alike, flexible dosing 5-15 mg per day
3265686|NCT00728299|Experimental|1|
3265687|NCT00728299|Placebo Comparator|2|
3265688|NCT00728286||Type 2 diabetes mellitus|We aim to determine the effects of dual antiplatelet therapy with aspirin 75mg once a day and clopidogrel 75mg once a day on platelet dependent thrombogenicity in patients with type 2 diabetes mellitus and acute coronary syndrome. Eighty patients (40 with type 2 diabetes and 40 without) have been studied one week after Non ST-elevation acute coronary syndrome. All patients were on secondary prevention therapy as recommended by international guidelines.
3265689|NCT00728273|Experimental|MMF|multi-micronutrient-fortified biscuit plus placebo deworming-treatment
3265690|NCT00728273|Experimental|Alb|placebo biscuit plus deworming treatment with Albendazole
3265691|NCT00728273|Experimental|MMF + Alb|multiple micronutrient-fortified biscuits with deworming treatment with Albendazole
3265692|NCT00728273|Placebo Comparator|placebo|placebo biscuit (non-fortified) and placebo deworming treatment
3265693|NCT00728260||Menactra Vaccine Recipients|"Children 2 years through 10 years of age who received Menactra vaccine within Kaiser Permanente during the study period. They served as their own controls for evaluation of acute (Days 0-30) events. Rates of events occurring during Days 0-30 following vaccination were compared to rates of events occurring during Days 31-60 following vaccination.~Six-month surveillance: For each individual receiving Menactra vaccine, the rate of an event in the 30-day follow-up period was compared with the rate of the same event in the 31-180-day follow-up period using age, sex, and seasonality as covariates in Cox regression analyses.~Menactra vaccine was administered according to routine clinical practice."
3265694|NCT00728234||1|all infants born below 30 weeks gestational age at the medical university vienna within the study period (01/2000 - 12/2002)
3265695|NCT00728221|Placebo Comparator|1|Placebo capsules (3g)
3265696|NCT00728221|Experimental|2|Whole Korean Red Ginseng root (3g)
3265697|NCT00728221|Experimental|3|Ginsenoside fraction of Korean Red Ginseng B (0.22g); bioequivalent to the original whole KRG root
3265698|NCT00728221|Experimental|4|Polysaccharide fraction of KRG root (0.21g); bioequivalent to the original whole KRG root
3265699|NCT00728208|Experimental|GSK372475|Drug
3265700|NCT00728195|Placebo Comparator|Placebo First, Then Olanzapine|Participants will receive 2 matching placebo capsules orally twice daily for 6 consecutive weeks, then 2 matching placebo capsules orally in the morning and olanzapine 10 milligram (mg) capsule along with matching placebo capsule orally in the evening for next 1 week, then 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with olanzapine 5 mg capsule orally in the evening for next 5 weeks.
3265701|NCT00728195|Experimental|JNJ-37822681 10 mg|Participants will receive 1 matching placebo capsule along with JNJ-37822681 10 mg capsule orally twice a day for 12 consecutive weeks.
3265702|NCT00728195|Experimental|JNJ-37822681 20 mg|Participants will receive 1 matching placebo capsule along with JNJ-37822681 20 mg capsule orally twice a day for 12 consecutive weeks.
3265703|NCT00728195|Experimental|JNJ-37822681 30 mg|Participants will receive JNJ-37822681 30 mg (one 10 mg capsule along with JNJ-37822681 20 mg capsule) orally twice a day for 12 consecutive weeks.
3265704|NCT00728195|Active Comparator|Olanzapine|Participants will receive 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with matching placebo capsule orally in the evening for 1 week, then 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with olanzapine 5 mg capsule orally in the evening for next 11 consecutive weeks.
3265705|NCT00728182|Experimental|NA-1|20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
3265706|NCT00728182|Placebo Comparator|Placebo|
3265707|NCT00728156|Active Comparator|C|Patients assigned to clopidogrel in addition to their standard care.(all patients will be on aspirin)We aim to study the effect of clopidogrel as dual antiplatelet therapy in patients with established coronary artery disease and type 2 diabetes. Ninety patients with type 2 diabetes and stable coronary artery disease has been randomly treated with clopidogrel or placebo (45 each) for one week in addition to their standard care (including aspirin,75 mg once daily).
3265708|NCT00728156|Placebo Comparator|P|Patients assigned to placebo in addition to their standard care.(all patients will be on aspirin).This is a single-centre randomised double-blind placebo-controlled parallel design study, comparing efficacy of clopidogrel versus placebo in patients with T2DM and coronary artery disease. Ninety patients have completed the study. All patients were on their routine medications as per standard practice. After informed consent, participants were randomised to receive either clopidogrel 75mg daily or placebo for 7 days.
3265709|NCT00728143|Active Comparator|1|Healthy subjects
3265710|NCT00728143|Experimental|2|Diabetic subjects
3265711|NCT00728130|Experimental|A|A neck dissection of at least the ipsilateral sub-level 1B will be performed in all patients
3265712|NCT00728117|Experimental|ibuprofen-feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen and 24 hours after the last dose of ibuprofen.
3265713|NCT00728117|Experimental|ibuprofen-fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen and 24 hours after the last dose of ibuprofen.
3265714|NCT00728117|Experimental|indomethacin-feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of indomethacin and 24 hours after the last dose of indomethacin.
3265715|NCT00728117|Experimental|indomethacin-fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of indomethacin and 24 hours after the last dose of indomethacin.
3265716|NCT00728104||1|The General Questionnaire: help to understand which characteristics of CVS patients are associated with both beneficial and harmful effects of these treatments
3265717|NCT00728104||2|The Co-Enzyme Q10 Questionnaire: to be completed by individuals who ever taken co-enzyme Q10
3265718|NCT00728104||3|The L-Carnitine Questionnaire: to be completed by individuals who have ever taken L-carnitine
3265719|NCT00728104||4|The Amitriptyline Questionnaire: to be completed by individuals who have ever taken amitriptyline
3265720|NCT00728091|Experimental|Satavaptan Dose 1|Fixed Low dose up to day 4, followed by optional titration up to day 30
3265721|NCT00728091|Experimental|Satavaptan Dose 2|Fixed High dose up to day 4, followed by optional titration up to day 30
3265722|NCT00728091|Placebo Comparator|Placebo|
3265723|NCT00728078|Experimental|1|low-dose thalidomide adjuvant therapy after RFA for HCC
3265724|NCT00728078|No Intervention|2|control group
3265725|NCT00728065|Experimental|1|White Bread (control)
3265726|NCT00728065|Experimental|2|White Bread (control)
3265727|NCT00728065|Experimental|3|White bread with 7.32 grams Salba hispanica
3265728|NCT00728065|Experimental|4|White bread with 15.58 grams Salba hispanica
3265729|NCT00728065|Experimental|5|White bread with 24 grams Salba hispanica
3265730|NCT00728065|Experimental|6|Rice Milk (control)
3265731|NCT00728065|Experimental|7|Rice Milk (control)
3265732|NCT00728065|Experimental|8|Rice Milk with 7.32 grams Salba hispanica
3265733|NCT00728065|Experimental|9|Rice Milk with 15.58 grams Salba hispanica
3265734|NCT00728065|Experimental|10|Rice Milk with 24 grams Salba hispanica
3265735|NCT00728052|Experimental|Subjects receiving treatment sequence ABCD|Subjects will receive treatment sequence ABCD; A= placebo, B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, and D = GSK598809 dose 3.
3265736|NCT00728052|Experimental|Subjects receiving treatment sequence BACD|Subjects will receive treatment sequence BACD; B= GSK598809 dose 1 (75 milligrams), A= placebo, C = GSK598809 dose 2 and D = GSK598809 dose 3
3265737|NCT00728052|Experimental|Subjects receiving treatment sequence BCAD|Subjects will receive treatment sequence BCAD; B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, A= placebo and D = GSK598809 dose 3.
3265738|NCT00728052|Experimental|Subjects receiving treatment sequence BCDA|Subjects will receive treatment sequence BCDA; B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, D = GSK598809 dose 3 and A= placebo.
3265739|NCT00728026||1|Cyclic Vomiting Syndrome
3265740|NCT00728026||2|Irritable Bowel Syndrome
3265741|NCT00728026||3|Postural Orthostatic Tachycardia Syndrome
3265742|NCT00728026||4|Functional Abdominal Pain
3265743|NCT00728026||5|Chronic Nausea
3265744|NCT00728013|Experimental|A|intensive statin group
3265745|NCT00728013|Experimental|B|moderate statin group
3265746|NCT00728000|Experimental|chemotherapy regimen|Gemcitabine and oxaliplatin are given intravenously (into the vein) every 2 weeks. Erlotinib is a pill that is taken by mouth daily.
3265747|NCT00727987|Experimental|CNTO 148 50 mg + methotrexate|
3265748|NCT00727987|Experimental|CNTO 148 100 mg + methotrexate|
3265749|NCT00727987|Placebo Comparator|Placebo + methotrexate|
3265750|NCT00727974||1|"Diagnostic Criteria for CVS:~3 or more different episodes of vomiting, normal health between episodes, no abnormal test results to account for vomiting [such as endoscopic biopsies (looking at a body part with a lighted tube), hydronephrosis (water block kidney drainage), cholelithiasis (gallstones), pancreatitis (swelling of the pancreas), and hypoglycemia (too little sugar in the blood)];"
3265751|NCT00727974||2|"Diagnostic Criteria for Migraine:~5 or more different headaches, complete return to health in between headaches, headaches last 2-48 hours and get in the way everyday activity, headache affects one side of head, with pounding moderate-to-severe pain, one of the following: nausea, vomiting, photophobia (fear of light), phonophobia (fear of sound)."
3265752|NCT00727961|Experimental|Arm 1|Caelyx Intravenous, 50 mg/m^2, given for 6 cycles
3265753|NCT00727922|Experimental|1|
3265754|NCT00727909|Experimental|Hearing Aid Treatments|"Hearing aid treatments:~TC (Traditional Custom), RITA (Receiver-in-the Aid), and RITE (Receiver-in the-Ear)"
3265755|NCT00727896|Experimental|1 is experimental with SMS|Arm 1 is experimental with SMS intervention
3265756|NCT00727896|Active Comparator|2 is (active comparator) standard care|Arm 2 is the usual care arm (standard care)
3265757|NCT00727883||1|Post menopausal women treated with adjuvant TAM for breast cancer
3265758|NCT00727870|Other|1|After the two biopsies, one site will be covered with the antibiotic ointment and the band-aid type bandage (physician's current standard of care) and the other site will be covered the Shapes by PolyMem dressing.
3265759|NCT00727870|Other|2|Arm 2: after the two biopsies, one site will be covered with the antibiotic ointment and the band-aid type bandage (physician's current standard of care) and the other site will be covered the Shapes by PolyMem Silver dressing.
3265760|NCT00727870|Other|3|Arm 3: after the two biopsies, one site will be covered with Shapes by PolyMem dressing and the other site will be covered the Shapes by PolyMem Silver dressing.
3265761|NCT00727857|Experimental|Pioglitazone 15 mg /Metformin 850 mg BID|
3265762|NCT00727857|Active Comparator|Pioglitazone 15 mg BID|
3265764|NCT00727844|Experimental|Delayed Start Linezolid|Subjects continued their existing regimen for 2 months after which LZD (600 mg once daily) was added. After 2 consecutive AFB negative sputum smears (not to exceed 4 months of LZD therapy), subjects were randomized to continue on 600 mg LZD once daily or to de-escalate to 300 mg once daily. Regardless of the dosage, subjects remained on LZD treatment for 18 months after sputum culture conversion or until they could no longer tolerate therapy.
3265765|NCT00727844|Experimental|Immediate Start Linezolid|Upon completion of entry criteria, subjects had LZD (600 mg once daily) added to their regimen. After 2 consecutive AFB negative sputum smears (or at 4 months) subjects were randomized to continue on 600 mg LZD once daily or to de-escalate to 300 mg once daily. Regardless of the dosage, subjects remained on LZD treatment for 18 months after sputum culture conversion or until they could no longer tolerate therapy.
3265766|NCT00727792|Experimental|Group 2 - Research MRI|Subjects will have additional sequences and/or modification to MRI sequences.
3265767|NCT00727792|Active Comparator|Group 1 - Clinical MRI|Clinically ordered MRI scan. Subjects will not have any additional sequences or modifications to their clinically ordered MRI
3265768|NCT00727779|Experimental|metabolic syndrome|intervention is to undergo eight weeks of progressive strength training; metabolic syndrome subjects will have baseline and post-intervention assessments including muscle biopsies and insulin clamps
3265769|NCT00727779|Active Comparator|control subjects|intervention is to undergo eight weeks of progressive strength training; non-obese sedentary subjects will have the same assessments as the metabolic syndrome subjects and exercise training simultaneously.
3265770|NCT00727766|Experimental|Cohort 1|Clofarabine 1 mg for 14 days followed by 14 days of rest. Each cycle is 28 days long.
3265771|NCT00727766|Experimental|Cohort 2|Clofarabine 2 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
3265772|NCT00727766|Experimental|Cohort 3|Clofarabine 3 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
3265773|NCT00727766|Experimental|Cohort 4|Clofarabine 4 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
3265774|NCT00727766|Experimental|Cohort 5|Clofarabine 5 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
3265775|NCT00727766|Experimental|Cohort 6|Clofarabine 6 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
3265776|NCT00727753||Ranibizumab|
3265777|NCT00727753||Bevacizumab|
3265778|NCT00727753||Dry AMD|
3265779|NCT00727740|Experimental|1|Indomethacin liquid suspension 100 mg (25 mg/5ml) which is 20 cc of suspension instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
3265780|NCT00727740|Placebo Comparator|2|Placebo suspension in the same volume (20 cc) which is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. The placebo suspension is also flushed with 5 cc of normal saline.
3265781|NCT00727727||Parkinsonian patients|
3265782|NCT00727701|Experimental|1|Will receive usual wound prevention care, aftercare summaries, and regular surveillance.
3265783|NCT00727701|No Intervention|2|Will receive usual wound prevention and surveillance only.
3265784|NCT00727701|No Intervention|3|Will receive usual wound prevention only.
3265785|NCT00727675|Other|1|Integrated Cognitive Behavioral Therapy for pain reduction and opioid dependence.
3265786|NCT00727662|Experimental|1|Yoga
3265787|NCT00727662|Active Comparator|2|A Wellness Seminar series
3265788|NCT00727649|Active Comparator|Arm 1|Fiber (psyllium) powder
3265789|NCT00727649|Active Comparator|Arm 2|Loperamide
3265790|NCT00727636|Experimental|Gardasil vaccine - Prospective Study|Prospective study participants received the Gardasil vaccine during the study
3265791|NCT00727636|No Intervention|Retrospective Study|Retrospective study participants had blood drawn in the study after they had received the Gardasil vaccine from their primary medical provider
3265792|NCT00727597|Experimental|Arm A : Boosted Lexiva plus Epzicom|Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg).
3265793|NCT00727597|Experimental|Arm B: Efavirenz plus Epzicom|QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)
3265794|NCT00727584|Active Comparator|Arm I (multi-fraction radiotherapy)|Patients undergo 5 fractions of 20 Gy external-beam radiotherapy.
3265795|NCT00727584|Experimental|Arm II (single-fraction radiotherapy)|Patients undergo 1 fraction of 8 Gy external beam radiotherapy.
3265796|NCT00727571||No CKD or Anemia|Chronic kidney disease (CKD) is based on estimated Glomerular Filtration Rate (GFR), calculated by the Modification of Diet in Renal Disease (MDRD) method, of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per World Health Organization (WHO) criteria. Participants completed the study after Week 1; data contributed to prevalence estimates.
3265797|NCT00727571||No CKD, but Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants completed the study at Week 2 and completed an anemia work-up; data contributed to prevalence estimates.
3265798|NCT00727571||CKD with Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants were observed for 26 weeks and completed an anemia work-up, and mobility and physical performance assessments.
3265799|NCT00727571||CKD with no Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants were observed for 26 weeks and completed mobility and physical performance assessments.
3265800|NCT00727558|Active Comparator|narafilcon A|spherical soft contact lens worn as a daily disposable modality for one week
3265801|NCT00727558|Active Comparator|nelfilcon A|spherical soft contact lens worn as a daily disposable modality for one week
3265802|NCT00727545|Experimental|1|
3265803|NCT00727532|Experimental|Sorafinib|Sorafinib 400mg orally twice daily on days 1-28
3265804|NCT00727519|Experimental|PG|
3265805|NCT00727519|Experimental|PL|
3265806|NCT00727506|Experimental|BIBW 2992|BIBW 2992 once daily
3265808|NCT00727506|Experimental|BIBW 2992 plus TMZ|BIBW 2992 once daily plus TMZ 21/28 days
3265809|NCT00727493|Active Comparator|1|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily, dental implant
3265810|NCT00727493|Placebo Comparator|2|placebo once weekly, calcium 1000mg and Vitamin D 800 IU daily; dental implant
3265811|NCT00727493|No Intervention|3|dental implant, calcium 1000mg and Vitamin D 800 IU daily
3265812|NCT00727480|Experimental|A|Ultrasound Imaging of fingertips
3265813|NCT00727467|Experimental|A|"On Days 1-8 of the trial, participants in Group A will be given the iPod with some music on the device to allow all participants to become familiar with the device i.e. turning device on and off, increasing and decreasing the volume. They will be instructed to use the device only when sitting at home, and that the device should not be turned on when walking or performing any mobility related or daily tasks.~On Days 8-15, participants in Group A will be allocated to the 'intervention' phase. Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks. On Days 15-23, participants in Group A will be allocated to the 'control' phase. During this time period, participants will be provided with the iPod shuffle containing no music or metronome beat."
3265814|NCT00727467|Active Comparator|B|"On Days 1-8 of the trial, participants in Group B will be given the iPod with some music on the device to allow all participants to become familiar with the device. They will be instructed to use the device only when sitting at home, and that the device should not be turned on when walking or performing any mobility related or daily tasks.~On Days 8-15, participants in Group B will be allocated to the 'control' phase. During this time period, participants will be provided with the iPod shuffle containing no music or metronome beat. On Days 15-23, participants in Group B will be allocated to the 'intervention phase'. Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks."
3265815|NCT00727454|Placebo Comparator|1 Control|No treatment
3265816|NCT00727454|Experimental|2 CPAP|Continuous Positive Airway Pressure (CPAP) - REMStar Pro with C-Flex; Respironics, Inc., Murrysville, PA
3265817|NCT00727441|Experimental|Arm A|Patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 1 and undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive an additional dose of the vaccine. Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1. Treatment with the vaccine repeats every 28 days for 4 courses.
3265818|NCT00727441|Experimental|Arm B|Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 courses.
3265819|NCT00727441|Experimental|Arm C|Patients receive GVAX pancreatic cancer vaccine ID on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Treatment with the vaccine and cyclophosphamide repeats every 28 days for 4 courses.
3265820|NCT00727428|Experimental|Group A|
3265821|NCT00727402||Observational|healthy patients fit into lotrafilcon A contact lenses for continuous wear
3265822|NCT00727389|Other|groups of women|To evaluate the capacity of muscular function and articular amplitude in the aged women
3265823|NCT00727376||Observation|Esophageal cancer patients
3265824|NCT00727363|Placebo Comparator|1|5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital. Patients fed through NG tube will be administered 5 drops of placebo through the NG tube followed by a 0.5 cc of a normal saline flush. Patients taking PO feeds will be administered 5 drops of placebo in posterior oropharynx after secretions have been suctioned.
3265825|NCT00727363|Experimental|2|5 drops of Lactobacillus reuteri DSM 17938 from an oil based suspension will be administered once a day until death or discharge home. Patients with NG feeds will be administered the probiotic in the amount of 5 drops through the NG tube followed by 0.5 cc of a normal saline flush. Patients with PO feeds will be administered 5 drops of the probiotics in the posterior oropharynx after secretions have been suctioned. If feeds are temporarily suspended because of feeding intolerance or NEC, the probiotic may be re-started once feeds are re-started.
3265826|NCT00727350|Experimental|1|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
3265827|NCT00727337|Experimental|LACE-DVD|Participants will complete the LACE training, however, not in an interactive computer mode but through a static DVD mode
3265828|NCT00727337|Experimental|LACE-COMPUTER|Participants will complete a computer-based auditory training program (i.e., LACE)
3265829|NCT00727337|Active Comparator|PLACEBO-DIRECTED LISTENING|Participants will complete a directed listening to books on CD treatment
3265830|NCT00727337|Active Comparator|CONTROL|Participants will be provided with hearing aids
3265831|NCT00727324|Experimental|1|BIAP
3265832|NCT00727311||PegIntron + Rebetol|Participants with chronic hepatitis C, who are either treatment-naïve or previously relapsed after receiving interferon monotherapy
3265925|NCT00726544|Active Comparator|Low Dose|
3265833|NCT00727298||Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
3265834|NCT00727285||A|CF patients followed by the Adult CF Program at National Jewish Health meeting criteria for an acute pulmonary exacerbation.
3265835|NCT00727272|Experimental|Quinine Sulfate Caps 324 mg - Fasting|A single dose of quinine sulfate 324 mg administered with 240 mL of room temperature water after an overnight fast of at least 10 hours.
3265836|NCT00727272|Experimental|Quinine Sulphate Tabs 300 mg - Fasting|A single dose of quinine sulphate 300 mg administered with 240 mL of room temperature water after an overnight fast of at least 10 hours.
3265837|NCT00727272|Experimental|Quinine Sulfate Caps 324 mg - Fed|A single dose of quinine sulfate 324 mg administered with 240 mL of room temperature water thirty minutes after the initiation of a standardized, high-fat breakfast.
3265838|NCT00727259||Patients with chronic hepatitis C|Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol.
3265839|NCT00727246|Experimental|CDP-Choline|Treatment with CDP-Choline
3265840|NCT00727246|Placebo Comparator|Placebo|Treatment with Placebo
3265841|NCT00727220||Insulin Pump Therapy|Children starting insulin pump therapy
3265842|NCT00727220||Insulin Injections|Children remaining on insulin injections.
3265843|NCT00727194|Experimental|1|eculizumab
3265844|NCT00727194|Placebo Comparator|2|Placebo
3265845|NCT00727181|Other|Trifecta Valve|The Trifecta valve is a tri-leaflet stented pericardial valve designed for supra-annular placement in the aortic position.
3265846|NCT00727155|Experimental|1|Treatment
3265847|NCT00727155|No Intervention|2|Waitlist
3265848|NCT00727142|Active Comparator|open shunt|functioning shunt
3265849|NCT00727142|Active Comparator|closed shunt|NON FUNCTIONING SHUNT
3265850|NCT00727116|Experimental|State-wide|All parents of newborns in Pennsylvania hospitals will receive the parent education materials
3265851|NCT00727116|Experimental|Central PA|All of Central PA new parents will receive the state-wide hospital-based intervention. In half of the 31 central PA counties, all primary care providers having offices in those counties provide an office-based booster intervention to new parents. The other half of central PA counties will receive the state-wide, hospital-based intervention, but not the office-based booster intervention.
3265852|NCT00727103|Active Comparator|1 Varenicline|Varenicline will be dispensed in 0.5 mg (blue capsules containing a 0.5 mg varenicline tablet) and 1 mg (red capsules containing a 1 mg varenicline tablet) capsules taken orally. During the first 3 days of medication, participants will take one blue capsule (0.5 mg tablet) of varenicline daily. If the medication is well-tolerated, the dose will be increased to one blue capsule (0.5 mg) po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 red capsule (1 mg) po twice daily. At the end of the 8th week, varenicline will be discontinued.
3265853|NCT00727103|Placebo Comparator|2 Placebo|Placebo will be dispensed in blue and red color coded capsules. During the first 3 days, participants will take one blue capsule po daily. If the medication is well-tolerated, the dose will be increased to one blue capsule po twice daily for 4 days. On day 8, the patients will take 1 red capsule po twice daily. At the end of the 8th week, placebo will be discontinued.
3265854|NCT00727090|Experimental|1|Conivaptan in addition to usual care at the discretion of the attending medical staff
3265855|NCT00727090|No Intervention|2|Usual care by the attending physician staff
3265856|NCT00727077||IntronA/Rebetol|Children age 3 to 17, with chronic hepatitis C, treated in clinical practice at 10 German sites
3265857|NCT00727064|Active Comparator|DVS/VEN|
3265858|NCT00727064|Active Comparator|VEN/DVS|
3265859|NCT00727051||1|Liver and lung transplant candidates referred for coronary angiography will be invited to participate in the study.
3265860|NCT00727038|Experimental|1|Lucentis (ranibizumab) with conventional treatment
3265861|NCT00727038|No Intervention|2|Conventional treatment
3265862|NCT00727012|Other|SJM® Rigid Saddle Ring|The SJM® Rigid Saddle Ring is an annuloplasty ring comprised of a titanium core surrounded by a double-velour, polyester fabric sewing cuff.
3265863|NCT00726999|Active Comparator|1|Gabapentin
3265864|NCT00726999|Placebo Comparator|2|Placebo Comparator -- pill matched in appearance to gabapentin
3265865|NCT00726986|Experimental|Sorafenib, Cisplatin, and Etoposide|
3265866|NCT00726973|Experimental|1|Reduced fluence (3300mW/cm2-50% standard fluence) PDT + ranibizumab
3265867|NCT00726973|Active Comparator|2|Ranibizumab monotherapy
3265868|NCT00726960|Experimental|1|Aprepitant
3265869|NCT00726960|Placebo Comparator|2|Placebo
3265870|NCT00726947|Experimental|1|Ultrasound imaging of Acute DVT (deep vein thrombosis)
3265871|NCT00726947|Experimental|2|Ultrasound imaging of Chronic DVT (deep vein thrombosis)
3265872|NCT00726934|Active Comparator|Neutropenic Diet|Participants will be instructed to follow a Neutropenic Diet. This group will receive the same information as the Food Safety Arm with some additional recommendations for avoiding high bacteria foods during length of time on study.
3265873|NCT00726934|Active Comparator|FDA Food Safety Guidelines|Participants will be instructed to follow the FDA Food Safety Guidelines
3265874|NCT00726895|Experimental|Quinine Sulfate Capsules 1 x 324 mg Dose|Quinine Sulfate 1 x 324 mg capsule dose.
3265875|NCT00726895|Experimental|Quinine Sulfate Capsules 2 x 324 mg Dose|Quinine Sulfate 2 x 324 mg capsules dose.
3265876|NCT00726882|Other|HCV-infected Participants|"Hepatitis C virus (HCV)-infected participants who received ABT-333 at any dose level or matching placebo in a prior clinical study involving ABT−333.~Participants received no treatment in this follow-up study."
3265877|NCT00726869|Experimental|Cohort 1|2.5 mg/kg
3265878|NCT00726869|Experimental|Cohort 2|5.0 mg/kg
3265879|NCT00726869|Experimental|Cohort 3|10.0 mg/kg
3265880|NCT00726869|Experimental|Cohort 4|20.0 mg/kg
3265881|NCT00726856||Patients|patients with dyslipidemia
3265882|NCT00726843|Active Comparator|1|8 weeks of Yoga, followed by 8 weeks of follow-up
3265883|NCT00726843|Active Comparator|2|8 weeks of follow-up, followed by 8 weeks of yoga
3265926|NCT00726544|Active Comparator|Medium Dose|
3265927|NCT00726544|Active Comparator|High Dose|
3265884|NCT00726830|Experimental|Arm I: Opioid rotation to oral methadone|Participants are switched from their current opioid medication (oxycodone or morphine) to methadone. Participants receive oral methadone 2-3 times daily for 4 weeks.
3265885|NCT00726830|Experimental|Arm II: Opioid rotation to another long-acting strong opioid|Participants currently receiving oxycodone are switched to sustained-release (SR) morphine. Participants currently receiving morphine are switched to SR oxycodone. Participants receive either oral SR morphine or oxycodone 2-3 times daily for 4 weeks.
3265886|NCT00726817|Placebo Comparator|1|enemas, once daily, containing saline
3265887|NCT00726817|Experimental|2|enemas, once daily, containing 50mM butyrate
3265888|NCT00726817|Experimental|3|enemas, once daily, containing 100mM butyrate
3265889|NCT00726804|Other|2|
3265890|NCT00726791|Experimental|1|high frequency rTMS applied to the motor cortex
3265891|NCT00726778||A, Observational|Healthy European American, African American, and Hispanic American children aged 7-12
3265892|NCT00726765||Referral Strategy 1|"Patient meets at least one of the following three criteria:~Inflammatory back pain~Human leukocyte antigen B27 (HLA-B27)~Sacroiliitis demonstrated by imaging (X-ray, magnetic resonance imagining [MRI], bone scan [if previously available])"
3265893|NCT00726765||Referral Strategy 2|"Patient meets at least two of the following six criteria:~Inflammatory back pain~HLA-B27~Sacroiliitis (on imaging)~Family history of AS~Good response of back pain to nonsteroidal anti-inflammatory drugs (NSAIDs)~Known Extra Articular Manifestations (Uveitis, Iridocyclitis, Psoriasis, Inflammatory Bowel Disease)"
3265894|NCT00726752|Experimental|Axitinib|
3265895|NCT00726739|Experimental|Arm I - LMI + aldesleukin|Patients receive allogeneic large multivalent immunogen vaccine (LMI) LP2307 intradermally on day 1 and aldesleukin subcutaneously (SC) on days 7 and 8. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3265896|NCT00726739|Active Comparator|Arm II (control) - aldesleukin|Patients receive aldesleukin SC on days 1 and 2. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over and receive treatment on arm I.
3265897|NCT00726739|Experimental|Arm III - Crossover Patients|"Patients who have progressive disease on Arm II were be offered crossover to Arm I provided they continued to meet all study criteria.~Patients receive allogeneic large multivalent immunogen vaccine (LMI) LP2307 intradermally on day 1 and aldesleukin subcutaneously (SC) on days 7 and 8. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity"
3265898|NCT00726726|Other|A|
3265899|NCT00726726|Experimental|B|
3265900|NCT00726726|Experimental|C|+ Other
3265901|NCT00726713|Experimental|1|Metanx
3265902|NCT00726713|Placebo Comparator|2|Placebo
3265903|NCT00726700|Active Comparator|Arm I (without rituximab)|Patients receive pegfilgrastim subcutaneously (SC) on day 2 or 4 and CHOP comprising cyclophosphamide IV, doxorubicin IV, vincristine IV on day 1, and oral prednisone on days 1-5. Treatment repeats every 2 weeks for up to 6-8 courses in the absence of disease progression or unacceptable toxicity.
3265904|NCT00726700|Experimental|Arm II (with rituximab)|Patients receive pegfilgrastim and CHOP for up to 6-8 courses as in arm I. They also receive rituximab (administered 2 hours before beginning CHOP) on day 1. Treatment with rituximab repeats every 2 weeks for up to 8 courses.
3265905|NCT00726687|Experimental|single|Single arm designed to elicit Maximum Tolerated Dose
3265906|NCT00726661||Chemotherapy Cohort|Eligible participants with HER2-negative disease who received their first cytotoxic chemotherapy and/or targeted therapy were observed until death, withdrawal of consent, loss to follow-up, or until study closure, whichever was sooner (approximately 4.5 years).
3265907|NCT00726661||Hormonal Therapy Cohort|Eligible participants with hormone receptor positive disease who received their first hormonal therapy for advanced disease were observed until death, withdrawal of consent, loss to follow-up, or until study closure, whichever was sooner (approximately 4.5 years).
3265908|NCT00726648|Experimental|1|
3265909|NCT00726648|Experimental|2|
3265910|NCT00726648|Experimental|3|
3265911|NCT00726648|Experimental|4|
3265912|NCT00726648|Placebo Comparator|5|
3265913|NCT00726635|Active Comparator|1|Women in this arm will not receive a psychological intervention but rather will have a conversation with a nurse for one hour (attention control).
3265914|NCT00726635|Experimental|2|Cognitive intervention: Women in this arm will receive a cognitive psychological intervention(cognitive technique:self-talk)
3265915|NCT00726635|Experimental|3|Psycho-physiological intervention: Women in this arm will receive a psycho-physiological intervention (relaxation and guided imagery)
3265916|NCT00726622|Active Comparator|Arm 1: Open laparotomy and rectal resection|Patients undergo open laparotomy and rectal resection. The standard form of surgery is open laparotomy rectal resection. During open laparotomy, the surgeon makes a large incision or cut in the abdomen, and goes in through that cut to remove the tumor and lymph nodes from the rectum.
3265917|NCT00726622|Experimental|Arm 2: Laparoscopic-assisted rectal resection|Patients undergo laparoscopic-assisted rectal resection. Laparoscopic-assisted rectal resection is performed using small instruments on long handles introduced into the abdomen through small ports called trocars in 3 - 6 positions on the abdomen through incisions measuring 5 -10 mm, under the guidance of a video camera. The abdominal wall is held up with carbon dioxide under pressure. The piece of bowel or intestine is removed through another incision (about 8 centimeters), and the ends of the intestine are reconnected to provide normal bowel function.
3265918|NCT00726609||Posaconazole (assigned by physician in normal practice)|"Treatment of invasive fungal infection.~Prophylaxis of invasive fungal infection."
3265919|NCT00726596|Experimental|Hydroxychloroquine|Hydroxychloroquine - 400 mg (cohort A) Hydroxychloroquine - 600 mg (cohort B)
3265920|NCT00726583|Experimental|Investigational Drug|Dose Escalation
3265921|NCT00726570|Experimental|SCD + LMWH|This group will receive sequential compression device therapy to the lower limbs from their ICU admission until the morning after surgery.
3265922|NCT00726570|Active Comparator|LMWH only|Patients in this group will receive only standard LMWH therapy during their ICU stay.
3265923|NCT00726557||PegIntron + Rebetol|There will be a distinction between the patients depending on the type of substitution drug used (secondary parameters).
3265924|NCT00726544|Placebo Comparator|Placebo|
3265928|NCT00726531|Experimental|OEP|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
3265929|NCT00726531|Experimental|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
3265930|NCT00726531|No Intervention|TAU|Treatment as usual
3265931|NCT00726505|Active Comparator|Group 1|Subjects with T2DM - Dapagliflozin 5 mg
3265932|NCT00726505|Active Comparator|Group 2|Subjects with T2DM - Dapagliflozin 20 mg
3265933|NCT00726505|Active Comparator|Group 3|Healthy Subjects - Dapagliflozin 20 mg
3265934|NCT00726492|Experimental|CSWD + Hydro|Continuous short wave diathermy and hydrotherapy
3265935|NCT00726492|Experimental|Hydro alone|Hydrotherapy alone
3265936|NCT00726492|Experimental|CSWD alone|Continuous short wave diathermy alone
3265937|NCT00726492|No Intervention|Control|No treatment
3265938|NCT00726466|Experimental|I|This is an open-label, study of 0.5 mg intravitreal dose of Ranibizumab in combination with 1 mg/kg/wk subcutaneous dose of Efalizumab in in subjects with AMD.
3265939|NCT00726453|Experimental|Resolute Zotarolimus-Eluting Coronary Stent|Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
3265940|NCT00726440|Active Comparator|Group1-patient|The patient will be encouraged to use the Navigator® all the time and to modify his treatment according to the continous blood glucose measurements. The patients will follow an educational process in order to adapt insulin doses according to each sensor data.
3265941|NCT00726440|Active Comparator|Group2-diabetologist|"The patient will follow the same educational process as group 1 concerning insulin dose adaptation. They will use the continous glucose monitoring device according to the diabetologist's prescription and they will receive precise instructions to make considering results. The duration of the use of the Navigator® will be increased if one of the following criteria is observed at the consultation each 3 months:~HbA1c>=7.5%~1 severe hypoglycaemia or more~More than 4 benign hypoglycaemia per week~According to these criteria, every 3 months, the duration of the use of the monitoring system will be increased as following:~step 1: 3 sensors per month~step 2: 4 sensors per month~step 3: 5 sensors per month~step 4: continuous use"
3265942|NCT00726440|Placebo Comparator|Group3-Control|Usual follow up with self-monitoring blood glucose.
3265943|NCT00726427|Experimental|1|8 increasing oral single doses given to 8 groups (3 on active and 1 on placebo in each group)
3265944|NCT00726427|Experimental|2|2 oral doses of AZD1656 given to 2 groups together with food
3265945|NCT00726414|Experimental|Quinine Sulfate Capsules 2 x 324 mg Capsules - Fasting|A single dose of Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
3265946|NCT00726414|Experimental|Quinine Sulfate Capsules 2 x 324 mg Capsules - Fed|A single dose of Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
3265947|NCT00726401|Active Comparator|1|
3265948|NCT00726401|Placebo Comparator|2|
3265949|NCT00726388|Experimental|A|IV administration of multiple doses of DIC075V (intravenous diclofenac sodium) over multiple days
3265950|NCT00726375|Experimental|Etanercept|a maximum of 8 SQ doses of 'Etanercept (Enbrel) at 0.4mg/kg per dose up to a maximum of 25 mg per dose
3265951|NCT00726362||1|patients with hyperlipidemia newly initiating a statin; or switched from current therapy to a statin, or require dosage adjustment for statin
3265952|NCT00726349||Observation|Patients undergoing isolated elective total hip or knee arthroplasty (primary or revision surgery for a non-malignant condition), aged 60 years or older and able to walk prior to surgery.
3265953|NCT00726323|Experimental|5/9 dosing|240 mg of foretinib on a 5 day on / 9 day off regimen every 14 days.
3265954|NCT00726323|Experimental|daily dosing|80 mg foretinib on a daily dosing regimen
3265955|NCT00726310||SpineLink® , SpineLink® II Group|Spinal fusion surgery with SpineLink®
3265956|NCT00726271|Experimental|active|"Subjects will complete the Zung Depression and Anxiety Scales. At the first visit the subject's medication list, weight, height, and waist measurement will be obtained. The goal is to recruit a minimum of 20 patients.~Subjects will receive light olive oil, and capsules of fish oil and flaxseed oil, to take daily at home with weight based dosing, based on the doses recommended in Dr. Roberts' work. Doses are within the recommended dietary ranges to improve intermediate outcomes for coronary artery disease subjects.~They will return weekly for measurement of weight, waist measurements, discussion of any problems with the oils, and dose adjustment of the oils."
3265957|NCT00726258|Placebo Comparator|1|Drip of physiological serum
3265958|NCT00726258|Active Comparator|2|Drip of ketamine
3265959|NCT00726245|Experimental|1|PRGF
3265960|NCT00726245|Placebo Comparator|2|physiological saline
3265961|NCT00726232|Experimental|Ruxolitinib 10 mg BID|Participants received 10 mg Ruxolitinib orally twice a day (BID) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
3265962|NCT00726232|Experimental|Ruxolitinib 25 mg BID|Participants received 25 mg Ruxolitinib orally twice a day (BID) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
3266011|NCT00725855|Experimental|4|50 mg dose
3266012|NCT00725855|Placebo Comparator|5|Placebo dose
3266060|NCT00725400|Active Comparator|1|Patients will receive a Cetuximab and Radiation Therapy.
3265963|NCT00726232|Experimental|Ruxolitinib 50 mg QD|Participants received 50 mg Ruxolitinib orally once a day (QD) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
3265964|NCT00726219|Other|1|Insertion distance of femoral catheter: 3cm
3265965|NCT00726219|Other|2|Insertion distance of femoral catheter: 7cm
3265966|NCT00726206|Other|1|Recording of the movements Recording of the electroencephalogram
3265967|NCT00726193||1 - standard films|Tibia reconstruction surgery with OsteoGen™ with standard radiographs
3265968|NCT00726193||2 - Standard films plus CT|Tibia reconstruction surgery with OsteoGen™ with standard radiographs and additional CT scan at 10 and 18 weeks.
3265969|NCT00726180|Experimental|Treatment arm|
3265970|NCT00726154|Other|IPSRT|Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.
3265971|NCT00726154|Other|Collaborative care|The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
3265972|NCT00726128||VueLock™ Anterior Cervical Plate Group|VueLock™ Anterior Cervical Plate, Implanted in subjects having an ACDF
3265973|NCT00726115|Placebo Comparator|1|arm placebo
3265974|NCT00726115|Experimental|2|arm drug
3265975|NCT00726102|Active Comparator|Meat|Provide locally available meat daily to infants from 6 to 18 mos of age
3265976|NCT00726102|Active Comparator|Control|Daily provision of cereal to infants from 6-18 mos
3265977|NCT00726102|Active Comparator|Fortified rice cereal|Provide equi-caloric serving of fortified rice cereal on daily basis from 6-18 months of age
3265978|NCT00726076|Experimental|Treatment|The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment.
3265979|NCT00726076|Experimental|Control|Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
3265980|NCT00726063|Experimental|Nanotite implant|Nanotite dental implant
3265981|NCT00726063|Active Comparator|Osseotite implant|Osseotite dental implant
3265982|NCT00726037|Experimental|1|Three doses of Ontak 9 mcg/Kg IV over 30 minutes every other day for 1 week
3265983|NCT00726011|Experimental|Tetrodotoxin|There is only one arm; active treatment with TTX
3265984|NCT00725998||1|"The ECAP characteristics have been analyzed in 13 children implanted younger than three years old.~Series Study Results:~During the first year of CI use there was a significant statistical growth for the amplitude of N1 peak, in basal electrodes, between the second and third returns. There were not any significant differences obtained for N1 peak, latency, slope, neither for p-NRT nor recovery time, among the returns."
3265985|NCT00725985|Experimental|Cladribine 5.25 mg/kg|
3265986|NCT00725985|Experimental|Cladribine 3.5 mg/kg|
3265987|NCT00725985|Placebo Comparator|Placebo|
3265988|NCT00725972|Experimental|Augmented Oxygen Delivery Group|"Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.~Intervention: Augment O2 Delivery by hemodynamic protocol. (7/30/17: deleted original text which apparently was pasted from an entirely unrelated study having to do with age of transfused blood, presumably by the creator of this record, Cynthia Hatfield, in 2010. SLW)"
3265989|NCT00725972|Sham Comparator|Control|Patients having the same types of surgery but receiving usual anesthetic care. Intervention: High Risk Surgery. (7/30/17: deleted original text which apparently was pasted from an entirely unrelated study having to do with age of transfused blood, presumably by the creator of this record, Cynthia Hatfield, in 2010. SLW)
3265990|NCT00725959|Experimental|Facebook Arm|Participants in this arm will have exposure to innovative, dynamic and regularly updated HIV Prevention messages on Facebook
3265991|NCT00725959|Active Comparator|Control arm|Participants in this arm will have exposure to static information on HIV prevention currently available online
3265992|NCT00725946|Experimental|Iodine-124 PET-CT scan|
3265993|NCT00725920|Experimental|Topiramate|patients receiving the active drug: topiramate
3265994|NCT00725920|Placebo Comparator|Placebo Control group|patients received pills content placebo, that were identical to the pills content active drug
3265995|NCT00725907|Experimental|1|PGRF
3265996|NCT00725907|Placebo Comparator|2|saline
3265997|NCT00725894||1|The Pediatric Locking Nail was designed to provide stable sub-rigid fixation of femoral fractures in children
3265998|NCT00725881|Experimental|1|.25 mg/kg TSC
3265999|NCT00725881|Experimental|2|.5 mg/kg TSC
3266000|NCT00725881|Experimental|3|.75 mg/kg TSC
3266001|NCT00725881|Experimental|4|1.0 mg/kg TSC
3266002|NCT00725881|Experimental|5|1.25 mg/kg TSC
3266003|NCT00725881|Experimental|6|1.5 mg/kg TSC
3266004|NCT00725881|Experimental|7|1.75 mg/kg TSC
3266005|NCT00725881|Experimental|8|2.0 mg/kg TSC
3266006|NCT00725881|Placebo Comparator|9|5.0 mL 0.9% normal saline
3266007|NCT00725868|Other|1|Data private hospitals, angioplasty, sampling of blood
3266008|NCT00725855|Experimental|1|1 mg dose
3266009|NCT00725855|Experimental|2|5 mg dose
3266010|NCT00725855|Experimental|3|15 mg dose
3266013|NCT00725842||Peg-IFN alfa-2b + ribavirin|Participants with chronic hepatitis C (CHC) treated with Peg-IFN alfa-2b + ribavirin as first treatment, in common clinical practice, who had negative hepatitis-C virus (HCV)-ribonucleic acid (RNA) by the end of treatment (24 or 48 weeks per product labeling).
3266014|NCT00725829|Experimental|1|simvastatin 40g + ezetimibe 10g once a day
3266015|NCT00725829|Placebo Comparator|2|simvastatin 40g + placebo once a day
3266016|NCT00725803|Experimental|Cohort 1|Subjects randomized 3:1 (active:placebo) to receive GS-9450 10 mg/day or placebo.
3266017|NCT00725803|Experimental|Cohort 2|Subjects randomized 3:1 (active:placebo) to receive GS-9450 40 mg/day or placebo.
3266018|NCT00725803|Experimental|Cohort 3|Subjects randomized 3:1 (active:placebo) to receive GS-9450 80 mg/day or placebo.
3266019|NCT00725803|Experimental|Cohort 4|Subjects randomized 3:1 (active:placebo) to receive GS-9450 5 mg/day or placebo. Cohort may or may not be conducted pending blinded review of previous cohorts.
3266020|NCT00725790|Experimental|A|Vardenafil treatment group
3266021|NCT00725790|Placebo Comparator|B|Placebo treatment group
3266022|NCT00725777|Experimental|A|
3266023|NCT00725764|Experimental|Single Arm|Participants who qualified for study entry received 240 mg of GSK1363089 (foretinib) on a 5-day on 9-day off schedule every 2 weeks.
3266024|NCT00725751||PegIFN-2b/ribavirin with substitution therapy|Participants in this cohort received antiviral treatment and substitution therapy (opioid medicines with long-lasting effects [methadone + buprenorphine] or morphine)
3266025|NCT00725751||PegIFN-2b/ribavirin without substitution therapy|Participants in this cohort received antiviral treatment but did not receive substitution therapy (opioid medicines with long-lasting effects [methadone + buprenorphine] or morphine)
3266026|NCT00725738|Experimental|A|"Stem Cell Transplantation Group: Between the fifth and seventh day post-primary angioplasty (PTCA) we extract the stem cell from iliac crest and during the same day the patient undergoes to a new cardiac catheterization in which we perform the intracoronary injection (about 1-2 million of CD34 cells) through the infarct related artery by a PTCA over-the-wire catheter."
3266027|NCT00725725|Experimental|4 mg Org 25935|Participants took a total of 3 doses of 4 mg Org 25935 prior to therapy sessions over a 2-week period.
3266028|NCT00725725|Experimental|12 mg Org 25935|Participants took a total of 3 doses of 12 mg Org 25935 prior to therapy sessions over a 2-week period.
3266029|NCT00725725|Placebo Comparator|Placebo|Participants took a total of 3 doses of placebo matched to Org 25935 prior to therapy sessions over a 2-week period.
3266030|NCT00725712|Experimental|5-days on/9-days off|Dosing for first 5 days in every 14-day period.
3266031|NCT00725712|Experimental|daily dosing|dosed every day
3266032|NCT00725673||1|GOLD II COPD patients with osteoporosis
3266033|NCT00725673||2|GOLD II COPD patients with a normal bone mineral density
3266034|NCT00725660||1|Pregnant women in second trimester that took the routine triple test, and are having an early routine detailed ultrasound examination.
3266035|NCT00725647||Treated PDA|Infants who had a PDA which the attending physicians treated medically or surgically.
3266036|NCT00725634|Experimental|AV-299 Dose Escalation Arm|AV-299 Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma
3266037|NCT00725634|Experimental|AV-299 in combination with erlotinib|AV-299 Administered by IV Infusion in Combination with Erlotinib (150 mg daily) in Advanced Solid Tumors
3266038|NCT00725621||Remicade|Patients with severe RA (indication according to Austrian labeling) will receive Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions. Remicade induction and maintenance therapy doses and intervals will be at the discretion of the physicians.
3266039|NCT00725608||Patients|Opioid dependent patients currently in maintenance treatment with another medication who are switched to Suboxone (buprenorphine plus naloxone)
3266040|NCT00725595||E, 2, III|To treat CSR with ASV and Bilevel ventilators
3266041|NCT00725582|Experimental|A|
3266042|NCT00725582|Placebo Comparator|B|
3266043|NCT00725569|Active Comparator|A|Bellis perennis and Staphysagria (C6)
3266044|NCT00725569|Active Comparator|B|Bellis perennis and Staphysagria (C30)
3266045|NCT00725569|Placebo Comparator|C|Placebo Remedy
3266046|NCT00725556|Other|1|Speech therapy
3266047|NCT00725543||Remicade|Subjects with AS with severe axial symptoms and elevated serological markers of inflammatory activity will receive Remicade induction therapy consisting of 3 Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians. Whole observation period cannot exceed 102 weeks per subject if the maximal therapy interval of 16 weeks as defined in Summary of Product Characteristics (SPC) is taken into consideration.
3266048|NCT00725530|Active Comparator|balafilcon A / etafilcon A|Balafilcon A worn first, with etafilcon A worn second. Each product worn bilaterally in an extended wear (overnight) basis for 7 days.
3266049|NCT00725530|Active Comparator|etafilcon A / balafilcon A|Etafilcon A worn first, with balafilcon A worn second. Each product worn bilaterally in an extended wear (overnight) basis for 7 days.
3266050|NCT00725517|Experimental|1|Icodextrin group
3266051|NCT00725517|No Intervention|2|Glucose group
3266052|NCT00725504|Experimental|Lidocaine infusion|Each participant will receive an intravenous infusion of lidocaine. Plasma concentrations will be increased gradually from 0-5 µg/ml.
3266053|NCT00725491|Experimental|1|ganirelix
3266054|NCT00725491|Active Comparator|2|triptorelin
3266055|NCT00725465||30|30 surgical patients, male and female undergoing laparoscopic surgical treatment for colorectal conditions managed with intra-operative CO2 colonoscopy
3266056|NCT00725452||Infliximab|Subjects with plaque psoriasis will receive Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.
3266057|NCT00725439|Experimental|A|Talarozole
3266058|NCT00725426|Experimental|1|Bosutinib
3266059|NCT00725413|Experimental|Arm 1|Healthy premenopausal women requiring a long-term method of contraception
3266192|NCT00724412|Active Comparator|Systane|Systane
3266061|NCT00725400|Active Comparator|2|Patients will undergo Surgery before or after Radiation Therapy.
3266062|NCT00725374|Active Comparator|Arm 1|Postmenopausal women of any age, requiring surgery for early invasive primary breast cancer, with estrogen receptor-positive tumor(s). Treated with tibolone
3266063|NCT00725374|Placebo Comparator|Arm 2|Postmenopausal women of any age, requiring surgery for early invasive primary breast cancer, with estrogen receptor-positive tumor(s). Treated with placebo
3266064|NCT00725361|Experimental|Active|Ambrisentan
3266065|NCT00725348|Experimental|A|R115866
3266066|NCT00725335|Experimental|group A,non-pringle group|Intervention of curative resection of HCC Without pringle manoeuvre in this arm
3266067|NCT00725335|Active Comparator|pringle group(B)|when the curative resection of HCC performed, the pringle manoeuvre will be routinely applied.
3266068|NCT00725322|Experimental|Placebo then Botox|
3266069|NCT00725322|Experimental|Botox then Placebo|
3266070|NCT00725296||Remicade (Infliximab)|Participants with active and progressive PsA who have responded inadequately to disease-modifying anti-rheumatic drugs will receive induction infusions of Remicade at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians. Whole observation period cannot exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in the Summary of Product Characteristics (SPC) is taken into consideration.
3266071|NCT00725283|Experimental|GSK2130579A Group|Patients with cytologically proven AML, as defined by the World Health Organization classification, who were administered a standard dose of GSK2130579A treatment. Patients received 24 doses of the study treatment over a period of approximately 4 years.
3266072|NCT00725270|Placebo Comparator|Placebo|Patients will be randomized to placebo
3266073|NCT00725270|Experimental|Mifepristone|Patients will be randomized to mifepristone
3266074|NCT00725257|Active Comparator|1|Low-carbohydrate, energy-restricted, Mediterranean-type diet
3266075|NCT00725257|Active Comparator|2|Low-fat diet
3266076|NCT00725244|Active Comparator|1|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
3266077|NCT00725244|Active Comparator|2|"Argon Plasma Coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
3266078|NCT00725231|Active Comparator|Arm A|Chemotherapy with dose dense CHOP-14, 6 cycles
3266079|NCT00725231|Experimental|Arm B|Chemotherapy with dose dense CHOP-14, 6-cycles, together with 30mg Alemtuzumab s.c. for the first 4 cycles
3266080|NCT00725218|Placebo Comparator|1|Saline 5 ml injection 10 min prior to propofol administration.
3266081|NCT00725218|Experimental|2|Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
3266082|NCT00725205||Chronic hepatitis C participants|Untreated chronic hepatitis C (CHC) participants starting Peginterferon alfa-2b (injection pen) and Ribavirin combination therapy as their usual medical treatment according to the approved dosage/regimen were selected for this study.
3266083|NCT00725192|Active Comparator|1|Cognitive Processing Therapy
3266084|NCT00725192|Experimental|2|Hypnosis plus Cognitive Processing Therapy.
3266085|NCT00725179||1|Patients receiving oral NAC treatment
3266086|NCT00725179||2|Patients receiving IV NAC treatment
3266087|NCT00725166||Young|Young men 19-25 years old
3266088|NCT00725166||Old|old men 70-76 years old, who participate in the PROOF study (NCT 00759304)
3266089|NCT00725153|Other|PureVision/Acuvue 2|PureVision contact lenses worn first, with Acuvue 2 contact lenses worn second. Both products worn for 10 hours each.
3266090|NCT00725153|Other|Acuvue 2/PureVision|Acuvue 2 contact lenses worn first, with PureVision contact lenses worn second. Both products worn for 10 hours each.
3266091|NCT00725140||Single|
3266092|NCT00725127|Active Comparator|1|100 mg/day ASA upon awakening.
3266093|NCT00725127|Active Comparator|2|100 mg/day ASA at bedtime
3266094|NCT00725114|Active Comparator|Tetrodotoxin|
3266095|NCT00725114|Placebo Comparator|Sugar injection|
3266096|NCT00725101||Fibromyalgia (FM) Participants|FM participants starting any new pharmacologic FM agent.
3266097|NCT00725088|Experimental|1|exercise training group
3266098|NCT00725088|No Intervention|2|control group
3266099|NCT00725075|Experimental|MK-8435 (Org 25935) 8-16 mg per day|Participants will be maintained on a stable dose of Second Generation Antipsychotic (SGA) and receive 4-8 mg MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days. The dose of MK-8435 (Org 25935) can be titrated upward or downward within the specified dose range, as needed, up to Day 42 of the study. The dose must remain stable after Day 42 for the remainder of the study.
3266100|NCT00725075|Experimental|MK-8435 (Org 25935) 24-32 mg per day|Participants will be maintained on a stable dose of SGA and receive 12-16 mg MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days. The dose of MK-8435 (Org 25935) can be titrated upward or downward within the specified dose range, as needed, up to Day 42 of the study. The dose must remain stable after Day 42 for the remainder of the study.
3266101|NCT00725075|Placebo Comparator|Placebo|Participants will be maintained on a stable dose of SGA and receive matching placebo for MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days.
3266102|NCT00725062|Experimental|Patients Receiving CD4+/CD25+ cells|CD4+/CD25+ cells given intravenously over 15-60 minutes on Day -2 (prior to peripheral blood progenitor cell transplant)
3266103|NCT00725049|Active Comparator|Dental implant (Nanotite)|Dental implants of short length placed without sinus lifts
3266104|NCT00725049|No Intervention|Control group|Dental implants of standard length placed simultaneously with sinus augmentation
3266105|NCT00725023|Experimental|1|Treatment: TDP© Lamp used Duration of each treatment 30min Course of treatment 3 times a week for 3-4 weeks
3266106|NCT00725023|Other|2|Treatment: Dummy TDP© Lamp used Duration of each treatment 30min Course of treatment 3 times a week for 3-4 weeks
3266107|NCT00725010||Patients|Participants with newly diagnosed Glioblastoma multiforme who were prescribed temozolomide and radiotherapy as standard care.
3266108|NCT00724997|Other|cohort I|dose level I: 6.4 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
3266109|NCT00724997|Other|cohort II|dose level II: 6.7 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
3266110|NCT00724997|Other|cohort III|dose level III: 7.0 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
3266111|NCT00724997|Other|cohort IV|dose level IV: 7.4 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
3266112|NCT00724997|Other|cohort V|dose level V: 7.7 log10 TCID50/volunteer, 16 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
3266113|NCT00724984|Experimental|1|
3266114|NCT00724971|Experimental|1|
3266115|NCT00724958||Remicade|Subjects with active luminal and/or fistulizing CD in the hospital or non-hospital setting.
3266116|NCT00724945|Active Comparator|senofilcon A / balafilcon A|senofilcon A multifocal lenses worn first, balafilcon A multifocal lenses worn second
3266117|NCT00724945|Active Comparator|balafilcon A/senofilcon A|balafilcon A multifocal lenses worn first, senofilcon A multifocal lenses worn second
3266118|NCT00724932|Experimental|Sugammadex|4.0 mg.kg-1 sugammadex at 1-2 PTC
3266119|NCT00724932|Experimental|Neostigmine|50 µg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2
3266120|NCT00724919||1|
3266121|NCT00724906|Experimental|Parkinsonian Syndromes|Subjects with Parkinsonian Syndromes
3266122|NCT00724906|Experimental|Non-Parkinsonian Syndromes|Subjects with Non-Parkinsonian Syndromes
3266123|NCT00724893||Stage 1 Participants|Participants with CHC receiving PegIFN-2b using Redipen™ formulation (1.5 mcg/kg) once weekly and ribavirin capsules (800-1400 mg) daily according to routine medical practice at participating study sites.
3266124|NCT00724893||Stage 2 Participants|Participants with CHC Genotype 1 receiving PegIFN-2b using Redipen™ formulation (1.5 mcg/kg) once weekly and ribavirin capsules (800-1400 mg) daily according to routine medical practice at participating study sites.
3266125|NCT00724880|Experimental|1|Clopidogrel is stopped 5 days prior to surgery
3266126|NCT00724880|Experimental|2|Clopidogrel is stopped 3 days prior to surgery
3266127|NCT00724880|Experimental|3|Clopidogrel is stopped 0 days prior to surgery
3266128|NCT00724867|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV every 28 days
3266129|NCT00724867|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV every 28 days
3266130|NCT00724854||Mono-infected with HCV|Participants infected with Hepatitis C Virus (HCV).
3266131|NCT00724854||Co-infected with HCV and HIV|Participants co-infected with HCV and Human Immunodeficiency Virus (HIV).
3266132|NCT00724841|Experimental|1|40 mg/m2 GMX1777 with Temozolomide
3266133|NCT00724841|Experimental|2|50 mg/m2 GMX1777 with Temozolomide
3266134|NCT00724841|Experimental|3|62 mg/m2 GMX1777 with Temozolomide
3266135|NCT00724841|Experimental|4|80 mg/m2 GMX1777 with Temozolomide
3266136|NCT00724841|Experimental|5|100 mg/m2 GMX1777 with Temozolomide
3266137|NCT00724841|Experimental|6|125 mg/m2 GMX1777 with Temozolomide
3266138|NCT00724828||1|
3266139|NCT00724815|Experimental|Sumatriptan|NP101 - sumatriptan iontophoretic transdermal patch
3266140|NCT00724815|Placebo Comparator|Placebo|Placebo iontophoretic transdermal patch
3266141|NCT00724789||Observational Cohort|Subjects with an ongoing pregnancy after controlled ovarian stimulations with recombinant follicle stimulating hormone/ganirelix followed by in vitro fertilization or intra cytoplasmatic sperm injection.
3266142|NCT00724789||Historical Controls|Subjects with an ongoing pregnancy after controlled ovarian stimulations with recombinant follicle stimulating hormone in a long protocol with a gonadotropin releasing hormone agonist followed by IVF or ICSI
3266143|NCT00724776|Experimental|1|Open-label treatment with albinterferon alfa 2b escalating single dose
3266144|NCT00724763|Experimental|1|Treatment group.
3266145|NCT00724763|Sham Comparator|2|control group
3266146|NCT00724750|Experimental|G-SUC|Gauze suction (G-SUC) Negative Pressure Wound Therapy, continuous wall suction at 75 to 80 mm Hg was applied and dressings were changed daily.
3266147|NCT00724750|Active Comparator|Vacuum Assisted Closure|Vacuum Assisted Closure Device (VAC) Negative Pressure Wound Therapy, continuous suction at 75 to 125 mm Hg and the dressing was changed every 48 hours.
3266148|NCT00724737|Active Comparator|fMRI of the brain, no surgery|Healthy volunteers will undergo an fMRI (functional MRI of the brain).
3266149|NCT00724737|Experimental|fMRI of the brain, presurgical|Patients scheduled to have brain surgery will undergo an fMRI (functional MRI of the brain).
3266150|NCT00724724|Experimental|1|Butylphthalide Soft Capsules + Aspirin
3266151|NCT00724724|Active Comparator|2|Aspirin
3266152|NCT00724711|Experimental|FTC/TDF (Truvada [TVD]) + PI/r|Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.
3266153|NCT00724711|Active Comparator|ABC/3TC + PI/r|Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.
3266154|NCT00724698||Group|Patients diagnosed with Allergic Rhinitis or Chronic Idiopathic Urticaria
3266155|NCT00724685|Placebo Comparator|Placebo|
3266156|NCT00724685|Experimental|Active|
3266157|NCT00724672||ETA|RA patients who were scheduled to receive etanercept 50 mg subcutaneously once weekly
3266158|NCT00724672||IFX|RA patients who were scheduled to receive infliximab 3 mg/kg IV at Weeks 0, 2, and 6
3266159|NCT00724672||ADA|RA patients who were scheduled to receive adalimumab 40 mg subcutaneously biweekly
3266193|NCT00724412|Active Comparator|Optive|Optive
3266363|NCT00723021|Experimental|PF-04191834 30mg|
3266160|NCT00724672||non-diseased controls|Healthy individuals who contributed their RNA/cDNA samples prior to the study and for whom ethical approval has already been obtained.
3266161|NCT00724659|Experimental|Ultrasound Pre-Arthrogram|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
3266162|NCT00724659|Experimental|Ultrasound Post-Arthrogram|Ultrasound of the joint(s) after the clinically scheduled arthrogram of the same joint(s), performed while the body still has a contrast agent in it from the arthrogram. The contrast agent varies with different joint areas, but is usually iodine based (like Ultravist.)
3266163|NCT00724646||1|Habilitation assistants
3266164|NCT00724646||2|Parents/ legal guardians
3266165|NCT00724633|Other|1|standard dialysate Na 140 mEq/L
3266166|NCT00724633|Active Comparator|2|dialysate sodium equal to patient's predialysis serum Na
3266167|NCT00724633|Active Comparator|3|dialysate sodium lower than patient's predialysis plasma sodium
3266168|NCT00724620|Experimental|Early Responders (ER)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have responded to therapy at Treatment Week 12 (ie, who are Early Responders defined by HCV-RNA[-] at Treatment Week 12) will continue the combined treatment for a total of 48 weeks and will complete 24 weeks of follow up to determine the Sustained Viral Response (SVR).
3266169|NCT00724620|Experimental|Slow Responders (SR): Decrease in viral load >=2 log|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have a slow response to therapy at Treatment Week 12 (ie, Slow Responders who are not HCV-RNA[-] at Treatment Week 12 but decrease >=2 log) will continue the combined treatment for a total of 72 weeks and will complete 24 weeks of follow up to determine the Sustained Viral Response (SVR).
3266170|NCT00724620|Experimental|Nonresponders (NR): Decrease in viral load <2 log|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have not responded to therapy at Treatment Week 12 (ie, Nonresponders who are not HCV-RNA[-] at Week 12 of Treatment and/or have a decrease in viral load <2 log) will stop treatment at Treatment Week 12.
3266171|NCT00724607||TBI (Case) Group|Members of the TBI group have sustained a TBI in accordance with inclusion/exclusion criteria. However, the investigative staff administering, scoring, analyzing and interpreting the data will be blinded to the group status of the participant.
3266172|NCT00724607||Non-TBI (Control) Group|Members of the Non-TBI group have not sustained a TBI and are in accordance with other provisions of the inclusion/exclusion criteria. However, the investigative staff administering, scoring, analyzing and interpreting the data will be blinded to the group status of the participant. This longitudinal study will utilize a control group to account for normal aging and other control factors.
3266173|NCT00724607||Non-TBI Non-deployed (Control) Group|Members of the Non-TBI Non-Deployed group have neither sustained a TBI nor have been deployed but are in accordance with other provisions of the inclusion/exclusion criteria. However, the investigative staff administering, scoring, analyzing and interpreting the data will be blinded to the group status of the participant. This longitudinal study will utilize this Non-deployed control group to account for deployment-specific factors.
3266174|NCT00724594|Experimental|N-acetylcysteine|Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.
3266175|NCT00724594|Active Comparator|Control|Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.
3266176|NCT00724581|Experimental|A|
3266177|NCT00724568|Experimental|Combination Drug Therapy|Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11, Doxil at indicated doses on day 4, Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels, and Revlimid at indicated doses on days 1-14 in 3-week cycles for 4-8 cycles. To determine the MTD of the combination of Revlimid, Velcade, dexamethasone, and Doxil, four dose levels are planned.
3266178|NCT00724555||1|Adults living in DC neighborhoods with high proportions of underserved adults. The age of the cohort members will reflect the age of DC residents who suffer most from stroke.
3266179|NCT00724542|No Intervention|Control|Placebo with lifestyle intervention
3266180|NCT00724542|Experimental|Drug|Voglibose tablets with lifestyle intervention
3266181|NCT00724529||Serious Active Crohns Disease|Patients with severe active Crohns Disease who do not show any response to treatment with corticosteroids or immunosuppressive agents, and have no drug tolerance or contraindications to such treatments.
3266182|NCT00724529||Fistula-Type Active Crohns Disease|Patients with fistula-type Crohns Disease who do not show any response to general treatments such as antibiotics, drainage, or immunosuppressant.
3266183|NCT00724529||Ankylosing Spondylitis|Patients with Ankylosing Spondylitis who do not show adequate response to general treatments and with increased serological indices related to severe axial symptoms and inflammation.
3266184|NCT00724516|Experimental|Novel Breast Compression Paddle|Women scheduled to undergo a breast mammography wire localization procedure will have a new breast compression paddle will be used Instead of using the regular wire localization mammography compression paddle.
3266185|NCT00724503|Active Comparator|A: FOLFOX alone|Systemic chemotherapy consisting of Oxaliplatin + Leucovorin + 5- Fluorouracil (FOLFOX)
3266186|NCT00724503|Active Comparator|B: FOLFOX + SIR-Spheres|A single injection of SIR-Spheres microspheres into the liver plus systemic chemotherapy consisting of Oxaliplatin + Leucovorin + 5-Fluorouracil (FOLFOX)
3266187|NCT00724477||Subjects treated with INEGY|Subjects suffering from primary hypercholesterolemia that are not controlled by statins as a monotherapy, and are treated with INEGY
3266188|NCT00724464||Participants with Chronic Hepatitis C|Treatment-naïve participants with chronic hepatitis C, undergoing treatment with a standard treatment regimen of PegIntron and Rebetol in clinical practice at approximately 28 sites in Greece
3266189|NCT00724451||Participants with Chronic Hepatitis C (CHC)|Peginterferon-naïve participants with CHC seen in general clinical practice in Italy and treated with either pegylated interferon alfa-2a or alfa-2b + ribavirin.
3266190|NCT00724438||1|Obese women: women with a body mass index (BMI) >30
3266191|NCT00724438||2|Normal weight women: women with a BMI <25
3266194|NCT00724399||Observations|Women attending screening mammography and gynecology visit
3266195|NCT00724399||A|Women attending their annual screening mammography and gynecology clinic visits.
3266196|NCT00724373||Participants with genotype 1 Hepatitis C Virus infection.|Participants with genotype 1 Hepatitis C Virus (HCV) infection who have been treated with pegylated interferon alfa-2b and ribavirin in the preceding 48 months
3266197|NCT00724347|Experimental|Arm 1|Hearing impaired listeners with hearing aids underwent two months of consonant identification training in their homes.
3266198|NCT00724334|Experimental|1|
3266199|NCT00724321|Other|Iloprost and placebo|Each participant will undergo testing at sea level and altitude after inhalation of iloprost and placebo, sequence is randomly assigned.
3266200|NCT00724308|Experimental|Arm 1|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
3266201|NCT00724308|Experimental|Arm 2|"The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state smoking cessation Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status."
3266202|NCT00724295||Arm 1|Overall study population
3266203|NCT00724282|Other|Eszopiclone or Placebo|Subjects receive either eszopiclone or placebo for 9 days, followed by 3 week washout, then crossover to opposite treatment. Treatment is double-blinded.
3266204|NCT00724269|Active Comparator|Opti Free RepliniSH|Opti Free RepliniSH
3266205|NCT00724269|Active Comparator|ReNu Multi-Plus|ReNu Multi-Plus
3266206|NCT00724256|Experimental|1|
3266207|NCT00724256|Active Comparator|2|
3266208|NCT00724243||Rheumatoid Arthritis Patients in Slovakia|Rheumatoid arthritis patients in Slovakia who are starting treatment with infliximab for the first time, in accordance with normal clinical practice.
3266209|NCT00724230||Arm 1|Overall study population.
3266210|NCT00724217|Experimental|Normal weight|BMI < 26
3266211|NCT00724217|Experimental|Overweight|BMI >= 26
3266212|NCT00724204|Placebo Comparator|A|Children that consumed a follow on formula without Lactobacillus salivarius CECT5713
3266213|NCT00724204|Active Comparator|B|Children that consumed a follow on formula with Lactobacillus salivarius CECT5713
3266214|NCT00724191||A|Evaluation of new MRI methods that measure information related to the chemical makeup of the brain in patients undergoing therapy for brain tumors.
3266215|NCT00724178|Experimental|A|Oral cholecalciferol (100,000 IU) administered orally every 60 days plus calcium carbonate (1 gram)given daily
3266216|NCT00724178|Placebo Comparator|B|Double placebo
3266217|NCT00724165|Experimental|1|
3266218|NCT00724165|Active Comparator|2|
3266219|NCT00724152|Experimental|Arm 1/Cognitive Behavioral Therapy|Participants randomly assigned to this experimental group received six weeks of tinnitus education plus cognitive behavioral therapy. Cognitive behavioral therapy for tinnitus participants addressed cognitive and behavioral skills targeting the management of tinnitus and the negative impacts of tinnitus. Long-term self-efficacy and self-sufficiency were emphasized. The major components of CBT for tinnitus included identification of individual responses and beliefs about tinnitus and hearing loss, re-conceptualization of the tinnitus experience as one in which the patient has personal control, presentation of skills to modify cognitions and change behaviors, and reinforcement of skills via goals setting, homework and activities. Skills related to attention control, sleep hygiene, relaxation training are provided. Tinnitus education also included causes, treatments, current research, etc.
3266220|NCT00724152|Active Comparator|Arm 2/Tinnitus Education|Participants randomly assigned to this group received six weeks of tinnitus education. Tinnitus education and skills related to attention control, sleep hygiene and relaxation training such as imagery techniques were provided. Tinnitus education included causes, treatments, current research, epidemiological information, basic anatomy of the ear and brain, and support resources.
3266221|NCT00724152|No Intervention|Arm 3/Standard Care|Participants randomly assigned to this control group received only standard care. Standard care involves audiological measurement and brief education during the standard care appointment.
3266222|NCT00724139|Experimental|1|patients (aged 50-75) with Symptomatic knee OA for at least 6 months, fulfilled American College of Rheumatology clinical criteria for OA of the knee and radiographically assessed osteoarthritis of the knee graded 1-2 according to the Kellgren & Lawrence scale.
3266223|NCT00724126|Placebo Comparator|Placebo|Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
3266224|NCT00724126|Experimental|Rifaximin|Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
3266225|NCT00724113|Active Comparator|1|infiltration intra articular
3266226|NCT00724113|Experimental|2|ARTHRO distension plus intensive mobilisation
3266227|NCT00724087|Experimental|5.5-hour bedtime|
3266228|NCT00724087|Experimental|8.5-hour bedtime|
3266229|NCT00724074|Experimental|S|Patients receive the On-Q local continuous wound infusion system intra-operatively and use it for up to three days post-operatively.
3266230|NCT00724074|Active Comparator|C|Usual care - post operative pain medications as per the knee arthroplasty care map.
3266231|NCT00724061|Experimental|PEG-IFN-α-2b + UV therapy|Pegylated interferon α-2b in combination with UV therapy (either PUVA or NB-UVB).
3266232|NCT00724048|Experimental|ACR16 10 mg|"Participants receive one ACR16 10mg twice daily:~First four weeks - ACR16 10mg qd - one active 10mg capsule daily. After four weeks - ACR16 10mg bid - two active 10mg capsules taken as two separate doses (20mg ACR16 per day)."
3266233|NCT00724048|Experimental|ACR16 22.5 mg|"Participants receive one ACR16 22.5mg capsule twice daily:~First four weeks - ACR16 22.5mg qd - one active 22.5mg capsule daily. After four weeks - ACR16 22.5mg bid - two active 22.5mg capsules taken as two separate doses (45mg ACR16 per day)."
3266311|NCT00723450|Experimental|lamictal|Flexible Dosing
3266312|NCT00723424|Experimental|1|AZD5672 + Digoxin (single dose on day 12)
3266364|NCT00723021|Experimental|PF-04191834 100mg|
3266234|NCT00724048|Experimental|ACR16 45 mg|"Participants receive one ACR16 45mg capsule twice daily:~First four weeks - ACR16 45mg qd - one active 45mg capsule daily. After four weeks - ACR16 45mg bid - two active 45mg capsule taken as two separate doses (90mg ACR16 per day)."
3266235|NCT00724048|Placebo Comparator|Placebo|"Weeks 1-4, Participants receive a one placebo capsule once daily for four weeks.~Weeks 5-26, Participants receive a one placebo capsule taken twice daily as two separate doses."
3266236|NCT00724035|Experimental|Infraclavicular|This group will receive an ultrasound-guided infraclavicular brachial plexus block.
3266237|NCT00724035|Active Comparator|Axillary|This group will receive an ultrasound-guided axillary brachial plexus block.
3266238|NCT00724022|Other|A|Standard: Advagraf, CellCept, Decortin H + 2x Simulect Day 0 + 4
3266239|NCT00724022|Experimental|B|Steroidfree: Advagraf, Cellcept, Decortin H until Day 8, 2x Simulect Day 0 + 4
3266240|NCT00724022|Experimental|C|Steroidfree: Advagraf, Cellcept, Decortin H until Day 8, 3 x Thymoglobulin
3266241|NCT00724009|Experimental|Clofarabine|Clofarabine 30 mg/m2/day IV infusion over one hour for 5 consecutive days
3266242|NCT00723996||Group 1|Women receiving a CRC-related questionnaire and a CRC educational video.
3266243|NCT00723996||Group 2|Women who receive only a CRC-related questionnaire.
3266244|NCT00723996||Group 3|Women who receive neither questionnaire nor educational video.
3266245|NCT00723983|Active Comparator|Period 1|Subject dosed with oral sumatriptan succinate during an acute migraine attack.
3266246|NCT00723983|Active Comparator|Period 2|Subject dosed with oral sumatriptan during a non-migraine period.
3266247|NCT00723983|Experimental|Period 3 and Period 6|Subject dosed with NP101 during an acute migraine attack.
3266248|NCT00723983|Experimental|Period 4 and Period 5|Subject dosed with NP101 study patch during a non-migraine period.
3266249|NCT00723970|Experimental|A|Use of quetiapine, flexible dose (150-300 mg/day) for 8 weeks, following a 2-week placebo lead-in phase
3266250|NCT00723957|Experimental|Ixabepilone, 32 mg/m^2 + Carboplatin (AUC 6)|
3266251|NCT00723957|Active Comparator|Paclitaxel, 200 mg/m^2 + Carboplatin (AUC 6)|
3266252|NCT00723944|Active Comparator|Osseotite Certain Prevail|Dental implant with lateralized design
3266253|NCT00723944|Placebo Comparator|Osseotite Certain|Dental implant without the lateralized design
3266254|NCT00723931||Participants with Chronic Hepatitis C|Surveillance will be conducted at digestive departments of internal medicine in university or general hospitals where participants with Chronic Hepatitis C are generally treated.
3266255|NCT00723918|Active Comparator|1|methadone plus SAB placebo
3266256|NCT00723918|Experimental|2|methadone plus active SAB
3266257|NCT00723918|Placebo Comparator|3|methadone placebo plus SAB placebo
3266258|NCT00723892||PegIntron/Rebetol and psychotherapy support program|Participants receiving a psychotherapy support program during PegIntron/Rebetol therapy for hepatitis C.
3266259|NCT00723892||PegIntron/Rebetol alone (no psychotherapy)|Participants receiving no psychotherapy support program during PegIntron/Rebetol therapy for hepatitis C.
3266260|NCT00723879||Patients with hepatitis C|Patients receiving a patient assistance program during therapy for hepatitis C will be enrolled into this study. All patients will receive PegIntron plus Rebetol (according to the label) and the patient assistance program.
3266261|NCT00723866|Experimental|1|BtxA+mCIMT (combination group)
3266262|NCT00723866|Placebo Comparator|2|BtxA+ conventional rehabilitation (control group)
3266263|NCT00723853|Experimental|Group 1|Reach-Out Program, Nutritional and Exercise Intervention
3266264|NCT00723853|Active Comparator|Group 2|Reach-In Program, Standard of Care
3266265|NCT00723840||Crohn's Disease Participants|"Participants with Crohn's Disease for at least 6 months, who have a Crohn's Disease Activity Index (CDAI) score >= 150. The CDAI score evaluates Crohn's disease symptoms - a score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.~These participants have active disease despite drug therapy."
3266266|NCT00723827||All Participants|Participants with newly diagnosed glioblastoma multiforme (treat with temozolomide & radiotherapy) or participants with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy (treat with temozolomide).
3266267|NCT00723801|Active Comparator|Subjects Randomized to Losartan|Losartan: 100 mg PO QD
3266268|NCT00723801|Active Comparator|Subjects Randomized to Atenolol|Atenolol: 50 mg PO QD
3266269|NCT00723788|Experimental|Only one arm|All patients enrolled will receive an MRI of the abdomen with detailed views of the appendix
3266270|NCT00723775|Other|Part 1|GSK706769 new vs. current formulation; GSK706769 alone vs. GSK706769 plus Kaletra
3266271|NCT00723775|Other|Part 2|GSK706769 alone for 10 days; GSK706769 + Kaletra for 14 days
3266272|NCT00723762||1|Resident of Hattie Larlham long-term care facility receiving VPA
3266273|NCT00723762||2|Control AED patients will be recruited based on similar AED regimens excluding VPA, length of time on AED (number of months to >1 year), age, and gender; one control patient per VPA patient.
3266274|NCT00723762||3|Control non-AED patients will be recruited based on age and gender; one control patient per VPA patient.
3266275|NCT00723749||Suboxone|Patients for whom a drug dependence therapy with SUBOXONE® is planned and indicated, and who have already been pre-treated with SUBUTEX®, or another maintenance drug for at least 6 months.
3266276|NCT00723736||Pediatric Patients|Those with allergic rhinitis or chronic idiopathic urticaria.
3266277|NCT00723723||Patients with coronary heart disease|Patients being treated with a statin for secondary prevention of coronary heart disease
3266278|NCT00723710||Intron A|Patients with malignant melanoma who are free of disease post-surgery but at high risk for systemic recurrence.
3266279|NCT00723697||Patients|Patients addicted to opiates and requiring replacement treatment. Patients in this non-interventional study were prescribed treatment as per usual clinical practice.
3266280|NCT00723684|Placebo Comparator|Placebo group|This group will receive no real EEG-Neurofeedback.
3266281|NCT00723684|Experimental|NF group|This group will receive real EEG-Neurofeedback
3266282|NCT00723671|Experimental|metabolic peaks|
3266283|NCT00723658|No Intervention|Observation|Non-symptomatic patients are monitored monthly for 3 months, then every 3 months thereafter.
3266284|NCT00723658|Experimental|Treatment|"Symptomatic pts: 2 cycles VTDPACE+R:~dex 40 mg PO D1-4 thalid 200 mg PO D1-4 cisplatin 10 mg/m2 IV D1-4 dox 10 mg/m2 IV D1-4 cyclophos 400 mg/m2 IV D1-4 etoposide 40 mg/m2 IV D1-4 bortezomib 1.0 mg/m2 IV D1,4,8,11 ritux 375 mg/m2 IV D1,8,15 lovenox 40 mg/d SQ D1-platelets >50,000/mcl GCSF 10 mcg/kg/d IV D9-WBC <2,000/mcl apheresis >/= 20x10^6 when WBC and CD34 within normal range, up to 4 cycles~st Trans: mel 200 mg/m2 IV D-1 bortezomib 1.3 mg/m2 IV D-4, -1 PBSC >/=3.0x10^6/kg CD34 cells IV D0 GCSF 5 mcg/kg/d SQ D6-WBC recovery D5NS 500 ml IV D-1 dex 40 mg/d PO D-4 to -1 ondansetron 24 mg OR granisetron 2 mg PO D-1~nd Trans: BCNU 300 mg/m2 IV D-5 etoposide 200 mg/m2 IV D-5 to -2 AraC 400 mg/m2 IV D-5 to -2 mel 140 mg/m2 IV D-1 PBSC infusion >/=3.0x10^6/kg CD34 cells IV D0 GCSF 5 mcg/kg/d SQ D6-WBC recovery D5NS 150 ml/hr IV D-5 to -1 dex 40 mg/d PO D-4 to -1 ondansetron 24 mg OR granisetron 2 mg PO D-1"
3266285|NCT00723645||PEG IFN alfa-2b + RBV|Adult participants with chronic hepatitis C who were treated for the first time with pegylated interferon alfa-2b plus ribavirin and achieved end-of-treatment response prior to the study. Participants received no treatment during this study.
3266286|NCT00723632||Peginterferon alfa-2b and ribavirin|All participants included in the study
3266287|NCT00723619||1|Children and adolescent from German schools in the region Wesel, Hannover and Düsseldorf, selected via special school lists
3266288|NCT00723606|Experimental|Intramuscular ziprasidone|
3266289|NCT00723606|Active Comparator|Intramuscular haloperidol|
3266290|NCT00723580|Experimental|Sleep and Activity by Treatment Condition|Actigraphic measurements were obtained by attaching an actigraphic watch device to the child's non-dominant wrist. The measurements will include three separate three week periods beginning with a baseline period and the period in which the child's pharmacological treatment was initiated. Two additional three week actigraphic measurement periods will occur at 22 months post-baseline period and at 23 months post-baseline period. The resulting five treatment conditions were: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.). Sleep and activity will be evaluated by treatment conditions.
3266291|NCT00723567||Affected Group|Family members of northern European descent in which members have different erythrocyte morphology ranging from atypical HPP to HE to normal and a novel Sp mutation.
3266292|NCT00723554|Experimental|Iloprost|"The study enrolled patients who were already using iloprost with PD-6 without any safety or tolerability concerns, thereby facilitating a direct comparison of the PD-15 to the PD-6.~The single-arm design allowed each patient to serve as his/her own control"
3266293|NCT00723541|Experimental|A|Develop a computer-aided diagnostic system that will aid in the screening and detection of breast abnormalities/cancer
3266294|NCT00723528|Placebo Comparator|Placebo (CP)|Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
3266295|NCT00723528|Active Comparator|Ustekinumab 45 mg (CP)|Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
3266296|NCT00723528|Active Comparator|Ustekinumab 90 mg (CP)|Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
3266297|NCT00723528|Placebo Comparator|Placebo A (After CP)|After the controlled period (that is [i.e.], during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
3266298|NCT00723528|Placebo Comparator|Placebo B (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
3266299|NCT00723528|Active Comparator|Ustekinumab 45 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
3266300|NCT00723528|Active Comparator|Ustekinumab 90 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
3266301|NCT00723515|Active Comparator|G1|NaF (sodium fluoride varnish) with 2.26% of fluoride
3266302|NCT00723515|Experimental|G2|NaF (sodium fluoride)2.71% of fluoride plus CaF2 (calcium fluoride)
3266303|NCT00723502|Experimental|1|
3266304|NCT00723502|Experimental|2|
3266305|NCT00723489|Experimental|YFV-17D (Right Deltoid)|Participants will be randomized within each atopic dermatitis (AD) severity subgroup or as non-atopic controls to either subcutaneous (SC) or transcutaneous (TC) vaccine administration. In this arm, participants will receive a standard vaccine dose (5.5x10^4 Plaque Forming Units) of YFV-17D administered subcutaneously in the right deltoid and placebo vaccination transcutaneously (then covered with a semi-occlusive dressing) in the left deltoid. The site pharmacist will maintain the blind and an unblinded (i.e., masked) site coordinator will administer assigned treatment: investigators, participants and assessors remain blinded to treatment assignments throughout the duration of the trial.
3266306|NCT00723489|Experimental|YFV-17D (Left Deltoid)|Participants will be randomized within each atopic dermatitis (AD) severity subgroup or as non-atopic controls to either subcutaneous (SC) or transcutaneous (TC) vaccination. In this arm, participants will receive YFV-17D vaccination (1x10^3 Plaque Forming Units) by transcutaneous administration (then covered with a semi-occlusive dressing to optimize YFV-17D absorption) in the left deltoid and placebo by subcutaneous administration in the right deltoid. The site pharmacist will maintain the blind and an unblinded (i.e., masked) site coordinator will administered treatment: investigators, participants and assessors remain blinded to treatment assignments throughout the duration of the trial.
3266307|NCT00723476|Active Comparator|A|Participants will receive three 60- to 90-minute health education control sessions.
3266308|NCT00723476|Experimental|B|Participants will receive three 60- to 90-minute Family Centered Advanced Care Planning sessions.
3266309|NCT00723463|Experimental|A|To determine if apparent diffusion coefficient values can differentiate tumors from normal tissues using a 3T MRI scan.
3266310|NCT00723450|Placebo Comparator|placebo|Placebo Controlled
3266313|NCT00723424|Experimental|2|AZD5672 (increasing dose up to 150mg) + digoxin (single dose on day 12)
3266314|NCT00723411|Active Comparator|A|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on Days 90 and 270.
3266315|NCT00723411|Active Comparator|B|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on Days 90 and 270.
3266316|NCT00723411|Placebo Comparator|C|This arm will receive 4 injections of placebo, 1 each on Days 1, 30, 90, and 270.
3266317|NCT00723398|No Intervention|1|Control
3266318|NCT00723398|Experimental|2|Raloxifene 60 mg
3266319|NCT00723398|Experimental|3|Raloxifene 30 mg
3266320|NCT00723398|Experimental|4|Lovaza 4 gm
3266321|NCT00723398|Experimental|5|Lovaza 4 gm plus Raloxifene 30 mg
3266322|NCT00723385|Placebo Comparator|Placebo|Placebo administration for 12 weeks with repeated 25-OH D determinations over 12 weeks, dietary, sunshine questionnaire recording
3266323|NCT00723385|Experimental|Vitamin D|Vitamin D (1000 or 2000 IU/day)
3266324|NCT00723359|Experimental|BT062|BT062 single agent dose escalation
3266325|NCT00723346|Experimental|1|
3266326|NCT00723346|Experimental|2|
3266327|NCT00723346|Experimental|3|
3266328|NCT00723346|Active Comparator|4|
3266329|NCT00723333||Affected Group|Patients > 60 years of age with Primary Myelofibrosis that have undergone an allogeneic transplant
3266330|NCT00723320|No Intervention|P+N|placebo without lifestyle intervention
3266331|NCT00723320|Experimental|D+N|Atorvastatin 10mg/d
3266332|NCT00723320|Experimental|P+A|lifestyle intervention without Atorvastatin
3266333|NCT00723320|Experimental|D+A|lifestyle intervention and Atorvastatin 10mg/d
3266334|NCT00723307|Experimental|Metformin|
3266335|NCT00723307|Placebo Comparator|Placebo|
3266336|NCT00723294|Experimental|Treatment (cryoablation)|A cryoprobe is inserted percutaneously under ultrasound guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively. Patients undergo surgical resection and sentinel lymph node biopsy and/or axillary dissection within 28 days after completion of cryoablation. Patients complete the Brief Pain Inventory before and after cryoablation and after surgery.
3266337|NCT00723268|Active Comparator|Prednisolone|
3266338|NCT00723268|Active Comparator|Colchicine|
3266339|NCT00723255|Experimental|Treatment (bevacizumab, temsirolimus)|Patients receive bevacizumab IV on days 1 and 15 and temsirolimus IV on days 1, 8, 15, and 22.
3266340|NCT00723229|Active Comparator|1|
3266341|NCT00723229|No Intervention|2|
3266342|NCT00723216|Active Comparator|1|Enoxaparin
3266343|NCT00723216|Other|2|Intermittent Pneumatic Compression (IPC)
3266344|NCT00723203|Experimental|Treatment (panobinostat)|"Patients receive oral panobinostat once on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~panobinostat: 40 mg Monday, Wednesday and Friday of every week in a 28 day cycle"
3266345|NCT00723190|Experimental|Arm A|CLONICEL (Clonidine HCl sustained release)
3266346|NCT00723177|Placebo Comparator|Placebo|This group will receive placebo drug
3266347|NCT00723177|Experimental|Low-dose AV411|This group will receive a low dose of AV411
3266348|NCT00723177|Experimental|High-dose AV411|This group will receive a high dose of AV411
3266349|NCT00723164|Active Comparator|FM|Premedication consisting of fentanyl 0.6 ug/kg and midazolam 9 ug/kg (FM), five minutes before tidal volume sevoflurane 8% induction with 6 L/min O2.
3266350|NCT00723164|Placebo Comparator|NaCl|A 2.5 ml NaCL placebo (NaCl) IV, five minutes before tidal volume sevoflurane 8% induction with 6 L/min O2.
3266351|NCT00723151|Experimental|Low Intensity|One hour of intervention per week
3266352|NCT00723151|Experimental|High Intensity|Five hours of intervention per week, one hour per day for five days per week
3266353|NCT00723125|Experimental|Cohort 1|"Avastin 10 mg/kg IV over 90 minutes day -14~Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10~Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles~Definitive surgery~Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks"
3266354|NCT00723125|Experimental|Cohort 2|"Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7~Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7~Definitive surgery~Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks"
3266355|NCT00723112||Affected Group|Adult subjects with the diagnosis of MDS based on the French-American-British classification system.
3266356|NCT00723112||Healthy Controls|Control subjects will be selected using frequency matching on gender and age by decade. That is for each MDS patient a healthy volunteer of the same gender and decade (50-59, 60-69, 70-79, etc) will be selected
3266357|NCT00723099|Experimental|Treatment (chemotherapy, transplant)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1-2 hours on day -6. Patients undergo a lower dose of TBI on day -1.~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo donor umbilical cord blood infusion on day 0.~IMMUNOSUPRESSIVE THERAPIES: Patients receive cyclosporine IV over 1 hour every 8-12 hours on days 0 to +180 and mycophenolate mofetil IV or PO every 8 hours on days -3 to +96."
3266358|NCT00723073||Caspofungin arm|All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an Absolute Neutrophil Count (ANC) < 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.
3266359|NCT00723073||Micafungin arm|All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an Absolute Neutrophil Count (ANC) < 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent
3266360|NCT00723060|Active Comparator|1|escitalopram high dose group
3266361|NCT00723060|Active Comparator|2|escitalopram conventional group
3266362|NCT00723047|Experimental|1|
3266365|NCT00723021|Experimental|PF-04191834 2000mg|
3266366|NCT00723021|Active Comparator|zileuton|
3266367|NCT00723021|Placebo Comparator|placebo|
3266368|NCT00723008|Experimental|A|Upon randomization, a double blinded Alpha Stim 100 device preset to the lowest effective setting (1/6) will be applied to the earlobes of the subject for one hour per day for 5 days per week for 4 weeks; after the blinded period is completed the patient will wear a different Alpha Stim device that has not been blinded for one hour per day for 5 days per week for 4 weeks, with settings at the patient's preference (1 to 6/6). Report of pain, anxiety will be assessed before and after each daily session during the 8 week period.
3266369|NCT00723008|Experimental|B|Upon randomization, a double blinded Alpha Stim 100 device preset to no stimulation (0/6)will be applied to the earlobes of the subject for one hour per day for 5 days per week for 4 weeks; after the blinded period is completed the patient will wear a different Alpha Stim device that has not been blinded for one hour per day for 5 days per week for 4 weeks, with settings at the patient's preference (1 to 6/6). Report of pain, anxiety will be assessed before and after each daily session during the 8 week period.
3266370|NCT00722995|Active Comparator|1|Sleeve gastrectomy
3266371|NCT00722995|Active Comparator|2|Gastric Bypass
3266372|NCT00722982||1|
3266373|NCT00722982||2|
3266374|NCT00722969|Experimental|A|
3266375|NCT00722956|Experimental|1|AZD5672 + atorvastatin
3266376|NCT00722943|Active Comparator|DMT group|These infants will receive tactile stimulation and developmental massage by a licensed therapist. This intervention will be done behind a screen in order to blind the therapy to NICU staff and parents.
3266377|NCT00722943|Placebo Comparator|SHAM control|These infants will have no tactile stimulation or developmental massage done. The therapist will stand behind a screen but will not touch the infant. The screen will blind the NICU staff and parents to the study arm.
3266378|NCT00722930|Experimental|1. Consolidation with Y90 Ibritumomab Tiuxetan|1. Consolidation with Y90 Ibritumomab Tiuxetan
3266379|NCT00722917|Experimental|TAK-379 25 mg QD|
3266380|NCT00722917|Experimental|TAK-379 100 mg QD|
3266381|NCT00722917|Experimental|TAK-379 200 mg QD|
3266382|NCT00722917|Active Comparator|Pioglitazone 30 mg QD|
3266383|NCT00722917|Placebo Comparator|Placebo|
3266384|NCT00722904||1|patients undergoing routine post-intervention surveillance of aortic coarctation
3266385|NCT00722904||2|Healthy volunteers
3266386|NCT00722891|Active Comparator|Balafilcon A with ReNu|Balafilcon A Lenses with ReNu Multiplus Solution
3266387|NCT00722891|Active Comparator|Balafilcon A with RepleniSH|Balafilcon A Lenses with Optifree RepleniSH Solution
3266388|NCT00722865|Other|Avastin (Bevacizumab)|single-arm, open-label
3266389|NCT00722852|Experimental|1|
3266390|NCT00722852|Placebo Comparator|2|
3266391|NCT00722839|Experimental|Group A|Participants receive either PADRE-CMV fusion peptide vaccine or tetanus-CMV fusion peptide vaccine subcutaneously (SC) on days 1, 21, 42, and 63 in the absence of unacceptable toxicity.
3266392|NCT00722839|Experimental|Group B|Participants receive either PADRE-CMV fusion peptide vaccine in CpG 7909 adjuvant SC or tetanus-CMV fusion peptide vaccine in CpG 7909 adjuvant SC on days 1, 21, 42, and 63 in the absence of unacceptable toxicity.
3266393|NCT00722800|Experimental|A|drospirenone and ethinyl estradiol
3266394|NCT00722800|Placebo Comparator|B|Placebo
3266395|NCT00722774|Experimental|1|Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
3266396|NCT00722761|Active Comparator|Drosperinone and Ethinyl estradiol|Drospirenone and Ethinyl estradiol (3mg/0.02mg)(YAZ)tablet once a day
3266397|NCT00722761|Placebo Comparator|Placebo tablet|Placebo tablet once a day
3266398|NCT00722748||Genebank|By creating a genebank from patient's blood donations we will ultimately be able to define genes for various cardiovascular conditions.
3266399|NCT00722735|Experimental|1|Group I: Finafloxacin tablets + Ciprofloxacin placebo capsule
3266400|NCT00722735|Active Comparator|2|Group II: Ciprofloxacin capsule + Finafloxacin placebo tablets
3266401|NCT00722722|Active Comparator|4 dose group|4 doses of bortezomib (1.3mg/m^2 of body surface area)
3266402|NCT00722722|Active Comparator|16 dose group|16 doses of bortezomib (1.3mg/m^2 of body surface area)
3266403|NCT00722722|Active Comparator|32 dose group|32 doses of bortezomib (1.3mg/m^2 of body surface area)
3266404|NCT00722709|Experimental|LA|Use of Ropivacaine
3266405|NCT00722709|Placebo Comparator|Placebo|Use of 0.9% saline
3266406|NCT00722683|Experimental|Ultrasound Imaging|Ultrasound Imaging with Contrast
3266407|NCT00722670|Experimental|Woman-focused (WF)|Woman-focused intervention (Women's CoOp)
3266408|NCT00722670|Active Comparator|Treatment as Usual (TAU)|TAU (substance abuse treatment only)
3266409|NCT00722631|Experimental|1|up to 30 mg pioglitazone, tablet, orally, once daily
3266410|NCT00722631|Active Comparator|2|up to 4 mg/day glimepiride, tablet, orally, once daily
3266411|NCT00722618|Active Comparator|Intervention|Written materials, telephone based education
3266412|NCT00722618|Other|Comparison|Written materials
3266413|NCT00722605|Experimental|1|cone-beam CT based
3266414|NCT00722592|Experimental|Vintafolide + PLD|Participants receive vintafolide 2.5 mg intravenous (IV) bolus on Days 1, 3, 5, 15, 17, and 19 and Pegylated Liposomal Doxorubicin (PLD) weight-based dose, IV on Day 1 of each 4-week cycle.
3266415|NCT00722592|Active Comparator|PLD Alone|Participants receive PLD on Day 1 of each 4-week cycle.
3266416|NCT00722579|Experimental|A|The PRESILLION TM Coronary Stent is an L-605 cobalt chromium (CoCr) stent.
3266417|NCT00722566|Experimental|1|VELCADE administered by subcutaneous injection
3266418|NCT00722566|Active Comparator|2|VELCADE administered by intravenous infusion
3266419|NCT00722540|Experimental|A|
3266420|NCT00722540|Experimental|B|
3266421|NCT00722540|Experimental|C|
3266422|NCT00722540|Experimental|D|
3266423|NCT00722540|Experimental|E|
3266424|NCT00722527||Affected Population|Subjects with an elevated hemoglobin concentration or an elevated platelet count
3266425|NCT00722514|Experimental|IG|Patient education
3266426|NCT00722514|Other|CG|without patient education
3266427|NCT00722501|Active Comparator|ERB-257|7 IV single doses of ERB-257 will be given to 6 healthy subjects per group - 1,4, 15, 45, 90, 180, and 300 mg
3266428|NCT00722501|Placebo Comparator|placebo|2 placebo subjects per group
3266429|NCT00722488|Experimental|1|MLN4924
3266430|NCT00722475|Experimental|IvIg|Repeated infusions of intravenous immunoglobulin in early pregnancy
3266431|NCT00722475|Placebo Comparator|placebo|infusion of human albumin CSL Behring 5%
3266432|NCT00722462|Experimental|1|Active acupuncture
3266433|NCT00722462|Sham Comparator|2|Sham Acupuncture- acupuncture at neutral points
3266434|NCT00722462|No Intervention|3|Embryo transfer with no acupuncture
3266435|NCT00722436|Experimental|Tranexamic acid|Tranexamic acid (100 mg/kg load, 10 mg/kg/hr) intravenous
3266436|NCT00722436|Placebo Comparator|Placebo|Saline was administered intravenously
3266437|NCT00722423|Experimental|Integrated Care Model|Integrated Care
3266438|NCT00722423|Experimental|Usual Care Model|Usual Care
3266439|NCT00722410|No Intervention|A|
3266440|NCT00722410|Experimental|B|VSL#3 for 4 weeks
3266441|NCT00722410|Experimental|C|Mechanical bowel cleansing followed by VSL#3 for 4 weeks.
3266442|NCT00722384|Experimental|1|0.1 mg bevasiranib in the study eye
3266443|NCT00722384|Experimental|2|0.33 mg bevasiranib in the study eye,
3266444|NCT00722384|Experimental|3|1.0 mg bevasiranib in the study eye
3266445|NCT00722384|Experimental|4|1.5 mg bevasiranib in the study eye
3266446|NCT00722384|Experimental|5|3.0 mg bevasiranib in the study eye.
3266447|NCT00722371|Experimental|Sitagliptin 100 mg|
3266448|NCT00722371|Experimental|Pioglitazone 15 mg|
3266449|NCT00722371|Experimental|Pioglitazone 30 mg|
3266450|NCT00722371|Experimental|Pioglitazone 45 mg|
3266451|NCT00722371|Experimental|Sitagliptin 100 mg/ Pioglitazone 15 mg|
3266452|NCT00722371|Experimental|Sitagliptin 100 mg/ Pioglitazone 30 mg|
3266453|NCT00722371|Experimental|Sitagliptin 100 mg/ Pioglitazone 45 mg|
3266454|NCT00722358|Active Comparator|BMS-650032|
3266455|NCT00722358|Placebo Comparator|Placebo|
3266456|NCT00722345|Placebo Comparator|1|
3266457|NCT00722345|Experimental|2|
3266458|NCT00722332|Experimental|1|HBV-related liver transplant patients
3266459|NCT00722319||A|Patients on long-term oral anticoagulation who are submitted to PCI-S because of acute coronary syndrome or stable angina. No further groups nor interventions are anticipated since the study is observational
3266460|NCT00722306|Experimental|A425|A425 Treated
3266461|NCT00722293|Experimental|Arm A|once daily oral administration of pazopanib for Days 1-21 days in combination with epirubicin given as a bolus intravenous administration on Day 3
3266462|NCT00722293|Experimental|Arm B|once daily oral administration of pazopanib for Days 1-8 of a 3-week cycle in combination with epirubicin (bolus intravenous administration) on Day 3
3266463|NCT00722293|Experimental|Arm C|epirubicin (bolus intravenous administration) on Day 1 with once-daily oral administration of pazopanib for Days 14-21 of a 3-week cycle
3266464|NCT00722293|Experimental|Arm D|once-daily oral administration of pazopanib (according to schedule selected from either Arm A, B, or C) (3 week cycle) in combination with doxorubicin (bolus intravenous administration) on Day 1 or 3, depending on the schedule selected from either Arm A, B, or C
3266465|NCT00722280|Experimental|Hand Transplantation|Described above
3266466|NCT00722254||PPH|Subjects diagnosed with primary pulmonary hypertension (PPH)
3266467|NCT00722254||Myelofibrosis|Subjects diagnosed with Primary or Secondary Myelofibrosis
3266468|NCT00722241||A|Adult subjects (at least 18 years of age) with a diagnosis of type 1 diabetes (~80%) or insulin-treated type 2 diabetes (~20%); method of insulin delivery may be multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII)
3266469|NCT00722228|Experimental|Autologous or Allogeneic tumor cells|Intervention: 5 vaccine doses, 3 weeks apart, injected subcutaneously.
3266470|NCT00722215|Placebo Comparator|1|Placebo control arm of study
3266471|NCT00722215|Experimental|2|BQ-123 arm of study
3266472|NCT00722215|Active Comparator|3|Nifedipine arm of study
3266473|NCT00722202|Active Comparator|ERB-257|7 IV single doses of ERB-257 will be given to 6 healthy subjects per group - 1, 4, 15, 45, 90, 180, and 300 mg
3266474|NCT00722202|Placebo Comparator|placebo|2 placebo subjects per group
3266475|NCT00722189||A|All patients treated
3266476|NCT00722176|Experimental|1|BL-1020 10 mg
3266477|NCT00722176|Experimental|2|BL-1020 10-30 mg
3266478|NCT00722176|Active Comparator|3|risperidone
3266479|NCT00722163|Experimental|1|behavioural
3266480|NCT00722163|Active Comparator|2|befriending
3266481|NCT00722163|No Intervention|3|TAU
3266482|NCT00722150|Active Comparator|Arm 1|"Oral Artesunate (standard dose)"
3266483|NCT00722150|Active Comparator|Arm 2|"Oral Artesunate (ARC1 dose)"
3266484|NCT00722150|Experimental|Arm 3|"Oral Artesunate (experimental high dose)"
3266485|NCT00722137|Active Comparator|R-CHOP|Rituximab 375 mg/m^2, Cyclophosphamide 750 mg/m^2, Doxorubicin 50 mg/m^2, Vincristine 1.4 mg/m^2, and Prednisone 100 mg/m^2
3266486|NCT00722137|Experimental|VcR-CAP|Rituximab 375 mg/m^2, Cyclophosphamide 750 mg/m^2, Doxorubicin 50 mg/m^2, VELCADE 1.3 mg/m^2, and Prednisone 100 mg/m^2
3266487|NCT00722124|Active Comparator|SAMe 800|Each subject randomized to this arm will take a 400 mg pill of SAMe and one matching placebo pill in the AM and again in the PM
3266488|NCT00722124|Active Comparator|SAMe 1600|Each person randomized to this arm will take 2 400 mg pills of SAMe in the AM and again in the PM
3266489|NCT00722124|Placebo Comparator|Placebo|Each subject randomized to this arm will take 2 placebo pills in the AM and again in the PM
3266490|NCT00722111|Experimental|Arm 1|lingual press (high-intensity, oral, non-swallowing)
3266491|NCT00722111|Experimental|Arm 2|effortful swallowing (high-intensity swallowing)
3266492|NCT00722111|Experimental|Arm 3|natural swallowing (high frequency, low intensity swallowing)
3266493|NCT00722111|Sham Comparator|Arm 4|non-oral sham (control) exercise
3266645|NCT00721019|Experimental|8.5-hour bedtime|
3266494|NCT00722098|Experimental|DC Vaccine & Cyclophosphamide|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
3266495|NCT00722098|Placebo Comparator|DC Vaccine & Placebo|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
3266496|NCT00722085||Observational|
3266497|NCT00722072|Experimental|Fulvestrant/ Sorafenib|"Fulvestrant: A loading dose will be administered intramuscularly to all subjects during cycle 1 of treatment as follows:~500 mg IM on Day 1~250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of Fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or unacceptable toxicity occurs requiring discontinuation.~Sorafenib: Subjects will take Sorafenib 800 mg/day administered as 400 mg bid (twice daily)each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until unacceptable toxicity occurs."
3266498|NCT00722059|Experimental|1|Subjects will undergo a 3D breast Tomosynthesis imaging scan. This is a one time breast imaging scan will last approximately 15 minutes.
3266499|NCT00722046|Experimental|PF-04360365 0.1 mg/kg|
3266500|NCT00722046|Experimental|PF-04360365 0.5 mg/kg|
3266501|NCT00722046|Experimental|PF-04360365 1 mg/kg|
3266502|NCT00722046|Placebo Comparator|Placebo|
3266503|NCT00722046|Experimental|PF-04360365 3 mg/kg|
3266504|NCT00722046|Experimental|PF-04360365 8.5 mg/kg|
3266505|NCT00722033|Other|A|< 30 weeks of gestation
3266506|NCT00722020|Experimental|Vest Arm|HFCWO treatments 2-3 times daily 15 minutes per treatment via the VEST
3266507|NCT00722020|No Intervention|Control|Historical control for PICU asthma patients
3266508|NCT00722007|Experimental|Cormet Hip Resurfacing Post-PMA Group|hip resurfacing
3266509|NCT00721994||1|IDE subjects who received the Cormet Hip Resurfacing device
3266510|NCT00721981||1|Regular treatment for non-small cell lung cancer (NSCLC)
3266511|NCT00721968|Active Comparator|1|Treatment Group (Group 1): Glaukos Trabecular Micro-Bypass Stent Model GTS400; implantation in conjunction with cataract surgery
3266512|NCT00721968|Placebo Comparator|2|Control Group (Group 2): Cataract surgery only
3266513|NCT00721955|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo, may repeat after 2 hours x 2
3266514|NCT00721955|Experimental|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, may repeat after 2 hours x 2
3266515|NCT00721955|Experimental|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, may repeat after 2 hours x 2
3266516|NCT00721929|Experimental|adrenal mass group|
3266517|NCT00721916|Experimental|1|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)
3266518|NCT00721916|Active Comparator|2|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)
3266519|NCT00721903|Active Comparator|Healthy Subjects|Ultrasound scan
3266520|NCT00721903|Active Comparator|Cancer|120 women diagnosed by biopsy to have breast cancer will have an ultrasound scan
3266521|NCT00721890|Experimental|1|
3266522|NCT00721877|Experimental|Arm I|Participants receive oral resveratrol once daily for 4 weeks.
3266523|NCT00721864||Affected Population|Subjects suspected of having Paroxysmal Nocturnal Hemoglobinuria (PNH)
3266524|NCT00721838||1|Surgery group
3266525|NCT00721838||2|Control - Lifestyle modification program
3266526|NCT00721825|Active Comparator|1|Neuroaid
3266527|NCT00721825|Placebo Comparator|2|Neuroaid matched placebo
3266528|NCT00721812|Other|Part A|Single dose escalation
3266529|NCT00721812|Other|Part B|14 day repeat dose escalation
3266530|NCT00721812|Other|Part C|Fixed dose food effect
3266531|NCT00721799|Experimental|FLT PET scan|"Subjects receive 2 18F-Fluorothymidine PET scans~Scan 1 at baseline (within 30 days prior to the start of chemotherapy and radiation therapy)~Scan 2 between fraction 5 and 6 of radiation therapy (after 10 Gray of radiation)"
3266532|NCT00721786|Experimental|San Francisco Internet Stop Smoking Site|"UCSF/SFGH Internet Stop Smoking Study site~Internet Stop Smoking site (TC4) with several intervention elements from which the participants may choose as many as they wish~The links (URLs) to register for the study are:~English: www.stopsmoking.ucsf.edu Spanish: www.dejardefumar.ucsf.edu"
3266533|NCT00721773|Experimental|ACE inhibitor, benazepril|Benazepril will be started at 10 mg/day and will be up-titrated to 20 mg/day according to BP control and tolerability.
3266534|NCT00721773|Experimental|Angiotensin receptor blocker, valsartan|Valsartan will be started at 80 mg/day and will be up-titrated to 160 mg/day according to BP control and tolerability.
3266535|NCT00721773|Experimental|RAS inhibitors, benazepril+valsartan|Benazepril will be started at 10 mg/day and will be up-titrated to 20 mg/day, and valsartan will be started at 80 mg/day and will be up-titrated to 160 mg/day according to BP control and tolerability.
3266536|NCT00721773|Active Comparator|non-RAS inhibitors, control|Drug: antihypertensive agents, except ACE inhibitors and ARBs. Administration of antihypertensive agents will select as follows: CCB→β-blocker→α-blocker.
3266537|NCT00721760|Experimental|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery~Placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind"
3266740|NCT00720278|Placebo Comparator|Placebo Nasal Spray|Placebo nasal spray
3266538|NCT00721760|Active Comparator|Enoxaparin|"Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
3266539|NCT00721747|Experimental|Unique arm|4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
3266540|NCT00721734|Experimental|Carfilzomib|"Carfilzomib, 15 mg/m², was administered intravenously (IV) on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles for a maximum of 12 cycles.~If the 15 mg/m² dose was tolerated the dose could be increased to 20 mg/m² starting at Cycle 2. If 20 mg/m² was tolerated, an additional dose escalation to 27 mg/m² was allowed at Cycle 3 or at subsequent cycles."
3266541|NCT00721721|Experimental|1|Participants will follow a low sodium diet for Days 1 through 7, a high sodium diet for Days 7 through 14, and a high sodium diet plus potassium supplement regimen for Days 14 through 21.
3266542|NCT00721708|Experimental|1|Carnosine(450 mg)
3266543|NCT00721708|Experimental|2|Beef (150g)
3266544|NCT00721708|Experimental|3|chicken (150g)
3266545|NCT00721708|Experimental|4|Chicken broth (obtained from 150 g of chicken breast)
3266546|NCT00721695|Experimental|1|OMS302 Irrigation Solution
3266547|NCT00721695|Active Comparator|2|OMS302-PE HCl Irrigation Solution
3266548|NCT00721695|Placebo Comparator|3|Standard topical mydriatics and BSS Irrigation Solution
3266549|NCT00721682||Case|The CASE group will be composed of children for whom the medical team will have chosen to carry out a sign of alert of ill-treatment during his hospitalization and with no plausible cause of traumatism
3266550|NCT00721682||control|The Control group will be composed of children, consulting with the emergency care for traumatism, not having a sign of alarm and having a plausible cause of traumatism.
3266551|NCT00721656|Placebo Comparator|Placebo|
3266552|NCT00721656|Experimental|KLS-0611|
3266553|NCT00721643|Experimental|1|Healthy control, 5g dry power of angel's plant (Angelica keiskei)
3266554|NCT00721643|Experimental|2|Metabolic syndrome, 5g dry powder of angel's plant (Angelica keiskei)
3266555|NCT00721630|Experimental|1|The regimen consists of capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily.
3266556|NCT00721617|Active Comparator|Obese subjects|Obese normotensive subjects will receive 24 hour challenges on 3 separate occasions, in a random order, with IV Normal Saline at 20ml/hour, IV Intralipid (20% solution at 20 ml/hour and an oral fat load (96g/24 hours)
3266557|NCT00721617|Active Comparator|Lean subjects|Lean normotensive subjects will receive 24 hour challenges on 3 separate occasions, in a random order, with IV Normal Saline at 20ml/hour, IV Intralipid (20% solution at 20 ml/hour and an oral fat load (96g/24 hours)
3266558|NCT00721604||1|patients with mean arterial pressure lower than 65 mmHg
3266559|NCT00721591||A|Subjects opting for treatment with unfractionated heparin
3266560|NCT00721591||B|Subjects opting for treatment with low molecular weight heparin
3266561|NCT00721578||1|
3266562|NCT00721565|Experimental|1|behavior change intervention
3266563|NCT00721565|No Intervention|2|written materials
3266564|NCT00721552|Experimental|I|prednisolone + sitagliptin
3266565|NCT00721552|Experimental|II|prednisolone + sitagliptin-placebo
3266566|NCT00721552|Experimental|III|prednisolone-placebo + sitagliptin
3266567|NCT00721552|Placebo Comparator|IV|prednisolone-placebo + sitagliptin-placebo
3266568|NCT00721552|No Intervention|Healthy controls|12 healthy men will be included to assess postprandial microvascular function.
3266569|NCT00721552|No Intervention|Type 2 diabetic subjects|12 men with type 2 diabetes will be included in order to assess postprandial microvascular function.
3266570|NCT00721539|Other|Transoral Robotic Surgery|Pilot study; single arm - use of da Vinci Surgical Robot Platform to access neoplastic disease of the upper aerodigestive tract.
3266571|NCT00721526|Experimental|Disulfiram plus lorazepam|Disulfiram plus lorazepam
3266572|NCT00721500|Experimental|narafilcon A / etafilcon A - etafilcon A - narafilcon A|First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A contact lenses worn in both eyes.
3266573|NCT00721500|Experimental|narafilcon A / etafilcon A - narafilcon A - etafilcon A|First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, narafilcon A contact lenses worn in both eyes. Third, etafilcon A contact lenses worn in both eyes.
3266574|NCT00721500|Experimental|narafilcon A - etafilcon A - narafilcon A / etafilcon A|First, narafilcon A contact lenses worn in both eyes. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.
3266575|NCT00721500|Experimental|etafilcon A - narafilcon A - narafilcon A / etafilcon A|First, etafilcon A contact lenses worn in both eyes. Second, narafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.
3266576|NCT00721487||Fluconazole|30 evaluable patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy.
3266577|NCT00721474|Experimental|1|Bosutinib fasting
3266578|NCT00721474|Experimental|2|Bosutinib fed
3266579|NCT00721461|Experimental|1|V930
3266580|NCT00721435|Experimental|3D Tomosynthesis & 3D Ultrasound for breast masses|Evaluate breast screening diagnostic device, 3D tomosynthesis. Assess utility of adding 3D ultrasound.
3266581|NCT00721435|Experimental|3D Tomosynthesis/ 3D Ultrasound for healthy subjects|Evaluate breast screening diagnostic device, 3D tomosynthesis. Assess utility of adding 3D ultrasound.
3266582|NCT00721422|Experimental|Group 1-Normal|
3266583|NCT00721422|Experimental|Group 2-Mild|
3266584|NCT00721422|Experimental|Group 3-Moderate|
3266585|NCT00721422|Experimental|Group 4-Severe|
3266586|NCT00721409|Experimental|Arm A|letrozole + PD 0332991
3266587|NCT00721409|Active Comparator|Arm B|letrozole
3266588|NCT00721396|Experimental|B+R246|Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations.
3266589|NCT00721396|Experimental|B246_R357|Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age.
3266590|NCT00721396|Experimental|B+R234|Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations.
3266591|NCT00721396|Active Comparator|R234|Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.
3266592|NCT00721383|Experimental|Treatment|Physical activity and caregiver skill-building
3266593|NCT00721383|Active Comparator|Control|caregiver skill-building
3266594|NCT00721370|Experimental|1|Patients imaged using ICG:HSA and NIR imaging system
3266595|NCT00721357||Stroke|Stroke subjects
3266596|NCT00721357||Control|neurologically healthy subjects
3266597|NCT00721344|Experimental|1|
3266598|NCT00721344|Experimental|2|
3266599|NCT00721344|Experimental|3|
3266600|NCT00721344|Experimental|4|
3266601|NCT00721331|Experimental|CRx-197 high dose (0.1% nortriptyline HCl + 0.3% loratadine)|
3266602|NCT00721331|Experimental|CRx-197 low dose (0.1% nortriptyline HCl + 0.1% loratadine)|
3266603|NCT00721331|Experimental|0.1% nortriptyline HCl|
3266604|NCT00721331|Active Comparator|0.1% mometasone furoate|
3266605|NCT00721331|Placebo Comparator|Active ingredient free vehicle cream of CRx-197|
3266606|NCT00721318||1|Patients diagnosed with rheumatoid arthritis
3266607|NCT00721318||2|Population controls to the subjects of group 1
3266608|NCT00721305|Experimental|1|In this arm, subjects will receive 40 mg of Lovastatin (2 tablets of 20 mg each, p.o.), in a daily doses, during twelve months
3266609|NCT00721305|Placebo Comparator|2|In this arm, subjects will receive placebo (2 tablets which will look externally identical to lovastatin: wrapped in the same way, with the same size, shape and color)
3266610|NCT00721266|Experimental|1|
3266611|NCT00721253|Active Comparator|ReSTOR Aspheric +4|ACRYSOF ReSTOR Aspheric +4 Model SN6AD3
3266612|NCT00721253|Active Comparator|Tecnis MF|Abbott Medical Optics Tecnis Multifocal Intraocular Lens (IOL) Model ZM900
3266613|NCT00721253|Active Comparator|Acri.LISA|Meditec Acri.LISA Intraocular Lens (IOL) Model 366D
3266614|NCT00721240|Experimental|single-arm|This investigation is a single-center, two-phase, single-arm study. In order to detect a potential placebo effect, the treatment phase will be preceded by a single-blinded two-week placebo run-in phase, followed by a 12 week open-label treatment phase.
3266615|NCT00721227|Active Comparator|Anterior Curve|Reduction Gastroplasty by Gastric Plication on Anterior Curve
3266616|NCT00721227|Active Comparator|Greater Curve|Reduction Gastroplasty by Gastric Plication on Greater Curve
3266617|NCT00721214|Experimental|Arm A: 5-azacytidine|5-azacytidine as pre-transplant cytoreduction prior to allogeneic stem cell transplantation for High Risk Myelodysplatic Syndromes.
3266618|NCT00721188|Experimental|Pharmacokinetic Population|All subjects who received study drug and completed Pharmacokinetic testing through 24 hours post-dose.
3266619|NCT00721175|Experimental|SEMS|self-expandable metal stent group
3266620|NCT00721175|Active Comparator|PS|plastic stent group
3266621|NCT00721162|Experimental|Ramucirumab|
3266622|NCT00721149|Experimental|NaviStar ThermoCool|
3266623|NCT00721136|Experimental|1|Moderate risk patients (afib, mechanical aortic valve) randomized to continue coumadin at their usual dose through the procedure.
3266624|NCT00721136|Active Comparator|2|Moderate risk patients randomized to hold their coumadin for 4-5 days prior to the procedure (to allow the INR to normalize).
3266625|NCT00721136|Experimental|3|High risk patients (mechanical mitral valve, prior stroke, current deep vein thrombosis, hypercoagulable syndrome) randomized to continue coumadin at the usual dose through the procedure.
3266626|NCT00721136|Active Comparator|4|"High risk patients randomized to holding coumadin for 4-5 days and using bridging anticoagulation with heparin while the coumadin is held."
3266627|NCT00721123|Experimental|Tocilizumab 8 mg/kg|All participants received tocilizumab 8 mg/kg to a maximum of 800 mg, administered by intravenous (IV) infusion over one hour, every 4 weeks. Concomitant therapies were limited to dosage and administration constraints detailed in the protocol.
3266628|NCT00721110|Active Comparator|Lidocaine|Intravenous Lidocaine Group - Lidocaine is administered intravenously throughout surgery and during the 24 hours following surgery
3266629|NCT00721110|Placebo Comparator|Placebo|A lidocaine placebo is administered intravenously throughout surgery and during the 24 hours after surgery.
3266630|NCT00721110|Active Comparator|Ketamine|Intravenous Ketamine Group - Ketamine is administered intravenously throughout surgery and during the 24 hours following surgery
3266631|NCT00721110|Active Comparator|ketamine + Lidocaine|both ketamine and Lidocaine are administered intravenously throughout surgery and during the 24 hours after surgery.
3266632|NCT00721084||Reduced sleep|Habitual sleep duration of less than 6 hours per night on most days of the week and total sleep of less than 43 hours per week.
3266633|NCT00721084||Reference sleep|Habitual sleep duration between 7 and 8.5 hours per night on most days of the week and total sleep of at least 53 hours per week.
3266634|NCT00721071|Experimental|1|
3266635|NCT00721058|Other|1|
3266636|NCT00721045|Active Comparator|A1|15 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection and mapping.
3266637|NCT00721045|Sham Comparator|A2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
3266638|NCT00721045|Active Comparator|B1|15 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection and mapping.
3266639|NCT00721045|Sham Comparator|B2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
3266640|NCT00721045|Active Comparator|C1|15 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection and mapping.
3266641|NCT00721045|Sham Comparator|C2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
3266642|NCT00721032|Experimental|1|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia.
3266643|NCT00721032|Active Comparator|2|Anti-arrhythmic group.
3266644|NCT00721019|Experimental|5-hour bedtime|
3266646|NCT00721006|Experimental|MESENDO|All subjects will receive active treatment in a blinded fashion in the left or right lower limb. The opposite lower limb will receive placebo.
3266647|NCT00721006|Placebo Comparator|placebo|All subjects will receive placebo injections in a blinded fashion in the left or right lower limb. The opposite lower limb will receive active stem cell infusion
3266648|NCT00720993||1|Control group - patients scheduled for routine colonoscopy procedures with no self or family history or other GI conditions.
3266649|NCT00720993||2|Case group - patients with confirmed colorectal carcinoma scheduled for surgery or observed during routine colonoscopy screening.
3266650|NCT00720967|Active Comparator|1|Control Group (Open heart surgery alone)
3266651|NCT00720967|Experimental|2|Intraoperative Modified Ultrafiltration (MUF) Group (Open heart surgery with intraoperative MUF)
3266652|NCT00720967|Experimental|3|Preoperative Hemodialysis Group (Open Heart Surgery after preoperative hemodialysis)
3266653|NCT00720954|Other|A|CT guided pleural needle biopsy
3266654|NCT00720954|Other|B|Thoracoscopy
3266655|NCT00720941|Active Comparator|Sunitinib|Control arm
3266656|NCT00720941|Experimental|Pazopanib|Experimental arm
3266657|NCT00720928|Other|single group|"Posterior uveitis patients having complete or incomplete type of Behcet's disease; typical ocular lesion and at least, one of the main symptoms or two of the additional symptoms.~Selection of study eye : For patients with unilateral uveitis, the study eye will be the affected eye; for patients with bilateral uveitis, the study eye will be the more severely affected eye (i.e., the eye having suffered more recurrences in the previous year, or if equal, the eye having received more therapy in the previous year, or if equal, the eye having the worse VA, or if equal, the eye clinically judged to be the more severely affected eye)."
3266658|NCT00720915|Other|No Anticoagulant Therapy|No Anticoagulant Therapy
3266659|NCT00720915|Other|Anticoagulant Therapy|Continue on anticoagulant therapy
3266660|NCT00720902|Active Comparator|A|Patients who have undergone transsphenoidal surgery for a pituitary adenoma and have normal growth hormone secretion.
3266661|NCT00720902|Active Comparator|B|Patients who have undergone transsphenoidal surgery for pituitary adenoma who are growth hormone deficient.
3266662|NCT00720889||Reduced sleep|Habitual sleep duration of less than 6 hours per night on most days of the week and total sleep of less than 43 hours per week.
3266663|NCT00720889||Reference sleep|Habitual sleep duration between 7 and 8.5 hours per night on most days of the week and total sleep of at least 53 hours per week.
3266664|NCT00720876|Experimental|Vorinostat and Rituximab|Vorinostat by mouth two times (2X) per day for two weeks followed by one week of rest. Rituximab intravenously once every three weeks .
3266665|NCT00720850|Experimental|lenalidomide|lenalidomide therapy p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT
3266666|NCT00720837|Experimental|Laser Interstitial Thermal Therapy|Laser Interstitial Thermal Therapy (LITT) - An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
3266667|NCT00720824|Active Comparator|1|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions
3266668|NCT00720824|Placebo Comparator|2|Office routine
3266669|NCT00720811|Experimental|ACT, antibiotic, paracetamol|CHWs will test children with acute febrile illness for malaria using RDTs, and for pneumonia by counting their respiratory rate with RRTs. Treatment will then be provided on the basis of the test results, in line with national guidelines. Children with a positive RDT will receive artemether-lumefantrine in Burkina Faso and Uganda, and artesunate-amodiaquine in Ghana. Children with a cough and a high respiratory rate will receive amoxicillin in Ghana and Uganda, and cotrimoxazole in Burkina Faso. Additionally, paracetamol (PCT) will be provided to all children with an axillary temperature > 38.5°C.
3266670|NCT00720811|No Intervention|Presumptive fever management|Presumptive treatment of malaria with ACTs. No antibiotic treatment available
3266671|NCT00720798|Experimental|Tocilizumab|Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.
3266672|NCT00720785|Experimental|1|NK Cell Infusion (cell /kg pt wt)
3266673|NCT00720785|Experimental|2|1.3 mg/m2/dose administered as a 3 to 5 second bolusintravenous injection
3266674|NCT00720772|Experimental|A|
3266675|NCT00720772|No Intervention|B|
3266676|NCT00720759|Experimental|Arm 1|D-cycloserine + distributed treatment
3266677|NCT00720759|Sham Comparator|Arm 2|D-cycloserine + condensed treatment
3266678|NCT00720759|Placebo Comparator|Arm 3|Placebo + distributed treatment
3266679|NCT00720759|Placebo Comparator|Arm 4|Placebo + condensed treatment
3266680|NCT00720733|Experimental|1|Skills Building Group
3266681|NCT00720733|Active Comparator|2|Personal Interview Group
3266682|NCT00720720|Active Comparator|1|plant sterol enriched margarine
3266683|NCT00720720|Placebo Comparator|2|placebo margarine
3266684|NCT00720707|Experimental|(CAF+ADM+EMD)|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
3266685|NCT00720707|Active Comparator|(CAF + ADM)|root coverage procedure by using a coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM)
3266686|NCT00720694|Active Comparator|Verum|"Device: Duolith SD1 (Storz Medical AG) - Focused Extracorporeal shock wave therapy.~The total energy flux density was increased continuously from 0.01 to 0.25 mJ/mm 2 within 500 introductory impulses. Thereafter, 2000 treatment impulses with 0.25 mJ/mm 2 (four impulses per second) were administered per session,and the interventionwas repeated up to a total of three sessions in weekly intervals."
3266687|NCT00720694|Sham Comparator|Placebo / Sham|Sham Duolith SD1 (Storz Medical AG). The placebo group received identical sham intervention with an air- filled standoff that prevented the transmission of shock waves. The placebo handpiece was identical in design, shape, and weight to ensure that there was no way for the participants to identify the placebo handpiece.
3266688|NCT00720668||1|patient with hepatocellular carcinoma after radiofrequency ablation
3266689|NCT00720655|Experimental|Fatty fish|
3266690|NCT00720655|Experimental|Lean Fish|
3266691|NCT00720655|Placebo Comparator|Control diet|
3266692|NCT00720642||PSAP|This is the population of patients in whom surgical intervention could possibly be avoided. These patients will be those in whom all imaging evidence (mammographic or sonographic) was removed during the Intact BLES procedure, and in whom a definitive diagnosis of ADH could be made using the pathology assessment criteria outlined in the protocol.
3266693|NCT00720642||NPSAP|Patients with a pathology diagnosis of ADH in whom all imaging evidence (mammographic or sonographic) of the target lesion was NOT removed OR in whom a definitive diagnosis of ADH COULD NOT be made by implementing the pathology criteria for evaluation outlined in the protocol AND patients with a diagnosis of DCIS will undergo open surgical excision and will be analyzed separately from the PSAP group.
3266694|NCT00720629|Experimental|First Study Stage: Study Treatment|Visilizumab, Tacrolimus and Methotrexate.
3266695|NCT00720629|Active Comparator|Second Study Stage: Standard Treatment|Second Stage: Antithymocyte-globulin (ATG), Tacrolimus and Methotrexate. The study was closed during first stage and did not proceed to the second stage comparison to ATG in combination with tacrolimus/methotrexate as originally planned.
3266696|NCT00720616|Experimental|1|Growth hormone or Placebo 0.1 mg/day self-administrated once a day.
3266697|NCT00720590|Experimental|1|Participants will receive treatment with atazanavir and placebo lopinavir/ritonavir.
3266698|NCT00720590|Experimental|2|Participants will receive treatment with lopinavir/ritonavir and placebo atazanavir.
3266699|NCT00720590|Placebo Comparator|3|Participants will receive treatment with placebos for both drugs.
3266700|NCT00720577|Active Comparator|1|
3266701|NCT00720577|Active Comparator|2|
3266702|NCT00720577|Active Comparator|3|
3266703|NCT00720538|Experimental|1|Thalidomide
3266704|NCT00720538|Placebo Comparator|2|Placebo
3266705|NCT00720525||1|Patients with diastolic heart failure
3266706|NCT00720525||2|Patients without diastolic heart failure
3266707|NCT00720512|Active Comparator|Arm I|Patients receive either irinotecan hydrochloride over 1 hour or oxaliplatin over 1 hour on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil IV over 46 hours continuously beginning on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3266708|NCT00720512|Experimental|Arm II|Patients receive combination chemotherapy as in arm I and bevacizumab IV on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3266709|NCT00720499|Experimental|BI 1744 CL low dose+tiotropium bromide|BI 1744 CL low dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
3266710|NCT00720499|Experimental|BI 1744 CL medium dose+tiotropium bromide|BI 1744 CL medium dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
3266711|NCT00720486|Experimental|1|Participants will receive Juvenile Justice Anger Management for Girls plus treatment as usual.
3266712|NCT00720486|Active Comparator|2|Participants will receive treatment as usual.
3266713|NCT00720473|Other|A: Other|Open Label Study
3266714|NCT00720473|No Intervention|B: Healthy Controls|
3266715|NCT00720460||Experimental|Healthy Volunteers
3266716|NCT00720434|Experimental|A|500 mg BID
3266717|NCT00720434|Experimental|B|300 mg BID
3266718|NCT00720434|Experimental|C|200 mg BID
3266719|NCT00720434|Placebo Comparator|D|Placebo
3266720|NCT00720421|Other|1|AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 1 mg/Lorazepam Placebo combination therapy
3266721|NCT00720421|Other|2|AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 1mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy
3266722|NCT00720421|Other|3|AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 1 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy
3266723|NCT00720421|Other|4|AZD7325 1 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy
3266724|NCT00720408|Experimental|Prograf-XL + MMF|
3266725|NCT00720408|Active Comparator|Prograf + MMF|
3266726|NCT00720395||1|Women with bipolar disorder who are preconception or pregnant. Primary focus on predictors of postpartum bipolar disorder relapse and burden of illness through first six months postpartum
3266727|NCT00720382|Experimental|1|0.15% azelastine hydrochloride 1644 mcg
3266728|NCT00720382|Experimental|2|Mometasone furoate 200 mcg
3266729|NCT00720369|Experimental|CoEnzyme Q10|Open Label Study
3266730|NCT00720369|No Intervention|Healthy Controls|Healthy controls completed all study procedures completed by the CoQ10 group but did not receive any study medication.
3266731|NCT00720356|Experimental|Treatment|erlotinib and bevacizumab
3266732|NCT00720343|Experimental|Choline|Oral choline
3266733|NCT00720343|Placebo Comparator|Placebo|Gelatin Capsule
3266734|NCT00720330|Active Comparator|Ropivacaine|Paravertebral Group - A local anesthetic (ropivacaine) will be injected near the spine before surgery. Participants will also receive midazolam and fentanyl intravenously (through your vein) for sedation
3266735|NCT00720330|Active Comparator|Lidocaine/ketamine|Participant will receive general anesthesia through the vein before surgery. Lidocaine and ketamine will be administered intravenously throughout surgery and for 60 minutes after surgery.
3266736|NCT00720330|Placebo Comparator|Placebo|General anesthesia plus placebo. Placebo will be administered intravenously until 60 minutes after surgery
3266737|NCT00720304|Experimental|oral erlotinib hydrochloride|
3266738|NCT00720291|Active Comparator|Metronidazole|Subjects who are randomly assigned to receive metronidazole 500 mg po for a period of 7 days following diagnosis of asymptomatic BV.
3266739|NCT00720291|Placebo Comparator|Placebo|Subjects who are randomly assigned to receive a placebo for a period of 7 days following the diagnosis of asymptomatic BV.
3266741|NCT00720278|Experimental|Astepro 0.1%|0.1% azelastine hydrochloride nasal spray
3266742|NCT00720278|Experimental|Astepro 0.15%|0.15% azelastine hydrochloride nasal spray
3266743|NCT00720265|Active Comparator|1|
3266744|NCT00720265|Experimental|2|
3266745|NCT00720252|Experimental|A|
3266746|NCT00720239|No Intervention|0|
3266747|NCT00720239|Experimental|1|Experimental Group 1 (n = 10) will receive TalidermR to the wound once during the treatment phase.
3266748|NCT00720239|Experimental|2|Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.
3266749|NCT00720239|Experimental|3|Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase.
3266750|NCT00720226|Experimental|Losartan|Losartan 100 mg daily
3266751|NCT00720226|Placebo Comparator|Placebo|Placebo 1 pill daily
3266752|NCT00720200|Experimental|1|
3266753|NCT00720200|Active Comparator|2|
3266754|NCT00720174|Experimental|Treatment (cixutumumab and doxorubicin hydrochloride)|Patients receive cixutumumab IV over 1 hour on days 1, 8, and 15 and doxorubicin hydrochloride IV continuously over 44-52 hours beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive cixutumumab in the absence of disease progression or unacceptable toxicity.
3266755|NCT00720161|Active Comparator|A|Metformin during 12 months and then 6 months Placebo
3266756|NCT00720161|Placebo Comparator|B|Placebo during 6 months, afterwards 12 months metformin
3266757|NCT00720135|Experimental|Arm I|Patients receive DI-Leu16-IL2 immunocytokine IV over 4 hours on 4 consecutive Wednesdays. Patients with detectable CD20-positive B-cells pretreatment also receive rituximab IV on 4 consecutive Tuesdays. Treatment repeats every 6-8 weeks for up to a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.
3266758|NCT00720122|Experimental|Anorexia Nervosa Females|
3266759|NCT00720109|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|See Detailed Description
3266760|NCT00720096|Experimental|Liposomal Doxorubicin|Liposomal Doxorubicin - Chemotherapy single agent systemic.
3266761|NCT00720096|Experimental|Topotecan|Topotecan - Chemotherapy single agent systemic.
3266762|NCT00720083|Active Comparator|RT + Cisplatin|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
3266763|NCT00720083|Experimental|RT + Cisplatin + Vandetanib|Patients undergo radiotherapy as in arm I and receive cisplatin IV over 1 hour once a week beginning on day 1 of radiotherapy. Patients also receive oral vandetanib once daily beginning 14 days prior to the start of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
3266764|NCT00720070|Experimental|Arm I|Patients receive standard concurrent chemoradiotherapy (CRT). Patients undergo PET/CT scan at 9-13 weeks after completion of CRT. Patients with complete response of primary site undergo neck dissection within 4 weeks.
3266765|NCT00720070|Active Comparator|Arm II|Patients undergo neck dissection and receive standard concurrent CRT. Patients undergo PET/CT scan at 9-13 weeks after completion of CRT.
3266766|NCT00720057|Experimental|Naproxen sodium ER (BAYH6689)|single dose (1 tablet) ER Naproxen sodium 660 mg with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
3266767|NCT00720057|Placebo Comparator|Placebo|Single dose (1 tablet) of placebo with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
3266768|NCT00720018|Experimental|Period 1|NP101 Patch
3266769|NCT00720018|Experimental|Period 2|NP101 Patch
3266770|NCT00720018|Experimental|Period 3|NP101 Patch
3266771|NCT00720018|Experimental|Period 4|NP101 Patch
3266772|NCT00720018|Experimental|Period 5|NP101 Patch
3266773|NCT00720005||Aspheric Acrysof ResTOR Lens|Implantation of Aspheric Acrysof ResTOR
3266774|NCT00719992|Experimental|1|positive ETT, High HS-CRP
3266775|NCT00719992|Active Comparator|2|positive ETT, Low HS-CRP
3266776|NCT00719979|Experimental|iCBT and TeleCoaching|Participants received the technology-assisted behavioral intervention (iCBT + TeleCoaching).
3266777|NCT00719979|Experimental|iCBT(MoodManager)|Participants received Internet-based cognitive behavioral therapy only.
3266778|NCT00719979|Active Comparator|Treatment as usual / Wait-list control|Participants received treatment as usual . For wait-list control, participants were not provided any intervention for 6 weeks, after which they were allowed to choose coached or self-directed moodManager.
3266779|NCT00719966||Group 1 (hormone receptor-positive)|Patients receive aromatase inhibition therapy for up to 6 months in the absence of unacceptable toxicity.
3266780|NCT00719966||Group 2 (hormone receptor-negative)|Patients do not receive adjuvant treatment.
3266781|NCT00719940|Experimental|1|Cognitive behavioral therapy
3266782|NCT00719940|Placebo Comparator|2|Waiting group
3266783|NCT00719927|Experimental|1|Comadre Treatment
3266784|NCT00719927|Active Comparator|2|Non Support Partner Treatment
3266785|NCT00719914|Active Comparator|1|Intracoronary injection of eptifibatide
3266786|NCT00719914|Placebo Comparator|2|Intra-coronary injection of normal saline.
3266787|NCT00719901|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive obatoclax mesylate IV over 3 hours and bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3266788|NCT00719888|Experimental|Treatment (myeloablative UCBT)|"Patients receive myeloablative conditioning comprising fludarabine phosphate IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 and -6, and undergo TBI BID on days -4 to -1. Patients then undergo single- or double-unit UCBT on day 0.~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred > day 30) after engraftment if there continues to be no evidence of acute GVHD."
3266789|NCT00719875|Experimental|1|
3266790|NCT00719862|Placebo Comparator|Placebo Nasal Spray|0mg Placebo Nasal Spray
3266791|NCT00719862|Active Comparator|0.15% azelastine hydrochloride nasal spray|0.15% azelastine hydrochloride
3266792|NCT00719849|Experimental|Cyclophosphamide/Fludarabine/TBI|"Subjects with hematological malignancies with prior autologous transplant, >2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months.~Refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy."
3266793|NCT00719849|Experimental|Cyclophosphamide/Fludarabine/TBI/ATG|Subjects with hematological malignancies with prior autologous transplant >12 mos or <1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months
3266794|NCT00719823|Other|1|
3266795|NCT00719810|Experimental|1|
3266796|NCT00719810|Experimental|2|
3266797|NCT00719810|Active Comparator|3|
3266798|NCT00719797|Experimental|Arm I (FOLFOXIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
3266799|NCT00719797|Experimental|Arm II (FOLFIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
3266800|NCT00719784|Experimental|1|All patients recruited will have VRI recordings done. There is no comparative arm.
3266801|NCT00719771|Other|Global® AP™ Shoulder|Global® AP™ Shoulder
3266802|NCT00719758|Experimental|1|Cross-over study
3266803|NCT00719745|Active Comparator|1|
3266804|NCT00719745|Experimental|2|
3266805|NCT00719732|Experimental|ReSTOR Aspheric +3|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
3266806|NCT00719706|Active Comparator|1|1000-3000mg/day of acetyl-l-carnitine PLUS 600-1800mg/day of alpha-lipoic acid
3266807|NCT00719706|Placebo Comparator|2|
3266808|NCT00719693|Experimental|A|ABT-143 under low-fat meal condition
3266809|NCT00719693|Experimental|B|ABT-143 under fasting meal condition
3266810|NCT00719680|Experimental|IgPro20|The IgPro20 dose will be the same as in the previous pivotal study ZLB04_009CR (NCT00419341) infused subcutaneously weekly or twice a week (in the latter case, half of a weekly dose will be used)
3266811|NCT00719654||EOS-Preeclampsia|Women with symptoms of early-onset preeclampsia
3266812|NCT00719654||Normal|Women who do not have symptoms of early-onset preeclampsia
3266813|NCT00719615||Thyroid Cancer in Remission Group|Thyroid Cancer-Remission Group & use of Vitamin D
3266814|NCT00719615||Thyroid Cancer with Active Disease Group|Thyroid Cancer-Active Group & use of Vitamin D
3266815|NCT00719615||Thyroid nodule group (no cancer) & Vit D|Thyroid nodule group without cancer and use of Vitamin D
3266816|NCT00719602|Active Comparator|1|Previously received single-dose nevirapine (SD NVP); assigned to receive either an NNRTI- or PI-based regimen as a part of the study IMPAACT P1060
3266817|NCT00719602|Active Comparator|2|Have not previously received SD NVP; assigned to receive either an NNRTI- or PI-based regimen as a part of the study IMPAACT P1060
3266818|NCT00719589||1|Patient who have had implantation of an interstim.
3266819|NCT00719576|Experimental|MACI|autologous cultured chondrocytes on porcine collagen membrane
3266820|NCT00719576|Active Comparator|Microfracture|Microfracture
3266821|NCT00719563|Experimental|Arm I|Patients receive oral American ginseng twice daily for 14 days. Treatment repeats every 2 weeks for 4 courses.
3266822|NCT00719563|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 14 days. Treatment repeats every 2 weeks for 4 courses.
3266823|NCT00719550|Placebo Comparator|Phase 2 Arm C|AMG 102 placebo plus ECX
3266824|NCT00719550|Other|Phase 1b|Phase 1b dose study with open-labe AMG 102 at 15mg/kg de-escalating to 7.5mg/kg and 5mg/kg if needed.
3266825|NCT00719550|Active Comparator|Phase 2 Arm B|AMG 102 at 7.5mg/kg plus ECX
3266826|NCT00719550|Active Comparator|Phase 2 Arm A|AMG 102 at 15mg/kg plus ECX
3266827|NCT00719537|Placebo Comparator|Aspirin plus Placebo Oral Tablet|Drug: Aspirin 81 mg, given orally once per day Drug: Placebo tablet given orally, once a day
3266828|NCT00719537|Active Comparator|Aspirin plus Progesterone|Drug: Aspirin 81mg, given orally once per day Drug: Progesterone 200mg given orally, once a day
3266829|NCT00719524|Experimental|1|
3266830|NCT00719511|Experimental|1|Patch allergen dose 1
3266831|NCT00719511|Experimental|2|Patch allergen dose 2
3266832|NCT00719511|Experimental|3|Patch allergen dose 3
3266833|NCT00719511|Experimental|4|Placebo
3266834|NCT00719485|Experimental|1|Educational program
3266835|NCT00719485|No Intervention|2|Standard care
3266836|NCT00719472|Experimental|Rituximab 375 mg/m^2|Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m^2 administered by intravenous (IV) infusion on Day 1 of each cycle.
3266837|NCT00719459|Experimental|1|Hospira Iron Sucrose
3266838|NCT00719459|Active Comparator|2|Venofer
3266839|NCT00719433|Experimental|1|
3266840|NCT00719433|Active Comparator|2|
3266841|NCT00719420|Experimental|1|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid for 14 days (with or without omeprazole 20 mg bid)
3266842|NCT00719420|Active Comparator|2|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
3266843|NCT00719407|Experimental|A|All enrolled patients will be in this single arm, who will receive experimental drug treatment.
3266844|NCT00719394|Experimental|GSI 136|
3266845|NCT00719394|Placebo Comparator|placebo|
3266846|NCT00719381|Active Comparator|1|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
3266847|NCT00719381|No Intervention|2|Patients in this arm will receive no intervention
3266848|NCT00719368||pain-free control|Pain-free controls from previous prospective study (KF 01294867), operated >2 years previously
3266849|NCT00719368||Pain Patients|Patients with persistent postherniotomy pain lasting >1 year and pain related impaired daily function
3266850|NCT00719355|Experimental|Walking with Poles|Patients were assigned to a 24 week walking with poles program of rehabilitation. The intervention was the additional of poles to the walking program.
3266851|NCT00719355|Active Comparator|Traditional walking program|Patients were assigned to a 24 week traditional walking program.
3266852|NCT00719329|Experimental|A|Chlorhexidine cleansing of the cord for seven days
3266853|NCT00719329|Experimental|B|Chlorhexidine cleansing of the cord for 1 day
3266854|NCT00719329|Placebo Comparator|C|Dry cord care, as recommended by WHO
3266855|NCT00719316|Experimental|Group 1|Patients receive Aliskiren 300mg for 6 weeks
3266856|NCT00719316|No Intervention|Group 2|4 weeks no antihypertensive medication
3266857|NCT00719303|Experimental|Group I (lifestyle intervention)|Participants receive a dietary intervention designed to promote increased levels of plasma carotenoids, control weight, and to ensure adequacy of micronutrient intake. Participants also undergo a physical activity intervention comprising a moderately low aerobic regimen to raise the usual activity level. Participants also undergo face-to-face counseling, receive educational materials and counseling focused on how to read food labels to estimate grams of fat per serving and serving size, and undergo telephone counseling by a lifestyle intervention counselor twice a week for 4 weeks, then weekly for 2 weeks, twice a month for 5 months, monthly for the subsequent 6 months, and then once every other month for 12 months. Participants complete daily fat gram and step diaries at least three times per week.
3266858|NCT00719303|Active Comparator|Group II (observation)|Participants receive a study notebook containing general study-related information. Participants are not asked to record diet or physical activity but are provided a single sample diary in their study notebook. Participants receive telephone contact on a sliding scale similar to the intervention group, but at less frequent intervals (22 versus 33 calls over the course of the intervention).
3266859|NCT00719290|Active Comparator|1|Phacoemulsification with intraocular lens implant alone
3266860|NCT00719290|Active Comparator|2|Phacoemulsification with intraocular lens implant and goniosynechialysis
3266861|NCT00719264|Experimental|bevacizumab, RAD001 (everolimus)|Participants received oral everolimus 10 mg qd plus intravenous bevacizumab 10mg/kg every 2 weeks
3266862|NCT00719264|Active Comparator|bevacizumab, interferon alfa-2a (IFN)|Participants received subcutaneous IFN dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3 of treatment and subsequently (if tolerated), 3 times per week plus intravenous bevacizumab 10 mg/kg every 2 weeks
3266863|NCT00719251|Experimental|HVG|The patients received standard nursing care and HVPC
3266864|NCT00719251|Experimental|LG|These patients received standard nursing care and LLLT
3266865|NCT00719251|Active Comparator|CG|The control group only was treated with standard nursing care
3266866|NCT00719238|Experimental|1|
3266867|NCT00719238|Active Comparator|2|
3266868|NCT00719212|Experimental|AMG 479|AMG 479 administered on day 1 of each 21-day cycle up to disease progression, unacceptable toxicity, withdrawal of consent or sponsor decision to stop the study.
3266869|NCT00719199|Experimental|1|IMO 2055 is a novel phosphorothioate oligodeoxynucleotide that is an agonist of Toll-like Receptor 9 (TLR9).
3266870|NCT00719186|Active Comparator|A|Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
3266871|NCT00719186|Active Comparator|B|Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
3266872|NCT00719173|Experimental|Arm I|Patients receive aprepitant 125 mg orally once daily on day 1 and 80 mg orally once daily on days 2 and 3. Beginning 1 hour after receiving aprepitant, patients receive an infusion of cyclophosphamide on day 1. During course 2, patients crossover and receive treatment as in arm II.
3266873|NCT00719173|Experimental|Arm II|Patients receive a placebo 125 mg orally once daily on day 1 and 80 mg orally once daily on days 2 and 3. Beginning 1 hour after receiving the placebo, patients will receive an infusion of cyclophosphamide infusion on day 1. During course 2, patients crossover and receive treatment as in arm I.
3266874|NCT00719160|Placebo Comparator|Esomeprazole|
3266875|NCT00719160|Active Comparator|Placebo|
3266876|NCT00719147||1|
3266877|NCT00719134|Experimental|1|Maxalt administration at onset of migraine
3266878|NCT00719134|Placebo Comparator|2|
3266879|NCT00719134|Experimental|3|
3266880|NCT00719134|Placebo Comparator|4|
3266881|NCT00719134|Experimental|5|
3266882|NCT00719134|Experimental|6|
3266883|NCT00719121|No Intervention|A|No Treatment
3266884|NCT00719121|Active Comparator|B|R115866 (0.35% gel)
3266885|NCT00719121|Active Comparator|C|R115866 Vehicle gel
3266886|NCT00719121|Active Comparator|D|Differin™, 0.1% adapalene gel
3266887|NCT00719108|Experimental|Wosulin R|Wosulin R, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml
3266888|NCT00719108|Active Comparator|Actrapid|Actrapid, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml
3266889|NCT00719095|Experimental|1-week buprenorphine taper|1-week buprenorphine taper + behavioral therapy + urine toxicology
3266890|NCT00719095|Experimental|2-week buprenorphine taper|2-week buprenorphine taper + behavioral therapy + urine toxicology
3266891|NCT00719095|Experimental|4-week buprenorphine taper|4-week buprenorphine taper + behavioral therapy + urine toxicology
3266892|NCT00719082||AARP Community|Members of AARP Geriatric Community
3266893|NCT00719069|Experimental|active/placebo|
3266894|NCT00719056|Experimental|1|Surgical chemoprophylaxis of one dose of teicoplanin upon introduction of anesthesia for total hip or knee arthroplasty.
3266895|NCT00719056|Active Comparator|2|Surgical chemoprophylaxis with multiple dose of other antimicrobials for up to six consecutive days for total hip or knee arthroplasty.
3266930|NCT00718861|Experimental|Zoledronic acid|
3266931|NCT00718848||1|These are patients treated with conventional hemodialysis (4 hours/session, 3 sessions/week) who convert to incentre nocturnal hemodialysis (8 hours/session, 3 sessions/week).
3267032|NCT00718120|Experimental|Fluviral Adult Group|Subjects aged between 18 and 60 years received a single dose of Fluviral® vaccine.
3266896|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F1-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 1 at Day 0 followed by one booster dose of A/turkey H5N1 vaccine formulation 1 at Day 182 and one dose of placebo (phosphate buffered saline, PBS) at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and Placebo vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, A/turkey H5N1 vaccine was administered intramuscularly in the deltoid region of the dominant arm.
3266897|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F2-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 2 at Day 0 followed by one booster dose of A/turkey H5N1 vaccine formulation 2 at Day 182 and one dose of placebo (phosphate buffered saline, PBS) at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and Placebo vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, A/turkey H5N1 vaccine was administered intramuscularly in the deltoid region of the dominant arm.
3266898|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F3-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 3 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 3 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
3266899|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F1-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) vaccine formulation 1 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 1 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
3266900|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F4-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 4 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 4 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
3266901|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F2-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 2 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 2 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
3266902|NCT00719043|Placebo Comparator|Naïve Placebo-A/turkey Influenza (H5N1)-F3-Group|Healthy subjects aged 18 years of age or older at the time of vaccination received one dose of placebo (phosphate buffered saline, PBS) at Day 0 followed by two doses of A/turkey H5N1 vaccine formulation 3, one dose administered at Day 182 and the other at Day 549. Placebo vaccine and one dose of A/turkey H5N1 vaccine (Day 549) was administered intramuscularly in the deltoid region of the non-dominant arm while the other dose of A/turkey H5N1 vaccine (Day 182) was administered intramuscularly in the deltoid region of the dominant arm.
3266903|NCT00719030|Experimental|1|Pomegranate pill
3266904|NCT00719030|Placebo Comparator|2|
3266905|NCT00719017|Experimental|Vaginectomy group|Upper vaginectomy
3266906|NCT00719017|Experimental|Brachytherapy group|Post-operative brachytherapy
3266907|NCT00719017|Active Comparator|Control group|Standard treatment
3266908|NCT00719004|Experimental|Normals|Normal volunteers having Ultrasound scan of foot.
3266909|NCT00718991|Experimental|1|CLI patients receiving excimer laser recanalisation for the treatment of long infrapopliteal lesions
3266910|NCT00718978|Other|B|the investigators grafted sheets based on the HYAFF11p80® scaffold (the one with the lowest degree of esterification)
3266911|NCT00718978|Other|A|the investigators grafted sheets based on the HYAFF11® scaffold (the one with the highest degree of esterification).
3266912|NCT00718978|Other|A-B|the investigators grafted sheets based on the HYAFF11® scaffold and sheets based on the HYAFF11p80 ® scaffold
3266913|NCT00718965|Experimental|25 mg/day AVE5530|
3266914|NCT00718965|Experimental|50 mg/day AVE5530|
3266915|NCT00718965|Placebo Comparator|Placebo|
3266916|NCT00718952|Experimental|A|Patients in group A will receive vardenafil in double-blinded treatment period.
3266917|NCT00718952|Placebo Comparator|B|Patients in group A will receive placebo in double-blinded treatment period.
3266918|NCT00718939|Other|Rheos ON|Study participants in this arm will have the device turn on for six months and remains on.
3266919|NCT00718939|Other|Rheos OFF|Study participants in this arm will have the device turned off for 6 months and then turned on.
3266920|NCT00718926||Sjogren|Sjogren syndrome with dry eye
3266921|NCT00718926||non-Sjogren|dry eye without Sjogren syndrome
3266922|NCT00718926||Short-BUT|Dry eye by shortened tear break up time
3266923|NCT00718926||control|normal patients
3266924|NCT00718913|Experimental|1|TCX ->RT -> TCX
3266925|NCT00718887|Experimental|Entecavir, 0.5 mg QD|
3266926|NCT00718887|Other|Adefovir, 10 mg QD/Entecavir, 0.5 mg QD|Control
3266927|NCT00718874|Experimental|A, 1|low-carbohydrate (42%)
3266928|NCT00718874|Experimental|A,2|standard carbohydrate (55%) based on ADA recommendations
3266929|NCT00718861|Placebo Comparator|Placebo|Matching placebo administered intravenously.
3266932|NCT00718848||2|These are patients treated with conventional hemodialysis (4 hours/session, 3 session/week) who elect to remain on this dialysis schedule and agree to the study-related investigations at baseline and one year thereafter.
3266933|NCT00718835|Active Comparator|Contingent Voucher condition|Subjects in this condition will receive a brief education intervention plus voucher-based incentives contingent on demonstrating objective evidence of recent smoking abstinence.
3266934|NCT00718835|Placebo Comparator|Noncontingent control condition|Subjects assigned to this control condition will receive the brief education and vouchers delivered independent of smoking status and yoked to the schedule of voucher earnings in the Contingent Voucher condition.
3266935|NCT00718822|Experimental|I|5% oxygen concentration in the culture atmosphere
3266936|NCT00718822|Experimental|II|20% oxygen concentration in the culture atmosphere
3266937|NCT00718809|Experimental|Arm I|Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3266938|NCT00718796|Experimental|1|Individualized naturopathic treatment consisting of dietary and lifestyle advice and individualized supplementation
3266939|NCT00718796|Active Comparator|2|Current care control provided by participants' medical doctor
3266940|NCT00718783||Retinoblastoma|
3266941|NCT00718770|Experimental|Bexarotene|Open label - all patients receive intervention
3266942|NCT00718757|Experimental|1|
3266943|NCT00718744|Experimental|A|In each individual patient, 10 mg/ml histamine dihydrochloride solution and a phenolated saline solution will be applied as positive and negative control respectively.
3266944|NCT00718731|Experimental|1|Subject on active drug
3266945|NCT00718731|Placebo Comparator|2|Subject on placebo
3266946|NCT00718718|Experimental|Part A, Group 1|Participants will receive placebo (Week 0 to Week 10) and later CNTO 136 100 mg (Week 12 to Week 22) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
3266947|NCT00718718|Experimental|Part A, Group 2|Participants will receive CNTO 136 100 mg (Week 0 to Week 10) and later placebo (Week 12 to Week 22) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
3266948|NCT00718718|Experimental|Part B, Group 1|Participants will receive placebo (Week 0 to Week 10) and later CNTO 136 100 mg (Week 12 to Week 24) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
3266949|NCT00718718|Experimental|Part B, Group 2|Participants will receive CNTO 136 100 mg (Week 0 to Week 24) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
3266950|NCT00718718|Experimental|Part B, Group 3|Participants will receive CNTO 136 100 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6, 10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
3266951|NCT00718718|Experimental|Part B, Group 4|Participants will receive CNTO 136 50 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6,10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
3266952|NCT00718718|Experimental|Part B, Group 5|Participants will receive CNTO 136 25 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6,10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
3266953|NCT00718705|Experimental|1|josamycin
3266954|NCT00718705|Placebo Comparator|2|Placebo
3266955|NCT00718692|Experimental|1|Patients treated with Sym001
3266956|NCT00718679|Experimental|1|Study drug
3266957|NCT00718679|Placebo Comparator|2|Placebo
3266958|NCT00718666|Experimental|Group A|Subjects who were previously vaccinated with one dose of GSK134612 at 12 months of age.
3266959|NCT00718666|Experimental|Group B|Subjects who were previously vaccinated with two doses of GSK134612, one each at 9 and 12 months of age.
3266960|NCT00718666|Experimental|Group C|Subjects aged 5-6 years not previously administered meningococcal vaccine.
3266961|NCT00718653|Experimental|1|lutein
3266962|NCT00718653|Experimental|2|Lutein plus green tea extract
3266963|NCT00718640|Experimental|Bortezomib and Dexamethasone|Bortezomib 1.3 milligram (mg) per meter^2 (m^2) bolus (a large amount) intravenous (into the vein) injection will be administered once daily on Days 1, 4, 8 and 11 of each 21-day cycle with addition of Dexamethasone 20 mg per day administered orally, once daily on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-day cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
3266964|NCT00718627|Experimental|HHLivC Therapy Group|
3266965|NCT00718614|Other|1|Patients with long standing IDDM (>10 years) and no diabetic retinopathy
3266966|NCT00718614|Other|2|Patients with long standing IDDM (>10 years) and mild non-proliferative diabetic retinopathy
3266967|NCT00718614|Other|3|Patients with long standing IDDM (>10 years) and moderate to severe non-proliferative diabetic retinopathy
3266968|NCT00718614|Other|4|healthy volunteers, matched for age and sex
3266969|NCT00718601|Experimental|1|3+3 cohort dose escalation
3266970|NCT00718575|Experimental|1|Deceased liver donors that are randomized to this arm will receive the Glucose/Ischemic Preconditioning pre-treatment intra-operatively prior to starting cold preservation of the organ
3266971|NCT00718575|No Intervention|2|Neither donors nor recipients receive any intervention. All procedures will be performed according to our institution's standard of care.
3266972|NCT00718562|Experimental|Nilotinib|
3266973|NCT00718549|Experimental|Induction: Rituximab, Cladribine, Cyclophosphamide|Participants will receive rituximab at a dose of 375 milligrams per meter squared (mg/m^2) as intravenous (IV) infusion on Day 1, cladribine at a dose of 0.12 milligrams per kilogram per day (mg/kg/day) as IV infusion on Days 2-4, and cyclophosphamide at a dose of 250 mg/m^2/day as IV infusion over 15-30 minutes on Days 2-4 in Cycle 1. Then, rituximab at a dose of 500 mg/m^2 as IV infusion on Day 1, cladribine at a dose of 0.12 mg/kg/day as IV infusion on Days 2-4, and cyclophosphamide at a dose of 250 mg/m^2/day as IV infusion over 15-30 minutes on Days 2-4 will be administered in Cycles 2-6. Each cycle will be of 28 days in duration.
3267030|NCT00718146|Experimental|Group 2|Age over 60 years
3267031|NCT00718133|Experimental|1|Children at school age from Haifa bay region
3267212|NCT00716807|Placebo Comparator|BMS 2|
3266974|NCT00718549|Experimental|Maintenance Arm: Rituximab|Participants with PR or CR after induction phase who will be randomized to maintenance arm will receive rituximab treatment for 8 cycles. Twelve weeks after the last induction cycle, participants will receive rituximab at a dose of 375 mg/m^2 as IV infusion on Day 1 of each 12-week cycle until disease progression (up to approximately 96 weeks).
3266975|NCT00718549|No Intervention|Observation Arm: No Intervention|Participants with PR or CR after induction phase who will be randomized to observation arm will not receive any intervention. Participants will be assessed every 4-weeks for the first 12 weeks and every 12-weeks afterwards up to 96 weeks.
3266976|NCT00718536|Experimental|1|Addition of raltegravir 800 mg QD to HAART
3266977|NCT00718523|Placebo Comparator|A|Placebo plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of placebo administered on Day 1 of each 21-day cycle.
3266978|NCT00718523|Experimental|B|AMG 479 plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of AMG 479 single agent administered on Day 1 of each 21-day cycle.
3266979|NCT00718510|Active Comparator|L-arginine first/placebo second|Patients with diagnosis of schizophrenia will be randomised to receive L-arginine first/placebo second 3 grams bid (cross-over design) in addition to treatment as usual. The active treatment period will be 3 weeks, with a wash-out period of 5 days and re-commencing on the alternative arm of the randomization
3266980|NCT00718510|Placebo Comparator|Placebo first/L-arginine second|Patients with diagnosis of schizophrenia will be randomised to receive placebo first/L-arginine second 3 grams bid (cross-over design) in addition to treatment as usual. The active treatment period will be 3 weeks, with a wash-out period of 5 days and re-commencing on the alternative arm of the randomization
3266981|NCT00718497||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
3266982|NCT00718484|Experimental|A|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
3266983|NCT00718484|Active Comparator|B|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
3266984|NCT00718471|Experimental|1|Enoxaparin
3266985|NCT00718471|Active Comparator|2|UFH
3266986|NCT00718458||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
3266987|NCT00718458||Non-ALS|Subjects not having either definite or probable ALS by El Escorial Criteria.
3266988|NCT00718445||MND|"Patients seen in the MDA/ALS Center of Hope at Drexel University College of Medicine~Patients seen in the Department of Neurology at Drexel University College of Medicine"
3266989|NCT00718432|Active Comparator|UC group|Usual care with education
3266990|NCT00718432|Experimental|ENIC group (IC group in 2009 study)|Exercise and nutritional integrated care
3266991|NCT00718432|Experimental|PSTIC group (IC group in 2009 study)|Problem solving therapy integrated care
3266992|NCT00718419|Experimental|A|
3266993|NCT00718406|Active Comparator|A|A=metoprolol
3266994|NCT00718406|Active Comparator|B|B=metoprolol plus morphine
3266995|NCT00718393||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
3266996|NCT00718380|Experimental|Group 1|Dose escalation from Open label 0.05 to 0.25 mg/kg once a day dosing for 21 days
3266997|NCT00718380|Experimental|Group 2|Open label 0.10 mg/kg once a day dosing after safety evolution of Group 1
3266998|NCT00718380|Experimental|Group 3|Open label 0.20 mg/kg once a day dosing after safety evolution of Group 2
3266999|NCT00718380|Experimental|Group 4|Open label 0.25 mg/kg once a day dosing after safety evolution of Group 3
3267000|NCT00718354|Active Comparator|B|Standard Chemotherapy (upto 6 cycles)
3267001|NCT00718354|Experimental|A|Enoxaparin: 1 mg/kg once daily in addition to standard chemotherapy up to 6 months
3267002|NCT00718341|Active Comparator|1|
3267003|NCT00718341|Placebo Comparator|2|
3267004|NCT00718328|Experimental|I|Simvastatin Group
3267005|NCT00718328|Placebo Comparator|II|Placebo Group
3267006|NCT00718315|Experimental|1|
3267007|NCT00718315|Experimental|2|
3267008|NCT00718315|Experimental|3|
3267009|NCT00718302|Experimental|Randomized treatment; antiglide plate|Randomized treatment; antiglide plate
3267010|NCT00718302|Experimental|Randomized treatment; lateral plate|Randomized treatment; lateral plate
3267011|NCT00718289|Experimental|Citrate|Citrate dialysate for haemodialysis
3267012|NCT00718289|Active Comparator|Acetate|Acetate dialysate
3267013|NCT00718276|Active Comparator|1|25(OH)D
3267014|NCT00718276|Active Comparator|2|vitamin D3
3267015|NCT00718263|Experimental|nilotinib|
3267016|NCT00718263|Active Comparator|imatinib|
3267017|NCT00718250|Experimental|cohort 1|AML Cell Vaccine alone
3267018|NCT00718250|Experimental|cohort 2|Donor leukocytes alone
3267019|NCT00718250|Experimental|cohort 3|AML cell vaccine and Donor Leukocyte Infusion (1x107/kg)
3267020|NCT00718250|Experimental|cohort 4|AML cell vaccine and Donor Leukocyte Infusion (1x108/kg)
3267021|NCT00718237|Experimental|1|RotaTeq™
3267022|NCT00718237|Placebo Comparator|2|Placebo
3267023|NCT00718224|Experimental|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery~To maintain the blind, placebo for Enoxaparin sodium:~12 and 24 hours after surgery, then once daily if no SRI~12 hours after surgery only if SRI"
3267024|NCT00718224|Active Comparator|Enoxaparin|"Enoxaparin sodium 30 mg twice daily (20 mg once daily if Severe Renal Impairment [SRI]) for 7-10 days with an initial dose given 12 hours after surgery~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
3267025|NCT00718198||1|Group admitted 1 (one) month before CPOE protocol changes were made
3267026|NCT00718198||2|Group admitted 1 (one) year after CPOE protocol changes were made
3267027|NCT00718185||A|Patients receiving sildenafil as standard of care
3267028|NCT00718159|Experimental|LY573636|
3267029|NCT00718146|Experimental|Group 1|Age 16 to 60 years
3267033|NCT00718120|Experimental|Fluviral Elderly Group|Subjects aged more than 60 years received a single dose of Fluviral® vaccine.
3267034|NCT00718107||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
3267035|NCT00718094|Experimental|Polyphenon E treatment|Polyphenon E® therapy was given for 56 days.
3267036|NCT00718094|Placebo Comparator|Placebo|Oral Placebo
3267037|NCT00718081|Experimental|1|Oral Sufentanil
3267038|NCT00718081|Experimental|2|Oral sufentanil
3267039|NCT00718081|Placebo Comparator|3|Oral dosage of placebo
3267040|NCT00718068|Experimental|Continuous|This group will receive potassium chloride by continuous infusion on a sliding-scale system based on serum potassium level.
3267041|NCT00718068|Active Comparator|Intermittent|This arm will form the control group and receive potassium chloride by intermittent infusion as per conventional management
3267042|NCT00718042|Experimental|1|All subjects will have their blood tested by the investigational Chagas screening assay.
3267043|NCT00718042|Experimental|2|Testing of blood donor samples with the investigational Chagas screening assay. Samples that test positive will be also tested with the Chagas confirmatory assay.
3267044|NCT00718016||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
3267045|NCT00718003||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
3267046|NCT00717990|Experimental|1|XELIRI/Avastin
3267047|NCT00717951|Experimental|A|"Arm A is docetaxol+capecitabine chemotherapy"
3267048|NCT00717951|Experimental|B|"Arm B is docetaxol+cisplatin chemotherapy"
3267049|NCT00717938|Other|A|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants.Used drugs=cisplatinum or carboplatin and e.g.etoposide.
3267050|NCT00717938|Experimental|B|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
3267051|NCT00717925|Experimental|1|
3267052|NCT00717912|Experimental|Arm 1|Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup
3267053|NCT00717912|Experimental|Arm 2|Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Experimental sweetener syrup
3267054|NCT00717912|Experimental|Arm 3|Experimental sweetener syrup / Classical sugar syrup / Experimental sweetener syrup / Classical sweetener syrup / Classical sugar syrup / Classical sugar syrup / Experimental sweetener syrup
3267055|NCT00717912|Experimental|Arm 4|Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup / Classical sugar syrup / Classical sweetener syrup
3267056|NCT00717912|Experimental|Arm 5|Classical sugar syrup / Experimental sweetener syrup / Classical sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup
3267057|NCT00717912|Experimental|Arm 6|Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Classical sugar syrup
3267058|NCT00717899|Active Comparator|1|School children from Haifa bay region, Israel.
3267059|NCT00717886|Experimental|1|Patients with documented axillary metastases (Stage II breast cancer) will undergo subdermal injection of technetium sulfur colloid (TSC) into the ipsilateral upper extremity approximately 3 hours before surgery.
3267060|NCT00717873|Experimental|HFCWO Arm|Airway clearance provided by the Vest Airway Clearance System
3267061|NCT00717873|No Intervention|CPT Arm|Airway clearance provided by manual CPT
3267062|NCT00717860|Experimental|Caspofungin|caspofungin acetate (MK0991)
3267063|NCT00717860|Active Comparator|Micafungin|Micafungin sodium
3267064|NCT00717847||1|Any patient with NSCLC receiving erlotinib or gefitinib
3267065|NCT00717847||2|Patients with unexpected and/or severe treatment related toxicity whilst receiving EGFR TKI.
3267066|NCT00717834|Experimental|Cohort 1, Treatment Arm 1|Randomization of a total of approx. 200 subjects to one of four treatment arms at 1:1:1:1 ratio to receive 1.25 µg of the RRV Vaccine with/without adjuvant (Al(OH)3), or 2.5 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Cohort 1 is subdivided into Cohort 1a (n = 60, i.e. 15 subjects per dose/adjuvantation combination) to receive the first vaccination on Day 0, with Day 7 safety data being reviewed by a Data Monitoring Committee and, following DMC recommendation, to receive the second vaccination at Day 21; Cohort 1b (n=140, i.e. 35 subjects per dose/adjuvantation combination) is to be vaccinated twice 21 days apart upon availability of DMC recommendation. Booster vaccination to follow 180 days after first vaccination.
3267067|NCT00717834|Experimental|Cohort 1, Treatment Arm 2|Same as Cohort 1, Treatment Arm 1
3267068|NCT00717834|Experimental|Cohort 1, Treatment Arm 3|Same as Cohort 1, Treatment Arm 1
3267069|NCT00717834|Experimental|Cohort 1, Treatment Arm 4|Same as Cohort 1, Treatment Arm 1
3267070|NCT00717834|Experimental|Cohort 2, Treatment Arm 1|Randomization of a total of approx. 100 subjects to one of two treatment arms at 1:1 ratio to receive 5 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Vaccinations take place upon review of Cohort 1a Day 7 safety data by DMC and recommendation to proceed. Booster vaccination to follow 180 days after first vaccination.
3267071|NCT00717834|Experimental|Cohort 2, Treatment Arm 2|Same as Cohort 2, Treatment Arm 1
3267072|NCT00717834|Experimental|Cohort 3, Treatment Arm 1|Randomization of a total of approx. 100 subjects to one of two treatment arms at 1:1 ratio to receive 10 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Vaccinations take place upon review of Cohort 1b and Cohort 2 Day 7 safety data by DMC and recommendation to proceed. Booster vaccination to follow 180 days after first vaccination.
3267073|NCT00717834|Experimental|Cohort 3, Treatment Arm 2|Same as Cohort 3, Treatment Arm 1
3267074|NCT00717821|Experimental|1|
3267075|NCT00717821|Active Comparator|2|
3267215|NCT00716768|Active Comparator|Laparoscopic Inguinal Hernia Repair|
3267216|NCT00716768|Active Comparator|Open Inguinal Hernia Repair|
3267076|NCT00717808|Active Comparator|1|During the study the patient will either receive tranilast (300mg twice a day) or a placebo drug for a period of seven days. The patient will then have a seven day break followed by another period of seven days in which the patient will receive the other medication.
3267077|NCT00717808|Placebo Comparator|2|The patient will receive the placebo twice a day for 7 days whilst taking their weekly methotrexate dose
3267078|NCT00717795||1|Arm 1 - Physical Activity intervention
3267079|NCT00717795||2|Arm 2 - Wait-list control
3267080|NCT00717782|Experimental|1|"Patients were injected with 0·6 ml of a solution containing 30 units botulinum toxin A (Botox; Allergan, Ireland).~A 27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter."
3267081|NCT00717782|Placebo Comparator|2|"Patients in the placebo group received a 0·6-ml injection of saline.~A27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter."
3267082|NCT00717769|Experimental|1|
3267083|NCT00717769|Placebo Comparator|2|
3267084|NCT00717756|Experimental|Lenalidomide|
3267085|NCT00717743||1|Patients diagnosed with RCC.
3267086|NCT00717730|Placebo Comparator|A|Placebo dietary supplement
3267087|NCT00717730|Experimental|B|Folic acid
3267088|NCT00717730|Experimental|C|Vitamin B12
3267089|NCT00717730|Experimental|D|Folic acid and Vitamin B12
3267090|NCT00717717|No Intervention|Control|No intervention except repeated measurements of physical capacity
3267091|NCT00717717|Experimental|Intervention|Intervention: One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
3267092|NCT00717704|Experimental|1|All participants will receive ixabepilone by vein once every three weeks as well as dasatinib by mouth once daily. All participants will receive the study drugs at a baseline dose. If the side effects are minimal and tolerable, the next cycle of study drugs will be given at same dosage. If side effects are intolerable, then the dose will be lowered.
3267093|NCT00717691|Experimental|1|Immediate fitting with dynamic splinting following diagnosis of hallux limitus.
3267094|NCT00717691|No Intervention|2|Control arm; patients only treated with standard of care following diagnosis of hallux limitus.
3267095|NCT00717678|Experimental|Prograf-XL + MMF|
3267096|NCT00717678|Active Comparator|Prograf + MMF|
3267097|NCT00717665|Experimental|A, 1, I|
3267098|NCT00717665|Active Comparator|A, 2, I|
3267099|NCT00717652|Experimental|1|arbutin, tretinoin, triamcinolone
3267100|NCT00717652|Active Comparator|2|Triluma
3267101|NCT00717639|Experimental|1|single arm study, all patients will undergo Vasovist-enhanced MRA
3267102|NCT00717626|Experimental|1|
3267103|NCT00717613||1|Observational cohort study
3267104|NCT00717600|Experimental|1|Oral probiotics
3267105|NCT00717574|Active Comparator|Sevoflurane group|Sevoflurane based general anesthesia
3267106|NCT00717574|Active Comparator|Propofol group|Propofol based general anesthesia
3267107|NCT00717561|Experimental|Arm 1|
3267108|NCT00717561|Active Comparator|Arm 2|
3267109|NCT00717548|Experimental|A|
3267110|NCT00717522|Experimental|Pomalidomide|7 mg pomalidomide taken orally once daily (QD) on days 1 through 21 of each 28-day cycle
3267111|NCT00717509||clozapine group|"chronic schizophrenia~have been taking clozapine at leaset one year~without diabetes, pulmonary tuberculosis"
3267112|NCT00717496|Experimental|A|The intervention will consist of outreach telephone calls daily by bilingual trained nursing staff for the first 2 weeks postpartum using the scripted protocols developed for this program. This group will receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream. The intervention nurse will ask the mothers on their initial intake call for the best time to call each day to minimize time needed to reach the mother.
3267113|NCT00717496|No Intervention|B|Mothers assigned to the control group will receive usual care. This group will also receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream.
3267114|NCT00717483||Type 1 diabetes|children with type 1 diabetes
3267115|NCT00717470|Active Comparator|Prograf + MMF + Steroids|oral
3267116|NCT00717470|Active Comparator|Advagraf (dose 1) + MMF + steroids|oral
3267117|NCT00717470|Active Comparator|Advagraf (dose 2) + MMF + steroids|oral
3267118|NCT00717470|Active Comparator|Advagraf + MMF + Basilixmab + steroids|oral
3267119|NCT00717457|Active Comparator|exenatide|
3267120|NCT00717457|Experimental|taspoglutide 10mg|
3267121|NCT00717457|Experimental|taspoglutide 10mg/20mg|
3267122|NCT00717444|Experimental|1|contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities
3267123|NCT00717444|Experimental|2|contingency management for abstinence plus 12-step facilitation therapy
3267124|NCT00717431|Experimental|Hippocampal Stimulation|Hippocampal Stimulation (Stimulator is turned ON) Surgical Intervention
3267125|NCT00717431|Sham Comparator|Hippocampal Implantation|Hippocampal Implantation (Stimulator is turned OFF)Surgical Intervention
3267126|NCT00717418||1|"cyclosporine ophthalmic emulsion 0.05%~artificial tears"
3267127|NCT00717405|Experimental|1|
3267128|NCT00717392||Hippotherapy_ADHD|10 children with ADHD who receive hippotherapy
3267129|NCT00717392||Hippotherapy_ASD|10 children with ASD who receive hippotherapy
3267130|NCT00717392||Control_ADHD|10 children with ADHD who DO NOT receive hippotherapy
3267131|NCT00717392||Control_ASD|10 children with ASD who DO NOT receive hippotherapy
3267132|NCT00717379|Active Comparator|1|steroid regimen 1
3267133|NCT00717379|Experimental|2|steroid regimen 2
3267213|NCT00716781||1 (first year)|Asymptomatic infants born to GBS-positive mothers or to mothers with risk factors and incomplete prophylaxis were managed according to the CDC protocol. Blood cultures and CBC were performed and the infant was observed for 48 hours. Participating hospital were free to perform any additional test, such as CRP, MiniESR, etc
3267134|NCT00717366|Experimental|MIRCERA Group 1: Intermediate-Conversion-Factor Group|Participants will receive methoxy polyethylene glycol-epoetin beta (MIRCERA) IV injection at a starting dose based on an intermediate conversion factor from their previous Erythropoiesis-stimulating Agent (ESA) dose (4 * previous weekly epoetin dose [international units {IU}]/250 or 4 * previous weekly darbepoetin alfa dose [micrograms {mcg}]/1.1) once every 4 weeks for 20 weeks. Participants who will complete the 20 weeks of treatment with hemoglobin (Hb) level within ± 1 grams per deciliter (g/dL) of their baseline Hb level and within the target range of 10-12 g/dL will enter an optional 52-weeks safety extension period. During this period, the participants will continue to receive MIRCERA IV injection once every 4 weeks.
3267135|NCT00717366|Experimental|MIRCERA Group 2: High-Conversion-Factor Group|Participants will receive MIRCERA IV injection based on a high conversion factor from their previous ESA dose (4 * previous weekly epoetin dose [IU]/125 or 4 * previous weekly darbepoetin alfa dose [mcg]/0.55) once every 4 weeks for 20 weeks. Participants who will complete the 20 weeks of treatment with Hb within ± 1 g/dL of their baseline Hb and within the target range of 10-12 g/dL will enter an optional 52-weeks safety extension period. During this period, the participants will continue to receive MIRCERA IV injection once every 4 weeks.
3267136|NCT00717353||1|Lung cancer
3267137|NCT00717340|Experimental|tivozanib (AV-951) + paclitaxel|
3267138|NCT00717314|Experimental|MMF, 50% CNI Reduction|Participants received mycophenolate mofetil (MMF), 1.5 to 2.0 grams (g) daily, orally (PO), twice per day (BID) from baseline (BL) to Week 52. Participants also received a 50 percent (%) reduced dose of calcineurin inhibitor (CNI) from BL to Week 52.
3267139|NCT00717314|Experimental|MMF, ≥75% CNI Reduction|Participants received MMF, 1.5 to 2.0 g daily, PO, BID from BL to Week 52. Participants also received a 75% reduced dose of CNI from BL to Week 52.
3267140|NCT00717301||Head Trauma|Patients presenting to any of the AHCC/ERNES Emergency Departments with head trauma.
3267141|NCT00717301||Control subjects|Patients presenting to the Univ of Rochester Medical Center/Strong Memorial Hospital Outpatient Laboratory for routine blood draw.
3267142|NCT00717288|Active Comparator|1|Detemir insulin dosed at 50% of calculated basal insulin infusion requirement injected once daily
3267143|NCT00717288|Active Comparator|2|Detemir insulin dosed at 65% of calculated basal insulin infusion requirement injected once daily
3267144|NCT00717288|Active Comparator|3|Detemir insulin dosed at 80% of calculated basal insulin infusion requirement injected once daily
3267145|NCT00717275|Experimental|Temozolomide|
3267146|NCT00717262|Experimental|1|HQK-1001
3267147|NCT00717262|Placebo Comparator|2|
3267148|NCT00717249|Experimental|Test Lens|galyfilcon A contact lens with a silver additive
3267149|NCT00717249|Active Comparator|Control Lens|galyfilcon A control contact lens
3267150|NCT00717236|Experimental|Certolizumab pegol (CZP)|
3267151|NCT00717236|Placebo Comparator|Placebo|
3267152|NCT00717223||Parents with children with diabetes|parents who have children 18 or younger with diabetes
3267153|NCT00717210|Active Comparator|A|Conventional Radiotherapy
3267154|NCT00717210|Experimental|B1/2|1:1 randomization between temozolomide and procarbazine/lomustine/vincristine (PCV)
3267155|NCT00717197|Experimental|Capecitabine|Capecitabine (1,000-1,250 mg/m2) taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
3267156|NCT00717171|Placebo Comparator|1|
3267157|NCT00717171|Experimental|2|
3267158|NCT00717158|No Intervention|I|Usual medical care. They received written healthy lifestyle information
3267159|NCT00717158|Active Comparator|2|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
3267160|NCT00717145|Experimental|1|One risedronate 20 mg DR tablet taken following an overnight fast, followed by a 4-hour fast.
3267161|NCT00717145|Experimental|2|One risedronate 20 mg DR tablet taken following an overnight fast, within 5 minutes after ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
3267162|NCT00717145|Experimental|3|One risedronate 35 mg DR tablet taken following an overnight fast, within 5 minutes after ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
3267163|NCT00717145|Experimental|4|One risedronate 35 mg IR tablet taken following an overnight fast, 30 minutes before ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
3267164|NCT00717132|Experimental|Individual Behavioral Modification|Individual behavioral weight control treatment; parent and child are treated separately for 15 total sessions.
3267165|NCT00717132|Active Comparator|Family-based Behavioral Modification|Family-based behavioral weight control treatment; parent and child are treated together for 15 total sessions.
3267166|NCT00717119||1|Patients with sprain of ankle treated with NSAID
3267167|NCT00717093|Experimental|Active|
3267168|NCT00717093|Placebo Comparator|Placebo|
3267169|NCT00717080|Experimental|Arm 1|IOL surgery with Capsular Tension Ring
3267170|NCT00717080|Placebo Comparator|Arm 2|IOL surgery without Capsular Tension Ring
3267171|NCT00717067|Experimental|Healthy Subjects|Subjects with Normal Renal Function (Creatinine Clearance > 80mL/min) (I) Maraviroc single dose, followed by (II) Maraviroc + Saquinavir/Ritonavir
3267172|NCT00717067|Experimental|Mild Renal Impairment|Subjects with Mild Renal Impairment (Creatinine Clearance >50 and ≤80 mL/min)
3267173|NCT00717067|Experimental|Moderate Renal Impairment|Subjects with Moderate Renal Impairment (Creatinine Clearance ≥30 and ≤50 mL/min)
3267174|NCT00717067|Experimental|Severe Renal Impairment|Subjects with Severe Renal Impairment (Creatinine Clearance <30 mL/min)
3267175|NCT00717067|Experimental|ESRD on Hemodialysis|Subjects with End Stage Renal Impairment receiving Hemodialysis(Creatinine Clearance <30 mL/min) (I) Maraviroc single dose one hour following completion of hemodialysis, followed by (II) Maraviroc single dose three hours prior to start of hemodialysis
3267214|NCT00716781||2 (second year)|Asymptomatic infants born to GBS-positive mothers or to mothers with risk factors and incomplete prophylaxis were managed with clinical observation only. Clinical surveillance was based on 3 signs: 1. Skin appearance (pink, pale, mottled, cyanotic); 2. Respiratory rate (>50 or <50 breaths per minute); 3. Dyspnea (Yes / No)
3267176|NCT00717054|Active Comparator|Aprepitant and Scopolamine group|Patients receive aprepitant and scopolamine for prevention of postoperative nausea and vomiting then were followed through the post operative period looking for nausea, vomiting, composite, and rescue medication utilization. This was compared to patients receiving aprepitant and scopolamine placebo looking for a difference in incidence of events.
3267177|NCT00717054|Placebo Comparator|Aprepitant and Scopolamine Placebo Group|Patients receiving aprepitant and placebo scopolamine for prevention of postoperative nausea and vomiting then followed through the post operative period looking for signs of nausea, vomiting, composite, and rescue medication utilization. This was compared to patients receiving aprepitant and scopolamine looking for a difference in incidence of events.
3267178|NCT00717041||Presenting to the ED|Patients who present to the ED
3267179|NCT00717002||1|Patients from Group 1 will undergo thoracoscopy as part of their routine clinical management to drain off excess pleural fluid. Even though taking a sample of the tumour tissue present on the pleural/ lining of the lung may not routinely form part of a routine thoracoscopy, it will be obtained for the study and sent to the laboratory for testing.
3267180|NCT00717002||2|Patients from Group 2 should have tumour samples obtained previously for diagnosis, and these will be obtained from the Department of Pathology. If they are undergoing thoracoscopy as part of their routine clinical management, a sample of the tumour tissue present on the pleural/ lining of the lung will also be obtained during the procedure and sent to the laboratory for testing.
3267181|NCT00716976|Experimental|STS Arm (sodium thiosulfate treatment)|Patients receive sodium thiosulfate IV (dosage 16 g/m2 or 533 mg per kg for patients whose therapeutic protocol administers cisplatin on a per kg basis due to young age or small body) over 15 minutes beginning 6 hours after the completion of each cisplatin infusion. Treatment with sodium thiosulfate continues until the completion of cisplatin therapy.
3267182|NCT00716976|Experimental|Observation Arm (No sodium thiosulfate treatment)|Patients do not receive sodium thiosulfate.
3267183|NCT00716963|Active Comparator|1|Fluticasone propionate (Flovent Diskus) 250 mcg
3267184|NCT00716963|Active Comparator|2|budesonide 400mcg
3267185|NCT00716963|Placebo Comparator|3|placebo
3267186|NCT00716950|Experimental|1|valsartan/amlodipine
3267187|NCT00716950|Active Comparator|2|losartan/amlodpine
3267188|NCT00716937|Experimental|1|Excision of the cyst and Karydakis flap
3267189|NCT00716937|Experimental|2|Excision of the cyst and laying open
3267190|NCT00716924|Experimental|1|300-mg loading dose of clopidogrel given ≥ 6 and ≤ 24 hours before PCI
3267191|NCT00716924|Experimental|2|600-mg loading dose of clopidogrel given ≥ 6 hours and ≤ 24 before PCI.
3267192|NCT00716924|Experimental|3|600-mg loading dose of clopidogrel given immediately (≤ 45 minutes) before PCI.
3267193|NCT00716898||1|"A. Patients with pathologically or cytologically confirmed diagnosis of advanced solid malignancy.~B. Venous thromboembolism: Deep vein thrombosis (DVT) confirmed by Doppler ultrasound, or pulmonary embolism confirmed by lung ventilation perfusion scan, or computerized tomography.~C. Treatment with therapeutic dose of low molecular weight heparin. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. Serum creatinine level < 1.5 mg/dl. G. Informed consent"
3267194|NCT00716898||2|"A. Patients with unstable angina pectoris/ atypical chest pain, with no evidence of acute myocardial infarction.~B. Treatment with therapeutic dose of low molecular weight heparin. C. No evidence of VTE. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. No history of malignancy. G. Serum creatinine level < 1.5 mg/dl. H. Informed consent"
3267195|NCT00716885||CHF|"Informed consented participants are recruited among all patients admitted to the OLVG hospital.~Inclusion criteria:~Chronic congestive heart failure patients of all ages selected for biventricular pacemaker implantation for resynchronization therapy~Dyspnoe NYHA class III and IV~Optimal and constant heart failure treatment according to the ESC guidelines~Exclusion criteria:~Renal failure (creatinine >1.70 mg/dl)~Signs of infection or inflammation"
3267196|NCT00716885||Control|The control group consists of ten age-matched volunteers with a normal left ventricular ejection fraction and without signs or symptoms of heart failure.
3267197|NCT00716872|Experimental|ImmedSHUTi/ImmedHyp|In the first part of the trial, participants are assigned to the Immediate SHUTi group; that is, they receive access to the SHUTi program right away. In the second part of the trial (3 months later), participants are assigned to the Immediate Hypnosis group; that is, they receive access to the Hypnosis recordings right away.
3267198|NCT00716872|Experimental|ImmedSHUTi/DelayHyp|In the first part of the trial, participants are assigned to the Immediate SHUTi group; that is, they receive access to the SHUTi program right away. In the second part of the trial (3 months later), participants are assigned to the Delayed Hypnosis group; that is, they receive access to the Hypnosis recordings at the end of the study.
3267199|NCT00716872|Experimental|DelaySHUTi/ImmedHyp|In the first part of the trial, participants are assigned to the Delayed SHUTi group; that is, they receive access to the SHUTi program at the end of the study. In the second part of the trial (3 months later), participants are assigned to the Immediate Hypnosis group; that is, they receive access to the Hypnosis recordings right away.
3267200|NCT00716872|No Intervention|DelaySHUTi/DelayHyp|In the first part of the trial, participants are assigned to the Delayed SHUTi group; that is, they receive access to the SHUTi program at the end of the study. In the second part of the trial (3 months later), participants are assigned to the Delayed Hypnosis group; that is, they receive access to the Hypnosis recordings at the end of the study.
3267201|NCT00716859|Active Comparator|Timolol|
3267202|NCT00716859|Experimental|latanoprost|
3267203|NCT00716846|Active Comparator|statin-1|simvastatin
3267204|NCT00716846|Active Comparator|statin-2|atorvastatin
3267205|NCT00716846|Active Comparator|statin-3|pitavastatin
3267206|NCT00716833|Active Comparator|Preemptive|Preemptive group patients get Etoricoxibe twice (before and after surgery) or just a single preoperative dose
3267207|NCT00716833|Placebo Comparator|Postoperative|Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery.
3267208|NCT00716820||SUNITINIB MALATE|Patients taking Sutent.
3267209|NCT00716807|Experimental|TMD 1|
3267210|NCT00716807|Placebo Comparator|TMD 2|
3267211|NCT00716807|Experimental|BMS 1|
3267217|NCT00716755|Experimental|Dose Reduction|See Intervention
3267218|NCT00716742||1|bimatoprost 0.03% latanoprost 0.005% travoprost 0.004%
3267219|NCT00716729||Pateints with longstanding hip and/groin pain|
3267220|NCT00716716|Experimental|rFIXFc|Six intravenous (IV) dose levels, 1, 5, 12.5, 25, 50, and 100 IU/kg
3267221|NCT00716703|Experimental|1|cohort = pediatric patients in the ED (3-18 yo) with abdominal pain suspicious for appendicitis that are to undergo CT scan
3267222|NCT00716690|Experimental|treatment|
3267223|NCT00716677||1|
3267224|NCT00716677||2|
3267225|NCT00716664|Experimental|1|The experimental group receives the intervention in addition to normal optimal care
3267226|NCT00716664|Active Comparator|2|The active comparator, or control group, receives normal optimal care only
3267227|NCT00716638|Experimental|Treatment group 1|Trauma-focused Cognitive Behavior Therapy (TF-CBT)
3267228|NCT00716638|Experimental|Treatment group 2|Eye Movement Desensitization and Reprocessing (EMDR)
3267229|NCT00716625||sunitinib malate|Patients taking sunitinib malate
3267230|NCT00716612|Placebo Comparator|2|PO Placebo QD
3267231|NCT00716612|Experimental|1|PO Coenzyme Q 10 QD
3267232|NCT00716599|No Intervention|Control|Health centers continue with standard-of-care empiric case management
3267233|NCT00716599|Experimental|RDT training|Health centers randomly selected to receive training and RDTs, for use in routine patient case management
3267234|NCT00716586|Experimental|1|Patients over the age of 18 years with cystoid macular edema and retinal degeneration will be treated with Trusopt.
3267235|NCT00716573|Experimental|1|Introduction of everolimus associated with CNI (ciclosporin or tacrolimus) reduction (50%) to the current immunosuppression schedule
3267236|NCT00716573|No Intervention|2|Maintain of their current immunosuppressive therapy
3267237|NCT00716560||A|Metastatic melanoma treatment with Dartmouth regimen
3267238|NCT00716547|Experimental|1|
3267239|NCT00716547|Experimental|2|
3267240|NCT00716547|Active Comparator|3|
3267241|NCT00716547|Placebo Comparator|4|
3267242|NCT00716534|Experimental|A|12.5 mg ABT-869 + Carboplatin/Paclitaxel
3267243|NCT00716534|Experimental|B|7.5 mg ABT-869 + Carboplatin/Paclitaxel
3267244|NCT00716534|Placebo Comparator|C|Placebo (7.5 mg or 12.5 mg) + Carboplatin/Paclitaxel
3267245|NCT00716521|Placebo Comparator|Placebo|groups of 3-4 subjects for overnight polysomnography assessments
3267246|NCT00716521|Experimental|Low dose Zolpidem|
3267247|NCT00716521|Experimental|High dose zolpidem|
3267248|NCT00716508|Active Comparator|A|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
3267249|NCT00716508|Active Comparator|B|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
3267250|NCT00716469|Experimental|LS11 Administration|"Treatment will be given with a standard 3+3 light dose escalation. The Treatment Period will be 28 days. The LS11 dose will be 30mg/m2. The initial light dose will be 50 J/cm. If criteria for dose escalation are met, then the light dose will be escalated to 100J/cm, 150J/cm and 200J/cm. Once the maximum light dose is determined, up to 6 additional patients will be treated at that level to gain further experience with this modality prior to phase II testing. In particular, at least 3 subjects <12 years of age will be enrolled at the maximum tolerable dose (MTD) to allow for further evaluation of safety in younger children. If grade 3 or 4 toxicities are noted at light dose level #1, the LS11 dose will be decreased to 20mg/m2 (2/3 of the standard dose)."
3267251|NCT00716456|Experimental|1|In the phase I portion, patients will be enrolled in cohorts of 3-6 patients;receiving daily erlotinib 100 mg along with cetuximab given every 2 weeks beginning at 250mg/m2 IV. Following the initial dose, for dose levels 1 and 2 (250 mg/m2 and 375 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 60 minutes. For dose level 3 (500 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 120 minutes. The infusion rate of cetuximab should never exceed 10 mg/minute (5 mL/min). The dose may subsequently be reduced for individual patients, depending on a patient's toxicity.
3267252|NCT00716443|Active Comparator|Pliaglis® Cream|tetracaine 4% / lidocaine 7% cream; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.
3267253|NCT00716443|Active Comparator|benzocaine 20% / lidocaine 6% / tetracaine 4% ointment|apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.
3267254|NCT00716430|Active Comparator|QI|Quality Improvement Centres
3267255|NCT00716430|No Intervention|Non-QI|No Quality Improvement Programme
3267256|NCT00716417|Experimental|A. BIBW 2992-cisplatin-paclitaxel|daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-paclitaxel
3267257|NCT00716417|Experimental|B. BIBW 2992-cisplatin-5FU|daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-5FU
3267258|NCT00716404||1|All (consecutive) patients in whom one or more components of the Benephit Infusion System are planned to be used are eligible for enrollment in the study and should be offered informed consent.
3267259|NCT00716391|Active Comparator|Group A|TPF plus concomitant treatment with cisplatin and conventional radiotherapy.
3268074|NCT00710827|Placebo Comparator|Arm 2|
3267260|NCT00716391|Experimental|Group B|TPF plus concomitant treatment with cetuximab and conventional radiotherapy
3267261|NCT00716365|Experimental|HemCon|"The purpose of this trial is to test HemCon pad after diagnostic percutaneous coronary angiography as an adjunct to manual compression to better control vascular access site bleeding and reduce time-to-hemostasis.~The HemCon bandage (containing a carbohydrate called chitosan, found in the shells of shrimp, lobster and beetles) will be used to shorten the time needed to achieve hemostasis, time to patient's ambulation, and patient's."
3267262|NCT00716339|Active Comparator|1|motivated
3267263|NCT00716339|No Intervention|2|control
3267264|NCT00716326|Active Comparator|1|Subjects in this study arm will receive active treatment with Cefar TENS device which delivers therapeutic electrical currents 2-3x over sensory threshold in the area of pain.
3267265|NCT00716326|Placebo Comparator|2|Subjects in this study arm will receive placebo treatment with manipulated Cefar TENS device which delivers electrical currents just below sensory threshold in the area of pain.
3267266|NCT00716300||1|obese and insulin resistant subjects
3267267|NCT00716300||2|lean and normolipidaemic subjects
3267268|NCT00716287||1|Anti-angiogenic targeted therapies are used in a wide range of solid tumors including NSCLC, breast cancer, GISTs, CRC, renal cell carcinoma and hepatocellular carcinoma.
3267269|NCT00716274|Experimental|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks (study period II). Participants who complete the study period II will be re-randomized in the study period III of 16-week duration to assess maintenance of benefit following discontinuation of treatment with atomoxetine. Participants assigned to atomoxetine during the study period II will be re-randomized to either atomoxetine or placebo whereas participants previously assigned to placebo will receive atomoxetine.
3267270|NCT00716274|Placebo Comparator|Placebo|Placebo will be packaged in the same way as active comparator to enforce double-blind study design
3267271|NCT00716248|Experimental|1|
3267272|NCT00716248|Active Comparator|2|
3267273|NCT00716235||DCD|Children with a diagnosis of DCD
3267274|NCT00716235||Autism|Children with a diagnosis of Autism disorder
3267275|NCT00716235||ADHD|Children with a diagnosis of ADHD
3267276|NCT00716235||Control|Control group - children with no neurological or psychiatric problems
3267277|NCT00716222||1|Obese adolescent and young adult with sleep disorder
3267278|NCT00716222||2|Obese adolescent and young adult without sleep disorder
3267279|NCT00716222||3|Lean adolescent and young adult with sleep disorder
3267280|NCT00716209||1|Patients with cancers of the gastrointestinal tract (eg. colorectal, gastric, pancreatic, esophageal)
3267281|NCT00716183|Experimental|Probiotic 1|Women receiving Lactobacillus salivarius HN6
3267282|NCT00716183|Experimental|Probiotic 2|Women receiving Lactobacillus reuteri CR20
3267283|NCT00716183|Experimental|Probiotic 3|Women receiving Lactobacillus fermentum LC40
3267284|NCT00716183|Active Comparator|beta-lactam|The evolution of the women ascribed to the other three arms will be compared with that of 100 women suffering lactational mastitis that will follow a conventional antibiotic treatment as prescribed by the pediatrician/gynecologist
3267285|NCT00716170||A:|Patients with type 2 diabetes mellitus
3267286|NCT00716157||Observation|Adult patients receiving both radiation therapy and chemotherapy
3267287|NCT00716144|Active Comparator|A|Talarozole 0.5 mg
3267288|NCT00716144|Active Comparator|B|Talarozole 1.0 mg
3267289|NCT00716144|Active Comparator|C|Talarozole 2.0 mg
3267290|NCT00716144|Placebo Comparator|D|Talarozole matching Placebo
3267291|NCT00716131||ALS|Diagnosed with ALS or other motor system disorder including PLS, Bulbar Palsy or Motor neuropathy
3267292|NCT00716131||Neuro|Diagnosed with other chronic neurologic illnesses (Alzheimers, multiple sclerosis, migraines, etc)
3267293|NCT00716131||Healthy|Normal Controls
3267294|NCT00716131||Autopsy|
3267295|NCT00716118||1|IVF patients.
3267296|NCT00716105|Placebo Comparator|Control|Standard Infant Formula
3267297|NCT00716105|Experimental|Test Product|Infant formula with different level of proteins
3267298|NCT00716105|No Intervention|Breast Milk|Breastfeeding reference group
3267299|NCT00716092|Placebo Comparator|Placebo|Patients received placebo matching 5mg linagliptin and placebo matching 100mg sitagliptin.
3267300|NCT00716092|Experimental|Linagliptin|Patients received 5mg linagliptin, and placebo matching 100mg sitagliptin.
3267301|NCT00716092|Active Comparator|Sitagliptin|Patients received 100mg sitagliptin, and placebo matching 5mg linagliptin.
3267302|NCT00716079|Other|Intensive BP lowering|Management policy to lower the systolic Blood pressure (BP) to a target of 140mmHg within 1 hour of randomization and sustained for 24 hours. Sites were provided with protocols for different intravenous agents and used whichever routinely available drugs were in their hospital.
3267303|NCT00716079|Other|Guideline recommended BP lowering|Patients received management of BP based on the standard guidelines at the time, as published by the American Heart Association (AHA) in 2007 and 2010. The attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, intravenous treatment may be started until the target systolic BP of 180 mmHg is achieved.
3267304|NCT00716066|Experimental|Treatment (immunosuppressive therapy followed by transplant)|Patients receive carmustine IV on day -6, etoposide IV and cytarabine IV BID on days -5 to -2, melphalan IV on day -1 and antithymocyte globulin IV on days -2 and -1. Patients then undergo autologous or syngeneic peripheral blood stem cell transplant on day 0. Patients also receive prednisone PO QD on days 7-21, followed by 2 week taper.
3267305|NCT00716053|Experimental|BLVR|
3267306|NCT00716053|Sham Comparator|Saline|
3267307|NCT00716040|Experimental|Intervention|The intervention group will be submitted to four social-psychological individual sessions with a pre-trained health professional.
3267308|NCT00716040|Other|Control|The control group will be submitted to the usual care of the health service.
3267350|NCT00715741|Active Comparator|2|Group 2 will receive 30% oxygen without PEEP for the duration of anesthesia and surgery
3268211|NCT00709787||Hypertensive Subjects undergoing primary prevention|
3267309|NCT00716027|Active Comparator|1|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
3267310|NCT00716027|Experimental|2|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
3267311|NCT00716014|Active Comparator|Foot 1|An active drug injection of TD101 is injected into a callus on the bottom of one foot.
3267312|NCT00716014|Placebo Comparator|Foot 2|An injection of placebo (normal saline) is injected into a callus on the bottom of one foot.
3267313|NCT00716001|Active Comparator|NAC|
3267314|NCT00716001|Placebo Comparator|nonNAC|
3267315|NCT00715988|Experimental|Scheme 1|Patients who are feeding or not feeding and mechanically ventilated, >/=3 d of age and 29 0/7wks-48 6/7 wks PMA, treated with i.v. bolus doses or infusion of fentanyl, morphine or methadone for clinical indications, with arterial/venous line in place & expected treatment for at least 1-2 more days. Pk sampling = 0.5 ml blood samples x6/infant. ECG monitoring. Three patients will be enrolled in 5 PMA groups. Should apnea or hypotension occur, dosages for Treatment Scheme 2 will be reduced (50%); more patients will be studied in Treatment Scheme 1 to insure that the lower dose is well tolerated & effective.
3267316|NCT00715988|Experimental|Scheme 2|Patients defined in Scheme 1, tolerating feeds for >/= 3 days will be studied twice, after i.v. methadone and after enteral methadone after the end of sampling after the first dose. 4-5 samples will be obtained after dose 1 and after dose 2 depending on PMA and weight. Patients will be divided into groups based on PMA..
3267317|NCT00715975|Experimental|1|The patients will be treated with halobetasol once a day for 15 days.
3267318|NCT00715975|Experimental|2|The patients will be treated with clobetasol once a day for 15 days.
3267319|NCT00715962|Active Comparator|Mobility Group|The Walking Intervention includes assistance to walk twice daily with or without a rolling walker. In addition, a behavioral intervention that included goal setting and discussion of how to overcome mobility barriers was used to encourage the mobility group to be more active throughout hospital stay. Participants will keep a diary of out of bed activity and will be encouraged to set goals for additional out of bed activity daily.
3267320|NCT00715962|Placebo Comparator|Control Group|The control group will receive twice daily friendly visits to counter the attention being paid to the intervention group. They will complete a diary but of visitors to their room.
3267321|NCT00715949||Mild Traumatic Brain Injury (MTBI) admits|admitted pediatric patients with mild traumatic brain injury (concussion)
3267322|NCT00715936|Active Comparator|Control|Routine services for infants and young children delivered by the Lady Health Workers of the National Programme for Family Planning and Primary Healthcare (Basic Health and Nutrition Education and Services)
3267323|NCT00715936|Experimental|ECD Group|Stimulation and care for development (plus basic health and nutrition education and services)
3267324|NCT00715936|Experimental|Enhanced Nutrition|Care for Nutrition: Enhanced education messages and Sprinkles for children aged 6-24 months (plus basic health and nutrition education and services)
3267325|NCT00715936|Experimental|ECD and Enhanced Nutrition|Stimulation and care for development and care for nutrition (plus basic health and nutrition education and services)
3267326|NCT00715923|Experimental|1|Modified consent form
3267327|NCT00715923|Active Comparator|2|Standard consent form
3267328|NCT00715910|Experimental|Nimenrix 1 Group|Subjects 11-25 years of age who were previously vaccinated with 1 dose of Nimenrix vaccine at the time of vaccination
3267329|NCT00715910|Active Comparator|Menactra Group|Subjects 11-25 years of age who were previously vaccinated with 1 dose of Menactra vaccine at the time of vaccination
3267330|NCT00715910|Experimental|Nimenrix 2 Group|Subjects 10<11 years of age who were previously vaccinated with 1 dose of Nimenrix vaccine at the time of vaccination
3267331|NCT00715910|Experimental|Nimenrix Naive Group|Subjects 15 to <31 years of age at the time of primary vaccination with 1 dose of Nimenrix vaccine at year 5 of the current study
3267332|NCT00715910|Experimental|Nimenrix Pooled Group|Pooled group of subjects 10-25 years of age from Nimenrix 1 and Nimenrix 2 groups in the primary study (NCT00454909) who had received 1 dose of Nimenrix vaccine in that study and will receive a booster dose in this current study.
3267333|NCT00715910|Active Comparator|Menactra Booster Group|Subjects 11-25 years of age who had received 1 dose of Menactra vaccine in primary study (NCT00454909) and will receive 1 dose of Nimenrix vaccine in this current study.
3267334|NCT00715897|Experimental|Treatment- HBOT|HBOT treatment: 8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
3267335|NCT00715897|No Intervention|control-HBOT|Cross group: Patients in the cross group were evaluated three times-baseline, after 2 months control period of no treatment and after a consequent 2 month of HBOT
3267336|NCT00715884|Experimental|1|CYPHER® ELITE™ Sirolimus-Eluting Stent System.
3267337|NCT00715884|Active Comparator|2|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System
3267338|NCT00715871|Experimental|Active Smokers|Active smokers who used the Smoke-Break nicotine delivery device in an attempt to quit smoking cigarettes.
3267339|NCT00715858|Active Comparator|1 AD doxycycline + rifampin|Participants with AD allocated to doxycycline 100 mg bid od and rifampin 300 mg od for 12 months
3267340|NCT00715858|Active Comparator|2 AD doxycycline|
3267341|NCT00715858|Active Comparator|3 AD rifampin|Participants with AD allocated to rifampin 300 mg od od and placebo matched to doxycycline bid for 12 months
3267342|NCT00715858|Placebo Comparator|4 AD placebo|Participants with AD allocated to placebo matched to doxycycline and placebo matched to rifampin for 12 months
3267343|NCT00715858|No Intervention|5 Control|Age-matched cognitively healthy participants (untreated)
3267344|NCT00715845|Experimental|2|
3267345|NCT00715806|Experimental|1|
3267346|NCT00715806|Active Comparator|2|
3267347|NCT00715793|Experimental|Single Arm|
3267348|NCT00715780||A|
3267349|NCT00715741|Active Comparator|1|Group 1 will receive 30% oxygen plus PEEP + 3 to 5 cm Water duration of anesthesia and surgery
3267632|NCT00713687|Experimental|1|Treatment by combination of photodynamic therapy and chemotherapy
3267351|NCT00715741|Active Comparator|3|Group 3 will receive > 90% oxygen plus PEEP + 3 to 5 cm of water for the duration of anesthesia and surgery
3267352|NCT00715741|Active Comparator|4|Group 4 will receive > 90% oxygen and no PEEP for the duration of anesthesia and surgery
3267353|NCT00715728||1: Bair Hugger|Intraoperative warming with Bair Hugger forced air system
3267354|NCT00715728||2: Hot Dog|Intraoperative warming with Hot Dog resistive heating system
3267355|NCT00715715|No Intervention|1|"Patients that meet the requirements listed above will be selected sequentially. Blood tests, including liver function tests and hepatitis profiles will be taken. A liver biopsy will be done before the treatment to evaluate the severity of hepatitis.~For randomly selected patients not treated with steroids: The patients will receive 6 weeks of sugar pills (placebo) before taking Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.~All patients will get another liver biopsy at week 48 to evaluate the improvement of liver inflammation after their treatment. Blood tests will be drawn in accordance with the standard treatment. Generally speaking, hospitalization is not required for this study."
3267356|NCT00715715|Experimental|2|"Patients that meet the requirements listed above will be selected sequentially. Blood tests, including liver function tests and hepatitis profiles will be taken. A liver biopsy will be done before the treatment to evaluate the severity of hepatitis.~For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.~All patients will get another liver biopsy at week 48 to evaluate the improvement of liver inflammation after their treatment. Blood tests will be drawn in accordance with the standard treatment. Generally speaking, hospitalization is not required for this study."
3267357|NCT00715702|Experimental|1|Patients with Moderate renal impairment and matched volunteers
3267358|NCT00715702|Experimental|2|Patients with Mild or Severe renal impairment and matched volunteers. Type of patient group determined after safety review of 1st group data
3267359|NCT00715689|Experimental|A|
3267360|NCT00715689|Experimental|B|
3267361|NCT00715689|Experimental|C|
3267362|NCT00715689|Experimental|D|
3267363|NCT00715676|Placebo Comparator|Group 1|
3267364|NCT00715676|Experimental|Group 2|220 ng
3267365|NCT00715676|Experimental|Group 3|440 ng
3267366|NCT00715663||A|
3267367|NCT00715650|Experimental|Arm 1|This counseling consists of four sessions each approximately 60 minutes each. The four sessions are organized as follows: a) Orientation to Benefits Counseling: Your Benefits and Your Goals b) Work and Claims c) Financial Review: Implications of Your Work Plan and d) Your Plans After the Benefits Notice. The first session focuses on the disability application process as a non-confrontational way to explore attitudes towards work. The second session more directly addresses the claimant's attitudes about work and beliefs about whether work will prevent receipt of disability benefits. The third session addresses the same issue as the second, ambivalence about work and disability, from a financial perspective. The fourth session occurs after the disability determination has been made, and it is possible the veteran may feel differently about a benefit that has been awarded.
3267368|NCT00715650|Active Comparator|Arm 2|This will consist of four-session orientation with the sessions organized as follows: a) overview of VHA services, b) Primary Care c) Pharmacy and laboratory services and d) specialty services. After the description of each service, participants will be invited to discuss which services they plan to utilize. The counselor will provide telephone numbers and directions to the sites at which these services are provided.
3267369|NCT00715637|Experimental|Arm A|Amonafide in Combination with Cytarabine
3267370|NCT00715637|Active Comparator|Arm B|Daunorubicin in Combination with Cytarabine
3267371|NCT00715624|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3267372|NCT00715624|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3267373|NCT00715611|Experimental|1|This is a multicenter phase II toxicity study of pleurectomy/decortication (P/D) followed by adjuvant chemotherapy and Intensity Modulated Radiation Therapy (IMRT) to the pleura in patients with malignant pleural mesothelioma. Alternatively, chemotherapy may be administered in the neoadjuvant setting prior to P/D, followed by IMRT. Patients deemed resectable at the time of enrollment will undergo P/D with the goal of a macroscopic complete resection (MCR). Those with disease progression or severe toxicity will stop chemotherapy and undergo a PET scan.
3267374|NCT00715598||Neuropathic Pain|Subjects in this group experience chronic neuropathic pain.
3267375|NCT00715598||Musculoskeletal Pain|Subjects in this group experience chronic musculoskeletal pain.
3267376|NCT00715585|Active Comparator|Active Control|patients receive 3 individualized visits with a health educator for education on general diabetes and health promotion
3267377|NCT00715585|Experimental|Intervention 1|patients receive 3 individualized visits with an rd-cde for education focused on modified plate method
3267378|NCT00715585|Experimental|intervention 2|patients receive 3 individualized visits with an rd-cde for education focused on carb counting
3267379|NCT00715572|Active Comparator|A|
3267380|NCT00715572|Active Comparator|B|
3267381|NCT00715559|Experimental|cysteamine bitartrate|Participants received cysteamine bitartrate by mouth up to 300 mg three times daily.
3267382|NCT00715520|Experimental|Aim 1|Healthy adult female and male subjects will receive study drugs and TMS training to measure M1 excitability.
3267383|NCT00715520|Experimental|Aim 2|Healthy adult female and male subjects will receive repetitive TMS (rTMS) at different times or frequencies with respect to the training movement or sham stimulation.
3267384|NCT00715520|Experimental|Aim 3|Female and male subjects who have experienced a cerebral ischemic infarction, will receive study drugs and TMS to measure M1 excitability.
3267385|NCT00715507||1|For the phase of the study in which the utility of the graphical medication monitor is assessed, the monitor will not be shown to anesthesiologists placed in the control condition.
3267386|NCT00715507||2|In the experimental condition, anesthesiologists will be shown the medication monitor to aid their expertise and decision-making.
3267387|NCT00715494|No Intervention|Group 1 - Control|Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
3267388|NCT00715494|Experimental|Group 2 - Intervention|Participants in the experimental group will receive a focused set of interdisciplinary home-based interventions over a 12 week period.
3267389|NCT00715455|Active Comparator|Unfractionated Heparin|Unfractionated Heparin
3267390|NCT00715455|Experimental|REG1 Partial Rev.|REG1 with partial reversal
3267391|NCT00715455|Experimental|REG1 Total Rev.|REG1 with total reversal
3267392|NCT00715442|Experimental|Sunitinib + Nephrectomy|Sunitinib 50 mg by mouth daily for 28 consecutive days. Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
3267393|NCT00715429|Experimental|vitamin D 50,000 U/d x 10d, + vitamin D 50,000 U weekly 7 wks|Vitamin D arm
3267394|NCT00715429|Placebo Comparator|placebo x 10d, + placebo weekly 7 wks|placebo
3267395|NCT00715416|Experimental|1|primary nitinol stent placement of superficial femoral artery lesions
3267396|NCT00715416|Active Comparator|2|balloon angioplasty of superficial artery lesions with secondary stent placement in case of >30% residual stenosis after the procedure
3267397|NCT00715390||1-Children receiving anesthesia|The sample of patients screened will be the entire electronic anesthesia record database from 1998 until 2004 looking for subjects that have dysrhythmias.
3267398|NCT00715377|Experimental|1|
3267399|NCT00715364|Experimental|1|
3267400|NCT00715364|Placebo Comparator|2|
3267401|NCT00715351||A|
3267402|NCT00715351||B|
3267403|NCT00715325|Experimental|A|
3267404|NCT00715312|Experimental|A|
3267405|NCT00715299|Other|Locomotor Training Group|persons who have sustained a stroke within greater than 6 months ago and less than 5 years.
3267406|NCT00715286|Active Comparator|A|Conventional arm: primary surgery followed by chemotherapy
3267407|NCT00715286|Experimental|B|Neoadjuvant chemotherapy followed by interval debulking
3267408|NCT00715273|Active Comparator|1 - single therapy group|Participants will receive atorvastatin, placebo niacin, and placebo colesevelam. The treatment target for LDL-C will be ≤80 mg/dl for the single therapy group.
3267409|NCT00715273|Experimental|2 - double therapy group|Participants will receive atorvastatin, niacin, and placebo colesevelam. The treatment target for LDL-C will be ≤80 mg/dl for the double therapy group.
3267410|NCT00715273|Experimental|3 - triple therapy group|Participants will receive atorvastatin, niacin, and colesevelam. The treatment target for LDL-C will be ≤60 mg/dl for the triple therapy group
3267411|NCT00715260||UP Patients on HD|Uremic Pruritus (UP) patients maintained on hemodialysis (HD)
3267412|NCT00715247||Affected Population|Patients suspected to have one of the following blood disorders: polycythemia vera, myelofibrosis or essential thrombocythemia.
3267413|NCT00715247||Healthy Female Controls|Healthy females who do not have the blood disorders; Polycythemia Vera, Essential Thrombocythemia and/or Myelofibrosis.
3267414|NCT00715234|Experimental|Reminder/recall notices for vaccines|This group will receive up to 4 recall messages (both letters and computer-generated phone messages) reminding them to get their vaccines. There are 4 separate study groups: 1) private pediatric patients 2) public pediatric patients 3) school-based health center patients and 4) family medicine patients.
3267415|NCT00715234|No Intervention|Usual Care|This group will receive usual care. There are 4 separate study groups: 1) private pediatric patients 2) public pediatric patients 3) school-based health center patients and 4) family medicine patients.
3267416|NCT00715221||1|Normal Weight
3267417|NCT00715221||2|Obese without diabetes
3267418|NCT00715221||3|Obese with diabetes
3267419|NCT00715208|Experimental|VELCADE R-CAP|VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 Intravenous on Day 1, cyclophosphamide 750 mg/m2 intravenous on Day 1, doxorubicin 50 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.
3267420|NCT00715208|Experimental|VELCADE R-CP|VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 intravenous on Day 1, cyclophosphamide 1000 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.
3267421|NCT00715195|Experimental|1|Cognitive-behavioral therapy : 50 patients planned
3267422|NCT00715195|No Intervention|2|50 patients planned
3267423|NCT00715182|Experimental|TKI258|
3267424|NCT00715169|Active Comparator|1|
3267425|NCT00715169|Placebo Comparator|2|
3267426|NCT00715156||A|Subjects with mild (S1) reaction to peach fruit
3267427|NCT00715156||B|Subjects with severe reaction to peach fruit
3267428|NCT00715143|Other|N|This treatment arm includes ceramic-on-ceramic hip device
3267429|NCT00715117|Placebo Comparator|Sugar pill|Subjects will receive placebo for for the first 8 weeks administered orally one time daily. After 8 weeks placebo treated subjects are then crossed over to active drug naltrexone 0.1 mg/kg not to exceed 4.5 mg PO once daily for an additional 8 weeks.
3267430|NCT00715117|Experimental|Naltrexone|Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally either in capsules or liquid blinded for 8 weeks followed by open-labeled naltrexone for an additional 8 weeks. Safety and toxicity will be compared to placebo. Also change in Crohn's activity index scores of naltrexone to placebo are compared.
3267431|NCT00715104|Experimental|Sipuleucel-T with Booster|Subjects were to receive 3 infusions of sipuleucel-T 12 weeks prior to RP, and then an additional booster infusion 13 weeks following RP.
3267432|NCT00715104|Experimental|Sipuleucel-T without Booster|Subjects were to receive 3 infusions of sipuleucel-T 12 weeks prior to RP, with no further sipuleucel-T treatment.
3267433|NCT00715091|Experimental|1|continuous (daily) treatment with diclofenac cholestyramine 150 mg (Voltaren Resinate), divided into 75mg Voltaren twice daily
3267434|NCT00715091|Active Comparator|2|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg (Voltaren Resinate). The treatment strategy of the control intervention (on-demand) reflects current clinical practice in AS.
3267435|NCT00715078|Active Comparator|Cohort A|Sipuleucel-T with the concentration of 10 μg/mL PA2024 in a cell suspension of 1 x 10^7 peripheral blood mononuclear cells (PBMCs) per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
3267633|NCT00713674|No Intervention|1|No Treatment
3267634|NCT00713674|Experimental|2|Theraworx intranasal
3267436|NCT00715078|Active Comparator|Cohort B|Sipuleucel-T with the concentration of 5 μg/mL PA2024 in a cell suspension of 1 x 10^7 PBMCs per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
3267437|NCT00715078|Active Comparator|Cohort C|Sipuleucel-T with the concentration of 2 μg/mL PA2024 in a cell suspension of 1 x 10^7 PBMCs per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
3267438|NCT00715065||2|Healthy control subjects (who do not faint at the sight of blood)
3267439|NCT00715065||1|People who faint at sight of blood
3267440|NCT00715052|Experimental|1|40 consecutive one hour treatments at 1.5 ATA with 100% O2
3267441|NCT00715052|No Intervention|2|
3267442|NCT00715039|Active Comparator|lorazepam|
3267443|NCT00715039|Placebo Comparator|placebo|
3267444|NCT00715039|Active Comparator|paroxetine|
3267445|NCT00715026|Other|Trilogy AB Acetabular Hip Implant System|Post Approval Study of Device.
3267446|NCT00715000|Experimental|1|SRO
3267447|NCT00715000|Active Comparator|2|classical hydration via intravenous infusion
3267448|NCT00714987||1: High level PEEP|
3267449|NCT00714987||2: Low level PEEP|
3267450|NCT00714974|No Intervention|1|Standard of care
3267451|NCT00714974|Experimental|2|Sedation based on BIS value, oer treating physician discretion.
3267452|NCT00714961|Experimental|1|
3267453|NCT00714961|Placebo Comparator|2|
3267454|NCT00714948|Experimental|1|This is a phase II trial of gemcitabine and Split-dose cisplatin plus sorafenib.
3267455|NCT00714935|Experimental|3|Decision Counseling Program(DCP) combined with Coronary Artery Disease Decision Aid (CAD-DA) described in Arm 2
3267456|NCT00714935|No Intervention|1|
3267457|NCT00714935|Experimental|2|"Behavioral: Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
3267458|NCT00714922|Active Comparator|1|PRK
3267459|NCT00714922|Active Comparator|2|SBK
3267460|NCT00714909||1|
3267461|NCT00714896|Other|1|Assessment only + referral list to State quitline and smoking cessation education classes at Kaiser
3267462|NCT00714896|Experimental|2|Participants will receive self-help information handouts, expert system intervention that includes a stage-based manual and individualized written feedback reports plus in-person brief stage-appropriate counseling at baseline and 3-month assessment. Current smokers who indicate desire to quit smoking or former smokers who indicate high cravings for cigarettes will be offered nicotine replacement medications. Participants will receive three telephone counseling sessions delivered between baseline and 3 month at weeks 2, 4 and 8. As-needed telephone check-calls will be provided to participants on and 2 days after quit date, or to participants who have quit smoking and anticipate high risk situations.
3267463|NCT00714870|Other|1|intervention: this group will attend the nutrition and exercise program control group: this group will not attend the nutrition and exercise program
3267464|NCT00714857|Experimental|1|Patients receiving dexmedetomidine sedation
3267465|NCT00714831|Active Comparator|CG|Control Group
3267466|NCT00714831|Experimental|IG|Intervention Group
3267467|NCT00714818|Experimental|GC|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
3267468|NCT00714818|Active Comparator|EB|Educational Booklet: One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants
3267469|NCT00714818|No Intervention|WT|Waitlist
3267470|NCT00714805||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
3267471|NCT00714805||Healthy Control|Subjects having no known ailment.
3267472|NCT00714792||1|Subjects with urge incontinence due to overactive bladder
3267473|NCT00714792||2|women with no urge symptoms
3267474|NCT00714779|Active Comparator|1|Fluoxetine
3267475|NCT00714779|Active Comparator|2|Short-term psychodynamic psychotherapy
3267476|NCT00714766|Experimental|A|
3267477|NCT00714727|Other|1|
3267478|NCT00714714|Experimental|Tretinoin and Adapalene gels|Adapalene facial gel and tretinoin facial gel applied daily for two weeks on opposite sides of the face (in a split-face model)
3267479|NCT00714701||High Risk Group 1|familial Peutz-Jeghers syndrome
3267480|NCT00714701||High Risk Group 2|familial pancreatic cancer relatives
3267481|NCT00714701||High Risk Group 3|germline mutation carriers BRCA1, BRCA2, PRSS, PALB2, p16
3267482|NCT00714701||High Risk Group 4|young-onset pancreatic cancer relative
3267483|NCT00714701||High Risk Group 5|both parents affected
3267484|NCT00714701||Control 1|negative controls
3267485|NCT00714701||Control 2|chronic pancreatitis
3267486|NCT00714701||Control 3|pancreatic cancer
3267487|NCT00714701||Control 4|intraductal papillary mucinous neoplasm (IPMN)
3267488|NCT00714688|Experimental|001|prolonged release (PR) OROS methylphenidate 54 mg 18+36mg once daily for 13 weeks
3267489|NCT00714688|Experimental|002|prolonged release (PR) OROS methylphenidate 72 mg 2x36mg once daily for 13 weeks
3267490|NCT00714688|Placebo Comparator|003|Placebo 2xplacebo once daily for 13 weeks
3267491|NCT00714675|Experimental|1|Citrulline
3267492|NCT00714675|Active Comparator|2|Amino acids
3267543|NCT00714285|Experimental|Quadrivalent influenza vaccine GSK 2115160A Group 1|Subjects in this group received 1 full dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
3267493|NCT00714649|Other|I-1|"This is a phase I/II trial. PhaseI: The delay between the last administration of cetuximab and surgery will be progressively reduced. Five delay schedules are pre-defined before final administration of 3 preoperative doses of cetuximab with a 24-hour delay between the last dose of cetuximab and surgery. The cohort size is 3 patients per delay schedule, extended to 6 patients if one limiting toxicity is observed.~Phase II: will proceed if delay schedule V is safe. The patients included in delay schedule V of the Phase I part of the study will be involved in the phase II analysis. Recruitment of a total of 12 patients (3-6 of delay schedule V in phase I plus an additional 3-9 patients)."
3267494|NCT00714636||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
3267495|NCT00714636||Non-ALS|Subjects not having either definite or probable ALS by El Escorial Criteria.
3267496|NCT00714610||1|Unilateral or bilateral large head metal on metal primary total hip arthroplasty
3267497|NCT00714597|Experimental|Semuloparin|Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 10-14 days
3267498|NCT00714597|Active Comparator|Enoxaparin|Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 10-14 days
3267499|NCT00714571|Active Comparator|MST healthy older adults Stage 1|Mnemonic strategy training
3267500|NCT00714571|Active Comparator|MST MCI Stage 1|Exposure training
3267501|NCT00714571|Active Comparator|XP healthy older adults Stage 1|XP healthy older adults Stage 1
3267502|NCT00714571|Active Comparator|XP MCI Stage 1|XP MCI Stage 1
3267503|NCT00714571|Active Comparator|MST healthy older adults Stage 2|MST healthy older adults Stage 2
3267504|NCT00714571|Active Comparator|SCT healthy older adults Stage 2|SCT healthy older adults Stage 2
3267505|NCT00714545|No Intervention|prospective study|This study is a prospective study of patients treated at Scripps Clinic with intracoronary brachytherapy for recurrent restenosis within drug-eluting stents. Beta irradiation with a 40-mm strontium/yttrium-90 source. No placebo will be used in this trial.
3267506|NCT00714532|Active Comparator|1|Expert system only, which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months.
3267507|NCT00714532|Experimental|2|"The intervention consists of 3 components:~Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months~scheduled smoking intervention, which includes a tailored-made 3-week smoking reduction schedule and a stage-matched tip guide to explain why and how to use the smoking reduction intervention~telephone check-in calls to provide brief counseling and technical support to motivate participants to use the intervention materials~a 2-week supply of nicotine gum or lozenge per participants' choice to use during smoking reduction"
3267508|NCT00714519|Experimental|1|
3267509|NCT00714519|Placebo Comparator|2|
3267510|NCT00714506|Experimental|Intervention|lifestyle weight reduction - low fat eating, low calorie and physical activity
3267511|NCT00714506|Active Comparator|Control|physical activity plus successful aging health education
3267512|NCT00714493|Other|001|Infliximab3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
3267513|NCT00714480|Other|Group I|Administration of anti-thymocyte globulin post-operative days -6,-4,-2, and 0
3267514|NCT00714480|Other|Group II|Administration of anti-thymoglobulin post-operative days -2, 0, 2 and 4
3267515|NCT00714480|Other|Group III|Administration of anti-thymocyte globulin post-operative days 0, 2, 4 and 6
3267516|NCT00714467|Active Comparator|1|Expert system (stage-based manual and 3 individualized tailored feedback reports) only for smokers, paired-supporters (family or friend participant) do not receive any study intervention
3267517|NCT00714467|Experimental|2|Expert system (stage-based manual and 3 individualized tailored feedback report) to all the smoker participants; a family assisted intervention in a form of a self-help booklet that discusses specific strategies to work with smokers at each stage of change to the paired-supporters
3267518|NCT00714454|Active Comparator|APS|
3267519|NCT00714454|Placebo Comparator|Vehicle|
3267520|NCT00714441|Active Comparator|2|Computer Automated Self-Management (CASM). Please see description below for CASM.
3267521|NCT00714441|Active Comparator|3|Computer Automated Self-Management and Problem Solving Therapy (CAPS). Please see descriptions below for CAPS (also refer to CASM with is included in the CAPS program).
3267522|NCT00714441|Active Comparator|1|Lifestyle and Activities Education Program (LEAP-AHEAD). Please see description below for LEAP-AHEAD.
3267523|NCT00714428||Group 1: Item Development|Individuals with TBI to provide input to relevant questions for quality of life measure in TBI
3267524|NCT00714428||Group 2: Item Development|Clinicians who treat those with deployment related TBI to obtain their feedback on relevant questions pertaining to quality of life measures in TBI.
3267525|NCT00714428||Group 3: Instrument Development|Individuals with deployment TBI who will complete the Beta version of the TBI QOL measure.
3267526|NCT00714415||A|Patients with Hemophilia B
3267527|NCT00714402||a|children with proven of probable invasive bacterial infections
3267528|NCT00714376|Experimental|Docetaxel|Docetaxel (Taxotere) 75 mg/m² IV every 3 weeks for 8 cycles.
3267529|NCT00714363|Active Comparator|1|LASIK
3267530|NCT00714363|Active Comparator|2|SBK
3267531|NCT00714350||Simulator Group - With Display|ICU nurses who viewed the new ICU display visualization
3267532|NCT00714350||Simulator Group - Without Display|"ICU nurses who did not view the new ICU display visualization, but instead viewed a traditional spreadsheet style presentation of ICU trends of data"
3267533|NCT00714337|Experimental|1|fasting state
3267534|NCT00714337|Experimental|2|fasting state
3267535|NCT00714337|Experimental|3|non-fasting state
3267536|NCT00714337|Experimental|4|fasting state
3267537|NCT00714337|Experimental|5|non-fasting state
3267538|NCT00714324||1|Paper screening
3267539|NCT00714324||2|Electronic screening
3267540|NCT00714311|Active Comparator|TFP|Transference-Focused Psychotherapy
3267541|NCT00714311|Active Comparator|ECP|treatment by experienced community psychotherapists
3267542|NCT00714298|Other|1|Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. Treating physicians, biologist physician will be blinded to the results of the markers.
3267544|NCT00714285|Experimental|Quadrivalent influenza vaccine GSK 2115160A Group 2|Subjects in this group received 1 low dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
3267545|NCT00714285|Active Comparator|Trivalent influenza vaccine GSK 2115160A Group 1|Subjects in this group received 1 low dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
3267546|NCT00714285|Active Comparator|Trivalent influenza vaccine GSK 2115160A Group 2|Subjects in this group received 1 full dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
3267547|NCT00714259|Other|Non Myeloablative Treatment|"Non-myeloablative Transplant Conditioning Chemotherapy :~Fludarabine - 30 mg/m2/day x 3 days Total Body Irradiation - 200cGy x1 dose Infusion of Stem Cells - On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight."
3267548|NCT00714246|Experimental|Phase I|Carboplatin 6 AUC, Docetaxel 60 mg/m^2, Bortezomib 1.0 mg/m^2 Docetaxel, Carboplatin, Bortezomib, PS341
3267549|NCT00714246|Experimental|Phase 2|Carboplatin 6 AUC, Docetaxel 75 mg/m^2, Bortezomib 1.3 mg/m^2 Docetaxel, Carboplatin, Bortezomib, PS341
3267550|NCT00714233|Experimental|1|Metformin
3267551|NCT00714233|Experimental|2|Oral Contraceptive Pills
3267552|NCT00714233|Active Comparator|3|lifestyle modification program
3267553|NCT00714233|Placebo Comparator|4|placebo to active metformin arm
3267554|NCT00714220||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
3267555|NCT00714220||Neurological Control|Subjects having been diagnosed with a non-ALS neurological condition
3267556|NCT00714220||Healthy Control|Subjects in good health without any neurological conditions
3267557|NCT00714207|Experimental|NOT Intervention|Students in this arm of the study were randomized to receive the reformatted NOT program
3267558|NCT00714207|Active Comparator|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets on smoking cessation
3267559|NCT00714207|Experimental|KB intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
3267560|NCT00714207|Active Comparator|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets on smoking cessation
3267561|NCT00714194|Other|1|Patients in the control group will receive continuous sedative infusions without daily interruption of sedatives based on the standard clinical practice of the TICU.
3267562|NCT00714194|Experimental|2|Patients in the intervention group will receive daily interruption of sedative.
3267563|NCT00714168|Active Comparator|1|Participants will take part in a standard behavioral weight loss program.
3267564|NCT00714168|Experimental|2|Participants will take part in a stepped-care weight loss program.
3267565|NCT00714155||1|Physical examination, questionnaires, retrospective chart review
3267566|NCT00714155||2|Questionnaires, retrospective chart review
3267567|NCT00714155||3|Retrospective chart review
3267568|NCT00714142|Active Comparator|1|Normal volunteers
3267569|NCT00714142|Active Comparator|2|Renal failure patients on dialysis
3267570|NCT00714142|Active Comparator|3|Renal artery stenosis patients
3267571|NCT00714129|Experimental|1|Weight loss diet - normal diet
3267572|NCT00714129|Experimental|2|Weight loss diet - low in simple sugars (specifically fructose)
3267573|NCT00714116|Experimental|SBI-087|
3267574|NCT00714103|Experimental|8-Chloro-Adenosine|Starting dose for first cohort of patients 45 mg/m2 intravenous over 1 hr daily for 5 days every 4 weeks (± 3 days).
3267575|NCT00714090|Active Comparator|A|Double active comparator : venlafaxine (150 mg/day) and rTMS (5 times/week)
3267576|NCT00714090|Experimental|B|active rTMS (5 times/week) and sham venlafaxine (150 mg/day)
3267577|NCT00714090|Sham Comparator|C|sham rTMS (5 times/week) and active venlafaxine (150 mg/day)
3267578|NCT00714077||adjuvant capecitabine|To compare different adjuvant concurrent chemoradiotherapy regimen (Oxaliplatin with capecitabine vs capecitabine) for patients with II/III rectal cancer
3267579|NCT00714077||adjuvant oxaliplatin and capecitabine|To compare different adjuvant concurrent chemoradiotherapy regimen (Oxaliplatin with capecitabine vs capecitabine) for patients with II/III rectal cancer
3267580|NCT00714064|Active Comparator|23vPPV in Pregnancy|
3267581|NCT00714064|Active Comparator|23vPPV at Birth|
3267582|NCT00714064|Other|Control|Control
3267583|NCT00714051|Experimental|Fall Prevention Training|The falls prevention training group participated in four weekly training sessions on a custom-built treadmill that produced trip-simulating perturbations (movements). While harnessed overhead to prevent actual falls, the treadmill stopped or moved suddenly. The goal for the participant was to try and prevent a fall. Each week, the level of difficulty of the task was increased.
3267584|NCT00714051|Active Comparator|Attention Control|The attention control group participated in four weekly treadmill walking sessions at a self-selected speed.
3267585|NCT00714038||1|Patients with asthma in primary care
3267586|NCT00714025|Experimental|I|40 patients with metastatic or locally advanced transitional bladder cancer with failed platinum-based chemotherapy receiving RAD001 10mg daily PO.
3267587|NCT00714012||1 Visualization users|End users of the domain specific visualizations.
3267588|NCT00713999|Experimental|STI/PZQ 1|Baseline and post-treatment follow-up (anti-STI and praziquantel Rx)
3267589|NCT00713986|Sham Comparator|Noanalgesia|Patients in this group wil receive 2 mL of water PO 2 minutes prior to vaccination, then they will rest in crib during cleansing of the right tigh, during injection of the right tigh for hepatitis B vaccination and 2 minutes after the injection. Infants will not receive any handling during the whole procedure outside the prespecified above.
3267630|NCT00713713|Experimental|1|Two different tidal volumes (6 and 12 ml.kg-1 of ideal weight) are alternatively delivered to patients 30 minutes each one. The order of the two tidal volumes is randomized. Between the two study tidal volumes, patient returns for 30 minutes to the tidal volume used before the study recruitment.
3267631|NCT00713700|Experimental|Device|
3267590|NCT00713986|Experimental|Skin-to-skin|Patients in this group wil receive 2mL of water 2 minutes prior vaccination and will be put on skin-to-skin contact with their mothers at the same time. After this time cleansing of the right tigh will be done followed by intra-muscular injection for hepatitis B vaccination. Patients will stay on skin-to-skin contact with their mothers for the following 2 minutes after injection. Infants will not receive any additional sensorial stimulation during the whole procedure outside the prespecified above.
3267591|NCT00713986|Experimental|Glucose|Patients in this group wil receive 2mL of glucose 25% 2 minutes prior vaccination, then they will rest in crib during cleansing of the right tigh, during injection of the right tigh for hepatitis B vaccination and 2 minutes after the injection. Infants will not receive any handling during the whole procedure outside the prespecified above.
3267592|NCT00713986|Experimental|Skin&Glucose|Patients in this group wil receive 2mL of glucose 25% PO 2 minutes prior vaccination and will be put on skin-to-skin contact with their mothers at the same time. After this time cleansing of the right tigh will be done followed by intra-muscular injection for hepatitis B vaccination. Patients will stay on skin-to-skin contact with their mothers for the following 2 minutes after injection. Infants will not receive any additional sensorial stimulation during the whole procedure outside the prespecified above.
3267593|NCT00713973||1|Submitted to the American protocol for prophylaxis of deep vein thrombosis
3267594|NCT00713973||2|Submitted to the Brazilian protocol for prophylaxis of deep vein thrombosis
3267595|NCT00713973||3|Submitted to the SBCP modified protocol for prophylaxis of deep vein thrombosis
3267596|NCT00713960||1|Patients in secondary prevention of cardiovascular disease in primary care
3267597|NCT00713947|Active Comparator|A|Amoxicillin, Clarythromycin or metronidazole,Pantoprazole,Placebo
3267598|NCT00713947|Experimental|B|Pantoprazole
3267599|NCT00713947|Placebo Comparator|C|Placebo
3267600|NCT00713934|Experimental|1|
3267601|NCT00713934|Experimental|2|
3267602|NCT00713921|Experimental|1|
3267603|NCT00713895|Active Comparator|1|receive a standard self-help manual in Chinese and English of the participants' choice at baseline
3267604|NCT00713895|Experimental|2|receive an expert system intervention that included the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
3267605|NCT00713882||Observational|
3267606|NCT00713869||1|Patients between the ages of 21 and 35 undergoing in-vitro fertilization will be included in this study.
3267607|NCT00713869||2|Recipients using only frozen donor eggs
3267608|NCT00713856|Active Comparator|1|
3267609|NCT00713856|Active Comparator|2|
3267610|NCT00713843|Experimental|1 Manual Therapy Utrecht|"Manual Therapy Utrecht (MTU) During the first consultation the manual therapist enquires about the complaints of the patient. The manual therapist conducts a number of measurements according to protocol. During treatment preferred movements are executed by the manual therapist in the patient's joints. The treatment techniques used by the manual therapist are very gentle mobilizations, without high velocity thrust techniques and are in general painless. In Manual Therapy Utrecht (MTU) it is common to give advices and recommend exercises.~A treatment session lasts between 30 and 60 minutes (repeated after one or two weeks). The maximum number of sessions is six.~The manual therapist has a minimum of five years of working experience."
3267611|NCT00713843|Active Comparator|2 Physical Therapy - Exercise Therapy|"The physical therapist conducts a complaint related function examination. Treatment consist of active exercises, manual traction or stretching and massage. The aims of active exercises are improvement of strength, mobility and movement coordination. Specific mobilization techniques are not a part of physiotherapeutic treatment. Treatment sessions take place no more than twice a week with a maximum of nine sessions (approximately 30 minutes) with a minimum of twenty minutes on active exercise therapy combined with instruction.~To prevent overlap with MTU (experimental arm), physical therapists are selected who are not (also) trained as manual therapists or have started this education.~The physical therapist has at least five years of working experience."
3267612|NCT00713830|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3267613|NCT00713830|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3267614|NCT00713817|Experimental|Sativex|
3267615|NCT00713817|Placebo Comparator|Placebo|
3267616|NCT00713804|Experimental|GC|Genetic counseling (GC): One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
3267617|NCT00713804|Active Comparator|EB|Educational Booklet (EB): One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
3267618|NCT00713804|No Intervention|WT|Waitlist (WT)
3267619|NCT00713791|Experimental|1|There are 5 variations of the ZD4054 (Zibotentan) 10mg tablet - A, B, C, D, and E. A minimum washout period of 1 week will occur between each treatment period.
3267620|NCT00713778|Experimental|1|Laparoscopic ovarian cystectomy using bipolar
3267621|NCT00713778|Experimental|2|Laparoscopic ovarian cystectomy using ultrasonic scalpel
3267622|NCT00713778|Active Comparator|3|Laparotomic ovarian cystectomy using suture
3267623|NCT00713765|Experimental|A|AZD3480 + Donepezil
3267624|NCT00713739|Experimental|1|Alfuzosin 10mg daily
3267625|NCT00713739|Active Comparator|2|Nifedipine XL 30mg daily
3267626|NCT00713739|Active Comparator|3|Doxazosin 4 mg daily
3267627|NCT00713739|Active Comparator|4|Prazosin 1 mg BID
3267628|NCT00713726|Active Comparator|F|Patients that received continued infusion of fentanyl at a steady dose for the first 48 hours and, then, doses were gradually decreases until stop
3267629|NCT00713726|Experimental|T|Patients that received continued infusion of tramadol at a steady dose for the first 48 hours and, then, doses were gradually decreases until stop
3267635|NCT00713674|Active Comparator|3|mupirocin antibiotic ointment intranasal
3267636|NCT00713661|Experimental|TachoSil®|
3267637|NCT00713648|Experimental|rFXIII|
3267638|NCT00713635||1|Fetuses and neonates with congenital heart disease consisting of hypoplastic left heart syndrome (HLHS)
3267639|NCT00713635||2|Fetuses and neonates with congenital heart disease consisting of transposition of the great arteries (TGA)
3267640|NCT00713635||3|Fetuses and neonates with congenital heart disease consisting of tetralogy of fallot
3267641|NCT00713635||4|Fetuses and neonates with lung masses but without congenital heart disease will serve as a control group
3267642|NCT00713622|Active Comparator|1|
3267643|NCT00713622|Active Comparator|2|
3267644|NCT00713609|Experimental|1|Benzoyl peroxide/clindamycin gel + tazarotene cream
3267645|NCT00713609|Active Comparator|2|Benzoyl peroxide/clindamycin gel + vehicle cream
3267646|NCT00713609|Active Comparator|3|Benzoyl peroxide gel + tazarotene cream
3267647|NCT00713609|Active Comparator|4|Clindamycin gel + tazarotene cream
3267648|NCT00713609|Active Comparator|5|Vehicle gel+ tazarotene cream
3267649|NCT00713609|Placebo Comparator|6|Vehicle gel + vehicle cream
3267650|NCT00713596|Sham Comparator|Control group|Septorhinoplasty with postoperative application of nasal taping and an external nasal cast. The tape and cast will be left in place for one week. No tissue glue will be used during the operation, although the nurse and surgical assistant will simulate the preparation and insertion of tissue glue using a syringe containing saline.
3267651|NCT00713596|Experimental|Fibrinogen, tape, and cast|Septorhinoplasty will be performed. At the termination of the procedure, prior to closure, fibrin sealant will be applied by the surgical assistant to the surgical site. Approximately 0.5 cc to 2 cc of tissue sealant will be applied. After closure, tape and cast will be applied and left in place for one week.
3267652|NCT00713596|Experimental|Fibrinogen and tape|Septorhinoplasty will be performed. At the termination of the procedure, prior to closure, 0.5 cc to 2 cc of tissue sealant will be applied. Nasal tape will be applied after closure.
3267653|NCT00713583|Experimental|Levodopa pharmacotherapy|Levodopa pharmacotherapy (800mg levodopa and 200mg carbidopa per day), cognitive behavioral therapy (CBT), and contingency management (CM).
3267654|NCT00713583|Placebo Comparator|Placebo|Placebo, cognitive behavioral therapy (CBT), and contingency management (CM).
3267655|NCT00713570||A,1,II|
3267656|NCT00713557||1|patients with acute ST-elevation myocardial infarction and receiving primary percutaneous coronary intervention Subgroup: Patient Transferring vs. Physician Transferring strategy
3267657|NCT00713557||2|patients with acute ST-elevation myocardial infarction treated by thrombolysis or facilitated PCI Subgroup: upstream use of Tirofiban + primary PCI vs. downstream use of tirofiban + primary PCI
3267658|NCT00713557||3|patients with non-ST-elevation ACS treated by immediate PCI
3267659|NCT00713557||4|patients with non ST-elevation ACS treated by elective PCI
3267660|NCT00713557||5|STEMI patient with multivessel disease, complete revascularization is planned to achieve during the index hospitalization.i.e.P-PCI for culprit lesion,combined with staged PCI for remaining diseased vessel.
3267661|NCT00713557||6|STEMI patient with multivessel disease, complete revascularization is planned to achieve at 6 weeks after STEMI onset.i.e.P-PCI for culprit lesion during index hospitalization,combined with staged PCI for remaining diseased vessel at 6-week's follow-up(secondary hospitalization).
3267662|NCT00713544|Active Comparator|1|
3267663|NCT00713544|Experimental|2|20mg
3267664|NCT00713544|Experimental|3|50mg
3267665|NCT00713544|Experimental|4|100mg
3267666|NCT00713544|Experimental|5|150mg
3267667|NCT00713544|Placebo Comparator|6|
3267668|NCT00713518|Active Comparator|Arm 1 ranibizumab|0.5 mg ranibizumab intravitreal injection given every 4 weeks from baseline to Week 12
3267669|NCT00713518|Experimental|Arm 2 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 3 mg PF-04523655 given by intravitreal injection every 2 weeks from Week 4 to Week 12
3267670|NCT00713518|Experimental|Arm 3 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 1 mg PF-04523655 given by intravitreal injection evey 4 weeks to Week 12
3267671|NCT00713518|Experimental|Arm 4 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 3 mg of PF-04523655 given by intravitreal injection every 4 weeks from Week 4 to Week 12
3267672|NCT00713518|Experimental|Arm 5 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 1 mg of PF-04523655 (30 minutes later) given in combination every 4 weeks from baseline to Week 12
3267673|NCT00713505|Experimental|Arm I (parent intervention program and usual care)|Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care). Parents also receive 8 weekly face-to-face training sessions (75-90 minutes each) with a therapist over approximately 2-3 months. Phone support/assistance is provided by the therapist within 2-3 days following each training session and then every 2 weeks for up to 6 months after completion of the training sessions.
3267674|NCT00713505|Active Comparator|Arm II (wait-list/usual care control [UCC])|Child participants and their families undergo usual care as in arm I and are placed on a wait-list.
3267675|NCT00713479|Placebo Comparator|Sugar pill|Sugar pill (placebo) drug dosing will begin at 0.5 mg once daily for the first 3 days of condition and will be increased to 0.5 mg twice daily for days 5-6 of this condition, and increased to 1 mg twice daily on days 7-10 of this condition.
3267676|NCT00713479|Active Comparator|Varenicline|Varenicline dosing will begin at 0.5 mg once daily for the first 3 days of condition and will be increased to 0.5 mg twice daily for days 5-6 of this condition, and increased to 1 mg twice daily on days 7-10 of this condition.
3267677|NCT00713466||1|all third year medical students entering their pediatric clerkship at the Medical College of Wisconsin
3267678|NCT00713440|Experimental|1|10 healthy Caucasian subjects without family history of diabetes
3267679|NCT00713427|Other|WallFlex Stent|All patients meeting eligibility criteria recieve the WallFlex™ Biliary Partially-Covered Stent, which has regulatory clearance in the areas in which the study is being conducted.
3267680|NCT00713401|Experimental|Cohort A|Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol low dose infusion
3267681|NCT00713401|Experimental|Cohort B|Period 1: 150 mcg, i.v. bolus. Period 2: 150 mcg, i.v. bolus + esmolol low dose infusion
3267682|NCT00713401|Experimental|Cohort C|Period 1: 300 mcg, i.v. bolus. Period 2: 300 mcg, i.v. bolus + esmolol low dose infusion
3267683|NCT00713401|Experimental|Cohort D|Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol high dose infusion
3267684|NCT00713401|Experimental|Cohort E|Period 1: 150 or 300 mcg, i.v. bolus. Period 2: 150 or 300 mcg, i.v. bolus + esmolol high dose infusion
3267685|NCT00713362|Active Comparator|1|Surgery: Video-assisted thoracoscopic surgery
3267686|NCT00713362|Active Comparator|2|Chest tube drainage
3267687|NCT00713349|Other|1|Xenaderm Vehicle
3267688|NCT00713349|Placebo Comparator|2|Placebo Comparator
3267689|NCT00713336|Experimental|1|ZD4054 + Moxifloxacin placebo
3267690|NCT00713336|Active Comparator|2|ZD4054 placebo + Moxifloxacin
3267691|NCT00713336|Experimental|3|ZD4054 + ZD4054 placebo + Moxifloxacin placebo
3267692|NCT00713336|Placebo Comparator|4|ZD4054 Placebo + Moxifloxacin placebo
3267693|NCT00713323|Experimental|Sativex|Active treatment
3267694|NCT00713310|Experimental|Low-Dose|1.2 - 2.4 g/day Asacol dependent on body weight
3267695|NCT00713310|Experimental|High-Dose|2.0 - 4.8 g/day Asacol dependent on body weight
3267696|NCT00713297||Observation|Those who will use the new CPOE system
3267697|NCT00713284|Experimental|1|All subjects who enroll in this study will be converted from their calcineurin inhibitor to sirolimus.
3267698|NCT00713271|Experimental|1|Low dose
3267699|NCT00713271|Experimental|2|intermediate dose
3267700|NCT00713271|Experimental|3|high dose
3267701|NCT00713271|Placebo Comparator|4|
3267702|NCT00713258|Active Comparator|PTH (1-84)|PTH (1-84) + placebo alendronate
3267703|NCT00713258|Active Comparator|Alendronate|PTH (1-84) placebo + alendronate
3267704|NCT00713232||test construction|university student living in Taiwan for more than 5 years No known neurological, psychiatric or speech language disorders
3267705|NCT00713232||normative data|normal subjects 20-80 y/o Living in Taiwan for at least 5 years No know neurological, psychiatric and speech-language disorders
3267706|NCT00713219|Experimental|1|CHEMORADIATION
3267707|NCT00713206|Active Comparator|Dental implant (Osseotite)|Dental implants placed simultaneously with graft augmentation material.
3267708|NCT00713206|No Intervention|Control group|Dental implants placed into graft augmentation material that has four months to heal.
3267709|NCT00713193|Experimental|1|Patients in this arm will receive cyclosporine (Neoral) at a dose of 2-3 mg/kg orally as an adjunct to plasma exchange.
3267710|NCT00713193|Active Comparator|2|Patients in this arm will receive prednisone at a dose of 1 mg/kg as an adjunct to plasma exchange.
3267711|NCT00713180|No Intervention|1|Pterygium free participants
3267712|NCT00713180|Experimental|2|Pterygium participants
3267713|NCT00713167|Experimental|Grape Seed Extract|Enrolled patients who are randomly assigned to receive Grape Seed Extract capsules
3267714|NCT00713167|Placebo Comparator|Placebo|Placebo enrolled patients who are randomly assigned to receive placebo of Grape Seed Extract
3267715|NCT00713154|Placebo Comparator|1|Placebo group
3267716|NCT00713154|Active Comparator|2|Control Group
3267717|NCT00713141||1|Early breast cancer
3267718|NCT00713102||1|The group includes 10189 patients with on board medical or surgical emergencies.
3267719|NCT00713089||1|75 subjects randomised into the placebo arm of an ongoing randomised double-blind placebo controlled clinical trial at National University Hospital, Singapore
3267720|NCT00713089||2|The expecting mothers visiting at the well mother clinics at Gadjah Mada University Hospital were invited to participate in the study
3267721|NCT00713076|Experimental|1|Polyquaternium-preserved Multi-purpose solution
3267722|NCT00713063|Experimental|1|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
3267723|NCT00713063|Active Comparator|2|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
3267724|NCT00713050|Experimental|Experimental|Computer-based Aphasia therapy
3267725|NCT00713050|Active Comparator|Control|Control Arm - Healthy subjects.
3267726|NCT00713037|Experimental|(18F)-FMISO/CT|The study utilizes PET/CT scanning with (18F)-FMISO/CT in addition to standard used CT and MRI. Patients enrolled in this trial completed 2 PET/CT investigations, the first before proton radiation therapy and the second at a dose of approximately 30 Gy (24-36 Gy).
3267727|NCT00713024||1|Healthy control subjects
3267728|NCT00713024||2|Patients having neuropathic pain
3267729|NCT00713011|Experimental|Arm 1|
3267730|NCT00713011|Active Comparator|Arm 2|
3267731|NCT00712998||1|Twenty subjects receiving health check program without X-ray computed tomography examination will be included as the control group.
3267732|NCT00712998||2|Twenty subjects receiving health check program including X-ray computed tomography examination of lung will be included as the treatment group-1.
3267733|NCT00712998||3|Twenty subjects receiving health check program including X-ray computed tomography examination of heart will be included as the treatment group-2.
3267734|NCT00712985|Experimental|Zometa (Zoledronic Acid) X 1 dose|Zometa (Zoledronic Acid) 5 mg IV X 1 dose
3267735|NCT00712972||1|"Patients enrolled in this study are those whom present to our institution for elective knee arthroscopy. All patients scheduled to receive a knee arthroscopy scheduled through the office of Dr. Harold Battenfield will be asked to participate in the study on the day of their procedure as long as they do not fall into one of the exclusion criteria categories.~Patients will not be allowed to participate in this study if they have an allergy to iodine or shell fish, if they have a knee effusion diagnosed clinically on the day of surgery, if the knee or surrounding tissues display cellulitis or other signs of infection, or if the patient has had a traumatic accident to their knee which significantly changes its anatomical relationships"
3267736|NCT00712959|Experimental|Group 1: Previous Tdap or Tdap-IPV Recipients|Participants received Tdap or Tdap-Inactivated Poliomyelitis Vaccine (IPV) in a previous study (TD9707 or TD9805)
3267819|NCT00712452|Other|1|systemic lupus erythematosus
3267737|NCT00712959|Active Comparator|Group 2: Tdap vaccine-naïve|Participants are age-balanced Tdap vaccine-naïve and will receive Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.
3267738|NCT00712959|No Intervention|Group 3|Past participants in Study TD9707 and TD9805 did not qualify for Tdap re-administration in this study or were unwilling to receive a second dose of Tdap. They were not included in the analysis for the study
3267739|NCT00712946||1|Arteriosclerosis obliterans patients undergoing elective vascular surgery
3267740|NCT00712946||2|Healthy age-matched volunteers
3267741|NCT00712933|Experimental|1|1 mg/kg dose of belimumab given IV every 28 days.
3267742|NCT00712933|Experimental|2.|10 mg/kg dose of belimumab given IV every 28 days.
3267743|NCT00712920|Placebo Comparator|1|Placebo
3267744|NCT00712920|Experimental|2|0.15% azelastine hydrochloride 1644 mcg/2 sprays per nostril 2 times a day for 4 weeks
3267745|NCT00712920|Experimental|3|0.1% azelastine hydrochloride 1096 mcg/2 sprays per nostril 2 times a day for 4 weeks
3267746|NCT00712907|Active Comparator|1|vitamin C (Mayrhofer)
3267747|NCT00712907|Placebo Comparator|2|Placebo
3267748|NCT00712894|Experimental|D|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of diltiazem via an infusion microcatheter distal to the angioplasty site was performed.
3267749|NCT00712894|Active Comparator|V|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of verapamil via an infusion microcatheter distal to the angioplasty site was performed.
3267750|NCT00712894|Active Comparator|N|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of nitroglycerin via an infusion microcatheter distal to the angioplasty site was performed.
3267751|NCT00712881|Experimental|(1) Investigational Product|
3267752|NCT00712881|Active Comparator|(2) Comparison Therapy|
3267753|NCT00712868|Experimental|1|Lactic Acid once a day during 21 days
3267754|NCT00712855|Experimental|A|mapatumumab and sorafenib
3267755|NCT00712842||1|Patients with non or mild non-proliferative diabetic retinopathy
3267756|NCT00712842||2|Healthy control subjects
3267757|NCT00712829|Experimental|1|123-I-MIP-1072 administration followed by 123-I-MIP-1095 administration two weeks later.
3267758|NCT00712829|Experimental|2|123-I-MIP-1095 administration followed by 123-I-MIP-1072 administration two weeks later.
3267759|NCT00712816|Experimental|A|
3267760|NCT00712816|Active Comparator|B|
3267761|NCT00712803|Experimental|1|One subcutaneous vaccination (10^3 dose of vaccine) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm.
3267762|NCT00712803|Experimental|2|One subcutaneous vaccination (10^5 dose of vaccine or placebo) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm OR one subcutaneous vaccination (10^1 dose of vaccine or placebo) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm.
3267763|NCT00712790|Experimental|Sequential Radioembolization-Sorafenib|Sorafenib (400 mg twice-daily) was initiated 14 days post-radioembolization with yttrium-90 (Y) resin microspheres given as a single procedure.
3267764|NCT00712777|Active Comparator|1|homozygote mutant: Insertion/Insertion (40 patients)
3267765|NCT00712777|Active Comparator|2|homozygote mutant: Deletion/Deletion (40 patients)
3267766|NCT00712764|Active Comparator|1|
3267767|NCT00712764|Placebo Comparator|2|
3267768|NCT00712751||1|usual care (UC) which is the standard care that patients receive
3267769|NCT00712751||2|Cancer Survivorship Intervention-Sexual Health (CSI-SH)plus Usual Care (US)
3267770|NCT00712725|Experimental|1|MK3207- 2.5 mg
3267771|NCT00712725|Experimental|2|MK3207- 5 mg
3267772|NCT00712725|Experimental|3|MK3207- 10 mg
3267773|NCT00712725|Experimental|4|MK3207- 20 mg
3267774|NCT00712725|Experimental|5|MK3207- 50 mg
3267775|NCT00712725|Experimental|6|MK3207- 100 mg
3267776|NCT00712725|Placebo Comparator|7|Placebo
3267777|NCT00712699|Experimental|Sequence 1: XR-MAS then placebo|Depending on whether 1) child has had previous medication trial or 2) is on psychotropic medication at time of screening, children will either enter the washout period of 3 days before extended release mixed amphetamine salts (XR-MAS) or placebo (PBO) is initiated or proceed directly to the active treatment sequence they were randomized to. Participants randomized to Sequence 1 first receive treatment with XR-MAR for 3 weeks and then placebo for 3 weeks. Flexible, forced dosing will start at 5 mg/day for the first week, increase to 10 mg/day for the second week and continue to 15 mg/day on the third week. No washout period otherwise occurs (XR-MAS is not clinically suspected to have lingering effects beyond initial dosing/day of administration), including the crossover week to PBO.
3267778|NCT00712699|Experimental|Sequence 2 Placebo then XR-MAS|Depending on whether 1) child has had previous medication trial or 2) is on psychotropic medication at time of screening, children will either enter the washout period of 3 days before extended release mixed amphetamine salts (XR-MAS) or placebo (PBO) is initiated or proceed directly to the active treatment sequence they were randomized to. Participants randomized to Sequence 2 will first receive treatment with PBO for 3 weeks and then XR-MAS for 3 weeks. Flexible, forced dosing will start at 5 mg/day for the first week, increase to 10 mg/day for the second week and continue to 15 mg/day on the third week. No washout period (stimulants are not clinically suspected to have lingering effects beyond initial dosing/day of administration)otherwise occurs, including the crossover week to XR-MAS.
3267779|NCT00712686|Active Comparator|A1|
3267780|NCT00712686|Active Comparator|B1|
3267781|NCT00712673|Experimental|Lixisenatide (Morning Injection)|2-step initiation morning regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
3267782|NCT00712673|Experimental|Lixisenatide (Evening Injection)|2-step initiation evening regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
3267783|NCT00712673|Placebo Comparator|Placebo (Morning Injection)|2-step initiation morning regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
3267784|NCT00712673|Placebo Comparator|Placebo (Evening Injection)|2-step initiation evening regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
3267820|NCT00712452|Other|2|breast cancer
3267785|NCT00712660|Experimental|A|In the active-ITAREPS group, the e-mail ALERT message feedback to the investigator will be activated. The core study intervention was 20% antipsychotic dose increase within 24 hours in response to a Pharmacological Intervention Requiring Event (PIRE) defined as either: A) the receipt of any INITIAL ALERT (IA) e-mail. A dose increase was obligatory in such cases regardless of the current clinical status of the patient; or B) the receipt of an ALERT EMERGENCY (AE) e-mail after which the investigator confirmed clinical worsening via phone contact with the patient. AE is defined as further worsening in EWSQ scores during 3 week period after announcement of IA.
3267786|NCT00712660|Placebo Comparator|TAU|In the treatment-as-usual study arm (control, non-active ITAREPS), the e-mail ALERT message feedback will not be activated. In this group, even in the presence of early warning sings, the investigators will be kept blinded to the EWSQ scores, will receive no ALERT message and thus no early pharmacologic intervention based on the ITAREPS program will be prompted. Treatment in the control group will consist of routine clinical and medication management with the frequency of visits common in the outpatient clinical settings. There will be no intevention based on ITAREPS.
3267787|NCT00712647|Active Comparator|1|Asbestos-exposed participants and heavy smokers
3267788|NCT00712647|Placebo Comparator|2|Asbestos-exposed participants and heavy smokers
3267789|NCT00712634|Experimental|CMV-seropositive participants|Participants are randomized to receive 1 of 4 escalating doses of CMVpp65-A*0201 peptide vaccine containing either helper T-lymphocyte (HTL) PADRE peptide or HTL tetanus toxoid peptide. Within each vaccine dose group, two participants are randomized to receive a placebo. Participants receive the vaccine or a placebo subcutaneously (SC) on days 0 and 28 in the absence of unacceptable toxicity.
3267790|NCT00712634|Experimental|CMV-seronegative participants|Participants are randomized to receive 1 of 4 established doses (established in CMV-seropositive participants) of CMVpp65-A*0201 peptide vaccine containing either HTL PADRE peptide or HTL tetanus toxoid peptide. Participants receive the vaccine on days 0, 28, and 56 in the absence of unacceptable toxicity. Participants with a partial or low-level immune response receive one additional booster vaccine on day 90.
3267791|NCT00712621|Other|I|"OUTLINE: This is a randomized, multicenter study. Patients are selected according to age ( 25 to 49 vs 50 to 85), time since initial completion of therapy (3 to 18 months), and are separated in two groups.~Arm I: Quality of life is assessed at baseline and at 3 and 6 months."
3267792|NCT00712621|Other|II|"OUTLINE: This is a randomized, multicenter study. Patients are selected according to age ( 25 to 49 vs 50 to 85), time since initial completion of therapy (3 to 18 months), and are separated in two groups.~Arm II: Quality of life is assessed at baseline and at 3 and 6 months."
3267793|NCT00712608|Active Comparator|1|Marketed cow's milk-based formula
3267794|NCT00712608|Experimental|2|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
3267795|NCT00712608|Experimental|3|Cow's milk based formula with prebiotic, different level of fatty acids and fat and a different calcium source
3267796|NCT00712595|Experimental|1|Mifepristone 10 mg daily for three months
3267797|NCT00712595|Experimental|2|Mifepristone 5 mg daily for three months
3267798|NCT00712582|Experimental|Consolidation A|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Patients whose disease is FDG-PET negative or patients whose FDG-PET scan is positive but repeat biopsy is negative and whose initial Ki-67 expression is < 80% will receive 3 cycles of standard dose ICE Chemotherapy."
3267799|NCT00712582|Experimental|Consolidation B|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Patients whose disease is FDG-PET negative or patients whose FDG-PET scan is positive but repeat biopsy is negative and whose initial Ki-67 expression is ≥80% will receive 2 cycles of augmented RICE Chemotherapy (as per MSKCC protocol 03-075)."
3267800|NCT00712582|Experimental|Consolidation C|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Consolidation C: Patients with biopsy proven disease after induction therapy. Patients whose bone marrow remain positive at interim restaging will have the option of getting an allogeneic[m3] stem cell transplant, in lieu of an ASCT, if they have an acceptable HLA match donor. The allogeneic[m4] stem cell transplant regimen will be decided by the MSK Bone Marrow Transplant Service."
3267801|NCT00712569||1|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information.
3267802|NCT00712569||2|Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information.
3267803|NCT00712569||3|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it.
3267804|NCT00712556||Flourine 18-fluorodeoxyglucose PET|PET using fluorine 18-fluorodeoxyglucose to image cancer tumors
3267805|NCT00712543|Experimental|1|Kristalose®, as prescribed, for 7 days.
3267806|NCT00712543|Experimental|2|Liquid lactulose, as prescribed, for 7 days.
3267807|NCT00712530|Experimental|1|"Single low-dose DermaVir immunization~0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir~Administered topically with DermaPrep under two skin patches (0.4 mL/patch)"
3267808|NCT00712530|Experimental|2|"Single medium-dose DermaVir immunization~0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir~Administered topically with DermaPrep under four skin patches (0.8 mL/patch)"
3267809|NCT00712530|Experimental|3|"Single high-dose DermaVir immunization~0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir~Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)"
3267810|NCT00712517|Active Comparator|1|Patients will receive propofol anesthesia during varicose vein stripping surgery.
3267811|NCT00712517|Active Comparator|2|Patients will receive sevoflurane anesthesia during varicose vein stripping surgery.
3267812|NCT00712504|Experimental|1|SU011248 in combination with docetaxel
3267813|NCT00712491|Experimental|1|
3267814|NCT00712491|Experimental|2|
3267815|NCT00712478||A|
3267816|NCT00712465|Experimental|1|AZD1305 tablet
3267817|NCT00712465|Experimental|2|AZD1305 tablet + digoxin
3267818|NCT00712465|Active Comparator|3|Digoxin
3267824|NCT00712426|Active Comparator|A|Randomized to receive creatine monohydrate (up to 40 grams daily)
3267825|NCT00712426|Placebo Comparator|B|Randomized to receive placebo (up to 40 grams daily)
3267826|NCT00712400|Active Comparator|1|Latanoprost 0.005%, Xalatan®
3267827|NCT00712400|Placebo Comparator|2|Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug)
3267828|NCT00712387|No Intervention|A|General surgical trainees who will receive the 'traditional' training programme; i.e. will receive whatever clinical training on a patient their supervising consultant deems appropriate. This is the way junior surgeons are currently trained. They will also receive the standard didactic teaching on the School for Surgeons e-learning resource.
3267829|NCT00712387|Active Comparator|B|Surgical trainees who are assigned to the 'proficiency-based progression' training programme. These trainees will be required to train on the virtual reality simulator (Lap Sim™) for a laparoscopic cholecystectomy. Trainees will have objectively set goals to reach on the simulator and will have to demonstrate proficiency before they are permitted to progress to the next, more challenging level. Group B will also receive the standard School for Surgeons instruction but, unlike Group A, they will have to demonstrate proficiency on the didactic module before they progress to the operating theatre
3267830|NCT00712374|Experimental|Intervention|Children 3 months to 10 years old will receive a treatment dose of SP+AQ on three occasions during the malaria transmission season, delivered by the local health post
3267831|NCT00712361|Experimental|Group A|The group A incorporates three subgroups of individuals at various ages. A.1 Age: 16 - 30 A.2 Age: 31 - 60 A.3 Age > 60 All subgroups will be randomly distributed according to the following factors: BMI, gender, race and hematocrit.
3267832|NCT00712348|Experimental|Taliglucerase alfa|Open label taliglucerase alfa treatment
3267833|NCT00712335|Experimental|1|"Asthmatic smokers treated with combination therapy:~Fluticasone propionate dosage - DPI 250 mcg BID for 3 months Salmeterol dosage - DPI 50 mcg BID for 3 months"
3267834|NCT00712335|Experimental|2|"Asthmatic smoker treated with Montelukast only:~Montelukast dosage: PO 10 mg QHS for 3 months"
3267835|NCT00712335|Active Comparator|3|"Non-smoking asthmatics treated with combination therapy:~Fluticasone propionate dosage - DPI 250 mcg BID for 3 months Salmeterol dosage - DPI 50 mcg BID for 3 months"
3267836|NCT00712335|Active Comparator|4|"Non-smoking asthmatic treated with Montelukast only:~Montelukast dosage: PO 10 mg QHS for 3 months"
3267837|NCT00712335|No Intervention|5|Normal controls
3267838|NCT00712322|Experimental|Cohort 1|Estimated pediatric study doses of darifenacin liquid oral suspension: (0.030 mg/kg/day).
3267839|NCT00712322|Experimental|Cohort 2|Estimated pediatric study doses of darifenacin liquid oral suspension: (0.0625 mg/kg/day).
3267840|NCT00712322|Experimental|Cohort 3|Estimated pediatric study doses of darifenacin liquid oral suspension: (0.125 mg/kg/day).
3267841|NCT00712322|Experimental|Cohort 4|Estimated pediatric study doses of darifenacin liquid oral suspension: (0.250 mg/kg/day).
3267842|NCT00712309|Active Comparator|1|Percutaneous transluminal angioplasty (PTA)
3267843|NCT00712309|Active Comparator|2|Primary stenting
3267844|NCT00712296|Experimental|1|ASHMI 6 capsules twice a day
3267845|NCT00712296|Experimental|2|ASHMI 2 capsules twice a day plus placebo 4 capsules twice a day
3267846|NCT00712296|Placebo Comparator|3|Placebo 6 capsules twice a day
3267847|NCT00712283|Placebo Comparator|D|healthy volunteers
3267848|NCT00712283|Active Comparator|C|healthy volunteers
3267849|NCT00712283|Active Comparator|B|healthy volunteers
3267850|NCT00712283|Active Comparator|A|healthy volunteers
3267851|NCT00712270|No Intervention|Standard of Care|Screening and Baseline Procedures followed by Referral to Community Care. Baseline Procedures may be repeated at a later time if appropriate.
3267852|NCT00712270|Active Comparator|Drug: Aripiprazole|Screening and Baseline Procedures followed by 16 weeks of treatment with aripiprazole, followed by repeat of baseline procedures and referral to community care.
3267853|NCT00712270|Active Comparator|Risperidone|Screening and Baseline Procedures followed by 16 weeks of treatment with Risperidone,followed by repeat of baseline procedures and referral to community care.
3267854|NCT00712257|Other|Spectranetics Laser plus Gore Viabahn Endoprosthesis|Spectranetics Laser for optimal debulking followed by adjunctive PTA plus GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface placement
3267855|NCT00712244|Active Comparator|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device during cataract surgery.
3267856|NCT00712244|Active Comparator|DuoVisc|Use of DuoVisc Viscoelastic System (Viscoat, Provisc) during cataract surgery.
3267857|NCT00712244|Active Comparator|Healon5|Use of Healon5 ophthalmic viscosurgical device (OVD) during cataract surgery.
3267858|NCT00712244|Active Comparator|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device during cataract surgery.
3267859|NCT00712231||phakic eyes|the cases did not accept any intraocular surgery
3267860|NCT00712231||pseudophakic eyes|tht cases did not accept any intraocular surgery expect for cataract surgery
3267861|NCT00712218|Active Comparator|A|
3267862|NCT00712218|Experimental|B|
3267863|NCT00712205|Placebo Comparator|A|20 Patients with asthma in a crossover design
3267864|NCT00712205|Active Comparator|B|20 Patients with asthma in a crossover design
3267865|NCT00712179||Stroke Survivors|Subjects walked with or with therapists' assistance at different speeds and different amounts of body weight support across conditions.
3267866|NCT00712166|Placebo Comparator|Placebo three times daily (TID)|
3267867|NCT00712166|Experimental|AZLI 75 mg three times daily (TID)|
3267868|NCT00712140|Active Comparator|Arm I|Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity. All patients also receive standard chemotherapy regimens as per local institutional protocols either concurrently with or sequentially to trastuzumab.
3267869|NCT00712140|Experimental|Arm II|Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. All patients also receive standard chemotherapy regimens as per local institutional protocols either concurrently with or sequentially to trastuzumab.
3267870|NCT00712127|Experimental|Diet and Exercise|Diet and Exercise for Class II and Class III Obesity
3267871|NCT00712127|Experimental|Diet and Exercise-Delayed|Diet and Exercise-Delayed for 6 months for Class II and Class III Obesity
3267872|NCT00712127|No Intervention|Control|Normal weight, overweight and Class I obesity
3267873|NCT00712114|Experimental|Cohort 1|10 mg HE3286 (1 x 5 mg HE3286, BID)
3267874|NCT00712114|Experimental|Cohort 2|20 mg HE3286 (2 x 5 mg HE3286 BID)
3267875|NCT00712114|Experimental|Cohort 3|40 mg HE3286 (4 x 5 mg HE3286 BID)
3267876|NCT00712101|Experimental|1|Abciximab bolus administration intracoronary
3267877|NCT00712101|Active Comparator|2|Abciximab bolus intravenously
3267878|NCT00712088|Experimental|1: Group Intervention|Group level intervention
3267879|NCT00712088|Active Comparator|2: HCT|Offer of HIV counseling and testing
3267880|NCT00712075|Experimental|CBSST+PDA|PDA-Assisted Cognitive-Behavioral Social Skills Training (CBSST+PDA): The CBSST rehabilitation intervention will be combined with the use of a PDA to facilitate homework completion and progress towards recovery goal attainment in consumers.
3267881|NCT00712075|Active Comparator|CBSST|Cognitive Behavioral Social Skills Training (CBSST): CBSST is a psychosocial rehabilitation intervention that combines skills from cognitive behavioral therapy and social skills training to assist consumers in improving functioning and recovery goal attainment.
3267882|NCT00712075|Active Comparator|PDA-Only|PDA-only: To control of device contact, the PDA-only arm will not receive CBSST and will only carry a PDA with access to the basic features of the device.
3267883|NCT00712062|Experimental|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
3267884|NCT00712049|Active Comparator|1|Nicotinic acid + Simvastatin
3267885|NCT00712049|Active Comparator|2|Simvastatin
3267886|NCT00712036|Active Comparator|Interim|Methadone maintenance for up to 4 months with emergency counseling only for individuals on program waiting lists.
3267887|NCT00712036|Active Comparator|Comprehensive|Methadone Treatment provided with counseling as usual.
3267888|NCT00712036|Active Comparator|Restored|Methadone Treatment with counseling provided by a clinician with a lower caseload than counseling as usual.
3267889|NCT00712023|Active Comparator|1|warming by circulating-water mattress
3267890|NCT00712023|No Intervention|2|Forced-air warming mattress
3267891|NCT00712010|Experimental|Whey protein native|Whey protein native versus the 6 other arms
3267892|NCT00712010|Experimental|Whey protein microgels|Whey protein microgels versus the 6 other arms
3267893|NCT00712010|Experimental|Hydrolyzed whey protein|Hydrolyzed whey protein versus the 6 other arms
3267894|NCT00712010|Experimental|Casein native|Casein native versus the 6 other arms
3267895|NCT00712010|Experimental|Hydrolyzed casein|Hydrolyzed casein versus the 6 other arms
3267896|NCT00712010|Experimental|Total milk protein native|Total milk protein native versus the 6 other arms
3267897|NCT00712010|Experimental|Hydrolyzed milk protein|Hydrolyzed milk protein versus the 6 other arms
3267898|NCT00711997|Experimental|BC-819|Intratumoral administration of BC-819
3267899|NCT00711984|Active Comparator|1|Renal artery stenting and Best medical treatment
3267900|NCT00711984|Active Comparator|2|Best medical treatment alone
3267901|NCT00711971|Active Comparator|EPA-rich fish oil supplement|EPA-rich fish oil supplement
3267902|NCT00711971|Active Comparator|DHA-rich fish oil supplement|DHA-rich fish oil supplement
3267903|NCT00711971|Placebo Comparator|Soy Oil placebo|Soy oil
3267904|NCT00711958|Experimental|HX575 epoetin alfa Hexal AG|HX575 (erythropoietin alfa of the Sponsor Hexal AG). Eligible patients to be randomized in ratio 2:1 and to be subcutaneously treated (solution for injection (s.c.)) for 12 weeks with HX575 in pre-filled syringes. The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range. Application of the drug required at least once per week and allowed maximum three times per week.
3267905|NCT00711958|Active Comparator|ERYPO® Janssen-Cilag|ERYPO® Janssen-Cilag, Germany. Eligible patients were treated subcutaneously (solution for injection (s.c.)) with ERYPO® (Janssen-Cilag, Germany) in pre-filled syringes for 12 weeks.The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range. Application of the drug required at least once per week and allowed maximum three times per week.
3267906|NCT00711919|Active Comparator|1|Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months. After administration, serum LDL-cholesterol should be kept between 100 and 80 mg/dL by controlling the dose of Pitavastatin or adding other anti-hyperlipidemia agents other than statins.
3267907|NCT00711919|Active Comparator|2|Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months. After administration, serum LDL-cholesterol should be kept under 80 mg/dL by controlling the dose of Pitavastatin or adding other anti-hyperlipidemia agents other than statins.
3267908|NCT00711906|Experimental|1|HIV-negative women taking CTX as chemoprophylaxis
3267909|NCT00711906|Active Comparator|2|HIV-negative women taking SP as IPT
3267910|NCT00711906|Experimental|3|HIV-positive women (CD4> 200) taking CTX as chemoprophylaxis
3267911|NCT00711906|Active Comparator|4|HIV-positive women (CD4 > 200) taking SP as IPT
3267912|NCT00711893||ICD and CRT-D|Patients indicated for an implantable defibrillator or cardiac resynchronization defibrillator
3267913|NCT00711880|Experimental|Sativex|
3267914|NCT00711880|Placebo Comparator|Placebo|
3267915|NCT00711867|Experimental|VH2|Dynatherm vitalHeat2 (VH2) temperature management system.
3267916|NCT00711867|Active Comparator|Bair Hugger|Arizant Bair Hugger temperature management system.
3267917|NCT00711854|Experimental|1|trimethoprim-sulfamethoxazole (TMP-SMX) plus rifampicin
3267918|NCT00711854|Active Comparator|2|Linezolid
3267919|NCT00711841|Placebo Comparator|saline solution|Placebo (saline solution), 2 mL, intravenous, every 12 hours, for 48 hours
3267920|NCT00711841|Active Comparator|Dexamethasone|Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
3267921|NCT00711828|Experimental|Treatment (R-CYBOR-D)|Patients receive rituximab IV on day 1and cyclophosphamide PO, bortezomib IV, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3267922|NCT00711815||UA|HPV positive
3267923|NCT00711802|Experimental|Daptomycin|"Administered intravenously (IV) every 24 hours for up to 14 days at the following age-dependent dosages.~Participants ages 7 to 17 years: daptomycin was dissolved in a volume of 50 milliliters (mL) 0.9% sodium chloride for injection over 30 minutes (min) with an infusion rate of 1.67 mL/min.~Participants 1 to 6 years-old: daptomycin was dissolved in a volume of 25 mL 0.9% sodium chloride for injection over 60 min with an infusion rate was 0.42 mL/min.~Age Group 1 (for ages 12 to 17 years): 5 milligrams/kilogram (mg/kg)~Age Group 2 (for ages 7 to 11 years): 7 mg/kg~Age Group 3 (for ages 2 to 6 years): 9 mg/kg~Age Group 4 (for ages 1 to <2 years): 10 mg/kg"
3267924|NCT00711802|Active Comparator|Standard of Care (SOC)|The comparator agent for this study was the SOC treatment and dosage deemed appropriate by the Investigator. The recommended SOC agents were IV vancomycin, IV clindamycin, and IV semisynthetic penicillins every 24 hours for up to 14 days.
3267925|NCT00711789|Active Comparator|Angiotensin II|
3267926|NCT00711789|Placebo Comparator|Placebo|
3267927|NCT00711776|Experimental|Subjects receiving new formulation in blank test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
3267928|NCT00711776|Active Comparator|Subjects receiving current formulation in blank test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
3267929|NCT00711776|Experimental|Subjects receiving new formulation in pre-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
3267930|NCT00711776|Active Comparator|Subjects receiving current formulation in pre-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
3267931|NCT00711776|Experimental|Subjects receiving new formulation in main-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
3267932|NCT00711776|Active Comparator|Subjects receiving current formulation in main-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
3267933|NCT00711724||MGH 1|Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
3267934|NCT00711711|Experimental|Manual lymphatic drainage|this arm will receive 5 manual lymphatic drainage treatments from day 2 to day 7 post surgery
3267935|NCT00711711|Placebo Comparator|Relaxation|This arm will receive 5 relaxation treatments from day 2 to day 7 post surgery
3267936|NCT00711698|Active Comparator|1|In this arm patients will be randomized to receive a bolus of narcotic followed by PCA.
3267937|NCT00711698|Active Comparator|2|In this arm patients will be randomized to the current standard of care of bolus narcotic treatment.
3267938|NCT00711672||1|Medical Oncologists treating patients with metastatic colorectal cancer
3267939|NCT00711672||2|Patients with metastatic colorectal cancer receiving re-staging CT scans
3267940|NCT00711659||1|all third year medical students starting their pediatric clerkship rotation
3267941|NCT00711646|Experimental|Sativex|
3267942|NCT00711646|Placebo Comparator|Placebo|
3267943|NCT00711633|Experimental|1|the fermented preterm formula (FPF)
3267944|NCT00711633|Placebo Comparator|2|formula adapted for preterm infants (PF)
3267945|NCT00711620|Experimental|Thymosin alpha 1+Standard Therapy|Patients receive treatment based on SSC guideline with additional thymosin alpha1
3267946|NCT00711620|Placebo Comparator|normal saline+standard therapy|Patients receive treatment based on SSC guideline with additional normal saline.
3267947|NCT00711607|Experimental|1|Group 1: NOMAC-E2 (days 1-24 and day 35)
3267948|NCT00711607|Placebo Comparator|2|Group 2: NOMAC-E2 (days 1-24) followed by Placebo (day 35)
3267949|NCT00711594|Experimental|BIBW 2992 MA2|Phase I step: Find maximum tolerated dose of the non-marketed substance:BIBW 2992 given orally. Escalating doses of BIBW 2992 starting at 20mg daily.
3267950|NCT00711594|Experimental|BIBW 2992 QD|Phase II step: Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop. Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs.
3267951|NCT00711581|Experimental|A|Subjects will undergo a laparoscopic cholecystectomy. The gallbladder will be retracted using the Endograb retractor.
3267952|NCT00711568|Experimental|Arm 1|Left dorsolateral frontal 20 Hz TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
3267953|NCT00711568|Experimental|Arm 2|Right dorsolateral frontal 20 Hz TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
3267954|NCT00711568|Sham Comparator|Arm 3|Left or right dorsolateral frontal 20 Hz sham TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
3267955|NCT00711542|Active Comparator|1|Intracoronary infusion of autologous bone marrow-derived progenitor cells after NSTEMI
3267956|NCT00711542|Placebo Comparator|2|Intracoronary infusion of Placebo after NSTEMI
3267957|NCT00711529|Experimental|Hypnotherapy|"Patients randomized to the experimental arm were scheduled for three one-hour inductions by a single hypnotherapist, each one week apart. Standardized outlines were used for each induction. The second and third sessions also began with a standardized induction, followed by the establishment of an anchor, or physical reference point (forefinger to thumb), used to invoke images of coolness, which were individualized according to patient preference.~Patients were also instructed by the same hypnotherapist in self-hypnosis and guided imagery techniques to be used at home with the assistance of standardized audio compact disks. Participation lasted eight weeks."
3267958|NCT00711529|Active Comparator|Gabapentin|Patients randomized to the gabapentin arm were prescribed 900mg of the drug daily (300 mg by mouth three times daily).
3267959|NCT00711516|Experimental|1|﻿Armodafinil treatment (200 mg/day) - Study drug was supplied as 50 mg tablets and the dose was titrated from a starting dose of 50 mg taken once daily in the morning (before 0800), increasing to 100 mg/day on Day 2, 150 mg/day on day 5, and then 200 mg/day beginning Day 8 and continuing through the end of the two week double-blind treatment period.
3267960|NCT00711516|Placebo Comparator|2|Placebo comparator - Placebo tablets matching the armodafinil 50 mg tablets drug were supplied and the dose was titrated from a starting dose of one tablet taken once daily in the morning (before 0800), increasing to two tablets/day on Day 2, three tablets/day on day 5, and then four tablets/day beginning Day 8 and continuing through the end of the two week double-blind treatment period.
3267961|NCT00711503|Placebo Comparator|2|The patients are instructed to administer placebo by subcutaneous injection
3267962|NCT00711503|Experimental|1|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection
3267963|NCT00711490|Experimental|Sirolimus|The study eye was treated with sirolimus.
3267964|NCT00711477|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/day
3267965|NCT00711477|Placebo Comparator|Placebo|Placebo tablets
3267966|NCT00711464|Experimental|100 mg|modafinil 100 milligrams oral dose
3267967|NCT00711464|Experimental|200 mg|modafinil 200 mg oral dose
3267968|NCT00711464|Experimental|400 mg|modafinil 400 mg oral dose
3267969|NCT00711464|Placebo Comparator|Placebo|Single oral placebo capsule
3267970|NCT00711451|Active Comparator|manual|Manual removal of placenta
3267971|NCT00711451|Active Comparator|expressed|expressed placental removal
3267972|NCT00711438|Experimental|FT|Breathlessness Intervention Service (BIS)
3267973|NCT00711438|Active Comparator|WL|Best supportive care
3267974|NCT00711425|Experimental|A|
3267975|NCT00711412|Experimental|Induction, Combination and surgery|"Weeks 1-6:~Capecitabine 1000mg/m2 twice daily Oxaliplatin 70mg/m2 on days 1 and 8~Weeks 7-12:~Capecitabine 825 mg/m2 twice daily Oxaliplatin 50mg/m2 weekly Radiation 1.8 Gy Monday-Friday~Evaluation for response and resection surgery"
3267976|NCT00711399||group A|Study group
3267977|NCT00711386|Experimental|Cohort A|50mg dose once daily for 7 days.
3267978|NCT00711386|Experimental|Cohort B|100mg dose once daily for 8 days.
3267979|NCT00711386|Experimental|Cohort C|200mg dose once daily for 8 days.
3267980|NCT00711386|Experimental|Cohort D|400mg dose once daily for 7 days.
3267981|NCT00711373|Experimental|Unilateral and Bilateral Amputees|
3267982|NCT00711347|Active Comparator|DisCoVisc|Alcon's DisCoVisc Ophthalmic Viscosurgical Device (OVD) used at time of cataract surgery
3267983|NCT00711347|Active Comparator|Healon5|Abbott Medical Optic's (AMO) Healon5 Ophthalmic Viscosurgical Device (OVD) used at time of cataract surgery
3267984|NCT00711321||2|AFFITOPE AD02 with adjuvant
3267985|NCT00711321||1|AFFITOPE AD02 without adjuvant
3267986|NCT00711308|Experimental|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
3267987|NCT00711308|Active Comparator|acenocoumarol|tinzaparin followed by acenocoumarol for 6 months
3267988|NCT00711295|Experimental|Cohort 1, Treatment Arm 1|"Stratum A (18-59 ys)/B(>=60 ys): 120 healthy volunteers per stratum will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.~Among Stratum A volunteers, 60 will participate in antibody kinetics evaluation and 30 in cellular immunity evaluation.~Randomization to Treatment Arms 1 and 2 at 2:1 ratio. Subjects in Treatment Arm 1 will be included in the immunologic determination of lot-to-lot consistency."
3267989|NCT00711295|Experimental|Cohort 1, Treatment Arm 2|"Stratum A (18-59 ys)/B(>=60 ys): 60 healthy volunteers per stratum will receive 2 vaccinations with 3.75 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.~Randomization to Treatment Arms 1 and 2 at 2:1 ratio."
3267990|NCT00711295|Experimental|Cohort 1, Treatment Arm 3|"Stratum A (18-59 ys): 2060 healthy volunteers will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in safety evaluation only.~Randomization within Treatment Arms 3 and 4 at 1:1:1 ratio per study site to receive one of three different lots of the H5N1 influenza vaccine."
3267991|NCT00711295|Experimental|Cohort 2, Treatment Arm 1|"300 immune compromised individuals 18 years or older will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21.~100 will participate in immunogenicity evaluation and 30 in cellular immunity evaluation."
3267992|NCT00711295|Experimental|Cohort 3, Treatment Arm 1|300 chronically ill patients 18 years or older will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.
3267993|NCT00711295|Experimental|Cohort 1, Treatment Arm 4|"Stratum A (18-59): 540 healthy volunteers will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity assessment.~Randomization within Treatment Arms 3 and 4 at 1:1:1 ratio per study site to receive one of three different lots of the H5N1 influenza vaccine.~Subjects in Treatment Arm 4 will be included in the immunologic determination of lot-to-lot consistency."
3267994|NCT00711282|Experimental|A|
3267995|NCT00711282|Experimental|B|
3267996|NCT00711269|Experimental|1|
3267997|NCT00711269|Experimental|2|
3267998|NCT00711269|Placebo Comparator|3|
3267999|NCT00711269|Active Comparator|4|
3268000|NCT00711256|Active Comparator|1|No sunscreen applied
3268001|NCT00711256|Active Comparator|2|Sunscreen applied 0.5 mg/cm2
3268002|NCT00711256|Active Comparator|3|Sunscreen applied 1mg/cm2
3268003|NCT00711256|Active Comparator|4|Sunscreen applied 2mg/cm2
3268004|NCT00711243|Experimental|Cohort 1a|Docetaxel 25 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
3268005|NCT00711243|Experimental|Cohort 2a|Docetaxel 30 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
3268006|NCT00711243|Experimental|Cohort 3a|Docetaxel 40 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
3268007|NCT00711243|Experimental|Cohort 4a|Docetaxel 50 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
3268008|NCT00711243|Experimental|Cohort 5a|Docetaxel 60 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
3268009|NCT00711230|Experimental|1: Low dose DermaVir|"Dosage: 0.2 mg DNA~Dosage form: 1.6 mL DNA/PEIm nanomedicine~Administration with 2 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 DermaVir treatments)"
3268010|NCT00711230|Experimental|2: Low dose Placebo|"Dosage form: 1.6 mL Placebo~Administration with 2 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 Placebo treatments)"
3268011|NCT00711230|Experimental|3: Medium dose DermaVir|"Dosage: 0.4 mg DNA~Dosage form: 3.2 mL DNA/PEIm nanomedicine~Administration with 4 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 DermaVir treatments)"
3268012|NCT00711230|Experimental|4: Medium dose Placebo|"Dosage form: 1.6 mL Placebo~Administration with 4 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 Placebo treatments)"
3268212|NCT00709761|Experimental|Single Arm|Single arm combination therapy of Lap and NabPaclitaxel combination
3268013|NCT00711230|Experimental|5: High dose DermaVir|"Dosage: 0.8 mg DNA~Dosage form: 6.4 mL DNA/PEIm nanomedicine~Administration with 8 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 DermaVir treatments)"
3268014|NCT00711230|Experimental|6: High dose Placebo|"Dosage form: 6.4 mL Placebo~Administration with 8 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 Placebo treatments)"
3268015|NCT00711217|Experimental|#1 Medical food|
3268016|NCT00711217|Placebo Comparator|#2 Control|
3268017|NCT00711204|Placebo Comparator|1|
3268018|NCT00711204|Active Comparator|2|
3268019|NCT00711191|Experimental|single arm|
3268020|NCT00711178|Active Comparator|A|2 hours sunlight
3268021|NCT00711178|Active Comparator|B|3 hours of sunlight
3268022|NCT00711165|Placebo Comparator|Placebo|Placebo, 2 puffs, bid
3268023|NCT00711165|Experimental|Memetasone|Mometasone
3268024|NCT00711152|Experimental|JADE with CHW|Patients will be enrolled into JADE program and will undergo annual comprehensive assessment (CA) with personalized JADE report with additional support by the CHW.
3268025|NCT00711152|Active Comparator|JADE only|Patients will be enrolled into JADE program and undergo annual comprehensive assessment (CA) with personalized JADE report without additional support by the CHW.
3268026|NCT00711139||1|AFFITOPE AD01
3268027|NCT00711139||2|AFFITOPE AD01 + Adjuvant
3268028|NCT00711126|Experimental|Arm 1|HVTs
3268029|NCT00711126|Experimental|Arm 2|HVTs
3268030|NCT00711126|Experimental|Arm 3|HVTs
3268031|NCT00711126|Experimental|Arm 4|HVTs
3268032|NCT00711126|Experimental|Arm 5|HVTs
3268033|NCT00711126|Experimental|Arm 6|HVTs
3268034|NCT00711113|Experimental|A|
3268035|NCT00711100|Experimental|Camel Snus|Camel Snus (oral smokeless tobacco product). Dosage: 1.74-1.97 mg nicotine per portion.
3268036|NCT00711100|Experimental|Marlboro Snus|Marlboro Snus (oral smokeless tobacco product). Dosage: 0.14 - 0.38 mg nicotine per portion.
3268037|NCT00711100|Experimental|Stonewall|Stonewall (oral dissolvable tobacco product). Dosage: 0.28-0.57 mg nicotine per portion.
3268038|NCT00711100|Experimental|Ariva|Ariva (oral dissolvable tobacco product). Dosage: 0.24-0.25 mg nicotine per portion.
3268039|NCT00711100|Experimental|General Snus|General Snus (oral smokeless tobacco product); Dosage: 3.37 mg nicotine.
3268040|NCT00711087|Placebo Comparator|ARM 2|Subjects randomized to receive placebo (saline) sham saline injections on Days 0 and 90.
3268041|NCT00711087|Active Comparator|ARM 1|Subjects randomized to receive 100 units BOTOX-A injections on Days 0 and 90.
3268042|NCT00711074|Experimental|1|
3268043|NCT00711061||1|18-25 year old males, growth hormone deficient, who completed growth hormone treatment 3-5 years prior to enrollment in study
3268044|NCT00711061||2|18-25 year old males, healthy, never treated with growth hormones.
3268045|NCT00711048|Experimental|1|30 mg, oral, single dose
3268046|NCT00711048|Experimental|2|95 mg, oral, single dose
3268047|NCT00711048|Placebo Comparator|3|Oral solution, single dose
3268048|NCT00711035|Experimental|Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection|If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line.
3268049|NCT00711022|Experimental|OsseoSpeed|
3268050|NCT00711009|Active Comparator|LPV/r + FTC/TDF|lopinavir/ritonavir 400/100 milligram (mg) tablet twice-daily + co-formulated emtricitabine/tenofovir disoproxil fumarate 200/300 mg once-daily
3268051|NCT00711009|Experimental|LPV/r + RAL|lopinavir/ritonavir 400/100 mg tablet twice-daily + raltegravir 400 mg twice-daily
3268052|NCT00710996||AcrySof Natural Intraocular Lens|"AcrySof Natural Intraocular Lens (IOL) - Patients with previous bilateral implant of any Alcon lens model starting with the letters SN"
3268053|NCT00710996||AcrySof clear intraocular lens|"AcrySof clear intraocular lens (IOL) - Patients with previous bilateral implant of any Alcon lens model starting with the letters SA"
3268054|NCT00710996||Phakic patients|Phakic patients - Age matched patients who have not had cataract surgery
3268055|NCT00710983|Active Comparator|A|Oral polio vaccine
3268056|NCT00710983|No Intervention|B|No oral polio vaccine
3268057|NCT00710970|Experimental|Single Arm Receiving 25mg Tamoxifen|
3268058|NCT00710957||CHS All Stars|CHS All Stars is an ancillary study of the Cardiovascular Health Study (CHS), a longitudinal, observational, population-based study of the onset, progression, and course of heart disease and stroke in the elderly which began in 1988. The All Stars study reexamined the survivors of CHS to determine the likelihood of maintaining function later in life. A focus was to determine whether age-related biological factors are long-term predicators of functional aging which was assessed through a follow-up exam (Yr 18 visit conducted in 2005-06, n=1674 older adults, mean age =84 years) and 3 yrs of subsequent 6 month interval phone contacts. Vitamin D status (serum 25(OH)D and PTH) is being assessed in all CHS All Stars participants who provided a blood sample at the Yr 18 visit (n~1100).
3268059|NCT00710944|Experimental|Extraction Sockets|Immediate loading in extraction sockets.
3268060|NCT00710944|Experimental|Healed Ridges|Immediate loading in healed ridges.
3268061|NCT00710944|Experimental|Grafted Sites|Immediate loading of implants placed in grafted sites (four months healing after grafting).
3268062|NCT00710931|Experimental|ReSTOR +3 Multifocal Lens|Bilateral implantation of the AcrySof ReSTOR +3 Intraocular Lens (IOL)
3268063|NCT00710905|Experimental|ReSTOR|Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, Acrysof ReSTOR +4 IOL in the other eye.
3268064|NCT00710892|Experimental|Dose Level 1-3|Administration of suicide gene-modified allodepleted T cells.
3268065|NCT00710879|Experimental|Multipurpose Solution|Multi-purpose solution administered to adapted FDA group I soft contact lens wearers and FDA group IV soft contact lens wearers.
3268066|NCT00710866|Experimental|1|2 doses 0.5mL VAXIGRIP® at months 0, 1
3268067|NCT00710866|Active Comparator|2|2 doses 0.25mL VAXIGRIP® at months 0, 1
3268068|NCT00710853|Experimental|1|YiRen Qi gong weekly class for 8 weeks
3268069|NCT00710853|Experimental|2|Tai Chi weekly class for 8 weeks
3268070|NCT00710853|Active Comparator|3|Hatha yoga weekly class for 8 weeks
3268075|NCT00710814|Experimental|Leptin - Placebo|Leptin self-administered subcutaneously twice each day for 16 weeks, then Placebo for 16 weeks.
3268076|NCT00710814|Placebo Comparator|Placebo - Leptin|Placebo self-administered subcutaneously twice each day for 16 weeks, then Leptin for 16 weeks.
3268077|NCT00710788|Experimental|1|sevelamer as Phosphate-binder treatment
3268078|NCT00710788|Active Comparator|2|Calcium carbonate
3268079|NCT00710775|Other|1|Patients undergoing surgical aortic valve replacement on cardiopulmonary bypass.
3268080|NCT00710762|Experimental|BIBF1120|
3268081|NCT00710762|Placebo Comparator|Placebo|
3268082|NCT00710749|Experimental|Disposable device first, then Digital device|
3268083|NCT00710749|Experimental|Digital device first, then Disposable device|
3268084|NCT00710736|Experimental|ARRY-334543 + capecitabine|
3268085|NCT00710723|Experimental|1|vitrification
3268086|NCT00710723|No Intervention|2|Slow freezing
3268087|NCT00710697|Experimental|Single Arm|Picoplatin
3268088|NCT00710684|Experimental|DONEPEZIL + SB-742457 15 MG|SB-742457 - 15mg added to existing donepezil treatment
3268089|NCT00710684|Placebo Comparator|DONEPEZIL + PLACEBO|Placebo added to existing donepezil
3268090|NCT00710684|Experimental|DONEPEZIL + SB-742457 35 MG|SB-742457 - 35mg added to existing donepezil
3268091|NCT00710671||Phase 1|Male, HIV+ participants from ages 16-24 who have had sex with another male in the past year and acquired HIV behaviorally. Participants will be drawn from four participating AMTU sites.
3268092|NCT00710671||Phase 2|Male, HIV+ participants from ages 16-24 who have had sex with another male in the past year and acquired HIV behaviorally. Participants will be drawn from all fifteen AMTU sites.
3268093|NCT00710658|Experimental|1|Patients had access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as to a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.
3268094|NCT00710658|No Intervention|2|The control group receiving usual care
3268095|NCT00710645||Arm I|50 subjects with multiple sclerosis will be tested one time on the Lido Workset. The test will take approximately 25 minutes. The servo-controlled torque motor system will analyze resistance to passive movement of the knee. This testing may be repeated for a group of randomly selected subjects. Each subject will be given the option to participate in the extended testing or to decline. The testing for this subset of subjects will be done as follows: first session, second session one week after the first session, third session three weeks after the first session. The total length of time for participation in this study may be up to three weeks.
3268096|NCT00710645||Arm II|25 normal subjects will be tested on the Lido workset. The testing will be performed one time for each patient and will take approximately 25 minutes. The servo-controlled torque motor system will analyze resistance to passive movement of the knee. This testing may be repeated for a group of randomly selected control subjects. Each subject will be given the option to participate in the extended testing or to decline. The testing for this subset of subjects will be done as follows: first session, second session one week after the first session, third session three weeks after the first session. The total length of time for participation in this study may be up to three weeks.
3268097|NCT00710619||A|
3268098|NCT00710606|Experimental|1- Obese Women /Nuvaring|Obese subjects (BMI 30-39.9)received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
3268099|NCT00710606|Active Comparator|2- Normal Weight / Nuvaring|Normal weight subjects (BMI 19-24.9) received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
3268100|NCT00710593|Active Comparator|A: HAART naive or no HAART in past 6 months|Participants who are ART naïve or, if ART-exposed, have not received highly active antiretroviral therapy (HAART) for at least the six months prior to study entry. All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
3268101|NCT00710593|Active Comparator|B: HAART atleast 6 months/ 2 viral loads <400 in last 6 months|Participants who have been receiving highly active antiretroviral therapy (HAART) for at least six months at the time of study entry, with two HIV-1 RNA plasma viral loads < 400 copies/ml on two previous clinical visits within the 6 months prior to study entry. All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
3268102|NCT00710580|Experimental|A|
3268103|NCT00710580|Active Comparator|B|
3268104|NCT00710580|Placebo Comparator|C|
3268105|NCT00710567|Other|Historical Data|"DuraHeart Patients will be implanted with a DuraHeart Left Ventricular Assist System (LVAS) as a bridge to transplant until a suitable heart can be found as a replacement. Parameters collected will be compared to a performance goal based on historical data for congestive heart failure patients"
3268106|NCT00710554|Experimental|Sativex|
3268107|NCT00710554|Placebo Comparator|Placebo|
3268108|NCT00710541|Experimental|NPPV group|Subjects in this arm receive standard COPD treatment, LTOT if indicated, and NPPV with ventilators designed for 'non invasive ventilation'(Resmed VPAP III ST-A, Weinmann Ventimotion, Tyco Healthcare Knight Star 330)
3268109|NCT00710541|No Intervention|control gorup|Subjects in this arm receive standard COPD treatment and LTOT if indicated.
3268110|NCT00710528|Experimental|one arm|
3268111|NCT00710515|Experimental|1|with food
3268112|NCT00710515|Experimental|2|without food
3268113|NCT00710502|Experimental|1|Transvaginal NOTES Cholecystectomy (Phase 1)
3268114|NCT00710502|Active Comparator|2|Laparoscopic Cholecystectomy (Phase 2)
3268115|NCT00710502|Experimental|3|Transvaginal NOTES cholecystectomy (Phase 2)
3268116|NCT00710476|Experimental|1|Insemination of the oocytes with a lower concentration of spermatozoa.
3268117|NCT00710476|No Intervention|2|Insemination with a normal concentration of spermatozoa.
3268213|NCT00709748|Active Comparator|1|Subjects in this study arm will receive treatment (fully active) Empi Select TENS devices.
3268118|NCT00710463||Control group|patients receive a hospital based comprehensive pulmonary rehabilitation programme, including endurance training, physiotherapy, medical therapy, and long term oxygen treatment when indicated.
3268119|NCT00710463||NIV treatment group|patients receive a hospital based comprehensive pulmonary rehabilitation programme, including endurance training, physiotherapy, medical therapy, and long term oxygen treatment when indicated, plus newly introduced nocturnal non invasive ventilation.
3268120|NCT00710450||1|Allergic Asthma
3268121|NCT00710450||2|Allergic Rhinitis
3268122|NCT00710437||1|Dexmedetomidine - used
3268123|NCT00710437||2|Dexmedetomidine - not used
3268124|NCT00710424|Experimental|Sativex|
3268125|NCT00710424|Placebo Comparator|Placebo|
3268126|NCT00710411||A, 2|Polytraumatized patients with ISS > 18 and healthy controls
3268127|NCT00710398|Experimental|Control|A group consuming twice daily (post-exercise and in morning/afternoon) drinks containing no dairy protein or calcium. Daily protein intake (15% total kcals) should be from non-dairy sources (i.e. meat, egg, fish, chicken, wheat gluten).
3268128|NCT00710398|Experimental|Dairy Protein|A group consuming twice daily drinks (post-exercise and morning) containing 1% chocolate milk (in 1.5 cup servings = 3 cups/d). Daily protein intake is set at 15% total kcals with ~8% coming from dairy sources.
3268129|NCT00710398|Experimental|High Dairy Protein|A group consuming twice daily drinks of 1% artificially sweetened chocolate milk (in 1.5 cup servings = 3 cups/d). Their diet contains 30% protein (as opposed to only 15% in the Con and DairyPro groups) with at least 50% of that coming from dairy sources.
3268130|NCT00710385|Active Comparator|Heroin|Heroin 25 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
3268131|NCT00710385|Active Comparator|Naloxone|Naloxone (NAL) .4 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
3268132|NCT00710385|Experimental|Low Bup Dose|Combined dosing groups of (4 mg and 8mg of Buprenorphine) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
3268133|NCT00710385|Experimental|Low Bup/Nal Dose|Combined dosing groups of (4/1 mg and 8/2mg of Buprenorphine + Naloxone) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
3268134|NCT00710385|Experimental|High Bup Dose|Combined dosing groups of (8mg and 16mg of Bup) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
3268135|NCT00710385|Experimental|High Bup/Nal Dose|Combined dosing groups of (8/2mg and 16/4mg of Buprenorphine + Naloxone) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
3268136|NCT00710385|Placebo Comparator|Placebo|Intravenous placebo (PCB) administration. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
3268137|NCT00710372|Experimental|1|CYT006-AngQb
3268138|NCT00710372|Placebo Comparator|2|
3268139|NCT00710359|Active Comparator|1|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma) given as a single intramuscular injection. The syringe is covered so it is impossible to see whether or not it contains any substance.
3268140|NCT00710359|Sham Comparator|2|"The controls receive an intramuscular injection, however, it is only an introduction of the needle into the muscle, but no injections are given. The syringe is covered so it is impossible to see whether or not it contains any substance."
3268141|NCT00710333|Placebo Comparator|1|500ng dose
3268142|NCT00710333|Experimental|2|
3268143|NCT00710320||Cover and Uncover|Procedure/Surgery
3268144|NCT00710281|Other|2D/3D Phase contrast MR|
3268145|NCT00710268|Experimental|1|Dose Escalation Study 50, 100, 200, 400 mg
3268146|NCT00710255||Asthmatics|Asthmatics with exercise induced bronchospasm
3268147|NCT00710242|Experimental|1|DF01
3268148|NCT00710242|Placebo Comparator|2|
3268149|NCT00710229|Active Comparator|A|Intravitreal injectin of Ranibizumab (3 monthly injection followed by monthly injectins as long as required
3268150|NCT00710229|Active Comparator|B|Intravitreal injectin of Bevacizumab (3 monthly injection followed by monthly injectins as long as required
3268151|NCT00710216|Active Comparator|A|
3268152|NCT00710216|Experimental|B|
3268153|NCT00710203|Active Comparator|Pulsed dye laser|Four lesions are selected on each subject for study. One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
3268154|NCT00710203|Active Comparator|Curettage|Four lesions are selected on each subject for study. A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
3268155|NCT00710203|Active Comparator|Electrodesiccation|Four lesions are selected on each subject for study. A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
3268156|NCT00710203|Active Comparator|No treatment|Four lesions are selected on each subject for study. A fourth lesion will not be treated and will serve as a control.
3268157|NCT00710190|Experimental|Rheos Implant|
3268158|NCT00710177||PPHN|Infants born at >= 34 weeks who are diagnosed with clinical and/or echocardiographic evidence of PPHN
3268159|NCT00710177||Control|Randomly selected, normal healthy infants born at >= 34 weeks gestational age and do not have PPHN
3268160|NCT00710164|Experimental|A|
3268161|NCT00710164|Placebo Comparator|B|
3268162|NCT00710151||1|Subjects with PCNSL who have survived disease-free for 2 years or more. Treatments will vary depending upon site of enrollment and will include chemotherapy, blood brain barrier disruption (BBBD) with chemotherapy, radiation, and stem cell transplantation.
3268163|NCT00710138|Active Comparator|1|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma) given as a single intramuscular injection. The syringe is covered so it is impossible to see whether or not it contains any substance.
3268346|NCT00708669|Active Comparator|TAXUS group|
3268164|NCT00710138|Sham Comparator|2|"The controls receive an intramuscular injection, however, it is only an introduction of the needle into the muscle, but no injections are given. The syringe is covered so it is impossible to see whether or not it contains any substance."
3268165|NCT00710125|Experimental|GPX-150 for Injection|GPX-150 is administered IV on Day 1, followed by a 20 day rest period, every 3 weeks.
3268166|NCT00710112||VLBW|infants less than 1500 grams at birth
3268167|NCT00710099|Experimental|1|
3268168|NCT00710099|Active Comparator|2|SNP iontophoresis
3268169|NCT00710086|Active Comparator|1|Intravenous administration of hydromorphone intermittently
3268170|NCT00710086|Experimental|2|Remifentanil intravenous patient-controlled analgesia
3268171|NCT00710073|Experimental|A|Combined sono-electro-magnetic therapy
3268172|NCT00710060|Experimental|1|Participating communities will receive the Community Popular Opinion Leader intervention and HIV/STD educational materials.
3268173|NCT00710060|Active Comparator|2|Participating communities will receive HIV/STD educational materials only.
3268174|NCT00710047|Experimental|1|Fasting state
3268175|NCT00710047|Experimental|2|after high-fat breakfast
3268176|NCT00710034|Active Comparator|Nicotine Gum|Nicotine replacement therapy (4 mg nicotine gum) was provided to the participants for an 12 weeks. Participants were encouraged to completely substitute nicotine gum for cigarettes and asked to use at least 6-8 pieces a day or optimally every 1-2 h and more if necessary. They were advised to reduce consumption by half during weeks 7-9 and three-quarters during weeks 10-12.
3268177|NCT00710034|Experimental|Snus|Oral tobacco (Camel Snus) was provided to the participants for an 12 weeks. Participants were encouraged to completely substitute snus for cigarettes and asked to use at least 6-8 pieces a day or optimally every 1-2 h and more if necessary. They were advised to reduce consumption by half during weeks 7-9 and three-quarters during weeks 10-12.
3268178|NCT00710021|Experimental|vitamin D3 2000 IU|Participants in this arm take a vitamin D3 dose of 2000 international units (IU) daily by mouth for a duration of 12 weeks.
3268179|NCT00710021|Experimental|vitamin D3 4000 IU|Participants in this arm take a vitamin D3 dose of 4000 international units (IU) daily by mouth for a duration of 12 weeks.
3268180|NCT00710021|Placebo Comparator|vitamin D3 placebo|Participants in this arm take a vitamin D3 placebo daily by mouth for a duration of 12 weeks.
3268181|NCT00709995|Experimental|Arm A: Enzastaurin + Sunitinib|"Part 1: Dose escalation.~Enzastaurin (Cohort 1): Cycle 1, Day 1 loading dose 250 milligram (mg) administered by mouth (po), twice a day (BID), followed by 125 mg, po, BID on Days 2-42 of 6 week cycle.~Enzastaurin (Cohort 2) Cycle 1, Day 1 loading dose 375 mg administered po three times a day (TID), followed by 250 mg, po, BID continuously until disease progression, unacceptable toxicity, death, or discontinuation from the study for any other reason.~Sunitinib (Cohort 1 and 2): 50 mg administered po, every day (QD), on Days 1-28, then rest (no drug given) on Days 29-42.~Part 2: Randomized Double-Blind: Dosing for Part 2 will be determined by outcome of Part 1.~Phase 2 was not activated per recommendation of safety review committee.~Enzastaurin: Cycle 1, Day 1 loading dose 375 mg administered po, TID, followed by Phase 1 dose BID on Days 2-42 of 6 week cycle.~Sunitinib: 50 mg administered po, QD, on Days 1-28, then rest Days 29-42."
3268182|NCT00709995|Placebo Comparator|Arm B: Sunitinib + Placebo|"Arm B is in Part 2 of the study only.~Sunitinib: 50 mg administered po, QD Day 1-28, then rest Days 29-42.~Placebo: Cycle 1 Day 1 loading dose 3 tablets on Day 1, then 2 tablets QD on Days 2-42."
3268183|NCT00709969|Experimental|1|Artemether-lumefantrine
3268184|NCT00709956|Experimental|Active / placebo|Single dose of iloprost (5 µg) on study day 2 followed by single dose of placebo on study day 3
3268185|NCT00709956|Placebo Comparator|Placebo / active|Single dose of placebo on study day 2 followed by single dose of iloprost (5 µg) on study day 3
3268186|NCT00709930|Active Comparator|1,Exposed to ELF-EMF|Device: Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF
3268187|NCT00709930|Placebo Comparator|2,Placebo|Device: Placebo device with no magnetic fields
3268188|NCT00709917||A|
3268189|NCT00709904|Experimental|Semuloparin extension treatment|Extension treatment with Semuloparin sodium 20 mg (10 mg if SRI) for 19-23 days following initial treatment with open-label Semuloparin 20 mg (10 mg if SRI) for 7-10 days.
3268190|NCT00709904|Placebo Comparator|Placebo extension treatment|Extension treatment with placebo (for Semuloparin sodium) for 19-23 days following initial treatment with open-label Semuloparin 20 mg (10 mg if SRI) for 7-10 days
3268191|NCT00709891|Experimental|cobas® 4800 HPV Test|The cobas 4800 human papillomavirus (HPV) Test combines in a single assay the identification of pooled high-risk oncogenic HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), as well as genotypes 16 and 18 individually.
3268192|NCT00709878||L|Patients treated with lapatinib who developed skin toxicities and have been biopsied for skin rash.
3268193|NCT00709878||C|Patients treated with cetuximab who developed skin toxicities and have been biopsied for skin rash.
3268194|NCT00709878||P|Patients treated with panitumumab who developed skin toxicities and have been biopsied for skin rash.
3268195|NCT00709878||E|Patients treated with erlotinib who developed skin toxicities and have been biopsied for a skin rash.
3268196|NCT00709865|Experimental|1|.03 mg/kg
3268197|NCT00709865|Experimental|2|.15 mg/kg
3268198|NCT00709865|Experimental|3|.3 mg/kg
3268199|NCT00709865|Placebo Comparator|4|Placebo
3268200|NCT00709852|Experimental|Gadobutrol then Gadoteridol|Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) in Period 1 and a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v. in Period 2.
3268201|NCT00709852|Experimental|Gadoteridol then Gadobutrol|Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v. in Period 1 and a single dose of gadobutrol 0.1 mmol/kg bw via i.v. in Period 2.
3268202|NCT00709826|Experimental|apricoxib + gemcitabine + erlotinib|400mg apricoxib + 1000mg/m2 gemcitabine + 100mg erlotinib
3268203|NCT00709826|Placebo Comparator|placebo + gemcitabine + erlotinib|placebo + 1000mg/m2 gemcitabine + 100mg erlotinib
3268204|NCT00709813|No Intervention|1|
3268205|NCT00709813|Experimental|2|
3268206|NCT00709800|Experimental|2|
3268207|NCT00709800|Experimental|3|
3268208|NCT00709800|Experimental|4|
3268209|NCT00709800|Placebo Comparator|5|
3268210|NCT00709800|Experimental|1|
3268214|NCT00709748|Placebo Comparator|2|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
3268215|NCT00709735|Experimental|Reactivation Propranolol (RP)|"0.67 mg/kg short-acting placebo capsules then 1 mg/kg long-acting placebo capsules 90 minutes later on Day 0 (non-reactivation) followed by 0.67 mg/kg short-acting propranolol capsules then 1 mg/kg long-acting propranolol capsules 90 minutes later on Day 2 (reactivation). All participants then underwent a script preparation session in which the investigator elicited five discrete personal memories, including two traumatic combat experiences."
3268216|NCT00709735|Active Comparator|Non-Reactivation Propranolol (NRP)|"0.67 mg/kg short-acting propranolol capsules then 1 mg/kg long-acting propranolol capsules 90 minutes later on Day 0 (non-reactivation) followed by 0.67 mg/kg short-acting placebo capsules then 1 mg/kg long-acting placebo capsules 90 minutes later on Day 2 (reactivation). All participants then underwent a script preparation session in which the investigator elicited five discrete personal memories, including two traumatic combat experiences."
3268217|NCT00709722|Experimental|1|NKT-01
3268218|NCT00709709|Experimental|1|Scan
3268219|NCT00709696|Placebo Comparator|1|Placebo Varenicline
3268220|NCT00709696|Active Comparator|2|Varenicline
3268221|NCT00709683||A|
3268222|NCT00709670|Experimental|whole population who receive both tests|this arm includes the whole study population who will receive both tests: MSCT and stress echocardiography
3268223|NCT00709657|Experimental|1|patients with age-related macular degeneration, which are already scheduled for intravitreal anti-VEGF therapy in one eye are measured before and after treatment.
3268224|NCT00709592|Experimental|ATG 1.7 mg/kg, TBI, transplant|(Rabbit-ATG;Thymoglobulin,Genzyme) ATG 5.1 mg/kg in three divided doses (1.7 mg/kg/d) given over three days (day -9 to -7) followed by 450 cGy TBI and tacrolimus plus MMF GVHD prophylaxis. Patients receive lower dose anti-thymocyte globulin IV on days -9 to -7. Patients undergo total-body radiation (TBI) twice daily (BID) on day -1 and once daily (QD) on day 0. Patients then undergo peripheral blood stem cells or bone marrow transplant on day 0. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: patients receive tacrolimus orally (PO) on days -2 to 90-120 with taper for 2 months, and mycophenolate mofetil (MMF) PO BID on days 0-30.
3268225|NCT00709592|Experimental|ATG 2.5 mg/kg/d, TBI, transplant|(Rabbit-ATG;Thymoglobulin,Genzyme) ATG 7.5 mg/kg in three divided doses (2.5 mg/kg/d) given over three days (day -9 to -7) followed by 450 cGy TBI and tacrolimus plus MMF GVHD prophylaxis. Patients receive higher dose anti-thymocyte globulin intravenously (IV) on days -9 to -7. Patients undergo total-body radiation (TBI) twice daily (BID) on day -1 and once daily (QD) on day 0. Patients then undergo peripheral blood stem cells or bone marrow transplant on day 0. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: patients receive tacrolimus orally (PO) on days -2 to 90-120 with taper for 2 months, and mycophenolate mofetil (MMF) PO BID on days 0-30.
3268226|NCT00709579|Placebo Comparator|placebo|
3268227|NCT00709579|Active Comparator|RV3391A|
3268228|NCT00709566|No Intervention|Control|Waiting List control.
3268229|NCT00709566|Active Comparator|Exercise therapy|
3268230|NCT00709566|Experimental|Combined therapy|Combined Exercise therapy and Manual Therapy
3268231|NCT00709553|Experimental|1|midazolam, one single dose of 705mg
3268232|NCT00709553|Experimental|2|ZD4054(Zibotentan)- 10mg od, 7 days + midazolam (one single dose of 7.5 mg on day 6 )
3268233|NCT00709540|Experimental|single|10 subjects (8 active and 2 placebo)
3268234|NCT00709527|Experimental|1|
3268235|NCT00709514|Experimental|DCB-WH1 ointment|DCB-WH1 ointment 1.25%, topical use, two times daily for 12 weeks or until ulcer closes completely or discontinuation due to treatment failure, whichever comes first.
3268236|NCT00709514|Placebo Comparator|Placebo|Placebo, topical use, two times daily for 12 weeks or until ulcer closes completely or discontinuation due to treatment failure, whichever comes first.
3268237|NCT00709501|Experimental|1|"Participants in the intervention condition are encouraged to access the Achieve Together website at least once each week. During each login, the following activities will occur:~Users will enter their weight and height, how well their plan for a healthy weight has been going, and clarify their goal weight.~Users will answer questions about each habit they are using to lose weight~Users will receive automated feedback about each habit and will be encouraged to change or delete habits that are being used but not helpful, more consistently use habits that are helpful but not used being used and to continue to use habits that are helpful and being used consistently.~Users are encouraged to search for habits that have helped people of similar age and gender to themselves."
3268238|NCT00709501|No Intervention|2|Participants in the control condition will have to wait 12 weeks before accessing the Achieve Together website. These participants will be a given a log where they can document weekly weight measurements (this part did not happen).
3268239|NCT00709488|Experimental|Litx™ BPH Therapy|
3268240|NCT00709475||A|
3268241|NCT00709449|Experimental|1|20 patients with age related macular degeneration
3268242|NCT00709449|Experimental|2|20 patients with primary open angle glaucoma
3268243|NCT00709449|Experimental|3|20 age and sex matched control subjects
3268244|NCT00709436|Experimental|1|PMI-150 (intranasal ketamine) at time 0 and specified time points thereafter.
3268245|NCT00709436|Placebo Comparator|2|Placebo at time 0 and specified time points thereafter.
3268246|NCT00709423|Active Comparator|1|
3268247|NCT00709423|Placebo Comparator|2|
3268248|NCT00709410|Experimental|1|This is a single arm study. All consenting, eligible participants will receive the oral cholera vaccine.
3268249|NCT00709397||Observation|antiretroviral-experienced patients requiring raltegravir to construct an adequately potent antiretroviral regimen.
3268250|NCT00709384|Experimental|Prophylactic intervention|"We performed a prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone). Conduction times between electrodes placed on both sides of the lesions are measured on the second postoperative day. Coronary angiography and electrophysiology study using an electroanatomic mapping system to assess conduction across the line and to try to induce atrial flutter are performed three month after the operation.~There is only an intervention arm, no control arm"
3268251|NCT00709371|Placebo Comparator|Placebo|Combination tablet containing Zonisamide SR placebo plus bupropion SR placebo SR = Sustained Release
3268347|NCT00708669|Active Comparator|Cypher group|
3268252|NCT00709371|Active Comparator|Bupropion 360|Combination tablet containing Zonisamide SR placebo plus bupropion SR 360 mg/day; SR = Sustained Release
3268253|NCT00709371|Active Comparator|Zonisamide 120|Combination tablet containing Zonisamide SR 120 mg/day plus bupropion SR placebo; SR = Sustained Release
3268254|NCT00709371|Active Comparator|Zonisamide 360|Combination tablet containing Zonisamide SR 360 mg/day plus bupropion SR placebo; SR = Sustained Release
3268255|NCT00709371|Experimental|Zonisamide 120/Bupropion 360|Combination tablet containing Zonisamide SR 120 mg/day plus bupropion SR 360 mg/day; SR = Sustained Release
3268256|NCT00709371|Experimental|Zonisamide 360/Bupropion 360|Combination tablet containing Zonisamide SR 360 mg/day plus bupropion SR 360 mg/day; SR = Sustained Release
3268257|NCT00709358|Active Comparator|2|Detection by blood culture
3268258|NCT00709358|Experimental|1|Test LightCycler SeptiFast® (Roche)
3268259|NCT00709345|Experimental|Group Home|Participants will receive cognitive behavioral sessions.
3268260|NCT00709345|Active Comparator|Control|Participants will receive time-matched attention control sessions.
3268261|NCT00709319||Primary|Subjects vitreomacular traction, visual acuity 20/63 to 20/400, retinal thickness >300 microns in the central subfield on OCT, and cataract extraction not being performed in conjunction with vitrectomy.
3268262|NCT00709306|Placebo Comparator|Education|Participants were given a packet of standard skin cancer prevention educational brochures and handouts from major professional organizations to review independently for 10-15 minutes.
3268263|NCT00709306|Active Comparator|Motivational Interviewing|Participants met with a trained counselor who reviewed any personalized feedback of risk derived from the baseline assessments (e.g., history of sunburns, self-reported UV exposure, protective behaviors). Counselors utilized the basic motivational interviewing skills of open-ended questions, reflection of participant statements, affirmations/positive feedback, and summation of major points throughout the discussion. These sessions took about 22 minutes.
3268264|NCT00709306|Active Comparator|UV-detect photos|"Participants were shown a regular black and white photo and a black and white UV-filtered photo of their face. Participants were told that Any dark, spotted, freckled, wrinkled, uneven, or pitted areas indicate existing underlying skin damage that is difficult to reverse. However, protecting the skin from UV radiation can prevent future damage. Participants were asked what they noticed about the photos, what their reactions were, and how this might affect their behavior. These sessions took 12 minutes on average."
3268265|NCT00709306|Experimental|UV-detect photos & MI|Participants met with a trained counselor who reviewed any personalized feedback of risk derived from the baseline assessments (e.g., history of sunburns, self-reported UV exposure, protective behaviors). Counselors utilized the basic motivational interviewing skills of open-ended questions, reflection of participant statements, affirmations/positive feedback, and summation of major points throughout the discussion. In addition to baseline feedback, participants were also interviewed about the black & white and UV-filtered photos of their faces. These sessions took about 25 minutes.
3268266|NCT00709293|Placebo Comparator|1|
3268267|NCT00709293|Active Comparator|2|
3268268|NCT00709280|Experimental|Active treatment group|7% Hypertonic Saline administered via inhalation twice daily for 48 ± 4 weeks
3268269|NCT00709280|Active Comparator|Control group|0.9% Isotonic Saline administered via inhalation twice daily for 48 ± 4 weeks
3268270|NCT00709254|Active Comparator|Treatment Group A|Subjects received an i.v. dose of fentanyl (200 µg)
3268271|NCT00709254|Experimental|Treatment Group B|Subjects received a single dose of 3 mL AeroLEF (500 µg/1 mL)
3268272|NCT00709254|Experimental|Treatment Group C|Subjects received multiple doses of 3 mL AeroLEF (500 µg/1 mL) every 12 hours for a total of five doses over a 3 days
3268273|NCT00709228||PegIntron plus Rebetol|Those with chronic Hepatitis C infected with HCV LVL G1
3268274|NCT00709202|Active Comparator|1|Subjects assigned to this arm will receive Betahistine.
3268275|NCT00709202|Placebo Comparator|2|Subjects in this group will received placebo.
3268276|NCT00709176|Experimental|Brief|Dyads randomized to BRIEF arm received the Brief FOCUS Program (two home visits and one phone call by a trained nurse) in addition to standard clinical care.
3268277|NCT00709176|Experimental|Extensive|Dyads randomized to EXTENSIVE arm received the Extensive FOCUS Program (4 home visits and two phone calls by a trained nurse) in addition to standard clinical care.
3268278|NCT00709176|No Intervention|Control|Dyads randomized to CONTROL arm continued with standard clinical care.
3268279|NCT00709163|Active Comparator|1|
3268280|NCT00709163|Placebo Comparator|2|
3268281|NCT00709150|Experimental|1|Patients will receive collaborative depression care management.
3268282|NCT00709150|Active Comparator|2|Patients will receive enhanced usual care.
3268283|NCT00709137|Active Comparator|1|this arm will include patients with resistant hypertension who are on 3 reasonably dosed agents (one being an appropriately dosed diuretic) and spironolactone will be added (dose range 12.5mg-50mg)
3268284|NCT00709137|Active Comparator|2|this arm will include patients with resistant hypertension who are on 3 reasonably dosed agents (one being an appropriately dosed diuretic) and amiloride will be added (dose range 2.5-10mg)
3268285|NCT00709124|Experimental|NMES|60 minute daily NMES sessions every day for the duration of subject's ICU stay.
3268286|NCT00709124|Sham Comparator|Sham|60 minute sham sessions every day for the duration of subjects ICU stay. No voltage will be applied to those receiving sham sessions.
3268287|NCT00709111|Experimental|Maraviroc|Maraviroc (MVC) was taken for 24 weeks, in addition to the subject's current antiretroviral therapy (ART) drug regimen. At week 24, subjects discontinued MVC and were followed for an additional 24 weeks off MVC, but still on current ART drug regimen.
3268288|NCT00709098|Active Comparator|iloprost power 6|iloprost power 15
3268289|NCT00709098|Experimental|iloprost power 15|iloprost power 15
3268290|NCT00709085||1|HCC patients without liver cirrhosis
3268291|NCT00709085||2|HCC patients with liver cirrhosis
3268292|NCT00709072|Experimental|1|SMS reminders
3268293|NCT00709072|No Intervention|2|control group
3268294|NCT00709059||PegIntron Plus Rebetol|Previously untreated patients infected with HCV genotype 1, 4, 5, or 6.
3268295|NCT00709046|Experimental|1|High dose pantoprazole infusion
3268296|NCT00709046|Active Comparator|2|standard dose pantoprazole infusion
3268297|NCT00709033|Experimental|autologous or syngeneic PBTLs and EBV-CTLs|The subject will be assigned a dose of CD19-CD28 chimeric receptor T cells at study entry.
3268298|NCT00709020|Experimental|White Button Mushroom Extract|
3268299|NCT00709007|Experimental|DAART|Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
3268300|NCT00709007|Active Comparator|SAT|Participants take their HIV medications on their own but visit the clinic for opioid agonist substitution therapy.
3268301|NCT00708994|Active Comparator|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
3268302|NCT00708994|Placebo Comparator|Placebo|• Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
3268303|NCT00708981|Active Comparator|Study Group|"Study group will receive multifactorial intervention for advanced diabetic nephropathy:~Elements of multifactorial intervention:~BP control of <130/80mmHg and renal protection with reduction of proteinuria to <0.5g/day using therapy with ACE inhibitors and/or ARBs.~Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.~Use of hypolipidemic therapy to achieve targets of LDL < 70 mg/dl, HDL > 40/50 mg/dl (M/F)and TG < 200 mg/dl.~Patient enhanced self-management provided by combined diabetes-renal education curriculum.~Behavior and social intervention~Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators."
3268304|NCT00708981|No Intervention|Control Group|Control Group will keep on receiving the usual treatment that they used to receive from their respective clinics and the Diabetes-Renal team would not alter their therapy or interfere in their management.
3268305|NCT00708968|Experimental|FOCUS Intervention|Dyads randomized to this arm received the FOCUS Program, 3 home visits and 2 phone calls by trained nurses.
3268306|NCT00708968|No Intervention|Standard Care|
3268307|NCT00708942|Active Comparator|1|HAL suppository (single administration, HAL 100mg), laser illumination (50J/cm2)
3268308|NCT00708942|Placebo Comparator|2|Placebo suppository (single administration), laser illumination (50J/cm2)
3268309|NCT00708942|No Intervention|3|
3268310|NCT00708942|Active Comparator|4|HAL ointment (5%, 100mg, single administration), LED diode illumination (50J/cm2)
3268311|NCT00708942|Placebo Comparator|5|Placebo ointment (single administration), no illumination
3268312|NCT00708929|Other|1|14 subjects homozygous HH for the Tyr402His single nucleotide polymorphism
3268313|NCT00708929|Other|2|14 subjects homozygous TT for the Tyr402His single nucleotide polymorphism
3268314|NCT00708916|Active Comparator|Apremilast|CC-10004 20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
3268315|NCT00708903|Experimental|1|HKI-272
3268316|NCT00708903|Placebo Comparator|2|Placebo
3268317|NCT00708903|Active Comparator|3|Moxifloxacin
3268318|NCT00708890|Experimental|Intervention group|
3268319|NCT00708890|No Intervention|Control group|Will only get a standard information about TSG group (information about meeting etc.)
3268320|NCT00708877|Experimental|All participants|
3268321|NCT00708851|Active Comparator|NB-UVB Light Device (311-315 nm)|the subject will receive full body NB-UVB light therapy
3268322|NCT00708851|Experimental|LCD Solution with NB-UVB Phototherapy|on half of the body will receive LCD while the full body receives NB-UVB therapy
3268323|NCT00708838||1|
3268324|NCT00708838||2|
3268325|NCT00708838||3|
3268326|NCT00708838||4|
3268327|NCT00708838||5|
3268328|NCT00708825||1|surgical outcome, observation
3268329|NCT00708812|Active Comparator|The control group|paclitaxel-carboplatin
3268330|NCT00708812|Experimental|The treatment group|paclitaxel-carboplatin plus Endostar
3268331|NCT00708799|Experimental|Arm 1|Standard antibiotic therapy +Azithromycin 500 mg intravenously daily for 5 days
3268332|NCT00708799|No Intervention|Arm 2|Standard antibiotic therapy
3268333|NCT00708773|Experimental|Single Arm|
3268334|NCT00708760||2|web based learning group
3268335|NCT00708760||1|paper based learning group
3268336|NCT00708747|Experimental|B|Patients were randomised to receive a commercially available standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) containing all important transport and inhibitor proteins as well as immunoglobulins
3268337|NCT00708747|Active Comparator|A|Patients were randomised to receive a 5% albumin solution
3268338|NCT00708734|Experimental|Arm 1|functional exercise training
3268339|NCT00708721|Experimental|All patients|All participants enrolled.
3268340|NCT00708708||A|Patients with moderate to severe plaque psoriasis
3268341|NCT00708695||Free Transportation|The 166 families in this treatment condition received free round-trip taxicab transportation for scheduled prenatal care appointments. This group did not receive any postpartum services or assessments.
3268342|NCT00708695||Free Transportation, Screening/Referral Service|The 514 families in this group received: 1) free transportation for scheduled prenatal care; and 2) developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life.
3268343|NCT00708695||Free Transportation, home-visit, postpartum visit|The 230 families in this treatment condition received: 1) free transportation for scheduled prenatal care; and 2) intensive nurse home-visitation services during pregnancy and one postpartum visit in the hospital before discharge and one postpartum visit in the home. This group did not receive any postpartum services or assessments.
3268344|NCT00708695||Free Transportation, home-visit, Screening/Referral Service|The 228 families in this condition received: 1) free transportation for scheduled prenatal care; 2) intensive nurse home-visitation services during pregnancy and through the child's second birthday; and 3) developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life.
3268345|NCT00708682|Experimental|A|
3268348|NCT00708656|Experimental|1: once daily|Three 800mg tablets of mesalazine (Asacol®) in the morning
3268349|NCT00708656|Active Comparator|2: tds|Mesalazine (Asacol®) 800mg given three times daily
3268350|NCT00708643|Active Comparator|Habitual silicone hydrogel|Habitual contact lens wear.
3268351|NCT00708643|Experimental|narafilcon A|Silicone hydrogel daily disposable contact lens
3268352|NCT00708630|Experimental|1|Provision of extended symptom side effects information
3268353|NCT00708630|No Intervention|2|Standard information on side effects
3268354|NCT00708604|Experimental|1|Islet transplantation
3268355|NCT00708591|Experimental|1|
3268356|NCT00708578|Active Comparator|1|Administration of 4 mg of Glimepiride with Insulin Glargine
3268357|NCT00708578|Active Comparator|2|Administration of 1500 mg of Metformin with Insulin Glargine
3268358|NCT00708578|Experimental|3|Administration of a combination of 4mg Glimepiride plus 1000mg Metformin with Insulin Glargine
3268359|NCT00708552|Experimental|SB-742457 - 15mg|SB-742457 - 15mg
3268360|NCT00708552|Placebo Comparator|Placebo|
3268361|NCT00708552|Experimental|SB-742457 - 35mg|SB-742457 - 35mg
3268362|NCT00708552|Active Comparator|Donepezil|
3268363|NCT00708539|Active Comparator|1|Crinone vaginal gel 8% 90 mg once daily
3268364|NCT00708539|Active Comparator|2|Progesterone mic 400 mg three times daily
3268365|NCT00708526|Experimental|Phase 1 Recovery|Quick Emergence Device is in place for phase 1 anesthesia recovery
3268366|NCT00708526|Other|Standard of care|Tidal volume and respiratory rate are not changed during phase 1 recovery from anesthesia
3268367|NCT00708500|Placebo Comparator|Placebo+PEG2b+RBV, x 44 weeks|Participants in Arm 1 (control) received pegylated interferon alfa 2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by boceprevir placebo + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
3268368|NCT00708500|Experimental|Boceprevir+PEG2b+RBV, Response Guided Therapy|"Participants in Arm 2 (experimental) were assigned either a 36-week or 48-week course of therapy based on their HCV-RNA status at Treatment Week 8.~PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 32 weeks, then:~36-week regimen: Participants who have undetectable HCV-RNA at Treatment Week 8 discontinue treatment and enter 36 weeks of post treatment follow-up.~48-week regimen: Participants who have detectable HCV-RNA at Treatment Week 8 are assigned an additional 12 weeks of therapy, followed by 24 weeks of post treatment follow-up. Placebo replaces boceprevir for the remaining 12 weeks of therapy, and this switch will occur in a blinded fashion."
3268369|NCT00708500|Experimental|Boceprevir+PEG2b+RBV, x 44 weeks|Participants in Arm 3 (experimental) received PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
3268370|NCT00708487|Experimental|1|5% oxygen embryo culture condition
3268371|NCT00708487|Active Comparator|2|21% oxygen embryo culture condition
3268372|NCT00708474|Experimental|OsseoFit™|Treatment of bone graft site with OsseoFit™ Porous Tissue Matrix™.
3268373|NCT00708474|No Intervention|Open|Treatment of bone graft site without OsseoFit™ Porous Tissue Matrix™.
3268374|NCT00708461|Experimental|Worksite Environmental Intervention|Changes to healthy food availability, physical activity opportunities and promotion, body weight scale access, and media enhancements to target weight gain prevention
3268375|NCT00708461|No Intervention|No-contact control|No-treatment control condition. Worksites were offered program materials upon completion of programs at intervention sites.
3268376|NCT00708448|Experimental|All patients|All participants enrolled.
3268377|NCT00708435|Experimental|Beriplex® P/N|
3268378|NCT00708435|Active Comparator|Fresh frozen plasma|
3268379|NCT00708422|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
3268380|NCT00708422|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
3268381|NCT00708409||1|Autograft operations with the subcoronary technique
3268382|NCT00708409||2|Autograft operations with the root replacement technique
3268383|NCT00708396|Experimental|Patients|Patients which diagnosed as OCD and schizophrenia
3268384|NCT00708383|Experimental|1|Embryo culture medium supplemented with 0.5% HSA and 10% SSS
3268385|NCT00708383|Active Comparator|2|Embryo culture medium supplemented with 0.5% HSA only
3268386|NCT00708370|Active Comparator|COACH|
3268387|NCT00708370|Placebo Comparator|Standard Care|
3268388|NCT00708357|Other|1|homozygous mutant: CC allele of the eNOS T-786C gene
3268389|NCT00708357|Other|2|homozygous mutant: TT allele of the eNOS T-786C gene
3268390|NCT00708344|Active Comparator|Group 1|Usual elective titration regimen
3268391|NCT00708344|Active Comparator|Group 2|Active elective titration regimen
3268392|NCT00708331|Experimental|1|
3268393|NCT00708318|Experimental|A, B, C|
3268394|NCT00708305|Experimental|NaF toothpaste (1450 parts per million [ppm] fluoride [F])|Participants brushed for one timed minute with 1.6g of NaF/silica and 0.4 percent carbopol toothpaste containing 1450ppmF as NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
3268395|NCT00708305|Active Comparator|NaF toothpaste (1400ppmF)|Participants brushed for one timed minute with 1.6g of NaF toothpaste containing 1400ppmF as NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
3268396|NCT00708305|Active Comparator|Sodium monofluorophosphate (NaMFP)/ NaF toothpaste (1450ppmF))|Participants brushed for one timed minute with 1.6g of NaMFP/NaF toothpaste containing 1450ppmF from NaMFP and NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
3268397|NCT00708305|Placebo Comparator|Placebo toothpaste (0ppmF)|Participants brushed for one timed minute with 1.6g of fluoride free toothpaste. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
3268398|NCT00708292|Experimental|Single Agent AUY922|
3268399|NCT00708292|Experimental|AUY922 + Bortezomib|
3268400|NCT00708292|Experimental|AUY922 + Bortezomib + Dexamethasone|
3268609|NCT00706888|Placebo Comparator|4|Male with placebo
3268401|NCT00708279|Experimental|A|After establishing a baseline for the first 4 weeks of trial involvement, thereby providing their own control group, all participants begin the intervention phase of osteopathic manipulation.
3268402|NCT00708266|Placebo Comparator|V2|28 hours continuous saline venous infusion.
3268403|NCT00708266|Experimental|V3|28 hours continuous lipid-heparin venous infusion.
3268404|NCT00708253|Active Comparator|SBE|
3268405|NCT00708253|Active Comparator|DBE|
3268406|NCT00708240|Experimental|Escitalopram|
3268407|NCT00708227||Whites ADRB2:ARG16ARG|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
3268408|NCT00708227||Whites ADRB2:GLY16GLY|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
3268409|NCT00708227||African American ADRB2:ARG16ARG|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
3268410|NCT00708227||African American ADRB2:GLY16GLY|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
3268411|NCT00708214|Experimental|BIBW 2992|To study BIBW 2992 in association with letrozole in hormonoresistant metastatic breast cancer
3268412|NCT00708214|Other|Letrozole|Hormonotherapy for metastatic breast cancer
3268413|NCT00708201|Experimental|Alvimopan|"12 milligrams (mg)~Alvimopan, 12mg, capsule. Administered orally. One 30 minutes to 5 hours before the scheduled start of surgery on Day 0, and twice daily beginning on Postoperative Day 1 (POD 1) until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment"
3268414|NCT00708201|Placebo Comparator|Placebo|"300 mg polyethylene glycol in a capsule~Administered orally at least 30 minutes and no later than 5 hours before the scheduled start of surgery on Day 0. On Day 1, a single dose of placebo was given twice a day for a maximum of 7 days in hospital after surgery."
3268415|NCT00708188|Experimental|Multidetector raw CT|
3268416|NCT00708175|Experimental|Pioglitazone|
3268417|NCT00708175|Placebo Comparator|Placebo|
3268418|NCT00708162|Experimental|Elvitegravir|"EVG 85 mg or 150 mg + RAL placebo + background regimen in the Randomized Phase, followed by EVG 85 mg or 150 mg + background regimen in the Open-Label Phase.~Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their background regimen will receive EVG 85 mg; all other participants will receive EVG 150 mg."
3268419|NCT00708162|Active Comparator|Raltegravir|"RAL 800 mg (400 mg twice daily) + EVG placebo + background regimen in the Randomized Phase, followed by EVG 85 mg or 150 mg + background regimen in the Open-Label Phase.~Participants receiving LPV/r or ATV/r as part of their background regimen in the Open-Label Phase will receive EVG 85 mg; all other participants will receive EVG 150 mg."
3268420|NCT00708149|Active Comparator|1|lansprazole 30 mg qd from NG route or orally
3268421|NCT00708149|Placebo Comparator|2|control group without any PPI, H2 blockers or other medications for treating peptic ulcers.
3268422|NCT00708123|Active Comparator|Sodium Fluoride (NaF) toothpaste[1350 parts per million(ppm)F]|Participants to brush their natural teeth twice daily with a full ribbon of NaF toothpaste (1350 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
3268423|NCT00708123|Experimental|NaF/Carbopol toothpaste (1400 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaF and 0.5% carbopol toothpaste (1450 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
3268424|NCT00708123|Active Comparator|NaMFP/NaF toothpaste (1450 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaMFPand NaF toothpaste (1450 ppm F - 1000 ppm F as NaMFP and 450 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
3268425|NCT00708123|Active Comparator|NaF toothpaste (250 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaF toothpaste (250 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
3268426|NCT00708123|Placebo Comparator|Placebo toothpaste (0 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of fluoride free toothpaste (0 ppm F) for one timed minute, after removing their partial denture from their mouth.
3268427|NCT00708110|Experimental|Treatment A|GSK1349572 2 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
3268428|NCT00708110|Experimental|Treatment B|GSK1349572 10 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
3268429|NCT00708110|Experimental|Treatment C|GSK1349572 50 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
3268430|NCT00708097|Experimental|NaF toothpaste(1450 ppmF)|Study toothpaste containing 1450 ppm F as NaF and 0.4% carbopol as excipient.
3268431|NCT00708097|Active Comparator|NaF toothpaste (1400 ppmF)|Study toothpaste containing 1400 ppm F as NaF
3268432|NCT00708097|Active Comparator|NaMFP/NaF toothpaste (1450 ppmF)|Reference toothpaste containing 1000 ppm F as NaMFP and 450 ppm F as NaF
3268433|NCT00708097|Active Comparator|NaF toothpaste (675 ppmF)|Study toothpaste containing 675 ppm F as NaF
3268434|NCT00708097|Placebo Comparator|Placebo toothpaste (0 ppmF)|Fluoride free placebo toothpaste (0 ppm F)
3268435|NCT00708084|Experimental|A|CL184 combined with rabies vaccination
3268436|NCT00708084|Active Comparator|B|HRIG combined with rabies vaccination
3268437|NCT00708071|Experimental|1|One side of the face is treated with FS VH S/D 4; the other side of the face is treated using standard of care.
3268438|NCT00708045|Experimental|All patients|All participants enrolled.
3268439|NCT00708032|Other|spectacles|habitual spectacles worn daily for 12 months
3268440|NCT00708032|Experimental|narafilcon A soft contact lenses|narafilcon A soft contact lenses worn as daily disposable for 12 months
3268610|NCT00706875||1|30 patients survived GTD post treatment for 0 - 5 years.
3268441|NCT00708019|Experimental|Low dose|Low dose of the psychoeducational intervention (i.e., 8.0 hours with the intervention nurse over 10 weeks)
3268442|NCT00708019|Experimental|High dose|High dose of the psychoeducational intervention (i.e., 12.3 hours with the intervention nurse over 10 weeks)
3268443|NCT00708006|Experimental|1|HGS1029
3268444|NCT00707993|Experimental|Alogliptin 25 mg QD|
3268445|NCT00707993|Active Comparator|Glipizide 5 mg QD|
3268446|NCT00707980|Experimental|Vortioxetine|Vortioxetine 2.5 mg, 5 mg or 10 mg, encapsulated tablets, orally, once daily for up to 52 weeks. For the first week of treatment all participants received 5 mg/day vortioxetine, thereafter, the dose could be increased to 10 mg/day or decreased to 2.5 mg/day, based on participant's response and tolerability as judged by the investigator.
3268447|NCT00707967|Experimental|Group A|Subjects receiving the candidate vaccine
3268448|NCT00707967|Placebo Comparator|Group B|Subjects receiving the adjuvant
3268449|NCT00707967|Placebo Comparator|Group C|Subjects receiving physiological saline
3268450|NCT00707954|Experimental|TA-7284|
3268451|NCT00707954|Placebo Comparator|Placebo of TA-7284|
3268452|NCT00707941|Experimental|1|Oseltamivir for 5 days for patients with illness duration < 48 hours
3268453|NCT00707941|Placebo Comparator|2|Placebo for 5 days for patients with illness duration < 48 hours
3268454|NCT00707941|Experimental|3|Oseltamivir for 5 days for patients with illness duration ≥ 48 hours
3268455|NCT00707941|Placebo Comparator|4|Placebo for 5 days for patients with illness duration ≥ 48 hours
3268456|NCT00707928|Active Comparator|1|1=nitroglycerine 100 microgram intravenous100-200 microgram of IV.
3268457|NCT00707928|Placebo Comparator|2|2=placebo with the same volume as NTG 100-200 microgram of IV.
3268458|NCT00707915|Experimental|Dose reduction|The benzodiazepine dose will be discontinued in 4 weeks by a weekly 25% reduction. Participants will be observed for 8 weeks.
3268459|NCT00707902|Active Comparator|2|"Drug: Echinacea/sage~patients received additionally a placebo-spray for the synthetical comparator (chlorhexidine/lidocaine) as the study was double dummy blinded.~Patients had to apply spray every 2 hours with two puffs to the pharyngeal area up to a maximum of 10 times daily. Treatment duration was until illness was resolved or for a maximum of 5 consecutive days.~Arms: 1"
3268460|NCT00707902|Active Comparator|1|"Drug: Chlorhexidine/lidocaine~patients received additionally a placebo-spray for the synthetical comparator (echinacea/sage) as the study was double dummy blinded.~Patients had to apply spray every 2 hours with two puffs to the pharyngeal area up to a maximum of 10 times daily. Treatment duration was until illness was resolved or for a maximum of 5 consecutive days."
3268461|NCT00707889|Active Comparator|A|Open-label to Bevacizumab plus mFOLFOX6
3268462|NCT00707889|Active Comparator|B|Open-label to High-dose ABT-869 arm plus mFOLFOX6
3268463|NCT00707889|Active Comparator|C|Open-label to low-dose ABT-869 arm plus mFOLFOX6
3268464|NCT00707876|Experimental|1|Dose 1 versus non-contrast MRA
3268465|NCT00707876|Experimental|2|Dose 2 versus non-contrast MRA
3268466|NCT00707876|Experimental|3|Dose 3 versus non-contrast MRA
3268467|NCT00707863|Other|Depressed Subjects Age: 18 - 25 yrs|Subjects receiving Escitalopram (trade name: Lexapro) that are in the age range of 18-25
3268468|NCT00707863|Other|Depressed Subjects Age: 16 - 50 yrs|Subjects receiving Escitalopram (trade name: Lexapro) in the age range of 26-50
3268469|NCT00707850|Experimental|1|Thalassemic Patients with HCV
3268470|NCT00707837|Experimental|Infant Formula|Preterm infant formulas containing lipid soluble compounds
3268471|NCT00707837|Active Comparator|Preterm formulas|Standard preterm infant formula and discharge formulas
3268472|NCT00707824|Placebo Comparator|1|1= placebo
3268473|NCT00707824|Active Comparator|2|2=nalbuphine 5 mg
3268474|NCT00707824|Active Comparator|3|3=nalbuphine 10 mg
3268475|NCT00707798|Experimental|Formulation 1|
3268476|NCT00707798|Experimental|Formulation 2|
3268477|NCT00707798|Experimental|Formulation 3|
3268478|NCT00707798|Experimental|Formulation 4|
3268479|NCT00707798|Experimental|Formulation 5|
3268480|NCT00707798|Experimental|Formulation 6|
3268481|NCT00707798|Active Comparator|23 valent pneumococcal vaccine|
3268482|NCT00707785|Experimental|1|Sepsis - vitamin A
3268483|NCT00707785|Placebo Comparator|2|Sepsis - placebo
3268484|NCT00707785|Experimental|3|NEC - vitamin A
3268485|NCT00707785|Placebo Comparator|4|NEC - Placebo
3268486|NCT00707772|Active Comparator|1|Genotype 2 or 3 in Hemophilic Patients with HCV
3268487|NCT00707772|Active Comparator|2|Other Genotypes (except 2 or 3) in Hemophilic Patients with HCV
3268488|NCT00707759|Experimental|A: withdrawal steroids|"Arms A: TAC + MMF + withdrawal steroids over a six-days following randomization.~1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~2ºday: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~3°day: Prednisone 2 mg/kg/d in 2 doses~4ºday: Prednisone 1 mg/kg/d in 2 doses~5ºday: Prednisone 0.5 mg/kg/d in 2 doses~6ºday: Prednisone 0.25 mg/kg/d in 2 doses~7ºday: Stop Prednisone"
3268489|NCT00707759|Active Comparator|B|"Arms B: TAC + MMF + prednisolone (see schedule)/day~10°days after Tx: 2 mg/kg/d~Day 11 - 20: 1 mg/kg/d~Day 21 - 30: 0.5 mg/kg/d~Day 31 - 60: 0.3 mg/k/d~Week 8 - 12: 0.25 mg/k/d~Week 12 - 16: 0.20 mg/k/d~Week 16 - 20: 0.15 mg/k/d~Month 6 - 12: 0.10 - 0.12 mg/k/d"
3268490|NCT00707746|Placebo Comparator|Placebo|1 mL placebo saline, weekly subcutaneous injections for 26 weeks
3268491|NCT00707746|Experimental|Mipomersen|200 mg (1 mL), weekly subcutaneous injections for 26 weeks
3268492|NCT00707720|Experimental|TERIS procedure|TERIS procedure for the treatment of obesity
3268493|NCT00707707|Experimental|1|paclitaxel + AZD2281
3268494|NCT00707694||Probands|Ashkenazi Jews ages 95 and older
3268495|NCT00707694||Offspring|Ashkenazi Jewish offspring of Ashkenazi Jewish parent(s) who lived to at least the age of 95
3268496|NCT00707694||Controls|Ashkenazi Jewish people with no family history of longevity
3268497|NCT00707681|Active Comparator|I|MS-20
3268498|NCT00707681|Placebo Comparator|2|Placebo
3268499|NCT00707668||Control|Chung-ju cohort populations aged over 30 year-old
3268611|NCT00706875||2|30 patients survived GTD post treatment 6 - 10+ years.
3268500|NCT00707655|Experimental|Zalutumumab 4 mg/kg|Zalutumumab in combination with radiotherapy for 8 weeks. The treatment period of 8 weeks is followed by a 3 week follow-up period where all adverse events are collected and then additionally a 2 year follow-up period where only serious adverse events are collected.
3268501|NCT00707655|Experimental|Zalutumumab 8 mg/kg|Zalutumumab in combination with radiotherapy for 8 weeks. The treatment period of 8 weeks is followed by a 3 week follow-up period where all adverse events are collected and then additionally a 2 year follow-up period where only serious adverse events are collected.
3268502|NCT00707642|Experimental|1|Low Dose WN-80E API (5 µg) + Alhydrogel (3.5 mg)
3268503|NCT00707642|Experimental|2|Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)
3268504|NCT00707642|Experimental|3|High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)
3268505|NCT00707642|Experimental|4|High Dose WN-80E API (50 µg), no adjuvant
3268506|NCT00707629||Insulin Pump Therapy|Children on insulin pumps for at least three years. Subjects must have type 1 diabetes for at least five years and diagnosed under the age of 5.
3268507|NCT00707616||A|Subjects without type 2 diabetes living in Olmsted County, MN
3268508|NCT00707603||Hepatitis C subjects|Due to start therapy for Hepatitis C
3268509|NCT00707603||Controls|Healthy males
3268510|NCT00707590|Experimental|Part A|"A: BMS-767778, Oral Solution, Oral, 1 mg, once daily, 1 day OR Placebo Comparator, Oral Solution, Oral, 0 mg, once daily, 1 day~B: BMS-767778, Oral Solution, Oral, 3 mg, once daily, 1 day OR Placebo Comparator, Oral Solution, Oral, 0 mg, once daily, 1 day~C: BMS-767778, Capsules, Oral, 10 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day~D: BMS-767778, Capsules, Oral, 30 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day~E: BMS-767778, Capsules, Oral, 100 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day~F: BMS-767778, Capsules, Oral, 300 mg, once daily, 2 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 2 days~G: BMS-767778, Capsules, Oral, 600 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day"
3268511|NCT00707590|Experimental|Part B|"A: BMS-767778, Capsules, Oral, 10 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~B: BMS-767778, Capsules, Oral, 30 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~C: BMS-767778, Capsules, Oral, 100 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~D: BMS-767778, Capsules, Oral, 300 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~E: BMS-767778, Capsules, Oral, 600 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days"
3268512|NCT00707590|Experimental|Part C|"A: BMS-767778, Capsules, Oral, Adaptive design (between 10 to 600 mg), 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, 14 days~B: BMS-767778, Capsules, Oral, Adaptive design (between 10 to 600 mg), 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, 14 days"
3268513|NCT00707577|Experimental|Internet-based maintenance program|9-month Internet based self-monitoring maintenance program to track weight, exercise, and food logs
3268514|NCT00707577|No Intervention|Control|No maintenance program provided
3268515|NCT00707564|Experimental|1|HemCon Dental Dressing
3268516|NCT00707564|Active Comparator|2|Gauze with pressure
3268517|NCT00707551|Experimental|1|Ketoconazole tablet + AZD1305 Extended Release tablet
3268518|NCT00707551|Experimental|2|Verapamil Extended Release tablet + AZD1305 Extended Release tablet
3268519|NCT00707551|Experimental|3|AZD1305 Extended Release tablet
3268520|NCT00707538|Experimental|1|
3268521|NCT00707525|No Intervention|1|Natural cycle oocyte donation
3268522|NCT00707525|Active Comparator|2|"Stimulated cycle oocyte donation.~Long protocol down-regulation with a GnRH agonist, starting on the midluteal phase of the previous cycle with leuprolide acetate (0.2mg/day).~Once evidence of downregulation is documented, leuprolide will be halved to 0.1 mg daily.~COH with be carried on with gonadotropins (150UI/day of rFSH and 75 UI/day of HP-hMG). The dose can be adjusted according to ovarian response as judged by ultrasound and by serum oestradiol (E 2 ) concentrations."
3268523|NCT00707499|Experimental|1|
3268524|NCT00707486|Experimental|Hemcon Dental Dressing|The HemCon® Bandage is an FDA-cleared chitosan-based flat bandage that controls severe arterial bleeding from traumatic injuries. In comparison to traditional bandages, the HemCon® Bandage provides superior control of bleeding, wound site adhesiveness, multiple injury site usage, biocompatibility and provides a barrier to infective agents.
3268525|NCT00707486|Active Comparator|Gauze with pressure and/or Gelfoam|Post operative care for oral surgery subjects consists of the subject biting on sterile cotton gauze to provide pressure to the extraction site. A common alternative practice involves the placement of Gelfoam (with or without antibiotic/steroid medication) into the extraction socket prior to application of the sterile gauze pressure dressing. This treatment was chosen as the study control to compare the HemCon Dental Dressing to the standard of care for oral surgery subjects, including the use of cotton gauze and/or Gelfoam to control post operative bleeding.
3268526|NCT00707473|Experimental|Docetaxel, Cisplatin, and 5-Fluorouracil|Docetaxel 75 mg/m^2 IV on day 1 of each cycle. Cisplatin 75 mg/m^2 IV over 30-120 minutes on day 1 of each cycle. 5-Fluorouracil 750 mg/m^2 continuous infusion on days 1 through 4 of each cycle.
3268527|NCT00707460|Active Comparator|1|Please, see design section for details.
3268528|NCT00707460|Experimental|2|"Traditional Diet~Please, see design section for details."
3268529|NCT00707460|Experimental|3|"Healthy Store-bought Diet~Please, see design section for details."
3268530|NCT00707447|Placebo Comparator|1/Control|Control group received written information about diabetes risks with instructions about healthy eating and increasing physical exercise
3268531|NCT00707447|Experimental|2/PREDIAS|Intervention consists of a group programme (PREDIAS) aiming at modification of lifestyle
3268532|NCT00707434|Experimental|Glucose Monitoring Device|Continuous glucose monitoring in critically ill patients.
3268533|NCT00707421|Placebo Comparator|1|placebo, artificial tears
3268534|NCT00707421|Active Comparator|3|corticosteroid , CS
3268535|NCT00707421|Active Comparator|2|non-steroidal anti-inflammatory drug, NSAID
3268577|NCT00707083|Active Comparator|Standard- or Intermediate-Risk Maintenance Arm I|Patients receive oral mercaptopurine and oral methotrexate on days 1-56, dexamethasone IV on days 1-5 and 29-33, vincristine IV on days 1 and 29, and methotrexate IT on day 50. Treatment repeats every 8 weeks for up to 8 (girls)-11 (boys) courses.
3268536|NCT00707382|Other|Genotyping for CYP4502D6 and 2C19 polymorphisms|"In this study arm (1) the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment in accordance with the current guidelines from Sct. Hans hospital. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described in the clinical guidelines."
3268537|NCT00707382|Other|(2) Intense clinical monitoring|In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
3268538|NCT00707382|No Intervention|(3) Control|In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
3268539|NCT00707369|Experimental|test|Mechanical debridement plus 500 mg amoxicillin and 400 mg metronidazole three times daily for 7 days. Supportive periodontal therapy in 3-month intervals.
3268540|NCT00707369|Placebo Comparator|control|Mechanical debridement plus two placebo tablets three times daily for 7 days. Supportive periodontal therapy in 3-month intervals.
3268541|NCT00707356|Experimental|WST11(TOOKAD® Soluble)|Treatment with WST11-mediated VTP
3268542|NCT00707343|Experimental|All patients|All participants enrolled.
3268543|NCT00707330|Experimental|1|Subjects randomised to this arm will first be treated with Clarithromycin for a week, then have a 2-week washout, and finally one week of no treatment
3268544|NCT00707330|Active Comparator|2|Subjects randomised to this arm will first receive one week of no treatment, then have a 2-week washout, and finally be treated with Clarithromycin for a week
3268545|NCT00707317||1|HIV infected individuals
3268546|NCT00707317||2|patients with chronic renal failure
3268547|NCT00707317||3|patients after solid organ transplantation (lung, liver, kidney, kidney-pancreas)
3268548|NCT00707317||4|patients with rheumatoid arthritis
3268549|NCT00707317||5|stem cell transplant recipients
3268550|NCT00707317||6|immunocompromised patients with confirmed tuberculosis
3268551|NCT00707317||7|immunocompetent controls with no known risk of exposure or tuberculosis
3268552|NCT00707304|Experimental|1|Talactoferrin alfa (talactoferrin or TLF, also known as recombinant human lactoferrin, rhLF or talactoferrinum alfa) is a recombinant version of the glycoprotein expressed in and purified from Aspergillus niger var. awamori. Talactoferrin is structurally and functionally similar to native human lactoferrin. The structural equivalence of talactoferrin to native human lactoferrin has been demonstrated by a comparison of the 3-dimensional structure, molecular weight, biological activity and other physicochemical properties, and is known to differ only in the nature of glycosylation.
3268553|NCT00707304|Placebo Comparator|2|Placebo contains the same phosphate-based buffer used as the diluent for the talactoferrin solution. In addition, the placebo will contain FD&C/EU grade dyes suitable for oral use to mimic the color of the vialed drug product.
3268554|NCT00707278|Experimental|All patients|All participants enrolled.
3268555|NCT00707265|Experimental|Investigational|Open bilateral posterolateral implantation of the rhBMP-2/CRM/CD HORIZON® Spinal System.
3268556|NCT00707265|Active Comparator|Control|The bilateral posterolateral implantation of the autogenous bone harvested from the iliac crest with the CD HORIZON® Spinal System.
3268557|NCT00707252|Experimental|Phase I/II|Phase I: Polyphenon E + Erlotinib - Polyphenon E 200, 400 and 800 mg/day dose levels evaluated in a step-wise manner with Erlotinib 150 mg/day to establish Maximum Tolerated Dose (MTD) of Polyphenon E. Phase II consists of MTD of Polyphenon E established in Phase I, administered alone for two weeks and thereafter together with Erlotinib 150 mg/day.
3268558|NCT00707239|Experimental|A|
3268559|NCT00707239|Experimental|B|
3268560|NCT00707239|Active Comparator|C|
3268561|NCT00707226||1|15 patients with primary open angle glaucoma
3268562|NCT00707226||2|15 age matched healthy subjects
3268563|NCT00707213|Other|1|
3268564|NCT00707200||1|Cases: Severe inpatient malaria, survivors or decedents. Severe malaria consists of any one or combination of severe malarial anemia (SMA), cerebral malaria (CM), lactic acidosis (LA), or a respiratory distress syndrome with hypoxia.
3268565|NCT00707200||2|Controls: Controls consist of mildly-affected children with P falciparum malaria who are either managed as inpatients or outpatients.
3268566|NCT00707187|Experimental|1|35 doses of study medication, IC 351 (20 mg) -- crossover to placebo
3268567|NCT00707187|Experimental|2|35 placebo pills followed with 35 study medication (20 mg)
3268568|NCT00707174|Active Comparator|1|"Topical imiquimod group:~treat the LM site two centimeters beyond the perimeter margin with topical imiquimod 5% cream Monday thru Friday of each week for a total of twelve weeks. After three months of topical treatment, a one-month wash out period will be observed to allow for resolution of inflammation that can obscure the pathologist's ability to evaluate the excised tumor/treatment site."
3268569|NCT00707174|Experimental|2|"Topical imiquimod and topical tazarotene 0.1% cream group:~Patients randomized to this group will undergo an identical treatment protocol as the topical imiquimod group with the addition of topical tazarotene 0.1% cream on Saturday and Sunday of each week."
3268570|NCT00707161|Experimental|All participants|
3268571|NCT00707148|Active Comparator|Group 2: Control|16 pregnant women to receive: antepartum: saline; postpartum; Tdap vaccine.
3268572|NCT00707148|Experimental|Group 1: Intervention|32 pregnant women to receive: antepartum: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) vaccine; postpartum: saline.
3268573|NCT00707148|Active Comparator|Group 3: Control|32 non-pregnant women to receive a single dose of Tdap vaccine.
3268574|NCT00707135|Experimental|1|
3268575|NCT00707122|Other|1, Albumin and Crystalloids|Treatment
3268576|NCT00707122|Other|2, Crystalloids|Control
3268578|NCT00707083|Experimental|Standard- or Intermediate-Risk Maintenance Arm II|Patients receive oral mercaptopurine once daily on days 8-28 and 36-56; oral methotrexate once on days 8,15, 22, 36, 43, and 50; dexamethasone IV on days 1-5 and 29-33; and vincristine IV on days 1 and 29. Patients also receive methotrexate IT on day 1, every 8 weeks, for 8 courses.
3268579|NCT00707070|Experimental|1|efalizumab 1 mg/kg/week subcutaneous plus acitretin 0.4 mg/kg/day oral
3268580|NCT00707070|Placebo Comparator|2|efalizumab 1 mg/Kg/week subcutaneous plus oral placebo
3268581|NCT00707057|Experimental|Ibuprofen 600 mg ER group|One-hundred and sixty subjects will be randomly assigned to the Ibuprofen 600 mg ER treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).
3268582|NCT00707057|Placebo Comparator|Placebo group|Eighty subjects will be randomly assigned to the Placebo treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).
3268583|NCT00707044|Experimental|A|Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
3268584|NCT00707044|Active Comparator|B|control group, care as usual, 24 hours intensive care stay
3268585|NCT00707031|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3268586|NCT00707031|Active Comparator|Exenatide|1-step initiation regimen of exenatide: 5 mcg twice daily (BID) for 4 weeks, followed by 10 mcg BID up to the end of treatment.
3268587|NCT00707018|Experimental|External rotation shoulder sling|External rotation shoulder sling
3268588|NCT00707018|Active Comparator|Internal rotation shoulder sling|Internal rotation shoulder sling
3268589|NCT00706992|Experimental|Arm I - Adj-4 A2 F5 cells|Patients receive anti-MART-1 F5 TCR-transduced peripheral blood lymphocytes (PBLs) intravenously (IV) over 20-30 minutes on day 0. 1 x 10e9 to 5 x 10e10 IV.
3268590|NCT00706992|Experimental|Arm II-Adj-4 A2 F5 cells + MART-1:26-35(27L) Peptide|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I and MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 subcutaneously (SC) on days 0 and 30. 1 x 10e9 to 5 x 10e10 IV + 1.0 mg peptide subcutaneously.
3268591|NCT00706992|Experimental|Arm III-Adj-4 A2 F5 cells + SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I and aldesleukin SC on days 0-4. 1 x 10e9 to 5 x 10e10 IV + IL-2 (based on body weight) 125,000 IU/kg/day subcutaneously.
3268592|NCT00706992|Experimental|Arm IV-Adj-4 A2 F5 cells + MART-1:26-35(27L) Peptide+SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I, MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 as in arm II, and aldesleukin as in arm III. 1 x 10e9 to 5 x 10e10 IV + 1.0 mg peptide subcutaneously + IL-2 (based on body weight) 125,000 IU/kg/day subcutaneously.
3268593|NCT00706992|Experimental|Arm V-Adj-4 A2 F5 cells + ALVAC MART-1:26-35(27L) Vaccine|Patients receive anti-MART-1 F5 TCR-transduced PBLs IV over 20-30 minutes on day 0, and ALVAC-MART-1 vaccine SC on days 0 and 14. 1 x 10e9 to 5 x 10e10 IV + ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL).
3268594|NCT00706992|Experimental|Arm VI-Adj-4 A2 F5 cells + ALVAC MART-1 VAccine + SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs and ALVAC-MART-1 vaccine as in arm V, and low-dose aldesleukin SC on days 0-4. 1 x 10e9 to 5 x 10e10 IV + ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL)+ 125,000 IU/kg/day subcutaneously.
3268595|NCT00706992|Experimental|Arm VII-Adj-4 A2 ALVAC MART-1:26-35(27L) Vaccine|Patients receive ALVAC-MART-1 vaccine SC on days 0 and 14. ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL).
3268596|NCT00706979|Experimental|1|Practice Quit Attempt plus Nicotine Replacement Therapy
3268597|NCT00706979|Active Comparator|2|Practice Quit Attempt only
3268598|NCT00706966|Experimental|Dutasteride|Dutasteride was administered at a dose of 3.5 mg as an oral soft gelatin capsule once daily for 6 months
3268599|NCT00706953|Active Comparator|001|
3268600|NCT00706914|Experimental|Once-daily aclidinium/formoterol|Aclidinium bromide 200 µg/ formoterol fumarate 12 µg fixed-dose combination (FDC) once-daily in the morning, plus placebo once-daily in the evening
3268601|NCT00706914|Experimental|Morning aclidinium/formoterol plus evening formoterol|Aclidinium bromide 200 µg/formoterol fumarate 12 µg FDC once-daily in the morning, plus formoterol fumarate 12µg once-daily in the evening
3268602|NCT00706914|Active Comparator|Formoterol BID|Formoterol fumarate 12 µg twice-daily (BID)
3268603|NCT00706901|Experimental|Arm 1 GMI|Patients randomized to GMI received four structured 75-minute sessions consistent with the central principles and style of motivational interviewing (Miller & Rollnick, 2012). The goal of MI is to develop a sense of discrepancy between personal goals and current behavior and enhance change talk among participants, particularly for taking responsibility of one's substance use and being proactive for remaining in treatment.
3268604|NCT00706901|Experimental|Arm 2 IHMD|Participants randomized to In-Home-Messaging Devices (IHMD) received a 27-day Care Coordination Home Telehealth (CCHT) program targeting their acute recovery from alcohol and other substance use disorder. Participants received their IHMD device through the Charleston VAMC CCHT program, including device accessories and a phone number to reach their CCHT provider. They were provided with specific instructions on how to set up their IHMD in their residence after discharge. The research associate followed-up with the patient one day after receiving the device to ensure that the device was successfully set up and to provide assistance as necessary. Participants received standard VA CCHT services.
3268605|NCT00706901|Active Comparator|Arm 3 TCC|Participants randomized to the Treatment Control Condition (TCC) received a psycho-educational group (e.g., addiction as a chronic disease, relapse prevention, developing a plan to prevent relapse) that was delivered with the aid of sequential standardized PowerPoint presentations. Group members were encouraged to ask questions and make comments. Therapists were encouraged to conduct the sessions using an instructional quality that minimized the use of GMI strategies. TCC consisted of four sessions, lasting 75 minutes, and was conducted on four consecutive days within the course of one week.
3268606|NCT00706888|Active Comparator|1|Female with active product
3268607|NCT00706888|Active Comparator|2|Male with active product
3268608|NCT00706888|Placebo Comparator|3|Female with placebo
3268612|NCT00706862|Experimental|1|Talactoferrin, Carboplatin, Paclitaxel
3268613|NCT00706862|Placebo Comparator|2|Placebo, Carboplatin, Paclitaxel
3268614|NCT00706849|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
3268615|NCT00706849|Placebo Comparator|Placebo|Participants received a placebo subcutaneous injection once a week for 26 weeks.
3268616|NCT00706836|Active Comparator|Pregabalin 50 mg|Pregabalin oral tablets (50 mg)
3268617|NCT00706836|Active Comparator|Pregabalin 200 mg|Pregabalin oral tablets (200 mg)
3268618|NCT00706836|Placebo Comparator|Placebo|Placebo
3268619|NCT00706823|Experimental|i-gel-SGA|Patients who received i-gel supraglottic device (i-gel airway) for intubation
3268620|NCT00706823|Active Comparator|LMA-Unique|Patients who received the Laryngeal Mask Airway-Unique (uLMA) for intubation
3268621|NCT00706810|Experimental|All participants|
3268622|NCT00706797|Active Comparator|Usual care|Utilized Disease-Modifying Antirheumatic Drugs (DMARDs) from a list of the 6 most commonly prescribed in the participating countries (Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, cyclosporine A and gold).
3268623|NCT00706797|Active Comparator|ETN + MTX|Etanercept (ETN) 50 milligrams (mg) sub-cutaneous (SC) injection once weekly (pre-filled syringe) plus continuation of current dose of Methotrexate (MTX) either oral (PO), SC, or intramuscular (IM).
3268624|NCT00706784|Experimental|A|
3268625|NCT00706771|Active Comparator|Sodium bicarbonate|sodium bicarbonate: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr
3268626|NCT00706771|Active Comparator|Sodium chloride|sodium chloride: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr
3268627|NCT00706758|Active Comparator|1|Structured patients group intervention - IBS school
3268628|NCT00706758|Active Comparator|2|Written information - IBS-guidebook
3268629|NCT00706745|Placebo Comparator|placebo|The control oil is based on the general fat consumption in a Western population and consists of an equal amount (4 gr) of fat. It is a blend of palm (80%) and soybean oil (20%). Two capsules will be taken in the morning and two in the evening.
3268630|NCT00706745|Active Comparator|oil rich in cis9, trans11 CLA|Subjects will receive daily 4 g of CLA oil (2.6 g cis9,trans11-CLA), 2 capsules to be taken in the morning and 2 in the evening.
3268631|NCT00706732|Active Comparator|T1|
3268632|NCT00706732|Active Comparator|T2|
3268633|NCT00706732|Placebo Comparator|C1|
3268634|NCT00706732|Placebo Comparator|C2|
3268635|NCT00706719|Experimental|25 mg Androxal no wash out|1 capsule daily for 6 months of 25 mg of Androxal in men without a 3 month wash out period
3268636|NCT00706719|Active Comparator|Testim 1% (topical testosterone)|Testim 1% Gel applied topically for 6 months
3268637|NCT00706719|Experimental|25 mg Androxal wash out|1 x 25 mg Androxal capsule daily for 6 months in men with a previous 3 month washout period of topical testosterone
3268638|NCT00706706|Experimental|sunitinib|single agent sunitinib, single arm
3268639|NCT00706693|Active Comparator|Glucose|BD glucose tablets (TM) are taken PO in response to a hypoglycemic event by participants randomized to this arm
3268640|NCT00706693|Active Comparator|Fructose|Fruit to Go (TM) is taken PO in response to a hypoglycemic event by participants randomized to this arm
3268641|NCT00706693|Active Comparator|Sucrose|Skittles (TM) are taken PO in response to a hypoglycemic event by participants randomized to this arm
3268642|NCT00706680|Experimental|1|All subjects meeting the entry criteria will be treated with the study immunosuppressive protocol.
3268643|NCT00706667|Placebo Comparator|1|Placebo for EPO and for Ferinject ®
3268644|NCT00706667|Active Comparator|2|Only Ferinject ® , Placebo for EPO
3268645|NCT00706667|Active Comparator|3|Ferinject ® + EPO
3268646|NCT00706654|Experimental|Aripiprazole depot 300 or 400 mg|Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.
3268647|NCT00706654|Active Comparator|Aripiprazole 10-30 mg orally|Patients received aripiprazole 10-30 mg orally daily for 38 weeks.
3268648|NCT00706654|Experimental|Aripiprazole depot 25 or 50 mg|Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.
3268649|NCT00706641|Experimental|Experimental: Neoadjuvant Dasatinib + Radical Cystectomy|Dasatinib 100 mg PO qd x 4 weeks followed by radical cystectomy 8-24 hours post last administered dasatinib dose
3268650|NCT00706602||1|Swiss COPD cohort
3268651|NCT00706602||2|Dutch COPD cohort
3268652|NCT00706589|Experimental|1|Aripiprazole 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)
3268653|NCT00706589|Placebo Comparator|2|Placebo 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)
3268654|NCT00706576|Experimental|Infusion of opioid growth factor|Volunteers will be treated with an intravenous infusion of opioid growth factor(OGF) starting at 100 µg/kg with a 50 µg/kg dose escalation with each succeeding group. The investigational drug, OGF, will be diluted in sterile saline to its appropriate concentration based upon the body weight of the volunteer and administered in a volume of 60 ml over 45 minutes (rate of 2 ml/min)
3268655|NCT00706563|Experimental|Fluarix Adult Group|Subjects who are 18-40 years of age received one dose of Fluarix™.
3268656|NCT00706563|Experimental|Fluarix Elderly Group|Subjects who are ≥ 60 years of age received one dose of Fluarix™.
3268657|NCT00706550|Other|Immediate|"Arm 1 will receive PV (23-valent pneumococcal polysaccharide vaccine) prior to starting antiretroviral treatment and will receive PLACEBO after at least 6 months of starting antiretroviral treatment.~PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine"
3268658|NCT00706550|Other|Delayed|"Arm 2 will receive PLACEBO prior to starting antiretroviral treatment and will receive PV (23-valent pneumococcal polysaccharide vaccine) after at least 6 months of starting antiretroviral treatment.~PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine"
3268659|NCT00706537|Experimental|CP-945598 20 mg|
3268660|NCT00706537|Placebo Comparator|Placebo|
3268661|NCT00706511|Experimental|1|Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
3268755|NCT00705822|Experimental|1|Docetaxel + Estramustine + Hydrocortisone
3268662|NCT00706511|No Intervention|2|Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol
3268663|NCT00706485|Experimental|Dural brachytherapy plaque|Patients undergoing spine tumor resection will undergo dural plaque brachytherapy.
3268664|NCT00706459||1|Patients with lumbar back pain scheduled for back surgery.
3268665|NCT00706459||2|Patients with degenerative disease without classic discogenic back pain
3268666|NCT00706459||3|Normal control without back pain.
3268667|NCT00706459||4|Post Surgical discectomy patients
3268668|NCT00706459||5|disc specimens
3268669|NCT00706446|Experimental|1 - Tio/ICS in the Arg/Arg genotype|Tiotropium bromide 18 mcg qd plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Arg genotype
3268670|NCT00706446|Experimental|2 - Tio/ICS in the Arg/Gly genotype|Tiotropium bromide 18 mcg QD plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Gly genotype
3268671|NCT00706446|Experimental|3 - Tio/ICS in the Gly/Gly genotype|Tiotropium bromide 18 mcg QD plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Gly/Gly genotype
3268672|NCT00706446|Active Comparator|4 - LABA/ICS in the Arg/Arg genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Arg genotype
3268673|NCT00706446|Active Comparator|5 - LABA/ICS in the Arg/Gly genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Gly genotype
3268674|NCT00706446|Active Comparator|6 - LABA/ICS in the Gly/Gly genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Gly-Gly genotype
3268675|NCT00706433|Active Comparator|ALA 1000 seconds|Aminolevulinic acid HCL (ALA) applied to the entire facial area 45 minutes prior to BLUE light treatment for 1000 seconds (16 minutes and 40 seconds)
3268676|NCT00706433|Active Comparator|ALA 500 seconds|Aminolevulinic acid HCL (ALA) applied to the entire facial area 45 minutes prior to BLUE light treatment for 500 seconds (8 minutes and 20 seconds)
3268677|NCT00706433|Placebo Comparator|Vehicle 1000 seconds|Vehicle (VEH) applied to the entire facial area 45 minutes prior to BLUE light treatment for 1000 seconds (16 minutes and 40 seconds)
3268678|NCT00706433|Placebo Comparator|Vehicle 500 seconds|Vehicle (VEH) applied to the entire facial area 45 minutes prior to BLUE light treatment for 500 seconds (8 minutes 20 seconds)
3268679|NCT00706420|Experimental|1|Islet cell transplantation alone
3268680|NCT00706407|Experimental|Fully integrated Uro-NIRS:UDS|
3268681|NCT00706394|Experimental|A|Powerlink 34mm cuff stent graft
3268682|NCT00706368|Experimental|1|Participants in this group will perform self-tests for the first half of the study and will have clinical examinations for the second half of the study
3268683|NCT00706368|Experimental|2|Participants in this group will have clinical examinations for the first half of the study and will perform self-tests for the second half of the study
3268684|NCT00706355|Experimental|1|
3268685|NCT00706342|Experimental|1|
3268686|NCT00706329|Experimental|Deflux|Treatment with Deflux.
3268687|NCT00706316|Experimental|EBV-Specific CTLs and CD45 Mab|A dose escalation schema will be employed. Three to six patients will be treated at each of the following dose levels with EBV-Specific CTLs and CD45 Mab: Dose Level I: 2 x 10^7 cells/m2. Dose Level II: 5 x 10^7 cells/m2. Dose Level III: 1 x 10^8 cells/m2. Dose escalation decisions will be made after review of the data from the current dose level. There will be no intra-patient escalation. An additional 6-10 patients with measurable disease will be treated at the recommended phase II dose to expand the experience at this dose level.
3268688|NCT00706303|Active Comparator|1 Intervention group|Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
3268689|NCT00706303|No Intervention|2|Usual care. The control group will receive usual care, as decided by their GP and or hospital consultant, and the patient themselves (e.g., NHS 24 helpline). They will be asked to complete diary cards and receive telephone follow up calls as an attention control, similar to the intervention group.
3268690|NCT00706290|Experimental|Intervention - CBT|Participants randomized to the intervention group received cognitive behavioral therapy (CBT) for anxiety after completing a baseline assessment consisting of clinician administered psychiatric evaluations and a psychosocial self-report battery. After completing the CBT intervention, consisting of 6-7 sessions over the course of 2-3 months, participants completed a post-intervention assessment identical to the baseline.
3268754|NCT00705835|Experimental|2|This is an ascending, multiple dose study in up to 18 patients. As many as eight patients are planned at each of two dose levels, intrapatient dose escalation is not allowed. Eight patients will start on 250μg rsPSMA + 1.0 mg Alhydrogel Weeks 1,2,3 and 7
3268691|NCT00706290|No Intervention|Routine Care Control|Participants randomized to the control condition completed a baseline assessment consisting of clinician administered psychiatric evaluations and a psychosocial self-report battery. They then received routine medical care. After 2 months and after completing the post clinical assessment identical to the baseline, they were offered the opportunity to receive the CBT intervention for free. This ensured that all participants ultimately received cognitive-behavioral therapy if desired, while permitting an examination of the effect size for the intervention compared to routine care.
3268692|NCT00706277|Active Comparator|TIVA|patients receiving total intravenous anesthesia (TIVA)
3268693|NCT00706277|Active Comparator|balanced|patients receiving balanced anesthesia
3268694|NCT00706264|No Intervention|1|Expectant management
3268695|NCT00706264|Experimental|2|Placement of arabin pessary since 23 weeks until 37 weeks
3268696|NCT00706251||Primary|All the patients in our medical center who underwent nasolacrimal intubation, due to mild epiphora, during the years 2000-2007.
3268697|NCT00706238|Experimental|Group A|
3268698|NCT00706225|Experimental|1|Bazedoxifene and Conjugated Estrogens (BZA & CE)
3268699|NCT00706199||Group A|donors
3268700|NCT00706173|Experimental|Hydrocortisone|
3268701|NCT00706173|Placebo Comparator|Placebo|
3268702|NCT00706147|Placebo Comparator|1|
3268703|NCT00706147|Active Comparator|2|
3268704|NCT00706134|Placebo Comparator|Placebo|
3268705|NCT00706134|Experimental|Aliskiren 75 mg|
3268706|NCT00706134|Experimental|Aliskiren 150 mg|
3268707|NCT00706134|Experimental|Aliskiren 300 mg|
3268708|NCT00706121|Experimental|Vitamin E + selenium placebo|Vitamin E and selenium placebo daily for 7 - 12 years
3268709|NCT00706121|Experimental|Selenium + vitamin E placebo|Selenium and vitamin E placebo daily for 7 - 12 years
3268710|NCT00706121|Experimental|Vitamin E + selenium|Vitamin E and selenium daily for 7 - 12 years
3268711|NCT00706121|Placebo Comparator|Vitamin E placebo + selenium placebo|Vitamin E placebo and selenium placebo daily for 7 - 12 years
3268712|NCT00706108||1|Simulation of anesthesia induction with critical incidents: Analysis of technical and non-technical performance (15 Teams)
3268713|NCT00706108||2|Analysis of technical and non-technical performance in live anesthesia inductions (40 teams)
3268714|NCT00706108||3|Simulation of anesthesia inductions with advanced simulated critical incidents or events and analysis of technical and non-technical performance (max. 50 teams)
3268715|NCT00706095|Experimental|E7389 1.4 mg/m^2|
3268716|NCT00706095|Experimental|E7389 1.1 mg/m^2|
3268717|NCT00706095|Experimental|E7839 0.7 mg/m^2|
3268718|NCT00706069|Experimental|1|Vinorelbine oral plus Capecitabine
3268719|NCT00706030|Experimental|neratinib 160 mg + vinorelbine|neratinib 160 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
3268720|NCT00706030|Experimental|neratinib 240 mg + vinorelbine|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
3268721|NCT00706030|Experimental|neratinib 240 mg + vinorelbine, No Prior Lapatinib|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
3268722|NCT00706030|Experimental|neratinib 240 mg + vinorelbine, Prior Lapatinib|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
3268723|NCT00706017||A|
3268724|NCT00705978|Experimental|1|
3268725|NCT00705978|Placebo Comparator|2|
3268726|NCT00705965|Experimental|1|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
3268727|NCT00705965|Active Comparator|2|Usual cardiological care including one information session.
3268728|NCT00705952|Experimental|1|
3268729|NCT00705939|Experimental|Naive 30 Units/kg|Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
3268730|NCT00705939|Experimental|Naive 60 Units/kg|Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
3268731|NCT00705939|Experimental|Switchover|Continue taliglucerase alfa treatment from PB-06-002 (NCT00712348)
3268732|NCT00705926|Experimental|A1|Antiretroviral therapy followed by discontinuation at Week 12.
3268733|NCT00705926|Experimental|A2|Antiretroviral therapy followed by discontinuation at Week 32.
3268734|NCT00705926|Placebo Comparator|B|No treatment.
3268735|NCT00705913|Active Comparator|1|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)
3268736|NCT00705913|Active Comparator|2|
3268737|NCT00705900|Experimental|1|LCD Solution: 2 applications / day
3268738|NCT00705900|Active Comparator|2|Calcipotriol cream: 2 applications / day
3268739|NCT00705887|No Intervention|Control|Brochure from the American Academy of Dermatology on protecting your skin from UV rays.
3268740|NCT00705887|Experimental|Intervention|Participation in a brief motivational enhancement session. These participants also received the same American Academy of Dermatology brochure on protecting your skin from UV rays.
3268741|NCT00705874|Experimental|1|CGC-11047 in combination with Gemcitabine
3268742|NCT00705874|Experimental|2|CGC-11047 in combination with Docetaxel
3268743|NCT00705874|Experimental|3|CGC-11047 in combination with Bevacizumab
3268744|NCT00705874|Experimental|4|CGC-11047 in combination with Erlotinib
3268745|NCT00705874|Experimental|5|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
3268746|NCT00705874|Experimental|6|CGC-11047 in combination with 5-Flurouracil / Leucovorin
3268747|NCT00705874|Experimental|7|CGC-11047 in combination with Sunitinib
3268748|NCT00705861|Placebo Comparator|1|
3268749|NCT00705861|Experimental|2|
3268750|NCT00705848||1|10 patients with tracheobronchomalacia
3268751|NCT00705848||2|10 patients with tracheal stenosis
3268752|NCT00705848||3|10 patients with normal airways (no known airway diseases)
3268753|NCT00705835|Experimental|1|This is an ascending, multiple dose study in up to 18 patients. As many as eight patients are planned at each of two dose levels, intrapatient dose escalation is not allowed. Six patients will start on 50μg rsPSMA +0.5 mg Alhydrogel® Weeks 1,2,3 and 7.
3268756|NCT00705822|Active Comparator|2|Docetaxel + Prednisone
3268757|NCT00705796|Experimental|Group 1|Group 1 will be treated with MPP10, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
3268758|NCT00705796|Active Comparator|Group 2|Group 2 will be treated with AndroGel® 50 mg, once daily in the morning after washing/showering.
3268759|NCT00705783|Experimental|Aripiprazole depot|Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.
3268760|NCT00705783|Placebo Comparator|Placebo depot|Patients received placebo intramuscularly every 28 days for 52 weeks.
3268761|NCT00705770|Placebo Comparator|1|Placebo treatment with vehicle
3268762|NCT00705770|Experimental|2|Low dose of study medication
3268763|NCT00705770|Experimental|3|Middle dose of study medication
3268764|NCT00705770|Experimental|4|High dose of study medication
3268765|NCT00705757|Active Comparator|Lumigan|Patients assigned to Lumigan/bimatoprost one drop before bedtime (qhs) to affected eye(s)
3268766|NCT00705757|Active Comparator|Xalatan|Patients assigned to Xalatan/latanoprost one drop before bedtime (qhs) to affected eye(s)
3268767|NCT00705757|Active Comparator|Travatan|Patients assigned to Travatan/travoprost one drop before bedtime (qhs) to affected eye(s)
3268768|NCT00705744|Experimental|I|
3268769|NCT00705718|Experimental|Endurant Bifurcated arm|The Bifurcated arm includes subjects who have received a bifurcated device. The Endurant Stent Graft System Bifurcated device is administered to treat patients with an Abdominal Aortic Aneurysm.
3268770|NCT00705718|Experimental|Endurant AUI arm|The AUI arm includes subjects who have received an AUI device. The Endurant Stent Graft System AUI device is administered to treat patients with an Abdominal Aortic Aneurysm.
3268771|NCT00705705|Experimental|1|Participating social networks will receive standard HIV risk-reduction counseling and network leadership training on HIV prevention.
3268772|NCT00705705|Active Comparator|2|Participating social networks will receive standard HIV risk-reduction counseling.
3268773|NCT00705692|Experimental|Levamisole|Two 50 mg levamisole tablets daily, six days before and six days after Td vaccination.
3268774|NCT00705692|Placebo Comparator|Placebo|Two placebo tablets daily, six days before and six days after Td vaccination.
3268775|NCT00705679|Experimental|1|TDF 300 mg tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
3268776|NCT00705679|Experimental|2|TDF placebo tablet taken orally once daily and one FTC 200 mg/TDF 300 mg tablet taken orally once daily for 12 to 36 months
3268777|NCT00705679|Experimental|3|TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
3268778|NCT00705679|Experimental|4|Application of tenofovir 1% vaginal gel once daily
3268779|NCT00705679|Experimental|5|Application of tenofovir placebo gel once daily
3268780|NCT00705666||PegIntron as monotherapy or in combination with Ribavirin.|Adult participants with chronic hepatitis C treated with PegIntron as monotherapy or in combination with ribavirin.
3268781|NCT00705653|Experimental|PG-11047|
3268782|NCT00705640|Experimental|Arm 1A|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
3268783|NCT00705640|Experimental|Arm 1B|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
3268784|NCT00705640|Experimental|Arm 1C|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
3268785|NCT00705640|Experimental|Arm 1D|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
3268786|NCT00705640|Experimental|Arm 1E|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (6 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
3268787|NCT00705640|Experimental|Arm 2A|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
3268788|NCT00705640|Experimental|Arm 2B|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
3268789|NCT00705640|Experimental|Arm 2C|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
3268790|NCT00705640|Experimental|Arm 2D|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
3268939|NCT00704665|Experimental|A|10ug/kg/day or 25/ug/kg/day
3268791|NCT00705640|Experimental|Arm 2E|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
3268792|NCT00705627|Experimental|B|Drug: cisplatin. Patients in the control arm received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
3268793|NCT00705614||Remicade Group|Particpiants with no prior exposure to Remicade, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who start on Remicade will constitute the Remicade Group, regardless of whether they continue with Remicade or switch to another treatment.
3268794|NCT00705614||Standard Therapy Group|Participants who are being treated with standard therapy and are not adequately maintained and will be offered an alternative treatment that does not include Remicade. Standard therapy participants must not have previously received Remicade.
3268795|NCT00705614||Switched to Remicade Group|Participants who started in the Standard Therapy Group but switched over to Remicade sometime during the follow-up period. Participants who switch to Remicade are evaluated in the Standard Therapy group until the time of the switch and are evaluated in the Switched to Remicade group thereafter.
3268796|NCT00705601|Other|1|
3268797|NCT00705588|Experimental|1|Patients treated with epoprostenol (Flolan) will be given tadalafil (Cialis).
3268798|NCT00705588|Experimental|2|Patients receiving iloprost (Ventavis) will receive vardenafil (Levitra)
3268799|NCT00705575|Experimental|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|
3268800|NCT00705575|Active Comparator|Aliskiren (300 mg)|
3268801|NCT00705562|Experimental|1|Experimental milk protein based infant formula with varying carbohydrate and protein source
3268802|NCT00705562|Experimental|2|Experimental milk protein based infant formula with varying carbohydrate and protein source
3268803|NCT00705562|Experimental|3|Experimental milk protein based infant formula with varying carbohydrate and protein source
3268804|NCT00705562|Experimental|4|Experimental milk protein based infant formula with varying carbohydrate and protein source
3268805|NCT00705562|Experimental|5|Experimental milk protein based infant formula with varying carbohydrate and protein source
3268806|NCT00705549|Experimental|1|Gemzar/Cisplatin
3268807|NCT00705549|Experimental|2|Taxotere/Cisplatin
3268808|NCT00705549|Experimental|3|Cisplatin/Navelbine metronomic
3268809|NCT00705549|Experimental|4|Taxotere/Gemzar
3268810|NCT00705549|Experimental|5|Gemzar
3268811|NCT00705549|Experimental|6|Taxotere
3268812|NCT00705549|Experimental|7|Navelbine metronomic
3268813|NCT00705549|Experimental|8|Alimta/Cisplatin
3268814|NCT00705549|Experimental|9|Alimta/Gemzar
3268815|NCT00705549|Experimental|10|Taxotere
3268816|NCT00705549|Experimental|11|Alimta
3268817|NCT00705536|Active Comparator|Humalog first, then Humalog + rHuPH20|"Humalog first, then Humalog + recombinant human hyaluronidase PH20 (rHuPH20)~A single subcutaneous (SC) injection of 20 units (U) Humalog on Day 1 of the study, followed by a single SC injection of 20 U Humalog + 300 U rHuPH20 after a washout period of at least 6 days"
3268818|NCT00705536|Active Comparator|Humalog + rHuPH20 first, then Humalog|"Humalog + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humalog~A single subcutaneous (SC) injection of 20 units (U) Humalog + 300 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humalog after a washout period of at least 6 days"
3268819|NCT00705536|Active Comparator|Humulin-R first, then Humulin-R + rHuPH20|"Humulin-R (recombinant human insulin) first, then Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20)~A single subcutaneous (SC) injection of 20 units (U) Humulin-R on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R + 240 U rHuPH20 after a washout period of at least 6 days"
3268820|NCT00705536|Active Comparator|Humulin-R + rHuPH20 first, then Humulin-R|"Humulin-R (recombinant human insulin) + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humulin-R~A single subcutaneous (SC) injection of 20 units (U) Humulin-R + 240 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R after a washout period of at least 6 days"
3268821|NCT00705523|Active Comparator|1|
3268822|NCT00705523|Placebo Comparator|2|
3268823|NCT00705510|Active Comparator|A|
3268824|NCT00705510|Placebo Comparator|B|
3268825|NCT00705497|Experimental|1|
3268826|NCT00705484||Remicade Group|Participants with no prior exposure to Remicade or who have been treated with Remicade in the past, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who have been treated in the past with Remicade must have a Remicade-free interval of no less than 90 days from the date of the next expected infusion.
3268827|NCT00705484||Standard Therapy Group|Participants who are scheduled to receive standard therapy (defined as initiation or dose-increase of corticosteroids and/or immunosuppressants) that does not include Remicade. Standard therapy participants must not have previously received Remicade for UC or any other condition.
3268828|NCT00705471||Infliximab|Because of the difficulty of finding subjects with exactly the same disease severity, information will be recorded for the time period for up to three years before and for one year after their initial infliximab infusion for comparison of health care costs and utilization prior to infliximab and post infliximab use.
3268829|NCT00705458|Experimental|CTA|Initial EKG-gated computed tomography angiography of the coronary arteries
3268830|NCT00705458|Active Comparator|MPI|Initial nuclear stress myocardial perfusion imaging
3268831|NCT00705445|Active Comparator|A|This group will not receive any of the intervention supplements. The group will only receive nutritional counselling and education, and treatment provided for any encountered illness according to IMCI guidelines.
3268832|NCT00705445|Experimental|B|"This group will receive micronutrient supplements containing microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid.~This group will also receive Nutritional Counselling and Education and treatment according to IMCI Guidelines for any serious illness."
3268940|NCT00704652||A|Diabetic patients suffering from renal insufficiency with stable haemoglobin levels (receiving no EPO supplementation)
3269330|NCT00701883|Active Comparator|Placebo/Atorvastatin 20 mg|
3268833|NCT00705445|Experimental|C|"This group will receive Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, Folic Acid, and Zinc.~This group will also receive nutritional counselling, education and treatment according to IMCI Guidelines in case of any untoward illness."
3268834|NCT00705432|Placebo Comparator|1. Placebo + PEG + RBV|PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks (lead in treatment) followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
3268835|NCT00705432|Experimental|2. Boceprevir + PEG + RBV - 24 Weeks (RGT)|"PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.~At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable from Treatment Weeks 8 to Treatment Week 24, will proceed to the 44-week follow-up.~At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up."
3268836|NCT00705432|Experimental|3. Boceprevir + PEG + RBV - 44 Weeks|PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
3268837|NCT00705419||Previous vicriviroc 30 mg QD|Subjects who previously received vicriviroc 30 mg daily in a Phase 2 or 3 clinical trial.
3268838|NCT00705419||Previous vicriviroc 20 mg QD|Subjects who previously received vicriviroc 20 mg daily in a Phase 2 or 3 clinical trial.
3268839|NCT00705419||Control Group|Subjects who previously received active control or placebo in a Phase 2 or 3 clinical trial involving vicriviroc.
3268840|NCT00705406|Experimental|Peramivir 600 mg|600 mg peramivir administered as bilateral 2-mL intramuscular injection.
3268841|NCT00705406|Placebo Comparator|Placebo|Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
3268842|NCT00705380|Experimental|1|Participants will receive cognitive behavioral therapy with panic control treatment.
3268843|NCT00705380|Active Comparator|2|Participants will receive cognitive behavioral therapy with panic control treatment after a 12-week waitlist period.
3268844|NCT00705367|Placebo Comparator|Placebo|
3268845|NCT00705367|Active Comparator|Abatacept, 30 mg/kg|
3268846|NCT00705367|Other|Abatacept, 10 mg/kg|Open-label long-term extension phase
3268847|NCT00705354|Active Comparator|1|Control group undergoing standard ESS will have a saline soaked Nasopore sponge placed during surgery and will receive routine oral antibiotics post-operatively
3268848|NCT00705354|Experimental|2|Treatment group undergoing ESS will have Nasopore sponge soaked with Bacitracin, but will not receive oral antibiotics post-operatively
3268849|NCT00705341|Active Comparator|Low dose fluticasone for phase 2|For people with asthma, fluticasone at 250 mcg per day; phase 2 of study
3268850|NCT00705341|Active Comparator|High dose fluticasone for phase 2|For people with asthma, fluticasone at 1000 mcg per day; phase 2 of study
3268851|NCT00705341|No Intervention|Nonasthmatic controls for phase 1|People without asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study
3268852|NCT00705341|No Intervention|Asthmatic controls for phase 1|People with asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study
3268853|NCT00705328|Experimental|1|
3268854|NCT00705328|Experimental|2|
3268855|NCT00705328|Experimental|3|
3268856|NCT00705315|Experimental|1|Bevacizumab->Epirubicin->Docetaxel
3268857|NCT00705302|Experimental|patient education including self-help|Patients in the arm will participate in a three months patient education and exercise program including a self-help group in 3 months of time.
3268858|NCT00705302|Active Comparator|patient education|Patients in arm 2 will participate in the same patient education and exercise program as arm 1, but without an additional self-help group.
3268859|NCT00705289||RA Subjects/ Infliximab 3 mg/kg|Subjects with rheumatoid arthritis (RA) in whom treatment with infliximab is started for the first time, in line with current clinical practice (and thus consistent with the European Summary of Product Characteristics [SPC] of Remicade®).
3268860|NCT00705276|Experimental|I|
3268861|NCT00705263||Patients with chronic hepatitis C|Patients with chronic hepatitis C who are treated with the PegIntron pen plus Rebetol will answer questions on the patient questionnaire.
3268862|NCT00705250|Experimental|1|bendamustine hcl 120mg/m^2
3268863|NCT00705224||Patients with chronic hepatitis C|Naïve patients with chronic hepatitis C (CHC) of any genotype will be treated with a standard treatment regimen (pegylated interferon and ribavirin) according to routine clinical practice in Russia.
3268864|NCT00705211||Zetia monotherapy|Patients to be treated with Zetia alone (10-mg tablets,) for hypercholesterolemia
3268865|NCT00705211||Zetia combination therapy|Patients to be treated with Zetia (10-mg tablets,) in combination with other lipid-lowering drugs for hypercholesterolemia
3268866|NCT00705198||Newly diagnosed patients|Patients treated with temozolomide for newly diagnosed malignant glioma
3268867|NCT00705198||Relapsed patients|Patients treated with temozolomide for relapsed malignant glioma
3268868|NCT00705198||Newly diagnosed anaplastic astrocytoma patients|Patients treated with temozolomide for newly diagnosed anaplastic astrocytoma
3268869|NCT00705185||1|Adults with Major Depressive Disorder- as defined by the criteria in the DSM-IV
3268870|NCT00705185||2|Healthy Controls- research subjects who have not met criteria for any lifetime Axis-I disorder (DSM-IV)
3268871|NCT00705172||A|
3268872|NCT00705159|Experimental|Loteprednol etabonate and tobramycin|Drug: Zylet (loteprednol etabonate and tobramycin)
3268873|NCT00705159|Active Comparator|Loteprednol etabonate|Drug: Lotemax (loteprednol etabonate)
3268874|NCT00705159|Active Comparator|Tobramycin|Drug: Tobramycin
3268875|NCT00705159|Placebo Comparator|Vehicle|Vehicle of Zylet
3268876|NCT00705146|Active Comparator|Comfort Cool Splint|Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks.
3269031|NCT00703924|Experimental|WR 279,396|WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin
3268877|NCT00705146|Active Comparator|Hybrid Custom-made splint|The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks.
3268878|NCT00705133|Experimental|Treprostinil-treated|Patients with pulmonary fibrosis with an advanced pulmonary hypertension phenotype will be treated with parenteral treprostinil in an open-label fashion
3268879|NCT00705120|Other|1|
3268880|NCT00705120|Other|2|
3268881|NCT00705107||All Treated Patients|All patients participating in the study
3268882|NCT00705094||1|Testicular cancer patients who have received surgery and are scheduled for surveillance
3268883|NCT00705094||2|Testicular cancer patients who have received surgery and are scheduled for chemotherapy
3268884|NCT00705081||Not previously treated|subjects with hypercholesterolemia, who had never been treated with any cholesterol-lowering agent, and received the combination of ezetimibe 10 mg and a statin as initiation therapy
3268885|NCT00705081||Previously treated with statin|subjects with hypercholesterolemia, who were previously treated with a statin, and received ezetimibe 10 mg as add-on therapy
3268886|NCT00705055||1|Normal Males
3268887|NCT00705055||2|Normal Females
3268888|NCT00705055||3|Abnormal Males
3268889|NCT00705055||4|Abnormal Females
3268890|NCT00705042|Experimental|A|25 mg
3268891|NCT00705042|Experimental|B|50 mg
3268892|NCT00705016|Experimental|Cilengitide 2000 mg once weekly+Cetuximab+5-FU+Cisplatin|
3268893|NCT00705016|Experimental|Cilengitide 2000 mg twice weekly+Cetuximab+5-FU+Cisplatin|
3268894|NCT00705016|Active Comparator|Cetuximab+5-FU+Cisplatin|
3268895|NCT00705003|Experimental|Active Drug Combination|BCI-024: over-encapsulated Buspirone tablet 15 mg at bedtime(QD) and BCI-049: over-encapsulated Melatonin tablet 3 mg QD
3268896|NCT00705003|Active Comparator|BCI-024 (Buspirone)|BCI-024: over-encapsulated Buspirone 15 mg QD
3268897|NCT00705003|Placebo Comparator|Matching placebo|Placebo: 1 capsule QD
3268898|NCT00704990|Experimental|A|All study participants take part in the experimental arm
3268899|NCT00704977|Active Comparator|1|Pterygium surgery using alcohol 20% + wound closure by bare sclera technique
3268900|NCT00704977|Active Comparator|2|"Alcohol 20% for pterygium separation + wound closure by sliding flap technique.~The main steps of surgery are described below.Wound closure technique is as follows.~Disection of conjunctiva adjascent to the wound, bringing the dissected conjunctiva to the wound area and suturing by vicril 6/0 sutures"
3268901|NCT00704977|Active Comparator|3|"Alcohol 20 % for pterygium separation + using amniotic membrane and biological glue for wound closure.~The steps of surgery are as described below, wound closure technique is as follows.~Amniotic membrane is applied with its mesenchimal side to conjunctiva and glued by biological glue (main ingradients: calcium and thrombin)"
3268902|NCT00704964||All participants|Each site will be evaluated by a site questionnaire and assigned as either a high or low participant management site. Participants are not randomized to a group. However, treatment completion rates will be evaluated based on the high vs low participant management sites.
3268903|NCT00704951||Patients|Immunosuppressed/Immunocompromised patients at high risk for invasive fungal infections
3268904|NCT00704938|Experimental|anti-p53 TCR PBL + DC + IL-2: Melanoma/RCC|Patients with melanoma and renal cell cancer will receive anti-p53 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + dendritic cells (DC) + interleukin-2 (IL-2)
3268905|NCT00704938|Experimental|anti-p53 TCR PBL + DC + IL-2: Other histology|Patients with other histologies, such as breast cancer, will receive anti-p53 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + dendritic cells (DC) + interleukin-2 (IL-2)
3268906|NCT00704912|Active Comparator|Lifestyle intervention|Orlistat/Meal Replacement/Lifestyle Modification
3268907|NCT00704912|Active Comparator|Oral Contraceptives (OCP)|Loestrin 1/20
3268908|NCT00704912|Active Comparator|Lifestyle/OCP Combined|Combination of treatments
3268909|NCT00704899|Experimental|2|anti-depressants
3268910|NCT00704899|Experimental|1|physiotherapy
3268911|NCT00704886|No Intervention|1|verbal
3268912|NCT00704886|Experimental|2|video
3268913|NCT00704860|Experimental|TR|TR- Subjects defined as having treatment resistant depression, who have failed at least 2 adequate trials of an antidepressant. Subjects will be treated in an open label trial for their depression, with the goal of sustained remission.
3268914|NCT00704847|Active Comparator|1|SMC021 Oral Calcitonin
3268915|NCT00704847|Placebo Comparator|2|SMC021 Placebo
3268916|NCT00704834||1|Normal Controls
3268917|NCT00704834||2|Patients with a clinically isolated syndrome (CIS)
3268918|NCT00704834||3|Patients with relapsing, remitting Multiple Sclerosis (RRMS) who are not on treatment
3268919|NCT00704834||4|Patients with Chronic Progressive Multiple Sclerosis who are not on treatment
3268920|NCT00704821|Experimental|1|PTC299
3268921|NCT00704808||Patients|Patients with newly diagnosed and operated glioblastoma multiforme.
3268922|NCT00704795||1|Patients with type 1 diabetes mellitus
3268923|NCT00704795||2|Healthy control subjects matched for body mass index (BMI), age and gender.
3268924|NCT00704782|Experimental|Dimebon|20 mg by mouth 3 times a day
3268925|NCT00704769||1|Children with a history of perennial allergic rhinitis
3268926|NCT00704756||Arm 1|Patients with chronic hepatitis C treated with PegIntron and Rebetol in clinical practice in Belgium.
3268927|NCT00704743|Active Comparator|1|Cylindrical cast
3268928|NCT00704743|Active Comparator|2|Modified sugar tong cast
3268929|NCT00704743|Active Comparator|3|Volar dorsal splint
3268930|NCT00704730|Experimental|1|
3268931|NCT00704730|Placebo Comparator|2|
3268932|NCT00704717||All Treated Patients|All patients participating in the study.
3268933|NCT00704691|Experimental|Lenalidomide|
3268934|NCT00704678|Experimental|1|1g bid
3268935|NCT00704678|Active Comparator|2|0.8 g tid
3268936|NCT00704678|Experimental|3|1.5 g tid
3268937|NCT00704678|Active Comparator|4|1.6 g tid
3268938|NCT00704665|Placebo Comparator|2|Placebo
3268941|NCT00704652||B|Diabetic patients with renal insufficiency and in need of recombinant human EPO (darbepoetin alfa) substitution because of inadequate erythropoiesis. In both groups the target haemoglobin level is 10-12 gHb/ml, all treatment is performed according to label.
3268942|NCT00704639|Experimental|Single arm|Chemoradiation (Cetuximab, Carboplatin and Radiotherapy)
3268943|NCT00704626||Cohort 1|Subjects with multiple sclerosis and other autoimmune and inflammatory disease of the nervous system
3268944|NCT00704600|Experimental|nelfinavir|see intervention
3268945|NCT00704574||A|
3268946|NCT00704561|Active Comparator|DES|Zotarolimus drug-eluting stent
3268947|NCT00704561|Active Comparator|BMS|bare metal stent
3268948|NCT00704548|Active Comparator|1|Simvastatin 40 mg
3268949|NCT00704548|Placebo Comparator|2|
3268950|NCT00704535||Subjects with hypercholesterolemia|Subjects with hypercholesterolemia that are using Ezetimibe either alone or in combination with a statin
3268951|NCT00704522||Patients with hepatitis C|Patients receiving a patient assistance program during therapy for hepatitis C at sites in Austria.
3268952|NCT00704509|Experimental|Bifeprunox|
3268953|NCT00704509|Placebo Comparator|Placebo|
3268954|NCT00704509|Active Comparator|Quetiapine|
3268955|NCT00704496|Placebo Comparator|Placebo|Placebo
3268956|NCT00704496|Active Comparator|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
3268957|NCT00704483|Experimental|1|1g tid
3268958|NCT00704483|Active Comparator|2|Sevelamer HCl
3268959|NCT00704483|Experimental|3|SBR759 1.5 g tid
3268960|NCT00704483|Active Comparator|4|Sevelamer HCl
3268961|NCT00704470|Active Comparator|1|Classic one-day simulator training for intensivists.
3268962|NCT00704470|Experimental|2|Crew resource management training
3268963|NCT00704457||A|One arm study. Urine collection.
3268964|NCT00704444||Zetia monotherapy|Patients to be treated with Zetia alone (10-mg tablets,) for hypercholesterolemia
3268965|NCT00704444||Zetia combination therapy|Patients to be treated with Zetia (10-mg tablets,) in combination with other lipid-lowering drugs for hypercholesterolemia
3268966|NCT00704431|Experimental|darapladib|darapladib
3268967|NCT00704418|Experimental|Bromfenac|Bromfenac ophthalmic solution 0.09%, dosed 1 drop daily
3268968|NCT00704418|Placebo Comparator|Placebo|Placebo, dosed 1 drop daily
3268969|NCT00704405|Experimental|24-wk Vaniprevir 600 mg + Peg-IFN/RBV|Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 24 weeks.
3268970|NCT00704405|Experimental|24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV|Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for an additional 24 weeks.
3268971|NCT00704405|Experimental|48-wk Vaniprevir 300 mg + Peg-IFN/RBV|Vaniprevir 300 mg (total daily dose, taken once daily [q.d.]) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
3268972|NCT00704405|Experimental|48-wk Vaniprevir 600 mg + Peg-IFN/RBV|Vaniprevir 600 mg and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
3268973|NCT00704405|Placebo Comparator|48-wk PBO + Peg-IFN/RBV|PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
3268974|NCT00704392|Experimental|1|
3268975|NCT00704379|Placebo Comparator|Placebo|Placebo will be given in a double blind fashion via an equal number of tablets (identical to the sertraline tablets) administered once daily.
3268976|NCT00704379|Experimental|Sertraline|Sertraline will be given in a double blind fashion via tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention.
3268977|NCT00704366|Experimental|1|AZD0530
3268978|NCT00704353|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
3268979|NCT00704353|Active Comparator|Standard Medical Care|Per product label
3268980|NCT00704340|Experimental|1|"DuraSeal Dural Sealant System - FDA Approved Device:~The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel."
3268981|NCT00704340|Active Comparator|2|"Standard of Care (control):~Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator."
3268982|NCT00704314|Active Comparator|1|Simvastatin therapy, 80 mg/d for 8 weeks
3268983|NCT00704314|Placebo Comparator|2|Placebo, one pill daily for 8 weeks
3268984|NCT00704301|Experimental|1|Haloperidol: aged 70 years or less: 1 mg haloperidol three times a day i.v. older than 70 years: 0,5 mg haloperidol three times a day i.v. Rivastigmine: two times 1,5 mg a day; The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
3268985|NCT00704301|Placebo Comparator|2|Haloperidol: aged 70 years or less: 1 mg haloperidol three times a day i.v. older than 70 years: 0,5 mg haloperidol three times a day i.v. Placebo: 2 times a day
3268986|NCT00704288|Experimental|1|
3268987|NCT00704275|Experimental|A|0.05% cyclosporin
3268988|NCT00704275|Active Comparator|B|Refresh
3268989|NCT00704262|Experimental|Calcipotriol plus hydrocortisone (LEO 80190)|
3268990|NCT00704249|Experimental|1|Full-dose nevirapine from baseline (200 mg bid).
3268991|NCT00704249|Active Comparator|2|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
3268992|NCT00704236|Experimental|A|
3268993|NCT00704236|Placebo Comparator|B|
3268994|NCT00704223||A|
3269331|NCT00701883|Experimental|MBX-8025 50 mg/Atorvastatin 20 mg|
3268995|NCT00704210|Sham Comparator|B|Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
3268996|NCT00704210|Experimental|A|For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.
3268997|NCT00704184|Placebo Comparator|Placebo + Peg-IFN/Ribavirin|Participants took double-blind Placebo + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
3268998|NCT00704184|Experimental|Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 300 mg twice daily (b.i.d.) + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
3268999|NCT00704184|Experimental|Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
3269000|NCT00704184|Experimental|Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
3269001|NCT00704184|Experimental|Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
3269002|NCT00704171|Experimental|PleuraSeal|PleuraSeal Lung Sealant System
3269003|NCT00704171|Active Comparator|Standard of Care|Standard tissue closure techniques (control) - sutures or staples only
3269004|NCT00704145|Experimental|A|Device, paclitaxel drug-eluting stent
3269005|NCT00704132|Experimental|sitagliptin|Participants randomized to this arm will be administered sitagliptin 100mg daily, for six weeks.
3269006|NCT00704132|Placebo Comparator|Placebo|Participants randomized to this arm will be administered matching placebo, daily for six weeks.
3269007|NCT00704106||Group 1|Persistent viremia after 48 weeks or longer.
3269008|NCT00704106||Group 2|<2 log IU/mL drop from initial HBVDNA after 12 weeks of adefovir
3269009|NCT00704106||Group 3|Patients who responded to adefovir and were switched to entecavir.
3269010|NCT00704106||Group 4|Patients with 160 copies/mL (100 IU/mL) or higher at the time of medication switch.
3269011|NCT00704080|Experimental|1|
3269012|NCT00704067|Experimental|1|Supported employment for 12 months plus cognitive training for the first 12 weeks
3269013|NCT00704067|Active Comparator|2|Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks
3269014|NCT00704054|Experimental|1|Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
3269015|NCT00704028|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
3269016|NCT00704028|Active Comparator|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
3269017|NCT00704015|Experimental|A|Smoking cessation
3269018|NCT00704015|No Intervention|B|
3269019|NCT00704002|Experimental|A|antegrade intramedullary splinting
3269020|NCT00704002|Active Comparator|B|conservative treatment
3269021|NCT00703989|Experimental|I|Patients with Type 1 diabetes
3269022|NCT00703989|No Intervention|II|Age-matched male subjects without Type 1 diabetes
3269023|NCT00703976|Active Comparator|Cetuximab, Pemetrexed and Radiation therapy|"Cetuximab, Pemetrexed and Radiation therapy Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.~Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.~Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks"
3269024|NCT00703976|Experimental|Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab|"Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.~Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.~Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks Bevacizumab: Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy."
3269025|NCT00703963|Active Comparator|Usual Care|Subjects will be having their INR tested by their Primary Care Provider as often as their Care Provider dictates. This study phase is twelve weeks long beginning at the day of discharge from our hospital.
3269026|NCT00703963|Active Comparator|Patient Self Testing|Subjects will be testing their INR at home using an FDA approved device (INRatio monitor by Hemosense) reporting their results to Quality Assured Services (QAS) via an 800 phone number; their Primary Care Provider will receive a fax with the INR result. We ask this group of patients to test at minimum one time a week, additional testing as requested by their Primary Care Provider. This phase lasts twelve weeks, beginning on the day of discharge from our hospital.
3269027|NCT00703950|Experimental|A,1|Cup feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
3269028|NCT00703950|Active Comparator|A,2|bottle feeding - conventional method Bottle feeding is the conventional method to feed preterm infant before breastfeeding or to substitute breastfeeding. We are using this method in the control group.
3269029|NCT00703937|Experimental|Ferric Carboxymaltose (FCM)|750 mg of iron as undiluted FCM (15 mg/kg up to a maximum of 750 mg) at 100 mg per minute weekly until the calculated iron deficit dose has been administered (to a maximum cumulative dose of 2,250 mg).
3269030|NCT00703937|Active Comparator|Standard Medical Care (SMC) for the treatment of IDA|SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA).
3269032|NCT00703924|Placebo Comparator|Placebo|Topical cream vehicle containing all of the components in WR 279,396 except the active ingredients.
3269033|NCT00703911||activated recombinant human factor VII|Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds
3269034|NCT00703885|Active Comparator|1|"0.25 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan.~One-time, single dose.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
3269035|NCT00703885|Active Comparator|2|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~One-time, single dose.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
3269036|NCT00703885|Placebo Comparator|Placebo|"Inactive ingredient in liquid matching appearance and volume of the two active alprazolam dose comparators.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
3269037|NCT00703872|Experimental|1|Oral HDV-Interferon
3269038|NCT00703872|Experimental|2|Injectable HDV-Interferon + ribavarin
3269039|NCT00703846|Other|KETOCONAZOLE|
3269040|NCT00703833|Experimental|1|Drug
3269041|NCT00703833|Placebo Comparator|2|Placebo
3269042|NCT00703820|Active Comparator|ADE|"Cytarabine + Daunorubicin + Etoposide~NK cells for infusion are prepared using the CliniMACS System."
3269043|NCT00703820|Active Comparator|Clo/AraC|"Clofarabine + Cytarabine~NK cells for infusion are prepared using the CliniMACS System."
3269044|NCT00703807|Experimental|1|Daily oral RAD001 for 21 days in combination with oral topotecan on days 1-5 of a 21 day cycle
3269045|NCT00703794||AXIUM Coils|
3269046|NCT00703781|Experimental|Bromfenac|Bromfenac Ophthalmic Solution 0.09%, Dosed 1 Drop Daily
3269047|NCT00703781|Placebo Comparator|Placebo|Placebo, Dosed 1 Drop Daily
3269048|NCT00703768||A|Patients who have been identified as having a doubling in PSA from nadir of greater than one year
3269049|NCT00703768||B|Patients who have been identified as having a doubling in PSA from nadir of less than one year.
3269050|NCT00703755|Experimental|1|
3269051|NCT00703755|Experimental|2|
3269052|NCT00703755|Experimental|3|
3269053|NCT00703755|Experimental|4|
3269054|NCT00703755|Experimental|5|
3269055|NCT00703755|Experimental|6|
3269056|NCT00703755|Placebo Comparator|7|
3269057|NCT00703742|Experimental|A,1|A: Escitalopram, 20 mg/day,8weeks
3269058|NCT00703729|Experimental|Cold Compression (CC)|The Game Ready device provides both active, continuous cold and intermittent, pneumatic compression to the post-op shoulder. The first group will use the Game Ready™ Device (CC) for one week following surgery and will use standard ice bags wrapped to the shoulder (IW) for the remainder of the study period.
3269059|NCT00703729|Active Comparator|Ice Wrap (IW)|The ice bag (IW)is secured to the shoulder using an elastic wrap. The second group will use standard ice bags wrapped to the shoulder (IW) for one week following surgery and will use the Game Ready™ Device (CC) for the remainder of the study period
3269060|NCT00703703|Experimental|1|Darifenacin
3269061|NCT00703703|Active Comparator|2|Tolterodine
3269062|NCT00703703|Placebo Comparator|3|Placebo
3269063|NCT00703690|Experimental|1|MK0767; 2.5 mg/day
3269064|NCT00703690|Experimental|2|MK0767; 5mg/day
3269065|NCT00703690|Experimental|3|MK0767; 10 mg/day
3269066|NCT00703690|Active Comparator|4|fenofibrate 200 mg
3269067|NCT00703690|Placebo Comparator|5|Matching Placebo
3269068|NCT00703677|Other|1|All participants will receive lithium. The dosage will be titrated over a 5-week period. Participants will then be followed prospectively for 6 months. Participants will be evaluated at the screening visit, baseline visit, and weeks 2 and 5 during the titration phase. Clinic study visits will then occur on alternate months through week 28. Telephone visits will occur between clinic study visits.
3269069|NCT00703664|Experimental|Treatment (vorinostat, bortezomib)|"Participants receive vorinostat orally (PO) once daily (QD) on days 1-5 and 8-12. Participants also receive bortezomib intravenously (IV) over 3-5 seconds on days 1, 4, 8, and 11. Vorinostat precedes bortezomib on days of concurrent administration. Courses repeat every 3 weeks in the absence of disease progression - or unacceptable toxicity. After completion of study therapy, participants are followed periodically.~Treatment arm consists of 3 cohorts, all receiving the same treatment:~A: Mantle Cell Lymphoma (MCL) - with no prior bortezomib.~B: Mantle Cell Lymphoma (MCL) - with no prior bortezomib.~C: Diffuse Large B-Cell Lymphoma (DLBCL) - with no prior bortezomib."
3269070|NCT00703651|Experimental|1|
3269071|NCT00703651|Experimental|2|
3269072|NCT00703651|Active Comparator|3|
3269073|NCT00703638|Experimental|Sorafenib/Pemetrexed/Cisplatin|Patients receiving a dose escalation scheme of daily oral sorafenib (200 mg or 400 mg bid) when given in combination with fixed dose intravenous pemetrexed and cisplatin for the treatment of solid tumors.
3269074|NCT00703625|Experimental|Cohort 1|"Temsirolimus IV 15 mg weekly~Docetaxel 60 mg/m2 IV once every three weeks."
3269075|NCT00703625|Experimental|Cohort 2|"Temsirolimus IV 25 mg weekly~Docetaxel IV 60 mg/m2 once every 3 weeks"
3269076|NCT00703625|Experimental|Cohort 1A|"Temsirolimus IV 15 mg weekly~Docetaxel IV 50 mg/m2 every 3 weeks."
3269077|NCT00703612|Experimental|Treatment Group|This is the only arm and that is the treatment group.
3269078|NCT00703599|Experimental|1|This is the only arm and that is the treatment group.
3269079|NCT00703586|Experimental|1|"ARM A:~Intensification with maraviroc for 24 weeks at one of the following doses:~150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor~600 mg orally BID when coadministered with efavirenz or nevirapine"
3269080|NCT00703586|Active Comparator|2|"ARM B~Intensification with an additional NRTI for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:~Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc~Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofovir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc."
3269332|NCT00701883|Experimental|MBX-8025 100 mg/Atorvastatin 20 mg|
3269081|NCT00703573|Experimental|Group A|S-777469 400 mg BID (two 200 mg tablets of S-777469 and two tablets of placebo BID)
3269082|NCT00703573|Experimental|Group B|S-777469 800 mg BID (four 200 mg tablets of S-777469 BID)
3269083|NCT00703573|Placebo Comparator|Group C|Placebo BID (four tablets of placebo BID)
3269084|NCT00703560||1|HIV and HCV genotype 1 coinfected (any race)
3269085|NCT00703560||2|HCV genotype 1 (any race)
3269086|NCT00703547|Experimental|Subjects receiving treatment in cohort 1|Subjects will receive one of the following sequences; ABDF,BADF, BDAF or BDFA (A=Placebo, B= GSK586529 dose 1 (3 milligrams), D = GSK586529 dose 3, F = GSK586529 dose 5).
3269087|NCT00703547|Experimental|Subjects receiving treatment in cohort 2|Subjects will receive one of the following sequences; ACEG,CAEG, CEAG or CEGA (A = Placebo, C= GSK586529 dose 2, E = GSK586529 dose 4, G = GSK586529 dose 6)
3269088|NCT00703534|Experimental|AZD3355|
3269089|NCT00703534|Placebo Comparator|Placebo|
3269090|NCT00703521|Placebo Comparator|1,2,3,4,5|"Rabies vaccine 1.0 mL IM on day 0, 7, 28,and 1 year~Rabies vaccine 0.5 mL IM on day 0, 7, 28,and 1 year~Rabies vaccine 0.1 mL Intradermal on day 0, 7, 28,and 1 year~Rabies vaccine 0.1 mL Intradermal on day 0, 28,and 1 year~Japanese encephalitis vaccine 0.25 mL subcutaneous"
3269091|NCT00703508|Experimental|Metformin|Metformin tablet, 500 mg/tablet, 2 tablets every twelve hours, 9 months duration
3269092|NCT00703482|Placebo Comparator|1|
3269093|NCT00703482|Active Comparator|2|
3269094|NCT00703482|Active Comparator|3|
3269095|NCT00703482|Experimental|4|
3269096|NCT00703482|Experimental|5|
3269097|NCT00703482|Experimental|6|
3269098|NCT00703482|Experimental|7|
3269099|NCT00703469|Experimental|1|
3269100|NCT00703469|Placebo Comparator|2|
3269101|NCT00703456|Experimental|1|Balance Training, 3 times a week for 4 weeks
3269102|NCT00703456|No Intervention|2|Education/No intervention
3269103|NCT00703430|Experimental|1|Memantine
3269104|NCT00703417||1|Healthy post-menopausal women
3269105|NCT00703417||2|Diabetic without fracture
3269106|NCT00703417||3|Diabetic with fracture
3269107|NCT00703391|Experimental|1|Active Treatment
3269108|NCT00703391|Placebo Comparator|2|Placebo Treatment
3269109|NCT00703378|Experimental|Group 1|Group 1: normal liver function
3269110|NCT00703378|Experimental|Group 2|Group 2: AST and/or ALT up to 1-5 x upper limit of normal; SAP 1- 5x upper limit of normal, total bilirubin within normal limits
3269111|NCT00703378|Experimental|Group 3|Group 3: Any SAP and AST/ALT >5-10 x upper limit of normal and/or total bilirubin 1-1.5 x upper limit of normal
3269112|NCT00703365|Experimental|1|Sorafenib
3269113|NCT00703352|Active Comparator|1|Eplerenone
3269114|NCT00703352|Placebo Comparator|2|Placebo
3269115|NCT00703326|Experimental|ramucirumab (IMC-1121B) + docetaxel|
3269116|NCT00703326|Placebo Comparator|placebo + docetaxel|
3269117|NCT00703313|Active Comparator|2|described in intervention
3269118|NCT00703313|Active Comparator|3|described in intervention
3269119|NCT00703313|Active Comparator|1|described in intervention
3269120|NCT00703300|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-5 or 1-10 and bortezomib IV on days 5 and 8 or days 5, 8, 12, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Once the maximum tolerated dose is determined, an additional 6 patients are treated at the recommended phase II dose.
3269121|NCT00703287|Sham Comparator|A2|Generic physiotherapy
3269122|NCT00703287|Experimental|A1|Specialized Physiotherapy
3269123|NCT00703274|Experimental|Navigation Group|Participants enrolled in this group will receive education concerning primary and secondary PROTECT DC goals. Primary PROTECT DC goals adhere to the following medication directives: 1) Anti-hypertensive, 2) Lipid Lowering, 3) Anti-Coagulant, and 4) Anti-Diabetic. PROTECT DC secondary goals include the following behaviors 1) Smoking Cessation, 2) Consuming an AHA Diet, 3) Regular Exercise, and 4) Knowledge of Stroke Risk and Warning Signs. Participants will also receive assistance with overcoming resource-related barriers to the PROTECT DC goals.
3269124|NCT00703274|No Intervention|Control Group|Participants enrolled in this group will receive periodic follow up through mailings, phone calls etc to ensure availability for 1 year assessment.
3269125|NCT00703261|Active Comparator|10 mg Atorvastatin|10 mg atorvastatin + placebo
3269126|NCT00703261|Active Comparator|80 mg Atorvastatin|80 mg atorvastatin + placebo
3269127|NCT00703248|Experimental|1|
3269128|NCT00703248|No Intervention|2|
3269129|NCT00703222|Experimental|Neuroblastoma vaccine|SJNB-JF-IL2 and SJNB-JF-Lptn vaccine and SKNLP vaccine
3269130|NCT00703209|Active Comparator|1|Patients who are randomized to receive surgical care, will receive the nerve decompression, along with similar incisions on the opposite leg, but no decompression on that leg. This will serve as the patient's control leg, and also blind them to the treatment leg.
3269131|NCT00703209|No Intervention|2|Subjects who are not randomized to receive the surgical procedure will be followed up with the same clinic visits as the patients who are receiving the surgical procedure.
3269132|NCT00703196|Experimental|Arm I|Patients receive oral folic acid pill once daily for 12 months in the absence of unacceptable toxicity or any other adverse effects.
3269133|NCT00703196|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 12 months in the absence of unacceptable toxicity or any other adverse effects.
3269134|NCT00703183|Experimental|1|ACU-4429
3269135|NCT00703183|Placebo Comparator|2|matching placebo
3269136|NCT00703170|Experimental|Dose Level 1 (original)|"Temsirolimus IV 20 mg weekly~Pegylated liposomal doxorubicin IV 30 mg/m2 once every 4 weeks"
3269137|NCT00703170|Experimental|Dose Level 1 (revised)|"Temsirolimus IV 20 mg weekly~Pegylated liposomal doxorubicin IV 25 mg/m2 once every 4 weeks"
3269138|NCT00703170|Experimental|Dose Level 2|"Temsirolimus IV 25 mg weekly~Pegylated liposomal doxorubicin IV 25 mg/m2 once every 4 weeks"
3269139|NCT00703157|Active Comparator|1|Arm 1: Catheter Ablation
3269140|NCT00703157|Active Comparator|2|Arm 2: Surgical Ablation.
3269141|NCT00703144|Experimental|Pharmacokinetic|
3269142|NCT00703131||1|Anal Fistula Plug
3269143|NCT00703118|Experimental|Group A: T12/PR48|Participants will receive 12 weeks of 750 mg telaprevir eight hourly followed by 4 weeks of Placebo in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
3269144|NCT00703118|Experimental|Group B: T12(DS)/PR48|Participants will receive 4 weeks of Placebo followed by 12 weeks of 750 mg telaprevir eight hourly in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
3269145|NCT00703118|Experimental|Group C: Pbo/PR48|Participants will receive placebo in combination with Peg- IFN-alfa-2a and ribavirin for 16 weeks. Participants will receive Peg- IFN-alfa-2a and ribavirin for next 32 weeks.
3269146|NCT00703105|Experimental|1|Administration of a single dose of Ontak at 18 µg/kg followed in 96 hours by DC vaccination with 1 x 10(6th) tumor lysate and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals (6 weeks)
3269147|NCT00703105|Experimental|2|DC vaccination with 1 x 10(6th) tumor lysate and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals(6 weeks)
3269148|NCT00703105|Experimental|3|administration of Ontak ,18 µg/kg at the same dose without vaccination.
3269149|NCT00703092|Experimental|Fiber-Stat|2 tablespoons daily
3269150|NCT00703079||Group A|>15 patients treated only with SSA (octreotide-LAR or lanreotide depot)
3269151|NCT00703079||Group B|>15 patients treated with surgery after a period of SSA treatment of 6-24 months
3269152|NCT00703079||Group C|>15 patients cured after surgery only
3269153|NCT00703079||Group D|>15 patients treated with surgery first and then with SSA after 6-12 months
3269154|NCT00703066|Experimental|1|three doses of 30µg GMZ2,
3269155|NCT00703066|Experimental|2|3 doses of 100 µg of GMZ2
3269156|NCT00703066|Active Comparator|3|Rabies vaccine
3269157|NCT00703053|Experimental|Group 1|25 subjects: Day 0, A/Vietnam/04 90 mcg; Day 7, A/Vietnam/04 90 mcg.
3269158|NCT00703053|Experimental|Group 9|100 subjects: Day 0, A/Vietnam/04 90 mcg; Day 28, A/Vietnam/04 90 mcg.
3269159|NCT00703053|Experimental|Group 8|100 subjects: Day 0, A/Vietnam/04 90 mcg.
3269160|NCT00703053|Experimental|Group 7|50 subjects: Day 0, A/Indonesia/05 90 mcg; Day 180, A/Indonesia/05 90 mcg.
3269161|NCT00703053|Experimental|Group 6|50 subjects: Day 0, A/Vietnam/04 90 mcg; Day 180, A/Indonesia/05 90 mcg.
3269162|NCT00703053|Experimental|Group 5|50 subjects: Day 0, A/Vietnam/04 45 mcg + A/Indonesia/05 45 mcg; Day 28, A/Vietnam/04 45 mcg + A/Indonesia/05 45 mcg.
3269163|NCT00703053|Experimental|Group 4|50 subjects: Day 0, A/Vietnam/04 90 mcg; Day 28, A/Indonesia/05 90 mcg.
3269164|NCT00703053|Experimental|Group 3|50 subjects: Day 0, A/Indonesia/05 90 mcg; Day 28, A/Indonesia/05 90 mcg.
3269165|NCT00703053|Experimental|Group 2|25 subjects: Day 0, A/Vietnam/04 90 mcg; Day 14, A/Vietnam/04 90 mcg.
3269166|NCT00703040||Component 1|Existing linkage to care protocols will be obtained from the 15 sites. This component does not involve study subjects.
3269167|NCT00703040||Component 2|Person-to-person or telephone interviews with ATN clinical site staff and staff from their community partners will be audio-taped.
3269168|NCT00703040||Component 3|Notes from direct observation of the linkage to medical care process within sites will be taken.
3269169|NCT00703014||Mothers Corifollitropin Alfa 150 µg|Participants from the Base Trial P05787 who received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recombinant Follicle Stimulating Hormone (recFSH); followed by daily SC injections with 200 IU recFSH up to the day of human chorionogonadotropin (hCG); multiple daily SC injections of Ganirelix from Stimulation Day 5 to the day of hCG; a single dose of hCG (5000 or 10,000 IU/USP) was administered when 3 follicles >= 17 mm were observed; and on the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the Base Trial were enrolled in Follow Up Trial P05712, where no study treatments were given, and pregnancy, delivery and neonatal outcome were monitored.
3269170|NCT00703014||Mothers recFSH 200 IU|Participants from the Base Trial P05787 who received a single SC injection of placebo Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 200 IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG; multiple daily SC injections of Ganirelix from Stimulation Day 5 to the day of hCG; a single dose of hCG (5000 or 10,000 IU/USP) was administered when 3 follicles >= 17 mm were observed; and on the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the Base Trial were enrolled in Follow Up Trial P05712, where no study treatments were given, and pregnancy, delivery and neonatal outcome were monitored.
3269171|NCT00703001|Active Comparator|1--Educational Intervention|Students in this arm will receive several in-class educational modules on basic oral health topics.
3269172|NCT00703001|Active Comparator|2--Referral intervention|Parents of student subjects will receive assistance in accessing oral health care for their child
3269173|NCT00702988||Experimental Group 1|all doses of Org 36286 (corifollitropin alfa) (60 μg, 120 μg and 180 μg)
3269174|NCT00702988||Experimental Group 2|150 IU recFSH
3269175|NCT00702962|Experimental|1 Vorinostat 200mg Carbo 6 (AUC)|Vorinostat 200 mg PO QD D1-14; Carbo 6 (AUC) D3; Etoposide 100 mg/m2 D1,2,3 Vorinostat, Carboplatin, Etoposide, SAHA
3269176|NCT00702962|Other|2 Vorinostat 300mg Carbo 6 (AUC)|Phase 2 is to determine progression free survival among patients with extensive disease SCLC receiving carboplatin plus etoposide with vorinostat.Vorinostat, Carboplatin, Etoposide, SAHA
3269177|NCT00702949|Experimental|Pregabalin75|Patients receive 75 mg of oral pregabalin twice daily for 6 weeks.
3269178|NCT00702949|Experimental|Pregabalin150|Patients receive 150 mg of oral pregabalin twice daily for 6 weeks.
3269179|NCT00702949|Placebo Comparator|Placebo|Patients receive oral placebo twice daily for 6 weeks.
3269180|NCT00702936|Active Comparator|R|Twenty-five patients assigned to ramipril 5 mg daily
3269181|NCT00702936|Active Comparator|T|Twenty-five patients assigned to Telmisartan 80 mg daily
3269182|NCT00702923|Experimental|1|Bicalutamide 150mg orally days 1-28 followed by CP-675,206 IV on day 29. Cycle is repeated once at month 3
3269183|NCT00702910|Experimental|GW642444M/lactose|GW642444M/lactose 6.25, 25 and 100 microgram, single inhaled dose for two days treatment in each treatment sequence (crossover design)
3269184|NCT00702910|Experimental|GW642444M/MgSt|GW642444M/MgSt 6.25, 25 and 100 microgram, single inhaled dose for two days treatment in each treatment sequence (crossover design)
3269185|NCT00702910|Placebo Comparator|Placebo|Placebo containing lactose, single inhaled dose for two days treatment in each treatment sequence (crossover design)
3269186|NCT00702884|Experimental|Sunitinib|Sunitinib 37.5 mg daily for a 4 week cycle
3269187|NCT00702871|Active Comparator|1|Arm 1 was given Injection Ranitidine 50mg i.v. 8 hourly for stress ulcer prophylaxis.
3269188|NCT00702871|Active Comparator|2|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
3269189|NCT00702858|Active Comparator|1|Blue Citrus either months 1-3 or 4-6
3269190|NCT00702858|Placebo Comparator|2|Placebo
3269191|NCT00702845|Experimental|corifollitropin alfa 100 µg|Participants received a single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of the menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day by intramuscular [IM] injection), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
3269192|NCT00702845|Active Comparator|recFSH 150 IU|Participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including the day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
3269193|NCT00702832|Experimental|Vestibular rehabilitation|early supported vestibular rehabilitation
3269194|NCT00702832|Active Comparator|standard|standard treatment
3269195|NCT00702806|Experimental|Org 36286 120 μg + Puregon® 150 IU|On Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 120 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
3269196|NCT00702806|Experimental|Org 36286 180 μg + Puregon® 150 IU|Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 180 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
3269197|NCT00702806|Experimental|Org 36286 240 μg + Puregon® 150 IU|Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 240 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
3269198|NCT00702806|Active Comparator|Puregon® 150 IU|On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
3269199|NCT00702793|Experimental|1|Smoking cessation drug - varenicline
3269200|NCT00702780|Experimental|Escitalopram|Escitalopram 20mg tablet by mouth once a day
3269201|NCT00702780|Placebo Comparator|Placebo|Placebo 20mg tablet by mouth once a day
3269202|NCT00702741|Experimental|A|Chondrogen (low dose)
3269203|NCT00702741|Experimental|B|Chondrogen (high dose)
3269204|NCT00702741|Placebo Comparator|C|Hyaluronan
3269205|NCT00702728|Experimental|1|Furosemide and matched saline hydration by RenalGuard system
3269206|NCT00702728|Active Comparator|2|Standard IV saline infusion
3269207|NCT00702715|Experimental|Participants with severe renal impairment|Participants with severe renal impairment will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC. Severe renal impairment was defined as creatinine clearance <30mL/min.
3269208|NCT00702715|Active Comparator|Participants with normal renal function|Participants with normal renal impairment will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC. Normal renal function was defined as creatinine clearance >=80mL/min.
3269209|NCT00702702|Experimental|A 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
3269210|NCT00702702|Experimental|B 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
3269211|NCT00702702|Placebo Comparator|C Placebo|Placebo, 2 capsules daily for 3 months
3269212|NCT00702689|Experimental|Imatinib mesylate in patients with cGVHD|"Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)"
3269213|NCT00702676|Experimental|1|Quetiapine Fumarate Immediate Release
3269214|NCT00702676|Experimental|2|Quetiapine Fumarate Extended Release
3269325|NCT00701896|Active Comparator|HIV Smoking Cessation Arm|Includes up to 365 subjects who are HIV positive and initiate smoking cessation
3269215|NCT00702650|Experimental|Testosterone MD-Lotion|"Participants received Testosterone Metered Dose (MD)-Lotion for 120 days. Participants started by receiving 3.0 mL (60 mg) of 2% Testosterone MD-Lotion, and based upon restoration to eugonadal levels, may have had their dose of testosterone adjusted upwards or downwards on Days 45 and 90.~Doses could be titrated to one of the following:~1.5 mL (30 mg) of 2% Testosterone MD-Lotion applied daily by 1 dose to the axilla (1.5 mL to one axilla).~3.0 mL (60 mg) of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to each axilla).~4.5 mL (90 mg) of 2% Testosterone MD-Lotion applied daily by 3 doses to the axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla).~6.0 mL (120 mg) of 2% Testosterone MD-Lotion applied daily by 4 doses to the axilla (2 x 1.5 mL to each axilla)."
3269216|NCT00702624||Corifollitropin alfa 100 μg|In follow-up study, no medication or investigational product was administered. In base study P05690 (NCT00702845), participants received single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants in base study P05690 also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day by intramuscular [IM] injection), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
3269217|NCT00702624||recFSH 150 IU|In follow-up study, no medication or investigational product was administered. In base study P05690 (NCT00702845), participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
3269218|NCT00702611|Experimental|1|Seven apheresis treatments over seven consecutive weeks (1/week) in conjunction with a starting dose of 40mg of oral prednisone per day at Week 00 for two weeks which will be tapered down to zero 5 mg/week within nine weeks
3269219|NCT00702611|Active Comparator|2|Treatment with starting dose of 40mg of oral prednisone per day at Week 00 for two weeks and tapered down to zero 5 mg/week within nine weeks
3269220|NCT00702598|Experimental|1|Telephone-based Cognitive Behaviour Therapy
3269221|NCT00702598|Placebo Comparator|2|Telephone reminder calls
3269222|NCT00702585|Experimental|Org 36286 7.5 µg|Org 36286 7.5 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
3269223|NCT00702585|Experimental|Org 36286 15 µg|Org 36286 15 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
3269224|NCT00702585|Experimental|Org 36286 30 µg|Org 36286 30 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
3269225|NCT00702585|Experimental|Org 36286 60 µg|Org 36286 60 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
3269226|NCT00702585|Placebo Comparator|Placebo|Placebo to Org 36286 administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
3269227|NCT00702572|Experimental|1|Phase I dose escalating scheme
3269228|NCT00702572|Experimental|2|Phase 2 will evaluate the toxicities and safety profile of the 4-drug regimen.
3269229|NCT00702546||Corifollitropin alfa 100 μg|In follow-up study, no medication or investigational product was administered. But in base study P05690 (NCT00702845), participants received single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of the menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants in base study P05690 also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
3269230|NCT00702546||recFSH 150 IU|In this follow-up study, no medication or investigational product was administered. However, in base study P05690 (NCT00702845), participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including the day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
3269231|NCT00702520||Corifollitropin alpha 100 ug|In the base study (P05788, 38833, NCT00702351), participants were pre-treated with daily subcutaneous (SC) injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase). After suppression of endogenous luteinizing hormone (LH) and follicle stimulating hormone (FSH) was confirmed by estradiol (E2) and progesterone (P) measurements, a single dose of corifollitropin alpha 100 μg was administered in participants weighing <= 60 kg. From stimulation Day 8 onwards, treatment was continued with daily SC of recombinant follicle stimulating hormone (recFSH) injections (maximally 200 IU) up to and including the day of administration of human chorionic gonadotprophin (hCG). No study medications were administered in the present P05783 study (38834, NCT00702520).
3269560|NCT00700375|Experimental|Sodium chloride|
3269232|NCT00702520||Corifollitropin alpha 150 ug|In the base study (P05788, 38833, NCT00702351), participants were pre-treated with daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase). After suppression of endogenous LH and FSH was confirmed by E2 and P measurements, a single dose of corifollitropin alpha 150 μg was administered in participants weighing >= 50 kg. From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG. No study medications were administered in the present P05783 study (38834, NCT00702520).
3269233|NCT00702507|Active Comparator|Miconazole Nitrate|
3269234|NCT00702494|Experimental|1|Multiple IV doses of TB-403, an antibody directed against PlGF
3269235|NCT00702481|Experimental|Nimotuzumab/CDDP/RT|Open label treatment arm of Nimotuzumab and cisplatin and radiation
3269236|NCT00702468|Experimental|Sativex|Sativex
3269237|NCT00702468|Placebo Comparator|Placebo|Placebo
3269238|NCT00702455|Active Comparator|Self-Directed|
3269239|NCT00702455|Active Comparator|Guided|
3269240|NCT00702442|Placebo Comparator|A|Placebo Administrated 30min prior to operation
3269241|NCT00702442|Experimental|B|0.625 mg Droperidol administrated i.v 30 min prior surgery
3269242|NCT00702429|Experimental|1|Patients achieve of parodontopathies
3269243|NCT00702429|Placebo Comparator|2|Patients without parodontales diseases
3269244|NCT00702416|Experimental|US Group|In this group, the continuous block will be performed under real-time ultrasound (US) guidance.
3269245|NCT00702416|Active Comparator|ENS Group|In this group, the continuous block will be performed with an electrical nerve stimulation (ENS) technique.
3269246|NCT00702403|Experimental|Treatment (prophylactic inhibition of BCR-ABL tyrosine kinase)|"Beginning after engraftment and blood count recovery (21 to 28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate PO QD until day 80 and then nilotinib PO BID on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO BID beginning after engraftment and blood count recovery until day 445.~Treatment continues in the absence of disease progression or unacceptable toxicity."
3269247|NCT00702377|Experimental|SYSTANE Ultra|SYSTANE Ultra Lubricant Eye Drops
3269248|NCT00702377|Active Comparator|OPTIVE|OPTIVE Lubricant Eye Drops
3269249|NCT00702364|Experimental|Atomoxetine|40mg atomoxetine twice a day for 2 weeks
3269250|NCT00702364|Placebo Comparator|placebo|Placebo twice a day for two weeks
3269251|NCT00702351|Experimental|Arm 1|150 µg Org 36286 (corifollitropin alfa)
3269252|NCT00702351|Experimental|Arm 2|100 µg Org 36286 (corifollitropin alfa)
3269253|NCT00702338||corifollitropin alfa + recFSH Mothers|Eligible participants in Stage 1a of base study P05693 (NCT00697255) were administered injection(s) with subcutaneous (SC) corifollitropin alfa (15mcg) and daily SC injections with recFSH (50 IU) when the largest follicle reached a size of ≥12 mm. A bolus injection of hCG (5000 IU) was then administered if at least one follicle was ≥18 mm and in total no more than two follicles ≥15 mm were observed. Eligible mothers in this group with an ongoing pregnancy established in the base study (confirmed at ≥10 weeks after hCG bolus injection) were then to be followed for safety and efficacy on the current follow-up (FU) study (P05713) according to standard practice (no treatment administered).
3269254|NCT00702338||corifollitropin alfa + hCG Mothers|Eligible participants in Stage 1b of base study P05693 (NCT00697255) were administered injection(s) with SC corifollitropin alfa (30 mcg) and daily SC injections with hCG (200 IU) when the largest follicle reached a size of ≥12 mm. A bolus injection of hCG (5000 IU) was then administered if at least one follicle was ≥18 mm and in total no more than two follicles ≥15 mm were observed. Eligible mothers in this group with an ongoing pregnancy established in the base study (confirmed at ≥10 weeks after hCG bolus injection) were then followed for safety and efficacy on the current FU study (P05713) according to standard practice (no treatment administered).
3269255|NCT00702325|Experimental|1|
3269256|NCT00702325|Active Comparator|2|
3269257|NCT00702312|Experimental|Study group|Study group that will attend low-salt educational community programme
3269258|NCT00702312|No Intervention|Control group|Subjects in this arm will have routine medical and dietetic treatment for low-salt reduction.
3269259|NCT00702299|Experimental|Receiving Treatment|Dose escalation of day 1 i.p. pemetrexed disodium accrued three patients to each of five dose levels (60-1,000 mg/m2), along with day 2 i.p. cisplatin (75 mg/m2) and day 8 i.p. paclitaxel (60 mg/m2) with a biologic sample preservation procedure
3269260|NCT00702286||1|Two arm, double blinded, comparative, randomized, placebo controlled (active:sham - 2:1) study
3269261|NCT00702286||2|Two arm, double blinded, comparative, randomized, placebo controlled (active:sham - 2:1) study
3269262|NCT00702273||150 µg Corifollitropin Alfa|Participants from the base study P05787 (NCT00696800), received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa (Org 36286) on menstrual cycle Day 2/3 (Day 1); 7 daily SC injections from Days 1 to 7 with placebo-recombinant Follicle Stimulating Hormone (recFSH); followed by daily SC injections with 200 IU recFSH up to the day of human chorionogonadotropin (hCG). Daily SC injections of Ganirelix were given from Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles >= 17 mm. On the day of oocyte pick up (OPU) daily doses of progesterone were started, for up to 6 weeks or menses. Eligible participants from the base study were enrolled in follow up study P05716, where no study treatments were given, and embryos obtained in the base study underwent FTET cycles.
3269263|NCT00702273||200 IU RecFSH|Participants from the base study P05787 (NCT00696800), received a single SC injection of placebo Corifollitropin Alfa on menstrual cycle day 2/3 (Day 1); 7 daily SC injections with 200 IU recFSH from Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Multiple daily SC injections of Ganirelix were given from Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles >= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the base study were enrolled in follow up study P05716, where no study treatments were given, and embryos obtained in the base study underwent FTET cycles.
3269264|NCT00702247|Experimental|1|
3269326|NCT00701896|Experimental|Motivational Intervention|Includes up to 100 subjects who are HIV positive, do not wish to quit smoking but are willing to undergo one-on-one Motivational Intervention
3269327|NCT00701883|Placebo Comparator|Placebo/Placebo|
3269265|NCT00702234||Women/Expectant Mothers - Corifollitropin Alfa 150 µg|In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of Gonadotropin Releasing Hormone (GnRH) antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin ([rec]hCG) (5,000-10,000 IU/250 µg). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh embryo transfer in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered.
3269266|NCT00702221|Experimental|ATV with CoVaccine HT™|Angiotensin Therapeutic Vaccine with CoVaccine HT™ adjuvant (an ingredient that may improve the immune response of the vaccine)
3269267|NCT00702221|Placebo Comparator|CoVaccine HT™ adjuvant alone|CoVaccine HT™ adjuvant alone
3269268|NCT00702208|Other|Single arm study|Paired laboratory results for clinician-collected and Screener collected specimens for cytology (and high-risk human papillomavirus testing for sub-sample)
3269269|NCT00702195||Experimental Group 1|all doses of Org 36286 (corifollitropin alfa) from trial 38805 (7.5 μg, 15 μg, 30 μg and 60 μg)
3269270|NCT00702195||Experimental Group 2|Placebo
3269271|NCT00702195||Experimental Group 3|all doses of Org 36286 (corifollitropin alfa) from trial 38807 (120 μg, 180 μg and 240 μg)
3269272|NCT00702195||Experimental Group 4|150 IU Puregon®
3269273|NCT00702182|Experimental|Conventional Vinorelbine, Erlotinib|Escalating doses of vinorelbine on Day 1 and Day 8 of 21 Day cycle; Erlotinib 100 mg OD
3269274|NCT00702182|Experimental|Metronomic Vinorelbine, Erlotinib|Escalating doses of vinorelbine TIW; erlotinib 100 mg OD
3269275|NCT00702169||1|Premature and term newborn infants (male/female)
3269276|NCT00702156|Experimental|1|Bisoprolol
3269277|NCT00702156|Placebo Comparator|2|Identical appearance matching placebo
3269278|NCT00702143|Experimental|AD subjects|
3269279|NCT00702143|Experimental|MCI Subjects|MCI (mild cognitive impairment)
3269280|NCT00702143|Experimental|Healthy controls|
3269281|NCT00702130|Experimental|A|this arm will receive Pravastatin 40 mg per os daily
3269282|NCT00702130|No Intervention|1|
3269283|NCT00702117|Active Comparator|A|IV flecainide in atrial fibrillation
3269284|NCT00702117|Experimental|B|IV ajmaline in atrial fibrillation
3269285|NCT00702117|Active Comparator|c|iv procainamide in ventricular tachycardia
3269286|NCT00702117|Experimental|d|iv ajmaline in ventricular tachycardia
3269287|NCT00702117|Active Comparator|e|iv flecainide in diagnosis of Brugada Sd
3269288|NCT00702117|Experimental|f|iv ajmaline in diagnosis of Brugada Sd
3269289|NCT00702078|Other|usual care|follow-up according to todays best practice.
3269290|NCT00702078|Experimental|cooperation|Follow-up from the hospital and the primary healthcare in cooperation
3269291|NCT00702065||1|
3269292|NCT00702065||2|
3269293|NCT00702052|Experimental|RAD001|
3269294|NCT00702039||1|Those patients receiving intravitreal injections who will be listening to classical music during injection.
3269295|NCT00702039||2|Those patients receiving intravitreal injections who will not be listening to any music during injection.
3269296|NCT00702026|Experimental|1|
3269297|NCT00702026|Placebo Comparator|2|
3269298|NCT00702013||1|
3269299|NCT00702013||2|
3269300|NCT00702013||3|
3269301|NCT00702013||4|
3269302|NCT00702013||5|
3269303|NCT00702013||6|
3269304|NCT00702013||7|
3269305|NCT00702013||8|
3269306|NCT00702000||1.|Those with ICU-acquired weakness
3269307|NCT00701987|Experimental|1|ALS-357 applied topically twice weekly for four weeks.
3269308|NCT00701987|Experimental|2|ALS-357 applied topically every other day for four weeks.
3269309|NCT00701987|Experimental|3|ALS-357 applied topically once daily for four weeks.
3269310|NCT00701987|Experimental|4|ALS-357 applied topically twice daily for four weeks.
3269311|NCT00701974|Experimental|1|patients treated with collagenase (IRUXOL)
3269312|NCT00701974|Experimental|2|patients treated with collagenase (Kollagenase)
3269313|NCT00701961|Experimental|1|Pregnat women receiving MQ-AS fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, dosed once daily such that mefloquine dose is approximately 8mg/kg/day for 3 days.
3269314|NCT00701961|Active Comparator|2|Non-pregnant women receiving MQ-AS fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, dosed once daily such that mefloquine dose is approximately 8mg/kg/day for 3 days.
3269315|NCT00701948||A-1|Proven nosocomial bacterial infection (NBI)
3269316|NCT00701948||A-2|Possible NBI
3269317|NCT00701948||B-1|Absence of NBI
3269318|NCT00701948||B-2|Probable absence of NBI
3269319|NCT00701935|Placebo Comparator|1|
3269320|NCT00701935|Experimental|2|
3269321|NCT00701909|Experimental|1|During the first wound care procedure, patients will receive either morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline (MS) or morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg (MK) before the WCP according to randomization. During the second wound care procedure, they will receive the drugs and doses that they had not received the first time.
3269322|NCT00701909|Active Comparator|2|During the second wound care procedure, patients will receive either morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline (MS) or morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg (MK), whichever drugs and doses that they had not received the first time.
3269323|NCT00701896|Other|Healthy Control - Non-smoking|Healthy Control arm with 51 subjects who are HIV negative and do not smoke
3269324|NCT00701896|Other|Healthy Control - Smoker|Healthy Control arm, includes 50 subjects who are HIV negative and are smokers.
3269328|NCT00701883|Experimental|MBX-8025 50 mg/Placebo|
3269329|NCT00701883|Experimental|MBX-8025 100 mg/Placebo|
3269333|NCT00701870|Experimental|ezatiostat hydrochloride (Telintra®)|Chemotherapy with docetaxel and carboplatin followed by Telintra until ANC recovery
3269334|NCT00701870|No Intervention|No Intervention|Chemotherapy with docetaxel and carboplatin alone
3269335|NCT00701857|Experimental|Pemetrexed, Cisplatin, Radiation Therapy|Concomitant Pemetrexed and CDDP Plus Radiation Therapy
3269336|NCT00701844|Experimental|Experimental Writing Type 1|
3269337|NCT00701844|Experimental|Experimental Writing type 2|
3269338|NCT00701844|Active Comparator|Control writing type 1|
3269339|NCT00701844|Placebo Comparator|Control writing type 2|
3269340|NCT00701831|Experimental|1|Insulin glargine
3269341|NCT00701805|Experimental|Paricalcitol 2 µg ± 1 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
3269342|NCT00701805|Experimental|Paricalcitol 2 µg ± 2 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
3269343|NCT00701805|Experimental|Paricalcitol 4 µg ± 1 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
3269344|NCT00701805|Experimental|Paricalcitol 4 µg ± 2 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
3269345|NCT00701792|Active Comparator|1|surgery : liver transplantation
3269346|NCT00701792|Active Comparator|2|standard care for liver disease
3269347|NCT00701779|Experimental|Dutasteride|"Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.~Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks."
3269348|NCT00701753||Olanzapine|Subjects treated with olanzapine as part of their routine clinical care
3269349|NCT00701753||Risperidone|Subjects treated with risperidone as part of their routine clinical care
3269350|NCT00701753||Quetiapine|Subjects treated with quetiapine as part of their routine clinical care
3269351|NCT00701740|Active Comparator|A|A - 21 subjects were treated 20mg isotretinoin 3/week plus moisturizer and sunscreen,for three months; 10 randomly selected were submitted to skin biopsies before and after the end of treatment
3269352|NCT00701740|Active Comparator|B|11 subjects received only the same moisturizer/sunscreen
3269353|NCT00701727|Experimental|1|ezetimibe (10mg/day)for 7 weeks
3269354|NCT00701727|Placebo Comparator|2|Placebo control
3269355|NCT00701714|Experimental|1|HX575, EPO HEXAL
3269356|NCT00701714|Active Comparator|2|ERYPO
3269357|NCT00701701|Experimental|Myozyme and Cyclophosphamide|Regimen A
3269358|NCT00701701|Experimental|Myozyme, Rituximab and Methotrexate|Regimen B
3269359|NCT00701688|Experimental|Dose Level 1|Palifermin 40 mcg/kg/day intravenous
3269360|NCT00701688|Experimental|Dose Level 2|Palifermin 60 mcg/kg/day intravenous
3269361|NCT00701688|Experimental|Dose Level 3|Palifermin 90 mcg/kg/day intravenous
3269362|NCT00701675|Experimental|Sertraline 50mg|sertraline 50 mg daily
3269363|NCT00701675|Experimental|Sertraline 100mg|sertraline 100mg daily
3269364|NCT00701675|Placebo Comparator|Placebo|placebo 50 or 100mg
3269365|NCT00701662|Experimental|Vivaglobin|Vivaglobin® is a 16% (160 mg/mL) liquid formulation of human normal immunoglobulin for subcutaneous infusion. Subjects will receive weekly infusions of Vivaglobin® at a weekly dosage calculated based on previous intravenous immunoglobulin treatment (between 0.1 to 0.5 g/kg body weight per week).
3269366|NCT00701649|Experimental|1|
3269367|NCT00701649|Placebo Comparator|2|
3269368|NCT00701636|Experimental|Cases|The first 15 subjects enrolled will receive the intervention drug daptomycin as surgical antibiotic prophylaxis.
3269369|NCT00701636|No Intervention|Controls|15 subjects will be enrolled in the standard of care antibiotic group to serve as the controls. Controls will receive no experimental medications or treatments. The purpose of enrolling control patients was to serve as a reference group for intervention patients. Specifically cases and controls will be compared for changes in commonly collected hematologic parameters, creatinine, and CPK. Additionally, parameters collected during anesthesia will be compared. Controls will be matched to the intervention group by age (+/- 10 years), gender, and ethnicity.
3269370|NCT00701623|Experimental|1|patients treated with heparin
3269371|NCT00701623|Experimental|2|Patients treated with heparin
3269372|NCT00701623|Active Comparator|3|patients treated with folder water directly on the injured area
3269373|NCT00701610||1|All infants born in our hospital between August 2007 and August 2009 will participate.
3269374|NCT00701571|Experimental|1|3 cohorts: 18-21 years, 40-60 years, and older than 60 years
3269414|NCT00701246|Placebo Comparator|II|II Treatment of anemic children with 4,2 mg/kg/day of ferrous sulfate and folic acid placebo.
3269967|NCT00697853|Active Comparator|Group A|
3269375|NCT00701558|Experimental|Erlotinib + Gemcitabine|Participants received erlotinib 150 mg/day, orally (po) on a continuous schedule in combination with gemcitabine at 1000 mg/m^2 administered intravenously (iv) on days 1, 8, 15 of each 4 week cycle for 6 cycles as per standard medical care, or until disease progression or participant's withdrawal due to any reason or death.
3269376|NCT00701545||1|Patients with von Willebrand disease treated with Humate P® ivr in Canada
3269377|NCT00701532|Experimental|1|active
3269378|NCT00701532|Placebo Comparator|2|Placebo
3269379|NCT00701506|Experimental|1|"15 Patients (may be expanded) will receive stimulation with the following parameters:~20-minute session, to each affected knee, 3 times per week for 12 weeks.~PENS for 20 minutes:~Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).~Minimal twitch for 5 minutes.~Moderate to strong, but well-tolerated twitch contractions for 15 minutes.~Electrodes placed on quadriceps and hamstrings."
3269380|NCT00701506|Placebo Comparator|2|"5 Patients (may be expanded) will receive stimulation with the following parameters:~20-minute session, to each affected knee, 3 times per week for 12 weeks.~Placebo PENS for 20 minutes:~Electrodes placed on quadriceps and hamstrings."
3269381|NCT00701480|Experimental|1|skin cleanser contained Hibiscus sabdariffa
3269382|NCT00701480|Active Comparator|2|marketed skin cleanser
3269383|NCT00701467||Observation|
3269384|NCT00701454||1|Healthy participants (physically and mentally).
3269385|NCT00701441||Control group: healthy individuals without OSA|healthy individuals without OSA who are matched in weight and age to the participating OSA patients
3269386|NCT00701441||OSA group|Patients in the OSA group receive CPAP for 12 weeks as part of their care. patients with OSA provide measures at baseline and after 12 weeks of CPAP treatment.
3269387|NCT00701428|Active Comparator|1|Hypertensive Men and Women Without OSA on Losartan (n=30)
3269388|NCT00701428|Active Comparator|2|Hypertensive Men and Women With OSA on Losartan (n=30)
3269389|NCT00701428|Experimental|3|Hypertensive Men and Women with OSA on Losartan and CPAP (n=30)
3269390|NCT00701415|Experimental|Fabrazyme 0.5 mg/kg|Fabrazyme 0.5 mg/kg was administered every 2 weeks (up to 131 infusion) up to 260 weeks, the total infusion time was not less than 45 minutes. In case of significant progression of Fabry disease, the dose was increased to 1.0 mg/kg every 2 weeks.
3269391|NCT00701415|Experimental|Fabrazyme 1.0 mg/kg|Fabrazyme 1.0 mg/kg was administered every 4 weeks (up to 66 infusion) up to 260 weeks, the total infusion time was not less than 90 minutes. In case of significant progression of Fabry disease, the dose was increased to 1.0 mg/kg every 2 weeks.
3269392|NCT00701389|Experimental|Sequence 1: A→C→D→B|Participants receive the following: Period 1: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A); Period 2: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C); Period 3: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D); Period 4: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B). Each dosing period is separated by a 5-day washout.
3269393|NCT00701389|Experimental|Sequence 2: B→D→C→A|Participants receive the following: Period 1: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 2: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D): Period 3: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C); Period 4:single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A). Each dosing period is separated by a 5-day washout.
3269394|NCT00701389|Experimental|Sequence 3: C→B→A→D|Participants receive the following: Period 1 :single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C), Period 2: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 3: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A): Period 4: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D). Each dosing period is separated by a 5-day washout.
3269395|NCT00701389|Experimental|Sequence 4: D→A→B→C|Participants receive the following: Period 1: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D), Period 2: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treament A); Period 3: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 4: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C). Each dosing period is separated by a 5-day washout.
3269396|NCT00701376|Other|liver function|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
3269397|NCT00701363|Experimental|Lanreotide Autogel 120 mg|
3269398|NCT00701350||1|Women presenting with preterm gestation and ruptured membranes
3269399|NCT00701337|Experimental|1 Oral|oestradiol by oral administration - Estrofem 2 mg
3269400|NCT00701337|Experimental|2 patch|oestradiol par patch - Estrapatch 60microg/24h
3269401|NCT00701324|Experimental|Arm A|BI 811283, 24h infusion d1 and d15 every 4 weeks
3269402|NCT00701324|Experimental|Arm B|BI 811283, 24h infusion d1 every 3 weeks
3269403|NCT00701311|Experimental|Study Drug CC-10004|Study drug CC-10004 20mg taken orally twice a day.
3269404|NCT00701298|Active Comparator|Group 1 (chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients whose disease is not responding after the first course may crossover to group 2.
3269405|NCT00701298|Experimental|Group 2 (chemotherapy and antineoplastic agent)|Patients receive decitabine as in group 1 and pegylated interferon alfa-2b subcutaneously on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3269406|NCT00701285|Active Comparator|1|strong statin
3269407|NCT00701285|Active Comparator|2|mild statin
3269408|NCT00701272||1|Patients undergoing liver transplant for end-stage liver disease due to Hepatitis C
3269409|NCT00701272||2|"Control population:~Patients undergoing liver transplantation for end-stage liver disease due to alcoholic cirrhosis"
3269410|NCT00701259|Experimental|1|15 mg lansoprazole
3269411|NCT00701259|Experimental|2|30 mg lansoprazole
3269412|NCT00701259|Placebo Comparator|3|placebo
3269413|NCT00701246|Experimental|I|I Treatment: a daily dose (5 times a week) of either 4,2 mg/kg/day of ferrous sulfate + folic acid (50 mcg)
3269666|NCT00699712|Experimental|A|Open-label regimen of doses 1 and 2 of CDNP
3269415|NCT00701246|Experimental|III|Prevention of anemia in non-anemic children ( 5 times a week)- 1,4 mg/kg/day of ferrous sulfate and folic acid
3269416|NCT00701246|Placebo Comparator|IV|1,4 mg/kg/day of ferrous sulfate plus folic acid placebo, five days a week.
3269417|NCT00701233|Active Comparator|2|Corticosteroid injection into Carpal Tunnel
3269418|NCT00701233|Active Comparator|1|Botulinum toxin injection into Carpal Tunnel
3269419|NCT00701220|Active Comparator|1|Patients with Ischemic Cardiomyopathy receiving Lipitor.
3269420|NCT00701220|Active Comparator|2|NonIschemic Cardiomyopathy receiving Lipitor treatment
3269421|NCT00701220|No Intervention|3|Healthy subjects with no history of high cholesterol, heart disease, or heart attacks
3269422|NCT00701207|No Intervention|2.|control group-no intervention
3269423|NCT00701207|No Intervention|3|Healthy control group-blood and sputum samples
3269424|NCT00701207|Experimental|1.|nicotine patch; transdermal patch 7mg, 14 mg., 21 mg. 3 months
3269425|NCT00701194|Experimental|1|EIFC/MTFC-P
3269426|NCT00701194|No Intervention|2|Services as usual
3269427|NCT00701194|No Intervention|Community Comparison|Non-maltreated community pre-schoolers from low-income biological families.
3269428|NCT00701181|Active Comparator|Laser|This is a procedure - not a drug intervention.
3269429|NCT00701181|Experimental|PF-04523655 (High)|
3269430|NCT00701181|Experimental|PF-04523655 middle|
3269431|NCT00701181|Experimental|PF-04523655 low|
3269432|NCT00701155||A|
3269433|NCT00701142|Active Comparator|Haemocomplettan® P|Intravenous infusion during aortic surgery
3269434|NCT00701142|Placebo Comparator|Saline solution|
3269435|NCT00701129|Experimental|Alglucosidase Alfa|Alglucosidase alfa (Myozyme®) 20 milligrams per kilogram (mg/kg) intravenous (IV) infusion every other week (qow) (or optionally 20 mg/kg IV infusion every week [qw]) beginning from Day 0 to a minimum of 18 months or if the patient was less than (<) 6 months of age at the time of enrollment, until the patient was 2 years of age, along with methotrexate 0.4 mg/kg subcutaneously for 3 consecutive days qow beginning from Day 0 to Week 6 (9 doses) and rituximab 375 milligrams per square meter (mg/m^2) (or 12.5 mg/kg for patients with body surface area less than or equal to 0.5 m^2) IV infusion qw beginning from Day -1 to Week 4 (4 doses) as per local prescribing information. An additional 4-week cycle of rituximab (up to 4 additional doses) and 6-week cycle of methotrexate (up to 9 additional doses) may have been administered within the first 6 months of the study as per local prescribing information.
3269436|NCT00701103|Experimental|Dalotuzumab 1.25 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 1.25 mg/kg (10 mg/mL) intravenous (IV) infusion 1 time every 1 week (Q1W).
3269437|NCT00701103|Experimental|Dalotuzumab 2.5 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 2.5 mg/kg (10 mg/mL) IV infusion Q1W.
3269438|NCT00701103|Experimental|Dalotuzumab 5 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 5 mg/kg (10 mg/mL) IV infusion Q1W.
3269439|NCT00701103|Experimental|Dalotuzumab 10 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 10 mg/kg (10 mg/mL) IV infusion Q1W.
3269440|NCT00701103|Experimental|Dalotuzumab 10 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 10 mg/kg (20 mg/mL) IV infusion Q1W.
3269441|NCT00701103|Experimental|Dalotuzumab 15 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 15 mg/kg (10 mg/mL) IV infusion Q1W.
3269442|NCT00701103|Experimental|Dalotuzumab 15 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 15 mg/kg (20 mg/ mL) IV infusion Q1W.
3269443|NCT00701103|Experimental|Dalotuzumab 20 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 20 mg/kg (10 mg/mL) IV infusion Q1W.
3269444|NCT00701103|Experimental|Dalotuzumab 20 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 20.0 mg/kg (20 mg/mL) IV infusion Q1W.
3269445|NCT00701103|Experimental|Dalotuzumab 20 mg/kg Q2W (20 mg/mL)|Participants received dalotuzumab 20 mg/kg (20 mg/mL) IV infusion 1 time every 2 weeks (Q2W).
3269446|NCT00701103|Experimental|Dalotuzumab 30 mg/kg Q3W (20 mg/mL)|Participants received dalotuzumab 30 mg/kg (20 mg/mL) IV infusion1 time every 3 weeks (Q3W).
3269447|NCT00701090|Experimental|1|sitagliptin
3269448|NCT00701090|Active Comparator|2|glimepiride
3269449|NCT00701077|Experimental|1|3,4-Di-amino-Pyridine : a single 20 mg dosing
3269450|NCT00701077|Placebo Comparator|2|
3269451|NCT00701064|Experimental|Bright Light Exposure|Bright Light (30 min/day)
3269452|NCT00701064|Placebo Comparator|Negative Ion Generator|Negative Ion Generator (30 min/day)
3269453|NCT00701051|Active Comparator|Arm 1|Older adults, normal glucose tolerance
3269454|NCT00701051|Experimental|Arm 2|Older adults, impaired glucose tolerance
3269455|NCT00701038|Experimental|Device|Provided with an auto adjusting bi-level positive airway pressure device
3269456|NCT00701038|No Intervention|Control|No device
3269457|NCT00701025||1|35 asthmatic participants with EIB
3269458|NCT00701025||2|35 without EIB
3269459|NCT00701012|Experimental|1|low ligation, which the IMA is ligated below the origin of the left colic artery
3269460|NCT00701012|Active Comparator|2|high ligation, which the IMA is ligated at its origin from the aorta
3269461|NCT00700999|Other|Arm 1|Intervention-Paroxetine
3269462|NCT00700999|No Intervention|Arm 2|No Intervention
3269463|NCT00700986|Experimental|1|
3269464|NCT00700986|Placebo Comparator|2|
3269465|NCT00700973|Active Comparator|Arm 1|Substance use disorder usual care
3269466|NCT00700973|Experimental|Arm 2|Interpersonal violence prevention intervention
3269467|NCT00700960||A|
3269468|NCT00700947|Experimental|1|Patients who are asymptomatic with normal left ventricular systolic function and who agree to be treated medically for severe primary mitral regurgitation with Beta-blocker therapy. Patients may entered into the Arm 2 (surgical treatment) later on when they develop symptoms or enlarged left ventricle or left ventricular dysfunction or wishes to have surgical treatment of severe primary mitral regurgitation.
3269469|NCT00700947|No Intervention|2|Patients will be surgically treated for severe primary mitral regurgitation as a routine clinical care if they want to be treated surgically or develop symptoms or significant adverse left ventricular remodeling or left ventricular dysfunction.
3269504|NCT00700713|Experimental|One-Dose Menactra Group|Participants received one dose of Menactra® in Study MTA26
3269968|NCT00697853|Experimental|Group B|
3269470|NCT00700947|No Intervention|3|Health Control includes the subjects with no remarkable past medical history and not currently taking any medications. Normal subjects will be used for comparison with patients with severe primary mitral regurgitation in term of clinical, echocardiographic and neuro-hormonal findings.
3269471|NCT00700921|Experimental|Active Drug (Lovastatin)|
3269472|NCT00700921|Placebo Comparator|Placebo (inactive comparator)|
3269473|NCT00700908|Experimental|1|Automated telephone intervention
3269474|NCT00700908|Active Comparator|2|Usual care
3269475|NCT00700895|Experimental|Pharmacogenetics-guided dosing group|For patients randomized to the pharmacogenetics-guided dosing group, this 10mls of blood will be immediately sent for genotyping studies. Genotyping results will be available for pharmacogenetics-guided dosing within 3 working days, (ranging 3 to 5 days). During this period, if patients need to be initiated on anticoagulation, a low molecular weight heparin, Fraxiparine, will be given. Fraxiparine will be overlapped with warfarin for 2 to 3 days until target INR is achieved. Elective cases should have the pharmacogenetics-based warfarin dose available at the time of warfarin therapy.
3269476|NCT00700895|Experimental|Traditional dosing group|For patients randomized to the traditional dosing regime, the blood will be stored and genotyped retrospectively at the end of the study. Overlapping of warfarin with Fraxiparine or heparin till target INR is achieved is allowed for this group as per normal clinical practice. All warfarin dosage adjustments based on INR results will be according to the current protocol used by the NUH Anticoagulant Clinic.
3269477|NCT00700869|Experimental|1|Tracheal tube withdrawal governs by respiratory behaviour status
3269478|NCT00700856|Experimental|1|metformin 2000 mg + pioglitazone 15-45 mg
3269479|NCT00700856|Active Comparator|2|metformin 2000 mg + glibenclamide 5-15 mg or metformin 2000 mg + gliclazide 30-120 mg or metformin 2000 mg + glimepiride 2-6 mg
3269480|NCT00700830||A|
3269481|NCT00700817|Experimental|Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg|Once-daily subcutaneous dose of liraglutide 1.2 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First week for up-titration of liraglutide from 0.6 mg to 1.2 mg. Subjects continued to receive liraglutide 1.2 mg once daily in extension period 1 (weeks 26-52) and extension period 2 (weeks 52-78).
3269482|NCT00700817|Experimental|Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg|Once-daily subcutaneous dose of liraglutide 1.8 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First 2 weeks for up-titration of liraglutide from 0.6 mg to 1.8 mg. Subjects continued to receive liraglutide 1.8 mg once daily in extension period 1 (weeks 26-52) and extension period 2 (weeks 52-78).
3269483|NCT00700817|Active Comparator|Sita -> Sita|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52).
3269484|NCT00700817|Experimental|Sita -> Sita -> Lira 1.2 mg|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52). In extension period 2 (weeks 52-78), subjects were randomised to liraglutide 1.2 mg + metformin.
3269485|NCT00700817|Experimental|Sita -> Sita -> Lira 1.8 mg|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52). In extension period 2 (weeks 52-78), subjects were randomised to liraglutide 1.8 mg + metformin.
3269486|NCT00700804|Experimental|High Calcium Diet|
3269487|NCT00700804|Experimental|Low Calcium Diet|
3269488|NCT00700791|Placebo Comparator|Group I Single Site Randomization|Patients with 1 surgical scar will be given both oral placebo and topical cream placebo
3269489|NCT00700791|Active Comparator|Group II Single Site Randomization|Single surgical site will be given oral placebo and topical TCT
3269490|NCT00700791|Active Comparator|Group III Single Site Randomization|Patients with 1 surgical scar will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream
3269491|NCT00700791|Active Comparator|Group IV Single Site Randomization|Patients with 1 surgical scar will be given both Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT).
3269492|NCT00700791|Placebo Comparator|Group I: Bilateral Site Randomization|Patients with bilateral surgical scars will be given both oral placebo and topical cream placebo on one surgical site.
3269493|NCT00700791|Active Comparator|Group II: Bilateral Site Randomization|Patients with bilateral surgical scars will be given oral placebo and Natural Vitamin E Tocotrienol Cream (TCT) to one of the surgical sites.
3269494|NCT00700791|Active Comparator|Group III: Bilateral Site Randomization|Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream on one surgical site.
3269495|NCT00700791|Active Comparator|Group IV: Bilateral Site Randomization|Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT) on one surgical site.
3269496|NCT00700791|No Intervention|Normal Skin and Adipost Tissue Group|Normal human skin and adipose tissue will be collected
3269497|NCT00700778|Experimental|Recombinant human chorionic gonadotropin|Patients receive recombinant human chorionic gonadotropin subcutaneously three times weekly. Treatment continues weekly for 90 days in the absence of unacceptable toxicity.
3269498|NCT00700765||A|
3269499|NCT00700752|Active Comparator|senofilcon A/balafilcon A|senofilcon A silicone hydrogel contact lens worn during first 4-week period, balafilcon A silicone hydrogel contact lens worn during the second 4-week period. Senofilcon A lenses worn daily on a 2-week replacement schedule; balafilcon A lenses worn daily on a 4-week replacement schedule. Lens replacement conducted in-office in a masked process.
3269500|NCT00700752|Active Comparator|balafilcon A/senofilcon A|balafilcon A silicone hydrogel contact lens worn worn during first 4-week period, senofilcon A silicone hydrogel contact lens worn during the second 4-week period. Senofilcon A lenses worn daily on a 2-week replacement schedule; balafilcon A lenses worn daily on a 4-week replacement schedule. Lens replacement conducted in-office in a masked process.
3269501|NCT00700739|Other|Anterior Cervical Discectomy and Fusion (ACDF)|Anterior Cervical Discectomy and Fusion with Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
3269502|NCT00700739|Active Comparator|Cervical Total Disc Replacement|DISCOVER™ Artificial Cervical Disc
3269503|NCT00700726||A.|participants with atopic and non-atopic asthma
3269505|NCT00700713|Experimental|Two-Dose Menactra Group|Participants received two doses of Menactra® in Study MTA26
3269506|NCT00700713|Active Comparator|Menactra vaccine-naïve Group|Participants had never received Menactra® vaccine.
3269507|NCT00700700|Active Comparator|CRT-ON/CRT-OFF|Group initially randomized to CRT-ON, then cross-over to CRT-OFF
3269508|NCT00700700|Active Comparator|CRT-OFF/CRT-ON|Group initially randomized to CRT-OFF, then cross-over to CRT-ON
3269509|NCT00700687|Experimental|1|PA32540
3269510|NCT00700687|Experimental|2|PA32540 and celecoxib
3269511|NCT00700687|Active Comparator|3|aspirin and celecoxib
3269512|NCT00700674||1|Entropy group
3269513|NCT00700674||2|Control
3269514|NCT00700661|Experimental|1|Drug
3269515|NCT00700661|Placebo Comparator|2|Pbo
3269516|NCT00700648||A|
3269517|NCT00700635|Experimental|Menactra® Group 1|Participants aged 2 to < 4 years
3269518|NCT00700635|Experimental|Menactra® Group 2|Participants aged 4 to < 6 years
3269519|NCT00700635|Active Comparator|Menactra® Group 3|Participants aged 6 to < 11 years
3269520|NCT00700622|Experimental|TI + Insulin glargine|Technosphere Insulin Inhalation Powder in combination with Lantus (insulin glargine)
3269521|NCT00700622|Experimental|Insulin lispro + Insulin glargine|Humalog (insulin lispro) in combination with Lantus (insulin glargine)
3269522|NCT00700609|Experimental|1|"Attachment Based Family Therapy (ABFT)~ABFT developed by Dr. Guy Diamond and colleagues is a brief, 12 week, manualized family-based intervention."
3269523|NCT00700609|Active Comparator|2|"Treatment as usual (TAU)~No attempt is made to standardize TAU. Regular clinical staff will provide mental health services."
3269524|NCT00700596|Active Comparator|1|Salvinorin A (SA)
3269525|NCT00700596|Placebo Comparator|2|Control or Placebo SA
3269526|NCT00700583|Experimental|1|
3269527|NCT00700570|Experimental|1|
3269528|NCT00700557|Active Comparator|Probiotics - Lactobacillus casei and Bifidobacterium breve|"Yakult LB®~1 sachet (1g) of Lactobacillus casei and Bifidobacterium breve - 6 x 108 UFC/g on a juice three times a day"
3269529|NCT00700557|Placebo Comparator|maize starch|725mg on juice three times a day
3269530|NCT00700544|Active Comparator|B|"Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR~maintenance therapy every 3 months = 6 courses of reinduction with :~-idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5 ), subcutaneously~between the courses, a continuous regimen of methotrexate and 6-mercaptopurine."
3269531|NCT00700544|Experimental|A|"Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR~maintenance therapy every 3 months = 6 courses of reinduction with :~idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5, subcutaneously)~10 to 20 mg (according to body weigh) of norethandrolone daily~between the courses, a continuous regimen of methotrexate and 6-mercaptopurine."
3269532|NCT00700531|Experimental|1|Participants will receive FLC removal HD undertaken using an extended dialysis schedule on the Gambro HCO 1100 dialysers
3269533|NCT00700531|Active Comparator|2|Patients receive standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
3269534|NCT00700518|Placebo Comparator|1.|placebo cream applied to 2 adjacent fingers on non-dominant hand one time
3269535|NCT00700518|Active Comparator|2|0.6mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand
3269536|NCT00700518|Active Comparator|3|1.2mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
3269537|NCT00700518|Active Comparator|4|1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers on non-dominant hand one time
3269538|NCT00700518|Active Comparator|5|2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
3269539|NCT00700505|Experimental|Heating Garment|FlowPants(R) Garment with Heating
3269540|NCT00700492|No Intervention|control|
3269541|NCT00700492|Experimental|utrogestan|daily use of vaginal progesterone capsules
3269542|NCT00700479|Experimental|A|Aldosterone plus low salt diet
3269543|NCT00700479|Experimental|B|Aldosterone plus high sodium diet
3269544|NCT00700479|Placebo Comparator|C|Placebo plus low sodium diet
3269545|NCT00700479|Placebo Comparator|D|placebo plus high sodium diet
3269546|NCT00700466||1|Patients with hypertension and/or tachycardia prior to induction of anesthesia requiring i.v. beta-blockade for treatment of raised hemodynamic
3269547|NCT00700466||2|Patients with normal hemodynamic values prior to induction of anesthesia not requiring treatment
3269548|NCT00700453|Active Comparator|Control 1 Group|Subjects randomized to the Control 1 group will abstain from playing any video games for the entire study participation.
3269549|NCT00700453|Active Comparator|VG1- Control 2 Group|Subjects randomized to the Control 2 group will play a selected violent video game for 60-120 minutes/day during week 2 of the study and will abstain from any video game play during week 3 of the study.
3269550|NCT00700453|Active Comparator|VG1- VG2 group|Subjects randomized for VG1-VG2 group will play 60-120 minutes/day of a violent video game during weeks 2 & 3 of study participation.
3269551|NCT00700453|Active Comparator|VG1-CT group|Subjects randomized to the VG1-CT group will play 60-120 minutes of a selected violent video game during week 2 of the study and play a selected computerized cognitive training program for 60-120 minutes/day during week 3 of the study.
3269552|NCT00700440|Experimental|Cetuximab|400mg/m^2 intravenous infusion one week before radiotherapy, then 250mg/m^2 intravenous infusion weekly during radiotherapy
3269553|NCT00700427|Experimental|Atomoxetine|Atomoxetine 40-100 milligrams per day (mg/day) orally, once daily or twice daily for 24 weeks, followed by atomoxetine 80-100 mg/day orally, once daily or twice daily for 25 weeks.
3269554|NCT00700427|Placebo Comparator|Placebo|Atomoxetine 40-100 mg/day orally, once daily or twice daily for 24 weeks, followed by placebo orally, once daily for 25 weeks.
3269555|NCT00700414||Participants|Any participant who meets eligibility criteria and consents to participate in the trial.
3269556|NCT00700401||Peginterferon Alfa-2a + Ribavirin|
3269557|NCT00700388|Experimental|1|TPEP added to conventional manually assisted breathing techniques (MABT)
3269558|NCT00700388|Active Comparator|2|Manually assisted breathing techniques (MABT) alone
3269559|NCT00700375|Experimental|Sodium bicarbonate|
3269561|NCT00700349|No Intervention|1|Individuals who were rejected from receiving a loan from a micro-lending organization were randomized to continue receiving no loan.
3269562|NCT00700349|Experimental|2|"Individuals who were rejected from receiving a loan from a micro-lending organization were randomized to receive a second look, to be reconsidered for a loan by loan officers."
3269563|NCT00700336|Experimental|Arm A|pemetrexed, cisplatin and CBP501
3269564|NCT00700336|Active Comparator|Arm B|pemetrexed and cisplatin
3269565|NCT00700323|Active Comparator|1|Patients receiving active product
3269566|NCT00700323|Placebo Comparator|2|Patients receiving placebo
3269567|NCT00700310|Active Comparator|1|
3269568|NCT00700310|Active Comparator|2|
3269569|NCT00700310|Active Comparator|3|
3269570|NCT00700310|Placebo Comparator|4|
3269571|NCT00700297|Active Comparator|Colchicine|Patients who received Colchicine and went on placebo after 4 months
3269572|NCT00700297|Placebo Comparator|Placebo|Patients who received placebo and went on Colchicine after 4 months
3269573|NCT00700284|Placebo Comparator|A|
3269574|NCT00700284|Experimental|B|
3269575|NCT00700271|Experimental|Morning Intake|After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP >= 140 mmHg and/or msDBP >= 90 mmHg or msSBP >= 130 mmHg and/or msDBP >= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP < 140 mmHg and msDBP < 90 mmHg or msSBP < 130 mmHg and msDBP < 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.
3269576|NCT00700271|Experimental|Evening Intake|After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP >= 140 mmHg and/or msDBP >= 90 mmHg or msSBP >= 130 mmHg and/or msDBP >= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP < 140 mmHg and msDBP < 90 mmHg or msSBP < 130 mmHg and msDBP < 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.
3269577|NCT00700258||1|Patients treated with Temsirolimus for metastatic renal cell carcinoma (mRCC) under usual care settings.
3269578|NCT00700258||2|Patients treated with Temsirolimus for mantle cell lymphoma (MCL) under usual care setting
3269579|NCT00700258||3|Patients treated with Sunitinib for metastatic renal cell carcinoma (mRCC) under usual care setting
3269580|NCT00700258||4|Patients treated with Sunitinib for gastro-intestinal stroma tumor (GIST) under usual care setting
3269581|NCT00700258||5|Patients treated with Axitinib after treatment with Sunitinib or Cytokine for metastatic renal cell carcinoma (mRCC)
3269582|NCT00700245|Active Comparator|EXO|Exercise-only (EXO-12 weeks of regular supervised exercise without diet restriction),
3269583|NCT00700245|Active Comparator|DIO|Diet-only (DIO-8 weeks of very low energy diet (VLED 600 kcal/d) followed by 4 weeks weight maintenance diet)
3269584|NCT00700245|Active Comparator|DEX|Diet+exercise (DEX-8 weeks VLED 800 kcal/d + a four weeks weight maintenance diet combined with regular supervised exercise throughout the 12 weeks).
3269585|NCT00700232||1|Normal multiparous pregnant women without intrahepatic cholestasis of pregnancy (control group)
3269586|NCT00700219||1|Women presenting in preterm labor with intact amniotic membranes
3269587|NCT00700206|Experimental|1|Dose Schedule 1: Two weeks treatment with Telintra 3000 mg per day in two divided doses followed by one week with no treatment per three week cycle.
3269588|NCT00700206|Experimental|2|Dose Schedule 2: Three weeks treatment with Telintra 2000 mg per day in two divided doses followed by one week with no treatment per four week cycle.
3269589|NCT00700193|Other|Group A|Equal to or greater 6 months to less than 3 years old
3269590|NCT00700193|Other|Group B|Equal to or greater 3 years to less than 9 years old
3269591|NCT00700180|Experimental|1|
3269592|NCT00700180|Experimental|2|
3269593|NCT00700167|Experimental|1|"The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months.~The vaccines will be given during an outpatient visit. If for some reason, you happen to be in the hospital, you can still receive the vaccines. These visits should take no longer than 15-30 minutes."
3269594|NCT00700154|Experimental|Insulin infusion (aspart)|
3269595|NCT00700154|No Intervention|Standard care|Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.
3269596|NCT00700128|Experimental|Group 2|Frovatriptan or placebo given in a certain sequence depending on what group that the woman are randomized to.
3269597|NCT00700128|Experimental|Group1|Group I will receive in a different sequence either frovatriptan 2.5 mg or placebo bid starting the last day of taking OC and continuing during the hormone free interval (HFI) of 4 days.
3269598|NCT00700115|Experimental|Kaletra + Isentress|Kaletra + Isentress
3269599|NCT00700115|Active Comparator|Standard HAART|Pre-study Antiretroviral regimen
3269600|NCT00700102|Active Comparator|Chemotherapy|Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
3269601|NCT00700102|Experimental|Chemotherapy + Bevacizumab|Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal
3269602|NCT00700089|Experimental|A|The concept is to support and guide the person shortly after the in-hospital treatment for self-injury through a recommended follow-up or after treatment based on assertive principles. The intervention is an indicated prevention strategy targeting people with suicide attempts and deliberate self-harm as a high-risk group. They will be offered 8-20 assertive outreach contacts. The outreach contacts will be home visits focusing on providing support and motivating patients to comply with follow-up treatment.
3269603|NCT00700089|Placebo Comparator|B|Standard treatment consists of referral to a range of different treatment modalities depending on the diagnosis and clinical and social condition of the patient. In standard treatment there is no procedure for ensuring that the patient will actually receive the recommended treatment. Patients are often referred to available treatment modalities such as general practitioner, psychological treatment, treatment for alcohol abuse, and most often, the patients are themselves responsible for getting into contact with the treatment to which they are referred.
3269604|NCT00700076|Active Comparator|1|
3269605|NCT00700076|Placebo Comparator|2|
3269606|NCT00700063|Experimental|1|
3269607|NCT00700063|Experimental|2|
3269608|NCT00700063|Experimental|3|
3269609|NCT00700063|Placebo Comparator|4|
3269610|NCT00700063|Experimental|5|
3269611|NCT00700063|Experimental|6|
3269612|NCT00700063|Experimental|7|
3269613|NCT00700063|Placebo Comparator|8|
3269614|NCT00700050|Experimental|1|
3269615|NCT00700050|Active Comparator|2|
3269616|NCT00700050|Active Comparator|3|
3269617|NCT00700050|Active Comparator|4|
3269618|NCT00700037|Experimental|1|Atorvastatin 20mg
3269619|NCT00700037|Active Comparator|2|atorvastatin 5mg
3269620|NCT00700024|Active Comparator|1|testim
3269621|NCT00700024|Experimental|2|placebo
3269622|NCT00700024|Experimental|3|training
3269623|NCT00700011|Active Comparator|10 mg/m2 group|Patients were treated with Clofarabine 10 mg/m2 daily x 5 days per cycle. Cycles were intended on being every 28 days but this was flexible due to the bone marrow neding to recover from each cycle before strting the next one. Neulasta was given on day 5 of each cycle. Patients were treated until disease progression, or intolerable toxicities.
3269624|NCT00700011|Active Comparator|5 mg/m2 group|Patients were treated with Clofarabine 5 mg/m2 daily x 5 days per cycle. Cycles were intended on being every 28 days but this was flexible due to the bone marrow neding to recover from each cycle before strting the next one. Neulasta was given on day 5 of each cycle. Patients were treated until disease progression, or intolerable toxicities.
3269625|NCT00699998|Experimental|Prasugrel|Prasugrel and Low-dose Commercially-available Aspirin
3269626|NCT00699998|Active Comparator|Clopidogrel|Clopidogrel and Low-Dose Commercially-available Aspirin
3269627|NCT00699985||1|Behcet's Disease patients that their diagnosis was based on the new International Criteria for Behcet's Disease (ICBD).
3269628|NCT00699985||2|Non-Behcet's Disease patients were patients mimicking BD.
3269629|NCT00699972|Experimental|1|
3269630|NCT00699972|Experimental|2|
3269631|NCT00699972|Placebo Comparator|3|
3269632|NCT00699959||1|patients with heart failure
3269633|NCT00699959||2|patients without heart failure
3269634|NCT00699946|Active Comparator|1|
3269635|NCT00699946|Placebo Comparator|2|
3269636|NCT00699933||1|Evaluation of one study cohort
3269637|NCT00699920|Experimental|1|Coarsucam double-layer artesunate/amiodaquine tablets
3269638|NCT00699920|Active Comparator|2|Coartem (artemether/lumefantrine) fixed-dose combination tablets
3269639|NCT00699907|Active Comparator|Treatment Arm|Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.
3269640|NCT00699907|No Intervention|High Risk Arm|High risk patients underwent risk-reducing salpingo-oophorectomy.
3269641|NCT00699907|No Intervention|Low Risk Arm|Low risk patients underwent salpingo-oophorectomy for a medical indication.
3269642|NCT00699894|Experimental|1|aprepitant 40 mg + normal saline IV
3269643|NCT00699894|Active Comparator|2|placebo PO + ondansetron 4 mg IV
3269644|NCT00699881|Experimental|A|administer cetuximab in combination with modified FOLFIRI
3269645|NCT00699868|Experimental|1|Infection to CMV
3269646|NCT00699868|Other|2|"Group control CMV"
3269647|NCT00699842|Experimental|Lenalidomide|Lenalidomide will be given orally on day 1-21, followed by a 7day rest (28 day cycle). Cycles will be repeated every 28 days.
3269648|NCT00699829||1|Mohs' micrographic surgery (MMS)
3269649|NCT00699829||2|Conventional surgery
3269650|NCT00699816|Experimental|Immunotherapy Group|Adjuvant adoptive immune therapy using a CIK cell agent(Immuncell-LC) 16 times(4 treatments at a frequency of once per week, followed by 4 treatments every 2 weeks, then 4 treatments every 4 weeks, and finally 4 treatments every 8 weeks.
3269651|NCT00699816|No Intervention|Control Group|Patients who had undergone curative treatment(surgical resection, radiofrequency ablation[RFA], or percutaneous ethanol injection[PEI]) for HCC of pretreatment clinical stage I or II according to the American Joint Committee on Cancer staging system(6th edition) based on radiologic imaging studies were eligible for this study with no adjuvant treatment
3269652|NCT00699803|Active Comparator|T-Pred|Tobramycin prednisolone acetate combination
3269653|NCT00699803|Active Comparator|Pred Forte|Prednisolone acetate
3269654|NCT00699790|Experimental|A1|
3269655|NCT00699790|Placebo Comparator|A2|
3269656|NCT00699777|Experimental|1|One risedronate 150 mg tablet administered orally after an overnight (10 hour) fast, followed by a 4 hour post-dose fast
3269657|NCT00699777|Active Comparator|2|Two risedronate 75 mg tablets administered as a single oral dose after an overnight (10 hour) fast, followed by a 4 hour post-dose fast
3269658|NCT00699764|Experimental|Group A|
3269659|NCT00699764|Placebo Comparator|Group B|
3269660|NCT00699751|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received radium-223 50 kilo Becquerel (kBq)/kg body weight (b.w.) for 6 intravenous (IV) administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).
3269661|NCT00699751|Placebo Comparator|Placebo|Participants received isotonic saline for 6 IV administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).
3269662|NCT00699738|Experimental|1|Healthy women during pregnancy and in the postpartum period, breastfeeding
3269663|NCT00699738|Active Comparator|2|Healthy women during pregnancy and in the postpartum period,bottlefeeding
3269664|NCT00699738|No Intervention|3|Healthy non-pregnant women
3269665|NCT00699725||1|NSAID patients with risk factors treated with gastroprotective drugs
3269667|NCT00699712|Experimental|B|Open-label regimen of doses 2 and 3 of CDNP
3269668|NCT00699712|Experimental|C|Open-label regimen of doses 3 and 4 of CDNP
3269669|NCT00699686|Active Comparator|Glargine|During this arm/phase patients take subcutaneous glargine daily for 3 months.
3269670|NCT00699686|Experimental|Detemir|During this arm/phase, patients take insulin Detemir subcutaneously for 3 months.
3269671|NCT00699660|Experimental|CAPS/WHODAS|PTSD assessed using Clinical Assessment of PTSD Symptoms (CAPS) and WHODAS functional impairment structured evidence-based interview
3269672|NCT00699660|Active Comparator|Nonstructured Interview|Usual clinical interview to assess PTSD, without CAPS or WHODAS
3269673|NCT00699621|Active Comparator|1|Platelet transfusion
3269674|NCT00699621|No Intervention|2|No platelet transfusion
3269675|NCT00699608|Experimental|Crossover|All subjects received all three treatments in a randomised order
3269676|NCT00699595||Term pregnant women|Healthy women scheduled for elective Cesarean section.
3269677|NCT00699582|Experimental|1|
3269678|NCT00699582|Experimental|2|
3269679|NCT00699582|Placebo Comparator|3|
3269680|NCT00699569|Experimental|1|Patients receiving active investigational product
3269681|NCT00699569|Placebo Comparator|2|Patients receiving Placebo
3269682|NCT00699556|Experimental|patch+spray|Within subject design. All volunteers complete two laboratory sessions. In one session they receive nicotine patch + nicotine nasal spray.
3269683|NCT00699556|Placebo Comparator|patch+placebo spray|Within subject design. All volunteers complete two laboratory sessions. In one session they receive nicotine patch + placebo nicotine nasal spray.
3269684|NCT00699543|Experimental|C|Coroflex Please stent implantation
3269685|NCT00699543|Active Comparator|T|Taxus stent implantation
3269686|NCT00699530||Hyperprolactinemia|Patients recently diagnosed with hyperprolactinemia
3269687|NCT00699517|Experimental|1|
3269688|NCT00699517|Placebo Comparator|2|
3269689|NCT00699504|Experimental|Lead in Phase|Supratherapeutic dose of cangrelor
3269690|NCT00699504|Experimental|A|therapeutic dose cangrelor treatment
3269691|NCT00699504|Experimental|B|supratherapeutic dose cangrelor treatment
3269692|NCT00699504|Active Comparator|C|active comparator treatment
3269693|NCT00699504|Placebo Comparator|D|placebo treatment
3269694|NCT00699491|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive temsirolimus IV over 30 minutes and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 (cixutumumab is given on days 8, 15, and 22 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3269695|NCT00699478|Experimental|1|post total gastrectomized patients due to gastric cancer who has vitamin B12 deficiency - given oral vitamin B 12 supplementation
3269696|NCT00699465|Active Comparator|1|Early enoxaparin
3269697|NCT00699465|Placebo Comparator|2|Late enoxaparin
3269698|NCT00699452|Active Comparator|1|Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)
3269699|NCT00699452|Placebo Comparator|2|Placebo
3269700|NCT00699439|Active Comparator|A|If a patient is identified as having an asthma exacerbation by the Bayesian Network, the paper-based flow-chart will be printed out to place on the chart.
3269701|NCT00699439|No Intervention|B|If a patient is identified as having an asthma exacerbation by the Bayesian Network, and assigned to the control group, no flow-chart will be printed out.
3269702|NCT00699426|Active Comparator|Nexium + Yoghurt|
3269703|NCT00699426|Placebo Comparator|Nexium + Placebo|
3269704|NCT00699426|Placebo Comparator|Placebo+ Yoghurt|
3269705|NCT00699426|Placebo Comparator|placebo+placebo|
3269706|NCT00699413|Active Comparator|1|nutrition education plus active supplement
3269707|NCT00699413|Placebo Comparator|2|nutrition education plus inactive supplement
3269708|NCT00699387|Experimental|Benznidazole|Treatment of pediatric Chagas disease with benznidazole
3269709|NCT00699374|Experimental|Arm A|sunitinib arm
3269710|NCT00699374|Active Comparator|Arm B|sorafenib arm
3269711|NCT00699361|Experimental|1|Measurement before Pantoprazole application
3269712|NCT00699361|Experimental|2|Measurements after Pantoprazole application
3269713|NCT00699348|Experimental|C.E.R.A.|
3269714|NCT00699322|Experimental|1|Sitagliptin
3269715|NCT00699322|Active Comparator|2|Glimepiride
3269716|NCT00699309||Taperloc® Microplasty™ Hip System|
3269717|NCT00699296|Experimental|1|
3269718|NCT00699283|Experimental|Brivaracetam (BRV) 1|50 mg daily
3269719|NCT00699283|Experimental|Brivaracetam (BRV) 2|100 mg daily
3269720|NCT00699270||Biomet Humeral Stems|Biomet Humeral Stems: Comprehensive®, BioModular®, and Bi-Angular® Shoulder Systems
3269721|NCT00699257||Oxford® Partial Knee System|
3269722|NCT00699244|Experimental|Peripheral placement of local anesthesia|to receive ultrasound guided peripheral placement of local anesthetic
3269723|NCT00699244|Active Comparator|Central placement of local anesthesia|to receive central placement of local anesthetic
3269724|NCT00699231|Active Comparator|Group A1|Non-responders to vaccination after at least 7 previous injections
3269725|NCT00699231|Experimental|Group A2|Non-responders to vaccination after at least 7 previous injections
3269726|NCT00699231|Active Comparator|Group B1|Vaccine-responders requiring a booster dose
3269727|NCT00699231|Experimental|Group B2|Vaccine-responders requiring a booster dose
3269728|NCT00699231|Active Comparator|Group C1|Volunteers participating in the hospital's vaccination program
3269729|NCT00699231|Experimental|Group C2|Volunteers participating in the hospital's vaccination program
3269730|NCT00699231|Active Comparator|Group D1|Unvaccinated haemodialysis patients
3269731|NCT00699231|Experimental|Group D2|Unvaccinated haemodialysis patients
3269732|NCT00699218|Experimental|rTMS treatment|Active rTMS treatment. Transcranial magnetic stimulation using a device called MagStim
3269733|NCT00699192|Experimental|Amlodipine/Valsartan 5/80 mg|1 capsule amlodipine 5 mg, 1 capsule valsartan 80 mg once daily
3269848|NCT00698542||1|Patients in the NCU at VUH
3269734|NCT00699192|Active Comparator|Amlodipine/Valsartan 5/40 mg|1 capsule amlodipine 5 mg, 1 capsule valsartan 40 mg once daily
3269735|NCT00699192|Active Comparator|Amlodipine 5 mg|1 capsule amlodipine 5 mg, 1 capsule placebo to match valsartan once daily
3269736|NCT00699179||A|
3269737|NCT00699166|Experimental|1|
3269738|NCT00699166|Experimental|2|
3269739|NCT00699166|Placebo Comparator|3|
3269740|NCT00699153|Experimental|Loteprednol Etabonate|Loteprednol Etabonate 0.5%
3269741|NCT00699153|Placebo Comparator|Vehicle|Vehicle of Ophthalmic Loteprednol Etabonate
3269742|NCT00699140|Experimental|1 treatment group with IGIV3I Grifols|"Open label, non-randomized treatment group with IGIV3I Grifols~Each patient received a total dose of 2 g/kg IGIV3I Grifols, given intravenously over either 2 days or 5 days in divided doses."
3269743|NCT00699127|Experimental|1|The group that will have lecture of information regarding infants in NICU.
3269744|NCT00699127|No Intervention|2|The group that will not have lecture of information regarding NICU hospitalization
3269745|NCT00699114|Placebo Comparator|Placebo|Single dose placebo capsule
3269746|NCT00699114|Active Comparator|Ibuprofen 400 mg|Single dose ibuprofen 400 mg capsule
3269747|NCT00699114|Active Comparator|Ibuprofen 600 mg|Single dose ibuprofen 600 mg capsule
3269748|NCT00699114|Active Comparator|Ibuprofen 800 mg|Single dose ibuprofen 800 mg capsule
3269749|NCT00699114|Active Comparator|Paracetamol 500 mg|Paracetamol 500 mg (acetaminophen) capsule
3269750|NCT00699114|Active Comparator|Paracetamol 1000 mg|Single dose paracetamol 1000 mg (acetaminophen) capsule
3269751|NCT00699114|Active Comparator|Paracetamol 1000 mg + codeine 60 mg|Single dose paracetamol (acetaminophen) 1000 mg + codeine 60 mg capsule
3269752|NCT00699101|Experimental|A|Conture Multi-Lumen Balloon
3269753|NCT00699088||Balance® Microplasty™ Hip System|
3269754|NCT00699062|Placebo Comparator|Placebo pill|The patients allocated into this placebo comparator arm will receive inhale corticosteroid plus long-acting bronchodilator plus placebo for 6 months.
3269755|NCT00699062|Experimental|Singular pill|The patients in this placebo comparator arm will receive inhale corticosteroid plus long-acting bronchodilator and montelukast for 6 months
3269756|NCT00699049|Placebo Comparator|Alpha blocker and placebo|
3269757|NCT00699049|Experimental|Alpha blocker and solifenacin|
3269758|NCT00699036|Experimental|1|avandia
3269759|NCT00699036|Experimental|2|avandia plus metformin
3269760|NCT00699036|Experimental|3|avandia plus losartan
3269761|NCT00699023|Experimental|1|ezetimibe tablets 10 mg/die + simvastatin tablets 20 mg/die six weeks
3269762|NCT00699023|Placebo Comparator|2|placebo + simvastatin tablets 20 mg/die six weeks
3269763|NCT00699010|Active Comparator|A|
3269764|NCT00699010|Active Comparator|B|
3269765|NCT00699010|Placebo Comparator|C|
3269766|NCT00699010|Active Comparator|D|
3269767|NCT00699010|Active Comparator|E|
3269768|NCT00698997|Experimental|1 Early Start Denver Model|"Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching & coaching parents to use the ESDM in all natural caretaking routines & play periods with their child. Parents are taught & coached on 1 aspect of the ESDM each week in the clinic session, & then practice it at home daily in natural family routines & play.~Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines & play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week."
3269769|NCT00698997|Other|2|Standard Care available in the Community
3269770|NCT00698984|Active Comparator|1|30 mg BONISTEIN(R) 150 ug Vitamin K1 800 IU Vitamin D3 1000 mg PUFA 500 mg Calcium
3269771|NCT00698984|Placebo Comparator|2|500 mg Calcium
3269772|NCT00698958|Active Comparator|1|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
3269773|NCT00698958|Experimental|2|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
3269774|NCT00698945|Active Comparator|2|Alphagan
3269775|NCT00698945|Active Comparator|1|Istalol and Optive
3269776|NCT00698932|Experimental|Saxagliptin 5mg|
3269777|NCT00698932|Placebo Comparator|Placebo|
3269778|NCT00698919||Development cohort|A first group of one hundred patients with SIRS will be included to evaluate the accuracy of this new test.
3269779|NCT00698919||Validation Cohort|Depending on the result of the previous (development) cohort we will more accurately evaluate the need of number of patients with SIRS to include in the second cohort of patients.
3269780|NCT00698906|Experimental|Group A|
3269781|NCT00698906|Experimental|Group B|
3269782|NCT00698906|Experimental|Group C|
3269783|NCT00698906|Experimental|Group D|
3269784|NCT00698906|Experimental|Group E|
3269785|NCT00698906|Active Comparator|Group F|
3269786|NCT00698893|Experimental|Group A|
3269787|NCT00698893|Experimental|Group B|
3269788|NCT00698880|Active Comparator|HVE|Hepatic vein embolization after portal vein embolization
3269789|NCT00698880|No Intervention|PVE|Only portal vein embolization, historical control group
3269790|NCT00698867||Discovery™ Elbow|Discovery™ Elbow minimally constrained
3269791|NCT00698854||Vanguard™ Complete Knee System|Vanguard Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
3269792|NCT00698854||Vanguard™ Patient-Specific Femur|Vanguard Total Knee System used in combination with Signature technique to provide a patient-specific femur
3269793|NCT00698841|Experimental|Cetuximab|
3269794|NCT00698828|Experimental|Group 1|SUN11031 for injection, low dose, twice daily for 12 weeks
3269795|NCT00698828|Experimental|Group 2|SUN11031 for injection, higher dose, twice daily for 12 weeks
3269796|NCT00698828|Placebo Comparator|Group 3|Placebo injection, twice daily for 12 weeks
3269849|NCT00698529|No Intervention|No POL Training|Participating NGOs and their staff will receive no specialized training.
3269969|NCT00697853|Experimental|Group C|
3269797|NCT00698815|Experimental|Arm I (pemetrexed)|Patients receive pemetrexed disodium 500 mg/m^2 IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive sunitinib malate as in Arm II as third-line therapy.
3269798|NCT00698815|Experimental|Arm II (sunitinib)|Patients receive sunitinib malate at 37.5 mg PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive pemetrexed disodium as in Arm I as third-line therapy.
3269799|NCT00698815|Experimental|Arm III (pemetrexed and sunitinib)|Patients receive pemetrexed disodium 500 mg/m^2 IV over 10 minutes on day 1 and sunitinib malate at 37.5 mg PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive third-line therapy at the discretion of the treating physician.
3269800|NCT00698802|Experimental|A|
3269801|NCT00698802|Active Comparator|B|
3269802|NCT00698789|Experimental|Treatment A|5 mg of INCB019602 in AM with placebo administration in PM
3269803|NCT00698789|Experimental|Treatment B|20 mg of INCB019602 in AM with placebo administration in PM
3269804|NCT00698789|Experimental|Treatment C|5 mg of INCB019602 in PM with placebo administration in AM
3269805|NCT00698789|Experimental|Treatment D|20 mg of INCB019602 in PM with placebo administration in AM
3269806|NCT00698789|Experimental|Treatment E|7.5 mg of INCB019602 in PM QoD with placebo administration in AM as well as PM on non active dose days
3269807|NCT00698789|Placebo Comparator|Treatment F|Placebo BID
3269808|NCT00698776|Experimental|Active|10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
3269809|NCT00698763|Experimental|A|Levosimendan
3269810|NCT00698763|Placebo Comparator|B|Placebo
3269811|NCT00698750||Copeland™ Humeral Resurfacing Head|Copeland™ Humeral Resurfacing Head
3269812|NCT00698724|Active Comparator|1|Group 1: Xibrom, Optive
3269813|NCT00698724|Active Comparator|2|Group 2: Xibrom, Pred Forte
3269814|NCT00698711|Experimental|1|"Three groups of 5 patients enrolled sequentially comprised from will receive MUC-2-KLH vaccines at the following g amounts of MUC-2-KLH per vaccination.~10 + 100 μg QS21 30 + 100 μg QS21 3 + 100 μg QS21"
3269815|NCT00698698||Non diabetic|Normal age and sex matched population
3269816|NCT00698698||Grade 1|Diabetic population with no retinopathy or Mild non proliferative diabetic retinopathy
3269817|NCT00698698||Grade 2|Moderate non proliferative diabetic retinopathy
3269818|NCT00698698||Grade 3|Severe non proliferative diabetic retinopathy
3269819|NCT00698698||Grade 4|Proliferative diabetic retinopathy and advanced diabetic eye disease
3269820|NCT00698685|Experimental|Preparative Regimen|"Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)~Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)~Followed by Allogeneic hematopoietic stem cell transplantation, related or unrelated donor, on day 0. Patients also receive cyclosporine intravenous (IV) continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper."
3269821|NCT00698672|Active Comparator|2|articulation Spectron EF CoCr/ Reflection All-Poly Eto-sterilized
3269822|NCT00698672|Active Comparator|3|articulation Spectron Ef CoCr/ Reflection All-Poly XLPE
3269823|NCT00698672|Active Comparator|4|articulation Spectron EF Oxinium/ Reflection All-Poly Eto-sterilized
3269824|NCT00698672|Active Comparator|5|articulation Spectron EF Oxinium/ Reflection XLPE
3269825|NCT00698672|Active Comparator|1|articulation Charnley/ Ogee
3269826|NCT00698659||patients on anti-VEGF therapy|"This study aims to assess the pharmacodynamic effects of anti-VEGF therapy. The following groups of patients will be approached:~Those who are starting on anti-VEGF therapy (such as but not limited to bevacizumab, sunitinib, and sorafenib) as part of routine clinical management or on clinical studies~All patients must be aged aged ≥ 21 years All patients must have a signed written informed consent prior to study enrollment. A separate consent will be obtained from patients already involved in a clinical study using anti-VEGF treatment.~Patients with a known allergy to intravenous contrast used in fluorescein and indocyanine green angiography will be exempt from these investigations but will undergo other study assessments."
3269827|NCT00698646|Active Comparator|Valsartan|(patients initiated on valsartan)
3269828|NCT00698646|Active Comparator|HCTZ|(patients initiated on HCTZ)
3269829|NCT00698646|Experimental|Valsartan + HCTZ|(patients initiated on Valsartan+HCTZ)
3269830|NCT00698633||M2a- Taper™ Hip System|M2a- Taper™ Hip System
3269831|NCT00698607|Experimental|E6|Everolimus-eluting stent 6-month clopidogrel therapy
3269832|NCT00698607|Active Comparator|S6|Sirolimus-eluting stent 6-month clopidogrel therapy
3269833|NCT00698607|Experimental|E12|Everolimus-eluting stent 12-month clopidogrel therapy
3269834|NCT00698607|Active Comparator|S12|Sirolimus-eluting stent 12-month clopidogrel therapy
3269835|NCT00698594|Active Comparator|1|Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
3269836|NCT00698594|Active Comparator|2|Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group
3269837|NCT00698594|Placebo Comparator|3|Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
3269838|NCT00698581|Experimental|Brivaracetam 50 mg|50 mg/day
3269839|NCT00698581|Experimental|Brivaracetam 100 mg|100 mg/day
3269840|NCT00698568|Experimental|Group A|
3269841|NCT00698568|Placebo Comparator|Group B|
3269842|NCT00698555|Experimental|Group A|
3269843|NCT00698555|Experimental|Group B|
3269844|NCT00698555|Experimental|Group C|
3269845|NCT00698555|Experimental|Group D|
3269846|NCT00698555|Experimental|Group E|
3269847|NCT00698555|Active Comparator|Group F|
3269850|NCT00698529|Experimental|Face-to-Face|Participating NGOs and their staff will receive training through face-to-face seminars held at the NGOs and through post-seminar consultation telephone calls.
3269851|NCT00698529|Experimental|Distance Learning|Participating NGOs and their staff will receive training through Web-based seminars and through post-seminar consultation telephone calls.
3269852|NCT00698516|Experimental|Open label, Single arm|Oral topotecan + IV Bevacizumab
3269853|NCT00698503||M2a- 38™ Hip System|
3269854|NCT00698490|Experimental|Group A|HSV-seronegative subjects
3269855|NCT00698490|Experimental|Group B|HSV-seropositive subjects
3269856|NCT00698490|Experimental|Group C|HSV-seronegative subjects
3269857|NCT00698490|Experimental|Group D|HSV-seronegative subjects
3269858|NCT00698490|Experimental|Group E|HSV-seronegative subjects
3269859|NCT00698464|Experimental|Pasireotide|
3269860|NCT00698451|Experimental|001|doxorubicin HCL liposome; bevacizumab; carboplatin30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
3269861|NCT00698438|Active Comparator|a|Implantation of Ex-PRESS mini glaucoma shunt under a scleral flap
3269862|NCT00698438|Active Comparator|b|Trabecolectomy
3269863|NCT00698425|Experimental|1: 0 mA-min (0 mA for 4 min)|Ocular iontophoresis 0 mA-min (0 mA for 4 minutes)
3269864|NCT00698425|Experimental|2: 4 mA-min (2 mA for 2 min), + polarity|Ocular iontophoresis 4 mA-min (2 mA for 2 minutes), positive polarity
3269865|NCT00698425|Experimental|3: 5 mA-min (2.5 mA for 2 min), +|Ocular iontophoresis 5 mA-min (2.5 mA for 2 minutes), positive polarity
3269866|NCT00698425|Experimental|4: 6 mA-min (3 mA for 2 min), + polarity|Ocular iontophoresis 6 mA-min (3 mA for 2 minutes), positive polarity
3269867|NCT00698425|Experimental|5: 7 mA-min (3.5 mA for 2 min), +|Ocular iontophoresis 7 mA-min (3.5 mA for 2 minutes), positive polarity
3269868|NCT00698425|Experimental|6: 8 mA-min (4 mA for 2 min), + polarity|Ocular iontophoresis 8 mA-min (4 mA for 2 minutes), positive polarity
3269869|NCT00698425|Experimental|7: 7 mA-min (3.5 mA for 2 min), -|7 mA-min (3.5 mA for 2 minutes), negative polarity
3269870|NCT00698425|Experimental|8: 8 mA-min (4 mA for 2 min), - polarity|Ocular iontophoresis 8 mA-min (4 mA for 2 minutes), negative polarity
3269871|NCT00698425|Experimental|9: 20 mA-min (4 mA for 5 min), +|Ocular iontophoresis 20 mA-min (4 mA for 5 minutes), positive polarity
3269872|NCT00698425|Experimental|10: 20 mA-min (2 mA for 10 min), +|Ocular iontophoresis 20 mA-min (2 mA for 10 minutes), positive polarity
3269873|NCT00698425|Experimental|11: 20 mA-min (4 mA for 5 min), -|Ocular iontophoresis 20 mA-min (4 mA for 5 minutes), negative polarity
3269874|NCT00698425|Experimental|12: 20 mA-min (2 mA for 10 min), -|Ocular iontophoresis 20 mA-min (2 mA for 10 minutes), negative polarity
3269875|NCT00698425|Experimental|13: 0 mA-min (0 mA for 10.5 min)|Ocular iontophoresis 0 mA-min (0 mA for 10.5 minutes)
3269876|NCT00698425|Experimental|14: 13.5 mA-min (4.5 mA for 3 min), +|Ocular iontophoresis 13.5 mA-min (4.5 mA for 3 minutes), positive polarity
3269877|NCT00698425|Experimental|15: 15 mA-min (5 mA for 3 min), +|Ocular iontophoresis 15 mA-min (5 mA for 3 minutes), positive polarity
3269878|NCT00698425|Experimental|16: 16.5 mA-min (5.5 mA for 3 min), +|Ocular iontophoresis 16.5 mA-min (5.5 mA for 3 minutes), positive polarity
3269879|NCT00698425|Experimental|17: 18 mA-min (6 mA for 3 min), +|Ocular iontophoresis 18 mA-min (6 mA for 3 minutes), positive polarity
3269880|NCT00698425|Experimental|18: 19.5 mA-min (6.5 mA for 3 min), +|Ocular iontophoresis 19.5 mA-min (6.5 mA for 3 minutes), positive polarity
3269881|NCT00698425|Experimental|19: 20 mA-min (7 mA for 3.84 min), +|Ocular iontophoresis 20 mA-min (7 mA for 3.84 minutes), positive polarity
3269882|NCT00698412|Experimental|1|Cane group
3269883|NCT00698412|No Intervention|2|Control Group
3269884|NCT00698399||1|Live Donor
3269885|NCT00698399||2|Cadaveric Donor
3269886|NCT00698373||1|PET study
3269887|NCT00698360||A|MDRD 10-30
3269888|NCT00698360||B|MDRD 30-60
3269889|NCT00698360||C|MDRD 60-80
3269890|NCT00698360||D|MDRD > 80
3269891|NCT00698347||M2a-Magnum™ Hip System|Patients who received the M2a-Magnum™ Hip System
3269892|NCT00698334|Experimental|HIV infected|HIV infected patients with active TB
3269893|NCT00698334|Active Comparator|HIV negative|HIV negative patients with active TB
3269894|NCT00698321|Experimental|1|Participating schools will deliver HIV/STD prevention modules.
3269895|NCT00698321|Active Comparator|2|Participating schools will deliver general health promotion modules.
3269896|NCT00698282|Experimental|1|
3269897|NCT00698282|Experimental|2|
3269898|NCT00698282|Placebo Comparator|3|
3269899|NCT00698269||A|
3269900|NCT00698269||B|
3269901|NCT00698269||C|
3269902|NCT00698256|Experimental|1|
3269903|NCT00698256|Placebo Comparator|2|
3269904|NCT00698243|Experimental|Schedule 1|Once daily for 3 days every 7 days
3269905|NCT00698243|Experimental|Schedule 2|Once weekly
3269906|NCT00698243|Experimental|Schedule 3|Once daily
3269907|NCT00698230|Experimental|Treatment A - INCB013739 & Metformin|INCB013739 5 mg QD and Metformin
3269908|NCT00698230|Experimental|Treatment B - INCB013739 & Metformin|INCB013739 15 mg QD and Metformin
3269909|NCT00698230|Experimental|Treatment C - INCB013739 & Metformin|INCB013739 50 mg QD and Metformin
3269910|NCT00698230|Experimental|Treatment D - INCB013739 & Metformin|INCB013739 100 mg QD and Metformin
3269911|NCT00698230|Experimental|Treatment E - INCB013739 & Metformin|INCB013739 200 mg QD and Metformin
3269912|NCT00698230|Placebo Comparator|Treatment F - Placebo|Matching placebo
3269913|NCT00698204|Experimental|I- Celecoxib|
3269914|NCT00698204|Placebo Comparator|II|
3269915|NCT00698191|Experimental|1|
3269916|NCT00698178||NERD|patients with typical gastro-reflux symptoms but no erosions were discernible on upper gastrointestinal endoscopy
3269917|NCT00698178||EE|Patients with both typical gastroesophageal reflux symptoms and characteristic flam-like erosions as demonstrated on upper gastrointestinal endoscopy
3269918|NCT00698178||FD|Patients report no typical reflux symptoms but fulfill diagnostic criteria of functional dyspepsia, whose upper gastrointestinal endoscopy are negative.
3269919|NCT00698165||Patients|1200 adults with mild to severe Alzheimer's disease
3269920|NCT00698165||Caregivers|1200 informal caregivers
3269921|NCT00698152||ArComXL® polyethylene|ArComXL® polyethylene
3269922|NCT00698139|Active Comparator|Intervention first, then control|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~On the first encounter, patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.~On the second encounter, patients will come to clinic in the morning for baseline measurements.Subsequently, they will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. The rest of the protocol will be as described for the first encounter."
3269923|NCT00698139|Active Comparator|Control first, then intervention|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~On the first encounter, patients will come to clinic in the morning for baseline measurements.Subsequently, the control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.~On the second encounter, patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The rest of the protocol will be as described for the first encounter."
3269924|NCT00698139|Active Comparator|Intervention Only|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour."
3269925|NCT00698126||A|
3269926|NCT00698126||B|
3269927|NCT00698113|Active Comparator|1|This group receives the massage intervention for a period of six weeks. Children and parents are asked to journal weekly for the six week period.
3269928|NCT00698113|No Intervention|2|The control group does not receive any massage intervention during the initial six weeks of the study. The children are asked to journal during this six week period.
3269929|NCT00698100|Experimental|1|Patients will get human tyrosinase vaccination.
3269930|NCT00698100|Experimental|2|Patient will get mouse tyrosinase DNA vaccination.
3269931|NCT00698087|Experimental|Group A|
3269932|NCT00698087|Active Comparator|Group B|
3269933|NCT00698087|Experimental|Group C|
3269934|NCT00698074|Experimental|1|Cardiac Resynchronisation Therapy
3269935|NCT00698061|Experimental|Group A|
3269936|NCT00698061|Active Comparator|Group B|
3269937|NCT00698048||1|Controls
3269938|NCT00698048||2|Sepsis
3269939|NCT00698048||3|Septic Shock
3269940|NCT00698035|Active Comparator|Testosterone Cream|Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
3269941|NCT00698035|Active Comparator|Estring|Estring 2mg ring inserted vaginally once every 12 weeks
3269942|NCT00698022|Experimental|Risperidone plus mifepristone|risperidone plus mifepristone daily for 28 days
3269943|NCT00698022|Placebo Comparator|risperidone plus mifepristone-matched placebo|risperidone plus mifepristone-matched placebo daily for 28 days
3269944|NCT00698022|Placebo Comparator|risperidone matched-placebo plus mifepristone|risperidone-matched placebo plus mifepristone daily for 28 days
3269945|NCT00698009|Experimental|Fludarabine + Cyclophosphamide + NK Cell Infusion|Fludarabine 25 mg/m^2 intravenous (IV) Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2. Cyclophosphamide 60 mg/kg IV Daily Over 2 Hours On Days -5 and -4. Natural Killer Cell Infusion on Day 0. Mesna 12 mg/kg By Vein, Over about 15 minutes, 5 Times Per Day on Days -5 and -4. Interleukin-2 subcutaneously three times weekly for 9 total doses following NK Cell Infusion.
3269946|NCT00697983||Fracture cohort|Patients of 50 years and above with a clinical, non-pathological fracture, who attend an osteoporosis outpatient clinic at the Maastricht University Medical Center for standard medical care (including bone densitometry by DXA-scan).
3269947|NCT00697970|Experimental|Group A|
3269948|NCT00697970|Experimental|Group B|
3269949|NCT00697970|Experimental|Group C|
3269950|NCT00697970|Experimental|Group D|
3269951|NCT00697970|Experimental|Group E|
3269952|NCT00697970|Active Comparator|Group F|
3269953|NCT00697957|No Intervention|2|Control group
3269954|NCT00697957|Experimental|1|Exercise
3269955|NCT00697931|Experimental|Group A|
3269956|NCT00697931|Active Comparator|Group B|
3269957|NCT00697918|Experimental|001|RWJ-333369100 mg to 400 mg twice daily
3269958|NCT00697905|Experimental|A|
3269959|NCT00697905|Active Comparator|B|
3269960|NCT00697892|Experimental|Group A4|healthy volunteers assigned to the efavirenz with artemether/lumefantrine intervention
3269961|NCT00697892|Experimental|Group A3|healthy volunteers assigned to the lopinavir/ritonavir with artemether/lumefantrine intervention
3269962|NCT00697879|Experimental|1|Oral, once daily administration of CHR-3996 to determine safety and tolerability
3269963|NCT00697866|Experimental|Group A|HBV-MPL Lot A
3269964|NCT00697866|Experimental|Group B|HBV-MPL Lot B
3269965|NCT00697866|Experimental|Group C|HBV-MPL Lot C
3269966|NCT00697866|Active Comparator|Group D|Engerix™-B
3269973|NCT00697840|Active Comparator|Group B|
3269974|NCT00697840|Experimental|Group C|
3269975|NCT00697827|Experimental|1|In-Space
3269976|NCT00697827|Active Comparator|2|X STOP
3269977|NCT00697814|Experimental|Clomiphene|Clomiphene 50 mg/day for 12 weeks
3269978|NCT00697801|Experimental|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
3269979|NCT00697801|Experimental|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
3269980|NCT00697801|Placebo Comparator|Placebo|Placebo delivered by nebulization twice daily for 6 weeks
3269981|NCT00697788|Experimental|Ascending dose study|Ascending doses of dexmedetomidine (as per protocol)
3269982|NCT00697775|Experimental|Group A|HBV-MPL Formulation A at months 0 and 6
3269983|NCT00697775|Experimental|Group B|HBV-MPL Formulation B at months 0 and 6
3269984|NCT00697775|Experimental|Group C|HBV-MPL Formulation A at month 0 and Engerix™-B at month 6
3269985|NCT00697775|Active Comparator|Group D|Engerix™-B at months 0, 1, 6
3269986|NCT00697762|Placebo Comparator|003|Placebo tablet twice daily for 12 weeks
3269987|NCT00697762|Experimental|002|RWJ-333369 200 mg tablet twice daily for 12 weeks
3269988|NCT00697762|Experimental|001|RWJ-333369 100 mg tablet twice daily for 12 weeks
3269989|NCT00697749|Experimental|Group A|
3269990|NCT00697749|Active Comparator|Group B|
3269991|NCT00697710|Experimental|Cohort A|50 mg S-777469 or Placebo, BID
3269992|NCT00697710|Experimental|Cohort B|200 mg S-777469 or Placebo, BID
3269993|NCT00697710|Experimental|Cohort C|800 mg S-777469 or Placebo, BID
3269994|NCT00697697|Experimental|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
3269995|NCT00697697|Experimental|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
3269996|NCT00697684|No Intervention|Cohort 1|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
3269997|NCT00697684|Experimental|Cohort 2|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
3269998|NCT00697684|Experimental|Cohort 3|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
3269999|NCT00697684|Experimental|Cohort 4|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
3270000|NCT00697671|Other|Strata A|Patients with ALL, CML, JMML, MDS, or NHL with bone marrow relapse after stem cell transplant.
3270001|NCT00697671|Other|Strata B|Patients with ALL, CML, JMML , MDS, or NHL with primary induction failure and persistent disease; or participants with relapsed ALL, CML, JMML, MDS, or NHL with persistent disease after re-induction
3270002|NCT00697658||001|
3270003|NCT00697645|Sham Comparator|1|Patients with stroke will be treated with usual stroke care and sham TMS will be applied
3270004|NCT00697645|Experimental|2|Deep TMS applied over the motor strip in patients with stroke in addition to usual stroke care.
3270005|NCT00697632|Experimental|1|
3270006|NCT00697619|Experimental|Test Group|Zometa (zoledronic acid) 4 mg over 15 min IV infusion, every 4 week Anti-neoplastic therapy .Patients can receive concomitant cycles of chemotherapy or radiotherapy.
3270007|NCT00697619|No Intervention|Contorl Group|Anti-neoplastic therapy alone. Patients can receive concomitant cycles of chemotherapy or radiotherapy.
3270008|NCT00697606|Experimental|A|Seprafilm®
3270009|NCT00697606|Sham Comparator|B|Control
3270010|NCT00697593|Experimental|Efalizumab|
3270011|NCT00697580|No Intervention|1|Control (C)
3270012|NCT00697580|Experimental|2|Nutrition (N)
3270013|NCT00697580|Experimental|3|Strength Training & Nutrition (ST + N)
3270014|NCT00697580|Experimental|4|Circuit Training & Nutrition (CT + N)
3270015|NCT00697567|Experimental|Group A|HSV seropositive subjects
3270016|NCT00697567|Experimental|Group B|HSV seronegative subjects
3270017|NCT00697567|Experimental|Group C|HSV seropositive subjects
3270018|NCT00697567|Experimental|Group D|HSV seronegative subjects
3270019|NCT00697554|Experimental|Group A|
3270020|NCT00697554|Active Comparator|Group B|
3270021|NCT00697541|Experimental|A|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after four hours
3270022|NCT00697541|Active Comparator|B|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
3270023|NCT00697528||Group control with healthy subjects|Healthy subjects without thyroid disease, ocular disease and previous surgery in the orbit or eye used in the study.
3270024|NCT00697528||Graves' Ophthalmopathy - fibrotic phase|Patients that are clinically inactive (CAS equal or lower than 2). This group will be subdivided in the miogenic and lipogenic groups.
3270025|NCT00697528||Graves' Ophthalmopathy - active phase|Patients that are clinically active, presenting a CAS of 4 or more points, with or without disthyroid optic neuropathy.
3270026|NCT00697515|Active Comparator|Lisdexamfetamine Dimesylate (LDX, SPD489)|
3270027|NCT00697515|Placebo Comparator|Placebo|
3270028|NCT00697502|Experimental|Group 2: TSER 3R/3R|Cohorts of 3-6 patients in each genotype group will receive escalating doses of capecitabine until MTD is reached. Once MTD is determined, an additional 6-9 patients (for a total of 12 patients) will receive treatment at that dose.
3270029|NCT00697502|Experimental|Group 1: TSER 2R/2R or 2R/3R|Cohorts of 3-6 patients in this genotype group will receive escalating doses of capecitabine until MTD is reached. Once MTD is determined, an additional 6-9 patients (for a total of 12 patients) will receive treatment at that dose.
3270030|NCT00697489|Active Comparator|1|unique surgery
3270031|NCT00697489|Active Comparator|2|Double surgery
3270032|NCT00697476|Experimental|Vorinostat/Topotecan|"Vorinostat/topotecan dose escalation regimen. vorinostat is administered orally once a day for 7 to 14 consecutive days, according to the dose level.Topotecan is administered I.V. for 5 consecutive days every three weeks.~Vorinostat dose levels go from 300 mg/day for 7 days to 400 mg/day for 14 days. Topotecan dose levels go from 1,2 mg/m2 to 1,5 mg/m2"
3270033|NCT00697463|Experimental|Women with Idiopathic osteoporosis (IOP)|Each subject will receive 20 micrograms of Teriparatide (PTH 1-34) subcutaneously daily for 18 -24 months
3270034|NCT00697450||All participants|
3270035|NCT00697437|Experimental|docetaxel only|
3270036|NCT00697437|Experimental|docetaxel with ketoconazole|
3270037|NCT00697424|Experimental|1|All subjects will be placed on continuous positive airway pressure (CPAP) therapy during a full night sleep study or polysomnography (PSG). The subjects will spend 2 hours on sub-therapeutic CPAP 4 cmH2O of pressure and the remainder on there therapeutic pressure. Values reported on the device will be compared to scored values from manual scoring of the sleep study.
3270038|NCT00697411||Experimental|Individuals with Aicardi syndrome and their first-degree relatives
3270039|NCT00697398|Placebo Comparator|1|Sound placebo
3270040|NCT00697398|Experimental|2|Sound
3270041|NCT00697385|Experimental|TA|on treatment
3270042|NCT00697372|Active Comparator|SES|Patients with coronary bifurcation lesions treated by Sirolimus eluting stent
3270043|NCT00697372|Active Comparator|EES|Patients with coronary bifurcation lesions treated by Everolimus eluting stent
3270044|NCT00697359|Experimental|1|There is only one group in this cohort study.
3270045|NCT00697346|Experimental|Part 1: PIC Dose Escalation|Alisertib 25 or 35 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 21 days followed by a 7-day recovery period in 28-day cycles or alisertib 35, 45, 65 or 90 mg PIC, orally, (QD for 14 days followed by a 14-day recovery period in 28-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 14 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose), followed by their respective dosage assignment.
3270046|NCT00697346|Experimental|Part 1: ECT Dose Escalation|Alisertib 40 mg, Enteric-coated Tablet (ECT) formulation, orally, QD for 14 days followed by a 14-day recovery period in 28-day cycles, or alisertib 30, 40 or 50 mg ECT, orally BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 15 cycles).
3270047|NCT00697346|Experimental|Part 2: PTCL|Participants with peripheral T-cell lymphoma (PTCL) received alisertib 50 mg ECT, orally, BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).
3270048|NCT00697333|No Intervention|A|Irradiation of all tumor manifestations detectable by CT and/or positron emission tomography using fluoro-deoxy-glucose including a part of eventual atelectasis and the whole affected lymph node stations by 60 - 74 Gy/2Gy) irradiation of elective lymph node stations up to 50 Gy/2 Gy
3270049|NCT00697333|Experimental|B|Irradiation of all tumor manifestations detectable by positron emission tomography using fluoro-deoxy-glucose including the whole affected lymph node stations by 60 - 74 Gy/2Gy
3270050|NCT00697320||A|
3270051|NCT00697294|Experimental|Supplement|Subjects will serve as their own control in this single-arm protocol. All subjects will receive 400 IU/day of vitamin D as the intervention. Comparisons will be made between Caucasian and Hispanic infants.
3270052|NCT00697281|Experimental|1|Dose level 1
3270053|NCT00697281|Experimental|2|Dose level 2
3270054|NCT00697281|Experimental|3|Dose level 3
3270055|NCT00697281|Experimental|4|Dose level 4
3270056|NCT00697281|Experimental|5|Dose level 5
3270057|NCT00697255|Experimental|corifollitropin alfa + recFSH|Eligible participants will receive a subcutaneous (SC) injection of corifollitropin alfa (Stage 1a: 15mcg, Stage Ib/II: 30 mcg) the first, second, or third day after onset of a progestagen-induced withdrawal bleeding. If the follicle growth is insufficient, the participant will receive a second or third dose of corifollitropin alfa (Stage 1a: 15 mcg, Stage Ib/II: 20 mcg). As soon as the largest follicle reaches a size of ≥12 mm, the participant will start daily SC injections with FSH (Stage 1A: 50 IU, Stage II: 75 IU) the same day. A bolus injection of hCG (5000 IU) will be administered if at least one follicle is ≥18 mm and in total no more than two follicles ≥15 mm are observed.
3270058|NCT00697255|Experimental|corifollitropin alfa + hCG|Eligible participants will receive a SC injection of corifollitropin alfa (Stage Ia:15 mcg, Stage Ib/II: 30 mcg) the first, second or third day after onset of a progestagen-induced withdrawal bleeding. If the follicle growth is insufficient the participant will receive a second or third dose of corifollitropin alfa (Stage IA: 15 mcg, stage Ib/II: 20 mcg). As soon as the largest follicle reaches a size of ≥12 mm the participant will start daily SC injections with hCG (Stage Ib/II: 200 IU) the same day. A bolus injection of hCG (5000 IU) will be administered if at least one follicle is ≥18 mm and in total no more than two follicles ≥15 mm are observed.
3270059|NCT00697242|Experimental|Group A|
3270060|NCT00697242|Experimental|Group B|
3270061|NCT00697242|Experimental|Group C|
3270062|NCT00697242|Active Comparator|Group D|
3270063|NCT00697242|Experimental|Group E|
3270064|NCT00697229|Experimental|Group A|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 2 months and will receive a booster dose of HBV-MPL vaccine at 70 months
3270065|NCT00697229|Experimental|Group B|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 2 months and will receive a booster dose of Engerix™-B vaccine at 70 months
3270119|NCT00696904|Other|3|Healthy volunteers, receiving 100 mg ABT-333, multi-dose, food effect
3270066|NCT00697229|Experimental|Group C|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 2 months and will receive a booster dose of HBV-MPL vaccine at 70 months
3270067|NCT00697229|Experimental|Group D|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 2 months and will receive a booster dose of Engerix™-B vaccine at 70 months
3270068|NCT00697229|Experimental|Group E|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 6 months and will receive a booster dose of HBV-MPL vaccine at 70 months
3270069|NCT00697229|Experimental|Group F|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 6 months and will receive a booster dose of Engerix™-B vaccine at 70 months
3270070|NCT00697229|Experimental|Group G|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 6 months and will receive a booster dose of HBV-MPL vaccine at 70 months
3270071|NCT00697229|Experimental|Group H|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 6 months and will receive a booster dose of Engerix™-B vaccine at 70 months
3270072|NCT00697216|Experimental|Group A|
3270073|NCT00697216|Active Comparator|Group B|
3270074|NCT00697203|Experimental|1|
3270075|NCT00697203|Experimental|2|
3270076|NCT00697203|Experimental|3|
3270077|NCT00697203|Placebo Comparator|4|
3270078|NCT00697190|Active Comparator|senofilcon A/galyfilcon A|senofilcon A silicone hydrogel toric contact lenses will be worn first. galyfilcon A silicone hydrogel toric contact lenses will be worn second.
3270079|NCT00697190|Active Comparator|galyfilcon A/senofilcon A|galyfilcon A silicone hydrogel toric contact lenses worn first. senofilcon A silicone hydrogel toric contact lenses worn second.
3270080|NCT00697164|Placebo Comparator|1|Patients in group I received intravenous quinine followed by oral ACT for a total period of 6 days.
3270081|NCT00697164|Experimental|2|Patients in group II received antimalarial drug as in group I and in addition 1500U/kg/day of rHUEPO for the initial 3 days.
3270082|NCT00697151|Active Comparator|Warfarin|Warfarin (target International Normalized Ratio: 1.4 to 2.8) plus placebo aspirin
3270083|NCT00697151|Active Comparator|Aspirin|Aspirin 325 mg plus placebo warfarin
3270084|NCT00697138|Experimental|A|
3270085|NCT00697125|Active Comparator|Group A|
3270086|NCT00697125|Experimental|Group B|
3270087|NCT00697125|Experimental|Group C|
3270088|NCT00697112||A|
3270089|NCT00697099|Experimental|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery~Placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind"
3270090|NCT00697099|Active Comparator|Enoxaparin|"Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
3270091|NCT00697086|Experimental|1|
3270092|NCT00697086|Placebo Comparator|2|
3270093|NCT00697073|Experimental|1|high dose Idebenone
3270094|NCT00697060|Experimental|Stage 1/2|Imexon plus docetaxel
3270095|NCT00697047|No Intervention|1- Usual Care|Usual Care (UC) includes an annual birthday letter with information on overdue screening tests including CRC screening.
3270096|NCT00697047|Experimental|2 - Automated Mailing|Usual care plus automated mailing. Mailing 1 is a pamphlet about screening choices and number to call for colonoscopy. Mailing 2 is a FIT kit if not requesting colonoscopy. Mailing 3 is a Reminder letter.
3270097|NCT00697047|Experimental|3 - Automated Mailing Plus Assisted|Usual care, automated mailing plus, if screening is still not completed, phone assistance by a medical assistant (MA) who asks about patients screening intent, and provides brief assistance to complete this (e.g. sends another fecal test, assists with provider order for a colonoscopy).
3270098|NCT00697047|Experimental|4 - Auto Plus Assisted Plus Navigation|Usual care, automated mailing, phone assistance by a medical assistant, plus navigation by a registered nurse (RN) if still not screened. Navigators are trained to use motivational interviewing techniques. They assess CRC and procedure risk, facilitate screening choice, address barriers, and provide follow-up until screening is completed.
3270099|NCT00697034|Experimental|1|Study subjects will be patients with chronic plaque-type psoriasis
3270100|NCT00697021|Active Comparator|1|Patients who suffered acute STEMI and were treated by PPCI and by Aspirin 100mg and Plavix 75mg and showed on treatment platelet over-reactivity observed by TEG system on the 5th day after admission to ICCU
3270101|NCT00697021|Other|2|Patients who suffered acute STEMI and were treated by PPCI and recieved by Aspirin 100mg and Plavix 75mg and showed platelet inhibition observed by TEG system on the 5th day after admission to ICCU
3270102|NCT00697008||GERD patients|Patients with typical GERD symptoms
3270103|NCT00696995||A|
3270104|NCT00696982|Experimental|A|diabetic patients who are treated with metformin wiyh HBA1C>7% will get sitagliptin
3270105|NCT00696982|Experimental|B|diabetic patients who are treated with metformin with HBA1C>7% will get glibenclamide
3270106|NCT00696969|Active Comparator|1|
3270107|NCT00696969|Experimental|2|
3270108|NCT00696969|Experimental|3|
3270109|NCT00696969|Experimental|4|
3270110|NCT00696956|Placebo Comparator|A|Normal balloon for balloon angioplasty (Submarine, Ampherion Deep by Invatec)
3270111|NCT00696956|Active Comparator|2|Paclitaxel coated balloon (same balloon like in the control group, but coated with 3 µg/mm2 Paclitaxel)
3270112|NCT00696943|Experimental|18F-ML-10,|Pre-treatment baseline and post treatment follow-up 18F ML-10 PET/CT sessions.
3270113|NCT00696917|Active Comparator|Group A|Three doses according to 0, 1, 6-month schedule
3270114|NCT00696917|Experimental|Group B|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
3270115|NCT00696917|Experimental|Group C|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
3270116|NCT00696917|Experimental|Group D|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
3270117|NCT00696904|Other|1|Healthy volunteers, receiving 10-1200 mg ABT-333 or placebo, single dose
3270118|NCT00696904|Other|2|HCV+ treatment-naive subjects receiving 100-300 mg ABT-333 or placebo, multi-dose, QD or BID
3270121|NCT00696891|Active Comparator|Group B|
3270122|NCT00696878|Experimental|Corifollitropin alfa 150 µg|Up to 3 COS cycles (also called treatment cycles) were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of GnRH antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin ([rec]hCG) (5,000-10,000 IU/250 µg). Administration of (rec)hCG occurred when 3 follicles ≥17 mm were observed on ultrasound scan (USS). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone for luteal phase support was administered starting on the day of oocyte pick-up (34-36 hours after [rec]hCG) and continued for approximately 6 weeks. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur.
3270123|NCT00696865|Experimental|1|
3270124|NCT00696865|Placebo Comparator|2|
3270125|NCT00696852|Active Comparator|Mindfulness Meditation|
3270126|NCT00696852|Active Comparator|Yoga|
3270127|NCT00696852|Active Comparator|Conventional Stress Reduction|
3270128|NCT00696839|No Intervention|1|Usual care (adherence education)
3270129|NCT00696839|Experimental|2|Usual care and Cognitive Behavioral Therapy sessions
3270130|NCT00696813||paliperidone ER|Newly switched to or started on Paliperidone ER, not longer than 2 weeks ago
3270131|NCT00696813||Any other oral antipsychotic|Newly switched to or started on any other oral antipsychotic treatment (either atypical or conventional), not longer than 2 weeks ago
3270132|NCT00696800|Experimental|150 µg Corifollitropin Alfa|Participants received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa (org 36286) on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recFSH; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were administered from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles >= 17 mm. On the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses.
3270133|NCT00696800|Active Comparator|200 IU recFSH|Participants received a single SC injection of placebo Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 200 IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were given from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was administered when 3 follicles >= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses.
3270134|NCT00696787|Placebo Comparator|Placebo|In the first stage, subjects were randomly assigned to receive placebo. Study was stopped after stage 1 by sponsor.
3270135|NCT00696787|Experimental|DVS SR|In the first stage, subjects were randomly assigned to receive DVS SR 200 mg/day. Study was stopped after stage 1 by sponsor.
3270136|NCT00696787|Active Comparator|Pregabalin|In the first stage, subjects were randomly assigned to receive Pregabalin 450 mg/day. Study was stopped after stage 1 by sponsor.
3270137|NCT00696774|Experimental|Duloxetine|Patients who met criteria in Study Period I (screening) were treated with duloxetine 60 milligrams (mg) once daily (QD) in an open-label manner for 4 weeks (Study Period II). Study Period II was considered the acute therapy period. Study Period III was a 4-week interval where patients who did not respond during Study Period II had their duloxetine doses optimized to 120 mg.
3270138|NCT00696761|Active Comparator|group1|Bladder outlet obstruction index(BOOI)≥ 20, Bladder contractility index(BCI)≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.
3270139|NCT00696761|Active Comparator|group2|BOOI≥ 20, BCI<100 Alfuzosin was administered daily (10 mg) for 12 month.
3270140|NCT00696761|Active Comparator|group 3|BOOI<20, BCI≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.
3270141|NCT00696761|Active Comparator|group 4|BOOI<20, BCI<100 Alfuzosin was administered daily (10 mg) for 12 month.
3270142|NCT00696748|Active Comparator|1|Men receiving Nebido
3270143|NCT00696748|Placebo Comparator|2|Men receiving Placebo
3270144|NCT00696735|Active Comparator|1|standard chemotherapy arm, the CHVP (cyclophosphamide, low-dose doxorubicin, teniposide, and prednisone) regimen consisted of cyclophosphamide (600 mg/m2), doxorubicin (25 mg/m2), and teniposide (60 mg/m2), all administered intravenously on day 1, and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.
3270145|NCT00696735|Experimental|2|VCAP (cyclophosphamide, high-dose doxorubicin, prednisone, and vincristine) regimen as a first-line therapy combining vindesine (3 mg/m2) on day 1, cyclophosphamide (1500 mg/m2) on day 2, doxorubicin (80 mg/m2) on day 2, and prednisolone (50 mg/m2) on days 1 to 5, every 3 weeks.19,31,32 Patients in CR, VGPR, or PR after the second or third VCAP cycle continued on to stem-cell harvesting and received, before transplantation, one course of IMVP16 (ifosfamide, methotrexate, and VP-16), which combined ifosfamide (1.5 g/m2) and VP16 (100 mg/m2) on days 1 through 3, and methotrexate (30 mg/m2) on days 1 and 10. Patients with less than PR after the VCAP cycles received, as salvage therapy, 2 to 3 courses of DHAP (dexamethasone, high-dose cytarabine, and cisplatin) combining cisplatine (100 mg/m2) on day 1, cytarabine (4 g/m2) on day 2, and dexamethasone (40 mg/m2) on days 1 through 4. If at least a PR was obtained after DHAP, stem cells were harvested or patients were considered as failures
3270146|NCT00696722|Experimental|1|Placebo treatment first, atazanavir treatment second
3270147|NCT00696722|Experimental|2|Atazanavir treatment first, placebo treatment second
3270148|NCT00696709|Experimental|1|heat-treated VZV vaccine
3270149|NCT00696709|Experimental|2|alternative inactivation method VZV vaccine A
3270150|NCT00696709|Placebo Comparator|3|Placebo
3270151|NCT00696709|Experimental|4|alternative inactivation method VZV vaccine B
3270152|NCT00696709|Experimental|5|alternative inactivation method VZV vaccine C
3270153|NCT00696696|Experimental|Combination GES|Combination of Gemcitabine, Erlotinib, and Sorafenib
3270154|NCT00696683||A|Patients from the identified scorpion envenomation cases, who met inclusion/exclusion criteria.
3270155|NCT00696657|Experimental|A|
3270169|NCT00696644||Patients with severe osteoporosis|Postmenopausal women and men aged > 21 years old affected by severe osteoporosis
3270170|NCT00696631|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
3270171|NCT00696631|Placebo Comparator|Placebo|matching placebo tablets
3270172|NCT00696618|Experimental|A|Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Normosol-R enema (iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home(Stage 2), Followed by Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
3270173|NCT00696618|Experimental|B|Normosol-R enema (iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 2), Followed by Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
3270174|NCT00696618|Experimental|C|Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 2), Followed by Normosol-R enema(iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
3270175|NCT00696579|Active Comparator|A|Group A received BCG instillation 14 days after II look-TURB:6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
3270176|NCT00696579|Experimental|2|14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
3270177|NCT00696566|Experimental|A|All subjects will receive Clopidogrel and Rifampicin.
3270178|NCT00696553|Active Comparator|B1|Nutrition
3270179|NCT00696553|Experimental|B2|Nutrition plus Exercise
3270180|NCT00696540|Experimental|1|Salbutamol is diluted in hypertonic (3%) saline.
3270181|NCT00696540|Active Comparator|2|Salbutamol is diluted in normal (0.9%) saline.
3270182|NCT00696527||1|
3270183|NCT00696514|Placebo Comparator|2|placebo capsule, once per day
3270184|NCT00696514|Experimental|1|Vitamin B12 and folic acid capsule, once a day
3270185|NCT00696488|Experimental|Fluorouracil 0.5%|each subject will receive the study medication: Carac® 0.5% Fluorouracil, a standard treatment for actinic keratoses. Carac® will be dispensed to the subjects in the original tube with MEMS electronic monitoring caps attached. Subjects will be asked to apply the medication daily to AK lesions
3270186|NCT00696475|Experimental|1|Diazoxide equivalent dose
3270187|NCT00696475|Experimental|2|Diazoxide equivalent dose
3270188|NCT00696475|Experimental|3|Diazoxide equivalent dose
3270189|NCT00696475|Placebo Comparator|4|
3270190|NCT00696462|No Intervention|A|Patients in Group A will undergo passive warming with a warmed cotton blanket placed over their upper extremities
3270191|NCT00696462|Active Comparator|B|Patients in Group B will have a forced-air warming device applied to the upper body above the waist at the 43 degree Celsius setting.
3270192|NCT00696449|Experimental|Frequent visits|This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.
3270193|NCT00696449|Experimental|Electronic reminder|This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.
3270194|NCT00696449|Experimental|Parent reminder|In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.
3270195|NCT00696449|Experimental|Standard of care|"This group is considered to be the standard of care arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits."
3270196|NCT00696436|Experimental|Azilsartan Medoxomil 40 mg QD|
3270197|NCT00696436|Experimental|Azilsartan Medoxomil 80 mg QD|
3270198|NCT00696436|Active Comparator|Valsartan 320 mg QD|
3270199|NCT00696436|Active Comparator|Olmesartan 40 mg QD|
3270200|NCT00696436|Placebo Comparator|Placebo QD|
3270201|NCT00696423|Experimental|Infanrix/Hib Single Injection Group|Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.
3270202|NCT00696423|Active Comparator|Infanrix + Hiberix Separate Injection Group|Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.
3270203|NCT00696410|Experimental|CHF patients Given Zinc Acetate|Patients with CHF received zinc acetate 50 mg po TID. This is a pre-post study
3270204|NCT00696410|No Intervention|Healthy controls|Health controls; no zinc acetate administered.
3270205|NCT00696397||A|adult men and women between 18 and 50 years of age with atopic dermatitis
3270206|NCT00696384|Experimental|Azilsartan Medoxomil QD-Open Label Phase (Baseline - Week 26)|
3270207|NCT00696384|Experimental|Azilsartan Medoxomil QD - Double-Blind Phase (Week 26-32)|
3270208|NCT00696384|Placebo Comparator|Placebo QD - Double-Blind Phase (Week 26- 32)|
3270209|NCT00696358|Active Comparator|A|308 nm excimer lamp
3270210|NCT00696358|Active Comparator|B|308 nm excimer laser
3270211|NCT00696345||1|Colorectal cancer patients, Stages I-IV
3270212|NCT00696345||2|Non colorectal cancer patients, verified by colonoscopy
3270213|NCT00696332|Experimental|Talampanel 50mg|50mg Talampanel 3 times per day
3270214|NCT00696332|Experimental|Talampanel 25mg|25mg Talampanel 3 times per day
3270215|NCT00696332|Placebo Comparator|Placebo|placebo 3 times per day
3270216|NCT00696319|Experimental|1|Arm 1 will go through a rehabilitation protocol with perturbation training exercises.
3270217|NCT00696319|Experimental|2|Arm 2 will go through a rehabilitation protocol with traditional exercises for balance and stability training.
3270218|NCT00696293|Experimental|1|"Duloxetine + clinical management~NOTE -- THIS WORK WAS CONDUCTED AS PART OF A CAREER DEVELOPMENT AWARD. THE CLINICALTRIALS.GOV DESCRIPTION OF THE STUDY WAS UPDATED 1/5/16 TO UPDATE THE OPEN LABEL NATURE OF THIS WORK. THIS IS WHAT IS REPORTED HERE AND HAS BEEN PEER REVIEWED AND PUBLISHED."
3270219|NCT00696280||Group 1|"All patients will be given the Functional Living Index - Emesis (FLIE) standardized questionnaire during their scheduled clinic visit prior to receiving chemotherapy.~This is a self-administered questionnaire. Patients will complete the questionnaire during the 5 days following carboplatin administration (at 24 hours, 48 hours, 72 hours, and 96 hours) of their first and third cycles of chemotherapy.~Patients will also be interviewed by a trained CRA or research nurse over the telephone 24-48 hours following carboplatin administration in order to assess the severity of the delayed nausea and vomiting."
3270220|NCT00696241|Experimental|Azilsartan Medoxomil 20 mg QD|
3270221|NCT00696241|Experimental|Azilsartan Medoxomil 40 mg QD|
3270222|NCT00696241|Experimental|Azilsartan Medoxomil 80 mg QD|
3270223|NCT00696241|Active Comparator|Olmesartan 40 mg QD|
3270224|NCT00696241|Placebo Comparator|Placebo QD|
3270225|NCT00696228|Placebo Comparator|AFN A|High Fat Diet Placebo
3270226|NCT00696228|Experimental|AFN B|MUFA
3270227|NCT00696228|Experimental|AFN C|PUFA
3270228|NCT00696228|Experimental|AFN D|SFA
3270229|NCT00696215|Placebo Comparator|1|
3270230|NCT00696215|Active Comparator|2|Rasagiline
3270231|NCT00696202|Experimental|Arm 1|
3270232|NCT00696176|Experimental|A|STAT 3 decoy administration
3270233|NCT00696163||A|
3270234|NCT00696150|Placebo Comparator|loss of resistance|Anterior psoas compartment nerve block inserted using loss of resistance
3270235|NCT00696150|Active Comparator|nerve stimulator|Anterior psoas compartment nerve block inserted using nerve stimulator
3270236|NCT00696150|Active Comparator|ultrasound|Anterior psoas compartment nerve block inserted using ultrasound
3270237|NCT00696137|Experimental|1|BEMA Fentanyl
3270238|NCT00696124|Experimental|Cohort 1|2mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
3270239|NCT00696124|Experimental|Cohort 2|4mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
3270240|NCT00696124|Experimental|Cohort 3|8mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
3270241|NCT00696124|Experimental|Cohort 4|16mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
3270242|NCT00696111|Experimental|1A|Randomized to receive depot Lupron for 6 weeks. Then randomized again to receive estrogen plus placebo for another 6 weeks.
3270243|NCT00696111|Experimental|1B|Randomized to receive depot Lupron for 6 weeks. Then randomized again to receive progesterone plus placebo for another 6 weeks.
3270244|NCT00696111|Experimental|3|Randomized to receive CPAP (continuous positive airway pressure) treatment for 6 weeks.
3270245|NCT00696098|Experimental|1|sodium butyrate
3270246|NCT00696098|Placebo Comparator|2|
3270247|NCT00696085|Other|I|Pregnant women are recruited and screened for alcohol use using a validated alcoholism screening questionnaire. Those who screen positive are then entered into the next phase of the study.
3270248|NCT00696072|Active Comparator|A1|
3270249|NCT00696072|Active Comparator|A2|
3270250|NCT00696059|Other|1|Open-label, one arm only. All patients receiving active drug according to recommendations (adalimumab (Humira) 40 mg subcutaneously every other week).
3270251|NCT00696033|Experimental|1|Oral Lorazepam
3270252|NCT00696033|Experimental|2|Oral Diazepam
3270253|NCT00696033|Placebo Comparator|3|Oral placebo
3270254|NCT00696020|Experimental|BI 1744 CL low dose/tiotropium bromide|BI 1744 CL low dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
3270255|NCT00696020|Experimental|BI1744CL medium dose/tiotropium bromide|BI 1744 CL medium dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
3270256|NCT00696020|Experimental|BI 1744 CL high dose/tiotropium bromide|BI 1744 CL high dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
3270257|NCT00696020|Experimental|tiotropium bromide|tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
3270258|NCT00696007|Experimental|1|A neoadjuvant chemotherapy (gemcitabine and cisplatin) regimen administered before surgery-nephroureterectomy for upper tract TCC
3270259|NCT00696007|Other|2|A retrospective cohort group (approximately 60 subjects) identified from an institutional cancer registry who have undergone a nephroureterectomy alone over the past five years
3270260|NCT00695994|Experimental|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle.
3270261|NCT00695994|Experimental|Gemcitabine and carboplatin|Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion.
3270262|NCT00695981|Active Comparator|Rotator cuff repair|Surgery following a 3 months period of active non-operative treatment
3270263|NCT00695981|Active Comparator|Conservative treatment|Physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
3270264|NCT00695955|Experimental|Azilsartan Medoxomil|
3270265|NCT00695942||1|pregnancy women
3270266|NCT00695903|Experimental|daptomycin 10 mg/kg|Daptomycin 10 mg/kg IV every 24 hours
3270267|NCT00695903|Experimental|vancomycin high-dose|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
3270268|NCT00695890||1|Healthy volunteers
3270269|NCT00695877|Experimental|1|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^9 virus particles (VP) given at Days 0, 28, and 168
3270270|NCT00695877|Experimental|2|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^10 virus particles (VP) given at Days 0, 28, and 168
3270271|NCT00695877|Experimental|3|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^11 virus particles (VP) given at Days 0, 28, and 168
3270272|NCT00695877|Experimental|4|1 injection of rAd5.ENVA.48 HIV-1 vaccine or placebo at a dose determined by the safety data from Arms 1, 2 and 3 given at Day 0.
3270273|NCT00695864|Placebo Comparator|Placebo - sugar pill|Placebo - sugar pill
3270274|NCT00695864|Experimental|Ondansetron|Ondansetron
3270275|NCT00695851|Experimental|1|15 mg/m2 weekly of PCK3145
3270276|NCT00695851|Experimental|2|7.5 mg/m2 twice per week of PCK3145
3270277|NCT00695838||1|
3270278|NCT00695825|Experimental|A1|Consumption of low GI food product on day 1 Consumption of high GI food product on day 2
3270279|NCT00695825|Experimental|A2|Consumption of high GI food product on day 1 Consumption of low GI food product on day 2
3270280|NCT00695812||1|Siblings of children with Autism
3270281|NCT00695812||2|Siblings of children with typical development
3270282|NCT00695799||1|Anesthesia Providers at UMDNJ
3270283|NCT00695786|Experimental|Cohort 1 - Follicular Lymphoma|"Schedule A: Lenalidomide 20 mg by mouth daily on Days 1 - 21 followed by 7 days rest (28 day cycle). Following cycle 3, if patients fail to show a response (partial or complete) dose increased to 25 mg/day.~Schedule A: Rituximab 375 mg/m^2 by vein over 4-8 hours on Day 1 of cycles 1-12."
3270284|NCT00695786|Experimental|Cohort 2 - Marginal Zone Lymphoma|"Schedule A: Lenalidomide 20 mg by mouth daily on Days 1 - 21 followed by 7 days rest (28 day cycle). Following cycle 3, if patients fail to show a response (partial or complete) the dose increased to 25 mg/day.~Schedule A: Rituximab 375 mg/m^2 by vein over 4-8 Hours on Day 1 of cycles 1-12."
3270285|NCT00695786|Experimental|Cohort 3 - Small Lymphocytic Lymphoma|"Schedule B: Lenalidomide administered orally at 10 mg total daily dose on Days 2 to 22 of a 28 day cycle. Following cycle 3, if patients fail to show a response (partial or complete) dose increased to 25 mg/day. Dose escalated by 5 mg every 28 days up to 20 mg if no toxicity is encountered. If no response is observed by cycle 3, dose increased to 25 mg.~Schedule B: Rituximab 375 mg/m^2 by vein over 4-8 Hours on Day 1, 8,15, and 22 of cycle 1 and on Day 1 of every subsequent cycle.~In the absence of progression or toxicity, patients remain on treatment for a total of 12 months. If patients attain a complete response following cycle 6 or 9, lenalidomide reduced to 10 mg daily for the remaining cycles with the same dosing schedule of Rituximab and Lenalidomide as described above."
3270286|NCT00695786|Experimental|Cohort 4 - Follicular Lymphoma (Schedule B)|"Schedule B: Lenalidomide administered orally at 20 mg total daily dose on Days 2 to 22 of a 28 day cycle. Following cycle 3, if patients fail to show a response (partial or complete) dose increased to 25 mg/day.~Schedule B: Rituximab 375 mg/m^2 by vein over 4-8 Hours on Day 1, 8,15, and 22 of cycle 1 and on Day 1 of every subsequent cycle."
3270287|NCT00695747|No Intervention|1|Standard 1 site Procedure using a fornix based incision, performed superiorly
3270288|NCT00695747|Experimental|2|2 Site Combined Procedure
3270289|NCT00695734||Hemodialysis|Patients under chronic hemodialysis for chronic end stage renal failure
3270290|NCT00695708|Experimental|BFT|20 schizophrenic patients
3270291|NCT00695708|Active Comparator|CP|19 schizophrenic patients
3270292|NCT00695708|No Intervention|HCG|20 healthy age and sex matched subjects
3270293|NCT00695669|Experimental|Influenza A (H5N1) 1 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm.
3270294|NCT00695669|Experimental|Influenza A (H5N1) 2 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 14. The vaccine was administered intramuscularly in the deltoid region of the arm.
3270295|NCT00695669|Experimental|Influenza A (H5N1) 3 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 7. The vaccine was administered intramuscularly in the deltoid region of the arm.
3270296|NCT00695669|Experimental|Influenza A (H5N1) 4 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0. The vaccine was administered intramuscularly in the deltoid region of the arm.
3270297|NCT00695656||1|
3270298|NCT00695643|Experimental|A|
3270299|NCT00695643|Placebo Comparator|B|
3270300|NCT00695630|Experimental|1|Flumazenil 2mL
3270301|NCT00695630|Placebo Comparator|2|Saline, 2mL SM
3270302|NCT00695617|Experimental|A|citrate first
3270303|NCT00695617|Experimental|B|no anticoagulation first
3270304|NCT00695604|Placebo Comparator|1|"Placebo Comparator~All patients assigned to this group will receive:~Placebo via Metered Dose Inhaler (MDI).~Albuterol via MDI."
3270305|NCT00695604|Active Comparator|2|"Active Comparator~All patients assigned to this group will receive:~Fluticasone via MDI.~Albuterol via MDI."
3270306|NCT00695591||1SevereRLD,NMD|Patients with FEV1<40%
3270307|NCT00695591||2VerySevereRLD,NMD|FEV1<30%
3270308|NCT00695591||3NINV|FEV1<25%,on non invasive ventilation
3270309|NCT00695591||ModerateRLD,NMD|Patients with FEV1 40-50% of predicted
3270310|NCT00695565|Placebo Comparator|Placebo Gel|Placebo Gel is vehicle without clonidine
3270311|NCT00695565|Active Comparator|Clonidine Topical Gel (ARC-4558)|Clonidine Topical Gel contains 0.1% clonidine hydrochloride
3270312|NCT00695552|Experimental|1|Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
3270313|NCT00695552|Placebo Comparator|2|Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises.
3270314|NCT00695526|Active Comparator|A|
3270315|NCT00695513|Experimental|I|BENEO synergy1
3270316|NCT00695500|Experimental|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
3270317|NCT00695500|Placebo Comparator|Placebo|Placebo tablets, 0 mg per day for 3 weeks
3270318|NCT00695487|Experimental|1|Receives 0.125mg/kg THC before emergence
3270319|NCT00695487|Placebo Comparator|2|Receives NaCl before emergence
3270320|NCT00695474||A|The cohort consists of type 2 diabetics from the outpatient clinic at Silkeborg Hospital.
3270321|NCT00695461|Experimental|1|Receives Lactobacillus plantarum 299v in an oatmeal drink, at a concentration of 10(9) colony-forming-units/ml, 100 ml per day, starting one week before surgery, finishing 5 days after surgery.
3270322|NCT00695461|Placebo Comparator|2|Receives oatmeal drink, 100 ml per day, starting one week before surgery, finishing 5 days after surgery.
3270323|NCT00695448|Experimental|Cohorts|The starting dose is 6mg once daily (QD); dose is to be escalated using a standard 3 + 3 dose escalation scheme.
3270324|NCT00695435|Experimental|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension
3270325|NCT00695435|Active Comparator|TOBREX® Ophthalmic Solution|TOBREX® Ophthalmic Solution
3270326|NCT00695435|Active Comparator|TOBRADEX® Ophthalmic Suspension|TOBRADEX® Ophthalmic Suspension
3270327|NCT00695422||Specimen Collection|Blood collection, anal cytology and biopsy of observed lesions. Additional cervical cytology and biopsy for females.
3270328|NCT00695409|Experimental|Treatment (RIT, ZBEAM, ASCT)|RADIOIMMUNOTHERAPY: Patients receive yttrium Y 90 ibritumomab tiuxetan IV following rituximab IV on day -14. HIGH-DOSE COMBINATION CHEMOTHERAPY: Patients receive carmustine IV on days -7 and -6; etoposide IV over 1 hour twice daily and cytarabine IV over 2 hours twice daily on days -5 to -2; and melphalan IV on day -1. STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplant on day 0. Patients also receive rituximab on day 8*. NOTE: * Some patients may also receive rituximab on day -1. Treatment continues in the absence of disease progression or unacceptable toxicity.
3270329|NCT00695396|Experimental|001|Epoetin alfa 40 000 IU subcutaneously once every week (1 mL dose) for 48 weeks
3270330|NCT00695396|Experimental|002|Epoetin alfa 80 000 IU subcutaneously once every week (2 mL dose) for 48 weeks
3270331|NCT00695396|Placebo Comparator|003|Placebo Matching volume 1 mL for 48 weeks
3270332|NCT00695396|Placebo Comparator|004|Placebo Matching volume 2 mLfor 48 weeks
3270333|NCT00695383|Experimental|1|
3270334|NCT00695383|Active Comparator|2|
3270335|NCT00695344|Experimental|1|Everolimus 2 times per day + cyclosporin low dose +/- steroids
3270336|NCT00695344|Active Comparator|2|Cyclosporin + azathioprine or mofetil mycophenolate +/- steroids (the same treatment that patient had before the study).
3270337|NCT00695331|Experimental|1|Titrated Oral Misoprostol Solution
3270338|NCT00695331|Active Comparator|2|Intravenous Oxytocin
3270339|NCT00695318|Experimental|A, 2, I 0.2 µg/Day + Sham|0.2 µg/Day
3270340|NCT00695318|Experimental|A, 2, II 0.5 µg/Day + Sham|0.5 µg/Day
3270341|NCT00695305|Placebo Comparator|placebo|placebo to match
3270342|NCT00695305|Active Comparator|rilapladib|250 mg/day
3270343|NCT00695292|Experimental|Intervention|"Patients in the study will receive the following for the duration of the study: irinotecan 60 mg/m2 intravenously on Days 1, 8, and 15 and carboplatin AUC=4 on Day 1. The study will consist of 28-day cycles, to a maximum of 6 cycles of therapy with irinotecan and carboplatin. After treatment with irinotecan and carboplatin, sunitinib will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During sunitinib maintenance therapy, patients will receive sunitinib at 25 mg orally daily. Sunitinib maintenance therapy will continue until progressive disease or irreversible toxicity occurs.~Re-staging will be performed every 2 cycles (every 8 weeks) during the study."
3270344|NCT00695279||Participants|Venipuncture
3270345|NCT00695266||1|
3270346|NCT00695253|Other|1|
3270347|NCT00695240|Experimental|Bupiv analgesia|Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. The catheter was placed in the operating room with a peel-away trocar and attached to the pump. The trocar was inserted through a 5 mm stab incision made near the superior part of the pubic bone between the genitoinguinal fold and the midline of the symphysis. Once through the incision, the trocar is advanced subcutaneously and made to exit the posterior fourchette just beneath the posterior vaginal mucosa where it is advanced by tenting up the skin.
3270348|NCT00695227|Experimental|Screening for Barrett's Esophagus|
3270349|NCT00695214|Other|1|OSA Patients considering surgical treatment
3270350|NCT00695201|Experimental|1|Patients will undergo pump placement and biopsy of diseased liver tissue. Chemotherapy will be initiated as soon as possible following verification of adequate pump placement and perfusion by radiographic pump study. Treatment will continue indefinitely unless a patient experiences a treatment endpoint.
3270351|NCT00695201|Experimental|2|Patients will undergo pump placement and biopsy of diseased liver tissue. Chemotherapy will be initiated as soon as possible following verification of adequate pump placement and perfusion by radiographic pump study. Treatment will continue indefinitely unless a patient experiences a treatment endpoint.
3270352|NCT00695188|Other|Standard dose|Escalating dose
3270353|NCT00695188|Active Comparator|High dose|25 mg
3270354|NCT00695162|Other|1|hearing impaired inpatients
3270355|NCT00695162|Other|2|Non-hearing-impaired inpatients
3270356|NCT00695136|Experimental|Open label single arm|Single group study of Donepezil
3270357|NCT00695110|Experimental|1|Testosterone undecanoate (TU) (300 mg T equivalents) BID for 7 days
3270358|NCT00695110|Experimental|2|TU + testosterone enanthate (TE) (400 mg T equivalents) BID for 7 days
3270359|NCT00695110|Experimental|3|TU (200 mg T equivalents) BID for 8 days
3270360|NCT00695110|Experimental|4|TU + TE (300 mg T equivalents) BID for 7 days
3270361|NCT00695097|Active Comparator|1|Rituximab Group: The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15) and followed up monthly for 1 year. Biopsy was done Baseline and Month 3 and other labs (CBC/Diff, Platelets, HACA, PK, Serum Creatinine, 24-hour protein, HLA antibodies, flow cytometry, and serology testing). Physical exam and vital signs were done.
3270414|NCT00694798|Experimental|Mw|All enrolled patients to receive Mycobacterium w
3270470|NCT00694499||Observation|Patients with blunt liver injury
3270362|NCT00695097|Active Comparator|2|No Rituximab: received standard immunosuppression and was followed up monthly for 1 year. Labs (CBC/Diff, Platelets, HACA, PK, Serum Creatinine, 24-hour protein, HLA antibodies, flow cytometry, and serology testing) vital signs, and physical exam was done.
3270363|NCT00695084|Experimental|1|Treatment with Constraint-Induced Movement Therapy
3270364|NCT00695071|Active Comparator|A|
3270365|NCT00695058|Experimental|1|Women with stress incontinence treated with active TMNS (vibration)
3270366|NCT00695058|Placebo Comparator|2|Women with stress incontinence treated with placebo TMNS (vibration)with an amplitude of 0
3270367|NCT00695058|Experimental|3|Women with overactive bladder syndrome treated with active TMNS (vibration)
3270368|NCT00695058|Placebo Comparator|4|Women with overactive bladder syndrome treated with placebo TMNS (vibration)with an amplitude of 0
3270369|NCT00695058|Experimental|5|males who are still incontinent at a minimum of one year after a radical prostatectomy treated with active TMNS (vibration)
3270370|NCT00695058|Placebo Comparator|6|males who are still incontinent at a minimum of one year after a radical prostatectomy treated with placebo TMNS (vibration)with an amplitude of 0
3270371|NCT00695045|Experimental|1|patients in this group got 100mcg of intrathecal morphine.
3270372|NCT00695045|Experimental|2|patients in this group got 200 mcg intrathecal morphine
3270373|NCT00695045|Experimental|3|patients in this group given 300 mcg intrathecal morphine.
3270374|NCT00695019|Experimental|500 IU qd|500 IU Interferon-alpha lozenge taken once per day plus 2 placebo lozenges per day
3270375|NCT00695019|Experimental|500 IU tid|500 IU interferon-alpha lozenge taken 3 times per day
3270376|NCT00695019|Placebo Comparator|placebo|placebo lozenges taken 3 times per day
3270377|NCT00695006|Sham Comparator|II|Sham Traction
3270378|NCT00695006|Active Comparator|I|Traction
3270379|NCT00694993|Experimental|Subjects receiving GSK1004723 + placebo in cohort I and II|Eligible subjects will receive GSK1004723 nasal spray with single doses of 50 micrograms, 100 micrograms, 200 micrograms, 500 micrograms and 1000 micrograms. Subjects will also receive placebo nasal spray.
3270380|NCT00694993|Experimental|Subjects receiving GSK1004723 200 micrograms in cohort III|Eligible subjects will receive nasal spray of GSK1004723 with escalated repeat doses of 200 micrograms given once daily for 14 days.
3270381|NCT00694993|Experimental|Subjects receiving placebo in cohort III|Eligible subjects will receive nasal spray of placebo given once daily for 14 days.
3270382|NCT00694993|Experimental|Subjects receiving GSK1004723 1000 micrograms in cohort IV|Eligible subjects will receive nasal spray of GSK1004723 with escalated repeat doses of 1000 micrograms given once daily for 14 days.
3270383|NCT00694993|Experimental|Subjects receiving placebo in cohort IV|Eligible subjects will receive nasal spray of placebo given once daily for 14 days.
3270384|NCT00694980|Experimental|1|
3270385|NCT00694967|Active Comparator|1|McDonald cerclage
3270386|NCT00694967|Active Comparator|2|17 hydroxyprogesterone caproate
3270387|NCT00694954|Experimental|1|Wireless capsule endoscopy
3270388|NCT00694954|Active Comparator|2|Standard Care
3270389|NCT00694941|Experimental|E|ONO-2506PO in the presence of Riluzole
3270390|NCT00694928|Experimental|1|clindamycin phosphate/butoconazole nitrate
3270391|NCT00694928|Active Comparator|2|butoconazole nitrate
3270392|NCT00694915|Experimental|Mw|Mycobacterium w
3270393|NCT00694915|Active Comparator|BCG|bacillus Calmette-Guerin (BCG)
3270394|NCT00694902|Experimental|Sequence 1 of Cohort-I|Subjects in Sequence 1 will receive Placebo during treatment period 1, 50 microgram GSK610677 during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
3270395|NCT00694902|Experimental|Sequence 2 of Cohort-I|Subjects in Sequence 2 will receive 10 microgram GSK610677 during treatment period 1, Placebo during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
3270396|NCT00694902|Experimental|Sequence 3 of Cohort-I|Subjects in Sequence 3 will receive 10 microgram GSK610677 during treatment period 1, 50 microgram GSK610677 during treatment period 2 and Placebo during treatment period 3.
3270397|NCT00694902|Experimental|Sequence 4 of Cohort-I|Subjects in Sequence 4 will receive 10 microgram GSK610677 during treatment period 1, 50 microgram GSK610677 during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
3270398|NCT00694902|Experimental|Sequence 5 of Cohort-II|Subjects in Sequence 5 will receive Placebo during treatment period 1, 100 microgram GSK610677 during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
3270399|NCT00694902|Experimental|Sequence 6 of Cohort-II|Subjects in Sequence 6 will receive 30 microgram GSK610677 during treatment period 1, Placebo during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
3270400|NCT00694902|Experimental|Sequence 7 of Cohort-II|Subjects in Sequence 7 will receive 30 microgram GSK610677 during treatment period 1, 100 microgram GSK610677 during treatment period 2 and Placebo during treatment period 3.
3270401|NCT00694902|Experimental|Sequence 8 of Cohort-II|Subjects in Sequence 7 will receive 30 microgram GSK610677 during treatment period 1, 100 microgram GSK610677 during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
3270402|NCT00694902|Experimental|Cohort III|Subjects in Cohort III after randomization will either receive 1000 microgram GSK610677 or placebo.
3270403|NCT00694889|Active Comparator|1|Participants will use commercially available computer games.
3270404|NCT00694889|Experimental|2|Participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation.
3270405|NCT00694889|Active Comparator|3|Healthy participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation.
3270406|NCT00694876||1|Adequate Health Literacy (as determined by TOFHLA)
3270407|NCT00694876||2|Inadequate Health Literacy (as determined by TOFHLA)
3270408|NCT00694863|Experimental|1|In this open-label study all patients included are treated in the experimental group.
3270409|NCT00694850|Experimental|Arm 1|
3270410|NCT00694837|Experimental|B|
3270411|NCT00694824||A|
3270412|NCT00694811|Experimental|A|1 week of re-feeding
3270413|NCT00694811|Experimental|B|6 weeks of re-feeding
3270415|NCT00694785|Experimental|Group NT3|Patients will receive a total dose of approximately 1.7 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 3 mcg/mL
3270416|NCT00694785|Experimental|Group T3|Patients will receive a total dose of approximately 1.4 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 3 mcg/mL. The infusion of ARC1779 will be tapered by 50% from 48 hours to 60 hours and again by 50% from 60 hours to 72 hours.
3270417|NCT00694785|Experimental|Group NT6|Patients will receive a total dose of approximately 3.9 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 6 mcg/mL.
3270418|NCT00694785|Experimental|Group T6|Patients will receive a total dose of approximately 3.1 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 6 mcg/mL. The infusion of ARC1779 will be tapered by 50% from 48 hours to 60 hours and again by 50% from 60 hours to 72 hours.
3270419|NCT00694772|Active Comparator|Electrocautery|
3270420|NCT00694772|Experimental|Coblation|
3270421|NCT00694759|Active Comparator|A|Pioglitazone will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
3270422|NCT00694759|Active Comparator|B|Metformin will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
3270423|NCT00694759|Placebo Comparator|C|Placebo will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
3270424|NCT00694746|Experimental|Fish oil|Omega-3-acid ethyl esters in the form of fish oil capsules with ram up from 1g to 4 g/day (capsules 1g)
3270425|NCT00694746|Placebo Comparator|Placebo|Placebo
3270426|NCT00694733|Placebo Comparator|1|Men on placebo injections for 4 months
3270427|NCT00694733|Active Comparator|2|Men who receive Depo Lupron for 4 months, then are replaced with testosterone and aromatase inhibitor for 4 months.
3270428|NCT00694733|Active Comparator|3|Men who receive Depo Lupron for 4 months, then are replaced with testosterone and placebo for 4 months.
3270429|NCT00694733|Placebo Comparator|4|Women on placebo cream
3270430|NCT00694733|Active Comparator|5|Women on estrogen cream
3270431|NCT00694720|Experimental|Dose Level 1|
3270432|NCT00694720|Experimental|Dose Level 2|
3270433|NCT00694720|Experimental|Dose Level 3|
3270434|NCT00694720|Experimental|Dose Level 4|
3270435|NCT00694720|Placebo Comparator|Placebo|12 subjects: 3 subjects per dose level
3270436|NCT00694707|Placebo Comparator|1|Placebo, oral administration, once daily dosing for 6 weeks
3270437|NCT00694707|Experimental|2|RGH-188 low dose, oral administration, once daily dosing for 6 weeks
3270438|NCT00694707|Experimental|3|RGH-188 medium dose, oral administration, once daily dosing for 6 weeks
3270439|NCT00694707|Experimental|4|RGH-188 high dose, oral administration, once daily dosing for 6 weeks
3270440|NCT00694707|Active Comparator|5|Active comparator, oral administration, once daily dosing for 6 weeks
3270441|NCT00694694|Experimental|1AZ+AQ|Azithromycin + artesunate
3270442|NCT00694694|Active Comparator|2AL|Artemether-lumefantrine
3270443|NCT00694668|Experimental|1|Cognitive Behavioural Treatment
3270444|NCT00694668|Experimental|2|Mindfulness Based Cognitive Therapy-training
3270445|NCT00694655|Other|vaccine|There are no arms for this study. All participants will receive the YFV vaccine if they meet the screening criteria.
3270446|NCT00694642|Active Comparator|selected CD133+cells|Transendocardial injection of selected CD133+cells
3270447|NCT00694642|No Intervention|no injection|Boths groups were treated with G-CSF, underwent an apheresis and NOGA mapping
3270448|NCT00694629|Active Comparator|1|rifampin, isoniazid, pyrazinamide, ethambutol
3270449|NCT00694629|Experimental|2|rifapentine 10 mg/kg, isoniazid, pyrazinamide, ethambutol
3270450|NCT00694629|Experimental|3|rifapentine 15 mg/kg, isoniazid, pyrazinamide, ethambutol
3270451|NCT00694629|Experimental|4|rifapentine 20 mg/kg, isoniazid, pyrazinamide, ethambutol
3270452|NCT00694616|Other|1|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
3270453|NCT00694616|Other|2|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
3270454|NCT00694603|Experimental|Cetuximab|400mg/m2 IV x 1 and then 250mg/m2 IV weekly
3270455|NCT00694590|Experimental|plerixafor|
3270456|NCT00694577|Experimental|Group 1|Study Participants 1-100 Partial Breast Irradiation using 32 Gy / 8 fractions BID in one week
3270457|NCT00694577|Experimental|Group 2|Study Participants 101-200 Partial Breast Irradiation using 36 Gy / 9 fractions BID in one week
3270458|NCT00694577|Experimental|Group 3|Study Participants 201-330 Partial Breast Irradiation using 40 Gy / 10 fractions BID in one week
3270459|NCT00694564|Experimental|Treatment|This an open-labeled study. All participants will be part of the treatment group and receive SAM-e. S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
3270460|NCT00694551|Experimental|A. Level 100 mcg Peptide Vaccine|Peptide vaccine dose level 100 mcg + Poly IC-LC
3270461|NCT00694551|Experimental|B. Level 300 mcg Peptide Vaccine|Peptide vaccine dose level 300 mcg + Poly IC-LC
3270462|NCT00694551|Experimental|C. Level 1 mg Peptide Vaccine|Peptide vaccine dose level 1 mg + Poly IC-LC
3270463|NCT00694538|Active Comparator|1|100 patients are being treated with a single laser beam over pain area.
3270464|NCT00694538|Experimental|2|100 patients are being treated with interferential laser from two independent sources
3270465|NCT00694525||1|Women in this group will have 21-OHD CAH.
3270466|NCT00694525||2|Women in this group will be healthy controls and will not have 21-OHD CAH.
3270467|NCT00694512|Placebo Comparator|1|low fat diet for two weeks.
3270468|NCT00694512|Active Comparator|2|High fat diet for two weeks followed by blood sampling.
3270469|NCT00694512|Active Comparator|3|Medium Chain Triglyceride diet
3270471|NCT00694486||1|Healthy adult volunteers
3270472|NCT00694473|Experimental|Freestyle Navigator|Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
3270473|NCT00694460|Experimental|1|
3270474|NCT00694460|Experimental|2|
3270475|NCT00694460|Experimental|3|
3270476|NCT00694460|Experimental|4|
3270477|NCT00694460|Active Comparator|5|
3270478|NCT00694447|Experimental|Real acupuncture|Real acupuncture
3270479|NCT00694447|Sham Comparator|Sham acupuncture|Sham acupuncture
3270480|NCT00694434||1|Patients with 2 or more frozen blastocyst that scored GES 70 or better in the fresh cycle.
3270481|NCT00694434||2|Patients with 2 or more frozen blastocysts scoring GES <70 in the fresh cycle.
3270482|NCT00694421||1|"adults who participate in study, Social and Psychological Risks for Infectious Disease here at Children's Hospital of Pittsburgh"
3270483|NCT00694421||2|"children 2-6 years who participate in Role of Virus and Genetic Susceptibility study here at Children's Hospital of Pittsburgh"
3270484|NCT00694408|Active Comparator|Steroid immunosuppressive regimen|Freedom from rejection and safety in children undergoing paediatric liver transplant using steroid containing immunosuppression regimen post transplant. This group of patients will receive steroids in conjunction with other prescribed immunosuppressive agents. Intervention is use of methyl prednisolone, hydrocortisone, prednisolone as routine post transplant management
3270485|NCT00694408|Active Comparator|Steroid free immunosuppressive regimen|Freedom from rejection and safety in children undergoing paediatric liver transplant using steroid free immunosuppression regimen post transplant. The patients in this arm will receive immunosuppression but not steroids to compare with those treated with steroids to measure differences in rejection and safety of a steroid free immunosuppressive regimen. Intervention is omission of methyl prednisolone, hydrocortisone, prednisolone as routine post transplant management. No steroids will be used routinely in this arm
3270486|NCT00694382|Experimental|Semuloparin|Semuloparin sodium 20 mg once daily until change in chemotherapy regimen
3270487|NCT00694382|Placebo Comparator|Placebo|Placebo (for semuloparin) once daily until change in chemotherapy regimen
3270488|NCT00694369|Experimental|1|etoricoxib 90 mg
3270489|NCT00694369|Experimental|2|etoricoxib 120 mg
3270490|NCT00694369|Active Comparator|3|ibuprofen 2400 mg
3270491|NCT00694369|Active Comparator|4|acetaminophen 2400 mg/codeine 240 mg
3270492|NCT00694369|Placebo Comparator|5|Matching Placebo
3270493|NCT00694356|Experimental|Dalotuzumab 5 mg/kg|Participants receive dalotuzumab 5 mg/kg by intravenous (IV) infusion once each week for up to 1 year or until participant withdraws consent, experiences an adverse event (AE), progressive disease or major protocol violation, has moved or is lost to follow up.
3270494|NCT00694356|Experimental|Dalotuzumab 10 mg/kg|Participants receive dalotuzumab 10 mg/kg by IV infusion once each week for up to 1 year or until participant withdraws consent, experiences an AE, progressive disease or major protocol violation, has moved or is lost to follow up.
3270495|NCT00694356|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg|Participants receive an initial dose of dalotuzumab 15 mg/kg by IV infusion followed by a maintenance dose of dalotuzumab 7.5 mg/kg by IV infusion once every 2 weeks for up to 1 year or until participant withdraws consent, experiences an AE, progressive disease or major protocol violation, has moved or is lost to follow up.
3270496|NCT00694343|Experimental|Group A|500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
3270497|NCT00694343|Active Comparator|Group B|1000 mL Ringer's Lactate solution
3270498|NCT00694330|Experimental|GM-K562 Vaccination|
3270499|NCT00694304|Experimental|Vortioxetine|
3270500|NCT00694291|Experimental|1|Sorafenib 400 mg orally twice daily
3270501|NCT00694291|Placebo Comparator|2|Placebo
3270502|NCT00694265||1|Surgical treatment
3270503|NCT00694265||2|Conservative treatment
3270504|NCT00694252|Experimental|1|Lapatinib
3270505|NCT00694239|No Intervention|B|Standard Care
3270506|NCT00694239|Experimental|A|Risk Assessment plus standard care
3270507|NCT00694226|Experimental|1|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
3270508|NCT00694226|Active Comparator|2|Treatment as usual (TTU): Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol. After completing the assessment individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis
3270509|NCT00694213|Experimental|1|
3270510|NCT00694213|Experimental|2|
3270511|NCT00694213|Experimental|3|
3270512|NCT00694213|Placebo Comparator|4|
3270513|NCT00694200|Experimental|1|Vinorelbine metronomic + bevacizumab
3270514|NCT00694174|Active Comparator|1|2 ml sucrose 25% oral solution one time only dose by mouth
3270515|NCT00694174|Placebo Comparator|2|sterile water 2 ml one time only dose given by mouth prior to heel lance
3270516|NCT00694161|Experimental|Fx-1006A|
3270517|NCT00694135|Active Comparator|EGP-437 1.6 mA-min at 0.4 mA|Ocular iontophoresis with EGP 437 1.6 mA-min at 0.4 mA
3270518|NCT00694135|Active Comparator|EGP-437 4.8 mA-min at 1.2 mA|Ocular iontophoresis with EGP-437 4.8 mA-min at 1.2 mA
3270519|NCT00694135|Active Comparator|EGP-437 10.0 mA-min at 2.5 mA|Ocular iontophoresis with EGP-437 10.0 mA-min at 2.5 mA
3270520|NCT00694135|Active Comparator|EGP-437 14.0 mA-min at 3.5 mA|Ocular iontophoresis with EGP-437 14.0 mA-min at 3.5 mA
3270521|NCT00694122|Active Comparator|Glargine (Lantus) insulin|"Long acting insulin, glargine, that subject currently used as an outpatient. SC injections. Dose given at 22:00 is based on past week blood glucose data during evening overnight hours and AM glucose. 20.2 +/- 11.7 units glargine (mean +/- SD).~Glargine (Lantus): Sanolfi Aventis~Hourly blood glucose from 22:00 to 08:00 while receiving glargine (Lantus) insulin will be compared with the NPH insulin arm."
3270522|NCT00694122|Active Comparator|NPH insulin|"Long acting insulin, NPH, that participant was currently while an outpatient. SC injections. Dose (units) given at 22:00 is based on past week blood glucose during evening overnight period and AM glucose. 20.7 +/- 10.0 units NPH (mean +/- SD).~NPH: Eli Lilly~Hourly blood glucose from 22:00 to 08:00 while receiving glargine (Lantus) insulin will be compared with the glargine (Lantus) insulin arm."
3270523|NCT00694109|Experimental|Mipomersen|Mipomersen Sodium once a week for up to 4 years (depending on participant's consent). Participants were followed for additional 24 week post-treatment.
3270524|NCT00694096|Experimental|1|
3270525|NCT00694083|Experimental|Ridaforolimus|Ridaforolimus (MK-8669), 20 or 40 mg administered orally on Day 1 followed by a washout of at least 6 days, then QD x5 (five consecutive days) followed by a 2-day holiday through Day 28 (Cycle 1), and QD x5 followed by a 2-day holiday for 21 days (Cycle 2 and subsequent cycles).
3270526|NCT00694070||health care professionals and lay users|h= 8 health care professionals p= 43 lay users
3270527|NCT00694057|Placebo Comparator|Placebo|Placebo capsules BID
3270528|NCT00694057|Experimental|Active|HE3286 10 mg (5 mg BID)
3270529|NCT00694044|Active Comparator|Weekly titration|
3270530|NCT00694044|Active Comparator|Two Week QD|
3270531|NCT00694044|Active Comparator|Two Week BID|
3270532|NCT00694044|Placebo Comparator|Placebo|
3270533|NCT00694031|Active Comparator|A|Hemodialysis
3270534|NCT00694031|Experimental|B|On-line hemodiafiltration
3270535|NCT00694018|Active Comparator|Education and Standard Care|Received standard care and participated in an educational program for individuals with chronic back pain. Also received an uploading pedometer but no feedback or goals about their walking activity.
3270536|NCT00694018|Experimental|Internet Mediated Enhanced Pedometer|In addition to standard care and participating in an educational program, participants received an enhanced pedometer for uploading step information, e-mail messages with weekly step goals and access to a website that provided step goals and feedback, tailored motivational messages and on on-line community for communication asynchronously with staff and other participants.
3270537|NCT00694005|Active Comparator|bifurcation stent techniqe|"cross over stenting without kissing balloon angioplasty leave alone"
3270538|NCT00694005|Experimental|bifurcation stent technique|kissing balloon angioplasty
3270539|NCT00693992|Experimental|Arm I (sunitinib malate)|Patients receive sunitinib malate 37.5 mg PO once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3270540|NCT00693992|Placebo Comparator|Arm II (placebo)|Patients receive placebo 37.5 mg PO once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3270541|NCT00693966|Experimental|Group A|Formulation 1 of the vaccine (MEDI-517 HPV-16/18 VLP AS04 vaccine)
3270542|NCT00693966|Experimental|Group B|Formulation 2 of the vaccine
3270543|NCT00693966|Experimental|Group C|Formulation 3 of the vaccine
3270544|NCT00693966|Experimental|Group D|Formulation 4 of the vaccine [with Al(OH)3]
3270545|NCT00693953||1|Year one
3270546|NCT00693953||2|Year two
3270547|NCT00693940|Experimental|1|Participants will receive treatment with group mediated cognitive behavioral sessions.
3270548|NCT00693940|Active Comparator|2|Participants will receive treatment with health education sessions.
3270549|NCT00693927|Active Comparator|1|Unmanipulated PBSC
3270550|NCT00693927|Experimental|2|CD8-Depleted PBSC
3270551|NCT00693914||1: Brain Tumor Survivors (n=50)|
3270552|NCT00693914||2: Healthy Sibling Controls (n=40)|
3270553|NCT00693914||Solid Tumor Survivors (n=40)|
3270554|NCT00693901|Experimental|1|Parks will be assigned to the community-based participatory research condition.
3270555|NCT00693901|Active Comparator|2|Parks will be assigned to the director-only condition.
3270556|NCT00693901|No Intervention|3|Parks will be assigned to the control condition and will receive no intervention.
3270557|NCT00693888|Experimental|interventional group|individual comprehensive primary advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)
3270558|NCT00693888|No Intervention|Control group|only informative flyer, no further advice in any direction
3270559|NCT00693862|Experimental|Stalevo|
3270560|NCT00693862|Active Comparator|levodopa/carbidopa|
3270561|NCT00693849|Active Comparator|A|Escitalopram
3270562|NCT00693849|Active Comparator|B|Sertraline
3270563|NCT00693849|Active Comparator|C|Venlafaxine-XR
3270564|NCT00693849|No Intervention|D|Healthy matched controls
3270565|NCT00693823|Active Comparator|1|Femoral-popliteal surgical bypass with prosthetic graft
3270566|NCT00693823|Active Comparator|2|Interventional angioplasty and placement of an ePTFE covered stent graft within the femoral-popliteal artery as an endoluminal bypass percutaneously
3270567|NCT00693797||I, observation|patients with aortic stenosis
3270568|NCT00693797||II, observation|patients with aortic stenosis
3270569|NCT00693784|Experimental|Biostat® Disc Augmentation System|Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
3270570|NCT00693771|Experimental|1|
3270571|NCT00693758|No Intervention|1|healthy volunteers without intervention
3270572|NCT00693758|No Intervention|2|patients with suspected coronary artery disease without intervention
3270573|NCT00693758|Experimental|3|Healthy volunteers during adenosine infusion
3270574|NCT00693758|Experimental|4|Healthy volunteers during changes of breathing gases (CO2, O2)
3270575|NCT00693758|Experimental|5|patients with suspected coronary artery disease during adenosine infusion
3270576|NCT00693758|Experimental|6|patients with suspected coronary artery disease during changes of breathing gases
3270966|NCT00691093||Not Specified|Not Specified
3270577|NCT00693758|Experimental|7|Assessment of reactive hyperemia in arms of healthy volunteers to improve sequences
3270578|NCT00693732|Active Comparator|1, IBS patients|
3270579|NCT00693732|Experimental|2,Healthy controls|
3270580|NCT00693719|Experimental|Etoposide and Irinotecan hydrochloride|Irinotecan 100 mg/m2 IV days 1 and 15. Etoposide 50 mg PO x14 days followed by 2 weeks off.
3270581|NCT00693706|Experimental|GSK 1388442A Group|Subjects aged 18 to 49 years of age at the time of vaccination received 1 dose of GSK 1388442A vaccine at Day 0. The GSK 1388442A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3270582|NCT00693706|Active Comparator|Fluarix Group|Subjects aged 18 to 49 years of age at the time of vaccination received 1 dose of Fluarix® vaccine at Day 0. The Fluarix® vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3270583|NCT00693693|Active Comparator|Cream-|topical hydrocortisone 17-butyrate 0.1% Cream preparation applied twice daily to all lesions of atopic dermatitis
3270584|NCT00693693|Active Comparator|Ointment|topical hydrocortisone 17-butyrate 0.1% Ointment preparation applied twice daily to all lesions of atopic dermatitis
3270585|NCT00693693|Active Comparator|Lipocream|topical hydrocortisone 17-butyrate 0.1% Lipocream preparation applied twice daily to all lesions of atopic dermatitis
3270586|NCT00693680|Active Comparator|1|zinc + imipramine
3270587|NCT00693680|Placebo Comparator|2|placebo + imipramine
3270588|NCT00693667|Placebo Comparator|A|Placebo
3270589|NCT00693667|Active Comparator|B|250 mg active ingredient
3270590|NCT00693667|Active Comparator|C|500 mg active ingredient
3270591|NCT00693667|Active Comparator|D|750 mg active ingredient
3270592|NCT00693654|Experimental|Sarna Lotion|1% pramoxine Sarna lotion
3270593|NCT00693654|Placebo Comparator|Placebo Cetaphil lotion|Placebo Cetaphil lotion
3270594|NCT00693641|Active Comparator|1|"Safe Sea™ jellyfish sting inhibitor (barrier, or repellent) lotion"
3270595|NCT00693641|Placebo Comparator|2|Regular sun lotion
3270596|NCT00693628|Active Comparator|Shrinker|Patients receive 20-30 mmHg compression shrinker, an elastic compression garment that is worn on the residual limb and is used to reduce edema and promote healing.
3270597|NCT00693628|No Intervention|No Shrinker|Control group - participants will not receive an intervention (compression shrinker).
3270598|NCT00693628|Active Comparator|Shrinker 2|Patients receive 30-40 mmHg compression shrinker, an elastic compression garment that is worn on the residual limb and is used to reduce edema and promote healing.
3270599|NCT00693615|Experimental|Group A|Formulation 1 of the vaccine (MEDI-517 HPV-16/18 VLP AS04 vaccine)
3270600|NCT00693615|Experimental|Group B|Formulation 2 of the vaccine [with Al(OH)3]
3270601|NCT00693615|Experimental|Group C|Formulation 3 of the vaccine (without adjuvant)
3270602|NCT00693602|Experimental|1|
3270603|NCT00693589|Active Comparator|R|Rosuvastatin treatment for 6 weeks and after that combined treatment with rosuvastatin and vitamin supplementation for additional 6 weeks
3270604|NCT00693589|Active Comparator|V|Vitamin supplementation with folic acid, vitamin B12 and B6 for 6 weeks and after that combined treatment with vitamin supplementation and rosuvastatin
3270605|NCT00693576|Experimental|A|patients who will take simvastatin 20 mg daily
3270606|NCT00693563|No Intervention|Control Group|The Control Group will receive usual care following discharge from the inpatient rehabilitation unit.
3270607|NCT00693563|Experimental|Treatment Group|Scheduled Telephone Intervention
3270608|NCT00693537|Experimental|A|4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)
3270609|NCT00693537|No Intervention|B|Control
3270610|NCT00693524|Experimental|1|Tacrolimus + Anti-IL2R AB + Mycophenolate mofetil
3270611|NCT00693524|Active Comparator|2|Tacrolimus + Steroid
3270612|NCT00693511|Experimental|Circuit Training|Participants received CT exercise training two times per week for approximately 60-90 min per session for 16 wk
3270613|NCT00693511|Experimental|Circuit training + motivational interviewing|Participants in the CT + MI group received the same CT classes but also received four individual MI and four group MI sessions throughout the 16-wk program by two trained research staff
3270614|NCT00693511|No Intervention|Control|No intervention
3270615|NCT00693498|Active Comparator|1|Standard leukoreduced irradiated blood cell transfusion group
3270616|NCT00693498|Experimental|2|Washed leukoreduced irradiated blood cell transfusion group
3270617|NCT00693485|Experimental|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
3270618|NCT00693485|Experimental|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
3270619|NCT00693485|Sham Comparator|Sham (no implant)|Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
3270620|NCT00693472|Experimental|Part 1: Preladenant|Preladenant 25 mg every 12 hours for 13 days
3270621|NCT00693472|Placebo Comparator|Part 1: Placebo|Placebo every 12 hours for 13 days
3270622|NCT00693472|Experimental|Part 2: Preladenant|Preladenant 25 mg every 12 hours for 13 days
3270623|NCT00693472|Active Comparator|Part 2: Standard of Care|Anticholinergic agents or Propranolol as standard-of-care dosing regimen (supplied by the study site)
3270624|NCT00693446|Other|2|"In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation.~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time."
3270625|NCT00693446|Other|1|Patients receive Tacrolimus from day 0 to the end of the study (Arm Tacrolimus).
3270626|NCT00693433|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive temsirolimus IV over 30 minutes once weekly on days 1, 8, 15, and 22 and oral dexamethasone once on days 1, 2, 8, 9, 15, 16, 22, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3270627|NCT00693420|Experimental|1|Bimatoprost 0.03% solution
3270628|NCT00693420|Placebo Comparator|2|Vehicle solution
3270629|NCT00693407|Experimental|1, FD patients|Eighty male and female FD patients according to Rome III criteria (Drossman, 2006), aged 18 to 70 years, will be recruited from primary and secondary care via advertisements and our referral networks
3270630|NCT00693407|Experimental|2,Healthy controls|Forty male and female healthy volunteers, aged 18 to 70 years without any gastrointestinal pathology or history of significant abdominal pain, bowel disorders, bloating or discomfort during the last 3 months will be recruited.
3270631|NCT00693381|Experimental|1|Tacrolimus/MMF/steroids throughout the study
3270632|NCT00693381|Experimental|2|Tacrolimus/MMF/steroids with MMF reduction from week 7 to 12 and MMF discontinuation at month 3
3270633|NCT00693355|Experimental|1|sodium butyrate
3270634|NCT00693355|Placebo Comparator|2|NaCl
3270635|NCT00693342|Experimental|Arm I|Patients receive polyvalent antigen-KLH conjugate vaccine in combination with OPT-821 subcutaneously (SC) once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.
3270636|NCT00693342|Experimental|Arm II|Patients receive OPT-821 SC once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.
3270637|NCT00693316|Experimental|ORM-12741|
3270638|NCT00693316|Placebo Comparator|Placebo|
3270639|NCT00693303|Experimental|Handwriting Training using My Scrivener|Subjects received 20 minutes of training per week which included writing letters and words with the My Scivener device.
3270640|NCT00693290|Active Comparator|1|Fleet plus low residue diet sheet.
3270641|NCT00693290|No Intervention|2|No intervention, usual care, Fleet plus liquid only diet
3270642|NCT00693264|Experimental|1|Participants will take 1- 750 mg capsule of Hoodia gordonii and have the primary and secondary outcomes measured over an 8 hour visit.
3270643|NCT00693264|Placebo Comparator|2|Participants will take a placebo capsule and have the primary and secondary outcome measures taken over an 8 hour study day.
3270644|NCT00693251|Experimental|bifurcation stent technique|crush technique
3270645|NCT00693251|Active Comparator|bifurcation stent techniqe|provisional T stenting
3270646|NCT00693238|Experimental|Low Risk Proton Radiation|70 Gy/CGE in 28 fractions of 2.5 Gy/CGE/fx
3270647|NCT00693238|Experimental|Intermediate Risk Proton Radiation|72.5 GY/CGE in 29 fractions of 2.5 Gy/CGE/fx
3270648|NCT00693225|Active Comparator|Omeprazole/sodium bicarbonate AM dose|8 weeks of therapy with omeprazole/sodium bicarbonate oral suspension 40 mg, once per day, taken in the morning
3270649|NCT00693225|Experimental|Omeprazole/sodium bicarbonate PM dose|8 weeks of therapy with omeprazole/sodium bicarbonate oral suspension 40 mg, once per day, taken at bedtime
3270650|NCT00693212|Experimental|a|This arm was only open to subjects entering the second, open-label phase. All subjects were given open-label methylphenidate. Dosing was flexible.
3270651|NCT00693212|Experimental|MPH|This is the active treatment arm of the double-blind placebo controlled phase. Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
3270652|NCT00693212|Placebo Comparator|PBO|This 2 week arm is the placebo part of the crossover design. Subjects receive placebo in a manner similar to the MPH arm. It lasts 2 weeks.
3270653|NCT00693199|Experimental|1|
3270654|NCT00693199|Active Comparator|2|
3270655|NCT00693199|Experimental|3|
3270656|NCT00693186|Experimental|1|
3270657|NCT00693186|Experimental|2|
3270658|NCT00693160|Experimental|Intrathecal Ketorolac|In the presence of a remifentanil infusion subject will receive a single intrathecal injection of ketorolac 2 mg Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.
3270659|NCT00693160|Placebo Comparator|Placebo intrathecal injection|In the presence of remifentanil the subject will receive a single intrathecal injection of placebo (preservative-free normal saline) Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.
3270660|NCT00693147|Active Comparator|A|mini Video Assisted Thyroidectomy (miVAT)
3270661|NCT00693147|Active Comparator|B|Classic Total Thyroidectomy
3270662|NCT00693134||Myocarditis Patients|Patients initially diagnosed with myocarditis.
3270663|NCT00693134||Control Patients|Patients with no known cardiomyopathies
3270664|NCT00693121|Placebo Comparator|Placebo|Identical capsule to amantadine hydrochloride active intervention, administered twice daily x 14 days
3270665|NCT00693121|Active Comparator|Amantadine|Amantadine hydrochloride 100mg capsule administered twice daily x 14 days
3270666|NCT00693108|Experimental|1|Transdermal testosterone treatment during the five days preceding gonadotropin therapy in IVF cycles
3270667|NCT00693108|No Intervention|2|
3270668|NCT00693095|Experimental|1|CMV-ALT + CMV-DCs
3270669|NCT00693095|Experimental|2|CMV-ALT + Saline
3270670|NCT00693082|Experimental|1|
3270671|NCT00693069|Active Comparator|1|Clopidogrel 300 mg the day before PCI
3270672|NCT00693069|Experimental|2|Clopidogrel 600 mg the day before PCI
3270673|NCT00693069|Experimental|3|300 mg followed by 75 mg daily started one week prior to angiography
3270674|NCT00693069|Experimental|4|300 mg followed by 150 mg daily started one week prior to angiography
3270675|NCT00693056|Placebo Comparator|1|
3270676|NCT00693056|Experimental|2|
3270677|NCT00693056|Experimental|3|
3270678|NCT00693056|Experimental|4|
3270679|NCT00693043|No Intervention|Standard anesthesia group|Patients randomized to arm 1 received standard of care anesthesia for pleuroscopy. Duration of the procedure will be recorded. Pain management will be monitored prior to, intraoperatively and at the end of the procedure.
3270680|NCT00693043|Experimental|Lidocaine Group|Patients randomized to arm two will receive a reduced topical dose of lidocaine of 2mg/kg and additional lidocaine 3mg/kg infused into the pleura cavity. Duration of procedure will be monitored from the time initial dose of intradermal lidocaine until the start of surgical wound closing, pain scale will be administered prior to the procedure and at the end of the procedure. Lidocaine serum levels will be monitored at 30, 60, and 120 minutes after initial intradermal administration of lidocaine.
3270681|NCT00693030|Active Comparator|1|Device, Sirolimus drug-eluting stents implanted in overlap
3270682|NCT00693030|Active Comparator|2|Device, paclitaxel polymer drug eluting stent
3270683|NCT00693030|Active Comparator|3|Device, zotarolimus drug eluting stent
3270684|NCT00693030|Active Comparator|4|bare metal coronary stents
3270685|NCT00693017|Active Comparator|Zonisamide|
3270686|NCT00693017|Placebo Comparator|Placebo|
3270687|NCT00693004|Placebo Comparator|Placebo|
3270688|NCT00693004|Experimental|PRX-03140|
3270689|NCT00693004|Active Comparator|donepezil|
3270690|NCT00692991||1|People undergoing percutaneous coronary interventions.
3270691|NCT00692978|Experimental|1|Monodisperse aerosols inhaled of Fluticasone Propionate 1.5microns size at 50micrograms dose with double-dummy placebo MDI inhaler
3270692|NCT00692978|Experimental|2|Monodisperse aerosols inhaled of Fluticasone Propionate 3.0microns size at 50micrograms dose with double-dummy placebo MDI inhaler
3270693|NCT00692978|Experimental|3|Monodisperse aerosols inhaled of Fluticasone Propionate 6 microns size at 50micrograms dose with double-dummy placebo MDI inhaler
3270694|NCT00692978|Experimental|4|etered dose inhaler of Fluticasone Propionate 250 micrograms dose, inhaled, with double-dummy placebo monodisperse aerosol
3270695|NCT00692952|Experimental|1|120 subjects using BenZalkonium Chloride Contraceptive Gel
3270696|NCT00692952|Active Comparator|2|120 subjects using Nonoxynol-9 contraceptive gel
3270697|NCT00692939|Experimental|1|High-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
3270698|NCT00692926|Other|20% primed UCB|20% of UCB is ALDHbr sorted and primed and give on transplant day after conventional graft
3270699|NCT00692926|Other|20% un-primed|20% of UCB is ALDHbr freshly sorted and give on transplant day 4-8 hrs after conventional graft
3270700|NCT00692926|Other|Double- 1 unit primed|patient receives 1 conventional UCB unit and 1 unit that has been ALDHbr sorted and primed
3270701|NCT00692926|Other|Double- 1 unit unprimed|Patient receives 1 UCB unit and a second UCB unit that has been freshly ALDHbr sorted
3270702|NCT00692913|Experimental|FOSAVANCE 5600|alendronate sodium (+) cholecalciferol
3270703|NCT00692913|Other|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.
3270704|NCT00692900|Experimental|1|intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin
3270705|NCT00692900|Experimental|2|intravenous (IV) oxaliplatin and intraperitoneal(IP) docetaxel
3270706|NCT00692887||1|Subjects diagnosed as new CNV or treated CNV
3270707|NCT00692848|Experimental|PCT+|Investigations include CBC, blood culture, urine analysis and culture and procalcitonin. In this arm procalcitonin result is revealed to the attending physician. The decision to treat with antibiotics or to hospitalize was left to him
3270708|NCT00692848|No Intervention|PCT-|Investigations include CBC, blood culture, urine analysis and culture and procalcitonin. In this arm, procalcitonin is not revealed to the attending physician. The decision to treat with antibiotics or to hospitalize was left to him.
3270709|NCT00692835|Active Comparator|A|Patients with mini Video Assisted Thyroidectomy (miVAT)
3270710|NCT00692835|Active Comparator|B|Immediate postoperative course of patients with classic Thyroidectomy (cTT)
3270711|NCT00692809||1|HIV+ve+LTBI (n=100)
3270712|NCT00692809||2|HIV+ve+clinical TB (n=50)
3270713|NCT00692809||3|HIV-ve+clinical TB (n=15)
3270714|NCT00692809||4|Normal control (n=15)
3270715|NCT00692796|Experimental|1|
3270716|NCT00692770|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (BID)
3270717|NCT00692770|Placebo Comparator|Placebo|Participants received 2 tablets of placebo orally twice daily (BID)
3270718|NCT00692757|Experimental|A|Hypochlorous acid
3270719|NCT00692757|Active Comparator|B|Iodopovidone
3270720|NCT00692744||Randomized microsurgical|After randomization, this group was constituted of patients treated by microsurgical clipping.
3270721|NCT00692744||Randomized endovascular|After randomization, this group was constituted of patients treated by endovascular coiling.
3270722|NCT00692744||Prospective observational microsurgical|The randomization was ethically unsuitable because of the aneurysm predisposed to the microsurgical clipping after discussion into the neurovascular interdisciplinary team.
3270723|NCT00692744||Prospective observational endovascular|The randomization was ethically unsuitable because of the aneurysm morphology predisposed to the endovascular coiling after discussion into the neurovascular interdisciplinary team.
3270724|NCT00692744||Prospective observational conservative|This group was constituted of patients whom no curative treatment of the aneurysm sac could not be proposed.
3270725|NCT00692731||Active|Tea catechin sport beverage
3270726|NCT00692731||Control|Control beverage
3270727|NCT00692705|Other|1|Alzheimer's Disease (AD) patients
3270728|NCT00692705|Other|2|Healthy volunteers
3270729|NCT00692692|Experimental|DermaMatrix|experimental group with DermaMatrix acellular dermis over tissue expanders in addition to skin/soft tissue and muscle to allow for more natural appearing breast and prevention of complications
3270730|NCT00692692|Active Comparator|Standard of care|standard of care using skin/soft tissue and muscle coverage of tissue expander for breast reconstruction after mastectomy without acellular dermal matrix
3270731|NCT00692653|Experimental|P4|Participant uses P4 program before meeting with his clinician to discuss treatment options.
3270732|NCT00692653|No Intervention|Usual care+|Usual care plus participant is directed to reputable websites highly rated in research literature to learn more about prostate cancer treatments.
3270733|NCT00692640|Experimental|1|
3270734|NCT00692614|Experimental|1|100 mcg triamcinolone acetonide
3270735|NCT00692614|Experimental|2|500 mcg triamcinolone acetonide
3270736|NCT00692614|Experimental|3|925 mcg triamcinolone acetonide
3270737|NCT00692614|No Intervention|4|sham control - not implanted, no medication
3270738|NCT00692601|Experimental|1|acute oral ingestion of 3 mg capsiate
3270739|NCT00692601|Experimental|2|acute oral ingestion of 10 mg capsiate
3270740|NCT00692601|Placebo Comparator|3|acute oral ingestion of 0 mg capsiate ( same number of capsules as two other trials and identical looking placebo capsules)
3270741|NCT00692588||Placebo|Subjects who received placebo in DARAD Trial
3270742|NCT00692588||Doxycycline|Subjects who received doxycycline in DARAD Trial
3270743|NCT00692588||Rifampicin|Subjects who received rifampicin in DARAD Trial
3270744|NCT00692588||Doxycycline and Rifampicin|Subjects who received doxycycline and rifampicin in DARAD Trial
3270745|NCT00692588||Control|Normal controls
3270746|NCT00692575|Experimental|1: Experimental|Problem-solving, education based telephone counseling.
3270747|NCT00692575|Sham Comparator|2: No intervention|Standard of care control group
3270748|NCT00692562|Experimental|A|
3270749|NCT00692549|Experimental|Ultrasound|use of ultrasound
3270750|NCT00692549|No Intervention|no ultrasound|no ultrasound
3270751|NCT00692536|Active Comparator|1|NNR
3270752|NCT00692536|Active Comparator|2|MPD
3270753|NCT00692523|Active Comparator|1|The control group will receive 8 recreational therapy sessions over a 2-week (14 day) period, to be scheduled in a flexible manner as long as all 8 sessions are completed within the 2 week period, and no more than 2 sessions are completed on any one day.
3270754|NCT00692523|Experimental|2|Patients randomized to Wii technology will receive an intensive program consisting of 8 Wii gaming sessions, 60 minutes each, over a 2-week (14 day) period. These 8 sessions can be scheduled in a flexible manner as long as all 8 sessions are completed within the 2 week period, and no more than 2 sessions are completed on any one day.
3270755|NCT00692510|Experimental|1|AZD3480 + cocktail
3270756|NCT00692510|Placebo Comparator|2|Placebo + cocktail
3270757|NCT00692497|Active Comparator|1|The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
3270758|NCT00692497|No Intervention|2|Patients in the control group are randomised to use the regular patient pathway prior to day case outpatient surgery. All these patients are referred to the surgical outpatient clinic. At the outpatient clinic patients are examined by a surgeon and indications for surgery is decided by the surgeon. If indicated, patients are then referred to outpatient surgery and the surgical procedure is performed several weeks after the examination.
3270759|NCT00692484|Experimental|1|Chlorhexidine gluconate 2%
3270760|NCT00692484|Active Comparator|2|Povidone iodine scrub and paint
3270761|NCT00692471||1|Patients meeting the diagnostic criteria for the Postural Tachycardia Syndrome, a form of Orthostatic Intolerance
3270762|NCT00692471||2|Healthy control subjects who do not meet the criteria for the Postural Tachycardia Syndrome
3270763|NCT00692458|Experimental|1|odanacatib
3270764|NCT00692458|Placebo Comparator|2|placebo
3270765|NCT00692445|Active Comparator|citalopram + TC-5214|
3270766|NCT00692445|Placebo Comparator|citalopram + placebo|
3270767|NCT00692419|Experimental|Symptom management nurse intervention|This arm of the study will have a symptom management nurse facilitate the management of pain, sexual dysfunction and depression. The nurse will work with the patient's renal provider to implement appropriate symptom alleviating treatment. The intervention is patient specific and entirely dependent on the treatment recommendation made by the symptom management nurse.
3270768|NCT00692419|Active Comparator|Feedback intervention|This arm of the study will have pain, sexual dysfunction and depression assessed monthly with feedback given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider. The intervention on symptoms is at the discretion of the renal provider. The interventions implemented were patient specific and consisted of therapies the patient's renal provider decided to implement.
3270769|NCT00692406|Experimental|Smokers not interested in quitting smoking|Smokers were scanned 24 hours after quitting smoking, and scanned after smoking as usual.
3270770|NCT00692393|Active Comparator|1|Surgery : Hartmann intervention
3270771|NCT00692393|Experimental|2|Surgery : primary resection with anastomosis with protective stoma
3270772|NCT00692380|Experimental|A|Fractionated Radiation Therapy followed by Carboplatin and Taxol
3270773|NCT00692367|Other|Exercise|Structured exercise program
3270774|NCT00692341|Experimental|Hepatic Function - Mild Impairment|Subjects with mild hepatic impairment (Child Pugh class A, score 5-6)
3270775|NCT00692341|Experimental|Hepatic Function - Moderate Impairment|Subjects with moderate hepatic impairment(Child Pugh class B,score 7-9)
3270776|NCT00692341|Experimental|Hepatic Function - Normal|"Group 1~1) subjects with normal hepatic function"
3270777|NCT00692328|Active Comparator|1|The subjects will be told they receive levodopa or acupuncture.
3270778|NCT00692328|Placebo Comparator|2|The subjects will be told they receive placebo/sham levodopa or acupuncture.
3270779|NCT00692328|Experimental|3|The subjects will be told they have 50% chance of receiving real or placebo/sham levodopa or acupuncture.
3270780|NCT00692315|Experimental|Methyl B12|Subcutaneous injection of 75 micrograms/Kg
3270781|NCT00692315|Experimental|Folinic Acid|400 micrograms orally twice a day
3270782|NCT00692302|Experimental|SAFETY I|Phase I participants who will receive SAFETY
3270783|NCT00692302|Experimental|SAFETY II|Phase II participants who will receive SAFETY
3270784|NCT00692302|Active Comparator|Control|Phase II participants who will receive enhanced usual care
3270785|NCT00692276|Experimental|1|Interspinous Process Spacer Device
3270786|NCT00692276|Active Comparator|2|Interspinous Process Spacer Device
3270787|NCT00692263|Experimental|A|Escitalopram - tramadol
3270788|NCT00692263|Experimental|B|Placebo - tramadol
3270789|NCT00692263|Experimental|C|placebo - placebo
3270790|NCT00692237|Active Comparator|1|Sildenafil 100 mg
3270791|NCT00692237|Placebo Comparator|2|Placebo 100 mg
3270792|NCT00692224|Active Comparator|1|study group received zinc gluconate in a dose of 10 mg/day
3270793|NCT00692224|Placebo Comparator|2|placebo group received placebo which was identical in color, taste and appearance and packaged in similar looking bottles.
3270794|NCT00692211|Experimental|Arm 1: Fecal Immunochemical Tests|Mailed fecal immunochemical tests
3270795|NCT00692211|Experimental|Arm 2: Fecal Occult Blood Tests|Mailed fecal occult blood tests
3270796|NCT00692198|Experimental|Supplemental oxygen therapy|Participants will receive treatment with supplemental oxygen therapy.
3271011|NCT00690755||Group 4|non-diabetic individuals who are considered to be overweight
3270797|NCT00692198|No Intervention|No supplemental oxygen therapy|Participants will receive no supplemental oxygen therapy, unless the participant becomes severely hypoxemic at rest (e.g., meets conventional Medicare criteria for 24-hour supplemental oxygen due to severe hypoxemia at rest).
3270798|NCT00692185|Experimental|1|Participants will take olanzapine.
3270799|NCT00692185|Placebo Comparator|2|Participants will take matched placebo.
3270800|NCT00692172|Experimental|1|
3270801|NCT00692159|Experimental|1|Dose finding single arm
3270802|NCT00692146|Experimental|1|36 subjects receiving a specified volume of the active component AZD1386 in a single dose.
3270803|NCT00692146|Placebo Comparator|2|36 subjects receiving a specified volume of placebo in a single dose.
3270804|NCT00692120|Experimental|1|
3270805|NCT00692120|Experimental|2|
3270806|NCT00692120|Experimental|3|
3270807|NCT00692120|Experimental|4|
3270808|NCT00692107|Active Comparator|1|68 Gy
3270809|NCT00692107|Experimental|2|78 Gy
3270810|NCT00692094|Experimental|1|Subjects will be given 0.5 mg at a time when melatonin should delay the timing of their body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
3270811|NCT00692094|Experimental|2|Subjects will be given 0.5 mg at a time when melatonin should advance the timing of their body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
3270812|NCT00692094|Experimental|3|Subjects will be given a larger dose (up to 10 mg) at a time when the melatonin should advance the timing of the body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
3270813|NCT00692094|Experimental|4|Subjects will be given a larger dose (up to 20 mg) at a time when the melatonin should advance the timing of the body clock. If the subject successfully responds to the treatment, the dose will be reduced gradually until the lowest effective dose is determined (down to 0.025 mg). If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
3270814|NCT00692081|Experimental|A|8 group sessions social competence training (CBT)
3270815|NCT00692081|Active Comparator|B|special vocational training as usual
3270816|NCT00692068||A|with residual renal function
3270817|NCT00692068||B|without residual renal function
3270818|NCT00692055|Experimental|1|PN400
3270819|NCT00692055|Active Comparator|2|naproxen 375 mg
3270820|NCT00692042|Experimental|1|
3270821|NCT00692016|Other|Arm 1|
3270822|NCT00692016|Other|Arm 2|
3270823|NCT00692003|Active Comparator|Zonisamide|
3270824|NCT00692003|Placebo Comparator|Placebo|
3270825|NCT00691990|Active Comparator|A|Classic thyroidectomy with drains
3270826|NCT00691990|Active Comparator|B|Classic thyroidectomy without drains
3270827|NCT00691977|Experimental|A|Radiation Therapy followed by prostatectomy
3270828|NCT00691964|Experimental|A|
3270829|NCT00691964|Active Comparator|B|
3270830|NCT00691964|Placebo Comparator|C|
3270831|NCT00691938|Experimental|Level 1|"LBH589 10 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
3270832|NCT00691938|Experimental|Level 2|"LBH589 15 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
3270833|NCT00691938|Experimental|Level 3|"LBH589 20 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
3270834|NCT00691938|Experimental|Level 4|"LBH589 30 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
3270835|NCT00691938|Experimental|Level 5|"LBH589 40 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
3270836|NCT00691938|Experimental|Level 5B|"LBH589 40 mg/day three times a week on nonconsecutive days for the first 2 weeks in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
3270837|NCT00691938|Experimental|Phase II|"LBH589 will be given in the dose and in the schedule that was found to work in the Phase I portion which was Level 5B.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
3270838|NCT00691925||1|bilateral post refractive surgery subject
3270839|NCT00691912|Experimental|Myocet/Paclitaxel|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
3270840|NCT00691899|Experimental|1|
3270841|NCT00691899|Placebo Comparator|2|
3270842|NCT00691886|No Intervention|1|Subjects randomized to arm 1 of the study will recieve standard of care conscious sedation for EBUS; midasolam and or fentanyl.
3270843|NCT00691886|Active Comparator|2|Subjects undergoing EBUS randomized to arm 2 of the study will recieve demedetomadine hydrochloride plus standard of care conscious sedation
3270844|NCT00691873|Placebo Comparator|1|Placebo will be compared to Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
3270845|NCT00691873|Experimental|2|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
3270846|NCT00691860|Experimental|1|Patients receiving conventional sigmoid end colostomy plus a lightweight mesh Ultrapro®
3270847|NCT00691860|Other|2|Patients receiving conventional sigmoid end colostomy, without mesh
3270848|NCT00691847||1|Bilateral post refractive procedure
3270849|NCT00691834|Experimental|1|Intracoronary delivery of unfractionated bone marrow mononuclear cells
3270850|NCT00691834|Placebo Comparator|2|Intracoronary delivery of placebo
3270851|NCT00691821|Active Comparator|1|Standard Dressings
3270852|NCT00691821|Experimental|2|Negative Pressure Wound Therapy
3270853|NCT00691808|Experimental|High Dose|
3270854|NCT00691808|Experimental|Low Dose|
3270855|NCT00691808|Placebo Comparator|Placebo|
3270856|NCT00691795|Experimental|CLONIDINE|Participants randomized to this arm of the study receive 75 micrograms clonidine with the bupivacaine in their epidural when requesting pain relief in advanced labor
3270857|NCT00691795|Experimental|FENTANYL|Participants randomized to this arm of the study receive 75 micrograms fentanyl with the bupivacaine in their epidural when requesting pain relief in advanced labor
3270858|NCT00691782||1|African American females between the ages of 21 and 60
3270859|NCT00691769||I|CCSA subjects will be recruited from patients who have been diagnosed through biopsy with CCSA and treated with standard of care for up to eight months in the Department of Dermatology clinic of Wake Forest University School of Medicine.
3270860|NCT00691769||II|patients with lichen planopilaris (LP) and patients with discoid lupus erythematosus (DLE) will be collected from patients who have been diagnosed through biopsy in the clinic.
3270861|NCT00691769||III|Healthy study subjects will be patients from the Wake Forest University School of Medicine Department of Dermatology population undergoing excisions for cosmetic purposes or excision of free margins around tumors that would have otherwise been discarded.
3270862|NCT00691756|Experimental|1|Cold blood renal perfusion
3270863|NCT00691756|Active Comparator|2|Cold crystalloid renal perfusion
3270864|NCT00691743||1|Primary care
3270865|NCT00691730|Other|Arm I|To analyze proteinuria/hypertension with anti-angiogenic therapies, specifically Bevacizumab, AZD2171, Sunitinib and VEGF Trap. Patients undergo blood and urine sample collection periodically. Urine samples are assessed for PGI2 and TXA2 levels using validated ELISA methods. Urine is also assessed for protein and creatinine levels, microalbumin, osmolality, and electrolytes. Blood samples are assessed for pharmacokinetics and sFlt1, VEGF, and bFGF levels by validated ELISA methods. Blood samples are also assessed for steady state drug concentration, renin, and aldosterone levels. Analyses will be considered purely exploratory and no testing will be performed for difference between treatments.
3270866|NCT00691717|Experimental|24 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 30 mg/mL, single depot administration of 0.8 mL in the study eye
3270867|NCT00691717|Experimental|48 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 60 mg/mL, single depot administration of 0.8 mL in the study eye
3270868|NCT00691717|Experimental|60 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 75 mg/mL, single depot administration of 0.8 mL in the study eye
3270869|NCT00691717|Placebo Comparator|Anecortave Acetate Vehicle|Single depot administration of 0.8 mL in the study eye
3270870|NCT00691704|Experimental|High-risk Multiple Myeloma|Lenalidomide Induction (with Low Dose Dexamethasone) Therapy Followed by Low Dose Melphalan, Prednisone, Lenalidomide and Bortezomib Sequential Maintenance Therapy
3270871|NCT00691691|Experimental|1|Eligible patient will be treated with 48 Gy in 4 fractions encompassing the entire target lesion in 2 weeks with a minimum of 48 hours between each dose.
3270872|NCT00691678|Experimental|chondroitin and glucosamine|Postmenopausal breast cancer patients that have joint symptoms induced by aromatase inhibitors and are receiving chondroitin and glucosamine.
3270873|NCT00691665|Experimental|Olopatadine HCL Nasal Spray, 0.6%|Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
3270874|NCT00691665|Active Comparator|Fluticasone Propionate Nasal Spray, 50 mcg|Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
3270875|NCT00691639||1|Patients who are or were participants in any Alcon AL-3789 study.
3270876|NCT00691626|Experimental|Arm 1: CBT for Insomnia plus Imagery Rehearsal|CBT for Insomnia plus Imagery Rehearsal
3270877|NCT00691626|Active Comparator|Arm 2: CBT for Insomnia|CBT for Insomnia
3270878|NCT00691613|Experimental|1|EPO
3270879|NCT00691613|Placebo Comparator|2|NaCl
3270880|NCT00691600|Placebo Comparator|TMP/SMX vs Placebo|subjects with abscesses less than 5cm will be randomized to either study med or placebo
3270881|NCT00691600|Other|Hospitalization vs. 23 HR OBS Unit|Patients with abscesses 5-10cm will be randomized to either inpatient stay or 23 hour short stay in the observation unit.
3270882|NCT00691587|Experimental|1|Low-dose KB001, a monoclonal antibody
3270883|NCT00691587|Experimental|2|High-dose KB001, a monoclonal antibody
3270884|NCT00691587|Placebo Comparator|3|Placebo
3270885|NCT00691574|Active Comparator|2|Subjects will sit in front of a fluorescent bright light box while completing plasma samples to test for melatonin suppression in blood. This will be completed by both the SMS patient group and the control group of elderly individuals.
3270886|NCT00691574|Experimental|1|Subjects will take up to 3 mg of melatonin daily and will complete frequent (every 2-4 weeks) of saliva and/or plasma sampling to test for a change in the timing of the body clock in response to the melatonin.
3270887|NCT00691561|Experimental|1|Participants receive HIV counseling and testing and 8 intervention sessions to assist them with reducing unsafe sexual behaviors.
3270888|NCT00691561|No Intervention|2|Participants receive HIV counseling and testing only.
3270889|NCT00691548|Experimental|1|
3270890|NCT00691496|Experimental|1|Receives HIV testing and counseling and 5 week intervention
3270891|NCT00691496|No Intervention|2|Receives only HIV Testing and Counseling
3270892|NCT00691483|Placebo Comparator|placebo|
3270893|NCT00691483|Experimental|varenicline|
3270894|NCT00691470|Experimental|1. ATI-5923|Dose adjusted ATI-5923
3270895|NCT00691470|Active Comparator|2. Coumadin|Dose adjusted Coumadin (warfarin)
3270896|NCT00691457|Experimental|1|Opti-Free contact lens solution
3270897|NCT00691457|Active Comparator|2|ReNu Multiplus contact lens solution
3270898|NCT00691457|Active Comparator|3|Clear Care contact lens solution
3270899|NCT00691444|Experimental|1|Subjects will be given up to 0.5 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
3270900|NCT00691444|Experimental|2|Subjects will be given up to 10 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
3271012|NCT00690755||Group 5|non-diabetic and type 2 diabetic individuals who will be subjected to an exercise study
3271225|NCT00689221|Active Comparator|Temozolomide + Radiotherapy|
3270901|NCT00691444|Experimental|3|Subjects will be given up to 20 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
3270902|NCT00691418|Active Comparator|1|600 mg per day of docosahexaenoic acid (DHA)
3270903|NCT00691418|Placebo Comparator|2|Placebo
3270904|NCT00691405|Experimental|A1|Arformoterol 5 mcg BID for 14 days
3270905|NCT00691405|Experimental|A2|Arformoterol 15 mcg BID for 14 days
3270906|NCT00691405|Experimental|A3|Arformoterol 25 mcg BID for 14 days
3270907|NCT00691405|Placebo Comparator|A4|Placebo inhalation solution BID for 14 days
3270908|NCT00691405|Experimental|B1|Arformoterol 15 mcg QD for 14 days
3270909|NCT00691405|Experimental|B2|Arformoterol 25 mcg QD for 14 days
3270910|NCT00691405|Experimental|B3|Arformoterol 50 mcg QD for 14 days
3270911|NCT00691405|Placebo Comparator|B4|Placebo inhalation solution QD for 14 days
3270912|NCT00691392|Experimental|1|Linezolid 600 mg po daily for 16 weeks (112 doses) given in addition to optimized background therapy for MDR TB
3270913|NCT00691392|Placebo Comparator|2|Over-encapsulated microcrystalline methylcellulose (Avicel) - an inert filler
3270914|NCT00691379|Experimental|1|Paclitaxel/Carboplatin/Bevacizumab
3270915|NCT00691340||1|Control 1 (young subjects)
3270916|NCT00691340||2|Control 2 (old subjects)
3270917|NCT00691340||3|Glaucoma patients
3270918|NCT00691340||4|Alzheimer patients
3270919|NCT00691327|Experimental|1|Primary reconstruction
3270920|NCT00691327|Experimental|2|Revision-reconstruction
3270921|NCT00691327|Experimental|3|Revision-augmentation
3270922|NCT00691314|Experimental|1|
3270923|NCT00691314|Active Comparator|2|
3270924|NCT00691301|Experimental|Pemetrexed and cisplatin|Pemtrexed plus cisplatin on day 1 every 21 days
3270925|NCT00691288|Experimental|1|
3270926|NCT00691288|Experimental|2|
3270927|NCT00691275|Placebo Comparator|2|Saline
3270928|NCT00691275|Active Comparator|1|Zofran
3270929|NCT00691262|Experimental|1|
3270930|NCT00691249|Experimental|1|Resistant starch type 4-Raw
3270931|NCT00691249|Experimental|2|Resistant starch type 4-Raw
3270932|NCT00691249|Experimental|3|Resistant starch type 4-Cooked
3270933|NCT00691249|Experimental|4|Resistant starch type 4-Cooked
3270934|NCT00691249|Placebo Comparator|5|Shredded wheat
3270935|NCT00691236|Active Comparator|A|standard chemotherapy which is Adriamycin, Cisplatinum and Ifosfamide
3270936|NCT00691236|Experimental|B|zoledronic acid prior to standard chemotherapy
3270937|NCT00691236|Experimental|C|zoledronic acid alone 4mg IV 3 weekly for 6 doses
3270938|NCT00691223||Experimental|Individuals with Goltz syndrome and their first degree relatives.
3270939|NCT00691210|Experimental|V/N: Level 1|Vorinostat: 400mg Niacinamide: 20 mg/kg rounded to 100mg
3270940|NCT00691210|Experimental|V/N: Level 2|Vorinostat: 400mg Niacinamide: 40 mg/kg rounded to 100mg
3270941|NCT00691210|Experimental|V/N: Level 3|Vorinostat: 400mg Niacinamide: 60 mg/kg rounded to 100mg
3270942|NCT00691210|Experimental|V/N: Level 4|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg
3270943|NCT00691210|Experimental|V/N: Level 5|Vorinostat: 400mg Niacinamide: 100 mg/kg rounded to 100mg
3270944|NCT00691210|Experimental|V/N/E: Level 1|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 25 mg/m2
3270945|NCT00691210|Experimental|V/N/E: Level 2|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 50 mg/m2
3270946|NCT00691210|Experimental|V/N/E: Level 3|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 100 mg/m2
3270947|NCT00691197|Experimental|Carboxymethylcellulose sodium and Glycerin|Carboxymethylcellulose sodium and Glycerin based rewetting drop
3270948|NCT00691197|Active Comparator|Carboxymethylcellulose sodium|Carboxymethylcellulose sodium based rewetting drop
3270949|NCT00691184|Experimental|Group 1|0% Terbinafine HCl Nail Lacquer for 28 days.
3270950|NCT00691184|Experimental|Group 2|10% Terbinafine HCl Nail Lacquer.
3270951|NCT00691184|Active Comparator|Group 3|1% Lamisil® Cream
3270952|NCT00691184|Active Comparator|Group 4|Dose of 250 mg Lamisil® Tablets (Groups 1,2,3) at end of study.
3270953|NCT00691171||1|GERD: Patients with established diagnoses of GERD based on ICD-9 codes
3270954|NCT00691171||2|Atypical GERD: Patients without an established diagnosis of GERD with atypical symptoms that could be due to GERD (e.g., asthma)
3270955|NCT00691171||3|Chronic NSAID users: Patients using chronic NSAIDs who are at increased risk of GI complications (defined as previous diagnosis of peptic ulcer disease; age 75 or older; or concomitant use of corticosteroids, anticoagulants, or aspirin)
3270956|NCT00691158|Placebo Comparator|1- Normal Saline|4.7 mls normal saline IV bolus
3270957|NCT00691158|Active Comparator|2 Metreleptin|IV Leptin bolus
3270958|NCT00691158|Active Comparator|3 Pramlintide|IV Pramlintide bolus at Timpoint +0 and +30 minutes
3270959|NCT00691158|Active Comparator|4 Leptin plus Pramlintide|leptin and pramlintide IV bolus injection at timpoints 0 and +30 minutes
3270960|NCT00691145|Experimental|1|
3270961|NCT00691132|Experimental|PEITC - Placebo (short-term trial)|Participants are asked to smoke only deuterated NNK cigarettes (provided by the study) and record the exact number of cigarettes smoked and alcoholic drinks consumed each day for 1 month. Participants receive oral phenethyl isothiocyanate (PEITC) four times daily for 5 days in week 2 and oral placebo four times daily for 5 days in week 4. Participants keep a diary of all food and beverages consumed on the days that PEITC or placebo are taken.
3270962|NCT00691132|Experimental|Placebo - PEITC (short-term trial)|Participants receive oral placebo four times daily for 5 days in week 2 and oral PEITC four times daily for 5 days in week 4. Participants are also asked to smoke only deuterated NNK cigarettes, record the number of cigarettes smoked and alcoholic drinks consumed each day, and keep a food and beverage diary as in arm I.
3270963|NCT00691119|Experimental|A|Relaxation and Visualization Therapy group
3270964|NCT00691119|Active Comparator|B|Health education group
3270965|NCT00691119|No Intervention|C|Control group
3270967|NCT00691080||ASD children|"ASD children as defined by:~Age greater than or equal to 4 or less than or equal to 9 years~Diagnosis of Autism Spectrum Disorder; supported by ADOS and the ADI or SCQ (subjects).~No current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.)~No current or use within the last 1 month of beta-blockers or melatonin~No current use of sleep aids~No presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD)~(6) No blindness."
3270968|NCT00691080||"Healthy control children"|"Healthy control children as defined by:~Age greater than or equal to 4 or less than or equal to 9 years~A SCQ score of less than 10 without parental or physician concern for another neurodevelopmental disorder will be used to define normal children.~No current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.)~No current or use within the last 1 month of beta-blockers or melatonin~No current use of sleep aids;~No presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD)~(6) No blindness. (7) No current or past diagnosis of ADHD, depression, anxiety or with any other psychiatric conditions.~(8) No sibling with a diagnosis of Autism Spectrum Disorder."
3270969|NCT00691067|Experimental|Mifepristone|600mg of Mifepristone
3270970|NCT00691067|Placebo Comparator|Placebos|Placebo
3270971|NCT00691054|Experimental|Abraxane|One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4.
3270972|NCT00691041|Experimental|1|HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
3270973|NCT00691041|No Intervention|2|HIV/STI counseling and testing and a single 15 minute session of resources available in the community
3270974|NCT00691028|Experimental|TA-650 3 mg/kg|
3270975|NCT00691028|Experimental|TA-650 6 mg/kg|
3270976|NCT00691028|Experimental|TA-650 10 mg/kg|
3270977|NCT00691015|Experimental|Chemotherapy or chemotherapy + total body irradiation|"Standard of care (SOC) chemotherapy or ( SOC) chemotherapy + total body irradiation (TBI) of one of the following regimens:~Regimen I: Patients receive fludarabine phosphate IV and busulfan IV; anti-thymocyte globulin IV.~Regimen II: Patients undergo total body irradiation (TBI) twice daily for 8 fractions and receive etoposide IV;anti-thymocyte globulin IV.~Regimen III: Patients undergo TBI once or twice daily for 11 fractions and receive cyclophosphamide IV; anti-thymocyte globulin IV.~Regimen IV: Patients undergo TBI and receive fludarabine phosphate IV and busulfan IV; anti-thymocyte globulin IV.~Regimen V: Patients receive carmustine IV, etoposide IV, cytarabine IV, and melphalan IV. Some patients also receive rituximab IV; anti-thymocyte globulin IV.~Regimen VI: Patients receive fludarabine phosphate IV and melphalan IV. Some patients also undergo TBI; anti-thymocyte globulin IV."
3270978|NCT00691002|Experimental|LEO 80190|
3270979|NCT00691002|Placebo Comparator|LEO 80190 vehicle|
3270980|NCT00691002|Active Comparator|Calcipotriol|
3270981|NCT00691002|Active Comparator|Betametasone|
3270982|NCT00690976|Experimental|1.Group Intervention|A group-based intervention consisting of 4 sessions lasting approximately 90 minutes each. Using a variety of pedagogical and interactive approaches, facilitators will introduce new concepts and skills.
3270983|NCT00690976|Active Comparator|2. HCT|Offer of HIV counseling and testing
3270984|NCT00690937|Experimental|1 ECS|Low dose treatment
3270985|NCT00690937|Experimental|2 ECS|High dose treatment
3270986|NCT00690937|Active Comparator|3 Colesevelam|Active control treatment
3270987|NCT00690937|Placebo Comparator|4 Placebo|Placebo matched to low dose treatment
3270988|NCT00690937|Placebo Comparator|5 Placebo|Placebo matched to high dose treatment
3270989|NCT00690924|Experimental|Calcitriol|
3270990|NCT00690911|Experimental|1|open label adalimumab 40mg
3270991|NCT00690898|Experimental|Lanreotide autogel 120 mg|
3270992|NCT00690885|Experimental|1|lozenges containing 150 IU of natural human interferon-alpha
3270993|NCT00690885|Placebo Comparator|2|matching placebo lozenges
3270994|NCT00690859||1|Ambulatory bipolar I and II patients, clinically stabilized for at least the two months prior to recruitment and who had at least one acute episode (depressive, manic, hypomanic or mixed) within the year prior to recruitment.
3270995|NCT00690846|Experimental|1|40 mg weekly subcutaneous injection of adalimumab
3270996|NCT00690833|Experimental|topical desonide hydrogel 0.05%|Approximately 40 male and female subjects (about 20 age 3 months to <13 years and 20 age 13 and up) with mild to moderate atopic dermatitis will apply desonate gel twice daily to ATD
3270997|NCT00690820|Experimental|A|
3270998|NCT00690820|Placebo Comparator|B|
3270999|NCT00690807|Experimental|1|PH-10 treatment
3271000|NCT00690794|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily for 90 days
3271001|NCT00690794|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily for 90 days
3271002|NCT00690781|Experimental|Casein Pulse|"casein is the main protein consumed, it is given during 6 weeks with a pulse protein feeding pattern : 8% for breakfast, 80% for lunch, 4% around 1600h, and 8% for dinner."
3271003|NCT00690781|Experimental|Casein Spread|"casein is the main protein consumed, it is given during 6 weeks with a spread protein feeding pattern : 25% for breakfast, 25% for lunch, 25% around 1600h, and 25% for dinner."
3271004|NCT00690781|Experimental|MSP Pulse|"Milk soluble proteins (MSP) are the main protein consumed, it is given during 6 weeks with a pulse protein feeding pattern : 8% for breakfast, 80% for lunch, 4% around 1600h, and 8% for dinner."
3271005|NCT00690781|Experimental|MSP Spread|"Milk soluble proteins (MSP) are the main protein consumed, it is given during 6 weeks with a spread protein feeding pattern : 25% for breakfast, 25% for lunch, 25% around 1600h, and 25% for dinner."
3271006|NCT00690768|Experimental|A|Preoperative Intravitreal bevacizumab and pars plana vitrectomy
3271007|NCT00690768|Active Comparator|B|Pars plana vitrectomy only
3271008|NCT00690755||Group 1|type 2 diabetic individuals
3271009|NCT00690755||Group 2|type 1 diabetic individuals or those with diabetes secondary to pancreatic disease
3271010|NCT00690755||Group 3|non-diabetic individuals who are not considered to be overweight
3271061|NCT00690404|Experimental|1|
3271013|NCT00690755||Group 6|individuals who have or are suspected of having glucose intolerance, including patients who have a history of gestational diabetes and patients who have polycystic ovary syndrome
3271014|NCT00690755||Group 7|healthy non-diabetic subjects who will receive one dose of metformin orally 1-2 hours before performing procedures
3271015|NCT00690729|Experimental|1|Bibliotherapy - cognitive behavior therapy focusing on exposure and response prevention directed by the family
3271016|NCT00690729|Active Comparator|2|Cognitive Behavioral Therapy - therapist-directed exposure response prevention over a 12-week period
3271017|NCT00690716|Experimental|1|Nasal CO2
3271018|NCT00690716|Placebo Comparator|2|Inactive Placebo
3271019|NCT00690703|Experimental|1|Treatment
3271020|NCT00690690|Experimental|video|
3271021|NCT00690690|Active Comparator|HCT|Offer of HIV counseling and testing
3271022|NCT00690664||B|Caucasian women
3271023|NCT00690664||A|African American women
3271024|NCT00690651|Active Comparator|2|this group will rest in bed with operated leg well elevated for 48 hour and then mobilize with physiotherapist with aim for discharge home when safe.
3271025|NCT00690651|Experimental|1|mobilize with physiotherapist within 24 hours of surgical fixation of fractured ankle
3271026|NCT00690638|Placebo Comparator|1|Placebo
3271027|NCT00690638|Experimental|2|PHX1149T 200 mg
3271028|NCT00690638|Experimental|3|PHX1149T 400 mg
3271029|NCT00690625|Experimental|A|MyoRx cream
3271030|NCT00690625|Placebo Comparator|B|Placebo cream, same composition as experimental cream, without Omega 3 fatty acid
3271031|NCT00690612|Experimental|1|investigator determines efficacious dose based on child's BP response.
3271032|NCT00690573|Experimental|Adalimumab|
3271033|NCT00690560|Experimental|R-CHOP14 chemotherapy|
3271034|NCT00690547||Test Group|
3271035|NCT00690534|Active Comparator|CMAY|Insulin in young
3271036|NCT00690534|Experimental|IMAY|L-NMMA + insulin in young
3271037|NCT00690534|Experimental|SNPY|SNP in young
3271038|NCT00690534|Active Comparator|CSNP|Insulin in elderly
3271039|NCT00690534|Experimental|ISNP|SNP in elderly
3271040|NCT00690534|Experimental|SNPE|SNP in elderly
3271041|NCT00690534|Active Comparator|CMealO|Meal in elderly
3271042|NCT00690534|Experimental|SMealO|SNP+meal in elderly
3271043|NCT00690534|Active Comparator|MealY|meal in young
3271044|NCT00690534|Experimental|ExIns|insulin+exercise in elderly
3271045|NCT00690534|Experimental|ExMeal|meal+exercise in elderly
3271046|NCT00690521|Active Comparator|1|Patients will be randomized to receive either metolazone or HCTZ in a randomized, double-blind, placebo controlled crossover trial. The patients will receive the alternative medication if The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance. A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day. A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5 If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
3271047|NCT00690521|Active Comparator|2|Patients will be randomized to receive either metolazone or HCTZ in a randomized, double-blind, placebo controlled crossover trial. The patients will receive the alternative medication if The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance. A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day. A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5 If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
3271048|NCT00690495|Experimental|1|Modified propofol (Propofol 0.5%)
3271049|NCT00690495|Active Comparator|2|Propofol 1%
3271050|NCT00690482|Experimental|AZD1981|AZD1981 Oral tablet, twice daily
3271051|NCT00690482|Placebo Comparator|Placebo|Placebo Oral tablet, twice daily
3271052|NCT00690469||Observational (biomarker analysis)|"Participants undergo a structured telephone interview questionnaire. The parental questionnaires collect basic demographic data (including age, race, education, and income), occupational history, medical radiation exposure, diet and supplement use (for the year before pregnancy for father, during pregnancy for mother), tobacco use, and alcohol use. The mothers are also asked about residential pesticides and prior assisted reproductive technology.~Controls (parents) provide saliva samples. If a patient is also enrolled on COG-ARET0332, then the patient blood and tumor samples should be submitted. Parents of patients on this protocol should also submit a blood sample. Blood samples from the affected child, and blood and/or sputum samples from the parents may be submitted. Tumor specimens should be submitted if available.~For some patients, a RB1 mutation detection assay on DNA derived from peripheral blood is performed. If the mutation is found, the parents? DNA is also screened."
3271053|NCT00690456|Experimental|Rimonabant|Rimonabant 20 mg once daily on top of metformin
3271054|NCT00690456|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily on top of metformin
3271055|NCT00690443|Active Comparator|2|2.5 mg AEGR 733 plus atorvastatin 20 mg weeks 1-4 followed by 5 mg AEGR 733 plus atorvastatin 20 mg weeks 5-8
3271056|NCT00690443|Active Comparator|1|Following 35-day washout + diet run-in, subjects receive atorvastatin 20 mg for 8 wks.
3271057|NCT00690430|Active Comparator|Pasireotide LAR|Patients assigned to pasireotide LAR will receive a 60 mg dose of pasireotide LAR i.m. depot injection once every 28 days (+/- 3 days) for 6 months at visits 2, 4, 5, 6, 7 and 8. A dose reduction to 40 mg is permitted if tolerability issues arise. In addition, after 24 hours of the first LAR injections the patients were permitted to use pasireotide s.c. formulation for breakthrough symptoms as needed.
3271058|NCT00690430|Active Comparator|Octreotide LAR|Patients assigned to octreotide LAR will receive a 40mg dose of octreotide LAR i.m. depot injection once every 28 days (+/- 3 days) for 6 months at visits 2, 4, 5, 6, 7 and 8. A dose reduction to 30 mg is permitted if tolerability issues arise. Patients requiring a dose reduction are to return to the higher dose once the tolerability issue is resolved, if required for efficacy In addition, after 24 hours of the first LAR injections the patients were permitted to use octreotide s.c. formulation for breakthrough symptoms as needed.
3271059|NCT00690417|Placebo Comparator|1|
3271060|NCT00690417|Active Comparator|2. 2500 IU vitamin D in a food preparation|Daily ingestion of 2500 IU vitamin D in a food preparation.
3271062|NCT00690391||Surgical observation|patients with cancer in a palliative setting and in need of surgical interventions
3271063|NCT00690378|Experimental|1|NXL/104 ceftazidime
3271064|NCT00690378|Active Comparator|2|comparator 4 x daily
3271065|NCT00690339|Experimental|1|Augmentation
3271066|NCT00690339|Experimental|2|Reconstruction
3271067|NCT00690339|Experimental|3|Revision-augmentation
3271068|NCT00690339|Experimental|4|Revision-reconstruction
3271069|NCT00690326|Experimental|A|"treatment type: behavioral(lifestyle counseling)~treatment name: behavioral change communication to promote physical activity"
3271070|NCT00690326|Placebo Comparator|B|Arm B given placebo comparator ie pamphlets
3271071|NCT00690313|Active Comparator|Arm 1|Arm 1: receives Vigamox eye drops 3Xday for 3 days prior to intravitreal injection
3271072|NCT00690313|Active Comparator|Arm 2|Arm 2: receives Vigamox eye drops 3Xday for 1 day prior to intravitreal injection
3271073|NCT00690287|Experimental|Part A, arm 1|1) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo together with food
3271074|NCT00690287|Experimental|Part A, arm 2|1) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo without food
3271075|NCT00690287|Experimental|Part B, arm1, 2, and 3|"AZD6370 dose x mg o.d.~dose x/2 mg b.i.d.~dose x/4 mg q.i.d."
3271076|NCT00690287|Experimental|Part B, arm 4|4) Placebo
3271077|NCT00690274|Other|2|Volunteers are given Placebo, up to 20mg per day
3271078|NCT00690274|Other|1|Volunteers are given BF2.649, up to 20mg per day
3271079|NCT00690261||lung cancer|patients diagnosed of lung cancer with malignant pleural effusions
3271080|NCT00690248||1|Bipolar patients admitted to a psychiatric Unit due to an acute mania episode.
3271081|NCT00690235|Other|2|Patients will be given the Placebo for injection twice daily
3271082|NCT00690235|Other|1|volunteers are given 180mg of pramlintide, twice daily
3271083|NCT00690222|No Intervention|TM|Topical mydriasis without pseudoexfoliation
3271084|NCT00690222|Experimental|ICM|Intracameral mydriasis without pseudoexfoliation
3271085|NCT00690222|No Intervention|TM - PXF|Topical mydriasis with pseudoexfoliation
3271086|NCT00690222|Experimental|ICM - PXF|Intracameral Mydriasis with pseudoexfoliation
3271087|NCT00690196|Experimental|1|Tai Chi Chih
3271088|NCT00690196|Active Comparator|2|Cognitive Behavioral Therapy
3271089|NCT00690170|Active Comparator|Ketamine and Nicotine|"0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~13.5 µg/kg of nicotine IV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"
3271090|NCT00690170|Placebo Comparator|Placebo Comparator|-Placebo administration: Normal saline (sodium chloride 0.9%)over 95 minutes
3271091|NCT00690170|Active Comparator|Ketamine and Placebo|"Ketamine administration: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes~Placebo administration: Normal saline (sodium chloride 0.9%)over 94 minutes"
3271092|NCT00690170|Active Comparator|Nicotine and Placebo|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg)IV (in the arm), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
3271093|NCT00690144|Experimental|simulation group|the trainees in the simulation group receive simulation-based training
3271094|NCT00690131|Experimental|1|
3271095|NCT00690131|No Intervention|2|
3271096|NCT00690118|Active Comparator|1|
3271097|NCT00690118|Placebo Comparator|2|
3271098|NCT00690105|Experimental|A|
3271099|NCT00690105|Active Comparator|B|
3271100|NCT00690092|Active Comparator|1|Volunteers with a history of pulmonary coccidioidomycosis verified by serology and/or histology or mycology.
3271101|NCT00690092|Active Comparator|2|Volunteers without a history of pulmonary coccidioidomycosis confirmed by serology (naive).
3271102|NCT00690092|Active Comparator|3|Volunteers with a history of pulmonary histoplasmosis but no history of coccidioidomycosis confirmed by serology.
3271103|NCT00690079|Experimental|AZD1386|7 groups receiving a specified volume of the active component AZD1386 at different points of time.
3271104|NCT00690079|Placebo Comparator|Placebo|7 groups receiving a specified volume of placebo at different points of time
3271105|NCT00690066|Experimental|A|PROCHYMAL®
3271106|NCT00690066|Placebo Comparator|B|Placebo
3271107|NCT00690053|Experimental|1|
3271108|NCT00690040|Active Comparator|1|Ripening of the unfavorable cervix is done with Single balloon catheter (Foley catheter)
3271109|NCT00690040|Active Comparator|2|Ripening of the unfavorable cervix is done with double balloon catheter (Atad catheter)
3271110|NCT00690027|Active Comparator|A|"Objective: See Brief Summary, page 2. Eligibility: Patients who require > 2 units blood transfusion for bleeding esophageal varices due to cirrhosis.~Randomization: By the blind card method to emergency portacaval shunt (EPCS) or emergency endoscopic sclerotherapy (EST) followed by long-term repetitive EST.~Diagnostic Workup: Completed within 6hr. Rapidity of Therapy: Within 8hr. Failure of Therapy: Bleeding requiring >6u PRBC in first 7 days, or 8 units PRBC during 12 months, or rebleeding after varices were obliterated.~Rescue Crossover Therapy: When primary therapy has failed. Followup: Lifelong. Data Collection on line, analysis by biostatistician Florin Vaida, PhD External Advisory, Data Monitoring and Safety Committee by 3 senior academicians."
3271111|NCT00690027|Active Comparator|B|Emergency endoscopic sclerotherapy
3271112|NCT00690014|Experimental|A|
3271113|NCT00690001||1|HIV-1 infected patients in Taiwan
3271114|NCT00689988|Experimental|SG|Study Group: five children with Down syndrome submitted to speech-language intervention with AAC intervention
3271115|NCT00689962|Experimental|1|Patients with unstable Lisfranc foot fracture-dislocations that receive bioabsorbable screw fixation through surgery.
3271116|NCT00689962|Active Comparator|2|Patients with unstable Lisfranc fracture-dislocations of the foot that receive steel screw fixation through surgery.
3271117|NCT00689949|Other|folic acid|
3271118|NCT00689936|Experimental|Lenalidomide / Dexamethasone until disease progression|Lenalidomide plus low-dose dexamethasone given until disease progression
3271119|NCT00689936|Experimental|Lenalidomide / Dexamethasone for 18 cycles|Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
3271120|NCT00689936|Active Comparator|Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles|Combination of Melphalan, Prednisone and Thalidomide given for 12 six-week cycles
3271121|NCT00689897|Experimental|1|In acupuncture treatment, immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation, the needles are retained for 30 minutes.
3271122|NCT00689897|Active Comparator|2|In acupuncture treatment, immediately after insertion of a needle, it is NOT manually rotated backwards or forwards to induce the DeQi sensation, and retained for 30 minutes.
3271123|NCT00689884|Experimental|Group A|All eligible patients will receive chemotherapy and one dose of Pegfilgrastim
3271124|NCT00689871|Experimental|1|Primary augmentation
3271125|NCT00689871|Experimental|2|Primary reconstruction
3271126|NCT00689871|Experimental|3|Revision-augmentation
3271127|NCT00689871|Experimental|4|Revision-reconstruction
3271128|NCT00689858|Experimental|1|Period 1: Cilostazol, Ginkgo biloba Period 2:Cilostazol, placebo
3271129|NCT00689858|Active Comparator|2|Period 1: Cilostazol, placebo Period 2: Cilostazol, Ginkgo biloba
3271130|NCT00689845|Experimental|Cohort 1|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1. Patients also receive oral prednisolone on days 1-5. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3271131|NCT00689845|Experimental|Cohort 2|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1, oral prednisolone on days 1-5, and filgrastim (G-CSF) subcutaneously (SC) on days 5-12. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
3271132|NCT00689845|Experimental|Cohort 3|Patients receive rituximab IV on days 1, 22, 43, 64, 85, and 106; cyclophosphamide IV and doxorubicin hydrochloride IV on days 1, 15, 29, 43, 57, and 71; methotrexate IV on days 8, 36, and 64; vincristine IV on days 8, 22, 36, 50 ,64, and 78; bleomycin IV on days 22, 50, and 78; and oral prednisolone on days 1-84, followed by a taper.
3271133|NCT00689845|Experimental|Cohort 4|Patients receive rituximab IV on days 1, 22, 43, 64, 85, and 106; cyclophosphamide IV on days 1, 29, and 57; doxorubicin hydrochloride IV on days 1, 15, 29, 43, 57, and 71; etoposide phosphate IV on days 15, 16, 43, 44, 71, and 72; vincristine IV and bleomycin IV on days 8, 22, 36, 50, 64, and 78; and oral prednisolone on days 1-84, followed by a taper.
3271134|NCT00689845|Experimental|Cohort 5|Patients receive rituximab IV, doxorubicin hydrochloride IV, and cyclophosphamide IV on day 1; vindesine IV and bleomycin IV on days 1 and 5; oral prednisone on days 1-5; methotrexate intrathecally on day 2; and G-CSF SC on days 6-13 for 4 courses in the absence of disease progression or unacceptable toxicity. After completion of 4 courses of R-ACVBP, patients receive consolidation therapy comprising high-dose methotrexate IV, rituximab IV, ifosfamide IV, etoposide phosphate IV, and cytarabine SC according to protocol GELA LNH03-2B.
3271135|NCT00689832|Experimental|A|
3271136|NCT00689832|Active Comparator|B|
3271137|NCT00689819|Active Comparator|BP < 140/90 mmHg|This arm will target a blood pressure of < 140/90 mmHg (or < 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
3271138|NCT00689819|Experimental|BP < 120/80 mmHg|This arm will target a more aggressive blood pressure target of < 120/80 mmHg.
3271139|NCT00689806|Placebo Comparator|Placebo|
3271140|NCT00689806|Active Comparator|Lovastin|
3271141|NCT00689793|Active Comparator|1|
3271142|NCT00689793|Placebo Comparator|2|
3271143|NCT00689780|Experimental|1|AZD1940 + Placebo
3271144|NCT00689780|Other|2|
3271145|NCT00689767|Experimental|A|This arm will receive the coated stent
3271146|NCT00689767|Active Comparator|B|This arm will receive a bare metal stent
3271147|NCT00689754|Active Comparator|NGA|Patients will receive the standard of care to proceed with nasogastric tube placement, aspiration and lavage up to 1L of normal saline
3271148|NCT00689754|No Intervention|NO NGA|Patient presenting with Upper GI hemorrhage going straight to endoscopy.
3271149|NCT00689741|Experimental|A|
3271150|NCT00689741|Placebo Comparator|B|
3271151|NCT00689728|Experimental|1|30 mg LY2127399
3271152|NCT00689728|Experimental|2|80 mg LY2127399
3271153|NCT00689728|Placebo Comparator|3|placebo
3271154|NCT00689715|Experimental|EP|Single treatment arm
3271155|NCT00689689|Active Comparator|Fully Coated Prodigy Stem (AML)|Total hip arthroplasty with fully coated prodigy stem (AML)
3271156|NCT00689689|Active Comparator|Cemented Endurance Hip Stem|Total hip arthroplasty with cemented Endurance hip stem component
3271157|NCT00689676||Study Group|20 very low birth weight preterm toddlers
3271158|NCT00689676||Control Group|20 full-term toddlers
3271159|NCT00689663|Active Comparator|1|Dissection staring at the triangle of calots. Dissection with electrocautery.
3271160|NCT00689663|Active Comparator|2|Dissection as fundus first with electrocautery.
3271161|NCT00689663|Active Comparator|3|Dissection as fundus first with ultrasonic dissection.
3271162|NCT00689650|Experimental|A|
3271163|NCT00689650|No Intervention|B|
3271164|NCT00689637|Experimental|1|AZD3480 + warfarin
3271165|NCT00689637|Experimental|2|Placebo+ warfarin
3271166|NCT00689624|Experimental|1|FOLFOXIRI+Erbitux
3271167|NCT00689611|Placebo Comparator|P|Half of patients will receive placebo for 9 weeks.
3271168|NCT00689611|Active Comparator|A|Half of patients will receive bupropion for 9 weeks.
3271169|NCT00689598|Placebo Comparator|III|Placebo
3271170|NCT00689598|Experimental|Experimental|Drug intervention
3271171|NCT00689585|Placebo Comparator|1|
3271172|NCT00689585|Experimental|2|
3271173|NCT00689572|Experimental|Ondansetron|Ondansetron + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
3271174|NCT00689572|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
3271175|NCT00689559|Experimental|1|AZD3480 + Aripiprazole
3271176|NCT00689559|Experimental|2|Placebo + Aripiprazole
3271226|NCT00689195|Experimental|C|Curcumin
3271177|NCT00689546||I/A|All cases of acute viral hepatitis irrespective of type (A, B, E) with underlying Type 2 diabetes mellitus
3271178|NCT00689546||I/B|Age and sex matched non- diabetic patients with acute viral hepatitis (irrespective of type) recruited from all the patients of acute viral hepatitis registered during the time period in which cases were recruited.
3271179|NCT00689546||II/A|All diabetic who have acute icteric viral hepatitis due to HEV infection
3271180|NCT00689546||II/B|Age and sex matched diabetic who have acute icteric viral hepatitis due to hepatiits virus other than HEV.
3271181|NCT00689520|Experimental|tinzaparin|tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months.
3271182|NCT00689520|Active Comparator|acenocoumarol|tinzaparin for 1 weeks followed by acenocoumarol for 6 months
3271183|NCT00689507|Experimental|Dose Escalation Phase(Part A):|1,10, 30, 100 or 300 mg of LY2127399 IV on day 1 of specific 21 day cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of each 21 day cycle
3271184|NCT00689507|Experimental|Dose Confirmation Phase (Part B1):|Dose determined by PK/PD modeling, LY2127399 IV on day 2 of Cycle 1 and on day 1 of specific cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of each cycle
3271185|NCT00689507|Experimental|Dose Confirmation Phase (Part B2):|Dose determined by PK/PD modeling, LY2127399 IV on day 1 of specific cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of specific cycles
3271186|NCT00689481|Experimental|U0267 foam|U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
3271187|NCT00689481|Placebo Comparator|Vehicle foam|Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
3271188|NCT00689468|Placebo Comparator|1|"Osteopathic sham treatment plus placebo Echinacea drops"
3271189|NCT00689468|Active Comparator|2|Active Echinacea drops plus sham osteopathic treatment
3271190|NCT00689468|Active Comparator|3|"Active osteopathic manipulation plus placebo Echinacea drops"
3271191|NCT00689468|Active Comparator|4|Active osteopathic manipulation plus active Echinacea drops.
3271192|NCT00689455||1|Primary care population
3271193|NCT00689442|Experimental|1|JTT-705 600 mg and atorvastatin 20 mg
3271194|NCT00689442|Placebo Comparator|2|Placebo and atorvastatin 20 mg
3271195|NCT00689416|Experimental|1|
3271196|NCT00689416|Placebo Comparator|2|
3271197|NCT00689403|Experimental|Part A: 2x2 crossover|4 different AZD1305 ER formulations
3271198|NCT00689403|Experimental|Part B: 3x3 crossover|2 different AZD1305 ER formulations and a reference formulation
3271199|NCT00689390|Other|Participants from Boceprevir Studies|Participants who previously participated in treatment studies in which boceprevir was administered were subsequently enrolled in Part 1 of the current follow-up study P05063 (NCT00689390). Participants may have received boceprevir or control peginterferon plus ribavirin (PR) in the previous treatment study. No treatment was administered in the current follow-up study.
3271200|NCT00689390|Other|Participants from Narlaprevir Studies|Participants who previously participated in treatment studies in which narlaprevir was administered were subsequently enrolled in Part 2 of the current follow-up study P05063 (NCT00689390). Participants may have received narlaprevir or control PR in the previous treatment study. No treatment was administered in the current follow-up study.
3271201|NCT00689377||1|Subjects of either sex, any race, with at least two CVD risk factors, with no overt cardiovascular diseases nor diabetes mellitus
3271202|NCT00689364||CTTCT+CWMT|"CTTCM:taking TCM decoction based on syndrome differentiation daily and each dosage is decocted two times for intervention one year with a Chinese patent medicine at least.~CWMT :with or without chemotherapy/or radiotherapy after the radical operation (R0) (according to the latest NCCN clinical guideline)."
3271203|NCT00689364||CWMT cohort|CWMT :with or without chemotherapy/or radiotherapy after the radical operation (R0) (according to the latest NCCN clinical guideline).
3271204|NCT00689351|Experimental|1|13vPnC
3271205|NCT00689351|Active Comparator|2|7vPnC
3271206|NCT00689338|Experimental|Treatment Group|Option to treat with oral azole therapy following treatment with anidulafungin
3271207|NCT00689312|Active Comparator|1|
3271208|NCT00689312|Experimental|2|
3271209|NCT00689312|Experimental|3|
3271210|NCT00689299|Placebo Comparator|Dose Group C|Standardized Allergenic Extract, Cat Hair (Felis domesticus) placebo
3271211|NCT00689299|Active Comparator|Dose Group A|Standardized Allergenic Extract, Cat Hair (Felis domesticus) 0.21 Units
3271212|NCT00689299|Active Comparator|Dose Group B|Standardized Allergenic Extract, Cat Hair (Felis domesticus)2.1 units
3271213|NCT00689286|Experimental|"BION twitch stimulation"|"The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation."
3271214|NCT00689286|Experimental|BION tetanic-frequency stimulation|The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions.
3271215|NCT00689286|No Intervention|Standardized program|A third group of experimental subjects will have a standardized program of voluntary exercise.
3271216|NCT00689273|Experimental|PF-04136309|
3271217|NCT00689273|Placebo Comparator|Placebo|
3271218|NCT00689260|Active Comparator|1 - Log Aware|Dose Log Aware (patient is aware that the device records their injection information) Half the subjects in the log aware arm will complete a diary. The other half in the log aware arm will not complete the diary.
3271219|NCT00689260|Active Comparator|2 - Log Unaware|Dose Log Unaware (patient is not aware that the device records their injection information) Half the subjects in the log unaware arm will complete a diary. The other half in the log unaware arm will not complete the diary.
3271220|NCT00689247|Experimental|A|AZD1305 given as oral solution
3271221|NCT00689247|Experimental|B|AZD1305 given as iv infusion
3271222|NCT00689234|Placebo Comparator|A|"At time of inclusion randomised in the no intervention arm (the subjects will be re-evaluated 6 months later and will get intervention at that time (cross-over protocol)"
3271223|NCT00689234|Active Comparator|B|At time of inclusion the subject get the intervention
3271224|NCT00689221|Experimental|Cilengitide + Temozolomide + Radiotherapy|
3271227|NCT00689195|Experimental|A|Ashwagandha extract
3271228|NCT00689182|Experimental|A|All patients will receive phlebotomy
3271229|NCT00689169|Experimental|Experimental|ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan) ASCT Rituximab
3271230|NCT00689156|Active Comparator|Regimen 1|Epirubicin 90 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times three followed by docetaxel 100 mg/m2 intravenously day 1 every 3 weeks times three
3271231|NCT00689156|Experimental|Regimen 2|Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
3271232|NCT00689117|Experimental|1|CT Gel
3271233|NCT00689117|Active Comparator|2|Clindamycin Gel (clindamycin)
3271234|NCT00689117|Active Comparator|3|Tretinoin Gel (tretinoin)
3271235|NCT00689117|Placebo Comparator|4|Vehicle Gel
3271236|NCT00689104|Placebo Comparator|Placebo|Participants received matching mirabegron placebo tablets and matching tolterodine slow release (SR) placebo capsules orally once a day for 12 weeks.
3271237|NCT00689104|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets and matching tolterodine SR placebo capsules orally once a day for 12 weeks.
3271238|NCT00689104|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 mg tablets and matching tolterodine SR placebo capsules orally once a day for 12 weeks.
3271239|NCT00689104|Active Comparator|Tolterodine SR 4 mg|Participants received tolterodine SR 4 mg capsules and matching mirabegron placebo tablets orally once a day for 12 weeks.
3271240|NCT00689091|Experimental|BIS group|This group will have BIS values visible and will receive alerts when the value is >60.
3271241|NCT00689091|Active Comparator|MAC Alert|This group will receive an alert if total MAC (including intravenous infusions) is <0.5 age-adjusted.
3271242|NCT00689078|Active Comparator|1|Prednisolone acetate 1%
3271243|NCT00689078|Active Comparator|2|Prednisolone acetate 0.12%
3271244|NCT00689078|Active Comparator|3|Loteprednol Etabonate 0.2%
3271245|NCT00689078|Placebo Comparator|4|Placebo
3271246|NCT00689065|Experimental|CALAA-01|
3271247|NCT00689052|Experimental|Pramipexole ER|0.75 mg to 4.5 mg tablets of Pramipexole ER, once daily in the evening
3271248|NCT00689052|Placebo Comparator|Placebo|Placebo tablets, once daily in the evening
3271249|NCT00689039|Experimental|A|AZD1305 ER tablet
3271250|NCT00689039|Placebo Comparator|B|Placebo tablet
3271251|NCT00689026|Experimental|Experimental|The lubiprostone group will receive an additional two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).
3271252|NCT00689026|Active Comparator|Control|All patients in the study will receive a standard oral dosing of 4L Polyethylene glycol with electrolytes colonoscopy preparation the day prior to their scheduled colonoscopy.
3271253|NCT00689013|No Intervention|1|Patients voluntarily presenting to community pharmacies who request receipt of the herpes zoster vaccine during the first month of observation. These patients have not been exposed to pharmacist-driven interventions utilized in this study. This group serves as the control group.
3271254|NCT00689013|Experimental|2|Patients voluntarily presenting to community pharmacies who request receipt of the herpes zoster vaccine during the second month of observation. These patients may or may not have been exposed to pharmacist-driven interventions utilized in this study. This group serves as the study/intervention group.
3271255|NCT00689000|Experimental|CHR-2797 (tosedostat)|oral, once daily administration of CHR-2797 to determine safety & anti-disease activity.
3271256|NCT00688987|Active Comparator|1|Subjects with AI will be randomized to each of three doses of hydrocortisone for 4 months on each dose.
3271257|NCT00688987|Active Comparator|2|isocaloric diet
3271258|NCT00688974||Roux-en-Y gastric bypass|Patients with class 3 obesity and type 2 diabetes submitted to Roux-en-Y gastric bypass
3271259|NCT00688974||Adjustable gastric banding|Patients with class 3 obesity and type 2 diabetes submitted to adjustable gastric banding
3271260|NCT00688974||Healthy controls|Non-obese, non-diabetic adults
3271261|NCT00688961|No Intervention|1|Baseline
3271262|NCT00688961|Experimental|2|Aspirin (1 day after a single, 625 mg dose)
3271263|NCT00688961|Experimental|3|Omacor
3271264|NCT00688961|Experimental|4|Omacor plus aspirin
3271265|NCT00688935|Experimental|1|Subjects may opt to enroll in this treatment sub-study involving melatonin treatment (0.1 - 3 mg, daily) for up to 1 year, with a minimum of 6 weeks. Throughout treatment, subjects will continue their saliva, plasma, and/or urine sampling to test for treatment efficacy.
3271266|NCT00688909|Experimental|Letrozole|This study will evaluate whether patients who are intolerant and discontinue anastrozole due to grade 2-3 arthralgia-myalgia have a decrease in rheumatological symptoms while taking letrozole
3271267|NCT00688896|Experimental|1|JTT-705 600 mg and pravastatin 40 mg
3271268|NCT00688896|Experimental|2|JTT-705 300 mg and pravastatin 40 mg
3271269|NCT00688896|Placebo Comparator|3|Placebo and pravastatin 40 mg
3271270|NCT00688883|Experimental|Arm 1|
3271271|NCT00688870|Experimental|1|13vPnC
3271272|NCT00688870|Active Comparator|2|7vPnC
3271273|NCT00688857|Experimental|A|Diazoxide choline controlled-release coated tablets administered orally once daily (Days 1 through 8). Diazoxide choline controlled-release uncoated tablets administered orally once daily (Days 9 through 16).
3271274|NCT00688857|Experimental|B|Diazoxide choline controlled-release uncoated tablets administered orally once daily (Days 1 through 8). Diazoxide choline controlled-release coated tablets administered orally once daily (Days 9 through 16)
3271275|NCT00688844||PKU subjects - baseline|Male and female subjects with PKU at baseline starting KuvanTM therapy.
3271276|NCT00688831|Experimental|A|AZD1305 solution for iv infusion
3271277|NCT00688831|Placebo Comparator|B|NaCl solution for iv infusion
3271278|NCT00688818|Experimental|Quetiapine and existing psychotropics|
3271279|NCT00688818|Placebo Comparator|Placebo and existing psychotropics|
3271280|NCT00688805|Experimental|Arm 1|
3271281|NCT00688805|Placebo Comparator|Arm 2|
3271282|NCT00688779|Experimental|1|
3271283|NCT00688779|Placebo Comparator|2|
3271284|NCT00688766|Experimental|IPI-504|retaspimycin hydrochloride (IPI-504) plus best supportive care
3271285|NCT00688766|Placebo Comparator|Placebo|Placebo plus best supportive care
3271286|NCT00688753|Experimental|RAD001|two 5 mg tablets of everolimus orally, once daily
3271287|NCT00688740|Experimental|TAC (Docetaxel)|docetaxel (75 mg/m^2) in combination with doxorubicin (50 mg/m^2) and cyclophosphamide (500 mg/m^2) on day 1 every 3 weeks for 6 cycles of treatment
3271288|NCT00688740|Active Comparator|FAC (5-fluorouracil)|5-fluorouracil (500 mg/m^2) in combination with doxorubicin (50 mg/m^2) and cyclophosphamide (500 mg/m^2) on day 1 every 3 weeks for 6 cycles of treatment
3271289|NCT00688727|Experimental|1|Cognitive behavioural Therapy
3271290|NCT00688727|Active Comparator|2|Standard Care
3271291|NCT00688714|Experimental|1|
3271292|NCT00688714|Placebo Comparator|2|
3271293|NCT00688701|Placebo Comparator|Placebo (Two-Step Titration)|2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 12.
3271294|NCT00688701|Placebo Comparator|Placebo (One-Step Titration)|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, then 20 mcg QD up to Week 12.
3271295|NCT00688701|Experimental|Lixisenatide (Two-Step Titration)|2-step initiation regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 12.
3271296|NCT00688701|Experimental|Lixisenatide (One-Step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to Week 12.
3271297|NCT00688688|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets and matching tolterodine extended release (ER) placebo capsules orally once a day for 12 months.
3271298|NCT00688688|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 mg tablets and matching tolterodine ER placebo capsules orally once a day for 12 months.
3271299|NCT00688688|Active Comparator|Tolterodine ER 4 mg|Participants received tolterodine ER 4 mg capsules and matching mirabegron placebo tablets orally once a day for 12 months.
3271300|NCT00688675||Treated GERD pts|Previously diagnosed GERD patients on treatment in Switzerland
3271301|NCT00688662|Active Comparator|1.ERCP with sphincterotomy|ERCP with sphincterotomy: cutting the biliary sphincter muscle (sphincterotomy)
3271302|NCT00688662|Placebo Comparator|2.ERCP without sphincterotomy|ERCP without cutting the biliary sphincter muscle (sphincterotomy)
3271303|NCT00688649|Active Comparator|1|Standard ONS
3271304|NCT00688649|Active Comparator|2|High Energy ONS
3271305|NCT00688636|Active Comparator|1|
3271306|NCT00688636|Placebo Comparator|2|
3271307|NCT00688623|Experimental|Everolimus|Everolimus
3271308|NCT00688597|Experimental|Cohort 1|Regimen 1: Low-dose duvoglustat (2.5 grams [g]) once a day (QD) for 3 days, followed by no drug for 4 days, for 11 weeks.
3271309|NCT00688597|Experimental|Cohort 2|Regimen 1: High-dose duvoglustat (5.0 g) QD for 3 days, followed by no drug for 4 days, for 11 weeks.
3271310|NCT00688597|Experimental|Cohort 3|Regimen 2: High-dose duvoglustat (5.0 g) QD for 7 days, followed by no drug for 7 days, for 11 weeks.
3271311|NCT00688584|Experimental|1|
3271312|NCT00688584|Placebo Comparator|2|
3271313|NCT00688584|No Intervention|No intervention control|
3271314|NCT00688571|Experimental|Melody TPV Implant|Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RV-PV conduit.
3271315|NCT00688558|Experimental|1|JTT-705 600 mg and simvastatin 40 mg
3271316|NCT00688558|Placebo Comparator|2|Placebo and simvastatin 40 mg
3271317|NCT00688545||Celecoxib|Patients treated with celecoxib as per treating physician's judgement
3271318|NCT00688545||nsNSAIDs (nonselective nonsteroidal anti-inflammatory drugs)|Patients treated with nsNSAIDs as per treating physician's judgement
3271319|NCT00688532||1|Prostate cancer patients treated with bicalutamide or not
3271320|NCT00688532||2|General population cohort
3271321|NCT00688519|Experimental|U0267 Foam|U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
3271322|NCT00688519|Placebo Comparator|Vehicle foam|Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
3271323|NCT00688506|Experimental|1|Combined sono-electro-magnetic therapy
3271324|NCT00688506|Placebo Comparator|2|placebo therapy
3271325|NCT00688493|Experimental|20 mg single dose of dapagliflozin|20 mg dapagliflozin
3271326|NCT00688493|Experimental|150 mg single dose of dapagliflozin2|150 mg dapagliflozin
3271327|NCT00688493|Active Comparator|400 mg single dose of moxifloxacin|Moxifloxacin
3271328|NCT00688493|Placebo Comparator|Placebo|Placebo
3271329|NCT00688480|Placebo Comparator|I|CKD Stage 3 (estimated GFR 30 - 60 ml/min/1.73m2), Echo LVH
3271330|NCT00688480|Active Comparator|2|
3271331|NCT00688467|Experimental|Navarixin → Placebo|Navarixin 30 mg capsule to be taken once daily in the morning for 10 days in Treatment Period 1, followed by a 2-4 week washout period, followed by matching placebo capsule to be taken once daily in the morning for 10 days in Treatment Period 2
3271332|NCT00688467|Experimental|Placebo → Navarixin|Matching placebo capsule to be taken once daily in the morning for 10 days in Treatment Period 1, followed by a 2-4 week washout period, followed by navarixin 30 mg capsule to be taken once daily in the morning for 10 days in Treatment Period 2
3271333|NCT00688454||Pt with hypercholesteremia|Patients treated with CRESTOR because of hypercholesteremia
3271334|NCT00688441|Experimental|Active|CO2 Gas
3271335|NCT00688441|Placebo Comparator|Placebo|Inactive Placebo Gas
3271336|NCT00688428|Experimental|1|combination capsule of Esomeprazole 40mg + ASA 325mg
3271337|NCT00688428|Experimental|2|Esomeprazole 40 mg capsule and ASA 325 mg tablet
3271338|NCT00688402|Experimental|1|IR Formulation 65 mg
3271339|NCT00688402|Experimental|2|IR Formulation 150 mg
3271340|NCT00688402|Experimental|3|MR formulation, 1h 65 mg
3271341|NCT00688402|Experimental|4|MR Formulation, 1h 150 mg
3271342|NCT00688402|Experimental|5|MR Formulation, 2h 150 mg
3271343|NCT00688389||healthy|
3271344|NCT00688389||DF|
3271345|NCT00688389||DHF|
3271346|NCT00688376|Experimental|1|
3271347|NCT00688376|Placebo Comparator|2|
3271348|NCT00688363|Experimental|1|No blood-glucose self-control, no HbA1c
3271349|NCT00688363|Experimental|2|Blood-glucose self-control, no HbA1c
3271350|NCT00688363|Experimental|3|No blood-glucose self-control, HbA1c
3271351|NCT00688363|Experimental|4|Blood-glucose self-control, HbA1c
3271352|NCT00688350|Experimental|Behavioral feedback|Behavioral feedback intervention to improve adherence to antihypertensive medication
3271353|NCT00688350|No Intervention|Control|Control group
3271354|NCT00688337||1|Patients with newly diagnosed breast cancer. Clinically nodal negative.
3271355|NCT00688324|Experimental|Single Arm|All subjects will have baseline measures, receive acamprosate for 2 weeks, then have measures repeated.
3271356|NCT00688311|Experimental|Synbiotic|Ingestion of synbiotic dietary supplement
3271357|NCT00688311|Placebo Comparator|Placebo|Ingestion of the Placebo
3271358|NCT00688298|Experimental|Arm 1|Female patients Greater than or 18 years of age, diagnosed with Stress Urinary Incontinence (SUI).
3271359|NCT00688285|Active Comparator|1|education and automated clinical alerts
3271360|NCT00688285|Active Comparator|2|education session alone
3271361|NCT00688272|Experimental|Arm 1|Eltrombopag 75 mg QD x 6 days
3271362|NCT00688272|Active Comparator|Arm 2|Ciprofloxicin 500mg BID x 6 days
3271363|NCT00688272|Placebo Comparator|Arm 3|Placebo QD x 6 days
3271364|NCT00688259|Experimental|Cognitive Behavioral Therapy for Psychosis (CBTp)|approximately 6 months of weekly individual manualized cognitive-behavioral psychotherapy for psychosis in which participants set personal goals, identify problematic/ illness-related beliefs and experiences that may interfere with achieving those goals, evaluate the data supporting those beliefs, and then modify the beliefs or behavior as warranted by the data to make progress on those goals.
3271365|NCT00688259|Active Comparator|Supportive Therapy (ST)|approximately 6 months of weekly manualized supportive psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to the participants' lives and concerns
3271366|NCT00688233|Experimental|F-seifi|
3271367|NCT00688220||1|Those wearing garments fabricated with Celliant
3271368|NCT00688220||2|Those not wearing garments fabricated using Celliant (placebo).
3271369|NCT00688207|Experimental|Rosiglitazone|An open-label, single, oral dose of 4mg of rosiglitazone in the morning under fasted conditions
3271370|NCT00688194|Active Comparator|Arm I|Patients receive fulvestrant intramuscularly (IM) on days 0, 14, and 28 of course 1 and on day 1 of all subsequent courses. Patients also receive oral placebo once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3271371|NCT00688194|Active Comparator|Arm II|Patients receive fulvestrant and placebo as in arm I. Patients also receive aromatase inhibitor (AI) therapy (e.g., exemestane, anastrozole, or letrozole) according to standard treatment regulations.
3271372|NCT00688194|Active Comparator|Arm III|Patients receive fulvestrant as in arm I and oral lapatinib tosylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3271373|NCT00688194|Active Comparator|Arm IV|Patients receive fulvestrant as in arm I and lapatinib as in arm III. Patients also receive AI therapy according to standard treatment regulations.
3271374|NCT00688181||Cohort 1|All patients presenting to the institution for treatment of female Urinary Stress Incontinence (SUI), excluding those patients meeting any of the contraindications as noted in the Directions For Use.
3271375|NCT00688168||Symptom Assessments|Patients diagnosed with multiple myeloma (MM) complete questionnaires with Neurocognitive Testing and Neurosensory Testing
3271376|NCT00688155|Experimental|Physical Activity Training|The Physical Activity Training ((PAT) intervention consisted of center-based and home-based sessions comprised of aerobic, strength, flexibility, and balance training with a targeted duration of 150 mins/wk.
3271377|NCT00688155|Experimental|Cognitive Training|The Cognitive Training (CT) intervention was developed to improve consciously-controlled memory processing or recollection of episodic memory information.
3271378|NCT00688155|Experimental|Combined Intervention|The Combined Intervention (PACT) was designed so that participants received both cognitive and physical activity training on the same day.
3271379|NCT00688155|Active Comparator|Healthy Aging Education|The Healthy Aging Education control intervention consisted of weekly lectures based on health education.
3271380|NCT00688142||1|Individuals with shift work sleep disorder
3271381|NCT00688142||2|Healthy night shift workers without shift work sleep disorder
3271382|NCT00688129|Experimental|KITS Program|The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
3271383|NCT00688129|No Intervention|Services as usual|
3271384|NCT00688116|Experimental|ganetespib|
3271385|NCT00688103|Active Comparator|ETN Alone|etanercept (25mg, twice/week, s.c.)
3271386|NCT00688103|Active Comparator|ETN+MTX|etanercept (25mg, twice/week, s.c.) combined with methotrexate (6-8mg/week)
3271387|NCT00688090|Experimental|Low-Dose Peptide Cohort|
3271388|NCT00688090|Experimental|High-Dose Peptide Cohort|
3271389|NCT00688077|Experimental|1|
3271390|NCT00688077|Placebo Comparator|2|NaCl 0,9% 2 ml, single subcutaneous injection
3271391|NCT00688064|Experimental|1|Adapalene-BPO + Doxycyline
3271392|NCT00688064|Active Comparator|2|Vehicle + Doxycycline
3271393|NCT00688051|Experimental|1|
3271394|NCT00688038|Experimental|Laser Ablation + MRTI|Magnetic resonance thermal imaging = MRTI
3271395|NCT00688025||1|Insomniacs: Individuals reporting difficulty falling asleep or staying asleep within the past month for more than 3 days per week. Individuals much also meet screening criteria based on an overnight polysomnograph of latency to persistent sleep >20 minutes and/or >60 minutes of wake after sleep onset.
3271472|NCT00687414||adults|male and female with MDS and MPD and AML
3271473|NCT00687414||Healthy|Healthy control group
3271708|NCT00685815|Placebo Comparator|12 participants|Placebo
3271396|NCT00688025||2|Controls: Individuals reporting no difficulty falling asleep or staying asleep and objective sleep measures based on an overnight polysomnograph of latency to persistent sleep <20 minutes and/or <60 minutes of wake after sleep onset.
3271397|NCT00687999|Other|1|
3271398|NCT00687986|Active Comparator|primary surgery|primary surgical resection
3271399|NCT00687986|Experimental|stereotactic radiotherapy|primary stereotactic radiotherapy
3271400|NCT00687973|Experimental|Valsartan/amlodipine 160/10 mg|Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.
3271401|NCT00687973|Active Comparator|Atenolol/amlodipine 100/10 mg|Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.
3271402|NCT00687960|Experimental|1|Resistant Starch Type 4-Raw
3271403|NCT00687960|Experimental|2|Resistant Starch Type 4-cooked
3271404|NCT00687960|Active Comparator|3|Puffed wheat
3271405|NCT00687960|Placebo Comparator|4|Dextrose
3271406|NCT00687947|Experimental|1|MA-patients
3271407|NCT00687947|Experimental|2|FHM-patients
3271408|NCT00687947|Active Comparator|3|Healthy controls
3271409|NCT00687934|Experimental|Ganetespib|Ganetespib once weekly infusion, dose escalation study, with treatment until progression
3271410|NCT00687921||A|patients over the age of 18 who had knee trauma, intent to or had MRI assessment and are scheduled for arthroscopy.
3271411|NCT00687908|Experimental|1|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel once daily
3271412|NCT00687908|Placebo Comparator|2|Vehicle Gel once daily
3271413|NCT00687895|Experimental|1|training in clinical algorithm plus microscopy
3271414|NCT00687895|Experimental|2|clinical algorithm
3271415|NCT00687895|No Intervention|3|Control
3271416|NCT00687882|Experimental|Intervention: A|Patients with non-occlusive thrombus or resolved thrombosis at 6 weeks.
3271417|NCT00687882|Active Comparator|B|Patients with non-occlusive thrombus or resolved thrombosis at 6 weeks.
3271418|NCT00687882|Other|Parallel Cohort: Persistent Occlusive Thrombosis|Patients with completely occlusive thrombosis at 6 weeks.
3271419|NCT00687882|Other|Parallel Cohort: Persistent Antiphospholipid Antibody|Patients with persistent Positive Antiphospholipid Antibody at 6 weeks.
3271420|NCT00687869|Experimental|Case management|Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal
3271421|NCT00687869|Active Comparator|usual care|Usual stroke aftercare plus patient-information-notes
3271422|NCT00687856||LVAD Recipients|Participants who have had or are about to have a left ventricular assist device (LVAD) implanted
3271423|NCT00687843|Active Comparator|1|The TS-1 group
3271424|NCT00687843|Experimental|2|The TS-1+PSK Group
3271425|NCT00687830|Active Comparator|Polythylene Glycol (PEG) in the evening|"Bowel preparation with Polyethylene Glycol given in the evening prior to the day of the afternoon colonoscopy.~'Polyethylene Glycol afternoon'"
3271426|NCT00687830|Experimental|Polythylene Glycol (PEG) in the Morning|"Bowel preparation with Polyethylene Glycol given on the morning of the day of the afternoon colonoscopy.~'Polyethylene Glycol morning'"
3271427|NCT00687804|Experimental|Ranibizumab 0.5 mg|"Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Patients also received sham laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
3271428|NCT00687804|Experimental|Ranibizumab 0.5 mg + laser|"Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Patients also received active laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
3271429|NCT00687804|Active Comparator|Laser|"Laser photocoagulation treatment was administered on Day 1 and at intervals of at least 3 months, if deemed necessary by the physician. Patients also received monthly sham intravitreal injection in the study eye for 3 consecutive months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
3271474|NCT00687401|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6, and 14.
3271475|NCT00687388|Active Comparator|Alpha-blocker|Alpha-blocker only
3271476|NCT00687388|Active Comparator|NSAID|NSAID only
3272543|NCT00679770|Experimental|Group 2|AN2690 Solution: 5%
3271430|NCT00687791|Experimental|1|20 enrolled patients will be chosen according to the enrollment acceptance criteria. The evidence for the determination of enrolled patients shall be recorded, reviewed and approved. 2> Phacotrabeculectomy is performed.3> After completing phacotrabeculectomy, implant/place ologen™ Collagen Matrix on top of the scleral flap under the conjunctiva. For every inspection and observation, the detailed description and/or inspection data shall be recorded. If any unwanted adverse event is observed during inspection and observation, it shall be recorded and be reported to the investigation conductor.
3271431|NCT00687778||1|100 patients with newly diagnosed tumors, which are often non-FDG avid or show only low intensity uptake: Soft tissue sarcomas, well-differentiated thyroid cancer, well-differentiated and bronchoalveolar lung cancer, indolent lymphomas, neuroendocrine tumors, GIST, uterine malignancies, mucin-producing cancer, teratoma, hepatoma, HCC and lobular breast carcinoma.
3271432|NCT00687765|Experimental|1|
3271433|NCT00687752||1|hydramnios
3271434|NCT00687752||2|normal
3271435|NCT00687739|Placebo Comparator|1|GnRH agonist + placebo
3271436|NCT00687739|Active Comparator|2|GnRH agonist + placebo + exercise
3271437|NCT00687739|Experimental|3|GnRH agonist + Estradiol
3271438|NCT00687739|Experimental|4|GnRH agonist + Estradiol + exercise
3271439|NCT00687726|Experimental|G1|Standing balance and mini squat training
3271440|NCT00687726|Active Comparator|G2|Isometric knee extension exercise
3271441|NCT00687713|Active Comparator|Bupropion|Subjects will receive bupropion 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.
3271442|NCT00687713|Placebo Comparator|Placebo|Subjects will receive a matched bupropion placebo 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.
3271443|NCT00687700|Experimental|All subjects|Eligible subjects will receive GSK961081 (400 micrograms or 1200 micrograms), GSK961081 matching placebo, propranolol (80 milligrams) and propranolol matching placebo in five treatment sessions through ten different crossover treatment sequences. There will be a washout period between treatment sessions of 7 to 14 days.
3271444|NCT00687687|Experimental|Pacitaxel/Carboplatin/Iniparib|Participants will be administered pacitaxel, carboplatin and BSI-201 (Iniparib) in 21 day treatment cycles. Treatment will continue until disease progression or adverse effects prohibit further therapy.
3271445|NCT00687674|Experimental|Sorafenib + Lenalidomide + Dexamethasone|
3271446|NCT00687661|Active Comparator|1|Arm #1 will include patients randomized to receive bisphosphonate therapy for 24 months.
3271447|NCT00687661|Placebo Comparator|2|Arm #2 will include patients randomized to receive placebo therapy for 24 months
3271448|NCT00687648|Experimental|Arm I|Patients receive aromatase inhibitor (anastrozole, letrozole, or exemestane) as previously prescribed. Patients also receive oral cyclophosphamide once daily on days 1-28 and oral methotrexate twice on days 15, 16, 22, and 23 of course 1. For all subsequent courses, patients receive oral cyclophosphamide once daily and oral prednisolone once daily on days 1-28 and oral methotrexate twice on days 1, 2, 8, 9, 15, 16, 22, and 23. Treatment with cyclophosphamide, methotrexate, and prednisolone repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3271449|NCT00687648|Active Comparator|Arm II|Patients receive cyclophosphamide, methotrexate, and prednisolone as in arm I.
3271450|NCT00687622|Experimental|GSK1120212|Part 1 will identify the maximum tolerated dose using a dose-escalation procedure. Part 2 will explore further the safety, tolerability, and clinical activity of GSK1120212 in subjects with pancreatic, melanoma, non-small cell lung, and KRAS or BRAF mutation-positive colorectal cancer. Part 3 will characterize the range of biologically effective doses by assessing pharmacodynamic markers in tumor tissue
3271451|NCT00687609|Experimental|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
3271452|NCT00687596|Experimental|A|Patients randomized to TAC 101 will receive TAC 101 20 mg (administered as 2 10 mg formulated tablets) PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) for 14 days followed by a 7 day recovery period. This cycle will be repeated every 21 days.
3271453|NCT00687596|Placebo Comparator|B|Patients randomized to placebo will receive 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.
3271454|NCT00687570|Other|B|Nutritional drinks 7 days before surgery instead of traditional Bowel preparation with Laxabon®
3271455|NCT00687570|Other|A|Traditional bowel preparation with Laxabon®
3271456|NCT00687544|Experimental|PEG-IFN + RBV|PEG-IFN + RBV therapy in previously untreated chronic HCV subjects coinfected with HIV
3271457|NCT00687531|Experimental|Mometasone Furoate|Mometasone Furoate 400 mcg once daily in the evening through 12 weeks.
3271458|NCT00687518|Experimental|1|erythropoietin
3271459|NCT00687518|Placebo Comparator|2|Saline serum
3271460|NCT00687505|Experimental|1|Single ascending doses
3271461|NCT00687479||1-NGT|normal glucose tolerance
3271462|NCT00687479||2-GDM|Gestational Diabetes mellitus
3271463|NCT00687479||3.GIGT|Gestational Impaired glucose tolerance
3271464|NCT00687466|Experimental|1|Insulin yes
3271465|NCT00687466|No Intervention|2|Insulin no
3271466|NCT00687453|Experimental|1|Insulin glargine at bedtime
3271467|NCT00687453|Active Comparator|2|NPH twice-daily
3271468|NCT00687440|Experimental|Caelyx, Docetaxel, Trastuzumab|"Stage 1: subjects will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles. At the end of this stage, based on the number of cardiac events, subjects will proceed to a second stage or restart with a lower dose of Caelyx.~Stage 2: subjects will be treated with the recommended dose of Caelyx (defined in the first stage) in combination with docetaxel and trastuzumab."
3271469|NCT00687427||A|Group A - 25 individuals or more, that start occupational therapy and agree to participate in the research.
3271470|NCT00687427||B|Group B- 25 individuals or more, half a year after hand injury that were treated in occupational therapy at the same institute.
3271471|NCT00687427||C|Group C - 25 individuals or more, a year after hand injury that were treated in occupational therapy at the same institute
3271477|NCT00687388|Experimental|alpha-blocker and NSAID|Combination treatment of alpha-blocker and NSAID
3271478|NCT00687375|Other|1|Laparoscopic Inguinal Hernia Repair- Transabdominal preperitoneal (TAPP) approach
3271479|NCT00687375|Other|2|Laparoscopic Inguinal Hernia Repair- Totally extra peritoneal (TEP) Approach
3271480|NCT00687362|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
3271481|NCT00687349|Experimental|Intervention Arm|The training program will assign resident or NP student to a rotation. They will be receiving the educational intervention during 8 half-day sessions.
3271482|NCT00687349|No Intervention|Control Arm|Resident or NP student is assigned to usual education.
3271483|NCT00687336|Active Comparator|1|Empirical eradication treatment
3271484|NCT00687336|Active Comparator|2|Eradication treatment according to a diagnostic test (URT, histological test, breath test or serology).
3271485|NCT00687323|Experimental|Temozolomide|Temozolomide capsules orally, once daily: 1 induction cycle (200 mg/m^2/day for 7 days in 1 28 day cycle), 1 consolidation cycle (200 mg/m^2/day for 7 days in 1 28 day cycle), then 200 mg/m^2/day for 7 days each 28-day cycle or for 5 days each 28-day cycle (12 cycle maximum). Alternatively participants could have received 100 mg/m^2/day for 21 days of each 28-day cycle (12 cycle maximum).
3271486|NCT00687310|Other|1|Educational Intervention At the initial visit (Visit 1), patients in the educational intervention group will complete a short Needs Assessment Questionnaire to help the investigator/nurse determine which section(s) of the tailored patient education booklet to give to, educate, and provide instruction on to the patient. This may, at the discretion of the investigator, include providing their patient with a peak flow meter and instructions on its use.Visit 2 will be scheduled for 1-month after the Visit 1 for the education intervention group. All educational materials provided at Visit 1 will be reviewed with the patient at Visit 2. The investigator/nurse will reassess the patient's use of the Turbuhaler® and asthma treatment plan. Patients will also be asked about any adverse events that may have occurred since Visit 1 and/or are observed at Visit 2. Once Visit 2 is completed with the patient, the investigator/nurse will complete the Educator Satisfaction Questionnaire.
3271487|NCT00687297|Active Comparator|Vandetanib Maintenance|Docetaxel day 1, carboplatin day 1 + vandetanib induction days 1 through 21 (daily) of a 28-day cycle for 4 cycles. If free of disease progression after 4 cycles, vandetanib maintenance daily until progression.
3271488|NCT00687297|Placebo Comparator|Placebo Maintenance|Docetaxel day 1, carboplatin day 1 + vandetanib induction days 1 through 21 (daily) of a 28-day cycle for 4 cycles. If free of disease progression after 4 cycles, placebo maintenance daily until progression.
3271489|NCT00687284||A|
3271490|NCT00687271|Experimental|1|MK6213 160mg
3271491|NCT00687271|Experimental|2|MK6213 160mg + atorvastatin 20mg
3271492|NCT00687271|Active Comparator|3|atorvastatin 20mg
3271493|NCT00687271|Placebo Comparator|4|Placebo
3271494|NCT00687258|Experimental|1|Vitamin E-bonded polysulfone dialyzer
3271495|NCT00687258|No Intervention|2|Polysulfone dialyzer without vitamin E alpha-tocopherol
3271496|NCT00687245|Experimental|1|esomeprazole magnesium 5 mg, weight 8 kg to < 20kg
3271497|NCT00687245|Experimental|2|esomeprazole magnesium 10 mg, weight 8 kg to < 20kg
3271498|NCT00687245|Experimental|3|esomeprazole magnesium 10 mg, weight > 20 kg
3271499|NCT00687245|Experimental|4|esomeprazole magnesium 20 mg, weight > 20 kg
3271500|NCT00687232|Experimental|1|AZD4818
3271501|NCT00687232|Placebo Comparator|2|
3271502|NCT00687219|Experimental|Peginterferon alfa-2b + Ribavirin|
3271503|NCT00687206|Experimental|1|
3271504|NCT00687193|Placebo Comparator|Placebo|
3271505|NCT00687193|Experimental|CP-690,550, 10mg|
3271506|NCT00687193|Experimental|CP-690,550, 15mg|
3271507|NCT00687193|Experimental|CP-690,550, 1mg|
3271508|NCT00687193|Experimental|CP-690,550, 3mg|
3271509|NCT00687193|Experimental|CP-690,550, 5mg|
3271510|NCT00687180|Active Comparator|I|MMF
3271511|NCT00687180|Active Comparator|II|
3271512|NCT00687167|Experimental|Zonisamide 100 mg Capsule|A single dose of zonisamide 100 mg administered 30 minutes after initiation of a standardized, high fat breakfast.
3271513|NCT00687167|Experimental|Zonisamide (Zonegran® ) 100 mg Capsule|A single dose of Zonegran® 100 mg administered 30 minutes after initiation of a standardized, high fat breakfast.
3271514|NCT00687154|Active Comparator|1 Sitting|Subjects with (1) OCT central subfield thickness ≤ 299 microns and (2) early proliferative or severe nonproliferative diabetic retinopathy for which investigator intends to perform full scatter photocoagulation in 1 sitting
3271515|NCT00687154|Active Comparator|4 Sittings|Subjects with (1) OCT central subfield thickness ≤ 299 microns and (2) early proliferative or severe nonproliferative diabetic retinopathy for which investigator intends to perform full scatter photocoagulation in 4 sittings.
3271516|NCT00687141|Experimental|1|
3271517|NCT00687141|Placebo Comparator|2|
3271518|NCT00687128|Experimental|1|Low-intensity aerobic exercise
3271519|NCT00687128|Experimental|2|Moderate-intensity aerobic exercise
3271520|NCT00687128|Active Comparator|3|Non-aerobic stretching exercise
3271521|NCT00687102|Experimental|Star participants assigned to Tamoxifen|Participants in the parent study, STAR assigned to Tamoxifen who were 65 or older at time of enrollment.
3271522|NCT00687102|Experimental|Star participants assigned to Raloxifene|Participants in the parent study, STAR assigned to Raloxifene who were 65 or older at time of enrollment.
3271523|NCT00687089||Subutex group|People who used opiates and willing to start with subutex treatment
3271524|NCT00687076|Experimental|1|Participants will receive standard of medical care and treatment with intensive lipid modification using a statin plus Ezetimibe and Niaspan.
3271525|NCT00687076|Active Comparator|2|Participants will receive standard of medical care and treatment with standard lipid modifying medications plus placebo Ezetimibe and placebo Niaspan.
3271526|NCT00687063||A|
3271527|NCT00687050|Active Comparator|1|HIV-positive hemodialysis patients (as a high risk group for cachexia) will be given daily drinks of Renilon 7.5 (125 ml, 2 kcal/ml) as peroral supplemental nutrition on top to their recommended high-protein, high-caloric diet.
3271750|NCT00685594|Experimental|1|Cholecalciferol 20.000 IU per week for 5 years
3271528|NCT00687050|No Intervention|2|Chronic hemodialysis patients randomized to no peroral supplemental nutrition
3271529|NCT00687050|Active Comparator|3|Chronic hemodialysis patients randomized to peroral supplemental nutrition.
3271530|NCT00687037|Experimental|I|Cetylpyridinium chloride during 21 days.
3271531|NCT00687011|Experimental|Palonosetron-dexamethasone|
3271532|NCT00686998|Experimental|AZD2624|AZD2624 40 mg
3271533|NCT00686998|Other|Olanzapine|Olanzapine 15 mg
3271534|NCT00686998|Placebo Comparator|Placebo|Matching Placebo
3271535|NCT00686985|Experimental|A|
3271536|NCT00686972|Experimental|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
3271537|NCT00686959|Experimental|Arm A: Pemetrexed + Cisplatin and TRT|"Participants were treated with Pemetrexed plus Cisplatin and concurrent thoracic radiation therapy (TRT) (Concurrent Phase) for three 21-day cycles, followed by a 3-5 week Recovery Period, then treated with consolidation chemotherapy with pemetrexed (Consolidation Phase) for up to four 21-day cycles~Concurrent Phase:~Pemetrexed: 500 milligrams per meter squared (mg/m^2), intravenous (IV) on Day 1 of each 21-day cycle for 3 cycles.~Cisplatin: 75 mg/m^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gray [Gy] per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.~Consolidation Phase:~Pemetrexed: 500 mg/m^2, IV on Day 1 of each 21-day cycle up to 4 cycles"
3271538|NCT00686959|Active Comparator|Arm B: Etoposide + Cisplatin and TRT|"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (Concurrent Phase) for two 28-day cycles, followed by a 3-5 week Recovery Period, then received consolidation treatment with cytotoxic chemotherapy of choice (Consolidation Phase) for up to 2 cycles~Concurrent Phase:~Etoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m^2, IV on Days1, 8, 29, and 36~Consolidation Phase options:~Option 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22"
3271539|NCT00686946||NRAMP|Participants take their antipsychotic medication as prescribed by their clinical treating teams.
3271540|NCT00686933|Experimental|1|
3271541|NCT00686920|Experimental|1|Open-label safety arm
3271542|NCT00686907|Experimental|A|Melatonin dosing regimen to determine the optimal dose and administration time to synchronize the circadian rhythms of blind individuals to the 24-hour day.
3271543|NCT00686894|Experimental|Infliximab 5 mg/kg|Infliximab infusions: 5 mg/kg at weeks 0, 2, and 6.
3271544|NCT00686881|Experimental|PegIFN-2b|Participants receiving PegIFN-2b at 0.5 ug/kg subcutaneously (SC) once a week for up to 156 weeks.
3271545|NCT00686881|Active Comparator|SNMC|Participants receiving SNMC 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for up to 156 weeks.
3271546|NCT00686868|Experimental|30mg|active
3271547|NCT00686868|Experimental|3mg|active
3271548|NCT00686868|Experimental|0.3mg|active
3271549|NCT00686868|Placebo Comparator|placebo|placebo
3271550|NCT00686868|Experimental|60mg|60mg
3271551|NCT00686868|Experimental|100mg|100mg
3271552|NCT00686855|Experimental|Tacrolimus|Tacrolimus Arm Closed to Accrual as of January 2012
3271553|NCT00686855|Experimental|Dexamethasone|
3271554|NCT00686842|Experimental|VEGF Inhibitor PTC299|Single arm study - all subjects received PTC299
3271555|NCT00686829|Experimental|Vicriviroc 30 mg QD|Vicriviroc 30 mg QD
3271556|NCT00686816|Placebo Comparator|1|
3271557|NCT00686816|Experimental|2|
3271558|NCT00686803|Experimental|PL3994 Dose A|PL3994 Dose A
3271559|NCT00686803|Experimental|PL3994 Dose B|PL3994 Dose B
3271560|NCT00686803|Experimental|PL3994 Dose C|PL3994 Dose C
3271561|NCT00686803|Experimental|PL3994 Dose D|PL3994 Dose D
3271562|NCT00686803|Experimental|PL3994 Dose E|PL3994 Dose E
3271563|NCT00686803|Placebo Comparator|Placebo|Placebo
3271564|NCT00686790|Experimental|PegIntron|All participants received PegIntron (Peginterferon alfa-2b) weekly based on their body weight.
3271565|NCT00686777|Experimental|PEG-IFN + Ribavirin|Pegylated Interferon alfa-2b was administered to participants at 1.5 μg/kg subcutaneously once weekly for 48 weeks. Ribavirin was administered orally every day after morning and evening meals for 48 weeks at 400 mg/day.
3271566|NCT00686764||Group 1|Trans-femoral amputees that meet the eligibility criteria.
3271567|NCT00686751|Experimental|A|"There is only one arm in this study. Each subject will be studied through 3 phases lasting a total of 4 weeks:~Phase 1: administration of study medication at the end of hemodialysis treatment.~Phase 2: no administration of study medication. Phase 3: administration of study medication at the beginning of hemodialysis."
3271568|NCT00686738||A|"Study group will be made up of patients hospitalized to National Cancer Center, Korea, aged between 5 and 40 years, and diagnosed with high grade osteosarcoma by histological exam.~In this group, TGF-b1 measurement, PET/CT and MRS examination at diagnosis, after 1st cycle chemotherapy, and 2nd or 3rd chemotherapy (just before surgery) will be made.~In addition, evaluation of NF-kB expression status in tumor specimens at diagnostic biopsy and tumor removing surgery will be done.~The results of above studies will be correlated with the necrosis fractions of the tumor tissues removed by surgery."
3271569|NCT00686725|Active Comparator|Temozolomide + Radiation|"Standard therapy regimen:~Treatment will start 4 weeks after surgery. Temozolomide will be administered concomitantly with radiotherapy, at 75 mg/m^2/day orally for 42 days. Four weeks after completing concomitant radiotherapy, temozolomide will be administered for an additional six cycles. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m^2/day, and may be increased to 200 mg/m^2/day for Cycle 2 and subsequent cycles depending on nonhematological toxicity observed and neutrophil and platelet count values. Capsules containing 20 mg or 100 mg of temozolomide will be used.~Radiotherapy will be administered in combination with temozolomide. Radiotherapy will be administered for a total daily dose of 60 Gy in 30 fractions, 5 days a week for 6 weeks."
3271705|NCT00685828|Active Comparator|Arm I|Patients receive low-dose oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
3271570|NCT00686725|Experimental|Temozolomide alone, then Temozolomide + Radiation|"Early postsurgery temozolomide chemotherapy plus standard regimen:~Treatment with temozolomide alone will start 2 weeks after surgery at 75 mg/m^2/day orally for 14 days. Then, starting on Day 29 after surgery, temozolomide will be administered according to standard treatment as described for the temozolomide + radiation arm (standard therapy regimen).~Radiotherapy will be administered in combination with temozolomide. Radiotherapy will be administered for a total daily dose of 60 Gy in 30 fractions, 5 days a week for 6 weeks."
3271571|NCT00686712|Experimental|1 - Insulin glargine QHS|Insulin glargine injected subcutaneously once daily at bedtime
3271572|NCT00686712|Experimental|2 - Insulin glargine QAM|Insulin glargine injected subcutaneously once daily in the morning
3271573|NCT00686712|Active Comparator|3 - NPH Insulin QHS|NPH insulin injected subcutaneously once daily at bedtime
3271574|NCT00686699|Experimental|Preladenant 25 mg BID→Placebo BID|Participants received one preladenant 25 mg capsule twice daily (BID) for 14 days during the first treatment period and received one matching placebo capsule BID during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.
3271575|NCT00686699|Placebo Comparator|Placebo BID→Preladenant 25 mg BID|Participants received one matching placebo capsule BID for 14 days during the first treatment period and received one preladenant 25 mg capsule during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.
3271576|NCT00686686|Experimental|Infliximab 5 mg/kg|Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
3271577|NCT00686673|Experimental|A|Providing Videotape-based material & tailored workbook to make informed choice of disclosing terminal illness to patients
3271578|NCT00686673|Other|B|"Attention control arm:~Providing videotape-based material & non-tailored workbook about pain control"
3271579|NCT00686660|Experimental|1|C-W G: in training period, patients do cycling on cycle ergometry at hospital. in non-training period, patients walk at community.
3271580|NCT00686660|Other|2|C-nonW G: in training period, patients do cycling at cycle ergometry at hospital, in non-training period, patients don't walk at community.
3271581|NCT00686660|Experimental|3|W-W G: in training period, patients do walking along 60 meters place at hospital, in non-training period, patients do walking in community
3271582|NCT00686660|Other|4|W-nonW G: in training period, patients do walking along 60 meter place, in non-training period,patients don't walk at community.
3271583|NCT00686634|Experimental|1|Sitagliptin 100 mg once daily
3271584|NCT00686621|Experimental|Single arm|
3271585|NCT00686608|Experimental|Aim 1|To measure fMRI signal change in hypothalamic and brainstem centers associated with control of food intake and energy expenditure in response to 1) IV glucose 2) IV fructose 3) IV saline in both lean and obese subjects.
3271586|NCT00686595|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg intravenous (IV) infusion administered at Baseline (Week 0), Visit 3 (Week 2), Visit 4 (Week 6), Visit 6 (Week 14), and Visit 8 (Week 22).
3271587|NCT00686582|Experimental|Group 1|
3271588|NCT00686582|Experimental|Group 2|
3271589|NCT00686582|Other|Group 4|
3271590|NCT00686556|Experimental|Cohort -1|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 12 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
3271591|NCT00686556|Experimental|Cohort 1|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 15 Gy on Days -5 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
3271592|NCT00686556|Experimental|Cohort 2|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 18 Gy on Days -6 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
3271593|NCT00686556|Experimental|Cohort 3|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 21 Gy on Days -7 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
3271594|NCT00686556|Experimental|Cohort 4|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 24 Gy on Days -8 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
3271595|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 200 mg TID Days 9-15|POS 200 mg three times a day (TID) on Days 1-8 followed by continued randomized dosing regimen of POS 200 mg TID on Days 9-15, administered with food or oral nutritional supplements.
3271596|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 400 mg BID Days 9-15|POS 200 mg TID on Days 1-8 followed by randomized dosing regimen of POS 400 mg twice a day (BID) on Days 9-15, administered with food or oral nutritional supplements.
3271597|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 400 mg TID Days 9-15|POS 200 mg TID on Days 1-8 followed by randomized dosing regimen of POS 400 mg TID on Days 9-15, administered with food or oral nutritional supplements.
3271598|NCT00686530||1|
3271599|NCT00686517|Experimental|PEG-IFN 24|pegylated interferon alpha-2b 1.5 ug/kg/week for 24 weeks
3271600|NCT00686517|Experimental|PEG-IFN 12|pegylated interferon alpha-2b 1.5 ug/kg/week for 12 weeks
3271601|NCT00686517|Experimental|PEG-IFN + RVB 12|pegylated interferon alpha-2b 1.5 ug/kg/week in combination with ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
3271602|NCT00686491||1|Triathletes
3271603|NCT00686491||2|Cold air athletes
3271604|NCT00686491||3|Swimmers
3271605|NCT00686491||4|Other sports elite athletes
3271606|NCT00686491||5|Control subjects
3271751|NCT00685594|Placebo Comparator|2|
3271607|NCT00686478|Experimental|interferon alpha 2b (Intron A)|1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
3271608|NCT00686478|Placebo Comparator|Placebo|Placebo administered subcutaneously once a day for 7 days, then three times a week for 23 weeks.
3271609|NCT00686465|Other|PET/CT scan|PET/CT scan
3271610|NCT00686452||1|Swimmers without AHR
3271611|NCT00686452||2|Swimmers with asymptomatic AHR
3271612|NCT00686452||3|Swimmers with symptomatic AHR and use only of beta-2 adrenargic
3271613|NCT00686452||4|Swimmers with asthma and inhaled corticosteroids
3271614|NCT00686452||5|Healthy Subjects
3271615|NCT00686452||6|Healthy subjects with AHR
3271616|NCT00686452||7|Healthy subjects with symptomatic AHR (asthma) but without treatment
3271617|NCT00686439|Experimental|adalimumab|
3271618|NCT00686426|Active Comparator|1|Low Dairy
3271619|NCT00686426|Experimental|2|Adequate Dairy
3271620|NCT00686413|Experimental|1|
3271621|NCT00686413|Experimental|2|
3271622|NCT00686400||1: FE|FE = first episode schizophrenia
3271623|NCT00686400||2: CO|CO = age and gender-matched control subjects
3271624|NCT00686374|Experimental|Any adalimumab|Adalimumab was administered via subcutaneous injection. Dosage was based on body weight and clinical status, and ranged from 10, 20, or 40 mg every other week to 20 or 40 mg every week.
3271625|NCT00686335|Experimental|Lodotra|After the 4 week run-in period with immediate release prednisone (Cortancyl), patients were switched to the identical dose of modified release prednisone tablets (Lodotra). Study medication for the Lodotra treatment period consisted of Lodotra in 2 dose strengths (5 mg and 1 mg prednisone per tablet). Patients were to take their tablets with or after the evening meal (at 10 pm +/- 30 minutes) for 4 weeks.
3271626|NCT00686335|Active Comparator|Cortancyl|During the 4 week run-in period, patients remained on their respective pre-study dose of prednisone or equivalent. However, patients were standardized to 5 mg and 1 mg tablets of immediate release prednisone (Cortancyl). Patients were to take their tablets with or after the morning meal (at 8am +/- 30 minutes) for 4 weeks.
3271627|NCT00686322|Other|1|Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
3271628|NCT00686296|Active Comparator|Group II|Taliderm™ dressing applied until the next scheduled dressing change (up to eight hours), then replaced by a gauze dressing. Gauze dressing changes will continue per standard of care until the scheduled follow-up visits (first or second visit). At the scheduled follow-up visits, the subject will have a Taliderm™ dressing applied and left in place until the next scheduled dressing change (up to eight hours), then will continue standard of care wet to dry gauze dressing changes until next scheduled follow-up visit.
3271629|NCT00686296|Other|III|standard wet to dry dressing with gauze
3271630|NCT00686296|Active Comparator|group I|Taliderm™ dressing applied until the next scheduled dressing change (up to eight hours), then replaced by a gauze dressing
3271631|NCT00686283|Other|Exercise prescription|Each adolescents with type 1 or type 2 diabetes received individual fitness testing and a personalized exercise program prescription developed by an exercise physiologist. Pretest and posttest measures of glucose control and cardiorespiratory fitness, heart rate variability, metabolic control, lipid profile, body composition, and inflammatory markers, as well as psychological outcomes (i.e., diabetes quality of life) were completed.
3271632|NCT00686270|Experimental|1|apricitabine
3271633|NCT00686257|Experimental|1|Patients receiving NPPV by the 'Total Face Mask'
3271634|NCT00686257|Active Comparator|2|Patients receiving NPPV by 'standard oronasal mask'
3271635|NCT00686244|Experimental|Training Group|"Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).~Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism"
3271636|NCT00686244|No Intervention|Control Group|No guided training. Exercise optional after detailed consulting and handing over an information dossier for adequate physical activity.
3271637|NCT00686231|Placebo Comparator|Placebo|Sorbolene cream
3271638|NCT00686231|Experimental|Lidocaine|Lidocaine 1 inch
3271639|NCT00686231|Experimental|Nitro|1 inch / 2 inches of Nitroglycerin applied topically to the wrist
3271640|NCT00686218|Experimental|Treatment (panobinostat, imatinib mesylate)|Patients receive oral panobinostat once daily on days 1, 3 and 5; 8, 10, and 12; 15, 17, and 19; and 22, 24, and 26. Patients also receive oral imatinib mesylate once daily on days 1-28. Treatment repeats every 21 or 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3271641|NCT00686205|Experimental|ABBOTT PRISM HIV O Plus assay for Specificity|All subjects will have their blood tested by the investigational HIV test.
3271642|NCT00686205|No Intervention|ABBOTT PRISM HIV O Plus Assay for Sensitivity|Samples collected from specimen vendors or from specimen collection studies were tested by the investigational HIV assay.
3271643|NCT00686179|Experimental|1|Escalating doses of AZD3480 during 6 days
3271644|NCT00686179|Experimental|2|Repeated doses of AZD3480 during 6 days
3271645|NCT00686179|Placebo Comparator|3|Placebo during 6 days
3271646|NCT00686179|Active Comparator|4|Placebo during 5 days, active day 6
3271647|NCT00686166|Experimental|Chemo + Chemo and radiation + Surgery|"Chemotherapy Cycle 1 (1 cycle is 35 days):~Oxaliplatin, 50 mg/m^2, IV, Days 1,8,15,22,29~Cetuximab, 400 mg/m^2, IV, Day 1~Cetuximab, 250 mg/m^2, IV, Days 8,15,22,29~Capecitabine, 1650 mg/m^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2:~Oxaliplatin, 50 mg/m^2, IV, Days 50,57,71,78~Cetuximab, 250 mg/m^2, IV, Days 50,57,64,71,78~Capecitabine, 1650 mg/m^1, PO, Monday-Friday (Day 50-84)~Radiation therapy: Planning target value 1: 4500 cGy (centigray) in 25 fractions; Planning target value 2 (stage T3 patients): Boost of 540 cGy in 3 fractions; Planning target value 2 (stage T4 patients): Boost of 900 cGy in 5 fractions.~Therapeutic Surgical procedure: Resection"
3271648|NCT00686140|Experimental|Celecoxib, immune adjustor|Celecoxib
3271649|NCT00686140|Placebo Comparator|Placebo|Placebo looks like the active drug celecoxib, with the same dose
3271706|NCT00685828|Experimental|Arm II|Patients receive high-dose oral imatinib mesylate twice daily in the absence of disease progression or unacceptable toxicity.
3271650|NCT00686127|Active Comparator|Lidocaine Patch|Drug: lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1 patch was applied topically to the affected site(s) for 12 hours each day.
3271651|NCT00686127|Placebo Comparator|Placebo Patch|Drug: placebo patch, 1 patch was applied topically to the affected site(s) for 12 hours each day.
3271652|NCT00686114|Experimental|A|Enlarged field + Paclitaxel + Cisplatin + Tarceva
3271653|NCT00686114|Experimental|B|Enlarged field + Paclitaxel + Cisplatin
3271654|NCT00686114|Active Comparator|C|Conventional field + Paclitaxel + Cisplatin + Tarceva
3271655|NCT00686114|Active Comparator|D|Conventional field + Paclitaxel + Cisplatin
3271656|NCT00686101||1|Normal control subjects (Males and females between 18-65 years, who smoke cigarettes daily, have an expired CO measurement of > 8 ppm to confirm cigarette smoking, who are not actively trying to quit smoking at the time of the interview, and who must be free from Axis I psychotic disorder.)
3271657|NCT00686101||2|Subjects with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder (Males and females between 18-65 years, who smoke cigarettes daily, have an expired CO measurement of > 8 ppm to confirm cigarette smoking, and who are not actively trying to quit smoking at the time of the interview.)
3271658|NCT00686075|Experimental|MEDI-534, Cohort 1|Participants aged 6 to less than (<) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
3271659|NCT00686075|Placebo Comparator|Placebo, Cohort 1|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
3271660|NCT00686075|Experimental|MEDI-534, Cohort 2|Participants aged 6 to <24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
3271661|NCT00686075|Placebo Comparator|Placebo, Cohort 2|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
3271662|NCT00686075|Experimental|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
3271663|NCT00686075|Placebo Comparator|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
3271664|NCT00686075|Experimental|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
3271665|NCT00686075|Placebo Comparator|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
3271666|NCT00686075|Experimental|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
3271667|NCT00686075|Placebo Comparator|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
3271668|NCT00686062|Experimental|1|Women in this arm view the interactive, computerized, prenatal testing decision tool (PT Tool) we created.
3271669|NCT00686062|Active Comparator|2|Women in this arm view the age-appropriate computerized version of the educational pamphlet on prenatal testing developed and distributed by the State of California
3271670|NCT00686049||Study Group|Participants will complete two audio computer assisted self interviews on laptop computers. This study will also involve the abstraction of participants' viral load and CD4 counts from their medical charts.
3271671|NCT00686036|Experimental|vandetanib|300 mg orally, once daily for up to 18 months
3271672|NCT00686036|Placebo Comparator|Placebo|orally, once daily for up to 18 months
3271673|NCT00686023|Active Comparator|1|DHS fixation
3271674|NCT00686023|Active Comparator|2|IMN fixation
3271675|NCT00686010|Placebo Comparator|1|Placebo
3271676|NCT00686010|Experimental|2|JTT-705 300mg
3271677|NCT00686010|Experimental|3|JTT-705 600mg
3271678|NCT00686010|Experimental|4|JTT-705 900mg
3271679|NCT00685984||1|
3271680|NCT00685984||2|
3271681|NCT00685984||3|
3271682|NCT00685971|Experimental|Vitamin D|vitamin
3271683|NCT00685971|Placebo Comparator|Placebo|
3271684|NCT00685945|Experimental|Control (bradykinin infusion)|Bradykinin (Clinalfa AG, Läufelfingen, Switzerland)
3271685|NCT00685945|Experimental|L-NMMA + bradykinin|N-monomethyl-L-arginine (L-NMMA, NO synthase inhibitor; Bachem, Torrance, CA)
3271686|NCT00685945|Experimental|Isosorbide + L-NMMA + bradykinin|Isosorbide (NO donor)
3271687|NCT00685945|Experimental|Sildenafil + L-NMMA + bradykinin|Sildenafil (phosphodiesterase type 5 (PDE5) inhibitor
3271688|NCT00685932|No Intervention|Control|This arm will be randomly assigned to have conventional retractions (ie Rich retractors and similar) used in the usual fashion during the cesarean procedure.
3271689|NCT00685932|Experimental|Mobius|This arm will be randomized to have the providers who are performing the cesarean section use the Mobius retractor during the cesarean section procedure after the peritoneal cavity is opened.
3271690|NCT00685919|Experimental|1|Carbidopa 200 mg every 6 hours orally
3271691|NCT00685919|Placebo Comparator|2|
3271692|NCT00685906|Experimental|1|
3271693|NCT00685906|Active Comparator|2|
3271694|NCT00685893|No Intervention|Control Arm|6 Community hospital ICUs receiving delayed intervention activities after the completion of the randomized trial
3271695|NCT00685893|Experimental|Intervention Arm|6 community hospital ICUs receiving 5-component intervention.
3271696|NCT00685880|Experimental|Prolotherapy group|Subjects randomized to this arm will receive injection(s) of 10% dextrose solution in the affected thumb joint.
3271697|NCT00685880|Active Comparator|Corticosteroid Group|Subjects randomized to this arm will receive injection(s) of betamethasone solution in the affected thumb joint.
3271698|NCT00685867|Experimental|1|Rapid detection
3271699|NCT00685867|Other|2|Enhanced infection control
3271700|NCT00685841|Experimental|A|Arformoterol 50 mcg QD and placebo MDI
3271701|NCT00685841|Experimental|B|Arformoterol 25 mcg BID and placebo MDI
3271702|NCT00685841|Experimental|C|Arformoterol 15 mcg BID and placebo MDI
3271703|NCT00685841|Active Comparator|D|Salmeterol MDI 42 mcg BID and placebo inhalation solution
3271704|NCT00685841|Placebo Comparator|E|Placebo BID MDI and inhalation solution
3271707|NCT00685815|Experimental|24 participants|Intravenous Iron (FCM)
3271709|NCT00685802|Experimental|Cilostazol 50 mg Tablets|A single dose of cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours.
3271710|NCT00685802|Experimental|Cilostazol (Pletal® ) 50 mg Tablets|A single dose of Cilostazol (Pletal® tablets, 2 x 50 mg ) administered after an overnight fast of at least 10 hours.
3271711|NCT00685789|Experimental|Acupuncture with Deqi|Needles were inserted and manipulated manually using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation of soreness, numbness, fullness, aching, cool, warmth, heaviness and radiating sensation (Deqi) occurred. The needles were retained for 30 min.
3271712|NCT00685789|Active Comparator|Acupuncture without Deqi|Needles were simply inserted and retained for 30 min, without any other stimulation.
3271713|NCT00685776|Experimental|Anacetrapib|Participants randomly assigned to anacetrapib in base study will continue same treatment if enrolled in study extension.
3271714|NCT00685776|Placebo Comparator|Placebo|Participants randomly assigned to placebo in base study will continue same treatment if enrolled in study extension.
3271715|NCT00685763|Experimental|Proton radiation and chemotherapy|"Chemotherapy and Radiation Combination~Proton radiation 59.4 cobalt gray equivalent(CGE) in 33 fx at 1.8 CGE per fx over 7 weeks.~Capecitabine (Xeloda ®) 1,000 mg by mouth approximately every 12 hrs, 5 days/week starting the first day of radiation until the end of radiation, but on radiation days only.~Consolidation Chemotherapy starting 4 weeks after the completion of radiation~Gemcitabine (Gemzar ®) Suggested Regimen - 1,000mg/m2 by IV over 30 minutes once a week for 3 weeks (followed by a week of rest) for 12 total doses."
3271716|NCT00685750|Other|ME1|Patients with cutaneous metastatic melanoma receiving dacarbazine or temozolomide as first line treatment
3271717|NCT00685750|Other|ME2|Patients with cutaneous metastatic melanoma receiving first line treatment other than dacarbazine or temozolomide only
3271718|NCT00685750|Other|ME3|Patients with cutaneous metastatic melanoma receiving any second-or higherline chemotherapy treatment
3271719|NCT00685750|Other|ME4|Patients with cutaneous metastatic melanoma receiving local irradiation of cutaneous/subcutaneous tumor lesions
3271720|NCT00685750|Other|ME5|Patients with cutaneous metastatic melanoma receiving local imiquimod
3271721|NCT00685750|Other|NSC|Non-small cell lung cancer patients
3271722|NCT00685750|Other|ME6|Patients with cutaneous metastatic melanoma receiving ipilimumab
3271723|NCT00685737|Active Comparator|1|1-MNA-Low Dose
3271724|NCT00685737|Active Comparator|2|1-MNA-High Dose
3271725|NCT00685737|Placebo Comparator|3|Placebo
3271726|NCT00685724|Experimental|1|Following 2 sessions of MET intervention received by all patients, patients in Condition 1 receive no further intervention.
3271727|NCT00685724|Experimental|2|Patients in Condition 2 will receive 8 sessions of the CBT (Cognitive Behavioral Therapy) intervention.
3271728|NCT00685724|Experimental|3|Patients in Condition 3 will receive 8 sessions of CBT plus aftercare treatment.
3271729|NCT00685711|Placebo Comparator|1|Placebo intradermal n = 2 with each dose level of Cat-PAD.
3271730|NCT00685711|Experimental|2|Intradermal injection of increasing single doses of Cat-PAD (0.03, 0.3, 3, 12 nmol) n = 6 per dose level. Based on review of blinded LPSR, an additional dose of Cat-PAD between 0.03 and 12 nmol may be administered to an additional cohort of 6 subjects.
3271731|NCT00685711|Placebo Comparator|3|Placebo subcutaneous n = 2 with each dose level of Cat-PAD.
3271732|NCT00685711|Experimental|4|Subcutaneous injection of increasing single doses of Cat-PAD (0.03, 0.3, 3, 12, 20 nmol) n = 6 per dose level. Based on review of blinded LPSR, an additional dose of Cat-PAD between 0.03 and 20 nmol may be administered to an additional cohort of 6 subjects.
3271733|NCT00685698|Other|Nemonoxacin|Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
3271734|NCT00685685|Experimental|Lovastatin 40 mg tablet|A single dose of Lovastatin 40 mg administered after an overnight fast of at least 10 hours.
3271735|NCT00685685|Experimental|Lovastatin (Mevacor®) 40 mg Tablet|A single dose of Lovastatin (Mevacor®) 40 mg administered after an overnight fast of at least 10 hours.
3271736|NCT00685672|Experimental|1|adrenalin
3271737|NCT00685672|Placebo Comparator|2|placebo
3271738|NCT00685659|Active Comparator|TAU only|Control condition that consists of treatment as usual, which is Intensive Outpatient Treatment (about 3 months long)
3271739|NCT00685659|Experimental|TMAC only|Adaptive telephone-based counseling
3271740|NCT00685659|Experimental|TMAC plus|Adaptive telephone-based counseling, plus incentives
3271741|NCT00685646|Experimental|Arm I|Patients receive maximum androgen-blockade therapy and zoledronic acid for up to 24 courses.
3271742|NCT00685646|Active Comparator|Arm II|Patients receive maximum androgen-blockade therapy for up to 24 courses.
3271743|NCT00685633|Active Comparator|Arm A|Patients are observed without treatment in weeks 1-12. Patients with a prostate-specific antigen (PSA) rise of > 50% above baseline or nadir (whichever is lowest) and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. In weeks 13-44, patients with a rise PSA ≥ 50% above baseline or nadir, and a PSA rise of at least 5 ng/mL confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue to receive bicalutamide up to 72 weeks.
3271744|NCT00685633|Active Comparator|Arm B|In weeks 1-12, patients receive oral enzastaurin hydrochloride twice daily. Patients with a PSA rise of > 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. In weeks 13-44, patients with a PSA rise of ≥ 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral enzastaurin twice daily and oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue on this combination therapy up to 72 weeks.
3271745|NCT00685620|No Intervention|Group 1|Standard care following detoxification
3271746|NCT00685620|Active Comparator|Group 2|Recovery housing following detoxification
3271747|NCT00685620|Experimental|Group 3|Recovery housing plus counseling
3271748|NCT00685607|Experimental|1|loperamide-simethicone
3271749|NCT00685607|Placebo Comparator|2|matching placebo
3271834|NCT00685048|Experimental|2|brief advice
3271752|NCT00685581|Experimental|A|Arms A: the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period
3271753|NCT00685581|Experimental|B|Arms B: the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed.
3271754|NCT00685581|Experimental|C|Arms C: the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed.
3271755|NCT00685568|Experimental|Arm I|Patients receive oral celecoxib twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
3271756|NCT00685568|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
3271757|NCT00685542|Experimental|1|Diacerein 50mg bid
3271758|NCT00685542|Placebo Comparator|2|placebo 50mg bid
3271759|NCT00685529|Active Comparator|A|12 µg of racemic formoterol fumarate BID
3271760|NCT00685529|Experimental|B|15 µg of nebulized arformoterol tartrate inhalation solution BID
3271761|NCT00685529|Active Comparator|C|24 µg of racemic formoterol fumarate BID
3271762|NCT00685516|Active Comparator|Arm I - Green Tea|Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.
3271763|NCT00685516|Placebo Comparator|Arm II - Water|Patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.
3271764|NCT00685516|Active Comparator|Arm III - Decaffeinated black tea|Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.
3271765|NCT00685490||Surgical|Retrospective chart review of 70 eyes of 70 consecutive patients who underwent PPV, with and without ILM peeling, for persistent macular edema associated with BRVO
3271766|NCT00685477|Active Comparator|Experimental Sequence ABC|CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg 60 minutes, with at least 2 days between each infusion
3271767|NCT00685477|Active Comparator|Experimental Sequence ACB|CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg 30 minutes, with at least 2 days between each infusion
3271768|NCT00685477|Active Comparator|Experimental Sequence BAC|CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg 60 minutes, with at least 2 days between each infusion
3271769|NCT00685477|Active Comparator|Experimental Sequence BCA|CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg 15 minutes, with at least 2 days between each infusion
3271770|NCT00685477|Active Comparator|Experimental Sequence CAB|CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg 30 minutes, with at least 2 days between each infusion
3271771|NCT00685477|Active Comparator|Experimental Sequence CBA|CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg 15 minutes, with at least 2 days between each infusion
3271772|NCT00685464|Active Comparator|2|Intravenous bolus Abciximab.
3271773|NCT00685464|Active Comparator|Abciximab|Intracoronary bolus abciximab.
3271774|NCT00685425|Experimental|A|Subjects randomized to the levalbuterol arm will complete 1 of 6 possible randomization sequences containing (a) levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
3271775|NCT00685425|Active Comparator|B|Subjects randomized to racemic albuterol will complete 1 of 6 possible randomization sequences containing (a) racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
3271776|NCT00685412|Experimental|0.6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 0.6mg DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
3271777|NCT00685412|Experimental|2mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 2mg of DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
3271778|NCT00685412|Experimental|6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
3271779|NCT00685399|Experimental|Cohort 1|Participants were administered with AIN457 (Sp2/0derived) 10 milligrams per kilogram (mg/kg) intravenous (i.v.) dose on Day 1 and Day 22.
3271780|NCT00685399|Experimental|Cohort 2|Participants were administered with AIN457 (Sp2/0 or Chinese hamster ovary cell (CHO) derived) 10 mg/kg, (CHO derived) 3 mg/kg or (CHO derived) 1 mg/kg i.v. dose on Day 1 and if needed a second dose of AIN457 10 mg/kg i.v. dose either on Day 15 or Day 22. 3 participants from cohort 1 rolled on into this cohort.
3271781|NCT00685399|Experimental|Cohort 3|Participants were administered with AIN457 10 mg/kg i.v. dose on Day 1 and Day 22.
3271782|NCT00685399|Experimental|Cohort 4|Extension period: Participants were administered with AIN457 10 mg/kg, i.v. (with or without a short course of corticosteroids) once a flare had occurred, or periodically at a frequency of not more than once per month at the discretion of the investigator.
3271783|NCT00685399|Experimental|Cohort 5|Participants were administered with AIN457 30 mg/kg single i.v. dose. A second dose was given when all 4 participants completed at least 29 days, and the 30 mg/kg dose was well tolerated by all.
3271784|NCT00685399|Experimental|Cohort 6 Arm 1|Participants were administered with AIN457 300 mg subcutaneously (s.c.) and saline i.v. infusion every two weeks (Days 1, 15, 29, and 43).
3271785|NCT00685399|Experimental|Cohort 6 Arm 2|Participants were administered with AIN457 10 mg/kg i.v. and s.c. saline injections every two weeks (Days 1, 15, 29, and 43).
3271786|NCT00685399|Experimental|Cohort 6 Arm 3|Participants were administered with AIN457 30 mg/kg i.v. and s.c. saline injections every 4 weeks (Days 1 and 29) and saline i.v. infusions and saline s.c. injections on Days 15 and 43 to maintain masking of treatment groups.
3271787|NCT00685386|Experimental|I|
3271788|NCT00685386|Placebo Comparator|II|Room air will be used for insufflation as the placebo comparator arm.
3271835|NCT00685048|Experimental|3|Motivational Enhancement Therapy (MET)/Cognitive-Behavioral Therapy (CBT)
3271864|NCT00684801||Usual care (control group)|Patients undergo usual care as determined by core cancer team.
3271789|NCT00685373|Experimental|Canakinumab (ACZ885)|Subcutaneous injection every 8 weeks based on participant's body weight. Body weight >40 kilogram (kg): 150 milligrams (mg) per injection and body weight <= 40 kg: 2 mg/kg per injection. For participants who did not experience sufficient symptomatic relief, an up-titration to the dose and/or more frequent doses were permitted as per protocol.
3271790|NCT00685360|Experimental|1|
3271791|NCT00685360|Experimental|2|
3271792|NCT00685360|Placebo Comparator|3|
3271793|NCT00685347|Experimental|A|Subjects randomized to the levalbuterol arm will complete 1 of 6 possible randomization sequences containing (a) levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
3271794|NCT00685347|Active Comparator|B|Subjects randomized to racemic albuterol will complete 1 of 6 possible randomization sequences containing (a) racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
3271795|NCT00685334|Experimental|1|Participants will take olanzapine
3271796|NCT00685334|Active Comparator|2|Participants will take aripiprazole
3271797|NCT00685321|Experimental|1|deep TMS treatment
3271798|NCT00685321|Sham Comparator|2|inactive treatment
3271799|NCT00685295|Experimental|Arm 1 / Fentora|"Intervention Group:~Subject receives:~placebo oral/swallowed pill~Fentanyl (Fentora) 100mcg rapidly dissolving transbuccal tablet"
3271800|NCT00685295|Active Comparator|Arm 2 / Percocet/Prevacid|"Active Comparator Group:~Subject receives:~Oxycodone/APAP (Percocet) 5/325 mg oral/swallowed pill~Lansoprazole 15 mg (Prevacid) comparator rapidly dissolving transbuccal tablet"
3271801|NCT00685282|Other|COGNITIVE BEHAVIORAL INTERVENTIONS|PSYCHOLOGICAL INTERVENTIONS TO INCLUDE, RELAXATION, STRESS REDUCTION, GUIDED IMAGERY, BREATHING EXERCISES
3271802|NCT00685269|Active Comparator|A|eszopiclone 3 mg QD
3271803|NCT00685269|Placebo Comparator|B|placebo tablet
3271804|NCT00685243|Active Comparator|Fraxel|Fraxel laser treatment
3271805|NCT00685243|Active Comparator|PDL|Pulsed dye laser treatment
3271806|NCT00685230|Experimental|1|Alacramyn and midazolam as needed
3271807|NCT00685230|Placebo Comparator|2|placebo and midazolam as needed
3271808|NCT00685217|Experimental|TVT Secur surgical device|Single incision tape device
3271809|NCT00685217|Active Comparator|TVT surgical device|Usual care retropubic tape device
3271810|NCT00685204|Experimental|A|This is a non-random, multicenter, open label, single agent study. Patients with mailgnanat mesothelioma that has reccured or progressed following chemotherapy, and who qualify for this study, will receive oral milataxel.
3271811|NCT00685191|Experimental|1|HIV-1-infected subjects initiating raltegravir-including salvage therapy
3271812|NCT00685178|Experimental|1 topiramate + CR|topiramate and contingency reinforcement for urine sample confirming cocaine abstinence
3271813|NCT00685178|Experimental|2 topiramate + NonCR|Topiramate and random reinforcement irrespective of cocaine use
3271814|NCT00685178|Placebo Comparator|4 Placebo + NonCR|
3271815|NCT00685178|Active Comparator|3 Placebo + CR|Placebo and contingency reinforcement for urine sample confirming cocaine abstinence
3271816|NCT00685165|Experimental|Primidone 50 mg Tablets|A single dose of primidone 50 mg administered after an overnight fast of at least 10 hours.
3271817|NCT00685165|Experimental|Primidone (Mysoline®) 50 mg Tablets|A single dose of Mysoline® 50 mg administered after an overnight fast of at least 10 hours.
3271818|NCT00685152|Experimental|Active rTMS|Repetitive Transcranial Magnetic Stimulation
3271819|NCT00685152|Sham Comparator|2|Device: Sham (placebo)
3271820|NCT00685139|Experimental|Zonisamide 100 mg Capsule|A single dose of zonisamide 100 mg administered after an overnight fast.
3271821|NCT00685139|Experimental|Zonisamide (Zonegran® ) 100 mg Capsule|A single dose of Zonegran® 100 mg administered after an overnight fast.
3271822|NCT00685126|Experimental|A|"Low dose levalbuterol (0.15 mg, 0.31 mg or 0.63 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
3271823|NCT00685126|Experimental|B|"High dose levalbuterol (0.31 mg, 0.63 mg or 1.25 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
3271824|NCT00685126|Active Comparator|C|"Racemic albuterol (0.63, 1.25 mg or 2.5 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
3271825|NCT00685113|Experimental|1|
3271826|NCT00685113|Experimental|2|
3271827|NCT00685113|Placebo Comparator|3|
3271828|NCT00685074|Experimental|Brief computer-delivered intervention for drug use|A single interactive computer intervention based primarily on Motivational Interviewing principles.
3271829|NCT00685074|Placebo Comparator|Time control for drug use|An series of innocuous and therapeutically inactive computer segments.
3271830|NCT00685061|Experimental|A|Thymoglobulin Induction
3271831|NCT00685061|Experimental|B|Campath-1H Induction
3271832|NCT00685061|Experimental|C|Daclizumab Induction
3271833|NCT00685048|Experimental|1|psychoeducation
3271836|NCT00685035|Active Comparator|HFCWC with higher pressure/variable frequency settings|Half patients randomly assigned to perform HFCWC therapy first with a higher pressure/variable frequency protocol. This entailed performing a 30 minute session with pressure of 10 and 5 minutes each at frequencies of 8,9, and 10 Hz followed by pressure of 6 and 5 minutes each at frequencies of 18, 19, and 20 Hz. This group subsequently crossed-over to the lower-pressure/mid-frequency HFCWC protocol after a washout period of 2 days. This entailed performing a HFCWC session using a pressure of 5 and frequency of 12 Hz for the entire 30 minute session. The other half of subjects were randomly assigned to perform the lower-pressure/mid-frequency protocol first followed by the higher pressure/mixed-frequency after the 2 day washout period
3271837|NCT00685035|Active Comparator|HFCWC with lower pressure/mid-frequency settings|lower-pressure/mid-frequency protocol first followed by the higher pressure/mixed-frequency
3271838|NCT00685022|Experimental|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses).~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. All study drug will be administered directly without using a spacer for the entire study."
3271839|NCT00685022|Active Comparator|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. All study drug will be administered directly without using a spacer for the entire study.
3271840|NCT00685009||1|Women from the Women's Health Initiative study taking estrogen hormone therapy
3271841|NCT00685009||2|Women from the WHI study taking estrogen plus progesterone hormone therapy
3271842|NCT00685009||3|Women from the WHI study taking placebo
3271843|NCT00684996|Active Comparator|Phase II Arm I|Patients receive bevacizumab (10mg/kg) IV over 30-90 minutes on days 1 and 15.
3271844|NCT00684996|Active Comparator|Phase II Arm II|Patients receive bevacizumab IV as in arm I at the RPTD determined in phase I, and humanized monoclonal antibody MEDI-522 (8mg/kg) IV over 30 minutes on days 1, 8, 15, and 22.
3271845|NCT00684983|Active Comparator|Arm A (lapatinib ditosylate, capecitabine)|Patients receive capecitabine PO BID on days 1-14 and lapatinib ditosylate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3271846|NCT00684983|Experimental|Arm B (cixutumumab, lapatinib ditosylate, capecitabine)|Patients receive capecitabine and lapatinib ditosylate as in Arm A. Patients also receive cixutumumab IV over 1 hour on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3271847|NCT00684970|Other|Hamsa-1™ TL-118|Once daily Hamsa-1™ TL-118 (single arm)
3271848|NCT00684957|Active Comparator|1|Subject taking growth hormone
3271849|NCT00684957|Active Comparator|2|Subject taking recombinant human IGF-1
3271850|NCT00684944|Active Comparator|1|30mg tid TRx0014
3271851|NCT00684944|Active Comparator|2|60mg tid TRx0014
3271852|NCT00684931|Experimental|1|patients with Attention Deficit Disorder with or without Hyperactivity
3271853|NCT00684931|Sham Comparator|2|healthy volunteer without Attention Deficit Hyperactivity Disorder
3271854|NCT00684918|Experimental|Experimental|In the Pilot Schedule portion of the study 3 hour vs 24 hour infusion schedules of obatoclax.
3271855|NCT00684892|Experimental|1|
3271856|NCT00684866|Experimental|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (8 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (8 cumulative doses).~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. Treatment will be administered with an AeroChamber Plus ™ spacer for the first cohort (spacer cohort) of subjects and without the AeroChamber Plus ™ spacer (non-spacer cohort) for the second cohort of subjects."
3271857|NCT00684866|Active Comparator|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. Treatment will be administered with an AeroChamber Plus ™ spacer for the first cohort (spacer cohort) of subjects and without the AeroChamber Plus ™ spacer (non-spacer cohort) for the second cohort of subjects.
3271858|NCT00684853|Active Comparator|1|
3271859|NCT00684853|Active Comparator|2|
3271860|NCT00684827|Experimental|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses).~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. An AeroChamber Plus spacer will be utilized for each dose"
3271861|NCT00684827|Active Comparator|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. An AeroChamber Plus spacer will be utilized for each dose.
3271862|NCT00684814|Experimental|Zolpidem Tartrate 10 mg Tablets|A single dose of zolpidem tartrate 10 mg administered after an overnight fast of at least 10 hours.
3271863|NCT00684814|Experimental|Zolpidem Tartrate (Ambien®) 10 mg Tablets|A single dose of Ambien® 10 mg administered after an overnight fast of at least 10 hours.
3271865|NCT00684801||DMP (experimental group)|Patients undergo a systematic approach regarding specific domains related to their disease focusing on supportive care and symptom management determined by a multidisciplinary team of providers to help patients and caregivers manage.
3271866|NCT00684788|No Intervention|No Intervention|Participants were offered depot naltrexone injections and were not required to take scheduled injections to work.
3271867|NCT00684788|Experimental|Employment-based reinforcement|Participants were offered depot naltrexone injections and were required to take scheduled injections to work.
3271868|NCT00684775|No Intervention|Work Plus Naltrexone Prescription|Participants could work and earn vouchers but did not to take Vivitrol Injections to work and earn vouchers.
3271869|NCT00684775|Experimental|Work Plus Naltrexone Contingency|Participants could work and earn vouchers and had to take Vivitrol Injections to work and earn vouchers: employment-based reinforcement.
3271870|NCT00684762|Experimental|Cilostazol|A single dose of cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours.
3271871|NCT00684762|Experimental|Pletal® (cilostazol)|A single dose of cilostazol (Pletal® 1 x 100 mg tablet) administered after an overnight fast of at least 10 hours.
3271872|NCT00684723|Experimental|Lovastatin 40 mg Tablet|A single dose of Lovastatin 40 mg administered under fed conditions.
3271873|NCT00684723|Experimental|Lovastatin (Mevacor®) 40 mg Tablet|A single dose of Lovastatin (Mevacor®) 40 mg administered under fed conditions.
3271874|NCT00684710|Experimental|PAZ-417|
3271875|NCT00684710|Placebo Comparator|Placebo|
3271876|NCT00684697|Placebo Comparator|1|low iron dose
3271877|NCT00684697|Active Comparator|2|intermediate iron dose
3271878|NCT00684697|Experimental|3|High Iron dose
3271879|NCT00684684|Experimental|1|
3271880|NCT00684671|Experimental|Twinrix Group|Subjects received a single challenge dose of combined hepatitis A/hepatitis B vaccine (Twinrix).
3271881|NCT00684671|Active Comparator|Engerix + Havrix Group|Subjects received separate administration of a single challenge dose of hepatitis B vaccine (Engerix) and hepatitis A vaccine (Havrix).
3271882|NCT00684671|Active Comparator|HB VAX PRO + Vaqta Group|Subjects received separate administration of a single challenge dose of hepatitis B vaccine (HB VAX PRO) and hepatitis A vaccine (Vaqta).
3271883|NCT00684658|Experimental|1|TeenCope: Internet-based Coping Skills Training
3271884|NCT00684658|Active Comparator|2|Managing Diabetes: Internet-based Diabetes Education
3271885|NCT00684645||Patients treated with SUTENT®|Patients with metastatic or advanced renal cell carcinoma after failure of cytokines therapy.
3271886|NCT00684632|Experimental|1|KW-2246
3271887|NCT00684632|Placebo Comparator|2|Placebo
3271888|NCT00684619|Experimental|Arm A|Nelarabine
3271889|NCT00684606|Experimental|1|Transcervical Foley catheter with IV Oxytocin
3271890|NCT00684606|No Intervention|2|Transcervical Foley catheter only
3271891|NCT00684593|Experimental|Navarixin|Navarixin 30 mg administered orally once daily for 28 days.
3271892|NCT00684593|Placebo Comparator|Placebo|Matching placebo to Navarixin administered orally once daily for 28 days.
3271893|NCT00684580||Observational Group|Data Collection
3271894|NCT00684567|Experimental|Single arm|It is the only arm of the study. Subjects receive a combination of radiotherapy and temozolomide, and then temozolomide monotherapy.
3271895|NCT00684554|Active Comparator|Unobserved-at home|Buprenorphine Unobserved at home induction
3271896|NCT00684554|Active Comparator|Observed|Buprenorphine Observed in office induction
3271897|NCT00684541|Experimental|Interpretation Modification Program|The IMP procedure was identical to the word-sentence association paradigm (WSAP; Beard & Amir, 2009) except participants received feedback about their responses. Participants received positive feedback when they endorsed benign interpretations or rejected threat interpretations of the ambiguous sentences on 100% of trials and negative feedback when they endorsed threat interpretations or rejected benign interpretations on 100% of trials. This feedback manipulation was intended to reinforce a benign interpretation bias and extinguish the threat interpretation bias. Participants completed two blocks of 110 training trials in each session. Participants who completed Set A during the WSAP assessment saw Set B during the IMP and vice versa. Each IMP session lasted approximately 20 min.
3271898|NCT00684541|Placebo Comparator|Interpretation Control Condition|The ICC was identical to the IMP, except that participants received positive feedback when they endorsed threat interpretations on half (50%) of the trials and negative feedback when they endorsed threat interpretations for the remaining half (50%) of trials. This frequency was the same for benign interpretations. Thus, the control group was reinforced equally for making threat and benign interpretations. The ICC was not intended to change interpretation significantly in either direction.
3271899|NCT00684528|Active Comparator|a|This group will receive Metformin and placebo.
3271900|NCT00684528|Experimental|2|The second arm will receive Metformin and Januvia
3271901|NCT00684515|Experimental|Vorapaxar 2.5 mg + Aspirin|Vorapaxar oral tablets; once daily for 60 days + Aspirin.
3271902|NCT00684515|Experimental|Vorapaxar 1 mg + Aspirin|Vorapaxar oral tablets; once daily for 60 days + Aspirin.
3271903|NCT00684515|Placebo Comparator|Placebo + Aspirin|Placebo oral tablets; once daily for 60 days + Aspirin
3271904|NCT00684502|Experimental|1|Oral solution.
3271905|NCT00684502|Placebo Comparator|2|Oral solution
3271906|NCT00684489|Active Comparator|A; B|
3271907|NCT00684489|Active Comparator|2|Arm A is assignment to a clinical hypertension specialist Arm B is assigned renin-guided therapeutics
3271908|NCT00684489|Active Comparator|A is clinical hypertension specialist|Arm A is assigned to a clinical hypertension specialist
3271909|NCT00684489|Active Comparator|Arm B is renin-guided therapeutics|This group will be assigned to renin-guided therapeutics
3271910|NCT00684463|Experimental|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent
3271911|NCT00684450|Active Comparator|1|in vivo protamine titration in cardiac surgery. The titration is done during administration of protamine each 3 minutes to reach 2 consecutive ACT defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds. .The protamine is stopped when this values are obtain. Follow-up is done 15 minutes and 3 hours post-protamine
3272544|NCT00679770|Experimental|Group 3|AN2690 Solution: 7.5%
3271912|NCT00684450|Active Comparator|2|standard protamine administration ACT is done during administration of protamine each 3 minutes the values are recorded but the totality of protamine is given. Follow-up is done 15 minutes and 3 hours post-protamine
3271913|NCT00684437|Experimental|Factual Gain-Framed|Smoking Risk Message - Factual Gain-Framed (FGF)
3271914|NCT00684437|Experimental|Factual Loss-Framed|Smoking Risk Message - Factual Loss-Framed (FLF)
3271915|NCT00684437|Experimental|Emotional Gain-Framed|Smoking Risk Message - Emotional Gain-Framed (EGF)
3271916|NCT00684437|Experimental|Emotional Loss-Framed|Smoking Risk Message - Emotional Loss-Framed (ELF)
3271917|NCT00684424||Outpatients with epilepsy|
3271918|NCT00684411|Experimental|Imatinib mesylate|The initial starting dose of imatinib mesylate was 400 mg by mouth once daily but intra-patient dose escalation for patients who did not achieve complete response (CR) was built in upon restaging at weeks 8 and 16. At week 8, patients with partial response (PR) or stable disease (SD) were dose escalated to 600 mg. At week 16, if these patients continued in PR or SD, dose escalated to 800 mg and for patients on 400 mg dose escalated to 600 mg. Patients who experienced disease progression could be dose escalated per MD discretion. Patients were treated as long as receiving clinical benefit and no unacceptable toxicity.
3271919|NCT00684385|Experimental|1|
3271920|NCT00684346|Experimental|1|
3271921|NCT00684333|Experimental|group 1|volunteers
3271922|NCT00684320|Active Comparator|2 Placebo Condition (PC)|The placebo, group will complete the PC procedure, which is identical to the ADT procedure except that during the presentation of the trials where a disgust or angry face is present, the probe will appear with equal frequency in the position of disgust or angry and neutral face. Thus, disgust, angry nor neutral face will have signal value regarding the position of the probe.
3271923|NCT00684320|Experimental|1 Attention Disengagement Training (ADT)|Those assigned to ADT condition will receive a computer delivered attention retraining protocol designed to enhance attention disengagement from socially threatening stimuli. The ADT protocol includes eight 30-min sessions delivered over a 6-week period (i.e., bi-weekly sessions). During each session, participants will see 320 trials that consist of the various combinations of probe type (E or F) probe position (top or bottom), and emotion type (Neutral, Disgust, Anger). 256 trials will include one neutral face and one disgust face or one angry face: 2 (probe type) X 2 (probe position) X 16 (person) X 4 (repetitions). On trials where participants see one neutral face and one disgust or angry face (i.e., 80% of the trials), the probe will always follow the neutral face.
3271924|NCT00684307|Experimental|1|AZD0837 450 mg
3271925|NCT00684307|Experimental|2|AZD0837 200 mg
3271926|NCT00684307|Experimental|3|AZD0837 300 mg
3271927|NCT00684307|Experimental|4|AZD0837 150 mg
3271928|NCT00684307|Active Comparator|5|Vitamin-K antagonist at INR 2-3
3271929|NCT00684294|Experimental|TAG Vaccine 1 x 10^7 cells/ injection|TAG Vaccine 1 x 10^7 cells/injection
3271930|NCT00684294|Experimental|TAG Vaccine 2.5 X 10^7 cells/injection|TAG Vaccine 2.5 X 10^7 cells/injection
3271931|NCT00684281|Other|1|Subject control
3271932|NCT00684281|Experimental|2|40 patients before hand include in a program
3271933|NCT00684268|Experimental|on treatment nonresponders|naive patients with null response to peginterferon/ribavirin at week 12 or partial response at week 24
3271934|NCT00684268|Experimental|Nonresponders to previous antiviral combination therapy|Nonresponders defined by viral status at weeks 4,12, and 24 of previous peginterferon/ribavirin combination therapy
3271935|NCT00684255|Experimental|Reduced Intensity Regimen for Refractory SLE|RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with medically refractory Systemic Lupus Erythematosus (SLE).
3271936|NCT00684255|Experimental|Reduced Intensity Regimen for SSc|RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with Systemic Sclerosis (SSc).
3271937|NCT00684242|Experimental|Lenalidomide|10 mg by mouth daily
3271938|NCT00684229|Active Comparator|Regional anesthesia and analgesia|Regional anesthesia and analgesia (either epidural or paravertebral anesthesia).
3271939|NCT00684229|Active Comparator|general anesthesia followed by opioid analgesia|Subjects randomized to arm 2 will receive general anesthesia followed by opioid analgesia.
3271940|NCT00684216|Active Comparator|1|capecitabine followed by hormonal treatment
3271941|NCT00684216|Active Comparator|2|hormonal treatment followed by capecitabine
3271942|NCT00684203|Experimental|Vorapaxar 20 mg/1 mg|Vorapaxar 20 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
3271943|NCT00684203|Experimental|Vorapaxar 20 mg/2.5 mg|Vorapaxar 20 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
3271944|NCT00684203|Experimental|Vorapaxar 40 mg/1 mg|Vorapaxar 40 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
3271945|NCT00684203|Experimental|Vorapaxar 40 mg/2.5 mg|Vorapaxar 40 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
3271946|NCT00684203|Placebo Comparator|Placebo|Placebo loading dose + daily placebo maintenance dose + standard of care (Aspirin + Ticlopidine)
3271947|NCT00684190|Experimental|1|AZD3355 150 mg
3271948|NCT00684190|Experimental|2|Esomeprazole 40mg
3271949|NCT00684190|Experimental|3|AZD3355 150mg/Esomeprazole 40mg
3271950|NCT00684177|Experimental|Retapamulin Ointment, 1%|
3271951|NCT00684177|Placebo Comparator|Placebo Ointment|
3271952|NCT00684164|Experimental|1|Subjects in the treatment group will receive standard medical treatment plus Conivaptan administered as a 20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
3271953|NCT00684164|Placebo Comparator|2|Subjects in the placebo control group will receive an equivalent volume loading dose of D5 followed by an infusion of D5 in the same manner as the experimental group.
3271954|NCT00684151||1|Patients with high cardiovascular risk who have been treated with lipid-lowering drugs at least 3 months
3271955|NCT00684138|Experimental|ReSTOR Aspheric +3.0D|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens
3271956|NCT00684138|Active Comparator|ReSTOR Aspheric +4.0D|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens
3272021|NCT00683709||Counselling as Usual|Discussing Clozapine medication, diet and exercise as per clinical protocol potential weight changes
3271957|NCT00684125|Experimental|1|mediastinal drainage will be accomplished using a 28F or 32F chest tube in the anterior mediastinum and a 19F Blake drain located in the posterior pericardial cavity.
3271958|NCT00684125|Active Comparator|2|mediastinal drainage will be accomplished using two 28F or 32F chest tubes located in the anterior mediastinum.
3271959|NCT00684112|Experimental|Gabapentin|Single dose preoperative gabapentin
3271960|NCT00684112|Placebo Comparator|Placebo Control|Single dose preoperative placebo control
3271961|NCT00684099|Experimental|1|
3271962|NCT00684073|Experimental|Subutex®/Suboxone®|Subutex® for first two days of study followed by Suboxone® for last 3 days of study
3271963|NCT00684060|Experimental|1|Participants will receive active stem cell infusion 2 to 3 weeks after a percutaneous coronary intervention (PCI).
3271964|NCT00684060|Placebo Comparator|2|Participants will receive placebo infusion (5% human serum albumin [HSA]) 2 to 3 weeks after a PCI.
3271965|NCT00684047|Experimental|FS Grifols Preliminary Part (I)|Open label administration of FS Grifols to all subjects
3271966|NCT00684047|Experimental|FS Grifols Primary Part (II)|Single-blind, randomized (2:1)
3271967|NCT00684047|Active Comparator|Manual Compression Primary Part (II)|Single-blind, randomized (2:1)
3271968|NCT00684034|Other|1|Volunteer healthy
3271969|NCT00684034|Other|2|Patient dialysis patient
3271970|NCT00684034|Other|3|Not dialysed chronic renal insufficient patient
3271971|NCT00684021|Active Comparator|1|Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).
3271972|NCT00684021|Active Comparator|2|Participants will receive active adult stem cell infusion 7 days after PCI.
3271973|NCT00684021|Placebo Comparator|3|Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.
3271974|NCT00684021|Placebo Comparator|4|Participants will receive placebo infusion (5% HSA) 7 days after PCI.
3271975|NCT00684008|Experimental|I|"Single arm dose escalation study. Three successive cohorts of 3 patients each. Doses to be evaluated: 10, 20, and 30 mcg/kg/dose for 3 consecutive doses.~CYT107 is a recombinant protein belonging to the class of growth factors known as cytokines.~CYT107 is a heavily glycosylated and sialylated form of recombinant human Interleukin-7.~CYT107 is supplied as a sterile colorless liquid at a concentration of 4 mg/ml."
3271976|NCT00683995|Experimental|1|KW-2246 (fentanyl citrate)
3271977|NCT00683982|Active Comparator|1|This group will receive oral nitazoxanide preparation
3271978|NCT00683982|Active Comparator|2|This group will receive a mix combination of probiotics
3271979|NCT00683982|Placebo Comparator|3|This is the control group receiving only oral or systemic hydration solutions
3271980|NCT00683969|Experimental|1|
3271981|NCT00683969|Placebo Comparator|2|
3271982|NCT00683930|Experimental|Mycophenolate Mofetil (MMF) 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
3271983|NCT00683930|Experimental|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
3271984|NCT00683930|Placebo Comparator|Placebo|
3271985|NCT00683917|Experimental|Proellex 25 mg|Proellex 25 mg
3271986|NCT00683917|Experimental|Proellex 50 mg|Proellex 50 mg
3271987|NCT00683917|Active Comparator|Lupron|Lupron Depot
3271988|NCT00683904|Active Comparator|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|
3271989|NCT00683904|Active Comparator|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|
3271990|NCT00683878|Experimental|Arm 1|
3271991|NCT00683878|Experimental|Arm 2|
3271992|NCT00683878|Placebo Comparator|Arm 3|
3271993|NCT00683865|Active Comparator|Arm 1|
3271994|NCT00683865|Experimental|Arm 2|
3271995|NCT00683852|Active Comparator|Drug 2mg/Drug 5mg|patients randomly assigned to the drug/drug sequence, the dose of aripiprazole will be 2 mg/day during the first phase of the study, and 5 mg/day in the second phase.
3271996|NCT00683852|Active Comparator|Placebo/Drug 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study.
3271997|NCT00683852|Placebo Comparator|Placebo/Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study.
3271998|NCT00683839|Experimental|2|"Dental practitioners provide the following intervention:~5As plus nicotine replacement therapy The 5As consist of: Ask, Advise, Assess, Assist and Arrange."
3271999|NCT00683839|No Intervention|1|Usual Care Control: Patients receive treatment as usual.
3272000|NCT00683826|Experimental|L-Leucine 4grams|This will be a triple arm design where subjects will be randomized into three groups. Arm #1 will be 4g of Leucine.
3272001|NCT00683826|Experimental|L-Leucine 8 grams|Arm number two of the study will be a dose of Leucine of 8g.
3272002|NCT00683826|Placebo Comparator|L-Leucine 0 grams|The third arm of the study will be composed of a control drink with no leucine in it.
3272003|NCT00683813|No Intervention|UC|usual care
3272004|NCT00683813|Experimental|vCRP|
3272005|NCT00683800|Experimental|1|desvenlafaxine succinate (DVS) SR
3272006|NCT00683800|Placebo Comparator|2|Placebo
3272007|NCT00683787|Active Comparator|Arm I|Patients receive docetaxel IV once every 3 weeks.
3272008|NCT00683787|Experimental|Arm II|Patients receive docetaxel IV as in arm I and oral vandetanib (100 mg) once daily.
3272009|NCT00683787|Experimental|Arm III|Patients receive docetaxel IV as in arm I and oral vandetanib (300 mg) once daily.
3272010|NCT00683774|Experimental|PCOS subjects|PCOS subjects given diazoxide
3272011|NCT00683774|Active Comparator|Normal subjects|Normal subjects given diazoxide
3272012|NCT00683761|Experimental|1|
3272013|NCT00683748||Kidney transplant|
3272014|NCT00683748||Liver transplant|
3272015|NCT00683735|Active Comparator|Treatment A|sitagliptin and placebo
3272016|NCT00683735|Active Comparator|Treatment B|placebo and metformin
3272017|NCT00683735|Active Comparator|Treatment C|sitagliptin and metformin
3272018|NCT00683735|Placebo Comparator|Treatment D|placebo
3272019|NCT00683722|Experimental|A|PROCHYMAL™
3272020|NCT00683722|Placebo Comparator|B|Placebo
3272022|NCT00683709||Cognitive Behavoural Therapy|Counselling about Clozapine medication, diet and exercise in a structured fashion using Cognitive Behavioural Therapy about potential weight changes
3272023|NCT00683696|Experimental|CRT=ON|Cardiac Resynchronization Therapy activated.
3272024|NCT00683696|Active Comparator|CRT=OFF|Cardiac Resynchronization Therapy deactivated.
3272025|NCT00683683|Other|Cooling|Cardiac arrest patients will be cooled to 32-34°C within 6 hours of ED arrival
3272026|NCT00683670|Experimental|Dendritic Cell Vaccine (First Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 3 weeks for a total of 6 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 and dose #6 in order to collect PBMC for immune monitoring. Patients with stable disease or better after 6 doses will be eligible to receive additional vaccinations as maintenance therapy every 2 months until progression.
3272027|NCT00683670|Experimental|Dendritic Cell Vaccine (Second Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 3 weeks for a total of 6 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 and dose #6 in order to collect PBMC for immune monitoring. Patients with stable disease or better after 6 doses will be eligible to receive additional vaccinations as maintenance therapy every 2 months until progression.
3272028|NCT00683670|Experimental|Dendritic Cell Vaccine (Third Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 6 weeks for a total of 3 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 in order to collect PBMC for immune monitoring.
3272029|NCT00683657|Experimental|Saxagliptin 5 mg + Metformin|
3272030|NCT00683657|Placebo Comparator|Placebo + Metformin|
3272031|NCT00683644|Experimental|1 - zinc placebo|Zinc sulfate (50 mg elemental zinc) taken once daily for 4 months. Washout 1 month. Placebo oral capsule taken once a day for 4 months.
3272032|NCT00683644|Experimental|2 - placebo zinc|Placebo oral capsule taken once a day for 4 months. Washout 1 month. Zinc sulfate (50 mg elemental zinc) taken once daily for 4 months.
3272033|NCT00683631|Experimental|TheraSphere|TheraSphere
3272034|NCT00683618|Experimental|1|Rosuvastatin 5mg qd
3272035|NCT00683618|Experimental|2|Rosuvastatin 10mg qd
3272036|NCT00683618|Active Comparator|3|Atorvastatin 10mg qd
3272037|NCT00683592|Experimental|1|vilazodone
3272038|NCT00683592|Placebo Comparator|2|
3272039|NCT00683579||1|Participants with CD4+ T cells above 350 cells/mm3 and HIV RNA >1,000 copies/ml who are initiating HAART with possibility of de-intensification (early treatment).
3272040|NCT00683579||2|Participants with CD4+ T cells above 350 cells/mm3 and HIV RNA >1,000 copies/ml who are not initiating treatment.
3272041|NCT00683579||3|Participants with CD4+ T cells < 350 cells/mm3 who are initiating treatment.
3272042|NCT00683579||4|Participants with CD4+ T cells < 350 cells/mm3 who are not initiating treatment.
3272043|NCT00683566|Experimental|1|A session in condition ON DOPAMINE and the other one in condition OFF DOPAMINE.
3272044|NCT00683553|Experimental|I5NP drug|
3272045|NCT00683553|Placebo Comparator|Placebo|
3272046|NCT00683527|Experimental|1|Starting oral iron at day 14 of life (Early Iron group)
3272047|NCT00683527|No Intervention|2|No iron supplementation till 60 days of life (Control group)
3272048|NCT00683514|Other|A|"cycle 1 & 2 (q 28 days) = chemotherapy : oral vinorelbine (50 mg/m2 d1, d8, d15) and cisplatin (20 mg/m2/d from d1 to d4) combined with radiotherapy~cycle 3 & 4 (q 21 days) = chemotherapy : oral vinorelbine (60 mg/m2 d1, d8 for cycle 1, 80 mg/m2 d1 & d8 for cycle 2) and cisplatin (80 mg/m2 d1) plus Best Supportive Care"
3272049|NCT00683514|Other|B|"cycle 1 & 2 (q 28 days) = chemotherapy : oral vinorelbine (50 mg/m2 d1, d8, d15) and cisplatin (20 mg/m2/d from d1 to d4) combined with radiotherapy~Best Supportive Care only"
3272050|NCT00683501|Experimental|1|dosage X mg BID
3272051|NCT00683501|Experimental|2|dosage Y mg BID
3272052|NCT00683501|Experimental|3|dosage Z mg BID
3272053|NCT00683501|Experimental|4|dosage 2Z mg BID
3272054|NCT00683501|Placebo Comparator|5|Placebo BID
3272055|NCT00683488|Experimental|1|Focus groups with adolescents with SA (Substance Abuse) will be conducted at each site (one group with 5 to 6 adolescents per site) to provide information on the areas of the intervention in need of adaptation in order to reflect the context of HIV infection.
3272056|NCT00683488|Experimental|2|The first intervention trial will enroll 9 participants (3 participants per site). Exit interviews of participants will assess acceptability, feasibility, and relevance of the intervention. Quantitative assessments pre and post intervention using audio computer-assisted self-interviewing (ACASI) will document immediate changes in substance use, sexual risk, and adherence to medical care. Additional qualitative feedback from interviews with mental health providers and study coordinators will address feasibility, acceptability, and relevance of the intervention and its methods.
3272057|NCT00683488|Experimental|3|The revised intervention will be implemented with 20 participants (6 to 8 at each site). Exit interviews with subjects and feedback from mental health providers and study coordinators will provide the same qualitative information as in the first intervention trial. Quantitative data on participant outcomes such as substance use, sexual risk, and adherence to medical care will be collected pre, post and 3 month post intervention through ACASI.
3272058|NCT00683475|Experimental|IMC-1121B (ramucirumab) + Mitoxantrone + Prednisone|
3272059|NCT00683475|Experimental|IMC-A12 + Mitoxantrone + Prednisone|
3272060|NCT00683462|Placebo Comparator|1|
3272061|NCT00683462|Experimental|2|
3272062|NCT00683462|Experimental|3|
3272063|NCT00683449|Experimental|IV infusion of MN-221|MN-221 total dose of 240 mcg
3272064|NCT00683449|Placebo Comparator|MN-221 PLACEBO|i.v. infusion of MN-221 Placebo for 15 min
3272065|NCT00683436|Experimental|1|adipiplon 6 mg
3272066|NCT00683436|Experimental|2|adipiplon 9 mg
3272067|NCT00683436|Placebo Comparator|3|Placebo
3272068|NCT00683436|Experimental|4|Ambien CR 12.5 mg
3272069|NCT00683423|Experimental|A|
3272070|NCT00683423|Placebo Comparator|B|
3272071|NCT00683410||1|
3272072|NCT00683397||A|Patients with acute or previous venous thromboembolism >18 years of age
3272073|NCT00683384||1|
3272074|NCT00683371|Active Comparator|1|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery
3272075|NCT00683371|Placebo Comparator|2|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery.
3272076|NCT00683358|Experimental|1|
3272077|NCT00683345|Active Comparator|Anakinra|Anakinra self-administered s.c. in a dose of 100mg daily
3272078|NCT00683345|Placebo Comparator|Placebo|Placebo self-adminsitered s.c in a dose 0.67ml daily
3272079|NCT00683332||A|
3272080|NCT00683306|Experimental|1|ZD 1839 (Iressa)
3272081|NCT00683293|Active Comparator|1|Randomized group of patients receiving conventional laparoscopic hysterectomy
3272082|NCT00683293|Active Comparator|2|Randomized group of patients receiving robot-assisted laparoscopic hysterectomy
3272083|NCT00683280|Active Comparator|Standard of Care|Medication (varenicline) for 12 weeks (Day 1 through 84) and brief counseling based on public health service guidelines for 5 weeks (Day 1 through 35).
3272084|NCT00683280|Experimental|Standard of Care plus Contingency Management|Medication (varenicline) for 12 weeks (Day 1 through 84), brief counseling based on public health service guidelines for 5 weeks (Day 1 through 35), plus prize-based contingency management for carbon monoxide samples and urinary cotinine samples that meet smoking abstinence criteria.
3272085|NCT00683267|Experimental|1|Study treatment, 4975, is instilled directly into surgical site
3272086|NCT00683267|Placebo Comparator|2|Placebo is instilled directly into surgical site
3272087|NCT00683241|Experimental|1|Subjects with stage II to IV recurrent epithelial ovarian carcinoma or recurrent primary peritoneal cancer, from whom solid tumor, ascites or pleural effusion will be harvested and available and sufficient for lysate preparation; and whose largest tumor nodule is ≤ 2.5 cm. Subjects may have undergone chemotherapy or other therapy following tumor harvesting and prior to enrollment (apheresis).
3272088|NCT00683228|Other|Counseling|some caregivers will be provided counseling related to the hazards of secondhand smoke exposure
3272089|NCT00683202|Active Comparator|1|Acetylsalicylic acid 100 mg daily perorally
3272090|NCT00683202|Placebo Comparator|2|Placebo daily perorally
3272091|NCT00683176|Active Comparator|1|
3272092|NCT00683176|Placebo Comparator|2|
3272093|NCT00683163|Active Comparator|A: 6 months both + 18 months oral only|Group A will receive 6 months of monthly oral ibandronate 150 mg, plus daily PTH 1-84, 1.4 mg; followed by 18 months of ibandronate only. Placebo injections will be given months 13-15. Calcium + Vitamin D supplements, plus multivitamins are provided.
3272094|NCT00683163|Active Comparator|B: (3 months injection + 9 months oral) x 2 years|Group B will receive 3 months of daily PTH 1-84, 1.4 mg; followed by 9 months of monthly oral ibandronate, 150 mg in year 1. In year 2, the group will receive another 3 months of daily PTH 1-84; followed by 9 months of monthly ibandronate. Placebo monthly pills will be given months 1-3 and months 13-15, and placebo injections will be given months 4-6. Calcium + Vitamin D supplements, plus multivitamins are provided.
3272095|NCT00683150||Endothelial Function Test|Patients scheduled to have major abdominal or thoracic surgery.
3272096|NCT00683137|Active Comparator|Arm 1|
3272097|NCT00683137|Active Comparator|Arm 2|
3272098|NCT00683137|Active Comparator|Arm 3|
3272099|NCT00683124|Experimental|Losartan|Losartan administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 100 mg/day for adults and 1,6 mg/kg/die for children minor than 16 years.
3272100|NCT00683124|Experimental|Nebivolol|Nebivolol administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 10 mg/day for adults and 0,16 mg/kg/die for children minor than 16 years.
3272101|NCT00683124|Experimental|Losartan+Nebivolol|"Losartan administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 100 mg/day for adults and 1,6 mg/kg/die for children minor than 16 years.~Nebivolol administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 10 mg/day for adults and 0,16 mg/kg/die for children minor than 16 years."
3272102|NCT00683111|Active Comparator|1|oral esomeprazole 20 mg daily
3272103|NCT00683111|Active Comparator|2|oral famotidine 40mg daily
3272104|NCT00683098||1|patients, who had a endoscopic total extraperitoneal repair of recurrent inguinal hernia between 1995 and 2008
3272105|NCT00683085|Experimental|Peptide vaccination|VEGFR1-derived HLA-A*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the safety and efficacy of this type of peptide.
3272106|NCT00683072||1|
3272107|NCT00683059|Experimental|Nab-paclitaxel|
3272108|NCT00683046|Experimental|Drug Intervention|
3272109|NCT00683033|Active Comparator|A|Brief counseling based on public health service guidelines.
3272110|NCT00683033|Experimental|B|Brief counseling based on public health service guidelines for quitting smoking plus prize-based contingency management
3272111|NCT00683020|Active Comparator|ATSM Intervention|ATSM Intervention: Automated Telephone Self-Management Support.
3272112|NCT00683020|No Intervention|WAIT LIST Control|WAIT LIST Control: six month Wait List.
3272113|NCT00683007|Active Comparator|1|Crystalloid
3272114|NCT00683007|Active Comparator|2|Hypertonic Saline
3272115|NCT00682994|Other|Decision Making|Questionnaire + Interview
3272116|NCT00682981|Experimental|Phase I A|Obatoclax for 3 hours for 3 days with carboplatin/etoposide.
3272117|NCT00682981|Experimental|Phase I B|Obatoclax for 24 hours for 3 days with carboplatin/etoposide.
3272545|NCT00679770|Placebo Comparator|Group 4|AN2690 Solution Vehicle
3272118|NCT00682981|Experimental|Phase II A|Obatoclax for 3 hours for 3 days with carboplatin/etoposide.
3272119|NCT00682981|Active Comparator|Phase II B|Carboplatin/etoposide without continued study treatment
3272120|NCT00682955|Active Comparator|B|This group has been given Zinc Sulphate in Suspension Form.
3272121|NCT00682955|Active Comparator|A|This group has been given Tablets of Zinc Sulphate.
3272122|NCT00682929|Active Comparator|1) Inhaled Cannabis|Inhaled cannabis is compared to oral placebo.
3272123|NCT00682929|Active Comparator|2) Oral THC|Inhaled placebo is compared to oral THC.
3272124|NCT00682929|Placebo Comparator|3) Placebo|Inhaled placebo is compared to oral placebo.
3272125|NCT00682916|Active Comparator|1|"Subjects will fast prior to the initial visit. Subjects' weight, blood pressure and heart rate will be recorded, waist and hip circumferences measured, and body composition determined. They will receive either the soluble fiber or placebo tablets, in a coded bottle. They will be instructed to take 2 tablets per fat containing meal, 3 times a day within one hour of consuming the meal. They will also be asked to keep records of missed doses and any gastrointestinal symptoms (e.g.: heartburn, indigestion, diarrhea, constipation). During the 4th week, they will be asked to record food intakes for 3 days.~After taking the supplement for 4 weeks, the participants will return to the clinic after an overnight fast. During this visit, they will turn in their 3-day dietary record. The studies performed during the initial baseline visit will be repeated. At this visit they receive the alternate supplement (placebo or active tablets) in a identical-looking coded bottle."
3272126|NCT00682916|Placebo Comparator|2|"Subjects will fast prior to the initial visit. Subjects' weight, blood pressure and heart rate will be recorded, waist and hip circumferences measured, and body composition determined. They will receive either the soluble fiber or placebo tablets, in a coded bottle. They will be instructed to take 2 tablets per fat containing meal, 3 times a day within one hour of consuming the meal. They will also be asked to keep records of missed doses and any gastrointestinal symptoms (e.g.: heartburn, indigestion, diarrhea, constipation). During the 4th week, they will be asked to record food intakes for 3 days.~After taking the supplement for 4 weeks, the participants will return to the clinic after an overnight fast. During this visit, they will turn in their 3-day dietary record. The studies performed during the initial baseline visit will be repeated. At this visit they receive the alternate supplement (placebo or active tablets) in a identical-looking coded bottle."
3272127|NCT00682903|Experimental|1|This arm will benefit from the nonstop measure of the subcutaneous glucose during the hospitalization and the week on returning to the place of residence,
3272128|NCT00682890|Placebo Comparator|1|Placebo tablet and birth control pill daily
3272129|NCT00682890|Active Comparator|2|metformin 2000 mg and birth control pill daily
3272130|NCT00682877||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
3272131|NCT00682877||Gastroparesis|Subjects with documented gastroparesis
3272132|NCT00682838|Experimental|Self-Management (SM)|Active Intervention - Self-management: Self-management Educational component focused on sleep apnea and CPAP from a self-management perspective
3272133|NCT00682838|Active Comparator|Telemonitored Care (TC)|Active Comparator - Telemonitored care: Telemonitored care Consists of CPAP therapist actively monitoring care at a distance, and acting on that data per a set protocol
3272134|NCT00682838|Experimental|SM + TC|Self-management and Telemonitored care: Combination of both SM + TC intervention
3272135|NCT00682838|No Intervention|Usual care (UC)|Control Group
3272136|NCT00682825|Experimental|1|Bispectral index-guided protocol
3272137|NCT00682825|Active Comparator|2|End-tidal anesthetic gas-guided protocol
3272138|NCT00682812|Active Comparator|1|125 womens with normal cervix
3272139|NCT00682812|Other|2|105 womens with an intraepithelial lesion
3272140|NCT00682812|Other|3|105 womens with a cancer of the cervix
3272141|NCT00682786|Experimental|Good Risk (Thymidylate Synthase (TYMS)*2/*2, *2/*3, *2/*4)|"Radiation 45 Gy in 25 fractions to the pelvis.~5FU CIVI 225 mg/m2/day by CIVI during radiation~Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable."
3272142|NCT00682786|Experimental|Poor Risk (Thymidylate Synthase (TYMS)*3/*3, *3/*4)|"Radiation 45 Gy in 25 fractions to the pelvis.~5FU CIVI 225 mg/m2/day by CIVI during radiation~Irinotecan 50 mg/m2 IV weekly for 5 doses.~Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable."
3272143|NCT00682773|No Intervention|1|Usual care, no educational intervention.
3272144|NCT00682773|Experimental|2|Usual care, nursing home nursing staff receive educational intervention on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
3272145|NCT00682760|Active Comparator|1|Korean botulinum toxin A treatment
3272146|NCT00682760|Placebo Comparator|2|Botox treatment
3272147|NCT00682747|Experimental|HBO|40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen)
3272148|NCT00682747|No Intervention|non HBO|
3272149|NCT00682734|Active Comparator|1|Metoclopramide 10 mg+ diphenhydramine 25 mg. This medication was administered as an intravenous drip over 20 minutes
3272150|NCT00682734|Experimental|2|metoclopramide 20 mg + diphenhydramine 25 mg. Administered as an intravenous drip over 20 minutes.
3272151|NCT00682734|Experimental|3|metoclopramide 40 mg + diphenhdyramine 25mg. Administered as an intravenous drip over 20 minutes.
3272152|NCT00682721|Active Comparator|2|Valacyclovir 1 gm daily x number of days active in the study
3272153|NCT00682721|Placebo Comparator|1|
3272154|NCT00682695||1|Healthy volunteers and people who have had a hemorrhagic stroke and live within University of Maryland, University of Cincinnati, Massachusetts General Hospital and Duke University area
3272155|NCT00682682|Experimental|1|all study participants will have 4 visits: VR alone, VR + opioid, opioid alone, and no VR/opioid
3272156|NCT00682669|Experimental|MBSR|A mindfulness-based stress reduction (MBSR) program consisting of an 8-week, 9-session intervention based on systematic and intensive training in mindfulness meditation and mindful hatha yoga and their application to every day life.
3272157|NCT00682669|Active Comparator|HLC|A Healthy Living Course (HLC) consisting of an 8-week program of lectures and discussion on health-related topics.
3272158|NCT00682656|Active Comparator|A - N- methyl glucamine|Glucantime® , max day of 1,215 mg
3272159|NCT00682656|Experimental|B - Azithromycin|Zithromax ® , one dose 500 mg
3272160|NCT00682643|Placebo Comparator|vehicle placebo nasal spray|
3272161|NCT00682643|Active Comparator|fluticasone furoate nasal spray|
3272162|NCT00682630|Experimental|Study Group 1|Study Period 1: Treatment A (clinical trial reference tablets) 43 Days wash out Study Period 2: Treatment B (to-be-marketed tablets) 43 Days follow-up
3272163|NCT00682630|Experimental|Study Group 2|Study Period 1: Treatment B (to-be-marketed tablets) 43 Days wash out Study Period 2: Treatment A (clinical trial reference tablets). 43 Days follow-up
3272164|NCT00682617|Experimental|1|Delayed intervention. 3 months on waitlist, crossover to intervention (3 additional months)
3272165|NCT00682617|Experimental|2|3 month exercise program
3272166|NCT00682578|Experimental|Artekin|Dihydroartemisinin+ Paperaquine (DHA+PPQ, Artekin)
3272167|NCT00682578|Active Comparator|Standard treatment|"The standard treatment for uncomplicated falciparum and vivax malaria are as follows:~Uncomplicated falciparum: artesunate-sulphadoxin/pyrimethamine Vivax malaria: chloroquine"
3272168|NCT00682565|Experimental|Mid Dose CK-1827452 or Placebo|CK-1827452 I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr or placebo, followed by 6 days three times a day oral dose and a final single oral dose
3272169|NCT00682565|Experimental|High Dose CK-1827452 or Placebo|CK-1827452 I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr or placebo, followed by 6 days three times a day oral dose and a final single oral dose
3272170|NCT00682552|Experimental|1|"A cervico-vaginal cervical smear will be realized before every colposcopique examination.~A new cervical taking for the search(research) and the detection of the HPV 16 and 18 will be realized."
3272171|NCT00682539|Active Comparator|Avastin|15 patients with clinical significant macular edema receive an injection of 2,5 mg Avastin every month. After three initial injections of Avastin re-injection is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns a sham injection is performed.
3272172|NCT00682539|Active Comparator|Triamciolone|30 patients with a clinical significant diabetic macular edema receive an intraocular injection of 8mg triamcinolone at baseline under sterile conditions. 1 and 2 month after the baseline injection, patients receive a sham injection. After three month re-injection of 8mg Triamcinolone is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns patients will receive a sham injection. In between two injection of 8mg Triamcinolone must be an temporal interval of at least 3 months.
3272173|NCT00682539|Active Comparator|Lucentis|15 patients with clinical significant macular edema receive an injection of 0,5 mg Lucentis every month. After three initial injections of Lucentis re-injection is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns a sham injection is performed.
3272174|NCT00682526||Pre-study Period (Group 1 and Group 2).|"The TIME-MC study was conducted from June 2003 to June 2008 at NEMC (Figure 1) and from May 2005 to September 2008 at the six larger medical centers (Figure 2). Two groups were studied. Group 1 included patients at NEMC and Group 2 included patients at the other six medical sites. The study was divided into three periods:~Pre-study period (Group 1 and Group 2). No PH-ECG transmission system was available."
3272175|NCT00682526||Study Period (Group 1 and Group 2)|Study period (Group 1 and Group 2). PH-ECG transmission to a cardiologist's hand-held device was attempted through pre-assigned EMS ambulances equipped with a wireless ECG transmission device in addition to a STEMI code system. In Group 1, this referred to the pilot study at NEMC from June 2003 to May 2005.
3272176|NCT00682526||Post-study period (Group 1)|Post-study period (Group 1). PH-ECG transmission and a STEMI code system implemented after the pilot study period.
3272177|NCT00682513||ATP1A3 Mutation|Those with RDP, AHC, unaffected carriers of ATP1A3 mutations, and non-carrying family members
3272178|NCT00682500|Experimental|1|Calfactant treatment
3272179|NCT00682500|Placebo Comparator|2|
3272180|NCT00682487||1|patients admitted to the cardiology department with acute Myocardial infarction.
3272181|NCT00682487||2|patients admitted to an internal medicine department due to reasons other than an acute thrombotic event
3272182|NCT00682474|Experimental|CI|Four 30-minute individual student-centered smoking cessation counseling intervention sessions delivered by school nurses to adolescent smokers in grades 9-12
3272183|NCT00682474|Active Comparator|II|Attention-control comparison condition consisting of four individual sessions with the school nurse to check smoking status and deliver a series of standardized pamphlets on smoking and cessation to adolescent smokers in grades 9-12
3272184|NCT00682461|Active Comparator|Marketed formulation|Marketed nicotine replacement therapy product
3272185|NCT00682461|Experimental|prototype|Nicotine prototype
3272186|NCT00682448|Active Comparator|1|Olanzapine plus metformin: olanzapine plus metformin 500 mg titrated up to but no greater than 2,000 mg based upon fasting blood glucose during study visits over six months.
3272187|NCT00682448|Placebo Comparator|2|Olanzapine plus Drug: Placebo. Subjects will remain on olanzapine plus placebo for 6 months.
3272188|NCT00682435|Experimental|Hydromorphone|1 mg IV hydromorphone, + optional 1 mg IV hydromorphone 15 minutes later
3272189|NCT00682422||Parent & Child Dyad|
3272190|NCT00682409|Other|1|Analysis of the value of the imaging of distribution and the late sequence to differentiate the cholesteatoma of the fibrosis in the follow-up operating post at the child
3272191|NCT00682383|Other|ARM 1|"Cisplatin 75 mg/m2 day 1 and 22~Etoposide 80mg/m2 days 1-3, 22-24~Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)~Filgrastim 5µg/kg* SQ injection days 4-13 and days 25-34~Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles~Pegfilgrastim 6 mg SQ injection day 2 of each cycle"
3272192|NCT00682370|Experimental|A1|0.3 mg/kg heme arginate
3272193|NCT00682370|Experimental|A2|1 mg/kg heme arginate
3272194|NCT00682370|Experimental|A3|3 mg/kg heme arginate
3272195|NCT00682370|Placebo Comparator|P|Placebo
3272196|NCT00682357|Experimental|1|Methylprednisone 80 mg and Lidocaine 20 mg
3272197|NCT00682357|Experimental|2|Methylprednisolone 16 mg and Lidocaine 20 mg
3272198|NCT00682357|Placebo Comparator|3|Placebo and Lidocaine 20 mg
3272199|NCT00682318|Experimental|Fish oil|Omega-3 polyunsaturated fatty acids (n-3 PUFA)
3272200|NCT00682318|Active Comparator|Safflower Oil|Omega-6 polyunsaturated fatty acids (n-6 PUFA)
3272201|NCT00682305|Other|Single-Arm|Single-Arm
3272202|NCT00682292|Active Comparator|1, ATG|Thymoglobulin induction during 8 days (1.25 mg/kg per day) associated with tacrolimus, mycophenolate mofetil and steroids
3272203|NCT00682292|Active Comparator|2, Daclizumab|Dacluzamb induction (five infusions, 1 mg/kg per infusion) associated with tacrolimus, mycophenolate mofetil and steroids
3272204|NCT00682279|No Intervention|This is a single-arm, dose escalation|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
3272205|NCT00682266|Experimental|Aerobic interval training|intensity-controlled interval training
3272206|NCT00682266|Experimental|MTG|multidisciplinary approach
3272207|NCT00682240|Active Comparator|group 3|"Group 3: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation.~Intervention: All patients will receive a multi-session panretinal laser treatment according to the conventional protocol, using a conventional laser system."
3272208|NCT00682240|Active Comparator|group 2|"Group 2: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation randomized into group 2.~Intervention: This group will receive multi-session panretinal laser treatment. The treatment will be performed using Pascal laser system."
3272209|NCT00682240|Active Comparator|group 1|"Group 1: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation randomized into group1.~Intervention: One group will receive a single-session panretinal laser treatment, performed using Pascal laser system."
3272210|NCT00682240|Active Comparator|group 4|"Group 4: 20 patients with persistent central or para-central diabetic macular edema receiving focal or grid laser treatment. As the treatment will be performed according to the conventional protocol (single spot), only the Pascal laser system will be used.~Intervention: focal or grid laser treatment"
3272211|NCT00682227|Experimental|1|
3272212|NCT00682214|Active Comparator|A, Choelcalciferol|Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
3272213|NCT00682214|Placebo Comparator|B, Lactose|
3272214|NCT00682201||1|Healthy pregnant women
3272215|NCT00682188|Experimental|CI|Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)
3272216|NCT00682188|Active Comparator|II|Six individual sessions with the school nurse over 2 months to check weight and behavior changes and provide a series of six pamphlets on weight and weight management
3272217|NCT00682175||Observation|Adult (age > 18 yrs) patients admitted to the Heart Failure Intensive Care Unit with Acute Heart Failure Syndrome requiring placement of a Pulmonary Artery catheter for hemodynamically guided therapy.
3272218|NCT00682162|Sham Comparator|Sham-laser acupuncture|The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
3272219|NCT00682162|Active Comparator|Acupuncture|The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, [22]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
3272220|NCT00682149|Placebo Comparator|Group 1|We planned to compare a study group of 60 subjects with a placebo group of 60 subjects
3272221|NCT00682149|Active Comparator|Group 2|We planned to compare a study group of 60 subjects with a placebo group of 60 subjects
3272222|NCT00682136|Active Comparator|1|Open Laparotomy Arm: All patients enrolled in the study who are undergoing elective open laparotomy surgery.
3272223|NCT00682136|Active Comparator|2|Laparoscopic Arm: All patients enrolled in the study who are undergoing elective laparoscopic abdominal surgery.
3272224|NCT00682097|Experimental|1|
3272225|NCT00682097|Experimental|2|
3272226|NCT00682097|Experimental|3|
3272227|NCT00682097|Experimental|4|
3272228|NCT00682097|Experimental|5|
3272229|NCT00682097|Experimental|6|
3272230|NCT00682097|Experimental|7|
3272231|NCT00682084||1|Patients recently diagnosed with Cushing's syndrome
3272232|NCT00682071||1|transabdominal ultrasound (TAS) guided embryo transfer
3272233|NCT00682071||2|transvaginal ultrasound (TVS) guided embryo transfer
3272234|NCT00682058||LABS patients|Bariatric surgery patients with 35>BMI kg/m2<60 prior to surgery will undergo follow-up post-bariatric surgery.
3272235|NCT00682045||T-SPOT.TB positive|T-SPOT.TB positive patients
3272236|NCT00682032|Experimental|AIM 2: subjects with suspected or definitive NSCLC diagnosis|1 (one) 250mg beta-glucan capsule 3 times a day for 14 days
3272237|NCT00682032|Experimental|AIM 3: subjects with resectable NSCLC|1 (one) 250mg beta-glucan capsule 3 times a day for 10 to 20 days
3272238|NCT00682019|Experimental|Arm 1|
3272239|NCT00682019|Placebo Comparator|Arm 2|
3272240|NCT00682006|Experimental|A|In this arm we recruited 2,400 subjects who received Intervention.
3272241|NCT00682006|Experimental|B|In this Arm, we recruited 2,400 subjects who received intervention.
3272242|NCT00682006|Experimental|C|In this Arm, we recruited 2,400 subjects who received intervention.
3272243|NCT00682006|No Intervention|D|In this Arm, we recruited 2,400 subjects for Observation and comparison. This was the prime control group.
3272244|NCT00681993|Active Comparator|1|Standard ddAC chemotherapy and concurrent radiation therapy
3272245|NCT00681993|Active Comparator|2|Standard AC chemotherapy and concurrent radiation therapy
3272246|NCT00681993|Active Comparator|3|Standard TCarbo H chemotherapy and concurrent radiation therapy
3272247|NCT00681993|Active Comparator|4|Standard TAC chemotherapy with concurrent radiation therapy
3272248|NCT00681993|Active Comparator|5|Standard TC chemotherapy with concurrent radiation therapy
3272249|NCT00681980|Experimental|A, 2, III|Patients with side effects to corticosteroids
3272250|NCT00681980|Experimental|B|patient with corticosteroids
3272251|NCT00681980|Experimental|3|Valproic acid and corticosteroids
3272252|NCT00681967|Experimental|Cohort 1|post operative combination of gefinib and RT
3272253|NCT00681967|Experimental|Cohort 2|combination of gefitinib with RT and Chemotherapy in non operated patients
3272254|NCT00681954||1, 2, 3|
3272255|NCT00681941|Experimental|1|Sevelamer Carbonate Tablets Dosed Three Times A Day
3272256|NCT00681928||Breast Cancer patients receiving aromatase treatment|
3272257|NCT00681928||Healthy female controls age 60 and older|
3272258|NCT00681915|Experimental|1|
3272259|NCT00681902|Experimental|1|Jet lidocaine
3272260|NCT00681902|Placebo Comparator|2|Jet saline
3272261|NCT00681889|Experimental|Treatment Arm|10 Patients will receive treatment (Ranibizumab)
3272262|NCT00681876|Experimental|1|Irinotecan+Avastin+Erbitux
3272263|NCT00681863|Active Comparator|pramipexole 0.0625 mg BID (twice daily)|all patients to receive one tablet of pramipexole 0.0625 mg BID for first 4 weeks (flexible dosing for all other arms)
3272264|NCT00681863|Active Comparator|pramipexole 0.0625 mg QD (once daily)|patients to receive one tablet of pramipexole 0.0625 mg QD
3272265|NCT00681863|Active Comparator|pramipexole 0.125 mg BID|patients to receive one tablet of pramipexole 0.125 mg BID
3272266|NCT00681863|Active Comparator|pramipexole 0.125 mg TID (three times daily)|patients to receive one tablet of pramipexole 0.125 mg TID
3272267|NCT00681863|Active Comparator|pramipexole 0.25 mg BID|patients to receive one tablet of pramipexole 0.25 mg BID
3272268|NCT00681850||1|Control group
3272269|NCT00681850||2|Benchmarking group
3272270|NCT00681837||1|children from 0 to 17 years old
3272271|NCT00681824|Experimental|FS VH S/D 500 s-apr|Application of FS VH S/D 500 s-apr on top of suture
3272272|NCT00681824|Active Comparator|Standard of Care (Control group)|The treatment of the control group consisted of Standard of Care (SoC) which was defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen based dura substitute.
3272273|NCT00681811|Experimental|HGT-1111 100 U/kg|
3272274|NCT00681811|Experimental|HGT-1111 200 U/kg|
3272275|NCT00681798|Active Comparator|Dose level 1|Vandetanib 100mg/day plus Gemcitabine
3272276|NCT00681798|Active Comparator|Dose level 2|Vandetanib 300mg/day plus Gemcitabine
3272277|NCT00681798|Active Comparator|Dose level 3|Vandetanib 100mg/day plus Gemcitabine plus CapecitabineDose
3272278|NCT00681798|Active Comparator|Dose level 4|Vandetanib 300mg/day plus Gemcitabine plus CapectiabineDose
3272279|NCT00681785|Active Comparator|A|5000IE dalteparine
3272280|NCT00681785|Placebo Comparator|B|NaCL 0.9%
3272281|NCT00681772|Experimental|Arm 1|
3272282|NCT00681759||1|Patients who have been prescribed Low Dose Aspirin (LDA) usage in the past 12 months, or those about to begin LDA, will complete a one-time in-office survey using an electronic personal digital assistant (PDA) device (termed SitePro).
3272283|NCT00681759||2|420 subjects stratified into three groups varying on length of time using Low Dose Aspirin (LDA)
3272284|NCT00681759||3|Up to 20 subjects from the three EMA groups will be interviewed to further debrief their experience with Low Dose Aspirin (LDA) and upper GI symptoms.
3272285|NCT00681746|Experimental|1|
3272286|NCT00681733|Experimental|A|Pioglitazone
3272287|NCT00681733|Active Comparator|B|Pentoxifylline
3272288|NCT00681720|Experimental|1|
3272289|NCT00681707||1|Hypertension patients recovering from stroke
3272290|NCT00681694||MRBT|MRI-assisted brachytherapy, the experimental arm
3272291|NCT00681694||USBT1|Standard ultrasound-guided brachytherapy performed by group 1 (control arm 1)
3272292|NCT00681694||USBT2|Standard ultrasound-guided brachytherapy performed by group 2 (control group 2)
3272293|NCT00681681||1|Men and women with 1 or more cardiovascular risk factors
3272294|NCT00681668|Experimental|Quetiapine Fumarate 150 - 800mg|Quetiapine 150-800mg
3272295|NCT00681655|Experimental|Responses to alcohol|Each subject completed a total of 2 2.8 hr-long clamping sessions.Within each session, procedures differed only by the content of the infusate. In one session, 6% ethanol was infused. In the other session, only vehicle was infused, quantifying the placebo response for every subject. The order of alcohol or placebo sessions was counterbalanced; subjects were blind to which session was which; sessions were scheduled to occur about 2 weeks apart. Measures were collected before, and at beginning and end of infusion, and included subjective perceptions, EMG, EEG, stop-signal performance, eye movements, and auditory responses. Design allowed analysis of effect of alcohol vs placebo, initial effect of alcohol and acute tolerance to alcohol.
3272296|NCT00681642||1|Corneal epithelial tissue with wound cultured in human autoserum
3272297|NCT00681642||2|Corneal epithelial tissue with wound cultured in umbilical cord serum
3272419|NCT00680732|Experimental|B1|Iron and folic acid (IFA) and weekly chloroquine (CQ)
3272595|NCT00679419||Group 3|eGFR 30 - 59 ml/min/1.73m^2
3272298|NCT00681629|Experimental|Quetiapine XR Alone|Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
3272299|NCT00681629|Experimental|Quetiapine XR With Integrated Care Program (ICP)|Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
3272300|NCT00681616|Placebo Comparator|1|Compartment Monitoring System with Active Fluid Removal
3272301|NCT00681616|Active Comparator|2|Compartment Monitoring System (CMS) without fluid removal
3272302|NCT00681603|Experimental|1|13 cases that accepted subconjunctival injection of bevacizumab
3272303|NCT00681590|Active Comparator|1|vitamin D (cholecalciferol) 400 IU daily orally - low dose
3272304|NCT00681590|Active Comparator|2|vitamin D (cholecalciferol) 2000 IU daily orally - high dose
3272305|NCT00681577|Experimental|A|
3272306|NCT00681564|Experimental|One-Stage Full-Mouth Disinfection|Scaling and root planing, four quadrants in one session Tongue brushing with a 1% chlorhexidine gel (1 minute) Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes) Subgingival chlorhexidine (1%) irrigation in all pockets Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention Basic oral hygiene instructions Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)
3272307|NCT00681564|Active Comparator|Periodontal care|Basic oral hygiene instructions Supragingival plaque removal
3272308|NCT00681551|Active Comparator|Arm 1|
3272309|NCT00681551|Experimental|Arm 2|
3272310|NCT00681538|Experimental|Sativex|"Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.~Subjects received study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose was 12 actuations (THC 32.4 mg:CBD 30 mg) in 24 hours"
3272311|NCT00681538|Placebo Comparator|Placebo|Contains no active drug but colourants and excipients. Subjects received placebo delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose was 12 actuations in 24 hours.
3272312|NCT00681525|Experimental|A|ABT-335 135 mg
3272313|NCT00681525|Experimental|B|Atorvastatin 80 mg and Ezetimibe 10 mg
3272314|NCT00681525|Experimental|C|ABT-335 135 mg, Atorvastatin 80 mg and Ezetimibe 10 mg
3272315|NCT00681499||malignant|eg. hepatocellular carcinoma, colorectal liver metastases
3272316|NCT00681499||benign|eg. liver cysts, traumatic liver injuries, adenoma etc
3272317|NCT00681486|Active Comparator|A, 1|Ghrelin
3272318|NCT00681486|Active Comparator|A, 2|Ghrelin.
3272319|NCT00681473|Experimental|Proton Radiation Therapy|Proton radiation therapy daily (Monday through Friday) for six weeks. This is a single arm study.
3272320|NCT00681460|Active Comparator|1|gestational diabetes, insulin therapy
3272321|NCT00681460|Experimental|2|gestational diabetes, metformin therapy
3272322|NCT00681447|Other|Group I|Lumbar interlaminar epidural injection with local anesthetic only
3272323|NCT00681447|Other|Group II|Lumbar Interlaminar Epidural Injection with local anesthetic wiht 6 mg of non-particulate Celestone
3272324|NCT00681434|Experimental|1|bilateral training
3272325|NCT00681434|Active Comparator|2|Unilateral training
3272326|NCT00681421|Experimental|A|
3272327|NCT00681408|Active Comparator|Omega 3 recipient arm|
3272328|NCT00681408|Placebo Comparator|Placebo|Placebo fish oil
3272329|NCT00681395|Experimental|1|ABT-143 capsules 20/135 mg
3272330|NCT00681395|Active Comparator|2|ABT-335 135mg and rosuvastatin 20mg
3272331|NCT00681395|Experimental|3|ABT-143 capsules 5/45mg
3272332|NCT00681395|Active Comparator|4|ABT-335 45mg and rosuvastatin 5mg
3272333|NCT00681382||1|Asthma patients using inhaled steroids as maintenance treatment
3272334|NCT00681369||1|Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
3272335|NCT00681356|Experimental|1|4975 - 15 mg
3272336|NCT00681356|Placebo Comparator|2|Placebo
3272337|NCT00681356|Experimental|3|4975 - truncated for Phase 3
3272338|NCT00681343|Experimental|A|Thymoglobulin Induction
3272339|NCT00681343|Experimental|B|Campath-1H Induction
3272340|NCT00681343|Experimental|C|Daclizumab Induction
3272341|NCT00681330|Experimental|A|
3272342|NCT00681317|Experimental|1|
3272343|NCT00681304||1|Only one group of participants will be studies. There are no controls.
3272344|NCT00681291|Active Comparator|1|lightweight polypropylene mesh
3272345|NCT00681291|Active Comparator|2|Strattice
3272346|NCT00681278||1|Hypertension patients with Type II Diabetes mellitus
3272347|NCT00681265|Experimental|glycerin|One eye will randomly receive a single instillation of one drop of a new formulation of an artificial tear containing glycerin 1% as an active with polylysine-graft-polyethylene glycol as an excipient.
3272348|NCT00681265|Active Comparator|polyethylene glycol 400/propylene glycol|The other eye will receive a single instillation of one drop of an artificial tear with propylene glycol (0.3%) and polyethylene glycol (0.4%) as active ingredients with hydroxypropyl-guar as a gelling agent.
3272349|NCT00681252|Experimental|A|
3272350|NCT00681239|Experimental|A|Patients will receive the modified Atkins diet in combination with a 10 oz KetoCal shake for the first month. The second month no shake will be given. Results at 1 month will be compared to 2 months, as well as to historical controls with the modified Atkins diet.
3272351|NCT00681213|Experimental|A|Tacrolimus/Sirolimus
3272352|NCT00681213|Experimental|B|Tacrolimus/MMF
3272353|NCT00681213|Experimental|C|Neoral/Sirolimus
3272354|NCT00681200|Active Comparator|Enhanced health education program|This active treatment group consists of classes in health education and a social support group to enhance participant motivation and positive reinforcement to make healthier lifestyle choices (e.g. wholesome diet, increased exercise, reduced salt intake, and decreased use of alcohol and smoking). Note that is comparison group does not have a stress management component.
3272540|NCT00679796||Group B|Age- and practice-matched control subjects
3272355|NCT00681200|Experimental|Transcendental Meditation program|Transcendental Meditation program plus health education. Basic AHA recommendations for lifestyle modification to reduce risk of heart disease will be given in a didactic classroom context.
3272356|NCT00681174|Active Comparator|Control|Control intervention will be intraoperative i.v. morphine administration 30 minutes before the end of anesthesia.
3272357|NCT00681174|Experimental|CROxy|The intervention group will receive controlled-release oxycodone 1 h pre-operatively
3272358|NCT00681161|Other|A|
3272359|NCT00681148|Experimental|A|Botox injection
3272360|NCT00681148|Placebo Comparator|B|Saline injection
3272361|NCT00681135|Experimental|1|
3272362|NCT00681135|Experimental|2|
3272363|NCT00681135|Experimental|3|
3272364|NCT00681135|Active Comparator|4|
3272365|NCT00681122||1|Standard therapy
3272366|NCT00681122||2|Standard therapy + educational material
3272367|NCT00681109|Active Comparator|Treatment Arm 1|2.5% IL-1Ra
3272368|NCT00681109|Placebo Comparator|Placebo|Artificial Tear
3272369|NCT00681109|Active Comparator|Treatment Arm 2|5% IL-1Ra
3272370|NCT00681083|Experimental|1|Heated breathing tube
3272371|NCT00681083|Active Comparator|2|Non heated breathing tube
3272372|NCT00681070|Active Comparator|Arm1: Non-absorbable sutures|use of non-absorbable sutures in facial laceration in this arm
3272373|NCT00681070|Active Comparator|Arm 2: Absorbable sutures|use of absorbable sutures in this arm
3272374|NCT00681044|Experimental|SCT with melphalan conditioning|Mobilization with Filgrastim Stem Cell Transplant Melphalan Conditioning Stem Cell infusion
3272375|NCT00681031|Experimental|All Enrolled|Participants received a single dose (0.65 mL) of shingles (herpes zoster) vaccine (live) ZOSTAVAX® by subcutaneous injection at Visit 1 (Day 0)
3272376|NCT00681018|Experimental|1|Liquid human milk fortifier
3272377|NCT00681018|Active Comparator|2|Powder human milk fortifier
3272378|NCT00681005|Active Comparator|Rabeprazole|Rabeprazole 1 # qd
3272379|NCT00681005|Active Comparator|pantoprazole|Pantoprazole 1# qd
3272380|NCT00680992|Experimental|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
3272381|NCT00680966|Experimental|TX1|Functional Family Therapy (FFT) followed by Adolescent Coping With Depression (ACWD)
3272382|NCT00680966|Experimental|TX 2|ACWD (Adolescent Coping With Depression) followed by FFT (Functional Family Therapy)
3272383|NCT00680966|Experimental|TX 3|Combination of an augmented FFT and ACWD - Integrated treatment
3272384|NCT00680953|Experimental|1|Denosumab (subcutaneously - every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).
3272385|NCT00680953|Placebo Comparator|2|Placebo (subcutaneously every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).
3272386|NCT00680953|Active Comparator|3|Alendronate sodium hydrate oral tablets weekly + daily calcium and vitamin D supplements for 24 months (open label reference arm).
3272387|NCT00680940|Active Comparator|Chemotherapy|Paclitaxel + Cisplatin
3272388|NCT00680940|Experimental|Chemoimmunotherapy|Paclitaxel + Cisplatin + Mycobacterium w
3272389|NCT00680914|Experimental|Synflorix Group|Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4.
3272390|NCT00680914|Active Comparator|Prevenar Group|Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4.
3272391|NCT00680901|Experimental|CapeOx plus Lapatinib|CapeOx plus Lapatinib
3272392|NCT00680901|Placebo Comparator|CapeOx plus Placebo|CapeOx plus Placebo
3272393|NCT00680888||1|Children and adolescents with psychosis in outpatients setting on treatment with quetiapine started from january 2003 to june 2006
3272394|NCT00680875|Experimental|Intervention|5th and 6th grade students who attend schools randomly assigned to the intervention condition.
3272395|NCT00680875|No Intervention|Usual Curriculum|5th and 6th grade students attending schools randomly assigned to the usual curriculum control condition.
3272396|NCT00680862||Group 1|VA employees
3272397|NCT00680849||1|Treatment condition from first study. This is a follow-up study.
3272398|NCT00680849||2|Control condition from first study.
3272399|NCT00680836|Active Comparator|Treatment Group|These patients have IBS and are receiving the rifaximin.
3272400|NCT00680836|Placebo Comparator|Placebo group|These patients have IBS and are receiving the placebo.
3272401|NCT00680823|Experimental|Ropivacaine Injections|Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of 0.5% ropivacaine on each side.
3272402|NCT00680823|Placebo Comparator|Normal Saline Injections|Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of normal saline on each side.
3272403|NCT00680823|No Intervention|Observation|Observation for 30 minutes.
3272404|NCT00680797|Experimental|+T +E|+Testosterone, +Estrogen
3272405|NCT00680797|Experimental|+T -E|+Testosterone, -Estrogen
3272406|NCT00680797|Experimental|-T +E|-Testosterone, +Estrogen
3272407|NCT00680797|No Intervention|-T -E|-Testosterone, -Estrogen
3272408|NCT00680784|Experimental|HKT-500 Ketoprofen Topical Patch|Randomized, double-blind, placebo-controlled, multicenter study in men and women 18 years of age or older who have a painful, acute, benign, ankle sprain of the lateral ligament(s) within the previous 48 hours.
3272409|NCT00680784|Placebo Comparator|Placebo Patch|Treatment with placebo patch
3272410|NCT00680771||1|Primary Insomnia
3272411|NCT00680771||2|Good Sleepers
3272412|NCT00680758|Experimental|Therapeutic Intervention|
3272413|NCT00680745|Experimental|1|dapagliflozin 2.5mg + Glimepiride
3272414|NCT00680745|Experimental|2|dapagliflozin 5mg + Glimepiride
3272415|NCT00680745|Experimental|3|dapagliflozin 10mg + Glimepiride
3272416|NCT00680745|Placebo Comparator|4|Placebo + Glimepiride
3272417|NCT00680732|Experimental|A1|Multiple micronutrients supplements (MMS) and weekly chloroquine (CQ)
3272418|NCT00680732|Experimental|A2|Multiple micronutrients supplements (MMS) and intermittent suplphadoxyne-pyrimethamine (SP)
3272420|NCT00680732|Experimental|B2|Iron and folic acid (IFA) and intermittent sulphadoxyne-pyrimethamine (SP)
3272421|NCT00680719|Active Comparator|1|Family Therapy plus HIV prevention
3272422|NCT00680719|Active Comparator|2|Family Therapy only.
3272423|NCT00680706|Experimental|Thiamine|Receives thiamine
3272424|NCT00680706|Placebo Comparator|Control|
3272425|NCT00680693|Experimental|1|Mindfulness-based stress management 8-week program
3272426|NCT00680693|Active Comparator|2|Psycho-educational support group for women with IBS
3272427|NCT00680667|Experimental|Trametes Versicolor|Females with Stage I-III infiltrating ductal adenocarcinoma of the breast being treated with Trametes versicolor capsules for 6 weeks after receiving radiation therapy.
3272428|NCT00680654|Experimental|Arm 1|
3272429|NCT00680641|Active Comparator|A|Simvastatin 40mg
3272430|NCT00680641|Placebo Comparator|B|Placebo
3272431|NCT00680628|Placebo Comparator|2|Saline + Enoxaparin
3272432|NCT00680628|Experimental|1|Tenecteplase + Enoxaparin
3272433|NCT00680615|Experimental|Usual Care|
3272434|NCT00680615|Experimental|Enhanced|
3272435|NCT00680602|Experimental|1|Group Cognitive Behavior Therapy
3272436|NCT00680602|Active Comparator|2|Selective Serotonin Reuptake Inhibitor
3272437|NCT00680589|Experimental|1|Injection of mouse TYRP2 DNA in patients with highrisk melanoma.
3272438|NCT00680576|Active Comparator|1|Eight weeks of individual CBT for adolescents who have completed six weeks of group therapy and continue to use drugs.
3272439|NCT00680576|Active Comparator|2|Eight weeks of FFT for adolescents who have received six weeks of group therapy and continue to use drugs.
3272440|NCT00680563|Experimental|1|
3272441|NCT00680537|No Intervention|1|Control group
3272442|NCT00680537|Experimental|2|Exercise group
3272443|NCT00680524|Experimental|Phone Based Outreach Intervention Group|Open pilot trial
3272444|NCT00680511|Active Comparator|1|Family therapy combined with methamphetamine-specific group treatment.
3272445|NCT00680511|Active Comparator|2|Family Therapy.
3272446|NCT00680498|Active Comparator|1|
3272447|NCT00680498|Active Comparator|2|
3272448|NCT00680472|Active Comparator|A,1 HKT-500 Ketoprofen Topical Patch|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Week Study to Assess the Efficacy and Safety of HKT-500 in Subjects with Acute Shoulder Pain
3272449|NCT00680472|Placebo Comparator|A,2 Placebo Patch|Treatment with placebo patch
3272450|NCT00680459|Experimental|1|70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
3272451|NCT00680459|Placebo Comparator|2|heparin flush 10 units/ml lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. heparin flush solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
3272452|NCT00680446|Experimental|1|
3272453|NCT00680433|Experimental|Active|Ketamine
3272454|NCT00680433|Placebo Comparator|Placebo|Saline (placebo)
3272455|NCT00680407|Experimental|silymarin 420 mg|420 mg Legalon (silymarin) three times daily
3272456|NCT00680407|Experimental|silymarin 700 mg|700 mg of Legalon (silymarin) three times daily
3272457|NCT00680407|Placebo Comparator|Placebo|Placebo (lactose pill)
3272458|NCT00680394|Experimental|mifepristone+misoprostol|200 mg mifepristone+ 800 mcg buccal misoprostol
3272459|NCT00680394|Experimental|misoprostol|800 mcg buccal misoprostol+placebo
3272460|NCT00680381|Active Comparator|1|Following 12 weeks of Functional Family Therapy (FFT), semi-weekly therapist phone calls for eight weeks.
3272461|NCT00680381|Active Comparator|2|Following 12 weeks of FFT, weekly one-hour group therapy for eight weeks
3272462|NCT00680381|Active Comparator|3|Following 12 weeks of FFT, an eight-week, customized series of therapist visits with the adolescent, family, teachers, coaches and others who can support the adolescent's reduced level of drug use.
3272463|NCT00680368||Residents and Attending Physicians|This group contains the residents and the attending physicians who consented to participate in the study. They participated in a survey administered by a research assistant. Both physician resident and attending physicians were administered the survey twice within 24-hours and their test-retest responses were compared for reliability. Responses to attending and resident physicians covering the care for the patient and clinical care encounter were compared for accuracy.
3272464|NCT00680355|Other|Golden rice meal with 10g fat|10 g corn oil in the Golden Rice meal
3272465|NCT00680355|Other|Golden Rice with 0g fat|0g corn oil eating with the Golden Rice meal
3272466|NCT00680355|Other|Golden Rice meal with 5 g fat|5 g corn oil in the Golden Rice meal
3272467|NCT00680342|Placebo Comparator|1|Placebo (lactose pill)
3272468|NCT00680342|Experimental|2|700mg of Legalon (silymarin) three times daily
3272469|NCT00680342|Experimental|3|420mg Legalon (silymarin) three times daily
3272470|NCT00680329||Travalert with DuoTrav|One drop in study eye(s) once daily in the evening for four months
3272471|NCT00680316|Experimental|Dornase alfa|
3272472|NCT00680316|Placebo Comparator|Placebo|
3272473|NCT00680303|Experimental|1|The child will receive the Lidcombe Program 2x per week
3272474|NCT00680303|Experimental|2|The child will receive the Lidcombe Program once every 2 weeks (fortnightly visits)
3272475|NCT00680303|Other|3|The child will receive the standard Lidcombe Program once per week (control)
3272476|NCT00680290|Experimental|1|Exercise group
3272477|NCT00680277|Experimental|1|
3272478|NCT00680277|Experimental|2|
3272479|NCT00680264||Operative|Diagnosis of Cerebral Palsy (standard definition of any brain injury before the age of 3) with total body involvement - any functional level Curve >40 degrees on sitting film, A spinal fusion is being undertaken and the patient/family is proceeding with the spinal fusion (with any level of distal fusion).
3272541|NCT00679783|Experimental|1|AZD2281, PARP inhibitor
3272542|NCT00679770|Experimental|Group 1|AN2690 Solution: 2.5%
3272480|NCT00680264||Non-operative|Diagnosis of Cerebral Palsy (standard definition of any brain injury before the age of 3) with total body involvement - any functional level, Curve >40 degrees on sitting film, A spinal fusion is not being undertaken either because the family has refused surgery or because it is not recommended at this point.
3272481|NCT00680238|No Intervention|A|Embryo selection for transfer based on a Day 3 score only.
3272482|NCT00680238|Active Comparator|B|Embryos for transfer by first selecting any embryos that had a positive sHLA-G expression of OD = 190 ±6 and correlating such with the highest GES score available.
3272483|NCT00680225|Experimental|Lucentis Injection|Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
3272484|NCT00680212|Other|1|dietary carotenoids
3272485|NCT00680199||1|Primary Insomnia
3272486|NCT00680199||2|Good Sleepers
3272487|NCT00680186|Experimental|Dabigatran etexilate (150mg bid)|Patients will receive 1 capsule containing 150 mg dabigatran etexilate/matching placebo twice daily
3272488|NCT00680186|Active Comparator|Warfarin (INR 2.0-3.0)|Patients will receive tablets PRN warfarin/matching placebo to maintain a target INR of 2.0-3.0
3272489|NCT00680173|Active Comparator|A|15 patients with HCV genotype 1 infection receiving peginterferon plus ribavirin achieve a sustained virological response
3272490|NCT00680173|Active Comparator|B|15 patients with HCV genotype 1 infection receiving peginterferon plus ribavirin did not achieve a sustained virological response
3272491|NCT00680147|Experimental|Brief HPV vaccine informational intervention|Because we anticipated that knowledge and awareness of the HPV vaccine would be low in our study population, our CASI survey included a brief, informational overview of key facts concerning HPV vaccination prior to assessing vaccine acceptance, perceived barriers to vaccination, and intentions to vaccinate. The overview lasted approximately 3 minutes and consisted of a brief overview of key HPV vaccination facts that were presented visually (on the computer screen) and read aloud using a digital recording. HPV and vaccine knowledge, awareness, and attitudes items were administered prior to participants hearing the informational overview.
3272492|NCT00680134|Experimental|Group/Cohort 1|AN2690 1% Solution (30 subjects)
3272493|NCT00680134|Experimental|Group/Cohort 2|AN2690 5% Solution (30 subjects)
3272494|NCT00680121|Placebo Comparator|Control Group|Placebo
3272495|NCT00680121|Experimental|Benfotiamine|Benfotiamine 600 mg
3272496|NCT00680095|Experimental|A|AN2690 Solution, 2.5%
3272497|NCT00680095|Experimental|B|AN2690 Solution, 7.5%
3272498|NCT00680095|Experimental|C|AN2690 Solution, 5.0%
3272499|NCT00680095|Active Comparator|D|AN2690 Solution, Vehicle
3272500|NCT00680095|Active Comparator|E|Sodium Lauryl Sulfate, 0.5%
3272501|NCT00680082||1|Patients to whom a statin was initiated or switched between 3 and 6 months before consultation
3272502|NCT00680069|Experimental|High Dose Group|Volunteers will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will get 1 dose, clade 1 vaccine-naive subjects receive 2 doses 28 days apart
3272503|NCT00680069|Experimental|Low Dose Group|Volunteers will receive 15 mcg intramuscularly (IM). Subjects who received previous clade 1 vaccine will get 1 dose, clade 1 vaccine-naive subjects receive 2 doses 28 days apart.
3272504|NCT00680056|Active Comparator|1|Formoterol plus Placebo (Tiotropium)
3272505|NCT00680056|Experimental|2|Formoterol plus Tiotropium
3272506|NCT00680043|Experimental|Peginesatide 0.04 mg/kg|
3272507|NCT00680043|Experimental|Peginesatide 0.08 mg/kg|
3272508|NCT00680043|Active Comparator|Epoetin Alfa|
3272509|NCT00680030||1|
3272510|NCT00680017|Experimental|ABT-335 plus rosuvastatin|ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
3272511|NCT00680017|Active Comparator|Rosuvastatin|Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
3272512|NCT00680004||1|Preoperative patients planned for a CT prior to an endograft implantation procedure
3272513|NCT00680004||2|Patients who underwent a complicated endograft implant and/or with increased risk of complications
3272514|NCT00679991|Active Comparator|PRT-201|
3272515|NCT00679991|Placebo Comparator|2|
3272516|NCT00679978||A|A: etidronate
3272517|NCT00679965|Experimental|Group 1|AN2690 Solution, 2.5%
3272518|NCT00679965|Experimental|Group 2|AN2690 Solution: 5%
3272519|NCT00679965|Experimental|Group 3|AN2690 Solution, 7.5%
3272520|NCT00679965|Placebo Comparator|Group 4|AN2690 Solution Vehicle
3272521|NCT00679952|Active Comparator|1|closed suction drainage group (CD group)
3272522|NCT00679952|Active Comparator|2|natural drainage group (ND group)
3272523|NCT00679939|Active Comparator|Arm 1 Treatment A|rosiglitazone up to 8mg/day
3272524|NCT00679939|Active Comparator|Arm 2 Treatment B|metformin up to 2000mg/day
3272525|NCT00679926|Experimental|1|Patients taking lopinavir/ritonavir and tenofovir once daily.
3272526|NCT00679913|Active Comparator|1|standard pancreatoduodenectomy
3272527|NCT00679913|Active Comparator|2|extended pancreatoduodenectomy
3272528|NCT00679900|Experimental|1|
3272529|NCT00679900|Active Comparator|2|
3272530|NCT00679887|Experimental|A|Ischemic compression on trigger points located around the shoulder. Active comparator. Ischemic compression, 5 weeks
3272531|NCT00679874||I|Consecutive patients with first-time diagnosis of metastatic breast cancer undergoing chemotherapy with anthracyclines and/or trastuzumab.
3272532|NCT00679861|Experimental|3|A practitioner delivered counselling and an expert system intervention is implemented in practices allocated to this arm
3272533|NCT00679861|Experimental|1|A practitioner delivered counselling intervention was implemented in practices allocated to this arm
3272534|NCT00679861|Experimental|2|A computer expert system intervention was implemented in practices allocated to this arm
3272535|NCT00679848|Experimental|1|Transoral Suturing
3272536|NCT00679835|Experimental|Group 1|8 mg/kg over a one hour infusion
3272537|NCT00679835|Experimental|Group 2|10mg/kg over a one or two hour infusion
3272538|NCT00679822||Heart Failure|Heart Failure Out Patients at OSU
3272539|NCT00679796||Group A|Subjects with PCR confirmed varicella
3272546|NCT00679744|Active Comparator|4 dose levels|Pyrimethamine at 6.25, 12.5, 25 and 37.5 mg/day will be evaluated sequentially, starting from 6.25 mg/day. Escalation from 6.25 mg/day to 12.5 mg/day, and from 12.5 mg/day to 25 mg/day, will not perform until all patients in the previous dose cohort have been treated for 4 weeks and until results obtained 4 weeks after treatment initiation do not reveal toxicity. Additionally, escalation from 25 mg/day to 37.5 mg/day will not perform until all patients in the 25-mg/day cohort have been treated for 8 weeks, and until results obtained 4 weeks after the 8-week treatment do not reveal toxicity. Dose escalation is considered complete, if 2 patients experience a Grade 3 Adverse Event (AE) or if 1 patient experiences a Grade 4 AE at a particular cohort.
3272547|NCT00679731|Experimental|A|ABT-874
3272548|NCT00679731|Active Comparator|B|Methotrexate
3272549|NCT00679705|Experimental|1|Ritodrine (Pre-Par)
3272550|NCT00679705|Experimental|2|Atosiban (Tractocile)
3272551|NCT00679705|Placebo Comparator|3|Placebo
3272552|NCT00679692||3:|three arms for study
3272553|NCT00679679|Experimental|Metformin|Every patient will be given diet and exercise counseling in both arms. Intervention arm will receive metformin
3272554|NCT00679679|Placebo Comparator|Placebo|Every patient will be given diet and exercise counseling in both arms. Intervention arm will receive metformin
3272555|NCT00679666|Sham Comparator|Sham treatment|Subjects are randomized to control (sham) group or a treatment group with the control group crossed over to the treatment group at the 3 month visit.
3272556|NCT00679666|Active Comparator|Treatment Arm|After randomization, the active arm will have the collagen crosslinking intervention.
3272557|NCT00679653|Active Comparator|1|verapamil/trandolapril
3272558|NCT00679653|Active Comparator|2|metoprolol/HCT
3272559|NCT00679653|Active Comparator|3|felodipine/ramipril
3272560|NCT00679640||1|Outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure
3272561|NCT00679627|Experimental|Galantamine|Galantamine 8mg/ day oral capsule increased to 16mg/day then to 24 mg per day
3272562|NCT00679627|Placebo Comparator|Placebo|Matching placeco
3272563|NCT00679614|Experimental|1|Group A oral tramacet 2 tablets preoperatively, 2 tablets every 6 hours for 5 days then 1-2 tablets of tramacet prn to a maximum of 8 tablets per day. Naloxone infusion starting preop at 0.25ug/kg/hr and continuing during hospital stay (an equivalent of 400ug over 24 hours in a 70 kg man). The infusion will be discontinued 1 hour before patient discharge.
3272564|NCT00679614|Active Comparator|2|Group B will receive oral tramacet 2 tablets preoperatively and then 2 tablets every 6 hours for five days. ( or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). This group will also receive saline infusion at 4-6mls / hour for the duration of the hospital stay.
3272565|NCT00679614|Active Comparator|3|Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay.
3272566|NCT00679588|Experimental|Semuloparin|Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery (placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind)
3272567|NCT00679588|Active Comparator|Enoxaparin|Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium (placebo for Semuloparin sodium 8 hours after surgery to maintain the blind)
3272568|NCT00679575||1|Cases : Patients with a first myocardial infarction
3272569|NCT00679575||2|Referents : Patients recruited by a GP during a routine consultation
3272570|NCT00679562|Experimental|1|
3272571|NCT00679562|Placebo Comparator|2|
3272572|NCT00679549|Experimental|DEVICE|Provided CPAP as an inpatient
3272573|NCT00679549|No Intervention|Control|No device provided
3272574|NCT00679536|Experimental|A|All patients on this trial will receive a conditioning regimen of Busulfan, Fludarabine, Anti-Thymocyte Globulin and Total Body Irradiation (400 cGy)
3272575|NCT00679523|Experimental|Group 1|AN2690 Solution, 5.0%
3272576|NCT00679523|Experimental|Group 2|AN2690 Solution, 7.5%
3272577|NCT00679510|Active Comparator|A|Rosuvastatin
3272578|NCT00679510|Placebo Comparator|B|Placebo
3272579|NCT00679497|Experimental|1|MVA HIV-B
3272580|NCT00679497|Placebo Comparator|2|Placebo
3272581|NCT00679484|Experimental|1|
3272582|NCT00679484|Experimental|2|
3272583|NCT00679471||Pre-Term|Infants born pre-term with birthweight less than 1KG
3272584|NCT00679471||Full-Term Infants|Well infants who are born full-term
3272585|NCT00679458|Experimental|1.|Study drug: buprenorphine and ultra-low-dose naloxone
3272586|NCT00679458|Active Comparator|2.|Study drug: buprenorphine
3272587|NCT00679445|Experimental|A|Device: NeoVista Ophthalmic System A single procedure using the NeoVista Ophthalmic System plus an injection of Lucentis.
3272588|NCT00679432|Experimental|1: budesonide-MMX® 6 mg|One budesonide-MMX® 6 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
3272589|NCT00679432|Experimental|2: budesonide-MMX® 9 mg|One budesonide-MMX® 9 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
3272590|NCT00679432|Placebo Comparator|3: Placebo|Two placebo Asacol® overencapsulated tablets plus one placebo Budesonide MMX® tablet daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
3272591|NCT00679432|Active Comparator|4: Asacol® 400 mg|Two Asacol® 400 mg overencapsulated tablets plus one placebo budesonide MMX® tablet daily in the morning after breakfast and two Asacol® 400 mg overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
3272592|NCT00679419||Group 0 (Controllgroup)|eGFR >= 90 ml/min/1.73m^2 and no proteinuria
3272593|NCT00679419||Group 1|eGFR >= 90 ml/min/1.73m^2 and proteinuria
3272594|NCT00679419||Group 2|eGFR 60 - 89 ml/min/1.73m^2
3272596|NCT00679419||Group 4|eGFR 15 - 29 ml/min/1.73m^2
3272597|NCT00679419||Group 5|eGFR < 15 ml/min/1.73m^2 or requiring dialysis
3272598|NCT00679406|Experimental|1|Brief Behavioral Treatment for Insomnia
3272599|NCT00679393|Other|Fix|Open reduction internal fixation of severely comminuted calcaneal fracture (Sanders IV)
3272600|NCT00679393|Other|Fuse|Primary subtalar fusion of severely comminuted calcaneal fractures (Sanders IV).
3272601|NCT00679380|Experimental|1: budesonide-MMX® 6 mg|One budesonide-MMX® 6 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.
3272602|NCT00679380|Experimental|2: budesonide-MMX® 9 mg|One budesonide-MMX® 9 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.
3272603|NCT00679380|Active Comparator|3: Entocort EC® 3 mg|Three Entocort EC® 3 mg overencapsulated capsules plus one placebo budesonide MMX® tablet daily in the morning after breakfast.
3272604|NCT00679380|Placebo Comparator|4: Placebo|Three placebo Entocort EC® overencapsulated capsules plus one placebo Budesonide MMX® tablet daily in the morning after breakfast.
3272605|NCT00679367|Experimental|Melphalan Revlimid and Dexamethasone|Melphalan Lenalidomide Dexamethasone
3272606|NCT00679354|Experimental|Treatment (cilengitide)|Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3272607|NCT00679341|Experimental|Trastuzumab emtansine|Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) administered over 30-90 minutes every 3 weeks on Day 1 of each 21-day cycle.
3272608|NCT00679341|Active Comparator|Trastuzumab + docetaxel|Patients received a loading dose of trastuzumab 8 mg/kg IV + docetaxel 75 or 100 mg/m^2 IV on Day 1 of Cycle 1 followed by trastuzumab 6 mg/kg IV + docetaxel 75 or 100 mg/m^2 IV on Day 1 of all subsequent 21-day cycles.
3272609|NCT00679328|Experimental|1|Surgical implantation of OP-1
3272610|NCT00679328|Active Comparator|2|Surgical implantation of bone graft material
3272611|NCT00679315|Experimental|Alpha blocker|alfuzosin hydrochloride XL 10mg
3272612|NCT00679315|Placebo Comparator|Placebo|Placebo
3272613|NCT00679302|Placebo Comparator|placebo group|Maalox and bitter mixture
3272614|NCT00679302|Active Comparator|antibiotic group|Trimethoprim-sulfamethoxazole suspension
3272615|NCT00679289|Experimental|Cohort 1|"KW2871: 5 mg/m^2 IV every 2 weeks until disease progression~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
3272616|NCT00679289|Experimental|Cohort 2|"KW2871: 10 mg/m^2 IV every 2 weeks until disease progression~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
3272617|NCT00679289|Experimental|Cohort 3|"KW2871: 20 mg/m^2 IV every 2 weeks until disease progression~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
3272618|NCT00679276||1|Patients having surgical repair of a vaginal prolapse .
3272619|NCT00679263|Experimental|MN-221|
3272620|NCT00679263|Placebo Comparator|PLACEBO|Placebo intravenous infusion with dosing volume equivalent to active treatment.
3272621|NCT00679250|Experimental|Levocetirizine|Active drug
3272622|NCT00679250|Placebo Comparator|placebo|placebo to levocetirizine
3272623|NCT00679237|Active Comparator|Multifactorial intervention|Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin
3272624|NCT00679237|No Intervention|Control|no intervention
3272625|NCT00679224||ambrisentan prescribed subjects|ambrisentan prescribed subjects
3272626|NCT00679211|Experimental|Trastuzumab emtansine|Trastuzumab emtansine (T-DM1) was administered to participants at a dose of 3.6 mg/kg by intravenous (IV) infusion every 3 weeks until documented disease progression, unmanageable toxicity, or study termination.
3272627|NCT00679198|Experimental|1|We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers
3272628|NCT00679198|No Intervention|2|Standard care
3272629|NCT00679185|Experimental|Experimental-EW|four emotion focused writing assignments
3272630|NCT00679185|Active Comparator|control group|non-emotional writing control
3272631|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 1|Dose of 5.0 x 10^9 colony forming units (CFU) S. typhi (Ty2 aroC‾ssaV‾) ZH9 or placebo, administered as a single, oral dose
3272632|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 2|Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9 or placebo, administered as a single, oral dose
3272633|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 3|Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9 or placebo, administered as a single, oral dose
3272634|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 4|Dose of of 1.7 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9 or placebo, administered as a single, oral dose
3272635|NCT00679159|Experimental|1|24 children (5 x 10^7pfu)
3272636|NCT00679159|Experimental|2|36 infants (2.5 x 10^7pfu)
3272637|NCT00679159|Experimental|3|36 infants (5 x 10^7 pfu)
3272638|NCT00679159|Experimental|4|36 infants (1 x 10^8pfu)
3272639|NCT00679159|Placebo Comparator|5|36 infants (Prevenar vaccine)
3272640|NCT00679146|Active Comparator|1|1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
3272641|NCT00679146|Active Comparator|2|2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
3272642|NCT00679133|Experimental|1|
3272643|NCT00679120|Active Comparator|1|Cemented single pegged femur with standard tibial bearing tray
3272644|NCT00679120|Active Comparator|2|Cemented twin pegged femur with standard tibial bearing tray
3272645|NCT00679120|Active Comparator|3|Cementless tibial bearing tray and femur (porous coated and HA coated)
3272646|NCT00679107|Experimental|1|autogenous bone graft with the addition of OP-1 Putty
3272647|NCT00679107|Active Comparator|2|autogenous bone graft alone
3272648|NCT00679094|Experimental|Arm I|Participants receive a single dose of oral BBIC or placebo, as an orange juice suspension, immediately followed by consumption of a defined low-fat breakfast. Participants continue to consume a low-fat diet for the next 48 hours and then resume their normal diet.
3272691|NCT00678704|Experimental|Arm 1|
3272649|NCT00679081|Experimental|CelTx|CelTx
3272650|NCT00679081|Active Comparator|Autologous CTG|Autologous sub-epithelial connective tissue graft
3272651|NCT00679068|Experimental|1|treatment with Bosentan
3272652|NCT00679055|Experimental|MK-0736|Participants will be orally administered 7 mg of MK-0736 once daily for 12 weeks
3272653|NCT00679055|Placebo Comparator|Placebo|Participants will be orally administered placebo once daily for 12 weeks.
3272654|NCT00679042|Experimental|A|All subjects will receive up to 3 transplantations of allogeneic human islets of Langerhans.
3272655|NCT00679029|Experimental|Arm I|See Detailed Description
3272656|NCT00679003|Experimental|1|Social learning and cognitive behavioral therapy (SLCBT)
3272657|NCT00679003|Active Comparator|2|Education and support (ES)
3272658|NCT00678990|Experimental|Open, single arm|Transplantation of islets with heparin coating.
3272659|NCT00678977|Experimental|Arm A|"Dose Escalation - Patients will be entered into dose cohorts of three patients. Each cohort will be assigned to a dose level for the duration of the study. There will be no intra-patient dose-escalation. The starting dose will be 400 mg daily of pazopanib, and 1000 mg/m2 gemcitabine. Intermediate dose levels may also be explored. Intravenous gemcitabine will be given on Day 1 and 8 of Cycle 1 and each subsequent cycle.~Cohort expansion phase - patients will receive gemcitabine alone, at the OTR dose starting on Day 1 of Cycle 1. Pazopanib will be administered at the OTR beginning on Day 2 Cycle 1 after the last blood sample for gemcitabine analysis is collected, and pazopanib administration will continue for the duration of the study. Patients will return to the clinic on Day 8 of Cycle 1 for simultaneous administration of gemcitabine and pazopanib. On Day 1 of Cycle 2 patients will receive the simultaneous administration of gemcitabine and pazopanib"
3272660|NCT00678977|Experimental|Arm B|"Dose Escalation - Patients will be entered into dose cohorts of three patients. Each cohort will be assigned to a dose level for the duration of the study. There will be no intra-patient dose-escalation. The starting dose will be 400 mg daily of pazopanib, 1000 mg/m2 gemcitabine and 60 mg/m2 cisplatin. Doses of gemcitabine may range from 600 to 1250 mg/m2. Doses of cisplatin may range from 60 to 80 mg/m2. Intermediate dose levels may also be explored. Pazopanib administered starting on Day 1 of Cycle 1, gemcitabine co-administration on Day 1 and 8, and cisplatin on Day 1 in each 21-day cycle.~Cohort expansion - patients will receive gemcitabine and cisplatin alone, at the OTR doses, starting on Day 1 of Cycle 1. Pazopanib will be administered at the OTR dose beginning on Day 2 of Cycle 1, and pazopanib administration will continue for the duration of the study. Patients will return to the clinic on Day 8 of Cycle 1 for simultaneous administration of gemcitabine and pazopanib"
3272661|NCT00678964|Experimental|A|
3272662|NCT00678964|Active Comparator|B|
3272663|NCT00678938|Experimental|1|
3272664|NCT00678938|Experimental|2|
3272665|NCT00678938|No Intervention|3|
3272666|NCT00678925|Active Comparator|1|Choline supplement given from 18-weeks pregnancy through 90 days postpartum
3272667|NCT00678925|Placebo Comparator|2|Placebo capsules given from 18 weeks pregnancy through 90 days postpartum
3272668|NCT00678912|Experimental|1|Children are mechanically ventilated with Smartcare/PS
3272669|NCT00678912|No Intervention|2|Children are mechanically ventilated with usual care
3272670|NCT00678899|Experimental|Surgery|Implantation with the Nucleus Hybrid L24 Cochlear Implant
3272671|NCT00678886|Experimental|otelixizumab|otelixizumab
3272672|NCT00678886|Placebo Comparator|placebo|Placebo
3272673|NCT00678873|Experimental|Surgical group|Patients with ultrasound proven symptomatic cholelithiasis (gallstones).
3272674|NCT00678847|Placebo Comparator|B|
3272675|NCT00678847|Active Comparator|A|
3272676|NCT00678834|Active Comparator|Arm 1|To surgery patients, Tocotrienol capsules. 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
3272677|NCT00678834|Active Comparator|Arm 2|To surgery patients, Tocopherol capsules. 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
3272678|NCT00678834|Active Comparator|Arm 3|Tocotrienol to healthy subjects - 200 mg to take orally two times a day (400 mg a day).
3272679|NCT00678821|Experimental|1|Patients with PH will be randomized to either aerobicexercise training plus education (AET) or education only (Ed-only) treatments
3272680|NCT00678821|Active Comparator|2|A comparison group of patients with ILD who do not have secondary PH (ILD- only) will also undergo the AET arm
3272681|NCT00678795|Experimental|Sativex|Each 100 ul actuation contains 27 mg delta-9-tetrahydrocannabinol (THC) and 25 mg cannabidiol (CBD). A maximum of 48 actuations (130 mg of THC and 120 mg of CBD) was permitted in any 24 hour period.
3272682|NCT00678795|Placebo Comparator|Placebo|Each 100 ul actuation contains the colorants plus excipients. A maximum of 48 actuations was permitted in any 24 hour period.
3272683|NCT00678769|Experimental|Group A (temsirolimus on days 15 and 22 course 1)|Patients receive temsirolimus IV over 30 minutes on days 15 and 22 for course 1 and on days 1, 8, 15, and 22 for all subsequent courses. Patients also receive cixutumumab IV over 60 minutes on days 1, 8, 15, and 22.
3272684|NCT00678769|Experimental|Group B (cixutumumab on days 15 and 22 of course 1)|Patients receive cixutumumab IV over 60 minutes on days 15 and 22 for course 1 and on days 1, 8, 15, and 22 for all subsequent courses. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
3272685|NCT00678769|Experimental|Group C (temsirolimus on days 1, 8, 15, and 22)|Patients receive temsirolimus IV over 30 minutes and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22.
3272686|NCT00678730|Active Comparator|1|"Very low dose (0.005 mg/kg = 0.35 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/10th of a marijuana cigarette, or joint.~Low dose (0.025 mg/kg = 1.75 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/2 of a marijuana cigarette, or joint.~Medium dose (0.05 mg/kg = 3.5 mg in a 70 kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1 marijuana cigarette, or joint."
3272687|NCT00678730|Placebo Comparator|2|small amount of ethanol, (quarter teaspoon), with no THC
3272688|NCT00678717|Active Comparator|Healthy|Healthy volunteers
3272689|NCT00678717|Experimental|Chronic Visceral Pain|Chronic Visceral Pain patients. Participants will be tested before and after implantation of a Spinal Cord Stimulator (implantation of the Spinal Cord Stimulator is done as usual care and is not a study procedure)
3272690|NCT00678704|Placebo Comparator|Arm 3|
3272693|NCT00678691|Experimental|A,1|armodafinil
3272694|NCT00678691|Placebo Comparator|A,2|placebo
3272695|NCT00678678|Active Comparator|I - Spirometer|
3272696|NCT00678678|Active Comparator|II - Kit Epap®|Device with Spring load by mask,produced by Brazil (critical med)
3272697|NCT00678652|Experimental|10 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 10 μg with Adjuvant
3272698|NCT00678652|Experimental|25 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 25 μg with Adjuvant
3272699|NCT00678652|Experimental|50 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 50 μg with Adjuvant
3272700|NCT00678652|Experimental|75 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 75 μg with Adjuvant
3272701|NCT00678639|Experimental|Emergency Department (ED) Observation unit|Emergency Department observation unit- Cardiac Magnetic Resonance Imaging (MRI) Protocol. Patients will be transferred to the observation unit and undergo a stress cardiac MRI evaluation.
3272702|NCT00678639|No Intervention|Usual care|This is the comparison arm. Patients are admitted to the hospital and undergo usual care.
3272703|NCT00678626|Experimental|Arm A|combination of CP-751,871 + docetaxel administered
3272704|NCT00678626|Active Comparator|Arm B|chemotherapy
3272705|NCT00678613|Placebo Comparator|1, Primary prophylaxis|"Patients with liver cirrhosis with ascites having ascitic fluid protein <1 gm/dl will be included in this arm.~They will be randomized between probiotics and placebo."
3272706|NCT00678613|Active Comparator|2, secondary prophylaxis|"Patients with liver cirrhosis with ascites having history of prior SBP will be included in this arm.~They will be randomized between probiotics and norfloxacin."
3272707|NCT00678600|Active Comparator|Standard (static) Computer Alerts|Participants in this arm will be assigned to standard care. Participants will be monitored for new laboratory toxicity, suboptimal follow up, and virologic failure. Provider computer alerts will be posted on the participant's electronic health record summary page.
3272708|NCT00678600|Experimental|Enhanced Computer Alerts|Participants in this arm will be assigned to the enhanced alert arm. Participants will be monitored for new laboratory toxicity, suboptimal follow up, and virologic failure. Providers will receive population and asynchronous computer alerts with improved functionality.
3272709|NCT00678587|Placebo Comparator|Placebo|placebo, once daily, oral
3272710|NCT00678587|Active Comparator|Active|75 mg, once daily, oral
3272711|NCT00678574|Experimental|Premenstrual Dysphoric Disorder (PMDD) group|PMDD group received fluoxetine 20 mg daily by mouth for 2-3 months
3272712|NCT00678574|No Intervention|Healthy controls|
3272713|NCT00678561|Experimental|2% CP-690,550 QD|
3272714|NCT00678561|Experimental|0.2% CP-690,550 QD|
3272715|NCT00678561|Experimental|0.02% CP-690,550 QD|
3272716|NCT00678561|Experimental|2% CP-690,550 BID|
3272717|NCT00678561|Experimental|0.2% CP-690,550 BID|
3272718|NCT00678561|Experimental|0.02% CP-690,550 BID|
3272719|NCT00678561|Placebo Comparator|Placebo Vehicle QD|
3272720|NCT00678561|Placebo Comparator|Placebo Vehicle BID|
3272721|NCT00678548|Experimental|guided imagery|CD
3272722|NCT00678548|Active Comparator|pain diary|Pain diary
3272723|NCT00678535|Experimental|Cetuximab plus Capecitabine plus Cisplatin|
3272724|NCT00678535|Active Comparator|Capecitabine plus Cisplatin|
3272725|NCT00678509|Experimental|A|
3272726|NCT00678496|Experimental|1|CBT software delivered in a primary care facility (n=6)
3272727|NCT00678496|Experimental|2|CBT delivered at home (n=6)
3272728|NCT00678496|Other|3|Treatment as usual (n=12)
3272729|NCT00678483|Experimental|1|10 mg
3272730|NCT00678483|Experimental|2|20 mg
3272731|NCT00678470|Experimental|Single Arm|Investigational intervention without random assignment
3272732|NCT00678457|Experimental|ondansetron/olanzapine|"ondansetron (4 μg/kg b.i.d.)~olanzapine (9 μg/kg)"
3272733|NCT00678457|Placebo Comparator|placebo|placebo
3272734|NCT00678444|No Intervention|Arm 1: Non-educational video self-cath|Randomized to not watching educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
3272735|NCT00678444|Experimental|Arm 2: Educational Video Self-cath|Randomized to watch educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
3272736|NCT00678431|Placebo Comparator|Arm 1|Liquid placebo
3272737|NCT00678431|Experimental|Arm 2|Liquid Resveratrol with Glucose, and Malate
3272738|NCT00678418|Experimental|VIVITROL® 380 mg|
3272739|NCT00678418|Placebo Comparator|Placebo|
3272740|NCT00678405|Active Comparator|WLm / WLnm|Best supportive care
3272741|NCT00678405|Experimental|FTm / FTnm|Breathlessness Intervention Service
3272742|NCT00678392|Experimental|Axitinib|
3272743|NCT00678392|Active Comparator|Sorafenib|
3272744|NCT00678379|Placebo Comparator|Normal Saline|1.5 ml injection of Normal Saline into each tonsillar fossa pre-tonsillectomy
3272745|NCT00678379|Active Comparator|Lidocaine (1%) + Bupivacaine 0.5%|Submucosal injection of 1.5 mL Lidocaine (1%) + Bupivacaine 0.5% into the tonsillar fossa, pre-tonsillectomy
3272746|NCT00678379|Experimental|Lidocaine + Bupivacaine + Clondine|Submucosal injection of 1.5 mL Lidocaine 1% + Bupivacaine 0.5% + Clondine 25mcg into the tonsillar fossa, pre-tonsillectomy
3272747|NCT00678366|Experimental|1|addition of 4% oxygen to the carbon dioxide pneumoperitoneum
3272748|NCT00678366|Active Comparator|2|pure carbon dioxide pneumoperitoneum
3272749|NCT00678353||1|Follow-up to S01-01US, conducted to expand information
3272750|NCT00678340|Active Comparator|1|WACA and PVI
3272751|NCT00678340|Active Comparator|2|PVAC
3272798|NCT00677989||OA|OA group:patients with perforated appendicitis treated by open approach
3272752|NCT00678327|Active Comparator|Arm I|Patients receive ABVD chemotherapy comprising doxorubicin hydrochloride IV, bleomycin IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3272753|NCT00678327|Active Comparator|Arm II|Patients receive AVD chemotherapy comprising doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3272754|NCT00678327|Experimental|BEACOPP-14 chemotherapy|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine hydrochloride and oral prednisolone on days 1-7; and bleomycin IV and vincristine IV on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 8-13 OR pegfilgrastim SC once on day 8. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3272755|NCT00678327|Experimental|BEACOPP-escalated chemotherapy|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine hydrochloride on days 1-7; oral prednisolone on days 1-14; and bleomycin IV and vincristine IV on day 8. Patients also receive G-CSF SC beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3272756|NCT00678314|Active Comparator|Group A|
3272757|NCT00678314|Active Comparator|Group B|
3272758|NCT00678314|Placebo Comparator|Group C|
3272759|NCT00678301|Experimental|SYNFLORIX™ + ZILBRIX™ HIB + POLIO SABIN™|Subjects in this group received 3 doses of Synflorix™ vaccine, according to a 3-dose schedule at 6-10-14 weeks of age co-administered with 3 doses of Expanded Program on Immunization (EPI) vaccines Zilbrix™ Hib and Polio Sabin™ according to the same schedule. The Synflorix™ and Zilbrix™ Hib vaccines were administered by intramuscular injection, in the right and left thigh respectively. The Polio Sabin™ vaccine was administered orally.
3272760|NCT00678301|Experimental|ZILBRIX™ HIB + POLIO SABIN™|Subjects in this group received 3 doses of Expanded Program on Immunization (EPI) vaccines Zilbrix™ Hib and Polio Sabin™ according to a 3-dose schedule at 6-10-14 weeks of age. The Zilbrix™ Hib vaccine was administered by intramuscular injection, in the left thigh. The Polio Sabin™ vaccine was administered orally.
3272761|NCT00678288|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) twice daily (bid) per os (po), continuously.
3272762|NCT00678288|Experimental|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) twice daily (bid) per os (po), continuously plus Interferon (IFN) alpha-2a 3 millions of international unit (MIU) five times a week (FIW) subcutaneous (s.c.), from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
3272763|NCT00678275|Other|A|Hematopoeitic Stem Cell Transplantation from HLA-identical sibling, RECEIVING ATG in conditioning regimen
3272764|NCT00678275|Other|B|Hematopoeitic Stem Cell Transplantation from HLA-identical sibling, NOT RECEIVING ATG in conditioning regimen
3272765|NCT00678249|Experimental|FLAIR|Primary PTA followed by placement of the FLAIR Endovascular Stent Graft
3272766|NCT00678249|Active Comparator|PTA Only|Percutaneous Transluminal Angioplasty
3272767|NCT00678249|Experimental|FLAIR Roll-in Participants|Primary Patency followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
3272768|NCT00678236|Active Comparator|1|Refobacin Bone Cement R
3272769|NCT00678236|Active Comparator|2|Refobacin Plus Bone Cement
3272770|NCT00678210|Experimental|1|
3272771|NCT00678210|Experimental|2|
3272772|NCT00678210|Experimental|3|
3272773|NCT00678210|Placebo Comparator|4|
3272774|NCT00678197|Experimental|A|
3272775|NCT00678197|Experimental|B|
3272776|NCT00678197|No Intervention|C|
3272777|NCT00678171|Experimental|OP-1 Putty|Patients randomized to the OP-1 Putty Spinal System arm will receive OP-1 Putty with AVS™TL PEEK Spacer System and XIA® Spinal System.
3272778|NCT00678171|Active Comparator|Autograft|Patients randomized to the Autograft Spinal System arm will receive iliac crest autograft with AVS™TL PEEK Spacer System and XIA® Spinal System.
3272779|NCT00678158|Experimental|1|Patients with metastatic disease to soft tissue.
3272780|NCT00678158|Experimental|2|Patients with metastatic disease to lymph nodes.
3272781|NCT00678158|Experimental|3|Patients with metastatic disease to the bone.
3272782|NCT00678145|Experimental|Healthy|Healthy individuals will receive drug (naloxone, morphine sulfate, epinephrine) and placebo comparator.
3272783|NCT00678145|Experimental|Type 1 Diabetes|T1D individuals will receive drug (naloxone, morphine sulfate, epinephrine) and placebo comparator.
3272784|NCT00678119|Experimental|1: AGS-003+sunitinib|Single arm study AGS-003 plus sunitinib
3272785|NCT00678106|Experimental|1|
3272786|NCT00678093|Experimental|SNAG|SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
3272787|NCT00678080|Experimental|Metformin|Metformin therapy
3272788|NCT00678080|Active Comparator|Insulin|Insulin
3272789|NCT00678067|Placebo Comparator|Placebo|12 hypercholesterolemic children 3-13 years of age
3272790|NCT00678067|Experimental|DHA+EPA group|12 hypercholesterolemic children 3-13 years of age
3272791|NCT00678067|Experimental|DHA Group|12 hypercholesterolemic children 3-13 years of age
3272792|NCT00678054|Experimental|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|
3272793|NCT00678041|Experimental|Arm 1: Nitrofurantoin Group|extended release nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
3272794|NCT00678041|Placebo Comparator|Arm 2: Placebo Group|identical appearing placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
3272795|NCT00678015|Experimental|1|
3272796|NCT00678002||QOL###|All child subjects in this cohort will be listed for or already have received a solid organ transplant (kidney, heart, or liver).
3272797|NCT00677989||LA|LA group: patients with perforated appendicitis treated by laparoscopic operation intentionally
3272799|NCT00677976||IBS|Children between the ages of 10 and 18 who meet Rome III criteria for IBS as determined by a pediatric gastroenterologist.
3272800|NCT00677976||Control|Healthy children between the ages of 10 and 18.
3272801|NCT00677963|Other|1|Patients with symptomatic 70-99% carotid stenosis who are operated on.
3272802|NCT00677950|Experimental|1|OP-1 Putty
3272803|NCT00677950|Active Comparator|2|Autograft
3272804|NCT00677937|Experimental|1|Intervention to include education and ongoing support
3272805|NCT00677937|No Intervention|2|Control to receive standard care
3272806|NCT00677924|Experimental|Zalutumumab 8 mg/kg|Zalutumumab in combination with Irinotecan
3272807|NCT00677924|Experimental|Zalutumumab 16 mg/kg|Zalutumumab in combination with Irinotecan
3272808|NCT00677898|Experimental|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
3272809|NCT00677898|Active Comparator|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
3272810|NCT00677872|Experimental|1|
3272811|NCT00677859|Experimental|Single dose Arm|There will be six cohorts of three patients each. Three escalating doses of MultiStem will be evaluated.
3272812|NCT00677859|Experimental|Repeat Dose Arm|There will be six cohorts of three patients each. Four dosing regimens will be evaluated,varying doses at three times weekly or five times weekly.
3272813|NCT00677846||3|Patients with symptoms of deep venous thrombosis less than for 2 weeks, with thrombus occluding without any reperfusion in color mode in the common femoral vein (CFV), the femoral vein (FV) or the popliteal vein (PV)
3272814|NCT00677833|Experimental|1|
3272815|NCT00677833|Experimental|2|
3272816|NCT00677820|Experimental|Trivalent influenza virus vaccine|Frozen trivalent vaccine containing new strains
3272817|NCT00677820|Placebo Comparator|Placebo|treatment with placebo
3272818|NCT00677807|Experimental|Indacaterol 150 µg|"Indacaterol 150 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3272819|NCT00677807|Experimental|Indacaterol 300 µg|"Indacaterol 300 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3272820|NCT00677807|Placebo Comparator|Placebo|"Placebo once-daily (o.d.) via SDDPI.~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3272821|NCT00677794|Active Comparator|1|Clear fluids only after lunch.
3272822|NCT00677794|Active Comparator|2|Two sachets of picosalax the evening prior to Video Capsule Endoscopy (VCE).
3272823|NCT00677794|Active Comparator|3|Polyethylene glycol, 2 liters the evening prior to Video Capsule Endoscopy (VCE).
3272824|NCT00677781||F64|We investigate a cohort of 20 consecutive patients undergoing hepatic or pancreatic surgery (Pilot study)
3272825|NCT00677768||Early ALS|
3272826|NCT00677768||Suspected ALS|
3272827|NCT00677768||Disease Mimics of ALS|
3272828|NCT00677768||Healthy Controls|
3272829|NCT00677755|Experimental|Mf+Ms|The women in mifepristone combined misoprostol group (Mf+Ms) received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
3272830|NCT00677755|Experimental|Ms-alone|The control group (Ms-alone) patients were only administered 0.8 mg of misoprostol orally on day 3.
3272831|NCT00677742|Experimental|1|enhanced initial supply of oral contraception
3272832|NCT00677742|Active Comparator|2|conventional initial supply of oral contraception
3272833|NCT00677729|Active Comparator|1|4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline (NaCl)
3272834|NCT00677729|Placebo Comparator|2|4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl)
3272835|NCT00677716|Experimental|131I-chTNT-1/B MAb (Cotara)|
3272836|NCT00677703|No Intervention|Standard Care|Participants will receive standard care without daily reminders.
3272837|NCT00677703|Experimental|Text Messages|Participants will receive a daily text message reminder for 6 months
3272838|NCT00677690|Active Comparator|NM+PR|Patients undergone to combination of neuromuscular stimulation and pulmonary rehabilitation (NM+PR)
3272839|NCT00677690|Placebo Comparator|SS+PR|Patients undergone to pulmonary rehabilitation
3272840|NCT00677664|Active Comparator|A|Group which received Copaxone
3272841|NCT00677664|Placebo Comparator|B|Group which received Mannitol
3272842|NCT00677651||1|Five caucasian women
3272843|NCT00677651||2|Five caucasian men
3272844|NCT00677638|Experimental|1|Embracer implantation
3272845|NCT00677625||Liver Disease (LD)|These child subjects have some form of liver disease (including those who need a liver transplant) or have already had a liver transplant.
3272846|NCT00677612|Experimental|A|
3272847|NCT00677599|Active Comparator|Intervention A|Experimental arm enriched with flavonoids
3272848|NCT00677599|Placebo Comparator|Intervention B|
3272849|NCT00677586|Experimental|1|simultaneous resection of liver metastasis and the colorectal primary tumor
3272850|NCT00677586|Active Comparator|2|staged resection of the liver metastasis and the colorectal primary tumor
3272851|NCT00677573|Active Comparator|UrFSH|
3272852|NCT00677560||1|Asthma
3272853|NCT00677560||2|COPD
3272854|NCT00677560||3|Normal subjects
3272855|NCT00677547||1|Kidney transplant recipients
3272856|NCT00677547||2|Healthy volunteers
3272857|NCT00677534|Experimental|1|Cholecalciferol (Vitamin D)
3272858|NCT00677521|Experimental|1|
3272859|NCT00677508||C FR|Children with constipation and fecal incontinence.
3272860|NCT00677508||C|Children with constipation but without fecal incontinence.
3272861|NCT00677508||P-C FR|Parents of children with constipation and/or fecal incontinence.
3272862|NCT00677495|Experimental|Gluten-free diet|Gluten-free diet
3272863|NCT00677482||1|Solid organ transplant recipients with both asymptomatic CMV viremia, and symptomatic CMV disease are eligible for inclusion in the study. THis includes liver, kidney, heart, pancreas, lung, intestinal and combined transplant recipients.
3272864|NCT00677469|Experimental|I|Cholestyramine 2g BID, Methimazole 10mg TID, and Propranolol 20mg BID
3272865|NCT00677469|Experimental|II|Cholestyramine 1g BID, Methimazole 10mg TID, and Propranolol 20mg BID
3272866|NCT00677469|Placebo Comparator|III|Placebo powder 1g BID, Methimazole 10mg TID, and Propranolol 20mg BID
3272867|NCT00677456|Active Comparator|1|Patients will receive R-Y reconstruction after total gastrectomy as intervention
3272868|NCT00677456|Active Comparator|2|Patients will receive P-Y reconstruction after total gastrectomy as intervention
3272869|NCT00677456|Active Comparator|3|Patients will receive Pouch reconstruction after total gastrectomy as intervention.
3272870|NCT00677456|Active Comparator|4|Patients will receive P-I reconstruction after total gastrectomy as intervention.
3272871|NCT00677443|Experimental|S-1 and Oxaliplatin|"S-1 and Oxaliplatin~S-1 : 80 mg/m2/day D1-14 Oxaliplatin : 130 mg/m2/day D1 Repeated every 3 weeks"
3272872|NCT00677443|Active Comparator|Capecitabine and Oxaliplatin|Capecitabine and Oxaliplatin
3272873|NCT00677430||Questionnaire + Digital Imaging|A brief questionnaire packet will be completed. Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
3272874|NCT00677404|Experimental|stem cell recipient|the patients with peripheral vascular disease who receive bone marrow derived mono nuclear cells
3272875|NCT00677391|Active Comparator|1|
3272876|NCT00677391|Placebo Comparator|2|
3272877|NCT00677378||EXPERIMENTAL|Children undergoing an endoscopy for retrosternal chest pain, epigastric pain, regurgitation, heart burn or dyspepsia.
3272878|NCT00677378||CONTROL|Children undergoing an endoscopy for reasons not stated in the experimental group condition (i.e. celiac disease, rectal bleeding, polyps, weight loss, malabsorption).
3272879|NCT00677365|Placebo Comparator|Placebo|Placebo inhaled either once or twice daily via the PARI eFlow nebulizer for 28 days
3272880|NCT00677365|Experimental|MP-376 120 mg QD|MP-376 120 mg inhaled Once Daily (QD) via the PARI eFlow nebulizer for 28 days
3272881|NCT00677365|Experimental|MP-376 240 mg QD|MP-376 240 mg inhaled QD bia the PARI eFlow nebulizer for 28 days
3272882|NCT00677365|Experimental|MP-376 240 mg BID|MP-376 240 mg inhaled twice daily (BID) via the PARI eFlow nebulizer for 28 days
3272883|NCT00677352|Experimental|1|
3272884|NCT00677352|Active Comparator|2|
3272885|NCT00677339|Active Comparator|1|Active L-arginine plus active vitamin D
3272886|NCT00677339|Active Comparator|2|Placebo L-arginine plus active Vitamin D
3272887|NCT00677339|Active Comparator|3|Active L-arginine plus placebo vitamin D
3272888|NCT00677339|Placebo Comparator|4|placebo L-arginine plus placebo vitamin D
3272889|NCT00677326|Experimental|A|Peptide administered
3272890|NCT00677313|Experimental|1|
3272891|NCT00677300|Experimental|Group A|Will receive Raltegravir (400mg twice daily) + Ritonavir-boosted (100mg once daily) Darunavir (800mg once daily)
3272892|NCT00677300|Active Comparator|Group B|Will receive Tenofovir (300mg once daily) + Emtricitabine (200mg once daily) + Ritonavir-boosted (100mg once daily) Darunavir (800mg once daily)
3272893|NCT00677287|Experimental|A|
3272894|NCT00677274|Active Comparator|1|Epidural analgesia initiated at the cervix 0cm
3272895|NCT00677274|Active Comparator|2|Epidural analgesia initiated at the cervix 0.5cm
3272896|NCT00677274|Active Comparator|3|Epidural analgesia initiated at the cervix 1.0cm
3272897|NCT00677274|Active Comparator|4|Epidural analgesia initiated at the cervix 1.5cm
3272898|NCT00677274|Active Comparator|5|Epidural analgesia initiated at the cervix 2.0cm
3272899|NCT00677274|Active Comparator|6|Epidural analgesia initiated at the cervix 3.0cm
3272900|NCT00677274|Active Comparator|7|Epidural analgesia initiated at the cervix 4.0cm
3272901|NCT00677274|Active Comparator|8|Epidural analgesia initiated at the cervix 5.0cm
3272902|NCT00677261|Experimental|1|
3272903|NCT00677261|Experimental|2|
3272904|NCT00677261|Sham Comparator|3|
3272905|NCT00677248|Placebo Comparator|1|Ezetimibe and placebo
3272906|NCT00677248|Experimental|2|Eprotirome dose 1 and ezetimibe
3272907|NCT00677248|Experimental|3|Eprotirome dose 2 and ezetimibe
3272908|NCT00677248|Experimental|4|Eprotirome dose 3 and ezetimibe
3272909|NCT00677235|Experimental|FLAIR|FLAIR Endovascular Stent Graft
3272910|NCT00677235|Active Comparator|PTA Only|Percutaneous Transluminal Angioplasty
3272911|NCT00677222|Experimental|1|Treatment arm
3272912|NCT00677222|No Intervention|2|Registry Arm -standard of care
3272913|NCT00677209|Active Comparator|A|house dust mite allergics will undergo autovaccine immunization
3272914|NCT00677196|Active Comparator|1|The LMA StoneBreakerTM
3272915|NCT00677196|Active Comparator|2|Pneumatic Lithotripsy
3272916|NCT00677183||SN###.#1|All children in this cohort will have biopsy-proven NASH.
3272917|NCT00677183||SN###.#2|This cohort will be parents (mother and father when possible) of child subjects with biopsy-proven NASH.
3272918|NCT00677170|Experimental|1|MLN4924
3272919|NCT00677144|Experimental|OS (oxalipaltin+S-1)|OS (oxaliplatin + S-1): Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
3272920|NCT00677144|Active Comparator|XELOX (oxalipaltin+capecitabine)|XELOX (oxalipaltin+capecitabine): Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
3272921|NCT00677131|Active Comparator|1|To read the package insert of the drug
3272922|NCT00677131|Active Comparator|2|To read the education information provided by the Pharmacy of NTUH
3272923|NCT00677131|Active Comparator|3|Oral education provided by the pharmacist
3272924|NCT00677118|Experimental|Concurrent and adjuvant|Concurrent chemoradiotherapy plus adjuvant chemotherapy
3272925|NCT00677118|Active Comparator|Concurrent|Concurrent chemoradiotherapy
3272926|NCT00677092|Experimental|Imatinib Mesylate (IM) Treatment|Imatinib mesylate 400 milligrams (mg) orally once daily for 4 months. Dosage was reduced to 200 mg if the participant developed gastrointestinal intolerance or alopecia.
3272927|NCT00677079|Experimental|Iniparib|Iniparib, twice weekly on Days 1 and 4 of each week during 8-week cycles
3272928|NCT00677066|Experimental|1|Children discharged home with oxygen
3272929|NCT00677066|No Intervention|2|Children remain in hospital for oxygen therapy
3272930|NCT00677053|Experimental|TAK-442 10 mg BID|Added with standard care for recurrent ischemic events.
3272931|NCT00677053|Experimental|TAK-442 20 mg BID|Added with standard care for recurrent ischemic events
3272932|NCT00677053|Experimental|TAK-442 40 mg QD|Added with standard care for recurrent ischemic events
3272933|NCT00677053|Experimental|TAK-442 40 mg BID|Added with standard care for recurrent ischemic events
3272934|NCT00677053|Experimental|TAK-442 80 mg QD|Added with standard care for recurrent ischemic events
3272935|NCT00677053|Experimental|TAK-442 80 mg BID|Added with standard care for recurrent ischemic events
3272936|NCT00677053|Experimental|TAK-442 160 mg QD|Added with standard care for recurrent ischemic events
3272937|NCT00677053|Experimental|TAK-442 120 mg BID|Added with standard care for recurrent ischemic events
3272938|NCT00677053|Placebo Comparator|Placebo|Added with standard care for recurrent ischemic events
3272939|NCT00677027|Experimental|1|
3272940|NCT00677027|Placebo Comparator|2|
3272941|NCT00677014|Active Comparator|Echo optimized AV delay|Echo optimized AV delay
3272942|NCT00677014|Active Comparator|Algorithm optimized AV delay|Algorithm optimized AV delay
3272943|NCT00677014|Active Comparator|Fixed AV Delay|Fixed AV Delay
3272944|NCT00676988||Observation|Subjects with Luminal Crohn's Disease receiving infliximab
3272945|NCT00676975|Active Comparator|Traditional Chinese Medicine|Traditional Chinese Medicine 17g herbal extract
3272946|NCT00676975|Placebo Comparator|Traditional Chinese Medicine Placebo|Placebo
3272947|NCT00676962|Experimental|Facilitation|Therapists receive assistance with adopting CBT
3272948|NCT00676949|Experimental|1|cyclophosphamide dose escalation, level 1:150mg/m2,level 2: 300mg/m2, level 3: 300mg/m2x2, with 5 kinds o tumor specific antigen peptides followed by low dose IL-2, 6 patients will be enrolled for each level.
3272949|NCT00676936|Experimental|Methylprednisolone|Methylprednisolone 16 mg twice daily
3272950|NCT00676936|Placebo Comparator|Placebo|Placebo capsules twice daily
3272951|NCT00676897|Experimental|1|Simvastatin 40 mg PO or NGT
3272952|NCT00676897|Placebo Comparator|2|Placebo
3272953|NCT00676884|Experimental|1|Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)
3272954|NCT00676884|Placebo Comparator|2|placebo control
3272955|NCT00676871|Experimental|1|MEDI-538
3272956|NCT00676871|Experimental|2|MEDI-538
3272957|NCT00676871|Experimental|3|MEDI-538
3272958|NCT00676871|Experimental|4|MEDI-538
3272959|NCT00676871|Experimental|5|MEDI-538
3272960|NCT00676871|Experimental|6|MEDI-538
3272961|NCT00676871|Experimental|7|MEDI-538
3272962|NCT00676845|Placebo Comparator|1|A 3-week placebo run-in period.
3272963|NCT00676845|Experimental|2|Olmesartan medoxomil oral tablets, at lowest study dosage for 52-week double-blind treatment period
3272964|NCT00676845|Experimental|3|Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 48 weeks.
3272965|NCT00676845|Experimental|4|Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 4 weeks followed by the highest study dose for 44 weeks.
3272966|NCT00676832|Placebo Comparator|Group 1|
3272967|NCT00676832|Experimental|Group 2|
3272968|NCT00676832|Experimental|Group 3|
3272969|NCT00676832|Experimental|Group 4|
3272970|NCT00676832|Experimental|Group 5|
3272971|NCT00676806|Experimental|Myeloablative conditioning|Umbilical cord blood for hematopoietic rescue following myeloablative conditioning
3272972|NCT00676806|Experimental|Reduced intensity conditioning|Umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
3272973|NCT00676793|Experimental|Polyphenon E|This is a single arm study comparing changes within patients before and after receiving the experimental drug Polyphenon E for the duration of the study, between recruitment and surgery for breast cancer.
3272974|NCT00676780|Experimental|ECGC Extract|Single arm for a phase II study
3272975|NCT00676767|Experimental|1|
3272976|NCT00676767|Active Comparator|2|
3272977|NCT00676767|Placebo Comparator|3|
3272978|NCT00676741||A|
3272979|NCT00676741||B|
3272980|NCT00676741||C|
3272981|NCT00676728|Experimental|JNJ-26481585|
3272982|NCT00676715|Placebo Comparator|Placebo|Participants received two intravenous (IV) infusions of matching placebo separated by 14 days in Cycle 1, followed by two infusions of ocrelizumab 300 mg separated by 14 days in cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4. Each cycle was of 168 days.
3272983|NCT00676715|Experimental|Ocrelizumab 600 mg|Participants two IV infusions of ocrelizumab 300 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 600 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
3272984|NCT00676715|Experimental|Ocrelizumab 1000 mg|Participants received two IV infusions of ocrelizumab 1000 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 1000 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 1000 mg was administered on Day 1 of Cycle 3 and a single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycle 4. Each cycle was of 168 days.
3272985|NCT00676715|Active Comparator|Avonex|Participants received weekly intramuscular injections of Avonex 30 microgram (mcg) in Cycle 1, followed by two infusions of OCR 300 mg separated by 14 days in Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
3272986|NCT00676702|Experimental|001|Pancrelipase in combination with Ensure Plus 3 pancrelipase MT 21 capsules containing a total of 63 000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
3272987|NCT00676702|Active Comparator|002|Ensure Plus A high-fat liquid meal of 500 ml of Ensure Plus
3272988|NCT00676689|Experimental|SAPIEN THV|
3272989|NCT00676676|Active Comparator|Testosterone|Testosterone patch delivering 300mcg daily for 8-weeks.
3272990|NCT00676663|Experimental|1|exemestane (Aromasin) 25mg daily plus entinostat 5mg PO once/week
3272991|NCT00676663|Placebo Comparator|2|exemestane (Aromasin) 25mg daily plus placebo PO once/week
3272992|NCT00676650|Experimental|A|Treatment Arm A - sunitinib + prednisone
3272993|NCT00676650|Placebo Comparator|B|Treatment Arm B - placebo + prednisone
3272994|NCT00676637||Travalert with DuoTrav|One drop in study eye(s) once daily in the evening for four months
3272995|NCT00676624||Uveitis|Patients suffering from uveitis, who have vitrectomy performed for diagnostic purpose
3272996|NCT00676624||Control group|"Patients suffering from either Epiretinal fibrosis og Macula hole who have vitrectomy performed for curative reasons"
3272997|NCT00676585|Placebo Comparator|2|Normal Saline
3272998|NCT00676585|Experimental|1|Hydrocortisone 100mg every 8 hours.
3272999|NCT00676572||Severe asthma|
3273000|NCT00676572||Non-severe asthma|
3273001|NCT00676559|Experimental|Group 1|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
3273002|NCT00676559|Experimental|Group 2|Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
3273003|NCT00676559|Experimental|Group 3|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks in combination with ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
3273004|NCT00676533|Experimental|Arm 1|
3273005|NCT00676520||1|Single-arm study
3273006|NCT00676507|Experimental|Treatment|Treatment Arm: This course of therapy is Best Support Care (BSC) plus monthly intradermal (ID) injections of Lucanix™ (belagenpumatucel-L) consisting of 25,000,000 cells in a volume of 0.40 mL.
3273007|NCT00676507|Placebo Comparator|Control Arm|Control Arm: This course of therapy is Best Support Care (BSC) plus a placebo injection that consists of 0.15% Intralipid® in solution composed of the cryopreservation formulation minus the gene modified cells and dimethyl sulfoxide (DMSO) in a volume of 0.40 mL.
3273008|NCT00676481|Active Comparator|1|Phase III participants who are educated about risk of HIV infection before receiving a rapid HIV test
3273009|NCT00676481|No Intervention|2|Phase III participants who are not educated about risk of HIV infection before receiving a rapid HIV test
3273010|NCT00676468|Other|1|Active Montelukast + Fish Oil Placebo
3273011|NCT00676468|Other|2|Active Fish Oil + Montelukast Placebo
3273012|NCT00676468|Other|3|Active Montelukast + Active Fish Oil
3273013|NCT00676442|Other|1|PN400 administered after meal
3273014|NCT00676442|Other|2|PN400 administered prior to meal
3273015|NCT00676442|Other|3|PN400 administered prior to meal
3273016|NCT00676442|Other|4|PN400 followed by fast
3273017|NCT00676429|Experimental|1|Ziprasidone Hydrochloride oral solution with individual titration from 5 mg to 40 mg per day
3273018|NCT00676429|Placebo Comparator|2|Placebo oral solution
3273019|NCT00676416||1|Propofol general anesthesia for asthmatic patients
3273020|NCT00676416||2|Propofol general anesthesia for non-asthmatic patients
3273021|NCT00676403|Placebo Comparator|1|Placebo
3273022|NCT00676403|Experimental|2|investigational treatment
3273023|NCT00676403|Experimental|3|investigational treatment
3273024|NCT00676403|Experimental|4|investigational treatment
3273025|NCT00676403|Experimental|5|investigational treatment
3273026|NCT00676403|Experimental|6|investigational treatment
3273027|NCT00676390|Other|1|Congestive Heart failure patients
3273028|NCT00676377|Experimental|1|Neostigmine
3273029|NCT00676377|Placebo Comparator|2|Placebo
3273030|NCT00676364|Active Comparator|4% lidocaine topical anesthetic cream|This group received topical 4% lidocaine anesthetic cream under occlusive dressing for 15 minutes prior to needle stick.
3273031|NCT00676364|Placebo Comparator|Placebo|This group received matching placebo cream under occlusive dressing for 15 minutes prior to needle stick.
3273032|NCT00676351|Other|A|body plethysmography Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
3273033|NCT00676338|Experimental|Exenatide Once Weekly|
3273034|NCT00676338|Active Comparator|Metformin|
3273035|NCT00676338|Active Comparator|Sitagliptin|
3273036|NCT00676338|Active Comparator|Pioglitazone|
3273037|NCT00676325|Active Comparator|1|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction were eligible for participation.traditional colporrhaphy in this group.
3273038|NCT00676325|Active Comparator|2|The NAZCA TC™ POP REPAIR SYSTEM (polypropylene mesh repair),promedon™ , cordoba, argentina, is used to repair anterior vaginal prolapse by a transobturator and pre pubic approach . Helical needles are used to anchor graft to the pelvic sidewall at two points transobturator, the other two arms pre pubic needles is used. We designed this randomized control trial to compare the anatomic success rates, effect on quality of life and sexual symptom scores, and rates of adverse events of the procedure with polypropylene mesh with that of anterior colporrhaphy, with planned follow-up of 1 years.
3273039|NCT00676312|Experimental|1|Cross-over treatment with increasing doses of PTH134, placebo and active comparator.
3273040|NCT00676273|Active Comparator|1|TVTO
3273041|NCT00676273|Active Comparator|2|TVTS
3273042|NCT00676260|Experimental|Pioglitazone QD|
3273043|NCT00676260|Placebo Comparator|Placebo QD|
3273044|NCT00676247||preterm|Very-low-birth-weight preterm infants with brain lesion
3273045|NCT00676247||full-term|Healthy fullterm infants
3273046|NCT00676234|No Intervention|1|
3273047|NCT00676234|Experimental|2|Administration of intravenous rhu Epo on Day 0
3273048|NCT00676208|Experimental|Shared Medical Appointments|Medical students participated in shared medical appointments for patients with diabetes for one month.
3273049|NCT00676208|No Intervention|No shared medical appointments|Medical students in this arm did not participate in shared medical appointments.
3273050|NCT00676195|Experimental|N-Acetyl Cysteine|"Dosage of orally administered N-Acetyl Cysteine is as follows:~Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day"
3273051|NCT00676182||Arm 1: Telerehabilitation|telerehabilitation
3273052|NCT00676169||Observational|Pa negative or concurrently enrolled in the EPIC Clinical Trial
3273053|NCT00676156|Active Comparator|A|This arm involves a 1-day pharmacokinetics study of three different formulations of oral lipoic acid.
3273054|NCT00676156|Active Comparator|B|This arm will examine the pharmacokinetics of LA with and without fish oil supplement in a cross over design.
3273055|NCT00676156|Active Comparator|C|This arm will include the study of a single dose of R enantiomer lipoic acid.
3273056|NCT00676143|Experimental|Bapineuzumab 0.5 mg/kg|
3273057|NCT00676143|Placebo Comparator|Placebo|
3273058|NCT00676130|Active Comparator|Standard therapy|cephalexin plus placebo
3273059|NCT00676130|Experimental|Standard plus anti-CA-MRSA|cephalexin plus trimethoprim-sulfamethoxazole
3273060|NCT00676117|Experimental|1|
3273061|NCT00676117|Active Comparator|2|
3273062|NCT00676104|Experimental|Treatment|
3273063|NCT00676104|Sham Comparator|Control|
3273064|NCT00676091|Experimental|13vPnC|13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).
3273065|NCT00676091|Active Comparator|7vPnC|7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).
3273066|NCT00676065||1|Women who take oral contraceptives containing drospirenone
3273067|NCT00676065||2|Women who take oral contraceptives containing levonorgestrel
3273068|NCT00676065||3|Women who take oral contraceptives containing other progestogens
3273069|NCT00676052|Experimental|Arm 1|GSK233705 12.5mcg
3273070|NCT00676052|Experimental|Arm 2|GSK233705 25mcg
3273071|NCT00676052|Experimental|Arm 3|GSK233705 50mcg
3273072|NCT00676052|Experimental|Arm 4|GSK233705 100mcg
3273073|NCT00676052|Experimental|Arm 5|GSK233705 200mcg
3273074|NCT00676052|Placebo Comparator|Arm 6|Placebo
3273075|NCT00676039|Active Comparator|1|"Crossover Effexor / NOVO-Venlafaxine~Examination of the bioequivalence of Effexor (Wyeth Pharmaceuticals) and NOVO-Venlafaxine (NOVOPHARM).~Both drugs will be given at the dose of 75 mg/day (one capsule per day) for 4 consecutive days. A washout period (corresponding to 10 half-life of the active metabolite desmethylvenlafaxine) will be respected after receiving each medication."
3273076|NCT00676039|Active Comparator|2|"Crossover Celexa/Gen-citalopram~Examination of the bioequivalence of Celexa (Lundbeck, Brand Name) and Gen-Citalopram (Genpharm, Generic). Both drugs will be given at the dose of 40 mg/day (one tablet per day) for 8 consecutive days. A washout period (corresponding to 10 half-life of citalopram) will be respected after receiving each medication."
3273077|NCT00676026|Experimental|Zolpidem 1|Zolpidem will be administered twice to each participant; once in the follicular and luteal phases of the menstrual cycle.
3273078|NCT00676026|Experimental|Progesterone 2|Progesterone will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.
3273079|NCT00676026|Experimental|Fluoxetine 3|Fluoxetine will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.
3273080|NCT00676013|Experimental|1|Use of AlloDerm with grafting
3273081|NCT00676013|Experimental|2|Use of Integra with grafting
3273082|NCT00676013|Experimental|3|Use of homograft with grafting
3273083|NCT00676013|Active Comparator|4|Use of autograft only for grafting
3273084|NCT00676000|Active Comparator|1|Interrupted vaginal closure
3273085|NCT00676000|Active Comparator|2|Continuous vaginal closure
3273086|NCT00675987|Active Comparator|Losartan|Losartan 100 mg 1 tab po QD
3273087|NCT00675987|Placebo Comparator|2|Placebo 1 tab po QD
3273088|NCT00675974|Experimental|1|Pressure garment therapy
3273089|NCT00675974|No Intervention|2|No pressure garment therapy
3273090|NCT00675961|Experimental|1|Behavioral Counseling Intervention (BCI) plus treatment as usual (TAU) (i.e. standard referral to and management by an addictions specialist)
3273091|NCT00675961|Experimental|2|Naltrexone/ Brief Behavioral Compliance Enhancement Treatment (BBCET) plus TAU
3273092|NCT00675961|Experimental|3|BCI + Naltrexone/BBCET plus TAU
3273093|NCT00675961|Active Comparator|4|Treatment as Usual (TAU)
3273094|NCT00675948|Experimental|Sativex|Active treatment
3273095|NCT00675948|Experimental|GW-2000-02|Active treatment
3273096|NCT00675935|Experimental|1|One high-risk medical unit at each hospital will be randomly assigned to receive the fall prevention toolkit
3273097|NCT00675935|No Intervention|2|One high-risk medical unit at each hospital will be randomly assigned to receive usual care as it relates to fall prevention; i.e., receives no intervention.
3273098|NCT00675922|Experimental|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon 5% Solution and Silver Nitrate soaked dressings to two different burned area. Sites were then monitored for infections during hospitalization.
3273099|NCT00675909|Active Comparator|Oral Midazolam|Oral midazolam 0.5mg/kg
3273100|NCT00675909|Experimental|Aerosolized intranasal midazolam|Intranasal midazolam 0.3mg/kg
3273101|NCT00675909|Experimental|Aerosolized buccal midazolam|Buccal midazolam 0.3mg/kg
3273102|NCT00675896|Experimental|1|Quetiapine Fumarate Sustained Release(Seroquel SR)50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator, using patient tolerance and response as guidelines over the duration of the trial.
3273103|NCT00675896|Placebo Comparator|2|Placebo
3273104|NCT00675883||Prospective|500 patients who will be enrolled in the MS Alliance program will be consented to participate in this study.
3273105|NCT00675883||Retrospective|500 patient chart reviews will be completed for patients who were enrolled in the MS Alliance program between two (2) to three (3) years ago.
3273106|NCT00675870|Experimental|1|
3273109|NCT00675844|Experimental|elvucitabine|Subjects currently receiving elvucitabine will continue elvucitabine as part of their ART regimen for an additional 48 months.
3273110|NCT00675831|Experimental|CD25+ Treg depleted DLI dose schema|"Patients will receive a defined dose of CD25+ Treg depleted DLI. 5 patients will be enrolled, initially at dose level B, and subsequent cohorts will be dose adjusted per the CD3+ dose escalation/de-escalation schema:~Dose level -C: 3x10^7 (CD3+Dose (#cells/kg*))~Dose level -B: 1x10^7 (CD3+Dose (#cells/kg*))~Dose level -A: 1x10^6 (CD3+Dose (#cells/kg*)) *Recipient's body weight in Kg"
3273111|NCT00675818|Experimental|1|CVVH: Patients in this arm will receive CVVH at a replacement fluid rate of 35 mL/kg/h.
3273112|NCT00675818|Active Comparator|2|CVVHD: Patients in this arm will receive CVVHD at a dialysate flow rate of 35 mL/kg/h.
3273113|NCT00675805|Active Comparator|Group I|IVIG infusion with filter
3273114|NCT00675805|Placebo Comparator|Group II|IVIG infusion without filter
3273115|NCT00675792|Experimental|Sugammadex|4 mg/kg sugammadex
3273116|NCT00675792|Active Comparator|Neostigmine|50 µg/kg neostigmine
3273117|NCT00675779|Experimental|2|oral contraceptive + atorvastatin
3273118|NCT00675779|Active Comparator|1|oral contraceptive
3273119|NCT00675766||Group 1|HIV-positive adults 50 and older/ HIV-positive adults 18-40 years old
3273120|NCT00675766||Group 2|HIV-negative controls 50 and older / HIV-negative controls 18-40 years old
3273121|NCT00675766||Group 3|HIV-negative controls 50 and older / HIV-negative controls 18-40 years old
3273122|NCT00675766||Group 4|HIV-negative controls 18-40 years old
3273123|NCT00675753||Preterm group|Preterm (36 6/7 weeks gestation or earlier) mothers and their newborns.
3273124|NCT00675753||Term group|Term (> 37 weeks gestation) mothers and their newborns.
3273125|NCT00675740|Experimental|1|
3273126|NCT00675740|Active Comparator|2|physical exercise
3273127|NCT00675740|No Intervention|3|control
3273128|NCT00675714|Experimental|1|Humatrope subcutaneous(SQ) 0.05-0.2 mg/kg/day for up to 2 years post burn
3273129|NCT00675714|Experimental|2|Ketoconazole by mouth (PO) given twice a day throughout hospitalization for up to 2 years post burn
3273130|NCT00675714|Experimental|3|Oxandrolone PO given daily throughout hospitalization for up to 2 years post burn
3273131|NCT00675714|Experimental|4|Propranolol PO given daily throughout hospitalization for up to 2 years post burn
3273132|NCT00675714|Experimental|5|Oxandrolone and propranolol PO to be given daily for up to 2 years post burn
3273133|NCT00675714|Experimental|6|Humatrope SQ and Propranolol PO to be given daily for up to 2 years post burn
3273134|NCT00675714|Placebo Comparator|7|Placebo PO to be given for up to 2 years post burn
3273135|NCT00675714|Experimental|8|Exercise--hospital supervised intensive exercise program
3273136|NCT00675714|Experimental|9|Exercise--home or community based exercise program
3273137|NCT00675701|Placebo Comparator|A|Placebo by mouth
3273138|NCT00675701|Experimental|B|lixivaptan
3273139|NCT00675701|Active Comparator|C|moxifloxacin
3273140|NCT00675688|Experimental|A|
3273141|NCT00675688|Active Comparator|B|
3273142|NCT00675688|Placebo Comparator|C|
3273143|NCT00675675|Active Comparator|Comprehensive Behavioral Intervention for Tics (CBIT)|Habit Reversal Training (HRT) plus functional assessment/intervention designed to identify and ameliorate environmental triggers for and consequences to tics that might serve to maintain and/or generalize these symptoms
3273144|NCT00675675|Other|Minimal Contact Waitlist|Bimonthly phone check-in to assess illness severity and maximize subject retention
3273145|NCT00675662|Experimental|1|Stratification by angiotensin converting enzyme (ACE) genotype
3273146|NCT00675662|Placebo Comparator|2|Waiting list controls
3273147|NCT00675649|Experimental|001|
3273148|NCT00675649|Placebo Comparator|002|
3273149|NCT00675623|Experimental|A|Dimebon, 5 mg orally three times daily
3273150|NCT00675623|Experimental|B|Dimebon 20 mg orally three times daily
3273151|NCT00675623|Placebo Comparator|C|Placebo orally three times daily for six months
3273152|NCT00675610|No Intervention|usual care|providers are not trained and patients are not coached
3273153|NCT00675610|Experimental|intervention arm|providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
3273154|NCT00675597|Experimental|1|Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients with Resected Stage I-III Non-small Cell Lung Cancer
3273155|NCT00675584|Active Comparator|Placebo Budesonide|Participants will receive 0.5 mg of ICS (budesonide as Pulmicort Respules®) once a day at night, except during respiratory tract illnesses. During respiratory tract illnesses, participants will receive placebo each morning and 0.5 mg of budesonide each night for 7 days.
3273156|NCT00675584|Experimental|Budesonide|Participants will receive 1 mg of ICS (budesonide as Pulmicort Respules®) twice a day for 7 days at the onset of a respiratory tract illness; they will receive placebo ICS once a day at all other times during the study.
3273157|NCT00675558||Non-Obese (NO)|Patients with a BMI < 29.9 scheduled for clinically indicated laparoscopic abdominal surgery.
3273158|NCT00675558||Morbidly Obese (MO)|Patients with a BMI > 40.0 scheduled for clinically indicated laparoscopic abdominal surgery.
3273159|NCT00675558||Super-morbidly Obese (SMO)|"Patients with a BMI > 50.0 scheduled for clinically indicated laparoscopic abdominal surgery.~10 subjects of the original 30 subjects enrolled into this group received a second bariatric procedure. The remaining 20 subjects of the original 30 subjects did not continue on to the second phase (second bariatric surgery) of the study."
3273160|NCT00675545|Experimental|docetaxel and prednisolone|"Patients in study will receive both chemotherapeutic agents on day 1 and day 8 of every 21-day cycle as described below:~Docetaxel 30 mg/m2 over 1 hour IV infusion, followed by~Carboplatin (AUC 2) over 1 hour IV infusion~Additonal medication required: IV Dexamethasone 10 mg followed by PO dexamethasone 4 mg 8 hourly x 4 doses, starting 12 hours after starting iv docetaxel."
3273161|NCT00675532|Experimental|1|Primary Care Counseling
3273162|NCT00675532|Experimental|2|Cognitive-behavioral psychotherapy (CBT)
3273163|NCT00675519|Experimental|BI|
3273914|NCT00670059|Active Comparator|A|group: single embryo transfer without aneuploidy screening
3273164|NCT00675506|Experimental|1|Participants will receive treatment with growth hormone releasing hormone 1-44 (TH9507).
3273165|NCT00675506|Placebo Comparator|2|Participants will receive treatment with placebo medication.
3273166|NCT00675493||A|
3273167|NCT00675480|Experimental|T|Patients treated with thrombectomy: T
3273168|NCT00675480|Active Comparator|P|Patients treated with standard PCI with stent implantation
3273169|NCT00675467||Group 1|Early cancer group-children ages 10-13 years
3273170|NCT00675467||Group 2|Early cancer group-children ages 14 to 18 years
3273171|NCT00675467||Group 3|Early cancer group-parents of patients ages 10-18 years
3273172|NCT00675467||Group 4|Advanced cancer group-children ages 10-13 years
3273173|NCT00675467||Group 5|Advanced cancer group-children ages 14-18 years
3273174|NCT00675467||Group 6|Advanced cancer group-parents of children ages 10-18 years
3273175|NCT00675467||Group 7|End of life group - parents of children ages birth to 18 years of age at time of death
3273176|NCT00675441|Experimental|Lenalidomide|Lenalidomide 10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
3273177|NCT00675428|Experimental|Natalizumab 300 mg|Intravenous (IV) infusions of natalizumab 300 mg once every 28 days for 6 months.
3273178|NCT00675428|Experimental|Natalizumab 450 mg|Intravenous (IV) infusions of natalizumab 450 mg once every 28 days for 6 months.
3273179|NCT00675415|Active Comparator|Capnography|"Capnography: Subjects randomized to capnography-titration arm: The endoscopy team would be made aware of the capnographic abnormalities as they arise.~In this arm, the endoscopy team will have the graphic representation of respiratory activity (capnography) as well as end-epxiratory levels of carbon dioxide in addition to the normal physiologic monitoring portfolio of pulse oximetry, blood pressure and electrocradiography.~This observation phase would take place for a baseline prior to sedation, during the administration of sedation as well as throughout the procedure. Monitoring for the study would stop upon completion of the endoscopic procedure."
3273180|NCT00675415|No Intervention|Standard Monitoring|Subjects randomized to capnography-blinded arm: In this arm, the endoscopy team will not have the graphic representation of respiratory activity (capnography) as well as end-expiratory levels of carbon dioxide available. Only a standard of care physiologic monitoring portfolio of pulse oximetry, blood pressure and electrocradiography at the disposal of the endoscopy team to titrate the sedative medications.
3273181|NCT00675402||1|Patients referred to the vascularsurgeon with complaints of claudication for their first time, will be asked to participate with the study, with respect toward the in- and exclusion criteria.
3273182|NCT00675389|Experimental|A|Peer Health Workers Intervention
3273183|NCT00675389|Experimental|B|Peer Health Workers and Mobile Phone Intervention
3273184|NCT00675389|No Intervention|C|Control
3273185|NCT00675363|Active Comparator|PS|Nurse-directed protocols for administering sedation and/or analgesia by continuous infusion.
3273186|NCT00675363|Active Comparator|PS + DI|Nurse-directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
3273187|NCT00675350|Experimental|Homoharringtonine|
3273188|NCT00675337|Active Comparator|perineum|infants maintained at the level of the perineum until umbilical cord clamping
3273189|NCT00675337|Experimental|abdomen|infants placed on the maternal abdomen prior to cord clamping
3273190|NCT00675324|Active Comparator|A|Traditional bowel preparation with Laxabon
3273191|NCT00675324|Active Comparator|B|Bowel preparation with nutritional drinks
3273192|NCT00675311|Active Comparator|DM-Standard|The conventional disease management group will receive management under the site's usual program offering, which includes, but is not limited to, compliance with the prescribed treatment regimens, dietary management, exercise programs, and other measures recommended by the American Diabetes Association (ADA) and the Association of American Endocrinologists (AACE).
3273193|NCT00675311|Active Comparator|DM-Plus|Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology that includes mobile phone client software with web-based companion software, Bluetooth glucose meter cradle, and web-based clinical management software for the clinical management team. The core of the system is the patient's cell phone which is used as an input device and which enables patients to maintain an electronic diary of information such as meal times, blood glucose, insulin use, weight, blood pressure, and exercise. The device is customizable to collect only the information relevant to the patient with diabetes and their healthcare provider. The patient with diabetes enters diary information on his or her mobile phone. No immediate or real-time information is provided to patients as part of this study.
3273194|NCT00675298||1|Men with chronic prostatitis/chronic pelvic pain syndrome
3273195|NCT00675298||2|Women with painful bladder syndrome/interstitial cystitis
3273196|NCT00675298||3|Children with overactive bladder
3273197|NCT00675298||4|Bulgarian cohort with chronic prostatitis/chronic pelvic pain syndrome, painful bladder syndrome/interstitial cystitis and children with overactive bladder
3273198|NCT00675298||5|Asymptomatic healthy controls
3273199|NCT00675285|Active Comparator|1|
3273200|NCT00675285|Placebo Comparator|2|
3273201|NCT00675272|Active Comparator|1|hydrocortisone treatment 50mg iv x4
3273202|NCT00675272|Placebo Comparator|2|Placebo iv every 6 hours
3273203|NCT00675259|Experimental|Neoadjuvant, Surgery, Adjuvant|Neoadjuvant chemotherapy : Nab-paclitaxel and carboplatin on days 1, 8, and 15 in combination with bevacizumab on days 1 and 15 administered every 28 days for 5 cycles followed by 1 cycle with Nab-paclitaxel and carboplatin on days 1, 8, and 15. Definitive surgery with either lumpectomy or mastectomy along with axillary lymph node dissection for all pre neo adjuvant chemotherapy node-positive patients approximately 4-5 weeks after the completion of NCT. Use of additional adjuvant chemotherapy and/or radiation therapy depends upon the treating physicians' judgment. Radiation therapy should begin no sooner than 6 weeks after breast cancer surgery. All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
3273204|NCT00675246|Experimental|A|Antenatal corticoid therapy
3273338|NCT00674180||3|a workbook, the addition of computerized tailoring using onsite computer kiosks with touch screen monitors, and staff consultations.
3273205|NCT00675233|Experimental|Treatment PDT|Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light to the tumor on day 2. At least 6 weeks later, patients achieving partial response, no response, or a geographical miss may undergo a second course of treatment.
3273206|NCT00675220||A|
3273207|NCT00675207|Active Comparator|1|Brimonidine purite 0.15%
3273208|NCT00675207|Active Comparator|2|Dorzolamide 2%
3273209|NCT00675207|Active Comparator|3|Brinzolamide 1%
3273210|NCT00675181|Active Comparator|A, 1|A, 1 = Melatonin
3273211|NCT00675181|Placebo Comparator|A, 2|A,2 = Placebo
3273212|NCT00675155|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
3273213|NCT00675142|Experimental|1|IUI 36 hours after ovulation induction
3273214|NCT00675142|Experimental|2|IUI 42 hours after ovulation induction
3273215|NCT00675142|Experimental|3|IUI 48 hours after ovulation induction
3273216|NCT00675129|Experimental|1|Dialectical behavioral therapy
3273217|NCT00675129|Active Comparator|2|Enhanced Usual Care (standard care plus monitoring and patient safety protocol implemented)
3273218|NCT00675103|Experimental|pegloticase|
3273219|NCT00675090|Experimental|GSK239512|GSK239512 oral tablets
3273220|NCT00675090|Placebo Comparator|Placebo|Placebo to match tablets
3273221|NCT00675077|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
3273222|NCT00675064|Experimental|Anti-malarial experimental drug|After randomization subjects will receive either 5, 25, 100, 250, 500, 1000, 2000 and 3000 mg of GSK3697969 orally . GSK3697969 will be available as 5, 25 and 250 mg capsules.
3273223|NCT00675064|Active Comparator|Matching placebo|After randomization subjects will receive matching placebo of GSK3697969.
3273224|NCT00675038||1|Study participants will be patients who are cared for by the St. Jude Hematology Division and have developed iron overload and require liver biopsy.
3273225|NCT00675025|Experimental|1|
3273226|NCT00675012|Experimental|A|
3273227|NCT00674999|Experimental|1|Amnion with processing procedures involving the use of trypsin-Edetic Acid(EDTA)
3273228|NCT00674999|Experimental|2|Amnion with processing procedures involving the use of Dispase II
3273229|NCT00674999|Active Comparator|3|Prepared Antibiotic ointment Polysporin, Bacitracin and Mycostatin
3273230|NCT00674986|Other|Active Control Group (ACG)|Participants in the Active Control Group received enhanced standard of care (more frequent clinic visits, free blood glucose meters and strips and point-of-care Hemoglobin A1c (HbA1c) test) for management of their Type 2 diabetes.
3273231|NCT00674986|Experimental|Structured Testing Group (STG)|Participants in the Structured Testing Group in addition to enhanced standard of care for the treatment of their Type 2 diabetes used the ACCU-CHEK® 360° View blood glucose analysis system (Tool) to monitor glucose levels at least quarterly.
3273232|NCT00674973|Experimental|Erlotinib|Participants with advanced pancreatic carcinoma with Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received erlotinib 150 mg orally once daily until disease progression, unacceptable toxicity, withdrawal, or death.
3273233|NCT00674973|Placebo Comparator|Placebo|Participants with advanced pancreatic carcinoma with ECOG PS score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received placebo matching to erlotinib 150 mg tablet orally once daily until disease progression, unacceptable toxicity, withdrawal, or death.
3273234|NCT00674960|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
3273235|NCT00674934|Experimental|1|Radiation
3273236|NCT00674921|Placebo Comparator|1|It will comprise patients randomized to receive the placebo (stop cotrimoxazole prophylaxis) at CD4 counts of 200 or more but less than 350 cells/ul as they continue with HAART. Patients will be followed until they achieve a CD4 count of 350 cells/ul.
3273237|NCT00674921|Active Comparator|2|It will comprise patients randomized to continue with cotrimoxazole prophylaxis and HAART at CD4 counts of 200 or more but less than 350 cells/ul. These patients will be followed until they achieve a CD4 count of 350 cells/ul and above, at which point they will be considered for the second randomization.
3273238|NCT00674921|Placebo Comparator|A|This arm will comprise patients who have achieved a CD4 count of 350 or more cells/ul either at the beginning of the study or once they have reached this threshold at the end of follow up in arms 1 and 2. They (including those previously in Arm 1) will receive the placebo (stop cotrimoxazole prophylaxis) after the second randomization but continue with HAART.
3273239|NCT00674921|Active Comparator|B|It will comprise patients randomized to continue or start with cotrimoxazole prophylaxis and HAART at CD4 of 350 or more cells/ul after second randomization. Some of them will have used cotrimoxazole prophylaxis whilst they were in arm 2 and others in arm 1 will restart cotrimoxazole prophylaxis at this stage.
3273240|NCT00674908|Experimental|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
3273241|NCT00674908|Active Comparator|Easy 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
3273242|NCT00674895|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
3273243|NCT00674882||Participants|Data Collection
3273244|NCT00674869|Experimental|1|pit and fissure sealant on one randomized tooth by pair of permanent molar
3273245|NCT00674869|No Intervention|2|No intervention
3273246|NCT00674856|Experimental|naproxcinod|naproxcinod 750mg(375mg caps x2), administered twice a day.
3273247|NCT00674843|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
3273248|NCT00674830|Experimental|1|professionally administered cognitive-behavioral therapy
3273249|NCT00674830|Experimental|2|self-administered form of cognitive behavioral therapy
3273250|NCT00674830|Placebo Comparator|3|usual care
3273251|NCT00674817|Experimental|400 microgrammes GSK961081 and salbutamol|400 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3x 200 microgrammes at 20 min intervals, administered via spacer) of salbutamol at 1h, 12h and 24h of dosing.
3273683|NCT00671814|Active Comparator|3|Oral doses of 600mg linezolid given twice daily for 21 days.
3273252|NCT00674817|Experimental|1200 microgrammes GSK961081 and salbutamol|1200 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (3x 200 microgrammes at 20 min intervals, administered via spacer) of salbutamol at 1h, 12h and 24h of dosing.
3273253|NCT00674817|Experimental|400 microgrammes GSK961081 and ipratropium bromide|400 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (20 microgrammes, 20 microgrammes and 40 microgrammes at 20 min intervals, administered via spacer) of ipratropium bromide at 1h, 12h and 24h of dosing.
3273254|NCT00674817|Experimental|1200 microgrammes of GSK961081 and ipratropium bromide|1200 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (20 microgrammes, 20 microgrammes and 40 microgrammes at 20 min intervals, administered via spacer) of ipratropium bromide at 1h, 12h and 24h of dosing.
3273255|NCT00674817|Placebo Comparator|400 microgrammes of GSK961081 and placebo|400 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3 doses at 20 min intervals, administered via spacer) of placebo at 1h, 12h and 24h of dosing.
3273256|NCT00674817|Placebo Comparator|1200 microgrammes of GSK961081 and placebo|1200 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3 doses at 20 min intervals, administered via spacer) of placebo at 1h, 12h and 24h of dosing.
3273257|NCT00674778|Experimental|1|Radial approach
3273258|NCT00674778|Active Comparator|2|Femoral approach
3273259|NCT00674765|Experimental|1|Seroquel
3273260|NCT00674765|Placebo Comparator|2|Placebo
3273261|NCT00674752|Experimental|A|
3273262|NCT00674752|Experimental|B|
3273263|NCT00674752|Placebo Comparator|C|
3273264|NCT00674739|Experimental|imiquimod cream|2.5% imiquimod cream applied daily to wart area for up to 8 weeks
3273265|NCT00674739|Experimental|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
3273266|NCT00674739|Placebo Comparator|placebo cream|placebo cream applied daily to wart areas for up to 8 weeks
3273267|NCT00674726||Group I|Patients with acute appendicitis
3273268|NCT00674726||Group II|Patients with acute gastroenteritis
3273269|NCT00674713|Experimental|A|Patients receiving acupuncture at P6 point plus physiological saline solution
3273270|NCT00674713|Active Comparator|B|Patients receiving ondansetron plus sham acupuncture
3273271|NCT00674713|Other|C|Patients receiving ondansetron plus acupuncture at P6 point
3273272|NCT00674713|Placebo Comparator|D|Patients receiving physiological saline solution plus sham acupuncture
3273273|NCT00674700|Active Comparator|300 IR|300 IR house dust mites allergen extract tablet
3273274|NCT00674700|Active Comparator|500 IR|500 IR house dust mites allergen extract tablet
3273275|NCT00674700|Placebo Comparator|Placebo|Placebo tablet
3273276|NCT00674687|Placebo Comparator|Sequence 1|
3273277|NCT00674687|Experimental|Sequence 2|
3273278|NCT00674661|Active Comparator|Corneal Collagen Cross-linking (CXL) Treatment Group|riboflavin ophthalmic solution and UVA irradiation
3273279|NCT00674661|Sham Comparator|Control Group|riboflavin opthalmic solution without UVA irradiation
3273280|NCT00674648|Experimental|1|This is a non-randomized single institution phase I dose escalation trial, designed to evaluate the toxicity and anti-viral activity of CMV-pp65 peptide-specific T cell lines, generated in vitro from CMV seropositive normal HSCT and 3rd party donors, when adoptively transferred to treat recipients of these transplants who have a CMV infection or persistent CMV antigenemia and are therefore at high risk of a life-threatening CMV infection.
3273281|NCT00674635|Placebo Comparator|Placebo|matching placebo
3273282|NCT00674635|Active Comparator|GSK315234A|Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose
3273283|NCT00674622|Experimental|Group 1-Prolotherapy|Deep injection with 15% dextrose in lidocaine
3273284|NCT00674622|Placebo Comparator|Group 2-Deep Saline/Lidocaine|Deep injection with saline/lidocaine
3273285|NCT00674622|Placebo Comparator|Group 3-Superficial Saline/lidocaine|Superficial injection with saline/lidocaine
3273286|NCT00674609|Placebo Comparator|Placebo|Placebo control
3273287|NCT00674609|Experimental|Sativex|Active treatment
3273288|NCT00674609|Experimental|THC Alone|Active treatment
3273289|NCT00674583|Experimental|Group A|
3273290|NCT00674583|Active Comparator|Group B|
3273291|NCT00674570|Experimental|Arm 1: Hydrocortisone|Hydrocortisone
3273292|NCT00674570|Experimental|Arm 2: D-Cycloserine|D-Cycloserine
3273293|NCT00674570|Placebo Comparator|Arm 3: Placebo|Placebo
3273294|NCT00674544|No Intervention|Control group|No intervention, regular kindergarten program
3273295|NCT00674544|Experimental|Intervention group|Kindergarten and homebased increases in physical activity, healthy nutrition, sleep duration and decrease in media use: Involvement of parents and siblings
3273296|NCT00674531|Other|1|Enterovirus RNA analysis
3273297|NCT00674518|Experimental|Counseling|One-on-one sessions conducted by a professional motivational counselor to explore ways to help motivate participants to exercise, eat healthier, and lose weight.
3273298|NCT00674518|Experimental|Group|A nutrition and exercise specialist will lead and teach a group of 4 to 5 subjects in healthy nutrition, exercise and weight loss habits
3273299|NCT00674518|Active Comparator|MD Advice|A physician will provide exercise and nutrition advice to participants immediately following testing
3273300|NCT00674505|Other|Treatment, Open label, Single Group Assignment|
3273301|NCT00674492||Hepatitis C patients|patients who initiated antiviral treatment for hepatitis C
3273302|NCT00674479|Experimental|INCB018424|The starting dose of INCB018424 will be 25 mg by mouth twice daily.
3273303|NCT00674466|Experimental|1|Twice-a-week dose of 1.5 mg CJC-1134-PC
3273304|NCT00674466|Experimental|2|Twice-a-week dose of 1.5 mg CJC-1134-PC for 4 weeks, then once-a-week dose of 2.0 mg CJC-1134-PC plus mid-week dosing of placebo
3273305|NCT00674466|Placebo Comparator|3|Twice-a-week placebo for CJC-1134-PC
3273306|NCT00674453|Experimental|Lasofoxifene 0.25 mg/d|
3273307|NCT00674453|Placebo Comparator|Placebo|
3273908|NCT00670124|No Intervention|1|Standard medical treatment
3274156|NCT00668135|Placebo Comparator|Arm 2|
3273308|NCT00674440|Experimental|1|Children diagnosed with hyperinsulinism who have failed other non-surgical interventions and will be scheduled for surgery. Eligible children in this arm will PET imaging with F-DOPA prior to surgery.
3273309|NCT00674440|Experimental|3|Children diagnosed with hyperinsulinism who have had partial pancreas removal but still display signs of hyperinsulinism. Eligible children in this arm may have PET imaging with F-DOPA.
3273310|NCT00674440|Experimental|2|Children diagnosed with hyperinsulinism who are successfully managed with diazoxide, octreotide, other medications,and/or tube feedings. Eligible children in this arm will PET imaging with F-DOPA.
3273311|NCT00674427|Experimental|CR|Subjects who are in CR ater 6-12 weeks after aDLI
3273312|NCT00674427|Experimental|Not in CR|Subjects not in CR after 6-12 weeks after aDLI
3273313|NCT00674414|Active Comparator|Arm I|Patients receive trastuzumab (Herceptin®) IV once weekly for 6 weeks. Patients then undergo surgery.
3273314|NCT00674414|Experimental|Arm II|Patients receive trastuzumab as in arm I and oral everolimus once daily for 6 weeks. Within 24 hours after completing everolimus, patients undergo surgery.
3273315|NCT00674401|Active Comparator|1|"In patients with paroxysmal atrial fibrillation: Empirical pulmonary vein antrum circumferential isolation.~In patients with persistent atrial fibrillation: Empirical circumferential PV antrum isolation w/out roof line."
3273316|NCT00674401|Active Comparator|2|"In patients with paroxysmal atrial fibrillation: High frequency sites ablation in the LA.~In patients with persistent atrial fibrillation: A combined approach involving pulmonary vein antrum isolation w/out roof line and high frequency sites ablation"
3273317|NCT00674375|Experimental|1|Primary care clinicians (physicians, nurse practitioners, and physician assistants) randomized to the intervention arm will receive electronic alerts within the electronic medical record system during office visits with patients complaining of chest pain.
3273318|NCT00674375|No Intervention|2|Primary care clinicians randomized to the 'no intervention' arm will evaluate and treat patients complaining of chest pain without the aid of electronic risk alerts.
3273319|NCT00674362|Experimental|Certolizumab pegol 200 mg (CDP870)|Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
3273320|NCT00674362|Placebo Comparator|Placebo|Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
3273321|NCT00674336|Experimental|Shellfish with Norovirus|We dosed shellfish with Norovirus and challenged human volunteers with Shellfish that had norovirus
3273322|NCT00674323|Experimental|Verteporfin and Ranibizumab|Photodynamic therapy with verteporfin in combination with ranibizumab injection. Patients received one treatment at baseline with verteporfin photodynamic therapy (PDT) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
3273323|NCT00674323|Active Comparator|Verteporfin monotherapy|Patients received one treatment at baseline with verteporfin photodynamic therapy in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab placebo (sham intravitreal injection) on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
3273324|NCT00674323|Active Comparator|Ranibizumab monotherapy|Patients received one treatment at baseline with verteporfin placebo (with sham photodynamic therapy) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
3273325|NCT00674297|Experimental|Fluvastatin|All patients will take Fluvastatin 40 mg daily for 3 months.
3273326|NCT00674271||Diabetics|100 patients with newly diagnosed (<5 years since diagnosis) type 2 diabetes referred from general practitioners to Medical Department M, Aarhus University Hospital, Denmark.
3273327|NCT00674271||Controls|100 healthy (no diabetes or prediabetes in oral glucose tolerance test) control subjects matched for age and gender
3273328|NCT00674258|Experimental|B|
3273329|NCT00674245|Active Comparator|Pantoprazole|40 mg once daily for four weeks improves sleep quality in patients with GERD
3273330|NCT00674245|Placebo Comparator|placebo|To determine if treatment with pantoprazole 40 mg once daily vs placebo improves sleep outcome in patients with GERD.
3273331|NCT00674232|Experimental|Misoprostol|Group 1 randomized to take single dose of 600 mcg oral misoprostol
3273332|NCT00674232|Other|Surgical treatment|Group 2 randomized to receive standard surgical treatment as per local protocol (D&C or MVA)
3273333|NCT00674219|Experimental|1|This was an open-label study- all subjects received the intervention.
3273334|NCT00674206|Experimental|Gemcitabine and Oxaliplatin|All patients enrolled on clinical trial will receive Gemcitabine 1000mg/m^2 on Day 1 and Oxaliplatin 100 mg/m^2 intravenously over 2 hours on Day 2.
3273335|NCT00674193||Observational (pharmacological study)|Patients undergo blood and urine collection prior to, periodically during, and after treatment with dactinomycin and vincristine for pharmacokinetic, pharmacodynamic, and pharmacogenetic analysis. Samples are analyzed using a liquid chromatography-tandem mass spectrometry assay. Genomic DNA extracted from peripheral blood mononuclear cells is isolated and analyzed by polymerase chain reaction and genotyping assays for genetic variation in genes relevant to the pharmacology of dactinomycin and vincristine.
3273336|NCT00674180||1|a workbook alone
3273337|NCT00674180||2|a workbook alone and the addition of computerized tailoring using onsite computer kiosks with touch screen monitors
3274157|NCT00668122|Experimental|Arm 1|
3273339|NCT00674167|Experimental|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel and cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
3273340|NCT00674167|Experimental|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
3273341|NCT00674167|Experimental|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycles.
3273342|NCT00674154|Experimental|Vitamin D group|Cholecalciferol 1400 IU, 2 tablets once daily in 52 weeks
3273343|NCT00674154|Placebo Comparator|Placebo group|Placebo, two tablets daily in 52 weeks.
3273344|NCT00674141|Other|1|only one experimental treated group
3273345|NCT00674128|Experimental|Adhesive|Cyanoacrylate tissue adhesive.
3273346|NCT00674128|Active Comparator|Suture|Polyglactin 910 suture.
3273347|NCT00674115|Experimental|Single Dose Zegerid for 1 or 7 days|Omeprazole 20 mg/Sodium Bicarbonate 1680 mg Powder for Oral Suspension
3273348|NCT00674115|Active Comparator|Single Dose Prilosec 1 or 7 days|Omeprazole magnesium 20 mg over-the-counter (OTC) Tablet
3273349|NCT00674115|Active Comparator|Sodium Bicarbonate|Sodium Bicarbonate 1680 mg Oral Suspension
3273350|NCT00674102|Experimental|ASA404|
3273351|NCT00674089|Active Comparator|1|Routine Post-partum Care and Vitamin A supplementation (50,000 IU) to the Newborn
3273352|NCT00674089|Placebo Comparator|2|Routine Post-partum Care with Placebo to the Newborn
3273353|NCT00674076||sleep apnea|a patient has been diagnosed as having obstructive sleep apnea
3273354|NCT00674076||control|a case who has a negative polysomography or noraml score of Pittsburg sleep questionaire
3273355|NCT00674063|Experimental|1|Dose regimen 1
3273356|NCT00674063|Experimental|2|Dose regimen 2
3273357|NCT00674050|Experimental|1|
3273358|NCT00674037|Experimental|inclusion with financial motivation|75 euros for each patient included
3273359|NCT00674037|No Intervention|no incentive|no incentive
3273360|NCT00673985|Active Comparator|1|"PTA Only: Active Comparator~Percutaneous transluminal angioplasty (PTA) alone"
3273361|NCT00673985|Experimental|2|"Test Arm: Experimental~The main objective of this study is to assess the safety and effectiveness of the Edwards Lifesciences LifeStent nitinol self expandable stent device and its delivery system in the treatment of occlusive superficial femoral artery (SFA) disease."
3273362|NCT00673972|Active Comparator|EPS|Patients with functional dyspepsia will be classified into EPS or PDS two subgroups according to Rome III diagnostic criteria.
3273363|NCT00673972|Active Comparator|PDS|Patients with functional dyspepsia will be classified into EPS or PDS two subgroups according to Rome III diagnostic criteria.
3273364|NCT00673959|Experimental|Lubricant Eye Drop FID 111421|Lubricant Eye Drop FID 111421 1 drop each eye one time
3273365|NCT00673959|Active Comparator|Optive Lubricant Eye Drop|Optive Lubricant Eye Drop 1 drop each eye one time
3273366|NCT00673946|Active Comparator|1|In this arm, patients are monitored with oximeters displaying true saturation values
3273367|NCT00673946|Experimental|2|In this arm, patients are monitored with oximeters with displayed saturations 3 percentage points above true values
3273368|NCT00673933|Experimental|1|PDT using MAL crem
3273369|NCT00673933|Placebo Comparator|2|PDT using Placebo cream
3273370|NCT00673920|Experimental|1|
3273371|NCT00673920|Experimental|2|
3273372|NCT00673920|Placebo Comparator|3|
3273373|NCT00673907|Sham Comparator|1|Clean air
3273374|NCT00673907|Experimental|2|Wood smoke particle concentration of 200 ug/m3
3273375|NCT00673907|Experimental|3|Wood smoke particle concentration of 400 ug/m3
3273376|NCT00673881|Experimental|Abt-335|ABT-335 (choline fenofibrate)
3273377|NCT00673868|Experimental|1|
3273378|NCT00673868|No Intervention|2|
3273379|NCT00673855|Experimental|Lubricant Eye Drops FID 112903|Lubricant Eye Drops FID 112903 1 drop each eye one time
3273380|NCT00673855|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye 1 time
3273381|NCT00673842|Experimental|Implantable Cardioverter Defibrillator + Usual Care|Medtronic ICD
3273382|NCT00673842|Active Comparator|Usual Care|Usual post-MI care
3273383|NCT00673829|Experimental|Phase Ia|
3273384|NCT00673829|Experimental|Phase Ib: Control|
3273385|NCT00673816|Experimental|Sunitinib Malate|Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
3273386|NCT00673803|Other|A|cataract surgery, implantation of a Polylens Y10
3273387|NCT00673803|Other|B|cataract surgery, implantation of a Polylens Y30
3273388|NCT00673790|Active Comparator|1|Nebivolol
3273389|NCT00673790|Active Comparator|2|HCTZ
3273390|NCT00673790|Placebo Comparator|3|Placebo
3273391|NCT00673777|Experimental|A|
3273392|NCT00673764|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
3273393|NCT00673764|Active Comparator|Optive|Optive Lubricant Eye Drops
3273394|NCT00673751|Placebo Comparator|2|subcutaneous isotonic saline
3273395|NCT00673751|Active Comparator|1|subcutaneous GLP-2
3273396|NCT00673738|Experimental|Cetuximab Plus Radiotherapy|Concurrent Cetuximab plus Conformal Thoracic Radiotherapy (CTRT). Patients were treated with definitive radiotherapy (70 Gy in 35 fractions, per our currently-existing institutional standard) with concurrent cetuximab followed by 3 cycles of consolidation docetaxel plus cetuximab.
3273397|NCT00673725|Experimental|1|
3273398|NCT00673712|Experimental|Continuous Sternal Block|Continuous Sternal block with infusion of local anesthetic via ON-Q Painbuster Silver Soaker system
3273399|NCT00673712|Active Comparator|Opioid based analgesia|Opioid based analgesia including Patient controlled analgesia plus IM, Oral narcotics and other analgesics
3273400|NCT00673699||A|Seventy dyspeptic consecutive patients that going upper gastrointestinal endoscopy
3273401|NCT00673686|Active Comparator|Arm 2|
3273402|NCT00673686|Experimental|Arm 1|
3273403|NCT00673673|Experimental|1|FOLFOX in combination with bevacizumab
3273404|NCT00673660||Statins|Patients with dyslipidemia who are taking or planning to take a statin treatment (Atorvastatin, Fluvastatin, Prevastatin, Rosuvastatin, Simvastatin or generics).
3273405|NCT00673647|Experimental|1|Individual psychotherapy including cognitive behavioral components, motivational interviewing techniques and case management
3273406|NCT00673647|No Intervention|2|Delayed treatment control group
3273407|NCT00673634|Active Comparator|1|Standard preoxygenation
3273408|NCT00673634|Active Comparator|2|BiPAP assisted preoxygenation
3273409|NCT00673621|Experimental|1|
3273410|NCT00673608|Experimental|Deferasirox|
3273411|NCT00673595|Active Comparator|Varenicline|Participants on this arm will receive varenicline tablets for 15 days.
3273412|NCT00673595|Placebo Comparator|Placebo|Participants on this arm will receive placebo tablets for 15 days.
3273413|NCT00673582|Experimental|1|10 mg/day rosuvastatin for 96 weeks
3273414|NCT00673582|Placebo Comparator|2|Placebo
3273415|NCT00673556|Experimental|Course A1|
3273416|NCT00673556|Placebo Comparator|Course A2|
3273417|NCT00673556|Experimental|Course B|Open label extension
3273418|NCT00673543||1|Pregnant women with insulin requiring diabetes
3273419|NCT00673543||2|Pregnant women without insulin requiring diabetes
3273420|NCT00673530|Experimental|1|evidence based clinical nutrition concept
3273421|NCT00673530|Other|2|care as usual
3273422|NCT00673517||1|Patients randomized to high frequency oscillation
3273423|NCT00673517||2|Patients randomized to conventional lung protective ventilation
3273424|NCT00673504|Experimental|A|Gemcitabine + Sunitinib
3273425|NCT00673504|Other|B|Gemcitabine
3273426|NCT00673491|Experimental|1|Patients treated according to clinical pathways
3273427|NCT00673491|No Intervention|2|Patients treated according to usual care
3273428|NCT00673465|Experimental|Treatment sequence 1: SCH 497079 → Placebo → Metformin|Participants received SCH 497079 daily for 4 weeks followed by placebo daily for 4 weeks followed by metformin daily for 4 weeks.
3273429|NCT00673465|Experimental|Treatment sequence 2: Placebo → Metformin → SCH 497079|Participants received placebo daily for 4 weeks followed by metformin daily for 4 weeks followed by SCH 497079 daily for 4 weeks.
3273430|NCT00673465|Experimental|Treatment sequence 3: Metformin → SCH 497079 → Placebo|Participants received metformin daily for 4 weeks followed by SCH 497079 daily for 4 weeks followed by placebo daily for 4 weeks.
3273431|NCT00673465|Experimental|Treatment sequence 4: SCH 497079 → Metformin → Placebo|Participants received SCH 497079 daily for 4 weeks followed by metformin daily for 4 weeks followed by placebo daily for 4 weeks.
3273432|NCT00673465|Experimental|Treatment sequence 5: Placebo → SCH 49709 → Metformin|Participants received placebo daily for 4 weeks followed by SCH 497079 daily for 4 weeks followed by metformin daily for 4 weeks.
3273433|NCT00673465|Experimental|Treatment sequence 6: Metformin → Placebo → SCH 497079|Participants received metformin daily for 4 weeks followed by placebo daily for 4 weeks followed by SCH 497079 daily for 4 weeks.
3273434|NCT00673452|Experimental|Duloxetine|60-120 mg, oral, every day, 12 weeks
3273435|NCT00673452|Placebo Comparator|Placebo|oral, daily, 12 weeks
3273436|NCT00673426|Experimental|A|
3273437|NCT00673400|Other|Stapled transanal rectum resection|patients operated with stapled transanal rectum resection
3273438|NCT00673387|Placebo Comparator|Placebo-P + Placebo-M|Placebo matched to pramlintide BID plus placebo matched to metreleptin BID
3273439|NCT00673387|Experimental|Pramlintide 360 mcg + Placebo-M|360 mcg pramlintide given twice per day (BID) plus Placebo matched to Metreleptin given BID
3273440|NCT00673387|Experimental|Placebo-P + Metreleptin 5.0 mg|Placebo matched to pramlintide BID plus metreleptin 5.0 mg BID
3273441|NCT00673387|Experimental|Pramlintide 180 mcg + Metreleptin 2.5 mg|Pramlintide 180 mcg BID plus Metreleptin 2.5 mg BID
3273442|NCT00673387|Experimental|Pramlintide 180 mcg + Metreleptin 5.0 mg|Pramlintide 180 mcg BID plus Metreleptin 5.0 mg BID
3273443|NCT00673387|Experimental|Pramlintide 360 mcg + Metreleptin 1.25 mg|Pramlintide 360 mcg BID plus Metreleptin 1.25 mg BID
3273444|NCT00673387|Experimental|Pramlintide 360 mcg + Metreleptin 2.5 mg|Pramlintide 360 mcg BID plus Metreleptin 2.5 mg BID
3273445|NCT00673387|Experimental|Pramlintide 360 mcg + Metreleptin 5.0 mg|Pramlintide 360 mcg BID plus Metreleptin 5.0 mg BID
3273446|NCT00673374||1|All consecutive emergency department patients undergoing abdominal CT for non-traumatic abdominal pain and tenderness will be prospectively enrolled, except for those meeting pre-specified exclusion criteria.
3273447|NCT00673361|Experimental|"Chemo-Switch Regimen"|
3273448|NCT00673348||1|Patients suspected of invasive fungal infection (proven or probable cases) with immunocompromised state (for example, during neutropenia, receiving HSCT) in Catholic Hematopoietic Stem Cell Transplantation [HSCT] Center in Seoul, Korea.
3273449|NCT00673335|Experimental|Treatment arm|Letrozole, 1 tablet
3273450|NCT00673335|Placebo Comparator|Placebo|Comparator, 1 tablet
3273451|NCT00673322|Experimental|Gene Modified T Cells|Modified T cells
3273452|NCT00673309|Experimental|1|Growth Hormone 0.05 to 0.2 mg/kg q day SQ until 95% wound healing.
3273453|NCT00673309|Experimental|2|IGF-1 (or IGF-1/IGFBP-3) administration daily until 95% wound healing
3273454|NCT00673309|Experimental|3|Insulin IV administered continuously to maintain serum glucose between 80-110 throughout hospitalization until wounds are 95% healed
3273455|NCT00673309|Experimental|4|Oxandrolone (or other Anabolic steroid-nandrolone or testosterone) administered daily until 95% wound healing
3273456|NCT00673309|Experimental|5|Propranolol (or other Beta adrenergic blockers-metoprolol) to be given IV or PO to decrease HR and BP throughout hospitalization until 95% wound healing
3273457|NCT00673309|Experimental|6|Clonidine (Alpha Adrenergic Agonist) to be given daily to decrease HR and BP and anxiety
3273458|NCT00673309|Experimental|7|Ketoconazole (or other glucocorticoid blockers- itraconazole, fluconazole) administered PO every 12 hours throughout hospitalization until 95% wound healing
3273459|NCT00673309|Experimental|8|Fenofibrate administered daily until 95% wound healing
3273460|NCT00673309|Experimental|10|Pioglitazone administered daily throughout hospitalization to 95% wound healing
3273461|NCT00673309|Experimental|11|Byetta (or other Glucagon like peptide drug-GLP, GLP-1, Exenatide) will be administered SQ daily throughout hospitalization until 95% wound healing
3273462|NCT00673309|Placebo Comparator|12|Placebo. Sterile water will be administered daily throughout hospitalization to 95% wound healing
3273463|NCT00673309|Experimental|9|Metformin PO administered daily throughout hospitalization to 95% wound healing
3273464|NCT00673309|Experimental|13|DHEA-S, Dehydroepiandrosterone-sulfate administered daily until 95% wound healing.
3273465|NCT00673296|Other|A|Patients receive intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
3273466|NCT00673283|Experimental|A|
3273467|NCT00673270|Experimental|1|Fludrocortisone and Hydrocortisone
3273468|NCT00673270|Experimental|2|Fludrocortisone and placebo of Hydrocortisone
3273469|NCT00673270|Experimental|3|Placebo of Fludrocortisone and Hydrocortisone
3273470|NCT00673270|Placebo Comparator|4|Placebo of Fludrocortisone and placebo of Hydrocortisone
3273471|NCT00673257|Experimental|Pharmacokinetics of Daunorubicin chemotherapy patients|Patients receiving a chemotherapy regimen including daunorubicin hydrochloride administered as an infusion of any duration < 24 hours on a 1 or a 2 day schedule. Pre-study evaluations no greater than 14 days prior to daunomycin administration. If patients have had significant intercurrent illness or treatment that might affect organ function, laboratory work should be performed at an appropriately closer interval to daunomycin administration. A complete history and physical examination including height, weight and body surface area. Patients should be weighed with only light clothing; shoes must be removed before weight is measured. Patients height should be measured using a stadiometer after removing shoes. Laboratory evaluation: a) CBC with differential and platelet count. b) ALT, AST, bilirubin, creatinine, total protein, albumin, alkaline phosphatase, GGT.
3273472|NCT00673244|Experimental|1|
3273473|NCT00673231|Experimental|1|2.5mg
3273474|NCT00673231|Experimental|2|5mg
3273475|NCT00673231|Experimental|3|10mg
3273476|NCT00673231|Placebo Comparator|4|
3273477|NCT00673218|Placebo Comparator|1|Saline injection to match active
3273478|NCT00673218|Experimental|Treatment|Active treatment with Xolair 150 to 375 mg is administered SC every 2 or 4 weeks
3273479|NCT00673205|Placebo Comparator|A|
3273480|NCT00673205|Active Comparator|B|
3273481|NCT00673179|Experimental|Outpatient Chemotherapy|Pre-Surgery, Regimen 1: Doxorubicin intravenous (IV) 90 mg daily, Cisplatin 60 mg/m^2/day for 2 days, Methotrexate 12 gm/m^2, Leucovorin Rescue 10 mg IV, with 10 mg orally every 6 hours; Surgery; Post-Surgery, Regimen 1: Methotrexate 12 gm/m^2, Doxorubicin IV 90 mg, Cisplatin 60 mg/ m^2 twice daily, Leucovorin Rescue.
3273482|NCT00673179|Experimental|Additional Risk-Adapted Outpatient Chemotherapy|Pre-Surgery, Regimen 2: Dexrazoxane 900 mg/m^2 intravenous (IV) then Doxorubicin IV 90 mg daily, Cisplatin 120 mg/m^2 (intra-arterial); Surgery; Post-Surgery, Regimen 2: Methotrexate 12 gm/m^2, Leucovorin Rescue 10 mg IV, with 10 mg orally every 6 hours; Ifosfamide 2.8 grams m^2/day and Mesna 2.8 gm/m^2/day continuous IV over 6 days; Lung-Directed Chemotherapy, Regimen 2: Gemcitabine, Sargramostim Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg).
3273483|NCT00673153|Experimental|Arm I|"REMISSION INDUCTION THERAPY: Patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 15-22 days for up to 3 courses. .~CONSOLIDATION THERAPY: Beginning within 60 days after the completion of remission induction therapy, patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8.~MAINTENANCE THERAPY: Patients receive oral vorinostat once daily on days 1-14. Treatment repeats every 28 days for 4 courses."
3273484|NCT00673140|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
3273485|NCT00673127|Experimental|KHAD|Ketoconazole, Hydrocortisone and Dutasteride Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Dutasteride: 0.5 mg once a day
3273486|NCT00673114|Other|Transplant Recipients|
3273487|NCT00673075|Active Comparator|1|Encapsulated Nebivolol
3273488|NCT00673075|Active Comparator|2|Encapsulated Carvedilol
3273489|NCT00673062|Experimental|SCH 900538|
3273490|NCT00673062|Active Comparator|Encapsulated pseudoephedrine|Encapsulated pseudoephedrine (2X30 mg immediate release tablets)
3273491|NCT00673062|Placebo Comparator|Placebo Capsules|
3273492|NCT00673049|Experimental|Arm A|"The CP 751,871 treatment in combination with erlotinib will be given in three week cycles.~CP 751,871 (20 mg/kg) + erlotinib (150 mg/day) CP 751,871 will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter."
3273493|NCT00673049|Active Comparator|Arm B|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food)
3273494|NCT00673036||1|Adults (female and male) with a acute coronary syndrome
3273495|NCT00673023|Experimental|1|
3273496|NCT00673023|Experimental|2|
3273497|NCT00673023|Experimental|3|
3273498|NCT00673010|Experimental|1|131 I-iodine (131-I), 124 I-iodine (124-I)
3273499|NCT00672997|Experimental|Travoprost/Timolol BAC-free|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
3273500|NCT00672997|Active Comparator|Travoprost/Timolol|Travoprost 0.004%/Timolol 0.5% ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
3273501|NCT00672984|Experimental|Immediate-release Guanfacine HCl|
3273502|NCT00672984|Active Comparator|Moxifloxacin HCl|
3273503|NCT00672984|Placebo Comparator|Placebo|
3273504|NCT00672971|Experimental|1|4% dimethicone foam
3273505|NCT00672971|Active Comparator|2|1% permethrin
3273506|NCT00672958|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.
3273507|NCT00672958|Experimental|Vortioxetine|Vortioxetine 5 mg, encapsulated tablet, orally, once daily for up to 6 weeks.
3273508|NCT00672945|Experimental|PRX-03140|
3273509|NCT00672945|Placebo Comparator|Placebo|
3273510|NCT00672932|Experimental|raltegravir group|The raltegravir dosing will be 400mg twice daily by mouth. Subjects will continue all of their regular medications throughout the protocol.
3274158|NCT00668122|Experimental|Arm 2|
3273511|NCT00672932|No Intervention|No augmented treatment|Subjects randomized not to receive augmented treatment will continue in the study with their regular antiretroviral regimen.
3273512|NCT00672919|Experimental|Pioglitazone QD|(and stable statin therapy)
3273513|NCT00672906|Experimental|1|Group Parent Training/Adolescent Skills Training
3273514|NCT00672906|Active Comparator|Active Comparator|Family Therapy according to the Maudsley Model
3273515|NCT00672893||Observation|Patients who present to the clinic with airway obstruction and who are designated to undergo intervention
3273516|NCT00672880|Experimental|1|Psychotherapy
3273517|NCT00672880|Active Comparator|2|Spine Education
3273518|NCT00672880|Placebo Comparator|3|Standard Care
3273519|NCT00672867|Experimental|1|Clevudine
3273520|NCT00672867|Active Comparator|2|Adefovir
3273521|NCT00672854|Active Comparator|Total Parenteral nutrition (TPN) given Intralipid 20%|Subjects who require TPN receiving Intralipid (soybean-based)
3273522|NCT00672854|Experimental|Total parenteral nutrition (TPN) given ClinOleic 20%|TPN subjects receive ClinOleic 20% (olive oil based)
3273523|NCT00672841|Active Comparator|2|Standard care/empiric therapy group
3273524|NCT00672841|Experimental|1|Active surveillance/ preemptive therapy group
3273525|NCT00672828|Active Comparator|Non-tailored CRC screening brochure|Participants undergo a baseline interview via telephone and receive a non-tailored CRC screening brochure in the clinic prior to visit with healthcare provider. Participants then undergo telephone interviews at 1 week, 6 months, and 15 months.
3273526|NCT00672828|Experimental|Interactive computer intervention|Participants undergo a baseline interview via telephone and complete an interactive computer intervention in the clinic prior to visit with healthcare provider. Participants then undergo telephone interviews at 1 week, 6 months, and 15 months.
3273527|NCT00672802|Experimental|Ramelteon 16 mg QD and Placebo QD|
3273528|NCT00672789|Experimental|1|Blood Smear Education
3273529|NCT00672789|Active Comparator|2|Standard education
3273530|NCT00672776|Experimental|1|paroxetine
3273531|NCT00672776|Placebo Comparator|2|placebo
3273532|NCT00672763|Active Comparator|A|Standard corticosteroid treatment PLUS Vitamin D3 (Colecalciferol).
3273533|NCT00672763|Placebo Comparator|B|Standard corticosteroid treatment PLUS placebo (Migliol Oil)
3273534|NCT00672750||I|Patients of Dr C Miller who have undergone laparoscopic myomectomy from 1999- to present
3273535|NCT00672737||Males at risk for OSA|"Males at risk for obstructive sleep apnea were invited to have a sleep study either at home or at Stanford Sleep Center.~A week after their sleep study (Polysomnography), all volunteers underwent quantitative sensory testing in the laboratory, during which their pain thresholds and tolerances to heat (Heat pain threshold and tolerance) and cold (Cold pain threshold and tolerance) stimuli were assessed, under two different concentrations (1 and 2 mcg/mL, in randomized order) of remifentanil, a short-acting opioid, given as a computer-controlled infusion."
3273536|NCT00672724|Experimental|Ramelteon 8 mg QD|
3273537|NCT00672724|Placebo Comparator|Placebo|
3273538|NCT00672711||C|APS
3273539|NCT00672711||B|HPS
3273540|NCT00672711||A|LPS
3273541|NCT00672698||I|VASCULAR SURGERY
3273542|NCT00672698||II|DIGESTIVE SURGERY
3273543|NCT00672698||III|BILIARY TRACT SURGERY
3273544|NCT00672685|Experimental|1|Omega-3 group without any intervention
3273545|NCT00672685|Experimental|2|Omega-3 combined group (Omega-3 + multi-domain intervention)
3273546|NCT00672685|Experimental|3|Placebo combined group (Placebo + multi-domain intervention)
3273547|NCT00672685|Placebo Comparator|4|Placebo group without any intervention
3273548|NCT00672672|Experimental|II|Patients who do not receive platlet gel.
3273549|NCT00672659|Active Comparator|1|Citalopram, 40 mg daily in combination with Pipamperone, 5 mg twice daily (bd)
3273550|NCT00672659|Placebo Comparator|2|Citalopram, 40 mg daily in combination with Placebo, dummy twice daily (bd)
3273551|NCT00672646|Experimental|AZD1386|
3273552|NCT00672646|Active Comparator|Naproxen|
3273553|NCT00672646|Placebo Comparator|Placebo|Placebo matching AZD1386
3273554|NCT00672633|Experimental|A , Experimental|Lovaza, 4 grams/day orally for 6 months
3273555|NCT00672633|Placebo Comparator|Corn Oil Pill|Corn Oil Pill, 4 pills/day orally for 6 months
3273556|NCT00672620|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
3273557|NCT00672620|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
3273558|NCT00672620|Active Comparator|Duloxetine 60 mg|Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsules, orally, once daily for 1 week after the treatment period.
3273559|NCT00672620|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
3273560|NCT00672607|Experimental|1|
3273561|NCT00672607|Placebo Comparator|2|
3273562|NCT00672594|Experimental|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
3273563|NCT00672581|Experimental|1|Control (healthy volunteers)
3273564|NCT00672581|Experimental|2|Mild Hepatic Impairment
3273565|NCT00672581|Experimental|3|Moderate Hepatic Impairment
3273566|NCT00672581|Experimental|4|Severe Hepatic Impairment
3273567|NCT00672568|Experimental|1|4975
3273568|NCT00672568|Experimental|2|4975
3273569|NCT00672568|Experimental|3|4975
3273570|NCT00672568|Placebo Comparator|4|Placebo
3273571|NCT00672555|Experimental|Pilonidal Sinus T. With Limberg F.|All patients treated by excision and covering of the defect by a Limberg-flap, who gave their informed consent to participate in the study, as there is only one study group.
3273572|NCT00672542|Experimental|A|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from untreated monocytes
3273573|NCT00672542|Experimental|B|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from monocytes transfected with control siRNA
3273574|NCT00672542|Experimental|C|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from monocytes transfected with siRNA targeting the three inducible immunoproteasome subunits
3273575|NCT00672529|Active Comparator|Intervention Group|
3273576|NCT00672529|Placebo Comparator|Placebo Group|
3273577|NCT00672503||1|Patients who acquired a CA-UTI in the PICU between 2004-2007.
3273578|NCT00672503||2|Patients who did not acquire a CA-UTI while hospitalized in the PICU but had an indwelling urinary catheter between 2004-2007.
3273579|NCT00672503||A|Nurses currently employed in the PICU at Children's Mercy Hospital.
3273580|NCT00672503||a|Root Cause Analysis on all patients who acquired a CA-UTI during 2009.
3273581|NCT00672490|Experimental|1|Quetiapine Fumarate - tablets
3273582|NCT00672490|Experimental|2|Quetiapine Fumarate - tablets and Lithium
3273583|NCT00672477|Experimental|Methylnaltrexone|Methylnaltrexone subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; or 0.4 mL (8 mg) every other day if weight between 38 and <62 kg. Subjects with impaired kidney function received reduced doses according to instructions in the Relistor prescribing information.
3273584|NCT00672477|Placebo Comparator|Placebo|Placebo subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL every other day if weight ≥ 62kg; or 0.4 mL every other day if weight between 38 and < 62 kg. Subjects with impaired kidney function received reduced volumes of placebo solution to match the volumes used in the experimental group.
3273585|NCT00672464|Active Comparator|Olanzapine only|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine
3273586|NCT00672464|Experimental|Added Metformin|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Metformin
3273587|NCT00672464|Experimental|Added Simvastatin|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Simvastatin
3273588|NCT00672464|Experimental|Added Metf. + Simv.|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Metformin and Simvastatin
3273589|NCT00672464|No Intervention|Matched Controls|Matched Control Subjects by age, race, and gender
3273590|NCT00672451|Experimental|rhubarb extract|will receive rhubarb extract
3273591|NCT00672451|Placebo Comparator|placebo|receive placebo
3273592|NCT00672438|Placebo Comparator|Saline placebo infusion|Subjects will receive an intravenous infusion of normal saline.
3273593|NCT00672438|Experimental|Alfentanil infusion|Subjects will receive an intravenous infusion of alfentanil.
3273594|NCT00672412|Experimental|1|Participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive liquid ZDV, 3TC, and NVP for the following 14 days of the study.
3273595|NCT00672412|Experimental|2|Participants receive liquid ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the following 14 days of the study.
3273596|NCT00672399|Experimental|Sequence 1|Period 1 = placebo exenatide/placebo moxifloxacin; Period II = exenatide/placebo moxifloxacin; Period III = placebo exenatide/moxifloxacin
3273597|NCT00672399|Experimental|Sequence 2|Period I = exenatide/placebo moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = placebo exenatide/placebo moxifloxacin
3273598|NCT00672399|Experimental|Sequence 3|Period 1 = placebo exenatide/moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = exenatide/placebo moxifloxacin
3273599|NCT00672399|Experimental|Sequence 4|Period I = placebo exenatide/moxifloxacin; Period II = exenatide/placebo moxifloxacin; Period III = placebo exenatide/placebo moxifloxacin
3273600|NCT00672399|Experimental|Sequence 5|Period I = placebo exenatide/placebo moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = exenatide/moxifloxacin
3273601|NCT00672399|Experimental|Sequence 6|Period I = exenatide/placebo moxifloxacin; Period II = placebo exenatide/placebo moxifloxacin; Period III = placebo exenatide/moxifloxacin
3273602|NCT00672386|Experimental|001|JNJ16269110 5 mg twice daily for 12 weeks
3273603|NCT00672386|Experimental|002|JNJ16269110 10 mg twice daily for 12 weeks
3273604|NCT00672386|Experimental|003|JNJ16269110 15 mg twice daily for 12 weeks
3273605|NCT00672386|Placebo Comparator|004|Placebo twice daily for 12 weeks
3273606|NCT00672373|Experimental|A|Active treatment with EGb-761 capsules (80mg each capsule), 3 capsules each day for 12 weeks
3273607|NCT00672373|Placebo Comparator|B|Matching placebo treatment
3273608|NCT00672360|Experimental|1|
3273609|NCT00672360|Placebo Comparator|2|
3273610|NCT00672347|Active Comparator|B|compare caudal anesthesia with bupivacaine alone or in addition to morphine, clonidine or both
3273611|NCT00672347|Active Comparator|C|compare caudal anesthesia with bupivacaine plus clonidine with caudal anesthesia with bupivacaine alone or in addition to morphine or morphine plus clonidine
3273612|NCT00672347|Active Comparator|M|compare caudal anesthesia with bupivacaine plus morphine with caudal anesthesia with bupivacaine alone or in addition to clonidine or morphine plus clonidine
3273613|NCT00672347|Active Comparator|CM|compares caudal anesthesia with bupivacaine, morphine and clonidine with caudal anesthesia with bupivacaine alone or in addition to morphine or clonidine
3273614|NCT00672334|Placebo Comparator|2|sodium chloride at 0.5 mmol/kg loading pre-induction and then at 0.2 mmol/kg/hr over 24 hours after induction until the next day
3273615|NCT00672334|Experimental|1|The active intervention is loading (05. mmol/kg) pre-surgery and continuous infusion of bicarbonate at 0.2 mmol/kg/hr for 24 hours after induction
3273616|NCT00672308|Experimental|1|Benefiber (25 g/L)
3273617|NCT00672308|Experimental|2|Benefiber (50 g/L)
3273618|NCT00672308|Experimental|3|the reduced-osmolarity WHO-ORS without Benefiber.
3273619|NCT00672295|Experimental|Dasatinib, paclitaxel,and carboplatin|Combination of dasatinib, paclitaxel,and carboplatin
3273620|NCT00672282|Placebo Comparator|A|
3273621|NCT00672282|Active Comparator|B|
3273622|NCT00672269||1|Families with carcinoid in multiple family members
3273623|NCT00672256|Experimental|Smokers not interested in quitting smoking|Smokers were scanned 24 hours after quitting smoking, and scanned after smoking as usual.
3273624|NCT00672243|Experimental|Erlotinib + Sirolimus|Erlotinib & sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of erlotinib and 5mg of sirolimus for patients not on concurrent Cytochrome P450, family 3 (CY3PA)-inducing anti-epileptics (EIAEDS) and 400 mg of erlotinib and 10 mg of sirolimus for patients on concurrent EIAEDS.
3273625|NCT00672230|Experimental|Lut Supp|
3273626|NCT00672217|Placebo Comparator|Behavioral Placebo Therapy|Behavioral Placebo Treatment
3273627|NCT00672217|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia (CBTI)
3273628|NCT00672204|Experimental|1|Allogeneic islets of Langerhans
3273629|NCT00672191|Experimental|1|
3273630|NCT00672165|Experimental|1|This is a phase I, dose-escalation trial. The starting dose level will be 0.5 μCi/kg of 225Ac-HuM195. Three to six patients will be treated at each dose level, and dose escalation will proceed if less than 33% of patients in a cohort experience dose limiting toxicity. Six patients will be treated at the maximum tolerated dose
3273631|NCT00672152|Experimental|A-WT1 derived peptides|"Wilms' tumor gene 1 (WT1) derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg Granulocyte-macrophage colony-stimulating factor (GM-CSF) in a total volume of 2ml:~WT peptide #1: (human leukocyte antigen) HLA-A2 restricted: RMFPNAPYL~WT peptide #2: HLA-A24 restricted: CMTWNQMNL~WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL~WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT~Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs."
3273632|NCT00672139|Experimental|Methylnaltrexone bromide|"Methylnaltrexone subcutaneously as needed no more than 1 dose in a 24-hour period for a maximum of 10 weeks in this study.~Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; or 0.4 mL (8 mg) every other day if weight between 38 and <62 kg. Subjects with impaired kidney function received reduced doses according to instructions in the Relistor prescribing information."
3273633|NCT00672113|Experimental|Arm 1|
3273634|NCT00672113|Active Comparator|Arm 2|
3273635|NCT00672100|Active Comparator|A|Initial Bolus 5 ml Ropivacaine
3273636|NCT00672100|Active Comparator|B|Initial Bolus 10 ml Ropivacaine
3273637|NCT00672100|Active Comparator|C|Initial Bolus 20 ml Ropivacaine
3273638|NCT00672087||A|Chronic prostatitis/chronic pelvic pain syndrome patients
3273639|NCT00672087||B|Painful bladder syndrome/interstitial cystitis patients
3273640|NCT00672087||C|Asymptomatic controls
3273641|NCT00672074|Active Comparator|1 Ipamorelin|
3273642|NCT00672074|Placebo Comparator|2 Placebo|
3273643|NCT00672061|Experimental|Ramelteon 16 mg QD or Placebo QD|
3273644|NCT00672048|Other|1|
3273645|NCT00672048|Other|2|Control group to receive annual continuing education
3273646|NCT00672035|Experimental|1|7.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
3273647|NCT00672035|Experimental|2|7.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
3273648|NCT00672035|Experimental|3|22.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
3273649|NCT00672035|Experimental|4|22.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
3273650|NCT00672035|Experimental|5|37.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
3273651|NCT00672035|Experimental|6|37.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
3273652|NCT00672035|Experimental|7|50µg LT Dose placed at the Deltoid on Day 0 and Day 21
3273653|NCT00672035|Experimental|8|50µg LT Dose placed at the Lower Back on Day 0 and Day 21
3273654|NCT00672035|Placebo Comparator|9|Placebo (0µg LT) placed at the Deltoid on Day 0 and Day 21
3273655|NCT00672035|Placebo Comparator|10|Placebo (0µg LT) placed at the Lower Back on Day 0 and Day 21
3273656|NCT00672009|Experimental|One|
3273657|NCT00671996|Active Comparator|A|Mangafodipir treatment
3273658|NCT00671996|Placebo Comparator|B|
3273659|NCT00671970|Experimental|Bevacizumab + Erlotinib|Bevacizumab + Erlotinib
3273660|NCT00671957||1|Patients undergoing gastric bypass surgery and who are participants in Longitudinal Assessment of Bariatric Surgery (LABS-2)
3273661|NCT00671944|Experimental|1|Low protein diet
3273662|NCT00671931|Active Comparator|I|Dexmedetomidine low infusion, Propofol low infusion
3273663|NCT00671931|Active Comparator|II|Dexmedetomidine high infusion, Propofol low infusion
3273664|NCT00671931|Active Comparator|IV|Dexmedetomidine high infusion, Propofol high infusion
3273665|NCT00671931|Active Comparator|V|Dexmedetomidine intermediate infusion, Propofol intermediate infusion
3273666|NCT00671931|Active Comparator|III|Dexmedetomidine low infusion, Propofol high infusion
3273667|NCT00671918|Experimental|Lymphoseek, Lymphatic mapping, Injection|
3273668|NCT00671905|Active Comparator|1|Circumferential PV isolation
3273669|NCT00671905|Active Comparator|2|HF stimulation-guided and anatomic ablation of the main right and left atrial GP.
3273670|NCT00671905|Active Comparator|3|HF stimulation-guided and anatomic ablation of the main right and left atrial GP followed by circumferential PV isolation
3273671|NCT00671892|Experimental|Challenge|"Experimental Challenge Challenge 1 saline 5000EU 10,000EU 20,000EU~Challenge 2 Saline 40,000EU 80,000EU"
3273672|NCT00671879|Experimental|Carisprodol SR 700 mg|Carisoprodol 700 mg twice daily
3273673|NCT00671879|Experimental|Carisoprodol SR 500mg|Carisoprodol SR 500 mg twice daily
3273674|NCT00671879|Placebo Comparator|Placebo|Placebo
3273675|NCT00671866||1|Agricultural Workers
3273676|NCT00671866||2|Non - Agricultural Workers
3273677|NCT00671866||3|Kibbitz Residents working else where
3273678|NCT00671853|Experimental|1|Quetiapine XR
3273679|NCT00671853|Placebo Comparator|2|Placebo for quetiapine XR
3273680|NCT00671827||Robotic Gynecologic Surgery|Patients who have undergone or will undergo a robotic-assisted gynecologic procedure.
3273681|NCT00671814|Experimental|1|Single oral dose of TR-701 given once at 200mg, 400mg, 600mg, 800mg, and 1200mg. Multiple oral doses of TR-701 given once daily for 21 days at 200mg, 300mg and 400mg.
3273682|NCT00671814|Placebo Comparator|2|Single oral dose of placebo given in cohorts 1-5. Multiple oral doses of placebo given once daily for 21 days in cohorts 6-8 and twice daily for 21 days in cohort 10.
3274159|NCT00668109|Experimental|Arm 1|
3273684|NCT00671801|Experimental|Irinotecan + Lenalidomide|Irinotecan 200 mg/m^2 intravenous once every 2 weeks on days 1 and 15; Lenalidomide orally 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
3273685|NCT00671788|Experimental|Treatment (dasatinib)|Patients receive oral dasatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3273686|NCT00671775||Bariatric surgery patients|
3273687|NCT00671775||Weight loss programs|
3273688|NCT00671749|Experimental|Study Treatment|"adapalene gel, 0.3%~Other Names:~Differin® Gel, 0.3% Applied once daily at bedtime~clindamycin/benzoyl peroxide gel~Other Names:~Duac® Gel Applied once daily in the morning"
3273689|NCT00671736|Experimental|1|daily inhalation
3273690|NCT00671736|Experimental|2|inhalation every other day
3273691|NCT00671736|Experimental|3|inhalation twice a week
3273692|NCT00671736|Placebo Comparator|4|daily inhalation
3273693|NCT00671723|Placebo Comparator|Normal saline|Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
3273694|NCT00671723|Active Comparator|Hypertonic saline|Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
3273695|NCT00671723|Active Comparator|Dornase alpha|2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
3273696|NCT00671697|Experimental|Dose Level 1 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.1 mg/kg/day IV x 5 days followed by weekly doses of 0.1 mg/kg IV for 15 additional weeks.~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
3273697|NCT00671697|Experimental|Dose Level 2 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.2 mg/kg/day IV x 5 days followed by weekly doses of 0.2 mg/kg IV for 15 additional weeks.~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
3273698|NCT00671697|Experimental|Dose Level 3 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.3 mg/kg/day IV x 5 days followed by weekly doses of 0.3 mg/kg IV for 15 additional weeks.~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
3273699|NCT00671671|Experimental|Cohort B|
3273700|NCT00671671|Experimental|Cohort A|Dose study drug in subjects who have previously failed to respond to interferon based therapies
3273701|NCT00671658|Experimental|HYPER-CVAD|Rituximab 375 mg/m2 by vein. Cyclophosphamide (CTX) 300 mg/m2 by vein. Doxorubicin 50 mg/m2 by vein. Vincristine 2 mg by vein. Dexamethasone 40 mg by vein or by mouth (P.O.). Methotrexate (MTX) 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7 - 200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8. Cytarabine 100 mg intrathecal for Courses 1,3,5,7 - 3 gm/m2 by vein for Courses 2,4,6,8. G-CSF 10 ug/kg subcutaneous injection. Mesna 600 mg/m2 a day by vein. Pegylated asparaginase 2000 International units/m2 by vein. Pegfilgrastim 6 mg (flat dose) within 72 hrs after completion of chemotherapy. Solumedrol 40 mg by vein for Courses 2,4,6,8.
3273702|NCT00671645|Experimental|1|
3273703|NCT00671632|Experimental|Ramelteon, triazolam, and placebo (56 poss. combinations)|Ramelteon, triazolam, and placebo (56 possible combinations total)
3273704|NCT00671606|Experimental|Intraoperative Lymphatic Mapping|Intraoperative sentinel lymph node identification (lymphatic mapping)
3273705|NCT00671593|Experimental|Experimental inhaled dust mite|All subjects receive the same experimental inhaled challenge interventions
3273706|NCT00671580|Experimental|A|PZ-601
3273707|NCT00671580|Experimental|B|PZ-601
3273708|NCT00671580|Active Comparator|C|Standard of Care
3273709|NCT00671567|Experimental|Ramelteon 8 mg QD|
3273710|NCT00671567|Experimental|Ramelteon 16 mg QD|
3273711|NCT00671567|Placebo Comparator|Placebo|
3273712|NCT00671554|Experimental|Melaxin and BCG|Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million Colony Forming Units (CFU) of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration
3273713|NCT00671541|Active Comparator|Merogel stent vs. Nasopore Stent|This study has two arms consiting of 50 subjects each (100 total) Arm 1 will recieve the standard stent (merogel)in their right sinus and a nasopore stent in their left sinus.
3273714|NCT00671541|Experimental|bacitracin vs. gentamicin treated stent|The second arm will consist of 50 new subjects. These 50 subjects will have a nasopore stent placed in the left sinus. The first 25 subjects will have nasopore stent placed postoperatively with a bacitracin soaked nasopore in right sinus the second 25 will have a gentamycin soaked nasopore stent in right sinus.
3273715|NCT00671528|Experimental|QUADRIDERME® cream|QUADRIDERME® cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)
3273716|NCT00671528|Active Comparator|Betamethasone and Gentamicin|Combination of betamethasone diproprionate cream and gentamicin sulfate cream
3273717|NCT00671528|Active Comparator|Betamethasone|Betamethasone diproprionate cream
3273718|NCT00671515|Experimental|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
3273719|NCT00671502|Experimental|Carisoprodol 700mg|tablet sustained release (SR)
3273720|NCT00671502|Experimental|Carisoprodol 500mg|sustained release(SR) tablet
3273721|NCT00671502|Placebo Comparator|Placebo|tablet
3273722|NCT00671463|Experimental|1|Pre-operative pancreatic duct stenting
3273723|NCT00671463|No Intervention|2|Control group, no endoscopy and no stent pre-operatively
3273724|NCT00671450||Group 1|Participants will be patients diagnosed with PTSD but with no history of TBI. Participants must be between the ages of 19 and 39. Participants must be compentent to sign a consent form and be willing ot participate in a vision screening.
3273725|NCT00671437|Experimental|Arm 1|"Whole body FDG-PET/CT scan and CT scan of neck and chest (within 28 days of Day 1)~Cetuximab 400 mg/m2 intravenously (IV) over 2 hours on day 1 and 250 mg/m2 IV over 1 hour on days 8, 15, 22, 29, 36, 43, and 50.~Whole Body FDG-PET/CT scan and CT scan of neck and chest on Day 57 (prior to cetuximab infusion)~Cetuximab 250 mg/m2 IV over 1 hour on Day 57~Cetuximab 250 mg/m2 IV over 1 hour weekly until progressive disease"
3273915|NCT00670059|Experimental|B|group: single embryo transfer with aneuploidy screening
3273726|NCT00671411|Experimental|1|Patients entering into this protocol will also have a preoperative renal contrast enhanced US for this research study. Renal mass US contrast enhancement results will be compared with surgical pathological findings to determine if contrast enhancement patterns of the renal masses correlate with benign and malignant histopathology, and/or malignant histologic subtype.
3273727|NCT00671398|Experimental|Ramelteon 8 mg QD|
3273728|NCT00671398|Experimental|Ramelteon 16 mg QD|
3273729|NCT00671398|Placebo Comparator|Placebo|
3273730|NCT00671385||Women 21-50 years old|Women without a diagnosis of cancer or a history of cancer.
3273731|NCT00671372|Experimental|Cohorts 1-5|
3273732|NCT00671372|Experimental|Cohorts 6, 6A, 7, 7A|
3273733|NCT00671359|Experimental|after fast|Administration of a single oral dose of 600mg TR-701 to subjects in the fasted state.
3273734|NCT00671359|Experimental|After high fat food|Administration of a single oral dose of 600mg TR-701 to subjects in the fed state.
3273735|NCT00671346||1|Participants in NORVIT and WENBIT allocated to daily oral treatment with folic acid 0.8 mg and vitamin B12 0.4 mg
3273736|NCT00671346||2|Participants in NORVIT and WENBIT allocated to daily oral treatment with folic acid 0.8 mg, vitamin B12 0.4 mg and B6 40 mg.
3273737|NCT00671346||3|Participants in NORVIT and WENBIT allocated to daily oral treatment with vitamin B6 40 mg.
3273738|NCT00671346||4|Participants in NORVIT and WENBIT allocated to daily oral treatment with placebo
3273739|NCT00671333|Active Comparator|1|(LRTI) Ligament reconstruction and tendon interposition
3273740|NCT00671333|Active Comparator|2|Ascension PyroDisk
3273741|NCT00671320|Active Comparator|Arm 1|
3273742|NCT00671320|Active Comparator|Arm 2|
3273743|NCT00671307|Placebo Comparator|Placebo|Placebo
3273744|NCT00671307|Experimental|Low dose|3 mg/kg of rhu-pGelsolin given as an IV infusion over 1 hour
3273745|NCT00671307|Experimental|Mid-dose|6 mg/kg of rhu-pGelsolin given as an IV infusion over 1 hour
3273746|NCT00671307|Experimental|High dose|6 mg/kg of rhu-pGelsolin given a an IV infusion over 1 hour once a day for 3 days
3273747|NCT00671294|Experimental|Ramelteon and Placebo QD (9 possible combinations total)|
3273748|NCT00671281|Experimental|B|This group will be the experimental group which will receive tranexamic acid in oral form three days before and six days after surgery.
3273749|NCT00671281|Placebo Comparator|A|This will be the control group which will take the placebo medication for 3 days before and six days after their functional endoscopic sinus surgery (FESS).
3273750|NCT00671268|Experimental|1|strict subcutaneous
3273751|NCT00671268|Placebo Comparator|2|strict subcutaneous
3273752|NCT00671255|Experimental|Ramelteon 4 mg QD|
3273753|NCT00671255|Experimental|Ramelteon 8 mg QD|
3273754|NCT00671255|Placebo Comparator|Placebo|
3273755|NCT00671242||I|L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer
3273756|NCT00671242||Nuclear|
3273757|NCT00671229||1|African American
3273758|NCT00671229||2|Caucasian
3273759|NCT00671216|Experimental|Period 1|Subjects will receive first placebo, then GSK233705, GW642444 and combination of GSK233705 and GW642444
3273760|NCT00671216|Experimental|Period 2|Subjects will receive first combination of GSK233705 and GW642444, then placebo, GSK233705 and GW642444
3273761|NCT00671216|Experimental|Period 3|Subjects will receive first GSK233705, then GW642444, combination of GSK233705 and GW642444 and later placebo
3273762|NCT00671216|Experimental|Period 4|Subjects will receive first GW642444, then combination of GSK233705 and GW642444, placebo, and later GSK233705
3273763|NCT00671190|Experimental|Ramelteon 1 mg QD|
3273764|NCT00671190|Experimental|Ramelteon 2 mg QD|
3273765|NCT00671190|Experimental|Ramelteon 4 mg QD|
3273766|NCT00671190|Experimental|Ramelteon 8 mg QD|
3273767|NCT00671190|Placebo Comparator|Placebo QD|
3273768|NCT00671177|Experimental|Water Immersion Colonoscopy|Water Immersion Colonoscopy
3273769|NCT00671177|Active Comparator|Standard Air Colonoscopy|Standard Air Colonoscopy
3273770|NCT00671151|Active Comparator|1|Low-dose theophylline on top of standard therapy for COPD exacerbation
3273771|NCT00671151|No Intervention|2|Standard therapy for COPD exacerbation
3273772|NCT00671138|Active Comparator|I|Arm I will be inoculated with the human hookworm necator americanus at weeks 0 and 12.
3273773|NCT00671138|Placebo Comparator|II|Arm II participants will receive and identical sham-inoculums comprising a diluted amount of 0.2ml McIlhenny & Co Tabasco Pepper Sauce®
3273774|NCT00671125|Experimental|Ramelteon 8 mg QD|
3273775|NCT00671125|Experimental|Ramelteon 16 mg QD|
3273776|NCT00671125|Placebo Comparator|Placebo|
3273777|NCT00671112|Experimental|Everolimus and Bortezomib|Patients will receive a combination of Everolimus by mouth and Bortezomib intravenously for a 21 day cycle.
3273778|NCT00671099|Experimental|1|Dietary Supplement: Omega-3 Polyunsaturated Fatty Acid
3273779|NCT00671099|Placebo Comparator|2|Placebo
3273780|NCT00671086|Experimental|Ramelteon 8 mg QD|
3273781|NCT00671086|Experimental|Ramelteon 16 mg QD|
3273782|NCT00671073|Active Comparator|1|Oglemilast low dose, oral administration once daily for 12 weeks
3273783|NCT00671073|Active Comparator|2|Oglemilast middle dose, oral administration, once daily for 12 weeks
3273784|NCT00671073|Active Comparator|3|Oglemilast high dose, oral administration, once daily for 12 weeks.
3273785|NCT00671073|Placebo Comparator|4|Placebo
3273786|NCT00671060|Active Comparator|2|Women in Group 1 will be administered two tablets (2 100 mcg misoprostol tablets), which she will be instructed to hold in her cheeks for 200 minutes, after which she will swallow any medication that remains. In cases where cervical dilation is not complete after six hours, women will be given a second dose of study drug. Study drug will continue to be administered at 6-hourly intervals through hour 42 after the study dose.
3273909|NCT00670124|Active Comparator|2|Standard medical treatment plus hypothermia (33°C) maintained for 72 hours
3274045|NCT00669097|Experimental|TKI258|
3274046|NCT00669071|Active Comparator|IPL / Tri-Luma® Cream|
3273787|NCT00671060|Placebo Comparator|1|Women in Group 1 will be administered two tablets (a 100 mcg misoprostol tablet and a placebo tablet made to resemble a 100 mcg misoprostol tablet), which she will be instructed to hold in her cheeks for 200 minutes, after which she will swallow any medication that remains. In cases where cervical dilation is not complete after six hours, women will be given a second dose of study drug. Study drug will continue to be administered at 6-hourly intervals through hour 42 after the study dose.
3273788|NCT00671047||1|SLE subjects with flares in the last 12 months in specific organ systems.
3273789|NCT00671034|Experimental|Arm I (combination chemotherapy)|Patients receive calaspargase pegol together with combination chemotherapy. Patients receive chemotherapy PO, IV, SC, and IT. Some patients also undergo radiation therapy to the head. Treatment may continue for up to 3 1/2 years.
3273790|NCT00671034|Experimental|Arm II (combination chemotherapy)|Patients receive calaspargase pegol together with combination chemotherapy. Patients receive chemotherapy PO, IV, SC, and IT. Some patients also undergo radiation therapy to the head. Treatment may continue for up to 3 1/2 years.
3273791|NCT00671034|Active Comparator|Arm III (combination chemotherapy)|Patients receive pegaspargase together with combination chemotherapy. Patients receive chemotherapy PO, IV, SC, and IT. Some patients also undergo RT to the head. Treatment may continue for up to 3 1/2 years.
3273792|NCT00671021||1|Patients suffering from stable CAD, on chronic ASA therapy
3273793|NCT00671008||A|
3273794|NCT00671008||B|
3273795|NCT00670982|Experimental|First line treatment|Patients with no prior therapy for metastatic breast cancer will receive bevacizumab intravenously every 2 weeks and vinorelbine intravenously once per week, and trastuzumab intravenously once per week
3273796|NCT00670982|Experimental|Second line treatment|Patients with 1 prior line for metastatic breast cancer will receive bevacizumab intravenously every two weeks, vinorelbine intravenously once per week, and trastuzumab intravenously once per week.
3273797|NCT00670969||A|People who will have the portable measurement taken first and handheld measurement taken second
3273798|NCT00670969||B|People who will have the handheld measurement taken first and portable measurement taken second
3273799|NCT00670956|Active Comparator|Active Study Group|STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart
3273800|NCT00670956|Placebo Comparator|Placebo Group|PLACEBO: IM x 2 doses 24 hours apart
3273801|NCT00670943||A|Patients with stable CAD with scheduled discontinuation of clopidogrel
3273802|NCT00670943||B|Patients with stable CAD not taking clopidogrel
3273803|NCT00670930|Active Comparator|omalizumab|Omalizumab was supplied as lyophilized, sterile powder in a single use, 5 ml vial that was designed to deliver 150 mg of omalizumab for subcutaneous (SQ) administration upon reconstitution with 1.4 ml sterile water for injection. The dose administered was individualized for each patient based on the patient's body weight and total serum Immunoglobulin E (IgE) level at Visit 1 and the number of injections and injection volume was determined using protocol-specified dosing tables. Omalizumab 75 to 375 mg was administered SQ every 2 or 4 weeks depending on the dose for the 78 weeks duration of double-blinded treatment.
3273804|NCT00670930|Placebo Comparator|Placebo|Omalizumab matching placebo was supplied as lyophilized, sterile powder in a single-use, 5 ml vial that was designed to deliver omalizumab matching placebo for subcutaneous (SQ) administration upon reconstitution with 1.4 ml sterile water for injection. The number of injections and injection volume was individualized for each patient based on the patient's body weight and total serum Immunoglobulin E (IgE) level at Visit 1 and was determined using protocol-specified dosing tables. Placebo was administered SQ every 2 or 4 weeks for the 78 weeks duration of double-blinded treatment.
3273805|NCT00670917|Active Comparator|L14 acupoint|
3273806|NCT00670917|Sham Comparator|Sham Point|
3273807|NCT00670904|Active Comparator|1|Pharmacist-delivered group program for smoking cession.
3273808|NCT00670904|Placebo Comparator|2|Brief standard care session for tobacco smoking cessation delivered over the telephone.
3273809|NCT00670891|Experimental|HBOT|HBOT
3273810|NCT00670878|Experimental|A|
3273811|NCT00670878|Active Comparator|B|
3273812|NCT00670865|Experimental|eDischarge|The eDischarge arm will consist of two teams on the General Internal Medicine ward at St. Michael's Hospital who have been randomly assigned to use the electronic discharge summary program.
3273813|NCT00670865|No Intervention|Traditional|"The traditional arm will consist of two teams on the General Internal Medicine ward at St. Michael's Hospital who have been randomly assigned to use traditional, dictated discharge summaries."
3273814|NCT00670852||I|Patients who received a total shoulder replacement with an anchor peg glenoid and autologous bone grafting from the investigator of this study will be recruited for this study.
3273815|NCT00670839|Active Comparator|A|GenHevac-B 20 microgram intramuscular use at M0, M1 and M6
3273816|NCT00670839|Experimental|B|GenHevac-B 40 microgram intramuscular use at M0, M1 and M6
3273817|NCT00670826|Experimental|1|Use of the Dynatherm Medical vitalHEAT vH2 Temperature Management System to warm patients undergoing orthopedic surgical procedures with an expected duration 2-3 hours and requiring general anesthesia.
3273818|NCT00670826|Active Comparator|2|Use of the Arizant Healthcare Bair Hugger Temperature Management System & Bair Hugger Upper Body Blanket to warm patients undergoing orthopedic surgical procedures with an expected duration 2-3 hours and requiring general anesthesia.
3273819|NCT00670813|Experimental|Modafinil (Vigil)|"Modafinil Arm: during the 40 h sleep deprivation period (morning until evening next day) the depressed patient receives 200 mg of Modafinil each at 12:00, 24:00 and again at 12:00 o' clock"
3273820|NCT00670813|Placebo Comparator|Placebo|"Placebo Arm: during the 40 h sleep deprivation period (morning until evening next day) the depressed patient receives Placebo at 12:00, 24:00 and again at 12:00 o' clock"
3273821|NCT00670800|No Intervention|Normal Controls|Control subjects will have 5 visits (screening, oral glucose tolerance test (OGTT), neuropsychological testing, functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) as they will receive no treatment and will not have repeat studies. The baseline values obtained from the control subjects will be compared to the baseline values acquired from the PCOS affected subjects.
3273910|NCT00670111|Experimental|RAP On then Off at 1 month visit|"Rate Adaptive Pacing (RAP) On for first cardiopulmonary exercise test (CPX) at one month.~Rate Adaptive Pacing (RAP) Off for second cardiopulmonary exercise test (CPX) at one month."
3273822|NCT00670800|Experimental|PCOS Affected Women-Metformin Treatment|Subjects with Polycystic Ovary Syndrome (PCOS) will be scheduled for 9 visits total: following the screening visit they will go through OGTT, neuro-psychological testing, fMRI and PET scan before and after 4 months of metformin use: 500mg tablets once daily with breakfast for 1 week, then increased to one tablet twice daily with breakfast & lunch for 1 week, then increased to one tablet three times daily with breakfast, lunch & dinner.
3273823|NCT00670787|Active Comparator|Combination pill|Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
3273824|NCT00670787|No Intervention|Control group|combination therapy of angiotensin receptor antagonists (losartan potassium 50mg, candesartan 8mg, valsartan 80mg, telmisartan 40mg or olmesartan 20mg) and thiazide or thiazide-like diuretics (hydrochlorothiazide 6.25-12.5mg, trichlormethiazide 0.5-1.0mg, indapamide 0.5-1.0mg or chlorthalidone 6.25-12.5mg)
3273825|NCT00670774|Experimental|Eculizumab|Patients received eculizumab intravenously according to details provided in the intervention description.
3273826|NCT00670761|Active Comparator|1|treatment with 600mcg oral misoprostol
3273827|NCT00670761|Active Comparator|2|treatment with 400mcg sublingual misoprostol
3273828|NCT00670761|Active Comparator|3|treatment with Manual Vacuum Aspiration (MVA)
3273829|NCT00670748|Experimental|#1 Anti-NY-ESO-1 TCR PBL+HD IL-2 Mel/RCC|Patients with melanoma or renal cell cancer (RCC) will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin.
3273830|NCT00670748|Experimental|#2 Anti-NY-ESO-1 TCR PBL+HD IL-2 OtherCa|Patients with cancers other than melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by anti-NY ESO-1 TCR PBL and high dose (HD) aldesleukin
3273831|NCT00670748|Experimental|#3ESO1 TCR PBL+ALVAC ESO1+HD IL2 Mel/RCC|Patients with melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by replication-defective recombinant canarypox virus (ALVAC) NY-ESO-1 vaccine, anti-NY ESO-1 TCR PBL and high dose aldesleukin
3273832|NCT00670748|Experimental|#4ESO1 TCR PBL+ALVAC ESO1+HD IL2 OtherCa|Patients with cancers other than melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by ALVAC NY-ESO-1 vaccine, anti-NY ESO-1 TCR PBL and high dose aldesleukin
3273833|NCT00670722||A|
3273834|NCT00670722||B|
3273835|NCT00670722||C|
3273836|NCT00670722||D|
3273837|NCT00670709||1|Subjects with mild or moderate Huntington's Disease
3273838|NCT00670709||2|Normal Controls
3273839|NCT00670696|Experimental|A|Rapydan medicated plaster administered 30 minutes prior to cannulation on Visit 1 and tetracaine gel administered 45 minutes prior to cannulation on Visit 2.
3273840|NCT00670696|Active Comparator|B|Tetracaine gel administered 45 prior to cannulation on Visit 1 and then Rapydan administered 30 minutes prior to cannulation on Visit 1
3273841|NCT00670683||A|
3273842|NCT00670670|Experimental|1|CPP-ACP (GC Tooth Mousse)
3273843|NCT00670670|Experimental|2|CPP-ACP (GC MI Paste Plus)
3273844|NCT00670670|No Intervention|3|Control group
3273845|NCT00670657|Experimental|1|AmBisome® 2 mg/kg/day in a unique daily IV administration
3273846|NCT00670631|Experimental|Tandem autologous stem cell transplant|"Induction: DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant 1: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide) Transplant 2: 8 weeks to 6 months after the first transplant, participants will have the second transplant Maintenance: Year 1- VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
3273847|NCT00670618|Experimental|1|CPP-ACP (GC Tooth Mousse)
3273848|NCT00670618|Experimental|2|GCC-ACP (GC MI Paste Plus)
3273849|NCT00670618|Experimental|3|Fluoride (Elmex Medical Gel)
3273850|NCT00670618|No Intervention|4|Control group
3273851|NCT00670592|Other|HCD122|
3273852|NCT00670566|Experimental|1|
3273853|NCT00670553|Experimental|LBH589|
3273854|NCT00670540||1|patients with suspected Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)
3273855|NCT00670514|Active Comparator|1 Nix Individual|High Treatment Intensity
3273856|NCT00670514|Placebo Comparator|2 Fimpa dig fri|Low Treatment Intensity
3273857|NCT00670501|Experimental|1|LY333334 40 micrograms/day plus calcium and vitamin D
3273858|NCT00670501|Experimental|2|LY333334 20 micrograms/day plus calcium and vitamin D
3273859|NCT00670501|Placebo Comparator|3|Placebo plus calcium and vitamin D
3273860|NCT00670488|Experimental|QOD Schedule|MK2206 every other day
3273861|NCT00670488|Experimental|QW Schedule|MK2206 once weekly
3273862|NCT00670475|Active Comparator|P (Pircoxicam Group)|in this arm 100 patients with osteoarthritis of knee will receive piroxicam gel in blinded 60 grams tubes,they will be instructed to use 1 gram of piroxicam gel (with inserted dispensing device) three times in a day on the affected knee.
3273863|NCT00670475|Experimental|O (olive oil group)|in this arm 100 patients with osteoarthritis of knee will receive virgin olive oil in blinded 60 grams tubes,they will be instructed to use 1 gram of olive oil (with inserted dispensing device) three times in a day on the affected knee.
3273864|NCT00670462|Active Comparator|Standard Behavioral Treatment (SBT)|"Standard Behavioral Treatment (SBT) for weight loss intervention introduces a core set of instructions on diet and exercise at the beginning of the intervention and then embellishes these instructions with suggested refinements of behavioral choices over time (e.g., different menus and amounts or types of physical activity)."
3273911|NCT00670111|Experimental|RAP Off then On at 1 month visit|"Rate Adaptive Pacing (RAP) Off for first cardiopulmonary exercise test (CPX) at one month.~Rate Adaptive Pacing (RAP) On for second cardiopulmonary exercise test (CPX) at one month."
3273912|NCT00670098|Experimental|1|
3273913|NCT00670098|Experimental|2|
3274160|NCT00668109|Active Comparator|Arm 2|
3273865|NCT00670462|Experimental|Maintenance-Tailored Treatment (MTT)|"Maintenance-Tailored Treatment (MTT) for weight loss intervention treats diet and exercise strategy embellishments as separate interventions with discrete and independent status. MTT differs from SBT in its emphasis on skills for long-term weight control, namely, the strategy of initiating varied weight-control strategies as a response to the demands of changing environmental challenges and to sustain effective cues and reinforcements needed to motivate weight-loss behaviors."
3273866|NCT00670449|Experimental|Fingolimod 0.5 mg|Patients who received fingolimod 0.5 orally once daily in the core study continued on the same dose in this extension study.
3273867|NCT00670449|Experimental|Fingolimod 1.25 mg|Patients who received fingolimod 1.25 mg orally once daily in the core study continued on the same dose in this extension study.
3273868|NCT00670449|Experimental|Placebo-fingolimod|Patients who were randomized to placebo in the core study were re-randomized to either fingolimod 0.5 or 1.25 mg (1:1) orally once daily in this extension study.
3273869|NCT00670436|Active Comparator|A 1|paclitaxel eluting PTCA balloon (SeQuent please) after bare-metal stenting of a chronic total occlusion in a native coronary artery
3273870|NCT00670436|Active Comparator|A2|historical population of patients with a chronic total occlusion in a native coronary artery treated with the paclitaxel eluting Taxus stent (Boston Scientific)
3273871|NCT00670410|Experimental|Arm A - Related Donor|Related donor transplant: Patients with a related donor (5/6 or 6/6 HLA matched) will receive immunotherapy with a non-myeloablative preparative regimen of Busulfan and Fludarabine followed by allogeneic stem cell transplant (AlloSCT).
3273872|NCT00670410|Experimental|Arm B - Cord Blood Donor|Unrelated cord blood transplant: Patients without a related donor will receive immunotherapy with a non-myeloablative preparative regimen of busulfan and fludarabine followed by allogeneic stem cell transplant (AlloSCT) with either an unrelated umbilical cord blood donor (4/6, 5/6, or 6/6 HLA matched), or a related umbilical cord blood donor (3/6, 4/6, 5/6, or 6/6 HLA matched). Patients will receive Thymoglobulin ((rabbit) Anti-Thymocyte Globulin (ATG)) during the preparative regimen. GVHD prophylaxis will be Tacrolimus and mycophenolate mofetil (MMF).
3273873|NCT00670397|Experimental|Treatment (PDT)|Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light treatment to the tumor bed on day 2. Treatment may repeat every 8 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3273874|NCT00670384|Active Comparator|Dose Group A|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)
3273875|NCT00670384|Active Comparator|Dose Group B|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)
3273876|NCT00670384|Placebo Comparator|Placebo|
3273877|NCT00670371||1|Patients having the following diagnoses are eligible for inclusion into the study: schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, delusional disorder, affective psychosis with mood incongruent delusions, psychotic disorder not otherwise specified or patients being actively psychotic.
3273878|NCT00670371||2|Closest relative(s) /informal caregiver(s)
3273879|NCT00670345|Experimental|1|Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
3273880|NCT00670345|Placebo Comparator|2|Patients belonging to the control group will receive the same volume of saline infusions.
3273881|NCT00670319|Experimental|1|Raloxifene HCL 60 mg orally once a day
3273882|NCT00670319|Experimental|2|Raloxifene HCL 120 mg orally once a day
3273883|NCT00670319|Placebo Comparator|3|
3273884|NCT00670306|Experimental|Cetrorelix 78 mg|Drug: Cetrorelix 52 mg week 0, and 26 mg week 2, intra muscular-2 doses in 2 weeks and follow up to week 26.
3273885|NCT00670293||Subjects with anorexia nervosa|Underweight participants with anorexia nervosa who will restore normal weight levels after inpatient treatment will undergo Positron Emission Tomography (PET) using [11C]raclopride as well as MRI
3273886|NCT00670293||Healthy weight controls|Participants who are healthy controls will undergo Positron Emission Tomography (PET) using [11C]raclopride as well as MRI
3273887|NCT00670280|Experimental|Intervention Group|Those randomized to the Intervention group will meet twice over a two-week period with a trained counselor while visiting the neonatal intensive care unit.
3273888|NCT00670280|Active Comparator|UC Group|Those randomized to the Usual Care group will receive written information on secondary smoke and infant health and will be assessed at 1 month, 3 months, and 6 months post-intervention.
3273889|NCT00670280|Active Comparator|UC-RM Group|Those randomized to the Usual Care - Reduced Measurement group will receive the same information as the Usual Care group but will be measured less often (only at 6 months post-intervention).
3273890|NCT00670267|Experimental|Open Label treatment with oral Nadolol|Dose escalation through 1.25mgs, 2.5mgs, 5.0mgs, 10mgs, 20mgs, and 40mgs of nadolol at 2 week intervals as tolerated.
3273891|NCT00670254|Experimental|Hydrocortisone|
3273892|NCT00670254|Placebo Comparator|Placebo|
3273893|NCT00670241|Active Comparator|1|
3273894|NCT00670241|Active Comparator|2|
3273895|NCT00670241|Placebo Comparator|3|
3273896|NCT00670228|Active Comparator|Intensive Insulin Therapy (IIT)|In IIT arm, subjects received intravenous (IV) insulin glulisine and subcutaneous (sc) insulin glargine to maintain a Blood Glucose (BG) concentration between 90-130 mg/dL.
3273897|NCT00670228|Active Comparator|Standard Glycemic Care (SGC)|"In SGC arm subjects assigned to standard of care received subcutaneous regular insulin per sliding scale."
3273898|NCT00670215|Experimental|Arm 1|
3273899|NCT00670215|Experimental|Arm 2|
3273900|NCT00670202|Experimental|Drug: Fasudil hydrochloride|Fasudil hydrochloride 40 mg three times a day X 14 days
3273901|NCT00670202|Placebo Comparator|Drug: Placebo oral tablet|Placebo 1 tablet three times daily x 14 days
3273902|NCT00670189|Experimental|BMS-833923|
3273903|NCT00670176|Experimental|I|
3273904|NCT00670163|Experimental|1|Participating community will provide Comunidades Positivas plus enhanced partner therapy.
3273905|NCT00670163|Experimental|2|Participating community will provide enhanced partner therapy alone.
3273906|NCT00670163|Experimental|3|Participating community will provide Comunidades Positivas alone.
3273907|NCT00670163|Active Comparator|4|Participating community will provide standard of care.
3273916|NCT00670046|No Intervention|Arm I (observation)|Patients undergo observation according to standard of care. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.
3273917|NCT00670046|Experimental|Arm II (valproic acid)|Patients receive oral valproic acid twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.
3273918|NCT00670033|Experimental|Travoprost new formulation|Travoprost ophthalmic solution (new formulation), 1 of 3 dose levels, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
3273919|NCT00670033|Active Comparator|TRAVATAN|Travoprost ophthalmic solution 0.004%, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
3273920|NCT00670033|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
3273921|NCT00670020|Experimental|1|supplemental perioperative oxygen
3273922|NCT00670020|No Intervention|2|Normal
3273923|NCT00670007|Experimental|Zemaira®|
3273924|NCT00669994|Experimental|Arm 1|
3273925|NCT00669981|Experimental|1|Participants will receive immediate cognitive behavioral couples therapy for PTSD.
3273926|NCT00669981|Active Comparator|2|Participants will receive delayed cognitive behavioral couples therapy for PTSD after a 3-month waitlist period.
3273927|NCT00669955|Active Comparator|OAC 7 days|Triple therapy, given for 7 days at a dose of omeprazole 20 mg twice daily, amoxicillin 500 mg 2 capsules twice daily, and clarithromycin 500 mg 1 tablet twice daily
3273928|NCT00669955|Experimental|OBMT 10 days|OBMT (Pylera), consisting of a 3 in 1 capsule, made of bismuth subcitrate potassium 120 mg, metronidazole 125 mg, and tetracycline 125 mg, administered as 3 capsules 4 times daily. Omeprazole 20 mg is administered twice daily.
3273929|NCT00669942|Experimental|Part 1 - AIN457A 0.3 mg/kg|AIN457A 0.3 mg/kg was administered intravenously as a single dose.
3273930|NCT00669942|Experimental|Part 1 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as a single dose.
3273931|NCT00669942|Experimental|Part 1 - AIN457A 3.0 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as a single dose.
3273932|NCT00669942|Experimental|Part 1 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as a single dose.
3273933|NCT00669942|Placebo Comparator|Part 1 - Placebo|Placebo to AIN457A was administered intravenously as a single dose.
3273934|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
3273935|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 3.0 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
3273936|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
3273937|NCT00669942|Placebo Comparator|Parts 2 and 3 - Placebo|Placebo to AIN457A was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
3273938|NCT00669942|Experimental|Part 1 - Healthy Volunteers - AIN457A 3 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as a single dose.
3273939|NCT00669942|Experimental|Part 1 - Healthy Volunteers - AIN457A 10 mg/kg|AIN457A 10 mg/kg was administered intravenously as a single dose.
3273940|NCT00669942|Placebo Comparator|Part 1 - Healthy Volunteers - Placebo|Placebo to AIN457A was administered intravenously as a single dose.
3273941|NCT00669929||1|patients visited to Severance hospital
3273942|NCT00669929||2|patients visited to Youngdong Severance hospital
3273943|NCT00669929||3|patients visited to Wonju Christian hospital
3273944|NCT00669916|Experimental|AIN457|AIN457A 3mg/kg was administered intravenously as a single dose.
3273945|NCT00669916|Placebo Comparator|Placebo|Placebo was administered intravenously as a single dose.
3273946|NCT00669903|Experimental|1|AZD0328 low dose
3273947|NCT00669903|Experimental|2|AZD0328 Optimal dose
3273948|NCT00669903|Experimental|3|AZD0328 High dose
3273949|NCT00669903|Placebo Comparator|4|Placebo Comparator
3273950|NCT00669890|Experimental|study 515|
3273951|NCT00669877|Experimental|Hyper-CVAD|Hyper-CVAD (odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses. Rituximab 375 mg/m2 days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses. Cyclophosphamide 300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3. Doxorubicin 50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses). Vincristine 2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses). Dexamethasone 40 mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses). G-CSF 10 mg/kg/day (rounded) until neutrophil recovery 1 x 10^9/L or higher can be substituted or can be added to pegfilgrastim if neutrophils have not recovered to 1 x 10^9/L by day 21.
3273952|NCT00669864|Experimental|BIAsp 30-30|Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 1000-2000mg, up to three times daily
3273953|NCT00669838||PL|Patients who receive local anesthesia with 2% lidocaine without epinephrine
3273954|NCT00669838||LE|Patients who receive local anesthesia with 2% lidocaine with 1:100.000 epinephrine
3273955|NCT00669825|Placebo Comparator|A|Placebo
3273956|NCT00669825|Active Comparator|B|ALV003 (Active Study Drug)
3273957|NCT00669799|Experimental|1|clyndamyacin
3273958|NCT00669799|Experimental|2|gentamicin
3273959|NCT00669786|Active Comparator|HMG|Human Menopausal Gonadotropin (HMG)
3273960|NCT00669786|Active Comparator|r-FSH|Recombinant Follicle Stimulating Hormone
3273961|NCT00669773|Experimental|Adriamycin|Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly
3273962|NCT00669773|Experimental|Docetaxel|
3273963|NCT00669760||Observation|CF-patients with persistent culture of Staphylococcus aureus in their respiratory specimens
3273964|NCT00669747|Experimental|A|Carboplatin infused into DCIS-involved duct on Days 1 & 15
3274047|NCT00669071|Active Comparator|IPL/Cetaphil® Moisturizing Cream as Inactive Control|
3273965|NCT00669747|Experimental|B|Carboplatin infused into DCIS-involved duct Day 1 and Normal Saline infused into DCIS-involved duct on Day 15
3273966|NCT00669747|Placebo Comparator|C|Normal Saline infused into DCIS-involved duct Days 1 & 15
3273967|NCT00669734|Experimental|Treatment (vaccine therapy, sargramostim)|Patients receive falimarev vaccine intratumorally using endoscopic ultrasound guidance on day 1. Patients also receive inalimarev vaccine SC on day 1 and sargramostim SC on days 1-4. Patients then receive falimarev vaccine SC on days 15 and 29 and sargramostim SC on days 15-18 and 29-32 in the absence of unacceptable toxicity. Beginning on day 43, patients with stable or improving pancreatic cancer receive falimarev vaccine SC and sargramostim SC (given on the day of and for 3 days after each falimarev vaccination) monthly in the absence of disease progression or unacceptable toxicity. Beginning on day 71, patients with no irreversible or dose limiting toxicity, receive falimarev vaccine SC and sargramostim SC (given on the day of and for 3 days after each falimarev vaccination) monthly in the absence of disease progression or unacceptable toxicity.
3273968|NCT00669721|Experimental|A|This patients start a run in period with LMWH schedule as hemodialysis circuit anticoagulation. Then they'll undergo hemodialysis with LMWH for a second period of two weeks: in this checking phase samples will be collected during the midweek hemodialysis sessions. After the checking phase the patients will be crossed to UFH schedule. A wash out period of two weeks with UFH will be done. At the end of this period two weeks of checking phase will starts.
3273969|NCT00669721|Active Comparator|B|The patients randomized to receive UFH will start a run in period with this heparin schedule. Then they'll undergo hemodialysis with UFH for a second period of two weeks: in this checking phase samples will be collected during the midweek hemodialysis sessions. After the checking phase the patients will be crossed to LMWH. A wash out period of two weeks with UFH will be done. At the end of this period two weeks of checking phase will starts.
3273970|NCT00669708|Active Comparator|1|ph5 Eucerin Lotion with cooling compound
3273971|NCT00669708|Placebo Comparator|2|ph5 Eucerin Lotion
3273972|NCT00669695|Placebo Comparator|Stat/CPAP|Atorvastatin and CPAP treatments
3273973|NCT00669695|Placebo Comparator|Stat/sham CPAP|Atorvastatin and sham CPAP treatments
3273974|NCT00669695|Sham Comparator|Placebo/CPAP|Placebo and CPAP treatments
3273975|NCT00669695|Active Comparator|Placebo/sham CPAP|Placebo and sham CPAP treatments
3273976|NCT00669682||Group A|The study group will include Class III to IV heart failure patients followed in the device clinic that have a chronically implanted (more than 90 days) Medtronic biventricular defibrillator with the ability to monitor intrathoracic impedance.
3273977|NCT00669669|Experimental|Treatment (chemotherapy, autologous stem cell transplant)|See Detailed Description
3273978|NCT00669656|Experimental|Prostate Health Cocktail|
3273979|NCT00669643|Active Comparator|R-MDT PB|R-MDT PB group: standard/regular treatment recommended by WHO - All patients presenting fewer than 6 skin lesions will receive the standard treatment regimen for paucibacillary patients as the intervention; Intervention - PB 6 doses of rifampicin and dapsone
3273980|NCT00669643|Experimental|U-MDT PB|U-MDT PB group: a unified treatment for all patients - All patients presenting fewer than 6 lesions (WHO PB) will receive 6 doses of rifampicin, clofazimine and dapsone as the intervention; Intervention - PB 6 doses of rifampicin, clofazimine and dapsone
3273981|NCT00669643|Experimental|R-MDT MB|R-MDT MB group: standard/regular treatment recommended by WHO - All patients presenting 6 skin or more lesions will receive the standard treatment regimen for multibacillary patients as the intervention; Intervention - MB 12 doses of rifampicin, clofazimine and dapsone
3273982|NCT00669643|Experimental|U-MDT MB|U-MDT MB group: a unified treatment for all patients - All patients presenting 6 lesions or more (WHO MB) will receive 6 doses of rifampicin, clofazimine and dapsone as the intervention; Intervention - MB 6 doses of rifampicin, clofazimine and dapsone
3273983|NCT00669617|Experimental|Ind 150μg, Salm/flut, Ind 300μg, Placebo, Salbut|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Indacaterol 150 μg (Ind 150μg), Salmeterol/fluticasone 50/500 μg (Salm/flut), Indacaterol 300 μg (Ind 300μg), Placebo, Salbutamol 200 μg (Salbut). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3273984|NCT00669617|Experimental|Ind 300μg, Ind 150μg, Salbut, Salm/flut, Placebo|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Indacaterol 300 μg (Ind 300μg), Indacaterol 150 μg (Ind 150μg), Salbutamol 200 μg (Salbut), Salmeterol/fluticasone 50/500 μg (Salm/flut), Placebo. At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3273985|NCT00669617|Experimental|Salm/flut, Placebo, Ind 150μg, Salbut, Ind 300μg|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Salmeterol/fluticasone 50/500 μg (Salm/flut), Placebo, Indacaterol 150 μg (Ind 150μg), Salbutamol 200 μg (Salbut), Indacaterol 300 μg (Ind 300μg). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3273986|NCT00669617|Experimental|Salbut, Ind 300μg, Placebo, Ind 150μg, Salm/flut|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Salbutamol 200 μg (Salbut), Indacaterol 300 μg (Ind 300μg), Placebo, Indacaterol 150 μg (Ind 150μg), Salmeterol/fluticasone 50/500 μg (Salm/flut). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3274088|NCT00668720|Experimental|1|
3274089|NCT00668720|Sham Comparator|2|
3273987|NCT00669617|Experimental|Placebo, Salbut, Salm/flut , Ind 300μg, Ind 150μg|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Placebo, Salbutamol 200 μg (Salbut), Salmeterol/fluticasone 50/500 μg (Salm/flut), Indacaterol 300 μg (Ind 300μg), Indacaterol 150 μg (Ind 150μg). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3273988|NCT00669591|Experimental|1|Patients will receive up to six (6) 28-day cycles of docetaxel plus weekly bavituximab during the treatment phase. During the follow-up phase, patients will continue to receive weekly bavituximab until disease progression
3273989|NCT00669578|Experimental|CC-4047|
3273990|NCT00669552||Medtronic defibrillator|Patients undergoing a percutaneous coronary intervention (PCI) with an implanted Medtronic defibrillator with the capability of telemetry of the intracardiac signal.
3273991|NCT00669539||Combined-Mechanism Amblyopia|
3273992|NCT00669539||Strabismus-Only Amblyopia|
3273993|NCT00669526|Active Comparator|SMHC referral|Referral to local Specialty Mental Health Care Services
3273994|NCT00669526|Experimental|BCBT|Brief Cognitive Behavioral Therapy
3273995|NCT00669513|No Intervention|1|
3273996|NCT00669513|Experimental|2|Partial sleep deprivation
3273997|NCT00669487|Experimental|1. GPO-VIR S 1 pill orally every 12 hours|
3273998|NCT00669487|Experimental|2 GPO-VIR Z 1 pill orally every 12 hours|
3273999|NCT00669487|Experimental|3 Truvada 1 pill oral q 24 hr and NVP 1 pill oral q 12 hr|
3274000|NCT00669474|Other|1|Suction curettage
3274001|NCT00669474|Active Comparator|2|Treatment with Botox
3274002|NCT00669461|Experimental|Patients|
3274003|NCT00669435|Active Comparator|1|Amlodipine and Simvastatin
3274004|NCT00669435|Experimental|2|Losartan and Simvastatin
3274005|NCT00669409|Experimental|10 mcg/kg|
3274006|NCT00669409|Experimental|100 mcg/kg|
3274007|NCT00669409|Experimental|200 mcg/kg|
3274008|NCT00669409|Experimental|25 mcg/kg|
3274009|NCT00669409|Experimental|50 mcg/kg|
3274010|NCT00669409|Placebo Comparator|Placebo|
3274011|NCT00669396|Experimental|1|IUD
3274012|NCT00669396|Active Comparator|2|Oral levonorgestrel
3274013|NCT00669383|Active Comparator|A|Betamethasone (Celestone) 12 mg IM q 24 hours x 2 doses
3274014|NCT00669383|Placebo Comparator|B|Placebo dose IM q 24 hours x 2 doses
3274015|NCT00669344|Placebo Comparator|II|Placebo
3274016|NCT00669344|Experimental|I|Rivastigmine
3274017|NCT00669331|Experimental|Mannitol|Inhaled mannitol 400mg
3274018|NCT00669331|Placebo Comparator|Control|Matched control - inhaled mannitol 50mg
3274019|NCT00669318|Experimental|Treatment (Pentostatin, Alemtuzumab, Rituximab)|"Course 1: Patients receive:~2 mg/m^2 pentostatin IV on days 8 and 22;~3 mg alemtuzumab subcutaneously (SC) on day 3;~10 mg alemtuzumab SC on day 4;~30 mg alemtuzumab SC on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33;~20 mg/m^2 rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33;~6 mg Sargramostim (GM-CSF) SC on days 10-14. Patients then proceed to course 2.~Courses 2 and 3: Patients receive:~2 mg/m^2 pentostatin IV on days 1 and 15;~30 mg alemtuzumab SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26;~20 mg/m^2 rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26;~6 mg GM-CSF SC on days 3-7. After completion of course 2, patients with a complete response proceed to observation. Patients with a partial response or stable disease receive another course of therapy (course 3)."
3274020|NCT00669305||Cohort 1|Human participants affected with sickle cell disease or thalassemia will donate bone marrow for use in experimental models
3274021|NCT00669279|Experimental|Carvedilol CR|
3274022|NCT00669279|Experimental|Atenolol|
3274023|NCT00669266||Tumor|Tumor material and corresponding biosamples from patients with adrenal tumors
3274024|NCT00669266||control group|Biomaterial from patients without adrenal tumor
3274025|NCT00669253|Experimental|1|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
3274026|NCT00669253|Active Comparator|2|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods (ultrasonic and manual means)
3274027|NCT00669253|Active Comparator|3|Surgery at baseline for all deep pockets using conventional methods (ultrasonic and manual means)
3274028|NCT00669240||1. Non-interventional|Patients prescribed varenicline in a non interventional manner.
3274029|NCT00669227|Active Comparator|1|autologous stem cells, Ficoll preparation, intracoronary administration at the same day of bone marrow cell aspiration
3274030|NCT00669227|Placebo Comparator|2|placebo is visually indistinguishable from verum due to integration of autologous erythrocytes, intracoronary administration the same day of bone marrow aspiration
3274031|NCT00669214|Experimental|Efalizumab|
3274032|NCT00669214|Placebo Comparator|Placebo|
3274033|NCT00669201||1|healthy young volunteers Inclusion: age 18-40, Exclusion: wrist trauma/surgery
3274034|NCT00669201||2|"patients with know osteoarthritis wrist changes according to pre-existing x-rays No age limits~exclusion: previous wrist surgery"
3274035|NCT00669201||3|Mixed group of 50 patients that perform routine MRI of the wrist for various indications
3274036|NCT00669162|Experimental|RT, Docetaxel, Hormonal Therapy|Radiation Therapy (RT) to 66 Gy in 33 treatment fractions at 2.0 Gy/fx Concurrent Docetaxel (with RT) at 20 mg/m2 weekly x 7 Casodex (50 mg po daily)x 6 months Zoladex (10.8 mg sc q 3 mos x 2) or Lupron (22.5 mg im q 3 mos x 2)
3274037|NCT00669149|Experimental|1|group without anticoagulant therapy
3274038|NCT00669149|Active Comparator|2|group with heparin
3274039|NCT00669149|Active Comparator|3|group with enoxaparin
3274040|NCT00669149|Active Comparator|4|group with bivalirudin
3274041|NCT00669136|Other|1|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
3274042|NCT00669123|Placebo Comparator|2|
3274043|NCT00669123|Experimental|1|Chondroitin sulphate
3274044|NCT00669110|Experimental|A|
3274048|NCT00669032|Experimental|hyaluronic acid|Cycles of 5 injections of hyaluronic acid at specified intervals
3274049|NCT00669032|Placebo Comparator|Placebo|Cycles of 5 injections of saline at specified intervals
3274050|NCT00669019|Experimental|Saracatinib|Patients receive saracatinib 175 mg oral once daily in the absence of disease progression or unacceptable toxicity.
3274051|NCT00669006||1|New patients with a diagnosis of Neuropathic Pain
3274052|NCT00668993|Experimental|A, B|A is treatment group B is waitlist group
3274053|NCT00668980||Study group|20 infants with Down syndrome
3274054|NCT00668980||Control Group|15 typically developing children
3274055|NCT00668967|Other|Reference|marketed extended release verapamil tablet
3274056|NCT00668967|Other|Test|reformulated extended release verapamil tablet
3274057|NCT00668954|Active Comparator|Pomegranate Juice|
3274058|NCT00668954|Placebo Comparator|Placebo Juice (non-Pomegranate)|
3274059|NCT00668941|Experimental|1|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will receive a continuous regimen of daily teriparatide (20 mcg subcutaneously) for 48 months, in addition to alendronate. Biopsies will be performed at Week 7 or Month 7.5. The participants will then have the option to be followed while taking alendronate alone for 24-48 months.
3274060|NCT00668941|Experimental|2|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will receive a cyclical regimen of teriparatide, in addition to alendronate. Teriparatide will be administered subcutaneously in 20-mcg doses daily for 3 months. They will receive no teriparatide for the following 3 months, and then teriparatide treatment will continue for the 3 months after that. This schedule will continue for 24 months with an aption to all participants to continue cyclic teriparatide for another 24 months. Biopsies will be performed at Week 7 or Month 7.5.
3274061|NCT00668941|Active Comparator|3|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will continue taking alendronate alone. Biopsies will be performed at Week 7 and then participants in this group will be offered teriparatide as part of Group 2 or 3.
3274062|NCT00668941|Experimental|4|Participants in this group will receive a continuous regimen of teriparatide (20 mcg delivered subcutaneously) daily for 48 months. Biopsies will be performed at Week 7 or Month 7.5. At 24 months the participants will then have the option of taking alendronate and remaining in the study for another 24 months.
3274063|NCT00668941|Experimental|5|Participants in this group will receive a cyclical regimen of teriparatide. Teriparatide will be administered subcutaneously in 20-mcg doses daily for 3 months. They will receive no teriparatide for the following 3 months, and then teriparatide treatment will continue for the 3 months after that. This schedule will continue for 24 months with an option to all participants to continue cyclic teriparatide for another 24 months. Biopsies will be performed at Week 7 or Month 7.5.
3274064|NCT00668941|Active Comparator|6|Participants in this group will take only calcium and vitamin D supplements. Biopsies will be performed at Week 7. Participants will then be offered the standard care for osteoporosis or they may enter the study in Group 4 or 5.
3274065|NCT00668915||A|Primary arthroplasty
3274066|NCT00668902|Experimental|EM of CYP2C19|CYP2C19 enzyme activity in extensive metabolizers of CYP2C19 (CYP2C19*1/*1 genotype, or wild type) was measured by 13C)Pantoprazole breath test.
3274067|NCT00668902|Experimental|IM of CYP2C19|CYP2C19 activity in heterozygous for deficient CYP2C19 alleles (*2 and *3, IM of CYP2C19) was measured by (13C)Pantoprazole breath test.
3274068|NCT00668902|Experimental|PM of CYP2C19|Homozygous for CYP2C19 null alleles (*2/*2, *2/*3 or *3/*3, Poor metabolizers) was measured by (13C)Pantoprazole breath test.
3274069|NCT00668876|Active Comparator|1|Group A: perioperative immunonutrition
3274070|NCT00668876|Active Comparator|2|Group B: postoperative immunonutrition
3274071|NCT00668876|Active Comparator|3|Group C: control
3274072|NCT00668863|Experimental|1|
3274073|NCT00668850|Experimental|1|Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
3274074|NCT00668850|Active Comparator|2|Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
3274075|NCT00668811|Experimental|Treatment Arm - Sutent|Sutent 37.5 mg/day will be given orally.
3274076|NCT00668798||A|mother CMV positive
3274077|NCT00668798||B|mother CMV negative
3274078|NCT00668785|Experimental|Ranibizumab|Ranibizumab is being used off-label to test the safety and efficacy of its use in Diabetic Macular Edema post panretinal photocoagulation. Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
3274079|NCT00668772|Experimental|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
3274080|NCT00668772|Active Comparator|Tiotropium QD|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
3274081|NCT00668772|Active Comparator|Salmeterol BID|Salmeterol Inhalation Powder, hard PE capsule
3274082|NCT00668772|Active Comparator|Tiotropium/Salmeterol QD + Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
3274083|NCT00668772|Placebo Comparator|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
3274084|NCT00668759|Experimental|1|"Vernakalant Injection:~In one infusion line, subjects will receive a 10-minute infusion of vernakalant followed by a 15-minute observation period, followed by an additional 10-minute infusion of vernakalant if required (if the subject is still in AF). To maintain blinding, a 60-minute infusion of placebo (D5W) will be administered in a second infusion line, followed by a maintenance infusion of placebo for a minimum of an additional 60 minutes."
3274085|NCT00668759|Active Comparator|2|"Amiodarone Injection:~In one infusion line subjects will receive a 60-minute infusion of amiodarone followed by a maintenance infusion of amiodarone over an additional 60 minutes. To maintain blinding, a 10-minute infusion of placebo (normal saline) will be administered in a second infusion line, followed by a 15 minute observation period, followed by a 10 minute infusion of placebo if the subject is still in AF."
3274086|NCT00668746|Experimental|Minocycline HCl microspheres|Minocycline HCl microspheres
3274087|NCT00668746|No Intervention|No drug intervention|No drug intervention
3274090|NCT00668707|Experimental|1|To receive 20 mg of melatonin nightly for 1 year
3274091|NCT00668707|Placebo Comparator|2|To receive matched supplement to the experimental arm in same schedule
3274092|NCT00668694|No Intervention|1|Anemia without stimulation.
3274093|NCT00668694|Experimental|2|Anemia with stimulation
3274094|NCT00668694|No Intervention|3|Non-anemic group: Hb >80-109 g/L ferritin levels >12 μg/L and TfR <6 will be enrolled without stimulation
3274095|NCT00668694|No Intervention|4|Non-anemic group: Hb >80-109 g/L ferritin levels >12 μg/L and TfR <6 will be enrolled with stimulation
3274096|NCT00668681|Active Comparator|Endorefix|Evaluation of EndoRefix Endovascular Delivery System and Staple
3274097|NCT00668655||1|Female Subjects aged 20 to 75 inclusive, with a diagnosis of moderate (Global Severity Score of 3) Rosacea
3274098|NCT00668642|Experimental|A: Dutasteride During First Off-Cycle|Arm A patients received dutasteride (0.5 mg/day) during the first off-cycle and received placebo during the second off-cycle
3274099|NCT00668642|Placebo Comparator|B: Placebo During First Off-Cycle|Arm B patients received placebo during the first off-cycle and received dutasteride (0.5 mg/day) during the second off-cycle
3274100|NCT00668616|Active Comparator|1|
3274101|NCT00668616|Experimental|2|
3274102|NCT00668603|Experimental|2|Postmenopausal women with severe vasomotor symptoms
3274103|NCT00668603|Experimental|1|Postmenopausal women without vasomotor symptoms
3274104|NCT00668590|Experimental|1|
3274105|NCT00668590|Active Comparator|2|
3274106|NCT00668564|Experimental|Intent-to-Treat|All patients treated with study regimen.
3274107|NCT00668551||1|Telemedicine care
3274108|NCT00668551||2|Standard of care
3274109|NCT00668525|Active Comparator|2|Escitalopram low dose
3274110|NCT00668525|Experimental|3|Escitalopram high dose
3274111|NCT00668525|Placebo Comparator|1|Placebo
3274112|NCT00668512|Experimental|Antimelanoma injection-GSL alpha-Gal|Intervention consists of injection of a single melanoma metastasis with two injections of GSL alpha-Gal separated by four weeks. Both injections done with the same dose of GSL alpha-GAL each time. Phase 1 dose escalating scheme: 0.1mg, 1 mg, 10mg
3274113|NCT00668473||1|Subjects with diffuse scleroderma
3274114|NCT00668473||2|Healthy controls
3274115|NCT00668447|Experimental|1|Soy protein and isoflavone tablets
3274116|NCT00668447|Active Comparator|2|Soy protein and placebo tablets
3274117|NCT00668447|Active Comparator|3|control protein and Isoflavone tablets
3274118|NCT00668447|Placebo Comparator|4|control protein and placebo tablets
3274119|NCT00668434|Experimental|Prednisone|Participants will receive a 15-day tapering course of prednisone capsules.
3274120|NCT00668434|Placebo Comparator|Placebo|Participants will receive a 15-day course of placebo capsules.
3274121|NCT00668421|Experimental|CEP-701 (Lestaurtinib)|Subject is to receives Lestaurtinib, in Phase 1: standard cohort dose escalation; Phase 2: single stage design to estimate the percentage of subjects with a 15% or greater reduction in JAK2 V617F allele frequency in peripheral blood granulocytes in 6 months of treatment
3274122|NCT00668408|Other|LTOT group|Study group: optimal medical therapy plus LTOT = or > 15 hours pro die
3274123|NCT00668408|Other|Non LTOT group|control group: optimal medical therapy without LTOT
3274124|NCT00668395|Other|CYP2B6*1/*1 genotype|Efavirenz clearance in this genotype was compared with the other genotypes
3274125|NCT00668395|Other|CYP2B6*1/*6|Efavirenz clearance in this genotype was compared with the other genotypes
3274126|NCT00668395|Other|CYP2B6*6/*6|Efavirenz clearance in this genotype was compared with the other genotypes
3274127|NCT00668382|Experimental|Alpha-Gal Glycosphingolipid injection|Intervention: Intratumoral injection of a single dose of Alpha-Gal Glycosphingolipid (0.1 mg,1mg, 10mg)
3274128|NCT00668369|Experimental|1|Liver transplant recipients with HCV infection fulfilling inclusion criteria.
3274129|NCT00668356|Experimental|1|
3274130|NCT00668356|Active Comparator|2|
3274131|NCT00668343|Active Comparator|1|
3274132|NCT00668343|Placebo Comparator|2|
3274133|NCT00668330|Active Comparator|Ibandronate+alfacalcidol+calcium|Bonviva
3274134|NCT00668330|Active Comparator|Placebo ibandronate+alfacalcidol+calcium|
3274135|NCT00668317|Active Comparator|omeprazole and ranitidine|20 mg oralomeprazole oral tablet twice daily and ranitidine 300 mg oral tablet once daily nocte
3274136|NCT00668304|Experimental|Arm 1|
3274137|NCT00668291||CNC|Primary pigmented nodular adrenocortical disease (PPNAD) and the Carney complex (CNC)
3274138|NCT00668291||MC-L|cardiac myxoma or isolated lentiginosis
3274139|NCT00668278|Active Comparator|A|Laryngeal Mask Airway insertion
3274140|NCT00668278|Active Comparator|B|I-gel insertion
3274141|NCT00668265|Experimental|Seroquel|
3274142|NCT00668252||1|Non menopausal women
3274143|NCT00668252||2|age matched men
3274144|NCT00668252||3|Menopausal women
3274145|NCT00668252||4|age matched men
3274146|NCT00668239|Active Comparator|1|Laser treatment: laser was applied to the macular region according to the modified grid technique in inverted C, preserving 500 μ of the foveolus and avascular zone, with 100μ diameter shots, energy varying from 0.2 to 0.5 joules, with a time of exposure between 0.2 and 0.4 seconds. One hundred and fifty to 200 shots were applied according to the size of the retinal area². ND YAG laser (Crystal Focus (EMERED®) was used
3274147|NCT00668239|Experimental|2|triamcinolone as previously described
3274148|NCT00668200|Other|zoledronic acid|5 mg of Reclast (ZOL446, zoledronic acid) injection in 100 mL ready to infuse solution administered intravenously via a vented line. The infusion time was to be not less than 15 minutes given over a constant infusion rate.
3274149|NCT00668187||Gangliosidosis Diseases Study Population|This study observes one cohort: 42 infantile or juvenile Tay-Sachs disease, Sandhoff disease, or GM1 gangliosidosis affected subjects; and 10 late-onset gangliosidosis disease affected subjects.
3274150|NCT00668174|Experimental|1|Exercise
3274151|NCT00668174|No Intervention|2|Control
3274152|NCT00668161|Experimental|1|Exercise
3274153|NCT00668161|No Intervention|2|Control
3274154|NCT00668148|Experimental|IMC-A12 (cixutumumab)|
3274161|NCT00668096|Placebo Comparator|Arm 2|
3274162|NCT00668096|Experimental|Arm 1|
3274163|NCT00668070|Experimental|ASP9831 Low Dose|
3274164|NCT00668070|Experimental|ASP9831 Higher Dose|
3274165|NCT00668070|Placebo Comparator|Placebo|
3274166|NCT00668057|Experimental|Arm 1|
3274167|NCT00668057|Experimental|Arm 2|
3274168|NCT00668057|Experimental|Arm 3|
3274169|NCT00668057|Placebo Comparator|Arm 4|
3274170|NCT00668057|Placebo Comparator|Arm 5|
3274171|NCT00668057|Placebo Comparator|Arm 6|
3274172|NCT00668044|Experimental|Arm 1|
3274173|NCT00668044|Experimental|Arm 2|
3274174|NCT00668031|Experimental|Arm 1|
3274175|NCT00668031|Placebo Comparator|Arm 2|
3274176|NCT00668018|Experimental|Arm 1|
3274177|NCT00668005|Experimental|Arm 1|
3274178|NCT00668005|Placebo Comparator|Arm 2|
3274179|NCT00667992|Active Comparator|Budesonide Hydrofluoroalkane (HFA) 100|Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks
3274180|NCT00667992|Active Comparator|Budesonide HFA 400|Budesonide HFA 400 mcg twice daily for 2 weeks
3274181|NCT00667992|Active Comparator|Budesonide Chlorofluorocarbon (CFC) 100|Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks
3274182|NCT00667992|Active Comparator|Budesonide CFC 400|Budesonide CFC 400 mcg twice daily for 2 weeks
3274183|NCT00667979|Experimental|Arm 1|
3274184|NCT00667979|Placebo Comparator|Arm 2|
3274185|NCT00667966|Experimental|Vardenafil + Placebo|Subjects received single dose of 10 mg vardenafil followed by 20 mg vardenafil and then crossed over to 10 mg placebo followed by 20 mg placebo.
3274186|NCT00667966|Experimental|Placebo + Vardenafil|Subjects received single dose of 10 mg placebo followed by 20 mg placebo and then crossed over to 10 mg vardenafil followed by 20 mg vardenafil.
3274187|NCT00667953|Experimental|Arm A:|
3274188|NCT00667940|Experimental|Workshop|Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
3274189|NCT00667940|No Intervention|Delayed workshop|No specific intervention until after follow-up assessment, then receives same workshop.
3274190|NCT00667927|Other|1|
3274191|NCT00667914|Experimental|Orthogeriatric unit|Geriatric work-up on hip-fracture patients
3274192|NCT00667914|Active Comparator|Orthopedic care as usual|Traditional care in the orthopedic unit
3274193|NCT00667888|Active Comparator|Intensity Modulated Radiotherapy (IMRT)|A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
3274194|NCT00667888|Experimental|Hypofractionated Intensity Modulated Radiotherapy (HIMRT)|A total dose of 72 Gy will be delivered in 30 fractions to the PTV.
3274195|NCT00667875|Placebo Comparator|1|
3274196|NCT00667875|Active Comparator|2|Naltrexone
3274197|NCT00667875|Active Comparator|3|Naltrexone + Aripiprazole
3274198|NCT00667862|Experimental|Panobinostat|
3274199|NCT00667849|Active Comparator|Exogen 4000+|Single arm, Exogen 4000+
3274200|NCT00667849|Sham Comparator|Sham|Single arm, sham (identical device with the exception of administration of ultrasound).
3274201|NCT00667823|Experimental|ACT-064992|ACT-064992
3274202|NCT00667810|Experimental|Bapineuzumab 0.5 mg/kg|
3274203|NCT00667810|Experimental|Bapineuzumab 1.0 mg/kg|
3274204|NCT00667810|Placebo Comparator|Placebo|
3274205|NCT00667797|Experimental|1|levalbuterol 1.25 mg
3274206|NCT00667797|Active Comparator|2|Racemic albuterol 2.5 mg
3274207|NCT00667784||Anxiety Assessment|Minor Donors + Sibling Non-Donors + Parents or Legal Guardians
3274208|NCT00667758|Experimental|1|Cetrorelix
3274209|NCT00667758|Placebo Comparator|2|NaCl solution
3274210|NCT00667745|Experimental|1|Participants received lithium plus optimized medication treatment, as needed.
3274211|NCT00667745|Active Comparator|2|Participants only received optimized medication treatment, as needed; lithium was not be used.
3274212|NCT00667732|Active Comparator|1|Participants will receive exenatide as part of their diabetes treatment
3274213|NCT00667732|Placebo Comparator|2|Participants will receive placebo rather than exenatide as part of their diabetes treatment
3274214|NCT00667719|Experimental|A|aliskiren 300/mg + amlodipine 10 mg + hydrochlorothiazide
3274215|NCT00667706|Active Comparator|1|Patients who will undergo Laparoscopic Sleeve Gastrectomy
3274216|NCT00667706|Active Comparator|2|Patients who will undergo Laparoscopic Roux-en-Y Gastric Bypass
3274217|NCT00667693|Active Comparator|Macintosh laryngoscope|Intubation with a Macintosh laryngoscope
3274218|NCT00667693|Active Comparator|Pentax AWS|Intubation with a Pentax AWS
3274219|NCT00667680|Active Comparator|1|anodal tDCS
3274220|NCT00667680|Sham Comparator|2|Sham tDCS
3274221|NCT00667667|Active Comparator|1|vertical vibration device (using Vibrafit whole body vibration platforms)
3274222|NCT00667667|Active Comparator|2|side-alternating vibration device (using Board 3000 whole body vibration platforms)
3274223|NCT00667667|Sham Comparator|3|wellness-control group
3274224|NCT00667654|Experimental|100-200 µg CNTX-4975|single dose
3274225|NCT00667654|Experimental|300-425 µg CNTX-4975|Total dose delivered as two separate lower doses
3274226|NCT00667654|Experimental|600-700 µg CNTX-4975|Total dose delivered as two separate lower doses
3274227|NCT00667654|Experimental|800 µg CNTX-4975|Total dose delivered as two separate lower doses
3274228|NCT00667654|Experimental|900-1000 µg CNTX-4975|Total dose delivered as two separate lower doses
3274229|NCT00667628|Experimental|A|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days
3274230|NCT00667628|Placebo Comparator|B|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
3274231|NCT00667615|Experimental|1|vorinostat in combination with cyclophosphamide, etoposide,prednisone and rituximab,peg-filgrastim or filgrastim
3274232|NCT00667602|Experimental|MenACWY-CRM197 (2 doses) + Concomitant Vaccines|Infants received two doses of MenACWY-CRM197 at 6 to 8 and 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months.
3274233|NCT00667602|Experimental|MenACWY-CRM197 (1 dose) + Concomitant Vaccines|Infants received one dose of MenACWY-CRM197 at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.
3274234|NCT00667602|Active Comparator|MenC (1 dose) + Concomitant Vaccines|Infants received one dose of MenC vaccine at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.
3274235|NCT00667589|Experimental|urea 40% cream|
3274236|NCT00667589|Experimental|fluocinonide 0.05% cream|
3274237|NCT00667589|Experimental|tazarotene 0.1% cream|
3274238|NCT00667589|Experimental|bland emollient cream|
3274239|NCT00667576|Experimental|Paricalcitol 2 µg ± 1 µg|Paricalcitol initial dosage 2 micrograms (µg) with incremental adjustment of 1 µg
3274240|NCT00667576|Experimental|Paricalcitol 2 µg ± 2 µg|Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg
3274241|NCT00667576|Experimental|Paricalcitol 4 µg ± 1 µg|Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg
3274242|NCT00667576|Experimental|Paricalcitol 4 µg ± 2 µg|Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg
3274243|NCT00667576|Other|Maxacalcitol 5 or 10 µg ± 2.5 µg|Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg
3274244|NCT00667563|Experimental|Gardasil Vaccination|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
3274245|NCT00667537|Experimental|Radium-223 chloride|IV administrations of 100 kBq/kg b.w (=110 kBq/kg based on the 2015 National Institute of Standards and Technology standardization). Two administrations took place with an interval of 6 weeks
3274246|NCT00667524||I|
3274247|NCT00667511|Active Comparator|Home Short Daily Hemodialysis|Intervention: Patients perform short daily hemodialysis (2 to 4 hour treatments) in the home setting using the NxStage System One.
3274248|NCT00667511|Experimental|Home Nocturnal Hemodialysis|Intervention: Patients perform nocturnal hemodialysis (6 to 10 hour treatments) in the home setting using the NxStage System One.
3274249|NCT00667498|Experimental|1|
3274250|NCT00667498|Placebo Comparator|2|
3274251|NCT00667485|Experimental|Weekly Rapamcyin|Rapamycin (liquid) taken weekly and Bevacizumab (IV infusion ) once every 3 weeks
3274252|NCT00667485|Experimental|Daily Rapamycin|Daily oral rapamycin (tablets) and Bevacizumab (IV infusion)once every 3 weeks
3274253|NCT00667472|Experimental|Ranibizumab|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
3274254|NCT00667472|Experimental|Pulsed Dye Laser|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
3274255|NCT00667459|Experimental|Investigational|PRESTIGE® LP Cervical Disc
3274256|NCT00667459|Active Comparator|Control|Control patients who received a ACDF fusion treatment from a previous IDE trial (NCT00642876)
3274257|NCT00667446|Experimental|Leuprolide Acetate 3M Depot 11.25 mg|Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months (3M) apart.
3274258|NCT00667446|Experimental|Leuprolide Acetate 3M Depot 30 mg|Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.
3274259|NCT00667433|Other|Single Arm|Single arm where subjects will receive Raltegravir 400 mg BID along with Truvada once a day for 104 weeks
3274260|NCT00667420|Experimental|EOXP chemotherapy|open-label, single-arm EOXP Epirubicin 50mg/m2 by IV on day 1 of each 21 day cycle, Oxaliplatin 100 mg/m2 by IV on day 1 of each 21 day cycle, Capecitabine 400 mg/m2 twice daily by mouth on days 1-21 of the 21 day cycle Panitumumab - 9mg/kg by IV on day 1 of each 21 day cycle
3274261|NCT00667407|Experimental|1|Levalbuterol 1.25 mg
3274262|NCT00667407|Active Comparator|2|Racemic Albuterol 2.5 mg
3274263|NCT00667394|Experimental|Tandutinib & Bevacizumab in GBM Patients|GBM (glioblastoma multiforme) Tandutinib 500 mg by mouth daily dose twice a day. Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
3274264|NCT00667394|Experimental|Tandutinib & Bevacizumab in AG Patients|AG (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, and malignant astrocytoma NOS (not otherwise specified)) Tandutinib 500 mg by mouth daily dose twice a day. Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
3274265|NCT00667381|No Intervention|Control|The combination of anatomic landmarks and fluoroscopic localization of the femoral head will be used to guide femoral arterial access.
3274266|NCT00667381|Experimental|Ultrasound|Patients randomized to Ultrasound will have anatomic landmarks checked and real-time ultrasound guidance to aid femoral arterial access.
3274267|NCT00667368|Experimental|Intervention|Metronidazole 500mg twice daily for 7 days for Bacterial Vaginosis (BV) detection
3274268|NCT00667368|No Intervention|Control|Bi-monthly testing for BV without treatment.
3274269|NCT00667355|Experimental|Adalimumab|Adalimumab 40 mg or 80 mg subcutaneously (SC) administered every other week (eow) until approval of adalimumab for Ankylosing Spondylitis (AS) in Japan. All subjects received 40 mg of adalimumab SC eow at Baseline. The subjects who completed 16 weeks of therapy and who failed to achieve Assessments in Ankylosing Spondylitis 20 (ASAS 20) response on or after Week 16, could increase the dose of adalimumab to 80 mg eow. When the dose was increased, the higher dose was to be continued during the rest of the study.
3274270|NCT00667342|Experimental|Localized Resectable Disease (Stratum A)|Participants with localized resectable disease receive Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin, and doxorubicin, or methotrexate. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, or methotrexate.
3274380|NCT00666627|Active Comparator|3|Alendronate 70mg once weekly
3274271|NCT00667342|Experimental|Metastatic Disease (Stratum B)|Participants with metastatic disease (Stratum B) receive Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin and doxorubicin, methotrexate or ifosfamide, and etoposide. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, methotrexate, or ifosfamide, and etoposide. Radiotherapy will be given post-operatively.
3274272|NCT00667342|Experimental|Unresectable Disease (Stratum C)|Participants with unresectable disease (Stratum C) receive treatment identical to Stratum B: Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin and doxorubicin, methotrexate or ifosfamide, and etoposide. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, methotrexate, or ifosfamide, and etoposide. Radiotherapy will be given post-operatively.
3274273|NCT00667329|Experimental|2CdA + Cyclophosphamide + Rituximab|2CdA 1.5 mg/m^2 subcutaneous injection three times daily x 7 days. Cyclophosphamide 40 mg/m^2 PO twice daily x 7 days. Rituximab 375 mg/m^2 IV once weekly x 4 weeks.
3274274|NCT00667316||A|Workers from companies and workers' health care organizations who go for their periodic medical checkup.
3274275|NCT00667303||1|
3274276|NCT00667290|Experimental|1|
3274277|NCT00667290|No Intervention|2|
3274278|NCT00667277|Experimental|bevacizumab (Avastin)|Use of bevacizumab (Avastin) in the treatment of myelofibrosis.
3274279|NCT00667264|Active Comparator|Active|3-7 days of perineural local anesthetic infusion
3274280|NCT00667264|Placebo Comparator|Placebo|3-7 days of perineural normal saline infusion
3274281|NCT00667251|Active Comparator|Lapatinib|Plus taxane based chemotherapy
3274282|NCT00667251|Active Comparator|Trastuzumab|Plus taxane based chemotherapy.
3274283|NCT00667225|Placebo Comparator|I|Subjects in this group will have topical application of cantharidin's vehicle at each visit.
3274284|NCT00667225|Experimental|II|Subjects in this group will have topical application of cantharidin at each visit.
3274285|NCT00667212|Active Comparator|2|Supportive Psychotherapy
3274286|NCT00667212|Active Comparator|1|Cognitive Behavioral Therapy (Cognitive Restructuring, Relaxation, and Coping Skills Training: CRCST)
3274287|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-5kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (5kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
3274288|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-25 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (25kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
3274289|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-50 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (50kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
3274290|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-100 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (100kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
3274291|NCT00667186|Active Comparator|Targeted Screening|"Targeted Screening~Participants approached at ED for voluntary HIV counseling and testing based on risk for HIV"
3274292|NCT00667186|Active Comparator|Routine Screening|"Routine Screening~Participants approached at ED for voluntary HIV counseling and testing regardless of established risk according to age criteria"
3274293|NCT00667173|Experimental|1|
3274294|NCT00667173|Placebo Comparator|2|
3274295|NCT00667173|Placebo Comparator|3|
3274296|NCT00667160|Experimental|1|
3274297|NCT00667160|Active Comparator|2|
3274298|NCT00667147|Experimental|A|
3274299|NCT00667147|Experimental|B|
3274300|NCT00667134||1|Subjects with diffuse scleroderma
3274301|NCT00667134||2|Subjects with limited scleroderma
3274302|NCT00667134||3|Subjects without a fibrosing or autoimmune disease.
3274303|NCT00667108|Experimental|Gabapentin 250 mg|
3274304|NCT00667108|Experimental|Gabapentin 500 mg|
3274305|NCT00667108|Placebo Comparator|Placebo|
3274306|NCT00667095|Experimental|Botox and DMSO instillation|Botulinum-A Toxin (Botox) 300 units in 50 cubic centimeters of Dimethyl Sulfoxide (DMSO) 50% w/w aqueous solution
3274307|NCT00667095|Placebo Comparator|DMSO instillation|Dimethyl Sulfoxide (DMSO) 50% w/w aqueous solution, 50 cubic centimeters
3274308|NCT00667082|Experimental|NPI-0052 + Vorinostat Dose-Escalation|4 dose-escalation cohorts
3274309|NCT00667056|Experimental|1|
3274310|NCT00667056|Placebo Comparator|2|
3274311|NCT00667043|Active Comparator|Study group 1|Midazolam and fentanyl; continuous intravenous infusions
3274312|NCT00667043|Active Comparator|Study group 2|Propofol and remifentanil; continuous intravenous infusion
3274313|NCT00667030|Experimental|Lifestyle Modification|Combined hypocaloric diet and aerobic exercise training
3274314|NCT00667004|Experimental|1|ecabet ophthalmic solution
3274315|NCT00667004|Placebo Comparator|2|Placebo comparator
3274316|NCT00666991|Experimental|Nanotax, 50 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 50 mg/m2 once every 28 days until progression or unacceptable toxicity
3274317|NCT00666991|Experimental|Nanotax, 82.5 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 82.5 mg/m2 once every 28 days until progression or unacceptable toxicity
3274318|NCT00666991|Experimental|Nanotax, 125 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 125 mg/m2 once every 28 days until progression or unacceptable toxicity
3274381|NCT00666627|No Intervention|4|Young women control group
3274319|NCT00666991|Experimental|Nanotax, 175 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 175 mg/m2 once every 28 days until progression or unacceptable toxicity
3274320|NCT00666991|Experimental|Nanotax, 225 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 225 mg/m2 once every 28 days until progression or unacceptable toxicity
3274321|NCT00666991|Experimental|Nanotax 275 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 275 mg/m2 once every 28 days until progression or unacceptable toxicity
3274322|NCT00666978|Experimental|Bupropion Arm|Subjects undergo smoking cessation intervention and take bupropion.
3274323|NCT00666978|Placebo Comparator|Health Education Arm|Subjects receive counseling intervention and take placebo.
3274324|NCT00666965|Placebo Comparator|1|inactive placebo
3274325|NCT00666965|Experimental|2|2.25 mg first week: 2.25 mg 1 sheet plus placebo 1 sheet 2nd to 6th week :2.25mg 1 sheet plus placebo 2 sheets
3274326|NCT00666965|Experimental|3|4.5 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 2 sheets pus placebo 1 sheet
3274327|NCT00666965|Experimental|4|6.75 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 3sheets
3274328|NCT00666952|Experimental|1|
3274329|NCT00666952|Active Comparator|2|
3274330|NCT00666939|Experimental|A|
3274331|NCT00666939|Experimental|B|
3274332|NCT00666939|Placebo Comparator|C|
3274333|NCT00666926|Experimental|1|
3274334|NCT00666926|Experimental|2|
3274335|NCT00666926|Experimental|3|
3274336|NCT00666926|Experimental|4|
3274337|NCT00666900|Experimental|1|
3274338|NCT00666900|Experimental|2|
3274339|NCT00666900|Placebo Comparator|3|
3274340|NCT00666887|Active Comparator|Minocycline|Minocycline 100 mg oral for up to 24 months
3274341|NCT00666887|Placebo Comparator|Placebo|Lactose Monohydrate NF (Spray-dried) 235 mg/cap Magnesium Stearate NF 1 mg/cap Croscarmellose Sodium NF 4 mg/cap Stearic Acid 10 mg/cap Placebo CAP Lt orange OP-Purple OP (APO 100)
3274342|NCT00666874|Experimental|1|Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
3274343|NCT00666874|Active Comparator|2|General information about healthy food choices and exercise
3274344|NCT00666848|Placebo Comparator|2 (enalapril 5mg)|Subjects received Enalapril 5mg on study day and a placebo pill for 5 days prior or subjects received enalapril 5mg on study day and sitagliptin 100mg/day for 5 days prior .
3274345|NCT00666848|Placebo Comparator|1 (placebo)|Subjects received a placebo pill on study day and received a placebo pill for 5 days prior or subjects received a Placebo pill on study day and sitagliptin 100mg for 5 days prior.
3274346|NCT00666848|Placebo Comparator|3 (enalapril 10mg)|Subjects received Enalapril 10mg on study day and a placebo pill for 5 days prior, or subjects received Enalapril 10mg on study day and sitagliptin 100mg for 5 days prior.
3274347|NCT00666835|Experimental|HX575 epoetin alfa Hexal AG|Eligible patients were switched from the comparator ERYPO®, to epoetin alfa HX575 Hexal AG in ratio 2:1 to be intravenously treated with HX575 in pre-filled syringes for 24 weeks (solution for injection i.v.). The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.
3274348|NCT00666835|Active Comparator|ERYPO®, Janssen-Cilag|Eligible patients were randomized and continued to be treated with ERYPO® Janssen-Cilag in pre-filled syringes intravenously (solution for injection i.v.) for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.
3274349|NCT00666809|Active Comparator|Arm 1|
3274350|NCT00666809|Placebo Comparator|Arm 2|
3274351|NCT00666796|Placebo Comparator|A|
3274352|NCT00666796|Experimental|B|
3274353|NCT00666796|Experimental|C|
3274354|NCT00666796|Experimental|D|
3274355|NCT00666783|Experimental|PAL|receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2)
3274356|NCT00666783|Active Comparator|GRA|receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2)
3274357|NCT00666770|Experimental|Gabapentin 250 mg|
3274358|NCT00666770|Experimental|Gabapentin 500 mg|
3274359|NCT00666770|Placebo Comparator|Placebo|
3274360|NCT00666757|Experimental|duloxetine|study drug
3274361|NCT00666757|Active Comparator|citalopram|
3274362|NCT00666757|Active Comparator|fluoxetine|
3274363|NCT00666757|Active Comparator|paroxetine|
3274364|NCT00666757|Active Comparator|sertraline|
3274365|NCT00666744|Experimental|1|Exercise Intervention - additional lower limb exercises will be completed by the person with stroke with the assistance of his/her family for 35 minutes daily for a period of 8 weeks.
3274366|NCT00666744|No Intervention|2|Participants in this group will receive routine exercise therapy following stroke
3274367|NCT00666718|Active Comparator|Glargine|Glargine plus Insulin Lispro (2-3 injections)
3274368|NCT00666718|Experimental|ILPS|Insulin Lispro Protamine Suspension (ILPS) plus Insulin Lispro (2-3 injections)
3274369|NCT00666705|Experimental|Maraviroc alone|
3274370|NCT00666705|Experimental|Maraviroc + Raltegravir|
3274371|NCT00666705|Experimental|Raltegravir alone|
3274372|NCT00666692|Experimental|1|Escalating doses of volociximab at 10, 20, and 30 mg/kg with carboplatin, paclitaxel, and bevacizumab
3274373|NCT00666679|Active Comparator|1|mometasone
3274374|NCT00666679|Placebo Comparator|2|montelukast followed by placebo; or placebo followed by montelukast.
3274375|NCT00666666|Experimental|AT101 (R-(-)-gossypol acetic acid)|Patients will receive Hormone therapy with at least one LHRH agent (Leuprolide Acetate or Goserelin) for 6 weeks and include bicalutamide. Patients will begin AT101 daily at 6 weeks for 3 weeks of every 4 weeks (4 weeks - 1 cycle) and continue for 8 cycles of combined therapy (combined AT101, and LHRH agonist). After 8 cycles patients will continue hormonal therapy.
3274376|NCT00666640||1|50 subjects who have suffered a hip fracture
3274377|NCT00666640||2|50 age matched controls
3274378|NCT00666627|Active Comparator|1|Ibandronate
3274379|NCT00666627|Active Comparator|2|Risedronate
3274382|NCT00666614|Other|Intervention|Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.
3274383|NCT00666614|Other|Standard Care|Normal Hospital Environment
3274384|NCT00666601|Experimental|Pilot study|3 subjects, open lable, microdialysis single dose.
3274385|NCT00666601|Experimental|Main Study|12 subjects, open label, single dose of 600 mg.
3274386|NCT00666588|Experimental|Bortezomib 1.3mg/m2-assess efficacy-low anthracycline exposure|Bortezomib 1.3mg/m2 to assess efficacy in low prior anthracycline exposure. Patients receive idarubicin IV (12 mg/m2/day) over 15 minutes on days 1-3, low-dose cytarabine IV (100 mg/m2/day) continuously over days 1-7, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity (closed as of 08/01/10). Dosage modification based on age < 3 years old.
3274387|NCT00666588|Experimental|Bortezomib 1.0mg/m2-assess feasibility high anthracycline exp|Bortezomib 1.0 mg/m2 to assess feasibility in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.0 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
3274388|NCT00666588|Experimental|Bortezomib 1.3 mg/m2-assess feasibility high anthracycline exp|Bortezomib 1.3 mg/m2 to assess feasibility in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity (dose-finding phase closed as of 10/10).
3274389|NCT00666588|Experimental|Bortezomib 1.3 mg/m2-assess efficacy high anthracycline exp|Bortezomib 1.3 mg/m2 to assess efficacy in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity
3274390|NCT00666575|Experimental|Gabapentin|
3274391|NCT00666575|Placebo Comparator|Placebo|
3274392|NCT00666562|Placebo Comparator|Arm I (placebo)|Patients receive six oral placebo capsules once daily for 14-28 days.
3274393|NCT00666562|Experimental|Arm II (polyphenon E, placebo)|Patients receive four oral polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.
3274394|NCT00666562|Experimental|Arm III (polyphenon E, trans-urethral resection or cystectomy)|Patients receive six oral polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
3274395|NCT00666536|Active Comparator|Aggressive treatment regimen (5/320 mg to 10/320 mg)|Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)
3274396|NCT00666536|Active Comparator|Moderate treatment regimen (5/160 mg)|Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)
3274397|NCT00666523|Experimental|1|
3274398|NCT00666523|Placebo Comparator|2|
3274399|NCT00666510||Bronchospasm|Patients who presented bronchospasm during anesthesia induction
3274400|NCT00666510||Asthma|Patients who presented bronchospasm during anesthesia induction and were identified as asthmatics
3274401|NCT00666510||Control|Patients who were submitted to anesthesia induction and showed no complications
3274402|NCT00666497|Experimental|A|Azacitidine
3274403|NCT00666497|Experimental|B|MGCD0103
3274404|NCT00666497|Experimental|C|Azacitidine + MGCD0103
3274405|NCT00666484|Experimental|Treatment Group 1: stages 1A, 1B, 2A: OEPA x 2|"OEPA (28day cycle):~Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15"
3274406|NCT00666484|Experimental|Treatment Group 2: stages 2AE, 2B, 3A: OEPA x 2 + COPP x 2|"OEPA (28 day cycle) Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15~COPP (28 day cycle) Cyclophosphamide 500mg/m^2 iv d1 and 8 Vincristine 1.5mg/m^2 iv d1,8 (capped 2mg/dose) Procarbazine 100mg/m^2 po d1-15* Prednisolone 40mg/m^2 po d1-15"
3274407|NCT00666484|Experimental|Treatment Group 3: stages 2BE, 3AE, 3B, 4: OEPAx2 + COPPx4|"OEPA (28 day cycle) Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15~COPP (28 day cycle) Cyclophosphamide 500mg/m^2 iv d1 and 8 Vincristine 1.5mg/m^2 iv d1,8 (capped 2mg/dose) Procarbazine 100mg/m^2 po d1-15* Prednisolone 40mg/m^2 po d1-15"
3274408|NCT00666471|Experimental|1|MICE
3274409|NCT00666471|Active Comparator|2|SPA ligation
3274410|NCT00666458|Experimental|1|saxagliptin add-on to metformin
3274411|NCT00666458|Active Comparator|2|sitagliptin add-on to metformin
3274412|NCT00666445||1|Patients diagnosed with Alzheimer's Disease
3274413|NCT00666445||2|Aged-matched normal controls
3274414|NCT00666432||1|Controls
3274415|NCT00666432||2|Patient Family
3274416|NCT00666432||3|Patients
3274417|NCT00666406|Experimental|1|Advate rAHF-PFM
3274418|NCT00666406|Active Comparator|2|Recombinate rAHF
3274419|NCT00666393|Experimental|001|
3274420|NCT00666380|Experimental|10 ug of FMP010 antigen in 0.5 mL AS01B adjuvant|
3274421|NCT00666380|Experimental|50 ug of FMP010 antigen in 0.5 mL AS01B adjuvant|
3274422|NCT00666367|Active Comparator|1|Vitamin D (D-cure) will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
3274423|NCT00666367|Placebo Comparator|2|Placebo will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
3274424|NCT00666354|Active Comparator|1|
3274425|NCT00666354|Active Comparator|2|
3274426|NCT00666354|Active Comparator|3|
3274427|NCT00666341|Placebo Comparator|Placebo|Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
3274428|NCT00666341|Experimental|20 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
3274429|NCT00666341|Experimental|40 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
3274430|NCT00666341|Experimental|80 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
3274431|NCT00666341|Experimental|120 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
3274432|NCT00666328|Experimental|clevidipine|This will be a single-arm study with no reference therapy.
3274433|NCT00666315||Harmonic|Group operated with Harmonic device
3274434|NCT00666315||Conventional|Group operated with Electrocauery and Clip/Suture
3274435|NCT00666302|Experimental|1|
3274436|NCT00666302|Active Comparator|2|
3274437|NCT00666276||linezolid (Zyvox)|Patients taking Linezolid.
3274438|NCT00666263|Experimental|IGIV, 10% Then Placebo|"STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: IGIV, 10% (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human)(Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3).~Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg body weight (BW) per infusion cycle)."
3274439|NCT00666263|Experimental|Placebo Then IGIV, 10%|"STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human) (Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: IGIV, 10% (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3).~Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg BW per infusion cycle)"
3274440|NCT00666250|No Intervention|Baseline|Baseline values off chocolate supplement
3274441|NCT00666250|Experimental|Low Dose|Low dose of dietary supplement 30 ml tid (Activ Xocai Drink)
3274442|NCT00666250|Experimental|High-dose|High dose of dietary supplement 90 ml tid (Xocai Activ drink)
3274443|NCT00666237|Active Comparator|1|
3274444|NCT00666237|Active Comparator|2|
3274445|NCT00666224|Experimental|Glatiramer acetate|Glatiramer acetate 20 mg once daily by subcutaneous injection is administered in both the double-blind and open label periods.
3274446|NCT00666224|Placebo Comparator|Placebo (DB) to GA (OL)|Placebo matching glatiramer acetate once daily by subcutaneous injection during the double-blind period (DB). Glatiramer acetate (GA) 20 mg once daily by subcutaneous injection during the open-label period (OL).
3274447|NCT00666211|Active Comparator|Standard of Care|Standard pain control drugs.
3274448|NCT00666211|Experimental|Opioid Titration|Pain will be Monitored and Medication Titrated
3274449|NCT00666198||SILDENAFIL|Patients taking SILDENAFIL.
3274450|NCT00666185|Experimental|1|
3274451|NCT00666185|Active Comparator|2|
3274452|NCT00666159|Experimental|1|
3274453|NCT00666159|Active Comparator|2|
3274454|NCT00666146||1|Case Families ( Family with a schizophrenia proband)
3274455|NCT00666146||2|Control Families
3274456|NCT00666146||3|Control subjects
3274457|NCT00666133|No Intervention|2|Women in Group II (standard of care) will receive an 8 mL loading dose containing 4g magnesium sulfate administered manually per standard hospital protocol. The solution will be diluted with normal saline according to standard hospital practice, and given IV over 20 minutes. For women in Group II, the IV loading dose will be followed immediately with 20 mL treatment by IM injection, given as 10 mL (5 g magnesium sulfate) into each buttock. This dose will be followed by 10 mL treatments (5g magnesium sulfate) every four hours, injected into alternate buttock. Treatment will be discontinued when clinically indicated.
3274458|NCT00666133|Experimental|1|Women in Group I (Springfusor® arm) will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4will be administered using the Springfusor® pump. For women in Group I, the administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours for upto 24 hours postpartum.
3274459|NCT00666120|Active Comparator|1|Cow's milk based infant formula
3274460|NCT00666120|Active Comparator|2|Partially hydrolyzed cow's milk based infant formula
3274461|NCT00666094|Active Comparator|endurance training|supervised endurance training
3274462|NCT00666094|Experimental|strength training|Supervised strength training
3274463|NCT00666081|Experimental|Cohort 1|GSK690693 for injection. This is a dose escalation study.
3274464|NCT00666068|Experimental|1|"Patients with hypopituitarism~Cross over design: see interventions 1-2"
3274465|NCT00666068|Placebo Comparator|2|"Parallel design:~Healthy controls to be compared with placebo condition in patients with hypopituitarism"
3274466|NCT00666055||Group 1|30 post-menopausal HIV-infected women
3274467|NCT00666055||Group 2|12 pre-menopausal HIV-infected women
3274468|NCT00666042|Experimental|A|Vigamox delivered as spray
3274469|NCT00666042|Active Comparator|B|Patients will receive the commercially available Vigamox drops
3274470|NCT00666029|Active Comparator|Atorvastatin|Active arm atorvastatin 40 mg. o.d.
3274471|NCT00666029|Placebo Comparator|Placebo|Placebo arm dummy pill
3274472|NCT00666016|Experimental|1|TRO19622 500 mg
3274473|NCT00665990|Other|Treatment|All participants will receive bevacizumab, sorafenib, and cyclophosphamide until maximum tolerated dose is reached.
3274474|NCT00665977|Sham Comparator|A|"To enter into the single-blind placebo phase, subjects will be setup with a Fisher & Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily."
3274475|NCT00665977|Active Comparator|Double Blind Treatment Group 2|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher & Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
3274476|NCT00665977|Active Comparator|Double Blind Treatment Goup 1|a Fisher & Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
3274477|NCT00665964|Experimental|X-3|X-3 polyethylene which is a new highly cross-linked poly that is theorized to be more durable in vivo
3274478|NCT00665964|Active Comparator|N2Vac polethylene|conventional polyethylene
3274479|NCT00665951|Active Comparator|A|Kaletra tablets
3274480|NCT00665951|Experimental|B|Lopimune granules
3274481|NCT00665951|Experimental|C|Lopimune tablets
3274482|NCT00665938|Active Comparator|1|
3274483|NCT00665938|Experimental|2|
3274484|NCT00665938|Experimental|3|
3274485|NCT00665925|Experimental|1|R788, 100 mg tablet, orally, twice-a-day
3274486|NCT00665925|Experimental|2|R788, 150 mg tablet, orally, once a day
3274487|NCT00665925|Placebo Comparator|3|Placebo, orally, either once a day, or twice a day
3274488|NCT00665912|Other|1|Standard post-lobectomy wound care plus use of PRP and PPPc in the thoracic cavity.
3274489|NCT00665912|Active Comparator|2|Standard post-lobectomy wound care in the thoracic cavity
3274490|NCT00665899|Experimental|Cancer-Focused Relationship Enhancement|Cancer-Focused Relationship Enhancement
3274491|NCT00665899|Experimental|Couple's Cancer Education|Couple's Cancer Education
3274492|NCT00665899|No Intervention|Usual Care|Cancer-Related Community and Internet Resources
3274493|NCT00665886|Experimental|1|"Experimental Group (Closed System):~Nexiva® Safety IV Catheter from BD (Becton Dickinson). The catheter has wings, a passive safety feature, an integrated Y extension tubing integrated and needle-less access using a split septum BD QSyte®. In order to completely close the Y connector a second Q-Syte® is added from the moment of catheter insertion"
3274494|NCT00665886|Active Comparator|2|"Control group (Open System):~A 'mounted' system consisting of the Vasocan® Safety catheter of B. Braun Medical, SA. To the control catheters a three-way tap ('stopcock') with extension tubing 10 cm long (Connecta® Extra 3, from BD) is added. This comes as one unit (tap and tubing are integrated). When not in use the three-way tap ('stopcock') remains closed using a red cork Luer/Luer-Lock Sollner®, made by Amebil, SA."
3274495|NCT00665873|Active Comparator|A|Antibiotics
3274496|NCT00665873|Active Comparator|B|No Antibiotics
3274497|NCT00665860|Placebo Comparator|1|Placebo
3274498|NCT00665860|Active Comparator|2|
3274499|NCT00665860|Active Comparator|3|
3274500|NCT00665847|Experimental|Etravirine (TMC125)|
3274501|NCT00665834|Placebo Comparator|1|Rosuvastatin 20 mg versus placebo 20 mg
3274502|NCT00665834|Active Comparator|2|rosuvastatin 20 mg versus atorvastatin 80 mg
3274503|NCT00665808||A|
3274504|NCT00665808||B|
3274505|NCT00665795||1Patients with Graves´orbitophathy.|Patients with Graves´orbitophathy.
3274506|NCT00665795||2 Patients with detected DON|Patients with Graves´orbitophaty and detected dysthyroid optic neuropathy (DON)
3274507|NCT00665769|Placebo Comparator|Hypercapnia|Hypercapnic ventilation. The goal will be to maintain transcutaneous CO2 55 mm Hg (50-60 mm Hg) during the first week of life, or until extubation. A written, laminated hypercapnic ventilator algorithm will be placed at the bedside.
3274508|NCT00665769|Active Comparator|Normocapnia|Normocapnic ventilation. The goal will be to maintain transcutaenous CO2 40 mm Hg (35-45 mm Hg) during the first week of life, or until extubation. A written, laminated normocapnic ventilator algorithm will be placed at the bedside.
3274509|NCT00665756|Active Comparator|1|second trabeculectomy
3274510|NCT00665756|Active Comparator|2|Ahmed silicone drainage device implantation
3274511|NCT00665743|Experimental|A|PN400 (naproxen/esomeprazole)
3274512|NCT00665743|Active Comparator|B|naproxen 500 mg
3274513|NCT00665743|Active Comparator|C|naproxen 500 mg
3274514|NCT00665730|Experimental|Sepraspray|Sepraspray Powder applied on the viscera directly under the midline incision followed by incision closure. Sepraspray dose applied was between 2 g and 4 g per patient.
3274515|NCT00665730|No Intervention|Control|No anti-adhesion treatment used.
3274516|NCT00665717|Active Comparator|A|Pravastatin 40 mg QD for 4 days
3274517|NCT00665717|Active Comparator|B|Raltegravir 400mg BD for 4 days
3274518|NCT00665717|Experimental|C|Interaction between pravastatin and raltegravir
3274519|NCT00665704|Experimental|Tobacco Tactics Website|Nine veteran smokers who will pilot test the Tobacco Tactics website
3274520|NCT00665691||1|
3274521|NCT00665678|Experimental|1|paroxetine
3274522|NCT00665678|Placebo Comparator|2|placebo
3274523|NCT00665665|Experimental|A|
3274524|NCT00665665|Experimental|B|
3274525|NCT00665665|Experimental|C|
3274526|NCT00665665|Experimental|D|
3274527|NCT00665639|Experimental|1|Daily dose
3274528|NCT00665639|Active Comparator|2|
3274529|NCT00665639|Experimental|3|Every other day dose, alternating with placebo
3274530|NCT00665626|Experimental|Arm 1|Fostamatinib disodium (R935788) 100 mg tablet, orally, twice-a-day
3274531|NCT00665626|Placebo Comparator|Arm 2|Placebo, orally, twice-a-day
3274532|NCT00665600|Experimental|1|Levalbuterol 0.63 mg TID
3274533|NCT00665600|Experimental|2|Levalbuterol 1.25 mg TID
3274534|NCT00665600|Active Comparator|3|Racemic Albuterol 2.5 mg TID
3274535|NCT00665600|Placebo Comparator|4|Placebo TID
3274536|NCT00665587||A = MAZE|Patients indicated to a cardiac surgery (bypass, valve repair or combinated surgery)with documented atrial fibrillation in 6 preoperative months undergo the operation together with MAZE procedure
3274537|NCT00665587||B = non-MAZE|Patients indicated to a cardiac surgery (bypass, valve repair or combinated surgery)with documented atrial fibrillation in 6 preoperative months undergo the operation (without MAZE procedure).
3274538|NCT00665574|Experimental|1|ActaVisc
3274539|NCT00665574|Experimental|2|ActaVisc Mx Intra-articular Injection
3274540|NCT00665574|Placebo Comparator|3|Saline
3274541|NCT00665574|Active Comparator|4|Corticosteroid
3274542|NCT00665561||Maraviroc exposed|
3274543|NCT00665561||Maraviroc unexposed|
3274544|NCT00665548||Normal Subjects|Female subjects scoring Kellgren & Lawrence grade 0.
3274545|NCT00665548||OA Subjects|Female subjects with Kellgren & Lawrence score of 2 or 3.
3274546|NCT00665535|Other|2. High Risk|High risk for pressure ulcers according to the Braden Scale for Predicting Pressure Sore Risk (Score 10-12)
3274547|NCT00665535|Other|1. Moderate Risk|Moderate risk for pressure ulcers according to the Braden Scale for Predicting Pressure Sore Risk (Score 13 and 14)
3274548|NCT00665522||001|fentanyl iontophoretic transdermal system (40mcg) No Placebo 40 mcg per dose maximum of 6 doses/hourtotal maximum 80 doses/24 hours
3274549|NCT00665522||002|IV PCA with standard of care opioid analgesia per 24 hour period
3274550|NCT00665509|Experimental|1|
3274551|NCT00665496|Experimental|Arm 1|
3274552|NCT00665496|Placebo Comparator|Arm 2|
3274553|NCT00665483|Experimental|1|Skin Prick Test
3274554|NCT00665470|Experimental|Cohort I - high dose Aldesleukin|Patients receive high-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).
3274555|NCT00665470|Experimental|Cohort II - low dose Aldesleukin|Beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion, patients receive low-dose aldesleukin subcutaneous (SC) once daily 5 days a week for up to 6 weeks.
3274556|NCT00665457|Experimental|Celecoxib|"•Neoadjuvant chemotherapy: Patients receive docetaxel IV over 1 hour on days 1, 8, and 15, oral capecitabine twice daily on days 1-14, and oral celecoxib twice daily on days 1-21. Courses repeat every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV once daily on day 1, oral celecoxib twice daily on days 1-14, and filgrastim subcutaneously once daily on days 3-10. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Celecoxib is stopped one week prior to surgery.~•Surgery: Patients undergo definitive surgery (either modified radical mastectomy or lumpectomy combined with axillary node dissection). Patients may also undergo adjuvant radiotherapy and hormonal therapy at the discretion of multidisciplinary breast team."
3274557|NCT00665444|Experimental|A|Aripiprazole
3274558|NCT00665431|Experimental|Arm 1 PN 400 (VIMOVO)|PN400: 500 mg naproxen/20 mg esomeprazole bid
3274559|NCT00665431|Active Comparator|Arm 2 (Celebrex)|Celecoxib 200 mg
3274560|NCT00665431|Placebo Comparator|Arm 3 (Placebo)|sugar pill
3274561|NCT00665418|Experimental|1|
3274562|NCT00665405||PN|Control - Induced or natural labor under anesthesia
3274563|NCT00665405||PC|Case - Cesarean section under anesthesia
3274564|NCT00665392|Experimental|cetuximab|
3274565|NCT00665379|Active Comparator|1|Regular compression therapy with non elastic trico bandaging
3274566|NCT00665379|Active Comparator|2|New two layer compression bandage coban 2
3274567|NCT00665366|Placebo Comparator|Placebo + valproate or lithium|Participants randomly received placebo (1:1 to study drug) as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks.
3274568|NCT00665366|Active Comparator|Aripiprazole + valproate or lithium|Participants randomly received aripiprazole as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks. Aripiprazole was provided in 5-, 10-, or 15-mg oral tablets and administered at a starting dose of 5 mg per day for Week 1. For Weeks 2 through 3, the dose was titrated up to 10 mg per day, and for Weeks 4 through 6, the dose increased to 15 mg per day. Flexible doses of either 15 or 30 mg per day were administered for Weeks 7 through 12. If participants were unable to tolerate the dose of 15 mg per day of study drug, the dose was decreased to 10 mg per day for Weeks 7 through 12.
3274569|NCT00665353|Experimental|PIO (step 1) then PIO+PEG-INF+RBV (step 2)|All participants in this study will receive pioglitazone therapy for 24 to 28 weeks. Participants will continue pioglitazone and add peginterferon and ribavirin to their treatment regimen for up to 48 additional weeks.
3274570|NCT00665340|Placebo Comparator|Arm 1|
3274571|NCT00665340|Experimental|Arm 2|
3274572|NCT00665327|Experimental|Arm 1|
3274573|NCT00665327|Active Comparator|Arm 2|
3274574|NCT00665314|Experimental|AMD3100 added to a G-CSF Mobilisation regimen|AMD3100 added to a G-CSF Mobilisation regimen
3274575|NCT00665314|Active Comparator|G-CSF plus placebo|G-CSF plus placebo
3274576|NCT00665262|Experimental|1|comibined use of tramacet and naloxone infusion perioperatively
3274577|NCT00665249|Active Comparator|Full Motivational Interviewing|"This condition consisted of all the standard elements of MI, both the non-directive and directive strategies (Miller & Rollnick, 2002). Rogerian elements, such as warmth, egalitarianism, genuineness, and a client-centered approach to the therapeutic relationship, are commonly referred to as MI Spirit (Moyers, Martin, Manual, Hendricksen, & Miller, 2005). MI is comprised of MI spirit and includes specific directive strategies geared to focus the client toward targeted behavior change, such as confidence and importance rulers, visualization of behavior change, or a decisional balance. The directive elements of MI are those that selectively reinforce positive change talk or enhance discrepancy between a client's wish to change and stay with the status quo."
3274578|NCT00665249|Active Comparator|No Intervention: Self Change|Participants in this condition were not assigned to treatment, but were asked to attempt to change on their own during the 8-week follow-up period. SC participants were told that research had shown that some individuals could reduce their drinking without professional help; that participating in the IVR might facilitate their efforts; and that they would be offered professional treatment at the end of the 8-week period. As noted in the Introduction, SC was selected rather than a traditional wait-list control because the aim of the study was to decompose MI into its 3 hypothesized components that include self-change.
3274579|NCT00665249|Active Comparator|Spirit-Only Motivational Interviewing|While this condition retained the Rogerian elements to MI, directive elements were excluded. For example, SOMI consisted of the non-directive elements including therapist stance (warmth, genuineness, egalitarianism), emphasis on client responsibility to change, extensive use of reflective listening skills (e.g., open-ended questions, simple reflections), and avoidance of MI-inconsistent behaviors (advise, confront, take expert role, interpretation). Reflective listening was focused on the whole experience of the client and the client's affect, and targeting a particular behavior or eliciting change talk about drinking was proscribed. Furthermore, tools utilized frequently in MI to develop discrepancy, such as amplified or double-sided reflections, were proscribed.
3274580|NCT00665236|Experimental|1|Craniosacral therapy administered once a week for an hour by a trained craniosacral therapist.
3274581|NCT00665236|Active Comparator|2|Low-strength static magnets placed around the body for periods of up to an hour once a week.
3274582|NCT00665223|Experimental|ACR16 - once daily dose|Participant received ACR16 45 mg once daily for four weeks. Weeks 5-26, ACR16 45 mg capsule and one placebo capsule were taken as two separate doses.
3274583|NCT00665223|Experimental|ACR16 - twice daily dose|Participant received ACR16 45 mg once daily for four weeks. Weeks 5-26, an ACR16 45 mg capsule was taken twice daily as two separate doses (total dose: 90 mg).
3274584|NCT00665223|Placebo Comparator|Placebo|Participant received a placebo capsule once daily for four weeks. Weeks 5-26, a placebo capsule was taken twice daily as two separate doses.
3274585|NCT00665197|Active Comparator|Protracted Course Radiotherapy|"High Dose Rate brachytherapy 8.0 Gy x 2~External beam radiotherapy 30 Gy in 10 fractions of 3.0 Gy"
3274586|NCT00665197|Experimental|Short Course Radiotherapy|"High Dose Rate brachytherapy 8.0 Gy x 2~External beam radiotherapy 20 Gy in 5 fractions of 4.0 Gy"
3274587|NCT00665184|Experimental|High force LE resistance training|High force lower extremity resistance training + Standard exercise care. The high force lower extremity resistance training group will participate in a 3 day per week progressive eccentric ergometry program that will be gradually increased over 3 weeks from 5-20 minutes per day and remain at that duration for the next 9 weeks. In addition, they will engage in exercises including moderate intensity aerobic training, concentric upper extremity resistance training and stretching (axial mobility exercises).
3274588|NCT00665184|Active Comparator|Standard Care Control Group|"Standard care exercise group: The standard care control group is an active control group, i.e., individuals who will engage in our standard of care (an evidence based exercise program). These exercises include moderate intensity aerobic training (15 minutes), concentric upper extremity resistance training (5-10 minutes), balance training (5 minutes), and stretching (axial mobility exercises-5-10 minutes)."
3274589|NCT00665158|Active Comparator|UC|Usual Care Group
3274590|NCT00665158|Active Comparator|BI|Behavioural Intervention Group
3274591|NCT00665145|Experimental|1|Cohort 1
3274592|NCT00665145|Experimental|2|Cohort 2
3274593|NCT00665145|Placebo Comparator|3|Cohort 3
3274594|NCT00665145|Experimental|4|Cohort 4
3274595|NCT00665132|Experimental|StimRouter (SR) for CTS|Percutaneous implantation of StimRouter System
3274596|NCT00665119|Experimental|treatment|Any patient alternatively receive both remifentanil and isotonic saline (placebo)infusion. The order of infusion is randomized. An interval of 30 minutes is planned between the two infusions.
3274597|NCT00665106|Experimental|cohort 1|5 up to 6 patients per arm. Emulsion at 0.8% of drug product.
3274598|NCT00665106|Experimental|cohort 2|5 up to 6 patients per arm. Emulsion at 0.8% of drug product.
3274599|NCT00665106|Experimental|cohort 3|5 up to 6 patients per arm. Emulsion at 3.2% of drug product.
3274600|NCT00665106|Experimental|cohort 4|5 up to 6 patients per arm. Oily solution at 3.4% of drug product.
3274601|NCT00665093||A|
3274602|NCT00665093||B|
3274603|NCT00665054|Experimental|Arm 1|
3274604|NCT00665054|Placebo Comparator|Arm 2|
3274605|NCT00665041|Experimental|PR1|
3274606|NCT00665041|Placebo Comparator|PL1|
3274607|NCT00665028||1|Postoperative myocardial ischemia
3274608|NCT00665002|Experimental|WT-1 Analog Peptide Vaccine|Participants received 6 bi-weekly vaccinations over 10 weeks. WT-1 vaccine was given with Montanide. Participants also received an injection of Sargramostim (GM-CSF) two days before each vaccination and again on the day of the WT-1 injection at the same spot.
3274609|NCT00664976|Experimental|1|Electroconvulsive therapy
3274610|NCT00664976|Active Comparator|2|Treatment as usual
3274611|NCT00664963|Experimental|1|YUKON Sirolimus-eluting Stent
3274612|NCT00664963|Active Comparator|2|YUKON Stent (uncoated)
3274613|NCT00664950|Active Comparator|SHS|sliding hip screw
3274614|NCT00664950|Active Comparator|InterTAn IM Nail|interTAN IM nail
3274680|NCT00664534|Experimental|Premixed Insulin Lispro|Premixed Insulin Lispro (mid-mixture or low-mixture) 1,2 or 3 injections plus OAMs
3274741|NCT00664092|No Intervention|1|Usual Aftercare Condition
3274615|NCT00664937|Placebo Comparator|I|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
3274616|NCT00664937|Placebo Comparator|II|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
3274617|NCT00664937|Placebo Comparator|III|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
3274618|NCT00664911|Other|Chemotherapy|chemotherapy regimen
3274619|NCT00664898|Experimental|1|
3274620|NCT00664885|Experimental|CSCT|
3274621|NCT00664872|Experimental|case management|
3274622|NCT00664859|Experimental|Single|Open-label LCP-AtorFen
3274623|NCT00664846|Experimental|1|
3274624|NCT00664846|Active Comparator|2|
3274625|NCT00664833|Experimental|Arm 2|
3274626|NCT00664833|Other|Arm 4|
3274627|NCT00664833|Experimental|Arm 3|
3274628|NCT00664833|Experimental|Arm 1|
3274629|NCT00664820|Experimental|Treatment group|Will receive two Urex-CAP-5 (probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14) capsules daily for 3 months.
3274630|NCT00664794|Active Comparator|without acromioplasty|
3274631|NCT00664794|Active Comparator|with acromioplasty|
3274632|NCT00664768|Experimental|New Neocate|new Neocate
3274633|NCT00664768|Active Comparator|Neocate Infant|Neocate Infant formula
3274634|NCT00664755|Experimental|Varenicline|Participant randomized to receive active varenicline and placebo transdermal nicotine patch.
3274635|NCT00664755|Active Comparator|Transdermal Nicotine Patch|Participant randomized to receive active transdermal nicotine patch and placebo varenicline.
3274636|NCT00664742|Experimental|Fluvastatin XL® Treatment|80 mg once daily, at bedtime.
3274637|NCT00664729|Active Comparator|1|Caloric Restriction
3274638|NCT00664729|Experimental|2|Caloric restriction + Moderate-intensity aerobic exercise
3274639|NCT00664729|Experimental|3|Caloric restriction + Vigorous-intensity aerobic exercise
3274640|NCT00664716|Placebo Comparator|Placebo|subcutaneous administration of placebo given for 12 weeks
3274641|NCT00664716|Experimental|One Dose|BG9924 - dosage level administered as per Biogen Idec protocol
3274642|NCT00664716|Experimental|Second Dose|BG9924 - dosage level administered as per Biogen Idec protocol
3274643|NCT00664716|Experimental|Third Dose|BG9924 - dosage level administered as per Biogen Idec protocol
3274644|NCT00664716|Experimental|Fourth Dose|BG9924 - dosage level administered as per Biogen Idec protocol
3274645|NCT00664716|Experimental|Fifth Dose|BG9924 - dosage level administered as per Biogen Idec protocol
3274646|NCT00664703|Experimental|Lobeline 7.5 mg|Sublingual tablet
3274647|NCT00664703|Experimental|Lobeline 15 mg|Sublingual tablet
3274648|NCT00664703|Experimental|Lobeline 30 mg|Sublingual tablet
3274649|NCT00664703|Active Comparator|Methylphenidate HCl 15 mg|Capsule
3274650|NCT00664703|Active Comparator|Methylphenidate HCl 30 mg|Capsule
3274651|NCT00664703|Placebo Comparator|Lobeline 0 mg (placebo)|Sublingual tablet
3274652|NCT00664703|Placebo Comparator|Methylphenidate HCl 0 mg (placebo)|Capsule
3274653|NCT00664690|Experimental|1|celebrex
3274654|NCT00664690|Placebo Comparator|2|placebo
3274655|NCT00664677|Experimental|Terameprocol (EM-1421)|Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off).
3274656|NCT00664664|Experimental|1|APD125 20 mg
3274657|NCT00664664|Experimental|2|APD125 40 mg
3274658|NCT00664664|Placebo Comparator|3|Matching Placebo
3274659|NCT00664625|Experimental|1|"BMS-791325 (100 mg)~or~placebo match for (100 mg)"
3274660|NCT00664625|Experimental|2|"BMS-791325 (300 mg)~or~placebo match for (300 mg)"
3274661|NCT00664625|Experimental|3|"BMS-791325 (900 mg)~or~placebo match for (900 mg)"
3274662|NCT00664625|Experimental|4|"BMS-791325 (potential dose between 10-800 mg)~or~placebo match for (10-800 mg)"
3274663|NCT00664612|Experimental|1|Air Traq then Macintosh
3274664|NCT00664612|Experimental|2|Macintosh then AirTraq
3274665|NCT00664599|Experimental|1|Rituximab
3274666|NCT00664599|Active Comparator|2|Cytotoxics combination
3274667|NCT00664586|Experimental|Terameprocol (EM-1421)|Terameprocol (EM-1421) will be administered as an intravenous infusion over 24 hours, weekly. Dose will commence in the first cohort with 100 mg per hour (2400 mg in a 24 hour period)with escalation in the 5 cohorts of 3 to 6 patients with increments of 25 mg per hour to a maximum of 200 mg/hr (4800 mg/24 hour period) or until MTD is defined. When the MTD has been declared, then 11 additional subjects will be enrolled at the MTD dose level (to total 14 subjects treated in dosage cohort).
3274668|NCT00664573|Experimental|Group 2|Drug: BG9924 - dose administered as per Biogen-Idec protocol
3274669|NCT00664573|Experimental|Group 1|Drug: BG9924 - dose administered as per Biogen-Idec protocol
3274670|NCT00664573|Experimental|Group 3|Drug: BG9924 - dose administered as per Biogen-Idec protocol
3274671|NCT00664573|Experimental|Group 4|Drug: BG9924 - dose administered as per Biogen-Idec protocol
3274672|NCT00664560|Experimental|ARM 1 PN 400 (VIMOVO)|PN400: 500 mg naproxen/20 mg esomeprazole
3274673|NCT00664560|Active Comparator|Arm 2 (celebrex)|Celecoxib 200 mg
3274674|NCT00664560|Placebo Comparator|Arm 3 (placebo)|sugar pill
3274675|NCT00664547|No Intervention|C|
3274676|NCT00664547|Active Comparator|DWL|Diet Weight Loss
3274677|NCT00664547|Active Comparator|EWL|Exercise Weight Loss
3274678|NCT00664547|Active Comparator|EWS|Exercise without weight loss
3274679|NCT00664534|Active Comparator|Glargine|Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)
3274681|NCT00664521|Experimental|Rituximab Plus Atacicept|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by atacicept 150 mg subcutaneously once a week from Week 7 to 32.
3274682|NCT00664521|Placebo Comparator|Rituximab Plus Placebo|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by placebo matched to atacicept subcutaneously once a week from Week 7 to 32.
3274683|NCT00664508|Active Comparator|Lateral approach|Lateral approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
3274684|NCT00664508|Active Comparator|Anterior approach|Anterior approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
3274685|NCT00664508|Active Comparator|Posterior approach|Posterior approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
3274686|NCT00664495|No Intervention|C|Control
3274687|NCT00664495|Active Comparator|DWL|Diet Weight Loss
3274688|NCT00664495|Active Comparator|EWL|Exercise Weight Loss
3274689|NCT00664495|Active Comparator|EWS|Exercise Without Weight Loss
3274690|NCT00664482|Experimental|1|AGS-006
3274691|NCT00664469|Experimental|EZE+statin|ezetimibe 10 mg per day is added to actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
3274692|NCT00664469|Active Comparator|Stat2|patients on statins has their dose doubled for 6 weeks followed by another 6 weeks in which ezetimibe is added or the statin dose is doubled again.
3274693|NCT00664456|Active Comparator|AHT group|Randomized patients undergo 3-month neoadjuvant therapy (NHT)within 14 days and receive 9-month adjuvant therapy (AHT) following after Iodine I-125 implantation (TPPB).
3274694|NCT00664456|Active Comparator|Non-AHT group|Rondomized patients undergo 3-month neoadjuvant therapy (NHT) within 14 days and receive Iodine I-125 implantation therapy (TPPB). 40 weeks observation is followed under no further treatment.
3274695|NCT00664443||Dispatch-assisted CPR|Emergency ambulance dispatcher interaction to provide dispatch-assisted CPR instructions in order to determine bystander CPR rates and the impact of instructions on survival to hospital discharge
3274696|NCT00664430|Other|Calcitriol challenge followed by paricalcitol|Participants began a controlled calcitriol therapy period (calcitriol challenge) to confirm calcitriol resistance. After this period, those who failed to reduce PTH (according to parameters in protocol) initiated paricalcitol therapy.
3274697|NCT00664417|Experimental|1|
3274698|NCT00664417|Experimental|2|
3274699|NCT00664417|Experimental|3|
3274700|NCT00664417|Experimental|4|
3274701|NCT00664417|Experimental|5|
3274702|NCT00664417|Experimental|6|
3274703|NCT00664417|Active Comparator|7|
3274704|NCT00664417|Active Comparator|8|
3274705|NCT00664417|Placebo Comparator|9|
3274706|NCT00664404|Other|fMRI|Functional Magnetic Resonance Imaging (fMRI)
3274707|NCT00664391|Experimental|1|
3274708|NCT00664378|Experimental|I|CYT997
3274709|NCT00664365|Experimental|Subjects receiving GSK958108 + placebo in cohort 1|Eligible subjects will receive GSK958108 with a starting dose of 1 milligram. The dose escalation will be continued up to 4 ascending doses. Subjects will also receive placebo. Each treatment period will be separated by at least 7 days washout period.
3274710|NCT00664365|Experimental|Subjects receiving GSK958108 + placebo in cohort 2|Eligible subjects will start dosing once the cohort 1 has completed the treatment phase and the initial dose will be the same as top dose in Cohort1.The dose escalation will be continued up to 4 ascending doses. Subjects will also receive placebo. Each treatment period will be separated by at least 7 days washout period.
3274711|NCT00664352|Experimental|1|
3274712|NCT00664352|Experimental|2|
3274713|NCT00664352|Experimental|3|
3274714|NCT00664352|Experimental|4|
3274715|NCT00664352|Other|5|
3274716|NCT00664339|Active Comparator|Vaccine|Flu Vaccine
3274717|NCT00664339|Other|Control|Conventional treatment therapy for heart failure
3274718|NCT00664326|Experimental|Regorafenib (Stivarga, BAY73-4506)|Participants received Regorafenib 160 mg per os (po) every day (qd) for 3 weeks on 1 week off of every 4 week cycle
3274719|NCT00664313|Experimental|1|Linezolid 600 mg po QD
3274720|NCT00664313|Placebo Comparator|2|Placebo
3274721|NCT00664300||2|One group with Gilles de la Tourette's Syndrome One group with healthy paired volunteers
3274722|NCT00664287|Experimental|Group 1|Patients will remain on existing lipid-modifying therapy throughout the study. Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
3274723|NCT00664287|Placebo Comparator|Group 2|Patients will remain on existing lipid-modifying therapy throughout the study. Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
3274724|NCT00664274|Other|CRT Group|
3274725|NCT00664248|Experimental|1|
3274726|NCT00664248|Active Comparator|2|
3274727|NCT00664248|Active Comparator|3|
3274728|NCT00664248|Placebo Comparator|4|
3274729|NCT00664209|Other|Active-placebo|These subject receive treatment with active triple therapy followed by treatment with placebo therapy.
3274730|NCT00664209|Other|Placebo-active|These subject receive treatment with placebo therapy followed by treatment with active triple therapy.
3274731|NCT00664196|Experimental|1|
3274732|NCT00664183|Experimental|1|
3274733|NCT00664183|Experimental|2|
3274734|NCT00664170|Experimental|1|ANX-514
3274735|NCT00664170|Active Comparator|2|Taxotere
3274736|NCT00664157|Other|2|40 patients with an idiopathic Parkinson's disease and 40 healthy paired volunteers (control group)
3274737|NCT00664131||1|
3274738|NCT00664118|Active Comparator|1|Doula combined epidural analgesia in the latent phase of first stage of labor
3274739|NCT00664118|Sham Comparator|2|Epidural analgesia in the latent phase of the first stage of labor without doula accompany
3274740|NCT00664105|Experimental|Therapeutic Intervention|
3274742|NCT00664092|Experimental|2|Oxford House Condition
3274743|NCT00664092|Experimental|3|Therapeutic Community Condition
3274744|NCT00664079||1|Patients who are receiving vasoactive medications and/or are mechanically ventilated.
3274745|NCT00664053|Experimental|1|DHEA and Yoga
3274746|NCT00664053|Active Comparator|2|DHEA and exercise
3274747|NCT00664053|Active Comparator|3|Placebo and Yoga
3274748|NCT00664053|Placebo Comparator|4|Placebo and exercise
3274749|NCT00664027|Experimental|25 mg|25 mg RTA 402 (Bardoxolone methyl)/Stratum 1
3274750|NCT00664027|Experimental|75 mg|75 mg RTA 402 (Bardoxolone methyl)/Stratum 1
3274751|NCT00664027|Experimental|150 mg|150 mg RTA 402 (Bardoxolone methyl)/Stratum 1
3274752|NCT00664027|Experimental|25/75 mg|25 mg -> 75 mg RTA 402 (Bardoxolone methyl)/Stratum 2
3274753|NCT00664014|Experimental|Tolvaptan|
3274754|NCT00664014|Placebo Comparator|Placebo|
3274755|NCT00664001|Placebo Comparator|Control|Placebo tablet
3274756|NCT00664001|Active Comparator|Intervention|Anti-oxidant supplementation
3274757|NCT00663988|Experimental|III|The effect of human partial facial allotransplantation
3274758|NCT00663975|Experimental|1|DCI-1020 Capsules contain an enteric-coated buffered microspheres of pancrelipase, encapsulated in clear capsules. Capsules are equivalent to 4,000 USP units of lipase
3274759|NCT00663962|Experimental|Perioperative pregabalin|Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-operatively (n=3) or Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-operatively (n=4).
3274760|NCT00663962|Placebo Comparator|Placebo control|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op. (N=8)
3274761|NCT00663949|Active Comparator|A,1,II|patients in this arm takes 25 mg captopril q8h
3274762|NCT00663949|Active Comparator|A,2,II|
3274763|NCT00663936|Experimental|1|T-817MA once daily
3274764|NCT00663936|Placebo Comparator|2|Placebo once daily
3274765|NCT00663923|Experimental|cross-cylinder|In this technique the laser is programmed with the axis and amount of cylinder,so that the steepest meridian is flattened with central cylindrical ablation and the flattest meridian steepens with paracentral ablation
3274766|NCT00663923|Active Comparator|single|In this technique ,cylinder is treated only on one meridian by performing an elliptical ablation to to flatten the steeper meridian to match the flatter meridian.
3274767|NCT00663897|Experimental|1|Treatment with lansoprazole (30 mg) once daily for 14 days
3274768|NCT00663897|Active Comparator|2|Treatment with mosapride (5 mg) thrice daily for 14 days
3274769|NCT00663884|Experimental|M|Mitiglinide
3274770|NCT00663884|Active Comparator|V|Voglibose
3274771|NCT00663871|Active Comparator|1|Participants will take fish oil supplements daily for 4 months.
3274772|NCT00663871|Placebo Comparator|2|Participants will take soybean oil (placebo) supplements daily for 4 months.
3274773|NCT00663858|Experimental|Cetrorelix 78+78|
3274774|NCT00663858|Experimental|Cetrorelix 78 + Placebo|
3274775|NCT00663858|Placebo Comparator|Placebo|
3274776|NCT00663845|Experimental|Arm 1|
3274777|NCT00663845|Placebo Comparator|Arm 2|
3274778|NCT00663832|Experimental|LBH589|
3274779|NCT00663819|Active Comparator|Device|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular staplers
3274780|NCT00663819|Other|Procedure/Surgery|Procedure/Surgery: colorectal, coloanal, and ileoanal anastomotic staple line without reinforcement
3274781|NCT00663806|Experimental|Arm 1|
3274782|NCT00663806|Experimental|Arm 2|
3274783|NCT00663793|Experimental|Oral testosterone|"(Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by immediate release T 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
3274784|NCT00663793|Experimental|Finasteride plus Oral Testosterone|"(Day -2 to Day 12) 1 mg Finasteride PO once daily for 14 days total. (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by immediate release T 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
3274785|NCT00663767|Placebo Comparator|Placebo|
3274786|NCT00663767|Experimental|Placebo, ARRY-371797|
3274787|NCT00663767|Experimental|ARRY-371797, Placebo|
3274788|NCT00663767|Experimental|ARRY-371797|
3274789|NCT00663767|Active Comparator|Celecoxib, Placebo|
3274790|NCT00663767|Experimental|Celecoxib, ARRY-371797|
3274791|NCT00663754|Active Comparator|1|Participants will receive a mailed brochure about body image only.
3274792|NCT00663754|Active Comparator|2|Participants will receive the 4-hour dissonance-based eating disorder prevention program.
3274793|NCT00663754|Experimental|3|Participants will receive the 8-hour dissonance-based eating disorder prevention program.
3274794|NCT00663741|Experimental|Arm 1|
3274795|NCT00663741|Experimental|Arm 2|
3274796|NCT00663741|Experimental|Arm 3|
3274797|NCT00663728|Experimental|Arm 1|
3274798|NCT00663728|Placebo Comparator|Arm 2|
3274799|NCT00663715||1|Pediatric Patients of ages 11-17
3274800|NCT00663702|Experimental|1|
3274801|NCT00663689|Experimental|1|non-randomized open-label uncontrolled phase II trial erlotinib 150mg qd until disease progression or unacceptable toxicity
3274855|NCT00663182|No Intervention|B|Untreated
3274856|NCT00663169|Experimental|Canakinumab|Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.
3275239|NCT00660491|No Intervention|2|moderate exercise training group
3274802|NCT00663663|Experimental|1|Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
3274803|NCT00663663|Experimental|2|Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
3274804|NCT00663650|Active Comparator|1|Permanent Section Control
3274805|NCT00663650|Active Comparator|2|Frozen Section Control
3274806|NCT00663624|Experimental|Experimental|Subcutaneous aspart insulin every 2 hours
3274807|NCT00663624|Placebo Comparator|Active Comparator|Usual care as prescribed by the ED physicians
3274808|NCT00663611|Experimental|Study I - IB|Each involve six subjects &amp; are designed to test the hypothesis that pulsatile subcutaneous infusion of GH via a subcutaneous infusion pump will yield a reasonable pulsatile GH pattern. The dose of GH used in Study IB will be three-fold higher than that in Study I. Study I and IB will be done first before proceeding to Study II
3274809|NCT00663611|Experimental|Study II|Is a randomized, double-blinded, placebo-controlled 12 week study involving 26 subjects divided into 2 groups: Group A and Group B. Group A will involve 13 subjects receiving pulsatile GH or placebo infusion for 4 weeks with 8 week washout after intervention. Group B will involve 13 subjects receiving conventional once a day subcutaneous infusion of GH or placebo for 4 weeks with 8 week washout after intervention.
3274810|NCT00663598|Experimental|Arm 1|
3274811|NCT00663585|Experimental|1|Structured Intervention Group
3274812|NCT00663585|Active Comparator|2.Comparison group|Unstructured comparison group
3274813|NCT00663559|Other|1|This study has only one arm with Sunitinib
3274814|NCT00663533|No Intervention|Device study only.|
3274815|NCT00663520||1|"Women with chest pain and Clean heart vessels"
3274816|NCT00663520||2|Healthy volunteers
3274817|NCT00663481|Experimental|1|CoFactor
3274818|NCT00663481|Experimental|2|CoFactor
3274819|NCT00663481|Active Comparator|3|Leucovorin
3274820|NCT00663468||A|
3274821|NCT00663455|Other|A|Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
3274822|NCT00663455|No Intervention|B|Standard CSA-dosing without reduction. Therapy control by C2-monitoring.
3274823|NCT00663442|Experimental|1|OROS methylphenidate 18, 36, 54m placebo in randomized order (except never starting with highest dose)
3274824|NCT00663416|Experimental|1|
3274825|NCT00663416|Placebo Comparator|2|
3274826|NCT00663390|Experimental|I|
3274827|NCT00663364|Active Comparator|I|Physiogel AI Lotion
3274828|NCT00663364|Active Comparator|II|Physiogel Lotion twice daily
3274829|NCT00663351|Active Comparator|1|Investigational: Reflection Ceramic-Ceramic Hip System. Ceramic femoral head component and the ceramic acetabular cup insert are composed of Biolox forte aluminum oxide material.
3274830|NCT00663351|Active Comparator|2|Control: Reflection FSO V (5 hole). Acetabular shell with a ultra high molecular weight polyethylene insert and an alumina ceramic femoral head with a Synergy or Spectron EF femoral stem. The Synergy femoral stem are composed of implant grade titanium while the Spectron EF stem is composed of implant grade cobalt chrome.
3274831|NCT00663338|Experimental|A|All patients receive placebo or rotigotine at some stage in the trial but the exact point is randomized.
3274832|NCT00663325|Experimental|1|Lactic acid in small quantity during 21 days
3274833|NCT00663299|Other|Trufill Detachable Coil System|There is only one treatment arm in the registry and it is all patients receiving treatment with Trufill Detachable Coil System. The use of bare platinum coils for the endovascular occlusion of cerebral aneurysms.
3274834|NCT00663286|Experimental|1|
3274835|NCT00663286|Active Comparator|2|
3274836|NCT00663286|Active Comparator|3|
3274837|NCT00663286|Placebo Comparator|4|
3274838|NCT00663273|Experimental|1|Lactic acid in small quantity during 21 days.
3274839|NCT00663260|Active Comparator|Dapagliflozin (10 mg)|
3274840|NCT00663260|Active Comparator|Dapagliflozin (5 mg)|
3274841|NCT00663260|Placebo Comparator|Placebo|
3274842|NCT00663247|Placebo Comparator|B|placebo used as control for comparison with active drug
3274843|NCT00663247|Active Comparator|A|
3274844|NCT00663234|Experimental|Age 10 to 14|Participants ages 10 to 14 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
3274845|NCT00663234|Experimental|Age 15 to 23|Participants ages 15 to 23 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
3274846|NCT00663221|Placebo Comparator|1|
3274847|NCT00663221|Experimental|2|
3274848|NCT00663208|Active Comparator|Group 1|"Daclatasvir (1 mg), once daily~or~Matching Placebo, once daily"
3274849|NCT00663208|Active Comparator|Group 2|"Daclatasvir (10 mg), once daily~or~Matching Placebo, once daily"
3274850|NCT00663208|Active Comparator|Group 3|"Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
3274851|NCT00663208|Active Comparator|Group 4|"Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
3274852|NCT00663208|Active Comparator|Group 5|"Group 5: Active Comparator~Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
3274853|NCT00663208|Active Comparator|Group 6|"Group 6: Active Comparator~Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
3274854|NCT00663182|Experimental|A|Patients with decompensated HBV-related cirrhosis
3274857|NCT00663169|Active Comparator|Dexamethasone|Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.
3274858|NCT00663156|Experimental|subject|10 subjects receiving breast augmentation with fat grafting
3274859|NCT00663156|Other|control|10 control will have breast augmentation using breast implants
3274860|NCT00663143||Stromal Cell Sample|
3274861|NCT00663130|Experimental|Arm 1|
3274862|NCT00663130|Active Comparator|Arm 2|
3274863|NCT00663117|Placebo Comparator|Placebo, Sugar pill|placebo for 3 months blinded then followed by an open-labelled study and all are treated with naltrexone 4.5 mg for 3 additional months
3274864|NCT00663117|Active Comparator|Naltrexone-HCl|Subjects are treated in a blinded fashion for 3 months with naltrexone 4.5 mg po for active Crohn's disease followed an open-labelled study where naltrexone is given an additional 3 months at 4.5 mg po; hence the total treatment interval in this arm is 6 months. The response to the intervention administered is measured in the activity index and mucosal healing by colonoscopy.
3274865|NCT00663104|Active Comparator|1|exercise (3 sessions/week)
3274866|NCT00663104|Active Comparator|2|"exercise and phytoestrogen (cimicifuga racemosa)"
3274867|NCT00663104|Placebo Comparator|3|wellness control, placebo
3274868|NCT00663091|Experimental|Bacteriophages|
3274869|NCT00663078|Experimental|A|Group A: Women from GP practices and area of Knowle West, Bristol
3274870|NCT00663078|Experimental|B|Group B: Women from Wellspring, GP practice or geographical area of Barton Hill Bristol.
3274871|NCT00663065|Experimental|arm 1|
3274872|NCT00663052|Experimental|Group A|A
3274873|NCT00663052|Experimental|Group B|B
3274874|NCT00663039|Active Comparator|1|Oxytocin
3274875|NCT00663039|Placebo Comparator|2|
3274876|NCT00663026|Experimental|A|5 mg/week
3274877|NCT00663026|Experimental|B|10 mg/week
3274878|NCT00663026|Experimental|C|Placebo
3274879|NCT00663013|Active Comparator|1|The first treatment session will involve 5-7 minutes of burn wound care while distracted by VR, and 5-7 minutes of burn wound care without the distraction of VR. The second session of burn wound care (performed within the next 3 days) will involve 5-7 minutes of burn wound care without the distraction of VR, and 5-7 minutes of burn wound care with the distraction of VR. The treatment order will be randomized.
3274880|NCT00663013|Active Comparator|2|The first treatment session will involve 5-7 minutes of burn wound care while distracted by VR, and 5-7 minutes of burn wound care without the distraction of VR. The second session of burn wound care (performed within the next 3 days) will involve 5-7 minutes of burn wound care without the distraction of VR, and 5-7 minutes of burn wound care with the distraction of VR. The treatment order will be randomized.
3274881|NCT00663000||acromegalics|"Acromegaly in adult subjects either controlled or uncontrolled (Diagnosis should be based on OGTT where Acromegaly is defined as a lack of suppression of GH nadir to < 0.5 ng/dL, after oral administration of 75 g of glucose, OGTT and IGF-I levels at least 10 % above the normal value ± 2 SD).~Written informed consent"
3274882|NCT00662987|Placebo Comparator|Group B|Received 3 days of amoxicillin followed by 4 days of placebo
3274883|NCT00662987|Active Comparator|Group A|Received 7 days of amoxicillin
3274884|NCT00662974|Experimental|A|parturients during the second stage of labor massaged by Wheat Germ Oil
3274885|NCT00662974|Experimental|B|parturients during the second stage of labor massaged by almond oil
3274886|NCT00662961|Experimental|1|Periosteum
3274887|NCT00662961|Experimental|2|Bone
3274888|NCT00662948|Experimental|A|Consolidation with one dose of 90Y Ibritumomab tiuxetan (Zevalin®) 0,4 mCi/Kg
3274889|NCT00662948|Active Comparator|B|Maintenance with 375 mg/m2 of Rituximab every 8 weeks during 24 months
3274890|NCT00662935|Experimental|2|the sequence of stimulation begins by OFF
3274891|NCT00662935|Experimental|1|the sequence of stimulation begins by ON
3274892|NCT00662922||1|patients with hypoglycemia during intensive care
3274893|NCT00662922||2|patients without hypoglycemia during intensive care
3274894|NCT00662909|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once a day for 12 weeks
3274895|NCT00662909|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks
3274896|NCT00662909|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 m tablets, orally once a day for 12 weeks
3274897|NCT00662896|Experimental|naproxcinod 375 mg bid|
3274898|NCT00662896|Active Comparator|naproxen 250 mg bid|
3274899|NCT00662896|Active Comparator|ibuprofen 600 mg tid|
3274900|NCT00662896|Experimental|naproxcinod 750 mg bid|
3274901|NCT00662896|Active Comparator|naproxen 500 mg bid|
3274902|NCT00662883|Experimental|A|"PMI-150 (intranasal ketamine HCl), day 1~mometasone furoate, days 2-15~PMI-150 (intranasal ketamine HCl), day 15"
3274903|NCT00662870|Experimental|DAPTACEL Lot 1|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 1
3274904|NCT00662870|Experimental|DAPTACEL Lot 2|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 2
3274905|NCT00662870|Experimental|DAPTACEL Lot 3|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 3
3274906|NCT00662870|Active Comparator|Pentacel|Participants receiving Pentacel vaccine
3274907|NCT00662857|Experimental|1: TI Inhalation Powder A|Technosphere® Insulin Inhalation Powder, two 15 U cartridges
3274908|NCT00662857|Experimental|2: TI Inhalation Powder B|Technosphere® Insulin Inhalation Powder, one 30 U cartridge
3274909|NCT00662857|Experimental|3: RAA Population|Rapid Acting Analogue subjects received 10 IU sc Insulin Lispro
3274910|NCT00662844|Placebo Comparator|A1 vitamin D3 400IU|Orally for one year
3274911|NCT00662844|Placebo Comparator|A2 vitamin D3 800IU|Orally for one year
3274912|NCT00662844|Placebo Comparator|A3 vitamin D3 1600IU|Orally for one year
3274913|NCT00662844|Placebo Comparator|A4 Vitamin D3 2400 IU|Orally for one year
3274914|NCT00662844|Placebo Comparator|Placebo|Placebo for one year
3274915|NCT00662831|Experimental|Active|Active study treatment
3274916|NCT00662831|Placebo Comparator|Placebo|Placebo
3274917|NCT00662818|Experimental|Telcagepant 300 mg→Acetaminophen/Paracetamol 1000 mg|Participants receive up to 12 doses of telcagepant (280 mg tablet/capsule 300 mg), orally, and placebo to acetaminophen/paracetamol (APAP) (2- 500 mg dry filled capsules), orally, for up to 12 migraine attacks in Period 1 (6 weeks). Participants receive APAP and placebo to telcagepant for up to 12 doses, for up to 12 migraine attacks in Period 2 (6 weeks). The participant may take a blinded optional second dose of study medication or their own rescue medication if 2 hours after initial treatment, the participant still has a moderate or severe migraine headache or if the headache has returned.
3274918|NCT00662818|Experimental|Placebo and APAP 1000 mg→Telcagepant 300 mg|Participants receive 1 dose of placebo to APAP and placebo to telcagepant for the first migraine attack and then up to 11 doses of APAP and placebo to telcagepant for up to 11 migraine attacks in Period 1 (6 weeks). Participants receive up to 12 doses of telcagepant and placebo to APAP for up to 12 migraine attacks in Period 2 (6 weeks). The participant may take a blinded optional second dose of study medication or their own rescue medication if 2 hours after initial treatment, the participant still has a moderate or severe migraine headache or if the headache has returned.
3274919|NCT00662805||Salmeterol/Fluticasone propionate (50/500 μg)|Open label, 6 visits, single arm study
3274920|NCT00662779|Experimental|1|15 mcg arformoterol nebulizer + 1 inhalation of placebo inhalation powder
3274921|NCT00662779|Active Comparator|2|1 inhalation of formoterol fumarate inhalation powder (12 mcg/inhalation) + 2 ml of normal saline nebulizer
3274922|NCT00662779|Placebo Comparator|3|1 inhalation of placebo inhalation powder + 2 ml of normal saline nebulizer
3274923|NCT00662753|Active Comparator|home monitoring|home blood pressure monitor
3274924|NCT00662753|Experimental|monitor & phone call|home blood pressure monitor + phone calls
3274925|NCT00662740|Experimental|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
3274926|NCT00662740|Active Comparator|Tiotropium QD|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
3274927|NCT00662740|Active Comparator|Salmeterol BID|Salmeterol Inhalation Powder, hard PE capsule
3274928|NCT00662740|Active Comparator|Tiotropium/Salmeterol QD+ Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
3274929|NCT00662740|Placebo Comparator|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
3274930|NCT00662727|Active Comparator|A|A - Treatment group. Patients in this group receive actual shockwave therapy.
3274931|NCT00662727|Placebo Comparator|B|Placebo group. This group of patients undergo the same procedure as the treatment group, however shockwaves are not delivered to the heart.
3274932|NCT00662714|Experimental|1|Repaglinide; oral
3274933|NCT00662714|Active Comparator|2|short-acting Insulin (Actrapid)
3274934|NCT00662701|Active Comparator|1|Catheter RF ablation with complete circumferential ablation around the right and PVs, and additional lines between the lower and upper PVs, and towards the mitral valve ring.
3274935|NCT00662701|Active Comparator|2|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
3274936|NCT00662688|Active Comparator|chemotherapy|chemotherapy at investigator's discretion
3274937|NCT00662688|Experimental|dalteparin|dalteparin: 5000 UI sub-cutaneous injection, from Day 1 to Day 28.
3274938|NCT00662675|Experimental|001|Pancrease MT 10.5 or MT 21 Pancrease MT capsules for maximum dose of 10 000 lipase units / Kg / day
3274939|NCT00662675|Experimental|002|Placebo for Pancrease MT 10.5 or MT 21 Capsules with Pancrease MT excipients without the active enzymes
3274940|NCT00662662||Oropharyngeal Cancer|
3274941|NCT00662662||Non-Oropharyngeal Cancer|
3274942|NCT00662649|Experimental|Fingolimod 1.25 mg|Patients continued the same dose to which they had been randomized in the Core study (CFTY720D2301/NCT00289978), fingolimod 1.25 mg/day, in this Extension study.
3274943|NCT00662649|Experimental|Fingolimod 0.5 mg|Patients continued the same dose to which they had been randomized in the Core study, fingolimod 0.5 mg/day, in this Extension study.
3274944|NCT00662649|Experimental|Placebo-fingolimod|Patients randomized to placebo in the Core study were re randomized to fingolimod (either 0.5 or 1.25 mg/day) in this Extension study.
3274945|NCT00662649|Experimental|Placebo-fingolimod 1.25 mg|Patients randomized to placebo in the Core study were re randomized to fingolimod 1.25 mg/day in this Extension study.
3274946|NCT00662649|Experimental|Placebo-fingolimod 0.5 mg|Patients randomized to placebo in the Core study were re randomized to fingolimod 0.5 mg/day in this Extension study.
3274947|NCT00662636|Experimental|Arm I|Patients receive oral dasatinib and lapatinib ditosylate once daily on days 1-28.
3274948|NCT00662623|Experimental|1|
3274949|NCT00662623|Active Comparator|2|Usual Care (Standard Care)
3274950|NCT00662610|Experimental|naproxcinod 375 mg - 750 mg -1125 mg bid|dose escalating
3274951|NCT00662610|Active Comparator|naproxen 250 mg -500 mg -750 mg bid|dose escalating
3274952|NCT00662597|Experimental|ASA404|
3274953|NCT00662597|Placebo Comparator|ASA40 Placebo|
3274954|NCT00662584|Experimental|1|This was an open-label study - all subjects received the intervention (rTMS treatment)
3274955|NCT00662571||A|"Our hypothesis is that effective acamprosate response in alcohol dependent subjects may be influenced by genetically controlled variation in the functionality of the N-methyl-D-aspartate receptor (NMDA) and/or the type 5 metabotropic glutamate receptor (mGluR5). Hypothesis confirmation could lead to development of effective individualized treatment recommendations for alcohol dependent patients based on pharmacogenomically relevant genetic variations.~There will be no placebo drug given. Just measurement of genetic response."
3274956|NCT00662558|Experimental|celecoxib|
3274957|NCT00662558|Active Comparator|tramadol|
3274958|NCT00662545|Experimental|A|Entecavir 1 mg for 24 weeks in addition to continued standard of care antiretroviral therapy containing tenofovir in addition to emtricitabine or lamivudine
3274959|NCT00662545|Active Comparator|B|continued standard of care antiretroviral therapy which will include tenofovir in addition to emtricitabine or lamivudine
3274960|NCT00662532|Experimental|Minocycline HCl|1 mg microspheres of minocycline hydrochloride
3274961|NCT00662532|No Intervention|No Intervention|Control group receiving no drug intervention
3275240|NCT00660491|Experimental|3|high intensity exercise group
3274962|NCT00662519|Experimental|Neulasta|Subjects will receive Neulasta subcutaneously every 2 weeks for 12 weeks (6 doses). In addition, the following test will be done: Mixed Meal Tolerance Test (MMTT), Hemoglobin A1C (HbA1c) blood test, and Human Leukocyte Antigen (HLA) DNA Test.
3274963|NCT00662519|Placebo Comparator|Placebo|Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. In addition, the following test will be done: Mixed Meal Tolerance Test (MMTT), Hemoglobin A1C (HbA1c) blood test, and Human Leukocyte Antigen (HLA) DNA Test.
3274964|NCT00662506|Experimental|Treatment (enzyme inhibitor therapy, chemotherapy, IMRT)|See Detailed Description
3274965|NCT00662493|Experimental|1|Motor control retraining program
3274966|NCT00662480|Experimental|1|Invited to screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm
3274967|NCT00662480|No Intervention|2|Participants which are not offered vascular screening
3274968|NCT00662467|Active Comparator|1|aspirin and clopidogrel
3274969|NCT00662467|Experimental|2|aspirin, clopidogrel, and warfarin
3274970|NCT00662454|Active Comparator|I|10 normal weight women (BMI < 25 kg/m2)
3274971|NCT00662454|Active Comparator|II|10 obese women (BMI >30 kg/m2)
3274972|NCT00662441|Experimental|Arm 1|
3274973|NCT00662428|Experimental|Intervention|
3274974|NCT00662428|Active Comparator|Control|
3274975|NCT00662415|Other|1|12 non-amputee control subjects will be scanned at 0, 2 and 4 weeks but will not recieve mirror therapy.
3274976|NCT00662415|Experimental|2|24 unilateral lower extremity amputee subjects will recieve daily mirror therapy for phantom limb pain and will be scanned at 0, 2, and 4 weeks.
3274977|NCT00662402|Experimental|1-Extensive Consultations|Intervention- Receives extensive consulting services
3274978|NCT00662402|No Intervention|2-Regular levels of service|Control - Receives regular levels of service; one hour free services from each of the 4 units, with option to pay for more.
3274979|NCT00662389|Experimental|A|
3274980|NCT00662376|Experimental|Test|oral nutritional supplement (assignment: according to consecutive random numbers)
3274981|NCT00662376|Placebo Comparator|Control|placebo (assignment: according to consecutive random numbers)
3274982|NCT00662363|Experimental|Lubiprostone and placebo Senna|Lubiprostone (Amitiza) 24 µg po BID given with meals for 6 days with two tabs placebo Senna at noon
3274983|NCT00662363|Active Comparator|Senna active plus Lubiprostone Placebo|Senna 2 tabs daily for 6 days at noon and placebo Lubiprostone 1 Cap BID
3274984|NCT00662350||Symptomatic Benign Protate Hypertrophy|Symptom Score (IPSS) greater than 15, requiring invasive treatment, Prostate size greater than 25 g, Prostatic urethra length between 2.0 cm and 5.5 cm
3274985|NCT00662337|Experimental|1|Diphenydramine HCl
3274986|NCT00662324||1|Trial experienced cancer patients and their primary caregivers.
3274987|NCT00662324||2|Trial naive cancer patients and their caregivers.
3274988|NCT00662324||3|Health care professionals who are involved in running Phase I, II or III clinical trials.
3274989|NCT00662311|Experimental|Treatment (vorinostat with paclitaxel and radiotherapy)|Patients receive vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.
3274990|NCT00662298|Experimental|Severe Asthma|
3274991|NCT00662285|Other|A: Niferex|100 mg Fe++
3274992|NCT00662272|Experimental|1|Arm includes treatment with Fluzone® vaccine mixed with study product JVRS-100 adjuvant
3274993|NCT00662272|Active Comparator|2|Arm includes treatment with half adult dose of Fluzone® vaccine
3274994|NCT00662272|Active Comparator|3|Arm includes treatment with full adult dose Fluzone® vaccine
3274995|NCT00662259|Experimental|alprazolam|Alprazolam, an FDA-approved drug, will be administered to 24 patients with generalized anxiety disorder.
3274996|NCT00662259|Placebo Comparator|placebo|A placebo comparator will be administered to 12 patients with generalized anxiety disorder
3274997|NCT00662246|Experimental|1|"Primary objectives :~to determine the recommended dose (i.e., the safest and most effective dose) by evaluating frequency of patients developing unacceptable (grade 3 or higher) acute toxicities attributable to proton beam radiotherapy for HCC."
3274998|NCT00662220|Active Comparator|Standard dose|Standard-dose ribavirin (12-15 mg/kg/day) in combination with peginterferon 180µg QW
3274999|NCT00662220|Experimental|High dose|High-dose ribavirin (25-29 mg/kg/day) in combination with peginterferon 180µg QW
3275000|NCT00662207|Experimental|Arm 1|Use a vibrator on the patient's bottom to determine if it will induce a bladder contraction; Use an anal dilator to determine if urethral relaxation will occur
3275001|NCT00662194||1|HIV-HBV co-infected and receiving anti-retroviral therapy (ART) and CD4 count > 500cells/mm3
3275002|NCT00662194||2|HIV-HBV co-infected and receiving ART and CD4 count 200-500 cells/mm3
3275003|NCT00662194||3|HIV-HBV co-infected and receiving ART and CD4 count <200cells/mm3
3275004|NCT00662194||4|HIV-HBV co-infected and not receiving ART
3275005|NCT00662194||5|HIV-HCV co-infected & receiving anti-retroviral therapy (ART) and CD4 count > 500cells/mm3
3275006|NCT00662194||6|HIV-HCV co-infected and receiving ART and CD4 count 200-500 cells/mm3
3275007|NCT00662194||7|HIV-HCV co-infected and receiving ART and CD4 count <200cells/mm3
3275008|NCT00662194||8|HIV-HCV co-infected and not receiving ART
3275009|NCT00662181||H, NH|HIV positive patients with and without lipodystrophy
3275010|NCT00662168||observation|Individuals with a diagnosis of carcinoid carcinoma
3275011|NCT00662155|Experimental|Continuous 1 (QHS-10)|continued nightly use with 10mg zolpidem
3275012|NCT00662155|Experimental|Partial Reinforcement (PRS-10)|partial reinforcement with 10mg zolpidem (PRS-10 [nightly pill use with 50% active meds and 50% placebos])
3275013|NCT00662155|Experimental|Intermittent (IDS-10)|intermittent dosing with 10mg zolpidem
3275014|NCT00662155|Experimental|Continuous 2 (QHS-5)|continued nightly use with 5mg zolpidem
3275015|NCT00662142|Experimental|1|DHA 400 mg/day (200mg twice daily), vs DHA 1200 mg/day (400 mg three times daily), vs placebo; 1:1:1 ratio
3275139|NCT00661271|Experimental|Mindfulness-Based Stress Reduction|8-week mindfulness-based stress reduction program with one retreat session
3275016|NCT00662129|Experimental|paclitaxel + gemcitabine + bevacizumab|"Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and after every other course, and then after completion of treatment.~After completion of study treatment, patients are followed periodically for 5 years."
3275017|NCT00662116|Experimental|1|
3275018|NCT00662116|Placebo Comparator|2|
3275019|NCT00662103|Active Comparator|progressive, aerobic exercise program|Patients undergo aerobic exercise training over approximately 45 minutes (not including warm-up or cool-down exercises) 3 days a week for 18 months.
3275020|NCT00662103|Active Comparator|progressive, resistance exercise program|Patients undergo resistance exercise training 3 days a week for 18 months.
3275021|NCT00662103|Active Comparator|flexibility and relaxation training [control]|Patients perform a series of whole body flexibility (stretching) and relaxation (guided imagery, progressive neuromuscular relaxation, focused breathing) exercises 3 days a week for 18 months.
3275022|NCT00662077|Experimental|1|Ibandronate + Lifestyle modifications
3275023|NCT00662077|Other|2|Lifestyle modifications
3275024|NCT00662064||1|Patients with lower urinary tract dysfunction
3275025|NCT00662064||2|Controls with normal lower urinary tract function
3275026|NCT00662051||OCP Users|
3275027|NCT00662051||Non-users of OCPs|
3275028|NCT00662038|Experimental|Treatment|pirfenidone
3275029|NCT00662025|Experimental|1|
3275030|NCT00662012|Experimental|Sodium Stibogluconate (SSG) 20 mg/kg|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with 20 mg/kg once daily intravenously with SSG.
3275031|NCT00661999|Experimental|Arm I|Patients receive darbepoetin alfa subcutaneously and sodium ferric gluconate complex IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
3275032|NCT00661999|Experimental|Arm II|Patients receive darbepoetin alfa as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
3275033|NCT00661999|Experimental|Arm III|Patients receive darbepoetin alfa as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
3275034|NCT00661986|Experimental|1|dark chocolate 6 g/day
3275035|NCT00661986|Active Comparator|2|dark chocolate 25 g/day
3275036|NCT00661960|No Intervention|1|HIV Negative volunteers
3275037|NCT00661960|Active Comparator|2|HIV-Positive volunteers taking raltegravir in combination with two other nucleoside reverse transcriptase inhibitors (NRTI) medications
3275038|NCT00661960|Active Comparator|3|HIV-Positive volunteers taking efavirenz or any other non-nucleoside reverse transcriptase inhibitors (NNRTI) in combination with two other nucleoside reverse transcriptase inhibitor (NRTI) medications
3275039|NCT00661947||Public|General public. Those who are not currently taking any medication besides birth control pills.
3275040|NCT00661934||1|Dialysis Group
3275041|NCT00661934||2|Cardiac Malfunction Group
3275042|NCT00661921|Active Comparator|40 mg AMG 108 Q2W|
3275043|NCT00661921|Active Comparator|150 mg AMG 108 Q2W|
3275044|NCT00661921|Active Comparator|75 mg AMG 108 Q2W|
3275045|NCT00661921|Placebo Comparator|Placebo Q2W|
3275046|NCT00661908||1|insulin-treated diabetic subjects of North-western part of Switzerland
3275047|NCT00661895|Experimental|Intervention|Intervention group subjects will receive education and assistance from a Community Health Center or Cardiac Center nurse practitioner or physician, health educator, dietitian, social worker, and Cardiac Center-trained community members called Community Health Advocates (CHAs).
3275048|NCT00661895|Active Comparator|Control|No intervention
3275049|NCT00661869|Active Comparator|Wellness Group|
3275050|NCT00661856|Active Comparator|1|Soy Protein group 25g of Soy protein with no Isoflavones
3275051|NCT00661856|Experimental|2|Soy Isoflavone group 25g of Soy Protein with 90mg of Isoflavones
3275052|NCT00661856|Placebo Comparator|3|25g of Milk protein
3275053|NCT00661843|Experimental|1|Intervention group: Intervention constitutes of 2 supervised yoga classes per week incorporating gentle Yoga postures, relaxation and meditation sequences In addition: daily home based sessions of yogic relaxation and meditation using a pre-recorded audio CD
3275054|NCT00661843|No Intervention|2|Control in waiting to be crossed over after control phase completed. Participants of this group studied using same objective and subjective outcome measures.
3275055|NCT00661830|Experimental|1|Gemcitabine + Sorafenib
3275056|NCT00661830|Placebo Comparator|2|Gemcitabine + Placebo
3275057|NCT00661817|Active Comparator|1|Participants in this group will receive usual medical care and reading materials on weight loss.
3275058|NCT00661817|Experimental|2|Participants in this group will take part in the lifestyle modification program.
3275059|NCT00661804||Thalassemia cohort|"Thalassemia as documented by clinical diagnosis, including:~thalassemia (intermedia or major); HbH disease; HbH with non-deletional mutations, e.g., HbH Constant Spring E beta-thalassemia; Homozygous alpha-thalassemia (i.e., 4-gene alpha deletion or equivalent null alpha mutation); Other thalassemic conditions not explicitly excluded; Thalassemia intermedia due to heterozygous beta mutation with alpha-gene excess."
3275060|NCT00661804||Successful SCT cohort|Individuals who have received a successful hematopoietic SCT, defined as engraftment of all three cell lines and transfusion independence by 100 days post-transplant, for any of the disorders listed above;Monitored for end-organ injury related to thalassemia prior to their successful SCT;Participants who were enrolled in TCRN Registry or had a successful SCT after 01 Jan 2002.
3275061|NCT00661791|No Intervention|A|Control Group receives routine care.
3275062|NCT00661791|Experimental|B.|massage group, receives massage only.
3275063|NCT00661791|Experimental|C.|Massage and Exercise group, receives both massage and exercise.
3275140|NCT00661271|Active Comparator|Healthy Topics|8-week health education program with one retreat session - based on a health curriculum developed by McGraw/Hill
3275241|NCT00660478|Active Comparator|1|Zotarolimus eluting stent
3275064|NCT00661778|Experimental|Bevacizumab + cisplatin + docetaxel|Participants received bevacizumab 15 mg/kg intravenously (IV) followed by docetaxel 75 mg/kg IV in combination with cisplatin 75 mg/m^2 IV on Day 1 of each 3-week cycle for a maximum of 6 cycles. After completing the 6 cycles of combined chemotherapy, participants received bevacizumab 15 mg/kg IV until disease progression, unacceptable toxicity, or withdrawal of consent.
3275065|NCT00661765|Active Comparator|Chantix immediate release tablet formulation|
3275066|NCT00661765|Experimental|Varenicline transdermal delivery system|
3275067|NCT00661752||FBP studies|standard filtered backprojection image processing/reconstruction of full-time acquisition data
3275068|NCT00661752||half-time WBR|wide-beam reconstruction of simulated half-time acquisitions from standard full-time acquisitions
3275069|NCT00661752||Quarter-time stress|4 seconds per stop post-stress SPECT acquisitions reconstructed by the wide-beam reconstruction method
3275070|NCT00661752||Quarter-time rest|6 seconds per stop rest SPECT acquisitions reconstructed by the wide-beam reconstruction method
3275071|NCT00661739|Experimental|Singular Arm|Bendamustine treatment
3275072|NCT00661726|Experimental|1|Participants will receive injected decitabine for 12 weeks.
3275073|NCT00661713|Experimental|rMenB06|Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and two injections of placebo (at month 1, month 2). A second injection of rMenB+OMV NZ vaccine was given later (month 6).
3275074|NCT00661713|Experimental|rMenB0|Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and three injections of placebo (month 1, month 2 and month 6).
3275075|NCT00661713|Experimental|rMenB016|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).
3275076|NCT00661713|Experimental|rMenB01|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and two injection of placebo (at month 2 and month 6).
3275077|NCT00661713|Experimental|rMenB026|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).
3275078|NCT00661713|Experimental|rMenB02|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and two injections of placebo (at month 1 and month 6).
3275079|NCT00661713|Experimental|rMenB012|Subjects received three injections of rMenB+OMV NZ vaccine (at month 0, month 1 and month 2) and one injection of placebo later (at month 6).
3275080|NCT00661713|Experimental|rMenB6|Subjects received three injections of placebo(at month 0, month 1 and month 2) and one injection of rMenB+OMV NZ vaccine(at month 6).
3275081|NCT00661700|Placebo Comparator|Arm 2|
3275082|NCT00661700|Experimental|Arm 1|
3275083|NCT00661687|Active Comparator|Purevision Contact Lens #1|PureVision Soft Contact Lens Design (currently marketed)
3275084|NCT00661687|Experimental|PureVision Contact Lens #2|Redesign of the currently marketed PureVision soft contact lens.
3275085|NCT00661674|Experimental|Sequence 1: Placebo, Combo, Palonosetron|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Placebo~Week 2: Palonosetron + Hydroxyzine Combo~Week 3: Palonosetron"
3275086|NCT00661674|Experimental|Sequence 2: Palonosetron, Combo, Placebo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron~Week 2: Palonosetron + Hydroxyzine Combo~Week 3: Placebo"
3275087|NCT00661674|Experimental|Sequence 3: Combo, Placebo, Palonosetron|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron + Hydroxyzine Combo~Week 2: Placebo~Week 3: Palonosetron"
3275088|NCT00661674|Experimental|Sequence 4: Placebo, Palonosetron, Combo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Placebo~Week 2: Palonosetron only~Week 3: Palonosetron + Hydroxyzine Combo"
3275089|NCT00661674|Experimental|Sequence 5: Combo, Palonosetron, Placebo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron + Hydroxyzine Combo~Week 2: Palonosetron only~Week 3: Placebo"
3275090|NCT00661674|Experimental|Sequence 6: Palonosetron, Placebo, Combo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron only~Week 2: Placebo~Week 3:Palonosetron + Hydroxyzine Combo"
3275091|NCT00661661|Experimental|CP-690,550|
3275092|NCT00661648|No Intervention|1|glucose levels were controlled using sliding scale
3275093|NCT00661648|Experimental|2|received programmed infusions of insulin determined by the control algorithm of the artificial pancreas
3275094|NCT00661635|Active Comparator|Arm 1|
3275095|NCT00661635|Active Comparator|Arm 2|
3275096|NCT00661635|Placebo Comparator|Arm 3|
3275097|NCT00661622|Experimental|Immunoembolization|Liver embolization treatment with injection of GM-CSF.
3275098|NCT00661622|Active Comparator|Plain embolization|Liver embolization with normal saline injected in place of GM-CSF
3275099|NCT00661609|Experimental|AZD4877|Single agent AZD4877
3275100|NCT00661596|Experimental|Arm 1|
3275101|NCT00661596|Placebo Comparator|Arm 2|
3275102|NCT00661583|Experimental|Ranibizumab alone|Treatment with ranibizumab 0.5 mg intravitreally injected (n=10)
3275103|NCT00661583|Experimental|Ranibizumab and MMC|Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10)
3275104|NCT00661583|Active Comparator|MMC alone|MMC therapy alone (n=10)
3275105|NCT00661570|Experimental|Early feasability arm|
3275106|NCT00661557|Experimental|MPS|Subjects who were vaccinated with Mencevax™ ACWY in a previous study
3275107|NCT00661557|Experimental|noMPS|Subjects who were never vaccinated with a meningococcal vaccine (or not in the previous 10 years)
3275108|NCT00661544|Experimental|Arsenic Trioxide + Vitamin C + Melphalan|Arsenic Trioxide + Ascorbic Acid + Melphalan as a preparative regimen for autologous stem cell transplantation (delivered on Day 0)
3275109|NCT00661531|Experimental|Estrace & Anastrozole|Estrace 10 mg three times a day for 3 months. After 3 months of estrace, the estrace will be stopped and anastrazole 1 mg daily will be administered
3275110|NCT00661518||1|Patients scheduled for conventional aneurysm repair
3275111|NCT00661518||2|Patients scheduled for endovascular aneurysm repair
3275112|NCT00661505|Experimental|C.E.R.A. 120, 200, or 360 mcg|Eligible participants were administered Continuous Erythropoietin Receptor Activator (C.E.R.A.) at a dose of 120, 200, or 360 microgram (mcg), intravenously (IV), every 4 weeks i.e. Weeks 4, 8, 12, 16 and 20 but not on Weeks 24 and 28. The initial dose of C.E.R.A.was based on the last dose of the previous Erythropoiesis Stimulating Agent (ESA). The ESA therapy was administered from enrollment to the 4 weeks stability verification period (SVP), weekly, either as epoetin (<8000 IU, 8000-16000 IU, or >16000 IU) or darbepoetin alpha (<40 mcg, 40-80 mcg, or >80 mcg). A telephone follow-up visit took place 4 weeks after the end of C.E.R.A. treatment (Week 28).
3275113|NCT00661492|Experimental|Arm 1|Erbitux (cetuximab) and Novantrone (mitoxantrone)
3275114|NCT00661492|Experimental|Arm 2|Novantrone (mitoxantrone)
3275115|NCT00661479|Experimental|400 µg Brimonidine Tartrate Implant Group B|400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
3275116|NCT00661479|Experimental|200 µg Brimonidine Tartrate Implant Group B|200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
3275117|NCT00661479|Experimental|100 µg Brimonidine Tartrate Implant Group B|100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
3275118|NCT00661479|Experimental|100 µg Brimonidine Tartrate Implant Group A|100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
3275119|NCT00661466|Experimental|1|Either three or four 5x5-cm bupivacaine sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
3275120|NCT00661466|Placebo Comparator|2|Either three or four 5x5-cm placebo sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
3275121|NCT00661453|Experimental|1|All patients will receive VPA and carnitine.
3275122|NCT00661440|Other|1|
3275123|NCT00661440|Other|2|
3275124|NCT00661427|Active Comparator|Cetuximab 500 mg/m^2|Cetuximab 500 mg/m^2 IV over 2 hours every other week
3275125|NCT00661427|Active Comparator|Cetuximab 750 mg/m^2|Cetuximab 750 mg/m^2 IV over 3 hours every other week
3275126|NCT00661388|Experimental|Continuous erythropoietin receptor activator (C.E.R.A.)|Eligible participants will be administered C.E.R.A subcutaneously, every 4 weeks for 44 weeks. The initial dose of C.E.R.A. will be 1.2 micrograms/kilogram. Subsequent doses will be adjusted to maintain the individual participant's hemoglobin within the target range of 10.0 and 12.0 grams/deciliter.
3275127|NCT00661375|Experimental|Arm 1|
3275128|NCT00661362|Experimental|1|Metformin + Saxagliptin
3275129|NCT00661362|Placebo Comparator|2|Metformin + Placebo
3275130|NCT00661349|Active Comparator|1|Nevirapine
3275131|NCT00661349|Experimental|2|Lopinavir/ritonavir
3275132|NCT00661323||1|Healthy volunteers will be recruited through the use of an approved study recruitment flyer.
3275133|NCT00661323||2|Chemotherapy patients will be approached at the time of their nuclear scan to rule out cardiac disease prior to chemotherapy. These patients will be referred to the study by their doctor for the assessment of heart function.
3275134|NCT00661310|Experimental|I|Intervention by team consisting of Doctor, pharmacist and nurse
3275135|NCT00661310|No Intervention|C|
3275136|NCT00661297|Experimental|Arm 1|
3275137|NCT00661297|Placebo Comparator|Arm 2|
3275138|NCT00661284||Ⅰ|Subject who have participated in previous studies and achieved DAS28 of < 3.2 at the last observation and at least one time point among the two previous assessment time points in a previous studies.
3275141|NCT00661258|Experimental|Intervention|The intervention group patients were given their electronic drug monitoring feedback data at each monthly visit. The study coordinator would quickly calculate whether the patient's adherence was below 95% in the previous month. If so, that patient was flagged for enhanced counseling with a clinic doctor and this counseling was based on a printout containing the electronic drug monitoring data.
3275142|NCT00661258|No Intervention|Comparison|"The comparison group patients were not given the data from the electronic data monitoring feedback data. Instead, they filled out a self report form that all patients fill out. If they indicated in this report that their adherence in the previous was less than 95%, then they were flagged for enhanced counseling with a doctor. This counseling was based on the patient's self report. Thus both groups received enhanced counseling if they indicated poor adherence, but only the intervention group were given their electronic data output."
3275143|NCT00661245|Experimental|TOGA|The TOGA procedure is an incision-free treatment using a set of flexible staplers introduced into the mouth and esophagus to create a sleeve in the stomach (transoral formation of a gastric sleeve). The TOGA sleeve limits the amount of food that can be eaten and gives the patient a feeling of fullness after a small meal.
3275144|NCT00661245|Sham Comparator|Control|A gastric sleeve is not formed.
3275145|NCT00661219|Active Comparator|Arm 1|
3275146|NCT00661219|Placebo Comparator|Arm 2|
3275147|NCT00661206|Active Comparator|Clopidogrel|
3275148|NCT00661206|Placebo Comparator|Placebo|
3275149|NCT00661193|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3275150|NCT00661193|Active Comparator|Arm II|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for 4 courses. Beginning in course 5 and for all subsequent courses, patients receive oral erlotinib hydrochloride alone on days 1-21. Courses with erlotinib hydrochloride repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3275151|NCT00661180|Experimental|Arm 1|
3275152|NCT00661167|Experimental|1|ABI-007
3275153|NCT00661141|Experimental|Cohort 1: Antizol 1.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 1.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.
3275154|NCT00661141|Experimental|Cohort 2: Antizol 3.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 3.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.
3275155|NCT00661141|Experimental|Cohort 3: Antizol 5.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 5.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.
3275156|NCT00661141|Experimental|Cohort 4: Antizol 1.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 7.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.
3275157|NCT00661128||1|European American people who have experienced SCA.
3275158|NCT00661128||2|European American people who have not experienced SCA.
3275159|NCT00661128||3|African American people who have experienced SCA.
3275160|NCT00661128||4|African American people who have not experienced SCA.
3275161|NCT00661115|Experimental|Arm 1|
3275162|NCT00661115|Placebo Comparator|Arm 2|
3275163|NCT00661102|Experimental|1|
3275164|NCT00661102|Active Comparator|2|
3275165|NCT00661102|Placebo Comparator|3|
3275166|NCT00661089|Experimental|Intramuscular OnabotulinumtoxinA|Injection of Botulinum Toxin type A - onabotulinumtoxinA into specified shoulder muscles at second visit
3275167|NCT00661089|Active Comparator|Intramuscular Placebo (Saline)|Injection of saline into specified shoulder muscles at Visit 2. Blind broken and subjects were offered study drug if initially in the placebo group, at week 12
3275168|NCT00661076|Experimental|1|
3275169|NCT00661076|Experimental|2|
3275170|NCT00661076|Active Comparator|3|
3275171|NCT00661063|Experimental|K|drug - ketamine 1% gel
3275172|NCT00661063|Placebo Comparator|P|vehicle gel
3275173|NCT00661063|Experimental|M|association of ketamine and clonidine gel
3275174|NCT00661063|Experimental|C|clonidine gel
3275175|NCT00661037||1|Patients having VF induction with shock termination at implant
3275176|NCT00661037||2|Patients not having VF induction at implant or during follow-up
3275177|NCT00661024|Placebo Comparator|1|RLN visualization alone
3275178|NCT00661024|Experimental|2|IONM of the RLN
3275179|NCT00661011|Experimental|A|Lobectomy followed by mediastinal concomitant chemoradiotherapy
3275180|NCT00660998|Experimental|Arm 1|
3275181|NCT00660998|Placebo Comparator|Arm 2|
3275182|NCT00660985|Experimental|Differin® Gel, 0.3%|Gel, 0.3%, 2g, once daily for 30 days
3275183|NCT00660985|Active Comparator|Differin® Gel, 0.1%|Gel, 0.1%, 2g, once daily for 30 days
3275184|NCT00660972|Experimental|1|Oral RAL and FTC/TDF for 72 weeks
3275185|NCT00660959|Experimental|Active Comparator|lixivaptan
3275186|NCT00660959|Placebo Comparator|Placebo|placebo
3275187|NCT00660946||37 dialysis patients|37 chronic hemodialysis patients on warfarin requiring Laboratory INR monitoring for anticoagulation management.
3275188|NCT00660933|Active Comparator|Group A|Group A: Administration of intravenous iron sucrose.
3275189|NCT00660933|Placebo Comparator|Group B|Group B: Administration of intravenous NaCl 0,9%.
3275190|NCT00660920|Experimental|ponatnib|Comparison of different dosages of ponatinib given orally once per day.
3275191|NCT00660907|Experimental|1|dapagliflozin plus metformin
3275192|NCT00660907|Active Comparator|2|glipizide plus metformin
3275193|NCT00660894|Experimental|tegafur-gimeracil-oteracil potassium|Patients receive tegafur-gimeracil-oteracil potassium(S-1) orally twice daily for 28 days with a subsequent pause of 14 days. This repeats 4 times every 6 weeks.
3275237|NCT00660504|Active Comparator|2|Etoposide-Cisplatin combined chemotherapy
3275238|NCT00660491|No Intervention|1|Control
3275194|NCT00660894|Active Comparator|tegafur-uracil and folinate calcium|Patients receive tegafur-uracil(UFT) plus folinate calcium(leucovorin) orally every 8 hours for 21 days with a subsequent pause of 7 days. This repeats 5 times every 5 weeks.
3275195|NCT00660881|Experimental|EMAB|1200 mg epratuzumab given in 2 doses every other week in 12 week treatment cycles.
3275196|NCT00660868||1|Patients with posttraumatic, idiopathic, and postinflammatory cause of smell loss; patients age between 18 and 50 years. Odor threshold better than 1.
3275197|NCT00660855|Other|Arm 1|
3275198|NCT00660842|Experimental|A|weekly chemotherapy
3275199|NCT00660842|Active Comparator|B|every 3 weeks chemotherapy
3275200|NCT00660829|Placebo Comparator|1|Placebo
3275201|NCT00660829|Active Comparator|2|0.15% Azelastine Hydrochloride
3275202|NCT00660816|Active Comparator|Arm I|Patients receive pemetrexed disodium IV over 10 minutes OR docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive standard chemotherapy with or without erlotinib hydrochloride in the absence of disease progression or unacceptable toxicity.
3275203|NCT00660816|Experimental|Arm II|Patients receive pemetrexed disodium IV over 10 minutes OR docetaxel IV over 60 minutes on day 1 and erlotinib hydrochloride PO once daily on days 2-19. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive standard chemotherapy with or without erlotinib hydrochloride in the absence of disease progression or unacceptable toxicity.
3275204|NCT00660803||1|Postmenopausal women with hormone-receptor positive, advanced breast cancer who have failed at least one previous endocrine therapy and who have been treated at any one of the participating centres with fulvestrant.
3275205|NCT00660790||diabetic subjects, above targets|
3275206|NCT00660777|Sham Comparator|1|Control Group
3275207|NCT00660777|Active Comparator|2|Therapy Group
3275208|NCT00660764||1|Patients eligible for the study were patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C ≥ 3.2 mmol/l. Patients were aged ≥ 18 years and ≤ 70 years (men) and ≤ 75 years (women), according to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention. The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation. Patient approved to place anonymous results at the disposal of AstraZeneca
3275209|NCT00660751|Active Comparator|1|
3275210|NCT00660751|Placebo Comparator|2|
3275211|NCT00660738||01|Patients with clinical and spirometric diagnosis of COPD, with FEV1<80%
3275212|NCT00660725|Other|Vandetanib/GEMOX|All subjects receive the same combination study drug and follow the same study schedule. As a phase 1 study, only the doses will vary between subjects.
3275213|NCT00660712||1|Patients with bipolar disorder
3275214|NCT00660699|Experimental|Arm 1 (gemcitabine, docetaxel, 5FU, radiation)|"Gemcitabine 1000 mg/m2 IV on Day 1 and Day 8 of a 21 day cycle for 2 cycles~Docetaxel 35 mg/m2 IV on Day 1 and Day 8 of a 21 day cycle for 2 cycles~5FU CIVI 225 mg/m2 per day throughout radiation (starts 3 weeks after start of cycle 2)~Radiation 5040 cGy or 5400 cGy for positive margins (starts 3 weeks after start of cycle 2). Daily dose of 1.8 Gy five days per week.~Gemcitabine 1000 mg/m2 IV on Days 1 and 8 of 21 day cycle for 2 cycles (this starts 4 weeks after radiation)~Docetaxel 35 mg/m2 IV on Days 1 and 8 of 21 day cycle for 2 cycles (this starts 4 weeks after radiation)"
3275215|NCT00660686|Experimental|1|Progressive resistance training program 3 times a week for 12 months
3275216|NCT00660686|Active Comparator|2|Seated flexibility training 3 times a week for 12 months
3275217|NCT00660673|Experimental|1|Levodopa-carbidopa intestinal gel
3275218|NCT00660660|Experimental|Nexium 20mg|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
3275219|NCT00660660|Placebo Comparator|Placebo|
3275220|NCT00660647|Experimental|methotrexate + adalimumab|Methotrexate and intraarticular triamcinolone hexacetonide plus adalimumab.
3275221|NCT00660647|Placebo Comparator|methotrexate + placebo|Methotrexate and intraarticular triamcinolone hexacetonide and placebo
3275222|NCT00660634|No Intervention|B|
3275223|NCT00660634|Experimental|A|Endovascular angioplasty/stenting
3275224|NCT00660595|Experimental|1|Oral
3275225|NCT00660595|Active Comparator|2|Oral
3275226|NCT00660569||1|Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion, previously treated with Pulmicort chlorofluorocarbons (CFC) who have changed their treatment to Pulmicort HFA
3275227|NCT00660543|Experimental|Ferumoxytol|Patients receive ferumoxytol non-stoichiometric magnetite IV on day 2 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose). Ferumoxytol non-stoichiometric magnetite administration continues in the absence of unacceptable toxicity.
3275228|NCT00660543|Active Comparator|Gadoteridol|Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).
3275229|NCT00660543|Active Comparator|Gadoteridol Leakage Corrected|Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).
3275230|NCT00660530|Active Comparator|1|Lanthanum 1 g to be chewed, three times daily with meals
3275231|NCT00660530|Experimental|2|Lanthanum carbonate 1 g crushed into a fine powder, three times daily with meal
3275232|NCT00660517|Experimental|MP29-02|azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray
3275233|NCT00660517|Active Comparator|azelastine Hcl 548 mcg|azelastine Hcl 548 mcg nasal spray
3275234|NCT00660517|Active Comparator|fluticasone propionate 200 mcg|fluticasone propionate 200 mcg nasal spray
3275235|NCT00660517|Placebo Comparator|placebo|placebo nasal spray
3275236|NCT00660504|Experimental|1|Amrubicin Hydrochloride-Cisplatin combined chemotherapy
3275242|NCT00660478|Active Comparator|2|Sirolimus stent
3275243|NCT00660465||A18|
3275244|NCT00660452|Active Comparator|1|360 active patients with house dust mites related asthma with or without allergic rhinitis
3275245|NCT00660452|Placebo Comparator|2|180 patients in the placebo group with house -dust mites related asthma with or without allergic rhinitis.
3275246|NCT00660439|Experimental|A|Treatment group, receives Narrative Exposure Therapy immediately after first assessment. Patients are assessed 1 and 6 months after treatment.
3275247|NCT00660439|No Intervention|B|Waiting list control group, receives no intervention for 3 months after first assessment. A second assessment is then administered and patients receives Narrative Exposure Therapy. Patients are assessed 1 and 6 months after treatment.
3275248|NCT00660426|Experimental|Dose Level 1 (starting level)|"Oxaliplatin 85 mg/m2 IV on days 1 and 15.~Gemcitabine 800 mg/m2 IV on days 1 and 15.~Capecitabine 600 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
3275249|NCT00660426|Experimental|Dose Level 2|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.~Gemcitabine 800 mg/m2 IV on days 1 and 15.~Capecitabine 600 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
3275250|NCT00660426|Experimental|Dose Level 3|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.~Gemcitabine 800 mg/m2 IV on days 1 and 15.~Capecitabine 800 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
3275251|NCT00660426|Experimental|Dose Level 4|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.~Gemcitabine 1000 mg/m2 IV on days 1 and 15.~Capecitabine 800 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
3275252|NCT00660413|Experimental|AMG|Acceleromygraphy monitoring
3275253|NCT00660413|Active Comparator|MMG|Mechanomyography monitoring
3275254|NCT00660400|Experimental|Combined Therapy|5-azacitidine therapy followed Allogeneic Hematopoietic Cell Transplantation (HCT).
3275255|NCT00660387|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG) + Placebo Capsules|Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
3275256|NCT00660387|Active Comparator|Placebo Gel + Levodopa-Carbidopa Capsules|Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.
3275257|NCT00660374|Active Comparator|A|
3275258|NCT00660374|Experimental|B|
3275259|NCT00660361||A|individuals co-infected with HIV-HBV and receiving tenofovir as aprt of their HAART regimen
3275260|NCT00660348|Active Comparator|morphine|morphine given traditionally (IV, pill, patch). This is standard of care dosing.
3275261|NCT00660348|Active Comparator|Intrathecal pump|Pump internal used to deliver morphine. This is a newer method for delivery of morphine. Morphine is FDA approved for intrathecal use. The intrathecal pump will be titrated gradually to effect by the interventional pain medicine team. These are the maximum doses and concentrations in keeping with the Polyanalgesic Consensus Conference guidelines: Dose (mg/day):15 ; Conc (mg/cc): 20
3275262|NCT00660335|Experimental|1|
3275263|NCT00660322|No Intervention|Control|Families assigned to the control arm will receive usual asthma care from the child's primary care provider.
3275264|NCT00660322|Experimental|Intervention|The Telephone Asthma Program and usual care.
3275265|NCT00660309|Experimental|Aliskiren|On Day 1 participants received a single oral dose of 25 mg captopril. Starting on Day 2 participants received aliskiren 300 mg tablets orally once a day for 14 days.
3275266|NCT00660309|Active Comparator|Irbesartan|On Day 1 participants received a single oral dose of 25 mg captopril. Starting on Day 2 participants received irbesartan 300 mg tablets orally once a day for 14 days.
3275267|NCT00660296|Other|2|Air insufflation in colonoscopy
3275268|NCT00660296|Other|1|CO2 insufflation in colonoscopy
3275269|NCT00660270|Experimental|Arm 1|"Surgery (pancreaticoduodenectomy, either standard or pylorus-preserving, with either standard or extended lymph node dissection, with or without portal vein resection) should occur at 8 weeks (plus or minus 2, not to exceed 10)~Radiation therapy will occur 8 weeks (plus or minus 2, not to exceed 10) postoperatively. Daily dose of 1.8 Gy five days per week. The first 45 Gy will be given to planning target volume 1. After 45 Gy, portals will be reduced to encompass planning target volume 2. The boost dose will be 5.4 Gy.~Cisplatin IV 25 mg/m2 on days 1, 8, 15, 22, 29, and 36 during radiation.~5-FU CIVI at 175 mg/m2/d on days 1-38 without interruption during radiation.~Alpha-interferon SQ 3,000,000 units on Mondays, Wednesdays, and Fridays during radiation therapy.~Gemcitabine IV 1000 mg/m2 4 weeks after conclusion of radiation (on a 3 weeks on/1 week off schedule) on days 71, 78, 85, 99, 106, and 113."
3275270|NCT00660257|Experimental|No.1: 1.25 ug|
3275271|NCT00660257|Experimental|No.2: 2.5 ug|
3275272|NCT00660257|Experimental|No.3: 5.0 ug|
3275273|NCT00660257|Experimental|No. 4: 10 ug|
3275274|NCT00660244||1|
3275275|NCT00660231|Experimental|GemBex|Gemcitabine days 1 and 8 of a 3 week cycle (4 cycles total - 12 weeks) Bexarotene daily: in combination with Gemcitabine during first 12 weeks, then Bexarotene maintenance until disease progression.
3275276|NCT00660218|Experimental|Radiation therapy, cetuximab, paclitaxel poliglumex|Radiation therapy to 69.96 Gy, 2.12 Gy per day for 33 treatments, starting week 2. Cetuximab loading dose of 400 mg/m² week 1, 250 mg/m² weekly for 7 weeks. Paclitaxel poliglumex starting week 2 40 mg/m².
3275277|NCT00660205||operation|Patients with upper gastro intestinal cancer who underwent surgery
3275278|NCT00660205||palliation|Patients with upper gastro intestinal cancer who did not underwent surgery
3275279|NCT00660205||control|Persons with no cancer who accepted to be control with blood samples and flow doppler ultrasound examination of both legs.
3275280|NCT00660192|Placebo Comparator|Placebo|Subjects are randomized to receive Placebo which is inactive saline (sterile salt water solution). The Subjects are injected with a comparable amount of placebo solution (2cc-3cc) as received by those randomized to receive active study drug. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.
3275281|NCT00660192|Active Comparator|Botox|Subjects are randomized to receive Active study drug Botox (onobotulinumtoxinA). The Botox is prepare by diluting 100units of toxin /1cc Saline. The Subjects are injected with 200-300units of units of Botox which is 2cc-3cc of solution. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.
3275282|NCT00660179|Experimental|1|Macitentan (ACT-064992) tablet, 3 mg, once daily
3275283|NCT00660179|Experimental|2|Macitentan (ACT-064992) tablet, 10 mg, once daily
3275284|NCT00660179|Placebo Comparator|3|Matching placebo, once daily
3275285|NCT00660166|Experimental|1|
3275286|NCT00660153|Experimental|single arm; multiple cohort|Single arm; multiple cohort
3275287|NCT00660140|Experimental|Gemcitabine + Carboplatin|"Gemcitabine 1000 mg/m2 IV for 30 minutes on days 1 and 8 of 21 day cycle. Maximum of 9 cycles.~Carboplatin AUC 5 IV for 1 hour on day 1 of 21 day cycle. Maximum of 9 cycles."
3275288|NCT00660101|Experimental|1|5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
3275289|NCT00660101|Experimental|2|2.5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
3275290|NCT00660101|Experimental|3|0.5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
3275291|NCT00660088||1|10 gram x 7 days, then 20 gram x 7 days active ingredient of original formulation
3275292|NCT00660088||2|20 grams x 14 days active ingredient of original formulation
3275293|NCT00660088||3|10 grams x 7 days; then 20 grams x 7 days of low protein formulation
3275294|NCT00660088||4|20 grams x 14 days of low protein formulation
3275295|NCT00660088||5|10 grams x 7 days; then 20 grams x 7 days of high protein formulation
3275296|NCT00660088||6|20 grams x 14 days of high protein formulation
3275297|NCT00660075|Experimental|1|Sitagliptin 100 mg/d for 6 weeks
3275298|NCT00660075|Placebo Comparator|2|Placebo for 6 weeks
3275299|NCT00660062|Experimental|Escitalopram 10 mg daily|Escitalopram 10 mg daily
3275300|NCT00660062|Experimental|Escitalopram 20 mg daily|Escitalopram 20 mg daily
3275301|NCT00660062|Experimental|escitalopram 30 mg daily|escitalopram 30 mg daily
3275302|NCT00660062|Active Comparator|Nortriptylin 100 mg daily|Nortriptylin 100 mg daily
3275303|NCT00660049|Experimental|SNaP application|"This is an open label pilot study of SNaP Advanced Wound Care System"
3275304|NCT00660036|Experimental|Gemtuzumab ozogamicin/Mitoxantrone/Etoposide|
3275305|NCT00660023|Experimental|Mircera in Renal Anemia|Participants with chronic renal anemia previously treated with ESA therapy will receive intravenous Mircera, also known as continuous erythropoietin receptor activator (CERA), every 4 weeks for a total of 52 weeks in this single-arm study. The first dose will be determined by the dose of ESA received prior to administration of study treatment, and subsequent doses will be adjusted to achieve target Hb concentrations.
3275306|NCT00660010|Experimental|1|
3275307|NCT00659997|Active Comparator|1|1 Individuals treated with Albendazole
3275308|NCT00659997|Active Comparator|2|Individuals treated with Levamisole
3275309|NCT00659984|Experimental|Ultratrace™ Iobenguane I 131|"Eligible patients received a diagnostic imaging dose of Ultratrace™ Iobenguane I 131 (1-5 mCi) within 7 days of study enrollment, followed by three dosimetry scans over 3-6 days. If the imaging dose demonstrated normal biodistribution and tumor uptake, then the patient received a therapeutic dose within 7-28 days of the diagnostic imaging dose, followed by a single imaging scan on Day 7 post therapy. As per protocol, therapeutic dosing was to begin at 12.0 mCi/kg and escalate to 15.0, 18.0, and 21.0 mCi/kg until the MTD was established or the 21.0 mCi/kg dose level was reached. Actual doses administered ranged from 8.8 to 18.6 mCi/kg. Based on actual doses administered, patients were grouped into 3 mean dose groups: 11.2, 15.5, and 18.2 mCi/kg.~The dosimetry dose was administered over a period of 1-3 minutes by injection; the therapeutic dose was diluted in up to 25 mL normal saline and infused intravenously over 30 to 60 minutes."
3275310|NCT00659971|Experimental|1|PAC113 0,15% mouthrinse
3275311|NCT00659971|Experimental|2|PAC113 0,075% mouthrinse
3275312|NCT00659971|Experimental|3|PAC113 0,0375% mouthrinse
3275313|NCT00659971|Active Comparator|4|Nystatin suspension
3275314|NCT00659958|Experimental|1|
3275315|NCT00659945|Active Comparator|1|Pre-op Aprepitant plus Ondansetron for PONV prophylaxis in patients undergoing outpatient plastic surgery
3275316|NCT00659945|Placebo Comparator|2|Pre-op Placebo plus Ondansetron for PONV prophylaxis in patients undergoing outpatient plastic surgery
3275317|NCT00659932|Experimental|1|
3275318|NCT00659932|Active Comparator|2|
3275319|NCT00659919|Placebo Comparator|Placebo|The patients in this arm received placebo
3275320|NCT00659919|Active Comparator|Trazodone|The patients on this arm received Trazodone for 3 consecutive days
3275321|NCT00659906|Experimental|1|Progressive resistance training program 3 times a week for 12 months
3275322|NCT00659906|Active Comparator|2|Flexibility training 3 times a week for 12 months
3275323|NCT00659893|Experimental|1|Cohort 1 One 25 cm2 treatment area; on one arm
3275324|NCT00659893|Experimental|2|Cohort 2 One 50cm2 contiguous treatment area; on one arm
3275325|NCT00659893|Experimental|3|Cohort 3 Two 25cm2 treatment areas; one on each arm
3275326|NCT00659893|Experimental|4|Cohort 4 One 25cm2 treatment area; and one 50cm2 contiguous treatment area; one on each arm
3275327|NCT00659893|Experimental|5|Cohort 5 One 75cm2 contiguous treatment area; on one arm
3275328|NCT00659893|Experimental|6|Cohort 6 Two 50cm2 contiguous treatment area; one on each arm
3275329|NCT00659893|Experimental|7|Cohort 7 One 25cm2 treatment area; and one 75cm2 contiguous treatment area; one on each arm
3275330|NCT00659893|Experimental|8|Cohort 8 One 100cm2 contiguous treatment area; on one arm
3275331|NCT00659867|Experimental|A|Chromoscopy-guided endomicroscopy with targeted biopsies
3275332|NCT00659867|Active Comparator|B|Standard endoscopy with random and targeted biopsies
3275333|NCT00659854|Placebo Comparator|Non milk or soy based formula|25 infants , non milk or soy based formula .
3275334|NCT00659854|Active Comparator|2|Intervention with milk based formula will be given to 25 infants.
3275335|NCT00659841|Active Comparator|1|Ciclesonide 200µg
3275336|NCT00659841|Placebo Comparator|2|Placebo
3275337|NCT00659828|Experimental|1|1 leptin-deficient male born in 2000
3275338|NCT00659815|Active Comparator|ReNu in Currently Marketed Bottle|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.
3275339|NCT00659815|Experimental|ReNu in Clear Resin Bottle|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.
3275340|NCT00659802|Placebo Comparator|placebo|placebo
3275341|NCT00659802|Experimental|low dose|
3275342|NCT00659802|Experimental|high dose|
3275343|NCT00659789|Experimental|Vacc-4x|Vacc-4x reconstituted in sterile water (0.1 mL) at a dose of 1.2mg per intradermal administration. Participants are given a total of 6 immunizations over 18 weeks (weeks 1, 2, 3, 4, 16, 18). Recombinant human granulocyte macrophage colony stimulating factor (rhuGM-CSF) Leukine (0.06mg in 0.1 mL) administered intradermally is used as a local adjuvant.
3275344|NCT00659789|Placebo Comparator|Placebo|Placebo injections consisting of sterile water (0.1 mL) in place of Vacc-4x. Placebo injections consisting of sterile water (0.1 mL) in place of Leukine.
3275345|NCT00659776|Active Comparator|1|Subjects with MS or any other inflammatory process
3275346|NCT00659776|Active Comparator|2|Subjects with stroke
3275347|NCT00659776|Active Comparator|3|Subjects receive ferumoxytol before cardiac surgery or CNS vascular surgery
3275348|NCT00659776|Active Comparator|4|Subjects receive ferumoxytol after cardiac surgery or CNS vascular surgery
3275349|NCT00659763||A|Patients suspected of irritable bowel syndrome referred from GP´s, who fulfill the ROM III criteria for IBS
3275350|NCT00659763||B|Patients suspected of irritable bowel syndrome referred from GP´s, who fulfill he ROME III criteria for IBS
3275351|NCT00659750|Active Comparator|1|Ciclesonide 200µg
3275352|NCT00659750|Placebo Comparator|2|Placebo
3275353|NCT00659737|Placebo Comparator|Aprepitant|"Oral Aprepitant pill and placebo transdermal patch at least 1 hour prior to surgical procedure.~Emend (Aprepitant) + Placebo"
3275354|NCT00659737|Active Comparator|Scopolamine|Oral Aprepitant pill and Scopolamine transdermal patch at least 1 hour prior to surgical procedure.
3275355|NCT00659711|Active Comparator|Januvia 100mg|The first group will be started on 100 mg sitagliptin daily for 12 weeks
3275356|NCT00659711|Placebo Comparator|placebo|will be placed on a placebo for 12 weeks.
3275357|NCT00659698|Experimental|1|received programmed infusions of insulin determined by the control algorithm of the artificial pancreas
3275358|NCT00659698|No Intervention|2|glucose levels were controlled using a manual injection of insulin according to the commonly used sliding scale
3275359|NCT00659685|Experimental|A|Subjects received Kali formulated products under fasting conditions
3275360|NCT00659685|Active Comparator|B|Subjects received GlaxoSmithKline formulated products under fasting conditions
3275361|NCT00659659|Experimental|1|MEDI-563
3275362|NCT00659659|Experimental|2|MEDI-563
3275363|NCT00659659|Placebo Comparator|4|Placebo
3275364|NCT00659659|Placebo Comparator|5|Placebo
3275365|NCT00659646|Experimental|A|Gentamicin sponge applied into wound plus levofloxacin, 750 mg by mouth (po) or intravenous (IV) every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing
3275366|NCT00659646|Active Comparator|B|Levofloxacin, 750 mg po or IV every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing
3275367|NCT00659633|Experimental|Lidocaine|Intravenous lidocaine for neuropathic pain
3275368|NCT00659620|Experimental|1|transplantation of mesenchymal stem cell
3275369|NCT00659594|Active Comparator|1|Ciclesonide 200µg
3275370|NCT00659594|Placebo Comparator|2|Placebo
3275371|NCT00659581||Patients with hypertension|
3275372|NCT00659555|Experimental|Treatment A receivers|Subjects received pazopanib, single dose as 2 x 40 microliter drops of 5 mg/mL solution in Period 1
3275373|NCT00659555|Experimental|Treatment B receivers|Subjects received ketoconazole, daily 400 mg oral dose on Days 1 to 8; pazopanib, single dose as 2 x 40 microliter drops of 5 mg/mL solution on Day 5 in Period 2
3275374|NCT00659542|No Intervention|1|mesh fixation by absorbable sutures
3275375|NCT00659542|Experimental|2|mesh fixation by cyanoacrylate glue
3275376|NCT00659529|Experimental|1|All subjects will receive oral sildenafil three times per day during the study. Study endpoints will be measured before the treatment period and at the end of the treatment period.
3275377|NCT00659516||1|intubated patients
3275378|NCT00659516||2|non intubated patients
3275379|NCT00659503|Active Comparator|1|Ciclesonide 200µg
3275380|NCT00659503|Placebo Comparator|2|Placebo
3275381|NCT00659490|Experimental|AZD1940|AZD1940 800ug given predose
3275382|NCT00659490|Active Comparator|Naproxen|Naproxen 500mg given pre-surgery
3275383|NCT00659490|Placebo Comparator|Placebo|Placebo given pre-surgery
3275384|NCT00659477|Experimental|single arm|
3275385|NCT00659464||1|Children who present to the heart center exercise stress lab for investigation of syncope
3275386|NCT00659451|Experimental|2|Losartan
3275387|NCT00659451|Active Comparator|1|Amlodipine
3275388|NCT00659438|Experimental|1|Bicalutamide 150mg + ZD6474 300mg
3275389|NCT00659438|Placebo Comparator|2|Bicalutamide 150mg + placebo
3275390|NCT00659425|Experimental|5 microgram per kilogram (mcg/kg)|Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
3275391|NCT00659425|Experimental|10 microgram per kilogram (mcg/kg)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
3275392|NCT00659425|Experimental|20 microgram per kilogram (mcg/kg): Schema A|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
3275393|NCT00659425|Experimental|20 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
3275394|NCT00659425|Experimental|30 microgram per kilogram (mcg/kg): Schema A|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
3275395|NCT00659425|Experimental|30 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
3275396|NCT00659425|Experimental|40 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
3275397|NCT00659425|Experimental|32 microgram per kilogram (mcg/kg): Schema C|Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
3275398|NCT00659425|Experimental|50 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
3275399|NCT00659425|Experimental|50 microgram per kilogram (mcg/kg): Schema C|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
3275400|NCT00659412|Experimental|Course A1|
3275401|NCT00659412|Placebo Comparator|Course A2|
3275402|NCT00659412|Experimental|Course B|Open-label extension
3275403|NCT00659386|Experimental|A|Patients with chronic idiopathic cardiomyopathy and EMB proven high PVB19 virus load.
3275404|NCT00659373|Active Comparator|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
3275405|NCT00659373|Experimental|T+OFS|Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
3275406|NCT00659373|Experimental|E+OFS|Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
3275407|NCT00659360|Experimental|Arm I|Patients receive oral AZD0530 (saracatinib ) at a dose of 175 mg, once daily, in the absence of disease progression or unacceptable toxicity.
3275408|NCT00659347|Active Comparator|1|
3275409|NCT00659347|Placebo Comparator|2|
3275410|NCT00659334|Active Comparator|1|Adults with brain tumor to receive Combidex infusion only
3275411|NCT00659334|Active Comparator|2|Adults with brain tumors to receive Combidex infusion and neurosurgery
3275412|NCT00659334|Other|3|Adults with brain tumors to receive neurosurgery only (NO Combidex)
3275413|NCT00659334|Active Comparator|4|Children with brain tumors to receive Combidex only
3275414|NCT00659334|Active Comparator|5|Children with brain tumors to receive Combidex and neurosurgery
3275415|NCT00659334|Other|6|Children with brain tumors to receive neurosurgery only, NO Combidex
3275416|NCT00659334|Active Comparator|7|Adults with Inflammatory lesions (stroke or MS) to receive Combidex only
3275417|NCT00659321|Active Comparator|1|16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
3275418|NCT00659321|Placebo Comparator|2|16 weeks treatment with placebo
3275419|NCT00659295||Type 1 diabetes|Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.
3275420|NCT00659295||Type 2 diabetes|Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.
3275421|NCT00659282||A|biphasic insulin aspart
3275422|NCT00659269|Active Comparator|Multivitamin (MV)|1 multivitamin pill will be taken orally, daily starting on the first day of chemotherapy and continuing for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts)
3275423|NCT00659269|Experimental|Multivitamin + Vitamin B12 + Vitamin B6|"1 multivitamin pill will be taken orally, daily starting on the first day of chemotherapy and continuing for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts).~The patient will also take the following, starting on the first day of chemotherapy:~pyridoxine 50 mg three times per day, orally and continue for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts)~Vitamin B12 one mg injected intramuscularly, every 3 or 4 weeks, depending on the timing of the chemotherapy for 4 doses."
3275424|NCT00659243|Experimental|rhBSSL|
3275425|NCT00659243|Placebo Comparator|Placebo|
3275426|NCT00659230|Placebo Comparator|Placebo|Arm 1
3275427|NCT00659230|Active Comparator|Nepicastat|Arm 2
3275428|NCT00659217|Experimental|2|mesenchymal stem cell Autologous MSC transplantation
3275429|NCT00659204|Experimental|nano-silver gel|
3275430|NCT00659204|Active Comparator|alcohol-based gel|
3275431|NCT00659178|Experimental|SB-485232 plus pegylated liposomal doxorubicin|Subjects will receive one dose of pegylated liposomal doxorubicin on Day 1 plus two doses of SB-485232 on Day 3 and Day 9 in each cycle.
3275432|NCT00659165|Experimental|Insulin Detemir|Insulin Detemir
3275433|NCT00659165|Experimental|Insulin Glargine|Insulin Glargine
3275434|NCT00659152||1: ALI/ARDS|
3275435|NCT00659126|Experimental|Diagnostic (Gd, ferumoxytol, 3T or 7T MRI)|Patients receive gadolinium IV on day 1 and ferumoxytol non-stoichiometric magnetite IV on day 2. Patients undergo anatomical MRI sequences with 3T or 7T at baseline and on days 1-3. Patients also undergo DSC MRI and DCE MRI on days 1-2. Day 1 and day 2 imaging sessions may be separated by up to 7 days.
3275436|NCT00659100|Experimental|A|
3275437|NCT00659087|Experimental|Femoral Block|Those receiving femoral block in addition to usual pain management
3275438|NCT00659087|Active Comparator|Usual Care|Those receiving only usual pain management without a femoral block
3275439|NCT00659074|Experimental|A|Ondansetron ODT
3275440|NCT00659074|Active Comparator|B|Zofran ODT
3275441|NCT00659061|Active Comparator|Intervention|Multiple micronutrient fortificant (Sprinkles) and nutrition education given by LHWs.
3275442|NCT00659061|No Intervention|Control|Routine public health massages by Lady Health Workers (LHWs) during their community visits.
3275443|NCT00659048|Active Comparator|1|Ciclesonide 200µg
3275444|NCT00659048|Placebo Comparator|2|Placebo
3275445|NCT00659035||IT|Subjects receiving 1-10 mg/day of morphine or its equivalent doses of opioid medications through intrathecal route. Intrathecal medications are administered through a catheter in spinal cord
3275446|NCT00659035||Oral|Subjects receiving oral opioids (morphine, oxycodone, hydrocodone, methadone), but not also receiving anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK
3275447|NCT00659035||Oral + Anticonvulsant|Subjects receiving oral opioids (morphine, oxycodone, hydrocodone, methadone) and anticonvulsants (gabapentin, pregabalin, topiramate), but not also receiving muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK
3275448|NCT00659035||Control -Pain|Subject not receiving opioid medications, anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK.
3275449|NCT00659035||Control -No Pain|Age-matched volunteers (NO PAIN) not receiving opioid medications, anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK.
3275450|NCT00659022|Active Comparator|A|immediate surgery of the primary colorectal tumor, no neoadjuvant therapy
3275451|NCT00659022|Experimental|B|neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary
3275452|NCT00659022|Experimental|C|neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
3275453|NCT00659022|Experimental|D|neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
3275454|NCT00659009|Active Comparator|1|Barometric pressure equivalent to sea level (760 mm Hg).
3275455|NCT00659009|Experimental|2|Barometric pressure equivalent to 6000 feet (609 mm Hg)
3275456|NCT00659009|Experimental|3|Barometric pressure equivalent to 8000 feet (565 mm Hg).
3275457|NCT00658996|Experimental|SofLens DD Toric|Bausch & Lomb SofLens Daily Disposable Toric Contact Lens
3275458|NCT00658996|Active Comparator|Ciba Vision Toric Lens|Ciba Vision Focus Dailies Toric Contact Lens
3275459|NCT00658983|Experimental|1|Autologous Platelet Enriched Gel
3275460|NCT00658983|Active Comparator|2|Metalloproteinase Inhibitor (Promogran)
3275461|NCT00658957|Experimental|A|Daily standard wound care and topical application of the gentamicin-collagen sponge twice weekly
3275462|NCT00658957|Placebo Comparator|B|Daily standard wound care and topical application of the placebo sponge twice weekly
3275463|NCT00658944||A|Patients suffering from stress or mixed urinary incontinence
3275464|NCT00658931|Experimental|Treatment|
3275465|NCT00658918|Active Comparator|1|Ciclesonide 200µg
3275466|NCT00658918|Active Comparator|2|Ciclesonide 100µg
3275467|NCT00658918|Active Comparator|3|Ciclesonide 25µg
3275468|NCT00658918|Placebo Comparator|4|Placebo
3275469|NCT00658905|Active Comparator|rhBSSL|
3275470|NCT00658905|Placebo Comparator|Placebo|
3275471|NCT00658879||Pegvisomant|Patients taking Pegvisomant.
3275472|NCT00658853|Active Comparator|1|High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a 5% graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.
3275473|NCT00658853|Active Comparator|2|4 times 4 minutes interval training in hyperoxia - 100% oxygen
3275474|NCT00658853|Active Comparator|3|One leg at a time training 4 times 4 minutes interval training using cycling ergometer
3275475|NCT00658840|Experimental|1|"Primary objectives :~To evaluate the tumor response rate, local control rate and compliance (acute and late toxicity, esp. gastrointestinal tract toxicity) of concurrent chemo-radiotherapy with oral capecitabine in patients with unresectable locally advanced pancreatic carcinoma~Secondary objectives :~To evaluate the impact of concurrent chemo-radiotherapy with oral capecitabine in patients with unresectable locally advanced pancreatic carcinoma by analyzing the progression-free survival rate and overall survival rate."
3275476|NCT00658827||Group 1a: Remicade Cohort|Female patients who were exposed to Remicade at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
3275477|NCT00658827||Group 1b: Remicade Cohort|Infants born to Group 1a patients.
3275478|NCT00658827||Group 2a: Other Anti-TNF agents Cohort|Female patients who were exposed to anti-TNFs other than Remicade at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
3275479|NCT00658827||Group 2b: Other Anti-TNF agents Cohort|Infants born to Group 2a patients.
3275480|NCT00658827||Group 3a: Non-biologic Systemic Therapy Control Cohort|Female patients who were exposed to systemic therapy other than biologic agents at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
3275481|NCT00658827||Group 3b: Non-biologic Systemic Therapy Control Cohort|Infants born to Group 3a patients.
3275482|NCT00658827||Group 4a: Population Control Cohort|Female patients with no record of the diseases of interest and no exposure to biologic or non-biologic systemic therapy at any time during pregnancy (and up to 3 months prior to LMP, if the information is available).
3275483|NCT00658827||Group 4b: Population Control Cohort|Infants born to Group 4a patients.
3275484|NCT00658814|Experimental|Treatment (azacitidine, gemtuzumab)|See Detailed Description
3275485|NCT00658788|Active Comparator|Study Treatment|"clobetasol propionate spray 0.05%~Other Names:~Clobex® Spray 0.05% clobetasol propionate spray, 0.05%, applied topically twice daily~calcitriol ointment~Other Names:~Calcitriol Ointment calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily"
3275486|NCT00658775|Experimental|1|
3275487|NCT00658775|Active Comparator|2|
3275488|NCT00658762|Experimental|PD 0332334 225 mg BID|
3275489|NCT00658762|Experimental|PD 0332334 300 mg BID|
3275490|NCT00658762|Active Comparator|Paroxetine 20 mg q am|
3275491|NCT00658762|Placebo Comparator|Placebo BID|
3275492|NCT00658749|Experimental|1|AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor) solution (diluent: physiologic saline solution)
3275493|NCT00658749|Placebo Comparator|2|Physiologic saline solution
3275494|NCT00658736|Experimental|1|EUS guided celiac block with bupivicaine and triamcinolone. Patient will undergo endoscopic ultrasound and celiac plexus blockade using an EUS needle inserted into the celiac plexus. 20 cc of injectate will be administered.
3275495|NCT00658736|Placebo Comparator|2|EUS guided celiac block with bupivicaine only. Patient will undergo endoscopic ultrasound and celiac plexus blockade using an EUS needle inserted into the celiac plexus. 20 cc of injectate will be administered.
3275496|NCT00658723|Experimental|1|
3275497|NCT00658723|Active Comparator|2|SURGICEL™ Absorbable Hemostat
3275498|NCT00658710|Active Comparator|1|patients who continue physical therapy sessions during two months.
3275499|NCT00658710|No Intervention|2|patients who stop physical therapy sessions during two months
3275500|NCT00658697|Experimental|Docetaxel, Bevacizumab, and ADT|"Docetaxel:~Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles~Bevacizumab:~Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles~ADT or Luteinizing hormone-releasing hormone agonist (LHRH):~Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)~Bicalutamide:~Oral Bicalutamide on day 84 once daily (after completing docetaxel, at 3 month) at dose of 50 mg for a total 15 months (4-18 months)"
3275501|NCT00658684|Experimental|Fesoterodine fumarate|
3275502|NCT00658671|Experimental|1|Dose-escalation
3275503|NCT00658671|Experimental|2|Advanced cancer, excluding patients with colorectal or ovarian cancers
3275504|NCT00658671|Experimental|3|Recurrent or resistant epithelial ovarian cancer
3275505|NCT00658671|Experimental|4|Colorectal cancer patients who have progressed and/or failed on irinotecan- and oxaliplatin-based regimens
3275506|NCT00658658|Experimental|Panitumumab|Participants received panitumumab at planned doses ranging from 2.5 mg/kg weekly (QW) to 9.0 mg/kg every 3 weeks (Q3W) until the patient experienced disease progression, was unable to tolerate study drug, withdrew consent, or other reasons that warranted removal from the study.
3275507|NCT00658645|Experimental|Bifeprunox|
3275508|NCT00658645|Placebo Comparator|Placebo|
3275509|NCT00658645|Active Comparator|Quetiapine|
3275510|NCT00658632|Experimental|1|
3275511|NCT00658632|Active Comparator|2|
3275512|NCT00658619|Other|400 µg Brimonidine Tartrate Implant Stage 1|Stage 1: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
3275513|NCT00658619|Other|200 µg Brimonidine Tartrate Implant Stage 1|Stage 1: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
3275514|NCT00658619|Other|400 µg Brimonidine Tartrate Implant Stage 2|Stage 2: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
3275515|NCT00658619|Other|200 µg Brimonidine Tartrate Implant Stage 2|Stage 2: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
3275516|NCT00658619|Sham Comparator|Sham (no implant) Stage 2|Stage 2: sham in both eyes on Day 1 and Month 6.
3275517|NCT00658606|Active Comparator|Alefacept alone|15 mg alefacept intramuscularly (IM) once weekly for 12 weeks
3275518|NCT00658606|Experimental|Alefacept + nbUVB|15 mg alefacept intramuscularly once weekly and narrow band Ultraviolet B (nbUVB) phototherapy 3 times per week for 12 weeks
3275519|NCT00658580|Active Comparator|A|Every 3 weeks intravenous cisplatin plus etoposide
3275520|NCT00658580|Experimental|B|Every 3 weeks intravenous epirubicin plus ifosfamide plus etoposide
3275521|NCT00658567|Experimental|2|pimavanserin tartrate (ACP-103) 20 mg, tablet, once daily by mouth, 6 weeks
3275522|NCT00658567|Placebo Comparator|Placebo|Placebo tablet, once daily by mouth, 6 weeks
3275523|NCT00658567|Experimental|1|pimavanserin tartrate (ACP-103) 10 mg, tablet, once daily by mouth, 6 weeks
3275524|NCT00658541|Experimental|Zolpidem Tartrate 10 mg Tablets|A single dose of zolpidem tartrate 10 mg administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
3275525|NCT00658541|Active Comparator|Zolpidem Tartrate (Ambien®) 10 mg Tablets|A single dose of Ambien® 10 mg administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
3275526|NCT00658528|Experimental|1|
3275527|NCT00658528|Active Comparator|2|
3275528|NCT00658515|Experimental|Dalcetrapib (RO4607381)|
3275529|NCT00658515|Placebo Comparator|Placebo|
3275530|NCT00658502||1|
3275531|NCT00658502||2|
3275532|NCT00658489|Active Comparator|1|Residents randomized to the promotion of oral health group will receive training consisting of 7 modules (3 on the Bright Futures curriculum and 4 on oral health promotion). They will then enroll 3 patient-child dyads from their practice who present for a well child care visit. Outcomes will be obtained by completing pre- and post-study surveys. Residents will be observed by a faculty preceptor during 3 different patient encounters, and will receive feedback at the end of the 6 month study period.
3275533|NCT00658489|Active Comparator|2|Residents randomized to the prevention of iron deficiency group will complete one web-based module.
3275534|NCT00658476|Experimental|Omega-3 Fatty Acids|Adolescents receive cognitive behavior therapy in combination with Omega-3 fatty acid supplements.
3275535|NCT00658476|Placebo Comparator|Placebo|Adolescents receive cognitive behavior therapy in combination with placebo.
3275536|NCT00658463|Experimental|1|The study is designed with a one-month steady state period with placebo then on a cross-over design with two 6-week periods of placebo or rosuvastatin (20 mg). An in vivo kinetic study will be performed at the end of each 6-week period.
3275537|NCT00658463|Placebo Comparator|2|The study is designed with a one-month steady state period with placebo then on a cross-over design with two 6-week periods of placebo or rosuvastatin (20 mg). An in vivo kinetic study will be performed at the end of each 6-week period.
3275538|NCT00658450|Experimental|Cognitive rehabilitation training|Children in this arm will the receive the intervention comprising of 16 cognitive rehabilitation training (CRT) exercises for 8 weeks. These exercises will train different cognitive skills including attention, visual spatial processing, logical skills and memory.
3275539|NCT00658450|No Intervention|Treatment as usual|Children in this group will not receive any intervention, they will undergo the usual post discharge treatment for brain injured children at Mulago Hospital (the study site). This is the treatment as usual (TAU) group.
3275540|NCT00658411|Experimental|All patients|Deferoxamine for >=2 weeks prior to stem cells
3275541|NCT00658398|Experimental|ICP to prevent alcohol misuse.|Interactive Computer Program (ICP) to prevent alcohol misuse.
3275542|NCT00658398|Sham Comparator|ICP to enhance balanced diet|2. Interactive Computer Program to enhance balanced diet (sham intervention)
3275543|NCT00658385|Experimental|1|GCSF (human recombinant granulocyte colony stimulating factor)Neupogen(Amgen), Filgrastim, Central venous line placement, Stem cell Collection (leukapheresis)
3275544|NCT00658372|Experimental|PD 0332334 225 mg BID|
3275545|NCT00658372|Experimental|PD 0332334 300 mg BID|
3275546|NCT00658372|Active Comparator|Paroxetine 20 mg QD|
3275547|NCT00658372|Placebo Comparator|Placebo BID|
3275548|NCT00658359|Active Comparator|Treatment Arm 1|Treatment Arm 1 will also receive standard of care medications
3275549|NCT00658359|Experimental|Treatment Arm 2|Treatment Arm 2 will also receive standard of care medications
3275550|NCT00658359|Experimental|Treatment Arm 3|Treatment Arm 3 will also receive standard of care medications
3275551|NCT00658346||1|HIV-1 group O infected patients
3275552|NCT00658346||2|HIV-1 group M infected patients
3275553|NCT00658333|Experimental|Enteric-coated Mycophenolate Acid|Equimolar dose of enteric-coated mycophenolate acid with mycophenolate mofetil placebo. 1000 mg mycophenolate mofetil = 720 mg enteric-coated mycophenolate acid (MPA equivalent dose). The active and placebo study medications were dispensed in separate bottles identified as Bottle A and Bottle B.
3275554|NCT00658333|Active Comparator|Mycophenolate Mofetil|Mycophenolate mofetil therapy with placebo enteric-coated mycophenolate acid. The active and placebo study medications were dispensed in separate bottles identified as Bottle A and Bottle B.
3275555|NCT00658320|Experimental|Everolimus + Reduced dose of cyclosporine|An initial everolimus dose of 0.75 mg orally twice daily (1.5 mg/day) was administered 24-36 hours from reperfusion after transplantation and dose adjustments based on everolimus trough level (target trough level 3-8 ng/mL). Reduced dose of cyclosporine was initiated either pre-transplantation or within 24 hours after transplantation following the local regimen. Patients were treated with antibody induction therapy using 20 mg basiliximab two hours prior to transplant and 20 mg basiliximab 4 days post transplant or according to local practice. Corticosteroids were administered according to local practice. Patients were treated for 12 months in the core study and 12 months in the extension study. Everolimus was available after 24 months for compassionate use.
3275556|NCT00658320|Active Comparator|Mycophenolate mofetil (MMF) + Standard dose of cyclosporine|Patients were treated with 1 gram twice a day (2 grams/day) of Mycophenolate mofetil (MMF) and standard dose of cyclosporine for 12 months post renal transplant. Patients were treated with antibody induction therapy using 20 mg basiliximab two hours prior to transplant and 20 mg basiliximab 4 days post transplant or according to local practice. Corticosteroids were administered according to local practice. Patients were treated for 12 months in the core study and 12 months in the extension study.
3275557|NCT00658307|Experimental|1|
3275558|NCT00658307|Experimental|2|
3275559|NCT00658307|Sham Comparator|3|
3275560|NCT00658281||OBI KV System + CBCT Scanning|Breast cancer patient radiation treatment set up using OBI KV system and CBCT scanning or CT-on-rail system to verify standard EPID for positioning.
3275561|NCT00658268|Experimental|1|
3275562|NCT00658268|Placebo Comparator|2|
3275563|NCT00658255|Experimental|1|
3275564|NCT00658255|Active Comparator|2|
3275565|NCT00658242||I|Subjects having Craniofacial surgery
3275566|NCT00658229|Experimental|Strength training group|A four months strength training program during androgen deprivation therapy for prostate cancer patietns.
3275567|NCT00658229|No Intervention|Control group|Patients in the control group are not discouraged from performing normal activities. They are however asked not to start a strength training program or increase their activity level in the same period as the experimental group is performing their strength training program. We will offer the control group a modified strength training program after the post-intervention assessment.
3275568|NCT00658216||Longitudinal|Prospective study : cohort of consecutive patients recruited over 2 years
3275569|NCT00658203|Active Comparator|1|PEA optimized CRT
3275570|NCT00658203|Other|2|Standard optimized CRT
3275571|NCT00658190||1|Women obtaining routine Pap tests for cervical cancer screening
3275572|NCT00658177|Experimental|Arm 1|
3275573|NCT00658177|Placebo Comparator|Arm 2|
3275574|NCT00658164|Experimental|1|
3275575|NCT00658138|Experimental|Adhesive A|
3275576|NCT00658138|Active Comparator|Adhesive B|
3275577|NCT00658112|Experimental|Benzoyl Peroxide 5%|Subjects will be given standard instructions in the use of topical benzoyl peroxide gel and will be provided with a supply of medication fitted with a Medication Event Monitoring System (MEMS) cap. This cap records dates and times the assembly is opened which can be downloaded at the final visit and tabulated with associated software. When the tubes are weighed, data from the MEMS Caps will be collected. Study coordinators will record adherence, while assessors are blinded to adherence rates. All subjects will be assigned to treatment with topical benzoyl peroxide to the entire face.
3275578|NCT00658099||A|
3275579|NCT00658099||B|
3275580|NCT00658086|Active Comparator|1|ALN-RSV01
3275581|NCT00658086|Placebo Comparator|2|Normal saline
3275582|NCT00658073|Active Comparator|A|Patients in Group A will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive standard regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF.
3275635|NCT00657774|Placebo Comparator|4|Placebo inhaler and/or placebo tablets
3275636|NCT00657761|Placebo Comparator|Placebo|Saline solution 0.9% sc/12h for 7 days
3275637|NCT00657761|Experimental|Enfuvirtide|Enfuvirtide 90 mg/12h sc for 7 days
3275638|NCT00657748|Experimental|1|
3275583|NCT00658073|Active Comparator|B|Patients in Group B will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive 80% less of calcineurin inhibitor than in Group A. Other immunosuppressive agents such as glucocorticoid and MMF remained the same doses as in Group A.
3275584|NCT00658073|Active Comparator|C|Patients in Group C will receive anti-interleukin 2 receptor antibody (Basiliximab)for induction therapy. Patients will receive the same doses of regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF as in Group A.
3275585|NCT00658060||1|"1.Fulfilling the Tel Hashomer criteria for the diagnosis of FMF [5].~2.Suffering from episodes of exertional leg pain and or exertional ankle edema~3.18-45 years old~4.On a stable (≥ 2 weeks) dose of oral colchicine therapy~5.Non-smokers"
3275586|NCT00658060||2|"Control group~1.Healthy subjects~2.18-45 years old~3.Non-smokers"
3275587|NCT00658047|Experimental|0.25 mg CH-1504|0.25 mg CH-1504
3275588|NCT00658047|Experimental|0.5 mg CH-1504|0.5 mg CH-1504
3275589|NCT00658047|Experimental|1.0 mg CH-1504|1.0 mg CH-1504
3275590|NCT00658047|Active Comparator|Methotrexate|Methotrexate (MTX) 10 mg/week for 2 weeks, 15 mg/week for 2 weeks, 20 mg/week for 8 weeks
3275591|NCT00658034|Active Comparator|1|Acupuncture
3275592|NCT00658034|Sham Comparator|2|Placebo Acupuncture
3275593|NCT00658021|Placebo Comparator|Placebo|Subcutaneous injection, twice a day
3275594|NCT00658021|Experimental|Exenatide 5 µg|Subcutaneous injection, twice a day
3275595|NCT00658021|Experimental|Exenatide 10 µg|Subcutaneous injection, twice a day
3275596|NCT00658008|Experimental|PD 0332334 175 mg BID|
3275597|NCT00658008|Experimental|PD 0332334 225 mg BID|
3275598|NCT00658008|Experimental|PD 0332334 75 mg BID|
3275599|NCT00658008|Active Comparator|Paroxetine 20 mg QD|
3275600|NCT00658008|Placebo Comparator|Placebo BID|
3275601|NCT00657995|Experimental|2|Thirty patients who underwent pancreatic resection for pancreatic neoplasm were prospectively randomized. Perioperative blood glucose levels were continuously monitored using an artificial endocrine pancreas (STG-22). Glucose levels were controlled using either the sliding scale method or the artificial pancreas.
3275602|NCT00657982|Experimental|1|RAD001 10 BID 6 weeks before definite treatment for localized prostate cancer
3275603|NCT00657969||1|CAD-group (Cervical Artery Dissection - group): consecutive patients with cervical artery dissection, with or without associated cerebral ischemia, hospitalized in one of the participating neurological centers; standardized inclusion and exclusion criteria apply
3275604|NCT00657969||2|IS-group (Ischemic Stroke - Group): patients selected among consecutive patients hospitalized for an ischemic stroke without CAD, in the same centers as patients from group1, frequency-matched on age and gender with group1; standardized inclusion and exclusion criteria apply
3275605|NCT00657969||3|HC-group (Healthy Control - Group): DNA of healthy individuals from existing DNA-databases will be used as controls for the Belgian, French, German and Swiss centers; the other centers are recruiting their own age- and sex-matched healthy controls; individuals from the 3 groups (CAD, IS and HC) are strictly matched on geographical origin in order to avoid stratification bias
3275606|NCT00657943|Experimental|1M|Metformin + Levemir x1
3275607|NCT00657943|Placebo Comparator|1P|Placebo + Levemir x1
3275608|NCT00657943|Experimental|2M|metformin + NovoMix
3275609|NCT00657943|Placebo Comparator|2P|Placebo + NovoMix
3275610|NCT00657943|Experimental|3M|Metformin + 4x therapy
3275611|NCT00657943|Placebo Comparator|3P|Placebo + 4x therapy
3275612|NCT00657930||A|
3275613|NCT00657904|Experimental|1|
3275614|NCT00657904|Placebo Comparator|2|
3275615|NCT00657891|Placebo Comparator|1|Placebo Injection
3275616|NCT00657891|Experimental|2|Xolair at 0.016 mg/kg/IgE(iu/ml)/4 wks
3275617|NCT00657878|Experimental|non platinum based chemotherapy|a non platinum based therapy (corresponding to stealth liposomal doxorubicin, or topotecan, or gemcitabine,or any other drug approved in clinical practice for the treatment of patients with ovarian cancer after previous platinum-based chemotherapy) followed by a platinum based chemotherapy at disease progression
3275618|NCT00657878|Active Comparator|platinum based chemotherapy|platinum based chemotherapy (corresponding to the combination of carboplatin + paclitaxel, or carboplatin + gemcitabine for patients with significant but lower than grade 3 neuropathy at baseline) followed by a non platinum based chemotherapy at disease progression
3275619|NCT00657865|Active Comparator|1|Ramipril
3275620|NCT00657865|Placebo Comparator|2|Placebo
3275621|NCT00657852|Experimental|Pamidronate|Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
3275622|NCT00657852|Placebo Comparator|Placebo|500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
3275623|NCT00657839|Experimental|Arm 1|
3275624|NCT00657839|Placebo Comparator|Arm 2|
3275625|NCT00657826|Experimental|19mm arotic valve implant|Single arm study for patients who require a smaller valve size of the ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm.
3275626|NCT00657813|Experimental|Access [123I]MNI-330 and SPECT Imaging|
3275627|NCT00657800|Experimental|Group 1|Behavioral - Intensified coordinated inpatient diabetes education program (IDEP)
3275628|NCT00657800|No Intervention|Group 2|Diabetes education as is typically provided by clinical staff
3275629|NCT00657787||PTSD|Combat-exposed men and women with PTSD deployed to OIF/OEF.
3275630|NCT00657787||High Utilizers|A comparison group of combat veterans who are high utilizers of VA medical care, but who have not received a diagnosis of PTSD
3275631|NCT00657787||Not OIF/OEF|A second comparison group will consist of veterans with similar service record and demographic backgrounds, who were not deployed to the OIF/OEF war zones
3275632|NCT00657774|Experimental|1|FlutiForm 250/10 ug
3275633|NCT00657774|Experimental|2|FlutiForm 100/10 ug
3275634|NCT00657774|Active Comparator|3|Oral Prednisone 10 mg
3275639|NCT00657735|Experimental|1|Deep TMS treatment
3275640|NCT00657735|Sham Comparator|2|inactive stimulation
3275641|NCT00657722|Experimental|1|Angiography and Computed Tomography
3275642|NCT00657709|Experimental|rMenB Lot1|Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
3275643|NCT00657709|Experimental|rMenB Lot2|Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
3275644|NCT00657709|Experimental|rMenB Lot3|Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
3275645|NCT00657709|Active Comparator|Routine|Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.
3275646|NCT00657709|Active Comparator|MenC + Routine|Subjects received the routinely administered infant vaccines and Men C vaccine at 2, 4 and 6 months of age.
3275647|NCT00657696||Group 1|Physicians and staff in VA non-contract primary care outpatient clinics and patients seen in last 12 months in the same clinics
3275648|NCT00657696||Group 2|Patients seen in last 12 months in Group 1 clinics
3275649|NCT00657683|Experimental|1|
3275650|NCT00657683|Placebo Comparator|2|
3275651|NCT00657670|Experimental|1|Ready-made spectacles
3275652|NCT00657670|Active Comparator|2|Spectacles
3275653|NCT00657657|Experimental|Group 1|Neonates from mother HBsAg (+) and HBeAg (+) had received HBV vaccine at Month 0, 1, 2, 12, 60 (5 doses)
3275654|NCT00657657|Experimental|Group 2|Neonates from mother HBsAg (+) and HBeAg (+) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
3275655|NCT00657657|Experimental|Group 4|Neonates from mother HBsAg (+) and HBeAg (-) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
3275656|NCT00657657|Experimental|Group 6|Neonates from mother HBsAg (-) and HBeAg (-) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
3275657|NCT00657644|Experimental|Arm 1|
3275658|NCT00657631|Experimental|A|Acceptance and Commitment Therapy will be administered to all subjects.
3275659|NCT00657618|Experimental|Treatment only|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with Sodium Stibogluconate (SSG).
3275660|NCT00657605|Experimental|1|Three adult patients with congenital leptin deficiency.
3275661|NCT00657579|Experimental|1|
3275662|NCT00657579|Experimental|2|
3275663|NCT00657579|Experimental|3|
3275664|NCT00657579|Placebo Comparator|4|
3275665|NCT00657566|Active Comparator|1|antibiotics received for up to two days following normalization of white blood cell count, temperature, and gastrointestinal function
3275666|NCT00657566|Experimental|2|4 +/- 1 days of antibiotics
3275667|NCT00657553|Active Comparator|Bortezomib/Treatment Arm|Bortezomib Maintenance Year 1 - bortezomib days 1, 4, 8, 11 every 28 days Year 2 - bortezomib days 1, 4, 8, 11 every 2 months Year 3 - bortezomib days 1, 4, 8, 11 every 3 months
3275668|NCT00657553|No Intervention|Observation Arm (watchful waiting)|monitor myeloma parameters every 3-6 months
3275669|NCT00657540|Experimental|Analatro|Antivenin Latrodectus (Black Widow) Equine Immune F(ab)2
3275670|NCT00657540|Placebo Comparator|Normal Saline Placebo|Normal Saline
3275671|NCT00657527|Experimental|1|Rosuvastatin
3275672|NCT00657527|No Intervention|2|Diet
3275673|NCT00657514|Active Comparator|A|Drug arm - 500mg tablet po bid up to 1000mg (2 500mg tablets) po bid
3275674|NCT00657514|Placebo Comparator|P|Placebo arm - 1 tablet po bid up to 2 tablets po bid if tolerated
3275675|NCT00657501|Experimental|testosterone gel|1% testosterone transdermal gel
3275676|NCT00657501|Placebo Comparator|Placebo gel|placebo transdermal gel
3275677|NCT00657488|Experimental|A|Thalidomide 100mg/day. Dexamethasone is administered at a dose of 40 mg/d, on 4 consecutive days (D1 - D4), with one course every four week in case of stable disease after 12 weeks of treatment or in case of Disease Progression
3275678|NCT00657488|Active Comparator|B|Thalidomide 400mg/day. Dexamethasone is administered at a dose of 40 mg/d, on 4 consecutive days (D1 - D4), with one course every four week in case of stable disease after 12 weeks of treatment or in case of Disease Progression
3275679|NCT00657475|Experimental|2|Cardiac surgery with Mini Extra Corporeal Circulation (MECC). Heparin low dose (150 UI/Kg).
3275680|NCT00657475|Active Comparator|1|Cardiac surgery with Mini Extra Corporeal Circulation (MECC). Heparin Full Dose (300 UI/Kg)
3275681|NCT00657462|Experimental|A|Receives the intervention (reminders displayed at the startup of the application) for both periods (period 1 and period 2) of the study.
3275682|NCT00657462|Active Comparator|B|Receives the intervention (reminders displayed at the application startup) only during the second period (period 2) of the study.
3275683|NCT00657449|Active Comparator|Arm 1|
3275684|NCT00657449|Active Comparator|Arm 2|
3275685|NCT00657423|Experimental|1|
3275686|NCT00657423|Active Comparator|2|
3275687|NCT00657410|Experimental|ARM A - PDN|PDN is administered orally at the daily dose of 1 mg/Kg for 4 consecutive weeks (from day 0 to day 28), then, therapy is tapered within 14 days. The patients considered NOT RESPONDER at day 42 or WHO HAVE LOST THE RESPONSE within the evaluation of final response (see paragraph 8.1), will be crossed to ARM B.
3275688|NCT00657410|Experimental|ARM B - DXM|"DXM is administered orally at single fixed daily doses of 40 mg for 4 consecutive days, every 14 days, for 3 consecutive courses. If platelet count is £ 20x109/L or bleeding symptoms related to thrombocytopenia are present, lowdose DXM (0.035 mg/Kg/day) between courses is given. The patients (either from ARM A+B or from ARM B) considered NOT RESPONDER at day 46 or who HAVE LOST THE RESPONSE within the evaluation of final response (see paragraph 8.1), will be considered OFF TREATMENT.~For these patients a second line therapy will be considered, according to the medical practice of the Centre (splenectomy or other)."
3275689|NCT00657397|Experimental|A|Methadone inducted by a primary care physician
3275690|NCT00657397|Active Comparator|B|Methadone inducted (in CSAPA)
3275691|NCT00657384|Experimental|acid tranexamic|acid tranexamic
3275692|NCT00657384|Placebo Comparator|2|Nacl 0.9%
3275693|NCT00657371|Experimental|Third Eye Retroscope|Colonoscopy exam using the Third Eye Retroscope device
3275694|NCT00657358|Experimental|Lidocaine|Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
3275695|NCT00657345||1|This is a tissue acquisition and collection protocol that will analyze potential cellular changes that occur after treatment with trastuzumab.
3275696|NCT00657319||A|
3275697|NCT00657306|Experimental|1|Hydrocortisone, 50 mg/6 h per day
3275698|NCT00657306|Placebo Comparator|2|dextrose solution 5%
3275699|NCT00657293|Sham Comparator|C|In an attempt to make the groups comparable in terms of attention, the control group will receive a sham.
3275700|NCT00657293|Active Comparator|ATP|Patients will undergo a specific arm training program (ATP).
3275701|NCT00657280|Experimental|All subjects recieve Sitagliptin|All subjects are aware of what they are taking. Nobody is blinded in this study. study
3275702|NCT00657267|Experimental|Single-Arm Study|
3275703|NCT00657254|Experimental|Arm 1|
3275704|NCT00657241|Active Comparator|A|Valsartan 160 mg (one week); valsartan 320 mg (3 weeks)
3275705|NCT00657241|Active Comparator|B|Coreg CR 20 mg (one week) and Coreg CR 40 mg (3 weeks).
3275706|NCT00657228|Placebo Comparator|2|Standard treatment (epinephrine, corticosteroids, diphenhydramine, and H2 blockers) plus an equal volume bolus of normal saline after the first doses are administered.
3275707|NCT00657228|Experimental|1|Standard therapy plus a one-time bolus of heparin at 80 U/kg (maximum dose of 10,000 Units) given immediately after the first doses of standard treatment.
3275708|NCT00657202|Experimental|Ranibizumab|
3275709|NCT00657189|Experimental|1|MEDI-545
3275710|NCT00657189|Experimental|2|MEDI-545
3275711|NCT00657189|Experimental|3|MEDI-545
3275712|NCT00657189|Experimental|4|MEDI-545
3275713|NCT00657189|Placebo Comparator|5|Placebo
3275714|NCT00657163|Experimental|1|fluoxetine
3275715|NCT00657163|Placebo Comparator|2|Placebo
3275716|NCT00657150|Experimental|Dabigatran etexilate|220 mg once daily
3275717|NCT00657150|Active Comparator|Enoxaparin|40 mg once daily
3275718|NCT00657137|Experimental|A|apricoxib + lapatinib + capecitabine
3275719|NCT00657137|Placebo Comparator|B|placebo + lapatinib + capecitabine
3275720|NCT00657124|Experimental|1|receive a preoperative supplementation with carbohydrate and branched-chain amino acids-enriched nutrient
3275721|NCT00657124|Placebo Comparator|2|receive a preoperative supplementation without carbohydrate and branched-chain amino acids-enriched nutrient
3275722|NCT00657111|Experimental|A1|Subjects 01-08; 5 mg CS-8958
3275723|NCT00657111|Placebo Comparator|A2|Subjects 01-08; placebo
3275724|NCT00657111|Experimental|B1|Subjects 09-16; 10 mg CS-8958
3275725|NCT00657111|Placebo Comparator|B2|Subjects 09-16; placebo
3275726|NCT00657111|Experimental|C1|Subjects 17-24; 20 mg CS-8958
3275727|NCT00657111|Placebo Comparator|C2|Subjects 17-24; placebo
3275728|NCT00657111|Experimental|D1|Subjects 25-32; 40mg CS-8958
3275729|NCT00657111|Placebo Comparator|D2|Subjects 25-32; placebo
3275730|NCT00657098||Observation|
3275731|NCT00657059|Active Comparator|Pred group|Pred Group: Prednisone treatment Patients will give methylprednisolone intravenously at a dose of 0.5 g/day for 3 days at the start of months 1, 3, and 5; then take oral prednisone (0.5 mg/kg/d) on alternate days. Prednison will be tapered 5 mg per month from the seventh month to the 12th month.
3275732|NCT00657059|Active Comparator|MMF Group|MMF Group: MMF treatment Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt ＜ 50kg) for the first 6-month of drug treatment phase, then 0.5 bid for the remaining 6-month.
3275733|NCT00657059|Active Comparator|Pred plus MMF Group|"Pred plus MMF Group: Prednisone plus MMF treatment. Patients will give methylprednisolone intravenously at a dose of 0.5 g/day for 3 days at the start of months 1, 3, and 5; then take oral prednisone (0.5 mg/kg/d) on alternate days. Prednison will be tapered 5 mg per month from the seventh month to the 12th month.~Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt ＜ 50kg) for the first 6-month of drug treatment phase, then 0.5 bid for the remaining 6-month."
3275734|NCT00657046|Active Comparator|1|Droxidopa at 400 mg (2 capsules each containing 200 mg droxidopa plus one capsule with Placebo)
3275735|NCT00657046|Active Comparator|2|Droxidopa at 600 mg (3 capsules each containing 200 mg droxidopa)
3275736|NCT00657046|Placebo Comparator|3|Placebo (3 capsules with mannitol substituted for droxidopa)
3275737|NCT00657033|Experimental|Arm 1|
3275738|NCT00657033|Experimental|Arm 2|
3275739|NCT00657020|Experimental|Nicotine lozenge|Nicotine lozenge containing 4 mg of nicotine to be placed in mouth and suck to dissolution.
3275740|NCT00657020|Placebo Comparator|Placebo lozenge|Placebo lozenge to be placed in mouth and suck to dissolution.
3275741|NCT00657007|Placebo Comparator|Placebo|IV infusion over 2 hours
3275742|NCT00657007|Experimental|Belimumab 1 mg/kg|1 mg/kg IV infused over 2 hours
3275743|NCT00657007|Experimental|Belimumab 4 mg/kg|4 mg/kg IV infused over 2 hours
3275744|NCT00657007|Experimental|Beimumab 10 mg/kg|10 mg/kg IV infused over 2 hours
3275745|NCT00657007|Experimental|Belimumab 20 mg/kg|20 mg/kg IV infused over 2 hours
3275746|NCT00656994|Experimental|Ramelteon 16 mg QD|
3275747|NCT00656994|Placebo Comparator|Placebo|
3275748|NCT00656981|Experimental|Arm 1|
3275749|NCT00656981|Placebo Comparator|Arm 2|
3275750|NCT00656968|Active Comparator|10-day concomitant therapy|esomeprazole and amoxicillin and clarithromycin and metronidazole for 10 days
3275751|NCT00656968|Experimental|10-day sequential therapy|esomeprazole and amoxicillin for 5 days, followed by esoprazole and clarithromycin and metronidazole for 5 more days
3275752|NCT00656955||Renal cancer patients|Renal cancer patients
3275753|NCT00656942||Healthy|"subjects with no pain and no opioid treatment for at least six months~subjects receive quantitative sensory testing (QST)"
3275754|NCT00656942||Pain, no opioid|"subjects have chronic pain but have not taken any opioid medication for at least 3 months~subjects receive QST"
3275755|NCT00656942||Pain, opioid|"subjects have chronic pain and have been taking opioid medication for at least 3 months~subjects receive QST"
3275756|NCT00656929|Active Comparator|1|Vitamin D3 50 mcg (2000 IU) daily
3275757|NCT00656929|Placebo Comparator|2|Placebo tablets
3275758|NCT00656916|Experimental|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
3275759|NCT00656916|No Intervention|Observational Group|Comparator group, no intervention.
3275760|NCT00656890|Placebo Comparator|2|sterile saline for injection
3275761|NCT00656890|Experimental|1|MDX-1100 for injection
3275762|NCT00656864|Active Comparator|1|Pioglitazone arm
3275763|NCT00656864|Placebo Comparator|2|Placebo arm
3275764|NCT00656851|Active Comparator|Pioglitazone|Pioglitazone (Actos, 30mg/day for 16 weeks)
3275765|NCT00656851|Active Comparator|Exercise Training|Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks
3275766|NCT00656838|Active Comparator|1|Patient has had PCP contact (letter, phone call, office visit, educational materials).
3275767|NCT00656838|No Intervention|2|Usual Care
3275768|NCT00656825|Active Comparator|Panel I|The first 12 subjects will be selected and ranodmized in order to receive the first treatment dose of 100 μg/mL or placebo in a 8:4 ratio
3275769|NCT00656825|Active Comparator|Panel II|The second 12 subjects will be selected and randomized in order to receive the second treatment dose of 200 μg/mL or placebo in a 8:4 ratio
3275770|NCT00656825|Active Comparator|Panel III|The third 12 subjects will be selected and randomized in order to receive the third treatment dose of 300 μg/mL or placebo in a 8:4 ratio
3275771|NCT00656825|Placebo Comparator|Placebo|Patients from each panel will be given placebo in a 4:8 ratio.
3275772|NCT00656812|Experimental|Treatment Arm|Combination therapy Rituximab plus 2CdA
3275773|NCT00656799|Experimental|Sugammadex|IV single bolus dose of 4.0 mg/kg sugammadex
3275774|NCT00656786|Experimental|Group 1|Subjects will be treated if, after starting treatment with an EGFRi, acute signs and symptoms of rash on the face/neck and/or upper chest emerge, that are suspected of being related to the EGFRi treatment.
3275775|NCT00656786|Experimental|Group 2|Subjects will receive pre-emergent rash treatment starting 1 day prior to beginning EGFRi therapy
3275776|NCT00656773|Experimental|1|
3275777|NCT00656773|Active Comparator|2|
3275778|NCT00656760|Experimental|A|All patients have PET/CT and biopsies with the surgeon blinded to the result of PET/CT. Additional biopsies are performed (or not) after the surgeon has the PET/CT results revealed.
3275779|NCT00656747|Active Comparator|Arm 2|
3275780|NCT00656747|Experimental|Arm 1|
3275781|NCT00656734|Experimental|MDX 1411|Dose Escalation Cohorts
3275782|NCT00656721|Experimental|Flutter Valve|This a crossover study, so all subjects performed both, control and experimental interventions. In Flutter Valve intervention the subjects remained comfortably seated, breathing through the device for 15 minutes, starting off from the total pulmonary capacity, and being free to cough. Thereafter, a 5-min session of cough ensued. In the control intervention the subjects followed the same sequence of the Flutter Valve intervention, but the metallic sphere and the cover of the device were removed. Since the patients were not acquainted with the valve, they did not know its proper assembly. As in the Flutter Valve intervention, during 15 minutes the patients could expectorate spontaneously and return to the device. A 5-min coughing session took place.
3275783|NCT00656708|Experimental|PB|All patients admitted to the burn unit during the prospective portion (interventional portion) of the study who have open wounds will have Kerlix AMD applied to their wounds; only those patients consenting to the study will have data abstracted.
3275784|NCT00656695|Experimental|1|taking Iminoral
3275785|NCT00656695|Active Comparator|2|taking Neoral
3275786|NCT00656682|Active Comparator|Dietitian Counseling Alone|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian. Registered Dietitian Counseling Alone
3275787|NCT00656682|Experimental|Dietitian Plus Community Group Lifestyle|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based diabetes prevention lifestyle intervention offered by the community. Dietitian Counseling Plus Community Group Lifestyle Intervention.
3275788|NCT00656669|Experimental|1|The study will be conducted in 3 sequential treatment segments.
3275789|NCT00656656|Other|Immunoadsorption/Dexamethasone/Rituximab|
3275790|NCT00656643|Experimental|1|
3275791|NCT00656643|Experimental|2|
3275792|NCT00656643|Experimental|3|
3275793|NCT00656643|Placebo Comparator|4|
3275794|NCT00656630|Active Comparator|1|Acamprosate
3275795|NCT00656630|Active Comparator|2|Naltrexone
3275796|NCT00656630|Placebo Comparator|3|
3275797|NCT00656617|Experimental|Idarubicin + Ara-C + Vorinostat|Idarubicin 12 mg/m^2 by vein (IV) over 1 hour daily for 3 days (days 4 to 6). Ara-C (Cytarabine) 1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7). Vorinostat initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
3275798|NCT00656604|Experimental|Women with breast cancer|Patients undergo DCE-MRI and MRS prior to their breast cancer surgery.
3275799|NCT00656604|No Intervention|Healthy volunteers|Women without breast cancer undergo DCE-MRI and MRS.
3275800|NCT00656578|Experimental|1|4975
3275801|NCT00656578|Placebo Comparator|2|Drug, Single dose, solution
3275802|NCT00656565||1|subjects with bronchiectasis
3275803|NCT00656539|Experimental|1|AzaSite®
3275804|NCT00656539|No Intervention|2|
3275805|NCT00656526|Placebo Comparator|A01L|
3275806|NCT00656526|No Intervention|B01C|
3275807|NCT00656513|Active Comparator|Pilocarpine: Phase III|
3275808|NCT00656513|Experimental|ALTENS: Phase III|
3275809|NCT00656513|Experimental|ALTENS: Phase II|
3275810|NCT00656500|Active Comparator|1|Brief assistance with smoking abstinence
3275811|NCT00656500|Experimental|2|Brief intervention to promote quitline utilization
3275812|NCT00656487|Experimental|Cannabis-dependent rimonabant|Cannabis dependent young adults administered rimonabant 90 mg at Day 0 and followed for 28 days post.
3275813|NCT00656487|Placebo Comparator|Cannabis-dependent placebo|Cannabis dependent young adults administered matched placebo at Day 0 and followed for 28 days post.
3275814|NCT00656487|No Intervention|Non-cannabis using control|Non-cannabis using demographically similar young adults followed for 28 days.
3275815|NCT00656474|Experimental|1|GLYC-101 Active Retro-auricular Site (1 per participant)
3275816|NCT00656474|Placebo Comparator|2 Comparator|"Placebo Retro-auricular Site (1 per participant)~This arm undergoes laser ablation with subsequent Placebo gel administration"
3275817|NCT00656461|Experimental|1|
3275818|NCT00656448|Experimental|Procrit Arm|Participants receive Procrit along with blood transfusions. Procrit 40,000 units subcutaneously every week starting within two weeks (before or after) from the start of induction chemotherapy.
3275819|NCT00656448|No Intervention|No Procrit: Standard Arm|Participants do not receive Procrit before receiving blood transfusions.
3275820|NCT00656435|Experimental|A|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
3275821|NCT00656435|No Intervention|B|Patients will not receive bevacizumab pretreatment
3275822|NCT00656422|Experimental|insulin Levemir|
3275823|NCT00656422|Experimental|insulin Lantus|
3275824|NCT00656396|Active Comparator|Control|Standard care
3275825|NCT00656396|Experimental|Intervention|Point of care monitoring used
3275826|NCT00656383|Active Comparator|1|Client is randomized to receive leg ulcer treatment in the home
3275827|NCT00656383|Active Comparator|2|Client randomized to receive leg ulcer care in the clinic
3275828|NCT00656370|Experimental|NS Infusion Group|Normal Saline (NS) and Hylenex
3275829|NCT00656370|Experimental|LR Infusion Group|Lactated Ringer's (LR) and Hylenex
3275830|NCT00656357|Placebo Comparator|A|SYN117 placebo and Ascending doses of cocaine (10, 20, 40 mg) and placebo
3275831|NCT00656357|Experimental|B|Ascending doses of SYN117 (placebo, 80 mg, 160 mg) and ascending doses of cocaine (10 mg, 20 mg, 40 mg) and placebo
3275832|NCT00656331|Active Comparator|1|Amlodipine
3275833|NCT00656331|Active Comparator|2|HCTZ
3275834|NCT00656318||Group 1 (Zovia)|Subjects will be randomized to receive either the oral contraceptive pill (OCP) Zovia or Necon for 2 months. Prior to beginning the OCP, women will undergo 1 imaging scan. Upon completion of the scan they will receive their first dose of their OCP. Three hours later they will undergo a 2nd imaging scan. Each scan last approximately 1 hour and 15 minutes. This test day is typically scheduled on a Saturday, and lasts approximately 7 hours. Upon completion of the Saturday test day, subjects will remain on their OCP for the remainder of that month and continue taking the pill for a 2nd month. At the end of the 2 months on the pill, subjects will have the option of discontinuing the pill or receiving 1 additional month at no charge before being discharged from the study.
3275835|NCT00656318||Group 2 (Necon)|Subjects will be randomized to receive either the oral contraceptive pill (OCP) Zovia or Necon for 2 months. Prior to beginning the OCP, women will undergo 1 imaging scan. Upon completion of the scan they will receive their first dose of their OCP. Three hours later they will undergo a 2nd imaging scan. Each scan last approximately 1 hour and 15 minutes. This test day is typically scheduled on a Saturday, and lasts approximately 7 hours. Upon completion of the Saturday test day, subjects will remain on their OCP for the remainder of that month and continue taking the pill for a 2nd month. At the end of the 2 months on the pill, subjects will have the option of discontinuing the pill or receiving 1 additional month at no charge before being discharged from the study.
3275836|NCT00656305|Experimental|1|ExAblate Treatment Test Arm
3275837|NCT00656305|Sham Comparator|2|ExAblate Sham Control Arm
3275838|NCT00656292|Placebo Comparator|Simvastatin|Subjects randomized to this arm will receive statin therapy (simvastatin 40 mg) two days before surgery -- allowing three doses of simvastatin before incision -- and these will be continued until patients are either discharged from the hospital or have completed a 3-day postoperative course (6 days of simvastatin therapy), whichever occurs earlier. If patients are unable to take oral medications, the enteral route via nasogastric tube (at our institution, nasogastric tubes are routinely placed for both lumbar and thoracic instrumentation) will be used to deliver either placebo or the statin, as no parenteral form of this drug is currently available.
3275839|NCT00656292|Experimental|Placebo|Subjects randomized to this arm will receive placebo two days before surgery -- allowing three doses of placebo before incision -- and these will be continued until patients are either discharged from the hospital or have completed a 3-day postoperative course (6 days of placebo), whichever occurs earlier. If patients are unable to take oral medications, the enteral route via nasogastric tube (at our institution, nasogastric tubes are routinely placed for both lumbar and thoracic instrumentation) will be used to deliver either placebo or the statin, as no parenteral form of this drug is currently available.
3275840|NCT00656279|Experimental|1|Intensive dietary phosphorus education
3275841|NCT00656279|No Intervention|2|Standard dietary education consists of the dietitian assessing laboratory values and dietary intake and providing dietary education for abnormal values using handouts developed for specific nutrients.
3275842|NCT00656266|Placebo Comparator|1|tacrolimus + steroids
3275843|NCT00656266|Experimental|2|low-dose tacrolimus + steroids + MMF
3275844|NCT00656253|Experimental|A|
3275845|NCT00656253|Placebo Comparator|B|
3275846|NCT00656240|Experimental|1|
3275847|NCT00656240|Experimental|2|
3275848|NCT00656214|Active Comparator|A|Patients with symptomatic oral lichen planus
3275849|NCT00656214|Placebo Comparator|B|Patients with symptomatic oral lichen planus
3275850|NCT00656201|Active Comparator|Crinone 8% Vaginal Gel|Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
3275851|NCT00656201|Active Comparator|Intramuscular Progesterone|Progesterone—50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.
3275852|NCT00656188|Placebo Comparator|Arm 2|
3275853|NCT00656188|Active Comparator|Arm 1|
3275854|NCT00656175|Active Comparator|Immediate|Immediate switch of PI or NNRTI to Raltegravir
3275855|NCT00656175|Active Comparator|Delayed|Continue current therapy unchanged for 24 weeks, then switch PI or NNRTI to Raltegravir
3275917|NCT00655655|Experimental|Arm I|See Detailed Description
3275918|NCT00655642|Active Comparator|Ondansetron|Ondansetron 4 mg intravenous administration
3275856|NCT00656149|Active Comparator|Telerehabilitation of hand function|Intervention: for one hour per day participants perform exercise therapy on a home-based tele-rehabilitation workstation, the Rehabilitation Joystick for Computerized Exercise (ReJoyce) with which participants play computer games associated with activities of daily life. A remote therapist coaches each one-hour session over the Internet, with the use of the ReJoyce tele-rehabilitation system. Hand grasp-release is assisted with functional electrical stimulation (FES) triggered voluntarily by the participant with the use of a wireless earpiece with a sensor that detects toothclicks.
3275857|NCT00656149|Active Comparator|Conventional exercise therapy|Intervention: for one hour per day participants perform conventional range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 with the use of the ReJoyce tele-rehabilitation min). A remote therapist coaches each one-hour session A remote therapist coaches each one-hour session over the Internet, with the use of the ReJoyce tele-rehabilitation system.
3275858|NCT00656136|Placebo Comparator|Placebo|Patients receive placebo once daily
3275859|NCT00656136|Experimental|BIBW 2992|Patients receive BIBW 2992 tablets once daily
3275860|NCT00656110|Experimental|1-T|Treatment Group
3275861|NCT00656110|Placebo Comparator|2-P|Placebo comparator
3275862|NCT00656097|Experimental|A|CL184 combined with rabies vaccination
3275863|NCT00656097|Active Comparator|B|HRIG combined with rabies vaccination
3275864|NCT00656097|Placebo Comparator|C|Placebo combined with rabies vaccination
3275865|NCT00656084|Experimental|Experimental arm|Patients will be treated a maximum of 8 cycles or until the patient has evidence of a response, progressive disease, or until intolerable toxicity develops. Patients with a complete response will receive an additional 2 cycles of treatment (not to exceed 8 cycles). Drug order is gemcitabine, mitoxantrone, and rituximab.
3275866|NCT00656071||1|Control -- postoperative mechanical ventilation patients without ARDS
3275867|NCT00656071||2|Cases -- postoperative mechanical ventilation patients with ARDS
3275868|NCT00656058|Experimental|Montelukast to Treat Bronchiolitis Obliterans|Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.
3275869|NCT00656045|Experimental|A|Arm A focuses on increasing the participant's physical activity level.
3275870|NCT00656045|Experimental|B|Arm B focuses on decreasing the amount of time the participant spends watching Television.
3275871|NCT00656032|Active Comparator|1|SOC medication for treatment of renal osteodystrophy
3275872|NCT00656032|Active Comparator|2|alternate SOC medication for treatment of renal osteodystrophy
3275873|NCT00656019|No Intervention|Normal Vitamin D Levels|No additional Vitamin D administered
3275874|NCT00656019|Experimental|Low-normal Vitamin D Levels|2000 IU dose of Vitamin D per day administered orally
3275875|NCT00656019|Experimental|Low Vitamin D Levels|4000 IU dose of Vitamin D per day administered orally
3275876|NCT00656019|Experimental|Very-low Vitamin D Levels|6000 IU dose of Vitamin D per day administered orally
3275877|NCT00655993|Placebo Comparator|1|placebo drug
3275878|NCT00655993|Active Comparator|2|simvastatin
3275879|NCT00655980|Experimental|Treatment|Vitamin B12 and folic acid
3275880|NCT00655980|Placebo Comparator|Comparator|Nitrous oxide and placebo
3275881|NCT00655980|Other|Standard of care|standard of care
3275882|NCT00655967|Experimental|1|Acamprosate(Campral)
3275883|NCT00655941|Experimental|1|Dietary instruction (low-energy diet. This is given by instructions in groups of 8
3275884|NCT00655941|Active Comparator|2|Exercise
3275885|NCT00655941|No Intervention|3|Control
3275886|NCT00655928|Experimental|1|
3275887|NCT00655928|Placebo Comparator|2|
3275888|NCT00655915||Injection Patients|Those patients who receive corticosteroid injections for carpal tunnel syndrome
3275889|NCT00655902|Experimental|1|
3275890|NCT00655902|Placebo Comparator|2|
3275891|NCT00655889|Experimental|Active|
3275892|NCT00655876|Experimental|Chemoradiation + Cetuximab|External beam radiation therapy (RT) with concurrent weekly paclitaxel, cisplatin, and cetuximab
3275893|NCT00655876|Active Comparator|Chemoradiation|External beam radiation therapy with concurrent weekly paclitaxel, and cisplatin
3275894|NCT00655863|Placebo Comparator|Placebo QD|
3275895|NCT00655863|Experimental|Alogliptin 25 mg QD|
3275896|NCT00655863|Experimental|Alogliptin 25 mg QD + Pioglitazone 30 mg QD|
3275897|NCT00655850|Experimental|Paclitaxel and Gemcitabine + Avastin|Patients will be treated with metronomic chemotherapy with paclitaxel and gemcitabine weekly for 3 out of 4 weeks which constitutes one cycle (4 weeks). Avastin will be administered every 2 weeks. Treatment with metronomic chemotherapy and Avastin will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with Avastin will continue until disease progression, intolerable toxicity, or withdrawal of consent.
3275898|NCT00655837|Experimental|1|
3275899|NCT00655824|Experimental|Ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
3275900|NCT00655811|Active Comparator|Capsaicin|Capsaicin 0.1% cream application to the volar side of forearm.
3275901|NCT00655811|Placebo Comparator|Placebo moisturizing cream|Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.) to the opposite forearm.
3275902|NCT00655798|Placebo Comparator|1|
3275903|NCT00655798|Active Comparator|2|
3275904|NCT00655798|Active Comparator|3|
3275905|NCT00655798|Active Comparator|4|
3275906|NCT00655785|Experimental|Phase 1/2 study|
3275907|NCT00655746|Experimental|1|
3275908|NCT00655733|Experimental|HMPL004|HMPL004 1200mg/d
3275909|NCT00655733|Placebo Comparator|placebo|Placebo
3275910|NCT00655720|Active Comparator|1|
3275911|NCT00655720|Experimental|2|
3275912|NCT00655720|Experimental|3|
3275913|NCT00655707|Experimental|Treatment|Autologous CD34+ cells
3275914|NCT00655681|Experimental|A|Receives pamidronate 1mg/kg
3275915|NCT00655681|Placebo Comparator|B|receives saline injection
3275916|NCT00655668|Experimental|Lenalidomide|Open-label, oral lenalidomide monotherapy
3275919|NCT00655642|Active Comparator|Metoclopramide|Metoclopramide 10 mg intravenous administration
3275920|NCT00655642|Active Comparator|Promethazine|Promethazine 10 mg intravenous administration
3275921|NCT00655642|Placebo Comparator|Saline Placebo|Volume-matched saline placebo
3275922|NCT00655629|Experimental|Vardenafil ODT (STAXYN, BAY38-9456)|Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
3275923|NCT00655629|Placebo Comparator|Placebo|Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
3275924|NCT00655616|Active Comparator|1|The active comparator arm consists of Flixotide® (fluticasone propionate) via accuhaler (Diskus) dry powder inhaler device as per current inhaled steroid dose plus oral montelukast
3275925|NCT00655616|Placebo Comparator|2|The placebo comparator arm consists of Seretide® (salmeterol plus equivalent dose of fluticasone) via accuhaler dry powder inhaler device as per current inhaled steroid dose plus placebo for montelukast
3275926|NCT00655603|Experimental|1|10 patients with Type 2 Diabetes Mellitus
3275927|NCT00655603|Experimental|2|10 healthy, matched control participants
3275928|NCT00655590|Experimental|Arm 1|
3275929|NCT00655590|Active Comparator|Arm 2|
3275930|NCT00655590|Placebo Comparator|Arm 3|
3275931|NCT00655577|No Intervention|2|Control group
3275932|NCT00655577|Experimental|1|Exercise group
3275933|NCT00655564|Experimental|Alefacept|Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.
3275934|NCT00655551|Experimental|Lacosamide 200 mg cohort|Single loading dose of intravenous (iv) lacosamide 200 mg followed by 6.5 days of oral lacosamide 100 mg twice daily
3275935|NCT00655551|Experimental|Lacosamide 300 mg combined cohorts|Single loading dose of intravenous (iv) lacosamide 300 mg dose followed by 6.5 days of oral lacosamide 150 mg twice daily
3275936|NCT00655551|Experimental|Lacosamide 400 mg cohort|Single loading dose of intravenous (iv) lacosamide 400 mg followed by 6.5 days of oral lacosamide 200 mg twice daily
3275937|NCT00655538|Experimental|1|
3275938|NCT00655538|Placebo Comparator|2|
3275939|NCT00655525|Active Comparator|1|
3275940|NCT00655525|Placebo Comparator|2|
3275941|NCT00655512|Active Comparator|1|
3275942|NCT00655512|Active Comparator|2|
3275943|NCT00655512|Active Comparator|3|
3275944|NCT00655512|Active Comparator|4|
3275945|NCT00655512|Placebo Comparator|5|
3275946|NCT00655486|Experimental|Lacosamide|Lacosamide 100 to 800 mg/day, flexible dosing, administered twice daily throughout the duration of the study (up to 2 years)
3275947|NCT00655473|Experimental|Dalcetrapib (RO4607381)|
3275948|NCT00655473|Placebo Comparator|Placebo|
3275949|NCT00655460|Experimental|eProtocol|
3275950|NCT00655447||1|all women having a hysterectomy with oophorectomy
3275951|NCT00655447||2|all women having a hysterectomy without removal of ovaries
3275952|NCT00655434||SAA|Sexually Active Adults- Intercourse in the last twelve months with at least one sexual partner. Subjects must be ≥ 18 years old. No more than 60% of one gender.
3275953|NCT00655421|Experimental|Unaided|Unaided Visual Inspection of the Oral Cavity
3275954|NCT00655421|Experimental|VelScope|VelScope assisted examination of the oral cavity
3275955|NCT00655421|Experimental|Toluidine|Examination of oral cavity after the local application of Toluidine Blue dye
3275956|NCT00655408|Active Comparator|A|"For infants with ages between six and 24 months, iron supplementation is the main treatment for iron deficiency.This study was carried out using two intervention groups. All children received 12 weekly doses of 25 mg of elemental iron.~Group 1 administered in the government healthcare clinic. Group 2 administered children's home.~The study showed treatment compliance in both groups."
3275957|NCT00655395|Experimental|1|"Laromustine 300 mg/m2 (cohort 1) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
3275958|NCT00655395|Experimental|2|"Laromustine 400 mg/m2 (cohort 2) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
3275959|NCT00655395|Experimental|3|"Laromustine 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
3275960|NCT00655395|Experimental|5|"Laromustine will be administered at the recommended phase II dose on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
3275961|NCT00655395|Experimental|4|"Laromustine 600 mg/m2 (cohort 4) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
3275962|NCT00655369|Experimental|15 mg|
3275963|NCT00655369|Experimental|25 mg|
3275964|NCT00655369|Experimental|35 mg|
3275965|NCT00655369|Experimental|5 mg|
3275966|NCT00655369|Experimental|50 mg|
3275967|NCT00655369|Placebo Comparator|Placebo|
3275968|NCT00655356|Experimental|Active|
3275969|NCT00655356|Placebo Comparator|Placebo|
3275970|NCT00655343|Experimental|ATG-F|"ATG-Fresenius S (20 mg/kg body weight at days -3 to -1 (total dose: 60 mg/kg)~cyclosporine A (target trough level > 200ng/ml (day -1 until day +100)~methotrexate: 15mg/m2 at day +1, 10mg/m2 at days +3, +6, and +11"
3275971|NCT00655343|No Intervention|non-ATG-F|"cyclosporine A (target trough level > 200ng/ml (day -1 until day +100)~methotrexate: 15mg/m2 at day +1, 10mg/m2 at days +3, +6, and +11"
3275972|NCT00655330|Active Comparator|1|Valsartan (160mg/day)is given in combination with Placebo
3275973|NCT00655330|Experimental|2|Valsartan (160mg/day) + Probucol (750mg/day)
3275974|NCT00655317|Active Comparator|1|Treatment Acupuncture Group (Therapeutic Acupuncture Treatment): treatment with actual acupuncture needles
3275975|NCT00655317|Sham Comparator|2|SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
3275976|NCT00655304|Active Comparator|1|Treatment with 6-8 hours of Prometheus (R) liver support dialysis
3275977|NCT00655304|Active Comparator|2|Treatment with 6-8 hours of CVVHDF
3275978|NCT00655291|Placebo Comparator|A|
3275979|NCT00655291|Experimental|B|
3275980|NCT00655278|Experimental|1|T2000 at 600-1000 mg daily
3275981|NCT00655265|Experimental|Colesevelam hydrochloride film-coated tablets|
3275982|NCT00655265|Placebo Comparator|Placebo|
3275983|NCT00655239|Active Comparator|Control|Participants will use commercially available computer games.
3275984|NCT00655239|Experimental|Active|Participants will receive targeted neuroadaptive cognitive training with neuroplasticity-based software created by Posit Science Corporation.
3275985|NCT00655239|Active Comparator|Healthy Control|Healthy participants will receive targeted neuroadaptive cognitive training with neuroplasticity-based software created by Posit Science Corporation.
3275986|NCT00655226|Experimental|CBT skills based group sessions|Cognitive Behavioral Therapy skills based group sessions
3275987|NCT00655226|Active Comparator|Hepatitis C educational support groups|Hepatitis C educational support groups
3275988|NCT00655213|Active Comparator|1|AAISafeR mode programming
3275989|NCT00655213|Active Comparator|2|DDD with long AV Delay programming
3275990|NCT00655213|Active Comparator|3|DDDAMC mode programming
3275991|NCT00655213|Other|4|AAISafer mode programming in non randomized patients
3275992|NCT00655200||A|
3275993|NCT00655187||Group A|Cases
3275994|NCT00655187||Group B|Controls
3275995|NCT00655174|Placebo Comparator|1|
3275996|NCT00655174|Experimental|2|
3275997|NCT00655174|Experimental|3|
3275998|NCT00655148|Experimental|A|DTaP-IPV vero vaccination at 2, 3½, 5 and 16 months of age
3275999|NCT00655148|Active Comparator|B|DTaP-IPV mkc vaccination at 2, 3½, 5 and 16 months of age
3276000|NCT00655135|Placebo Comparator|1|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received placebo administered intravenously to patients on Day 1 and Day 29.
3276001|NCT00655135|Experimental|2|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received 0.5 mg/kg of LDP-02 administered intravenously to patients on Day 1 and Day 29.
3276002|NCT00655135|Experimental|3|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received 2 mg/kg of LDP-02 administered intravenously to patients on Day 1 and Day 29.
3276003|NCT00655122|Active Comparator|Dalteparin sodium|
3276004|NCT00655122|Placebo Comparator|Placebo|
3276005|NCT00655109|Active Comparator|1|Olopatadine
3276006|NCT00655109|Active Comparator|2|Fluticasone
3276007|NCT00655109|Placebo Comparator|3|Placebo nasal spray
3276008|NCT00655109|Placebo Comparator|4|Placebo Eyedrops
3276009|NCT00655083|Experimental|1|Nepadutant 0.1 mg/kg
3276010|NCT00655083|Experimental|2|Nepadutant 0.5 mg/kg
3276011|NCT00655057|Active Comparator|1|Healthy participants will undergo TRODAT-1 SPECT imaging.
3276012|NCT00655057|Experimental|2|Participants with depression will undergo TRODAT-1 SPECT imaging and treatment with s-citalopram.
3276013|NCT00655057|Active Comparator|3|Participants with depression will undergo TRODAT-1 SPECT imaging and treatment with cognitive behavioral therapy.
3276014|NCT00655044||Type 1 and type 2 diabetes patients|
3276015|NCT00655031|Experimental|1|Pomegranate concentrate (POMx)
3276016|NCT00655031|Placebo Comparator|2|Fruit flavored juice low in antioxidants
3276017|NCT00655018|Experimental|Vitamin group|alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
3276018|NCT00655018|Placebo Comparator|2|placebo and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
3276019|NCT00654992|Active Comparator|EPO group|
3276020|NCT00654992|Placebo Comparator|Placebo group|
3276021|NCT00654979|Experimental|Single arm|SafeFlo IVC Filter
3276022|NCT00654966|Experimental|1|Heart failure patients
3276023|NCT00654966|Active Comparator|2|Healthy subjects
3276024|NCT00654953|Placebo Comparator|1|Placebo capsules
3276025|NCT00654953|Experimental|2|sertraline (200 mg/day)
3276026|NCT00654953|Experimental|3|sertraline (200 mg/day) plus gabapentin (1,200 mg/day)
3276027|NCT00654940|Active Comparator|A|
3276028|NCT00654940|Placebo Comparator|B|
3276029|NCT00654914|Experimental|Arm 1|
3276030|NCT00654901|Experimental|DTaP-IPV-Hep B-PRP~T Batch 1|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651); and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
3276031|NCT00654901|Experimental|DTaP-IPV-Hep B-PRP~T Batch 2|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651) and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
3276032|NCT00654901|Experimental|DTaP-IPV-Hep B-PRP~T Batch 3|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651) and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
3276087|NCT00654472||B|Mitral valve area 1.5 cm2 and below 1.5 cm2
3276088|NCT00654459||A|
3276033|NCT00654901|Active Comparator|Infanrix Hexa™|Participants had received 3 primary doses of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), (Infanrix Hexa™) plus Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed in Study A3L11 (NCT00404651) and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
3276034|NCT00654888|Active Comparator|1|Group one submitted to automated lamellar keratectomy(ALK) with mitomycin (0,02% in 30 seconds after keratectomy).
3276035|NCT00654888|Active Comparator|2|automated lamellar keratectomy without mitomycin
3276036|NCT00654875|Experimental|Aliskiren 300 mg (Once a Day)|Participants received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening for a total of 10 weeks.
3276037|NCT00654875|Experimental|Aliskiren 150 mg (Twice a Day)|Participants received Aliskiren 150 mg tablet + Placebo to Aliskiren matching 300 mg tablet daily in the morning and Aliskiren 150 mg tablet daily in the evening for the first 6 weeks then for the next 4 weeks received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening.
3276038|NCT00654862|Experimental|1|Subjects with stage 1 hypertension
3276039|NCT00654862|Experimental|2|Subjects with optimal blood pressure
3276040|NCT00654849|Experimental|1|compare security and effectiveness of use Electrosurgical Bipolar Plasmakinetic Vessel Sealing
3276041|NCT00654849|Active Comparator|2|traditional abdominal hysterectomy technique with the use of sutures
3276042|NCT00654836|Experimental|Carboplatin, ABI-007 and Bevacizumab|Participants will receive combination carboplatin, nanoparticle albumin-bound paclitaxel (ABI-007-Abraxane), and bevacizumab (Avastin)
3276043|NCT00654810|Experimental|1|Low intensity group (40% of maximal exercise capacity)
3276044|NCT00654810|Experimental|2|High intensity group (80% of maximal exercise capacity)
3276045|NCT00654797|Experimental|eProtocol|
3276046|NCT00654784|Experimental|1|
3276047|NCT00654784|Placebo Comparator|2|
3276048|NCT00654771||1|women undergoing evaluation for pre-eclampsia
3276049|NCT00654758|Experimental|1|Escalating doses of volociximab at 10, 20, and 30 (or 15) mg/kg with carboplatin and paclitaxel.
3276050|NCT00654745|Experimental|aml + olm + hctz|amlodipine; and olmesartan medoxomil, if required; and hydrochlorothiazide, if required.
3276051|NCT00654732|Experimental|R-ABVD Therapy|Rituximab 375 mg/m^2 IV Weekly Over 7 Hours On Days 1, 8, 15, 22. Adriamycin 25 mg/m^2 IV Over 1 Hour On Day 1 and 15. Bleomycin 10 U/m^2 IV Over 1 Hour On Day 1 and 15. Vinblastine 6 mg/m^2 IV Over 1 Hour On Day 1 and 15. Dacarbazine 375 mg/m^2 IV Over 1 Hour On Day 1 and 15.
3276052|NCT00654732|Active Comparator|ABVD Therapy|Adriamycin 25 mg/m^2 IV Over 1 Hour On Day 1 and 15. Bleomycin 10 U/m^2 IV Over 1 Hour On Day 1 and 15. Vinblastine 6 mg/m^2 IV Over 1 Hour On Day 1 and 15. Dacarbazine 375 mg/m^2 IV Over 1 Hour On Day 1 and 15.
3276053|NCT00654719|Active Comparator|NutriDrink|Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
3276054|NCT00654719|Placebo Comparator|Placebo|
3276055|NCT00654706|Experimental|Sertindole|
3276056|NCT00654706|Active Comparator|Quetiapine|
3276057|NCT00654693||monitored|patients hospitalized for longer than 24 hours and are located on the 4th, 5th, and 6th floors of the Vanderbilt University Medical Center Round Wing
3276058|NCT00654680|Experimental|Arm 1|
3276059|NCT00654680|Placebo Comparator|Arm 2|
3276060|NCT00654667|Placebo Comparator|2|Placebo
3276061|NCT00654667|Experimental|Experimental 1|Resveratrol
3276062|NCT00654654|Experimental|Active|
3276063|NCT00654641|Experimental|Negative pressure wound closure|Negative Pressure wound closure
3276064|NCT00654641|Active Comparator|Standard wound closure|Standard Wound Closure
3276065|NCT00654628|Experimental|1|Patients with intermediate or high risk dyslipidemia will be enrolled to receive treatment with Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks
3276066|NCT00654615|Active Comparator|1|"Intramedullary Radius Fixation (Micronail) - Group 1~A new device was developed to provide intramedullary distal radius fracture fixation. This new device allows the placement of the orthopaedic hardware inside the medullary canal of the radius."
3276067|NCT00654615|Active Comparator|2|"Volar Plate Fixation - Group 2~Volar locking plates provide rigid external fixation and are placed on the outside of the radius. Volar plates are placed directly on the distal radius using a metal plate contoured to the shape of the distal radius."
3276068|NCT00654589|Experimental|deferasirox|
3276069|NCT00654576|Active Comparator|1|the comparator arm will only receive one of the seven antipsychotic
3276070|NCT00654576|Experimental|2|the experimental group will receive one of the seven study drugs combination with psychosocial intervention
3276071|NCT00654550|Experimental|1|
3276072|NCT00654537|Experimental|1|Rosuvastatin
3276073|NCT00654537|Active Comparator|2|Atorvastatin
3276074|NCT00654537|Active Comparator|3|Pravastatin
3276075|NCT00654537|Active Comparator|4|Simvastatin
3276076|NCT00654524|Experimental|1|Patients in this arm will be treated with goserelin depot-3.6mg plus add-back therapy.
3276077|NCT00654524|No Intervention|2|The patient with advanced endometriosis（stage III-IV）confirmed histologically after conservative laparoscopic surgery will be suggested to prepare for spontaneous pregnancy rather than any medical administration.
3276078|NCT00654511|Active Comparator|Fentanyl 1|Fentanyl 1 micrograms (mcg)/kilogram (kg)
3276079|NCT00654511|Active Comparator|Fentanyl 2|Fentanyl 2 micrograms (mcg)/kilogram (kg)
3276080|NCT00654511|Experimental|Dex 3|Dexmedetomidine 2 micrograms (mcg)/kilogram (kg)
3276081|NCT00654511|Experimental|Dex 4|Dexmedetomidine 4 micrograms (mcg)/kilogram (kg)
3276082|NCT00654498|Other|Pramipexole|4 weeks of individual dose titration starting with Pramipexole 0.125 mg, next dose steps 0.25 mg, 0.5 mg and 0.75 mg, fixed dose for 2 weeks, once daily
3276083|NCT00654498|Other|Placebo|4 weeks of individual dose titration as for the investigational product, once daily
3276084|NCT00654485|Experimental|1|Rosuvastatin
3276085|NCT00654485|Active Comparator|2|Atorvastatin
3276086|NCT00654472||A|Mitral valve area above 1.5 cm2
3276090|NCT00654446|Experimental|1|Rosuvastatin
3276091|NCT00654446|Active Comparator|2|Simvastatin
3276092|NCT00654433|Experimental|I|
3276093|NCT00654420|Experimental|Ph I: Dalotuzumab 5 mg/kg + Erlotinib|During the Phase I part of the study, participants receive dalotuzumab intravenously (IV) at 5 mg/kg weekly plus open-label erlotinib at 150 mg daily for 4 weeks. After 4 weeks of therapy, participants in Phase I who do not have disease progression and are satisfactorily tolerating study drug can continue to receive study drug.
3276094|NCT00654420|Experimental|Ph I: Dalotuzumab 10 mg/kg + Erlotinib|During the Phase I part of the study, participants receive dalotuzumab intravenously (IV) at 10 mg/kg weekly plus open-label erlotinib at 150 mg daily for 4 weeks. After 4 weeks of therapy, participants in Phase I who do not have disease progression and are satisfactorily tolerating study drug can continue to receive study drug.
3276095|NCT00654420|Experimental|Ph II: Dalotuzumab 10 mg/kg + Erlotinib|During the Phase II part of the study, participants are randomized to receive dalotuzumab intravenously (IV) at 10 mg/kg weekly plus open-label erlotinib at 150 mg daily until disease progression or occurrence of unacceptable toxic effects.
3276096|NCT00654420|Active Comparator|Ph II: Erlotinib|During the Phase II part of the study, participants are randomized to receive open-label erlotinib at 150 mg daily until disease progression or occurrence of unacceptable toxic effects.
3276097|NCT00654407|Experimental|1|Rosuvastatin
3276098|NCT00654407|Active Comparator|2|Atorvastatin
3276099|NCT00654407|Active Comparator|3|Simvastatin
3276100|NCT00654394|Experimental|1|
3276101|NCT00654381|Active Comparator|voglibose 0.2 mg three times a day (TID)|patient to receive a tablet containing 0.2 mg voglibose TID plus 2 placebo tablets matching BI 1356
3276102|NCT00654381|Experimental|BI 1356 low dose|patient to receive a tablet containing BI 1356 and matching placebo plus 3 placebo tablets matching voglibose
3276103|NCT00654381|Experimental|BI 1356 high dose|patient to receive 2 tablets containing BI 1356 plus 3 placebo tablets matching voglibose
3276104|NCT00654381|Placebo Comparator|placebo|patient to receive 2 placebo tablets matching BI 1356 plus 3 placebo tablets matching voglibose
3276105|NCT00654368|Active Comparator|Etanercept + Methotrexate|After six months of treatment with 50 mg/week subcutaneous etanercept added to existing methotrexate therapy of at least 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses) participants were randomized to continue both etanercept plus methotrexate for an additional 18 months.
3276106|NCT00654368|Experimental|Etanercept Only|After six months of treatment with 50 mg/week subcutaneous etanercept added to existing methotrexate therapy of at least 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses) participants were randomized to discontinue methotrexate (tapered over 6 weeks) and continue etanercept alone for an additional 18 months.
3276107|NCT00654355|Experimental|Active Drug|tacrolimus ointment
3276108|NCT00654342|Other|1|In vivo injection group
3276109|NCT00654342|Other|2|Ex vivo injection group
3276110|NCT00654329|Experimental|Dexmedetomidine 1microgram/kilogram|Dexmedetomidine 1microgram/kilogram intranasal
3276111|NCT00654329|Experimental|Dexmedetomidine 2 micrograms/kilogram|Dexmedetomidine 2 micrograms/kilogram intranasal
3276112|NCT00654329|Active Comparator|Fentanyl 2 micrograms/kilogram|Fentanyl 2 micrograms/kilogram intranasal
3276113|NCT00654329|Placebo Comparator|Normal saline placebo|Normal saline placebo intranasal
3276114|NCT00654316|Experimental|1|BCG delivered intradermally into the deltoid region in volunteers who have received BCG 10 - 20 years previously.
3276115|NCT00654303|Experimental|1|Rosuvastatin
3276116|NCT00654290|Experimental|P|Propranolol from 7 days pre-operation to 5 days post CABG
3276117|NCT00654290|Active Comparator|A|Amiodarone treated 7 days pre-operation to 5 days post CABG
3276118|NCT00654290|Active Comparator|AP|Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
3276119|NCT00654277|Experimental|A|Subjects received Kali formulated products under fasting conditions
3276120|NCT00654277|Active Comparator|B|Subjects received GlaxoSmithKine product under fasting conditions
3276121|NCT00654264|Other|1|Patients will have water immersion on first day and sitting in a tub without water on the second day.
3276122|NCT00654264|Other|2|Patients will sit in a tub without water on the first day and have water immersion on the second day.
3276123|NCT00654238|Experimental|1|This is a single arm study.
3276124|NCT00654225|Experimental|1|Rosuvastatin
3276125|NCT00654225|Active Comparator|2|Atorvastatin
3276126|NCT00654212|Active Comparator|1|endoluminal stenting followed by laparoscopic resection (endo-laparoscopic limb, the study group)
3276127|NCT00654212|Other|2|emergency open surgery (open limb, the control group)
3276128|NCT00654186|Experimental|1|
3276129|NCT00654173|Experimental|1|Rosuvastatin
3276130|NCT00654173|Active Comparator|2|Simvastatin
3276131|NCT00654173|Active Comparator|3|Atorvastatin
3276132|NCT00654147|Active Comparator|Raltegravir & Lopinavir/ritonavir|Raltegravir 400 mg tablet and Lopinavir/ritonavir capsule by mouth, every 12 hours for 48 weeks
3276133|NCT00654147|Active Comparator|Raltegravir & emtricitabine/tenofovir|Raltegravir 400 mg tablet bu mouth, every 12 hours for 48 weeks and tenofovir/embritcitabine 200 mg/100 mg table by mouth, once daily for 48 weeks
3276134|NCT00654121|Active Comparator|1|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
3276135|NCT00654121|No Intervention|2|
3276136|NCT00654108|Experimental|Cohort 1: vaccine dosage level 1 or placebo|Vaccine dose level 1: 1 X 10^7 colony forming unit (CFU) or placebo, treated with Cipro on days 7-11.
3276137|NCT00654108|Experimental|Cohort 4: vaccine dosage level 4 or placebo|Vaccine dose level 4: 1 X 10^10 CFU or placebo, treated with Cipro on days 7-11.
3276138|NCT00654108|Experimental|Cohort 2: vaccine dosage level 2 or placebo|Vaccine dose level 2: 1 X 10^8 CFU or placebo, treated with Cipro on days 7-11.
3276139|NCT00654108|Experimental|Cohort 3: vaccine dosage level 3 or placebo|Vaccine dose level 3: 1 X 10^9 CFU or placebo, treated with Cipro on days 7-11.
3276140|NCT00654095|Experimental|Ezetimibe + Atorvastatin|Ezetimibe 10 mg + Atorvastatin 20 mg
3276141|NCT00654082|Active Comparator|Arm 1|
3276142|NCT00654082|Placebo Comparator|Arm 2|
3276143|NCT00654069|Placebo Comparator|Placebo|Tablet
3276144|NCT00654069|Active Comparator|Acurox 5/30mg|Oxycodone HCl 5mg/Niacin 30mg tablet
3276145|NCT00654069|Placebo Comparator|Acurox 7.5/30|Oxycodone HCl 7.5mg/Niacin 30mg tablet
3276146|NCT00654056|Experimental|L1|Actrapid infusion, 0.5 mU/kg/min.
3276147|NCT00654056|Experimental|L2|Actrapid infusion 1.5 mU/kg/min
3276148|NCT00654056|Experimental|H1|Actrapid infusion 3.0 mU/kg/min
3276149|NCT00654056|Experimental|H2|Actrapid infusion 5.0 mU/kg/min
3276150|NCT00654043|Experimental|A|Subjects received Par formulated products under fed conditions
3276151|NCT00654043|Active Comparator|B|Subjects received Roche formulated products
3276152|NCT00654030|Experimental|1650-G Vaccine|Patients receive 2 injections of 1650-G Vaccine given 4 weeks apart, for a total of 52 weeks on study.
3276153|NCT00654017|Placebo Comparator|placebo|
3276154|NCT00654017|Active Comparator|sildenafil|
3276155|NCT00654004||Subjects|Subjects are patients with a long-chain fatty acid oxidation disorder including CPT2, VLCAD, TFP or LCHAD deficiency.
3276156|NCT00654004||Controls|Subjects do not have a fatty acid oxidation disorder.
3276157|NCT00653991|Experimental|SOLVE-IT|Participants will receive SOLVE-IT.
3276158|NCT00653991|Active Comparator|Waitlist Control|Participants will receive SOLVE-IT after a 6-month waitlist period.
3276159|NCT00653978|Experimental|1|patients receiving one stent
3276160|NCT00653978|Active Comparator|2|patients receiving two stents
3276161|NCT00653965|Experimental|1|Rosuvastatin
3276162|NCT00653965|Active Comparator|2|Atorvastatin
3276163|NCT00653952|Experimental|001|
3276164|NCT00653952|Active Comparator|002|
3276165|NCT00653939|Active Comparator|Arm 1: Chemotherapy+Bevacizumab|Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg)administered intravenously on Day 1 of a 21-day cycle for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab (15 mg/kg) alone on Day 1 every 3 weeks until progression or until 12 months from randomization.
3276166|NCT00653939|Experimental|Arm 2: Active Comparator+Fosbretabulin|Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg), administered intravenously Day 1 of a 21-day cycle and fosbretabulin (60 mg/m2) on Days 7, 14, and 21 for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab (15 mg/kg) on Day 1 and fosbretabulin on Days 1, 7 and 14 every 3 weeks until progression or until 12 months from randomization.
3276167|NCT00653926|Active Comparator|A|Group A (Active) receives a multimodal injection intra- and postoperatively
3276168|NCT00653926|Placebo Comparator|P|Group P (Placebo) receives no injection intraoperatively and a saline injection postoperatively
3276169|NCT00653913|Active Comparator|Group A|SCH 58235 (Period 1) Pitavastatin (Period 2) Coadministration (Period 3)
3276170|NCT00653913|Active Comparator|Group B|SCH 58235 (Period 1) Coadministration (Period 2) Pitavastatin (Period 3)
3276171|NCT00653913|Active Comparator|Group C|Pitavastatin (Period 1) SCH 58235 (Period 2) Coadministration (Period 3)
3276172|NCT00653913|Active Comparator|Group D|Pitavastatin (Period 1) Coadministration (Period 2) SCH 58235 (Period 3)
3276173|NCT00653913|Active Comparator|Group E|Coadministration (Period 1) SCH 58235 (Period 2) Pitavastatin (Period 3)
3276174|NCT00653913|Active Comparator|Group F|Coadministration (Period 1) Pitavastatin (Period 2) SCH 58235 (Period 3)
3276175|NCT00653900||1|All patients undergoing elective, invasive cardiac procedure on plavix prior to admission
3276176|NCT00653887|Active Comparator|A|biofeedback (active group)
3276177|NCT00653887|Placebo Comparator|B|discussion about digestive tract (placebo group)
3276178|NCT00653874|Experimental|1: TcB|transcutaneous bilirubinometry (TcB) was used for deciding the need for blood sampling to measure serum total bilirubin (STB)
3276179|NCT00653874|Active Comparator|2: CaB|clinical assessment of jaundice (CaB) was used for deciding the need for blood sampling to measure serum total bilirubin (STB)
3276180|NCT00653861|Experimental|Juvederm with Lidocaine|Subjects receive Juvederm with Lidocaine (either Ultra or Ultra Plus at investigator's discretion) in one nasolabial fold.
3276181|NCT00653861|Active Comparator|Juvederm|Subjects receive Juvederm without Lidocaine (either Ultra or Ultra Plus at investigator's discretion) in the other nasolabial fold.
3276182|NCT00653848|Experimental|Docetaxel arm|six of docetaxel every third week + hormonal treatment
3276183|NCT00653848|No Intervention|Control|hormonal treatment only
3276184|NCT00653835|Experimental|Ezetimibe + Simvastatin|
3276185|NCT00653835|Active Comparator|Simvastatin|
3276186|NCT00653822|Experimental|1a|IV
3276187|NCT00653822|Placebo Comparator|1b|IV
3276188|NCT00653822|Experimental|2a|Lower SC dose
3276189|NCT00653822|Placebo Comparator|2b|SC to match lower dose
3276190|NCT00653822|Experimental|3a|Higher SC dose
3276191|NCT00653822|Placebo Comparator|3b|SC to match higher dose
3276192|NCT00653809||A, 1, I|Caucasian women without preeclampsia or PIH, delivering their first child
3276193|NCT00653809||A, 1, II|Caucasian women with preeclampsia or PIH, delivering their first child
3276194|NCT00653809||A, 2, I|African-american women without preeclampsia or PIH, delivering their first child
3276195|NCT00653809||A, 2, II|African-American women with preeclampsia or PIH, delivering their first child
3276196|NCT00653809||B, 1, I|Caucasian women without preeclampsia or PIH, delivering at least their second child
3276197|NCT00653809||B, 1, II|Caucasian women with preeclampsia or PIH, delivering at least their second child
3276198|NCT00653809||B, 2, I|African-american women without preeclampsia or PIH, delivering at least their second child
3276199|NCT00653809||B, 2, II|African-american women with preeclampsia or PIH, delivering at least their second child
3276200|NCT00653796|Experimental|Ezetimibe + Atorvastatin|
3276201|NCT00653796|Active Comparator|Atorvastatin|
3276202|NCT00653770|Experimental|1|FP85A at day 0
3276203|NCT00653770|Experimental|2|MVA85A at day 0 and FP85A at day 28
3276204|NCT00653770|Experimental|3|FP85A at day 0 and MVA85A at day 28
3276205|NCT00653744|Experimental|1|Rosuvastatin
3276206|NCT00653744|Active Comparator|2|Atorvastatin
3276207|NCT00653731|Experimental|Snoezelen ©|
3276208|NCT00653731|Experimental|Reminiscence|
3276209|NCT00653731|Experimental|10 min activation|
3276210|NCT00653731|Active Comparator|Talk|
3276211|NCT00653705|Active Comparator|Probiotic|Children given probiotic BB12 enriched yogurt drink.
3276212|NCT00653705|Placebo Comparator|Control|Children given dairy drink.
3276213|NCT00653692||Observational|Poly drug dependent women
3276214|NCT00653653||Group A|Recruited patients will be prospectively observed as one cohort with genotyping/medication interaction analysis after 3 months, followed up by a further 3 month observational period.
3276215|NCT00653640|Experimental|1|body weight supported treadmill training
3276216|NCT00653640|Placebo Comparator|2|traditional physical therapy
3276217|NCT00653627|Experimental|A|Study of BCG quantification and immunogenicity 2 weeks after BCG vaccination
3276218|NCT00653627|Experimental|B|Study of BCG quantification and immunogenicity 4 weeks after BCG vaccination
3276219|NCT00653614|Experimental|Arm 1|E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for 24 days and DRSP (ZK 30595) dose 1 (SHT04984F) for one day and placebo for three days in a 28 day cycle
3276220|NCT00653614|Experimental|Arm 2|E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for 24 days and DRSP (ZK 30595) dose 1 (SHT04984F) for two days and placebo for two days in a 28 day cycle
3276221|NCT00653614|Experimental|Arm 3|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for days 9-16, E2/DRSP (BAY 86-4891) dose 3 (80458755) for days 17-24, and placebo for days 25-28 in a 28 day cycle
3276222|NCT00653614|Experimental|Arm 4|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for days 9-16, E2/DRSP (BAY 86-4891) dose 3 (80458755) for days 17-24, placebo for 3 days, and DRSP (ZK 30595) dose 1 (SHT04984F) for one day in a 28 day cycle
3276223|NCT00653614|Experimental|Arm 5|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 4 (80458720) for days 9-16, E2/DRSP (BAY 86-4891) dose 5 (80458712) for days 17-24, and placebo for 4 days in a 28 day cycle
3276224|NCT00653614|Experimental|Arm 6|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 4 (80458720) for days 9-16, E2/DRSP (BAY 86-4891)dose 5 (80458712) for days 17-24, placebo for 3 days, and DRSP (ZK 30595) dose 2 (80458690) for one day in a 28 day cycle
3276225|NCT00653601||1|Patients who receive bridge therapy with tirofiban who were previously on plavix for drug eluting or bare metal stent prior to scheduled invasive procedures
3276226|NCT00653601||2|"Patients who do NOT receive bridge therapy previously on plavix for drug eluting or bare metal stent prior to scheduled invasive procedures. This will entail of a matching case-control for the following characteristics.~# of RF for stent thrombosis~types of stents~time frame when the stents were placed~procedure type"
3276227|NCT00653588|Experimental|1|rosuvastatin (40 mg)
3276228|NCT00653588|Active Comparator|2|atorvastatin (80 mg)
3276229|NCT00653575||1|Women who report a history of childhood sexual abuse
3276230|NCT00653575||2|Women who do not report a history of childhood sexual abuse
3276231|NCT00653562|Experimental|1|Patients will receive placebo in one part and zolpidem in the other part
3276232|NCT00653549|Experimental|A|Subjects received Par formulated product under fasting conditions
3276233|NCT00653549|Active Comparator|B|Subjects received Roche formulated product under fasting conditions
3276234|NCT00653523|Experimental|Ezetimibe + Simvastatin|Ezetimibe 10 mg + Simvastatin 20 mg
3276235|NCT00653510|Experimental|Euglycemic|The patients will be examined with a blood glucose at around 5-7 mmol/L.
3276236|NCT00653510|Experimental|Hyperglycemic|The patients will be examined with a blood glucose at around 18-20 mmol/L
3276237|NCT00653497|Experimental|1|Community-based aquatic exercise program (Arthritis Foundation Aquatics Program). Two classes per week, 45-60 minutes in duration.
3276238|NCT00653497|No Intervention|2|Usual care; abstention from initiation of new exercise programs. Invited to participate in Arthritis Foundation Aquatics Program after study completion.
3276239|NCT00653484|Experimental|Physical Activity Only|Physical Activity
3276240|NCT00653484|Experimental|Dietary Energy Restriction|Energy restriction
3276241|NCT00653484|Experimental|Physical Activity+Dietary Energy Restriction|Physical Activity ad Energy Restriction
3276242|NCT00653471|Active Comparator|Lean|Lean patients
3276243|NCT00653471|Active Comparator|Obese no OSA|Obese patients without osa
3276244|NCT00653471|Active Comparator|Obese osa|Obese patients with osa
3276245|NCT00653458|Experimental|A|Subjects received Kali formulated products under fed conditions
3276246|NCT00653458|Active Comparator|B|Subjects received GlaxoSmithKline's formulated products under fed conditions
3276247|NCT00653445|Experimental|1|Rosuvastatin 40mg/Ezetimibe 10mg combination therapy
3276248|NCT00653445|Experimental|2|Rosuvastatin 40 mg
3276249|NCT00653432|Experimental|A|Hyaluronic acid
3276250|NCT00653419|Experimental|A|Subjects received the Par formulated product (Buspirone HCl) under fasting conditions
3276251|NCT00653419|Active Comparator|B|Subjects received the Bristol-Myers Squibb formulated product (Buspar) under fasting conditions
3276252|NCT00653393|Experimental|A|Subjects received Kali product under fasting conditions
3276253|NCT00653393|Active Comparator|B|Subjects received Parnate product under fasting conditions
3276254|NCT00653380|Experimental|A|Subjects received the Par product (Doxycycline Monohydrate) under fasting conditions.
3276255|NCT00653380|Active Comparator|B|Subjects received Oclassen's product (Monodox) under fasting conditions.
3276256|NCT00653367|Experimental|NS|Nerve section of intercostal nerve during surgery
3276257|NCT00653367|No Intervention|Control|Control
3276258|NCT00653354|Active Comparator|Arm 1|
3276259|NCT00653354|Active Comparator|Arm 2|
3276260|NCT00653354|Placebo Comparator|Arm 3|
3276261|NCT00653328|Experimental|Therapeutic Intervention|
3276262|NCT00653315|Experimental|A|Subjects received kali product under fasting conditions
3276263|NCT00653315|Active Comparator|B|Subjects received Ortho-Mcneil product under fasting conditions
3276264|NCT00653302|Experimental|1|Lantus once a day plus Glucophage 1000mg, twice a day per os
3276265|NCT00653276|Active Comparator|Treatment A|Treatment A: subjects will be given a single oral dose of cyclosporine 100 mg capsules on Day 1.
3276266|NCT00653276|Active Comparator|Treatment B|Treatment B: subjects will receive single oral daily doses of ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through 6, followed by coadministration of a single oral dose of ezetimibe 20 mg (2 x 10 mg tablets) and cyclosporine 100 mg capsule on Day 7.
3276267|NCT00653263||Methamphetamine dependent|Methamphetamine dependent participants admitted to Recovery Centers of Arkansas
3276268|NCT00653250|Experimental|Therapeutic Intervention|Correlative
3276269|NCT00653237|Other|1|crossover trial. insertion of both devices consecutively, computer randomized order
3276270|NCT00653224|Placebo Comparator|Placebo|Matched placebo tablets
3276271|NCT00653224|Experimental|LCTZ|5 mg tablet
3276272|NCT00653198||A|Cases
3276273|NCT00653198||B|Controls
3276274|NCT00653185|Experimental|SYR-472 25 mg QD|(with lifestyle modification and/or metformin therapy)
3276275|NCT00653185|Experimental|SYR-472 50 mg QD|(with lifestyle modification and/or metformin therapy)
3276276|NCT00653185|Experimental|SYR-472 100 mg QD|(with lifestyle modification and/or metformin therapy)
3276277|NCT00653185|Experimental|SYR-472 200 mg QD|(with lifestyle modification and/or metformin therapy)
3276278|NCT00653185|Placebo Comparator|Placebo QD|(with lifestyle modification and/or metformin therapy)
3276279|NCT00653172|Experimental|1|NXL103
3276280|NCT00653172|Active Comparator|3|
3276281|NCT00653172|Experimental|2|NXL103
3276282|NCT00653159|Active Comparator|Mirena IUD [LNG-IUS]|Participants in this arm had a Levonorgestrel-releasing intrauterine device (LNG-IUS), also known as the Mirena IUD, inserted within the first 5 days of the adolescent's menstrual cycle, at least 7 weeks after a vaginal or cesarean delivery or second-trimester abortion or at least 3 weeks after a first-trimester abortion. For participants who had used depot-medroxyprogesterone acetate, insertions occurred at least 6 months after the participant's last injection. Participants were blinded to the device type; however, investigators and research assistants were not.
3276283|NCT00653159|Active Comparator|Paragard IUD [Copper T380A]|Participants in this arm had a Copper T380A intrauterine device (CuT380A), also known as the Paragard IUD, inserted within the first 5 days of the adolescent's menstrual cycle, at least 7 weeks after a vaginal or cesarean delivery or second-trimester abortion or at least 3 weeks after a first-trimester abortion. For participants who had used depot-medroxyprogesterone acetate, insertions occurred at least 6 months after the participant's last injection. Participants were blinded to the device type; however, investigators and research assistants were not.
3276284|NCT00653146|Experimental|Mindfulness-based stress reduction|The MBSR program includes meditation techniques, body scan, awareness of breathing, mindful yoga, eating meditation, and walking meditation, and meets for 2 hours, once weekly for 8 weeks.
3276285|NCT00653146|Placebo Comparator|Healthy Lifestyles Program|The Healthy Lifestyles Program includes information on nutrition and physical activity, and meets for 2 hours, once weekly for 8 weeks.
3276286|NCT00653133|Active Comparator|USPNB|Ultrasound imaging guided peripheral nerve block
3276287|NCT00653133|Active Comparator|NSPNB|Peripheral nerve stimulator guided peripheral nerve block catheter placement for continuous infusion of local anesthetic
3276288|NCT00653120|Experimental|A|Subjects received Par Products under fasting conditions
3276289|NCT00653120|Active Comparator|B|Subjects received Wyeth Pharmaceuticals product under fasting conditions
3276290|NCT00653107|Experimental|A|Stent followed by 3 brachytherapy fractions
3276291|NCT00653107|Active Comparator|B|3 fractions of brachytherapy
3276292|NCT00653094|Other|A|
3276293|NCT00653081|Active Comparator|A|Supervised Exercises performed at ulleval Hospital for patients with shoulder pain. Dosage: 45 minutes each time, max 2-3 times a week in max 12 weeks
3276294|NCT00653081|Active Comparator|B|Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
3276295|NCT00653068|Experimental|Treatment|"Within 2-6 weeks after induction therapy or radiation therapy, patients receive high-dose carboplatin IV and high-dose thiotepa IV on days 1 and 2 and undergo autologous PBSC rescue on approximately day 4. Patients also receive G-CSF IV or SC once daily until ANC recovers.~Consolidation therapy followed by stem cell rescue repeats every 28 days for 3 courses (C) and 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks (R), the order of which depends on patient age, in the absence of disease progression or unacceptable toxicity."
3276296|NCT00653055|Experimental|A|Subjects received the test product, Cabergoline 0.5 mg tablets under fasting conditions
3276297|NCT00653055|Active Comparator|B|Subjects received the reference product, Dostinex under fasting conditions
3276298|NCT00653003|Experimental|A|Subjects received Kali formulated product under fed conditions
3276299|NCT00653003|Active Comparator|B|Subjects received Aventis formulated products under fed conditions
3276300|NCT00652977|Active Comparator|I|The delivery of the fetal head should be managed by Ritgens maneuver, i.e. lifting the fetal chin anteriorly, using the fingers of one hand placed between the anus and the coccyx, and thereby extending the fetal neck, whereas the other hand should be placed on the fetal occiput to control the pace of the expulsion of the fetal head.
3276301|NCT00652977|Other|II|Standard care at delivery: Manual support of the perineum
3276302|NCT00652964||Observation|a family of congenital central hypoventilation syndrome
3276303|NCT00652951|Active Comparator|Synflorix + Infanrix hexa Group|Subjects received 3 doses of SynflorixTM vaccine co-administered with Infanrix hexaTM at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (SynflorixTM) or left (Infanrix hexaTM) thigh or deltoid.
3276304|NCT00652951|Experimental|Synflorix + Pediacel Group|Subjects received 3 doses of SynflorixTM vaccine co-administered with PediacelTM at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (SynflorixTM) or left (PediacelTM) thigh or deltoid.thigh or deltoid.
3276344|NCT00652717|Experimental|1|arm 1 - Ezetimibe 10 mg daily that was added on Statin Therapy (prescribed clinically suitable dose by the physician).
3276717|NCT00650091|Placebo Comparator|2|Participants will receive placebo for 60 weeks.
3276305|NCT00652951|Active Comparator|Prevenar + Pediacel Group|Subjects received 3 doses of PrevenarTM co-administered with PediacelTM vaccine at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (PrevenarTM) or left (PediacelTM) thigh or deltoid.
3276306|NCT00652938|Active Comparator|Cervarix & Engerix Group|Subjects received 3 doses of Cervarix™ (Human Papillomavirus [HPV] vaccine) co-administered with Engerix™ (Hepatitis B [HBV] vaccine) according to a 0, 1, 6-month schedule.
3276307|NCT00652938|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ (Human Papillomavirus [HPV] vaccine) according to a 0, 1, 6-month schedule.
3276308|NCT00652938|Active Comparator|Engerix Group|Subjects received 3 doses of Engerix™ (Hepatitis B [HBV] vaccine) according to a 0, 1, 6-month schedule.
3276309|NCT00652925|Experimental|High Dose|
3276310|NCT00652925|Experimental|Low Dose|
3276311|NCT00652925|Active Comparator|Naproxen|Control comparator, 15 mg/kg/dy target dose
3276312|NCT00652912|Experimental|A|Subjects received the Kali formulated products under fasting conditions
3276313|NCT00652912|Active Comparator|B|Subjects received the Roche's product under fasting conditions
3276314|NCT00652899|Experimental|Total Body Irradiation|"This group includes patients that received all chemotherapy, infusion of natural killer (NK) cells and total body irradiation per protocol.~1. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m^2 on Days 6 through 2 preceding NK cell infusion. 4. Radiation: total-body irradiation 200 cGy Day 1 preceding NK cell infusion. 5. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 * 10^7/kg. 6. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0."
3276315|NCT00652899|Experimental|No Total Body Irradiation|"This group includes patients that received chemotherapy and infusion of natural killer cells, but did not receive total body irradiation.~1. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m^2 on Days 6 through 2 preceding NK cell infusion. 4. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 * 10^7/kg. 5. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0."
3276316|NCT00652886|Experimental|A|Subjects received Kali's products under fasting conditions
3276317|NCT00652886|Active Comparator|B|Subjects received BTG products under fasting conditions
3276318|NCT00652873|Experimental|A|Subjects received the test product, Cabergoline 0.5 mg tablets under fed conditions
3276319|NCT00652873|Active Comparator|B|Subjects received the reference product, Dostinex under fed conditions
3276320|NCT00652847|Experimental|group 1|group 1: ezetimibe 10 mg per day is added to actual statin regimen for 6 weeks followed by an observational phase of 6 months.
3276321|NCT00652847|Active Comparator|Group 2|Group 2: patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase.
3276322|NCT00652834|Other|kidney recipients with GI symptoms|This was a four-week study designed to investigate GI mucosal lesions by SBCE in kidney transplant recipients who were using MMF, and to examine the changes in clinical symptoms and intestinal mucosa lesions 30 days after switching over from MMF to EC-MPS. The patient was switched from MMF to EC-MPS (Myfortic) on the equimola basis.
3276323|NCT00652821|Experimental|A|Subjects received Kali product under fed condition
3276324|NCT00652821|Active Comparator|B|Subjects received Ortho-Mcneil product under fed conditions
3276325|NCT00652808|Active Comparator|Arm 1|
3276326|NCT00652808|Active Comparator|Arm 2|
3276327|NCT00652795|Experimental|A|Subjects received the Par product (Doxycycline Monohydrate) under fasting conditions.
3276328|NCT00652795|Active Comparator|B|Subjects received the Oclassen's product (Monodox) Capsules under fasting conditions.
3276329|NCT00652782|Experimental|1|rolofyline 2.5 mg IV QD
3276330|NCT00652782|Experimental|2|rolofyline 15 mg IV QD
3276331|NCT00652782|Experimental|3|rolofyline 30 mg IV QD
3276332|NCT00652782|Experimental|4|rolofyline 60 mg IV QD
3276333|NCT00652782|Placebo Comparator|5|placebo for rolofyline IV QD
3276334|NCT00652769|Active Comparator|B|Control arm: Current practice for diagnosing and staging lung cancer. Most patients with intra-thoracic disease suspected of lung cancer will undergo bronchoscopy (or CT guided biopsy), PET scan and possibly mediastinoscopy.
3276335|NCT00652769|Experimental|A|Active arm: A new pathway for the diagnosis and staging of lung cancer with endobronchial (EBUS) or endoscopic ultrasound (EUS) as a first test. If EBUS or EUS is negative the patient will have PET scan +/- mediastinoscopy.
3276336|NCT00652756|Experimental|1|Patient is placed on a transport ventilator.
3276337|NCT00652756|Other|2|Patient is ventilated using the current standard at this institution.
3276338|NCT00652743|Experimental|GSK1562902A M6 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) and boosted 6 months (M6) after primary vaccination with one dose of Pandemic influenza candidate vaccine (GSK1562902A) in study 109630 (NCT00449670), administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
3276339|NCT00652743|Experimental|GSK1562902A M12 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) in study 109630 (NCT00449670) receiving one dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, at 12 Months (M12) after the primary vaccination, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
3276340|NCT00652743|Experimental|GSK1562902A M36 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) in study 109630 (NCT00449670) receiving one dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, at 36 Months (M36) after the primary vaccination, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
3276341|NCT00652730|Experimental|A|Subjects received the Par formulated product under fasting conditions
3276342|NCT00652730|Experimental|B|Subjects received the Par formulated product under fed conditions
3276343|NCT00652730|Active Comparator|C|Subjects received the Bristol-Myers Squibb formulated product under fed conditions
3276345|NCT00652717|Active Comparator|2|arm 2- simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
3276346|NCT00652704|Experimental|A|Subjects received the test product, Doxycycline Monohydrate Capsules (Par) under fed conditions
3276347|NCT00652704|Active Comparator|B|Subjects received the reference product, Monodox (Oclassen) under fed conditions
3276348|NCT00652704|Experimental|C|Subjects received the test product, Doxycycline Monohydrate Capsules (Par) under fasting conditions
3276349|NCT00652665|Experimental|A|Subjects received kali product under fasting conditions
3276350|NCT00652665|Active Comparator|B|Subjects received Aventis product under fasting conditions
3276351|NCT00652639|Experimental|A|Subjects received the kali formulated products under fasting conditions
3276352|NCT00652639|Active Comparator|B|Subjects received the Roche formulated products under fasting conditions
3276353|NCT00652626|Experimental|Azacitidine 25 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 25 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
3276354|NCT00652626|Experimental|Azacitidine 50 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 50 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
3276355|NCT00652626|Experimental|Azacitidine 75 mg/m^2|Participants with normal renal function received subcutaneous doses of azacitidine 75 mg/m^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
3276356|NCT00652626|Experimental|Azacitidine 100 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 100 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
3276357|NCT00652626|Experimental|Severe RI: azacitidine 75 mg/m^2|Participants with severe renal impairment (RI; defined as creatinine clearance < 30 mL/min/1.73 m^2) received subcutaneous doses of azacitidine 75 mg/m^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
3276358|NCT00652613|Active Comparator|1|3 dimensional conformal radiotherapy
3276359|NCT00652613|Experimental|2|Intensity Modulated Radiation Therapy (IMRT)
3276360|NCT00652600|Experimental|A|Subjects received Par formulated product under fed conditions
3276361|NCT00652600|Active Comparator|B|Subjects received Wyeth Pharmaceuticals formulated product under fed conditions
3276362|NCT00652587|Experimental|A, LRTACE|hepatectomy with adjuvant transcatheter arterial chemoembolization
3276363|NCT00652587|Active Comparator|B, LR|hepatectomy alone
3276364|NCT00652574|Experimental|Dasatinib|Dasatinib = BMS-354825, Sprycel
3276365|NCT00652561|Experimental|1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks.
3276366|NCT00652522|Active Comparator|A|Best Medical Treatment, ICD/CRT implant
3276367|NCT00652522|Experimental|B|AF Ablation, ICD/CRT implant
3276368|NCT00652509|Experimental|1|IDEA
3276369|NCT00652509|Active Comparator|2|IE
3276370|NCT00652509|No Intervention|3|UC: Patients receive no research intervention.
3276371|NCT00652496|Experimental|1|Bimatoprost 0.01% ophthalmic solution
3276372|NCT00652496|Experimental|2|Bimatoprost 0.015% formulation 1 ophthalmic solution
3276373|NCT00652496|Experimental|3|Bimatoprost 0.015% formulation 2 ophthalmic solution
3276374|NCT00652496|Experimental|4|Bimatoprost 0.02% ophthalmic solution
3276375|NCT00652496|Active Comparator|5|Bimatoprost 0.03% ophthalmic solution
3276376|NCT00652483|Experimental|1|Brimonidine ophthalmic solution 0.1%
3276377|NCT00652483|Active Comparator|2|Brimonidine ophthalmic solution 0.2%
3276378|NCT00652470|Active Comparator|ETV|
3276379|NCT00652470|Active Comparator|CSF Shunt|
3276380|NCT00652457|Experimental|1|Memantine 10 mg BID for three months
3276381|NCT00652444|Experimental|1|Coadministration arm: simvastatin 20mg and ezetimibe 10mg
3276382|NCT00652444|Experimental|2|Monotherapy arm: simvastatin 20mg and ezetimibe placebo
3276383|NCT00652431|Experimental|Vytorin + Niaspan|NIASPAN 1000 mg (1 x 1000 mg tablet) once-daily in the morning on Days 1 to 2, followed by NIASPAN 2000 mg (2 x 1000 mg tablets) once-daily in the morning on Days 3 to 7 + VYTORIN 10/20 mg (1 x 10/20 mg tablet containing ezetimibe 10 mg and simvastatin 20 mg) once-daily in the morning for 7 days
3276384|NCT00652431|Active Comparator|Vytorin|VYTORIN 10/20 mg (1 x 10/20 mg tablet containing ezetimibe 10 mg and simvastatin 20 mg) once-daily in the morning for 7 days
3276385|NCT00652431|Active Comparator|Niaspan|NIASPAN 1000 mg (1 x 1000 mg tablet) once-daily in the morning on Days 1 to 2, followed by NIASPAN 2000 mg (2 x 1000 mg tablets) once-daily in the morning on Days 3 to 7 for a total of 7 days of treatment
3276386|NCT00652418|Active Comparator|Arm 1|
3276387|NCT00652418|Experimental|Arm 2|
3276388|NCT00652405|Experimental|treatment A|four weeks of white wine consumption (25g alcohol/day; ~2.5 standard drinks)
3276389|NCT00652405|Placebo Comparator|Treatment B|Four weeks of water
3276390|NCT00652392|Experimental|1|
3276391|NCT00652392|Placebo Comparator|2|
3276392|NCT00652379|Experimental|1|Co-treatment with Pegvisomant (15-30 mg twice a week) and a 50 percent reduced somatostatin-analog dose
3276393|NCT00652379|Active Comparator|2|Somatostatin analog, unaltered dosage
3276394|NCT00652366|Active Comparator|Gemcitabine, Erlotinib Standard Dose|Participants received erlotinib, 100 milligrams (mg), orally (PO), once daily until disease progression or unacceptable toxicity. Participants also received gemcitabine, 1000 mg per (/) square meter (m^2), intravenously (IV), on Days 1, 8, and 15 of consecutive 4 week cycles until disease progression or unacceptable toxicity.
3276537|NCT00651378|Active Comparator|Ezetimibe + Atorvastatin|
3276538|NCT00651378|Active Comparator|Double Atorvastatin|
3276539|NCT00651365|Experimental|001|
3276540|NCT00651352|Experimental|2 mg nicotine prototype|2 mg nicotine prototype
3276395|NCT00652366|Experimental|Gemcitabine, Erlotinib Escalating Dose|Participants received erlotinib, beginning at 150 mg/day, PO, once daily, and increasing in increments of 50 mg every 2 weeks up to a maximum of 250 mg/day, until development of a grade 2 rash, or occurrence of other, non-rash, dose-limiting toxicity; treatment was continued until disease progression, unacceptable toxicity, death or withdrawal. Participants also received gemcitabine, 1000 mg/m^2, IV, on Days 1, 8, and 15 of consecutive 4 week cycles until disease progression or unacceptable toxicity.
3276396|NCT00652353|Experimental|Intervention|Participants will be given a standardized information sheet providing a mnemonics to help remember the Ottawa Ankle and foot Rules.
3276397|NCT00652353|Placebo Comparator|0|control group
3276398|NCT00652340|Experimental|A|
3276399|NCT00652340|Placebo Comparator|B|
3276400|NCT00652327|Experimental|Ezetimibe + Statin|
3276401|NCT00652327|Active Comparator|Double Statin|
3276402|NCT00652314|Experimental|1 - Thrombi-gel treatment|Thrombi-gel treatment
3276403|NCT00652314|Active Comparator|2 - Gelatin Sponge (Gelfoam)|Gelatin Sponge (Gelfoam) plus thrombin
3276404|NCT00652301|Experimental|1|ezetimibe 10 mg tablet plus simvastatin 20 mg tablet
3276405|NCT00652301|Active Comparator|2|ezetimibe 10 mg tablet
3276406|NCT00652301|Active Comparator|3|simvastatin 20 mg tablet
3276407|NCT00652301|Placebo Comparator|4|matching placebo
3276408|NCT00652288|Active Comparator|Catheter day 4|Adolescents with type 1 diabetes with catheters day #4
3276409|NCT00652288|Active Comparator|Catheter day 1|Adolescents with type 1 diabetes with catheter day #1
3276410|NCT00652288|Active Comparator|Aspart and Detemir|Adolescents with type 1 diabetes
3276411|NCT00652288|Active Comparator|Lispro and Glargine|Adolescents with type 1 diabetes
3276412|NCT00652275|Experimental|A|"Biological/Vaccine: 189 volunteers will receive the Malaria vaccine MSP3 Long Synthetic Peptide (LSP)~Arms: MSP3 LSP vaccine Biological/Vaccine:MSP3 LSP 30 micrograms of MSP3 LSP~Arms: I, MSP3 LSP vaccine"
3276413|NCT00652275|Active Comparator|B|189 volunteers will receive standard vaccine against rabies on the similar schedule on days 0, 28, and 56
3276414|NCT00652262|Experimental|Arm 1|
3276415|NCT00652249||Extraventricular Drainage/Pressure|Includes pediatric hydrocephalus patients that are in recovery from shunt explanation.
3276416|NCT00652236||FCT|Patients passing a function- centred rehabilitation
3276417|NCT00652236||PCT|Patients passing a pain-centred rehabilitation
3276418|NCT00652223|Experimental|1|
3276419|NCT00652210|Experimental|MPM|Subject tissue was reviewed using multiphoton microscopy
3276420|NCT00652197||Extraventricular Drainage|Includes pediatric hydrocephalus patients that are in recovery from shunt explanation.
3276421|NCT00652184|Placebo Comparator|1|Placebo cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10
3276422|NCT00652184|Active Comparator|2|Placebo cream BID for 10 days and active valaciclovir caplets TID from days 1-10
3276423|NCT00652184|Experimental|3|Active cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10
3276424|NCT00652184|Other|4|Active cream BID for 10 days and active valaciclovir caplets TID from days 1-10
3276425|NCT00652171|Active Comparator|1|17 Patients - Mean age of 26 years old, 14 female and 3 male - with major depressive disorder in single or recurrent episodes, with moderate to severe intensity. Besides, They also had a history of treatment-resistant depression stage II or above according to the criteria of by Thase and Rush: failure to respond to treatment with at least 2 antidepressants of different classes, at the maximum tolerated dose for at least 6 weeks and absence of psychotic symptoms.
3276426|NCT00652171|Placebo Comparator|2|17 Patients - 11 females and 6 males mean age of 29 years old - with major depressive disorder in single or recurrent episodes, with moderate to severe intensity. Besides, They also had a history of treatment-resistant depression stage II or above according to the criteria of by Thase and Rush: failure to respond to treatment with at least 2 antidepressants of different classes, at the maximum tolerated dose for at least 6 weeks and absence of psychotic symptoms.
3276427|NCT00652158|Experimental|A|
3276428|NCT00652145|Experimental|Increase mesalamine dose by 2.4g/day|Increase dose of mesalamine by 2.4 gm per day
3276429|NCT00652145|No Intervention|Maintain mesalmine dose|Maintain current mesalamine dose at 2.4 g/day
3276430|NCT00652132|Active Comparator|Arm I (cisplatin)|Neoadjuvant and adjuvant cisplatin: patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
3276431|NCT00652132|Experimental|Arm II (cisplatin + STS)|Neoadjuvant and adjuvant cisplatin and sodium thiosulphate (STS): patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (beginning 6 hours after completion of cisplatin) on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (as in neoadjuvant therapy) on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
3276432|NCT00652119|Experimental|Paclitaxel + Carboplatin + Avastin|"Paclitaxel Cycle 1 = 60 mg/m^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m^2 IP weekly over 1 hour x 3 weeks of each cycle.~Carboplatin Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.~Avastin Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle."
3276433|NCT00652106|Experimental|1|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution
3276434|NCT00652106|Active Comparator|2|Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution
3276435|NCT00652106|Active Comparator|3|0.2% brimonidine ophthalmic solution
3276541|NCT00651352|Active Comparator|2 mg nicotine lozenge|marketed formulation
3276542|NCT00651352|Experimental|4 mg nicotine prototype|4 mg
3276543|NCT00651352|Active Comparator|4 mg nicotine lozenge|4 mg
3276544|NCT00651339||A|
3276436|NCT00652093|Experimental|Opana then darvocet then placebo|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
3276437|NCT00652093|Experimental|Opana then placebo then darvocet|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
3276438|NCT00652093|Experimental|Placebo then opana then darvocet|Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
3276439|NCT00652093|Experimental|Placebo then darvocet then opana|Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
3276440|NCT00652093|Experimental|Darvocet then opana then placebo|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
3276441|NCT00652093|Experimental|Darvocet then placebo then opana|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
3276442|NCT00652080|Experimental|1|Active Cream 3%; AM & PM
3276443|NCT00652067||1|Only one patient is being treated under a single patient IND.
3276444|NCT00652054|Experimental|1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks.
3276445|NCT00652041|Experimental|1|Induction: 6 alternating cycles Bortezomib-Melfalan-Prednisone or Bortezomib- Adriamycine-Melfalan-Prednisone and Thalidomide-Cyclophosphamide-Dexamethasone, followed by other 6 maintenance cycles
3276446|NCT00652028|Other|Group 1|Dose level 1
3276447|NCT00652028|Other|Group 2|Dose level 2
3276448|NCT00652028|Other|Group 3|Dose level 3
3276449|NCT00652028|Other|Group 4|Dose level 4
3276450|NCT00652015||1|Patients having developed an in-stent-thrombosis (40 SAT, 40 LT)
3276451|NCT00652015||2|Patients having not developed an in-stent-thrombosis after stent implantation using PTCA
3276452|NCT00652002|Experimental|1|
3276453|NCT00652002|Active Comparator|2|budesonide
3276454|NCT00652002|Active Comparator|3|formoterol
3276455|NCT00651989||A|healthy individuals
3276456|NCT00651976|Experimental|treatment|
3276457|NCT00651950||Operator Dependence|
3276458|NCT00651937|Active Comparator|Standard Dose|Melphalan + Stem Cell Infusion (Standard Dose): Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10^6 cluster of differentiation 34 (CD34)/kg on Day 0. Melphalan 100 mg/m^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion. Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days. Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
3276459|NCT00651937|Active Comparator|High Dose|Melphalan + Stem Cell Infusion (High Dose): High Dose (Arm 2) = Stem cell dose of between 10-15 x 10^6 CD34/kg On Day 0. Melphalan 100 mg/m^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion. Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days. Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
3276460|NCT00651924|No Intervention|Phase 1|Review the materials and provide feedback regarding how understandable, engaging, and informative the materials are
3276461|NCT00651924|Experimental|Phase 2|Piloting the 'IVR-based Cognitive-behavior therapy' using the new materials
3276462|NCT00651898||A|This group will receive the circulating water garment
3276463|NCT00651898||B|This group will receive the circulating water mattress and be covered by a forced air warming device for both the upper body and lower body connected to two warmers.
3276464|NCT00651885|Placebo Comparator|2 arm|
3276465|NCT00651885|Experimental|1 arm|treprostinil dienthalomine
3276466|NCT00651872||Marx|
3276467|NCT00651859|Experimental|1|Bimatoprost 0.01% Ophthalmic Solution
3276468|NCT00651859|Experimental|2|Bimatoprost 0.03% Ophthalmic Solution
3276469|NCT00651859|Placebo Comparator|3|Bimatoprost Vehicle Ophthalmic Solution
3276470|NCT00651846|Experimental|Arm 1|
3276471|NCT00651846|Active Comparator|Arm 2|
3276472|NCT00651833|Experimental|1|All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. Patient will also receive cisplatin, 75 mg/m2 as a 1- to 3-hour infusion on Day 1 of each cycle.
3276473|NCT00651820|Experimental|Collagenase Santyl Rate of Wound Closure|Dermatome-induced skin wounds treated with drug active (collagenase).
3276474|NCT00651820|Placebo Comparator|Vehicle Rate of Wound Closure|Dermatome-induced skin wounds treated with Vehicle alone.
3276475|NCT00651807|Active Comparator|Arm 1|etonogestrel
3276476|NCT00651807|Placebo Comparator|Arm 2|Placebo
3276477|NCT00651794|Active Comparator|Control (NRP Curriculum with LFT and no team training)|Standard Neonatal Resuscitation Program (NRP) curriculum with no team training; simulated resuscitation using low-fidelity simulators for low-fidelity training (LFT)
3276478|NCT00651794|Experimental|NRP with LFT and team training|Standard Neonatal Resuscitation Program (NRP) curriculum + team training; simulated resuscitation using low-fidelity simulators for low-fidelity training (LFT)
3276479|NCT00651794|Experimental|NRP with HFT and team training|Standard Neonatal Resuscitation Program (NRP) curriculum + team training; simulated resuscitations using high-fidelity simulators for high-fidelity training (HFT)
3276480|NCT00651781|Experimental|1|"Phase I:3 dose levels Cytarabine (200 mg/m2- 500 mg/m2-1000 mg/m2) with scheme Flag-Ida in combination with Velcade until determinate the appropriate dose.~Phase II:~Fludarabine, Cytarabine and Idarubicin in combination with 2 times per week of Velcade administration. Each 28-day treatment, patients will be evaluated, and in absence of disease progression or unacceptable toxicity, patients will start second cycle with Bortezomib in monotherapy two times per week followed by a 10 days rest period. That is, patients who response with acceptable toxicity will receive the combined sequential scheme twice (as induction and consolidation)."
3276481|NCT00651768|Experimental|1|
3276482|NCT00651768|Sham Comparator|2|
3276483|NCT00651755|Experimental|Aprepitant + CHOP/R-CHOP|Aprepitant 125 mg oral (PO) Day 1 of Cycle 1 followed by 80 mg PO Daily Days 2-3 with CHOP (steroid in CHOP) or R-CHOP plus Rituximab 375 mg/m^2 intravenous Day 1. CHOP or R-CHOP chemotherapy: (1) bolus or 48-hour infusion CHOP [cyclophosphamide 750 mg/m^2 IV Day 1, doxorubicin 25 mg/m^2/day IV given bolus or over 48 hours continuous infusion Days 1-2, vincristine 2 mg IV Day 1, prednisone PO 100 mg * 5 days]; or (2) Bolus or 48-hour infusion R-CHOP [Rituximab 375 mg/m^2 on Day 1 + CHOP as above]. [For patients receiving R-CHOP, CHOP may be administered starting on Day 2 at the discretion of the treating physician]
3276484|NCT00651755|Experimental|Standard of Care (Control) + CHOP/R-CHOP|Anti-emetics, Ondansetron 8 mg daily for 2 days, plus steroids in CHOP or R-CHOP regimen.
3276485|NCT00651742|Experimental|1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks.
3276486|NCT00651729|Experimental|1|Botulinum Toxin Type A
3276487|NCT00651716||Allogeneic Stem Cell Transplant Patients|Patients undergoing allogeneic stem cell transplant (SCT). Potential study candidates will be identified by participating physicians.
3276488|NCT00651703|Experimental|1|
3276489|NCT00651703|Experimental|2|
3276490|NCT00651703|Experimental|3|
3276491|NCT00651703|Experimental|4|
3276492|NCT00651690|Experimental|1|Botulinum Toxin Type A
3276493|NCT00651690|Placebo Comparator|2|Saline
3276494|NCT00651677|Active Comparator|HAL Proctectomy|Hand-assisted laparoscopic proctectomy
3276495|NCT00651677|Active Comparator|SL Proctectomy|"straight laparoscopic proctectomy"
3276496|NCT00651664|Experimental|1|MLN8237
3276497|NCT00651651|Experimental|1|Symbicort
3276498|NCT00651651|Active Comparator|2|budesonide
3276499|NCT00651651|Active Comparator|3|formoterol
3276500|NCT00651625|Experimental|1|The intervention is the use of the reciprocating procedure device (RPD) (AVANCA Re No. 1091001) (intervention) (Arm 1) with and without ultrasound guidance (intervention) in a syringe and needle procedure in comparison to a conventional syringe (BD Ref 309604) (control, Arm 2).
3276501|NCT00651625|Active Comparator|2|The conventional syringe (BD Ref 309604) is used to performed the syringe and needle procedure and outcome (effect of procedure (pain scores at 2 weeks and 6 months compared to preprocedural pain scores), and procedural pain (pain scores during procedure) are determined) and compared to Arm 1.
3276502|NCT00651612|Experimental|1|Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
3276503|NCT00651612|Active Comparator|2|Concurrent Brimonidine 0.2% and 0.5% Timolol
3276504|NCT00651599|Placebo Comparator|Arm 2|
3276505|NCT00651599|Experimental|Arm 1|
3276506|NCT00651586|Experimental|1|Gatifloxacin 0.3% ophthalmic solution
3276507|NCT00651586|Active Comparator|2|Ciprofloxacin 0.3% ophthalmic solution
3276508|NCT00651573|Active Comparator|1|Red blood cell transfusion will be given when hematocrit values fall below the assigned group 1 value which is 24%. When the hematocrit value falls to less 25%,a 1 unit RBC transfusion will be administered. Following administration of the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to transfusion and is greater than or equal to 25%, no further transfusions will be administered.
3276509|NCT00651573|Active Comparator|2|Red blood cell transfusion will be given when hematocrit values fall below the assigned group 1 value which is 28%. When the hematocrit value falls to less 28%,a 1 unit RBC transfusion will be administered. Following administration of the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to transfusion and is greater than or equal to 85%, no further transfusions will be administered.
3276510|NCT00651547|Experimental|1|
3276511|NCT00651547|Active Comparator|2|
3276512|NCT00651547|Active Comparator|3|
3276513|NCT00651521||1|CKD stage 1 patients
3276514|NCT00651521||2|CKD stage 2 patients
3276515|NCT00651521||3|CKD stage 3a patients
3276516|NCT00651521||4|CKD stage 3b patients
3276517|NCT00651521||5|CKD stage 4 patients
3276518|NCT00651521||6|CKD stage 5 patients
3276519|NCT00651508|Experimental|Single Arm 25mg/m2|KOS-1584 25mg/m2
3276520|NCT00651495|Experimental|1|Participants receive a $50 financial incentive if they view at least 3 of 5 patient decision aids in a group screening.
3276521|NCT00651495|Active Comparator|2|No financial incentive for watching patient decision aids in group screenings
3276522|NCT00651482|Experimental|Bevacizumab + RAD001 (everolimus)|"Study treatment, consisting of bevacizumab + everolimus, was administered as 28-day cycles~Bevacizumab 10 mg/kg administered by IV infusion every 14 days (dose suspension permitted, dose reduction not permitted)~Everolimus 10 mg daily was administered orally (dose reduction to 5 mg daily and then 5 mg every other day, was permitted as needed for toxicity or tolerability)"
3276523|NCT00651469|Experimental|Arm 1|
3276524|NCT00651469|Placebo Comparator|Arm 2|
3276525|NCT00651456|Active Comparator|1|Standard Chemotherapy
3276526|NCT00651456|Experimental|2|Standard Chemotherapy + bevacizumab (Avastin)
3276527|NCT00651443|Experimental|1|
3276528|NCT00651430||A|
3276529|NCT00651417|Active Comparator|1|Organic Germanium tablets 5 times a day
3276530|NCT00651417|Placebo Comparator|2|Placebo tablets 3 -5 times per day
3276531|NCT00651404|Experimental|Ezetimibe|
3276532|NCT00651404|Placebo Comparator|Placebo|
3276533|NCT00651391|Experimental|Ezetimibe + Simvastatin|
3276534|NCT00651391|Active Comparator|Simvastatin|
3276535|NCT00651391|Placebo Comparator|Placebo|
3276536|NCT00651378|Experimental|Rosuvastatin|
3276545|NCT00651326|Active Comparator|Antiandrogen; LHRH; Docetaxel, Radiation Therapy|Antiandrogen (Flutamide or Bicalutamide) LHRH agonist (Eligard) Docetaxel
3276546|NCT00651326|Active Comparator|Antiandrogen; LHRH; Radiation Therapy|Antiandrogen (Flutamide or Bicalutamide) LHRH agonist (Eligard)
3276547|NCT00651313|Active Comparator|Active|Lidocaine 10% (150mg) vaginal gel
3276548|NCT00651313|Placebo Comparator|Placebo|Placebo vaginal gel
3276549|NCT00651300|Experimental|Group 1|
3276550|NCT00651300|Placebo Comparator|Group 2|
3276551|NCT00651287|Active Comparator|quinapril 20 mg|
3276552|NCT00651287|Active Comparator|quinapril 20 mg+hydrochlorothiazide 12.5 mg|
3276553|NCT00651287|Active Comparator|quinapril 40 mg|
3276554|NCT00651274|Experimental|Ezetimibe|
3276555|NCT00651274|Placebo Comparator|Placebo|
3276556|NCT00651261|Experimental|Induction and consolidation chemotherapy plus midostaurin|Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and the experimental drug midostaurin. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with the experimental drug midostaurin. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with midostaurin for twelve (12) months.
3276557|NCT00651261|Active Comparator|Induction and consolidation chemotherapy plus placebo|Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and placebo. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with placebo. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with placebo for twelve (12) months.
3276558|NCT00651235|Experimental|B|In combination therapy,the maximal dose of Losartan is 100 mg/day for adult and 50 mg/day for children. 50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children
3276559|NCT00651235|Active Comparator|A|The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
3276560|NCT00651222||1|All deceased patients who underwent brachytherapy at Chicago Prostate Center between 10/14/1997 and 6/15/2007
3276561|NCT00651209|Experimental|1|Sub-group 1- continue telbivudine if HBV DNA non-detectable at week 24 Sub-group 2- tenofovir added to telbivudine in patients if HBV DNA detectable at week 24
3276562|NCT00651196||1|Type 1 diabetics
3276563|NCT00651196||Healthy controls|Healthy age and sex matched controls
3276564|NCT00651157|Experimental|Treatment (viral therapy)|Patients receive wild-type reovirus (Reolysin®) IV administered at a dose of 3 x 10^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3276565|NCT00651144|Experimental|Ezetimibe + Rosuvastatin|
3276566|NCT00651144|Active Comparator|Ezetimibe|
3276567|NCT00651144|Active Comparator|Rosuvastatin|
3276568|NCT00651144|Placebo Comparator|Placebo|
3276569|NCT00651118|Active Comparator|fluticasone propionate|
3276570|NCT00651118|Experimental|azelastineHcl/fluticasone propionate|
3276571|NCT00651118|Placebo Comparator|Placebo|
3276572|NCT00651118|Active Comparator|azelastine Hcl|
3276573|NCT00651105|Experimental|1|
3276574|NCT00651105|Placebo Comparator|2|
3276575|NCT00651092|Active Comparator|A1|since the two methods of turbinectomy are in used on a regular basis there is no way to perform double blind study- both the surgeon and the patients are well aware of the operation they are about to go. we just compare several parameters in patients who are anyway about to undergo an operation in a specific method that is used by their surgeon
3276576|NCT00651092|Active Comparator|A2|the resection of the inferior turbinates will be performed endonasally with an endoscopical instruments
3276577|NCT00651066|Experimental|1|RBT (150 mg TPW during 3 weeks switch to 150mg OD for the following 3 weeks) associated with LPV/r based ART
3276578|NCT00651066|Experimental|2|RBT (150 mg OD during 3 weeks switch to 150mg TPW for the following 3 weeks) associated with LPV/r based ART
3276579|NCT00651040|Active Comparator|Prednison|"Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms.~ARM 1 has only Prednisone"
3276580|NCT00651040|Active Comparator|Prednison + methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
3276581|NCT00651027|Experimental|A|
3276582|NCT00651027|Experimental|B|
3276583|NCT00651027|Experimental|C|200 mg
3276584|NCT00651014|Experimental|Ezetimibe|
3276585|NCT00651014|Placebo Comparator|Placebo|
3276586|NCT00650988|Experimental|Barrett's Esophagus with intramucosal carcinoma (IMCA)|
3276587|NCT00650988|Experimental|Barrett's Esophagus with High Grade Dysplasia (HGD)|
3276588|NCT00650975|Active Comparator|ELCA|Laser Thromboablation
3276589|NCT00650975|Active Comparator|PTCA|PTCA (Direct Stenting)
3276590|NCT00650962|Active Comparator|CPR first|Compression First (CF)
3276591|NCT00650962|Active Comparator|Analysis First|Rhythm analysis first
3276592|NCT00650949|Experimental|CYT997|
3276593|NCT00650936|Experimental|I|
3276594|NCT00650923|Experimental|Arm 1|See Detailed Description
3276649|NCT00650520|Experimental|1|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL)and BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
3277232|NCT00646685|Other|2|
3276595|NCT00650910|Experimental|lapatinib + digoxin|All subjects received 0.5mg digoxin on Days 1 and 9 with daily dosing of 1500mg oral lapatinib starting on Day 2 and continuing through Day 9. Subjects could continue past Day 9 on daily oral lapatinib until Week 10 when they could transfer into a rollover study (EGF19060 or EGF111767).
3276596|NCT00650897|Experimental|A|Patients with Diabetes Mellitus and Major Depression
3276597|NCT00650884|No Intervention|1|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). CONTROL PATIENTS will only be treated with Standard of Care during this 12 week trial, but will also be treated with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch after completion of this study.
3276598|NCT00650884|Experimental|2|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). EXPERIMENTAL PATIENTS will also be treated with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch while sleeping.
3276599|NCT00650884|Other|3|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). CROSS-OVER patients will be initially treated only with Standard of Care, and after six weeks, they will be Crossed-Over and fit with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch while sleeping.
3276600|NCT00650858|Active Comparator|0.3 mg rt-PA|In stage 1 of the protocol, dose finding, subjects were randomized to either this 0.3 mg dose arm or the 1.0 mg dose arm. Subjects in this arm (0.3 mg) received up to 8 doses of 0.3 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.
3276601|NCT00650858|Active Comparator|1.0 mg rt-PA|In stage 1 of the protocol, dose finding, subjects were randomized to either this 1.0 mg dose arm or the 0.3 mg dose arm. Subjects in this arm (1.0 mg) received up to 8 doses of 1.0 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.
3276602|NCT00650858|Experimental|1.0 mg Rt-PA q8h|In stage 2 of the protocol, dose frequency, subjects received up to 8 doses of 1.0 mg of rt-PA (Cathflo) every 8 hours through the intraventricular catheter to treat intraventricular hemorrhage.
3276603|NCT00650845|Experimental|Dotarem®-enhanced MRI|Patients undergoing Dotarem®-enhanced MRI for diagnostic purposes
3276604|NCT00650845|Other|Non-enhanced MRI|Patients undergoing non-enhanced MRI for diagnostic purposes
3276605|NCT00650819|Experimental|Ezetimibe + Simvastatin|
3276606|NCT00650819|Active Comparator|Simvastatin|
3276607|NCT00650819|Active Comparator|Ezetimibe|
3276608|NCT00650806|Experimental|Canagliflozin 50 mg|Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
3276609|NCT00650806|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
3276610|NCT00650806|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
3276611|NCT00650806|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 12 weeks.
3276612|NCT00650780||1|All of the subjects will have measurements of Gc concentration and phenotype
3276613|NCT00650767|Experimental|ARRY-438162 (Schedule 1)|
3276614|NCT00650767|Experimental|ARRY-438162 (Schedule 2)|
3276615|NCT00650767|Experimental|ARRY-438162 (Schedule 3)|
3276616|NCT00650767|Placebo Comparator|Placebo|
3276617|NCT00650754|Experimental|DHEA|Dehydroepiandrosterone (DHEA) administered at a dose of 25 mg tid po. DHEA is a weak androgen produced naturally by the adrenal in men and women. DHEA production is diminished with increasing age. Peak levels of DHEA occur in the late teenage years.
3276618|NCT00650754|Placebo Comparator|Placebo|Blinded placebo
3276619|NCT00650741||1|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), no repetition of test
3276620|NCT00650741||2|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), Repetition with Nitroglycerin
3276621|NCT00650741||3|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), repetition of test with the Endotect
3276622|NCT00650715|Active Comparator|VG|Vibration Group (VG) underwent a protocol with whole-body vibration exercise twice a week for a total of six weeks. The group continued with their usual pharmacological treatment.
3276623|NCT00650715|Placebo Comparator|CG|The Control Group (CG) underwent the same protocol of exercises than VG but without vibratory stimulus. The CG continued with their usual pharmacological treatment.
3276624|NCT00650702|Experimental|1|Low Latanoprost-PPDS
3276625|NCT00650702|Experimental|2|Medium Latanoprost-PPDS
3276626|NCT00650702|Experimental|3|High Latanoprost-PPDS
3276627|NCT00650689|Experimental|Ezetimibe + Atorvastatin|
3276628|NCT00650689|Active Comparator|Atorvastatin|
3276629|NCT00650676||A|
3276630|NCT00650663|Experimental|Ezetimibe + Simvastatin|
3276631|NCT00650663|Active Comparator|Simvastatin|
3276632|NCT00650637|Experimental|1|
3276633|NCT00650637|Experimental|2|
3276634|NCT00650624|Active Comparator|Arm 1|
3276635|NCT00650624|Active Comparator|Arm 2|
3276636|NCT00650624|Active Comparator|Arm 3|
3276637|NCT00650624|Placebo Comparator|Arm 4|
3276638|NCT00650611|Active Comparator|Low-Dose Ziprasidone|
3276639|NCT00650611|Active Comparator|High-Dose Ziprasidone|
3276640|NCT00650598|Active Comparator|Arm 1|
3276641|NCT00650598|Active Comparator|Arm 2|
3276642|NCT00650585|No Intervention|Control group|Did not receive Project ALERT
3276643|NCT00650585|Experimental|Treatment group|Received Project ALERT
3276644|NCT00650572|Experimental|ARRY-380|
3276645|NCT00650559|Experimental|1|Experimental surgical intervention.
3276646|NCT00650546|Experimental|A pre treatment NAS score|liver biopsy score pre treatment with exenatide 5 micrograms SQ (sub-cutaneous) twice a day titrated to 10 mcg SQ twice a day as tolerated
3276647|NCT00650533|Experimental|1|Glimepiride Tablets 1 mg
3276648|NCT00650533|Active Comparator|2|Amaryl® Tablets 1 mg
3276716|NCT00650091|Active Comparator|1|Participants will receive N-acetylcysteine (NAC) for 60 weeks.
3276650|NCT00650520|Active Comparator|2|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL) and Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
3276651|NCT00650507|Experimental|1|
3276652|NCT00650507|Active Comparator|2|
3276653|NCT00650494|Experimental|1|Valacyclovir Hydrochloride Tablets 1000mg
3276654|NCT00650494|Active Comparator|2|Valtrex® Tablets 1000 mg
3276655|NCT00650481|Experimental|1|Oxybutynin Chloride Extended-release Tablets 5 mg
3276656|NCT00650481|Active Comparator|2|Ditropan XL® Tablets 5 mg
3276657|NCT00650468|Experimental|1|early steroid cessation
3276658|NCT00650468|Experimental|2|long-term maintenance steroids
3276659|NCT00650455|Active Comparator|Arm 2|
3276660|NCT00650455|Placebo Comparator|Arm 3|
3276661|NCT00650455|Active Comparator|Arm 1|
3276662|NCT00650442|Experimental|1|Estradiol Transdermal System Placebo - Alternate Adhesive
3276663|NCT00650442|Placebo Comparator|2|Estradiol Transdermal System Placebo - Current Adhesive
3276664|NCT00650429|Experimental|Arm A|
3276665|NCT00650416|Experimental|1|Carvedilol Tablets 12.5 mg
3276666|NCT00650416|Active Comparator|2|Coreg® Tablets 12.5 mg
3276667|NCT00650403|Experimental|1|Paroxetine hydrochloride 40 mg tablet
3276668|NCT00650403|Active Comparator|2|Paxil® 40 mg Tablet
3276669|NCT00650377|Experimental|1|Finasteride Tablets 5 mg
3276670|NCT00650377|Active Comparator|2|Proscar® Tablets 5 mg
3276671|NCT00650364|Experimental|1|Midodrine HCl Tablets 5 mg
3276672|NCT00650364|Active Comparator|2|ProAmatine® Tablets 5 mg
3276673|NCT00650351|Experimental|1|Ciprofloxacin Extended-Release Tablets 1000 mg
3276674|NCT00650351|Active Comparator|2|Cipro® XR Tablets 1000 mg
3276675|NCT00650338|Experimental|1|<described in intervention>
3276676|NCT00650338|Experimental|2|<described in intervention>
3276677|NCT00650338|Experimental|3|<described in intervention>
3276678|NCT00650338|Placebo Comparator|4|<described in intervention>
3276679|NCT00650338|Active Comparator|5|<described intervention>
3276680|NCT00650325|Experimental|1|Sertraline Hydrochloride Tablets 100 mg
3276681|NCT00650325|Active Comparator|2|Zoloft® Tablets 100 mg
3276682|NCT00650312|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
3276683|NCT00650312|Active Comparator|2|Glucophage® XR Tablets 500 mg
3276684|NCT00650299|Experimental|1|Alprazolam Extended-release Tablets 3 mg
3276685|NCT00650299|Active Comparator|2|Xanax XR® Tablets 3 mg
3276686|NCT00650286|Experimental|1|Modafinil Tablets 200 mg
3276687|NCT00650286|Active Comparator|2|Provigil® Tablets 200 mg
3276688|NCT00650273|Experimental|1|Azithromycin Tablets 600 mg
3276689|NCT00650273|Active Comparator|2|Zithromax® Tablets 600 mg
3276690|NCT00650260|Experimental|vH2 System Group|The vital heat vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical. The vital heat vH2 System will be used for patient warming during these surgical procedures. Monitoring of core temperature via esophageal probe will be done for the purpose of data collection.
3276691|NCT00650260|Active Comparator|Control Group|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket. The Bair Hugger System is the site's current approach to patient warming during these surgical procedures. Monitoring of core temperature via esophageal probe will be done for the purpose of data collection.
3276692|NCT00650247|Experimental|1|Sumatriptan Succinate Tablets 100 mg
3276693|NCT00650247|Active Comparator|2|Imitrex® Tablets 100 mg
3276694|NCT00650234|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
3276695|NCT00650234|Active Comparator|2|Glucophage® XR Tablets 500 mg
3276696|NCT00650221|Experimental|1|
3276697|NCT00650221|Active Comparator|2|
3276698|NCT00650208|Experimental|1|Lamotrigine Tablets 25 mg
3276699|NCT00650208|Active Comparator|2|Lamictal® Tablets 25 mg
3276700|NCT00650195|Experimental|1|Metolazone Tablets 10 mg
3276701|NCT00650195|Active Comparator|2|Zaroloxyn® Tablets 10 mg
3276702|NCT00650169|Experimental|1|Clopidogrel Bisulfate Tablets 75 mg
3276703|NCT00650169|Active Comparator|2|Plavix® Tablets 75 mg
3276704|NCT00650156|Experimental|40 mg adalimumab|
3276705|NCT00650156|Experimental|80 mg Adalimumab|
3276706|NCT00650143|Active Comparator|1|"Application G-CSF (10µg/kg/d divided in two doses subcutaneously) over a period of 5 days and Sitagliptin 100 mg each day for 28 days.~n=74"
3276707|NCT00650143|Placebo Comparator|2|"NaCl 0.9% applied twice daily over a period of 5 days and oral Placebo given once a day for 28 days.~n=74"
3276708|NCT00650130||1|drivers of motorised vehicles suspected of being under the influence of psychoactive drugs
3276709|NCT00650117|Experimental|1|Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)
3276710|NCT00650117|Experimental|2|Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
3276711|NCT00650117|Experimental|3|Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)
3276712|NCT00650117|Experimental|4|Duragesic 25 mcg/h + Scotch Duct Tape (3M)
3276713|NCT00650117|Experimental|5|Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
3276714|NCT00650117|Experimental|6|Duragesic 25 mcg/h + Microfoam Tape (3M)
3276715|NCT00650104|Active Comparator|Active|Open label medication - Ropinirole CR
3276718|NCT00650078|Experimental|NP01|Modified Release (MR) prednisone 5 mg
3276719|NCT00650078|Placebo Comparator|Placebo|
3276720|NCT00650065|Experimental|1|Cetirizine HCl Tablets 10 mg
3276721|NCT00650065|Active Comparator|2|Zyrtec® Tablets 10 mg
3276722|NCT00650052|Experimental|1|Zonisamide Capsules 100 mg
3276723|NCT00650052|Active Comparator|2|Zonegran® Capsules 100 mg
3276724|NCT00650039|Active Comparator|Arm 1|
3276725|NCT00650039|Active Comparator|Arm 2|
3276726|NCT00650039|Placebo Comparator|Arm 3|
3276727|NCT00650013|Experimental|1|Midodrine HCl Tablets 5 mg
3276728|NCT00650013|Active Comparator|2|ProAmatine® Tablets 5 mg
3276729|NCT00650000|Experimental|1|Modafinil Tablets 200 mg
3276730|NCT00650000|Active Comparator|2|Provigil® Tablets 200 mg
3276731|NCT00649987|Experimental|1|Albuterol Sulfate Extended-Release Tablets 8 mg
3276732|NCT00649987|Active Comparator|2|VoSpire® ER Tablets 8 mg
3276733|NCT00649974|Experimental|1|Valacyclovir Hydrochloride Tablets 1000 mg
3276734|NCT00649974|Active Comparator|2|Valtrex® Tablets 1000 mg
3276735|NCT00649948|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
3276736|NCT00649948|Active Comparator|2|Glucophage XR 500 mg
3276737|NCT00649935|Experimental|1|Azithromycin Tablets 600 mg
3276738|NCT00649935|Active Comparator|2|Zithromax® Tablets 600 mg
3276739|NCT00649922|Placebo Comparator|Double Blind|
3276740|NCT00649922|Experimental|Open Label|
3276741|NCT00649909||Observation|Type 2 diabetic patients with reduced laboratory response to aspirin.(Aspirin Resistance)and with HbA1c >8%.
3276742|NCT00649896|Experimental|1|Mylan Estradiol Transdermal System 0.025 mg/day
3276743|NCT00649896|Active Comparator|2|Climara® Transdermal System 0.025 mg/day
3276744|NCT00649883|Experimental|1|
3276745|NCT00649883|Active Comparator|2|
3276746|NCT00649870|Experimental|1|Valacyclovir Hydrochloride Tablets 1000 mg
3276747|NCT00649870|Active Comparator|2|Valtrex® Tablets 1000 mg
3276748|NCT00649857|Experimental|1|Cetirizine HCl Tablets 10 mg
3276749|NCT00649857|Active Comparator|2|Zyrtec® 10 mg
3276750|NCT00649844|Active Comparator|A|
3276751|NCT00649844|Experimental|B|
3276752|NCT00649831|Active Comparator|Group 2|
3276753|NCT00649831|Active Comparator|Group 1|
3276754|NCT00649818|Experimental|1|Lorazepam Tablets 2 mg
3276755|NCT00649818|Active Comparator|2|Ativan Tablets 2 mg
3276756|NCT00649805|Experimental|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
3276757|NCT00649805|Active Comparator|2|Verelan® PM extended-release capsules controlled-onset 300 mg
3276758|NCT00649779|Experimental|1|albuterol sulfate extended-release 8 mg tablets
3276759|NCT00649779|Active Comparator|2|VoSpire™ ER 8 mg tablets
3276760|NCT00649766|Active Comparator|1|tailored print messages to encourage eye examination behavior
3276761|NCT00649766|Active Comparator|2|targeted print messages to encourage eye examination behavior
3276762|NCT00649753|No Intervention|A|
3276763|NCT00649753|Experimental|B|
3276764|NCT00649753|Experimental|C|
3276765|NCT00649753|Experimental|D|
3276766|NCT00649740|Experimental|1|Topiramate Sprinkle Capsules 25 mg
3276767|NCT00649740|Active Comparator|2|Topamax® Sprinkle Capsule 25 mg
3276768|NCT00649727|Experimental|1|Oxybutynin Chloride ER Tablets 10 mg
3276769|NCT00649727|Active Comparator|2|Ditropan XL® Tablets 10 mg
3276770|NCT00649714|Experimental|1|Zonisamide Capsules 100 mg
3276771|NCT00649714|Active Comparator|2|Zonegran® Capsules 100 mg
3276772|NCT00649701|No Intervention|1|
3276773|NCT00649701|Experimental|2|Text-based webpage
3276774|NCT00649701|Experimental|3|Talking about HIV video
3276775|NCT00649701|Experimental|4|The Morning After video
3276776|NCT00649701|Experimental|5|Both videos
3276777|NCT00649688|Experimental|1|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
3276778|NCT00649688|Active Comparator|2|Lopressor HCT® Tablets 100/50 mg
3276779|NCT00649675|Experimental|1|Meloxicam Tablets 15 mg
3276780|NCT00649675|Active Comparator|2|Mobic® Tablets 15 mg
3276781|NCT00649662|Experimental|1|Ciprofloxacin Extended-Release Tablets 1000 mg
3276782|NCT00649662|Active Comparator|2|Cipro® XR Tablets 1000 mg
3276783|NCT00649649|Experimental|1|Quinapril Hydrochloride Tablets 40 mg
3276784|NCT00649649|Active Comparator|2|Accupril® Tablets 40 mg
3276785|NCT00649636|Experimental|1|Fluoxetine Capsules 40 mg
3276786|NCT00649636|Active Comparator|2|Prozac Pulvules 40 mg
3276787|NCT00649623|Experimental|1|Olmesartan Medoxomil Tablets 40 mg
3276788|NCT00649623|Active Comparator|2|Benicar® Tablets 40 mg
3276789|NCT00649610|Active Comparator|Arm 1|
3276790|NCT00649610|Active Comparator|Arm 2|
3276791|NCT00649597|Experimental|1|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
3276792|NCT00649597|Active Comparator|2|Lotensin HCT® Tablets 20 mg/25 mg
3276793|NCT00649584|Experimental|1|SGN-35 alone or in combination with gemcitabine
3276794|NCT00649571|Experimental|1|Doxycycline Monohydrate Tablets 100 mg
3276795|NCT00649571|Active Comparator|2|Adoxa Tablets 100 mg
3276796|NCT00649558|Experimental|1|Pioglitazone HCl Tablets 45 mg
3276797|NCT00649558|Active Comparator|2|Actos® Tablets 45 mg
3276798|NCT00649532|Experimental|1|Ondansetron Tablets 24 mg
3276799|NCT00649532|Active Comparator|2|Zofran® Tablets 24 mg
3276800|NCT00649519|Experimental|1|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
3276801|NCT00649519|Active Comparator|2|Lotrel® Capsules 10 mg/20 mg
3276802|NCT00649506|Experimental|1|Nitrofurantoin Macrocrystals 100 mg Capsules
3276803|NCT00649506|Active Comparator|2|Macrodantin® 100 mg Capsules
3276804|NCT00649493|Experimental|1|Rabeprazole Sodium Tablets 20 mg
3276805|NCT00649493|Active Comparator|2|Aciphex® Tablets 20 mg
3276806|NCT00649480|Experimental|1|BALSALAZIDE DISODIUM CAPSULES, 750 MG
3276807|NCT00649480|Active Comparator|2|COLAZAL® Capsules 750 mg
3276808|NCT00649467|Experimental|1|Topiramate Sprinkle Capsules 25 mg
3276809|NCT00649467|Active Comparator|2|Topamax® Sprinkle Capsules 25 mg
3276810|NCT00649454|Experimental|1|Glipizide and Metformin HCl Tablets 5 mg/500 mg
3276811|NCT00649454|Active Comparator|2|Metaglip® Tablets 5 mg/500 mg
3276812|NCT00649441|Experimental|1|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
3276813|NCT00649441|Active Comparator|2|Accuretic™ Tablets 20 mg/25 mg
3276814|NCT00649428|Experimental|Active|
3276815|NCT00649428|Placebo Comparator|Control|
3276816|NCT00649415|Active Comparator|Arm 1|
3276817|NCT00649415|Active Comparator|Arm 2|
3276818|NCT00649402|Experimental|1|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
3276819|NCT00649402|Active Comparator|2|Lotrel® Capsules 10 mg/20 mg
3276820|NCT00649389|Experimental|OM40/AML10|olmesartan medoxomil 40mg and amlodipine 10mg
3276821|NCT00649389|Active Comparator|OM40/HCTZ25|olmesartan medoxomil 40mg and hydrochlorothiazide 25mg
3276822|NCT00649389|Active Comparator|AML10/HCTZ25|amlodipine 10mg and hydrochlorothiazide 25mg
3276823|NCT00649389|Active Comparator|OM40/AML10/HCTZ25|olmesartan medoxomil 40mg, amlodipine 10mg, and hydrochlorothiazide 25mg
3276824|NCT00649376|Experimental|1|Fexofenadine Tablets 180 mg
3276825|NCT00649376|Active Comparator|2|Allegra® Tablets 180 mg
3276826|NCT00649363|Experimental|1|Ondansetron Orally Disintegrating Tablets 8 mg
3276827|NCT00649363|Active Comparator|2|Zofran ODT® Tablets 8 mg
3276828|NCT00649350|Experimental|1|Metformin Hydrochloride ER Tablets 750 mg
3276829|NCT00649350|Active Comparator|2|Glucophage XR 750 mg
3276830|NCT00649337|Experimental|1|Adjunct screening with sonocine
3276831|NCT00649324|Experimental|1|Hydrochlorothiazide Tablets 50 mg
3276832|NCT00649324|Active Comparator|2|Hydrochlorothiazide Tablets 50 mg
3276833|NCT00649311|Experimental|Eplerenone group|
3276834|NCT00649311|Active Comparator|Losartan group|
3276835|NCT00649298|Experimental|extended hours|24 or more hours per week of hemodialysis
3276836|NCT00649298|Active Comparator|standard hours|18 or less hours per week of hemodialysis
3276837|NCT00649285|Experimental|1|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
3276838|NCT00649285|Active Comparator|2|Macrobid® Capsules 100 mg
3276839|NCT00649272|Experimental|1|Oxybutynin Chloride Extended-Release Tablets, 15 mg
3276840|NCT00649272|Active Comparator|2|Ditropan XL® Extended-release tablets, 15 mg
3276841|NCT00649259|Experimental|1|Oxybutynin Chloride ER Tablets 10 mg
3276842|NCT00649259|Active Comparator|2|Ditropan XL® Tablets 10 mg
3276843|NCT00649246||1|"controls:~healthy individuals with no family history of type 1 diabetes"
3276844|NCT00649246||2|"high-risk:~Subjects with islet autoantibodies or high-risk diabetes genes"
3276845|NCT00649246||3|"type 1 diabetes:~subjects with type 1 diabetes"
3276846|NCT00649233|Experimental|1|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
3276847|NCT00649233|Active Comparator|2|Lopressor HCT® Tablets 100/50 mg
3276848|NCT00649220|Experimental|Memantine|
3276849|NCT00649207|Experimental|1|"This is an open label study; therefore, there are no numbered/labeled study arms.~This is a dose escalation study, ABT-888 dose will be escalated in conjunction with two schedules of whole brain radiation therapy (WBRT). Subjects may be treated WBRT for 3 weeks (15 days) or 2 weeks (10 days)."
3276850|NCT00649194|Experimental|1|Rabeprazole Sodium Delayed-Release Tablets 20 mg
3276851|NCT00649194|Active Comparator|2|Aciphex® Tablets 20 mg
3276852|NCT00649181|Experimental|1|Metolazone Tablets 5 mg
3276853|NCT00649181|Active Comparator|2|Zaroloxyn® Tablets 5 mg
3276854|NCT00649168|Experimental|1|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL)and BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
3276855|NCT00649168|Active Comparator|2|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL) and Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
3276856|NCT00649155|Experimental|1|Ciprofloxacin Extended-Release Tablets 500 mg
3276857|NCT00649155|Active Comparator|2|Cipro® XR Tablets 500 mg
3276858|NCT00649142|Active Comparator|A|Open sutured mesh repair
3276859|NCT00649142|Active Comparator|B|Laparoscopic mesh glue fixation
3276860|NCT00649129|Experimental|1|Oxybutynin Chloride ER Tablets 10 mg
3276861|NCT00649129|Active Comparator|2|Ditropan XL® Tablets 10 mg
3276862|NCT00649116|Experimental|1|Metoprolol Tartrate Tablets 100 mg
3276863|NCT00649116|Active Comparator|2|Lopressor® Tablets 100 mg
3276864|NCT00649103|Experimental|1|Quinapril Hydrochloride Tablets 40 mg
3276865|NCT00649103|Active Comparator|2|Accupril® Tablets 40 mg
3276866|NCT00649090|Active Comparator|Exemestane group|
3276867|NCT00649077|Experimental|1|Meloxicam Tablets 15 mg
3276868|NCT00649077|Active Comparator|2|Mobic® Tablets 15 mg
3276869|NCT00649064|Experimental|Ziprasidone|
3276870|NCT00649051|Experimental|1|Metolazone Tablets 2.5 mg
3276871|NCT00649051|Active Comparator|2|Zaroloxyn® Tablets 2.5 mg
3276872|NCT00649038|Experimental|1|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
3276873|NCT00649038|Active Comparator|2|Lotensin HCT® Tablets 20 mg/25 mg
3276874|NCT00649025|Experimental|1|FlutiForm 250/10ug
3276875|NCT00649025|Active Comparator|2|SKP Fluticasone 250ug
3276876|NCT00649025|Active Comparator|3|Flovent Fluticasone HFA
3276877|NCT00649012|Experimental|1|Pioglitazone HCl Tablets 45 mg
3276878|NCT00649012|Active Comparator|2|Actos® Tablets 45 mg
3276879|NCT00648999|Active Comparator|1|
3276880|NCT00648999|Active Comparator|2|
3276881|NCT00648986|Experimental|1|Uncontrolled, Open-Label Pilot Study
3276882|NCT00648973|Experimental|1|Diphenhydramine 50 mg
3276883|NCT00648973|Experimental|2|Diphenhydramine 25 mg
3276884|NCT00648973|Active Comparator|3|Pseudoephedrine 120 mg
3276885|NCT00648960|Experimental|1|
3276886|NCT00648960|Active Comparator|2|
3276887|NCT00648947|Experimental|1|Clopidogrel Bisulfate Tablets 75 mg
3276888|NCT00648947|Active Comparator|2|Plavix® Tablets 75 mg
3276889|NCT00648934|Experimental|1|Topiramate Sprinkle Capsules 25 mg
3276890|NCT00648934|Active Comparator|2|Topamax® Sprinkle Capsules 25 mg
3276891|NCT00648921|Experimental|1|Olanzapine Tablets 5 mg
3276892|NCT00648921|Active Comparator|2|Zyprexa® Tablets 5 mg
3276893|NCT00648895|Active Comparator|1|Nebivolol
3276894|NCT00648895|Active Comparator|2|Metoprolol ER (TM)
3276895|NCT00648882|Experimental|1|LEVOTHYROXINE SODIUM TABLETS,USP 300 mcg;
3276896|NCT00648882|Active Comparator|2|SYNTHROID® 300 mcg Tablets
3276897|NCT00648856|Experimental|1|Sertraline Hydrochloride Tablets 100 mg
3276898|NCT00648856|Active Comparator|2|Zoloft® Tablets 100 mg
3276899|NCT00648843|Experimental|1|Oxybutynin Chloride Extended-release Tablets 5 mg
3276900|NCT00648843|Active Comparator|2|Ditropan XL® Tablets 5 mg
3276901|NCT00648830|Experimental|1|Clarithromycin 250 mg immediate-release oral tablet
3276902|NCT00648830|Active Comparator|2|Biaxin® (Clarithromycin) 250 mg tablet
3276903|NCT00648817|Placebo Comparator|Group 1|"Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil) for the first 14 days of the study.~Tenofovir DF placebo tablet QD for the last 14 days of the study."
3276904|NCT00648817|Active Comparator|Group 2|"Tenofovir DF placebo tablet QD for the first 14 days of the study.~Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil) for the last 14 days of the study."
3276905|NCT00648804|Experimental|1|Ondansetron Orally Disintegrating Tablets 8 mg
3276906|NCT00648804|Active Comparator|2|Zofran ODT® Tablets 8 mg
3276907|NCT00648791|Experimental|1|Finasteride Tablets 5 mg
3276908|NCT00648791|Active Comparator|2|Proscar Tablets 5 mg
3276909|NCT00648778|Experimental|1|Loxapine Succinate Capsules 25 mg
3276910|NCT00648778|Active Comparator|2|Loxitane® Capsules 25 mg
3276911|NCT00648765|Experimental|1|Anagrelide Hydrochloride Capsules 1 mg
3276912|NCT00648765|Active Comparator|2|Agrylin® Capsules 1 mg
3276913|NCT00648739|Experimental|1, 2, 3, 4, 5, 6, and 7|ALXN6000 dose ranging cohorts numbered 1-7 with dosages of 50 mg/m2 to 600 mg/m2.
3276914|NCT00648726|Active Comparator|Arm 1|
3276915|NCT00648726|Active Comparator|Arm 2|
3276916|NCT00648726|Active Comparator|Arm 3|
3276917|NCT00648713|Experimental|1|Terbinafine Hydrochloride Tablets 250 mg
3276918|NCT00648713|Active Comparator|2|Lamisil® Tablets 250 mg
3276919|NCT00648700|Experimental|1|Levothyroxine Sodium Tablets 300 μg
3276920|NCT00648700|Active Comparator|2|Levothroid® Tablets 300 μg
3276921|NCT00648687|Experimental|I|this group will receive oral water and glucose prior to eye exam
3276922|NCT00648687|No Intervention|II|this group is the control group.
3276923|NCT00648674|Experimental|1|Apligraf
3276924|NCT00648661|Experimental|1|Escitalopram Oxalate Tablets 20 mg
3276925|NCT00648661|Active Comparator|2|Lexapro® Tablets 20 mg
3276926|NCT00648648|Experimental|Part 1: MK1775 single dose|Part 1: MK1775 capsules will be given on Day 1 of a 14-day cycle: starting dose of MK1775 is 325 mg and will escalate up to 1300 mg or until MTD achieved
3276927|NCT00648648|Experimental|Part 3: Confirmation and Expansion|Part 3: Patients will be treated with MTD of MK1775 from Part 2-B in combination with the MTD from Part 2-B of either gemcitabine, cisplatin, or carboplatin.
3276928|NCT00648648|Experimental|Part 2-A Gemcitabine|Starting single dose of MK1775, 100 mg with gemcitabine IV infusions dosage ranging from 1000 mg/m^2 to 600 mg/m^2 in a 28-day cycle
3276929|NCT00648648|Experimental|Part 2-A Cisplatin|Starting single dose of MK1775, 100 mg with cisplatin IV infusion dosage ranging from 75 mg/m^2 to 50 mg/m^2 in a 21-day cycle.
3276930|NCT00648648|Experimental|Part 2-A Carboplatin|Starting single dose of MK1775, 100 mg with carboplatin IV infusion dosage ranging from AUC/time curve of 5 mg/min/mL to AUC 3 in a 21-day cycle.
3276931|NCT00648648|Experimental|Part 2-B Gemcitabine|Starting multiple dose of MK1775, 50 mg with gemcitabine IV infusions dosage ranging from 1000 mg/m^2 to 600 mg/m^2 in a 28-day cycle
3276932|NCT00648648|Experimental|Part 2-B Cisplatin|Starting multiple dose of MK1775, 50 mg with cisplatin IV infusion dosage ranging from 75 mg/m^2 to 50 mg/m^2 in a 21-day cycle
3276933|NCT00648648|Experimental|Part 2-B Carboplatin|Starting multiple dose of MK1775, 75 mg with cisplatin IV infusion dosage ranging from AUC/time curve of 5 mg/min/mL to AUC 3 in a 21-day cycle.
3276934|NCT00648635||PET + QOL|Survey of how recurrent rectal cancer treatment affects well being + QOL
3276935|NCT00648622|Experimental|1|Carvedilol Tablets 12.5 mg
3276936|NCT00648622|Active Comparator|2|Coreg® Tablets 12.5 mg
3276937|NCT00648609||Home-based palliative care services|Patients who are 60 or more years of age and have a diagnosis of COPD.Patients who have received two or more unscheduled acute care visits during the 12 months prior to the start of the study.
3276938|NCT00648609||Standard of care|Patients who are 60 or more years of age and have a diagnosis of COPD.Patients who have received two or more unscheduled acute care visits during the 12 months prior to the start of the study.
3276939|NCT00648596|Placebo Comparator|Arm 2|
3276940|NCT00648596|Active Comparator|Arm 1|
3276941|NCT00648583|Experimental|1|Ondansetron Tablets 24 mg
3276942|NCT00648583|Active Comparator|2|Zofran® Tablets 24 mg
3276943|NCT00648570|Experimental|1|Escitalopram Oxalate Tablets 20 mg
3276944|NCT00648570|Active Comparator|2|Lexapro® Tablets 20 mg
3276945|NCT00648557|Experimental|1|Levothyroxine Sodium Tablets 200 mg
3276946|NCT00648557|Active Comparator|2|Synthroid Tablets 200 mg
3276947|NCT00648544|Experimental|1|
3276948|NCT00648544|Active Comparator|2|
3276949|NCT00648531|Experimental|1|Balsalazide Disodium Capsules 750 mg
3276950|NCT00648531|Active Comparator|2|Colazal® Capsules 750 mg
3276951|NCT00648518|Experimental|1|Metformin Hydrochloride ER Tablets 750 mg
3276952|NCT00648518|Active Comparator|2|Glucophage® XR Tablets 750 mg
3276953|NCT00648505|Experimental|1|Glipizide and Metformin HCl Tablets 5 mg/500 mg
3276954|NCT00648505|Active Comparator|2|Metaglip® Tablets 5 mg/500 mg
3276955|NCT00648492|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
3276956|NCT00648492|Active Comparator|2|Glucophage® XR 500 mg
3276957|NCT00648479|Experimental|1|
3276958|NCT00648479|Active Comparator|2|
3276959|NCT00648466|Experimental|1|Sumatriptan Succinate Tablets 100 mg
3276960|NCT00648466|Active Comparator|2|Imitrex® Tablets 100 mg
3276961|NCT00648440|Experimental|1|Midodrine HCl Tablets 5 mg
3276962|NCT00648440|Active Comparator|2|ProAmatine® Tablets 5 mg
3276963|NCT00648427|Experimental|1|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg
3276964|NCT00648427|Active Comparator|2|Paxil CR™ Tablets 25 mg
3276965|NCT00648414|Experimental|1|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1 - blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
3276966|NCT00648414|Experimental|2|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2 - tourniquet applied just below patch application site and above blood draw site
3276967|NCT00648414|Experimental|3|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3 - tourniquet applied just above patch application site
3276968|NCT00648414|Experimental|4|Duragesic 25 mcg/h + Clinical Procedure 1 - blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
3276969|NCT00648414|Experimental|5|Duragesic 25 mcg/h + Clinical Procedure 2 - tourniquet applied just below patch application site and above blood draw site
3276970|NCT00648414|Experimental|6|Duragesic 25 mcg/h + Clinical Procedure 3 - tourniquet applied just above patch application site
3276971|NCT00648401|Experimental|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
3276972|NCT00648401|Active Comparator|2|Verelan® PM Extended-Release Capsules, 300 mg
3276973|NCT00648388|Experimental|1|Cilostazol Tablets 100 mg
3276974|NCT00648388|Active Comparator|2|Pletal® Tablets 100 mg
3276975|NCT00648375|Experimental|A|Participants will take propranolol for 14 weeks.
3276976|NCT00648375|Placebo Comparator|B|Participants will take placebo for 14 weeks.
3276977|NCT00648362|Experimental|1|Glimepiride Tablets 1 mg
3276978|NCT00648362|Active Comparator|2|Amaryl® Tablets 1 mg
3276979|NCT00648349|Experimental|1|Rabeprazole Sodium Delayed-Release Tablets 20 mg
3276980|NCT00648349|Active Comparator|2|Aciphex® Delayed-Release Tablets 20 mg
3276981|NCT00648336|Experimental|1|Mercaptopurine 50 mg
3276982|NCT00648336|Active Comparator|2|Purinethol® Tablets 50 mg
3276983|NCT00648323|Experimental|A|
3276984|NCT00648310|Active Comparator|1|arm 1: Tolterodine 4 mg once daily for 12 weeks
3276985|NCT00648310|Experimental|2|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks
3276986|NCT00648297|Experimental|1|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
3276987|NCT00648297|Active Comparator|2|Corzide® Tablets 80 mg/5 mg
3276988|NCT00648271|Experimental|1|Metoprolol Tartrate Tablets 25 mg
3276989|NCT00648271|Active Comparator|2|Lopressor® Tablets 50 mg
3276990|NCT00648258|Active Comparator|Arm 1|
3276991|NCT00648258|Active Comparator|Arm 2|
3276992|NCT00648245|Experimental|1|
3276993|NCT00648245|Experimental|2|
3276994|NCT00648245|Experimental|3|
3276995|NCT00648245|Placebo Comparator|4|
3276996|NCT00648245|Experimental|5|
3276997|NCT00648232|Experimental|A|Participants will receive voluntary brief HIV counseling and testing plus enhanced linkage to care.
3276998|NCT00648232|Experimental|B|Participants will receive voluntary brief HIV counseling and testing plus routine referral to care.
3276999|NCT00648232|Experimental|C|Participants will receive voluntary longer, more detailed HIV counseling and testing plus enhanced linkage to care.
3277000|NCT00648232|Experimental|D|Participants will receive voluntary longer, more detailed HIV counseling and testing plus routine referral to care.
3277001|NCT00648232|Active Comparator|E|Participants who are found to be healthy will receive voluntary brief HIV counseling and testing only.
3277002|NCT00648232|Active Comparator|F|Participants who are found to be healthy will receive voluntary longer, more detailed HIV counseling and testing only.
3277003|NCT00648219|Experimental|1|Olmesartan Medoxomil Tablets 40 mg
3277004|NCT00648219|Active Comparator|2|Benicar® Tablets 40 mg
3277005|NCT00648206||1|drivers of motorised vehicles suspected of driving under the influence of psychoactive drugs or alcohol
3277006|NCT00648206||2|drivers stopped in police traffic controls and breathalysed positive for alcohol
3277007|NCT00648193|Experimental|1|Paroxetine hydrochloride 40 mg tablet
3277008|NCT00648193|Active Comparator|2|Paxil® 40 mg Table
3277009|NCT00648180|Experimental|1|Doxycycline Monohydrate Tablets 100 mg
3277010|NCT00648180|Active Comparator|2|Adoxa Tablets 100 mg
3277011|NCT00648167|Experimental|KRX-0502 (ferric citrate)|All patients will be switched from their current phosphate binder to Zerenex, and titrated to the maximum tolerated dose (up to about 12g/day) based on their serum phosphorus levels.
3277012|NCT00648154|Experimental|1|Letrozole Tablets 2.5 mg
3277013|NCT00648154|Active Comparator|2|Femara® Tablets 2.5 mg
3277014|NCT00648141|Experimental|A|
3277015|NCT00648141|Experimental|B|
3277016|NCT00648141|Active Comparator|C|
3277017|NCT00648128|Active Comparator|2|
3277018|NCT00648128|Experimental|1|
3277019|NCT00648115|Other|Basic Vocational Services|Veteran receives basic vocational services
3277020|NCT00648115|Active Comparator|Self-Study|Veteran participates in self-study vocational program
3277021|NCT00648115|Active Comparator|Group program|Group based vocational program
3277022|NCT00648089|Experimental|1|
3277023|NCT00648089|No Intervention|2|
3277024|NCT00648076|Experimental|1|Divalproex Sodium Extended-Release Tablets 500 mg
3277025|NCT00648076|Active Comparator|2|Depakote ER® Tablets 500 mg
3277026|NCT00648063|Experimental|1|Letrozole Tablets 2.5 mg
3277027|NCT00648063|Active Comparator|2|Femara® Tablets 2.5 mg
3277028|NCT00648050|Experimental|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
3277029|NCT00648050|Active Comparator|2|Verelan® PM Extended-Release Capsules, 300 mg
3277030|NCT00648037|Experimental|Rituximab|Patients following a T cell depleted HLA-mis-matched related or unrelated hematopoietic stem cell transplant (HSCT) will be treated with monthly Rituximab.
3277031|NCT00648024|Experimental|1|Anagrelide Hydrochloride Capsules 1 mg
3277032|NCT00648024|Active Comparator|2|Agrylin® Capsules 1 mg
3277033|NCT00648011|Experimental|1|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
3277034|NCT00648011|Active Comparator|2|Accuretic™ Tablets 20 mg/25 mg
3277035|NCT00647998|Experimental|Darbepoetin|Patients received 1mg/kg IV Darbepoetin immediately prior to surgery
3277036|NCT00647998|Placebo Comparator|Standard care|No Darbepoetin
3277037|NCT00647985|Experimental|1|Fexofenadine Tablets 180 mg
3277038|NCT00647985|Active Comparator|2|Allegra® Tablets 180 mg
3277039|NCT00647972|Experimental|1|Olanzapine Tablets 20 mg
3277040|NCT00647972|Active Comparator|2|Zyprexa® Tablets 20 mg
3277041|NCT00647959|Experimental|1|Doxycycline Tablets, 150mg
3277042|NCT00647959|Active Comparator|2|Adoxa Tablets 150 mg
3277043|NCT00647946|Experimental|A|Stop zidovudine (ZDV) or stavudine (d4T) and start tenofovir DF 300mg once daily along with the other antiviral drugs that are used as part of their HAART regimen
3277044|NCT00647946|Active Comparator|B|Stop zidovudine (ZDV) or stavudine (d4T) and start abacavir 300mg twice daily along with the other antiviral drugs that are used as part of their HAART regimen
3277045|NCT00647933|Experimental|Org 36286 15 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 15 μg.
3277046|NCT00647933|Experimental|Org 36286 30 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 30 μg.
3277047|NCT00647933|Experimental|Org 36286 60 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 60 μg.
3277048|NCT00647933|Experimental|Org 36286 120 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 120 μg.
3277049|NCT00647920|Experimental|40 mg|
3277050|NCT00647920|Placebo Comparator|Placebo|
3277051|NCT00647907|Experimental|A|
3277052|NCT00647894|Experimental|1|Alprazolam Extended-Release Tablets 1 mg
3277053|NCT00647894|Active Comparator|2|Xanax XR Tablets 1 mg
3277054|NCT00647881|Experimental|1|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg
3277055|NCT00647881|Active Comparator|2|Paxil CR™ Tablets 25 mg
3277056|NCT00647868|Experimental|Groups 1 and 2|Twice daily (7:00 am and 12:00 am or 7:00 am and 10:00 pm) dosing with intranasal testosterone for 14 days
3277057|NCT00647868|Experimental|Groups 3a and b|Single daily administration of testosterone (at 7:00 am or 10:00 pm) for 14 days
3277058|NCT00647868|No Intervention|Group 4|24-h blood sampling in healthy eugonadal controls
3277059|NCT00647855|Experimental|1|Levothyroxine Sodium Tablets 300 μg
3277060|NCT00647855|Active Comparator|2|Synthroid® Tablets 300 μg
3277061|NCT00647842|Experimental|1|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay
3277062|NCT00647842|Active Comparator|2|Fentanyl Transdermal System 25 mcg/h
3277063|NCT00647829|Active Comparator|Arm 1|
3277064|NCT00647829|Active Comparator|Arm 2|
3277065|NCT00647829|Placebo Comparator|Arm 3|
3277066|NCT00647816|Experimental|1|Propranolol Hydrochloride Extended-Release Capsules 160 mg
3277067|NCT00647816|Active Comparator|2|Inderal® LA Capsules 160 mg
3277068|NCT00647790||1|Patients with a confirmed diagnosis of invasive breast cancer who are undergoing surgery.
3277069|NCT00647777|Experimental|1|Olanzapine Tablets 5 mg
3277070|NCT00647777|Active Comparator|2|Zyprexa® Tablets 5 mg
3277071|NCT00647764|Experimental|Single Arm|
3277072|NCT00647751|Experimental|1|Lamotrigine Tablets 25 mg
3277073|NCT00647751|Active Comparator|2|Lamictal® Tablets 25 mg
3277074|NCT00647738|Experimental|1|
3277075|NCT00647738|Active Comparator|2|
3277076|NCT00647725|Active Comparator|I|Active phrase analgesia
3277077|NCT00647725|Active Comparator|II|Latent phrase analgesia
3277078|NCT00647712|Experimental|1|Divalproex Sodium Extended-Release Tablets 500 mg
3277079|NCT00647712|Active Comparator|2|Depakote ER® Tablets 500 mg
3277080|NCT00647699|Active Comparator|Corneal Collagen Cross-linking (CXL) Treatment Group|riboflavin ophthalmic solution and UVA irradiation
3277081|NCT00647699|Sham Comparator|Control Group|riboflavin ophthalmic solution without UVA irradiation.
3277082|NCT00647686|Experimental|1|Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay
3277083|NCT00647686|Active Comparator|2|Fentanyl Transdermal System 25 mcg/h
3277084|NCT00647673|Experimental|1|Verapamil HCL Extended-Release Capsules 300 mg
3277085|NCT00647673|Active Comparator|2|Verelan® PM Extended-release Capsules 300 mg
3277086|NCT00647660|Experimental|1|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
3277087|NCT00647660|Active Comparator|2|Corzide® Tablets 80 mg/5 mg
3277088|NCT00647647|Experimental|1|Terbinafine Hydrochloride Tablets 250 mg
3277089|NCT00647647|Active Comparator|2|Lamisil® Tablets 250 mg
3277090|NCT00647634|Experimental|1|Alprazolam Extended-Release Tablets 3 mg;
3277091|NCT00647634|Active Comparator|2|Xanax XR® Tablets 3 mg
3277092|NCT00647621|Experimental|1|Extended Phenytoin Sodium Capsules 100 mg
3277093|NCT00647621|Active Comparator|2|Dilantin® Kapseals® 100 mg
3277094|NCT00647608|Experimental|1|Propranolol Hydrochloride Extended-Release Capsules 160 mg
3277095|NCT00647608|Active Comparator|2|Inderal® LA Capsules 160 mg
3277096|NCT00647595|Experimental|A|Women in this group will exercise 3x per week at a moderate/vigorous level for 45 min per session through their 36 week of pregnancy.
3277097|NCT00647595|No Intervention|B|Women in this group will continue their usual activities throughout their pregnancy.
3277098|NCT00647569|Experimental|A|No previous major abdominal surgery
3277099|NCT00647569|Experimental|B|Previous major abdominal surgery
3277100|NCT00647556|Active Comparator|adapalene|adapalene
3277101|NCT00647556|Active Comparator|tretinoin|Tretinoin
3277102|NCT00647543|Experimental|High Risk|
3277103|NCT00647543|Experimental|Low Risk|
3277104|NCT00647543|Experimental|Medium Risk|
3277105|NCT00647530|Experimental|Pre&Post Op Chemo|12 weeks of OxFP neuoadjuvantly followed by surgery and 18 weeks of OxFP
3277106|NCT00647530|Experimental|Pre&Post Op Chemo with P-mab|12 weeks of OxFP and panitumumab neuoadjuvantly followed by surgery and 18 weeks of OxFP alone.
3277107|NCT00647530|Active Comparator|Post Op Chemo|surgery followed by 24 weeks of OxFP.
3277108|NCT00647517|Experimental|ultracet|
3277109|NCT00647517|Placebo Comparator|placebo|
3277110|NCT00647504||1|Restenosis in Bare metal stent
3277111|NCT00647504||2|Restenosis in Drug eluting stent
3277112|NCT00647504||3|Stent thrombosis
3277113|NCT00647504||4|Control group
3277114|NCT00647491|Experimental|20 mg|20 mg adalimumab eow
3277115|NCT00647491|Experimental|40 mg|40 mg adalimumab eow
3277116|NCT00647491|Experimental|80 mg|80 mg adalimumab eow
3277117|NCT00647491|Placebo Comparator|Placebo|Placebo eow
3277118|NCT00647478||1|AD
3277119|NCT00647478||2|Control elderly subjects with normal cognitive function
3277120|NCT00647478||3|MCI
3277121|NCT00647465|Active Comparator|1|IFNalpha 2b
3277122|NCT00647465|Placebo Comparator|2|Placebo
3277123|NCT00647452|Experimental|1|Healthy male volunteers
3277124|NCT00647452|Experimental|2|Healthy female volunteers
3277125|NCT00647426|Experimental|Arm 1|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
3277126|NCT00647413|No Intervention|1|
3277127|NCT00647413|Experimental|2|expert system intervention on smoking behaviour + feedback of a biomarker
3277128|NCT00647400|Experimental|Adalimumab 40 mg every other week|
3277129|NCT00647400|Experimental|Adalimumab 80 mg every other week|
3277130|NCT00647387|Experimental|1|Implantation with the device
3277131|NCT00647374||1|
3277132|NCT00647361|Experimental|NAVA|
3277133|NCT00647348|Active Comparator|1|Simvastatin 80mg OD
3277134|NCT00647348|Placebo Comparator|2|Placebo
3277135|NCT00647335||1|Women with diagnosis of PCOS
3277136|NCT00647322|Experimental|1|Reduction in anti-epileptic medications
3277137|NCT00647322|Active Comparator|2|No change in medication. Unchanged treatment
3277138|NCT00647309||1|
3277139|NCT00647309||2|
3277140|NCT00647296|Placebo Comparator|matched placebo|
3277141|NCT00647296|Experimental|low-dose KNS-760704|
3277142|NCT00647296|Experimental|mid-dose KNS-760704|
3277143|NCT00647296|Experimental|high-dose KNS-760704|
3277144|NCT00647283|Experimental|1|Stable liver transplant recipients fulfilling inclusion criteria.
3277145|NCT00647270|Placebo Comparator|Placebo|Placebo 12 weeks, 40mg adalimumab remaining 12 weeks
3277146|NCT00647270|Active Comparator|40 mg|40 mg every other week
3277147|NCT00647270|Active Comparator|80 mg|80 mg monthly
3277148|NCT00647257|Active Comparator|A|
3277149|NCT00647257|Placebo Comparator|B|
3277150|NCT00647244|Active Comparator|1|Tenofovir
3277151|NCT00647244|Active Comparator|2|Abacavir
3277152|NCT00647231|Experimental|A, 2, II, HKT-500 Topical Patch|A Randomized, Multicenter, Double-Blind, Single Dose Study of the Analgesic Properties of HKT-500 and Placebo in Subjects With Pain Caused by Mild to Moderate Osteoarthritis of the Knee
3277153|NCT00647231|Placebo Comparator|Placebo Patch|Treatment with placebo patch
3277154|NCT00647218|Experimental|Experimental|
3277155|NCT00647205|Sham Comparator|1|HIV infected antiretroviral naïve patients originated from low TB prevalence countries without any active TB with CD4 cell count > 350/mm3
3277156|NCT00647205|Sham Comparator|2|HIV infected antiretroviral naïve patients originated from low TB prevalence countries without any active T with CD4 < 350/mm3)
3277157|NCT00647205|Sham Comparator|3|HIV infected antiretroviral naïve patients originated from high TB prevalence countries without any active TB with CD4 < 350/mm3)
3277158|NCT00647205|Sham Comparator|4|HIV infected antiretroviral naïve patients originated from high TB prevalence countries without any active TB with CD4 > 350/mm3)
3277159|NCT00647205|Sham Comparator|5|HIV infected patients with active TB
3277160|NCT00647205|Sham Comparator|6|HIV negative patients with active TB
3277161|NCT00647192|Active Comparator|1|Eplerenone treatment
3277162|NCT00647192|Placebo Comparator|2|
3277163|NCT00647179||1|Patients recently diagnosed with acromegaly
3277164|NCT00647166|Experimental|1|Drug: corticosteroid and azathioprine
3277165|NCT00647166|Placebo Comparator|2|Drug: corticosteroid and placebo
3277166|NCT00647153|Experimental|Radiation: iodine I 123 anti-CEA recombinant diabody T84.66|
3277167|NCT00647140|Experimental|1|18F-L6DOPA PET
3277168|NCT00647127|Active Comparator|Buprenorphine|
3277169|NCT00647127|Active Comparator|Fentanyl|
3277170|NCT00647127|Placebo Comparator|Placebo|
3277171|NCT00647114|Experimental|1|V930
3277172|NCT00647114|Experimental|2|V932
3277173|NCT00647101|Experimental|Latanoprost group|
3277174|NCT00647088||aortic stenosis|various age and disease severity
3277175|NCT00647088||Controls|Controls free of valvular disease
3277176|NCT00647075|Experimental|1|Yunzhi extract 3.5 g/day
3277177|NCT00647075|Placebo Comparator|2|Placebo
3277178|NCT00647049|Experimental|A|first diagnosis of PCNSL: combined chemotherapy with methotrexate
3277179|NCT00647049|Experimental|B|Patients with relapse or progressive disease of PCNSL after methotrexate containing chemotherapy
3277180|NCT00647036|Active Comparator|1|Dipeptiven (L-glutamine- Lalanine)
3277181|NCT00647036|Placebo Comparator|2|Isonitrogenous Vaminolact
3277182|NCT00647023|Experimental|A|
3277183|NCT00646997||1|Patients with postoperative atrial fibrillation
3277184|NCT00646997||2|Patients without postoperative atrial fibrillation.
3277185|NCT00646984|Active Comparator|1|Standard continuous antiretroviral therapy
3277186|NCT00646984|Experimental|2|CD-4 guided interruption arm
3277187|NCT00646984|Experimental|3|Viral load driven treatment interruption
3277188|NCT00646971|Experimental|1|CPAP
3277189|NCT00646971|Sham Comparator|2|sham CPAP
3277190|NCT00646958|Experimental|1|Radezolid 450 mg PO QD
3277191|NCT00646958|Experimental|2|Radezolid 450 mg PO BID
3277192|NCT00646958|Active Comparator|3|Linezolid 600 mg PO BID
3277193|NCT00646945|Experimental|A|50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)
3277194|NCT00646945|Placebo Comparator|B|50% oxygen/50% Nitrogen premix
3277195|NCT00646932|Experimental|1|
3277196|NCT00646932|Experimental|2|
3277197|NCT00646932|Experimental|3|
3277198|NCT00646932|Experimental|4|
3277199|NCT00646919||1|All pre-operative pediatric patients in our outpatient clinic
3277200|NCT00646906|Experimental|Acetaminophen 1000mg|"All subjects in this arm (smokers (n=8) and non-smokers (n=8) will receive 81 mg aspirin at approximately 8 am followed by 1000 mg acetaminophen at approximately 10 am during one treatment phase (see Aspirin first intervention). During the other treatment phase, beginning after a 2 week washout, the order will be reversed and the subjects will receive 1000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see Aspirin last intervention). The occurrence of the two study phases (interventions) will be randomized by order. Smokers and non-smokers will be matched for age and gender."
3277201|NCT00646906|Experimental|Acetaminophen 2000mg|"All subjects in this arm (smokers (n=8) and non-smoking volunteers (n=8)) will receive 81 mg aspirin at approximately 8 am followed by 2000 mg acetaminophen at approximately 10 am during one treatment phase (see Aspirin first intervention). During the other treatment phase, beginning after a 2 week washout, the order will be reversed and the subjects will receive 2000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see Aspirin last intervention). The occurrence of the two study phases (interventions) will be randomized by order. Smokers and non-smokers will be matched for age and gender."
3277202|NCT00646906|Experimental|Acetaminophen 325 mg|In Part B of this protocol, non-smokers (N=8), we propose to establish the measurement of the acetylation of COX-1 in human platelets. Just like in Part A of this study, healthy, non-smoking male and female volunteers will be administered a single tablet of plain 325mg aspirin. Blood will be drawn and spot urine samples collected at 2 hrs, 4 hrs, 8 hrs, 24 hrs, 48 hrs (2 days), 96 hrs (4 days), 168 hrs (7 days), 240 hrs (10 days) after the Platelet COX-1 acetylation will be measured at various time points following drug administration to determine the kinetics of COX acetylation. Platelet and COX enzyme function assays will be performed at the same time to allow correlation of the enzyme acetylation kinetics with biological function.
3277203|NCT00646893|No Intervention|1|Control: assisted hatching, without Preimplantation Genetic Diagnosis
3277204|NCT00646893|Experimental|2|Test: embryo biopsy with Preimplantation Genetic Diagnosis
3277205|NCT00646880|Active Comparator|Propiverine/tolterodine group|
3277206|NCT00646880|Active Comparator|Tolerodine/propiverine group|
3277207|NCT00646867|Experimental|1|Experimental
3277208|NCT00646867|Placebo Comparator|2|Placebo
3277209|NCT00646854|Active Comparator|Arm A|
3277210|NCT00646854|Experimental|Arm B|
3277211|NCT00646841|Experimental|A|
3277212|NCT00646828||without PHA1|patients without mineralocorticoid receptor mutation
3277213|NCT00646828||PHA 1|patients with a rare disease, pseudohypoaldosteronism type 1, due to heterozygous inactivating mutations of the mineralocorticoid receptor
3277214|NCT00646815|Experimental|a|the aim of the present study is to characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic-intramyocellular lipids in 12 adult patients, recently diagnosed with growth hormone deficiency
3277215|NCT00646815|No Intervention|Control|Intramyocellular, intrahepatic and intraabdominal lipid content, lean body mass and body fat percentage, are assessed in ten healthy controls matched on age, gender and BMI.
3277216|NCT00646802|Active Comparator|A|Progesterone 200 mg
3277217|NCT00646802|Placebo Comparator|B|Placebo
3277218|NCT00646789|Experimental|1|MK0633
3277219|NCT00646776|Active Comparator|A|
3277220|NCT00646776|Active Comparator|B|
3277221|NCT00646763|Active Comparator|Abdomen|These subjects will have their cytokine injections administered only to their abdomen.
3277222|NCT00646763|Active Comparator|Extremities|The extremity arm will have their injections administered to their upper and/or lower extremities.
3277223|NCT00646750|Experimental|1|BEAM preceded by Ybritumomab Tiuxetan (Zevalin)
3277224|NCT00646737|Experimental|1|Mycophenolate sodium
3277225|NCT00646724|Experimental|1|cotransplantation of islet and mesenchymal stem cell
3277226|NCT00646711|Experimental|Sequence Group I|Depakote Delayed Release/Depakote Sprinkle
3277227|NCT00646711|Experimental|Sequence Group II|Depakote ER
3277228|NCT00646698||1|Premenopausal Upper Body Obese (UBO) women with waist-hip ratio > 0.85 and BMI > 28
3277229|NCT00646698||2|Premenopausal Lower Body Obese (LBO) women with waist hip ratio < 0.8 and BMI > 28
3277230|NCT00646698||3|Premenopausal lean women with BMI < 25
3277231|NCT00646685|Other|1|
3277233|NCT00646646|Active Comparator|propofol|active drug
3277234|NCT00646646|Active Comparator|dexmedetomidine|sedative
3277235|NCT00646646|Active Comparator|midazolam|Sedative
3277236|NCT00646646|Placebo Comparator|placebo|placebo control
3277237|NCT00646633|Active Comparator|Acupuncture & educ|Patients will receive a total of 8 acupuncture treatments. In each of the first four sessions, they will also receive patient education.
3277238|NCT00646633|No Intervention|2. Standard care|Patients in the control arm will continue to receive standard care from their physician.
3277239|NCT00646620|Experimental|1|budesonide/formoterol
3277240|NCT00646620|Active Comparator|2|fluticasone/salmeterol
3277241|NCT00646620|Active Comparator|3|albuterol
3277242|NCT00646607|Experimental|A|FOLFOX-4 (infusional 5-Fluouracil, leucovorin and oxaliplatin) for 3 months or XELOX (capecitabine and oxaliplatin) for 12 weeks.
3277243|NCT00646607|Active Comparator|B|FOLFOX-4 (infusional 5-Fluouracil, leucovorin and oxaliplatin) for 6 months or XELOX (capecitabine and oxaliplatin) for 24 weeks.
3277244|NCT00646594|Experimental|1|budesonide/formoterol
3277245|NCT00646594|Active Comparator|2|fluticasone/salmeterol
3277246|NCT00646581|Placebo Comparator|Placebo (1)|Subjects are given a one-time, single dose of placebo intranasal spray
3277247|NCT00646581|Experimental|Single-Dose Intranasal Insulin|Subjects are given a one-time, single dose of intranasal insulin
3277248|NCT00646542|Experimental|1|
3277249|NCT00646542|Placebo Comparator|2|
3277250|NCT00646529|Experimental|1|budesonide/formoterol
3277251|NCT00646529|Active Comparator|2|budesonide
3277252|NCT00646516|Experimental|1|
3277253|NCT00646503|Experimental|1|600 mg/day, oral telbivudine for 52 weeks
3277254|NCT00646490||A|patients with parapneumonic pleural effusion due to community acquired pneumonia
3277255|NCT00646490||B|patients with pleural effusion of other etiologies
3277256|NCT00646477|Experimental|A|Phase 1 : manual Phase 2 : automatic Descent rate pressure : slow
3277257|NCT00646477|Experimental|B|Phase 1 : manual Phase 2 : automatic Descent Rate Pressure : fast
3277258|NCT00646477|Experimental|C|Phase 1 : automatic Phase 2 : manual Descent rate pressure : slow
3277259|NCT00646477|Experimental|D|Phase 1 : automatic Phase 2 : manual Descent Rate Pressure : fast
3277260|NCT00646464||2|Children 6-12 years old diagnosed as not suffering from ADHD
3277261|NCT00646464||1|children 6-12 diagnosed as ADHD
3277262|NCT00646451|Experimental|1|Pregabalin 75 mg bid to a maximum dose of 300 mg bid
3277263|NCT00646451|Placebo Comparator|2|Placebo to 4 capsules bid
3277264|NCT00646438|Active Comparator|1|strict glucose control (study arm)
3277265|NCT00646438|No Intervention|2|standard insulin treatment (control arm)
3277266|NCT00646425|Experimental|1|Basiliximab
3277267|NCT00646425|Placebo Comparator|2|
3277268|NCT00646412|Experimental|A|A-Part® Gel
3277269|NCT00646412|No Intervention|B|untreated control group
3277270|NCT00646399|Placebo Comparator|Placebo|Phosphate Buffered Saline
3277271|NCT00646399|Experimental|Pagibaximab 50 mg/mL|Pagibaximab at 100 mg/kg intravenously at Days 0, 1, 2, 9, 16 and 23.
3277272|NCT00646386|Active Comparator|A|
3277273|NCT00646386|Placebo Comparator|B|
3277274|NCT00646360|Experimental|1|Docosahexonic acid (400 mg/day)
3277275|NCT00646360|Placebo Comparator|2|
3277276|NCT00646347|Experimental|A|Conventional stroke upper limb rehabilitation is given
3277277|NCT00646347|Active Comparator|B|Neuro Hand Orthosis Program is given
3277278|NCT00646334|Experimental|A|Optilene® Mesh Elastic
3277279|NCT00646334|Active Comparator|B|Ultrapro® Mesh
3277280|NCT00646321|Experimental|1|budesonide/formoterol
3277281|NCT00646321|Active Comparator|2|budesonide
3277282|NCT00646308||I|Adult patients with GH deficiency due to a nonsecreting pituitary tumor
3277283|NCT00646308||2|Adult patients with a nonsecreting pituitary tumor but without GH deficiency
3277284|NCT00646295|Experimental|A|To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes
3277285|NCT00646282|Experimental|Doxercalciferol|Stable kidney transplant recipients will receive Doxercalciferol
3277286|NCT00646282|No Intervention|Control|Stable kidney transplant recipients will not receive any drug
3277287|NCT00646269|Active Comparator|1|
3277288|NCT00646269|Experimental|2|
3277289|NCT00646269|Experimental|3|
3277290|NCT00646269|Experimental|4|
3277291|NCT00646256|No Intervention|no training|
3277292|NCT00646256|Experimental|COGPACK training|
3277293|NCT00646243||1 Heart Failure|216 consecutive consenting patients with refractory heart failure candidate to cardiac resynchronization therapy by clinical and electrocardiographic criteria
3277294|NCT00646243||2 Healthy subjects|120 healthy subject includes defined as absence of history and symptoms of any cardiovascular disease, normal physical examination and ECG.
3277295|NCT00646230|Experimental|Single arm of CIV infusion of emulsion 4-HPR|Single arm study of continuous intravenous infusion (CIV) of emulsion 4-HPR
3277296|NCT00646217|Experimental|1|SELF CARE Talk
3277297|NCT00646217|No Intervention|2|Comparison Group
3277298|NCT00646204|Experimental|1|memantine 10 mg bid
3277299|NCT00646204|Placebo Comparator|2|2 tabs bid
3277300|NCT00646191|Active Comparator|A|
3277301|NCT00646191|Active Comparator|B|
3277302|NCT00646191|Active Comparator|C|
3277303|NCT00646178|Active Comparator|A|
3277304|NCT00646178|Placebo Comparator|B|
3277305|NCT00646126|Active Comparator|1|1:Active comparator sulfadoxine-pyrimethamine plus artesunate
3277306|NCT00646126|Placebo Comparator|2|2:placebo comparator
3277307|NCT00646113|Experimental|OsseoSpeed™|OsseoSpeed™ 3.0 mm diameter
3277308|NCT00646100|Active Comparator|TACE|chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization
3277309|NCT00646100|No Intervention|control|best support care
3277310|NCT00646087|Experimental|Ketamine (6K)|6K: 6 ketamine injections (0.5 mg/kg of ketamine) every other day for 12 days
3277311|NCT00646087|Active Comparator|Ketamine/Placebo (2K4P)|2K4P = two active ketamine injections(2K) and four placebo (saline) injections over 12 days.
3277312|NCT00646074|Experimental|1|Self-Care TALK
3277313|NCT00646074|No Intervention|2|
3277314|NCT00646061|Experimental|1|morphine, ketorolac, and buscopan
3277315|NCT00646061|No Intervention|2|morphine and ketorolac
3277316|NCT00646048|Experimental|Arm 1|This arm is for patient that receive the TriVascular Stent-Graft System.
3277317|NCT00646035|Placebo Comparator|A|
3277318|NCT00646035|Placebo Comparator|B|
3277319|NCT00646009|Experimental|1|budesonide/formoterol
3277320|NCT00646009|Active Comparator|2|fluticasone/salmeterol
3277321|NCT00646009|Active Comparator|3|albuterol
3277322|NCT00645996|Experimental|1|
3277323|NCT00645996|Placebo Comparator|2|Cornflour
3277324|NCT00645983|Experimental|1|Chamomile Extract
3277325|NCT00645983|Placebo Comparator|2|Anxiolytic Therapy
3277326|NCT00645970||Group 1|
3277327|NCT00645957|Active Comparator|2|This group will have a red rubber drain(s) placed during surgery. This drain(s) will be irrigated intra and post-operatively
3277328|NCT00645957|Active Comparator|1|This group will have a penrose drain(s) placed during surgery to facilitate drainage post-operatively. This drain (s) will not be irrigated.
3277329|NCT00645944|Experimental|Eszopiclone Group|Participants assigned to this arm will receive Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
3277330|NCT00645944|Placebo Comparator|Placebo Group|"Participants assigned to this arm will receive placebo (an inactive substance or a sugar pill) to be taken each night for all weeks of the study."
3277331|NCT00645918|Active Comparator|A|"Tailored clopidogrel regimen - an additional clopidogrel 600-mg loading dose (eight 75-mg tablets taken orally; daily 150 mg clopidogrel dose plus additional 450 mg clopidogrel) on the day of randomization and then 150-mg clopidogrel every day thereafter for 6 months."
3277332|NCT00645918|Placebo Comparator|B|"Standard clopidogrel regimen - a placebo loading dose (six placebo tablets taken orally plus daily dose of one placebo tablet plus 75 mg clopidogrel) on the day of randomization followed by one placebo tablet plus 75 mg clopidogrel every day thereafter for 6 months."
3277333|NCT00645918|Placebo Comparator|C|Responders: A random sample of clopidogrel responders treated with a placebo loading dose (six placebo tablets taken orally plus daily dose of one placebo tablet plus 75 mg clopidogrel) on the day of randomization followed by one placebo tablet plus 75 mg clopidogrel every day thereafter for 6 months.
3277334|NCT00645905|Active Comparator|A|
3277335|NCT00645905|Placebo Comparator|B|
3277336|NCT00645892|Active Comparator|A|
3277337|NCT00645892|Placebo Comparator|B|
3277338|NCT00645879|Experimental|OKG, Glutamine, and Disodium Citrate|Ornithine Alpha Ketoglutarate for 4 weeks, followed by 2 week washout period. 4 weeks Glutamine, followed by 2 week washout period. 4 weeks Disodium Citrate, followed by 2 to 12 week washout period. Then continue an additional 30 weeks on Disodium Citrate (drug producing the best increment in plasma glutamine levels).
3277339|NCT00645853|Experimental|1|
3277340|NCT00645853|Active Comparator|2|
3277341|NCT00645827|Experimental|Insulin infusion conversion equation|Insulin infusion conversion equation is used to determine subcutaneous insulin dosing for first 24 hours after cessation of an IV insulin infusion.
3277342|NCT00645827|Active Comparator|Control|Judgment of patient's healthcare provider is used to determine subcutaneous insulin dosing for first 24 hours after cessation of IV insulin infusion.
3277343|NCT00645814|Placebo Comparator|A|
3277344|NCT00645814|Active Comparator|B|
3277345|NCT00645814|Active Comparator|C|
3277346|NCT00645801|Active Comparator|1|Patients will receive both Amitiza and GoLYTELY
3277347|NCT00645801|Placebo Comparator|2|Patients will receive Amitiza Placebo plus GoLYTELY
3277348|NCT00645788|Experimental|32.50 mg Ciprofloxacin DPI (BAYQ3939)|32.50 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days
3277349|NCT00645788|Experimental|48.75 mg Ciprofloxacin DPI (BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days
3277350|NCT00645788|Placebo Comparator|Matching Placebo for 32.50 mg|Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days
3277351|NCT00645788|Placebo Comparator|Matching Placebo for 48.75 mg|Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days
3277352|NCT00645775|Placebo Comparator|1|Compare active to placebo
3277353|NCT00645762|Active Comparator|Balloon Dilation|Balloon dilation with FinESS device
3277354|NCT00645749|Experimental|Helminth ova|Subjects serving as their own controls (baseline - end-of-treatment) will receive a dose of 2,500 ova, in liquid form, every 2 weeks
3277355|NCT00645736||1|Single cohort
3277356|NCT00645723|Experimental|A|Intravenous colistin and nebulized colistin
3277357|NCT00645723|Placebo Comparator|B|intravenous colistin and saline solution nebulized
3277358|NCT00645710|Experimental|Arm I|"Patients receive floxuridine as a continuous hepatic arterial infusion on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 9 and 11. Patients also receive yttrium Y 90 anti-CEA monoclonal antibody cT84.66 IV over 25 minutes on day 9. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients may receive an additional course of floxuridine in combination with systemic therapy at the discretion of the treating physician."
3277359|NCT00645684|Experimental|A|one layer running suture technique
3277360|NCT00645684|Experimental|B|two-layer suture technique
3277361|NCT00645671|Experimental|Loteprednol Etabonate|Loteprednol etabonate 0.5% ophthalmic ointment
3277362|NCT00645671|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate ointment
3277363|NCT00645645||holoprosencephaly (HPE)|individuals with overt or subtle clinical findings consistent with the HPE spectrum are eligible to participate
3277364|NCT00645619||1|Patients with pure viral pneumonia
3277365|NCT00645619||2|Patients with viral pneumonia along with secondary bacterial pneumonia
3277366|NCT00645619||3|Patients with significant bacterial pneumonia
3277367|NCT00645619||4|Patients with congenital heart disease undergoing cardiopulmonary bypass who have no pneumonia
3277368|NCT00645606|No Intervention|Observation|Observation every 8 weeks during 2 years
3277369|NCT00645606|Experimental|rituximab arm|rituximab :500 mg/m² every 8 weeks during 2 years
3277370|NCT00645593|Active Comparator|Arm 1, Gemcitabine and Cisplatin|Gemcitabine and Cisplatin, as described in the intervention
3277371|NCT00645593|Experimental|Arm 2, Cetuximab, Gemcitabine and Cisplatin|Gemcitabine and Cisplatin with Cetuximab, as described in the intervention
3277372|NCT00645580|Experimental|A|
3277373|NCT00645567||Unassisted manual transfer|this group will use no additional aid in transfer.
3277374|NCT00645567||Standard sliding board transfer|The standard transfer board is a flat surface board designed to bridge the gap that exists with transfers from wheelchair to vehicle and/or other horizontally displaced seating surfaces.
3277375|NCT00645567||Glide n' Go Lift|The Glide n' Go lift is a flip down power list seat that enables the person to enter and exit the vehicle by lifting them from their wheelchair up tot eh vehicle seat that they can make an easy transfer into the vehicle. Trunk stability may be required to successfully use the device.
3277376|NCT00645567||Easy Reach lift|The Easy Reach lift seat allows the vehicles original seat to swivel out of the vehicle and lower to wheelchair height. the chair extends far from the vehicle to provide access for a safe, easy transfer.
3277377|NCT00645567||Ryno lift|The Ryno lift is an under-vehicle list (UVL) system. Using this lift, the wheelchair user is raised into the vehicle cab using independent controls and can then maneuver into a convenient position in the cab. The wheelchair is locked down and the lift stored beneath the vehicle chassis. This technology eliminated the need to store and retrieve a wheelchair during transit.
3277378|NCT00645541|Experimental|Axillary Reverse Mapping (ARM)|
3277379|NCT00645528|Experimental|Insulin Education Class Participants|Participation in an insulin educational class at week 0 and again at week 2
3277380|NCT00645515|Experimental|Arm A|
3277381|NCT00645515|Active Comparator|Arm B|
3277382|NCT00645489|Other|1|Control condition is wait-list control.
3277383|NCT00645489|Experimental|2|Active treatment condition: psychoeducational intervention for patients with HF
3277384|NCT00645463|Experimental|Group A|
3277385|NCT00645463|Experimental|Group B|
3277386|NCT00645450|Experimental|Arm 1|Propranolol
3277387|NCT00645450|Placebo Comparator|Arm 2|Placebo
3277388|NCT00645424|Experimental|Arm A|
3277389|NCT00645424|Experimental|Arm B|
3277390|NCT00645424|Experimental|Arm C|
3277391|NCT00645411|Experimental|Cohorts 1 + Cohort 2 (9-17 Yrs) cTIV|All subjects received one 0.5 mL IM injection, of cell culture-derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like, and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
3277392|NCT00645411|Active Comparator|Cohorts 1 + Cohort 2 (9-17 Yrs) eTIV|All subjects received one 0.5 mL injection, of egg -derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere.
3277393|NCT00645411|Experimental|Cohort 3 (3-8 Yrs) cTIV|All subjects received two 0.5 mL injections, administered four weeks apart, of cell culture-derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
3277394|NCT00645411|Active Comparator|Cohort 3 (3-8 Yrs) eTIV|All subjects received two 0.5 mL injections, administered four weeks apart of egg -derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
3277395|NCT00645398|Experimental|A|
3277396|NCT00645398|Experimental|B|
3277397|NCT00645398|Experimental|C|
3277398|NCT00645398|Placebo Comparator|D|
3277399|NCT00645372|Active Comparator|A|
3277400|NCT00645372|Experimental|B|
3277401|NCT00645359||Diffusion MRI|Patients will undergo a Diffusion MRI (dMRI) at baseline and 7 days.
3277402|NCT00645346|Experimental|1|Subjects will receive either 5, 10 or 20 mcg of the vaccine
3277403|NCT00645346|Placebo Comparator|2|Subjects will receive placebo control
3277404|NCT00645333|Experimental|MK-0752, Docetaxel, Pegfilgrastim|MK-0752, Docetaxel, Pegfilgrastim in combination with escalating doses of MK-0752
3277405|NCT00645320|Experimental|A|
3277406|NCT00645294|Other|Treatment Group A|ADV (0.14 mg/kg) oral suspension formulation on Day 1 followed by ADV (0.3 mg/kg) oral suspension formulation on Day 8 in 2-6 and 7-11 year old age group
3277407|NCT00645294|Other|Treatment Group B|ADV (0.3 mg/kg) oral suspension formulation on Day 1 followed by ADV (0.14 mg/kg) oral suspension formulation on Day 8 in 2-6 and 7-11 year old age group
3277408|NCT00645294|Other|Treatment Group C|ADV 10 mg single dose on Day 1 in 12-17 year old age group
3277409|NCT00645281|Experimental|tolterodine ER group|
3277410|NCT00645268|Active Comparator|Arm 1|
3277411|NCT00645268|Placebo Comparator|Arm 2|
3277412|NCT00645268|Other|Open-Label Arm|
3277413|NCT00645255|Other|1|Single-blind Placebo Run-in with behavioral intervention called Health Management Resources Maintenance Program which provided weekly classes for 12 months with meal replacement
3277414|NCT00645255|Placebo Comparator|2|Double-blind Treatment with behavioral intervention called Health Management Resources Maintenance Program which provided weekly classes for 12 months with meal replacement
3277415|NCT00645242|Experimental|Arm A|
3277416|NCT00645229|Experimental|Arm A|
3277417|NCT00645216|Experimental|CP-945,598 with Grapefruit Juice|CP-945,598 with Grapefruit Juice
3277418|NCT00645216|Experimental|CP-945,598 alone|CP-945,598 alone
3277419|NCT00645203|Other|1|
3277603|NCT00643825|Other|B : Stop and Go|Rechallenging patients with TMZ at relapse
3277420|NCT00645177|Active Comparator|A|"In study, this arm is a randomized (blinded) to ABT-869 arm plus paclitaxel.~Note: Prior to randomization, approximately 6-12 subjects will be enrolled in open-label lead-in to assess the tolerability of the combination. The initial open-label, lead-in cohort of six subjects will be monitored for 2 cycles (8 weeks) to assess the PK interactions and the safety of the combination of 0.20 mg/kg QD ABT-869 and paclitaxel (90 mg/m2). Enrollment into the randomized portion will begin after a cohort has completed two cycles (8 weeks) of therapy and no toxicities prohibit the cohort from continuing on to Cycle 3.~Alternative doses may be explored based on the tolerability of the combination"
3277421|NCT00645177|Placebo Comparator|B|"In study, this arm is a randomized (blinded) to placebo for ABT-869 plus paclitaxel arm.~Note: Prior to randomization, approximately 6-12 subjects will be enrolled in open-label lead-in to assess the tolerability of the combination. The initial open-label, lead-in cohort of six subjects will be monitored for 2 cycles (8 weeks) to assess the PK interactions and the safety of the combination of 0.20 mg/kg QD ABT-869 and paclitaxel (90 mg/m2). Enrollment into the randomized portion will begin after a cohort has completed two cycles (8 weeks) of therapy and no toxicities prohibit the cohort from continuing on to Cycle 3.~Alternative doses may be explored based on the tolerability of the combination"
3277422|NCT00645164|Experimental|Xenaderm|Subject serves as own control
3277423|NCT00645151|Experimental|High Risk|
3277424|NCT00645151|Experimental|Low Risk|
3277425|NCT00645151|Experimental|Medium Risk|
3277426|NCT00645138|Active Comparator|Paravertebral Block|Patients receiving Paravertebral Block.
3277427|NCT00645138|Active Comparator|General Anesthesia|Patients receiving General Anesthesia.
3277428|NCT00645125|Active Comparator|1|
3277429|NCT00645125|Active Comparator|2|
3277430|NCT00645112|Active Comparator|1|
3277431|NCT00645112|Active Comparator|2|
3277432|NCT00645099|Experimental|001|paliperidone ER 6-mg or 9-mg tablet once daily flexible dosing for 6 months
3277433|NCT00645099|Active Comparator|002|olanzapine 10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
3277434|NCT00645086|Active Comparator|A|
3277435|NCT00645086|Active Comparator|B|
3277436|NCT00645073|Active Comparator|A|
3277437|NCT00645073|Active Comparator|B|
3277438|NCT00645060|Experimental|Y-90-DOTA-M5A anti-CEA antibody|
3277439|NCT00645047|Experimental|Telemedicine CBT|Cognitive behaviour therapy (CBT) delivered using videoconference telemedicine.
3277440|NCT00645047|Active Comparator|In-Person CBT|Cognitive behaviour therapy (CBT) delivered using in-person consultation.
3277441|NCT00645034|Active Comparator|Arm 1|
3277442|NCT00645034|Placebo Comparator|Arm 2|
3277443|NCT00645021|Experimental|Mild hepatic function|
3277444|NCT00645021|Experimental|Moderate hepatic function|
3277445|NCT00645021|Experimental|Normal hepatic function|
3277446|NCT00644995|Active Comparator|Usual Care Control|Participants will receive usual care which includes advice to stop smoking and referral to standard care treatment available through participants' health insurance and health plan.
3277447|NCT00644995|Experimental|Step Up Intervention|Participants will receive the Step Up Wellness Program. The intervention is detailed below.
3277448|NCT00644982|Experimental|Sertaline group|
3277449|NCT00644982|Active Comparator|Venlafaxine group|
3277450|NCT00644969|Placebo Comparator|Placebo Arm|Randomization 2:1 treatment to placebo
3277451|NCT00644969|Active Comparator|Treatment Arm|
3277452|NCT00644956|Active Comparator|Arm 1|
3277453|NCT00644956|Active Comparator|Arm 2|
3277454|NCT00644943|Active Comparator|1|
3277455|NCT00644943|Active Comparator|2|
3277456|NCT00644930|Experimental|1|ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated.
3277457|NCT00644930|Active Comparator|2|Patients in the standard therapy group without indications for urgent intubation were only given standard medical therapy (such as oxygen, antibiotics, and bronchodilators), and IMV through an endotracheal tube was applied when intubation criteria were met.
3277458|NCT00644917|Experimental|A|Drug
3277459|NCT00644917|Placebo Comparator|B|Placebo comparator
3277460|NCT00644917|No Intervention|C|Subjects serve as own controls.
3277461|NCT00644904|Experimental|Treatment|Starting dose of 4,000 IU per day of Vitamin D3 titrating up to a dose of 40,000 IU per day of Vitamin D3 by month six. In the second six-month part of the trial, patients titrate back down to 4,000 IU per day of Vitamin D3 and then discontinue it completely at the end of the 12 month trial period.
3277462|NCT00644904|Other|Control|Patients are allowed to supplement with up to 4,000 IU per day of Vitamin D3 if desired.
3277463|NCT00644891|Active Comparator|1|
3277464|NCT00644891|Active Comparator|2|
3277465|NCT00644878|Experimental|Nilotinib|
3277466|NCT00644852||001|
3277467|NCT00644839|Experimental|CP-945,598|
3277468|NCT00644826|Experimental|1|
3277469|NCT00644826|No Intervention|2|
3277470|NCT00644813||1|
3277471|NCT00644800|Experimental|Arm A|
3277472|NCT00644787|Experimental|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14. Participants who met the predefined criteria at the end of Titration Phase enter the Double Blind Phase.
3277473|NCT00644787|Experimental|Fentanyl 1-day transdermal patch (Double Blind Phase)|Participants who meet the predefined criteria at the end of Titration Phase and enter the Double Blind Phase receive fentanyl 1-day application transdermal patch and placebo matched to fentanyl 3-day application (JNS005) transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
3277541|NCT00644228|Active Comparator|Arm I (dexamethasone and lenalidomide)|Patients receive dexamethasone PO QD on days 1, 8, 15, and 22 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3277474|NCT00644787|Active Comparator|Fentanyl 3-day transdermal patch (Double Blind Phase)|Participants who meet the predefined criteria at the end of Titration Phase and enter the Double Blind Phase receive fentanyl 3-day application transdermal patch and placebo matched to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
3277475|NCT00644774|Active Comparator|1|
3277476|NCT00644774|Active Comparator|2|
3277477|NCT00644761|Other|Treatment Arm 1|Adefovir dipivoxil 10 mg once daily with tacrolimus or cyclosporine for 14 days
3277478|NCT00644748|Experimental|Gabapentin group|
3277479|NCT00644735|Experimental|1|Nexium
3277480|NCT00644735|Active Comparator|2|Prevacid
3277481|NCT00644722|Active Comparator|1|Single use metallic blades
3277482|NCT00644722|Active Comparator|2|Classic reusable metallic blades
3277483|NCT00644709|Experimental|Arm A|
3277484|NCT00644696|Experimental|Irinotecan and Bortezomib|Irinotecan and Bortezomib will both be administered
3277485|NCT00644670|Experimental|Previous Treatment with a Usual Maintenance Dose of a Statin|
3277486|NCT00644670|Experimental|Statin-Naive|
3277487|NCT00644644||1|monitored
3277488|NCT00644644||2|control
3277489|NCT00644631|Active Comparator|Arm 1|
3277490|NCT00644631|Placebo Comparator|Arm 2|
3277491|NCT00644618|Active Comparator|A|
3277492|NCT00644618|Experimental|B|
3277493|NCT00644605|Active Comparator|Arm 1|
3277494|NCT00644605|Active Comparator|Arm 2|
3277495|NCT00644605|Active Comparator|Arm 3|
3277496|NCT00644605|Placebo Comparator|Arm 4|
3277497|NCT00644592|Active Comparator|1-Fenofibrate then Placebo|4 weeks of drug at 160 mg orally per day, 4 week washout, then 4 weeks of placebo
3277498|NCT00644592|Active Comparator|2 Placebo then Fenofibrate|4 weeks of placebo then 4 week washout then 4 weeks of Fenofibrate at 160 mg/day orally.
3277499|NCT00644579|Active Comparator|1|bLAC high dose
3277500|NCT00644579|Active Comparator|2|bLAC low dose
3277501|NCT00644579|Placebo Comparator|3|
3277502|NCT00644566|No Intervention|TAU|Treatment as usual. These subjects and their providers were told to pursue treatment services as they normally would do.
3277503|NCT00644566|Experimental|shared care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
3277504|NCT00644553|Active Comparator|A|
3277505|NCT00644553|Active Comparator|B|
3277506|NCT00644540|Experimental|1|
3277507|NCT00644540|Active Comparator|2|
3277508|NCT00644527|Experimental|1|Listening to one of two different specific music programs (Group A), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
3277509|NCT00644527|Experimental|2|Listening to one of two different specific music programs (Group B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
3277510|NCT00644527|Sham Comparator|3|Control I (Group C) : Listening 30 min in the morning and 30 min in the evening to unspecific music (Mozart) over 5 weeks.
3277511|NCT00644527|No Intervention|4|Control II (Group D): Waiting list. - Each 50% of the subjects will be assigned randomly to either Group A (arm 1) and B (arm 2) after 5 weeks of waiting time.
3277512|NCT00644514|Experimental|LPS endotoxin inh f/u bronchoscopy|Participants receive inhalation of LPS endotoxin, followed by bronchoscopy in this study.
3277513|NCT00644501|Experimental|1|
3277514|NCT00644488|Experimental|A1|Active
3277515|NCT00644475|Experimental|2|Imidapril
3277516|NCT00644475|Active Comparator|1|Candesartan
3277517|NCT00644462||1|Asthmatic subjects
3277518|NCT00644462||2|Healthy subjects
3277519|NCT00644449|Experimental|1|
3277520|NCT00644449|Experimental|2|
3277521|NCT00644436|Experimental|1|Single topical application
3277522|NCT00644436|Active Comparator|2|Single topical application
3277523|NCT00644423|Active Comparator|1|Omega-3 Fatty Acid
3277524|NCT00644423|Placebo Comparator|2|Placebo
3277525|NCT00644410|Active Comparator|1|The number of mesenchymal stromal cells reached after two culture expansion passages.
3277526|NCT00644410|Placebo Comparator|2|Saline
3277527|NCT00644397||Blade Plate Group|95-degree Angled Blade Plate
3277528|NCT00644397||Locking Plate Group|4.5mm Condylar Locking Plate
3277529|NCT00644371|Experimental|1|
3277530|NCT00644358|Experimental|Vilazodone|Vilazodone titrated up to 40 mg/day for 1 year.
3277531|NCT00644306|Placebo Comparator|A|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
3277532|NCT00644306|Active Comparator|B|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
3277533|NCT00644293|Experimental|1|
3277534|NCT00644293|Experimental|2|
3277535|NCT00644280|Active Comparator|Ranibizumab|Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at 3 time points: 9 days before Ahmed tube insertion for open-angle glaucoma, 1 month post-surgery, and 2 months post-surgery
3277536|NCT00644280|No Intervention|Usual care|Standard of care Ahmed tube insertion for open-angle glaucoma without injections of Ranibizumab
3277537|NCT00644267|Active Comparator|1|Subjects will use a telemedicine system for blood pressure control
3277538|NCT00644267|No Intervention|2|Patients with hypertension receiving usual care by a primary care physician
3277539|NCT00644254||Resected DPAC|145 consecutive resections for primary ductal pancreatic adenocarcinoma (DPAC)performed between 1998 and 2005.
3277540|NCT00644241|Experimental|stem cell|
3277602|NCT00643825|Active Comparator|A: prolonged adj TMZ|
3277542|NCT00644228|Experimental|Arm II (dexamethasone, lenalidomide, bortezomib)|Patients receive dexamethasone PO QD on days 1, 2, 4, 5, 8, 9, 11, and 12; lenalidomide PO QD on days 1-14; and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
3277543|NCT00644215|Experimental|1|5-FU injection has been done
3277544|NCT00644215|Experimental|2|Mitomycin drop has been administrated
3277545|NCT00644202|Experimental|Group 1|Intervention Group
3277546|NCT00644202|No Intervention|Group 2|Usual Care Group
3277547|NCT00644189|Other|Clofarabine|Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
3277548|NCT00644176|Experimental|1|
3277549|NCT00644176|Experimental|2|
3277550|NCT00644163|Experimental|1|Participants will receive Eban HIV/STD Risk Reduction Intervention.
3277551|NCT00644163|Active Comparator|2|Participants will receive Eban Health Promotion Intervention.
3277552|NCT00644150|Experimental|1|Physicians of county level will receive Ai Shi Zi training provided by experts in the fields of HIV/STIs, behavioral counseling, and stigma reduction.
3277553|NCT00644150|Experimental|2|Physicians of township level will receive Ai Shi Zhi training provided by the county level physicians.
3277554|NCT00644150|Experimental|3|HIV/STI patients will receive standard of care and specialized care from physician participants trained in Ai Shi Zi.
3277555|NCT00644150|No Intervention|4|Physicians of county level who will not participate in Ai Shi Zi training
3277556|NCT00644150|No Intervention|5|Physicians of township level who will not participate in Ai Shi Zi training
3277557|NCT00644150|Sham Comparator|6|HIV/STI patients who will receive standard care only
3277558|NCT00644137|Experimental|A|pregabalin 300mg/day given in conjunction with smoking cigarettes.
3277559|NCT00644137|Experimental|2|cigarettes given in conjunction with pregabalin
3277560|NCT00644124|Experimental|Aflibercept RCHOP 14|Aflibercept (25 mg/ml by IV over an hour) in combination with fixed dose of rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) administered every 2 weeks. A dose of 2.0 mg/kg administered as Dose Level 1, 4.0 mg/kg as Dose Level 2, and 6.0 mg/kg dose as Dose level 3.
3277561|NCT00644124|Experimental|Aflibercept RCHOP 21|Aflibercept (25 mg/ml by IV over an hour) in combination with fixed dose of rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) administered every 3 weeks. A dose of 3.0 mg/kg administered as Dose Level 1, 6.0 mg/kg as Dose Level 2, and 8.0 mg/kg dose as Dose level 3.
3277562|NCT00644111|Placebo Comparator|1|Control group receiving saline placebo through an epidural catheter
3277563|NCT00644111|Active Comparator|2|Experimental group receiving active medication through the epidural catheter
3277564|NCT00644098|Placebo Comparator|Placebo|cellulose and soybean oil
3277565|NCT00644098|Experimental|Intervention|soluble fibre complex and medium chain triglycerides
3277566|NCT00644085|Experimental|1|oral administration of aspirin 100 mg
3277567|NCT00644085|Placebo Comparator|2|oral administration of placebo
3277568|NCT00644059|Experimental|TIV-adj|Adjuvanted trivalent inactivated subunit influenza vaccine
3277569|NCT00644059|Active Comparator|Flu-control|Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine
3277570|NCT00644059|Sham Comparator|Non-flu Control|Novartis meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
3277571|NCT00644046|No Intervention|1|Chronic kidney disease patient with standardized nephrology care
3277572|NCT00644046|Active Comparator|2|chronic kidney disease patient with multidisciplinary predialysis care
3277573|NCT00644033|Active Comparator|1|
3277574|NCT00644033|Active Comparator|2|
3277575|NCT00644033|Placebo Comparator|3|
3277576|NCT00644020||Group 1|the Tyroserleutide for injection at the dosage of 3mg/d
3277577|NCT00644020||Group 2|the Tyroserleutide for injection at the dosage of 6mg/d
3277578|NCT00644020||Group 3|the Tyroserleutide for injection at the dosage of 12mg/d
3277579|NCT00644020||Group 4|the placebo group
3277580|NCT00644007|Placebo Comparator|Group 1|
3277581|NCT00644007|Experimental|Group 2|
3277582|NCT00643994|Experimental|CyberKnife Stereotactic Radiosurgery|
3277583|NCT00643968|Active Comparator|1|TDF+EFV
3277584|NCT00643968|Experimental|2|TDF+3TC+EFV
3277585|NCT00643955||DS|Individual with Down Syndrome
3277586|NCT00643942||1|
3277587|NCT00643929||Observational|Subjects who have participated in a prior eltrombopag study, receiving either placebo or eltrombopag
3277588|NCT00643916|Experimental|Vaccinated at Age 9 and 12 Months|Participants received Menactra® vaccine at 9 and 12 Months of age
3277589|NCT00643916|Experimental|Vaccinated at Age 9 and 15 Months|Participants received Menactra® vaccine at 9 and 15 Months of age
3277590|NCT00643916|Experimental|Vaccinated at Age 12 and 15 Months|Participants received Menactra® vaccine at Age 12 and 12 Months of age
3277591|NCT00643916|Experimental|Vaccinated at Age 15 Months|Participants received Menactra® vaccine at 15 Months of age
3277592|NCT00643916|Experimental|Vaccinated at Age 18 Months|Participants received Menactra® vaccine at 18 Months of age
3277593|NCT00643916|Active Comparator|Vaccinated at Age 3 Years to <6 Years|Participants received Menomune® vaccine at Age 3 years to <6 years of age
3277594|NCT00643903|Experimental|1|Participants will receive five individual sessions of coping effectiveness training.
3277595|NCT00643903|Active Comparator|2|Participants will receive standard care and one delayed group workshop of coping effectiveness training.
3277596|NCT00643877|Experimental|B|PHRAC was performed 7 days before surgery. Adjuvant chemotherapy using FOLFOX7 was done for 8 cycle with 28 days after surgery.
3277597|NCT00643877|No Intervention|A|Adjuvant chemotherapy using FOLFOX7 was done for 8 cycle with 28 days after surgery.
3277598|NCT00643851|Experimental|Arm 1|Dapagliflozin (5 mg) + Metformin XR (up to 2000 mg)
3277599|NCT00643851|Experimental|Arm 2|Dapagliflozin (5 mg)
3277600|NCT00643851|Active Comparator|Arm 3|Metformin XR (500 mg up to 2000 mg)
3277601|NCT00643838|Experimental|A|Misture of 50% nitrous oxide and 50% oxygen
3277604|NCT00643812|Experimental|1|"The Early intervention arm received a gun locker at baseline"
3277605|NCT00643812|Active Comparator|2|Households in this arm received a gun locker at 12 months following the baseline survey
3277606|NCT00643799|Experimental|A|
3277607|NCT00643799|Active Comparator|B|
3277608|NCT00643799|Placebo Comparator|C|
3277609|NCT00643786|Experimental|A|Oxygène
3277610|NCT00643786|Placebo Comparator|B|Air Médical
3277611|NCT00643773|Experimental|A|Leucine supplement
3277612|NCT00643773|Placebo Comparator|B|Wheat flour
3277613|NCT00643760|Placebo Comparator|Placebo|Placebo
3277614|NCT00643760|Other|Pregabalin|Pregabalin 300mg/day (positive control), maintenance treatment 14 weeks
3277615|NCT00643760|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks
3277616|NCT00643760|Experimental|GEn 2400mg/day|gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks
3277617|NCT00643760|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, maintanance treatment 14 weeks
3277618|NCT00643747|Experimental|A|Injection of vector
3277619|NCT00643734|Experimental|1|
3277620|NCT00643734|Experimental|2|
3277621|NCT00643721||D,FR|Young healthy athletes
3277622|NCT00643708||A|14 cases
3277623|NCT00643708||B|14 cases
3277624|NCT00643708||C|14 cases
3277625|NCT00643708||D|14 Cases
3277626|NCT00643695|Experimental|1|Home-based walking program
3277627|NCT00643695|Other|2|educational intervention
3277628|NCT00643682|Experimental|A|Patients in this arm will be given an educational card in addition to the standard pre-endoscopy instructions.
3277629|NCT00643682|No Intervention|B|Patients in this arm will be given the standard pre-endoscopy instructions.
3277630|NCT00643669|Experimental|AL-3789|AL-3789 Sterile Suspension, single depot administration of 0.8 mL in the study eye
3277631|NCT00643669|No Intervention|No treatment|Fellow eye, as randomized
3277632|NCT00643656|Experimental|A|Mixture of 50% nitrous oxide and 50% oxygen
3277633|NCT00643656|Placebo Comparator|B|Mixture of 50% oxygen and 50% nitrogen
3277634|NCT00643643|Experimental|A|
3277635|NCT00643643|Experimental|B|
3277636|NCT00643643|Experimental|C|
3277637|NCT00643643|Experimental|D|
3277638|NCT00643643|Placebo Comparator|E|
3277639|NCT00643630|Experimental|1|Twice daily topical application
3277640|NCT00643630|Placebo Comparator|2|Twice daily topical application
3277641|NCT00643617|Other|Heterogeneous dose|38 Gy delivered in 4 fractions of 9.5 Gy per fraction with CyberKnife Stereotactic Radiosurgery
3277642|NCT00643604|Experimental|treprostinil sodium|all subjects had switched from IV epoprostenol to IV treprostinil sodium
3277643|NCT00643591||Observational|Patients with a primary glioblastoma
3277644|NCT00643578|Active Comparator|2|a single dose of 24 mcg of formoterol
3277645|NCT00643578|Active Comparator|1|a single dose of 12 mcg of formoterol
3277646|NCT00643565|Experimental|1|
3277647|NCT00643565|Active Comparator|2|
3277648|NCT00643539|Experimental|1|
3277649|NCT00643539|Experimental|2|
3277650|NCT00643526|Experimental|Injection Site: First Thigh Then Abdomen|Participants will self inject subcutaneously placebo using auto injector at thigh followed by self injection of placebo subcutaneously at abdomen on Day 1.
3277651|NCT00643526|Experimental|Injection Site: First Abdomen then Thigh|Participants will self inject subcutaneously placebo using auto injector at abdomen followed by self injection of placebo subcutaneously at thigh on Day 1.
3277652|NCT00643487||1|observation of the behavior of the infrapatellar plica
3277653|NCT00643474|Experimental|A|
3277654|NCT00643474|Experimental|B|
3277655|NCT00643461||Adhesive A|
3277656|NCT00643461||Adhesive B|
3277657|NCT00643461||Adhesive C|
3277658|NCT00643448|Experimental|AZD1305 loading dose 250 mg + 125 mg|Tablets
3277659|NCT00643448|Experimental|AZD1305 loading dose 500 mg + placebo|Tablets
3277660|NCT00643448|Placebo Comparator|Placebo corresponding to AZD1305 loading dose|Tablets
3277661|NCT00643435|Experimental|1|These residents receive training provided by standardized patient instructors, in use of self-efficacy enhancing interviewing techniques to support patient health behavior change,
3277662|NCT00643435|Active Comparator|2|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
3277663|NCT00643422||Observation|
3277664|NCT00643409|Experimental|1|
3277665|NCT00643409|Experimental|2|
3277666|NCT00643383|Active Comparator|1|
3277667|NCT00643383|Placebo Comparator|2|
3277668|NCT00643370||1|single arm study
3277669|NCT00643357|Experimental|A|50% Oxygen/50% Nitrous oxide premix (Kalinox® 170 bar)
3277670|NCT00643357|Placebo Comparator|B|50%Oxygen/50% Nitrogen premix
3277671|NCT00643344|Experimental|CALMM+|Participants receiving CALMM intervention, ie program that combines stress reduction, mindful eating practices with diet and exercise
3277672|NCT00643344|Active Comparator|TLC|Participants receiving diet and exercise classes only
3277673|NCT00643331|Experimental|1|Exercise performed at the gym and at home
3277674|NCT00643331|No Intervention|2|Usual care no additional exercise
3277675|NCT00643318|Experimental|CyberKnife Stereotactic Radiosurgery|
3277676|NCT00643305|Experimental|1|Skills Building with Motivational Interviewing (SB-MI)- combines education and general skills-building participants can use to reduce their at-risk behavior for HIV with increasing motivation to change HIV risk behaviors
3277677|NCT00643305|Active Comparator|2|Skills Building (SB) - provides education and general skills-building for reduction of HIV risk behaviors.
3277678|NCT00643292|Experimental|1|
3277679|NCT00643292|Experimental|2|
3277680|NCT00643266|Experimental|1|Recollection training via graduated increases in task difficulty, carried out over 36 sessions over 9 training days
3277681|NCT00643266|Active Comparator|2|Computer-delivered information sessions about memory and aging with Jeopardy-like games to engage participants
3277682|NCT00643253|Experimental|1|Receipt of behavioral interventions to encourage breastfeeding.
3277683|NCT00643253|No Intervention|2|Standard of Care
3277684|NCT00643240|Experimental|111 In-BU-12|111In-BU-12 is the 111Indium-labeled murine monoclonal antibody used for imaging and dosimetry.
3277685|NCT00643227|Experimental|1|
3277686|NCT00643227|Experimental|2|
3277687|NCT00643214|Experimental|1|Twice daily topical application
3277688|NCT00643214|Placebo Comparator|2|Twice daily topical application
3277689|NCT00643201|Active Comparator|Apixaban|apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.
3277690|NCT00643201|Experimental|Enoxaparin + Warfarin|Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until international normalized ratio (INR) ≥2.
3277691|NCT00643188|Experimental|1|"Radiofrequency ablation of atrial fibrillation:~Subjects assigned to the catheter AF ablation strategy will undergo ablation within 48 hours after baseline evaluation. The aim of the procedure is to achieve isolation of all Pulmonary Veins (PVs) and to restore sinus rhythm. Only radiofrequency catheter based AF ablation is permitted; other methods, like cryoablation, ultrasound and laser, are not permitted in this study.~Before ablation, a transesophageal echocardiogram must be performed in order to rule out presence of atrial thrombi.~Anticoagulation should be initiated, or continued, for at least six months post ablation. Six months after successful ablation and in absence of any recurrence of AF, antiarrhythmic drugs should be discontinued."
3277692|NCT00643188|Active Comparator|2|"Conventional treatment:~Subjects assigned to the conventional treatment strategy will be treated according to current guidelines for the management of patients with chronic heart failure and/or atrial fibrillation. Efforts to maintain sinus rhythm in this study arm are recommended.~Anticoagulation will be initiated, if not already started, and maintained throughout the study according to current guidelines."
3277693|NCT00643175||1|Osteoporosis in patients with fragility hip fractures.
3277694|NCT00643162|Experimental|Swedish Massage|Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.
3277695|NCT00643162|Sham Comparator|Light-Touch|Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.
3277696|NCT00643149|Experimental|1|
3277697|NCT00643149|Experimental|2|
3277698|NCT00643136|Experimental|Pregabalin|
3277699|NCT00643136|Placebo Comparator|Placebo|
3277700|NCT00643123|Experimental|Allopurinol|Subjects will be randomized to allopurinol at a fixed dose of 300 mg/day for the first week and then 600mg/day while continuing their current medications during the 7-week study. A battery of assessments will be administered at baseline and weeks 1, 2, 4, 6 after baseline. At each assessment, subjects will also be asked about side effects including potential side effects of allopurinol. Side effects will be assessed by the Treatment Emergent Side Effects Scale. Serum levels of lithium, valproic acid, carbamazepine, atypical antipsychotics or atypical antipsychotic metabolite, uric acid blood levels will be drawn at screen and at week 6 after baseline. Subjects taking only lithium, valproic acid, and/or carbamazepine will also have their serum levels drawn at week 2.
3277701|NCT00643123|Placebo Comparator|Placebo|Subjects will be randomized to placebo and will follow the same protocol as the allopurinol group.
3277702|NCT00643097|Experimental|Arm I (ACTIVATE)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)-specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, every 2 weeks starting 4 weeks after the completion of radiation. Subsequent vaccinations were given once a month until clinical or radiographic evidence of progression or death.
3277703|NCT00643097|Experimental|Arm II (ACT II STD)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)- specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, biweekly starting within 6 weeks of completing radiation. Additional vaccinations were given until clinical or radiographic evidence of progression or death. Patients subsequently receive temozolomide at a targeted dose of 200 mg/m2 for the first 5 days of a 28 day cycle.
3277704|NCT00643097|Experimental|Arm III (ACT II DI)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)- specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, biweekly starting within 6 weeks of completing radiation. Additional vaccinations were given until clinical or radiographic evidence of progression or death. Patients subsequently receive temozolomide at a targeted dose of 100 mg/m2 for the first 21 days of a 28 day cycle.
3277705|NCT00643084|Experimental|1|patients will consume a low residue diet prior to surgery and have no routine bowel preparation
3277706|NCT00643084|Other|2|standard bowel preparation
3277707|NCT00643071|Experimental|1|
3277708|NCT00643058|Experimental|1|Sterile Saline, LPS endotoxin
3277709|NCT00643045|Experimental|1|Low dose (50-100mg/day)
3277710|NCT00643045|Experimental|2|High dose (150-200 mg/day)
3277711|NCT00643045|Placebo Comparator|3|
3277712|NCT00643032|Active Comparator|I|
3277713|NCT00643032|Active Comparator|II|
3277714|NCT00643019|Experimental|SAFE Intervention|Behavioral Intervention
3277715|NCT00643019|Other|Control|Sexually Transmitted Infection Risk Reduction Counseling
3277716|NCT00643006|Experimental|A. High intensive exercise|High intensive exercise
3277717|NCT00643006|Active Comparator|B. Low-intensive exercise|Low-to-moderate intensive supervised walks
3277718|NCT00642993|Experimental|SCH 497079|SCH 497079, administered orally, once daily
3277719|NCT00642993|Placebo Comparator|Placebo|Placebo capsules, administered orally, once daily
3277720|NCT00642980|Active Comparator|Clindamycin Cure 1|Arm 1
3277721|NCT00642980|Active Comparator|Clindamycin Cure 2|Arm 2
3277722|NCT00642980|Placebo Comparator|Placebo|Arm placebo
3277723|NCT00642967|Experimental|1|
3277751|NCT00642863|Experimental|Low birth iron|Infants with low birth iron who receive vitamins A and D + iron
3277752|NCT00642863|Experimental|Marginal birth iron 1|Infants with marginal birth iron randomized to receive vitamins A and D + iron
3277724|NCT00642954|Experimental|Phase I|"Dose escalation study. Level 1: 300 mg daily (q.d.) vorinostat orally (p.o.) for 14 days in combination with 10 mg q.d. lenalidomide p.o. for 21 days. Level 2: 400 mg q.d. vorinostat p.o. for 14 days in combination with 10 mg q.d. lenalidomide p.o. for 21 days. Level 3: 400 mg q.d. vorinostat p.o. for 14 days in combination with 15 mg q.d. lenalidomide p.o. for 21 days. Level 4: 400 mg q.d. vorinostat p.o. for 14 days in combination with 20 mg q.d. lenalidomide p.o. for 21 days. Level 5: 400 mg q.d. vorinostat p.o. for 14 days in combination with 25 mg q.d. lenalidomide p.o. for 21 days. 40 mg q.d. Dexamethasone p.o. will be given in each level on days 1, 8, 15, and 22 of each treatment cycle. Each treatment cycle will be 28 days with a maximum of 8 treatment cycles.~Participants who do not have disease progression and who continue to meet the eligibility criteria after the 8 cycles will be offered continued treatment at the same dose level and schedule."
3277725|NCT00642941|Experimental|Cohort 1: Ewing's Sarcoma Primary Cohort|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.
3277726|NCT00642941|Experimental|Cohort 2: Ewing's Sarcoma Secondary Cohort|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.
3277727|NCT00642941|Experimental|Cohort 3: Ewing's Sarcoma Expanded Cohort|Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.
3277728|NCT00642941|Experimental|Cohort 4: Osteosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.
3277729|NCT00642941|Experimental|Cohort 5: Synovial Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.
3277730|NCT00642941|Experimental|Cohort 6: Rhabdomyosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.
3277731|NCT00642941|Experimental|Cohort 7a: Alveolar Soft Part Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a includes individuals with alveolar soft part sarcoma.
3277732|NCT00642941|Experimental|Cohort 7b: Desmoplastic Small Round Cell Tumors.|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.
3277733|NCT00642941|Experimental|Cohort 7c: Extraskeletal Myxoid Chondrosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.
3277734|NCT00642941|Experimental|Cohort 7d: Clear Cell Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.
3277735|NCT00642941|Experimental|Cohort 7e: Myxoid Liposarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.
3277736|NCT00642941|Experimental|Cohort 8: Diagnosis Not Specified|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.
3277737|NCT00642928|Placebo Comparator|Placebo|
3277738|NCT00642928|Experimental|BF 2.649-5 mg|
3277739|NCT00642928|Experimental|BF 2.649 10 mg|
3277740|NCT00642928|Experimental|BF 2.649 20 mg|
3277741|NCT00642928|Experimental|BF 2.649 40 mg|
3277742|NCT00642902|Experimental|Atacicept 25 mg|
3277743|NCT00642902|Experimental|Atacicept 75 mg|
3277744|NCT00642902|Experimental|Atacicept 150 mg|
3277745|NCT00642902|Placebo Comparator|Placebo|
3277746|NCT00642889|Experimental|High Dose|150-200mg/day
3277747|NCT00642889|Experimental|Low dose|50-100mg/day
3277748|NCT00642889|Placebo Comparator|Placebo|
3277749|NCT00642876|Active Comparator|Control|The Control cohort are patients that receive the fusion treatment.
3277750|NCT00642876|Experimental|Investigational|The Investigational cohort are the study patients that received the PRESTIGE® Cervical Disc.
3277753|NCT00642863|Active Comparator|Marginal birth iron 2|Infants with marginal birth iron randomized to receive vitamins A and D without iron
3277754|NCT00642863|Active Comparator|Normal birth iron|Infants with normal birth iron who receive vitamins A and D without iron
3277755|NCT00642863|Experimental|Combined ID|Marginal-birth-iron vitamins only-treated infants who have IDA at 9 mo.
3277756|NCT00642863|Experimental|Early postnatal IDA|Infants with IDA at 9 months whose cord blood was collected at birth but who were not assessed and assigned to vitamins with or without iron at 6 weeks
3277757|NCT00642863|Experimental|Late postnatal IDA|Infants with IDA at 18 months whose cord blood was collected at birth but who were not assessed and assigned to vitamins with or without iron at 6 weeks. These infants were also not anemic when screened at 9 months.
3277758|NCT00642850|Experimental|1|
3277759|NCT00642837||001|
3277760|NCT00642837||002|
3277761|NCT00642837||003|
3277762|NCT00642837||004|
3277763|NCT00642837||005|
3277764|NCT00642837||006|
3277765|NCT00642837||007|
3277766|NCT00642837||008|
3277767|NCT00642837||009|
3277768|NCT00642824|Experimental|1|
3277769|NCT00642811|Experimental|1|Aspirin + Ticagrelor
3277770|NCT00642811|Active Comparator|2|Aspirin + Clopidogrel
3277771|NCT00642785||1|Patients with active oral or genital HSV skin lesions
3277772|NCT00642785||2|Patients with a history of recurrent oral or genital HSV but without an active lesion at the time of treatment
3277773|NCT00642785||3|Patients with active shingles/zoster
3277774|NCT00642785||4|Patients with post herpetic neuralgia
3277775|NCT00642772|Experimental|Group Physical Therapy|12-week group-based program of physical therapy. Participants will meet approximately every other week for a total of 6 visits. The group sessions will include education about appropriate self-care for knee osteoarthritis and instructions and participation in group exercises. Participants will also be instructed in a home exercise program.
3277776|NCT00642759|Experimental|Chemotherapy|Carboplatin, nab-paclitaxel, and bevacizumab
3277777|NCT00642746|Experimental|FOLFOX with Erlotinib|Subjects received FOLFOX (Leucovorin, Fluorouracil, and Oxaliplatin) and Erlotinib. Treatment consisted of a 28 day cycle. Subjects received FOLFOX on days 1, 2, and 3, and 15-16, followed by Erlotinib on days 3-8, and 17-22.
3277778|NCT00642746|Experimental|FOLFIRI with Erlotinib|Subjects received FOLFIRI (Leucovorin, Fluorouracil, and Irinotecan) and Erlotinib. Treatment consisted of a 28 day cycle. Subjects received FOLFIRI on days 1, 2, and 3, and 15-16, followed by Erlotinib on days 3-8, and 17-22.
3277779|NCT00642733|Experimental|1|
3277780|NCT00642720|Other|pegvisomant-placebo|patients in this arm received(as addition)for the first 8 weeks Pegvisomant and the later for 8 weeks Placebo. This was divided by a 4 weeks wash-out period.
3277781|NCT00642720|Other|placebo-pegvisomant|Patient received for the first 8 weeks Pegvisomant and after a wash out period of 4 weeks the received 8 of placebo treatment
3277782|NCT00642707|Active Comparator|Arm 1|PRO 140 for three single SC doses: Days 1, 8, and 15
3277783|NCT00642707|Active Comparator|Arm 2|PRO 140 for three single SC doses: Days 1, 8 and 15
3277784|NCT00642707|Active Comparator|Arm 3|PRO 140 for two single SC doses: Days 1 and 15 plus one SC dose of PBO at Day 8
3277785|NCT00642707|Placebo Comparator|Arm 4|PBO for three single SC doses: Days 1, 8 and 15
3277786|NCT00642694|Experimental|1|Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Ramelteon (One 8 mg capsule at night)
3277787|NCT00642694|Placebo Comparator|2|Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Matching Placebo (One capsule at night)
3277788|NCT00642681||1: TI Inhalation Powder|Technosphere® Insulin (TI) Inhalation Powder
3277789|NCT00642668|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants received methoxy polyethylene glycol-epoetin beta treatment monthly for 36 weeks with an efficacy evaluation period (EEP) during weeks 29-36 and followed by a 4 week follow-up period.
3277790|NCT00642642|Experimental|Double blinded active|Subject will receive autologous fibroblast treatment on either their left or right side of their face
3277791|NCT00642642|Placebo Comparator|Double blinded placebo|Subject will receive placebo treatment on the opposite side of the face from active treatment
3277792|NCT00642629|Active Comparator|1|STA-5326 mesylate
3277793|NCT00642629|Placebo Comparator|2|Placebo
3277794|NCT00642616|Experimental|Technosphere® Insulin (Asthma)|Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Asthma
3277795|NCT00642616|Active Comparator|Usual Care (Asthma)|Usual anti diabetic care in Diabetic participants with Asthma
3277796|NCT00642616|Experimental|Technosphere® Insulin (COPD)|Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
3277797|NCT00642616|Active Comparator|Usual Care (COPD)|Usual anti diabetic care in Diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
3277798|NCT00642603|Experimental|XELOX + bevacizumab (Q2W)|
3277799|NCT00642603|Experimental|XELIRI + bevacizumab (Q2W)|
3277800|NCT00642590||1|Healthy couples who are planning their first pregnancy.
3277801|NCT00642577|Experimental|1|
3277802|NCT00642577|Active Comparator|2|
3277803|NCT00642564||001|
3277804|NCT00642551|Active Comparator|MK-7|1 capsule per day existing of 180 µg menaquinone-7
3277805|NCT00642551|Placebo Comparator|Placebo|1 placebo capsule per day for three years
3277806|NCT00642538|Experimental|1|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
3277807|NCT00642538|Experimental|2|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
3277808|NCT00642538|Experimental|3|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
3277809|NCT00642538|Placebo Comparator|4|TIP (placebo comparison)
3277810|NCT00642538|Active Comparator|5|10 ug subcutaneous control
3277811|NCT00642525|Experimental|A|A prospective, blinded, intraindividual controlled study is conducted with patients with transthoracic esophagectomy due to esophageal cancer. A radiographic contrast study is performed prior to endoscopy at the 5th to 7th postoperative day.
3277812|NCT00642512|Experimental|1|
3277813|NCT00642512|Active Comparator|2|
3277814|NCT00642512|Other|3|
3277818|NCT00642486|Active Comparator|1|laboratory-based testing
3277819|NCT00642486|Active Comparator|2|home-based testing
3277820|NCT00642473|Experimental|Prevention (Erlotinib + Metronidazole Actavis)|Participants will receive erlotinib orally daily. Metronidazole actavis treatment will be initiated at the same day as the start of erlotinib. Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks. Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
3277821|NCT00642473|Experimental|Treatment (Erlotinib + Metronidazole Actavis)|Participants will receive erlotinib orally daily. Metronidazole actavis treatment will be initiated when participants develop rash. Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks. Left side of the face and chest was treated according to local standard procedures (ie, with non-active moisturizing cream).
3277822|NCT00642460|Experimental|1|
3277823|NCT00642460|Placebo Comparator|2|
3277824|NCT00642447|Experimental|1|
3277825|NCT00642434|Active Comparator|1|study drug
3277826|NCT00642434|Active Comparator|2|study drug
3277827|NCT00642421|Experimental|Population A|Based on the dose of their previous Sandostatin-LAR treatment, Population A will receive 10 or 20 mg of C2L-OCT-01 PR at 5-week intervals.
3277828|NCT00642421|Experimental|Population B|Population B, naive patients and patients who have stopped their treatment with prolonged release octreotide for at least 12 weeks, will receive 20 mg C2L-OCT-01 PR at 5-week intervals.
3277829|NCT00642408|Experimental|MMN|multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
3277830|NCT00642408|Active Comparator|IFA|iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
3277831|NCT00642395|Experimental|1|bortézomib
3277832|NCT00642382|Active Comparator|Active|Agilus (Hyaluronic Acid)
3277833|NCT00642382|Placebo Comparator|Control|Normal Saline
3277834|NCT00642369|Experimental|quetiapine fumarate|quetiapine fumarate was administered 25mg on the 1st day,738±41mg/day on the 14th day, and 738±48mg/day on the 28th day.
3277835|NCT00642369|Active Comparator|haloperidol|haloperidol was administered 2mg on the 1st day,16±7mg/day on the 14th day, and 18±6mg/day on the 28th day.
3277836|NCT00642356|Experimental|Carbidopa/levodopa/entacapone|
3277837|NCT00642356|Active Comparator|Immediate release carbidopa/levodopa|
3277838|NCT00642343|Placebo Comparator|1|Children with severe to profound deafness that have not received any intervention.
3277839|NCT00642343|Active Comparator|2|Children with an unilateral cochlear implant.
3277840|NCT00642343|Active Comparator|3|Children with bilateral cochlear implants.
3277841|NCT00642343|Active Comparator|4|Children who receive their second implant during the duration of the study.
3277842|NCT00642330|Active Comparator|I|
3277843|NCT00642330|Active Comparator|O|
3277844|NCT00642317||Asian Youth and Tobacco Control|Smoking Questionnaire for self-identified Chinese or Vietnamese participants.
3277845|NCT00642304|Experimental|methoxy polyethylene glycol-epoetin beta|
3277846|NCT00642291|Experimental|1|Treatment naive pediatric patients (Group 1: ages 3 to 24 months)were to receive emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if <30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if >=7 to <15kg; 10/2.5 mg/kg BID if >=15 to <=40 kg)
3277847|NCT00642291|Experimental|2|Treatment naive or experienced pediatric patients (Group 2: ages 7 to 12 years; Group 3: ages 13-17 years) received emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
3277848|NCT00642278|Experimental|Canagliflozin 50 mg daily|Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
3277849|NCT00642278|Experimental|Canagliflozin 100 mg daily|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
3277850|NCT00642278|Experimental|Canagliflozin 200 mg daily|Each patient will receive 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
3277851|NCT00642278|Experimental|Canagliflozin 300 mg daily|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo capsule once daily (in the evening).
3277852|NCT00642278|Experimental|Canagliflozin 300 mg twice daily|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.
3277853|NCT00642278|Active Comparator|Sitagliptin 100 mg daily|Each patient will receive 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
3277854|NCT00642278|Placebo Comparator|Placebo|Each patient will receive matching placebo twice daily for 12 weeks.
3277855|NCT00642265|Experimental|1|operative treatment
3277856|NCT00642265|Active Comparator|2|conservative treatment
3277857|NCT00642252|Experimental|B|226 ppm fluoride + 30 ppm calcium 'prototype/new' mouthrinse
3277858|NCT00642252|Active Comparator|A|ADA-accepted over-the-counter 226 ppm fluoride mouthrinse (i.e. ACT, 226 ppm fluoride mouthrinse distributed by Chattem, Inc.)
3277859|NCT00642239|Placebo Comparator|2|Concurrent radiochemotherapy and placebo
3277860|NCT00642239|Experimental|1|concurrent radiochemotherapy and Sodium Glycididazole
3277861|NCT00642226|Active Comparator|1|Grid Laser
3277862|NCT00642226|Experimental|2|Vitrectomy in combination with 20 mg triamcinolone
3277863|NCT00642213||ischemic stroke sample with DNA|We prospectively collected 450(1999), 502(2005), and 512(2010) ischemic stroke patients who agreed to participate and also most provided a sample for DNA. The cohort data consists of a baseline interview, medical record abstraction and various timeframes of followup interviews from 3m to 3yrs. See website (www.gcnkss.com for data forms)
3277864|NCT00642213||stroke data from medical record review|The second part of the study is a retrospective medical record review of all potential ischemic strokes, TIAs, and Hemorrhagic strokes in our 5 county region that occurred in all study years.
3277865|NCT00642200|Active Comparator|1|Patients receive Lichtenstein hernioplasty as a treatment for recurrent inguinal hernia.
3277866|NCT00642200|Active Comparator|2|Patients receive laparoscopic TEP as a treatment for recurrent inguinal hernia.
3277867|NCT00642187|Experimental|1|Pulmicort
3277868|NCT00642187|Placebo Comparator|2|Placebo
3277869|NCT00642174|Experimental|Prasugrel|Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.
3277870|NCT00642174|Active Comparator|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.
3277871|NCT00642148|Active Comparator|Seretide|
3277872|NCT00642148|Placebo Comparator|Placebo|Placebo tablet
3277873|NCT00642148|Experimental|GW856553|
3277874|NCT00642135|Active Comparator|1|Premature newborns and neonates treated using Phenylephrine and tropicamide eyedrops
3277875|NCT00642135|Active Comparator|2|Premature newborns and neonates treated using insert Mydriasert®
3277876|NCT00642122|Experimental|1|Pulmicort RESPULES
3277877|NCT00642122|Experimental|2|Pulmicort TURBUHALER
3277878|NCT00642109|Other|TVT|Tension-free Vaginal Tape (TVT)
3277879|NCT00642109|Other|TOT|Transobturator Tape outside-in (TOT Monarc)
3277880|NCT00642109|Other|TVT-O|Transobturator Tape inside-out (TVT-O)
3277881|NCT00642096|Experimental|1|Metoprolol Succinate + Hydrochlorothiazide
3277882|NCT00642096|Active Comparator|2|Metoprolol Succinate
3277883|NCT00642096|Active Comparator|3|Hydrochlorothiazide
3277884|NCT00642083|Experimental|1|viabahn stent-graft
3277885|NCT00642070||Host|Women with current symptoms of a urinary tract infection
3277886|NCT00642044|Experimental|A|The eye with the worst visual acuity receives the treatment. (the other eye serve as control).
3277887|NCT00642044|No Intervention|B|The eye with the best visual acuity do not receive the treatment.
3277888|NCT00642031|Experimental|Triciribine|Triciribine 15 mg/m^2 intravenous (IV) Weekly Over 1 Hour On Days 1, 8, and 15.
3277889|NCT00642018|Active Comparator|A|SOC docetaxel 75 mg/m2 IV every 3 weeks and prednisone 5 mg orally twice daily continuously while receiving docetaxel therapy
3277890|NCT00642018|Experimental|B|LY2181308 administered with docetaxel 75 mg/m2 IV every 3 weeks and prednisone 5 mg orally twice daily continuously while receiving docetaxel
3277891|NCT00642005|Experimental|1|Humidified and warmed carbon dioxide laparoscopic insufflation.
3277892|NCT00642005|Placebo Comparator|2|Cold and dry carbon dioxide laparoscopic insufflation.
3277893|NCT00641992||1|Response to medical treatment
3277894|NCT00641992||2|Failure to medical treatment (surgery or percutaneous resolution)
3277895|NCT00641979|Experimental|1|Rhinocort
3277896|NCT00641979|Placebo Comparator|2|
3277897|NCT00641953|Experimental|A|IMX-150 (0.3%) 0.5 g topically BID each foot
3277898|NCT00641953|Experimental|B|IMX-150(0.6%) 0.5 g topically BID to each foot
3277899|NCT00641953|Placebo Comparator|C|Placebo 0.5 g topically BID to each foot for 4 weeks
3277900|NCT00641940|Experimental|1|Girls in Transition (GT) program
3277901|NCT00641940|Other|2|Waitlist control
3277902|NCT00641927|Experimental|1|Antidepressant
3277903|NCT00641927|Active Comparator|2|Drug
3277904|NCT00641914|Experimental|1|
3277905|NCT00641914|Placebo Comparator|2|
3277906|NCT00641901||Observation|Pregnant women with gingivitis
3277907|NCT00641888||1|10 patients starting on non-nucleoside reverse transcriptase inhibitor based regimen. 5 women and 5 men.
3277908|NCT00641888||2|10 patients starting a protease inhibitor based regimen. 5 women and 5 men.
3277909|NCT00641862|Active Comparator|Vitamin B12|Vitamin B12
3277910|NCT00641862|Placebo Comparator|Placebo|Placebo
3277911|NCT00641849|Active Comparator|Group A|Minimum Intervention Group A will fill out data forms at zero (0), two (2), four (4), and six (6) months.
3277912|NCT00641849|Active Comparator|Group B|Maximum Intervention Group B will fill out data forms at zero (0), one (1), two (2), three (3), four (4), five (5), and six (6) months.
3277913|NCT00641823||1|
3277914|NCT00641823||2|
3277915|NCT00641823||3|
3277916|NCT00641810|Experimental|A|After one week at usual levels of caffeine use, patients are asked to reduce their caffeine consumption to no more than 2 cups of coffee (or equivalent) for one week and then to zero for two weeks.
3277917|NCT00641797|Active Comparator|Arm 1, Conventional Therapy|Patients will receive standard conventional medication therapy (i.e., meclizine, diphenhydramine, lorazepam, ondansetron).
3277918|NCT00641797|Experimental|Arm 2, Epley Maneuver|Patients will receive vestibular rehabilitation (the Epley Maneuver).
3277919|NCT00641784|Experimental|1|Oral Nifedine
3277920|NCT00641784|Active Comparator|2|Intravenous Magnesium
3277921|NCT00641771|Experimental|1|MK0217A
3277922|NCT00641771|Placebo Comparator|2|Placebo
3277923|NCT00641758|Placebo Comparator|Placebo|
3277924|NCT00641758|Active Comparator|Pycnogenol|
3277925|NCT00641745|Experimental|1|Lurasidone
3277926|NCT00641745|Active Comparator|2|Risperidone
3277927|NCT00641732|Experimental|TAK-442 40 mg QD|
3277928|NCT00641732|Experimental|TAK-442 80 mg QD|
3277929|NCT00641732|Experimental|TAK-442 10 mg BID|
3277930|NCT00641732|Experimental|TAK-442 20 mg BID|
3277931|NCT00641732|Experimental|TAK-442 40 mg BID|
3277932|NCT00641732|Experimental|TAK-442 80 mg BID|
3277933|NCT00641732|Active Comparator|Enoxaparin 30 mg BID|
3277934|NCT00641719|Experimental|Duloxetine 40 mg|Duloxetine 40 milligrams (mg) once daily (QD), orally (PO), 1 year
3277935|NCT00641719|Experimental|Duloxetine 60 mg|Duloxetine 60 mg QD, PO, 1 year
3277936|NCT00641706|Experimental|Stratum 1 (not undergoing surgery)|Patients receive oral vorinostat (SAHA) once daily on days 1-14 and bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3278056|NCT00640822|Active Comparator|Tacalcitol|Tacalcitol once daily for up to 8 weeks
3277937|NCT00641706|Experimental|Stratum 2 (undergoing surgery)|Patients receive oral SAHA once daily for 2 days prior to surgery and then on the day of surgery. Patients also receive bortezomib IV on the day of surgery. After receiving the 3rd dose of SAHA, patients undergo surgery to remove the tumor. Beginning at least 7 days after surgery, patients receive SAHA and bortezomib as in stratum 1.
3277938|NCT00641693|Experimental|1|Nasal Spray
3277939|NCT00641693|Placebo Comparator|2|
3277940|NCT00641680|Experimental|1|Budesonide
3277941|NCT00641680|Active Comparator|2|Fluticasone propionate
3277942|NCT00641680|Placebo Comparator|3|
3277943|NCT00641667|Experimental|Fentanyl|
3277944|NCT00641654|Active Comparator|A|Patients having previously received 24 weeks of therapy with pegylated interferon and ribavirin will be treated with pegylated interferon alfa-2a kD (PEGASYS) plus ribavirin, (Copegus) for a treatment period of 48 weeks, with a follow-up period of 24 weeks irrespective of the level of HCV-RNA measured in plasma on treatment day 27.
3277945|NCT00641654|Active Comparator|B|Patients having previously received less than 24 weeks but at least 12 weeks of therapy with pegylated interferon and Ribavirin and having detectable HCV-RNA in a plasma sample obtained on treatment day 27 (i.e. the day before the 5th dose of pegylated interferon in this study) as analyzed by means of COBAS TaqMan 48TM will be treated with pegylated interferon alfa-2a KD (PEGASYS®) plus ribavirin, (Copegus®) for a treatment period of 48 weeks, with a follow-up period of 24 weeks.
3277946|NCT00641654|Active Comparator|C|Patients having previously received less than 24 weeks but at least 12 weeks of therapy with pegylated interferon and Ribavirin and having undetectable HCV-RNA in a plasma sample obtained on treatment day 27 (i.e. the day before the 5th dose of pegylated interferon in this study) as analyzed by means of COBAS TaqMan 48TM will be treated with pegylated interferon alfa-2a KD (PEGASYS®) plus ribavirin, (Copegus®) for a treatment period of 24 weeks, with a follow-up period of 24 weeks.
3277947|NCT00641641|Experimental|antiretroviral therapy|tenofovir (TDF) + emtricitabine (FTC) as a fixed dose combination administered orally once per day and raltegravir (RAL) administered orally twice per day.
3277948|NCT00641628||1|
3277949|NCT00641615|Experimental|Phase 1|
3277950|NCT00641602|Experimental|1|Nexium
3277951|NCT00641602|Active Comparator|2|Prevacid
3277952|NCT00641563|Active Comparator|Dex/Remi followed by Mida/Remi|Sedation with dexmedetomidine and remifentanil followed by sedation with midazolam and remifentanil separated by one week
3277953|NCT00641563|Active Comparator|Mida/Remi followed by Dexa/Remi|Sedation with midazolam and remifentanil followed by sedation with dexmedetomidine and remifentanil separated by one week
3277954|NCT00641550|Experimental|2|Pregnant women starting to practice physical exercise at 13 weeks(Walking moderate activity)
3277955|NCT00641550|Experimental|3|Pregnant women starting exercise at 20 weeks
3277956|NCT00641550|No Intervention|1|Pregnant women without exercise practice.
3277957|NCT00641537|Placebo Comparator|Cladribine Low/Placebo (LLPP)|
3277958|NCT00641537|Placebo Comparator|Cladribine High Dose/Placebo (HLPP)|
3277959|NCT00641537|Experimental|Cladribine Low/Low Dose (LLLL)|
3277960|NCT00641537|Experimental|Cladribine High/Low Dose (HLLL)|
3277961|NCT00641537|Experimental|Placebo/Cladribine Low Dose (PPLL)|
3277962|NCT00641524|Other|treatment|Iron depletion via phlebotomy
3277963|NCT00641511|Experimental|1|SYN 117 120 mg/day
3277964|NCT00641511|Placebo Comparator|2|
3277965|NCT00641498|No Intervention|Control|Usual therapy
3277966|NCT00641498|Experimental|Active group|Individual supportive psychotherapy initiated in the Emergency department
3277967|NCT00641472|Experimental|1|Budesonide inhalation suspension
3277968|NCT00641472|Active Comparator|2|Montelukast sodium
3277969|NCT00641459||001|
3277970|NCT00641446|Experimental|1|Pulmicort
3277971|NCT00641446|Active Comparator|2|Varivax
3277972|NCT00641433|Experimental|experimental|Subjects will daily dress their nail bed with oxidized regenerated cellulose collagen-silver, until healing occurs.
3277973|NCT00641433|Active Comparator|Control|Topical silver sulfadiazine cream will be applied daily to the wound bed until healing has occured.
3277974|NCT00641420|Experimental|1|Patients receive fractional laser resurfacing to 17% of the face five times one month apart at 10mJ.
3277975|NCT00641420|Experimental|2|Patients receive fractional laser resurfacing to 17% of the face five times one month apart at 40mJ.
3277976|NCT00641407|Experimental|1|
3277977|NCT00641407|Active Comparator|2|
3277978|NCT00641394|Experimental|1|Psychotherapy: Emotional Freedom Techniques (EFT), a psychotherapy intervention with a somatic component
3277979|NCT00641394|Active Comparator|2|Psychotherapy: Cognitive Behavioral Therapy (CBT), a psychotherapy intervention
3277980|NCT00641394|No Intervention|3|
3277981|NCT00641381|Experimental|Treatment (high-dose chemotherapy, anti-HIV therapy)|Patients undergo leukapheresis to obtain PBSCs for transplantation. At least 5 days later, patients with an adequate number of collected cells proceed to high-dose chemotherapy. Patients receive carmustine IV over 4 hours on days -7 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. Patients receive an autologous PBSC infusion on day 0.
3277982|NCT00641368|Experimental|1|R4Power Program
3277983|NCT00641368|Other|2|Waitlist Control
3277984|NCT00641342|Active Comparator|onlay mesh|
3277985|NCT00641342|Active Comparator|sublay mesh|
3277986|NCT00641342|No Intervention|no mesh|
3277987|NCT00641329|Experimental|1|
3277988|NCT00641329|Placebo Comparator|2|
3277989|NCT00641316|Experimental|1|Teeth extraction followed by natural healing
3277990|NCT00641316|Experimental|2- FDBA/TCP|
3277991|NCT00641316|Experimental|3 FDBA/TCP+PRP|
3277992|NCT00641316|Experimental|4 FDBA/TCP + PDGF|
3277993|NCT00641303|Sham Comparator|Arm I (control)|Patients receive 8 weekly sessions of sham acupuncture treatment comprising 20 minutes of a non-penetrating device consisting of a retractable needle and an adhesive tube on the skin using the Park Sham Device (PSD) in 14 non-acupuncture points. Patients may receive 4 free acupuncture sessions (not sham) after the 12 or 24-week follow-up visit.
3278118|NCT00640393|Active Comparator|Part 1 - Etanercept|All participants received etanercept 50 mg twice a week for 12 weeks.
3277994|NCT00641303|Experimental|Arm II (treatment)|Patients receive 8 weekly sessions of acupuncture treatment comprising 20 minutes of needle insertion in 15 acupuncture points including CV 4, CV 6, CV12 and bilateral LI 4, MH 6, GB 34, ST 36, KI 3, BL 65.
3277995|NCT00641251|Active Comparator|1|intensive medical management
3277996|NCT00641251|Active Comparator|2|Roux-en-Y gastric bypass with intensive medical management
3277997|NCT00641238||Early stage NSCLC|Early stage non-small cell lung cancer
3277998|NCT00641225|Experimental|1|SBI-087
3277999|NCT00641212|Experimental|1|Budesonide
3278000|NCT00641212|Placebo Comparator|2|
3278001|NCT00641199|Active Comparator|1|Jarrow-Dophilus EPS
3278002|NCT00641199|Placebo Comparator|2|Placebo
3278003|NCT00641186|Experimental|A|sodium oxybate 4.5 to 9.0 gms per night
3278004|NCT00641173|Experimental|1|paroxetine v placebo
3278005|NCT00641173|Placebo Comparator|2|placebo
3278006|NCT00641160|Experimental|Cohort 1|
3278007|NCT00641160|Experimental|Cohort 2|
3278008|NCT00641160|Experimental|Cohort 3|
3278009|NCT00641147|Experimental|Arm I (curcumin)|Patients receive curcumin PO BID for 12 months. Laboratory Biomarker Analysis
3278010|NCT00641147|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 12 months. Laboratory Biomarker Analysis
3278011|NCT00641134|Other|A|A:Home-Based exercise program,-at discharge from in-Hospital CR program-, with one reinforcement session each month for the first 6 months.
3278012|NCT00641134|No Intervention|B|Usual care, after CR, consisting of recommendation on usefulness of physical exercise and standard follow-up visits and functional assessment at 6 and 12 months.
3278013|NCT00641108|Experimental|ADAM SPECT|Participants with depression will undergo ADAM SPECT scans and cognitive behavioral therapy.
3278014|NCT00641108|Active Comparator|Control|Healthy subjects without depression will undergo ADAM SPECT scans.
3278015|NCT00641082|Experimental|1|Clevudine
3278016|NCT00641082|Active Comparator|2|Adefovir
3278017|NCT00641056|Experimental|1|
3278018|NCT00641056|Active Comparator|2|
3278019|NCT00641043|Experimental|BI 1356 (5 mg)|BI 1356 5mg in initial combination therapy with pioglitazone 30 mg
3278020|NCT00641043|Placebo Comparator|Placebo matching BI 1356 5 mg|Placebo in initial combination therapy with pioglitazone 30 mg
3278021|NCT00641017|Experimental|1 and 2 - Adults|One immunization of 1x10^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
3278022|NCT00641017|Experimental|3A - Seropositive Children|One immunization of 1x10^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
3278023|NCT00641017|Placebo Comparator|3B - Seropositive Children|One dose of 1x10^6 TCID50 rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
3278024|NCT00641017|Experimental|4A - Seronegative Infants and Children|One immunization of 1x10^5 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
3278025|NCT00641017|Placebo Comparator|4B - Seronegative Infants and Children|One dose of 1x10^5 TCID50 rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
3278026|NCT00641017|Experimental|5A - Seronegative Infants and Children|One immunization of 1x10^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
3278027|NCT00641017|Placebo Comparator|5B - Seronegative Infants and Children|One dose of rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
3278028|NCT00641004|Experimental|1|Rebamipide 100mg TID for 12 weeks
3278029|NCT00641004|Active Comparator|2|Esomeprazole 40mg OD + Esomeprazole-matching placebo BID for 12 weeks
3278030|NCT00640991|No Intervention|Control|Patients assigned to the control arm will receive usual care for AMI, according to local practice of each participating centre.
3278031|NCT00640991|Experimental|Intervention|The experimental arm will have an IV infusion of glulisine insulin started directly after randomization for at least 24 hours and for as long as CCU-level care is required, and the insulin infusion will be adjusted to achieve and maintain a target glucose range of 5.0-6.6 mmol/L (90-118 mg/dL). Once transferred to the ward, patients in the experimental arm will switch to glargine insulin and will continue this treatment for the remainder of their hospitalization and after hospital discharge, for a total duration of 30 days post randomization.
3278032|NCT00640978|Experimental|Erlotinib + RAD001|Erlotinib 150 mg orally daily for 28 Days + RAD001 (Everolimus) 30 mg orally weekly for 4 Weeks
3278033|NCT00640965|Experimental|A|DP-VPA
3278034|NCT00640965|Placebo Comparator|B|
3278035|NCT00640939|Active Comparator|A|Topical diclofenac sodium patch
3278036|NCT00640939|Placebo Comparator|B|Topical patch identical in appearance to active comparator
3278037|NCT00640926|Experimental|1|Radezolid 300 mg
3278038|NCT00640926|Experimental|2|Radezolid 450 mg
3278039|NCT00640926|Experimental|3|Radezolid 450 mg BID
3278040|NCT00640913||I|Twenty consecutive patients operated on with low anterior resection of the rectum for cancer with a defunctioning stoma who accept participation.
3278041|NCT00640900|Experimental|Commercial program at center|
3278042|NCT00640900|Experimental|Commercial program over the telephone|
3278043|NCT00640900|Other|Usual care|Weight loss counseling
3278044|NCT00640887|Experimental|1|RBT associated with EFV based ART
3278045|NCT00640887|Experimental|2|RBT associated with NVP based ART
3278046|NCT00640887|Experimental|3|RBT associated with LPV/r based ART
3278047|NCT00640874||PIPET C|Contact group members of people with diagnosed influenza who are recommended to receive NA inhibitor prophylaxis for short periods of time will be enrolled following provision of informed consent.
3278048|NCT00640848|Experimental|1|
3278049|NCT00640848|Experimental|2|
3278050|NCT00640848|Experimental|3|
3278051|NCT00640848|Experimental|4|
3278052|NCT00640848|Experimental|5|
3278053|NCT00640835|Experimental|Sublingual administration|Buprenorphine/naloxone film strip administered sublingually
3278054|NCT00640835|Experimental|Buccal administration|Buprenorphine/naloxone film strip administered buccally
3278055|NCT00640822|Experimental|Calcipotriol plus Hydrocortisone ointment|Calcipotriol plus Hydrocortisone ointment once daily for up to 8 weeks
3278057|NCT00640822|Placebo Comparator|Calcipotriol plus Hydrocortisone ointment vehicle|Calcipotriol plus Hydrocortisone ointment vehicle once daily for up to 8 weeks
3278058|NCT00640809|Experimental|A|
3278059|NCT00640809|Placebo Comparator|B|
3278060|NCT00640809|Active Comparator|C|
3278061|NCT00640796|Experimental|Treatment|Participants undergo haploidentical donor derived natural killer cell infusion (cells obtained from donors and selected using CliniMACS cell selection system) and chemotherapy (cyclophosphamide, fludarabine, interleukin-2, mesna).
3278062|NCT00640783|Experimental|1|Mediterranean diet
3278063|NCT00640783|Active Comparator|2|Control diet
3278064|NCT00640770|Active Comparator|balloon angioplasty|balloon angioplasty
3278065|NCT00640770|Experimental|Drug eluting stent|CYPHER SELECT+ Coronary or Infrapopliteal Stent
3278066|NCT00640757|Active Comparator|Low Methionine 1|Methionine deficient diet
3278067|NCT00640757|Placebo Comparator|Placebo 2|Placebo comparator methionine complete diet
3278068|NCT00640744|Other|A|An untreated carotid plaque will be obtained at the first endarterectomy. Atorvastatin 80mg will be administered for 3 months. The contralateral (treated) plaque will be obtained at the second endarterectomy. Hence, each patient will be his/her own control
3278069|NCT00640705|Active Comparator|A|Topical diclofenac sodium patch
3278070|NCT00640705|Placebo Comparator|B|Topical patch identical in appearance to active comparator, except without diclofenac sodium
3278071|NCT00640692||1|
3278072|NCT00640692||2|
3278073|NCT00640679|Active Comparator|Clopidogrel Tapering|
3278074|NCT00640679|Active Comparator|Abrupt Clopidogrel Interruption|
3278075|NCT00640666|Experimental|Physical activity intervention|Behavior change intervention
3278076|NCT00640666|No Intervention|Standard of care with written materials|Written materials
3278077|NCT00640653|Experimental|Abstinence-only|Participants will receive the abstinence-only HIV/STD risk-reduction intervention.
3278078|NCT00640653|Experimental|Safer-sex only|Participants will receive the safer-sex-only HIV/STD risk-reduction intervention.
3278079|NCT00640653|Experimental|Comprehensive-long|Participants will receive the 12-h long comprehensive HIV/STD risk-reduction intervention.
3278080|NCT00640653|Experimental|Comprehensive-short|Participants will receive the 8-h short comprehensive HIV/STD risk-reduction intervention.
3278081|NCT00640653|Active Comparator|Health-promotion control|Participants will receive the health promotion control intervention.
3278082|NCT00640640|Experimental|A|All study patients will be evaluated in a similar way
3278083|NCT00640627|Experimental|A|
3278084|NCT00640627|Placebo Comparator|B|
3278085|NCT00640614|Experimental|Sensitives|Subjects with a clinical history and positive patch test (current or previous) to any of the seven allergens. Subjects must otherwise be healthy and fulfill entry criteria.
3278086|NCT00640614|Experimental|Consecutives|Subjects who are being seen for standard allergy patch testing, that are asked to participate in the study.
3278087|NCT00640588|Experimental|1|Telbivudine
3278088|NCT00640588|Active Comparator|2|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
3278089|NCT00640575|Experimental|A|Local
3278090|NCT00640575|Active Comparator|B|Systemic
3278091|NCT00640562|Experimental|Quetiapine Extended Release|
3278092|NCT00640562|Active Comparator|Risperidone|
3278093|NCT00640549|Placebo Comparator|2|
3278094|NCT00640549|Active Comparator|1|
3278095|NCT00640536||1|Newly diagnosed obstructive sleep apnea patients without systemic and pulmonary arterial hypertension
3278096|NCT00640536||2|Age, sex and and body mass index-matched matched healthy subjects
3278097|NCT00640510|Experimental|IM olanzapine 10mg|Patients will receive at least one injection of Intramuscular (IM) olanzapine 10mg. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
3278098|NCT00640510|Placebo Comparator|IM placebo|Patients will receive at least one injection of Intramuscular placebo. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
3278099|NCT00640497|Experimental|1|Treatment arm
3278100|NCT00640484|Experimental|A|CHF 4226 (carmoterol) 2 μg once a day, in the morning
3278101|NCT00640484|Experimental|B|CHF 4226 (carmoterol) 4 μg once a day, in the morning
3278102|NCT00640484|Placebo Comparator|C|placebo once a day, in the morning
3278103|NCT00640484|Active Comparator|D|salmeterol 50 μg twice daily, in the morning and in the evening
3278104|NCT00640471|Active Comparator|Brivanib|
3278105|NCT00640471|Active Comparator|Placebo|
3278106|NCT00640458|Placebo Comparator|Placebo|Study Period 1 or 2
3278107|NCT00640458|Experimental|Experimental|Study Period 1 or 2
3278108|NCT00640445|Experimental|Expressive Writing|Participants assigned to the Expressive Writing (EW) condition will write about their deepest thoughts and feelings associated with their experience transitioning from being a soldier to being a civilian for 20 minutes a day for 4 days within a week.
3278109|NCT00640445|Active Comparator|Control Writing|Those assigned to control writing condition will write factually about the information needs of veterans transitioning from active duty to civilian status for 20 minutes on 4 days within one week.
3278110|NCT00640445|No Intervention|No Writing Control|Treatment As Usual
3278111|NCT00640432|Active Comparator|A|
3278112|NCT00640432|Experimental|B|
3278113|NCT00640419|Experimental|1|
3278114|NCT00640419|Experimental|2|
3278115|NCT00640419|Placebo Comparator|3|
3278116|NCT00640406|Experimental|STN|Device: Dynamic Renal Stent plus Best Medical Treatment
3278117|NCT00640406|Active Comparator|BMT|Drug: Best Medical Treatment
3278119|NCT00640393|Active Comparator|Part 2 - Etanercept and nbUVB|Participants who did not reach a 90 percent reduction in psoriasis area and severity index (PASI-90) after 12 weeks and were randomized to the narrow band ultra violet B (nbUVB) group. They received nbUVB treatments three times a week and 50 mg Etanercept once per week.
3278120|NCT00640393|Active Comparator|Part 2 - Etanercept|Participants who did not reach PASI-90 after 12 weeks and were randomized to the Etanercept group. They received 50 mg Etanercept once per a week.
3278121|NCT00640380|Experimental|1|CPVB with NS
3278122|NCT00640380|Active Comparator|2|CPVB with LOR
3278123|NCT00640367|Experimental|IA thrombolysis|IA recombinant tissue plasminogen activator and/or mechanical thrombolysis
3278124|NCT00640367|Active Comparator|IV rtPA|IV recombinant tissue plasminogen activator
3278125|NCT00640354|Experimental|1|Pediatric residents randomized to having an automated external defibrillator
3278126|NCT00640354|Active Comparator|2|Pediatric residents randomized to having a manual defibrillator
3278127|NCT00640341|Experimental|PureVision|PureVision Contact Lens
3278128|NCT00640341|Active Comparator|Acuvue Oasys|Acuvue Oasys Contact Lens
3278129|NCT00640341|Active Comparator|O2Optix|O2Optix Contact Lens
3278130|NCT00640328|Experimental|Cohort 1.1|100mg ofatumumab then placebo
3278131|NCT00640328|Experimental|Cohort 1.2|placebo then 100mg ofatumumab
3278132|NCT00640328|Experimental|Cohort 2.1|300mg ofatumumab then placebo
3278133|NCT00640328|Experimental|Cohort 2.2|placebo then 300mg ofatumumab
3278134|NCT00640328|Experimental|Cohort 3.1|700mg ofatumumab then placebo
3278135|NCT00640328|Experimental|Cohort 3.2|placebo then 700mg ofatumumab
3278136|NCT00640315|Experimental|Riociguat (Adempas, BAY63-2521) 1.0 mg|Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.
3278137|NCT00640315|Experimental|Riociguat (Adempas, BAY63-2521) 2.5 mg|Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.
3278138|NCT00640302||PIPET A|Patients presenting at study sites with the recognised clinical case definition for pandemic influenza (to be distributed by State and Commonwealth Departments of Health when first clinical case occurs) will be eligible to be enrolled on the study. Informed consent to participate in the study will be sought including parental/guardian consent for minors and presumed consent for adults who are incapacitated (consistent with NHMRC requirements).
3278139|NCT00640289|Experimental|A|Treatment
3278140|NCT00640276|Active Comparator|T|Lifestyle modification + active drug(Pitavastatin)
3278141|NCT00640276|Other|C|Lifestyle Modification
3278142|NCT00640263|Experimental|1|infant peri-exposure prophylaxis with lopinavir/ritonavir
3278143|NCT00640263|Active Comparator|2|infant peri-exposure prophylaxis with lamivudine
3278144|NCT00640250|Experimental|Sensitives|Subjects with a clinical history and positive patch test (current or previous) to either Disperse Blue 106 or Bronopol. Subjects must otherwise be healthy and fulfill entry criteria.
3278145|NCT00640237|Experimental|1|Arm 1 - the patients will receive two large doses of vitamin D.
3278146|NCT00640237|No Intervention|2|Arm 2 - the patients vitamin D status will be checked during the hospitalization and they will receive the recommendation to treat the vitamin D deficiency in the out-patient department.
3278147|NCT00640224|Active Comparator|Rosiglitazone|Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
3278148|NCT00640224|Active Comparator|Drospirenone/ethinyl estradiol|Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
3278149|NCT00640224|No Intervention|Overweight/Obese without PCOS|Overweight adolescent females without PCOS to use as comparison of normal developmental changes. *No participants were enrolled in this Arm.
3278150|NCT00640224|No Intervention|Lean without PCOS|Lean healthy girls without PCOS to serve as controls for the cardiovascular markers. *No participants were enrolled in this Arm.
3278151|NCT00640211||PIPET B|Participants in this study will be health care and other essential workers receiving long term neuraminidase inhibitor prophylaxis.
3278152|NCT00640198|Active Comparator|Group 1 Memantine|Patients included in this group will receive memantine alone followed by memantine combined with intensive speech-language therapy.
3278153|NCT00640198|Placebo Comparator|Group 2|Patients included in this group will receive placebo alone followed by memantine combined with intensive speech-language therapy.
3278154|NCT00640185|Placebo Comparator|1|
3278155|NCT00640185|Experimental|2|
3278156|NCT00640185|Experimental|3|
3278157|NCT00640172||Anemic Elderly|
3278158|NCT00640172||Non-anemic adults (non-elderly, without bone marrow biopsy)|
3278159|NCT00640172||Non-anemic adults (non-elderly, with bone marrow biopsy)|
3278160|NCT00640172||Non-anemic Elderly (control without bone marrow biopsy)|
3278161|NCT00640172||Non-anemic Elderly (control, with bone marrow biopsy)|
3278162|NCT00640159|Experimental|A|Open label switch from current oral selegiline dose to orally disintegrating selegiline (Zelapar) titrated to a dose of 2.5 mg QD.
3278163|NCT00640146|Experimental|1|MNTX bromide (MOA-728)
3278164|NCT00640146|Placebo Comparator|2|Placebo Comparator
3278165|NCT00640133|Active Comparator|Active DBS|Participants will receive deep brain stimulation.
3278166|NCT00640133|Sham Comparator|Sham DBS|Participants will receive sham deep brain stimulation for several months and then active deep brain stimulation thereafter.
3278167|NCT00640120||1|Asthmatic subjects
3278168|NCT00640120||2|Healthy subjects
3278169|NCT00640094|Experimental|A: Melatonin|Melatonin: intravenous infusion and intracoronary bolus
3278170|NCT00640094|Placebo Comparator|B: Placebo of melatonin|Placebo: intravenosus infusion and intracoronary bolus
3278171|NCT00640081|Active Comparator|D|Intermittent chemotherapy plus intermittent cetuximab treatment comprising 12 weeks of chemotherapy plus cetuximab followed by a period off all therapy, with reintroduction of the same chemotherapy and cetuximab regimen for a further 12 weeks after initial progression off treatment
3278264|NCT00639418||Participants 5 to 8 years|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 5 to 8 years of age
3278429|NCT00638196|Experimental|1|placebo/active crossover
3278430|NCT00638170|Active Comparator|A|Cranberry juice
3278172|NCT00640081|Experimental|E|Intermittent chemotherapy plus continuous cetuximab treatment comprising 12 weeks of chemotherapy plus cetuximab followed by a period of withdrawal of the chemotherapy, but continued weekly cetuximab monotherapy (maintenance cetuximab), with reintroduction of the same chemotherapy regimen to the cetuximab for a further 12 weeks after initial progression off chemotherapy treatment
3278173|NCT00640068||1|All patients in whom a clinical CCTA was ordered by their physician at a participating site. Patient must have a prescription for CCTA ordered by their physician.
3278174|NCT00640055|Active Comparator|1|Coordinator (non-physician)
3278175|NCT00640055|Placebo Comparator|2|Physician
3278176|NCT00640042|Experimental|1|
3278177|NCT00640029|Experimental|1|Cervical - Arthroplasty
3278178|NCT00640029|Active Comparator|2|Cervical - Arthrodesis
3278179|NCT00640029|Experimental|3|Lumbar - Over 50 years - Arthroplasty
3278180|NCT00640029|Active Comparator|4|Lumbar - Over 50 years - Arthrodesis
3278181|NCT00640029|Experimental|5|Lumbar - Under 50 years - Arthroplasty
3278182|NCT00640016|Placebo Comparator|Placebo|Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
3278183|NCT00640016|Experimental|CAT-354 1 mg/kg|CAT-354 1 milligram per kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
3278184|NCT00640016|Experimental|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
3278185|NCT00640016|Experimental|CAT-354 10 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56
3278186|NCT00640003|Experimental|1|
3278187|NCT00640003|Experimental|2|
3278188|NCT00639990|Active Comparator|Control|Patients without lung injury and brain injury
3278189|NCT00639990|Experimental|Brain No ALI 1|Patients with brain injury and no lung injury within 72 hours from ICU entry
3278190|NCT00639990|Experimental|Brain No ALI 2|Patients with brain injury and no ALI after 72 hours from ICU entry
3278191|NCT00639990|Experimental|Brain ALI|Patients with brain injury and Acute Lung Injury (ALI)
3278192|NCT00639977|Sham Comparator|2|20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
3278193|NCT00639977|Active Comparator|1|20-minute session of acupuncture with needles inserted in specific points (Tong Zi Liao, Yang Bai and Jing Ming)
3278194|NCT00639977|No Intervention|3|
3278195|NCT00639964|Other|type 1 diabetic pregnant women|type 1 diabetic pregnant women
3278196|NCT00639964|Other|type 2 diabetic pregnant women|type 2 diabetic pregnant women
3278197|NCT00639964|Other|healthy pregnant women|healthy pregnant women with normal glucose tolerance
3278198|NCT00639951|Active Comparator|A Normal dose Group|20 vials up front in a Single Dose of Antivipmyn in 500 ml of solution IV, administered in 60 minutes. After 12 hours, it has to be perfomed a clinical evaluation of the patient. Each patient is going to have clinical studies of coagulation time and also the fibrinogen measures, this at 2, 4, 6, 8, 10, 12, 48, 72, 96 hours.All patients who have received at least one dose of medication study will be contacted by telephone to investigate the presence of symptoms suggestive of continuing with effect snake venom, or the presence of an adverse event, or any signs or symptoms indicating the presence of a hypersensitivity response to Antivipmyn® including serum sickness. If symptoms suggestive of an adverse event were discovered, the patient will referred for appropriate treatment.
3278199|NCT00639951|Placebo Comparator|B Placebo Group|20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®. The treatment schedule for each subject is a dose of 5 vials Antivipmyn® every 2 hours to complete 20 vials, the total duration is 6 hours of the treatment. Each dose IV shall apply in physiological solution 250ml, and finish its application in 15 minutes. For pediatric patients the volume administered should not exceed the recommended fluid volume according to your body weight. After the assessment at 12 hours, it can be administered at the discretion of more antivenom attending by the physician.
3278200|NCT00639938|Active Comparator|1|"Mother dosing regimen: Single dose of 200 mg NVP taken orally at onset of labor~Infant dosing regimen: Single dose of 2 mg/kg NVP taken orally within the first week after delivery"
3278201|NCT00639938|Experimental|2|"Mother dosing regimen: Single dose of 200 mg NVP taken orally at onset of labor~Infant dosing regimen: 2 mg/kg NVP taken orally within the first week after delivery and 5 mg NVP taken orally daily from Day 8 through Week 6"
3278202|NCT00639938|Experimental|3|"Mother dosing regimen: Single 12 gm intravenous dose of HIVIGLOB at 36 - 37 weeks gestation and 200 mg NVP taken orally at onset of labor~Infant dosing regimen: Single 1.2 gm intravenous dose HIVIGLOB within 18 hours of birth and 2 mg/kg NVP taken orally within the first week after delivery"
3278203|NCT00639925|Experimental|Phase I study|
3278204|NCT00639912|Active Comparator|A: low volume saline|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 1 ml/kg/hour for 12 hours after the procedure, starting in the Cath Lab.
3278205|NCT00639912|Active Comparator|B: high volume saline|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath lab.
3278206|NCT00639912|Active Comparator|C: low volume sodium bicarbonate|Solution of 154 mEq/L of sodium bicarbonate. Rate of infusion: 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath Lab.
3278207|NCT00639912|Active Comparator|D: high volume sodium bicarbonate|Solution of 154 mEq/L of sodium bicarbonate. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath Lab.
3278208|NCT00639873|Experimental|AS 2mg/kg|Artesunate monotherapy 2mg/kg/day for 7 days
3278209|NCT00639873|Experimental|AS 4mg/kg|Artesunate monotherapy 4mg/kg/day for 7 days
3278210|NCT00639873|Active Comparator|QD Control|Quinine-doxycycline for 7 days
3278211|NCT00639860|Experimental|Placing OSSIX-Plus in Extraction Site|Placement of OSSIX-Plus, a resorbable collagen membrane, and the promotion of bone healing following exodontia.
3278212|NCT00639847|No Intervention|group 1|this is the standard of care control group. The control group will be instructed to return to their regular physicians for routine follow up at a time to be specified by the physician.
3278213|NCT00639847|Active Comparator|Group 2|Group 2 will receive routine home visits from nurses provided by a home health care agency.
3278431|NCT00638170|Placebo Comparator|B|Placebo juice
3278214|NCT00639847|Active Comparator|Group 3|In-home asthma management program (AMP) provided by respiratory therapists. The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
3278215|NCT00639834|Experimental|1|Active MDX-1342 given in combination with Methotrexate
3278216|NCT00639821||inflammatory bowel disease|Patients with refractory inflammatory bowel disease (ulcerative colitis and Crohn's disease) before and after treatment with infliximab.
3278217|NCT00639808|Placebo Comparator|1|
3278218|NCT00639808|Experimental|2|TZP-101
3278219|NCT00639795|Active Comparator|A|Patients randomized to receive thoracic paravertebral nerve blockade in addition to general endotracheal anesthesia during video assisted thoracoscopy procedure
3278220|NCT00639795|Sham Comparator|B|Patients randomized to receive sham single-injection thoracic peripheral nerve blockade (no injection) in addition to general endotracheal anesthesia
3278221|NCT00639782|Active Comparator|ONX|On-X heart Valve Replacement
3278222|NCT00639782|Active Comparator|SJM|SJM heart valve replacement
3278223|NCT00639769|Experimental|Therapeutic Intervention|
3278224|NCT00639756|Other|1|Placebo
3278225|NCT00639756|Active Comparator|2|Allopurinol given for 2 weeks with diet
3278226|NCT00639743|Experimental|group A|tenecteplase (group A)
3278227|NCT00639743|Placebo Comparator|group B|placebo ( group B)
3278228|NCT00639730|Experimental|A|This is open-label - all patients are placed on the diet. There is no control or placebo arm.
3278229|NCT00639717|Experimental|Etanercept and ECP|"Etanercept and ECP (Extracorporeal Photopheresis) in addition to standard GVHD prevention:~Etanercept will be given twice weekly by subcutaneous injection starting on the day of HSCT (Hematopoietic stem cell transplantation) conditioning until 8 weeks post transplant. ECP treatments will begin at once weekly starting at 4 weeks post transplant and continue at less frequent intervals until 6 months post transplant.~GVHD prophylaxis will consist of a standard two drug regimen: mycophenolate for 4 weeks and tacrolimus (titrated to a therapeutic level) for 8 weeks, then weaned over 4 months with discontinuation by 6 months post-transplant."
3278230|NCT00639691|Experimental|1|
3278231|NCT00639678|Experimental|1|
3278232|NCT00639678|Experimental|2|
3278233|NCT00639678|Placebo Comparator|3|
3278234|NCT00639678|Placebo Comparator|4|
3278235|NCT00639652||1. 3D-histology|Nodular, micronodular, or sclerosing BCCs
3278236|NCT00639652||2. Shave excision|Superficial BCCs
3278237|NCT00639639|Experimental|Arm I (first randomization)|Patients receive CMV-ALT IV over 45-90 minutes (course 1 only) and CMV pp65-LAMP mRNA-loaded DC (CMV-DC) vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
3278238|NCT00639639|Experimental|Arm II (first randomization)|Patients receive CMV-DC vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
3278239|NCT00639639|Experimental|Arm I (second randomization)|Within 6 to 24 hours prior to vaccination, patients undergo skin site preparation with unpulsed DCs at the vaccination site in one inguinal region. Patients then receive indium In 111-labeled CMV-DC.
3278240|NCT00639639|Experimental|Arm II (second randomization)|Within 6 to 24 hours prior to vaccination, patients undergo vaccination skin site preparation in the opposite inguinal region with tetanus toxoid. Patients then receive 111 In-labeled CMV-DC.
3278241|NCT00639626|Experimental|Levemir|
3278242|NCT00639613||1|Patients with type 2 diabetes
3278243|NCT00639613||2|Healthy subjects
3278244|NCT00639561|Experimental|A|diet composed of 10g of fibre per day
3278245|NCT00639561|Experimental|B|diet composed of 40g of fibre per day
3278246|NCT00639522|Experimental|A|
3278247|NCT00639509|Experimental|Treatment (monoclonal antibody therapy)|Patients receive anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
3278248|NCT00639496|Experimental|1|patients taking NAC 600 mg t.i.d.
3278249|NCT00639496|Placebo Comparator|2|
3278250|NCT00639483|Experimental|A|
3278251|NCT00639483|Placebo Comparator|B|
3278252|NCT00639457|Experimental|Pioglitazone|Pioglitazone (Actos; 30mg/day) for 16 weeks.
3278253|NCT00639457|Active Comparator|Pioglitazone + Exercise training|Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.
3278254|NCT00639444|Active Comparator|Gluten free diet|the intervention in this group is keeping a gluten-free diet from 0 to 12 months
3278255|NCT00639444|No Intervention|Gluten containing diet|infants in this group are started on gluten-containing cereals at 6 months (control group)
3278256|NCT00639431|Experimental|1|Direct observation of a sequence of right foot movements performed by the experimenter while visualizing moving the amputated or phantom right foot.
3278257|NCT00639431|Experimental|2|Direct observation of a sequence of left foot movements performed by the experimenter while visualizing moving the amputated or phantom left foot.
3278258|NCT00639431|Experimental|3|Direct observation of a sequence of left and right foot movements performed by the experimenter while visualizing moving the amputated or phantom left and right feet.
3278259|NCT00639431|Experimental|4|Mental visualization with closed eyes of a sequence movements performed with the right amputated or phantom foot.
3278260|NCT00639431|Experimental|5|Mental visualization with closed eyes of a sequence movements performed with the left amputated or phantom foot.
3278261|NCT00639431|Experimental|6|Mental visualization with closed eyes of a sequence movements performed with the left and right amputated or phantom feet.
3278262|NCT00639418||Participants 6 to 23 months|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 6 to 23 months of age
3278263|NCT00639418||Participants 24 to 59 months|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 24 to 59 months of age
3278265|NCT00639418||Participants 9 to 17 years|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 9 to 17 years of age
3278266|NCT00639405||1|subjects who are diagnosed with parathyroid adenomas. There will be 6 subjects who have not had surgery and 25 subjects who have had surgery.
3278267|NCT00639392|Placebo Comparator|2|Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive placebo are 1 out of 3.
3278268|NCT00639392|Experimental|1|Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive Zolendronic Acid are 2 out of 3.
3278269|NCT00639379|Experimental|senofilcon A|senofilcon A toric daily wear contact lenses
3278270|NCT00639379|Active Comparator|alphafilcon A|alphafilcon A toric daily wear contact lenses
3278271|NCT00639353|Active Comparator|spherical contact lens|Subjects will wear and evaluate a spherical soft contact lens daily for 2 weeks
3278272|NCT00639353|Experimental|toric contact lens|Subjects will wear and evaluate a toric soft contact lens daily for 2 weeks
3278273|NCT00639327|Experimental|A|CPT-11+ S-1
3278274|NCT00639327|Active Comparator|B|CPT-11
3278275|NCT00639314|Experimental|1|In PpPD, the proximal duodenum was divided 3-4cm distal to the pylorus ring
3278276|NCT00639314|Active Comparator|2|In PrPD, the stomach is divided just above the pylorus ring. the nearly total stomach more than 95% was preserved.
3278277|NCT00639301||1|adult survivors of retinoblastoma
3278278|NCT00639288|Experimental|1|modified CPT-C
3278279|NCT00639262|Experimental|Cohort 1 - Brain Metastasis|Sorafenib and Radiotherapy
3278280|NCT00639262|Experimental|Cohort 2 - Gliomas|Sorafenib and Radiotherapy, plus Temozolomide
3278281|NCT00639249|Placebo Comparator|P|Placebo
3278282|NCT00639249|Experimental|A1|SA4503
3278283|NCT00639249|Experimental|A2|SA4503
3278284|NCT00639223|Active Comparator|Pravastatin|
3278285|NCT00639223|Experimental|Red yeast Rice|
3278286|NCT00639210|Other|A|Supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.
3278287|NCT00639210|No Intervention|B|
3278288|NCT00639197|Active Comparator|1|To Tunnel
3278289|NCT00639197|Active Comparator|2|Not to tunnel
3278290|NCT00639184|Experimental|1|Home intervention program
3278291|NCT00639184|Active Comparator|2|health education counseling
3278292|NCT00639171||1|Subjects with suspicious breast lesions that warrant further evaluation will be followed to determination and confirmation of diagnosis.
3278293|NCT00639171||2|Normal subjects used to evaluate software and to develop and optimize MR sequences will be examined.
3278294|NCT00639158|Active Comparator|ABT-335 + atorvastatin + ezetimibe|
3278295|NCT00639158|Placebo Comparator|Placebo + atorvastatin + ezetimibe|
3278296|NCT00639106|Experimental|A|Expander Placement WITH Alloderm
3278297|NCT00639106|Active Comparator|B|Expander Placement WITHOUT Alloderm
3278298|NCT00639093|Experimental|1|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, 45 of the participants will use a virtual reality arm to catch and crush virtual cigarettes (on a computer)."
3278299|NCT00639093|Active Comparator|2|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, the 45 participants in the control condition will use a virtual reality arm to catch and crush virtual fruits (on a computer)."
3278300|NCT00639080||Entire study population|All study subjects.
3278301|NCT00639067||1|"Asymptomatic High Risk Subjects. Smokers aged >=18 undergoing chest CT.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
3278302|NCT00639067||2|"Symptomatic High Risk Subjects Without a Tissue Diagnosis. This group will comprise patients who are undergoing medical evaluation for a pulmonary symptom such as chronic unexplained cough or hemoptysis.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
3278303|NCT00639067||3|"Symptomatic High Risk Subjects With a Tissue Diagnosis. This group will be found to include a. lung cancer, and b. diseases other than lung cancer e.g. sarcoidosis, COPD or pulmonary infection.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
3278304|NCT00639067||4|"Apparently healthy individuals having no signs and symptoms of lung carcinoma.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
3278305|NCT00639054||Newly diagnosed patients|Newly diagnosed high-dose therapy candidates. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) and blood samples (24 ml of peripheral blood) for biochemical and genetic analyses regarding multiple myeloma, and granting access to clinical data relating to multiple myeloma.
3278306|NCT00639054||Relapse patients|Formerly high-dose treated patients with progressive disease. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) and blood samples (24 ml of peripheral blood) for biochemical and genetic analyses regarding multiple myeloma, and granting access to clinical data relating to multiple myeloma.
3278307|NCT00639054||Healthy controls|Healthy blood and bone marrow donors. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) for genetic analyses serving to compare normal bone marrow with bone marrow from multiple myeloma patients.
3278308|NCT00639041|Placebo Comparator|placebo|
3278309|NCT00639041|Active Comparator|n-3 LC-PUFA|
3278310|NCT00639028|Other|1|Ankle echography
3278311|NCT00639028|Other|2|echography + stress radiography
3278312|NCT00639028|Other|3|stress radiography
3278313|NCT00639015|Experimental|1|Phenylephrine
3278314|NCT00639015|Active Comparator|2|Norepinephrine
3278369|NCT00638612|Experimental|A resectable|Arm A is for resectable tumors. The first AdV-tk course is given prior to surgery by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery again followed by 14 days of valacyclovir.
3278432|NCT00638157|Active Comparator|Daptomycin Alone|daptomycin 6 mg/kg q24h for treatment of right-sided infective endocarditis
3278315|NCT00639002|Experimental|Ruxolitinib then Ruxolitinib + Dexamethasone|Patients received ruxolitinib 25 mg orally twice daily (bid) in each treatment cycle of 28 days. For those patients who had disease progression at any time or stable disease for 3 cycles and did not meet a withdrawal criterion, or withdrew consent, then 40 mg of dexamethasone was added to ruxolitinib on Days 1 to 4, 9 to 12, and 17 to 20 of four 28-day cycles. After the 4th cycle, 40 mg of dexamethasone was administered only on Days 1 to 4 of each subsequent cycle. Patients could continue to receive monotherapy or combination therapy indefinitely as long as no withdrawal criterion was met, did not have progressive disease and were receiving some clinical benefit.
3278316|NCT00638989|Experimental|CAT-354 150 mg (intravenous)|A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
3278317|NCT00638989|Experimental|CAT-354 150 mg (subcutaneous)|A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
3278318|NCT00638989|Experimental|CAT-354 300 mg (subcutaneous)|A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
3278319|NCT00638976|Other|1.Integrilin, GSK|Pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide (Integrilin, GSK) vs matched placebo.
3278320|NCT00638976|Placebo Comparator|2|Pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide (Integrilin, GSK) vs matched placebo.
3278321|NCT00638963|Experimental|Temozolomide|
3278322|NCT00638963|No Intervention|Observational|
3278323|NCT00638950|Placebo Comparator|Placebo|
3278324|NCT00638950|Active Comparator|n-3 LC-PUFA|
3278325|NCT00638937|Experimental|Treatment (saracatinib)|Patients receive saracatinib PO, at a dose of 175 mg QD on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression
3278326|NCT00638924||Exercise Capacity|Individuals from the female gender; age range of 20 to 30 years old; considered healthy (i.e. with no diagnosed health condition; considered sedentary (i.e. performing less than 150 minutes of moderate intensity physical activity per week); will be asked to volunteer in the research and perform a exercise capacity test.
3278327|NCT00638911||Patients with hypertention|
3278328|NCT00638898|Experimental|Arm I|See Detailed Description
3278329|NCT00638885||Group 1|
3278330|NCT00638872|Experimental|1|PDRN
3278331|NCT00638872|Placebo Comparator|placebo|placebo
3278332|NCT00638846|Experimental|senofilcon A toric|senofilcon A, daily wear, toric contact lens worn for two weeks
3278333|NCT00638846|Active Comparator|balafilcon A toric|balafilcon A, daily wear, toric contact lens worn for two weeks
3278334|NCT00638833|Active Comparator|A|Memantine 30 mg/day
3278335|NCT00638833|Placebo Comparator|B|Placebo
3278336|NCT00638820|Experimental|Intent-To-Treat|Patients enrolled and received study treatment.
3278337|NCT00638807|Experimental|A|
3278338|NCT00638807|Placebo Comparator|B|
3278339|NCT00638794||Surgical|Patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications.
3278340|NCT00638794||Observational|Consecutive patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications
3278341|NCT00638781|Active Comparator|1|Desmoteplase 62.5 µg/kg BW i.v. bolus
3278342|NCT00638781|Active Comparator|2|Desmoteplase 90 µg/kg BW i.v. bolus
3278343|NCT00638781|Active Comparator|3|Desmoteplase 125 µg/kg BW i.v. bolus
3278344|NCT00638781|Placebo Comparator|4|Placebo i.v. bolus
3278345|NCT00638768|Active Comparator|Physiotherapy|Including 10 individual visits with a physiotherapist and home exercises
3278346|NCT00638768|No Intervention|2|Usual care
3278347|NCT00638755|Experimental|1|The following treatment sequence: A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide), D (placebo)
3278348|NCT00638755|Experimental|2|The following treatment sequence: B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide), D (placebo), A (Nasal Carbon Dioxide)
3278349|NCT00638755|Experimental|3|The following treatment sequence: C (Nasal Carbon Dioxide), D (placebo), A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide)
3278350|NCT00638755|Experimental|4|The following treatment sequence: D (placebo), A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide)
3278351|NCT00638742|Experimental|1|
3278352|NCT00638729|Active Comparator|Midazolam|Pre-anesthetic medication with midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
3278353|NCT00638729|Active Comparator|Clonidine|pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
3278354|NCT00638729|Placebo Comparator|Placebo|Pre-anesthetic medication with an inert tablet, p.o., 60-90 min prior to estimated induction time
3278355|NCT00638716|Experimental|1|12 weekly doses of 1.5 mg CJC-1134-PC
3278356|NCT00638716|Experimental|2|4 weekly doses of 1.5 mg CJC-1134-PC followed by 8 weekly doses of 2.0 mg CJC-1134-PC
3278357|NCT00638716|Placebo Comparator|3|12 weekly doses of placebo
3278358|NCT00638703|Experimental|I|Size 2 enteric coated capsule containg lyophilized Oxalobacter formigenes
3278359|NCT00638703|Placebo Comparator|II|Size 2 enteric coated capsule containg placebo
3278360|NCT00638690|Experimental|Abiraterone acetate plus prednisone/prednisolone|
3278361|NCT00638690|Placebo Comparator|Placebo plus prednisone/prednisolone|
3278362|NCT00638677|Placebo Comparator|1|Sorbitol tablet
3278363|NCT00638677|Placebo Comparator|2|Xylitol tablet
3278364|NCT00638677|Active Comparator|3|Xylitol + BB12 tablet
3278365|NCT00638651|Active Comparator|1|The tattoo will be treated with laser and imiquimod 5% cream
3278366|NCT00638651|Placebo Comparator|2|The tattoo will be treated with laser and placebo topical cream
3278367|NCT00638638|Experimental|1|"Early Abciximab bolus during prehospital transportation in ambulance 0.25 mg/Kg iv with Heparin 40 UI/kg bolus.~Abciximab placebo bolus and Abciximab infusion 10 µg/Kg/min after coronary angiography and before angioplasty."
3278368|NCT00638638|Experimental|2|"Abciximab placebo bolus during prehospital transportation in ambulance with Heparin 40 UI/kg bolus.~Abciximab 0.25 mg/Kg bolus after coronary angiography and before angioplasty followed by Abciximab infusion 10 µg/Kg/min."
3278427|NCT00638209|Active Comparator|I|
3278428|NCT00638209|Placebo Comparator|P|
3278370|NCT00638612|Experimental|B locally advanced|"Arm B is for locally advanced tumors for which chemoradiation is the planned standard of care treatment. AdV-tk is delivered by CT or EUS guided injection into the tumor. The first AdV-tk injection is given prior to starting chemoradiation and the second in week 3 of chemoradiation. Both injections are followed by 14 days of valacyclovir.~Enrollment has been completed for Arm B."
3278371|NCT00638599|Experimental|1|LMA® is placed after anesthesia induction till the end of operation
3278372|NCT00638599|Active Comparator|2|Standard tracheal tube is inserted after anesthesia induction till the end of operation
3278373|NCT00638586||1|Femoral access
3278374|NCT00638586||2|Radial access
3278375|NCT00638560|Experimental|1|"Antioxidant treatment arm:~Vitamin E, 400 IU po, once daily Vitamin C, 1g po, twice daily"
3278376|NCT00638560|Placebo Comparator|2|Control
3278377|NCT00638547|Experimental|Intent-to-Treat|All patients who have received at least one dose of Laronidase.
3278378|NCT00638508|Active Comparator|Ketorolac|Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
3278379|NCT00638508|Experimental|Ketorolac with Ropivacaine|Patients will receive Ketorolac 5 mg and Ropivacaine 0.5% (Group 2) via an infusion catheter at the incision site
3278380|NCT00638495|Experimental|1|
3278381|NCT00638495|Placebo Comparator|2|
3278382|NCT00638482|Experimental|1|Hydrochlorothiazide
3278383|NCT00638469|Other|left/right|left or right body side
3278384|NCT00638456|Active Comparator|1|oral viscous budesonide plus Prevacid
3278385|NCT00638456|Placebo Comparator|2|placebo plus Prevacid
3278386|NCT00638443|Other|Pregabalin then Diphenhydramine|Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days; no drug for 7 days; diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
3278387|NCT00638443|Other|Diphenhydramine then Pregabalin|diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days; no drug for 7 days; pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
3278388|NCT00638430||1|low myopic group
3278389|NCT00638430||2|moderate myopic group
3278390|NCT00638417|Experimental|maximal strength training|maximal dynamic strength training
3278391|NCT00638417|Other|conventional rehabilitation|rehabilitation as usual
3278392|NCT00638404||1|Elective Cesarean Sections-this portion completed
3278393|NCT00638404||3|Any in-patient gynecologic procedure- this portion completed
3278394|NCT00638391||1|all patients treated with Anastrozole
3278395|NCT00638378|Experimental|Ruxolitinib|Participants received ruxolitinib 25 mg orally twice daily in 12-hour intervals for 21-day cycles for as long as the study medication was tolerated and provided clinical benefit.
3278396|NCT00638365|Experimental|1|KB001, a monoclonal antibody
3278397|NCT00638365|Placebo Comparator|2|Placebo
3278398|NCT00638339||1|critically ill patients undergoing invasive mechanical ventilation in medical ICU and CCU
3278399|NCT00638339||2|critically ill patients undergoing noninvasive mechanical ventilation in medical ICU and CCU
3278400|NCT00638326|No Intervention|1|Patients who show adequate response to 600 mg loading dose of clopidogrel and receive standard 1x75 mg clopidogrel
3278401|NCT00638326|Experimental|2|Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x150 mg clopidogrel for 28 days
3278402|NCT00638326|Active Comparator|3|Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x75 mg clopidogrel
3278403|NCT00638313|Placebo Comparator|Placebo|
3278404|NCT00638313|Experimental|PF-04603629|
3278405|NCT00638300|Experimental|1|large pore dialyzers (FX80, Fresenius, Germany)
3278406|NCT00638300|Experimental|2|small pore dialyzers ( F8HPS, Fresenius, Germany)
3278407|NCT00638300|Experimental|A|dialysate bicarbonate concentration of 33 mEq/l
3278408|NCT00638300|Experimental|B|dialysate bicarbonate concentration of 40 mEq/l
3278409|NCT00638300|Experimental|I|dialysate calcium concentration of 3 mEq/L
3278410|NCT00638300|Experimental|II|dialysate calcium concentration of 2.5 mEq/L
3278411|NCT00638274|Active Comparator|1|Air 3 ml used to identify epidural space
3278412|NCT00638274|Active Comparator|2|Saline 3 ml used to identify epidural space
3278413|NCT00638261|Other|left/right|left or right body side
3278414|NCT00638248|Active Comparator|1|Desmoteplase 90µg/kg BW
3278415|NCT00638248|Active Comparator|2|Desmoteplase 125 µg/kg BW
3278416|NCT00638248|Placebo Comparator|3|Placebo
3278417|NCT00638235||Phase I (IntePro, US only)|AMS Apogee™ with IntePro(Began May 2006 - Closed)
3278418|NCT00638235||Phase I (InteXen LP, US only)|AMS Apogee™ with InteXen LP (Began May 2006 - Closed)
3278419|NCT00638235||Phase II (France only)|AMS Perigee™ with IntePro (Began February 2007 - Closed)
3278420|NCT00638235||Phase III/IV (Perigee IntePro Lite, US only)|AMS Perigee™ with IntePro Lite (Began April 2007 - Closed)
3278421|NCT00638235||Phase III/IV (Apogee IntePro Lite, US only)|AMS Apogee™ with IntePro Lite (Began April 2007 - Closed)
3278422|NCT00638235||Phase V (Elevate Posterior IntePro Lite, US & EU)|AMS Elevate™ Apical & Posteiror with IntePro Lite (Began April 2008 - Closed)
3278423|NCT00638235||Phase V (Elevate Posterior InteXen, US only)|AMS Elevate™ Apical & Posteiror with IntXen LP (Began April 2008 - Closed)
3278424|NCT00638235||Phase VI (Elevate Anterior Gen 1, For Study Use Only, EU only)|AMS Elevate™ Anterior & Apical with IntePro Lite (Generation 1, For Study Use Only, Began October 2008 - Closed)
3278425|NCT00638235||Phase VII (Elevate Anterior Gen 2, US & EU)|AMS Elevate™ Anterior & Apical with IntePro Lite (Generation 2, Began April 2009 - Closed)
3278426|NCT00638222|Active Comparator|All Study Participants|All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
3278433|NCT00638157|Experimental|Daptomycin plus gentamicin|daptomycin 6 mg/kg q24h with concomitant initial gentamicin dosed for the first 2 days of therapy for the treatment of right-sided infective endocarditis
3278434|NCT00638144||1|patients with resolved infection
3278435|NCT00638144||2|chronically infected patients
3278436|NCT00638131|Experimental|1|Bosentan 62.5mg bid x4 weeks; up-titrated to 125mg bid x12 weeks;
3278437|NCT00638131|Placebo Comparator|2|placebo given bid same as experimental arm;
3278438|NCT00638092|Experimental|Iodine|This is the hypothetical active arm
3278439|NCT00638092|Placebo Comparator|Placebo|this is the hypothetical placebo
3278440|NCT00638079|Experimental|A|Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) with a high fat meal
3278441|NCT00638079|Active Comparator|B|Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) following an overnight fast
3278442|NCT00638066|Experimental|1|
3278443|NCT00638066|Active Comparator|2|
3278444|NCT00638053|Experimental|1|
3278445|NCT00638040||1|The purpose of this study is to analyze the gene expression patterns associated with various microenvironmental stresses in tumors to understand their roles in tumor progression and treatment responses. To achieve this goal, we will perform gene expression analysis of the tumor samples collected from an IRB-approved study (IRB #: 4516-05-2R2) International Phase III Study of Chemoradiotherapy versus Chemoradiotherapy Plus Hyperthermia for Locally Advanced Cervical Cancer directed by Dr. Mark Dewhirst. We will correlate the gene expression signatures of different microenvironmental stresses with the measured physiological parameters to understand their role in tumor progression, treatment response and clinical outcomes.
3278446|NCT00638027|Experimental|1|Memantine 10 mg bid
3278447|NCT00638027|Placebo Comparator|2|Placebo
3278448|NCT00638014|Active Comparator|1|Conventional wires only
3278449|NCT00638014|Experimental|2|Rapid Sternal Closure System supplemented with wires
3278450|NCT00637988|Experimental|1|Nexium 40mg
3278451|NCT00637988|Experimental|2|Nexium 40mg + aspirin
3278452|NCT00637988|Experimental|3|Nexium 40mg + Rofecoxib 25 mg
3278453|NCT00637988|Active Comparator|4|Rofecoxib 25mg
3278454|NCT00637975|Experimental|A|oxycodone 20 mg/day plus pregabalin at increasing dose starting from 50 mg/day for 15 days or until unacceptable toxicity develops
3278455|NCT00637975|Active Comparator|B|pregabalin 50 mg/day plus oxycodone at increasing dose starting from 20 mg/day. For 15 days or until unacceptable toxicity develops
3278456|NCT00637962|Experimental|Active product|CN54gp140 + gel
3278457|NCT00637962|Placebo Comparator|Gel alone|Gel alone
3278458|NCT00637949|Experimental|1|
3278459|NCT00637949|Active Comparator|2|
3278460|NCT00637936|Active Comparator|1|Group 1 is given 30% oxygen during and 2 hours after surgery
3278461|NCT00637936|Active Comparator|2|Group 2 is given 80% during and 2 hours after surgery.
3278462|NCT00637923|Experimental|1|One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
3278463|NCT00637923|Placebo Comparator|2|One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
3278464|NCT00637910|Experimental|Erlotinib Arm|
3278465|NCT00637910|Active Comparator|Docetaxel Arm|
3278466|NCT00637897|Experimental|Paricalcitol (Zemplar)|Paricalcitol (Zemplar)
3278467|NCT00637871|Experimental|1|
3278468|NCT00637871|Active Comparator|2|
3278469|NCT00637858|Placebo Comparator|1|
3278470|NCT00637858|Active Comparator|2|Lyc-o-Mato 5mg
3278471|NCT00637858|Active Comparator|3|Lyc-o-Mato 15mg
3278472|NCT00637858|Active Comparator|4|Lyc-o-Mato 30mg
3278473|NCT00637858|Active Comparator|5|Lycopene capsules (non Lyc-o-mato) 15 mg
3278474|NCT00637845|Experimental|1|40mg once daily
3278475|NCT00637845|Active Comparator|2|30mg twice daily
3278476|NCT00637806|Active Comparator|1|Megestrol acetate concentrated suspension 110 mg/mL
3278477|NCT00637806|Active Comparator|2|Megestrol acetate concentrated suspension 60 mg/mL
3278478|NCT00637806|Placebo Comparator|3|
3278479|NCT00637793|Placebo Comparator|1|Placebo capsules
3278480|NCT00637793|Experimental|2|2 capsules in the am of each treatment period
3278481|NCT00637793|Experimental|3|2 capsules in the am of each treatment period
3278482|NCT00637793|Experimental|4|2 capsules in am of each treatment period
3278483|NCT00637780|Experimental|1|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 6 days
3278484|NCT00637741|Experimental|Everflex 200|study group treated with at least one 200 mm Everflex stent
3278485|NCT00637728|Active Comparator|1|Megestrol acetate concentrated suspension 110 mg/mL
3278486|NCT00637728|Placebo Comparator|2|Placebo suspension
3278487|NCT00637702|Experimental|ARRY-334543|
3278488|NCT00637676|Active Comparator|1|Implantation of PleurX-Pleural catheter plus talc pleurodesis
3278489|NCT00637676|Active Comparator|2|talc pleurodesis, no implantation of PleurX-Pleural catheter
3278490|NCT00637663|Experimental|A|entecavir 0.5 mg QD
3278491|NCT00637663|Active Comparator|B|lamivudine 100 mg QD
3278492|NCT00637650|Experimental|B|"Experimental group: patients in whom stone dust was left for spontaneous elimination"
3278493|NCT00637650|Other|A|Control group: Patients in whom all fragments resulting from laser lithotripsy of ureteral stones were actively retrieved
3278494|NCT00637624|Active Comparator|1|N-Acetylcysteine
3278495|NCT00637624|Placebo Comparator|2|Placebo
3278496|NCT00637598|Experimental|Tomosynthesis scans|This is a case-only study with only one group/cohort. All women receive both mammography and tomosynthesis imaging.
3278497|NCT00637572|Experimental|Megestrol acetate oral suspension nanocrystal dispersion|Megestrol acetate oral suspension nanocrystal dispersion formulation 115 mg/mL
3278498|NCT00637572|Active Comparator|Megestrol acetate oral suspension micronized formulation|Megestrol acetate oral suspension micronized formulation 60 mg/mL
3278551|NCT00637208|Experimental|1|
3278499|NCT00637559|Experimental|1|40mg twice daily
3278500|NCT00637559|Experimental|2|40mg three times daily
3278501|NCT00637559|Experimental|3|20mg three times daily
3278502|NCT00637546|Experimental|A,1|Physiotherapy
3278503|NCT00637533|Placebo Comparator|Placebo|Saline injection
3278504|NCT00637533|Experimental|Botulinum Toxin Type A|Sympathetic Blockade containing Botulinum Toxin Type A
3278505|NCT00637520||1|Subjects with NAFLD
3278506|NCT00637520||2|Subjects without liver disease
3278507|NCT00637520||3|Subjects with non-steatotic hepatitis
3278508|NCT00637507|No Intervention|2|Patients treated solely with a pressure- and volume-limited ventilatory strategy (target plateau pressure of 30 cm H2O) aimed at minimizing lung stress and strain, and thus, ventilator-induced lung injury.
3278509|NCT00637507|Experimental|1|Intermittent application of High-frequency Oscillation (HFO) and Tracheal Gas Insufflation (TGI) according to pre-specified criteria described in the Detailed Description. HFO-TGI sessions are interspersed with lung protective conventional mechanical ventilation until the PaO2/FiO2 ratio stabilizes at >150 mm Hg.
3278510|NCT00637494|Active Comparator|1|Mifepristone followed by an antidepressant
3278511|NCT00637494|Placebo Comparator|2|Placebo followed by an antidepressant
3278512|NCT00637481|Experimental|Arm I (lower dose atorvastatin calcium)|Participants receive oral atorvastatin once daily for 3 months.
3278513|NCT00637481|Experimental|Arm II (atorvastatin calcium)|Participants receive oral atorvastatin (at a higher dose than in arm I) once daily for 3 months.
3278514|NCT00637481|Experimental|Arm III (higher dose atorvastatin calcium)|Participants receive oral atorvastatin (at a higher dose than in arm II) once daily for 3 months.
3278515|NCT00637481|Other|Arm IV (no intervention)|Participants do not receive treatment. Participants undergo blood sample collection and fine needle aspiration of breast tissue at baseline and at 3 months for correlative biomarker studies.
3278516|NCT00637468|Experimental|1|Local intra-arterial fibrinolysis (LIF)
3278517|NCT00637468|Active Comparator|2|Conservative standard therapy
3278518|NCT00637442|Experimental|CASL-MRI|Drug monitoring with CASL-MRI for new diagnosed patients with mild to moderate Alzheimer's Disease treated with Reminyl
3278519|NCT00637429||General Co-infection|Individuals with HIV infection and hepatitis B surface antigen positive results who are currently receiving or planning to commence HAART.
3278520|NCT00637416|Active Comparator|Lansoprazole and dietary control|Lansoprazole and dietary control
3278521|NCT00637416|Placebo Comparator|Placebo and dietary control|Dietary control and placebo
3278522|NCT00637403|Active Comparator|I|Megestrol acetate concentrated suspension in subjects with normal renal function
3278523|NCT00637403|Experimental|II|Megestrol acetate concentrated suspension in subjects with mild renal impairment
3278524|NCT00637403|Experimental|III|Megestrol acetate concentrated suspension in subjects with moderate renal impairment
3278525|NCT00637403|Experimental|IV|Megestrol acetate concentrated suspension in subjects with severe renal impairment
3278526|NCT00637403|Experimental|V|Megestrol acetate concentrated suspension in subjects with end stage renal disease
3278527|NCT00637390|Experimental|one|
3278528|NCT00637377|Active Comparator|Ranibizumab 0.5mg Q4|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
3278529|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
3278530|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
3278531|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
3278532|NCT00637351||Group A|Subjects with diagnosed pneumonia & positive culture of streptococcus pneumoniae
3278533|NCT00637351||Group B|Subjects with diagnosed pneumonia & positive culture of non-typable haemophilus influenzae
3278534|NCT00637338|Experimental|PF-04603629|The dose range initially planned is 3 mg up to 70 mg, although the specific doses administered may be modified based on emerging study data.
3278535|NCT00637338|Placebo Comparator|Placebo|
3278536|NCT00637325|Experimental|A|"In the maintenance study:~ARM A: maintenance of trastuzumab~In the 2nd line study:~ARM A: trastuzumab plus chemotherapy treatment"
3278537|NCT00637325|No Intervention|B|"In the maintenance study:~ARM B: interruption of trastuzumab treatment~In the 2nd line study:~ARM B: chemotherapy alone"
3278538|NCT00637312|Experimental|Advent™ Cervical Disc|Cervical artificial disc replacement: Advent™ Cervical Disc
3278539|NCT00637312|Active Comparator|Standard care - Control|Anterior cervical discectomy and fusion (ACDF) with Hallmark™ Anterior Cervical Plate System
3278540|NCT00637299|Active Comparator|Active osteopathic treatment (OMT+PR)|The examination was performed by osteopathic practitioners with emphasis on the neuromusculoskeletal system including palpatory diagnosis for somatic dysfunction and viscerosomatic change, in the context of total patient care. The examination was concerned with range of motion of all parts of the body, performed with the patient in multiple positions to provide static and dynamic evaluation.
3278541|NCT00637299|Sham Comparator|SOT + PR|Sham osteopathic treatment (manipulation)
3278542|NCT00637273|Experimental|1|
3278543|NCT00637273|Active Comparator|2|
3278544|NCT00637273|Active Comparator|3|
3278545|NCT00637260|Experimental|A|
3278546|NCT00637260|Sham Comparator|B|
3278547|NCT00637247|Experimental|imexon + gemcitabine|imexon + gemcitabine
3278548|NCT00637247|Active Comparator|Placebo + gemcitabine|Placebo in combination with gemcitabine
3278549|NCT00637234|Experimental|1|
3278550|NCT00637234|Placebo Comparator|2|
3278552|NCT00637208|No Intervention|2|Watch-full follow-up
3278553|NCT00637195|Experimental|Cervarix™ & Engerix™ Group|Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™) (Months 0, 1 & 6) and 4 doses of Hepatitis B (Engerix™) vaccine (Months 0, 1, 2 & 12).
3278554|NCT00637195|Active Comparator|Engerix™ Group|Subjects received 4 doses of Hepatitis B (HBV) vaccine (Months 0, 1, 2 & 12).
3278555|NCT00637169|Experimental|1|Supplemental oxygen to maintain functional arterial oxygen saturations in the range of 85-89%. Dose of oxygen is determined by the individual infant's need to achieve the target oxygen saturations.
3278556|NCT00637169|Active Comparator|2|Supplemental oxygen to maintain functional arterial oxygen saturations in the range of 91-95%. Dose of oxygen is determined by the individual infant's need to achieve the target oxygen saturations.
3278557|NCT00637156|Experimental|PRESTIGE LP Device|
3278558|NCT00637156|Other|ATLANTIS Cervical Plate System|
3278559|NCT00637143|Experimental|1|Oral
3278560|NCT00637143|Active Comparator|2|Oral
3278561|NCT00637130|Experimental|Travoprost 0.0008%|Travoprost ophthalmic solution, 0.0008%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
3278562|NCT00637130|Experimental|Travoprost 0.001%|Travoprost ophthalmic solution, 0.001%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
3278563|NCT00637130|Experimental|Travoprost 0.0012%|Travoprost ophthalmic solution, 0.0012%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
3278564|NCT00637130|Active Comparator|TRAVATAN + Vehicle|TRAVATAN, one drop in study eye(s) once daily (8 PM), and Vehicle, one drop in study eye(s) once daily (8 AM), for two weeks
3278565|NCT00637130|Placebo Comparator|Vehicle|Vehicle, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
3278566|NCT00637104|Experimental|A - Mar-tyn|It includes the implant of the Mar-tyn TiN coated stent
3278567|NCT00637104|Active Comparator|B - Vision|Includes all the patients treated with the Vision stent
3278568|NCT00637091|Experimental|EGFR expression|Patients' accrual will be adjusted by EGFR expression (positive vs. negative)
3278569|NCT00637078|Active Comparator|1|Drug: Fix dose combination therapy
3278570|NCT00637078|No Intervention|2|Guidelines based management
3278571|NCT00637065|Active Comparator|1|Bosentan tablets (62.5mg bd for first 4 weeks, then 125mg bd as tolerated)
3278572|NCT00637065|Placebo Comparator|2|Placebo tablets
3278573|NCT00637052|Experimental|ARRY-520|
3278574|NCT00637013|Active Comparator|Acromioplasty|Acromioplasty + physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
3278575|NCT00637013|Active Comparator|Physiotherapy|Physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
3278576|NCT00637000|Experimental|Buprenorphine soluble film|"Day 1: Buprenorphine soluble film administered at a dose of 4 mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.~Days 2-5: Buprenorphine soluble film administered at a dose of 16 mg to 24 mg once per day, plus placebo. Dosing occurred at 0900 hours."
3278577|NCT00637000|Experimental|Buprenorphine/naloxone soluble film|"Day 1: Buprenorphine/naloxone soluble film administered at a dose of 4mg/1mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.~Days 2 to 5: Buprenorphine/naloxone soluble film administered at a dose of 16mg/4 mg to 24 mg/6 mg once per day, plus placebo. Dosing occurred at 0900 hours."
3278578|NCT00636987|Other|Implanted with Biocor or Biocor Supra Valves|
3278579|NCT00636961|Experimental|Sequence 1: Indacaterol 300μg followed by Placebo|In period I, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. In period II, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. For each treatment period and for each patient, the doses were to be administered between 7am and 12am. A period of at least 4 days but no more than 21 days separated each treatment period. Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
3278580|NCT00636961|Experimental|Sequence 2 : Placebo followed by Indacaterol 300μg|In period I, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. In period II, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. For each treatment period and for each patient, the doses were to be administered between 7am and 12am. A period of at least 4 days but no more than 21 days separated each treatment period. Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
3278581|NCT00636935|Experimental|1|Antibiotic only therapy in patients with PCP and a pO2 of > 70mmHg.
3278582|NCT00636935|Experimental|2|Antibiotics and Corticosteroid therapy in patients with PCP and pO2 >70 mmHg.
3278583|NCT00636935|Active Comparator|3|Standard of care therapy for patients with PCP and pO2 < 70mmHg.
3278584|NCT00636922|Experimental|Everolimus with 5-azacitidine|Everolimus increasing oral doses days 5-21 each cycle 5-azacitidine 75mg sub cutaneously 7 doses in 21 days
3278585|NCT00636909|Experimental|1|Study treatment arm with G-CSF
3278586|NCT00636896|Experimental|1|Olanzapine 10 mg plus modafinil 200 mg
3278587|NCT00636896|Placebo Comparator|2|Olanzapine plus Placebo
3278588|NCT00636857|Experimental|I|Perioperative fluid management based on body weight
3278589|NCT00636857|Active Comparator|II|Perioperative fluid management based on Lean Body Mass (LBM)
3278590|NCT00636844||Group A|Patients receiving chemotherapy (anthracycline and/or adjuvant trastuzumab) for the first time
3278591|NCT00636831|Placebo Comparator|cont|
3278592|NCT00636831|Active Comparator|intervention|
3278593|NCT00636818|Experimental|Atomoxetine|
3278594|NCT00636805|Experimental|1|Patient receives IV Aloxi
3278595|NCT00636792|Experimental|1|This is a phase 2, single-arm, open label, multicenter study evaluating the efficacy and safety of the combination of VELCADE, bendamustine, and rituximab in subjects with relapsed or refractory follicular lymphoma, who have received 4 or more doses of rituximab. Subjects may be sensitive or refractory to prior therapies, including rituximab.
3278596|NCT00636779||1|Up to five hundred eligible patients seen at each of the nine participating Integrative Medicine Centers will be approached (by mail, phone, at the time of their visit, etc.) and invited to consent to the paper and pencil study.
3278597|NCT00636766|Experimental|1|
3278598|NCT00636753||1|schizophrenic patients
3278599|NCT00636753||2|controls
3278600|NCT00636740|Experimental|B|MER-101 20mg Tablets Regimen 1
3278601|NCT00636740|Experimental|C|MER-101 20mg Tablets Regimen 2
3278602|NCT00636740|Active Comparator|A|Zometa Injection
3278603|NCT00636727|Active Comparator|1|arthrocentesis
3278604|NCT00636727|Active Comparator|2|arthroscopy
3278605|NCT00636727|Active Comparator|3|arthroplasty
3278606|NCT00636714|Experimental|Nurse-directed|Using nursing judgement to control blood glucose
3278607|NCT00636714|Active Comparator|Nomogram-directed|Blood glucose control directed by pre-approved paper nomogram
3278608|NCT00636701|Experimental|Primed rTMS|Receive 10 min. of 6-Hz rTMS Repetitive Transcranial Magnetic Stimulation at 90% RMT (3,600 pulses). Followed by 30 min. of 1-Hz rTMS at 95% RMT (1,880 pulses)
3278609|NCT00636701|Placebo Comparator|Unprimed rTMS)|Receive 10 min. of sham rTMS Repetitive Transcranial Magnetic Stimulation. Followed by 30 min. of 1-Hz rTMS at 95% RMT (1,880 pulses)
3278610|NCT00636688|Experimental|1|Behavioral (Lifestyle Counseling)
3278611|NCT00636688|Active Comparator|2|Control group
3278612|NCT00636675|Experimental|Fall QI|Falls QI includes quality improvement training about falls to be implement by indigenous nursing home staff with support of study personnel.
3278613|NCT00636675|Experimental|Connect & Falls QI|Connect is delivered, followed by Falls. Behavioral intervention to improve staff interaction for better care planning and execution. Connect will be delivered, followed by the Falls quality improvement intervention.
3278614|NCT00636662||all|any patient exhibiting symptoms of influenza
3278615|NCT00636649|Experimental|A|Escitalopram
3278616|NCT00636649|Placebo Comparator|B|Placebo
3278617|NCT00636636|Experimental|G-ER|Gabapentin - Extended Release
3278618|NCT00636636|Placebo Comparator|Placebo|Sugar pill
3278619|NCT00636623|Other|2|Pilates exercises
3278620|NCT00636623|Other|1|Connective tissue massage
3278621|NCT00636610|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily starting on Day 3 of each 2-week treatment cycle. In addition, patients received either Modified FOLFOX (FOL=leucovorin calcium [folinic acid], F=fluorouracil, OX=oxaliplatin) + bevacizumab or FOLFIRI (FOL=leucovorin calcium [folinic acid] F=fluorouracil, IRI=irinotecan hydrochloride) + bevacizumab on Days 1-3 of each 2-week treatment cycle. The decision of which regimen (FOLFOX or FOLFIRI) to use was made by the treating physician and patient.
3278622|NCT00636610|Placebo Comparator|Placebo to vismodegib|Patients received placebo to vismodegib orally once daily starting on Day 3 of each 2-week treatment. In addition, patients received either Modified FOLFOX (FOL=leucovorin calcium [folinic acid], F=fluorouracil, OX=oxaliplatin) + bevacizumab or FOLFIRI (FOL=leucovorin calcium [folinic acid] F=fluorouracil, IRI=irinotecan hydrochloride) + bevacizumab on Days 1-3 of each 2-week treatment cycle. The decision of which regimen (FOLFOX or FOLFIRI) to use was made by the treating physician and patient.
3278623|NCT00636597||1|
3278624|NCT00636584|Experimental|1|arm1: sodium nitroprusside group
3278625|NCT00636584|Placebo Comparator|2|arm2: control group,saline infused instead of sodium nitroprusside
3278626|NCT00636558|Experimental|CVA21|IV administration of CVA21 in a dose escalation manner
3278627|NCT00636545|Experimental|Part 1|Cohort 1- Genasense will be administered as a 2-hour intravenous infusion once weekly for 3 weeks at a dose of 300 mg to the first subject enrolled and, in the absence of dose-limiting toxicity, in increasing increments of 100 mg to each successive subject enrolled to a maximum dose of 1000 mg.
3278628|NCT00636545|Experimental|Part 2|Genasense will be administered as a 2-hour intravenous infusion twice weekly for 3 weeks at a dose established based on Part 1 of the study.
3278629|NCT00636545|Experimental|Cohort 2|Also in Part 1 of the study, Genasense will be administered as a 2-hour intravenous infusion once weekly for 3 weeks at a starting dose of 1100 mg and increasing in increments of 100 mg to the MTD. Patients will be pretreated with a corticosteroid.
3278630|NCT00636519|Experimental|Stage A|Botulism Antitoxin Bivalent (Equine) Types A and B Vs. Placebo
3278631|NCT00636519|Experimental|Stage B|Botulism Antitoxin Heptavalent (Equine) Types A-G Vs. Placebo
3278632|NCT00636493|Experimental|Vein Occlusion Eye|Eye with retinal vein occlusion receiving fluocinolone acetonide sustained drug delivery device
3278633|NCT00636480|Experimental|CHG 2%-26 ml|Chlorhexidine gluconate in an aqueous base, 26 ml applicator
3278634|NCT00636480|Active Comparator|ChloraPrep 26 ml|ChloraPrep One-Step 26 ml Active drug contains chlorhexidine gluconate and alcohol
3278635|NCT00636480|Placebo Comparator|Sterile Saline|Sterile salt water administered topically.
3278636|NCT00636467|Experimental|No label|Injection of Nanocis® or Nanocoll® (Tc-colloid) on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)
3278637|NCT00636454|Active Comparator|1|This group will serve as the control group and will receive only the care usually given to OA patients.
3278638|NCT00636454|Experimental|2|This group will take part in the 10-session treatment program that will teach patients cognitive and behavioral skills to cope with pain.
3278639|NCT00636441|Active Comparator|Guided Arm|"Genomically-guided treatment allocation.~This arm has the following cohorts:~AC sensitive patients [>60% probability of response to AC]~TC sensitive patients [>60% probability of response to TC]~Patients sensitive to neither AC nor TC; randomized to AC or TC"
3278640|NCT00636441|Active Comparator|Non-Guided Arm|"Non-genomically-guided treatment allocation.~This arm has the following cohorts:~In patients randomly assigned to AC:~Patients sensitive to AC~Patients sensitive to TC~Patients sensitive to neither AC nor TC~In patients randomly assigned to TC:~Patients sensitive to AC~Patients sensitive to TC~Patients sensitive to neither AC nor TC"
3278641|NCT00636428|Active Comparator|1|Oral midazolam
3278642|NCT00636428|Active Comparator|2|IV Midazolam
3278643|NCT00636415|Experimental|A|G1 patients received morphine intra-articular route G2 patients received bupivacaine without epinephrine.
3278644|NCT00636402|Experimental|1|Vessel Sealing System Tonsillectomy (VSST)
3278645|NCT00636402|Active Comparator|2|Cold Knife Tonsillectomy (CKT)
3278687|NCT00636142|Placebo Comparator|2|Placebo
3278646|NCT00636389|Other|HD-C4 First, then 210H|Subjects will be randomly assigned to begin the first week of three consecutive treatments with the Polyflux HD-C4 dialyzer. Following the third treatment, the subjects will be switched to the Polyflux 210H dialyzer for a second week of three consecutive treatments. Therefore each subject will have a total of six consecutive dialysis treatments.
3278647|NCT00636389|Other|210H First, then HD-C4|Subjects will be randomly assigned to begin the first week of three consecutive treatments with the Polyflux 210H dialyzer. Following the third treatment, the subjects will be switched to the Polyflux HD-C4 dialyzer for a second week of three consecutive treatments. Therefore each subject will have a total of six consecutive dialysis treatments.
3278648|NCT00636376|Experimental|1|Single arm--no randomization. All subjects enrolled will have vitals collected and three ultrasounds at different levels of head of the bed elevations.
3278649|NCT00636363|Experimental|Multipurpose Solution - Rub Care|Bausch & Lomb Multipurpose Solution for use with contact lens care
3278650|NCT00636363|Experimental|Multipurpose Solution - No Rub Care|Bausch & Lomb Multipurpose Solution for use with contact lens care
3278651|NCT00636363|Active Comparator|Ciba Vision Aquify Multipurpose Solution|Ciba Vision Aquify Multipurpose Solution for use with contact lens care
3278652|NCT00636337|Experimental|1|Participants meeting inclusion criteria will be provided with a laptop computer outfitted with a wireless card for the duration of the intervention and will be trained in the use of RoboMemo in the clinic by study personnel. Although many participants may have ready access to home computers, we decided that all participants will be required to use laptops provided by the study for two reasons: 1) to ensure that coaches and participants are blind to treatment condition (as described above), and 2) to ensure that participants will always have access to the intervention program (i.e., they will not compete with other family members for computer time). Once trained, children will complete the intervention at home. The intervention will consist of four 30- to 45-minute sessions per week for 8 weeks (total = 32 sessions). This intervention schedule is similar to the schedule employed by Klingberg and colleagues in their home-based CT trials with ADHD children.
3278653|NCT00636337|Placebo Comparator|2|The design will be a double-blind, placebo-controlled trial in which half of the participants will be randomized to the intervention condition and half will receive a comparison computer program. Specifically, participants assigned to the comparison (placebo) condition will complete a modified version of the CT at home. The treatment and comparison CT programs begin identically, at the lowest difficulty level. Those in the treatment condition will complete activities of increasing difficulty over the intervention period. Those in the placebo condition, in contrast, will complete the same basic tasks during each session of the intervention, regardless of performance. In this way, a true estimate can be obtained of the efficacy of the treatment program.
3278654|NCT00636324|Experimental|1|Nasal CPAP, level of 7 to 9 cmH2O
3278655|NCT00636324|Active Comparator|2|Nasal CPAP, level 4 to 6 cmH2O
3278656|NCT00636311|Active Comparator|1|IGEV regimen (Ifosfamide, Gemcitabine, Vinorelbine)
3278657|NCT00636311|Experimental|2|B-IGEV (Bortezomib + IGEV)
3278658|NCT00636298|Experimental|A|Single arm treatment with combination of cetuximab and bevacizumab
3278659|NCT00636285|Placebo Comparator|1|Placebo
3278660|NCT00636285|Experimental|2|BSYX-A110, Dosed intravenously, 3mg/kg
3278661|NCT00636285|Experimental|3|BSYX-A110, Dosed intravenously, 10mg/kg
3278662|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-satellite150/4|
3278663|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-satellite150/6|
3278664|NCT00636246|Active Comparator|sertraline-satellite|
3278665|NCT00636246|Active Comparator|sertraline-main|
3278666|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-satellite150/2|
3278667|NCT00636246|Placebo Comparator|Placebo|
3278668|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-main|
3278669|NCT00636246|Active Comparator|[S,S]-reboxetine-main|
3278670|NCT00636233||Anencephaly|Fetuses with anencephaly, parents and siblings
3278671|NCT00636220||A, Observational|
3278672|NCT00636207|Experimental|Montelukast 0.1 mg|"Participants receive Montelukast inhalation powder, 0.1 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period."
3278673|NCT00636207|Experimental|Montelukast 0.3 mg|"Participants receive Montelukast inhalation powder, 0.3 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period."
3278674|NCT00636207|Experimental|Montelukast 1 mg|"Participants receive Montelukast inhalation powder, 1 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered once daily (QD) for 5 days followed by at least a 3-day washout period."
3278675|NCT00636207|Experimental|Montelukast 3 mg|"Participants receive Montelukast inhalation powder, 3 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered QD for 5 days followed by at least a 3-day washout period.~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
3278676|NCT00636207|Experimental|Montelukast 10 mg|"Participants receive Montelukast inhalation powder, 10 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered QD for 5 days followed by at least a 3-day washout period.~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
3278677|NCT00636207|Placebo Comparator|Placebo|"Participants receive Placebo to Montelukast inhalation powder.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered QD for 5 days followed by at least a 3-day washout period.~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
3278678|NCT00636194|Experimental|B&L Multipurpose solution|Bausch & Lomb Multipurpose Contact Lens Solution
3278679|NCT00636194|Active Comparator|Alcon Multipurpose Solution|Alcon OptiFree Replenish Multipurpose Contact Lens Solution
3278680|NCT00636181|Active Comparator|Auto Aflex|auto adjusting positive pressure therapy with AFLEX
3278681|NCT00636181|Active Comparator|Auto CPAP|auto adjusting positive pressure therapy
3278682|NCT00636181|Active Comparator|CPAP|continuous positive airway pressure
3278683|NCT00636168|Active Comparator|A|
3278684|NCT00636168|Placebo Comparator|B|
3278685|NCT00636155|Experimental|all patients|EL625 combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide)
3278686|NCT00636142|Active Comparator|1|Infliximab
3278688|NCT00636129||1|Relaxation Response + Stress Management Curriculum
3278689|NCT00636116|Experimental|Group 1|Anavip with Anavip Maintenance Therapy
3278690|NCT00636116|Experimental|Group 2|Anavip with Placebo Maintenance Therapy
3278691|NCT00636116|Active Comparator|Group 3|CroFab with CroFab Maintenance Therapy
3278692|NCT00636103|Experimental|CUF2|
3278693|NCT00636103|Placebo Comparator|Placebo|
3278694|NCT00636077|Other|HD-C4 Big|3 consecutive treatments with the HD-C4 Big dialyzer.
3278695|NCT00636077|Other|HD-C4 Small|3 consecutive treatments with the HD-C4 Small dialyzer.
3278696|NCT00636077|Other|F160NR|3 consecutive treatments with the F160NR dialyzer.
3278697|NCT00636077|Other|F200NR|3 consecutive treatments with the F200NR dialyzer.
3278698|NCT00636064|Placebo Comparator|A|
3278699|NCT00636064|Experimental|B|
3278700|NCT00636064|Experimental|C|
3278701|NCT00636051||1|staff Registered Nurses receiving EBP peer mentoring
3278702|NCT00636051||2|staff Registered Nurses not receiving EBP peer mentoring
3278703|NCT00636025||Observational|
3278704|NCT00636012|Experimental|1|verum acupuncture
3278705|NCT00636012|Sham Comparator|2|sham acupuncture
3278706|NCT00635999|Experimental|Purely Behavioral therapy|Participants will receive treatment with progressive and applied relaxation and self-control desensitization.
3278707|NCT00635999|Experimental|Cognitive-Behavioral Therapy|Participants will receive treatment with cognitive therapy, progressive and applied relaxation, and self-control desensitization
3278708|NCT00635999|Experimental|Cognitive Therapy (CT)|Participants will receive purely cognitive therapy including identification of maladaptive thought processes and training in cognitive restructuring.
3278709|NCT00635986|Experimental|A|group 1 (n = 14) patients received 5 mL of a 100 mcg Fentanyl solution in saline without preservative by the epidural route and 2 mL saline intravenously. Group 2 (n = 15) patients received 5 mL saline by the epidural route and 2 mL (100 mcg) Fentanyl intravenously
3278710|NCT00635960|Experimental|1|Patients randomly assigned to treatment
3278711|NCT00635960|Placebo Comparator|2|Patients randomly assigned to placebo
3278712|NCT00635947|Active Comparator|1|isotonic solution - 1.5L
3278713|NCT00635947|Active Comparator|2|water- 1.5L
3278714|NCT00635947|Placebo Comparator|3|water-200mL
3278715|NCT00635934|Experimental|A-MAV™disc|
3278716|NCT00635921|Active Comparator|I ziprasidone|
3278717|NCT00635921|Placebo Comparator|II placebo|
3278718|NCT00635895|Active Comparator|1|Manual Lymph Drainage Therapy is a manual therapy method
3278719|NCT00635895|Active Comparator|2|Connective Tissue Massage
3278720|NCT00635882|Experimental|MF/F MDI 100/10 mcg|
3278721|NCT00635882|Experimental|MF/F MDI 200/10 mcg|
3278722|NCT00635882|Experimental|MF/F MDI 400/10 mcg|
3278723|NCT00635882|Experimental|MF DPI 200 mcg|
3278724|NCT00635882|Experimental|MF MDI 200 mcg|
3278725|NCT00635882|Experimental|Placebo|
3278726|NCT00635869||ARCC standard|RNs on unit receiving basic ARCC information with staff nurse champion
3278727|NCT00635869||ARCC enhanced|RNs on unit receiving ARCC standard content plus with an EBP mentor
3278728|NCT00635869||C|RNs on the unit receiving the placebo intervention
3278729|NCT00635843|Experimental|MAVERICK™ Disc|
3278730|NCT00635843|Active Comparator|Fusion|
3278731|NCT00635830|Experimental|1|Open Label
3278732|NCT00635817|Experimental|Leuprolide acetate 11.25 mg|There are 2 arms that received leuprolide acetate 11.25 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm A and subjects who have previously been treated with leuprolide acetate are designated to be in Arm B.
3278733|NCT00635817|Experimental|Leuprolide acetate 30 mg|There are 2 arms that received leuprolide acetate 30 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm C and subjects who have previously been treated with leuprolide acetate are designated to be in Arm D.
3278734|NCT00635804|Experimental|Pt 1: MK-3281 100 mg BID (Panel A)|Healthy male participants in this Part I serial panel receive 100 mg MK-3281 orally twice daily (BID) for 10 consecutive days for a total daily dose administered of 200 mg. The evening (PM) dose of MK-3281 was not administered on Day 10.
3278735|NCT00635804|Experimental|Pt 1: MK-3281 200 mg BID (Panel B)|Healthy male participants in this Part I serial panel receive 200 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 400 mg. The PM dose of MK-3281 was not administered on Day 10.
3278736|NCT00635804|Experimental|Pt 1: MK-3281 400 mg BID (Panel C)|Healthy male participants in this Part I serial panel receive 400 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 800 mg. The PM dose of MK-3281 was not administered on Day 10.
3278737|NCT00635804|Experimental|Pt 1: MK-3281 800 mg BID (Panel D)|Healthy male participants in this Part I serial panel receive 800 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 10.
3278738|NCT00635804|Experimental|Pt 2: MK-3281 800 mg BID (Panel E)|Genotype (GT)1 HCV-infected male participants in this Part II serial panel receive 800 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 7.
3278739|NCT00635804|Experimental|Pt 2: MK-3281 800 mg BID (Panel F)|GT1a/GT1-nontypeable/GT3/GT1b HCV-infected male participants in this Part II serial panel receive 800 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 7.
3278740|NCT00635804|Experimental|Pt 2: MK-3281 1200 mg BID (Panel G)|GT1a (and/or GT1 nontypeable) and GT1b HCV-infected male participants in this Part II serial panel receive 1200 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 2400 mg. The PM dose of MK-3281 was not administered on Day 7.
3278741|NCT00635804|Placebo Comparator|Placebo|Participants receive dose-matched placebo to MK-3281 orally BID for 7 or 10 consecutive days depending on randomization. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
3278893|NCT00634725|Experimental|Arm 2 (B1) Gemcitabine + Erlotinib|B1 Gemcitabine + Erlotinib (100mg/d) 2 months, then erlotinib maintenance (150 mg/d)until progression
3278742|NCT00635791|Experimental|Sorafenib tosylate and vorinostat|Patients receive sorafenib tosylate by mouth twice a day on days 1-21 and vorinostat by mouth every day on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3278743|NCT00635778|Experimental|Part 1|Part 1 is for determination of leading dose. It consists of three patients (up to a maximum of six) per dose level will be treated at rising dose levels of MK-0646 consisting of a loading dose (2.5, 5, 10, 15 and 20 mg/kg) followed by a subsequent every other week maintenance dose (of at least 2.5 mg/kg) starting two weeks after the completion of the loading dose.
3278744|NCT00635778|Experimental|Part 2|Part 2 is for determination of maintenance dose. It consists of at least three new patients (up to a maximum of six) per dose level will be treated at rising maintenance dose levels of MK-0646. All patients will receive the previous determined loading infusion from Part I, followed by a subsequent every other week maintenance infusion (2.5, 5, 10, 15, 20 mg/kg) starting two weeks after the loading infusion.
3278745|NCT00635778|Experimental|Part 3|Part 3 is refinement of safety and pharmacokinetics. At the recommended phase 2 loading and every other week maintenance dose and schedule determined from Parts I and II, an additional 14-17 patients (for 20 patients total) will be enrolled for further refinement of the pharmacokinetics and safety of MK-0646 administered at this dose and schedule.
3278746|NCT00635752|Experimental|1|Participants will receive trauma-focused cognitive behavioral therapy (TF-CBT)
3278747|NCT00635752|Active Comparator|2|Participants will receive sessions of treatment as usual (TAU)
3278748|NCT00635739|Active Comparator|A, 1|
3278749|NCT00635739|Placebo Comparator|A, 2|
3278750|NCT00635726|Experimental|1|MVAC -> GEM+CDDP
3278751|NCT00635713|Experimental|1|Faslodex 125mg and Arimidex 1 mg
3278752|NCT00635713|Experimental|2|Faslodex 250mg and Arimidex 1mg
3278753|NCT00635700|Experimental|1|
3278754|NCT00635700|Placebo Comparator|2|
3278755|NCT00635687|Experimental|Fibroscan|
3278756|NCT00635674|Experimental|Group I - compliant|CPAP use for more than 4 hr/night
3278757|NCT00635674|Active Comparator|Group 2-noncompliant|CPAP for less than 4 hr/night
3278758|NCT00635648|Experimental|Caspofungin 50 mg Intravenous (IV)|
3278759|NCT00635635|Active Comparator|1|Guided Imagery Audio
3278760|NCT00635635|Active Comparator|2|Music Audio
3278761|NCT00635622|Experimental|1|Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10^9 cfu/dose. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
3278762|NCT00635622|Placebo Comparator|2|Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
3278763|NCT00635609|Experimental|Doxycycline hyclate (Doryx)|
3278764|NCT00635609|Active Comparator|Doxycycline hyclate|
3278765|NCT00635596|Experimental|I|
3278766|NCT00635583|Experimental|Increased Dairy Consumption|Increased Dairy Consumption - Each subject in this arm will receive three additional servings of dairy to consume each day for 18 months.
3278767|NCT00635583|No Intervention|Control|This group will not receive the intervention but will continue their normal diet; they will act as the control.
3278768|NCT00635570|Active Comparator|Contraceptive vaginal ring|Contraceptive vaginal ring (NuvaRing)
3278769|NCT00635570|Active Comparator|Oral contraceptive pill|Oral contraceptive pill (Ortho Tri-cyclen Lo)
3278770|NCT00635544|Experimental|1|dietary treatment with a high-glycemic index low-fibre diet (HGI-LF)
3278771|NCT00635544|Active Comparator|2|dietary treatment with a low-glycemic index high-fibre diet (LGI-HF)
3278772|NCT00635531|Placebo Comparator|Placebo group|
3278773|NCT00635531|Active Comparator|Alprazolam XR group|
3278774|NCT00635518|Other|I, Intervention|
3278775|NCT00635505|Experimental|T|albuterol HFA 180 mcg QID
3278776|NCT00635505|Active Comparator|R|180 mcg QID 12 weeks
3278777|NCT00635505|Placebo Comparator|P|2 actuations QID 12 weeks or until use of rescue drug
3278778|NCT00635492||1|exenatide
3278779|NCT00635492||2|insulin
3278780|NCT00635479|Experimental|VAC Device placement|will have the VAC device used for post-operative management of acetabular fractures and pelvic fractures.
3278781|NCT00635479|Active Comparator|Gauze dressing|will receive current traditional surgical wound management with daily dressing changes in post operative management of acetabular fractures and pelvic fractures.
3278782|NCT00635466|Experimental|Lap, 1|Patients undergoing laparoscopic surgery for rectal carcinoma
3278783|NCT00635453|Other|I, Intervention|
3278784|NCT00635440|Active Comparator|A|
3278785|NCT00635440|Sham Comparator|B|
3278786|NCT00635427|Experimental|VPRIV 60 U/kg(VPRIV Parent Study 45 or 60 U/kg- TKT032,GCB039)|"This arm is the Overall velaglucerase alfa (VPRIV) 60 U/kg and includes patients from the following groups:~VPRIV 45 U/kg or 60 U/kg, IV, EOW for 51 weeks in parent study TKT032 (NCT00430625) and switched to 60 U/kg in HGT-GCB-044 to maintain blindness or 60 U/kg, IV, EOW for 39 weeks in parent study HGT-GCB-039 (NCT00553631)"
3278787|NCT00635427|Experimental|VPRIV 60 U/kg (Parent study-imiglucerase(60 U/kg) HGT-GCB-039)|imiglucerase 60 U/kg, IV, EOW for 39 weeks in parent study HGT-GCB-039 (NCT00553631)and switched 60 U/kg VPRIV in HGT-GCB-044
3278788|NCT00635427|Experimental|VPRIV 15-60 U/kg (Parent study VPRIV (15-60 U/kg) TKT034)|VPRIV 15- 60 U/kg, IV, EOW for 51 weeks in parent study TKT034 (NCT00478647) and continued in HGT-GCB-044 at the same dose as prescribed in TKT034
3278789|NCT00635414|Experimental|1|40mg administered orally
3278790|NCT00635414|Experimental|2|15 minute intravenous infusion
3278791|NCT00635401|Experimental|0.5 mg BID|
3278792|NCT00635388|Sham Comparator|1|
3278793|NCT00635388|Experimental|2|
3278794|NCT00635388|Experimental|3|
3278795|NCT00635375|Experimental|1|LED fiberoptic blanket phototherapy
3278796|NCT00635375|Experimental|2|metal halide phototherapy
3278797|NCT00635375|Active Comparator|3|LED bank phototherapy
3278798|NCT00635375|Experimental|4|Combination metal halide phototherapy plus LED fiberoptic blanket phototherapy
3278799|NCT00635362|Experimental|postplacental insertion after cesarean|"Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta~Device of intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)"
3278800|NCT00635362|Active Comparator|delayed insertion group|"Insertion of the LNG-IUS 4-8 weeks after cesarean delivery~Device of intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)"
3278801|NCT00635349|Active Comparator|Non-steroidal Anti-inflammatory Drug (NSAIDs)|Participants will receive fixed dose combination of tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg, 1 to 3 tablets per day along with meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 1 to Day 28. Participants who will have the numeric rating scale score 4 or less on Day 29 will be randomly assigned to the treatment of NSAIDs to receive either meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 29 to Day 85.
3278802|NCT00635349|Experimental|Tramadol Hydrochloride Plus Acetaminophen|Participants will receive fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 1 to Day 28. Participants who will have the numerical rating scale score 4 or less on Day 29 will be randomly assigned to the treatment of fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
3278803|NCT00635323|Experimental|A|
3278804|NCT00635310|Active Comparator|HD patients with CHC or CHB|Chronic hepatitis C (CHC) or chronic hepatitis B (CHB) patients with hemodialysis (HD), pretreated with DDAVP 0.3 ug/kg body weight infusion 30-60 minutes before percutaneous liver biopsies (PLBs)
3278805|NCT00635310|Active Comparator|Ordinary patients with CHC or CHB|Chronic hepatitis C (CHC) or chronic hepatitis B (CHB) patients with normal renal function (NRF) receiving percutaneous liver biopsies (PLBs)
3278806|NCT00635297|Active Comparator|1|50 osteoporotic patients with a vertebral insufficiency fracture will receive treatment of the vertebrae with standard vertebroplasty
3278807|NCT00635297|Experimental|2|50 osteoporotic patients with a vertebral insufficiency fracture will receive treatment of the vertebrae with standard vertebroplasty. The adjacent vertebrae will be treated with 3-5 ml of PMMA
3278808|NCT00635284|Experimental|ABI-009|
3278809|NCT00635258||GnRH-ant|Patients were treated with a GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
3278810|NCT00635258||GnRH-a|GnRH long protocol using 0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state. Furthermore, the triptorelin administration was maintained until the day of donor's hCG administration.
3278811|NCT00635232|Active Comparator|Irbesartan 300mg|Irbesartan 300 mg once daily
3278812|NCT00635232|Placebo Comparator|Placebo|Blinded Placebo Treatment
3278813|NCT00635232|Experimental|PS433540 200mg|PS433540 200mg once daily
3278814|NCT00635232|Experimental|PS433540 400mg|PS433540 400mg once daily
3278815|NCT00635232|Experimental|PS433540 800mg|PS433540 800mg once daily
3278816|NCT00635219|Placebo Comparator|Placebo|
3278817|NCT00635219|Experimental|Vortioxetine: 2.5 mg|
3278818|NCT00635219|Experimental|Vortioxetine: 5 mg|
3278819|NCT00635219|Experimental|Vortioxetine: 10 mg|
3278820|NCT00635219|Other|Duloxetine: 60 mg|Active reference
3278821|NCT00635206|Active Comparator|1|Auto M series device set to Bi Flex
3278822|NCT00635206|Active Comparator|2|Set to standard CPAP
3278823|NCT00635193|Other|Cohort 1|Three subjects will be treated with liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab, 7.5 mg/kg qwk
3278824|NCT00635193|Other|Cohort 2|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk
3278825|NCT00635193|Other|Group A|liposomal doxorubicin, 40 mg/m2 q4wk
3278826|NCT00635193|Other|Group B|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg q2wk (or other dose and schedule)
3278827|NCT00635193|Other|Group C|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk (or other dose and schedule)
3278828|NCT00635180|Experimental|1|1: Healthy subjects
3278829|NCT00635167|Experimental|Contrast Enhanced Transrectal Ultrasound (TRUS)|
3278830|NCT00635154|Experimental|Anakinra with/without Dexamethasone|"Anakinra was given alone for 6 months at which time response was assessed.~If participants achieved a minor response or better they continued on Anakinra alone until disease progression.~If participants achieved stable disease, they added low dose Dexamethasone to Anakinra until progression.~If at any time a participant progresses, they were administered high dose Dexamethasone with Anakinra."
3278831|NCT00635141|Experimental|1|
3278832|NCT00635141|Experimental|2|
3278833|NCT00635128|Experimental|BOOSTRIX-POLIO GROUP|Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™-Polio vaccine in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
3278834|NCT00635128|Experimental|BOOSTRIX + IPV MÉRIEUX GROUP|Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™ and IPV Mérieux® vaccines in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
3278835|NCT00635115|Experimental|1|
3278836|NCT00635115|Active Comparator|2|
3278837|NCT00635102|Active Comparator|Alcohol dependent|Alcohol dependent patients will receive 4 interventions
3278838|NCT00635102|Active Comparator|Healthy subjects|Healthy subjects will receive 4 interventions
3278839|NCT00635089|Other|Open-Label Reslizumab|Open-label reslizumab intravenous (IV) infusion at an initial dose of 1 mg/kg monthly
3278840|NCT00635076|Placebo Comparator|Placebo group|
3278841|NCT00635076|Active Comparator|Alprazolam XR group|
3278842|NCT00635063|Experimental|AD 923|
3278843|NCT00635063|Active Comparator|MSIR|
3278894|NCT00634725|Experimental|Arm 3 (A2) CRT|A2 CRT then stop until progression
3278895|NCT00634725|Experimental|Arm 4 (B2) CRT then erlotinib|B2 CRT then erlotinib maintenance (150mg/d) until progression
3278844|NCT00635050|Experimental|Doxil, Paclitaxel, Cyclophosphamide + Avastin|Two stage phase II single arm trial to evaluate the pathologic complete response rate to sequential dose dense chemotherapy using Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, in patients with locally advanced invasive breast cancer.
3278845|NCT00635037|Experimental|A|"G1 (n=15)received trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.~G2(n=15) was submitted to classical and trigger point acupuncture twice a week."
3278846|NCT00635024|Experimental|Anti-thymocyte Globulin/Melphalan|Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m^2)
3278847|NCT00634998|Placebo Comparator|2|1000mg Placebo capsules orally twice daily for 90 days
3278848|NCT00634998|Experimental|1|1000mg Vitamin C capsules orally twice daily for 90 days
3278849|NCT00634985|Experimental|A|
3278850|NCT00634972|Experimental|1|
3278851|NCT00634972|Placebo Comparator|2|
3278852|NCT00634959|Experimental|1|
3278853|NCT00634959|Experimental|2|
3278854|NCT00634959|Experimental|3|
3278855|NCT00634959|Experimental|4|
3278856|NCT00634959|Placebo Comparator|5|
3278857|NCT00634946|Experimental|I|
3278858|NCT00634946|Experimental|II|
3278859|NCT00634946|Experimental|III|
3278860|NCT00634946|Placebo Comparator|IV|
3278861|NCT00634933|Experimental|Arm 1|Consists of Arms 1a and 1b
3278862|NCT00634933|Experimental|Arm 2|Consists of Arms 2a and 2b
3278863|NCT00634933|Placebo Comparator|Arm 3|Consists of Arms 3a and 3b.
3278864|NCT00634920|Experimental|Everolimus (CNI-free)|Patients in this group were converted to everolimus immunosuppressive therapy. The patients in the everolimus group were treated with everolimus, off-label (CNI-free) use, and EC-MPS and corticosteroids in accordance with local practice and approved label. Conversion to everolimus was as follows: Day 1: begin everolimus 3 mg in the evening. Usual morning dose of CsA and 50% reduced evening dose of CsA Day 2: everolimus 2 mg in the morning and 2 mg in the evening, complete discontinuation of CsA Day 3 or 4, and onwards: everolimus according to trough level 6-10 ng/mL.The given total daily dose of the immunosuppressive drugs (everolimus) was divided into two (equal) doses, applied 12 hours apart.
3278865|NCT00634920|Active Comparator|Control (CsA)|Patients in the control group continued on an immunosuppressive regimen. The patients in this Control group were treated with CsA, EC-MPS and corticosteroids in accordance with local practice and approved label. The given total daily dose of the immunosuppressive drugs (CsA and EC-MPS) was divided into two (equal) doses, applied 12 hours apart.
3278866|NCT00634907|Experimental|Pharmacogenetic-based warfarin dosing|"Pharmacogenetic-based warfarin dosing: Warfarin dosing based on formula that incorporates genetic testing results.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm, as noted above."
3278867|NCT00634907|Active Comparator|Standard of care (control)|"Control or usual care warfarin dosing~NOTE: Standard of care (usual care) for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm, as noted above."
3278868|NCT00634894|Experimental|Femara|
3278869|NCT00634894|Placebo Comparator|Placebo|
3278870|NCT00634881|Experimental|Cohort A: Alemtuzumab i.v.|Intravenous administration of alemtuzumab according to the 3 + 3 dose escalation design.
3278871|NCT00634881|Experimental|Cohort B: Alemtuzumab s.c.|After i.v. MTD (maximum tolerable dosage) has been determined, subcutaneous dose escalation is performed according to the same escalation rules as for cohort A, starting with the recommended dose level of i.v. application.
3278872|NCT00634868|Sham Comparator|1|The device is emitting a sham light
3278873|NCT00634868|Experimental|2|The device is emitting curative light
3278874|NCT00634855||Complicated|Women with pregnancies complicated by intrauterine growth restriction or preeclampsia
3278875|NCT00634855||Normal|Women with normal pregnancies
3278876|NCT00634842|Experimental|FPG 70-90 mg/dL|Aggressive FPG (fasting plasma glucose) titration target range group
3278877|NCT00634842|Experimental|FPG 80-110 mg/dL|Conventional FPG (fasting plasma glucose) titration target range group
3278878|NCT00634829|Experimental|T|Armstrong Albuterol HFA Inhalation Aerosol
3278879|NCT00634829|Active Comparator|R|2 inhalations Proventil-HFA Albuterol Sulfate, 108 mcg, prior to exercise
3278880|NCT00634829|Placebo Comparator|P|Placebo-HFA
3278881|NCT00634816||Chemotherapy recipients|Subjects who have undergone chemotherapy will receive DXA scan
3278882|NCT00634803|Experimental|CBT for POD|Integrated cognitive behavioral therapy for chronic pain and opioid dependence
3278883|NCT00634803|Active Comparator|Educational Counseling for POD|Educational Counseling is a didactic, lecture-discussion format to supplement the information and advice provided by physicians in physician management (PM)
3278884|NCT00634803|Active Comparator|Physician Management|PM is a relatively brief intervention that approximates the medically focused advice and brief counseling about medical issues that is typically provided by physicians to patients with chronic pain or other chronic medical conditions, such as diabetes or asthma.
3278885|NCT00634790|Active Comparator|alprazolam group|
3278886|NCT00634764||Pregnant|Pregnant women who present to MUSC's Cannon Place or Prenatal Wellness Center
3278887|NCT00634751|Experimental|Phase I: 200mg Sorafenib+2DOC|"Cohort 1: 200mg Sorafenib+2DOC~Oxaliplatin + Oral Capecitabine + Sorafenib"
3278888|NCT00634751|Experimental|Phase I: 400mg Sorafenib BID+2DOC|"Cohort 2: 400mg Sorafenib+2DOC~Oxaliplatin + Oral Capecitabine + Sorafenib"
3278889|NCT00634751|Experimental|Phase II: Pancreatic Cancer|Oxaliplatin + Oral Capecitabine + Sorafeni
3278890|NCT00634751|Experimental|Phase II: Biliary Tract Cancer|Oxaliplatin + Oral Capecitabine + Sorafeni
3278891|NCT00634738|Experimental|one|
3278892|NCT00634725|Active Comparator|Arm 1 (A1) - Gemcitabine|Gemcitabine 2 months, then stop until progression
3278896|NCT00634712|Active Comparator|1|
3278898|NCT00634699|Experimental|One|Ischemic Compression on Triggers Points on Muscles along the Median Nerve. Active Comparator
3278899|NCT00634686|Experimental|1|
3278900|NCT00634686|Placebo Comparator|2|
3278901|NCT00634673|Other|TT|patients homozygous for Thr54 (TT)
3278902|NCT00634673|Other|AA|patients homozygous for Ala54 (AA)
3278903|NCT00634660|Active Comparator|0.001 mg/kg|One subcutaneous injection of 0.001 mg/kg of rAvPAL-PEG.
3278904|NCT00634660|Active Comparator|0.003 mg/kg|One subcutaneous injection of 0.003 mg/kg of rAvPAL-PEG.
3278905|NCT00634660|Active Comparator|0.01 mg/kg|One subcutaneous injection of 0.01 mg/kg of rAvPAL-PEG.
3278906|NCT00634660|Active Comparator|0.03 mg/kg|One subcutaneous injection of 0.03 mg/kg of rAvPAL-PEG.
3278907|NCT00634660|Active Comparator|0.1 mg/kg|One subcutaneous injection of 0.1 mg/kg of rAvPAL-PEG.
3278908|NCT00634660|Active Comparator|0.3 mg/kg|One subcutaneous injection of 0.3 mg/kg of rAvPAL-PEG.
3278909|NCT00634660|Active Comparator|1.0 mg/kg|One subcutaneous injection of 1.0 mg/kg of rAvPAL-PEG.
3278910|NCT00634647|Experimental|Satraplatin|satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days
3278911|NCT00634634|Experimental|Sorafenib and Letrozole|
3278912|NCT00634608|No Intervention|Survey|Control group participants are sent a survey within one week of clinic visit
3278913|NCT00634608|Experimental|Health Information Prescription|Health Information Prescription is emailed to participants within 24 hours of clinic visit.
3278914|NCT00634595|Experimental|A|E10A combined with Cisplatin and Paclitaxel
3278915|NCT00634595|Active Comparator|B|Cisplatin and Paclitaxel
3278916|NCT00634569|Experimental|Flebogamma 5% DIF|
3278917|NCT00634556|Experimental|levodopa solution 2mg/ml for i.v. use|"levodopa solution in saline, given intravenously, dosed as per final protocol in Black et al 2003."
3278918|NCT00634556|Placebo Comparator|Placebo|normal saline i.v.
3278919|NCT00634543|Experimental|Tramadol hydrochloride (HCl)/ Acetaminophen|Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3, 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
3278920|NCT00634543|Active Comparator|Gabapentin|Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
3278921|NCT00634530|Other|I, Intervention|
3278922|NCT00634517|Experimental|T|Armstrong Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
3278923|NCT00634517|Active Comparator|R|Proventil-HFA, Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
3278924|NCT00634504|Experimental|A|High-dose methotrexate, leucovorin, and Voraxaze
3278925|NCT00634504|Active Comparator|B|High-dose methotrexate and leucovorin without Voraxaze (glucarpidase)
3278926|NCT00634491|Active Comparator|1|150 meq/l NaHco3 3cc/kg/hr one Hour before and 1cc/kg/hr 6 hour after angiography
3278927|NCT00634491|Active Comparator|2|Acetazolamide 250 mg + 1cc/kg/hr normal salin 6 hour before and after angiography
3278928|NCT00634491|Active Comparator|3|normal salin 1cc/kg/hr before and after angiography
3278929|NCT00634478|Experimental|1|preleminiscal radiation deep brain stimulation
3278930|NCT00634478|Active Comparator|2|VIM deep brain stimulation
3278931|NCT00634465||1|
3278932|NCT00634452|Experimental|MDX-1401|MDX-1401 iv at various doses
3278933|NCT00634439||A|All patients 18 years or older who received a first dispensing of atomoxetine during the time period of the study (January 1, 2003 through December 31, 2006) and had at least 6 months of continuous enrollment prior to first dispensing are included in the study cohort. Patients are excluded for presence of pre-existing arrhythmia and heart failure during the baseline period. The study entry date for this cohort is the date of first atomoxetine dispensing.
3278934|NCT00634439||B|All patients 18 years or older who received a first dispensing of a stimulant medication (methylphenidate or mixed salts of amphetamine) during the time period of the study with no dispensing of the same drug in the prior 6 months and had at least 6 months of continuous enrollment prior to the first dispensing are identified. Patients are excluded for presence of pre-existing arrhythmia and heart failure during the baseline period. Patients who are matched to atomoxetine initiators using this propensity score method are retained and followed as one comparator cohort. The study entry date is the date of the first dispensing of a comparator ADHD medication.
3278935|NCT00634439||C|Patients with at least 6 months of continuous enrollment in the database, and without a history of arrhythmia or heart failure during the baseline period are sampled and frequency matched on age and gender to the atomoxetine cohort in a 2:1 ratio. Study entry dates are assigned so as to be similar to the distribution of study entry dates in the atomoxetine cohort. Patients identified and matched as initiators of atomoxetine or stimulant ADHD medications are not eligible for inclusion in this cohort
3278936|NCT00634426||1|De novo surgical cohort
3278937|NCT00634426||2|Nonoperative treatment cohort
3278938|NCT00634426||3|Secondary surgical treatment cohort
3278939|NCT00634413|Experimental|1|
3278940|NCT00634413|Placebo Comparator|2|
3278941|NCT00634400|Active Comparator|1|
3278942|NCT00634400|Placebo Comparator|2|
3278943|NCT00634387|Active Comparator|A|Anthocyans
3278944|NCT00634387|Placebo Comparator|B|no effective agent
3278945|NCT00634374|No Intervention|1|Oral Syringe
3278946|NCT00634374|Active Comparator|2|Rx medibottle
3278947|NCT00634361|Experimental|A|
3278948|NCT00634348|Active Comparator|Aripiprazole|
3278949|NCT00634348|Active Comparator|Ziprasidone|
3278950|NCT00634335||sk|professional Israeli bicyclists
3278951|NCT00634322|Experimental|A|HDMTX-LV with glucarpidase
3278952|NCT00634322|Active Comparator|B|HDMTX-LV with placebo
3278953|NCT00634322|Experimental|C|compassionate use group to treat or prevent life threatening toxicity in the event of delayed elimination of MTX and/or renal impairment
3278954|NCT00634309|Active Comparator|1|
3278955|NCT00634309|Placebo Comparator|2|
3278956|NCT00634296|Active Comparator|G2|Inspiratory muscle training added by aerobic training to aerobic training alone
3278957|NCT00634283|Experimental|1|Five weeks of treatment with venlafaxine IR
3278958|NCT00634270|Experimental|Sirolimus|"Design~Sirolimus oral solution will be administered orally BID on a continuous dosing schedule (28 days = 1 treatment course) with pharmacokinetically-guided dosing.~Disease status will be evaluated using volumetric MRI analysis at regular intervals.~The plasma pharmacokinetics and pharmacodynamics of sirolimus will be evaluated, as will pharmacogenetic polymorphisms and their influence on the metabolism of sirolimus in this patient population.~Pain reduction and quality of life outcomes will also be assessed.~Toxicity of chronic sirolimus administered will be evaluated using physical and laboratory evaluations."
3278959|NCT00634257||Patients|Patients with advanced cancer receiving palliative care.
3278960|NCT00634257||Caregivers|Primary caregivers of Patients with advanced cancer receiving palliative care.
3278961|NCT00634244|Experimental|Arm A (carboplatin and topotecan hydrochloride)|Patients receive carboplatin and topotecan hydrochloride IV continuously over 24 hours on days 1-5.
3278962|NCT00634244|Experimental|Arm B (alvocidib, mitoxantrone, cytarabine)|Patients receive alvocidib IV over 4.5 hours QD on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9.
3278963|NCT00634244|Experimental|Arm C (sirolimus, mitoxantrone, etoposide, cytarabine)|Patients receive sirolimus PO QD on days 2-9, mitoxantrone hydrochloride IV over 15 minutes QD, etoposide IV over 1 hour QD, and cytarabine IV over 3 hours QD on days 4-8 or 5-9. (Closed to accrual)
3278964|NCT00634231|Experimental|AdV-tk|AdV-tk + valacyclovir in combination with standard of care radiation
3278965|NCT00634218|Active Comparator|1|Mail-based Self Help (MSH) treatment. Participants will receive the self-help manual developed specifically for LGBT smokers.
3278966|NCT00634218|Active Comparator|2|Mail-based Self Help plus an Internet-based Smoking Treatment (IST). In the IST condition, participants will receive the manual plus access to an Internet-based intervention that includes social support.
3278967|NCT00634218|Active Comparator|3|Mail-based Self-Help plus Telephone Counseling (TC). In the TC condition, participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions.
3278968|NCT00634218|Active Comparator|4|Mail-based Self-Help plus an Internet-based Intervention plus Telephone Counseling. Participants will receive a self-help manual, have access to an internet-based smoking treatment and participante in 6 telephone counseling sessions.
3278969|NCT00634205|Experimental|A|Continuous oral administration of valproate plus every 3 weeks, intravenous administration of doxorubicin
3278970|NCT00634192|Experimental|1|
3278971|NCT00634192|Experimental|2|
3278972|NCT00634179|Experimental|Treatment (VR-CHOP regimen)|"INDUCTION: Patients receive bortezomib IV on days 1 and 8; rituximab IV, doxorubicin hydrochloride IV over 3-5 minutes, cyclophosphamide IV over 60 minutes, and vincristine sulfate IV over 10 minutes on day 1; and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression.~MAINTENANCE: Patients achieving complete response (CR) receive rituximab IV once every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or partial response (PR) receive rituximab IV and bortezomib once weekly for 4 weeks every 6 months for up to 2 years in the absence of disease progression or unacceptable toxicity."
3278973|NCT00634166|Other|Historical Control|Treated within the last 5 years (if possible) with topical prophylactic therapies that did not include mafenide acetate or mafenide salt forms.
3278974|NCT00634166|Experimental|Prospective Patients/Active Drug|Prospective subjects with thermal injuries of 20-60% TBSA on the chest, abdomen, or proximal upper and lower extremities requiring meshed autografts on these areas will receive SS5% as the initial topical moist dressing over the meshed autograft(s) placed at the initial graft procedure (Day 1).
3278975|NCT00634140|Experimental|1|ezetimibe
3278976|NCT00634140|Placebo Comparator|2|placebo for 4-6 weeks
3278977|NCT00634114|Experimental|1|Esomeprazole and Omeprazole
3278978|NCT00634114|Experimental|2|Esomeprazole
3278979|NCT00634101|Active Comparator|nefilcon A|Subjects randomized to this arm received the nelfilcon A lens throughout the entire duration of the study.
3278980|NCT00634101|Experimental|narafilcon A|Subjects randomized to this arm received the narafilcon A lens throughout the entire duration of the study.
3278981|NCT00634088|Experimental|Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|Dose Level 1
3278982|NCT00634088|Experimental|Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|Dose Level 2
3278983|NCT00634088|Experimental|Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|Dose Level 3
3278984|NCT00634088|Experimental|Ixabepilone + Lapatinib + Capecitabine|Triplet Combination
3278985|NCT00634075|Experimental|1|
3278986|NCT00634075|Placebo Comparator|2|
3278987|NCT00634062|Active Comparator|1|
3278988|NCT00634062|Placebo Comparator|2|
3278989|NCT00634049|Experimental|Isavuconazole|Administration of isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days followed by daily administration of isavuconazole (IV) or oral
3278990|NCT00634036|Active Comparator|1|
3278991|NCT00634036|Placebo Comparator|2|
3278992|NCT00634010|Active Comparator|Morphine Capsule|Morphine 15 mg slow release orally every 12 hours + additional doses as needed
3278993|NCT00634010|Active Comparator|Methadone Capsule|Methadone 5 mg orally every 12 hours + additional as needed doses up to 40-50 mg/day
3278994|NCT00633997|Experimental|1|Healthy volunteers
3278995|NCT00633997|Experimental|2|Type II diabetics
3278996|NCT00633984|Active Comparator|Cognitive Behavioral Group Therapy + D-Cycloserine|Participants received Cognitive Behavioral Group Therapy and 50mg D-Cycloserine.
3278997|NCT00633984|Placebo Comparator|Cognitive Behavioral Group Therapy + Placebo|Participants received Cognitive Behavioral Group Therapy and 50mg Placebo.
3278998|NCT00633971|Experimental|A|Complex lymphedema therapy (which includes compression stocking use)
3278999|NCT00633971|Other|B|Standard of care (compression stocking use at 30-40 mm Hg)
3279000|NCT00633958|Experimental|18F-FLT|All subjects will receive 18F-FLT prior to PET imaging.
3279001|NCT00633932|Experimental|1|Esomeprazole 20mg
3279002|NCT00633932|Experimental|2|Esomeprazole 40mg
3279003|NCT00633932|Active Comparator|3|Omeprazole 20mg
3279004|NCT00633919|Active Comparator|Active|SLITone Dermatophagoides Mix
3279005|NCT00633919|Placebo Comparator|Placebo|SLITone Placebo
3279006|NCT00633906|Experimental|1|HORIZONS HIV Intervention. Two-session, group-based interactive intervention.
3279007|NCT00633906|Active Comparator|2|Enhanced standard-of-care session. One hour, video-based and brief discussion.
3279008|NCT00633893|Experimental|1|2.5 mg
3279009|NCT00633893|Experimental|2|5.0 mg
3279010|NCT00633893|Active Comparator|3|0 mg
3279011|NCT00633880|Experimental|Droxidopa|Double-blind
3279012|NCT00633880|Placebo Comparator|Placebo|Double-blind
3279013|NCT00633867|Active Comparator|Intubation c McGrath videolaryngoscope|Tracheal Intubation using McGrath video-laryngoscope
3279014|NCT00633867|Active Comparator|Intubation using Macintosh Laryngoscope|Tracheal intubation using Macintosh Laryngoscope
3279015|NCT00633854||1|30 volunteer subjects who are age 60 and older
3279016|NCT00633841|Active Comparator|1|AFFITOPE AD02 without adjuvant
3279017|NCT00633841|Active Comparator|2|AFFITOPE AD02 with adjuvant
3279018|NCT00633828|Experimental|A Intervention group|Increased physical education in primary school (daily)
3279019|NCT00633828|No Intervention|B Control group|Normal physical education in primary school (typically once per week)
3279020|NCT00633815||Fontan patients|Subjects will undergo exercise testing in both the supine and upright positions
3279021|NCT00633815||Healthy controls|Subjects will undergo exercise testing in both the supine and upright positions
3279022|NCT00633802|Placebo Comparator|2|
3279023|NCT00633802|Experimental|1|
3279024|NCT00633789|Experimental|1|
3279025|NCT00633789|Placebo Comparator|2|
3279026|NCT00633776|Experimental|1|Formoterol fumarate 20 mcg (Perforomist) nebulized via Pari C nebulizer at Test Visit 1; Formoterol 12 mcg (Foradil) via aerosolizer dry powder inhaler at Test Visit 2
3279027|NCT00633776|Active Comparator|2|Formoterol fumarate 12 mcg (Foradil) via aerosolizer dry powder inhaler at Test Visit 1; Formoterol fumarate 20 mcg (Perforomist) nebulized via Pari C nebulizer at Test Visit 2
3279028|NCT00633763||1|Healthy individuals with normal C-peptide levels following i.v. glucagon challenge. These individuals will be administered 18F-fallypride and then subjected to PET-CT scanning of the pancreas and brain. The subject will be positioned in the PET/CT scanner and a low-dose CT (15-20 secs) of the abdomen carried out (with subjects breathing normally). A 30-min PET acquisition will then be started (three 10 min static frames or one 30 min static frame). The subject will then be repositioned for a low-dose CT scan of the head (15-20 secs) following which a 20-min PET acquisition will then be started (two 10 min static frames or one 20 min static frame).
3279029|NCT00633763||2|Patients with longstanding T1DM and <20% C-peptide levels following i.v. glucagon challenge will be consented. 18F-Fallypride injected intravenously and subjects allowed to wait for approx 1 hr for the uptake.(b) Subject positioned in the PET/CT scanner and a low-dose CT (15-20 secs) of the abdomen (pancreas) carried out (with subjects breathing normally).(c) A 30-min PET acquisition will then be started (three 10 min static frames or one 30 min static frame).(d) Subject repositioned for a low-dose CT scan of the head (15-20 secs).(e) A 20-min PET acquisition will then be started (two 10 min static frames or one 20 min static frame).(f) End of PET/CT scanning procedures. Subject taken out of the scanner.
3279030|NCT00633750|Experimental|Tarceva|
3279031|NCT00633737|Experimental|1|Stress reduction intervention
3279032|NCT00633737|No Intervention|2|Standard care
3279033|NCT00633724|Experimental|1|
3279034|NCT00633711|Active Comparator|fixed CPAP|
3279035|NCT00633711|Experimental|Auto-CPAP|"Auto-CPAP Weinmann Somnosmart2"
3279036|NCT00633698|Active Comparator|1|Nicotinic acid (niacin)
3279037|NCT00633698|Placebo Comparator|2|Placebo
3279038|NCT00633685|Experimental|Fluoxetine|Receives Fluoxetine at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
3279039|NCT00633685|Placebo Comparator|Placebo|
3279040|NCT00633672|Experimental|1|20mg Oral tablet daily
3279041|NCT00633672|Experimental|2|40mg oral tablet daily
3279042|NCT00633672|Active Comparator|3|150mg oral twice daily
3279043|NCT00633659|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
3279044|NCT00633659|Experimental|Control|Voluven (HES 130/0.4)
3279045|NCT00633646|Active Comparator|1|low protein diet
3279046|NCT00633646|Active Comparator|2|low protein diet with keto acids
3279047|NCT00633646|Active Comparator|3|high protein diet
3279048|NCT00633633|Other|Group 1|Usual Care
3279049|NCT00633633|Experimental|Group 2|Exercise Training + Dietary Counseling
3279050|NCT00633620|Experimental|colonoscopy|Non-NBI HDTV colonoscopy
3279051|NCT00633594|Experimental|rituximab/bortezomib/lenalidomide|"Patients in Phase I & II to receive treatment with rituximab, bortezomib and lenalidomide in 21-day cycles up to 6 cycles.~Phase I: Cohorts of 3 patients will be enrolled at escalating dose levels to determine the maximum tolerated dose (MTD). Doses may be de-escalated if necessary.~Phase II: patients will be treated with the MTD determined in Phase I."
3279052|NCT00633581|Experimental|1|Intravenous injections of 10 grams(20ml as a solution) of vitamin C with 100ml of normal saline over 30 minutes.
3279053|NCT00633581|Placebo Comparator|2|Intravenous injections of 120ml of normal saline over 30 minutes.
3279054|NCT00633568|Active Comparator|A|One course of chemotherapy with cisplatin and docetaxel followed by induction chemoradiotherapy followed by two courses of consolidation chemotherapy
3279055|NCT00633568|Experimental|B|Three courses of induction chemotherapy followed by consolidation chemoradiotherapy
3279056|NCT00633542|Experimental|TD|thalidomide-dexamethasone
3279057|NCT00633542|Active Comparator|ID|Interferon-dexamethasone
3279058|NCT00633529|Experimental|I|Single arm: triple combination
3279562|NCT00629395|Experimental|1|Participate in 12 week computer program.
3279059|NCT00633516||Medical tool|Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
3279060|NCT00633503||A-Observation|All patients undergoing pedicle and free tissue transfer.
3279061|NCT00633490|Experimental|A|
3279062|NCT00633477|Experimental|Resatorvid 2.4 mg/kg/day|
3279063|NCT00633477|Placebo Comparator|Placebo|
3279064|NCT00633464|Experimental|Arm A (ixabepilone 40 mg^2)|ixabepilone 40 mg/m^2 every 3 weeks
3279065|NCT00633464|Experimental|Arm B (cetuximab 250 mg/m^2 + ixabepilone 40 mg/m^2)|cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks
3279066|NCT00633451|Experimental|1|Manual Therapy + Exercise
3279067|NCT00633451|Active Comparator|2|Exercise Only
3279068|NCT00633438|Placebo Comparator|B|
3279069|NCT00633438|Experimental|A|
3279070|NCT00633412|Experimental|1|20mg Oral tablet daily
3279071|NCT00633412|Experimental|2|40mg Oral tablet daily
3279072|NCT00633412|Active Comparator|3|150mg oral twice daily
3279073|NCT00633399|Experimental|1|Patients in group 1 will receive Ziprasidone for the full 8 weeks of Phase 2. If they are in remission following phase two, and decide to enter phase three, they will continue on Ziprasidone for 12 months.
3279074|NCT00633399|Placebo Comparator|2|Patients in group 2 will receive Placebo for the full 8 weeks of Phase 2. If they are in remission following phase two, and decide to enter phase three, they will continue on Placebo for 12 months.
3279075|NCT00633386|Experimental|A|
3279076|NCT00633386|Placebo Comparator|B|
3279077|NCT00633360|Experimental|Drospirenone and ethinyl estradiol|
3279078|NCT00633360|Placebo Comparator|Placebo|
3279079|NCT00633347|Active Comparator|A|A: Antagonist
3279080|NCT00633347|Active Comparator|B|Agonist GnRH
3279081|NCT00633321|Experimental|1|TA-NIC 100 μg
3279082|NCT00633321|Experimental|2|TA-NIC 250 μg
3279083|NCT00633321|Placebo Comparator|3|
3279084|NCT00633308|Experimental|A|Long hemodialysis
3279085|NCT00633295|Experimental|nilotinib|
3279086|NCT00633282|Experimental|Lifestyle intervention|Life style intervention including aerobic exercise and reducing energy intake(-500kcal) without drug
3279087|NCT00633282|Experimental|Life style intervention, pioglitazone|Life style intervention with pioglitazone 15mg qd for 16 weeks
3279088|NCT00633282|Experimental|Life style intervention, berberine|Life style intervention with berberine 0.5g tid for 16 weeks
3279089|NCT00633256|Experimental|Cycloserine|50 mg cycloserine
3279090|NCT00633256|Sham Comparator|Placebo|Matched placebo
3279091|NCT00633243|Experimental|Modified Directly Observed Therapy (mDOT)|Hepatitis C Virus (HCV) Treatment in Modified Directly Observed Therapy (mDOT) in Methadone Maintenance Treatment (MMT)
3279092|NCT00633243|Active Comparator|Self-Administered Therapy at Liver Specialty Clinic (SAT)|Hepatitis C virus (HCV) at a liver specialty clinic as self-administered therapy
3279093|NCT00633230|Active Comparator|1|standardized herbal formula, Sho-saiko-to (SST): 3 capsules containing 700 mg of the SST herbal extract/capsule and 28 mg of the excipients, magnesium stearate and silicon dioxide/capsule 2 x day
3279094|NCT00633230|Placebo Comparator|2|placebo capsules that look and smell identical to the active Sho-saiko-to (SST) capsules
3279095|NCT00633217|Active Comparator|arm 1|
3279096|NCT00633217|Experimental|arm 2|
3279097|NCT00633191|Experimental|Anti-pseudomonas IgY gargle|Intervention: Gargles with anti-pseudomonas IgY every night
3279098|NCT00633178|Experimental|Group Interpersonal Therapy (IPT)|Participants will receive group interpersonal therapy.
3279099|NCT00633178|Active Comparator|Treatment as Usual (ETAU)|Participants will receive psychiatric treatment as usual.
3279100|NCT00633178|No Intervention|No Treatment|Participants are healthy and will receive no treatment.
3279101|NCT00633152|Experimental|Ceftaroline|Intramuscular every 12 hours
3279102|NCT00633152|Active Comparator|linezolid plus optional aztreonam|Intravenous every 12 hours
3279103|NCT00633139|Experimental|Cohort 1|Cohort 1: 50 U/kg Recombinant human Arylsulfatase A (rhASA)
3279104|NCT00633139|Experimental|Cohort 2|Cohort 2: 100 U/kg Recombinant human Arylsulfatase A (rhASA)
3279105|NCT00633139|Experimental|Cohort 3|Cohort 3: 200 U/kg Recombinant human Arylsulfatase A (rhASA)
3279106|NCT00633126|Experimental|A|ceftaroline
3279107|NCT00633113|Active Comparator|1|- Medial Parapatellar Arthrotomy (MPPA) technique
3279108|NCT00633113|Active Comparator|2|- Subvastus (SV) technique
3279109|NCT00633087|Experimental|2-deoxyglucose|
3279110|NCT00633074|Experimental|Thiomersal-free FluAS25 adjuvanted vaccine group|Subjects received 1 dose of thiomersal-free FluAS25 adjuvanted vaccine
3279111|NCT00633074|Experimental|Thiomersal reduced FluAS25 adjuvanted vaccine group|Subjects received 1 dose of thiomersal reduced FluAS25 adjuvanted vaccine
3279112|NCT00633061|Experimental|A|Patients diagnosed with asymptomatic catheter-related DVT who are randomized to treatment with enoxaparin for 6 weeks
3279113|NCT00633061|No Intervention|B|Patients diagnosed with asymptomatic catheter-related DVT who are randomized to close observation for 6 weeks
3279114|NCT00633048|Experimental|NSA-789|active drug
3279115|NCT00633048|Placebo Comparator|placebo|placebo
3279116|NCT00633035|Active Comparator|1|oral esomeprazole tablet dissolved in water given through NG tube
3279117|NCT00633035|Active Comparator|2|intravenous famotidine injection
3279118|NCT00633022|Experimental|A|GW856553 7.5 mg twice a day
3279119|NCT00633022|Placebo Comparator|B|placebo
3279120|NCT00633022|Experimental|C|GW856553 7.5 mg once a day
3279121|NCT00633009|Active Comparator|LtSTA 15 ug|Naive volunteers tested with 15 ug injection of LtSTA. Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin tests were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
3279171|NCT00632606|Active Comparator|Arm 1|magnesium sulfate 2 grams intravenously w/ acetaminophen 1 gram orally
3279172|NCT00632606|Active Comparator|Arm 2|metoclopramide 10 mg intravenously w/ 1 gram acetominophen orally
3279122|NCT00633009|Active Comparator|LtSTA 30 ug|Naive volunteers tested with 30 ug injection of LtSTA.Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin testes were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
3279123|NCT00633009|Active Comparator|LtSTA 50 ug|Naive volunteers tested with 50 ug injection of LtSTA.Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin testes were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
3279124|NCT00632996|Experimental|1|
3279125|NCT00632970|Experimental|Raltegravir plus Truvada|Raltegravir (400mg), 1 tablet, administered twice daily (BID) and Truvada (Emtricitabine/Tenofovir disoproxil fumarate) (200mg/300mg), 1 tablet administered once daily (QD)
3279126|NCT00632970|Active Comparator|Lopinavir/Ritonavir plus Truvada|Lopinavir/Ritonavir (400mg/100mg) (Kaletra), 2 tablets administered twice daily (BID) and Truvada (Emtricitabine/Tenofovir disoproxil fumarate) (200mg/300mg), 1 tablet administered once daily (QD)
3279127|NCT00632957|Active Comparator|Fish oil|
3279128|NCT00632957|Placebo Comparator|Placebo|
3279129|NCT00632931|Experimental|A|Arm A: Drug/Placebo
3279130|NCT00632931|Experimental|B|Arm B: Placebo/Drug
3279131|NCT00632905||1|Normal - BMD with T-score at or above -1.0
3279132|NCT00632905||2|Osteopenic - BMD with T-score between -1.1 and -2.4
3279133|NCT00632905||3|Osteoporotic - BMD with T-score at or below -2.5
3279134|NCT00632866|Experimental|1|Active treatment : Hydroxychloroquine
3279135|NCT00632866|Placebo Comparator|2|Placebo
3279136|NCT00632853|Active Comparator|Arm A - Standard Radiotherapy + Chemotherapy|"Radiotherapy (every day, Monday-Friday, for a total of 3 weeks) XRT: 45 Gy BID (1.5 Gy/fx) starting on day 1 of Cycle 1 or 2, every day, for 3 weeks~Chemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):~Cisplatin 80 mg/m2 IV on day 1 OR Carboplatin AUC 5 IV day 1, every 21 days~Etoposide 100 mg/m2 IV Register/ on days 1, 2, and 3, every 21 days"
3279137|NCT00632853|Experimental|Arm B - High Dose Radiotherapy + Chemotherapy|"Radiotherapy (every day, Monday-Friday, for a total of 7 weeks) XRT: 70 Gy QD (2.0 Gy/fx), starting on day 1 of Cycle 1 or 2, every day, for 7 weeks~Chemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):~Cisplatin 80 mg/m2 IV on day 1 OR Carboplatin AUC 5 IV day 1, every 21 days~Etoposide 100 mg/m2 IV on days 1, 2, and 3, every 21 days"
3279138|NCT00632840|Placebo Comparator|P|placebo group
3279139|NCT00632840|Active Comparator|Feno|Fenofibrate
3279140|NCT00632840|Active Comparator|ATV|Atorvastatin
3279141|NCT00632827|Experimental|Treatment A|Gemcitabine/Navelbine/Doxil Days 1 and 8 G-CSF Days 4-6 and 10-15
3279142|NCT00632827|Experimental|Treatment B|Cyclophosphamide/Doxorubicin/Vincristine on Day 1 Prednisone Days 1-5 Methotrexate Day 15
3279143|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg qw|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection once per week [qw] (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
3279144|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), biw (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection twice per week [biw] (30 IU/kg [day 1] + 40 IU/kg [day 4]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
3279145|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), tiw (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 75 IU/kg, dosing by injection three times per week [tiw] (3 x 25 IU/kg [day 1, 3, 5]) for 9 months. No escalation opportunity for participants in this group
3279146|NCT00632801|Other|A|Chewing gum or not
3279147|NCT00632788||intervention group|patients presented with acute ST-elevation myocardial infarction and received emergency cardiac catheterization between March 1, 2007 and Oct. 31, 2007
3279148|NCT00632788||control group|patients presented with acute ST-elevation myocardial infarction and received emergency cardiac catheterization between April 1, 2006 and Feb. 28, 2007
3279149|NCT00632775|Active Comparator|1|Subjects in this arm will receive hypotonic (0.45% NaCl/5% dextrose) intravenous (IV) maintenance fluids.
3279150|NCT00632775|Active Comparator|2|Subjects in this arm will receive isotonic (0.9% NaCl/5% dextrose) intravenous (IV) maintenance fluids.
3279151|NCT00632762|Active Comparator|1|Amantadine MANTADIX
3279152|NCT00632762|Placebo Comparator|2|placebo
3279153|NCT00632749|Experimental|Schedule A|BI 811283 on days 1 and 15 in combination with Cytarabine 20 mg twice daily on Days 1-10
3279154|NCT00632749|Experimental|Schedule B|BI 811283 on Day 1 in combination with Cytarabine 20 mg twice daily on Days 1-10
3279155|NCT00632736|Active Comparator|Ropinirole XL (formerly CR)|Ropinirole XL (formerly CR)
3279156|NCT00632710|Experimental|b|laser
3279157|NCT00632710|Placebo Comparator|a|laser placebo
3279158|NCT00632697|Active Comparator|1|
3279159|NCT00632697|Placebo Comparator|2|
3279160|NCT00632684|Active Comparator|1|Participants in Phase 1 will undergo four interviews, including a single treatment planning session.
3279161|NCT00632684|Experimental|2|Participants in Phase 2 will receive the adaptive treatment model.
3279162|NCT00632671||Obese persons cohorte|constitution of a prospective data collection (biological, clinical, paraclinical and questionnaires) in morbidly obese persons.
3279163|NCT00632658||Patients with cGVHD|Pediatric Patients with cGVHD will be asked to participate in an interview with their Physician. The interview will ask the pediatric patients questions about their cGVHD. The interview will be audio-recorded.
3279164|NCT00632645|Experimental|1|Olanzapine Mylan
3279165|NCT00632645|Active Comparator|2|Xenazine
3279166|NCT00632645|Active Comparator|3|Tiapridal
3279167|NCT00632632|Experimental|D-Cycloserine (DCS)|
3279168|NCT00632632|Placebo Comparator|Placebo|
3279169|NCT00632619|Active Comparator|1|Participants will receive stimulant medication therapy and referrals to community-based psychosocial treatments.
3279170|NCT00632619|Experimental|2|Participants will receive stimulant medication therapy and group-based behavior therapy.
3279334|NCT00631267|Placebo Comparator|1|Manual Manipulation
3279173|NCT00632593|Active Comparator|Circular Stapled|Patients operated performing the gastric pouch of the gastric bypass with a circular staple device
3279174|NCT00632593|Active Comparator|Handsewn anastomosis|Patients operated performing the gastric pouch of the gastric bypass in a handsewn manner
3279175|NCT00632580|Active Comparator|1|intraarticular injection with local anesthetic
3279176|NCT00632580|Experimental|2|intracapsular injection with local anesthetic
3279177|NCT00632567|Experimental|1|caesarean section
3279178|NCT00632567|Active Comparator|2|vaginal delivery
3279179|NCT00632554|Experimental|1|prednisolone therapy for three months
3279180|NCT00632554|Active Comparator|2|prednisolone therapy for six months
3279181|NCT00632541|Experimental|Single Arm A|Sorafenib 200mg po daily, Bevacizumab 5mg/kg every other week, 1 Cycle = 4 weeks. Imaging every third cycle
3279182|NCT00632528|Experimental|1|Administration of MEOPA gaz during postoperative physical therapy
3279183|NCT00632528|Placebo Comparator|2|Administration of medical air during postoperative physical therapy
3279184|NCT00632515||Questionnaire|Patients with Colorectal Cancer and their First Degree Relatives (FDRs).
3279185|NCT00632502|Experimental|Navarixin|Navarixin (MK-7123, SCH 527123) 30 mg capsule, to be taken by mouth once daily in the morning for 4 weeks
3279186|NCT00632502|Placebo Comparator|Placebo|Placebo capsule to match navarixin, to be taken by mouth once daily in the morning for 4 weeks
3279187|NCT00632489|Experimental|LBH589 with Capecitabine|MTD, LBH589 with Capecitabine
3279188|NCT00632489|Experimental|LBH589 and Lapatinib|LBH589 and Lapatinib
3279189|NCT00632489|Experimental|LBH589, Capecitabine and Lapatinib|LBH589, Capecitabine and Lapatinib (Breast Cancer Patients)
3279190|NCT00632476|Placebo Comparator|A|Participants will receive a placebo capsule throughout pregnancy.
3279191|NCT00632476|Active Comparator|B|Participants will receive a vitamin C capsule throughout pregnancy.
3279192|NCT00632476|No Intervention|C|A group of non-smoking pregnant women will not receive placebo or vitamin C.
3279193|NCT00632463|Experimental|1|Dose regimen 1
3279194|NCT00632463|Experimental|2|Dose regimen 2
3279195|NCT00632463|Placebo Comparator|3|Placebo
3279196|NCT00632450||1|
3279197|NCT00632437||Speckle-Contrast Imaging|
3279198|NCT00632424|Experimental|1|
3279199|NCT00632411|Experimental|Proactive group|Research study staff will contact participant to initiate the program. Half of participants will be randomized to the proactive condition and the other half to the reactive conditions.
3279200|NCT00632411|Experimental|Reactive group|Participant will contact the research study staff to initiate the program.
3279201|NCT00632398|Active Comparator|Attention control (reading)|Caregivers read to patients from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks.
3279202|NCT00632398|Experimental|Touch, Caring and Cancer DVD program|Caregivers apply the instruction of the Touch, Caring and Cancer DVD program for patients for recommended 20 minutes at least 3 times per week for 4 weeks.
3279203|NCT00632385|Experimental|A|
3279204|NCT00632372|Experimental|HeartPOD™ System with Cardiac Resynchronization Therapy|All patients will receive both a HeartPod device and a CRT-D device.
3279205|NCT00632359|Experimental|Lenalidomide|Lenalidomide 10 mg daily given for 12 months.
3279206|NCT00632346||1 group|200 patients presenting to the Adolescent Medicine Clinic at Brooke Army Medical Center between the ages of 18 and 23 years-old.
3279207|NCT00632333|Experimental|1|
3279208|NCT00632320||S, 1, A|group (success or failure), case number, measurement method
3279209|NCT00632307||1|COPD
3279210|NCT00632307||2|lung cancer
3279211|NCT00632307||3|airway infection
3279212|NCT00632307||4|interstitial lung disease
3279213|NCT00632307||5|sleep apnea
3279214|NCT00632307||6|pulmonary disorders with pleural infusions
3279215|NCT00632307||7|sarcoidosis
3279216|NCT00632307||8|healthy persons
3279217|NCT00632294||Retrieved Allograft|Patients that require the retrieval of a bone allograft (transplant).
3279218|NCT00632268|Experimental|A|Drug:RAD001 Drug:Cisplatin Drug:5-FU
3279219|NCT00632255||1|Patients with CML who have been treated with Imatinib (Glivec) within 6 months of diagnosis as first line therapy. Initial therapy with Hydroxyurea is permitted
3279220|NCT00632242|Experimental|TTP Remission Cohort 1|Patients will receive a total dose of 0.47 mg/kg of ARC1779 over 4 hours to achieve a target plasma concentration of 6 mcg/mL
3279221|NCT00632242|Experimental|TTP Remission Cohort 2|Patients will receive a total dose of 1.67 mg/kg of ARC1779 over 24 hours to achieve a target plasma concentration of 6 mcg/mL
3279222|NCT00632242|Experimental|TTP Remission Cohort 3|Patients will receive a total dose of 3.34 mg/kg of ARC1779 over 24 hours to achieve a target plasma concentration of 12 mcg/mL
3279223|NCT00632242|Experimental|Acute TTP Cohort 4|Patients will receive up to a total dose of 40.78 mg/kg of ARC1779 for ≤ 14 days to achieve a target plasma concentration of 12 mcg/mL
3279224|NCT00632242|Experimental|vWD-Type2b Cohort 5|Subjects will receive either ARC1779, desmopressin or a combination of ARC1779 and desmopressin in a 3-period crossover design. The maximum dose of ARC1779 will be 0.47 mg/kg to achieve a target plasma concentration of 6 mcg/mL.
3279225|NCT00632229|Experimental|Paliperidone|Recieves study medication called paliperidone
3279226|NCT00632229|Placebo Comparator|Pill placebo|Placebo comparator
3279227|NCT00632203|Experimental|Temozolomide treatment|Subjects will receive temozolomide at a dose of 75 mg/m^2 orally (PO) daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
3279228|NCT00632203|No Intervention|Observation|Observation
3279229|NCT00632164||1|Cervical adjustments
3279230|NCT00632164||2|Thoracic adjustments
3279231|NCT00632125|Experimental|HX575 epoetin alfa i.v.|This post-authorization safety study was designed as a multi-center, multinational, prospective, single-arm clinical study with a 6-month HX575 (recombinant human) erythropoietin alfa treatment period. It was planned to include approximately 1,500 patients.
3279232|NCT00632099|Placebo Comparator|Placebo|matched placebo
3279335|NCT00631267|Active Comparator|2|Finger Trap Traction
3279233|NCT00632099|Experimental|Oral micronized progesterone|Oral micronized progesterone (up to 400 mg/day)
3279234|NCT00632086|Experimental|1|Single oral dose of 325 mg aspirin administered as PA32540
3279235|NCT00632086|Experimental|2|aspirin core
3279236|NCT00632086|Active Comparator|3|active
3279237|NCT00632073|Experimental|VCV + Failing HAART|Vicriviroc plus failing highly-active antiretroviral therapy
3279238|NCT00632060|No Intervention|1|Standard Care Control Group - Participants randomized to the standard care group will continue their use of non-prescription or prescription medication and reduced duty loads, as prescribed by the credentialed medical provider.
3279239|NCT00632060|Experimental|2|Manual / Manipulative Therapy Group: Participants randomized to the M/MT group will receive a course of M/MT along with standard care. The patient will see the chiropractor twice a week for the entire course of the study, regardless of manipulation or not.
3279240|NCT00632034|Experimental|1|
3279241|NCT00632021|No Intervention|1|Patients will receive usual care at hospital discharge, which generally includes physician reconciliation of medications and a nurse-provided explanation of how to take medications at the time of discharge.
3279242|NCT00632021|Experimental|2|Participants will receive pharmacist-led medication reconciliation, pharmacist counseling prior to discharge, a follow-up telephone call 1-4 days after discharge, and additional telephone support as needed.
3279243|NCT00632008|Experimental|1|SBG
3279244|NCT00632008|Placebo Comparator|2|
3279245|NCT00631995|Experimental|Group 1|
3279246|NCT00631995|Experimental|Group 2|
3279247|NCT00631995|Experimental|Group 3|
3279248|NCT00631995|Experimental|Group 4|
3279249|NCT00631995|Experimental|Group 5|
3279250|NCT00631995|Active Comparator|Group 6|
3279251|NCT00631982|Experimental|Group I|patients with PCO undergoing in vitro maturation and subsequently IVF and embryo transfer
3279252|NCT00631969|Experimental|Vardenafil ODT (STAXYN, BAY38-9456)|Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
3279253|NCT00631969|Placebo Comparator|Placebo|Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
3279254|NCT00631943|Experimental|1|
3279255|NCT00631917|Experimental|Aliskiren|For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration.
3279256|NCT00631917|Active Comparator|Ramipril|For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study.
3279257|NCT00631904||Single Observation|Patients with permanent pacemakers undergoing medically indicated MRI scanning.
3279258|NCT00631878|Placebo Comparator|Placebo|
3279259|NCT00631878|Experimental|10 mg/kg|10 mg/kg was given on Days 0, 14
3279260|NCT00631878|Experimental|30 mg/kg|30 mg/kg was given on Days 0, 14
3279261|NCT00631878|Experimental|60 mg/kg|60 mg/kg was given on Days 0, 14
3279262|NCT00631878|Experimental|90 mg/kg|90 mg/kg was given on Days 0, 14
3279263|NCT00631865|Experimental|cell transplantation group|Epidermal Cell transplantation in patients with vitiligo
3279264|NCT00631852|Experimental|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
3279265|NCT00631839||1|There is only one group in this study. The patients of this group will go through procedures as follow: basic pre-treatment information collected,treatment include platinum-based chemotherapy and 3-D conformal radiotherapy, blood test during RT 6am every Monday and follow-up visits with treatment-induced injury assessed.
3279266|NCT00631813|Active Comparator|1|Prucalopride 0.5 mg
3279267|NCT00631813|Active Comparator|2|Prucalopride 1 mg
3279268|NCT00631813|Active Comparator|3|Prucalopride 2 mg
3279269|NCT00631813|Placebo Comparator|4|
3279270|NCT00631800|Placebo Comparator|Placebo|Placebo
3279271|NCT00631800|Experimental|60 mg/kg|60 mg/kg was given on Days 0, 7, 14
3279272|NCT00631800|Experimental|90 mg/kg|90 mg/kg was given on Days 0, 7, 14
3279273|NCT00631774|Active Comparator|1|a meal replacement program with Glucerna SR on top of the exchange-diet plan
3279274|NCT00631774|Active Comparator|2|an caloric-matched exchange-diet plan only.
3279275|NCT00631761|Experimental|1|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas of the human bladder.
3279276|NCT00631761|Placebo Comparator|2|The control group will be instructed to read a urethrocystoscopy textbook chapter at home
3279277|NCT00631748|Experimental|Study Drug|Subjects randomized to the experimental arm of the study will be initially administered 50mg/day quetiapine fumarate (Seroquel XR) to be titrated up to 400mg/day by the end of the second week. Subjects will be stabilized at a dose of 400mg/day or alternatively 300, 200, 100, or 50mg/day or quetiapine fumarate as tolerated. During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
3279278|NCT00631748|Placebo Comparator|Placebo|Subjects randomized to the placebo arm of the study will follow the same titration and dosing procedure as the experimental arm but will receive matched placebo tablets. During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
3279279|NCT00631722|Experimental|A|
3279280|NCT00631722|Active Comparator|B|
3279281|NCT00631709|Experimental|1|Pacemaker Patients
3279282|NCT00631696|Experimental|1|
3279283|NCT00631696|Placebo Comparator|2|
3279284|NCT00631683||MICU-1|Mechanically ventilated patients who are about to start a weaning trial at the medical intensive care unit of Memorial Hermann Hospital.
3279285|NCT00631670|Experimental|Single Treatment Group|15 Gy dose in one stereotactic body radiation treatment
3279286|NCT00631670|Experimental|25 Treatments Group|25 treatments, given once a day, Monday through Friday for about five weeks; Dose: 70 Gy at 2.8 Gy/treatment
3279287|NCT00631657|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine 4.5 mg tablets, administered once a day for 6 months
3279288|NCT00631657|Placebo Comparator|Placebo|Participants receive placebo tablets, administered once a day for 6 months
3279289|NCT00631631||Mifamurtide (L-MTP-PE)|Mifamurtide (L-MTP-PE), intravenous, at a dose of 2 mg/m^2 twice weekly (at least 3 days apart) for 12 weeks, and then weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.
3279290|NCT00631618|Experimental|Suntinib|Suntinib
3279291|NCT00631605||1|
3279292|NCT00631605||2|
3279293|NCT00631592|Other|GSK1349572|GSK1349572
3279294|NCT00631566|Experimental|1|
3279295|NCT00631566|Placebo Comparator|2|
3279296|NCT00631566|No Intervention|No MRSA colonization|
3279297|NCT00631540|Experimental|1|renal artery stenting
3279298|NCT00631527|Experimental|Sunitinib Malate, Hormone Ablation + RT|Sunitinib Malate + Hormone Ablation (Leuprolide or Goserelin + Bicalutamide) + Radiation Therapy (RT)
3279299|NCT00631514|No Intervention|1|Hypertensive persons taking either lisinopril/hydrochlorothiazide fixed combination or amlodipine all the time.
3279300|NCT00631514|Experimental|2|Intervention: NSAID. Hypertensives with osteoarthritis taking already amlodipine (5-10 mg o.d. per os) were randomized to the following drug interventions: to take either acetaminophen (1000 mg t.i.d. per os), piroxicam (10-20 mg o.d. per os) or ibuprofen (400-600 mg t.i.d. per os) for 1 month
3279301|NCT00631514|Experimental|3|Hypertensives with osteoarthritis taking already lisinopril/hydrochlorothiazide (20/12.5 mg o.d. per os), were sequentially randomized to the following drug interventions: acetaminophen (1000 mg t.i.d.), ibuprofen (400-600 mg t.i.d.) or piroxicam (10-20 mg o.d.), for 1 month each
3279302|NCT00631501|Placebo Comparator|2|
3279303|NCT00631501|Experimental|Doxycycline|100 mg twice daily
3279304|NCT00631488|Experimental|MK-0893 + Sitagliptin|
3279305|NCT00631488|Experimental|MK-0893 + Metformin|
3279306|NCT00631488|Active Comparator|Sitagliptin + Metformin|
3279307|NCT00631475|Experimental|1|"For patients who were administered bosentan during BUILD 3 (NCT00391443):~Same dose will continue~For patients who were administered placebo during BUILD 3 (NCT00391443):~Initial dose: 62.5 mg for 4 weeks Maintenance dose: 125 mg"
3279308|NCT00631462|Experimental|1|
3279309|NCT00631449|Active Comparator|Raltegravir|For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
3279310|NCT00631449|Placebo Comparator|Placebo|For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
3279311|NCT00631436||1|If the individuals who meet the blast exposure criteria have a PCL score above 50 and meet the Hoge et al PCL criteria, thus indicating likely PTSD, they will be invited to participate as members of the Blast Exposed + PTSD group.
3279312|NCT00631436||2|Other individuals meeting the blast exposure criteria will be invited to participate in the as members of the Blast Exposed + No PTSD group if they have PCL scores below 30.
3279313|NCT00631436||3|Individuals reporting that they were not exposed to explosive blast will be recruited to participate. Those not exposed to blast but with PCL scores over 50 and meeting the Hoge et al PCL criteria will be invited to participate as members of the No Blast + PTSD group.
3279314|NCT00631436||4|Individuals not exposed to blast with PCL scores below 30 will be invited to participate as members of the No Blast + No PTSD group.
3279315|NCT00631423||1|Patients with vena cava inferior thrombosis
3279316|NCT00631423||2|Patients with isolated lower-extremity DVT matched for gender and age
3279317|NCT00631410|Experimental|A|
3279318|NCT00631410|Experimental|B|
3279319|NCT00631397||Premature Infants|Premature Infants weighing less than 1500 gms
3279320|NCT00631384|Experimental|1|Women to be asked to bring husbands for couple VCT
3279321|NCT00631384|Active Comparator|2|Women to receive individual VCT
3279322|NCT00631371|Experimental|1|Bevacizumab 10 mg/kg intravenous (IV) q8wks + Temsirolimus 25 mg IV weekly
3279323|NCT00631371|Active Comparator|2|Bevacizumab 10 mg/kg intravenous (IV) q8wks + Interferon-Alfa 9MU SC TIW
3279324|NCT00631358|Experimental|Maxidex|Maxidex
3279325|NCT00631358|Sham Comparator|No treatment|Healthy normal control group receiving no treatment
3279326|NCT00631345|Experimental|Lifestyle|This Group-Based Lifestyle Intervention (Phases 1 and 2) will be led by lay health counselors (LHCs). The 6-month Phase 1 includes weekly meetings on nutrition and physical activity, psychosocial factors related to health behaviors, and question and answer periods. The 18-month Phase 2 will consist of monthly group meetings and individual telephone contacts. Intervention participants who choose to participate in the study continuation (Phase 3) will be further randomized to receive either extended group or self-directed maintenance. Those who are randomized to receive Extended Group Maintenance (Phase 3) will continue attending monthly meetings; those who receive Self-Directed Maintenance (Phase 3) will no longer attend groups.
3279327|NCT00631345|Other|Comparison|The comparison condition exceeds the usual care provided to similar community members and is an individual education program that builds on an increased awareness of existing community resources. In the initial trial, these subjects will receive two individual sessions with the RD and a monthly newsletter. In the study continuation, comparison participants will receive biannual nutrition counseling and a monthly newsletter.
3279328|NCT00631306||Bottle number 615|Patients are randomized to either Bottle number 615 or Bottle number 429 (actual product vs. placebo). This is a blinded study.
3279329|NCT00631306||Bottle number 429|Patients are randomized to either Bottle number 615 or Bottle number 429 (actual product vs. placebo). This is a blinded study.
3279330|NCT00631293|Experimental|1|administration of lactisole
3279331|NCT00631293|Placebo Comparator|2|administration of placebo
3279332|NCT00631280|Experimental|Choice|
3279333|NCT00631280|Active Comparator|Recommendation|
3279336|NCT00631254|Active Comparator|1|"Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.~Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
3279337|NCT00631254|Active Comparator|2|"Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
3279338|NCT00631241|Experimental|Intraoperative Lymphatic Mapping|Single Photon Emission Computed Tomography - First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients. Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
3279339|NCT00631228||1|The group will be monitored to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
3279340|NCT00631215|Experimental|1|Healthy Adults
3279341|NCT00631202|Experimental|I|Treatment arm
3279342|NCT00631189|Active Comparator|1|Rosuvastatin and Pravastatin
3279343|NCT00631189|Active Comparator|2|Rosuvastatin and Atorvastatin
3279344|NCT00631176|No Intervention|1|
3279345|NCT00631176|Experimental|2|
3279346|NCT00631163|Experimental|Deferasirox|"The recommended initial daily dose of Deferasirox is 20 mg/kg body weight for most patients.~An initial daily dose of 30 mg/kg or 10mg/kg should be considered for patients requiring more intensive or less intensive chelation, respectively"
3279347|NCT00631137|Placebo Comparator|Arm 1: Control Group|whey protein powder
3279348|NCT00631137|Active Comparator|ARM 2 : Treatment Group|Testosterone Gel (10g pouch/day) applied to skin
3279349|NCT00631124|Experimental|Arm 1|
3279350|NCT00631124|Experimental|Arm 2|
3279351|NCT00631111|Experimental|1|
3279352|NCT00631111|Active Comparator|2|
3279353|NCT00631111|Active Comparator|3|
3279354|NCT00631111|Placebo Comparator|4|
3279355|NCT00631098|Experimental|1|Cannulation of external jugular vein and cannulation of cubital vein
3279356|NCT00631085|Other|1|
3279357|NCT00631072|Other|GM-CSF +INKT|"INKT will be administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.~GM-CSF will be given subcutaneously once daily for 10 days beginning the second day of the second and third infusion"
3279358|NCT00631046|Experimental|Fish Oil|containing n-3 LCPUFA
3279359|NCT00631046|Placebo Comparator|Sunflower oil|containing n-6 PUFA
3279360|NCT00631033|Placebo Comparator|1|Placebo
3279361|NCT00631033|Experimental|2|Diazoxide
3279362|NCT00631033|Experimental|3|Metformin + Diazoxide
3279363|NCT00631020|Experimental|CBME +/- NRT|6 weeks CBME with optional 4 weeks NRT
3279364|NCT00631007|Experimental|INT131 besylate 0.5 mg|INT131 besylate 0.5 mg once-daily administration and matching placebo to pioglitazone HCl.
3279365|NCT00631007|Experimental|INT131 besylate 1 mg|INT131 besylate 1 mg once-daily administration and matching placebo to pioglitazone HCl
3279366|NCT00631007|Experimental|INT131 besylate 2 mg|INT131 besylate 2 mg administered once-daily and matching placebo to pioglitazone HCl
3279367|NCT00631007|Experimental|INT131 besylate 3 mg|INT131 besylate 3 mg administered once-daily and matching placebo to pioglitazone HCl
3279368|NCT00631007|Active Comparator|pioglitazone HCl 45 mg|pioglitazone HCl 45 mg administered once-daily and matching placebo to INT131 besylate
3279369|NCT00631007|Placebo Comparator|placebo|placebo administered once-daily, matching placebo to INT131 besylate and matching placebo to pioglitazone HCl
3279370|NCT00630981||Intervention group|"Combined psychotherapy and pharmacological treatment~Open single arm 'pilot' clinical trial in patients with dissociative disorders, admitted to the psychiatric emergency unit of Geneva and in the Hogan Psychotherapeutic Center in Montreux.~Patients will be interviewed according to the Dissociative Experiences Scale (DES) and, if their score is 30 or higher, the Structured Clinical Interview for DSM-IV Dissociative Disorders (SCID) will be administered."
3279371|NCT00630955|Experimental|1|20 mg memantine
3279372|NCT00630955|Experimental|2|40 mg memantine
3279373|NCT00630955|Placebo Comparator|3|
3279374|NCT00630942|Experimental|Single Arm, active treatment|
3279375|NCT00630929|Active Comparator|A|
3279376|NCT00630929|Placebo Comparator|C|
3279377|NCT00630929|Experimental|B|
3279378|NCT00630916|No Intervention|A|
3279379|NCT00630903|Active Comparator|A|8-MOP + UVA x 24 weeks
3279380|NCT00630903|Active Comparator|B|IFN alone, 2 weeks, 8-MOP + UVA irradiation + IFN, 22 weeks
3279381|NCT00630890|Experimental|1|External beam radiation with Cyberknife radiosurgery boost and concurrent capecitabine
3279382|NCT00630877|Experimental|NER/ASA|
3279383|NCT00630877|Experimental|NER/ASA Placebo|
3279384|NCT00630877|Experimental|NER Placebo/ASA Placebo|
3279385|NCT00630864|Experimental|1|Fx-1006A 20mg soft gelatin capsules once daily for 12 months
3279386|NCT00630851|Experimental|1|
3279387|NCT00630851|Placebo Comparator|2|
3279388|NCT00630838|Experimental|1|VSL#3 probiotic
3279389|NCT00630838|Placebo Comparator|2|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
3279390|NCT00630825|Experimental|1.0/2.0 milligram (mg) LY2189265|LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks
3279391|NCT00630825|Experimental|1.0/1.0 milligram (mg) LY2189265|LY2189265: 1.0 mg, subcutaneous (SC) injection, once weekly (QW) for 16 weeks
3279392|NCT00630825|Experimental|0.5/1.0 milligram (mg) LY2189265|LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks
3279393|NCT00630825|Placebo Comparator|Placebo|Placebo: subcutaneous (SC) injection, once weekly (QW) for 16 weeks
3279394|NCT00630812|Experimental|A|active treatment
3279395|NCT00630812|Placebo Comparator|B|
3279396|NCT00630799|Experimental|1|leuprolide acetate administered by i.m. injection as two doses of 17 mg each during a period of 6 months (one dose every 3 months)
3279397|NCT00630786|Experimental|Panitumumab plus conatumumab|Participants received 10 mg/kg conatumumab and 6 mg/kg panitumumab administered on the same day by sequential intravenous (IV) infusions once every 2 weeks until progressive disease, intolerability, withdrawal, or death.
3279398|NCT00630760|Experimental|1|NRX 194204 capsules in escalating doses, starting at 3mg/m2.
3279399|NCT00630747|Experimental|Idursulfase|
3279400|NCT00630734|Experimental|SLCO1B1 Group 1|Participants with the SLCO1B1 *1A/*1A diplotype; Interventions: pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
3279401|NCT00630734|Experimental|SLCO1B1 Group 2|Participants with the SLCO1B1 *1A/*1B or *1B/*1B diplotype; Interventions: Pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
3279402|NCT00630734|Experimental|SLCO1B1 Group 3|Participants who carry at least one SLCO1B1 *5, *15, or *17 diplotype; Interventions: Pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
3279403|NCT00630721|Other|IFNbeta-1b|no drug was given under study. patients already taking IFNbeta-1b were enrolled for blood draw only.
3279404|NCT00630708|Active Comparator|1|Benazepril group
3279405|NCT00630708|Active Comparator|2|Losartan group
3279406|NCT00630708|Active Comparator|3|Benazepril+Losartan group
3279407|NCT00630695|Experimental|1|Lanreotide LP 90
3279408|NCT00630695|Placebo Comparator|2|
3279409|NCT00630682|Active Comparator|Dextroamphetamine|Active drug
3279410|NCT00630682|Placebo Comparator|Placebo|Placebo of drug
3279411|NCT00630669|Active Comparator|1|Rubber band ligation
3279412|NCT00630669|Active Comparator|2|Bipolar coagulation
3279413|NCT00630656|Experimental|1|Talactoferrin alfa
3279414|NCT00630656|Placebo Comparator|2|Placebo
3279415|NCT00630643|Placebo Comparator|1|
3279416|NCT00630643|Experimental|2|
3279417|NCT00630630|Experimental|1|
3279418|NCT00630630|Placebo Comparator|2|
3279419|NCT00630591|Experimental|Standardized Materials Group|
3279420|NCT00630591|Experimental|Independent Tailored Intervention|
3279421|NCT00630591|Experimental|Partner-Assisted Tailored Intervention|
3279422|NCT00630578|Active Comparator|1|Cognitive Processing Therapy
3279423|NCT00630578|No Intervention|2|Arm 2 participants will monitor their symptoms for a period of 10 weeks, prior to being crossed over into active treatment. This will allow investigators to account for the passage of time without intervention when tracking symptoms.
3279424|NCT00630565|Experimental|Bone Marrow Transplant (2-70 Years old)|Patients over the age of two will receive a cytoreductive regimen of total-body irradiation and cyclophosphamide (TBI/CY) as well as sargramostim, dexamethasone, etoposide, transplantation (bone marrow transplantation/hematopoietic stem cell transplantation/peripheral blood stem cell transplantation).
3279425|NCT00630565|Experimental|Bone Marrow Transplant (less and 2 years old)|Patients under the age of two, and patients who cannot receive total body irradiation (TBI), will receive a cytoreductive regimen of Busulfan and cyclophosphamide (BU/CY) as per the Johns Hopkins University Hospital regimen as well as sargramostim, dexamethasone, etoposide, transplantation (bone marrow transplantation/hematopoietic stem cell transplantation/peripheral blood stem cell transplantation).
3279426|NCT00630552|Placebo Comparator|Placebo + Gemcitabine|
3279427|NCT00630552|Experimental|AMG 655 + Gemcitabine|
3279428|NCT00630552|Experimental|AMG 479 + Gemcitabine|
3279429|NCT00630539|Placebo Comparator|Subjects on placebo|Subjects will self-administer 1 placebo tablet daily (in the morning with food) for 12 weeks
3279430|NCT00630539|Experimental|Subjects on ospemifene 5 mg/day|Subjects will self-administer 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks
3279431|NCT00630539|Experimental|Subjects on ospemifene 15 mg/day|Subjects will self-administer 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks
3279432|NCT00630539|Experimental|Subjects on ospemifene 30 mg/day|Subjects will self-administer 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks
3279433|NCT00630513|Experimental|E|3 days regimen with Ertapenem
3279434|NCT00630513|Active Comparator|AS|3 days treatment with Ampicillin-Sulbactam
3279435|NCT00630500|Active Comparator|Memantine|Active treatment with memantine
3279436|NCT00630500|Placebo Comparator|Placebo|Placebo matching active study drug
3279437|NCT00630487|Placebo Comparator|Placebo|
3279438|NCT00630487|Active Comparator|Verum|
3279439|NCT00630474|Active Comparator|1|nasal application of xylometazoline
3279440|NCT00630474|Placebo Comparator|2|nasal application of placebo
3279441|NCT00630448||Group 1|Control Group. Normal (healthy) individuals without Von Willebrand Disease.
3279442|NCT00630448||Group 2|Case Group. Individuals with known Von Willebrand Disease.
3279443|NCT00630435|Experimental|1|
3279444|NCT00630435|Experimental|2|
3279445|NCT00630435|Experimental|3|
3279446|NCT00630435|Active Comparator|4|
3279447|NCT00630422||64|All Patients
3279448|NCT00630409|Experimental|Treatment|Patients will receive 3 cycles of therapy as an outpatient. Each 21-day cycle of therapy will comprise: Gemcitabine: IV on days 1 and 8. Doxil: on day 1. Patients with either responding or stable disease will continue to receive additional 3 cycles of therapy with gemcitabine and Doxil until there is radiological evidence of disease progression or they are unable or unwilling to continue treatment.
3279449|NCT00630383|Experimental|1|Patients will receive 25 live hookworm larvae.
3279450|NCT00630383|Placebo Comparator|2|Patients will receive 0.01 % histamine solution.
3279563|NCT00629382|Experimental|1|
3279451|NCT00630370|Placebo Comparator|1|2 Placebo tablets, TID, orally, 58 days
3279452|NCT00630370|Experimental|2|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
3279453|NCT00630370|Experimental|3|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
3279454|NCT00630370|Experimental|4|2 ATI 40mg tablets, TID, orally, 58 days
3279455|NCT00630344|Experimental|RAD001 + Bicalutamide|"RAD001: once daily dose of 10 mg (5 mg tablets)~Bicalutamide: once daily dose of 50 mg (50 mg tablets)~1 cycle=28 days~Both agents are administered continuously until progression of disease or unacceptable toxicity."
3279456|NCT00630331|Experimental|CCI|Subjects received one dose of cell culture-derived influenza vaccine.
3279457|NCT00630331|Experimental|IVV|Subjects received one dose of the trivalent egg-derived influenza vaccine.
3279458|NCT00630331|Placebo Comparator|Placebo|Subjects received one dose of phosphate buffered solution (PBS).
3279459|NCT00630305|Other|Session A|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session A only contains senofilcon A toric and alphafilcon A toric lenses.
3279460|NCT00630305|Other|Session B|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session B only contains senofilcon A toric and alphafilcon A toric lenses.
3279461|NCT00630305|Other|Session C|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session C only contains senofilcon A toric and lotrafilcon B toric lenses.
3279462|NCT00630305|Other|Session D|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session D only contains senofilcon A toric and lotrafilcon B toric lenses.
3279463|NCT00630292|Experimental|1|
3279464|NCT00630279|Placebo Comparator|1|
3279465|NCT00630279|Experimental|2|
3279466|NCT00630279|Experimental|3|
3279467|NCT00630279|Experimental|4|
3279468|NCT00630253|Experimental|Cyclophosphamide/Fludarabine/ATG|Patients with Fanconi Anemia receiving cyclophosphamide, fludarabine phosphate, antithymocyte globulin followed by matched sibling donor hematopoietic stem cell transplantation (HSCT). Patients also receive Mycophenolate Mofetil, methylprednisolone, cyclosporine and filgrastim.
3279469|NCT00630240||1|only one arm for study
3279470|NCT00630227|Experimental|Single|all patients are treated with the experimental therapy
3279471|NCT00630214|No Intervention|C|No supplements after total thyroidectomy and central neck dissection
3279472|NCT00630214|No Intervention|D|No central neck dissection group (total thyroidectomy alone)
3279473|NCT00630214|Active Comparator|A|Oral calcium plus vitamin D supplements after total thyroidectomy and central neck dissection
3279474|NCT00630214|Active Comparator|B|Oral calcium alone supplement after total thyroidectomy and central neck dissection
3279475|NCT00630201|Experimental|Probuphine|buprenorphine implant
3279476|NCT00630188|Experimental|1|"For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with physician~For Physicians: a one-time educational session on prostate cancer and the value of shared decision making"
3279477|NCT00630188|Active Comparator|2|Highway Safety video
3279478|NCT00630149|Experimental|1|
3279479|NCT00630136||A|Adult parent or legally authorized representative (LAR) of child who has consented to undergo an out-patient endoscopy at Children's Mercy Hospital as a diagnostic procedure
3279480|NCT00630123||1|Electroconvulsive Therapy (ECT): blood sample taken from this group at start and after therapy; subjects not randomized to therapy option.
3279481|NCT00630123||2|Transcranial Magnetic Stimulation (TMS): blood sample taken from this group at start and after therapy; subjects not randomized to therapy option.
3279482|NCT00630110|Active Comparator|docetaxel|docetaxel (75 mg/m2)
3279483|NCT00630110|Experimental|NPI-2358 + docetaxel|NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
3279484|NCT00630084|Active Comparator|A|40 naïve CHC patients concomitant with malignancy other than hepatocellular carcinoma
3279485|NCT00630084|Active Comparator|B|80 naïve CHC patients without malignancy
3279486|NCT00630058|Experimental|Group A (MP-424 High)|
3279487|NCT00630058|Experimental|Group B (MP-424 Low)|
3279488|NCT00630045|Experimental|1|2~3 cycles of neoadjuvant chemotherapy before resection of liver metastasis
3279489|NCT00630045|Active Comparator|2|no neoadjuvant chemotherapy, resect the liver metastasis directly
3279490|NCT00630032|Active Comparator|Arm A|3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of D (100 mg/m² every 3 weeks)
3279491|NCT00630032|Experimental|Arm B|3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of Ixabepilone (40 mg/m² every 3 weeks);
3279492|NCT00630019|Experimental|1|
3279493|NCT00630019|Active Comparator|2|
3279494|NCT00629993|Experimental|Multi-component Academic Detailing|"Multi-component, academic detailing regarding ACS guidelines on cervical cancer screening approaches.~Includes an interactive, digitized CD-ROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients."
3279495|NCT00629980|Experimental|1|
3279496|NCT00629980|No Intervention|2|
3279497|NCT00629967|Active Comparator|A|Eligible patients will be randomized into two groups with a ratio of 1:1 (Arm A & B)
3279498|NCT00629967|Active Comparator|B|Eligible patients will be randomized into two groups with a ratio of 1:1 (Arm A & B)
3279499|NCT00629954||I|
3279500|NCT00629941|Experimental|1|
3279501|NCT00629928|Experimental|1|20mg capsule once daily
3279502|NCT00629928|Experimental|2|40mg capsule daily
3279503|NCT00629928|Placebo Comparator|3|
3279504|NCT00629902||A1|Patients with prosthesis-patient mismatch after mitral valve replacement
3279505|NCT00629902||A2|Patients without prosthesis mismatch after mitral valve replacement
3279561|NCT00629434|Active Comparator|2|diabetes education in-person
3279506|NCT00629889|Active Comparator|Levetiracetam|Patients assigned to Levetiracetam are treated with the initial dose of 2 x 250mg per day up to one year
3279507|NCT00629889|Active Comparator|Pregabalin|Patients assigned to Pregabalin are treated with the initial dose of 2 x 75mg per day up to one year
3279508|NCT00629876|Experimental|Peginesatide|
3279509|NCT00629850|Experimental|Powerlung Performer|The arm will receive the lung trainer device to use for 10 weeks
3279510|NCT00629850|No Intervention|Control|Control. This arm will not receive any device
3279511|NCT00629837|Experimental|Arm 1|
3279512|NCT00629837|Experimental|Arm 2|
3279513|NCT00629837|Active Comparator|Arm 3|
3279514|NCT00629837|Active Comparator|Arm 4|
3279515|NCT00629824|Active Comparator|A|110 naïve CHC patients who are 65 to 80 years of age
3279516|NCT00629824|Active Comparator|B|140 naïve CHC patients who are 50 to 64 years of age
3279517|NCT00629824|Active Comparator|C|40 HCV-1 infected patients with an RVR who are 65-80 years of age will receive 24 weeks of treatment
3279518|NCT00629798|Experimental|1|This is a single arm phase II trial to assess the efficacy (decrease the transplant related mortality) and safety of peri-transplant Palifermin in combination with a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with advanced MDS and AML evolved from MDS. The addition of Palifermin is to decrease the toxicity and the infection rate associated with this regimen and transplant type and to foster earlier immune reconstitution.
3279519|NCT00629772|Placebo Comparator|Placebo then infliximab|Placebo at weeks 0, 2, 6 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.
3279520|NCT00629772|Active Comparator|Infliximab|Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
3279521|NCT00629759|Experimental|1|1e8 pfu (plaque forming units)total dose each treatment day
3279522|NCT00629759|Experimental|2|3e8 pfu (plaque forming units) total dose each treatment day
3279523|NCT00629759|Experimental|3|1e9 pfu (plaque forming units) total dose each treatment day
3279524|NCT00629759|Experimental|4|3e9 pfu (plaque forming units) total dose each treatment day
3279525|NCT00629746|Experimental|NIM (Nerve Integrity Monitor)|
3279526|NCT00629733|Experimental|Ro-14|
3279527|NCT00629707|Active Comparator|1|Slower infusion rate: Patients in this arm will receive an initial intravenous fluid bolus of 10cc/Kg followed by rehydration calculated to replace a deficit of 7.5% of body weight over 48 hours.
3279528|NCT00629707|Active Comparator|2|More rapid infusion: Patients in this arm will receive an initial bolus of 20 cc/Kg of intravenous fluids followed by replacement of an estimated deficit of 10% of body weight over 36 hours plus replacement of 1/2 of urine output volume.
3279529|NCT00629694|Active Comparator|A-T|
3279530|NCT00629694|Experimental|A-M|
3279531|NCT00629681|Experimental|1|
3279532|NCT00629655||1|healthy people, male
3279533|NCT00629655||2|male patients with cerebral infarction, chronic stage
3279534|NCT00629642|Experimental|I.Solifenacin succinate 10mg (2x5mg 1/day)|Oral
3279535|NCT00629642|Experimental|II.Solifenacin succinate 5mg (5mg 1/day)|Oral
3279536|NCT00629642|Active Comparator|III.Oxybutynin hydrochloride 15mg (5mg 3/day)|Oral
3279537|NCT00629642|Placebo Comparator|IV. Placebo|Oral
3279538|NCT00629629|Other|I, Intervention|
3279539|NCT00629616|Experimental|Arm A|Anastrozole
3279540|NCT00629616|Experimental|Arm B|Fulvestrant
3279541|NCT00629603|Experimental|cytokine polymorphisms, HCV infection|Relate the fibrosis cytokine gene polymorphisms with disease severity of HCV-related chronic liver disease
3279542|NCT00629590|Experimental|1|
3279543|NCT00629590|No Intervention|2|
3279544|NCT00629564|Active Comparator|1|20mg oral
3279545|NCT00629564|Active Comparator|2|15 minute intravenous infusion
3279546|NCT00629551|Experimental|Saredutant 100mg and Paroxetine 20 mg|combined saredutant 100mg and paroxetine 20mg once daily for a maximum of 8 weeks
3279547|NCT00629551|Experimental|Saredutant 30mg and Paroxetine 20mg|combined saredutant 30mg and paroxetine 20mg once daily for a maximum of 8 weeks
3279548|NCT00629551|Active Comparator|Paroxetine 20 mg and saredutant placebo|paroxetine 20mg and saredutant placebo once daily for a maximum of 8 weeks
3279549|NCT00629551|Placebo Comparator|Placebo|Saredutant placebo and paroxetine placebo once daily for one week during screening period and maximum of 8 weeks for the active phase
3279550|NCT00629525|Experimental|RAD001|RAD001 at a dose of 10 mg PO daily
3279551|NCT00629512|Experimental|1|20mg oral daily
3279552|NCT00629512|Experimental|2|40mg oral daily
3279553|NCT00629512|Placebo Comparator|3|
3279554|NCT00629499|Experimental|Intervention|100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle) in combination with 600 mg/m2 of IV cyclophosphamide once every 3 weeks for 4 cycles (i.e., a total treatment period of 12 weeks [84 days]). Patients with fluorescence in situ hybridization (FISH) HER2+ or IHC3+ breast cancer will also receive treatment with trastuzumab in addition to the nab paclitaxel / cyclophosphamide combination therapy. Maintenance therapy with trastuzumab will continue (for the HER2+ patients who are receiving trastuzumab) after the 12-week treatment period with combination nab paclitaxel/cyclophosphamide/trastuzumab. The total treatment time for trastuzumab will be 52 weeks rather than only 12 weeks.
3279555|NCT00629486|Experimental|cytokines were determined|prevalence of genetic polymorphisms of interleukin 1B was measured in HBV-related hepatocellular carcinoma
3279556|NCT00629473|Experimental|Arm AM: advanced malignancies|Dose Escalation - 9 dose cohorts NPI-0052 on Days 1, 8, 15 every 28 days NPI-0052 doses ranging from 0.1 to 0.9 mg/m2
3279557|NCT00629473|Experimental|Arm MM: multiple myeloma|Dose Escalation - 8 dose cohorts NPI-0052 on Days 1, 4, 8, 11 every 21 days NPI-0052 doses ranging from 0.075 to 0.6 mg/m2 Dexamethasone 20 mg oral or IV day before and day after NPI-0052 dosing.
3279558|NCT00629460||1|there is only one group/cohort. This is a non-therapeutic study.
3279559|NCT00629447|Experimental|1|The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
3279560|NCT00629434|Experimental|1|This arm will receive diabetes education via telemedicine
3279565|NCT00629369|Experimental|A|subjects with Occlusion Support Device with active pushing in the second stage of labor
3279566|NCT00629369|No Intervention|2|Subjects without Occlusal Support Device with active pushing in the second stage of labor
3279567|NCT00629343|Experimental|Treatment|
3279568|NCT00629330|Experimental|Multi-component Academic Detailing|Includes an interactive, digitized CDROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients.
3279569|NCT00629317|Active Comparator|A|
3279570|NCT00629317|Placebo Comparator|B|
3279571|NCT00629304|Placebo Comparator|1|standard visit at 3 and 6 months
3279572|NCT00629304|Active Comparator|2|PDA-FIT system + standard visit at 3 and 6 months
3279573|NCT00629304|Active Comparator|3|PDA-FIT system + 12 telephone visits + standard visit at 6 months
3279574|NCT00629291||1|Sickle cell anemia patients
3279575|NCT00629291||2|Sickle cell β thalassemia
3279576|NCT00629265|Active Comparator|Active NMES + Swallowing Exercise|Active Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES) therapy will be paired concomitantly with repeated effortful sallowing exercises, for 60 swallows, 2 times per day, 6 days per week, for 12 weeks.
3279577|NCT00629265|Sham Comparator|Sham NMES + Swallowing Exercise|Sham (inactive) Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES) therapy will be paired concomitantly with repeated effortful sallowing exercises, for 60 swallows, 2 times per day, 6 days per week, for 12 weeks.
3279578|NCT00629252|Experimental|1|Schizophrenic patients treated with sertindole
3279579|NCT00629252|Active Comparator|2|Schizophrenic patients treated with risperidone
3279580|NCT00629252|No Intervention|3|Healthy controls without any treatment.
3279581|NCT00629239|Experimental|1|AZD4818
3279582|NCT00629239|Placebo Comparator|2|Placebo
3279583|NCT00629226|Experimental|Group I|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8, 11, 22, 25, 29, 32, 43, 46, 50, and 53. Beginning on day 8 or 9, patients undergo standard intensity-modulated radiotherapy (IMRT) once daily, 5 days a week, for up to 8 weeks.
3279584|NCT00629226|Experimental|Group II|Patients receive cetuximab, bortezomib (beginning at one dose level below the MTD determined in group I), and IMRT as in group I. Patients also receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, and 57.
3279585|NCT00629213|Active Comparator|1|
3279586|NCT00629213|Placebo Comparator|2|
3279587|NCT00629200|Experimental|SSG + Intron A|Sodium Stibogluconate (SSG) 400 mg/m^2 intravenous (IV) daily on days 1-5 + Interferon Alfa-2b (Intron A) 3x10^6 units subcutaneously three times weekly
3279588|NCT00629187|Experimental|1|
3279589|NCT00629174|Experimental|1|Exercise
3279590|NCT00629174|Experimental|2|Mental training (computer lessons)
3279591|NCT00629174|No Intervention|3|
3279592|NCT00629161|Experimental|A|
3279593|NCT00629161|Placebo Comparator|B|
3279594|NCT00629148|Active Comparator|combination chemotherapy|Simultaneous use of Vinorelbine and Capecitabine
3279595|NCT00629148|Experimental|sequential chemotherapy|Sequential use of Vinorelbine and Capecitabine
3279596|NCT00629135|Experimental|1|For adult patients with intra-abdominal abscesses matching the criteria to be included will and enrolled in the study arm 1: Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily.
3279597|NCT00629135|Active Comparator|2|For adult patients with intra-abdominal abscesses matching the criteria to be included will and enrolled in the study arm 2: Piperacillin / Tazobactam 4,5 g administered intravenously three times daily
3279598|NCT00629122|Experimental|A: Tacrolimus and Nystatin Suspension|"Administer sublingual tacrolimus 2 mg every 12 hours (subject weight < 90 kg) or 3 mg every 12 hours (subject weight > 90kg) (study day 1 - 3). Tacrolimus capsules will be opened and the contents placed under the participants tongue. Oral tacrolimus at same dose every 12 hours (study day 6 - 8). Tacrolimus capsules will be administered by mouth.~Nystatin suspension 5 mL every 12 hours (study days 1 - 3 and 6 - 8)."
3279599|NCT00629122|Experimental|B: Tacrolimus and Clotrimazole Troche|"Administer sublingual tacrolimus 1 mg every 12 hours (subject weight < 90 kg) or 2 mg every 12 hours (subject weight > 90 kg) (study day 1 - 3). Tacrolimus capsules will be opened and the contents placed under the participants tongue. Oral tacrolimus at same dose every 12 hours (study day 6 - 8). Tacrolimus capsules will be administered by mouth.~Clotrimazole troche 10 mg every 12 hours (study day 1 - 3 and 6 - 8)."
3279600|NCT00629096|Experimental|1|All included patients are assigned to arm 1, in which they are treated by the intervention
3279601|NCT00629083|Experimental|1|Bulkamid Hydrogel injection
3279602|NCT00629083|Active Comparator|2|Contigen injection
3279603|NCT00629070|Experimental|ST|Traditional strength training
3279604|NCT00629070|Experimental|VT|Velocity-enhanced training
3279605|NCT00629057|Experimental|1|Lowest dose level
3279606|NCT00629057|Experimental|2|Middle level dose
3279607|NCT00629057|Experimental|3|Highest dose level
3279608|NCT00629044|Active Comparator|G|
3279609|NCT00629044|Active Comparator|AMD|
3279610|NCT00629044|Active Comparator|Healthy subjects|
3279611|NCT00629031|Active Comparator|2|Paromomycin for 21 days @ 11mg/kg
3279612|NCT00629031|Experimental|1|Paromomycin for 14 days @ 11mg/kg
3279613|NCT00629018|Experimental|SC Group|"SC therapy,'Bone Marrow Stimulation','CD34+ autologous stem cell transplantation':~In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect"
3279614|NCT00629018|No Intervention|Controls|Patients receiving no cell therapy.
3279615|NCT00629005|Experimental|Arm 1|Constraint-Induced Movement Therapy (wear a mitt on non-paretic hand for 90% of waking hours + functional task practice for 3 hours) plus 1 hour of strength training for the arms and hands 3x/week
3279874|NCT00627289||1|patients with chronic postherniotomy pain (>1 year), affecting everyday activities severely
3279616|NCT00629005|Active Comparator|Arm 2|Constraint-Induced Movement Therapy (wear a mitt on non-paretic hand for 90% of waking hours + functional task practice for 3 hours) plus non-resisted arm and hand movements for 1 hour 3x/week
3279617|NCT00628992|Other|1|
3279618|NCT00628992|Active Comparator|2|
3279619|NCT00628992|Active Comparator|3|
3279620|NCT00628992|Active Comparator|4|
3279621|NCT00628979|Other|1|CBT
3279622|NCT00628966|Experimental|1|Participants will wear the LifeVest defibrillator for 3 months
3279623|NCT00628966|No Intervention|2|Participants will receive usual care.
3279624|NCT00628953|Experimental|1|
3279625|NCT00628953|Placebo Comparator|2|
3279626|NCT00628940|Experimental|1|18F-fluoromethylcholine
3279627|NCT00628927||METH and/or cocaine dependent group|The METH and/or cocaine dependent group were also enrolled in CTN0031 (NCT00573183) and seeking treatment. This group will be analyzed based on whether or not they completed treatment as defined by the study.
3279628|NCT00628927||Non METH and/or cocaine dependent group|The Non METH and/or cocaine dependent group participants are normal controls recruited from the community.
3279629|NCT00628914|Experimental|1|Open label escitalopram plus eszopiclone for 8 weeks
3279630|NCT00628914|Other|2|Escitalopram and eszopiclone for initial 4 weeks, then switch to escitalopram and placebo for final 4 weeks.
3279631|NCT00628914|Placebo Comparator|3|Escitalopram plus placebo for 8 weeks
3279632|NCT00628901|Experimental|Arm 1|
3279633|NCT00628901|Active Comparator|Arm 2|
3279634|NCT00628888|Experimental|Unified Protocol for Adolescents (UP-A)|Participants receive the UP-A intervention for 8-21 weeks immediately following randomization.
3279635|NCT00628888|Experimental|Delayed Treatment/Waitlist|Participants receive an 8-week waitlist condition with some attentional-control via monitoring for clinical deterioration. After a post-waitlist assessment, participants in this condition are offered the UP-A treatment for 8-21 weeks.
3279636|NCT00628862|Experimental|F 4.5 bid|Formoterol 4.5 ug twice daily (bid)
3279637|NCT00628862|Experimental|F 9.0 bid|Formoterol 9.0 ug bid
3279638|NCT00628862|Placebo Comparator|PBO|Placebo
3279639|NCT00628849||1|This group will have 2 mm plates and screws placed according to Champy principles
3279640|NCT00628849||2|This group will have 2 mm plates placed according to modified Champy principles
3279641|NCT00628849||3|This group will have larger (2.3 mm or greater) plates and screws placed according to the AO technique
3279642|NCT00628836|Active Comparator|SE group|surface stimulation
3279643|NCT00628836|Experimental|BE group|BION stimulation
3279644|NCT00628823|No Intervention|A1|Gluten-containing diet
3279645|NCT00628823|Active Comparator|A2|Gluten-free diet
3279646|NCT00628810|Experimental|FOLFIRI fort plus bevacizumab|Bevacizumab 5 mg/kg D1, irinotecan 260 mg/m2 D1, LV 400 mg/m2 D1, 5FU 400 mg/m2 IV bolus D1, and 5FU 2,400 mg/m2 46-hour infusion D1-2 every 2 weeks. Treatment was started within 2 weeks after inclusion in the study.
3279647|NCT00628797|Other|A UVA1 B no UVA1|half body irradiation with random allocation right and left; after three months of treatment treatment of both sides
3279648|NCT00628797|Experimental|A UVA1|
3279649|NCT00628784|Experimental|Group 1|Specialized intestinal metaplasia (Barrett's esophagus) documented via endoscopic esophageal biopsy, with standard surveillance biopsies (four-quadrant biopsies obtained every 2-cm the entire length of the specialized intestinal metaplasia in the esophagus) performed within the past two years prior to study enrollment. Biopsies show either low grade dysplasia, indeterminate for dysplasia, or no dysplasia.
3279650|NCT00628784|Experimental|Group 2|Diagnosis of Barrett's esophagus and high grade dysplasia or intramucosal carcinoma. Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney, or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement). Endoscopic ultrasound* (EUS) demonstrating no evidence of metastatic lymph node involvement or extension of carcinoma beyond the mucosa (T1).
3279651|NCT00628784|Experimental|Group 3|Diagnosis of esophageal carcinoma (T1smN0 or T2N0 via EUS). Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney, or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement).
3279652|NCT00628784|Experimental|Group 4|Diagnosis of severe dysplasia within esophageal squamous mucosa on pathology review. Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement). EUS with no evidence of metastatic lymph node involvement or extension of carcinoma beyond the mucosa.
3279653|NCT00628771|Active Comparator|Usual Care|Participants will receive usual care for their prenatal visits.
3279654|NCT00628771|Experimental|CenteringPregnancy Plus|Participants will receive the CenteringPregnancy Plus treatment program, which includes an HIV/STD prevention component.
3279655|NCT00628758|Experimental|Symbicort|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
3279656|NCT00628758|Experimental|Conventional BP|Conventional Best Practice for Treatment of Asthma
3279657|NCT00628745||Observational|
3279658|NCT00628732|Experimental|1|
3279659|NCT00628719|Experimental|1|a single dose of 10 mg/kg of liposomal amphotericin B
3279660|NCT00628719|Active Comparator|2|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
3279661|NCT00628706|Experimental|A|Inhalation of THC, using a Volcano vaporizer
3279662|NCT00628706|Placebo Comparator|B|Inhalation of vehicle, using a Volcano vaporizer
3279663|NCT00628680|Experimental|AAT-023 (Zuragen Arm)|Active experimental consisting of AAT-023 (Zuragen)solution
3279664|NCT00628680|Active Comparator|Heparin|5000 units diluted with normal saline to the exact catheter lumen volume
3279665|NCT00628667|Experimental|1|
3279666|NCT00628667|Placebo Comparator|2|
3279667|NCT00628654||Volunteers|Serum samples will be obtained from volunteers, but no tissue specimens. Volunteers will complete a questionnaire.
3279668|NCT00628654||Patients with cancer|Ascites from patients with ovarian, peritoneal, and fallopian tube cancers for basic science studies
3279669|NCT00628628|Experimental|Group A|As Needed Rasburicase .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
3279670|NCT00628628|Experimental|Group B|Fixed Dose Rasburicase .15 mg/kg IV Over 30 Minutes Daily
3279671|NCT00628615||2|male patients with lower urinary tract symptoms
3279672|NCT00628615||1|Female patients with overactive bladder syndrome
3279673|NCT00628602|Experimental|Rx Group|BION Therapy Group
3279674|NCT00628602|Placebo Comparator|Control Group|control group
3279675|NCT00628589|Experimental|Inhaled Loxapine 5 mg|Inhaled Loxapine 5 mg, may repeat x 1 or 2 after 2 hours
3279676|NCT00628589|Experimental|Inhaled Loxapine 10 mg|Inhaled Loxapine 10 mg, may repeat x 1 or 2 after 2 hours
3279677|NCT00628589|Placebo Comparator|Inhaled placebo|Inhaled Loxapine placebo, may repeat x 1 or 2 after 2 hours
3279678|NCT00628576|Active Comparator|1|UFH: patients treated with unfractionated heparin
3279679|NCT00628576|Experimental|2|FH: patients treated with low-molecular-weight (fractionated) heparin
3279680|NCT00628563||1|Asthma patients
3279681|NCT00628550|Experimental|1|Pediatric patients that experience in-hospital CPA who remain in cardiac arrest despite CPR and an initial, standard dose of epinephrine (0.01 mg/kg), will be randomly assigned to receive vasopressin (0.8 units/kg) rescue as the second vasopressor medication.
3279682|NCT00628550|Active Comparator|2|Pediatric patients that experience in-hospital CPA who remain in cardiac arrest despite CPR and an initial, standard dose of epinephrine (0.01 mg/kg), will be randomly assigned to receive standard dose epinephrine (0.01 mg/kg)rescue as the second vasopressor medication.
3279683|NCT00628537|Experimental|1|BION™ Experimental Group
3279684|NCT00628537|Active Comparator|2|Surface Stimulation Group
3279685|NCT00628537|Active Comparator|3|Control Group with conservative therapy (Range of motion exercises)
3279686|NCT00628524||1|> 500 consecutive patients with coronary artery disease fulfilling eligibility criteria.
3279687|NCT00628511||observation|
3279688|NCT00628498|Experimental|Defibrotide|Defibrotide 25 mg/kg day given in 4 divided doses approximately every 6 hours
3279689|NCT00628485|Experimental|Low Stimulation|"The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation."
3279690|NCT00628485|Experimental|High Stimulation|"The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions."
3279691|NCT00628485|Placebo Comparator|Control Group|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises.
3279692|NCT00628459|Active Comparator|1|
3279693|NCT00628459|Experimental|2|
3279694|NCT00628459|Experimental|3|
3279695|NCT00628433|Placebo Comparator|1|Placebo
3279696|NCT00628433|Experimental|2|HE3286 5 mg daily
3279697|NCT00628433|Experimental|3|HE3286 10 mg daily
3279698|NCT00628433|Experimental|4|HE3286 20 mg daily
3279699|NCT00628433|Experimental|5|HE3286 4 mg daily
3279700|NCT00628420|Other|1|Patients recieved single low dose of ACP-104
3279701|NCT00628420|Other|2|Patients recieved a high dose of ACP-104
3279702|NCT00628420|Other|3|Patients recieved a placebo
3279703|NCT00628394|Other|1|Patients are given the drug Atomoxetine and Cognitive Remediation training.
3279704|NCT00628394|Other|2|Patients are given the drug Atomoxetine and Remediation Control training.
3279705|NCT00628394|Other|3|Patients are given a Placebo and Cognitive Remediation training.
3279706|NCT00628394|Other|4|Patients are given Placebo and Remediation Control training.
3279707|NCT00628381|Experimental|AA|24 ICU patients with severe sepsis will get a L-citrulline 8 h enteral supplementation.
3279708|NCT00628381|Active Comparator|AB|24 ICU patients with severe sepsis will get an alternative isocaloric amino acid supplementation (L-alanine) during 8 hours
3279709|NCT00628355|Experimental|lidocaine injection|"Lidocaine injection. Women randomized for this treatment was submitted to 2 milliliters of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point.~Patients received lidocaine injections once a week for 4 weeks"
3279710|NCT00628355|Experimental|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation (TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
3279711|NCT00628342|Experimental|1|
3279712|NCT00628342|Experimental|2|
3279713|NCT00628342|Placebo Comparator|3|
3279714|NCT00628329||1|
3279715|NCT00628329||2|
3279716|NCT00628303|Experimental|1|Motavizumab
3279717|NCT00628303|Placebo Comparator|2|Placebo
3279718|NCT00628290|Experimental|1|
3279719|NCT00628290|Active Comparator|2|
3279720|NCT00628277|Experimental|1|Arm 1: high caloric expenditure exercise plus dietary counseling
3279721|NCT00628277|Active Comparator|2|Arm 2: low caloric expenditure exercise plus dietary counseling
3279722|NCT00628264|Experimental|AP214|
3279723|NCT00628264|Placebo Comparator|Placebo|
3279724|NCT00628251|Experimental|1|AZD2281 Oral 200 mg BID
3279725|NCT00628251|Active Comparator|2|Liposomal Doxorubicin
3279726|NCT00628251|Experimental|3|AZD2281 Oral 400 mg BID
3279727|NCT00628238|Active Comparator|A|Subjects younger than 65 years old.
3279728|NCT00628238|Active Comparator|B|Subjects aged 65 years and older
3279729|NCT00628225|No Intervention|1|Usual Care
3279730|NCT00628225|Experimental|2|Multifacetted smoking cessation intervention (aimed at professional (training and education) and at patients (counseling + nicotine replacement)
3279731|NCT00628225|Experimental|3|Multifacetted smoking cessation intervention (aimed at professional (training and education) and at patients (counseling + nicotine replacement + bupropion-SR)
3279732|NCT00628212|Experimental|Teneligliptin 10 mg|Teneligliptin 10 mg, orally, once daily
3279733|NCT00628212|Experimental|Teneligliptin 20 mg|Teneligliptin 20 mg, orally, once daily
3279734|NCT00628212|Experimental|Teneligliptin 40 mg|Teneligliptin 40 mg, orally, once daily
3279735|NCT00628212|Placebo Comparator|Placebo|Teneligliptin placebo-matching tablets, orally, once daily
3279736|NCT00628186|Experimental|1|Pancreaticojejunostomy has a risk factor of pancreatic fistula. Type of stent tube (external stent vs. short stent)across pancreaticojejunostomy was randomized for the patients with pancreaticoduodenectomy.
3279737|NCT00628173|Experimental|1|patients with refractory glaucoma who were candidate for AGV implantation allocated in superior site
3279738|NCT00628173|Experimental|2|patients with refractory glaucoma who were candidate for AGV implantation allocated in inferior site
3279739|NCT00628160|Experimental|Terlipressin group|Terlipressin in continuous infusion plus alpha adrenergic drugs (noradrenaline and/or dopamine in continuous infusion)
3279740|NCT00628160|Active Comparator|Control group|Alpha adrenergic drugs (noradrenaline and/or dopamine in continuous infusion)
3279741|NCT00628147|Experimental|Narrow band imaging colonoscope|narrow band imaging colonoscope
3279742|NCT00628147|No Intervention|White Light|Conventional White Light Examination
3279743|NCT00628134|Experimental|1|Subjects inhaled calfactant then isotonic saline
3279744|NCT00628134|Experimental|2|Subjects inhaled isotonic saline then calfactant
3279745|NCT00628121|Experimental|Cetrorelix 1 mg|
3279746|NCT00628121|Experimental|Cetrorelix 2 mg|
3279747|NCT00628121|Experimental|Cetrorelix 3 mg|
3279748|NCT00628108|Placebo Comparator|Placebo|
3279749|NCT00628108|Experimental|Levocetirizine|
3279750|NCT00628095|Experimental|Active|
3279751|NCT00628095|Placebo Comparator|Placebo|
3279752|NCT00628082||HfpEF|Patients with Heart Failure with preserved ejection fraction
3279753|NCT00628082||Control|Healthy Volunteers
3279754|NCT00628069||Group 1|performers who will participate in the training sessions.
3279755|NCT00628069||Assistants|Assisants-paired with the performers and will be allowed to assists only, without the opportunity to practice the technical skills related to the task.
3279756|NCT00628056|Active Comparator|1|
3279757|NCT00628056|Placebo Comparator|2|
3279758|NCT00628043|Experimental|EPOCH|
3279759|NCT00628043|Placebo Comparator|placebo|
3279760|NCT00628030|Experimental|NOURISH|The first 2 waves and second 2 waves of participants will receive a 12 and 6 week face-to-face intervention (NOURISH), respectively. The interventions differ only in duration. They cover the same concepts which are grounded in Social Cognitive Theory (SCT). Throughout the interventions the influence of social learning on behavioral outcomes (e.g., parent's modeling of healthy behavior) will be emphasized. Weekly topics provide information about implementing healthy lifestyle behaviors, authoritarian parenting approaches, and strategies for overcoming barriers to change. Parents will receive pedometers for themselves and 1 of their children. A one-hour booster session will be available for all intervention participants 2 months after completion of the interventions.
3279761|NCT00628030|Placebo Comparator|Wellness Group|The placebo control group will attend a group session moderated by an independent interventionist. This interventionist will be blinded to the Specific Aims and hypotheses of this study. The session will address the role of diet and exercise in pediatric overweight. In addition, control parents will receive pedometers (and instructions on their use) for themselves and 1 of their children. Finally, control participants will be mailed publicly available brochures on pediatric overweight on 2 occasions during the study. Control participants will also be sent home one additional packet of information (essentially a review of previous mail outs) 2 months after post-testing.
3279762|NCT00628017|Experimental|1|omega-3 PUFAs(180mg eicosapentaenoic acid[EPA] + 120mg docosahexaenoic acid[DHA]/capsule), 3 capsules twice daily, total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA
3279763|NCT00628017|Placebo Comparator|2|three identical placebo capsules twice daily which contained olive oil esters.
3279764|NCT00628004|Experimental|1|
3279765|NCT00628004|Active Comparator|2|
3279766|NCT00628004|No Intervention|No treatment|No treatment as wound was healed
3279767|NCT00627978|Experimental|Ixabepilone|Participants are treated with Ixabepilone.
3279768|NCT00627978|No Intervention|Control|
3279769|NCT00627965|Experimental|1|Sildenafil citrate
3279770|NCT00627965|Placebo Comparator|2|Placebo
3279771|NCT00627952|Active Comparator|amlodipine 10 mg|
3279772|NCT00627952|Active Comparator|manidipine 20 mg|
3279773|NCT00627926|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
3279774|NCT00627926|Experimental|Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week|Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.
3279775|NCT00627926|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.
3279776|NCT00627913|Active Comparator|1|Healon 5
3279777|NCT00627913|Experimental|2|Retrobulbar Anesthetic Injection
3279778|NCT00627900|Other|BMS|Implantation of a bare metal stent
3279779|NCT00627900|Other|SES|Implantation of a sirolimus-eluting stent
3279780|NCT00627887|Experimental|ECT+pharmacotherapy|Unilateral brief pulse ECT weekly for 6 weeks thereafter every 2 weeks; Venlafaxine target dose 300mg/day; Lithium target dose 0,5-0,8 mmol/L.
3279781|NCT00627887|Active Comparator|pharmacotherapy|Venlafaxine target dose 300mg/day; Lithium 0,5-0,8 mmol/L.
3279782|NCT00627874|Experimental|1|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
3279783|NCT00627874|No Intervention|2|
3279784|NCT00627861|Experimental|Aliskiren and metoprolol succinate|
3279785|NCT00627835|Experimental|Treatment Group 1: Cohort 1|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
3279786|NCT00627835|Experimental|Treatment Group 1: sorafenib and radiation: Cohort 2|Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
3279787|NCT00627835|Experimental|Treatment Group 2: Cohort 3|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
3279788|NCT00627835|Experimental|Treatment Group 2: Cohort 4|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
3279789|NCT00627835|Experimental|Treatment Group 2:Cohort 5|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
3279790|NCT00627822||Ward|Patients in the hospital ward
3279791|NCT00627822||Emergency room|Patients in the emergency waiting room
3279792|NCT00627822||Intensive care unit|Family members of patients admitted to the intensive care unit
3279793|NCT00627809|Experimental|1|Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given
3279794|NCT00627809|Active Comparator|2|Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed
3279795|NCT00627796|Experimental|A|Newly diagnosed patients with acromegaly
3279796|NCT00627783|Experimental|Intervention|Patients are referred to a cardiologist for a systematic detection of silent ischemia by a bicycle exercise test performed according to the French Society of Cardiology protocol after washout of cardiovascular medications likely to interfere with the test. Dipyridamole Single Photon Emission Computed Tomography (SPECT) is used in patients unable to perform the exercise test, with a sub-maximal negative exercise test result or with electrocardiographic abnormalities impairing the interpretation of the exercise test. Subsequent investigations (such as coronary angiography) and treatments (such as revascularization procedures) are left at the cardiologist's decision.
3279797|NCT00627783|No Intervention|Control|Patients are treated according current guidelines but are not referred to a cardiologist
3279798|NCT00627757||Food challenge test|"Patients~51 patients included"
3279799|NCT00627757||C|Controls 93 healthy controls are included
3279800|NCT00627744|Placebo Comparator|BE 1|Patients in this arm are randomly assigned to treatment with placebo
3279801|NCT00627744|Active Comparator|BE 2|Patients in this arm are randomly assigned to treatment with Sitagliptin
3279802|NCT00627731|Active Comparator|1|mPSL 240 mg per day for 5 days
3279803|NCT00627731|Experimental|2|PSL 40mg per day for 10 days
3279804|NCT00627718|Other|A|All patients with possible neovascular ARMD are assessed with HRT to determined the positive predictive value of the test
3279805|NCT00627705|Active Comparator|N-Acetyl Cysteine|active compound N-Acetyl Cysteine
3279806|NCT00627705|Placebo Comparator|Sugar pill|Placebo or sugar pill
3279807|NCT00627692|Active Comparator|1|Prucalopride
3279808|NCT00627692|Active Comparator|2|Prucalopride
3279809|NCT00627692|Active Comparator|3|Prucalopride
3279810|NCT00627692|Placebo Comparator|5|Placebo
3279811|NCT00627692|Active Comparator|4|Prucalopride
3279812|NCT00627679|Experimental|Treatment sequence: A, B, D, C|Treatment visits were separated by a 48-72 hour washout period. Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 2; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 3; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 4; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 5
3279813|NCT00627679|Experimental|Treatment sequence: B, C, A, D|Treatment visits were separated by a 48-72 hour washout period. Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 2; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 3; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 4; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 5
3279814|NCT00627679|Experimental|Treatment sequence: C, D, B, A|Treatment visits were separated by a 48-72 hour washout period. Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 2; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 3; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 4; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 5
3279815|NCT00627679|Experimental|Treatment sequence: D, A, C, B|Treatment visits were separated by a 48-72 hour washout period. Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 2; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 3; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 4; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 5
3279816|NCT00627653|Experimental|1|
3279817|NCT00627640|Experimental|1|1 active (50 - 100 mg/day)
3279818|NCT00627640|Placebo Comparator|2|
3279819|NCT00627627|Experimental|1|IPI-504
3279820|NCT00627614|Experimental|breast imaging study|
3279821|NCT00627588|Experimental|Dose Evaluation|To assess the safety and efficacy of up to three dose levels of ProSavin
3279822|NCT00627588|Sham Comparator|Sham element|The potential use of sham comparator to confirm efficacy
3279823|NCT00627575|Active Comparator|Lamotrigine|Subjects will receive 40 milligram (mg) of Atrovastatin from Days 1-7, from Days 8-56 subjects will receive Lamotrigine and Subjects will receive 300 mg/day of Lamotrigine and 40 mg/day of atorvastatin each morning on Days 57-77.
3279875|NCT00627276|Experimental|Arm I|Patients receive oral omega-3 fatty acid capsules 3 times daily for up to 8 weeks.
3279876|NCT00627276|Placebo Comparator|Arm II|Patients receive oral placebo olive oil capsules 3 times daily for up to 8 weeks.
3279824|NCT00627575|Active Comparator|phenytoin|Subjects will receive 40 mg of Atrovastatin from Days 1-7, from Days 8-28, subjects will receive 4mg/kg/day of phenytoin in the morning and will continue to take 40 mg/day of atorvastatin each morning. Subjects will receive taper dose of phenytoin from Days 29-30.
3279825|NCT00627562|Experimental|1|robot assisted endoscopic head and neck surgery
3279826|NCT00627549|Active Comparator|1|
3279827|NCT00627549|Active Comparator|2|
3279828|NCT00627536|Experimental|1|Avotermin 5ng/100μL/linear cm wound margin
3279829|NCT00627536|Placebo Comparator|2|Placebo
3279830|NCT00627536|Experimental|3|Avotermin 50ng/100μL/linear cm wound margin
3279831|NCT00627536|Placebo Comparator|4|Placebo matched to avotermin 50ng/100μL/linear cm
3279832|NCT00627536|Experimental|5|Avotermin 200ng/100μL/linear cm
3279833|NCT00627536|Placebo Comparator|6|Placebo matched to avotermin 200ng/100μL/linear cm
3279834|NCT00627536|Experimental|7|Avotermin 500ng/100μL/linear cm wound margin
3279835|NCT00627536|Placebo Comparator|8|Placebo matched to avotermin 500ng/100μL/linear cm
3279836|NCT00627523|Experimental|Active|The active treatment arm
3279837|NCT00627523|Experimental|Control|Control
3279838|NCT00627510||A|all patients consecutively admitted to psychiatric inpatient treatment (naturalistic sample from routine psychiatric hospital intake)
3279839|NCT00627497|Experimental|DIAM Group1|
3279840|NCT00627497|Active Comparator|Single-Level Posterior Decompression|
3279841|NCT00627497|Experimental|DIAM Group2|
3279842|NCT00627497|Active Comparator|Posterolateral Interbody Fusion|
3279843|NCT00627484||Group 1: GBP non-diabetic|Non-diabetic subjects scheduled to receive gastric bypass
3279844|NCT00627484||Group 2: BND non-diabetic|Non-diabetic subjects scheduled to receive gastric banding
3279845|NCT00627484||Group 3: GBP diabetic|Diabetic subjects scheduled to receive gastric bypass
3279846|NCT00627484||Group 4: VLCD diabetic|Diabetic subjects scheduled to receive very low calorie diet
3279847|NCT00627484||Group 5: SG diabetic|Diabetic subjects scheduled to receive sleeve gastrectomy
3279848|NCT00627471|Active Comparator|A|This group must follow a defined algorithm. Only the physicians assigned to this group will know the algorithm.
3279849|NCT00627471|Active Comparator|B|This is the control group, following the physician's standard practice.
3279850|NCT00627458|Experimental|INFANRIX HEXA PF GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-free (PF) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
3279851|NCT00627458|Experimental|INFANRIX HEXA PC GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-containing (PC) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
3279852|NCT00627458|Active Comparator|CONTROL GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the licensed formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
3279853|NCT00627445|Experimental|BIAsp 50-50-30|Biphasic insulin aspart 50 administered before breakfast and lunch + biphasic insulin aspart 30 at dinner combined with metformin
3279854|NCT00627445|Active Comparator|BIAsp 30-30|Biphasic insulin aspart 30 administered before breakfast and dinner combined with metformin
3279855|NCT00627419|Experimental|1|IPI-504
3279856|NCT00627406|Experimental|A|More than 14 follicles with a diameter of > 11mm: triggering of ovulation with 0.5 mg GnRHa (Buserelin) (s.c.) + 1500 IU hCG (Pregnyl)
3279857|NCT00627406|Active Comparator|B|More than 14 follicles with a diameter of > 11mm: triggering of ovulation with hCG (Pregnyl) 5.000 IU (s.c.)
3279858|NCT00627406|Experimental|C|14 or less follicles with a diameter of > 11mm: triggering of ovulation with 0.5 mg GnRHa (Buserelin) (s.c.) + 1500 IU hCG (Pregnyl) (s.c.) at 35 hours and 1500 IU hCG (Pregnyl) (s.c.) 7 days after triggering of ovulation (OPU + 5)
3279859|NCT00627406|Active Comparator|D|14 or less follicles with a diameter of > 11mm: triggering of ovulation with 5000 IU hCG (Pregnyl) (s.c.)
3279860|NCT00627393|Experimental|1|Participants will receive granulocyte transfusions in addition to standard antimicrobial therapy
3279861|NCT00627393|Active Comparator|2|Participants will receive standard antimicrobial therapy alone
3279862|NCT00627393|Other|3|Participants will donate granulocytes after receiving a combination of two drugs, G-CSF and dexamethasone
3279863|NCT00627380|Placebo Comparator|STOC|Standard of care arm continues to receive standard of care treatment for HIV, but does not receive any new treatment/intervention or change in anti-HIV medications. Runs parallel to experimental group. At the end of this 16-wk control period, participants are invited to crossover into the experimental group
3279864|NCT00627380|Experimental|YOGA|Yoga lifestyle intervention administered by certified yoga instructor.
3279865|NCT00627367|Experimental|Protocolized|"1mg IV hydromorphone followed by an additional 1mg at 15 minutes if the patient answer yes to the question, Do you want more pain medication?"
3279866|NCT00627367|Active Comparator|Nonprotocolized|An IV opioid the type and dose of which will be determined by the treating clincian
3279867|NCT00627341|Experimental|Exposure and Response Prevention|Participants will receive Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa for 6 months.
3279868|NCT00627341|Active Comparator|Cognitive Behavior Therapy|Participants will receive cognitive behavioral therapy for anorexia nervosa for 6 months.
3279869|NCT00627328||1|pacemaker patients with previously diagnosed AT.
3279870|NCT00627328||2|pacemaker patients without previously diagnosed AT.
3279871|NCT00627315||Surgery|Obese adult men and women who are undergoing bariatric surgery (gastric bypass or gastric banding).
3279872|NCT00627302|Active Comparator|2|Systane
3279873|NCT00627302|Active Comparator|1|PEG-400
3279877|NCT00627263|No Intervention|1|Participants will receive the usual cardiologic care for ICD patients provided by their medical team.
3279878|NCT00627263|Experimental|2|In addition to the usual cardiologic care for ICD patients provided by the participants medical team, those randomized to Intervention will receive the stress reduction treatment (SRT) program (see below).
3279879|NCT00627250|Experimental|A|Amantadine 100 mg every morning and 12 noon
3279880|NCT00627250|Placebo Comparator|B|Placebo tablet every morning and 12 noon
3279881|NCT00627237|Experimental|Immediate start|Starts the 12 week intervention immediately after enrollment
3279882|NCT00627237|Experimental|Waitlist group|Starts the 12 week intervention 12 weeks after initial enrollment
3279883|NCT00627211|No Intervention|Room air insufflation|Air used for insufflation during gastroscopy to expand the lumen for inspection of the mucosal lining. This is current standard procedure, i.e. no experimental intervention.
3279884|NCT00627211|Experimental|CO2 insufflation|CO2 used for insufflation during gastroscopy to expand the lumen for inspection of the mucosal lining. This is not standard procedure and therefore experimental intervention.
3279885|NCT00627185|Experimental|1|Intervention group (dental practices) that received the interactive motivational website for patient tobacco cessation
3279886|NCT00627185|Placebo Comparator|2|Control group (dental practices) that did not receive any materials or resources on tobacco cessation. This is a wait-list control.
3279887|NCT00627159|Other|1|high risk
3279888|NCT00627159|Other|2|low to moderate risk
3279889|NCT00627146|Placebo Comparator|B|
3279890|NCT00627146|Active Comparator|A|ChAgly CD3
3279891|NCT00627133|Experimental|1|
3279892|NCT00627120|Experimental|1|1mg dose group
3279893|NCT00627120|Experimental|2|10mg dose group
3279894|NCT00627120|Experimental|3|100mg dose group
3279895|NCT00627120|Experimental|4|200mg dose group
3279896|NCT00627120|Experimental|5|400mg dose group
3279897|NCT00627120|Experimental|6|800mg dose group
3279898|NCT00627107|Experimental|A|A group of paraplegics.
3279899|NCT00627094|Experimental|Biatain Ibu|Biatain Ibu
3279900|NCT00627094|Active Comparator|Biatain|Biatain
3279901|NCT00627081|Placebo Comparator|1|general anesthesia and thoracic epidural administration of saline
3279902|NCT00627081|Active Comparator|2|general anesthesia and thoracic epidural administration of chirocaine
3279903|NCT00627068||1|High cardiovascular risk age over 61 years.
3279904|NCT00627068||2|Low Cardiovascular risk age over 61.
3279905|NCT00627068||3|High cardiovascular risk age over 25 but under 61.
3279906|NCT00627068||4|Low cardiovascular risk age over 25 under 61.
3279907|NCT00627055|Experimental|1|LPV/r monotherapy
3279908|NCT00627055|Active Comparator|2|LPV/r + 2NRTIs (TDF/FTC or TDF/3TC)
3279909|NCT00627042|Experimental|Ramucirumab (IMC-1121B)|
3279910|NCT00627029|Experimental|Intervention|Care coordination, consisting variously (depending on the demonstration site)--nurse telephonic counseling, nurse in-person home visits, home telemonitoring equipment, and physician education and feedback.
3279911|NCT00627029|No Intervention|Control|Usual care in Medicare fee-for-service from beneficiaries' physicians and other health care providers
3279912|NCT00627016|Experimental|Dexlansoprazole 30 mg QD|
3279913|NCT00627016|Placebo Comparator|Placebo|
3279914|NCT00627003|Experimental|1|
3279915|NCT00627003|Experimental|2|
3279916|NCT00626990|Active Comparator|RT alone|radiation therapy alone
3279917|NCT00626990|Active Comparator|RT & Concurrent CT|Radiotherapy and concurrent temozolomide chemotherapy
3279918|NCT00626990|Active Comparator|RT + Adjuvant CT|Radiotherapy plus adjuvant temozolomide chemotherapy
3279919|NCT00626990|Active Comparator|RT & Concurrent CT + adjuvant CT|Radiotherapy and concurrent chemotherapy plus adjuvant temozolomide chemotherapy
3279920|NCT00626977||R|R group:15 mL of 0.125% ropivacaine (18.75 mg)
3279921|NCT00626977||RC|RC group:0.0625% ropivacaine (9.375 mg) plus 75 ug clonidine
3279922|NCT00626964||Lifestyle or bariatric surgery|Morbid Obesity with BMI >= 40 kg/m2 or BMI >= 35 with Comorbidity
3279923|NCT00626951|Experimental|1|LMA Supreme
3279924|NCT00626951|Experimental|2|LMA ProSeal
3279925|NCT00626938||sarcoidosis|sarcoidosis patients
3279926|NCT00626938||controls|healthy volunteers and other interstitial lung disease (ILD) patients
3279927|NCT00626925|Active Comparator|Total Topiramate Group|topiramate capsules beginning at 25 mg/day with gradual increase to a maximum of 200 mg orally)
3279928|NCT00626925|Placebo Comparator|Total Placebo Group|inactive placebo matched in appearance with topiramate capsules
3279929|NCT00626912|Active Comparator|1|platinum coils
3279930|NCT00626912|Active Comparator|2|hydrogel coils
3279931|NCT00626886|Experimental|1|Two, 5x5cm bupivacaine collagen sponges implanted during surgery
3279932|NCT00626886|Placebo Comparator|2|Placebo collagen sponge implanted during surgery
3279933|NCT00626873|Experimental|Definity|Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.
3279934|NCT00626847||1|Primary Open Angle Glaucoma (POAG)
3279935|NCT00626847||2|Controls (Normals, patients without glaucoma)
3279936|NCT00626834|Experimental|Vigabatrin Dose 1|
3279937|NCT00626834|Experimental|Vigabatrin Dose 2|
3279938|NCT00626834|Experimental|Vigabatrin Dose 3|
3279939|NCT00626834|Placebo Comparator|Matching placebo|
3279940|NCT00626821|Experimental|1|
3279941|NCT00626808||1|Children less than 24 months of age
3279942|NCT00626808||2|Children 24 to 59 months of age with a claim associated with a diagnosis of asthma
3279943|NCT00626808||3|Children 24 to 59 months of age without a claim associated with a diagnosis of asthma, but with dispensed medication for wheezing
3279944|NCT00626808||4|Children 24-59 months of age with immunosuppression
3279945|NCT00626795|Experimental|1|
3279946|NCT00626795|Experimental|2|
3279948|NCT00626782|Experimental|A: Ranibizumab 0.5mg (0.05mL) injection|Ranibizumab 0.5mg (0.05mL) injection at end of trabeculectomy surgery. This intra-operative adjunct therapy was administered sub-conjunctivally 8-10mm posteriorly to the limbus as an antifibrotic agent.
3279949|NCT00626782|Active Comparator|B: Mitomycin C 0.4 mg/ml sponge|Mitomycin C 0.4 mg/ml soaked sponge applied to sclera (for up to 2 min) after flap is made during trabeculectomy surgery. This is the typical method used as an antifibrotic agent.
3279950|NCT00626769||1|Postmenopausal women with established osteopenia receiving aglycone genistein 54 mg/day for 3 years
3279951|NCT00626769||2|Postmenopausal women with established osteopenia receiving placebo (Calcium and vitD) for 3 years
3279952|NCT00626756|Experimental|LI|arm controled by LIDCO technology
3279953|NCT00626756|No Intervention|CA|standard approach
3279954|NCT00626743|Experimental|SK3530|Active Drug
3279955|NCT00626743|Placebo Comparator|Placebo|Tablet which has the same appearance and taste but doesn't contain active ingredient
3279956|NCT00626717|Experimental|1|
3279957|NCT00626717|Sham Comparator|2|
3279958|NCT00626704|Experimental|Arm 1|AMG 655 + Doxorubicin
3279959|NCT00626704|Placebo Comparator|Arm 2|Placebo + Doxorubicin
3279960|NCT00626678|Experimental|1|Oral administration of prednisone and azathioprine throughout study
3279961|NCT00626678|Placebo Comparator|2|Oral administration of prednisone and placebo throughout study
3279962|NCT00626665|Placebo Comparator|Placebo|One placebo tablet every alternate day for 6 weeks
3279963|NCT00626652|Experimental|1|
3279964|NCT00626639|Placebo Comparator|Placebo|Three days before the start of radiotherapy (Day -3), participants received a single intravenous (IV) bolus injection of matching placebo. During radiotherapy (beginning on Day 1), participants received a weekly single IV bolus injection of matching placebo after the last radiation fraction of that week (usually on Fridays) until grade ≥3 oral mucositis occurred, or for a maximum 8 doses (completion of radiotherapy). Participants also received cisplatin 100 mg/m^2 on days 1, 22 and 43.
3279965|NCT00626639|Experimental|Palifermin|Three days before the start of radiotherapy (Day -3), participants received a single intravenous (IV) bolus injection of palifermin at 120 μg/kg. During radiotherapy (beginning on Day 1), participants received a weekly single IV bolus injection of palifermin at 120 μg/kg after the last radiation fraction of that week (usually on Fridays) until grade ≥3 oral mucositis occurred, or for a maximum 8 doses (completion of radiotherapy). Participants also received cisplatin 100 mg/m^2 on days 1, 22 and 43.
3279966|NCT00626626|Experimental|"Clofar, Cyclophos, Alemtuzumab"|"Phase 1: 1-3 patients will be treated in order to establish Cyclophosphamide and Clofarabine dose and to confirm reasonable safety and engraftment efficacy.~Drug - Clofarabine,Cyclophosphamide & Alemtuzumab - Clofar (30mg/m2) D -8 to -4; Cyclo (500mg/m2) D -8 & -7 & Alem (20mg over 2hrs)"
3279967|NCT00626626|Experimental|"Clofar, Cyclophos,Alemtuzumab(Ph II)"|"Phase II patients 4-9 will treat at the selected dose level of Clofarabine and Cyclophosphamide.~Drug - Clofarabine, Cyclophosphamide & Alemtuzumab Clofar (30mg/m2) D -8 to -4; Cyclo (1000mg/m2) D -8 & -7 & Alem (20mg)-pts."
3279968|NCT00626587|Placebo Comparator|A|Conventional diagnostic procedures (transbronchial biopsy and bronchial washing) for peripheral pulmonary lesions
3279969|NCT00626574|Active Comparator|A|Group A will receive Procrit® intravenous injections (40,000U) once daily for 3 days (Study Days 1, 2, and 3). The first dose of Procrit® will be given within 36 hours of the initial SAH event / symptoms and immediately before the vascular clipping procedure.
3279970|NCT00626574|Placebo Comparator|B|Group B will receive Saline intravenous injections once daily for 3 days (Study Days 1, 2, and 3).
3279971|NCT00626561|Experimental|Bevacizumab + Paclitaxel|Bevacizumab 10 mg/kg intravenous (IV) twice weekly and Paclitaxel 60 mg/m^2 IV weekly.
3279972|NCT00626548|Placebo Comparator|Placebo|Matching Placebo
3279973|NCT00626548|Experimental|ZD4054|ZD4054 (Zibotentan)
3279974|NCT00626535|Experimental|1|20mg once daily
3279975|NCT00626535|Placebo Comparator|2|Oral once daily
3279976|NCT00626522|Experimental|1|
3279977|NCT00626522|Experimental|2|
3279978|NCT00626522|Experimental|3|
3279979|NCT00626522|Placebo Comparator|4|
3279980|NCT00626522|Placebo Comparator|5|
3279981|NCT00626522|Placebo Comparator|6|
3279982|NCT00626483|Experimental|CMV pp65-LAMP mRNA-loaded DC vaccination|Basiliximab will be safe in combination with CMV pp65-LAMP mRNA-loaded DC vaccination and GM-CSF
3279983|NCT00626470|Active Comparator|-TSP|Patients operated without TSP
3279984|NCT00626470|Active Comparator|+TSP|Patients operated with TSP
3279985|NCT00626457|Experimental|Maintenance First|
3279986|NCT00626457|Active Comparator|Weight Loss First|
3279987|NCT00626444|Experimental|1|Intravenous vitamin C
3279988|NCT00626431|Experimental|Leuprolide acetate - Formulation A|Leuprolide acetate 45 mg, 6-month depot
3279989|NCT00626431|Experimental|Leuprolide acetate - Formulation B|Leuprolide acetate, 45 mg, 6-month depot
3279990|NCT00626418|Placebo Comparator|1|This will be a crossover study. Ascending doses of active drug will be administered on study nights 3-5 with an option of 3 additional nights in an attempt to identify a tolerable efficacious dose. Night 1 will be an adaptation night and night two will be a placebo night.
3279991|NCT00626418|Active Comparator|2|This will be a crossover study. Ascending doses of active drug will be administered on study nights 3-5 with an option of 3 additional nights in an attempt to identify a tolerable efficacious dose. Night 1 will be an adaptation night and night two will be a placebo night.
3279992|NCT00626405|Experimental|Arm I|Patients receive oral temozolomide on days 1-5 and bevacizumab IV over 30-90 minutes on days 1 and 15.
3279993|NCT00626405|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1.
3279994|NCT00626392|Experimental|NER 500; ASA run-in, ASA coadmin|Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
3279995|NCT00626392|Experimental|NER 500; ASA Pbo run-in, ASA coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
3279996|NCT00626392|Experimental|NER 500; ASA Pbo run-in, ASA Pbo coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
3279997|NCT00626392|Experimental|NER 1000; ASA run-in, ASA coadmin|Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
3279998|NCT00626392|Experimental|NER 1000; ASA Pbo run-in, ASA coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
3279999|NCT00626392|Experimental|NER 1000; ASA Pbo run-in, ASA Pbo coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
3280000|NCT00626366|Experimental|1|This arm of the study will contain subjects who will spray 2-4 sprays of a nasal contrast solution in their nares. Following administration of the spray, the subjects will then have a Xoran mini-CAT scan of their sinuses.
3280001|NCT00626366|Experimental|2|This arm will contain subjects who will place two drops of a nasal contrast solution in each nose. Following administration of the nasal contrast, the subjects will then have a Xoran miniCAT scan of their sinuses.
3280002|NCT00626353|Experimental|Intervention|Patients treated by an interdisciplinary, intersectoral and interventional team responsible for providing home-based rehabilitation.
3280003|NCT00626353|Active Comparator|Control|Control patients treated following standard care procedures in our department with no interference from the interventional team.
3280004|NCT00626340|Active Comparator|MDD diagnosis and Estrogen treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen alone.
3280005|NCT00626340|Active Comparator|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
3280006|NCT00626340|Active Comparator|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
3280007|NCT00626340|Active Comparator|No depression and estrogen treatment|Non-depressed menopausal women between the ages of 40-70 receiving treatment with estrogen alone.
3280008|NCT00626327|Experimental|MenACWY-CRM+ MMRV|
3280009|NCT00626327|Active Comparator|MMRV|
3280010|NCT00626327|Experimental|MenACWY-CRM|
3280011|NCT00626314|Experimental|1|myoblast
3280012|NCT00626314|Sham Comparator|2|sham injection procedure
3280013|NCT00626301|Experimental|1|Children who have completed HIV-NAT 017. Children treated with other double boosted PIs such as indinavir plus lopinavir/ ritonavir are also included.
3280014|NCT00626288|Experimental|A|Mesalazine cpr 800 mg t.i.d. for 12 weeks
3280015|NCT00626288|Placebo Comparator|B|Placebo cpr t.i.d. for 12 weeks
3280016|NCT00626275|Experimental|ADL5859 -- 200 mg (Part A)|ADL5859: 200 milligrams (mg), capsules, administered orally as a single dose during 1 of 3 Treatment Periods in Part A of the study
3280017|NCT00626275|Active Comparator|Naproxen -- 500 mg (Part A)|Naproxen: 500 mg, capsules, administered orally as a single dose during 1 of 3 Treatment Periods in Part A of the study
3280018|NCT00626275|Placebo Comparator|Placebo (Part A)|Matching placebo, capsules, administered orally, as a single dose during 1 of 3 Treatment Periods in Part A of the study
3280019|NCT00626275|Experimental|ADL5859 - 100 mg (Part B)|ADL5859: 100 mg, capsules, administered orally, twice daily (BID) for 2 weeks during Part B of the study
3280020|NCT00626275|Placebo Comparator|Placebo (Part B)|Matching placebo, capsules, administered orally, BID for 2 weeks during Part B of the study
3280021|NCT00626262|Experimental|1|20mg oral
3280022|NCT00626262|Experimental|2|20mg IV
3280023|NCT00626249|Experimental|T Inhalation powder in diabetic subjs w/ normal renal func|T inhalation powder in diabetic subjects with normal renal function, Single dose, 30 units
3280024|NCT00626249|Experimental|T Inhalation powder diabetic subj w/mild or moderate nephrop|T Inhalation powder in diabetic subjects w/mild or moderate nephropathy - Single dose, 30 units
3280025|NCT00626236|Experimental|Treatment 1|
3280026|NCT00626236|Experimental|Treatment 2|
3280027|NCT00626236|Experimental|Treatment 3|
3280028|NCT00626236|Experimental|Treatment 4|
3280029|NCT00626223|Experimental|A|patients treated with intravenous 5-MTHF (Prefolic®, Knoll, Milan, Italy) 50 mg at the end of each hemodialysis session; The group will receive supplementation with vitamin B6 300 mg (Benadon®, Roche, Milan, Italy) and vitamin B12 1000 mcg (Dobetin®, A.C.R.A.F, Rome, Italy) administered by intravenous injection at the end of the hemodialysis session three times per week
3280030|NCT00626223|Active Comparator|B|"treated with 5 mg per day of oral folic acid (Folina® Schwarz Pharma, Milan, Italy).~The group will receive supplementation with vitamin B6 300 mg (Benadon®, Roche, Milan, Italy) and vitamin B12 1000 mcg (Dobetin®, A.C.R.A.F, Rome, Italy) administered by intravenous injection at the end of the hemodialysis session three times per week"
3280031|NCT00626210|Experimental|Modafinil|
3280032|NCT00626197|Experimental|1|
3280033|NCT00626197|Placebo Comparator|2|
3280034|NCT00626184|Placebo Comparator|A|Placebo
3280035|NCT00626184|Active Comparator|B|Active study Drug: ALV003
3280036|NCT00626171|Other|1|Allergen challenge
3280037|NCT00626158|Experimental|Gem/Cape|
3280038|NCT00626145|Placebo Comparator|1|Patients receive intracoronary injections of saline 7 days after PCI.
3280039|NCT00626145|Experimental|2|Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
3280040|NCT00626132|Experimental|Eucommia|Eucommia capsules two orally three times a day for 2 weeks
3280041|NCT00626132|Placebo Comparator|1|
3280042|NCT00626119||Control|
3280043|NCT00626119||diseased|
3280044|NCT00626106|Placebo Comparator|Placebo|
3280045|NCT00626106|Active Comparator|Investigational Product|
3280046|NCT00626106|Other|Roll-over|
3280209|NCT00624845|Placebo Comparator|Vehicle|
3280251|NCT00624624||2|"Hypogonadal men with Lapband"
3280047|NCT00626093|Other|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)|Patients in the study who received a Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for it. It's a single arm study in which patients underwent defibrillation threshold (DFT) testing at implant and 6 months.
3280048|NCT00626067|Active Comparator|1 Fully functional monitoring device|Fully functional monitoring device
3280049|NCT00626067|Active Comparator|2 Partially functional monitoring device|Partially functional monitoring device
3280050|NCT00626067|Sham Comparator|3 Non-functional monitoring device|Non-functional monitoring device
3280051|NCT00626054|Active Comparator|1|Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
3280052|NCT00626054|Active Comparator|2|Group 2 will receive half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test.
3280053|NCT00626041|Other|1|referral to primary care network for management of blood pressure, lipids and diabetes.
3280054|NCT00626028|Active Comparator|Nitric Oxide|Nitric Oxide
3280055|NCT00626028|Sham Comparator|Oxygen|Oxygen
3280056|NCT00626028|Active Comparator|Nitric Oxide plus Oxygen|
3280057|NCT00626015|Experimental|Arm I|Temozolomide, PEP-3-KLH conjugate vaccine, and daclizumab
3280058|NCT00626015|Experimental|Arm II|Temozolomide, PEP-3-KLH conjugate vaccine, and normal saline
3280059|NCT00626015|Experimental|Basiliximab|Patients will receive basiliximab 20 mg IV with vaccine # 1 only and continue with PEP-3-KLH, temozolomide.
3280060|NCT00626002|Experimental|1|
3280061|NCT00625989|Placebo Comparator|Diluent|Inhalation challenge preformed with diluent.
3280062|NCT00625989|Active Comparator|Allergen|Inhalation challenge preformed with allergen.
3280063|NCT00625976|Experimental|1|
3280064|NCT00625976|Experimental|2|
3280065|NCT00625963||I,A|I=Pulmonary Hypertension Patients A=ILD patients with Pulmonary Hypertension Patients
3280066|NCT00625924||1|autogenous tissue breast reconstruction
3280067|NCT00625924||2|tissue expander/implant breast reconstruction
3280068|NCT00625924||3|mastectomy alone
3280069|NCT00625911|Active Comparator|morphine only|standard analgesia protocol
3280070|NCT00625911|Experimental|morphine ketamine|alterantive regimen for intravenous patient controlled analgesia
3280071|NCT00625898|Active Comparator|1A: TCH-H|Docetaxel (T), Carboplatin (C), and Trastuzumab (H) followed by Trastuzumab (H)
3280072|NCT00625898|Experimental|1B: TCHB-HB|Docetaxel (T), Carboplatin (C), Trastuzumab (H), Bevacizumab (B) followed by Trastuzumab (T) and Bevacizumab (B)
3280073|NCT00625898|Active Comparator|2A: TH-FEC-H|Docetaxel (T) and Trastuzumab (H) followed by 5-fluorouracil (F), Epirubicin (E), and Cyclophosphamide (C) followed by Trastuzumab (H)
3280074|NCT00625898|Experimental|2B: THB-FEC-HB|Docetaxel (T), Trastuzumab (H), and Bevacizumab (B) followed by 5-Fluorouracil (F), Epirubicin (E), and Cyclophosphamide (C) followed by Trastuzumab (H) and Bevacizumab (B)
3280075|NCT00625872|Active Comparator|Treatment Group|Somatropin for 12 months
3280076|NCT00625872|Other|Control Group|In the first 6 months no intervention, afterwards Somatropin for 12 months
3280077|NCT00625859|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive treatment A in period 1, treatment B in period 2 and treatment C in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
3280078|NCT00625859|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive treatment B in period 1, treatment C in period 2 and treatment A in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
3280079|NCT00625859|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive treatment C in period 1, treatment A in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
3280080|NCT00625859|Experimental|Subjects receiving treatment sequence 4|Eligible subjects will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
3280081|NCT00625859|Experimental|Subjects receiving treatment sequence 5|Eligible subjects will receive treatment B in period 1, treatment A in period 2 and treatment C in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
3280082|NCT00625859|Experimental|Subjects receiving treatment sequence 6|Eligible subjects will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
3280083|NCT00625846|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3280084|NCT00625833|Placebo Comparator|Placebo|
3280085|NCT00625833|Experimental|2|
3280086|NCT00625820|Experimental|6R BH4|Subjects will receive 6R-BH4 400mg bid for 6 weeks, sequentially followed by 6R-BH4 plus Vitamin C 500mg bid for another 6 weeks. Patients will have scheduled visits at Weeks 0,3,6,9 and 12, with an exit-visit at week 16. Albuminuria will be assessed in 24-hour urine collections as well as early morning spot urine samples for albumin:creatinine ratio. Blood and urine will be tested for routine clinical laboratory tests, blood nitric oxide (NO), and also archived for later assays for special biomarkers. The primary outcome will be level of albuminuria as measured in a 24-hour urine collection at 6 and 12 weeks of therapy. Secondary outcomes will include urine albumin/creatinine ratio, estimated glomerular filtration rate (eGFR), and blood pressure .
3280087|NCT00625807|Active Comparator|Program A - Relaxation Response (RR)|One of the 2 stress reduction courses
3280088|NCT00625807|Active Comparator|Program B - Mindfullness-based stress reduction (MBSR)|One of the 2 stress reduction courses
3280089|NCT00625794|Experimental|1|8 weeks or counseling plus 6 weeks of nicotine nasal spray
3280090|NCT00625794|Active Comparator|2|8 weeks or counseling only.
3280091|NCT00625781|Experimental|B2|IGT randomized to treatment
3280092|NCT00625781|No Intervention|B1|"IGT randomized to no treatment"
3280250|NCT00624624||1|"Eugonadal men with Lapband"
3280345|NCT00624026|Experimental|1|
3280093|NCT00625742|Experimental|Multimodal Treatment Strategy|Exercise Program + Pharmacologic Intervention (Melatonin + Atenolol + Ibuprofen) + Nutritional Supplementation (Juven) - Resistance training sessions twice weekly using Thera-bands. Walking or running for 3-4 minutes at 70-80% of maximum predicted heart rate. Melatonin 20 mg by mouth (PO) Daily. 90 calories of Juven, twice a day.
3280094|NCT00625729|Experimental|Treated Patients|Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with donor natural killer cells infusion, rituximab, aldesleukin and chemotherapy.
3280095|NCT00625703|Experimental|A|
3280096|NCT00625677|Experimental|1|"Pediacel - 2,3,4 months Prevenar - 2,4 months Menjugate - 3 months Hib/ pneumo conjugate/ Men C conjugate - 12 months~Blood collected - 4,5,12,13 months"
3280097|NCT00625677|Experimental|2|"Pediacel - 2,3,4 months Prevenar - 2,4 months Neis-vacC - 3 months Hib/ pneumo conjugate/ Men C conjugate - 12 months~Blood collected - 4,5,12,13 months"
3280098|NCT00625664|Experimental|1|
3280099|NCT00625664|Active Comparator|2|
3280100|NCT00625651|Experimental|AMG 655 Low Dose|AMG 655 (low dose) + mFOLFOX6 + Bevacizumab
3280101|NCT00625651|Placebo Comparator|Placebo|Placebo + mFOLFOX6 + Bevacizumab
3280102|NCT00625651|Experimental|AMG 655 High Dose|AMG 655 (high dose) + mFOLFOX6 + Bevacizumab
3280103|NCT00625638|Experimental|Standard Care Only|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
3280104|NCT00625638|Experimental|Standard Care + IVR System|Standard Care + Interactive Voice Response (IVR) System Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes. Phone calls made once daily, each taking about 3-5 minutes to complete.
3280105|NCT00625612|Placebo Comparator|2|
3280106|NCT00625612|Experimental|1|Denufosol Tetrasodium (INS37217) Inhalation Solution
3280107|NCT00625599||1|Salvadorian students at the Evangelical University in non-health track studies over the age of 18. The students must accept the invitation to participate along with signing the informed consent to be eligible.
3280108|NCT00625599||2|Patients over the age of 45 presenting to Hospital Zacamil with an acute fracture. Patients must accept the invitation to the study and sign the informed consent to be eligible.
3280109|NCT00625586|Experimental|RAV12 plus gemcitabine|
3280110|NCT00625560|Experimental|A|entecavir 1.0 mg QD
3280111|NCT00625560|Active Comparator|B|lamivudine 100 mg QD
3280112|NCT00625547|Experimental|1|
3280113|NCT00625547|Experimental|2|
3280114|NCT00625534|Experimental|1|Laparoscopic repair
3280115|NCT00625534|Active Comparator|2|Open tension free inguinal hernia mesh repair
3280116|NCT00625521|Experimental|1|Drug: ASF 1096 0.5 % cream applied twice daily
3280117|NCT00625521|Placebo Comparator|2|Cream vehicle for ASF 1096 cream applied twice daily
3280118|NCT00625495|Experimental|1|IV Nexium
3280119|NCT00625495|Experimental|2|Oral Nexium
3280120|NCT00625482|Active Comparator|Boys 1|OPV as usual
3280121|NCT00625482|Experimental|Boys 2|OPV plus BCG
3280122|NCT00625482|Active Comparator|Girls 1|OPV as usual
3280123|NCT00625482|Experimental|Girls 2|OPV plus BCG
3280124|NCT00625469|Experimental|treatment with bosentan|patients with resting or exercise induced PAH receive bosentan in a randomized open label fashion
3280125|NCT00625469|No Intervention|PAH group with no therapy|patients with resting or exercise PAH get randomized to receive no specific therapy
3280126|NCT00625469|No Intervention|No PAH and no therapy|patients with no evidence of either resting or exercise PAH receive no intervention but are followed until lung transplantation
3280127|NCT00625456|Experimental|Single Arm, dose escalation|dose escalation starting dose 1e5 pfu/kg bw to 3e7 pfu/kg bw; Recombinant Vaccinia GM-CSF (JX-594)
3280128|NCT00625443|Experimental|Placebo (double-blind)|
3280129|NCT00625443|Experimental|Avatrombopag tablets (open-label)|
3280130|NCT00625443|Experimental|Avatrombopag tablets (double-blind)|
3280131|NCT00625430|Experimental|1|Six Cohorts with escalating vector dose
3280132|NCT00625417|Experimental|Optical spectroscopy on tumor margins|Optical spectroscopy is performed on breast tumor margins obtained from patients undergoing surgery
3280133|NCT00625404|Experimental|Truvada Arm|Daily single oral tablet of Truvada (TDF/FTC), a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
3280134|NCT00625404|Placebo Comparator|Placebo Arm|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
3280135|NCT00625391|Placebo Comparator|Placebo pill|24 weeks of placebo.
3280136|NCT00625391|Active Comparator|Green Tea Polyphenols (GTP)|24 weeks of green tea polyphenols
3280137|NCT00625391|Active Comparator|Placebo+Tai Chi (TC)|24 weeks of placebo plus Tai Chi exercise.
3280138|NCT00625391|Active Comparator|GTP+TC|24 weeks of green tea polyphenols plus Tai Chi exercise.
3280139|NCT00625378|Experimental|Sorafenib (Nexavar, BAY43-9006)|All patients are treated with sorafenib according to the dosage scheme of their previous trial
3280140|NCT00625365|Other|DEFINITY® (Perflutren Lipid Microsphere)|Patients who had undergone unenhanced echocardiography yielding suboptimal images and who were determined by the Principal Investigator to require DEFINITY-enhanced echocardiography
3280141|NCT00625339|Experimental|A|entecavir 0.5 mg QD
3280142|NCT00625339|Active Comparator|B|lamivudine 100 mg QD
3280143|NCT00625326|Experimental|75 µg/g COL-121 Ointment|75 µg/g COL-121 Ointment
3280144|NCT00625326|Experimental|150 µg/g COL-121 Ointment|150 µg/g COL-121 Ointment
3280145|NCT00625326|Experimental|300 µg/g COL-121 Ointment|300 µg/g COL-121 Ointment
3280146|NCT00625326|Active Comparator|50 µg/g Calcipotriene Ointment|50 µg/g Calcipotriene Ointment (active control)
3280147|NCT00625326|Placebo Comparator|Placebo Ointment|Placebo Ointment
3280148|NCT00625313|Experimental|HMY Model YA-60BB IOL|Patients receiving a Hoya HMY Acrylic Foldable Intraocular Lens.
3280149|NCT00625300|Active Comparator|1|Active treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
3280150|NCT00625300|Sham Comparator|Placebo|Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (sham) over the motor cortex and the prefrontal cortex.
3280151|NCT00625274|Experimental|1|Oral
3280152|NCT00625274|Experimental|2|Oral
3280153|NCT00625274|Experimental|3|Oral
3280154|NCT00625261|Experimental|1|The mothers of the two-years old children in the intervention group took part at the Heidelberg Parent-based Language Intervention HPLI
3280155|NCT00625261|No Intervention|2|Waiting group, no intervention until children were three years of age
3280156|NCT00625248||no anthithrombotic|procedures where there were no antithrombotics
3280157|NCT00625248||Antithrombotic - continued|patients who are on antithrombotics
3280158|NCT00625248||Discontinued Antithrombotic|Patients who were on antithrombotics but have been discontinued
3280159|NCT00625235|Other|1|High Carbohydrate diet
3280160|NCT00625235|Other|2|High Protein diet
3280161|NCT00625222|Experimental|1|
3280162|NCT00625209|Placebo Comparator|1|placebo of hydrocortisone, placebo of fludrocortisone and placebo of activated protein C
3280163|NCT00625209|Active Comparator|2|Hydrocortisone plus fludrocortisone and a placebo of activated protein C
3280164|NCT00625209|Active Comparator|3|placebo of hydrocortisone, placebo of fludrocortisone and activated protein C
3280165|NCT00625209|Active Comparator|4|hydrocortisone plus fludrocortisone plus activated protein C
3280166|NCT00625196|Experimental|Subjects receiving fluticasone foroate/ vilanterol|Eligible subjects will receive single dose of fluticasone foroate/ vilanterol combination treatment 800 micrograms/ 50 micrograms administered using a novel powder inhaler. There will be a washout period of 7 to 10 days between treatments.
3280167|NCT00625196|Active Comparator|Subjects receiving fluticasone foroate|Eligible subjects will receive single dose of fluticasone foroate 800 micrograms administered using a novel powder inhaler.
3280168|NCT00625196|Active Comparator|Subjects receiving vilanterol|Eligible subjects will receive single dose of vilanterol 50 micrograms administered using a novel powder inhaler.
3280169|NCT00625196|Placebo Comparator|Subjects receiving placebo|Eligible subjects will receive single dose of placebo administered using a novel powder inhaler.
3280170|NCT00625183|Experimental|Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy|Oxaliplatin: 50 mg/m2 weekly x 5 Capecitabine 725 mg/m2BID on days of RT Selenomethionine: 4000mcg/m2 PO BID X 7 days prior to RT, then 4000mcg/m2 PO QD from first to last day of RT, including weekends
3280171|NCT00625170|Active Comparator|1|Healthy men
3280172|NCT00625170|Active Comparator|2|Healthy men with a positive family anamneses of schizophrenia
3280173|NCT00625157|Experimental|1|
3280174|NCT00625157|Placebo Comparator|2|
3280175|NCT00625131|Active Comparator|Active Nicotine Patch Group|Transdermal nicotine patch
3280176|NCT00625131|Placebo Comparator|Placebo Patch Group|Transdermal placebo patch
3280177|NCT00625118||1|Children in receipt of a Hib containing vaccine at pre-school booster (3.5-6 years old).
3280178|NCT00625105|Active Comparator|Biofeedback|HRV coherence biofeedback procedure
3280179|NCT00625105|Sham Comparator|Sham intervention|Passive monitor viewing
3280180|NCT00625092|Experimental|Hyperthermic Treatment|Patients receiving combination of hyperthermic intraperitoneal chemotherapy (HIPC) with oxaliplatin plus intraperitoneal 5-Fu and intraperitoneal leucovorin with peritoneal metastases.
3280181|NCT00625079|Placebo Comparator|Pre-transplant placebo|There are two placebo comparators.... one for the group of patients with resting PAH and another for the group of patients with exercise PAH
3280182|NCT00625079|Experimental|Pre-transplant sildenafil|There are two active comparators, one group with resting PAH and another with exercise PAH, both receiving drug.
3280183|NCT00625079|No Intervention|Pre-transplant no PAH-specific therapy|this group of patients has no evidence for either resting or exercise PAH but will be followed without specific drug intervention
3280184|NCT00625053|Experimental|1|Laparoscopic repair
3280185|NCT00625053|Active Comparator|2|Open repair
3280186|NCT00625040||A|Obese patients without diabetes with a Body Mass Index > 37 kg/m2
3280187|NCT00625027||Group 1|Children presenting to the Emergency Department under the care of a parent or guardian, between 0600 and 2400 during the study period.
3280188|NCT00625014|Experimental|1|Healthy men
3280189|NCT00625001||1|Women with Turner syndrome
3280190|NCT00625001||2|Healthy control women
3280191|NCT00624988|Experimental|Vibration Therapy|Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
3280192|NCT00624975|Experimental|Vaccine|
3280193|NCT00624975|Placebo Comparator|Placebo|
3280194|NCT00624962|Other|Correlative/Supportive Care|
3280195|NCT00624949||1|women with Turner syndrome
3280196|NCT00624949||2.|Control women
3280197|NCT00624936|Experimental|Vidaza and Velcade|Vidaza 75mg/m2 IV over 30 min daily on days 1-7 This dose is the same for all dose levels. Velcade will be given immediately after Vidaza is completed at one of the following dose levels: 1, 2, 3, 4
3280198|NCT00624923|Experimental|1- Active Pharmacologic|Salsalate
3280199|NCT00624923|Placebo Comparator|2|Placebo
3280200|NCT00624910|Experimental|1|A total of three 5 × 5-cm bupivacaine sponges implanted at specified layers in the wound prior to wound closure
3280201|NCT00624910|Placebo Comparator|2|A total of three 5 × 5-cm collagen sponges implanted at specified layers in the wound prior to wound closure
3280202|NCT00624910|No Intervention|3|The patient will recieve the standard of care, but no implant during surgery
3280203|NCT00624884||A|Patients with moderate-to-severe aortic regurgitation having normal left ventricular ejection fraction
3280204|NCT00624884||B|Age, sex and bodymass index matched healthy subjects
3280205|NCT00624871|Active Comparator|A|Infants will receive intravenous ascorbic acid and oral ibuprofen for 3 days
3280206|NCT00624871|Placebo Comparator|B|Infants will receive equivalent amount of placebo
3280207|NCT00624858|Experimental|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg/ day
3280208|NCT00624845|Experimental|Drug|
3280210|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 30-300 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.
3280211|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 700-2000 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 700- 2000 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.
3280212|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 301-699 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 301- 699 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.
3280213|NCT00624832|Placebo Comparator|Placebo|By subcutaneous injection of a solution with a concentration of 125 mg/mL placebo in a supine position: Patients in Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL) group received doses of 150 mg to 375 mg of placebo every 2 or 4 weeks for 12 or 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL) group received doses of 450 mg, 525 mg, or 600 mg of placebo every 2 weeks for 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 301- 699 IU/mL) group received doses of 225 mg to 375 mg of placebo every 2 weeks for 6 weeks.
3280214|NCT00624819|Experimental|10Pn-10Pn Group|Subjects having received four doses of GlaxoSmithKline Biological's 10-valent pneumococcal conjugate vaccine (GSK1024850A) in primary vaccination study and in booster vaccination study
3280215|NCT00624819|Active Comparator|7Pn-7Pn Group|Subjects having received four doses of Prevenar vaccine in primary vaccination study and in booster vaccination study
3280216|NCT00624819|Experimental|7Pn-10Pn Group|Subjects having received three doses of Prevenar in primary vaccination study and one dose of GSK1024850A vaccine in booster vaccination study
3280217|NCT00624806|Experimental|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers
3280218|NCT00624806|Active Comparator|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
3280219|NCT00624793|Experimental|I. Standard|Standard - Formula Acup Protocol
3280220|NCT00624793|Experimental|2. Individualized|Individualized Acup protocol based on TCM diagnosis
3280221|NCT00624793|Sham Comparator|3|(Control Group) Sham acupuncture
3280222|NCT00624780|Experimental|1|
3280223|NCT00624780|Active Comparator|2|
3280224|NCT00624780|Experimental|3|
3280225|NCT00624780|Placebo Comparator|4|
3280226|NCT00624767|Experimental|1|Insulin Nasal Spray
3280227|NCT00624767|Active Comparator|2|NovoLog
3280228|NCT00624754|Experimental|1|Patients with OAD will receive Symbicort® at the dose of two puffs morning and evening, each delivering 400/12 µg of budesonide/formoterol. Symbicort® will be administered by inhalation using the Turbuhaler (TH) system
3280229|NCT00624754|Placebo Comparator|2|Patients with OAD will receive lactose as a placebo, administered by inhalation using the Turbuhaler (TH) system
3280230|NCT00624728|Experimental|A|
3280231|NCT00624715|Active Comparator|THC|"High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking a full joint~Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual)IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint~Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol.Equivalent to smoking 1/10 of a joint"
3280232|NCT00624715|Placebo Comparator|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
3280233|NCT00624702|Active Comparator|1|Active Comparator 1 different salt formulation of Indacaterol.
3280234|NCT00624702|Active Comparator|2|Active Comparator 2 different salt formulation of Indacaterol.
3280235|NCT00624702|Active Comparator|3|Active Comparator 3 different salt formulation of Indacaterol.
3280236|NCT00624702|Placebo Comparator|4|
3280237|NCT00624689|Experimental|1|Modified formula
3280238|NCT00624689|No Intervention|2|Standard formula
3280239|NCT00624689|No Intervention|3|Breastfed
3280240|NCT00624676|Experimental|A|LHA formulation
3280241|NCT00624676|Active Comparator|B|5% benzoyl peroxide
3280242|NCT00624663|Active Comparator|1|(1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule) X 2 per day, total of 5 intakes
3280243|NCT00624663|Active Comparator|2|(2 x 1.5 mg Exelon® Capsules) X 2 per day, total of 5 intakes
3280244|NCT00624663|Placebo Comparator|3|(2 x Placebo Capsules) X 2 per days, total of 5 intakes
3280245|NCT00624650|Active Comparator|Modified FACTT (control)|The investigators control arm consists of a simplified algorithm for conservative management of fluids in patients with ALI, as to be published by the ARDSnet group, based on the protocol used in the FACTT trial. The protocol calls for strict adherence to ARDSnet ventilation, our weaning protocol and use of only select vasoactive, beta-adrenergic drugs as it is felt that variation in these treatments could seriously confound our results. Albuterol administration will not be permitted in the either arm except for life threatening bronchospasm not responsive to ipratropium. Ipratropium may be administered at the treating physician's discretion for bronchospasm. PiCCO's will be placed in each control patient and data recorded twice daily. The treating physician's will be blinded to this data.
3280246|NCT00624650|Experimental|EVLW|"When EVLW exceeds 9 ml/kg PBW the algorithmic treatment is begun and continued until EVLW ≤9 ml/kg PBW or extubation whichever comes first as tolerated (see figure 6). Furosemide and volume contraction are initiated when sufficient volumetric preload (GEDI) is available to enact volume contraction as a means to decrease measured EVLW without causing concomitant hypoperfusion. Fluid administration is also guided by changes in EVLW. An increase in EVLW > 2ml/kg PBW as a result of fluid administration curtails any further fluid administration until the next scheduled measurement.~Our ultimate treatment goal is to maximally lower EVLW towards the normal range - thus improving lung mechanics and gas exchange - without causing concomitant hemodynamic compromise and end-organ injury. By doing so we feel this algorithmic, goal directed, therapeutic approach should improve outcome."
3280247|NCT00624637|Other|A|infants after craniofacial surgery receive one massage with aromatherapy three hours postoperatively
3280248|NCT00624637|Other|B|infants after craniofacial surgery receive one massage with carrier oil three hours postoperatively
3280249|NCT00624637|No Intervention|C|no intervention, standard postoperative care
3280252|NCT00624624||3|Eugonadal men with gastric bypass procedure
3280253|NCT00624624||4|Hypogonadal men with gastric bypass procedure
3280254|NCT00624611|Active Comparator|1|Residual pump blood management post aortic cannula removal
3280255|NCT00624611|Experimental|2|Residual pump blood management post aortic cannula removal
3280256|NCT00624598|Experimental|SMART Group|The experimental group will have a nutrition program based solely on measured resting metabolic rate. The nutrition plan will be a specific calorie level that will promote a 1-2.5 lb per week weight reduction. No experimental participants' nutrition plan will be below 1200 Kcal/day for women or 1600 Kcal/day for men. Second, the experimental group will receive a downloadable copy of a computerized nutrition software program (BalanceLog: Microlife USA, Inc. Golden, CO) that functions s on a Windows 2000-XP or Palm operating system.
3280257|NCT00624598|Active Comparator|Usual Care|Standard 1200 kcal/day diet (women) 1600 kcal/day diet (men) using a sample 3-day menu program. The diet will be follow current government based recommendations for carbohydrates (i.e. 55%), fat (30%), and protein (15%). Study participants will receive a standard paper-based food and exercise journal
3280258|NCT00624585|Experimental|Dasatinib Dose Escalation|Patients will be started on dasatinib at a continuous oral daily dose of 100 mg per day. At 8 weeks, if the initial dose is well tolerated and patient has not achieved a partial response, the dose may be increased to 150 mg per day. All patients will be followed per protocol for a total core period of 16 weeks from the first dose. Responding patients will continue dasatinib treatment for up to 48 weeks in the absence of treatment failure, disease progression, limiting toxicity or death. Patients continuing after 48 weeks will be enrolled in a separate extension study for future follow up.
3280259|NCT00624559|Experimental|Celebrex; Low sodium|Subject completes a normal sodium diet (3 days), a low salt diet (7 days), followed by a high salt diet (7 days) while taking a celebrex pill (100 mg twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
3280260|NCT00624559|Experimental|Celebrex, High Sodium|Subject completes a normal sodium diet (3 days), a high salt diet (7 days), followed by a low salt diet (7 days) while taking a celebrex pill (100 mg twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
3280261|NCT00624559|Placebo Comparator|Placebo, Low Sodium|Subject completes a normal sodium diet (3 days), a low salt diet (7 days), followed by a high salt diet (7 days) while taking a placebo pill (twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
3280262|NCT00624559|Placebo Comparator|Placebo, High Sodium|Subject completes a normal sodium diet (3 days), a high salt diet (7 days), followed by a low salt diet (7 days) while taking a placebo pill (twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
3280263|NCT00624546||1|gerd patients
3280264|NCT00624546||2|non gerd controls
3280265|NCT00624533|Active Comparator|A|Primary Health Care Conventional Physiotherapy Treatment (based in electrotherapy)
3280266|NCT00624533|Experimental|B|Group B was treated with the GDS Method (muscular and articular chains physiotherapy method)
3280267|NCT00624520|Active Comparator|Cognitive Behavioral Stress Management|10 week program of Cognitive Behavioral Stress Management (CBSM) group sessions
3280268|NCT00624520|Active Comparator|Patient Education|10 week program of once weekly Patient Education group sessions
3280269|NCT00624494|Active Comparator|Conventional monitoring|hemodynamic monitoring - conventional monitoring
3280270|NCT00624494|Active Comparator|Advanced monitoring|hemodynamic monitoring - advanced monitoring
3280271|NCT00624481|Active Comparator|1|
3280272|NCT00624481|Experimental|2|
3280273|NCT00624481|Experimental|3|
3280274|NCT00624481|Experimental|4|
3280275|NCT00624481|Experimental|5|
3280276|NCT00624468|Experimental|Atacicept|
3280277|NCT00624468|Placebo Comparator|Placebo|
3280278|NCT00624455|Active Comparator|1|One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.
3280279|NCT00624455|Placebo Comparator|2|Placebo
3280280|NCT00624442|Experimental|Cohort 1|4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
3280281|NCT00624442|Experimental|Cohort 2|4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
3280282|NCT00624442|Experimental|Cohort 3|4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
3280283|NCT00624442|Experimental|Cohort 4|4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
3280284|NCT00624442|Experimental|Cohort 5|2 treatment periods with a 72 hour infusion. The 2 treatment periods are randomly assigned and consist of 1 dose level of CK-1827452 (with dose de-escalation possible depending on tolerability) and 1 placebo treatment. Treatment period 2 occurs at least 7 days after the conclusion of period 1.
3280285|NCT00624416|Other|Prednisolone and Isoproteronol Together|Beta-adrenergic agonists and corticosteroid
3280286|NCT00624403|Active Comparator|1|LMA ProSeal
3280287|NCT00624403|Experimental|2|I-Gel
3280288|NCT00624390|Experimental|Sepraspray|Sepraspray applied directly to both sides of the uterus, Fallopian tubes, and ovaries (or opposing sites if not possible to apply directly). Sepraspray was applied via a sterile cannula at a tissue concentration of approximately 5 mg/cm^2.
3280289|NCT00624390|No Intervention|Control|No anti-adhesion treatment was used.
3280290|NCT00624377||COPD patients|
3280291|NCT00624351|Placebo Comparator|Placebo|Phosphate-buffered Saline (PBS) infusions at study weeks 0, 1, 2, and 3.
3280292|NCT00624351|Experimental|EMAB 600mg|600 mg Epratuzumab infusions at study weeks 0, 1, 2, and 3.
3280293|NCT00624351|Experimental|EMAB 100mg|100 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
3280294|NCT00624351|Experimental|EMAB 400mg|400 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
3280295|NCT00624351|Experimental|EMAB 1200mg|1200 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
3280296|NCT00624351|Experimental|EMAB 1800mg|1800 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
3280297|NCT00624338|Experimental|Atacicept 75 mg|
3280298|NCT00624338|Experimental|Atacicept 150 mg|
3280299|NCT00624338|Placebo Comparator|Placebo|
3280300|NCT00624325|Experimental|1|12 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
3280301|NCT00624325|Experimental|2|9 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
3280302|NCT00624325|Experimental|3|6 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
3280303|NCT00624312|Active Comparator|1|Pre-operatively randomized to Procrit
3280304|NCT00624312|Placebo Comparator|2|Pre-operatively randomized to placebo
3280305|NCT00624299|Experimental|Botox|Botox
3280306|NCT00624299|Placebo Comparator|Placebo|Saline injection
3280307|NCT00624286|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3280308|NCT00624286|Placebo Comparator|Placebo to indacaterol|Patients inhaled placebo to indacaterol once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3280309|NCT00624273|Other|1, active ulcers|sildenafil treatment
3280310|NCT00624260|Active Comparator|2|Usual follow up : Pet-TDM for current indication (high isolated markers or before a metastasis curative resection)
3280311|NCT00624260|Experimental|1|Semi-annual systematic PET-TDM (M6, M12, M18, M24, M30 and M36 after initial surgery)
3280312|NCT00624247|Other|Immediate|Individuals assigned to be approached for routine HIV testing immediately upon admission to the jail.
3280313|NCT00624247|Other|Following Day|Individuals assigned to be approached for routine HIV testing the day following admission to the jail.
3280314|NCT00624247|Other|Delayed|Individuals assigned to be approached for routine HIV testing several days following admission to the jail.
3280315|NCT00624234|Experimental|NF-Tutoring Program 1|Tutoring Program I
3280316|NCT00624234|Experimental|NF-Tutoring Program 2|Tutoring Program II
3280317|NCT00624234|No Intervention|Typically Developing Readers|Control group
3280318|NCT00624234|Experimental|IRD-Tutoring Program 1|Tutoring Program I
3280319|NCT00624234|Experimental|IRD-Tutoring Program 2|Tutoring Program II
3280320|NCT00624234|No Intervention|Waitlist Control|Intervention Control Group (RD)
3280321|NCT00624221|Active Comparator|1|An Eye bank pre-cut the donor grafts used for the corneal transplant procedures.
3280322|NCT00624221|Active Comparator|2|The surgeon dissected the donor grafts used for the transplant procedures.
3280323|NCT00624208|Active Comparator|1|Intravenous injection of droperidol 20 mcg.kg-1 and saline (group 1)
3280324|NCT00624208|Active Comparator|2|Intravenous injection of ondansetron 0.1 mg.kg-1 and saline (group 2
3280325|NCT00624208|Active Comparator|3|Intravenous injection of droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1 (group 3)
3280326|NCT00624208|Placebo Comparator|4|Intravenous injection of saline and saline (group 4)
3280327|NCT00624195|Experimental|CNS-targeted|"CNS-T will comprise two components: 1) initial selection of agents to optimize CNS penetration of the overall regimen; and 2) modification of the regimen if an interim pharmacokinetic (PK) assessment determines that plasma ARV exposure is not appropriate (overdosing, under dosing).~Possible regimens include combinations of these FDA approved antiretroviral agents: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
3280328|NCT00624195|Active Comparator|non-CNS-targeted|"Subjects in the non-CNS-T (Comparison) arm will be randomized to receive a regimen (see list of FDA approved antiretrovirals listed below) designed to suppress plasma Viral Load, but not expected to have targeted CNS penetration.~Combinations of FDA approved antiretroviral agents: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
3280329|NCT00624182|Experimental|Phase I study|
3280330|NCT00624156||1|emotional disclosure writing intervention
3280331|NCT00624156||2|control writing
3280332|NCT00624143|Active Comparator|1|Oral Voriconazole
3280333|NCT00624143|Active Comparator|2|IV Amphotericin B
3280334|NCT00624130|Experimental|Arm 1|
3280335|NCT00624130|Active Comparator|Arm 2|
3280336|NCT00624117|Experimental|A|
3280337|NCT00624104||1|Lean male
3280338|NCT00624104||2|Males with type 2 diabetes
3280339|NCT00624091|Experimental|1|Early-surgery, within 48 hours from randomization
3280340|NCT00624091|Active Comparator|2|State-to-the-art group. Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
3280341|NCT00624078|Experimental|1|Patients who arrive to emergency room with scorpion sting envenomation will be evaluated according to inclusion/exclusion criteria. After informed consent has been signed they will be assigned to unique treatment arm with Anascorp.
3280342|NCT00624065|Experimental|carvedilol CR + lisinopril|
3280343|NCT00624065|Active Comparator|lisinopril + placebo|
3280344|NCT00624039|Other|1|ultrasound biomicrocopic examinations and pilocarpine instillation
3280346|NCT00624013|Placebo Comparator|Placebo|Placebo 50 mg up to 100 mg daily for 6 months
3280347|NCT00624013|Active Comparator|Sertraline (Zoloft)|Sertraline (Zoloft) 50 mg up to 100 mg daily for 6 months
3280348|NCT00624000|Experimental|1|IA administration of Alteplace vs. IV administration of Alteplace
3280349|NCT00624000|Active Comparator|2|IA administration of Alteplase vs.IV administration of Alteplase
3280350|NCT00623987|Active Comparator|A|warfarin treatment
3280351|NCT00623987|No Intervention|B|withholding warfarin therapy
3280352|NCT00623974|Experimental|Calcium + Calcitriol|1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
3280353|NCT00623974|Experimental|Teriparatide 20 mcg|Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
3280354|NCT00623974|Experimental|Teriparatide 40 mcg|Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
3280355|NCT00623974|Experimental|Teriparatide 60 mcg|Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
3280356|NCT00623948|Other|Arm 1|
3280357|NCT00623935|Experimental|Fludarabine plus Busulfan (CR)|Patients in CR will receive a reduced intensity transplant regimen consisting of Fludarabine plus Busulfan (FluBu2).
3280358|NCT00623935|Experimental|Fludarabine plus Busulfan (PR)|Patients in PR will receive a full intensity transplant regimen consisting of Fludarabine plus Busulfan (FluBu4).
3280359|NCT00623922|Experimental|1|Patient education
3280360|NCT00623922|No Intervention|2|Usual care
3280361|NCT00623909|Experimental|1|To demonstrate the safety of the AvicennaTM class IV laser for application over the skin of human subjects. This study was terminated prior to subject enrollment and closed.
3280362|NCT00623883|Experimental|1|All identified ACF eliminated by cold or hot colonoscopic biopsy forceps
3280363|NCT00623883|Sham Comparator|2|ACF quantified and observed, re-evaluated after one year
3280364|NCT00623870|Experimental|1|
3280365|NCT00623857|Active Comparator|1|Zinc
3280366|NCT00623857|Active Comparator|2|Vitamins and minerals other than zinc
3280367|NCT00623857|Active Comparator|3|Vitamins plus zinc and other minerals
3280368|NCT00623857|Placebo Comparator|4|Placebo for all vitamins and minerals
3280369|NCT00623844|Experimental|Intervention|Physical activity intervention: structured daily 30-min activity classes at preschool, activity homeworks, parent and teacher education
3280370|NCT00623844|No Intervention|Control|Keep usual activities in kindergarten
3280371|NCT00623831|Experimental|Cohort 1|Subjects received MBV at a starting dose of 250 EU (dose level 1) twice weekly, with intrasubject dose escalations for each subsequent administration in the absence of a DLT until the desired pyrogenic effect was observed. The maximum possible dose to be investigated was 547,000 EU (dose level 8).
3280372|NCT00623831|Experimental|Cohort 2|Subjects received MBV twice weekly at the fixed dose (60,800 EU [dose level 6]) that was determined to be the pyrogenic dose level in Cohort 1.
3280373|NCT00623805|Active Comparator|Bevacizumab+capecitabine+oxaliplatin|Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.
3280374|NCT00623805|Experimental|Bevacizumab(B)+capecitabine(C)+oxaliplatin followed by B+C|Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle for 6 cycles followed by bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.
3280375|NCT00623792|No Intervention|1|Usual preoperative care
3280376|NCT00623792|Experimental|2|Preoperative Lifestyle Intervention
3280377|NCT00623766|Experimental|Ipilimumab, 10 mg/kg, IV in corticosteroid-free patients|Participants who had not received corticosteroid therapy for at least 10 days before starting study drug received ipilimumab,10 mg/kg, as a 90-minute intravenous (IV) infusion every 3 weeks (Weeks 1, 4, 7, and 10) during the Induction Phase. Those eligible (patients who did not discontinue due to toxicity, did not show progression at 24 weeks, and who remained clinically stable) for the Maintenance Phase continued to receive ipilimumab, 10 mg/kg IV, every 12 weeks, beginning at Week 24.
3280378|NCT00623766|Experimental|Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients|Participants who were dependent on corticosteroid therapy received ipilimumab, 10 mg/kg, as a 90-minute intravenous (IV) infusion every 3 weeks (Weeks 1, 4, 7, and 10) during the Induction Phase. Those eligible (patients who did not discontinue due to toxicity, did not show progression at 24 weeks, and who remained clinically stable) for the Maintenance Phase continued to receive ipilimumab, 10 mg/kg IV, every 12 weeks, beginning at Week 24.
3280379|NCT00623753|Experimental|A|
3280380|NCT00623740|Experimental|1: hydrocortisone|1: active arm treated with low doses of HC during the first 10 days of life
3280381|NCT00623740|Placebo Comparator|2: Placebo|2:placebo arm treated with placebo at the same conditions than active arm
3280382|NCT00623727|Experimental|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight of BAY79-4980 1x/week plus 2 dummy injections/week (dummy = rFVIII (recombinant factor VIII)-FS (formulated with sucrose) excipient reconstituted in WFI (sterile water for injection))
3280383|NCT00623727|Active Comparator|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight of rFVIII-FS 3x/week (employing 1 percent POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)-alone liposome (rFVIII-FS-POPC) as blinding agent used for first weekly injection and rFVIII-FS in WFI for 2nd and 3rd injection)
3280384|NCT00623714|Experimental|Arm 1|study medication + Pbo
3280385|NCT00623714|Experimental|Arm 2|Pbo + study medication
3280386|NCT00623701|Placebo Comparator|1|sublingual placebo preparation
3280387|NCT00623701|Experimental|2|Sublingual preparation, 40 micro grams Phl p 5 maintenance dose
3280388|NCT00623688|Experimental|1|Subjects receive active medication (albuterol) delivered by a Proair metered dose inhaler used with an Opti-chamber and placebo (normal saline solution) by nebulizer aerosol.
3280389|NCT00623688|Active Comparator|2|Subjects receive active medication (albuterol) delivered by nebulizer and placebo (no medicine) delivered by a demonstrator Placebo metered dose inhaler demonstrator.
3280391|NCT00623662|Active Comparator|1|Glucose infusion.
3280392|NCT00623662|Placebo Comparator|2|Normal saline infusion.
3280393|NCT00623649|Experimental|Cohort 1|VCH-916 100 mg three times a day (t.i.d.)
3280394|NCT00623649|Experimental|Cohort 2|VCH-916 200 mg (t.i.d.)
3280395|NCT00623649|Experimental|Cohort 3|VCH-916 300 mg twice daily for three days
3280396|NCT00623649|Experimental|cohort 4|VCH-916 400 mg twice daily for three days
3280397|NCT00623636|Experimental|MAP0004|MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks.
3280398|NCT00623636|Other|Placebo|Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks.
3280399|NCT00623623|Experimental|Tenecteplase|Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention
3280400|NCT00623623|Other|primary PCI|Standard primary PCI
3280401|NCT00623597|Experimental|1|
3280402|NCT00623584|Experimental|1|Patients in this arm randomly receive a corneal graft cultured in a serum free culture medium
3280403|NCT00623584|Active Comparator|2|Patients in this arm randomly receive a corneal graft cultured in a serum supplemented culture medium
3280404|NCT00623571|Experimental|1|Patients treated by hospital-at-home service (GHHS)
3280405|NCT00623571|Active Comparator|2|Patients treated in a general medical ward (GMW)
3280406|NCT00623558|Active Comparator|1|Docetaxel+CDDP
3280407|NCT00623558|Experimental|2|Docetaxel+CDDP+Cetuximab
3280408|NCT00623545|Experimental|Exenatide|Exenatide. Dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks Each subject serves as their own control for outcome measures taken before and during drug treatment.
3280409|NCT00623532|Experimental|CA|"Cognition and action are an inseparable whole while functioning, a new intervention based approach using familiarity based movements and non judgmental approach was labeled cognition-action."
3280410|NCT00623532|Active Comparator|AT|Adapted Tai Chi is based on Tai Chi like movements
3280411|NCT00623532|No Intervention|C|Control
3280412|NCT00623519||1|Women with hormone receptor positive breast cancer under adjuvant treatment with Anastrozole
3280413|NCT00623506|Active Comparator|1|Pregnenolone
3280414|NCT00623506|Placebo Comparator|2|Placebo
3280415|NCT00623480|Experimental|Recombinant Factor VIII prophylaxis treatment|Participants received 25 IU/kg of Recombinant Factor VIII (Kogenate FS, BAY14-2222) intravenously (IV), 3 times per week. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) for patients exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
3280416|NCT00623480|Experimental|Recombinant Factor VIII on-demand treatment|Participants received Recombinant Factor VIII (Kogenate FS, BAY14-2222) IV for bleeds in accordance with package insert instructions and study physician recommendations.
3280417|NCT00623467|Experimental|Gadobutrol (Gadavist, BAY86-4875)|Participants were administered a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) bolus administration using a power injector via a peripheral vein (an antecubital vein was preferred). Gadobutrol was injected at a rate of 2 mL/second followed by a 20-mL 0.9% saline flush at the same rate.
3280418|NCT00623428|Experimental|PEG-IFN alfa-2a + Ribavirin for 24 weeks|After 24 weeks of treatment with pegylated interferon alfa-2a (PEG-IFN alfa-2a) 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, at which time treatment was stopped. Participants were followed for an additional 48 weeks during the treatment-free follow-up period.
3280419|NCT00623428|Active Comparator|PEG-IFN alfa-2a + Ribavirin for 48 weeks|After 24 weeks of treatment with PEG-IFN alfa-2a 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, and continued treatment for another 24 weeks (for a total of 48 weeks of treatment). Participants were followed for an additional 24 weeks during the treatment-free follow-up period.
3280420|NCT00623415|Active Comparator|Verum|flupirtine + interferon beta 1b
3280421|NCT00623415|Placebo Comparator|Placebo|placebo + interferon beta 1b
3280422|NCT00623402|Experimental|A|
3280423|NCT00623389|Experimental|A|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.
3280424|NCT00623376|Active Comparator|1|first on treatment then on Placebo
3280425|NCT00623376|Placebo Comparator|2|first on placebo then on treatment
3280426|NCT00623363|Active Comparator|piclozotan|
3280427|NCT00623363|Placebo Comparator|0.9 % sodium chloride (normal saline)|
3280428|NCT00623350|Active Comparator|1|Acute Stroke Telephone consult for the decision of tPA within 3 hours of symptoms onset.
3280429|NCT00623350|Active Comparator|2|Acute Stroke consult via audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
3280430|NCT00623337|Experimental|Newhints|Home visits
3280431|NCT00623337|No Intervention|Control|Community based surveillance volunteers will continue with current duties eg urging attendance at immunisation clinics and child health weeks
3280432|NCT00623324|Active Comparator|1|Aplindore titrated to safe and tolerable dose
3280433|NCT00623324|Placebo Comparator|2|
3280434|NCT00623298|Experimental|1|NET
3280435|NCT00623298|No Intervention|3|6-months baseline
3280436|NCT00623298|Experimental|2|group IPT
3280437|NCT00623285|Experimental|Group 1|
3280438|NCT00623285|Placebo Comparator|Group 2|
3280439|NCT00623259|Experimental|1|
3280440|NCT00623246|Active Comparator|1|Participants will receive motivational enhancement therapy (MET) for 12 weeks.
3280441|NCT00623246|Active Comparator|2|Participants will receive educational therapy (ED) for 12 weeks.
3280442|NCT00623246|No Intervention|3|Participants will receive standard clinical care.
3280443|NCT00623233|Experimental|Gemcitabine + Bevacizumab|"Gemcitabine 2500 milligrams per square meter (mg/m^2) intravenous (IV) over 30 minutes given on Day 1 every 14 days (q 14 days) until disease progression (PD) or unacceptable toxicity.~Bevacizumab 10 milligrams per kilogram (mg/kg) initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity."
3280444|NCT00623220|Experimental|A|O2 and N2O
3280445|NCT00623220|Active Comparator|B|O2 only
3280446|NCT00623207|Placebo Comparator|1|Pateints who achieve target haert rate or conclusive test will not be given Atropine
3280447|NCT00623207|Active Comparator|2|Patients who won't achieve tarhet heart rate or conclusive results will be given Atropine
3280448|NCT00623194|Experimental|insulin detemir|Insulin detemir up to twice daily plus insulin aspart at larger meals, doses are adjusted individually (treatment up to 104 weeks)
3280449|NCT00623181|Experimental|Fluzone Intradermal First, Then Fluzone Intramuscular|
3280450|NCT00623181|Experimental|Fluzone Intramuscular First, Then Fluzone Intradermal|
3280451|NCT00623168|Experimental|Treatment Only|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with Ribavirin.
3280452|NCT00623155|No Intervention|1|Control group
3280453|NCT00623155|Experimental|2|Test group
3280454|NCT00623142|No Intervention|A|Patients in this arm were not treated with HBO prior to CABG
3280455|NCT00623142|Experimental|B|Patients in this arm were treated with HBO prior to CABG
3280456|NCT00623103|Experimental|Rivastigmine capsule|Rivastigmine capsules starting at a total dose of 3 mg/day (1.5 mg twice daily orally) titrated up in 3 mg/day increments every 4 weeks to a final dose of 12 mg/day (6 mg twice daily orally). The 12 mg/day dose or the highest dose tolerated was maintained until week 76.
3280457|NCT00623103|Experimental|Rivastigmine patch|Rivastigmine patch once a day in the morning, worn for 24 hours, starting at 5 cm^2 (delivering 4.6 mg rivastigmine over a 24 hour period) for 4 weeks then titrated up to 10 cm^2 daily (delivering 9.5 mg rivastigmine over a 24 hour period). The 10 cm^2 patch or the highest well tolerated dose was maintained until week 76.
3280458|NCT00623090|Experimental|1 Website|Participants receive the Login information for the Internet we developed on prostate cancer screening.
3280459|NCT00623090|Active Comparator|2 Booklet|Participants receive the education booklet we developed on prostate cancer screening.
3280460|NCT00623090|Placebo Comparator|3 Usual Care|Usual care: participants receive no intervention.
3280461|NCT00623077|Experimental|Total Marrow Irradiation (MTI) with Tomotherapy|TMI given prior to alkylator intensive conditioning regimen (Busulfan 9.6 mg/kg intravenously (IV) (>4 yrs of age) or 13.2 mg/kg IV (< 4 years of age), Melphalan 100 mg/m^2, Thiotepa 500 mg/m^2 for high risk solid tumor patients, Whole lung radiation 1500cGy in 10 fractions by Day 60, stem cell transplantation on day 0. Ifosfamide, etoposide, and mesna are given Days 0-4 followed by filgrastim for 3 doses. Cohorts of patients (n=3) will be treated with increasing doses of TMI (600, 1000, 1200 cGy) directed toward the bones.
3280462|NCT00623051|Experimental|1|Male circumcision by experimented doctor or nurse
3280463|NCT00623025|Experimental|1|
3280464|NCT00623025|Placebo Comparator|2|
3280465|NCT00623012|Experimental|1|
3280466|NCT00622999||All|All patients
3280467|NCT00622986|Experimental|A1|perimenopausal women
3280468|NCT00622986|Placebo Comparator|A2|perimenopausal women
3280469|NCT00622986|Experimental|B1|early staged postmenopausal women
3280470|NCT00622986|Placebo Comparator|B2|early staged postmenopausal women
3280471|NCT00622973|Other|A|Diffusion-weighted MRI
3280472|NCT00622973|Other|B|Sinerem (USPIO)- enhanced MRI
3280473|NCT00622960|Experimental|High MUFA diet|Those subjects assigned to a high monounsaturated fat diet
3280474|NCT00622960|Active Comparator|High CHO diet|Those subjects assigned to a high carbohydrate diet
3280475|NCT00622947|Active Comparator|1|A Magstim Rapid stimulator (the Magstim Company Ltd, Whiteland, UK)with a 90 mm circular is used. Low frequency rTMS at 1 Hz of right temporal cortex. Each session covering 2 trains of 60 sec. and 180 sec intertrain interval.
3280476|NCT00622947|Placebo Comparator|2|
3280477|NCT00622934|Active Comparator|1|
3280478|NCT00622934|Placebo Comparator|2|
3280479|NCT00622921|Other|1|Couples-based behavioral psychotherapy
3280480|NCT00622908|Experimental|ISV-403|ISV-403 0.6%
3280481|NCT00622908|Placebo Comparator|Vehicle|Vehicle of ISV-403
3280482|NCT00622895|Experimental|Treatment: allogeneic UCB after reduced intensity conditioning|Patients receive fludarabine phosphate IV on days -4, -3 and -2, cyclophosphamide IV over 1-2 hours on days -6, -5, 3, and 4, and undergo low-dose TBI on day -1. Patients receive hematopoietic cell transplantation on day 0.
3280483|NCT00622882|Active Comparator|ID|Patients receiving an early Infectious disease consultation ( within first 48 hours of a positive blood culture)
3280484|NCT00622882|No Intervention|NO ID|Includes those patients who do not receive an Infectious disease consultation in the first 48 hours
3280485|NCT00622869|Experimental|Everolimus + reduced tacrolimus|Low dose tacrolimus (tacrolimus reduced) + everolimus + corticosteroids.
3280486|NCT00622869|Experimental|Tacrolimus elimination|Low-dose tacrolimus (until Month 4, then tacrolimus eliminated) + everolimus + corticosteroids.
3280487|NCT00622869|Active Comparator|Tacrolimus control|Control dose tacrolimus + corticosteroids.
3280488|NCT00622856|Experimental|1|Psychological intervention for strengthening parental authority
3280489|NCT00622856|Active Comparator|2|Diabetes education- 5 sessions with diabetes nurse, taking place once a week
3280490|NCT00622856|No Intervention|3|Control group- regular treatment without any intervention
3280491|NCT00622843|Experimental|Group 1|PCV, 210 patients
3280492|NCT00622843|Active Comparator|Group 2|PPV, 110 patients
3280493|NCT00622843|Active Comparator|Group 3|PPV, HIV-negative, 25 patients
3280494|NCT00622817|Active Comparator|1|Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
3280495|NCT00622817|Experimental|2|Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
3280496|NCT00622804|Other|1|Billroth-II (B-II)reconstruction
3280497|NCT00622804|Other|2|Roux en Y gastrojejunostomy (RY-GJ)
3280498|NCT00622804|Other|3|uncut Roux en Y gastrojejunostomy (uncut RY-GJ)
3280499|NCT00622791||CABG group|Patients undergoing coronary artery bypass graft with cardiopulmonary bypass
3280500|NCT00622791||OPCAB group|Patients undergoing off-pump coronary artery bypass graft
3280501|NCT00622778||1|Patients from daily practice
3280502|NCT00622765|Experimental|001|R256918 5 mg capsule twice daily
3280503|NCT00622765|Experimental|002|R256918 10 mg capsule twice daily
3280504|NCT00622765|Experimental|003|R256918 15 mg capsule twice daily
3280505|NCT00622765|Placebo Comparator|004|placebo Placebo capsule twice daily
3280506|NCT00622752|Experimental|1|EVT 302, 10 mg
3280507|NCT00622752|Experimental|2|EVT 302, 10 mg + NRT patch, 21 mg
3280508|NCT00622752|Experimental|3|NRT patch, 21 mg
3280509|NCT00622752|Placebo Comparator|4|Placebo to match EVT 302 and placebo patch to match NRT patch
3280510|NCT00622739|Active Comparator|ziprasidone rapid dose|Rapid Dose Titration Group
3280511|NCT00622739|Active Comparator|ziprasidone slow dose|Slow Dose Titration Group
3280512|NCT00622726|Experimental|Bevacizumab for ROP|Intravitreal Bevacizumab Therapy is the Experimental Arm of this Study
3280513|NCT00622726|Active Comparator|Conventional Laser for ROP|Conventional Laser to the Peripheral Retina is the Control Arm of this Study
3280514|NCT00622700|Placebo Comparator|Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg|"Core treatment period: Placebo matched to teriflunomide tablet once daily orally.~Extension treatment period: Re-randomized in 1:1 ratio to either teriflunomide 7 mg or 14 mg once daily orally."
3280515|NCT00622700|Experimental|Teriflunomide 7 mg/7 mg|"Core treatment period: Teriflunomide 7 mg tablet once daily orally.~Extension treatment period: Teriflunomide 7 mg tablet once daily orally."
3280516|NCT00622700|Experimental|Teriflunomide 14 mg/14 mg|"Core treatment period: Teriflunomide 14 mg tablet once daily orally.~Extension treatment period: Teriflunomide 14 mg tablet once daily orally."
3280517|NCT00622687|Active Comparator|A|low dose iloprost therapy 0.5 ng/kg x min
3280518|NCT00622687|Active Comparator|B|high-dose therapy
3280519|NCT00622674|Experimental|Bortezomib and Cetuximab|The starting dose of bortezomib will be 1.3 mg/m2 with a 0.1 increment increase with each successive dose level to a maximum of 2.0 mg/m2. A loading dose of cetuximab will be given on day 1 (400 mg/m2) followed by a weekly dose of 250 mg/m2.
3280520|NCT00622661|Other|1|Normal weight
3280521|NCT00622661|Other|2|Overweight
3280522|NCT00622648|Experimental|A|Enoxaparin: 40 mg once daily for 6 to 14 days (10 ± 4 days)
3280523|NCT00622648|Placebo Comparator|B|Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
3280524|NCT00622635|Experimental|Indacaterol 300 μg - placebo to indacaterol - salmeterol 50 μg|In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3280525|NCT00622635|Experimental|Placebo to indacaterol - salmeterol 50 μg - indacaterol 300 μg|In treatment period 1, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); and in treatment period 3, patients received indacaterol 300 μg once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3280526|NCT00622635|Experimental|Salmeterol 50 μg - indacaterol 300 μg - placebo to indacaterol|In treatment period 1, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); in treatment period 2, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); and in treatment period 3, patients received placebo to indacaterol once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3280527|NCT00622635|Experimental|Placebo to indacaterol - indacaterol 300 μg - salmeterol 50 μg|In treatment period 1, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received indacaterol 300 μg once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3280528|NCT00622635|Experimental|Indacaterol 300 μg - salmeterol 50 μg - placebo to indacaterol|In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); and in treatment period 3, patients received placebo to indacaterol once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3280630|NCT00621829|Active Comparator|2|"Low susceptibility ALOX5 gene polymorphisms. Low susceptibility ALOX5 gene polymorphisms. Patients will be classified as having high susceptibility ALOX5 gene polymorphisms based on the number of repeats of the SP1 promoter."
3280529|NCT00622635|Experimental|Salmeterol 50 μg - placebo to indacaterol - indacaterol 300 μg|In treatment period 1, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); and in treatment period 3, patients received indacaterol 300 μg once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3280530|NCT00622622|Experimental|Phase I study|
3280531|NCT00622609|Experimental|Subjects receiving GSK249320A|Eligible subjects will receive escalating doses of GSK249320A in cohort 1 to 6 with a starting dose of 0.04 milligrams/kilograms up to the maximum dose of 25 milligrams/kilograms, administered as a slow intravenous infusion over 1 hour on Day 1.
3280532|NCT00622609|Placebo Comparator|Subjects receiving placebo|Eligible subjects will receive single dose of sodium chloride in cohort 1 to 6, administered as a slow intravenous infusion over 1 hour on Day 1.
3280533|NCT00622596|Experimental|Mobile Access to Buprenorphine|High risk populations accessing a mobile health care system can obtain Buprenorphine for treatment.
3280534|NCT00622583||Observation Group|Subjects who meet the inclusion/exclusion criteria who have had a hernia repair.
3280535|NCT00622570|Experimental|1|Pentobarbital
3280536|NCT00622570|Active Comparator|2|thiopental
3280537|NCT00622557||Surgical|
3280538|NCT00622531||BNP Open|Subjects treated based on clinical assessment and knowledge of BNP values
3280539|NCT00622531||Control|Subjects treated based on clinical assessment alone
3280540|NCT00622518|Active Comparator|1|homeopathic ear drops in addition to standard care for otitis media
3280541|NCT00622518|No Intervention|2|No ear drops, standard care for otitis
3280542|NCT00622505|Experimental|zoldronic acid|
3280543|NCT00622492||VV-ECMO|newborn infants with reversible causes of PPHN eligible for ECMO treatment
3280544|NCT00622492||VA-ECMO|newborn infants with reversible causes of PPHN eligible for ECMO treatment
3280545|NCT00622479|Experimental|Arm 1|
3280546|NCT00622466|Experimental|Sorfenib + Paclitaxel|Oral sorafenib tosylate twice daily on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15
3280547|NCT00622453||Registry of Arrhythmias|Screening of individuals with myotonic muscular dystrophy to evaluate the utility of non-invasive electrocardiographic screening methods and history in predicting serious arrhythmic events.
3280548|NCT00622440|Active Comparator|1|
3280549|NCT00622440|Placebo Comparator|2|
3280550|NCT00622427|Experimental|Ramelteon then placebo|8 mg tablets every night for 2 weeks, then a 2 week washout,then crossover to placebo tablets for 2 weeks.
3280551|NCT00622427|Experimental|Placebo then Ramelteon|placebo tablets for every night for 2 weeks, then a 2 week washout, followed by 8 mg tablets every night for 2 weeks.
3280552|NCT00622414|Experimental|Treatment (ziv-aflibercept)|"PART 1: Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days for 2 years in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive aflibercept until the maximum tolerated dose (MTD) is determined.~PART 2: Patients receive aflibercept as in part 1 at 150% of the MTD determined in part 1. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity."
3280553|NCT00622401|Experimental|Group 1|Dendritic Cell/Tumor Fusion Vaccine Only
3280554|NCT00622401|Experimental|Group 2|Dendritic Cell/tumor fusion vaccine and low dose IL-12
3280555|NCT00622401|Experimental|Group 3|Dendritic Cell/tumor fusion vaccine and higher dose IL-12
3280556|NCT00622388|Experimental|Ofatumumab|8 weekly intra-venous (I.V.) infusions, 1 x 300mg and 7 x 1000mg
3280557|NCT00622375|Experimental|1|
3280558|NCT00622362|Active Comparator|A|Subcutaneous administration
3280559|NCT00622362|Experimental|B|Sublingual administration
3280560|NCT00622362|Placebo Comparator|C|Sublingual administration
3280561|NCT00622349|Experimental|A|
3280562|NCT00622349|Active Comparator|B|
3280563|NCT00622349|Experimental|C|
3280564|NCT00622336|Experimental|Lenalidomide 25mg (CC-5013)|Oral 25mg daily on Days 1-21 every 28 days
3280565|NCT00622310|Experimental|1 Exercise|Subjects in the EX group will perform supervised exercise 5 d/wk. Exercise will consist primarily of walking on an inclined motor-driven treadmill, but alternate activities will be permitted for 20% of the total exercise sessions (1 of 5 days). Exercise sessions will be preceded by a 5 min warm-up performed at a HR corresponding to 40% of VO2max. The initial exercise duration and intensity at baseline will be 20 minutes at an intensity that elicits a heart rate (HR) corresponding to 60% of VO2max. The target EE will be achieved by a gradual progression of exercise duration and intensity over the first 8 weeks of the exercise program. The target exercise intensity will be the workload corresponding to 75% of VO2max.
3280566|NCT00622310|Experimental|2 Walk|Subjects in the WALK group will also perform exercise 5 d/wk. Exercise will consist exclusively of walking on level grades, and will be prescribed in two equal duration bouts each day. Subjects in the WALK group will be individually prescribed a walking program based on the EE during moderate intensity walking. The target exercise intensity will be walking speeds corresponding 45% of VO2max.
3280567|NCT00622284|Experimental|BI 1356 5mg, once daily|patient to receive a tablet containing 5mg BI 1356 plus one (two in US) inactive placebo capsule matching Glimepiride
3280568|NCT00622284|Active Comparator|Glimepiride|patient to receive 1mg or 2mg or 3mg (not in US) or 4mg Glimepiride capsule plus one inactive placebo tablet matching BI 1356 (plus one inactive placebo capsule in US)
3280569|NCT00622271|Other|Wait List Control|Patients and their families will be enrolled into either a treatment group or a wait list control (WLC) group to receive the group therapy intervention.
3280570|NCT00622258|Experimental|Everolimus|
3280571|NCT00622245|Experimental|Lu AA34893: 4 mg|
3280572|NCT00622245|Experimental|Lu AA34893: 12 mg|
3280573|NCT00622245|Experimental|Lu AA34893: 18 mg|
3280574|NCT00622245|Other|Quetiapine fumarate|Active reference 300 mg
3280575|NCT00622245|Placebo Comparator|Placebo|
3280576|NCT00622219|Experimental|Drug Testing|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
3280577|NCT00622219|No Intervention|Control|Adolescents randomized to the control condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated) but will not be called for drug tests.
3280578|NCT00622206|Active Comparator|1|Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
3280579|NCT00622193|Experimental|1 Active 50 mg|
3280580|NCT00622193|Experimental|2 Active 100 mg|
3280581|NCT00622193|Placebo Comparator|3 Placebo|
3280582|NCT00622180|Active Comparator|1|Right hand treated with narrow-band UVB light and left hand treated with focal 308-nm light
3280583|NCT00622180|Active Comparator|2|Right hand treated with focal 308-nm light and left hand treated with narrow-band UVB light
3280584|NCT00622167|Other|1|All patients will receive integrated backscatter IVUS and dual source CT.
3280585|NCT00622141|Active Comparator|A|Day 1: receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg 7-day washout period will follow. Day 8: take generic GPO squinavir/Norvir
3280586|NCT00622141|Active Comparator|B|Day 1: take generic GPO squinavir/Norvir 7-day washout period will follow. Day 8: receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg
3280587|NCT00622128|Experimental|1|Pilot study. Developing intervention
3280588|NCT00622115|Experimental|A|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 4 hours following the last injection of enoxaparin
3280589|NCT00622115|Experimental|B|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 6 hours following the last injection of enoxaparin
3280590|NCT00622115|Experimental|C|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 10 hours following the last injection of enoxaparin
3280591|NCT00622102|Experimental|1|50% of the consenting subjects will take part in the lottery and use the Med-eMonitor as a device to monitor adherence
3280592|NCT00622102|Other|2|50% of the consenting subjects will use only the Med-eMonitor as a device to monitor adherence
3280593|NCT00622089|Experimental|1|150mg DIO-902 + 10mg Atorvastatin
3280594|NCT00622089|Experimental|2.|300mg DIO-902 + 10mg Atorvastatin
3280595|NCT00622089|Experimental|3|450mg DIO-902 + 10mg Atorvastatin
3280596|NCT00622076|Active Comparator|1|postoperative catheterization after anterior colporrhaphy during five days.
3280597|NCT00622076|Active Comparator|2.|postoperative catheterization after anterior colporrhaphy during two days
3280598|NCT00622050|Experimental|1|This arm will be experiencing the same protocol as the control group, only their TV viewing time will be reduced. The TV viewing time reduction is the experimental intervention.
3280599|NCT00622050|Active Comparator|Control|The control group will be experiencing the exact protocol; only their TV viewing time will not be reduced.
3280600|NCT00622037|Active Comparator|1|PEG-400 based artificial tear
3280601|NCT00622037|Active Comparator|2|Systane
3280602|NCT00622011|Experimental|1|zolpidem , start from 50mg/day then titrate according to individual case
3280603|NCT00622011|Active Comparator|2|Risperidone, start from 1mg/day
3280604|NCT00621998|Experimental|1|Flexible dose of olanzapine
3280605|NCT00621998|Active Comparator|2|Flexible dose of risperidone
3280606|NCT00621985|Experimental|Experimental|Experimental therapy with nocturnal dexamethasone.
3280607|NCT00621972||Observation|Chronic kidney disease patients presenting for fisulta evaluation with documented GFR<30ml/min by abbreviated MDRD calculation.
3280608|NCT00621959|Placebo Comparator|Placebo|Matched placebo tablets once daily
3280609|NCT00621959|Experimental|LCTZ|5 mg levocetirizine dihydrochloride tablet
3280610|NCT00621946|Placebo Comparator|Placebo|Placebo Matching Escitalopram given orally daily (for a 12-week duration).
3280611|NCT00621946|Active Comparator|Escitalopram|Once daily oral administration (for a 12-week duration) of 10 mg escitalopram tablets with an increase to 20 mg in those with a less than 30% decrease in HAM-D scores at week 4.
3280612|NCT00621933||All Patients Receiving Cataract Surgery|All Patients Receiving Cataract Surgery
3280613|NCT00621907|Experimental|1|patient who received levobupivacaïne
3280614|NCT00621907|Placebo Comparator|2|patient who received placebo
3280615|NCT00621894|Experimental|LGD4665|LGD-4665: Experimental Thrombopoietin mimetic
3280616|NCT00621894|Placebo Comparator|Placebo|Placebo
3280617|NCT00621881|Experimental|1|750 mg naproxcinod
3280618|NCT00621868|Experimental|1|Lowest dose
3280619|NCT00621868|Experimental|2|Low-middle dose
3280620|NCT00621868|Experimental|3|High-middle dose
3280621|NCT00621868|Experimental|4|Highest dose
3280622|NCT00621868|Placebo Comparator|5|placebo
3280623|NCT00621855|Experimental|Dabigatran etexilate 50mg|twice daily dosing,
3280624|NCT00621855|Experimental|Dabigatran etexilate 75mg|twice daily dosing, patients with moderate renal impairment allocated 50mg bid
3280625|NCT00621855|Experimental|Dabigatran etexilate 110mg|twice daily dosing, patients with moderate renal impairment allocated 75mg bid
3280626|NCT00621855|Experimental|dabigatran etexilate 150mg|twice daily dosing, patients with moderate renal impairment allocated 110mg bid
3280627|NCT00621855|Placebo Comparator|placebo|matched placebo
3280628|NCT00621842|Experimental|Open-Label Lamotrigine Treatment|
3280629|NCT00621829|Active Comparator|1|"High susceptibility ALOX5 gene polymorphisms. Patients will be classified as having high susceptibility ALOX5 gene polymorphisms based on the number of repeats of the SP1 promoter."
3280631|NCT00621816|Active Comparator|1|Blinded nitroprusside infusion
3280632|NCT00621816|Placebo Comparator|2|Blinded placebo infusion
3280633|NCT00621790|Experimental|Fenoldopam|Fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min) for up to 4 days
3280634|NCT00621790|Placebo Comparator|Placebo|Placebo (normosaline), continuous perfusion
3280635|NCT00621777|Active Comparator|Randomized Phase: Varenicline|Varenicline is a partial agonist at alpha4beta2 nicotinic acetylcholine receptors (nAChRs) and a full agonist at alpha 7 nAChRs that has been shown to be effective for smoking cessation compared with placebo and bupropion, with effects on abstinence rates for up to one year. Varenicline has demonstrated safety when dosed at 1 mg twice per day for up to one year. Because varenicline, at a dose of 1 mg twice per day, may be a more effective treatment for sustained abstinence than bupropion, it was chosen as the medication intervention for this study.
3280636|NCT00621777|Placebo Comparator|Randomized Phase: Placebo|
3280637|NCT00621764|Experimental|JE-CV/Hepatitis A (Group 1)|Participants aged 2 to 5 years at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
3280638|NCT00621764|Experimental|Hepatitis A/JE-CV (Group 2)|Participants aged 2 to 5 years at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)
3280639|NCT00621764|Experimental|JE-CV/Hepatitis A (Group 3)|Participants aged 12 to 24 months at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
3280640|NCT00621764|Experimental|Hepatitis A/JE-CV (Group 4)|Participants aged 12 to 24 months at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)
3280641|NCT00621751|Experimental|A|Carbamazepine 800 mg daily
3280642|NCT00621751|Placebo Comparator|B|Placebo
3280643|NCT00621725|Experimental|1|
3280644|NCT00621712|Active Comparator|A|Patients in group A will be provided with a commercially available and CE certified standard double lumen catheter without surface coating (GamCath® catheter, No. CE 76891).
3280645|NCT00621712|Experimental|B|Patients in group B will be treated with a CE certified double lumen catheter with a new antibacterial bismuth-containing surface coating (GamCath Dolphin® Protect, No. CE 90671).
3280646|NCT00621699|Experimental|C|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg tacrolimus)
3280647|NCT00621699|Active Comparator|A|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe)
3280648|NCT00621699|Active Comparator|B|administration of 1 capsule Prograf(R) (5 mg tacrolimus)
3280649|NCT00621686|Experimental|Sorafenib + Bevacizumab/Group A|"Patients receive oral sorafenib 400 mg (200 mg twice daily) days 1-5 and 8-12 and 5 mg/kg bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days.~Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies.~Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment.~After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years."
3280650|NCT00621686|Experimental|Sorafenib + Bevacizumab /Group B|"Patients receive oral sorafenib 200 mg once daily on days 1-14 and 5 mg/kg bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days.~Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies.~Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment.~After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years."
3280651|NCT00621673|Other|Arm 1|
3280652|NCT00621660|Experimental|Acupuncture|
3280653|NCT00621660|Placebo Comparator|Sham|
3280654|NCT00621647|Experimental|1|1st fixed dose
3280655|NCT00621647|Experimental|2|2nd fixed dose
3280656|NCT00621647|Sham Comparator|3|Placebo
3280657|NCT00621634|Experimental|1|Active treatment with omega-3 fish oil capsules (1 g each capsule, 50% DHA), 6 capsules each day for 12 weeks
3280658|NCT00621634|Placebo Comparator|2|Matching placebo treatment
3280659|NCT00621621|Experimental|Freezor Catheter for AVNRT|Subjects with Atrio Ventricular Reentrant Tachycardia (AVNRT)will be treated with cryo (freezing) energy to ablate the slow pathway causing the arrythmia.
3280660|NCT00621621|Other|External Data Supporting the Study|This arm was taken from pier reviewed published reports that include adult subjects ablated with the Freezor catheter for AVNRT.
3280661|NCT00621608|Experimental|1|Hyperbaric Oxygen Therapy
3280662|NCT00621608|Sham Comparator|2|Placebo Hyperbaric Oxygen Chamber
3280663|NCT00621595|Active Comparator|1|Fasting
3280664|NCT00621569|Active Comparator|1|Group intervention with no dietary focus
3280665|NCT00621569|Experimental|2|DASH diet intervention
3280666|NCT00621556|Experimental|1|Drug + MR with MRCP
3280667|NCT00621543|Experimental|Observation- All subjects|Women choosing intra-uterine contraception after medical abortion.
3280668|NCT00621530|Experimental|Ketorolac|ketorolac 2 mg ketorolac tromethamine opthalmic solution
3280669|NCT00621530|Placebo Comparator|Placebo|placebo will be added to the patient's routine spinal anesthetic for surgery
3280670|NCT00621517|Experimental|1|Participants will receive 150MG Bupropion nightly.
3280671|NCT00621517|Placebo Comparator|2|Participants will receive matching placebo capsule nightly.
3280672|NCT00621504|Experimental|Ceftaroline fosamil for Injection|"Ceftaroline fosamil was administered in two consecutive 300-mg IV infusions over 30 minutes, every 12 hours (q12h).~In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism."
3280704|NCT00621270|Experimental|2|BCI-540 80 mg three times a day (t.i.d.)
3280705|NCT00621270|Placebo Comparator|3|Placebo
3280706|NCT00621257|Active Comparator|Treatment A|2,000 IU/day of ergocalciferol orally for 6 weeks (control arm)
3280673|NCT00621504|Active Comparator|IV Ceftriaxone|"Ceftriaxone was administered as a 1-g IV infusion over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h).~In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism."
3280674|NCT00621491|Placebo Comparator|1|Single daily dose of Placebo during six months
3280675|NCT00621478|Active Comparator|Cohort 1|"Cohort 1 (preconsented) patients will involve obtaining informed consent from the legally authorized representative of a potential study subject before they present to the ED in SE. Patient assent will be obtained for patients as per local IRB rules. The consent document (enclosed in this application) will inform parents that if their child comes to the ED and qualifies for the study based on study inclusion/exclusion criteria, they will be enrolled.~Patients who cannot be contacted to confirm consent will be enrolled in Cohort 2 (EFIC) as detailed below.~Patients in Cohort 1 will be randomized in a blinded fashion to either lorazepam 0.1 mg/kg or diazepam 0.2 mg/kg"
3280676|NCT00621478|Active Comparator|Cohort 2|"Cohort 2 (EFIC) will include patients who appear in the ED with SE and qualify for the study but have not given prior consent. These patients will be enrolled under the EFIC regulations. The parent/guardian will be given the opportunity to object to participation or ask additional questions.~The child will be enrolled (dosed) with study medication under an EFIC. Once the child is stabilized, a research staff member will approach the parent or LAR to obtain informed consent to continue the child's participation in the study. If a parent or LAR refuses continued participation, then no further study procedures will be performed. Safety and data will be collected in accordance with federal regulations.~Cohort 2 will be randomized, like Cohort 1, to either lorazepam 0.1 mg/kg or diazepam 0.2 mg/kg"
3280677|NCT00621465|Active Comparator|1|Participants will receive standard aftercare and community care services.
3280678|NCT00621465|Experimental|2|Participants will receive usual care and the Critical Time Intervention.
3280679|NCT00621452|Experimental|Treatment (autologous CD20 specific T-cells)|"CHEMOTHERAPY: Patients receive cyclophosphamide IV over 60 minutes.~IMMUNOTHERAPY: Beginning 2 days after completion of cyclophosphamide, patients receive autologous CD20-specific T-cells IV over 30 minutes. Treatment repeats every 2-5 days for 3 courses.~MAINTENANCE THERAPY: Beginning 2 hours after the last T-cell infusion, patients receive low-dose aldesleukin subcutaneously twice daily for 14 days.~Subjects who have achieved at least a partial remission lasting a minimum of 6 months may, on a case-by-case basis, receive additional stored T cells following relapse."
3280680|NCT00621439|Experimental|I|Receives 1 dose of Pegylated Interferon
3280681|NCT00621439|Placebo Comparator|II|Receives placebo
3280682|NCT00621426||Observation|Patients with end-stage renal disease (ESRD) treated with hemodialysis three (3) times per week for at least 3 continuous months
3280683|NCT00621387|Experimental|1|ofloxacin and roxithromycin
3280684|NCT00621387|Placebo Comparator|2|placebo
3280685|NCT00621374|Experimental|Random Order 1|Randomization Order 1= 1)CONT, 2)CBT, 3)HYP, 4) CBT-HYP
3280686|NCT00621374|Experimental|Random Order 2|Randomization order 2= 1)CONT, 2)HYP, 3)CBT, 4) CBT-HYP
3280687|NCT00621361|Experimental|1|
3280688|NCT00621361|Active Comparator|2|Etoposide + Cisplatin
3280689|NCT00621348|Active Comparator|Isotonic fluid group|Normal saline in 5% dextrose at standard maintenance rate
3280690|NCT00621348|Active Comparator|Fluid restriction group|Reduced volume (2/3 maintenance rate) of N/5 saline in 5% dextrose
3280691|NCT00621348|Active Comparator|Hypotonic fluid group|N/5 saline in 5% dextrose at standard maintenance rate
3280692|NCT00621322|Placebo Comparator|Control Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the control GSK Biologicals' AS01B adjuvanted system, at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
3280693|NCT00621322|Active Comparator|GSK692342_F1 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the non-adjuvanted GSK692342 vaccine formulation 1 (F1), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
3280694|NCT00621322|Experimental|GSK692342_F2 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 2 (F2), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
3280695|NCT00621322|Experimental|GSK692342_F3 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 3, at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
3280696|NCT00621322|Experimental|GSK692342_F4D1 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 4 dosage 1 (F4D1), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
3280697|NCT00621322|Experimental|GSK692342_F4D2 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 4 dosage 2 (F4D2), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
3280698|NCT00621309|Active Comparator|1|Subjects are given 300 mg / 7 days of rifampicin to induce CYP3A4. Midazolam clearance is measured on the 8th day.
3280699|NCT00621309|Active Comparator|2|Sulforaphane (SFN), a natural product derived from broccoli sprouts, is utilized as a putative inhibitor of ligand (Rifampin) activation of the Pregnane X-receptor. In this arm, both SFN (putative inhibitor of ligand binding to PXR) and Rifampin (strong activating ligand of PXR) are given together.
3280700|NCT00621309|Active Comparator|3|This arm involves the administration of Sulforaphane (SFN) alone, in the absence of the PXR ligand, rifampicin. The hypothesis is that SFN will have no effect on the expression of PXR-regulated genes. Alternatively, it is possible that SFN could inhibit as yet unidentified endogenous ligands to the PXR receptor, thereby causing down-regulations of genes regulated wholely or in part by PXR. SFN is administered as a broccoli sprout extract at a dose rate of 75 mg (~420 umoles) per day for 7 days.
3280701|NCT00621296|Experimental|MP-424|
3280702|NCT00621283|Experimental|1|Drug + MR with MRCP
3280703|NCT00621270|Experimental|1|BCI-540 80 mg once a day (q.d.)
3280707|NCT00621257|Experimental|Treatment B|2,000 IU/day of cholecalciferol orally for 6 weeks
3280708|NCT00621257|Experimental|Treatment C|50,000 IU of ergocalciferol once a week orally for 6 weeks
3280709|NCT00621257|Active Comparator|Maintenance A|400 IU/day of ergocalciferol orally over 2 years (control arm)
3280710|NCT00621257|Experimental|Maintenance B|2,000 IU/day of ergocalciferol orally from November 1 to April 30, and 1,000 IU/day of ergocalciferol orally for the remainder of the year over 2 years
3280711|NCT00621244|Experimental|Arm 1, Group X|
3280712|NCT00621244|Experimental|Arm 1, Group Y|
3280713|NCT00621244|Experimental|Arm 2, Group X|
3280714|NCT00621244|Experimental|Arm 2, Group Y|Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week, as part of a 28-day treatment cycle. Group Y is a sub-arm, based on disease indication.
3280715|NCT00621231|Placebo Comparator|1|
3280716|NCT00621231|Experimental|2|
3280717|NCT00621218|Active Comparator|1|
3280718|NCT00621218|Placebo Comparator|2|
3280719|NCT00621192|Experimental|Meropenem|"These~Participants were subdivided into the following four groups based on Gestational Age (GA) and Postnatal Age (PNA):~Group 1: GA at birth below 32 weeks - PNA <2 weeks; Group 2: GA at birth below 32 weeks - PNA ≥2 weeks and <91 days; Group 3: GA at birth 32 weeks or older - PNA <2 weeks; Group 4: GA at birth 32 weeks or older - PNA ≥2 weeks and <91 days."
3280720|NCT00621179|Active Comparator|Group 1|Positive endometrial alpha v, beta 3 vitronectin expression. Standard controlled ovarian stimulation protocol
3280721|NCT00621179|Experimental|Group 2|Intervention: Positive endometrial alpha v beta 3 vitronectin expression, 3 months of leuprolide acetate in depot suspension administration prior to initiation of controlled ovarian stimulation
3280722|NCT00621179|Experimental|Group 3|Negative endometrial alpha v, beta 3 vitronectin and administration of leuprolide acetate in depot suspension for 3 months prior to initiation of controlled ovarian stimulation
3280723|NCT00621179|Active Comparator|Group 4|Negative endometrial alpha v, beta 3 vitronectin expression and standard controlled ovarian stimulation protocol.
3280724|NCT00621166|Active Comparator|1|generic lopinavir/ritonavir
3280725|NCT00621153|Active Comparator|1|Candesartan cilexetil 16mg monotherapy
3280726|NCT00621153|Experimental|2|Candesartan cilexetil 16mg/HCT combination therapy
3280727|NCT00621153|Active Comparator|3|candesartan cilexetil 32mg monotherapy
3280728|NCT00621153|Experimental|4|Candesartan Cilexetil 32 mg/HCT combination therapy
3280729|NCT00621140|Experimental|linagliptin 5 mg|linagliptin 5 mg once daily
3280730|NCT00621140|Placebo Comparator|placebo|placebo matching linagliptin 5 mg tablets
3280731|NCT00621114|Active Comparator|1|Patients in group 1 will be provided with a commercially available and CE certified standard double lumen catheter without surface coating (GamCath® catheter, No. CE 76891).
3280732|NCT00621114|Experimental|2|Patients in group 2 will be treated with a CE certified double lumen catheter with a new antibacterial bismuth-containing surface coating (GamCath Dolphin® Protect, No. CE 90671).
3280733|NCT00621101|Active Comparator|A|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe)
3280734|NCT00621101|Active Comparator|B|administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus)
3280735|NCT00621101|Experimental|C|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus)
3280736|NCT00621088|Active Comparator|Intertan|
3280737|NCT00621075||1|Pulmonary Arterial Hypertension
3280738|NCT00621062|Active Comparator|High Ligation of the GSV|
3280739|NCT00621062|Active Comparator|Endovenous Laser Ablation|
3280740|NCT00621062|Active Comparator|Radiofrequency ablation|
3280741|NCT00621062|Active Comparator|Foam Sclerotherapy|
3280742|NCT00621049|Experimental|Docetaxel/Carboplatin/Bevacizumab/Erlotinib|
3280743|NCT00621049|Active Comparator|Docetaxel and Carboplatin|
3280744|NCT00621023|Experimental|1|Drug: Decitabine, Arsenic Trioxide and Ascorbic Acid for MDS
3280745|NCT00621010|Experimental|Cohort|
3280746|NCT00620997|Experimental|1|"patients randomized to 0.05% Proparacaine drops on a PRN basis for up to 7 days~Acetaminophen with Codeine for breakthrough pain~topical Gatifloxacin drops"
3280747|NCT00620997|Placebo Comparator|2|"placebo drops on a PRN basis for up to 7 days post injury~Acetaminophen with Codeine for breakthrough pain~Gatifloxacin drops"
3280748|NCT00620971|Experimental|1|NC/Avastin->DG/Avastin
3280749|NCT00620971|Experimental|2|DG/Avastin
3280750|NCT00620958|Experimental|1|Participants will receive individual cognitive behavioral therapy with parent reinforcement training.
3280751|NCT00620958|Experimental|2|Participants will receive individual cognitive behavioral therapy with parent relationship training.
3280752|NCT00620958|Active Comparator|3|Participants will receive individual cognitive behavioral therapy alone.
3280753|NCT00620945|Experimental|1|Treatment Group
3280754|NCT00620932|No Intervention|Control Group|These patients will continue with whatever routine exercise they already engage in.
3280755|NCT00620932|Experimental|Exercise Arm|These patients will participate in a controlled, supervised exercise program.
3280756|NCT00620919|Experimental|1|Drug + MDCT
3280757|NCT00620906|Other|A|Manipulation
3280758|NCT00620893|Active Comparator|1|1. PEG-400 based artificial tear
3280759|NCT00620893|Active Comparator|2|2. Systane
3280760|NCT00620867|Experimental|Ibuprofen|
3280761|NCT00620867|Experimental|Celecoxib|
3280762|NCT00620867|Placebo Comparator|placebo|
3280763|NCT00620854|Experimental|rsCTA|Oral Tablet
3280764|NCT00620854|Experimental|rsCTB|Oral Tablet
3280765|NCT00620854|Active Comparator|Fortical|Nasal Spray
3280766|NCT00620841||A|Patients treated with tacrolimus and experiencing a drug interaction
3280767|NCT00620828|Placebo Comparator|Block Negative|Subjects receive intra-op saline injection per protocol
3280768|NCT00620828|Experimental|Block Positive|Subjects receive intra-op Ropivicaine 0.5% injection per protocol
3280769|NCT00620815|Experimental|T/P-A|One dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Aflunov (A) on day 22
3280770|NCT00620815|Experimental|A/P-T|One dose of the Aflunov (A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Tetravalent influenza vaccine (T) on day 22.
3280771|NCT00620815|Active Comparator|A/S-A|One dose of Aflunov (A) and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed Aflunov (A) on day 22.
3280772|NCT00620815|Experimental|T/P-A (V2 blood draw)|One dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by a blood draw at visit 2 (V2) prior to Aflunov (A) vaccination on day 22.
3280773|NCT00620815|Experimental|A/P-T (V2 blood draw)|One dose of the Aflunov(A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by additional blood draw at visit 2 (V2) prior to the Tetravalent influenza vaccination (T) on day 22.
3280774|NCT00620815|Active Comparator|A/S-A (V2 blood draw)|One dose of Aflunov (A)and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed by an additional blood draw at visit 2 (V2) prior to Aflunov (A) vaccination on day 22.
3280775|NCT00620802|Experimental|A|CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg)
3280776|NCT00620802|Active Comparator|B|Plavix (clopidogrel 75 mg)
3280777|NCT00620789|Active Comparator|1|Cognitive-Behavior Therapy for insomnia (CBT-I) + Antidepressant medication
3280778|NCT00620789|Placebo Comparator|2|Cognitive Behavior Therapy for Insomnia (CBT-I) + placebo medication
3280779|NCT00620789|Sham Comparator|3|Antidepressant medication + Sleep Hygiene Control (SH)
3280780|NCT00620776|Experimental|Combined Treatment|Patients who receive combined cognitive behavioral therapy (CBT) plus medication (venlafaxine XR, flexibly dosed between 75-225 mg/day) treatment for GAD. CBT was once/week sessions for 12 weeks. Medication continued for the full 6 months.
3280781|NCT00620776|Active Comparator|Venlafaxine XR 75-225 mg alone|These patients receive only medication treatment for GAD. Patients take venlafaxine (flexibly dosed from 75-225 mg/day) as part of NCT00183274 and are assessed over a 6 month period. Medication continued for the full 6 months.
3280782|NCT00620763|Experimental|A|Dietary Intervention: High meat and high acid load diet followed by low meat and low acid load diet
3280783|NCT00620763|Experimental|B|Dietary Intervention: Low meat and low acid load diet followed by high meat and high acid load diet
3280784|NCT00620750|Experimental|Extended release injectable naltrexone|
3280785|NCT00620737|Experimental|Active Arm|Active Treatment
3280786|NCT00620737|Placebo Comparator|Control Arm|Placebo treatment
3280787|NCT00620724|Placebo Comparator|A|Placebo three times daily
3280788|NCT00620724|Experimental|B|20 mg of slow-release Nifedipine three times daily
3280789|NCT00620711|Experimental|1|Babies that meet criteria will be offered participation in feasibility trial, there are no other arms.
3280790|NCT00620698||ALS patients|Patients with clinically established amyotrophic lateral sclerosis
3280791|NCT00620685|Placebo Comparator|1|
3280792|NCT00620685|Experimental|2|
3280793|NCT00620685|Experimental|3|
3280794|NCT00620672|Other|1|The dietary supplement is 400 mg/day of the omega 3 fatty acid docosahexaenoic acid . The docosahexaenoic acid is provided in triglycerides from Martek Biosciences, Maryland. The supplement is a blend of soybean and canola oil, blended to resemble the usual fat composition of the diet. Both the supplement and placebo provide a total of about 10 calories per day to the diet.
3280795|NCT00620672|Other|2|Dietary supplement is vegetable oil, the placebo.
3280796|NCT00620659|Experimental|1|Arm 1: Treatment period 1: MK0249; Treatment period 2: Placebo; Treatment period 3: modafinil
3280797|NCT00620659|Experimental|2|Arm 2: Treatment period 1: Placebo; Treatment period 2: modafinil; Treatment period 3: MK0249
3280798|NCT00620659|Experimental|3|Arm 3: Treatment period 1: modafinil; Treatment period 2: MK0249; Treatment period 3: Placebo
3280799|NCT00620659|Experimental|4|Arm 4: Treatment period 1: MK0249; Treatment period 2: modafinil; Treatment period 3: Placebo
3280800|NCT00620659|Experimental|5|Arm 5: Treatment period 1: Placebo; Treatment period 2: MK0249; Treatment period 3: modafinil
3280801|NCT00620659|Experimental|6|Arm 6: Treatment period 1: modafinil; Treatment period 2: Placebo; Treatment period 3: MK0249
3280802|NCT00620646|Experimental|A|Aspirin plus increasing clopidogrel group
3280803|NCT00620646|Experimental|B|Aspirin, clopidogrel plus cilostazol group
3280804|NCT00620633|Experimental|1|Patients with leukemia or myelodysplastic syndrome (MDS) who, following an HLA-matched allogeneic hematopoietic cell transplant, have relapsed with leukemia as demonstrated morphologically on peripheral blood smear or bone marrow aspirate
3280805|NCT00620620|Placebo Comparator|Inhaled Placebo|Staccato Placebo
3280806|NCT00620620|Experimental|Inhaled Zaleplon 0.5 mg|Staccato Zaleplon 0.5 mg
3280807|NCT00620620|Experimental|Inhaled Zaleplon 1 mg|Staccato Zaleplon 1 mg
3280808|NCT00620620|Experimental|Inhaled Zaleplon 2 mg|Staccato Zaleplon 2 mg
3280809|NCT00620620|Experimental|Inhaled Zaleplon 4 mg|Staccato Zaleplon 4 mg
3280810|NCT00620594|Experimental|BEZ235 Alone, Dose Escalation|
3280811|NCT00620594|Experimental|BEZ235 + trastuzumab, Dose Escalation|
3280812|NCT00620594|Experimental|BEZ235 Alone, MTD Expansion|
3280813|NCT00620594|Experimental|BEZ235 + Trastuzumab, MTD Expansion|
3280814|NCT00620581|Placebo Comparator|Paroxetine 10mg;paroxetine 20mg; Placebo|
3280815|NCT00620568|Experimental|1|
3280816|NCT00620568|Experimental|2|
3280817|NCT00620568|Experimental|3|
3280818|NCT00620568|Experimental|4|
3280819|NCT00620555|Experimental|gabapentin|
3280820|NCT00620542|Experimental|Rosuvastatin 20 mg|Rosuvastatin 20 mg distributed in 2-week run-in period
3280821|NCT00620542|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg distributed in 2-week run-in period
3280822|NCT00620542|Experimental|Rosuvastatin 40 mg|Rosuvastatin 40 mg distributed in core 2-year study
3280823|NCT00620542|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg distributed in core 2-year study
3280824|NCT00620529|Experimental|1|20/50 fish oil, 1000mg capsules, Ocean Nutrition 2050,4g/day.
3280825|NCT00620529|Placebo Comparator|2|olive oil capsules
3280826|NCT00620503|Experimental|A|Proellex 25 mg formulation A
3280827|NCT00620503|Experimental|B|Proellex 25 mg formulation B
3280828|NCT00620503|Experimental|C|Proellex 25 mg formulation B
3280829|NCT00620490|Experimental|1|Ropivacaine 0.5% 0.1 ml/kg per hour
3280830|NCT00620490|Placebo Comparator|2|
3280831|NCT00620477|Experimental|1|injection in the knee joint with 20 ml of chirocaine 0.125%
3280832|NCT00620477|Placebo Comparator|2|injection in the knee joint with 20 ml of physiological fluid
3280833|NCT00620464|Active Comparator|Radiopaque Implanon (ro imp)|The radiopaque rod (Radiopaque Implanon) is similar to the Implanon rod except for the addition of barium sulfate.
3280834|NCT00620464|Active Comparator|Implanon (imp)|"Implanon® (Org 32222) is a single rod contraceptive implant of 4 cm length and~2 mm in diameter. Implanon® contains approximately 68 mg etonogestrel (ENG) (Org 3236, 3-ketodesogestrel) dispersed in a matrix of ethylene vinyl acetate (EVA)copolymer, surrounded by an EVA membrane.~The ENG dose released by Implanon® amounts to about 60-70 μg/day shortly after~insertion and decreases to about 40 μg/day at the start of the second year, and to about 25-30 μg/day at the end of the third year."
3280835|NCT00620451|Experimental|Larazotide acetate 4 mg|larazotide acetate capsules 4 mg TID
3280836|NCT00620451|Experimental|Larazotide acetate 8 mg|Larazotide acetate capsules 8 mg TID
3280837|NCT00620451|Placebo Comparator|Placebo|Placebo capsules
3280838|NCT00620438|Experimental|1|nevirapine arm
3280839|NCT00620438|Experimental|2|efavirenz arm
3280840|NCT00620438|Experimental|3|Rifampicin arm
3280841|NCT00620412|Active Comparator|treatment|
3280842|NCT00620412|Placebo Comparator|placebo|
3280843|NCT00620399|Experimental|1|brace
3280844|NCT00620399|Placebo Comparator|2|no brace
3280845|NCT00620386|Experimental|1|Intubation with Bonfils intubating fiberscope
3280846|NCT00620386|Active Comparator|2|Intubation with Macintosh laryngoscopy
3280847|NCT00620373|Experimental|Mammography and Molecular Breast Imaging|Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (20-mCi) Technetium (99mTc) sestamibi injection.
3280848|NCT00620360|Experimental|fructose|acute fructose administration
3280849|NCT00620347|Experimental|Single arm|Single arm (sunitinib arm) until PD, unacceptable toxicity, patients refused
3280850|NCT00620334||1|"ASTHMA:~PREVOUSLY DIAGNOSED MILD ASTHMA PATIENTS"
3280851|NCT00620334||2|"CONTROL:~PATIENTS WHO HAVE NEVER BEEN DIAGNOSED WITH ASTHMA"
3280852|NCT00620321|Experimental|LY2181308 sodium, idarubicin, cytarabine|
3280853|NCT00620308|Experimental|CD-NP low-dose study drug|
3280854|NCT00620308|Experimental|CD-NP high-dose study drug|
3280855|NCT00620308|Placebo Comparator|Placebo|
3280856|NCT00620295|Experimental|Gemcitabine / Bortezomib|"Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose on day 1 and day 8 of a 21 day cycle.~Bortezomib will be given 1 hour after gemcitabine by IVP over 3 to 5 seconds followed by a standard saline on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles."
3280857|NCT00620282|Experimental|Lira 1.8|Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)
3280858|NCT00620282|Placebo Comparator|Placebo|Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)
3280859|NCT00620282|Active Comparator|Glimepiride|Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12
3280860|NCT00620269|Experimental|study arm 1|Induction (with Erlotinib X 3 cycles) -> CCRT with Erlotinib (X 2 cycles) -> continue Erlotinib (X 6 cycles)
3280861|NCT00620269|Experimental|study arm 3|Induction (IP X 3 cycles) -> CCRT with IP (X 2 cycles)
3280862|NCT00620269|Active Comparator|control arm|CCRT with IP (X 2 cycles) -> consolidation IP (X 3 cycles)
3280863|NCT00620269|Experimental|study arm 2|Induction (Erlotinib X 3 cycles) -> CCRT with IP (X 2 cycles) -> recurrence -> Erlotinib (until PD)
3280864|NCT00620256|Experimental|AL-37807|AL-37807 ophthalmic suspension, 0.1%, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
3280865|NCT00620256|Active Comparator|Timolol|Timolol gel forming solution, 0.5%, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
3280866|NCT00620256|Placebo Comparator|AL-37807 vehicle|AL-37807 ophthalmic solution vehicle, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
3280867|NCT00620243|Experimental|1|The study will evaluate the potential of PET imaging to identify early responders to chemotherapy. Patients entered into this study will undergo FDG PET within 2 weeks prior to chemotherapy and prior to initiation of the second course of chemotherapy. All images will be carried out in the same manner with respect to equipment, acquisition parameters, and time post injection, to ensure that changes in standard uptake value(SUV) correlate with metabolic changes. This will be correlated with response determined by changes in serum CA 125 levels.
3280868|NCT00620230|Experimental|1|
3280869|NCT00620230|Placebo Comparator|2|
3280870|NCT00620217|Experimental|1|intramyocardial injection of bicistronic VEGF-A165/bFGF plasmid
3280871|NCT00620217|Placebo Comparator|2|intramyocardial injection of placebo plasmid
3280872|NCT00620204|Experimental|A|Atorvastatin group
3280873|NCT00620204|No Intervention|B|Control group
3280874|NCT00620191|Placebo Comparator|P|placebo identical to metformin.
3280875|NCT00620191|Experimental|metformin|metformin 1000 mg twice a day
3280876|NCT00620178||1|Candesartan
3280877|NCT00620178||2|Losartan
3280878|NCT00620165|Experimental|1|
3280879|NCT00620165|Placebo Comparator|2|
3280880|NCT00620152|Experimental|1|Low glycemic load diet
3280881|NCT00620152|Active Comparator|2|Low fat diet
3280882|NCT00620139||A|Some patients presenting with suspicious lesions of the oropharynx or oral cavity will need to undergo transoral biopsy in the clinic to confirm the diagnosis of carcinoma. Of those patients who choose to participate in the study, an extra piece of tumor will be harvested for investigational purposes related to this trial.
3280883|NCT00620126|Experimental|Intervention|UC Home Automated Telemanagement
3280884|NCT00620126|Active Comparator|Control|Best Available Care
3280885|NCT00620113|Placebo Comparator|Placebo|After an observation period of ~5 weeks, participants receive dose-matched placebo to odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 International Units (IU) vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
3280886|NCT00620113|Experimental|Odanacatib 10 mg|After an observation period of ~5 weeks, participants receive 10 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
3280887|NCT00620113|Experimental|Odanacatib 25 mg|After an observation period of ~5 weeks, participants receive 25 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
3280888|NCT00620113|Placebo Comparator|Odanacatib 50 mg|After an observation period of ~5 weeks, participants receive 50 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
3280889|NCT00620087|Other|Diagnostic Arm|Women with core-biopsy proven atypia, LCIS, or radial scar who have not yet undergone surgical excision were enrolled in the diagnostic arm. A molecular breast imaging study will be obtained.
3280890|NCT00620087|Other|Surveillance arm|Women with a diagnosis of ADH, ALH, or LCIS within the past 5 years were enrolled in the surveillance arm. A molecular breast imaging study was done at enrollment (Year 0) and repeated at Yer 2 and Year 4. Patients continued with routine screening mammography during this time period.
3280891|NCT00620074|Experimental|combination 2|anidulafungin plus voriconazole
3280892|NCT00620074|Experimental|combination 1|anidulafungin plus voriconazole
3280893|NCT00620061|Experimental|1|
3280894|NCT00620048|Experimental|Low dose of autologous CD34-positive cells (stem cells)|
3280895|NCT00620048|Experimental|High dose of autologous CD34-positive cells (stem cells)|
3280896|NCT00620035|Experimental|Radiopaque Etonogestrel Implant|"Radiopaque Etonogestrel Implant (drug) inserted with the Next Generation Applicator (NGA)~The Radiopaque Implant is a single rod contraceptive implant of 4 cm length and~2 mm in diameter which is placed at the inner side of the non-dominant upper-arm~about 8-10 cm above the medial epicondyle. The Radiopaque Implant contains~approximately 68 mg etonogestrel (ENG) dispersed in a matrix of ethylene vinyl acetate (EVA) copolymer and barium sulfate, surrounded by an EVA membrane. The barium-sulfate provides radio-opacity and allows detection by X-ray.~The ENG dose released from the implant amounts to about 60-70 mcg/day shortly after insertion and decreases to about 40 mcg/day at the start of the second year, and to about 25-30 mcg/day at the end of the third year."
3280897|NCT00620022|Experimental|Indacaterol 300 μg followed by placebo|Patients first received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning for 3 weeks. After a 3-week washout period, patients received placebo delivered od via a SDDPI in the morning for 3 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3280898|NCT00620022|Experimental|Placebo followed by indacaterol 300 μg|Patients first received placebo delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning for 3 weeks. After a 3-week washout period, patients received indacaterol 300 μg delivered od via a SDDPI in the morning for 3 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3280899|NCT00620009|No Intervention|Control|Therapists and patients record their estimates of the patient's Global Assessment of Functioning, but do not discuss these estimates in therapy sessions.
3280900|NCT00620009|Experimental|Empathy Feedback|Therapists and patients record their ratings of the patient's Global Assessment of Functioning and discuss these ratings.
3280901|NCT00619996|Experimental|1|
3280902|NCT00619983|Active Comparator|Donepezil|Donepezil 5 mg once per day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
3280903|NCT00619983|Active Comparator|Duloxetine|Group 2: Will receive duloxetine 30 mg twice a day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
3280904|NCT00619983|Active Comparator|Donepezil + Duloxetine|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
3280905|NCT00619983|Placebo Comparator|Placebo|Group 4:Will receive placebo pills. Gabapentin will be titrated in all groups beginning at week 8.
3280906|NCT00619970|Active Comparator|Healthy Control|Healthy controls
3280907|NCT00619970|Active Comparator|Children receiving Rifaximin|2/3 Patients with CAP
3280908|NCT00619970|Placebo Comparator|Children receiving Placebo|1/3 patients with CAP
3280909|NCT00619957|Placebo Comparator|1|Placebo tablet once a week for 2 years followed by once a week Risedronate for 2 years
3280910|NCT00619957|Experimental|Risedronate|35 mg risedronate tablet once a week for 2 years followed by open label 35 mg risedronate once a week for 2 years
3280911|NCT00619944|Experimental|1|Lumefantrine lopinavir drug interaction arm
3280912|NCT00619944|Active Comparator|2|lumefantrine only arm
3280913|NCT00619931||1|APD791 or placebo
3280914|NCT00619931||2|APD791 or placebo
3280915|NCT00619931||3|APD791 or placebo
3280916|NCT00619931||4|APD791 or placebo
3280917|NCT00619931||5|APD791 or placebo
3280918|NCT00619918|Experimental|1|3% saline
3280919|NCT00619918|Placebo Comparator|2|Normal saline
3280920|NCT00619905|Experimental|1|
3280921|NCT00619905|Placebo Comparator|2|
3281033|NCT00619021|Experimental|Cohort 2|Patient receives gemcitabine 800 mg/m^2.
3281034|NCT00619021|Experimental|Cohort 3|Patient receives gemcitabine 1000 mg/m^2.
3281035|NCT00619021|Experimental|Cohort 4|Patient receives gemcitabine 1200 mg/m^2.
3280922|NCT00619892|Active Comparator|Quetiapine XR|Our target daily dose for quetiapine XR was 200 mg/day. The detailed quetiapine XR dosing guidelines were as follows: 50 mg 1 tab po at HS × 3 days, then, if 50 mg tolerated, increase to 50 mg 2 tabs at HS × 4 days; at the beginning of week 2, if the last dose was tolerated increase to 50 mg 3 tabs at HS × 3 days, then, if 150 mg tolerated, increase to 4 tabs at HS; at the beginning of week 3, if no efficacy & the 200 mg dose was well tolerated, increase to one 300 mg tab at HS-otherwise remain at 200 mg one tab at HS; at week 4 if still no improvement, & 300 mg was tolerable, increase to 200 mg tablet 2 at HS. From the beginning of week 5 to the end of the trial, quetiapine XR doses were held. We used quetiapine XR tablets provided by Astra Zeneca (50, 200, and 300 mg designations).
3280923|NCT00619892|Placebo Comparator|Placebo|Subjects received identical-appearing placebo tablets provided by Astra Zeneca (50, 200, and 300 mg designations).
3280924|NCT00619866|Experimental|1|NBI-56418 - 150 mg tablet dose level
3280925|NCT00619866|Experimental|2|NBI-56418 - 250 mg tablet dose level
3280926|NCT00619866|Placebo Comparator|3|Placebo to match
3280927|NCT00619840|Active Comparator|1|
3280928|NCT00619840|Placebo Comparator|2|
3280929|NCT00619827|Experimental|300 IR|300 IR grass pollen allergen extract tablet
3280930|NCT00619827|Placebo Comparator|Placebo|Placebo tablet
3280931|NCT00619814|Other|Cohort group|Cohort group of asymptomatic patients 50-80 years old with a positive fecal occult blood test done for colorectal cancer screening.
3280932|NCT00619801|Placebo Comparator|Placebo|
3280933|NCT00619801|Experimental|Levocetirizine|
3280934|NCT00619788|Experimental|1|Patients receiving 4.0-5.0mm AngioSculpt Scoring Balloon Catheter (AngioScore, Inc.) for femoropopliteal use
3280935|NCT00619749|Experimental|1|
3280936|NCT00619749|Placebo Comparator|2|
3280937|NCT00619736|Experimental|NSA-789|
3280938|NCT00619736|Placebo Comparator|Placebo|
3280939|NCT00619723|Active Comparator|Citicoline|Participants will receive active medication throughout the study. Citicoline will be given beginning at two capsules (500 mg/day) with an increase to four capsules (1000 mg/day) at week 2, six capsules (1500 mg/day) at week 4, and eight capsules (2000 mg/day) at week 6. Doses will be decreased, based on clinician judgment, due to side effects.
3280940|NCT00619723|Placebo Comparator|Placebo|Participants will receive placebo identical in appearance to Citicoline throughout the study. Placebo will be given beginning at two capsules (500 mg/day) with an increase to four capsules (1000 mg/day) at week 2, six capsules (1500 mg/day) at week 4, and eight capsules (2000 mg/day) at week 6. Doses will be decreased, based on clinician judgment, due to side effects.
3280941|NCT00619710|Experimental|1|Meropenem
3280942|NCT00619710|Active Comparator|2|Imipenem-cilastatin
3280943|NCT00619684|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity.
3280944|NCT00619658|Experimental|1|All women undergoing medical abortion will have telephone follow-up approximately one week after using mifepristone and misoprostol.
3280945|NCT00619645|Other|RIST for Heme malignancies|Busulfan 3.3 mg/kg over 3 hours on day -6 and day -5 Fludarabine 30 mg/m2 IV over 30 minutes on day -6 to day -2 followed by Transplant followed by Immunosuppressive/GVHD therapy
3280946|NCT00619632|Experimental|1|LC- Primary-care based lactation consultant meeting women pre- and post-natally.
3280947|NCT00619632|Experimental|2|Provider Prompt
3280948|NCT00619632|Experimental|3|LC+Provider Prompt
3280949|NCT00619632|No Intervention|Control|
3280950|NCT00619619|Experimental|A|
3280951|NCT00619593|Active Comparator|2|Standard follow-up in patients without appropriate ICD therapy
3280952|NCT00619593|Experimental|1|Following 1st appropriate ICD therapy, the patients have to be called to the clinic for intensified clinical diagnostics and, if necessary or useful, intensified therapy.
3280953|NCT00619580||positive E coli|positive E coli at UPMC
3280954|NCT00619567|Experimental|Cognitive Stimulation|Subjects will be given Internet access to the Smartbrain cognitive stimulation program. They will complete exercises for ~30 minutes, at least three times per week, for a period of 24 weeks.
3280955|NCT00619567|No Intervention|Control|"These individuals will receive usual care during the 24 week follow-up period."
3280956|NCT00619541|Experimental|A|"5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days~Sorafenib 400 mg bid orally continuously~5-FU will be administered for a maximum of 12 cycles.~Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease."
3280957|NCT00619528|Experimental|1|No separate arms: All Enrolled Receive Same Treatment
3280958|NCT00619515|Experimental|CyberKnife® stereotactic radiosurgery|
3280959|NCT00619502|Experimental|DTaP-IPV-Hep B-PRP~T Vaccine Group|Participants received a primary series of 3 vaccinations with DTaP-IPV-Hep B-PRP~T, with 1 dose each at 2, 3, and 4 months of age, in Study A3L10; they will receive a booster dose of DTaP-IPV-HepB-PRP~T at 15 to 18 months of age in the present study
3280960|NCT00619502|Active Comparator|Pentaxim™ + Engerix B™ Vaccines Group|Participants received a primary series of 3 vaccinations with Pentaxim™ and Engerix B™ vaccines, with 1 dose each at 2, 3, and 4 months of age, in Study A3L10; they will receive a booster dose of DTaP-IPV-Hep B-PRP~T at 15 to 18 months of age in the present study.
3280961|NCT00619489|Experimental|Vedolizumab 2 mg/kg|Participants received vedolizumab, 2 mg/kg, intravenously (IV), on Days 1, 15 and 43, and thereafter once every 8 weeks for up to 78 weeks.
3280962|NCT00619489|Experimental|Vedolizumab 6 mg/kg|Participants received vedolizumab, 6 mg/kg, IV, on Days 1, 15 and 43, and thereafter once every 8 weeks for up to 78 weeks.
3280963|NCT00619476|Placebo Comparator|Placebo|placebo
3280964|NCT00619476|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks
3280965|NCT00619476|Experimental|GEn 2400mg/day|gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks
3280966|NCT00619476|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, maintenance treatment 14 weeks
3280967|NCT00619463|Experimental|exercise then monitor|8 weeks of aerobic exercise followed by 16 weeks of monitoring
3280968|NCT00619463|Experimental|monitor than exercise|8 weeks of monitoring followed by 16 weeks of aerobic exercise
3281036|NCT00619008|Experimental|1|Ad libitum low carbohydrate diet
3280969|NCT00619424|Experimental|pazopanib + erlotinib|Pazopanib and erlotinib are to be combined at different specified dose levels until an optimally tolerated dose level is identified. Pazopanib, a multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, and -3, PDGFR-alpha and beta, and c-kit and erlotinib, an epidermal growth factor (EGFR) inhibitor, are to be combined in an effort to simultaneously block two tightly woven cell signaling pathways.
3280970|NCT00619424|Experimental|pazopanib + pemetrexed|Pazopanib and pemetrexed are to be combined at different specified dose levels until an optimally tolerated dose regimen is identified. Combination of an anti-VEGF therapy (such as bevacizumab) with systemic chemotherapy has demonstrated increased clinical efficacy in comparison with systemic chemotherapy alone in several malignancies. Hence, pazopanib, a multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, and -3, PDGFR-alpha and beta, and c-kit, was chosen to be combined with pemetrexed, a chemotherapeutic agent that inhibits the enzyme thymidylate synthase, in an effort to determine if an anti-angiogenesis inhibitor would enhance the activity of the approved chemotherapeutic agent pemetrexed.
3280971|NCT00619411|Experimental|I|
3280972|NCT00619398|Active Comparator|1|
3280973|NCT00619398|Experimental|2|
3280974|NCT00619385|Experimental|Proellex 100 mg|Proellex 100 mg daily for 7 days
3280975|NCT00619385|Experimental|Proellex 150 mg|Proellex 150 mg daily for 7 days
3280976|NCT00619385|Experimental|Proellex 200 mg|Proellex 200 mg daily for 7 days
3280977|NCT00619372|Experimental|B|Low dose OKT3 with GC
3280978|NCT00619372|Experimental|C|Mid dose OKT3
3280979|NCT00619372|Experimental|D|Mid OKT3 dose with GC
3280980|NCT00619372|Experimental|E|High dose OKT3
3280981|NCT00619372|Experimental|F|GC only
3280982|NCT00619372|Experimental|A|Low dose OKT3
3280983|NCT00619359|Experimental|1|Arm 1: study medication
3280984|NCT00619359|Active Comparator|2|Arm 2: Active comparator
3280985|NCT00619346|Placebo Comparator|1|Placebo tablets resembling 100 mg tablet of active drug BID X 14 days
3280986|NCT00619346|Active Comparator|2|Pafuramidine maleate, 100 mg tablet, BID X 14 days
3280987|NCT00619333|Other|1|
3280988|NCT00619320|Experimental|Safer Sex Skill Building (SSB)|Safer Sex Skill Building Intervention (SSB) A five session behavioral intervention focused on HIV/STD prevention and safer sex negotiation skills
3280989|NCT00619320|Active Comparator|2|one group session focused on standard HIV/STD education
3280990|NCT00619307|Active Comparator|Transition with prophylactic ibuprofen|
3280991|NCT00619307|Active Comparator|Transition with PRN ibuprofen|
3280992|NCT00619281||Oberservation|600 consecutive patients undergoing cardiac surgery
3280993|NCT00619268|Experimental|A|
3280994|NCT00619268|Active Comparator|B|
3280995|NCT00619268|Active Comparator|C|
3280996|NCT00619255|Experimental|Intervention|Adolescent Trauma Support Program
3280997|NCT00619255|No Intervention|Control|Usual Care Control Condition
3280998|NCT00619242|Experimental|sorafenib|sorafenib 2 tablets by mouth
3280999|NCT00619229|Experimental|Alprostadil|Alprostadil
3281000|NCT00619229|Placebo Comparator|Placebo|Placebo
3281001|NCT00619203|Active Comparator|A|Two active ingredients
3281002|NCT00619203|Active Comparator|B|One active ingredient
3281003|NCT00619203|Active Comparator|C|One (other) active ingredient
3281004|NCT00619203|Placebo Comparator|D|
3281005|NCT00619190|Experimental|open aripipraprazole|Openly provided, flexibly dosed aripiprazole in doses from 1mg to 30mg
3281006|NCT00619190|No Intervention|no medication control|group of children whose parents do not want them to take medications for autism over the year following enrollment in the trial.
3281007|NCT00619164|Experimental|1|
3281008|NCT00619164|Experimental|2|
3281009|NCT00619164|Experimental|3|
3281010|NCT00619164|Placebo Comparator|4|
3281011|NCT00619151|Active Comparator|1|CarboMedics Supra-annular Top Hat Valve
3281012|NCT00619151|Active Comparator|2|St. Jude Medical Regent Valve
3281013|NCT00619138|Active Comparator|1|
3281014|NCT00619138|Active Comparator|2|
3281015|NCT00619125||A|20 patients with IBS C
3281016|NCT00619125||D|20 Subjects without IBS
3281017|NCT00619125||B|20 patients with IBS D
3281018|NCT00619125||C|20 patients with IBS M
3281019|NCT00619112|Experimental|Temozolomide|single arm trial; Patients treated with temozolomide at a dose of 150mg/m2 daily for seven consecutive days of every other week. One 28-day cycle will include treatment with temozolomide on days 1-7 and days 15-21 with no treatment on days 8-14
3281020|NCT00619099|Experimental|1|
3281021|NCT00619099|Experimental|2|
3281022|NCT00619086|Placebo Comparator|A, 1|Placebo 45 minutes prior to surgery
3281023|NCT00619086|Active Comparator|A, 2|8 mg Dexamethasone 45 minutes prior to surgery
3281024|NCT00619073|Active Comparator|Clopidogrel + aspirin|The subjects will be randomized to clopidogrel 75 mg plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., clopidogrel) will then be discontinued and aspirin continued for another 43 days.
3281025|NCT00619073|Placebo Comparator|Placebo + aspirin|The subjects will be randomized to placebo plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., placebo) will then be discontinued and aspirin continued for another 43 days.
3281026|NCT00619060|Experimental|Myristyl (right), Placebo (Left)|Participants apply topical myristyl nicotinate to the right forearm and topical placebo to the left forearm once daily for 4 weeks; Myristyl (Right), Placebo (Left) Topical Myristyl Nicotinate Cream and Placebo
3281027|NCT00619060|Experimental|Myristyl (Left), Placebo (Right)|Participants apply topical myristyl nicotinate to the left forearm and topical placebo to the right forearm once daily for 4 weeks; Myristyl (Left), Placebo (Right)Topical Myristyl Nicotinate Cream and Placebo
3281028|NCT00619047||Observation|
3281029|NCT00619034|Experimental|latanoprost|Medical intervention cross-over
3281030|NCT00619034|Active Comparator|diclofenac|medical intervention
3281031|NCT00619034|Experimental|dorzolamide|dorzolamide eyedrops twice daily in one week
3281032|NCT00619021|Experimental|Cohort 1|Patient receives gemcitabine 600 mg/m^2.
3281279|NCT00617253|Experimental|D|
3281037|NCT00619008|Experimental|2|Ad libitum high complex carbohydrate diet
3281038|NCT00619008|Experimental|3|Energy-restricted high complex carbohydrate diet
3281039|NCT00618995|Experimental|A|Arm A: ER niacin/laropiprant + Placebo to laropiprant
3281040|NCT00618995|Experimental|B|Arm B: ER niacin + Placebo to laropiprant
3281041|NCT00618995|Experimental|C|Arm C: laropiprant + Placebo to ER Niacin/laropiprant
3281042|NCT00618995|Placebo Comparator|D|Arm D: Placebo
3281043|NCT00618982|Experimental|Sorafenib (Nexavar, BAY43-9006)|Intrapatient dose escalation of sorafenib from 400 mg orally twice daily (bid) for the first cycle, 600 mg bid for the second cycle and 800 mg bid until disease progression, unacceptable toxicity or withdrawal of consent. Dose reductions due to toxicities were allowed.
3281044|NCT00618969|Experimental|Haploidentical allogeneic PBSC transp|Non-myeloablative preparative regimen (reduced-intensity) of busulfan, melphalan and alemtuzumab followed by a haploidentical-related peripheral blood stem cell transplant.
3281045|NCT00618956|Experimental|1|
3281046|NCT00618956|Placebo Comparator|2|
3281047|NCT00618930|Experimental|1|
3281048|NCT00618930|Active Comparator|2|Use of Fleet
3281049|NCT00618917|Experimental|MnSOD|
3281050|NCT00618904|Experimental|1|Probiotic containing Lactobacillus and Bifidobacterium
3281051|NCT00618904|Placebo Comparator|2|Placebo
3281052|NCT00618878|Active Comparator|1|Electroacupuncture
3281053|NCT00618878|Active Comparator|2|Laser Therapy
3281054|NCT00618865|Experimental|1|omega-3 fatty acid with 2.2 g of eicosapentanoic acid (EPA) and 1.2 g of docosahexanoic acid (DHA)
3281055|NCT00618865|Placebo Comparator|2|Placebo (olive oil ethyl esters)
3281056|NCT00618852|Experimental|1|Furosemide
3281057|NCT00618852|Placebo Comparator|2|
3281058|NCT00618839|Experimental|StrataGraft : cadaver allograft|All patients enrolled received StrataGraft skin tissue and an intrapatient control area treated with cadaver allograft in a split-wound design
3281059|NCT00618826|Experimental|Treatment Period|Treatment will be administered once every 2 weeks. One cycle of therapy will consist of 14 days. Paclitaxel is administered first after appropriate premedications. Gemcitabine is administered second and Avastin is administered after chemotherapy, all given on day 1 of each cycle.
3281060|NCT00618813|Experimental|Treatment (combination chemotherapy)|See Detailed Description
3281061|NCT00618800|Experimental|Pharmacist Care|Pharmacist Intervention
3281062|NCT00618800|Active Comparator|Control|Written information only group
3281063|NCT00618787|Active Comparator|Arm 1|
3281064|NCT00618787|Active Comparator|Arm 2|
3281065|NCT00618761|Experimental|1|kidney-pancreas recipients
3281066|NCT00618761|Active Comparator|2|kidney recipients
3281067|NCT00618761|Active Comparator|3|healthy controls
3281068|NCT00618761|Active Comparator|4|beta-cell recipients
3281069|NCT00618748|Experimental|Pre-Olanzapine|Participants who received olanzapine 5-20 mg/day in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
3281070|NCT00618748|Experimental|Pre-Placebo|Participants who received placebo in acute phase of Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
3281071|NCT00618748|Experimental|New Olanzapine|Participants who did not participate in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 48 weeks.
3281072|NCT00618735|Experimental|1|Subjects in Schedule A will take BIIB021 in the morning at approximately 0800 with at least 6 ounces of water following an overnight fast (Beginning at midnight).
3281073|NCT00618735|Experimental|2|Subjects in Schedule B will take BIIB021 in the morning at approximately 0800 with at least 6 ounces of water following an overnight fast (beginning at midnight). The second dose will be taken, following at least a 2-hour fast, 12 hours (+/- 2 hours) after the first dose, except on Day 1 of Cycle 1 and Day 1 of Cycle 2.
3281074|NCT00618722|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received 0.5% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (1 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3281075|NCT00618722|Experimental|Deoxycholic acid Injection 2 mg/cm²|Participants received 1.0% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (2 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3281076|NCT00618722|Experimental|Deoxycholic acid Injection 4 mg/cm²|Participants received 2.0% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (4 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3281077|NCT00618722|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3281078|NCT00618709|Experimental|Cohort 1|ATX-101 (1 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid
3281079|NCT00618709|Experimental|Cohort 2|ATX-101 (2 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid
3281080|NCT00618709|Experimental|Cohort 3|3 subgroups in Cohort 3: 3a: ATX-101 (4 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid 3b: ATX-101 (2 mg/cm2) at a volume of 0.2 ml on a 0.7 cm grid 3c: ATX-101 (2 mg/cm2) at a volume of 0.4 ml on a 1.0 cm grid
3281081|NCT00618709|Experimental|Cohort 4|3 subgroups in Cohort 4: 4a: ATX-101 (8 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid 4b: ATX-101 (4 mg/cm2) at a volume of 0.2 ml on a 0.7 cm grid 4c: ATX-101 (4 mg/cm2) at a volume of 0.4 ml on a 1.0 cm grid
3281082|NCT00618696|Experimental|AHN-12|2.0, 5.0, 7.5, 10.0 or 12.5 mCi/m^2 of ^90Y-AHN-12 at Day 7/8
3281083|NCT00618683|Other|Study Arm|Mapping and Ablation
3281084|NCT00618670|Experimental|1|Home-based program with progressive increases in exercise duration and intensity (i.e., cadence); walking duration will be longer for the home-based group because the intensity of walking will be lower than the graded treadmill walking performed by the supervised group
3281085|NCT00618670|Experimental|2|Supervised program consisting of graded treadmill walking, with progressive increments in exercise duration from 15 to 40 minutes, and progressive increments in exercise intensity from 50 to 70% of exercise capacity
3281086|NCT00618670|Active Comparator|3|Light resistance training without any walking exercise
3281280|NCT00617240|Experimental|1|metformin in doses from 250mg to 2000mg/day for 26 weeks
3281087|NCT00618657|Experimental|Arm I (HER-2 positive)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes, carboplatin IV over 60 minutes, and trastuzumab IV over 90 minutes , then weekly over 30-60 minutes. Treatment repeats every week for 12 weeks in the absence of disease progression or unacceptable toxicity. In both arms, beginning 21-40 days later, patients undergo surgery.
3281088|NCT00618657|Experimental|Arm II (HER-2 negative)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as in Arm I. Patients also receive bevacizumab IV over 90 or 60 or 30 minutes once every two weeks for 5 doses in the absence of disease progression or unacceptable toxicity. In both arms, beginning 21-40 days later, patients undergo surgery.
3281089|NCT00618644|Experimental|1|Ranibizumab injection
3281090|NCT00618618|Experimental|Deoxycholic Acid Injection 0.2 mL/0.7 cm|Participants received deoxycholic acid administered in 0.2 mL injections, 0.7 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3281091|NCT00618618|Placebo Comparator|Placebo 0.2 mL/0.7 cm|Participants received placebo administered in 0.2 mL injections, 0.7 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3281092|NCT00618618|Experimental|Deoxycholic Acid Injection 0.2 mL/1.0 cm|Participants received deoxycholic acid administered in 0.2 mL injections, 1.0 cm apart, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3281093|NCT00618618|Placebo Comparator|Placebo 0.2 mL/1.0 cm|Participants received placebo administered in 0.2 mL injections, 1.0 cm apart, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3281094|NCT00618618|Experimental|Deoxycholic Acid Injection 0.4 mL/1.0 cm|Participants received deoxycholic acid administered in 0.4 mL injections, 1.0 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3281095|NCT00618618|Placebo Comparator|Placebo 0.4 mL/1.0 cm|Participants received placebo administered in 0.4 mL injections, 1.0 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3281096|NCT00618605|Experimental|1|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^9 virus particles (VP) given at Days 0, 28, and 168
3281097|NCT00618605|Experimental|2|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^10 VP given at Days 0, 28, and 168
3281098|NCT00618605|Experimental|3|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^11 VP given at Days 0, 28, and 168
3281099|NCT00618605|Experimental|4|2 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at a dose to be determined by the safety data from Arms 1, 2 and 3 given at Days 0 and 168
3281100|NCT00618592|Experimental|CHO|
3281101|NCT00618592|No Intervention|FAST|
3281102|NCT00618579|Experimental|LMWH arm - active LMWH|
3281103|NCT00618579|Placebo Comparator|LMWH arm - placebo|
3281104|NCT00618579|Experimental|Warfarin arm - active warfarin|
3281105|NCT00618579|Other|Warfarin arm - control|
3281106|NCT00618566|Experimental|Oregon|
3281107|NCT00618553|Experimental|Pulmonary Rehabilitation|Pulmonary Rehabilitation - Rehabilitation treatment given over about 3-4 weeks. Questionnaire regarding quality-of-life that lasts about 30 minutes.
3281108|NCT00618540|Experimental|Alemtuzumab|Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
3281109|NCT00618527|Experimental|1|Rebif with Cellcept
3281110|NCT00618527|Placebo Comparator|2|Rebif alone
3281111|NCT00618514|Active Comparator|1|Bright Tip Laser Fiber - FDA-cleared study device
3281112|NCT00618514|Active Comparator|2|Standard bare tip Laser Fiber - Any commercially available laser device (the control)
3281113|NCT00618488|Experimental|1|Bifidobacterium lactis
3281114|NCT00618488|Placebo Comparator|2|Placebo
3281115|NCT00618475|Experimental|Treatment|Individual cognitive behavioral therapy (CBT)
3281116|NCT00618475|Other|Wait-list control|Individual cognitive behavioral therapy (CBT) after 3 month wait-list period
3281117|NCT00618462|Experimental|1|Participants will receive psychoeducation therapy plus case management and a referral to Gamblers Anonymous.
3281118|NCT00618462|Experimental|2|Participants will receive cognitive behavioral therapy plus contingency management and a referral to Gamblers Anonymous.
3281119|NCT00618462|Experimental|3|Participants will receive cognitive behavioral therapy and a referral to Gamblers Anonymous.
3281120|NCT00618449|Experimental|Arm 2|Subjects residing in villages assigned to treatment arm 2 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0), as well as receive an initial treatment with 1 gm oral dose of Azithromycin; receive a second 1 gm oral dose of Azithromycin at Day 30; be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60 and Day 360.
3281121|NCT00618449|Active Comparator|Arm 1|Subjects residing in villages assigned to treatment arm 1 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0); be treated at Day 30 with the WHO standard of care for trachoma - 1 gm oral dose of Azithromycin; be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60 and Day 360.
3281122|NCT00618436|Active Comparator|Levetiracetam|Group 1 - The levetiracetam (Keppra®) group will receive a loading dose of 20 mg/kg IV over 15 minutes (rounded to the nearest 250mg) up to a maximum of 2000 mg, then started on maintenance dose (1000 mg, IV BID)as prophylaxis for 7 days.
3281123|NCT00618436|Active Comparator|Phenytoin|Group 2-The phenytoin group will receive a loading dose of 20 mg/kg IV to a maximum of 2000mg, then started on maintenance dose at 5 mg/kg/day (rounded to nearest 100mg dose, IV, divided into three doses a day) as prophylaxis for 7 days. Phenytoin levels are to be checked daily and dose adjusted as needed to maintain therapeutic levels of 10-20 µg/dL.
3281124|NCT00618423|Placebo Comparator|Physiologic saline|
3281125|NCT00618423|Active Comparator|Ketamine|
3281126|NCT00618410|Active Comparator|Carbon dioxide|nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge
3281127|NCT00618410|Placebo Comparator|Placebo|nasal placebo administered 30 minutes prior to nasal challenge
3281374|NCT00616538|Active Comparator|Cutivate(r)|Topical mid-strength steroid
3281128|NCT00618397|Experimental|Arm 1|Ketamine will be administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to in PICU patients that meet eligibility criteria.
3281129|NCT00618384|Active Comparator|1|Patients with TACE therapy will be treated with Sorafenib (2 x 400 mg/day) until progressive disease
3281130|NCT00618371|Experimental|Raltegravir intensification|Patients will be administered raltegravir 400 mg orally twice daily in addition to antiretroviral therapy
3281131|NCT00618358|Experimental|Vascular Sealant)|
3281132|NCT00618358|Active Comparator|Gelfoam/Thrombin|
3281133|NCT00618332|Active Comparator|1|2 weeks of treatment
3281134|NCT00618332|Placebo Comparator|2|2 weeks of treatment
3281135|NCT00618319|Experimental|1|BIIB021
3281136|NCT00618293|Active Comparator|1|intravenous infusion of Haemate (dosage dependent on body weight)
3281137|NCT00618293|Placebo Comparator|2|intravenous infusion of 0.9% NaCl solution
3281138|NCT00618280|Active Comparator|1|schizophrenic and non schizophrenic patient stratified by smoking and non smoking will get nicotine and placebo on first day on the second day placebo and nicotine
3281139|NCT00618280|Placebo Comparator|2|schizophrenic and non schizophrenic patient stratified by smoking and non smoking will get nicotine and placebo on first day on the second day placebo and nicotine
3281140|NCT00618241|Experimental|A|"Group A: day 1-5 Raltegravir 400 mg oral BD (twice daily). Lamotrigine one oral dose 100 mg on day 4. Wash-out 6-31. Followed by one oral dose Lamotrigine 100 mg on day 34.~5 days Raltegravir 400 mg oral BD. Lamotrigine one oral dose 100mg on day 34."
3281141|NCT00618241|Active Comparator|B|"Group B: day 4 Lamotrigine one oral dose on day 4. Wash-out day 6-28 followed by Raltegravir 400 mg oral BD day 29-33. One dose Lamotrigine 100 mg oral on day 32.~One dose Lamotrigine 100 mg oral."
3281142|NCT00618215|Experimental|I|"ROE Group~Interventions:behaviorial"
3281143|NCT00618215|Experimental|2|"MIM Group~Interventions:behaviorial"
3281144|NCT00618176|Experimental|B|
3281145|NCT00618176|Experimental|A|
3281146|NCT00618176|Experimental|C|
3281147|NCT00618150|Experimental|A|
3281148|NCT00618124|Experimental|A|
3281149|NCT00618098|Experimental|Octaplex (human prothrombin complex concentrate)|Participants to receive1 or more Octaplex infusions intravenously until their International Normalized Ratio (INR) was < 1.5.
3281150|NCT00618098|Active Comparator|Fresh frozen plasma|Participants to receive1 or more fresh frozen plasma infusions intravenously until their International Normalized Ratio (INR) was < 1.5.
3281151|NCT00618085|Experimental|1|"All patients will receive the occupational therapy and physiotherapy normally given in their setting.~In addition; the experimental group will receive 2 instruction DVD's introducing them to motor imagery practice, taking 35 minutes in total. The research therapist will also attend the first session with the physiotherapist and with the occupational therapist to help incorporate motor imagery within the therapy. Thereafter the therapist will help the patient use motor imagery as part of their normal treatment. The total amount spent on motor imagery during therapy sessions will be 6.5 hours in 6 weeks."
3281152|NCT00618085|Active Comparator|2|"All patients will receive the occupational therapy and physiotherapy normally given in their setting.~In addition; the control group will receive 2 DVDs for 35 minutes in total. These will show background information on their condition, explaining the importance of practice of activities, and on the principles of motor learning and phased movement which underlie most therapy.The research therapist will also attend the first session with the physiotherapist and with the occupational therapist to control for attention. The total amount the physiotherapist and occupational therapist spend with the patients should be the same in both groups."
3281153|NCT00618072|Placebo Comparator|A: Study diet|EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of placebo metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of placebo rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day.
3281154|NCT00618072|Active Comparator|B: Study diet plus Metformin|"Metformin and Rosiglitazone Placebo~EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of placebo rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day."
3281155|NCT00618072|Active Comparator|C: Study diet plus metformin and avandia|"Metformin and Rosiglitazone~EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day."
3281156|NCT00618033|Active Comparator|1|
3281157|NCT00618033|Active Comparator|2|
3281158|NCT00618007|Experimental|30 mg QD|
3281159|NCT00618007|Experimental|20 mg QD|
3281160|NCT00618007|Placebo Comparator|Placebo|
3281161|NCT00617994|Experimental|A|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a small percent BSA.
3281162|NCT00617994|Experimental|B|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 1.
3281163|NCT00617994|Experimental|C|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 2.
3281164|NCT00617981|Experimental|1|ThermoDox 50 mg/m2 start infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
3281165|NCT00617981|Sham Comparator|2|Sham infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
3281166|NCT00617955||Surgical|Cardiac surgery patients that received Aprotinin or Amicar
3281167|NCT00617942|Experimental|Neo-adjuvant cohort 1|
3281168|NCT00617942|Experimental|Neo-adjuvant cohort 2|
3281169|NCT00617942|Experimental|Adjuvant cohort 1|
3281170|NCT00617942|Experimental|Adjuvant cohort 2|
3281171|NCT00617929|Experimental|Conditioning for Graft Failure|Primary or secondary graft failure after hematopoietic stem cell transplantation defined as a > 50% loss of previously best donor chimerism or less than 25% donor chimerism beyond day +42 with pancytopenia and no evidence of relapse. Patients with any diagnosis, type of donor, hematopoietic cell graft or conditioning regimen should be considered for this study. Patients receive anti-thymocyte globulin, rituximab, and clofarabine.
3281172|NCT00617903|Experimental|Azelaic acid foam, 15% (BAY39-6251)|Participants received azelaic acid foam, 15% topically twice daily for 12 weeks
3281173|NCT00617903|Placebo Comparator|Vehicle foam|Participants received vehicle foam topically twice daily for 12 weeks
3281174|NCT00617890|Experimental|Group 1: 0.3 mg/kg|Participants received robatumumab 0.3 mg/kg intravenously (IV) as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 0.3 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
3281175|NCT00617890|Experimental|Group 1: 10 mg/kg|Participants who received robatumumab 10 mg/kg IV as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 10 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
3281176|NCT00617890|Experimental|Group 2: 10 mg/kg|Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with relapsed and unresectable osteosarcoma refractory to prior chemotherapy with a platinum- and doxorubicin-containing regimen.
3281177|NCT00617890|Experimental|Group 3: 10 mg/kg|Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, or vincristine.
3281178|NCT00617877|Experimental|1|Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day in case of BP more than 140/90 mm Hg. HCTZ 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
3281179|NCT00617864|Experimental|1|Group will receive infusion of human albumin
3281180|NCT00617864|Placebo Comparator|2|Group will receive infusion of saline
3281181|NCT00617851|Experimental|Influenza virus vaccine (lot A)|Lot A of the investigational influenza virus vaccine
3281182|NCT00617851|Experimental|Influenza virus vaccine (lot B)|Lot B of the investigational influenza virus vaccine
3281183|NCT00617851|Experimental|Influenza virus vaccine (lot C)|Lot C of the investigational influenza virus vaccine
3281184|NCT00617851|Experimental|Influenza virus vaccine (pooled)|Pooled data of all three lots (Lot A, B and C) of the investigational influenza virus vaccine
3281185|NCT00617851|Active Comparator|Comparator influenza vaccine|A US licensed influenza virus vaccine
3281186|NCT00617838|Active Comparator|1|Optimization of gluten introduction by nutritional councelling
3281187|NCT00617838|No Intervention|2|No specific nutritional councelling. Follow-up of gluten introduction
3281188|NCT00617812|Experimental|Shan5|
3281189|NCT00617773|Experimental|hu3S193|
3281190|NCT00617760|Experimental|1|Concomitant administration of MenC-TT vaccine and PCV7, 170 subjects
3281191|NCT00617760|Active Comparator|2|PCV7 administration only, 85 subjects
3281192|NCT00617760|Active Comparator|3|MenC-TT vaccine only, 85 subjects
3281193|NCT00617747|Experimental|1|
3281194|NCT00617747|Placebo Comparator|2|
3281195|NCT00617734|Experimental|IMC-A12 (cixutumumab)|
3281196|NCT00617734|Experimental|IMC-A12 (cixutumumab) + cetuximab|
3281197|NCT00617721||1|patients with unexplained bleeding disorder
3281198|NCT00617721||2|healthy volunteers
3281199|NCT00617708|Experimental|Arm I (erlotinib, gemcitabine, cixutumumab)|Patients receive erlotinib hydrochloride PO once daily on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3281200|NCT00617708|Active Comparator|Arm II (erlotinib, gemcitabine)|Patients receive erlotinib hydrochloride and gemcitabine hydrochloride as in arm I. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3281201|NCT00617695|Experimental|1|
3281202|NCT00617695|Placebo Comparator|2|
3281203|NCT00617682|Active Comparator|Group 1|Group 1 (experimental)
3281204|NCT00617682|Placebo Comparator|Group 2|Group 2 (placebo comparator)
3281205|NCT00617669|Active Comparator|Placebo + Docetaxel|placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks
3281206|NCT00617669|Experimental|ZD4054 + Docetaxel|ZD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks
3281207|NCT00617656|Active Comparator|A|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
3281208|NCT00617656|Experimental|B1|Low RAP expression and any levels of BRCA1 expression: Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
3281209|NCT00617656|Experimental|B2|Intermediate or high RAP expression and low or intermediate BRCA1 expression: Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
3281210|NCT00617656|Experimental|B3|Intermediate or high RAP expression and high BRCA1 expression: Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
3281211|NCT00617643|Active Comparator|2|Triomune® 30 one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
3281212|NCT00617643|Experimental|1|Triomune® 30 one tablet twice daily for two weeks
3281213|NCT00617617|Experimental|A|Dietary Supplement: Prevastein HC®
3281214|NCT00617617|Placebo Comparator|B|Placebo
3281215|NCT00617604|Placebo Comparator|Placebo|Participants received placebo administered intra-operatively as an intravenous (IV) bolus on Day 0, another IV bolus on Day 3 and weekly subcutaneous injections thereafter for 12 weeks. Participants also received tacrolimus, mycophenolate mofetil (MMF) and steroid treatment.
3281216|NCT00617604|Experimental|Alefacept|Participants received 7.5 mg alefacept administered intra-operatively as an IV bolus on Day 0, another 7.5 mg IV bolus on Day 3, and weekly subcutaneous injections of 15 mg alefacept thereafter for 12 weeks. Participants also received tacrolimus, MMF and steroid treatment.
3281217|NCT00617591|Experimental|Induction and Maintenance Therapy|"Induction Phase Followed by Maintenance Therapy.~Patients received lenalidomide 25 mg orally on days 1-21, dexamethasone 40 mg orally on days on 1-4, and Pegylated Liposomal Doxorubicin (PLD) 40 mg/m^2 intravenously on day 1 (reduced to 30 mg/m^2 after the initial 29 patients were treated). Cycles were repeated every 28 days.~At the best response (4-8 cycles of induction), patients could proceed with either high-dose therapy or maintenance with lenalidomide and dexamethasone at the tolerated doses on the same schedule until disease progression.~Dd-R: Lenalidomide (Revlimid®) combined with Pegylated Liposomal Doxorubicin (Doxil®) and Dexamethasone (Decadron®) as outlined in the Detailed Description."
3281218|NCT00617578|Experimental|1|programming of VF therapy: ATP (antitachycardia pacing) One Shot ON
3281219|NCT00617578|Active Comparator|2|programming of VF therapy: ATP (antitachycardia pacing) One Shot OFF
3281220|NCT00617552|Placebo Comparator|1|
3281221|NCT00617552|Experimental|2|
3281222|NCT00617552|Experimental|3|
3281223|NCT00617552|Experimental|4|
3281224|NCT00617552|Experimental|5|
3281225|NCT00617552|Experimental|6|
3281226|NCT00617552|Experimental|7|
3281227|NCT00617552|Experimental|8|
3281228|NCT00617539|Experimental|irinotecan and temozolomide|
3281229|NCT00617526|Experimental|RDEA806 400 mg|Placebo or RDEA806 400 mg twice daily (BID) for 7 days and a single morning dose on Day 8.
3281230|NCT00617526|Experimental|RDEA806 600 mg|Placebo or RDEA806 600 mg once daily (QD) for 7 days with an additional dose on the morning of Day 8.
3281231|NCT00617526|Experimental|RDEA806 800 mg|Placebo or RDEA806 800 mg QD using enteric coated tablets for 7 days with an additional morning dose on Day 8.
3281232|NCT00617526|Experimental|RDEA806 1000 mg|Placebo or RDEA806 1000 mg QD using enteric coated tablets for 7 days with an additional dose on the morning of Day 8.
3281233|NCT00617513|Active Comparator|1|
3281234|NCT00617513|Active Comparator|2|
3281235|NCT00617513|Active Comparator|3|
3281236|NCT00617513|Placebo Comparator|4|
3281237|NCT00617500|Active Comparator|Hormone|
3281238|NCT00617500|Experimental|flower therapy|
3281239|NCT00617500|Experimental|therapeutic touch|
3281240|NCT00617500|Experimental|auriculotherapy|
3281241|NCT00617474|Experimental|1|Group of patient with anemia, that treated by erythropoietin
3281242|NCT00617474|Placebo Comparator|2|Patients group with anemia that treated by placebo
3281243|NCT00617461|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, 4 weeks treatment in either the first or second treatment period
3281244|NCT00617461|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, 4 weeks treatment in either the first or second treatment period
3281245|NCT00617448|Active Comparator|I|conventional diathermy haemorrhoidectomy under spinal anaesthesia
3281246|NCT00617448|Active Comparator|II|conventional diathermy haemorrhoidectomy with local anaesthesia combined with intravenous sedation (group II)
3281247|NCT00617448|Active Comparator|III|Ligasure haemorrhoidectomy under spinal anesthesia
3281248|NCT00617448|Active Comparator|IV|Ligasure haemorrhoidectomy under local anesthesia
3281249|NCT00617435|Experimental|V|
3281250|NCT00617435|Experimental|N|
3281251|NCT00617435|Experimental|J|
3281252|NCT00617409|Active Comparator|Standard of Care|Arm A - Active Comparator: Observation (Standard of Care) + Second Line Chemotherapy
3281253|NCT00617409|Experimental|Ad.p53-DC Vaccines|Arm B - Experimental: Ad.p53-DC vaccines + Second Line Chemotherapy
3281254|NCT00617409|Experimental|Ad.p53-DC Vaccines + ATRA|Arm C - Experimental: Ad.p53-DC vaccines + All -trans Retinoic Acid (ATRA) + Second Line Chemotherapy
3281255|NCT00617396|Experimental|Quetiapine treatment group|All subjects will receive seroquel treatment for 8 weeks. Seroquel is the intervention.
3281256|NCT00617370|Experimental|1|The regimen consists of EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 with pegfilgrastim subcutaneously (SQ) on day # 2, followed by paclitaxel (175 mg/m2) q 14 days x 6 with pegfilgrastim SQ on day # 2.
3281257|NCT00617357|Experimental|1|Strattice Reconstructive Tissue Matrix
3281258|NCT00617344|Experimental|Group 1|Participants received the CYD 5555 formulation.
3281259|NCT00617344|Experimental|Group 2|Participants received the CYD 5553 formulation.
3281260|NCT00617344|Experimental|Group 3|Participants received the CYD 4444 formulation.
3281261|NCT00617331|Experimental|Dose 7.5 mcg|7.5 micrograms of vaccine administered on Day 0 and Day 28.
3281262|NCT00617331|Experimental|Dose 30 mcg|30 micrograms of vaccine administered on Day 0 and Day 28.
3281263|NCT00617318|Experimental|A|
3281264|NCT00617318|Placebo Comparator|B|
3281265|NCT00617305|Experimental|Ambrisentan|Patients were assigned ambrisentan at open-label enrollment or randomization, and received at least one dose of ambrisentan plus an approved phosphodiesterase type-5 (PDE-5) inhibitor (PDE-5i; sildenafil or tadalafil).
3281266|NCT00617305|Active Comparator|Placebo|Patients were assigned placebo at randomization and received at least one dose of placebo plus an approved PDE-5i (sildenafil or tadalafil).
3281267|NCT00617292||Category 1, Group 1|Children who have 21OHD and received prenatal dexamethasone treatment
3281268|NCT00617292||Category 1, Group 2|Children who have 21OHD and did not receive prenatal dexamethasone treatment (control)
3281269|NCT00617292||Category 2|Mothers of children who received prenatal dexamethasone treatment
3281270|NCT00617279|Active Comparator|GORE PROPATEN Vascular Graft:|
3281271|NCT00617279|Active Comparator|Disadvantaged Autologous Vein Graft|
3281272|NCT00617266|Active Comparator|Arm 1 Control Group|Distribution of pamphlets containing information on the hazards of tobacco
3281273|NCT00617266|Experimental|Arm 2|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
3281274|NCT00617266|Experimental|Arm 3|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
3281275|NCT00617266|Experimental|Arm 4|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
3281276|NCT00617253|Experimental|A|
3281277|NCT00617253|Experimental|B|
3281278|NCT00617253|Experimental|C|
3281281|NCT00617240|Placebo Comparator|2|Matched placebo to metformin, doses between 250/0mg and 2000/0mg per day
3281282|NCT00617214||All|Schizophrenic outpatients who are treated with Seroquel IR and who are additionally intended to start with an integrated care program
3281283|NCT00617201|Experimental|1|Atomoxetine
3281284|NCT00617201|Placebo Comparator|2|Matched Placebo
3281285|NCT00617188|Experimental|Fulvestrant|Fulvestrant 500 milligrams (mg) Day 1; 250 mg Day 1, 29 and every 28 days thereafter.
3281286|NCT00617175|Experimental|Long NID|Programming a number of 30 out of 40 intervals to detect (NID)ventricular arrhythmia
3281287|NCT00617175|Active Comparator|Short NID|Programming a number of 18 out of 24 intervals to detect (NID)ventricular arrhythmia
3281288|NCT00617136|Experimental|III|Prewarming by HotDog
3281289|NCT00617136|Active Comparator|I|Intraoperative warming by Bair Hugger
3281290|NCT00617136|Active Comparator|II|Intraoperative warming by HotDog
3281291|NCT00617123|Experimental|Vorapaxar|Participants receive a vorapaxar 2.5 mg tablet administered orally once daily for 1 year
3281292|NCT00617123|Placebo Comparator|Placebo|Participants receive a matching placebo tablet to vorapaxar administered orally once daily for 1 year
3281293|NCT00617110|Sham Comparator|allergic clean air|subjects with allergic rhinitis will be exposed to clean air followed by LAIV
3281294|NCT00617110|Active Comparator|Allergic diesel|subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
3281295|NCT00617110|Sham Comparator|control clean air|Healthy control subjects will be exposed to clean air followed by LAIV
3281296|NCT00617110|Sham Comparator|Control diesel|Healthy control will be exposed to diesel followed by LAIV
3281297|NCT00617097|Active Comparator|paracervical block with lidocaine|Subjects who receive pain control using paracervical block with lidocaine during first trimester surgical abortion
3281298|NCT00617097|Experimental|paracervical block with ketorolac and lidocaine|Subjects who receive pain control using paracervical block with ketorolac and lidocaine during first trimester surgical abortion
3281299|NCT00617084|Active Comparator|1. Resolute|Medtronic Endeavor Resolute
3281300|NCT00617084|Active Comparator|2. XIENCE V|Abbott Xience V
3281301|NCT00617058|Experimental|1|metformin, 250mg-2000 mg/day, in BID to TID doses for 26 weeks. Open, flexibly adjusted.
3281302|NCT00617058|Experimental|2|Healthy lifestyle intervention. Additional meeting at each psychiatric visit to review weight changes, level of physical activity and healthy eating behaviors
3281303|NCT00617058|No Intervention|3|Self-selected patients will be followed at major timepoints to assess weight and related measures.
3281304|NCT00617045|Experimental|Duloxetine|type of experimental agent
3281305|NCT00617032|Active Comparator|1|1x10^10 DRP/mL tgAAC94
3281306|NCT00617032|Active Comparator|2|1x10^11 DRP/mL tgAAC94
3281307|NCT00617032|Placebo Comparator|3|Single dose tgAAC94 placebo
3281308|NCT00617019||Parkinson's patients|Observational study to compare rates of impulse control disorders in patients taking different medications for Parkinson's Disease
3281309|NCT00617006||Before (Control)|Study group representative of standard practice
3281310|NCT00617006||After(Treatment)|After treatment group with the personal hand hygiene device ie. Device Group.
3281311|NCT00616993|Placebo Comparator|2|Vehicle
3281312|NCT00616993|Experimental|1|Difluprednate
3281313|NCT00616980|Active Comparator|Low Dose|
3281314|NCT00616980|Active Comparator|High Dose|
3281315|NCT00616980|Placebo Comparator|Saline|
3281316|NCT00616967|Active Comparator|Arm I|Patients receive carboplatin IV and paclitaxel albumin-stabilized nanoparticle formulation IV on day 1 and an oral placebo on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
3281317|NCT00616967|Experimental|Arm II|Patients receive carboplatin and paclitaxel albumin-stabilized nanoparticle formulation as in arm I and oral vorinostat on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
3281318|NCT00616954|Experimental|1|with ATG-F
3281319|NCT00616954|No Intervention|2|control
3281320|NCT00616941|Experimental|Cohort 1|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) once every 3 weeks for a total of 5 vaccinations.
3281321|NCT00616941|Experimental|Cohort 2|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) in combination with Montanide ISA-51 vegetable grade (VG) once every 3 weeks for a total of 5 vaccinations.
3281322|NCT00616941|Experimental|Cohort 3|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) in combination with Montanide ISA-51 VG and poly-ICLC once every 3 weeks for a total of 5 vaccinations.
3281323|NCT00616928|Experimental|Influenza A (H5N1) 18-64Y Group|Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3281324|NCT00616928|Placebo Comparator|Placebo 18-64Y Group|Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3281325|NCT00616928|Experimental|Influenza A (H5N1) >64Y Group|Subjects aged > 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3281326|NCT00616928|Placebo Comparator|Placebo >64Y Group|Subjects aged > 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3281375|NCT00616538|Experimental|EpiCeram(r)|EpiCeram(r) topical barrier repair cream.
3281376|NCT00616512|Experimental|1|GF Strong Water Protocol/ water allowed between meals after oral care for selected clients/ Fraser Water Protocol
3281377|NCT00616486|Experimental|1|
3281378|NCT00616486|Placebo Comparator|2|
3281327|NCT00616928|Experimental|Influenza A (H5N1) Group|Pooled group of subjects aged >18 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3281328|NCT00616928|Placebo Comparator|Placebo Group|Pooled group of subjects aged >18 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3281329|NCT00616928|Experimental|Influenza A (H5N1) 18-60Y Group|Subjects aged 18-60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3281330|NCT00616928|Placebo Comparator|Placebo 18-60Y Group|Subjects aged 18-60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3281331|NCT00616928|Experimental|Influenza A (H5N1) >60Y Group|Subjects aged >60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3281332|NCT00616928|Placebo Comparator|Placebo >60Y Group|Subjects aged > 60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3281333|NCT00616915|Other|1|Wellbutrin SR switched to Wellbutrin XL
3281334|NCT00616902|Active Comparator|Paricalcitol Injection 4 mcg/mL|Paricalcitol Injection 4 mcg/mL given intravenously 3 times per week during dialysis
3281335|NCT00616902|Placebo Comparator|Placebo Injection 4 mcg/mL|Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
3281336|NCT00616889||1|Seroquel added to medication regime and sleep quality measured
3281337|NCT00616876|Experimental|1|Study group will receive 1% lactulose in all their feeds (human milk or preterm formula)
3281338|NCT00616876|Placebo Comparator|2|Control group will receive 1% dextrose placebo in all their feeds (human milk or preterm formula).
3281339|NCT00616850|Active Comparator|Group A|Group A subjects will receive a continuous femoral block catheter and a Patient Controlled Analgesia (PCA).
3281340|NCT00616850|Experimental|Group B|Group B subjects will receive a low dose lidocaine (1.33 mg/kg/hr) infusion and a Patient Controlled Analgesia.
3281341|NCT00616850|Placebo Comparator|Group C|Group C subjects will receive placebo (preservative free normal saline) infusion and a Patient Controlled Analgesia.
3281342|NCT00616837|Active Comparator|Standard consultation|Standard care in orthopaedic outpatient clinic
3281343|NCT00616837|Experimental|Telemedicine consultation|Orthopaedic care in outpatient clinic by use of telemedicine.
3281344|NCT00616824|Active Comparator|Traditional Method|Arm which uses the Serratus Anterior muscle mobilization for lateral coverage of the tissue expander
3281345|NCT00616824|Experimental|Dermamatrix Arm|Arm which uses Dermamatrix as the lateral expander coverage
3281346|NCT00616811|Experimental|Vildagliptin|
3281347|NCT00616811|Active Comparator|Sitagliptin|
3281348|NCT00616798|Experimental|3|
3281349|NCT00616798|Placebo Comparator|4|
3281350|NCT00616798|Experimental|1|
3281351|NCT00616798|Experimental|2|
3281352|NCT00616772|Experimental|ABT-335 + Atorvastatin|ABT-335 (135 mg) and atorvastatin (up to 40 mg) once daily for 2 years.
3281353|NCT00616772|Placebo Comparator|Placebo + Atorvastatin|Placebo and atorvastatin (up to 40 mg) once daily for 2 years.
3281354|NCT00616759|Active Comparator|1|ECT as usual
3281355|NCT00616759|Experimental|2|ECT-induced seizures terminated with propofol
3281356|NCT00616746|Experimental|1|Three test days, within-subject design.
3281357|NCT00616733|Experimental|1|
3281358|NCT00616733|Experimental|2|
3281359|NCT00616733|Experimental|3|
3281360|NCT00616655|Active Comparator|1|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
3281361|NCT00616655|Active Comparator|2|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
3281362|NCT00616655|Placebo Comparator|3|Placebo total daily dose 0.9 mg
3281363|NCT00616642|Experimental|Group 1 (ACTH-secreting adenomas)|Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 6 months in the absence of disease progression or unacceptable toxicity.
3281364|NCT00616642|Experimental|Group 2 (non-secreting macroadenomas)|Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 12 months in the absence of disease progression or unacceptable toxicity.
3281365|NCT00616616|Experimental|1|all subjects
3281366|NCT00616603|Other|Group A|This is the control arm and subjects in Group A will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 2ml IV of normal saline.
3281367|NCT00616603|Experimental|Group B|Subjects in Group B will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 8mg Dexamethasone + 2ml IV of normal saline.
3281368|NCT00616603|Active Comparator|Group C|Subjects in Group C will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 2ml IV (8mg)of Dexamethasone.
3281369|NCT00616577|Experimental|Group CB|Subjects in this arm will receive caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine after induction of general anesthesia prior to surgical incision.
3281370|NCT00616577|Active Comparator|Group CA|Group CA (Caudal After—control group) will receive caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine after completion of surgery but before emergence from anesthesia.
3281371|NCT00616577|Active Comparator|Group LIA|Group LIA (Local Infiltration After—control group) will receive local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site at the conclusion of surgery but before emergence from anesthesia.
3281372|NCT00616551|Experimental|A|
3281373|NCT00616551|Active Comparator|B|
3281379|NCT00616473||1 Nursing Home Staff|Direct care staff
3281380|NCT00616473||2 Family Members|Family members/Significant other of nursing home resident.
3281381|NCT00616460|Experimental|Bivalirudin|
3281382|NCT00616447|Experimental|1|
3281383|NCT00616447|Sham Comparator|2|
3281384|NCT00616434|Experimental|Interferon beta-1a|Interferon beta-1a 30 µg intramuscular (IM) injection twice weekly for 12 weeks
3281385|NCT00616434|Placebo Comparator|Placebo|Placebo IM injection twice weekly for 12 weeks
3281386|NCT00616421|Experimental|MenACWY-CRM (1 dose)|1 injection of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study day 1.
3281387|NCT00616421|Active Comparator|Licensed polysaccharide vaccine|1 injection of a licensed meningococcal MenACWY polysaccharide-protein conjugate vaccine administered by intramuscular (IM) injection on study day 1
3281388|NCT00616421|Experimental|MenACWY-CRM (2 doses)|2 injections of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study days 1 and 61.
3281389|NCT00616408||A|Newly diagnosed active acromegaly out of the 297 patients coming to our Department for acromegaly who received first-line treatment with LAR
3281390|NCT00616395||no grouping|IDE used for outcome measurement not for an intervention.
3281391|NCT00616382|Experimental|Stepwise Indo|Stepwise escalating doses of indomethacin, until ductal closure or maximum of 1 mg/kg/dose.
3281392|NCT00616382|Experimental|PTX|Combined administration of indomethacin and pentoxifylline, an inhibitor of TNF alpha
3281393|NCT00616369||1|"I:~For those patients who have had blood samples drawn as a result of participating in current protocol, Identification of Genetic Markers for Primary Pulmonary Hypertension study (X980515002), we would like to use their previously obtained blood and continue to draw samples (12mL; less than 3 tablespoons) ONLY if they change disease therapies.~For those patients who participated in Pulmonary Arterial Hypertension (PAH) Database study (X030403017), these participants will also sign a consent form to participant in this new trial. We would like to use the previously obtained data from the X030403017 in part with this study.~As for the X980515002 expired patients, we would like to use the previously obtained data ONLY in part for this study that was collected as a result of the X980515002 study."
3281394|NCT00616369||2|"II:~Group 2: After signing a consent form, these participants will have a 12mL (less than 3 teaspoons) blood sample drawn at baseline, at 3-4 month, at 6-8 month, at 12 month, and at 24 month visits. With each disease therapy change, the blood draws (12mL samples) will begin again at baseline and continue through the 3-4, 6-8, 12, and 24 month visits."
3281395|NCT00616343|Active Comparator|Zonisamide|
3281396|NCT00616330|Experimental|1|clindamycin phosphate/butoconazole nitrate
3281397|NCT00616330|Active Comparator|2|clindamycin phosphate
3281398|NCT00616330|Active Comparator|3|butoconazole nitrate
3281399|NCT00616304|Active Comparator|A|L-arginine infusion
3281400|NCT00616304|Placebo Comparator|S|Normal saline infusion
3281401|NCT00616291|Experimental|Group I|MHC Class I binding peptide at 1000 mcg
3281402|NCT00616291|Experimental|Group II|MHC Class II binding peptide at 1000 mcg
3281403|NCT00616291|Experimental|Group III|Combination MHC Class I and II binding peptide at 1000 mcg each
3281404|NCT00616265|No Intervention|B|Group B. Only Usual Control
3281405|NCT00616265|Experimental|A|Group A: Cpap treatment plus Usual control
3281406|NCT00616239|Active Comparator|A|Subjects randomized to have the right side of the face peeled with salicylic acid every 2 weeks for a total of 4 peels (first 2 at 20% and last 2 at 30%). Subjects will apply 4% hydroquinone cream to affected areas on entire face for 14 weeks.
3281407|NCT00616239|Active Comparator|B|Subjects randomized to have the left side of the face peeled with salicylic acid every 2 weeks for a total of 4 peels (first 2 at 20% and last 2 at 30%). Subjects will apply 4% hydroquinone cream to affected areas on entire face for 14 weeks.
3281408|NCT00616200|Experimental|A|
3281409|NCT00616187|Active Comparator|interferon|
3281410|NCT00616187|Sham Comparator|untreated|
3281411|NCT00616174|Other|1|Active warming with Bair Hugger blanket
3281412|NCT00616161|Experimental|1|Istaroxime dose of 0.5 microgram/kg body weight/minute of iv infusion for six ours
3281413|NCT00616161|Experimental|2|Istaroxime dose of 1.0 microgram/kg body weight/minute of iv infusion for six ours
3281414|NCT00616161|Experimental|3|Istaroxime dose of 1.5 microgram/kg body weight/minute of iv infusion for six ours
3281415|NCT00616161|Placebo Comparator|4|Placebo iv infusion for six ours
3281416|NCT00616148|Placebo Comparator|Placebo|
3281417|NCT00616148|Experimental|YKP3089|
3281418|NCT00616122|Experimental|Sunitinib, Cyclophosphamide, and Methotrexate|
3281419|NCT00616109|Experimental|Maintenance Sunitinib|"Main interventional arm of study. Subjects who received maintenance sunitinib experimentally on this study were from a population of (consenting) patients with histologically or cytologically documented Extensive-State Small Cell Lung Cancer (ES-SCLC) who did not progress (were classified as Complete Response or CR, Partial Response or PR, or Stable Disease or SD) after an induction chemotherapy (Cisplatin and etoposide)"
3281420|NCT00616096|Experimental|1|
3281421|NCT00616083||1|Healthy breast fed infants
3281422|NCT00616070|Experimental|1|Difluprednate
3281423|NCT00616070|Placebo Comparator|2|Vehicle
3281424|NCT00616057|Placebo Comparator|B|Maltodextrin, non digestible carbohydrate
3281425|NCT00616057|Experimental|A|fructans, non digestible carbohydrates fermented in the caeco-colon
3281426|NCT00616044|Experimental|CSA|For CSA, an 22-G catheter (Spinocath, B.Braun Melsungen, Germany) over a 27-G Quincke needle was used. After identification of the epidural space with a Crawford needle, the catheter with the spinal needle inside was advanced through the epidural space until the dural puncture was felt and CSF was seen in the catheter. The catheter was then fed over the needle into the intrathecal space. The spinal needle and the modified Tuohy needle were removed and a luer connector and a filter previously filled with the anesthetic solution were attached to the catheter.
3281485|NCT00615498||Controls|Subjects who qualify for bariatric surgery but do not undergo the procedure
3281486|NCT00615472|Experimental|Group 1|Inhaled Anesthesia - isoflurane
3281427|NCT00616044|Experimental|CSE|"CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany). The block consists of performing a spinal block via a 27-G spinal needle (Spinocan 125mm) introduced through an 18-G Tuohy needle (Perican 88mm) which was placed cranially directed in the epidural space. We did rotate the Tuohy needle between the spinal block and the insertion of the epidural catheter."
3281428|NCT00616018|Experimental|A|all subjects receive 4 g/day of acetaminophen for 10 consecutive days in this open-label study
3281429|NCT00616005|Other|1|Pts taking EIAEDs
3281430|NCT00616005|Other|2|Pts not taking EIAEDs
3281431|NCT00615979||Miniature echo machine|Diagnostic capabilities Wireless transfer
3281432|NCT00615966|Experimental|1|
3281433|NCT00615966|Experimental|2|
3281434|NCT00615966|Placebo Comparator|3|
3281435|NCT00615940|Experimental|1|Capecitabine, 1000 mg/m2, twice daily by mouth, on Days 1 to 14, followed by a 7 day rest in each 21 day cycle given in combination with WX-671 once daily by mouth, Days 1-21 inclusive.
3281436|NCT00615940|Experimental|2|Capecitabine, 1000 mg/m2, twice daily by mouth, on Days 1 to 14, followed by a 7 day rest in each 21 day cycle given in combination with placebo once daily by mouth, Days 1-21 inclusive.
3281437|NCT00615927|Experimental|Astrocytoma|Grade II Astrocytoma
3281438|NCT00615927|Experimental|Oligodendroglioma|Grade II Oligodendroglioma or oligoastrocytomas
3281439|NCT00615901|Experimental|1|This is a pilot study using 8 cycles of CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2), at 14 day intervals supported by PEG-filgrastim for a cohort of 38 patients. A safety analysis will then be performed.
3281440|NCT00615888|Active Comparator|A|Traditional management including preoperative bowel washout, patient controlled analgesia (PCA), delayed start of enteral feeding
3281441|NCT00615888|Experimental|B|Fast track management including no bowel washout, patient controlled epidural anesthesia, early enteral feeding
3281442|NCT00615875|Active Comparator|A|
3281443|NCT00615875|Placebo Comparator|P|
3281444|NCT00615862||AUD+ and AUD-|AUD stands for alcohol use disorders. Patients with alcohol use disorders are assigned the label AUD+. Patients without alcohol use disorders are assigned the label AUD-.
3281445|NCT00615836|Experimental|Desmopressin Melt 10 μg|Participants received desmopressin melt 10 μg once a day, placed under the tongue one hour before bedtime until they were re-randomized to one of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).
3281446|NCT00615836|Experimental|Desmopressin Melt 25 μg|Participants received desmopressin melt 25 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
3281447|NCT00615836|Experimental|Desmopressin Melt 50 μg|Participants received desmopressin melt 50 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
3281448|NCT00615836|Experimental|Desmopressin Melt 100 μg|Participants received desmopressin melt 100 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
3281449|NCT00615823|Active Comparator|1|Atorvastatin group: receive atorvastatin 10 mg daily in addition to supportive care
3281450|NCT00615823|Placebo Comparator|2|Placebo group: receive matching placebo in addition to supportive care.
3281451|NCT00615810|Active Comparator|2|Open label Kivexa (abacavir (as sulfate) 600 mg/lamivudine 300 mg) once daily for oral administration plus Sustiva (efavirenz 600 mg) once daily for oral administration
3281452|NCT00615810|Experimental|1|Open label Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir DF 300 mg) once daily for oral administration to be taken on an empty stomach
3281453|NCT00615797|Experimental|1|Group randomized to receive intravenous immunoglobulins in addition to standard therapy for sydenham's chorea
3281454|NCT00615797|Placebo Comparator|2|Group randomized to receive standard intervention for sydenham's chorea alone
3281455|NCT00615784|Experimental|A|
3281456|NCT00615771|Experimental|Day 2 embryo transfer|Embryos are transferred 2 days after fertilization.
3281457|NCT00615771|Active Comparator|Day 3 embryo transfer|Standard of care for women undergoing IVF with a limited number of embryos is to transfer all embryos on Day 3 after fertilization
3281458|NCT00615758|Experimental|1|Tarceva
3281459|NCT00615745|Experimental|Single Arm|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
3281460|NCT00615732|Experimental|1|qigong
3281461|NCT00615732|Active Comparator|2|exercise therapy
3281462|NCT00615732|No Intervention|3|
3281463|NCT00615719||ED patients undergoing coronary CTA|Emergency Department patients suspected of having acute coronary syndrome undergoing Coronary Computed Tomographic angiography.
3281464|NCT00615706||1|Asthmatics
3281465|NCT00615706||2|Healthy volunteers (without asthma)
3281466|NCT00615693|Experimental|1|
3281467|NCT00615667|Experimental|tacrolimus(fk506) treatment|tacrolimus(fk506) treatment
3281468|NCT00615654|Other|2|
3281469|NCT00615641||1|3 year old children
3281470|NCT00615641||2|4 year old children
3281471|NCT00615641||3|5 year old children
3281472|NCT00615628||family members|family members of the proband and father identified
3281473|NCT00615602|Experimental|1|FEC -> TXT+H 12m
3281474|NCT00615602|Experimental|2|FEC -> TXT+H 6m
3281475|NCT00615589|Experimental|Flu-Bu4|Fludarabine Busulfan chemotherapy regimen(Flu-Bu4), followed by allogeneic stem cell transplant from best available, matched donor.
3281476|NCT00615576|Experimental|Subjects receiving SB-656933|Eligible subjects will be randomized to receive once daily doses of 100 milligrams of SB- 656933 for 14 days.
3281477|NCT00615576|Placebo Comparator|Subjects receiving placebo|Eligible subjects will be randomized to receive placebo for 14 days.
3281478|NCT00615563||genotype test|
3281479|NCT00615563||combined phenotype/genotype test|
3281480|NCT00615550|Placebo Comparator|Placebo|placebo vaginal gel
3281481|NCT00615550|Active Comparator|Prochieve|Progesterone 8% Vaginal Gel
3281482|NCT00615511|Placebo Comparator|placebo|Approximately one third of subjects
3281483|NCT00615511|Experimental|Pregnenolone|
3281484|NCT00615498||Surgical cases|Subjects who are undergoing bariatric surgery
3281487|NCT00615472|Experimental|Group 2|Intravenous Anesthesia - propofol, remifentanil
3281488|NCT00615459|Experimental|Sequence 1: Placebo,Tiotropium, Indacaterol 150 μg|In period I, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. In period II, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via single dose dry powder inhaler (SDDPI). In period III, indacaterol 150 μg once daily delivered via SDDPI and placebo to tiotropium was delivered once daily via the tiotropium inhalation device. Daily inhaled corticosteroid (ICS) monotherapy (where applicable) was provided to remain stable throughout study. The Short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3281489|NCT00615459|Experimental|Sequence 2: Indacaterol 300 μg, Indacaterol 150 μg, Tiotropium|In period I,indacaterol 300 μg once daily delivered via single dose dry powder inhaler (SDDPI)and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period II, indacaterol 150 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period III, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via SDDPI. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
3281490|NCT00615459|Experimental|Sequence 3: Indacaterol 150 μg, Indacaterol 300 μg, Placebo|In period I, indacaterol 150 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period II, indacaterol 300 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period III, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
3281491|NCT00615459|Experimental|Sequence 4: Tiotropium, Placebo, Indacaterol 300 μg|In period I, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via SDDPI. In period II, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. In period III, indacaterol 300 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
3281492|NCT00615446|Experimental|A|
3281493|NCT00615433|Experimental|Lurasdione 40mg tablets|
3281494|NCT00615433|Experimental|120mg|
3281495|NCT00615433|Active Comparator|15mg Olz|
3281496|NCT00615433|Placebo Comparator|Sugar pill|
3281497|NCT00615420|Experimental|1|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed
3281498|NCT00615420|Placebo Comparator|2|Sugar-free placebo gel 5ml 4 times a day, swished and held in mouth for 30 secs then swallowed
3281499|NCT00615407||Alcohol Drinkers|Asthmatics who consume 3 or more alcoholic beverages per day (on average)
3281500|NCT00615407||Non Drinkers|Asthmatics who do not drink alcohol or consume less than or equal to 2 alcoholic beverages per month
3281501|NCT00615381|Active Comparator|Normal insulin|Maintenance of intraoperative euglycemia (blood glucose 80--110 mg/dL) using normal intensive insulin infusion rates (0-10 U/hr).
3281502|NCT00615381|Experimental|Supraphysiologic insulin|Maintenance of intraoperative euglycemia (blood glucose 80--110 mg/dL) using supraphysiologic insulin infusion doses (0.3 U/kg/hr) and exogenous dextrose to provide stable blood glucose levels .
3281503|NCT00615368|Placebo Comparator|Placebo|Isotonic NaCl, intravenously injection
3281504|NCT00615368|Experimental|Active|Epoetin alfa, injected
3281505|NCT00615355|Other|Body location|Different body locations receive specific treatments
3281506|NCT00615355|Active Comparator|Control|Treatment with narrow-band UVB
3281507|NCT00615329||Soft tissue tumor|Any patient with soft tissue tumor will be asked to give a sample for this study
3281508|NCT00615316|Experimental|A|
3281509|NCT00615316|Placebo Comparator|B|
3281510|NCT00615303|Placebo Comparator|2|
3281511|NCT00615303|Active Comparator|1|
3281512|NCT00615277|Active Comparator|1|1: omega-3 fatty acid supplement
3281513|NCT00615277|Placebo Comparator|2|2: olive oil
3281514|NCT00615264|Experimental|DiaPep277|DiaPep277 1.0 mg + 40 mg Mannitol in 0.5 mL lipid emulsion.
3281515|NCT00615264|Placebo Comparator|Placebo|Mannitol 40 mg in 0.5 mL lipid emulsion.
3281516|NCT00615251|Experimental|1|
3281517|NCT00615251|Active Comparator|2|
3281518|NCT00615238|Experimental|Diet plus continuous bouts|diet-plus-continuous bouts of vigorous aerobic exercise
3281519|NCT00615238|Experimental|Diet plus short bouts|diet-plus-short bouts of vigorous aerobic exercise accumulated throughout the day
3281520|NCT00615238|Experimental|Diet plus moderate lifestyle activity|diet-plus-moderate intensity lifestyle activity accumulated throughout the day
3281521|NCT00615225||Brain dead patients|All patients meeting criteria for brain death
3281522|NCT00615225||Healthy control|Any healthy volunteers accepting to give some blood
3281523|NCT00615225||Volunteers having hip surgery|Patients undergoing hip surgery for degenerative non-inflammatory hip disease
3281524|NCT00615212|Active Comparator|Subjects receiving midazolam|Eligible subjects will receive midazolam oral syrup with a dose of 5 milligrams on Day 1.
3281525|NCT00615212|Active Comparator|Subjects receiving rosiglitazone|Eligible subjects will receive rosiglitazone oral tablet with a dose of 4 milligrams on Day 2.
3281526|NCT00615212|Active Comparator|Subjects receiving flurbiprofen|Eligible subjects will receive flurbiprofen oral tablet with a dose of 50 milligrams on Day
3281527|NCT00615212|Experimental|Subjects receiving GSK376501|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams from Day 4 to Day 10.
3281528|NCT00615212|Experimental|Subjects receiving GSK376501+ midazolam|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with midazolam oral tablet of 5 milligrams on Day 11.
3281706|NCT00613964|Active Comparator|Carperitide Therapy|Addition of carperitide administration to standard heart failure therapy
3281529|NCT00615212|Experimental|Subjects receiving GSK376501 + rosiglitazone|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with rosiglitazone oarl tablet of 4 milligrams on Day 12.
3281530|NCT00615212|Experimental|Subjects receiving GSK376501 + flurbiprofen|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with flurbiprofen oral tablet of 50 milligrams on Day 13.
3281531|NCT00615199|Experimental|1mg BD|
3281532|NCT00615199|Experimental|5mg BD|
3281533|NCT00615199|Experimental|15mg BD|
3281534|NCT00615199|Placebo Comparator|Placebo BID|
3281535|NCT00615186|Experimental|A|"Prior Surgery~Rickham Catheter placement 99mTc-DTPA Flow Study~Neuradiab Dosimetry Study~Neuradiab Therapeutic Dose Administration~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
3281536|NCT00615186|Active Comparator|B|"Prior Surgery: Gross total resection (< 1 cm. enhancing rim)~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
3281537|NCT00615173|Experimental|1|tacrolimus(fk506) treatment in induction and maintenance phase
3281538|NCT00615173|Active Comparator|2|intravenous cyclophosphamide pulses treatment in induction phase; and Aza in the maintenance phase
3281539|NCT00615160|Experimental|A|PTK787/ZK 222584 (PTK-ZK) taken orally with a daily flat dose of 1250 mg on days 1 to 28 (= 1 cycle)
3281540|NCT00615160|Experimental|B|combined treatment with DTIC 850 mg/m² on day 1 + PTK-ZK 1250 mg flat dose on days 1 to 28
3281541|NCT00615147||1|Patients to have a CT pulmonary angiogram for suspected pulmonary embolism will have a d-dimer drawn as is routinely done.
3281542|NCT00615134|Experimental|1|
3281543|NCT00615134|Active Comparator|2|
3281544|NCT00615121||arteries from PAD patients|peripheral arteries from patients undergoing amputation for end stage peripheral arterial occlusive disease
3281545|NCT00615121||arteries from Free Fib transfers|peripheral arteries from patients without evidence of peripheral arterial occlusive disease
3281546|NCT00615095||1|Cases will be patients 18 years or older with a histologically confirmed, second or multiple primary melanoma.
3281547|NCT00615095||2|Controls will be patients 18 years or older with a histologically confirmed first primary melanoma diagnosed no earlier than 12 months prior to the study start date.
3281548|NCT00615095||3|Healthy controls will be subjects 18 years or older recruited from the general population through random digit dialing. These subjects will have no history of melanoma. They will also be frequency matched to cases on the basis of sex and 10-year age group.
3281549|NCT00615082|Experimental|Mindfulness-Based Stress Reduction|
3281550|NCT00615082|Active Comparator|Caregiver Education & Social Support|
3281551|NCT00615069|Experimental|31 mm GORE EXCLUDER® Test Subjects|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
3281552|NCT00615056|Active Comparator|B|Bevacizumab (avastin)
3281553|NCT00615056|Experimental|C|AG-013736 (axitinib)
3281554|NCT00615056|Experimental|A|AG-013736 (axitinib)
3281555|NCT00615056|Active Comparator|D|bevacizumab (avastin)
3281556|NCT00615043||TURBT group|Subjects undergoing transurethral resection of bladder tumor or other transurethral biopsy procedure who agree to provide bladder tissue specimens
3281557|NCT00615030|Experimental|Indacaterol Morning,Indacaterol Evening, Salmeterol|In period I, indacaterol 300 μg once a day in the morning delivered via single dose dry powder inhaler (SDDPI) with a placebo to salmeterol delivered via dry powder inhaler (DPI). Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, Salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and second dose in the evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3281558|NCT00615030|Experimental|Indacaterol Evening,Indacaterol Morning, Placebo|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3281559|NCT00615030|Experimental|Salmeterol, Placebo, Indacaterol Morning|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose was in the evening along with placebo matching indacaterol delivered by SDDPI. In period II, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3281707|NCT00613951|Experimental|SIAC 30 (B)|
3281708|NCT00613951|Experimental|SIAC 45 (B)|
3281560|NCT00615030|Experimental|Placebo, Salmeterol, Indacaterol Evening|In period I, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, salmeterol 50 μg twice daily delivered via dry powder inhaler (DPI). One of the two daily doses of salmeterol was administered in the morning and the second dose was in the evening along with placebo matching indacaterol delivered by SDDPI. In period III, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via dry DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3281561|NCT00615030|Experimental|Indacaterol Morning, Placebo, Indacaterol Evening|In period I, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, During morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, Patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3281562|NCT00615030|Experimental|Indacaterol Evening,Salmeterol, Indacaterol Morning|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period II, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3281563|NCT00615030|Experimental|Salmeterol, Indacaterol Evening, Placebo|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3281564|NCT00615030|Experimental|Placebo, Indacaterol Morning, Salmeterol|In period I, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via dry powder inhaler DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3281565|NCT00615030|Experimental|Indacaterol Morning, Salmeterol, Placebo|In period I, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3281566|NCT00615030|Experimental|Indacaterol Evening, Placebo, Salmeterol|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via dry powder inhaler DPI. In period II, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3281567|NCT00615030|Experimental|Salmeterol, Indacaterol Morning, Indacaterol Evening|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3281709|NCT00613951|Active Comparator|BIAsp 30|
3281710|NCT00613938|Placebo Comparator|004|placebo 1 capsule q4-6 hrs for 3 days
3281568|NCT00615030|Experimental|Placebo, Indacaterol Evening, Indacaterol Morning|In period, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3281569|NCT00615017|Experimental|AZD9773 cohort 1 (50 units/kg)|AZD9773: single infusion of 50 units/kg
3281570|NCT00615017|Experimental|AZD9773 cohort 2 (250 units/kg)|AZD9773: single infusion of 250 units/kg
3281571|NCT00615017|Experimental|AZD9773 cohort 3 (250/50 units/kg)|AZD9773: loading infusion of 250 units/kg then 9 maintenance doses of 50 units/kg q12hrs
3281572|NCT00615017|Experimental|AZD9773 cohort 4 (500/100 units/kg)|AZD9773: loading infusion of 500 units/kg then 9 maintenance doses of 100 units/kg q12hrs
3281573|NCT00615017|Experimental|AZD9773 cohort 5 (750/250 units/kg)|AZD9773: loading infusion of 750 units/kg then 9 maintenance doses of 250 units/kg q12hrs
3281574|NCT00615017|Placebo Comparator|Placebo|Placebo
3281575|NCT00615004||1-SSA|All patients receiving first-line depot SSA treatment, with either octreotide-LAR or lanreotide, achieving control of the disease, and with available follow-up after 12 months of treatment.
3281576|NCT00615004||2-Surgery|All patients treated with first-line surgery via trans-sphenoidal route by microscopic and/or endoscopic approach, who did not require any additional therapy for acromegaly and with available follow-up after 12 months of treatment
3281577|NCT00614991|Active Comparator|Group A|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg BID Period 3-Fosamprenavir 1400mg BID + Raltegravir 400mg BID
3281578|NCT00614991|Active Comparator|Group B|Period 1-Raltegravir 400mg BID Period2-Fosamprenavir 1400mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg BID
3281579|NCT00614991|Active Comparator|Group C|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID
3281580|NCT00614991|Active Comparator|Group D|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 700mg BID + Raltegravir 100mg BID
3281581|NCT00614991|Active Comparator|Group E|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID
3281582|NCT00614991|Active Comparator|Group F|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
3281583|NCT00614978|Experimental|I|Lapatinib plus temozolomide
3281584|NCT00614965|Experimental|1|IC
3281585|NCT00614965|Experimental|2|PC
3281586|NCT00614952|Experimental|PR|
3281587|NCT00614952|Active Comparator|PSG|
3281588|NCT00614939|Experimental|Saxa|Saxagliptin
3281589|NCT00614939|No Intervention|Placebo|Placebo to match
3281590|NCT00614926|Experimental|Modafinil|Eligible patients will be treated at baseline through Week 4. Those who choose to continue will have additional in-person visits at Weeks 8 and 12 visits (and Week 16 for those starting modafinil at Week 4).
3281591|NCT00614926|Placebo Comparator|Placebo|Sugar pill equivalent to the active comparator. Dosing schedule will be the same as the dosing schedule for Modafinil.
3281592|NCT00614887||2|Patients scheduled for elective cerebral aneurysmal surgery
3281593|NCT00614887||1|Patients with subarachnoid hemorrhage
3281594|NCT00614874|Experimental|1|Subjects took rosiglitazone 2 mg for 4 weeks, then 4mg for 4 weeks, then 8 mg for 4 weeks
3281595|NCT00614861||001|
3281596|NCT00614848|Experimental|1|Endeavor Drug Eluting Coronary Stent
3281597|NCT00614848|Active Comparator|2|Driver bare-metal coronary stent
3281598|NCT00614835|Experimental|1 patients with completely resected uterine leiomyosarcoma|Docetaxel plus Gemcitabine
3281599|NCT00614822|Other|one arm for study|Carboplatin, Pemetrexed and Bevacizumab are given day 1 every 3 weeks for 6 cycles and will be continued if patient tolerates treatments and has stable disease. The Bevacizumab will be continued every 3 weeks for 1 year if the patient tolerates treatment and has stable disease.
3281600|NCT00614809|Experimental|1|non-randomized open-label uncontrolled phase II trial
3281601|NCT00614796|Experimental|1|5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
3281602|NCT00614796|No Intervention|2|daily physical activity is assessed at baseline, 3 months, 9 months and 15 months. No counseling.
3281603|NCT00614770|Experimental|1|Standard White Light Colonoscopy
3281604|NCT00614770|Experimental|2|High Definition White Light Colonoscopy
3281605|NCT00614770|Experimental|3|Narrow Band Imaging Colonoscopy
3281606|NCT00614757|No Intervention|2|One half of the patients will take not medication for 30 days and then have labs redrawn
3281607|NCT00614757|Experimental|1|one half of the patients with insulin resistance will take 4ml of 20% N-acetylcysteine BID for 30 days
3281608|NCT00614744|Experimental|Whole-body Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
3281609|NCT00614744|Active Comparator|Normothermia|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
3281610|NCT00614731|Experimental|ID immunizations (100 mcg)|Participants will receive a total of two 100 mcg intradermal (ID) KLH carrier-protein immunizations with 1 mg/ml KLH per immunization. Immunizations will be given 21 days apart at Visits 5 and 6.
3281611|NCT00614731|Experimental|Scarification by 3 jabs|Participants will receive two scarification immunizations by 3 jabs containing 20 mg/ml of KLH carrier-protein. The immunizations will occur 21 days apart at Visits 5 and 6.
3281711|NCT00613938|Active Comparator|003|oxycodone 10mg capsule q4-6 hrs for 3 days
3281712|NCT00613938|Experimental|001|Tapentadol (CG5503) 50mg capsule q4-6 hrs for 3 days
3281612|NCT00614731|Experimental|ID immunizations (250 mcg)|Enrollment will begin after the safety data for Groups 1A and 2A have been reviewed. Participants in this group will receive two 250 mcg ID KLH vaccinations containing 10 mg/ml of KLH carrier-protein. Immunizations will occur 21 days apart at Visits 5 and 6.
3281613|NCT00614731|Experimental|Scarification by 15 jabs|Enrollment will begin after the safety data from groups 1A and 2A has been examined. Participants in this group will receive a total of two scarification immunizations by 5 needles used to administer 15 jabs, each containing, 20 mg/ml of KLH carrier-protein. Immunizations will occur 21 days apart at Visits 5 and 6.
3281614|NCT00614718||1|Total number of patients receiving an ICD between 1993 and 2004 and not having re interventions due to malfunctioning leads.
3281615|NCT00614718||2|Patients with ICD lead failure receiving a new ICD lead
3281616|NCT00614718||3|Patients with ICD lead failure but intact shock-coil of the ICD lead receiving only an additional pace/sense lead.
3281617|NCT00614705|Experimental|1|
3281618|NCT00614705|Placebo Comparator|2|
3281619|NCT00614679|Experimental|1|single arm trial of experimental catheter lock solution
3281620|NCT00614666|Experimental|A|nikkomycin Z 50 mg BID versus placebo BID x 14 days
3281621|NCT00614666|Experimental|B|nikkomycin Z 250 mg BID versus placebo BID x 14 days
3281622|NCT00614666|Experimental|C|nikkomycin Z 500 mg BID versus placebo BID x 14 days
3281623|NCT00614666|Experimental|D|nikkomycin Z 750 mg TID versus placebo TID x 14 days
3281624|NCT00614653|Experimental|Bevacizumab, Erlotinib + Capecitabine|Bevacizumab intravenous (IV) every 2 weeks at 5 mg/kg, Erlotinib 100 mg orally (PO) daily + Capecitabine 400 mg/m2 PO twice daily (BID) only on days of radiation. Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy.
3281625|NCT00614640|Experimental|1|One 0.8 ml vaccine-containing patch and 1 placebo patch placed on upper back or upper thigh for 24 hours on Days 0, 42, and 84
3281626|NCT00614640|Experimental|2|Four 0.8 ml vaccine-containing patches placed on upper back or upper thigh for 24 hours on Days 0, 42, and 84
3281627|NCT00614640|Experimental|3|Four 0.8 ml vaccine-containing patches placed on upper back or upper thigh for 24 hours on Days 0, 7, 42, 49, 84, and 91
3281628|NCT00614614|Experimental|Menhibrix 1 Group|Subjects received 3 doses of Menhibrix vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age during the Primary Vaccination Phase. For the Booster Vaccination Phase, subjects were re-randomized and received either 1 dose of Nimenrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) [Nimenrix 1 Group] or a fourth dose of Menhibrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) [Menhibrix 2 Group], or 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine (at 15-18 months of age) [Nimenrix 2 Group].
3281629|NCT00614614|Active Comparator|ActHIB- Infanrix Group|Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age and 1 booster dose of Infanrix vaccine at 15-18 months of age.
3281630|NCT00614601|Experimental|1|Vaccine + chemo + chemoradiation therapy
3281631|NCT00614601|Experimental|2|Vaccine Only
3281632|NCT00614588||observation group|Patients undergoing laparoscopic surgery requiring general anesthesia and a bladder catheter.
3281633|NCT00614575||BI-Sifrol® Tablets (Pramipexole)|BI-Sifrol® Tablets, pramipexole dose: 0.125 mg, 0.5 mg, No reference therapy
3281634|NCT00614562|Experimental|NAVA|
3281635|NCT00614549||Levetiracetam|Patients treated with Levetiracetam
3281636|NCT00614536||001|
3281637|NCT00614523|Experimental|Romiplostim|Weekly subcutaneous dosing based on platelet count for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period. Starting dose is at 750 μg, up to a maximum dose of 1000 μg, or reduced to a minimum of 250 μg.
3281638|NCT00614523|Placebo Comparator|Placebo|Weekly subcutaneous dosing with blinded matching placebo dose level for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period.
3281639|NCT00614484|Experimental|Proton therapy with chemotherapy|"Induction Chemotherapy - Two cycles Taxol 200mg/m2 and Carboplatin AUC6 on day 1 and day 22. Weekly chemotherapy concurrent with radiotherapy Taxol 50mg/m2 and Carboplatin AUC 2 weekly for 5 weeks.~Proton therapy - 76 Gy in 5 weeks to lung tumor."
3281640|NCT00614471|Active Comparator|1|
3281641|NCT00614471|Experimental|2|
3281642|NCT00614471|Experimental|3|
3281643|NCT00614458|Experimental|Raltegravir and VPA to ART|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
3281644|NCT00614445|Experimental|Diclectin®|Diclectin® (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) delayed release tablet
3281645|NCT00614445|Placebo Comparator|Placebo|Placebo tablets identical in size, shape, taste, and color to the experimental treatment (Diclectin®)
3281646|NCT00614432||1|Women who are anticoagulated.
3281647|NCT00614432||2|Matched case controls.
3281648|NCT00614419|Active Comparator|1|The Lichtenstein tension-free hernioplasty with polypropylene mesh
3281649|NCT00614419|Experimental|2|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
3281650|NCT00614406|Experimental|1|
3281651|NCT00614406|Placebo Comparator|2|
3281652|NCT00614393|Experimental|Dalotuzumab 10 mg/kg Q1W (DB)|In double-blind (DB) Week 1, participants receive cetuximab 400 mg/m^2 intravenously (IV) loading dose and irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV one time each week (Q1W) maintenance dose, irinotecan IV Q1W and DB dalotuzumab 10 mg/kg IV Q1W for up to 32 months of treatment.
3281713|NCT00613938|Experimental|002|Tapentadol (CG5503) 75mg capsule q4-6 hrs for 3 days
3281714|NCT00613925|Active Comparator|Pipelle Group|Women were randomized to have an endometrial biopsy collected using Pipelle de Cornier instrument.
3281715|NCT00613925|Active Comparator|Explora group|Women were randomized to have an endometrial biopsy collected using Explora curette instrument.
3281653|NCT00614393|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (OL)|In the open-label (OL) portion of the study, ≥6 participants receive cetuximab 400 mg/m^2 Q1W + irinotecan Q1W at their pre-study dosage + OL dalotuzumab (loading dose of 15 mg/kg IV followed by a maintenance dose of 7.5 mg/kg 2 weeks later) to verify the safety of the regimen. In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV. In DB Week 2, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV + DB dalotuzumab 15 mg/kg IV. In DB Week 3, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV. Starting with DB Week 4, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 7.5 mg/kg IV Q2W for up to 32 months of treatment.
3281654|NCT00614393|Experimental|Dalotuzumab 10 mg/kg Q1W (OL)|In the OL portion of the study, ≥6 participants receive cetuximab 400 mg/m^2 Q1W+ irinotecan Q1W at their pre-study dosage + OL dalotuzumab 10 mg/kg IV Q1W to verify the safety of the regimen. In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 10 mg/kg IV Q1W for up to 32 months of treatment.
3281655|NCT00614393|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (DB)|In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. In DB Week 2, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV + DB dalotuzumab 15 mg/kg IV. In DB Week 3, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV. Starting with DB Week 4, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 7.5 mg/kg IV Q2W for up to 32 months of treatment.
3281656|NCT00614393|Active Comparator|Placebo + Cetuximab + Irinotecan (DB)|In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB normal saline (placebo) IV Q1W for up to 32 months of treatment.
3281657|NCT00614354|Experimental|1|
3281658|NCT00614341|Active Comparator|1, 2|"Pulse MedRelief SE 55~Continuous MedRelief SE 55"
3281659|NCT00614328|Active Comparator|1|Naltrexone (50 mg once a day) + placebo baclofen + behavioral therapy (n=10)
3281660|NCT00614328|Active Comparator|2|Placebo naltrexone + baclofen (10 mg t.i.d) + behavior therapy (n=10)
3281661|NCT00614328|Active Comparator|3|Baclofen (10 mg t.i.d) + naltrexone (50 mg once per day) + behavior therapy (n=10)
3281662|NCT00614328|Placebo Comparator|4|Placebo baclofen + placebo naltrexone + behavior therapy
3281663|NCT00614315|Experimental|FLAIR Endovascular Stent Graft and Delivery System|
3281664|NCT00614276||Phase I - Focus Groups|
3281665|NCT00614276||Phase II TENDRILS|Phase II - TENDRILS Program only.
3281666|NCT00614276||Phase II TENDRILS + Counseling|Phase II - TENDRILS + Sexual Counseling Sessions.
3281667|NCT00614263||Blinded Group|SEDline output is unknown to anesthesiologist.
3281668|NCT00614263||Unblinded Group|SEDline output is known to anesthesiologist.
3281669|NCT00614250|Experimental|Dose Level 1|
3281670|NCT00614250|Experimental|Dose Level 2|
3281671|NCT00614250|Experimental|Dose Level 3|
3281672|NCT00614250|Experimental|Dose Level 4|
3281673|NCT00614250|Placebo Comparator|Placebo|12 subjects: 3 subjects per dose level
3281674|NCT00614224|Experimental|A|Treadmill training group (TAEX)
3281675|NCT00614224|Active Comparator|B|Attention control group (CON)
3281676|NCT00614211|Active Comparator|1|Total Abdominal Radical Hysterectomy
3281677|NCT00614211|Experimental|2|Total Laparoscopic or Robotic Radical Hysterectomy
3281678|NCT00614198|Experimental|Gluten- and casein-free diet|Stage 1: Gluten- and casein-free dietary intervention for first 8 or 12 months. 8 or 12 months: Interim analysis based on surpassing statistical thresholds. If showed group significant improvements then progressed to stage 2 (continued on a gluten- and casein-free diet for a further 12 months).
3281679|NCT00614198|No Intervention|No dietary intervention|Stage 1: No special dietary intervention for first 8 or 12 months. 8 or 12 months: Interim analysis based on surpassing statistical thresholds. If gluten- and casein-free dietary group showed group significant improvements then progressed to stage 2 (introduction of a gluten- and casein-free diet for 12 months).
3281680|NCT00614172|Experimental|Proton Radiotherapy|Two week course of proton radiotherapy to the breast.
3281681|NCT00614159||GI Endoscopy|
3281682|NCT00614146|Experimental|1|
3281683|NCT00614146|Active Comparator|2|
3281684|NCT00614133|Experimental|1|Preoperative nutrition.
3281685|NCT00614133|Active Comparator|2|Preoperative fasting.
3281686|NCT00614120|Experimental|Lira 0.6 + Met|Liraglutide 0.6 mg + metformin + glimepiride placebo
3281687|NCT00614120|Experimental|Lira 1.2 + Met|Liraglutide 1.2 mg + metformin + glimepiride placebo
3281688|NCT00614120|Experimental|Lira 1.8 + Met|Liraglutide + metformin + glimepiride placebo
3281689|NCT00614120|Experimental|Glim + Met|Glimepiride 4.0 mg + metformin + liraglutide placebo
3281690|NCT00614081|Experimental|1|Renal transplant recipients
3281691|NCT00614068|Experimental|A|Participants will receive 12 sessions of trauma-focused cognitive behavioral therapy over 3 months.
3281692|NCT00614068|Active Comparator|B|Participants will receive 12 sessions of treatment as usual over 3 months.
3281693|NCT00614055|Active Comparator|Insulin glargine|
3281694|NCT00614055|Experimental|SIAC 30 (B)|
3281695|NCT00614055|Experimental|SIAC 45 (B)|
3281696|NCT00614042|Experimental|1|Dose escalation and expansion cohorts
3281697|NCT00614029|Experimental|A|IMITREX -abd. to Intraject-abd. to IMITREX -thigh to Intraject-thigh
3281698|NCT00614029|Experimental|B|Intraject-abd. to IMITREX -abd. to Intraject-thigh to IMITREX -thigh
3281699|NCT00614029|Experimental|C|Intraject-abd to IMITREX -abd to Intraject-arm. to IMITREX -arm.
3281700|NCT00614029|Experimental|D|IMITREX-abd to Intraject-abd to IMITREX-arm. to Intraject-arm.
3281701|NCT00614029|Experimental|E|IMITREX-arm to Intraject-arm to IMITREX-thigh to Intraject-thigh
3281702|NCT00614029|Experimental|F|Intraject-thigh to IMITREX-thigh to Intraject-arm to IMITREX-arm
3281703|NCT00614016|Experimental|single|8 subjects total (6 active and 2 placebo)
3281704|NCT00614003|Experimental|1|decision support
3281705|NCT00613964|Placebo Comparator|Standard Therapy|Standard heart failure therapy excluding carperitide administration
3281716|NCT00613912||A|Ambulant patients with major depression
3281717|NCT00613899|Other|Telesurveillance|"At time of discharge from hospital, 40 ALS patients willbe enrolled in a telesurveillance program (TP) for the management of cought at home.~Two hours of an in-hospital educational training will be provided to patients and caregivers on the use of:~air stacking with Ambu balloon~manual manoeuvres and~in-Exoflator device indications and use"
3281718|NCT00613886|Experimental|1|Subjective comparisons made for patients - before and after external lumbar drain, before and after shunt surgery
3281719|NCT00613873||1|Women participating in a community based mammography or cervical screening program will also participate in colonoscopy screening. Participation will be measured by stating an interest in colorectal cancer screening and then following through with colonoscopy screening. Furthermore we will assess whether those complying with colonoscopy will also recommend colonoscopy screening for their spouses or household members.
3281720|NCT00613847|Active Comparator|1|Patients with invasive solid tumors
3281721|NCT00613847|Active Comparator|2|Patients with advanced solid tumors that express HER2 with tumors that are HER2 1+ by IHC or FISH.
3281722|NCT00613834|Experimental|1|
3281723|NCT00613834|Placebo Comparator|2|
3281724|NCT00613821|Experimental|Lidocaine infusion|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
3281725|NCT00613821|Active Comparator|Paracervical block only|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
3281726|NCT00613808|No Intervention|A - Standard of Care (control)|Standard of care - dressings and sustained compression only for the two week screening period and then for 20 weeks thereafter
3281727|NCT00613808|Active Comparator|B Same treatment for 6 weeks, 200ppm NO gas|Subjects were treated by topical application of 200ppm Nitric Oxide gas delivered to the wound area for 8 hours per day for 6 weeks
3281728|NCT00613795|Active Comparator|1|Lactobacillus
3281729|NCT00613795|Placebo Comparator|2|placebo
3281730|NCT00613782|Active Comparator|1|Reandron 100 treatment
3281731|NCT00613782|Placebo Comparator|2|Placebo
3281732|NCT00613769|Active Comparator|ordinary per operative prophylaxis|cefuroxime(1500mg) i.v.+ metronidazole (1500mg)i.v.given at the time point of induction of anesthesia
3281733|NCT00613769|Experimental|Per oral alternative|Trimethoprim-sulfamethoxazole(160mg/800mg)p.o.+metronidazole (1200mg)p.o.given 06.00 am on the day of operation
3281734|NCT00613743|Placebo Comparator|1|D1-D3 receive placebo
3281735|NCT00613743|Active Comparator|2|receive D1 D3 morphine
3281736|NCT00613730|Experimental|Gemcitabine + panitumumab|Panitumumab 6 mg/kg was administered intravenously (IV) before gemcitabine on Day 1 of Weeks 1, 3, 5, and 7, and then every 2 weeks (day 1 and 15) of each subsequent 4-week chemotherapy cycle. Gemcitabine 1000 mg/m^2 was administered IV once weekly (on Day 1) for 7 weeks, followed by a 1-week rest period. In subsequent cycles, gemcitabine was given once weekly (on Day 1) for 3 consecutive weeks followed by 1 week of rest. Panitumumab and gemcitabine treatment continued until disease progression, unacceptable adverse events, death, or study withdrawal occurred.
3281737|NCT00613717|Experimental|a|pre- and early postnatal iron
3281738|NCT00613717|Experimental|b|iron prenatal only
3281739|NCT00613717|Experimental|c|iron early postnatal only
3281740|NCT00613717|Active Comparator|d|no iron pre- or postnatal
3281741|NCT00613691|Experimental|SPI-1620|SPI-1620 an endothelin B agonist
3281742|NCT00613678|Active Comparator|1|Exercise + Education: Eight group sessions (8-15 people) during which participants engage in muscular strength and flexibility exercises. In addition, weekly educational lectures on topics germane to osteoarthritis management are included.
3281743|NCT00613678|Experimental|2|Exercise + Activity Strategy Training: 7/8 sessions will be in a group format in which participants engage in muscular strength & flexibility exercises and listen to education lessons on management strategies for osteoarthritis. The remaining session includes a home assessment by an occupational therapist to facilitate adequate participation in daily living and leisure activities.
3281744|NCT00613665|Experimental|1|
3281745|NCT00613665|Experimental|2|
3281746|NCT00613665|Experimental|3|
3281747|NCT00613665|Experimental|4|
3281748|NCT00613665|Placebo Comparator|5|
3281749|NCT00613665|Experimental|6|
3281750|NCT00613665|Experimental|7|
3281751|NCT00613626|Placebo Comparator|Arm A: ZD6474 Matched Placebo|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 matched placebo oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
3281752|NCT00613626|Active Comparator|Arm B: ZD6474|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
3281753|NCT00613626|Experimental|Safety Lead-In|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator. The safety lead-in will be conducted to determine the safety of the combination of ZD6474 and cisplation + etopiside. If this combination is found to be unsafe, no patients will be randomized in the Phase II portion of the trial. If the combination is deemed safe according to the protocol, participants from the safety lead-in cohort will not be included in the efficacy analysis.
3281754|NCT00613613|Active Comparator|1|High drug metabolism genotype All receive fenofibrate
3281755|NCT00613613|Active Comparator|2|Low drug metabolism genotype All receive fenofibrate
3281756|NCT00613600|Experimental|1|Two 665 mg capsules of glucomannan three times a day for eight weeks
3281757|NCT00613600|Placebo Comparator|2|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
3281758|NCT00613548|Active Comparator|1|CABG Alone
3281759|NCT00613548|Active Comparator|2|CABG + Mitral repair
3281760|NCT00613535|Active Comparator|Lavage debridement to remove loose fragments|Articular cartilage defect left untreated by surgical tool during partial meniscectomy
3281761|NCT00613535|Active Comparator|Mechanical Debridement|Remove large chondral flaps and loose fragments
3281762|NCT00613535|Active Comparator|RF based Debridement|Debridement to remove loose fragments followed by use of Paragon T-2 RF wand to smooth the base of the shoulder of the tear
3281763|NCT00613522||case|Fist ischaemic hemispheric stroke or TIA
3281764|NCT00613522||control|No ischaemic hemispheric stroke or TIA
3281765|NCT00613509|Experimental|Study Group 1: ALVAC melanoma vaccine|Participants will receive a multi-antigen of modified canarypox virus (ALVAC[2]) melanoma vaccine and granulocyte macrophage colony stimulating factor (GM-CSF) every 3 weeks, followed by 4 weeks of high-dose interferon alpha-2b 5 times per week.
3281766|NCT00613509|Active Comparator|Study Group 2: Interferon alpha-2b|Participants on 4 weeks of high-dose interferon alpha-2b 5 times per week. Participants who showed disease progression after Cycle 1 will be permitted to cross over to Group 1 treatment.
3281767|NCT00613496|Placebo Comparator|2|Placebo treatment in each patient during the study (9 weeks) using an intraindividual cross-over design
3281768|NCT00613496|Active Comparator|1|Irbesartan treatment in each patient during the study (9 weeks) using an intraindividual cross-over design
3281769|NCT00613470|Experimental|Citalopram and escitalopram|"Citalopram tablet or solution starting at 20 mg, increase to 40 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5.~Escitalopram tablets starting at 10 mg, increase to 20 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5."
3281770|NCT00613457|Experimental|I|o Arm I (closed to accrual as of 6/30/2006): Patients receive prednisone (PRED) on days 8-28.
3281771|NCT00613457|Experimental|II|o Arm II (closed to accrual as of 6/30/2006): Patients receive dexamethasone (DEXA) on days 8-28.
3281772|NCT00613457|Experimental|Reintensification Arm I|o Arm I (standard reinduction therapy, protocol II [closed to accrual as of 6/30/2006]): SR and IR patients receive DEXA on days 1-22; VCR and doxorubicin hydrochloride (DOX) in weeks 2-5; ASP on days 8, 11, 15, and 18; CPM on day 36; ARA-C and thioguanine (TG) on days 36-49; and MTX IT on days 38 and 45. Patients then proceed to maintenance therapy.
3281773|NCT00613457|Experimental|Reintensification Arm II|• Arm II (reduced-intensity reinduction therapy, protocol III [closed to accrual as of 6/30/2006]): SR patients receive DEXA on days 1-15; VCR and DOX on days 1 and 8; ASP on days 1, 4, 8, and 11; CPM on day 15; ARA-C and TG on days 15-28; and MTX IT on days 16 and 23. Patients then proceed to maintenance therapy.
3281774|NCT00613457|Experimental|Reintensification Arm III|• Arm III (reduced-intensity reinduction/second delayed reinduction therapy [double reintensification therapy] [closed to accrual as of 6/30/2006]): IR patients receive reduced-intensity reintensification therapy as in arm II. After a 10-week interim maintenance phase, treatment repeats once for a second delayed course of reintensification therapy. Patients then proceed to maintenance therapy.
3281775|NCT00613457|Experimental|Reintensification Arm IV|"• Arm IV (standard reintensification therapy [closed to accrual as of 6/30/2006]): HR patients receive one sequence of the following HR therapy elements, in this order: 1, 2, 3, following standard reinduction therapy protocol II repeated twice after a four weeks Interim Maintenance phase. Patients then proceed to maintenance therapy.~Element HR-1: Patients receive DEXA on days 1-5; VCR on days 1 and 6; ARA-C twice on day 5; MTX and CPM every 12 hours on days 2-4 (5 doses); ASP on day 6 ; and MTX/ARA-C/PRED IT on day 1.~Element HR-2: Patients receive DEXA on days 1-5; vindesine on days 1 and 6; DNR on day 5; MTX and ifosfamide every 12 hours on days 2-4 (5 doses); ASP on day 6; and MTX/ARA-C/PRED IT on day 1.~Element HR-3: Patients receive DEXA on days 1-5; ARA-C every 12 hours on days 1-2 (4 doses); etoposide five times daily on days 3-5; ASP on day 5; and MTX/ARA-C/PRED IT on day 1."
3281776|NCT00613457|Experimental|Reintensification Arm V|"• Arm V (extended reintensification therapy [triple protocol III] [closed to accrual as of 6/30/2006]): HR patients receive HR therapy elements 3, 2, and 1 following reintensification therapy repeated the therapy element three times with 4-week interim maintenance phases in between. Patients then proceed to maintenance therapy.~Interim maintenance/maintenance therapy: Patients receive MTX once weekly and MP daily until week 104 plus IT MTX every eight weeks.~Radiotherapy: HR patients or patients with T-cell acute lymphoblastic leukemia or CNS disease undergo CNS radiotherapy."
3281777|NCT00613444|Experimental|LumaCare LC-122M non-coherent light source|"Split Face Comparison. One half of subject's face will receive topical photosensitizer applications followed by LumaCare LC-122M non-coherent light source illumination. Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.~The other half of the face will not receive any treatment and will serve as internal control."
3281778|NCT00613431|Experimental|1|6 dose groups, 9 subjects on active, 3 subjects on placebo in each group
3281779|NCT00613431|Placebo Comparator|2|3 subjects on placebo in each group
3281780|NCT00613418|Other|single|Historical control
3281781|NCT00613405|Experimental|Stress + cue exposure|Individuals were exposed to the Trier Social Stress Test (TSST) as well as neutral cues and marijana cues.
3281782|NCT00613405|Experimental|No stress + cue exposure|Individuals were not exposed to a stress test, but were exposed to neutral cues and marijuana cues.
3281783|NCT00613392|Experimental|1|
3281784|NCT00613392|Placebo Comparator|2|
3281785|NCT00613379|Experimental|Arm 1|10 mg/kg PRO 140, one IV dose (N=10)
3281786|NCT00613379|Experimental|Arm 2|5 mg/kg PRO 140, one IV dose (N=10)
3281787|NCT00613379|Placebo Comparator|Arm 3|Placebo, one IV dose (N=10)
3281788|NCT00613366|Experimental|Misoprostol|Cervical preparation with misoprostol prior to intrauterine device insertion
3281789|NCT00613366|Placebo Comparator|Placebo|Cervical preparation with placebo prior to intrauterine device insertion
3281790|NCT00613353||I|Caucasian and African American females between the ages of 18 and 65.
3281791|NCT00613340|Experimental|1|Cervical medial branch blocks with 0.25 ml of injectate
3281792|NCT00613340|Experimental|2|Cervical medial branch blocks with 0.5 ml of local anesthetic and contrast
3281793|NCT00613327|Experimental|Oxybutynin Chloride OROS|
3281794|NCT00613288|Experimental|A|
3281795|NCT00613249|Experimental|A|
3281796|NCT00613249|Experimental|B|
3281797|NCT00613249|Placebo Comparator|C|
3281860|NCT00612755|Experimental|1|Peginterferon alfa-2a 180 mcg/week + 1000-1200 mg/day ribavirin during 24 weeks
3281798|NCT00613223|Experimental|Vandetanib and Etoposide|Patients will be stratified based on whether they are receiving an enzyme-inducing anti-epileptic drug (EIAED). The dose level of vandetanib will be increased in successive cohorts of subjects. Etoposide will be given daily at a dose of 50 mg/ day for 21 days followed by 7 days with no etoposide.
3281799|NCT00613210||1|women without contraction at 24-34 weeks of gestation
3281800|NCT00613210||2|women without contractions between 24-34 weeks of gestation with a history of preterm labor
3281801|NCT00613210||3|women with preterm contractions 24-34 weeks of gestation
3281802|NCT00613197|Experimental|1 Epanova|
3281803|NCT00613197|Placebo Comparator|2 Placebo|
3281804|NCT00613184|Experimental|1|Nylon Flocked swab Left Nasal Wash right
3281805|NCT00613184|Experimental|2|Nylon Flocked swab R Nasal Wash L
3281806|NCT00613184|Experimental|3|Nasal Wash Left Nylon Flocked swab Right
3281807|NCT00613184|Experimental|4|Nasal Wash R Nylon flocked swab L
3281808|NCT00613171|Experimental|1|
3281809|NCT00613158||1|Participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with significant subclinical atherosclerosis (SA) and a low Framingham risk score
3281810|NCT00613158||2|Participants from MESA with no SA and a low Framingham risk score
3281811|NCT00613158||3|Healthy participants from Northwestern University
3281812|NCT00613145|Active Comparator|A|Treatment with Capecitabine and Sorafenib
3281813|NCT00613145|Active Comparator|B|Treatment with Capecitabine and Sorafenib
3281814|NCT00613132|Experimental|1|Pts receiving EIACDs
3281815|NCT00613132|Experimental|2|Pts not receiving EIACDs
3281816|NCT00613106|Experimental|HZT-501|HZT-501: ibuprofen 800mg/famotidine 26.6mg
3281817|NCT00613106|Active Comparator|Ibuprofen|Ibuprofen 800mg
3281818|NCT00613093|Active Comparator|Patients with glioblastoma multiforme|
3281819|NCT00613093|Active Comparator|Patients with Anaplastic Glioma|
3281820|NCT00613080|Other|IMRT + Chemotherapy , Resection, Postoperative Chemotherapy|Radiation therapy (intensity modulated radiation therapy [IMRT] + three dimensional conformal radiation therapy [3D-CRT]) + neoadjuvant chemotherapy (capecitabine and oxaliplatin) followed by resection and postoperative chemotherapy (FOLFOX)
3281821|NCT00613067|Experimental|GAD|35 patients with Generalized Anxiety disorder
3281822|NCT00613054|Experimental|Zactima + Gleevec + Hydrea|
3281823|NCT00613041||1|Patients with one or more pulmonary nodules 5-15 mm in diameter.
3281824|NCT00613028|Experimental|Temo + Avastin|Patients treated with bevacizumab + temozolomide
3281825|NCT00613028|Experimental|VP-16 + Avastin|Patients treated with bevacizumab and VP-16 (etoposide)
3281826|NCT00613015|Experimental|Modafinil/Stress|Participants received placebo for 2 days. modafinil on the third day and participated in the TRIER social stress task on the third day.
3281827|NCT00613015|Experimental|Modafinil/no stress|Participants received placebo for 2 days. modafinil on the third day and did not participate in the TRIER social stress task on the third day.
3281828|NCT00613015|Experimental|Guanfacine/stress|Participants received guanfacine for 3 days and participated in the TRIER social stress task on the third day.
3281829|NCT00613015|Experimental|Guanfacine/no stress|Participants received guanfacine for 3 days and did not participate in the TRIER social stress task on the third day.
3281830|NCT00613015|Placebo Comparator|Placebo/Stress|Participants received placebo for 3 days and participated in the TRIER social stress task on the third day.
3281831|NCT00613015|Placebo Comparator|Placebo/no stress|Participants received placebo for 3 days and did not participate in the TRIER social stress task on the third day.
3281832|NCT00613002|Experimental|testosterone gel|1% testosterone transdermal gel
3281833|NCT00613002|Placebo Comparator|placebo gel|placebo transdermal gel
3281834|NCT00612989|Experimental|1|Schedule 1
3281835|NCT00612989|Experimental|2|Schedule 2
3281836|NCT00612989|Experimental|3|Schedule 2, Neulasta-supported
3281837|NCT00612976||1|Patients with COPD treated with budesonide/formoterol
3281838|NCT00612950|Experimental|GLP-1|
3281839|NCT00612950|Experimental|GIP|
3281840|NCT00612950|Placebo Comparator|saline|
3281841|NCT00612924|Experimental|Anaconda|
3281842|NCT00612911||Major group|Patients with Idiopathic dilated cardiomyopathy
3281843|NCT00612898|Experimental|1|800mg BID apricitabine plus optimised background
3281844|NCT00612898|Active Comparator|2|150mg BID lamivudine plus optimised background
3281845|NCT00612872|Experimental|Assess [123-I]CLINDE and brain imaging|Subjects will be injected with up to 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) of 123-I CLINDE followed by serial SPECT imaging.
3281846|NCT00612846|Experimental|A|
3281847|NCT00612846|Experimental|B|
3281848|NCT00612833|Active Comparator|cautery excision with fascial interposition|Contraception using cautery and excision with fascial interposition
3281849|NCT00612833|Active Comparator|B|Cautery and excision without fascial interposition
3281850|NCT00612833|Active Comparator|C|Ligation and excision with fascial interposition
3281851|NCT00612807|Active Comparator|Control|Medication management with a study doctor every other week.
3281852|NCT00612807|Experimental|Combination|Medication management with a study doctor every other week plus weekly marital therapy.
3281853|NCT00612794|Experimental|1|exenatide once weekly, 0.8mg
3281854|NCT00612794|Experimental|2|exenatide once weekly, 2.0mg
3281855|NCT00612794|Placebo Comparator|3|volume equivalent to 0.8mg of exenatide once weekly
3281856|NCT00612794|Placebo Comparator|4|volume equivalent to 2.0mg of exenatide once weekly
3281857|NCT00612781|Other|A|
3281858|NCT00612781|Other|B|
3281859|NCT00612768|Experimental|T.R.U.E. Test allergens Fragrance Mix and Thimerosol|"Concordance (agreement) between positive patch reactions to~fragrance mix (0.43 mg/cm2) in polyvinylpyrrolidone (PVP) vs fragrance mix (0.43 mg/cm2) in hydroxypropylcellulose (HPC)~thimerosol (0.008 mg/cm2) in polyvinylpyrrolidone (PVP) vs thimerosol (0.008 mg/cm2) in hydroxypropylcellulose (HPC)~fragrance mix T.R.U.E. Test allergen vs fragrance mix reference allergen (petrolatum)~thimerosol T.R.U.E. Test allergen vs thimerosol reference allergen (petrolatum)~will be measured"
3281861|NCT00612755|No Intervention|2|
3281862|NCT00612742|Experimental|testosterone gel|1% testosterone transdermal gel
3281863|NCT00612742|Placebo Comparator|placebo gel|placebo transdermal gel
3281864|NCT00612716|Experimental|Allogeneic Transplantation|Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.
3281865|NCT00612690|Experimental|Links to Learning|Participants received the community mental health consultation model program.
3281866|NCT00612690|Active Comparator|Services as Usual|Participants received treatment as usual and referrals.
3281867|NCT00612677|Experimental|Premetrexed and Oxaliplatin|Patients will be treated with oxaliplatin 120 mg/m^2 i.v. over 2 hours and pemetrexed 500 mg/m^2 i.v. over 10 minutes on Day 1 of a 21day cycle. Cycles of treatment will be repeated every 3 weeks. Folic acid and B12 supplementation is obligatory.
3281868|NCT00612664|Active Comparator|Arm 1|0.1 mg/kg every 3 weeks
3281869|NCT00612664|Active Comparator|Arm 2|1 mg/kg every 3 weeks
3281870|NCT00612664|Active Comparator|Arm 3|1 mg/kg every 6 weeks
3281871|NCT00612664|Active Comparator|Arm 4|5 mg/kg every 3 weeks
3281872|NCT00612651|Other|enzyme-inducing anti-epileptic drugs (EIAEDs)|Patients receiving enzyme-inducing anti-epileptic drugs (EIAEDs)such as carbamazepine, phenobarbitol, phenytoin, phosphenytoin, oxcarbamazepine, primadone)
3281873|NCT00612651|Other|no enyzme-inducing anti-epileptic drugs|Patients on non CYP3A4-inducing anti-convulsants or patients not on any anti-convulsants.
3281874|NCT00612638|Experimental|1|Pts receiving Dilantin, Tegretol or Phenobarbital
3281875|NCT00612638|Experimental|2|Pts on anti-convulsants other than Dilantin, Tegretol / Phenobarbital / pts not on any anti-convulsants
3281876|NCT00612625|Experimental|GLP-1|A graded glucose infusion with an infusion of GLP-1 (1½ pmol/kg/min)
3281877|NCT00612625|Experimental|Saline|A graded glucose infusion together with a continuous infusion of saline
3281878|NCT00612612|Experimental|Treatment (obatoclax mesylate, fludarabine, rituximab)|"Patients receive obatoclax mesylate IV over 3 hours on days 1 and 3, fludarabine IV over 20-30 minutes on days 1-5, and rituximab IV over 4 hours on day 1 (days 1 and 3 of course 1 only). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo peripheral blood collection for correlative studies. Samples are analyzed for expression of pro- and anti-apoptotic Bcl-2 family members by western blot; apoptosis induction by measurement of lymphocyte count, Annexin V staining, and Caspase and PARP cleavage; activated Bax by immunoprecipitation; and Bax promoter polymorphism by PCR amplification and direct sequencing."
3281879|NCT00612586|Experimental|A|5-FU/LV plus bevacizumab in combination with enzastaurin
3281880|NCT00612586|Placebo Comparator|B|5-FU/LV plus bevacizumab in combination with placebo
3281881|NCT00612573|Experimental|Doxycyline 0.6 mg/kg/day|Doxycycline dosed at 40 mg/day to subjects of appropriate weights
3281882|NCT00612573|Experimental|Doxycycline 1.2 mg/kg/day|Doxycycline dosed at 80 mg/day to subjects of appropriate weights
3281883|NCT00612573|Experimental|Doxycycline 2.4 mg/kg/day|Doxycycline dosed at 160 mg/day to subjects of appropriate weights
3281884|NCT00612573|Placebo Comparator|Placebo|
3281885|NCT00612560|Experimental|2|Flaxseed 25 mg per day and 1 placebo pill per day
3281886|NCT00612560|Experimental|3|25 mg flaxseed per day and 1 mg anastrozole pill per day
3281887|NCT00612560|Placebo Comparator|4|Placebo pill 1 per day
3281888|NCT00612560|Experimental|1|Anastrozole 1 mg pill per day
3281889|NCT00612547||Observation|Children under the age of five years (2 months to 5 years) residing in the zone covered by the community-based service provider throughout the entire follow-up period
3281890|NCT00612534|Experimental|1|
3281891|NCT00612534|Experimental|2|
3281892|NCT00612534|Experimental|3|
3281893|NCT00612534|Placebo Comparator|4|
3281894|NCT00612521|Other|1|Either Placebo or Adenosine mixed with normal saline at a concentration of 6 micrograms per milliliter.
3281895|NCT00612521|Other|2|Either Placebo or Adenosine mixed with normal saline at a concentration of 6 micrograms per milliliter.
3281896|NCT00612508|Active Comparator|Desogen|"Drug: ethinyl estradiol and desogestrel~1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol; secen inactive pills every 28 days.~Subjects receive baseline vaginal biopsy, followed by treatment with the OC for six cycles and repeat biopsy at 3 and after 6 cycles"
3281897|NCT00612508|Active Comparator|NuvaRing|"Intravaginal Contraception~ethinyl estradiol (0.15 mg/d) and etonogestrel (0.12 mg/d) Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring~Subjects had baseline vaginal biopsy followed by 6 cycles of ring use and repeat biopsy at 3 and after 6 cycles"
3281898|NCT00612482|No Intervention|1|"Participants in the no intervention condition will receive the usual high school science curriculum."
3281899|NCT00612482|Experimental|2|"Participants in the experimental arm will receive the 5-lesson, science-based substance abuse prevention curriculum in their science classes."
3281900|NCT00612469|Placebo Comparator|NaF|Sodium fluoride application
3281901|NCT00612469|Experimental|V3|Topical application of 3% vancomycin
3281902|NCT00612469|Experimental|V10|Topical application of 10% vancomycin
3281903|NCT00612469|Active Comparator|CHX|Topical application of 1% chlorhexidine
3281904|NCT00612456|Experimental|Arm 1|Pazopanib eye drops formulation 5 mg/mL daily for 28 days
3281905|NCT00612456|Experimental|Arm 2|Pazopanib eye drop formulation 5mg/mL TID for 28 days
3281906|NCT00612456|Experimental|Arm 3|Pazopanib eye drop formulation 2mg/mL TID for 28 days
3281907|NCT00612443|Experimental|1|non-contact Healing Touch treatment for 20-30 minutes once a week during the course of radiation therapy
3281908|NCT00612443|Sham Comparator|2|A RN graduate assistant will provide a sham treatment of 20-30 minutes of presence.
3281909|NCT00612430|Experimental|Bevacizumab + Etoposide|Grade III and IV patients will receive: Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If patient tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day.
3281910|NCT00612417|Experimental|1|recombinant FVIII
3281911|NCT00612417|Placebo Comparator|2|Placebo
3281912|NCT00612404||1|patients with gastrointestinal disorders who need an endoscopy.
3281913|NCT00612391|Experimental|Lateral, Minimally Invasive Approach|Lateral, Minimally Invasive Approach in GT fractures treated operatively (plates and screws)
3281914|NCT00612391|Active Comparator|Deltopectoral approach:|Deltopectoral approach for GT fracture treated operatively
3281915|NCT00612378|Experimental|1|
3281916|NCT00612365||1|Participants from the Multi-Ethnic Study of Atherosclerosis (MESA) for abdominal aortic calcium (AAC) who have undergone computed tomography (CT) scans of the abdomen
3281917|NCT00612352|Active Comparator|Family HIstory Positive|Subjects with a positive family history of alcoholism.
3281918|NCT00612352|Active Comparator|Family History Negative|Subjects with a negative family history of alcoholism.
3281919|NCT00612339|Experimental|Avastin and Temozolomide|Avastin administered at 10 mg/kg every 2 weeks beginning a minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide dosed at 200 mg/m2 daily for 5 days in a 28-day cycle.
3281920|NCT00612326||1|Patients with newly diagnosed locally or regionally advanced transitional cell carcinoma of the bladder.
3281921|NCT00612313|Active Comparator|Continued medication alone|Participants will receive antidepressant treatment with fluoxetine for 30 weeks
3281922|NCT00612313|Experimental|Continued medication plus CBT|Participants will receive antidepressant treatment with fluoxetine for 30 weeks plus relapse prevention cognitive behavioral therapy for the last 24 weeks of treatment
3281923|NCT00612300|Experimental|A-B|Gait training by an automatic gait trainer (Lokomat) for 3 weeks followed by 3 weeks of categorized gait training by a physical therapist
3281924|NCT00612300|Experimental|B-A|Categorized gait training by physical therapists for 3 weeks followed by 3 weeks of lokomat training
3281925|NCT00612287|Experimental|A|
3281926|NCT00612274|Experimental|1|sirolimus, tacrolimus and short course methotrexate
3281927|NCT00612261|Experimental|1|The group 1 patients receive AV sheathotomy for macular edema secondary to branch retinal vein occlusion.
3281928|NCT00612261|Active Comparator|2|The group 2 patients receive IVTA.
3281929|NCT00612248|Experimental|SG|Study group
3281930|NCT00612248|No Intervention|CG|Control group
3281931|NCT00612235||1|Lamotrigine Monotherapy
3281932|NCT00612235||2|Levetiracetam Monotherapy
3281933|NCT00612235||3|Carbamazepine Monotherapy
3281934|NCT00612235||4|Phenytoin Monotherapy
3281935|NCT00612235||5|Normal control (no epilepsy)
3281936|NCT00612222|Experimental|ALVAC plus anti-MART-1 F5 TCR PBL + HD IL-2|"ALVAC plus anti-MART-1 F5 T cell receptor (TCR ) peripheral blood lymphocytes (PBL) + high dose (HD) interleukin 2 (IL-2): ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 cell culture infectious dose 50% (CCID50) (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.~Aldesleukin - 720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days."
3281937|NCT00612209|Experimental|1|
3281938|NCT00612196|Experimental|1|
3281939|NCT00612196|Experimental|2|
3281940|NCT00612196|Experimental|3|
3281941|NCT00612196|Experimental|4|
3281942|NCT00612196|Experimental|5|
3281943|NCT00612196|Experimental|6|
3281944|NCT00612196|Experimental|7|
3281945|NCT00612196|Experimental|8|
3281946|NCT00612196|Experimental|9|
3281947|NCT00612196|Placebo Comparator|10|
3281948|NCT00612170|Experimental|3|
3281949|NCT00612170|Sham Comparator|4|
3281950|NCT00612170|Experimental|1|
3281951|NCT00612170|Experimental|2|
3281952|NCT00612157|Active Comparator|OSA CPAP|
3281953|NCT00612157|Placebo Comparator|Placebo|
3281954|NCT00612144|Experimental|1|Amaryl M group
3281955|NCT00612144|Active Comparator|2|Metformin group
3281956|NCT00612105|Experimental|1|Retigabine
3281957|NCT00612105|Placebo Comparator|2|Placebo
3281958|NCT00612092|Experimental|1|Standard spiral CT protocol
3281959|NCT00612092|Active Comparator|2|Sequential CT protocol
3281960|NCT00612079|Experimental|2|Healthy volunteers with high sensory gating levels.
3281961|NCT00612079|Experimental|1|Healthy volunteers with low sensory gating levels.
3281962|NCT00612066|Experimental|Rosiglitazone|
3281963|NCT00612040|Experimental|SIBA (D)|
3281964|NCT00612040|Experimental|SIBA (E)|
3281965|NCT00612040|Experimental|IGlar|
3281966|NCT00612027||1|patients with gastrointestinal disorders and patients with acid associated gastrointestinal symptoms treated with esomeprazole.
3281967|NCT00612014|Placebo Comparator|1|
3281968|NCT00612014|Experimental|2|40 micrograms/kg
3281969|NCT00612014|Experimental|3|80 micrograms/kg
3281970|NCT00612014|Experimental|4|160 micrograms/kg
3281971|NCT00612014|Experimental|5|320 microgram/kg
3281972|NCT00612014|Experimental|6|600 microgram/kg
3281973|NCT00612001|Experimental|dendritic cell vaccine|
3281974|NCT00611988|Experimental|1|The intervention includes individual therapy, group reinforcement, and follow-up phone contact
3281975|NCT00611988|Active Comparator|2|Attention control group will receive routine follow-up phone calls
3281976|NCT00611975|Experimental|A|Participants will receive treatment with fluoxetine for 2 months
3281977|NCT00611975|Experimental|B|Participants will receive treatment with bupropion for 2 months
3281978|NCT00611949|Active Comparator|1 Geranium Oil|
3281979|NCT00611949|Active Comparator|2 Geramium Oil|
3281980|NCT00611936|Placebo Comparator|2|Second arm is placebo
3281981|NCT00611936|Experimental|1|One arm is atomoxetine 40 mg per day
3281982|NCT00611923|Placebo Comparator|B|Participants will take placebo flutamide
3281983|NCT00611923|Experimental|A|Participants will take flutamide
3281984|NCT00611910|Experimental|DES|drug-eluting stents
3281985|NCT00611910|Active Comparator|BMS|bare metal stents
3282078|NCT00611156|Experimental|D|Spice
3282079|NCT00611156|Placebo Comparator|E|Placebo
3281986|NCT00611897|Active Comparator|Arm I|The NAC capsules were administered orally in divided doses: 2000 mg followed by 1000 mg 2 hours later. Each morning, 165 min after NAC administration, subjects received a 1-min bolus of normal saline, followed by a 70-minlong saline infusion during which behavioral, cognitive, and ERP data were collected. Ketamine was administered intravenously as a bolus of .23 mg/kg over 1 min followed by .58 mg/kg for 30 min (SPM and RVP), and then .29 mg/kg for 40 min (P300 and MMN).
3281987|NCT00611897|Placebo Comparator|Arm II|The placebo capsules were administered orally in divided doses: 2000 mg followed by 1000 mg 2 hours later. Each morning, 165 min after placebo administration, subjects received a 1-min bolus of normal saline, followed by a 70-minlong saline infusion during which behavioral, cognitive, and ERP data were collected. Ketamine was administered intravenously as a bolus of .23 mg/kg over 1 min followed by .58 mg/kg for 30 min (SPM and RVP), and then .29 mg/kg for 40 min (P300 and MMN).
3281988|NCT00611884|Experimental|SIBA (D)|
3281989|NCT00611884|Experimental|SIBA (E)|
3281990|NCT00611884|Experimental|SIBA (D) M, W, F|
3281991|NCT00611884|Active Comparator|IGlar|
3281992|NCT00611871|Experimental|1|Propranolol following traumatic memory
3281993|NCT00611871|Active Comparator|2|Propranolol following neutral memory
3281994|NCT00611871|Placebo Comparator|3|Placebo following traumatic memory
3281995|NCT00611832|Active Comparator|Standard|"Standard information-only version of the television series that includes only modeling and demonstration of the targeted parenting skills"
3281996|NCT00611832|Experimental|Enhanced|"Enhanced behavior activation version of the television series that includes all of the content of the standard information-only version, but is also designed to actively promote parental behavior change, through additional content elements addressing attributions, self-efficacy and expectancies, social support, and emotional reactivity."
3281997|NCT00611832|No Intervention|Control|Waitlist control
3281998|NCT00611819|Experimental|1|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 24 weeks
3281999|NCT00611819|Active Comparator|2|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
3282000|NCT00611806|Active Comparator|Folate with B12|Participants will take folic acid plus B12 for 18 weeks.
3282001|NCT00611806|Placebo Comparator|Placebo|Participants will take placebo for 18 weeks.
3282002|NCT00611793|Experimental|1|PTK787/ZK222584 and Bevacizumab
3282003|NCT00611780|Experimental|1|Reduced tube voltage of 100kV.
3282004|NCT00611780|Active Comparator|2|Standard tube voltage of 120kV.
3282005|NCT00611767|Active Comparator|Family History Negative for Alcoholism|Family History Negative for Alcoholism subjects will receive 2 interventions
3282006|NCT00611767|Placebo Comparator|Family History Positive for Alcoholism|Family History Positive for Alcoholism subjects will receive 2 interventions
3282007|NCT00611741|Experimental|Drug intervention, longitudinal|Furosemide and Na supplements
3282008|NCT00611715|Experimental|First line/hormone-therapy naive|
3282009|NCT00611715|Experimental|Second-line/prev hormone-therapy tx|
3282010|NCT00611689|Experimental|A|Imatinib and PTK/ZK222584
3282011|NCT00611676|Experimental|A|All subjects receive placebo for the first two weeks and then Venlafaxine for the next 10 weeks, but they are blind to what they are receiving
3282012|NCT00611663|Experimental|1|Vaccination with conjugate vaccine Prevenar® (WYETH-LEDERLE) at week 0 and Poly Saccharidic vaccine Pneumo23® (Sanofi Pasteur MSD) after 6 months (W24)
3282013|NCT00611663|Placebo Comparator|2|Vaccination with placebo at W0 and Poly Saccharidic vaccine Pneumo23® at W24
3282014|NCT00611650|Experimental|Arm I|Patients receive oral Polyphenon E twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
3282015|NCT00611650|Placebo Comparator|Arm II|Patients receive a placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
3282016|NCT00611637|Experimental|1|
3282017|NCT00611624|Experimental|Five Days of Mammosite Therapy|Five Days of Mammosite Therapy (Radiotherapy)
3282018|NCT00611611||1|SLE
3282019|NCT00611611||2|healthy controls
3282020|NCT00611598||1|second primary lung cancer
3282021|NCT00611598||2|single primary lung cancer
3282022|NCT00611585|Other|Hip Resurfacing|Birmingham Hip Resurfacing
3282023|NCT00611572|Active Comparator|1|Active iomazenil and ketamine
3282024|NCT00611572|Placebo Comparator|2|placebo iomazenil and ketamine
3282025|NCT00611559|Experimental|Infanrix hexa Preservative-Free Formulation Group|Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa
3282026|NCT00611559|Active Comparator|Infanrix hexa Preservative-Containing Formulation Group|Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa
3282027|NCT00611559|Active Comparator|Infanrix penta Preservative-Free Formulation Group|Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta.
3282028|NCT00611546|Placebo Comparator|1|Perenteral nutrition bottle and tubing are not protected from light
3282029|NCT00611546|Active Comparator|2|Perenteral nutrition bottle and tubing are protected from light
3282030|NCT00611533|Active Comparator|Atomoxetine|Subjects were enrolled into a double-blind, placebo-controlled cross over study where they will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks or placebo (PBO) for 6 weeks, followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week. Subjects undergo assessments of cognition, mood, and menopausal symptoms prior to randomization, after 6 weeks in the first treatment condition (ATX or PBO) and then finally after the second 6-week period of the alternate treatment condition. Subjects are monitored every other week to assess medication compliance and side effects. Subjects will be instructed to take one capsule of ATX 40mg/d or placebo per day. If tolerated, the number of pills of ATX will be increased to 2 per day at the end of Week 1 of both Trials A and B. Subjects will remain on two capsules per day for the remaining 5 weeks of Trials A and B.
3282080|NCT00611143|Experimental|1|Atorvastatin group
3282081|NCT00611143|No Intervention|2|Control group
3282082|NCT00611130|Experimental|1|3 Vigabatrin Tablets, 500 mg, bid, for 9 weeks
3282083|NCT00611130|Placebo Comparator|2|3 Placebo Tablets, bid, for 9 weeks
3282031|NCT00611533|Placebo Comparator|Placebo|Subjects were enrolled into a double-blind, placebo-controlled cross over study where they will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks or placebo (PBO) for 6 weeks, followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week. Subjects undergo assessments of cognition, mood, and menopausal symptoms prior to randomization, after 6 weeks in the first treatment condition (ATX or PBO) and then finally after the second 6-week period of the alternate treatment condition. Subjects are monitored every other week to assess medication compliance and side effects. Subjects will be instructed to take one capsule of ATX 40mg/d or placebo per day. If tolerated, the number of pills of ATX will be increased to 2 per day at the end of Week 1 of both Trials A and B. Subjects will remain on two capsules per day for the remaining 5 weeks of Trials A and B.
3282032|NCT00611520||1|Patients with COPD treated with budesonide/formoterol
3282033|NCT00611494|Active Comparator|A|MMF
3282034|NCT00611494|Active Comparator|B|EC-MPS
3282035|NCT00611481|Experimental|Tai Chi|
3282036|NCT00611481|Active Comparator|B. Strength training|
3282037|NCT00611481|Other|C. Low-Impact|
3282038|NCT00611468|Experimental|Intravenous Topotecan and Oral Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
3282039|NCT00611455|Experimental|ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
3282040|NCT00611455|Placebo Comparator|1000 ml Saline|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
3282041|NCT00611442|Active Comparator|1|split-dose PEG solution without dietary restrictions plus lubiprostone 24mcg gelcap pretreatment
3282042|NCT00611442|Placebo Comparator|2|split-dose PEG solution without dietary restrictions plus placebo pretreatment
3282043|NCT00611429|Experimental|Group A|Participants will receive treatment consisting of at least three individual counseling sessions and one group workshop over 12 months
3282044|NCT00611429|Active Comparator|Group B|Participants will receive treatment consisting of one individual counseling session and one group workshop during the last month of the study
3282045|NCT00611416|Experimental|1|Active treatment A
3282046|NCT00611416|Experimental|2|Active treatment B
3282047|NCT00611416|Experimental|3|Active treatment C
3282048|NCT00611416|Active Comparator|4|Positive control
3282049|NCT00611416|Placebo Comparator|5|Placebo
3282050|NCT00611403|Active Comparator|RESTASIS®|Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)
3282051|NCT00611403|Active Comparator|REFRESH ENDURA®|Artificial Tears (REFRESH ENDURA®)
3282052|NCT00611390|Active Comparator|1|treatment with spray containing aromatic essential oils of some herbal plants.
3282053|NCT00611390|Placebo Comparator|2|spray containing placebo.
3282054|NCT00611377||1|
3282055|NCT00611364|Experimental|Study group|
3282056|NCT00611364|Active Comparator|Control group|
3282057|NCT00611351|Experimental|Unrelated Donor Allogeneic|Matched unrelated donor allogeneic stem cell transplantation with a conditioning regimen of targeted busulfan, cyclophosphamide and thymoglobulin.
3282058|NCT00611325|Experimental|EIAED|Patients taking enzyme-inducing anti-epileptic drugs (EIAEDs). Avastin was administered intravenously at a dose of 15 mg/kg every 3 weeks. Bortezomib was adminstered intravenously at a dose of 2.5 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day cycle.
3282059|NCT00611325|Experimental|Non-EIAED|Patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs). Avastin was administered intravenously at a dose of 15 mg/kg every 3 weeks. Bortezomib was adminstered intravenously at a dose of 1.7 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day cycle.
3282060|NCT00611312|Experimental|1|Cognitive Training
3282061|NCT00611286|Experimental|1|treatment with Aspirin and clopidogrel for 24 months after coronary intervention with stents. This group of patients will be randomized in a 1:1:1:1 ratio to receive bare metal stent, Zotarolimus-eluting stent, paclitaxel-eluting stent or everolimus-eluting stent.
3282062|NCT00611286|Active Comparator|2|Treatment with aspirin and clopidogrel for minimum 1 or 6 month(s) after BMS or DES implantation, respectively. This group of patients will be randomized in a 1:1:1:1 ratio to receive bare metal stent, Zotarolimus-eluting stent, paclitaxel-eluting stent or everolimus-eluting stent
3282063|NCT00611273|Experimental|1|Patients who have presented to the investigator for correction of glabellar furrows, as classified per the Rated Numeric Kinetic Line Scale Score for Facial Wrinkles Secondary to Hyperkinetic Function (Note: Class 1 or Higher)7 (Appendix R) are candidates for this study.
3282064|NCT00611260|Experimental|Meditation Cohort|25 patients will be given instruction in vipassana meditation. Vipassana meditation is thought to reduce the incidence of atrial and ventricular arrhythmias in patients with congestive heart failure, and improve their overall psychological profile.
3282065|NCT00611260|Active Comparator|Standard Care|25 patients will receive current standard of care to manage their congestive heart failure, implanted cardiac devices, and psychological health.
3282066|NCT00611247|Experimental|Methylated AGAT Promoter (Group 1)|Induction: 200 mg/m2/day oral Temozolomide x 7 days
3282067|NCT00611247|Experimental|Un-Methylated AGAT Promoter (Group 2)|Priming: 100 mg/m2/day oral Temozolomide x 14 days, followed by Induction: 200 mg/m2/day oral Temozolomide x 7 days
3282068|NCT00611221|Active Comparator|1|Massage therapy by a regulated massage therapist
3282069|NCT00611221|Active Comparator|2|Massage by anyone else, eg. husband, nurse, doula
3282070|NCT00611208|Experimental|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diptheria toxin)
3282071|NCT00611195|Other|1|Larynx assessment under stimulation
3282072|NCT00611182||1|Patients with Pulmonary Fibrosis
3282073|NCT00611169|Experimental|1|Aspirin, clopidogrel, unfractionated heparin plus tirofiban infusion at high bolus dose
3282074|NCT00611169|No Intervention|2|Aspirin, clopidogrel, unfractionated heparin
3282075|NCT00611156|Experimental|A|Spice
3282076|NCT00611156|Experimental|B|Spice
3282077|NCT00611156|Experimental|C|Spice
3282084|NCT00611117|Experimental|1|High intensity exercise and high fat diet
3282085|NCT00611117|Experimental|2|Low intensity exercise and high fat diet
3282086|NCT00611091|Experimental|I|Intervention Group - (receive intervention) randomized at patient level - includes all health plan members, aged 65+, hospitalized at the study site hospital and discharged to an outpatient health plan clinic provider.
3282087|NCT00611091|No Intervention|C|Control Group - (do not receive intervention) randomized at patient level - includes all health plan members, aged 65+, hospitalized at the study site hospital and discharged to an outpatient health plan clinic provider.
3282088|NCT00611052|Experimental|1|Group cognitive intervention (the Adolescent Coping with Stress)
3282089|NCT00611052|Active Comparator|2|Treatment as usual
3282090|NCT00611052|Active Comparator|3|Healthy controls, receive usual health education in school health care
3282091|NCT00611039|Experimental|1|Darunavir 900mg + ritonavir 100 mg once a day
3282092|NCT00611039|Active Comparator|2|Darunavir 600mg + ritonavir 100mg twice day
3282093|NCT00611026|Active Comparator|1|
3282094|NCT00611026|Placebo Comparator|2|
3282095|NCT00611026|Experimental|3|
3282096|NCT00610987|Active Comparator|Cefazolin|Group I will receive 1-g doses of cefazolin every eight hours for the next 24 hours after surgical repair of the closed limb fracture.
3282097|NCT00610987|Placebo Comparator|Placebo|Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo, after the intraoperative dose(s) of cefazolin
3282098|NCT00610974|Active Comparator|1|One of 2 types of body-weight supported treadmill training (BWSTT) with the Lokomat, which differ only in the level of assistance that the Lokomat provides to leg movements while walking.
3282099|NCT00610974|Experimental|2|One of 2 types of body-weight supported treadmill training (BWSTT) with the Lokomat, which differ only in the level of assistance that the Lokomat provides to leg movements while walking.
3282100|NCT00610961||Basiliximab (Simulect) Induction|Prospective group: patients are scheduled to receive a kidney transplant; and will receive Simulect®, Myfortic® and Prograf® with or without steroids according to routine care (Standard of Care).
3282101|NCT00610961||Thymoglobulin Induction|Retrospective (historical or control) group: patients have already received a kidney transplant and were treated with Thymoglobulin®, Myfortic®, and Prograf® with or without steroids. This treatment was Standard of Care at a time of transplant.
3282102|NCT00610948|Experimental|Group 1|Patients receive oral everolimus once daily on days 1-28. Patients also receive leucovorin calcium IV followed by fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3282103|NCT00610948|Experimental|Group 2|Patients receive oral everolimus once daily on days 1-28 and panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3282104|NCT00610948|Experimental|Group 3|Patients receive oral everolimus once daily on days 1-28, leucovorin calcium IV followed by fluorouracil IV continuously over 46 hours beginning on day 1, and oxaliplatin IV over 2-4 hours on day 1. Some patients may also receive panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3282105|NCT00610935|Placebo Comparator|Placebo|Placebo intramuscular injection
3282106|NCT00610935|Experimental|Peramivir|Single intramuscular injection of 300mg peramivir
3282107|NCT00610922|No Intervention|1|
3282108|NCT00610922|Experimental|2|
3282109|NCT00610909|Experimental|1|Those in the active treatment group will receive doses of Paxil CR in increments of 12.5 mg daily for the first week and increased at 12.5 mg increments at visit weeks to a maximum of 50 mg daily, as determined by the investigator. The investigator will adjust dosage based on clinical response. Following the completion of the double-blind phase, patients on placebo and non-responders to the study drug will be tapered off the study drug back to 0 over 2 weeks, and they will be referred to their Primary Care Physician, Internist or Gastroenterologist to be prescribed treatment for Irritable Bowel Syndrome.
3282110|NCT00610909|Placebo Comparator|2|Same shape placebo
3282111|NCT00610896||Observation|30 Patients with dualchamber pacemakers or implantable cardioverter-defibrillators (ICDs)
3282112|NCT00610883|Experimental|1 - LSA4|
3282113|NCT00610870|Experimental|1|Atorvastatin group
3282114|NCT00610870|No Intervention|2|Control group
3282115|NCT00610857|Experimental|Anti-CTLA4 monoclonal antibody and HDI|Specific Aim #1: Test the hypothesis that the combination of IFNa-2b and anti-CTLA-4 monoclonal antibody will improve the response rate in patients with recurrent inoperable AJCC stage III and stage IV melanoma. Our therapeutic target is achieving, with acceptable toxicity, a 20% or better rate of objective response, CR or PR by RECIST criteria, as compared to the 5% to 10% expected in patients eligible for study. Study size is planned in terms of our primary efficacy endpoint, objective response.
3282116|NCT00610844|Experimental|1|pulmonary radiofrequency ablation
3282117|NCT00610831|Experimental|DirectView CR Mammography|Each subject will have routine clinical care imaging obtained and 4 standard mammogram views (RMLO, RCC, LMLO, LCC) using CR mammography. If routine mammograms were obtained on a day previous to enrollment in the study, those images (4 views; 2 views for mastectomy patients) will not be repeated for this study; only the CR images will be obtained.
3282118|NCT00610818||A|Patients receiving palifermin to prevent mucositis from bone marrow transplant.
3282119|NCT00610805|Experimental|1|Participants randomized to this arm (n=15) will be followed by Preventive Cardiology and will have appropriate goal oriented interventions on their risk factor levels for 2 years.
3282120|NCT00610805|Other|2|Participants randomized to this arm (n=15) will receive usual care. The PI will send a letter of all testing results to their primary care physician. No standard care will be withheld.
3282121|NCT00610792|Experimental|1|
3282122|NCT00610779|Active Comparator|1|treatment with spray containing aromatic essential oils of some herbal plants.
3282123|NCT00610779|Placebo Comparator|2|spray containing placebo.
3282124|NCT00610766||1|
3282125|NCT00610753|Experimental|Family Behavioral Therapy|This intervention focuses on counseling the parents (and other family members) on refeeding their child. When weight is being steadily regained the focus of therapy shifts to allow the child more independence.
3282126|NCT00610753|Active Comparator|Systems Family Therapy|This therapy focuses primarily on clarifying psychological processes within the family.
3282127|NCT00610740|Experimental|Patients Treated with CerviPrep™|CerviPrep™, a novel drug delivery device, was developed specifically for applying pharmaceuticals directly on the cervix. It consists of a syringe-like tube attached to a plastic cap that covers the cervix. Drug can be delivered through the tube, directly to the cervix without spillage onto vaginal or vulvar tissues.
3282128|NCT00610727|Other|1|Crossover for absolute bioavailability
3282129|NCT00610727|Experimental|2|Dose 2 vs. placebo
3282130|NCT00610727|Experimental|3|Dose 3 vs. Placebo
3282131|NCT00610727|Experimental|4|Dose 4 vs. Placebo
3282132|NCT00610727|Experimental|5|Dose 5 vs. Placebo
3282133|NCT00610714|Active Comparator|Active Comparator|carboplatin plus paclitaxel
3282134|NCT00610714|Experimental|2|AZD0530 in combination with carboplatin plus paclitaxel
3282135|NCT00610701|Experimental|Anterior pin placement|Anterior pin placement
3282136|NCT00610701|Experimental|Lateral pin placement|Lateral pin placement
3282137|NCT00610688|Placebo Comparator|Prenatal Vitamin D3|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3)along with a placebo tablet containing 0IU of Vitamin D
3282138|NCT00610688|Experimental|2|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3)along with a tablet containing 1600IU of Cholecalciferol (Vitamin D3)
3282139|NCT00610688|Experimental|3|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3) along with a tablet containing 3600IU of Cholecalciferol (Vitamin D3).
3282140|NCT00610675|Experimental|Esmirtazapine|One tablet of Esmirtazapine, 4.5 mg orally, daily for up to 52 weeks
3282141|NCT00610649|Experimental|Part 1: Block A MK-8777|Participants receive MK-8777 initiated at 100 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 16 days.
3282142|NCT00610649|Placebo Comparator|Part 1: Block A Placebo|Participants receive placebo BID for a total of 16 days.
3282143|NCT00610649|Experimental|Part 1: Block B MK-8777|Participants receive MK-8777 initiated at 200 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 13 days.
3282144|NCT00610649|Placebo Comparator|Part 1: Block B Placebo|Participants receive placebo BID for a total of 13 days.
3282145|NCT00610649|Experimental|Part 1: Block C MK-8777|Participants receive MK-8777 initiated at 300 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 10 days.
3282146|NCT00610649|Placebo Comparator|Part 1: Block C Placebo|Participants receive placebo BID for a total of 10 days.
3282147|NCT00610649|Experimental|Part 1: Block D MK-8777|Participants receive MK-8777 initiated at 100 mg BID and titrated to a maximum dose determined by the results of Block A. Participants receive MK-8777 for a total of 13 days.
3282148|NCT00610649|Placebo Comparator|Part 1: Block D Placebo|Participants receive placebo BID for a total of 13 days.
3282149|NCT00610649|Experimental|Part 2: MK-8777 200 mg|Participants receive MK-8777 100 mg BID for 27 days followed by one day of 100 mg QD. Participants receive MK-8777 for a total of 28 days.
3282150|NCT00610649|Experimental|Part 2: MK-8777 800 mg|Participants receive MK-8777 200 mg BID for 3 days followed by 400 mg BID for 24 days followed by one day of 400 mg QD. Participants receive MK-8777 for a total of 28 days.
3282151|NCT00610649|Placebo Comparator|Part 2: Placebo|Participants receive placebo BID for 27 days followed by one day of placebo QD. Participants receive placebo for 28 days.
3282152|NCT00610636|Experimental|1|The patients with secondary resectable colorectal hepatic metastasis undergoing surgery
3282153|NCT00610636|Active Comparator|2|The patients with secondary resectable colorectal hepatic metastasis who underwent continuous chemotherapy
3282154|NCT00610623|Experimental|1|azithromycin iv 300 mg/day
3282155|NCT00610623|Placebo Comparator|2|Placebo
3282156|NCT00610610|Experimental|A|Paroxetine - Controlled Release
3282157|NCT00610610|Placebo Comparator|B|Same colour, shape placebo
3282158|NCT00610597||1|alcoholic liver disease
3282159|NCT00610597||2|chronic hepatitis C virus infection
3282160|NCT00610584|Experimental|1|verum acupuncture plus rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
3282161|NCT00610584|Placebo Comparator|2|minimal (sham) acupuncture plus rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
3282162|NCT00610584|Active Comparator|3|rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))alone
3282163|NCT00610571|Experimental|Oral Topotecan and Temodar|Two separate strata to accrue independently. Stratum 1: Patients taking receiving Dilantin, Tegretol, Trileptal or Phenobarbital. Stratum 2: Patients on anti-convulsants other than Dilantin, Tegretol, Trileptal or Phenobarbital or patients not on any anti-convulsants
3282164|NCT00610545|Active Comparator|1|Use Atorvastatin 80mg for 60 days , and the vascular surgery will be made between day-7 and day-60
3282165|NCT00610545|Active Comparator|2|Use Atorvastatin 20 mg for 60 days , and the vascular surgery will be made between day-7 and day-60
3282166|NCT00610532|Experimental|A|intravenous phenytoin alone
3282167|NCT00610532|Experimental|B|intravenous phenytoin plus probenecid
3282168|NCT00610519|Active Comparator|1|treatment with spray containing aromatic essential oils of some herbal plants.
3282169|NCT00610519|Placebo Comparator|2|spray containing placebo.
3282170|NCT00610506|Experimental|A|Lexapro
3282171|NCT00610493|Experimental|Bevacizumab + Temsirolimus|Bevacizumab 5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle. Temsirolimus 5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle. First tumor biopsy during screening visit and Second at the end of Cycle 1. DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1.
3282172|NCT00610480|Active Comparator|1 Optive|
3282173|NCT00610480|Active Comparator|2 Systane|
3282174|NCT00610441|Experimental|MK-8777 FD→PBO|Participants receive a fixed dose (FD) of MK-8777 100 mg twice each day (BID) for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive a fixed dose of placebo (PBO) BID for 3 weeks (Treatment Period 2).
3282175|NCT00610441|Experimental|PBO→MK-8777 FD|Participants receive a fixed dose of placebo BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive a fixed dose of MK-8777 100 mg BID for 3 weeks (Treatment Period 2).
3282176|NCT00610441|Experimental|MK-8777 RD→PBO|Participants receive rising doses (RD) of MK-8777 100-300 mg BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive rising doses of placebo BID for 3 weeks (Treatment Period 2).
3282177|NCT00610441|Placebo Comparator|PBO→MK-8777 RD|Participants receive rising doses of placebo BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive rising doses of MK-8777 100-300 mg BID for 3 weeks (Treatment Period 2).
3282178|NCT00610428|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo
3282179|NCT00610428|Experimental|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
3282180|NCT00610428|Placebo Comparator|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
3282181|NCT00610402||blood sample tear drop sample|blood sample tear drop sample
3282182|NCT00610389|Experimental|1|
3282183|NCT00610376|Experimental|1A|Preschools randomized to this group received a multicomponent intervention to improve handwashing behavior of the children. Children within the preschool intervention group were individually randomized to a home intervention or a home control intervention program. The children in this arm received the home intervention component.
3282184|NCT00610376|Active Comparator|2|This group did not receive any special treatment during the study, but did receive the intervention at the close of the study
3282185|NCT00610376|Experimental|1B|Preschools randomized to this group received a multicomponent intervention to improve handwashing behavior of the children. Children within the preschool intervention group were individually randomized to a home intervention or a home control intervention program. The children in this arm received the home control component.
3282186|NCT00610363|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 16.
3282187|NCT00610363|Experimental|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 16.
3282188|NCT00610350|Experimental|L|
3282189|NCT00610350|Experimental|P|
3282190|NCT00610337|Placebo Comparator|1|
3282191|NCT00610337|Experimental|2|1mg Cethrin®
3282192|NCT00610337|Experimental|3|3mg Cethrin®
3282193|NCT00610337|Experimental|4|6mg Cethrin®
3282194|NCT00610337|Experimental|5|12mg Cethrin®. Administration of this dose is dependent on data from lower doses.
3282195|NCT00610337|Experimental|6|18mg Cethrin®. Administration of this dose is dependent on data from lower doses.
3282196|NCT00610324|Experimental|1|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
3282197|NCT00610324|Active Comparator|2|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
3282198|NCT00610311|Experimental|ALVAC plus anti-gp100:154-162 TCR PBL + HD IL-2|"ALVAC plus anti-gp100:154-162 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + high dose (HD) interleukin-2 (IL-2): ALVAC vaccine two hours prior to cell infusion patients will receive 0.5 ml containing a target dose of 10^7 cell culture infectious dose 50% (CCID50) (with a range of approximately 10^6.4 to 107.9/mL of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2mL. This will be repeated on day 14.~Aldesleukin (IL2, Proleukin, Recombinant human interleukin 2)- 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)"
3282199|NCT00610298|Experimental|I|Subjects who receive whole body vibration
3282200|NCT00610298|No Intervention|N|Subjects do not receive whole body vibration intervention
3282201|NCT00610285||non-invasive immobilization system|This is a feasibility study to evaluate the accuracy of an alternative, non-invasive immobilization system in combination with image guided patient setup for SRS treatments. The aim is to determine whether or not the non-invasive system can provide comparable accuracy as the conventional invasive head ring system. If successful, patient discomfort can be significantly reduced for such treatments.
3282202|NCT00610272|Experimental|Single Site Radiation 4Gy Fraction|4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
3282203|NCT00610272|Active Comparator|Single Site Radiation 8Gy Fraction|8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
3282204|NCT00610272|Active Comparator|Multiple Sites Radiation 8Gy Fraction|8 Gy in a single fraction; retreatments > 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
3282205|NCT00610272|Experimental|Multiple Sites Radiation 12Gy Fraction|12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments > 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
3282206|NCT00610259|Experimental|1|brief behavioral therapy for insomnia (bBT-I) in addition to treatment as usual (TAU)
3282207|NCT00610259|Active Comparator|2|Treatment as usual (TAU)
3282208|NCT00610246|Experimental|A|
3282209|NCT00610233|Active Comparator|A|Urodynamic investigation with deep brain stimulation ON
3282210|NCT00610233|Experimental|B|Urodynamics with deep brain stimulation OFF
3282211|NCT00610220|Active Comparator|1|
3282212|NCT00610220|Experimental|2|
3282213|NCT00610207|Experimental|AFP|Anal fistula plug placement performed during surgical procedure
3282268|NCT00609804|Experimental|Sorafenib+Erlotinib|Sorafenib 400 mg twice daily by mouth Erlotinib 150 mg once daily by mouth
3282214|NCT00610194|Experimental|Arm 1|In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
3282215|NCT00610181||Breast MRI|Magnetic resonance imaging (MRI) of breast for patients with invasive lobular carcinoma of the breast.
3282216|NCT00610168|Experimental|BOOSTRIX I GROUP|Subjects, who had received Boostrix™ vaccine in the primary study (263855/004), received one additional booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.
3282217|NCT00610168|Experimental|BOOSTRIX II GROUP|Subjects, who had received Wyeth's (formerly Lederle) combined adult diphtheria and tetanus vaccine and GSK Biologicals' acellular pertussis vaccine in the primary study (263855/004), received one booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.
3282218|NCT00610155|Placebo Comparator|1|
3282219|NCT00610155|Experimental|2|
3282220|NCT00610155|Experimental|3|
3282221|NCT00610142|Active Comparator|1|
3282222|NCT00610142|Active Comparator|2|
3282223|NCT00610129|Experimental|1|MK-0646
3282224|NCT00610116|Other|LV lead electronically repositioning|Single arm study
3282225|NCT00610103|Active Comparator|KW-6500|Drug: KW-6500 (apomorphine hydrochloride (USAN))
3282226|NCT00610103|Placebo Comparator|Placebo|Placebo
3282227|NCT00610090|Experimental|Treatment - UniFit AAA Stent Graft|
3282228|NCT00610077|Experimental|1|Letrozole
3282229|NCT00610077|Active Comparator|2|Clomiphene citrate
3282230|NCT00610064|Other|A|Baseline neuroimaging
3282231|NCT00610064|Other|B|Neuroimaging during sacral neuromodulation
3282232|NCT00610051|Placebo Comparator|trial arm|6 months central continuous infusion with Papeilin by infusion pump.
3282233|NCT00610051|Active Comparator|Placebo arm|6 months central infusion with NS by infusion pump with exact infusion rat as trial arm.
3282234|NCT00610038|Experimental|1|Glibenclamide
3282235|NCT00610025|Active Comparator|1|10 patients with no previous abdominal surgeries, pre-insufflation of the abdomen using a veress needle (standard procedure for insufflating the abdomen for laparoscopic surgery)
3282236|NCT00610025|Active Comparator|2|10 patients with history of previous abdominal surgeries, pre-insufflation of the abdomen using veress needle (standard procedure for insufflating the abdomen for laparoscopic surgery)
3282237|NCT00610025|Active Comparator|3|10 patients with no previous history of abdominal surgeries, no veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
3282238|NCT00610025|Active Comparator|4|10 patients with history of previous abdominal surgeries, no veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
3282239|NCT00610025|Active Comparator|5|10 patients, all with no previous mid to upper abdominal surgeries, no Veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
3282240|NCT00610025|Active Comparator|6|10 patients, all with previous mid-to-upper abdominal surgeries, no Veress needle pre-insufflation, endoscopic take-down of intra-abdominal adhesions (if identified)
3282241|NCT00609999|Experimental|Stratum A|Pts not on EIAEDs
3282242|NCT00609999|Experimental|Stratum B|Pts on EIAEDs
3282243|NCT00609986|Experimental|Intensive|The experimental group will receive the intravenous regular insulin infusion protocol for the maintenance of blood sugar levels 70-110 mg/dL while hospitalized up to 7 am post operative day #3 and after hospitalization will receive subcutaneous insulin to maintain blood sugar levels 70-140 mg/dL.
3282244|NCT00609986|Active Comparator|Control|The control group will receive subcutaneous insulin injections (NPH or glargine and aspartame) to maintain a blood sugar level between 70-180 mg/dL while hospitalized and after hospitalization subcutaneous insulin to maintain blood sugar levels 90-180 mg/dL.
3282245|NCT00609973|Active Comparator|A|Ciprofloxacin 500 mg bid
3282246|NCT00609973|Placebo Comparator|B|Placebo bid
3282247|NCT00609960|No Intervention|1|no medication or clowns present during the preopertaive phase
3282248|NCT00609960|Active Comparator|2|midazolam a anxiolytic drug was given in the preoperative phase
3282249|NCT00609960|Active Comparator|3|clowns where present during the preoperative phase
3282250|NCT00609947|Experimental|Endeavor Zotarolimus-Eluting Coronary Stent|Zotarolimus-eluting stent (ZES) implanted using standard percutaneous coronary intervention (PCI) technique via the femoral approach
3282251|NCT00609934|Experimental|Sorafenib and palliative radiotherapy|
3282252|NCT00609921|Active Comparator|1|ARQ197
3282253|NCT00609908|Active Comparator|A1|Acute Burn Wounds: Wound debridement and split skin grafting
3282254|NCT00609908|Experimental|A2|Acute Burn Wounds: excision of the burn wound and primary closure, using a skin stretching device
3282255|NCT00609908|Active Comparator|B1|Scar reconstruction: serial excision
3282256|NCT00609908|Experimental|B2|Scar reconstruction: primary closure, using skin stretching device
3282257|NCT00609882|Active Comparator|HHFNC|Infants randomized to the Humidified High Flow Nasal Cannula (HHFNC) treatment group post extubation
3282258|NCT00609882|Active Comparator|nCPAP|Infants randomized to the nasal Continuous Positive Airway Pressure (nCPAP) treatment group
3282259|NCT00609869|Experimental|Lenalidomide and Rituximab|"28 day cycles of Lenalidomide administered orally and Rituximab administered intravenously.~Lenalidomide: Escalating doses starting with of 2.5 mg daily on 28-days cycles.~Rituximab: at 375 mg/m^2 on a weekly basis for the first cycle starting on day 15."
3282260|NCT00609856|Active Comparator|1|Pioglitazone
3282261|NCT00609856|Active Comparator|2|Insulin glargine
3282262|NCT00609843|Experimental|1|
3282263|NCT00609830|Experimental|Tailored Materials|
3282264|NCT00609830|Experimental|Physician Feedback|
3282265|NCT00609830|Active Comparator|Generic Materials|
3282266|NCT00609830|Placebo Comparator|Placebo Comparator|Participants receive no information
3282267|NCT00609817|Experimental|GCS-100|
3282462|NCT00608179|Experimental|4|control-hypoglycemia
3282269|NCT00609804|Active Comparator|Sorafenib|Sorafenib 400 mg twice daily by mouth.
3282270|NCT00609791|Experimental|nab-paclitaxel|
3282271|NCT00609778|Experimental|1:Mechanical CPR with LUCAS|A Mechanical device that provides chest compressions
3282272|NCT00609778|Active Comparator|2 Manual CPR|Manual chest compressions
3282273|NCT00609765|Experimental|Protocol Specified Chemotherapy|"Protocol Specified Chemotherapy Every 28 Days: Avastin, Fluorouracil, Doxorubicin, Streptozocin.~Premedications: Dexamethasone, Ondansetron"
3282274|NCT00609752|Active Comparator|1|
3282275|NCT00609752|Active Comparator|2|
3282276|NCT00609739|Experimental|Cytarabine + Mitoxantrone|This is a phase I-II study designed to evaluate the efficacy of the administration of high dose cytosine arabinoside and mitoxantrone followed by HCT in patients with JMML who have residual disease or have relapsed after initial HCT.
3282277|NCT00609713|Experimental|1|Comprehensive 12-month family-based obesity treatment with separate adolescents and parents group sessions
3282278|NCT00609713|Active Comparator|2|Individual 12-month nutrition education program
3282279|NCT00609700||1|Historical group: patients treated with Ringer's Lactate solution after severe burn injury
3282280|NCT00609700||2|Actual group: patients treated with Ringer's Acetate solution after severe burn injury
3282281|NCT00609687|Other|A|Patients with suspected sarcoid-related posterior segment inflammation with inconclusive clinical exam findings, ancillary testing, and laboratory results
3282282|NCT00609674|Experimental|fluticasone furoate nasal spray|
3282283|NCT00609674|Placebo Comparator|Placebo|
3282284|NCT00609661||1|Patients presenting to the Ohio State University Emergency Department or directly admitted to the Ohio State University Burn Unit following thermal burn.
3282285|NCT00609661||2|Healthy volunteers
3282286|NCT00609648|Experimental|CARL|CARL computer program
3282287|NCT00609648|Active Comparator|Pamphlet|Reassuring pamphlet about dental injections
3282288|NCT00609622|Experimental|A|Treatment arm A - sunitinib plus mFOLFOX6
3282289|NCT00609622|Active Comparator|B|Treatment arm B - bevacizumab plus mFOLFOX6
3282290|NCT00609609|Experimental|Corticosteroids|Methylprednisolone at a dose of 2 mg/kg/day with a taper to no less than 1 mg/kg/day by day 14, and no less than 0.4 mg/kg/day by day 28.
3282291|NCT00609609|Experimental|ECP + Corticosteroids|Extracorporeal Photopheresis (ECP) 8-9 treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60 + Methylprednisolone at a dose of 2 mg/kg/day with a taper to no less than 1 mg/kg/day by day 14, and no less than 0.4 mg/kg/day by day 28.
3282292|NCT00609596|Other|Arm 1|
3282293|NCT00609570|Experimental|Fruit and vegetables|Fruits and vegetables
3282294|NCT00609570|Active Comparator|Whey protein|Whey protein
3282295|NCT00609570|Active Comparator|Ca|Calcium pills
3282296|NCT00609557|Experimental|A|All subjects receive placebo for the first two weeks and then duloxetine for the next 10 weeks, but they are blind to what they are receiving.
3282297|NCT00609544|Experimental|1|
3282298|NCT00609544|Placebo Comparator|2|
3282299|NCT00609531|Experimental|Active|Individuals with an Autism Spectrum Disorder receiving citalopram
3282300|NCT00609531|Placebo Comparator|Placebo|Individuals with an Autistic Spectrum Disorder receiving placebo
3282301|NCT00609518|Active Comparator|Standard Vitamin and Steroid Schedule + Pemetrexed|Standard vitamin and steroid schedule that is used with pemetrexed consisting of a minimum of 5 daily doses of folic acid before first pemetrexed dose and dexamethasone on day before, day of, and day after treatment.
3282302|NCT00609518|Experimental|Simplified Vitamin and Steroid Schedule + Pemetrexed|Simplified vitamin and steroid schedule to be used with pemetrexed consisting of 2 daily doses of folic acid before first pemetrexed dose and dexamethasone on day of treatment only.
3282303|NCT00609505|Other|TM|Telemedicine genetic counseling group
3282304|NCT00609505|Other|FTF|Face-to-face genetic counseling group
3282305|NCT00609492|Experimental|Preterm I Group|Children born after a gestation period of 27-30 weeks
3282306|NCT00609492|Experimental|Preterm II Group|Children born after a gestation period of 31-36 weeks
3282307|NCT00609492|Active Comparator|Full term Group|Children born after a gestation period of more than 36 weeks
3282308|NCT00609479|Experimental|1|Internal fixation with Micronail. 41 patients.
3282309|NCT00609479|Experimental|2|External fixation with Hoffmann-II-non-bridging. 41 patients.
3282310|NCT00609466|Experimental|1|CG5503 IR 75mg 4 to 6 hourly for 72 hours
3282311|NCT00609466|Active Comparator|2|Morphine IR 30 mg 4 to 6 hourly for 72 hours
3282312|NCT00609466|Placebo Comparator|3|Matching placebo 4 to 6 hourly for 72 hours
3282313|NCT00609453|Experimental|1|Individuals with major depressive disorder receiving therapy
3282314|NCT00609440|Other|A|A single case study, of a patient that was submitted to a physiotherapeutic treatment.
3282315|NCT00609427|Experimental|EA|Training in external memory aids
3282316|NCT00609427|Experimental|MT|Mnemonic training intervention
3282317|NCT00609427|No Intervention|WL|Wait-list control
3282318|NCT00609401|Experimental|1|Sorafenib 400 bid + IL-2 3 MU per 5 day/week for 2 weeks every 4
3282319|NCT00609401|Experimental|2|Sorafenib 400 mg bid
3282320|NCT00609388|Active Comparator|A|Group A receives an intraportal Tacrolimus-infusion, ATG Induction, Tacrolimus and Steroids.
3282321|NCT00609388|Placebo Comparator|B|Group B receives a placebo-Saline solution (0.9%)-Infusion, ATG induction, Tacrolimus and Steroids.
3282322|NCT00609375|Experimental|I|Administration of cefepime in continuous infusion (3 Gr over 24 hours) for at least 7 days and no more than 14 days days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
3282323|NCT00609375|Active Comparator|II|Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for at least 7 days and no more than 14 days days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
3282324|NCT00609362|Active Comparator|Rosiglitazone|25 women age 60 to 75 years receiving rosiglitazone 8 mg/day
3282325|NCT00609362|Placebo Comparator|Placebo|25 women 60 to 75 years of age receiving placebo once a day for 14 weeks
3282326|NCT00609349|Other|connective tissue disease|all patients suffer from a connective tissue disease representing a risk for the development of pulmonary hypertension
3282327|NCT00609336|Experimental|Treatment (chemotherapy, radiation, pancreaticoduodenectomy)|See Detailed Description
3282328|NCT00609323|Experimental|1|
3282329|NCT00609323|Placebo Comparator|2|
3282330|NCT00609310|Experimental|I|Flavonoid treatment
3282331|NCT00609297||Supportive Care|Alive Hospice Patients with Pain
3282332|NCT00609284|Experimental|1|Radiotherapy 70Gy, Erbitux, Carboplatin-5FU
3282333|NCT00609284|Active Comparator|2|Radiotherapy 70Gy, Erbitux
3282334|NCT00609271|Experimental|1|low carbohydrate diet
3282335|NCT00609271|Active Comparator|2|therapeutic lifestyle change diet
3282336|NCT00609245|Experimental|Placebo then Valproic Acid (VPA)|all patients will have placebo on day 1 and VPA infusion on day 2
3282337|NCT00609219|Experimental|EBV specific CTL|autologous EBV specific CTLs
3282338|NCT00609193||1|Study subjects receiving lithium
3282339|NCT00609193||2|Study subjects receiving quetiapine
3282340|NCT00609180|Experimental|1|Participants will receive initial minimal (trophic) enteral feeding and the omega-3 fatty acid and anti-oxidant supplements
3282341|NCT00609180|Experimental|2|Participants will receive initial full-calorie enteral feeding and the omega-3 fatty acid and anti-oxidant supplements
3282342|NCT00609180|Experimental|3|Participants will receive initial minimal (trophic) enteral feeding and the placebo supplement
3282343|NCT00609180|Placebo Comparator|4|Participants will receive initial full-calorie enteral feeding and the placebo supplement
3282344|NCT00609154|Experimental|A|Type 2 diabetes
3282345|NCT00609154|Experimental|B|non diabetic control, matched
3282346|NCT00609141|Experimental|Treatment (monoclonal antibody therapy)|Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for up to 2 years in the absence of unacceptable toxicity or disease progression.
3282347|NCT00609128|Experimental|1|
3282348|NCT00609115|Experimental|T|The Test Group will have 18 half hour AMES (Assisted Movement with Enhanced Sensation) treatments per qualified subject limb with the AMES device. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
3282349|NCT00609115|Sham Comparator|C-1|Eighteen treatment sessions for each qualifying subject limb using the AMES device programed to provide placebo therapy. Each treatment session consisting of 30 minutes of placebo therapy. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
3282350|NCT00609115|Active Comparator|C-2|Crossover treatment of subjects who received placebo treatment during Phase 1 of the study to provide 18 regular (i.e., non-placebo) AMES (Assisted Movement with Enhanced Sensation) treatment sessions. Sessions to be scheduled preferably 2 to 3 times per week with each session one-half hour in length.
3282351|NCT00609102|Placebo Comparator|Placebo|
3282352|NCT00609102|Active Comparator|antioxidant drug|n-acetylcysteine
3282353|NCT00609089|Experimental|I|Community Reinforcement and Family Training for Retention in Treatment and Recovery and Reduction of HIV Risk Behavior (CRAFT-T)
3282354|NCT00609089|Active Comparator|II|Treatment As Usual
3282355|NCT00609063|Experimental|1|Participants will receive atorvastatin for 6 months.
3282356|NCT00609063|Placebo Comparator|2|Participants will receive matching placebo for 6 months.
3282357|NCT00609050|Active Comparator|1|Self-Regulated Exercise with Telephone Reinforcement
3282358|NCT00609050|Active Comparator|2|Attention Control
3282359|NCT00609037||1|Individuals who has had a weight reduction procedure such as gastric bypass and have body contouring surgery to remove the excessive skin due to the weight loss
3282360|NCT00609037||2|Normal controls include individuals who schecule to have an abdominoplasty and are within normal for height and weight
3282361|NCT00608985|Experimental|1|almorexant 200 mg
3282362|NCT00608985|Experimental|2|almorexant 100 mg
3282363|NCT00608985|Placebo Comparator|3|Placebo
3282364|NCT00608985|Active Comparator|4|zolpidem 10 mg
3282365|NCT00608972|Experimental|Doxil, Carboplatin and Bevacizumab|
3282366|NCT00608959|Experimental|omiganan 1% gel|Omiganan has a rapid bactericidal and fungicidal effect which is under development for the prevention of infections arising from short-term central venous catheters, as well as for the prevention of surgical wound infections in contaminated wounds.
3282367|NCT00608959|Active Comparator|chlorhexidine 2%|
3282368|NCT00608946|Experimental|1|efficacy of the intake of 8 mg of copper daily per os for one year under observation of cognitive status unless unacceptable side effects appear
3282369|NCT00608946|Placebo Comparator|2|placebo
3282370|NCT00608933|Active Comparator|Arm I (intervention)|Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
3282371|NCT00608933|Other|Arm II (wait-list)|Health providers are enrolled on a wait-list. After 2 months, the educational materials in arm I (educational intervention) are made available to the wait-list health providers.
3282372|NCT00608920|Experimental|SPECT lymph node mapping|"Diagnostic pelvic CT~Nuclear tracer injection (Tc-99m) - same time as the ACCULOC seed implantation~CT simulation (2 hours after prostate markers are placed)~SPECT lymphoscintigraphy (first set of images 3-6 hours after injection and second set may be obtained 18-24 hours after injection)"
3282373|NCT00608907|Experimental|VELCADE|Control arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle.
3282374|NCT00608907|Experimental|VELCADE + rifampicin|Treatment Arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3.
3282463|NCT00608153||1|Patient with essential hypertension under treatment with candesartan or candesartan HCT
3282375|NCT00608907|Experimental|VELCADE + dexamethasone|Treatment arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3.
3282376|NCT00608894|Experimental|LCP-Tacro|LCP-Tacro tablets(1,2,and 5mg tacrolimus)+ prednisone tablets(5mg)
3282377|NCT00608894|Active Comparator|Azathioprine|Azathioprine tablets(50mg)+ prednisone tablets(5mg)
3282378|NCT00608881|Active Comparator|A - coenzyme Q10 2400 mg/day|Randomized to active treatment (coenzyme Q10 2400 mg/day)
3282379|NCT00608881|Placebo Comparator|B - Placebo|Randomized to placebo
3282380|NCT00608842|Experimental|Deoxycholic Acid 1%|Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
3282381|NCT00608842|Experimental|Deoxycholic Acid 2%|Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
3282382|NCT00608842|Experimental|Deoxycholic Acid 4%|Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
3282383|NCT00608842|Placebo Comparator|Placebo|Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
3282384|NCT00608829|Experimental|GORE TAG® Thoracic Endoprosthesis|Gore 45mm TAG Thoracic Endograft Implantation
3282385|NCT00608816|Experimental|1|Hyperinsulinemic euglycemic glucose clamp study on day 1 Hyperinsulinemic euglycemic clamp study on day 2 with epinephrine infusion
3282386|NCT00608816|Experimental|2|Hyperinsulinemic hypoglycemic glucose clamp x 2 on day 1 Hyperinsulinemic euglycemic clamp with epinephrine infusion on Day 2
3282387|NCT00608803|Experimental|Single arm|Once the maximum tolerated dose (MTD) is determined, an expanded cohort of 20 subjects with advanced, ifosfamide and doxorubicin naive soft-tissue sarcoma subjects will be dosed at the MTD and evaluated for efficacy.
3282388|NCT00608790|Experimental|1|
3282389|NCT00608764||NHW COPD Participants|Non-Hispanic white participants with COPD
3282390|NCT00608764||NHW Control Group|Non-Hispanic white participants with normal spirometry (do not have COPD)
3282391|NCT00608764||AA COPD Participants|African-American participants with COPD
3282392|NCT00608764||AA Control Group|African-American participants with normal spirometry (do not have COPD)
3282393|NCT00608751|Experimental|IMRT|External beam radiation with 6 MV photons will be delivered in 200 cGy daily fractions, 35 fractions over 7 weeks for a total dose of 7000 cGy.
3282394|NCT00608725|Other|Patients|Patients with orthostatic intolerance
3282395|NCT00608725|Other|Healthy Control Subjects|"Healthy subjects to determine normal response"
3282396|NCT00608673|Experimental|1|Patients in arm one used twice daily pimecrolimus 1% cream on their facial discoid lupus erythematosus lesions for 8 weeks.
3282397|NCT00608673|Active Comparator|2|Twice daily betamethasone valerate 0.1% cream to facial lesions of discoid lupus erythematosus for 8 weeks
3282398|NCT00608660|Experimental|A|staging acupuncture for treating Bell's Palsy
3282399|NCT00608660|Experimental|B|staging acupuncture and moxibustion for treating Bell's Palsy
3282400|NCT00608660|Experimental|C|staging electroacupuncture for treating Bell's Palsy
3282401|NCT00608660|Experimental|D|staging acupuncture along Yangming musculature for treating Bell's Palsy
3282402|NCT00608660|Experimental|E|non-staging acupuncture for treating Bell's Palsy
3282403|NCT00608634|Placebo Comparator|Placebo|Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
3282404|NCT00608634|Experimental|Low Dose POH 0.30%|Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
3282405|NCT00608634|Experimental|High Dose POH 0.76%|Patients apply perillyl alcohol (POH) cream (0.76%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
3282406|NCT00608621||1-physostigmine|"Physostigmine 4 mg in 50 ml NaCl 0.9% per 24 h as syringe pump continuously for 48 hours, plus physostigmine 2mg (in NaCl 0.9% 50 ml)at termination of sedation~PCA: Patient-controlled analgesia with piritramide 1 mg/ml, on demand: bolus of 2 mg, maximum of 10 mg in 60 min"
3282407|NCT00608621||2-placebo|"NaCl 0.9% 50 ml per 24 h continuously over 48 hours, plus 50 ml NaCl 0.9% at termination of sedation~PCA: Patient-controlled analgesia with piritramid 1 mg/ml, on demand: bolus of 2 mg, maximum of 10 mg in 60 min"
3282408|NCT00608595|Experimental|Therapeutic Intervention/Celecoxib|Celecoxib
3282409|NCT00608582|Experimental|Real rTMS|These patients receive a series of 10 Real Transcranial Magnetic Stimulation, Repetitive (rTMS), treatments, only. There is pre-testing, and post-testing at 2 months after the last Real rTMS treatment.
3282410|NCT00608582|Sham Comparator|Sham rTMS|Patients receive a series of 10 Sham Transcranial Magnetic Stimulation, Repetitive (rTMS) treatments, followed by a series of 10 Real rTMS treatments. Sham rTMS treatments are identical to the Real rTMS treatments, however, no magnetic pulse is released. There is pre-testing, and post-testing at 2 months after the last Sham rTMS treatment.
3282411|NCT00608569|Experimental|mDOT arm|Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.
3282412|NCT00608569|Active Comparator|non-mDOT arm|Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.
3282413|NCT00608543|Other|Aripiprazole augmentation|This is a single arm trial in which all participants recieved open label aripiprazole augmentation of their current escitalopram, citalopram or sertraline treatment.
3282414|NCT00608530|Experimental|Cognitive Behavioral Therapy-Psychologist-Delivered|10 hours of Cognitive Behavioral Training delivered by a psychologist over 8 weeks by telephone and face-to-face contact
3282415|NCT00608530|Active Comparator|Supportive Psychotherapy-Psychologist-Delivered|10 hours of Rogerian Psychotherapy delivered by a psychologist over 8 weeks by telephone and face-to-face contact
3282601|NCT00607243|Experimental|Conventional dose group|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
3282416|NCT00608530|Experimental|Cognitive Behavioral Therapy-Nurse-Delivered|10 hours of Cognitive Behavioral Training delivered by a primary care medical nurse over 8 weeks by telephone and face-to-face contact
3282417|NCT00608530|Active Comparator|Supportive Psychotherapy-Nurse-Delivered|10 hours of Rogerian Psychotherapy delivered by a primary care medical nurse over 8 weeks by telephone and face-to-face contact
3282418|NCT00608517|Experimental|Pediatric Myeloablative conditioning|Patients undergo total-body irradiation on days -7 to -4, and receive cyclophosphamide IV over 1 hour on days -3 and -2, methylprednisolone IV twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4 hours on days -3 to -1.
3282419|NCT00608517|Experimental|Adult Myeloablative conditioning|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -4, cyclophosphamide IV over 1 hour on days -5 and -4, and undergo total-body irradiation on days -3 to -1.
3282420|NCT00608517|Experimental|Reduced-intensity conditioning|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on day -6 and undergo total-body irradiation on day -1.
3282421|NCT00608491|Active Comparator|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
3282422|NCT00608491|Experimental|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
3282423|NCT00608465|Active Comparator|Treatment A|Eplerenone (study drug)
3282424|NCT00608465|Active Comparator|Treatment B|Ramipril
3282425|NCT00608452||1|
3282426|NCT00608439|Placebo Comparator|Placebo|Placebo CAST
3282427|NCT00608439|Active Comparator|Centella asiatica selected triterpenes|Active CAST
3282428|NCT00608426|No Intervention|Usual Care|Group who can elect to receive reactive (usual) care for smoking cessation.
3282429|NCT00608426|Experimental|Proactive Care|Group who will be proactively offered smoking cessation care with their choice of smoking cessation services (telephone care or in-person care).
3282430|NCT00608400|Experimental|1|CLA 1.5 g/d
3282431|NCT00608400|Experimental|2|CLA 3.0 g/d
3282432|NCT00608400|Placebo Comparator|3|
3282433|NCT00608387|Experimental|A|Participants will receive usual care from their healthcare providers and have access to a Web-based CVD risk-factor management program.
3282434|NCT00608387|No Intervention|B|Participants will receive usual care from their healthcare providers.
3282435|NCT00608361|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3282436|NCT00608348|Experimental|1|Hyperinsulinemic euglycemic or hypoglycemic clamp with Muscle and skin sympathetic nerve activity recording in arm and/or leg
3282437|NCT00608348|Experimental|2|Exercise with insulin or no insulin infused with muscle and skin sympathetic nerve activity measurements
3282438|NCT00608335|Experimental|1. Micafungin 3.0 mg|IV
3282439|NCT00608335|Experimental|2. Micafungin 4.5 mg|IV
3282440|NCT00608322|Experimental|1|Subjects receive inhaled nitric oxide (40 parts per million) for six hours.
3282441|NCT00608322|Sham Comparator|2|Subjects receive sham inhaled nitric oxide for six hours.
3282442|NCT00608296||1|Study subjects on lithium
3282443|NCT00608296||2|study subjects on quetiapine
3282444|NCT00608283||Live Kidney Donors|People who are going to donate a kidney at one of the three transplant centers from August 2007 until June 2011
3282445|NCT00608244|Experimental|LCP-Tacro|"Prograf was administrated BID, doses per product labeling, with an interval of 12±1 hours between the morning and evening doses. Patients continued on the same dose from Day 0 through Day 7. On Day 8, all patients were converted to LCP Tacro QD for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro was administered orally once daily in the morning, with an interval of 24 ± 1 h between doses. Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL.~LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
3282446|NCT00608231|Experimental|PD-STN|Parkinson's Disease -- STN target
3282447|NCT00608231|Experimental|PD - GPi|Parkinson's Disease -- GPi target
3282448|NCT00608231|Experimental|ET - VIM|Essential Tremor -- VIM target
3282449|NCT00608231|Experimental|Dystonia - GPi|Dystonia -- GPi target
3282450|NCT00608231|Placebo Comparator|PD - STN Control|Parkinson's Disease -- STN target
3282451|NCT00608231|Placebo Comparator|PD - GPi Control|Parkinson's Disease -- GPi target
3282452|NCT00608231|Placebo Comparator|ET - VIM Control|Essential Tremor -- VIM target
3282453|NCT00608231|Placebo Comparator|Dystonia - GPi Control|Dystonia -- GPi target
3282454|NCT00608218||Artist|
3282455|NCT00608205|Active Comparator|Arm A: Radiation with concurrent Cisplatin|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
3282456|NCT00608205|Experimental|Arm B: Radiation with concurrent 5-FU and Cisplatin|Patients undergo radiotherapy as in arm I and receive fluorouracil IV and cisplatin IV continuously on days 1-4 and 22-25 of radiotherapy.
3282457|NCT00608192|Active Comparator|Testing, Education, & Counseling (TEC)|HIV and hepatitis screening is done on-site, but vaccination and medical care will be provided by off-site referral. HIV and Hepatitis, Testing, Education, & Counseling (TEC) participants will receive standard HIV and hepatitis education & counseling. TEC participants will not receive case management services.
3282458|NCT00608192|Experimental|Hepatitis Care Coordination (HCC)|Participants will receive on-site HIV and viral hepatitis screening. Hepatitis A and B combination vaccination will be provided on-site. Participants will receive on-site theory-based HIV and hepatitis education, counseling, and 6 months of case management to promote adherence to HIV and HCV evaluation.
3282459|NCT00608179|Experimental|1|
3282460|NCT00608179|Experimental|2|
3282461|NCT00608179|Experimental|3|control-euglycemia
3282464|NCT00608140|Experimental|1|Participants will receive optimal medical therapy plus surgical mitral valve repair with complete annular ring placement
3282465|NCT00608140|Active Comparator|2|Participants will receive optimal medical therapy alone
3282466|NCT00608140|Experimental|3|Participants will receive optimal medical therapy plus 18-month delayed surgical mitral valve repair with complete annular ring placement
3282467|NCT00608127|Experimental|1|Single arm open label
3282468|NCT00608101|Experimental|1|Day 1 hyperinsulinemic euglycemic clamps with either 0.2 mg fludrocortisone, 0.75 mg Dexamethasone, or both given orally before each morning and afternoon clamp. Day 2 hyperinsulinemic hypoglycemic glucose clamp.
3282469|NCT00608101|Experimental|2|Fludrocortisone will be administered in doses of 0.05mg, 0.1mg and 0.2 mg form at the start of each clamp period on day 1. Dexamethasone will be administered orally in the doses of 0.18 mg, 0.375mg and 0.75mg doses. The combination of the 0.05mg fludrocortisone and 0.18mg dexamethasone and 0.1mg of fludrocortisone and 0.375 mg doses will be administered at the start of each day 1 clamp period. Day 2 90 minutes of moderate exercise.
3282470|NCT00608088|Active Comparator|1|Usual Care
3282471|NCT00608088|Active Comparator|2|Health Nurse/Peer Councelor Intervention
3282472|NCT00608075|Other|1|Manic Patients
3282473|NCT00608075|Other|2|Depressed Patients
3282474|NCT00608062|Experimental|Pre1|Premenopausal - GnRHant plus estradiol
3282475|NCT00608062|Placebo Comparator|Pre2|Premenopausal - GnRHant plus placebo
3282476|NCT00608062|Experimental|Peri1|Perimenopausal (early) - GnRHant plus estradiol
3282477|NCT00608062|Placebo Comparator|Peri2|Perimenopausal (early) - GnRHant plus placebo
3282478|NCT00608062|Experimental|Peri3|Perimenopausal (late) - GnRHant plus estradiol
3282479|NCT00608062|Placebo Comparator|Peri4|Perimenopausal (late) - GnRHant plus placebo
3282480|NCT00608062|Experimental|Post1|Postmenopausal - GnRHant plus estradiol
3282481|NCT00608062|Placebo Comparator|Post2|Postmenopausal - GnRHant plus placebo
3282482|NCT00608049|Experimental|1|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/high GI, high carbohydrate/low GI, low carbohydrate/high GI, and low carbohydrate/low GI
3282483|NCT00608049|Experimental|2|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/high GI, high carbohydrate/low GI, low carbohydrate/low GI, and low carbohydrate/high GI
3282484|NCT00608049|Experimental|3|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/low GI, high carbohydrate/high GI, low carbohydrate/high GI, and low carbohydrate/low GI
3282485|NCT00608049|Experimental|4|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/low GI, high carbohydrate/high GI, low carbohydrate/low GI, and low carbohydrate/high GI
3282486|NCT00608049|Experimental|5|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/high GI, low carbohydrate/low GI, high carbohydrate/high GI, and high carbohydrate/low GI
3282487|NCT00608049|Experimental|6|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/high GI, low carbohydrate/low GI, high carbohydrate/low GI, and high carbohydrate/high GI
3282488|NCT00608049|Experimental|7|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/low GI, low carbohydrate/high GI, high carbohydrate/high GI, and high carbohydrate/low GI
3282489|NCT00608049|Experimental|8|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/low GI, low carbohydrate/high GI, high carbohydrate/low GI, and high carbohydrate/high GI
3282490|NCT00608023|Experimental|Tesamorelin 12 months (T-T)|Tesamorelin 2 mg/day for 12 months
3282491|NCT00608023|Experimental|Tesamorelin-Placebo (T-P)|Tesamorelin 2 mg/day for 6 months - Placebo for 6 months
3282492|NCT00608023|Experimental|Placebo-Tesamorelin (P-T)|Placebo 6 months - Tesamorelin 2 mg/day for 6 months
3282493|NCT00608010|Experimental|1|Vitrification
3282494|NCT00608010|Active Comparator|2|Slow freezing
3282495|NCT00607997|Experimental|All Study Patients|"Schedule A: 72 mg/m2 vosaroxin Days 1, 8 and 15~Schedule B: 72 mg/m2 vosaroxin on Days 1 and 8~Schedule C: 72 mg/m2 on Days 1 and 4, or~Schedule C: 90 mg/m2 on Days 1 and 4"
3282496|NCT00607984|Experimental|single|
3282497|NCT00607971|Experimental|1|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
3282498|NCT00607958|Experimental|1|dose reduction
3282499|NCT00607945|Placebo Comparator|0 g CLA|Avandia (Rosiglitazone) 4-8mg/day OR other diabetes medication currently prescribed to participant, 0 g CLA, 8 g Placebo oil (based on typical American diet)
3282500|NCT00607945|Experimental|3.2 g CLA|Avandia 4-8mg/day OR other diabetes medication currently prescribed to participant, 3.2 g CLA, 4.8 g placebo oil (based on typical American diet)
3282501|NCT00607945|Experimental|6.4 g CLA|Avandia 4-8mg/day OR other diabetes medication currently prescribed to participant, 6.4 g CLA, 1.6 g placebo oil (based on typical American diet)
3282502|NCT00607932|Experimental|Brassica Vegetables Diet Intervention|
3282503|NCT00607932|Experimental|Pill|
3282504|NCT00607919|Experimental|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 milligram/kilogram/day (mg/kg/day) given orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine
3282505|NCT00607919|Placebo Comparator|Placebo|Placebo will be packaged in the same way as experimental drug to enforce double-blind study design. Placebo will be administered orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine.
3282506|NCT00607906|Experimental|Subjects receiving treatment in cohort A1|Eligible subjects will receive oral immediate release capsules of SB-756050 with doses of 5 milligrams, 15 milligrams, 50 milligrams, or 100 milligrams.
3282507|NCT00607906|Experimental|Subjects receiving treatment in cohort A2|Eligible subjects will receive oral immediate release capsules of SB-756050 with doses of 100 milligrams, 200 milligrams, 300 milligrams, or 400 milligrams.
3282508|NCT00607906|Experimental|Subjects receiving treatment in cohort A3|Eligible subjects will receive oral immediate release capsules of SB-756050 with a dose of 150 milligrams. Subjects will also receive oral modified release capsules of SB-756050 with doses of 150 milligrams, 300 milligrams, or 400 milligrams.
3282509|NCT00607906|Experimental|Subjects receiving treatment in cohort A4|Eligible subjects will receive SB-756050 in this additional cohort.
3282510|NCT00607906|Experimental|Subjects receiving treatment in cohort B1|Eligible subjects will receive oral modified release capsules of SB-756050 with doses of 50 milligrams, 150 milligrams or 400 milligrams. Subjects will also receive immediate release oral capsules of SB-756050 with a dose of 150 milligrams.
3282511|NCT00607893|Sham Comparator|Sham CPAP|Participants will receive sham continuous positive airway pressure (CPAP) for a 2 month period. Sham CPAP involves wearing a device that appears similar to a standard CPAP device, but administers a negligible pressure. Adherence will be tracked while the participant wears the device.
3282512|NCT00607893|Active Comparator|Treatment CPAP|Participants will receive continuous positive airway pressure for a 2 month period. The optimal treatment pressure will be identified during a titration study prior to trial enrollment. Adherence will be tracked while the participant wears the device.
3282513|NCT00607880|Active Comparator|Standard Port|Patients undergo insertion of the conventional vascular access port (C. R. Bard, Inc., Murray Hill, NJ). Patients then receive standard chemotherapy.
3282514|NCT00607880|Experimental|Vortex Implantable Access Port|Patients undergo insertion of the Vortex® implantable vascular access port (Horizon Medical Products, Manchester, GA). Patients then receive standard chemotherapy.
3282515|NCT00607867|Active Comparator|Arm 1|A LoBAG30, weight maintenance diet will be given to subjects on metformin. All food will be provided for 5 weeks.
3282516|NCT00607867|Placebo Comparator|Arm 2|A weight maintenance, control diet consisting of 55% carbohydrate, 15% protein, 30% fat will be given to subjects on metformin. All food will be provided for 5 weeks.
3282517|NCT00607854|Experimental|Zevalin|Zevalin associated with a Fludarabine-based reduced-intensity conditioning regimen,all patients will receive Zevalin in the conditioning regimen
3282518|NCT00607841|Experimental|1|"Phase I dose escalation to determine maximum tolerated dose (MTD).~Phase II using fixed dose determined in Phase I portion of study."
3282519|NCT00607815|Active Comparator|Cognitive Processing Therapy|Cognitive Processing Therapy
3282520|NCT00607815|Active Comparator|Present Centered Therapy|Present Centered Therapy
3282521|NCT00607789|Experimental|Duloxetine Group|Start with 30 mg duloxetine hydrochloride capsule/day to be increased up to 120 mg per day.
3282522|NCT00607789|Placebo Comparator|Placebo Group|Sugar pill with matching dosage as Duloxetine
3282523|NCT00607776|Active Comparator|1|Systane
3282524|NCT00607776|Experimental|2|Blink tears
3282525|NCT00607763|Experimental|1. Micafungin|
3282526|NCT00607750|Placebo Comparator|1|
3282527|NCT00607750|Experimental|ATG003|
3282528|NCT00607737|Experimental|1|insulin detemir
3282529|NCT00607737|Placebo Comparator|2|saline
3282530|NCT00607724|Experimental|Stage 1: GDC-0449 (150 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 milligram (mg) on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 150 mg, orally, continuing until disease progression (deterioration of evaluable lesions and/or tumor-related symptoms defined using Response Evaluation Criteria in Solid Tumors Version 1.0 (RECIST v1.0), maximum benefit, or intolerability.
3282531|NCT00607724|Experimental|Stage 1: GDC-0449 (270 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 270 mg, orally, continuing until disease progression, maximum benefit, or intolerability.
3282532|NCT00607724|Experimental|Stage 1: GDC-0449 (540 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 540 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 540 mg, orally, continuing until disease progression, maximum benefit, or intolerability.
3282533|NCT00607724|Experimental|Stage 2: BCC [GDC-0449 (150 mg)]|Participants with basal cell carcinoma (BCC) received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
3282534|NCT00607724|Experimental|Stage 2: BCC [GDC-0449 (270 mg)]|Participants with BCC received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
3282535|NCT00607724|Experimental|Stage 2:Safety Expansion Cohort [GDC-0449 (150 mg)]|Participants received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
3282536|NCT00607724|Experimental|Stage 2: New Formulation [GDC-0449 (150 mg )]|Participants received a daily oral dose of GDC-0449 Phase II drug product hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
3282537|NCT00607711|Experimental|Single arm|
3282538|NCT00607685|Experimental|1|The participants will receive a subconjunctival injection of a mixture of 5FU with hyaluronic acid.
3282539|NCT00607685|Active Comparator|2|Participants will receive a subconjunctival injection of 5 Fluorouracil only.
3282540|NCT00607672|Placebo Comparator|1|Patients are randomized to placebo prior to surgery
3282541|NCT00607672|Active Comparator|2|Patients are randomized to Ramipril prior to surgery
3282542|NCT00607672|Active Comparator|3|Patients are randomized to Candesartan (ARB) prior to surgery
3282543|NCT00607659||Chlamydia Positive|Adolescent females, 11-21 years old, evaluated for pelvic examinations or STI screening will be asked to participate in this study. Participants are being asked to give us permission to collect:additional cervical or vaginal swabs, rectal swabs, blood draws where three tablespoons of blood, a urine pregnancy test, and a comprehensive health history. You may be asked to provide a urine specimen at the initial visit instead of having a cervical swab. The study team will obtain a cervical swab when you come back for your follow-up appointments. If your culture is positive for Chlamydia, you will be asked attend 3 additional follow-up appointments after 3 months, 6 months, 1 year, 2 years, and 3 years .
3282711|NCT00606515|Experimental|A|Liposomal paclitaxel
3282544|NCT00607659||Control/Chlamydia Negative|Some participants with negative cultures will be included in this study as a control group. The same specimens, exams and blood draws will apply for those subjects with visits at 3 months, 6 months, 1 year, 2 years, and 3 years
3282545|NCT00607646|Experimental|1|Hyperinsulinemic (high dose insulin) hypoglycemic clamp studies with oral administration of DHEA or placebo prior to each clamp x 2 on day 1. Day 2 hyperinsulinemic hypoglycemia. Participant randomized to either DHEA or placebo for baseline trial (arm 1) and 6 weeks treatment.
3282546|NCT00607646|Experimental|2|Following 6 weeks randomized treatment, Day 1 hyperinsulinemic hypoglycemic clamps x 2 with DHEA or placebo dose given prior to each clamp. Day 2 hypoglycemia with prior dose of randomized treatment.
3282547|NCT00607646|Experimental|Arm 3 (optional)|Individuals will be asked to return after at least 2 months and repeat the trial they did not complete (for example, placebo if they were in the DHEA trial before). Again Day 1 would consist of two hyperinsulinemic clamps with placebo or DHEA given orally. Day 2 hyperinsulinemic hypoglycemic clamp with oral administration of placebo or DHEA.
3282548|NCT00607646|Experimental|Arm 4|Following 6 weeks randomized treatment, Day 1 hyperinsulinemic hypoglycemic clamps x 2 with DHEA or placebo dose given prior to each clamp. Day 2 hypoglycemia with prior dose of randomized treatment.
3282549|NCT00607633||1|Patient with essential hypertension and LVH under treatment with candesartan or candesartan HCT
3282550|NCT00607620|Experimental|Intervention|Providers receive training in alcohol screening and brief interventions from study staff in compliance with American College of Surgeons' Alcohol Screening and Brief Intervention Mandate
3282551|NCT00607620|No Intervention|Usual Care|Usual care for alcohol use problems after American College of Surgeons' Alcohol Screening and Brief Intervention Mandate
3282552|NCT00607607|Experimental|A|Ovarian Cancer Patients
3282553|NCT00607607|Experimental|B|Endometrial Cancer Patients
3282554|NCT00607594|Experimental|Treatment (kinase inhibitor therapy)|Patients receive saracatinib PO, at a dose of 175 mg QD in the absence of disease progression or unacceptable toxicity.
3282555|NCT00607581|Experimental|1|"The participants receive up to 9 28-day cycles of~cyclophosphamide: 500 mg orally on days 1, 8, 15;~lenalidomide: 15 mg orally on days 1-21;~dexamethasone: 40 mg orally on days on days 1, 8, 15, 22."
3282556|NCT00607568|Experimental|1|atomoxetine 40mg per day
3282557|NCT00607568|Placebo Comparator|2|second arm is placebo, sugar pill
3282558|NCT00607555||Observation|Premature infants over 23 weeks of gestation and less than 1.25 kilograms at birth, who are tolerating feedings, and are clinically stable
3282559|NCT00607542|Active Comparator|1|starting dose of baclofen 2.5 mg PO TID with dose escalation as tolerated
3282560|NCT00607529||1|Patients having a creatinine drawn
3282561|NCT00607516|Active Comparator|Cemented|Cemented primary bipolar hemiarthroplasty of the hip
3282562|NCT00607516|Active Comparator|Uncemented|Uncemented primary bipolar hemiarthroplasty of the hip
3282563|NCT00607503|Experimental|1|
3282564|NCT00607490|Experimental|Cognitive-behavioral Therapy|10 weekly individual 60-minute sessions
3282565|NCT00607490|Active Comparator|Supportive Psychotherapy|10 weekly individual 60-minute sessions
3282566|NCT00607477|Active Comparator|1|Minoxidil
3282567|NCT00607477|Active Comparator|2|Hydralazine
3282568|NCT00607464|Experimental|1|Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
3282569|NCT00607464|No Intervention|2|Standard care
3282570|NCT00607451|Experimental|1|
3282571|NCT00607451|Experimental|2|
3282572|NCT00607451|Experimental|3|
3282573|NCT00607451|Experimental|4|
3282574|NCT00607425||1|Non-small cell lung cancer patients
3282575|NCT00607425||2|Healthy control subjects
3282576|NCT00607412|Experimental|1|Present focused, integrated psychotherapy for PTSD and substance use disorders
3282577|NCT00607412|Active Comparator|2|Supportive therapy using 12-step model
3282578|NCT00607399|Experimental|Single arm|
3282579|NCT00607386|Other|Idursulfase|Open-label treatment with idursulfase
3282580|NCT00607373|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
3282581|NCT00607373|Placebo Comparator|Placebo|Participants received placebo as a subcutaneous injection once a week for 26 weeks.
3282582|NCT00607360|No Intervention|Standard Drug Court|Participants received standard services from drug court
3282583|NCT00607360|Experimental|Drug Court plus Therapeutic Workplace|Participants receive standard drug court services plus therapeutic workplace intervention
3282584|NCT00607347|Experimental|A|The subjects will be undergoing a oral glucose tolerance test.
3282585|NCT00607334|Experimental|GP|Children with Developmental Language Impairments were enrolled in this group.
3282586|NCT00607334|Experimental|GC|Children with normal language development were enrolled in this group.
3282587|NCT00607321|Experimental|1|Medtronic Bifurcation Stent System
3282588|NCT00607308|Experimental|0.1 mg/kg|
3282589|NCT00607308|Experimental|0.5 mg/kg|
3282590|NCT00607308|Experimental|1 mg/kg|
3282591|NCT00607308|Experimental|5 mg/kg|
3282592|NCT00607308|Placebo Comparator|Placebo|
3282593|NCT00607308|Experimental|10 mg/kg|
3282594|NCT00607295|Experimental|1|Clino-san 2ml vaginal application 3 times per week for 12 weeks
3282595|NCT00607295|Placebo Comparator|2|placebo 2ml vaginal application 3 times per week for 12 weeks
3282596|NCT00607282|Placebo Comparator|Placebo|normal control group
3282597|NCT00607282|Experimental|Udenafil|oral administration of placebo for Udenafil (Dong-A Pharmaceutical co., Ltd, Seoul, Korea)
3282598|NCT00607269|No Intervention|Control|Control condition receiving minimal incentives for service program attendance and participation.
3282599|NCT00607269|Experimental|Contingency Management|Contingency management (Voucher-Based Reinforcement Therapy) intervention providing positive reinforcement for service program participation and attendance, enactment of prosocial/health behavior, and/or clean urine samples (i.e., no illicit drug use) and clean breathalyzer tests (i.e., BA < 0.05).
3282600|NCT00607256|Experimental|Open Label|
3282712|NCT00606515|Active Comparator|B|Paclitaxel
3282602|NCT00607243|Experimental|Low dose group|Diluted CJ-50300 2.5 x 10000pfu/dose vaccination
3282603|NCT00607230|Experimental|E|BCG vaccination
3282604|NCT00607230|Placebo Comparator|P|Saline vaccination
3282605|NCT00607217|Experimental|CAD-Exp|Enrolled coronary artery disease patients who are randomly assigned to receive influenza vaccine
3282606|NCT00607217|Placebo Comparator|CAD-Control|Enrolled coronary artery disease patients who are randomly assigned to receive placebo of influenza vaccine
3282607|NCT00607217|Experimental|Healthy-Control|Enrolled healthy subjects serve as control for CAD-Exp
3282608|NCT00607178|Experimental|Influenza vaccine|Enrolled patients who are randomly assigned to receive influenza vaccine
3282609|NCT00607178|Placebo Comparator|Placebo|Enrolled patients who are randomly assigned to receive placebo of influenza vaccine
3282610|NCT00607152|Experimental|1|IV infusion at a dose level of 0.20mg/kg per day
3282611|NCT00607152|Active Comparator|2|100mg tablets, administered orally, according to standard medical practice
3282612|NCT00607126|Experimental|1|locomotor training using body weight support on a treadmill, using robotic device to provide locomotor training. Locomotor training will be done using the Lokomat device. the patient is suspended over a treadmill while their legs are in the Lokomat, which moves the legs on the treadmill.
3282613|NCT00607126|Active Comparator|2|resistive training using weights and therabands
3282614|NCT00607113|Experimental|Avastin|Cycle 1 (First 3 weeks of study) - Avastin 15 mg/kg intravenous (IV)
3282615|NCT00607113|Experimental|Avastin + RAD001|Cycle 2: Avastin 15 mg/kg intravenous (IV) every 3 weeks + RAD001 10 mg orally daily for 3 weeks
3282616|NCT00607113|Experimental|RAD001|Cycle 1 (First 3 weeks of study)- RAD001 10 mg orally daily for 21 Days
3282617|NCT00607100||1|Patients with Band atrophy of the optic nerve
3282618|NCT00607100||2|Normal Controls
3282619|NCT00607087|Experimental|sequence 1|sequence 1: insulin glulisine / insulin aspart / insulin lispro.
3282620|NCT00607087|Experimental|Sequence 2|Sequence 2: insulin aspart / insulin lispro / insulin glulisine
3282621|NCT00607087|Experimental|Sequence 3|Sequence 3: insulin lispro / insulin glulisine / insulin aspart
3282622|NCT00607074|Experimental|1|
3282623|NCT00607061|Other|1|Full term newborn babies with gestational age > 37 weeks of amenorrhea and weight of birth > tenth percentile.
3282624|NCT00607061|Other|2|Low birth weight newborn babies (gestational age < 32 weeks of amenorrhea and/or weight of birth < 1500 g and/or weight of birth < third percentile for their gestational age.
3282625|NCT00607061|Other|3|Full term newborn babies (gestational age > 37 weeks of amenorrhea and weight of birth > tenth percentile).
3282626|NCT00607048|Other|Schedule A|Schedule A (CP-870,893 administration schedule)
3282627|NCT00607048|Other|Schedule B|Schedule B (CP-870,893 administration schedule)
3282628|NCT00607035|Experimental|A|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
3282629|NCT00607035|Experimental|H|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
3282630|NCT00607022|Active Comparator|immediate load|immediate load of dental implant based on the bone quality determined by the insertion torque value
3282631|NCT00607022|Active Comparator|Loading at 6 weeks|delayed load (6 weeks post surgery) of dental implants based on bone quality determined by the insertion torque value
3282632|NCT00607022|Active Comparator|Loading at 12 weeks|traditional loading of dental implants (12 weeks post surgery) based on bone quality determined by the insertin torque value.
3282633|NCT00607009|Experimental|1|received emails
3282634|NCT00607009|Placebo Comparator|2|no contact
3282635|NCT00606996|Experimental|IPT-G|Group Interpersonal Psychotherapy
3282636|NCT00606996|Active Comparator|PSYCHOED|Psychoeducation
3282637|NCT00606983|No Intervention|1|
3282638|NCT00606983|Experimental|2|oral administration of Tamsulosin
3282639|NCT00606970|Experimental|Intervention group|Seigen Alpha EV Treatment
3282640|NCT00606970|Placebo Comparator|2|Identically packaged placebo packets taken 3x daily for 3 months maximum
3282641|NCT00606944|Experimental|ERP group|fast-track rehabilitation with early ambulation and diet after elective colorectal resection
3282642|NCT00606944|No Intervention|control group|traditional, conventional care group
3282643|NCT00606931|Experimental|one arm|
3282644|NCT00606918||1|Individuals with ALS
3282645|NCT00606918||2|Healthy Adults
3282646|NCT00606905|Active Comparator|1|IVIG, either Gamimune N (Talecris Biotherapeutics, Inc., Clayton, NC) or Gamunex 10% (Talecris Biotherapeutics, Inc., Clayton, NC), both as a 10% solution
3282647|NCT00606905|Placebo Comparator|2|normal saline
3282648|NCT00606892|Experimental|Placebo First, varenicline, + IV Nic|Subjects received a Placebo tablet once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg).After a minimum of a 5 day washout subjects then received varenicline tablet (1mg). once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,0.7 mg per 70kg).
3282649|NCT00606892|Experimental|Varenicline first, placebo, + IV Nic|Subjects received Varenicline tablet (1 mg) per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg). After a washout of a minimum of 5 days subjects then received placebo tablet for per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,, and 0.7mg per 70 kg).
3282650|NCT00606879|Experimental|Single arm|
3282651|NCT00606866|Placebo Comparator|I|placebo pill
3282652|NCT00606866|Active Comparator|II|Sorafenib, 200 mg bid
3282653|NCT00606866|Active Comparator|III|Sorafenib, 400 mg bid
3282654|NCT00606853|Experimental|1|Standard Treatment plus prize contingency management for abstinence with an expected probability of winning about $250 in prizes and twice-weekly breath and urine samples.
3282655|NCT00606853|Experimental|2|Standard Treatment plus prize contingency management for abstinence with an expected probability of winning about $560 in prizes and twice-weekly breath and urine samples.
3282710|NCT00606528||Group B|Healthy volunteers willing to donate blood on 2 separate occasions
3282656|NCT00606853|Experimental|3|Standard Treatment plus prize contingency management for attendance with an expected probability of winning about $250 in prizes and twice-weekly breath and urine samples.
3282657|NCT00606853|No Intervention|4|Standard Treatment
3282658|NCT00606840|Experimental|1|One arm is a large changes group in which participants will be asked to make periodic large changes in their eating and activity, aimed at producing initial weight loss, in order to prevent weight gain over time.
3282659|NCT00606840|Experimental|2|The second arm is a small changes group in which participants will be asked to make small changes to their eating and activity and maintain these changes forever in order to prevent weight gain.
3282660|NCT00606827|Experimental|A|Bicarbonate
3282661|NCT00606827|Active Comparator|B|Saline
3282662|NCT00606801|Active Comparator|Galantamine 8 mg/day|Galantamine 8 mg/day
3282663|NCT00606801|Placebo Comparator|Placebo|placebo
3282664|NCT00606788|Active Comparator|AW|Patients received computer-driven protocolized weaning (= Automated Weaning)
3282665|NCT00606788|Active Comparator|CW|Patients received physician-directed non-protocolized weaning (= Conventional Weaning)
3282666|NCT00606775|Experimental|Carvedilol|
3282667|NCT00606775|No Intervention|Control|
3282668|NCT00606762|Active Comparator|LPLC, HPLC|LPLC: Low pressure pneumoperitoneum is defined as intraabdominal pressure kept at8 mm Hg after initial trocar insertion at 12 mm Hg HPLC: High pressure pneumoperitoneum is defined as intra abdominal pressure kept at 12 mm Hg throughout the procedure
3282669|NCT00606736||patients|subjects with right ventricular outflow tract arrhythmia
3282670|NCT00606736||control|subjects ,age match,healthy
3282671|NCT00606723|Experimental|1|"Group I: Relapsed AML-patients with blast cell reduction to <20% before the second course of induction therapy. These patients will receive conventional SCT.~Group II: Patients with non response to frontline treatment of AML, patients with blast cells <20% before the second course of induction therapy who do not achieve a second remission and relapsed AML-patients with blast cells >=20% before the second course of induction therapy. If these patients have a matched donor (MSD/MD) they will receive SCT with FLAMSA.~Group III: Patients who are eligible for Group II but have no matched donor. These patients will receive SCT from a haploidentical donor."
3282672|NCT00606697|Active Comparator|Overall study|Male and female subjects, 18-64 years of age (inclusive), with a primary diagnosis of primary insomnia
3282673|NCT00606684|Active Comparator|GW642444|GW642444
3282674|NCT00606684|Placebo Comparator|placebo|
3282675|NCT00606671||1|lean control women without PCOS
3282676|NCT00606671||2|lean women with PCOS
3282677|NCT00606671||3|Obese control women without PCOS
3282678|NCT00606671||4|Obese women with PCOS
3282679|NCT00606671||1xx - 04 LC|lean control women
3282680|NCT00606671||1xx-04 LP|lean women with PCOS
3282681|NCT00606671||1xx-04 OC|obese control women
3282682|NCT00606671||1xx-04 OP|obese women with PCOS
3282683|NCT00606658|Other|Oil dripping therapy|Single Arm
3282684|NCT00606645|Experimental|1|XmAb2513
3282685|NCT00606632|Other|124-Iodine-cG250 (124I-cG250)|Single arm study, comparing 124I cG250 PET/CT and CT. Each patient underwent a PET/CT and CT scan days (+/-2days) after receipt of 124I cG250.
3282686|NCT00606619|No Intervention|1|Conventional feeding : They begin ingesting sips of water on third postoperative day and continued with a liquid diet for the next two days. Patients were given a soft diet on sixth postoperative day.
3282687|NCT00606619|Experimental|2|Early oral feeding : The patients begin ingesting sips of water on the first postoperative day. If they are tolerable, they continued with a clear liquid diet the next day and a soft diet on the third post operative day.
3282688|NCT00606606|Experimental|I - Intervention units|nursing home units, provided HIT CDS intervention
3282689|NCT00606606|No Intervention|C - control units|nursing home units, not provided the HIT CDS intervention
3282690|NCT00606593|Experimental|ABECD|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3282691|NCT00606593|Experimental|BCADE|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3282692|NCT00606593|Experimental|CDBEA|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3282693|NCT00606593|Experimental|DECAB|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3282694|NCT00606593|Experimental|EADBC|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3282695|NCT00606593|Experimental|DCEBA|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3282696|NCT00606593|Experimental|EDACB|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3282697|NCT00606593|Experimental|AEBDC|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3282698|NCT00606593|Experimental|BACED|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3282699|NCT00606593|Experimental|CBDAE|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3282700|NCT00606580|Experimental|WR 279,396 Topical Treament|WR 279,396 topical cream (15% paromomycin + 0.5% gentamicin topical cream)
3282701|NCT00606580|Experimental|Paromomycin Alone Topical treatment|Paromomycin Alone topical cream (15% paromomycin topical cream)
3282702|NCT00606580|Placebo Comparator|Vehicle Placebo Cream|The cream base without the addition of paromomycin or gentamicin
3282703|NCT00606567|Active Comparator|1-treatment|remote monitoring with carelink every 3 months
3282704|NCT00606567|No Intervention|2- control|device interrogations in clinic every 3 months
3282705|NCT00606554|Experimental|Computer-assisted weaning|Group assigned to the computer-assisted weaning program
3282706|NCT00606554|Active Comparator|Standard of care weaning|Group assigned to receive current, evidence-based, standard of care for discontinuation of mechanical ventilation.
3282707|NCT00606541|Experimental|1|Quetiapine XR 50mg-400mg per day
3282708|NCT00606541|Placebo Comparator|2|Placebo
3282709|NCT00606528||Group A|patients with chronic Hepatitis C Virus infection who have not previously received antiviral therapy
3282713|NCT00606502|Experimental|Pralatrexate|Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
3282714|NCT00606502|Active Comparator|Erlotinib|"150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
3282715|NCT00606489|Placebo Comparator|1|
3282716|NCT00606489|Experimental|2|
3282717|NCT00606476|Active Comparator|1|0.15 mg/kg active bapineuzumab
3282718|NCT00606476|Active Comparator|2|0.5 mg/kg active bapineuzumab
3282719|NCT00606476|Active Comparator|3|1.0 mg/kg active bapineuzmab
3282720|NCT00606463|Experimental|(Gen2 Cardiac Ablation System)|Ablation of isthmus-dependent atrial flutter
3282721|NCT00606450|Experimental|20 mg Apremilast daily|20 mg of CC-10004 daily
3282722|NCT00606450|Experimental|20mg Apremilast twice daily|CC-10004 twice daily
3282723|NCT00606450|Placebo Comparator|Placebo|Placebo arm
3282724|NCT00606437|Experimental|I|Total Body Irradiation (TBI)/Flu Conditioning followed by combined UCB
3282725|NCT00606411|Active Comparator|Topiramate|Study medication arm, 25-300mg of Topiramate
3282726|NCT00606411|Placebo Comparator|Placebo|Placebo arm of study, 25-300mg of sugar pill
3282727|NCT00606385|Experimental|laparoscopic liver resection|Patients who underwent laparoscopic liver resection for HCC
3282728|NCT00606385|Active Comparator|open liver resection|Patients who underwent open liver resection for HCC
3282729|NCT00606372||1|Patients with ischemic heart disease, with EuroSCORE 6 additive points and more, operated with use of the cardio-pulmonary bypass
3282730|NCT00606372||2|Patients with ischemic heart disease, with EuroSCORE 6 additive points and more, operated without use of the cardio-pulmonary bypass
3282731|NCT00606359|Experimental|Study Group 1|
3282732|NCT00606359|Active Comparator|Study Group 2|
3282733|NCT00606346||Anti TNF therapy including infliximab|Treatments will be prescribed according to investigator judgement.
3282734|NCT00606346||No Biologics|Treatments will be prescribed according to investigator judgement.
3282735|NCT00606333|Experimental|Investigational arm|Subjects randomized to treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
3282736|NCT00606333|Active Comparator|Control Arm|Subjects randomized to treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System.
3282737|NCT00606320|Experimental|Aripiprazole|
3282738|NCT00606307|Experimental|ITF2357|
3282739|NCT00606294|Experimental|Cohort 1 (closed to accrual)|There will be no change or intervention in a patient's treatment regime using chemoradiation where both the primary and the neck nodes receive 70Gy if the tumors are not associated with HPV or if there is no resolution of hypoxia on their repeat 18F-FMISO PET/CT scan. This is currently one accepted standard of care. Patients in Cohort 1 with tumors that are positive for HPV who exhibited no evidence of hypoxia on their baseline 18F-FMISO PET/CT scan or whose tumors have early resolution of hypoxia on their repeat early response 18F-FMISO PET/CT scan will undergo an alternative treatment where the primary tumor site receives 70Gy while the neck nodes receive 60Gy followed by a planned FDG PET/CT scan and observation.
3282740|NCT00606294|Experimental|Cohort 2|Cohort 2 HPV+ tumors that demonstrate no evidence of hypoxia on an 18F-FMISO PET scan will receive 30Gy to the surgical bed and neck lymph nodes concurrent with standard chemotherapy followed by a 3-month post-treatment neck dissection. In patients who exhibit a complete response with this method of treatment, no further treatment is necessary. For patients within this select group who still have pathologic nodal disease, further standard chemoradiation will be given. All other patients in this cohort (i.e. those who are not in the select HPV+ tumor group outlined above) will receive standard of care treatment following their surgery.
3282741|NCT00606281|Experimental|1|
3282742|NCT00606281|Placebo Comparator|2|
3282743|NCT00606268|Experimental|1|1.0 mg/kg
3282744|NCT00606268|Experimental|2|1.5 mg/kg
3282745|NCT00606255||A|Active training group: Electronic Pill-Boxes with SMS service 1/week, training material provided
3282746|NCT00606255||B|Passive training group: Electronic Pill-Boxes ,Training material provided
3282747|NCT00606255||C|Usual treatment group: Electronic Pill-Boxes, maintain current treatment method
3282748|NCT00606242|Active Comparator|Low dose steroid|Fluticasone, 100 mcg per day
3282749|NCT00606242|Active Comparator|High dose steroid|Fluticasone, 1000 mcg per day
3282750|NCT00606229|Experimental|1|
3282751|NCT00606216||A|TBI and Chemotherapy Conditioning Regimen. Twenty (20) patients will undergo conditioning treatment with TBI and chemotherapy prior to receiving a myeloablative allogeneic or an autologous HSCT.
3282752|NCT00606216||B|Chemotherapy Alone Conditioning Regimen Twenty (20) patients will undergo conditioning treatment with an all chemotherapy regimen prior to receiving an allogeneic or an autologous HSCT.
3282753|NCT00606216||C|A cohort of twenty (20) healthy controls, frequency matched on age, gender, and education, will be recruited at WCMC to participate in the study.
3282754|NCT00606203|Experimental|A|The aims of this study are to investigate the prophylactic effect of milnacipran in post stroke depression.
3282755|NCT00606203|Placebo Comparator|B|Placebo
3282756|NCT00606190|Active Comparator|Retrograde brain perfusion|Pt may be randomized to retrograde brain perfusion when having a repair of the ascending aortic artery (aorta) including the aortic arch. This is one of the standard methods used while the body and the brain are cooled down to sub-normal levels (hypothermia). This will take place while on the heart-lung machine.
3282757|NCT00606190|Active Comparator|Antegrade brain perfusion|Pt may be randomized to antegrade brain perfusion when having a repair of the ascending aortic artery (aorta) including the aortic arch. This is one of the standard methods used while the body and the brain are cooled down to sub-normal levels (hypothermia). This will take place while on the heart-lung machine.
3282758|NCT00606177|Experimental|1|
3282759|NCT00606177|Placebo Comparator|2|
3282760|NCT00606164|Placebo Comparator|Placebo|
3282761|NCT00606164|Experimental|10 ug/m2 Bryostatin|
3282762|NCT00606164|Experimental|15 ug/m2 Bryostatin|
3282763|NCT00606138|Experimental|Anti-VEGF injection|Intravitreal injection of 0.5-mg dose of ranibizumab
3282824|NCT00605761|Experimental|Cohort 1|50 mg treatment
3282764|NCT00606138|Active Comparator|PRP Laser|Additional panretinal photocoagulation (up to 500 300-500 um laser spots)
3282765|NCT00606125|Experimental|Arm 1|
3282766|NCT00606112|Placebo Comparator|1|
3282767|NCT00606112|Placebo Comparator|2|
3282768|NCT00606112|Placebo Comparator|3|
3282769|NCT00606112|Placebo Comparator|4|
3282770|NCT00606099|Experimental|1|telbivudine
3282771|NCT00606099|Active Comparator|2|adefovir dipivoxil
3282772|NCT00606086|Experimental|1|GI-5005 monotherapy continuing on to triple therapy
3282773|NCT00606086|Active Comparator|2|Standard of care alone
3282774|NCT00606073|Active Comparator|I|IVF Procedure-IVF Medium
3282775|NCT00606073|Active Comparator|II|IVF Procedure - ISM1 Medium
3282776|NCT00606073|Active Comparator|III|ICSI Procedure - IVF Medium
3282777|NCT00606073|Active Comparator|IV|ICSI Procedure - ISM1 Medium
3282778|NCT00606060|Experimental|Arm 1|
3282779|NCT00606047||Asymptomatic patients|Asymptomatic, healthy patients (without hip pain or prior hip disease) will be recruited. Patients will undergo a magnetic resonance imaging (MRI) of the hip joints to evaluate for the prevalence of femoroacetabular impingement (FAI).
3282780|NCT00606034|Experimental|All subjects active|All subjects will receive the experimental treatment (U-500 insulin via Omnipod) since they have already failed all other previous insulin treatment regimens.
3282781|NCT00606021|Experimental|A: Pemetrexed + Best Supportive Care|"Pemetrexed: 500 milligrams per square meter (mg/m²) , intravenous (IV), Day 1 of each 21-day cycle for 6 cycles~Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."
3282782|NCT00606021|Active Comparator|B: Best Supportive Care|Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
3282783|NCT00606008|Experimental|Sutent Treatment|Sutent was administered daily for 4 weeks at a dose of 50 mg followed by a 2 week study drug free break.
3282784|NCT00605995|Experimental|Simvastatin|Simvastatin, 20 mg Tablet, given once daily. Dosage increased to 40 mg/day at the end of week 4 until endpoint.
3282785|NCT00605995|Placebo Comparator|Placebo|Placebo pill, similar in its appearance to Simvastatin, taken once daily for the duration of the trial.
3282786|NCT00605982|Experimental|1|Women with core biopsy proven DCIS with or without microinvasion seen for surgical consultation at Memorial Sloan-Kettering Cancer Center and for whom operative intervention is planned.
3282787|NCT00605969|Active Comparator|FAI patients|
3282788|NCT00605969|Placebo Comparator|Control|
3282789|NCT00605956|Experimental|1|NatrOVA Creme Rinse - 1% Spinosad
3282790|NCT00605956|Experimental|2|NatrOVA Vehicle - no Spinosad
3282791|NCT00605956|Placebo Comparator|3|Blank Patch
3282792|NCT00605930|Active Comparator|Pyruvate, creatine, niacinamide|Pyruvate, creatine, niacinamide administered
3282793|NCT00605930|Placebo Comparator|Placebo|placebo
3282794|NCT00605917||Sertraline hydrochloride.|The patients of Panic disorder taking Sertraline hydrochloride.
3282795|NCT00605904|Experimental|Acamprosate|Subjects received 3 tablets of 333mg acamprosate orally, three times daily (total dose of 999 mg) for a minimum of 2 weeks.
3282796|NCT00605904|Placebo Comparator|Placebo|Subjects received 3 tablets of placebo orally, three times daily, for a minimum of 2 weeks.
3282797|NCT00605891|Experimental|A|carmoterol (CHF 4226) 1.0 μg once a day, in the morning
3282798|NCT00605891|Experimental|B|carmoterol (CHF 4226) 2.0 μg once a day, in the morning
3282799|NCT00605891|Experimental|C|carmoterol (CHF 4226) 4.0 μg once a day, in the morning
3282800|NCT00605891|Placebo Comparator|D|Placebo once a day, in the morning
3282801|NCT00605891|Active Comparator|E|Salmeterol 50 μg BID, in the morning and in the evening
3282802|NCT00605878||Group 1|Healthy (adult) volunteers
3282803|NCT00605878||Group 2|AD patients
3282804|NCT00605878||Grouo 3|Healthy (pediatric) controls
3282805|NCT00605878||Group 4|Patients diagnosed with the primary immunodeficiency hyperIgE syndrome (HIES)
3282806|NCT00605878||Group 5|Patients diagnosed with the primary immunodeficiency Wiskott-Aldrich Syndrome (WAS)
3282807|NCT00605878||Group 6|Patients diagnosed with the combined immunodeficiency associated with DOCK8 mutation (DOCK8)
3282808|NCT00605865||Sertraline hydrochloride.|Patients taking Sertraline hydrochloride.
3282809|NCT00605852|Experimental|Subjects receiving treatment in cohort I|Eligible subjects will receive three single doses of GSK835726 and one single dose of placebo in cohort I.
3282810|NCT00605852|Experimental|Subjects receiving GSK835726 in cohort II|Eligible subjects will receive repeat doses of GSK835726 once daily for 7 days.
3282811|NCT00605852|Placebo Comparator|Subjects receiving placebo in cohort II|Eligible subjects will receive repeat doses of placebo once daily for 7 days.
3282812|NCT00605852|Experimental|Subjects receiving treatment in cohort III|Eligible subjects will receive two single doses of GSK835726 and one single dose of placebo in cohort III.
3282813|NCT00605839|Experimental|Glucopak Care|Glucopak cell phone and intensive monitoring. This group will be given the experimental device, and placed in close communication with the clinic.
3282814|NCT00605839|Active Comparator|Cell Phone Care|Cell phone only, without the Glucopak. Participants will be given cell phones and encouraged to communicate more closely with the clinic, but will not use the Glucopak.
3282815|NCT00605839|Placebo Comparator|Usual Care|Usual care, without cell phone or glucopak
3282816|NCT00605826|Experimental|1|Blinded injection of NASHA/Dx Gel
3282817|NCT00605826|Sham Comparator|2|Blinded sham injection
3282818|NCT00605813||Sertraline hydrochloride.|Patients taking Sertraline hydrochloride.
3282819|NCT00605800||1|normal healthy volunteers
3282820|NCT00605800||2|Patients undergoing major liver resections
3282821|NCT00605787|Active Comparator|Single group|Single group all treated similarly, outcome evaluated as changes within individuals during intervention
3282822|NCT00605774|Experimental|1|Hyperinsulinemic euglycemic glucose clamps x 2 on Day 1 Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion on Day 2
3282823|NCT00605774|Experimental|2|Day 1 euglycemic exercise period x 2 Day 2 hyperinsulinemic euglycemic glucose clamp with epinephrine infusion
3282825|NCT00605761|Experimental|Cohort 2|150 mg treatment
3282826|NCT00605748|Active Comparator|1|Segmental PV-Isolation of the arrhythmogenic vein(s)
3282827|NCT00605748|Active Comparator|2|Segmental PV-Isolation of all veins
3282828|NCT00605735|Experimental|A1|
3282829|NCT00605735|Placebo Comparator|P1|
3282830|NCT00605722|Experimental|bevacizumab + erlotinib|Participants received bevacizumab (Avastin) 5 mg/kg intravenous (iv) on day 1 of each 2 week cycle plus erlotinib (Tarceva) 150 mg orally once a day until disease progression or unmanageable toxicity.
3282831|NCT00605709|Experimental|1|Active Cream 3% ; AM & PM
3282832|NCT00605709|Active Comparator|2|Placebo Cream AM; 3% Active Cream PM
3282833|NCT00605709|Active Comparator|3|Placebo Cream AM; 1.5% Active Cream PM
3282834|NCT00605709|Placebo Comparator|4|Placebo Cream AM & PM
3282835|NCT00605696|Experimental|1|Participants will receive insulin to target glucose 80-110 mg/dl within 6-12 hours after presenting to ED.
3282836|NCT00605696|Active Comparator|2|Participants will receive insulin to target 150-180 mg/dl for 48 hours after ICU admission followed by usual clinical care.
3282837|NCT00605683|Active Comparator|1|50 mg/day Safinamide
3282838|NCT00605683|Active Comparator|2|Safinamide 100mg/day
3282839|NCT00605683|Placebo Comparator|3|Placebo 0mg/Safinamide
3282840|NCT00605670||1|Postoperative Breast Surgery Patients
3282841|NCT00605670||2|Preoperative Breast Surgery Patients
3282842|NCT00605657|Experimental|Valproic acid|Single arm study involving oral administration of valproic acid and monitoring of its efficacy by CT scans done before and after the intervention. Blood samples were also obtained to monitor safety labs and biomarkers.
3282843|NCT00605644|Placebo Comparator|1|Placebo
3282844|NCT00605644|Experimental|2|MOA-728
3282845|NCT00605644|Experimental|3|MOA-728
3282846|NCT00605644|Experimental|4|MOA-728
3282847|NCT00605644|Experimental|5|MOA-728
3282848|NCT00605631|Experimental|1|
3282849|NCT00605631|Active Comparator|2|
3282850|NCT00605631|Other|3|
3282851|NCT00605618|Experimental|Single Arm|
3282852|NCT00605605|Experimental|1|
3282853|NCT00605592|Experimental|1|Islet cell transplant
3282854|NCT00605566|Experimental|I|Patients will receive sorafenib and cyclophosphamide.
3282855|NCT00605553|Experimental|1|Active medication Tozadenant 20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
3282856|NCT00605553|Placebo Comparator|2|Crossover from arm 1 to arm 2 with one week washout. One of the arms is placebo control
3282857|NCT00605540||Study COPD population|Patients with diagnosis of mild to very severe chronic obstructive pulmonary disease
3282858|NCT00605488|Experimental|1|Pet Scan
3282859|NCT00605475|Experimental|Canakinumab|"Eligible participants were assigned to receive canakinumab in one of four cohorts; 1) Single IV infusion of canakinumab 0.3 mg/kg; 2) Singe IV infusion of canakinumab 10 mg/kg; 3) single IV infusion of canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of canakinumab 0.03 mg/kg.~All participants were required to take a concomitant stable daily dose of metformin during the study."
3282860|NCT00605475|Placebo Comparator|Placebo|"Eligible participants were assigned to receive placebo to canakinumab in one of four cohorts; 1) Single IV infusion of placebo to canakinumab 0.3 mg/kg; 2) Singe IV infusion of placebo to canakinumab 10 mg/kg; 3) single IV infusion of placebo to canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of placebo to canakinumab 0.03 mg/kg.~All participants were required to take a concomitant stable daily dose of metformin during the study."
3282861|NCT00605436|Experimental|A|Restorative yoga therapy group: one orientation workshop for 3 hours, then twice-weekly group yoga therapy classes for first 5 weeks followed by once-weekly group yoga classes for another 5 weeks. The group will also be asked to practice their yoga postures at home for 30 minutes three times per week.
3282862|NCT00605436|No Intervention|B|The control group is a wait-list control group with no active intervention.
3282863|NCT00605423|Active Comparator|1|Dose 0.2 ug/day Medidur implant
3282864|NCT00605423|Active Comparator|2|Dose 0.5 ug/day Medidur implant
3282865|NCT00605410|Active Comparator|1|
3282866|NCT00605410|Placebo Comparator|2|
3282867|NCT00605397|Experimental|1|breast cancer pt receiving trastuzumab therapy will undergo two complete PET studies.
3282868|NCT00605397|Experimental|2|breast cancer pt receiving trastuzumab therapy will undergo one complete PET studies
3282869|NCT00605384|Experimental|1|
3282870|NCT00605384|Experimental|2|
3282871|NCT00605371|Experimental|Subjects receiving regimen A|Eligible subjects will receive regimen A containing lamotrigine extended release tablet of 200 milligrams plus 50 milligrams in fasted state
3282872|NCT00605371|Experimental|Subjects receiving regimen B|Eligible subjects will receive regimen B containing lamotrigine extended release caplet of 250 milligrams in fasted state.
3282873|NCT00605371|Experimental|Subjects receiving regimen C|Eligible subjects will receive regimen C containing lamotrigine extended release caplet of 250 milligrams in fed state.
3282874|NCT00605358|Active Comparator|Open Door Intervention|Subjects who receive the Open Door Intervention will work with the study counselor to identify barriers to participation in mental health treatment, set goals, and problem-solve, in addition to receiving a referral.
3282875|NCT00605358|No Intervention|Services Referral|"Subjects who do not receive the Open Door intervention will receive:~an evaluation~referral to a local mental health provider~booklet information on depression and mental health care, and will complete an application for HEAP, a Westchester County service that provides reduced rates from oil companies on heating to seniors."
3282876|NCT00605345|Experimental|CERA Treatment Once Monthly|
3282877|NCT00605345|Active Comparator|Darbepoetin Alfa Once Biweekly|
3282878|NCT00605332|Experimental|1|Investigative Device (Crux Biomedical IVC Filter) will be evaluated for its ability to capture thrombus for the prevention of pulmonary embolism.
3282879|NCT00605319|Other|Toviaz (Fesoterodine)|Toviaz 4mg to 8mg
3282880|NCT00605306|Experimental|indacaterol maleate/mometasone furoate|Participants received 2 inhalations of indacaterol maleate / mometasone furoate 250/400 μg once daily in the evening (full dose 500/800 μg) delivered via the Twisthaler device for 14 days.
3282980|NCT00604513|Experimental|1|
3282881|NCT00605306|Placebo Comparator|Placebo|Participants received 2 inhalations of placebo to indacaterol maleate / mometasone furoate once daily in the evening delivered via the Twisthaler device for 14 days.
3282882|NCT00605293|Experimental|C.E.R.A|Participants received starting dose of 120, 200 or 360 mcg of C.E.R.A IV once monthly for 6 months. The starting dose was based on the dose of epoetin alfa administered in Week -1.
3282883|NCT00605293|Active Comparator|Epoetin Alfa|Participants received IV injection of 6000 International Units (IU) of epoetin alfa every 3 weeks (q3wk) during the Stability Verification Period (SVP; Week -4 to -1), and 7443 IU of epoetin alfa q3wk during Dose Titration Period (DTP; Week 0 to 15), 7363 IU of epoetin alfa q3wk during Efficacy Evaluation Period (EEP; Week 16 to 23) up to 23 weeks.
3282884|NCT00605280|Sham Comparator|Sham Control|
3282885|NCT00605280|Experimental|Macugen|
3282886|NCT00605267|Active Comparator|1|Tamoxifen
3282887|NCT00605267|Experimental|2|Anastrazole (Arimidex)
3282888|NCT00605241|Other|GSK598809|Drug
3282889|NCT00605228|Experimental|1|
3282890|NCT00605228|Active Comparator|2|
3282891|NCT00605215|Experimental|Laquinimod|0.6 mg Laquinimod oral once daily
3282892|NCT00605215|Placebo Comparator|Placebo|oral placebo once daily
3282893|NCT00605215|Active Comparator|Interferon|Interferon β-1a (Avonex®) 30 mcg IM once weekly
3282894|NCT00605202|Active Comparator|Licorice|
3282895|NCT00605202|Active Comparator|Licorice and HCTZ|
3282896|NCT00605189|Active Comparator|I|
3282897|NCT00605189|Active Comparator|II|
3282898|NCT00605176|Active Comparator|3.75% imiquimod cream|
3282899|NCT00605176|Active Comparator|2.5% imiquimod cream|
3282900|NCT00605176|Placebo Comparator|Placebo cream|
3282901|NCT00605150||Patients enrolled|Total number of patients enrolled
3282902|NCT00605124|Experimental|exercise|progressive exercise, home-based exercise program, tree exercise sessions weekly, chec-up visits every third month
3282903|NCT00605124|Active Comparator|Conventional treatment|Normal treatment, single guidance to home exercise
3282904|NCT00605098|Active Comparator|1|
3282905|NCT00605098|Experimental|2|
3282906|NCT00605085|Experimental|1|IC51
3282907|NCT00605085|Placebo Comparator|2|Placebo
3282908|NCT00605072|Experimental|Candesartan|Angiotensin Receptor Blocker
3282909|NCT00605072|Experimental|Lisinopril|Angiotensin-Converting Enzyme (ACE) Inhibitor
3282910|NCT00605072|Active Comparator|HCTZ|Hydrochlorothiazide (diuretic)
3282911|NCT00605059|Experimental|Assess [123I] AV94 and SPECT imaging|
3282912|NCT00605046|Experimental|Asses [123I] AV151 and SPECT imaging|
3282913|NCT00605033|Active Comparator|Suboxone|Double-blind, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) plus matching Subutex placebo during Week 1 followed by open-label, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.
3282914|NCT00605033|Active Comparator|Subutex|Double-blind, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) plus matching Suboxone placebo during Week 1 followed by open-label, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.
3282915|NCT00604994||Malignant|Patients with malignant gynaecological conditions including cancers of the cervix, uterus, ovary, vulva and vagina
3282916|NCT00604994||Benign|Patients without malignant gynaecological cancers
3282917|NCT00604981|Experimental|1|Multisystemic Therapy (MST)
3282918|NCT00604981|Active Comparator|2|Shapedown
3282919|NCT00604968|Experimental|Caelyx|
3282920|NCT00604955|Experimental|A|Paromomycin IM Injection (approved product in India)
3282921|NCT00604942|Experimental|Achalasia|Long vs Short Myotomy repair of Achalasia
3282922|NCT00604942|Experimental|Dysphagia control|Conservative Management
3282923|NCT00604942|Experimental|GORD for surgery|Partial vs Full Fundoplication repair
3282924|NCT00604942|Experimental|GORD not for surgery|esomeprazole 40 mg vs no esomeprazole
3282925|NCT00604929|Experimental|1|
3282926|NCT00604916|Experimental|E|received a 7 day standardized oral care protocol
3282927|NCT00604916|Placebo Comparator|C|received a 7 day mimic protocol
3282928|NCT00604903|Experimental|Patients implanted with Pressure Sensor|Implant of Pressure sensor. These are patients, who were implanted with the Remon CHF Implantable Pressure Sensor utilizing the corresponding delivering system.
3282929|NCT00604890|Experimental|1|Active cream, 3% AM & PM
3282930|NCT00604890|Placebo Comparator|2|Placebo cream AM ; 3% active cream PM
3282931|NCT00604890|Placebo Comparator|3|Placebo cream AM; 1.5% active cream PM
3282932|NCT00604890|Placebo Comparator|4|Placebo AM and PM
3282933|NCT00604877|Experimental|1|
3282934|NCT00604877|Active Comparator|2|
3282935|NCT00604864|Experimental|1|women with a deep endometriosis nodule of at least 1 cm in diameter; and severe pain (at least one severe pain score on Biberoglu Behrman scale)
3282936|NCT00604864|Placebo Comparator|2|women with a deep endometriosis nodule of at least 1 cm in diameter; and severe pain (at least one severe pain score on Biberoglu Behrman scale)
3282937|NCT00604838|Experimental|I|
3282938|NCT00604825|Placebo Comparator|Placebo|Placebo
3282939|NCT00604825|Active Comparator|GSK232802|GSK232802
3282940|NCT00604825|Experimental|PREMARIN|PREMARIN
3282941|NCT00604812|Experimental|Panel A Rizatriptan|"Subjects allocated to Panel A and randomized to receive a single dose of rizatriptan 5 mg orally disintegrating tablet (ODT) on Day 1.~Subjects weighing 20-39 kg were allocated to Panel A."
3282942|NCT00604812|Placebo Comparator|Panel A Placebo|"Subjects allocated to Panel A and randomized to receive a single dose of rizatriptan 5 mg orally disintegrating tablet (ODT) placebo on Day 1.~Subjects weighing 20-39 kg were allocated to Panel A."
3282943|NCT00604812|Experimental|Panel B Rizatriptan|"Subjects allocated to Panel B and randomized to receive a single dose of rizatriptan 10 mg orally disintegrating tablet (ODT) on Day 1.~Subjects weighing 40 kg and above were allocated to Panel B."
3282981|NCT00604513|Sham Comparator|2|
3283018|NCT00604149||1|case of out-of-hospital cardiac arrest
3282944|NCT00604812|Placebo Comparator|Panel B Placebo|"Subjects allocated to Panel B and randomized to receive a single dose of rizatriptan 10 mg orally disintegrating tablet (ODT) placebo on Day 1.~Subjects weighing 40 kg and above were allocated to Panel B."
3282945|NCT00604812|Experimental|Panel C Rizatriptan|"Subjects allocated to Panel C and randomized to receive a single dose of rizatriptan ODT on Day 1. Subjects in Panel C weighing 20-39 kg received a 5 mg dose and subjects weighing 40 kg and above received a 10 mg dose.~Panel C was added to the study by amendment to increase the number of male subjects in the 12-17 year old age group."
3282946|NCT00604812|Placebo Comparator|Panel C Placebo|"Subjects allocated to Panel C and randomized to receive a single dose of rizatriptan ODT placebo on Day 1. Subjects in Panel C weighing 20-39 kg received a 5 mg placebo dose and subjects weighing 40 kg and above received a 10 mg placebo dose.~Panel C was added to the study by amendment to increase the number of male subjects in the 12-17 year old age group."
3282947|NCT00604799|Active Comparator|Test (Enrollment Completed)|Patients diagnosed with a TAA of degenerative etiology that are considered candidates for open surgical repair whom are low to moderate risk (0, 1, & 2) per the modified SVS/AAVS criteria who meet inclusion/exclusion criteria. The aneurysm must be at least 20 mm distal to the left common carotid artery & 20 mm proximal to the origin of the celiac artery.
3282948|NCT00604799|Other|Registry (Enrollment Completed)|Surgical candidates of low to moderate risk (SVS 0, 1, 2) that meet the Registry Inclusion/Exclusion criteria.
3282949|NCT00604799|Other|High Risk (Enrollment Completed)|"Patients that meet one or more of the following:~High Risk (SVS 3)~Non-surgical candidates not associated with SVS scoring~Traumatic thoracic injuries"
3282950|NCT00604799|Other|Talent Captivia (Recruiting)|Patients diagnosed with a TAA of degenerative etiology that are considered candidates for open surgical repair who meet inclusion/exclusion criteria.
3282951|NCT00604786|Experimental|Omalizumab subcutaneous|"This active are will receive treatment with omalizumab subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).~The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks"
3282952|NCT00604786|Placebo Comparator|Placebo Subcutaneous|"This placebo arm will receive identical treatment with placebo injections subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).~The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks."
3282953|NCT00604773||delirious patients|minimal one positive CAM-ICU score during ICU admission
3282954|NCT00604773||non-delirious patients|without any positive CAM-ICU scores during ICU admission
3282955|NCT00604760|Experimental|A|
3282956|NCT00604760|Experimental|B|
3282957|NCT00604760|Experimental|C|
3282958|NCT00604760|Placebo Comparator|D|
3282959|NCT00604747|Other|1, 2|
3282960|NCT00604734|Other|ReCap|ReCap Total Hip Resurfacing System
3282961|NCT00604721|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive a single dose of selumetinib on day 1 and undergo blood collection for PK sampling pre-dose (within 30 min of dosing), 15 and 30 minutes and 1, 2, 4, 8, 12, 24 and 48 hours post-dose. Beginning 48 hours after the initial dose and continuing until day 21, patients receive oral selumetinib twice daily. Patients also undergo blood collection for PK sampling on day 15 of course 1. In all subsequent courses, patients receive selumetinib on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3282962|NCT00604708|Experimental|IC51|6 mcg (microgram) i.m. (intramuscular) on Day0, 14 and 28
3282963|NCT00604708|Active Comparator|JE-VAX|given s.c. on Day 0, 7 and 28
3282964|NCT00604695|Active Comparator|1|Two (4mg) doses of tenecteplase
3282965|NCT00604695|Placebo Comparator|2|Two (4mL) doses of sterile saline
3282966|NCT00604682|Experimental|Administration of CC10004|
3282967|NCT00604630|Placebo Comparator|placebo|50ml 0.9% NaCL
3282968|NCT00604630|Active Comparator|verum|erythropoietin alfa 40,000 IU iv in 50ml 0.9% NaCl
3282969|NCT00604604|No Intervention|1|Control group (usual postpartum care)
3282970|NCT00604604|Experimental|2|Experimental group (usual postpartum care plus telephone-based support from an experienced mother who has participated in a 4-hour training session)
3282971|NCT00604591|Placebo Comparator|Placebo then Tolcapone|"Participants take placebo during study week 1 and then tolcapone during week 3.~On Day 1, 100 mg of tolcapone/placebo will be taken at three specific times: once in the morning, once in the afternoon, once at night. Then, from Days 2-6, 200 mg of tolcapone/placebo will be taken three times a day: once in the morning, once in the afternoon, once at night. On Day 7, 200 mg of tolcapone/placebo will be taken only in the morning and afternoon. On Day 8, 200 mg of tolcapone/placebo will be taken only in the morning. After the last dose on Day 8 is taken, the wash-out period begins and lasts through Day 14."
3282972|NCT00604591|Experimental|Tolcapone then Placebo|"Participants take tolcapone during study week 1 and then placebo during week 3.~On Day 1, 100 mg of tolcapone/placebo will be taken at three specific times: once in the morning, once in the afternoon, once at night. Then, from Days 2-6, 200 mg of tolcapone/placebo will be taken three times a day: once in the morning, once in the afternoon, once at night. On Day 7, 200 mg of tolcapone/placebo will be taken only in the morning and afternoon. On Day 8, 200 mg of tolcapone/placebo will be taken only in the morning. After the last dose on Day 8 is taken, the wash-out period begins and lasts through Day 14."
3282973|NCT00604565|Experimental|SFP dialysate|dialysate with added soluble ferric pyrophosphate (SFP)
3282974|NCT00604565|Placebo Comparator|standard dialysate|standard dialysate without soluble ferric pyrophosphate (SFP)
3282975|NCT00604552|Other|Lifeline Registry|All comers registry for the on-label treatment of AAA with the AneuRx Stent Graft sponsored by the Foundation of Society for the Vascular Surgery (SVS)
3282976|NCT00604552|Other|PS Registry|All comers registry for the on-label treatment of AAA with the AneuRx Stent Graft sponsored by Medtronic
3282977|NCT00604539|Experimental|1|Chondroitin sulphate
3282978|NCT00604539|Placebo Comparator|2|
3282979|NCT00604526|Experimental|1|Questionnaires, Iridium 192 radioactive seeds
3282982|NCT00604500|Experimental|MF/F MDI 100/10 mcg BID with dose counter|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MFF MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
3282983|NCT00604487|Active Comparator|1|Insertion of the Atad double balloon ripener device (100 ml NS in each balloon).
3282984|NCT00604487|Active Comparator|2|Insertion of the double balloon instillation device (100 ml NS in each balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
3282985|NCT00604487|Active Comparator|3|Insertion of the folly catheter (40 ml NS in the balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
3282986|NCT00604474|Active Comparator|1|
3282987|NCT00604461|Experimental|Dose Escalation Followed by Maintenance Therapy|"A: Tiered Dose Escalation/Phase II Dose -~Tier -1: Carboplatin AUC 4 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.~Tier 1: Carboplatin AUC 5 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.~Tier 2: Carboplatin AUC 6 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.~B: Maintenance Therapy -~Patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first."
3282988|NCT00604448|Experimental|Pulse group|a group receiving a meal with pulses (5 cups/week) for 8 weeks
3282989|NCT00604448|Experimental|Energy-restricted group|a group with a diet restriction of 500 kcal/day for 8 weeks
3282990|NCT00604435|Active Comparator|chemotherapy|neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin
3282991|NCT00604435|Experimental|chemotherapy plus endostatin|neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin plus endostatin
3282992|NCT00604422||A|Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease
3282993|NCT00604409|Experimental|Treatment (SIRT and capecitabine)|Patients receive capecitabine PO twice daily on days 1-14. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients undergo SIRT on day 2 and may undergo a second course of SIRT on day 58.
3282994|NCT00604383|Experimental|Ruboxistaurin|
3282995|NCT00604383|Placebo Comparator|Placebo|
3282996|NCT00604370||1|Acutely ill medical and surgical patients who were hospitalized at BWH, and at-risk for VTE, but were not treated with prophylaxis at hospital discharge.
3282997|NCT00604370||2|Acutely ill medical and surgical patients who were at risk for VTE at time of hospital discharge and prescribed a prophylaxis strategy.
3282998|NCT00604357|Experimental|1|Prior to reperfusion 500 mg Prednisolone will be administered i.v.. After the transplantation, a combination of anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure), and MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake) will be applied. Earliest, on day 10 after LT Sirolimus will be introduced aiming at 24 hours trough-levels for Sirolimus between 4 and 8 ng/mL. Steroids will be started on day 1 after transplantation with 1mg/kg BW and will be tapered every 2 days for 5 mg to a dosage of 20 mg and for 2.5 mg every two days to 7.5 mg. Thereafter the dosage will be reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter. Additionally, every patient with risk constellation will receive cytomegalovirus (CMV) prophylaxis and prophylaxis against Pneumocystis carinii infection during the first 3 months after liver transplantation.
3282999|NCT00604331|Active Comparator|A|Pyruvate
3283000|NCT00604318|Placebo Comparator|placebo|To receive the placebo treatment in connection with the primary RI therapy and the T3 tablets and rh-TSH injections prior to second RI uptake measurement
3283001|NCT00604318|Active Comparator|rh-TSH|To continue with L-T3 and to receive rh-TSH stimulation with 0,9 mg Thyrogen® (Genzyme) x 2 days minus 1 and 2 prior to RI therapy, and following this to have placebo tablets and placebo injections with isotone NaCl prior to the RI uptake measurement 4-6 months later
3283002|NCT00604305|Active Comparator|Acrysof|Routine monofocal IOL
3283003|NCT00604305|Active Comparator|Acuity's AIOL|Accomodaing IOL
3283004|NCT00604292||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases
3283005|NCT00604279|Experimental|Paliperidone palmitate|Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion.
3283006|NCT00604279|Active Comparator|Risperidone long acting injection (LAI)|Risperidone LAI intramuscular at a dose of 25 milligram (mg) on Day 8 and Day 22; flexible dose of either 25 or 37.5 mg on Day 36 with same dose on Day 50; and either 25, 37.5, or 50 mg on Day 64 with same dose on Day 78; along with oral risperidone 2 mg tablet on Day 1, flexible doses (1-6 mg/day) for first 28 days; and 1-2 mg/day during Day 36-57 and Day 64-85 if the dose of risperidone LAI was increased on Day 36 and Day 64.
3283007|NCT00604266||1|10-15 patients with potentially resectable hiilar cholangiocarcinoma
3283008|NCT00604240||1|Parents / caregivers of any infant who has a length of stay of at least 1 week in the NICU at Christiana Hospital or Thomas Jefferson University Hospital.
3283009|NCT00604227|Experimental|1|high altitude exposure
3283010|NCT00604214|Experimental|Drotrecogin alfa (activated)|
3283011|NCT00604214|Placebo Comparator|Placebo|
3283012|NCT00604188|Experimental|Direct Suboxone Induction|Participants received 8 mg of Suboxone and placebo Subutex on Day 1, 16 mg of Suboxone and placebo Subutex on Day 2, and all participants received open label Suboxone from Day 3 to Day 28. Suboxone dosage may be titrated from Day 4 to Day 28 up to 24 mg per day.
3283013|NCT00604188|Active Comparator|Subutex-to-Suboxone Induction|Participants received 8 mg Subutex and placebo Suboxone on Day 1, 16 mg Subutex and placebo Suboxone on Day 2, and all participants received open label Suboxone from Day 3 to Day 28. Suboxone dosage may be titrated from Day 4 to Day 28 up to 24 mg per day.
3283014|NCT00604175|Experimental|Stratum A|Participants with screening CD4 count >350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
3283015|NCT00604175|Experimental|Stratum B|Participants with screening CD4 count >200 to <=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
3283016|NCT00604175|Experimental|Stratum C|Participants with screening CD4 count <=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
3283017|NCT00604162|Experimental|PillCam COLON and Colonoscopy|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases, had capsule endoscopy with PillCam COLON after bowel preparation and before standard colonoscopy.
3283020|NCT00604149||3|controls without coronary disease
3283021|NCT00604123|Experimental|JNJ-17166864|
3283022|NCT00604123|Placebo Comparator|Placebo|
3283023|NCT00604097|Experimental|1|Attachment-Based Family Therapy
3283024|NCT00604097|Active Comparator|2|Enhanced Usual Care
3283025|NCT00604084|Experimental|Ivermectin|Non-pregnant, non-breastfeeding, taller than 90cm and 5 years or older
3283026|NCT00604084|Experimental|Permethrin|Pregnant, breastfeeding, children under 90cm or under 5 years old
3283027|NCT00604071||1|subjects with AMD related lesions: New onset (up to 60 days) non-treated CNV
3283028|NCT00604058|Experimental|Group A|
3283029|NCT00604058|Active Comparator|Group B|
3283030|NCT00604045|Experimental|1 Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
3283031|NCT00604045|Placebo Comparator|2 Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
3283032|NCT00604032|Placebo Comparator|1|
3283033|NCT00604019|Active Comparator|Dopamine|Patients that get Dopamine as an infusion for hypotension
3283034|NCT00604019|Active Comparator|Norepinephrine|Patients that get norepinephrine as an infusion for hypotension
3283035|NCT00604006|Experimental|Group A|
3283036|NCT00604006|Placebo Comparator|Group B|
3283037|NCT00603993|Experimental|Adalimumab|Adalimumab 40 mg or 80 mg (same dose subject was receiving in preceding Study M03-651 [NCT 00235872]) subcutaneously (sc) administered every other week (eow) until approval of adalimumab in Japan
3283038|NCT00603980|Experimental|1|Low dose
3283039|NCT00603980|Experimental|2|Middle dose
3283040|NCT00603980|Experimental|3|High dose
3283041|NCT00603980|Active Comparator|4|Low dose
3283042|NCT00603980|Active Comparator|5|Middle dose
3283043|NCT00603980|Active Comparator|6|High dose
3283044|NCT00603980|Placebo Comparator|7|Double placebo
3283045|NCT00603967|Other|Aromatase inhibitor|
3283046|NCT00603954|Active Comparator|1|Conditioning regimen consisting of fludarabine 30 mg/m2 on days -4, -3 and -2 (total dose 90 mg/m2), followed by a singe dose of 2 Gy TBI administered on day 0, at a low dose-rate (≈ 7 cGy/min), before infusion of cells.
3283047|NCT00603954|Active Comparator|2|Conditioning consisting of 8 Gy TLI and ATG. TLI will be administered by linear accelerator at a dose of 80 cGy daily, starting 11 days before transplantation, until a total of 10 doses (800 cGy) has been delivered. The irradiation will consist of a supradiaphragmatic mantle field, a subdiaphragmatic field including an inverted Y and splenic ports, encompassing all major lymphoid organs, including the thymus, spleen, and lymph nodes, as used in the treatment of Hodgkin's disease (Kaplan HS, Cancer Research 26:1268-1276, 1966). The Waldeyer ring is not included. ATG (Thymoglobulin®, Genzyme), at a dose of 1.5 mg/kg/d, will be given intravenously on days -11 through -7.
3283048|NCT00603941|Experimental|1|
3283049|NCT00603902|Experimental|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening
3283050|NCT00603902|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
3283051|NCT00603902|Placebo Comparator|Matching Placebo|Matching placebo tablet each morning and evening
3283052|NCT00603889|Experimental|Na-ASP-2 Hookworm Antigen Skin Test|All participants will have the same number of concentrations of the Na-ASP-2 skin test reagent applied to their arms, using both the prick-puncture and intradermal techniques.
3283053|NCT00603876|Experimental|2|Step 1 dietary counseling plus 100-110 grams of almonds daily
3283054|NCT00603876|No Intervention|1|Step 1 dietary counseling
3283055|NCT00603863|Experimental|multiple dose levels|1 of 3 different dose levels of 90Y-hPAM4 given once weekly for 3 weeks along with 4 weekly doses of gemcitabine.
3283056|NCT00603850||1|Intermediate AMD Patients
3283057|NCT00603837|Experimental|Blanket|This arm includes those Extremely low gestational age newborns (ELGANs) who are to be placed on a sodium acetate warming blanket after delivery.
3283058|NCT00603837|Experimental|Wrap|This arm includes those ELGANs randomized to be wrapped in polyethylene after delivery.
3283059|NCT00603824|Experimental|A|Fondaparinux
3283060|NCT00603824|Active Comparator|B|Direct thrombin inhibitor
3283061|NCT00603811|Experimental|1|VAX102, a recombinant fusion protein that links the influenza A virus M2e antigen to S. typhimurium flagellin, a TLR5 ligand.
3283062|NCT00603811|Placebo Comparator|2|Vaccine buffer
3283063|NCT00603798|Active Comparator|3.75% imiquimod cream|
3283064|NCT00603798|Active Comparator|2.5% imiquimod cream|
3283065|NCT00603798|Placebo Comparator|Placebo cream|
3283066|NCT00603785|Placebo Comparator|A|Subjects to receive placebo treatment for 6 months
3283067|NCT00603785|Experimental|B|Subjects to receive Xolair treatment for 6 months
3283068|NCT00603772|Experimental|1|Safety when exposed to sunlight
3283069|NCT00603759|Active Comparator|1|
3283070|NCT00603759|Placebo Comparator|2|
3283071|NCT00603746|Experimental|GW685698X|GW685698X
3283072|NCT00603733|Experimental|Pentasa® modified extended release|5-ASA (5-Aminosalicylate)
3283073|NCT00603733|Active Comparator|Pentasa®|5-ASA (5-Aminosalicylate)
3283074|NCT00603720|Active Comparator|L-Name in Young|20 individuals age 18-35 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME.
3283075|NCT00603720|Active Comparator|Phenylephrine|25 individuals age 18-35 will be getting an infusion of phenylephrine (primarily an alpha agonist) during 3 separate PET study days
3283232|NCT00602537|Active Comparator|II|Mood stabilizer therapy
3283076|NCT00603720|Active Comparator|L-arginine in Young|20 individuals age 18-35 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
3283077|NCT00603720|Active Comparator|L-arginine in Old|20 individuals age 60-75 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
3283078|NCT00603720|Experimental|L-NAME in Old|20 individuals age 60-75 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME
3283079|NCT00603707||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
3283080|NCT00603707||Constipated|Adult subjects with functional constipation as define by Rome II criteria
3283081|NCT00603694||1|(Experimental group): Receiving > 2 Gy SRS to left hippocampus (n=10)
3283082|NCT00603694||2|(Low-dose control group): Receiving < 0.5 Gy SRS to left hippocampus (n=10)
3283083|NCT00603694||3|(High-dose control group): Receiving whole brain PCI (n=10)
3283084|NCT00603681|Experimental|T|Test product
3283085|NCT00603681|Active Comparator|C|Reference product
3283086|NCT00603668|Experimental|milatuzumab|different doses of hLL1
3283087|NCT00603655|Experimental|A|This group will receive a low glycemic load
3283088|NCT00603655|Active Comparator|B|This group will receive a high glycemic load
3283089|NCT00603642|Placebo Comparator|AMG 531|Double blinded placebo-controlled study
3283090|NCT00603642|Placebo Comparator|Placebo|
3283091|NCT00603629||I|People with acute asthma in the Emergency department or inpatient settings
3283092|NCT00603616|Placebo Comparator|1|Placebo pills
3283093|NCT00603616|Active Comparator|2|Rifaximin
3283094|NCT00603603|Experimental|80% inhaled oxygen-non-rebreather|10 liters of oxygen via non re-breather mask during cesarean section and up to two hours post-operatively
3283095|NCT00603603|Active Comparator|30% inhaled oxygen-nasal cannula|2 liters of oxygen via nasal cannula (standard of care) during cesarean section only
3283096|NCT00603590|Experimental|Polypill|Fixed dose combination therapy with Aspirin 81mg, Hydrochlorothiazide 12.5mg, Enalapril 2.5mg and Atorvastatin 20mg
3283097|NCT00603590|Placebo Comparator|Control|Identical placebo
3283098|NCT00603577|Placebo Comparator|Placebo|
3283099|NCT00603577|Experimental|Xaliproden|
3283100|NCT00603564|Active Comparator|1|CPAP delivered by a helmet
3283101|NCT00603564|No Intervention|2|O2 administration via a conventional Venturi mask
3283102|NCT00603551||Chemotherapy|Postmenopausal women who have been diagnosed with a breast or gynecological cancer and who have undergone chemotherapy as a result of that diagnosis
3283103|NCT00603538|Experimental|CP-751,871|
3283104|NCT00603525|Experimental|Ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each treatment cycle consisting of two IV infusion taken 14 days apart. A total of 8 infusion cycles given over a 144 week period
3283105|NCT00603525|Placebo Comparator|1000 ml Saline|1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
3283106|NCT00603512|Placebo Comparator|CP-690,550, 0mg|
3283107|NCT00603512|Experimental|CP-690,550, 10mg|
3283108|NCT00603512|Experimental|CP-690,550, 1mg|
3283109|NCT00603512|Experimental|CP-690,550, 3mg|
3283110|NCT00603512|Experimental|CP-690,550, 5mg|
3283111|NCT00603499|Active Comparator|1|Magnesium chloride
3283112|NCT00603499|Placebo Comparator|2|Placebo
3283113|NCT00603473|Experimental|gabapentin|
3283114|NCT00603460|Active Comparator|A|
3283115|NCT00603460|Active Comparator|B|
3283116|NCT00603447|Experimental|Carfilzomib + Lenalidomide + Dexamethasone|Treatment during Cycles 1 through 12 consisted of carfilzomib (15, 20, or 20/27 mg/m²) on Days 1, 2, 8, 9, 15, and 16; lenalidomide (10, 15, 20, or 25 mg) on Days 1 to 21; and low-dose dexamethasone (40 mg) given 30 minutes to 4 hours before the carfilzomib dose on Days 1, 8, and 15, as well as on Day 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
3283117|NCT00603434|Experimental|1|Osmotic-Release Methylphenidate
3283118|NCT00603434|Experimental|2|Osmotic-Release Methylphenidate
3283119|NCT00603434|Experimental|3|Osmotic-Release Methylphenidate
3283120|NCT00603421|Experimental|1|Patient benefits from treatment as usual plus access to a crisis 24 hour phone line.
3283121|NCT00603421|Active Comparator|2|Patient benefits from treatment as usual
3283122|NCT00603408|Experimental|Cisplatin + Radiation + Recommended Surgery|"Cisplatin 75 mg/m^2 IV Day 1 Week 1, Day 1 Week 2, Day 1 Week 7, Day 1 Week 10~Radiation = Total dose to breast or chest wall will be 50-60 Gy in 1.8-2.0 Gy daily fractions. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks.~Surgery (recommended) mastectomy with/without axillary lymph node dissection"
3283123|NCT00603395|Other|ReCap|ReCap Total Hip Resurfacing System
3283124|NCT00603382|Placebo Comparator|Placebo|
3283125|NCT00603382|Experimental|GW685698X|
3283126|NCT00603369|Experimental|1|13 session group intervention including sexual health information, affect management skills, cognitive monitoring, and communication skills training.
3283127|NCT00603369|Active Comparator|2|2 session group intervention including sexual health information training.
3283128|NCT00603356|Experimental|1|Dose Escalation
3283129|NCT00603343|Active Comparator|1|
3283130|NCT00603343|Placebo Comparator|2|
3283131|NCT00603330|Experimental|1|MSC infusion for steroid-refractory grade II-IV acute GVHD. In this arm, 4 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
3283132|NCT00603330|Experimental|2|MSC infusion for poor graft function. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
3283133|NCT00603330|Experimental|3|MSC + DLI for poor donor T-cell chimerism after allogeneic HCT. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
3283134|NCT00603317|Experimental|1|Order 1 : Firstly Amoxicillin-Acid clavulanic, and Secondly Placebo
3283135|NCT00603317|Experimental|2|Order 2 : Firstly Placebo, and Secondly Amoxicillin-Acid clavulanic
3283136|NCT00603304|Placebo Comparator|Placebo|Participants will take one 320 mg placebo gelcap daily for 24 weeks one gelcap); followed by 640 mg daily for 24 weeks (two gelcaps) followed by 960 mg daily for 24 weeks (three gelcaps).
3283137|NCT00603304|Active Comparator|Saw Palmetto|Extract of Serenoa Repens 320 mg once daily for 24 weeks (one gelcap); followed by 640 mg daily for 24 weeks (two gelcaps) followed by 960 mg daily for 24 weeks (three gelcaps).
3283138|NCT00603291|Experimental|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening
3283139|NCT00603291|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
3283140|NCT00603291|Placebo Comparator|Matching Placebo|Matching placebo tablet each morning and evening
3283141|NCT00603278|Placebo Comparator|Arm 1|
3283142|NCT00603278|Experimental|Arm 2|
3283143|NCT00603265|Experimental|ADL5859|2 x 50 milligrams (mg) ADL5859 capsules administered orally once in the morning and once in the evening for 28 days
3283144|NCT00603265|Active Comparator|Duloxetine|2 x 30 mg duloxetine capsules administered orally once in the morning and 2 placebo capsules filled with lactose administered orally once in the evening for 28 days
3283145|NCT00603265|Placebo Comparator|Placebo|2 placebo capsules filled with lactose administered orally once in the morning and once in the evening for 28 days
3283146|NCT00603239|Experimental|Exenatide twice daily (BID)|
3283147|NCT00603239|Placebo Comparator|Placebo|
3283148|NCT00603226||1|Patients diagnosed with slow coronary artery flow during coronary angiography
3283149|NCT00603226||2|Patients with normal coronary artery flow observed during coronary angiography
3283150|NCT00603200||Group 1|Patients with cirrhosis, who have refractory ascites requiring large volume paracentesis
3283151|NCT00603174|Experimental|A|Intubated and mechanically ventilated infants with respiratory failure (age < 1 year old). see inclusion-exclusion criteria.
3283152|NCT00603135|Experimental|A|
3283153|NCT00603122|Experimental|1|fast ascent
3283154|NCT00603122|Active Comparator|2|slow ascent
3283155|NCT00603109|Experimental|I|Subjects receive rimonabant 20 mg per day PO
3283156|NCT00603109|Placebo Comparator|II|Subjects take placebo capsule one a day PO
3283157|NCT00603096|Experimental|1|patients will benefit from a complete polysomnography under NIV
3283158|NCT00603096|Active Comparator|2|settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas
3283159|NCT00603083|Active Comparator|A|This group receive local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg 10 and 22 hours after the operation. The medicine solution is given in a catheter, wich is placed in the hip at the end of the operation.
3283160|NCT00603083|Placebo Comparator|B|This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, wich is placed in the hip at the end of the operation.
3283161|NCT00603070||1|All physicians and nurse practitioners at 1 ambulatory care clinics
3283162|NCT00603070||2|All physicians and nurse practitioners at 1 ambulatory care clinics
3283163|NCT00603057||Lung Cancer Imaging Patients|Adult patients (>18 years of age)with histologically confirmed or clinically diagnosed lung cancer who require radiation therapy, with or without surgery and with or without chemotherapy.
3283164|NCT00603044|Active Comparator|Fluticasone furoate|55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy
3283165|NCT00603044|No Intervention|No treatment|
3283166|NCT00603031|Experimental|GLP-1|time -30-90 min: Continuous infusion with GLP-1 (1,2pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
3283167|NCT00603031|Placebo Comparator|NaCl|time -30-90 min: Continuous infusion with NaCl time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
3283168|NCT00603031|Experimental|GIP|time -30-90 min: Continuous infusion with GIP-1 (3,6pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
3283169|NCT00603018|Experimental|Annorexia nervosa|Participants recovered from anorexia nervosa before and after administration of fluoxetine
3283170|NCT00603005|Experimental|1|
3283171|NCT00603005|Experimental|2|
3283172|NCT00603005|Experimental|3|
3283173|NCT00603005|Experimental|4|
3283174|NCT00602979|Other|Macintosh laryngoscope|Macintosh laryngoscope (control group/direct laryngoscopy) - current standard
3283175|NCT00602979|Other|Airtraq Optical Laryngoscope|Airtraq® Optical Laryngoscope (an experimental group/indirect laryngoscopy)
3283176|NCT00602979|Other|Storz DCI Video Laryngoscope|Storz DCI Video Laryngoscope® (an experimental group/indirect laryngoscopy)
3283177|NCT00602979|Other|GlideScope Video Laryngoscope|GlideScope® Video Laryngoscope (an experimental group/indirect laryngoscopy)
3283178|NCT00602979|Other|McGRATH Video Laryngoscope|McGRATH® Video Laryngoscope (an experimental group/indirect laryngoscopy)
3283179|NCT00602966||Slow Freeze|
3283180|NCT00602966||Vitrification|
3283181|NCT00602953||Healthy volunteers|Normal weight and normal glucose tolerance.
3283182|NCT00602953||Pre-diabetes|Impaired fasting glucose of impaired glucose tolerance.
3283183|NCT00602953||Overweight|Overweight or obese volunteers, but with normal fasting and postprandial glucose levels.
3283184|NCT00602953||Type 2 diabetes|Patients with type 2 diabetes.
3283185|NCT00602953||Type 1 diabetes|Patients with type 1 diabetes.
3283186|NCT00602940|Experimental|1|Active acupuncture treatment
3283187|NCT00602940|Sham Comparator|2|Sham acupuncture treatment
3283188|NCT00602927|Placebo Comparator|Placebo|
3283189|NCT00602927|Active Comparator|Varenicline|
3283190|NCT00602914|Experimental|1|10 healthy volunteers will receive 0.1 U/kg. Once administered with a conventional needle (SQ) and then with MicronJet needle (ID) in a randomized order
3283191|NCT00602914|Experimental|2|10 Type II DM subject will receive 0.2 U/kg. Once administered with a conventional needle (SQ) and then with MicronJet needle (ID) in a randomized order
3283192|NCT00602901|Experimental|HVLA-SM|High-velocity low amplitude spinal manipulation (HVLA-SM)
3283193|NCT00602901|Experimental|LVVA-SM|Low-velocity variable amplitude spinal manipulation (LVVA-SM)
3283194|NCT00602901|Active Comparator|Usual Medical Care|Usual medical care - (Celebrex, Aleve, Bextra, Naproxen)
3283195|NCT00602862|Experimental|1|10 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/1mg 111In-Bevacizumab. Patients are then treated with Sorafenib 200 mg 2dd2 po for 4 weeks. In the last week of treatment, the same injection is given to determine tumor accumulation of the radiolabeled mAb after Sorafenib treatment. Whole-body scintigraphic images are recorded 1 week after both injections to calculate tumor uptake. After Sorafenib treatment, patients will undergo surgery.
3283196|NCT00602862|Experimental|2|10 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/10mg 111In-cG250. Patients are then treated with Sorafenib 200 mg 2dd2 po for 4 weeks. In the last week of treatment, the same injection is given to determine tumor accumulation of the radiolabeled mAb after Sorafenib treatment. Whole-body scintigraphic images are recorded 1 week after both injections to calculate tumor uptake. After Sorafenib treatment, patients will undergo surgery.
3283197|NCT00602862|Active Comparator|3|5 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/1mg 111In-Bevacizumab. Whole-body scintigraphic images are recorded 1 week after the injection to calculate tumor uptake. Hereafter, patients will undergo surgery.
3283198|NCT00602836|Experimental|PCR-Lenalidomide|Pentostatin, Cyclophosphamide, Rituximab + Lenalidomide
3283199|NCT00602797|Experimental|Treatment (vinorelbine tartrate, paclitaxel)|Patients receive vinorelbine tartrate IV over 6-10 minutes and paclitaxel IV over 1 hour once weekly for 6 weeks.
3283200|NCT00602784|Experimental|IC41-B-01/02|peptide dose 0.00 mg, polyarginine dose 2.00 mg
3283201|NCT00602784|Experimental|IC41-C-01/02|peptide dose: 5.00 mg, polyarginine dose: 0.00 mg
3283202|NCT00602784|Experimental|IC41-G-01/02|peptide dose: 2.50 mg, polyarginine dose: 1.25 mg
3283203|NCT00602784|Experimental|IC41-H-01/02|peptide dose: 2.50 mg, polyarginine dose: 2.00 mg
3283204|NCT00602784|Experimental|IC41-K-01/02|peptide dose: 5.00 mg, polyarginine dose: 2.00 mg
3283205|NCT00602771|Experimental|Arm I|Patients receive 600 mg of oral tipifarnib twice daily on days 1-14 and 100 mg of oral etoposide once daily on days 1-3 and 8-10.
3283206|NCT00602771|Experimental|Arm II (closed to accrual as of November 2008)|Patients receive 400 mg of oral tipifarnib twice daily on days 1-14 and 200 mg of oral etoposide once daily on days 1-3 and 8-10.
3283207|NCT00602758|Experimental|Enhanced Counseling|Participants meet with a counselor trained in motivational interviewing and cognitive behavioral techniques
3283208|NCT00602758|No Intervention|Standard Care|Participants receive usual clinical care provided by health care providers and they participate only in evaluation components of the study
3283209|NCT00602758|Experimental|Enhanced Counseling/Modified Directly Observed Therapy|Participants receive their ART medications delivered to them by study staff and they receive the enhanced counseling
3283210|NCT00602745|Active Comparator|5-Fluorouracil|
3283211|NCT00602745|Experimental|S-1|
3283212|NCT00602732|Experimental|1|Participants assigned to the ROSE program
3283213|NCT00602732|Active Comparator|2|Participants assigned to enhanced care as usual
3283214|NCT00602693|Experimental|UCB post-transplant Treg Cell Infusion|Includes patients with high risk malignancy receiving allopurinol, fludarabine phosphate, cyclophosphamide, sirolimus, total body irradiation, double umbilical cord blood transplantation and Treg infusion cells after transplant. Patients will receive differing dose levels as they are entered and assigned to determine the maximum tolerated dose.
3283215|NCT00602680|Experimental|1|dose 1
3283216|NCT00602680|Experimental|2|dose 2
3283217|NCT00602680|Experimental|3|dose 3
3283218|NCT00602680|Placebo Comparator|4|
3283219|NCT00602680|Active Comparator|5|
3283220|NCT00602667|Experimental|Low-Risk Patients|"Patients with GTR/M0 medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.~Note: Accrual to the low-risk medulloblastoma cohort is closed as of 12/2/2015. Accrual to the low-risk high grade glioma remains open."
3283221|NCT00602667|Experimental|High-Risk Patients|Patients with CNS metastatic disease will receive induction chemotherapy and high-risk therapy.
3283222|NCT00602667|Experimental|Intermediate-Risk Therapy|Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.
3283223|NCT00602641|Active Comparator|Arm I (thalidomide)|"INDUCTION THERAPY: Patients receive melphalan PO and prednisone PO QD on days 1-4, and thalidomide PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive thalidomide PO QD and continue in the absence of disease progression."
3283224|NCT00602641|Experimental|Arm II (lenalidomide)|"INDUCTION THERAPY: Patients receive melphalan PO and prednisone PO QD on days 1-4, and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive lenalidomide PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression."
3283225|NCT00602576|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.
3283226|NCT00602576|Experimental|Arm II|Patients receive sorafenib tosylate as in arm I and oral TMZ once daily on days 1-5 and 29-33.
3283227|NCT00602563|Experimental|1 Attention Modification Program (AMP)|The AMP is a computer-delivered attention modification
3283228|NCT00602563|Active Comparator|Applied Relaxation (AR)|Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev & Chambless, 2007)
3283229|NCT00602563|Placebo Comparator|Clinical monitoring control|participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions ; however, they will not be randomized to treatment until after the 3-month follow-up assessment. To control for the effects of psychoeducation, symptom monitoring, contact by project staff, and maturation effects, participants will be asked to complete pre-, mid- and post-assessments, and will be informed that they will receive treatment.
3283230|NCT00602563|Experimental|Combining the AMP and AR|Both AMP and AR
3283231|NCT00602537|Experimental|I|Antidepressant therapy
3283233|NCT00602511|Active Comparator|1|Bortezomib - dexamethasone
3283234|NCT00602511|Experimental|2|Thalidomide - dexamethasone
3283235|NCT00602472|Experimental|linagliptin 5 mg|linagliptin 5 mg once daily
3283236|NCT00602472|Placebo Comparator|placebo|placebo matching linagliptin 5 mg tablets
3283237|NCT00602459|Active Comparator|Arm A (rituximab, fludarabine phosphate)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: Patients receive rituximab IV over 1-4 hours on days 1 (50 mg/m^2), 3 (325 mg/m^2), and 5 (375 mg/m^2) of course 1 and on day 1 (375 mg/m^2) of all subsequent courses. Patients also receive fludarabine phosphate 25 mg/m^2/day IV over 30 minutes or PO on days 1-5.
3283238|NCT00602459|Experimental|Arm B (rituximab, fludarabine phosphate, lenalidomide)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: rituximab IV over 1-4 hours on days 1 (50 mg/m^2), 3 (325 mg/m^2), and 5 (375 mg/m^2) of course 1 and on day 1 (375 mg/m^2) of all subsequent courses. Patients also receive fludarabine phosphate 25 mg/m^2/day IV over 30 minutes or PO on days 1-5. Participants without progression receive consolidation therapy lenalidomide 5mg/day cycle 1, 10 mg/day cycles 2-6 PO QD on days 1-21 of 28 day cycle.
3283239|NCT00602459|Experimental|Arm C (rituximab, fludarabine phosphate, cyclophosphamide)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: rituximab IV over 4 hours on days 1 (50mg/m^2) and 3 (325 mg/m^2) of course 1 and on day 1 (500 mg/m^2) of all subsequent courses. Patients then receive fludarabine phosphate (age < 70: 25 mg/m^2/day; age >= 70: 20 mg/m^2/day) IV piggyback over 30 minutes or PO (32 mg/m^2/day) followed by cyclophosphamide (age < 70: 250 mg/m^2/day; age >= 70: 150 mg/m^2/day) IV piggyback over 30 minutes on days 1-3.
3283240|NCT00602459|Experimental|Arm D (rituximab, fludarabine, cyclophosphamide, lenalidomide)|Patients receive the first course of induction therapy as in Arm A or B before being re-assigned to Arm D. Beginning in course 2, patients receive rituximab IV (500 mg/m^2) on day 1 and fludarabine phosphate (age < 70: 25 mg/m^2/day; age >= 70: 20 mg/m^2/day) IV piggyback over 30 minutes or PO (32 mg/m^2/day) and cyclophosphamide IV (age < 70: 250 mg/m^2/day; age >= 70: 150 mg/m^2/day) piggyback over 30 minutes on days 1-3. Participants without progression receive consolidation therapy: lenalidomide 5mg/day cycle 1, 10 mg/day cycles 2-6PO QD on days 1-21 of 28 day cycle.
3283241|NCT00602446|Experimental|Deferasirox Treated|Includes patients that were treated with deferasirox for 6 months.
3283242|NCT00602433||questionnaire and laboratory biomarker analysis|Subjects with advanced non-small cell lung cancer and take erlotinib as part of their anticancer therapy for at least 3 months. Subjects have had some changes in hair growth, acne or menses (periods) that might be a side effect of erlotinib. Subjects will complete a questionnaire and blood collected for biomarker analysis.
3283243|NCT00602420|Experimental|Naproxen|Patients receive oral naproxen twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.
3283244|NCT00602420|Placebo Comparator|Placebo|Patients receive an oral placebo twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.
3283245|NCT00602355|Placebo Comparator|1 (Placebo)|Participants receiving placebo pill with clinical management plus mothercrafting
3283246|NCT00602355|Active Comparator|2 (Sertraline)|Participants receiving active medication sertraline with clinical management plus mothercrafting
3283247|NCT00602355|Active Comparator|3 (IPT)|Participants receiving interpersonal psychotherapy (IPT) alone
3283248|NCT00602329|Experimental|Arm I|Patients receive leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours (FOLFOX) beginning on day 1. Patients also receive bevacizumab at 5 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
3283249|NCT00602329|Experimental|Arm II|Patients receive FOLFOX as in arm I and bevacizumab at 10 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
3283250|NCT00602329|Active Comparator|FOLFOX alone (control)|Patients receive FOLFOX as in arm I.
3283251|NCT00602290|Active Comparator|1 - Citalopram and placebo|Participants will take a combination of citalopram and placebo for 16 weeks
3283252|NCT00602290|Active Comparator|2 - Methylphenidate and placebo|Participants will take a combination of methylphenidate and placebo for 16 weeks
3283253|NCT00602290|Active Comparator|3 - Methylphenidate and Citalopram|Participants will take a combination of methylphenidate and citalopram for 16 weeks
3283254|NCT00602277|Experimental|Treatment (viral therapy)|Patients receive wild-type reovirus IV over 60 minutes on days 1-5 in course 1, followed by insertion of an IP access port. Beginning in course 2, patients receive wild-type reovirus IV over 60 minutes on days 1-5 and wild-type reovirus IP over 10 minutes on days 1 and 2*. Treatment with IV and IP wild-type reovirus repeats every 28 days in the absence of disease progression or unacceptable toxicity. (phase II closed as of 1/7/2011). NOTE: *Patients receive IP wild-type reovirus on days 2 and 3 in course 3.
3283255|NCT00602264||1|Treatment-naïve patients with a recent diagnosis of anorexia nervosa
3283256|NCT00602264||2|The weight recovered subgroup of group 1
3283257|NCT00602264||3|Recovered patients with a previous history of anorexia nervosa but normal menstrual cycles and body weight at the present time
3283258|NCT00602264||4|Control group
3283259|NCT00602225|Experimental|Arm I|See Detailed Description
3283260|NCT00602212|Active Comparator|VR + Mobile Phone without Biofeedback|In this experimental condition patients received an eight-session VR-based treatment including relaxation and exposure
3283261|NCT00602212|Experimental|VR + Mobile Phone with biofeedback|The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
3283262|NCT00602186|Experimental|1|taking Tamsulosin
3283263|NCT00602186|Active Comparator|2|taking prasosin
3283264|NCT00602160|Active Comparator|1|2 different dosages
3283265|NCT00602160|Placebo Comparator|2|
3283266|NCT00602147||Retrospective sample|People who have been diagnosed with multiple myeloma and have received high-dose melphalan.
3283267|NCT00602147||Prospective sample|People who have been diagnosed with multiple myeloma and will be receiving high-dose melphalan.
3283268|NCT00602095|Experimental|1|Labour induction with misoprostol
3283269|NCT00602095|Active Comparator|2|Labour induction with dinoprostone
3283270|NCT00602095|Experimental|3|Labour induction with bard
3283271|NCT00602069|Experimental|1|Participants will receive cognitive behavioral therapy through the Helping to Overcome PTSD through Empowerment program
3283272|NCT00602069|Active Comparator|2|Participants will receive standard shelter services
3283273|NCT00602056|Experimental|1|Redesigned immunization card
3283274|NCT00602056|Experimental|2|Center based education to mothers/caregivers
3283275|NCT00602056|Experimental|3|Redesigned immunization card with center based education to mothers/caregivers
3283276|NCT00602056|No Intervention|4|Standard care only
3283277|NCT00602043|Experimental|Diagnostic (FES)|Patients undergo [^18F] FES PET scan. Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan.
3283278|NCT00602030|Experimental|1|Lead in Open Label Phase 1 dose-finding study to identify a safe dose of entinostat in combination with erlotinib for further evaluation
3283279|NCT00602030|Experimental|2|erlotinib (Tarceva) and entinostat
3283280|NCT00602030|Placebo Comparator|3|"erlotinib (Tarceva) and matched Placebo~patients in this arm who progress will be offered the opportunity to receive SNDX-275 with erlotinib for up to 6 28-day treatment cycles"
3283281|NCT00601978|Active Comparator|1|Immediate-Release Carbidopa/Levodopa
3283282|NCT00601978|Active Comparator|2|Carbidopa/Levodopa/Entacapone
3283283|NCT00601965|Experimental|CBT/Escitalopram|12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.
3283284|NCT00601965|Active Comparator|No CBT/escitalopram|12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks.
3283285|NCT00601965|Placebo Comparator|CBT/placebo|12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.
3283286|NCT00601965|Placebo Comparator|No CBT/placebo|"12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks pill placebo~12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks."
3283287|NCT00601952|Experimental|1 Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
3283288|NCT00601952|Placebo Comparator|2 Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
3283289|NCT00601939|Experimental|1|Culturally competent group empowerment psychoeducational treatment
3283290|NCT00601939|Active Comparator|2|Enhanced treatment as usual that includes an adherence protocol
3283291|NCT00601926|Experimental|Bevacizumab|15 mg/kg over 90 minutes
3283292|NCT00601913|Experimental|Erlotinib|Erlotinib
3283293|NCT00601900|Experimental|Arm I (endocrine therapy with monoclonal antibody)|Patients receive endocrine therapy* (tamoxifen citrate* or letrozole) PO QD on days 1-21 and bevacizumab 15 mg/kg IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3283294|NCT00601900|Active Comparator|Arm II (endocrine therapy)|Patients receive endocrine therapy* (tamoxifen citrate* or letrozole) PO QD on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3283295|NCT00601861|Experimental|A|
3283296|NCT00601835|Experimental|Canadian Td Vaccine Group|Participants received Canadian manufactured Td vaccine
3283297|NCT00601835|Active Comparator|United States Td Vaccine Group|Participants received US manufactured Td vaccine
3283298|NCT00601822|Experimental|1|Group receiving cognitive behavioral therapy for anorexia nervosa (CBT-AN)
3283299|NCT00601822|Experimental|2|Group receiving cognitive behavioral therapy for anorexia nervosa, plus cognitive remediation therapy (CBT-AN+CRT)
3283300|NCT00601809|Experimental|GG|
3283301|NCT00601809|Other|TT|
3283302|NCT00601796|Experimental|Combination Immunotherapy|Vaccine + Cytoxan + ATRA as outlined in Detailed Description
3283303|NCT00601770|Experimental|IC41|8 injections of 4 x 0.125mL
3283304|NCT00601757|Other|1|Participants assigned to the Postpartum Prevention Program
3283305|NCT00601757|Other|2|Participants assigned to enhanced care as usual
3283306|NCT00601744||Patient|Diagnosis of orbital or head and neck cancer and a history of orbital exenteration.
3283307|NCT00601744||Family Member/Friend|Family member or close friend of a patient with a diagnosis of orbital or head and neck cancer and a history of orbital exenteration.
3283308|NCT00601731|Experimental|Adjuvanted MenACWY vaccine group|Blood test
3283309|NCT00601731|Active Comparator|Non-adjuvanted MenACWY vaccine group|Blood test
3283354|NCT00601250|Experimental|Linagliptin|Patients receive linagliptin 5 mg tablets once daily
3283451|NCT00600496|Experimental|3|AZD6244 + Erlotinib
3283310|NCT00601718|Experimental|Treatment (enzyme inhibitor, monoclonal antibody, chemotherapy|Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
3283311|NCT00601705|Experimental|Epirubicin, Oxaliplatin and Fluorouracil|
3283312|NCT00601692|Experimental|Regimen 1|Patients receive docetaxel IV over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 8, patients receive docetaxel IV over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 (week 8) and 8 (week 9). Patients also undergo radiotherapy once daily, 5 days a week, in weeks 8-10. Treatment with chemoradiotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
3283313|NCT00601692|Experimental|Regimen 2|Patients receive docetaxel IV and irinotecan hydrochloride as in regimen 1 induction chemotherapy. They also receive cisplatin IV over 20-30 minutes on days 1 and 8. Treatment with irinotecan hydrochloride, docetaxel, and cisplatin repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients receive docetaxel IV, irinotecan hydrochloride IV, and undergo radiotherapy as in regimen 1 chemoradiotherapy. Patients also receive cisplatin IV over 20-30 minutes on days 1 (week 8) and 8 (week 9). Treatment with irinotecan hydrochloride, docetaxel, cisplatin, and radiotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
3283314|NCT00601679|Experimental|NT-proBNP|Surveillance NT-proBNP levels disclosed to physicians. Intervention (e.g. Diuretic management) based on NT-proBNP results.
3283315|NCT00601679|No Intervention|Usual Care|Surveillance NT-proBNP levels blinded. Intervention (e.g. Diuretic management) based on clinical judgments.
3283316|NCT00601653|Active Comparator|1|Cognitive behavioral therapy plus general nutrition counseling
3283317|NCT00601653|Experimental|2|Cognitive behavioral therapy plus low energy density diet counseling
3283318|NCT00601640|Experimental|Eflornithine HCL|Patients apply Eflornithine HCL ointment to their left forearm twice daily on days 1-90.
3283319|NCT00601640|Active Comparator|Diclofenac Na|Patients apply topical Diclofenac Na gel to their left forearm once daily on days 1-90.
3283320|NCT00601640|Experimental|Eflornithine HCL and Diclofenac Na|Eflornithine HCl ointment and Diclofenac Na gel applied twice and once daily, respectively on days 1-90.
3283321|NCT00601627|Experimental|Panitumumab|"Chemotherapy concurrent with radiation: Radiation 5 days per week for 5½ weeks; Panitumumab on days 1, 15, and 29 of radiation therapy 5-fluorouracil (5FU) continuous infusion, starting on day 1 and through last day of radiation.~4-6 weeks after completion of radiation therapy: Gemcitabine on days 1, 8, and 15 of each cycle, for 3 cycles; Panitumumab on days 1 and 15 of each cycle, for 3 cycles. Maintenance therapy: Panitumumab on days 1 and 15 of each cycle, for 6 cycles."
3283322|NCT00601549|Experimental|1|Patients with low rectal cancer after CCRT undergoing laparoscopic surgery
3283323|NCT00601549|Active Comparator|2|Patients with low rectal cancer after CCRT undergoing traditional open surgery
3283324|NCT00601523|Active Comparator|Pramipexole|Patient to receive Pramipexole ER 0.375-4.5 mg tabl form daily
3283325|NCT00601523|Placebo Comparator|Placebo|Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
3283326|NCT00601510|Experimental|Imatinib mesylate|Imatinib mesylate 300mg/day(maximum dose will be 800 mg) on day -4, -3, -2, -1, 1, 2, 3 through d21 in combination with capecitabine 1250 mg/m2 twice daily (d1-d14) and iv cisplatin 60mg/m2
3283327|NCT00601497|Experimental|1|
3283328|NCT00601497|Placebo Comparator|2|
3283329|NCT00601484|Experimental|1|
3283330|NCT00601484|Placebo Comparator|2|
3283331|NCT00601471|Experimental|1|proximal tibiofibular manipulation
3283332|NCT00601471|Experimental|2|distal tibiofibular manipulation
3283333|NCT00601471|No Intervention|3|no treatment
3283334|NCT00601458|Active Comparator|Arm 1: Pregabalin 300 mg|
3283335|NCT00601458|Active Comparator|Arm 2: naproxen sodium 550 mg|
3283336|NCT00601458|Placebo Comparator|Arm 3: Placebo|
3283337|NCT00601419||Somatropin|Patients administered Somatropin.
3283338|NCT00601393|Active Comparator|1|Participants will receive treatment as usual followed by 8 weeks of Internet-based cognitive behavioral therapy treatment
3283339|NCT00601393|Experimental|2|Participants will receive 8 weeks of Internet-based cognitive behavioral therapy treatment
3283340|NCT00601367|Experimental|flibanserin flexible dose|"Initial dosage:~Patients were to take one 50 mg flibanserin tablet in the evening.~Subsequent dosage titrations:~Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.~Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.~Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site."
3283341|NCT00601354|Experimental|Emotion Regulation Group therapy + alli|Group taking the weight loss medication orlistat (alli), in conjunction with the alli weight loss program, plus 12 weekly sessions of guided self-help group psychotherapy
3283342|NCT00601354|Active Comparator|Orlistat/alli program meds only|Group taking the weight loss medication orlistat (alli), in conjunction with the alli weight loss program alone
3283343|NCT00601341|Experimental|1|lumbosacral joint manipulation
3283344|NCT00601341|Experimental|2|lumbar passive range of motion
3283345|NCT00601341|Other|3|lie on exam table for 3 minutes
3283346|NCT00601276|Experimental|1|
3283347|NCT00601276|Active Comparator|2|
3283348|NCT00601263|Active Comparator|1a|Low dose ASHMI (2 caps bid).
3283349|NCT00601263|Placebo Comparator|1b|Placebo 2 caps bid.
3283350|NCT00601263|Active Comparator|2a|Medium dose ASHMI (4 caps bid).
3283351|NCT00601263|Placebo Comparator|2b|Placebo 4 caps bid.
3283352|NCT00601263|Active Comparator|3a|High dose ASHMI (6 caps bid).
3283353|NCT00601263|Placebo Comparator|3b|Placebo 6 caps bid.
3283355|NCT00601250|Placebo Comparator|Placebo|Patients receive placebo tablets matching linagliptin 5 mg tablets once daily
3283356|NCT00601237|Experimental|A|Participants will receive HIV-related text messages
3283357|NCT00601237|Active Comparator|B|Participants will receive nutrition-related text messages
3283358|NCT00601237|No Intervention|C|Participants will attend a 90-minute focus group to develop messages for the cell-phone program
3283359|NCT00601224|Experimental|1|Participants will receive social cognition and interaction training plus treatment as usual
3283360|NCT00601224|Active Comparator|2|Participants will receive treatment as usual
3283361|NCT00601198|Experimental|Treatment Period|The chemotherapy regimen will be given for 2 consecutive days. On day #1, pt. will be premedicated with drugs to prevent nausea and vomiting in addition to intravenous fluids. Then they will receive amifostine intravenously followed by oxaliplatin, 5FU and leucovorin. This will be followed by an infusion of 5FU given in a pump over 22 hours. If the doctor decides on giving the pt. Avastin, this will be given on day #1. On day #2, they will receive the same treatment except for oxaliplatin.
3283362|NCT00601185||1|Patients undergoing a shave biopsy and confocal microscopy.
3283363|NCT00601172|Placebo Comparator|Control|Placebo + standard antiemetics
3283364|NCT00601172|Experimental|Single Dose IV|Casopitant + standard antiemetics
3283365|NCT00601159|Experimental|gemcitabine and cisplatin|cisplatin and gemcitabine in the management of triple negative metastatic breast cancer
3283366|NCT00601133||Patient Postural Instability|Participants having difficulty walking and with balance after cancer treatment that are leaving the M.D. Anderson rehabilitation hospital or after treatment through the rehabilitation mobile team.
3283367|NCT00601107|Experimental|Doxercalciferol 2.5 mcg/day|Doxercalciferol 2.5 microgram (mcg) capsule orally once daily up to Week 24.
3283368|NCT00601107|Experimental|Doxercalciferol 5 mcg/day|Doxercalciferol 5 mcg capsules orally once daily up to Week 24.
3283369|NCT00601107|Experimental|Doxercalciferol 7.5 mcg/day|Doxercalciferol 7.5 mcg capsules orally once daily up to Week 24.
3283370|NCT00601107|Placebo Comparator|Placebo|Placebo matching to doxercalciferol capsules orally once daily up to Week 24.
3283371|NCT00601094|Experimental|experimental arm|
3283372|NCT00601081||1|Very low birth weight and preterm infants who will likely receive fortification of breast milk with HMF
3283373|NCT00601068||Observational|Group of patients with osteochemonecrosis related to oral bisphosphonate use
3283374|NCT00601055|Experimental|Problem Solving-Rx Adherence (PSA)|Participants will receive problem-solving therapy integrated with adherence-enhanced procedures (PSA).
3283375|NCT00601055|Active Comparator|PID-C|Participants will receive adherence-enhanced (PID-C) procedures, a treatment mobilizing patients to participate in their care.
3283376|NCT00601042|Experimental|1|Swedish snus ad libitum as a substitute for cigarettes
3283377|NCT00601042|Placebo Comparator|2|Tobacco-free, nicotine-free placebo snus ad libitum as a substitute for cigarettes
3283378|NCT00601029||1|Winter Phase - Observational
3283379|NCT00601029||2|Summer Phase - Observational
3283380|NCT00601003|Experimental|Nifurtimox|
3283381|NCT00600977|Active Comparator|doxorubicine|VAD
3283382|NCT00600977|Experimental|Doxorubicine pegylated|Doxorubicine pegylated 40 MG/M² J1
3283383|NCT00600964|Experimental|GX15-070MS|GX15-070MS at various doses and schedules
3283384|NCT00600951||1|Patients with moderate chronic kidney disease (stage 3, according to the classification of chronic kidney disease by the National Kidney Foundation, i.e., with eGFR comprised between 30 and 59 mL/min/1.73m2)
3283385|NCT00600951||2|Patients with severe chronic kidney disease or kidney failure (stages 4 and 5, according to the classification of chronic kidney disease by the National Kidney Foundation, i.e., with eGFR stably below 30 mL/min/1.73m2)
3283386|NCT00600938|Experimental|Deferasirox|20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
3283387|NCT00600938|Active Comparator|Deferasirox Placebo|50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
3283388|NCT00600938|Experimental|Extension: deferoxamine to deferasirox|"DFO to ICL (patients who switched from DFO to deferasirox in extension)"
3283389|NCT00600938|Experimental|Extension: deferasirox to deferoxamine|"ICL to DFO (patients who switched from deferasirox to DFO in extension)"
3283390|NCT00600925|Experimental|1|Insertion of 2 gentamicin-collagen sponges before closure of the laparotomy (each 10 x 10 cm sponge contains 280 mg collagen and 130 mg gentamicin).
3283391|NCT00600925|No Intervention|2|Standard of care, ie, no gentamicin-collagen sponge.
3283392|NCT00600912|Experimental|1-SMOFlipid®|lipid emulsion based on soybean oil, medium-chain triglycerides, olive oil and fish oil SMOFlipid®-Group (n = 21)
3283393|NCT00600912|Active Comparator|2-ClinOleic 20%®|olive and soybean oil-group (n=21)
3283394|NCT00600899|Experimental|A|Group A patients will receive perisciatic continuous infusion of ropivacaine 2 mg/ml through an elastomeric pump (Baxter, Deerfield, IL, USA)) 8 ml/h (reservoir of 500 ml)as postoperative analgesia.
3283395|NCT00600899|Active Comparator|B|Group B patients will receive standard treatment: continuous perisciatic infusion of 2 mg/ml ropivacaine 5 ml/t (Baxter infusor with 275 ml reservoir)
3283396|NCT00600886|Experimental|Pasireotide LAR|Patients in this arm received Pasireotide LAR 40 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 20 or 60 mg, respectively. Patients who responded to Pasireotide LAR (i.e. the randomized treatment) at the end of the core (Month 12), continued Pasireotide LAR treatment in the extension. Patients who did not respond to Pasireotide LAR at the end of the core (Month 12) were allowed to switch to receive Octreotide LAR in the extension.
3283397|NCT00600886|Active Comparator|Octreotide LAR|Patients in this arm received Octreotide LAR 20 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 10 or 30 mg, respectively. Patients who responded to Octreotide LAR (i.e. the randomized treatment) at the end of the core (Month 12) continued Octreotide LAR treatment in the extension (up to 2 years of treatment). Patients who did not respond to Octreotide LAR at the end of the core (Month 12) were allowed to switch to receive Pasireotide LAR in the extension.
3283398|NCT00600873|Experimental|1|patients with early ALS
3283450|NCT00600496|Experimental|2|AZD6244 + Dacarbazine
3283399|NCT00600860||MDS patients|Patients with MDS according to current WHO criteria and International Prognostic Scoring System (IPSS) classification
3283400|NCT00600847|Active Comparator|1|desloratadine 20 mg
3283401|NCT00600847|Active Comparator|2|desloratadine 5 mg
3283402|NCT00600847|Placebo Comparator|3|
3283403|NCT00600834||1|patients with moderate CKD (stage 3, according to the classification of CKD by the National Kidney Foundation, i.e., with eGFR comprised between 30 and 59 mL/min/1.73m2)
3283404|NCT00600834||2|patients with severe CKD or kidney failure (stages 4 and 5, according to the classification of CKD by the National Kidney Foundation, i.e., with eGFR stably below 30 mL/min/1.73m2).
3283405|NCT00600821|Active Comparator|B|Bevacizumab will be administered in combination with carboplatin and paclitaxel.
3283406|NCT00600821|Experimental|A|AG-013736 will be administered in combination with carboplatin and paclitaxel.
3283407|NCT00600795||A|Patients diagnosed with Normal Pressure Hydrocephalus
3283408|NCT00600782|Experimental|Group A|These subjects were further stratified into 3 groups according to the size of their PPD skin test reactions
3283409|NCT00600769|Other|treatment of MAC and other NTM|Clarithromycin drug given twice daily.
3283410|NCT00600756|Experimental|Quetiapine XR|
3283411|NCT00600756|Active Comparator|Risperidone|
3283412|NCT00600743|Placebo Comparator|1 'Instructions to eat normally'|'Instructions to eat normally' Placebo 1 mg dose
3283413|NCT00600743|Active Comparator|2 'Instructions to eat normally'|'Instructions to eat normally' drug 1 mg dose 'GSKI181771X (CCK-1R agonist)'
3283414|NCT00600743|Placebo Comparator|3 'Instructions to eat normally'|'Instructions to eat normally' 2 mg placebo
3283415|NCT00600743|Active Comparator|4 'Instructions to eat normally'|'Instructions to eat normally' 2 mg drug 'GSKI181771X (CCK-1R agonist)'
3283416|NCT00600743|Placebo Comparator|5 'Instructions to eat normally'|'Instructions to eat normally' 4 mg placebo
3283417|NCT00600743|Active Comparator|6 'Instructions to eat normally'|'Instructions to eat normally' 4 mg drug 'GSKI181771X (CCK-1R agonist)'
3283418|NCT00600743|Placebo Comparator|7 Instructions to binge eat|Instructions to binge eat 4 mg placebo
3283419|NCT00600743|Active Comparator|8 Instructions to binge eat|Instructions to binge eat 4 mg drug 'GSKI181771X (CCK-1R agonist)'
3283420|NCT00600730|Experimental|1|Hyperinsulinemic euglycemic clamp with fMRi
3283421|NCT00600730|Experimental|2|Hyperinsulinemic hypoglycemic clamp with fMRI
3283422|NCT00600717||Pediatric Patients and Healthy Children|Healthy children without dental works. Pediatric patients with epilepsy and migraine (headache).
3283423|NCT00600704|Active Comparator|RESTRICTED FLUIDS|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary Bypass
3283424|NCT00600704|Active Comparator|FREE FLUIDS|Free fluid infusion unless Hb< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
3283425|NCT00600691|Experimental|1|5mg finasteride orally, daily for 2 weeks prior to prostate biopsy and one week following prostate biopsy.
3283426|NCT00600678|Experimental|1|
3283427|NCT00600665|Active Comparator|Usual Care|In Part 1 of the study, participants will access PAINReportIt and computer games. PAINReportIt helps the patient describe the pain experienced. In Part 2 of the study, participants will continue to access PAINReportIt when they are seen in the clinic, emergency department (ED), acute care center (ACCA), and hospital. They will gain access to the PAINUCope computer-based programs, which provides multimedia education tailored to the patient's misconceptions about pain management. They will receive medial usual care at the outpatient clinic, ED, ACC, and hospital.
3283428|NCT00600665|Experimental|PAINUCope/PAINConsultN|In Part 1 of the study, participants will access PAINReportIt and PAINUCope computer-based programs. PAINReportIt helps the patients describe the pain experiences and PAINUCope provides multimedia education tailored to the patient's misconceptions about pain management. In Part 2 of the study, participants will continue to access PAINReportIt and PAINUCope programs when they are seen in the clinic, emergency department (ED), acute care center (ACC), and hospital. Their doctors will have access to PAINConsultN when seen at the ED, ACC, and hospital. PAINConsultN is just-in-time decision support for the physicians with the pain data summarized and suggestions for analgesics that may be useful to help manage the patient's pain.
3283429|NCT00600652||1|glucocorticoid-resistant patients
3283430|NCT00600652||2|glucocorticoid-sensitive patients
3283431|NCT00600652||3|normal controls
3283432|NCT00600639|Experimental|1|non-invasive ventilation with BiPAP Vision or another ICU ventilator with NIV option
3283433|NCT00600639|Active Comparator|2|standard therapy + oxygen
3283434|NCT00600613|Experimental|1|Patients going for treatment of liver metastases with radiation therapy.
3283435|NCT00600600|Experimental|Tigecycline|tigecycline titrated dose according to patient age and clinical status
3283436|NCT00600587|Experimental|A|Erlotinib targeted NSCLC population based on EGFR gene analysis(EGFR gene status: activating mutation)
3283437|NCT00600587|Active Comparator|B|Non-erlotinib targeted NSCLC population based on EGFR gene analysis
3283438|NCT00600574|Active Comparator|S|physiotherapy in warm pool by means of stretching
3283439|NCT00600574|Experimental|AI|physiotherapy in warm pool by means of Ai Chi
3283440|NCT00600561|Active Comparator|1-Day MBSR|One-day condensed MBSR class
3283441|NCT00600561|Experimental|8-week MBSR|8-week Mindfulness-Based Stress Reduction Intervention
3283442|NCT00600548|Experimental|1.1|Cutaneous leishmaniasis patients in Manaus-Amazonas randomized to receive Miltefosine.
3283443|NCT00600548|Active Comparator|1.2|Cutaneous leishmaniasis patients in Manaus-Amazonas randomized to receive Meglumine antimoniate (standard treatment).
3283444|NCT00600548|Experimental|2.1|Cutaneous leishmaniasis patients in Corte de Pedra-Bahia randomized to receive Miltefosine.
3283445|NCT00600548|Active Comparator|2.2|Cutaneous leishmaniasis patients in Corte de Pedra-Bahia randomized to receive Meglumine antimoniate (standard treatment).
3283446|NCT00600535|Experimental|Abiraterone acetate (non-fasting)|
3283447|NCT00600535|Experimental|Abiraterone acetate (fasting)|
3283448|NCT00600522||1|Patients selected for hepatectomy because carriers of hepatocellular carcinoma or colorectal cancer liver metastases invading the middle hepatic vein at caval confluence (last 4 cm).
3283449|NCT00600496|Experimental|1|AZD6244 + docetaxel
3283452|NCT00600496|Experimental|4|AZD6244 + Temsirolimus
3283453|NCT00600483|Experimental|1|Insertion of 2 gentamicin-collagen sponges between the sternal halves before closure of the sternotomy
3283454|NCT00600483|No Intervention|2|Standard of care, ie, insertion of no gentamicin-collagen sponge.
3283455|NCT00600470|Experimental|1|Doctor-office collaborative care management
3283456|NCT00600470|Active Comparator|2|"Treatment as usual: psychoeducation and outside referral to treatment (PORT). In papers, this arm is referred to as Enhanced Usual Care (EUC)."
3283457|NCT00600457||A,1|
3283458|NCT00600444|Active Comparator|A|Venae Sectio technique will be used to insert totally implantable access port (TIAP) by a surgeon
3283459|NCT00600444|Experimental|B|Punction of Vena Subclavia will be used to insert totally implantable access port (TIAP) by a radiologist.
3283460|NCT00600431||1|Study group: 16 children under 18 years undergoing systemic chemotherapy
3283461|NCT00600431||2|Control group: 16 age and sex matched healthy children under 18 years
3283462|NCT00600405|Experimental|I|Subjects randomized to the experimental group receive ibuprofen, oxycodone, and tamsulosin 0.4 mg orally daily for ten days.
3283463|NCT00600405|Other|II|Standard therapy arm: subjects randomized to standard therapy receive ibuprofen and oxycodone alone.
3283464|NCT00600392||1|patients who meet criteria for CRT-D implantation
3283465|NCT00600379|Experimental|A,|Virtual Reality training for an overall of 18 sessions 2/week + usual care.
3283466|NCT00600379|No Intervention|B,|Usual care
3283467|NCT00600353|Experimental|Melphalan, dexamethasone, aprepitant, palonosetron|"Group A: Subjects with Multiple Myeloma~Conditioning regimen, over a 7 day period, includes:~Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion~Group B: Subjects with Lymphoma~Conditioning regimen, over a 7 day period, includes: (BEAC)~BCNU 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant"
3283468|NCT00600340|Active Comparator|A|"Bevacizumab 10 mg/kg i.v., days 1 and 15, every 4 weeks Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks~In both arms, treatment will be given until first disease progression (PD), unacceptable toxicity or withdrawal of patient consent."
3283469|NCT00600340|Active Comparator|B|"Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks Capecitabine twice-daily 1000 mg/m², day 1 to 14, every 3 weeks~In both arms, treatment will be given until first disease progression (PD), unacceptable toxicity or withdrawal of patient consent."
3283470|NCT00600327|Experimental|1|
3283471|NCT00600314||High risk|Patients who are at high risk of developing acute or chronic GVHD
3283472|NCT00600314||GVHD|Patients who currently have either grade II or greater acute GVHD, or clinically extensive chronic GVHD
3283473|NCT00600288|Experimental|1|
3283474|NCT00600288|Placebo Comparator|2|
3283475|NCT00600275|Experimental|BGT226|
3283476|NCT00600223||1|Patients undergoing laryngectomy and pharyngeal reconstruction
3283477|NCT00600210|Experimental|I|
3283478|NCT00600197|Experimental|Back school|a kind of educational program for low back pain
3283479|NCT00600197|Experimental|back school|
3283480|NCT00600184|Experimental|One|
3283481|NCT00600171|Placebo Comparator|Placebo|Placebo Multi dose dry powder inhlaer
3283482|NCT00600171|Experimental|GW642444M|GW642444M
3283483|NCT00600158|Experimental|2|lidocaine intravenously
3283484|NCT00600158|Active Comparator|1|epidural local anesthetic
3283485|NCT00600145|Experimental|1|Mirtazapine
3283486|NCT00600145|Placebo Comparator|2|Placebo
3283487|NCT00600119|Placebo Comparator|A|Placebo
3283488|NCT00600119|Experimental|B|NKTR-118
3283489|NCT00600106|Active Comparator|Hormone replacement therapy|Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
3283490|NCT00600106|Placebo Comparator|Placebo|1mg placebo
3283491|NCT00600093|Experimental|A|
3283492|NCT00600080|Other|etafilcon A first nelfilcon A second|etafilcon A worn daily during week 1, nelfilcon A worn daily for week 2
3283493|NCT00600080|Other|nelfilcon A first, etafilcon A second|nelfilcon A worn daily during week 1, etafilcon A worn daily for week 2
3283494|NCT00600067|Experimental|1|
3283495|NCT00600067|Placebo Comparator|2|
3283496|NCT00600054|Experimental|Single arm|
3283497|NCT00600041|Experimental|A|Pantoprazole IV
3283498|NCT00600041|Placebo Comparator|B|NaCl 0.9% IV
3283499|NCT00600028|Experimental|Experimental: Thalidomide, then placebo|Participants first received Thalidomide tablet for 12 weeks. After a washout period of two weeks, they then received placebo tablet for 12 weeks.
3283500|NCT00600028|Experimental|Experimental: Placebo, then Thalidomide|Participants first received Placebo tablet for 12 weeks. After a washout period of two weeks, they then received Thalidomide tablet for 12 weeks.
3283501|NCT00600015|Experimental|Combination Therapy|Erlotinib + Sorafenib
3283502|NCT00600015|Placebo Comparator|Placebo|Erlotinib + Placebo
3283503|NCT00600002|Experimental|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
3283504|NCT00599963|Experimental|1|paricalcitol 1 mg/day for 12 weeks, followed by a washout period of 4 weeks, then crossed over to no treatment for another 12 weeks
3283505|NCT00599963|Active Comparator|2|no treatment for 12 weeks, followed by a washout period of 4 weeks, then crossed over to paricalcitol for another 12 weeks
3283506|NCT00599950|Experimental|1|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
3283507|NCT00599950|Placebo Comparator|2|Photorefractive keratectomy (PRK)without mitomycin C.
3283562|NCT00599586|Sham Comparator|group 4|Non-acupoints
3283563|NCT00599573|Experimental|1|Ondansetron
3283678|NCT00598611|Active Comparator|2|desloratadine 20 mg
3283679|NCT00598585|Experimental|sidenafil|sidenafil
3283508|NCT00599937|No Intervention|ATRA ->Chemo|Patients 65 years of age with a WBC count less than 5,000 were randomized to receive the reference ATRA treatment of our previous trial (APL91 trial), ie, 45 mg/m2/d ATRA followed by CT or ATRA plus CT (ATRA+CT). In the ATRA followed byCT group, patients received 45 mg/m2/d ATRA orally until CR, with a maximum of 90 days. After CR achievement, they received a course of 60 mg/m2/d daunorubicin (DNR) for 3 days and 200 mg/m2/d AraC for 7 days (course I). However, course I was added to ATRA if the WBC count was increased to greater than 6,000, 10,000, or 15,000 by day 5, 10, and 15 of ATRA treatment, respectively, because, from our experience, patients were at risk of ATRA syndrome above those thresholds.
3283509|NCT00599937|Experimental|ATRA+CT|Patients randomized to the ATRA+CT group received the same combination of ATRA and CT, with course I of CT starting on day 3 of ATRA treatment. This 48-hour interval before onset of CT was based on our previous report, because it allowed correction of coagulopathy.
3283510|NCT00599937|No Intervention|High WBC|Patients with a WBC count greater than 5,000 at presentation (irrespective of their age) and patients 66 to 75 years of age with a WBC count 5,000 were not randomized but received ATRA plus CT course I from day 1 (high WBC group) and the same schedule as in the ATRA->CT group (elderly group), respectively.
3283511|NCT00599937|No Intervention|no maintenance|No maintenance
3283512|NCT00599937|Experimental|maintenance ATRA|Intermitent ATRA as maintenance
3283513|NCT00599937|Experimental|maintenance Cxt|continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally) as maintenance
3283514|NCT00599937|Experimental|maintenance both|continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally) AND ATRA as maintenance
3283515|NCT00599924|Experimental|Single arm|"SU011248 [sunitinib] in combination with FOLFOX; FOLFOX is a chemotherapy regimen that combines oxaliplatin and leucovorin with bolus and infusion 5-FU. The modified FOLFOX 6 (mFOLFOX6) regimen is one of several different regimens of FOLFOX used in clinic, according to different dosages of the 4 drugs. mFOLFOX6 was administered every 2 weeks on Days 1 and 2 of each cycle.~25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in three different dosing regimens: schedule 2/2 (2 weeks on, 2 weeks off), schedule 4/2 (4 weeks on, 2 weeks off), and continuous daily dosing (every day); FOLFOX will be administered every 2 weeks, using the modified FOLFOX 6 (mFOLFOX6) regimen, consisting of: oxaliplatin 85 mg/m2 + leucovorin 400 mg/m2 as a 2-hr IV infusion; 5-FU 400 mg/m2 IV bolus, followed by - 5-FU 2400 mg/m2 as a 46-hr IV infusion"
3283516|NCT00599911|Experimental|Lu AA24530: 5 mg|
3283517|NCT00599911|Experimental|Lu AA24530: 10 mg|
3283518|NCT00599911|Experimental|Lu AA24530: 20 mg|
3283519|NCT00599911|Active Comparator|Duloxetine: 60 mg|
3283520|NCT00599911|Placebo Comparator|Placebo|
3283521|NCT00599898|Experimental|1|
3283522|NCT00599898|Experimental|2|
3283523|NCT00599885|Active Comparator|1|
3283524|NCT00599885|Active Comparator|2|
3283525|NCT00599872|Active Comparator|Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract administered via the sublingual oral route (27.6 to 77.3 Amb a 1 Units)
3283526|NCT00599872|Placebo Comparator|Placebo|Standardized Ragweed Allergenic Extract Placebo via the sublingual oral route
3283527|NCT00599859|Active Comparator|1|Participants in arm 1 are grouped as lactose digesters based on genetic analysis and breath hydrogen results. In discrepant cases the genetic status is accepted. Arm 1 is initially withdrawn from dairy foods(lactose) and then asked to consume lactose 50g in divided doses mixed in water for 2 weeks.
3283528|NCT00599859|Active Comparator|2|Arm 2 are lactose maldigesters: 2 interventions are a. withdrawal from lactose for 2 weeks and b. consumption of 50g lactose in divided doses mixed in water for a 2 week period.
3283529|NCT00599807|Active Comparator|1: 2000 IU D3/day|2000 IU vitamin D3 taken orally each day for 2 years
3283530|NCT00599807|Active Comparator|2: 800 IU D3 / day|800 IU vitamin D3 taken orally each day for 2 years
3283531|NCT00599794||1|Healty volunteers who are euvolemic.
3283532|NCT00599794||2|Critically ill patients who will be having a central venous catheter with a monitor to measure central venous pressure placed as part of their planned care independent of this study.
3283533|NCT00599781|Experimental|PBL/HSC|
3283534|NCT00599755|Experimental|Gem/Cis or Gem/Carbo|
3283535|NCT00599742|Active Comparator|A|Balance training group
3283536|NCT00599742|Active Comparator|B|Motor Training
3283537|NCT00599729||1|patient demonstrating degenerative changes in the knee joint (osteoarthritis)
3283538|NCT00599716|Experimental|1|study drug
3283539|NCT00599716|Placebo Comparator|2|vehicle control
3283540|NCT00599703||1|neurosurgical patients
3283541|NCT00599690|Experimental|A|Epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
3283542|NCT00599677|Experimental|group 1|specific acupoints of Stomach meridians
3283543|NCT00599677|Experimental|group 2|Non-specific acupoints of Stomach meridians
3283544|NCT00599677|Experimental|group 3|alarm and transport points
3283545|NCT00599677|Experimental|group 4|acupoints of the other meridian
3283546|NCT00599677|Sham Comparator|group 5|non-acupoints
3283547|NCT00599677|Active Comparator|group 6|Itopride
3283548|NCT00599664|Experimental|1|Drug
3283549|NCT00599664|Placebo Comparator|2|Vehicle
3283550|NCT00599651|Experimental|1|Surfactant by LMA
3283551|NCT00599651|Other|2|Standard of care
3283552|NCT00599638|Active Comparator|1|
3283553|NCT00599638|Experimental|2|
3283554|NCT00599638|Placebo Comparator|3|
3283555|NCT00599625|Experimental|1|Patients with active Crohn's Disease
3283556|NCT00599612|Experimental|Healthy male volunteers|Six healthy male volunteers aged between 30-60 years old will be recruited for this study,
3283557|NCT00599599|Experimental|1|Prolonged Exposure Therapy.
3283558|NCT00599599|No Intervention|2|Weekly monitoring/Waitlist Control Group.
3283559|NCT00599586|Experimental|group 1|specific acupoints of Shaoyang meridians
3283560|NCT00599586|Experimental|Group 2|Non-specific acupoints of Shaoyang meridians
3283561|NCT00599586|Experimental|group 3|Acupoints of other meridians
3283564|NCT00599560|Experimental|1. Meniere's disease|Patients were eligible for enrollment if they had received a clinical diagnosis of Meniere's disease according to the 1995 AAO-HNS criteria (Committee, 1995). These criteria can be briefly described as follows: 1) Repeated attacks of vertigo: A definitive spell is spontaneous vertigo lasting at least 20 minutes. A mixed type of spontaneous nystagmus is observed during attacks. 2) Fluctuating cochlear symptoms: The hearing test usually reveals a marked fluctuation of the threshold in the low and middle tone range.
3283565|NCT00599560|No Intervention|2. Acoustic neurinoma|Diagnosed by CT and/or MRI
3283566|NCT00599547|Experimental|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
3283567|NCT00599534|Active Comparator|1|4 mg tablet for 16 weeks
3283568|NCT00599534|Placebo Comparator|2|5 mg for 16 weeks
3283569|NCT00599521|Experimental|Adapalene lotion 0.1%|
3283570|NCT00599521|Placebo Comparator|Adapalene Lotion vehicle|
3283571|NCT00599508|Active Comparator|grape juice active intervention|Concord grape juice administered daily for 12 or 16 weeks
3283572|NCT00599508|Placebo Comparator|juice placebo|berry placebo juice administered daily for 12 or 16 weeks
3283573|NCT00599508|Active Comparator|blueberry juice active intervention|wild blueberry juice administered daily for 12 weeks
3283574|NCT00599508|Active Comparator|blueberry powder intervention|whole fruit blueberry powder administered daily for 16 weeks
3283575|NCT00599508|Placebo Comparator|powder placebo|placebo powder administered daily for 16 weeks
3283576|NCT00599482|Other|1|Far Infrared Radiation
3283577|NCT00599469|Other|1|Far Infrared Radiation
3283578|NCT00599456|Experimental|1|Omega 3 vitamin supplements
3283579|NCT00599456|Placebo Comparator|2|Placebo capsule
3283580|NCT00599443|Experimental|1|
3283581|NCT00599443|Placebo Comparator|2|
3283582|NCT00599430|Placebo Comparator|1|Placebo
3283583|NCT00599430|Active Comparator|Active 1|One probiotic strain
3283584|NCT00599430|Active Comparator|Active 2|Blend of two strains
3283585|NCT00599417|Experimental|1|
3283586|NCT00599417|Placebo Comparator|2|
3283587|NCT00599391|Other|1|Far Infrared Radiation
3283588|NCT00599378|Experimental|1|Implementation Intentions-based telephone counseling. Partnership intervention between rural Primary Care Physicians, their patients, and CRC Information Specialists using an implementation intentions based approach.
3283589|NCT00599378|No Intervention|2|Healthy Living information on Physical Activity and Nutrition
3283590|NCT00599365|Experimental|Pharmacy Care arm|"The pharmacist:~will take all the patient's medication bottles, and give medication boxes filled with medications in the order the patient should take them in.~will need to obtain a complete list of medications.~will teach the patient about the medications.~will provide a medication schedule, and other papers about the medications.~will count the pills in the medication boxes.~will review all the medications with the patient and answer any question.~will check to see if the medication is working for the patient.~will work with the patient's kidney doctor to adjust medications if needed.~will give the medication boxes filled with medications to take home."
3283591|NCT00599365|No Intervention|Control|"The pharmacist:~will obtain a complete list of medications.~will count the pills in the patients' medication bottles.~will inform patients to take their medications from these bottles."
3283592|NCT00599352|Experimental|1|Magnesium infusion
3283593|NCT00599339||Neupro|Neupro at study onset
3283594|NCT00599339||Dopamine Agonist|Other Dopamine-Agonist at study onset
3283595|NCT00599339||L-Dopa|L-Dopa
3283596|NCT00599339||Neupro + L-Dopa|Neupro in combination with L-Dopa at study onset
3283597|NCT00599339||Dopamine Agonist + L-Dopa|Other Dopamine Agonist in combination with L-Dopa at study onset
3283598|NCT00599326|Experimental|A|
3283599|NCT00599313|Experimental|Sunitinib Malate|Sunitinib Malate (Sutent) (50 mg/day on Days 1-28 of 42-day cycles)
3283600|NCT00599287|No Intervention|1|No intervention
3283601|NCT00599287|Experimental|2|Methylphenidate
3283602|NCT00599287|Experimental|3|Rivastigmine
3283603|NCT00599287|Experimental|4|Haloperidol
3283604|NCT00599274||A|This group was treated with Avonex once a week
3283605|NCT00599274||B|This group was treated with Rebif three times a week
3283606|NCT00599261|Experimental|1|Removal of the fibrotic pocket surrounding the generator and leads
3283607|NCT00599261|Experimental|2|Tissue is not removed
3283608|NCT00599248|Experimental|1|TissueGene-C single intraarticular injection of 3x10e6 cells/joint
3283609|NCT00599248|Experimental|2|TissueGene-C single intraarticular injection of 1x10e7 cells/joint
3283610|NCT00599248|Experimental|3|TissueGene-C single intraarticular injection of 3x10e7 cells/joint
3283611|NCT00599248|Placebo Comparator|4|Placebo control single intraarticular injection
3283612|NCT00599235|Experimental|1|
3283613|NCT00599235|Active Comparator|2|
3283614|NCT00599222|Active Comparator|TTT|TTT is given every three months
3283615|NCT00599222|Sham Comparator|Sham TTT|Sham TTT is given every three months
3283616|NCT00599209|Experimental|A - coded unit ID|Nursing home units provided the CDS intervention
3283617|NCT00599209|No Intervention|B - coded unit ID|Nursing home units not provided the CDS intervention
3283618|NCT00599196|Experimental|Rotigotine|Rotigotine
3283619|NCT00599183|Other|1|Participants will receive baseline conventional MRI of the cervical spine as part of their clinical care with an additional diffusion tensor imaging (DTI)sequence as part of the research; they will complete an anonymized questionnaire about their condition. Participants will receive an MRI with DTI and tractography as part of the research and will complete an anonymized questionnaire about their condition. The baseline and follow up data will be compared.
3283620|NCT00599170|Experimental|Arm 1|Rituximab 375 mg/m2 iv on day 1 q 15 days just prior to CHOP, beginning with cycle 1.
3283621|NCT00599144|Experimental|1|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
3283622|NCT00599144|Experimental|2|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
3283623|NCT00599144|No Intervention|3|Group3: control group without any local anesthetic use.
3283624|NCT00599131|Experimental|Chemotherapy/Radiation/Surgery|"Patients will undergo induction chemotherapy with (TPF): Docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 on day 1, and 5-FU 750 mg/m2 days 1-4.~On day 20 patients will receive a single dose of cetuximab (C-225) 400 mg/m2.~Depending upon disease response, patients will undergo salvage laryngectomy followed by radiation therapy and chemotherapy."
3283625|NCT00599118||atrial fibrillation|Atrial fibrillation
3283626|NCT00599118||Control|Control subjects with no atrial fibrillation
3283627|NCT00599079|Experimental|Azithromycin|Azithromycin combined with 2 other drugs given 3 times weekly for MAc lung disease
3283628|NCT00599066||Study cases|Application of a second M-Entropy probe on the forehead of the patient; at the end the patient will have 2 probes on the forehead, one in the right and one in the left.
3283629|NCT00599053|Experimental|1|Early treatment with azithromycin
3283630|NCT00599053|No Intervention|2|Expectant (usual) management
3283631|NCT00599040|Active Comparator|Weight loss|Weight loss diet focused on the DASH diet
3283632|NCT00599040|Active Comparator|DASH diet|The DASH diet without weight loss
3283633|NCT00599040|Active Comparator|Diary|Dairy Intervention
3283634|NCT00599027|Experimental|Mometasone furoate nasal spray|Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
3283635|NCT00599027|Placebo Comparator|Placebo nasal spray|Placebo nasal spray once daily (two puffs per nostril) in the morning.
3283636|NCT00599001|Experimental|Escalating Dose of SD-101|
3283637|NCT00599001|Placebo Comparator|Placebo|
3283638|NCT00598988|Experimental|A|Traditional Chinese acupuncture in conjunction with standard medical care
3283639|NCT00598988|Active Comparator|B|standard medical care
3283640|NCT00598975|Experimental|NKTR-102 100 mg/m2 + Cetuximab|NKTR-102 100 mg/m2 + Cetuximab
3283641|NCT00598962|Experimental|azithromycin and rifabutin/rifampin|Azithromycin and rifabutin/rifampin administered three times weekly.
3283642|NCT00598936||Cardiac Surgery or Hospitalization|"Patients scheduled for a Cardiac Surgery procedure, two types of cerebral oximetry devices were compared at the same time during the surgical procedure.~The second group were patients hospitalized (in the Intensive Care Unit or ICU, with any diagnosis, excluding head trauma patients. Those patients were monitored using two types of cerebral oximetry devices at the same time for up to 72 hours."
3283643|NCT00598923|Experimental|1|Phenytoin 20mg/kg load, then Topiramate, 100 mg twice daily, starting at 24 hours post-TBI for 6 days.
3283644|NCT00598923|Experimental|2|topiramate for 3 months after loading dose of phenytoin
3283645|NCT00598923|Placebo Comparator|3|Phenytoin 20 mg/kg as loading dose than 300 mg/day for total of 7 days
3283646|NCT00598910|Experimental|A|
3283647|NCT00598910|Placebo Comparator|B|
3283648|NCT00598897|Experimental|clarithromycin and rifabutin/rifampin|Clarithromycin and rifabutin/rifampin with ethambutol given three times weekly.
3283649|NCT00598884|Experimental|6-week delay start|This group begins treatment 6 weeks after recruitment and baseline.
3283650|NCT00598884|Experimental|No delay start|This group begins treatment after enrollment and assessment with no wait period.
3283651|NCT00598871|Placebo Comparator|2|There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of eyedrops to the affected eye, identical to the active drug but with no thymosin beta 4 (0.00% thymosin beta 4, w/w), 2 drops 4 times a day (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
3283652|NCT00598871|Active Comparator|1|There are 2 groups: active drug and placebo. The patients in the active comparator arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times a day (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
3283653|NCT00598858|Experimental|Treatment (docetaxel and prednisone)|Patients receive docetaxel IV over 60 minutes on days 1 and 2 and prednisone PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3283654|NCT00598845||Consecutive numbers|Patients with endometrial cancer
3283655|NCT00598832|Experimental|Adapalene lotion 0.1%|
3283656|NCT00598832|Placebo Comparator|Adapalene Lotion vehicle|
3283657|NCT00598819|Experimental|Healthy Volunteers|Healthy subjects testing the device.
3283658|NCT00598806|Experimental|Apaziquone|TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
3283659|NCT00598806|Placebo Comparator|Placebo|TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT
3283660|NCT00598780||1|Patients with newly diagnosed persistent allergic rhinitis, within the approved age limits.
3283661|NCT00598741|Experimental|1|
3283662|NCT00598728||1|Hodgkin lymphoma Survivors
3283663|NCT00598715|Experimental|Same drug|sirolimus-eluting stent will be implanted for restenosis after previous the implantation of a sirolimus-eluting stent
3283664|NCT00598715|Active Comparator|Different drug|paclitaxel eluting stent will be implanted for restenosis after previous the implantation of a sirolimus-eluting stent
3283665|NCT00598702|Experimental|IV Acetaminophen|40 to 75 mg/kg/day every 4 to 6 hours
3283666|NCT00598689|Experimental|Lubricant|Patients scheduled to receive LASIK surgery and randomized to receive 0.3% hypromellose ophthalmic solution prior to surgery.
3283667|NCT00598689|No Intervention|No Lubricant|Patients scheduled to receive LASIK surgery and randomized to receive no intervention of 0.3% hypromellose ophthalmic solution prior to surgery
3283668|NCT00598676|Experimental|BPRES|biodegradable polymer rapamycin-eluting stent
3283669|NCT00598676|Active Comparator|PPRES|permanent polymer rapamycin-eluting stent
3283670|NCT00598676|Active Comparator|PPEES|permanent polymer everolimus-eluting stent
3283671|NCT00598663|Experimental|A|Paradigm Real-Time system: insulin pump with continuous glucose sensing
3283672|NCT00598663|Other|B|Paradigm Real-Time insulin pump with self-monitoring blood glucose
3283673|NCT00598650|Experimental|1|
3283674|NCT00598637|Active Comparator|EES|Everolimus-eluting stent (Xience)
3283675|NCT00598637|Experimental|ZES|Zotarolimus-eluting stent (Endeavor Resolute)
3283676|NCT00598624|Experimental|A|
3283677|NCT00598611|Active Comparator|1|desloratadine 20 mg
3283680|NCT00598585|Placebo Comparator|placebo|placebo
3283681|NCT00598572|Experimental|1|All participants will receive various dose-regimens of the study drug (deferoxamine mesylate). Each dose cohort will consist of at least 3 subjects.
3283682|NCT00598559|Experimental|1 g IV Acetaminophen|1 g q6h IV Acetaminophen
3283683|NCT00598559|Experimental|650 mg IV Acetaminophen|650 mg q4h IV Acetaminophen
3283684|NCT00598559|Other|Standard of Care|The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
3283685|NCT00598546||1|
3283686|NCT00598533|Experimental|Dual-DES|Rapamycin + Probucol-eluting stent
3283687|NCT00598533|Active Comparator|ZES|Polymer based Zotarolimus-eluting stent
3283688|NCT00598507|Experimental|Chemotherapy - ZK-EPO|ZK-EPO (ZK 219477) (Sagopilone), 16 mg/m^2, was administered intravenously over 3-hours every 21 days until progression or unacceptable toxicity.
3283689|NCT00598481|Experimental|CD34+ cells|infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with Busulphan
3283690|NCT00598442|Experimental|Peginesatide 0.025 mg/kg|
3283691|NCT00598442|Experimental|Peginesatide 0.04 mg/kg|
3283692|NCT00598442|Active Comparator|Darbepoetin alfa|
3283693|NCT00598429|Active Comparator|High dose|PGE1 300 ng/kg/min via nebulizer over a 72-hour period
3283694|NCT00598429|Active Comparator|Low dose|PGE1 150 ng/kg/min via nebulizer over a 72-hour period
3283695|NCT00598429|Placebo Comparator|Placebo|Normal saline, the diluent for the drug, via nebulizer over a 72-hour period
3283696|NCT00598416|Experimental|Psychoeducation|
3283697|NCT00598403|Experimental|1|Cefditoren pivoxil
3283698|NCT00598403|Active Comparator|2|Ciprofloxacin
3283699|NCT00598377|Active Comparator|1|Patients with autosomal dominant polycystic kidney disease
3283700|NCT00598377|Active Comparator|2|Healthy subjects
3283701|NCT00598364||Thyroidectomy or neck dissection|Patients with thyroid cancer or benign thyroid disease (nodules or goiter) who underwent thyroidectomy and/or neck dissection as standard of care.
3283702|NCT00598338|Active Comparator|1|Prucalopride
3283703|NCT00598338|Placebo Comparator|2|Placebo
3283704|NCT00598325|Experimental|NicVAX|
3283705|NCT00598325|Experimental|NicVAX Lot 2|2nd cohort receives a different lot of vaccine from the 1st cohort
3283706|NCT00598299||A|Healthy adult serum
3283707|NCT00598299||B|cord blood serum
3283708|NCT00598273|Experimental|Peginesatide 0.025 mg/kg|
3283709|NCT00598273|Experimental|Peginesatide 0.04 mg/kg|
3283710|NCT00598273|Active Comparator|Darbepoetin Alfa|
3283711|NCT00598260|Experimental|1- study group|study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
3283712|NCT00598260|No Intervention|2 - control group|control group
3283713|NCT00598247|Experimental|A|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks. A
3283714|NCT00598234|Active Comparator|1|Celecoxib (Celebrex)
3283715|NCT00598234|Placebo Comparator|2|Placebo
3283716|NCT00598208|Experimental|1|60 µg Org 36286 (corifollitropin alfa)
3283717|NCT00598208|Experimental|2|120 µg Org 36286 (corifollitropin alfa)
3283718|NCT00598208|Experimental|3|180 µg Org 36286 (corifollitropin alfa)
3283719|NCT00598208|Active Comparator|4|Follitropin beta injection
3283720|NCT00598195|No Intervention|Ketamine Pharmacokinetics|The pharmacokinetic action of Ketamine used in Children having heart surgery.
3283721|NCT00598169|Experimental|CD20+ Non-Hodgkin Lymphoma|"Part A: Velcade Day 1 and Day 8, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2. Dexamethasone 20 mg IV and etoposide 100 mg/m2 IV Days 8-10, carboplatin dosed to AUC=5 (maximum 750 mg) IV and ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna on Day 9 of a 28-day cycle.~Part B: Velcade on Days 1 and 8, dexamethasone 20 mg IV Days 1-3 and Day 8; etoposide 100 mg/m2 IV on Days 1-3; carboplatin dosed to AUC=5 (maximum 750 mg) IV on Day 2; ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna and administered as a continuous IV infusion over 24 hours on Day 2, rituximab 375mg/m2 on Day 1 of a 21-day cycle."
3283722|NCT00598169|Experimental|CD20- Non-Hodgkin Lymphoma|"Part A: Velcade Day 1 and Day 8, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2. Dexamethasone 20 mg IV and etoposide 100 mg/m2 IV Days 8-10, carboplatin dosed to AUC=5 (maximum 750 mg) IV and ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna on Day 9 of a 28-day cycle.~Part B: Velcade on Days 1 and 8, dexamethasone 20 mg IV Days 1-3 and Day 8; etoposide 100 mg/m2 IV on Days 1-3; carboplatin dosed to AUC=5 (maximum 750 mg) IV on Day 2; ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna and administered as a continuous IV infusion over 24 hours on Day 2, 21-day cycle."
3283723|NCT00598156|Experimental|1|bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab and erlotinib as maintenance treatment until progression
3283724|NCT00598156|Experimental|2|bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab every third week until progression
3283725|NCT00598143||Group A|Ten healthy smokers will provide a saliva sample used to genotype UGT1A7 and complete a questionnaire to assess understanding of and willingness to participate in molecular risk assessments.
3283726|NCT00598143||Group B|Thirty smokers will receive standard smoking cessation therapy and provide urine specimens for PGE-M analysis at approximate 3-monthly intervals over one year. Self-reported smoking status and expired-air carbon monoxide (CO) will also be recorded at 3-monthly clinic visits.
3283727|NCT00598130|Experimental|I|patients who will be treated in accordance with standard of care
3283728|NCT00598130|Active Comparator|II|patients for which the Fibrin Fleece will be applied directly on the active bleeding site.
3283729|NCT00598117||1|Group 1 (newly diagnosed patients) Initial assessment → first post op visit → 6 and 12 months post surgery
3283730|NCT00598117||2|Group 2 (post-treatment patients) A one-time assessment will be conducted at least 18 months following treatment
3283731|NCT00598104|Experimental|1|
3283732|NCT00598104|Placebo Comparator|2|
3283733|NCT00598091|Active Comparator|A|
3283734|NCT00598091|Active Comparator|B|
3283738|NCT00598052|Active Comparator|A|Escitalopram + cognitive-behavior treatment
3283739|NCT00598052|Placebo Comparator|B|Placebo + cognitive-behavior therapy
3283740|NCT00598026|Experimental|1|Tele- follow-up: remote transmission to the implantation centre every 3 months
3283741|NCT00598026|Active Comparator|2|Conventional follow-up: visits at the implantation centre every 3 months
3283742|NCT00598013|Experimental|1|
3283743|NCT00598013|No Intervention|2|
3283744|NCT00598000||1|Determine the impact, in terms of quality of life (QOL), of minimally invasive, video-assisted thoracic surgery (VATS)
3283745|NCT00598000||2|Determine the impact, in terms of quality of life (QOL), in traditional thoracotomy and anatomic lung resection in early stage lung cancer.
3283746|NCT00597987||1|RNA samples
3283747|NCT00597974||Patients having angioplasty (case)|Patients undergoing carotid artery angioplasty and/or stent-supported angioplasty for the treatment of carotid artery stenosis will receive neurological and neuropsychological evaluations
3283748|NCT00597974||Patients having angiography (control)|Patients undergoing coronary angiography for the treatment of carotid artery stenosis will receive neurological and neuropsychological evaluations
3283749|NCT00597948|Experimental|1|Workshop Group: Receives Healthy Lifestyles curriculum and subsequent support.
3283750|NCT00597948|No Intervention|2|Comparison Group: Does not receive Healthy Lifestyles curriculum and subsequent support.
3283751|NCT00597935|Experimental|1|SSLF and PMT
3283752|NCT00597935|Experimental|2|ULS and PMT
3283753|NCT00597935|Experimental|3|SSLF without PMT
3283754|NCT00597935|Experimental|4|ULS without PMT
3283755|NCT00597922||1|2,000 women between the ages of 18 and 55 years who are hospitalized with a heart attack
3283756|NCT00597922||2|1,000 men between the ages of 18 and 55 years who are hospitalized with a heart attack
3283757|NCT00597909|Experimental|Arm 1|
3283758|NCT00597909|Experimental|Arm 2|
3283759|NCT00597909|Placebo Comparator|Arm 3|
3283760|NCT00597896|Experimental|Active pramipexole|Day 1: Random assignment to drug or placebo and dosage starting at 0.125 mg BID, which will be increased every week to a target dose of 1.5 mg/day. Targeted maximum dose of 1.5 mg/day is expected to be reached by week 4, however, dosing will be flexible based upon side effects reported. The maximum dose will be 1.5 mg/day.
3283761|NCT00597896|Placebo Comparator|Placebo pramipexole|Day 1: Random assignment to drug or placebo and dosage starting at 0.125 mg BID, which will be increased every week to a target dose of 1.5 mg/day. Targeted maximum dose of 1.5 mg/day is expected to be reached by week 4, however, dosing will be flexible based upon side effects reported. The maximum dose will be 1.5 mg/day.
3283762|NCT00597870|Experimental|Treatment of Thoracic Lesions|Endoluminal treatment of thoracic lesions
3283763|NCT00597857|Placebo Comparator|1|receipt of a placebo pill for 16 days
3283764|NCT00597857|Active Comparator|2|oral pill of hydrocortisone (ranging from 20mg - 2.5mg) taken for 10 days with a taper for 6 days (based on Pitman et al, 2002).
3283765|NCT00597844|Experimental|1|voice evaluation and fMRI prior to surgical rehabilitation of UVCP
3283766|NCT00597844|Other|2|Healthy volunteers-voice evaluation and fMRI
3283767|NCT00597831||A|All patients in the Rijnstate Hospital with an indication for unilateral ECT treatment and a major depression or psychotic depression according to DSM IV-TR criteria.
3283768|NCT00597818|Placebo Comparator|1|
3283769|NCT00597818|Experimental|2|Cobiprostone 18 mcg once daily (QD)
3283770|NCT00597818|Experimental|3|Cobiprostone 18 mcg twice daily (BID)
3283771|NCT00597818|Experimental|4|Cobiprostone 18 mcg three times daily (TID)
3283772|NCT00597805||1|Patients scheduled for a total, anterior or posterior pelvic exenteration
3283773|NCT00597792|Active Comparator|A|Active Plicator Treatment
3283774|NCT00597779|Active Comparator|EM device|Extramedullary Device (EM)
3283775|NCT00597779|Active Comparator|IM device|Intramedullary Device (IM)
3283776|NCT00597766|Active Comparator|Low Dose|"Drug: Lidocaine (Neer's Test)~Drug: 20 mg Triamcinolone + Lidocaine"
3283777|NCT00597766|Active Comparator|Standard Dose|"Drug: Lidocaine (Neer's Test)~Drug: 40 mg Triamcinolone + Lidocaine"
3283778|NCT00597766|Experimental|High Dose|"Drug: Lidocaine (Neer's Test)~Drug: 60 mg Triamcinolone + Lidocaine"
3283779|NCT00597753|Experimental|Peginesatide|
3283780|NCT00597753|Active Comparator|Epoetin alfa|
3283781|NCT00597727|Active Comparator|Blinded Peanut SLIT|Blinded subjects who received peanut sublingual drops for the initial 12 month blinded phase of the study.
3283782|NCT00597727|Placebo Comparator|Blinded Placebo SLIT|Blinded subjects who received placebo sublingual drops for the initial 12 month blinded phase of the study.
3283783|NCT00597727|Other|Ext. maint. open label peanut SLIT|After completing the blinded phase of the study, subjects receiving Blinded Peanut SLIT continued on extended maintenance open-label peanut SLIT for the duration of the study. Subjects receiving Blinded Placebo SLIT were crossed over and underwent the 12 month buildup protocol on open label peanut SLIT and then continued on extended maintenance treatment for the duration of the study.
3283784|NCT00597727|Other|Early unblinded peanut SLIT|Subjects who were unblinded prematurely during the blinded phase of the study and then re-enrolled as an open label cohort.
3283785|NCT00597727|Other|Pilot peanut SLIT rollover cohort|Subjects from the original phase 1 study of peanut SLIT (NCT00429429) who were rolled over into the current protocol as an open label peanut SLIT cohort.
3283786|NCT00597714|Experimental|Cohort A - Lymphoid Disease|Group A: Patients with a high chance of progressive lymphoid or myelomatous disease undergo Non-myeloablative Stem Cell Transplantation.
3283787|NCT00597714|Experimental|Cohort B - Myeloid Disease|Group B: Patients with a high chance of progressive myeloid diseases, marrow failure syndromes or myeloproliferative disorders undergo Non-myeloablative Stem Cell Transplantation.
3283788|NCT00597714|No Intervention|Donor|Donor priming and apheresis will include filgrastim 8 mcg/kg subcutaneously twice daily for 4 days prior to stem cell collection and continuing until pheresis is completed. Alternative mobilization strategies may be employed at the investigator's discretion.
3283789|NCT00597701|Active Comparator|Baclofen|Standard benzodiazepine therapy plus baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
3283790|NCT00597701|Placebo Comparator|Placebo|Standard benzodiazepine therapy plus placebo every eight hous as inpatients for 72 hours or until discharge if less than 72 hours.
3283791|NCT00597688|Active Comparator|1|Chlorhexidine gel
3283792|NCT00597688|Placebo Comparator|2|Placebo gel
3283793|NCT00597675|Placebo Comparator|Placebo|Oat flour ingested daily as a placebo
3283794|NCT00597675|Active Comparator|Peanut OIT|Peanut flour ingested daily as oral mucosal immunotherapy
3283795|NCT00597662|Experimental|1|
3283796|NCT00597662|Active Comparator|2|
3283797|NCT00597649|Experimental|1|Bicifadine 800 mg/day for a year
3283798|NCT00597649|Experimental|2|Bicifadine 1200 mg/day for a year
3283799|NCT00597636||1|NEVER SMOKERS WITH LUNG CANCER
3283800|NCT00597636||2|NEVER SMOKERS WITHOUT ANY CANCER
3283801|NCT00597623|Experimental|1|2 injections of Adalimumab (Humira®)
3283802|NCT00597623|Placebo Comparator|2|2 injection of Placebo
3283803|NCT00597610|Experimental|1|
3283804|NCT00597597|Experimental|A|Open label; all subjects receive active drug, Erlotinib
3283805|NCT00597584|Experimental|Peginesatide|
3283806|NCT00597584|Active Comparator|Epoetin|
3283807|NCT00597558|Experimental|Egg white protein|Subjects, who are egg allergic, are given egg white protein for desensitization with the hypothesis they will develop tolerance.
3283808|NCT00597545|Active Comparator|Conventional Shunt|"Patients with diabetes mellitus (DM) undergoing carotid endarterectomy will receive a shunt only if it is indicated by EEG, by conventional management."
3283809|NCT00597545|Experimental|Prophylactic Shunt|Patients with diabetes mellitus (DM) undergoing carotid endarterectomy will receive a shunt even when by standard criteria they would not need to receive one.
3283810|NCT00597532|Experimental|1|soy (soy protein supplementation 50 grams/day)
3283811|NCT00597532|Placebo Comparator|2|milk protein supplementation 50 grams/day
3283812|NCT00597519|Experimental|Treatment|Patients with hematopoietic malignancy at high-risk for relapse or with advanced disease will receive myeloablative conditioning with cyclophosphamide (Cy), low dose fludarabine (Flu) and total body irradiation (TBI) with post transplantation cyclosporine (CSA) and mycophenolate mofetil (MMF) for GVHD prophylaxis.
3283813|NCT00597506|Experimental|Bevacizumab and Everolimus|10 mg Everolimus(RAD001) daily by mouth, days 1-28 10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle
3283814|NCT00597493|Experimental|Sorafenib + Temozolomide|"Subjects receive 400mg of Sorafenib twice daily and 50mg/m^2 of Temozolomide once daily~Subjects continue to receive treatment until any of the following: progressive disease, unacceptable toxicity, non-compliance with study guidelines, withdrawal of patient consent, intercurrent non-cancer-related illness that prevents continuation of therapy or regular follow-up, general or specific changes in a subject's condition which render the patient unacceptable for treatment in the judgement of the investigator, or study closure"
3283815|NCT00597480|Active Comparator|1|the recommended dose in the EU of rhGH (Norditropine SimpleXx®)
3283816|NCT00597480|Active Comparator|2|"the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)"
3283817|NCT00597467|Experimental|1|
3283818|NCT00597467|Active Comparator|2|
3283819|NCT00597454|Experimental|1|
3283820|NCT00597441|Experimental|I|Thymic tissue from third party donor
3283821|NCT00597428|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
3283822|NCT00597428|Experimental|Lubiprostone|24 mcg capsules twice daily (BID)
3283823|NCT00597415|Placebo Comparator|A 1|A 1=placebo
3283824|NCT00597415|Active Comparator|A 2|A 2=celecoxib
3283825|NCT00597402|Experimental|Avastin, radiation, temozolomide, and irinotecan|
3283826|NCT00597389|Active Comparator|1|oral solution of propranolol (propranolol HCL 20 mg/5 ml solution) or a liquid placebo twice daily for 10 days (and taper for 5 days; based on Pitman et al, 2002). Dose was calculated as determined by Famularo et al. (1988) to be 2.5 mg/kg/d with a maximum dose of 40 mg bid (Green, 2001).
3283827|NCT00597389|Placebo Comparator|2|A 25/5ml solution of placebo (a sugar solution that looks and tastes like the propranolol solution)
3283828|NCT00597376|Experimental|1|On Cerefolin NAC and open-label multivitamin supplement
3283829|NCT00597376|Placebo Comparator|2|On placebo and open label multivitamin supplement
3283830|NCT00597363|Experimental|1|Neptune PAD utilization to accelerate closure of the vascular access site
3283831|NCT00597363|Active Comparator|2|manual compression for closure of the vascular access site
3283832|NCT00597350||1|Group with diabetes mellitus
3283833|NCT00597337|Experimental|1|Receiving FearNot
3283834|NCT00597337|No Intervention|2|Control: Treatment as usual (normal curriculum)
3283835|NCT00597324|Active Comparator|1|Patients with normal Allen's test
3283836|NCT00597324|Experimental|2|Patients with intermediate Allen's test
3283837|NCT00597324|Experimental|3|Patients with abnormal Allen's test
3283838|NCT00597311|Experimental|1|preoperative short term radiation group 5x5 Gy and surgery after 6 weeks
3283839|NCT00597311|Experimental|2|preoperative chemoradiotherapy group 50Gy + 5FU/Lv and surgery after 6 weeks.
3283840|NCT00597298|Active Comparator|1|inspiratory muscle training program using a pressure threshold device
3283841|NCT00597298|Sham Comparator|2|
3283842|NCT00597272|Experimental|1|Vaccine- KLH conjugates with GD2L and GD3L
3283843|NCT00597259|Experimental|A|
3283844|NCT00597259|Active Comparator|B|Entecavir Alone
3283845|NCT00597246|Experimental|1|
3283846|NCT00597220|Experimental|1|Omega 3
3283847|NCT00597220|Placebo Comparator|2|
3283848|NCT00597207|Experimental|1|Mechanical CPR with AutoPulse
3283849|NCT00597207|Other|2|Manual CPR
3283850|NCT00597194|Active Comparator|OH|Inguinal hernia operated using a classic open herniotomy(OH)
3283851|NCT00597194|Active Comparator|LH|Laparoscopic herniorraphy (LH) for inguinal hernia
3283852|NCT00597181|Active Comparator|1|Trabeculectomy with Mitomycin C 0.2 mg/cc for 2 minutes
3283853|NCT00597181|Active Comparator|2|Ex-Press mini shunt; Model R50 with mitomycin C 0.2 mg/cc for 2 minutes
3283854|NCT00597142|Experimental|1|
3283855|NCT00597129|Experimental|Multi Dose levels|different doses of 90YhPAM4 will be given only once.
3283856|NCT00597116|Active Comparator|1|Vinorelbine
3283857|NCT00597116|Experimental|2|Vandetanib
3283858|NCT00597103||1|Prevalent patients who have been receiving more frequent dialysis.
3283859|NCT00597103||2|Incident patients new to more frequent dialysis
3283860|NCT00597103||3|Patients who switch from one more frequent hemodialysis treatment regimen to another more frequent dialysis regimen.
3283861|NCT00597090||1|
3283862|NCT00597077|Active Comparator|Rate control|
3283863|NCT00597077|Active Comparator|Rhythm control|
3283864|NCT00597038|Experimental|Phase I Dose Escalation|Dasatinib and Dacarbazine (DTIC). The first cohort was a dasatinib dose of 50 mg by mouth (PO) twice a day (BID) given days 2-19 with DTIC given at a dose of 800 mg/m2 once every 3 weeks. The dose escalation was continued until MTD and a recommended Phase II dose was established.
3283865|NCT00597038|Experimental|Phase II Dose Treatment|Dasatinib and Dacarbazine (DTIC). The recommended phase II dose was dasatinib 70 mg BID with dacarbazine 800 mgm^2.
3283866|NCT00597025|Active Comparator|Group A|Center Hemodialysis patients
3283867|NCT00597025|Active Comparator|Group B|Center hemodialysis patients
3283868|NCT00597025|No Intervention|Group C|Center Hemodialysis Patients
3283869|NCT00597025|Active Comparator|Group D|Peritoneal dialysis patients
3283870|NCT00597025|No Intervention|Group E|Peritoneal dialysis patients
3283871|NCT00597012|Experimental|Surgical|Participants will undergo arthroscopic partial menisectomy (APM) surgery and offered postoperative rehabilitative physical therapy.
3283872|NCT00597012|Active Comparator|Nonoperative|Participants will undergo standard physical therapy that will include strengthening and stretching sessions one to three times a week for 8 weeks.
3283873|NCT00596999||1|all subjects will be treated with UCB and HPDSC
3283874|NCT00596986|Active Comparator|AD|Antidepressant Duloxetine
3283875|NCT00596986|Active Comparator|PT|Psychotherapy (CBASP) - Cognitive Behavioural Analysis System of Psychotherapy
3283876|NCT00596973|Experimental|Ileal transposition with SG|Procedure: Surgical Treatment
3283877|NCT00596960|Experimental|Motivational Enhancement Therapy|Motivational enhancement therapy
3283878|NCT00596960|Active Comparator|Health Education|health education intervention
3283879|NCT00596947|Experimental|Prednisone Withdrawal|Participants randomized to the prednisone withdrawal group, received 4 medications to prevent rejection. Thymoglobulin (rabbit antithymocyte globulin) was given intravenously in the operating room at the time of transplant. Subsequent intravenous doses were administered to participants an inpatient or outpatient for a total of 3 to 5 doses. Participants also began taking Prograf (tacrolimus) and CellCept (mycophenolate mofetil)orally within 24 hours of transplant and continued indefinitely. The steroids were initially given in the operating room intravenously at time of transplant as Solu-medrol (methylprednisolone)and were then switched to daily oral prednisone doses. The participant's dose of prednisone was rapidly decreased until it was completely eliminated by day 6 post-transplant.
3283880|NCT00596947|Active Comparator|Prednisone Maintenance|Participants randomized to the prednisone maintenance group, received 4 medications to prevent rejection. Thymoglobulin (rabbit antithymocyte globulin) was initiated intravenously in the operating room at the time of transplant. Subsequent intravenous doses were administered an inpatient or outpatient for a total of 3 to 5 doses. Participants began taking Prograf (tacrolimus) and CellCept (mycophenolate mofetil)orally within 24 hours of transplant and continued on them indefinitely. The steroids were initially given intravenously in the operating room at time of transplant as Solu-medrol (methylprednisolone) and were then switched to daily oral prednisone tablets. Participants remained on all drugs according to their doctor's standard of care, and the prednisone was not be eliminated.
3283881|NCT00596934|Experimental|Metreleptin treatment group|Treatment group
3283882|NCT00596908||1|Subjects with Parkinsonian Tremor (PT)
3283883|NCT00596908||2|Subjects with non Parkinsonian Tremor (nPT)
3283884|NCT00596895|Experimental|1|Isoflavone treatment
3283885|NCT00596882|Other|1|Threat only message. Participants hear information about the negative health consequences of smoking
3283886|NCT00596882|Other|2|Genetic threat + threat. Participants will bear infomration about genetic influences of smoking in additon to the negative health consequences of smoking.
3283887|NCT00596856|Active Comparator|1|25 randomly selected pediatric practices that have never participated in IMB will receive the newly developed risk assessment forms and guidelines through the mail with instructions on how to implement them in the practice. (Passive dissemination to non-participating practices)
3283888|NCT00596856|Experimental|2|25 randomly selected pediatric practices currently participating in IMB will receive the newly developed risk assessment forms and guidelines through the mail with instructions on how to implement them in the practice. (Passive dissemination to participating practices)
3283889|NCT00596856|Experimental|3|25 randomly selected pediatric practices currently participating in IMB will receive the newly developed risk assessment forms and guidelines through an intense in-office intervention. (Intense intervention with participating practices)
3283890|NCT00596843|Experimental|1|Motivational intervention
3283891|NCT00596843|Active Comparator|2|Educational intervention
3283892|NCT00596830|Experimental|A|Patients in Arm A will receive CP-751, 871 in combination with paclitaxel and carboplatin intravenously every 21 days for up to six cycles.`
3283893|NCT00596830|Active Comparator|B|Patient in Arm B will receive paclitaxel and carboplatin intravenously every 21 days for up to six cycles.
3283894|NCT00596817|Placebo Comparator|Placebo|
3283895|NCT00596817|Experimental|Vortioxetine: 5 or 10 mg|
3283896|NCT00596791|Other|1 arm|Open-lable study with one arm.
3283897|NCT00596778|Other|C, CP|Thirty-one adults were randomly assigned to control (C) and chest physiotherapy (CP) groups. Chest physiotherapy group received treatment at the post-anesthesia unit care and control group did not.
3283943|NCT00596427|Placebo Comparator|Placebo tablet 3 tablets 2x/day|Type-2 diabetes mellitus patients
3283944|NCT00596427|Experimental|Colesevelam HCL 625 mg: 3 tablets 2x/day|Type-2 diabetes mellitus patients
3283945|NCT00596414|Placebo Comparator|1|
3283946|NCT00596414|Experimental|2|midazolam
3283947|NCT00596414|Experimental|3|midazolam + pethidine
3283898|NCT00596765|Experimental|1|Neuropsychological cognitive behavioral psychotherapy for patients with acquired brain injury consists of 25 weekly 1-hr sessions of individualized outpatient treatment. The therapeutical intervention is modularised, patients are assigned to specific interventional modules according to the results of cognitive testing and interviews. Modules concern on the one hand the treatment of deficits in attention, memory, and executive functions. On the other hand psychosocial adjustment to chronic illness is addressed through modules that concern the development of a positive self-concept, the adjustment of life-goals and coping with negative affect (e.g. depressive symptoms, irritability, guilt).
3283899|NCT00596765|Other|2|"Waiting list: Patients are randomly assigned to one of two existing groups after completion of the first session of various neuropsychological tests and interviews.~Patients assigned to the experimental group receive therapy immediately after completing the first session of various neuropsychological tests and interviews. Patients randomized to the waiting list receive the treatment as specified above after waiting for 5 month."
3283900|NCT00596752|Experimental|Alprostadil|Prostavasin® 40 μg will be infused intravenously twice daily over 2 hours in 50 to 150 ml isotonic sodium chloride solution during a Treatment Phase of 4 weeks.
3283901|NCT00596752|Placebo Comparator|Placebo|Placebo will be infused intravenously twice daily over 2 hours in 50 to 150 ml isotonic sodium chloride solution during a Treatment Phase of 4 weeks.
3283902|NCT00596713||1|Both genders aged 20 to 80 years and living in private households in the city of São Paulo. Pregnant or lactating women, people with physical or mental impairment and workers in night shifts are not part of the population of interest.
3283903|NCT00596700|Experimental|Device|"Patient preparation procedure will be done according to chapter 4 in the Given Diagnostic System user manual. In brief: to drink only clear liquids beginning 12:00 noon the day before.at least 8 hours (since 12:00 PM) fast prior to the procedure. Patient will undergo a standard capsule endoscopy. Patients will be allowed to drink clear liquids 2 hours post ingestion, and eat 4 hours post ingestion.~Eight hours post ingestion, data recorder will be removed and the patient will be dismissed.~A local experienced reader will review the RAPID video to determine the diagnosis blinded to the results of the standard workup procedures, and to each other results. Results will be recorded in the case report forms. A decoded video will be transferred to the principal investigator for reevaluation"
3283904|NCT00596687|Experimental|1|Glargine once daily plus glulisine given before meals plus supplemental glulisine for BG > 140
3283905|NCT00596687|Active Comparator|2|Sliding scale regular insulin four-times daily achs.
3283906|NCT00596674|Experimental|Lifestyle Counts Intervention|A wellness intervention that includes 8 weeks of behavior change classes focused on acquiring the skills and knowledge to improve health behaviors (e.g., exercise, stress management), followed by 3 months of phone support.
3283907|NCT00596674|Placebo Comparator|Attention Countrol|8 weeks of general health classes followed by phone calls for 3 months
3283908|NCT00596661|Experimental|TRIMAXX|TRIMAXX Coronary Stent
3283909|NCT00596648|Experimental|Phase 1 Arm|Escalating doses of XL184 + erlotinib
3283910|NCT00596648|Experimental|Phase 2 Arm 1|XL184 + erlotinib (dose determined from Phase 1 portion of study)
3283911|NCT00596648|Experimental|Phase 2 Arm 2|XL184 administered as a single agent
3283912|NCT00596635|No Intervention|Control Group|No cranberry capsules administered
3283913|NCT00596635|Active Comparator|One cranberry capsule|1 650mg cranberry capsule daily
3283914|NCT00596635|Active Comparator|Two cranberry capsules|1 650 mg cranberry capsule twice daily (bid)
3283915|NCT00596622|Experimental|Bipolar Manic Subjects Treated|Bipolar mania picture response during fMRI before and after treatment with lithium
3283916|NCT00596622|Experimental|Bipolar Depressed Subjects Treated|Bipolar depression picture response during fMRI before and after treatment with lithium
3283917|NCT00596622|Experimental|Bipolar Euthymic Subjects Treated|Bipolar euthymia picture response before and after treatment with lithium
3283918|NCT00596609||1|Group 1 will be subjects who receive Intrathecal Morphine.
3283919|NCT00596609||2|Group 2 will be subjects who do not receive Intrathecal Morphine.
3283920|NCT00596596|Active Comparator|1|0,5 mg prucalopride
3283921|NCT00596596|Active Comparator|2|1 mg prucalopride
3283922|NCT00596596|Active Comparator|3|2 mg prucalopride
3283923|NCT00596596|Placebo Comparator|5|Placebo arm
3283924|NCT00596596|Active Comparator|4|4 mg prucalopride
3283925|NCT00596583|Active Comparator|High Dose|
3283926|NCT00596583|Active Comparator|Low Dose|
3283927|NCT00596570||1|Patient with atrial fibrillation who underwent PCI
3283928|NCT00596557|Experimental|Everolimus, Immunosupression|everolimus and reduced dose CNI: reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
3283929|NCT00596544||1|FSFI score <= 26
3283930|NCT00596544||2|FSFI score >26
3283931|NCT00596531|Active Comparator|A|"Subjects will take acamprosate (Campral) at a dose of 666 mg. three times daily (morning, lunch time, bed time) for 28 days. Only responders will be included in the subsequent double-blind cross over arms after a minimum washout period of 4 weeks.~Subjects will randomly be assigned to Group 1 (A/B) or Group 2 (B/A) after completion of Phase I and its subsequent washout period (Figure 1, periods 1 and 2). Group 1 will receive acamprosate (Campral) at a dose of 666 mg. three times daily for 24 weeks followed by a 4-week washout period"
3283932|NCT00596531|Placebo Comparator|B|Group 2 will be assigned to the placebo group and take matched placebos for next 24 weeks followed by a 4-week washout period. After the washout period each group will be assigned to the other intervention (acamprosate or placebo) and complete another trial for 24 weeks.
3283933|NCT00596518|Experimental|PF-00734200|
3283934|NCT00596505||1|Group 1 will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
3283935|NCT00596505||2|Group 2 will not receive bevacizumab pretreatment
3283936|NCT00596492|Active Comparator|High Dose|
3283937|NCT00596492|Active Comparator|Low Dose|
3283938|NCT00596466|Experimental|1|
3283939|NCT00596453|Placebo Comparator|Placebo|
3283940|NCT00596453|Experimental|Ciprofloxacin hydrochloride|
3283941|NCT00596440||1|Relatives of Cancer Patients
3283942|NCT00596440||2|Relatives of Orthopedic Patients
3283948|NCT00596401||1|HP eradication group
3283951|NCT00596388||1|Subjects diagnosed as intermediate AMD
3283952|NCT00596375|No Intervention|Routine Care Group|The routine care group will help us to quantify the routine amount of distress associated with catheterization.
3283953|NCT00596375|Experimental|Lidocaine Group|A experimental group will include patients who will have 2% Lidocaine instilled into the urethra prior to catheterization. This group of subjects receiving routine care plus Lidocaine, will be evaluated during each of the four phases of the intervention.
3283954|NCT00596375|Experimental|Instillation|This group will undergo catheterization utilizing routine care plus lubricant jelly instilled into the urethra. This placebo group will aid in discerning the effects of instillation into the urethra on pain and associated distress.
3283955|NCT00596362|Experimental|1|AVASTIN
3283956|NCT00596349||A|epithelial ovarian cancer survivors (women disease-free at 5 to 10 years from diagnosis of ovarian cancer)
3283957|NCT00596349||B|women in second- or greater remission (women who have had one or more relapses from ovarian cancer but are considered to be currently clinically disease-free 5 to 10 years from original diagnosis of ovarian cancer).
3283958|NCT00596349||C|women surviving with epithelial ovarian cancer (women alive with disease 5 to 10 years from original diagnosis of ovarian cancer)
3283959|NCT00596336|Active Comparator|Group A CLL patients|Vaccination with current trispecific influenza vaccine Day 1
3283960|NCT00596336|Experimental|Group B CLL patients|Vaccination with current trispecific influenza vaccine Day 1, together with the application of Imiquimod cream to the vaccination site on day 2 to 6.
3283961|NCT00596336|Active Comparator|Group C volunteers|Vaccination with current trispecific influenza vaccine Day 1
3283962|NCT00596310|Experimental|1|Screening CT
3283963|NCT00596297|Experimental|A|Preoperative Intravitreal bevacizumab and pars plana vitrectomy
3283964|NCT00596297|Active Comparator|B|Pars plana vitrectomy only
3283965|NCT00596284|Experimental|CBT-AD|Participants will receive Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)
3283966|NCT00596284|Active Comparator|EUC|EUC will consist of regular ongoing care from healthcare providers and phone assessments at 1-month and 2-month. Following the 6 month assessment, participants in EUC will be offered a half-day Cognitive Behavior Workshop.
3283967|NCT00596271|Active Comparator|IC51 and Placebo|6 mcg i.m. IC51 with 2 injections (day 0 and 28)and placebo 0.5 mL with 1 injection (day 0)
3283968|NCT00596271|Active Comparator|HAVRIX and placebo|HAVRIX with 1 injection (day 0) and placebo 0.5 mL with 2 injections (day 0 and 28)
3283969|NCT00596271|Active Comparator|IC51 and HAVRIX|IC51 6 mcg i.m. with 2 injections (day 0 and 28) and HAVRIX with 1 injection (day 0)
3283970|NCT00596258|Experimental|A-007|Single arm open label
3283971|NCT00596245|Experimental|1|MT 400, naproxen sodium 550mg
3283972|NCT00596232||Asthma|People who have been diagnosed with Asthma
3283973|NCT00596232||Cystic Fibrosis|People who have been diagnosed with Cystic Fibrosis
3283974|NCT00596232||Healthy|People who are non-asthmatic, non smokers with less than 10 pack years and who do not have cystic fibrosis
3283975|NCT00596219|Experimental|1|
3283976|NCT00596206|Experimental|1|100 mg of leflunomide
3283977|NCT00596206|Active Comparator|2|20 mg of leflunomide
3283978|NCT00596193||Group I|patients with normal or irreversible pulpitis teeth with capsaicin administered at increasing volumes.
3283979|NCT00596193||Group II|Patients with normal teeth only with capsaicin added at a specific volume only
3283980|NCT00596180||1|HBOT
3283981|NCT00596167|Experimental|Intravenous antibiotics|Intervention: administer intravenous vancomycin, gentamicin and levofloxacin. This study will determine the pharmacokinetics of intravenous vancomycin, gentamicin and levofloxacin in subjects receiving short-daily hemodialysis. There will not be a control arm for this study. The intervention for this arm will be to administer intravenous vancomycin, gentamicin and levofloxacin and draw blood samples at periodic intervals. The blood samples will be tested for these medications and pharmacokinetic analysis will be performed.
3283982|NCT00596154|Experimental|1|Rituximab, methotrexate (MTX), procarbazine and vincristine (R-MPV). The peripheral blood stem cell (PBSC) harvest procedure will be performed at the discretion of the hematology attending (usually after the 1st or 2nd cycle of R-MPV)and high dose chemotherapy Busulfan, Thiotepa, and Cyclophosphamide.
3283983|NCT00596141|Experimental|1|Conventional postoperative care and instructions on dental hygiene will be provided along with the TOWE treatment which consists of the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site 3 times daily for a period of 7 days. At three (3) days and seven (7) days postoperatively, photographs will be taken of all vertical releasing incisions (before suture removal).
3283984|NCT00596141|No Intervention|2|Conventional postoperative care and instructions on dental hygiene.
3283985|NCT00596128|No Intervention|1|Blood sugar monitoring and intervention as clinical routine, no SOP defined and implemented
3283986|NCT00596128|Experimental|2|Blood sugar monitoring after implementation of SOP
3283987|NCT00596089||1|Men and women 60 years and older
3283988|NCT00596089||2|Men and women 20-30 years of age
3283989|NCT00596076|Experimental|1|Workers with low back pain
3283990|NCT00596063|Experimental|Wosulin R|Regular insulin for subcutaneous injection (recombinant human insulin), 600nmol, 100 IU
3283991|NCT00596063|Active Comparator|Novolin R|Regular insulin for injection (recombinant human insulin)
3283992|NCT00596050|Active Comparator|ketamine and midazolam|ketamine and midazolam
3283993|NCT00596050|Active Comparator|etomidate and fentanyl and lidocaine|etomidate and fentanyl and lidocaine
3283994|NCT00596037|Experimental|LB03002 throughout|administered LB03002 for preceding 26 weeks
3283995|NCT00596037|Experimental|Switched to LB03002|administered placebo for preceding 26 weeks
3283996|NCT00596024|Experimental|1|Daily Lutein/zeaxanthin supplementation with a meal
3283997|NCT00596024|Placebo Comparator|2|
3283998|NCT00596011|Active Comparator|Polyphenon E Treatment|Polyphenon E, 200 mg epigallocatechin gallate (EGCG) twice a day (BID)
3283999|NCT00596011|Placebo Comparator|Placebo Administration|Matching placebo BID
3284000|NCT00595998||1|newly onset CNV secondary to AMD
3284001|NCT00595998||2|Intermediate AMD
3284002|NCT00595985|Experimental|A|administer sorafenib 400mg bid until disease progression or intolerable toxicity or patients withdrawal of consent
3284003|NCT00595972|Experimental|A|patients will be treated by ECF regimen (epirubicin, cisplatin plus 5-FU) combined with endostar
3284004|NCT00595959|Experimental|Laser Treatment|CLiRpath Photoablation Atherectomy System
3284005|NCT00595946|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
3284006|NCT00595946|Experimental|Lubiprostone|24 mcg capsules twice daily (BID)
3284007|NCT00595933|Experimental|1|Each participant will receive an unidentified product to use for a one week period. This will continue until all 7 dry-mouth products have been evaluated.
3284008|NCT00595920|Experimental|Tovaxin, open-label|Tovaxin; 30-45 million autologous myelin reactive T cells
3284009|NCT00595894||1|CLEAR enrollees include African American patients with early rheumatoid arthritis, as defined using ACR criteria
3284010|NCT00595894||2|VARA enrollees will include male veterans with established RA diagnosed using ACR criteria
3284011|NCT00595881||Ultrasound|One group of patients will undergo emergency bedside ultrasound in addition to the clinical examination.
3284012|NCT00595868|Experimental|Varenicline|
3284013|NCT00595868|Placebo Comparator|Placebo|
3284014|NCT00595855|Active Comparator|TE|trabeculectomy
3284015|NCT00595855|Experimental|DS|deep sclerectomy
3284016|NCT00595842||Group one|Subjects are drawn from a search of all patients treated with MTA between ages 5-40
3284017|NCT00595829|Experimental|1|
3284018|NCT00595816|Experimental|1|Active treatment: physical training and counselling
3284019|NCT00595790|Active Comparator|IC51 2 x 6 mcg|2 x 6 mcg (microgram)
3284020|NCT00595790|Active Comparator|IC51 1 x 12 mcg|1 x 12 mcg (microgram)
3284021|NCT00595790|Active Comparator|IC51 1 x 6 mcg|1 x 6 mcg (microgram)
3284022|NCT00595777|No Intervention|1. Comparison|The centres allocated to the comparison group will continue to provide usual care only.
3284023|NCT00595777|Experimental|2. Experimental|The EPAT package consists of an educational programme, which deals with the common barriers to effective cancer pain control and the bedside pain tool.
3284024|NCT00595764|Active Comparator|1|Physician Management
3284025|NCT00595764|Experimental|2|Physician Management plus Cognitive Behavioral Therapy
3284026|NCT00595738||Heart Failure Patients|Patients admitted with advanced heart failure for tailoring of heart failure therapy via placement of a pulmonary artery (PA) catheter. In our study, the patients will already have a PA catheter placed for clinical/treatment reasons when we approach them for the study.
3284027|NCT00595725|Experimental|1|
3284028|NCT00595712|Active Comparator|A|Using Iliac crest allograft in high tibial osteotomy
3284029|NCT00595712|Active Comparator|B|Using iliac crest autograft in high tibial osteotomy
3284030|NCT00595699|Placebo Comparator|2|Double-blind
3284031|NCT00595699|Experimental|1|escitalopram group
3284032|NCT00595686|Experimental|Single Arm|
3284033|NCT00595660|Active Comparator|1|Needle 21 for FNA
3284034|NCT00595660|Active Comparator|2|22 needle for FNA
3284035|NCT00595660|Active Comparator|3|23 needle for FNA
3284036|NCT00595660|Active Comparator|4|24 needle for FNA
3284037|NCT00595647|Active Comparator|1|Percutaneous coronary intervention
3284038|NCT00595647|Placebo Comparator|2|Percutaneous coronary intervention
3284039|NCT00595621|Active Comparator|1|Experimental Pacemaker on for 6 weeks
3284040|NCT00595621|Active Comparator|2|Experimental Pacemaker on or off for 4 weeks
3284041|NCT00595608|Active Comparator|1|Nasal Sterimar spray
3284042|NCT00595608|Active Comparator|2|Nasal saline spray
3284043|NCT00595582|Other|single arm|Curcumin + Bioperine
3284044|NCT00595569||Type 1 diabetes|
3284045|NCT00595556|Experimental|A|Zonisamide
3284046|NCT00595556|Placebo Comparator|B|placebo
3284047|NCT00595543|Active Comparator|1|
3284048|NCT00595543|Active Comparator|2|
3284049|NCT00595543|Active Comparator|3|
3284050|NCT00595530|Experimental|Ketamine|This group will receive ketamine
3284051|NCT00595517|Experimental|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
3284052|NCT00595504|Experimental|1|Ramelteon 8mg/day
3284053|NCT00595504|Placebo Comparator|2|sugar pill
3284054|NCT00595491|Experimental|allergic asthmatic, allergic nonasthmatic, healthy|Adults who are allergic asthmatics, allergic nonasthmatics, or healthy controls will receive segmental allergen challenge to the lung
3284055|NCT00595478|Experimental|1|Motivational Enhancement Therapy (MET)/CBT+CM/BPT
3284056|NCT00595478|Active Comparator|2|Motivational Enhancement Therapy (MET)/CBT
3284057|NCT00595465|Active Comparator|IC51 Batch A|
3284058|NCT00595465|Active Comparator|IC51 Batch B|
3284059|NCT00595465|Active Comparator|IC51 Batch C|
3284060|NCT00595426|Experimental|1. YM150 Dose X, twice daily|
3284061|NCT00595426|Experimental|2. YM150 Dose Y, once daily|
3284062|NCT00595426|Experimental|3. YM150 Dose Y, twice daily|
3284063|NCT00595426|Experimental|4. YM150 Dose Z, once daily|
3284064|NCT00595426|Active Comparator|5. Warfarin|various doses
3284065|NCT00595413|Experimental|Atacicept 150 mg with loading dose|
3284066|NCT00595413|Experimental|Atacicept 150 mg without loading dose|
3284067|NCT00595413|Active Comparator|Adalimumab|
3284068|NCT00595413|Placebo Comparator|Placebo|
3284069|NCT00595387|Active Comparator|1|Participants receiving supportive psychotherapy
3284070|NCT00595387|Experimental|2|Participants receiving cognitive behavioral therapy
3284071|NCT00595361|Active Comparator|Arg/Arg|Arg/Arg subjects on 2 week salmeterol treatment
3284072|NCT00595361|Active Comparator|Gly/Gly|Gly/Gly subjects on 2 week salmeterol treatment
3284073|NCT00595335|Experimental|Rituximab|Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion.
3284074|NCT00595335|Placebo Comparator|Placebo|Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
3284075|NCT00595322|Experimental|1|bevacizumab and radiation (IMRT)
3284076|NCT00595309|Active Comparator|A|
3284077|NCT00595296||1|All eligible patients.
3284078|NCT00595283|Experimental|1|Participants assigned to Parent-Child Interaction Therapy-Emotional Development
3284079|NCT00595283|Active Comparator|2|Participants assigned to Developmental Education Parenting Intervention
3284080|NCT00595270|Other|IC51|In study IC51-305, subjects who had received IC51 in study IC51-304 were tested for seroconversion 6 months after the first vaccination. Subjects who had protective titers were again tested for persistence of immunity at 12 months after the first immunization,whereas subjects who had titers below the seroconversion threshold by Month 6 received a booster dose of 1x6 mcg IC51 at Month 11. Their immune response was also assessed at Month 12. Thereafter, subjects who had no protective titer by Month 12 received a booster dose of 1x6 mcg IC51 at Month 23, regardless of prior treatment; and neutralizing antibody titers were reassessed at Month 24. Subjects who had protective titers at month 12 did not receive a booster at Month 23, and their neutralizing antibody titer was also assessed at Month 24.
3284081|NCT00595257|Experimental|1|injection of BMAC into ischemic limb
3284082|NCT00595257|Active Comparator|2|Injection and Infusion of BMAC into ischemic lower limb
3284083|NCT00595231|Placebo Comparator|B|Placebo
3284084|NCT00595231|Active Comparator|SYN111|500 mg 1 week, followed by 1000 mg for 7 weeks
3284085|NCT00595218|No Intervention|1|Patients whose radiation oncologist are blinded to their patient preference survey results
3284086|NCT00595218|Active Comparator|2|Patients whose radiation oncologist are not blinded to their patient preference survey results
3284087|NCT00595205||Group IS|Subjects <1 year of age with definite intussusception cases who had received Rotarix™.
3284088|NCT00595166||B|Speculum Sheath group. Participants all received the speculum sheath.
3284089|NCT00595153|Active Comparator|B|Asthmatics not on inhaled corticosteroids who will be put on an inhaled steroid during the study
3284090|NCT00595153|No Intervention|A|Healthy, non-asthmatics who will not be put on any intervention
3284091|NCT00595153|Active Comparator|C|Asthmatics, who are already on inhaled corticosteroids who will be put on standardized dose of inhaled corticosteroids
3284092|NCT00595140|No Intervention|1|patients with acromegaly on stable pegvisomant therapy
3284093|NCT00595140|Active Comparator|2|Patients with acromegaly on stable pegvisomant therapy and additional application of octreotide 100µg
3284094|NCT00595140|Active Comparator|3|Patients with acromegaly on stable pegvisomant therapy and additional application of cabergoline 0.5mg orally
3284095|NCT00595127|Experimental|1|This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m^2 dose [intended specific activity of ~20 mCi/mg protein] preceded by administration of 50mg/1.73m^2 of unlabeled 8H9.
3284096|NCT00595114||MIA 1|Participants from the MIA trial who are polymerase chain reaction (PCR) negative and have received treatment with placebo
3284097|NCT00595114||MIA 2|Participants from the MIA trial who are PCR negative and have received treatment with the antibiotic clarithromycin
3284098|NCT00595114||MIA 3|Participants from the MIA trial who are PCR positive and have received treatment with placebo
3284099|NCT00595114||MIA 4|Participants from the MIA trial who are PCR positive and have received treatment with the antibiotic clarithromycin
3284100|NCT00595114||LEUKO 1|Participants from the LEUKO trial who have received treatment with placebo
3284101|NCT00595114||LEUKO 2|Participants from the LEUKO trial who have received treatment with zileuton
3284102|NCT00595101|Experimental|PF-03187207 High Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
3284103|NCT00595101|Experimental|Latanoprost 0.005% and PF-03187207 Vehicle|A single drop of each, once daily in study eye for 28 days
3284104|NCT00595101|Experimental|PF-03187207 Medium Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
3284105|NCT00595101|Experimental|PF-03187207 Low Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
3284106|NCT00595088|Experimental|20 mg of BC-819/PEI|Six intravesical instillations of 20 mg of plasmid DNA (BC-819) complexed with PEI into the bladder of patients with intermediate-risk superficial bladder cancer [recurrent stages Ta (low or high grade) and T1 (low grade) TCC] who have failed prior intravesical therapies including BCG and/or chemotherapy.
3284107|NCT00595075|Experimental|1|Ramelteon 8 mg will be given once prior to a 2-hour nap
3284108|NCT00595075|Placebo Comparator|2|Placebo will be given once prior to a 2-hour nap
3284109|NCT00595062|Experimental|1|
3284110|NCT00595049|Experimental|bosentan|
3284111|NCT00595023||1|All eligible subjects
3284112|NCT00595010|Experimental|Managing Child Behavior|Families with a high risk for or a history of child abuse and are enrolled in Comprehensive Home-Based Services and receive services as usual, which includes SafeCare, plus Managing Child Behavior module if they report significant behavior problems with their child between the ages of 2-12.
3284113|NCT00594997|Experimental|A|Students who receive an educational intervention which consists of a 45 minute interactive presentation as well as a 30 minute health education entertainment by a juggler.
3284114|NCT00594997|Active Comparator|B|Students who fill out pre and post surveys and receive the intervention after the post-survey
3284115|NCT00594984|Active Comparator|Arm 1 - Phase 1|"Cetuximab + Irinotecan + Brivanib~OR~Cetuximab + Irinotecan + Brivanib Placebo"
3284116|NCT00594984|Placebo Comparator|Arm 2 - Phase 2|"Cetuximab + Irinotecan + Brivanib~OR~Cetuximab + Irinotecan + Brivanib Placebo"
3284117|NCT00594971|Other|B|90 terminally ill cancer patients will be referred to a specialist palliative care team at time of discharge.
3284118|NCT00594971|Other|C|90 terminally ill cancer patients will be discharged from hospital with extra effort put into improving the communication between the hospital and the primary sector.
3284119|NCT00594971|No Intervention|A|90 terminally ill cancer patients will be discharged from hospital, receiving usual care.
3284120|NCT00594958|Active Comparator|IC51 Group A|IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
3284121|NCT00594958|Active Comparator|IC51 Group B|IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
3284122|NCT00594958|Active Comparator|IC51 Group C|IC51 (JE‐PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
3284123|NCT00594945|Experimental|Intranasal Clonazepam 2 mg|
3284124|NCT00594945|Experimental|Intranasal Clonazepam 3 mg|
3284125|NCT00594945|Experimental|Intranasal Clonazepam both Dose Groups 2 mg & 3 mg|
3284126|NCT00594932|Experimental|Arm I:|Participants randomly assigned to Arm I will receive mycophenolate mofetil in ascending doses during Month 1, and 3 grams/day (or less if there are tolerance issues) for Months 2 through 6.
3284127|NCT00594932|Placebo Comparator|Arm 2a|Patients Randomly Assigned to Arm 2 will enter Arm 2a for three months as a placebo comparator. The placebo treatment will be structured so that they will undergo the same type of dosing in Month 1 that the ascending dose patient from Arm 1 undergo, but will have placebo in both bottles of pills. At the end of three months, after assessment of primary outcome, these patients enter Arm 2b which is a treatment arm.
3284128|NCT00594932|Active Comparator|Arm 2b Open Lable Mycophenolate Mofetil|Arm 2b begins for patients in Arm 2 after three months. They will receive ascending doses of mycophenolate for the first month (which is Month 4 of the study). This will still be blinded since patients in Arm 1 will be undergoing an identical ascending dose regimen during this month, except that there will be active treatment in both bottles. At the end of Month 4 all patients will know that they are on full dose of 3 gms/day mycophenolate (or a lower dose if there are tolerance issues).
3284129|NCT00594919||AKI group|Acute kidney injury group after cardiac surgery.
3284130|NCT00594919||NKF group|Normal kidney function group after cardiac surgery
3284131|NCT00594906|Active Comparator|Injection|30 participants will receive teriparatide (Forteo) injection pens.
3284132|NCT00594906|Placebo Comparator|Placebo|30 participants will receive placebo injection pens.
3284133|NCT00594893|Active Comparator|1|Mini Incision Approach
3284134|NCT00594893|Active Comparator|2|2 Incision Approach
3284135|NCT00594880|Active Comparator|Pegasys 180 mcg/week|ART replacement treatment with Pegylated Interferon-alpha 2a, 180 mcg/week sc
3284136|NCT00594880|Active Comparator|Pegasys 90 mcg/week|ART replacement treatment with Pegylated Interferon-alpha 2a, 90 mcg/week sc
3284137|NCT00594867|Active Comparator|1|Acetaminophen - 4 grams per day + Placebo
3284138|NCT00594867|Active Comparator|2|Aspirin - 325 mg per day + Placebo
3284139|NCT00594867|Experimental|3|Acetaminophen 4 gram per day + Aspirin 325 mg per day
3284140|NCT00594854|Experimental|PN400|PN 400 (esomeprazole/naproxen) dosed twice daily
3284141|NCT00594854|Active Comparator|Diclofenac/Misoprostol|diclofenac 75mg/misoprostol 200 mcg dosed twice daily
3284142|NCT00594841|Active Comparator|1|Conservative (nonoperative) management of the AC joint dislocation.
3284143|NCT00594841|Experimental|2|Operative fixation (i.e., ORIF) of the dislocation with a hook plate and screws.
3284144|NCT00594828|Experimental|1|6 months of supervised patient self testing using an expert system
3284145|NCT00594828|Active Comparator|2|6 months of routine medical care by the anticoagulation management service
3284146|NCT00594815|Experimental|1|
3284147|NCT00594802||CHART REVIEW ONLY|CHART REVIEW OF PATIENTS WITH SYSTEMIC REACTIONS
3284148|NCT00594789|Experimental|1 (physician-only)|Physician(s) connected with a fracture that meets study inclusion criteria.
3284149|NCT00594789|Experimental|2 (physician/patient)|Physician(s) and patient connected with a fracture that meets study inclusion criteria.
3284150|NCT00594789|No Intervention|Control|Usual care.
3284151|NCT00594776||1|Patients who have received a structrual allograft or vascularized fibular autograft surgery to reconstruct their tibia, femur, ulna/radius or humerus for treatment of a bone tumor.
3284152|NCT00594763||TS|Women with Turner syndrome
3284153|NCT00594750||Asthma|People who have been diagnosed with Asthma
3284154|NCT00594724|Experimental|1|
3284155|NCT00594711||1|Case-group
3284156|NCT00594711||2|Control-group
3284157|NCT00594685||Isolated HIT|Hospitalized patients with isolated Heparin-Induced Thrombocytopenia (HIT), diagnosed by a fall in platelet count and a positive Platelet Factor 4 (PF4)-heparin Enzyme-Linked ImmunoSorbent Assay (ELISA) test
3284158|NCT00594659|Active Comparator|1|Therapist delivered cognitive behavioral treatment
3284159|NCT00594659|Experimental|2|Computerized Cognitive Behavioral treatment
3284160|NCT00594659|Active Comparator|3|Motivational enhancement therapy
3284161|NCT00594646|Other|Group 1|TRUVADA + raltegravir
3284162|NCT00594633|Experimental|1|donepezil and questionaires
3284163|NCT00594620|Experimental|1|Subjects receive supplement
3284164|NCT00594620|Placebo Comparator|2|Subjects will receive placebo
3284165|NCT00594607|Active Comparator|1: AN69ST|Hemodialysis sessions with use of the dialysis filter AN69ST.
3284166|NCT00594607|Active Comparator|2:Fx8|Hemodialysis sessions with use of the dialysis filter Fx8
3284167|NCT00594594|Experimental|1|Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
3284168|NCT00594581|Active Comparator|1|Juvista (avotermin) 50ng/100μl/linear cm wound margin
3284169|NCT00594581|Active Comparator|2|Juvista (avotermin) at 200ng/100μl/linear cm
3284170|NCT00594568|Placebo Comparator|Placebo|Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 milligrams (mg) orally once daily until Week 88.
3284171|NCT00594568|Experimental|100 mg LY450139|Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.
3284172|NCT00594568|Experimental|140 mg LY450139|Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.
3284173|NCT00594555|Experimental|Single Arm - treatment period|"Drug Name/Days Administered~Neupogen/Days 1-6~CLAG/Days 2-6~Gleevec/Days 2-15"
3284174|NCT00594542|Experimental|0.5% lidocaine group|Group that receives 0.5% lidocaine with 1:200,000 epinephrine
3284175|NCT00594542|Experimental|1.0% lidocaine group|Group that receives 1.0% lidocaine with 1:100,000 epinephrine
3284176|NCT00594529|Other|1|
3284330|NCT00593281|Experimental|2|SC Morphine with Hylenex
3284331|NCT00593281|Active Comparator|3|SC Morphine with Saline
3284177|NCT00594516|Experimental|001|tapentadol (CG5503) Immediate Release (IR) Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100 150 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second,tapentadol (CG5503) Immediate Release IR 21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period
3284178|NCT00594516|Experimental|002|tapentadol (CG5503) Extended Release (ER) During 2 double blind periods: Tapentadol ER 100 150 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second
3284179|NCT00594503|Experimental|Hyperbaric oxygen therapy-TBI|Low pressure hyperbaric oxygen therapy
3284180|NCT00594490||Silicone|patients undergoing placement of silicone breast prosthetics
3284181|NCT00594477|Experimental|IMRT|The prescribed dose for all patients will be 5040 cGy in 28 fractions. Patients will receive external beam treatment once a day, five days a week for approximately five and a half weeks.
3284182|NCT00594464|Experimental|1|Rotigotine
3284183|NCT00594451||I|multicenter Veteran Affairs Rheumatoid Arthritis (VARA) registry
3284184|NCT00594451||II|NIH-funded Consortium for the Longitudinal Evaluation of African Americans with Early RA (CLEAR)
3284185|NCT00594438|Experimental|1, A|Femoral reaming with the Synthes Reamer-Irrigator-Aspirator (RIA)
3284186|NCT00594438|Active Comparator|2 B|Femoral reaming with a Zimmer Sentinel Reamer.
3284187|NCT00594425|Experimental|1|PDT using MAL concentration A
3284188|NCT00594425|Experimental|2|PDT using MAL concentration B
3284189|NCT00594425|Placebo Comparator|3|PDT using Placebo cream
3284190|NCT00594399|Experimental|Arm 1 Physical Activity counseling|Physical activity (PA) counseling program with the following components: baseline in-person counseling session; telephone calls, one physician endorsement of PA in a primary care clinic visit, monthly automated telephone calls from the primary care provider encouraging PA; and quarterly mailed materials providing personalized feedback.
3284191|NCT00594399|No Intervention|Arm 2|Usual care from primary, womens or geriatric clinics
3284192|NCT00594386|Experimental|Rotigotine|
3284193|NCT00594373|Experimental|1|Application of 1% tenofovir gel for 14 consecutive days between menses
3284194|NCT00594373|Placebo Comparator|2|Application of 1% tenofovir placebo gel for 14 consecutive days between menses
3284195|NCT00594360|Active Comparator|1|
3284196|NCT00594347|Experimental|Group A|Pneumo 23
3284197|NCT00594347|Active Comparator|Group B|Prevnar
3284198|NCT00594334|Experimental|E, I|
3284199|NCT00594321|Active Comparator|2|Subjects randomized to the control arm of the study will have a standard vertebroplasty with any FDA-approved bone cement done in accordance with the usual method employed by the treating physician.
3284200|NCT00594321|Experimental|1|Subjects randomized to the experimental arm of the study will have a vertebroplasty with the SPACE CpsXL Bone cement (FDA-approved) and SPACE 360 Delivery System (FDA-approved).
3284201|NCT00594282|Experimental|1|Enhanced Mammography (EM) - Women who are randomized to the Enhanced Mammography (EM) condition will receive a mammogram in which a MammoPad radiolucent breast plate cushion is used.
3284202|NCT00594282|No Intervention|2|Routine Mammography (RM) - Women who are randomized to the Routine Mammography (RM) condition will obtain a routine, un-altered mammogram during which typical exam protocol will be followed and no radiolucent cushion is used.
3284203|NCT00594269|Placebo Comparator|A|Discontinuation of antipsychotic or antidepressants
3284204|NCT00594256|Experimental|Sodium oxybate|Active treatment
3284205|NCT00594243|Experimental|Intervention|8-week mindfulness based stress reduction program
3284206|NCT00594243|Active Comparator|Wait-list control|Wait-list received no intervention during the time the treatment group received the 8-week program
3284207|NCT00594230|Experimental|Panobinostat 20 mg|Treatment with LBH589 (Panobinostat) 20 mg
3284208|NCT00594230|Experimental|Panobinostat 30 mg|Treatment with LBH589 (Panobinostat) 30 mg
3284209|NCT00594217|Experimental|Progesterone|oral micronized progesterone suspension, single 100 mg oral dose
3284210|NCT00594217|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
3284211|NCT00594204|Active Comparator|varenicline|
3284212|NCT00594204|Placebo Comparator|placebo|
3284213|NCT00594191|Placebo Comparator|A|Placebo treatment
3284214|NCT00594191|Experimental|B|
3284215|NCT00594178|Experimental|A|Exercise group
3284216|NCT00594165|Experimental|Rotigotine|Rotigotine
3284217|NCT00594152|No Intervention|1Control|Standard treatment of type 1 diabetes mellitus with 3-4 subcutaneous injections of insulin daily
3284218|NCT00594152|Experimental|Treatment|Intervention: three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to standard subcutaneous insulin.
3284219|NCT00594139|Experimental|1|Receipt of autologous neo-bladder construct
3284220|NCT00594126|Other|1|3+3 cohort dose escalation
3284221|NCT00594113|Experimental|1|Multimedia Colorectal Cancer Screening
3284222|NCT00594100|Experimental|GFRS Pivotal Subjects|All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).
3284223|NCT00594087|Active Comparator|1|Lunesta 2 or 3 mg
3284224|NCT00594087|Placebo Comparator|2|Placebo 2mg or 3 mg
3284225|NCT00594074|Experimental|1|This group will receive 3.25 ounces of white wine with lunch and dinner
3284226|NCT00594074|No Intervention|2|This group receives the same amount of calories as the experimental group
3284227|NCT00594061|Experimental|A|There is no arm to this study--(each participant serves ashis or her own control). Blinding or masking procedures are not included in the design, as it is not possible to conceal the presence or absence of a cochlear implant from device recipients and/or clinical investigators.
3284228|NCT00594048|Experimental|1|15 hypertensive patients use the Resperate for 9 weeks and measure their blood pressure before and after using this device
3284229|NCT00594048|Active Comparator|2|15 patients use a discman with freely chosen music for 9 weeks and measure their blood pressure before and after use of this device
3284230|NCT00594035|Experimental|1|Spinal Sealant
3284231|NCT00594035|Active Comparator|2|Standard of care
3284232|NCT00594022|Active Comparator|"Group 1- VirtuSom - Stim"|Normal sleepers (7.5 - 9.0 hours), MSLT (multiple sleep latency test) >=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with active device (electric stimulation of the Vestibular nerve).
3284233|NCT00594022|Placebo Comparator|"Group 2- VirtuSom- Sham"|Normal sleepers (7.5 - 9.0 hours), MSLT >=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with placebo / sham device (NO electric stimulation of the Vestibular nerve).
3284234|NCT00594009|Experimental|1|All patients enrolled in the trial will receive the proposed intervention
3284235|NCT00593996|Placebo Comparator|1|oral placebo 3 times weekly
3284236|NCT00593983|Experimental|1|
3284237|NCT00593983|Placebo Comparator|2|Control
3284238|NCT00593970||1|All women presenting to our prenatal clinic and postpartum floor during the study period.
3284239|NCT00593957|Experimental|DM1( 0.25 mg/kg /day)|Dextromethorphan 0.25 mg/kg per day
3284240|NCT00593957|Experimental|DM2 (2.5 mg/kg/day)|Dextromethorphan 2.5 mg/kg/day
3284241|NCT00593957|Experimental|DM3 (5mg/kg/day)|Dextromethorphan 5mg/kg/day
3284242|NCT00593944|Experimental|1|Patients will receive active MDX-1342.
3284243|NCT00593931|Experimental|A|Normal Subjects
3284244|NCT00593918||Toll-like Receptor 4 -2026/GG Genotype|Toll-like Receptor 4 (TLR4) -2026/GG Genotype of interest hypothesized to be associated with less inflammation during Respiratory Syncytial virus (RSV) infection
3284245|NCT00593918||Toll-like Receptor 4 -2026/AG and AA Genotypes|Toll-like Receptor 4 (TLR4) -2026/AG and AA control genotypes hypothesized to be associated with more inflammation during respiratory syncytial virus (RSV) infection
3284246|NCT00593905||Group 1|"GROUP 1~Patients have to be currently enrolled or previously enrolled in STRIDE FPH01, FPH01-XC FPH02, FPH02x, FPH03, FPH04 or FPH06.~WHO Group 1 Pulmonary arterial Hypertension: Idiopathic, Familial, Associated with (APAH) Collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, Drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan, methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy) Associated with significant venous or capillary involvement, Pulmonary veno-occlusive disease, Pulmonary-capillary hemangiomatosis."
3284247|NCT00593905||Group 2|"Group 2~Patients currently receiving bosentan or ambrisentan OR who have previously received bosentan or ambrisentan for greater than 4 (four) months.~WHO Group 1 Pulmonary Arterial Hypertension: Idiopathic, Familial, Associated with (APAH), collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan, methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, or splenectomy), associated with significant venous or capillary involvement, pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis."
3284248|NCT00593892||Observation|All patients who are admitted to UAB for trauma, are 19 years of age and older, and whose Injury Severity Score (ISS) is greater than 9.
3284249|NCT00593879|Placebo Comparator|1|Placebo
3284250|NCT00593879|Experimental|2|
3284251|NCT00593866|Experimental|Radiation Dose Escalation with Gemcitabine|"INTENSITY MODULATED RADIOTHERAPY~Radiation dose escalation:~Total dose Dose per fraction BED* Dose equivalent (1.8 Gy/fraction) Level 1 45.0 1.8 53.1 45.0 Level 2 50.0 2.0 60.0 50.4 Level 3 52.5 2.1 63.5 54.0 Level 4 55.0 2.2 67.1 57.0 Level 5 57.5 2.3 70.7 60.0 Level 6 60.0 2.4 74.4 63.0 Level 7 62.5 2.5 78.1 66.2 Level 8 65.0 2.6 81.9 69.4~BED=Biological Effective Dose; =10 Five fractions weekly, fraction size determined by dose level~Gemcitabine:~1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment"
3284252|NCT00593853|Active Comparator|1|
3284253|NCT00593853|Placebo Comparator|2|
3284254|NCT00593840|Experimental|Intensity modulated radiation therapy (IMRT)|-This study provides guidelines for volume to be contoured during IMRT based on tumor site and stage of tumor site. The clinical tumor volume (CTV)1 will be treated to 66 Cy in 33 fractions or 60 Gy in 30 fractions. The CTV2 will be treated to 54 Gy in 33 fractions or 52 Gy in 30 fractions. The CTV3 will be modified based on tumor site and stage of tumor site in order to reduce volume.
3284255|NCT00593827|Active Comparator|Arm 1|ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest
3284256|NCT00593827|Active Comparator|Arm 2|ixabepilone 40 mg/m^2 every 3 weeks
3284257|NCT00593801|Active Comparator|2: late rhEPO|late EPO treatment from the fourth week for 6 weeks
3284258|NCT00593801|No Intervention|3: no EPO|control group, no EPO treatment
3284259|NCT00593801|Active Comparator|1: early rhEPO|early rhEPO treatment from the first week until 9 weeks
3284260|NCT00593788||1|Normal-hearing adults between 18 and 31 years of age.
3284261|NCT00593775|No Intervention|control|control group without intervention
3284262|NCT00593775|Active Comparator|AH group|assisted hatching performed on the embryo
3284263|NCT00593749|Active Comparator|HCS|Intervention group
3284264|NCT00593749|Placebo Comparator|Control|Control
3284265|NCT00593736|Experimental|Ramelteon 1 mg QD|
3284266|NCT00593736|Experimental|Ramelteon 4 mg QD|
3284267|NCT00593736|Experimental|Ramelteon 8 mg QD|
3284268|NCT00593736|Placebo Comparator|Placebo QD|
3284269|NCT00593723|Experimental|IMRT + Concurrent chemotherapy|"180 cGy daily fractions to a total dose of 5400 cGy to PTV1 and 200 cGy daily fractions to a total dose of 6000 cGy to PTV2. Once a day, five days a week, for approximately 6 weeks.~Planned chemotherapy: cisplatin (75 mg/m2) day 1 and 5-FU (1000 mg/m2) days 1-4 on weeks 1, 5, 10, and 14 of therapy. Please note that drug regimens and doses may vary and will be at the discretion of the medical oncologist."
3284270|NCT00593710|Experimental|1|Losartan
3284271|NCT00593710|Active Comparator|2|Atenolol
3284272|NCT00593697|Active Comparator|A|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) (HT x3 -> FE75C x3)
3284397|NCT00592670|Experimental|1|Baseline measures followed by a randomized 6 weeks treatment of Prozac.
3284273|NCT00593697|Active Comparator|B|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)
3284274|NCT00593684|Experimental|Algidex patch|Infants in this group received the Algidex patch on top of the line insertion sites of any of the following lines: umbilical arterial line, umbilical venous line, peripheral arterial line, peripheral long line, and central venous line. This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2. Every 7 days, each insertion site was cleansed and then a new patch was placed and covered with a fresh occlusive dressing (Tegaderm, Opsite).
3284275|NCT00593684|No Intervention|Control group|Infants in this group served as the control group and received line-dressing changes every 7 days according to standard hospital protocol specific for the type of line inserted. Insertion sites were covered with only an occlusive dressing (Tegaderm, Opsite).
3284276|NCT00593671|Active Comparator|PGS group|
3284277|NCT00593671|No Intervention|control group|
3284278|NCT00593658|Experimental|single|
3284279|NCT00593645|Experimental|Arm 1: Non-myeloablative conditioning regimen|"Clofarabine 40mg/m2/day IV over two hours daily x 5 days on Days -6 thru -2~Cytarabine 1gm/m2/day IV over two hours daily x 5 days on Days -6 thru -2 after the START of Clofarabine.~Thymoglobulin 1.0mg/kg IV over 6 hours X 1 day on Day -4, then 2.5mg/kg/day x 2 days on Days -3 and -2.~Stem Cell Transplant - On day 0 a minimum of total CD34+ cell dose of 2 x10E6/kg (actual weight of recipient) will be infused."
3284280|NCT00593632|Experimental|High Fiber Intake|Two 3/4 Cup servings of high fiber Uncle Sam cereal daily
3284281|NCT00593619|Active Comparator|Iron Dextran|
3284282|NCT00593619|Active Comparator|Iron Sucrose|
3284283|NCT00593606|Experimental|Rotigotine|Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.
3284284|NCT00593580|Active Comparator|1|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
3284285|NCT00593580|Placebo Comparator|2|
3284286|NCT00593567|Experimental|A|Daily topical gentamicin sponge and standard daily wound care
3284287|NCT00593567|Active Comparator|B|Daily oral levofloxacin 750 mg and standard daily wound care
3284288|NCT00593554|Active Comparator|1|Total body Irradiation; Thiotepa; Fludarabine; Rabbit ATG;
3284289|NCT00593554|Experimental|2|Palifermin; Total Body Irradiation; Thiotepa; Fludarabine; Rabbit ATG
3284290|NCT00593528|Active Comparator|A|Naked Stents
3284291|NCT00593528|Experimental|B|PTFE Covered Stents
3284292|NCT00593515|Experimental|1|Family CBT
3284293|NCT00593515|Active Comparator|2|Child-focused CBT
3284294|NCT00593502|Active Comparator|1|Oseltamivir
3284295|NCT00593502|Placebo Comparator|2|Placebo
3284296|NCT00593489|Experimental|Basal Insulin Initiation Strategy|
3284297|NCT00593489|No Intervention|Usual Practice|
3284298|NCT00593476|Active Comparator|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
3284299|NCT00593476|Active Comparator|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
3284300|NCT00593463|Experimental|1|Receives 2-4 of the interventions listed
3284301|NCT00593450|Active Comparator|1|Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.
3284302|NCT00593450|Experimental|2|Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.
3284303|NCT00593450|Experimental|3|Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.
3284304|NCT00593450|Experimental|4|Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.
3284305|NCT00593437||1|diagnosed with normal bone density by Norland Excel
3284306|NCT00593437||2|diagnosed with osteopenia by Norland Excel densitometer
3284307|NCT00593437||3|diagnosed with osteoporosis by Norland Excel densitometer
3284308|NCT00593424|Active Comparator|1|Low Fat/High Carbohydrate
3284309|NCT00593424|Active Comparator|2|High Monounsaturated Fat/Low Carbohydrate
3284310|NCT00593385|Other|iCAST covered stent|This is a one arm trial. All subjects received the iCAST covered stent.
3284311|NCT00593372|Experimental|I|Drug Plus Behavioral Therapy
3284312|NCT00593372|No Intervention|II|Drug Therapy Only
3284313|NCT00593359||A|Lactated Ringer's replacement for blood loss and placebo eye drops
3284314|NCT00593359||B|Lactated Ringer's replacement for blood loss and brimonidine eye drops
3284315|NCT00593359||C|Albumin replacement for blood loss and placebo eye drops;
3284316|NCT00593359||D|Albumin replacement for blood loss and brimonidine eye drops
3284317|NCT00593346|Experimental|Accelerated partial breast brachytherapy|Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
3284318|NCT00593333|Active Comparator|1, A|Standard femoral intramedullary nail that utilizes a piriformis fossa portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur.
3284319|NCT00593333|Experimental|2, B|Trigen Trochanteric Femoral Nail (Smith & Nephew, Memphis)using a trochanteric insertion portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur
3284320|NCT00593320|Active Comparator|1|Low-dose arm Single-fraction Stereotactic Radiosurgery (SRS) to 14 Gy
3284321|NCT00593320|Active Comparator|2|High-dose arm Single-fraction Stereotactic Radiosurgery (SRS) to 18Gy
3284322|NCT00593307|Experimental|Low GI|low GI breakfast
3284323|NCT00593307|Experimental|Low GI -low carb|Low GI and Low carb breakfast
3284324|NCT00593307|Experimental|High GI|High GI breakfast
3284325|NCT00593307|Experimental|High GI Low Carb|high GI low carb breakfast
3284326|NCT00593294|Experimental|A,1,I|
3284327|NCT00593294|Active Comparator|B, 2, II|
3284328|NCT00593294|Placebo Comparator|C,3,III|
3284329|NCT00593281|No Intervention|1|IV Morphine
3284332|NCT00593242|Experimental|infusions|infants who arrive at the study site within the first 14 postnatal days and had a history of moderate to severe hypoxic ischemic encephalopathy, and have cells available for infusion that pass Carolinas Cord Blood Bank Quality checks Outcomes will be measured at 22-26 months fby neurodevelopment assessment
3284333|NCT00593242|Other|historical control|Infants who had moderate to severe hypoxic ischemic encephalopathy in the neonatal period but did not receive autologous cord blood cells.
3284334|NCT00593229||3|Familial atypical HUS
3284335|NCT00593229||4|Thrombotic thrombocytopenic purpura (TTP)
3284336|NCT00593229||1|Severe diarrhea-associated hemolytic uremic syndrome (D+HUS)
3284337|NCT00593229||2|Non-familial atypical HUS
3284338|NCT00593216||Healthy|Healthy volunteers devoid of any ear problems
3284339|NCT00593216||Vertigo|Patients with the symptoms of vertigo
3284340|NCT00593190|Experimental|1|
3284341|NCT00593177|Experimental|Treatment Group 1|0.05% PTH (1-34) Gel
3284342|NCT00593177|Experimental|Treatment Group 2|0.10% PTH (1-34) Gel
3284343|NCT00593177|Placebo Comparator|Treatment Group 3|Placebo (Vehicle) Gel
3284344|NCT00593164|Experimental|1|Comatose post-resuscitation patients cooled with ThermoSuit and treated with intravenous magnesium sulfate (30 mg per kg IV over 15 min).
3284345|NCT00593164|Active Comparator|2|Comatose post-resuscitation patients cooled with ThermoSuit and treated with intravenous normal saline.
3284346|NCT00593151|Experimental|A, C, 320 mcg|Bi-weekly subcutaneous doses of Locteron (controlled-release interferon alpha 2b) with oral ribavirin.
3284347|NCT00593151|Experimental|B, C, 640 mcg|Bi-weekly subcutaneous doses of Locteron (controlled-release interferon alpha 2b) with oral ribavirin.
3284348|NCT00593151|Active Comparator|A, B, C PEG|Weekly subcutaneous injections of 1.5 ug/kg PegIntron (12 kDalton pegylated interferon alpha 2b) with oral ribavirin.
3284349|NCT00593138|Experimental|1|
3284350|NCT00593125|Experimental|1|levetiracetam
3284351|NCT00593112|Experimental|OROS Methylphenidate|
3284352|NCT00593112|Other|Control|Healthy Volunteer Control group
3284353|NCT00593099|Experimental|1|Buproprion
3284354|NCT00593099|Placebo Comparator|2|Placebo
3284355|NCT00593086|Active Comparator|A|Standard of care pain management
3284356|NCT00593086|Experimental|B|SnoWorld Virtual Reality Game
3284357|NCT00593073|Experimental|1|Tailored Reminder Message
3284358|NCT00593073|Experimental|2|General Reminder Message
3284359|NCT00593047|Placebo Comparator|1|Statin + placebo
3284360|NCT00593047|Experimental|2|Statin + KB2115 dose 1
3284361|NCT00593047|Experimental|3|Statin + KB2115 dose 2
3284362|NCT00593047|Experimental|4|Statin + KB2115 dose 3
3284363|NCT00593034||1|"Participants in this study will be 12-21 year old patients who have been referred to the Adolescent Substance Abuse Program for evaluation of drug or alcohol use and are participating in the parent study, Medical Office Intervention for Adolescent Drug Abuse."
3284364|NCT00592995|Placebo Comparator|1|
3284365|NCT00592995|Active Comparator|2|
3284366|NCT00592943|Active Comparator|Armodafinil (100mg)|
3284367|NCT00592943|Active Comparator|Armodafinil (250 mg)|
3284368|NCT00592930|Experimental|1|olanzapine
3284369|NCT00592930|Placebo Comparator|2|matching placebo
3284370|NCT00592917|Active Comparator|Ia|1718 subjects randomised for active calcium and vitamin-D -intervention, data collection with questionnaires at baseline and end of the study, data of falls and fractures in telephone-interviews annually except Ib (every four months)
3284371|NCT00592917|Active Comparator|Ib|random sample of 292 of 1718 (Ia), data collection by questionnaires mentioned in Ia, data of falls an fractures by telephone interviews every four months, bone density measurements, clinical tests, laboratory sample collections at baseline and end of follow-up as described in study design
3284372|NCT00592917|No Intervention|IIa|1714 subjects randomised to no intervention group, data collection with questionnaires at baseline and end of the study, data of falls and fractures in telephone-interviews annually except IIb (every four months)
3284373|NCT00592917|No Intervention|IIb|random sample of 314 of 1714 (IIa), data collection by questionnaires mentioned in IIa, data of falls an fractures by telephone interviews every four months, bone density measurements, clinical tests, laboratory sample collections at baseline and end of follow-up as described in study design
3284374|NCT00592904|Experimental|1|
3284375|NCT00592891|Experimental|Hyperbaric oxygen therapy|Patients undergoing low pressure HBOT for chronic brain injury
3284376|NCT00592852|Experimental|Fluoxetine|
3284377|NCT00592839|Experimental|1|0.3 mg SCE-B Daily
3284378|NCT00592839|Experimental|2|0.625 mg SCE-B Daily
3284379|NCT00592839|Placebo Comparator|3|Placebo
3284380|NCT00592813|Experimental|1|
3284381|NCT00592813|Placebo Comparator|cardiovascular education (attention control)|
3284382|NCT00592800||1|children between 11 and 13 years of age
3284383|NCT00592800||2|children between 14 to 15 years of age
3284384|NCT00592800||3|children between 16 and 18 years of age
3284385|NCT00592774|Placebo Comparator|Placebo Cohort 1|
3284386|NCT00592774|Experimental|Perampanel Cohort 1, 3-week Titration|
3284387|NCT00592774|Experimental|Placebo Cohort 2|
3284388|NCT00592774|Experimental|Perampanel Cohort 2, 1-week Titration|
3284389|NCT00592774|Experimental|Perampanel Cohort 2, 2- Week Titration|
3284390|NCT00592761|Experimental|Within subjects treatment, no-treatment|Within subject, treatment and no-treatment periods. Each participant served as his/her own control in this AABB/BBAA alternating treatment conditions design. Results were also compared across groups (treatment v. no-treatment).
3284391|NCT00592748|Active Comparator|Group 1|40-44 Treatments
3284392|NCT00592748|Active Comparator|Group 2|37-40 Treatments
3284393|NCT00592735||1|
3284394|NCT00592696||Observation|
3284395|NCT00592683|Active Comparator|Aripiprazole plus Fish Oil|Subjects administered aripiprazole and randomized to receive fish oil
3284396|NCT00592683|Placebo Comparator|Aripiprazole plus Placebo|Subjects administered aripiprazole and randomized to receive placebo
3284398|NCT00592670|Placebo Comparator|2|Baseline followed by a 6 week randomized treatment of placebo.
3284399|NCT00592657||1|Patients diagnosed with rhabdomyolysis and no history of jimsonweed ingestion
3284400|NCT00592657||2|Patients diagnosed with rhabdomyolysis and history of jimsonweed ingestion
3284401|NCT00592644|Experimental|1|Pulse Dye Laser
3284402|NCT00592644|Active Comparator|2|Traditional surgeries
3284403|NCT00592631|Experimental|CPAP|Subjects will use CPAP of 8-12 during days 2 through 6 of the study.
3284404|NCT00592631|Sham Comparator|SHAM|Subjects will use sham CPAP of 0-2 during days 2 through 6 of the study.
3284405|NCT00592592|Experimental|Proton Beam Radiation|Proton Beam Radiation
3284406|NCT00592579|Experimental|1|Open label, oral administration of 2ME2
3284407|NCT00592566|No Intervention|1|Standard supportive care
3284408|NCT00592566|Experimental|2|Dexamethasone treatment
3284409|NCT00592566|Experimental|3|Desmopressin treatment
3284410|NCT00592553|Active Comparator|PTC124 High Dose|PTC124 - 20-, 20-, 40-mg/kg dose level (high-dose PTC124) for 48 weeks.
3284411|NCT00592553|Active Comparator|PTC124 Low Dose|PTC124 - 10-, 10-, 20 mg/kg dose level (low-dose PTC124) for 48 weeks.
3284412|NCT00592553|Placebo Comparator|Placebo|Placebo PO TID for 48 weeks.
3284413|NCT00592540|Experimental|Unrelated Donor BMT|
3284414|NCT00592501|Experimental|Proton/Photon Radiotherapy, Cisplatin, Fluorouracil|
3284415|NCT00592488|Other|A|Placebo for first 6 hours then Acetyl-L-Carnitine (ALC) for 12 hours
3284416|NCT00592488|Other|B|Acetyl-L-Carnitine (ALC) for first 12 hours then placebo for next 6 hours
3284417|NCT00592475|Experimental|Regimen 1 Conivaptan 12.5 mg|Conivaptan intravenous loading dose (10 mg) + 2.5 mg continuous infusion over 6.5 hours
3284418|NCT00592475|Experimental|Regimen 2 Conivaptan 25 mg|Conivaptan intravenous loading dose (20 mg) + 5 mg continuous infusion over 6.5 hours
3284419|NCT00592475|Placebo Comparator|Regimen 3 Placebo|Placebo continuous intravenous infusion over 6.5 hours
3284420|NCT00592462||Whole Body MRI|
3284421|NCT00592449|No Intervention|1|Participants with knee OA who meet research diagnostic criteria for insomnia will partake in Phase 1
3284422|NCT00592449|No Intervention|2|Participants with knee OA who meet research diagnostic criteria for normal sleep will partake in Phase 1
3284423|NCT00592449|No Intervention|3|Participants without knee OA or a pain syndrome who meet research diagnostic criteria for primary insomnia will partake in Phase 1
3284424|NCT00592449|No Intervention|4|Participants without knee OA or a pain syndrome who meet research diagnostic criteria for normal sleep will enroll in Phase I
3284425|NCT00592449|Experimental|5|Phase 1 participants with knee OA who meet research diagnostic criteria for insomnia will enroll in Phase 2 of the study and are assigned to receive behavioral desensitization treatment for insomnia
3284426|NCT00592449|Experimental|6|Phase 1 participants with knee OA who meet research diagnostic criteria for insomnia will enroll in Phase 2 of the study and are assigned to receive cognitive behavior therapy for insomnia
3284427|NCT00592436||1|
3284428|NCT00592423|Other|1|"A convenience sample of children will be utilized for this study, which will include both genders and all ethnicities. There is no known predilection for any racial or gender inequalities with regard to subject recruitment or outcome variables related to this study."
3284429|NCT00592410|Experimental|1|
3284430|NCT00592397|Experimental|1|All participants underwent the same dietary intervention
3284431|NCT00592384|Placebo Comparator|placebo|identically encapsulated placebo pills 37.5 - 300 mg/day for 12 weeks
3284432|NCT00592384|Experimental|venlafaxine XR|venlafaxine XR 37.5 - 300 mg/day for 12 weeks
3284433|NCT00592358|Experimental|1|
3284434|NCT00592332|Experimental|2|Hyperinsulinemic glucose clamp with Xanax given orally at beginning of each 2 hour clamp on day 1.
3284435|NCT00592332|Experimental|1|Hyperinsulinemic glucose clamp in group with no drug.
3284436|NCT00592319|Experimental|PDL+Celebrex|endoscopic treatment with once-time PDL radiation at 6.0-8.0 J on laryngeal papilloma, followed by oral taking of 9-month Celebrex (100mg, BID), in 15 subjects
3284437|NCT00592319|Active Comparator|standard surgery|"once-time and routine surgery, with either of carbon dioxide (CO2) laser radiation at 10.0-20.0 W or cold surgery with microinstruments, in 15 subjects"
3284438|NCT00592306|Placebo Comparator|thymoglobulin (intraoperative)|we plan to blindly randomize these 25 lung transplant patients to intraoperative dosing of thymoglobulin followed by 3 additional postoperative doses (the first of these 3 postoperative doses will be placebo)
3284439|NCT00592306|Placebo Comparator|thymoglobulin (postoperative dosing)|We plan to blindly randomize these 25 lung transplant patients to 3 postoperative doses of thymoglobulin (the intraoperative dose will be placebo)
3284440|NCT00592293|Experimental|Proton Beam Radiation|Proton Beam Radiation
3284441|NCT00592280|Experimental|1|
3284442|NCT00592267||1|
3284443|NCT00592254||A|
3284444|NCT00592241|No Intervention|A|Subject is diagnosed as a diabetic, or subject is parent/guardian of a diabetic child age under 18 years.
3284445|NCT00592228|Other|1|Fractional flow guided drug-eluting stent implantation arm
3284446|NCT00592228|Other|2|Routine drug-eluting stent implantation
3284447|NCT00592215|Experimental|A|Mifepristone followed by labor induction with misoprostol after 6-8 hours
3284448|NCT00592202|Experimental|1|Adolescents between the ages 14 through 17 with a BMI of 40 or more or with a BMI of 35 or more and with an obesity related comorbidity will undergo placement of an adjustable gastric band
3284449|NCT00592189|Experimental|1|Amnion tissue and blood collection
3284450|NCT00592176|Experimental|Bevacizumab|Bevacizumab injection: 0.1ml, 6 monthly doses plus baseline and 1 week post baseline
3284451|NCT00592163|Experimental|Single Arm|
3284452|NCT00592150|Experimental|1|Fenoldopam infusion
3284453|NCT00592150|Placebo Comparator|2|Placebo infusion
3284454|NCT00592137|Placebo Comparator|C|During one three week session of a controlled diet subjects will receive a smoothie based on soy protein two times per day that does not contain any additional calcium
3284455|NCT00592137|Active Comparator|B|During one three week period half of the participants will receive two smoothies per day based on soy protein that contain 650 mg Ca as calcium carbonate
3284456|NCT00592137|Active Comparator|A|During one three week session subjects will receive two smoothies per day based on dairy protein containing 650 mg calcium
3284457|NCT00592124|Experimental|1|Oral tenofovir disoproxil fumarate (TDF) for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
3284458|NCT00592124|Experimental|2|Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
3284459|NCT00592124|Experimental|3|Oral TDF and vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and vaginal tenofovir gel application for Weeks 15 through 20
3284460|NCT00592124|Experimental|4|Oral TDF and vaginal tenofovir gel application for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF for Weeks 15 through 20
3284461|NCT00592124|Experimental|5|Oral TDF for Weeks 1 through 6, oral TDF and vaginal tenofovir gel application for Weeks 8 through 13, and vaginal tenofovir gel application for Weeks 15 through 20
3284462|NCT00592124|Experimental|6|Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF and vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF for Weeks 15 through 20
3284463|NCT00592111|Experimental|1|
3284464|NCT00592111|Experimental|2|
3284465|NCT00592111|Experimental|3|
3284466|NCT00592098|Experimental|1|2PX
3284467|NCT00592098|Placebo Comparator|2|Placebo
3284468|NCT00592085|Active Comparator|Relapse Prevention Counseling|Motivational Relapse Counseling: 6 counseling calls over two weeks accompanied by questionnaires
3284469|NCT00592085|Active Comparator|Relapse Prevention + Alcohol Counseling|Motivational Relapse Prevention Plus Alcohol Risk Reduction Counseling: 6 counseling calls over two weeks for both smoking cessation and at-risk alcohol use accompanied by questionnaires
3284470|NCT00592072|Experimental|Medium chain fatty acid (Octanoic and Decanoic acid)|
3284471|NCT00592072|Placebo Comparator|Splenda (Placebo Control)|
3284472|NCT00592046|Experimental|Single Arm|
3284473|NCT00592033|No Intervention|2|Rehabilitation, no supplemental oxygen
3284474|NCT00592033|Experimental|1|Rehabilitation plus supplemental oxygen
3284475|NCT00592020|Active Comparator|1|Short Transverse Incision
3284476|NCT00592020|Active Comparator|2|Hockey Stick Incision
3284477|NCT00592007|Experimental|A|Single-arm study
3284478|NCT00591981||Primary|All patients 70 years old and above scheduled for a thoracic oncologic surgery (typically esophageal or lung cancer) will be approached for entry into this study
3284479|NCT00591968|No Intervention|1|The control group will receive traditional ultrasound consults (i.e. travel to nearest tertiary center for intraabdominal sonographic evaluation and return with radiologist's report).
3284480|NCT00591968|Experimental|2|The experimental group will receive the teleultrasound service. Participants are randomly assigned to this group. All patients will receive a traditional clinical work-up. An ultrasound examination will be offered if, based on initial clinical evaluation by an attending physician, the patient is found to have symptoms consistent with any the following abnormalities: ascites, blunt abdominal trauma, cholelithiasis, cholecystitis, cholangitis, pancreatitis, hydronephrosis, abdominal aortic aneurysm, hepatitis, portal hypertension, urolithiasis, abnormal uterine bleeding, ovarian mass or torsion.
3284481|NCT00591942|Active Comparator|VivaGlass dental cement|36 subjects (TOTAL) received two crowns each and another group of 11 subjects received a three-unit fixed dental bridge. Cross over design. One dental crown cemented with VivaGlass Cement/subject. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
3284482|NCT00591942|Active Comparator|MultiLink dental cement|36 subjects (TOTAL) received two crowns each and another group of 11 subjects received a three-unit fixed dental bridge. Cross Over design. One dental crown per subject was cemented with Multilink Dental Cement. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
3284483|NCT00591929|No Intervention|1|No Continuous passive motion following ORIF of fractures around the knee
3284484|NCT00591929|Active Comparator|2|Continuous Passive Motion following ORIF of fractures around the knee
3284485|NCT00591916|Experimental|1|Microbial Nanocellulose (NC), an inert material produced by Acetobacter xylinum is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
3284486|NCT00591916|Experimental|2|fine mesh gauze impregnated with hyaluronan and thrombin (HT) is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
3284487|NCT00591916|Active Comparator|3|Scarlet Red is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
3284488|NCT00591890|Experimental|Single Arm|
3284489|NCT00591877|Active Comparator|AC|"Acupuncture:~The patients will receive acupuncture by a trained doctor with acupuncture expertise, at 3 points relevant to reflux symptoms. Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation."
3284490|NCT00591877|Sham Comparator|SAC|The patients randomized to this arm will receive acupuncture for a similar duration and number of sessions. The sham acupoints are at least 2 cm away from the actual acupoints to prevent acupressure effects
3284491|NCT00591877|Active Comparator|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
3284492|NCT00591851|No Intervention|1|single arm study
3284824|NCT00589173|Active Comparator|Control|"Patients receiving standard preventive care"
3284493|NCT00591838|Experimental|Phase I|"SBRT~Dose Level A 9Gy x 5~Dose Level B 10 Gy x 5~Dose Level C 11 Gy x 5~Dose Level D 12 Gy x 5)"
3284494|NCT00591838|Experimental|Phase II|Dose will be determined in Phase II portion of study
3284495|NCT00591825|Placebo Comparator|Non-Phobic Control - Placebo|Participants without phobia will be given one placebo administration.
3284496|NCT00591825|Active Comparator|Non-Phobic Control - DCS|Participants without phobia will be given one D-cycloserine (DCS) administration of 100mg.
3284497|NCT00591825|Placebo Comparator|Spider-phobic Placebo|Participants with phobia will be given one placebo administration.
3284498|NCT00591825|Experimental|Spider-phobic DCS|Participants with phobia will be given one D-cycloserine (DCS) administration of 100mg.
3284499|NCT00591812|Experimental|1 - ComPreSs system|
3284500|NCT00591799|Experimental|Jarvik 2000 Ventricular Assist System|Jarvik 2000 Ventricular Assist System
3284501|NCT00591786|Experimental|1|Sugammadex
3284502|NCT00591786|Placebo Comparator|2|Placebo
3284503|NCT00591773|Experimental|Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD|
3284504|NCT00591773|Experimental|Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD|
3284505|NCT00591773|Active Comparator|Chlorthalidone 25 mg QD|
3284506|NCT00591760|Experimental|GH|Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0.012 mg/kg every second day, added to their background optimized CHF therapy
3284507|NCT00591760|No Intervention|Placebo|PLacebo will be admistred with the same devices of GH, also on top of Optimal CHF treatment
3284508|NCT00591747|Experimental|1|Progressive resistance training program 3 times a week for 12 months
3284509|NCT00591747|Active Comparator|2|Flexibility training 3 times a week for 12 months
3284510|NCT00591734|Experimental|Intervention|All patients received bevacizumab 15 mg/kg, administered by intravenous (IV) infusion on day 1 of each 21 day course. In addition, patients received everolimus 10 mg orally on a daily basis.
3284511|NCT00591721|Experimental|Energy conservation education|Participants received 6-70 minute group teleconference sessions with an occupational therapist facilitator. The intervention provided education, guided discussion, and peer support for learning about and applying energy conservation principles
3284512|NCT00591721|Other|Wait list control|Participants received 6-70 minute group teleconference sessions with an occupational therapist facilitator. The intervention provided education, guided discussion, and peer support for learning about and applying energy conservation principles.
3284513|NCT00591708|Experimental|B|Supplementation of a higher level of calcium (500-1300 mg/d) via calcium fortified beverages (calcium citrate malate) to a basal diet of 600 mg/d for 21 consecutive days. All excreta will be collected.
3284514|NCT00591708|Experimental|A|Supplementation of a lower level of calcium (0-400 mg/d) via calcium fortified beverages (calcium citrate malate) to a basal diet of 600 mg/d for 21 consecutive days. All excreta will be collected.
3284515|NCT00591695|Active Comparator|A|positioning in emergency of a prosthetic metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
3284516|NCT00591695|Active Comparator|B|emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
3284517|NCT00591682|Experimental|1|MSX-122
3284518|NCT00591669|Experimental|1|IBD patients
3284519|NCT00591669|Other|2|Control subjects
3284520|NCT00591643|Experimental|Imaging, Adrenal acans & Radiation|
3284521|NCT00591630|Active Comparator|Zevalin + BEAM + Rituximab +Stem Cell Transplant + Rituximab|Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab
3284522|NCT00591630|Active Comparator|Zevalin + BEAM + Rituximab +Stem Cell Transplant|Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant
3284523|NCT00591630|Active Comparator|BEAM + Rituximab + Stem Cell Transplant + Rituximab|BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab
3284524|NCT00591630|Active Comparator|BEAM + Rituximab + Stem Cell Transplant|BEAM + Rituximab Followed by Stem Cell Transplant
3284525|NCT00591617|Active Comparator|1: MM|Medical Management: group receives medical management from study physician and Suboxone pharmacotherapy
3284526|NCT00591617|Active Comparator|2: CBT|Cognitive Behavioral Therapy (CBT) group receives CBT, medical management and Suboxone pharmacotherapy
3284527|NCT00591617|Active Comparator|3: CM|Contingency Management (CM) group receives CM, medical management, and Suboxone pharmacotherapy
3284528|NCT00591617|Active Comparator|4: CBT + CM|Cognitive Behavioral Therapy (CBT) and Contingency Management (CM) group receives CBT, CM, medical management, and Suboxone pharmacotherapy
3284529|NCT00591604|Experimental|1|Vitamin D administration
3284530|NCT00591591|Experimental|OSA|Persons with suspected obstructive sleep apnea (OSA) undergoning overnight sleep evaluation
3284531|NCT00591591|No Intervention|Controls|Healthy controls
3284532|NCT00591578|Experimental|Azilsartan Medoxomil 40 mg QD|
3284533|NCT00591578|Experimental|Azilsartan Medoxomil 80 mg QD|
3284534|NCT00591578|Active Comparator|Valsartan 320 mg QD|
3284535|NCT00591565|Experimental|1|acamprosate tablets
3284536|NCT00591552|Active Comparator|Group A|Electrocautery used for dissection.
3284537|NCT00591552|Active Comparator|Group B|Harmonic Scalpel used for dissection
3284538|NCT00591539||Carotid Ultrasound|Carotid Ultrasound: Irradiated and non-irradiated sides of the neck in long-term survivors of pediatric cancers who received unilateral radiation therapy involving the carotid artery as part of their treatment
3284539|NCT00591526|No Intervention|A|"Patients aged ≤ 60 years and with initial WBC ≤ 10000/mm3 Induction treatment~a) ATRA and chemotherapy ATRA 45 mg/m2/d until hematological CR first intensive chemotherapy course : DNR 60 mg/m2/d during 3 days AraC 200 mg/m2/d during 7 days~2) Consolidation treatment~First consolidation course (=2nd chemotherapy course) DNR 60 mg/m2/d d1-3 (intravenous bolus injection) AraC 200 mg/m2/d d1-7 (continuous infusion)~Second consolidation course AraC 1g/m2/12h d1-4 (1 hour infusion) Daunorubicin 45 mg/m2/d d1-3 (intravenous bolus injection) 3) Maintenance treatment~Consists of the combination of continuous low dose chemotherapy and intermittent ATRA, during 2 years~Continuous low dose chemotherapy~Intermittent ATRA"
3284913|NCT00588367||1|Suspected pancreatic ductal adenocarcinoma.
3284540|NCT00591526|Experimental|B|Patients aged ≤ 60 years and with initial WBC ≤ 10000/mm3 (Group B) Same treatment as Group A but without AraC.
3284541|NCT00591526|No Intervention|C|"First consolidation course (=2nd chemotherapy course) DNR 60 mg/m2/d d1-3 (intravenous bolus injection) AraC 200 mg/m2/d d1-7 (continuous infusion)~Second consolidation course AraC 1g/m2/12h d1-4 (1 hour infusion) Daunorubicin 45 mg/m2/d d1-3 (intravenous bolus injection)~CNS prophylaxis : consists of 5 intrathecal (IT) injections of MTX 15mg and AraC 50 mg (12 mg/m2 maximum 15 mg, and 30mg/m2, maximum 50 mg, respectively, in children) + depomedrol IT. I~3) Maintenance treatment"
3284542|NCT00591526|No Intervention|D|"Patients aged >60 years and initial WBC ≤ 10000/mm3 Induction treatment~a) ATRA and chemotherapy ATRA 45 mg/m2/d until hematological CR first intensive chemotherapy course : DNR 60 mg/m2/d during 3 days (intravenous bolus injection) NO ARA C DURING THIS FIRST COURSE~2) Consolidation treatment~First consolidation course DNR 60 mg/m2/d d1-3 AraC 100 mg/m2/d d1-5 G-CSF~Second consolidation course DNR45 mg/m2/d d1-3 AraC 100 mg/m2/d d1-5 G-CSF~3) maintenance treatment: similar to other groups"
3284543|NCT00591513|Active Comparator|Acute burn wounds|Comparative grafting of acute burn wounds with autologous engineered skin and meshed, split-thickness autograft skin.
3284544|NCT00591513|Experimental|2|Reconstruction of burn scars.
3284545|NCT00591513|Active Comparator|3|Congenital, giant melanocytic nevus.
3284546|NCT00591500||Control|The control group comprises patients with a first primary melanoma diagnosed in a twelve-month period.
3284547|NCT00591500||Cases|Cases are patients diagnosed with a second or higher order primary in a six-year period.
3284548|NCT00591487|Active Comparator|I|Infiltration with 0.9% saline+1:1,000,000 epinephrine+0.06% Lidocaine
3284549|NCT00591487|Placebo Comparator|II|Infiltration with 0.9% saline+1:1,000,000 epinephrine
3284550|NCT00591474|Experimental|1|VRE positive patients
3284551|NCT00591474|Placebo Comparator|2|VRE positive patients
3284552|NCT00591461||1|Study participants must be older than 18 years of age who are having an endoscopy performed to evaluate symptoms of GERD such as heartburn, acid taste in the mouth, dysphagia, dyspepsia, or those who are having a screening/surveillance exam for BE.
3284553|NCT00591448|Experimental|Virtual Reality|Patients with burns participate in VR during occupational therapy (OT) or physical therapy (PT) sessions ranging from 2 to 9 min in length
3284554|NCT00591435||1|200 laparoscopic cholecystectomies will be included, consultant cases will be compared to resident cases
3284555|NCT00591435||2|200 laparoscopic pelviscopies will be included, consultant cases will be compared to resident cases
3284556|NCT00591435||3|200 transurethral resection of urinary bladder or prostate gland will be included, consultant cases will be compared to resident cases
3284557|NCT00591422|Experimental|Single Arm|
3284558|NCT00591409|Placebo Comparator|1|rocuronium + placebo
3284559|NCT00591409|Experimental|2|rocuronium + 0.5 mg/kg Org 25969
3284560|NCT00591409|Experimental|3|rocuronium + 1.0 mg/kg Org 25969
3284561|NCT00591409|Experimental|4|rocuronium + 2.0 mg/kg Org 25969
3284562|NCT00591409|Experimental|5|rocuronium + 4.0 mg/kg Org 25969
3284563|NCT00591409|Placebo Comparator|6|vecuronium + placebo
3284564|NCT00591409|Experimental|7|vecuronium + 0.5 mg/kg Org 25969
3284565|NCT00591409|Experimental|8|vecuronium + 1.0 mg/kg Org 25969
3284566|NCT00591409|Experimental|9|vecuronium + 2.0 mg/kg Org 25969
3284567|NCT00591409|Experimental|10|vecuronium + 4.0 mg/kg Org 25969
3284568|NCT00591396|Experimental|Single Arm|
3284569|NCT00591383|Experimental|Single Arm|Once Maximum Tolerated Dose (MTD) is determined an expanded cohort will be enrolled to evaluate efficacy.
3284570|NCT00591370|Experimental|1 - Temozolomide (TMZ)|
3284571|NCT00591357|Active Comparator|A|Loperamide
3284572|NCT00591357|Placebo Comparator|B|Placebo
3284573|NCT00591344|Active Comparator|Progressive resistance training|Subjects will perform between 60 and 90 minutes of progressive resistance training two times a week for two years at a local gym. These sessions will be supervised by a personal trainer two times a week for the first six months of training and then once a week for the remaining 18 months of training.
3284574|NCT00591344|Active Comparator|Modified Fitness Counts|Subjects will perform between 60 and 90 minutes of modified Fitness Counts two times a week for two years at a local gym. These sessions will be supervised by a personal trainer two times a week for the first six months of training and then once a week for the remaining 18 months of training.
3284575|NCT00591331|Experimental|1|NatrOVA Creme Rinse - 1%
3284576|NCT00591331|Experimental|2|NatrOVA Creme Rinse Vehicle Only
3284577|NCT00591331|Placebo Comparator|3|Blank patch
3284578|NCT00591318|Experimental|A|IV Ceftriaxone 2 grams/day
3284579|NCT00591318|Placebo Comparator|B|IV Placebo (Normal Saline)
3284580|NCT00591305|Experimental|PDL+DIM pill|once-time 585 nm pulsed dye laser (PDL) treatment on the lesions, immediately followed by 3-month oral taking diindolylmethane (DIM, at 1.2-1.75mg/kg/day), in 15 subjects
3284581|NCT00591305|Placebo Comparator|PDL+placebo pill|once-time PDL treatment on the lesions, then followed by 3-month oral taking DIM placebo, in other 15 subjects
3284582|NCT00591292|Experimental|Single Arm|
3284583|NCT00591279||A|Barium enema and colonoscopy at one and three years after entry.
3284584|NCT00591279||B|Barium enema and colonoscopy at three years only after entry.
3284585|NCT00591266|Experimental|Azilsartan Medoxomil 40 mg QD and Amlodipine 5 mg QD|
3284586|NCT00591266|Experimental|Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD|
3284587|NCT00591266|Active Comparator|Amlodipine 5 mg QD|
3284588|NCT00591253|Experimental|Azilsartan Medoxomil 40 mg QD|
3284589|NCT00591253|Experimental|Azilsartan Medoxomil 80 mg QD|
3284590|NCT00591253|Placebo Comparator|Placebo QD|
3284591|NCT00591240||Multiplex pathogen identification.|Urine samples of patients at risk for urinary tract infections were collected. Biosensor based assays were used to detect the most common uropathogens in these samples. Analytical validity of the biosensor assays was examined by comparing biosensor results to those obtained using standard clinical microbiology laboratory methods. No interventions were performed.
3284687|NCT00590460|Experimental|Single Arm Study: Stem Cell Transplant|CAMPATH-1H Anti-CD45 Fludarabine Stem Cell Infusion
3284592|NCT00591240||Antimicrobial susceptibility testing.|Urine samples of patients at risk of urinary tract infections were collected. Biosensor based antimicrobial susceptibility test, in concert with pathogen identification assay was directly performed on these samples. Analytical validity of the biosensor assays was examined by comparing biosensor results to those obtained using standard clinical microbiology laboratory methods. No interventions were performed.
3284593|NCT00591227|Active Comparator|1-aspart detemir|these subjects will be treated with insulin aspart every 2 hours if blood glucose is more than 200 mg/dl during their ER evaluation. If they are admitted to hospital then they will receive a weight-based dose of insulin detemir immediately prior to admission and then every 24 hours thereafter combined with mealtime doses of insulin aspart if they are eating.
3284594|NCT00591227|No Intervention|2 usual care|these subjects will receive no insulin per protocol during their ER stay or during a possible inpatient admission. The care for their diabetes will be solely determined by the physician(s) in the ER and by the physician(s) caring for them in the hospital if they are admitted. They may receive no therapy, oral agents or insulin per primary physician preference.
3284595|NCT00591214|Experimental|MP-424|
3284596|NCT00591201|Experimental|A|Infliximab
3284597|NCT00591201|Placebo Comparator|B|Placebo
3284598|NCT00591188|Experimental|1|All patients will receive capecitabine and interferon-alpha.
3284599|NCT00591175||1|Standard Care
3284600|NCT00591175||2|Standard Care with Hygienist Counseling
3284601|NCT00591175||3|Standard Care with Hygienist Counseling & Personalized Risk Communication
3284602|NCT00591162|Active Comparator|1|Compare bone density of severly burned children to normal non-burned population
3284603|NCT00591149|Experimental|1|"Patients will be treated with oxaliplatin 130 MG/M2 IV over 2 hours on day 1 and docetaxel 60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle. Cycles of treatment will be repeated every 3 weeks for a total of 4 cycles or until disease progression or intolerable toxicity.~Patients who were treated with 4 cycles of oxaliplatin and docetaxel and had a response or stable disease will be treated with cetuximab at 400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks, or until disease progression or intolerable toxicity."
3284604|NCT00591136|Experimental|Single Arm|
3284605|NCT00591123|Experimental|single arm|
3284606|NCT00591110|Active Comparator|1|Educational intervention communicating practical information about vision, eye conditions and eye care.
3284607|NCT00591110|Sham Comparator|2|
3284608|NCT00591097||pediatric|
3284609|NCT00591084|Experimental|ginsenoside-Rd 10mg|both a ginsenoside-Rd injection (10mg/1ml/each) and a specific dilution (10%, 1ml trimethylene glycol) were respectively diluted by a specific dilution (10%, 9 ml trimethylene glycol) and then mixed.
3284610|NCT00591084|Placebo Comparator|placebo|2 specific dilutions (10%, 1ml trimethylene glycol) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed.
3284611|NCT00591084|Experimental|ginsenoside-Rd 20mg|2 ginsenoside-Rd injections (10mg/1ml/each) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed
3284612|NCT00591071|Active Comparator|B|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
3284613|NCT00591071|Experimental|A|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
3284614|NCT00591058|Experimental|Cohort 1|0.04 mg/kg TM-601 dose per administration
3284615|NCT00591058|Experimental|Cohort 2|0.08 mg/kg TM-601 dose per administration
3284616|NCT00591058|Experimental|Cohort 3|0.16 mg/kg TM-601 dose per administration
3284617|NCT00591058|Experimental|Cohort 4|0.3 mg/kg TM-601 dose per administration
3284618|NCT00591058|Experimental|Cohort 5|0.6 mg/kg TM-601 dose per administration
3284619|NCT00591058|Experimental|Cohort 6|1.2 mg/kg TM-601 dose per administration
3284620|NCT00591045|Experimental|1|The patients will undergo neoadjuvant chemotherapy with mFOLFOX and then an operation and then individualized adjuvant chemotherapy.
3284621|NCT00591045|No Intervention|2|No neoadjuvant chemotherapy and surgery and then adjuvant chemotherapy.
3284622|NCT00591019|Active Comparator|modafinil|
3284623|NCT00591019|Placebo Comparator|Placebo|
3284624|NCT00591006|Experimental|Four Treatments Per Participant|This study has one arm due to a crossover design. All 17 subjects received 4 treatments: placebo then placebo, phenytoin then placebo, placebo then hydrocortisone, and phenytoin then hydrocortisone. Each treatment was randomly assigned and had a unique sequence out of 24 possible sequences.
3284625|NCT00590993||1 - MRSI / MRI|
3284626|NCT00590980||Observation|Patients with intracranial or extracranial vertebrobasilar occlusion or stenosis ≥ 50% presenting with vertebrobasilar distribution TIA or stroke.
3284627|NCT00590967|Experimental|Treatment Group 1|"Pelvic Lymph Nodes Only Positive on FDG PET.~IMRT External Beam radiation to the para-aortic region (45 Gy)~Pelvis intracavitary brachytherapy (6 HDR treatments)~Weekly cisplatin 40 mg/m^2"
3284628|NCT00590967|Experimental|Treatment Group 2|"Para-Aortic Lymph Nodes Positive on FDG PET~IMRT (50.4 Gy to para-aortic lymph node bed with a 10.8 Gy boost to nodes)~IMRT external beam pelvic radiation therapy as appropriate for stage~Intracavitary brachytherapy (6 HDR treatments)~Weekly cisplatin (40 mg/m^2)"
3284629|NCT00590954|Experimental|Treatment|Following a diagnosis of tumor recurrence or progression, all patients will receive perifosine monotherapy until toxicity, progression, or death.
3284630|NCT00590941|No Intervention|R-CHOP|Patients receiving R-CHOP via standard of care which consists of cyclophosphamide 750 mg/m2 IV day 1 of each 21 day cycle, doxorubicin 50 mg/m2 IV day 1 of each 21 day cycle, vincristine 1.4 mg/m2 IV day 1 of each 21 day cycle, prednisone 100 mg PO days 1-5 of each 21 day cycle, and rituximab 375 mg/m2 IV day 1 of each 21 day cycle.
3284631|NCT00590928|Active Comparator|1|patients with indication for stress ulcer prophylaxis and gastric pH < 4
3284632|NCT00590928|Active Comparator|2|patients with indication for stress ulcer prophylaxis and gastric pH < 4
3284633|NCT00590902|Experimental|1 - OSI-774|
3284634|NCT00590889|Other|St. Jude Medical (SJM) Conventional|St. Jude Medical (SJM) Standard Masters Series Mechanical Heart Valve with Conventional Cuff
3284635|NCT00590889|Other|St. Jude Medical (SJM) Silzone|St. Jude Medical (SJM) Masters Series Mechanical Heart Valve with Silzone Coating
3285378|NCT00584753|Active Comparator|2|Breast PET/CT scan
3284636|NCT00590876||1|T1DM patients with a history of severe hypoglycemia and/or hypoglycemia unawareness who have been selected based upon this history to undergo islet cell transplantation at the University of Minnesota.
3284637|NCT00590876||2|T1DM patients (C-peptide negative) who are matched for age, gender, and duration of diabetes, who also have a history of severe hypoglycemia and/or hypoglycemia unawareness meeting the criteria for islet cell transplantation. The hemoglobin A1c for each of these subjects will fall within 1% of the islet transplant recipient to whom they are matched.
3284638|NCT00590876||3|Nondiabetic subjects (fasting plasma glucose < 110 mg/dl) who are matched for age and gender to the islet transplant recipient to whom they are matched.
3284639|NCT00590863|Active Comparator|SSRI + placebo|Participants will take escitalopram plus placebo.
3284640|NCT00590863|Active Comparator|Escitalopram + Bupropion SR|Participants will take escitalopram + bupropion-SR.
3284641|NCT00590863|Active Comparator|Venlafaxine XR + Mirtazapine|Participants will take venlafaxine-XR + mirtazapine.
3284642|NCT00590850|No Intervention|1|Closed Treatment
3284643|NCT00590850|Active Comparator|2|Open Reduction and Internal Fixation (ORIF) with Plate and Screws
3284644|NCT00590850|Active Comparator|3|Pin Fixation
3284645|NCT00590837|Experimental|1|Patients will be treated by adding lomustine to chemotherapy
3284646|NCT00590837|No Intervention|2|Patients will be treated without adding lomustine to chemotherapy
3284647|NCT00590824|Experimental|A|Hu14.18-IL2 -->Resection-->Hu14.18-IL2
3284648|NCT00590824|Experimental|B|Resection -->Hu14.18-IL2-->Hu14.18-IL2
3284649|NCT00590811||adolescents|3rd year high school girls (14-16 years old)
3284650|NCT00590811||young adults|1st year university young females (18 - 20 years old)
3284651|NCT00590798|Experimental|1|Patients are asked to walk within 30 minutes after implantation of the Star- Close vascular closure system.
3284652|NCT00590785|Experimental|1|
3284653|NCT00590785|Experimental|2|
3284654|NCT00590772|Active Comparator|montelukast|montelukast 10 mg daily
3284655|NCT00590772|Placebo Comparator|Placebo|Placebo tablet
3284656|NCT00590759|Other|GORE TAG® Thoracic Endoprosthesis|
3284657|NCT00590720|Experimental|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
3284658|NCT00590720|Placebo Comparator|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
3284659|NCT00590707|Active Comparator|Deeper sedation|"Patients randomly assigned to this arm will receive enough sedative drugs to keep their level of awareness during the hip fracture repair, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), at an OAA/S score of 0. This is the deeper sedation arm."
3284660|NCT00590707|Active Comparator|Moderate sedation|"Patients randomly assigned to this arm will receive enough sedative drugs to keep their level of awareness during the hip fracture repair, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), at an OAA/S score of 4-5. This is the moderate sedation arm."
3284661|NCT00590694|Active Comparator|Group1|Will receive ranibizumab treatments until resolution of macular edema only and as macular edema recurs.
3284662|NCT00590694|Active Comparator|Group 2|Will receive ranibizumab treatments until resolution of both macular edema and PED, and as macular edema or PED recur.
3284663|NCT00590681|Experimental|one|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
3284664|NCT00590655|Active Comparator|2|Treatment B includes a four month weight loss programme (10 weeks on a VLED and 17 weeks behavior modification visits). Treatment lasts 17 weeks and after that there will be one and two year control visits including weighing and questionnaires for eating behavior and quality of life.
3284665|NCT00590655|Experimental|1|Treatment includes a four month weight loss programme (10 weeks on a VLED and 17 weeks behavior modification visits). After that a maintenance programme starts with monthly sessions for one year. Weight loss, quality of life, and eating behavior will be assessed at the end of the maintenance program and one year later.
3284666|NCT00590642||1|
3284667|NCT00590616||1|
3284668|NCT00590603|Experimental|1|Dose escalation study with two cohorts. A standard dose of Arsenic Trioxide will be given with escalating dose of Bortezomib.
3284669|NCT00590590|Placebo Comparator|3 (Placebo)|
3284670|NCT00590590|Experimental|1 (Lidocaine)|
3284671|NCT00590590|Experimental|2 (Lidocaine/Diphenhydramine)|
3284672|NCT00590577|Experimental|001|Paliperidone palmitate 25 mg eq. Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8 36 64
3284673|NCT00590577|Experimental|002|Paliperidone palmitate 100 mg eq. Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8 36 64
3284674|NCT00590577|Experimental|003|Paliperidone palmitate 150 mg eq. Paliperidone palmitate 150 mg eq. i.m. Days 1 8 36 64
3284675|NCT00590577|Placebo Comparator|004|Placebo Placebo i.m. Days 1 8 36 64
3284676|NCT00590564|Experimental|1|All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal.
3284677|NCT00590551|Experimental|1-6|
3284678|NCT00590538|Active Comparator|Phenylbutyrate|"The standard oral adult dose is 20 g/day for 4 days.~Every participant will receive Genistein during the NPD."
3284679|NCT00590538|Placebo Comparator|Placebo|The placebo is given to match the active comparator for 4 days. Every participant will receive Genistein.
3284680|NCT00590525||1|
3284681|NCT00590512|Active Comparator|High Sodium|High sodium
3284682|NCT00590512|Active Comparator|Low sodium|Low sodium
3284683|NCT00590499||agitation group|The Riker sedation-agitated scale (SAS) levels 5-7.
3284684|NCT00590499||non-agitation group|The Riker sedation-agitated scale (SAS) levels 1-4.
3284685|NCT00590473|Active Comparator|1|Unilateral Placement of Interstim IPG
3284686|NCT00590473|Active Comparator|2|Bilateral Placement of Interstim IPG
3284688|NCT00590447|Experimental|A|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients achieving a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 further courses of single agent rituximab on days 50, 72, 94 and 116.
3284689|NCT00590447|Experimental|B|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients who do not achieve a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 courses of R-CHOP on days 50, 72, 94 and 116.
3284690|NCT00590434||1|Patients older than 80 years presenting for average risk screening or surveillance colonoscopy
3284691|NCT00590434||2|Patients younger than 80 years presenting for average risk screening or surveillance colonoscopy
3284692|NCT00590421||1|145 individuals treated by irradiation in their childhood
3284693|NCT00590421||2|150 matched control subjects with no history of irradiation
3284694|NCT00590408|Active Comparator|1|
3284695|NCT00590408|Placebo Comparator|2|
3284696|NCT00590395|Experimental|1|20 patients with suspected acute cholecystitis and a positive HIDA will be included in the study. This is purposely a highly selective population which most likely will have surgical proof of the findings. Subjects will receive an FDG PET/CT exam to determine the presence of gallbladder inflammation/infection(cholecystitis). Please note that 18FDG is an FDA approved radiopharmaceutical.
3284697|NCT00590369|Active Comparator|1|KCI VAC type negative pressure wound therapy device
3284698|NCT00590369|Experimental|2|Versatile One (EZCare) negative wound therapy device
3284699|NCT00590356|Active Comparator|A2|AngioSeal®
3284700|NCT00590356|Experimental|A1|StarClose®
3284701|NCT00590343|Experimental|1|Intervention=Patients will receive treatment with PTK787/ZK222584 daily. A treatment cycle will be defined as a 28-day period. Subjects will continue on their present treatment regimen of receiving Sandostatin LAR 30mg IM every 4 weeks.
3284702|NCT00590317|Active Comparator|Prochlorperazine|Patients receiving Prochlorperazine 10mg IV
3284703|NCT00590317|Active Comparator|Ondansetron|Patient receiving Ondansetron 4mg IV
3284704|NCT00590304||EU, LV, MA, EL, DU|The population will consist of 120 English-speaking participants ages 4-17 years from four rural schools with physician-diagnosed asthma or symptoms of asthma in the previous 12 months. As of June 2008, an additional rural school has been added to the population criteria, making a total of five rural schools.
3284705|NCT00590291||Cases|premature CAD and MI, AVM
3284706|NCT00590291||Controls|No CAD, MI, AVM
3284707|NCT00590265|Experimental|1|
3284708|NCT00590265|Placebo Comparator|2|
3284709|NCT00590252||Scheduled for an MRI|Clinically Indicated Adults
3284710|NCT00590226|Experimental|detremir + aspart insulin|Detemir insulin once daily + aspart insulin before meals three times a day at an initial total dose of 0.5 units/kg/day, subcutaneously
3284711|NCT00590226|Active Comparator|NPH + regular insulin|NPH insulin once a day + regular insulin before breakfast and dinner at an initial total dose of 0.5 units/kg/day, subcutaneously
3284712|NCT00590187|Experimental|A|
3284713|NCT00590187|Experimental|B|
3284714|NCT00590187|Experimental|C|
3284715|NCT00590187|Experimental|Arm D|
3284716|NCT00590187|Experimental|Arm E|
3284717|NCT00590187|Experimental|Arm F|
3284718|NCT00590187|Experimental|Arm G|
3284719|NCT00590187|Experimental|Arm H|
3284720|NCT00590187|Experimental|Arm I|
3284721|NCT00590174|Experimental|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
3284722|NCT00590174|Active Comparator|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
3284723|NCT00590161|Experimental|1|Pentoxifylline (PTX) 400 mg by mouth (PO) three times daily (TID)
3284724|NCT00590161|Placebo Comparator|2|Placebo three times daily (TID)
3284725|NCT00590135|Experimental|AORTIC STENOSIS PATIENTS|Atorvastatin (Lipitor) 40mg by mouth daily is administered to patients with aortic stenosis
3284726|NCT00590122|Experimental|b|Parcopa at equivalent dosage to subjects surrent stable dose
3284727|NCT00590122|Active Comparator|a|carbidopa-levodopa at subjects current stable dose
3284728|NCT00590109||1|
3284729|NCT00590083|Experimental|Virus Specific Cytoxic T lymphocytes|Virus Specific Cytoxic T lymphocytes
3284730|NCT00590070|Active Comparator|1|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered.
3284731|NCT00590070|Active Comparator|2|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered.
3284732|NCT00590070|Placebo Comparator|3|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered
3284733|NCT00590044|Experimental|glargine (Lantus) + glulisine (Apidra)|Daily insulin glargine (Lantus) + glulisine (Apidra) before meals
3284734|NCT00590044|Active Comparator|Split-mixed NPH + Regular insulin|Split-mixed NPH + Regular insulin twice daily
3284735|NCT00590031|Experimental|1|External Beam Radiation Therapy, Cisplatin, Irinotecan
3284736|NCT00590018|Experimental|1|Subjects in this arm will receive a 5 day tapering course of hydrocortisone.
3284737|NCT00590018|Placebo Comparator|2|Subjects in this arm will receive 5 days of placebo.
3284738|NCT00590005||Children with severe asthma|This group consists of children with severe asthma as defined per ATS workshop criteria (published in 2000).
3284739|NCT00590005||Children with non-severe asthma|This group includes children with asthma who do not meet the ATS criteria for severe asthma as outlined in the 2000 workshop report.
3284740|NCT00589979|Experimental|Lidoderm (Lidocaine 5% Patch)|Lidoderm (lidocaine 5% patch) 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)
3284741|NCT00589979|Placebo Comparator|Placebo Patch|Placebo Patch 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)
3284742|NCT00589966|Experimental|Coping Skills Training|
3284743|NCT00589966|Active Comparator|Prostate Cancer Education|
3284744|NCT00589953|Placebo Comparator|EPO###|"All subjects will be identified as a such by the study identifier EPO### where EPO designates enrollment in this study and ### is a numeric identifier (e.g. 103)."
3284745|NCT00589953|Experimental|EPO ###|"All subjects will be identified as a such by the study identifier EPO### where EPO designates enrollment in this study and ### is a numeric identifier (e.g. 103)."
3284746|NCT00589927|Experimental|cilostazol|Cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
3284747|NCT00589927|Placebo Comparator|placebo|Control placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
3284748|NCT00589914|Active Comparator|RISPERDAL CONSTA|RISPERDAL CONSTA 25-50 mg eq every 2 weeks
3284749|NCT00589914|Experimental|R092670|Paliperidone Palmitate 50-150 mg eq every 4 wks
3284750|NCT00589901|Experimental|A|phase II trial of capecitabine and cyclophosphamide in the management of metastatic breast cancer
3284751|NCT00589888|Active Comparator|Intralipid 20%@ 20cc/hour|Intralipid 20% IV infusion at 20cc/hour
3284752|NCT00589888|Active Comparator|Intralipid 20% @ 40cc/hour|Intralipid 20% IV infusion at 40cc/hour
3284753|NCT00589888|Placebo Comparator|Normal Saline infusion @ 40cc/hour|Normal Saline continuous IV infusion at 40cc/hour for 8 hours
3284754|NCT00589888|Active Comparator|32-gram oral fat load|32-gram oral fat load once
3284755|NCT00589888|Active Comparator|64-gram oral fat load|64-gram oral fat load once
3284756|NCT00589875|Experimental|Single arm|This study is an extension of evaluation of the surgical resection arm, Arm B, from a phase Ib study in which dose escalation on arm B was completed.
3284757|NCT00589862|Experimental|1|
3284758|NCT00589849||1|
3284759|NCT00589836||Cardiac Pathologies|Patients with cardiomyopathy, ischemic heart disease, will have tissue Doppler echocardiograms performed
3284760|NCT00589823|Active Comparator|1|Immediate Release Morphine sulphate capsules taken at start of relevant BTCP episode. Each episode treated with either this medication OR the experimental comparator.
3284761|NCT00589823|Experimental|2|Nasalfent spray taken at start of relevant BTCP episode. Each episode to be treated with either this medication OR the active comparator (IRMS)
3284762|NCT00589810||Controls|Controls = Patients in Genebank that had BMS placed that did not go on to have ISR within 1 year of BMS placement and have not had prior ISR in any vessel ever. If testing is available, the Control status will be further verified by angiographic documentation of <50% luminal loss with the stent or negative stress test six or more months after stenting.
3284763|NCT00589810||Cases|Cases = Patients in Genebank that had BMS placed that went on to have ISR which is defined as PCI or CABG to the Target Vessel within 1 year of the BMS placement.
3284764|NCT00589797|Experimental|1|Implantation of the Activ-L Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
3284765|NCT00589797|Active Comparator|2|Implantation of either the ProDisc Total Disc Replacement or the Charité Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
3284766|NCT00589784|Experimental|Treatment|Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks, followed by a two-week rest period. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Imaging studies will be performed after every other cycle. Patients may continue on study as long as they are tolerating treatment and in the absence of disease progression.
3284767|NCT00589771|Experimental|A|"Capsule Saccharomyces boulardii 250 mg TDS for six weeks.~Ispahgula husk 1 Tsf daily after dinner for six weeks."
3284768|NCT00589771|Placebo Comparator|B|"Capsule Placebo TDS for six weeks.~Ispaghula husk 1 Tsf daily after dinner for six weeks"
3284769|NCT00589758||Acute Decompensated Heart Failure|"Admitted to Heart Failure ICU for acute decompensated heart failure. 2D and 3D echocardiography will be obtained at baseline, 24 -48 hours and 1-2 weeks post discharge.~Blood and urine will be collected for biomarker evaluation at each timepoint"
3284770|NCT00589745|Other|Subjects being evaluated for CF|Subjects will be referred from physicians who are clinically concerned about the possibility of Cystic Fibrosis. Nasal potential difference measurement will be obtained to potentially help aid in diagnosis.
3284771|NCT00589732|Experimental|Valsartan treatment gorup|Valsartan 160mg per day group
3284772|NCT00589732|No Intervention|No Valsartan treatment group|No valsartan treatment
3284773|NCT00589719||2000,3000,4000|Children at risk for asthma were identified using a cross-sectional asthma screening survey.
3284774|NCT00589706|Experimental|A|All patients receive the same treatment of MAb-425 +Iodine 125 in a total of three injections. The purpose of this protocol is to allow you to receive course(s) of 1251-MAB 425 until your brain tumor begins to grow, you develop side effects to the treatment, or your medical condition changes (ie: become affected with human immunodeficiency virus (HIV) or develop another cancer).
3284775|NCT00589693|Experimental|Doripenem|Doripenem from Days 1 to 7 and imipenem-cilastatin placebo from Days 1 to 10
3284776|NCT00589693|Active Comparator|Imipenem-Cilastatin|Imipenem-Cilastatin Days 1 to 10 and doripenem placebo from Days 1 to 7
3284777|NCT00589680||2|Patients treated for DKA under DKA protocol implemented by hospital
3284778|NCT00589680||1|To establish a baseline on how patients are being treating with DKA in general and without a standardized DKA protocol
3284779|NCT00589667|Experimental|Treatment|Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle.
3284780|NCT00589654||1|
3284781|NCT00589641|Experimental|CBT-RP + Enhanced TAU|CBT-RP augmenting relapse prevention intervention, in addition to enhanced treatment as usual, monthly check-ins, and monitoring
3284782|NCT00589641|Active Comparator|Enhanced TAU (Treatment as Usual)|Treatment as usual in the community, monthly monitoring regarding service use and needs, monitoring
3284783|NCT00589628|Active Comparator|1|5mg/kg/dose of infliximab IV every 4 weeks for 9 doses
3284784|NCT00589628|Active Comparator|2|10mg/kg/dose of infliximab IV every 4 weeks for 9 doses.
3284785|NCT00589615|Active Comparator|1|The multidisciplinary osteoporosis prevention study started with a five-day program at a rehabilitation centre and will be followed by one-day group appointments twice.
3284786|NCT00589615|No Intervention|2|The control group will get information about osteoporosis through media and health care system.
3284787|NCT00589602|Experimental|T-Cell Depletion Transplant|"Our protocol is designed to attempt to improve the current results of matched unrelated donor (MUD) allo bone marrow transplant (BMT) and will be a major step towards the introduction and refinement of graft engineering. Our approach will address in a rational fashion all major technical and clinical aspects of MUD allo BMT.~Peripheral blood lymphocyte therapy; cyclophosphamide, tacrolimus, peripheral blood stem cell transplantation; total-body irradiation; 'allogeneic hematopoietic stem cell transplantation'"
3284788|NCT00589589|Active Comparator|A|
3284789|NCT00589563|Experimental|Fludarabine/Melphalan Conditioning|"Fludarabine/Melphalan Conditioning with~Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis"
3284790|NCT00589563|Experimental|FTBI/Cytoxan Conditioning|FTBI/Cytoxan Conditioning with Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis
3284791|NCT00589563|Experimental|FTBI/Etoposide Conditioning|"FTBI/Etoposide Conditioning with~Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis"
3284792|NCT00589550|Experimental|Peginterferon alfa-2b|Peginterferon alfa-2b will be administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
3284793|NCT00589498|Experimental|1|Subjects who are randomized to overfeed will visit with the General Clinical Research Center dieticians as often as necessary to gain 2 kg of fat (about 4 kg overall) over a period of 8 weeks.
3284794|NCT00589498|No Intervention|2|Subjects who are randomized to non-overfeeding will continue with their normal diet and activity levels for a period of 8 weeks.
3284795|NCT00589485||1|
3284796|NCT00589485||2|
3284797|NCT00589472|Experimental|Treatment (Antihormone therapy and enzyme inhibitor therapy)|Patients receive bicalutamide PO QD for 1 month and leuprolide acetate IM or goserelin acetate SC once a month until surgery. Patients also receive vorinostat PO QD beginning on the first day of androgen depletion therapy and continuing for up to 8 weeks or until the day of surgery. Patients then undergo an open or laparoscopic radical prostatectomy. Patients with positive surgical margins undergo immediate adjuvant external beam radiotherapy to the prostatic fossa, based on the judgment of the treating physician.
3284798|NCT00589459||1|non-diabetic women with acute coronary syndrome (ACS)
3284799|NCT00589459||2|non-diabetic men with acute coronary syndrome (ACS)
3284800|NCT00589446|Experimental|1|Embryoscopy will be evaluated in women with at least two previous miscarriages, after confirmation of missed abortion by ultrasound. Embryoscopy will only be performed in patients in whom curettage is clinically indicated, and will only be added to the D&C if there is a possibility of visualizing embryonic tissue, i:e. from approximately 5½ weeks onwards when there is an embryonic pole detected on ultrasound.
3284801|NCT00589433||1|
3284802|NCT00589394|Other|pneumococcal vaccination (Pneumovax)|"Intervention:~Patients receive one dose of the Pneumovax vaccine. The 23 pneumococcal serotypes are measured before and after vaccination in order to measure response in a healthy population."
3284803|NCT00589368||1|stroke group
3284804|NCT00589368||2|control group
3284805|NCT00589355||1|postmenopausal women with glucose intolerance (either pre-diabetes or diet-controlled diabetes)
3284806|NCT00589355||2|postmenopausal women with normal glucose tolerance
3284807|NCT00589329|Experimental|A|"roup A will be assigned to receive antibiotics:~Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days."
3284808|NCT00589329|Placebo Comparator|B|Group B will not receive antibiotics for pregnancy prolongation, but will receive a matching masked placebo (IV saline and pill) regimen.
3284809|NCT00589316|Experimental|Treatment (chemo, TBI, transplant, immunosuppression)|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 via central line on day -14.~NONMYELOABLATIVE CONDITIONING: Patients receive FLU IV over 30 minutes on days -6 to -2 and CY IV over 1 hour on days -6 and -5. Patients undergo TBI on day -1.~TRANSPLANTATION: Patients undergo allogeneic bone marrow transplantation on day 0.~POST-TRANSPLATATION IMMUNOSUPPRESSION: Patients receive CY IV over 1-2 hours on day 3, MMF IV or PO TID on days 4 to 35, and tacrolimus IV over 1-2 hours or PO on days 4 to 180 with taper on day 84."
3284810|NCT00589303|Active Comparator|Drug Therapy|FDA approved rate and rhythm control drugs
3284811|NCT00589303|Active Comparator|Atrioventricular Node (AVN) Ablation / Pacing|AV Node ablation and device implant
3284812|NCT00589290|Experimental|Belinostat Treatment|1000 mg/m^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
3284813|NCT00589277|Experimental|1|"Yale coaching counseling + Yale print information"
3284814|NCT00589277|Placebo Comparator|2|Standard care counseling + standard care print information
3284815|NCT00589264|Experimental|1|iron + copper + zinc
3284816|NCT00589264|Active Comparator|2|iron + copper only
3284817|NCT00589251|Other|penicillin skin test|Patients will have the skin test placed
3284818|NCT00589238|Other|Arm 1 (Standard Arm)|Arm 1 (Standard Arm) Preoperative (primary/ neoadjuvant) intravenous weekly paclitaxel 80 mg/m2 for 12 weeks followed by doxorubicin 60 mg/m2 in combination with cyclophosphamide 600 mg/m2 every 21 days for 4 cycles.
3284819|NCT00589238|Experimental|Arm 2 (Experimental Arm)|Arm 2 (Experimental Arm) Preoperative intravenous weekly paclitaxel 80 mg/m2 in combination with carboplatin AUC 2 on D1, D8 and D15 every 28 days for 4 cycles followed by doxorubicin 60 mg/m2 in combination with cyclophosphamide 600 mg/m2 every 21 days for 4 cycles.
3284820|NCT00589225||1|Genetic Analysis
3284821|NCT00589212|Experimental|1|Patients with 1-3 brain metastases
3284822|NCT00589199|Experimental|1|Procedure/Surgery: Surface electrodes will be applied to the abdominal wall and over the posterior lower thoracic rib cage.
3284823|NCT00589173|Experimental|Intervention|Patients referred to the IPHR
3284825|NCT00589147|Active Comparator|1|One study group will consist of patients treated with the modular cemented tibia.
3284826|NCT00589147|Active Comparator|2|Study arm will consist of patients that are treated with non-modular cemented tibia.
3284827|NCT00589147|Active Comparator|3|Study arm will consist of patients that are treated with non-modular uncemented tibia.
3284828|NCT00589134|Experimental|1|type of beverage
3284829|NCT00589121|Experimental|Cohort A - Chemotherapy|Radiation therapy with neoadjuvant or adjuvant or concurrent or interdigitated chemotherapy followed by surgery followed by, for patients with positive margins, radiation therapy boost
3284830|NCT00589121|Experimental|Cohort B - No Chemotherapy|Radiation therapy followed by surgery followed by, for patients with positive margins, radiation therapy boost
3284831|NCT00589108|Active Comparator|Mobile-Bearing Knee|Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
3284832|NCT00589108|Active Comparator|Modular-Metal-Backed Knee|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
3284833|NCT00589108|Active Comparator|All-Polyethylene Knee|Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray
3284834|NCT00589095||1|
3284835|NCT00589082|Active Comparator|1|standard 3+7
3284836|NCT00589082|Experimental|2|DNX 3+7
3284837|NCT00588991|Experimental|Treatment (veliparib, topotecan hydrochloride, carboplatin)|Patients receive veliparib orally twice daily on days 1-8, 1-14, or 1-21 and topotecan hydrochloride with or without carboplatin IV continuously over 120 hours on days 3-7. Treatment repeats every 28-63 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3284838|NCT00588978|Active Comparator|1|Diet alone
3284839|NCT00588978|Active Comparator|2|Exercise alone
3284840|NCT00588978|Active Comparator|3|Diet and exercise (combined)
3284841|NCT00588965|Placebo Comparator|1|Subjects are assigned to placebo.
3284842|NCT00588965|Active Comparator|2|Subjects will take propranolol LA 80 mg daily for one week then 160 mg for one week followed by the exercise test.
3284843|NCT00588952|Experimental|Family History Positive|Subjects with a positive family history of alcoholism
3284844|NCT00588952|Experimental|Family History Negative|Subjects with a negative family history of alcoholism
3284845|NCT00588939||I|participants with symptoms of acid reflux disease (heartburn)
3284846|NCT00588926|Experimental|A|The patients get a period of sedation with remifentanil, before, during and after which, the changes in the electrical activity of the Basal Ganglia is recorded.
3284847|NCT00588900|Experimental|irinotecan + cediranib|"Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and oral cediranib once daily on days 1-21. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.~After completion of study therapy, patients are followed up every 3 months for up to 2 years from study entry."
3284848|NCT00588887||1|
3284849|NCT00588887||2|
3284850|NCT00588874||1|men 50 yrs of age or older
3284851|NCT00588861|Active Comparator|Answer® hip stem with Simplex Cement|Femoral stem replacement with Answer® hip stem & Simplex Bone Cement
3284852|NCT00588861|Active Comparator|Answer® hip stem with Palacos Cement|Femoral stem replacement with Answer® hip stem & Palacos Bone Cement
3284853|NCT00588848|Experimental|Autoadjusting CPAP (VPAP auto)|The intervention will be the use of an Autoadjusting CPAP unit that will be applied to the subject during the 8 hours overnight the first night after surgery (study night). During this time, they will undergo a full night attended polysomnogram in their hospital room.
3284854|NCT00588848|Active Comparator|CPAP arm (usual care)|The intervention will be the use of the subject's own CPAP machine and this will be applied to the subject during the 8 hours overnight the first after surgery (study night). During the study night, they will undergo full polysomnography in their hospital room.
3284855|NCT00588835|Experimental|A|Aprepitant 125mg oral on day 1 and 80mg on day 2 and 3 during CE treatment.
3284856|NCT00588835|Active Comparator|B|CE cycle with standard anti-emetic regimen.
3284857|NCT00588822|Experimental|Rituximab|"Subjects will receive rituximab administered at the standard dose and schedule as an initial cycle of therapy, followed by a re-evaluation at 6 months. If the neuropathy is stable or responding at 6 months, the subject will receive Cycle 2 of rituximab, followed by a re-evaluation at 12 months.~Rituximab will be given as a 375 mg/m^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22)."
3284858|NCT00588809|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
3284859|NCT00588796||Healthy Volunteers|Healthy Volunteers
3284860|NCT00588796||Burn patients|Patients who have sustained burn injury greater than or equal to 20% of total body surface area
3284861|NCT00588796||Trauma patients|Patients who have undergone trauma
3284862|NCT00588783||1|
3284863|NCT00588783||2|
3284864|NCT00588770|Active Comparator|Arm IA (docetaxel, cisplatin)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3284865|NCT00588770|Experimental|Arm IB (docetaxel, cisplatin, bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and docetaxel and cisplatin as in Arm IA.
3284866|NCT00588770|Active Comparator|Arm IIA (docetaxel, carboplatin)|Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3284867|NCT00588770|Experimental|Arm IIB (docetaxel, carboplatin, bevacizumab)|Patients receive bevacizumab as in Arm IB and docetaxel and carboplatin as in Arm IIA.
3284868|NCT00588770|Active Comparator|Arm IIIA (cisplatin, fluorouracil)|Patients receive cisplatin IV over 1-2 hours on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3284869|NCT00588770|Experimental|Arm IIIB (cisplatin, fluorouracil, bevacizumab)|Patients receive bevacizumab as in Arm IB and cisplatin and fluorouracil as in Arm IIIA.
3284912|NCT00588380|Experimental|GLP-1|All participants recieved GLP-1 intravenously at 0.75 pmol/kg/min for the first hour and then at 1.5 pmol/kg/min for the next hour
3284870|NCT00588770|Active Comparator|Arm IVA (carboplatin, fluorouracil)|Patients receive carboplatin IV over 30 minutes on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3284871|NCT00588770|Experimental|Arm IVB (carboplatin, fluorouracil, bevacizumab)|Patients receive bevacizumab as in Arm IB and carboplatin and fluorouracil as in Arm IVA.
3284872|NCT00588757|Active Comparator|1|Optease filter
3284873|NCT00588757|Active Comparator|2|Tulip filter
3284874|NCT00588731|Experimental|Cannabidiol|
3284875|NCT00588731|Placebo Comparator|Placebo|
3284876|NCT00588718||Cases|Infants who meet the entry criteria
3284877|NCT00588718||Controls|Banked blood samples from newborns who do not meet inclusion criteria for this study will be held at Stanford University Core Laboratory and will constitute controls. Proteomic and genomic profiles in blood samples of cases will be compared with blood samples of controls.
3284878|NCT00588705||focus group & questionaire|The group will discuss its views about how and when to talk about the risk of getting breast cancer. The focus group will be video recorded and the video recorded material will be later transcribed and carefully analyzed. In addition you will be asked to answer questions about yourself, such as education and marital status.
3284879|NCT00588692|Active Comparator|SphygmoCor Unblinded|The use of the sphygmocor values will determine medication adjustments to optimize HF treatment.
3284880|NCT00588692|Placebo Comparator|SphygmoCor Blinded|Sphygmocor values will be blinded to the investigator.
3284881|NCT00588679|Experimental|1|Patients taking part in this study will have one MRI and one MRSI scan acquired in succession during a single MR examination. For those patients who have undergone prostate biopsy it is recommended that this should be done at least eight weeks after the prostate biopsy and should take one hour to one hour and ten minutes total to complete.
3284882|NCT00588666|Experimental|Bevacizumab, Carboplatin, Gemcitabine|Patients will initially receive bevacizumab 10 mg/kg followed by a 2 week treatment-free interval. Treatment will then begin with combination therapy. Gemcitabine 1000 mg/m2 will be administered intravenously on day 1 and 8 and carboplatin AUC 4.5 on day 1 with treatment recycled every 21 days. Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of each 21-day cycle. Restaging evaluations will be performed after every 3 cycles of treatment (approximately 9 weeks). Patients will receive a total of 6 cycles of chemotherapy unless disease progression or unacceptable toxicity occurs. Patients who achieve stable disease, a partial response, or a complete response after completion of 6 cycles, will be eligible to continue bevacizumab at the same dose and schedule until disease progression for a maximum of 18 additional doses.
3284883|NCT00588653|Active Comparator|1|All patients were to undergo all 4 diagnostic modalities, and each of these was compared to the consensus clinical diagnosis. Readers of each modality were blinded to the results of the other 3.
3284884|NCT00588640|Experimental|Phase I, Group|This is an open label dose-ranging trial. The first cohort of 8 patients will receive 40mg of d-methadone every 12 hours.
3284885|NCT00588640|Experimental|Phase II, Group I|patients receiving around the clock opioid therapy-No patients were accrued to this group
3284886|NCT00588640|Experimental|Phase II, Group II|patients not receiving around the clock opioid therapy.No patients were accrued to this group
3284887|NCT00588627||1|Post Nasal Drip and chronic cough
3284888|NCT00588627||2|Post nasal drip and no cough
3284889|NCT00588588|Active Comparator|1|Bronchoscopy
3284890|NCT00588588|Active Comparator|2|CPIS
3284891|NCT00588562||Primary Hyperoxaluria patients|Registry will include data on patients with confirmed diagnosis of Primary Hyperoxaluria.
3284892|NCT00588562||Dent Disease Patients|Registry will include data on patients with confirmed diagnosis of Dent Disease.
3284893|NCT00588562||Cystinuria Patients|Registry will include data on patients with confirmed diagnosis of Cystinuria.
3284894|NCT00588562||APRT deficiency Patients|Registry will include data on patients with confirmed diagnosis of APRT deficiency.
3284895|NCT00588536|Experimental|1|MTX, 6-TG, Leucovorin
3284896|NCT00588523|Experimental|1|temozolomide followed by high dose busulfan and thiotepa
3284897|NCT00588510||Blood draw|Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible.
3284898|NCT00588497||Study Group|Twenty-five subjects for this study will be recruited from patients who have requested a form of permanent sterilization, and who, after considering all the options, choose the trans-cervical hysteroscopic sterilization for this end. Any subject who is deemed suitable for the micro-insert hysteroscopic sterilization system (Essure micro-insert system, Conceptus Incorporated, Mountain View, California) placement will be offered the opportunity to participate in the study.
3284899|NCT00588484||1|Men, age 35 to 65, being seen at the Mayo Clinic Department of Cardiovascular Health clinic, or has an appointment for a carotid duplex ultrasound exam.
3284900|NCT00588484||2|Women, age 35 to 65, being seen at the Mayo Clinic Department of Cardiovascular Health clinic, or has an appointment for a carotid duplex ultrasound exam.
3284901|NCT00588471|Active Comparator|Simvastatin|Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
3284902|NCT00588471|Placebo Comparator|Placebo|Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
3284903|NCT00588458|Experimental|single arm|All patients with PSC in will have CT cholangiography.
3284904|NCT00588445|Experimental|Treatment|
3284905|NCT00588432||1|Hemiparesis as the result of an ischemic hemispheric stroke.
3284906|NCT00588432||2|Immobilization following severe Achilles tendon tear or rupture, ankle injury or plantar fascial pain.
3284907|NCT00588432||3|Myofascial trigger points in trapezius muscle.
3284908|NCT00588432||4|Hyperthyroid Myopathy
3284909|NCT00588419||1|Patients who have undergone mastectomy Patients who have undergone immediate, twostage expander/implant breast reconstruction; Patients who have undergone immediate, autogenous tissue flap reconstruction including: pedicled and/or free TRAM flap or DIEP flap reconstruction
3284910|NCT00588406|Experimental|B|Budesonide, 2mg, 4 doses, plus standard care
3284911|NCT00588406|Placebo Comparator|P|Placebo plus standard care
3284914|NCT00588367||2|Chronic pancreatitis and slated for decompression treatment.
3284915|NCT00588367||3|Autoimmune pancreatitis.
3284916|NCT00588354|Experimental|Clonidine|Transforaminal epidural clonidine injection
3284917|NCT00588354|Active Comparator|Steroid|Transforaminal epidural steroid injection
3284918|NCT00588341|Experimental|Treatment|
3284919|NCT00588328|Experimental|1|
3284920|NCT00588315||1|skin lesions
3284921|NCT00588315||2|normal skin
3284922|NCT00588302|Experimental|A, 1|All patients received an open-label moexipril during the study period.
3284923|NCT00588276|Experimental|1|Patients will receive 124IAZGP(124I-Iodo-Azomycin Galacto-Pyranoside).
3284924|NCT00588250|Experimental|A|
3284925|NCT00588250|No Intervention|B|
3284926|NCT00588237|Experimental|1|Paclitaxel, Cisplatin, Bevacizumab
3284927|NCT00588224||1|adults
3284928|NCT00588224||2|adolescents
3284929|NCT00588211||1|We will recruit fifteen New York University College of Dentistry (NYUCD) clinic patients who report current tobacco use.
3284930|NCT00588211||2|Second, we will recruit thirty dental clinic smokers (10 per day for 3 days) from the NYUCD waiting room.
3284931|NCT00588211||3|Third, we will survey 200 student participants from Adelphi University.
3284932|NCT00588211||4|Queens Hospital Center with 800 patients.
3284933|NCT00588198||1|Melanoma patients
3284934|NCT00588185|Experimental|1|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
3284935|NCT00588172|Sham Comparator|1|Individuals with no nsSNPs or mutations known to alter oct1 function
3284936|NCT00588172|Active Comparator|2|Individuals with nsSNPs or mutations known to alter oct1 function
3284937|NCT00588159|Experimental|Gabapentin preoperatively|Preoperative gabapentin 600 mg orally within 2 hours prior to surgery.
3284938|NCT00588159|Placebo Comparator|Active placebo|Diphenhydramine 12.5 mg orally 2 hours preoperatively.
3284939|NCT00588146|Experimental|Pegylated Interferon Alpha2b, then Standard Care|Weekly subcutaneous injection of pegylated interferon alpha2b 1 microgram/kg/week for 6 months, then standard care for 6 months.
3284940|NCT00588146|Experimental|Standard Care, then Pegylated Interferon Alpha2b|Standard care for 6 months, then weekly subcutaneous injection of pegylated interferon alpha2b 1 microgram/kg/week for 6 months.
3284941|NCT00588133|Experimental|1|New drug dosing schedule
3284942|NCT00588133|Active Comparator|2|Standard drug dosing schedule
3284943|NCT00588120|Experimental|C-13 labeled oxalate|Hyperoxaluric patients
3284944|NCT00588107|Experimental|Web site access|Web intervention- and access to pharmacotherapy
3284945|NCT00588107|Active Comparator|print materials|Receives tailored print materials and access to pharmacotherapy (Materials condition)
3284946|NCT00588094|Experimental|Treatment|R-ICEesc will be administered with the intent of administering 2 cycles, each 21 days apart admixed with 4 doses of rituximab. G-CSF will be administered at 960 ug or 10 ug/kg if patient is > 100 kg after cycles one and two for PBPC collection for the first 10 patients enrolled. G-CSF will be administered in standard dosing for cycle one and then at 960 ug or 10 ug/kg (if patient is > 100 kg) after cycle two for PBPC collection for the remaining 22 patients. All responding patients who make at least 2 x 106 CD34+ cells/kg will receive high dose therapy and ASCT on other protocols.
3284947|NCT00588081|Other|1|Participants will receive a cover letter, questionnaire and invitation to participate in a post-operative interview.
3284948|NCT00588068||1|Tumor and Marrow Markers
3284949|NCT00588042|Active Comparator|1|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
3284950|NCT00588042|Sham Comparator|2|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
3284951|NCT00588029||1|breast cancer patients
3284952|NCT00588029||2|control subjects without breast cancer
3284953|NCT00588016|Experimental|Itraconazole|Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
3284954|NCT00588003|Experimental|1|This is an exploratory study utilizing micro-array technology and immunohistochemistry to test the hypothesis that changes in gene expression occur as an early event in response to endocrine therapy and that these changes can be correlated with changes in surrogate biological markers.
3284955|NCT00588003|Placebo Comparator|2|no medication before surgery
3284956|NCT00587990|Experimental|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive lower dose mesenchymal stem cell injections for a total of 2 x 10^7 cells
3284957|NCT00587990|Experimental|Higher dose MSC injection|Participants will receive higher dose of mesenchymal stem cell injections for a total of 2 x 10^8 cells
3284958|NCT00587990|Placebo Comparator|(3) Placebo|Participants will receive placebo injections
3284959|NCT00587977||1|Aortic aneurysm repair
3284960|NCT00587977||2|Aortic aneurysm growth
3284961|NCT00587977||3|Aortic aneurysm growth stable.
3284962|NCT00587964|Experimental|Treatment|
3284963|NCT00587951||A|Candidates for epilepsy surgery, undergoing pre-surgical evaluation at Mayo Clinic, and in whom SISCOM was ordered by the treating physician as part of that evaluation
3284964|NCT00587938||A|BNP level from protocol blood tests initiated in the ED, reported to ED physician prior to ED disposition.
3284965|NCT00587938||B|BNP level from protocol blood tests initiated in the ED, NOT reported to ED physician prior to ED disposition.
3284966|NCT00587925|Experimental|1|Bone Mineral Density
3284967|NCT00587899|Other|1|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation.
3284968|NCT00587899|No Intervention|2|The control group of patients will undergo operation for mitral valve disease without the additional Pulmonary Vein Isolation
3284969|NCT00587886||Cases|Cases will be women with newly diagnosed endometrial or ovarian cancer who are residents of six counties in New Jersey.
3285114|NCT00586677|Active Comparator|RF|Relationship focused where the primary goals are to strengthen the relationship between the parent and the child and to give the parent additional skills that can be used to manage the behavior of the child.
3284970|NCT00587886||Controls|Controls will be selected from the general population in those counties by use of random digit dialing for those under 65 years of age, from Centers for Medicare and Medicaid Services (CMS) lists for those aged 65 years and over, and from neighborhood sampling.
3284971|NCT00587873|Experimental|1|MTX, 6-TG, and Leucovorin combination
3284972|NCT00587860|Placebo Comparator|Placebo|
3284973|NCT00587860|Active Comparator|St. John's Wort|
3284974|NCT00587847|Other|Campath maintenance treatment|Single arm, open label trial of Campath on a maintenance schedule for patients who have had a response to prior conventional chemotherapy. Treatments consist of dose escalation (3, 10 and 30mg) during week 1 followed by weekly dosing of Campath at 30 mg once weekly for 7 weeks followed by Campath 30 mg every 2 weeks for 16 weeks followed by Campath 30 mg once every 3 weeks for 24 weeks. Total duration of treatment up to 48 weeks.
3284975|NCT00587834|Experimental|1|Within-subject design: one side of the mouth receives Gintuit
3284976|NCT00587834|Active Comparator|2|Within-subject control: one side of mouth receives tissue harvested from the palate
3284977|NCT00587821||1|The first 250 samples will be used as a training set and results of these breast biopsies (benign or malignant) will be used to determine the peptide profile characteristic of a diagnosis of breast cancer on biopsy.
3284978|NCT00587821||2|The predictive capacity of this profile will then be prospectively assessed using the next 250 samples, which will serve as a validation set. Subjects who are candidates for enrollment on cohort B of this study (metastatic disease)
3284979|NCT00587808||HFpEF|Patients with a history of HFpEF
3284980|NCT00587808||control|Patients with a without a history of CHF
3284981|NCT00587795|Active Comparator|StabilAir Wrist Brace|One study group will consist of patients treated with the StabilAir Wrist Brace.
3284982|NCT00587795|Placebo Comparator|Control|Study arm will consist of patients that are treated with placement of sugar tong splint or plaster cast.
3284983|NCT00587769|Experimental|Bupropion SR & Varenicline|All 38 smokers will receive open-label bupropion SR and varenicline. Bupropion SR is an oral medication with recommended dosing of 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day. Varenicline is an oral medication with recommended dosing of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment. Subjects will quit on Day #8 after starting both medications.
3284984|NCT00587756||1|Prospective cohort of consecutive patients who undergo surgery for colorectal cancer liver metastases
3284985|NCT00587730|Active Comparator|Clinical SPECT|GE Hawkeye Attenuation Correction Camera is being compared to the approved clinical use SPECT camera.
3284986|NCT00587717|Active Comparator|1|Two 80 mg pills simvastatin taken 24 hours prior to surgery
3284987|NCT00587717|Placebo Comparator|2|Two 80 mg pills placebo are taken 24 hours prior to surgery
3284988|NCT00587704|Other|Nerve Stimulation|Use of nerve stimulator for placement of PVB nerve block
3284989|NCT00587704|Other|Anatomic landmarks|Use of anatomic landmarks for placement of PVB block
3284990|NCT00587691|Experimental|Dose Level 1|6-9 million MRTC
3284991|NCT00587691|Experimental|Dose Level 2|30-45 million MRTC
3284992|NCT00587691|Experimental|Dose Level 3|60-90 million MRTC
3284993|NCT00587678|Experimental|Randomized|Patients are imaged at baseline and randomized to Simvistatin 40 mg each night or Simvistatin 40mg/Zetia 10mg each night for 2 years
3284994|NCT00587678|Experimental|Ezetemibe|Patients are imaged at baseline and treated with ezetimibe 10mg each night for 2 years.
3284995|NCT00587665|Experimental|1|Low dose ketamine given
3284996|NCT00587665|Placebo Comparator|2|Saline given as control
3284997|NCT00587652||1|Intermediate Segment Barrett's (2-4cm)
3284998|NCT00587652||2|Long segment Barrett's (>4 cm)
3284999|NCT00587639|Experimental|rTMS Treatment|All subjects will have active rTMS treatment (10Hz, L-DLPFC - 3,000 Stimulations/treatment)
3285000|NCT00587626|Active Comparator|1|InterX treatment plus rehabilitation exercises
3285001|NCT00587626|Placebo Comparator|2|Inactive InterX treatment plus rehabilitation exercises
3285002|NCT00587600|Active Comparator|Photodynamic therapy|will have photodynamic therapy
3285003|NCT00587600|Active Comparator|radiofrequency ablation of barretts esophagus|radiofrequency ablation of barretts esophagus
3285004|NCT00587587|Experimental|A|Apligraf (bilayered living cell therapy)
3285005|NCT00587587|Active Comparator|B|Dressing regimen comprised of a primary nonadherent dressing, dry gauze dressing and bolster gauze dressing, if necessary
3285006|NCT00587574||I|Chronic graft-versus-host disease
3285007|NCT00587574||II|No chronic graft-versus-host disease
3285008|NCT00587561|Experimental|1|Will receive 20-26 sessions of a manualized group treatment called Social Cognition Interaction Training
3285009|NCT00587561|Other|2 WLC|Wait list control; 6 months of treatment as usual followed by Social Cognition Interaction Training group
3285010|NCT00587535||Hemochromatosis|Hemochromatosis
3285011|NCT00587535||Living-related liver donation|Living-related liver donation
3285012|NCT00587522|Experimental|A|NDO Full-thickness Plicator Procedure
3285013|NCT00587496|Experimental|1|placebo, 6 capsules per day for 30 days
3285014|NCT00587496|Experimental|2|500 mg Valtrex one capsule per day plus 5 capsules of placebo per day for 30 days
3285015|NCT00587496|Experimental|3|500 mg Valtrex capsule one per day, Acetylsalicylic acid (aspirin) 325 mg capsules three per day, plus 2 placebo capsules per day for 30 days
3285016|NCT00587483|Active Comparator|Lidocaine 1.5 mg /kg|Lidocaine is a class I (sodium channel block) antiarrhythmic drug.
3285017|NCT00587483|Active Comparator|Amiodarone 300 mg|Amiodarone is used to treat and prevent certain types of serious, life-threatening ventricular arrhythmias (a certain type of abnormal heart rhythm) when other medications did not help or could not be tolerated. Amiodarone is in a class of medications called antiarrhythmics. It works by relaxing overactive heart muscles.
3285018|NCT00587483|Placebo Comparator|placebo (saline)|
3285019|NCT00587470|Experimental|1|Atacand treatment.
3285020|NCT00587470|Placebo Comparator|2|Placebo
3285115|NCT00586677|Active Comparator|HS|The physical health and safety are the primary components of this parenting program where the parent is taught about basic healthcare and safety in the home.
3285021|NCT00587457|Experimental|CAT-8015 5 microgram per kilogram (mcg/kg)|Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
3285022|NCT00587457|Experimental|CAT-8015 10 mcg/kg|Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
3285023|NCT00587457|Experimental|CAT-8015 20 mcg/kg|Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
3285024|NCT00587444|Other|1|control standard dose heparin dose
3285025|NCT00587444|Active Comparator|2|high dose heparin dose
3285026|NCT00587444|Active Comparator|3|hepcon guided therapy
3285027|NCT00587431|Experimental|1|
3285028|NCT00587431|Active Comparator|2|
3285029|NCT00587418|Experimental|Arginine|
3285030|NCT00587418|Placebo Comparator|Placebo|
3285031|NCT00587405|Active Comparator|1|Cryotherapy
3285032|NCT00587405|Active Comparator|2|Argon Plasma Coagulation
3285033|NCT00587392||A|Active NDO Endoscopic Full-thickness Plicator Procedure
3285034|NCT00587379|Active Comparator|1|Patients randomized to take 1 40mg Atorvastain pill per day for 6 week study period
3285035|NCT00587379|Placebo Comparator|2|Patients randomized to 1 40mg placebo pill per day for 6 week study
3285036|NCT00587340||1|15 subjects with subjective sleep disturbance based on the Pittsburgh Sleep Quality Index
3285037|NCT00587340||2|mild/moderate subjective sleep disturbance (insomnia) based on the Pittsburgh Sleep Quality Index
3285038|NCT00587340||3|severe subjective sleep disturbance (insomnia)based on the Pittsburgh Sleep Quality Index
3285039|NCT00587327|Experimental|Barusiban|
3285040|NCT00587327|Experimental|Atosiban|
3285041|NCT00587327|Placebo Comparator|Placebo|
3285042|NCT00587314||1|Patients with Barrett's Esophagus or early esophageal adenocarcinoma who will or have had ablation therapy will be enrolled in this long term follow up study
3285043|NCT00587301|Experimental|Lap-Band|Lap-band surgery in treatment of morbidly obese adolescents
3285044|NCT00587288|Experimental|Reslizumab 3 mg/kg|Reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles
3285045|NCT00587288|Placebo Comparator|Placebo|Saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles
3285046|NCT00587275|Experimental|1|AST-120, 2 gram sachets
3285047|NCT00587275|Placebo Comparator|2|Celphere CP-305, stained to match appearance of AST-120 in 2g sachets.
3285048|NCT00587262||1|Two pediatric participants with high frequency hearing loss post cochlear implant with either long or short electrode array.
3285049|NCT00587262||2|Eight participants with high frequency hearing loss post cochlear implant with either short or long electrode array.
3285050|NCT00587262||3|Fifteen participants from the existing Cochlear Implant data base.
3285051|NCT00587249|Experimental|3|50 mcg of ICC-1132 with alhydrogel adjuvant.
3285052|NCT00587249|Experimental|2|20 mcg of ICC-1132 with alhydrogel adjuvant.
3285053|NCT00587249|Experimental|1|10 mcg of ICC-1132 with alhydrogel adjuvant.
3285054|NCT00587236||1|Patients with chronic ulcerative colitis and concurrent primary sclerosing cholangitis.
3285055|NCT00587236||2|Patients with chronic ulcerative colitis and known dysplasia or cancer.
3285056|NCT00587223|Experimental|1|Apligraf (a living bilayered cell therapy product)
3285057|NCT00587223|Active Comparator|2|Dressing regimen comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer.
3285058|NCT00587210||Suspected or known Crohn Disease|Suspected or known Crohn Disease
3285059|NCT00587184||1|patients who were seen clinically indicated endoscopic surveillance and biopsies of BE and confocal microscopy was performed.
3285060|NCT00587171|Active Comparator|Active|2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
3285061|NCT00587171|Sham Comparator|Control|2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
3285062|NCT00587158|Other|Immunosuppression without paricalcitol (control)|Subjects will receive the standard immunosuppressive therapies consisting of induction therapy with Alemtuzumab (Campath®) and Methylprednisolone (Solumedrol®), then maintained with corticosteroid avoidance using Mycophenolate Mofetil (Cellcept®) and Tacrolimus (Prograf®).
3285063|NCT00587158|Active Comparator|Immunosuppression with paricalcitol|Subjects will receive the standard immunosuppressive therapy consisting of induction therapy with Alemtuzumab (Campath®) and Methylprednisolone (Solumedrol®), then maintained with corticosteroid avoidance using Mycophenolate Mofetil (Cellcept®) and Tacrolimus (Prograf®). In addition, subjects will receive the study medication paricalcitol (Zemplar®).
3285064|NCT00587132|Experimental|New Onset Diabetes|"Adults diagnosed diabetes within two years, and at least one of the following: no family history of diabetes, abdominal discomfort, anorexia, weight loss, elevated serum cancer antigen 19-9 (CA 19-9), or those undergoing endoscopic ultrasound (EUS) with or without Fine Needle Aspiration (FNA) for pancreatic cancer screening.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
3285065|NCT00587132|Experimental|Familial Pancreatic Cancer|"Adults age 35-99 with familial pancreatic cancer with two or more first degree relatives with pancreatic cancer.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
3285066|NCT00587132|Experimental|Peutz-Jeghers Syndrome|"Adults age 35-99 with Peutz-Jeghers syndrome.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
3285116|NCT00586664|Experimental|Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5%|
3285117|NCT00586664|Experimental|Bepotastine Besilate Ophthalmic Solution 1.0%|
3285118|NCT00586664|Placebo Comparator|Placebo|
3285119|NCT00586651|Experimental|lestaurtinib|
3285067|NCT00587132|Experimental|Clinical Symptoms of Pancreatic Cancer, Normal CT|"Adults age 35-99 with suspicious clinical symptoms of pancreatic cancer, but had normal CT of the abdomen with iodinated contrast within 2 weeks.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
3285068|NCT00587119|Experimental|1|Single arm, active treatment
3285069|NCT00587106||1|One cohort group of patient with PNDS or suspected PNDS
3285070|NCT00587093|Other|1|CT scan and CA-125
3285071|NCT00587067|Experimental|1|
3285072|NCT00587054|Experimental|Transplant Patients|
3285073|NCT00587041|Placebo Comparator|Placebo|Participants received placebo for 6 weeks: 1 placebo packet daily and 1 placebo capsule twice daily
3285074|NCT00587041|Active Comparator|Oxadrop|Participants received Oxadrop for 6 weeks: Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis)
3285075|NCT00587041|Active Comparator|Agri-King Synbiotic|Participants received AKSB for 6 weeks: AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
3285076|NCT00587028||Oral Omnipaque MCA|Ten participant minimum: for stool tagging two days preceding the CT colonography, if applicable, with oral Omnipaque. This cohort at Scottsdale Mayo Clinic only.
3285077|NCT00587028||IV Iodine MCR|Ten participant minimum: for intravenous iodine contrast dye. This cohort at Rochester Mayo Clinic only.
3285078|NCT00587028||NO oral and no IV MCR|Five participant minimum for no oral or IV contrast.
3285079|NCT00587028||Replacement Group|Five participant minimum for either cohorts 1, 2, or 3 as above should there be poor imaging results. A like prepped participant will replace that who had poor quality imaging to meet 25 imaging data sets.
3285080|NCT00587015|Active Comparator|1|CAT-8015
3285081|NCT00587002|Active Comparator|1|Gender comparison
3285082|NCT00586989||1|Patient with Barrett's Esophagus with a history of High grade dysplasia or early esophageal adenocarcinoma
3285083|NCT00586976|Experimental|1|Ropivicaine infusion into the sternal wound
3285084|NCT00586976|Placebo Comparator|2|Normal saline infusion into the sternal wound
3285085|NCT00586937||1|Lung Cancer Survivors
3285086|NCT00586924|Experimental|1|CAT 8015
3285087|NCT00586911|Active Comparator|Cystadane|
3285088|NCT00586911|Placebo Comparator|Identical Placebo|
3285089|NCT00586898|Experimental|1|
3285090|NCT00586885|Experimental|1|Single arm, active treatment
3285091|NCT00586872||1|patients with barretts esophagus and/or early esophageal adenocarcinoma who have undergone endoscopic mucosal resection
3285092|NCT00586859|Experimental|A|NDO Full-thickness Plicator Procedure
3285093|NCT00586846|Experimental|1|
3285094|NCT00586833||1|No CHF/HTN Never diagnosed with CHF and undergoing current treatment for HTN
3285095|NCT00586833||2|CHF with HFpEF HFpEF Cases will be recruited from the community. Subjects will be largely drawn from an existing Mayo database examining all incident cases of HF in Olmsted County.
3285096|NCT00586833||3 Healthy normal adults|No identifiable cardiac issues at time of exercise.
3285097|NCT00586820|Experimental|BQ-123|BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
3285098|NCT00586820|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
3285099|NCT00586807|Other|Infliximab|Subjects on infliximab
3285100|NCT00586794|Active Comparator|A|
3285101|NCT00586794|Placebo Comparator|B|from the 26th weeks on open-label, all patients were treated with Sildenafil
3285102|NCT00586781|Experimental|3|The S.T.A.R. ankle system is the study device. The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants. Both ankles of every subject will be treated with the STAR ankle.
3285103|NCT00586755|Experimental|Intensive Induction-BMT|Patients will undergo induction regimen and stem cell mobilization with cyclophosphamide for bone marrow transplant (BMT). This will be immediately followed by high dose therapy with stem cell support.
3285104|NCT00586742|Active Comparator|1|Labral repair with suture anchors
3285105|NCT00586742|Active Comparator|2|Biceps tenodesis with suture anchor
3285106|NCT00586742|Sham Comparator|3|only a diagnostic arthroscopy performed
3285107|NCT00586729|Experimental|Vashe|Vashe Wound Therapy applied to gauze dressing every 6 hours or as necessary to keep dressing moist for a total treatment duration of 5 days.
3285108|NCT00586729|Active Comparator|5% Mafenide Acetate|5% Mafenide Acetate applied to gauze dressing every 6 hours or as necessary to keep dressing moist for a total treatment duration of 5 days.
3285109|NCT00586716|Other|Group 1 intravenous immune globulin|Intravenous immunoglobulin for: patients who do not have a living donor, have a PRA greater than 30% for 3 consecutive months, and have one positive crossmatch with a cadaveric donor while on kidney transplant waiting list
3285110|NCT00586716|Other|Group 2 intravenous immune globulin|Intravenous immune globulin for patients who have living donors with positive crossmatch results.
3285111|NCT00586703|Experimental|NK-CD56|NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors
3285112|NCT00586690|Experimental|NK Cell Infusion|Natural Killer (NK) Cell infusion using CD56 monoclonal antibody
3285113|NCT00586690|Other|Donor Apheresis|Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for >24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
3285120|NCT00586638|Experimental|1|Video Game play with training strategy
3285121|NCT00586638|Active Comparator|2|Video game play without training strategy
3285122|NCT00586638|No Intervention|3|Minimal contact control
3285123|NCT00586625|Experimental|Bepreve|bepotastine besilate ophthalmic solution 1.5%
3285124|NCT00586625|Placebo Comparator|Placebo|vehicle
3285125|NCT00586612|Experimental|Preterm group|Subjects born after a gestation period of less than or equal to 36 weeks and who received 3 doses (at 2, 4 and 6 months of age) of Menitorix™, Infanrix™ penta and Prevenar™ and a booster dose of Menitorix™, Infanrix™ IPV and Prevenar™ at 16-18 months of age.
3285126|NCT00586612|Active Comparator|Full-term group|Subjects born after a gestation period of more than 36 weeks and who received 3 doses (at 2, 4 and 6 months of age) of Menitorix™, Infanrix™ penta and Prevenar™ and a booster dose of Menitorix™, Infanrix™ IPV and Prevenar™ at 16-18 months of age.
3285127|NCT00586599|Other|Control|Subjects who have no inflammatory disease who will be age/gender matched controls for the 2 other arms.
3285128|NCT00586599|Other|IBD and infliximab|Subjects who have IBD and will be receiving infliximab for the first time.
3285129|NCT00586599|Other|Newly Diagnosed IBD|Subjects who are newly diagnosed with IBD and given corticosteroid therapy.
3285130|NCT00586586|Experimental|Group CBT|The behavioral intervention FRIENDS (cognitive behavior therapy program developed by P. Barratt) delivered in groups of 4 to 8. 10 weekly sessions plus 2 booster sessions.
3285131|NCT00586586|Experimental|Individual CBT|"The behavioral intervention FRIENDS (cognitive behavior therapy program developed by P. Barratt) delivered individually.~10 weekly sessions plus 2 booster sessions."
3285132|NCT00586586|No Intervention|Wait-list control|Wait-list control condition for 5 weeks after last child has been included.
3285133|NCT00586573|Experimental|Namenda|
3285134|NCT00586560|Experimental|1|Stratum 1 (~ 25 patients) will include patients with known bone marrow metastases or those who have had prior intensive myelosuppression therapy (including autologous or allogeneic stem cell rescue [SCR], total body irradiation [TBI], craniospinal irradiation [CSI], or hemipelvic radiation).
3285135|NCT00586560|Experimental|2|Stratum 2 (~ 25 patients) will include patients without previous intensive myelosuppressive therapy and bone marrow metastases.
3285136|NCT00586534|Active Comparator|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
3285137|NCT00586534|Experimental|I/GDC + VR/CER|Second Arm:NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
3285138|NCT00586521|Experimental|rFVIII-FS (octocog-alfa), (Kogenate FS)|On-demand treatment was to follow the same treatment pattern the subject was using before entering the study. While on prophylactic treatment, all subjects were to be treated at a dose of 20-40 IU/kg, 3 times per week at a stable dose.
3285139|NCT00586508|Experimental|A|
3285140|NCT00586495|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 200 mg tablets (400 mg [2 x 200 mg tablets] twice daily [bid] or 400 mg once daily [od] or 400 mg every other day [qod]) administered orally
3285141|NCT00586482|Active Comparator|Nicotine lozenge|"Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.~Subjects also received an abstinence advisement: a brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times."
3285142|NCT00586482|Placebo Comparator|Placebo lozenge|"Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day.~Subjects also received an abstinence advisement: a brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times."
3285143|NCT00586469|Experimental|Old Bulk|This group receives a full dose of Fluviral made from aged bulk material
3285144|NCT00586469|Active Comparator|New Bulk|This group receives a full dose of Fluviral made from new material
3285145|NCT00586443|Other|I|This is a Phase I safety study. There is only one arm.
3285146|NCT00586430|Active Comparator|1|single 2 mg dose of lorazepam
3285147|NCT00586430|Placebo Comparator|2|single dose of placebo
3285148|NCT00586417|Experimental|1|This is a basic research study. There are no treatments with drugs or devices. Wound healing is being studied in healthy volunteers.
3285149|NCT00586404||A|Patients with confirmed Barrett's Esophagus
3285150|NCT00586391|Experimental|CD19CAR-28-zeta T cells|"Three dose levels of CTLs will be evaluated. Each patient will receive one injection according to their assigned dose over 1-10 minutes IV.~*At the discretion of the attending physician, if after a 4 to 6-week evaluation period the patient has had apparent clinical benefit (as determined by symptoms, physical exam or radiological studies); repeat infusions separated by 4 to 6 weeks (up to a maximum of 3 extra doses) of modified T cells at the same dose level or below the patient's original dose can be administered."
3285151|NCT00586365|Experimental|1|Will receive 500 mg Naproxen twice a day for two weeks
3285152|NCT00586365|No Intervention|2|Will not receive naproxen
3285153|NCT00586352|Active Comparator|Normal|Subjects who have normal endoscopic findings
3285154|NCT00586352|Active Comparator|Newly diagnosed Crohn's disease|Subjects who are newly diagnosed with Crohn's disease after endoscopy.
3285155|NCT00586352|Active Comparator|Newly diagnosed Ulcerative Colitis|Subjects diagnosed with Ulcerative Colitis after endoscopy
3285156|NCT00586339|Experimental|HIV+/Cervarix Group|Human immunodeficiency virus positive (HIV+) subjects received 3 doses of Cervarix™ vaccine at Day 0, Month 1 and Month 6. Cervarix™ vaccines was administrated by intramuscular injection into the deltoid region of the non-dominant arm according to a 0, 1, 6 month schedule.
3285157|NCT00586339|Active Comparator|HIV+/Aluminium Hydroxide Group|Human immunodeficiency virus positive (HIV+) subjects received 3 doses of control Aluminium Hydroxide [Al(OH)3] vaccine at Day 0, Month 1 and Month 6. Aluminium Hydroxide vaccine was administrated by intramuscular injection into the deltoid region of the non-dominant arm according to a 0, 1, 6 month schedule.
3285158|NCT00586339|Experimental|HIV-/Cervarix Group|Human immunodeficiency virus negative (HIV-) subjects received 3 doses of Cervarix™ vaccine at Day 0, Month 1 and Month 6. Cervarix™ vaccines was administrated by intramuscular injection into the deltoid region of the non-dominant arm according to a 0, 1, 6 month schedule.
3285159|NCT00586326|Experimental|Women with DCIS|Women with DCIS
3285160|NCT00586313|Experimental|a1: Tru-Cut biopsy for liver|Tru-Cut Biospy.
3285161|NCT00586300|Active Comparator|1|Physical training program
3285162|NCT00586300|Active Comparator|2|Self-management training program
3285163|NCT00586300|Active Comparator|3|Physical and self-management training programs
3285164|NCT00586287|Experimental|A|Algorithm which uses serum albumin and weight to determine the loading dose of phenprocoumon within the first 5 days
3285165|NCT00586287|Experimental|B|Algorithm which uses serum age and weight to determine the loading dose of phenprocoumon within the first 5 days
3285166|NCT00586287|Active Comparator|C|The physician chooses the loading dose of phenprocoumon according to his/her experience
3285167|NCT00586274|Experimental|CD34 selected haploidentical PBSCT|CD34 selected haploidentical PBSCT
3285168|NCT00586261|Placebo Comparator|Placebo|Placebo 30 mg daily for 6 months, nitroglycerin was given to check the brachial reactivity.
3285169|NCT00586261|Active Comparator|Pioglitazone|Pioglitazone 30 mg daily for 6 months, nitroglycerin was given to check the brachial reactivity.
3285170|NCT00586235||1|patients with indeterminate kidney or liver lesions
3285171|NCT00586222|Placebo Comparator|2|
3285172|NCT00586222|No Intervention|Healthy Comparsions|We will compare the BP group with 32 age-, gender-, and handedness-matched healthy adolescents. Subjects who have a first or second degree relative with a psychiatric history will be excluded from the healthy comparison group. Subjects must be safe to undergo MRI scanning as per Mayo MRI safety screening which is explained in detail elsewhere in this protocol. We will exclude the subjects with cardiac pacemakers, metallic clips, other bodily metallic implants and dental braces because of the MRS procedure. Subjects who cannot complete clinical assessments or the MRI scan and subjects who are not fluent in English will be excluded from the study.
3285173|NCT00586222|Experimental|1|
3285174|NCT00586209|Experimental|L-glutamine|"L-glutamine group will be given at the following dosage:~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily >66.7 at 15 g 2X daily"
3285175|NCT00586209|Placebo Comparator|Placebo|"Maltodextrin group will be given at the following dosage:~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily >66.7 at 15 g 2X daily"
3285176|NCT00586196|Active Comparator|1|
3285177|NCT00586196|Placebo Comparator|2|
3285178|NCT00586183|Experimental|1|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
3285179|NCT00586170|Experimental|EBI Bone Healing System + Surgery|Subject will be using the EBI Bone Healing System (active device) in conjunction with ORIF surgery of the nonunion site.
3285180|NCT00586170|Placebo Comparator|Placebo Device + Surgery|Subject will be using a placebo device in conjunction with ORIF surgery of the nonunion site.
3285181|NCT00586157|Active Comparator|Methylphenidate Transdermal System (MTS)|
3285182|NCT00586157|Placebo Comparator|Placebo|
3285183|NCT00586131|Active Comparator|Low normal pH (arterial pH 7.36-7.38)|Ammonium chloride or sodium citrate/citrate acid as needed to achieve the target pH
3285184|NCT00586131|Active Comparator|High Normal pH (arterial pH 7.44-7.46)|High Normal pH (7.44-7.46) with use of increasing doses of sodium bicarbonate up until the desired pH is achieved
3285185|NCT00586118||1-Sevo|Sevoflurane/ACD group (n=60)
3285186|NCT00586118||2-Propofol|Propofol group (n=60)
3285187|NCT00586105|Experimental|Sorafenib (Nexavar, BAY43-9006)|400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
3285188|NCT00586092|Other|1|This trial employs a phase I design with a dose escalation stage (stage I) and an expansion stage (stage 2) to better describe the tolerability of this combination and the effect of this combination on several biomarkers. In this second stage there will be two groups, each with ten patients, to better describe the tolerability of the bevacizumab/ABT-510 combination and the effect of this combination on several biomarkers. The primary objective of this study is to estimate the MTD/recommended phase II dose regimen. All other objectives are exploratory in nature.
3285189|NCT00586079|Experimental|A|Ten patients who have had deep brain stimulation surgery for Parkinson's disease at Mayo Clinic Arizona.
3285190|NCT00586079|Experimental|B|Ten patients who are scheduled to have deep brain stimulation surgery for Parkinson's disease at Mayo Clinic Arizona.
3285191|NCT00586066|Placebo Comparator|Placebo|Placebo-matching memantine 5 mg tablet once per day for 1 week; dose increase if tolerated to placebo-matching memantine 5 mg twice a day, in the morning and the evening in Week 2; dose increase if tolerated to placebo-matching memantine 5 mg in the morning and placebo-matching memantine 10 mg in the evening in Week 3; dose increase if tolerated to placebo-matching memantine 10 mg twice a day, in the morning and the evening Weeks 4 to 12.
3285192|NCT00586066|Experimental|Memantine|Re-purposed Alzheimer's drug to treat cognitive dysfunction associated with bipolar disorder. Memantine 5 mg tablet once per day for 1 week; dose increase if tolerated to memantine 5 mg twice a day, in the morning and the evening in Week 2; dose increase if tolerated to memantine 5 mg in the morning and memantine 10 mg in the evening in Week 3; dose increase if tolerated to memantine 10 mg twice a day, in the morning and the evening Weeks 4 to 12.
3285193|NCT00586053||1|485 patients,who have an average risk (asymptomatic and without colon screening in the last 5 years) or those who have a high risk for colon cancer (strong family history of colon cancer or polyps and/or personal history of colon cancer or polyps).
3285194|NCT00586053||2|160 patients, with a known colorectal lesion at or greater than 1 cm.
3285195|NCT00586053||3|610 patients, who are of average risk for colon cancer (asymptomatic and no colon cancer screening in the last 5 years).
3285196|NCT00586040|Experimental|1|superficial closure with PTB
3285197|NCT00586040|Active Comparator|2|superficial sutures
3285198|NCT00586027||NT-proBNP|150 consecutive patients undergoing cardiac surgery with an intraoperative measured cardiac output <2L/min/m².
3285260|NCT00585585|Experimental|Arm 1: Betahistine dihydrochloride|Oral betahistine dihydrochloride; daily dose 50-300 mg
3285199|NCT00586014|Experimental|I|High-dose sequential cyclophosphamide and VP-16 followed by myeloablation with high-dose BCNU and melphalan with autologous stem cell transplant
3285200|NCT00586001|Experimental|1|Unified treatment
3285201|NCT00586001|No Intervention|2|Wait-list control
3285202|NCT00585988|Other|1|
3285203|NCT00585988|Other|2|
3285204|NCT00585975|Experimental|Bromfenac Ophthalmic Solution 0.18%|
3285205|NCT00585975|Experimental|Xibrom 0.09%|
3285206|NCT00585949||Angio|Patients undergoing angiography without percutaneous coronary angioplasty
3285207|NCT00585949||Percutaneous Coronary Angioplasty|Patients undergoing angioplasty
3285208|NCT00585936||1|Normal controls without evidence of diabetes or islet specific autoimmunity
3285209|NCT00585936||2|Individuals within 6 months of diagnosis with type 1 diabetes
3285210|NCT00585936||3|Individuals at high risk for the development of type 1 diabetes
3285211|NCT00585936||4|Individuals with longstanding autoimmune diabetes
3285212|NCT00585923|Active Comparator|Usage of Fixed hole C-Tek™ Plate|Fixed Hole Plate - The fixed hole plate means that the screws do not move, restricting motion and providing additional stability
3285213|NCT00585923|Active Comparator|Usage of Slotted hole C-Tek™ Plate|Slotted Hole Plate - Bone screw translates while plate is stationary, which ultimately promotes grafts settling through load sharing.
3285214|NCT00585910|Experimental|1|Total treatment period is 7 weeks. Atomoxetine treatment will be initiated and maintained for 4 weeks. If the subject is a partial responder to atomoxetine treatment, OROS methylphenidate will then be added to his or her treatment regimen for the final 3 weeks of the study.
3285215|NCT00585897|Experimental|Behavioral counseling|Individual sessions which utilize motivational interviewing to assist participants to discontinue sugar sweetened beverages from their diet.
3285216|NCT00585871|Experimental|Clonidine therapy group|clonidine 0.1 TID
3285217|NCT00585871|Active Comparator|Metoprolol control group|metoprolol 25 TID
3285218|NCT00585858||1|Subjects on mimimal or no immunosuppression and no rejection history
3285219|NCT00585858||2|Subjects who have had rejection on conventional immunosuppression
3285220|NCT00585858||3|Subjects who have not had acute or chronic rejection who are on conventional immunosuppression
3285221|NCT00585845|Experimental|CRS-207|
3285222|NCT00585832|Experimental|A|DASH-4-Teens Intervention
3285223|NCT00585832|Other|B|Routine Care
3285224|NCT00585819|Experimental|2. Free breathing|Freebreathing in Body fix mold
3285225|NCT00585819|Experimental|1. breathing cycle|reproducing breathing cycles
3285226|NCT00585806||1|Subjects with Heart Failure and ejection fraction greater than or equal to 45%
3285227|NCT00585806||2|Healthy Volunteers
3285228|NCT00585793||PEPFAR 1|
3285229|NCT00585780|Active Comparator|PZ|Prazosin 16 mg/day (tid) will be administered for 12 weeks with contingency management vouchers for treatment attendance and manualized CBT relapse prevention counseling.
3285230|NCT00585780|Placebo Comparator|PLA|Placebo tablets administered tid for 12 weeks with contingency management vouchers for treatment attendance and manualized CBT relapse prevention counseling.
3285231|NCT00585767||1|Patients with two kidneys
3285232|NCT00585767||2|Patients with solitary kidney
3285233|NCT00585754|Active Comparator|Guanfacine|
3285234|NCT00585754|Placebo Comparator|PLA|
3285235|NCT00585741|Experimental|2. Head and neck|Imaging with 18F-FLT PET
3285236|NCT00585741|Experimental|3. Lung|Imaging with 18F-FLT PET
3285237|NCT00585741|Experimental|4. prostate|Imaging with 18F-FLT PET
3285238|NCT00585741|Experimental|5. esophagus|Imaging with 18F-FLT PET
3285239|NCT00585741|Experimental|1.CNS|Imaging with 18F-FLT PET
3285240|NCT00585728|Other|1|CT virtual proctoscopy
3285241|NCT00585715|Experimental|Candela DCD with cooling|Laser treatment with Candela DCD cooling which produces a cryogenic fluid that cools the epidermis prior to each laser pulse. Treatment will be conducted on either the left or the right thigh, which will also be randomly determined. The contra-lateral side will not be treated and will serve as a control. The laser system to be used in is Candela GentleYAG, a 1064nm Nd:YAG laser. This arm will receive a coolant during the laser procedure.
3285242|NCT00585715|Active Comparator|Candela DCD without Cooling|Laser treatment without cooling before each laser pulse. Treatment will be conducted on either the left or the right thigh, which will also be randomly determined. The contra-lateral side will not be treated and will serve as a control. The laser system to be used in is Candela GentleYAG, a 1064nm Nd:YAG laser. This arm will not receive a coolant during the laser procedure.
3285243|NCT00585702||1|Pregnant women with bipolar disorder
3285244|NCT00585702||2|Pregnant women without bipolar disorder
3285245|NCT00585689|Experimental|Neoadjuvant ABI-007, Carboplatin, and Gemcitabine|Neoadjuvant ABI-007 (260 mg/m^2) on day 1, Carboplatin (Target AUC [Area under the curve] =5) on day 1, and Gemcitabine (800 mg^m2) on days 1 and 8, every 21 days.
3285246|NCT00585676||Diabetic|Patients with Diabetes
3285247|NCT00585676||Abnormal glucose level|Patients who were screened and had abnormal blood glucose levels
3285248|NCT00585676||Control|Non-diabetic (normal glucose screening)
3285249|NCT00585650|Experimental|Treatment Group|Etanercept (Enbrel)50mg twice weekly injections for 12 weeks
3285250|NCT00585650|Placebo Comparator|Placebo Group|Placebo
3285251|NCT00585637|Active Comparator|1|No Vitamin D
3285252|NCT00585637|Active Comparator|2|1000 IU of Vitamin D
3285253|NCT00585637|Active Comparator|3|2000 IU of Vitamin D
3285254|NCT00585637|Active Comparator|4|4000 IU of Vitamin D
3285255|NCT00585624|Experimental|1|Supplement: 3 servings/day of Impact Advanced Recovery in addition to regular food or any other supplements recommended or desired by patient or primary care/surgical team.
3285256|NCT00585624|Placebo Comparator|2|Standard Care: Food, beverages, or supplements as recommended or desired by patient or primary care/surgical team.
3285257|NCT00585611|Experimental|Atorvastatin|Heart failure patients assigned to atorvastatin
3285258|NCT00585611|Placebo Comparator|2|
3285259|NCT00585598||1|all patients that are admitted to the trauma bay with a supralaryngeal airway
3285261|NCT00585559|Placebo Comparator|1|Placebos for acetaminophen and N-acetylcysteine
3285262|NCT00585559|Active Comparator|2|Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
3285263|NCT00585559|Active Comparator|3|N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
3285264|NCT00585559|Active Comparator|4|Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
3285265|NCT00585559|Active Comparator|5|Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
3285266|NCT00585546|Experimental|LVAD and Clenbuterol|
3285267|NCT00585533|Other|A|
3285268|NCT00585520|Active Comparator|PG|
3285269|NCT00585520|Placebo Comparator|PLA|
3285270|NCT00585507|Experimental|single|fulvestrant 500mg
3285271|NCT00585494||Preoperative orthopedic|Patients undergoing elective total hip, knee and spinal surgery at University of Wisconsin hospital, having their preoperative visit between December 1, 2007 and November 30, 2008.
3285272|NCT00585481||1|All subjects will perform samples collection for RSV analysis. Subject's enrolled in Porto Alegre's site will perform lung function tests.
3285273|NCT00585468|Experimental|Myfortic - Fed State|Mycophenolate sodium taken with a meal.
3285274|NCT00585468|Experimental|Myfortic - Fasting State|Mycophenolate sodium taken separately from food by 2 hours.
3285275|NCT00585455||A|Chronic heart failure patients with concomitant depression
3285276|NCT00585442|Experimental|Calcitriol|
3285277|NCT00585442|Placebo Comparator|Placebo|
3285278|NCT00585429||1|ESLD subjects on active liver transplant waiting list
3285279|NCT00585429||2|Subjects post-liver transplant with good liver function
3285280|NCT00585429||3|Subjects without liver disease undergoing kidney biopsy for diagnostic purposes
3285281|NCT00585416|Experimental|1|CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
3285282|NCT00585403||Children|Early and late pubertal girls and boys
3285283|NCT00585390|Experimental|Essential omega-3 fatty acid replacement|
3285284|NCT00585390|Placebo Comparator|Placebo|
3285285|NCT00585377|Other|1|
3285286|NCT00585364||CF (non-ABPA)|cystic fibrosis and culture positive for A. fumigatus in airway cultures.
3285287|NCT00585364||CF and ABPA|cystic fibrosis and diagnosis of ABPA
3285288|NCT00585364||healthy control|healthy non-CF
3285289|NCT00585351|Experimental|I|Advanced Notification + Ranitidine
3285290|NCT00585351|Active Comparator|II|Advanced Notification + Placebo
3285291|NCT00585351|Active Comparator|III|No advanced notification + Ranitidine
3285292|NCT00585351|Placebo Comparator|IV|No advanced notification + Placebo
3285293|NCT00585338|Experimental|Tandem 532/1064 nm Laser|Treatment of Vascular LesionsWith a Tandem 532/1064 nm Laser
3285294|NCT00585325|Experimental|Instilled 1% Lidocaine|5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
3285295|NCT00585325|Placebo Comparator|Instilled Placebo (0.9% Normal Saline)|receive .9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
3285296|NCT00585312|Experimental|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
3285297|NCT00585312|Placebo Comparator|Placebo|Masked, placebo comparator
3285298|NCT00585299|Experimental|Low-fat diet|20% kcals from fat diet followed for 8 weeks then 8 weeks of maintenance diet with visits to dietitian every other week
3285299|NCT00585299|Active Comparator|Traditional|Traditional low-fat diet given and dietitian follows up in 16 weeks
3285300|NCT00585286|Experimental|Fractional carbon dioxide laser system|Thirty total healthy subjects from two research centers with skin type I-IV of moderate to severe acne scarring received treatment with the 10,600 nm fractional carbon dioxide laser system.
3285301|NCT00585273||1|Incident users of antipsychotics.
3285302|NCT00585273||2|Non-users of antipsychotics
3285303|NCT00585260|Active Comparator|1|guideline based dose adjustment
3285304|NCT00585260|Experimental|2|mannitol
3285305|NCT00585260|Active Comparator|3|methacholine challenge
3285306|NCT00585247|Experimental|Imiquimod|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
3285307|NCT00585247|Placebo Comparator|Placebo|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
3285308|NCT00585234||1|We intend to photograph male and female subjects from age 1 through skeletal maturity. Healthy children will be photographed to determine the normative characteristics of thoracic function using this technique. We will also enroll patients with thoracic pathology to determine how digital imaging can document thoracic dysfunction. There are no specific disease related exclusion criteria. Participation is voluntary.
3285309|NCT00585221|Experimental|All patients|All participants enrolled in the study.
3285310|NCT00585208|Active Comparator|Active drug|Ramelteon - this group receives active drug at a fixed dose of 8mg daily throughout study
3285311|NCT00585208|Placebo Comparator|Placebo (sugar pill)|placebo (sugar pill) - this arm receive the fake pill, also know as placebo or the sugar pill
3285312|NCT00585195|Experimental|1|
3285313|NCT00585182|Experimental|1|
3285314|NCT00585169|Experimental|memantine|10 to 30 mg/day memantine. The study consisted of 10 weeks of open-label memantine. All eligible study subjects were started at 10 mg/day for 2 weeks. The dose was increased to 20 mg/day after 2 weeks and then to 30 mg/day after 4 weeks unless remission of PG symptoms was attained at a lower dose.
3285315|NCT00585156|Experimental|Arm #1|Celebrex treatment group
3285316|NCT00585143|Experimental|1|
3285317|NCT00585117|Experimental|1 CNS|imaging with CuATSM
3285318|NCT00585117|Experimental|2. Head and Neck|Imaging with CuATSM
3285319|NCT00585117|Experimental|3. Lung|imaging with CuATSM
3285320|NCT00585117|Experimental|4. Prostate|PET imaging with CuATSM
3285321|NCT00585117|Experimental|5. Esophagus|PET imaging with CuATSM
3285322|NCT00585104|Experimental|1|All randomized patients receive drug.
3285323|NCT00585091|Other|A|All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
3285377|NCT00584753|Other|1|Normal volunteers
3285324|NCT00585078|Experimental|CAPOX|Participants self-administered capecitabine 1,000 mg/m2 orally twice daily (total daily dose 2,000 mg/m2), days 1-14 in 21-day cycles. Only 500 mg tablets were used, and doses were rounded to the nearest dose that could be administered with 500 mg tablets. Oxaliplatin 130 mg/m2 was administered intravenously on day 1 every 21 (±2) days. Treatment continued until tumor progression or toxicity requiring discontinuation of therapy.
3285325|NCT00585065||1|
3285326|NCT00585052|Experimental|Paclitaxel and lovastatin|Paclitaxel given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly. Lovastatin self-administered at 80mg daily.
3285327|NCT00585039|Experimental|A|levalbuterol nebulization
3285328|NCT00585013|Experimental|Nitric Oxide Delivery Group|Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
3285329|NCT00585013|No Intervention|Placebo|Placebo delivery of oxygen at standard dose.
3285330|NCT00585000|Experimental|1|
3285331|NCT00584987|Placebo Comparator|Placebo FF + Placebo OXY|Placebo Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
3285332|NCT00584987|Active Comparator|FF + Placebo OXY|Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
3285333|NCT00584987|Active Comparator|Placebo FF + OXY|Placebo Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
3285334|NCT00584987|Active Comparator|FF + OXY|Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
3285335|NCT00584974|Experimental|0.5 mg SEP-225289|0.5 mg SEP-225289
3285336|NCT00584974|Experimental|2.0 mg of SEP-225289|2.0 mg of SEP-225289
3285337|NCT00584974|Active Comparator|Venlafaxine|150 mg Venlafaxine
3285338|NCT00584974|Placebo Comparator|Placebo|placebo
3285339|NCT00584961||600 patients|Patients with diagnosis of Bipolar Disorder (DSM-IV TR)
3285340|NCT00584948|Experimental|Memantine|
3285341|NCT00584948|Placebo Comparator|Placebo|
3285342|NCT00584935|Experimental|Rituximab|The Rituximab dose is 1000 mg (1gm) given as an IV infusion every two weeks for 2 doses (Days 1 and 15).
3285343|NCT00584922||1|Patients undergoing catheter ablation of atrial fibrillation or left atrial macroreentrant tachycardia.
3285344|NCT00584909|Experimental|Open Label|
3285345|NCT00584870|Active Comparator|Naproxen|
3285346|NCT00584870|Placebo Comparator|Placebo|
3285347|NCT00584870|Experimental|RN624|
3285348|NCT00584857|Experimental|Chemotherapy|Single
3285349|NCT00584844|Experimental|F tularensis Vaccine (0.0025 mL)|Subjects receive a small amount of F tularensis vaccine (0.0025mL) placed on a cleansed site on the skin on the volar surface of the forearm. A bifurcated needle was used to make 15 superficial punctures at the vaccination site to permit percutaneous penetration of the vaccine.
3285350|NCT00584831|Active Comparator|Group 2 LSBO|contact lenses worn in this order: lotrafilcon B toric, senofilcon A toric, balafilcon A toric, omafilcon A toric
3285351|NCT00584831|Active Comparator|Group 3 LOSB|contact lenses worn in this order: lotrafilcon B toric, omafilcon A toric, senofilcon A toric, balafilcon A toric
3285352|NCT00584831|Active Comparator|Group 4 LBSO|contact lenses worn in this order: lotrafilcon B toric, balafilcon A toric, senofilcon A toric, omafilcon A toric
3285353|NCT00584831|Active Comparator|Group 5 LBOS|contact lenses worn in this order: lotrafilcon B toric, balafilcon A toric, omafilcon A toric, senofilcon A
3285354|NCT00584831|Active Comparator|Group 6 SLOB|contact lenses worn in this order: senofilcon A toric, lotrafilcon B toric, omafilcon A toric, balafilcon A toric
3285355|NCT00584831|Active Comparator|Group 7 SLBO|contact lenses worn in this order: senofilcon A toric, lotrafilcon B toric, balafilcon A toric, omafilcon A toric
3285356|NCT00584831|Active Comparator|Group 8 SOLB|contact lenses worn in this order: senofilcon A toric, omafilcon A toric, lotrafilcon B toric, balafilcon A toric
3285357|NCT00584831|Active Comparator|Group 9 SBLO|contact lenses worn in this order: senofilcon A toric, balafilcon A toric, lotrafilcon B toric, omafilcon A toric
3285358|NCT00584831|Active Comparator|Group 10 SBOL|contact lenses worn in this order: senofilcon A toric, balafilcon A toric, omafilcon A toric, lotrafilcon B toric
3285359|NCT00584831|Active Comparator|Group 11 OSLB|contact lenses worn in this order: omafilcon A toric, senofilcon A toric, lotrafilcon B toric, balafilcon A toric
3285360|NCT00584831|Active Comparator|Group 12 OSBL|contact lenses worn in this order: omafilcon A toric, senofilcon A toric, balafilcon A toric, lotrafilcon B toric
3285361|NCT00584831|Active Comparator|Group 13 OBLS|contact lenses worn in this order: omafilcon A toric, balafilcon A toric, lotrafilcon B toric, senofilcon A toric
3285362|NCT00584831|Active Comparator|Group 14 OBSL|contact lenses worn in this order: omafilcon A toric, balafilcon A toric, senofilcon A toric, lotrafilcon B toric
3285363|NCT00584831|Active Comparator|Group 15 BLSO|contact lenses worn in this order: balafilcon A toric, lotrafilcon B toric, senofilcon A toric, omafilcon A toric
3285364|NCT00584831|Active Comparator|Group 16 BLOS|contact lenses worn in this order: balafilcon A toric, lotrafilcon B toric, omafilcon A toric, senofilcon A toric
3285365|NCT00584831|Active Comparator|Group 17 BSOL|contact lenses worn in this order: balafilcon A toric, senofilcon A toric, omafilcon A toric, lotrafilcon B toric
3285366|NCT00584831|Active Comparator|Group 18 BOLS|contact lenses worn in this order: balafilcon A toric, omafilcon A toric, lotrafilcon B toric, senofilcon A toric
3285367|NCT00584831|Active Comparator|Group 19 BOSL|contact lenses worn in this order: balafilcon A toric, omafilcon A toric, senofilcon A toric, lotrafilcon B toric
3285368|NCT00584831|Active Comparator|Group 1 LSOB|contact lenses worn in this order: lotrafilcon B toric/senofilcon A toric/omafilconA toric/balafilcon A toric
3285369|NCT00584805|Experimental|Vaccination|Inactivated, Dried, TSI-GSD 104, EEE
3285370|NCT00584792||1|Controls (No prostate cancer)
3285371|NCT00584792||2|Cases (Prostate Cancer Diagnosed)
3285372|NCT00584779|Experimental|1|
3285373|NCT00584779|Experimental|2|
3285374|NCT00584779|Experimental|3|
3285375|NCT00584779|Experimental|4|
3285376|NCT00584766|Experimental|1|
3285379|NCT00584753|Active Comparator|3|Whole body and breast PET/CT
3285380|NCT00584740|Experimental|AIN457|AIN457 10 mg/kg was given as an intravenous infusion at day 1 and day 22.
3285381|NCT00584740|Placebo Comparator|Placebo|Matching placebo to AIN457 was given as an infusion at day 1 and day 22.
3285382|NCT00584727|Active Comparator|senofilcon A/alphafilcon A/etafilcon A|First intervention:senofilcon A toric contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: etafilcon A sphere contact lenses
3285383|NCT00584727|Active Comparator|alphafilcon A/etafilcon A/senofilcon A|First intervention: alphafilcon A toric contact lenses Second intervention: etafilcon A sphere contact lenses Third intervention: senofilcon A toric contact lenses
3285384|NCT00584727|Active Comparator|etafilcon A/senofilcon A/alphafilcon A|First intervention: etafilcon A sphere contact lenses Second intervention:senofilcon A toric contact lenses Third intervention: alphafilcon A toric contact lenses
3285385|NCT00584727|Active Comparator|senofilcon A/etafilcon A/alphafilcon A|First intervention: senofilcon A toric contact lenses Second intervention: etafilcon A sphere contact lenses Third intervention: alphafilcon A toric contact lenses
3285386|NCT00584727|Active Comparator|alphafilcon A/senofilcon A/etafilcon A|First intervention: alphafilcon A toric contact lenses Second intervention: senofilcon A toric contact lenses Third intervention: etafilcon A sphere contact lenses
3285387|NCT00584727|Active Comparator|etafilcon A/alphafilcon A/senofilcon A|First intervention: etafilcon A sphere contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: senofilcon A toric contact lenses
3285388|NCT00584701|Experimental|Risperidone|Risperidone was started at 0.5mg at bedtime for 4 days. If that dosage was tolerated and there were continued behavioral symptoms, the dose was increased to 1mg at bedtime for an additional 4 days. If tolerated and indicated, 0.5mg was added in the morning for a daily total of 1.5 mg.
3285389|NCT00584662|Active Comparator|1|Oxymetazoline Hydrochloride
3285390|NCT00584649|Other|Single Group Assignment|electrophysiology study and radiofrequency ablation
3285391|NCT00584636|Experimental|Pulmicort Respules|using pulmicort respules
3285392|NCT00584610|Experimental|1|Levonorgestrel-containing intrauterine device insertion
3285393|NCT00584610|Active Comparator|2|Copper containing intrauterine device
3285394|NCT00584597|Placebo Comparator|1|Saline
3285395|NCT00584597|Experimental|2|Traumeel S 1 mL
3285396|NCT00584597|Experimental|3|Traumeel S 2 mL
3285397|NCT00584597|Experimental|4|Traumeel S 3 mL
3285398|NCT00584584|Experimental|1|
3285399|NCT00584584|Placebo Comparator|2|
3285400|NCT00584571|Active Comparator|Sensory Adaptation training|a large compliant balloon is placed in the rectum attached to a barostat. The balloon is distended in 1 mm increments until patient reports moderate discomfort and then increased in 1 mm increments until maximum tolerable pressure. Gradually over 6 training sessions, administered biweekly, the maximum tolerable pressure is increased over 3 months, if treatment is successful.
3285401|NCT00584571|Experimental|Escitalopram Therapy|Patients randomized to this arm will receive daily 10 mg escitalopram for 3 months. If the medication is effective their bowel symptoms and pain thersholds will improve.
3285402|NCT00584558||1|Patients undergoing catheter ablation.
3285403|NCT00584532|Placebo Comparator|A|A=Placebo ARM of Study
3285404|NCT00584532|Active Comparator|B|B=GCP Capsules. Ten 500 mg capsules per day for a total of 5 grams a day.
3285405|NCT00584519||500 patients|Patients with diagnosis of schizophrenia, schizophreniform or schizoaffective disorder (DSM-IV TR) with BMI (body mass index) more or equal to 25 Kg/m2
3285406|NCT00584480|Active Comparator|1|Active Hyperbaric Oxygen Treatment (HBOT)
3285407|NCT00584454|Experimental|Q Fever Vaccine (NDBR 105)|Volunteers will receive and intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase 1, MNLBR 110) in the volar aspect of the arm. Skin test will be evaluated; if erythema occurs after the skin test, it is medically contraindicated to vaccinate that volunteer. Volunteers with skin test reactions will not be vaccinated and withdrawn from the study.
3285408|NCT00584441||1|Women with pre-menstrual asthma (PMA): As defined by a 20% or more fall in PEFR and / or change by 20% or more of daily symptom score.
3285409|NCT00584441||2|Women without pre-menstrual asthma
3285410|NCT00584441||3|Women on oral contraceptives
3285411|NCT00584428|Experimental|1|
3285412|NCT00584415|Active Comparator|GP + PVI ablation|This study contains only one arm, which is GP ablation + PV antrum isolation. The intervention (GP ablation + PV isolation) was performed using ThermoCool Navistar catheters in all patients
3285413|NCT00584402|Experimental|Contrast sonography|Contrast-enhanced sonography perflutren lipid microspheres
3285414|NCT00584389|Experimental|1|Rimonabant treatment (20mg/d) for 12 weeks
3285415|NCT00584389|Other|2|Dietary intervention
3285416|NCT00584376|Active Comparator|1|Pregabalin
3285417|NCT00584376|Placebo Comparator|2|Placebo
3285418|NCT00584350|Experimental|A: Hydratation according LVEDP + NaHCO3|"Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours."
3285419|NCT00584350|Active Comparator|B: Standard hydratation|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
3285420|NCT00584350|Experimental|C: Hydratation with sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
3285421|NCT00584337||1|
3285422|NCT00584337||2|
3285423|NCT00584324|Experimental|Bispectral Index (BIS) 40|Target BIS 40
3285424|NCT00584324|Experimental|Bispectral Index (BIS) 60|Target BIS 60
3285425|NCT00584311|Experimental|1|All patients (with no structural damage on the plain x-ray) will receive a MRI and Ultrasound (US) of their most involved joint and an asymptomatic joint.
3285426|NCT00584298|Experimental|1|
3285427|NCT00584298|Placebo Comparator|2|
3285428|NCT00584285|Active Comparator|1|
3285429|NCT00584246|Experimental|1|Pregabalin (Lyrica)
3285430|NCT00584246|Placebo Comparator|2|Placebo
3285431|NCT00584233|Experimental|Breast CT and Breast MRI|Four hundred women who will be having breast biopsy as part of their standard care (BIRADS 4 and 5) will undergo pre- and post- contrast breast computed tomography and pre- and post- contrast magnetic resonance imaging.
3285432|NCT00584220|Other|senofilcon A toric / alphafilcon A toric|senofilcon A toric contact lenses worn daily during the first period, then alphafilcon A toric contact lenses worn daily during the second period
3285433|NCT00584220|Other|alphafilcon A toric / senofilcon A toric|alphafilcon A toric contact lenses worn daily during the first period, then senofilcon A toric contact lenses worn daily during the second period
3285434|NCT00584194|Experimental|TSI-GSD 200 RVF Vaccine|Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine, will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to < 1:40.
3285435|NCT00584181||Lung transplant recipients|Lung transplant recpients enrolled as study subjects will undergo pulmonary function tests (spirometry and lung volume measurements) and initial HRCT of chest. These subjects will receive nebulized ipratropium followed by pulmonary function tests (spirometry and lung volume measurements) and repeat HRCT.
3285436|NCT00584168|Placebo Comparator|2|Patient will receive a placebo.
3285437|NCT00584168|Experimental|1|Patient will receive dexamethasone.
3285438|NCT00584155|Placebo Comparator|1|Each patient will receive a bottle containing normal saline and 0.03% ofloxacin.
3285439|NCT00584155|Experimental|2|Each patient will receive a bottle containing Lactated Ringer's solution and 0.03% ofloxacin.
3285440|NCT00584142|Experimental|1|
3285441|NCT00584142|No Intervention|2|
3285442|NCT00584129|Experimental|1|Patients will receive pre-treatment swallowing exercises.
3285443|NCT00584129|Active Comparator|2|Post-treatment swallowing exercises.
3285444|NCT00584103|Experimental|Beta P Experimental|Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
3285445|NCT00584103|Other|Alpha P Control|Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
3285446|NCT00584090|Experimental|1|
3285447|NCT00584090|Placebo Comparator|2|
3285448|NCT00584077||Stable lung transplant recipients|All enrolled subjects receive the same procedures; bronchoscopy with administration of mechanical and chemical irritants to the airway mucosa
3285449|NCT00584051||1|
3285450|NCT00584051||2|
3285451|NCT00584051||3|
3285452|NCT00584038|No Intervention|1 Standard Care (SC)|Participants receive usual contraceptive care administered by clinic provider.
3285453|NCT00584038|Other|2 Standard Care + Educational (SCE)|Participants receive standard contraceptive care from clinic provider, followed by 45-minute educational intervention.
3285454|NCT00584038|Other|3 Standard Care + Educational + Phone Calls (SCEP)|Participants receive standard contraceptive care from clinic provider, followed by phone calls weekly until onset of menses and monthly thereafter for six consecutive months.
3285455|NCT00584025|Experimental|1|Keppra IV
3285456|NCT00584025|Placebo Comparator|2|Placebo
3285457|NCT00583999||A|bariatric surgery
3285458|NCT00583986|Experimental|1|Levalbuterol HFA MDI with top mounted actuation indicator
3285459|NCT00583973||1|Chronic hemodialysis patients
3285460|NCT00583947|Other|ARF/LEV|"Cross-over phase: one day active treatment with arformoterol 7.5 microgram per nebulization followed by a 7 day washout. Then a one day active treatment with levalbuterol 0.63 milligram per nebulization.~Open-label phase: Following another 7 day washout, one day treatment with arformoterol 15 micrograms per nebulization."
3285461|NCT00583947|Other|LEV/ARF|"Cross-over phase: one day active treatment with levalbuterol 0.63 milligram per nebulization followed by a 7 day washout. Then a one day active treatment with arformoterol 7.5 micrograms per nebulization.~Open-label phase: Following another 7 day washout, one day treatment with arformoterol 15 micrograms per nebulization."
3285462|NCT00583934||A|Those six months post treatment for head and neck cancer.
3285463|NCT00583908|Active Comparator|Group 1: lotrafilcon B/senofilcon A/balafilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. Period 1: lotrafilcon B /period 2: senofilcon A / period 3: balafilcon A / period 4: omafilcon A
3285464|NCT00583908|Active Comparator|Group 2 lotrafilcon B/omafilcon A/senofilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: lotrafilcon B / period 2: omafilcon A / period 3: senofilcon A / period 4: balafilcon A
3285465|NCT00583908|Active Comparator|Group 3 lotrafilcon B/balafilcon A/senofilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: lotrafilcon B / period 2: balafilcon A / period 3: senofilcon A / period 4: omafilcon A
3285466|NCT00583908|Active Comparator|Group 4 senofilcon A/lotrafilcon B/omafilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: lotrafilcon B / period 3: omafilcon A / period 4: balafilcon A
3285467|NCT00583908|Active Comparator|Group 5 senofilcon A/omafilcon A/balafilcon A/lotrafilcon B|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: omafilcon A / period 3: balafilcon A / period 4: lotrafilcon B
3285573|NCT00583063|Experimental|A|Sunitinib taken by mouth every day. Rapamycin (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.
3285468|NCT00583908|Active Comparator|Group 6 senofilcon A/balafilcon A/lotrafilcon B/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: balafilcon A / period 3: lotrafilcon B / period 4: omafilcon A
3285469|NCT00583908|Active Comparator|Group 7 omafilcon B/lotrafilcon B/senofilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: omafilcon A / period 2: lotrafilcon B / period 3: senofilcon A / period 4: balafilcon A
3285470|NCT00583908|Active Comparator|Group 8 balafilcon A/lotrafilcon B/senofilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: lotrafilcon B / period 3: senofilcon A / period 4: omafilcon A
3285471|NCT00583908|Active Comparator|Group 9 balafilcon A/lotrafilcon B/omafilcon A/senofilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: lotrafilcon B / period 3: omafilcon A / period 4: senofilcon A
3285472|NCT00583908|Active Comparator|Group 10 balafilcon A/senofilcon A/lotrafilcon B/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: senofilcon A / period 3: lotrafilcon B / period 4: omafilcon A
3285473|NCT00583908|Active Comparator|Group 11 balafilcon A/senofilcon A/omafilcon A//lotrafilcon B|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: senofilcon A / period 3: omafilcon A / period 4: lotrafilcon B
3285474|NCT00583908|Active Comparator|Group 12 balafilcon A/omafilcon A/lotrafilcon B/senofilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: omafilcon A / period 3: lotrafilcon B / period 4: senofilcon A
3285475|NCT00583895|Active Comparator|1|Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
3285476|NCT00583895|Placebo Comparator|2|Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
3285477|NCT00583882|Other|1|Change every 6 days, rewire every 6 days
3285478|NCT00583882|Other|2|New site every 6 days
3285479|NCT00583882|Other|3|New site every 12 days
3285480|NCT00583869|Placebo Comparator|1|Patient to receive placebo beginning on the day of surgery until discharge.
3285481|NCT00583869|Experimental|2|Patient to receive 75mg PO BID pregabalin beginning on the day of surgery until discharge.
3285482|NCT00583869|Experimental|3|Patient to receive 150mg PO BID pregabalin beginning on the day of surgery until discharge.
3285483|NCT00583843||Ultrasound|The group of women who are being followed by Ultrasound.
3285484|NCT00583830|Active Comparator|A|Paclitaxel and carboplatin
3285485|NCT00583830|Experimental|B|Paclitaxel, carboplatin and Mapatumumab 10 mg/kg
3285486|NCT00583830|Experimental|C|Paclitaxel, carboplatin and Mapatumumab 30 mg/kg
3285487|NCT00583817|Experimental|Ascending Aortic Arm|Investigational endovascular stent-graft implantation to exclude aneurysm or repair dissection of the ascending aorta.
3285488|NCT00583817|Experimental|Arch Branch Arm|Investigational endovascular stent-graft implantation to exclude aneurysm or repair dissection of the aortic arch.
3285489|NCT00583804|Experimental|Stimulation ON|Individuals implanted with stimulator/sensor device. Stimulator is turned on and is active.
3285490|NCT00583804|Active Comparator|Stimulation OFF|Function with stimulation turned off.
3285491|NCT00583791|Experimental|1|
3285492|NCT00583778|Active Comparator|1|levalbuterol 1.25 mg every 20 minutes for 3 doses plus placebo (saline)
3285493|NCT00583778|Experimental|2|ipratropium 0.5 mg nebulized every 20 minutes for 3 doses added to levalbuterol 1.25 mg every 20 minutes for 3 doses
3285494|NCT00583765||A|Critically ill patients with acute renal failure requiring continuous renal replacement therapy
3285495|NCT00583752|Experimental|Arm B|On Arm B, subjects will be started on androgen deprivation therapy (ADT) 14 days prior to beginning the vaccinations.
3285496|NCT00583752|Experimental|Arm A|On Arm A, subjects can begin the three vaccinations immediately.
3285497|NCT00583739|Active Comparator|1|Yoga intervention
3285498|NCT00583739|No Intervention|2|Control. No Yoga for 8 weeks.
3285499|NCT00583726|Active Comparator|1|The control arm receives written information and pedometers
3285500|NCT00583726|Experimental|2|This arm also receives telephone counseling.
3285501|NCT00583713|Experimental|Renal Group|Patients with moderate renal impairment
3285502|NCT00583713|Active Comparator|Healthy volunteers|Healthy volunteers
3285503|NCT00583713|Experimental|Hepatic Group|Patients with mild/moderate hepatic impairment.
3285504|NCT00583700|No Intervention|1|Control for study - watchful waiting.
3285505|NCT00583700|Experimental|2|Combined treatment with Pentoxifylline and Vitamin E.
3285506|NCT00583674|Experimental|B|
3285507|NCT00583674|Experimental|A|
3285508|NCT00583674|Active Comparator|C|
3285509|NCT00583661|Experimental|EXCOR Pediatric|Implantation of the EXCOR Pediatric Ventricular Assist Device
3285510|NCT00583648|Experimental|1|Recieves urinalysis by nurse per set protocol based off of inclusion criteria
3285511|NCT00583648|No Intervention|2|ordering of test will be up to the treating physician
3285512|NCT00583635||1|Low Risk Pregnancy, Placebo
3285513|NCT00583635||2|Low Risk Pregnancy, Active Food Supplement
3285514|NCT00583635||3|High Risk Pregnancy, Placebo
3285515|NCT00583635||4|High Risk Pregnancy, Active Food Supplement
3285610|NCT00582699||2|Patients with pancreatic cancer who do not meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25)
3285516|NCT00583622|Experimental|Bevacizumab + High-Dose Chemotherapy|Bevacizumab 5 mg/kg by vein (IV) daily over 90 minutes for 2 Days + Carboplatin 333 mg/m^2 by vein over 2 hours for 3 Days + Docetaxel 300 mg/m^2 by vein over 2 hours for 1 Day + Gemcitabine 1,800 mg/m2 by vein over 3 hours for 4 Days + Melphalan 50 mg/m^2 by vein over 15 minutes for 3 Days + Stem Cell Transplant
3285517|NCT00583609|Experimental|1|PEG3350
3285518|NCT00583596|Experimental|implant to close PDA|
3285519|NCT00583570|Experimental|A|
3285520|NCT00583557|Experimental|Belimumab|
3285521|NCT00583544|Placebo Comparator|1|
3285522|NCT00583544|Experimental|2|
3285523|NCT00583531|Experimental|I|Active treatment with AST-120
3285524|NCT00583492|Experimental|Ad5-yCD/mutTKSR39rep-ADP + IMRT|Gene Therapy + IMRT
3285525|NCT00583492|Active Comparator|IMRT Alone|IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
3285526|NCT00583479|Other|A|subjects who get one medication injection into the celiac ganglion during the EUS
3285527|NCT00583479|Other|B|subjects who get divided dose of the medication injected into two locations within the celiac ganglion during the EUS
3285528|NCT00583466|Active Comparator|1 Normal saline arm|Polypectomy with normal saline injected for submucosal cushion creation
3285529|NCT00583466|Active Comparator|2 HPMC arm|Polypectomy after injection of hydroxypropyl methylcellulose (HPMC) to create submucosal cushion
3285530|NCT00583466|Experimental|3 Blood arm|Polypectomy after injection of autologous blood
3285531|NCT00583453|Active Comparator|A|Celecoxib 200 mg tablets
3285532|NCT00583453|Placebo Comparator|B|Placebo with same dosing schedule as the active comparator arm
3285533|NCT00583440|Experimental|1|
3285534|NCT00583440|Active Comparator|2|
3285535|NCT00583427|Experimental|Sulodexide|
3285536|NCT00583414|Experimental|Endovascular Aneurysm Repair|Investigational stent-graft implant to exclude aneurysm
3285537|NCT00583388||A|42 healthy subjects aged 18 to 60 will be be randomly assigned to 6 different treatment sequences.
3285538|NCT00583375|Active Comparator|Group 1|"Standard Rigid Fixation plus autograft~Standard of Care: Autologous Bone Graft"
3285539|NCT00583375|Experimental|Group 2|Standard Rigid Fixation plus Augment® Bone Graft
3285540|NCT00583362|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV over one hour every 28 days.
3285541|NCT00583349|Experimental|Abraxane administration|Patients will restrict their fluid intakes the morning of treatments and will have emptied their bladders at each of their visits and have up to 100ml of Abraxane solution administered to their bladder via urinary catheter once weekly for six weeks.
3285542|NCT00583336|Experimental|Diagnostic|
3285543|NCT00583323|Experimental|1|Lomotil given
3285544|NCT00583323|Placebo Comparator|2|Normal Saline given
3285545|NCT00583310|No Intervention|Control|Subjects receive standard written educational information at baseline, but do not receive the telephone-based intervention. Subjects may participate in the intervention following completion of the study.
3285546|NCT00583310|Experimental|Intervention|Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
3285547|NCT00583297||ABCD Subjects|The cohort will consist of original subjects of the ABCD trial who consent to participate in the genetic sub-study
3285548|NCT00583271||1|subjects who are getting a celiac block for chronic pancreatitis
3285549|NCT00583271||2|subjects who are getting a celiac block for pancreatic cancer
3285550|NCT00583258|Experimental|A|
3285551|NCT00583258|Placebo Comparator|B|
3285552|NCT00583245|Experimental|1|Gait training
3285553|NCT00583232|Active Comparator|Corticosteroid|Subjects receiving corticosteroid therapy (1-2 mg/kg/day up to 60mg/day) with taper.
3285554|NCT00583232|Active Comparator|infliximab|Subjects receiving infliximab therapy (5 mg/kg at 0, 2 and 6 weeks, followed by every 8 week therapy)
3285555|NCT00583219|Experimental|Botox/DMSO Solution|"Subjects received Botulinum-A toxin and Dimethyl sulfoxide solution. The first 3 subjects in Phase 1 underwent bladder instillation of 50 cc of the solution utilizing 200 units of botulinum-A toxin and 50cc DMSO. The next 6 subjects in the Phase 1 trial received 300 units of botulinum-A toxin and 50cc DMSO.~All subjects in the Phase 2 trial received 300 units of botulinum-A toxin and 50cc DMSO."
3285556|NCT00583193|Other|1|Open-label Study
3285557|NCT00583180||A|Capsaicin treated patients
3285558|NCT00583180||P|Placebo treated patients
3285559|NCT00583167||A1|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA >20,000 copies/mL. CD4+ T cell count >200 cells/mm3. Group A1 will undergo continuous CSF ( cerebrospinal fluid) sampling via intrathecal catheter.
3285560|NCT00583167||A2|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA >20,000 copies/mL. CD4+ T cell count <200 cells/mm3. Group A2 will undergo continuous CSF sampling via intrathecal catheter.
3285561|NCT00583167||B|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA >20,000 copies/mL. Group B will not undergo continuous CSF sampling, but will undergo sparse CSF sampling by lumbar punctures.
3285562|NCT00583154|Experimental|1|BLI-801 Dose 1
3285563|NCT00583154|Experimental|2|BLI-801 Dose 2
3285564|NCT00583154|Experimental|3|BLI-801 Dose 3
3285565|NCT00583154|Experimental|4|BLI-801 Dose 4
3285566|NCT00583128|Experimental|1|AST-120, 2 gram sachets
3285567|NCT00583128|Placebo Comparator|2|Celphere® CP-305, stained to match appearance of AST-120, in 2g sachets
3285568|NCT00583115|Experimental|Gleevec|Drug taken orally 260mg/M2/day once per day
3285569|NCT00583102|Experimental|Lovastatin followed by Cytarabine|The subject will receive high dose cytarabine as well as lovastatin. The subject will take doses of lovastatin twice a day, about 12 hours apart. On the third day, the subject will begin high-dose cytarabine IV over 3 hours, twice a day, starting 1 hour after the lovastatin dose for 5 days.
3285570|NCT00583089||1|Algorithm Test Set
3285571|NCT00583089||2|Algorithm Development Set
3285572|NCT00583076|Experimental|1|AST-120, 2grams, three times daily
3285737|NCT00581542|Active Comparator|Moxifloxacin Opthalmic solution|
3285574|NCT00583063|Experimental|B|Rapamycin taken by mouth every day. Sunitinib (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.
3285575|NCT00583050|Experimental|Endovascular Aneurysm Repair|Endovascular Aneurysm Repair of TAAA/AAA with Fenestrated/Branched Stent Grafts
3285576|NCT00583037|Experimental|NAVA|Implementation of NAVA for 24 hours
3285577|NCT00583024|Experimental|Arm A|
3285578|NCT00583011|Experimental|A|Local anesthesia group
3285579|NCT00583011|Placebo Comparator|B|Placebo normal saline group
3285580|NCT00582998|Active Comparator|1, A|Standard post-operative wound dressing
3285581|NCT00582998|Active Comparator|2, B|Vacuum Assisted Closure (VAC) device
3285582|NCT00582972|Experimental|Experimental|Subjects will receive omeprazole 40 mg daily for 30 days
3285583|NCT00582959|Other|1|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
3285584|NCT00582946|Experimental|Magnetic Contact Hearing Aid|Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss. Acute performance and safety assessed at 4 months compared to unaided baseline pre-treatment, followed by longer-term assessment of safety up to 10 months.
3285585|NCT00582933|Experimental|1|25 research participants with HLA Identical Related Donor using PBSC, 6 with BMT
3285586|NCT00582933|Experimental|2|70 research participants with HLA-Matched Unrelated Donor using PBSC, 17 with BMT
3285587|NCT00582933|Experimental|3|25 research participants with HLA-Mismatched Related Donor using PBSC, no BMT
3285588|NCT00582907|Experimental|1|Treatment Arm A: Rilonacept (IL-1 Trap) at a dose of 2.2 mg/kg/wk (max 160 mg)given by subcutaneous injection for 3 months plus colchicine at a stable dose for those subjects already taking colchicine, or without colchicine for those intolerant or non-compliant with colchicine. Since the colchicine dose is stable throughout the study for each subject, at the prestudy dose, colchicine was not considered an intervention
3285589|NCT00582907|Placebo Comparator|2|Treatment Arm B: Placebo given by subcutaneous injection weekly with or without colchicine for 3 months. Since the colchicine dose is stable throughout the study for each subject, at the prestudy dose, colchicine was not considered an intervention.
3285590|NCT00582894|Other|A|Preparative regimen of 1)Busulfex 3.2 mg/kg/day for 2 days, infused over 3 hours, on Day-6 and Day-5 2)Fludarabine 30 mg/m2/day for 5 days on Day-6 to D-2 and 3) Alemtuzumab 10 mg/day IV on days - 5 to -1
3285591|NCT00582868||Hemorrhage|Patients having experienced subarachnoid hemorrhage and have in place a ventriculostomy
3285592|NCT00582855|Experimental|1|
3285593|NCT00582855|Placebo Comparator|2|
3285594|NCT00582842||1|Men with prostate cancer
3285595|NCT00582842||2|Men with prostate cancer
3285596|NCT00582829||1|"Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant."
3285597|NCT00582829||2|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
3285598|NCT00582829||3|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
3285599|NCT00582816|Experimental|1|patients will undergo a standard pre-transplant evaluation, but will also have blood drawn to evaluate their HLA class I killer immunoglobulin-like receptor (KIR) ligand typing. Parents will undergo KIR genotyping and phenotyping, and a donor will be selected based on which parent shows the greatest degree of KIR receptor-ligand mismatching. Once the donor has been selected he/she will undergo a peripheral blood stem cell (PBSC) collection utilizing G-CSF and GM-CSF for stem cell mobilization. The PBSC collection will be performed utilizing standard procedures. The PBSC will then be processed in the UW BMT Laboratory in order to deplete the graft of T cells. This will be accomplished using the CliniMACS cell separation system. T cell depletion is a standard procedure for patients receiving haploidentical stem cell grafts. The resulting stem cell product will be analyzed for T cell, stem cell and NK cell content.
3285600|NCT00582790|Experimental|1|Interleukin-2 subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles in combination with Zoledronic acid IV on day 1 of every 4 week (28 days) cycle.
3285601|NCT00582777|Active Comparator|USUAL|USUAL treatment - The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
3285602|NCT00582777|Experimental|HS Dosing|"HS DOSING - In this period, the patient's antihypertensive regimen at the baseline visit will be standardized for the once/day medications to be given at bedtime.~For those on monotherapy with a once/day antihypertensive regimen, the time of administration will be changed to bed time.~For those on multi-drug therapy, the time of administration of all once a day antihypertensive drugs will be changed to bed time."
3285603|NCT00582777|Experimental|ADD-ON DOSING|ADD-ON DOSING - This regimen will start with the USUAL regimen to which an additional agent will be added at bed time. An additional dose of ramipril, diltiazem, or hydralazine are three possible options for the add on medication. The intent of the ADD ON therapy is to lower nocturnal BP with minimal impact on daytime BP. Thus, agents with < 24 hr duration of action are preferred. The specific choice and dose of add-on therapy (of the three agents) will be up to the site investigator considering the clinical situation of each participant based on the guidelines below.
3285604|NCT00582764||1|Any patient undergoing MRI guided preoperative needle localization or MRI guided biopsy of the breast.
3285605|NCT00582738|Active Comparator|CsA-TAC|Continuation of current immunosuppressive regimen (continuation of Calcineurin Inhibitor [CNI] with or without Enteric-coated mycophenolate sodium (myfortic) or mycophenolate mofetil(Cellcept)[MPA], with or without steroids) / no everolimus introduction.
3285606|NCT00582738|Experimental|everolimus|Initiation of everolimus with discontinuation of CNI/MPA, with or without steroids.
3285607|NCT00582725|Experimental|R-CHOP + GM-CSF|R-CHOP therapy (6-8 cycles) with GM-CSF
3285608|NCT00582712|Experimental|Lithium Capsules|Lithium carbonate
3285609|NCT00582699||1|Patients with pancreatic cancer who meet DSMIV criteria for a current diagnosis of a Major Depressive Episode (N=25).
3285611|NCT00582699||3|Healthy controls who meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25).
3285612|NCT00582699||4|Healthy controls who do not meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25).
3285613|NCT00582686|Active Comparator|ORIF with Bone Grafting|This study will be designed as a randomized, prospective, blinded evaluation of patients who have sustained an intra-articular calcaneous fracture that would require open reduction with internal fixation as the preferred method of treatment. Group A will be made up of patients that undergo ORIF and Tricortical iliac crest bone grafting.
3285614|NCT00582686|Active Comparator|ORIF without Bone Grafting|This study will be designed as a randomized, prospective, blinded evaluation of patients who have sustained an intra-articular calcaneous fracture that would require open reduction with internal fixation as the preferred method of treatment. Group B will consist of patients that undergo open reduction with internal fixation without bone grafting
3285615|NCT00582673|Experimental|1|
3285616|NCT00582673|Placebo Comparator|2|
3285617|NCT00582660|Active Comparator|study drug BID for 7 days before surgery|400 mg Celecoxib the study drug will be given for 7 days before surgery
3285618|NCT00582660|Placebo Comparator|Placebo for 7 days before surgery|Placebo in a one to one randomization prior to surgery
3285619|NCT00582634|Experimental|Docetaxel followed by cisplatin|Docetaxel (75mg/m2) given IV followed by cisplatin (75mg/m2) given IV on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for 4 cycles.
3285620|NCT00582608|Experimental|131I-8H9 and 8H9|This is an open-label single arm study of 131 I-8H9. injected intravenously at 10mCi/1.73m^2 dose [intended specific activity of `20mCi/mg protein] preceded by administration of 50mg/1.73m2 of unlabeled -8H9.
3285621|NCT00582582|Experimental|A|Docetaxel plus doxercalciferol
3285622|NCT00582582|Placebo Comparator|B|Docetaxel plus placebo
3285623|NCT00582556|Active Comparator|1|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
3285624|NCT00582556|Active Comparator|2|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given at mo 6
3285625|NCT00582556|Active Comparator|3|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
3285626|NCT00582543|Experimental|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position.
3285627|NCT00582530||1 men with prostate cancer|Patients who have opted for radical prostatectomy as treatment for prostate cancer.
3285628|NCT00582517|Active Comparator|Group A External Brace|Group A will have a non-invasive range of motion external brace placed following surgery
3285629|NCT00582517|Experimental|Group B Compass Knee Hinge|Group B will have a Compass Knee Hinge placed
3285630|NCT00582504|Experimental|Vaccination|VEE TC-83
3285631|NCT00582491|Experimental|I|Modafinil 400mg orally everyday for 16 days
3285632|NCT00582491|Placebo Comparator|II|Placebo orally everyday for 16 days
3285633|NCT00582478||1|women with breast cancer
3285634|NCT00582465||Observation|Lupus
3285635|NCT00582452||2|Affected patients who are at high risk for metachronous colorectal tumors due to mutation status.
3285636|NCT00582452||1|Unaffected patients who are at high risk for developing colon cancer based on family history and/or mutation status.
3285637|NCT00582439|Other|1|Repair of Orthopaedic Trauma Fractures and Non-Unions
3285638|NCT00582426|Experimental|Octreotide Long Acting Release|Prevention of Chemotherapy Induced Diarrhea (CID)
3285639|NCT00582426|Other|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
3285640|NCT00582413||1|Patients who have been diagnosed with Carcinoma of the oral cavity
3285641|NCT00582400|Experimental|I|
3285642|NCT00582387||nonmuscle invasive bladder cancer|This is a hospital-based cohort study in which subjects with non-muscle invasive bladder cancer diagnosed within the previous 12 months will be evaluated to determine whether candidate genetic variants in patients with superficial bladder cancer can predict the risk of disease recurrence and/or progression, with the goal of modifying surveillance schedules as a function of predicted risk of recurrence or progression. All patients will be treated according to the treatment plan as outlined by their attending physician. The study will not require any deviation from the planned usual treatment.
3285643|NCT00582374||A|Pregnant Women
3285644|NCT00582361|Active Comparator|1, A|Group A patients will have a standard dressing applied following initial treatment of their open fracture.
3285645|NCT00582361|Experimental|2, B|Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture.
3285646|NCT00582309|Active Comparator|Glucommander|Glucommander-Guided Intravenous Insulin Infusion
3285647|NCT00582309|Active Comparator|Standard|Standard Intravenous Insulin Infusion Algorithm consists of four levels (Algorithm 1-3 and a doubling of the insulin rate). Most patients begin in algorithm 1, where the insulin rate varies from 0.2 units per hour for BG in the range 70-109 mg/dl up to 6 units/hr for BG > 360 mg/dl. If algorithm 1 fails to bring the patient's BG into target range in 2 hrs, then the patient is moved up to algorithm 2, where the insulin rate varies from 0.5 to 12 units/hr; and if that fails, the patient moved up to algorithm 3, where insulin rate varies from 1 to 16 units/hr depending on the latest BG. Algorithm failure is a blood glucose outside the target range for 2 hrs, and the blood glucose does not decrease by at least 60 mg/dl within 1 hr. If algorithm 3 fails, the insulin rate is doubled.
3285648|NCT00582309|Active Comparator|Simple|Simple Calculated Intravenous Insulin Infusion consists of an initial insulin infusion rate varying from 0.5 units per hour for BG in the target range 80-120 mg/dl up to 8 units/hour for BG > 400 mg/dl. After the initial insulin rate and if BG is still > 120 mg/dl, then the insulin rate is increased by 1-2 units every 1 hour until BG is in the target range. If BG is still >120 mg/dl in 2 hours, then the insulin rate is doubled.
3285649|NCT00582296||1|multi-organ follow-up
3285650|NCT00582296||2|control follow-up
3285651|NCT00582283|Other|Diagnostic: iodine I-124 NM404 CT/PET scan|Patients undergo iodine I-124 NM404 CT/PET scan at 1-2, 4-6, 24, and 48 hours and at 5-10 days.
3285652|NCT00582270||1|Follicular Lymphoma
3285653|NCT00582270||2|Non-follicular Lymphoma
3285654|NCT00582257||High Genetic Risk:|"Early Onset Gastric Cancer - diagnosis of gastric cancer before the age of 50 without a family history of the disease.~Familial Gastric Cancer - having a family history of gastric cancer as defined as one first degree relative or 2 second degree relatives.~Relative - Relatives of participants eligible for the High Genetic Risk Cohort will be eligible for participation. These relatives may also be at high risk of developing gastric cancer. These individuals will fall under the Cancer Cohort. Eligible relatives will be defined as someone having a relative who meets criteria for either the Early Onset Cancer Cohort or the Familial Gastric Cancer Cohort, or having a family history of a genetic mutation known to be associated with gastric cancer."
3285655|NCT00582257||Low Genetic Risk: Closed to Accrual|"Sporadic Gastric Cancer - gastric cancer that appears to have occurred by random or sporadic mutation. Specifically, a patient with gastric cancer not eligible for either High Genetic Risk cohort.~Control (closed to accrual) - A participant that is not a blood relative of a patient or relative participant, without gastric cancer and without a family history of a CDH1 gene mutation. Select MSK participants with Hereditary Diffuse Gastric Cancer with identified CDH1 germline genetic mutation will be invited by MSKCC only to complete the onetime Pre-implantation Genetic Diagnosis (HDGC PGD) survey. These patients may be verbally consented over the telephone."
3285656|NCT00582244|Experimental|1|CBT and relaxation.
3285657|NCT00582244|Experimental|2|Physical activity
3285658|NCT00582244|Experimental|3|CBT and physical activity
3285659|NCT00582244|No Intervention|4|Control group
3285660|NCT00582231||1|Participants that are starting penile injections therapy.
3285661|NCT00582205|Experimental|Paclitaxel, Cisplatin IP|There is only one arm for this study and it represents the participants receiving the intraperitoneal chemotherapy
3285662|NCT00582192||1|Participants with certain types of cancers that are eligible for studies at Memorial Sloan-Kettering Cancer Center.
3285663|NCT00582179|Active Comparator|1, A|Group A patients will be treated with a pressure dressing and observation.
3285664|NCT00582179|Active Comparator|2, B|Group B patients will be treated with a Vacuum Assisted Closure device (VAC).
3285665|NCT00582166|Experimental|Ibritumomab Tiuxetan (Zevalin) with Rituximab maintenance|
3285666|NCT00582140|Experimental|Cohort Level 1|pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
3285667|NCT00582140|Experimental|Cohort Level 2|pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
3285668|NCT00582140|Experimental|Cohort Level 3|pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
3285669|NCT00582127||1|Mild-moderate Alzheimer's Disease
3285670|NCT00582127||2|Age-matched Controls
3285671|NCT00582114|Active Comparator|1|Atenolol
3285672|NCT00582114|Experimental|2|Lisinopril
3285673|NCT00582101|Experimental|Family-based HIV|
3285674|NCT00582101|Active Comparator|Family-based HP|
3285675|NCT00582088|Experimental|Vaccine|VEE C-84 - Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI-GSD 205
3285676|NCT00582075|Experimental|Radiosurgery 15-24 Gy + Adjuvant Temozolomide|
3285677|NCT00582062||1|Positive controls will include patients who have positive cytology or positive biopsy of peritoneal metastases. Cell lines which over-express these tumor markers will also be used as positive controls. Sensitivity will be defined using serial dilutions of several established gastric and pancreatic tumor cell lines. The mRNA of the tumor markers will be normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA expression.
3285678|NCT00582062||2|Patients who are scheduled to undergo laparoscopy for benign disease (e.g., laparoscopic cholecystectomy, hernia repair, or prophylactic BSO) will be recruited as negative controls. A leukemia cell line which does not express epithelial cell markers will also be used as a negative control for the RT-PCR reactions.
3285679|NCT00582049||1|Cases: retinoblastoma patients
3285680|NCT00582049||2|Controls: first cousins or other blood relatives of the retinoblastoma patients (relative controls) or friends of the retinoblastoma patients or children of friends of the parents (friend controls).
3285681|NCT00582036|Active Comparator|Arm 1|Regular Sliding Scale Insulin administration for hyperglycemia
3285682|NCT00582036|Experimental|Arm 2|MiniMed Paradigm monitoring device for hyperglycemia
3285683|NCT00582010|Experimental|1. Experimental|iNO administration
3285684|NCT00582010|Placebo Comparator|2. Placebo|Placebo (nitrogen)
3285685|NCT00581997|Experimental|1|QAX576
3285686|NCT00581997|Placebo Comparator|2|Placebo
3285687|NCT00581971|Experimental|Celecoxib+Carboplatin/Paclitaxel+Radiation Therapy|
3285688|NCT00581958||Patients undergoing HSCT|Research subjects will have blood and/or urine sampled at three time points in the Department of Radiation Oncology. Participating patients will have at least a total two samples collected at each time point. The first sampling will occur before the first TBI treatment is given. The second sampling will occur before the second TBI treatment, usually 3 to 8 hours after the first treatment (in the case of multifraction TBI). If a patient is being treated with single fraction TBI, then the second sampling will occur approximately 3-8 hours after the first TBI treatment. The third and final sampling will occur at the next morning blood draw, prior to the fourth TBI treatment (in the case of multifraction TBI), 24 hours after the first TBI treatment.
3285689|NCT00581945|Experimental|Canakinumab|Participants received an initial dose of 1 mg/kg canakinumab (ACZ885) via intravenous infusion. Four weeks later, participants received a dose of 3 mg/kg canakinumab, and another dose of 3 mg/kg two weeks later. Thereafter, participants received doses of 6 mg/kg every four weeks until completion of the 45-week treatment period.
3285690|NCT00581945|Placebo Comparator|Placebo|Participants received a matching placebo intravenous infusion at weeks 1, 5, 7, and thereafter every four weeks until completion of the 45-week treatment period.
3285691|NCT00581932||A|One group, all subjects with DSM-IV diagnosis of Schizophrenia, age 18-65 who are initiating clozapine therapy.
3285692|NCT00581919|Experimental|Bort, Dex, and Dox with ALCAR|
3285693|NCT00581906||pts undergoing surgery or chemo-radiation treatment|
3285694|NCT00581893|Experimental|1|Phenytoin administration
3285695|NCT00581893|Placebo Comparator|2|Placebo
3285696|NCT00581880||1|Terminally Ill patients
3285738|NCT00581542|Active Comparator|Polymyxin B-trimethoprim opthalmic solution|
3285697|NCT00581867|Experimental|Intranasal Insulin Aspart|Participants were administered intranasal insulin aspart (40 IU) in a double-blinded fashion approximately 30 minutes prior to functional MRI scanning. After a washout period of 48 hours, participants completed the other arm. The order of saline vs. insulin was counterbalanced.
3285698|NCT00581867|Active Comparator|Intranasal Saline (placebo)|Participants were administered intranasal saline (placebo) in a double-blinded fashion approximately 30 minutes prior to functional MRI scanning. After a washout period of 48 hours, participants completed the other arm. The order of saline vs. insulin was counterbalanced.
3285699|NCT00581841||1|Healthy adult participants with no history of knee injury or osteoarthritis.
3285700|NCT00581828|Experimental|1|Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).
3285701|NCT00581815|Experimental|1|
3285702|NCT00581802||1|Intensively studied participants initiating potentially suppressive drug therapy. Group 1 participants may undergo optional leukapheresis. Group 1 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 1 participants will default to either Group 3 or Group 4.
3285703|NCT00581802||2|Intensively studied, well-suppressed participants on HAART. Participants in Group 2 may undergo optional leukapheresis. Group 2 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 2 participants will default to either Group 3 or Group 4.
3285704|NCT00581802||3|Nonintensively studied participants initiating potentially suppressive drug therapy
3285705|NCT00581802||4|Nonintensively studied well-suppressed participants on HAART
3285706|NCT00581802||5|Intensively studied participants who are currently participating in the Merck Expanded Access Program and receiving raltegravir. Participants in Group 5 may undergo optional leukapheresis. Group 5 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 5 participants will default to either Group 3 or Group 4.
3285707|NCT00581789|Experimental|1|Erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
3285708|NCT00581776|Experimental|VCR-CVAD with rituximab maintenance|Induction chemotherapy with Bortezomib, cyclophosphamide, rituximab, vincristine, doxorubicin, and dexamethasone. Subjects will receive 6 cycles of induction chemotherapy, of 21 days each. After completing induction, subjects will receive rituximab consolidation (4 weeks), and then rituximab maintenance therapy for up to 5 years.
3285709|NCT00581763||Observation|Those with a condition
3285710|NCT00581750||LCIS diagnosis|Patient with LCIS diagnosis
3285711|NCT00581724||1|"First 50 breast cancer survivors and then after demonstrating feasibility of the study design in the first 50 participants, recruitment will be opened to the other services Colorectal, Genitourinary, Head and Neck, and Thoracic.~Participants will be recruited in allotments of 50 patients from each service."
3285712|NCT00581711|No Intervention|Control|Usual Care
3285713|NCT00581711|Experimental|HIT Intervention without feedback|3-Part Intervention: Training, Otitis Media Episode Grouper, Clinical Decision Support
3285714|NCT00581711|Experimental|HIT Intervention with feedback|4-Part Intervention: Training, Episode Grouper, Clinical Decision Support, and Physician Feedback.
3285715|NCT00581711|Experimental|Feedback only|1 part intervention: Physician Feedback
3285716|NCT00581698||Surgical|Patients with primary melanomas Clark III and Breslow thickness > 1 mm, or Clark IV-V and any Breslow thickness, and clinically negative regional nodes
3285717|NCT00581685|Placebo Comparator|2|Prospective, single center, randomized, double-blinded, placebo controlled study
3285718|NCT00581672||questionnaires|Black men with prostate cancer
3285719|NCT00581659||Lens A, Lens B|The first independent variable is the contact lens. Each subject will wear both PureVision (TM0 aspheric contact lenses and conventional spherical contact lenses on separate visits. The second independent variable is visibility condition. Subjects will complete the study drive both in clear nighttime conditions and at night under glare conditions. In both cases, the driver will experience oncoming traffic; however, in the glare condition, the simulator will be equipped with a point light source sufficient to provide glare similar to that provided by oncoming traffic in the real world.
3285720|NCT00581646||1|gynecologic cancer survivors
3285721|NCT00581646||2|survivors of any type of malignancy with history of BMT/SCT
3285722|NCT00581646||3|non-cancer infertile women awaiting third party reproduction
3285723|NCT00581633|Experimental|1|saline infusion for sodium loading
3285724|NCT00581620|Active Comparator|G1|G1: HIV+
3285725|NCT00581620|Active Comparator|G2|G2: Sicle Cell disease
3285726|NCT00581620|Active Comparator|G3|G3: neprotic symdrome
3285727|NCT00581620|Active Comparator|G4|G4: Chronic pulmonary disease
3285728|NCT00581607|Active Comparator|Bosentan for 16 weeks|Active drug
3285729|NCT00581607|Placebo Comparator|Placebo|Placebo for 16 weeks
3285730|NCT00581594|Other|1|Posterior repair with graft augmentation.
3285731|NCT00581594|Other|2|Posterior repair without graft augmentation.
3285732|NCT00581581||1|Randomized to cooling (original randomized clinical trial): All children, now 6-8 years old who were randomized to cooling in the original trial were included in this arm. Cooling was achieved via the CoolCap system (Olympic Medical/Natus Corporation) in these babies.
3285733|NCT00581581||2|Randomized to standard care (original randomized clinical trial): All children, now 6-8 years old, who were treated using the standard of care at the time (normal temperature) were included in this arm. Infants' temperatures were monitored per standard of care. Most infants were cared for on an open wamer that was servo-controlled to normal body temperature (37 C) or in a standard bassinette.
3285734|NCT00581568|Experimental|Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
3285735|NCT00581555|Experimental|etanercept|Participants were administered a 50 mg dose of etanercept subcutaneously once a week after an initial course of ciclosporin.
3285736|NCT00581555|Placebo Comparator|placebo|Participants were administered placebo subcutaneously once a week after an initial course of ciclosporin.
3285739|NCT00581529|Experimental|Radiotherapy|IMRT (Intensity-modulated Radiation Therapy), 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
3285740|NCT00581503||diagnostic|oct imaging
3285741|NCT00581490||Idiopathic premature pubarche|Children with premature pubarche without precious puberty, adrenal hyperplasia or androgen secreting tumors
3285742|NCT00581477|Placebo Comparator|2|
3285743|NCT00581477|Experimental|1|
3285744|NCT00581464|Active Comparator|1|
3285745|NCT00581464|Active Comparator|2|
3285746|NCT00581451|Experimental|A|bifeprunox 25 day
3285747|NCT00581451|Experimental|B|bifeprunox 14 day
3285748|NCT00581451|Experimental|C|bifeprunox 14 day
3285749|NCT00581451|Experimental|D|bifeprunox 9 day
3285750|NCT00581438||1|
3285751|NCT00581425|Experimental|Treated|
3285752|NCT00581399|Experimental|NO-NUMO Chest Tube|The NO-NUMO™ High Vacuum Body Cavity Drainage System consist of disposable NO-NUMO™ body cavity drainage tubes, disposable Vario™ fluid management canisters Vario™ portable vacuum pump
3285753|NCT00581399|Active Comparator|Standard Chest Tube|Classic PVC Chest Tube
3285754|NCT00581386|Experimental|LTS-D|All the cases were divided into one of the group LTS-D, PLMA, and ETC
3285755|NCT00581386|Experimental|ProSeal Laryngeal Mask Airway|All patients were divided into either LTS-D, PLMA, or the ETC group.
3285756|NCT00581386|Experimental|Esophageal Tracheal Combitube (ETC)|All patients are divided into one of the group, LTS-D, PLMA, or the ETC.
3285757|NCT00581373|Experimental|1|water 16 oz
3285758|NCT00581360|Other|Bortezomib + Doxorubicin|Patients with incurable adenoid cystic carcinoma of the head and neck who receive doxorubicin and bortezomib
3285759|NCT00581347|Other|Outreach|Receives outreach services
3285760|NCT00581347|No Intervention|Standard of Care|Receives standard medical care provided by primary care practice.
3285761|NCT00581321|Experimental|1|water ingestion
3285762|NCT00581308|Experimental|GORE® HELEX® Septal Occluder|Subjects who received a GORE® HELEX® Septal Occluder
3285763|NCT00581295||trauma|Diffuse optical spectroscopy measurment
3285764|NCT00581282||1|Cocaine abstinent group
3285765|NCT00581282||2|Normal healthy control group
3285766|NCT00581269|Active Comparator|1|low-impact aerobic exercise group
3285767|NCT00581269|Active Comparator|2|dietary restriction group
3285768|NCT00581269|No Intervention|3|control group
3285769|NCT00581256|Experimental|1|Best Delivery-optimized radiotherapy technique (IMRT)
3285770|NCT00581256|Active Comparator|2|Best 3-dimensional standard PWTF technique
3285771|NCT00581243|Experimental|1|2 mg SLV-313 SR (fixed dose)
3285772|NCT00581243|Experimental|2|5 mg SLV-313 SR (fixed dose)
3285773|NCT00581243|Experimental|3|10 mg SLV-313 SR (fixed dose)
3285774|NCT00581243|Experimental|4|xx mg SLV-313 SR (titration)
3285775|NCT00581230|Experimental|Laryngoscopy without RAMP|First, laryngoscopy will be preformed utilizing a traditional Macintosh size 4 blade laryngoscope. The view of the laryngeal aperture will be recorded, and a photo will be taken by the Airway Cam™.
3285776|NCT00581230|Experimental|Laryngoscopy with RAMP|Next, the Rapid Airway Management Positioner (RAMP) will be positioned and inflated underneath the patient so that the patient is placed in the optimal sniffing position. The investigator will again perform laryngoscopy utilizing the same technique and the laryngeal view will be recorded.
3285777|NCT00581217||Single arm study|Burn patients or patients with skin loss requiring split-thickness skin graft
3285778|NCT00581204||Diagnostic Tool|Near-Infrared Diffuse Optical Spectroscopy Imaging
3285779|NCT00581191|Experimental|1|0.5 mg SLV-351 (fasted)
3285780|NCT00581191|Experimental|2|1 mg SLV-351 (fasted)
3285781|NCT00581191|Experimental|3|2.5 mg SLV-351 (fasted)
3285782|NCT00581191|Experimental|4|5 mg SLV-351 (fasted)
3285783|NCT00581191|Experimental|5|10 mg SLV-351 (fasted)
3285784|NCT00581191|Experimental|6|15 mg SLV-351 (fasted)
3285785|NCT00581191|Experimental|7|20 mg SLV-351 (fasted)
3285786|NCT00581191|Experimental|8|30 mg SLV-351 (fasted)
3285787|NCT00581191|Experimental|9|xx mg SLV-351 (fasted and fed)
3285788|NCT00581139|Active Comparator|1|
3285789|NCT00581139|Active Comparator|2|
3285790|NCT00581139|Active Comparator|3|
3285791|NCT00581139|Active Comparator|4|
3285792|NCT00581126|Experimental|1|Patients will receive Benefix IV according to blood amount
3285793|NCT00581113|Active Comparator|1|Standard Whole Brain Radiotherapy
3285794|NCT00581113|Experimental|2|Neural Stem Cell-Preserving Whole Brain Radiotherapy
3285795|NCT00581100|Active Comparator|1|etanercept 50 mg SC injection twice weekly for 12 weeks reducing to etanercept 50 mg once weekly to week 24
3285796|NCT00581100|Active Comparator|2|etanercept 50 mg SC once weekly for the complete 24 week treatment period
3285797|NCT00581087|Experimental|1|DHEA
3285798|NCT00581087|Placebo Comparator|2|Placebo
3285799|NCT00581074|Active Comparator|G|grapefruit
3285800|NCT00581074|Active Comparator|J|Juice
3285801|NCT00581074|Placebo Comparator|W|placebo
3285802|NCT00581061|Experimental|Vesicare Treatment|
3285803|NCT00581048|Experimental|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
3285804|NCT00581035|Experimental|1|Prevenar and Meningitec
3285805|NCT00581035|Experimental|2|Prevenar
3285806|NCT00581035|Experimental|3|Meningitec
3285807|NCT00581022||1|Patients with Chronic Orthostatic Intolerance
3285808|NCT00581009|Experimental|1|chronobiological augmentation group
3285809|NCT00581009|Experimental|2|medication only group
3285810|NCT00581009|Experimental|MDD Mechanism|
3285811|NCT00580996|Experimental|1|16 oz water in AM
3285812|NCT00580996|Active Comparator|2|water 1 oz in AM
3285852|NCT00580710||conventionally treated|conventionally treated, relatively poorly controlled patients with type 1 diabetes
3285853|NCT00580710||intensively treated|intensively treated, well controlled patients with type 1 diabetes
3285813|NCT00580983|Experimental|Chemo-IMRT|"Chemotherapy:~Chemotherapy will consist of Paclitaxel 30mg/m² IV over 1 hour, followed by Carboplatin (AUC 1) IV over 30 minutes, or Carboplatin 100mg/m² per IV over 30 minutes or Cisplatin 100mg/m² per IV over 1 hour, or Cisplatin (80mg/m²) or Carboplatin (AUC 5) IV on day 1 and 5-Fluorouracil (1000mg/m²) as a 24-hour continuous infusion, daily x 4 days.~Intensity-modulated Radiation Therapy (IMRT):~Primary RT: 70 Gy to gross disease and 56-63 Gy to subclinical disease in 35 fractions.~Post-operative RT: 64 Gy to high-risk targets (postoperative tumor bed, first-echelon nodes) and 57.6 Gy to low-risk targets, in 32 fractions."
3285814|NCT00580970|Experimental|Lovastatin for 1 yr|Lovastatin (20-80 mg/d) was started on day 1 of radiation and continued for 12 months. Patients were followed for an additional 12 months. Lovastatin once per day for 1 year. After the implant, they are asked to return for checkups (study visits 4-13) 4 weeks, 8 weeks, 4 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months and 24 months after the procedure. At 8 weeks, 4 months, 6 months, 9 months and 12 months, will also have a blood test to check their liver.
3285815|NCT00580957|Experimental|Blocked|Active treatment arm. Transient autonomic blockade with Trimethaphan and blood pressure restoration with L-NMMA will be used during insulin clamp
3285816|NCT00580957|Placebo Comparator|Intact|Saline will be used instead of trimethaphan during insulin clamp
3285817|NCT00580944|Experimental|Port Wien Stain Birthmark|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
3285818|NCT00580931|Experimental|1|Subjects will receive experimental drug in a blinded fashion.
3285819|NCT00580931|Placebo Comparator|2|Identical in size, shape and color to experimental drug.
3285820|NCT00580918||1|Mild Traumatic Brain Injury group
3285821|NCT00580918||2|Normal healthy control group
3285822|NCT00580905|Active Comparator|1|To compare the effects of adenosine at a dose of 80 mcg/kg/min for 30 minutes, Sodium nitroprusside will be used at a dose that produce similar systemic effects (5 mcg/kg/.min)
3285823|NCT00580905|Active Comparator|2|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
3285824|NCT00580892||Airway and Pleural Disorders|Optical Coherence Tomography imaging
3285825|NCT00580866|Experimental|Joint Active Systems Brace (JAS Brace)|Elbow is placed in a brace to apply an extension force
3285826|NCT00580866|No Intervention|PT Only Group|No brace is used
3285827|NCT00580853|Experimental|varenicline|varenicline 2mg/day
3285828|NCT00580853|Experimental|Bupropion|Bupropion 300mg/day
3285829|NCT00580853|Placebo Comparator|Placebo|Placebo Control
3285830|NCT00580840|Active Comparator|Certolizumab pegol 400 mg and placebo|400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
3285831|NCT00580840|Experimental|Certolizumab pegol 200 mg and placebo|200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
3285832|NCT00580840|Placebo Comparator|Placebo|Placebo administered as two injections every 2 weeks
3285833|NCT00580827|Placebo Comparator|placebo disulfiram|placebo disulfiram (0 mg/day)
3285834|NCT00580827|Experimental|disulfiram 62.5|disulfiram at 62.5 mg/day
3285835|NCT00580827|Experimental|disulfiram 125|disulfiram at 125 mg/day
3285836|NCT00580827|Experimental|disulfiram 250|disulfiram at 250 mg/day
3285837|NCT00580801|Experimental|Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin|Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 2 to 50.
3285838|NCT00580801|Experimental|Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin|Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily), from Week 1 to 48.
3285839|NCT00580801|Active Comparator|Placebo+Pegylated-interferon-alfa-2a+Ribavirin|Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks along with pegylated-interferon-alfa 2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily), from Week 1 to 48.
3285840|NCT00580788|Experimental|PTHrP(1-36) 2 pmol/kg/hr|PTHrP(1-36) at 2 picomoles/kg/hr for one week.
3285841|NCT00580788|Experimental|PTHrP (1-36) 4 pmol/kg/hr|PTHrP(1-36) at 4 picomoles/kg/hr for one week.
3285842|NCT00580788|Experimental|PTHrP(1-36) 5 pmol/kg/hr|PTHrP(1-36) at 5 picomoles/kg/hr for one week.
3285843|NCT00580788|Experimental|PTHrP(1-36) 6 pmol/kg/hr|PTHrP(1-36) at 6 picomoles/kg/hr for one week.
3285844|NCT00580775||Placebo|Observing heart rate variability in placebo and active estrogen preparations
3285845|NCT00580775||Active estogen|Observing heart rate variability in placebo and active estrogen preparations
3285846|NCT00580762|Experimental|ESRD|End-Stage Renal Disease (ESRD) patients on dialysis who meet the NIH guidelines and preoperative requirements for RYGB will undergo laparoscopic RYGB
3285847|NCT00580762|Active Comparator|Non-ESRD|Non-ESRD patients who meet the NIH guidelines and preoperative requirements for RYGB will undergo laparoscopic RYGB
3285848|NCT00580749|Active Comparator|DJ|Naso disal jejunal(DJ) feedings randomized to 50% of subjects meeting criteria.
3285849|NCT00580749|Active Comparator|NG|Placement of naso gastric feeding tube through nare into stomach for enteral feeding.
3285850|NCT00580736|Experimental|Optical Clearing|Optical Clearing
3285851|NCT00580723|Experimental|PRK 124|Topical PRK 124 (Pyratine-6)(0.125%) moisturizing lotion applied twice daily to the face for 48 weeks. Subjects will wash their faces prior to application. The applications will occur in the mornings and one hour before bedtime.
3285937|NCT00580047|Active Comparator|1|Zoledronic Acid 4mg intravenously once a year for 2 years
3285854|NCT00580710||lean healthy|age- and sex- matched non-diabetic, normal weight (BMI > or = 18.5 but < or = 25 kg/m2) control subjects
3285855|NCT00580710||obese subjects|obese individuals defined as BMI > or = 30kg/m2
3285856|NCT00580710||type 2 diabetics|Type 2 diabetics on diet only or diet and Metformin
3285857|NCT00580710||type 1 diabetes unaware|Type 1 diabetics unaware of hypoglycemic symptoms
3285858|NCT00580710||type 1 diabetes aware|Type 1 diabetics aware of hypoglycemic symptoms
3285859|NCT00580684|Active Comparator|G1|G1: prevenar
3285860|NCT00580684|Active Comparator|G2|G2: pneumo 23
3285861|NCT00580671|Experimental|MET/CBT+CM/BPT|Integrated psychosocial counseling. 14 weekly session. Twice weekly urine testing. Abstinence-based incentives based on urine test results. 14 weekly behavioral parenting sessions.
3285862|NCT00580671|Experimental|MET/CBT+CM|Integrated psychosocial counseling. 14 weekly sessions. Twice weekly urine testing. Abstinence-based incentives based on urine test results.
3285863|NCT00580671|Active Comparator|MET/CBT|Integrated psychosocial counseling. 14 weekly sessions.
3285864|NCT00580645|Experimental|varenicline|varenicline 1mg/day or 2mg/day
3285865|NCT00580645|Placebo Comparator|Placebo|Placebo Controlled
3285866|NCT00580619|Experimental|1 (markers of sympathetic activity)|To evaluate if the various indices of sympathetic activity (Autonomic Function Testing) differ between patients with chronic fatigue syndrome and postural tachycardia syndrome (CFS-P), and CFS without POTS.
3285867|NCT00580619|Experimental|2 (saline)|To test the null hypothesis that there is no difference between two saline therapies (pulse saline vs. sham saline) in improving both the fatigue score and postural tachycardia syndrome.Saline infusions
3285868|NCT00580619|Experimental|3 (NO inhibition/ autonomic blockade)|Response to nitric oxide inhibition in the presence and absence of an intact autonomic nervous system will be evaluated. L-NMMA trimethaphan will be used for NO inhibition and autonomic blockade, respectively.
3285869|NCT00580619|Active Comparator|4 (methyldopa)|The effects of chronic autonomic withdrawal on improving symptoms of chronic fatigue and postural tachycardia syndrome will be evaluated
3285870|NCT00580606|Experimental|Low Dose Peanut SLIT (Double Blind to Open Label)|Subjects ingest peanut protein (glycerinated peanut allergenic extract) daily starting with 0.000165 mcg, followed by a build-up phase (escalating peanut doses every 2 weeks, achieving maintenance dose by 36 weeks). Thereafter, subjects are on a maximally tolerated maintenance dose (165 mcg to 1,386 mcg) for >= 8 weeks. After Week 44, subjects are given a 5,000 mg Oral Food Challenge (OFC) using peanut powder. Subjects/study staff are unblinded following this OFC and continue on an open label peanut protein maintenance dose of 1,386 mcg/day or may attempt escalation up to this dose. Subjects who at the Week 116 OFC are unable to consume >= 5,000 mg peanut powder or 10-fold the amount of peanut powder compared to the baseline OFC will discontinue study therapy. SLIT=Sublingual Immunotherapy.
3285871|NCT00580606|Placebo Comparator|Placebo (DB) Crossed Over to High Dose Peanut SLIT (OL)|Subjects ingest placebo (glycerin) daily beginning with a dose of 0.000165 mcg, followed by a build-up phase (escalating placebo doses every 2 weeks, achieving a maintenance dose by 36 weeks). Thereafter, subjects are on a maximally tolerated maintenance dose (165 mcg to 1,386 mcg) for >= 8 weeks. After Week 44, subjects are given a 5,000 mg Oral Food Challenge (OFC) using peanut powder. Subjects/study staff are unblinded following this OFC and subjects no longer receive placebo dosing but are crossed over and receive open label high dose peanut SLIT; the study procedures and schedule are the same as for the Low Dose Peanut SLIT group, the only difference is the maximum maintenance dose is almost 3-fold higher at 3,696 mcg/day. DB=Double Blind, SLIT=Sublingual Immunotherapy, OL=Open Label.
3285872|NCT00580593|Active Comparator|1|
3285873|NCT00580593|Sham Comparator|2|
3285874|NCT00580580|Active Comparator|1|"Administration of Optison (0.1-0.4 mL) intravenously followed by Contrast Pulse Sequencing to image both the coronary and carotid arteries.~Use will depend on availability of the contrast for the given study Optison will not be used on patients with blood allergies or Jehovah Witnesses"
3285875|NCT00580580|Active Comparator|2|Intravenous injection of Definity (0.05-0.20 mL) followed by Contrast Pulse Sequencing to image both coronary and carotid arteries
3285876|NCT00580580|Active Comparator|3|intravenous Injection of PESDA at a rate of 0.05-0.20 mL followed by image of coronary and carotid arteries PESDA will be used exclusively in patients who are eligible for other IRB studies
3285877|NCT00580567||1|Pathological Gamblers
3285878|NCT00580567||2|Non-Pathological Gamblers
3285879|NCT00580528|Experimental|1|
3285880|NCT00580528|Experimental|2|
3285881|NCT00580528|No Intervention|3|
3285882|NCT00580515|Experimental|1|6 sessions of Family Focused Group Therapy
3285883|NCT00580515|Experimental|2|10 Sessions of Family Focused Group Therapy
3285884|NCT00580515|Active Comparator|3|Standard Care- Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request
3285885|NCT00580502|Experimental|LAGB for low BMI patients|the LAP-BAND® Adjustable Gastric Band (LAGB®) for patients with BMI between 30-40 kg/m2 with co-morbidities
3285886|NCT00580489|Active Comparator|C|either fentanyl or morphine
3285887|NCT00580489|Active Comparator|D|either fentanyl or morphine
3285888|NCT00580476||1|150 patients will be women with breast cancer (75 early stage and 75 late stage)
3285889|NCT00580476||2|150 will be men with prostate cancer (75 early stage and 75 late stage)
3285890|NCT00580450|No Intervention|2|
3285891|NCT00580450|Experimental|1|
3285892|NCT00580437|Experimental|Arm 1|stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
3285893|NCT00580411||Alcohol Problem First|Alcohol Problem precedes Insomnia
3285894|NCT00580411||Insomnia First|Insomnia Precedes Alcohol Problem
3285895|NCT00580398|No Intervention|Control|Usual care included physician advice to quit smoking.
3285896|NCT00580398|Experimental|Intervention|Intervention participants were provided with a cognitive-behavioral 12-week program consisting of varenicline (1mg bid, with initial titration up over week 1) and smoking cessation counseling targeted to the issues of thoracic cancer patients. We offered 7 counseling sessions but were flexible in offering additional counseling when needed. Counseling was delivered by a certified Tobacco Treatment Counselor using Motivational Interviewing (MI) techniques.
3285897|NCT00580385|Experimental|1|
3285898|NCT00580372|Experimental|Study Treatment|Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.
3285899|NCT00580359|Active Comparator|A|S-1 40mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
3285900|NCT00580359|Active Comparator|B|Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
3285901|NCT00580346|Experimental|2|
3285902|NCT00580333|Experimental|Cisplatin/Avastin|Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide , adjuvant (optional) paclitaxel, adjuvant (optional)
3285903|NCT00580320|Experimental|A|dacarbazine + bortezomib
3285904|NCT00580307|Placebo Comparator|Septoplasty|Septoplasty only
3285905|NCT00580307|Experimental|Septoplasty and correction|Septoplasty and endoscopic contact point correction
3285906|NCT00580294|Experimental|oxymorphone|participants switched to oxymorphone extended release (ER) via both oral and intravenous patient-controlled analgesia (IV-PCA) oxymorphone. After 24 hours, participants were discharged with oral oxymorphone ER and oxymorphone immediate release (IR) as needed
3285907|NCT00580281|Experimental|blood, urine, and dexa scan|This study will involve venipuncture for obtaining blood samples; a spot second void (whenever possible) urine sample will be obtained at the same time. A Dexa scan to evaluate bone density will be obtained at the beginning, middle and end of the study.
3285908|NCT00580268||H|Pregnant women with bipolar disorder
3285909|NCT00580242|Experimental|1|This is a Phase I dose escalation trial with three cohorts of 3-6 patients each plus 10 additional patients (up to a maximum total of 28 patients) treated at the candidate maximum tolerated dose.Cohorts will receive increasing doses of bortezomib at 0.7, 1, and 1.3 mg/m2 on days 1, 4, 8, and 11 in combination with lenalidomide at 10 mg a day for Days 1-21. Each cycle will be 28 days. Patients will receive up to 9 cycles of treatment, with efficacy assessed after 3, 6, and 9 cycles.
3285910|NCT00580229|Experimental|prednisone|Prednisone 40mg by mouth 30-60 minutes prior to rituximab.
3285911|NCT00580216|Experimental|Idrabiotaparinux|"Idrabiotaparinux sodium, 3.0 mg, once-weekly for 7 weeks followed a maintenance dosing adjusted according to the age and to the renal function for a minimum total treatment duration of 6 months.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or overdosage)."
3285912|NCT00580216|Active Comparator|Warfarin|Warfarin, INR-adjusted dose, for a minimum total treatment duration of 6 months.
3285913|NCT00580203||1|Patients with head and neck cancers
3285914|NCT00580190|Active Comparator|1|
3285915|NCT00580190|Placebo Comparator|2|
3285916|NCT00580190|Experimental|3|
3285917|NCT00580177|Active Comparator|L|The Lichtenstein procedure for repair of inguinal hernia (Single On-lay patch)
3285918|NCT00580177|Active Comparator|P|The well-konown PerFixPlug technique for inguinal hernia repair.
3285919|NCT00580177|Active Comparator|PHS|The well-known Prolene Hernia System method for inguinal hernia repair.
3285920|NCT00580164||1|Splint
3285921|NCT00580164||2|No Splint
3285922|NCT00580151|Experimental|1|
3285923|NCT00580151|Placebo Comparator|2|
3285924|NCT00580138||Stroke or Head & Neck Cancer|Any subject who has suffered a stroke or has some form of head & neck cancer (non-laryngectomee) may be enrolled.
3285925|NCT00580125|Experimental|A2|
3285926|NCT00580125|Placebo Comparator|A5|
3285927|NCT00580125|Active Comparator|A4|
3285928|NCT00580125|Experimental|A3|
3285929|NCT00580125|Experimental|A1|
3285930|NCT00580112|Experimental|Group A|Participants with triple negative phenotype: estrogen receptor, progesterone receptor and human estrogen receptor-2 (HER-2) negative status for breast cancer (abnormal tissue that grows and spreads in the body until it kills) will receive trabectedin 1.3 milligram per meter square (mg/m^2) intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over 3-hours (hrs) every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 milligram (mg) orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72hrs after the start of study drug infusion from Day 1 to 3.
3285931|NCT00580112|Experimental|Group B|Participants with overexpressing HER-2 breast cancer will receive trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 milligram (mg) orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion from Day 1 to 3.
3285932|NCT00580112|Experimental|Group C|Participants with familial breast cancer gene 1 (BRCA1) or breast cancer gene 2 (BRCA2) mutation carriers cancer will receive trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 mg orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion from Day 1 to 3.
3285933|NCT00580099|Experimental|1|4 weeks of assisted exercise using passive range of motion on all major joints
3285934|NCT00580099|Active Comparator|2|cuddle for 20 minutes
3285935|NCT00580086||1|
3285936|NCT00580073|Experimental|1|FOLFOX4 + Cetuximab
3285938|NCT00580047|Active Comparator|2|Alendronate 70mg orally once a week for 2 years
3285939|NCT00580047|Placebo Comparator|3|Combination drug entity: calcium 1200 mg with vitamin D 800 International Units daily
3285940|NCT00580034|Experimental|Campath Purged Non-myeloablative ASCT|Campath Purged Non-myeloablative Allo Stem Cell Transplant (ASCT) in lymphoma, myeloma, or marrow failure: leukemia or myelodysplasia; and solid tumors
3285941|NCT00580034|Other|Donor Apheresis|"Donor must be a sibling, half sibling, parent, child or first cousin familial relationship and 3-5/6 Human Leukocyte Antigen matched related to subject. They must not have any medical condition which would make apheresis and G-CSF administration more than a minimal risk, and should have the following:~Adequate cardiac function by history and physical examination~bilirubin and hepatic transaminases < 2.5 x upper limit of normal~normal hematologic parameters Females should have a negative serum pregnancy test."
3285942|NCT00580021||1|Patients with breast and pancreas cancer.
3285943|NCT00579995|No Intervention|1, oral N-Acetylcysteine|
3285944|NCT00579995|No Intervention|2, Intravenous Sodium Bicarbonate|
3285945|NCT00579982|Experimental|Arm 1|Lamictal orally disintegrating tablet (ODT)
3285946|NCT00579969|Experimental|1|prostaglandin analogue
3285947|NCT00579969|Experimental|2|prostaglandin analogue
3285948|NCT00579956|Experimental|Meropenem|Meropenem
3285949|NCT00579956|Active Comparator|Ceftazidime|Ceftazidime
3285950|NCT00579943||premature infants|Inpatient very low birth weight infants who are ventilated and have an umbilical arterial catheter in place
3285951|NCT00579917||1 Cognitive-behavioral therapy (CBT)|Cognitive-behavioral therapy (CBT) involves one-on-one counseling
3285952|NCT00579917||2 Usual Care|Usual Care
3285953|NCT00579904|Active Comparator|walnuts|Patients will be randomized to receive walnuts
3285954|NCT00579904|Active Comparator|almonds|Patients will be randomized to receive almonds
3285955|NCT00579878|Active Comparator|1- Leflunomide alone - vs combination therapy|Group A: Leflunomide alone
3285956|NCT00579878|Active Comparator|Methotrexate-Sulfasalazine-Hydroxychloroquine|"Methotrexate: Dosing will start at 10mg/week. If total remission (according to ACR criteria) has not been achieved and labs are acceptable at the 8-week evaluation, the dosage will be increased to a dose of 15 mg/week Accordingly, if total remission has not been achieved and labs remain acceptable at the 16-week evaluation, the dosage will be increased to the top dose of 20 mg/week This dose will remain stable until the end of the study.~Sulfasalazine: Dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable, the dosage will be increased to the top dose of 1000 mg bid (2000 mg/day)~Hydroxychloroquine: Dosing will be started and maintained throughout the study at a dose of 200 mg bid (400 mg/day).~Intervention will remain as listed above."
3285957|NCT00579878|Active Comparator|3|Leflunomide-Sulfasalazine-Hydroxychloroquine
3285958|NCT00579865||Group A|Patients scheduled for percutaneous drainage
3285959|NCT00579865||Group B|Patients scheduled for a surgical bypass or resection of a high bile duct tumor.
3285960|NCT00579852||1|Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day.
3285961|NCT00579839|Experimental|A|Delayed Cord Clamping
3285962|NCT00579839|Active Comparator|B|Immediate cord clamping
3285963|NCT00579826|Experimental|Letrozole|Letrozole, 2.5 mg daily for 6 months
3285964|NCT00579826|Placebo Comparator|Placebo|Placebo, daily for 6 months
3285965|NCT00579813|No Intervention|1|Baseline studies (OGTT, DXA, RMR, FSIGT, and biopsies) on normal control subjects. Oral glucose tolerance tests, body composition assessment, resting metabolic rate, insulin sensitivity measurement with the frequently sampled method and Minimal Model. These studies will establish baseline data in lean subjects on adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition. There is no intervention.
3285966|NCT00579813|Active Comparator|2|Baseline studies (OGTT, DXA, RMR, FSIGT, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment. All of the studies described in arm 1 are repeated after treatment. The subjects in this group have impaired glucose tolerance. After the measurement of adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition, subjects are treated with pioglitazone, working up to 45 mg/day, for 10 weeks. After this time, adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition are repeated.
3285967|NCT00579800|Experimental|women undergoing routine breast MRI|Conventional images will be taken using the standard sequences consisting of T2-weighted imaging and T1-weighted imaging before and after contrast; these will be used for the diagnostic examination. FIESTA will be performed on 50 patients, while Vibrant-DE and IDEAL will be performed on the other 50 patients.
3285968|NCT00579787||1|Women with early stage cervical cancer undergoing radical trachelectomy
3285969|NCT00579787||2|Women with early stage cervical cancer undergoing radical hysterectomy
3285970|NCT00579774|Experimental|1 - Low AGE Diet|Low Age Diet
3285971|NCT00579774|Active Comparator|2 - Regular Diet|Regular Diet
3285972|NCT00579748||1|
3285973|NCT00579709|Experimental|1|Thymus Tissue for Transplantation
3285974|NCT00579683||1|This is a protocol to study tissue specimens to identify changes in tumor DNA in NSCLC patients who have previously responded to therapy and who have subsequently experienced disease progression.
3285975|NCT00579657|Placebo Comparator|1|"Intervention: 'control diet, supported by dietary supplement twice daily'~control diet [carbohydrates 55(50 - 60)% , protein 15(10 - 20)% protein; fat ca. 30% of energy content; dietary fiber < 15 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement daily)]"
3285976|NCT00579657|Experimental|2|"Intervention: 'high cereal fiber diet, supported by dietary supplement twice daily'.~high cereal fiber diet [carbohydrates 55(50 - 60)% , protein 15(10 - 20)% protein; fat ca. 30% of energy content; dietary fiber > 20 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 15 g cereal fiber daily)]"
3286040|NCT00579098|Active Comparator|Atorvastatin|Lipitor (atorvastatin) 80 mg tablet taken once daily by mouth for 90 days
3286041|NCT00579098|Placebo Comparator|Placebo|Placebo (dummy) tablet taken once daily by mouth for 90 days
3285977|NCT00579657|Experimental|3|"Intervention: 'high protein diet, supported by dietary supplement twice daily'~high protein diet [carbohydrates 40 - 45% , protein > 25 - 30%; fat ca. 30% of energy content; dietary fiber < 15 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 25 g whey and plant protein daily)]"
3285978|NCT00579657|Experimental|4|"Intervention: diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily.~high cereal fiber/high protein (MIX) moderately high cereal fiber/high protein diet (carbohydrates 45- 50)% , protein 20 - 25%; fat ca. 30% of energy content; dietary fiber 15 - 20 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 15 g cereal fiber and 2 x 25 g whey and plant protein daily)"
3285979|NCT00579644|Active Comparator|1 Methotrexate* & minocycline|"Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg"
3285980|NCT00579644|Active Comparator|2|"Methotrexate Dosing:~Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month~12 month evaluation: End of the blinded portion of the study."
3285981|NCT00579631||1|Questionnaire or Interview
3285982|NCT00579605|Experimental|1|1 intervention group 1 attention intervention group Behavioral: Motivational Interviewing Client-centered strategy that may decrease ambivalence in behavior performance
3285983|NCT00579592|Experimental|1|Campath, Rituximab, Myfortic, and 10-20 days of cyclosporine
3285984|NCT00579579||1|Patients Undergoing Surgery for Rectal Cancer
3285985|NCT00579566||1|Sarcoma patients undergoing core biopsy, incisional biopsy or definitive surgical resection for soft tissue masses of extremity, trunk or retroperitoneum
3285986|NCT00579553|Active Comparator|A|Intramuscular Progesterone
3285987|NCT00579553|Experimental|B|Vaginal Progesterone
3285988|NCT00579540|Active Comparator|1|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
3285989|NCT00579540|Active Comparator|2|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
3285990|NCT00579540|Active Comparator|3|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
3285991|NCT00579527|Experimental|#1 Typ & Atyp cDGA w immunosuppression|Three doses of 2 mg/kg of rabbit anti-thymocyte globulin IV pre thymus transplantation or pre thymus and parathyroid transplantation.
3285992|NCT00579527|Experimental|#2 Atypical cDGA w immunosuppression|Pre-thymus or pre thymus & parathyroid transplant cyclosporine (Csa) are started as soon as complete DiGeorge anomaly (cDGA) is diagnosed. Csa continued with target trough levels of 180 to 220 ng/ml. If subject cannot tolerate Csa, Csa may be changed to tacrolimus (FK506) with target trough level 7 to 10 ng/ml. When trough levels are outside of range, dosing is modified appropriately. Pre-transplant steroids are used is pre-transplant T cells >4,000cumm. Three doses of 2 mg/kg of rabbit anti-thymocyte globulin IV are given pre-thymus transplant or thymus & parathyroid transplant. Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.
3285993|NCT00579527|Experimental|#3 Atyp cDGA w additional suppression|Pre-thymus or thymus & parathyroid transplant, cyclosporine (Csa) and steroids are started after complete DiGeorge anomaly (cDGA) is diagnosed. After PHA response is documented >40,000 cpm on suppression, peri-transplant Csa target trough levels are 250-300 ng/ml. (Levels outside of range, dose modified.) If subject cannot tolerate Csa, change to tacrolimus (target trough level 10-15 ng/ml). When trough levels are outside of range, dosing is modified appropriately. Three doses of 2 mg/kg of rabbit anti-thymocyte globulin IV are given pre-transplant. Medications (diphenhydramine, steroids, & acetaminophen) are given with rabbit anti-thymocyte globulin. Daclizumab 1 mg/kg single dose IV and Mycophenolate mofetil 15 mg/kg/dose every 8 hours IV/orally may be given depending on T cell counts.
3285994|NCT00579514|Active Comparator|1|"All incident second primary cancers of colon, breast, bladder, kidney, prostate, ovarian cancer lung cancer and lymphoid cancer diagnosed between 1999 and present will be included in the secondary design to compare second primary cancer cases and first primary controls."
3285995|NCT00579514|Placebo Comparator|2|Controls will be volunteer blood donors from the New York Blood Center as well as normal volunteers from other AMDeC sites.
3285996|NCT00579501|Experimental|Trabectedin|Trabectedin at a dose of 1.5 milligram per meter square (mg/m^2) will be given as an intravenous (iv) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 24-hour every 3 weeks for a minimum of 3 and a maximum of 6 cycles prior to definitive surgery. Dexamethasone 20 mg iv will also be administered within 30 minutes before start of each trabectedin infusion.
3285997|NCT00579475|Placebo Comparator|Placebo|
3285998|NCT00579475|Active Comparator|I|Mifepristone (Mifegyne) 50 mg every other day for 3 months
3285999|NCT00579462||1|Patients with advanced lung cancer.
3286000|NCT00579449|Active Comparator|HF 36|For those randomly assigned to the 3-year HFD group, services begin during the third trimester of pregnancy. These families are assigned a Family Support Worker, who begins to initiate contact with the family at approximately 6 months gestation, when possible, so that the family can be engaged and services begun at seven months gestation. The Family Support Worker will provide home visiting services according the existing HFD model, which combines the empirically supported Parents as Teachers Curriculum (see attached description of the Parents as Teachers curriculum) provided in accordance with Healthy Families America standards of service delivery. The 3-year HFD group will receive services to the child's third birthday.
3286001|NCT00579449|Active Comparator|HF 18|For those randomly assigned to the 18-month HFD group, services begin during the third trimester of pregnancy. These families are assigned a Family Support Worker, who begins to initiate contact with the family at approximately 6 months gestation, so that the family can be engaged and services begun at seven months gestation. The Family Support Worker will provide home visiting services according the existing HFD model, which combines the empirically supported Parents as Teachers Curriculum (see attached description of the Parents as Teachers curriculum) provided in accordance with Healthy Families America standards of service delivery. Services for this group are terminated when the child is 18 months old, with clinically necessary referrals made for ongoing psychosocial and health needs.
3286002|NCT00579449|Active Comparator|YC|For those assigned to the Yearly Checkup group, a clinically-trained member of the HFD team will make yearly home visits to conduct the evaluation assessment. Information about community services and assistance with referrals are provided based on needs identified.
3286003|NCT00579449|No Intervention|MCC|Women placed in the community services as usual (Maternity Care Coordination only) group will receive no additional services or assessments as a part of this study.
3286004|NCT00579436|Active Comparator|Fish oil group|4g Lovaza (omega-3 fatty acid) daily.
3286005|NCT00579436|Placebo Comparator|Control group|placebo (4 non-active capsules daily)
3286006|NCT00579423|Experimental|vaccine|Patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administrated at the standard dose of 100ug.
3286007|NCT00579410||A|Patients with Barrett's Esophagus
3286008|NCT00579410||B|Patients with reflux symptoms but no Barrett's Esophagus
3286009|NCT00579410||C|Patients without reflux symptoms and a normal endoscopy
3286010|NCT00579397||1|"For Objective #1:~Healthy adult volunteers"
3286011|NCT00579397||2|"For Objectives #2 & #3:~Recipients undergoing an allogeneic stem cell transplant"
3286012|NCT00579384|Experimental|001|
3286013|NCT00579371|Experimental|1|
3286014|NCT00579345|Experimental|cTIV|Cell culture derived seasonal trivalent influenza vaccine (cTIV)
3286015|NCT00579345|Active Comparator|eTIV_a|Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)
3286016|NCT00579345|Experimental|FLU (cTIV or eTIV_a)|Cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
3286017|NCT00579345|Active Comparator|FLU (cTIV or eTIV_a) + PV|23-valent Pneumococcal vaccine (PV) concomitantly administered with cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
3286018|NCT00579332|Placebo Comparator|1|one a day placebo
3286019|NCT00579332|Experimental|2|Brassica intake
3286020|NCT00579332|Experimental|3|indole-3-carbinol supplement
3286021|NCT00579306||SPS3 patient cohort|All SPS3 patients who participate in Baseline and 1-Year F/U blood draw
3286022|NCT00579280|Active Comparator|Quetiapine SR|Quetiapine SR
3286023|NCT00579280|Active Comparator|Divalproex Sodium ER|Divalproex Sodium ER
3286024|NCT00579280|Placebo Comparator|Placebo|placebo
3286025|NCT00579241|Experimental|1|Transcranial imaging using Doppler ultrasound
3286026|NCT00579228||1|Normal controls both men and women
3286027|NCT00579228||2|Individuals with type 2 Diabetes with good control
3286028|NCT00579228||3|Individuals with type 1 diabetes with good control
3286029|NCT00579215|Experimental|1|Enhance Care (EC) will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits.
3286030|NCT00579215|Other|2|As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
3286031|NCT00579189|Experimental|Moxidex|Moxidex otic solution
3286032|NCT00579189|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
3286033|NCT00579150||Exenatide|Exposure to any form of exenatide during pregnancy for treatment of type 2 diabetes. Patients also taking Insulin may be included, though only as part of a combination treatment.
3286034|NCT00579150||Non-exenatide group|Exposure to non-insulin antidiabetic medication not including exenatide for treatment of pre-existing type 2 diabetes during pregnancy. Patients also taking Insulin may be included, though only as part of a combination treatment.
3286035|NCT00579137|Experimental|Participants With SCID or Primary Immunodeficiency Disorder|all patient will receive an allogeneic transplant with the following conditioning regimen Campath -1H, Fludarabine, Anti-CD45
3286036|NCT00579124|Other|1. CliniMACS CD3+/CD19+ depletion|"6/6 or 8/8 matched (fully matched)~1 antigen or allele mismatched (mismatch at A or B or DRB1)~2 antigen or allele mismatched (mismatch ONLY at A and B but NOT at DRB1 plus either A or B).~Patients will receive grafts that have undergone CD3+ and CD19+ depletion. The CD3(-) fraction will be infused."
3286037|NCT00579124|Other|2. CliniMACS CD3+/CD19+ depletion|"Stratum 2. CliniMACS CD3+/CD19+ depletion:~Haploidentical match~2 antigen and/or allele mismatched where one of the mismatches includes DRB1~For patients in Stratum 2 we will perform CD3+ (T cell) and CD19+ (B cell) depletion. There will be no T cell add back in this stratum."
3286038|NCT00579111|Experimental|HLA-identical sibling transplant|Recipients of HLA identical sibling stem cell transplants
3286039|NCT00579111|Experimental|Unrelated Matched or Single Antigen Mismatched transplant|Recipients of unrelated matched or single antigen mismatched donor stem cell transplant or single antigen mismatched family donor stem cell transplants
3286042|NCT00579085|Placebo Comparator|1|
3286043|NCT00579085|Experimental|2|"INFUSION PLAN:~All patients will be infused intravenously with 100 ml of normal saline with or without ketamine for four hours (25 ml/hr) daily for 10 days. The maximum intravenous ketamine infusion dose for this study will be 0.35 mg/kg/hr, not to exceed 25 mg/hr (100 mg of ketamine over a 4 hour period). On the first day, the intravenous ketamine infusion will be set to 50% of the maximum rate. On the second day, the intravenous ketamine infusion will be increased to 75% of the maximum rate. On the third day, the intravenous ketamine infusion will be increased to the maximum rate. The daily ketamine infusion rate is maintained at this level for the duration of the ten day study."
3286044|NCT00579072||Longitudinal Study|Take part in this study because subject has prostate cancer and are over 64 years old. To run this study,need men from two groups. First, we need men who are about to start hormone treatment. Second, we need men who do not plan to use this treatment in the future. We will use this second group as a control group and compare this group to the men who are using this treatment.
3286045|NCT00579072||Group Comparison|Take part in this study because subject has prostate cancer and are over 64 years old. Also, because subject has been on hormone therapy for about two to three years.
3286046|NCT00579059|Other|1|Maxim® Pop-Top® Tibia
3286047|NCT00579059|Other|2|Maxim® Regular Tibia
3286048|NCT00579046|Experimental|1|
3286049|NCT00579033|Sham Comparator|1|
3286050|NCT00579033|Active Comparator|2|
3286051|NCT00579020|Experimental|Moxidex|Moxifloxacin/dexamethasone phosphate ophthalmic solution, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
3286052|NCT00579020|Active Comparator|Moxifloxacin|Moxifloxacin ophthalmic solution 0.5%, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
3286053|NCT00579020|Active Comparator|Dexamethasone|Dexamethasone phosphate solution, 0.1%, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
3286054|NCT00579007||1|Women with a strong family history of breast cancer.
3286055|NCT00578994||Oxford® Meniscal Unicompartmental Knee|Patients with PKA using the Oxford® Meniscal Unicompartmental Knee System
3286056|NCT00578981|Experimental|Arm 1|
3286057|NCT00578981|No Intervention|Arm 2|
3286058|NCT00578968|Experimental|Tiotropium|Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of 18 mcg tiotropium powder.
3286059|NCT00578968|Placebo Comparator|Placebo|Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose.
3286060|NCT00578968|No Intervention|Healthy Controls|Healthy age and gender matched controls were recruited for comparing cardiovascular responses to participants with chronic obstructive pulmonary disease prior to the intervention.
3286061|NCT00578955|Experimental|1|
3286062|NCT00578955|Active Comparator|2|
3286063|NCT00578955|Active Comparator|3|
3286064|NCT00578942|Experimental|Campath Purged Non-myeloablative ASCT|Campath Purged Non-myeloablative Allo Stem Cell Transplant (ASCT) in lymphoma, myeloma, or marrow failure: leukemia or myelodysplasia; and solid tumors
3286065|NCT00578929|Experimental|Olopatadine 0.6% 1 Spray|Olopatadine HCl 0.6% 1 spray per nostril twice daily
3286066|NCT00578929|Placebo Comparator|Vehicle 1 spray|Vehicle 1 spray per nostril twice daily
3286067|NCT00578929|Experimental|Olopatadine 0.6% 2 sprays|Olopatadine HCl 0.6% 2 sprays per nostril twice daily
3286068|NCT00578929|Placebo Comparator|Vehicle 2 sprays|Vehicle 2 sprays per nostril twice daily
3286069|NCT00578916|Experimental|1|
3286070|NCT00578903|Experimental|Patients|"Patients with a diagnosis of severe aplastic anemia who require an allogeneic stem cell transplant but lack an Human Leukocyte Antigen (HLA) identical family member.~Cytoxan, Campath, TBI-Total Body Irradiation, FK-506, Methotrexate, Stem Cell Infusion"
3286071|NCT00578890|Experimental|1|
3286072|NCT00578877|Active Comparator|Arm 1|Gynol II (2% N-9 gel)
3286073|NCT00578877|Experimental|Arm 2|Buffer Gel
3286074|NCT00578864|Experimental|Protracted Oral Etoposide|Protracted etoposide for cycles 1, 2 and 4 of induction. If a subject does not respond after cycle 2, cycle 4 will be bolus etoposide.
3286075|NCT00578864|Active Comparator|IV Cisplatin and IV Bolus Etoposide|This arm is for patients whose tumor does not respond satisfactorily to the first two cycles of chemotherapy with IV cisplatin and oral protracted etoposide. Patients on this arm will receive cycle 4 etoposide given as a bolus IV dose.
3286076|NCT00578864|Experimental|Adriamycin and Cyclophosphamide|Induction chemotherapy will consist of 5 cycles given 21 days apart. Cycle 3 and 5 will be adriamycin and cyclophosphamide
3286077|NCT00578851||C2a Taper recipients|Patients who receive a THA with the C2a - Taper™ Acetabular System
3286078|NCT00578838||1|25 patients with metastatic colorectal cancer. Each patient will have 4 MR exams: prior to or within one week of the start of the chemotherapy regimen, one after 6 weeks of chemotherapy, a third after completion of chemotherapy (between 12 and 24 weeks post-initiation of chemotherapy) and a long term followup study at least 4 months after the completion of chemotherapy.
3286079|NCT00578838||2|25 patients with non-metastatic colorectal cancer. Each patient will have 4 MR exams: prior to or within one week of the start of the chemotherapy regimen, one after 6 weeks of chemotherapy, a third after completion of chemotherapy (between 12 and 24 weeks post-initiation of chemotherapy) and a long term followup study at least 4 months after the completion of chemotherapy.
3286080|NCT00578838||3|11 healthy volunteers, who will also undergo two scans 2-3 weeks apart.
3286081|NCT00578812|Experimental|PCM Cervical Disc - Investigational|PCM Cervical Disc replacement at one level from C3 to T1
3286082|NCT00578812|Active Comparator|ACDF - Control Group|Anterior cervical discectomy and fusion (ACDF) at one level from C3 to T1
3286083|NCT00578799|Active Comparator|Kyo-Dophilus|Kyo-Dophilus (5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening)
3286084|NCT00578799|Placebo Comparator|Placebo|placebo capsules (potato starch)
3286085|NCT00578786|Experimental|Ambrisentan|2.5, 5 or 10 mg ambrisentan
3286086|NCT00578773|Experimental|Moxidex|Moxidex otic solution
3286087|NCT00578773|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
3286088|NCT00578773|Other|TT only|Tympanostomy tubes only
3286089|NCT00578760|Placebo Comparator|2|placebo OD during course of chemotherapy
3286090|NCT00578760|Experimental|1|325mg ASA OD during course of chemotherapy
3286091|NCT00578734|Experimental|Lucinactant|SURFAXIN® (lucinactant) for intratracheal instillation
3286092|NCT00578734|Sham Comparator|Sham Air|Sham air (placebo) instillation
3286093|NCT00578721|Experimental|325 mg Aspirin|325 mg aspirin po qd with arginine-restricted diet
3286094|NCT00578708|Experimental|1|
3286095|NCT00578695|Experimental|Active|Lixivaptan
3286096|NCT00578695|Placebo Comparator|Placebo|Placebo
3286097|NCT00578682|Experimental|1|Single IV dose of 0.3 mg/kg MEDI-557
3286098|NCT00578682|Experimental|2|Single IV dose of 3 mg/kg MEDI-557
3286099|NCT00578682|Experimental|3|Single IV dose of 15 mg/kg MEDI-557
3286100|NCT00578682|Experimental|4|Single IV dose of 30 mg/kg MEDI-557
3286101|NCT00578669|Active Comparator|1|Sequential antidepressant pharmacotherapy with (20mg) fluoxetine, begun 8 weeks prior to and extended throughout brief (behavioral) standard smoking cessation treatment with transdermal nicotine patch.
3286102|NCT00578669|Placebo Comparator|2|Sequential placebo medication, begun 8 weeks prior to and extended throughout brief (behavioral) standard smoking cessation treatment with transdermal nicotine patch.
3286103|NCT00578656|Experimental|1|Baked milk and at least 4 oral food challenges as clinically indicated
3286104|NCT00578643|Experimental|Allogeneic unrelated transplant|Conditioning from Day -9 to Day -1. Stem cells given on Day 0. Busulfan, alemtuzumab, cyclophosphamide, fludarabine, cyclosporine, stem cell infusion.
3286105|NCT00578630||1|All Pediatric Oncology and Bone Marrow Transplantation Service patients with a histologically proven tumor for whom there is an intent to treat with chemotherapy
3286106|NCT00578617|Active Comparator|Pharmacologic Therapy|Pharmacologic Therapy Rate and/or Sinus Rhythm Control: Patients without other heart disease will receive beta or calcium channel blockers as first line rate control therapy. Patients with underlying coronary artery disease will receive beta-blockers, patients with limited ventricular hypertrophy not warranting exclusion would receive either beta- or calcium channel blockers, while patients with heart failure would be expected to receive carvedilol or metoprolol. Patients randomized to drug therapy may be started on a membrane active drug, in an approach consistent with the recommended Guidelines for Management of Subjects with AF. Each patient will be placed on an anti-arrhythmic drug for an appropriate period and the patient cardioverted to sinus rhythm if necessary. Patients will then be followed for a period of up to 3 months, during which dosage adjustment can be made or the drug replaced with a different anti-arrhythmic drug.
3286107|NCT00578617|Active Comparator|Ablation Therapy|Left Atrial Catheter Ablation: The specific choice of ablation catheters will be left to the investigator from the following list: Lifewire TC XLS, Therapy Dual/Thermocouple, NAVI-STAR/NAVI-STAR DS, Celsius Braided Tip, NAVI-STAR Thermo-Cool, Freezor/FreezorMax, Stinger, Blazer II RF/RPM/SteeroCath /XP, Chilli Cooled.
3286108|NCT00578604||Patients with a diabetic wound|Patients with a diabetic wound
3286109|NCT00578604||Control|Patients without a diabetic wound
3286110|NCT00578591|Experimental|Patient|Four Rituximab doses administered to patients who have developed SR-aGVHD following allogeneic hematopoietic transplant (AHT)
3286111|NCT00578578|Active Comparator|1|"Active Arm:~1000 mg Lemon flavored Capsules. Three capsules every morning."
3286112|NCT00578578|Placebo Comparator|2|"Placebo Arm:~Cornstarch Capsules provided by Clinical Encapsulation services. Three capsules every morning."
3286113|NCT00578565|Experimental|1|open label, all subjects will receive rituximab
3286114|NCT00578552|Placebo Comparator|Placebo|Non active placebo pill
3286115|NCT00578552|Active Comparator|Gabapentin - 1800 mg/day|Gabapentin - 1800 mg/day
3286116|NCT00578552|Active Comparator|Gabapentin - 2700 mg/day|Gabapentin - 2700 mg/day
3286117|NCT00578539|Experimental|Stem Cell Transplant|All patients will receive Ara C IV every 12 hours for 6 doses starting at 1400 hours on day -8. Cyclophosphamide IV once daily on day -7 and day -6 starting at 1400 hours. MESNA will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide. Campath 1h will be given on day -4, day -3, day -2 and day-1. TBI (Total Body Irradiation) will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1. Stem cell Infusion are infused on day 0.
3286118|NCT00578526|Active Comparator|Arm 1|SU011248 - 4 weeks on followed by 2 weeks rest period every 6 weeks
3286119|NCT00578526|Placebo Comparator|Arm 2|1 50 mg capsule OD PO for 4 weeks with 2 week rest until disease progression. Any patient with disease progression will be unblinded and patients on the placebo arm may then be considered for the open label Sutent treatment.
3286120|NCT00578500|Active Comparator|OCCT|Patients referred to ovarian cryopreservation.
3286121|NCT00578474|Experimental|Moxidex|Moxidex otic solution
3286122|NCT00578474|Active Comparator|FLOXIN|Ofloxacin otic solution
3286123|NCT00578461|Experimental|Stem Cell Transplant|patient's will be recieving a stem cell transplant on study Conditioning includes: Ara C, Cyclophosphamide, MESNA, TBI-Total Body Irradiation
3286124|NCT00578448|Active Comparator|A|"10mg/kg~6 doses (Day 1, 5, week 2, 4, 8 and 12) for 12 weeks"
3286125|NCT00578448|Active Comparator|B|"5mg/kg~33 doses (every 4 weeks) for 144 weeks"
3286126|NCT00578422||Arm I: In Vitro IVUS Plaque studies|IVUS of Amputation Specimens
3286127|NCT00578422||Arm 2: Obserational Study|IVUS for patients undergoing standard lower extremity angiography for PAD.
3286128|NCT00578396|Active Comparator|Dose Level 1|1 lb/day fresh red grapes
3286129|NCT00578396|Active Comparator|Dose Level 2|2/3 lb/day fresh red grapes
3286130|NCT00578396|Active Comparator|Dose Level 3|1/3 lb/day fresh red grapes
3286131|NCT00578383|Sham Comparator|Sham (inactive) Treatment BPD|20 minutes of sham treatment with the Low Field Magnetic Stimulation Device (LFMS)in bipolar depressed subjects
3286132|NCT00578383|Active Comparator|Active LFMS treatment in BPD|20 minutes of active treatment with the Low Field Magnetic Stimulation Device (LFMS)in bipolar depressed subjects
3286133|NCT00578383|Sham Comparator|Sham LFMS Comparator: in MD|20 minutes of sham treatment with the Low Field Magnetic Stimulation Device (LFMS) in major depressed subjects
3286176|NCT00578084||surgery|those subjects who went to surgery to treat their lung cancer
3286134|NCT00578383|Active Comparator|Experimental LFMS: in MD|20 minutes of active treatment with the Low Field Magnetic Stimulation Device (LFMS) in major depressed subjects
3286135|NCT00578370|Experimental|1|
3286136|NCT00578370|Experimental|2|
3286137|NCT00578370|Active Comparator|3|
3286138|NCT00578370|Active Comparator|4|
3286139|NCT00578370|Placebo Comparator|5|
3286140|NCT00578357|Experimental|1|immediate intervention
3286141|NCT00578357|No Intervention|2|note: participants in this arm will receive the intervention after the 6-month follow-up (serving as control during the trial)
3286142|NCT00578344|Experimental|Allogeneic BMT/SCT Transplant|"Busulfan, Campath 1H, Cyclophosphamide and MESNA:~Bone marrow infusion with pre-meds as per SOPs to take place on Day 0.~Bone marrow dose: To ensure the probability for bone marrow engraftment, 4 x 10^8 nucleated cells/kg patient weight will be the target at donor bone marrow harvest."
3286143|NCT00578331|Experimental|Olopatadine 0.6% Nasal Spray|2 sprays each nostril twice daily
3286144|NCT00578331|Placebo Comparator|Placebo Nasal Spray|2 sprays each nostril twice daily
3286145|NCT00578318|Experimental|Motivational Interviewing Active|Patients received a stepped progression of talk based treatment utilizing Motivational Interviewing as the basis.
3286146|NCT00578318|Active Comparator|Delayed Control|Patients received Treatment as usual (TAU) (i.e. no specific intervention and supportive check-ins from the study staff)
3286147|NCT00578305|Experimental|Rituximab 500 mg|Participants received rituximab 500 mg iv on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants received further treatment courses on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
3286148|NCT00578305|Experimental|Rituximab 1000 mg|Participants received rituximab 1000 mg iv on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants received further treatment courses on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
3286149|NCT00578305|Placebo Comparator|Placebo|Participants received placebo intravenously (iv) on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants were switched to receive rituximab 1000 mg iv on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
3286150|NCT00578292|Experimental|Bone Marrow or Stem Cell Infusion|"Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H~Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.~Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor."
3286151|NCT00578279|Other|A|subject randomized to 10ml of dehydrated alcohol
3286152|NCT00578279|Experimental|B|subject randomized to 20ml of dehydrated alcohol
3286153|NCT00578266|Other|No Arms|
3286154|NCT00578227|Experimental|Cervarix™ & Twinrix™ Group|Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A & Hepatitis B (HAB) vaccine (Months 0, 1 & 6).
3286155|NCT00578227|Experimental|Cervarix™ Group|Subjects received 3 doses of HPV vaccine (Months 0, 1 & 6).
3286156|NCT00578227|Active Comparator|Twinrix™ Group|Subjects received 3 doses of HAB vaccine (Months 0, 1 & 6).
3286157|NCT00578214|Active Comparator|Randomized Midazolam|Single-dose midazolam
3286158|NCT00578214|Placebo Comparator|Placebo|
3286159|NCT00578214|Experimental|Prospective Midazolam|
3286160|NCT00578201|Experimental|1|radiochemotherapy,combination Cetuximab-FOLFOX
3286161|NCT00578188||RP100-400|Subjects with Chlamydia. The control group will also be identified with these numbers.
3286162|NCT00578175|Experimental|Group A|Subjects received refrigerator-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation A) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
3286163|NCT00578175|Experimental|Group B|Subjects received freezer-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation B) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
3286164|NCT00578175|Active Comparator|Group C|Subjects received ProQuad® co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
3286165|NCT00578162||1|Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory.
3286166|NCT00578136|Active Comparator|1|1) One group will receive the rectus sheath block prior to Umbilical hernia repair.
3286167|NCT00578136|Active Comparator|2|2) The second group will receive local anesthetic infiltration of the surgical site at the end the umbilical hernia repair.
3286168|NCT00578123|Other|1 Questionnaire|Quality of Life Questionnaires
3286169|NCT00578110|Experimental|Group 1|Glaucoma Patients
3286170|NCT00578110|Experimental|Group 2|Glaucoma suspects
3286171|NCT00578110|Active Comparator|Group 3|Controls
3286172|NCT00578097|Experimental|A - 125 units|
3286173|NCT00578097|Experimental|B - 250 units|
3286174|NCT00578097|Experimental|C - 500 units|
3286175|NCT00578097|Placebo Comparator|D|
3286444|NCT00575822|Sham Comparator|2|Sham control procedure
3286177|NCT00578084||no surgery|those subjects who did not go to surgery for their lung cancer
3286178|NCT00578084||NSCLC|subjects with NSCLC
3286179|NCT00578084||Small cell lung cancer|those with small cell lung cancer
3286180|NCT00578071|Experimental|Treatment|panitumumab, oxaliplatin, capecitabine and EBRT
3286181|NCT00578058|Other|1|Counseling plus everyday noise type 1
3286182|NCT00578058|Other|2|Counseling plus static noise type 2
3286183|NCT00578058|Other|3|Counseling plus static noise type 3
3286184|NCT00578058|Other|4|Hearing aid and counseling plus everyday noise type 1
3286185|NCT00578058|Other|5|Hearing aid and counseling plus static noise type 2
3286186|NCT00578058|Other|6|Hearing aid and counseling plus static noise type 3
3286187|NCT00578045|Experimental|1|Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
3286188|NCT00578032||1|Patients with head and neck malignancies that require simultaneous surgical resection and reconstruction of the ablative defect will be eligible to participate.
3286189|NCT00578019|Active Comparator|1, A|
3286190|NCT00578019|Experimental|2, B|Group B patients will have their fracture stabilized with the LISS plates (Synthes [USA], Paoli, PA, USA).
3286191|NCT00578006|Experimental|A|If you are in group A, the investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
3286192|NCT00578006|Experimental|B|If you are in group B, the investigators will provide you with access to the STAR website using a computer in the waiting area, into which you can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy. The investigators may also provide you with a website address so that you can access STAR from home (or any other location) to report your symptoms at any time.
3286193|NCT00577993|Active Comparator|1: FND + Rituximab Followed by Interferon|Fludarabine/Novantrone/Decadron + Rituximab Followed by Interferon
3286194|NCT00577993|Active Comparator|2: FND Followed by Interferon & Rituximab|Fludarabine/Novantrone/Decadron Followed by Interferon & Rituximab
3286195|NCT00577993|Active Comparator|3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon|Cyclophosphamide/Vincristine/Doxorubicin/Bleomycin (1st Sequence) + Rituximab; Etoposide/Cisplatin/Ara-C/Methyl-Prednisol (2nd Sequence); Novantrone/Vincristine/Procarbazine/Prednisone + Rituximab (3rd Sequence) Followed by Interferon
3286196|NCT00577980|Experimental|Testosterone|Testosterone 200 mg administered parenterally by intramuscular (IM) injection every 2 weeks
3286197|NCT00577954||1|Patients in a coma condition after a traumatic brain injury (250), stroke, cerebral anoxia or subarachnoid hemorrhage (150), for at least 7 days.
3286198|NCT00577928||1|
3286199|NCT00577928||2|
3286200|NCT00577915|Experimental|Breast MR Spectroscopy|Conventional images will be taken with standard pulse sequences. These images will be used for the diagnostic examination for which the patient will have been scheduled. Following the diagnostic study, a pulse sequence designed to obtain spectroscopy data will be used.This will be used on the existing magnets 1.5T and 3T. Memorial Sloan-Kettering Cancer Center has 1.5T and 3T magnets. The patient will have only one injection of contrast (gadolinium-DTPA) for the initial diagnostic study. No additional contrast will be administered. The additional sequence should take about 10 minutes, depending on breast size.
3286201|NCT00577902||Observational|This is an observational study
3286202|NCT00577889|Experimental|Arm I (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 154 mg/m2 tanespimycin IV over 1 hour on day 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
3286203|NCT00577889|Experimental|Arm II (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 154 mg/m2 tanespimycin IV over 1 hour on days 2 and 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
3286204|NCT00577889|Experimental|Arm III (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on day 8 and 154 mg/m2 tanespimycin IV over 1 hour on days 1 and 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
3286205|NCT00577876|Experimental|1|Day of Surgery:Patient is admitted through the Preoperative Surgical Center (PSC). If a large APA is identified, then subject will continue on study Dissect APA (without any changes from what is routinely done) with a penile injection of Trimix. Once the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion.
3286206|NCT00577850|Experimental|1|0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks
3286207|NCT00577850|Active Comparator|2|0.45 mg 14C-labeled alendronate, followed 7 days later with oral 70 mg of alendronate once a week for 52 weeks
3286208|NCT00577837|Active Comparator|1|5 mg risedronate, once daily for 6 months
3286209|NCT00577837|Experimental|2|100 mg risedronate, once a month for 6 months
3286210|NCT00577837|Experimental|3|150 mg risedronate, once a month for 6 months
3286211|NCT00577837|Experimental|4|200 mg risedronate, once a month for 6 months
3286212|NCT00577824|Experimental|1|
3286213|NCT00577824|Experimental|2|
3286214|NCT00577824|Placebo Comparator|3|
3286215|NCT00577811||1|Patients from 6 different Special Need Plans
3286216|NCT00577811||2|
3286217|NCT00577785||cystectomy group|Subjects undergoing planned cystectomy who agree to provide bladder tissue from removed bladder post cystectomy and/or cystoscopic biopsy tissue prior to cystectomy
3286264|NCT00577395|Placebo Comparator|1|Placebo tablet once a month, orally
3286398|NCT00576212|No Intervention|B|Subjects in the control group will receive no intervention.
3286443|NCT00575822|Active Comparator|1|NDO Endoscopic Full-thickness Plicator procedure
3286218|NCT00577772|Active Comparator|Healthy Participants|Healthy Participants will report for simultaneous lactulose hydrogen breath test (H_2BT) and SmartPill study after an overnight fast. They will swallow the SmartPill Capsule at the study site. After 4 hours, they will be allowed to leave the study site and consume their usual diet. They will return for removal of the data recorder 5 days later.
3286219|NCT00577772|Active Comparator|Symptomatic Participants|"Subjects with symptoms suggestive of small bowel bacterial overgrowth (SBBO) (e.g., diarrhea, bloating, abdominal discomfort) for at least 3 months will be divided into 2 groups based on the results of their previous testing for SBBO (5 SBBO positive patients, 5 SBBO negative patients).~The symptomatic participants will report for simultaneous lactulose hydrogen breath test (H_2BT) and SmartPill study after an overnight fast. They will swallow the SmartPill Capsule at the study site. After 4 hours, they will be allowed to leave the study site and consume their usual diet. They will return for removal of the data recorder 5 days later.~After the capsule has been demonstrated to be passed from the subject, the subjects with SBBO present will then enter into an open-label treatment using Rifaximin (400 mg PO TID) for 7 days."
3286220|NCT00577759|Experimental|Active Intervention|Direct referral to community organizations, with support for practices to do so. These include the North Carolina Tobacco Quitline, public health department dietitians, and the YMCA.
3286221|NCT00577759|Experimental|Passive Intervention|Provision of information about community organizations to patients as above.
3286222|NCT00577759|Placebo Comparator|Usual Care|Usual care
3286223|NCT00577746||surgery|Those subjects who went to surgery for treatment for their lung cancer.
3286224|NCT00577746||no surgery|The subjects who did not go to surgery for treatment of their lung cancer.
3286225|NCT00577733||obese|obese
3286226|NCT00577733||healthy volunteers|healthy volunteers
3286227|NCT00577720|Active Comparator|35 mg IRBB|35 mg immediate release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
3286228|NCT00577720|Experimental|35 mg DRFB|35 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
3286229|NCT00577720|Experimental|50 mg DRFB|50 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
3286230|NCT00577720|Experimental|50 mg DRBB|50 mg delayed release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
3286231|NCT00577707|Experimental|Patients With Stage IB-IIIA NSCLC With EGFR Mutations|This is a open label, single center, phase II trial for patients with clinical stage IB-IIIA NSCLC (T1-3N0-2M0) who have resectable tumors that harbor EGFR activating mutations. Patients will receive erlotinib x 3 weeks prior to initiation of concurrent erlotinib and chemotherapy.
3286232|NCT00577694|Other|single arm study|1
3286233|NCT00577681||1|Participants from the SMART study who were randomly assigned to episodic or continuous ART and who have no history of CVD
3286234|NCT00577681||2|Participants from the SMART study who were randomly assigned to episodic or continuous ART and who experienced a major CVD event during the study, analyzed along with 2 matched controls
3286235|NCT00577681||3|Participants from the SMART study who have no previous use of ART or have taken ART but not done so within 6 months prior to study entry; allows for a comparison of immediate ART versus deferred ART
3286236|NCT00577668|Experimental|VDT and Melphalan|To find out if three drugs, bortezomib, thalidomide, and dexamethasone in addition to high doses of melphalan (M-VTD) and autologous transplant can be given safely and effectively to subjects who have failed previous regimens with transplant(s).
3286237|NCT00577655|Experimental|Albuterol|Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days. HFA-MDI refers to a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant.
3286238|NCT00577655|Placebo Comparator|Placebo|"A placebo of a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant. (Hereafter noted as Placebo-HFA-MDI.)"
3286239|NCT00577642|Other|Single arm|Single arm biomarker study after a single dose of zoledronic acid
3286240|NCT00577629|Experimental|Induction + Consolidation + Bexxar|Induction:Cyclophosphamide, Etoposide, and Rituxan (rituximab) followed by Consolidation: Cytarabine and Doxorubicin followed by radioimmunotherapy: Bexxar (tositumomab)
3286241|NCT00577616|Other|1|Endovascular repair
3286242|NCT00577616|Other|2|conventional surgery repair
3286243|NCT00577603|Active Comparator|2|mesh reinforcement at stoma
3286244|NCT00577603|Active Comparator|Arm 1|standard stoma
3286245|NCT00577590|Placebo Comparator|Metformin Alone|Participants assigned to take Metformin alone.
3286246|NCT00577590|Experimental|Metformin and Rosiglitazone|Participants assigned to take Metformin and Rosiglitazone
3286247|NCT00577590|Experimental|Metformin and Lovaza|Participants assigned to take Metformin and Lovaza
3286248|NCT00577538||1|
3286249|NCT00577538||2|
3286250|NCT00577525||1|Case : Patients with steroid sensitive nephrotic syndrome
3286251|NCT00577525||2|Controls (matched for age and sexe with the first group)
3286252|NCT00577512|Experimental|HD DTPACE|DTPACE
3286253|NCT00577499||Only group|adult cystic fibrosis patients who are not at goal body mass index and have started lubiprostone therapy within one month of study enrollment
3286254|NCT00577473|Active Comparator|1|mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
3286255|NCT00577473|Experimental|2|mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
3286256|NCT00577460|Active Comparator|Pramipexole|Patients to receive Pramipexole ER 0.375 - 4.5 mg in tablet form daily
3286257|NCT00577460|Placebo Comparator|Placebo|Patients to receive placebo tablets identical to Pramipexole ER tablets only during transfer phase
3286258|NCT00577447|Active Comparator|1|DHA supplemented group
3286259|NCT00577447|Placebo Comparator|2|Placebo group
3286260|NCT00577421|Experimental|1|5 mg/day risedronate
3286261|NCT00577408|Experimental|Depot Naltrexone|Depot Naltrexone. Vivitrol (380 mg)given monthly
3286262|NCT00577408|Active Comparator|Oral Naltrexone|Oral Naltrexone. For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday).
3286263|NCT00577395|Experimental|2|one 150 mg risedronate once a month, orally
3286265|NCT00577382|Experimental|Sunitinib|"Cohort A participants received 50 mg sunitinib orally daily for 4 weeks followed by a two-week break from treatment. These 6-week cycles would be repeated until progression or unacceptable toxicity up to 1 year.~Cohort B participants received 37.5 mg sunitinib daily on a continuous basis until progression or unacceptable toxicity up to 1 year."
3286266|NCT00577369|Active Comparator|1|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
3286267|NCT00577330|Experimental|Myalgesin|Subjects receive Myalgesin twice daily
3286268|NCT00577330|Active Comparator|Acetaminophen|Subjects receive acetaminophen 1000 mg three times a day
3286269|NCT00577317|Experimental|Arm 1|Patients receive standard home maintenance therapy and perform self-manual lymphatic drainage once daily for 60 minutes for 24 weeks.
3286270|NCT00577317|Experimental|Arm II|Patients receive Flexitouch® home maintenance therapy once daily for 60 minutes for 24 weeks
3286271|NCT00577304|Other|2|Placebo - Topical AmphiMatrix
3286272|NCT00577304|Active Comparator|1|Topical AmphiMatrix with Nitroglycerin
3286273|NCT00577278|Experimental|Treatment (chemo, monoclonal antibody therapy, transplant)|REDUCED-INTENSITY CONDITIONING: Patients receive rituximab IV followed by indium In-111 ibritumomab tiuxetan IV over 10 minutes on day -21 and rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14. Patients also receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. STEM CELL TRANSPLANTATION: Patients undergo APBSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO and sirolimus PO beginning on day -3 and continuing for up to 6 months with taper.
3286274|NCT00577252||1|Adolescents with CF.
3286275|NCT00577226||1 Shilla Technique|The patients whose data is observed are those who have undergone the shilla surgical technique.
3286276|NCT00577200|No Intervention|Control|Control group subjects are not undergoing any surgical procedures and will not be randomized to any anesthetic drug group.
3286277|NCT00577200|Experimental|Midazolam + Sufentanil + Propofol|"Midazolam 0.03 mg/kg + Sufentanil 0.1 µg/kg + Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.~For subjects who are chronic pain patients undergoing minor surgical procedures."
3286278|NCT00577200|Experimental|Midazolam and Sufenatnil|"Midazolam 1-5 mg in holding area + Sufentanil 5-10 mcg.~For subjects who are chronic pain patients undergoing minor surgical procedures."
3286279|NCT00577174||1. Controls|Healthy children ages 8 to 18 years
3286280|NCT00577174||2. Obese childrens|Obese children, ages 8 to 18 years
3286281|NCT00577161|Active Comparator|Comparator|fludarabine and rituximab
3286282|NCT00577161|Experimental|Experimental|fludarabine, rituximab, pixantrone
3286283|NCT00577148|Experimental|Rimonabant|Rimonabant 20 mg once daily.
3286284|NCT00577148|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
3286285|NCT00577135|Experimental|Q12 hour bolus|Furosemide-Q12 hour bolus
3286286|NCT00577135|Experimental|Continuous Infusion|Furosemide-Continuous Infusion
3286287|NCT00577135|Experimental|Low Intensification|Furosemide-Low Intensification
3286288|NCT00577135|Experimental|High Intensification|Furosemide-High Intensification
3286289|NCT00577122|Experimental|Cohort I (MPA)|Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.
3286290|NCT00577122|Experimental|Cohort II (MPA, low-dose chemotherapy)|"Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.~Cyclophosphamide will be administered orally as a single daily dose. Methotrexate will be administered twice daily on days 1 and 2 of each week."
3286291|NCT00577109|Experimental|1|
3286292|NCT00577096|Experimental|Exercise|Study participants were computer randomized to an individualized exercise program. Participants were stratified within Arm according to whether or not they received thalidomide with heparin, and by age (60 and younger versus older than 60)
3286293|NCT00577096|Active Comparator|usual care|Study participants were asked to remain as active as possible but not prescribed an individualized exercise program. Participants were stratified within Arm according to whether or not they received thalidomide with heparin, and by age (60 and younger versus older than 60)
3286294|NCT00577083|Experimental|Initial cap-fitted|Initial cap-fitted colonoscopy for the first insertion
3286295|NCT00577083|Active Comparator|Initial regular|Initial regular no cap on the end of the colonoscope for the first insertion
3286296|NCT00577070|Active Comparator|H1|"Includs 20 patients.These patients will be given 4 weeks (5 days a week) of deep TMS,20 minutes each session, to the left prefrontal cortex using H1 coil, in frequency of 20 HZ, with intensity of 120 % of motor threshold. H1-coil is an extracorporeal device positioned on the patient's scalp, designed to stimulate deep prefrontal brain regions, preferentially in the left hemisphere. The effective part of the coil, which has contact with the patient's scalp, includes 14 strips of 7-12 cm length. These strips are oriented in an anterior-posterior axis.This coil stimulates neuronal fibers in anterior-posterior orientation.~During deep TMS exposure patients will listen to a clinical interview in which they describe the different expressions of their depression including their ruminations and depressive schemas."
3286297|NCT00577070|Experimental|H2|Includs 20 patients.These patients will be given 4 weeks (5 days a week) of deep TMS, 20 minutes each session, to the prefrontal cortex bilateraly using H2 coil, in frequency of 0.1 HZ, with intensity of 120 % of motor threshold. H2-coil is designed to stimulate deep prefrontal brain regions bilaterally (without any preferencefor either hemisphere). The effective part of the coil, which has contact with the patient's scalp, includes 10 strips of 14-22 cm length.These strips are oriented in a right-left direction (lateral-medial axis).This coil is destined to stimulate lateral-medial neuronal fibers. During deep TMS exposure patients will listen to a clinical interview in which they describe the different expressions of their depression including their ruminations and depressive schemas.
3286298|NCT00577031|Experimental|1|
3286299|NCT00577018|Active Comparator|1|
3286300|NCT00577018|Active Comparator|2|
3286301|NCT00577018|Placebo Comparator|3|
3286302|NCT00577005|Experimental|1|Levetiracetam tablets
3286303|NCT00577005|Placebo Comparator|2|matching placebo
3286304|NCT00576992||GI observation|Patients presenting for an upper endoscopy procedure with gastrointestinal symptoms or complaints.
3286396|NCT00576225|Active Comparator|Control|
3286445|NCT00575809||Obsevational|
3286305|NCT00576979|Experimental|Treatment (radiation therapy, chemotherapy, transplant)|PREPARATIVE REGIMEN: Patients undergo IMRT using helical tomotherapy once or twice daily on days -10 to -6 or -10 to -7. Patients also receive etoposide IV on day -6 or -5 and cyclophosphamide IV on day -4 or -3. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell or bone marrow transplantation on day -1 or day 0.
3286306|NCT00576940|Experimental|IMEN: 1|Enteral nutrition with immunostimulating diet (IMEN group: formula supplemented with arginine, glutamine, omega-3 fatty acids)
3286307|NCT00576940|Active Comparator|SEN|postoperative enteral nutrition - standard oligopeptic diet
3286308|NCT00576927|Experimental|Group1|SHI followed by Active Drug Ramelteon
3286309|NCT00576927|Placebo Comparator|Group 2|SHI Followed by Placebo
3286310|NCT00576914|Active Comparator|A|vinorelbine plus cisplatin plus recombinant human endostatin
3286311|NCT00576914|No Intervention|B|vinorelbine plus cisplatin
3286312|NCT00576901|Experimental|1|
3286313|NCT00576888||Vascular Anomaly with Coagulopathy|All patients diagnosed with Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) or with a vascular anomaly with coagulopathy
3286314|NCT00576875||Depressed|Older individuals with major depression
3286315|NCT00576875||Non-depressed|Older individuals without major depression
3286316|NCT00576862|Experimental|1|
3286317|NCT00576849|Experimental|A|Total balanced volume replacement regimen consisting of a balanced HES 130/0.42 plus a balanced crystalloid
3286318|NCT00576849|Active Comparator|B|Conventional volume replacement strategy consisting of 6% HES 130/0.4 prepared in saline solution plus Ringer`s lactate
3286319|NCT00576836|Experimental|2|Thymus Tissue for Transplantation With Parathyroid Tissue for Transplantation
3286320|NCT00576836|Experimental|1|Thymus Tissue for Transplantation Without Parathyroid Tissue for Transplantation
3286321|NCT00576823|Experimental|Alfuzosin solution - 2-7 years|Alfuzosin solution, daily dose divided in 3 doses given at breakfast, lunch and dinner to children 2-7 years of age.
3286322|NCT00576823|Experimental|Alfuzosin solution - 8-16 years|Alfuzosin solution, daily dose divided in 3 doses given at breakfast, lunch and dinner to children and adolescents 8-16 years of age who were not able to swallow tablets or preferred to take the solution or had a body weight < 30 kg.
3286323|NCT00576823|Experimental|Alfuzosin tablet - 8-16 years|Alfuzosin tablet, daily dose divided in 2 doses given at breakfast and dinner to children and adolescents 8-16 years of age who were able to swallow tablets and had a body weight ≥ 30 kg.
3286324|NCT00576784|Active Comparator|A|pioglitazone/glimepiride
3286325|NCT00576771|Experimental|1|"ALI/ARDS patients~evaluated the effect of PSV, NAVA and assisted controlled mechanical ventilation by patient through a button"
3286326|NCT00576758|Experimental|Obinutuzumab|Participants received 1000 mg obinutuzumab intravenous (IV) infusion once a week on Days 1, 8, 15, and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression, were eligible to receive a 1000 mg IV infusion every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
3286327|NCT00576758|Active Comparator|Rituximab|Participants received 375 mg/m^2 rituximab IV infusion once a week on Days 1, 8, 15 and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression were eligible to receive a 375 mg/m^2 rituximab IV infusion once every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
3286328|NCT00576745|Active Comparator|1 Vicryl Suture|Patients will have their incision closed with vicryl suture
3286329|NCT00576745|Experimental|2 Steri-Strips|Patients will have their incisions closed with 3M Surgical-Strips
3286330|NCT00576732|Experimental|001|Risperidone low dose Risperidone oral solution 0.125 mg (if <45 kg) or 0.175 mg (if >=45 kg) qd or bid for 6 weeks
3286331|NCT00576732|Experimental|002|Risperidone high dose Risperidone oral solution 1.25 mg (if <45 kg) or 1.75 mg (if >=45 kg) qd or bid for 6 weeks
3286332|NCT00576732|Placebo Comparator|003|Placebo Oral solution qd or bid for 6 weeks
3286333|NCT00576719|Experimental|1|Participants will receive intensive cognitive behavioral therapy treatment without parent involvement
3286334|NCT00576719|Experimental|2|Participants will receive intensive cognitive behavioral therapy treatment with parent involvement
3286335|NCT00576719|Placebo Comparator|3|Waitlist control group
3286336|NCT00576706|Experimental|1|
3286337|NCT00576706|Active Comparator|2|
3286338|NCT00576693|Experimental|intensive medical management plus stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl).
3286339|NCT00576693|Experimental|intensive medical management alone|Intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl)
3286340|NCT00576667|Experimental|Rimonabant|Rimonabant 20 mg once daily.
3286341|NCT00576667|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
3286342|NCT00576654|Experimental|Dose escalation (irinotecan hydrochloride and veliparib)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and veliparib PO BID on days -1 to 14 (days 3-14 of course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3286343|NCT00576654|Experimental|Expansion portion (irinotecan hydrochloride and veliparib)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and veliparib PO BID on days 1-15 (days 2-15 of course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3286397|NCT00576212|Experimental|A|Subjects in the intervention group will receive supportive telephone calls biweekly for 6 months.
3286344|NCT00576654|Experimental|Intermittent dose escalation (irinotecan, ABT-888)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 3 and 10 and veliparib PO BID on days 1 to 4 and 8-11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3286345|NCT00576641|Experimental|Vaccine|
3286346|NCT00576628|Experimental|C.E.R.A|Participants received methoxy polyethylene glycol-epoetin beta (Continuous Erythropoietin Receptor Activator [C.E.R.A]) subcutaneously every four weeks for 44 weeks. The participants received initial dose of 1.2 microgram per kilogram (mcg/kg) of C.E.R.A. Once the Hemoglobin (Hb) concentration was attained within the target range of 11.0 and 13.0 gram per deciliter (g/dL), the dose was adjusted to maintain the Hb concentration within the target range.
3286347|NCT00576615||1: placebo|placebo solution
3286348|NCT00576615||2: propofol|propofol
3286349|NCT00576602|Experimental|1|
3286350|NCT00576602|Active Comparator|2|
3286351|NCT00576589|Experimental|CE-326,597|
3286352|NCT00576589|Placebo Comparator|Placebo|
3286353|NCT00576576|Experimental|A|All patients in this arm are given atorvastatin therapy.
3286354|NCT00576563|Other|FDG PET CT|To investigate the evolution of the 18F-deoxyglucose (FDG) uptake and the tumour characteristics determined in the plasma of patients with rectal cancer during and after radiotherapy or combined radiotherapy and chemotherapy.
3286355|NCT00576550|Experimental|1:1|Part 1 of the study (maintenance part)
3286356|NCT00576550|No Intervention|1:2|Part 1 of the study (maintenance part)
3286357|NCT00576550|Experimental|2:1|Part 2 of the study (eczema part)
3286358|NCT00576550|Active Comparator|2:2|Part 2 of the study (eczema part)
3286359|NCT00576537|Experimental|1|
3286360|NCT00576524|Experimental|Sham Device first, ITD next|Subjects will be randomized to recieve sham device first, ITD next after washout of 7 days.
3286361|NCT00576524|Experimental|ITD first, sham device next|Subjects will be randomized to receive ITD first, sham device next, after washout of 7 days.
3286362|NCT00576511|Active Comparator|1|Prucalopride
3286363|NCT00576511|Placebo Comparator|2|
3286364|NCT00576498|Experimental|1- Narrow Band Imaging|"NBI-AFI imaging - Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.~Autofluorescence Imaging (AFI)- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm)"
3286365|NCT00576498|Other|2-Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars
3286366|NCT00576485|Experimental|1|Cataract surgery and implantation of a spherical intraocular lens
3286367|NCT00576485|Experimental|2|Cataract surgery and implantation of a spherical intraocular lens
3286368|NCT00576472|Experimental|Treatment|
3286369|NCT00576459|Experimental|Fluocinolone acetonide 0.59 mg|0.59 mg fluocinolone acetonide intravitreal implant
3286370|NCT00576459|Experimental|Fluocinolone acetonide 2.1 mg|2.1 mg fluocinolone acetonide intravitreal implant
3286371|NCT00576459|Active Comparator|Laser photocoagulation|standard of care laser photocoagulation
3286372|NCT00576446|Experimental|1|
3286373|NCT00576433|Experimental|1|
3286374|NCT00576420|Experimental|FS VH S/D 500 s-apr - 60-Seconds|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) will be applied to the study suture line, 60-second polymerization time
3286375|NCT00576420|Experimental|FS VH S/D 500 s-apr - 120-Seconds|FS VH S/D 500 s-apr will be applied to the study suture line, 120-second polymerization time
3286376|NCT00576420|Active Comparator|Control Group- Manual compression with surgical gauze pads|Treatment of the study-suture line will be manual compression with surgical gauze pads.
3286377|NCT00576407|Experimental|1|Thymus Tissue for Transplantation in Complete DiGeorge Syndrome
3286378|NCT00576394|Active Comparator|1Moderate Glycemic Control|Patients will receive an insulin drip to keep blood glucose levels between 120-180mg/dl
3286379|NCT00576394|Active Comparator|2Aggressive Glycemic Control|Patients will receive an insulin drip designed to maintain serum glucose between 80-120mg/dl
3286380|NCT00576381|Experimental|A|Neonates will be administered a single bolus dose of dexmedetomidine followed by a continuous infusion for up to 24 hours post cardiac surgery.
3286381|NCT00576368|Experimental|1|
3286382|NCT00576355|Active Comparator|2|Participants will receive treatment as usual
3286383|NCT00576355|Experimental|1|Participants will receive interpersonal and social rhythm therapy for adolescents
3286384|NCT00576342|Other|AL-3862+timolol, then COSOPT|AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, followed by dorzolamide+timolol ophthalmic solution,1 drop in both eyes, 1 day later.
3286385|NCT00576342|Other|COSOPT, then AL-3862+timolol|Dorzolamide+timolol ophthalmic solution, 1 drop in both eyes, followed by AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, 1 day later.
3286386|NCT00576329|Placebo Comparator|A|
3286387|NCT00576329|Experimental|B|
3286388|NCT00576303|Experimental|RO0503821 (C.E.R.A.), 1x/4weeks|Eligible participants started RO0503821 (Continuous Erythropoietin Receptor Activator [C.E.R.A]) intravenously, at a dose of 120, 200 or 360 microgram (µg) every four weeks. The dose of C.E.R.A was based on the epoetin alfa or beta dose of<8000, 8000-16000, or >16000 international units (IU)/week, administered during the stability verification period (SVP) of 4 weeks. The SVP period was followed by dose titration period (DTP) of 16 weeks, efficacy evaluation period (EEP) of 8 weeks and long term safety period (LTSP) of 28 weeks
3286389|NCT00576251|Experimental|Tobramycin 0.3%/Dexamethasone 0.05%|Tobramycin 0.3%/Dexamethasone 0.05% 1 drop 4 times daily in both eyes
3286390|NCT00576251|Active Comparator|TOBRADEX|TOBRADEX 1 drop 4 times daily in both eyes
3286391|NCT00576238|Experimental|1:1|Part 1 - eczema treatment
3286392|NCT00576238|Active Comparator|1:2|Part 1 - eczema treatment
3286393|NCT00576238|Experimental|2:1|Part 2 - maintenance treatment
3286394|NCT00576238|No Intervention|2:2|Part 2 - maintenance treatment
3286395|NCT00576225|Experimental|Experimental|
3286399|NCT00576199|Experimental|Bevacizumab 5 mg/kg|Participants received bevacizumab 5 mg/kg intravenously every 2 weeks and within 24-48 hours prior to each transarterial chemoembolization (TACE) until disease progression or unmanageable toxicity. TACE was conducted for 4 sessions at 8-10 week intervals.
3286400|NCT00576186||1|Patients being referred for the routine Equilibrium Radionuclide Angiocardiography (ERNA) for assessment of their left ventricular function will be asked to participate in the study. All patients will be asked to sign the consent form. Patients will be given a choice to participate in either or both studies (i.e. ERNA plus ACGBS or ERNA plus ACGBS and 3 DE).
3286401|NCT00576160|No Intervention|A|"Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin.~Usual Care: Participants assigned to UCC will only receive the pre- and post-assessment session, and any adherence education or encouragement that is regularly provided by their treating physicians."
3286402|NCT00576160|Experimental|B|Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin. After Baseline, there is an initial session telephone session with PST therapist. Subsequent treatment sessions provide a context for the patient to discuss the problems and difficulties they face and that give rise to medication non-adherence.
3286403|NCT00576147|Experimental|CT scan|The standard head CT done to head trauma patients
3286404|NCT00576121||1|Left ventricular ejection fraction (LVEF) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
3286405|NCT00576121||2|End-diastolic volume (LVEDV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
3286406|NCT00576121||3|End-systolic volume (LVESV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
3286407|NCT00576108|Experimental|KD7040 topical gel|
3286408|NCT00576108|Placebo Comparator|Placebo gel|
3286409|NCT00576095||PMD|Patients diagnosed with major depression with psychotic features
3286410|NCT00576095||NPMD|Patients diagnosed with major depression without psychotic features
3286411|NCT00576095||Controls|Participants with no psychiatric or depression history
3286412|NCT00576069||asthma, quality of life, lung function|All Asthmatics will be treated with 1 of 3 long acting beta 2 agonist + corticosteroid using low or medium dose of inhaled (Advair) fluticasone or equivalent corticosteroid 200-500mcg/day plus salmeterol 100 mcg/day or (Symbicort) budesonide 320-640 mcg +formoterol 18 mcg/day or (Dulera) mometasone 400-800mcg + formoterol 20 mcg/day. In addition tiotropium 18ucg/day will be used. Additionally, albuterol 0.083%/ipratropium 0.02% solution or MDI HFA for acute exacerbation.Will measure lung function and asthma quality of life questionaire
3286413|NCT00576056|Experimental|Tace and Sorafenib|Patients with unresectable HCC will be treated with TACE in combination with oral sorafenib administration. TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin. Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment.
3286414|NCT00576043|Active Comparator|1: Training|3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator
3286415|NCT00576043|No Intervention|2: No Training|No simulator training before starting endoscopy training on real patients
3286416|NCT00576030|Other|H|habitual coffee drinkers
3286417|NCT00576030|Other|N|non-habitual coffee drinkers
3286418|NCT00576004|Active Comparator|group A|Pelvic organ prolapse repair plus concomitant Burch Colposuspension
3286419|NCT00576004|Active Comparator|group B|Pelvic organ prolapse without Burch colposuspension
3286420|NCT00575991|Experimental|A|
3286421|NCT00575991|Placebo Comparator|B|
3286422|NCT00575978|Experimental|Hydralazine|"The objective of this study is to determine the MTD for hydrazaline added to standard neoadjuvant chemotherapy for operable breast cancer. Four dose levels of hydrazalline are planned:~Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID"
3286423|NCT00575965|Experimental|Simvastatin|Simvastatin at 20 mg daily for the first week, then dose escalated weekly by 20 mg a day to a maximum of 80 mg daily by week 4. Patients were maintained on therapy until progression.
3286424|NCT00575952|Experimental|Treatment (doxorubicin hydrochloride, cisplatin, paclitaxel)|"Patients receive doxorubicin hydrochloride IV over 30 minutes followed by cisplatin IV over 1 hour on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive doxorubicin hydrochloride IV and cisplatin IV or IP on day 1, and paclitaxel IP on days 1 or 8. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3286425|NCT00575939||HIV positive|HIV infected treatment naive with CD4 cell count of at least 400
3286426|NCT00575939||Healthy controls|Healthy controls
3286427|NCT00575926|Active Comparator|A: Lingzhi extract|Oral 300mg capsules containing Lingzhi extract (4 to 6 capsules per day as dosed by patients' age)
3286428|NCT00575926|Placebo Comparator|B: Placebo|Starch with same appearance and taste as LingZhi
3286429|NCT00575900|Experimental|1|Low carbohydrate and low fat.
3286430|NCT00575900|Experimental|2|Low carbohydrate fat rich diet
3286431|NCT00575900|Active Comparator|3|A balanced low fat diet
3286432|NCT00575887|Experimental|1|
3286433|NCT00575874|Experimental|1|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
3286434|NCT00575874|Experimental|2|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
3286435|NCT00575874|Experimental|3|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
3286436|NCT00575874|Active Comparator|4|30 mg pioglitazone HCl capsules once daily for 12 weeks
3286437|NCT00575874|Placebo Comparator|5|Matching rivoglitazone HCL placebo tablets and/or matching pioglitazone HCL placebo capsules
3286438|NCT00575861|Active Comparator|1|Advair 250/50 (baseline) fluticasone/salmeterol 250/50
3286439|NCT00575848|Active Comparator|1|
3286440|NCT00575848|Placebo Comparator|2|
3286441|NCT00575835|Active Comparator|1|
3286442|NCT00575835|Experimental|2|
3286446|NCT00575796|Experimental|1|"Children will be treated with Vinblastine Sulphate chemotherapy via intravenous administration once a week over a period of 26 weeks. MRI disease evaluation should be performed at weeks 12 and 26 (+/- 1 week). If response on MRI at week 26 > stable (i.e. stable disease, objective or partial or complete response compared to the baseline MRI exam), continue weekly Vinblastine to the total duration of treatment (i.e. 70 weeks).~All children will be followed until they demonstrate clear signs tumour progression."
3286447|NCT00575783||1A, 1B|"Type 1 diabetic subjects with a history of severe hypoglycemia and hypoglycemia unawareness who:~1A) meet criteria for islet cell transplantation and are referred by a participating islet cell transplantation center~1B) meet similar criteria but are not currently planning islet cell transplantation"
3286448|NCT00575783||2|Type 1 diabetics who are not optimally controlled (>8% HbA1c) and rarely experience hypoglycemia
3286449|NCT00575783||3|Healthy non-diabetics
3286450|NCT00575757||Primary|HIV infected with abnormal liver enzymes in the absence of HCV or HBV coinfections.
3286451|NCT00575744|No Intervention|1|
3286452|NCT00575731|Experimental|Fine-Tuning|2-month intervention (8 lifestyle counseling classes)
3286453|NCT00575731|Active Comparator|Record-Keeping|2-month intervention (8 lifestyle counseling classes)
3286454|NCT00575718|Active Comparator|1|Hospital Counseling + Nicotine Replacement Therapy (HC+NRT)
3286455|NCT00575718|Experimental|2|Hospital Counseling + Nicotine Replacement Therapy + Pre-surgical Schedule Reduced Smoking (HC+NRT+PS/SRS)
3286456|NCT00575692||PulmoHypertension|Patients with suspected, latent or manifest pulmonary hypertension
3286457|NCT00575692||Controls|Controls without history of cardiac or pulmonary diseases
3286458|NCT00575679|Experimental|1|Brief motivational interview
3286459|NCT00575679|No Intervention|2|No discussion
3286460|NCT00575666|Experimental|A|Intranasal Insulin Treatment
3286461|NCT00575666|Placebo Comparator|B|Drug: Placebo
3286462|NCT00575653||11-18 (Primary)|Enrolled members of one of the participating health plans who are ages 11-18 at any time during the study period, March 1, 2005 through August 31, 2008.
3286463|NCT00575653||19-21 (Secondary)|Enrolled members of one of the participating health plans who are ages 19-21 at any time during the study period, March 1, 2005 through August 31, 2008.
3286464|NCT00575640|Active Comparator|1|"The objective of this study is to determine the MTD for Hydralazine added to standard neoadjuvant chemotherapy for operable recta cancer. Four dose levels of hydralazine are planned:~Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID"
3286465|NCT00575627|No Intervention|2|
3286466|NCT00575627|Experimental|1|Drug: peginterferon α-2a (40 kDa) plus ribavirin for 24-48 weeks
3286467|NCT00575614|Active Comparator|1|
3286468|NCT00575614|Placebo Comparator|2|
3286469|NCT00575601|Active Comparator|A|
3286470|NCT00575601|Placebo Comparator|B|
3286471|NCT00575588|Experimental|Saxagliptin|
3286472|NCT00575588|Experimental|Glipizide|
3286473|NCT00575575|Experimental|A,2|
3286474|NCT00575536||Rhizotomy for children with spasticity|Children with spasticity needing Rhizotomy surgery
3286475|NCT00575523|Active Comparator|1: Atropine|Atropine 0,5mg is administered intravenously immediately before starting percutaneous ethanol instillation.
3286476|NCT00575523|Placebo Comparator|2: Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
3286477|NCT00575510|Experimental|Intervention|Culturally targeted behavioral and normative beliefs + knowledge/skills + salience + environmental constraints/barriers counseling
3286478|NCT00575510|Active Comparator|Active Control|nontargeted behavioral and normative beliefs + knowledge/skills + salience + environmental constraints/barriers counseling
3286479|NCT00575510|No Intervention|Standard Care Only|Clinical standard of care at time of study
3286480|NCT00575497|Experimental|A|Six Day per week short daily hemodialysis
3286481|NCT00575497|Experimental|B|Six nights per week nocturnal hemodialysis
3286482|NCT00575497|Experimental|C|Every other day short daily hemodialysis
3286483|NCT00575497|Experimental|D|Every other night hemodialysis
3286484|NCT00575497|Experimental|E|5 days per week short daily hemodialysis
3286485|NCT00575497|Experimental|F|5 nights per week hemodialysis
3286486|NCT00575497|Active Comparator|G|Conventional three time per week short daily hemodialysis
3286487|NCT00575484|Placebo Comparator|1|
3286488|NCT00575484|Active Comparator|2|
3286489|NCT00575471|Experimental|1|rivoglitazone HCl 0.5 mg tablets once daily for 12 weeks
3286490|NCT00575471|Experimental|2|rivoglitazone HCl 1 mg tablets once daily for 12 weeks
3286491|NCT00575471|Experimental|3|rivoglitazone HCl 1.5 mg tablets once daily for 12 weeks
3286492|NCT00575471|Placebo Comparator|4|Matching placebo tablets once daily for 12 weeks
3286493|NCT00575458||1|Static Splint
3286494|NCT00575458||2|Dynamic Splint
3286495|NCT00575445||1|Pediatric patients with previously diagnosed asthma
3286496|NCT00575432||1|
3286497|NCT00575419|Experimental|1, IV NAC|N-acetylcysteine administered intravenously
3286498|NCT00575419|Experimental|2, IA NAC|N-acetylcysteine administered intra-arterial
3286499|NCT00575406|Active Comparator|R-CHOP|Treatment with Rituximab, Cyclophosphamide, Doxorubicin, Vincristin and Prednisolone
3286500|NCT00575406|Experimental|R-COMP|Treatment with Rituximab, Cyclophosphamide, liposomal Doxorubicin, Vincristin and Prednisolone
3286501|NCT00575380|Active Comparator|AzaSite Eye Drops|One drop two times a day for two days and once a day for the next five days
3286502|NCT00575380|Active Comparator|Vigamox Eye Drops|One drop three times a day for seven days
3286503|NCT00575367|Active Comparator|AzaSite|
3286504|NCT00575367|Active Comparator|Vigamox|
3286505|NCT00575354|Active Comparator|1|Sevoflurane: induction 3-6%, maintenance 2-3%
3286506|NCT00575354|Active Comparator|2|Isoflurane: induction 3-6%, maintenance 2-3%
3286507|NCT00575341|Active Comparator|1|substitution of DHEA-hormone, oral, once daily
3286508|NCT00575341|Placebo Comparator|2|substitution of placebo, oral, once daily
3286624|NCT00574379|Placebo Comparator|5|
3286509|NCT00575328|Experimental|1. Maca Root|Subjects in this arm will be given 3g/day of Maca Root.
3286510|NCT00575328|Placebo Comparator|2. Control|Subjects in this arm will receive placebo.
3286511|NCT00575302|Active Comparator|300|administration of 300 IU Gonal-f® in a short agonist protocol.
3286512|NCT00575302|Experimental|450|administration of 450 IU Gonal-f® in a short agonist protocol.
3286513|NCT00575276||1|Females with acute cholecystitis
3286514|NCT00575276||2|Females with Chronic Cholecystitis
3286515|NCT00575276||3|Males with acute cholecystitis
3286516|NCT00575276||4|Males with Chronic Cholecystitis
3286517|NCT00575263||Normal Teeth|Normal molar teeth
3286518|NCT00575263||painful teeth|Painful molar teeth
3286519|NCT00575250|Active Comparator|1|Osteoporosis Prevention and Self-Management Course (4 x 2 1/2 hours)
3286520|NCT00575250|Active Comparator|2|"One introductory osteoporosis education session (1 x 2 1/2 hours)"
3286521|NCT00575237|No Intervention|Control|In the control group, CO2 was removed by passive deflation of the abdominal cavity through the holes of the trocar.
3286522|NCT00575237|Experimental|Intervention|
3286523|NCT00575224|Other|A|Pegylated interferon and ribavirin for 24 weeks
3286524|NCT00575224|Other|B|Pegylated interferon and ribavirin for 48 weeks
3286525|NCT00575211||Cardiomyopathy|
3286526|NCT00575198|Experimental|1|No drainage threshold
3286527|NCT00575198|Active Comparator|2|Drainage <2 mL/kg
3286528|NCT00575185|Active Comparator|Valomaciclovir|Valomaciclovir 2 grams orally twice daily for 21 days
3286529|NCT00575185|Placebo Comparator|placebo|placebo 2 tablets twice daily for 21 days
3286530|NCT00575172||U|Intensified insulin therapy with ultrarapid insulin-analogue (Insulin-Aspart)
3286531|NCT00575172||R|Intensified insulin therapy with human regular insulin
3286532|NCT00575159|Experimental|Arm a|GSK189075
3286533|NCT00575159|Placebo Comparator|Arm b|Placebo
3286534|NCT00575146|Experimental|1|ketogenic diet
3286535|NCT00575120|No Intervention|A|Endothelial Function of forearm assessed by FMD, PAT, BOLD-MRI before 15 min. ischemia reperfusion of forearm
3286536|NCT00575120|Active Comparator|B|Endothelial Function of forearm assessed by FMD, PAT, BOLD-MRI after 15 min. ischemia reperfusion
3286537|NCT00575107|Experimental|VSC-VLC|velocity-controlled variable resistance, lengthening contraction
3286538|NCT00575107|Active Comparator|SC|Constant weight shortening contraction
3286539|NCT00575081||Stereotactic Brain Procedures|Patients who need Deep Brain Stimulation, GPi for Dystonia, and/or patients who have consented to undergo or have undergone a stereotactic brain procedure for any reason
3286540|NCT00575068|Experimental|1|
3286541|NCT00575055|Experimental|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
3286542|NCT00575055|Placebo Comparator|Placebo Dose|infusion every 13 weeks for a total of 6 infusions.
3286543|NCT00575055|Experimental|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions.
3286544|NCT00575042|Experimental|Patients treated with Fenofibrate|Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) 160 mg table per day for 1 year
3286545|NCT00575029|Experimental|megace treatment|Study subjects will be given 600mg of MA for oral ingestion per day for duration of 8 weeks. They will be monitored every week clinically for the development of adrenal insufficiency by review of symptoms, physical exam, body weight, pulse, and blood pressure. Subjects also will undergo biochemical evaluation of adrenal status every two weeks by measurement of serum electrolytes, serum cortisol, serum adrenocorticotropic hormone(ACTH) levels, and the adrenal response to a low dose ACTH (1µgm) stimulation test(see methods).
3286546|NCT00575016|Experimental|1|botulinum toxin Type A (50U); botulinum toxin Type A (200U)
3286547|NCT00575016|Experimental|2|botulinum toxin Type A (100U); botulinum toxin Type A (200U)
3286548|NCT00575016|Experimental|3|botulinum toxin Type A (200U)
3286549|NCT00575016|Other|4|placebo; botulinum toxin Type A (200U)
3286550|NCT00575003|Experimental|1|
3286551|NCT00575003|Placebo Comparator|2|
3286552|NCT00574990||VA Physicians|VA providers who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
3286553|NCT00574990||VA Nurses|VA nurses who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
3286554|NCT00574990||VA Pharmacists|VA pharmacists who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
3286555|NCT00574977|Experimental|A|Subjects who have been vaccinated with vaccinia virus (small pox)and will receive vvDD-CDSR by intratumoral injection
3286556|NCT00574977|Experimental|B|Subjects will include those who have not been vaccinated with vaccinia virus (small pox)and will receive vvDD-CDSR by intratumoral injection.
3286557|NCT00574977|Experimental|C|Subjects will be those who have been vaccinated with vaccinia virus (small pox)and will be receiving the vvCD-CDSR via intravenous infusion
3286558|NCT00574964|Experimental|1|
3286559|NCT00574951|Experimental|AMG 706|AMG 706 daily
3286560|NCT00574912|Experimental|Placebo then Insulin Glargine|"Placebo: administer single dose of Placebo subcutaneously (SC) with blood glucose monitoring over 24 hours.~Then Insulin Glargine SQ 8 weeks later, in increasing doses (0.5, 1.0, 1.5, 2.0 u/kg body wt.) with blood glucose monitoring monitoring over a 24 hour period. Each dose is separated by 8 weeks (5 separate study visits)"
3286561|NCT00574899||1|patients scheduled to receive standard of care with a Radical prostatectomy
3286562|NCT00574899||2|patients scheduled to receive standard of care with radiation therapy
3286563|NCT00574886|Experimental|1|
3286564|NCT00574873|Experimental|1|Bosutinib
3286565|NCT00574873|Active Comparator|2|Imatinib
3286566|NCT00574860|Experimental|EN3285 (NAC ProGelz)|The EN3285 arm is the product under development
3286567|NCT00574860|Placebo Comparator|No active ingredients (placebo)|This will be an oral product that contains no active ingredient
3286568|NCT00574860|Other|Standard of Care|This arm will reflect the typical standard of care for the patient
3286569|NCT00574847|Experimental|Escitalopram|Escitalopram treatment
3286570|NCT00574847|Placebo Comparator|Placebo|Placebo
3286571|NCT00574834|Active Comparator|Ramipril|Patients randomized to 6 months treatment of Ramipril.
3286572|NCT00574834|Active Comparator|HCTZ|PAtients randomized to 6 months treatment of HCTZ.
3286573|NCT00574834|Active Comparator|Ramipril+HCTZ|Patients randomized to 6 months treatment of Ramipril+HCTZ.
3286574|NCT00574808|Experimental|intervention|Outreach Facilitation implementing elements of the Chronic Care Model. The facilitators will provide hands on support to practices and help to implement tools and processes designed to incorporate evidence-based practice into the routine delivery of cardiovascular care. Specifically, they will a) assist with practice performance assessment, feedback, and consensus building towards goal setting, b) offer clinical, technical, organizational resources and practical advice, and c) provide encouragement to face and overcome the challenges of implementing system change.
3286575|NCT00574808|No Intervention|control|Baseline data before implementation of the program will serve as the control. Comparisons will be made between baseline and post-intervention within each divisions of primary care practices as well as between divisions (ie. baseline information from one division will serve as the control for another).
3286576|NCT00574769|Experimental|1|
3286577|NCT00574756|Other|1|Active drug for 2 weeks, then washout period for 2 weeks, then placebo for 2 weeks
3286578|NCT00574756|Other|2|Placebo for 2 weeks, then washout for 2 weeks, then ranolazine for 2 weeks
3286579|NCT00574743|No Intervention|2|
3286580|NCT00574743|Active Comparator|1|
3286581|NCT00574730|Experimental|Arm 1|
3286582|NCT00574717|Experimental|A|Infants will receive spectacle under-correction of their hyperopia.
3286583|NCT00574704|Experimental|1|
3286584|NCT00574704|Placebo Comparator|2|
3286585|NCT00574704|Experimental|3|
3286586|NCT00574704|Placebo Comparator|4|
3286587|NCT00574691|Other|1|Vascular Closure Device
3286588|NCT00574678|No Intervention|1|
3286589|NCT00574665|Experimental|1|
3286590|NCT00574652|Other|1|it is a single arm study
3286591|NCT00574639|Experimental|Arm 1|Day 1 study two hyperinsulinemic (high Insulin dose) euglycemic (normal glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
3286592|NCT00574639|Experimental|Arm 2|Day 1 study two hyperinsulinemic (high Insulin dose) euglycemic (normal glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
3286593|NCT00574639|Experimental|Arm 3|Day 1 study two hyperinsulinemic (high Insulin dose) hypoglycemic (low glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
3286594|NCT00574639|Experimental|Arm 4|Day 1 study two hyperinsulinemic (high Insulin dose) hypoglycemic (low glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
3286595|NCT00574626|Experimental|PBSCT|Peripheral Blood Stem Cell Transplant
3286596|NCT00574626|Active Comparator|BMT|Bone Marrow Transplantation
3286597|NCT00574613|Experimental|1|
3286598|NCT00574613|Placebo Comparator|2|
3286599|NCT00574600|Experimental|Vaccine|SAAVI DNA-C2 administered as 1 ml intramuscularly in either deltoid at study entry and Months 1 and 2; SAAVI MVA-C administered as 0.5 ml intramuscularly in either deltoid at Months 4 and 5
3286600|NCT00574600|Placebo Comparator|Placebo|Placebo administered at Months 0, 1, 2, 4 and 5
3286601|NCT00574587|Experimental|1|
3286602|NCT00574574|Experimental|1|500mg/d of anthocyanin, contained in 4 X 250mg capsules (125mg anthocyanin/ capsule). 2 capsules to be taken with food, twice per day (n=4 in total).
3286603|NCT00574574|Placebo Comparator|2|500mg/d of placebo control containing no anthocyanin, 2 X 250mg capsules to be taken with food, twice per day (n=4, 250mg capsules in total / d).
3286604|NCT00574548|Experimental|Group 1.1|Group 1.1 = 13vPnC then 13vPnC
3286605|NCT00574548|Experimental|Group 1.2|Group 1.2 = 13vPnC then 23vPS
3286606|NCT00574548|Experimental|Group 2|Group 2 = 23vPS then 13vPnC
3286607|NCT00574522|Other|1|Infrared Radiation, wavelength between 5 and 20 microns
3286608|NCT00574509|Experimental|131I-Anti-B1|BEAM + 131Iodine-Anti-B1 radioimmunotherapy and autologous HSCT
3286609|NCT00574496|Experimental|High-Risk or Relapsed Hodgkin Lymphoma|This is a phase 2 intention-to-treat study of salvage chemotherapy followed by allogeneic HSC transplant for the treatment of primary refractory or relapsed HL. Patients who 1) do not progress on salvage chemotherapy, and 2) have both suitable HSC donors and 3) a satisfactory pre-allograft work-up will proceed to allograft. Patients who fail any of these 3 criteria will be off-study and considered treatment failures for the purposes of the intention-to-treat study.
3286610|NCT00574483|Experimental|1|Unblinded treatment arm
3286611|NCT00574470|Experimental|1|Treatment with daclizumab/infliximab
3286612|NCT00574457|Other|All subjects that meet the inclusion criteria invited|
3286613|NCT00574444|Experimental|Procedure|Procedure/Surgery: transvaginal diagnostic peritoneoscopy For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
3286614|NCT00574431|Other|Observation|Observation
3286615|NCT00574431|Active Comparator|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
3286616|NCT00574418|Other|1|
3286617|NCT00574405|Active Comparator|1|MDI = 3-4+ insulin injections/day, using split-mix NPH insulin + regular insulin or Lantus + Novolog® (or Humalog®).
3286618|NCT00574405|Experimental|2|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
3286619|NCT00574392||1|Multiwavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented lesions on skin in vivo
3286620|NCT00574379|Experimental|1|Bilastine 20mg once per day
3286621|NCT00574379|Experimental|2|Bilastine 20mg twice per day
3286622|NCT00574379|Experimental|3|Bilastine 10mg once per day
3286623|NCT00574379|Experimental|4|Bilastine 10mg twice per day
3286625|NCT00574366|Experimental|Erlotinib/RAD001 Ph I|"Tarceva (OSI-774; erlotinib) Everolimus (RAD001)~Study did not progress to Phase II:~Experimental: Erlotinib/RAD001 Phase II Maximum tolerated dose of erlotinib (Tarceva,OSI-774) and RAD001 (Everolimus)"
3286626|NCT00574353|Experimental|1|FMISO PET study.
3286627|NCT00574340|Active Comparator|Control study then antecedent hypoglycemia study group|Day 1 euglycemia, day 2 hypoglycemia Hyperinsulinemic Hypoglycemic Clamp: hyperinsulinemic glucose clamp separated by 8 weeks then participants proceeded to antecedent hypoglycemia study Day 1 hypoglycemia, Day 2 hypoglycemia
3286628|NCT00574340|Active Comparator|Antecedent Hypoglycemic clamp study|Day 1 hypoglycemia, day 2 hypoglycemia Hyperinsulinemic Hypoglycemic Clamp: hyperinsulinemic glucose clamp separated by 8 weeks then participants proceeded to control study Day 1 euglycemia, Day 2 hypoglycemia
3286629|NCT00574327||A- Barrett's Esophagus subjects|Patients with documented Barrett's Esophagus with or without dysplasia (LGD or HGD) that will undergo surveillance endoscopies dictated by the grade of dysplasia.
3286630|NCT00574327||B- gastroesophageal reflux subjects|Patients undergoing endoscopy for evaluation of GERD symptoms.
3286631|NCT00574327||C-subjects without BE or GERD|The control group would include patients undergoing upper endoscopy for reasons other than stated above, such as evaluation of iron deficiency anemia, weight loss, positive fecal occult blood, etc.
3286632|NCT00574314||Women|Women with varying backgrounds
3286633|NCT00574301|Experimental|1|
3286634|NCT00574288|Experimental|Dose Escalation: Daratumumab|
3286635|NCT00574288|Experimental|Dose Expansion: Daratumumab|
3286636|NCT00574275|Placebo Comparator|Placebo and Gemcitabine|Participants with metastatic pancreatic cancer administered Placebo and 1000 mg/m^2 Gemcitabine.
3286637|NCT00574275|Experimental|Aflibercept and Gemcitabine|Participants with metastatic pancreatic cancer administered 4 mg/kg Aflibercept and 1000 mg/m^2 Gemcitabine.
3286638|NCT00574249|Active Comparator|adalimumab + placebo|adalimumab + placebo (vehicle ointment)
3286639|NCT00574249|Active Comparator|adalimumab + calcipotriol/betamethasone|adalimumab + calcipotriol/betamethasone ointment
3286640|NCT00574236|Experimental|A|
3286641|NCT00574223|Experimental|Arm 1|
3286642|NCT00574223|Placebo Comparator|Arm 2|
3286643|NCT00574210|Experimental|1|Bilastine oral 20 mg once per day (1 x 20 mg bilastine tablet plus 1 placebo tablet)
3286644|NCT00574210|Experimental|2|Bilastine oral 20 mg twice per day (2 x 20 mg bilastine tablets)
3286645|NCT00574210|Experimental|3|Bilastine oral 10 mg once per day (1 x 10 mg bilastine tablet plus 1 placebo tablet)
3286646|NCT00574210|Experimental|4|Bilastine oral 10 mg twice per day (2 x 10 mg bilastine tablets)
3286647|NCT00574210|Placebo Comparator|5|Placebo oral twice per day (2 placebo tablets)
3286648|NCT00574197|Other|1|all subjects switched from Mycophenolate Mofetil to Mycophenolate Sodium
3286649|NCT00574171|Experimental|1|
3286650|NCT00574145|Experimental|Radiotherapy/Supportive Care (A)|Patients receive radiotherapy and healing touch therapy from a healing touch therapist once a week for the duration of their radiotherapy
3286651|NCT00574145|Sham Comparator|Control ARM (B)|Patients receive radiotherapy and sham healing touch therapy from a sham healing touch therapist once a week for the duration of their therapy
3286652|NCT00574132|Experimental|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
3286653|NCT00574132|Placebo Comparator|Placebo Control|infusion every 13 weeks for a total of 6 infusions.
3286654|NCT00574132|Experimental|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions.
3286655|NCT00574119|Experimental|Results with spironolactone|patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.
3286656|NCT00574106|Other|1|Infrared Radiation
3286657|NCT00574093|Experimental|A|A: This will be a single arm study. Patients will be administered Lucentis™ on Day 1,at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
3286658|NCT00574080|Experimental|Arm A|DPACE Induction, Melphalan/DPACE Transplant 1, BEAM Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases
3286659|NCT00574080|Experimental|Arm B|DPACE Induction, Melphalan/DPACE + VTD Transplant 1, BEAM + VTD Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases
3286660|NCT00574067|Experimental|Buprenorphine+OTP|Buprenorphine and counseling in prison and continued at opioid treatment program (OTP) upon release.
3286661|NCT00574067|Experimental|Buprenorphine+CHC|Buprenorphine and counseling in prison and continued at a community health center (CHC) upon release.
3286662|NCT00574067|Active Comparator|Counseling + OTP|Counseling only in prison and Buprenorphine upon release at a opioid treatment program (OTP)
3286663|NCT00574067|Active Comparator|Counseling + CHC|Counseling only in prisons and Buprenorphine upon release at a community health center (CHC)
3286664|NCT00574054|Other|1|
3286665|NCT00574041|Experimental|1|titrated dose of Avonex
3286666|NCT00574041|Active Comparator|2|full dose Avonex
3286667|NCT00574015|Active Comparator|oral|administration of oral analgesia
3286668|NCT00574015|Experimental|Dental Block|Administration of supraperiosteal nerve block to effected tooth
3286669|NCT00574002||Group A|Patients that have their chest tube removed when drainage is 400mL or less in 24 hours.
3286670|NCT00574002||Group B.|Patients that have their chest tube removed when drainage is 200mL or less in 24 hours.
3286671|NCT00573989|Experimental|Erlotinib|Erlotinib
3286672|NCT00573963|Active Comparator|1|Ropivacaine
3286673|NCT00573963|Placebo Comparator|2|Placebo
3286674|NCT00573950|Experimental|Cilostazol|cilostazol group
3286675|NCT00573950|Placebo Comparator|Placebo|placebo group
3286676|NCT00573937|Active Comparator|Methadone|Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
3286712|NCT00573599|Experimental|1|prochlorperazine and benadryl IV, saline subQ
3286677|NCT00573937|Active Comparator|Morphine|Oral slow-release morphine (15 mg) every 8 hours, and immediate-release morphine (10 mg) every 4 hours as needed for breakthrough pain.
3286678|NCT00573924|Active Comparator|1|Oral PPI
3286679|NCT00573924|Active Comparator|2|Intravenous PPI
3286680|NCT00573885|Experimental|Arm I|Patients receive oral defined green tea catechin extract twice daily for 6 months.
3286681|NCT00573885|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 6 months.
3286682|NCT00573872|Experimental|Spinal Radiosurgery|Patients will be fitted in a custom immobilization device. A CT simulation scan will then be performed to pinpoint intended radiosurgery target producing a computer optimized radiation plan to be confirmed by planning radiation physicist. Patient will then be placed in their immobilization device and aligned with the treatment planning position. Patient then receives radiosurgery. Treatment delivery will be divided into components of 3-5Gy with repeat CT based localization in between each of these components. For all patients, a nominal prescription dose of 24Gy will be entered into the tomotherapy cost function. Once the plan that provides maximal spinal sparing has been generated, the plan will be renormalized to produce no more than 8Gy (prior RT) or 10Gy (no prior RT) to 0.5cc of spinal cord by dividing the single fraction treatment into fractions of 3-5Gy.
3286683|NCT00573859|Experimental|ADHD medication versus placebo|For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication (e.g., Dextroamphetamine; Amphetamine mixed salts; Atomoxetine; O-Methylphenidate; Lisdexamfetamine). For the placebo condition, a placebo pill was administered.
3286684|NCT00573833|Experimental|HDR Brachytherapy|9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days
3286685|NCT00573820|Other|1|
3286686|NCT00573807|Other|1|
3286687|NCT00573794|Experimental|Adalimumab 40 mg EOW/EW|Open-label adalimumab 40 mg every other week (EOW) or every week (EW). Participants who entered from an open-label cohort continued their previous dosing regimen of adalimumab EOW or EW; participants who entered from a double-blind cohort received adalimumab EOW.
3286688|NCT00573781|Experimental|A|Diet with increased intake of rye bread, berries and fish
3286689|NCT00573781|Experimental|B|Increased intake of whole grain and rye bread
3286690|NCT00573781|Active Comparator|C|Control diet with decreased intake of rye bread, berries and fish
3286691|NCT00573768|Active Comparator|1|
3286692|NCT00573768|Placebo Comparator|2|
3286693|NCT00573768|Active Comparator|3|
3286694|NCT00573755|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3286695|NCT00573755|Active Comparator|Arm II|Patients receive oral placebo twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3286696|NCT00573729|Experimental|Pulsed Dye Laser 577 nm|Pulsed Dye Laser Treatment 577 nm treatment of Port Wine Stain Birthmarks
3286697|NCT00573729|Experimental|Pulsed Dye Laser 595 nm|Pulsed Dye Laser Treatment 595 nm treatment of Port Wine Stain Birthmarks
3286698|NCT00573716||1|15 subjects who are taking aripiprazole monotherapy
3286699|NCT00573716||2|15 subjects who are taking Risperidone therapy
3286700|NCT00573716||3|30 healthy volunteers with an ethnicity, sex, and pubertal stage match of subjects taking aripiprazole monotherapy and Risperidone therapy
3286701|NCT00573703|Active Comparator|Group A|
3286702|NCT00573703|Experimental|Group B|
3286703|NCT00573690|Experimental|Group 1|Patients receive cisplatin IV over 1 hour on day 2 of courses 1 and 2 and on day 1 of all subsequent courses; etoposide IV over 30 minutes on days 1-3; and oral sorafenib tosylate once or twice daily on days 1-21. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.
3286704|NCT00573690|Experimental|Group 2|Patients receive carboplatin IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Patients also receive sorafenib tosylate as in group 1. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.
3286705|NCT00573664|Active Comparator|1|Gabapentin
3286706|NCT00573664|Placebo Comparator|2|Placebo
3286707|NCT00573651|Other|Group A pauciarticular JIA|Females age 9-26 with pauciarticular JIA. All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some Blood Draws for serum titres taken to measure antibody and RNA titers.
3286708|NCT00573651|Other|Group B polyarticular JIA|Females age 9-26 with polyarticular JIA. All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some Blood Draws for Serum Titers taken to measure antibody and RNA titers.
3286709|NCT00573651|Other|Group C seronegative arthritis|Females age 9-26 with seronegative arthritis (including ankylosing spondylitis and psoriatic arthritis). All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers.
3286710|NCT00573612|Placebo Comparator|1|Telephone Call for the Attention Control Group Each AC call will follow the same format as the MI call. During the AC call, study subjects will receive health information on important topics relevant to their illness. Specifically, there will be one topic during each phone call that includes the following: (a) overview of FMS, (b) pain, (c) fatigue (d) sleep, (e) stress, and (f) living well with FMS. The AC calls will be an avenue to transfer relevant health information from the RA to the study subject. The scheduled topics during each contact will give the call face validity (i.e., establish a credible pretense for the contact) while being neutral with respect to encouragement of exercise.
3286711|NCT00573612|Active Comparator|2|Telephone-delivered Motivational Interviewing Participants will receive 6 telephone calls throughout the study. Harland et al reported that the most effective intervention for promoting exercise in the primary care setting was the most intensive treatment arm that included six MI sessions (208). Importantly, in our pilot study, participants who completed 5 to 6 phone calls achieved greater symptomatic benefits than participants who had ≤ 4 phone calls. The phone calls will be scheduled at week 3, 4, 6, 8, 10 and 12 of the study. Telephone sessions may run for 30 minutes on the average
3286713|NCT00573599|Active Comparator|2|imitrex SubQ, saline IV
3286714|NCT00573573|Other|1|
3286715|NCT00573534|Experimental|Open Label Vyvanse|Open Label Vyvanse (lisdexamphetamine) in doses of 30-70 mgs over 8 weeks in younger siblings of substance abusing older siblings with a history of treatment for ADHD
3286716|NCT00573508|Active Comparator|Placebo|Matching placebo tablet taken once daily
3286717|NCT00573508|Experimental|Solifenacin Succinate|5mg or 10mg tablet taken once daily
3286718|NCT00573495|Experimental|hTERT/Survivin Multi-Peptide Vaccine|
3286719|NCT00573482|Active Comparator|control group|Control (only exposure to the food labels and the new lower ED foods).
3286720|NCT00573482|Experimental|intervention group|Education in REDE techniques plus exposure to the food labels and the new lower ED foods.
3286721|NCT00573469|Active Comparator|1|D9421-C 9 mg
3286722|NCT00573469|Active Comparator|2|D9421-C 15 mg
3286723|NCT00573469|Placebo Comparator|3|Placebo
3286724|NCT00573456|Other|1|
3286725|NCT00573443|Experimental|DM 30 mg/Q 10 mg|AVP-923-30/10 Capsules (30 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
3286726|NCT00573443|Experimental|DM 20 mg/ Q 10 mg|AVP-923-20/10 Capsules (20 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
3286727|NCT00573443|Placebo Comparator|Placebo|Placebo Capsules once daily for 1 week and then twice daily for an additional 11 weeks
3286728|NCT00573430|Experimental|1|Candesartan Cilexetil
3286729|NCT00573430|Experimental|2|Candesartan Cilexetil
3286730|NCT00573430|Experimental|3|Candesartan Cilexetil
3286731|NCT00573417|Experimental|modafinil|modafinil 100mg, 200mg, or 300mg (dose escalation)
3286732|NCT00573417|Placebo Comparator|placebo|placebo
3286733|NCT00573404|Experimental|Therapeutic Intervention|
3286734|NCT00573391|Experimental|VTD = Velcade, Thal, and Dex|VTD = Velcade, Thalidomide, and Dexamethasone
3286735|NCT00573391|Experimental|VMD = velcade, melphalan, and dex|VMD = velcade, melphalan, and dexamethasone
3286736|NCT00573378|Experimental|1|
3286737|NCT00573365|Experimental|Treatment|LED treatment with Gentlewaves Select™ handheld high energy LED array 5 to 10 minutes before each radiation treatment and again 5-10 minutes after each radiation treatment
3286738|NCT00573365|Other|Control|Radiation only
3286739|NCT00573352|Other|1|Far infrared radiation
3286740|NCT00573339||Normal Controls|
3286741|NCT00573326|Experimental|1|Imatinib 200 mg p.o. once a day for 6 months
3286742|NCT00573313|Experimental|S-adenosylmethionine (SAMe)|Alcoholic liver disease patients receiving S-adenosylmethionine (SAMe)at 400 mg capsule three times daily for 24 weeks
3286743|NCT00573313|Placebo Comparator|Sugar pill|ALD subjects receiving Placebo three times daily for 24 weeks.
3286744|NCT00573300||Schizophrenia|Schizophrenia Patients
3286745|NCT00573300||Healthy Controls|Healthy Controls
3286746|NCT00573287|Experimental|Clozapine|clozapine: clozapine--tablets, 12.5-100 mg, daily for 24 weeks
3286747|NCT00573287|Active Comparator|Risperidone|risperidone: risperidone--tablets, 0.5-5.0mg daily for 24 weeks
3286748|NCT00573274||1|Elective cesarean section patients
3286749|NCT00573261|Experimental|Pregabalin|Pregabalin medication
3286750|NCT00573261|Placebo Comparator|Placebo|Placebo
3286751|NCT00573248|Experimental|4|
3286752|NCT00573209|Other|1|
3286753|NCT00573196|Experimental|1|
3286754|NCT00573183|Experimental|STAGE-12|STAGE-12 received 3 individual and 5 group 12-step facilitation sessions focusing on 12-step principles plus an intensive referral in which counselors linked participants to community-based 12-step volunteers. These sessions took the place of 3 individual and 5 group sessions in the standard intensive outpatient drug treatment program and were integrated into treatment as usual.
3286755|NCT00573183|Active Comparator|Treatment as Usual|Treatment as usual received standard care provided in intensive outpatient drug treatment program without the STAGE-12 components.
3286756|NCT00573170|Other|TPB|TREXIMET® (Attack 1), placebo (Attack 2), BCM (Attack 3)
3286757|NCT00573170|Other|TBP|TREXIMET® (Attack 1), BCM (Attack 2), placebo (Attack 3)
3286758|NCT00573170|Other|BTP|BCM (Attack 1), TREXIMET® (Attack 2), placebo (Attack 3)
3286759|NCT00573170|Other|BPT|BCM (Attack 1), placebo (Attack 2), TREXIMET® (Attack 3)
3286760|NCT00573170|Other|PTB|placebo (Attack 1), TREXIMET® (Attack 2), BCM (Attack 3)
3286761|NCT00573170|Other|PBT|placebo (Attack 1), BCM (Attack 2), TREXIMET® (Attack 3)
3286762|NCT00573157|Experimental|Atacicept Plus Mycophenolate mofetil Plus Corticosteroids|
3286763|NCT00573157|Placebo Comparator|Placebo Plus Mycophenolate mofetil Plus Corticosteroids|
3286764|NCT00573144|Placebo Comparator|Placebo|Infusion of 72 hours of saline solution (packaged to match active comparator).
3286765|NCT00573144|Active Comparator|Nesiritide|Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
3286766|NCT00573131|Experimental|Group 1|OncoGel, radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.
3286767|NCT00573131|Active Comparator|Group 2|Radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.
3286768|NCT00573118||1|The study group included 49 patients with a previous history of one or more of the following pregnancy complications: preeclampsia (n = 17), severe IUGR (n = 13), IUFD (n = 14) or placental abruption (n = 5).
3286769|NCT00573118||2|The control group included 49 healthy women who delivered during the study period, who did not smoke during pregnancy and in whom pregnancy and delivery were uneventful
3286770|NCT00573105|Experimental|1|Laparoscopic Ventral hernia repair by heavy weight mesh
3286771|NCT00573105|Experimental|2|Laparoscopic Ventral hernia repair by lighter weight mesh
3286772|NCT00573092||1|Data and specimens from three large population-based studies of heart attack, sudden death, and stroke in people treated for high blood pressure with one of the four major classes of high blood pressure drugs
3286773|NCT00573079||Observation|Premature infants in the NICU; 500-1500g birthweight, >=25 weeks gestation
3286774|NCT00573066|Experimental|Dosing level|A predetermined dose of Dexmedetomidine
3286775|NCT00573053|Active Comparator|High|Arterial oxygen saturations in the range of 91-95%
3286776|NCT00573053|Experimental|Low|Arterial oxygen saturations in the range of 85-89%
3286777|NCT00573040||1|"Inclusion criteria~Histological or cytological proven NSCLC~UICC stage I-III~Performance status 0-2~FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)~Stage IV~Performance status 3 or more~FeV 1 or DLCO < 30% of the age-predicted value"
3286778|NCT00573027|Other|Single Arm|"fill out baseline demographic and health/medical history questionnaires, CV risk factors, reasons of diagnosis of ischemia, information of coronary artery, and medication use~undergo clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory (Appendix);~undergo noninvasive Peripheral Artery Tonometry (PAT) testing (Appendix);~undergo clinically indicated Cardiac Magnetic Resonance (CMR) imaging (Appendix) to detect subendocardial ischemia (if indicated and referred by the treating physician). The three tests (heart catheterization with adenosine coronary flow reserve testing, acetylcholine provocative vasomotor testing during heart catheterization, cardiac MRI) are performed for standard care.~have blood and urine testing.~fill out health questionnaires~be followed prospectively 6-week, 6-month, and annually for clinical status"
3286779|NCT00573014||OBTP|Obtunded blunt trauma patients with normal CT C-spine
3286780|NCT00573001|Experimental|1|
3286781|NCT00573001|Experimental|2|
3286782|NCT00573001|Experimental|3|
3286783|NCT00573001|Active Comparator|4|
3286784|NCT00572975|Experimental|1|
3286785|NCT00572962|Experimental|1|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
3286786|NCT00572949||1|Patients with chest pain syndrome
3286787|NCT00572936|Other|Latanoprost/Dorzolamide/Timolol|The participants received latanoprost at night and vehicle in the morning for two weeks, then 6 week washout, then Dorzolamide BID for two weeks, then 6 week washout, then Timolol BID for two weeks. The order in which the participants received the three different drugs was random.
3286788|NCT00572923||1|"Inclusion criteria~Histological or cytological proven SCLC~UICC stage I-III, limited disease~Performance status 0-2~FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~Not SCLC or mixed SCLC and other histologies (e.g. non-small cell carcinoma)~stage IV~performance status 3 or more~FeV 1 or DLCO< 30% of the age-predicted value"
3286789|NCT00572910|Experimental|V710 - Group 1|V710 (60 mcg without MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
3286790|NCT00572910|Experimental|V710 - Group 2|V710 (60 mcg without MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
3286791|NCT00572910|Experimental|V710 - Group 3|V710 (60 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
3286792|NCT00572910|Experimental|V710 - Group 4|V710 (60 mcg with MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
3286793|NCT00572910|Experimental|V710 - Group 5|V710 (90 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
3286794|NCT00572910|Placebo Comparator|Group 6|Placebo on Day 1, 28 and 180.
3286795|NCT00572897|Experimental|Fludarabine, Melphalan +/- ATG|Fludarabine, Melphalan +/- ATG
3286796|NCT00572871||Exercise after fasting|Will complete 2 resistance exercise sessions and 2 plyometric exercise sessions after a 10-hour fast
3286797|NCT00572871||No exercise|Will complete a ten-hour fast but do no exercise
3286798|NCT00572871||Exercise after snack|Will complete 2 resistance exercise sessions and 2 plyometric exercise sessions 2 hours following a 500 calorie nutritional supplement
3286799|NCT00572858||Premenopausal women|Female patients who have undergone coronary angiography and are under the age of 55
3286800|NCT00572845|Experimental|1|Weaning of Spasticity Medication over a three day period while measuring Modified Ashworth Scale and Penn Spasm Frequency Score. Then titration of medication back to previous dose over a three day period.
3286801|NCT00572832|Active Comparator|6 mon. 3rd dose of quadrivalent human papillomavirus vaccine|Receipt of three doses of quadrivalent human papillomavirus vaccine according to the regular schedule of 0,2, and 6 months.
3286802|NCT00572832|Active Comparator|12 mon. 3rd dose of quadrivalent human papillomavirus vaccine|Receipt of three doses of quadrivalent human papillomavirus vaccine on a delayed schedule of 0,2, and 12 months.
3286803|NCT00572819|Active Comparator|Misoprostol|
3286804|NCT00572819|Placebo Comparator|Placebo|
3286805|NCT00572780||CTE with CD|Crohn's disease patients who underwent a CT enteroclysis as part of their clinical evaluation for symptomatic Crohn's disease.
3286806|NCT00572767|Experimental|1|
3286807|NCT00572767|Placebo Comparator|2|
3286808|NCT00572741|Experimental|1|Nutritional supplementation
3286809|NCT00572741|Placebo Comparator|2|Placebo
3286810|NCT00572728|Experimental|Diagnostic (18F-FLT)|Patients undergo 18F-FLT PET /CT at baseline (prior to chemotherapy, FLT-1), early therapy (5-10 days after the initiation of the first course of chemotherapy, FLT-2), and post therapy (within 3 weeks prior to surgery, FLT-3). Patients undergo standard surgical resection of residual tumor following completion of neoadjuvant chemotherapy.
3286811|NCT00572715||Observation|"Inclusion criteria - Families of infants (birthweight >1500g) be asked to participate in the study.~Exclusion criteria - Infants with prenatal renal ultrasound diagnosis of severe hydronephrosis or other known renal abnormalities will be excluded"
3286812|NCT00572702|Active Comparator|A|Patients with 3 compartment pelvic organ prolapse after hysterectomy, treated with Amreich-Richter procedure; it will be set randomly
3286813|NCT00572702|Active Comparator|B|Patients with 3 compartment pelvic organ prolapse after hysterectomy, treated with total Prolift procedure; it will be set randomly
3286814|NCT00572689|Experimental|A|Subject receives injection of 10 micrograms of Exenatide sub-cutaneously the given mixed meal test and blood samples will be drawn for laboratory testing.
3286815|NCT00572689|No Intervention|B|Patients given mixed meal test and blood samples drawn for laboratory testing
3286816|NCT00572650|Active Comparator|1|
3286817|NCT00572624|Experimental|Diet|Participants who received counseling and instruction about weight loss through diet and exercise
3286818|NCT00572624|Experimental|Gastric bypass surgery|Participants who received gastric bypass surgery
3286819|NCT00572611|Experimental|I|Single oral dose of 20 mg [14C]-bilastine
3286820|NCT00572585|Experimental|AEB071|
3286821|NCT00572585|Placebo Comparator|Placebo|
3286822|NCT00572572|Experimental|Arm A: Aprepitant, Then Placebo|Participants first received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 1, then received matched placebo PO daily on days 3 through 7 during study cycle 2
3286823|NCT00572572|Experimental|Arm B: Placebo, Then Aprepitant|Participants first received matched placebo PO daily on days 3 through 7 during study cycle 1, then received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 2
3286824|NCT00572559|Experimental|1|
3286825|NCT00572559|Experimental|2|
3286826|NCT00572533|Active Comparator|Control|ESA Dose Adjustment per standard Anemia Management Protocol
3286827|NCT00572533|Experimental|Treatment|"ESA Dose Adjustment per Smart Anemia Manager Algorithm"
3286828|NCT00572520|Active Comparator|1|Evidence-based behavioral weight loss treatment with health education counseling
3286829|NCT00572520|Experimental|2|Evidence-based behavioral weight loss treatment with brief behavior therapy for depression
3286830|NCT00572507|Experimental|MonoMax|MonoMax is used for abdominal wall closure
3286831|NCT00572494|Experimental|1|Stenting with AMS
3286832|NCT00572494|Active Comparator|2|PTA alone
3286833|NCT00572481|Other|Sentinel Lymph Node Biopsy Only|Axillary Reverse Mapping
3286834|NCT00572481|Other|Full Axillary Lymph Node Dissection|Axillary Reverse Mapping
3286835|NCT00572468|Active Comparator|Simvastatin|Twenty-two men will be on the Statin arm and take 40 mg of simvastatin.
3286836|NCT00572468|Placebo Comparator|Placebo|Twenty-two men will be on the placebo arm.
3286837|NCT00572455|Experimental|Stage 1: PF-04217329 - Lowest Dose|
3286838|NCT00572455|Experimental|Stage 1: PF-04217329 - Low Dose|
3286839|NCT00572455|Experimental|Stage 1: PF-04217329 - Middle Dose|
3286840|NCT00572455|Experimental|Stage 1: PF-04217329 - High Middle Dose|
3286841|NCT00572455|Experimental|Stage 1: PF-04217329 - High Dose|
3286842|NCT00572455|Experimental|Stage 1: PF-02417329 - Highest Dose|
3286843|NCT00572455|Experimental|Stage 1: PF-04217329 - Vehicle|
3286844|NCT00572455|Experimental|Stage 2: PF-04217329 - Low Dose + Latanoprost Vehicle|
3286845|NCT00572455|Experimental|Stage 2: PF-04217329 - Middle Dose + Latanoprost Vehicle|
3286846|NCT00572455|Experimental|Stage 2: PF-04217329 - High Dose + Latanoprost Vehicle|
3286847|NCT00572455|Experimental|Stage 2: PF-04217329 - Low Dose + Latanoprost 0.005%|
3286848|NCT00572455|Experimental|Stage 2: PF-04217329 - Middle Dose + Latanoprost 0.005%|
3286849|NCT00572455|Experimental|Stage 2: PF-04217329 - High Dose + Latanoprost 0.005%|
3286850|NCT00572455|Experimental|Stage 2: PF-04217329 - Vehicle + Latanoprost 0.005%|
3286851|NCT00572442||1|"Subjects without any cardiovascular risk factors:~Age ≥ 45 in men; Age ≥ 55 in women.~Hypertension: BP > 140/90 mmHg or on BP meds.~Diabetes Mellitus: Known fasting blood sugar >126 mg/dl or on DM meds.~Dyslipidemia: On lipid lowering medication or LDL ≥ 160 mg/dl in absence of other risk factors; ≥ 130 mg/dl if other non-diabetic risk factors; ≥ 100 mg/dl if diabetic. Known HDL < 40 mg/dl.~Cigarette smoking (past or present).~Family history of premature CAD in first degree relatives: Age < 55 in men; Age < 65 in women."
3286852|NCT00572442||2|Subjects with 1 cardiovascular risk factor (listed above)
3286853|NCT00572442||3|Subjects with 2 cardiovascular risk factors (listed above)
3286854|NCT00572442||4|Subjects with more than 2 cardiovascular risk factors (listed above)
3286855|NCT00572429|Placebo Comparator|A|
3286856|NCT00572416|Experimental|1|Four component behavioral sleep intervention comprised of activity-rest, sleep-wake, phychological distress and symptom management. Four components of the Individual Sleep Promotion Plan are: stimulus control, sleep restruction, relaxation, and sleep hygiene.
3286857|NCT00572416|Placebo Comparator|2|Equal time and attention, information about healthy eating and general conversation
3286858|NCT00572390|Placebo Comparator|1|No oestrogen treatment
3286859|NCT00572390|Experimental|2|Oestrogen treatment
3286860|NCT00572377|Active Comparator|FemLife Gel|
3286861|NCT00572377|Placebo Comparator|Placebo|
3286862|NCT00572351|Active Comparator|Red Wine|
3286863|NCT00572351|Active Comparator|White Wine|
3286864|NCT00572338||patients with myeloma/related diseases|
3286865|NCT00572325||1|"Inclusion criteria~Histological or cytological proven NSCLC~UICC stage I-III~Performance status 0-2~FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)~stage IV~performance status 3 or more~FeV 1 or DLCO< 30% of the age-predicted value"
3286866|NCT00572299||glucocorticoids|patients receiving glucocorticoid treatment
3286867|NCT00572299||glucocorticoids and bisphosphonates|patients receiving both glucocorticoids and bisphosphonates
3286868|NCT00572286||1|heart transplant patient ( pre or post)
3286869|NCT00572260|Experimental|A|Daptomycin as a single preoperative dose within 30 minutes prior to surgery Dosage: if creatinine clearance ≥ 30 ml/min: 6 mg/kg IV
3286870|NCT00572247|Experimental|1|Behavioral
3286871|NCT00572247|No Intervention|2|
3286872|NCT00572234|Experimental|1|receiving bupropion SR
3286873|NCT00572234|No Intervention|2|
3286874|NCT00572221|Other|CQI Program Only|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. (The SAVE+ intervention, the CQI system with facility responsible for identifying or designing care protocols for the identified problem condition.)
3286875|NCT00572221|Other|CQI Program and Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions. (The SAVE+ intervention, a CQI system plus best-practice protocols designed by study team to address identified problem condition.)
3286876|NCT00572208|Active Comparator|1|Gabapentin group
3286877|NCT00572208|No Intervention|2|placebo
3286926|NCT00571766|Experimental|1|Oral L-Arginine 2 g twice a day for 14 weeks
3286878|NCT00572195|Experimental|Evaluation Group (stimulation ON)|Group of subjects that have an RNS® System implanted, completed the RNS® System Pivotal or Feasibility study, and elected to continue to receive RNS® System responsive stimulation for the long term.
3286879|NCT00572169|Experimental|VDTPACE|Velcade, Dexamethasone, Thalidomide, Cisplatinin, Adriamycin, Cyclophosphamide and Etoposide
3286880|NCT00572156|Active Comparator|1. rhGH Alone|
3286881|NCT00572156|Experimental|2. Combination Dose|
3286882|NCT00572156|Experimental|3. Combination Dose|
3286883|NCT00572156|Experimental|4. Combination Dose|
3286884|NCT00572143|Active Comparator|1|Postoperative follow-up of ca coli patients at the surgical outpatient dpt
3286885|NCT00572143|Active Comparator|2|Postoperative follow-up of ca coli patients by GP`s
3286886|NCT00572130|Experimental|Rexin-G Dose 1|
3286887|NCT00572130|Experimental|Rexin-G Dose 2|
3286888|NCT00572117|Placebo Comparator|Placebo (inert pill) Arm|Half the participants will receive topiramate and half will receive placebo. Neither participants nor study staff will know who is receiving which pills until the end of the study. Subjects will receive placebo pills identical to the active pills (pills that contain the study drug, topiramate) for the 12 treatment weeks of the study and will have the pills discontinued over the next four weeks of the study. All subjects will be re-evaluated at 26 and 52 weeks.
3286889|NCT00572117|Experimental|Topiramate|Half the participants will receive topiramate and half will receive placebo. Neither participants nor study staff will know who is receiving which pills until the end of the study. The pills will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
3286890|NCT00572104|Experimental|resistance exercise|12 month resistance exercise training
3286891|NCT00572104|Experimental|plyometric exercise|12 month plyometric exercise training
3286892|NCT00572091|Experimental|1|Patient is screened for study and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
3286893|NCT00572078|Experimental|Sorafenib, Bevacizumab & Paclitaxel|Paclitaxel is given as i.v infusion over 60 min on days 1, 8, 15 every 28 days. Sorafenib is given orally starting with cycle 1 day 2. Bevacizumab is given as i.v infusion on days 1 and 15 every 28 days.
3286894|NCT00572065|Experimental|All Patients|Arsenic trioxide [TrisenoxTM Injection], will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12.
3286895|NCT00572039|Experimental|PST|Problem Solving Treatment (PST)
3286896|NCT00572039|Placebo Comparator|ST|Supportive Therapy (ST)
3286897|NCT00572026|Experimental|1|Daytrana
3286898|NCT00572026|No Intervention|2|No treatment for ADHD
3286899|NCT00572013|Experimental|Arm I|
3286900|NCT00571987|Other|1|This is a non-randomized one arm study, all subjects receive treatment (radiofrequency ablation).
3286901|NCT00571974|Experimental|Phase 1 light dose escalation|"During Phase I, to determine the maximum tolerated energy density of the Pulse Dye Laser operated at 585 nm with a pulse time of 1.5 ms (PDL-585), when used in combination with 5-aminolevulinic acid (5-ALA) applied topically to the premalignant lesion.~The maximum tolerated energy density will be called the Maximum Tolerated Dose (MTD). Procedure: Fluorescence Diagnosis Imaging Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 6, 7 and 8 J/cm2."
3286902|NCT00571974|Experimental|Phase 2 - Treatment efficacy of PDT|"Procedure: Fluorescence Diagnosis Imaging~Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 8 J/cm2."
3286903|NCT00571961|Experimental|1|HIV negative subjects currently enrolled in a long-term buprenorphine maintenance therapy program for at least 3 months who have been on stable dose of buprenorphine for at least 3 weeks will be admitted to the General Clinical Research Center (GCRC) for pharmacokinetic (PK) blood draws at intervals over a 24-hour period. Subjects will then receive Kaletra and buprenorphine coadministered for 14 days. Subjects will be admitted to the GCRC for a second PK sampling day.
3286904|NCT00571948|Active Comparator|Babyfood with usual meat content and corn oil|Infants in the control group received vegetable-potato-meat-meals as part of complementary food containing common amounts of meat and corn oil marketed in Germany.
3286905|NCT00571948|Experimental|more meat and a vegetable oil rich in omega-3 fatty acids|Infants in the intervention group received vegetable-potato-meat-meals as part of complementary food containing higher amounts of meat than the control group and rapeseed oil instead of corn oil.
3286906|NCT00571922|Active Comparator|Acamprosate|
3286907|NCT00571922|Placebo Comparator|Placebo|
3286908|NCT00571909|Experimental|video thoracoscopic splanchnicectomy (VSPL)|
3286909|NCT00571896|Experimental|SennaS|This group of participants will receive SennaS to use after surgery.
3286910|NCT00571896|Placebo Comparator|Placebo|This group of participants will receive placebo pills to use after surgery.
3286911|NCT00571870|Active Comparator|A|Stimulated as conventional protocol
3286912|NCT00571870|Experimental|B|GnRH antagonist stopped one day earlier than conventional protocol
3286913|NCT00571844|Experimental|DASH diet|
3286914|NCT00571844|Experimental|DASH diet plus Weight loss|
3286915|NCT00571844|No Intervention|Usual Care|Usual Care Control Group: Patients in the Usual Care control group will be asked to maintain their usual dietary and exercise habits for 4 months until they are re-evaluated. At biweekly intervals we will ask patients to describe any spontaneous changes in their eating habits or food preferences. To ensure patient safety, BPs will also be monitored biweekly by our staff.
3286916|NCT00571831|No Intervention|letter|a blue-filtering IOL an UV-filtering IOL
3286917|NCT00571818|Active Comparator|EP|
3286918|NCT00571818|Active Comparator|HP|
3286919|NCT00571818|Active Comparator|EK|
3286920|NCT00571818|Active Comparator|HC|
3286921|NCT00571805|Active Comparator|1|Varenicline
3286922|NCT00571805|Placebo Comparator|2|placebo
3286923|NCT00571792||1|Individuals with normal lung function who do not smoke
3286924|NCT00571792||2|Individuals who smoke but who do not demonstrate symptoms of chronic obstructive pulmonary disease
3286925|NCT00571792||3|Individuals who smoke that demonstrate symptoms of COPD
3286927|NCT00571766|Placebo Comparator|2|Placebo 2 g, twice a day for 14 weeks
3286928|NCT00571753|Experimental|Test|Isoniazid dose adapted according to NAT2 status i.e. appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively
3286929|NCT00571753|Active Comparator|Control|Treatment with standard isoniazid dose (appr. 5 mg/kg b.w.)
3286930|NCT00571740|Active Comparator|Arm I (second-line therapy)|Patients receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 46 hours beginning on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
3286931|NCT00571740|Experimental|Arm II (second-line therapy)|Patients receive bevacizumab and modified FOLFOX7 as in arm I. Patients also receive cetuximab IV over 2 hours on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
3286932|NCT00571727|Experimental|mecasermin, injections BID of rhIGF-1|
3286933|NCT00571714|Active Comparator|1|Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day)in 2 divided daily doses
3286934|NCT00571714|Active Comparator|2|Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day) in 2 divided daily doses plus betaine (20gm/day) in 2 divided doses for 12 weeks followed by Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day) in 2 divided daily doses for 36 weeks
3286935|NCT00571701|Active Comparator|celecoxib first, then placebo|Patients randomized to start celecoxib 6 months after enrollment. Then cross over to placebo after 1 year. Celecoxib dosing will be given orally 400mg once a day for adults, 200 mg once a day for pediatric patients between 12-25kg, 100mg once a day for pediatric patients < 12kg
3286936|NCT00571701|Placebo Comparator|Placebo first, then celecoxib|Patients randomized to start placebo 6 months after enrollment. One placebo capsule will be taken orally once a day. Placebo will match appearance of active celecoxib capsules. Cross over to 12 months of treatment with celecoxib after 1 year.
3286937|NCT00571688|Experimental|Risperdal Consta|Risperdal Consta injection in conjunction with existing treatment
3286938|NCT00571688|Active Comparator|Treatment As Usual|Clinician and patient decide upon treatment, as in a non-research clinical setting. The only treatment exclusion is any form of risperidone.
3286939|NCT00571675|Experimental|1|AT-101, prednisone and docetaxel
3286940|NCT00571675|Placebo Comparator|2|Placebo, prednisone and docetaxel
3286941|NCT00571662|Experimental|Cohort I|Pentostatin to be administered intravenously on days - 10, -9, and -8 at a dose of 4mg/m2/day
3286942|NCT00571649|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 10 mg oral rivaroxaban tablet once daily (OD) for 35 +/- 4 days, plus subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
3286943|NCT00571649|Active Comparator|Enoxaparin|Participants received oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days, plus 40 mg subcutaneous enoxaparin solution OD for 10 +/- 4 days
3286944|NCT00571636|Active Comparator|fentanyl|Patients assigned to this arm will receive continuous infusion of fentanyl + open label boluses of Fentanyl if necessary.
3286945|NCT00571636|Placebo Comparator|placebo|Patients assigned to this arm will receive continuous infusion of placebo+ open label boluses of Fentanyl if necessary.
3286946|NCT00571623||1|All subjects act as their own contral
3286947|NCT00571610|Experimental|1|Patient is screened for study and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
3286948|NCT00571571|Experimental|TFP-A|Specific aspects of TFP-A involve the setting up of a treatment contract/collaboration between patient and therapist to deal with the likely threats both to the treatment and to the patient's well being that may occur in the course of the treatment. After the behavioral symptoms of identity pathology are contained through structure and limit setting, the psychological structure that is believed to be the core of identity pathology are analyzed. In particular, treatment would involve the family in setting up the contract parameters, provide a psychoeducational component to the family and patient, inclusion of school personnel as appropriate to reinforce contract parameters, place an emphasis on the technique of clarification to understand specific emotional states.
3286949|NCT00571571|Active Comparator|Control|The Control Group is treatment as usual in the outpatient clinic. Treatment in this arm will be carried out by therapists in the Outpatient Department. Treatment will be determined by the therapist(s) and carried out according to their particular orientation and their assessment of patient's needs. It is expected based on clinic data that the majority of patients will be seen at least one time per week.
3286950|NCT00571558|Experimental|Treatment (aminolevulinin acid and photodynamic therapy)|Patients receive aminolevulinic acid PO 3-4 hours before undergoing photodynamic therapy using pulsed dye laser on day 1.
3286951|NCT00571545|Experimental|1|Subjects recruited from the community with a history of traumatic brain injury were enrolled into a 10 week supervised exercise program and encouraged to exercise at home as well.
3286952|NCT00571545|Other|2|Controls were wait-listed for the supervised exercise program but were not treated during the 10 week wait period.
3286953|NCT00571519|Experimental|1|rivoglitazone HCl 0.5mg
3286954|NCT00571519|Experimental|2|rivoglitazone HCl 1.0 mg
3286955|NCT00571519|Experimental|3|rivolglitazone HCl 1.5 mg
3286956|NCT00571519|Placebo Comparator|4|placebo matching rivoglitazone HCl tablets
3286957|NCT00571519|Active Comparator|5|pioglitazone HCl 15 mg
3286958|NCT00571519|Active Comparator|6|pioglitazone HCl 30 mg
3286959|NCT00571519|Active Comparator|7|pioglitazone HCl 45 mg
3286960|NCT00571519|Placebo Comparator|8|matching placebo for pioglitazone
3286961|NCT00571506|Experimental|1|Rosiglitazone 4 mg by mouth daily
3286962|NCT00571506|Active Comparator|2|Pioglitazone 30 mg by mouth daily
3286963|NCT00571493|Experimental|Bortezomib Dose Escalation|"The phase I section of the study will follow a standard 3 + 3 design to determine the maximum tolerated dose (MTD) of bortezomib when added to a standard BEAM (BCNU (carmustine), etoposide, cytarabine, melphalan) conditioning regimen followed by autologous hematopoietic stem cell transplantation (ASCT).~After the MTD is defined, additional patients will enroll in Phase II to obtain preliminary estimates of survival using the Phase I regimen."
3286964|NCT00571480|Experimental|1 true acupuncture|acupuncture needles are inserted into three preselected ear acupuncture points which are thought to be specific for low back pain
3286965|NCT00571480|Sham Comparator|2|three acupuncture needles are inserted to three ear acupuncture points which are not specific for low back pain during pregnancy
3286966|NCT00571480|Other|3|standard of care
3286967|NCT00571467|Experimental|PRTX-100 (Staphylococcal protein A)|"Cohort 1: 0.075 mcg/kg~Cohort 2: 0.15 mcg/kg~Cohort 3: 0.30 mcg/kg"
3286968|NCT00571454|Experimental|1|Telephone depression care management + treatment as usual
3286969|NCT00571454|No Intervention|2|Treatment as usual
3286970|NCT00571441||Primary|All subjects are included in this group, non-randomized observational study.
3286971|NCT00571428|Experimental|15 mcg BID / 30 mcg QD|Arformoterol 15 microgram twice a day (BID) taken each morning and evening for one visit followed by Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for the next visit.
3286972|NCT00571428|Experimental|30 mcg QD / 15 mcg BID|Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for one visit followed by Arformoterol 15 microgram twice a day (BID) in the morning and evening for the next visit.
3286973|NCT00571415||cervix cancer patients|
3286974|NCT00571402|Experimental|FFT|Family-focused therapy (FFT) and pharmacotherapy for adolescents, a 21 session family psychoeducational interventio0n administered with best practice medication treatment
3286975|NCT00571402|Active Comparator|Echanced Care|Enhanced care (EC) and pharmacotherapy for adolescents
3286976|NCT00571376||1|Those exposed to health information technology or health information exchange
3286977|NCT00571376||2|Those not exposed to health information technology or health information exchange
3286978|NCT00571363|Active Comparator|standard surgery|basal cell carcinomas were excised with 4 mm margins
3286979|NCT00571363|Active Comparator|Mohs|Basal cell carcinoma were removed via Mohs Micrographic surgery
3286980|NCT00571350|Active Comparator|A|women with vaginal prolapse who underwent TVT O
3286981|NCT00571324|Experimental|Exendin-(9-39) first, the Vehicle|Exendin-(9-39) will be administered intravenously (IV) after an overnight fast. Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. The following day, after another overnight fast, normal saline (control) vehicle infusion will be administered intravenously (IV) over 6 hours. During both infusions, blood glucose levels will be measured every 20 minutes.
3286982|NCT00571324|Placebo Comparator|Vehicle first, then Exendin-(9-39)|Normal saline vehicle infusion will be administered intravenously (IV) after an overnight fast. The infusion will be given over 6 hours. The following day, after another overnight fast, Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. During both infusions, blood glucose levels will be measured every 20 minutes.
3286983|NCT00571298|Experimental|Extrapleural pneumonectomy (EPP)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
3286984|NCT00571298|Experimental|Pleurectomy/Decortication (P/DC)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
3286985|NCT00571298|Experimental|Tumor Debulking (TD)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
3286986|NCT00571285|Placebo Comparator|Placebo|Placebo capsule once a week and 600 IU vitamin D daily for 26 weeks
3286987|NCT00571285|Experimental|Vitamin D|50K IU vitamin D3 (high dose) weekly plus 600 IU Vitamin D3 capsule daily for 26 weeks
3286988|NCT00571272||1|Infants less than 6 months old with a cholestatic liver disease who were initially enrolled into the Childhood Liver Disease Research and Education Network (ChiLDREN) Prospective Biliary Atresia Epidemiology study (PROBE study; P003)
3286989|NCT00571272||2|Participants with a cholestatic liver disease who are between birth and 25 years old who were NOT initially enrolled into the Childhood Liver Disease Research and Education Network (ChiLDREN) Prospective Biliary Atresia Epidemiology study (PROBE study; P003)
3286990|NCT00571272||3|Post-liver transplant participants with a cholestatic liver disease who are between 1 day and 25 years old. Affected parents of patients enrolled in the study are eligible for enrollment if they are 25 years old or less
3286991|NCT00571272||4|A screening group of participants, birth through 25 years old, suspected of having ALGS, PFIC (or BRIC) or BAD, who do not meet complete enrollment criteria for Group 1, 2, or 3.BRIC)
3286992|NCT00571272||5|Affected siblings (without evidence of liver disease) of Alpha-1 Antitrypsin Deficiency participants who are enrolled in LOGIC.
3286993|NCT00571259|Active Comparator|1|Catheter lock with heparin 1,000 units/mL
3286994|NCT00571259|Active Comparator|2|Catheter lock with gentamicin 320 micrograms/mL in sodium citrate 4%
3286995|NCT00571233||1|Group one consists of children 1 month - 6 years old who have structurally normal hearts, no heart failure, and a patent ductus arteriosus (PDA).
3286996|NCT00571233||2|Group two consists of children 1 month - 6 years old who have single ventricle physiology. Children with and without heart failure may participate.
3286997|NCT00571220||Gastric bypass surgery|Surgical group of obese patients with type 2 diabetes undergoing gastric bypass surgery
3286998|NCT00571220||Diet induced weight loss|Diet group of obese patient with type 2 diabetes, matched with the surgical group for diabetes duration, diabetes control (HbA1C), BMI, age.
3286999|NCT00571207||I|Drivers suspected of driving under the influence of drugs
3287000|NCT00571207||II|Drivers not suspected of driving under the influence of drugs
3287001|NCT00571194|Other|peritoneal dialysis (CCPD)|PK profile of pravastatin
3287002|NCT00571181|Experimental|1|
3287003|NCT00571181|Active Comparator|2|
3287004|NCT00571168|Experimental|A|Aprepitant plus standard therapy (Kevatril + Dexamethason) on day 1-4
3287005|NCT00571168|Placebo Comparator|B|Placebo plus standard therapy (Kevatril + Dexamethason) on day 1-4
3287006|NCT00571155|Other|1|
3287007|NCT00571142|Active Comparator|1|Renal disease
3287008|NCT00571142|Active Comparator|2|Without renal disease
3287009|NCT00571129|Other|surgical|
3287010|NCT00571116|Experimental|Disulfiram and arsenic trioxide|Patients receive disulfiram PO twice daily and arsenic trioxide IV over 1-2 hours on Monday through Friday, alternating two weeks on treatment followed by two weeks off treatment. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
3287011|NCT00571103|Experimental|1 Open Label|Open Label. At visit 2, all participants were started on Acamprosate, 1,998 mg divided into 3 equal doses.
3287012|NCT00571090||Thyroid nodule|Subjects who present with thyroid nodules will be enrolled into the study. Euthyroid and hypothyroid subjects with a solitary thyroid nodule or multinodular goiter will be enrolled. For subjects with a suppressed TSH, a thyroid scan will be performed. Subjects with a hypoactive nodule in the thyroid scan and a low TSH will be enrolled.
3287013|NCT00571077||A|"This is a a single arm study evaluating the efficacy and accuracy of EIS in detecting malignant thyroid nodules.~PAtients with thyroid nodules scheduled for surgery will undergo EIS examination."
3287014|NCT00571064|Experimental|1|
3287015|NCT00571051|Experimental|1|MBSR 8 week course
3287016|NCT00571051|No Intervention|2|8 weeks of natural history
3287017|NCT00571038|Experimental|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
3287018|NCT00571038|Active Comparator|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
3287019|NCT00571025|Experimental|1|AD risk assessment based on family history and APOE genotype
3287020|NCT00571025|Active Comparator|2|AD risk assessment based on family history alone
3287021|NCT00571012||Only one group- A|Healthy young subjects aged 18-45.
3287022|NCT00570999|Experimental|Arm A|Palifermin once daily at a dose of 60 mg/kg/day for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
3287023|NCT00570999|Placebo Comparator|Arm B|Placebo at a dose of 1.2 mL (saline 0,9%) once daily for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
3287024|NCT00570986|Placebo Comparator|1|Arm #1 is used for entire study. At week 12, arm is rerandomized.
3287025|NCT00570986|Active Comparator|2|Arm #2 is used for entire study. At week 12, arm is rerandomized.
3287026|NCT00570986|Active Comparator|3|Arm #3 is not used for weeks 0-11. At week 12, arm is rerandomized.
3287027|NCT00570973|Active Comparator|1|Endoscopic Band ligation combined with medical therapy (orally, daily administered propranolol and mononitrate)
3287028|NCT00570973|Active Comparator|2|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent
3287029|NCT00570960|Experimental|1: Dextran 70|antibiotic therapy in addition to dextran 70, 1.0 g/kg on days one, two and three
3287030|NCT00570960|Active Comparator|2: Standard of Care Human Albumin|antibiotic therapy in addition to human albumin, 1.5 g/kg on day one and 1.0 g/kg on day three
3287031|NCT00570947|Active Comparator|Class|The control group will be advised to take a traditional CPR class and be offered a list of local classes.
3287032|NCT00570934|Experimental|Placebo|order of interventions placebo,calcium, cholecalciferol, calcium plus cholecalciferol
3287033|NCT00570934|Experimental|Calcium|order of treatment calcium, placebo, calcium plus cholecalciferol, cholecalciferol
3287034|NCT00570934|Experimental|Cholecalciferol|order of treatments cholecalciferol, calcium and Cholecalciferol, placebo, and calcium
3287035|NCT00570934|Experimental|Calcium and cholecalciferol|order of treatment calcium and cholecalciferol, cholecalciferol, calcium, placebo
3287036|NCT00570921|Experimental|Fulvestrant + Everolimus|"Fulvestrant + Everolimus~Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses—one on each side on day 1, then 250 mg on day 14, and then 250 mg on day 28 and every 4 weeks ± 3 days thereafter. Everolimus was administered initially at a dose of 5 mg daily in the first 5-patient cohort for the first month of treatment and then increased to 10 mg PO daily after that."
3287037|NCT00570908|Experimental|Study Group|capecitabine administered concurrently with WBRT followed by combination the combination of capecitabine with sunitinib
3287038|NCT00570895|Active Comparator|A|Subjects in Arm A will receive the juice without ascorbic acid in addition to the muffin with ferrous fumarate.
3287039|NCT00570895|Active Comparator|B|Subjects in Arm A will receive the juice with 25mg ascorbic acid in addition to the muffin with ferrous fumarate
3287040|NCT00570882|Active Comparator|Sunitinib 4/2|Sunitinib 50 mg PO 4-week on and 2-week off
3287041|NCT00570882|Experimental|Sunitinib 2/1|Sunitinib 50 mg PO 2-week on 1-week off
3287042|NCT00570869|Active Comparator|CPR Class|mothers who are currently certified in CPR (i.e., have taken the traditional CPR class, or have been recertified in CPR by classroom instruction, within the past two years).
3287043|NCT00570856|Experimental|1|Folic acid supplementation
3287044|NCT00570856|Placebo Comparator|2|
3287045|NCT00570843|Active Comparator|1.|
3287046|NCT00570843|Placebo Comparator|2.|
3287047|NCT00570830|Other|1|single armed case series in which all patients underwent the same treatment.
3287136|NCT00570245|Active Comparator|C|The donor will receive NO for 3 hours and the recipient will receive NO for up to 48 hours
3287137|NCT00570232|Other|Tarceva|All patients will be prescribed erlotinib 150mg daily
3287048|NCT00570817|Other|1|"The child will receive prehydration at the methotrexate infusions in the following order:~At the 1st methotrexate infusion the child will receive 4 hours prehydration. At the 2nd methotrexate infusion the child will receive 12 hours prehydration. At the 3rd methotrexate infusion the child will receive 4 hours prehydration. At the 4th methotrexate infusion the child will receive 12 hours prehydration. At the 5th methotrexate infusion the child will receive 4 hours prehydration. At the 6th methotrexate infusion the child will receive 12 hours prehydration. At the 7th methotrexate infusion the child will receive 4 hours prehydration. At the 8th methotrexate infusion the child will receive 12 hours prehydration."
3287049|NCT00570817|Other|2|"The child will receive prehydration at the methotrexate infusions in the following order:~At the 1st methotrexate infusion the child will receive 12 hours prehydration. At the 2nd methotrexate infusion the child will receive 4 hours prehydration. At the 3rd methotrexate infusion the child will receive 12 hours prehydration. At the 4th methotrexate infusion the child will receive 4 hours prehydration. At the 5th methotrexate infusion the child will receive 12 hours prehydration. At the 6th methotrexate infusion the child will receive 4 hours prehydration. At the 7th methotrexate infusion the child will receive 12 hours prehydration. At the 8th methotrexate infusion the child will receive 4 hours prehydration."
3287050|NCT00570804|Other|MAPS+|"MAPS+ (Motivation and Problem-Solving Plus):~Counseling using specific treatment approach that focuses on combined smoking cessation and the reduction of at-risk alcohol use."
3287051|NCT00570804|Other|MAPS|"MAPS (Motivation and Problem-Solving):~Counseling treatment approach with a focus on smoking cessation."
3287052|NCT00570791||Effect of age on intraocular pressure|Correlation between age and IOP with GAT compared to other tonometers.
3287053|NCT00570791||Effect of CCT and IOP|Correlation between CCT and IOP among all tonometers
3287054|NCT00570778|Experimental|indacaterol/glycopyrrolate 300/50 μg|One indacaterol/glycopyrrolate 300/50 μg capsule + 1 placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.
3287055|NCT00570778|Active Comparator|indacaterol 600 μg|Two indacaterol 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
3287056|NCT00570778|Active Comparator|indacaterol 300 μg|One capsule indacaterol 300 μg + one placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.
3287057|NCT00570778|Placebo Comparator|placebo|Two placebo capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
3287058|NCT00570765|Experimental|10 mg PO QD|
3287059|NCT00570765|Experimental|50 mg PO QD|
3287060|NCT00570765|Placebo Comparator|Placebo PO QD|
3287061|NCT00570752|Active Comparator|Placebo + background low to moderate dose statin|Placebo + background low to moderate dose statin Tablets, Oral, 0 mg, once daily, for 12 weeks
3287062|NCT00570752|Experimental|BMS-582949 + Background low to moderate dose statin|BMS-582949 + Background low to moderate dose statin Tablets, Oral, 100 mg, once daily for 12 weeks
3287063|NCT00570752|Active Comparator|Atorvastatin|Atorvastatin Tablets, oral, 80 mg once daily for 12 weeks
3287064|NCT00570739|Placebo Comparator|Diabetic Participants: Metformin HCl+Placebo for Colesevelam|Participants will receive either 850 mg or 1700 mg of metformin HCl, depending on tolerability + 6 placebo tablets matching colesevelam 625 mg. Study medication is to be administered once daily for 16 weeks.
3287065|NCT00570739|Experimental|Diabetic participants: Metformin HCl + Colesevelam|Participants will receive either 850 mg or 1700 mg of metformin HCl, depending on tolerability + 6 colesevelam tablets, 625 mg. Study medication is to be administered once daily for 16 weeks.
3287066|NCT00570739|Placebo Comparator|Pre-diabetic Participants: Colesevelam Placebo|Participants will receive 6 placebo tablets matching colesevelam 625 mg. Study medication is to be administered once daily for 16 weeks.
3287067|NCT00570739|Experimental|Pre-diabetes Participants: Colesevelam|Participants will receive 6 colesevelam tablets, 625 mg. Study medication is to be administered once daily for 16 weeks.
3287068|NCT00570713|Experimental|MORAb-009|MORAb-009 plus gemcitabine ('MORAb-009'): MORAb-009 was administered at 5 mg/kg on Day 1 of Weeks 1 through 7 during the first cycle and on Day 1 of Weeks 1 through 3 of subsequent cycles. Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
3287069|NCT00570713|Active Comparator|Placebo|Placebo plus gemcitabine ('Placebo') Placebo was administered on Day 1 of Weeks 1 through 7 during the first cycle and on Day 1 of Weeks 1 through 3 of subsequent cycles. Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
3287070|NCT00570700|Experimental|Dasatinib|Patients receive oral dasatinib once daily in the absence of disease progression or unacceptable toxicity.
3287071|NCT00570687|Experimental|1|Technosphere Insulin
3287072|NCT00570674|Experimental|Phase I Dose Level 1: ACE-RT|Phase I Dose Level 1 participants received Abraxane 20mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. One dose (400 mg/m2 IV) of Erbitux was given prior to start of radiation, then weekly at 250 mg/m2 IV. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
3287073|NCT00570674|Experimental|Phase I Dose Level -1: AC-RT|Phase I Dose Level -1 participants received Abraxane 20mg/m2 IV then carboplatin AUC 1.5 weekly IV during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
3287074|NCT00570674|Experimental|Phase I Dose Level 2: AC-RT|Phase I Dose Level 2 participants received Abraxane 30mg/m2 IV then carboplatin AUC 1.5 weekly IV during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
3287138|NCT00570219|Experimental|B|Gradual benzodiazepine discontinuation and valproate treatment
3287139|NCT00570219|No Intervention|A|Gradual benzodiazepine discontinuation
3287260|NCT00569140|No Intervention|1|E10030
3287075|NCT00570674|Experimental|Phase I Dose Level 3: AC-RT|Phase I Dose Level 3 participants received Abraxane 40mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
3287076|NCT00570674|Experimental|Phase I Dose Level 4: AC-RT|Phase I Dose Level 4 participants received Abraxane 50mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
3287077|NCT00570661|Experimental|ITF2357|
3287078|NCT00570648|Experimental|1|1% sodium hyaluronate (Healoon) applied at the end of surgery to the surface of the corneal transplant
3287079|NCT00570648|No Intervention|2|Nothing applied at the end of surgery
3287080|NCT00570635|Experimental|A|
3287081|NCT00570635|Experimental|B|
3287082|NCT00570622|Active Comparator|1|Patients receive 60mg of pioglitazone once a day orally for 9 days
3287083|NCT00570622|Placebo Comparator|2|Patients receive Placebo orally once a day for 9 days
3287084|NCT00570609|Experimental|CPR Anytime|Participants will be asked to complete the program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
3287085|NCT00570583||Depressed|Older individuals with major depression
3287086|NCT00570583||Non-depressed|Older individuals without psychiatric disorder
3287087|NCT00570570|Other|group 1|Muscular Strengthening for paretic knee flexor and extensor
3287088|NCT00570570|Active Comparator|group 2|conventional physiotherapy
3287089|NCT00570557|No Intervention|Group A Nurses|Participants receive neither web-based refresher courses nor periodic feedback by SLP
3287090|NCT00570557|Experimental|Group B Nurses|Participants receive web-based skill refresher courses but no periodic feedback by SLP
3287091|NCT00570544||1|patients with moderate to severe copd with varying extent of emphysema
3287092|NCT00570531|Experimental|Bevacizumab|
3287093|NCT00570518||1|randomly stopped drivers of motorised vehicles and bicycles
3287094|NCT00570518||2|drivers of motorised vehicles and bicycles injured or killed in road traffic accidents
3287095|NCT00570505|Experimental|LapBand|All subjects who receive the LAP-BAND System.
3287096|NCT00570492|Placebo Comparator|Placebo nasal spray|
3287097|NCT00570492|Experimental|Fluticasone furoate nasal spray|
3287098|NCT00570479|Active Comparator|1|50 mgs of anecortave acetate (0.5 ml of a 10% suspension)
3287099|NCT00570479|Active Comparator|2|Patients will receive 30 mgs of anecortave acetate (0.5 ml of a 6% suspension)
3287100|NCT00570479|Active Comparator|3|Patients will receive 24 mgs of anecortave acetate (0.4 ml of a 6% suspension)
3287101|NCT00570479|Active Comparator|4|Patients will receive 12 mgs of anecortave acetate (0.2 ml of a 6% suspension)
3287102|NCT00570466|Experimental|Video games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit, vegetable and water intake, physical activity and decrease TV viewing.
3287103|NCT00570466|Placebo Comparator|Web and DVD knowledge|Parallel web and DVD based knowledge games on fruit, vegetable, water, physical activity and physical inactivity.
3287104|NCT00570440|Experimental|A|
3287105|NCT00570440|Active Comparator|B|
3287106|NCT00570427|Experimental|1.|All participants
3287107|NCT00570414|Active Comparator|1|Laryngeal mask airway (LMA)
3287108|NCT00570414|Active Comparator|2|Endotracheal tube (ETT)
3287109|NCT00570401|Experimental|Dasatinib|"Beginning 1 week after completion of erlotinib hydrochloride or gefitinib therapy, patients receive oral dasatinib twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.~Response is assessed by CT scan at 4 weeks, 8 weeks, and then every 8 weeks thereafter."
3287110|NCT00570388|Active Comparator|2|Subjects in the active Prometa group will receive flumazenil, gabapentin, and hydroxyzine per the Prometa Protocol.
3287111|NCT00570388|Placebo Comparator|1|"Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine"
3287112|NCT00570375|Experimental|Single Arm|All patients will receive 150 mg of Erlotinib
3287113|NCT00570349|Experimental|Low Dose Cohort|Subjects in the low dose cohort receive 20 part per million (ppm) of nitric oxide via nasal cannula over a 44 hour period.
3287114|NCT00570349|Experimental|High-Dose Cohort|Subjects in the high dose cohort receive 40 ppm of nitric oxide via nasal cannula over a 44 hour period.
3287115|NCT00570349|Placebo Comparator|Nitrogen|100% Nitrogen (placebo) will be administer at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
3287116|NCT00570336|Experimental|2.5 milligram (mg) CTS-1027|2.5 mg CTS-1027
3287117|NCT00570336|Experimental|5 mg CTS-1027|5 mg CTS-1027
3287118|NCT00570336|Experimental|10 mg CTS-1027|10 mg CTS-1027
3287119|NCT00570336|Experimental|30 mg CTS-1027|30 mg CTS-1027
3287120|NCT00570336|Placebo Comparator|Placebo|Placebo
3287121|NCT00570323|Active Comparator|ARM A / Arimidex with Faslodex|Arimidex with Faslodex in postmenopausal women
3287122|NCT00570323|Active Comparator|ARM B Arimidex without Faslodex|Arimidex without Faslodex in postmenopausal women.
3287123|NCT00570310|Active Comparator|A|Patients in Group A will remain on pregabalin (up to 600 mg/day po) treatment for the entire double-blind period.
3287124|NCT00570310|Placebo Comparator|B|Patients in Group B will be treated with placebo.
3287125|NCT00570284|Experimental|LBH589|
3287126|NCT00570271|Experimental|1|
3287127|NCT00570271|Experimental|2|
3287128|NCT00570271|Experimental|3|
3287129|NCT00570271|Experimental|4|
3287130|NCT00570271|No Intervention|5|
3287131|NCT00570271|No Intervention|6|
3287132|NCT00570258|Placebo Comparator|2|"Fulvestrant: 250 mg IM Q 4 weeks~Placebo: 150 mg PO QD"
3287133|NCT00570258|Active Comparator|1|"Fulvestrant: 250 mg IM Q 4 weeks~Erlotinib: 150 mg PO QD"
3287134|NCT00570245|No Intervention|A|Neither donors or recipients will receive NO
3287135|NCT00570245|Active Comparator|B|Donor will not receive NO, recipient will receive up to 48 hours of NO
3287140|NCT00570206|Experimental|1|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
3287141|NCT00570206|No Intervention|2|Probation officers who are interested in Motivational Interviewing, but have not yet been trained to use it while conducting meetings with probationers.
3287142|NCT00570206|No Intervention|3|Treatment as usual. Regular probation officers conduct standard meetings with probationers.
3287143|NCT00570193|Experimental|I|Combined treatment with verteporfin (Visudyne) and ranibizumab (Lucentis)
3287144|NCT00570193|Experimental|II|Treatment with ranibizumab (Lucentis)
3287145|NCT00570180|Experimental|Single Arm|Please see intervention description for Bortezomib (Velcade)
3287146|NCT00570167|Active Comparator|2|Total cementless hip arthroplasty with metal-on-metal bearings
3287147|NCT00570167|Active Comparator|1|Hip resurfacing
3287148|NCT00570141|Active Comparator|OASIS Wound Matrix (Oasis)|This is a single arm study with only the test article Oasis used on all subjects
3287149|NCT00570128|Active Comparator|1|
3287150|NCT00570128|Placebo Comparator|2|
3287151|NCT00570115||A|The subjects for this group are matched for age, gender, body mass index. The presence of obstructive sleep apnea will divide the cohort in 02 subgroups: non-Obstructive Sleep Apnea and Obstructive Sleep Apnea
3287152|NCT00570102|Active Comparator|A highly hydrolyzed casein formula|
3287153|NCT00570102|Placebo Comparator|A conventiona cow's milk based formula|
3287154|NCT00570089|Experimental|Study Drug Ranexa, Then Placebo|"Participants first received study drug Ranexa, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.~After a washout period of 2 weeks, they then received Placebo tablet (matching Ranexa tablet)."
3287155|NCT00570089|Experimental|Placebo, Then Study Drug Ranexa(Ranolazine)|"Participants first received Placebo tablet (matching Ranexa tablet) for two weeks.~After washout period of 2 weeks, they then received Ranexa 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval."
3287156|NCT00570063|Placebo Comparator|1|PF-02545920 15 mg tablets taken twice a day by mouth for 21 days
3287157|NCT00570063|Placebo Comparator|2|Matching placebo tablets taken twice a day by mouth for 21 days
3287158|NCT00570050|Experimental|Intranasal Insulin nasal spray|
3287159|NCT00570050|Experimental|Placebo nasal spray (i.e., no active treatment)|
3287160|NCT00570037|Active Comparator|Immunization Program|Intervention Hospital - Standing postpartum vaccine orders, influenza vaccine clinic on postpartum ward for household contacts, mailed vaccine reminders
3287161|NCT00570037|No Intervention|No Immunization Program|Comparison Hospital - Receipt of vaccine through routine clinical care
3287162|NCT00570024|Active Comparator|TA|Active TA
3287163|NCT00570024|Other|AA|
3287164|NCT00570024|No Intervention|Waiting Group|
3287165|NCT00570011|Experimental|1|
3287166|NCT00570011|Experimental|2|
3287167|NCT00569985|Experimental|Treatment (autologous HCT)|CONDITIONING: Patients receive carmustine IV over 1-2 hours on days -7 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. TRANSPLANTATION: Patients undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells IV on day 0.
3287168|NCT00569972|Experimental|15 mg PD 0200390|
3287169|NCT00569972|Experimental|30 mg PD 0200390|
3287170|NCT00569972|Experimental|45 mg PD 0200390|
3287171|NCT00569972|Experimental|60 mg PD 0200390|
3287172|NCT00569972|Experimental|Placebo PD 0200390|
3287173|NCT00569959|Other|Fasting|
3287174|NCT00569959|Other|Non-fasting|
3287175|NCT00569946|Experimental|AG-013736|
3287176|NCT00569933|Other|A/B/C|Patients are randomized to voice/music/ or no CD
3287177|NCT00569920|Placebo Comparator|1|Placebo
3287178|NCT00569920|Active Comparator|2|"dexamethasone low-dose"
3287179|NCT00569920|Active Comparator|3|"Dexamethasone high-dose"
3287180|NCT00569894||2|TIV
3287181|NCT00569894||1|FluMist
3287182|NCT00569894||3|Unvaccinated
3287183|NCT00569881||1|Corneal epithelial wound healing with moxifloxacin
3287184|NCT00569881||2|Corneal epithelial wound healing with gatifloxacin
3287185|NCT00569868|Experimental|Velcade|"Treatment on this study will last 2 cycles. Each cycle consists of 3 weeks, or 21 days. After you have gone off study, you will be followed every three months for approximately 2 years.~Each cycle will consist of 3 weeks (21 days) according to the schedule below.~DRUG ROUTE DOSE DAYS Velcade IV 1.3 mg/m2 1,4,8, and 11 This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a two cycles."
3287186|NCT00569855|Experimental|1|Receive phenoxybenzamine in preparation for cardiopulmonary bypass during open-heart surgery
3287187|NCT00569842||observational|
3287188|NCT00569829|Experimental|1|Cognitive behavioral therapy
3287189|NCT00569829|No Intervention|2|Waitlist
3287190|NCT00569816|Active Comparator|Group 1|Propofol as the primary anesthetic
3287191|NCT00569816|Experimental|Group 2|Sevoflurane administered continuously after induction of anesthesia until initiation of cardiopulmonary bypass.
3287192|NCT00569816|Experimental|Group 3|Sevoflurane administered repetitive up to 1 MAC from induction of anesthesia until initiation of cardiopulmonary bypass. Wash in and wash out performed twice.
3287193|NCT00569803|Active Comparator|Belatacept 50 mg Subcutaneous Injection|Belatacept 50 mg subcutaneous (SC) injection
3287194|NCT00569803|Active Comparator|Belatacept 100 mg Subcutaneous Injection|Belatacept 100 mg SC injection
3287195|NCT00569803|Active Comparator|Belatacept 125 mg Subcutaneous Injection|Belatacept 125 mg SC injection
3287196|NCT00569803|Active Comparator|Belatacept 150 mg Subcutaneous Injections|2 SC injections of 75 mg Belatacept
3287259|NCT00569153|Experimental|Arm 4 (TAK-700 at 600 mg)|
3287197|NCT00569803|Active Comparator|Belatacept 200 mg Subcutaneous Injections|2 SC injections of 100 mg Belatacept
3287198|NCT00569803|Active Comparator|Belatacept 250 mg Subcutaneous Injections|2 SC injections of 125 mg Belatacept
3287199|NCT00569803|Active Comparator|Belatacept 125 mg Intravenous Infusion|125 mg Belatacept intravenous (IV) injection
3287200|NCT00569803|Placebo Comparator|Placebo|SC injection of placebo solution
3287201|NCT00569790|Experimental|1|S-1, Irinotecan, Bevacizumab
3287202|NCT00569777|Experimental|K-lens|etafilcon A contact lens with ketotifen.
3287203|NCT00569777|Placebo Comparator|Placebo|etafilcon A contact lens without ketotifen
3287204|NCT00569764||observational|patients with schizophrenia who want to change an antipsychotics due to metabolic side effect
3287205|NCT00569738||A|patients with neuroendocrine tumors
3287206|NCT00569699|Experimental|1|S-1, Bevacizumab
3287207|NCT00569686|Active Comparator|1|treatment with lovaza
3287208|NCT00569686|Placebo Comparator|2|
3287209|NCT00569660|Experimental|Azacitidine|75 mg/m^2 Subcutaneous Daily for 7 days every 4 weeks
3287210|NCT00569647|Experimental|v|Use of VRH headset
3287211|NCT00569647|Placebo Comparator|c|
3287212|NCT00569634|Other|1|
3287213|NCT00569621|Experimental|1|
3287214|NCT00569621|Placebo Comparator|2|
3287215|NCT00569608|Experimental|EDA|Neonates submitted to the protocol of early discharge.
3287216|NCT00569608|No Intervention|SDP|Discharge following the standard protocol of the neonatal intensive care unit.
3287217|NCT00569595|Experimental|1|Multi-Level, Patient-Directed, Lifestyle Change, Health Promotion Program
3287218|NCT00569595|Sham Comparator|2|"Patient health counseling program by lay health educators Entitled Fighting Cancer with Advice."
3287219|NCT00569582|Experimental|1|
3287220|NCT00569569|Experimental|1|Patients treated with Retaane
3287221|NCT00569556|No Intervention|Usual Care|Patients receive care through primary care provider
3287222|NCT00569556|Experimental|Case Management|Specially trained nurse case managers contact patients by telephone; monitor blood pressure, LDL, and HgbA1C;, and recommend lifestyle and medication changes as needed
3287223|NCT00569530|Active Comparator|Treatment Surfactant (Infasurf) ONY, NY|Patients receive inhaled nitric oxide and scheduled doses of Infasurf on study days 0, 3, 7, 10, and 14, if infant remains ventilated.
3287224|NCT00569530|Placebo Comparator|Sham (no treatment)|Infants receiving inhaled nitric oxide will receive Sham (no treatment) on study days 0, 3, 7, 10, and 14, if infant remains ventilated.
3287225|NCT00569517|Experimental|1|6-CBT-sessions for weight loss
3287226|NCT00569517|Experimental|2|Single educational intervention for weight
3287227|NCT00569504||A, observatoin|inpatients and outpatients in Seoul National Hospital
3287228|NCT00569478|Active Comparator|1|rehabilitation
3287229|NCT00569478|No Intervention|2|controls
3287230|NCT00569465|Placebo Comparator|A|
3287231|NCT00569465|Experimental|B|
3287232|NCT00569452|Experimental|A|
3287233|NCT00569452|Experimental|B|
3287234|NCT00569439|Experimental|D5|5% Dextrose Solution in Normal Saline
3287235|NCT00569439|Experimental|D10|
3287236|NCT00569439|Placebo Comparator|NS|
3287237|NCT00569413||1|Healthy control subjects (n=20) age 21-65 who do not suffer from a psychiatric diagnosis or neurological damage, are under age, or are pregnant women
3287238|NCT00569413||2|20 patients who suffer from sexual disorder (reduced sexual desire or sexual function) from a sexual disorder clinic, age 21-65, without any other psychiatric disorder, neurological damage, are not under age or pregnant women.
3287239|NCT00569387|Experimental|Vaccine group|
3287240|NCT00569361|Other|A|Collection of nasal epithelial cells by brushing
3287241|NCT00569335|Experimental|1|S-1, Irinotecan, Bevacizumab
3287242|NCT00569309|Experimental|Prevnar|The conjugate vaccine for Streptococcus pneumoniae will be administered during weeks 9, 17, and 25 after autologous HSCT - the study nurse will arrange for the vaccine to be administered at the specified time and the patient will be instructed to notify an investigator or study nurse of any side effects of vaccine administration. At the specified times, patients will fill out the quality-of-life assessment. All patients enrolled on this trial will have samples procured for all proposed laboratory correlative studies.
3287243|NCT00569296|Experimental|T-cells|EGFRBi-armed autologous activated T cells
3287244|NCT00569270|Active Comparator|Tiotropium 18 µg capsule, bronchodilator|tiotropium 18 µg capsule for 1 month versus placebo. To study bronchodilation and effect following metronome paced hyperventilation and induced dynamic hyperinflation of active tiotropium versus placebo
3287245|NCT00569270|Placebo Comparator|2|placebo 18ug tiotropium for 1 month
3287246|NCT00569244|Experimental|Arm 1|
3287247|NCT00569244|Active Comparator|Arm 2|
3287248|NCT00569231|Experimental|Candida Antigen|
3287249|NCT00569192|Experimental|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
3287250|NCT00569192|Placebo Comparator|Placebo|Placebo delivered by nebulization twice daily for 12 weeks
3287251|NCT00569192|Experimental|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
3287252|NCT00569179|Experimental|Alloreactive NK cell infusion|Escalating doses of alloreactive NK cells.
3287253|NCT00569166|Active Comparator|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
3287254|NCT00569166|Active Comparator|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
3287255|NCT00569166|Placebo Comparator|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
3287256|NCT00569153|Experimental|Arm 1 (TAK-700)|
3287257|NCT00569153|Experimental|Arm 2 (TAK-700 at 400 mg & 5 mg prednisone)|
3287258|NCT00569153|Experimental|Arm 3 (TAK-700 at 600 mg & 5 mg prednisone)|
3287261|NCT00569127|Experimental|Arm I (octreotide acetate and bevacizumab)|Patients receive depot octreotide acetate IM and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3287262|NCT00569127|Experimental|Arm II (octreotide acetate and recombinant interferon alfa-2b)|Patients receive octreotide acetate IM as in arm I on day 1 and recombinant interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3287263|NCT00569114|Other|1|
3287264|NCT00569101|Experimental|single|single arm study (tacrolimus trial group)
3287265|NCT00569088|Experimental|B|A combined treatment would be used in the arm.That means Chinese herb formula would be used with the current Modern Medicine therapy for stroke in this arm.
3287266|NCT00569088|Active Comparator|A|just the current Modern Medicine therapy for stroke would be available in the arm.
3287267|NCT00569075||High Risk|High risk disease prone population
3287268|NCT00569075||Low Risk|Low risk disease population
3287269|NCT00569062|Experimental|Arm 1|GW856553X 7.5mg BID for 6 weeks
3287270|NCT00569062|Placebo Comparator|Placebo|Placebo to match, BID, 6 weeks
3287271|NCT00569036|Experimental|BMS-754807|Single arm, multiple-ascending dose escalation study
3287272|NCT00569023|Experimental|A,1,I|
3287273|NCT00569010|Experimental|Low-Dose Ara-C + AZA-Level 0|"Group 1 = Low-Dose Ara-C + Azacitidine-Level 0~Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days Azacitidine (AZA): 37.5 mg/m^2 intravenous (IV) Over 20-30 minutes Daily for 7 Days"
3287274|NCT00569010|Experimental|Low-Dose Ara-C + AZA-Level 1|"Group 2 = Low-Dose Ara-C + Azacitidine-Level 1~Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days AZA: Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days"
3287275|NCT00569010|Experimental|High-Dose Ara-C + AZA-Level 0|Group 3 = High-Dose Ara-C + Azacitidine-Level 0 High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age<65years) or 3 days (age>=65years) AZA: 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days
3287276|NCT00569010|Experimental|High-Dose Ara-C + AZA-Level 1|"Group 4 = High-Dose Ara-C + Azacitidine-Level 1~High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age<65years) or 3 days (age>=65 years) AZA:Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days"
3287277|NCT00568997||1|Single-group Open Label Registry of patients exposed to Elidel/Pimecrolimus
3287278|NCT00568971|Experimental|weekly chemo|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
3287279|NCT00568958|Experimental|Naltrexone|Active naltrexone (25 mg daily +25 targeted)+ BASICS counseling
3287280|NCT00568958|Placebo Comparator|Placebo Naltrexone|Placebo Naltrexone (targeted + daily) + BASICS Counseling
3287281|NCT00568945|Experimental|Arm 1|
3287282|NCT00568893|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
3287283|NCT00568854|Active Comparator|Participants with diabetes|Persons with diagnosis of diabetes. Received biological intervention: BCG
3287284|NCT00568854|Active Comparator|Participants without diabetes|Persons with no diagnosis of diabetes and negative diabetes screening labs. Received biological intervention: BCG.
3287285|NCT00568841|Experimental|1|
3287286|NCT00568815|Experimental|Chemo|
3287287|NCT00568789|Experimental|Ramelteon 8 mg, zolpidem 10 mg and placebo|
3287288|NCT00568776|Placebo Comparator|1|
3287289|NCT00568776|Active Comparator|2|
3287290|NCT00568776|Active Comparator|3|
3287291|NCT00568776|Active Comparator|4|
3287292|NCT00568750|Experimental|Dasatinib|
3287293|NCT00568737|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
3287294|NCT00568737|Placebo Comparator|2|0.9% sodium chloride
3287295|NCT00568724||1|Children referred to surgical treatment of congenital hydronephrosis
3287296|NCT00568724||2|15 age- and sex-matched controls
3287297|NCT00568724||Children with healthy pelvic tissue|Children referred to nephrectomy due to nephrotic syndrome
3287298|NCT00568724||Adults with healthy pelvic tissue|Adults referred to nephrectomy due to another cause than hydronephrosis
3287299|NCT00568711|Active Comparator|1|a 5-day course of daily 200-mg doses of doxycycline
3287300|NCT00568711|Active Comparator|2|a 5-day course of daily 600-mg doses of rifampin
3287301|NCT00568685|Active Comparator|Atomoxetine 0.2 milligram per kilogram per day (mg/kg/day)|
3287302|NCT00568685|Active Comparator|Atomoxetine 0.5 mg/kg/day|
3287303|NCT00568685|Active Comparator|Atomoxetine 1.2 mg/kg/day|
3287304|NCT00568672|Active Comparator|1|Olanzapine 5 mg / day
3287305|NCT00568672|Placebo Comparator|2|Placebo
3287306|NCT00568659|Experimental|1|
3287307|NCT00568646|Experimental|1|
3287308|NCT00568633|Experimental|Hematopoietic Cell Transplantation|
3287309|NCT00568620|Experimental|1: Nasogastric feeding tube|
3287310|NCT00568620|Experimental|2: Placement of nasojejunal feeding tube|
3287311|NCT00568607|Experimental|IFO, VP-16, DDP, DXM|
3287312|NCT00568594|Experimental|1|
3287313|NCT00568594|Placebo Comparator|2|
3287314|NCT00568568|Experimental|Growth hormone|
3287315|NCT00568555|Experimental|Low Dose Naltrexone first|LDN first, then placebo.
3287316|NCT00568555|Placebo Comparator|Placebo - sugar pill first|Placebo first, then LDN.
3287317|NCT00568542|Active Comparator|1|35 I.E. erythropoetin beta given by subcutaneous injection once per week for 6 months. The drug is self-administered.
3287318|NCT00568542|Placebo Comparator|2|Placebo to erythropoetin beta.
3287319|NCT00568529|Experimental|Combine Chemotherapy|XELOX(Xeloda and oxaliplatin combination)
3287320|NCT00568516|Experimental|1.Low dose group|
3287321|NCT00568516|Experimental|2.High dose group|
3287322|NCT00568503|Active Comparator|1|QAX028 high dose
3287323|NCT00568503|Placebo Comparator|2|Placebo
3287324|NCT00568503|Active Comparator|3|Tiotropium bromide
3287325|NCT00568503|Active Comparator|4|QAX028 medium dose
3287326|NCT00568503|Active Comparator|5|QAX028 low dose
3287327|NCT00568477|Experimental|Arm 1|Treatment with rituximab
3287328|NCT00568477|No Intervention|Arm 2|Treatment without rituximab
3287329|NCT00568464|Experimental|A|
3287330|NCT00568451|Experimental|PC (previously treated)|Previously chemotherapy treated cohorts: Paclitaxel and Carboplatin (PC)
3287331|NCT00568451|Experimental|PC (chemo naive)|Chemotherapy-naive cohorts: Paclitaxel and Carboplatin (PC)
3287332|NCT00568451|Experimental|TMZ (previously treated)|Previously chemotherapy treated cohorts: Temozolomide (TMZ)
3287333|NCT00568451|Experimental|TMZ (chemo naive)|Chemotherapy-naive cohorts: Temozolomide (TMZ)
3287334|NCT00568412|Active Comparator|1|Zarzenda applied topically twice daily for three weeks
3287335|NCT00568412|Active Comparator|2|Elidel 1% cream, applied topically twice daily for three weeks
3287336|NCT00568399|Experimental|Active Treatment|This is the only arm and involves active treatment with sodium thiosulfate in those subjects with high coronary artery calcium scores.
3287337|NCT00568386|Experimental|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop in each eye one time
3287338|NCT00568386|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each one time
3287339|NCT00568373|Experimental|Treatement|All subjects that meet the requirement for gastric stimulator placement
3287340|NCT00568347||long acting bronchodilator|salmeterol 50mcg bid by DPI, no fluticasone in patients with COPD/emphysema to evaluate effect on bronchodilation and exhaled nitric oxide
3287341|NCT00568347||bronchodilator/ inhaled corticosteroid|fluticasone 250mcg/salmeterol 50 mcg bid X 3momths to evaluate effect on lung function and exhaled nitric oxide
3287342|NCT00568347||C|Fluticasone 100mcg/salmeterol 50mcg
3287343|NCT00568334|Experimental|VARILRIX HSA-FREE GROUP|Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine produced without human serum albumin (HSA-Free), administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).
3287344|NCT00568334|Experimental|VARILRIX GROUP|Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine, administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).
3287345|NCT00568321|Experimental|1|
3287346|NCT00568321|Active Comparator|2|
3287347|NCT00568321|Placebo Comparator|3|
3287348|NCT00568308|Placebo Comparator|1|
3287349|NCT00568308|Experimental|2|
3287350|NCT00568295|Experimental|Acetaminophen|Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP
3287351|NCT00568295|Active Comparator|Refecoxib 12.5 mg|Rofecoxib: Capsules 12.5 mg, oral, C-904-1A
3287352|NCT00568295|Active Comparator|Rofecoxib 12.5 x 2|Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A
3287353|NCT00568269|Active Comparator|Lichtenstein|
3287354|NCT00568269|Experimental|TEP|
3287355|NCT00568256|Experimental|Experimental|Mind/Body Course
3287356|NCT00568256|Other|Other|Mind/Body Course
3287357|NCT00568230|Experimental|1|Patient is screened for study, and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
3287358|NCT00568217|Active Comparator|1 drug|diclofenac 15 mg/kg suppository once
3287359|NCT00568217|Placebo Comparator|2 drug|Placebo suppository once
3287360|NCT00568217|Active Comparator|3 drug|acetaminophen mixture 15 mg/kg up to four times a day
3287361|NCT00568217|Active Comparator|4 drug|ibuprofen mixture 10 mg/kg up to four times a day
3287362|NCT00568217|Placebo Comparator|5 drug|oral placebo mixture up to four times a day
3287363|NCT00568204|Experimental|1|Mexyn-A
3287364|NCT00568191||1|retinal thickness program Stratus OCT software 4.0
3287365|NCT00568191||2|retinal cube 200x200 program of Cirrus OCT
3287366|NCT00568178|Experimental|Losartan Double-Blind Base Study (12-weeks)|"Normotensive participants received losartan.~Hypertensive participants received either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo)."
3287367|NCT00568178|Active Comparator|Amlodipine Double-Blind Base Study (12-weeks)|Hypertensive participants were randomized to receive either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo) for 12 weeks.
3287368|NCT00568178|Experimental|Losartan Open-Label Extension Phase (Month 36)|Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
3287369|NCT00568178|Active Comparator|Enalapril Open-Label Extension Phase (Month 36)|Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
3287370|NCT00568165|Experimental|1|Mobile Team
3287371|NCT00568165|Active Comparator|2|Standard care
3287372|NCT00568152|Experimental|Low PA apple puree|230grams of low PA apple puree (Golden Delicious) consumed daily for 14 days.
3287373|NCT00568152|Experimental|High PA apple puree|High PA apple puree (Mitchalin) 230grams consumed daily for 14 days
3287374|NCT00568152|Placebo Comparator|Aspirin|75mg dispersable aspirin taken daily for 14 days
3287375|NCT00568139||Mitotane|Patients with adrenocortical carcinoma treated with mitotane
3287376|NCT00568139||Control|Patients with adrenocortical carcinoma not treated with mitotane
3287377|NCT00568126|Experimental|1. Maca Root|Subjects in this arm will be given 3g/day of maca root
3287378|NCT00568126|Placebo Comparator|2. Control|Subjects in this arm will receive placebo.
3287379|NCT00568113|Experimental|NAC group|NAC given plus 17Oh progesterone caproate
3287380|NCT00568113|Active Comparator|Progesterone group|17 OH progesterone caproate
3287381|NCT00568100|Experimental|1|COPD patients
3287382|NCT00568087|Active Comparator|N-acetylcysteine|Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
3287621|NCT00566267|Experimental|2|Low carb diet plus simvastatin 20 mg/ezetimibe 10 mg
3287383|NCT00568087|Placebo Comparator|Placebo|Patients will take oral placebo (identical matching placebo) during the study period.
3287384|NCT00568061|Active Comparator|NO|
3287385|NCT00568048|Experimental|Combination Therapy Temozolomide & Bevacizumab|"Combination therapy~Temozolomide 150 mg/m2 p.o., days 1-7, repeated every 14 days~Bevacizumab 10 mg/kg i.v., day 1, repeated every 14 days"
3287386|NCT00568035|Active Comparator|QR-333|
3287387|NCT00568035|Placebo Comparator|Placebo|
3287388|NCT00568022|Experimental|Ixabepilone + Capecitabine|
3287389|NCT00567996|Experimental|Indacaterol 150 μg|"Indacaterol 150 μg once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3287390|NCT00567996|Placebo Comparator|Placebo|"Placebo to Indacaterol once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3287391|NCT00567996|Active Comparator|Salmeterol 50 μg|"Salmeterol 50 μg twice daily delivered via a proprietary dry powder inhaler in the morning and in the evening. Placebo to Indacaterol daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI).~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3287392|NCT00567983|Active Comparator|1.|
3287393|NCT00567983|Placebo Comparator|2.|
3287394|NCT00567957|Placebo Comparator|C|Saline starting before induction till entry to abdominal cavity
3287395|NCT00567957|Active Comparator|R|Remifentanil starting before induction till entry to abdominal cavity
3287396|NCT00567931|Experimental|Treatment (Immunomodulating therapy)|Patients receive oral 1-methyl-d-tryptophan (1-MT) once or twice daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3287397|NCT00567918|Experimental|1|FK506 ophthalmic suspension
3287398|NCT00567905|Experimental|A|Green tea extract
3287399|NCT00567905|Placebo Comparator|B|
3287400|NCT00567892|Experimental|1. rTMS|"Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
3287401|NCT00567892|Sham Comparator|2. Sham rTMS|Sham rTMS appears identical to and mimics sounds and sensations of active magnet.
3287402|NCT00567879|Experimental|Panobinostat with trastuzumab|Panobinostat intravenously (i.v.) or orally was given in combination with trastuzumab.
3287403|NCT00567866|Experimental|1|placebo -50 mg quetiapine- 100 mg quetiapine
3287404|NCT00567866|Experimental|2|50 mg quetiapine -100 mg quetiapine- placebo
3287405|NCT00567866|Experimental|3|50 mg quetiapine -placebo- 100 mg quetiapine
3287406|NCT00567853|Other|MEMO 3D ring|All patients in the study will be implanted with the MEMO 3D ring
3287407|NCT00567840|Experimental|1|PA-824 200 mg/qd
3287408|NCT00567840|Experimental|2|PA-824 600 mg/qd
3287409|NCT00567840|Experimental|3|PA-824 1000 mg/qd
3287410|NCT00567840|Experimental|4|PA-824 1200 mg/qd
3287411|NCT00567840|Active Comparator|5|Rifafour e-275 mg
3287412|NCT00567814|Active Comparator|1|Lower dose combination of metyrapone with oxazepam
3287413|NCT00567814|Active Comparator|2|Higher dose combination of metyrapone with oxazepam
3287414|NCT00567814|Placebo Comparator|3|
3287415|NCT00567801|Active Comparator|1|conventional embolectomy/thrombectomy
3287416|NCT00567801|Experimental|2|embolectomy/thrombectomy with controlled reperfusion
3287417|NCT00567788|Active Comparator|1|Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
3287418|NCT00567788|Active Comparator|2|Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
3287419|NCT00567762|Experimental|1|FK506 ophthalmic suspension
3287420|NCT00567762|Placebo Comparator|2|Base of eye drops
3287421|NCT00567749||A, Observational|
3287422|NCT00567736|Active Comparator|1|Disci/Rhus toxicodendron comp.®
3287423|NCT00567736|Placebo Comparator|2|placebo solution
3287424|NCT00567736|No Intervention|3|waiting list group
3287425|NCT00567723||1|Test group: Patients who have received a minimum of 12 consecutive weeks of treatment with Fosrenol
3287426|NCT00567723||2|Historical control group: Patients with no lanthanum exposure
3287427|NCT00567723||3|Concomitant therapy group: Patients being treated for hyperphosphatemia with any marketed product
3287428|NCT00567710|Experimental|I|BL - 1020 lowdose
3287429|NCT00567710|Experimental|II|BL 1020 high dose
3287430|NCT00567710|Placebo Comparator|III|
3287431|NCT00567710|Active Comparator|IV|Risperidone
3287432|NCT00567697|Active Comparator|A|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection
3287433|NCT00567697|Sham Comparator|B|
3287434|NCT00567684|Experimental|CTU + IVU|CTU = Computed Tomography Urography + IVU = Intravenous Urography
3287435|NCT00567671|Experimental|Treatment|Corneal collagen cross-linking
3287436|NCT00567671|Sham Comparator|Control|Sham Treatment
3287437|NCT00567658|Placebo Comparator|A 1|Arm I: placebo group receives BID placebo
3287438|NCT00567658|Experimental|A2|subjects receive active drug, esomeprazole 40 mg BID
3287439|NCT00567606|Experimental|1|Subjects in the G1 group receive 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week and strength/weight training exercises for upper and lower extremities and the spine.
3287440|NCT00567606|Experimental|2|Subjects in the G2 group receive the calcium, vitamin D, and risedronate, but do not participate in strength/weight training exercises.
3287441|NCT00567593|Other|Rosiglitazone|Rosiglitazone; 8mg tablet once a day for 14 days
3287442|NCT00567580|Active Comparator|Arm I|(Prostate bed radiotherapy [PBRT] alone): Patients undergo PBRT once daily, 5 days a week, Monday through Friday, for approximately 7-8 weeks (36 to 39 fractions).
3287443|NCT00567580|Experimental|Arm II|(PBRT and short-term androgen deprivation [STAD]): Beginning 2 months before the start of PBRT, patients undergo STAD, using a combination of antiandrogen (AA) and LHRH agonist therapy, for a total of 4-6 months. Patients receive AA therapy comprising either oral flutamide 3 times daily or oral bicalutamide once daily for at least 4 months. Patients receive LHRH agonist injection beginning concurrently with or 2 weeks after the start of AA therapy. LHRH agonist injection consists of analogs approved by the FDA (or by Health Canada for Canadian institutions) (e.g., leuprolide, goserelin, buserelin, or triptorelin) and may be given in any possible combination (may be given as a single 4-month injection and one to two 1-month injection[s], two 3-month injections, or a 6-month injection), such that the total LHRH agonist treatment time is 4-6 months. Approximately 2 months after beginning of STAD, patients undergo PBRT as in arm I.
3287444|NCT00567580|Experimental|Arm III|(Pelvic lymph node radiotherapy [PLNRT], PBRT, and STAD): Beginning 2 months before the start of radiotherapy, patients receive STAD therapy as in arm II. Approximately 2 months after beginning of STAD, patients undergo PBRT and PLNRT once daily, 5 days a week, Monday through Friday, for approximately 5 weeks (25 fractions) followed by PBRT only once daily, 5 days a week for approximately 2-3 weeks (11-14 fractions).
3287445|NCT00567567|Active Comparator|Consolidation Arm A: single myeloablative consolidation|Patients receive melphalan IV over 15-30 minutes on days -7 to -5, etoposide IV over 24 hours and carboplatin IV over 24 hours on days -7 to -4, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Patients undergo autologous PBSCT on day 0.
3287446|NCT00567567|Experimental|Consolidation Arm B: tandem myeloablative consolidation|Patients receive thiotepa IV over 2 hours on days -7 to -5, cyclophosphamide IV over 1 hour on days -5 to -2, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Following clinical recovery from initial myeloablative therapy, patients also receive melphalan, etoposide, and carboplatin as in Arm A. Patients undergo autologous PBSCT on day 0.
3287447|NCT00567567|Other|Not Assigned|Patients either failed during Induction therapy or refused randomization, and hence did not receive any of the Consolidation therapy (i.e., Consolidation Arm A: single HST (CEM) myeloablative consolidation or Consolidation Arm B: tandem HST (CEM) myeloablative consolidation).
3287448|NCT00567554|Experimental|1|EC-T
3287449|NCT00567554|Experimental|2|EC-T +/- B
3287450|NCT00567554|Experimental|3|Pw
3287451|NCT00567554|Experimental|4|Pw + RAD001
3287452|NCT00567554|Experimental|5|EC-T + H
3287453|NCT00567554|Experimental|6|EC-T + L
3287454|NCT00567541|Active Comparator|Active BBPM stimulation|Therapeutic Stimulation is applied via the Battery Powered Microneuromodulator (BBPM) which is programmed to deliver set stimulation parameters with approximate frequency of 30 Hz, current 5mA for 200 microseconds for the first 12 weeks of the study. The BBPM is implanted near the axillary nerve within the quadrilateral space.
3287455|NCT00567541|Placebo Comparator|Sham BBPM stimulation|The Battery Powered Microneuromodulator is implanted near the axillary nerve within the quadrilateral space. The BBPM is programmed for the first 12 weeks of the study to deliver short bursts of extremely low amplitude electrical stimulation at very wide time intervals to give appearance, impression, and sensation of therapeutic treatment. After 24 weeks, the device will be reprogrammed to deliver therapeutic stimulation over a 12 week period.
3287456|NCT00567528|Other|1|Active ibuprofen liposomal transdermal gel with placebo ibuprofen capsule
3287457|NCT00567528|Other|2|Placebo ibuprofen liposomal transdermal gel with active ibuprofen capsules
3287458|NCT00567515|Experimental|LAA Clip|AtriCure LAA Exclusion System
3287459|NCT00567502||1|XAGRID® (anagrelide hydrochloride)
3287460|NCT00567502||2|Xagrid + Other cytoreductive
3287461|NCT00567502||3|Other cytoreductive
3287462|NCT00567489|Active Comparator|Non glucose sparing|Dianeal only
3287463|NCT00567489|Experimental|glucose sparing|PEN solutions: Nutrineal, Extraneal, and Physioneal
3287464|NCT00567476|Active Comparator|Omalizumab + Conventional Therapy|Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 20 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of immunoglobulin E (IgE). Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued using their current formulation of inhaled corticosteroid (ICS) and long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.
3287465|NCT00567476|Active Comparator|Conventional Therapy|Participants continued using their current formulation of inhaled corticosteroid (ICS) and a long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.
3287466|NCT00567463|Placebo Comparator|Placebo|Placebo inhalator will be used by subjects in the placebo group(same course as patients in the treated group)
3287467|NCT00567450|Active Comparator|B|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
3287468|NCT00567450|Experimental|A|30 ml of ropivacaine 0.75%
3287469|NCT00567437|Other|A|10 patients with no aortic stenosis
3287470|NCT00567437|Other|B|100 patients with asymptomatic AS
3287471|NCT00567411|Active Comparator|I|Eyes receiving Apraclonidine 0.5% (Iopidine) prior to SLT
3287472|NCT00567411|Active Comparator|A|Eyes receiving Brimonidine 0.1% (Alphagan) prior to SLT
3287473|NCT00567398|Active Comparator|non glucose sparing|Dianeal only
3287474|NCT00567398|Experimental|Glucose sparing|Physioneal, Extraneal, Nutrineal
3287878|NCT00564317|Experimental|1 KIDNET|Narrative Exposure Therapy for Children
3287475|NCT00567346|Active Comparator|grass pollen extract twice weekly|Current standard dose regimen of grass pollen immunotherapy (9,500 BU), given twice weekly. Note: patients in twice weekly dosing regimen will also receive placebo on days no active treatment is given.
3287476|NCT00567346|Active Comparator|Grass pollen extract, daily|Grass pollen immunotherapy, 9,500 BU, given daily
3287477|NCT00567346|Active Comparator|Increased dose of grass pollen extract|Increased dose of grass pollen immunotherapy, 19,000 BU, given daily
3287478|NCT00567346|Placebo Comparator|Placebo control|Patients randomized to placebo will receive placebo daily.
3287479|NCT00567333|Other|1|
3287480|NCT00567333|Other|2|
3287481|NCT00567320|Active Comparator|Varenicline|
3287482|NCT00567320|Active Comparator|Sugar Pill or Placebo|Placebo is compared to active drug varenicline
3287483|NCT00567307|Experimental|The Red Heart Pill 2b (Polypill) (A)|The Polypill is composed of 75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide
3287484|NCT00567307|Active Comparator|Standard Practice Group (B)|Standard Practice
3287485|NCT00567294|Active Comparator|A|Participants will receive mailed education materials on osteoporosis and medication use.
3287486|NCT00567294|Experimental|B|Participants will receive a telephone coaching program.
3287487|NCT00567294|Experimental|C|Participants will receive a telephone coaching program, and doctors of these participants will receive medication adherence alert notifications.
3287488|NCT00567281|Experimental|1|Active bilateral rTMS to left/right Wernicke's area and opposite side middle temporal gyrus
3287489|NCT00567281|Active Comparator|2|Active rTMS to left/right Wernicke's region plus sham rTMS to opposite hemisphere middle temporal cortex
3287490|NCT00567281|Experimental|Non-randomized bilateral rTMS|Active bilateral rTMS to left/right Wernicke's area and opposite side middle temporal gyrus
3287491|NCT00567268||Gabapentin|Patients taking Gabapentin
3287492|NCT00567255|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/day with ancillary therapy
3287493|NCT00567255|Placebo Comparator|Placebo|Placebo with ancillary therapy
3287494|NCT00567242|Experimental|Word-finding with intention component|Treats word-finding (picture naming, category member generation) with an intention manipulation (complex left-hand movement to initiate word-finding trials)
3287495|NCT00567242|Active Comparator|Word-finding with no intention component|Word-finding trials similar to intention mediated treatment, but without intention manipulation
3287496|NCT00567229|Experimental|Lenalidomide and Rituximab|This study will employ a Simon optimal two-stage design. Patients will receive lenalidomide 25 mg daily for days 1-21 of each 28 day cycle. Rituximab 375 mg/m2 will be given weekly for 4 weeks beginning 1 week after the start of lenalidomide therapy (weeks 2-5), and then once 8 weeks later (week 13). Patients with stable disease or better after 4 cycles (week 16, in the absence of delays for toxicity) will be able to continue on therapy on the same lenalidomide schedule and with rituximab 375 mg/m2 given once every 8 weeks.
3287497|NCT00567216|No Intervention|G|Endoscopic injection of cyanoacrylate alone
3287498|NCT00567216|Active Comparator|C|Combination of GVO and nadolol
3287499|NCT00567203|Experimental|1|
3287500|NCT00567203|Experimental|2|
3287501|NCT00567203|Placebo Comparator|3|
3287502|NCT00567190|Experimental|Pertuzumab, trastuzumab, docetaxel|Participants will receive pertuzumab on Day 1 of Cycle 1 followed by trastuzumab and then docetaxel on Day 2 of Cycle 1 (1 Cycle length = 21 days). Participants will continue to receive pertuzumab followed by trastuzumab and then docetaxel every 3 weeks (Q3W) for subsequent cycles until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity.
3287503|NCT00567190|Placebo Comparator|Placebo, trastuzumab, docetaxel|Participants will receive pertuzumab matching placebo on Day 1 of Cycle 1 followed by trastuzumab and then docetaxel on Day 2 of Cycle 1 (1 Cycle length = 21 days). Participants will continue to receive pertuzumab followed by trastuzumab and then docetaxel Q3W for subsequent cycles until nvestigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity.
3287504|NCT00567177|Active Comparator|1|
3287505|NCT00567177|Placebo Comparator|2|
3287506|NCT00567164|Experimental|Flexible (extended) regimen no. 1 of EE20/DRSP (BAY86-5300)|Minimum of 3 cycles of treatment, each cycle comprising 120 days (maximum) intended treatment with one tablet daily of BAY86-5300 (SH T00186D) followed by a 4-day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred between days 25 to 120 of the treatment cycle, a 4-day tablet-free interval was advised. The minimum period between 2 tablet-free intervals was 24 days. After each 4-day tablet-free interval, a new 124-day intended treatment cycle was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment
3287507|NCT00567164|Experimental|Flexible (extended) regimen no. 2 of EE20/DRSP (BAY86-5300)|Minimum of 3 cycles of treatment, each cycle comprising 120 days (maximum) uninterrupted treatment with one tablet daily of BAY86-5300 (SH T00186D) and a 4-day tablet-free interval. Subjects were permitted to schedule their withdrawal bleeding (ie, 4-day tablet-free interval) at any time between days 25 to 120 of the cycle. Subjects had the option to follow the bleeding rules of the flexible (extended) regimen no. 1 of BAY86-5300. The minimum period between 2 tablet-free intervals was 24 days. After each 4-day tablet-free interval, a new 124-day intended treatment cycle was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
3287508|NCT00567164|Active Comparator|Conventional regimen of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets of BAY86-5300 (YAZ, SH T00186D) followed by 4 days of tablets without active substance (together resulting in one cycle of 24+4 standard treatment). 13 withdrawal bleeding episodes during one year of treatment were expected.
3287509|NCT00567125||I|Patients with cholelithiasis operated on using standard laparoscopy method
3287510|NCT00567125||II|Patients with cholelithiasis operated on using low-pressure CO2 pneumoperitoneum laparoscopy
3287511|NCT00567112|Experimental|DFC (fasted)|
3287512|NCT00567112|Experimental|OCT (fasted)|
3287513|NCT00567112|Experimental|OCT (after meal)|
3287514|NCT00567112|Active Comparator|OCT (before meal)|
3287515|NCT00567086|Placebo Comparator|A|
3287516|NCT00567086|Experimental|B|
3287517|NCT00567086|Experimental|C|
3287518|NCT00567086|Experimental|D|
3287519|NCT00567073||Pregnant Women Receiving Treatment for Pompe Disease|Pregnant Women with Pompe Disease Enrolled in the Pompe Disease Registry (NCT00231400)That Are Receiving Treatment of alglucosidase alpha (Myozyme)
3287520|NCT00567073||Pregnant Women Receiving No Treatment for Pompe Disease|Pregnant Women with Pompe Disease Enrolled in the Pompe Disease Registry (NCT00231400)That Are Not Receiving Treatment
3287521|NCT00567073||Infants Born to Mothers Receiving Treatment for Pompe|The Infants of Mothers with Pompe Disease Enrolled in the Pompe Disease Registry (NCT00231400)Where the Mothers Are Receiving Treatment of alglucosidase alpha (Myozyme)
3287522|NCT00567073||Infants Born to Mothers Receiving No Treatment for Pompe|The Infants of Mothers with Pompe Disease Enrolled in the Pompe Disease Registry (NCT00231400)Where the Mothers Are Not Receiving Treatment
3287523|NCT00567047|Experimental|1|Vildagliptin
3287524|NCT00567034|Active Comparator|1|taking naltrexone
3287525|NCT00567034|Placebo Comparator|2|taking placebo
3287526|NCT00567021||1|patients with GERD or NSAID-related ulcers
3287527|NCT00567008|Experimental|1|Varenicline (Chantix)
3287528|NCT00567008|Placebo Comparator|2|Placebo
3287529|NCT00566995|Experimental|Vandetanib in Participants with Kidney Cancer|300 mg/day (starting dose) oral dose of vandetanib once a day for 28 days
3287530|NCT00566982|Experimental|Ospemifene 60 mg/day|Ospemifene will be taken orally, once daily, in the morning, with food for 52 weeks.
3287531|NCT00566982|Placebo Comparator|Placebo|Placebo will be taken once daily, in the morning, with food for 52 weeks.
3287532|NCT00566969|Placebo Comparator|Sugar Pill|To be compared to active drug
3287533|NCT00566969|Active Comparator|Carvedilol 25 mg|To be compared to placebo and Carvedilol 50 mg
3287534|NCT00566969|Active Comparator|Carvedilol 50 mg|To be compared to placebo and Carvedilol 25 mg
3287535|NCT00566956|Experimental|1|For those assigned to Group 1, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
3287536|NCT00566956|No Intervention|2|Patients assigned to group 2 will not have the hydrosalpinx aspirated
3287537|NCT00566943|Active Comparator|Control|"Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple lines including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine). intestine or mesentery.~Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without buttress at the GJ anastomosis. Linear buttress at the stomach/pouch staple line is required."
3287538|NCT00566943|Experimental|PSD Veritas|"Linear Peri-Strips Dry Veritas Group: Patients who have laparoscopic Roux-en-Y gastric by-pass surgery with PSD Veritas used as a staple line buttress at the stomach/pouch.~In addition to buttress of the stomach/pouch, patients may have PSD Veritas linear buttress at any of the following staple lines: intestine, mesentery, or anastomosis junction (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine).~Circular Peri-Strips Dry Veritas Group: Patients who have laparoscopic Roux-en-Y gastric by-pass surgery with PSD Veritas circular buttress used as a staple line buttress at the GJ anastomosis. Linear buttress at the stomach/pouch is required."
3287539|NCT00566930|No Intervention|1|
3287540|NCT00566930|Active Comparator|2|spinal manipulation
3287541|NCT00566930|Experimental|3|Spinal manipulation + exercises
3287542|NCT00566917|Active Comparator|1|Anterior colporrhaphy (standardised)
3287543|NCT00566917|Experimental|2|Anterior PROLIFT
3287544|NCT00566904|Experimental|1|Participants will receive one of three different topical treatments on Days 8, 15, or 22.
3287545|NCT00566891|Active Comparator|A|Tirofiban
3287546|NCT00566891|Placebo Comparator|B|Clopidogrel
3287547|NCT00566865|Experimental|2|mitiglinide + gemfibrozil
3287548|NCT00566865|Placebo Comparator|1|mitiglinide + placebo for gemfibrozil
3287549|NCT00566852|Experimental|WBRT+Memantine|Whole brain radiation therapy (WBRT) and memantine
3287550|NCT00566852|Active Comparator|WBRT+Placebo|Whole brain radiation therapy (WBRT) and placebo
3287551|NCT00566839|Experimental|1|
3287552|NCT00566839|Active Comparator|2|
3287553|NCT00566826|Experimental|1|Patient support treatment sessions
3287554|NCT00566826|Active Comparator|2|Treatment as usual
3287555|NCT00566813|Active Comparator|Group 1|Islet transplantation and the Edmonton protocol of steroid free immunosuppression
3287556|NCT00566813|Active Comparator|Group 2|Edmonton Protocol,etanercept,exenatide
3287557|NCT00566774|Experimental|1|
3287558|NCT00566774|Active Comparator|2|
3287559|NCT00566735|Placebo Comparator|1|
3287560|NCT00566735|Active Comparator|2, Galantamine|
3287561|NCT00566722|Experimental|Open Label|
3287562|NCT00566709|Experimental|RBCT based on rSO2 value|Intervention: In the rSO2 - strategy group, patients will be transfused to attain a post-transfusion rSO2 values higher than 60%.
3287563|NCT00566709|Active Comparator|RBCT based on hemoglobin level value|Intervention: In the hemoglobin - strategy group, patients will be transfused to reach post-transfusion hemoglobin levels between 8.5 g/dL and 10 g/dL.
3287564|NCT00566696|Experimental|High-Risk Hematologic Malignancies|"Participants meeting eligibility criteria undergo haploidentical stem cell transplantation along with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (after January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.~Grafts from suitable haploidentical donors are processed using the CliniMACS system."
3287565|NCT00566683|Active Comparator|1|Diazemuls-Pethidine
3287566|NCT00566683|Active Comparator|2|Propofol- Alfentanil
3287567|NCT00566670||Observation (all participants)|Stage 5 Chronic Kidney Disease and hemodialysis patients
3287568|NCT00566657|Experimental|Riferminogene pecaplasmid|4 administrations of riferminogene pecaplasmid 4 mg at 2-week intervals
3287569|NCT00566657|Placebo Comparator|Placebo|4 administrations of placebo (for riferminogene pecaplasmid) at 2-week intervals
3287570|NCT00566631|Experimental|Paliperidone Extended Release (ER)|
3287571|NCT00566618|Experimental|Dasatinib + Zoledronic Acid|"Dasatinib Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Zoledronic Acid Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort. Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
3287572|NCT00566605|Active Comparator|Group 1|
3287573|NCT00566605|Active Comparator|Group 2|
3287574|NCT00566592|Experimental|1|Oral ethanol, overnight
3287575|NCT00566592|Experimental|2|IV ethanol, overnight
3287576|NCT00566592|Placebo Comparator|3|Placebo, overnight
3287577|NCT00566592|Placebo Comparator|4|Placebo, daytime
3287578|NCT00566579|Experimental|A|Double-freezing cryotherapy was done within one month after the primary hpv testing was positive. Pap smear and colposcopy were done at 6 months and 12 months. HPV testing was repeated again at 12 months.
3287579|NCT00566579|No Intervention|B|Pap smear and colposcopy were done at 6 months and 12 months. HPV testing was repeated again at 12 months.
3287580|NCT00566566||1|ALL survivors 5 years after completion of treatment, during routine medical follow up
3287581|NCT00566553|Active Comparator|Grape Seed Extract # 1|200 mg [1 pill]
3287582|NCT00566553|Active Comparator|Grape Seed Extract # 2|200 mg [2 pills]
3287583|NCT00566553|Active Comparator|Grape Seed Extract # 3|200 mg [3 pills]
3287584|NCT00566553|Active Comparator|Grape Seed Extract # 4|200 mg [4 pills]
3287585|NCT00566540|Experimental|Treatment (neoadjuvant, adjuvant chemotherapy and radiation)|"PREOPERATIVE:Patients receive cisplatin IV over 2 hours three times weekly in week 1 once daily(QD),5 days a week, in weeks 1-2.~SURGERY:Patients undergo triple endoscopy and biopsy with submandibular gland transfer in week 3.~INTRAOPERATIVE: Patients also undergo Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation.~POSTOPERATIVE: Patients receive paclitaxel IV over 3 hours in weeks 7-10 and cisplatin IV over 1-2 hours three times weekly in weeks 7 and 10. Patients also undergo Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation QD, 5 days a week, in weeks 7-10."
3287586|NCT00566527|Experimental|Arm 1: ProQuad® at 9 and 12 months|Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 at 12 months of age.
3287587|NCT00566527|Experimental|Arm 2: ProQuad® at 11 and 14 months|Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 at 14 months of age.
3287588|NCT00566527|Active Comparator|Arm 3: ProQuad at 12 and 15 months|Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 at 15 months of age.
3287589|NCT00566514|Active Comparator|1|D-ribose 5 grams TID orally
3287590|NCT00566514|Placebo Comparator|2|Dextrose 5 grams TID
3287591|NCT00566501|Experimental|23 mg SR in Study 326|Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.
3287592|NCT00566501|Experimental|10 mg IR in Study 326|Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.
3287593|NCT00566488|Experimental|Thymus and Parathyroid transplantation|Thymus/Parathyroid Transplantation in Complete DiGeorge Syndrome Infants
3287594|NCT00566475|No Intervention|1|usual care
3287595|NCT00566475|Experimental|2|Telemedicine intervention in the school involving school personnel, the child with diabetes and at least 1 parent of the child
3287596|NCT00566462|Experimental|perampanel|
3287597|NCT00566462|Placebo Comparator|1|
3287598|NCT00566449|Experimental|001|JNJ-31001074 10 mg daily for 4 weeks
3287599|NCT00566449|Placebo Comparator|003|Placebo one dose daily for 4 weeks
3287600|NCT00566449|Experimental|002|JNJ-31001074 30 mg daily for 4 weeks
3287601|NCT00566436|Active Comparator|REA|Patients presenting with a long occlusion of the superficial femoral artery enrolled in REA arm will undergo remote endarterectomy of the occluded superficial femoral artery
3287602|NCT00566436|Active Comparator|Bypass|Patients presenting with a long occlusion of the superficial femoral artery enrolled in Bypass arm will undergo suprageniculate femoropopliteal bypass surgery to bypass the occluded superficial femoral artery
3287603|NCT00566423|Experimental|1|Patients with Pulmonary Arterial Hypertension
3287604|NCT00566397|Experimental|1|
3287605|NCT00566397|Experimental|2|
3287606|NCT00566397|Placebo Comparator|3|
3287607|NCT00566384|Active Comparator|Arm 1|
3287608|NCT00566384|Placebo Comparator|Arm 2|
3287609|NCT00566371|Experimental|1|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
3287610|NCT00566371|Placebo Comparator|2|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
3287611|NCT00566358|Experimental|1|Duodenal exclusion
3287612|NCT00566345|Experimental|1|Vero-cell derived influenza vaccine
3287613|NCT00566345|Placebo Comparator|2|Phosphate buffered saline (packaged in syringes identical to those used for the investigational vaccine)
3287614|NCT00566332|Active Comparator|1|Chlorambucil 8mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months
3287615|NCT00566332|Active Comparator|2|Fludarabine
3287616|NCT00566319|Experimental|1|
3287617|NCT00566319|Active Comparator|2|
3287618|NCT00566306|Experimental|A|PHMG will be introduced in three wards for hand hygiene and environmental disinfection in CDAD patients' rooms. The rooms for showers and toilets will be coated with biocide coating (PHMG) as well as bed frames in investigational wards.
3287619|NCT00566306|No Intervention|B|Three wards will be control wards and continue using alcohol based hand disinfectants and routine environmental cleaning and disinfection with quats/chloramines.
3287620|NCT00566280|Other|Molecular Breast Imaging|
3287622|NCT00566254|Placebo Comparator|Placebo|Participants had a starting dose of 1 mg/kg/day of placebo matching Zonisamide. Dose was titrated upwards with weekly dose increases until a dose of 8 mg/kg/day was reached at the end of the Titration Period (Week 8). Dose during the Maintenance Period remained unchanged from Week 8.
3287623|NCT00566254|Experimental|Zonisamide|Participants had a starting dose of 1 mg/kg/day of Zonisamide. Dose was titrated upwards with weekly dose increases until a dose of 8 mg/kg/day was reached at the end of the Titration Period (Week 8). Dose during the Maintenance Period remained unchanged from Week 8.
3287624|NCT00566241|Experimental|IGF-1|Recombinant human IGF-1
3287625|NCT00566241|Placebo Comparator|Placebo|Placebo
3287626|NCT00566228|Experimental|Immunologic autograft engineering|Patients' stem cells are collected according to modified Amicus settings (i.e., MNC OFFSET = 0.0 and RBC = 7.0). Patients undergo ASCT IV on the day of apheresis (lymphocyte enriched autograft).
3287627|NCT00566228|Active Comparator|Standard autograft collection|Patients' stem cells are collected according to standard Amicus settings (i.e., MNC OFFSET = 1.5 and RBC OFFSET = 5.0). Patients undergo ASCT IV on the day of apheresis.
3287628|NCT00566215|Experimental|1|Duodenal exclusion plus total omentectomy
3287629|NCT00566215|Active Comparator|2|Duodenal exclusion without omentectomy
3287630|NCT00566202|Experimental|JNJ-18038683|
3287631|NCT00566202|Placebo Comparator|Placebo|
3287632|NCT00566202|Active Comparator|Escitalopram|
3287633|NCT00566189|Experimental|1|Roux-en-Y bypass gastroplasty
3287634|NCT00566150|Active Comparator|Levetiracetam|
3287635|NCT00566150|Placebo Comparator|Placebo|
3287636|NCT00566124|Active Comparator|1|Insulin detemir
3287637|NCT00566124|Active Comparator|2|Insulin glargine
3287638|NCT00566124|Active Comparator|3|NPH insulin
3287639|NCT00566111|Active Comparator|A|
3287640|NCT00566111|Placebo Comparator|P|
3287641|NCT00566085|Other|Molecular Breast Imaging|
3287642|NCT00566072|Experimental|1|instructions and coaching on the use and intake of ganciclovir
3287643|NCT00566072|No Intervention|2|
3287644|NCT00566046|Experimental|Levetiracetam|
3287645|NCT00566046|Placebo Comparator|Placebo|
3287646|NCT00566033|Experimental|1|
3287647|NCT00566033|No Intervention|2|Patients in this arm (arm 2) will undergo to standard care.
3287648|NCT00566020|Experimental|Lamotrigine|study drug
3287649|NCT00566007|Active Comparator|1|Discectomy/micro discectomy
3287650|NCT00566007|Active Comparator|2|Intradiscal ozone infiltration
3287651|NCT00566007|Active Comparator|3|Intradiscal oxygen infiltration (control arm)
3287652|NCT00565994||Hemodialysis patients|Male and female patients undergoing hemodialysis therapy as outpatients
3287653|NCT00565994||Control|Male and female healthy volunteers
3287654|NCT00565994||Pre-dialysis patients|Male and female patients with Stage 3, 4, or 5 chronic kidney disease, but not yet on dialysis
3287655|NCT00565981|Experimental|Overall study|The FLUSALEM protocol combines 4 cycles of oral fludarabine phosphate (40mg/m² d1-3; q 29d) and an intensive dose schedule of alemtuzumab (30mg sc.3 times weekly for 16 weeks) in an outpatient setting
3287656|NCT00565968|Experimental|Sorafenib dose escalation|
3287657|NCT00565955|Active Comparator|A1|Children Between 5-15 Years of Age Receiving Montelukast
3287658|NCT00565955|Placebo Comparator|A2|Children Between 5-15 Years of Age Receiving Placebo
3287659|NCT00565942|Active Comparator|Usual care|Treatment as usual coordinated by general practitioners in primary care.
3287660|NCT00565942|Active Comparator|Integrative care|Selected complementary therapies (Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong) added to usual care.
3287661|NCT00565929|Experimental|Group A: MVA-BN 1 X 10^7 TCID 50|10 participants to receive vaccine dose 1X10^7 TCID 50; 2 participants to receive placebo.
3287662|NCT00565929|Experimental|Group B: MVA-BN 1 X 10^8 TCID 50|10 participants to receive vaccine dose 1X10^8 TCID 50; 2 participants to receive placebo.
3287663|NCT00565916|Experimental|1|Hormone replacement therapy (HRT): estrogen plus progesterone
3287664|NCT00565916|Active Comparator|2|Hormone replacement therapy (HRT): estrogen plus placebo
3287665|NCT00565890|No Intervention|2|No replacement therapy
3287666|NCT00565877|Experimental|1 - Neck Ultrasound|post-PICC insertion ultrasound inspection of the ipsilateral neck
3287667|NCT00565877|No Intervention|2 - Control|No post-PICC insertion ultrasound inspection of the ipsilateral neck
3287668|NCT00565864|Experimental|1 (Low-normal TSH target)|Treatment arm 1 targets a thyroid stimulating hormone (TSH) of 0.28 -2.49 milliunits/liter (mU/L) (the theoretical optimal range). The intervention is as follows: Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses.
3287669|NCT00565864|Experimental|2 (High-normal TSH target)|"Treatment arm 2 targeting a TSH of 2.5 - 5.0 mU/L. The intervention is as follows:~Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses."
3287670|NCT00565864|Experimental|3 (Mildly elevated TSH target)|"Treatment arm 3 is targeting a TSH level o f 5.1-12.0 mU/L. The intervention is as follows:~Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses."
3287671|NCT00565851|Active Comparator|Arm I (paclitaxel, docetaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours or docetaxel IV over 1 hour and carboplatin over 30 minutes on day 1. Treatment repeats every 21 days.
3287879|NCT00564317|Experimental|2 Meditation/Relaxation|mixed Meditation/Relaxation Protocol
3287672|NCT00565851|Experimental|Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab)|Patients receive chemotherapy as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days.
3287673|NCT00565851|Experimental|Arm III (gemcitabine hydrochloride, carboplatin)|Patients receive gemcitabine hydrochloride IV over 60 minutes on days 1 and 8 and carboplatin as in Arm I.
3287674|NCT00565851|Experimental|Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin)|Patients receive gemcitabine hydrochloride IV as in Arm III, bevacizumab IV and carboplatin IV as in Arm II.
3287675|NCT00565838||2|G1 - Autologous Fascial Sling G2 - TVT
3287676|NCT00565812|Active Comparator|200 mg|High dose active comparator
3287677|NCT00565812|Active Comparator|50 mg|Low dose active comparator
3287678|NCT00565812|Placebo Comparator|Placebo|Placebo comparator to be used for control purposes
3287679|NCT00565799|Active Comparator|1. Omentectomy|LAGB & Omentectomy
3287680|NCT00565799|Placebo Comparator|2 No Omentectomy|LAGB Only
3287681|NCT00565786||ArCom® Polyethylene|ArCom® Polyethylene
3287682|NCT00565786||ArComXL® Polyethylene|ArComXL® Polyethylene
3287683|NCT00565773|Experimental|1|"All patients will be given a single dose of alemtuzumab on the day of transplantation. All patients will receive belatacept and sirolimus for 1 year.~Ten patients in the first group of 20 subjects received a single dose of donor bone marrow 7 days after transplantation.~At the time of transplant, all patients will receive a single dose of 500 mg of methylprednisolone IV over 30 minutes followed within 1 hour by an IV infusion of 30 mg. of alemtuzumab over 3 hours."
3287684|NCT00565773|Experimental|2|"All patients will be given a single dose of alemtuzumab on the day of transplantation. All patients will receive belatacept and sirolimus for one year.~Half of the initial 20 subjects did not receive an infusion of donor bone marrow. None of the additional 20 subjects in the second group will receive donor bone marrow.~At the time of transplant, all patients will receive a single dose of 500 mg of methylprednisolone IV over 30 minutes, followed within 1 hour by an IV infusion of 30 mg of alemtuzumab over 3 hours."
3287685|NCT00565760|Experimental|1|
3287686|NCT00565760|Placebo Comparator|2|
3287687|NCT00565747|Experimental|Test culture|Culture with GM-CSF
3287688|NCT00565747|Placebo Comparator|Control culture|Culture without GM-CSF
3287689|NCT00565734||Posterior surgical approaches|Posterior surgical approaches for symptomatic cervical spondylotic myelopathy (CSM)
3287690|NCT00565734||Anterior surgical approaches|Anterior surgical approaches for symptomatic cervical spondylotic myelopathy (CSM).
3287691|NCT00565721|Experimental|Fluciclatide Injection - (AH111585 (F18))|Using of the drug product named, AH111585 (F18) Injection. It's generic chemical name is Fluciclatide.
3287692|NCT00565708|Experimental|acetylsalicylic acid|200mg OD for 3 years
3287693|NCT00565708|Placebo Comparator|Placebo|200mg OD for 3 years
3287694|NCT00565682|Experimental|A|Etoricoxib 120 mg
3287695|NCT00565669|Active Comparator|Cyclosporin A Restasis®|Topical cyclosporin A 0.05% ophthalmic emulsion (Restasis®, Allergan, Irvine, CA)
3287696|NCT00565656|Experimental|A|Bevacizumab
3287697|NCT00565643|Experimental|HA-CMC Group|Hyaluronic Acid-Carboxymethylcellulose placed as an adhesion barrier
3287698|NCT00565643|Placebo Comparator|Routine Closure Group|Routine Closure without placement of an adhesion barrier
3287699|NCT00565630|Experimental|1|Vigamox via the experiemntal device
3287700|NCT00565630|Active Comparator|2|Vigamox drops from the commercially available bottles
3287701|NCT00565617|Experimental|Synergy, Epidural cortical stimulation|Epidural cortical stimulation (medial prefrontal cortex) for treatment resistant depression. The primary aim of this pilot study was to assess the feasibility and safety of EpCS in patients with treatment-resistant depression. Ultimately, for EpCS to be found effective, a much larger double blind placebo controlled study would be needed.
3287702|NCT00565604|Experimental|Short Catheter Delviery|Patients with duplex ultrasound documented incompetent perforator veins will be treated using a short catheter delivery system in conjunction with a Bright Tip Laser fiber.
3287703|NCT00565591|Placebo Comparator|Dose escalation|
3287704|NCT00565565|Experimental|BAY60-4552, 1 mg|Subjects were planned to receive 1 mg of BAY60-4552 as solution
3287705|NCT00565565|Experimental|BAY60-4552, 2.5 mg|Subjects were planned to receive 2.5 mg of BAY60-4552 as tablet
3287706|NCT00565565|Experimental|BAY60-4552, 5 mg|Subjects were planned to receive 5.0 mg of BAY60-4552 as tablet
3287707|NCT00565565|Experimental|BAY60-4552, 7.5 mg|Subjects were planned to receive 7.5 mg of BAY60-4552 as tablet
3287708|NCT00565565|Experimental|BAY60-4552, 10 mg|Subjects were planned to receive 10 mg of BAY60-4552 as tablet
3287709|NCT00565552|Active Comparator|1|Each patient uses the silicone gel on one half of the scar, leaving the other one blank as an internal control.
3287710|NCT00565513|Other|A|cord blood and maternal milk tests
3287711|NCT00565500|Experimental|1|
3287712|NCT00565500|Experimental|2|
3287713|NCT00565500|Placebo Comparator|3|
3287714|NCT00565487|Experimental|Single arm|This is a single arm dose escalation study with a cohort expansion.
3287715|NCT00565474|Active Comparator|1|fluvastatin 40mg b.i.d.
3287716|NCT00565474|Placebo Comparator|2|Placebo b.i.d.
3287717|NCT00565461|Experimental|Group 1|40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT patch on the left deltoid by a Clinician on Day 0. Two weeks later will have the same treatment repeated on the right deltoid by the clinician
3287718|NCT00565461|Experimental|Group 2|40 subjects will be pretreated with SPS:Buffer and a patch containing 37.5ug will be applied on the left deltoid by the Clinician. Fourteen days later, the same procedure will occur on the left thigh by the clinician.
3287719|NCT00565461|Experimental|Group 3|40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT on the left deltoid by the clinician. Two weeks later subject will have the same treatment repeated by self-application in the clinic on the left thigh.
3287720|NCT00565461|Experimental|Group 4|40 subjects will have skin prepared using SPS:Buffer and will have 37.5ug LT patch on the left deltoid by a clinician. Two weeks later subjects will have the same treatment repeated by self-application at home on the left thigh.
3287880|NCT00564317|Experimental|3 KIDNET + Meditation/Relaxation|KIDNET according to protocol, waiting time of 5 months, then Meditation/Relaxation according to protocol
3287721|NCT00565448|Experimental|Docetaxel/Cisplatin/5-FU (TCF)|"Docetaxel 75 milligrams per square meter (mg/m²) over 1 hour on Day 1 every 3 weeks~Cisplatin 75 mg/m² Day 1 over 6 hours every 3 weeks~5-Fluorouracil 750 mg/m²/day continuous infusion Days 1 to 4 every 3 weeks as an induction therapy~Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks."
3287722|NCT00565448|Active Comparator|Cisplatin/5-FU (CF)|"Cisplatin 80 mg/m² Day 1 over 6 hours every 3 weeks~5-Fluorouracil 1000 mg/m²/day continuous infusion Day 1 to 4 every 3 weeks as an induction therapy.~Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks."
3287723|NCT00565422|Experimental|Single Arm|Escitalopram
3287724|NCT00565409|Active Comparator|1|
3287725|NCT00565409|Active Comparator|2|
3287726|NCT00565409|Placebo Comparator|3|
3287727|NCT00565396|Active Comparator|1|Fosinopril 10mg/day(oral)
3287728|NCT00565396|Active Comparator|2|Fosinopril 20mg/day(oral)
3287729|NCT00565396|Active Comparator|3|Losartan 50mg/day(oral)
3287730|NCT00565396|Active Comparator|4|Losartan 100mg/day(oral)
3287731|NCT00565383|Active Comparator|Intravenous fentanyl analgesia|Intravenous fentanyl (50 mcg) analgesia
3287732|NCT00565383|Experimental|Combined spinal-epidural analgesia|Combined spinal-epidural analgesia (intrathecal fentanyl 2.5 mg plus bupivacaine 2.5 mg) single administration
3287733|NCT00565370|Experimental|A|XP+sorafenib
3287734|NCT00565370|Placebo Comparator|B|XP
3287735|NCT00565357|Experimental|E|
3287736|NCT00565357|No Intervention|C|
3287737|NCT00565331|Active Comparator|1|Rituximab
3287738|NCT00565331|Placebo Comparator|2|Placebo
3287739|NCT00565318|Active Comparator|A|
3287740|NCT00565318|Placebo Comparator|B|
3287741|NCT00565305|Experimental|Healing Touch|Healing Touch + Standard Treatment Healing Touch treatments daily following standard Radiation Therapy. Standard radiation therapy is part of their medical care and is not administered as part of this study. Protocol of 4 HT techniques will be used including Pain Drain, Chakra connection, Magnetic Unruffling, and Mind Clearing. Treatments will be approximately 20-30 minutes.
3287742|NCT00565305|Active Comparator|Usual Care|Standard Treatment. These patients receive usual medical care but no additional intervention. Standard treatment is not administered as part of this study but as part of their medical treatment.
3287743|NCT00565279|Experimental|ASF1057|
3287744|NCT00565279|Placebo Comparator|ASF1057 placebo|
3287745|NCT00565279|Placebo Comparator|ASF1057 Vehicle|
3287746|NCT00565266|Experimental|"Tio + 1xICS || LABA + 1xICS || 2xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
3287747|NCT00565266|Experimental|"TIO + 1xICS || 2xICS || LABA + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
3287748|NCT00565266|Experimental|"LABA + 1xICS || Tio + 1xICS || 2xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
3287749|NCT00565266|Experimental|"LABA + 1xICS || 2xICS || Tio + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
3287750|NCT00565266|Experimental|"2xICS || Tio + 1xICS| || LABA + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~beclomethasone dipropionate 160 mcg twice daily (2xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
3287751|NCT00565266|Experimental|"2xICS || LABA + 1xICS || Tio + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~beclomethasone dipropionate 160 mcg twice daily (2xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
3287752|NCT00565240|Experimental|Oral Contraceptive|
3287753|NCT00565240|Experimental|Contraceptive Ring|
3287754|NCT00565240|Experimental|Aromatase Inhibitors|
3287755|NCT00565240|No Intervention|Control|
3287756|NCT00565227|Experimental|docetaxel plus vorinostat|
3288003|NCT00563030||1|Patients undergoing CABG with CPB
3287757|NCT00565214|Active Comparator|Group 1|On Day 1, Group 1 will initiate in a double-blinded fashion, a once daily vitamin combination of selenomethionine(400 μg), vitamin E(400 IU), and vitamin C (1000 mg) orally for 30 days at home. After 30 days of treatment with Vitamin supplements, the gene expression of the airway epithelium will be compared to that of the Placebo group.
3287758|NCT00565214|Placebo Comparator|Group 2|On Day 1, Group 2 will initiate the placebo in a double-blinded fashion.
3287759|NCT00565201|Experimental|Botox and Rehab|"Patients will receive BOTOX® (100 to 360 U) injected into the any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site).~Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs."
3287760|NCT00565201|Placebo Comparator|Placebo and Rehab|Patients will placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
3287761|NCT00565188|Experimental|I|
3287762|NCT00565188|No Intervention|C|
3287763|NCT00565175|Experimental|famotidine|
3287764|NCT00565175|Placebo Comparator|Placebo|
3287765|NCT00565149|Experimental|1|Normal Protein (15%) diet
3287766|NCT00565149|Experimental|2|Low Protein (5%) diet
3287767|NCT00565149|Experimental|3|High Protein (25%) diet
3287768|NCT00565136|Experimental|TOPAS|TOPAS AMS Pelvic Floor Repair System
3287769|NCT00565123|Experimental|Group A|Experimental dosage
3287770|NCT00565123|Active Comparator|Group B|Classical dosage
3287771|NCT00565110|No Intervention|Enhanced Usual Care|EUC patients receive medical center standard oncology care and supportive services routinely provided to all patients with cancer. In addition, EUC patients are given a patient focused and a family focused educational pamphlet on depression and cancer and a listing of financial and community resources (in Spanish for Spanish-speaking patients). With patient consent, as described in the informed written consent, the treating oncologist is informed via medical chart note if EUC patients screen positive for major depression. Treating oncology attending physicians, fellows and residents are invited to attend a didactic session led by the study psychiatrist on treating depression in cancer patients.
3287772|NCT00565110|Experimental|ADAPt-C intervention|Intervention patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
3287773|NCT00565097|Placebo Comparator|2|Placebo
3287774|NCT00565097|Experimental|1|Lanreotide
3287775|NCT00565084|Active Comparator|1|Ibuprofen
3287776|NCT00565084|Placebo Comparator|2|Placebo 1
3287777|NCT00565084|Placebo Comparator|3|Placebo 2
3287778|NCT00565071|Other|Field microscopy|Field microscopy is the main method of malaria diagnosis
3287779|NCT00565071|Other|Paracheck Pf® device|Paracheck Pf® device (Rapid Diagnostic Test) is the main method for malaria diagnosis
3287780|NCT00565071|No Intervention|Presumptive diagnostic method|
3287781|NCT00565058|Experimental|Pilot|Pilot PD Study (Delayed GTI-2040) Group: In the Pilot PD Study Group, addition of GTI-2040 is delayed until 24 hours after initiation of HiDAC.
3287782|NCT00565058|Experimental|Phase II arm|Phase II PD Study (Early GTI-2040) Group: In the Phase II PD Study Group, GTI-2040 is given 24 hours prior to addition of HiDAC.
3287783|NCT00565045|Experimental|CCFES|"CCFES - Contralaterally Controlled Functional Electrical Stimulation~Stimulation to finger and thumb extensors and flexors only in response to and with an intensity proportional to opening and closing of the contralateral unimpaired hand~A glove instrumented with sensors and worn on the unimpaired hand detects the degree of hand opening and determines stimulation intensity~Therapy sessions are done with the subject being assisted by the CCFES system."
3287784|NCT00565045|Active Comparator|cNMES|"cNMES - Cyclic NeuroMuscular Electrical Stimulation.~Preprogrammed cycles of finger and thumb flexor and extensor stimulation repeatedly and automatically close and open the hand without any effort or voluntary intent required by the subject.~Subject instructed to relax, not attempt to assist the stimulation, and not to move the contralateral arm/hand during stimulation~Therapy sessions are done without the stimulation system"
3287785|NCT00565019|No Intervention|Control|
3287786|NCT00565019|Experimental|Steroid|
3287787|NCT00564993|Active Comparator|A|"necessary re-intervention (pulmonary valve replacement) after repair of Fallot:~2 Visits with cardiac imaging under rest and stress (Dobutamin) before and after pulmonary valve replacement"
3287788|NCT00564993|Active Comparator|B|"comparison group: with a good result of repair of tetralogy of fallot and good ventricular function:~1 Visit with cardiac imaging under rest and stress (Dobutamin)"
3287789|NCT00564980|Active Comparator|1|Wafer Procedure
3287790|NCT00564980|Active Comparator|2|Ulnar shortening osteotomy
3287791|NCT00564967|Experimental|1|CBT via the Internet
3287792|NCT00564967|Experimental|2|15 weeks, CBT group therapy, 1 session/week (2.5 hours).
3287793|NCT00564954|Experimental|Dex-methylphenidate hydrochloride (Focalin XR)|20 mg capsule orally once a day for 7 days
3287794|NCT00564954|Placebo Comparator|Placebo|orally once a day for 7 days
3287795|NCT00564941|Experimental|Deferasirox|
3287796|NCT00564928|Experimental|IPI-504: Group A|No Prior treatment for prostate cancer with cytotoxic chemotherapy (adjuvant or neoadjuvant chemotherapy is acceptable if completed >2 years prior to study)
3288004|NCT00563030||2|Patients undergoing off-pump CABG
3287797|NCT00564928|Experimental|IPI-504: Group B|"Must have evidence of radiographic metastatic disease~Must have been treated with a docetaxel-based chemotherapy regimen for HRPC with a minimum of 2 cycles with either PSA or RECIST defined radiographic progression during or witin 60 days of completeing docetaxel based chemotheraph or be intolerant of docetaxel-based chemotherapy~No more than three prior chemotherapies regimens for HRPC"
3287798|NCT00564902|Placebo Comparator|Lutein|9 mg of Lutein for 12 months
3287799|NCT00564902|Active Comparator|Zeaxanthin and Lutein|3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
3287800|NCT00564902|Active Comparator|Zeaxanthin|3R 3'R Zeaxanthin 8 mg per day during 12 months
3287801|NCT00564889|Experimental|CRD|"Lenalidomide 15mg daily (days 1-21)~Cyclophosphamide 300 mg/m^2 (days 1, 8, 15)~Dexamethasone 40 mg weekly"
3287802|NCT00564876|Experimental|Treatment|Neoadjuvant dasatinib is to be administered as an oral dose of 70 mg PO twice daily on a continuous basis for 3 weeks prior to surgery. Patients will begin adjuvant dasatinib (70 mg PO twice daily) between 4-6 weeks after standard adjuvant therapy is complete or 4-8 weeks after surgery for those patients that do not receive adjuvant chemotherapy. Adjuvant dasatinib will be given on a continuous basis for up to 3 months after adjuvant chemotherapy or after surgery if no adjuvant chemotherapy is given.
3287803|NCT00564863|Other|CS19 expressing ETEC strain|Ascending dose finding study in 5-10 subjects per dose; to identify the dose able to give a diarrheal attack rate greater than or equal to 80%.
3287804|NCT00564850|Experimental|Triptorelin pamoate 11.25mg (Decapeptyl® SR)|
3287805|NCT00564837|Experimental|Home-based|Home-based post-operative rehabilitation program with 4 scheduled physiotherapy sessions over the first 3 post-op months
3287806|NCT00564837|Active Comparator|Physiotherapy supervised|Physiotherapy-supervised rehabilitation program including 17 scheduled physiotherapy sessions in the first 3 post-op months
3287807|NCT00564824|Experimental|CAD patients|Patients with prior history of coronary artery disease (CAD) (myocardial infarction, cerebrovascular accident, coronary angioplasty, S/p CABG operation) who will be given on the first day either caffeine of placebo tablet and 1-2 hours thereafter a brachial artery endothelial function testing (BRT) will be assessed for measuring the FMD. After 1 week the patients will come for a second BRT on placebo/caffeine tablets. If the patient received caffeine tablet the first BRT, he will be receiving placebo tablet the second week, however, if the patient received placebo the first BRT, a caffeine tablet will be given prior to the second BRT.
3287808|NCT00564824|Experimental|Placebo|Patients with prior history of coronary artery disease (CAD) (myocardial infarction, cerebrovascular accident, coronary angioplasty, S/p CABG operation) who will be given on the first day either caffeine of placebo tablet and 1-2 hours thereafter a brachial artery endothelial function testing (BRT) will be assessed for measuring the FMD. After 1 week the patients will come for a second BRT on placebo/caffeine tablets. If the patient received caffeine tablet the first BRT, he will be receiving placebo tablet the second week, however, if the patient received placebo the first BRT, a caffeine tablet will be given prior to the second BRT.
3287809|NCT00564811|No Intervention|G1|
3287810|NCT00564811|Experimental|G2|
3287811|NCT00564798||1|Study Group
3287812|NCT00564798||2|Control Group
3287813|NCT00564785|Placebo Comparator|Placebo|
3287814|NCT00564785|Experimental|Synera(TM)|
3287815|NCT00564772|Experimental|single arm|all subjects dosed the same
3287816|NCT00564746|Experimental|6 subjects in a single cohort|Each subject will be administered a single 10 milligrams (50 microcurie) oral dose of [14C]SB-681323.
3287817|NCT00564733|Experimental|Chemotherapy|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients undergo FDG PET/CT (fludeoxyglucose F 18 positron emission tomography/computed tomography) scan between days 18-21. The FDG PET/CT is an imaging biomarker analysis. Patients that are responding to treatment receive paclitaxel IV and carboplatin IV on day 1. Treatment repeats every 3 weeks for up to 3 additional courses in the absence of disease progression or unacceptable toxicity.Patients that are not responding to chemotherapy per FDG PET then receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 3 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Non-responding patients undergo an additional FDG PET/CT scan between days 18-21 of course 2.
3287818|NCT00564720|Experimental|1|GEM/TAR
3287819|NCT00564720|Experimental|2|GEM/OX/TAR
3287820|NCT00564707|Active Comparator|1|Standard biofeedback therapy will be given for painful levator ani syndrome over a course of eight weeks.
3287821|NCT00564707|Active Comparator|2|Botulinum toxin type A will be injected under EMG guidance into spastic and painful levator ani muscles. This may be repeated only twice on separate visits.
3287822|NCT00564681|Active Comparator|botulinum toxin Type A|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
3287823|NCT00564681|Active Comparator|botulinum toxin Type A Formulation 2|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
3287824|NCT00564681|Other|Placebo (Normal Saline) / botulinum toxin Type A|Intramuscular injections of the assigned study medication into the affected muscles (placebo for treatment cycle 1 and botulinum toxin Type A for subsequent treatments). Maximum dose of 360 units. Subjects may receive up to three treatments.
3287825|NCT00564681|Other|Placebo (Normal Saline) / botulinum toxin Type A Formulation 2|Intramuscular injections of the assigned study medication into the affected muscles (placebo for treatment cycle 1 and botulinum toxin Type A Formulation 2 for subsequent treatments). Maximum dose of 360 units. Subjects may receive up to three treatments.
3287826|NCT00564655|Active Comparator|1|Patients in the control group will receive localized infiltration of local anesthesia at the beginning of the procedure as is current standard practice.
3287827|NCT00564655|Experimental|2|Patients in the experimental group will receive a regional anesthetic blockade of the anterior abdominal wall via the transversus abdominis plane.
3287828|NCT00564629|Experimental|IV acetaminophen plus oral placebo.|Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever. Randomization to receive 1 g of acetaminophen in 100 ml of intravenous solution and oral placebo.
3288005|NCT00563004|Active Comparator|A|Patients receive the herbal medication DBCARE for 3 months
3287829|NCT00564629|Active Comparator|Oral acetaminophen plus IV placebo.|Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever. Randomization to receive oral acetaminophen 1 g plus 100 ml of intravenous placebo solution.
3287830|NCT00564616|Placebo Comparator|voice group|"the voice group received voice CPR instruction via a voice-only cell phone"
3287831|NCT00564616|Experimental|video group|"the video group received interactive voice and video instruction via a video cell phone"
3287832|NCT00564603|Placebo Comparator|1|Saline with same volume added to tramadol infusion combined with morphine PCA.
3287833|NCT00564603|Active Comparator|2|Dexamethasone 10mg in 2mL added to tramadol infusion adjunct to morphine PCA.
3287834|NCT00564590|Experimental|A|Melatonin treatment group
3287835|NCT00564590|Active Comparator|B|Omeprazole 20 mg once a day for 3 months
3287836|NCT00564590|Experimental|C|Placebo once a day for 3 months
3287837|NCT00564577|Other|CFA/I and CS17 challenge strain|Colonization factor antigen (CFA/I) and CS17 challenge strainAscending dose finding study in 5-10 subjects per dose; to identify the dose able to give a diarrheal attack rate greater than or equal to 80%.
3287838|NCT00564564|Experimental|Quetiapine augmentation|Quetiapine up to 200mg/day plus SSRI at maximum tolerated or recommended dosage
3287839|NCT00564564|Active Comparator|Clomipramine augmentation|Clomipramine up to 150mg/day plus SSRI at maximum tolerated or recommended dosage
3287840|NCT00564551|Active Comparator|2|High dairy intake and calcium supplement. High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.
3287841|NCT00564551|Placebo Comparator|1|Usual diet of low dairy and calcium intake. Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet.
3287842|NCT00564538|Experimental|1|Patients in arm 1 will receive induction with thymoglobulin at time of transplant with delayed initiation of tacrolimus
3287843|NCT00564538|Active Comparator|2|patients in arm 2 will not receive thymo induction at time of transplant and will have immediate initiation of tacrolimus
3287844|NCT00564525|Placebo Comparator|1|
3287845|NCT00564525|Experimental|2|Amitriptyline given
3287846|NCT00564512|Experimental|FCCAM|Fludarabine-Cyclophosphamide-Campath (FCCam) Oral Fludarabine: 40 mg/m2 per os, D1 to D3 Oral Cyclophosphamide: 250 mg/m2/day as one dose at noon, D1 to D3 Campath®: 30 mg sc, D1 to D3 without dose escalation
3287847|NCT00564512|Active Comparator|FCR|"Fludarabine-Cyclophosphamide-Rituximab (FCR)~First course:~Rituximab 375 mg/m2 on D1.~D2 to D4:~oral Fludarabine: 40 mg/m2/day as a single morning dose oral Cyclophosphamide: 250 mg/m2/day as a single dose at noon~Subsequent courses (2 to 6)~Rituximab 500 mg/m2 on D1~D1 to D3:~oral Fludarabine: 40 mg/m2/day as a single morning dose oral Cyclophosphamide: 250 mg/m2/day as a single dose at noon"
3287848|NCT00564486|Placebo Comparator|IV Placebo 100 ml|IV Placebo 100 ml dosed every every 6 hours for 24 hours (4 doses total).
3287849|NCT00564486|Placebo Comparator|IV Placebo 65 ml|IV Placebo 65 ml dosed every every 4 hours for 24 hours (6 doses total).
3287850|NCT00564486|Experimental|IV Acetaminophen 1 gm|IV Acetaminophen 1 gm dosed every every 6 hours for 24 hours (4 doses total).
3287851|NCT00564486|Experimental|IV Acetaminophen 650 mg|IV Acetaminophen 650 mg dosed every every 4 hours for 24 hours (6 doses total).
3287852|NCT00564473||A|patients hospitalized in the Department of Internal Medicine of the Shaare Zedek Medical Center, Jerusalem, Israel.
3287853|NCT00564460|Active Comparator|1|Finasteride 5 mg PO once daily for 8 weeks prior to TURP
3287854|NCT00564460|Placebo Comparator|2|Placebo
3287855|NCT00564447|Experimental|Azithromycin-30 minutes Post dose|
3287856|NCT00564447|Experimental|Azithromycin-2 hours post dose|
3287857|NCT00564447|Experimental|Azithromycin-12 hours post dose|
3287858|NCT00564447|Experimental|Azithromycin-24 hours post dose|
3287859|NCT00564447|Experimental|Moxifloxacin-30 minutes post dose|
3287860|NCT00564447|Experimental|Moxifloxacin-2 hours post dose|
3287861|NCT00564447|Experimental|Moxifloxacin-12 hours post dose|
3287862|NCT00564447|Experimental|Moxafloxacin-24 hours post dose|
3287863|NCT00564421|Experimental|Epinastine low concentration:low dose volume|
3287864|NCT00564421|Experimental|Epinastine low concentration:high dose volume|
3287865|NCT00564421|Experimental|Epinastine high concentration:low dose volume|
3287866|NCT00564421|Experimental|Epinastine high concentration:high dose volume|
3287867|NCT00564421|Placebo Comparator|Placebo nasal spray|
3287868|NCT00564408|Experimental|I|
3287869|NCT00564395|Experimental|Insulin Detemir+RAI, then Insulin Detemir and RAI separately|Participants first received, Insulin Detemir mixed with RAI, twice daily as subcutaneous injection for 10 days. Then they received Insulin Detemir and RAI as separate subcutaneous injections, twice daily for the next 10 days.
3287870|NCT00564395|Active Comparator|Insulin Detemir and RAI separately, then Insulin Detemir+RAI|Participants first received Insulin Detemir and RAI as separate subcutaneous injections, twice daily for 10 days. Then they received Insulin Detemir mixed with RAI, twice daily as subcutaneous injection for the next 10 days.
3287871|NCT00564382|Other|1|Patients with ACS in the emergency department and primary tests (ECG, TNT) negative for myocardial ischemia
3287872|NCT00564369|Experimental|1|2006 CDC recommendations
3287873|NCT00564369|Active Comparator|2|Prior CDC recommendations
3287874|NCT00564356|Other|A|patients under coumadin and antiaggregants operated by phacoemulsification
3287875|NCT00564343||ChSt, water training, Observation|Subjects suffer from chronic hemiplegia (a year or more post stroke) that upon questioning was judged to meet the following inclusion criteria: (a) able to stand independently 90 seconds; (b) able to walk 10 meters (with cane if necessary); (c) able to understand verbal instructions. The exclusion criteria will be: (a) Serious visual impairment; (b) Inability to ambulate independently (cane acceptable, walker not). (c) Severely impaired cognitive status (score less then 24 in Mini Mental State Examination). (d) Persons with impaired communication capabilities.
3287876|NCT00564330|Active Comparator|esomeprazole|Esomeprazole 20mg twice daily
3287877|NCT00564330|Placebo Comparator|placebo|Placebo tablet twice daily
3287881|NCT00564317|Experimental|4 Meditation/Relaxation + KIDNET|Med/Relax according to protocol, 5 months waiting time, KIDNET according to protocol
3287882|NCT00564291||1|Healthy volunteers
3287883|NCT00564291||2|CSME secondary to diabetic retinopathy
3287884|NCT00564291||3|ARMD with CNV before and after therapy
3287885|NCT00564291||4|ARMD atrophic
3287886|NCT00564291||5|Retinal vein occlusion
3287887|NCT00564291||6|retinitis pigmentosa
3287888|NCT00564291||7|vitreoretinal proliferation
3287889|NCT00564278|Active Comparator|Standard antidepressant therapy|Participants will receive standard antidepressant therapy, including selecting among 9 FDA-approved antidepressants from several classes.
3287890|NCT00564278|Experimental|Motivational antidepressant therapy|Participants will receive motivational antidepressant therapy, including selecting among the same list of 9 FDA-approved antidepressants from several classes as in the control arm.
3287891|NCT00564265||GIST|GIST from all gastrointestinal origins: esophagus, stomach, duodenum, jejunum, ileum, colon and rectum
3287892|NCT00564239|Experimental|A|
3287893|NCT00564239|Active Comparator|B|
3287894|NCT00564239|No Intervention|C|
3287895|NCT00564226|Experimental|SSR240600C Dose Level 1|
3287896|NCT00564226|Experimental|SSR240600C Dose Level 2|
3287897|NCT00564226|Experimental|SSR240600C Dose Level 3|dose level 3
3287898|NCT00564226|Active Comparator|Tolterodine|
3287899|NCT00564226|Placebo Comparator|Placebo|
3287900|NCT00564213|Experimental|1|A single intraoperative topical application of mitomycin C 0.02% for 15 seconds
3287901|NCT00564213|Experimental|2|A single intraoperative topical application of mitomycin C 0.02% for 30 seconds
3287902|NCT00564187|Active Comparator|1|"Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
3287903|NCT00564187|Active Comparator|2|• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B
3287904|NCT00564174|Experimental|a|
3287905|NCT00564174|Active Comparator|b|Low dose aspirin only
3287906|NCT00564161||1|
3287907|NCT00564161||2|
3287908|NCT00564148|Experimental|A,1, II|
3287909|NCT00564135|Experimental|A B C|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
3287910|NCT00564122||All subjects|
3287911|NCT00564096|Active Comparator|Real TMS|10 patients will be given 20 minutes stimulation with real deep H1-Coil TMS to the Left Temporo-parietal Cortex in frequency of 1 Hz with 120% motor threshold during 20 consecutive working days.
3287912|NCT00564096|Placebo Comparator|Sham & real TMS|10 patients will be given 20 minutes stimulation with sham deep H1-Coil TMS to the Left Temporo-parietal Cortex in frequency of 1 Hz with 120% motor threshold during 10 consecutive working days, and thereafter 20 sessions of real TMS with the same parameters (=Left Tempor-oparietal Cortex in frequency of 1 Hz with 120% motor threshold).
3287913|NCT00564070|Active Comparator|Enhanced treatment as usual|Enhanced treatment as usual plus single-session life-steps treatment
3287914|NCT00564070|Experimental|CBT-AD|Enhanced treatment as usual plus multiple-session CBT treatment (CBT-AD)
3287915|NCT00564057|Experimental|1|candesartan 8-16 mg once daily
3287916|NCT00564057|Active Comparator|2|lercanidipine 10-20 mg once daily
3287917|NCT00564044|Active Comparator|2|
3287918|NCT00564031|Placebo Comparator|1|
3287919|NCT00564031|Experimental|2|
3287920|NCT00564031|Experimental|3|
3287921|NCT00564031|Experimental|4|
3287922|NCT00564018|Experimental|Detemir|24 subjects randomized to therapy with a combination of insulins detemir and aspart at diagnosis of diabetes.
3287923|NCT00564018|Experimental|Glargine|24 subjects randomized to therapy with a combination of insulins glargine and aspart at diagnosis of diabetes.
3287924|NCT00564018|Experimental|NPH|24 subjects randomized to therapy with a combination of insulins NPH and aspart at diagnosis of diabetes.
3287925|NCT00564005|Experimental|1|constraint-induced therapy
3287926|NCT00564005|Experimental|2|bilateral arm training
3287927|NCT00564005|Experimental|3|combined therapy
3287928|NCT00564005|Active Comparator|Control intervention|
3287929|NCT00563992|Experimental|1|Participants will take lithium for 12 months
3287930|NCT00563992|Experimental|2|Participants will take valproate for 12 months
3287931|NCT00563979|Active Comparator|1|VitaluxPlus®
3287932|NCT00563979|Active Comparator|2|Omega 3
3287933|NCT00563953|Experimental|1|Primary chemotherapy regimen consisting of four cycles of pegylated-liposomal doxorubicine at 35 mg/m² IV plus CPM 600 mg/m² on Day 1 every 4 weeks followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
3287934|NCT00563940||1|
3287935|NCT00563940||2|
3287936|NCT00563914|Experimental|1|
3287937|NCT00563914|Active Comparator|2|
3287938|NCT00563901||1|Adults with a high risk for high blood pressure from the ALLHAT study
3287939|NCT00563888|Experimental|A|Narrative Exposure Therapy (NET)
3287940|NCT00563888|No Intervention|B|Waitinglist Control Group
3287941|NCT00563836|Experimental|1|
3287942|NCT00563797|Experimental|Mecamylamine|Mecamylamine is a noncompetitive, high-affinity nAChR antagonist with low selectivity for the alpha-7 receptor. Those receiving mecamylamine started at 2.5mg once daily (second dose was placebo). The dose was increased to 5.0 mg twice daily over 3 weeks.
3287943|NCT00563797|Placebo Comparator|Placebo|Placebo capsules were prepared by the pharmacy and were identical in size and color to the medication capsules.
3287944|NCT00563784|Experimental|Erlotinib + Paclitaxel + Carboplatin|Oral Erlotinib 150 mg daily + Paclitaxel 45 mg/m^2 by vein weekly + Carboplatin 2 AUC by vein weekly and Radiation Therapy 63 GY/35 fractions for 7 weeks cycles
3287945|NCT00563745|Experimental|Telemedicine|Patients were submitted to a Telemedicine program for 1 year
3288006|NCT00563004|Placebo Comparator|B|PATIENTS RECEIVE PLACEBO PILLS
3287946|NCT00563745|No Intervention|Control group|Patients were submitted to usual care (i.e: educational plan and outpatient visits every 3 months)
3287947|NCT00563706|Experimental|1|
3287948|NCT00563706|Active Comparator|2|4mg/day
3287949|NCT00563706|Placebo Comparator|3|matching placebo
3287950|NCT00563693|Experimental|A|The patients use ASV
3287951|NCT00563693|Active Comparator|B|Patients without ASV
3287952|NCT00563680|Experimental|Exploratory Cohort|If a total of two or more responses (partial and complete) in EFTs/DSRCTs are documented in this or the ongoing phase 1 study (20050118), then the study will allow enrollment of up to 10 additional EFT/DSRCT subjects who have been exposed to prior anti-IGF-1R targeting therapy.
3287953|NCT00563680|Experimental|Main Cohort|Subjects with relapsed Ewing's Family Tumors (EFTs) and Desmoplastic Small Round Cell Tumors (DSRCTs) who have not received prior anti-IGF-1R therapy will receive AMG 479 at 12mg/kg.
3287954|NCT00563641|Experimental|1|Early NCPAP plus very early surfactant
3287955|NCT00563641|Active Comparator|2|NCPAP alone
3287956|NCT00563602|Active Comparator|2|Standard Therapy: Endoscopic ligation (LEV) + Nadolol + Isosorbide mononitrate (MNI)(drugs carefully titrated until achieve maximum tolerated dose)
3287957|NCT00563602|Experimental|1|"Hemodynamic guided therapy:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
3287958|NCT00563576|Experimental|Depo-Provera/Femring|Subjects will receive an estrogen vaginal ring (100 mcg) during the first 90 days of Depo-Provera use.
3287959|NCT00563576|Other|Depo-Provera Injection Alone|Subjects will receive Depo-Provera intramuscular injection.
3287960|NCT00563563|Experimental|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg daily subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
3287961|NCT00563537|Experimental|1|18F-X PET Scan imaging
3287962|NCT00563524|Placebo Comparator|1|
3287963|NCT00563472|Active Comparator|1|10 mg estetrol
3287964|NCT00563472|Active Comparator|2|20 mg estetrol
3287965|NCT00563472|Active Comparator|3|20 mg estetrol and 150 microg desogestrel
3287966|NCT00563472|Active Comparator|4|20 mg E4 and 200 mg progesterone
3287967|NCT00563459|Experimental|001|carisbamate 400-1200 mg/day for 12 months
3287968|NCT00563459|Active Comparator|002|topiramate 200-400mg/day for 12 months
3287969|NCT00563459|Active Comparator|003|levetiracetam 1000-3000mg/day for 12 months
3287970|NCT00563433|Active Comparator|1|an oral antibiotic (ofloxacin 400 mg) twice a day and a placebo vehicle topical cream twice a day for 14 days, extended up to 28 days if clinically warranted
3287971|NCT00563433|Active Comparator|2|an oral placebo twice a day and MSI-78 1%/2% Topical Cream twice a day for 14 days, extended up to 28 days if clinically warranted.
3287972|NCT00563394|Active Comparator|1|an oral antibiotic (ofloxacin 400 mg) twice a day and a placebo vehicle topical cream twice a day for 14 days, extended up to 28 days if clinically warranted
3287973|NCT00563394|Active Comparator|2|an oral placebo twice a day and MSI-78 1%/2% Topical Cream twice a day for 14 days, extended up to 28 days if clinically warranted.
3287974|NCT00563381|Active Comparator|Tiotropium + Placebo|patients inhale Tiotropium 18mcg once daily via HandiHaler and Placebo MDI twice daily
3287975|NCT00563381|Active Comparator|Salmeterol + Placebo|patients inhale Salmeterol 50mcg twice daily via MDI and Placebo HandiHaler once daily
3287976|NCT00563368|Experimental|VI-0521 Top|VI-0521; high dose phentermine/topiramate
3287977|NCT00563368|Experimental|VI-0521 Mid|VI-0521; mid dose phentermine/topiramate
3287978|NCT00563368|Active Comparator|TPM 46|mid dose topiramate
3287979|NCT00563368|Active Comparator|TPM 92|high dose topiramate
3287980|NCT00563368|Active Comparator|PHEN 7.5|mid dose phentermine
3287981|NCT00563368|Active Comparator|PHEN 15|high dose phentermine
3287982|NCT00563368|Placebo Comparator|Placebo|
3287983|NCT00563316|Experimental|Panitumumab + Irinotecan|Participants received panitumumab 6 mg/kg and irinotecan 180 mg/m² administered by intravenous (IV) infusion every 2 weeks until disease progression or intolerance of panitumumab, irinotecan or both.
3287984|NCT00563303|Experimental|H|Hydrocortisone
3287985|NCT00563303|Placebo Comparator|P|Treatment by NaCl (placebo)
3287986|NCT00563290|Experimental|Arm I (dasatinib 100 mg PO BID)|Patients receive 100 mg dasatinib PO BID on days 1-28
3287987|NCT00563290|Experimental|Arm II (dasatinib 70 mg PO BID)|Patients receive 70 mg dasatinib PO BID on days 1-28
3287988|NCT00563264|Active Comparator|1|Participants receive monthly newsletter (for 10 months) including general health and reading information for child and mother and incentives for completing the baseline and 2 follow-up assessments
3287989|NCT00563264|Experimental|2|Mothers and preschoolers in the intervention group will receive monthly mailed family kits that encourage interactive mother/child exercises for healthy lifestyle change. Mailings are supported by counseling calls and two in-person motivational/informational group sessions. The content of the intervention addresses parenting skills, healthy eating, and physical activity. Families can earn $40 for returning postcards describing their activities in the past month.
3287990|NCT00563238|No Intervention|Control|
3287991|NCT00563238|Active Comparator|Metoprolol|
3287992|NCT00563212|Experimental|A1|
3287993|NCT00563186|Experimental|A|Hospital admission to a ward with novel infection control design features (e.g., abundance of sinks, predominance of private rooms, absence of shared bathrooms/curtains, etc.)
3287994|NCT00563186|No Intervention|B|Hospital admission to a ward with traditional design features.
3287995|NCT00563173|Other|1|Low dose
3287996|NCT00563173|Other|2|Medium dose
3287997|NCT00563173|Other|3|High dose
3287998|NCT00563147|Experimental|A|tivozanib (AV-951) plus temsirolimus
3287999|NCT00563082||1|SLE participants positive for both APA and CHD
3288000|NCT00563082||2|Normal participants with a high titer of APA
3288001|NCT00563056|Experimental|Flutiform|2 puffs 50/5 or 125/5 mcg
3288002|NCT00563056|Active Comparator|Flixotide plus Foradil|Flixotide 2 puffs 50 or 125 mcg; Foradil 1 puff 12 mcg
3288007|NCT00562991||FeNO group|asthma patients, exhaled NO is used to monitor asthma
3288008|NCT00562991||Symptom group|asthma patients, exhaled NO is not used to monitor asthma
3288009|NCT00562978|Experimental|Treatment|"Preparation for transplantation: Peripheral blood stem cells (PBSCs) are collected via leukapheresis. Samples are analyzed by cytogenetic studies, immunophenotyping, and gene rearrangement. Patients with an adequate number of collected CD34-positive cells (≥ 3 times 10^6 /kg) proceed to radioimmunotherapy.~Radioimmunotherapy: Patients receive yttrium Y 90 ibritumomab tiuxetan IV on days -21 and -14. Patients undergo bone marrow biopsy and dose estimation on day -7.~Chemotherapy: Patients receive etoposide IV on day -4 and cyclophosphamide IV over 2 hours on day -2.~Transplantation: Patients undergo reinfusion of PBSCs on day 1.~Growth factor therapy: Patients receive filgrastim (G-CSF) IV beginning on day 1 and continuing until blood counts recover.~Treatment continues in the absence of disease progression or unacceptable toxicity."
3288010|NCT00562965|Experimental|A|Subjects will receive rituximab intravenously at a dose level of 375 mg/m² on day 1 of each cycle followed by inotuzumab ozogamicin administered intravenously at a dose level of 1.8 mg/m2 on day 2. The sequence will be repeated every 28 days.
3288011|NCT00562965|Active Comparator|B|Subjects will receive the investigator's choice from the following rituximab-containing regimens: R-CVP or R-FND. The investigator's choice of therapy will be administered every 21 days. Dosing for R-CVP will be intravenous rituximab at a dose of 375 mg/m2 on day 1, intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1, intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1, and oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5. Dosing for R-FND will be as follows: rituximab 375 mg/m2 intravenous on day 1, mitoxantrone 10 mg/m2 intravenous on day 2, fludarabine 25 mg/m2 intravenous on days 2 through 4 and oral dexamethasone 20 mg/day on days 1-5.
3288012|NCT00562952|Active Comparator|1|Patient will receive cardiac therapy to decrease NT-proBNP levels. This will be primarily RAAS-Antagonists and Betablocker. Blood pressure will be lowered to target values. A decrease of NT-proBNP is also known form life-style changes. Thus the patient will be educated to be trained
3288013|NCT00562952|Placebo Comparator|2|Patients will be followed 2 years. Care will be given by the responsible unit ( Dept.of Endocrinology) as clinical appropriate. Event rates will be obtained. After one year NT-proBNP will be measured.
3288014|NCT00562939|Experimental|A|1 mg CpG 7909 + pneumococcal vaccines
3288015|NCT00562939|Placebo Comparator|B|Pneumococcal vaccines
3288016|NCT00562913|Experimental|Arm 1|
3288017|NCT00562900|Active Comparator|A, robotic|
3288018|NCT00562900|Active Comparator|B, laparoscopic|
3288019|NCT00562887|Placebo Comparator|1|
3288020|NCT00562887|Experimental|400 mg|
3288021|NCT00562887|Experimental|700mg|
3288022|NCT00562874|Experimental|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months.
3288023|NCT00562874|Active Comparator|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy flour as an ingredient for 5 days each week for 12 months.
3288024|NCT00562874|Sham Comparator|Wheat Biscuit|75 women and one of their children will receive a biscuit containing pm;u wheat flour as a source of protein as an ingredient for 5 days each week for 12 months.
3288025|NCT00562861|Active Comparator|citalopram + mood stabilizer|All patients are on baseline mood stabilizers and are randomized to receive citalopram or placebo. In this arm, they are randomly assigned to citalopram.
3288026|NCT00562861|Placebo Comparator|placebo + mood stabilizer|All patients are on baseline mood stabilizers and are randomized to receive citalopram or placebo. In this arm, they are randomly assigned to placebo
3288027|NCT00562848|Experimental|Subjects enrolled in single dose escalation cohort|Subjects will receive escalated doses of GSK962040 with a starting dose of 1 milligrams along with placebo in fasted state.
3288028|NCT00562848|Experimental|Subjects enrolled in gastric emptying cohort|Subjects will receive escalated doses of GSK962040 with a starting dose of 1 milligrams along with placebo in fasted state.
3288029|NCT00562848|Experimental|Subjects enrolled in gastro-enteral contractility cohort|Eligible subjects will receive GSK962040 and placebo in the fasted state in crossover manner.
3288030|NCT00562835|Active Comparator|1|Methylprednisolone
3288031|NCT00562835|Placebo Comparator|2|
3288032|NCT00562822|Active Comparator|Arthroscopic Surgery|Arthroscopic surgery optimized with physical and medical therapy
3288033|NCT00562822|Active Comparator|Physical and medical therapy|treatment with physical and medical therapy alone
3288034|NCT00562796||1|Participants with abdominal obesity without growth hormone deficiency
3288035|NCT00562796||2|Participants with abdominal obesity with growth hormone deficiency
3288036|NCT00562796||3|Participants who are lean controls
3288037|NCT00562770|Active Comparator|1|Valacyclovir
3288038|NCT00562770|Active Comparator|2|Valganciclovir
3288039|NCT00562757||A|Post myocardial infarction patients who received an ICD, stratified into low versus high WMI groups
3288040|NCT00562744|Experimental|SIM|Participants complete training and assessment of performance in PALS scenarios using high-fidelity simulator
3288041|NCT00562744|No Intervention|MAN|Participants complete training and assessment of performance in PALS scenarios using mannequin
3288042|NCT00562705|Experimental|1|Growth hormone and nutritional intervention
3288043|NCT00562705|Active Comparator|2|growth hormone
3288044|NCT00562692|Experimental|A|Nesiritide
3288045|NCT00562692|Placebo Comparator|B|Placebo
3288046|NCT00562679||2 groups|The cohort is grouped according to one group with sleep apnea and one group without sleep apnea
3288047|NCT00562666|Experimental|1|Single hepatic intra arterial administration of 500 millions T gamma delta lymphocytes
3288048|NCT00562666|Experimental|2|Single hepatic intra arterial administration of 1000 millions T gamma delta lymphocytes
3288049|NCT00562666|Experimental|3|Single hepatic intra arterial administration of 2000 millions T gamma delta lymphocytes
3288050|NCT00562666|Experimental|4|Single hepatic intra arterial administration of 4000 millions T gamma delta lymphocytes
3288051|NCT00562653||1|infective endocarditis patients before treatment
3288052|NCT00562653||2|infective endocarditis treatment after treatment
3288053|NCT00562653||3|control
3288054|NCT00562640|Experimental|WT1-Specific T Cells|This is a phase I dose escalating trial designed to identify tolerable, clinically active doses of Wilms' tumor gene (WT1) peptide sensitized T cells when administered alone or with nonmyelosuppressive chemotherapy in patients with recurrent or persistent, evaluable WT1+ ovarian, primary peritoneal, or fallopian tube carcinomas.
3288055|NCT00562627|Experimental|LIA IV|Local infiltration analgesia with ropivacaine and adrenaline and intravenous ketorolac and morphine
3288056|NCT00562627|Experimental|LIA IA|Local infiltration analgesia with ropivacaine, adrenaline and ketorolac and morphine
3288057|NCT00562627|Active Comparator|EDA|standard continuous epidural analgesia
3288058|NCT00562614|Experimental|1|SLx-2101
3288059|NCT00562614|Placebo Comparator|2|Comparative Placebo Dose
3288060|NCT00562575|Experimental|1|SLx-4090
3288061|NCT00562575|Placebo Comparator|2|Matching Placebo Dose
3288062|NCT00562562|Other|MOT|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
3288063|NCT00562549|Experimental|1|SLx-2101
3288064|NCT00562549|Placebo Comparator|2|Matching Placebo Dose
3288065|NCT00562536|Experimental|A 1|Delayed umbilical cord clamping 30-45 seconds.
3288066|NCT00562536|No Intervention|A 2|Immediate umbilibcal cord clamping
3288067|NCT00562523|Experimental|Arm 1|
3288068|NCT00562510|Experimental|Raltegravir|
3288069|NCT00562510|Placebo Comparator|Raltegravir matching placebo|
3288070|NCT00562497|Placebo Comparator|2|Placebo
3288071|NCT00562497|Active Comparator|1|Subjects assigned to the active treatment group will receive Prochymal™.
3288072|NCT00562484|Experimental|1|
3288073|NCT00562484|Other|2|
3288074|NCT00562471|Experimental|1|Adhesion Prevention Gel Arm
3288075|NCT00562471|Other|2|Standard of Care Comparator Arm (standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure)
3288076|NCT00562445||1|Peptic bleeding
3288077|NCT00562445||2|Portal hypertension bleeding
3288078|NCT00562445||3|Severe acute pancreatitis
3288079|NCT00562432|Experimental|Plexisyl-AF|Plexisyl-AF implants
3288080|NCT00562432|Sham Comparator|No Treatment|Surgery without experimental treatment
3288081|NCT00562419|Experimental|1|CT-322
3288082|NCT00562419|Experimental|2|CT-322 and irinotecan hydrochloride
3288083|NCT00562406|Active Comparator|1|laser photocoagulation to the retina at the area of edema
3288084|NCT00562406|Experimental|2|intravitreal injection of ranibizumab
3288085|NCT00562406|Experimental|3|laser photocoagulation to the retina at the area of edema and intravitreal injection of ranibizumab
3288086|NCT00562393|Experimental|Overfeeding|4 weeks of 1250 kcal added daily
3288087|NCT00562354|Experimental|1|Stratum 1: >= 65 years of age
3288088|NCT00562354|Experimental|2|Stratum 2: 50 to 64 years of age
3288089|NCT00562341||bariatric surgery|description of enrollees
3288090|NCT00562328|Experimental|Alemtuzumab + Rituximab + GM-CSF|Alemtuzumab + Rituximab + GM-CSF
3288091|NCT00562315|Other|FACBC PET-CT and ProstaScint CT|Participants diagnosed with localized prostate carcinoma with subsequent definitive therapy or suspicion of recurrent cancer will undergo an FACBC PET-CT scan and the ProstaScinct CT.
3288092|NCT00562302|Experimental|Bio-Seal Group|Bio-Seal Plug Implanted
3288093|NCT00562302|No Intervention|Control Group|Control group with no intervention
3288094|NCT00562289|Active Comparator|aspirin|aspirin use like antiplatelet
3288095|NCT00562289|Experimental|anticoagulant|Antivitamins K or rivaroxaban or dabigatran or apixaban
3288096|NCT00562289|Experimental|Devices for PFO closure|Devices for PFO closure
3288097|NCT00562276|Experimental|1|Immediate IUD insertion following suction aspiration between 5 and 12 weeks gestation
3288098|NCT00562276|No Intervention|2|Delayed IUD insertion 2-6 weeks following suction aspiration between 5 and 12 weeks gestation
3288099|NCT00562263|Experimental|Lifestyle Modification|Parents are randomized to attend 12 educational sessions covering strategies to manage children's health behaviors.
3288100|NCT00562263|No Intervention|Control|Teen participates in lifestyle intervention, but parent does not attend parent education sessions
3288101|NCT00562250|Experimental|Arm 1|
3288102|NCT00562250|Active Comparator|Arm 2|
3288103|NCT00562250|Active Comparator|Arm 3|
3288104|NCT00562237|Placebo Comparator|1|
3288105|NCT00562237|Experimental|2|
3288106|NCT00562237|Experimental|3|
3288107|NCT00562237|Experimental|4|
3288108|NCT00562237|Experimental|5|
3288109|NCT00562237|Experimental|6|
3288110|NCT00562237|Experimental|7|
3288111|NCT00562224|Experimental|Arm 1|All study subjects will receive PCI-24781 (study drug).
3288112|NCT00562211|Experimental|1|
3288113|NCT00562211|Active Comparator|2|
3288114|NCT00562198|Experimental|1|Investigational drug Stalevo 200
3288115|NCT00562172|Experimental|1|
3288116|NCT00562172|Active Comparator|2|
3288117|NCT00562159|Placebo Comparator|Placebo|Matching Placebo
3288118|NCT00562159|Experimental|SCH 697243|
3288119|NCT00562146||1|Successful progression of spiral tube to duodenum within 3 days
3288120|NCT00562146||2|Failure of progression to duodenum within 3 days
3288121|NCT00562133|Experimental|1|One Day Treatment with Insulin Glulisine
3288122|NCT00562133|Active Comparator|2|One day Treatment with Human insulin
3288123|NCT00562120|Placebo Comparator|Placebo|
3288124|NCT00562120|Active Comparator|Allegra|
3288125|NCT00562120|Active Comparator|Allegra-D|
3288126|NCT00562120|Experimental|PF-03654746|
3288127|NCT00562107|Experimental|1|AAIsafeR /SafeR Patient randomized with the SafeR switched ON
3288128|NCT00562107|Experimental|2|DDD(R) mode. Patients randomized with the SafeR mode switched OFF
3288129|NCT00562094||Pantoprazole|
3288130|NCT00562081|Placebo Comparator|1|Patient does not have 24/7 access to a Certified Asthma Educator.
3288131|NCT00562081|Active Comparator|2|Patient has 24/7 access to a Certified Asthma Educator.
3288132|NCT00562042||1|Patients diagnosed with acute pulmonary embolism were enrolled in this study.
3288133|NCT00562029|Experimental|DJB patient|Patient has undergone a duodeno-jejunal bypass
3288134|NCT00562016|Experimental|IMPELLA LP 2.5|
3288135|NCT00562016|Active Comparator|IABP Intra-aortic balloon pump|
3288136|NCT00561990|Active Comparator|Nimotuzumab|Nimotuzumab
3288137|NCT00561990|Placebo Comparator|Placebo|Placebo
3288138|NCT00561977|Active Comparator|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
3288139|NCT00561977|Active Comparator|Low Saturated Fat|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal per day.
3288140|NCT00561977|Active Comparator|Combination Diet|Combination low saturated fat (≤7% of total calories);high fiber (>30g fiber per day) -500 kcal from RMR, not less than 1200 kcal/day.
3288141|NCT00561964|Experimental|1|
3288142|NCT00561964|Placebo Comparator|2|
3288143|NCT00561951|Experimental|Fesoterodine fumarate 4 mg (Double-Blind)|
3288144|NCT00561951|Placebo Comparator|Placebo (Double-Blind)|
3288145|NCT00561951|Experimental|Fesoterodine fumarate 8 mg (Double-Blind)|
3288146|NCT00561925|Experimental|nevirapine XR|400 mg QD
3288147|NCT00561925|Active Comparator|nevirapine IR|200 mg BID
3288148|NCT00561912|Experimental|Decitabine + Interferon Alfa-2b|Decitabine 15 mg/m^2 intravenous (IV) daily over one hour for 5 days + Interferon Alfa-2b 0.5 million Units Subcutaneously Twice Daily Continuously, as of Cycle 3, Day 1.
3288149|NCT00561899|Experimental|1|SP+AQ
3288150|NCT00561899|Experimental|2|Piperaquine plus SP arm
3288151|NCT00561899|Experimental|3|Du-Cotecxin
3288152|NCT00561886|Experimental|1|Patients with COPD receiving once 24 µg formoterol
3288153|NCT00561860|No Intervention|1|This pathway represents our standard clinical protocol when a patient has been diagnosed with sleep apnea and CPAP therapy is initiated. After prescription of CPAP, all patients will be seen by our CPAP coordinator and oriented to the device during a 20 minute session. Patients are also provided the telephone number of the CPAP coordinator who can be contacted if any problems or questions arise.
3288154|NCT00561860|Experimental|2|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
3288155|NCT00561834|Experimental|Ranibizumab|To determine the mean change in best corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study testing system at 6 months in NAION patients treated as needed (PRN) with ranibizumab.
3288156|NCT00561821|Experimental|Esmirtazapine 0.5 mg|one placebo tablet daily for 14 days, followed by one 0.5 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
3288157|NCT00561821|Experimental|Esmirtazapine 1.5 mg|one placebo tablet daily for 14 days, followed by one 1.5 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
3288158|NCT00561821|Experimental|Esmirtazapine 3.0 mg|one placebo tablet daily for 14 days, followed by one 3.0 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
3288159|NCT00561821|Placebo Comparator|Placebo|one placebo tablet daily for 14 days, followed by one placebo tablet daily for 16 days, and then one placebo tablet daily for 7 days
3288160|NCT00561808|Experimental|Observational|
3288161|NCT00561795|Experimental|Arm A|Oral Pazopanib 800 mg once a day+ carboplatin area under the concentration-time curve (AUC) 5 intravenous (IV) over 1 hour every 3 weeks + paclitaxel 175 mg/m^2 IV over three hours day one q 3 weeks for six cycles
3288162|NCT00561795|Experimental|Arm B|Oral Pazopanib 800 mg once a day+ carboplatin AUC 6 IV over 1 hour every 3 weeks + paclitaxel 175 mg/m^2 IV over three hours day one q 3 weeks for six cycles
3288163|NCT00561782||Group 1|Spinal cord injured with chronic central neuropathic pain.
3288164|NCT00561782||Group 2|Spinal cord injured without chronic central neuropathic pain.
3288165|NCT00561782||Group 3|Able-bodied without history of chronic pain of any type
3288166|NCT00561782||Group 4|Traumatically Brain Injured with a history of pain that onset after their TBI
3288167|NCT00561769||A|poor responder
3288168|NCT00561756|Experimental|Vaccine Therapy|This single arm, open-label, phase I clinical trial of xenogeneic CD20 DNA vaccination is designed to evaluate its safety in patients with B cell lymphoma. The study is a dose escalation study at three test doses, 0.5 mg, 2 mg and 4 mg of purified plasmid DNA per injection. There will be an initial cohort of three patients receiving a pre-level 1 dose of 0.1 mg/vaccination before proceeding to the three test doses.
3288169|NCT00561730||Pantoprazole|All patients enrolled
3288170|NCT00561717|Experimental|Arm 1|
3288171|NCT00561717|Active Comparator|Arm 2|
3288172|NCT00561717|Active Comparator|Arm 3|
3288173|NCT00561717|Placebo Comparator|Arm 4|
3288174|NCT00561678|Experimental|Precedex|Precedex (Dexmedetomidine)
3288175|NCT00561678|Placebo Comparator|Placebo|Placebo - normal saline
3288176|NCT00561652|Active Comparator|Education + exercise|Education was provided in four, 1-hour sessions to improve patients' understanding of their back problem, reduce unwarranted concern about serious outcomes, & empower them to maintain normal activities & reduce risk of future back problems. Patients were taught that recovery depends on moving & restoring normal function & fitness. Patients were shown stretching & strengthening exercises to perform daily at home to enhance mobility & increase trunk endurance while minimizing spinal load. At follow-up, therapists reviewed exercise form & adherence. Participants allocated to no chiropractic care also were scheduled for 10 weekly 10-15 minute sessions to equalize provider attention vs. the group also receiving chiropractic care & not to provide education, exercise instruction, or therapy.
3288308|NCT00560807|Active Comparator|B|Frequency of Mobilization:1/week Duration of Mobilization Treatment: 3 weeks
3288743|NCT00557388|Experimental|6|Old men 70-85 years, BMI < 27 kg/m2
3288177|NCT00561652|Experimental|Education + exercise + chiropractic|In addition to education & exercise, all participants in this arm will be assigned chiropractic treatment. A minimum of 4 & up to 12 treatments will be provided over 6 weeks, based on patient response (i.e. treatments stopped if symptoms resolve). Each treatment visit will last 10-20 minutes. After 6 weeks, if the treating chiropractor determined that the patient's LBP was continuing to improve but hadn't reached therapy goals defined at baseline, the patient could receive up to 12 additional treatments over the next 6 weeks. Chiropractic treatment was delivered following standardized protocols. Treatment consisted of manual therapies, including SMT and mobilization techniques, with the assistance of light soft tissue techniques as indicated to facilitate the SMT.
3288178|NCT00561626|Experimental|A|
3288179|NCT00561626|Experimental|B|
3288180|NCT00561613|Placebo Comparator|1|SILCS with K-Y Jelly
3288181|NCT00561613|Active Comparator|2|SILCS with N-9
3288182|NCT00561600|Active Comparator|A|ASR™-XL Modular Acetabular Cup System stem
3288183|NCT00561600|Active Comparator|B|Pinnacle™ acetabular shell, with a 28mm or 36mm ULTAMET® metal liner, and a 28mm or 36mm Articul/eze M head.
3288184|NCT00561587|Active Comparator|1|
3288185|NCT00561587|No Intervention|2|
3288186|NCT00561574|Experimental|Esmirtazapine 1.5 mg|Participants receive esmirtazapine 1.5 mg tablets, one tablet administered orally once daily for up to 52 weeks
3288187|NCT00561574|Experimental|Esmirtazapine 3.0 mg|Participants receive esmirtazapine 3.0 mg tablets, one tablet administered orally once daily for up to 52 weeks
3288188|NCT00561561||1|subjects with schizophrenia
3288189|NCT00561561||2|health controls
3288190|NCT00561561||3|family members of subjects with schizophrenia
3288191|NCT00561561||4|family members of healthy controls
3288192|NCT00561548|Other|A|Patients with active Crohn disease and with azathioprine treatment
3288193|NCT00561548|Other|B|Patient with active crohn disease and without azathioprine disease
3288194|NCT00561535|Experimental|A|Lactobacillus FARCIMINIS
3288195|NCT00561535|Placebo Comparator|B|Placebo
3288196|NCT00561522|Experimental|Intervention treatment|Capecitabine
3288197|NCT00561522|No Intervention|No intervention treatment|No other preventive treatment
3288198|NCT00561509||A|SSRIs
3288199|NCT00561509||B|Dual antidepressants
3288200|NCT00561496|Other|Twice daily|Tenofovir gel intravaginal twice daily for 14 days
3288201|NCT00561496|Other|Once daily|Tenofovir gel intravaginal once daily for 14 days
3288202|NCT00561483||Observation|Patients admitted to the hospital with decompensated heart failure
3288203|NCT00561470|Placebo Comparator|Placebo/FOLFIRI|Participants with Metastatic Colorectal Cancer administered Placebo followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
3288204|NCT00561470|Experimental|Aflibercept/FOLFIRI|Participants with Metastatic Colorectal Cancer administered Aflibercept followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
3288205|NCT00561457|Experimental|Iliac Stenting|Stent placement in the iliac artery
3288206|NCT00561444||Quality of Life Study|Prostate cancer patients
3288207|NCT00561431|Active Comparator|1|Standard dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 20 ml/kg/hr
3288208|NCT00561431|Experimental|2|High dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 35 ml/kg/hr
3288209|NCT00561418|Experimental|Vorinostat (SAHA)|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles with the dose escalations.
3288210|NCT00561405|Experimental|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner.
3288211|NCT00561405|Active Comparator|Body weight supported treadmill training|Body Weight Supported Treadmill Training. Participants walk on a treadmill while partially supported with an overhead harness system. Mass repetition of the normal gait cycle is encouraged through the support of the harness, the movement of the treadmill, and the assistance of one or two trainers to position limbs and trunk.
3288212|NCT00561392|Experimental|Rivastigmine 5 and 10 cm^2 patch|For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm^2 patch, with adjustments as necessary for safety and tolerability.
3288213|NCT00561379|Active Comparator|1|
3288214|NCT00561379|Active Comparator|2|
3288215|NCT00561366|Placebo Comparator|1|
3288216|NCT00561366|Experimental|2|
3288217|NCT00561353|Experimental|TMC435 25 mg (Cohort 1/Panel A and B)|Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with peginterferon alpha-2a (PegIFNα-2a) (P) and ribavirin (R) for 21 days (Panel A) OR TMC435 25 mg once daily coadministered with PR for 28 days (Panel B).
3288218|NCT00561353|Experimental|TMC435 75mg (Cohort 1/Panel A and B)|Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily for 21 days with PegIFNα-2a (P) and ribavirin (R) OR TMC435 75 mg once daily coadministered with PR for 28 days (Panel B).
3288219|NCT00561353|Placebo Comparator|Placebo (Cohort 1/Panel A and B)|Treatment-naïve participants received placebo (identical in appearance to TMC435 25/75 mg) once daily for 7 days followed by placebo once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR and Placebo once daily coadministered with PR for 28 days (Panel B).
3288220|NCT00561353|Experimental|TMC435 200 mg (Cohort 2, Panel A and B)|Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR TMC435 200 mg once daily coadministered with PR for 28 days (Panel B).
3288309|NCT00560807|Active Comparator|C|Frequency of Mobilization: 1/week Duration of Mobilization Treatment: 6 weeks
3288310|NCT00560807|Active Comparator|D|Frequency of Mobilization: 1/week Duration of Mobilization Treatment: 12 weeks
3288221|NCT00561353|Placebo Comparator|Placebo (Cohort 2/Panel A and B)|Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed by placebo once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR placebo once daily coadministered with PR for 28 days (Panel B).
3288222|NCT00561353|Experimental|TMC435 75 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
3288223|NCT00561353|Experimental|TMC435 150 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
3288224|NCT00561353|Experimental|TMC435 200 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
3288225|NCT00561353|Placebo Comparator|Placebo (Cohort 4/Panel C)|Treatment-experienced non-responders received placebo once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
3288226|NCT00561353|Experimental|TMC435 200 mg (Cohort 5/Panel D)|Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
3288227|NCT00561340|Experimental|1 Can of Pediasure Supplement Plus Nutritional Counseling|Pediasure and nutritional counseling
3288228|NCT00561340|Active Comparator|Counseling by the Provider on Ways to Encourage Caloric Intake|Behavioral intervention - Nutritional Counseling
3288229|NCT00561327||A|Patients chronically treated with drug losartan
3288230|NCT00561327||B|Patients not chronically treated with losartan
3288231|NCT00561301|No Intervention|1|
3288232|NCT00561288|Experimental|1|2000 mg acetaminophen per day
3288233|NCT00561288|Placebo Comparator|2|2000 mg cornstarch per day
3288234|NCT00561249|Experimental|1|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo.
3288235|NCT00561249|No Intervention|2|No intervention
3288236|NCT00561223|Experimental|1|"This study will examine the hypothesis that iloprost maintains and improves ventilation perfusion matching in patients with COPD as reflected by 1) a constant or reduced alveolar to arterial O2 difference as calculated from the measured arterial blood gases obtained before and after iloprost administration, 2) an improvement in the lung diffusing capacity for carbon monoxide that occurs in the absence of a change in spirometry, 3) an improvement in the ventilatory equivalent for oxygen and CO2 measured by expired gas analysis.~It is anticipated that a positive result in this pilot study would lead to a larger long-term study examining the effect of iloprost on gas exchange, exercise tolerance and quality of life in patients with COPD."
3288237|NCT00561210|Experimental|I|Total enteral tube feeding
3288238|NCT00561210|Active Comparator|II|Total enteral tube feeding
3288239|NCT00561184|Experimental|1|
3288240|NCT00561184|Experimental|2|
3288241|NCT00561171|Experimental|1|high dose
3288242|NCT00561171|Experimental|2|lower dose
3288243|NCT00561158|Experimental|A|
3288244|NCT00561158|No Intervention|2|
3288245|NCT00561145|Experimental|Young men|Energy restriction period
3288246|NCT00561145|Experimental|Elderly men|Energy restriction period
3288247|NCT00561132|Experimental|1|
3288248|NCT00561132|Placebo Comparator|2|
3288249|NCT00561119|No Intervention|Arm 1|Observation after 6 cycles of gemcitabine plus paclitaxel till progression
3288250|NCT00561119|Experimental|Arm 2|Maintenance chemotherapy with gemcitabine plus paclitaxel after 6 cycles of gemcitabine plus paclitaxel till progression
3288251|NCT00561106|Active Comparator|1|
3288252|NCT00561106|Placebo Comparator|2|
3288253|NCT00561093|Experimental|A|Group A (n=25) Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
3288254|NCT00561093|Experimental|B|Group B (n=25) Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND Placebo to imitate pentoxiphylline while undergoing hemodialysis and the following non-dialysis day (6 days per week)
3288255|NCT00561093|Experimental|C|Group C (n=25) Placebo dietary supplement to imitate Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
3288256|NCT00561093|Placebo Comparator|D|Group D (n=25) Placebo to imitate Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND Placebo to imitate pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
3288257|NCT00561080|Experimental|Single Dose of Zostavax|Zostavax 0.65mL intramuscular injection administered on Day 0
3288258|NCT00561080|Experimental|Zostavax - Day 0 and Month 1|Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 1
3288259|NCT00561080|Experimental|Zostavax - Day 0 and Month 3|Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 3
3288260|NCT00561067|Active Comparator|1|Methylprednisolone
3288261|NCT00561067|Experimental|2|Erythropoietin
3288262|NCT00561054|No Intervention|1|CISPLATIN gENCITABINE cETUXIMAB
3288263|NCT00561041|Experimental|1|Brief phone aftercare intervention composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
3288264|NCT00561041|Experimental|2|Individual aftercare therapy - composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
3288265|NCT00561041|No Intervention|3|No intervention
3288266|NCT00561028||1|ST-elevation acute myocardial infarction.
3288267|NCT00561028||2|high-risk unstable angina or non-ST-elevation myocardial infarction.
3288268|NCT00561028||3|known coronary artery disease, either asymptomatic or with stable angina.
3288269|NCT00561028||4|blood donors without known coronary artery disease.
3288311|NCT00560807|Active Comparator|F|Frequency of Mobilization: 2/week Duration of Mobilization Treatment: 3 weeks
3288312|NCT00560807|Active Comparator|G|Frequency of Mobilization: 2/week Duration of Mobilization Treatment:6 weeks
3288313|NCT00560807|Active Comparator|H|Frequency of Mobilization: 2/week Duration of Mobilization Treatment: 12 weeks
3288270|NCT00561015|Experimental|TVR then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 2|Participants who are never treated for chronic hepatitis C (inflammation of the liver) genotype 2 will receive telaprevir (TVR) 750 milligram (mg) tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15. Participants will then be treated with standard treatment regimen of pegylated interferon (Peg-IFN)-alfa-2a and ribavirin (RBV) from Day 15 to Week 26 (standard treatment phase). Each dose of pegylated interferon 180 microgram (mcg) will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 26 weeks.
3288271|NCT00561015|Experimental|TVR with Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 2|Participants who are never treated for CHC genotype 2 will receive TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
3288272|NCT00561015|Active Comparator|Pbo with Peg-IFN-alfa-2a + RBV (Pbo/PR24) - Genotype 2|Participants who are never treated for CHC genotype 2 will receive TVR matching placebo (Pbo) tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
3288273|NCT00561015|Experimental|TVR then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 will receive TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15. Participants will then be treated with standard treatment regimen of Peg-IFN-alfa-2a and RBV from Day 15 to Week 26 (standard treatment phase). Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 26 weeks.
3288274|NCT00561015|Experimental|TVR with Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 received TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
3288275|NCT00561015|Active Comparator|Pbo with Peg-IFN-alfa-2a + RBV (Pbo/PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 will receive TVR matching Pbo tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
3288276|NCT00561002|Experimental|Influenza vaccine Naive/Inadequately Primed|Participants had no more than one previous lifetime dose of influenza vaccine and received two doses of Fluzone®, on Days 0 and 14.
3288277|NCT00561002|Experimental|Influenza Vaccine Primed|Participants had previously received 2 injections of Influenza vaccine in the same season and received a single dose of Fluzone® on Day 0.
3288278|NCT00560989||1|CBD cases
3288279|NCT00560989||2|Beryllium-exposed, non-diseased control subjects
3288280|NCT00560989||3|Sarcoidosis cases
3288281|NCT00560989||4|Sarcoidosis control subjects
3288282|NCT00560976|Experimental|Iron Saccharate (Venofer)|IV Iron Saccharate (Venofer)100 mg
3288283|NCT00560963|Experimental|1 RAD001|
3288284|NCT00560950|Experimental|1st Revaccination Group|
3288285|NCT00560950|Experimental|2nd Revaccination Group|
3288286|NCT00560937|Active Comparator|1|Pregnenolone
3288287|NCT00560937|Placebo Comparator|2|Placebo
3288288|NCT00560911|Other|1Self-management|
3288289|NCT00560911|Other|2 Routine control|
3288290|NCT00560898|Experimental|2|contact lenses disinfected in multipurpose solution
3288291|NCT00560898|Experimental|3|contact lenses disinfected in multipurpose solution
3288292|NCT00560898|Experimental|4|contact lenses disinfected in multipurpose solution
3288293|NCT00560898|Experimental|1|contact lenses disinfected in multipurpose solution
3288294|NCT00560885|Experimental|AtriCure Bipolar System|The AtriCure Synergy Bipolar Ablation system is used to create lesions outlined in the Maze IV procedure during a concomitant open cardiac surgical procedure.
3288295|NCT00560872|Other|1|conventional ablation with manual catheter navigation
3288296|NCT00560872|Active Comparator|2|ablation with remote magnetic catheter navigation
3288297|NCT00560859|Active Comparator|Early AT Surgery|There will be removal of tonsils and adenoids that will be performed within 4 weeks of the baseline visit.
3288298|NCT00560859|Other|Watchful Waiting|Children will be closely monitored and re-evaluated for AT by an otolaryngologist after the primary 7 month monitoring period.
3288299|NCT00560846|Experimental|Nutrition|Pre-operative immunonutritrion, pre-operative glucose load, post-operative early immunonutrition
3288300|NCT00560846|No Intervention|Control|No immunonutrition, no glucose load, no early enteral immunonutrition
3288301|NCT00560833|Placebo Comparator|Placebo|Participants receive placebo, encapsulated tablets, orally (PO), once daily (QD) for up to 12 weeks
3288302|NCT00560833|Experimental|Esmirtazapine 2.25 mg|Participants receive esmirtazapine 2.25 mg, encapsulated tablets, PO, QD for up to 12 weeks
3288303|NCT00560833|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine 4.5 mg, encapsulated tablets, PO, QD for up to 12 weeks
3288304|NCT00560833|Experimental|Esmirtazapine 9 mg|Participants receive esmirtazapine 9 mg, encapsulated tablets, PO, QD for up to 12 weeks
3288305|NCT00560833|Experimental|Esmirtazapine 18 mg|Participants receive esmirtazapine 18 mg, encapsulated tablets, PO, QD for up to 12 weeks
3288306|NCT00560820|Experimental|Deferasirox|30 mg/kg/day
3288307|NCT00560807|No Intervention|A|Zero treatment/3 weeks
3288744|NCT00557388|Experimental|7|Old men 70-85 years, BMI < 27 kg/m2
3288314|NCT00560807|Active Comparator|J|Frequency of Mobilization: 3/week Duration of Mobilization Treatment: 3 weeks
3288315|NCT00560807|Active Comparator|K|Frequency of Mobilization: 3/week Duration of Mobilization Treatment:6 weeks
3288316|NCT00560807|Active Comparator|L|Frequency of Mobilization: 3/week Duration of Mobilization Treatment:12 weeks
3288317|NCT00560807|No Intervention|E|Zero treatment/6 weeks
3288318|NCT00560807|No Intervention|I|Zero treatment/12 weeks
3288319|NCT00560794|Experimental|Blinatumomab|Participants received blinatumomab as continuous intravenous infusion at constant flow rate over 4 weeks followed by a 2 week treatment-free period (defined as one treatment cycle), for up to a maximum of 10 cycles. The initial dose was 15 μg/m^2/day. A dose increase to 30 μg/m^2/day was permitted with evidence for insufficient response to blinatumomab treatment.
3288320|NCT00560781|Active Comparator|1|Pregnenolone
3288321|NCT00560781|Placebo Comparator|2|Placebo
3288322|NCT00560768|Experimental|1|
3288323|NCT00560755|Experimental|ProQuad®|Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.
3288324|NCT00560742|Active Comparator|Control|
3288325|NCT00560742|Experimental|Intramuscular|
3288326|NCT00560742|Experimental|Intracoronary|
3288327|NCT00560729|No Intervention|I|
3288328|NCT00560729|Active Comparator|II|oral nutrition
3288329|NCT00560729|Experimental|III|oral nutrition
3288330|NCT00560729|Experimental|IV|oral nutrition
3288331|NCT00560703|Active Comparator|COL-101 (doxycycline, USP) capsules|COL-101
3288332|NCT00560703|Placebo Comparator|Placebo|Sugar capsule
3288333|NCT00560690|Placebo Comparator|Placebo|standard treatment with pegylated interferon and ribavirin + placebo
3288334|NCT00560690|Experimental|Metformin|standard treatment with pegylated interferon and ribavirin + metformin
3288335|NCT00560664|Experimental|1|Autologous chondrocytes transplantation
3288336|NCT00560664|Active Comparator|2|Mosaicoplasty
3288337|NCT00560651||1|Cross linked eyes
3288338|NCT00560638|Experimental|Loteprednol Etabonate TID|loteprednol etabonate ophthalmic suspension, 0.5%, TID
3288339|NCT00560638|Experimental|Loteprednol Etabonate QID|loteprednol etabonate ophthalmic suspension, 0.5%, QID
3288340|NCT00560638|Placebo Comparator|Vehicle|vehicle of loteprednol etabonate
3288341|NCT00560612|Active Comparator|Paroxetine|Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
3288342|NCT00560612|Placebo Comparator|Placebo|
3288343|NCT00560599|No Intervention|1: Standard of care|Standard of care (no body decolonization regimen) and Standard of care (no environmental decolonization regimen)
3288344|NCT00560599|Experimental|2: Body decolonization regimen|Body decolonization regimen and Standard of care (no environmental decolonization regimen)
3288345|NCT00560599|Experimental|3 Environmental decolonization regimen|Standard of care (no body decolonization regimen) and Environmental decolonization regimen
3288346|NCT00560599|Experimental|4 Body and Environmental decolonization regimens|Body decolonization regimen and Environmental decolonization regimen
3288347|NCT00560586|Experimental|Budesonide|Budesonide for 6 weeks followed by crossover to placebo
3288348|NCT00560586|Placebo Comparator|Placebo|Placebo for 6 weeks followed by crossover to treatment.
3288349|NCT00560573|Experimental|1|
3288350|NCT00560560|Experimental|1|Single arm study
3288351|NCT00560547|Experimental|1|
3288352|NCT00560521|Active Comparator|1|
3288353|NCT00560508|Experimental|Pramipexole Extended Release|patient to receive a tablet containing 0.375 mg Pramipexole ER once a day plus containing 0.125 mg Pramipexole IR placebo twice a day -> a tablet containing 1.5 mg Pramipexole ER three times daily (TID) plus 0.5 mg Pramipexole IR placebo TID
3288354|NCT00560508|Active Comparator|Pramipexole Immediate Release|patient to receive a tablet containing 0.125 mg Pramipexole IR twice a day plus containing 0.375 mg Pramipexole ER placebo once a day -> a tablet containing 0.5 mg Pramipexole IR three times daily (TID) plus 1.5 mg Pramipexole ER placebo TID
3288355|NCT00560482|Active Comparator|A|
3288356|NCT00560482|Placebo Comparator|B|
3288357|NCT00560469||1|Men and Women over age 40 who are obese (BMI>30) and insulin-resistant.
3288358|NCT00560469||2|Men and women over age 40 who are obese (BMI>30) and insulin-sensitive.
3288359|NCT00560456|Experimental|1|snorers
3288360|NCT00560456|Other|2|healthy volonters (control)
3288361|NCT00560456|Experimental|3|young subjects
3288362|NCT00560456|Experimental|4|mature subjects
3288363|NCT00560443|Active Comparator|1|children 4-17 y. old with not compound bone fracture treated with ketorolac
3288364|NCT00560443|Experimental|2|children 4-17 y. old with not compound bone fracture treated with tramadol
3288365|NCT00560430|Active Comparator|T1|Telmisartan 80 mg/d
3288366|NCT00560430|Active Comparator|T2|Telmisartan 160 mg/d
3288367|NCT00560430|Placebo Comparator|P|placebo
3288368|NCT00560417|Active Comparator|ILPS|Insulin Lispro Protamine Suspension (ILPS)
3288369|NCT00560417|Active Comparator|Glargine|Insulin Glargine
3288370|NCT00560404|Experimental|1|
3288371|NCT00560404|Active Comparator|2|
3288372|NCT00560391|Experimental|Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 70 mg QD, lenalidomide, 15 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
3288373|NCT00560391|Experimental|Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 70 mg QD, lenalidomide, 20 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
3288374|NCT00560391|Experimental|Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 100 mg QD, lenalidomide, 20 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
3288375|NCT00560391|Experimental|Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 100 mg QD, lenalidomide, 25 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
3288376|NCT00560391|Experimental|Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, lenalidomide, and dexamethasone in varying doses in 28-day cycles.
3288377|NCT00560378|Experimental|Tacrolimus Ointment 0.1%|
3288378|NCT00560352|Experimental|Dasatinib + Bortezomib + Dexamethasone|Phase I dose escalation study
3288379|NCT00560326|Experimental|1|
3288380|NCT00560313|Experimental|4CMenB|
3288381|NCT00560313|Experimental|MenACWY CRM|
3288382|NCT00560300|Experimental|1|Doxercalciferol + Calcium Carbonate
3288383|NCT00560300|Experimental|2|Doxercalciferol + Sevelamer
3288384|NCT00560300|Experimental|3|Calcitriol + Calcium Carbonate
3288385|NCT00560300|Experimental|4|Calcitriol + Sevelamer
3288386|NCT00560287|Active Comparator|1|Volume assist non-invasive ventilation
3288387|NCT00560287|Active Comparator|2|Pressure Assist mode
3288388|NCT00560274|Experimental|1|
3288389|NCT00560261|Experimental|1:Children with sickle cell disease|"NO-CO inhalation and expiration:~Children with sickle cell disease"
3288390|NCT00560261|Active Comparator|2: Healthy volunteers|"NO-CO inhalation and expiration:~Healthy volunteers"
3288391|NCT00560248||I|Patients presenting to the Emergency Department with chest pain suspected to be of cardiac origin.
3288392|NCT00560235|Experimental|1|
3288393|NCT00560222|Active Comparator|A|This group will receive daily lactoferrin supplementation
3288394|NCT00560222|Placebo Comparator|B|placebo
3288395|NCT00560209|Placebo Comparator|P|
3288396|NCT00560209|Experimental|E2|
3288397|NCT00560209|Experimental|E1|
3288398|NCT00560196||1|Patients with panic anxiety disorder without pain
3288399|NCT00560196||2|Patients with depression without pain
3288400|NCT00560196||3|Healthy controls
3288401|NCT00560183|Experimental|1|
3288402|NCT00560183|Placebo Comparator|2|
3288403|NCT00560170|Experimental|high dose statin|40mg of Simvastatin (n=20)
3288404|NCT00560170|Active Comparator|combination arm|10mg/10mg of Ezetimibe/Simvastatin (n=20)
3288405|NCT00560157|Active Comparator|I|Sondalis HP
3288406|NCT00560157|Experimental|II|Crucial
3288407|NCT00560144|Experimental|1|
3288408|NCT00560144|Experimental|2|
3288409|NCT00560144|Experimental|3|
3288410|NCT00560105|Active Comparator|Acapella|The Active Comparator is the Acapella, a OPEP device
3288411|NCT00560105|Experimental|Lung Flute|The Active Comparator is the Lung Flute, a new indication of this device
3288412|NCT00560092|Experimental|intrathecal magnesium sulfate|
3288413|NCT00560079|Experimental|1|Lithium 900mg/day plus allopurinol 600mg/day
3288414|NCT00560079|Active Comparator|2|
3288415|NCT00560079|Placebo Comparator|3|
3288416|NCT00560066|Experimental|cTIV|Subjects received one vaccination of cell culture-derived influenza vaccine
3288417|NCT00560066|Active Comparator|TIV|Subjects received one vaccination of egg-derived influenza vaccine
3288418|NCT00560014|Experimental|1|Arginine and Canola oil supplemented group
3288419|NCT00560014|Experimental|2|Arginine and Coromega
3288420|NCT00560014|No Intervention|3|Control
3288421|NCT00560001|Experimental|A|Those subjects that receive an MD.2 Medication Dispenser
3288422|NCT00560001|No Intervention|B|Control subjects that do not receive an MD.2 Medication Dispenser, but continue to take their medications utilizing standard care, such as pill boxes, etc.
3288423|NCT00559988|Experimental|Home Monitoring Guided OAC|Home Monitoring is fully enabled and continuous remote surveillance data is available to investigators. Patients will be treated according to a predefined anticoagulation plan, which uses the total duration of AF/AFL combined with patients' CHADS2 score to determine the start, stop, and restart of OAC.
3288424|NCT00559988|Active Comparator|Physician-Directed OAC|"In Control (Group 2), Home Monitoring is active for Safety Net alerts, but the remote AF/AFL data is not revealed to the patient or treating physician. These patients receive physician-directed OAC consistent with current standards of care.~Safety Net data include:~ERI/EOS~Special Implant Status~Implant in Backup Mode (ROM)~VT/ VF Detection Inactive~Emergency Pacing~250 Ω > RV Pacing Impedance > 1500 Ω~Symptomatic VT/VF therapies including both ATP and shock~VT/VF storm~HM transmission failure >3 days"
3288425|NCT00559975|Active Comparator|1|
3288426|NCT00559975|Active Comparator|2|
3288427|NCT00559975|Experimental|3|
3288428|NCT00559975|Experimental|4|
3288429|NCT00559975|Experimental|5|
3288430|NCT00559962|Placebo Comparator|1|Placebo
3288431|NCT00559962|Active Comparator|2|2.5 mg AEGR-733
3288432|NCT00559962|Active Comparator|3|5 mg AEGR-733
3288433|NCT00559962|Active Comparator|4|7.5 mg AEGR-733
3288434|NCT00559962|Active Comparator|5|10 mg AEGR-733
3288435|NCT00559962|Active Comparator|6|5 mg AEGR-733 + 20 mg atorvastatin
3288436|NCT00559962|Active Comparator|7|5 mg AEGR-733 + 145 mg fenofibrate
3288437|NCT00559962|Active Comparator|8|5 mg AEGR-733 + 10 mg ezetimibe
3288438|NCT00559949|Experimental|Arm I|Patients receive oral selumetinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression.
3288439|NCT00559936|Experimental|Topical Avastin 1.0%|Each patient will receive topical Avastin in one eye.
3288440|NCT00559910|Experimental|PH-797804|PH-797804 at four dose levels
3288441|NCT00559910|Placebo Comparator|Placebo|Placebo
3288442|NCT00559897|Experimental|3'-deoxy-3'-[18F]FLT PET & zoledronic acid|"Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid~Single photon emission computed tomography. Patient should receive the dose of zoledronic acid within 48 hrs of the first '3'-deoxy-3'-[18F]FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid."
3288443|NCT00559871|Placebo Comparator|1|One placebo tablet administered tid from Day 1 to 28
3288444|NCT00559871|Active Comparator|2|One 30-mg tablet of Fipamezole tid from Day 1 to 28
3288445|NCT00559871|Active Comparator|3|One 30-mg tablet of Fipamezole tid from Day 1 to 7; and one 60-mg tablet of Fipamezole tid from Day 8 to 28
3288446|NCT00559871|Active Comparator|4|One 30-mg tablet of Fipamezole tid from Day 1 to 7; one 60-mg tablet of Fipamezole tid from Day 8 to 14; and one 90-mg tablet of Fipamezole tid from Day 15 to 28
3288447|NCT00559845|Experimental|Bevacizumab|Participants will receive FEC, followed by paclitaxel, given concomitantly with bevacizumab for approximately 3-12 months.
3288448|NCT00559832|No Intervention|Normoxia|Sleeping in normoxia for 14 nights prior to one night at 4500 m
3288449|NCT00559832|Experimental|Hypoxia|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
3288450|NCT00559819|Active Comparator|Alcohol|Alcohol
3288451|NCT00559819|Placebo Comparator|Placebo|Orange juice
3288452|NCT00559806|Experimental|1|9 healthy elderly males
3288453|NCT00559806|Experimental|2|11 healthy young males
3288454|NCT00559780|Experimental|1|12 weeks of resistance training
3288455|NCT00559780|Experimental|2|12 weeks of neuromuscular electrical stimulation
3288456|NCT00559780|Other|3|12 weeks of standard rehabilitation
3288457|NCT00559754|Experimental|1|
3288458|NCT00559715|Experimental|A|
3288459|NCT00559715|Active Comparator|B|
3288460|NCT00559702|Experimental|1|Natalizumab IV (Participants with secondary progressive multiple sclerosis)
3288461|NCT00559702|Experimental|2|Natalizumab IM (Participants with secondary progressive multiple sclerosis)
3288462|NCT00559702|Experimental|3|Natalizumab SC (Participants with secondary progressive multiple sclerosis)
3288463|NCT00559702|Other|4|Standard of care as determined by the Investigator and Treating Neurologist (Participants with secondary progressive multiple sclerosis)
3288464|NCT00559702|Experimental|5|Natalizumab SC (Participants with relapsing forms of multiple sclerosis)
3288465|NCT00559702|Experimental|6|Natalizumab IV (Participants with relapsing forms of multiple sclerosis)
3288466|NCT00559689||1|receive once-daily administration of inhaled glucocorticosteroids at bedtime
3288467|NCT00559689||2|receive twice-daily administration of inhaled glucocorticosteroids
3288468|NCT00559663|Active Comparator|GT|The green tea group is given initially green tea treatment and then after a washout period of four weeks switched to the dark chocolate treatment.
3288469|NCT00559663|Active Comparator|DC|The dark chocolate group is given initially dark chocolate treatment and then after a washout period of four weeks switched to the green tea treatment.
3288470|NCT00559650|Placebo Comparator|Arm 1|
3288471|NCT00559650|Experimental|Arm 2|
3288472|NCT00559637|Experimental|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month. The starting dose will be 1.2 mcg/kg of body weight. Further dose adjustments will be performed during the study depending on the hemoglobin value. Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
3288473|NCT00559611|Experimental|Endobronchial Ultrasound vs. Mediastinoscopy|"Endobronchial Ultrasound - A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.~Mediastinoscopy - Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS."
3288474|NCT00559585|Active Comparator|Subcutaneous (SC) Abatacept|Participants received 125 mg weekly SC abatacept injections (with an intravenous [IV] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
3288475|NCT00559585|Active Comparator|Intravenous (IV) Abatacept|Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).
3288476|NCT00559572|Experimental|1|Exercise information group
3288477|NCT00559572|Active Comparator|2|General health information group
3288478|NCT00559559|Other|Control Group|Patient Notifier turned OFF
3288479|NCT00559559|Experimental|Treatment group|Patient Notifier turned ON
3288480|NCT00559546|Active Comparator|1|3 weeks of Montelukast and 3 weeks of placebo treatment
3288481|NCT00559546|Active Comparator|2|3 weeks of placebo and 3 weeks of montelukast treatment
3288482|NCT00559533|Experimental|1|
3288483|NCT00559520|Active Comparator|Impact|"patient receiving 3 drinks Impact a day during 5 days before surgery"
3288484|NCT00559520|Experimental|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
3288485|NCT00559507|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3288486|NCT00559494|Experimental|Minocycline|
3288487|NCT00559494|Placebo Comparator|Placebo|
3288488|NCT00559494|Experimental|SCPP augmentation|
3288489|NCT00559494|Sham Comparator|SCPP control|
3288490|NCT00559468|Experimental|Propofol maintenance anesthesia|Propofol maintenance anesthesia, continuous infusion of rocuronium and 4.0 mg/kg Org 25969
3288491|NCT00559468|Experimental|Sevoflurane maintenance anesthesia|Sevoflurane maintenance anesthesia, continuous infusion of rocuronium and 4.0 mg/kg Org 25969
3288492|NCT00559455|Experimental|1|
3288493|NCT00559442|Experimental|1|high altitude exposure without prior acclimatization
3288494|NCT00559429|Active Comparator|C1|
3288495|NCT00559429|Active Comparator|C2|
3288496|NCT00559429|Active Comparator|C3|
3288497|NCT00559429|Active Comparator|C4|
3288498|NCT00559403|Experimental|HIV/STD Sessions|The HIV/STD Risk-Reduction Intervention arm focuses on reducing the risk of STDs, including HIV.
3288499|NCT00559403|Active Comparator|Health Promotion Control Sessions|The Health Promotion Intervention arm focuses on physical activity, diet, and other behaviors linked to risk of heart disease, high blood pressure, stroke, diabetes, and certain cancers, which are all leading causes of morbidity and mortality among South Africans.
3288500|NCT00559390||Pre-PCOS|First degree relatives, either sisters or daughters, of women with Polycystic Ovary Syndrome.
3288501|NCT00559390||Controls|Sisters and daughters of women who do not have PCOS
3288502|NCT00559377|Experimental|Diagnostic FMISO AND FDG PET|Patients receive ^18F FMISO IV over 1 minute followed by PET scanning. Patients undergo a second ^18F FMISO PET scan 4-8 weeks later. Patients who have not had a prior ^18F FDG PET scan as part of their routine clinical management undergo ^18F FDG PET scanning at baseline.
3288503|NCT00559364|Experimental|Viokase® 16|
3288504|NCT00559364|Placebo Comparator|Placebo|
3288505|NCT00559351|Active Comparator|S|esophagectomy
3288506|NCT00559351|Experimental|CHTS|neoadjuvant chemotherapy followed by esophagectomy
3288507|NCT00559351|Experimental|CHRTS|neoadjuvant chemoradiotherapy followed by esophagectomy
3288508|NCT00559338|Active Comparator|1|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
3288509|NCT00559338|Placebo Comparator|2|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
3288510|NCT00559312|Experimental|FSC 250/50|fluticasone 250μg/salmeterol 50μg combination
3288511|NCT00559312|Placebo Comparator|Placebo|matched placebo inhaler
3288512|NCT00559286|Experimental|A|treatment with 80 mg Telmisartan per day for 30 days
3288513|NCT00559286|Active Comparator|B|treatment with 20mg Telmisartan per day for 30 days
3288514|NCT00559273|Experimental|Mircera|Participants will receive Mircera (Methoxy polyethylene glycol-epoetin beta), administered subcutaneously (SC) at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.
3288515|NCT00559273|Active Comparator|Darbepoetin Alfa|Participants will receive darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.
3288516|NCT00559247|Experimental|or Placebo - Dose Panel 1|Oral Suspension, 10 mg
3288517|NCT00559247|Experimental|or Placebo - Dose Panel 2|Oral Suspension 50 mg
3288518|NCT00559247|Experimental|or Placebo - Dose Panel 3|Oral Suspension, 200 mg
3288519|NCT00559247|Experimental|or Placebo - Dose Panel 4|Oral Suspension or Solution, 2.5 to 600 mg
3288520|NCT00559221|No Intervention|1|
3288521|NCT00559208||Children's Aid Societies|Comparing differential response (Wraparound) with usual care
3288522|NCT00559182|Experimental|Parts A and B: MK-8033|Dose Escalation Study
3288523|NCT00559182|Experimental|Part C: MK-8033 +/- omeprazole|Crossover Study
3288524|NCT00559143|Active Comparator|1|DDD(R)-RV pacing
3288525|NCT00559143|Experimental|2|DDD(R)- BIV pacing
3288526|NCT00559117|Experimental|Cohort|
3288527|NCT00559104|Active Comparator|Irradiation in conditioning|total-body irradiation, etoposide, cyclophosphamide, infusion of peripheral blood stem cells, granulocyte-colony stimulating factor (G-CSF), autologous hematologic stem cell transplantation, peripheral blood stem cell transplantation
3288528|NCT00559104|Active Comparator|Carmustine in conditioning|Carmustine, etoposide, cyclophosphamide, infusion of peripheral blood stem cells, granulocyte-colony stimulating factor (G-CSF), autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
3288529|NCT00559091|Experimental|I|Ribavirin
3288530|NCT00559078||CAH|Women diagnosed with CAH (either simple virilizing or salt-losing)
3288531|NCT00559052|No Intervention|1|Baseline measurement. No drug with the liquid meal during perfusion procedure to establish baseline secretion.
3288532|NCT00559052|Experimental|2|The Viokase 16 is to be taken as 3 tablets with the liquid meal during perfusion procedure.
3288533|NCT00559026|Active Comparator|1|
3288534|NCT00559026|Experimental|2|
3288535|NCT00559013|Active Comparator|1|PSD Veritas Collagen Matrix Reinforcement Arm
3288536|NCT00559000|No Intervention|Waitinglist Control|
3288537|NCT00559000|Experimental|KIDNET|
3288538|NCT00558987|Experimental|1|
3288539|NCT00558987|Sham Comparator|2|
3288540|NCT00558961|Experimental|I|Gleevec Chlorambucil
3288541|NCT00558896|Experimental|Relapsed Myeloma (<4 Prior Regimens)|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
3288542|NCT00558896|Experimental|Lenalidomide Refractory Myeloma|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
3288543|NCT00558896|Experimental|Bortezomib/Lenalidomide Refractory/Relapsed Myeloma|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
3288544|NCT00558896|Experimental|Bortezomib/Lenalidomide Relapsed/Refractory Myeloma|"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
3288545|NCT00558896|Experimental|Relapsed Myeloma (< 4 Prior Regimens)|"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
3288546|NCT00558896|Experimental|Relapsed/Refractory Myeloma|"Pomalidomide: 4 mg orally once daily, days 1-21 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
3288547|NCT00558896|Experimental|Relapsed Amyloidosis|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
3288548|NCT00558883|Active Comparator|1|treatment with Acarbose: 2 weeks 1 x 50mg; 2 weeks 3 x 50mg; 16 weeks 3 x 100mg
3288549|NCT00558883|Placebo Comparator|2|treatment with placebo: 2 weeks 1 x 50mg 2 weeks 3 x 50mg 16 weeks 3 x 100mg
3288550|NCT00558870|Active Comparator|Morphine Only|"Morphine - Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain."
3288551|NCT00558870|Active Comparator|Morphine + Methadone|"Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain.~1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)"
3288552|NCT00558857|Active Comparator|DSM|Treatment using DSM to guide ablation
3288553|NCT00558844|Active Comparator|A|Arikace at 560 mg
3288554|NCT00558844|Placebo Comparator|B|Matching placebo
3288555|NCT00558831|Active Comparator|Benzoyl Peroxide|Benzoyl Peroxide (BP) 2.5%
3288556|NCT00558831|Active Comparator|Benzoyl Peroxide plus moisturizing lotion|Benzyol Peroxide 2.5% plus moisturizing lotion
3288557|NCT00558805|Active Comparator|1|Usual Care + Family Intervention for Suicide Prevention (FISP)
3288558|NCT00558805|Other|2|Usual Care
3288559|NCT00558792|Experimental|Isovue 370, 70 mL|iopamidol injection 370, 70 mL
3288560|NCT00558792|Experimental|Isovue 370, 80 mL|iopamidol injection 370, 80 mL
3288561|NCT00558792|Experimental|Isovue 370, 90 mL|iopamidol injection 370, 90 mL
3288562|NCT00558779|Experimental|1|
3288563|NCT00558779|Active Comparator|2|
3288564|NCT00558753|Placebo Comparator|1 Placebo|Half of the patients will receive PO placebo for 14 days
3288565|NCT00558753|Experimental|2 Pregabalin|PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
3288566|NCT00558740||healthy volunteers|
3288567|NCT00558701|Active Comparator|Microcurrent Stimulator + Silverlon|Patients receiving active electrical stimulation (15-50 microamps) during treatment of skin donor sites with Silverlon wound contact dressing. Intervention is active electrical stimulation via microcurrent stimulator.
3288568|NCT00558701|Sham Comparator|Silverlon alone|Patients receiving treatment of skin donor sites with Silverlon wound contact dressing alone (i.e., without active electrical stimulation)
3288569|NCT00558688|Experimental|1|Light Therapy
3288570|NCT00558688|Experimental|2|Light Therapy
3288571|NCT00558675|Experimental|1|Single intravenous infusion of AlloStim
3288572|NCT00558675|Experimental|2|Intravenous AlloStim infusion on day 1 and day 7
3288573|NCT00558675|Experimental|3|Intravenous AlloStim infusion on day 1, day 7 and day 14
3288574|NCT00558675|Experimental|4|Intravenous AlloStim infusion on day 1, day 7, day 14 and day 21
3288575|NCT00558662|Active Comparator|1|Coban 2 Layer Compression System
3288576|NCT00558662|Active Comparator|2|Short-Stretch Bandage
3288577|NCT00558649|Experimental|1|Low dose flu vaccine delivered intradermally using microneedles
3288578|NCT00558649|Experimental|2|Medium dose flu vaccine delivered intradermally using microneedles
3288579|NCT00558649|Active Comparator|3|Standard dose flu vaccine delivered intramuscularly with a regular needle
3288580|NCT00558636|Experimental|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), [400 mg, (2 tablets x 200 mg each) orally, twice daily] on Study Days 2-19 and paclitaxel (175 mg/m^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
3288581|NCT00558636|Placebo Comparator|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
3288582|NCT00558623|Placebo Comparator|1|Placebo
3288583|NCT00558597||1|30 patients with stable graft function
3288584|NCT00558597||2|30 patients with acute rejection after lung transplantation
3288585|NCT00558584|Active Comparator|IA/IgG group|immunoadsorption using IA columns and subsequent IgG substitution
3288586|NCT00558584|Placebo Comparator|control group|pseudo-immunoadsorption followed by an intravenous infusion without IgG
3288587|NCT00558571|Placebo Comparator|Placebo|
3288588|NCT00558571|Experimental|BI 10773 low dose|
3288589|NCT00558571|Experimental|BI 10773 medium dose|
3288590|NCT00558571|Experimental|BI 10773 high dose|
3288591|NCT00558558|Other|Fermented Soy Supplement|4 oz Haelan orally twice daily for 8 weeks
3288592|NCT00558532||Surgical|Those subjects undergoing bariatric surgery or abdominal surgery following a previous bariatric surgery.
3288593|NCT00558532||Control|Volunteers who have dietary habits similar to the subjects.
3288594|NCT00558519|Experimental|Treatment (chemotherapy, radiotherapy)|"Patients are given a series of leukemia treatments that are divided into several sequential courses and different chemotherapy combinations of treatment. Please see the Detailed Description section for more information."
3288595|NCT00558506|Experimental|A|Abatacept
3288596|NCT00558493|Experimental|1|switching treatment from lamivudine to clevudine
3288597|NCT00558480|Active Comparator|1|Vitamin A
3288598|NCT00558480|Placebo Comparator|2|Vitamin A placebo
3288599|NCT00558467|Other|Pramipexole|
3288600|NCT00558467|Placebo Comparator|Placebo|
3288601|NCT00558454|Placebo Comparator|1|Placebo
3288602|NCT00558454|Experimental|2|1 mg/kg/day from age 6 weeks to 6 months
3288603|NCT00558454|Experimental|3|2 mg/kg/day from age 6 weeks to 6 months
3288604|NCT00558441|Experimental|1|
3288605|NCT00558402|Experimental|1|Meditation class, 90min/week for 8 weeks, with home assignments, adapted from MBCT program
3288606|NCT00558402|Active Comparator|2|Education
3288607|NCT00558402|Active Comparator|3|Respite care only, 90 mins per week for 8 weeks
3288608|NCT00558376|Active Comparator|1|Ingestion of 3L polyethylene Glycol
3288609|NCT00558376|Active Comparator|2|Ingestion of 2 doses of sodium phosphate 45 cc
3288610|NCT00558363|Experimental|Avodart|Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months.
3288611|NCT00558363|Placebo Comparator|Placebo Arm|Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months.
3288612|NCT00558350||1|lobectomy / segmentectomy in patients with lung cancer
3288613|NCT00558337|Active Comparator|A|
3288614|NCT00558337|Active Comparator|B|
3288615|NCT00558324|Experimental|I|Corneal flaps were created with mechanical microkeratome (Hansatome 160μm (Chiron Vision Corp, Claremont, Calif)
3288616|NCT00558324|Experimental|II|Corneal flaps were created with mechanical microkeratome K3000 130μm ( BD Ophthalmic Systems, Waltham, Mass) .
3288617|NCT00558324|Experimental|III|Corneal flaps were created with microkeratome femtoseconds laser (Intralase Corp, Irvine, Calif.)
3288618|NCT00558311|Experimental|1 A|clazosentan
3288619|NCT00558311|Placebo Comparator|2 B|placebo
3288620|NCT00558285|Experimental|indacaterol/glycopyrrolate 600/100 μg|"Two capsules indacaterol/glycopyrrolate 300/50 μg delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
3288621|NCT00558285|Experimental|indacaterol/glycopyrrolate 300/100 μg|"One capsule indacaterol/glycopyrrolate 300/100 μg and one placebo capsule delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
3288622|NCT00558285|Experimental|indacaterol/glycopyrrolate 150/100 μg|"One capsule indacaterol/glycopyrrolate 150/50 μg and one capsule 50 μg glycopyrrolate delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
3288623|NCT00558285|Active Comparator|indacaterol 300 μg|"One capsule indacaterol 300 μg and one placebo capsule delivered via s single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
3288624|NCT00558285|Placebo Comparator|placebo|"Two placebo capsules delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
3288625|NCT00558272|Experimental|AZD0530 175 mg|AZD0530 (saracatinib) 175 mg once daily
3288626|NCT00558272|Experimental|Zoledronic Acid 4 mg|Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period
3288627|NCT00558259|Experimental|dabigatran etexilate 150 mg BID|Patient to receive dabigatran etexilatate capsules 150 mg twice daily
3288628|NCT00558259|Placebo Comparator|matching placebo twice daily (BID)|Patient to receive dabigatran extexilate matching placebo capsules twice daily
3288629|NCT00558246|Experimental|I|On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.
3288630|NCT00558246|Active Comparator|II|On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.
3288631|NCT00558233|Experimental|Intervention group|
3288632|NCT00558233|Placebo Comparator|Placebo group|
3288633|NCT00558220|Experimental|A|Intensive induction followed by high-dose consolidation with stem cell support ± radiotherapy
3288634|NCT00558207|Experimental|1|ARQ 197
3288635|NCT00558207|Active Comparator|2|Gemcitabine
3288636|NCT00558194|Experimental|1|Standard behavioral weight loss treatment with cognitive and affective skills training
3288637|NCT00558194|Active Comparator|2|Standard behavioral weight loss treatment
3288638|NCT00558181|Experimental|Rituximab, Methylprednisolone|
3288639|NCT00558155|Experimental|SEN|standard enteral nutrition
3288640|NCT00558155|Experimental|IMEN|immunostimulating enteral nutrition
3288641|NCT00558155|Experimental|SPN|standard parenteral nutrition
3288642|NCT00558155|Experimental|IMPN|immunostimulating parenteral nutrition
3288643|NCT00558142|Active Comparator|1|Healthy volunteers will be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
3288644|NCT00558142|Active Comparator|2|Volunteers with CKD III will be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
3288645|NCT00558142|Active Comparator|3|Healthy volunteers will receive a single IV dose of 100mls Visipaque 320 (iodixanol, equivalent to 320 mg iodine/ml). They will then be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
3288646|NCT00558142|Active Comparator|4|Volunteers with CKD III will receive Visipaque 320 during coronary angiography. They will have been randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
3288647|NCT00558129|Experimental|Investigational|X-STOP® PEEK IPD
3288648|NCT00558129|Active Comparator|Control|Laminectomy
3288649|NCT00558116|Experimental|1|Treatment with Dynasplint device
3288650|NCT00558116|No Intervention|2|Control group; does not receive conservative or surgical treatment.
3288651|NCT00558103|Active Comparator|arm 1|Lapatinib
3288652|NCT00558103|Active Comparator|arm2|Pazopanib monotherapy (open label)
3288653|NCT00558103|Experimental|arm3|Lapatinib+ pazopanib
3288654|NCT00558090|Active Comparator|A|patients receive 2,5 mg morphine iv, before the first intervention on the day after admission in the ICU
3288655|NCT00558077|Experimental|A|Metformin plus clomiphene citrate
3288656|NCT00558077|Active Comparator|B|Laparoscopic ovarian drilling
3288657|NCT00558051|Active Comparator|Intradermal administration|Intradermal administration
3288658|NCT00558051|Active Comparator|Intranodal administration|Intranodal administration
3288659|NCT00558051|Active Comparator|Intralymphatic infusion|Intralymphatic infusion
3288660|NCT00558038|Active Comparator|1|
3288661|NCT00558038|Experimental|2|
3288662|NCT00558025|Experimental|Pramipexole Extended Release (ER)|Pramipexole Extended Release (ER) once daily
3288663|NCT00558025|Experimental|Pramipexole Immediate Release (IR)|Pramipexole Immediate Release (IR) once daily
3288664|NCT00558012|Experimental|Active Medication Group|One-time dose: Intravenous Zoledronic Acid 5.0 mg; Vitamin D (800 IU/daily); Calcium 1200 mg/daily (supplement plus diet)
3288665|NCT00558012|Placebo Comparator|Placebo|One-time dose: intravenous saline; Vitamin D (800 IU/daily); 1200 mg calcium (supplement plus diet)
3288666|NCT00557999|Other|Experimental group|Application of a weaning mechanical ventilation protocol
3288667|NCT00557999|No Intervention|Control group|
3288668|NCT00557986|No Intervention|A|Standard Systemic Therapy only group (no primary surgery)
3288669|NCT00557986|Other|B|Surgery group
3288670|NCT00557973|Experimental|XP19986 SR1 10 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 10 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
3288671|NCT00557973|Experimental|XP19986 SR1 20 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 20 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
3288672|NCT00557973|Experimental|XP19986 SR1 30 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 30 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
3288673|NCT00557947|Experimental|I|Dermabond Protape-Incision segments are randomized & patient is own control
3288674|NCT00557947|Active Comparator|II|Intradermal Suture - Incision segments are randomized & patient is own control. Investigator selected suture on the basis of standard local practice.
3288675|NCT00557934|Experimental|1|
3288676|NCT00557921|Experimental|1|
3288677|NCT00557921|Active Comparator|2|
3288678|NCT00557908||VWF/FVIII product infusions|One to three infusions of factor replacement as needed to control bleeding.
3288679|NCT00557882|Active Comparator|mesh|Vaginal reconstructive surgery with synthetic polypropylene mesh
3288680|NCT00557882|Active Comparator|no mesh|Vaginal reconstructive surgery without mesh
3288681|NCT00557856|Experimental|1|
3288682|NCT00557843|Active Comparator|bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
3288683|NCT00557843|Placebo Comparator|Placebo|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
3288684|NCT00557830|Active Comparator|Group A: Escalated Dose|Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen). Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
3288685|NCT00557830|Active Comparator|Group B: Standard Dose|Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen). Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
3288686|NCT00557817|No Intervention|1|No medication given
3288687|NCT00557817|Active Comparator|2|Aranesp 300 µg/15 days
3288688|NCT00557817|Active Comparator|3|Aranesp 300 µg/15 days. Venofer 200 mg on days 28, 42, and 56 after the transplant.
3288689|NCT00557791|Active Comparator|A|Lucentis® (0.5 mg) every 4 weeks.
3288690|NCT00557791|Experimental|B|Bevasiranib (1.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
3288691|NCT00557791|Experimental|C|Bevasiranib (2.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
3288692|NCT00557791|Experimental|D|Bevasiranib (2.5 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
3288693|NCT00557778||1|Receives treatment with rosuvastatin, according to International and National Guidelines on hypercholesterolemia.
3288694|NCT00557778||Group 2|Receives the same treatment as group 1 and information on health improvement, diet and exercises applied to the disease that is being treated. The positive impact of the information upon treatment will be statistically evaluated.
3288695|NCT00557752|Active Comparator|1|Addition to the standard therapy of non-invasive mechanical ventilation. Continuously for the first 24 hours, then trials to discontinuation every 24 hours. Interface adjusted for the associated injuries.
3288696|NCT00557752|No Intervention|2|Standard therapy for severe post-traumatic hypoxia: pain control with epidural anesthesia and oxygen.
3288697|NCT00557739|Experimental|1|CRx-191 (0.1% mometasone furoate + 0.05% nortriptyline HCl)
3288698|NCT00557739|Experimental|2|CRx-191 (0.1% mometasone furoate + 0.1% nortriptyline HCl)
3288699|NCT00557739|Active Comparator|3|0.1% mometasone furoate
3288700|NCT00557739|Active Comparator|4|0.05% nortriptyline HCl
3288701|NCT00557739|Active Comparator|5|0.1% nortriptyline HCl
3288702|NCT00557739|Placebo Comparator|6|Vehicle (placebo)
3288703|NCT00557713|Experimental|A|"-Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)~-Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))~-Surgery (6-8 weeks after last bevacizumab dose)~-Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)"
3288704|NCT00557700|Placebo Comparator|2|Administration of placebo
3288705|NCT00557700|Experimental|1|Administration of inhaled tiotropium bromide
3288706|NCT00557648|Experimental|1|CBT for children only
3288707|NCT00557648|Experimental|2|CBT for children with parental involvement
3288708|NCT00557648|No Intervention|3|No intervention control group: families free to seek treatment on their own
3288737|NCT00557401|Placebo Comparator|Placebo|Placebo for approximately 32 days
3288738|NCT00557388|Experimental|1|Young men 18-30 years, BMI < 27 kg/m2
3288739|NCT00557388|Experimental|2|Young men 18-30 years, BMI < 27 kg/m2
3288740|NCT00557388|Experimental|3|Old men 70-85 years, BMI < 27 kg/m2
3288741|NCT00557388|Experimental|4|Old men 70-85 years, BMI < 27 kg/m2
3288742|NCT00557388|Experimental|5|Old men 70-85 years, BMI < 27 kg/m2
3288709|NCT00557622|Experimental|paroxetine|Drug 2 (20 mg/day or placebo) will be administered once daily after supper for the first two weeks after the run-in phase. If the investigator/subinvestigator judges that a sufficient response is achieved, Drug 2 will be continued for the remaining period. If a sufficient response is not achieved with Drug 2 but treatment is well tolerated, the dose will be titrated to one step higher level until a sufficient response is achieved [i.e., Drug 3 (30 mg/day or placebo) → Drug 4 (40 mg/day or placebo) → Drug 5 (50 m/day or placebo)] at intervals of at least two weeks by once daily administration after supper. Once a sufficient response is achieved, that dose will be continued.
3288710|NCT00557622|Placebo Comparator|placebo|placebo
3288711|NCT00557557|Experimental|IHP with Oxaliplatin and 5-Fluorouracil (5-FU)|Isolated Hepatic Perfusion with Oxaliplatin and 5-Fluorouracil (5-FU)
3288712|NCT00557544|Experimental|1|metoclopramide 0,15 mg/kg and Ketoprofen 1 mg/Kg per os in single dose
3288713|NCT00557544|Active Comparator|2|metoclopramide 0,15 mg/Kg + placebo per os
3288714|NCT00557544|Active Comparator|3|ketoprofen 1 mg/Kg and placebo in single dose
3288715|NCT00557531|Experimental|BL-1040|
3288716|NCT00557518|Active Comparator|1|
3288717|NCT00557518|Placebo Comparator|2|
3288718|NCT00557505|Experimental|PF-03732010|Single Arm study
3288719|NCT00557492|Experimental|Single Arm|"Intervention: Drug: Avastin (bevacizumab) 10 mg/kg, days 1, 15, 29 and 43~Intervention: Drug: Gemzar (Gemcitabine) On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).~Intervention:Radiation: external beam radiotherapy 3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy"
3288720|NCT00557466|Experimental|indacaterol 62.5 μg|Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3288721|NCT00557466|Experimental|indacaterol 125 μg|Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3288722|NCT00557466|Experimental|Indacaterol 250 μg|Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3288723|NCT00557466|Experimental|indacaterol 500 μg|Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3288724|NCT00557466|Active Comparator|formoterol|Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3288725|NCT00557466|Placebo Comparator|placebo|Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3288726|NCT00557453||A|Antibiotic treatment
3288727|NCT00557453||B|Non antibiotic treatment
3288728|NCT00557440|Experimental|Ind/M - FP/Salm - Pbo|"In Treatment Period 1 (Days 1 & 2) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via multi-dose dry powder inhaler (MDDPI), one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 & 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 & 16) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
3288729|NCT00557440|Experimental|FP/Salm - Pbo - Ind/M|"In Treatment Period 1 (Days 1 & 2) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 & 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 & 16) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
3288730|NCT00557440|Experimental|Pbo - Ind/M - FP/Salm|"In Treatment Period 1 (Days 1 & 2) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 & 9) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 & 16) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
3288731|NCT00557427|Experimental|A|hypericum 250mg tablets twice daily for 8 weeks
3288732|NCT00557427|Active Comparator|B|fluoxetine 20mg - 40mg daily for 8 weeks
3288733|NCT00557401|Experimental|XP19986 SR3, 20 mg QD|XP19986, 20 mg QD for approximately 32 days
3288734|NCT00557401|Experimental|XP19986 SR3, 40 mg QD|XP19986, 40 mg QD for approximately 32 days
3288735|NCT00557401|Experimental|XP19986 SR3, 60 mg QD|XP19986, 60 mg QD for approximately 32 days
3288736|NCT00557401|Experimental|XP19986 SR3, 30 mg BID|XP19986, 30 mg BID for approximately 32 days
3288745|NCT00557388|Experimental|8|Old men 70-85 years, BMI < 27 kg/m2
3288746|NCT00557388|Experimental|9|Old men 70-85 years, BMI < 27 kg/m2
3288747|NCT00557388|Experimental|10|Old men 70-85 years, BMI < 27 kg/m2
3288748|NCT00557375||1|Brain tumor patients
3288749|NCT00557375||2|Caregivers of brain tumor patients
3288750|NCT00557362|Active Comparator|1|Topical voriconazole with corneal de-epithelialization
3288751|NCT00557362|Active Comparator|2|Topical voriconazole without corneal de-epithelialization
3288752|NCT00557362|Active Comparator|3|Topical natamycin with corneal de-epithelialization
3288753|NCT00557362|Active Comparator|4|Topical natamycin without corneal de-epithelialization
3288754|NCT00557349|Active Comparator|Omeprazole|40 mg Omeprazole daily
3288755|NCT00557349|Active Comparator|Famotidine|40 mg Famotidine daily
3288756|NCT00557323||1|Patients being treated for hyperphosphatemia with any marketed product
3288757|NCT00557310|Experimental|Teriparatide|20 micrograms (mcg) teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
3288758|NCT00557284|Experimental|1|Montelukast
3288759|NCT00557284|Placebo Comparator|2|
3288760|NCT00557245|Active Comparator|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
3288761|NCT00557245|Active Comparator|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
3288762|NCT00557245|Placebo Comparator|Placebo|Placebo TDF + Placebo FTC/TDF orally, once daily.
3288763|NCT00557219|Placebo Comparator|Placebo|Control group receiving placebo
3288764|NCT00557219|Experimental|Ketanserin|patients receiving ketanserin infusion
3288765|NCT00557219|Experimental|Fenoldopam|patients receiving fenoldopam infusion
3288766|NCT00557206|Experimental|1|This is a single arm trial.
3288767|NCT00557193|Experimental|Arm A (standard risk MLL-G)|See Detailed Description
3288768|NCT00557193|Active Comparator|Arm B (IR/HR MLL-R chemotherapy)|See Detailed Description
3288769|NCT00557193|Experimental|Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)|See Detailed Description
3288770|NCT00557180||BASALT|Participants in the ACRN BASALT study
3288771|NCT00557180||TALC|Participants in the ACRN TALC study
3288772|NCT00557154|Experimental|1|Ultrasound used to visualize peripheral venous anatomy. This guides subsequent attempts at venipuncture.
3288773|NCT00557154|Active Comparator|2|Routine venipuncture using standard methods.
3288774|NCT00557141||1|Age > 18 years, Asthma with irregular or regular use of short acting beta-agonists and / or: Asthma treatment with inhaled steroids, Ability to understand the questionnaire
3288775|NCT00557115|No Intervention|Usual Care|Usual Care (UC): usual follow up care post acute COPD exacerbation
3288776|NCT00557115|Experimental|EPR|Early pulmonary rehabilitation (EPR): pulmonary rehabilitation commenced within 1-week of hospital discharge from an acute COPD exacerbation
3288777|NCT00557102|Other|cetuximab, FOLFIRI|
3288778|NCT00557089|Other|1|This arm will receive the active treatment for 28 days, followed by a 28 day washout period and then the placebo treatment for 28 days.
3288779|NCT00557089|Other|2|This arm will receive the placebo treatment for 28 days, followed by a 28 day washout period and then the active treatment for 28 days.
3288780|NCT00557076|Experimental|Arm 1|high dose of familiar voice stimulation
3288781|NCT00557076|Sham Comparator|Arm 2|sham auditory stimulation
3288782|NCT00557037|Experimental|A|Patients with chemotherapy naïve androgen independent disease
3288783|NCT00557037|Experimental|B|Patients with rising PSA after radical prostatectomy or radiotherapy that are androgen dependent
3288784|NCT00557024|Experimental|1|radiotherapy after RFA
3288785|NCT00557024|Active Comparator|2|RFA alone
3288786|NCT00557011|Experimental|1|NRP104
3288787|NCT00557011|Active Comparator|2|Adderall XR
3288788|NCT00557011|Placebo Comparator|3|Placebo
3288789|NCT00556998|Experimental|1|
3288790|NCT00556972|Experimental|Fecal Incontinence management system|Fecal Incontinence Management System is based on the same principle as fecal pouches. A barrier around anus to ensure adhesion and prevent leakage.
3288791|NCT00556959|Experimental|1|CLONICEL High Dose
3288792|NCT00556959|Experimental|2|CLONICEL Low Dose
3288793|NCT00556959|Placebo Comparator|3|Placebo
3288794|NCT00556946|Other|Combined Photodynamic & Pulsed Dye Laser Treatment|Treatment of Port Wine Stains
3288795|NCT00556933|Experimental|Group 1|Kidney transplant recipients given a single large dose of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression.
3288796|NCT00556933|Experimental|Group 2|Kidney transplant recipients given 4 small doses of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression.
3288797|NCT00556933|Experimental|Group 3|Kidney transplant recipients given a single large dose of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression until tacrolimus is replaced with mycophenolate mofetil after about 6 months.
3288798|NCT00556933|Experimental|Group 4|Kidney transplant recipients given 4 small doses of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression until tacrolimus is replaced with mycophenolate mofetil after about 6 months.
3288799|NCT00556907|Other|1|Patients will receive IORT
3288800|NCT00556894|Experimental|CF101 0.1 mg|CF101 0.1 mg was given orally q12h
3288801|NCT00556894|Experimental|CF101 1 mg|CF101 1 mg was given orally q12h
3288802|NCT00556894|Placebo Comparator|Placebo|Matched placebo was given orally q12h
3288803|NCT00556868|Experimental|A|Breakfast on the first day of intervention, fasting (no breakfast) on the second day of intervention
3288804|NCT00556868|Experimental|B|Fasting (no breakfast) on the first day of intervention, breakfast on the second day of intervention
3288805|NCT00556855|Experimental|A|applied on one hand
3288806|NCT00556855|Placebo Comparator|B|applied on the other hand
3288807|NCT00556842|Active Comparator|1|Participants will undergo total hip arthroplasty.
3288808|NCT00556842|Active Comparator|2|Participants will undergo hemi-arthroplasty.
3288809|NCT00556816|Active Comparator|Conventional outpatient clinic|Conventional outpatient clinic
3288810|NCT00556816|Experimental|On demand outpatient clinic|On demand outpatient clinic
3288811|NCT00556803|Experimental|1|TACE after RFA within one month as an adjuvant therapy
3288812|NCT00556803|Active Comparator|2|RFA alone
3288813|NCT00556790|Other|1|Standard Care
3288814|NCT00556790|Other|2|Fast Track Care
3288815|NCT00556764|Experimental|2 cohorts|"In this observational study 2 cohorts will participate. Cohort 1 will include people with Parkinson disease and Cohort 2 will include healthy volunteers.~A subset of twelve subjects (8 PD and 4 HC) will be enrolled in the [123I] IBVM and SPECT imaging portion of this study"
3288816|NCT00556738|Experimental|nHFPV|Intrapulmonary Percussive Ventilation
3288817|NCT00556738|Active Comparator|nCPAP|Nasal Continuous Positive Airway Pressure ventilation
3288818|NCT00556712|Experimental|Erlotinib|Participants received erlotinib, 150 milligrams (mg), orally (PO), daily from randomization until progressive disease (PD), death, or unacceptable toxicity.
3288819|NCT00556712|Placebo Comparator|Placebo|Participants received a placebo, PO, daily, from randomization until PD, death, or unacceptable toxicity.
3288820|NCT00556699|Experimental|1|
3288821|NCT00556686||1|Individuals with a history of canker sores.
3288822|NCT00556686||2|Individuals with no history of canker sores.
3288823|NCT00556673|Experimental|Indacaterol/mometasone - Placebo|In Treatment Period 1 (Day 1) participants received 2 inhalations of indacaterol maleate 250 μg / mometasone furoate 200 μg once a day in the morning via the Twisthaler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of placebo via the Twisthaler device once a day in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.
3288824|NCT00556673|Experimental|Placebo - indacaterol/mometasone|In Treatment Period 1 (Day 1) participants received 2 inhalations of placebo in the morning via the Twistheler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of indacaterol maleate 250 μg / mometasone furoate 200 μg via the Twisthaler device in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.
3288825|NCT00556660|Experimental|1|SPECT imaging
3288826|NCT00556647||A|Fast-track diagnosis
3288827|NCT00556634|Active Comparator|B|
3288828|NCT00556634|Experimental|A|
3288829|NCT00556621|Other|gemcitabine, cisplatine, radiotherapy|
3288830|NCT00556608|Experimental|Sinovial|3 intra-articular injections of Sinovial®
3288831|NCT00556608|Active Comparator|Sinvisc|
3288832|NCT00556595|Experimental|1|primary electrophysiological approach
3288833|NCT00556595|Active Comparator|2|primary anatomical approach
3288834|NCT00556569|Experimental|Intervention|2 Intervention schools are cluster randomized to receive CHAM JAM (previously known as the Moving Smart Program) in Year 1
3288835|NCT00556569|No Intervention|Wait-Listed Control|2 Wait-Listed Control Schools will receive CHAM JAM (previously known as the Moving Smart Program) in Year 2 of the study
3288836|NCT00556543|Other|Treatment|
3288837|NCT00556504|Experimental|TCM-700C|an add-on drug (2 tablets/t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
3288838|NCT00556504|Placebo Comparator|Placebo|placebo add on(2 tablets/t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
3288839|NCT00556491|Active Comparator|minocycline|
3288840|NCT00556491|Placebo Comparator|placebo|
3288841|NCT00556478|Active Comparator|Double-Blind Active|Double-blind Phase: Subjects will be randomised to PSD502 respectively if the patient meets all the entry criteria.
3288842|NCT00556478|Placebo Comparator|Double-Blind Placebo|Double-blind Phase: Subjects will be randomised to Placebo respectively if the patient meets all the entry criteria.
3288843|NCT00556478|Active Comparator|Open Label Phase|Subjects will all receive PSD502 if they wish to continue in the trial.
3288844|NCT00556465|Experimental|A, 1,III|in this arm patients took 1200 mg N-acetylcysteine
3288845|NCT00556465|No Intervention|B,2, III|
3288846|NCT00556452|Experimental|Clo/BU4|"Study will start at the 2nd dose level of three Clofarabine levels, in combination with Busulfan. The Clofarabine level that each subsequent patient is treated at is determined by a method using continual reassessment.~After pre-conditioning, subjects will receive a peripheral blood stem cell transplant."
3288847|NCT00556439|Experimental|A and C|This is a randomized withdrawal design protocol. All participants will receive abatacept and prednisone (a glucocorticoid) for the first 3 months. Abatacept will be given intravenously on selected days. Prednisone will be started at a dose of 40 to 60mg, then tapered to 20mg by Month 3, and finally further tapered until discontinuation is reached. At Month 3, participants who have achieved remission will be randomly assigned under double-blind conditions to receive monthly infusions of either abatacept or placebo. Participants who are assigned to abatacept at this point will be in Group A for giant cell arteritis and Group C for Takayasu arteritis.
3288848|NCT00556439|Placebo Comparator|B and D|This is a randomized withdrawal design protocol. All participants will receive abatacept and prednisone (a glucocorticoid) for the first 3 months. Abatacept will be given intravenously on selected days. Prednisone will be started at a dose of 40 to 60mg, then tapered to 20mg by Month 3, and finally further tapered until discontinuation is reached. At Month 3, participants who have achieved remission will be randomly assigned under double-blind conditions to receive monthly infusions of either abatacept or placebo. Participants who are assigned to placebo at this point will be in Group B for giant cell arteritis and Group D for Takayasu arteritis.
3288849|NCT00556426|Experimental|Filter|All subjects enrolled to the study are in this arm. All subjects receive a filter.
3288850|NCT00556400|Active Comparator|Lo-ovral|1 tablet of lo-ovral is administered twice a day
3288851|NCT00556400|Placebo Comparator|sugar pill|Sugar pill was provided as a placebo
3288852|NCT00556387|Placebo Comparator|1|Placebo Group receiving Saline Infusion.
3288853|NCT00556387|Experimental|2|Case Group receiving Ketamine infusion.
3288854|NCT00556374|Experimental|Denosumab|Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
3288855|NCT00556374|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
3288856|NCT00556361|Placebo Comparator|1|
3288857|NCT00556361|Experimental|2|
3288858|NCT00556348|Experimental|1|
3288859|NCT00556335|Experimental|manual aspiration|manual aspiration
3288860|NCT00556335|Active Comparator|conventional drainage|conventional drainage
3288861|NCT00556322|Experimental|1|
3288862|NCT00556322|Active Comparator|2|
3288863|NCT00556309||Diagnostic Tool|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
3288864|NCT00556296|Experimental|1|
3288865|NCT00556296|Experimental|2|
3288866|NCT00556296|Experimental|3|
3288867|NCT00556296|Placebo Comparator|4|
3288868|NCT00556283|Experimental|1|STARR
3288869|NCT00556283|Active Comparator|2|Biofeedback
3288870|NCT00556270||Matrix II|
3288871|NCT00556257|Active Comparator|Treatment Arm 1|Treatment Arm 1 will also receive standard of care medications.
3288872|NCT00556257|Experimental|Treatment Arm 2|Treatment Arm 2 will also receive select standard of care medications.
3288873|NCT00556244|Active Comparator|2|
3288874|NCT00556231||1|Children with congenital heart lesions - males/females, ages 6-20, scheduled for a regular stress test
3288875|NCT00556231||2|Children without congenital heart lesions - males/females, ages 6-20, scheduled for a regular stress test
3288876|NCT00556231||3|
3288877|NCT00556231||4|
3288878|NCT00556231||5|
3288879|NCT00556231||6|
3288880|NCT00556218|Other|Tibetan Meditation|
3288881|NCT00556218|Other|No Meditation|
3288882|NCT00556205|Active Comparator|1|Bevacizumab monotherapy 10 mg/kg IV q2 weeks
3288883|NCT00556205|Active Comparator|2|Combination Sunitinib & Bevacizumab Bevacizumab 10 mg/kg IV q2 weeks Sunitinib 50 mg PO QD on 4/2 schedule
3288884|NCT00556192|Active Comparator|1|Rituximab
3288885|NCT00556192|Active Comparator|2|Rituximab + Cyclophosphamide
3288886|NCT00556192|Active Comparator|3|Cyclophosphamide
3288887|NCT00556179|Experimental|1|
3288888|NCT00556166|Experimental|Enterra Therapy|The Enterra Therapy Gastric Stimulator will be used on subjects who have failed all other medical options to treat gastroparesis and all have a gastric stimulator implanted.
3288889|NCT00556153||Phase I|Children, ages 5-15 years with brain tumors
3288890|NCT00556140|Experimental|Major Depression with Psychotic Features|
3288891|NCT00556127|Experimental|1|
3288892|NCT00556114||Optical Coherence Tomography|Optical Coherence Tomography
3288893|NCT00556088|Experimental|Part 1|"Part I Phase I dose escalation trial. LBH589 will be administered orally on Monday and Thursday or Tuesday and Friday each week (twice weekly). Paclitaxel and carboplatin will be administered intravenously every 21 days.~Part II LBH589, paclitaxel, and carboplatin dosing will be determined in the first phase of this study (Phase I). The drug dosages to be administered will be reduced one level from the determined Maximum Tolerated Dose (MTD). In addition, bevacizumab 15 mg/kg will be added to the second portion of this trial."
3288894|NCT00556075|Placebo Comparator|Placebo|Placebo once daily
3288895|NCT00556075|Experimental|25 mg|Proellex 25 mg once daily
3288896|NCT00556075|Experimental|50 mg|Proellex 50 mg once daily
3288897|NCT00556062|Experimental|1: Lot 1|
3288898|NCT00556062|Experimental|2: Lot 2|
3288899|NCT00556062|Experimental|3: Lot 3|
3288900|NCT00556062|Active Comparator|4: control vaccine|
3288901|NCT00556049|Experimental|1|Sunitinib and gemcitabine
3288902|NCT00556036||1|lean healthy women, age 18-45
3288903|NCT00556036||2|overweight healthy women, age 18-45
3288904|NCT00556036||3|women with hypothalamic amenorrhea (have not had a period in three months), age 18-45
3288905|NCT00556036||4|women with anorexia nervosa, age 18-45
3288906|NCT00556023|Experimental|CP-675,206 and gemcitabine|
3288907|NCT00555997|Active Comparator|1|Patients in group 1 will receive Ziprasidone for the full 12 weeks of the study.
3288908|NCT00555997|Active Comparator|2|Patients in Group 2 will receive placebo for the first 6 weeks of the study, then will receive Ziprasidone for the last 6 weeks.
3288909|NCT00555997|Placebo Comparator|3|Patients in Group 3 will receive placebo for the full 12 weeks of the study.
3288910|NCT00555984|Active Comparator|Total Intravenous anesthetic|Intravenous anesthetics (propofol + remifentanil) for maintenance of General Anesthesia
3288911|NCT00555984|Active Comparator|Volatile Anesthetic|Inhalational anesthetics (sevoflurane+remifentanil) for maintenance of General Anesthesia. Patients receive Sevoflurane as a volatile anesthetic and remifentanil as an IV agent for maintenance of general anesthesia.
3288912|NCT00555971|Placebo Comparator|Placebo|Subjects with aspirin exacerbated respiratory disease enrolled and randomized to either omalizumab or placebo (2:1) in a blinded fashion, administered for 16 weeks. The study is double-blind.
3288913|NCT00555971|Active Comparator|Omalizumab|Subjects with aspirin exacerbated respiratory disease enrolled and randomized to either omalizumab or placebo (2:1) in a blinded fashion, administered for 16 weeks. The study is double-blind.
3288914|NCT00555958|Experimental|A|All study subjects will be implanted with the Maestro System, and all will receive VBLOC therapy.
3288915|NCT00555945|Active Comparator|1|Gamma3 intramedullary nail
3288916|NCT00555945|Active Comparator|2|Sliding hip screw
3288917|NCT00555932|Active Comparator|1|The research head ultrasound (HUS) will be performed at the bedside in the Neonatal Unit. The ultrasound examination will be performed within 10 hours time window of the MR and or CT study.
3288918|NCT00555919|Experimental|Arm 1|
3288919|NCT00555919|Experimental|Arm 2|
3288920|NCT00555906|Experimental|1|
3289032|NCT00555074|Experimental|1|Sodium Tungstate
3289033|NCT00555074|Placebo Comparator|2|
3289034|NCT00555061|Experimental|Arm 1|Single Arm Retapamulin 1% Ointment
3288921|NCT00555893|Experimental|Active Drug|"Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:~for weight <=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)"
3288922|NCT00555893|Placebo Comparator|Placebo|Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: <=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
3288923|NCT00555880|Experimental|1|
3288924|NCT00555880|Placebo Comparator|2|
3288925|NCT00555867||1|Standard routine care for breast cancer
3288926|NCT00555867||2|Standard + Intervention arm: standard routine care for breast cancer and additional information material via post
3288927|NCT00555841|Experimental|ALC|I g three times daily
3288928|NCT00555841|Placebo Comparator|Placebo|1 g three times daily
3288929|NCT00555828|Experimental|A1|5 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection
3288930|NCT00555828|Other|A2|5 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
3288931|NCT00555828|Experimental|B1|5 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection
3288932|NCT00555828|Other|B2|3 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
3288933|NCT00555828|Experimental|C1|5 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection
3288934|NCT00555828|Other|C2|2 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
3288935|NCT00555815||1|Extended hygiene measures
3288936|NCT00555815||2|Standard hygiene measures
3288937|NCT00555789|Active Comparator|1|mycophenolic and tacrolimus
3288938|NCT00555789|Experimental|2|mycophenolic and tacrolimus
3288939|NCT00555776|Active Comparator|1|Randomly,half of the subjects are given Gabapentin.
3288940|NCT00555776|Placebo Comparator|2|Randomly,half of the subjects receive placebo.
3288941|NCT00555763|Active Comparator|1|
3288942|NCT00555750|Experimental|eszopiclone (3mg)|active medication (eszopiclone 3mg tablet) by mouth nightly 30 min before bed
3288943|NCT00555750|Placebo Comparator|placebo|identical placebo tablet by mouth nightly 30 min before bed
3288944|NCT00555724|Experimental|BIIB022|
3288945|NCT00555711||Modulated Imaging|Modulated Imaging
3288946|NCT00555698|Experimental|DBS|DBS
3288947|NCT00555685|Active Comparator|A|Group of patients that will receive hypertonic saline solution (NaCl 7,5%)
3288948|NCT00555685|Placebo Comparator|B|Group of patients that will receive placebo
3288949|NCT00555672|Experimental|A|
3288950|NCT00555646|Experimental|1|Each subject's study plaque areas will be assigned by the investigator to two PH-10 treatment plaque areas and one control plaque area.
3288951|NCT00555620|Experimental|A|
3288952|NCT00555620|Experimental|B|
3288953|NCT00555607|Active Comparator|steroid|Group receiving oral prednisolone (0.5 mg/kg bodyweight per day) during 14 days.
3288954|NCT00555607|Placebo Comparator|placebo|Group receiving placebo tablets during 14 days, followed by an open prednisolone treatment (0.5 mg/kg bodyweight per day) during a following 14 days.
3288955|NCT00555594|Active Comparator|A|Patients with corneal neovascularization of infectious etiology, steroid reactors, and know glaucoma or glaucoma suspects. They received one dose of 0.1cc of subconjunctival Bevacizumab (Avastin™ Genentech, Inc, USA) in bulbar conjunctiva, 2 mm from the limbus, according to the location of the vessels.
3288956|NCT00555594|Active Comparator|B|Patients with corneal neovascularization of any cause except for infectious disease. Patients of this group received one application of 0.1cc of subconjunctival Bevacizumab™ + 0.1cc of triamcinolone acetonide (ATLC; Grin laboratories, México city) in bulbar conjunctiva, 2 mm from de limbus, according to the location of the vessels.
3288957|NCT00555581|Experimental|400 mg daily of Imatinib Mesylate|All patients were treated with imatinib mesylate at a target dose of 400 mg daily by mouth for 12 months. Dose modifications and interruptions were made for AE and were recorded. After 12 months of treatment, imatinib was stopped for 3 months. Patients were reassessed and offered entrance to an extension phase of the trial.
3288958|NCT00555568|Experimental|Peer-led Groups|Arm 1 is a 3-month recovery-focused mental health education and support group led by peer facilitators
3288959|NCT00555568|Experimental|Clinician-led Groups|Arm 2 is a 3-month recovery-focused mental health education and support group led by a mental health clinician
3288960|NCT00555568|No Intervention|Treatment as Usual|Arm 3 is treatment as usual (no intervention)
3288961|NCT00555555|Experimental|Coagulation FVIII/VWF|Anti-Hemophilic/von Willebrand Factor VIII (Human) Alphanate SD/HT
3288962|NCT00555542|Experimental|1|Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15.
3288963|NCT00555529||1|
3288964|NCT00555529||2|
3288965|NCT00555516|Active Comparator|1|"The chemotherapy regimen of group 1 is restricted to AC or CAF during the first cycle~Group 1 will receive EW02 for 15 consecutive days during the second cycle~will receive EW02 at 700mg tid/day for 15 consecutive days during the third cycle."
3288966|NCT00555516|Placebo Comparator|2|"The chemotherapy regimen of group 2 is restricted to AC or CAF during the first cycle~Group 2 will receive 15 consecutive days of Placebo~Group 2 will receive EW02 at 700mg tid/day for 15 consecutive days during the third cycle"
3288967|NCT00555503||1|Patients who have risk-reduction mastectomy of any type, per protocol inclusion and exclusion criteria.
3288968|NCT00555490|Experimental|1|
3288969|NCT00555477|Experimental|anastrozole|
3289035|NCT00555048|Experimental|Alemtuzumab|Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant.
3289124|NCT00554281|No Intervention|A|Run in period
3289125|NCT00554281|Experimental|B|
3288970|NCT00555464|Experimental|1|Vincristine is a drug that has been used to treat cancers in children (including infants). It has been effective in treating a small number of infants with hemangiomas, most of whom failed previous therapies including steroids. Vincristine must be administered into a vein. Given the encouraging response data and documented safety record, Vincristine is a good choice for a clinical trial treating infants with complicated hemangiomas.
3288971|NCT00555464|Active Comparator|2|The standard treatment for hemangioma at most centers is oral steroids (Prednisolone). Prednisolone has been used to stop the growth of infantile hemangiomas that are life threatening, that could harm important functions, or are likely to result in severe disfigurement (scarring) without treatment.
3288972|NCT00555438|Experimental|1|patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery
3288973|NCT00555425|Active Comparator|1|Buprenorphine/naloxone maintenance (Mtn) is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services.
3288974|NCT00555425|Experimental|2|Buprenorphine/naloxone detoxification (Dtx) is identical to Mtn for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Buprenorphine/naloxone.
3288975|NCT00555412|Experimental|A - 10 mg loxapine q 4 h x 3 (30 mg total)|
3288976|NCT00555412|Experimental|B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|
3288977|NCT00555412|Experimental|C - 5 mg loxapine q 4 h x 3 (15 mg total)|
3288978|NCT00555412|Placebo Comparator|D - inhaled placebo q 4 h x 3|
3288979|NCT00555399|Experimental|Ph I: Arm 1|Vorinostat plus isotretinoin
3288980|NCT00555399|Experimental|Ph I: Arm 2|Temozolomide plus isotretinoin
3288981|NCT00555399|Experimental|Ph I: Arm 3|Vorinostat plus isotretinoin plus temozolomide
3288982|NCT00555399|No Intervention|Ph II: Arm 1|Non-Surgical
3288983|NCT00555399|Other|Ph II: Arm 2|Surgical Arm
3288984|NCT00555386|Active Comparator|1|6g of chocolate (supplemented with selenium and isoflavones) per day for the duration of one menstrual cycle (25-35 days)
3288985|NCT00555386|Placebo Comparator|2|6g of chocolate (control) per day for the duration of one menstrual cycle (25-35 days)
3288986|NCT00555373|Other|Sirolimus|Single arm
3288987|NCT00555360|Experimental|Arm 1|Veterans with heart failure that can identify an out-of-home informal caregiver
3288988|NCT00555360|Active Comparator|Arm 2|Veterans with heart failure that can identify an out-of-home informal caregiver
3288989|NCT00555347|Active Comparator|Armnodafinil|Armodafinil
3288990|NCT00555347|Placebo Comparator|Placebo|
3288991|NCT00555334|Experimental|1|nucleoid antiviral therapy after RFA
3288992|NCT00555334|Active Comparator|2|RFA only
3288993|NCT00555321|Experimental|Group 1: Basiliximab+Belatacept (MI) + MMF|
3288994|NCT00555321|Experimental|Group 2: Belatacept (MI) + MMF|
3288995|NCT00555321|Experimental|Group 3: Belatacept Less Intensive (LI) + MMF|
3288996|NCT00555321|Other|Group 4: Tacrolimus + MMF|Other
3288997|NCT00555321|Active Comparator|Group 5: Tacrolimus|
3288998|NCT00555308|Experimental|one|undergo EDTU
3288999|NCT00555282|Experimental|1|coated central venous catheter
3289000|NCT00555282|Active Comparator|2|standard central venous catheter
3289001|NCT00555269||MB|
3289002|NCT00555269||IFCG|
3289003|NCT00555256|Experimental|1|Patients will be instructed to take sunitinib and rapamycin every morning for 4 weeks, then to take 2 weeks off. The sunitinib dose will be 25mg in the first cohort and the rapamycin dose will be 2 mg.
3289004|NCT00555243|Experimental|1|Laparoscopic Simulation Education
3289005|NCT00555243|Placebo Comparator|2|
3289006|NCT00555230|Experimental|1|Rosuvastatin
3289007|NCT00555230|Placebo Comparator|2|Placebo
3289008|NCT00555217|Experimental|Combination of ARB and ACEI|Combination of an angiotensin converting enzyme inhibitor (ACEI) with an angiotensin receptor blocker (ARB)
3289009|NCT00555217|Active Comparator|Monotherapy ARB|Mono therapy arm. Standard treatment with angiotensin receptor blocker (ARB)
3289010|NCT00555204|Experimental|A|
3289011|NCT00555204|Experimental|B|
3289012|NCT00555204|Experimental|C|
3289013|NCT00555204|Experimental|D|
3289014|NCT00555204|Experimental|E|
3289015|NCT00555204|Experimental|F|
3289016|NCT00555204|Placebo Comparator|G|
3289017|NCT00555191|Active Comparator|1|PATIENTS IN THIS ARM IS INSTRUCTED IN FRUCTOSE REDUCED DIET FOR A PERIOD OF 3 MONTHS
3289018|NCT00555191|No Intervention|2|these patients use their usual diet
3289019|NCT00555178||1|Patients with polymorphic light eruption without medical photohardening treatment
3289020|NCT00555178||2|Patients with polymorphic light eruption treated with medical photohardening
3289021|NCT00555178||3|Patients with other disorders (including psoriasis) treated with phototherapy
3289022|NCT00555178||4|Normal healthy subjects
3289023|NCT00555165|Experimental|I|
3289024|NCT00555152|Experimental|Arm I (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO once QD for 2-6 weeks until the time of surgery.
3289025|NCT00555152|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 2-6 weeks until the time of surgery.
3289026|NCT00555139|Experimental|GW876008|The subjects will be randomized to one of the six sequences A/B/D A/D/B B/A/D B/D/A D/A/B D/B/A across three treatment periods where A represents placebo, B represents GW876008 and D represents alprazolam.
3289027|NCT00555139|Experimental|GSK561679|The subjects will be randomized to one of the six sequences A/C/D A/D/C C/A/D C/D/A D/A/C D/C/A across three treatment periods where A represents placebo, C represents GSK561679 and D represents alprazolam.
3289028|NCT00555126|Active Comparator|Warming with Forced Air|Forced Air Warming
3289029|NCT00555126|Experimental|Endovascular Warming|Warming with Endovascular Catheter
3289030|NCT00555113||1|pseudoxanthoma elasticum
3289031|NCT00555087|Experimental|A= Nebido|It is and intervention study with 1 arm
3289036|NCT00555022|Experimental|All subjects|Eligible subjects will receive one of the following treatment in cohort I and cohort II in five different treatment periods; Placebo, GSK1160724 (10 micrograms, 50 micrograms or 125 micrograms) and tiotropium bromide
3289037|NCT00555009|Experimental|Genotropin treatment arm|Not Specified
3289038|NCT00555009|Placebo Comparator|Placebo|
3289039|NCT00554996|Other|E. coli 83972 coated urinary catheter|E. coli 83972 coated urinary catheter
3289040|NCT00554983|Placebo Comparator|2|
3289041|NCT00554983|Experimental|1|
3289042|NCT00554970|Other|Treatment 1 then Treatment 2|Subjects received Treatment 1 in period 1 followed by a 7 day washout period and then Treatment 2 in period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.
3289043|NCT00554970|Other|Treatment 2 then Treatment 1|Subjects received Treatment 2 in period 1 followed by a 7 day washout period and then Treatment 1 period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.
3289044|NCT00554970|Other|Treatment 3 then Treatment 4|Subjects received Treatment 3 in period 1 followed by a 7 day washout period and then Treatment 4 period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.
3289045|NCT00554970|Other|Treatment 4 then Treatment 3|Subjects received Treatment 4 in period 1 followed by a 7 day washout period and then Treatment 3 in period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.
3289046|NCT00554957||NBC|All dancers with the National Ballet of Canada will be given the opportunity to participate in the study.
3289047|NCT00554957||TDT|All dancers with the Toronto Dance Theatre will be given the opportunity to participate.
3289048|NCT00554957||KDC|All members of the Kibbutz Contemporary Dance company will be given the opportunity to participate.
3289049|NCT00554957||BDC|All dancers with the Batsheva Dance Company or Ensemble will be given the opportunity to participate.
3289050|NCT00554957||RSB|All dancers with the Royal Swedish Ballet will be given the opportunity to participate.
3289051|NCT00554957||RDB|All dancers with the Royal Danish Ballet will be given the opportunity to participate.
3289052|NCT00554905|Experimental|1|TACE first, then RFA within 2 weeks
3289053|NCT00554905|Active Comparator|2|RFA alone
3289054|NCT00554892|Active Comparator|1|Bowel preparation
3289055|NCT00554892|Experimental|2|without bowel preparation
3289056|NCT00554879|Experimental|1|Acupuncture
3289057|NCT00554879|Sham Comparator|2|Sham Acupuncture
3289058|NCT00554866|Experimental|VLBW between 6 and12 hours after birth|"Blood sample and buccal swab sample. One blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.~Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab."
3289059|NCT00554853|Other|Pioglitazone then placebo|Oral daily pioglitazone 30 mg tablets daily for 2 weeks, followed by 45 mg daily tablets until end of study for 3 months compared to placebo in tablets of equal presentation for 3 months, then crossover after a 2 month washout.
3289060|NCT00554853|Other|placebo then study drug (pioglitazone)|Oral daily placebo for 3 months compared to pioglitazone for 3 months, then crossover after a 2 month washout. Similar doses as mentioned above.
3289061|NCT00554840|Active Comparator|varenicline|
3289062|NCT00554840|Placebo Comparator|placebo|
3289063|NCT00554814|Experimental|3|Blédilait Biofer® milk (1,1mg/100kcal)
3289064|NCT00554814|Experimental|1|Blédilait Biofer® milk (2mg/100kcal)
3289065|NCT00554814|Active Comparator|2|Milk supplemented with ferrous sulphate (2mg/100kcal)
3289066|NCT00554801|Experimental|Blast|The study group includes soldiers who have recently been exposed to a high-explosive blast while stationed in Iraq or Afghanistan. They will be recruited at Walter Reed Army Medical Center, Washington, DC. They will undergo audiological testing.
3289067|NCT00554801|Active Comparator|Control|Control group are subjects matched to the experimental group by age, gender, and hearing loss, but who have not been exposed to a blast. They will undergo the same audiological testing as the experimental group
3289068|NCT00554788|Experimental|Treatment (chemotherapy, radiotherapy, autologous SCI)|"INDUCTION: Patients receive vincristine IV; cisplatin IV; cyclophosphamide IV; and G-CSF SC beginning on day 3 and continuing until blood counts recover.~CONSOLIDATION (stage 4a or 4b disease only): Patients receive carboplatin IV; thiotepa IV; and etoposide IV.~AUTOLOGOUS STEM CELL INFUSION (stage 4a or 4b disease only): Patients undergo autologous stem cell infusion on day 0 and receive G-CSF SC beginning on day 1 and continuing until blood counts recover.~RADIOTHERAPY: Patients with stage 2 or 3 disease (orbital and/or regional involvement) undergo radiotherapy to sites that were initially involved beginning within 42 days after the start of course 4 of induction chemotherapy. Patients with stage 4a or 4b disease undergo radiotherapy to sites initially involved based on response beginning approximately 42 days after autologous stem cell infusion."
3289069|NCT00554775|Experimental|erlotinib hydrochloride|WBRT plus Tarceva (OSI-774, erlotinib) PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
3289070|NCT00554775|Placebo Comparator|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride arm
3289071|NCT00554749|Other|1 Behavioral intervention|Behavioral intervention in all seven subjects Weekly sessions in the home and the kindergarten using defocused communication and stimulus fading interventions
3289072|NCT00554736|Experimental|1|In the first phase, subjects with a history of grass pollinosis, with positive skin tests to grass, will be studied out of season and will be randomized to active treatment for 4 months.
3289073|NCT00554723|Experimental|A|NeuroAid
3289074|NCT00554723|Placebo Comparator|B|NeuroAid matched Placebo
3289123|NCT00554294|Experimental|Intervention group|Intervention schools received water dispensers, drinking bottles and lessons as intervention.
3289271|NCT00552981|Active Comparator|1|
3289075|NCT00554710|Experimental|1|Patients received three infusions of infliximab 5 milligrams per kilogram (weeks 0, 2 and 6) in combination with azathioprine 2-2.5 milligrams per kilogram per day from day 0 onwards. If the patients responded and tolerated both drugs, azathioprine was continued for the duration of the trial. Patients who were intolerant to azathioprine received methotrexate at an initial dose of 25 milligrams administered subcutaneously each week for 12 weeks with dose reduction to 15 milligrams per week thereafter. Following initial therapy, patients who developed worsening symptoms were retreated with additional infusions of infliximab. If symptoms persisted methylprednisolone was initiated and azathioprine or methotrexate was continued.
3289076|NCT00554710|Active Comparator|2|Induction with methylprednisolone (MP) or budesonide (BUD): MP 32 mg/day for 3 weeks was followed by tapering by 4 mg per week to 0; BUD 9 mg per day for 8 weeks with tapering to 0 by 3 mg per week thereafter.Patients who worsened during the tapering had the dose increased to the initial dose and tapered again. If patients worsened, azathioprine (2-2.5 mg per day) was introduced. Patients who relapsed following withdrawal of steroids received a second course in combination with azathioprine. For patients who failed 4 weeks of steroids, MP dose was given at 64 mg/day for 2 weeks, tapered by 8 mg per week; azathioprine was added. Patients who remained symptomatic despite 16 weeks of azathioprine received infliximab (5 mg/kg IV at weeks 0, 2 and 6). Patients who relapsed despite methotrexate or those intolerant to both azathioprine and methotrexate also received infliximab, without antimetabolite therapy. Infliximab was repeated upon relapse of symptoms in these patients.
3289077|NCT00554697||1|
3289078|NCT00554697||2|
3289079|NCT00554671|Experimental|Pharmacist-led Group Visits|Algorithm driven medication titration, Behavioral: Monitoring, Behavioral: Group support, Behavioral: Self efficacy
3289080|NCT00554671|No Intervention|Usual Care|Patient continues on usual care for diabetes
3289081|NCT00554658|Active Comparator|A|Patients will be taken quetiapine for the treatment of first episode schizophrenia.
3289082|NCT00554645|Experimental|1|Multi-disciplinary group intervention
3289083|NCT00554645|Active Comparator|2|traditional information
3289084|NCT00554632|Active Comparator|1|Use of transdermal hormonal contraceptive
3289085|NCT00554632|Active Comparator|2|Use of oral hormonal contraceptive
3289086|NCT00554619|Experimental|GSK1325760A|
3289087|NCT00554606|Experimental|1|ACZ885
3289088|NCT00554580|Active Comparator|A|Usual care of pulmonary acute oedema
3289089|NCT00554580|Experimental|B|CPAP + usual care of pulmonary acute oedema
3289090|NCT00554567|Experimental|Intervention Arm|Fully Decentralized HIV Testing and Care Services
3289091|NCT00554541||Normal Body-Mass|BMI Index: 18.5-24.9 Ankle Brachial Index Venous physiologic study
3289092|NCT00554541||Obese Body-Mass|BMI Index: 30.0-39.9 Ankle Brachial Index Venous physiologic study
3289093|NCT00554541||Morbidly Obese Body-Mass|BMI Index: ≥ 40 Ankle Brachial Index Venous physiologic study
3289094|NCT00554528|Other|A|patient receiving cervical disc prosthesis with a mobile insert named Mobi-C and product by LDR médical
3289095|NCT00554528|Other|B|patient receiving intersomatic cage
3289096|NCT00554515|Experimental|HD IL2|Participants received high-dose (HD) IL2, 600,000 IU/kg/dose (Prometheus Laboratories Inc.) i.v. every 8 hours for 5 days (maximum of 14 doses) beginning on day 1 and again on day 15. One course generally consisted of 5 days of treatment, 9 days of rest, 5 more days of treatment, and 9 weeks of rest, followed by up to two additional courses of HD IL2 for patients who benefited and tolerated most of the planned IL2 doses. A treatment delay of up to 4 weeks was allowed for resolution of side effects between courses. Patients were eligible to receive a maximum of three courses of treatment.
3289097|NCT00554502|Active Comparator|A|
3289098|NCT00554502|Active Comparator|B|
3289099|NCT00554463|Experimental|Combined Modality Therapy with Growth Factor Support|Radiation therapy, concurrent chemotherapy and Filgrastim followed by adjuvant chemotherapy and Pegfilgrastim
3289100|NCT00554450|Experimental|Arm 1|50 mg single dose
3289101|NCT00554450|Experimental|Arm 2|20 mg up to 7 days
3289102|NCT00554437|Experimental|1|Intermediate-intensity, community-based, multifactorial falls intervention
3289103|NCT00554437|Active Comparator|2|Occupational therapist home safety evaluation
3289104|NCT00554424|Active Comparator|LA|Intravaginal and pre-peritoneal injection of 1% lignocaine into each side of the upper vagina under ultrasound guidance immediately prior to ultrasound guided transvaginal oocyte retrieval
3289105|NCT00554424|Placebo Comparator|P|Intravaginal saline placebo injection into each side of upper vagina under ultrasound guidance immediately prior to transvaginal oocyte retrieval
3289106|NCT00554398|Experimental|A|MK-0518 400mg twice a day
3289107|NCT00554398|No Intervention|B|No intervention
3289108|NCT00554385|Experimental|1|
3289109|NCT00554372|Experimental|Low Dose|1e8 pfu (plaque forming units) total dose of JX-594 (recombinant vaccinia virus) on each of three (3) treatment days (2 weeks apart)
3289110|NCT00554372|Experimental|High Dose|1e9 pfu (plaque-forming units) total dose of JX-594 (recombinant vaccinia virus) on each of three (3) treatment days (2 weeks apart)
3289111|NCT00554359|Experimental|I5NP drug|
3289112|NCT00554359|Placebo Comparator|Placebo|
3289113|NCT00554346|Active Comparator|1|Etoricoxib 90mg
3289114|NCT00554346|Placebo Comparator|2|placebo
3289115|NCT00554333|Experimental|1|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
3289116|NCT00554333|Active Comparator|2|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
3289117|NCT00554320|Active Comparator|A|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most [or predominant] painful side [or the side where the symptoms begin or the left as a default]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
3289118|NCT00554320|Placebo Comparator|C|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
3289119|NCT00554307||Indo|Infants that are treated with indomethacin
3289120|NCT00554307||Neo|Infants treated with neoprofen
3289121|NCT00554307||Control|Infants without PDA
3289122|NCT00554294|No Intervention|Control group|Control schools had school curriculum as usual and did not receive environmental intervention.
3289126|NCT00554268|Experimental|PBI-05204|PBI-05204 starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle.
3289127|NCT00554229|Experimental|ZD4054|ZD4054 10 mg oral tablet once daily
3289128|NCT00554229|Placebo Comparator|Placebo|Matching Placebo, oral tablets once daily
3289129|NCT00554216|Experimental|VI-0521 Low|VI-0521; low dose phentermine/topiramate (PHEN/TPM 3.75 mg/23 mg)
3289130|NCT00554216|Experimental|VI-0521 Top|Top Dose VI-0521 consisting of 15 mg of Phentermine and 92 mg of Topiramate.
3289131|NCT00554216|Placebo Comparator|Placebo|Placebo to match
3289132|NCT00554190|Experimental|1|AdvaCoat compared to Merogel Injectable Bioresorbable Nasal Dressing
3289133|NCT00554190|Active Comparator|2|Merogel Injectable Bioresorbable Nasal Dressing compared to AdvaCoat
3289134|NCT00554177|Experimental|1|Medicane (mifepristone)
3289135|NCT00554177|Placebo Comparator|2|Placebo
3289136|NCT00554164|Active Comparator|B1|Six cycles of the (R-)CHOP regimen.
3289137|NCT00554164|Experimental|B2|Six blocks of the B-ALL protocol.
3289138|NCT00554164|Active Comparator|A1|Four cycles of the (R-)CHOP regimen.
3289139|NCT00554164|Active Comparator|A2|Four cycles of the (R-)CHOP regimen plus two additional doses rituximab.
3289140|NCT00554138|Placebo Comparator|1|
3289141|NCT00554138|Experimental|2|
3289142|NCT00554125|Active Comparator|2, III ,intervention|
3289143|NCT00554112|Active Comparator|1|Exercise
3289144|NCT00554112|Active Comparator|2|Exercise
3289145|NCT00554112|No Intervention|3|Control
3289146|NCT00554099|Placebo Comparator|Placebo|Days 1 thru Days 10 to 14 (Visit 2): daily antibiotic therapy, dietary advice, and 6 placebo tablets (matching mesalamine) once a day. Visit 2 thru Week 12 : 1 placebo capsule (matching probiotic) and 6 placebo tablets (matching mesalamine) daily.
3289147|NCT00554099|Active Comparator|Mesalamine|Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once a day. Visit 2 thru Week 12: 1 placebo capsule (matching probiotic) and 6 - 400 mg mesalamine tablets daily.
3289148|NCT00554099|Active Comparator|Mesalamine & Probiotic|Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once daily. Visit 2 thru Week 12: 1- Bifidobacterium infantis 35624 capsule and 6 - 400 mg mesalamine tablets daily
3289149|NCT00554047|Experimental|1|Multidisciplinary Memory Clinic
3289150|NCT00554047|Active Comparator|2|General practitioner
3289151|NCT00554021||1|Department of Traumatology and Critical Care Medicine, National Defense Medical College
3289152|NCT00554008|Active Comparator|1|children randomized to open appendectomy
3289153|NCT00554008|Active Comparator|2|children randomized to laparoscopic appendectomy
3289154|NCT00553995|Experimental|Salsalate|Salsalate
3289155|NCT00553995|Placebo Comparator|Placebo|Placebo
3289156|NCT00553982|Experimental|1|Patellar resurfacing
3289157|NCT00553982|Active Comparator|2|Patellar retention
3289158|NCT00553969|Experimental|1|Coreg CR + lisinopril
3289159|NCT00553969|Experimental|2|Coreg CR + placebo
3289160|NCT00553969|Experimental|3|lisinopril + placebo
3289161|NCT00553969|Placebo Comparator|4|placebo + placebo
3289162|NCT00553956|Experimental|1|Intervention group A treatment combination of Narrative Exposure Therapy and Interpersonal Psychotherapy (5 individual sessions NET in addition to 3 individual sessions IPT)
3289163|NCT00553956|No Intervention|2|Waiting list control
3289164|NCT00553943|Experimental|Rituximab + Cytarabine|
3289165|NCT00553930|Experimental|G 2/3|Patients with chronic hepatitis or compensated cirrhosis by hepatitis C virus, genotypes 2 or 3, and HIV-coinfected.
3289166|NCT00553917||1|Pregnant women currently taking Prozac for the treatment of depression
3289167|NCT00553917||2|Pregnant women currently taking Zoloft for the treatment of depression
3289168|NCT00553917||3|Pregnant women not currently using medication for the treatment of depression
3289169|NCT00553917||4|Pregnant women with no history of, symptoms of, or treatment for depression
3289170|NCT00553891|Experimental|Nasonex Nasal Spray|
3289171|NCT00553891|Placebo Comparator|Placebo Nasal Spray|
3289172|NCT00553878|Placebo Comparator|dutasteride|
3289173|NCT00553865|Experimental|Group 1|OJP-2028 1mg/day
3289174|NCT00553865|Experimental|Group 2|OJP-2028 2mg/day
3289175|NCT00553865|Experimental|Group 3|OJP-2028 4mg/day
3289176|NCT00553865|Placebo Comparator|Group 4|Placebo
3289177|NCT00553865|Other|Group 5|Reference drug
3289178|NCT00553852|Experimental|1|The clinical examination will determine anthropometric indexes (weight, height, BMI, waist circumference). The biochemical evaluation will include the measurement of lipid profile, fasting plasma glucose and insulin, liver test function, FT3, FT4, GHRH + Arginine test to detect GHD, plasma IGF-I levels. The instrumental evaluation will include DEXA Total Body and bioimpedance analysis to determine body composition, and liver ultrasounds.
3289179|NCT00553852|Placebo Comparator|2|PHASE II: In the medical treatment protocol very severe obese patients with persistent GHD after LASGB will be inclosed. Starting from 15-day, GHD patients were re-evaluated by GHRH + Arginine test. After evaluation, the patients with persistent GHD will be randomized to be treated with Recombinant GH replacement therapy (Group A: Recombinant GH replacement therapy at the initial dose 0.15-0.30 mg/die; dose adjustment will be made according to IGF-I levels; Group B: no GH treatment).
3289180|NCT00553839|Other|Ketamine|Then a 2 mg/kg IV bolus of Ketamine hydrochloride will be given as part of general anesthesia for procedure
3289181|NCT00553800|Experimental|Bevacizumab & Erlotinib|bevacizumab 15 mg/kg intravenous every three weeks and erlotinib pill 150 mg by mouth every day
3289182|NCT00553787|Experimental|VI-0521 Top|high dose experimental treatment
3289183|NCT00553787|Experimental|VI-0521 Mid|mid dose experimental treatment
3289184|NCT00553787|Placebo Comparator|Placebo|Placebo
3289185|NCT00553774|Experimental|Flavanol|Cocoa Flavanol
3289186|NCT00553774|Placebo Comparator|Placebo|
3289187|NCT00553748|Experimental|I|
3289272|NCT00552981|Sham Comparator|2|
3289273|NCT00552942|Experimental|1|surgery plus omentectomy
3289274|NCT00552942|No Intervention|2|standard gastric bypass
3289188|NCT00553735|Active Comparator|Cyclosporine A 0.05%|"If patients pass the screening criteria, both eyes are randomized to therapy. One eye will receive Cyclosporine A 0.05% (Restasis) and the other eye will receive Placebo (Artificial Tear)~The objective signs will be corneal and conjunctival staining, Schirmer test (with and without anesthesia), and tear break-up time. The subjective endpoints will be the SANDE symptom global score."
3289189|NCT00553735|Placebo Comparator|Artificial Tear|"If patients pass the screening criteria, both eyes are randomized to therapy. One eye will receive Cyclosporine A 0.05% (Restasis) and the other eye will receive Placebo (Artificial Tear)~The objective signs will be corneal and conjunctival staining, Schirmer test (with and without anesthesia), and tear break-up time. The subjective endpoints will be the SANDE symptom global score."
3289190|NCT00553722|Experimental|Eplerenone|Administer Eplerenone, 25 mg, orally twice daily for 4 weeks.
3289191|NCT00553722|Placebo Comparator|placebo|Administer a placebo tablet orally twice daily for 4 weeks
3289192|NCT00553709|Experimental|Nicotine patch|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
3289193|NCT00553709|Placebo Comparator|Placebo patch|Placebo patch 10 cm2
3289194|NCT00553696|Experimental|A|
3289195|NCT00553683|Experimental|poly ICLC|
3289196|NCT00553670||1|Patients with elective coronary intervention for LAD-diagonal bifurcation lesion with provisional side branch intervention strategy with successful intravascular ultrasound and fractional flow reserve measurement
3289197|NCT00553644|Experimental|Treatment (bortezomib, lenalidomide)|Patients receive induction therapy comprising bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete or partial response as best response after completion of induction therapy receive maintenance therapy comprising bortezomib IV on days 1 and 8 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 6 years in the absence of disease progression or unacceptable toxicity.
3289198|NCT00553631|Experimental|GA-GCB|VPRIV™ ,velaglucerase alfa
3289199|NCT00553631|Active Comparator|imiglucerase|
3289200|NCT00553618|Experimental|Proleukin/DTIC Arm|Adjucant proleukin and DTIC
3289201|NCT00553605|Active Comparator|I|Ketoprofen plus placebo parecoxib
3289202|NCT00553605|Active Comparator|II|Parecoxib plus placebo ketoprofen
3289203|NCT00553592|Experimental|Drug|Bicifadine
3289204|NCT00553592|Experimental|Drug: 2|Bicifadine
3289205|NCT00553592|Placebo Comparator|Control|Placebo of Bicifadine
3289206|NCT00553579||DE|All subjects will have clinically significant dry eye.
3289207|NCT00553553|Active Comparator|1|IV morphine group
3289208|NCT00553553|Experimental|2|Remifentanil-intrathecal morphine group
3289209|NCT00553540|No Intervention|Control Group|Patients in this group will receive physical therapy and posture education for low back pain
3289210|NCT00553540|Active Comparator|Test Group|Patients in this group will receive spinal / back supports in addition to physical therapy and posture education for low back pain
3289211|NCT00553527|Other|1|Patient will receive standard of care humeral stem replacement. Only a data collection study. There will be no changes in standard of care for diagnosis.
3289212|NCT00553514|Experimental|AS900672-Enriched 10 mcg|
3289213|NCT00553514|Experimental|AS900672-Enriched 20 mcg|
3289214|NCT00553514|Experimental|AS900672-Enriched 30 mcg|
3289215|NCT00553514|Experimental|AS900672-Enriched 40 mcg|
3289216|NCT00553514|Active Comparator|Follitropin alfa 75 IU|
3289217|NCT00553501|Experimental|Epratuzumab Plus Rituximab|"Induction Therapy (Month 1): Epratuzumab 360 mg/m^2 by IV days 1, 8, 15 & 22; Rituximab 375 mg/m^2 by IV day 3, 8, 15 & 22~Extended Induction (Weeks 12, 20, 28 & 36) Epratuzumab 360 mg/m^2 by IV weeks 12, 20, 28 & 36; Rituximab 375 mg/m^2 by IV weeks 12, 20, 28 & 36"
3289218|NCT00553488|Active Comparator|1|Regular insulin SC at -17 mins
3289219|NCT00553488|Active Comparator|2|Regular insulin ID at -17 mins
3289220|NCT00553488|Active Comparator|3|Regular insulin ID at -2 mins
3289221|NCT00553488|Active Comparator|4|Insulin lispro given SC at -2 mins
3289222|NCT00553488|Experimental|5|Insulin lispro given ID at -2 mins
3289223|NCT00553475|Placebo Comparator|Placebo|
3289224|NCT00553475|Experimental|Pregabalin 300 mg/day|
3289225|NCT00553475|Experimental|Pregabalin 600 mg/day|
3289226|NCT00553462|Experimental|paclitaxel + carboplatin + radiation + erlotinib|"Patients receive paclitaxel IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses. Patient with rapid disease progression outside of the chest after induction therapy are removed from study.~Patients with intrathoracic disease progression within the potential radiation field may continue protocol therapy at the discretion of the Study Chair. Patients with no disease progression outside the planned radiation field (either regional or distant) proceed to concurrent erlotinib hydrochloride and radiotherapy.~Beginning on day 43 (week 7), patients receive oral erlotinib hydrochloride once daily. Patients also undergo concurrent radiotherapy 5 days a week for up to 7 weeks (33 fractions) in the absence of rapid disease progression outside of the chest or unacceptable toxicity.~After completion of study therapy, patients are followed every 3 months for 1 year, and then every 6 months for up to 2 years"
3289227|NCT00553436|Experimental|Enrolled Subjects treated with TAS device|All enrolled subjects treated with the Tissue Apposition System (TAS) device
3289228|NCT00553423|Experimental|1|Lactulose 30 ml q6h for 48 hrs
3289229|NCT00553423|Placebo Comparator|2|Placebo 30 ml q6 hrly for 48hrs
3289230|NCT00553410|Active Comparator|Continuous letrozole|Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)
3289231|NCT00553410|Experimental|Intermittent letrozole|Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months
3289232|NCT00553397||Live Lung Donors|Participants had a living donor lobectomy at one of the two participating study centers, the University of Southern California and the Washington University Medical Center between 1993 and 2006.
3289275|NCT00552929|Experimental|1|Sugammadex
3289276|NCT00552929|Placebo Comparator|2|Placebo
3289717|NCT00549601|Experimental|Rivastigmine patch (9.5 mg/day)|
3289233|NCT00553358|Experimental|Arm 1 Lapatinib|1500 mg lapatinib for 6 weeks followed by lapatinib plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib.
3289234|NCT00553358|Active Comparator|Arm 2 Trastuzumab|4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks followed by 2 mg/kg trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
3289235|NCT00553358|Experimental|Arm 3 Lapatinib plus Trastuzumab|1000 mg lapatinib plus 4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks, followed by 750 mg lapatinib plus 2 mg/kg IV weekly trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib (1000 mg) in combination with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
3289236|NCT00553332|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3289237|NCT00553319|Placebo Comparator|Placebo|Placebo
3289238|NCT00553319|Experimental|Adderall-XR 60 mg|Adderall-XR 60 mg
3289239|NCT00553319|Experimental|Adderall-XR 80 mg|Adderall-XR 80 mg
3289240|NCT00553306|Experimental|Arm I|Beginning 48 hours before T-cell infusion, patients receive cyclophosphamide IV. Patients then receive antigen-specific CD8+ T cells IV alone or with CD4+ T helper clones over 1-2 hours on day 0. Patients also receive aldesleukin subcutaneously twice daily on days 0-13. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3289241|NCT00553293|Active Comparator|A,1|rFSH + rLH arm
3289242|NCT00553293|Placebo Comparator|A,2|rFSH alone
3289243|NCT00553280|Experimental|pregabalin|
3289244|NCT00553254|Experimental|1|
3289245|NCT00553241||1|"Dept. of Neurology, Beijing Anzhen Hospital, Capital Medical University Beijing 100029, P.R.China~Every patient admitted to Beijing anzhen hospital with transient ischemic attack will be enrolled in this study, from 06/2007 to 12/2008. duration of the symptom not larger than 1 hour."
3289246|NCT00553228|Experimental|group I|Tdap
3289247|NCT00553228|Active Comparator|group 2|Td
3289248|NCT00553202|Experimental|Treatment (chemotherapy and allogeneic SCT)|"Patients receive busulfan IV every 6 hours on days -9 to -6, high-dose cyclophosphamide IV over 1 hour on days -5 to -2, anti-thymocyte globulin IV once or twice daily over 4 hours on days -3 to -1, and methylprednisolone IV on days -3 to -1.~Patients undergo allogeneic hematopoietic stem cell transplantation (SCT) or allogeneic bone marrow transplantation (BMT) on day 0.~Patients receive cyclosporine or tacrolimus IV or orally beginning on day -2 and continuing until day 50, followed by a taper until week 24. Patients also receive methotrexate IV on days 1, 3, 6, and 11.~Blood samples will be collected periodically from both patients and donors for studies of natural killer cells in support of the pharmacological study objectives"
3289249|NCT00553176||Patients with Crohn's disease|The Registry is an observational research program featuring clinical, economic, and humanistic measures characterizing the treatment of Crohn's disease
3289250|NCT00553163|Active Comparator|A|Gut-focussed hypnotherapy (GFH).
3289251|NCT00553163|Sham Comparator|B|
3289252|NCT00553150|Experimental|Everolimus (RAD001), Radiation (RT), Temozolomide (TMZ)|"Patients receive oral everolimus and oral temozolomide and 3D-conformal radiotherapy or IMRT as in phase I. Patients will undergo a 4-6 week rest period in course 2 and then proceed to adjuvant therapy.~Adjuvant therapy with everolimus and temozolomide (courses 3-8): Patients receive oral everolimus and oral temozolomide as in phase I.~Adjuvant therapy with everolimus alone (courses 9 and all subsequent courses): Patients receive oral everolimus as in phase I.~All patients undergo fludeoxyglucose (FDG)- or fluorothymidine-labeled PET/CT scans at baseline and periodically during treatment."
3289253|NCT00553137|Active Comparator|1|single dose fluconazole (750 mg) and placebos 150 mg tablets once daily for 14 days
3289254|NCT00553137|Active Comparator|2|150 mg fluconazole once daily for 14 days and placebos (5 placebos tablets) 750 mg once
3289255|NCT00553111|Experimental|1|pre survey, intervention, post test survey
3289256|NCT00553111|No Intervention|2|pre test survey and post test survey
3289257|NCT00553111|Experimental|3|video intervention and post test survey
3289258|NCT00553111|No Intervention|4|post test survey
3289259|NCT00553098|Experimental|Treatment (chemotherapy, low dose radiation)|"CONDITIONING REGIMEN: *Patients with no life-threatening viral or fungal infections within 1 month before the planned HCT receive alemtuzumab IV over 6 hours on day -10 and fludarabine phosphate IV over 30 minutes on days -4 to -2. They also undergo low-dose TBI on day 0. Patients with HLH, IPEX syndrome, DiGeorge syndrome, or life-threatening viral or fungal infections within 1 month before the planned HCT receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo 2 low doses of TBI on day 0.~HEMATOPOIETIC CELL TRANSPLANTATION: Patients undergo HCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV or PO 2-3 times daily beginning on day -3 and continuing until day 100 followed by a taper until day 180. They also receive mycophenolate mofetil IV or PO 3 times daily beginning on day 0 and continuing until day 40 followed by a taper until day 96."
3289260|NCT00553085||Anx group|
3289261|NCT00553085||ADHD group|
3289262|NCT00553085||Nonanx/nonadhd group|
3289263|NCT00553072|Active Comparator|Magnesium sulphate, neurological outcome|Magnesium sulphate 250mg/kg after every 24 hours starting within 6 hours from birth
3289264|NCT00553072|Placebo Comparator|Placebo|Placebo every 24 hours for 3 doses starting from 6 hours after birth
3289265|NCT00553059|Experimental|Arm I: Palonosetron, Dexamethasone + Dronabinol|Palonosetron hydrochloride intravenous (IV) and dexamethasone IV 30 minutes before chemotherapy administration on day 1, and oral dronabinol 3 times a day for 5 days beginning 30 minutes before chemotherapy administration on day 1.
3289266|NCT00553059|Active Comparator|Arm II: Palonosetron + Dexamethasone|Palonosetron hydrochloride and dexamethasone as in arm I, and oral placebo 3 times a day for 5 days beginning 30 minutes before chemotherapy on day 1.
3289267|NCT00553046||family burden|chronich respiratory failure home ventilated patients
3289268|NCT00553033||A|
3289269|NCT00552994|Active Comparator|1|Cypher Select plus stent
3289270|NCT00552994|Active Comparator|2|Xience V stent
3289277|NCT00552916|Other|1|Participants will be randomized to either an intervention arm where they will receive 'true' FES and the other control arm where they will receive 'false' FES. The sham group will receive 'false' FES.
3289278|NCT00552916|Other|2|The intervention group will receive 'true' FES
3289279|NCT00552903|Experimental|1|Active intervention - personal health coaching provided
3289280|NCT00552903|No Intervention|2|Control arm - no intervention, data on health outcomes collected at baseline (entry to the study) and during the 12 month follow-up
3289281|NCT00552890|Experimental|ATK|modified Atkins diet
3289282|NCT00552890|Experimental|ADA|subjects assigned to follow ADA recommended diet for 1 year
3289283|NCT00552877|Active Comparator|1|Cypher Select plus stent
3289284|NCT00552877|Active Comparator|2|Xience V stent
3289285|NCT00552864|Active Comparator|R|
3289286|NCT00552864|Active Comparator|L|
3289287|NCT00552851|Other|Pegvisomant|patients with active acromegaly and impaired cardiac function
3289288|NCT00552838|No Intervention|A|Physicians in this arm did not have any intervention with the AUT. Antimicrobial prescriptions were based on hospital guidelines or on the physician's medical knowledge.
3289289|NCT00552825||1|all were in a single group
3289290|NCT00552812|Experimental|Stent therapy of aortic coarctation|Stenting of aortic coarctation
3289291|NCT00552799|Experimental|1|Penicillin VK 250 mg b.d.
3289292|NCT00552799|Placebo Comparator|2|placebo tablet b.d.
3289293|NCT00552786|Experimental|Acetin|
3289294|NCT00552786|Placebo Comparator|Glucose|
3289295|NCT00552773|Experimental|Cyclamen Europaeum|
3289296|NCT00552773|Placebo Comparator|Placebo|
3289297|NCT00552760|Experimental|Ramelteon|8 mg
3289298|NCT00552760|Placebo Comparator|Placebo|
3289299|NCT00552747|Active Comparator|1|fenofibrate 160 mg capsules (QD) Taken once daily with the largest meal of the day
3289300|NCT00552747|Placebo Comparator|2|placebo (capsules identical to those of fenofibrate) taken once daily (QD)with the largest meal of the day
3289301|NCT00552734||Control|The other half of the patients were randomized to the control group who were followed for their routine diabetes care and had to visit the clinic on the same schedule as the experimental group.
3289302|NCT00552734||Experimental|Half of the subjects were randomized to this group using insulin guidance software on a PDA to adjust their insulin dose at home based on the prescription provided by the provider.
3289303|NCT00552721|Experimental|A|Physical therapy with strength training.
3289304|NCT00552721|Active Comparator|B|Physical therapy without strength training.
3289305|NCT00552695|Active Comparator|1|Lidocaine 70 mg/tetracaine 70 mg skin patch
3289306|NCT00552695|Placebo Comparator|2|
3289307|NCT00552682|Experimental|A|Duloxetine 60 mg, 1 tablet/day
3289308|NCT00552682|No Intervention|B|To continue with the antidepressive treatment if exist
3289309|NCT00552669|Experimental|A--Oral Rapamycin plus BMS|Oral sirolimus plus bare metal stent implantation
3289310|NCT00552669|Active Comparator|B -- Drug Eluting Stent|Drug Eluting Stents
3289311|NCT00552656||1|the group of patients with angiographic results of complex coronary lesions(refer to the definition of protocol)are enrolled and given a clinical follow up and angiographic follow up during the following one year.
3289312|NCT00552643|Experimental|1|Treatment with Polyheal 1
3289313|NCT00552643|Active Comparator|2|Saline
3289314|NCT00552630|Experimental|1|This group will receive d-penicillamine for 6 weeks
3289315|NCT00552630|Placebo Comparator|2|This group will receive placebo for 6 weeks
3289316|NCT00552617|Placebo Comparator|1|rocuronium and placebo
3289317|NCT00552617|Experimental|2|rocuronium and 0.5 mg/kg Org 25969
3289318|NCT00552617|Experimental|3|rocuronium and 1.0 mg/kg Org 25969
3289319|NCT00552617|Experimental|4|rocuronium and 2.0 mg/kg Org 25969
3289320|NCT00552617|Experimental|5|rocuronium and 4.0 mg/kg Org 25969
3289321|NCT00552617|Placebo Comparator|6|vecuronium and placebo
3289322|NCT00552617|Experimental|7|vecuronium and 0.5 mg/kg Org 25969
3289323|NCT00552617|Experimental|8|vecuronium and 1.0 mg/kg Org 25969
3289324|NCT00552617|Experimental|9|vecuronium and 2.0 mg/kg Org 25969
3289325|NCT00552617|Experimental|10|vecuronium and 4.0 mg/kg Org 25969
3289326|NCT00552604|Experimental|1|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
3289327|NCT00552604|Placebo Comparator|2|matching placebo capsules, twice daily
3289328|NCT00552591|Experimental|1|Family Heart Health Program
3289329|NCT00552591|No Intervention|2|Usual Care
3289330|NCT00552578|Active Comparator|Tapering doses of buprenorphine|Participants assigned to this arm will receive tapering doses of buprenorphine for detoxification.
3289331|NCT00552578|Experimental|Steady doses of buprenrophine|Participants assigned to this arm will receive a steady dose of buprenorphine for maintenance.
3289332|NCT00552565|Placebo Comparator|1|
3289333|NCT00552565|Experimental|2|
3289334|NCT00552565|Experimental|Rezular 37.5mg|
3289335|NCT00552565|Experimental|Rezular - 75mg|
3289336|NCT00552552|Experimental|1|
3289337|NCT00552552|Other|2|waiting control group
3289338|NCT00552539|Experimental|1|pre test survey, educational video, post test survey
3289339|NCT00552539|No Intervention|2|no intervention
3289340|NCT00552539|Experimental|3|educational video and post test survey
3289341|NCT00552539|No Intervention|4|post test survey
3289342|NCT00552526|Active Comparator|Ketogenic diet|
3289343|NCT00552526|Active Comparator|AED|Most appropriate antiepileptic drug
3289344|NCT00552513|Other|Early Coronary Intervention|Coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) as soon as possible (within 24 hours of randomisation).
3289345|NCT00552513|Other|Delayed Coronary Intervention|Delayed intervention: Coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) any time after 36 hours after randomisation.
3289346|NCT00552500|Active Comparator|Schizophrenics|i) meets DSM-IV criteria for schizophrenia, any type, treated with atypical or high potency typical neuroleptics for at least 3 months; ii) aged 18 to 60 years; iii) able to give informed consent; iv) no antipsychotic medication changes for 3 months, and no other medication changes for 2 weeks prior to Baseline Evaluations.
3289347|NCT00552487|Other|1|healthy people without Hashimoto disease receive a 1µg ACTH stimulation test
3289348|NCT00552487|Other|2|patients with Hashimoto disease with well being receive a 1 µg ACTH stimulation test
3289349|NCT00552487|Other|3|patients with Hashimoto disease an impaired well-being receive a 1 µg ACTH stimulation test
3289350|NCT00552487|Other|4|patients with Hashimoto disease and negative TPO antibodies receive a 1µg ACTH stimulation test
3289351|NCT00552474|Placebo Comparator|Group B|Implanted but no active stimulation
3289352|NCT00552474|Experimental|Group A|Active Stimulation
3289353|NCT00552461|Experimental|1|
3289354|NCT00552448|Experimental|1|Use of the HFCC device in addition to standard therapy for status asthmaticus. The use of HFCC will not affect the therapy received
3289355|NCT00552448|No Intervention|2|This group will not use the VEST or HFCC. They will just have standard therapy for status asthmaticus. The standard therapy will not be affected if they are in this group.
3289356|NCT00552435|Experimental|1|Micropulse 810nm diode laser
3289357|NCT00552435|Active Comparator|2|Argon laser photocoagulation
3289358|NCT00552422|Experimental|Domperidone Arm|Study subjects will self-administer oral domperidone 10mg four times a day. If symptoms persist for more than 7 days, the investigator may increase the dose to 20mg four times a day. 20mg four times a day will be the maximal dose. Subjects with signiﬁcant renal impairment will received a starting dose of 10mg twice a day. The maximal dose in subjects with signiﬁcant renal impairment will be 20mg twice a day.
3289359|NCT00552409|Experimental|Cholecalciferol|
3289360|NCT00552409|Placebo Comparator|Placebo|
3289361|NCT00552344|Experimental|Certolizumab Pegol|Certolizumab Pegol 200 mg/vial; 400 mg subcutaneously at Week 0, 2 and 4, thereafter 400 mg subcutaneously at every 4 weeks.
3289362|NCT00552331|Active Comparator|LISS|Treatment of distal femur fracture with less invasive stabilization system
3289363|NCT00552331|Active Comparator|Standard Treatment|Treatment of distal femoral fractures using locking condylar plates or dynamic condylar screws
3289364|NCT00552305|Experimental|Lacosamide|50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing
3289365|NCT00552279|Experimental|Cervarix-12 Group|Women received 3 doses of Cervarix TM (human papillomavirus (HPV) vaccine) administered according to a 0, 1, 12-month schedule
3289366|NCT00552279|Active Comparator|Cervarix-6 Group|Women received 3 doses of Cervarix TM (HPV vaccine) administered according to a 0, 1, 6-month schedule.
3289367|NCT00552253|Experimental|1|under eltroxin
3289368|NCT00552240|Active Comparator|NVP 200mg bis indie (BID)|after receiving nevirapine (NVP) 200 mg quaue die (QD) for 2 weeks, pt titrated to NVP 200 mg bis in die (BID) combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks
3289369|NCT00552240|Active Comparator|Atazanavir 300 mg QD/ritonavir 100 mg QD|patients to receive atazanavir 300 mg QD boosted with ritonavir 100 mg QD combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks
3289370|NCT00552227|Experimental|1|
3289371|NCT00552227|Placebo Comparator|2|
3289372|NCT00552188|Experimental|VIA-2291|VIA-2291 100mg
3289373|NCT00552188|Placebo Comparator|Placebo|Matching placebo
3289374|NCT00552175|Experimental|Duloxetine 60|duloxetine 60 milligram (mg) taken orally every day
3289375|NCT00552175|Experimental|Duloxetine 40|Duloxetine 40 mg taken orally every day
3289376|NCT00552175|Placebo Comparator|Placebo|placebo comparator taken orally every day
3289377|NCT00552162|Active Comparator|1|NOTES Transvaginal cholecystectomy The gallbladder will be dissected free and will be removed through an incision in the vagina.
3289378|NCT00552162|Active Comparator|2|NOTES Transvaginal Appendectomy. The appendix will be dissected free and will be removed through an incision in the vagina.
3289379|NCT00552149|Active Comparator|1|GEMOX
3289380|NCT00552149|Experimental|2|GEMOX + CETUXIMAB
3289381|NCT00552110|Experimental|Combination1|Mometasone Furoate nasal spray (MFNS) with oxymetazoline nasal spray (OXY) 1 spray once daily
3289382|NCT00552110|Experimental|Combination3|MFNS with OXY 3 sprays once daily
3289383|NCT00552110|Active Comparator|Mometasone|MFNS once daily
3289384|NCT00552110|Active Comparator|Oxymetazoline|OXY twice daily
3289385|NCT00552110|Placebo Comparator|Placebo|Placebo nasal spray
3289386|NCT00552097|Experimental|EZ/Simva|
3289387|NCT00552097|Placebo Comparator|Placebo/Simva|
3289388|NCT00552084|Experimental|Fish Oil|4 grams fish oil daily for 24 weeks
3289389|NCT00552084|Placebo Comparator|Placebo|corn oil taken daily for 24 weeks
3289390|NCT00552071|Other|1|3 months of ultrasound guided IM injections of octreotide LAR followed by 3 months of non-ultrasound guided injections of octreotide LAR
3289391|NCT00552071|Other|2|3 months of non-ultrasound guided octreotide LAR IM injections followed by ultrasound guided IM injections of LAR
3289392|NCT00552058|Experimental|Certolizumab pegol|Certolizumab pegol 400 mg for subcutaneous (sc) injection
3289393|NCT00552058|Placebo Comparator|Placebo|Placebo, saline solution for sc injection
3289394|NCT00552045||subject|individuals with epilepsy
3289395|NCT00552032|Experimental|Mometasone Furoate nasal spray|
3289396|NCT00552032|Placebo Comparator|Placebo|
3289397|NCT00552006|Experimental|NET|
3289398|NCT00552006|Active Comparator|AC|
3289399|NCT00552006|No Intervention|WL|Waiting list
3289400|NCT00551993|Active Comparator|2|Robotic Sacral Colpopexy
3289401|NCT00551993|Active Comparator|1|Laparoscopic Sacral Colpopexy
3289402|NCT00551980|Experimental|Cognitive and physical program|Randomized group of workers of the same institution ( City of Turin, Italy).
3289403|NCT00551980|No Intervention|Control group|Randomized group of workers of the same institution ( City of Turin, Italy).
3289437|NCT00551707|Placebo Comparator|Placebo|placebo administered twice per day at 8 AM and 1 PM
3289404|NCT00551967|Active Comparator|E1 polyethylene|All patients received an E1 polyethylene liner which is the material being monitored in this study.
3289405|NCT00551954|Experimental|1|20 weeks of treatment with acarbose (100 mg t.i.d.)
3289406|NCT00551954|Placebo Comparator|2|20 weeks of treatment with placebo (one tablet t.i.d.)
3289407|NCT00551941|Active Comparator|2|non-union of diaphysary tibial fractures will be treated with allograft together with DBM
3289408|NCT00551941|Experimental|1|non-union of diaphysary tibial fractures will be treated with BMP-7 in adjunct to fresh frozen allograft
3289409|NCT00551928|Active Comparator|A|Oral therapy with Lenalidomide Melphalan and Prednisone.
3289410|NCT00551928|Active Comparator|B|High dose Melphalan therapy (200mg/sm)with autologous stem cell support, for 2 cycles every 4 months (only 1 cycle if the patient reached almost a VGPR after the 1st MEL200)
3289411|NCT00551915|Experimental|AR51 (12, 10)|Participants were vaccinated with 0.5 ml of AR51 (12,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
3289412|NCT00551915|Experimental|PR51 (3, 10)|Participants were vaccinated with 0.5 ml of PR51 (3,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
3289413|NCT00551915|Experimental|PR51 (6, 10)|Participants were vaccinated with 0.5 ml of PR51 (6,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
3289414|NCT00551915|Active Comparator|PENTACEL™ + RECOMBIVAX HB™|Participants were vaccinated with 0.5 ml each of PENTACEL™ + RECOMBIVAX HB™ via intramuscular injection as a primary series at 2, 4, and 6 months of age, and with 0.5 ml PENTACEL™ as a booster at 12 to 14 months of age.
3289415|NCT00551902|Experimental|1|Trabeculectomy with anterior chamber infusion system
3289416|NCT00551902|Active Comparator|2|Trabeculectomy without anterior chamber infusion system
3289417|NCT00551863|Active Comparator|IVPT|Intervention based on Motivational Interviewing and CBT
3289418|NCT00551850|Experimental|1|
3289419|NCT00551824|Experimental|1|"First dilation session with topical mitomycin applied over esophageal mucosa after dilation.~Second dilation session (after 14 days): standard dilation without topical mitomycin."
3289420|NCT00551824|Experimental|2|"First dilation session: standard dilation without topical mitomycin.~Second dilation session (after 14 days) with topical mitomycin applied over esophageal mucosa after dilation."
3289421|NCT00551811|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive single doses of placebo in period 1, SB-656933-AAA with a dose of 50 milligrams in period 2 and 150 milligrams in period 3.
3289422|NCT00551811|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive single doses of SB-656933-AAA with a dose of 50 milligrams in period 1, placebo in period 2 and SB-656933-AAA 150 milligrams in period 3.
3289423|NCT00551811|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive single doses of SB-656933-AAA with a dose of 50 milligrams in period 1, 150 milligrams in period 2 and placebo in period 3.
3289424|NCT00551785||1|Women prescribed Intrinsa and estrogen therapy
3289425|NCT00551785||2|Women prescribed estrogen therapy
3289426|NCT00551759|Experimental|Neoadjuvant therapy, Surgery, adjuvant therapy|"Neoadjuvant chemoradiotherapy and cetuximab: Patients (pts) receive oxaliplatin IV over 2 hours on days 1, 15, and 29, cetuximab IV over 1-2 hours on days 1, 8, 15, 22, and 29, and 5-FU IV over 24 hours on days 1-35. Pts also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33. Pts then proceed to surgery.~Surgery: Pts undergo surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab. Pts with an R0 or R1 resection proceed to adjuvant therapy. Pts whose tumors have not been completely resected or who have metastatic disease discontinue protocol therapy and receive further therapy at the discretion of the treating physician.~Adjuvant therapy: Within 4-8 weeks after surgery, pts receive docetaxel IV over 1 hour on days 1, 8, 15, 22, and 29 and cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
3289427|NCT00551746|Active Comparator|1|Grape Juice
3289428|NCT00551746|Placebo Comparator|2|Grape Juice Placebo
3289429|NCT00551733|Experimental|Arm I|Patients receive paclitaxel poliglumex IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3289430|NCT00551733|Active Comparator|Arm II|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3289431|NCT00551720|Experimental|Standard Care|
3289432|NCT00551720|Experimental|Motivational Enhancement|
3289433|NCT00551707|Experimental|CRx-102 (2.7/180)|CRx-102 dose 1 total daily dose during treatment period (days 14-98) 2.7 mg prednisolone plus 180 mg dipyridamole administered as 1.8 mg prednisolone plus 90 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 90 mg dipyridamole at 1 PM titration dose (days 0-13) 2.7 mg prednisolone plus 90 mg dipyridamole administered as 1.8 mg prednisolone plus 45 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 45 mg dipyridamole at 1 PM
3289434|NCT00551707|Experimental|CRx-102 (2.7/360)|CRx-102 Dose 2 total daily dose during treatment period (days 14-98) 2.7 mg prednisolone plus 360 mg dipyridamole administered as 1.8 mg prednisolone plus 180 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 180 mg dipyridamole at 1 PM titration dose 1 (days 0-6) 2.7 mg prednisolone plus 90 mg dipyridamole administered as 1.8 mg prednisolone plus 45 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 45 mg dipyridamole at 1 PM titration dose 2 (days 7-13) 2.7 mg prednisolone plus 180 mg dipyridamole administered as 1.8 mg prednisolone plus 90 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 90 mg dipyridamole at 1 PM
3289435|NCT00551707|Active Comparator|Prednisolone|treatment dose ( days 0-98) total daily dose of 2.7 mg prednisolone administered as 1.8 mg prednisolone at 8 AM and 0.9 mg prednisolone at 1 PM
3289436|NCT00551707|Active Comparator|Dipyridamole|total daily dose during treatment period (days 14-98) 360 mg dipyridamole administered as 180 mg dipyridamole at 8 AM and and 180 mg dipyridamole at 1 PM titration dose 1 (days 0-6) 90 mg dipyridamole administered 45 mg dipyridamole at 8 AM and 45 mg dipyridamole at 1 PM titration dose 2 (days 7-13) 180 mg dipyridamole administered as 90 mg dipyridamole at 8 AM and 90 mg dipyridamole at 1 PM
3289563|NCT00550641|Experimental|2|
3289438|NCT00551681|Active Comparator|1|Epicardial left ventricular lead placement
3289439|NCT00551681|Active Comparator|2|transvenous left ventricular lead
3289440|NCT00551668|Experimental|1|Operative
3289441|NCT00551668|Experimental|2|Nonoperative
3289442|NCT00551642|Other|Group A|24+0-25+6 days weeks gestational age
3289443|NCT00551642|Other|Group B|26+0 - 28+6 days weeks Gestational Age
3289444|NCT00551629|Experimental|AR51 (12, 10)|Participants were vaccinated with 0.5 ml of AR51 (12, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
3289445|NCT00551629|Experimental|PR51 (3, 10)|Participants were vaccinated with 0.5 ml of PR51 (3, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
3289446|NCT00551629|Experimental|PR51 (6, 10)|Participants were vaccinated with 0.5 ml of PR51 (6, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
3289447|NCT00551629|Experimental|PR51 (6, 15)|Participants were vaccinated with 0.5 ml of PR51 (6, 15) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
3289448|NCT00551616|Experimental|1|
3289449|NCT00551616|Active Comparator|2|
3289450|NCT00551603|Experimental|1|Group Epo will receive anaemia treatment according to the Romanian Best Practice Guidelines recommendation, with once-weekly SC epoetinum beta during the first phase, then will be switched to receive SC once-fortnightly darbepoetinum. Anaemia treatment schedule will continue according to the Romanian Best Practice Guidelines recommendations, with the same dose. A conversion factor of 1:200 will be used.
3289451|NCT00551603|Active Comparator|2|Subjects in the Darbepo Group will receive anaemia treatment according to the Romanian Best Practice Guidelines recommendation, with once-fortnightly or once-monthly darbepoetin SC administration, continuing their previous schedule and will continue their previous schedule of anaemia treatment during the second phase of the study
3289452|NCT00551590|Placebo Comparator|1|placebo PO (placebo control for sitagliptin) for three days. Saline IV (placebo control for exendin(9-39) on two consecutive study days.
3289453|NCT00551590|Experimental|2|Sitagliptin 100 mg PO for three days. Saline IV (placebo control for exendin(9-39)) on two consecutive study days
3289454|NCT00551590|Experimental|3|Sitagliptin 100 mg PO for three days. Exendin(9-39) IV on two consecutive study days.
3289455|NCT00551590|Placebo Comparator|4|placebo PO (placebo control for sitagliptin) for three days. Exendin(9-39)IV on two consecutive study days.
3289456|NCT00551577|Active Comparator|A1|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
3289457|NCT00551577|Experimental|A2|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
3289458|NCT00551564|Experimental|Subjects in healthy normal and overweight control arm|Subjects in the Healthy Normal or Overweight Control Population will be included in this arm and they will receive Rosiglitazone 4 milligram twice daily.
3289459|NCT00551564|Experimental|Subjects in healthy obese with T2DM arm|Subjects who are in the Healthy Obese or T2DM Population will be included in this arm and they will receive Rosiglitazone 4 milligram twice daily.
3289460|NCT00551551|Experimental|Rééducation|Standardized pelvic floor muscle training program with a physiotherapist in 8 sessions (20-30 minutes each) between 24 and 36 weeks of gestation AND Written instructions about personal (Kegel) pelvic floor exercises
3289461|NCT00551551|Active Comparator|Control|Written instructions about personal (Kegel) pelvic floor exercises
3289462|NCT00551538|Active Comparator|1|Lispro mixture 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
3289463|NCT00551538|Active Comparator|2|Glargine, once-daily, SC injection, given in conjunction with oral antidiabetic medications.
3289464|NCT00551525|Experimental|Radiotherapy + Samarium 153|Samarium 153 infusion followed by radiotherapy 12 weeks later
3289465|NCT00551512|Experimental|CBP501 and Cisplatin|Dose escalation study
3289466|NCT00551499|No Intervention|CRT for patients with CSA|Patients suffering from HF with central Sleep Apnea (CSA) programmed to DDD/45 (CRT) for 12 weeks. Intervention is CRT.
3289467|NCT00551499|Active Comparator|CRT + AOP for patients with CSA|Patients suffering from HF with central Sleep Apnea programmed to DDD/+15 bpm nocturnal rate (CRT + AOP) for 12 weeks. Intervention is the AOP in addition to CRT.
3289468|NCT00551486||1|Patients with thyroid incidentaloma underwent ultrasound-guided fine needle aspiration biopsy
3289469|NCT00551460|Experimental|Treatment|"Induction:~ATRA 45mg/m2 PO D1-CR Gemtuzumab Ozogamicin 9 mg/m2 IV D1 Arsenic Trioxide 0.15 mg/kg/d IV 5days/wk D10-CR~Consolidation 1 and 2:~Arsenic Trioxide 0.15 mg/kg/d IV 5days/wk x 5 weeks, repeat after 2 weeks rest~Consolidation 2 and 3:~ATRA 45 mg/m2 PO D1-7 Daunomycin 50 mg/m2/d IV D1-3~Consolidation 5 and 6:~GO 9mg/m2 IV D1~Maintenance:~ATRA 45 mg/m2/d PO D1-7 every 14 days 6-MP 60 mg/m2/d PO daily for 1 year Methotrexate 20 mg/m2 PO once/wk for 1 year"
3289470|NCT00551434|Experimental|1|
3289471|NCT00551434|Experimental|2|
3289472|NCT00551434|Experimental|3|
3289473|NCT00551434|Placebo Comparator|4|
3289474|NCT00551421|Experimental|Arm I|"Phase I: Patients receive pertuzumab IV over 30-60 minutes on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 2, 8, and 15 of course 1 and on days 1, 8, and 15 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Phase II: Patients receive treatment as in phase I. Pertuzumab is administered at the recommended phase II dose (determined in phase I)."
3289475|NCT00551408||A|
3289476|NCT00551408||B|
3289477|NCT00551395|Experimental|SLT Early Completion (Arm 1)|Intervention: 180 degrees of laser on Day 1, 180 degrees of laser on the other 180 degree on Day 2
3289478|NCT00551395|Active Comparator|SLT Late Completion (Arm 2)|Intervention: 180 degrees of laser on Day 1, 180 degrees of laser on the other 180 degrees at 1 month follow up appointment.
3289479|NCT00551382|Experimental|A|
3289480|NCT00551382|Placebo Comparator|B|
3289481|NCT00551369|Experimental|SBRT|Stereotactic body radiation therapy (SBRT)
3289482|NCT00551356|Active Comparator|2|Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
3289714|NCT00549614|Experimental|1|
3289483|NCT00551356|Active Comparator|1|Lispro mix 25 SC twice-daily in conjunction with oral antidiabetic medications.
3289484|NCT00551343|Other|PWS|
3289485|NCT00551343|Other|Controls|
3289486|NCT00551330|Experimental|1|Vicriviroc 30 mg QD
3289487|NCT00551330|Placebo Comparator|2|Placebo
3289488|NCT00551291|Experimental|Mycophenolate Mofetil + Prednisone + Erythropoietin Beta|Mycophenolate mofetil (MMF) 1 gm twice daily orally and prednisone 10 mg/day orally until the end of the study. Recombinant human erythropoietin beta 30,000 IU/week, subcutaneously for 6 weeks was added in case of no significant response at Week 12.
3289489|NCT00551278||1|Patients with previous diagnosis of breast cancer scheduled for sentinel lymph node dissection.
3289490|NCT00551265|Experimental|Arm I|Patients undergo delayed-type hypersensitivity (DTH) skin testing with oregovomab and a standard anergy panel (i.e., mumps, Candida, and tetanus toxoid) on day 0 (at baseline) and at week 14. The skin test response is measured 48 hours later. Patients receive cyclophosphamide IV on day 6 and oregovomab IV over 20 minutes on day 9 or 10. Patients then receive oregovomab alone at weeks 6 and 10 and then every 12 weeks for up to 2 years (10 doses) in the absence of disease progression or unacceptable toxicity.
3289491|NCT00551265|Active Comparator|Arm II|Patients undergo DTH skin testing and receive oregovomab as in arm I.
3289492|NCT00551252|Experimental|I|
3289493|NCT00551239|Active Comparator|Arm I (control)|Patients receive rituximab IV on day 1 and fludarabine phosphate IV on days 2-4. Treatment repeats every 28 days for up to 6 courses.
3289494|NCT00551239|Experimental|Arm II|Patients receive rituximab and fludarabine phosphate as in arm I. Patients also receive pixantrone IV on day 2. Treatment repeats every 28 days for up to 6 courses.
3289495|NCT00551226||1|Patients with tuberculosis
3289496|NCT00551226||2|Healthy controls
3289497|NCT00551213|Experimental|Robatumumab→Robatumumab|Participants receive 1 dose of robatumumab 0.3 mg/kg intravenously (IV) followed by 1 dose of robatumumab 10 mg/kg IV once every 2 weeks (Q2W) until disease progression. A cycle of robatumumab is defined as 2 weeks of treatment (i.e., 1 dose of robatumumab) with no recovery period between cycles.
3289498|NCT00551213|Active Comparator|Chemotherapy→Robatumumab|Participants receive 1 cycle of standard colorectal cancer chemotherapy currently approved and available on the market for use in colorectal cancer (to be selected by the Investigator based on participant's prior treatment) followed by 1 dose of robatumumab 10 mg/kg IV Q2W until disease progression. A cycle of robatumumab is defined as 2 weeks of treatment (i.e., 1 dose of robatumumab) with no recovery period between cycles.
3289499|NCT00551200|Active Comparator|BUPHENYL® to HPN-100 vs. HPN-100|Buphenyl treatment for one week was followed by dose escalation to HPN-100. Dose of Buphenyl was gradually decreased while HPN-100 dose was gradually increased until subject reached dosing of 100% HPN-100. HPN-100 at 100% of the dose was given for 1 week before subject was switched back to original Buphenyl treatment.
3289500|NCT00551187|Experimental|1|V504 + Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
3289501|NCT00551187|Placebo Comparator|2|Placebo + Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
3289502|NCT00551174|Experimental|1|
3289503|NCT00551174|Active Comparator|2|
3289504|NCT00551161|Experimental|single-arm|24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 20 mg per day, in addition to their ongoing stable cholinesterase inhibitor treatment
3289505|NCT00551148|Experimental|15 mg|
3289506|NCT00551148|Experimental|30 mg|
3289507|NCT00551148|Experimental|5 mg|
3289508|NCT00551148|Experimental|60 mg|
3289509|NCT00551148|Placebo Comparator|Placebo|
3289510|NCT00551135|Experimental|3|
3289511|NCT00551135|Placebo Comparator|4|
3289512|NCT00551135|Experimental|2|
3289513|NCT00551135|Experimental|1|
3289514|NCT00551122|Experimental|Paclitaxel, gemcitabine, cisplatin, ifosfamide|"Day 1 Dexamethasone sodium phosphate 25mg I/V ) before Chlorphenamine 10mg I/V 30 - 60 mins ) paclitaxel Ranitidine 50mg I/V ) Paclitaxel - 175 mg m2 I/V in 500ml normal saline over 3 hours Gemcitabine - 1200mg per m2 I/V in 500ml normal saline over 30 mins Days 1-5 Cisplatin 20mg per m2 in 1 litre normal saline over 4 hours 2 litres normal saline over 16 hours, each litre containing 10 mmol MgSO4 and 20mmol KCL.~If urine output is insufficient (less than 600ml per 6 hours) or if excessive weight gain (greater than 2kg) 100 - 200ml 10% mannitol should be used. Alternatively, low dose frusemide (20mg I/V) can be used.~Days 2 - 6 Ifosfamide 1G per m2 + MESNA 0.5G m2 in 500 ml normal saline over 1 hour after the cisplatin infusion.~MESNA 0.5G m2 to be included in first 1 litre post cisplatin hydration bag Pegylated G-CSF will be given on day 7 as an alternative to daily G-CSF."
3289515|NCT00551109|Placebo Comparator|P|Placebo
3289516|NCT00551109|Experimental|A1|SA4503
3289517|NCT00551109|Experimental|A2|SA4503
3289518|NCT00551096|Experimental|Gemcitabine, capecitabine and ZD6474|"Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.~Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off .~ZD6474 administered orally at 300 mg/day once daily. One cycle will consist of 28 days."
3289519|NCT00551083|Experimental|CDSS-D|Computer Decision Support System for Depression (CDSS-D) - This arm provided physicians with a computerized treatment algorithm and a decision support system to treat their patients suffering Major Depressive Disorder
3289520|NCT00551083|Active Comparator|UC|Usual Care (UC) - This group of physicians treated their patients suffering from Major Depressive Disorder with their standard treatment as usual, and received no algorithm support with regard to treatment decisions
3289521|NCT00551070|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3289522|NCT00551044|Active Comparator|Bicalutamide|Osteoporotic patients (T score ≤ -2.5) on bicalutamide
3289523|NCT00551031|Experimental|Influenza Virus Vaccine Formulation 1|Influenza Virus Vaccine Formulation 1
3289524|NCT00551031|Experimental|Influenza Virus Vaccine Formulation 2|Influenza Virus Vaccine Formulation 2
3289525|NCT00551031|Active Comparator|Fluzone® Elderly Group|
3289715|NCT00549614|Placebo Comparator|2|
3289526|NCT00551031|Active Comparator|Fluzone® High-dose Group|Participants enrolled at age ≥ 65 years
3289527|NCT00551031|Active Comparator|Fluzone® Adults Group|Participants enrolled at age 18-49 years.
3289528|NCT00551018|Experimental|Vicriviroc + Reyataz + ritonavir|vicriviroc 30 mg tablet QD + Reyataz® (atazanavir sulfate) 300 mg (1x300 mg capsule or 2x150 mg capsules) QD + Norvir® (ritonavir) 100 mg capsule QD
3289529|NCT00551018|Active Comparator|Truvada® + Reyataz + ritonavir|Truvada® 200/300 combination tablet QD + Reyataz® (atazanavir sulfate) 300 mg (1x300 mg capsule or 2x150 mg capsules) QD + Norvir® (ritonavir) 100 mg capsule QD
3289530|NCT00550979||1|Black women with history of pregnancy/ies complicated by gestational diabetes mellitus
3289531|NCT00550979||2|Black women with history of normal, uncomplicated pregnancy/ies
3289532|NCT00550979||3|White women with a history of pregnancy/ies complicated by gestational diabetes.
3289533|NCT00550979||4|White women with a history of normal, uncomplicated pregnancy/ies.
3289534|NCT00550966|Active Comparator|1|"Randomized controlled trial with a 12-month follow-up involving two groups, one of which is the intervention group that includes patients receiving a psychoeducative program and the other is the control group formed by patients treated for FM in the usual way.~Setting. Three urban PC centers in the province of Barcelona (Spain) Sample. The total sample comprises 218 patients (over 18 years of age) suffering FM, selected from a database (Rheumatology service-Viladecans hospital) of patients with this illness. Only those patients introduced in the database between the years 2005 and 2007 are included in the selection. Selected patients are asked for written informed consent to participate in the study."
3289535|NCT00550914||Control arm|The conventional therapy arm will undergo debridement with either a powered microdebrider or cold instrumentation excision as per the preference of the individual surgeon. Debridement will be deemed complete after removal of gross papilloma to the extent that the individual surgeon feels can be safely accomplished. Standard microsurgical principles of the larynx will guide debridement in that no opposing mucosal surfaces of the true vocal folds, laryngeal ventricle or inter-arytenoid space will be simultaneously debrided
3289536|NCT00550914||Experimental Arm|Patients enrolled into the conventional therapy plus PDL treatment arm will undergo debridement of the supraglottis and subglottis via conventional techniques as per the individual surgeons preferences followed by therapy to anterior commissure, true vocal folds, laryngeal ventricle and inter-arytenoid space with the pulsed dye laser. Standard laser settings will be a 450 microsecond pulse width, 5 J per pulse maximum of 1Hz, 1 mm spot fiber, 1-2 mm spot size and fluences of 38-255 J/cm2.
3289537|NCT00550875|Experimental|1|
3289538|NCT00550875|Experimental|2|10* concentration of arm 1
3289539|NCT00550875|Placebo Comparator|3|
3289540|NCT00550862|Experimental|INT-747 10 mg|INT-747 10 mg once daily in combination with URSO for 12 weeks.
3289541|NCT00550862|Experimental|INT-747 25 mg|INT-747 25 mg once daily in combination with URSO for 12 weeks.
3289542|NCT00550862|Experimental|INT-747 50 mg|INT-747 50 mg once daily in combination with URSO for 12 weeks.
3289543|NCT00550862|Placebo Comparator|Placebo|Placebo once daily in combination with URSO for 12 weeks.
3289544|NCT00550849|Experimental|1|RTA 402
3289545|NCT00550849|Experimental|2|RTA 402
3289546|NCT00550849|Experimental|3|RTA 402
3289547|NCT00550836|Active Comparator|Arm A: GE|Patients receive 1000 mg/m^2 gemcitabine hydrochloride IV on days 1, 8, and 15; and 100 mg oral erlotinib hydrochloride on days 1-28. Treatment repeats every 28 days for 2 courses. Patients achieving a complete response (CR) after 2 courses receive 2 additional courses of treatment; patients achieving a partial response (PR) receive retreatment as above. Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride and erlotinib hydrochloride until second progression.
3289548|NCT00550836|Experimental|Arm B: PGE|Patients receive 1000 mg/m^2 gemcitabine hydrochloride IV on days 1, 8, and 15; 100 mg oral erlotinib hydrochloride on days 1 - 28; and 4.0 mg/kg panitumumab IV on days 1 and 15. Treatment repeats every 28 days for 2 courses. Patients achieving a CR after 2 courses receive 2 additional courses of treatment; patients achieving a PR receive retreatment as above. Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride and panitumumab until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride, erlotinib hydrochloride, and panitumumab until second progression.
3289549|NCT00550823|Experimental|A,1|
3289550|NCT00550797|Experimental|No.1 ASM8 (oligonucleotide)|TPI ASM8 1mg/mL in phosphate buffered saline (PBS) solution; 1 mg will be administered daily (morning) by inhalation
3289551|NCT00550797|Placebo Comparator|Phosphate Buffer solution|Placebo solution (PBS) will be administered daily in the form of 1 mL of PBS (phosphate buffered saline) by inhalation
3289552|NCT00550771|Active Comparator|Doxorubicin Based Regimen|
3289553|NCT00550771|Experimental|Pegylated Liposomal Doxorubicin (PLD) Based Regimen|
3289554|NCT00550745|Experimental|1|Arm 1: vaccine
3289555|NCT00550745|Placebo Comparator|2|Arm 2: Placebo Comparator
3289556|NCT00550732|Experimental|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
3289557|NCT00550706||1Pediatric Dept A|Children's files from this department will be analysed once weekly and medication prescription data will be registered
3289558|NCT00550706||2 Pediatric Dept B|Children's files from this department will be analysed once weekly and medication prescription data will be registered
3289559|NCT00550693|Placebo Comparator|A|The patients in this arm continued with the local catheter care protocol.
3289560|NCT00550680|Experimental|Mircera in Renal Anemia|Participants with chronic renal anemia who have been previously treated with erythropoiesis-stimulating agent (ESA) therapy will receive IV Mircera every 4 weeks for a total of 24 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment. Subsequent doses will be adjusted to maintain Hb concentrations within target of 10.5 and 12.5 grams per deciliter (g/dL).
3289561|NCT00550654|Experimental|Radiation Therapy in Metastatic Cancer|Patients undergo hypofractionated highly conformal radiotherapy with helical tomotherapy once every other day over 5 days for a total of 3 fractions.
3289562|NCT00550641|Active Comparator|1|
3289564|NCT00550628||resection of a non-sarcomatous primary colon neoplasm|The surgically removed colon will undergo ex-vivo imaging after examination in pathology. A PET scanner will be used to acquire a scan of the whole specimen.
3289565|NCT00550615|Active Comparator|Dose Cohort # 1|
3289566|NCT00550615|Active Comparator|Dose Cohort # 2|
3289567|NCT00550615|Active Comparator|Dose Cohort # 3|
3289568|NCT00550589|Experimental|Cidofovir|1.0% topical cidofovir cream
3289569|NCT00550576|Experimental|digibind|Injection of digibind and psychological tests
3289570|NCT00550563|Experimental|Oral Cholecalciferol|Patients receive oral cholecalciferol 2000 IU once daily for 1 year
3289571|NCT00550550|Placebo Comparator|Placebo|Matching Placebo
3289572|NCT00550550|Experimental|SCH 697243|Grass Sublingual Tablet (Phleum pratense extract)
3289573|NCT00550537|Experimental|Treatment|Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
3289574|NCT00550524|Experimental|A|Knee osteoarthritis
3289575|NCT00550511|Other|Ultrasound|Surgeon-performed ultrasound as intervention, as a complement to clinical investigation and standardized laboratory testing.
3289576|NCT00550511|No Intervention|Control|Control group examined with clinical examination including standardized laboratory tests.
3289577|NCT00550498|Experimental|A|Behcet's Disease with ocular lesions
3289578|NCT00550485|Other|1|Healthy subjects with a single nucleotide polymorphism (SNP) of the ABCB1-gene (Genotype A)
3289579|NCT00550485|Other|2|Healthy subjects with a single nucleotide polymorphism (SNP) of the ABCB1-gene (Genotype B)
3289580|NCT00550472|Experimental|Probiotic|intervention
3289581|NCT00550459|Placebo Comparator|1|Placebo tablet given once a day for 21 days
3289582|NCT00550459|Active Comparator|2|Tolvaptan 15 mg-60 mg tablet given once a day for 21 days.
3289583|NCT00550446|Active Comparator|1|
3289584|NCT00550446|Experimental|2|
3289585|NCT00550446|Experimental|3|
3289586|NCT00550446|Experimental|4|
3289587|NCT00550446|Experimental|5|
3289588|NCT00550446|Experimental|6|
3289589|NCT00550446|Placebo Comparator|7|
3289590|NCT00550420|Experimental|Arm 1|Rosiglitazone XR
3289591|NCT00550407|Placebo Comparator|Placebo|
3289592|NCT00550407|Active Comparator|BW430C(lamotrigine)|
3289593|NCT00550394|Active Comparator|Quetiapine and Placebo|Quetiapine and Placebo
3289594|NCT00550394|Experimental|Quetiapine and Topiramate|Quetiapine and Topiramate
3289595|NCT00550381|Placebo Comparator|1|10mg
3289596|NCT00550381|Placebo Comparator|2|20mg
3289597|NCT00550381|Placebo Comparator|3|40mg
3289598|NCT00550381|Placebo Comparator|4|80mg
3289599|NCT00550381|Placebo Comparator|5|160mg
3289600|NCT00550381|Placebo Comparator|6|240mg
3289601|NCT00550381|Placebo Comparator|7|400mg
3289602|NCT00550381|Placebo Comparator|8|640mg
3289603|NCT00550381|Placebo Comparator|9|960mg
3289604|NCT00550381|Placebo Comparator|10|placebo
3289605|NCT00550368|Experimental|Helicobacter pylori negative|Persons who tested negative for H. pylori by both serology and Urea breath test. All participants will receive the Biological intervention: Enteropathogenic E. coli.
3289606|NCT00550368|Experimental|Helicobacter pylori positive|Persons who tested positive for H. pylori by both serology and Urea breath test. All participants will receive the Biological intervention: Enteropathogenic E. coli.
3289607|NCT00550355|Experimental|1|
3289608|NCT00550355|Experimental|2|
3289609|NCT00550355|Experimental|3|
3289610|NCT00550355|Placebo Comparator|4|
3289611|NCT00550342|Experimental|Rituximab|Rituximab (375 mg/m2) will be administered intravenously as per current package label in a facility capable of handling infusion reactions. Subjects would be pre dosed with diphenhydramine and acetaminophen. Solu-Medrol, 1.5 mg/kg would be dosed 1 hour prior to the first dose of rituximab. Three subsequent doses of rituximab will be given at weekly intervals.
3289612|NCT00550290|No Intervention|1|
3289613|NCT00550290|Active Comparator|2|Patients receiving 24 hours of prophylactic antibiotics in the post-operative period following vulvectomy.
3289614|NCT00550277|Other|Treatment|LBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring, all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles. Patients with objective response or stable disease after re-evaluation at week 8 will continue LBH589 at the same dose until disease progression, unacceptable toxicity and/or at the discretion of the investigator.
3289615|NCT00550264|Experimental|1|
3289616|NCT00550264|No Intervention|2|
3289617|NCT00550251|Active Comparator|Acupressure Bands|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
3289618|NCT00550251|Placebo Comparator|Placebo|Elasticated wrist bands without active bead.
3289619|NCT00550238|Experimental|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
3289620|NCT00550225|Experimental|Sequence 1|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by placebo in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and 1500 micrograms of GSK961081 edisylate in session 4.
3289621|NCT00550225|Experimental|Sequence 2|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by 1500 micrograms of GSK961081 edisylate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and placebo in session 4.
3289622|NCT00550225|Experimental|Sequence 3|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by placebo in session 2. The subjects will receive 1500 micrograms of GSK961081edisylate in session 3 and an additional dose of GSK961081 succinate in session 4.
3289623|NCT00550225|Experimental|Sequence 4|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by 1500 micrograms of GSK961081 edisylate in session 2. The subjects will receive placebo in session 3 and an additional dose of GSK961081 succinate in session 4.
3289716|NCT00549601|Experimental|Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|
3289624|NCT00550225|Experimental|Sequence 5|In session 1, subjects will receive 1500 micrograms of GSK961081 edisylate followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and placebo in session 4.
3289625|NCT00550225|Experimental|Sequence 6|In session 1, subjects will receive placebo followed by 900 micrograms of GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and 1500 micrograms of GSK961081 edisylate in session 4.
3289626|NCT00550225|Experimental|Sequence 7|In session 1, subjects will receive 1500 micrograms of GSK961081 edisylate followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive placebo in session 3 and an additional dose of GSK961081 succinate in session 4.
3289627|NCT00550225|Experimental|Sequence 8|In session 1, subjects will receive placebo followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 edisylate in session 3 and an additional dose of GSK961081 succinate in session 4.
3289628|NCT00550212|Experimental|1|240 mg
3289629|NCT00550199|Experimental|LBH589 and Gemcitabine|Phase I dose escalation study
3289630|NCT00550186|Placebo Comparator|1|No preload
3289631|NCT00550186|Active Comparator|2|Preload with cristalloid infusion
3289632|NCT00550186|Active Comparator|3|Preload with collid infusion
3289633|NCT00550173|Experimental|Pemetrexed + Erlotinib|Pemetrexed 500 milligrams per meter squared (mg/m^2) of body surface area, administered by intravenous (IV) infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
3289634|NCT00550173|Active Comparator|Erlotinib|Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
3289635|NCT00550173|Active Comparator|Pemetrexed|Pemetrexed 500 mg/m^2 of body surface area, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months.
3289636|NCT00550160|Active Comparator|1|The Home Management of Malaria (HMM) is a strategy aimed at improving access to prompt and effective antimalarial treatment of all fevers in children under 5 years. Community Drug Distributors (CDD) have been trained and equipped for this task.
3289637|NCT00550160|Experimental|2|An Intermittent Preventive Treatment (IPTc) schedule for asymptomatic pre-school children during high malaria transmission seasons alongside an ongoing Home Management of Malaria programme
3289638|NCT00550147|Experimental|1|Oros Methylphenidate and Quetiapine
3289639|NCT00550134||1, Non Cancer group|A noncancer control group (N=35), frequency matched on age (< 50 and ≥ 50) and education (less than college or some college and above) will also be recruited and evaluated with the same neuropsychological test battery on a schedule that matches the inter-test interval of the patients.
3289640|NCT00550134||2 Breast Cancer Patients Scheduled for chemotherapy|We will recruit patients with localized breast cancer undergoing adjuvant chemotherapy for the first time and will test the effects of chemotherapy will be given a battery of neuropsychological tests and an MRI evaluation prior to beginning chemotherapy and approximately one month (plus/minus 4 weeks) following completion of treatment.
3289641|NCT00550134||3 Breast Cancer Patients Not Scheduled for Chemotherapy|We will recruit patients with localized breast cancer not undergoing adjuvant chemotherapy.
3289642|NCT00550121|Experimental|1|
3289643|NCT00550121|Placebo Comparator|2|
3289644|NCT00550108|No Intervention|A|Observation of pancreatic cysts
3289645|NCT00550108|Experimental|B|Ethanol lavage of pancreatic cysts
3289646|NCT00550095|Experimental|1|valsartan
3289647|NCT00550056|Experimental|1|NET
3289648|NCT00550056|Experimental|2|TC
3289649|NCT00550056|No Intervention|3|Monitoring Group
3289650|NCT00550043|Experimental|Cohort 1: Treatment Group A|INCB018424 15 mg twice daily (BID) or matching placebo
3289651|NCT00550043|Experimental|Cohort 2: Treatment Group B|INCB018424 5 mg BID or matching placebo
3289652|NCT00550043|Experimental|Cohort 2: Treatment Group C|INCB018424 25 mg BID or matching placebo
3289653|NCT00550043|Experimental|Cohort 2: Treatment Group D|INCB018424 50 mg once daily (QD) or matching placebo
3289654|NCT00550043|Placebo Comparator|Placebo|Matching placebo, oral
3289655|NCT00550030|Experimental|left/right|half-body comparison
3289656|NCT00550017|Experimental|1|
3289657|NCT00550004|Active Comparator|Arm 1|RP101 and Gemcitabine
3289658|NCT00550004|Placebo Comparator|Arm 2|Placebo and Gemcitabine
3289659|NCT00549978|Other|1|Two compartments with cross-over and parallel
3289660|NCT00549978|Other|2|Two compartments with cross-over and parallel
3289661|NCT00549939|Placebo Comparator|Placebo|Matching placebo 0.1 mg/kg/day or 0.2 mg/kg/day
3289662|NCT00549939|Experimental|Alfuzosin 0.1 mg/kg/day|
3289663|NCT00549939|Experimental|Alfuzosin 0.2 mg/kg/day|
3289664|NCT00549926|Active Comparator|1|
3289665|NCT00549926|Active Comparator|2|
3289666|NCT00549926|Active Comparator|3|
3289667|NCT00549926|Active Comparator|4|
3289668|NCT00549913|Experimental|1|10 subjects to receive lowest dose of NeoFuse (MPCs)
3289669|NCT00549913|Active Comparator|2|4 subjects standard posterolateral spinal fusion with instrumentation
3289670|NCT00549913|Experimental|3|10 subjects to receive middle dose of NeoFuse
3289671|NCT00549913|Active Comparator|4|3 subjects standard posterolateral spinal fusion with instrumentation
3289672|NCT00549913|Experimental|5|10 subjects to receive highest dose of NeoFuse
3289673|NCT00549913|Active Comparator|6|3 subjects with standard posterolateral spinal fusion with instrumentation
3289674|NCT00549900|Experimental|Cervarix Group|Subjects received 3 doses of GSK580299 vaccine (Cervarix™, HPV -16/18 L1 VLP AS04 vaccine) according to a 0, 1, 6-month schedule.
3289675|NCT00549887||Rapid acting to short acting|Patients on rapid-acting analog insulins who switch to short-acting human insulin
3289676|NCT00549887||Short acting to rapid acting|Patients on short-acting human insulins who switch to rapid-acting analog insulin
3289677|NCT00549874|Experimental|1|
3289678|NCT00549874|Experimental|2|
3289679|NCT00549861|No Intervention|A1|CMR study for the assessment of irreversible tissue damage
3289680|NCT00549848|Experimental|HD PEG|"Participants randomized to receive higher dose PEG-asparaginase during the continuation phase.~Interventions:~Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine~Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib"
3289681|NCT00549848|Active Comparator|CD PEG|"Participants randomized to receive conventional dose PEG-asparaginase during the continuation phase..~Interventions:~Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine~Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib"
3289682|NCT00549835|Active Comparator|Real Acupuncture|Participants will have acupuncture performed at a rate of 3 times (Mon, Wed, Fri) / week for total of 2 weeks (total of 6 sessions). We will follow Saam Acupuncture methods, which have been the mainstream of acupuncture methodology in most Korean Oriental Medical Colleges and among clinical practitioners >400 years. Standardized acupuncture prescriptions for mucositis will be acupuncture points tonifying Spleen Meridian (R side) and Small Intestine Meridian (L side). In Oriental Medicine, the spleen has functions of promoting water metabolism, transporting nutrients, and controlling blood. Mouth belongs to the spleen system according to Five element theory. Small intestine is related with mucositis symptoms including thirst and tongue ulcers. We will use sterile, disposable, filiform needles, size 0.16 (40Gauge) - 0.30 mm (30Gauge) in diameter and 15-40 mm long. Total number of acupuncture needles will be 8 (4 needles each side) and needles will be retained for 20 minutes.
3289683|NCT00549835|Sham Comparator|Sham Acupuncture|Newly diagnosed leukemia patients will be recruited from the large patient population on the Leukemia Inpatient Services who will be receiving high dose preperative regimens such as Busulfan + Cytarabine for marrow transplantation.
3289684|NCT00549822|Experimental|Intermittent letrozole therapy|Letrozole 2.5 mg administered by mouth daily during each 28 day treatment cycle. Treatment is intermittent with possible breaks between each 28 day treatment cycle based on CA 15-3 or CA 27.29 levels. Letrozole is administered until the participant has disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors), experiences severe side effects, or decides to stop treatment.
3289685|NCT00549809|Active Comparator|IMV, SIMV|
3289686|NCT00549796|Active Comparator|1|PCI performed at a hospital with co-located (on-site) cardiac surgery
3289687|NCT00549796|Other|2|PCI performed at a hospitals without co-located (on-site) cardiac surgery
3289688|NCT00549783|Active Comparator|Botulinum toxin type A 900kD|First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
3289689|NCT00549783|Placebo Comparator|Placebo|First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
3289690|NCT00549770|Experimental|LCZ696 100 mg|Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
3289691|NCT00549770|Experimental|LCZ696 200 mg|Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
3289692|NCT00549770|Experimental|LCZ696 400 mg|Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
3289693|NCT00549770|Active Comparator|Valsartan 80 mg|Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
3289694|NCT00549770|Active Comparator|Valsartan 160 mg|Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsatan and AHU377 (5 tablets and 2 capsules) daily.
3289695|NCT00549770|Active Comparator|Valsartan 320 mg|Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
3289696|NCT00549770|Experimental|AHU377 200 mg|Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.
3289697|NCT00549770|Placebo Comparator|Placebo|Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
3289698|NCT00549757|Experimental|Aliskiren|"In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.~With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment"
3289699|NCT00549757|Placebo Comparator|Placebo|"In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.~With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment."
3289700|NCT00549718|Experimental|Lurasidone 40mg|
3289701|NCT00549718|Experimental|Lurasidone 80mg|
3289702|NCT00549718|Experimental|Lurasidone 120mg|
3289703|NCT00549718|Placebo Comparator|Sugar Pill|
3289704|NCT00549692|Experimental|Omacor|
3289705|NCT00549692|Placebo Comparator|Placebo Omacor|
3289706|NCT00549679|Experimental|25 mcg|25 microgram inhaled once daily
3289707|NCT00549679|Experimental|87.5 mcg|87.5 microgram inhaled once daily
3289708|NCT00549679|Placebo Comparator|Placebo|Placebo inhaled once daily
3289709|NCT00549666|Experimental|Lurasidone 40 mg|
3289710|NCT00549666|Placebo Comparator|Placebo|
3289711|NCT00549666|Active Comparator|Ortho Tri-Cyclen|
3289712|NCT00549640|Active Comparator|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
3289713|NCT00549640|Placebo Comparator|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
3289718|NCT00549601|Active Comparator|Rivastigmine capsules (6 mg to 12 mg/day)|
3289719|NCT00549575|Experimental|A|Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories). Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venous was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
3289720|NCT00549575|Placebo Comparator|B|After double blind randomization, patients received a placebo. Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venous was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
3289721|NCT00549562|Other|Paliperidone ER|8-Week Open-Label
3289722|NCT00549549|Active Comparator|1|
3289723|NCT00549549|Experimental|2|
3289724|NCT00549549|Experimental|3|
3289725|NCT00549549|Experimental|4|
3289726|NCT00549536|No Intervention|2|
3289727|NCT00549536|Active Comparator|1|Patients on calcium supplementation
3289728|NCT00549523|Placebo Comparator|Placebo|Placebo (capsule filled with inert materials)
3289729|NCT00549523|Experimental|Low Dose|400 mg bid Lessertia Frutescens
3289730|NCT00549523|Experimental|Mid Dose|800 mg bid Lessertia Frutescens
3289731|NCT00549523|Experimental|High Dose|1200 bid Lessertia Frutescens
3289732|NCT00549497|Other|GW870086X|
3289733|NCT00549484||1|10 mL/kg platelet transfusion
3289734|NCT00549484||2|15 mL / kg platelet transfusion
3289735|NCT00549471|Experimental|BG|cooperative quadriplegic CP children ages 8-11 years, gross motor function level 4 with troublesome hypertonia that will respond to treatment. BG children will be given Botulinum Toxin A, as clinically required, in addition to an equivalent program of intensive therapy
3289736|NCT00549471|No Intervention|Control Group|control group: Twenty cooperative quadriplegic CP children ages 8-11 years, gross motor function level 4 with troublesome hypertonia that will respond to treatment.CG children will undergo a program of intensive therapy.
3289737|NCT00549445||Azithromycin-treated|Participants in the COPD Network Macrolide Study who received azithromycin for 1 year.
3289738|NCT00549445||Placebo-treated|Participants in the COPD Network Macrolide Study who received placebo for 1 year.
3289739|NCT00549432|Experimental|1|
3289740|NCT00549419|Experimental|1|In the Treatment group, the traditional vital signs and APCO are made continuously available for fluid and catecholamine optimization and clinical decision making.
3289741|NCT00549419|Active Comparator|2|
3289742|NCT00549406|Experimental|1|computer-based visual-training program UFOV
3289743|NCT00549406|Experimental|2|video-game based visual training
3289744|NCT00549406|Placebo Comparator|3|computerized word puzzles
3289745|NCT00549393|Experimental|1|Daily bathing with 2% chlorhexidine gluconate
3289746|NCT00549393|No Intervention|2|Standard bathing with soap and water basin or disposable cloth
3289747|NCT00549380|Experimental|1|
3289748|NCT00549367|Other|1|Clients in the control arm of the study will receive nutrition assessment only for the first 24 weeks and the be transferred to nutrition counselling group
3289749|NCT00549341|Active Comparator|1|
3289750|NCT00549341|Placebo Comparator|2|
3289751|NCT00549328|Experimental|Pazopanib Open-label|Single-arm, non-randomised, single-stage pazopanib monotherapy.
3289752|NCT00549315|Experimental|1|
3289753|NCT00549302|Active Comparator|20 mg tadalafil|20 milligram (mg) tadalafil taken once a day
3289754|NCT00549302|Active Comparator|40 mg tadalafil|40 mg tadalafil tablet taken once a day
3289755|NCT00549237|Active Comparator|Nutrition|Pre-operative Glucose load and post-operative immediate enteral nutrition
3289756|NCT00549237|No Intervention|Control|No pre-operative glucose load. No early post-operative nutrition
3289757|NCT00549198|Experimental|ABC/3TC + EFV|
3289758|NCT00549198|Active Comparator|TDF/FTC + EFV|
3289759|NCT00549172|Active Comparator|Operative (O)|Partial resection of degenerative tear of medial meniscus
3289760|NCT00549172|Sham Comparator|Conservative (K)|Arthroscopy (diagnostic)
3289761|NCT00549159|Experimental|Cavaterm|
3289762|NCT00549159|Active Comparator|TCRE|Transcervical resection of the endometrium
3289763|NCT00549120|Experimental|Propranolol alone|Propranolol 80 mg (5 doses at 6 hourly intervals)
3289764|NCT00549120|Experimental|Propranolol + salbutamol|Propranolol 80 mg (5 doses at 6 hourly intervals) + salbutamol 600 μg (4 doses at 6 hourly intervals)
3289765|NCT00549120|Experimental|Salbutamol alone|Salbutamol 600 μg (4 doses at 6 hourly) + placebo (5 doses at 6 hourly intervals)
3289766|NCT00549120|Placebo Comparator|Placebo|Placebo (5 doses at 6 hourly)
3289767|NCT00549120|Experimental|Propranolol + ipratropium + salbutamol|Propranolol 80 mg (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose)
3289768|NCT00549120|Experimental|Placebo + ipratropium + salbutamol|Placebo (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose)
3289769|NCT00549107|Experimental|1|
3289770|NCT00549107|Active Comparator|2|
3289771|NCT00549081|Experimental|1|IVF patients who had a low ovarian response in a previous hormonal-stimulation treatment, treated with recombinant FSH and LH.
3289772|NCT00549081|No Intervention|2|IVF patient who had a low ovarian response in a previous hormonal-stimulation treatment, treated with recombinant FSH and LH.
3289773|NCT00549055||1|Patients who obtained reimbursement of Macugen.
3289774|NCT00549042|Experimental|Oros Hydromorphone|
3289775|NCT00549042|Placebo Comparator|placebo|
3289776|NCT00549029||1,2|Group 1 for the patients with rhabdomyolysis Group 2 for the control without any myopathy
3289777|NCT00549016|Experimental|1|
3289778|NCT00548990|Experimental|1|a 10-month moderate aerobic exercise training program
3289779|NCT00548990|Placebo Comparator|2|flexibility/balance control group
3289780|NCT00548964|Experimental|Ketamine + Lithium|All participants receive the study drug, IV ketamine, open-label
3289781|NCT00548964|Active Comparator|Ketamine + Placebo|All participants receive the study drug, IV ketamine, open-label
3289782|NCT00548951|Active Comparator|1|Subject receives Snoezelen sessions once per week.
3289783|NCT00548951|Active Comparator|2|Subject receives Snoezelen sessions three times per week.
3289784|NCT00548951|Other|3|Subject receives no sessions per week.
3289785|NCT00548925|Experimental|1|
3289786|NCT00548925|Placebo Comparator|2|
3289787|NCT00548899|Other|Sorafenib|Single Arm: All patients receive sorafenib in addition to the established chemotherapy
3289788|NCT00548886|Experimental|Epinephrine|Healthy pediatric subjects will receive epinephrine. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes.The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes. The epinephrine infusion is then discontinued.
3289789|NCT00548860|Experimental|Ferric Carboxymaltose (FCM)|Undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg)
3289790|NCT00548860|Active Comparator|Standard Medical Care (SMC)|Varied as determined by the Investigator
3289791|NCT00548847|Experimental|GM-CSF, Interferon-α-2b|
3289792|NCT00548821|Experimental|2|ARM 2: Weekly cisplatin 40mg/m2, concurrent with radiotherapy.
3289793|NCT00548821|Experimental|1|ARM 1: 5-day 3 weekly cisplatin 20mg/m2 for 5 days, concurrent with radiotherapy
3289794|NCT00548808|Experimental|Insulin lispro low mixture|Insulin lispro low mixture (1, 2 or 3 daily injections)
3289795|NCT00548808|Active Comparator|Insulin glargine|Insulin glargine (alone or with 1, 2 or 3 daily injections of insulin lispro)
3289796|NCT00548782|Active Comparator|A|Subjects will be placed on Paleolithic diet and markers of insulin resistance, lipid profiles and vascular reactivity will be measured.
3289797|NCT00548782|Active Comparator|B|Subjects will be placed on ADA ( American Diabetes Association) recommended diet and markers of insulin resistance, lipid profiles and vascular reactivity will be measured.
3289798|NCT00548769|Experimental|Sequence ADBC|Subjects will be administered formulation A, formulation D, formulation B and formulation C across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
3289799|NCT00548769|Experimental|Sequence BACD|Subjects will be administered formulation B, formulation A, formulation C and formulation D across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
3289800|NCT00548769|Experimental|Sequence CBDA|Subjects will be administered formulation C, formulation B, formulation D and formulation A across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
3289801|NCT00548769|Experimental|Sequence DCAB|Subjects will be administered formulation D, formulation C, formulation A and formulation B across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
3289802|NCT00548756|Experimental|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy
3289803|NCT00548756|Other|Observation|Observation
3289804|NCT00548743|Experimental|1|Intervention arm
3289805|NCT00548743|Placebo Comparator|2|Usual care
3289806|NCT00548730||Observation|Patients with known or suspected malignancies of the lung and with a medical indication for a bronchoscopy
3289807|NCT00548717|Experimental|Siro/MMF|Sirolimus and Mycophenolate Mofetil as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF)
3289808|NCT00548717|Experimental|Siro/MMF/Bort|Sirolimus, Mycophenolate Mofetil, and Bortezomib as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF) Bortezomib (Velcade) *added with study reopening in 2012
3289809|NCT00548691|Experimental|Ferric Carboxymaltose (FCM)|Subjects received an undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg) or subjects received 200 mg of FCM IV push undiluted directly into the venous line of the dialyzer.
3289810|NCT00548691|Active Comparator|Standard Medical Care (SMC)|SMC for IDA (as determined by the Investigator) for treating CKD related anemia.
3289811|NCT00548678|Experimental|A|intravenous diclofenac sodium
3289812|NCT00548678|Active Comparator|B|intravenous ketorolac
3289813|NCT00548678|Active Comparator|C|oral diclofenac (Cataflam)
3289814|NCT00548678|Active Comparator|D|oral aspirin
3289815|NCT00548665|Experimental|1|Carotid plaque screening and brief advice for smoking cessation: Smokers with at least one carotid plaque will receive pictures of their own plaques with a structured explanation on the general significance of plaques.
3289816|NCT00548665|Active Comparator|2|Brief advice for smoking cessation (without carotid ultrasound for plaque screening): to ensure equal contact conditions, smokers not undergoing ultrasound will receive a relevant explanation on the risks associated with tobacco smoking.
3289817|NCT00548652|No Intervention|1|standard nutrition counselling
3289818|NCT00548652|Experimental|2|MOVE -weight loss intervention
3289819|NCT00548652|Experimental|3|MOVE plus medical crisis counselling
3289820|NCT00548652|Experimental|4|MOVE plus methylphenidate
3289821|NCT00548652|Experimental|5|MOVE plus methyphenidate plus medical crisis counselling
3289822|NCT00548639|Experimental|1|Statin Choice Decision Aid
3289823|NCT00548639|Sham Comparator|2|Control Pamphlet
3289824|NCT00548626|Active Comparator|A|Patients assigned to simple needle group (SN) will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
3289865|NCT00548314|Experimental|2|After excision and adequate hemostasis, the selected wound will be treated with the dermal substitute Matriderm, a split skin graft (SSG), mesh 1:1.5.
3289825|NCT00548626|Experimental|B|Patients assigned to multiple needle group (MN) will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
3289826|NCT00548613|Experimental|A|Patients with documented acute myocardial infarction (heart attack) occurring within 4-24 hours after onset of symptoms
3289827|NCT00548613|Experimental|B|Candidates for coronary artery bypass grafting that suffered a myocardial infarction (heart attack) within the past 12 months
3289828|NCT00548600|Experimental|1|Iridium implant plus external beam irradiation
3289829|NCT00548600|Active Comparator|2|Standard external beam irradiation alone
3289830|NCT00548587|Active Comparator|1|Participants will receive one 50 mg E5555 tablet and two 100 mg placebo tablets, once daily for 12 weeks.
3289831|NCT00548587|Active Comparator|2|Participants will receive one 50 mg placebo tablet, one 100 mg E5555 tablet, and one 100 mg placebo tablet, once daily for 12 weeks.
3289832|NCT00548587|Active Comparator|3|Participants will receive one 50 mg placebo tablet and two 100 mg E5555 tablets, once daily for 12 weeks.
3289833|NCT00548587|Placebo Comparator|4|Participants will receive one 50 mg placebo tablet and two 100 mg placebo tablets, once daily for 12 weeks.
3289834|NCT00548548|Experimental|Bevacizumab|Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.
3289835|NCT00548548|Placebo Comparator|Placebo|Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.
3289836|NCT00548522||1|Pregnant (12 - 16 wks gestation) women with Type 1 diabetes
3289837|NCT00548522||2|Pregnant women (34-38 wks gestation) with Type 1 diabetes
3289838|NCT00548522||3|Post partum women with Type 1 diabetes
3289839|NCT00548522||4|Non pregnant women with Type 1 diabetes
3289840|NCT00548496|Experimental|Placebo-Controlled based on the two Intervention Groups below|Placebo-Controlled based on the two Intervention Groups below.
3289841|NCT00548483|Active Comparator|1|dexamethasone 5mg was administered every 6 hour for 1 day
3289842|NCT00548483|Active Comparator|2|dexamethasone 10mg was administered every 6 hour for 1 day
3289843|NCT00548470|Experimental|vareniciline|open label varenicline 2mg/day
3289844|NCT00548457||A|
3289845|NCT00548444|Experimental|Group 1|Volunteers will receive a single dose of MVA85A followed by regular blood tests to measure the resulting cellular immune response.
3289846|NCT00548444|Experimental|Group 2|Volunteers will receive a single dose of MVA85A followed by an infusion of labelled (deuterated) glucose and regular blood tests.
3289847|NCT00548444|Experimental|Group 3|Volunteers will receive a single dose of MVA85A followed by an infusion of labelled (deuterated) glucose and regular blood tests.
3289848|NCT00548431|Experimental|6 mercaptopurine arm|All patients received basic daily 6MP (6-mercaptopurine) (25 mg/m^2) and in addition high-dose methotrexate(HDM) every 3rd week (3 times HDM in total) and PEG-asparaginase every 14th day. Patients increased the dose of 6MP 2 weeks after each HDM if if the myelotoxicity had been acceptable. This means 2 increments since the study stopped 2 weeks after the last HDM
3289849|NCT00548418|Experimental|I|"Cisplatin 50 mg/m2 IV day 1 of a 21 day cycle~Topotecan 0.75 mg/m2 IV Days 1, 2, 3 of a 21 day cycle~Bevacizumab 15 mg/kg day 1 of a 21 day cycle"
3289850|NCT00548405|Experimental|Alemtuzumab 12 mg|Alemtuzumab (Lemtrada™) 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
3289851|NCT00548405|Experimental|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
3289852|NCT00548405|Active Comparator|Interferon Beta-1a|Interferon Beta-1a (Rebif®) 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
3289853|NCT00548379|Active Comparator|1|Vitamin D
3289854|NCT00548379|Placebo Comparator|2|
3289855|NCT00548366|Experimental|1|4 gram sodium diet
3289856|NCT00548366|Active Comparator|2|2 gram sodium diet
3289857|NCT00548353|Experimental|1|MK3207 Orally administered to patients with water. During each period (with and without acute migraine).
3289858|NCT00548353|Placebo Comparator|2|MK3207 placebo as tablets will be Orally administered to patients with water. During each period (with and without acute migraine).
3289859|NCT00548340|Experimental|VEC-162 20 mg|VEC-162 (tasimelteon) 20 mg capsules PO daily for five weeks
3289860|NCT00548340|Experimental|VEC-162 50 mg|VEC-162 (tasimelteon) 50 mg capsules PO daily for five weeks
3289861|NCT00548340|Placebo Comparator|Placebo|Placebo capsules PO daily five weeks
3289862|NCT00548327|Active Comparator|Atomoxetine|"Atomoxetine 80 mg final dose. Arm lasts 14 days.~Schedule 25 mg Day 1 (or Day 22), 40 mg Day 2-3 (or Days 23-24), 60 mg Days 4-5 (or Days 25-26), 80 mg Days 6-14 (or Days 27-35).~After 14 days, subjects undergo functional magnetic resonance imaging (MRI) and neuropsychological testing in addition to psychopathology ratings"
3289863|NCT00548327|Placebo Comparator|Placebo|"Placebo administered for 14 days. Schedule Atomoxetine 25 mg Placebo Day 1 (or Day 22), Atomoxetine 40 mg Placebo Day 2-3 (or Days 23-24), Atomoxetine 60 mg Placebo Days 4-5 (or Days 25-26), Atomoxetine 80 mg Placebo Days 6-14 (or Days 27-35).~After 14 days, subjects undergo functional magnetic resonance imaging and neuropsychological testing in addition to psychopathology ratings"
3289864|NCT00548314|Experimental|1|After excision and adequate hemostasis, the selected wound will be treated with the dermal substitute Matriderm, a split skin graft (SSG), mesh 1:1.5 and VAC therapy. The VAC system will be set at 125mmHg, continuous mode, for 3-5 days.
3289957|NCT00547573|Active Comparator|2|10 mg tadalafil tablet
3289958|NCT00547573|Active Comparator|3|20 mg tadalafil tablet
3289866|NCT00548314|Experimental|3|After excision and adequate hemostasis, the selected wound will be treated with a split skin graft (SSG), mesh 1:1.5 and VAC therapy. The VAC system will be set at 125mmHg, continuous mode, for 3-5 days.
3289867|NCT00548314|Active Comparator|4|After excision and adequate hemostasis, the selected wound will be treated with a split skin graft (SSG), mesh 1:1.5.
3289868|NCT00548275|Experimental|1|Enhanced Sexual Risk Management (ESRM): Patients assigned to ESRM will attend 4 individual gender-specific interactive counseling sessions, once weekly over a four-week period. They will attend 2 sessions (20 minutes, weeks 2 and 3) followed by 2 sessions (40 minutes, weeks 4 and 5) that will be gender-specific to the patient and gender-matched with the study physicians (one female and one male) who will be trained in HIV testing and risk counseling. Sessions will include skill-building in condom use, safer sex negotiation, self-control of triggers and coping skills, didactic materials, and distribution of written material and address self-perception of risk, barriers to risk reduction, and negotiation of a risk-reduction plan.
3289869|NCT00548275|Active Comparator|2|Standard Sexual Risk Management (SSRM): In SSRM, patients will attend two 10-minute gender non-specific individual educational sessions about HIV/AIDS provided by one of the study physicians who will be trained in HIV testing and risk counseling. Session 1 will coincide with the physician visit at the time of randomization. The patient will receive pre-test counseling at this time and undergo HIV antibody testing. Session 2 will take place 7 days later when the patient returns to receive their HIV test results and post-test counseling. In addition, subjects will receive didactic prevention messages about HIV relevant to their reported risks and will be asked if they have questions regarding this information.
3289870|NCT00548262|Experimental|1|
3289871|NCT00548249|Placebo Comparator|0 µg iron/dL of dialysate|Placebo 0 micrograms (µg) of iron/ deciliter (dL) of dialysate
3289872|NCT00548249|Experimental|5 µg iron/dL of dialysate|5 micrograms (µg) of iron/ deciliter (dL) of dialysate
3289873|NCT00548249|Experimental|10 µg iron/dL of dialysate|10 micrograms (µg) of iron/ deciliter (dL) of dialysate
3289874|NCT00548249|Experimental|12 µg iron/dL of dialysate|12 micrograms (µg) of iron/ deciliter (dL) of dialysate
3289875|NCT00548249|Experimental|15 µg iron/dL of dialysate|15 micrograms (µg) of iron/ deciliter (dL) of dialysate
3289876|NCT00548236|Experimental|1|Immediate participation in a 16-week exercise program
3289877|NCT00548236|No Intervention|2|Control population; will receive exercise plan after 16-week control period
3289878|NCT00548223|Experimental|Dengzhan Shengmai capsule|Dengzhan Shengmai capsule 0.18g by mouth twice a day for 1year
3289879|NCT00548223|Placebo Comparator|Placebo|Placebo 0.18g by mouth twice a day for 1year
3289880|NCT00548197|Experimental|A|Intravitreal Bevacizumab will be injected in this group before performing pars plana vitrectomy
3289881|NCT00548184|Experimental|Single Group Assignment|Lapatinib Trastuzumab Endocrine
3289882|NCT00548171|Experimental|Group A|Subjects who had received the dTpa vaccine in study 263855/002
3289883|NCT00548171|Active Comparator|Group B|Subjects who had received the Td + pa vaccines in either sequences (i.e. Td vaccine followed by the pa vaccine or pa vaccine followed by the Td vaccine) in study 263855/002
3289884|NCT00548145|Experimental|1|
3289885|NCT00548145|Active Comparator|2|
3289886|NCT00548132|No Intervention|1|Patients in this arm will continue to get routine care
3289887|NCT00548132|Experimental|Chlorhexidine-impregnated foam dressing|Patient's catheters were cleaned with chlorhexidine-alcohol solution at least weekly before application of the Biopatch. These were evaluated daily and if the dressing was bloody, soiled or damaged, the dressing and the Biopatch were replaced prior to the 7-day period.
3289888|NCT00548119|Experimental|NeoCart|
3289889|NCT00548119|Active Comparator|microfracture|
3289890|NCT00548106|Experimental|1|Infants will be fed the new hydrolyzate formula.
3289891|NCT00548106|Placebo Comparator|2|Nan HA infant formula
3289892|NCT00548093|Experimental|1|descriptive: adenocarcinoma histology
3289893|NCT00548093|Experimental|2|descriptive: non-adenocarcinoma histology
3289894|NCT00548067|Active Comparator|1|
3289895|NCT00548067|Active Comparator|2|
3289896|NCT00548067|Active Comparator|3|
3289897|NCT00548067|Experimental|4|
3289898|NCT00548054|Experimental|Vaccine Group for Vibriocidal Assay|Killed whole cell cholera vaccine bled at day 42 for vibriocidal assay
3289899|NCT00548054|Experimental|Vaccine Group for EPI Assay|Killed whole cell cholera vaccine bled at day 56 for EPI immunogenicity testing
3289900|NCT00548054|Placebo Comparator|Placebo Group for Vibriocidal Assay|Placebo bled at day 42 for vibriocidal assay
3289901|NCT00548054|Placebo Comparator|Placebo Group for EPI Assay|Placebo bled at day 56 for EPI immunogenicity testing
3289902|NCT00548054|Experimental|Vaccine Group for Vibriocidal and Measles Assay|Killed whole cell cholera vaccine bled at day 14 and 28 for measles immunogenicity testing
3289903|NCT00548054|Placebo Comparator|Placebo Group for Vibriocidal and Measles Assay|Placebo bled at day 14 and 28 for measles immunogenicity testing
3289904|NCT00548041|Other|Rapid HIV Tested|Subjects have HIV testing by oral swab performed.
3289905|NCT00548015|Active Comparator|State of the Art strategy|education, reminders, performance feedback,
3289906|NCT00548015|Experimental|extended strategy|state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
3289907|NCT00548002||1 and 2|Patients were randomly assigned to receive either 1) standard treatment or 2) standard treatment combined with a fluoroquinolone (trovafloxacin or levofloxacin).
3289908|NCT00547989|Active Comparator|1|control
3289909|NCT00547989|Experimental|2|PVB with ropivacaine and postoperative pump 5ml/h
3289910|NCT00547989|Experimental|Experimental 1|PVB with ropivacaine, 10 patients included but not analysed
3289911|NCT00547963|Experimental|1|two brief counseling sessions delivered to ED patients who report conjoint alcohol and marijuana use
3289912|NCT00547950|Experimental|1|drug
3289913|NCT00547937|Sham Comparator|Sham-CPAP|The sham CPAP device consisted of a conventional CPAP device, in which the area of the exhalation port was amplified, thereby nearly cancelling nasal pressure; an orifice resistor was connected between the tubing and the CPAP unit that loads the blower with the same airflow resistance as in effective CPAP
3289914|NCT00547937|Active Comparator|CPAP|
3289915|NCT00547911|Experimental|LDOPS + Placebo; LDOPS + CAR; LDOPS + ENT|Each subject received 400 mg of droxidopa (LDOPS) with three separate interventions, i.e., LDOPS with 200 mg placebo, LDOPS with 200 mg carbidopa (CAR), and LDOPS with 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days. This arm received the three interventions in the order of: LDOPS + Placebo, followed by LDOPS + CAR, followed by LDOPS + ENT.
3289916|NCT00547911|Experimental|LDOPS + Placebo; LDOPS + ENT; LDOPS + CAR|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + Placebo, followed by LDOPS + ENT, and lastly LDOPS + CAR.
3289917|NCT00547911|Experimental|LDOPS + CAR; LDOPS + Placebo; LDOPS + ENT|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + CAR, followed by LDOPS + Placebo, and lastly LDOPS + ENT.
3289918|NCT00547911|Experimental|LDOPS + CAR; LDOPS + ENT; LDOPS + Placebo|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + CAR, followed by LDOPS + ENT, and lastly LDOPS + Placebo.
3289919|NCT00547911|Experimental|LDOPS + ENT; LDOPS + Placebo; LDOPS + CAR|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + ENT, followed by LDOPS + Placebo, and lastly LDOPS + CAR.
3289920|NCT00547911|Experimental|LDOPS + ENT; LDOPS + CAR; LDOPS + Placebo|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + ENT, followed by LDOPS + CAR, and lastly LDOPS + Placebo.
3289921|NCT00547898|Experimental|Placebo|
3289922|NCT00547898|Experimental|Crofelemer 125 mg|
3289923|NCT00547898|Experimental|Crofelemer 250 mg|
3289924|NCT00547898|Experimental|Crofelemer 500 mg|
3289925|NCT00547885|Active Comparator|1|Active dihydrocodeine, long acting and Placebo dihydrocodeine short acting
3289926|NCT00547885|Active Comparator|2|Placebo dihydrocodeine, long acting and active dihydrocodeine short acting.
3289927|NCT00547872|Experimental|1|Best medical/behavioral treatment according to guidelines suggestions plus CAD screening by ECG tolerance testing followed by revascularization in case of coronary stenosis.
3289928|NCT00547872|No Intervention|2|Best medical/behavioral treatment according to guidelines suggestions
3289929|NCT00547833||Experimental|Children with language-learning disabilities reading at approximately a 6th grade level
3289930|NCT00547833||Age-Matched|Typical language learners each of whom is pair match to an experimental participant by age and gender.
3289931|NCT00547833||Language-Matched|Typical language learners, each of whom is pair-matched to an experimental participant by reading comprehension skills and gender.
3289932|NCT00547820|Experimental|A|with application of urinary sensor
3289933|NCT00547820|Placebo Comparator|B|without use of urinary sensor
3289934|NCT00547794||CRT-D + AVJ Ablation|
3289935|NCT00547794||Single-Chamber ICD + Pharmacological Therapy|
3289936|NCT00547729|Experimental|HeartPOD™ System|Implantation of HeartPOD™ System
3289937|NCT00547716|Experimental|1.|Omega-3 Fatty Acids 4 grams/day
3289938|NCT00547716|Placebo Comparator|2.|Placebo comparator along with interferon.
3289939|NCT00547703|Active Comparator|Nortriptyline|Patients in this group will receive Nortriptyline 25mg at night for 8 weeks.
3289940|NCT00547703|Placebo Comparator|Sugar pill|Patients in this group will receive an identical placebo capsule at night for 8 weeks.
3289941|NCT00547690|Experimental|1|Acupuncture and strength training
3289942|NCT00547690|Other|2|Strength training
3289943|NCT00547664|Experimental|A|
3289944|NCT00547664|Placebo Comparator|B|
3289945|NCT00547651|Experimental|Amrubicin|Amrubicin
3289946|NCT00547651|Active Comparator|Topotecan|Topotecan
3289947|NCT00547638|Experimental|Dermabond Protape|DERMABOND PROTAPE (Prineo) Topical Skin Adhesive
3289948|NCT00547638|Active Comparator|Dermabond HVD|DERMABOND HVD Topical Skin Adhesive
3289949|NCT00547625|Placebo Comparator|1|Placebo run in followed by 5 mg treatment phase 1 and then 20 mg treatment phase 2 which both include a placebo control.
3289950|NCT00547625|Active Comparator|2|Treatment phase 1 includes 5 mg tadalafil 6 weeks then treatment phase 2 which includes 20 mg tadalafil for 6 weeks.
3289951|NCT00547599|Active Comparator|1|20 mg tadalafil tablet
3289952|NCT00547586|Placebo Comparator|1|
3289953|NCT00547586|Experimental|2|
3289954|NCT00547586|Experimental|3|
3289955|NCT00547586|Experimental|4|
3289956|NCT00547586|Experimental|5|
3289959|NCT00547573|Placebo Comparator|1|placebo tablet
3289960|NCT00547560|Other|GSI+Placebo|
3289961|NCT00547547|Experimental|Treatment (high-selenium therapy and chemotherapy)|
3289962|NCT00547534|Experimental|Lymphoma Subjects receiving protocol therapy|Subjects that met all eligibility criteria and were treated with Bendamustine, Rituxan and Bortezomib.
3289963|NCT00547521|Experimental|Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort|In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants were also administered a stable MTX dose of greater than or equal to 10 mg once weekly for at least 4 weeks prior to first injection of SC abatacept.
3289964|NCT00547521|Experimental|SC Abatacept Monotherapy Cohort|In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants did not receive MTX at screening i.e., MTX naive, or discontinued MTX due to lack of efficacy or tolerability at least 4 weeks prior to first injection of SC abatacept.
3289965|NCT00547508|Placebo Comparator|1|Placebo
3289966|NCT00547508|Placebo Comparator|2|Placebo
3289967|NCT00547508|Active Comparator|3|tadalafil
3289968|NCT00547508|Active Comparator|4|tadalafil
3289969|NCT00547508|Active Comparator|5|tadalafil
3289970|NCT00547508|Active Comparator|6|tadalafil
3289971|NCT00547495|Placebo Comparator|1|Placebo tablet
3289972|NCT00547495|Active Comparator|2|5 mg tadalafil
3289973|NCT00547495|Active Comparator|3|10 mg tadalafil
3289974|NCT00547495|Active Comparator|4|20 mg tadalafil
3289975|NCT00547482|Sham Comparator|Control|They will all be implanted but not activated for the Initial Study Period (24 weeks), followed by all subjects assigned to treatment (Control Group with device activation) in the Study Extension Period (an additional 24 weeks). Subjects will remain in the study (Safety Monitoring Period) with semi-annual evaluations until a determination of safety and efficacy is made by the FDA.
3289976|NCT00547482|Active Comparator|Treatment|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation). They will be followed for the Initial Study Period (24 weeks), followed by the Study Extension Period (an additional 24 weeks). Subjects will remain in the study (Safety Monitoring Period) with semi-annual evaluations until a determination of safety and efficacy is made by the FDA."
3289977|NCT00547456|Other|Decrease in oxygen level when sleeping|Patients are their own controls and tested pre and post the addition of night time supplemental oxygen
3289978|NCT00547443|Active Comparator|Arm I|Patients receive chemoradiotherapy comprising paclitaxel, carboplatin, and high-dose external beam radiotherapy (HDRT) as in phase I. Patients also receive consolidation therapy comprising paclitaxel and carboplatin as in phase I.
3289979|NCT00547443|Experimental|Arm II|Patients receive chemoradiotherapy comprising paclitaxel, carboplatin, and HDRT as in phase I. Patients also receive consolidation therapy comprising paclitaxel, carboplatin, and sorafenib tosylate at the MTD as in phase I, as well as maintenance therapy comprising sorafenib tosylate at the MTD as in phase I.
3289980|NCT00547417|Active Comparator|1|tadalafil
3289981|NCT00547391|No Intervention|1|patients on waiting list for a minimum of 5 months. These patients receive no prophylactic intervention for their recurrent pharyngitis episodes.
3289982|NCT00547391|Active Comparator|2|Tonsillectomy as soon as possible after randomization (within 2-3 weeks).
3289983|NCT00547378|Other|1|InterStim Therapy
3289984|NCT00547378|Active Comparator|2|Standard Medical Therapy
3289985|NCT00547365|Experimental|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
3289986|NCT00547352|Active Comparator|1|sildenafil treatment for at least 10 weeks prior to a 1 week wash out
3289987|NCT00547352|Active Comparator|2|Tadalafil treatment for 8 weeks following the 1 week washout period.
3289988|NCT00547326|Experimental|1|Treatement with osteopatic cranial techniques
3289989|NCT00547326|Placebo Comparator|2|Treatment with placebo
3289990|NCT00547287|Active Comparator|1|Currently prescribed dosage of sildenafil is continued until wash-out period.
3289991|NCT00547287|Active Comparator|2|20 mg tadalafil given after one week sildenafil wash-out period.
3289992|NCT00547261|Experimental|Arm A|1 hour IV infusion D1
3289993|NCT00547261|Experimental|Arm B|1 hour IV infusion D1, D8, D15
3289994|NCT00547248|Experimental|Group A|Receiving pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biological's DTPw-HBV/Hib vaccine (Tritanrix-HepB +Hiberix) and OPV (Polio Sabin) in the Philippines or IPV (Poliorix) in Poland.
3289995|NCT00547248|Active Comparator|Group B|Receiving Prevenar (Wyeth) co-administered with GSK Biological's DTPw-HBV/Hib vaccine (Tritanrix-HepB +Hiberix) and OPV (Polio Sabin) in the Philippines or IPV (Poliorix) in Poland.
3289996|NCT00547209|Active Comparator|1|ventilation with air and oxygen
3289997|NCT00547209|Experimental|2|ventilation with nitrous oxide and oxygen
3289998|NCT00547196|Experimental|Regimen I (age < 50 years, no contraindication to FTBI)|Patients undergo FTBI 2-3 times a day on days -9 to -6 for a total of 11 fractions. Patients also receive cyclophosphamide IV over 2 hours on days -5 and -4 and fludarabine phosphate IV on days -5 to -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
3289999|NCT00547196|Experimental|Regimen II (age < 50 and unable to tolerate FTBI)|Patients receive a test dose of busulfan on day -10 and then dose adjusted busulfan IV 3-4 times daily on days -9 to -6, melphalan IV on days -5 and -4, and fludarabine phosphate IV on days -5 to -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
3290000|NCT00547196|Experimental|Regimen III (unable to tolerate regimen I or II)|Patients receive fludarabine phosphate IV on days -8 to -4 and cyclophosphamide IV over 2 hours on day -3 and undergo TBI (single dose) on day -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
3290001|NCT00547196|Experimental|Regimen IV (unable to tolerate regimen I or II)|Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
3290002|NCT00547183|Active Comparator|2|2.5 mg tadalafil
3290003|NCT00547183|Active Comparator|3|5 mg tadalafil
3290004|NCT00547183|Placebo Comparator|1|
3290005|NCT00547170|Experimental|1|Half of enrolled women will be randomly assigned to group 1.
3290006|NCT00547170|Active Comparator|2|Half of enrolled women will be randomly assigned to group 2
3290007|NCT00547157|Active Comparator|ARM 1 CRT|Cisplatin plus RT
3290008|NCT00547157|Experimental|ARM 2 PRT|Panitumumab plus RT
3290009|NCT00547144|Experimental|Gemcitabine|
3290010|NCT00547118|Experimental|1|Rimonabant
3290011|NCT00547118|Placebo Comparator|2|Placebo
3290012|NCT00547105|Experimental|erlotinib in combination with SBRT|Patients enrolled on the trial will have been receiving or will begin to receive erlotinib at standard doses (150 mg po per day). SBRT will commence within 4 weeks of the initiation of erlotinib
3290013|NCT00547092|Active Comparator|1|tadalafil given the first 12 weeks and after a 4 week washout sildenafil is given for 12 weeks.
3290014|NCT00547092|Active Comparator|2|sildenafil given the first 12 weeks and after a 4 week washout tadalafil is given for 12 weeks.
3290015|NCT00547066|Experimental|veltuzumab|veltuzumab is a humanized CD20 antibody administered subcutaneously.
3290016|NCT00547040||A|incident renal transplant patients
3290017|NCT00547014|Experimental|Cohort 1 1mg|
3290018|NCT00547014|Experimental|Cohort 2|
3290019|NCT00547014|Experimental|Cohort 3|
3290020|NCT00547014|Experimental|Cohort 4|
3290021|NCT00547014|Experimental|Cohort 5|
3290022|NCT00547001|Active Comparator|1|Group A will be tapered over 4 weeks, starting at baseline (week 0). Subjects in this group will take one tablet of ET daily (effective dose, 0.75 mg) for week 1, then one 0.50 mg tablet daily for week 2, then one 0.25 mg tablet daily for week 3, and finally one 0.125 mg tablet daily for week 4.
3290023|NCT00547001|Placebo Comparator|2|Group B will be administered placebo. These tablets will appear identical to those administered to subjects in Group A, but the tablets will contain no estrogen. Subjects in this group will be instructed to take one pill every day for the 4 weeks. Thus, while patients will, in effect, be stopped abruptly from their therapy, there is still the potential of a placebo effect.
3290024|NCT00547001|No Intervention|3|"Group C will have their therapy discontinued acutely at baseline (week 0); i.e., these subjects will not take any tablets after the 8-week stabilization phase ends. While we recognize that this group will not be blinded to the regimen they are receiving, we feel that group C will be important to include in light of the consistent decrease in vasomotor symptoms experienced by women taking placebo. Because women taking placebo have approximately a 35% decrease in vasomotor symptoms, it will be important to compare our taper regimen to the real life scenario of stopping medication abruptly."
3290025|NCT00546988|No Intervention|Standard risk IFN|Administration of interferon alpha as a maintenance treatment following autologous stem cell transplantation
3290026|NCT00546988|No Intervention|Standard risk PEGIFN|Maintenance treatment with pegylated interferon following autologous stem cell transplantation
3290027|NCT00546988|Experimental|High risk allo|Allogeneic stem cell transplantation from an HLA identical related or unrelated donor
3290028|NCT00546988|No Intervention|High risk auto|Second cycle of high-dose melphalan in subjects without an HLA-identical donor
3290029|NCT00546975|Experimental|1|Resource Support® Novartis
3290030|NCT00546975|Active Comparator|2|Resource Protein®, Novartis
3290031|NCT00546975|Placebo Comparator|3|
3290032|NCT00546949|Active Comparator|decompression|Minimal invasive decompression
3290033|NCT00546949|Experimental|x-stop|X-stop, an interspinous decompression device
3290034|NCT00546936|Experimental|ranibizumab intravitreal injection|0.5 mg intravitreal injection of ranibizumab
3290035|NCT00546936|Active Comparator|Photodynamic Therapy|Photodynamic therapy with Visudyne
3290036|NCT00546910|Experimental|Atomoxetine|0.5 milligram per kilogram (mg/kg) per day lead-in dose for 1 weeks followed by 7 weeks at 1.2 mg/kg per day dose.
3290037|NCT00546910|Placebo Comparator|Placebo|Placebo matched to 1 week lead-in and 7 week standard target dose of atomoxetine
3290038|NCT00546897|Experimental|Cohort 1|"Lenalidomide 50 mg/day oral for 14 days followed by 30 days of rest. Lenalidomide 50 mg/day oral for 21 days (this is Cycle 1 and Cycle 2).~If no progressive disease (PD) then lenalidomide 10 mg/day oral for 28 days for 12 cycles."
3290039|NCT00546897|Experimental|Cohort 2|"Cycle 1: Oral lenalidomide 50 mg/day x 28 days induction therapy. Treatment will then depend on the response to Cycle 1: if patients obtain a complete remission (CR) they will proceed to low dose lenalidomide therapy, if patients have a non-CR they will receive a second high dose cycle of lenalidomide 50 mg/day x 28 days (Cycle 2) Cycle 2 consists of lenalidomide 50mg/day x 28 days Further treatment will depend on the response to Cycle 2: if patients obtain a CR/partial remission (PR)/stable disease (SD) they will proceed to low dose lenalidomide therapy, if patients have PD they will be removed from the study.~Low Dose Cycles: low dose lenalidomide therapy consisting of 10 mg daily for a 28 day cycle.be 1) For patients that achieve a CR, 2 cycles of low dose lenalidomide will be administered, and then patients observed off therapy. For patients with PR/SD, low dose lenalidomide will continue for a total of 6 cycles and then patients will be observed off therapy."
3290040|NCT00546884|Placebo Comparator|MI|The MI condition will expose participants to the provision of an advance directive and written instructions, roughly mimicking community standards and the requirements of the federal Patient Self Determination Act.
3290041|NCT00546884|Active Comparator|GI|Subjects randomized to the GI group will be invited to meet individually with a health care professional specializing in EOL care
3290042|NCT00546858||Survey|Patients with interstitial cystitis
3290043|NCT00546832|Placebo Comparator|1|placebo
3290044|NCT00546832|Active Comparator|2|celecoxib 200 mg qd p.o.
3290045|NCT00546832|Experimental|3|TDS-943 40 mg bid topically
3290046|NCT00546819|Experimental|ZOSTAVAX™|Participants administered ZOSTAVAX™ on Day 1.
3290047|NCT00546819|Placebo Comparator|Placebo|Participants administered Placebo on Day 1.
3290048|NCT00546806|Experimental|1|"AVIVA Soft Tissue Injury Care Model"
3290049|NCT00546806|Experimental|2|Pre-approved Framework Guideline for Grade I and II Whiplash Associated Disorders (PAF)
3290050|NCT00546806|Active Comparator|3|Physician-based Education and Activation
3290051|NCT00546793|Experimental|veltuzumab|veltuzumab is a humanized CD20 antibody administered subcutaneously in this study.
3290052|NCT00546780|Active Comparator|Arm A|Tanespimycin + Bortezomib
3290053|NCT00546780|Active Comparator|Arm B|Bortezomib
3290054|NCT00546767|Experimental|Mail and Live Phone|
3290055|NCT00546767|Experimental|IVR|
3290056|NCT00546767|Experimental|Computer Kiosk|
3290057|NCT00546767|Active Comparator|Traditional|
3290058|NCT00546754|Experimental|1|Drug Arm
3290059|NCT00546754|Active Comparator|2|active comparator
3290060|NCT00546741|Experimental|1|
3290061|NCT00546741|Active Comparator|2|
3290062|NCT00546741|Active Comparator|3|
3290063|NCT00546728|Experimental|Exenatide|Subjects were randomlly assigned to treatment arm: Exenatide 10 mcg twice daily vs. Metformin 500 mg twice daily.
3290064|NCT00546728|Active Comparator|Metformin|Subjects were randomlly assigned to treatment arm: Exenatide 10 mcg twice daily vs. Metformin 500 mg twice daily.
3290065|NCT00546715|Active Comparator|Dose Panel A|"Daclatasvir - 1 mg~Placebo - 0 mg"
3290066|NCT00546715|Active Comparator|Dose Panel B|"Daclatasvir - 10 mg~Placebo - 0 mg"
3290067|NCT00546715|Active Comparator|Dose Panel C|"Daclatasvir - 100 mg~Placebo - 0 mg"
3290068|NCT00546715|Active Comparator|Dose Panel D|"Daclatasvir - 0.5 - 200 mg (to be determined)~Placebo - 0 mg"
3290069|NCT00546689||1 , 2|those with HIV
3290070|NCT00546663|Experimental|Open-label|
3290071|NCT00546650|Experimental|A|NP101 patch applied to the upper arm and left in place for 4 hours. The NP101 patch is designed to deliver ~ 10 mg of sumatriptan utilizing up to 600 mA minutes.
3290072|NCT00546650|Active Comparator|B|Sumatriptan succinate (Imitrex®) tablet: 100 mg orally.
3290073|NCT00546650|Active Comparator|C|Sumatriptan succinate (Imitrex®) injection: 6 mg subcutaneously (SQ).
3290074|NCT00546650|Active Comparator|D|Sumatriptan (Imitrex®) nasal spray: 20 mg (one spray) intranasal (IN) into one nostril.
3290075|NCT00546650|Experimental|E|NP101 patch applied to the upper arm and left in place for 4 hours. The NP101 patch is designed to deliver ~ 10 mg of sumatriptan utilizing up to 600 mA minutes.
3290076|NCT00546637|Experimental|Fesoterodine 4mg or 8mg|
3290077|NCT00546637|Placebo Comparator|Placebo|
3290078|NCT00546611|Active Comparator|1|Three day application of 0.05% PEP005 Topical Gel to one or two common warts located on the hand.
3290079|NCT00546598|Other|Duraloc Option COC Hip|
3290080|NCT00546585|Experimental|90 mcg of Influenza A/H7N7|25 subjects to receive 90 mcg of Influenza A/H7N7.
3290081|NCT00546585|Experimental|15 mcg of Influenza A/H7N7|25 subjects to receive 15 mcg of Influenza A/H7N7.
3290082|NCT00546585|Experimental|7.5 mcg of Influenza A/H7N7|25 subjects to receive 7.5 mcg of Influenza A/H7N7.
3290083|NCT00546585|Experimental|45 mcg of Influenza A/H7N7|25 subjects to receive 45 mcg of Influenza A/H7N7.
3290084|NCT00546585|Placebo Comparator|Saline placebo|25 subjects to receive placebo.
3290085|NCT00546572|Experimental|1|Receives 13vPnC at year 0 and 13vPnC at year 1
3290086|NCT00546572|Active Comparator|2|Receives 23vPS at year 0 and 13vPnC at year 1
3290087|NCT00546546|No Intervention|control = conventional treatment|conventional treatment: use of immunosuppressants only if steroid dependency or chronic active disease
3290088|NCT00546546|Experimental|Immunossuppresive treatment|Switch to different immunosuppresive treatment in case of relapse.
3290089|NCT00546507|Placebo Comparator|A|placebo
3290090|NCT00546507|Active Comparator|B|celecoxib 200 mg qd p.o.
3290091|NCT00546507|Experimental|C|TDS-943 40 mg bid topically
3290092|NCT00546481|Experimental|Correction Phase: CERA|
3290093|NCT00546481|Active Comparator|Correction Phase: Epoetin Beta|
3290094|NCT00546468|Experimental|Laparoscopy assisted distal gastrectomy|Laparoscopy assisted distal gastrectomy with D2 lymph node dissection.Surgery will be done in similar operative extent with control open distal gastrectomy. Omentectomy will be omitted.
3290095|NCT00546468|Active Comparator|Open Distal Gastrectomy|Conventional standard D2 open distal gastrectomy without omentectomy.
3290096|NCT00546455|Experimental|A|Subjects in this cohort will be given Fenretinide
3290097|NCT00546455|Placebo Comparator|B|Subjects in this cohort will be given placebo.
3290098|NCT00546442|Placebo Comparator|2|Placebo of metformine 850-2550 mg/daily for 48 weeks
3290099|NCT00546442|Experimental|1|Metformine 850-2550 mg/daily for 48 weeks
3290100|NCT00546429|Other|A|Monitoring of trochanteric fractures after treatment with the ATN system.
3290101|NCT00546403|Placebo Comparator|Placebo|Adjunctive treatment with placebo
3290102|NCT00546403|Experimental|Modafinil|Treatment with titrated dose of study drug, modafinil.
3290103|NCT00546390|Experimental|1|Will receive rIP
3290104|NCT00546390|No Intervention|2|
3290105|NCT00546377|Experimental|Mitoxantrone|
3290106|NCT00546364|Experimental|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|
3290107|NCT00546364|Experimental|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|
3290108|NCT00546364|Active Comparator|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|
3290109|NCT00546351|Experimental|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.
3290110|NCT00546325|Experimental|1|Rimonabant
3290111|NCT00546325|Placebo Comparator|2|Placebo
3290112|NCT00546286|Experimental|1|dorzolamide HCl/timolol maleate
3290113|NCT00546286|Experimental|2|dorzolamide hydrochloride/timolol maleate + prostaglandin
3290114|NCT00546273|Experimental|RUTI 5 micrograms of FCMtb|RUTI dose: 5 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
3290115|NCT00546273|Experimental|RUTI 25 micrograms of FCMtb|RUTI dose: 25 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
3290116|NCT00546273|Experimental|RUTI 100 micrograms of FCMtb|RUTI dose: 100 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
3290117|NCT00546273|Experimental|RUTI 200 micrograms of FCMtb|RUTI 200 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
3290118|NCT00546273|Placebo Comparator|placebo|placebo of the vaccine RUTI (total n=8, n=2 for each period)
3290119|NCT00546260|Placebo Comparator|1|Placebo for each Dose cohort: 10, 20, 40, and 60 mg
3290120|NCT00546260|Experimental|2|Experimental drug for each Dose cohort: 10, 20, 40, and 60 mg
3290121|NCT00546247|Experimental|1|
3290122|NCT00546234|Active Comparator|1|
3290123|NCT00546234|Active Comparator|2|
3290124|NCT00546221|Experimental|Psychosocial support|Comprising 22 participants engaging in the experimental exercise programme, exercising with psychosocial support.
3290125|NCT00546221|Active Comparator|Prescribed exercise|Comprising 21 participants engaging in a programme of typical prescribed exercise.
3290126|NCT00546208||1|adolescents and young adults who underwent, as newborns, unilateral low loop cutaneous ureterostomy for severe bilateral hydro-ureteronephrosis, and that, afterwards, underwent stomal closure
3290127|NCT00546169||A|
3290128|NCT00546156|Active Comparator|HR+, HER2-|Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.
3290129|NCT00546156|Active Comparator|Triple Negative Breast Cancer Cohort|Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.
3290130|NCT00546143|Experimental|1|Omalizumab 900 mg
3290131|NCT00546143|Experimental|2|Omalizumab 1050 mg
3290132|NCT00546143|Experimental|3|Omalizumab 1200 mg
3290133|NCT00546130|Experimental|1|Irinotecan hydrochloride + Cisplatin + Krestin Therapy
3290134|NCT00546117|Experimental|Lansoprazole (Prevacid)|Prevacid SoluTab (15 or 30 mg tab) once daily for 2 months
3290135|NCT00546117|Placebo Comparator|Placebo|Placebo SoluTab once daily for 2 months
3290136|NCT00546104|Experimental|Dasatinib|50- 100 mg PO BID
3290137|NCT00546078|Experimental|Cervarix™ 4-Dose Group|Subjects who had received 3 doses of Cervarix™ in study 580299/001 (NCT00689741), received a 4th dose of Cervarix™ on Day 0 in the current study.
3290138|NCT00546078|Experimental|Cervarix™ 3-Dose Group|Subjects who had received 3 doses of placebo in study 580299/001 (NCT00689741), received 3 doses of Cervarix™ (Day 0, Month 1 and Month 6) in the current study.
3290139|NCT00546065|Other|ablation of Barretts with concomitant esomeprazole therapy|comparison of recurrence-free survival
3290140|NCT00546065|No Intervention|non ablation|non ablation only surveillance
3290141|NCT00546052|Experimental|1|Losartan (MK0954) / Losartan + HCTZ (MK0954A)
3290142|NCT00546039|Active Comparator|1|
3290143|NCT00546039|Placebo Comparator|2|
3290144|NCT00546026|Active Comparator|Active group|Receive assessment of placental function
3290145|NCT00546013||AAA group, control group|AAA group : with AAA Control group: without AAA
3290146|NCT00546000|Experimental|1|Receive between 22 and 29 days of Cutivate lotion treatment
3290147|NCT00545987|Active Comparator|intramuscular injection|administration of an HIV-1 vaccine by conventional intramuscular injection
3290148|NCT00545987|Experimental|TriGrid Delivery System|electroporation-mediated intramuscular delivery using the TriGridTM device by Ichor Medical Systems, Inc.
3290149|NCT00545974|Experimental|1|Memantine 10mg BID
3290150|NCT00545974|Placebo Comparator|2|Placebo condition
3290151|NCT00545961|Placebo Comparator|1|placebo Ora-Plus (registered trademark) mixture with an strawberry sweetening agent to make the placebo mixture similar in appearance and taste to active drug
3290152|NCT00545961|Active Comparator|2|amoxicillin-clavulanate acid
3290153|NCT00545948|Other|Arm A-Vinorelbine|Resected tumor was used for genomic expression profiling. Patients with a genomic expression pattern suggestive of vinorelbine sensitivity were given cisplatin + vinorelbine.
3290154|NCT00545948|Other|Arm B-Pemetrexed|Resected tumor was used for genomic expression profiling. Patients with a genomic expression pattern suggestive of pemetrexed sensitivity were given cisplatin + pemetrexed.
3290155|NCT00545935|Active Comparator|1-Methylenblue-Amodiaquine|
3290156|NCT00545935|Active Comparator|2-Methylenblue-Artesunate|
3290157|NCT00545935|Active Comparator|3-Artesunate-Amodiaquine|
3290158|NCT00545922|Experimental|A|7 weekly sessions of group cognitive behavioral therapy
3290159|NCT00545922|Active Comparator|B|Minimal Telephone Contact
3290160|NCT00545909|Experimental|1|
3290161|NCT00545909|Active Comparator|2|
3290162|NCT00545870|Experimental|A|Bevacizumab treatment
3290163|NCT00545870|Active Comparator|B|Ranibizumab treatment
3290164|NCT00545857|Experimental|Pioglitazone|
3290165|NCT00545857|Placebo Comparator|Placebo control|
3290166|NCT00545844|Experimental|1|montelukast sodium
3290167|NCT00545831|Experimental|A|Use of taurolidine in prevention of bloodstream infection related to central venous access
3290168|NCT00545831|Placebo Comparator|B|Use of Physiologic Serum to compare to arm A
3290169|NCT00545818|Experimental|1|
3290170|NCT00545818|Active Comparator|2|
3290171|NCT00545805|Experimental|OM group|
3290172|NCT00545805|Active Comparator|CT group|Control group
3290173|NCT00545792|Experimental|Avastin|Avastin
3290174|NCT00545779|Experimental|Ibandronate|Participants completed Candidate Identification Questionnaire (CIQ) in Part A and received Ibandronate 150 milligram (mg) tablet orally once-monthly up to 6 months in Part B of the study.
3290175|NCT00545766|Experimental|Interventional|
3290176|NCT00545753|Experimental|A - NatrOVA 1% - no nit combing|NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
3290177|NCT00545753|Experimental|B - NatrOVA 1% - nit combing required|NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
3290178|NCT00545753|Active Comparator|C - NIX|NIX Creme Rinse (permethrin 1%) applied to Over the Counter (OTC) Instructions for Use
3290179|NCT00545740|Experimental|SPD476 (1.2 g)|
3290180|NCT00545740|Experimental|SPD476 (2.4 g)|
3290181|NCT00545740|Experimental|SPD476 (4.8 g)|
3290182|NCT00545740|Placebo Comparator|Placebo|
3290183|NCT00545727|Other|HGI|High/standard glycemic index diet
3290184|NCT00545727|Experimental|LGI|Low glycemic index diet
3290185|NCT00545714|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants will receive 6 cycles (1 cycle = 28 days) of treatment with rituximab (375 milligrams per meter-squared [mg/m^2] as intravenous [IV] infusion on Day 1 of cycle 1, and 500 mg/m^2 as IV infusion on Day 1 of cycles 2-6); fludarabine (25 mg/m^2 on Days 1 to 3) and cyclophosphamide (250 mg/m^2 on Days 1 to 3). Participants with a partial or complete response (and appropriate neutrophil conditions) will receive maintenance treatment with rituximab (375 mg/m^2 as IV infusion every 2 months) from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
3290186|NCT00545701|Experimental|1|
3290187|NCT00545688|Experimental|1|
3290188|NCT00545688|Experimental|2|
3290189|NCT00545688|Experimental|3|
3290190|NCT00545688|Experimental|4|
3290191|NCT00545675|Experimental|1|Abilify(aripiprazole) + Depakote(divalproate)
3290192|NCT00545675|Placebo Comparator|2|Divalproate + Placebo
3290193|NCT00545662|Experimental|Placebo|Placebo tablets formulated to resemble the citicoline treatment.
3290194|NCT00545662|Experimental|Citicoline|Experimental treatment administered orally or enterally depending upon whether the participant can swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.
3290195|NCT00545649|Experimental|1|Exercise and education
3290196|NCT00545649|Active Comparator|2|Education only
3290197|NCT00545623|Active Comparator|ACU+RR|acupuncture + relaxation response CD
3290198|NCT00545623|Active Comparator|SHAM+RR|sham acupuncture + relaxation response CD
3290199|NCT00545623|Active Comparator|ACU+EDU|acupuncture+control CD
3290200|NCT00545623|Sham Comparator|SHAM+EDU|sham acupuncture+control CD
3290201|NCT00545610||Test 1 (n=50)|1 x 10^5 (+/-10%) CD34+ cells/kg of body weight
3290202|NCT00545610||Test 2 (n=50)|5 x 10^5 (+/-10%) CD34+ cells/kg of body weight
3290203|NCT00545610||Placebo (n=50)|Saline plus 5% autologous plasma
3290204|NCT00545584|Experimental|Sitagliptin with Standard of Care|Subjects received sitagliptin 100 mg once daily for 26 Weeks, and: No specific intervention (standard recommendation) on physical exercise and diet.
3290205|NCT00545584|Experimental|Sitagliptin with Diet Advice|"Subjects received sitagliptin 100 mg once daily for 26 Weeks,~and:~Intervention on diet which includes advice on diet with a leaflet and a diary"
3290206|NCT00545584|Experimental|Sitagliptin with Diet and Physical Activity Advice|"Subjects received sitagliptin 100 mg once daily for 26 Weeks,~and:~Intervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week."
3290207|NCT00545571|Experimental|Mircera in Renal Anemia|Participants will receive intravenous Mircera every 4 weeks for a total of 52 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
3290208|NCT00545558|Experimental|1|Participants will receive ART consisting of efavirenz and the co-formulation of emtricitabine and tenofovir disoproxil fumarate. If participants are unable to tolerate the treatment, a different regimen will be prescribed.
3290209|NCT00545545|Experimental|Arm 1, Cohort 1|2.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
3290210|NCT00545545|Experimental|Arm 1, Cohort 2|4.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
3290211|NCT00545545|Experimental|Arm 1, Cohort 3|6.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
3290212|NCT00545545|Experimental|Arm 2, Cohort 1|2.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
3290213|NCT00545545|Experimental|Arm 2, Cohort 2|4.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
3290214|NCT00545545|Experimental|Arm 2, Cohort 3|6.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
3290215|NCT00545532|Experimental|Conventional dose|Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.
3290216|NCT00545532|Experimental|Double dose|Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.
3290217|NCT00545519|Experimental|Dose Level 1|Thymoglobulin 2.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
3290218|NCT00545519|Experimental|Dose Level 2|Thymoglobulin 3.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
3290219|NCT00545519|Experimental|Dose Level 3|Thymoglobulin 4.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
3290259|NCT00545285|Active Comparator|3|Total hip Arthroplasty E-Poly™ liner with Regenerex Ringloc +™ shell
3290260|NCT00545285|Active Comparator|4|Total hip Arthroplasty ArcomXL® polyethylene liner with Regenerex Ringloc +™ shell
3290220|NCT00545506|Active Comparator|conventional bandage|conventional bandage on sternal wound after skin closure after cardiac surgery. conventional gauze covered with elastic adhesive (Medipore™ Dress-it) The designated bandage will be positioned in the operating room by the surgeons after the skin will be closed. The conventional elastic bandage consists of several layers of gauze covered with a special adhesive bandage
3290221|NCT00545506|Active Comparator|warming bandage|The Warm-Up bandage consists of an adhesive shell and a foam frame that supports a clear window about one cm above the surface of the wound. A battery-powered heating card can then be inserted into the window to provide gentle warming of the wound. The surface temperature of heating card is fixed at 38°C, and heat is usually provided for two hours at a time. That is, the experimental bandage will be continuously applied to the wound and heated to 38°C using a two-hour on/off cycle.
3290222|NCT00545493|Experimental|Group 1|"Tacrolimus capsules (Prograf; dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter)"
3290223|NCT00545493|Experimental|Group 2|"Intravenous immunoglobulins (IVIG) infusions (Octagam; dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months)."
3290224|NCT00545480|Experimental|1|
3290225|NCT00545480|Active Comparator|2|
3290226|NCT00545467|Active Comparator|1|fast tapering of the previous medication within 1 week after initiating aripiprazole for 2 weeks
3290227|NCT00545467|Active Comparator|2|slow tapering of the previous medication within 4 weeks after initiating aripiprazole for 2 weeks
3290228|NCT00545454|Experimental|SSR150106 QD|90 micro grams oral solution once daily (QD)
3290229|NCT00545454|Experimental|SSR150106 OEQD|90 micro grams oral solution once every other day (OEQD)
3290230|NCT00545454|Placebo Comparator|Placebo|oral solution QD or OEQD
3290231|NCT00545441|Experimental|1|Surgisis® AFP
3290232|NCT00545441|Active Comparator|2|Flap
3290233|NCT00545428|Experimental|1|Rhinoplasty
3290234|NCT00545415|Experimental|1|
3290235|NCT00545415|Experimental|2|
3290236|NCT00545415|Experimental|3|
3290237|NCT00545415|Experimental|4|
3290238|NCT00545415|Experimental|5|
3290239|NCT00545415|Experimental|6|
3290240|NCT00545402|Experimental|MMF, Adjusted Dose; Tacrolimus; Corticosteroids|Participants received mycophenolate mofetil (MMF) 3 grams per day (g/d), orally (PO), twice per day (BID) with meals from Day 0 to Day 4; the dose was adjusted based on total exposure (AUC) using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12. Participants also received tacrolimus adjusted to a target trough level of 8 to (-) 12 nanograms per milliliter (ng/mL) from Day 0 to Month 1; the dose was adjusted to reach a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12. Participants also received corticosteroids 10-15 milligrams per kilogram (mg/kg), intravenously (IV), pre-operation on Day 0.
3290241|NCT00545402|Active Comparator|MMF, Standard Dose; Tacrolimus; Corticosteroids|Participants received MMF 2 g/d, PO, BID with meals from Day 0 to Month 12. Participants also received tacrolimus adjusted to a target trough level of 8-12 ng/mL from Day 0 to Month 1; the dose was reduced to reach a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12. Participants also received corticosteroids 10-15 mg/kg, IV, pre-operation on Day 0; followed by 20 mg/d, PO, 4 times per day (QDS) from Day 0 through Month 1; 15 mg/d, PO, 3 times per day (TID) from the end of Month 1 through Month 2; 10 mg/d, PO, BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
3290242|NCT00545376|No Intervention|1|This group will leave after the first visit without additional instruction and will be asked to return in two weeks for a follow up lung assessment.
3290243|NCT00545376|Experimental|2|This group, at the first visit, will be taught three home OMT techniques that a family member or friend can administer to them. They will be asked to do these techniques at least 4 times a week, up to every day, for two weeks before returning for a follow up lung assessment.
3290244|NCT00545376|Experimental|3|This arm is the physicians that I will recruit participants through. They will be exposed to education about the use of OMT for asthma.
3290245|NCT00545363|Experimental|Bone Marker Feedback (BMF) Participants|"Postmenopausal women will receive ibandronate 150 milligrams (mg) once monthly (QM) orally for 6 months. Participants, in this arm, will receive BMF at Month 3. BMF will be given in terms of providing serum carboxy-terminal collagen crosslinks (CTX) level at Month 3. A BMF-form will be provided to the physicians to allow offering the bone marker result in an easy way. Participants will be informed if their results are within or outside of the desired range. In addition, participants will also supported by PRP, to be carried out by supplying alarm devices, specifically designed to support the participant's regular drug intake."
3290246|NCT00545363|Active Comparator|No BMF Participants|Postmenopausal women will receive ibandronate 150 milligrams (mg) once monthly (QM) orally for 6 months. Participants will be supported by PRP, to be carried out by supplying alarm devices, specifically designed to support the participant's regular drug intake.
3290247|NCT00545350|No Intervention|1|Usual activity / care
3290248|NCT00545350|Experimental|2|"Physical exercise classes plus home exercises:~Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home. The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises."
3290249|NCT00545311|Experimental|1|NVA237
3290250|NCT00545311|Experimental|2|NVA237
3290251|NCT00545311|Experimental|3|NVA237
3290252|NCT00545311|Experimental|4|NVA237
3290253|NCT00545311|Placebo Comparator|5|Placebo
3290254|NCT00545298|No Intervention|A - Standard of Care (control)|Standard of care - dressings and sustained compression only
3290255|NCT00545298|Experimental|B Same treatment for 6 weeks|200ppm NO gas 8hrs/day 6 weeks NO gas in nitrogen is delivered constantly to a patch over the wound
3290256|NCT00545298|Experimental|C - modified treatment, 5 wks lower dose|200 ppm No gas 8 hrs/day 1 wk, 20ppm 8hrs/day 5 weeks Gas is NO in nitrogen delivered constantly for 8 hours to a patch over the wound
3290257|NCT00545285|Active Comparator|1|Total hip Arthroplasty E-Poly™ liner in a titanium plasma sprayed RingLoc® shell
3290258|NCT00545285|Active Comparator|2|Total hip Arthroplasty ArcomXL® polyethylene liner in a titanium plasma sprayed RingLoc® shell
3290261|NCT00545272|Experimental|indacaterol 62.5 μg|Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3290262|NCT00545272|Experimental|indacaterol 125 μg|Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3290263|NCT00545272|Experimental|indacaterol 250 μg|Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3290264|NCT00545272|Experimental|indacaterol 500 μg|Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3290265|NCT00545272|Active Comparator|formoterol|Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3290266|NCT00545272|Placebo Comparator|placebo|Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3290267|NCT00545259|Experimental|1|AEB071
3290268|NCT00545246|Experimental|aflibercept + docetaxel|
3290269|NCT00545233|Experimental|PEG-INF alpha-2a + ribavirin+ pioglitazone|Participants received pioglitazone in a 16 week run-in period (30 mg per day orally for 8 weeks followed by 45 mg per day orally for 8 weeks). Participants then received piogliatzone 45 mg daily orally plus 18 μg of Peginterferon Alfa-2a (PEG-INF alpha-2a) subcutaneous (sc) once a week plus ribavirin (1000 - 1600 mg/day orally as a split dose in the morning and the evening based on the participant's body weight) for 48 weeks in the anti-HCV treatment phase. Participants received 45 mg of pioglitazone per day orally in the 24 week follow-up period.
3290270|NCT00545233|Active Comparator|PEG-INF alpha-2a + ribavirin|Participants received 18 μg of Peginterferon Alfa-2a (PEG-INF alpha-2a) subcutaneous (sc) once a week plus ribavirin (1000 - 1600 mg/day orally as a split dose in the morning and the evening based on the participant's body weight) for 48 weeks in the anti-HCV treatment phase followed by a treatment free 24 week follow-up period.
3290271|NCT00545220|Experimental|1|PST
3290272|NCT00545220|Sham Comparator|2|Attention Control
3290273|NCT00545207|Experimental|1|
3290274|NCT00545207|Placebo Comparator|2|
3290275|NCT00545194|Active Comparator|A|sustained release preparation of prostaglandin E2
3290276|NCT00545194|Active Comparator|B|short-acting (instant-released) preparation of prostaglandin E2
3290277|NCT00545181|Experimental|Metronidazole plus gel|Receive metronidazole plus vaginal gel
3290278|NCT00545181|Active Comparator|Control- metronidazole alone|Oral Metronidazole antibiotic therapy alone
3290279|NCT00545168|Experimental|A - NatrOVA 1% - no nit combing|NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
3290280|NCT00545168|Experimental|B - NatrOVA 1% - nit combing required|NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
3290281|NCT00545168|Active Comparator|C - NIX|Nix Creme Rinse (permethrin 1%) applied according to OTC Instructions for Use
3290282|NCT00545155||Geriatric EMS Patients|Cohort for reliability and concurrent validity testing.
3290283|NCT00545129|Experimental|Tanezumab 10 mg IV + opioids|
3290284|NCT00545129|Placebo Comparator|Placebo + opioids|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
3290285|NCT00545116|Experimental|a|Active carrier 1: biscuit providing 250 mg hesperidin per piece(6g)
3290286|NCT00545116|Experimental|b|Active carrier 2: liquid skim milk providing 250 mg hesperidin/serve (200 ml) and containing around 300 mg calcium/serving
3290287|NCT00545116|Placebo Comparator|c|Placebo carrier 1: biscuit with the same nutrient composition and appearance as the active biscuit carrier but minus hesperidin
3290288|NCT00545116|Placebo Comparator|d|Placebo carrier 2: liquid skim milk with the same nutrient composition and appearance as the active milk carrier but minus hesperidin
3290289|NCT00545103|Experimental|SPD476 (1.2 g)|
3290290|NCT00545103|Experimental|SPD476 (2.4 g)|
3290291|NCT00545103|Experimental|SPD476 (4.8 g)|
3290292|NCT00545103|Placebo Comparator|Placebo|
3290293|NCT00545090|Experimental|1|
3290294|NCT00545077|Active Comparator|A|• Endocrine treatment consisting of either letrozole or fulvestrant.The patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
3290295|NCT00545077|Experimental|B|Bevacizumab: 15 mg/Kg i.v. on day 1 every 3 weeks plus Endocrine treatment consisting of either letrozole or fulvestrant.
3290296|NCT00545051|Experimental|Ibandronate|Participants received monthly oral ibandronate (150 milligrams [mg]) for 12 months.
3290297|NCT00545051|Placebo Comparator|Placebo|Participants received monthly oral placebo for 12 months.
3290298|NCT00545025|Experimental|GSK1247446A Group|Subjects aged between 18 and 60 years, having previously received one dose of the AS03-adjuvanted GSK1247446A vaccine in the primary study NCT00374842, received a single dose of GSK1247446A vaccine adjuvanted with a half dose of AS03 adjuvant at Day 0 of the current follow-up study NCT00545025. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Subjects in this group originated from either the GSK1247446A Formulation 1 or GSK1247446A Formulation 2 groups in study NCT00374862.
3290299|NCT00545025|Active Comparator|Fluarix Group|Subjects aged between 18 and 60 years, having previously received one dose of Fluarix™ vaccine during the primary study NCT00374842, received one dose of Fluarix™ vaccine at Day 0 of the current follow-up study NCT00545025. The vaccine was administered intramuscularly, in the deltiod region of the non-dominant arm. Subjects in this group originated from the Fluarix Group in study NCT00374862.
3290300|NCT00544960|Experimental|1|AT-101 and docetaxel
3290301|NCT00544960|Placebo Comparator|2|placebo and docetaxel
3290302|NCT00544947||D, F|"Group D will be patients at Princess Royal Maternity Hospital in Glasgow, where supplementation with intrathecal diamorphine 300mcg is the current anaesthetic technique of choice.~Group F will be patients at the Queen Mother's Maternity Hospital in Glasgow, where supplementation with intrathecal fentanyl 15mcg plus post-operative morphine PCA is the current anaesthetic technique of choice for elective caesarean section."
3290303|NCT00544934|Experimental|250 mg|
3290304|NCT00544934|Experimental|500 mg|
3290305|NCT00544934|Experimental|750 mg|
3290306|NCT00544934|Placebo Comparator|Placebo|
3290307|NCT00544921|Experimental|50 mg|
3290308|NCT00544921|Experimental|100 mg|
3290309|NCT00544921|Experimental|250 mg|
3290310|NCT00544921|Experimental|500 mg|
3290311|NCT00544921|Experimental|750 mg|
3290312|NCT00544921|Experimental|1000 mg|
3290313|NCT00544921|Placebo Comparator|Placebo|
3290314|NCT00544908|Experimental|Dasatinib|Dasatinib 70 mg po bid (1 cycle=28 days)
3290315|NCT00544882|Experimental|DR-1021|After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).
3290316|NCT00544882|Active Comparator|Mircette|After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).
3290317|NCT00544869|Experimental|1|
3290318|NCT00544856|Experimental|1|cognitive intervention
3290319|NCT00544856|Placebo Comparator|2|
3290320|NCT00544830|Experimental|Androgen Deprivation and Radiation Therapy|Androgen deprivation subcutaneously with goserelin or leuprolide, radiation therapy to all known metastatic sites.
3290321|NCT00544817|Experimental|Combination Therapy|"In the combined modality portion of the study, patients were administered:~Radiation Therapy - 2 Gy/fraction, Single daily fractions M-F, to 60 Gy total Temozolomide - 75 mg/m2 by mouth once daily~Patients took a four week break before beginning follow-up systemic therapy:~Temozolomide - 150 mg /m2 by mouth on days 1-5 every 28 days for 6 cycles Sorafenib - 400 mg by mouth twice a day for 6 months"
3290322|NCT00544804|Experimental|Lapatinib|Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer
3290323|NCT00544791|Experimental|A|melatonin 5 mg, daily dose for 6 months
3290324|NCT00544791|Placebo Comparator|B|
3290325|NCT00544778|Experimental|Arm 1|High-dose chemotherapy with doxorubicin at 120 mg/m2 and ifosfamide at 2 g/m2 followed by a prolonged schedule of CPT-11 at 20 mg/m2.
3290326|NCT00544765|Experimental|resp: 4xTAC|Patients sufficiently responding (iPR, iCR) will recieve 4 further cycles of TAC
3290327|NCT00544765|Experimental|resp: 6xTAC|Patients sufficiently responding (iPR, iCR) will recieve 6 further cycles of TAC
3290328|NCT00544765|Experimental|nonResp: 4xTAC|Patients non-sufficiently responding (iNC) will recieve 4 further cycles of TAC
3290329|NCT00544765|Experimental|nonResp: 4xNX|Patients non-sufficiently responding (iNC) will recieve 4 further cycles of NX
3290330|NCT00544752|Experimental|16|indoor temperature of 16 degrees celcius
3290331|NCT00544752|Experimental|20|indoor temperature 20 degrees celcius
3290332|NCT00544752|Experimental|24|indoor temperature of 24 degrees celcius
3290333|NCT00544739||1|323 women with established coronary artery disease before 55 year of age
3290334|NCT00544739||2|347 clinically healthy, age matched women selected from the National Health Survey WOBASZ study with negative history of CVD or negative exertional chest pain.
3290335|NCT00544726|Active Comparator|1|Physical training
3290336|NCT00544726|Placebo Comparator|2|No physical training
3290337|NCT00544713|Experimental|Carboxymethylcellulose and Glycerin based artificial tear|Carboxymethylcellulose and Glycerin based artificial tear
3290338|NCT00544713|Active Comparator|Carboxymethylcellulose based artificial tear|Carboxymethylcellulose based artificial tear
3290339|NCT00544700|Active Comparator|Arm A: Bevacizumab monotherapy|Bevacizumab maintenance monotherapy
3290340|NCT00544700|Other|Arm B: No maintenance|No antitumor treatment until progression
3290341|NCT00544687|Experimental|1|CRx-191 (0.1% mometasone furoate + 0.05% nortriptyline HCl)
3290342|NCT00544687|Experimental|2|CRx-191 (0.1% mometasone furoate + 0.1% nortriptyline HCl)
3290343|NCT00544687|Active Comparator|3|0.1% mometasone furoate
3290344|NCT00544687|Active Comparator|4|0.1% nortriptyline HCl
3290345|NCT00544687|Active Comparator|5|Karison® Creme (clobetasol-17-propinate 0.05%)
3290346|NCT00544687|Placebo Comparator|6|Vehicle (placebo)
3290347|NCT00544674|Experimental|PR104|PR104 will be administered once every 21 days by IV
3290348|NCT00544648|Experimental|Treatment|nab-paclitaxel+ carboplatin + radiation
3290349|NCT00544635|Experimental|A|scars will be treated with light
3290350|NCT00544635|Placebo Comparator|B|no intervention
3290351|NCT00544609|Other|Sorafenib|2 weeks:Sorafenib, 6 weeks and a half:Sorafenib with radiotherapy, 4 weeks:Sorafenib
3290384|NCT00544115|Active Comparator|Regimen II|Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2.
3290385|NCT00544115|Active Comparator|Regimen III|Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3.
3290386|NCT00544115|Active Comparator|Regimen IV|Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2.
3290533|NCT00542685|Placebo Comparator|Placebo BID|
3290534|NCT00542685|Experimental|PD 0332334 225 mg BID|
3290352|NCT00544596|Experimental|Treatment (R-(-)-gossypol acetic acid, cisplatin, etoposide)|"Patients receive oral R-(-)-gossypol twice daily on days 1-3, cisplatin IV over 60 minutes on day 1*, and etoposide IV over 30 minutes on days 1*-3. Treatment repeats every 21 days for up to 6 courses during the dose escalation and 4 courses in the expanded extensive stage small cell lung cancer cohort, in the absence of disease progression or unacceptable toxicity.~Blood samples are collected on day 1 of courses 1 and 2 for pharmacokinetic analysis, biomarker assays, and correlative studies.~After completion of study treatment, patients are followed for 30 days.~[Note: *Cisplatin and etoposide will be started on day 2 during course 1; they will be given on day 1 during all subsequent courses.]"
3290353|NCT00544583|Active Comparator|A|Interrupted closure with Vicryl equivalent sutures (USP 2, 45 cm)
3290354|NCT00544583|Experimental|B|Continuous closure with PDS II equivalent sutures (USP 1, 150 cm loops)
3290355|NCT00544557||Patients with Ankylosing Spondylitis|
3290356|NCT00544544|Experimental|Riluzole|Riluzole 50 mg twice daily for 2 weeks, increased to riluzole 50 mg in the morning and 100 mg in the evening for 1 week if tolerated, with a further increase to riluzole 100 mg twice daily if tolerated for 3 weeks.
3290357|NCT00544518|Experimental|2|
3290358|NCT00544518|Active Comparator|1|
3290359|NCT00544492|Experimental|A1|Buttonhole cannulation technique
3290360|NCT00544492|Active Comparator|A2|Rope ladder cannulation technique
3290361|NCT00544492|Experimental|B1|Catheter with bevel point
3290362|NCT00544492|Active Comparator|B2|Catheter with cylindrical point
3290363|NCT00544466|Experimental|Treatment (enzyme inhibitor, radiation therapy, transplant)|PREPARATIVE REGIMEN*: Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. Patients also undergo helical tomotherapy twice daily on days -7 to -4. TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0. NOTE: *Treatment begins 2 days earlier in patients receive tacrolimus and/or sirolimus for GVHD prophylaxis.
3290364|NCT00544440|Experimental|Abiraterone acetate plus prednisone|Patients will be treated orally with abiraterone acetate 1000 mg daily and prednisone 5 mg twice a day until clinical disease progression.
3290365|NCT00544414|Experimental|Treatment|"Patients receive neoadjuvant induction chemotherapy comprising docetaxel IV over 1 hour on day 1 and cisplatin IV, leucovorin IV, and fluorouracil IV over 24 hours on days 1-4. Induction chemotherapy repeats every 28 days for 3 courses.~Patients with partial response at the primary site may undergo radical or functional resection of the primary tumor within 3 weeks of completion of neoadjuvant therapy.~Beginning within 4 weeks of completion of neoadjuvant therapy, patients with persistent disease or complete response after chemotherapy at the primary or neck then undergo radiotherapy 5 days a week for 7 weeks and receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 60 minutes on day 1 of each week of radiotherapy."
3290366|NCT00544401|Experimental|1|Hypnopuncture Treatment
3290367|NCT00544401|No Intervention|2|Conventional IVF/ICSI treatment only
3290368|NCT00544375||Neonatal Tissues|Optical measurement neonatal tissues
3290369|NCT00544362|Experimental|Neoadjuvant chemoradiotherapy|Weekly cetuximab (400 mg/m2 one week before start of radiotherapy RT and 250 mg/m2 during radiotherapyRT), and 5 FU (500 mg/m2 per day D1-D4) combined with cisplatin CDDP (40 mg/m2 D1) on week 1 and 5
3290370|NCT00544336||Supportive|
3290371|NCT00544310|Experimental|1|Post surgery adhesion prevention treatment
3290372|NCT00544297|Experimental|PEP005 gel administration|0.05% PEP005 Topical Gel administered for two consecutive days to a 25cm2 contiguous AK treatment area on the top of the hand
3290373|NCT00544284|Experimental|Treatment (temozolomide, bortezomib)|GROUP A: Patients receive oral temozolomide once a day on days 1-5 and bortezomib IV on days 2, 5, 9, and 12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. GROUP B: Patients receive temozolomide and bortezomib as in group A. Cohorts of patients in both groups receive escalating doses of both study drugs until the maximum tolerated doses are determined. All patients undergo blood sample collection periodically for pharmacokinetic studies. Samples are analyzed for bortezomib concentration (groups A and B) and trough levels of anticonvulsants (group A only).
3290374|NCT00544258|Experimental|1|Two days consecutive days of application of 0.05% PEP005 Topical Gel to a 100cm2 contiguous AK treatment area of the arm.
3290375|NCT00544232|Experimental|epirubicin, paclitaxel and CMF +/- darbepoetin|"Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel"
3290376|NCT00544232|Experimental|EC followed by paclitaxel +/- darbepoetin|"Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF"
3290377|NCT00544219|Other|R-Chop 14|Standard treatment
3290378|NCT00544206|Experimental|#1|Diabetes specific enteral feeding product
3290379|NCT00544206|Active Comparator|#2|Standard enteral feeding product
3290380|NCT00544167|Experimental|Intervention|All patients received doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC) both administered intravenously day 1 every 3 weeks for four cycles, followed by paclitaxel 175 mg/m2 intravenously day 1 every 3 weeks for four cycles or 80 mg/m2 for twelve weeks (physician discretion), combined with sorafenib 400 mg orally twice daily. Sorafenib was held during radiation therapy where indicated and resumed once completed. Sorafenib was continued for a total of 12 months and in combination with adjuvant hormonal therapy where indicated.
3290381|NCT00544128|Active Comparator|Epzicom Arm|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
3290382|NCT00544128|Active Comparator|Truvada Arm|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg
3290383|NCT00544115|Active Comparator|Regimen I|Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.
3290477|NCT00543296|Experimental|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
3290387|NCT00544115|Active Comparator|Regimen V|Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.
3290388|NCT00544115|Active Comparator|Regimen VI|Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2.
3290389|NCT00544076|Experimental|Arm I|Patients receive intraurethral alprostadil once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months.
3290390|NCT00544076|Active Comparator|Arm II|Patients receive 3 doses of oral sildenafil citrate on 3 separate occasions at least 48 hours apart monthly for 18 months.
3290391|NCT00544076|Experimental|Arm III|Patients receive oral sildenafil citrate once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months.
3290392|NCT00544037||Group 1|
3290393|NCT00544024||Reference|Lariam was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
3290394|NCT00544024||T1|Mephaquin was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
3290395|NCT00544024||T2|Mefloquine-AC Farma was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
3290396|NCT00543998||Optical Measurement transillumination|Optical Measurement of sinus
3290397|NCT00543985|Experimental|Stress Echocardiography|Echocardiography was performed prior to and within 60 seconds of completing the standard Bruce treadmill protocol.
3290398|NCT00543959|Experimental|Part1 - Arm 1|Part1: Arm 1: drug
3290399|NCT00543959|Placebo Comparator|Part1 - Arm 2|Part1 - Arm 2: Pbo comparator
3290400|NCT00543959|Placebo Comparator|Part 2 - Arm 1|Part 2 - Arm 1: Pbo
3290401|NCT00543959|Experimental|Part 2 - Arm 2|Part 2- Arm 2: drug 5mg
3290402|NCT00543959|Experimental|Part 2 - Arm 3|Part 2 - Arm 3: drug 15mg
3290403|NCT00543959|Experimental|Part 2 - Arm 4|Part 2 - Arm 4: drug 30mg
3290404|NCT00543959|Active Comparator|Part 2 - Arm 5|Part 2 - Arm 5: active comparator
3290405|NCT00543933|Experimental|iNO administered|iNO administered at 40 ppm via a non-rebreather mask
3290406|NCT00543907||Pre programmatic development|Patients who have undergone mastectomy for breast cancer prior to implementation of the deep inferior epigastric perforator flap microsurgical breast reconstruction program
3290407|NCT00543907||Post programmatic development|Patients who have undergone mastectomy for breast cancer after implementation of the deep inferior epigastric perforator flap microsurgical breast reconstruction program
3290408|NCT00543881|Experimental|1|Interventional group
3290409|NCT00543881|Active Comparator|2|Usual care group
3290410|NCT00543855|Experimental|3 mg Donepezil hydrochloride|
3290411|NCT00543855|Experimental|5 mg Donepezil hydrochloride|
3290412|NCT00543855|Experimental|10 mg Donepezil hydrochloride|
3290413|NCT00543855|Placebo Comparator|Placebo|
3290414|NCT00543842|Experimental|Bevacizumab + Erlotinib + Capecitabine + Radiation Therapy|Bevacizumab 5 mg/kg intravenous (IV) every 2 weeks for 3 Doses (Weeks 1, 3, 5). Erlotinib starting dose 50 mg orally daily Weeks 1-3. Capecitabine starting dose 650 mg/m^2 orally twice daily Monday-Friday for 6 Weeks. Radiation Therapy 30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments. At least 8 weeks after radiation therapy, surgical removal of rectal tumor.
3290415|NCT00543829|Experimental|1|4 cycles of doxorubicin and docetaxel with tamoxifen
3290416|NCT00543829|Active Comparator|2|4 cycles of doxorubicin and docetaxel without tamoxifen
3290417|NCT00543790|Experimental|1|
3290418|NCT00543777|Experimental|MRE + 2PD MRI|MRE - Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue. 2PD MRI - Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
3290419|NCT00543764||Pre pathway|Pre pathway
3290420|NCT00543764||Post pathway|Post pathway
3290421|NCT00543725|Active Comparator|002|efavirenz 600 mg tablet once daily for 96 weeks
3290422|NCT00543725|Experimental|001|TMC278 25 mg tablet once daily for 96 weeks
3290423|NCT00543686|Active Comparator|1|Montelukast
3290424|NCT00543686|Active Comparator|2|Fluticasone
3290425|NCT00543673|Experimental|Milk based formula A|Experimental milk based infant formula
3290426|NCT00543673|Active Comparator|Standard formula|standard milk based infant formula
3290427|NCT00543673|Other|Reference|Human milk
3290428|NCT00543673|Experimental|Milk based formula C|Experimental milk based infant formula
3290429|NCT00543660|Experimental|Intervention arm DSEK|Intervention: DSEK
3290430|NCT00543647|Experimental|1|
3290431|NCT00543647|Placebo Comparator|2|
3290432|NCT00543634|Active Comparator|1|
3290433|NCT00543634|Active Comparator|2|
3290434|NCT00543608|Experimental|1|Dose 1 iclaprim
3290435|NCT00543608|Experimental|2|Dose 2 iclaprim
3290436|NCT00543608|Active Comparator|3|vancomycin
3290437|NCT00543582|Experimental|1|
3290438|NCT00543569|Active Comparator|Tacrolimus/MMF/Basiliximab|Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.
3290478|NCT00543270|Experimental|A|EVAR (Powerlink System)
3290479|NCT00543270|Active Comparator|B|Open Surgical Control
3290535|NCT00542685|Experimental|PD 0332334 175 mg BID|
3290536|NCT00542633|Experimental|A|VIAject™
3290537|NCT00542633|Active Comparator|B|Regular Human Insulin
3290439|NCT00543569|Experimental|Alefacept QW/Tacrolimus/MMF|Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.
3290440|NCT00543569|Experimental|Alefacept QW/Tacrolimus|Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.
3290441|NCT00543569|Experimental|Alefacept QOW/Tacrolimus/MMF|Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.
3290442|NCT00543543|Experimental|Low-dose V503|V503 (9-Valent Human Papillomavirus [HPV] Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study.
3290443|NCT00543543|Experimental|Mid-dose V503|V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study. A subset of participants (Cohort 1) received a fourth V503 mid-dose vaccination in the extension study.
3290444|NCT00543543|Experimental|High-dose V503|V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study.
3290445|NCT00543543|Active Comparator|Gardasil|Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study. Participants (Cohort 2) were offered the V503 mid-dose 3-dose regimen in the extension study.
3290446|NCT00543504|Experimental|Bevacizumab + Sunitinib|Arm 1: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Sunitinib 12.5 mg orally daily for 4 weeks, then 2 weeks off.
3290447|NCT00543504|Experimental|Bevacizumab + Sorafenib|Arm 2: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Sorafenib 200 mg by mouth daily for 28 Days
3290448|NCT00543504|Experimental|Bevacizumab + Erlotinib + Cetuximab|Arm 3: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Erlotinib 50 mg By Mouth Daily for 28 Days + Cetuximab loading dose 100 mg/m² IV and maintenance 75 mg/m² on Days 1, 8, 15, 22.
3290449|NCT00543504|Experimental|Bevacizumab + Trastuzumab + Lapatinib|Arm 4: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Trastuzumab loading dose 2 mg/kg IV then maintenance dose 1 mg/kg IV on Day 1 + Lapatinib 250 mg By Mouth Daily for 21 Days.
3290450|NCT00543478|Active Comparator|1|Receive active drug Saccharomyces boulardii 250mg twice a day for 8 weeks.
3290451|NCT00543478|Placebo Comparator|2|Placebo will be given twice a day for 10 weeks
3290452|NCT00543452|Active Comparator|oxygen|4 liters of oxygen a minute
3290453|NCT00543452|Placebo Comparator|air|4 liters of room air
3290454|NCT00543439|Experimental|1|On-Demand therapy for 6 months, followed by Routine Prophylaxis treatment for 1 year.
3290455|NCT00543439|Experimental|2|Routine Prophylaxis Crossover
3290456|NCT00543426|Experimental|1|Fuzheng Huayu Tablets
3290457|NCT00543426|Sham Comparator|2|sham Fuzheng Huayu Tablets
3290458|NCT00543413|Experimental|1|Arm 1: Drug 250 mg
3290459|NCT00543413|Experimental|2|Arm 2: Drug 500 mg
3290460|NCT00543413|Active Comparator|3|Arm 3: Active Comparator
3290461|NCT00543413|Placebo Comparator|4|Arm 4: Pbo Comparator
3290462|NCT00543400|Active Comparator|70 U/kg of unfractionated heparin given IV|Venous injection (IV) of 70 units per kilogram (U/kg) of unfractionated heparin prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
3290463|NCT00543400|Experimental|50 IU/KG of M118|Venous injection of 50 international units per kilogram (IU/kg) of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
3290464|NCT00543400|Experimental|75 IU/KG of M118|Venous injection of 75 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
3290465|NCT00543400|Experimental|100 IU/KG of M118|Venous injection of 100 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
3290466|NCT00543387|Experimental|MK-5108|Participants entered into the MK-5108 group (Panel 1) will receive MK-5108 as monotherapy; MK-5108 will be administered to cohorts of participants in sequentially rising doses. MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1.
3290467|NCT00543387|Experimental|MK-5108 + Docetaxel|The MK-5108 + Docetaxel group (Panel 2) will receive MK-5108 in combination with an intravenous (I.V.) dose of docetaxel (60 mg/m^2). MK-5108 will be administered to cohorts of participants in sequentially rising doses. MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 21 days in Panel 2.
3290468|NCT00543374|Placebo Comparator|1|Placebo
3290469|NCT00543374|Active Comparator|2|Low dose (total of 600 million cells)
3290470|NCT00543374|Active Comparator|3|High dose (total of 1200 cells)
3290471|NCT00543348|Active Comparator|1|CUTTING BALLOON
3290472|NCT00543348|Placebo Comparator|2|
3290473|NCT00543335|Experimental|Sorafenib + Radiation Therapy|Sorafenib starting dose 200 mg orally daily + 45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
3290474|NCT00543309|Experimental|I- nesiritide|Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
3290475|NCT00543309|Active Comparator|II- Milrinone|Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
3290476|NCT00543309|Placebo Comparator|III- placebo|Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
3290480|NCT00543257||Parents|Parents of children with ADHD will be recruited from the greater Boston community. We are interested in enrollment of parents with a range of educational and technical backgrounds, and specifically will look to enroll parents who may not have much computer experience.
3290481|NCT00543244||1|Patients with chronic hepatitis C who receive pegylated interferon plus ribavirin for 24 weeks (genotype 1 or 2) and for 48 weeks (genotype 1)
3290482|NCT00543218|Active Comparator|A|teriparatide 20 micrograms/day subcutaneous
3290483|NCT00543218|Active Comparator|B|
3290484|NCT00543166|Placebo Comparator|2|180 patients divided to two separate groups (each containing 90 patients). This study has a cross-over, wash-out design, which consists of two 4 month treatment period separated by a one month long wash-out period. During one treatment period the patient gets placebo and during one of the treatment periods the patient gets 50mg of dehydroepiandrosterone (DHEA) in the morning.
3290485|NCT00543153||Patients diagnosed with cancer|
3290486|NCT00543140|Other|REALIZE™ Swedish Adjustable Gastric Band|All subjects have the REALIZE™ Swedish Adjustable Gastric Band. Single arm - no comparator.
3290487|NCT00543127|Experimental|1|Fulvestrant charge dose days 0,14, 28 (250 mg) and later each 28 days concomitant with anastrozol (1 mg daily) for the three first years followed by 2 years with anastrozol (1mg daily)alone.
3290488|NCT00543127|Active Comparator|2|Anastrozol 1 mg daily for 5 yeras.
3290489|NCT00543114|Experimental|Lenalidomide, fludarabine and rituximab|Lenalidomide-Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period fludarabine- Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days Rituximab- Given intravenously on Day 1 of each 28 day cycle
3290490|NCT00543101|Active Comparator|Switch to DRV/r|Switch to DRV/r at a dose of 600/100 BID for 48 weeks
3290491|NCT00543101|Active Comparator|Continue on Current Dual Boosted PI|Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (< 400 copies/ml) for the first 24-weeks of the study and are followed for an additional 24 weeks
3290492|NCT00543062|Other|4-period crossover study|"The 4 treatments were presented in 4 sequences:~Inhaled prochlorperazine 10 mg + Oral placebo Inhaled prochlorperazine 5 mg + Oral placebo Inhaled prochlorperazine placebo + Oral placebo Inhaled prochlorperazine placebo + Oral moxifloxacin 400 mg"
3290493|NCT00543049|Other|1 non-continuous|Subjects will receive open-label sunitinib = SU11248 at a dose of 50.0 mg once daily. After 28 days, treatment will be paused for 14 days and cycle one is completed, followed by resumption of therapy as cycle one for up to one year (therapy can be continued in case of tumor response and benefit for the patient for more than one year).
3290494|NCT00543049|Other|2 continuous|Subjects will receive open-label sunitinib = SU11248 at a dose of 37.5 mg once daily continuously. Treatment period up to one year (therapy can be continued in case of tumor response and benefit for the patient for more than one year).
3290495|NCT00543023|Experimental|A|teriparatide 20 micrograms/day subcutaneous
3290496|NCT00543023|Active Comparator|B|salmon calcitonin 100 IU/day subcutaneous
3290497|NCT00542997|Experimental|IgPro20|
3290498|NCT00542984|Active Comparator|A|teriparatide 20 micrograms/day subcutaneous
3290499|NCT00542984|Active Comparator|B|salmon calcitonin 100 IU/day subcutaneous
3290500|NCT00542971|Experimental|Sorafenib + Idarubicin + Ara-C|Sorafenib starting dose 400 mg orally for 7 days; Idarubicin 12 mg/m^2 intravenous (IV) daily (days 1-3); and Ara-C 1.5 g/m^2 IV over 24 hours daily (days 1-4)
3290501|NCT00542958|Experimental|1|
3290502|NCT00542945|Experimental|A|Heart Failure nonischemic ethiology
3290503|NCT00542945|Active Comparator|B|
3290504|NCT00542932|No Intervention|I|
3290505|NCT00542932|Active Comparator|II|Exercise
3290506|NCT00542919|Experimental|1|Indolent B-Cell
3290507|NCT00542919|Experimental|2|Aggressive B-Cell
3290508|NCT00542919|Experimental|3|T-Cell
3290509|NCT00542906|Other|1|healthy volunteers
3290510|NCT00542893|Experimental|Group 1|Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
3290511|NCT00542893|Experimental|Group 2|Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
3290512|NCT00542880|Experimental|Symbicort Turbuhaler First, then Seretide Diskus|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg First, then Seretide Diskus (salmeterol/fluticasone) 50/500 μg
3290513|NCT00542880|Experimental|Seretide Diskus First, then Symbicort Turbuhaler|Seretide Diskus (salmeterol/fluticasone) 50/500 μg First, then Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg
3290514|NCT00542854||MP3|4 different brands of MP3 players will be tested at 3 distances from pacemakers and ICDs.
3290515|NCT00542841|Experimental|1|
3290516|NCT00542828|Experimental|Thymoglobulin|
3290517|NCT00542815|Experimental|1|
3290518|NCT00542815|Active Comparator|2|
3290519|NCT00542802|Experimental|LEV|Levetiracetam
3290520|NCT00542802|Active Comparator|CAR|Carbamazepina
3290521|NCT00542789|Placebo Comparator|1|Placebo
3290522|NCT00542789|Experimental|2|Esomeprazole 20 mg
3290523|NCT00542776||1|IBD patients on immunosuppressive therapy
3290524|NCT00542776||2|IBD patients on non-immunosuppressive therapy (e.g., aminosalicylates, antibiotics) or on no medications
3290525|NCT00542750|Experimental|N-Acetylcysteine|All participants will receive N-Acetylcysteine 1200 mg twice daily during four weeks of participation. Tolerability, marijuana use, and reactivity to marijuana cues will be investigated.
3290526|NCT00542737|Active Comparator|Early Intervention Group|
3290527|NCT00542737|Active Comparator|Delayed Intervention Group|
3290528|NCT00542724|Experimental|A|VIAject™
3290529|NCT00542724|Active Comparator|B|Regular Human Insulin
3290530|NCT00542698|No Intervention|Control|Control group uses 90 minutes of standard diabetes education/ 7 days using the International Diabetes Center curriculum & update phone call at 4 weeks.
3290531|NCT00542698|Experimental|Intervention|Interventional group received standard diabetes education, CGMS monitor, and extra educational topics including CGMS counceling.
3290532|NCT00542685|Experimental|PD 0332334 300 mg BID|
3290538|NCT00542620|Experimental|Mixed injection|
3290539|NCT00542620|Active Comparator|Separate injection|
3290540|NCT00542581|Experimental|The Acrysof toric SN60T3 IOL|Multifocal Intraocular Lens
3290541|NCT00542568|Experimental|1|Cohort 1 (Low Dose group) 18-25 IU/kg/day
3290542|NCT00542568|Experimental|2|Cohort 2 (Intermediate Dose group): 35-45 IU/kg/day
3290543|NCT00542568|Experimental|3|Cohort 3 (High Dose group): 55-65 IU/kg/day
3290544|NCT00542555|Placebo Comparator|Placebo bid|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
3290545|NCT00542555|Experimental|Naproxcinod 375 mg bid|
3290546|NCT00542555|Active Comparator|Naproxen 500 mg bid|
3290547|NCT00542555|Experimental|Naproxcinod 750 mg bid|
3290548|NCT00542542|Active Comparator|Paravertebral Block + General Anesthesia|Group 1: Paravertebral Block + General Anesthesia (Ropivacaine)
3290549|NCT00542542|Active Comparator|General Anesthesia Alone|Group 2: General Anesthesia Alone (Propofol, Midazolam, Fentanyl)
3290550|NCT00542529|Placebo Comparator|Cohort 1|Placebo or 2.0 mg/kg of Imprime PGG dosed in 7 different treatment regimens in combination with G-CSF for up to 4 consecutive days.
3290551|NCT00542529|Placebo Comparator|Cohort 2|Placebo or 4.0 mg/kg of Imprime PGG dosed in 7 different treatment regimens in combination with G-CSF for up to 4 consecutive days.
3290552|NCT00542516|Experimental|HES 130/04|Pre-expansion with HES
3290553|NCT00542516|Active Comparator|Ringer's lactate|Pre-expansion with Ringer's lactate
3290554|NCT00542490|Experimental|Vaginal Cuff Brachytherapy|
3290555|NCT00542464|Placebo Comparator|Cohort 1|1.0 mg/kg Imprime PGG administered daily over 1 hr for 7 consecutive days
3290556|NCT00542464|Placebo Comparator|Cohort 2|2.0 mg/kg Imprime PGG administered daily over 1 hr for 7 consecutive days
3290557|NCT00542464|Placebo Comparator|Cohort 3|4.0 mg/kg Imprime PGG administered daily over 2 hr for 7 consecutive days
3290558|NCT00542438|Active Comparator|Physical Activity Recall|Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
3290559|NCT00542438|Active Comparator|Environmental Assessment|Environmental assessments on a palm pilot either 3 times a day or once a day. Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
3290560|NCT00542425|Placebo Comparator|Placebo|
3290561|NCT00542425|Experimental|BA058 20 µg|
3290562|NCT00542425|Experimental|BA058 40 µg|
3290563|NCT00542425|Experimental|BA058 80 µg|
3290564|NCT00542425|Active Comparator|teriparatide|
3290565|NCT00542399|Experimental|1|once a day
3290566|NCT00542399|Experimental|2|twice a day
3290567|NCT00542386|Experimental|1|
3290568|NCT00542386|Placebo Comparator|2|
3290569|NCT00542373|Experimental|PS2 + MDM + Fast EEM4|PS2 imaging system that shines different wavelengths (colors) of light in the mouth and can collect and analyze fluorescence and reflected light. MDM imaging system that takes fluorescence and reflectance pictures through a dental microscope. Different colors of light are used to shine in the mouth and pictures are taken using a digital camera. Fast EEM4 - Different colors of light are directed through fibers to the lining of the mouth and then light is collected and sent to a special camera and a computer to be analyzed.
3290570|NCT00542360|Experimental|Social marketing program|Behavioral: Social marketing program to motivate exercise class participation
3290571|NCT00542360|No Intervention|Control|Control: No intervention
3290572|NCT00542347|Active Comparator|1|"esomeprazole 20mg po once per day for 7 days~24hr pH study on day 7~followed by washout for 7 days~generic omeprazole 20mg po once per day for 7 days~24hr pH study on day 7"
3290573|NCT00542347|Active Comparator|2|"generic omeprazole 20mg po once per day for 7 days~24hr pH study on day 7~followed by washout for 7 days~esomeprazole 20mg po once per day for 7 days~24hr pH study on day 7"
3290574|NCT00542321|Experimental|Kinetic Therapy Bed|Kinetic Therapy Bed: Continuous automated turning to 45 degrees with head of the bed elevated 30 degrees or more for up to 7 continuous days
3290575|NCT00542321|Active Comparator|Manual Turn|Manual Turn: lateral rotation every 2 hours from back to left to back to right to back, with >/= 45 degree lateral rotation angle and 30 degree head of bed elevation
3290576|NCT00542308|Experimental|Zalutumumab 4-16 mg/kg|Zalutumumab iv infusion once weekly. The dose was titrated until grade 2 rash occurred.
3290577|NCT00542295|Experimental|A|
3290578|NCT00542295|Placebo Comparator|B|
3290579|NCT00542282||1, 2, 3|known moderate to severe COPD, known moderate or severe Asthma, suspected obstructive moderate to severe airways disease
3290580|NCT00542269|Experimental|Aliskiren / ramipril / amlodipine|6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
3290581|NCT00542269|Experimental|Aliskiren / amlodipine|6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
3290629|NCT00541970|Experimental|Cervarix 2/Placebo/Cervarix 2 Group|Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
3290669|NCT00541593|Experimental|NOTES pancreatic pseudocystgastrostomy|Patients who undergo pancreatic pseudocystgastrostomy via a NOTES technique.
3290582|NCT00542269|Active Comparator|Ramipril / amlodipine|6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
3290583|NCT00542256|Active Comparator|1|Each subject will receive 14 days (2 week period: 10 weekdays and 2 weekends) of constraint induced movement therapy. In addition, on the 10 weekdays during the treatment period, the subjects will come into the laboratory and receive up to 6 hours per day of training of the affected arm in a variety of tasks. At the beginning of each of the 10 weekday training sessions, participants will receive 40 minutes of active tDCS over the primary motor cortex.
3290584|NCT00542256|Sham Comparator|2|Each subject will receive 14 days (2 week period: 10 weekdays and 2 weekends) of constraint induced movement therapy. In addition, on the 10 weekdays during the treatment period, the subjects will come into the laboratory and receive up to 6 hours per day of training of the affected arm in a variety of tasks. At the beginning of each training day tDCS will be applied for 40 minutes with the current active for only 30 seconds over the primary motor cortex.
3290585|NCT00542243|Active Comparator|Finasteride|"The recommended dosage of PROSCAR© is one 5 mg tablet daily with or without food. If a tablet is missed at its usual time, an extra dose should not be taken. The next dose should be taken as usual.~PROSCAR© 5 mg tablets are blue, apple-shaped; film coated with the code MSD 72 on one side and PROSCAR on the other. They will be provided in bottles of 35 tablets."
3290586|NCT00542243|Placebo Comparator|Placebo|Patient will receive a placebo comparator each day for 6 months.
3290587|NCT00542217|Placebo Comparator|Cohort 1|Single dose of 0.5 mg/kg Imprime PGG administered over 1 hr
3290588|NCT00542217|Placebo Comparator|Cohort 2|Single dose of 1.0 mg/kg Imprime PGG administered over 1 hr
3290589|NCT00542217|Placebo Comparator|Cohort 3|Single dose of 2.0 mg/kg Imprime PGG administered over 1 hr
3290590|NCT00542217|Placebo Comparator|Cohort 4|Single dose of 4.0 mg/kg Imprime PGG administered over 2 hr
3290591|NCT00542217|Placebo Comparator|Cohort 5|Single dose of 6.0 mg/kg Imprime PGG administered over 3 hr
3290592|NCT00542204|Experimental|Online disease management|The PAMFOnline-mediated Personalized Health Care Program, which couples a multidisciplinary diabetes care management team with an EHR-integrated Online Disease Management (ODM) system.
3290593|NCT00542204|No Intervention|Usual care|Usual medical care. No access to the PHCP electronic system and self-management tools supporting this care management.
3290594|NCT00542191|Other|Single arm study; taxol, XRT, gemzar and carbo|
3290595|NCT00542178|Experimental|Intensive glycemia control|A strategy of intensive glycemia treatment to HbA1c less than 6%
3290596|NCT00542178|Active Comparator|Standard glycemia control|A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%
3290597|NCT00542178|Experimental|Intensive BP control|A strategy of BP treatment for SBP less than 120 mm Hg
3290598|NCT00542178|Active Comparator|Standard BP control|A strategy of BP treatment for SBP less than 140 mm Hg
3290599|NCT00542178|Experimental|Fibrate|Blinded fenofibrate + simvastatin 20-40 mg/d
3290600|NCT00542178|Placebo Comparator|Fibrate Placebo|Blinded placebo + simvastatin 20-40 mg/d
3290601|NCT00542152|Active Comparator|CICLO|"Cyclosporine will be administered by continuous intravenous infusion at the initial dose regimen of 2mg/kg per day.~After 24 hours of treatment, cyclosporine trough level will be measured and the dose adapted in order to obtain a cyclosporinaemia level between 150 and 250 ng/ml. Cyclosporinaemia will be reassessed every 48 hours for the duration of the continuous intravenous treatment."
3290602|NCT00542152|Active Comparator|INFLIXIMAB|"INFLIXIMAB (REMICADE) Infliximab in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution, and slowly infused at the dose of 5mg/kg in 2 hours.~In patients with clinical response at D7 (Lichtiger Index score < 10 for 2 consecutive days), two additional infliximab infusions will be administered at the dose of 5mg/kg at D14 and D42."
3290603|NCT00542139|Experimental|1|
3290604|NCT00542139|Active Comparator|2|
3290605|NCT00542126|Active Comparator|1|GnRH analog administration following embryo transfer
3290606|NCT00542126|No Intervention|2|
3290607|NCT00542113|Experimental|1|Parents of elementary school children in grades 2-6 participating in Program ENERGY -Intervention 1
3290608|NCT00542113|Experimental|2|Parents of elementary school children in grades 2-6 participating in Program ENERGY -Intervention 2
3290609|NCT00542113|Sham Comparator|3|Parents of elementary school children in grades 2-6 participating in Program ENERGY matched to the intervention groups
3290610|NCT00542100|Experimental|1|
3290611|NCT00542100|Experimental|2|
3290612|NCT00542074|Experimental|1|
3290613|NCT00542074|Active Comparator|2|
3290614|NCT00542061|Experimental|A|Device: monitoring services
3290615|NCT00542061|No Intervention|B|Control group: no monitoring procedures
3290616|NCT00542048|Experimental|1|
3290617|NCT00542035|Experimental|ARRY-371797|
3290618|NCT00542035|Experimental|Placebo, ARRY-371797|
3290619|NCT00542035|Placebo Comparator|Placebo|
3290620|NCT00542009|Experimental|CE-326,597 100 mg QD|
3290621|NCT00542009|Experimental|CE-326,597 50 mg QD|
3290622|NCT00542009|Experimental|CE-326,597 25 mg QD|
3290623|NCT00542009|Placebo Comparator|Placebo|
3290624|NCT00542009|Experimental|CE-326,597 5mg QD|
3290625|NCT00541983|Active Comparator|1|
3290626|NCT00541983|Placebo Comparator|2|
3290627|NCT00541970|Experimental|Cervarix 1/Placebo Group|Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
3290628|NCT00541970|Experimental|Cervarix 1/Placebo/Cervarix 1 Group|Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
3290630|NCT00541970|Experimental|Cervarix 2 Group|Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.
3290631|NCT00541957|Other|2|Medication prescribed by PCP
3290632|NCT00541957|Experimental|1|Medication prescribed by PCP + behavior therapy
3290633|NCT00541931|Other|Nonsmoker|Nonsmokers Intervention: Dietary Supplement: LifePak Nano
3290634|NCT00541931|Other|Smoker|Smoker arm Intervention: Dietary Supplement: LifePak Nano
3290635|NCT00541918|Active Comparator|1|propofol
3290636|NCT00541918|Experimental|2|sevoflurane
3290637|NCT00541905|Experimental|NT 201 (50-300 Units)|"NT 201 (Xeomin®, also know as IncobotulinumtoxinA or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
3290638|NCT00541892|Experimental|1|Medium with no human serum albumine added
3290639|NCT00541892|Active Comparator|2|Conventional medium
3290640|NCT00541879|Experimental|I|Elementary school children -grades 2-6 participating in Program ENERGY
3290641|NCT00541879|Sham Comparator|II|Elementary school children in grades 2-6 matched to the intervention classes not receiving any intervention
3290642|NCT00541866|Experimental|Voreloxin injection and cytarabine|"Dose-escalation Phase~Schedule A:~Schedule B:~Expansion Phase~Schedule A:~Schedule B:"
3290643|NCT00541853|Active Comparator|A|ADPKD patients with blood pressure above 130/85 are enrolled. The patients whose blood pressure is controlled under 130/85 by Candesartan alone are classified into group A.
3290644|NCT00541853|Experimental|B|The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group B, blood pressure is controlled by Candesartan plus Cilnidipine. If blood pressure is not lowered by Candesartan plus Cilnidipine alone, another antihypertensive agents except CCB and ACEI are allowable.
3290645|NCT00541853|Active Comparator|C|The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group C, blood pressure is controlled by Candesartan plus non-CCB agents such as beta- or alpha- adrenergic blockers or another ARB. Any CCB and ACEI are not allowable.
3290646|NCT00541814|Active Comparator|1|CNI [Cyclosporine] minimisation Group. Conversion from azathioprine to Myfortic followed by a three month period of cyclosporine weaning to target blood level of 50-100 ng/ml.
3290647|NCT00541814|Experimental|2|CNI [Cyclosporine] withdrawal Group. Conversion from azathioprine to Myfortic followed by a three month period of cyclosporine weaning to the point of withdrawal.
3290648|NCT00541788|Experimental|1|Administration of Common Sage
3290649|NCT00541775|Experimental|Sitagliptin|sitagliptin 100 mg
3290650|NCT00541775|Active Comparator|Rosiglitazone|rosiglitazone 8 mg
3290651|NCT00541775|Placebo Comparator|Placebo|placebo
3290652|NCT00541762|Other|A, 3; B, 3; C, 3|A, 3: Fat with and without orlistat or placebo. B, 3: LCF vs MCF vs placebo. C, 3: LCF with and without DEXLOX or placebo.
3290653|NCT00541736|Experimental|Patients|GTN-infusion
3290654|NCT00541736|Active Comparator|Controls|GTN-infusion
3290655|NCT00541723|Experimental|IncobutolinumtoxinA (Xeomin), 4-injection scheme|"IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:~Clostridium Botulinum neurotoxin Type A free of complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl); total volume 0.24 mL per side, i.e. 4 x 0.06 mL (4 x 3 units = 12 units); mode of administration: intramuscular injection."
3290656|NCT00541723|Placebo Comparator|Placebo 4-injection scheme|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; total volume 0.24 mL per side, i.e. 4 x 0.06 mL placebo solution; mode of administration: intramuscular injection.
3290657|NCT00541723|Experimental|IncobotulinumtoxinA (Xeomin), 3-injection scheme|"IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:~Clostridium Botulinum neurotoxin Type A free of complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl); total volume 0.24 mL per side, i.e. 3 x 0.08 mL (3 x 4 units = 12 units); Mode of administration: intramuscular injection."
3290658|NCT00541723|Placebo Comparator|Placebo 3-injection Scheme|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; total volume 0.24 mL per side, i.e. 3 x 0.08 mL placebo solution; mode of administration: intramuscular injection.
3290659|NCT00541710|Placebo Comparator|Lifestyle counseling|Placebo tablets. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
3290660|NCT00541710|Experimental|Genistein|Genistein 54 mg/day in 2 tablets for 12 months. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
3290661|NCT00541671|Placebo Comparator|1|Patients will then be randomized to receive placebo, consisting of 10ml of normal saline solution to be administered intravenously with the narcotic
3290662|NCT00541671|Active Comparator|2|Patients will be randomized to 6.25mg of promethazine, consisting of 0.25ml of promethazine diluted in 9.75ml of normal saline.
3290663|NCT00541658|Active Comparator|5 mg Before Breakfast|5 mg / Immediate-release Risedronate (At Least 30 Minutes Before Breakfast)
3290664|NCT00541658|Experimental|35 mg After Breakfast|35 mg / Delayed-release Risedronate (Immediately Following Breakfast)
3290665|NCT00541658|Experimental|35 mg Before Breakfast|35 mg / Delayed-release Risedronate (At Least 30 Minutes Before Breakfast)
3290666|NCT00541619||A|hypertensives with proteinuria
3290667|NCT00541606|Experimental|Intervention|Received collaborative care including a clinical pharmacist practitioner.
3290668|NCT00541606|Active Comparator|Control|Patients received usual care directed by their physician.
3290674|NCT00541515|Experimental|closed loop system|Device: continuous glucose sensors and insulin pump
3290675|NCT00541489|Placebo Comparator|1|
3290676|NCT00541489|Active Comparator|2|Naproxen 500 mg
3290677|NCT00541489|Experimental|3|Naproxcinod 750 mg
3290678|NCT00541450|Experimental|Sita/Met FDC|"In Phase A (Treatment Day 1 to Week 12), participants were administered 100 mg once daily (q.d.) of sitagliptin and matching placebo to 15 mg pioglitazone q.d. for 6 weeks followed by matching placebo to 30 mg pioglitazone for the next 6 weeks.~In Phase B (Treatment Week 12-Week 40), participants were switched to the Sita/Met Fixed-Dose Combination (FDC) at a dose of 50/500 mg twice a day (b.i.d.), which was increased to 50/1000 mg b.i.d. over a period of 4 weeks; as well as matching placebo to 45 mg pioglitazone."
3290679|NCT00541450|Active Comparator|Pioglitazone|"In Phase A (Treatment Day 1 up to Week 12), randomized participants in the pioglitazone group were administered 15 mg q.d. of pioglitazone and matching placebo to sitagliptin. At Week 6, participants were up-titrated to 30 mg pioglitazone q.d.~In Phase B (Treatment Week 12 to Week 40), participants were administered 45 mg pioglitazone q.d.; as well as matching placebo to Sita/Met FDC (50/500 increased to 50/1000 b.i.d. after 4 weeks)."
3290680|NCT00541424||PET/CT Scanning|Patients that have newly diagnosed mantle cell lymphoma will first undergo CT colonography (CT or CTC) and PET followed by conventional colonoscopy.
3290681|NCT00541398|Experimental|A|
3290682|NCT00541398|No Intervention|B|
3290683|NCT00541385|Experimental|1|60mg pyronaridine and 20mg artesunate fixed dose combination granule formulation for 3 consecutive days
3290684|NCT00541385|Active Comparator|2|120mg lumefantrine and 20mg Artemether fixed dose combination crushed tablets, twice a day for 3 days
3290685|NCT00541372|Experimental|1|Needle 5 mm
3290686|NCT00541372|Active Comparator|2|Needle length 8 mm
3290687|NCT00541359|Experimental|Arm I|"PART I (completed as of 09/06/06; all patients enrolled in study after 09/06/06 are enrolled in part II): Patients receive escalating doses of topotecan hydrochloride IV over 30 minutes on days 1 and 8 followed 6 hours later by bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.~PART II: Patients receive bortezomib IV on days 1, 4, 8, and 11 followed 6 hours later by escalating doses of topotecan hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.~In both parts of the study, patients who achieve a response may receive additional courses of treatment."
3290688|NCT00541346|Experimental|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
3290689|NCT00541333|Active Comparator|Copaxone|
3290690|NCT00541333|Sham Comparator|Sham|
3290691|NCT00541307|Experimental|GORE VIABHAN Endoprothesis|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
3290692|NCT00541294||B|M.tb unexposed HIV-infected and uninfected children <15 years of age
3290693|NCT00541294||A|M.tb exposed HIV-infected and uninfected children <15 years of age
3290694|NCT00541281|Active Comparator|A|weekly docetaxel and prednisone
3290695|NCT00541281|Active Comparator|B|weekly docetaxel (35mg/m&) plus prednisone 10mg a day associated with estramustine form day 1to 5 and 8 to 12
3290696|NCT00541268|Experimental|A|Heart Failure nonischemic etiology
3290697|NCT00541268|Active Comparator|B|
3290698|NCT00541242|Active Comparator|1|bimatoprost 0.03% eye drops
3290699|NCT00541242|Active Comparator|2|latanoprost 0.005% eye drops
3290700|NCT00541229|Experimental|1|sitagliptin 100 mg
3290701|NCT00541229|Experimental|2|sitagliptin 200 mg
3290702|NCT00541229|Placebo Comparator|3|Placebo
3290703|NCT00541190|Experimental|cystic fibrosis|Cystic fibrosis patients
3290704|NCT00541190|Experimental|healthy controls|Healthy control subjects
3290705|NCT00541177|Experimental|1|use 0.25% atropine once a week
3290706|NCT00541177|Active Comparator|2|use 0.5% tropicamide everyday
3290707|NCT00541164|Experimental|1|300 mg CoQ10 chewable wafer twice a day
3290708|NCT00541164|Placebo Comparator|2|Chewable placebo wafer twice a day for 24 weeks with crossover to 300mg CoQ10 twice a day for weeks 24-48.
3290709|NCT00541125|Other|FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire|FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire
3290710|NCT00541099|Experimental|Avastin & Docetaxel|Avastin 10.0 mg/kg on days 1 and 15; Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel; Docetaxel 35 mg/m2 on day 1, 8, 15
3290711|NCT00541086|Experimental|A - anastrozole|Up-front adjuvant anastrozole for 5 years
3290712|NCT00541086|Experimental|B - exemestane|Up-front adjuvant exemestane for 5 years
3290713|NCT00541086|Experimental|C - letrozole|Up-front adjuvant letrozole for 5 years
3290714|NCT00541086|Active Comparator|D - tamoxifen followed by anastrozole|Switch adjuvant treatment with tamoxifen for 2 years followed by anastrozole for 3 years
3290715|NCT00541086|Active Comparator|E - tamoxifen followed by exemestane|Switch adjuvant treatment with tamoxifen for 2 years followed by exemestane for 3 years
3290716|NCT00541086|Active Comparator|F - tamoxifen followed by letrozole|Switch adjuvant treatment with tamoxifen for 2 years followed by letrozolefor 3 years
3290717|NCT00541060|Active Comparator|A|250 young patients presenting several carious lesions
3290718|NCT00541060|Placebo Comparator|B|160 young adults totally caries free
3290719|NCT00541047|Experimental|RADICALS-RT: Early RT|
3290720|NCT00541047|Experimental|RADICALS-RT: Salvage RT|
3290721|NCT00541047|Experimental|RADICALS-HD: Radiotherapy Alone|
3290722|NCT00541047|Experimental|RADICALS-HD: Radiotherapy + 6 months|
3290723|NCT00541047|Experimental|RADICALS-HD: Radiotherapy + 24 months|
3290724|NCT00541034|Experimental|cyclophosphamide, pentostatin & rituximab|Patients receive cyclophosphamide IV followed by pentostatin IV on day 1 in course 1. Beginning in course 2 and in all subsequent courses, patients receive cyclophosphamide IV on day 1, pentostatin IV on day 1, and rituximab IV on day 1 or on days 1 and 2. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3290859|NCT00539994|Placebo Comparator|Treatment C|200mg BID placebo 5 days
3290725|NCT00540995|Experimental|Arm I|"PREPARATIVE CHEMOTHERAPY: Patients receive busulfan IV once daily over 2 hours on days -15 and -13 and then every 6 hours on days -12 to -9. Patients also receive etoposide IV on day -3. Patients undergo image-guided intensity-modulated radiation therapy using helical tomotherapy on days -8 to -5.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0.~GRAFT-VS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive GVHD prophylaxis that excludes methotrexate."
3290726|NCT00540982|Experimental|Normal Liver Function|
3290727|NCT00540982|Experimental|Mild Liver Dysfunction|
3290728|NCT00540982|Experimental|Moderate Liver Dysfunction|
3290729|NCT00540982|Experimental|Severe Liver Dysfunction|
3290730|NCT00540969|Experimental|Arm I (percutaneous cryoablation)|Cryoprobes are inserted percutaneously under CT scan or ultrasound guidance, to the malignant soft tissue-bone interface. Patients undergo ablations using a freeze-thaw-freeze cycle lasting approximately 10-5-10 minutes, respectively.
3290731|NCT00540969|Active Comparator|Arm II (external-beam radiotherapy)|Patients undergo external-beam radiotherapy comprising either a single 8 Gy dose or 20 Gy/5 fractions administered over 1 week.
3290732|NCT00540943|Experimental|Single Arm|irinotecan and cetuximab in combination with pazopanib.
3290733|NCT00540917|Experimental|cooling spray|cooling spray during laser treatment
3290734|NCT00540904|Active Comparator|sodium bicarbonate|Solution 154 mEq/L of sodium bicarbonate
3290735|NCT00540904|Active Comparator|Sodium chloride|Solution of 154 mEq/L of NaCl
3290736|NCT00540865|Experimental|A|Participants will receive problem-solving therapy and case management
3290737|NCT00540865|Active Comparator|B|Participants will receive case management
3290738|NCT00540852|Other|Diagnostic Tool|Diffuse Optical Spectroscopy Imaging
3290739|NCT00540839|Experimental|Montelukast|Participants receive montelukast 4 mg oral granules (OG) or 4 mg chewable tablets (CT) once daily (QD) for 24 weeks and placebo to fluticasone 50 mcg inhalation aerosol twice daily (BID) for 24 weeks. Participants aged >6 months to <2 years receive montelukast 4 mg packet of OG QD for 24 weeks. Participants aged >2 years to <64 months receive montelukast 4 mg CT QD for 24 weeks.
3290740|NCT00540839|Active Comparator|Fluticasone|Participants receive fluticasone 50 mcg inhalation aerosol twice daily (BID) for 24 weeks and placebo to montelukast 4 mg QD for 24 weeks. Participants aged >6 months to <2 years receive placebo packet of OG QD for 24 weeks. Participants aged >2 years to <64 months receive placebo CT QD for 24 weeks.
3290741|NCT00540826||A|A: ADHD-patients receiving non-stimulants (e.g. atomoxetine)
3290742|NCT00540826||B|B: ADHD-patients receiving stimulants
3290743|NCT00540813|Experimental|Drug Eluting Balloon|
3290744|NCT00540800|Active Comparator|A|Three-weekly chemotherapy
3290745|NCT00540800|Experimental|B|Weekly chemotherapy
3290746|NCT00540787|Active Comparator|Drug Treatment|
3290747|NCT00540787|Active Comparator|ThermoCool Radiofrequency Catheter|Radiofrequency catheter used.
3290748|NCT00540774||Oral tissue|detection of oral pathology
3290749|NCT00540761|Experimental|OFDI imaging|OFDI catheter advanced to the distal coronary artery
3290750|NCT00540761|Experimental|Intravenous Ultrasound|Randomization to determine whether Intravenous Ultrasound will be conducted before or after OFDI imaging.
3290751|NCT00540748|Experimental|A1|
3290752|NCT00540748|No Intervention|A2|
3290753|NCT00540735|Experimental|1|PDT
3290754|NCT00540735|No Intervention|2|
3290755|NCT00540722|Experimental|Treatment (R-(-)-gossypol acetic acid)|"Patients receive oral R-(-)-gossypol once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Laboratory Biomarker Analysis: Patients undergo tumor tissue and blood sample collection at baseline and periodically during study for biomarker correlative studies. Archived tumor tissue samples, if available, are analyzed for Bcl-2 family protein expression (e.g., Bcl-2, Bcl-xL, MCl-1, Bax, Bak, and BH3 domain for BH3 members only) and MGMT gene methylation status. Blood samples are analyzed for apoptotic protein levels (Bcl-2) by enzyme-linked immunosorbent assay."
3290756|NCT00540696|Experimental|darbepoetin alfa|
3290757|NCT00540670|Experimental|1|
3290758|NCT00540670|Experimental|2|
3290759|NCT00540670|Experimental|3|
3290760|NCT00540670|Placebo Comparator|4|
3290761|NCT00540657|Experimental|1|
3290762|NCT00540657|Placebo Comparator|2|
3290763|NCT00540644|Experimental|Revlimid, Cyclophosphamide, Prednisone|"Lenalidomide orally on Days 1-21 followed by 7 days rest, repeated every 28 days.~Cyclophosphamide twice daily, orally on Days 1-21 followed by 7 days rest, repeated every 28 days.~Prednisone every other day orally."
3290764|NCT00540631|No Intervention|P|subcutaneous treatment with placebo Placebo- physiological saline containing histamine-dihydrochloride 0.1mL, 0.2mL, 0.4mL, 0.6mL of strength A(1000TU/mL) followed by 0.1mL, 0.4mL, 0.6mL by strength B (10000TU/mL) in weekly intervals
3290765|NCT00540631|Experimental|A|Active treatment with house dust mite extract
3290766|NCT00540618|Active Comparator|1|MEDI-507
3290767|NCT00540618|Placebo Comparator|2|
3290768|NCT00540618|Active Comparator|3|MEDI-507
3290769|NCT00540618|Active Comparator|4|MEDI-507
3290770|NCT00540605|Experimental|1|4g tenofovir 1% gel applied vaginally 2 hours prior to expected time of cesarean delivery
3290771|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 1 Group|Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
3290772|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 2 Group|Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
3290773|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 3 Group|Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
3290774|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 4 Group|Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
3290775|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 5 Group|Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
3290860|NCT00539994|Experimental|Treatment A|200mg BID retapamulin 3 days and placebo BID 2 days for a total of 5 days
3290776|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 6 Group|Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
3290777|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 7 Group|Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
3290778|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 8 Group|Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
3290779|NCT00540592|Active Comparator|Fluarix elderly Group|Subjects aged ≥65 years received one dose of Fluarix vaccine.
3290780|NCT00540592|Active Comparator|Fluarix young Group|Subjects aged 18-40 years received one dose of Fluarix vaccine.
3290781|NCT00540579|Experimental|Intervention|All patients received gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of a 28 day cycle. Pomalidomide was administered orally on days 1-21 at doses escalated from 2 mg to 10 mg daily.
3290782|NCT00540566||Optical Biopsy|Optical Biopsy imaging
3290783|NCT00540527|Experimental|1|local intraarterial recombinant tissue plasminogen activator
3290784|NCT00540527|Active Comparator|2|intravenous (IV) rt-PA
3290785|NCT00540514|Experimental|Albumin-bound paclitaxel + Carboplatin|Participants received albumin-bound paclitaxel (ABRAXANE®) 100 mg/m^2 administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. Carboplatin was given at an Area Under the Curve (AUC) = 6 mg*min/mL on Day 1 only of each 21-day cycle, beginning immediately after the completion of albumin-bound paclitaxel administration. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
3290786|NCT00540514|Active Comparator|Paclitaxel + Carboplatin|Participants received 200 mg/m^2 paclitaxel (Taxol®) administered by intravenous infusion followed by carboplatin at AUC = 6 mg*min/mL on Day 1 of a 21 day cycle. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
3290787|NCT00540501|Experimental|Oseltamivir 150mg and zanamivir 50mg/hour|Oseltamivir1 150mg PO q12h for 5 doses + Zanamivir IV continuous infusion at 50mg/hour for 72 hours
3290788|NCT00540501|Experimental|Zanamivir IV 50mg/hour|Zanamivir IV continuous infusion 50mg/hour for 16 hours (total dose of 800mg)
3290789|NCT00540501|Experimental|Oseltamivir 150mg and zanamivir 600mg|Oseltamivir 150mg PO q12h for 5 doses + Zanamivir 600mg IV q12h
3290790|NCT00540501|Active Comparator|Oseltamivir 150mg|Oseltamivir 150mg PO q12h for 3 days
3290791|NCT00540462|No Intervention|1|Medical Group
3290792|NCT00540462|Active Comparator|2|Surgical Group with gastric bypass
3290793|NCT00540462|Active Comparator|3|Sugical Group with Sleeve gastrectomy
3290794|NCT00540449|Active Comparator|Efavirenz|Efavirenz 600mg once daily for 96 weeks
3290795|NCT00540449|Experimental|TMC278|TMC278 25 mg tablet once daily for 96 weeks
3290796|NCT00540436|Experimental|GSK1325760A|Single arm safety and efficacy
3290797|NCT00540423|Experimental|SB-497115-GR group|Subject will initiate treatment with SB-497115-GR 12.5mg once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR may be adjusted at 12.5mg, 25mg or 50mg.
3290798|NCT00540423|Placebo Comparator|placebo group|Subject will initiate treatment with SB-497115-GR 12.5mg matching placebo once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR 12.5mg matching placebo may be increased to 2 tablet of SB-497115-GR 12.5mg matching placebo.
3290799|NCT00540410|Experimental|1|
3290800|NCT00540410|Active Comparator|2|
3290801|NCT00540384|Experimental|NESP - Schedule 1 Part A|Part A - 4.5, 6.75, 9.0 or 13.5 mcg/kg Q3W for 12 weeks
3290802|NCT00540384|Experimental|NESP - Schedule 2 Part A|NESP 9.0, 12.0, 15.0 or 18.0 mcg/kg Q4W for 12 weeks
3290803|NCT00540384|Placebo Comparator|Placebo - Schedule 1 Part A|Placebo Q3W for 12 weeks
3290804|NCT00540384|Experimental|NESP - Schedule 1 Part B|Open-label NESP at the dose of study drug administered at the end of Part A. Increase dose at week 19 if hgb < 13.0g/dL and/or RBC transfusion in previous 2 weeks.
3290805|NCT00540384|Placebo Comparator|Placebo - Schedule 2 Part A|Placebo Q4W for 12 weeks
3290806|NCT00540384|Experimental|NESP - Schedule 2 Part B|Open-label NESP at the dose of study drug administered at the end of Part A
3290807|NCT00540371||Port wine stain Birthmark|Port wine stain Birthmark
3290808|NCT00540358|Active Comparator|Arm G/C|Standard chemotherapy with gemcitabine/carboplatin on Days 1 and 8 of 21-day cycle(s)
3290809|NCT00540358|Experimental|Arm G/C/I|Standard chemotherapy with gemcitabine/carboplatin on Days 1 and 8, plus iniparib on Days 1, 4, 8, and 11 of 21-day cycle(s)
3290810|NCT00540345|Active Comparator|A, RVR LD RBV|Patients who have a RVR will be randomized into two groups with a ratio of 1:1 (Arm A & B)B, RVR SD RBV A, RVR LD RBV B, RVR SD RBV
3290811|NCT00540345|Active Comparator|B, RVR SD RBV|Patients who have a RVR will be randomized into two groups with a ratio of 1:1 (Arm A & B)B, RVR SD RBV
3290812|NCT00540345|Active Comparator|C, non-RVR 24w|For patients who do not have a RVR will be randomized into two groups with a ratio of 1:1 (Arm C & D) (C, non-RVR 24w) (D, non-RVR 48w)
3290813|NCT00540345|Active Comparator|D, non-RVR 48w|For patients who do not have a RVR will be randomized into two groups with a ratio of 1:1 (Arm C & D)(C, non-RVR 24w) (D, non-RVR 48w)
3290814|NCT00540332|Placebo Comparator|Placebo|"Approximately 17 subjects to receive palifermin. Subjects will be enrolled as follows:~PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects~Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects."
3290815|NCT00540332|Experimental|Palifermin|"Approximately 23 subjects to receive palifermin. Subjects will be enrolled as follows:~PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects~Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects."
3290816|NCT00540306||Diagnostic Tool|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
3290817|NCT00540293|Experimental|Treatment group|this patient group consists of dyslipidemia patients with various CVD risk factors
3290818|NCT00540280|Active Comparator|Surgery alone|Surgery alone
3290819|NCT00540267||Schizophrenia|Chronic schizophrenia with aged 18-80 years
3290902|NCT00539565|Active Comparator|A|oral corticosteroids
3290820|NCT00540254|Active Comparator|Arm 1|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
3290821|NCT00540254|Active Comparator|Arm 2|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
3290822|NCT00540241||Second-line pemetrexed treatment in NSCLC|Patients with NSCLC who will start second-line treatment with pemetrexed.
3290823|NCT00540228|Experimental|GSK1247446A 1 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3290824|NCT00540228|Experimental|GSK1247446A 2 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3290825|NCT00540228|Experimental|GSK1247446A 3 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3290826|NCT00540228|Experimental|GSK1247446A 4 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3290827|NCT00540228|Active Comparator|Fluarix Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3290828|NCT00540215|Active Comparator|1|450 nmol GLP-2 SC
3290829|NCT00540215|Placebo Comparator|2|1 ml isotonic saline SC
3290830|NCT00540202|Experimental|1.Oral quinine|Patients will be given oral quinine at the dose of 10mg/kg 8 hourly for 7 days
3290831|NCT00540202|Active Comparator|2. Coartem|Tablets
3290832|NCT00540189|Other|Initial appendectomy|children with complicated appendicitis will undergo initial appendectomy
3290833|NCT00540189|Other|Interval appendectomy|children with complicated appendicitis will undergo initial antibiotic treatment followed by an interval appendectomy
3290834|NCT00540176|Experimental|Cohort A|Recurrent disease with previous surgery, radiation therapy and/or chemotherapy
3290835|NCT00540176|Experimental|Cohort B|Newly diagnosed disease with no previous therapy
3290836|NCT00540150|Active Comparator|1|Standard specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany
3290837|NCT00540150|Active Comparator|2|Shortened specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany
3290838|NCT00540137|Active Comparator|NRTIs plus NNRTI arm|nevirapine 400 mg once daily (after 12 weeks induction)with a nucleoside backbone
3290839|NCT00540137|Active Comparator|NRTIs plus PI arm|atazanavir 300 mg once daily, ritonavir 100 mg once daily with a nucleoside backbone
3290840|NCT00540124|Experimental|Tadalafil|
3290841|NCT00540124|Placebo Comparator|Placebo|
3290842|NCT00540124|Active Comparator|Tamsulosin|
3290843|NCT00540111|Other|1|"Study of intervention, prospective,uncontrolled Group Number: 1~Group Type:Other - the subjects of group were compared the initial moment (M0 - moment without soluble fiber supplementation)with the others two moments: M1 (one month after soluble fiber supplementation) and M2 (four months after soluble fiber supplementation).~Group Description - HIV-positive individuals with hypertriglyceridemia (serum levels ≥ 200 to ≤ 500 mg/dL),who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study.~Intervention:Received 20g/day of soluble fiber® (partially hydrolyzed guar gum) for 4 months at pre-established times."
3290844|NCT00540098|Experimental|1|Paroxetine + aerobic exercise
3290845|NCT00540098|Active Comparator|2|Paroxetine + relaxation
3290846|NCT00540098|Active Comparator|3|Placebo + aerobic exercise
3290847|NCT00540098|Placebo Comparator|4|Placebo + relaxation
3290848|NCT00540085|Active Comparator|A|Rocuronium dosed after ideal body weight
3290849|NCT00540085|Active Comparator|B|Rocuronium dosed after corrected body weight 20%
3290850|NCT00540085|Active Comparator|C|Rocuronium dosed after corrected body weight 40%
3290851|NCT00540046|Active Comparator|A/Immediate|The patients in the immediate arm will have the Copper T 380A IUD inserted within 15 minutes after delivery of the placenta immediately following procedure
3290852|NCT00540046|Active Comparator|B/Delayed|The delayed group will have the Copper T 380A IUD inserted at the post-operative visit within 2-4 weeks following the procedure.
3290853|NCT00540033|Experimental|2|Study arm was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks; the control arm was fed with breast milk or mixed feeding without probiotics.
3290854|NCT00540020|Experimental|Cognitive-Didactic|Developed by Sohlberg & Mateer to target four cognitive domains often impaired by TBI: attention, memory, executive functions, and pragmatic communication. Subjects practiced progressively more difficult paper-and-pencil or computerized cognitive tasks in 1:1 cognitive therapy sessions (1.5-2.5 hours daily).
3290855|NCT00540020|Experimental|Functional-Experiential|The works of Giles and Clark-Wilson and Hartley guided the basic concepts and treatment of the functional-experiential arm (Functional). The objective of the functional protocol was to use real life performance situations and common tasks to remediate or compensate for functional deficits after brain injury. Functional protocol treatment interventions (1.5-2.5 hours daily) typically occurred in group settings and natural environments (hospital recreation areas, group rooms, simulated home environments in the dining room, community outings, etc.).
3290856|NCT00540007|Experimental|Cohort 1 - Lenalidomide daily on days 1-21|"The first group of participants will be assigned to Cohort 1 and if no unacceptable toxicities occur in Cohort 1 then the second group of participants will be assigned to Cohort 2~Lenalidomide 25 mg per day PO daily on days 1-21 of a 28 day cycle."
3290857|NCT00540007|Experimental|Cohort 2 - Lenalidomide daily on days 1-28|"The first group of participants will be assigned to Cohort 1 and if no unacceptable toxicities occur in Cohort 1 then the second group of participants will be assigned to Cohort 2~Lenalidomide 25 mg per day PO daily on days 1-28 of a 28 day cycle."
3290858|NCT00539994|Experimental|Treatment B|200mg BID retapamulin 5 days
3290861|NCT00539981|Experimental|FluBlok|Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2007/08 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/3/2006(H1N1), A/Wisconsin/67/2005(H3N2), and B/Malaysia/2506/2004
3290862|NCT00539981|Placebo Comparator|Placebo|0.9% Sodium Chloride
3290863|NCT00539968|Experimental|Docetaxel plus lonafarnib (single arm)|Docetaxel plus lonafarnib
3290864|NCT00539955|Other|1|Standard 40 hour state-mandated batterer intervention
3290865|NCT00539955|Other|2|Brief alcohol intervention combined with standard batterer intervention
3290866|NCT00539942|Active Comparator|Intermittent compression devices (ICD)|All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
3290867|NCT00539942|Experimental|Arixtra (fondaparinux sodium)|Patients randomized to treatment arm will initiate Arixtra (fondaparinux sodium) treatment on post-operative day 1 and continue treatment until post-operative day 22 (21 consecutive days). Subjects randomized to this arm are to receive the standard prophylactic dose for major abdominal surgery of 2.5 mg/day for a total of 21 consecutive days (including hospitalization time and after hospital discharge).
3290868|NCT00539929|Experimental|E6201 0.005% BID|Participants applied E6201 0.005% cream to a pre-identified marker lesion twice a day (BID) for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
3290869|NCT00539929|Experimental|E6201 0.01% BID|Participants applied E6201 0.01% cream to a pre-identified marker lesion BID for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
3290870|NCT00539929|Experimental|E6201 0.03% BID|Participants applied E6201 0.03% cream to a pre-identified marker lesion BID for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
3290871|NCT00539929|Experimental|E6201 0.03% QD|Participants applied E6201 0.03% cream to a pre-identified marker lesion once a day (QD) for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
3290872|NCT00539916|Experimental|Jus d'orange|
3290873|NCT00539916|Placebo Comparator|Boisson contrôle|
3290874|NCT00539864|Experimental|FluBlok|"Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004~135μg total"
3290875|NCT00539864|Active Comparator|TIV (Fluzone)|"Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004~45μg total~(Fluzone, sanofi pasteur)"
3290876|NCT00539838|Experimental|1|
3290877|NCT00539838|Placebo Comparator|2|
3290878|NCT00539812|Other|1|Standard Care only (standard batterer intervention program)
3290879|NCT00539812|Other|2|Brief alcohol intervention combined with standard care
3290880|NCT00539799|Active Comparator|1|Long-term low-dose prednisolone (5 - 7.5 mg/day)
3290881|NCT00539799|Placebo Comparator|2|
3290882|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xa (Cohort 1-5)|Eligible subjects will receive GSK1827771 with the starting dose of 0.3 milligram (mg)
3290883|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xa (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
3290884|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xb (Cohort 1-5)|Eligible subjects will receive GSK1827771 via injection
3290885|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xb (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
3290886|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xc (Cohort 1-5)|Eligible subjects will receive GSK1827771 via injection
3290887|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xc (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
3290888|NCT00539721|Experimental|Rolapitant Dose 1|
3290889|NCT00539721|Experimental|Rolapitant Dose 2|
3290890|NCT00539721|Experimental|Rolapitant Dose 3|
3290891|NCT00539721|Experimental|Rolapitant Dose 4|
3290892|NCT00539721|Active Comparator|Ondansetron|
3290893|NCT00539721|Placebo Comparator|Placebo|
3290894|NCT00539708|Experimental|NIV|Non-invasive ventilation
3290895|NCT00539708|Active Comparator|Control|Oxygen therapy
3290896|NCT00539695|Experimental|IL2 Administration|"SCHEDULE OF IL-2 ADMINISTRATION: Patients will receive a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT.~Time will be measured as 'week beginning with first IL-2 injection.'~T cell Induction via IL-2 to reduce GVHD"
3290897|NCT00539643|Active Comparator|Bead Arm|Hepatic arterial embolization with Bead Block microspheres, beginning with 100 - 300 micron beads, and using larger particles if necessary until stasis is evident.
3290898|NCT00539643|Active Comparator|Bead + Dox Arm|Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
3290899|NCT00539617|Experimental|Tarceva and FOLFOX|
3290900|NCT00539591|Experimental|Temozolomide/peginterferon alfa-2b|"Stratum B: Resected Stage IIIC, unresectable Stage III, Stage IV, and recurrent patients~Stratum B is divided into 2 groups based on the presence (Stratum B1) or absence (Stratum B2) of measurable disease. Subjects will receive 8 weekly doses of peginterferon alfa-2b 0.5 mcg/kg/dose subcutaneously (SQ) in combination with temozolomide 75mg/m2/dose by mouth (PO) daily for 6 weeks followed by 2 week break. The duration of each treatment course will be 8 weeks. Strata B2 (no measurable disease) will proceed with 7 courses as outlined."
3290901|NCT00539591|Experimental|Peginterferon alfa-2b/non-pegylated interferon alfa-2b|Stratum A: Resected Stages IIC, IIIA, and IIIB patients will receive recombinant interferon alfa-2b 20 million units/m2/day intravenously (IV) 5 consecutive days per week for 4 weeks followed by peginterferon alfa-2b 1mcg/kg subcutaneously (SQ) once a week for 48 weeks.
3290903|NCT00539565|Placebo Comparator|B|as for active regimen
3290904|NCT00539539|Active Comparator|Feedback On|Automated real-time feedback on CPR Process activated
3290905|NCT00539539|No Intervention|Feedback Off|For the first three to six months, participating EMS agencies will have defibrillators with automated, real-time feedback inactivated. During this period, the baseline rate of ROSC (and secondary outcomes) will be collected. At the end of this baseline period, EMS agencies will be randomized to one of two interventions, with randomization stratified within site by agency, station, or device. All clusters will cross-over to the opposite feedback strategy at least once during the intervention phase.
3290906|NCT00539526|Experimental|1|bimatoprost 0.03%
3290907|NCT00539526|Active Comparator|2|travoprost 0.004%
3290908|NCT00539526|Active Comparator|3|latanoprost 0.005%
3290909|NCT00539513|Experimental|N-Acetylcysteine|Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose titrated to 3000 mg within the first week, in addition to the medication regimen they are on at enrollment
3290910|NCT00539513|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
3290911|NCT00539500|Experimental|Transplantation CD133+ cells|Transplantation of CD133+ cells using the ClinicMACS in combination with Carboplatin + Etoposide + Melphalan
3290912|NCT00539474|Active Comparator|1|Wireguided localisation
3290913|NCT00539474|Experimental|2|Radioguided occult lesion localisation
3290914|NCT00539448|Experimental|1|combination of insulin Glargine & insulin Glulisine as basal bolus regimen
3290915|NCT00539435|Active Comparator|1|Diabetic patients will complete cardiac quality of life questionnaires at baseline and monthly thereafter to monitor and assess progress with complications resulting from their heart disease. Comparisons will be performed on carotid ultrasounds,echocardiograms and lab values performed at baseline and every six months and medication information collected at weekly Pulsatile Intravenous Insulin treatment sessions
3290916|NCT00539422|Case|I|group I of 15 women with benign breast lesion
3290917|NCT00539422|Case|II|group II of 16 women with breast cancer
3290918|NCT00539422|Control|III|13 women were taken as a control group
3290919|NCT00539409|No Intervention|1|Diabetic patients will complete quality of life questionnaires at baseline and quarterly thereafter to monitor and assess progress with complications resulting from their diabetes. Comparisons will be performed on lab values performed at baseline and every six months and medication information collected at weekly Pulsatile Intravenous Insulin treatment sessions.
3290920|NCT00539409|Active Comparator|Pulsatile Intravenous Insulin Therapy|
3290921|NCT00539383|Experimental|1|
3290922|NCT00539357|Experimental|1|All patients self-administered stimulation for 60 consecutive minutes each day. Participants self-administered the treatment for a period of 6 weeks, 7 days a week between the hours of 15:00 and 19:00. Assessments took place every 2 weeks during the treatment period.
3290923|NCT00539344|Experimental|1|
3290924|NCT00539331|Placebo Comparator|1|Paclitaxel/Carboplatin
3290925|NCT00539331|Experimental|2|Paclitaxel/Carboplatin + AZD2171
3290926|NCT00539318||GI Cancer|
3290927|NCT00539305|Experimental|Study drug; testosterone transdermal gel|Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl
3290928|NCT00539305|Placebo Comparator|2|
3290929|NCT00539292|Experimental|1|Silastic Spring-Loaded Silo
3290930|NCT00539292|Active Comparator|2|Primary Closure of Abdomen
3290931|NCT00539279|Experimental|Prolonged Exposure Therapy (PE)|Prolonged Exposure Therapy (PE)
3290932|NCT00539279|Active Comparator|Relaxation Training (RT)|Relaxation Training (RT)
3290933|NCT00539266|Active Comparator|1|non diabetic patients with Fontaine IIb-IV peripheral artery disease
3290934|NCT00539266|Placebo Comparator|2|non diabetic patients with Fontaine IIb-IV peripheral artery disease
3290935|NCT00539266|Active Comparator|3|diabetic patients with Fontaine IIb-IV peripheral artery disease
3290936|NCT00539266|Placebo Comparator|4|diabetic patients with Fontaine IIb-IV peripheral artery disease
3290937|NCT00539253|Other|Gadobenate Dimeglumine (Multi Hance)|If patient did not participate in this study (by signing consent), they could receive any other contrast used routinely at this facility including the contrast used in this study
3290938|NCT00539240|Placebo Comparator|Rabeprazole morning/evening placebo bedtime|AciPhex 20 mg BID and once daily placebo
3290939|NCT00539240|Placebo Comparator|Rabeprazole breakfast, placebo dinner and bedtime|AcipHex 20 mg once daily and BID placebo
3290940|NCT00539240|Active Comparator|Rabeprazole breakfast, placebo dinner, nortriptyline bedtime|AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily
3290941|NCT00539227||NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC). Questionnaires taking about 20-30 minutes to complete.
3290942|NCT00539188|Experimental|N-Acetylcysteine|Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose (3000 mg daily), in addition to the medication regimen they are on at enrollment
3290943|NCT00539188|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
3290944|NCT00539175|Active Comparator|2|active treatment with infrared light
3290945|NCT00539175|Placebo Comparator|1|sham (placebo) treatment without infrared light
3290946|NCT00539162||CA 125 Analysis|Participants considered to be at low risk for ovarian cancer complete questionnaires.
3290947|NCT00539149|Active Comparator|1|
3290948|NCT00539149|Placebo Comparator|2|
3290949|NCT00539123|Experimental|1|Physician Management (PM): medically focused advice and brief counseling
3290950|NCT00539123|Experimental|2|Physician Management (PM) plus Abstinence Contingent Buprenorphine (ACB) dispensing
3290951|NCT00539123|Experimental|3|PM plus Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
3290952|NCT00539123|Experimental|4|PM plus BDRC plus ACB
3290953|NCT00539110|Experimental|zolpidem|zolpidem or ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
3291286|NCT00536510|Experimental|1|laropiprant/niacin (MK0524A)
3290954|NCT00539110|Active Comparator|ramelteon|ramelteon or zolpidem dosed at 2200 and 0200 per the feeding tube depending on randomization
3290955|NCT00539097|Experimental|A, treated|treated with Juven po supplement x 3 weeks postop
3290956|NCT00539097|No Intervention|B, control|Usual nutrition therapy received postop
3290957|NCT00539084|Experimental|1|Intradermal injection of Lidocaine followed by a painful stimulus (venipuncture)
3290958|NCT00539084|Placebo Comparator|2|Intradermal injection of placebo followed by a painful stimulus (venipuncture)
3290959|NCT00539071|Active Comparator|Conventional dose|All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks (given as two injections - active 50 mg plus placebo injection).As advised by the package insert for Consta, oral risperidone will be given (3-4 mg qd x 3 days followed by 6mg qd up to Week 3 unless symptoms warrant a quicker titration) along with the injections.Any oral risperidone the patients receive will be discontinued after Week 4.At Week 6, psychopathology will be assessed with a PANSS. Dose will remain at 50 mg q 2 weeks for those in the conventional Consta dose group.
3290960|NCT00539071|Active Comparator|High Dose group|Those who are randomized to high dose Consta will receive Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose after consent. As advised by the package insert for Consta, oral risperidone will be given (3-4 mg qd x 3 days followed by 6mg qd up to Week 4 unless symptoms warrant a quicker titration) along with the injections. Any oral risperidone the patients receive will be discontinued after Week 4.Psychopathology will be assessed with a PANSS at Week 6. If no improvement since baseline, dose will be increased to two 50 mg injections q 2 weeks for the remainder of the study.
3290961|NCT00539045||A|The study population will consist of patients who are admitted to The New York Presbyterian Hospital-Weill Medical College of Cornell University (NYP-WMC) with ST elevation myocardial infarctions (STEMI). STEMI will be established based on standard clinical and ECG criteria.
3290962|NCT00539032|Experimental|Group 1: Menactra® Booster Group|Participants who had received 2 doses of quadrivalent (A, C, Y, and W-135) meningococcal polysaccharide vaccine before age 2 years received a booster vaccination with Menactra® vaccine.
3290963|NCT00539032|Experimental|Group 2: Menactra® Primary Vaccine (Control) Group|Participants who had not previously been given any meningococcal vaccine (meningococcal vaccine naive) received a primary vaccination with Menactra® vaccine.
3290964|NCT00539019||A, observed|measure REE via indirect calorimetry at various time points post burn
3290965|NCT00539006|Active Comparator|FFNS, FPNS|active compound
3290966|NCT00539006|Active Comparator|FPNS, FFNS|active compound
3290967|NCT00539006|Placebo Comparator|placebo FFNS, placebo FPNS|placebo arm
3290968|NCT00539006|Placebo Comparator|placebo FPNS, placebo FFNS|placebo arm
3290969|NCT00538993|Experimental|1|Provider receives cue sheet to assist with counseling.
3290970|NCT00538993|No Intervention|2|Provider does not receive cue sheet.
3290971|NCT00538980|Experimental|All patients|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
3290972|NCT00538967|No Intervention|1|
3290973|NCT00538967|Active Comparator|2|doxycycline 50 mg/day
3290974|NCT00538967|Active Comparator|3|doxycycline 100 mg
3290975|NCT00538967|Active Comparator|4|doxycycline 300 mg
3290976|NCT00538954|Active Comparator|1|Follow a standard Enhanced Recovery After Surgery protocol
3290977|NCT00538954|Experimental|2|Follow a standard Enhanced Recovery After Surgery protocol and will receive 1 g of Magnesium Oxide laxative twice daily from the day after surgery until discharge
3290978|NCT00538954|Experimental|3|Follow a standard Enhanced Recovery After Surgery protocol and will receive preconditioning with carbohydrate and fluid loading prior to surgery (800ml of Nutricia Preop the evening before surgery and 400 the morning of surgery 2 hours prior to anaesthesia) and postoperative nutritional supplements (200 ml Nutricia Fortisip twice daily) after surgery for 30 days
3290979|NCT00538954|Experimental|4|Follow a standard Enhanced Recovery After Surgery protocol and will receive preconditioning with carbohydrate and fluid loading prior to surgery (800ml of Nutricia Preop the evening before surgery and 400 the morning of surgery 2 hours prior to anaesthesia) and postoperative nutritional supplements (200 ml Nutricia Fortisip twice daily) after surgery for 30 days and will receive postoperative laxative in the form of 20 ml of Magnesium Oxide twice daily form the day after surgery until discharge
3290980|NCT00538941|Active Comparator|1|daily intake of 40gr chocolate (Nestlé Noir intense) in the morning and 40gr chocolate in the evening.
3290981|NCT00538941|Placebo Comparator|2|Nestlé Placebo Chocolate 40gr in the morning and 40gr chocolate in the evening.
3290982|NCT00538928|Experimental|1|Intervention: Implantation of the iLA - adaptation of the ventilation strategy, explantation of the iLA after corresponding improvement (see treatment plan for details) - weaning from the ventilation and extubation according to specified criteria.
3290983|NCT00538928|Active Comparator|2|no device: Ventilation strategy based on the concept of lung-protective ventilation without extracorporeal support, weaning from the ventilation and extubation according to specified criteria (see treatment plan for details).
3290984|NCT00538915|Experimental|Nabi-IGIV Infused Every 3- or 4-Weeks|
3290985|NCT00538902|Placebo Comparator|Placebo|Placebo administered subcutaneously every other week
3290986|NCT00538902|Experimental|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously every other week
3290987|NCT00538902|Experimental|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week
3290988|NCT00538863|Experimental|Fentanyl sublingual spray titration|Patients received fentanyl sublingual spray to treat up to a maximum of 4 breakthrough pain episodes per day with a minimum separation of 4 hours between treatments. Patients started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 26 days was reached.
3291126|NCT00537745|Experimental|Vivitrol|Vivitrol 380 mg/monthly, plus individual compliance enhancement therapy (Medication Management Therapy).
3290989|NCT00538863|Experimental|Fentanyl sublingual spray maintenance|Patients received fentanyl sublingual spray up to a maximum of 4 times per day with a minimum separation of 4 hours between treatments for 90 days. Patients received a dose of 100 to 1600 µg determined in a previous study (INS-05-001, NCT00538850) or in the open-label dose titration period of the current study. The dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects.
3290990|NCT00538850|Experimental|Fentanyl sublingual spray|Participants received fentanyl sublingual spray 7 times or placebo 3 times in random order to treat up to a maximum of 2 breakthrough pain episodes per day with a minimum separation of 2 hours between treatments. Patients received a dose of 100 to 1600 µg determined in the open-label dose titration period of the current study.
3290991|NCT00538824|Experimental|DexTR (all patients)|All patients were treated with the DexTR (dexamethasone / thalidomide, lenalidomide (Revlimid®)), which consisted of lenalidomide 25mg/day during days 1-21, dexamethasone 40mg/day on days 1-4, 9-12, and 17-20, and thalidomide 50mg/day for the first 7 days, followed by 100mg/day for all subsequent days, for a total of 4 cycles of 28 days each.
3290992|NCT00538811|Experimental|1|Interferon alpha, ribavirin, interferon gamma
3290993|NCT00538811|Active Comparator|2|Interferon alpha, ribavirin, amantadine
3290994|NCT00538785|Experimental|Motavizumab|Motavizumab was administered as an intramuscular injection at 15 mg/kg every 30 days during the RSV season for a maximum of 5 scheduled doses. Additionally, children who underwent cardiac surgery with cardiopulmonary bypass through Study Day 150 were to receive a protocol-specified replacement dose of study drug immediately following the surgery when determined by the physician to be medically stable for an IM injection.
3290995|NCT00538785|Active Comparator|Pailvizumab|Palivizumab was administered as an intramuscular injection at 15 mg/kg every 30 days during the RSV season for a maximum of 5 scheduled doses. Additionally, children who underwent cardiac surgery with cardiopulmonary bypass through Study Day 150 were to receive a protocol-specified replacement dose of study drug immediately following the surgery when determined by the physician to be medically stable for an IM injection.
3290996|NCT00538772||Biomarker|
3290997|NCT00538759|Experimental|EBRT|External beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty.
3290998|NCT00538746|Experimental|1|BIPAP (Bilevel Positive Airway Pressure) targeted on: TV 6-8 ml/kg, total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92% (with spontaneous RR between 20-40%)
3290999|NCT00538746|Experimental|2|PSV (pressure support ventilation) targeted on: TV 6-8 ml/kg,total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92, a minimum of 7 cmH2O of PS is tolerated.
3291000|NCT00538746|Experimental|3|PSV+CPAP (continuous positive airway pressure) targeted on: PSV: TV 6-8 ml/kg,total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92, a minimum of 7 cmH2O of PS is tolerated, CPAP (5-10 cmH2O) at least 2 hours a day. If during the CPAP periods at least 1 of the criteria T tube test failure occurs, the patients will come back immediately to PSV.
3291001|NCT00538733|Experimental|T-BiRD Therapy|"All patients were treated with the same regimen, starting with T-BIRD therapy (Cycles 1-4).~After 4 cycles, Patients with disease progression will be taken off study. Patients who achieve maximum response will receive maintenance. Patients who achieve VGPR or PR will be given T-BiRD for 2 cycles (cycles 5-6). After 6 cycles of T-BiRD, Patients who achieve maximum response will receive maintenance; those with disease progression will be taken off study; all other patients will receive BIRD.~Patients who progress on BiRD will reinitiate T-BiRD. If disease progression continues after 2 cycles, patients will be taken off study.~Patients in CR/sCR or that achieve a plateau of disease for > 2 cycles on BiRD or T-BiRD therapy will receive maintenance."
3291002|NCT00538720|Experimental|Vitamin D|Vitamin D starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
3291003|NCT00538707|Experimental|Young subjects|
3291004|NCT00538707|Experimental|Older subjects|
3291005|NCT00538681|Experimental|A|
3291006|NCT00538681|Placebo Comparator|B|
3291007|NCT00538668|Experimental|1|20 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
3291008|NCT00538668|Experimental|2|25 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
3291009|NCT00538668|Experimental|3|30 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
3291010|NCT00538668|Experimental|4|35 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
3291011|NCT00538668|Experimental|5|40 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
3291012|NCT00538668|Experimental|6|45 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
3291013|NCT00538668|Experimental|7|50 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
3291014|NCT00538668|Experimental|8|55 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
3291015|NCT00538668|Experimental|9|25 mCi/m2 of 177Lu-J591 will be given every 2 weeks.
3291016|NCT00538655|Experimental|modafinil|
3291017|NCT00538642|No Intervention|Stay on current antipsychotic|Subjects stay on same daily oral antipsychotic treatment as at baseline. Dose adjustments allowable as clinically indicated.
3291018|NCT00538642|Active Comparator|ziprasidone treatment|Subjects switch to daily oral ziprasidone from current antipsychotic(s). Dose titrated to clinically effective level.
3291019|NCT00538629||Schizophrenia|Patients with schizophrenia
3291020|NCT00538629||Bipolar disorder|Patients with bipolar disorder
3291021|NCT00538616|Active Comparator|Precedex-Propofol|Patients received an infusion of precedex for six hours and then a washout and then a propofol infusion for six hours.
3291022|NCT00538616|Active Comparator|Propofol- Precedex|Patients received an infusion of propofol for six hours and then a washout and then a precedex infusion for six hours.
3291023|NCT00538590|Active Comparator|MITOMYCIN-C|Following ethics committee approval, 20 patients with uncontrolled glaucoma will be will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with Mitomycin-C.
3291024|NCT00538590|Experimental|ologen (Oculusgen)|20 patients will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with ologen implant. The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
3291025|NCT00538564|Experimental|Tadalafil|Participants assigned to this arm were given oral 10 mg tadalafil tablets to take 3 times a week for 16 weeks.
3291026|NCT00538564|Placebo Comparator|Placebo|Participants assigned to this arm were given a placebo pill 3 times a week for the first 8 weeks, and then Tadalafil 10 mg 3 times a week for weeks 9-16.
3291027|NCT00538538|Active Comparator|A|Does not receive Gas bubble
3291028|NCT00538538|Active Comparator|B|Does receive gas bubble
3291029|NCT00538525|Active Comparator|Arm 1|Doxorubicin, Docetaxel, Cisplatin
3291030|NCT00538512|Active Comparator|TIV|the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur
3291031|NCT00538512|Active Comparator|LAIV|live-attenuated influenza vaccine Flumist, manufactured by MedImmune
3291032|NCT00538512|Placebo Comparator|Placebo|Physiologic saline administered as a nasal spray or intramuscular injection
3291033|NCT00538499|Other|Fentanyl citrate|
3291034|NCT00538499|Experimental|bupivcaine hydrochloride|
3291035|NCT00538499|Other|videothoracoscopy|
3291036|NCT00538486|Experimental|Group T|Telmisartan
3291037|NCT00538486|Experimental|Group T+M|Telmisartan plus Metformin
3291038|NCT00538486|Experimental|Group C|Candesartan
3291039|NCT00538486|Experimental|Group C+M|Candesartan pus Metformin
3291040|NCT00538486|Active Comparator|Group A|Amlodipine
3291041|NCT00538486|Experimental|Group A+M|Amlodipine plus Metformin
3291042|NCT00538473|Experimental|FluAS25 (GSK576389A) Group|Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A).
3291043|NCT00538473|Active Comparator|Fluarix Group|Subjects received 1 dose of Fluarix™.
3291044|NCT00538434|Experimental|Reslizumab 1 mg/kg|reslizumab 1 mg/kg intravenous (IV) on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
3291045|NCT00538434|Experimental|Reslizumab 2 mg/kg|reslizumab 2 mg/kg IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
3291046|NCT00538434|Experimental|Reslizumab 3 mg/kg|reslizumab 3 mg/kg IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
3291047|NCT00538434|Placebo Comparator|Placebo|saline placebo IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
3291048|NCT00538421|Active Comparator|1|
3291049|NCT00538421|Active Comparator|2|
3291050|NCT00538382|Experimental|Case|Cases are defined as parasitemic pregnant women during the second trimester (22-26 weeks gestation) and the third trimester (32-36 weeks gestation).
3291051|NCT00538382|Active Comparator|Non-pregnant Control|Non-pregnant controls are defined as parasitemic non-pregnant women recruited from the same community as the cases.
3291052|NCT00538382|Active Comparator|Internal Control|Internal controls are defined as the same women(cases)at three months postpartum.
3291053|NCT00538369|Active Comparator|standard-of-care|The standard-of-care group will receive sedation assessment and monitoring with the Ramsay scale, which is the accepted tool at this university
3291054|NCT00538369|Experimental|standard + BIS|Subjects in the standard-of-care + BIS group will receive sedation assessment and monitoring using the Ramsay scale and values from the bispectral index (BIS) monitor.
3291055|NCT00538356|Experimental|Home Monitoring|ICD or CRT-D with Home Monitoring feature activated Home Monitoring data will be analyzed regularly and patients will be contacted and scheduled for additional follow-up after predefined events
3291056|NCT00538356|Active Comparator|Control|ICD or CRT-D with Home Monitoring feature deactivated Patients will be treated as per standard of care in each participating clinic
3291057|NCT00538343|Experimental|RTA 744|
3291058|NCT00538317|Experimental|1|tirofiban bolus + perfusion started at the site of caring
3291059|NCT00538317|Active Comparator|2|tirofiban bolus + perfusion started at the beginning of coronarography (usual use of tirofiban)
3291060|NCT00538304|Experimental|1|bimatoprost eye drops
3291061|NCT00538304|Placebo Comparator|2|placebo
3291062|NCT00538291|Experimental|Arm 1|Cetuximab 400mg/m2 IV on day 1 over 2 hours then 250 mg/m2 over 1 hour weekly + Xeloda(Capecitabine) 1000mg/m2 BID on days 1-14 repeated every 21 days.
3291063|NCT00538265|Active Comparator|A|tacrolimus + steroids
3291064|NCT00538265|Experimental|B|ATG+ tacrolimus without steroids in maintenance therapy
3291065|NCT00538265|Experimental|C|ATG+ Mycophenolate Mofetil + tacrolimus a reduced dosage without steroids in maintenance therapy
3291066|NCT00538239|Experimental|Ridaforolimus|
3291067|NCT00538239|Placebo Comparator|Placebo|
3291068|NCT00538213|Experimental|Adjuvanted influenza vaccine GSK576389A Group|Subjects aged ≥ 66 years who previously received 1 dose of adjuvanted influenza vaccine GSK576389A in NCT00318149 and NCT00386698 studies were administered 1 dose of adjuvanted influenza vaccine GSK576389A.
3291069|NCT00538213|Active Comparator|Fluarix young Group|Subjects aged 19-42 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine.
3291070|NCT00538213|Active Comparator|Fluarix elderly Group|Subjects aged ≥ 66 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine.
3291071|NCT00538200|Other|1|Dietary Advice
3291072|NCT00538200|Other|2|Supplements
3291073|NCT00538187|Experimental|Treatment (obatoclax mesylate, bortezomib)|Patients will receive a 3-hour infusion of obatoclax and an infusion of bortezomib once a week for 4 weeks
3291074|NCT00538174|Experimental|Arm 1|2.5 mg
3291075|NCT00538174|Experimental|Arm 2|10 mg
3291076|NCT00538174|Experimental|Arm 3|20 mg
3291077|NCT00538174|Placebo Comparator|Arm 4|
3291078|NCT00538161|Experimental|Low tidal volume arm|
3291079|NCT00538161|Active Comparator|Conventional tidal volume arm|
3291080|NCT00538135|Experimental|1|"Cognitive Behaviour Therapy plus Treatment as Usual (CBT plus TAU) for borderline personality disorder.~CBT is a structured, time limited, psycho-social intervention developed to treat Cluster B personality disorder. Patients are encouraged to engage in treatment through a formulation of their problems within a cognitive framework. Interventions focus on the patient's beliefs and behaviour that impair social and adaptive functioning. Thirty sessions of CBT over one year, each lasting up to one hour, are required to work on long-standing problems and develop new ways of thinking and behaving. Priority is given to behaviours that cause harm to self or others. In addition, participants received the usual treatment they would have received if the trial had not been in place"
3291081|NCT00538135|Active Comparator|2|"Treatment as Usual.~All participants received the standard treatment (TAU) they would have received if the trial had not been in place. Although standard treatment may vary across the three sites, and depend on the specific problems of the individual participant, it was thought that all participants would be in contact with mental health services and would have some contact with Accident and Emergency services for repeated self-harm episodes. TAU will be documented carefully after each patient exits the trial."
3291082|NCT00538122||Thioridazine Group|Patients must have been treated with (Mellaril) thioridazine at least three months at time of enrollment.
3291083|NCT00538096|Experimental|1|MEDI-538
3291084|NCT00538096|Experimental|2|MEDI-538
3291085|NCT00538096|Experimental|3|MEDI-538
3291086|NCT00538083|Experimental|1, 2|acute phase, solid dark chocolate, placebo
3291087|NCT00538083|Experimental|3, 4, 5|acute phase, sugared cocoa, sugar-free cocoa, placebo
3291088|NCT00538083|Experimental|6, 7, 8|sustained phase, sugared cocoa, sugar-free cocoa, placebo
3291089|NCT00538070|Placebo Comparator|Placebo|You will receive two grams of placebo per day. You will take two 500 mg placebo capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
3291090|NCT00538070|Experimental|Sarcosine|You will receive two grams of sarcosine per day. You will take two 500 mg capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
3291091|NCT00538057|Experimental|arm 1|study drug
3291092|NCT00538044|Experimental|1simvastatin group|before the operation, the patient start the simvastatin medication on the dosage of 40mg per day
3291093|NCT00538044|No Intervention|2contral group|just do routin operation with no use of simvastatin, other medication is exact the same as the simvastatin group
3291094|NCT00538031|Active Comparator|Arm I|Patients receive oral cyclophosphamide once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3291095|NCT00538031|Experimental|Arm II|Patients receive oral cyclophosphamide once daily and oral celecoxib twice daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3291096|NCT00537979|Active Comparator|Paricalcitol injection|ABT-358 Zemplar
3291097|NCT00537979|Active Comparator|Paricalcitol capsules|ABT-358 Zemplar
3291098|NCT00537966|No Intervention|Control|Patients with primary HIV-1 infection who do not want to undergo early combination antiretroviral treatment
3291099|NCT00537966|Active Comparator|Intervention|In this arm patients with primary HIV-1 infection will receive early combination antiretroviral therapy with standard drugs approved by Swiss Medic.
3291100|NCT00537940|Active Comparator|A|
3291101|NCT00537940|Active Comparator|B|
3291102|NCT00537927|Active Comparator|0|fixation of mesh with a single crown of tacks and absorbable sutures
3291103|NCT00537927|Active Comparator|1|fixation of mesh with a double crown of tacks and no sutures
3291104|NCT00537927|Active Comparator|2|fixation of mesh with a single crown of tacks and non-absorbable sutures
3291105|NCT00537914|Other|1|single-arm non-comparative somatropin safety study (PASS)
3291106|NCT00537875|Active Comparator|1|
3291107|NCT00537875|Placebo Comparator|2|
3291108|NCT00537836|Experimental|ZK 283197, 3 mg|Postmenopausal women with hot flushes received 3 mg (3 x 1 mg tablets) ZK 283197, administered orally once daily over 8 weeks
3291109|NCT00537836|Placebo Comparator|Matching placebo|Postmenopausal women with hot flushes received placebo (3 tablets) orally once daily over 8 weeks
3291110|NCT00537836|Experimental|ZK 283197, 2 mg|Postmenopausal women with hot flushes received 2 mg (2 x 1 mg tablet) ZK 283197 plus 1 placebo tablet, once daily orally over 8 weeks
3291111|NCT00537836|Active Comparator|17ß-estradiol|Postmenopausal women with hot flushes received 1 mg (2 x 0.5 mg tablet) 17ß-estradiol plus 1 placebo tablet, once daily orally over 8 weeks
3291112|NCT00537823|Experimental|Arm 1 - Wildtype|"Neoadjuvant therapy~Week 1~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2/day over 46 hours~Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly~Weeks 3, 5, 7~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2/day over 46 hours~Wait 3-8 weeks after completion of therapy~Liver resection~Wait 4 weeks or until clinical status allows~Adjuvant Therapy~Week 1, 3, 5, 7, 9, 11, 13, 15~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2/day over 46 hours~Weeks 2, 4, 6, 8, 10, 12, 16~*Cetuximab 250 mg/m^2 IV weekly"
3291113|NCT00537823|Experimental|Arm 2 K-Ras 12/13 codon mutation|"Neoadjuvant Therapy~Weeks 1, 3, 5~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV~Bevacizumab 5 mg/kg IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2~Week 7~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2~Wait 3-8 weeks after completion of therapy~Liver resection~Wait 4 weeks or until clinical status allows~Adjuvant Therapy~Weeks 1, 3, 5, 9, 11, 13~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV~Bevacizumab 5 mg/kg IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2~Week 7, 15~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2"
3291114|NCT00537810|Experimental|Sibutramine|Sibutramine 15 mg daily
3291115|NCT00537810|Placebo Comparator|Placebo|Placebo Daily
3291116|NCT00537810|Experimental|Placebo/CBTsh|Placebo and Self-help CBT Placebo daily, Cognitive behavioral self-help manual for binge eating
3291117|NCT00537810|Experimental|Sibutramine/CBTsh|Sibutramine and Self-help CBT 15 mg daily Cognitive behavioral treatment manual for binge eating
3291118|NCT00537797|Experimental|Arm 1|"18-FDG-PET exam with SUV determination~Thyroid operation to remove nodule~Pathologic confirmation of nodule histology~Determine sensitivity and specificity of FDG-PET, correlative studies"
3291119|NCT00537784|Active Comparator|1|Injection of autologous platelet concentrate into repair site
3291120|NCT00537784|Placebo Comparator|2|No injection
3291121|NCT00537771|Experimental|1|Anastrozole (ARIMIDEX)
3291122|NCT00537771|Active Comparator|2|Tamoxifen
3291123|NCT00537758|Experimental|1|Cognitive Behavior Therapy
3291124|NCT00537758|Experimental|2|Behavioral Weight Loss Treatment
3291125|NCT00537758|Experimental|3|CBT + BWL
3291127|NCT00537732|Active Comparator|control group|3 tablets, only 20 mg omeprazole, genotype independent
3291128|NCT00537732|Active Comparator|intervention group|20 vs. 60 mg daily, genotype dependent
3291129|NCT00537719|Active Comparator|GSK716155|albiglutide subcutaneous injection
3291130|NCT00537719|Placebo Comparator|placebo|placebo injection
3291131|NCT00537693|Active Comparator|1|CRRT via Convection
3291132|NCT00537693|Active Comparator|2|CRRT via Diffusion
3291133|NCT00537680|Experimental|1|mid dose Idebenone
3291134|NCT00537680|Experimental|2|high dose Idebenone
3291135|NCT00537680|Placebo Comparator|3|
3291136|NCT00537667|Active Comparator|A|anakinra
3291137|NCT00537667|Experimental|B|anakinra and PEGsTNF-R1
3291138|NCT00537654|Experimental|Fasted state|Subjects will be required to fast overnight. Subjects will participate in 3 treatment periods and assigned to one of 12 treatment sequences ( ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) in accordance with the randomization schedule. The three treatment periods will be separated by a minimum washout period of 28 days
3291139|NCT00537654|Experimental|Fed state|Subjects will be served high fat breakfast 30 minutes prior to dosing. Subjects will participate in 3 treatment periods and assigned to one of 12 treatment sequences ( ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) in accordance with the randomization schedule. The three treatment periods will be separated by a minimum washout period of 28 days
3291140|NCT00537602|Experimental|A|Oral miglustat capsules 200 mg t.i.d. for 1 week and a single 200 mg dose on day 8
3291141|NCT00537602|Placebo Comparator|B|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. for 1 week and a single dose on day 8
3291142|NCT00537576|Experimental|1|5.0 x 10^8 cfu/dose LACTIN-V
3291143|NCT00537576|Experimental|2|1.0 x 10^9 cfu/dose LACTIN-V
3291144|NCT00537576|Experimental|3|2.0 x 10^9 cfu/dose LACTIN-V
3291145|NCT00537576|Placebo Comparator|4|Placebo
3291146|NCT00537537|Active Comparator|1|Telbivudine
3291147|NCT00537537|Active Comparator|2|Telbivudine
3291148|NCT00537537|Active Comparator|3|Telbivudine
3291149|NCT00537524|Experimental|Arm 1|0.5mL of H5N1 vaccine 7.5ug
3291150|NCT00537524|Active Comparator|Arm 2|0.25 or 0.5mL of H5N1 vaccine
3291151|NCT00537511|Experimental|Dose-finding arm: Pomalidomide + Cisplatin + Etoposide|Oral pomalidomide 1 mg - 5 mg daily (QD) for 14 consecutive days of a 21-day cycle, in combination with intravenous (IV) cisplatin 25 mg/m^2 and IV etoposide 100 mg/m^2 on Days 1, 2 and 3 of each cycle during the dose-finding phase (Treatment and Extension Periods; 6 cycles in total). Dose escalation followed a standard phase 1 3+3 design. Participants continuing took only their pomalidomide dose (monotherapy) for an additional 3-week Recovery Period (14 days of consecutive dosing followed by 7 days of no study medication). Participants continuing took oral pomalidomide 5 mg QD as monotherapy for 14 consecutive days of each 21-day cycle until disease progression in the Maintenance Phase.
3291152|NCT00537498|Experimental|1|Interventional group
3291153|NCT00537485|Experimental|1|
3291154|NCT00537485|Placebo Comparator|2|
3291155|NCT00537472|Experimental|I|
3291156|NCT00537472|Active Comparator|II|
3291157|NCT00537446|Active Comparator|High-level ventilation|Each subject will spend 2 hours receiving high-level noninvasive ventilation.
3291158|NCT00537446|Active Comparator|Low-level ventilation|Each subject will receive 2 hours of low-level noninvasive positive pressure ventilation.
3291159|NCT00537433|No Intervention|Standard counseling|Families in the control group receive standard care, including routine counseling regarding medications prescribed from their physician and post-visit counseling by the pediatric nursing staff. Dosing instruments are given at the discretion of the physician or nurse.
3291160|NCT00537433|Experimental|Pictogram|Parents randomized to the pictogram-based intervention group receive medication counseling utilizing the pictogram-based medication instruction sheets. These sheets help to facilitate medication counseling, including teaching about dosage and adherence.
3291161|NCT00537420|Placebo Comparator|1|Nasal Placebo
3291162|NCT00537420|Placebo Comparator|2|Capsule Placebo
3291163|NCT00537420|Experimental|3|Nasal PYY3-36 200 ug
3291164|NCT00537420|Experimental|4|Nasal PYY3-36 400 ug
3291165|NCT00537420|Experimental|5|Nasal PYY3-36 600 ug
3291166|NCT00537420|Active Comparator|6|Sibutramine 10 mg
3291167|NCT00537407|Experimental|Treatment Arm A|Debio 025 (alisporivir) 400 mg orally once daily + peg-IFNα2a 180 μg subcutaneously (sc) once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
3291168|NCT00537407|Experimental|Treatment Arm B|Debio 025 (alisporivir) 400 mg orally once daily for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
3291169|NCT00537407|Experimental|Treatment Arm C|Debio 025 (alisporivir) 400 mg orally once daily + peg-IFNα2a 180 μg sc once weekly for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
3291170|NCT00537407|Experimental|Treatment Arm D|Debio 025 (alisporivir) 800 mg orally once daily + peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
3291171|NCT00537407|Experimental|Treatment Arm E|Debio 025 (alisporivir) orally at a loading dose of 400 mg twice daily for 7 days followed by 400 mg/day for 22 days + peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
3291172|NCT00537394|Experimental|A|Regimen with higher predicted activity assigned by the study plus at least 2 NRTIs (personalized choice from expert recommendation) for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
3291173|NCT00537394|Experimental|B|Regimen with higher predicted activity assigned by the study without NRTIs for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
3291197|NCT00537225|Experimental|A-Exercise group|Home based exercise
3291198|NCT00537225|No Intervention|B- Usual Care|Exercise as usually prescribed by provider
3291174|NCT00537394|Other|C|Regimen with lower predicted activity assigned plus at least 2 NRTIs (personalized choice from expert recommendation) for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
3291175|NCT00537381|Active Comparator|Docetaxel + Prednisone + Placebo|Matching placebo as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) every week for initial 6 weeks, then every 3 weeks; along with docetaxel 75 milligram per square meter (mg/m^2) as intravenous infusion every 3 weeks and prednisone 5 mg orally twice daily were administered till 6 months or disease progression.
3291176|NCT00537381|Experimental|Docetaxel + Prednisone + Intetumumab|Intetumumab 10 mg per kilogram (mg/kg) as intravenous infusion every week for initial 6 weeks, then every 3 weeks; along with docetaxel 75 mg/m^2 as intravenous infusion every 3 weeks and prednisone 5 mg orally twice daily were administered till 6 months or disease progression.
3291177|NCT00537355|Active Comparator|TOLAMBA™|
3291178|NCT00537355|Sham Comparator|Histamine|Histamine simulates mild redness/swelling effect seen with active comparator, TOLAMBA™. Prevents study staff from easily identifying subjects who received active comparator.
3291179|NCT00537342|Experimental|A|Biological Vaccine
3291180|NCT00537342|Placebo Comparator|B|
3291181|NCT00537329|Other|Open|This is an open-label, multi-center, non-comparative 12 week study evaluating the efficacy and safety of anidulafungin in subjects with candidemia.
3291182|NCT00537316|Experimental|Infliximab (IFX)|Part 1: IFX 5 mg/kg of body weight intravenous (IV) infusions was to be administered at Weeks 0, 2, and 6 and placebo to AZA was to be taken orally every day for 16 weeks. Responders to IFX at Week 8, were to receive one more IFX infusion at Week 14; non-responders to IFX were to receive placebo IFX infusions at Weeks 8 and 10 and an additional IFX infusion at Week 14. Part 2: Participants in steroid-free remission at Week 16 of Part 1 were to be randomized to either maintenance (every 8 weeks [q8w]) or intermittent (upon relapse) open-label IFX (last IFX infusion administered at Week 86) plus double-blind oral AZA/placebo treatment as allocated in Part 1 (last dose at the final visit, Week 94). Responders at Week 16 who had not achieved steroid-free remission were to continue to receive IFX infusions every 8 weeks.
3291183|NCT00537316|Active Comparator|Azathioprine (AZA)|AZA 2.5 mg/kg of body weight orally every day for 16 weeks. Responders to AZA monotherapy at Week 8 were to continue on AZA therapy and receive one placebo infusion at Week 14; non-responders to AZA at Week 8 would be eligible to receive an IFX infusion at Weeks 8, 10, and 14. Participants in steroid-free remission at Week 16 were to continue on AZA monotherapy and were to be followed up for safety in Part 2. Participants who experienced a relapse of disease after Week 16 were to continue daily AZA monotherapy and receive 3 infusions of IFX (induction therapy at Weeks 0, 2, and 6) followed by infusions every 8 weeks (maintenance therapy).
3291184|NCT00537316|Experimental|IFX/AZA|IFX 5 mg/kg of body weight IV infusions at Weeks 0, 2, and 6 plus AZA 2.5 mg/kg orally every day for 16 weeks. Responders to IFX/AZA at Week 8 were to receive one more IFX infusion at Week 14; non-responders to IFX/AZA were to receive placebo infusions at Weeks 8 and 10 and one additional IFX infusion at Week 14. Part 2: Participants in steroid-free remission at Week 16 of Part 1 were to be randomized to either maintenance (every 8 weeks [q8w]) or intermittent (upon relapse) open-label IFX (last IFX infusion administered at Week 86) plus double-blind oral AZA/placebo treatment as allocated in Part 1 (last dose at the final visit, Week 94). Responders at Week 16 who had not achieved steroid-free remission were to continue to receive IFX infusions every 8 weeks.
3291185|NCT00537316|Experimental|Maintenance IFX/AZA (during Part 2)|Participants randomized to maintenance IFX/AZA in Part 2 of the study were to receive IFX 5 mg/kg of body weight IV infusions every 8 weeks (beginning at Week 22, Week 6 for direct entry) plus AZA 2.5 mg/kg of body weight daily. Four participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
3291186|NCT00537316|Experimental|Maintenance IFX (during Part 2)|Participants randomized to maintenance IFX were to receive IFX 5 mg/kg of body weight IV infusions every 8 weeks (beginning at Week 22, Week 6 for direct entry) in Part 2 of the study. Placebo to AZA therapy was to continue as allocated in Part 1 of the study. All participants were from Part 1 of the study.
3291187|NCT00537316|Experimental|Intermittent IFX/AZA (during Part 2)|Participants randomized to intermittent IFX/AZA were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained) plus AZA 2.5 mg/kg of body weight daily in Part 2 of the study. Three participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
3291188|NCT00537316|Experimental|Intermittent IFX (during Part 2)|Participants randomized to intermittent IFX were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained). Placebo to AZA therapy was to continue as allocated in Part 1 of the study. One participant was from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
3291189|NCT00537303|Experimental|Advanced|Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the meals with the largest prandial increments and individually adjusted insulin aspart based mainly on postmeal SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
3291190|NCT00537303|Active Comparator|Basic|Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the largest meals and individually adjusted insulin aspart based mainly on pre-meal and bedtime SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
3291191|NCT00537290|Experimental|Rituximab|All patients will receive 1000 milligrams of rituximab by intravenous infusion on Days 1 and 15.
3291192|NCT00537277|Experimental|BIAsp 30|Biphasic insulin aspart 30 administered once daily for 16 weeks. If HbA1c is higher than 7.0 % after 16 weeks of treatment, dose is increased to twice daily for another 16 weeks. If HbA1c is higher than 7.0 % after 32 weeks of treatment, dose is increased to three times daily until week 48 (end of trial).
3291193|NCT00537264|Experimental|Computer|Health-related quality of life questionnaires will be administered using a computerised multimedia touchscreen system.
3291194|NCT00537264|Experimental|Interviewer|Health-related quality of life questionnaire will be administered via face-to-face interviews.
3291195|NCT00537238|Active Comparator|B|
3291196|NCT00537238|Active Comparator|A|
3291199|NCT00537212|Active Comparator|1|"Subjects will receive phototherapy and dietary counselling consistent with The South Beach diet."
3291200|NCT00537212|Active Comparator|2|"Subjects will receive phototherapy and dietary counselling consistent with The Ornish Diet."
3291201|NCT00537212|No Intervention|3|Subjects will receive phototherapy alone, without dietary counselling.
3291202|NCT00537199|Other|OraTest + Visual Exam|OraTest dye
3291203|NCT00537186|Other|1|Iron oligosaccharide
3291204|NCT00537173||Arm 1|Paclitaxel 90 mg/m2 IV D1, 8, and 15 + Avastin 10 mg/kg IV, day 1 and 15
3291205|NCT00537147|Experimental|1|1 vaccination of a 10^4 plaque-forming units (PFU) dose of WN/DEN4delta30 vaccine administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
3291206|NCT00537147|Experimental|2|1 vaccination of a 10^5 PFU dose of WN/DEN4delta30 vaccine administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
3291207|NCT00537147|Placebo Comparator|3|1 vaccination of a placebo administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
3291208|NCT00537134|No Intervention|1|Conservative management (watchful observation)
3291209|NCT00537134|Active Comparator|2|Endovascular treatment
3291210|NCT00537108|Experimental|HV|Intervention arm.
3291211|NCT00537108|No Intervention|Cntr|Usual care control
3291212|NCT00537095|Experimental|vandetanib (ZD6474)|vandetanib (ZD6474) 300 mg per os once daily
3291213|NCT00537095|Placebo Comparator|Placebo|Placebo
3291214|NCT00537082|Experimental|FTY720 0.5 mg|FTY720
3291215|NCT00537082|Experimental|FTY720 1.25 mg|FTY720
3291216|NCT00537082|Placebo Comparator|Placebo|
3291217|NCT00537056|Experimental|F-18 FDG PET/CT and DCE MRI|FDG PET CT F-18 Fluoro-deoxi-glucose: 15 mCi iv Gadolinium-DTPA: 0.1 mmol/kg Sunitinib: 50 mg/day po
3291218|NCT00537030|Experimental|Erwinia asparaginase|Patients receive 6 doses of Erwinia asparaginase (dosage 25,000 IU/m2 intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase remaining on the original treatment protocol. All other chemotherapy continues according to the original treatment protocol.
3291219|NCT00537017|Experimental|Preladenant 5 mg BID|Preladenant 5 mg twice daily (BID) given open-label for 36 weeks to participants with moderate to severe Parkinson's Disease who are on a long-term and stable L-dopa treatment regimen.
3291220|NCT00537004||PPA (Primary Progressive Aphasia)|Individuals with primary progressive aphasia
3291221|NCT00537004||Control|Individuals with no diagnosis of any type of dementia
3291222|NCT00536991|Experimental|Treatment (calcitriol, ketoconazole, hydrocortisone)|"PHASE I: Patients receive calcitriol PO QD on days 1-3, 8-10, 15-17, and 22-24. Patients also receive ketoconazole PO TID on days 1-24 and therapeutic hydrocortisone PO BID on days -1 to 24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive calcitriol and therapeutic hydrocortisone as in phase I. Patients also receive ketoconazole PO TID on days 4-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3291223|NCT00536978|Experimental|NK Cell/T-Cell Infusion|Possible Cell Adback - infusion NK cells or T-cells from donor given after blood stem cell transplantation for either Reduced intensity chemotherapy of campath, modified BEAM regimen of Campath-IH 15 mg intravenous (IV) Daily for 3 Days + BEAM Daily for 4 days (BCNU 300 mg/m^2 IV, Etoposide 100 mg/m^2 IV, Ara-C 100 mg/m^2 IV Daily for 4 days and Melphalan 100 mg/m^2 IV Over 30 Minutes for 1 Day) + Rituximab 375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks]; or Non-myeloablative Preparative Regimen [Fludarabine 30 mg/m^2 IV Daily Over 1 Hour for 3 Days; Cyclophosphamide 1000 mg/m^2 IV Daily Over 1 Hour for 3 Days; Rituximab 375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks; Campath-IH 15 mg IV Daily Over 30 Minutes for 3 Days; plus Total Body radiation (TBI)].
3291224|NCT00536952|Experimental|Arm 1|Pulmozyme
3291225|NCT00536952|Placebo Comparator|Arm 2|Placebo
3291226|NCT00536939|Experimental|A|
3291227|NCT00536939|Placebo Comparator|B|
3291228|NCT00536926|Active Comparator|A|home spirometry alone
3291229|NCT00536926|Experimental|B|Home spirometry with data transfer via cellphone to clinical database
3291230|NCT00536913|Experimental|With Spacer|Budesonide/formoterol pMDI 40/2.25ug + spacer
3291231|NCT00536913|Experimental|Without Spacer|Budesonide/formoterol pMDI 40/2.25 ug
3291232|NCT00536900|Experimental|1|Advisor-Teller Money Manager
3291233|NCT00536900|Active Comparator|2|FIT (finance instruction therapy)
3291234|NCT00536874|Experimental|Gemcitabine And Oxaliplatin|A Phase II Study of Neoadjuvant Gemcitabine And Oxaliplatin In Patients With Potentially Resectable Previously Untreated Pancreatic Adenocarcinoma
3291235|NCT00536861|Experimental|1|
3291236|NCT00536848|Experimental|A|Metronidazole for 10 days, probiotics for 6 months
3291237|NCT00536848|Placebo Comparator|B|Metronidazole for 10 days, placebo for 6 months
3291238|NCT00536835|Experimental|Stage A|Stage A will identify maximum tolerated doses for either Schedule 1 - GSK461364 given once weekly on Day 1, 8 and 15 every 28 days; Schedule 2 - GSK 461364 given twice weekly Days 1, 2, 8, 9, 15 and 16; Schedule 3 Daily on Day 1 to Day 15 every 21 days.
3291239|NCT00536835|Experimental|Stage B|Evaluate safety, PK, pharmacodynamic (PD) & tumor response in expanded cohorts at the MTD for at least one schedule from Stage A.
3291240|NCT00536809|Experimental|Phase I|Dose escalation of lapatinib along with capecitabine and oxaliplatin until the maximum tolerated dose is reached.
3291241|NCT00536809|Experimental|Phase II|Treatinng subjects at the maximum tolerated dose of lapatinib, capecitabine, and oxaliplatin
3291242|NCT00536796||Patients at very high risk|
3291243|NCT00536796||Patients at high risk|
3291244|NCT00536796||Patients at medium risk|
3291245|NCT00536796||Patients at low risk|
3291246|NCT00536770|Placebo Comparator|A|Placebo + gemcitabine
3291247|NCT00536770|Placebo Comparator|B|Placebo + gemcitabine + erlotinib
3291248|NCT00536770|Active Comparator|C|DN-101 + gemcitabine
3291249|NCT00536770|Active Comparator|D|DN-101 + gemcitabine + erlotinib
3291250|NCT00536744|Active Comparator|Active PACE application - 4 applications|Application of acoustical pulse energy (extracorporeal shockwaves) to target ulcer + standard of care
3291251|NCT00536744|Sham Comparator|Inactive, non-energy application|Non-energized (inactive - Sham)) application + standard of care
3291252|NCT00536731|Active Comparator|Symbicort pMDI|Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
3291253|NCT00536731|Active Comparator|Symbicort Turbuhaler|Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
3291254|NCT00536731|Active Comparator|Pulmicort Turbuhaler|Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
3291255|NCT00536679|Experimental|Sequence ABC|Subjects will be randomized to sequence ABC, where A=1 milligram (mg) GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
3291256|NCT00536679|Experimental|Sequence ACB|Subjects will be randomized to sequence ACB, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
3291257|NCT00536679|Experimental|Sequence BAC|Subjects will be randomized to sequence BAC, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
3291258|NCT00536679|Experimental|Sequence BCA|Subjects will be randomized to sequence BCA, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
3291259|NCT00536679|Experimental|Sequence CAB|Subjects will be randomized to sequence CAB, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
3291260|NCT00536679|Experimental|Sequence CBA|Subjects will be randomized to sequence CBA, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
3291261|NCT00536666|Other|1|Iron oligosaccharide
3291262|NCT00536653|Active Comparator|Osteporosis Group|Patients with a presenting T score < -2.5 (osteoporosis), treated with bicalutamide and Ca/VitD
3291263|NCT00536653|Active Comparator|Osteopenia Group|Patients with a presenting T score between -1.0 and -2,4 (osteopenia), treated with LHRH agonists and Ca/VitD
3291264|NCT00536653|Active Comparator|Normal Group|Patients with a presenting T score > -1.0(normal BMD), treated with LHRH agonists
3291265|NCT00536640|Experimental|Arm A (Erlotinib, Bevacizumab)|
3291266|NCT00536640|Active Comparator|Arm B (Gemcitabine, Cisplatin, Bevacizumab)|
3291267|NCT00536627|Experimental|1|Patients will receive 5 injections of DNA vaccine at weeks 0, 8, 16, 40, 44.
3291268|NCT00536627|No Intervention|2|
3291269|NCT00536614|No Intervention|A|arm A) gemcitabine/cisplatin in combination with Cetuximab arm B) gemcitabine/cisplatin alone
3291270|NCT00536601|Experimental|Regimen CBV (patients with HL or NHL)|Patients receive etoposide intravenously (IV) continuously over 34 hours on day -8, cyclophosphamide IV over 2 hours on days -7 to -4, and carmustine IV over 2 hours on day -3. Patients undergo ASCT on day 0.
3291271|NCT00536601|Experimental|Regimen M200/M120 (patients with MM or amyloidosis)|Patients receive 200 or 120 mg/m^2 of melphalan IV over 30 minutes on day -2. Patients undergo ASCT on day 0.
3291272|NCT00536601|Experimental|Regimen BuC2iv (patients with ALL, AML, HL, or NHL)|Patients receive busulfan IV over 2 hours then every 6 hours on days -7 to -4 for 16 total doses and cyclophosphamide IV over 2 hours on days -3 and -2. Patients undergo ASCT on day 0.
3291273|NCT00536601|Experimental|Regimen CT6 (patients with ALL)|Patients receive cyclophosphamide IV over 2 hours on days -5 to -4. Patients then undergo TBI twice daily on days -3 to -1. Patients undergo ASCT on day 0.
3291274|NCT00536601|Experimental|Regimen CTtCp (patients with other solid tumors)|Patients receive cyclophosphamide IV continuously, carboplatin IV continuously, and thiotepa IV continuously over 24 hours on days -7 to -4. Patients undergo ASCT on day 0.
3291275|NCT00536601|Experimental|Regimen VCp (patients with testicular cancer)|Patients receive etoposide IV over 2-3 hours and carboplatin IV over 30 minutes on days -6 to -4. Patients undergo ASCT on day 0. At least 4 weeks after the first transplant, patients receive etoposide IV over 2-3 hours and carboplatin IV over 30 minutes on days -6 to -4. Patients then undergo a second ASCT on day 0.
3291276|NCT00536601|Experimental|Regimen TtC1500/ECpM (patients with NBL or SRBCT)|Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 2 hours on days -5 to -2. Patients undergo ASCT on day 0. At least 4 weeks after the first transplant, patients receive carboplatin IV continuously over 24 hours on days -7 to -4, etoposide IV continuously over 24 hours on days -7 to -4, and melphalan IV over 30 minutes on days -7 to -5. Patients undergo a second ASCT on day 0.
3291277|NCT00536588|Experimental|SCH 721015 with SCH 209702|
3291278|NCT00536575|Experimental|Intervention|The trial was designed as a single-arm Phase I/II study of sorafenib and bortezomib with dose optimization in initial patients. Phase I consisted of cohorts of 3 patients at each of three dose levels. Patients received bortezomib (Dose Level 1 - 1.3 mg/m2; Dose Level 2 - 1.6 mg/m2) by IV bolus on days 1, 8, 15, and 22 of each 5-week cycle with continuous oral dosing of sorafenib at 200 mg twice daily. Dose level 3 was planned as bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 with sorafenib 400 mg by mouth twice daily throughout each 5-week cycle.
3291279|NCT00536562|No Intervention|Usual Care|Usual Care as provided through the Stroke Prevention Clinic
3291280|NCT00536562|Active Comparator|Cardiac Rehabilitation|Usual Care plus Comprehensive Cardiac Rehabilitation Program
3291281|NCT00536549|Experimental|A|Guardina RT monitoring
3291282|NCT00536549|Active Comparator|B|
3291283|NCT00536536|Active Comparator|Hospital|Care of Childhood Obesity Clinic (COCO)
3291284|NCT00536536|Active Comparator|Primary Care|Primary care clinics (x2)
3291285|NCT00536523||Patients Receiving Chemotherapy|Patients with newly diagnosed ovarian, fallopian tube or primary peritoneal cancer for which 6 cycles of a taxane and platinum containing regimen is planned
3291287|NCT00536510|Placebo Comparator|2|placebo
3291288|NCT00536484|Experimental|Fesoterodine (Double-Blind)|
3291289|NCT00536484|Placebo Comparator|Placebo (Double-Blind)|
3291290|NCT00536471|Experimental|A|duloxetine 60 milligrams (mg) every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months
3291291|NCT00536471|Placebo Comparator|B|placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months
3291292|NCT00536458|Experimental|radiotherapy|minichep + radiotherapy
3291293|NCT00536458|Active Comparator|B|MINI CHEP
3291294|NCT00536419|Placebo Comparator|2|4 days of placebo
3291295|NCT00536419|Experimental|1|MPH-SODAS at day 1 (0.3/mg/kg/day); day 2 (0.7/mg/kg/day);days 3 and 4 (1.0 mg/kg/day)
3291296|NCT00536406|Experimental|A|Participants will receive the BE-ACTIV treatment
3291297|NCT00536406|Active Comparator|B|Participants will receive treatment as usual
3291298|NCT00536393|Active Comparator|Doxorubicine|CHOP 8 courses every 21 days
3291299|NCT00536393|Experimental|Doxorubicine pegylated|CLOP 8 courses every 21 days
3291300|NCT00536380|Experimental|5-mg Desloratadine|5-mg Desloratadine once daily
3291301|NCT00536380|Experimental|10-mg Desloratadine|10-mg Desloratadine once daily
3291302|NCT00536380|Experimental|20-mg Desloratadine|20-mg Desloratadine once daily
3291303|NCT00536367||Patients seen for ADHF at OSUMC|
3291304|NCT00536341|Experimental|lenalidomide, fludarabine, rituximab|"Phase I Non-stratified, dose-escalation: >=3 patients per dose level. Safety and tolerability will be evaluated every 2 weeks during the active treatment. Doses of lenalidomide will be escalated, while the fludarabine and rituximab doses remain fixed.~Phase II The Phase II regimen will be chosen following a review of the Phase I data. Following selection of the Phase II schedule, 40 treatment naive patients will be enrolled and treated with the Phase II regimen every 28 days for up to 6 courses. For those patients achieving a CR after 3 cycles, one additional cycle of treatment will be administered beyond CR confirmation."
3291305|NCT00536315||COPD|Patients with cough and/or shortness of breath who may have windpipe collapse.
3291306|NCT00536315||Healthy adults|Subjects without symptoms for comparison.
3291307|NCT00536315||Tracheomalacia|Patients with cough and/or shortness of breath who may have windpipe collapse.
3291308|NCT00536302|Experimental|1|Collagen Hydrolysate
3291309|NCT00536302|Placebo Comparator|2|
3291310|NCT00536289|Active Comparator|1|Sharp needles
3291311|NCT00536289|Experimental|2|Blunt tipped needles
3291312|NCT00536263|Active Comparator|PEG 1.0 mcg/kg weekly (QW) * 24 weeks|PegIntron 1.0 mcg/kg weekly (QW) * 24 weeks + 24 weeks follow-up
3291313|NCT00536263|Experimental|PEG 1.5 mcg/kg QW * 24 wks|PegIntron 1.5 mcg/kg QW * 24 wks + 24 wks follow-up
3291314|NCT00536263|Experimental|PEG 1.5 mcg/kg QW * 48 wks|PegIntron 1.5 mcg/kg QW * 48 wks + 24 wks follow-up
3291315|NCT00536224|Active Comparator|2|Minimal counseling
3291316|NCT00536224|Experimental|1|Full counseling
3291317|NCT00536211|Experimental|1|Exercise
3291318|NCT00536211|Active Comparator|2|Metformin
3291319|NCT00536198|Experimental|Sertraline|Participants will take sertraline that is dosed between 50 and 100 mgs during the symptomatic period. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
3291320|NCT00536198|Placebo Comparator|Placebo|Participants will take similar looking placebo during the symptomatic period.
3291321|NCT00536185|Experimental|1|
3291322|NCT00536185|Placebo Comparator|2|
3291323|NCT00536172|Experimental|Escitalopram|Participants will receive treatment with escitalopram
3291324|NCT00536172|Placebo Comparator|Placebo|Participants will receive treatment with placebo
3291325|NCT00536159|Active Comparator|Community Care|Medicaid eligible/insured pregnant women and their infants are eligible for risk assessment and up to 18 home visits (9/pregnancy and 9/infancy) from community professional providers as part of a state-sponsored enhanced prenatal and postnatal Medicaid program.
3291326|NCT00536159|Experimental|Nurse-CHW Team|Nurse-CHW team provided both nursing care, with additional focus on mental health and stress, and intensive relationship-based support from a CHW similar in characteristics to women served in the context of state-sponsored Medicaid program.
3291327|NCT00536133|Experimental|Zinc group|children with recurrent acute lower respiratory infections receiving zinc supplementation
3291328|NCT00536133|Placebo Comparator|Placebo group|children with recurrent acute lower respiratory infections receiving placebo syrup
3291329|NCT00536120|Experimental|Tysabri Plus Vaccinations|Participants receive 9 monthly doses of Tysabri 300 mg intravenous (IV), and receive vaccinations with neoantigen and recall antigen (keyhole limpet hemocyanin [KLH] and tetanus diphtheria toxoid [Td], according to manufacturer's prescribing information) at Month 6 (following the 7th dose of Tysabri) for both KLH and Td, and 14 and 28 days later for KLH.
3291330|NCT00536120|Other|Vaccinations Only|Participants receive only vaccinations with neoantigen and recall antigen (KLH and Td, according to manufacturer's prescribing information) at Month 0 for both KLH and Td, and 14 and 28 days later for KLH. They do not receive any treatment for their MS and remain in the study through Month 2.
3291331|NCT00536107|Active Comparator|Docetaxel|docetaxel
3291332|NCT00536107|Experimental|Gefitinib|Gefitinib (IRESSA)
3291333|NCT00536094|Experimental|1|Participants will receive cognitive behavioral therapy for anxiety that includes exposure
3291334|NCT00536094|Active Comparator|2|Participants will receive treatment as usual as delivered by school-based clinicians
3291335|NCT00536081|Active Comparator|A|Pegfilgrastim during all 6 cycles of chemotherapy
3291336|NCT00536081|Experimental|B|Pegfilgrastim during the first two cycles of chemotherapy
3291337|NCT00536068|Experimental|1, 2, 3, 4|"acetylsalicylic acid 100 mg/po,acetaminophen 3x1g/po~acetylsalicylic acid 100 mg/po,diclofenac 3x50mg/po~acetylsalicylic acid 100 mg/po,naproxen 3x250mg/po~acetylsalicylic acid 100 mg/po,placebo 3x1/po"
3291338|NCT00536042|Experimental|minocycline|addition of minocycline to standard asthma care as add-on therapy: 150 mg bid to 250 mg bid for up to one year
3291339|NCT00536029|Case|A|Subject with pigmented skin lesion suspect for malignant melanoma
3291342|NCT00535977|Experimental|1|Dietary intervention of ITC-enriched broccoli
3291343|NCT00535977|Experimental|2|Dietary intervention of frozen peas
3291344|NCT00535964||1|Psychologically healthy adolescents, evenly divided across the various stages of smoking uptake
3291345|NCT00535951|Experimental|LBH589|
3291346|NCT00535938||Naïve to Botox® treatment|Initiating treatment with BOTOX® upon entry to the project.
3291347|NCT00535938||Non-naïve to Botox® treatment|Receiving ongoing treatment with BOTOX® upon entry to the project.
3291348|NCT00535925|Active Comparator|1|Control group patients will continue their usual therapy. During the study such patients could receive all the therapeutic modifications according to the good medical practice of the specialist.
3291349|NCT00535925|Experimental|2|"An intensive multifactorial intervention is performed to achieve the goals for the following risk factors: hypertension, hyperglycaemia, lipids, anaemia.~In particular, new antihypertensive drugs will be added one by one until the achievement of blood pressure target (<130/80 mmHg)."
3291350|NCT00535912|No Intervention|A|¨Chemotherapy by 12 courses of CHOP
3291351|NCT00535912|Active Comparator|B|¨Chemotherapy by 3 courses of CHOP, intensification and autograft
3291352|NCT00535886|Active Comparator|Elaidic Acid|
3291353|NCT00535886|Experimental|Vaccenic Acid|
3291354|NCT00535886|Placebo Comparator|Oleic Acid|
3291355|NCT00535873|Experimental|Lenalidomide|Lenalidomide starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
3291356|NCT00535860|Experimental|50 mcg|ViaDerm transdermal delivery
3291357|NCT00535860|Experimental|80 mcg|Add Via-Derm transdermal delivery
3291358|NCT00535860|Active Comparator|20 mcg|Subcutaneous injection
3291359|NCT00535847|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 24 weeks.
3291360|NCT00535847|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
3291361|NCT00535847|Experimental|Other|"Subjects received telaprevir 750 mg tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects <75 kg and 1200 mg/day for subjects weighing >=75 kg, discontinued treatment before Week 12 in this study (VX06-950-107 [NCT00535847]) and had a partial response, viral breakthrough, or relapse in the parent study (VX05-950-104 [NCT00336479], VX05-950-104EU [NCT00372385] or VX06-950-106 [NCT00420784]) were included in Other reporting group."
3291362|NCT00535821|Experimental|MiCHO|A 6-hour resuscitation protocol utilizing the esophageal Doppler monitoring (EDM)
3291363|NCT00535821|Active Comparator|EGDT|A 6-hour resuscitation protocol utilizing CVP/ScvO2
3291364|NCT00535808|Experimental|1|Administration of nitroprusside
3291365|NCT00535808|Experimental|2|Administration of nitroglycerine
3291366|NCT00535808|Experimental|3|Administration of sevoflurane
3291367|NCT00535795|Active Comparator|1|Conventional Radiation Therapy (XRT), one fraction per day, from Sunday to Thursday every week.
3291368|NCT00535795|Experimental|2|Conventional Plus accelerated boost Radiation Therapy (XRT), from Sunday to Thursday every week.
3291369|NCT00535782|Experimental|TCZ + MTX|Participants received 8 mg/kg tocilizumab (TCZ) by intravenous infusion (IV) every 4 weeks plus methotrexate (MTX) 7.5-25 mg (oral or parenteral) weekly for the first 24 weeks. From Week 24 to Week 104, participants received open-label TCZ 8 mg/kg every 4 weeks plus 7.5-25 mg MTX weekly.
3291370|NCT00535782|Placebo Comparator|Placebo + MTX|Participants received placebo intravenous infusion (IV) every 4 weeks plus methotrexate (MTX) 7.5-25 mg (oral or parenteral) weekly for the first 24 weeks. From Week 24 to 104, participants received open-label tocilizumab (TCZ) 8 mg/kg every 4 weeks plus 7.5-25 mg MTX.
3291371|NCT00535769|Placebo Comparator|Electronic monitor + no text message|The control or placebo comparator group of subjects will receive the study sunscreen with the attached electronic monitor. They will be instructed to apply sunscreen once a day in the morning to the sun-exposed areas of the body. If the subjects are to have continuous sun exposure (for example, at a beach), they are to re-apply the sunscreen every 3 hours.
3291372|NCT00535769|Experimental|Electronic monitor + Text message|The text message experimental group of subjects will receive the study sunscreen with the attached electronic monitor. In addition, this group will receive daily text messages on their cellular phone to remind them to apply the sunscreen. The text message will also contain the daily weather information. This group will also be instructed to apply sunscreen once a day in the morning to the sun-exposed areas of the body. If subjects are to have continuous sun exposure (for example, at a beach), they are to re-apply the sunscreen every 3 hours.
3291373|NCT00535756|Experimental|1|
3291374|NCT00535756|Placebo Comparator|2|
3291375|NCT00535743|Placebo Comparator|Placebo|
3291376|NCT00535743|Experimental|Sugammadex|5 different doses of Sugammadex (2 ,4, 8, 12 and 16 mg/kg)
3291377|NCT00535730|Placebo Comparator|1|Placebo Comparator
3291378|NCT00535730|Experimental|2|vaccine
3291379|NCT00535704|Experimental|1|The Strong AFrican American FAmilies-Teen program is a five part educational program has been designed to help teens and their parents create successful futures and avoid the risky behaviors that sometimes keep teens from reaching their goals.
3291380|NCT00535704|Other|2|The FUEL program is a family-based adaptation of a curriculum designed to assist teens to develop lifestyles that prevent health problems such as heart disease, diabetes, and being overweight. This program deals with diet and exercise, the influence of TV and magazines on eating habits, and handling stress.
3291381|NCT00535691|Active Comparator|1|Tacrolimus ointment 0.03% once daily, placebo once daily
3291382|NCT00535691|Active Comparator|2|Tacrolimus ointment 0.03% twice daily
3291383|NCT00535665|Experimental|1: 10 ug, 14 days|
3291384|NCT00535665|Experimental|2: 5 ug, 28 days|
3291385|NCT00535665|Experimental|3: 10 ug, 28 days|
3291386|NCT00535665|Experimental|4: 15 ug, 28days|
3291387|NCT00535652|Experimental|Ertapenem|Administration of 1 gram ertapenem I.V.
3291388|NCT00535626|Other|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell used in revision total hip replacement
3291389|NCT00535613|Experimental|1|propofol
3291390|NCT00535613|Sham Comparator|2|no propofol
3291391|NCT00535587|Experimental|1|
3291392|NCT00535587|Experimental|2|
3291393|NCT00535587|Experimental|3|
3291394|NCT00535587|Experimental|4|
3291395|NCT00535574|Placebo Comparator|Bexarotene (Targretin LGD1069)|
3291396|NCT00535574|Active Comparator|placebo|
3291397|NCT00535561|Active Comparator|1|Oral iron treatment only- for iron deficiency anemia and subclinical hypothyroidism coexisting patients
3291398|NCT00535561|Active Comparator|2|Oral iron plus levothyroxine treatment- for iron deficiency anemia and subclinical hypothyroidism coexisting patients
3291399|NCT00535522|Experimental|TAK-285|
3291400|NCT00535496|Experimental|1|sugammadex 1.0 mg/kg, TOF-Watch® SX (dominant forearm) and PNS (non-dominant forearm)
3291401|NCT00535496|Experimental|2|sugammadex 1.0 mg/kg, TOF-Watch® SX (non-dominant forearm) and PNS (dominant forearm)
3291402|NCT00535496|Experimental|3|sugammadex 4.0 mg/kg, TOF-Watch® SX (dominant forearm) and PNS (non-dominant forearm)
3291403|NCT00535496|Experimental|4|sugammadex 4.0 mg/kg, TOF-Watch® SX (non-dominant forearm) and PNS (dominant forearm)
3291404|NCT00535470|Experimental|1|Open label 0.04% Mechlorethamine gel
3291405|NCT00535457|Experimental|1|"Children will watch tricks (magic) before anesthesia induction"
3291406|NCT00535444|Active Comparator|Control|assisted appointment with physician
3291407|NCT00535431|Experimental|A|AER 001
3291408|NCT00535431|Placebo Comparator|P|sterile saline
3291409|NCT00535418|Experimental|Letrozole|
3291410|NCT00535405|Experimental|1|Each patient will receive 1 active treatment dose & 2 Placebo (Pbo) doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
3291411|NCT00535405|Experimental|2|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
3291412|NCT00535405|Experimental|3|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
3291413|NCT00535405|Experimental|4|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
3291414|NCT00535405|Experimental|5|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
3291415|NCT00535392|Experimental|Levetiracetam|
3291416|NCT00535379|Experimental|1|
3291417|NCT00535366|Experimental|Tiotropium+salmeterol+fluticasone|
3291418|NCT00535366|Experimental|Tiotropium+salmeterol+ciclesonide low|
3291419|NCT00535366|Experimental|Tiotropium+salmeterol+ciclesonide high|
3291420|NCT00535366|Placebo Comparator|Placebo|
3291421|NCT00535314|Experimental|RTA 402 Dose1|Dose1 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
3291422|NCT00535314|Experimental|RTA 402 Dose2|Dose2 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
3291423|NCT00535301|Placebo Comparator|Anterior Colporrhaphy (sutured repair)|Anterior vaginal prolapse repair with anterior colporrhaphy (no graft) using sutures.
3291424|NCT00535301|Active Comparator|Perigee (grafted repair)|Anterior vaginal prolapse repair with graft
3291425|NCT00535288|Placebo Comparator|Placebo|Participants receive encapsulated tablets, orally, once daily (QD) for up to 12 weeks.
3291426|NCT00535288|Experimental|Esmirtazapine 2.25 mg|Participants receive esmirtazapine, 2.25 mg, encapsulated tablets, orally QD for up to 12 weeks.
3291427|NCT00535288|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine, 4.5 mg, encapsulated tablets, orally QD for up to 12 weeks.
3291428|NCT00535288|Experimental|Esmirtazapine 9 mg|Participants receive esmirtazapine, 9 mg, encapsulated tablets, orally QD for up to 12 weeks.
3291429|NCT00535288|Experimental|Esmirtazapine 18 mg|Participants receive esmirtazapine, 18 mg, encapsulated tablets, orally QD for up to 12 weeks.
3291430|NCT00535275|Experimental|A|
3291431|NCT00535275|Active Comparator|B|Docetaxel monotherapy
3291432|NCT00535262|Experimental|EmSam|EmSam will be administered in open-label fashion for 8-weeks during phase I of the study during which symptoms of depression will be assessed weekly. Those whose depression responds after 8-weeks will be entered into an 8-month open-label continuation phase during which they will be maintained on EmSam and be assessed on a monthly basis.
3291433|NCT00535236|Experimental|1|Arm 1: Vaccine
3291434|NCT00535236|Placebo Comparator|2|Arm 2: Pbo Comparator
3291435|NCT00535223|Experimental|Group Based Exposure Therapy|"Behavioral:~GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking."
3291436|NCT00535223|Experimental|Present Centered Group Therapy|"Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus. This lasted for 16 weeks."
3291437|NCT00535210|Other|1|
3291438|NCT00535210|Other|2|
3291533|NCT00534352|Experimental|001|TMC125; darunavir; ritonavirTMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
3291439|NCT00535145|Experimental|001|Treatment as usual (TAU), Paliperidone ERTreatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
3291440|NCT00535132|Experimental|002|Oral Risperidone 4 or 6 mg MG once daily for 0-2 weeks
3291441|NCT00535132|Experimental|001|Paliperidone ER 6, 9 or 12 MG once daily for 4-6 weeks
3291442|NCT00535119|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 3 and veliparib PO twice daily on days 1-7 until the recommended phase II dose is determined. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression or unacceptable toxicity.
3291443|NCT00535106|Active Comparator|Standard resusc|Patients in this arm will be treated with standard resuscitation efforts, including the delivery of an immediate defibrillatory shock for all patients presenting in VF.
3291444|NCT00535106|Experimental|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
3291445|NCT00535106|Active Comparator|Delayed defib|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation. Data is being collected on this population as well, thereby providing a cohort population for comparative purposes.
3291446|NCT00535093|No Intervention|1|All patients fulfilling inclusion criteria will be evaluated for GAS infection using both a rapid streptococcus test and also a standard throat culture
3291447|NCT00535067||Breast Cancer Survivors|
3291448|NCT00535054|Experimental|Tears Again|All subjects shall be treated with Tears Again.
3291449|NCT00535028|Experimental|A|AER 001 s.c. once daily for 28 days
3291450|NCT00535028|Placebo Comparator|P|placebo s.c. once daily for 28 days
3291451|NCT00535002|Other|Cocaine Females, Yohimbine then Placebo|Cocaine dependent females, received yohimbine day 1 and placebo day 2
3291452|NCT00535002|Other|Cocaine Females, Placebo the Yohimbine|Cocaine dependent females, received placebo day 1 and yohimbine day 2
3291453|NCT00535002|Other|Cocaine Males, Yohimbine then Placebo|Cocaine dependent males, received yohimbine day 1 and placebo day 2
3291454|NCT00535002|Other|Cocaine Males, Placebo thenYohimbine|Cocaine dependent males, received placebo day 1 and yohimbine day 2
3291455|NCT00535002|Other|Control Females, Yohimbine then Placebo|Non-dependent females, received yohimbine day 1 and placebo day 2
3291456|NCT00535002|Other|Control Females, Placebo then Yohimbine|Non-dependent females, received placebo day 1 and yohimbine day 2
3291457|NCT00535002|Other|Control Males, Yohimbine then Placebo|Non-dependent males, received yohimbine day 1 and placebo day 2
3291458|NCT00535002|Other|Control Males, Placebo then Yohimbine|Non-dependent males, received placebo day 1 and yohimbine day 2
3291459|NCT00534976|Experimental|Montelukast Sodium|"Participants 4-5 years: A single dose of 4 mg Montelukast chewable tablet daily, crossing over to matching placebo (Pbo) after a 3- to 7-day washout period (no participants 4-5 years were enrolled)~Participants 6-14 years: A single dose of 5 mg Montelukast chewable tablet daily, crossing over to matching Pbo after a 3- to 7-day washout period"
3291460|NCT00534976|Experimental|Placebo|"Participants 4-5 years: A single dose of 4 mg Pbo chewable tablet daily, crossing over to Montelukast 4 mg chewable tablet after a 3- to 7-day washout period (no participants 4-5 years of age were enrolled)~Participants 6-14 years: A single dose of 5 mg Pbo chewable tablet daily, crossing over to Montelukast 5 mg chewable tablet after a 3- to 7-day washout period"
3291461|NCT00534937|Active Comparator|Standard compression|Patients in this arm will receive current standard of care (once-weekly short-stretch compression wrapping).
3291462|NCT00534937|Experimental|Flexitouch|Patients in this arm will receive once-a-week short stretch compression wrapping AND once-daily Flexitouch pump application (including Flexitouch application once-a-week in the clinic setting).
3291463|NCT00534924|Placebo Comparator|1|No intervention after IR injury
3291464|NCT00534924|Experimental|2|Postconditioning
3291465|NCT00534924|Experimental|3|Vit. C
3291466|NCT00534911|Experimental|Cognitive Behavioral Therapy|Primary & Secondary Control Enhancement Training (PASCET)
3291467|NCT00534911|Active Comparator|Supportive Non-Directive Therapy (SNDT)|Supportive Non-Directive Therapy
3291468|NCT00534885|Experimental|1: Healive® Lot 1|
3291469|NCT00534885|Experimental|2: Healive® Lot 2|
3291470|NCT00534885|Experimental|3: Healive® Lot 3|
3291471|NCT00534885|Active Comparator|4: control vaccine (Havrix)|
3291472|NCT00534872|Experimental|SB649868|10 mg
3291473|NCT00534846|Placebo Comparator|A placebo|The participants were randomly allocated to receive toremifene (20 mg) or placebo during the luteal phase for three consecutive menstrual cycles.
3291474|NCT00534846|Active Comparator|B toremifene|The participants were randomly allocated to receive toremifene (20 mg) or placebo during the luteal phase for three consecutive menstrual cycles.
3291475|NCT00534833|Experimental|Group 1|DTaP-Hep B-PRP-T + OPV vaccine group
3291476|NCT00534833|Active Comparator|Group 2|Tritanrix-HepB/Hib™ + OPV vaccine group
3291477|NCT00534794|Experimental|Elestat|
3291478|NCT00534794|Active Comparator|Pataday|
3291479|NCT00534781|Experimental|A|plasma microtenotomy
3291480|NCT00534781|Active Comparator|B|Standard Surgical Debridement
3291481|NCT00534768|Active Comparator|1|debridement on 1st, 3-5th and 7th postoperative days
3291482|NCT00534768|Active Comparator|2|
3291483|NCT00534755|Other|Breast database|Database
3291484|NCT00534703|Active Comparator|AAV1/SERCA2A|SERCA gene therapy
3291485|NCT00534703|Placebo Comparator|Placebo|Placebo (saline solution)
3291486|NCT00534690|Other|1|
3291487|NCT00534690|Other|2|
3291488|NCT00534677|Active Comparator|A|
3291489|NCT00534677|Active Comparator|B|
3291490|NCT00534638|Experimental|Cervarix/Engerix-B A Group|90% of male and female adolescents will receive GSK Biologicals' HPV Vaccine GSK580299. Rest of the subjects will receive Engerix-B™ vaccine.
3291583|NCT00533988|No Intervention|5592|Standard triple lumen catheter
3291491|NCT00534638|Experimental|Cervarix/Engerix-B B Group|90% of the female adolescents will receive GSK Biologicals' HPV Vaccine GSK580299. Male adolescents and rest of the female adolescents will receive Engerix-B™ vaccine.
3291492|NCT00534638|Active Comparator|Engerix-B Group|All adolescents will receive Engerix-B™ vaccine.
3291493|NCT00534625|Placebo Comparator|1|
3291494|NCT00534625|Experimental|2|150 mg zileuton by intravenous injection
3291495|NCT00534625|Experimental|3|300 mg zileuton by intravenous injection
3291496|NCT00534612|Experimental|1|fine needle aspiration biopsy of the parotid gland mass
3291497|NCT00534599|Other|1|Adjunctive Placebo Seroquel XR to anxiety treatment
3291498|NCT00534599|Experimental|2|Adjunctive Seroquel XR to anxiety treatment
3291499|NCT00534586|Active Comparator|1|remifentanil
3291500|NCT00534586|Active Comparator|2|propofol
3291501|NCT00534586|Active Comparator|3|sevoflurane
3291502|NCT00534586|Active Comparator|4|s-ketamine
3291503|NCT00534573|Active Comparator|Moclobemide,|treatment during 2 weeks
3291504|NCT00534573|Active Comparator|Amisulpride|Comparison
3291505|NCT00534560|Experimental|1|
3291506|NCT00534560|Experimental|2|
3291507|NCT00534560|Placebo Comparator|3|
3291508|NCT00534534|Active Comparator|1|All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion. No drugs will be used. In addition, they also will undergo repeated similar interventions at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
3291509|NCT00534534|No Intervention|Standard|All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion. No drugs will be used. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
3291510|NCT00534521|Active Comparator|Active Treatment Arm|Subjects will have their leg and foot draped to remain blinded to the test. They will be in a supine position with the knees abducted and flexed. The medial aspect of the lower extremity is palpated and a needle insertion site is identified. Between the posterior margin of the tibia and the soleus muscle, an acupuncture-like needle is inserted. An adhesive grounding pad is placed on the bottom of the foot just below the smallest toe. The needle and grounding pad are connected to the stimulator and the stimulation is increased as tolerated.
3291511|NCT00534521|Sham Comparator|Sham Arm|"Since subjects with the PTNS will feel foot stimulation, the sham was devised to mimic this feeling without the tibial nerve being stimulated. Again the leg and foot will be draped and out of view from the subject. The medial aspect of the lower extremity is palpated (Figure 4) and the tibial nerve site is identified approximately 5 cm cephalad from the medial malleolus. A Streitberger needle is used at the tibial nerve insertion site to simulate needle placement without puncturing the skin. The needle will be taped in place as in the PTNS procedure. The grounding pad will be a gel electrode pad from a TENS unit device that is placed on the bottom of the foot just below the smallest toe."
3291512|NCT00534495|Experimental|Group 1|Loading dose of rilonacept (4.4mg/kg) at Week 0, followed by rilonacept 2.2 mg/kg/week for the remainder of the study
3291513|NCT00534495|Placebo Comparator|Group 2|Placebo for 4 weeks, followed by rilonacept loading dose (4.4mg/kg), followed by rilonacept 2.2 mg/kg/week for the remainder of the study
3291514|NCT00534482|Experimental|A, 1, I|Practice-level treatment group
3291515|NCT00534482|Active Comparator|A, 1, II|Practice-level comparison group
3291516|NCT00534482|Experimental|B, 1, I|Patient-level treatment group
3291517|NCT00534482|Active Comparator|B, 1, II|Patient-level comparison group
3291518|NCT00534469|Active Comparator|HD ARA-C with Idarubicin|HD ARA-C with Idarubicin Consolidation, Busulfan/FTBI/VP16/PSC/BMT
3291519|NCT00534469|Active Comparator|HD ARA-C without Idarubicin|HD ARA-C Consolidation, Busulfan/FTBI/VP16/PSC/BMT
3291520|NCT00534456|Experimental|Active|
3291521|NCT00534456|Placebo Comparator|Placebo|
3291522|NCT00534443|Experimental|1|A total of 130 patients with peptic ulcer disease and /or chronic gastritis will be enrolled in the study after written informed consent. Patients will be prescribed oral treatment with rabeprazole or esomeprazole according to standard guidelines. Rabeprazole is administered 20mg twice daily and esomeprazole 10 mg once daily. Selection of rabeprazole or esomeprazole is at the discretion of the attending physicians. The drug is administered for four weeks in patients with duodenal ulcers, for eight weeks in patients with gastric ulcers and for four weeks in patients with chronic gastritis.
3291523|NCT00534430|Experimental|Busulfan, FTBI and VP16|IV Busulfan + 12 cGy FTBI + VP16 prior to allogeneic Bone Marrow Transplant
3291524|NCT00534417|Experimental|Capecitabine and fulvestrant|"Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po AM and 500 mg po PM in patients of body weight < 80 kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 kg.~Fulvestrant will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days."
3291525|NCT00534404|Experimental|NRT Patch, Phone Counseling, Internet|As adjuncts to internet-assisted tobacco treatment (iQuit Smoking website), research participants in this arm will have access to free 8-week supply of nicotine patches, contingent upon participation in proactive telephone counseling. Patch therapy will begin with the 21 mg patch for 4 weeks, followed by 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks.
3291526|NCT00534404|Active Comparator|Nicotine Patches and Internet|As adjuncts to internet-assisted tobacco treatment (iQuit Smoking website), research participants in this arm will have access to free 8-week supply of nicotine patches. Patch therapy will begin with the 21 mg patch for 4 weeks, followed by 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks.
3291527|NCT00534404|Placebo Comparator|Internet|Research participants in this arm will have free access to internet-assisted tobacco treatment (iQuit Smoking website).
3291528|NCT00534391|Placebo Comparator|B|Artificial tear containing antibiotic solution base
3291529|NCT00534391|Experimental|A|combined antibiotic ophthalmic solution (neomycin sulfate, polymyxin B sulfate and gramicidin)
3291530|NCT00534378|No Intervention|1|
3291531|NCT00534365|Active Comparator|1|Tension-free vaginal tape procedure (TVT)
3291532|NCT00534365|Active Comparator|2|TVT-SECUR device
3291848|NCT00531700|Experimental|III|Exposure to reports about influenza related contextualized risk
3291534|NCT00534326|Active Comparator|1|Standard Reaming of femoral shaft fracture prior to intramedullary nailing
3291535|NCT00534326|Active Comparator|2|Reamer/Irrigator/Aspirating of femoral shaft fracture prior to intramedullary nailing
3291536|NCT00534313|Active Comparator|Abatacept (30/10)|Abatacept (30 mg/kg) was administered as intravenous (iv) infusion over approximately 30 minutes on Days 1 and 15, followed by 10 mg/kg (fixed dose) abatacept infusion on Day 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants for dosing on Days 1 and 15 followed by fixed dosing as per rheumatoid arthritis label (participants weighing <60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing >100 kg received 1000 mg) thereafter.
3291537|NCT00534313|Active Comparator|Abatacept (10/10)|Abatacept (10 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141 in the double-blind period and continued for next 18 months in the open-label period till Day 729. All participants received a dose based on their screening visit weight as per rheumatoid arthritis label (participants weighing <60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing >100 kg received 1000 mg).
3291538|NCT00534313|Active Comparator|Abatacept (3/3)|Abatacept (3 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants.
3291539|NCT00534313|Placebo Comparator|Placebo|Placebo solution (5% dextrose in water for injection, 0.9% sodium chloride injection) by iv infusion was administered on Days 1, 15, and 29 and every 28 days thereafter till Day 141.
3291540|NCT00534300|Experimental|A|
3291541|NCT00534300|Placebo Comparator|B|
3291542|NCT00534287|Active Comparator|MeroMono|Monotherapy with meropenem
3291543|NCT00534287|Active Comparator|MeroMoxi|Combination therapy with meropenem + moxifloxacin
3291544|NCT00534274|Experimental|TEP FLT|
3291545|NCT00534261|Experimental|1|patients received Avonex IM injections and be evaluated for quality of life criteria
3291546|NCT00534248|Experimental|Zostavax™|Participants randomized to receive Zoster Vaccine, Live (Zostavax™).
3291547|NCT00534248|Placebo Comparator|Placebo|Participants randomized to receive Placebo.
3291548|NCT00534235|Active Comparator|Posterolateral Fusion w/Pedicle Screws|Control: Posterolateral fusion and implantation of pedicle screws after decompression
3291549|NCT00534235|Active Comparator|coflex Interlaminar Technolgy|Investigative: Implantation of coflex Interlaminar Technology after decompression
3291550|NCT00534222||Quetiapine|
3291551|NCT00534222||Olanzapine|
3291552|NCT00534222||Risperidone|
3291553|NCT00534209|Experimental|Arm I: Allogeneic B7.1/HLA-A1|"Patients will receive Allogeneic B7.1/HLA-A1 vaccine once every other week for 2 courses over 12 weeks, for a maximum of 6 vaccines.~Given intradermally."
3291554|NCT00534209|Placebo Comparator|Arm II: Placebo|Patients receive a placebo vaccine intradermally once every other week for 2 courses over 12 weeks, for a maximum of 6 vaccines.
3291555|NCT00534196||Group under operation of brachytherapy|Patients with histologically confirmed adenocarcinoma of the prostate and who are planning to undergo brachytherapy with PI (permanent iodine) or combination of PI with other tratement.
3291556|NCT00534183|Experimental|1|Olanzapine
3291557|NCT00534183|Active Comparator|2|Risperidone
3291558|NCT00534183|Active Comparator|3|haloperidol
3291559|NCT00534170|Experimental|A,F,T,K|Two arms are for intervention and two are for control or placebo
3291560|NCT00534144|Active Comparator|Iron Sucrose|
3291561|NCT00534144|Active Comparator|Ferric Gluconate|
3291562|NCT00534131|Active Comparator|Arm 1|Patients for whom a standard abdominal approach is adequate to excise the distal third of the rectum (without jeopardising oncological clearance if appropriate).
3291563|NCT00534131|Experimental|Arm 2|Combined abdominal and trans-perineal approach to excise the distal third of the rectum, while preserving the anal canal
3291564|NCT00534131|Active Comparator|Arm 3|Standard proctectomy to excise the distal third of the rectum and the anal canal
3291565|NCT00534118|Experimental|Infusion|Patients receive up to four donor lymphocyte infusions at least 1 month apart in the absence of disease progression, unacceptable toxicity, or uncontrolled graft-versus-host disease
3291566|NCT00534105||Gestational Diabetics|Patients with Gestational Diabetes
3291567|NCT00534105||2|Normal pregnant women without gestational diabetes
3291568|NCT00534079|Experimental|Dornase alfa|28 days of sinonasal inhalation (Pari Sinus)
3291569|NCT00534079|Placebo Comparator|isotonic saline|28 days of sinonasal inhalation (Pari Sinus)
3291570|NCT00534066|Other|Admitted|Patients presenting to the ED with acute exacerbation of CHF who require admission to the hospital directly from the ED
3291571|NCT00534066|Other|Observational|Patients who present to the ED for acute exacerbation of CHF who are transferred to the Observation Unit from the ED for up to 24 hours.
3291572|NCT00534053|Experimental|1|400 patients will be given a mailed educational reminder 10 days after picking up their FOBT cards from the VA laboratory.
3291573|NCT00534053|No Intervention|2|400 patients will not receive a mailed educational reminder to return their FOBT cards after they have picked up the FOBT cards from the VA laboratory
3291574|NCT00534027|Experimental|Arm 2|Low Dose AMG 655 with paclitaxel/carboplatin
3291575|NCT00534027|Placebo Comparator|Arm 3|Placebo with paclitaxel/carboplatin
3291576|NCT00534027|Experimental|Arm 1|AMG 655 High doseplus paclitaxel/carboplatin
3291577|NCT00534014|Placebo Comparator|A|0 mg of Vitamin C
3291578|NCT00534014|Active Comparator|B|250 mg Vitamin C
3291579|NCT00534014|Active Comparator|C|500 mg Vitamin C
3291580|NCT00534014|Active Comparator|D|1000 mg Vitamin C
3291581|NCT00534001|Experimental|Arm I (1-week run-in)|Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
3291582|NCT00534001|Experimental|Arm II (4-week run-in)|Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
3291584|NCT00533988|Active Comparator|5593|Antimicrobial impregnated catheter (chlorhexidine silver-sulfadiazine)
3291585|NCT00533949|Active Comparator|60 Gy RT|60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
3291586|NCT00533949|Experimental|74 Gy RT|74 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
3291587|NCT00533949|Experimental|60 Gy RT + Cetuximab|60 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin
3291588|NCT00533949|Experimental|74 Gy RT + Cetuximab|74 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin
3291589|NCT00533910|Placebo Comparator|Placebo|Will be given placebo and follow the exact procedures as the experimental section
3291590|NCT00533910|Experimental|Drug|
3291591|NCT00533897|Experimental|Abatacept|
3291592|NCT00533897|Placebo Comparator|Placebo|
3291593|NCT00533884||Treatment|Patients undergoing treatment for head and neck, lung, and esophagus cancers
3291594|NCT00533871|Control|Normotensive|Pregnant women in the third trimester with normal blood pressure this pregnancy and no history of HTN or pre-eclampsia in a previous pregnancy
3291595|NCT00533871|Other|Chronic Hypertensive|Pregnant women in their third trimester with known hypertension prior to the current pregnancy
3291596|NCT00533871|Other|Pre-eclampsia|Pregnant women in their third trimester who meet ACOG diagnostic criteria for pre-eclampsia
3291597|NCT00533845|Experimental|Bupivacaine|On-Q pump containing Bupivacaine implanted
3291598|NCT00533845|Placebo Comparator|Placebo/control|Saline used in the implanted On-Q device
3291599|NCT00533832|Active Comparator|1|Patients implanted with the vagus nerve stimulation (VNS) device and receiving VNS Intervention: vagus nerve stimulation (VNS)
3291600|NCT00533832|Placebo Comparator|2|Implanted with vagus nerve stimulation (VNS) device, but not receiving VNS
3291601|NCT00533819|Experimental|1|
3291602|NCT00533819|No Intervention|2|would have routine physical activity
3291603|NCT00533806|Experimental|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy.
3291604|NCT00533806|Active Comparator|Relaxation therapy.|Participants will receive relaxation therapy.
3291605|NCT00533793|Active Comparator|SoC|Standard of Care
3291606|NCT00533793|Active Comparator|SoC plus 0.133 mg/mL|
3291607|NCT00533793|Active Comparator|SoC plus 0.4 mg/mL|
3291608|NCT00533793|Active Comparator|SoC plus 1.0 mg/mL|
3291609|NCT00533741|Experimental|1c (10 mcg)|4 subjects randomized in a 1:3 fashion to receive a two dose regimen of placebo or vaccine with 10 mcg of antigen and no adjuvant.
3291610|NCT00533741|Experimental|2 (dose comparison stage)|54 subjects (9 per vaccine group) randomized 1:1:1:1:1:1 to receive vaccines containing, 2.5, 5.0, or 10.0 mcg of antigen without adjuvant, or 2.5 or 5.0 mcg of antigen with Alum, or placebo.
3291611|NCT00533741|Experimental|1a (2.5 mcg)|7 subjects randomized in a 1:3:3 fashion to receive a 2 dose regimen of placebo, vaccine containing 2.5 mcg of antigen and no adjuvant, or 2.5 mcg of antigen and Alum adjuvant.
3291612|NCT00533741|Experimental|1b (5.0 mcg)|7 subjects randomized in a 1:3:3 fashion to receive a 2 dose regimen of placebo, vaccine containing 5.0 mcg of antigen and no adjuvant, or 5.0 mcg of antigen and Alum adjuvant.
3291613|NCT00533715|Control|>100|"The study included healthy children (2.5-6.5 years old) from a number of public kindergartens. An initial screening questionnaire based on the ATA-DLD-78-A for adults, adapted for children and translated into Hebrew, concerning the child's birth, past and present health status, was completed by the parents.~Exclusion criteria: Previous symptoms or treatment for asthma, current respiratory symptoms or other present respiratory diseases."
3291614|NCT00533702|Experimental|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab)
3291615|NCT00533702|Active Comparator|IMC-1121B (ramucirumab) + dacarbazine|IMC-1121B (ramucirumab) + dacarbazine
3291616|NCT00533663|Experimental|Healing Touch (HT)|A a gentle, non-invasive form of energy-balancing work that promotes relaxation and can help manage the side effects of chemotherapy. It occurs every other week (during their infusion).
3291617|NCT00533663|Active Comparator|Guided relaxation|Guided relaxation every other week (during their infusion).
3291618|NCT00533663|Active Comparator|standard care|Standard care
3291619|NCT00533637|Experimental|1|NLA Nasal Spray
3291620|NCT00533637|Active Comparator|2|
3291621|NCT00533637|Placebo Comparator|3|
3291622|NCT00533624|Active Comparator|1: Myfortic|Myfortic Group: Myfortic® 1,440 mg/day in two divided doses (induced with either the IL-2 receptor inhibitors or thymoglobulin). Tacrolimus will be dosed to 12-hour trough levels of 8-10 ng/ml. Methylprednisolone is to be given as per our center protocols, weaning to dose levels of <0.1 mg/kg by 3-6 months post-operatively.
3291623|NCT00533624|Active Comparator|2. Cellcept|Cellcept® 2,000 mg/day, in divided doses (induced with either the IL-2 receptor inhibitors or thymoglobulin). Tacrolimus will be dosed to 12-hour trough levels of 8-10 ng/ml. Methylprednisolone is to be given as per our center protocols, weaning to dose levels of <0.1 mg/kg by 3-6 months post-operatively.
3291624|NCT00533585|Experimental|BAY 43-9006 + Bevacizumab|BAY 43-9006 (Sorafenib) + Bevacizumab + Paclitaxel + Carboplatin
3291625|NCT00533559|Experimental|buphenyl|
3291626|NCT00533559|Placebo Comparator|Placebo|
3291627|NCT00533546|Experimental|Tier One|Participants will receive APC by intravenous injection, receiving 50% of dose as a bolus and the remainder as an infusion over one ho.
3291628|NCT00533520|Active Comparator|0.5mg ranibizumab|Subjects will be treated with 0.5mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
3291629|NCT00533520|Active Comparator|1.0mg ranibizumab|Subjects will be treated with 1.0mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
3291630|NCT00533520|Active Comparator|2.0mg ranibizumab|Subjects will be treated with 2.0 mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
3291849|NCT00531700|Active Comparator|IV|Comparison group exposed to community level health promotion messages not generated by the study
3291631|NCT00533507|Experimental|Synflorix group|Subjects receiving Synflorix co-administered with Infanrix™ hexa at 1.5, 3 and 6 months of age, and co-administered with Rotarix™ at 1.5 and 3 months of age.
3291632|NCT00533494|Active Comparator|B|Feedback to physicians + reminder letters to patients
3291633|NCT00533494|Active Comparator|A|Feedback information to physicians
3291634|NCT00533442|Active Comparator|Tacrolimus plus MMF plus Steroids|Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Mycophenolate Mofetil (MMF), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.
3291635|NCT00533442|Experimental|Tacrolimus plus Rapamycin plus Steroids|Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Rapamycin (Sirolimus), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.
3291636|NCT00533429|Experimental|A|
3291637|NCT00533429|Placebo Comparator|B|
3291638|NCT00533390|Experimental|EFAVIRENZ 800mg|Efavirenz 800 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin
3291639|NCT00533390|Active Comparator|EFAVIRENZ 600mg|Efavirenz 600 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin
3291640|NCT00533377|Experimental|CP-533,536 Dose Level 2|
3291641|NCT00533377|Placebo Comparator|Placebo|
3291642|NCT00533377|Other|Standard of Care|
3291643|NCT00533377|Experimental|CP-533,536 Dose Level 1|
3291644|NCT00533377|Experimental|CP-533,536 Dose Level 3|
3291645|NCT00533377|Experimental|CP-533.536 Dose Level 4|
3291646|NCT00533351|Experimental|AGN201781|AGN201781 50 mg capsules three-time daily for 2 weeks
3291647|NCT00533351|Placebo Comparator|Placebo|placebo 50 mg capsules three-times daily for 2 weeks
3291648|NCT00533338|Experimental|Weight Gain Prevention Program|Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling. Packet of questionnaires will be completed.
3291649|NCT00533338|Active Comparator|Standard Care Group|Packet of questionnaires will be completed.
3291650|NCT00533299|Experimental|1|Topotecan hydralazine valproate
3291651|NCT00533299|Placebo Comparator|2|Placebo, hydralazine, valproate
3291652|NCT00533286|Placebo Comparator|A|placebo (2 tablets daily)
3291653|NCT00533286|Experimental|B|diazepam (2 x 5 mg)
3291654|NCT00533273|Experimental|AA4500 0.58 mg|
3291655|NCT00533273|Placebo Comparator|Placebo|
3291656|NCT00533221|Active Comparator|Somatotropin|subcutaneous application of somatotropin over 12 weeks followed by 8 weeks wash out period followed by 12 weeks subcutaneous placebo application
3291657|NCT00533221|Placebo Comparator|Placebo|12 weeks placebo subcutaneous application followed by 8 weeks wash out and 12 weeks subcutaneous application of somatotropin
3291658|NCT00533195|Active Comparator|0|5-MOP photochemotherapy. Intake of Geralen capsules (1.2 mg/kg) 2 hours before irradiation. Determination of the minimal phototoxic dose (MPD) and Geralen serum level prior to treatment. Start with 70 % of the MPD, no dose increments in the first treatment week. From the second week increments of the UVA dose by 20 % in the absence of an erythemal reaction, respectively by 10 % in cases of a barely perceptible erythemal response. Increments of the UVA dose at the earliest 96 hours after the last increments. Treatment frequency 3 x week for 5 weeks (=15 exposures). No maintenance therapy except emollients.
3291659|NCT00533195|Experimental|1|UVA1 phototherapy. Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability. No maintenance therapy except emollients.
3291660|NCT00533169|Experimental|ZD6474 + Retinoic Acid|Part A = ZD6474 Alone, Starting dose 50 mg/m^2 by mouth daily for 28 days; Part B, C = ZD6474 + Retinoic Acid 80 mg/m^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
3291661|NCT00533143|Experimental|2|Non-invasive ventilation
3291662|NCT00533130|Case|1|Pediatric patients under 16 years old with long bones fractures
3291663|NCT00533117|Experimental|Dialectical Behavior Therapy Fluoxetine|Dialectal behavior therapy (DBT) is a form of Cognitive behavior therapy (CBT) targeting suicidal and non-suicidal self injury in borderline personality disorder and is delivered over a 12 month period,and fluoxetine, a selective serotonin reuptake inhibitor (SSRI) that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
3291664|NCT00533117|Placebo Comparator|Dialectical Behavior Therapy placebo|Dialectal behavior therapy and placebo Dialectal behavior therapy (DBT) is a form of Cognitive behavior therapy targeting suicidal and non-suicidal self injury in borderline personality disorder and is delivered over a 12 month period, and placebo for fluoxetine, an SSRI that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
3291665|NCT00533117|Experimental|Supportive therapy Fluoxetine|Supportive psychotherapy and fluoxetine Supportive therapy is a manualized psychotherapy aimed at strengthening coping skills and is delivered over a 12 month period, and fluoxetine, an SSRI that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
3291666|NCT00533117|Active Comparator|Supportive therapy placebo|Supportive psychotherapy and placebo See above for descriptions.
3291667|NCT00533104|Experimental|BM-MNC|Patients are implanted with bone marrow - mononuclear cells
3291668|NCT00533104|Experimental|PB-MNC|Patients are implanted with peripheral blood - mononuclear cells
3291669|NCT00533091|Active Comparator|1|MEDI-545
3291670|NCT00533091|Other|2|Placebo
3291671|NCT00533078|Other|1|
3291672|NCT00533052|Experimental|Affective and Cognitive Skills Training|Standard Behavioral Weight Loss Treatment Plus Affective and Cognitive Skills Training
3291673|NCT00533039|Placebo Comparator|Control|Subjects take 2 tablets BID. Placebo tablets are identical to active medication.
3291674|NCT00533039|Experimental|Varespladib (A-002)|Subjects take 250mg tablets BID beginning 3-5 days pre-angioplasty and for 5 days post-angioplasty.
3291792|NCT00532155|Placebo Comparator|Aflibercept/Docetaxel|Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Aflibercept immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
3291675|NCT00533026|Active Comparator|A|Subjects received warfarin QD, PO for approximately 12 days. Subjects with stabilized INR after approximately 12 days continued to receive warfarin QD, PO for an additional 14 days and also received duloxetine 60mg QD, PO for the 14 days. Duloxetine doses were tapered, subjects received 30mg QD, PO for 4 days. No warfarin was received during the taper phase.
3291676|NCT00533026|Active Comparator|B|Subjects received warfarin QD, PO for approximately 12 days. Subjects with stabilized INR after approximately 12 days continued to receive warfarin QD, PO for an additional 14 days and also received duloxetine 60 mg QD, PO for 4 days followed by duloxetine 120 mg QD, PO for 10 days. Duloxetine doses were tapered, subjects received 60mg QD, PO for 4 days followed by 30mg QD, PO for 4 days. No warfarin was received during the taper phase.
3291677|NCT00533013|Active Comparator|Usual care|Management of heart failure is provided by primary practitioners and consultant cardiologists
3291678|NCT00533013|Experimental|Disease Management|Disease management led by nurse specialists in regional Heart Failure Clinics and a national Call Center. Tele-Monitoring of body weight, pulse rate and blood pressure is performed at participants' homes.
3291679|NCT00533000|Experimental|A|Smoking cessation
3291680|NCT00533000|No Intervention|B|
3291681|NCT00532961|Experimental|Zylet|Zylet (loteprednol etabonate and tobramycin)
3291682|NCT00532961|Active Comparator|Tobradex|TobraDex (dexamethasone and tobramycin)
3291683|NCT00532948|Experimental|1|
3291684|NCT00532935|Experimental|1|Sitagliptin phosphate (+) metformin hydrochloride
3291685|NCT00532935|Active Comparator|2|pioglitazone
3291686|NCT00532922||1|Chinese asthma patient prescribed Symbicort® Turbuhaler®
3291687|NCT00532896||bariatric surgery|patients with morbid obesity undergoing a bariatric surgery
3291688|NCT00532896||No bariatric surgery|patients with morbid obesity on a waiting list for a bariatric surgery but who will have their surgery in more than one year.
3291689|NCT00532883|Placebo Comparator|Placebo Pills and Placebo Liquid|
3291690|NCT00532883|Active Comparator|Hydroxyurea Pills and Placebo Liquid|
3291691|NCT00532883|Active Comparator|Placebo Pills and Magnesium Pidolate Liquid|
3291692|NCT00532883|Active Comparator|Hydroxyurea Pills and Magnesium Pidolate Liquid|
3291693|NCT00532870|Active Comparator|1|laparoscopy
3291694|NCT00532857|Experimental|Paclitaxel/Gemcitabine/Trastuzumab|
3291695|NCT00532844|Experimental|6R-BH4|6R-BH4 5 mg/kg BID for 13.5 days
3291696|NCT00532844|Experimental|6R-BH4 + Vitamin C|6R-BH4 5 mg/kg BID + 500 mg Vitamin C BID for 13.5 days
3291697|NCT00532831||Obese asthmatics|Obese subjects with asthma (on inhaled bd only)
3291698|NCT00532831||Non-obese asthmatics|Non-obese subjects with asthma(on inhaled bd only)
3291699|NCT00532818|Placebo Comparator|1|
3291700|NCT00532818|Experimental|2|
3291701|NCT00532792|Experimental|Group 1|
3291702|NCT00532792|Experimental|Group 2|
3291703|NCT00532792|Experimental|Group 3|
3291704|NCT00532792|Experimental|Group 4|
3291705|NCT00532792|Experimental|Group 5|
3291706|NCT00532792|Experimental|Group 6|
3291707|NCT00532792|Experimental|Group 7|
3291708|NCT00532792|Experimental|Group 8|
3291709|NCT00532792|Experimental|Group 9|
3291710|NCT00532792|Placebo Comparator|Group 10|
3291711|NCT00532779|Experimental|NB16|Naltrexone SR 16 mg/Bupropion SR 360 mg /day with ancillary therapy
3291712|NCT00532779|Experimental|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg /day with ancillary therapy
3291713|NCT00532779|Placebo Comparator|Placebo|Placebo with ancillary therapy
3291714|NCT00532766|Experimental|2|Jusline Humulin
3291715|NCT00532740||All Patients|Patients with metastatic cancer of the liver who are not surgical resection candidates and who will be treated with TheraSphere per institutional standard of care.
3291716|NCT00532727|Experimental|Arm A|Carboplatin
3291717|NCT00532727|Active Comparator|Arm B|Docetaxel
3291718|NCT00532714|No Intervention|Irinotecan plus capecitabine|Irinotecan 80 mg/m2 (intravenously once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period) Capecitabine (orally at a dose of 1,000 mg/m2 twice daily 3-week cycles (2 weeks of treatment followed by a 1-week rest period))
3291719|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 16 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-16 in patients with RVR
3291720|NCT00532701|Active Comparator|Peg-IFN + LD RBV for 16 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-6, and then low dose ribavirin (800 mg/day) from weeks 6-16 in patients with RVR
3291721|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 24 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-24 in patients without RVR
3291722|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 48 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-48 in patients without RVR
3291723|NCT00532701|Active Comparator|Peg-IFN + LD RBV for 24 weeks|Low dose ribavirin (800 mg/day) from weeks 1-24 in patients with or without RVR
3291724|NCT00532688|Experimental|1|5 patients: 28 days of n-acetylcysteine (in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period.
3291725|NCT00532688|Placebo Comparator|2|28 days of oral distilled water (5ml) (in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to intervention (N-acetylcysteine 500mg oral bd) for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
3291726|NCT00532675|Experimental|Panobinostat|
3291727|NCT00532662|Experimental|1|epidural s(+)-ketamine for supplementation of caudal anesthesia
3291728|NCT00532662|Active Comparator|2|intravenous ketamine for supplementation of caudal anesthesia
3291729|NCT00532636|Active Comparator|1|Children 1-5 years of age
3291730|NCT00532636|Active Comparator|2|Children 6-10 years of age
3291731|NCT00532623|Active Comparator|Combination|
3291732|NCT00532623|Active Comparator|Seqeuntial|"Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."
3291733|NCT00532597|Experimental|O|
3291734|NCT00532597|Active Comparator|L|
3291735|NCT00532584|Experimental|treatment with inhaled beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
3291736|NCT00532584|No Intervention|Control - healthy smokers|Group B will act as control and include healthy smokers who receive no treatment.
3291737|NCT00532584|No Intervention|control - healthy non-smokers|Group C will act as control and include healthy non-smokers who receive no treatment.
3291738|NCT00532558|Experimental|Lapaquistat Acetate 50 mg QD|
3291739|NCT00532558|Placebo Comparator|Placebo QD|
3291740|NCT00532545|Experimental|A|Teriparatide
3291741|NCT00532532|Experimental|1|AV650 low dose
3291742|NCT00532532|Experimental|2|AV650 high dose
3291743|NCT00532532|Experimental|3|Placebo
3291744|NCT00532493|Active Comparator|Prazosin Group|Subjects randomized to this arm will be on prazosin.
3291745|NCT00532493|Placebo Comparator|Placebo Group|Subjects randomized to this arm will be on placebo.
3291746|NCT00532480|Other|Duolxetine|Open-label duloxetine 30 - 60 mg oral administration
3291747|NCT00532454|Other|tamoxifen|observation for clinical efficacy on tamoxifen according to CYP2D6 genotype
3291748|NCT00532441|Experimental|Erlotinib and Docetaxel: Biliary|"Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28~Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15"
3291749|NCT00532441|Experimental|Erlotinib and Docetaxel: Hepatocellular|"Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28~Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15"
3291750|NCT00532428|Active Comparator|1|
3291751|NCT00532428|Active Comparator|2|
3291752|NCT00532428|Placebo Comparator|3|
3291753|NCT00532415|Experimental|Triamcinolone|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
3291754|NCT00532389|Experimental|Panobinostat (LBH589)|
3291755|NCT00532363||Obese asthmatics|Obese subjects with asthma (on inhaled corticosteroids)
3291756|NCT00532363||Non obese asthmatics|Non obese subjects with asthma (on inhaled corticosteroids)
3291757|NCT00532350|Experimental|1|QAT370
3291758|NCT00532350|Placebo Comparator|2|Placebo
3291759|NCT00532350|Active Comparator|3|Tiotropium
3291760|NCT00532337|Placebo Comparator|P|
3291761|NCT00532337|Experimental|E1|
3291762|NCT00532337|Experimental|E2|
3291763|NCT00532337|Experimental|E3|
3291764|NCT00532337|Active Comparator|A|
3291765|NCT00532324|No Intervention|A|Pregnant women not receiving CA-MRSA decolonization therapy.
3291766|NCT00532324|Other|B|Pregnant women receiving CA-MRSA decolonization therapy.
3291767|NCT00532311|Experimental|Lapaquistat Acetate 50 mg QD|(and stable statin therapy)
3291768|NCT00532311|Active Comparator|Stable statin therapy|
3291769|NCT00532298|Experimental|GSK576389A- 2006/2007 Season - 1 container Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.
3291770|NCT00532298|Experimental|GSK576389A - 2006/2007 Season - 2 containers Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.
3291771|NCT00532298|Active Comparator|Fluarix 2006/2007 Season Group|Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
3291772|NCT00532298|Experimental|GSK576389A - 2007/2008 Season - 1 container Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.
3291773|NCT00532298|Experimental|GSK576389A - 2007/2008 Season - 2 containers Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.
3291774|NCT00532298|Active Comparator|Fluarix 2007/2008 Season Group|Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
3291775|NCT00532285|Experimental|Paclitaxel/Gemcitabine|paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8) every 3 weeks, 4 cycles
3291776|NCT00532272|Experimental|letrozole|letrozole(2.5mg orally daily)
3291777|NCT00532272|Active Comparator|goserelin plus letrozole|goserelin (3.6mg subcutaneously every 28 days) plus letrozole(2.5mg orally daily)
3291778|NCT00532259|Experimental|CT-011|The monoclonal antibody termed CT-011 (currently, pidilizumab).
3291779|NCT00532246|Experimental|A|raloxifene
3291780|NCT00532246|Placebo Comparator|B|placebo
3291781|NCT00532233|Experimental|1|QAX576
3291782|NCT00532220|Active Comparator|A|
3291783|NCT00532220|Placebo Comparator|B|
3291784|NCT00532207|Experimental|A|
3291785|NCT00532194|Placebo Comparator|A (reference)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral placebo tablet for the duration of chemotherapy and then until protocol defined disease progression occurs.
3291786|NCT00532194|Active Comparator|B (concurrent cediranib)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy only and then an oral daily placebo tablet until protocol defined disease progression occurs.
3291787|NCT00532194|Active Comparator|C (concurrent and maintenance cediranib)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy until protocol defined disease progression occurs.
3291788|NCT00532168|Experimental|1|tenofovir plus emtricitabine plus efavirenz
3291789|NCT00532168|Experimental|2|tenofovir plus emtricitabine plus lopinavir-ritonavir
3291790|NCT00532168|Experimental|3|tenofovir plus emtricitabine plus atazanavir-ritonavir
3291791|NCT00532155|Experimental|Placebo/Docetaxel|Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Placebo immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
3291847|NCT00531700|Experimental|II|Exposure to tailored/targeted health messages
3291793|NCT00532129|Experimental|Rituximab plus Chlorambucil|Participants will receive combination therapy of rituximab plus chlorambucil for first 6 cycles and then chlorambucil alone for a maximum of 6 additional cycles.
3291794|NCT00532116|Active Comparator|A|EMSAM 6mg
3291795|NCT00532116|Active Comparator|B|EMSAM (Selegiline Transdermal System) 12mg
3291796|NCT00532090|Experimental|1|
3291797|NCT00532090|Experimental|2|
3291798|NCT00532090|Experimental|3|
3291799|NCT00532064||Early Cardiotoxicity Detection|Patients with advanced cancer receiving sunitinib malate or sorafenib chemotherapy.
3291800|NCT00532025|Experimental|1|Sorafenib treatment
3291801|NCT00531999|Active Comparator|1|Raltegravir 400 mg twice daily for the first 14 days of the study. Lopinavir/ritonavir 400/100 mg twice daily for the last 14 days of the study
3291802|NCT00531999|Active Comparator|2|"Lopinavir/ritonavir 400/100 mg twice daily for the first 14 days of the study.~Raltegravir 400 mg twice daily for the last 14 days of the study."
3291803|NCT00531986|Experimental|Monotherapy|Ritonavir-boosted lopinavir (Kaletra®) will be used as monotherapy
3291804|NCT00531986|Active Comparator|Continued ART|Continuation Therapy, conventional triple HAART
3291805|NCT00531973|Experimental|A|Liposomal doxorubicin
3291806|NCT00531973|Active Comparator|B|epirubicin
3291807|NCT00531960|Active Comparator|Bevacizumab, Chemotherapy|Participants received bevacizumab, 15 milligrams (mg) per (/) kilogram (kg), intravenously (IV), on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received 4 to 6 cycles of a standard platinum-containing regimen of chemotherapy: either gemcitabine, 1250 mg/ square meter (m^2), IV, on Days 1 and 8 of Cycles 1 through 4 or 6, and cisplatin 80 mg/m^2, IV, on Day 1 of Cycles 1 through 4 or 6; or paclitaxel, 200 mg/m^2, IV, and carboplatin area under the curve (AUC) 6 mg/ milliliter (ml) multiplied by (*) minute (min) on Day 1 of Cycles 1 through 4 or 6. The chemotherapy regimen and number of cycles was up to the discretion of the investigator.
3291808|NCT00531960|Experimental|Bevacizumab, Erlotinib|Participants received bevacizumab, 15 mg/kg, IV, on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received erlotinib, 150 mg, orally (PO), daily until disease progression, unacceptable toxicity, death, or withdrawal.
3291809|NCT00531947|Experimental|EMSAM|Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg
3291810|NCT00531947|Placebo Comparator|Placebo|Placebo Selegiline Transdermal System 6, 9 or 12
3291811|NCT00531934|Experimental|1|
3291812|NCT00531934|Active Comparator|2|
3291813|NCT00531921||Kidney transplants|patients from 5 specific sites
3291814|NCT00531921||Liver transplants|patients from 5 specific sites
3291815|NCT00531921||Heart transplants|patients from 5 specific sites
3291816|NCT00531921||Lung transplants|patients from 5 specific sites
3291817|NCT00531908|Experimental|A|To compare natriuretic effect of a single dose administration of amiloride (20 mg) in patients with acromegaly
3291818|NCT00531882|Experimental|1-pioglitazone|Pioglitazone
3291819|NCT00531882|Experimental|2-simvasatin|Simvastatin
3291820|NCT00531882|Active Comparator|3-Ibuprofen 1000-1600 mg/day|Ibuprofen 1000-16-- mg/day, maximum 3200 mg/day
3291821|NCT00531856|Experimental|1|5.97 mg/L of carbon monoxide in 30% oxygen
3291822|NCT00531856|Placebo Comparator|2|Oxygen 30% in Nitrogen
3291823|NCT00531843|Experimental|1A|Patients at high risk for venous thromboembolism (criteria: age>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with Abbreviated Injury Scale (AIS) >=3). These patients will receive fondaparinux 2.5mg via subcutaneous administration (SubQ) daily.
3291824|NCT00531843|Active Comparator|1B|Patients at high risk for venous thromboembolism (criteria: age>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with AIS >=3) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure with creatine clearance <30 mL/min, head injury with head AIS >=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression.
3291825|NCT00531843|Experimental|2A|Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days >3, 2 or more high risk factors). These patients will receive fondaparinux 2.5mg SubQ daily and mechanical compression.
3291826|NCT00531843|Active Comparator|2B|Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days >3, 2 or more high risk factors) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure creatine clearance <30 mL/min, head injury with head AIS >=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression and possibly temporary inferior vena cava (IVC) filter(as determined by the patient's care givers).
3291827|NCT00531830|Treatment Comparison|1|Preschool children with PDD
3291828|NCT00531830|Control|2|Preschool children without PDD
3291829|NCT00531817|Experimental|Tocilizumab 8 mg/kg + DMARDs|
3291830|NCT00531817|Placebo Comparator|Placebo + DMARDs|
3291831|NCT00531804|Experimental|1|
3291832|NCT00531791|Active Comparator|1|
3291833|NCT00531791|Experimental|2|
3291834|NCT00531778||NYU OCEDP Population|
3291835|NCT00531765|Active Comparator|1|hydration with normal saline
3291836|NCT00531765|Experimental|2|hydration with sodium bicarbonate
3291837|NCT00531752|Experimental|Flexible Dose|
3291838|NCT00531752|Placebo Comparator|Placebo|
3291839|NCT00531752|Experimental|Fixed Dose|
3291840|NCT00531739|No Intervention|A|Colorectal Surgery without use of SurgiWrapTM
3291841|NCT00531739|Active Comparator|B|Colorectal Surgery with use of SurgiWrapTM film secured in two study areas: the posterior pelvic rim and directly below the abdominal incision
3291842|NCT00531726|Sham Comparator|B|
3291843|NCT00531726|Experimental|A|
3291844|NCT00531713|No Intervention|1|Usual T4 dose is given
3291845|NCT00531713|Active Comparator|2|20 microgram of T3 is given and 50 microgram of T4 is withdrawn
3291846|NCT00531700|Experimental|I|Exposure to both tailored/targeted health messages about influenza and also to reports about contextualized influenza risk
3291850|NCT00531687|Other|GCT|cisplatin Paclitaxel gemcitabine
3291851|NCT00531674|Experimental|1|Nutritional supplementation for pregnant and lactating women
3291852|NCT00531674|Experimental|2|Nutritional supplementation for children
3291853|NCT00531661|Active Comparator|TREATMENT Group|Standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System
3291854|NCT00531661|Placebo Comparator|CONTROL Group|Standard of care HF management
3291855|NCT00531648|Case|1|Families with toddlers that having feeding disorders and SPD
3291856|NCT00531622|Experimental|Saredudant/Escitalopram|Saredutant 100 mg and Escitalopram 10 mg once daily for a maximum of 8 weeks
3291857|NCT00531622|Active Comparator|Placebo and Escitalopram|Placebo for saredutant and Escitalopram 10 mg once daily for a maximum of 8 weeks
3291858|NCT00531622|Placebo Comparator|Placebo|Placebo for saredutant and Placebo for Escitalopram once daily for one week during the screening phase and for a maximum of 8 weeks during the active phase
3291859|NCT00531596|Active Comparator|A|EMSAM 6mg/24hr
3291860|NCT00531596|Active Comparator|B|EMSAM 9mg/24Hr
3291861|NCT00531596|Active Comparator|C|EMSAM 12mg/24Hr
3291862|NCT00531557|Other|1|Darunavir 600mg BID with ritonavir 100mg BID administered orally.
3291863|NCT00531518|No Intervention|Control group|This is the control arm. Participants will be offered only case management. Participants may seek outside treatment, without guidance from study staff.
3291864|NCT00531518|Experimental|Family-aided Assertive Community Treatment|This is the experimental intervention arm for high-risk-for-psychosis participants. The intervention includes psychiatric drugs (aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine), psychoeducational multifamily group treatment and supported employment and education .
3291865|NCT00531505||2a|Morbid Obese individuals undergoing bariatric surgery (i.e. Laparoscopic Banding, Gastric Bypass). These individuals are a subset population of the greater Longitudinal Assessment of Bariatric Surgery (LABS-1) study population. This subpopulation engaged in memory tests as well as tissue extraction.
3291866|NCT00531492|Experimental|A|
3291867|NCT00531492|Active Comparator|B|
3291868|NCT00531479|Active Comparator|Voriconazole|Voriconazole monotherapy
3291869|NCT00531479|Experimental|Voriconazole and Anidulafungin|Combination therapy with voriconazole and anidulafungin
3291870|NCT00531466|Active Comparator|1|
3291871|NCT00531466|Placebo Comparator|2|
3291872|NCT00531453|Experimental|1|bortezomib, dexamethasone, and thalidomide
3291873|NCT00531453|Experimental|2|bortezomib, dexamethasone, thalidomide, and cyclophosphamide
3291874|NCT00531427|Experimental|1|Buprenorphine transdermal system 10 and 20 applied for 7-day wear
3291875|NCT00531427|Placebo Comparator|2|Placebo transdermal system to match BTDS patches, applied for 7-day wear
3291876|NCT00531362||Patients|All patients (acute or stable) presenting to a cardiovascular clinic and on aspirin.
3291877|NCT00531349|Active Comparator|A|General anesthesia and opioid analgesia for the treatment of pain after surgery.
3291878|NCT00531349|Active Comparator|B|Regional anesthesia and analgesia (epidural) combined with deep sedation or general anesthesia.
3291879|NCT00531336|Experimental|1|Avastin first followed by retreatment of Macugen
3291880|NCT00531336|Active Comparator|2|Avastin intravitreally every 6 weeks
3291881|NCT00531336|Active Comparator|3|Macugen intravitreally every 6 weeks
3291882|NCT00531323|Other|1|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
3291883|NCT00531323|Other|2|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
3291884|NCT00531310|Experimental|Matched Family Donor|Matched Family Donor
3291885|NCT00531310|Experimental|Unrelated Donor|Unrelated Donor Transplant/ Cord Blood Transplant
3291886|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291887|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/27 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 27 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291888|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/36 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291889|NCT00531284|Experimental|Phase 2 Solid Tumors: Carfilzomib 20/36 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291890|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 36 mg/m²|Participants received carfilzomib 36 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291891|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 45 mg/m²|Participants received carfilzomib 45 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291992|NCT00530374|Placebo Comparator|2|Each child in this group will receive daily supplementation of placebo Sprinkles with a single sachet for 60 days
3291993|NCT00530348|Experimental|Alemtuzumab|
3291892|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/45 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291893|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291894|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291895|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/36 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291896|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/45 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291897|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291898|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291899|NCT00531284|Experimental|Phase 1b Lymphoma: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291900|NCT00531284|Experimental|Phase 1b Lymphoma: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291901|NCT00531284|Experimental|Phase 1b MM: Carfilzomib 20/45 mg/m² + Dexamethasone|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291902|NCT00531284|Experimental|Phase 1b MM: Carfilzomib 20/56 mg/m² + Dexamethasone|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3291903|NCT00531258|Active Comparator|1|
3291904|NCT00531258|Placebo Comparator|2|
3291905|NCT00531232|Experimental|clofarabine 25 mg/day|
3291906|NCT00531219||1|Group #1 NOTES Appendectomy - Transgastric approach
3291907|NCT00531219||2|Group #2 NOTES Cholecystectomy - Transgastric approach
3291908|NCT00531206||All participants|
3291909|NCT00531193|Other|1|Various protocol-specified doses of BIIB014 will be used (doses to be determined by PET scan results)
3291910|NCT00531180||4-DCT Ventilation Validation|Patients diagnosed with esophageal or lung cancer.
3291911|NCT00531167|Experimental|A|combination therapy
3291912|NCT00531167|Active Comparator|B|entecavir
3291913|NCT00531141||A|examination twice by examiner 1
3291914|NCT00531141||B|examination first by examiner 1 thereafter by examiner 2
3291915|NCT00531141||C|examination first by examiner 2 thereafter by examiner 1
3291916|NCT00531141||D|examination performed twice by examiner 2
3291917|NCT00531115|Experimental|1|
3291918|NCT00531102|Experimental|1|"Resuscitation will proceed as per standard of care and infants are only to receive respiratory support if they remain cyanotic despite 60 seconds of spontaneous regular respirations. All infants will have a pulse oximetry probe placed on the right hand (pre-ductal position) immediately after birth. Infants that meet the entry criteria will be randomized to resuscitation with one of two neonatal T-piece resuscitator circuits:~GROUP 1 - infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes."
3291919|NCT00531102|Active Comparator|2|"Resuscitation will proceed as per standard of care and infants are only to receive respiratory support if they remain cyanotic despite 60 seconds of spontaneous regular respirations. Infants that meet the entry criteria will be randomized to resuscitation with one of two neonatal T-piece resuscitator circuits:~GROUP 2 - infants will receive 50% oxygen at a rate of 6 liters per minute continuously for at least 5 minutes using a modified neonatal T-piece resuscitator circuit that does not generate pressure. Fifty percent oxygen was chosen because it reflects the actual inspired oxygen concentration when 100% oxygen is blown towards the infant's face."
3291920|NCT00531089|Experimental|Study group|"All patients in the study will be in the study group and will receive rituximab. There is no control arm."
3291921|NCT00531050|Experimental|Part 1: Sequence A, Part 2: Sequence A|"Part 1: Sequence 'A' consisted of - Period 1, patient received a single inhaled dose of indacaterol 300μg capsule via the Concept1 inhaler device. Period 2, patient received single dose of salmeterol 50μg via Diskus dry powder inhaler (DPI). Period 3, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device.~Part 2: Sequence 'A' consisted of - Period 1, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 3, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
3291922|NCT00531050|Experimental|Part 1 : Sequence B, Part 2: Sequence B|"Part 1: Sequence 'B' consisted of - Period 1, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 2, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patient received single dose of salmeterol 50μg via Diskus DPI.~Part 2: Sequence 'B' consisted of - Period 1, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 3, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
3291923|NCT00531050|Experimental|Part 1: Sequence C, Part 2: Sequence C|"Part 1: Sequence 'C' consisted of - Period 1, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patient received single dose of salmeterol 50μg via Diskus DPI. Period 3, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device.~Part 2: Sequence 'C' consisted of - Period 1, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 2, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 3, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device . In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
3291924|NCT00531050|Experimental|Part 1; Sequence D, Part 2: Sequence D|"Part 1: Sequence 'D' consisted of - Period 1, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 3, patient received single dose of salmeterol 50μg via Diskus DPI.~Part 2: Sequence 'D' consisted of - Period 1, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 2, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
3291925|NCT00531050|Experimental|Part 1: Sequence E, Part 2: Sequence E|"Part 1: Sequence 'E' consisted of - Period 1, patient received single dose of salmeterol 50μg via Diskus DPI. Period 2, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 3, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device.~Part 2: Sequence 'E' consisted of - Period 1, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 2, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
3291926|NCT00531050|Experimental|Part 1: Sequence F, Part 2: Sequence F|"Part 1: Sequence 'F' consisted of - Period 1, patient received single dose of salmeterol 50μg via Diskus DPI. Period 2, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device.~Part 2: Sequence 'F' consisted of - Period 1, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 2, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 3, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
3291927|NCT00531024|Experimental|1|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
3291928|NCT00531024|Placebo Comparator|2|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
3291929|NCT00531011|Active Comparator|XIENCE V|Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)
3291930|NCT00531011|Active Comparator|TAXUS® Liberté™|Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System
3291931|NCT00530998||1|Group #1 NOTES Appendectomy - Transvaginal approach
3291932|NCT00530998||2|Group #2 NOTES Cholecystectomy - Transvaginal approach
3291933|NCT00530985|Experimental|1|Benefits Counseling
3291934|NCT00530985|Active Comparator|2|VA Orientation
3291935|NCT00530972|Experimental|Peginterferon alfa-2a plus ribavirin|
3291936|NCT00530946|Active Comparator|CI-1038 2.5mg/5mg|
3291937|NCT00530946|Active Comparator|CI-1038 2.5mg/10mg|
3291938|NCT00530946|Active Comparator|CI-1038 5mg/5mg|
3291939|NCT00530946|Active Comparator|CI-1038 5mg/10mg|
3291940|NCT00530933|Sham Comparator|1|Sham tibial nerve stimulation
3291941|NCT00530933|Experimental|2|Percutaneous tibial nerve stimulation
3291942|NCT00530933|Experimental|3|Transcutaneous tibial nerve stimulation
3291994|NCT00530348|Active Comparator|Interferon Beta-1a|
3291943|NCT00530907|Experimental|Valproic Acid + Bevacizumab|"Valproic acid administered at a dose of 5.3 mg/Kg/day on days 1 - 28. Depending on the calculated dose, patients will take capsules once or twice a day per mouth.~Bevacizumab administered at a dose of 2.5 mg/kg by vein every 2 weeks."
3291944|NCT00530894|Experimental|1|Cohort A: Sapien Valve
3291945|NCT00530894|Active Comparator|2|Cohort A: other surgical valve
3291946|NCT00530894|Experimental|3|Cohort B: Sapien Valve
3291947|NCT00530894|Active Comparator|4|Cohort B: Medical therapy
3291948|NCT00530881|Placebo Comparator|4|
3291949|NCT00530881|Placebo Comparator|3 active, 1 placebo|
3291950|NCT00530868|Experimental|Letrozole + Avastin|
3291951|NCT00530868|Experimental|Letrozole alone|
3291952|NCT00530855|Experimental|Lacosamide|Lacosamide tablets for dosing 100 -800 mg/day
3291953|NCT00530829|Experimental|1|Mothers recieve a blister pack of zinc tablets in home every two months for use when child in home under 5 years has diarrhea. ORS satchets also given. Instructions on when and how to use zinc and ORS and when to take child in clinic are given by community health worker. Zinc will also be given in clinic if child visits clinic with diarrhea and has not yet started zinc at home.
3291954|NCT00530829|Active Comparator|2|Mothers recieve ORS satchets at home every two months for use when child in home under 5 years has diarrhea. Instructions on when and how to use ORS and when to take child in clinic are given by community health worker. Zinc will be given in clinic if child visits clinic with diarrhea.
3291955|NCT00530816|Experimental|Carfilzomib|"Participants received carfilzomib 20 mg/m² intravenous (IV) injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.~Starting with Amendment 3, if all doses in Cycle 1 were well-tolerated the dose was escalated to 27 mg/m² IV for subsequent cycles."
3291956|NCT00530803|Active Comparator|EMLA Cream|Participants will have a dose of EMLA Cream applied to the venipuncture site 1 hour before the procedure. Dosage based on age and weight: 4-6 years old and heavier than 10kg will receive 10g of EMLA; 7-12 years old and more than 20kg will receive 20g of EMLA.
3291957|NCT00530803|Active Comparator|Synera Patch|Participants will have a Synera Patch applied to the venipuncture site 20 minutes prior to the procedure.
3291958|NCT00530790|Experimental|ropinirole CR-RLS|"Subjects will orally take ropinirole CR-RLS tablet(s) once daily 1-2 hours before the onset of RLS symptoms at about the same time of the day. The time of taking ropinirole must be after 16:00.Adjustment of the Ropinirole CR-RLS tablets should be completed after the Week 1 visit up to the Week 10 visit. The dose will be increased at intervals of at least one week until sufficient efficacy is obtained (use much improved as a guide) without safety problem. Dose escalation will start at the initial dose 0.5 mg/day to 1 mg/day; after 1 mg/day, the dose will be increased by 1 mg/day to the maximum 6 mg/day."
3291959|NCT00530777|Experimental|1|500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
3291960|NCT00530777|Placebo Comparator|2|oral placebo twice daily from 34 weeks gestation to 1 year postpartum
3291961|NCT00530764|Experimental|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
3291962|NCT00530764|Experimental|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
3291963|NCT00530764|Experimental|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
3291964|NCT00530764|No Intervention|Placebo|Range of 1-16 sprays per day of placebo spray.
3291965|NCT00530738|Experimental|1|treatment with Lipoplus & Nutriflex plus (commercially available and marketed 2 Chamber Bag)
3291966|NCT00530738|Active Comparator|2|treatment with Lipofundin MCT & Nutriflex plus (commercially available and marketed 2 Chamber Bag)
3291967|NCT00530725|Active Comparator|chest drainage|This represents the best current standard of care although this is quite controversial
3291968|NCT00530725|Experimental|close observation|This is the novel approach that has some justification in the literature
3291969|NCT00530712|Experimental|PTA and Stenting with EverFlex device|Qualified subjects undergo treatment of atherosclerotic lesions in the native SFA/SFA/PPA with PTA and stenting using the PROTÉGÉ® EverFlex™ Self-Expanding Stent System
3291970|NCT00530634|Experimental|Gemcitabine + Cisplatin|Surgical resection followed by (within 60 days) by chemotherapy (Gemcitabine at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle and Cisplatin at 75 mg/m2 IV over 1 hour on day 8 of a 21 day cycle) followed by radiation therapy (treated using linear accelerator with photon beam energy of 6-21 MV) upon completion of 3 cycles of chemotherapy.
3291971|NCT00530621|Active Comparator|A|
3291972|NCT00530621|Placebo Comparator|B|
3291973|NCT00530530|Experimental|1|Dose 1
3291974|NCT00530530|Experimental|2|Dose 2
3291975|NCT00530530|Experimental|3|Dose 3
3291976|NCT00530530|Placebo Comparator|4|
3291977|NCT00530517|Experimental|1|
3291978|NCT00530504|Experimental|Intervention|
3291979|NCT00530491|Active Comparator|1|conventional perioperative management for lung surgery
3291980|NCT00530491|Experimental|2|fast track management for lung surgery
3291981|NCT00530452|Experimental|A|2.0 mg (loading dose, Day 0) followed by 0.3 mg/day (Days 1-20)
3291982|NCT00530452|Experimental|B|4.0 mg (loading dose, Day 0) followed by 0.6 mg/day (Days 1-20)
3291983|NCT00530452|Experimental|C|8.0 mg (loading dose, Day 0) followed by 1.2 mg/day (Days 1-20)
3291984|NCT00530452|Placebo Comparator|D|Placebo (identical number of capsules to active drug groups) (Days 0-20)
3291985|NCT00530439|Experimental|Lifestyle intervention|physical activity, dietetic counselling
3291986|NCT00530439|No Intervention|Control|
3291987|NCT00530413|Experimental|1|Phenobarbital - dose based by weight range
3291988|NCT00530413|Placebo Comparator|2|Placebo group
3291989|NCT00530400|Experimental|1|intravenous 1.5g cefuroxime
3291990|NCT00530400|Placebo Comparator|2|intravenous placebo
3291991|NCT00530374|Active Comparator|1|Each child in this group will receive daily supplementation of Iron Sprinkles with a single sachet for 60 days
3291995|NCT00530335|Experimental|Atomoxetine|
3291996|NCT00530322|Control|A|"Patients who have had previous open colorectal surgery and are referred for a further operative procedure, at which time a second-look laparoscopy can be performed."
3291997|NCT00530322|Case|B|"Patients who have had a previous laparoscopic colorectal procedure and are having a second-look procedure"
3291998|NCT00530309|Experimental|Subjects receiving GSK716155 + placebo|Eligible subjects will receive GSK716155 with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks. Subjects will also receive placebo.
3291999|NCT00530283||A|Patients with Squamous cell cancer of neck nodes, unknown primary
3292000|NCT00530270|Active Comparator|Dexamethasone|
3292001|NCT00530270|Placebo Comparator|Placebo|
3292002|NCT00530257|Placebo Comparator|Placebo|Placebo (sugar pill);Subjects will be equally randomized and will receive one week of treatment with placebo and compared to subjects who were randomized to receive one week of OROS-methylphenidate.
3292003|NCT00530257|Active Comparator|OROS-methylphenidate|Subjects will be equally randomized and will receive one week of treatment with the optimal dose of OROS methylphenidate compared with subjects randomized to receive one week of placebo.
3292004|NCT00530244|Experimental|1|Infants will be fed formula supplemented with docosahexaenoic acid
3292005|NCT00530244|Placebo Comparator|2|Infants will be fed standard formula (Enfamil)
3292006|NCT00530218|Experimental|All Study Participants|Ganciclovir IV 5 mg/kg/bid x 7 days followed by Ganciclovir Oral 1000 mg tid 7 days per week x 5 weeks
3292007|NCT00530179|Active Comparator|Arm A|Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined negative for disease intensity patient receives 4 more cycles R-CHOP (total 6 cycles R-CHOP)
3292008|NCT00530179|Active Comparator|Arm B|Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined positive for disease intensity the patient receives one cycle or R-DICEP/R-BEAM the autologous blood stem cell transplantation.
3292009|NCT00530166|Experimental|002|sham comparator 3(100 mg) tablets once daily for 12 weeks
3292010|NCT00530166|Experimental|001|JNJ-18054478 3(100 mg) tablets once daily for 12 weeks
3292011|NCT00530140|Experimental|A|All patients will receive the same vaccination schedule/formulation
3292012|NCT00530127|Placebo Comparator|A|Placebo solution
3292013|NCT00530127|Experimental|B|Deferiprone oral solution 20 mg/kg/day
3292014|NCT00530127|Experimental|C|Deferiprone oral solution 40 mg/kg/day
3292015|NCT00530127|Placebo Comparator|D|Placebo solution
3292016|NCT00530127|Experimental|E|deferiprone oral solution 60 mg/kg/day
3292017|NCT00530114|Placebo Comparator|Placebo|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
3292018|NCT00530114|Experimental|AMG 223|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
3292019|NCT00530088|Experimental|Porfimer Sodium|Patients receive porfimer sodium subcutaneously followed by photodynamic therapy (PDT) comprising laser light delivered by a single or a diffuser (i.e., for broad areas of dysplasia) fiberoptic lens fiber.
3292020|NCT00530075|Experimental|1|Gusperimus
3292021|NCT00530062|Active Comparator|Albuterol HFA-BAI|Albuterol Hydrofluoroalkane (HFA) Breath-Actuated Inhaler (BAI)
3292022|NCT00530062|Active Comparator|Albuterol HFA-MDI|Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)
3292023|NCT00530049||questionnaires|"The purpose of this study is to develop a PRO instrument that measures quality of life as relates to facial appearance after head and neck cancer reconstruction surgery and after dermatologic surgery for patients with cutaneous skin cancers. . To develop this measure, we will adhere to the following sequential steps recommended by quality of life experts. Thus, the study will have three parts:~Questionnaire content generation and development of preliminary instrument~Field-testing the preliminary questionnaire with item reduction and development of final questionnaire~Psychometric evaluation of final questionnaire"
3292024|NCT00530036|Control|Continent|"54% of 699 patients followed as outpatient by the Fondation des Services d'Aide et de Soins à Domicile in Geneva without urinary incontinence"
3292025|NCT00530036|Case|Incontinent|"46% of 699 patients followed by the Fondation des Services d'Aide et de Soins à Domicile in Geneva and with an urinary incontinence"
3292026|NCT00530023|Active Comparator|1. 722|722 arm: MiniMed Paradigm REAL-Time System
3292027|NCT00530023|No Intervention|2. Multiple Daily Injections (MDI)|MDI arm: Continue with currently prescribed Multiple Daily Injection therapy. No change in treatment or regime for study.
3292028|NCT00529997|Experimental|1|Posterior Dynamic Stabilization with the Stabilimax NZ
3292029|NCT00529997|Active Comparator|2|Posteriolateral instrumented fusion
3292030|NCT00529984|Experimental|Cohort 1|
3292031|NCT00529984|Experimental|Cohort 2|
3292032|NCT00529984|Experimental|Cohort 3|
3292033|NCT00529984|Experimental|Cohort 4|
3292034|NCT00529984|Experimental|Cohort 5|
3292035|NCT00529971|Experimental|1|Participants in the first arm participate in an 8-week MBSR group
3292036|NCT00529971|Active Comparator|2|Participants assigned to the control arm do not receive the MBSR program but may or may not be receiving current psychotherapy or counselling
3292037|NCT00529958|Active Comparator|Patellar Tendon (PT)|ACL reconstruction using a patellar tendon autograft
3292038|NCT00529958|Active Comparator|Hamstring (HT)|ACL reconstruction using a quadruple-strand semitendinosus/gracilis (hamstring) tendon single-bundle autograft
3292039|NCT00529958|Active Comparator|Double-Bundle (DB)|ACL reconstruction using a semitendinosus/gracilis (hamstring) tendon double-bundle autograft
3292040|NCT00529932|Active Comparator|1|Enriched CD133+, bone marrow-derived, autologous progenitor cells for this trial will be infused in the coronary arteries
3292041|NCT00529932|Placebo Comparator|2|Control group patients will receive 3 injections of 0.3 mL each of buffered normal saline (the vehicle used for cell suspension) into comparable vessels. Subjects will have an identical intra-coronary injection procedure to those randomized to autologous CD133+ progenitor cell injections.
3292042|NCT00529919|Active Comparator|1|MCT oil consumption
3292043|NCT00529919|Placebo Comparator|2|Olive oil consumption
3292044|NCT00529867|Active Comparator|A|
3292045|NCT00529867|Active Comparator|B|
3292046|NCT00529854||1|Observational evaluation of current billing and documentation practices
3292047|NCT00529854||2|Use of SIC-IR Billing Module
3292048|NCT00529841|Experimental|1 (Hydrocortisone sodium acetate)|Subcutaneous administration of Hydrocortisone sodium acetate via insulin pump
3292049|NCT00529815|Experimental|1CGM and SBGM|Intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
3292050|NCT00529815|Active Comparator|2 SBGM|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
3292051|NCT00529802|Experimental|Everolimus (RAD001) 10mg daily|All patients were to receive 10mg everolimus (RAD001) daily.
3292052|NCT00529789|Experimental|Duloxetine|
3292053|NCT00529776|Active Comparator|1|Continuous lateral rotation therapy
3292054|NCT00529776|No Intervention|2|Standard manual positioning (Supine position)
3292055|NCT00529763|Experimental|1|
3292056|NCT00529750|Experimental|Irbesartan Group|150 mg p.o. once a day, 30 minutes before breakfast during 12 weeks
3292057|NCT00529750|Active Comparator|Atenolol Group|50 mg p.o. once a day, 30 minutes before breakfast during 12 weeks.
3292058|NCT00529737|Experimental|Group 1|Post Procedure Mammogram Projection View A -- (view same projection as used in the biopsy procedure), then View B (view orthogonal projection to the first view).
3292059|NCT00529737|Experimental|Group 2|Post Procedure Mammogram Projection View B than View A
3292060|NCT00529711|Experimental|Group 1|Hypertonic lactate
3292061|NCT00529711|Active Comparator|Group 2|Ringer's lactate
3292062|NCT00529698|Other|A|Subjects were immunized subcutaneously with Tat, 3 dosage groups (7.5, 15 or 30 micrograms), in association with Alum as adjuvant, or with Saline + Alum, as placebo.
3292063|NCT00529698|Other|B|Subjects were immunized intradermally with Tat, 3 dosage groups (7.5, 15 or 30 micrograms), or with Saline, as placebo.
3292064|NCT00529672|Active Comparator|1|Surgery: crossectomy plus short stripping
3292065|NCT00529672|Active Comparator|2|ultrasound guided sclerotherapy with foam (3% polidocanol)
3292066|NCT00529672|Active Comparator|3|Endovenous laser therapy (940 nm, about 70 J/cm)
3292067|NCT00529659|Experimental|MK-0773|MK-0773
3292068|NCT00529659|Placebo Comparator|Placebo|Placebo
3292069|NCT00529633|Active Comparator|Thalidomide|"12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months~Serum C reactive protein level of ≥ 0.8 mg/dl~Serum albumin < 3.8 g/dl (BCG)~Patients will receive 100mg Thalidomide for a period of 4 weeks; if somnolence tolerated, dosage is increased to 200mg nightly for a period of 20 more weeks -- to total of 24 weeks on Thalidomide."
3292070|NCT00529633|Placebo Comparator|No Drug|"12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months~Serum C reactive protein level of ≥ 0.8 mg/dl~Serum albumin < 3.8 g/dl (BCG)~Patients will receive Placebo (Sugar pill) for a period of 24 weeks."
3292071|NCT00529620|Active Comparator|1|sulfalene pyrimethamine plus amodiaquine
3292072|NCT00529620|Active Comparator|2|dihydroartemisinin piperaquine
3292073|NCT00529620|Active Comparator|3|sulfadoxine-pyrimethamine plus piperaquine
3292074|NCT00529607||1|- patients with acute ST elevation myocardial infarction and consecutive percutaneous coronary intervention of the infarct-related artery
3292075|NCT00529607||2|- 30 patients with stable CAD (control group 1)
3292076|NCT00529607||3|- 30 healthy volunteers regarding cardiovascular diseases (control group 2)
3292077|NCT00529594|Placebo Comparator|Control Group|Patients who received placebo
3292078|NCT00529594|Active Comparator|Treatment Group|Patients who received etoricoxib 120 mg
3292079|NCT00529568|Experimental|eltrombopag|active treatment arm
3292080|NCT00529568|Placebo Comparator|placebo|placebo control arm
3292081|NCT00529555|Sham Comparator|Scaling and root planing + SHAM TX|sham treatment
3292082|NCT00529555|Placebo Comparator|Scaling and root planing + Vehicle|Placebo
3292083|NCT00529555|Active Comparator|Scaling & root planing + Periocline Gel|Minocycline HCL 2.1%
3292084|NCT00529542|Experimental|Atorvastatin|
3292085|NCT00529542|Placebo Comparator|Placebo|
3292086|NCT00529529|Experimental|Indacaterol 300 μg|Patients received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 300 μg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3292087|NCT00529529|Experimental|Indacaterol 600 μg|Patients received indacaterol 600 μg (2 x 300 μg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 600 μg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3292088|NCT00529529|Active Comparator|Salmeterol 50 μg|Patients received salmeterol 50 μg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 07:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 μg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3292089|NCT00529516|Experimental|FluAS25 Group|Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.
3292090|NCT00529516|Active Comparator|Fluarix ≥ 65 years age Group|Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.
3292146|NCT00529113|Experimental|Phase 1 Cohort 4|Bardoxolone methyl 200 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3292091|NCT00529516|Active Comparator|Fluarix 18-40 years age Group|Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.
3292092|NCT00529503|Experimental|1|SGN-40, rituximab, etoposide, carboplatin, ifosfamide
3292093|NCT00529503|Placebo Comparator|2|placebo, rituximab, etoposide, carboplatin, ifosfamide
3292094|NCT00529490|Experimental|HL|Hypertonic lactate group
3292095|NCT00529490|Active Comparator|RL|Ringer's lactate
3292096|NCT00529477|Active Comparator|1|The Wright Nebulizer will be used to perform the methacholine challenge in arm 1.
3292097|NCT00529477|Active Comparator|2|The Pari LC nebulizer will be used to perform the methacholine challenge in arm 2.
3292098|NCT00529477|Active Comparator|3|The Pari Sinustar nebulizer will be used to perform the methacholine challenge in arm 3.
3292099|NCT00529464|Experimental|Colposcopy|Colposcopy - a direct magnified inspection of cervix
3292100|NCT00529464|Experimental|Colposcopy + Fluorescence Spectroscopy|Colposcopy - a direct magnified inspection of cervix + Fluorescence Spectroscopy - electromagnetic spectroscopy which analyzes fluorescence from a sample.
3292101|NCT00529464|Experimental|Colposcopy + LEEP Procedure|Colposcopy - a direct magnified inspection of cervix + loop electrosurgical excision procedure (LEEP) - thin, low-voltage electrified wire loop to cuts out cervix abnormal tissue.
3292102|NCT00529451|Experimental|Aliskiren 300 mg|Aliskiren 300 mg once daily
3292103|NCT00529451|Experimental|Aliskiren 150 mg|Aliskiren 150 mg once daily
3292104|NCT00529451|Experimental|Aliskiren 75 mg|Aliskiren 75 mg once daily
3292105|NCT00529451|Active Comparator|Ramipril 5 mg|Ramipril 5 mg once daily
3292106|NCT00529438|Experimental|Bardoxolone methyl capsules|"Bardoxolone methyl to be taken orally for 21 consecutive days, once a day, in the morning prior to food intake.~Patients to continue to receive treatment for the first 21 days of each 28-day cycle until they experience intolerable toxicity, show evidence of disease progression, or receive a maximum of 18 cycles (18 months)."
3292107|NCT00529425|Active Comparator|Ropivacaine|
3292108|NCT00529425|Placebo Comparator|Saline|
3292109|NCT00529412|No Intervention|control|no Seprafilm
3292110|NCT00529412|Active Comparator|Seprafilm|
3292111|NCT00529399|Experimental|1|3 injections of GAD-Alum vaccine
3292112|NCT00529399|Experimental|2|2 injections of GAD-Alum vaccine and one injection with Aluminum hydroxide alone
3292113|NCT00529399|Placebo Comparator|3|3 injections of Aluminum hydroxide alone
3292114|NCT00529386|Experimental|Botox|300 IU botox
3292115|NCT00529386|Active Comparator|Lidocaine|1% Lidocaine
3292116|NCT00529373|Experimental|Odanacatib|Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly for 5 years. All participants will also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.
3292117|NCT00529373|Placebo Comparator|Placebo|Participants receive 50 mg of blinded placebo to odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly for 5 years. All participants will also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.
3292118|NCT00529360|Experimental|Part A|Part A will be the dose escalation phase to determine the MTD and/or safe/tolerated dose of clofarabine.
3292119|NCT00529360|Experimental|Part B|Part B will accrue patients to further define the event free, disease free and overall survival at the MTD or safe/tolerated dose of clofarabine.
3292120|NCT00529334|Experimental|1|CyberKnife Partial Breast Irradiation (PBI)
3292121|NCT00529308|Active Comparator|Active|
3292122|NCT00529308|Sham Comparator|Sham|
3292123|NCT00529295|Experimental|1|Titrated oral misoprostol
3292124|NCT00529295|Active Comparator|2|Vaginal misoprostol
3292125|NCT00529282|Experimental|001|Ceftobiprole Medocaril 500 mg every 8 hours 120-minute infusion [250 mL]
3292126|NCT00529282|Active Comparator|002|Cefepime with or without vancomycin 2 g every 8 hrs-30 min infusion vancomycin 1 000mg every 12 hrs-60 min infusion
3292127|NCT00529256|No Intervention|2|No intervention
3292128|NCT00529243|Experimental|MK-0518 (raltegravir)|Open label, single arm. All patients to receive MK-0518 400mg orally twice a day for 24 weeks, as substitution for enfuvirtide.
3292129|NCT00529230||Chronic opioid therapy + Gonadal function|Males on chronic opioid therapy for cancer-related pain syndromes
3292130|NCT00529217|Experimental|Open-Label Active rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS)
3292131|NCT00529204|Experimental|Exenatide|exenatide 5 µg BID s.c. daily for 28 days, followed by 10 µg BID s.c. daily from day 29 to week 24
3292132|NCT00529191|Experimental|Atorvastatin|Two out of every three patients will receive atorvastatin.
3292133|NCT00529191|Placebo Comparator|Placebo|One out of three subjects will receive a placebo.
3292134|NCT00529165|Experimental|A|with injection-meal-interval,cross over after 3 month, than without injection-meal-interval for 3 month
3292135|NCT00529165|Experimental|B|without injection-meal-interval,cross over after 3 month, than with injection-meal-interval for 3 month
3292136|NCT00529152|Other|A|Ferriprox Oral Solution single treatment
3292137|NCT00529139|Active Comparator|A|
3292138|NCT00529139|Active Comparator|B|
3292139|NCT00529126|Experimental|SKY0402 high dose|SKY0402, single administration
3292140|NCT00529126|Experimental|SKY0402 middle dose|SKY0402, single administration
3292141|NCT00529126|Experimental|SKY0402 low dose|SKY0402, single administration
3292142|NCT00529126|Active Comparator|Bupivacaine HCl|Bupivacaine HCl
3292143|NCT00529113|Experimental|Phase 1 Cohort 1|Bardoxolone methyl 150 mg/day x 21 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3292144|NCT00529113|Experimental|Phase 1 Cohort 2|Bardoxolone methyl 300 mg /day for 21 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3292145|NCT00529113|Experimental|Phase 1 Cohort 3|Bardoxolone methyl 150 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3292147|NCT00529113|Experimental|Phase 1 Cohort 5|Bardoxolone methyl 250 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3292148|NCT00529113|Experimental|Phase 1 Cohort 6|Bardoxolone methyl 300 mg/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3292149|NCT00529113|Experimental|Phase 1 Cohort 7|Bardoxolone methyl 350 mg/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3292150|NCT00529113|Experimental|Phase 2 Cohort 1|Bardoxolone methyl maximum tolerated dose(as determined in the Phase 1 portion of the study)/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3292151|NCT00529113|Placebo Comparator|Phase 2 Cohort 2|Placebo capsules/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3292152|NCT00529100|Experimental|Pemetrexed/Cisplatin/Radiation Phase 1|Treatment included: radiation as 61-65 Gray (Gy) in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent pemetrexed intravenous (IV) bolus with doses escalating from 300 milligrams per square meter (mg/m^2) IV through 500 mg/m^2 IV on Days 1 and 22; concurrent cisplatin 25 mg/m^2 IV on Days 1-3 and 22-24 for Cohorts 1-3 and cisplatin 20 mg/m^2 IV on Days 1-5 and 22-26 for Cohort 4. Participants then received 2 additional consolidation cycles repeated every 3 weeks (q3 weeks) of pemetrexed 500 mg/m^2 IV and cisplatin 75 mg/m^2 IV.
3292153|NCT00529100|Experimental|Pemetrexed/Cisplatin/Radiation Phase 2|Treatment included: radiation, 61-65 Gy in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m^2 IV on Days 1 and 22 ; concurrent cisplatin 20 mg/m^2 IV as determined by Phase 1 trial with cycles commencing on Days 1 and 22; 2 additional consolidation cycles (q3 weeks) of pemetrexed 500 mg/m^2 IV and cisplatin 75 mg/m^2 IV.
3292154|NCT00529087|Placebo Comparator|1|
3292155|NCT00529087|Experimental|2|
3292156|NCT00529087|Experimental|3|
3292157|NCT00529048||T2DM|T2DM patients (WHO-criteria)
3292158|NCT00529048||CTRL|Healthy control subjects matched individually to the cases.
3292159|NCT00529035|Experimental|Interleukin-2|"Interleukin-2 (IL-2) will be given daily through an injection under the skin for a period of 8 weeks. To determine the highest safest dose of IL-2, the dose participants receive will increase as lower doses are determined to be safe. There will be three dose levels:~Dose Level -A 0.3 x 106 (IU/m2/d) Dose Level -B 1 x 106 (IU/m2/d) Dose Level-C 3 x 106 (IU/m2/d)"
3292160|NCT00529022|Experimental|Azacitidine + Valproic Acid + Carboplatin|Azacitidine 75 mg/m^2 subcutaneous injection or by vein daily for 5 Days. Valproic Acid 40 mg/kg by mouth daily for 7 days. Carboplatin area under the curve (AUC) 2 by vein on Days 3 and 10 over 60 Minutes.
3292161|NCT00528983|Experimental|Subcutaneous (SC) Azacitidine and Oral Azacitidine|Cycle 1 subjects receive SC Azacitidine for first 7 days of 28 day cycle. For Cycle 2 and beyond subjects receive Oral Azacitidine (experimental) for first 7 days of 28 day cycle.
3292162|NCT00528983|Experimental|Oral Azacitidine|Subjects receive Oral Azacitidine (experimental) QD or BID for the first 14 or 21 days of 28 day cycle.
3292163|NCT00528970|Placebo Comparator|1|
3292164|NCT00528970|Experimental|2|
3292165|NCT00528970|Experimental|3|
3292166|NCT00528957|Experimental|Tenofovir DF|
3292167|NCT00528957|Active Comparator|stavudine or zidovudine|
3292168|NCT00528944||Cohort A|Patients with obstructive defects and radiological evidence of emphysema
3292169|NCT00528944||Cohort B|Patients with obstructive ventilatory defects and no radiological evidence of emphysema
3292170|NCT00528944||Cohort C|Non-smokers without obstructive ventilatory defects or history of cardiopulmonary disease
3292171|NCT00528931|Experimental|AA4500 0.58 mg|
3292172|NCT00528918|Active Comparator|Apidra|Direct 1:1 comparison of Apidra and Regular insulin.
3292173|NCT00528918|Active Comparator|Regular|Direct 1:1 comparison of Apidra and Regular insulin.
3292174|NCT00528905|Placebo Comparator|1|Placebo
3292175|NCT00528905|Experimental|2|AZD3480 oral
3292176|NCT00528905|Experimental|3|AZD3480 oral dose
3292177|NCT00528892|Experimental|1|Switch current boosted-PI to raltegravir 400 mg BID.
3292178|NCT00528892|Active Comparator|2|Continue current regimen (ritonavir-boosted PI plus at least 2 other drugs)
3292179|NCT00528879|Placebo Comparator|Placebo + Metformin|Participants received dapagliflozin-matching placebo once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
3292180|NCT00528879|Experimental|Dapagliflozin, 2.5 mg + Metformin|Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
3292181|NCT00528879|Experimental|Dapagliflozin, 5 mg + Metformin|Participants received dapagliflozin, 5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
3292182|NCT00528879|Experimental|Dapagliflozin, 10 mg + Metformin|Participants received dapagliflozin, 10 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
3292183|NCT00528866|Experimental|Androgen suppression + RT + docetaxel|LHRH agonist and oral antiandrogen (flutamide or bicalutamide), radiation therapy (RT), and docetaxel
3292184|NCT00528840|Experimental|AA4500 0.58 mg|
3292185|NCT00528827|Placebo Comparator|1|
3292186|NCT00528827|Experimental|2|5 mcg
3292187|NCT00528827|Experimental|3|2.5
3292188|NCT00528827|Experimental|4|0.5
3292189|NCT00528814|Experimental|Two Step Hand-Hygiene|Hand washing plus hand sanitizer
3292190|NCT00528814|No Intervention|Usual Care Hand Hygiene|
3292191|NCT00528801||Cases (CLOSED)|These are patients diagnosed with sickle cell disease (confirmed by hemoglobin electrophoresis).
3292192|NCT00528801||Controls (CLOSED)|These are persons that do not have sickle cell disease (confirmed by hemoglobin electrophoresis); matched to cases by age, gender, and education level
3292193|NCT00528788|Experimental|Pre and post doxicalciferol|ESRD: all patients with secondary hyperparathyroidism who are vitamin D naive will receive doxercalciferol 2 mcg or 4 mcg 3 times per week fopr 30 days (1 month). Blood work and vascular laboratory studies will be performed pre and post treatment.
3292194|NCT00528775|Experimental|HPPH|Patients will receive 4 mg/m2 HPPH (given light exposure precautions) and approximately 2 days later be treated endoscopically with 150J/cm of 665 +-5nm light.
3292305|NCT00527891||Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI Scan
3292195|NCT00528762||Focus Group|Mexican American or African American females (aged 6-12 years old) and their parents
3292196|NCT00528723|Experimental|A|BDP/salbutamol HFA pMDI
3292197|NCT00528723|Active Comparator|B|BDP/salbutamol CFC pMDI
3292198|NCT00528710|Placebo Comparator|P|Placebo Control Group
3292199|NCT00528697|Experimental|1|Lowest ABT-089 dose
3292200|NCT00528697|Experimental|2|Low-medium ABT-089 dose
3292201|NCT00528697|Experimental|3|Medium-high ABT-089 dose
3292202|NCT00528697|Experimental|4|Highest ABT-089 dose
3292203|NCT00528697|Active Comparator|5|atomoxetine
3292204|NCT00528697|Placebo Comparator|6|placebo
3292205|NCT00528671|Active Comparator|A|Low dose oral anticoagulation, INR self-management once a week
3292206|NCT00528671|Active Comparator|B|very low dose oral anticoagulation, INR self-management once a week
3292207|NCT00528671|Experimental|C|very low dose oral anticoagulation, INR self-management twice a week
3292208|NCT00528658|Experimental|1|
3292209|NCT00528658|Experimental|2|
3292210|NCT00528658|Experimental|3|
3292211|NCT00528645|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily for up to 2 years in the absence of disease progression or unacceptable toxicity. Blood samples are obtained at baseline and periodically during study to determine levels of circulating tumor cells for defined translational studies.
3292212|NCT00528632||Cholesterolosis|I. Patients with gallbladder cholesterolosis and symptomatic cholelithiasis
3292213|NCT00528632||Cholelithiasis|II. Patients without gallbladder cholesterolosis and with symptomatic cholelithiasis
3292214|NCT00528619|Experimental|A|
3292215|NCT00528606|Experimental|AA4500 0.58 mg|
3292216|NCT00528606|Placebo Comparator|Placebo|
3292217|NCT00528593|Active Comparator|1|
3292218|NCT00528580|Experimental|1|Simvastatin 80 mg once daily PO (or via NG or G-tube)
3292219|NCT00528580|Placebo Comparator|2|Identical-appearing placebo PO (or via NG or G-tube)
3292220|NCT00528567|Experimental|Bevacizumab and Chemotherapy|Participants randomized to receive bevacizumab in combination with chemotherapy as prescribed.
3292221|NCT00528567|Active Comparator|Chemotherapy|Participants randomized to receive standard adjuvant chemotherapy as prescribed.
3292222|NCT00528554|Active Comparator|A|Active laser acupuncture
3292223|NCT00528554|Placebo Comparator|B|Placebo laser acupuncture
3292224|NCT00528541|Active Comparator|BOTOX®|botulinum toxin type A (BOTOX®)
3292225|NCT00528541|Active Comparator|Dysport®|botulinum toxin type A (Dysport®)
3292226|NCT00528528|Experimental|Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet|Telaprevir tablets at the dose of 750 milligram (mg) orally administered every 8 hours (hr) for 12 weeks, in combination with standard treatment composed of pegylated interferon (Peg-IFN)-alfa-2a solution for subcutaneous injection at the dose of 180 microgram per week (mcg/week) and ribavirin (RBV) oral tablets at the dose of 1000-1200 mg/day up to 48 weeks.
3292227|NCT00528528|Experimental|Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule|Telaprevir tablets at the dose of 750 mg orally administered every 8 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2b solution for subcutaneous injection at the dose of 1.5 mcg/kilogram/week (mcg/kg/week) and RBV oral capsules at the dose of 800-1200 mg/day up to 48 weeks.
3292228|NCT00528528|Experimental|Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet|Telaprevir tablets at the dose of 1125 mg orally administered every 12 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2a solution for subcutaneous injection at the dose of 180 mcg/week and RBV oral tablets at the dose of 1000-1200 mg/day up to 48 weeks.
3292229|NCT00528528|Experimental|Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule|Telaprevir tablets at the dose of 1125 mg orally administered every 12 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2b solution for subcutaneous injection at the dose of 1.5 mcg/kg/week and RBV oral capsules at the dose of 800-1200 mg/day up to 48 weeks.
3292230|NCT00528515|Active Comparator|1|propofol
3292231|NCT00528515|Experimental|2|desflurane
3292232|NCT00528502|Experimental|Saline|Saline misted into the air breathe during the surgery.
3292233|NCT00528502|Experimental|Lidocaine|Lidocaine misted into the air during the surgery.
3292234|NCT00528489|Experimental|1|PENNVAX-B with 0.8 mg IL-15 administered in both deltoids at Months 0, 1, 3, and 6
3292235|NCT00528489|Experimental|2|PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
3292236|NCT00528489|Experimental|3|PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
3292237|NCT00528489|Experimental|4|PENNVAX-B with 2 mg IL-15 injected into both deltoids at Months 0, 1, 3, and 6
3292238|NCT00528476|Case|1|Patients, who were treated because of recurrent (2 or more urinary tract infections per year) pyelonephritis or cystitis.
3292239|NCT00528476|Control|2|Patients with nonrecurrent urinary tract infections (patients who had no history of more than one urinary tract infections in last year).
3292240|NCT00528463|Experimental|sciatic block|One arm, all patient studied received a block
3292241|NCT00528450|Experimental|Tretinoin and Arsenic Trioxide With or Without Idarubicin|See Outline for details
3292242|NCT00528437|Other|Myeloablative Chemo-Temozolomide, Thiotepa, and Carboplatin.|
3292243|NCT00528424|Experimental|AA4500 0.58 mg|
3292244|NCT00528411|Active Comparator|1|Aspirin + Placebo
3292245|NCT00528411|Active Comparator|2|Aspirin + clopidogrel
3292246|NCT00528411|Experimental|3|Aspirin + Ticagrelor
3292247|NCT00528398|Experimental|Treatment (idarubicin, cytarabine)|Patients receive cytarabine IV over 3 hours every 12 hours on days 1-4 and idarubicin IV over 5-10 minutes on days 1-3. Patients undergo bone marrow aspirate and biopsy 7 days after completion of induction chemotherapy. Patients with > 25% cellular biopsy or > 10% abnormal cells on aspirate receive 4 more doses of cytarabine and 1 dose of idarubicin.
3292248|NCT00528372|Experimental|Group 1: Dapagliflozin, 2.5 mg AM|Participants with hemoglobin A1c (HbA1c) ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each morning for up to 102 weeks.
3292249|NCT00528372|Experimental|Group 1: Dapagliflozin, 10 mg AM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each morning for up to 102 weeks.
3292250|NCT00528372|Experimental|Group 1: Dapagliflozin 2.5 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each evening for up to 102 weeks.
3292251|NCT00528372|Experimental|Group 1: Dapagliflozin, 5 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 5 mg, once each evening for up to 102 weeks.
3292252|NCT00528372|Experimental|Group 1: Dapagliflozin, 10 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each evening for up to 102 weeks.
3292253|NCT00528372|Experimental|Group 2: Dapagliflozin, 5 mg AM|Participants with HbA1c ≥10.1% and ≤12% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
3292254|NCT00528372|Experimental|Group 2: Dapagliflozin, 10 mg AM|Participants with HbA1c ≥10.1% and ≤12% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
3292255|NCT00528372|Experimental|Group 1: Dapagliflozin placebo AM & PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin placebo once each morning and evening for up to 102 weeks.
3292256|NCT00528372|Experimental|Group 1: Dapaglifozon, 5 mg AM|Participants with (HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
3292257|NCT00528359||A|36 lean schizophrenic subjects free of metabolic syndrome(M:F 24:12; Caucasian n=23; North-African n=12; South-Asian n=1)aged 35±9 years
3292258|NCT00528346|Active Comparator|1|Participants will see their own brain activation.
3292259|NCT00528346|Placebo Comparator|2|Participants will see simulated data that does not come from their own brains.
3292260|NCT00528333|Experimental|1|Lintuzumab plus low dose cytarabine
3292261|NCT00528333|Active Comparator|2|Placebo plus low dose cytarabine
3292262|NCT00528307|Active Comparator|1|First 3 months of biventricular pacing, second 3 months right ventricular apical pacing
3292263|NCT00528307|Active Comparator|2|First 3 months of right ventricular apical pacing, second 3 months biventricular pacing
3292264|NCT00528294|Experimental|1|GRID-radiotherapy followed by biological imaging guided IMRT
3292265|NCT00528281|Experimental|Lapatinib + pemetrexed|This is a single-arm, two-stage, multicenter Phase II study to determine the clinical activity of pemetrexed with lapatinib.
3292266|NCT00528268|Experimental|Cohort 1|Family history of SMA type I 0-3 months old Confirmation of no more than 3 SMN2 copies
3292267|NCT00528268|Experimental|Cohort 2|Family history of SMA type II 0-6 months old Confirmation of no more than 4 SMN2 copies
3292268|NCT00528255|Experimental|1|
3292269|NCT00528242|Experimental|1|SLx-2101
3292270|NCT00528242|Placebo Comparator|2|Matching Placebo Dose
3292271|NCT00528190|Experimental|Itraconazole|Itraconazole 5mg/kg/day for 24 weeks
3292272|NCT00528190|Placebo Comparator|Placebo|Placebo/day for 24 weeks
3292273|NCT00528177|Active Comparator|O|This arm will receive intravenous oxycodone at the end of surgery and PCA oxycodone for postoperative pain relief.
3292274|NCT00528177|Active Comparator|M|This arm will receive intravenous morphine at the end of surgery and PCA morphine for postoperative pain relief.
3292275|NCT00528164|Experimental|Team PLAY Group|6-month family-centered intervention to increase physical activity and healthy eating patterns, primarily directed at parents. Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
3292276|NCT00528164|No Intervention|Standard Care Group|Participants receive standard care by primary care physician.
3292277|NCT00528151|Placebo Comparator|2|"curcumin~placebo"
3292278|NCT00528138||1|Simple appendicitis
3292279|NCT00528138||2|Perforated appendicitis
3292280|NCT00528125|Active Comparator|A|Active laser acupuncture
3292281|NCT00528125|Placebo Comparator|B|placebo laser acupuncture
3292282|NCT00528112|Experimental|LCS12|Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro
3292283|NCT00528112|Experimental|LCS16|Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro
3292284|NCT00528086||1|Parkinson disease patients and their family members or caregivers randomly assigned to receive their PD care in group visit format.
3292285|NCT00528086||2|Parkinson disease patients and their family members or caregivers randomly assigned to receive their PD care in standard of care format (one-on-one physician-patient visits).
3292286|NCT00528073|Experimental|A|Rifaximin-EIR tablet 1x400 mg + Placebo 2 tablets bid
3292287|NCT00528073|Experimental|B|Rifaximin-EIR tablet 2x400 mg + Placebo 1 tablet bid
3292288|NCT00528073|Experimental|C|Rifaximin-EIR tablet 3x400 mg bid
3292289|NCT00528073|Placebo Comparator|D|Placebo 3 tablets bid
3292290|NCT00528047|Experimental|PRLX 93936|
3292291|NCT00528034|Experimental|Lymphoscintigraphy|
3292292|NCT00528021|Active Comparator|1|
3292293|NCT00528021|Active Comparator|2|
3292294|NCT00528021|Active Comparator|3|
3292295|NCT00528021|Placebo Comparator|4|
3292296|NCT00528008|Active Comparator|A|povidone-iodine
3292297|NCT00528008|Active Comparator|B|chlorhexidine gluconate
3292298|NCT00527982|Experimental|Celecoxib treatment|600 mg orally (PO) daily
3292299|NCT00527982|No Intervention|No treatment|
3292300|NCT00527943|Placebo Comparator|Placebo|Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.
3292301|NCT00527943|Experimental|Vorapaxar|Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.
3292302|NCT00527917|Experimental|Uracyst|Sodium chondroitin sulfate
3292303|NCT00527917|Placebo Comparator|Placebo|placebo
3292304|NCT00527904|Experimental|PN 400 (VIMOVO)|500 mg delayed release naproxen/20 mg immediate release esomeprazole
3292306|NCT00527878|Experimental|Placebo/Ranitidine crossover|Patients took placebo for 12 months and then ranitidine for 12 months
3292307|NCT00527878|Experimental|Ranitidine/placebo crossover|Ranitidine for one year followed by placebo for one year
3292308|NCT00527865|Experimental|1|6 subjects DAS181 dosage 0.5 mg; 3 subjects placebo
3292309|NCT00527865|Experimental|2|6 subjects DAS181 dosage 1.0 mg; 3 subjects placebo
3292310|NCT00527865|Experimental|3|6 subjects DAS181 dosage 2.25 mg; 3 subjects placebo
3292311|NCT00527865|Experimental|4|6 subjects DAS181 dosage 4.5 mg; 3 subjects placebo
3292312|NCT00527826|Active Comparator|arm 1|
3292313|NCT00527826|Active Comparator|arm 2|
3292314|NCT00527813|Experimental|A|prone position for at least 16 hours per day
3292315|NCT00527813|No Intervention|B|semi-recumbent position
3292316|NCT00527800|Experimental|1|Treatment for episodes of uncomplicated malaria
3292317|NCT00527800|Active Comparator|2|Treatment for uncomplicated malaria
3292318|NCT00527800|Experimental|A|Prevention of malaria in HIV uninfected, exposed children
3292319|NCT00527800|No Intervention|B|Prevention of malaria in HIV uninfected, exposed children
3292320|NCT00527787|Experimental|PN400|Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily
3292321|NCT00527787|Active Comparator|Naproxen|Naproxen 500 mg dosed twice daily
3292322|NCT00527774||A|HCV(+) maintenance hemodialysis patients
3292323|NCT00527774||B|HCV(-) maintenance hemodialysis patients
3292324|NCT00527761|Experimental|Temozolomide, Docetaxel + Cisplatin|
3292325|NCT00527748|No Intervention|Standard of care|Patient ankle range of motion will be assessed at clinic visit. No stretching exercises with the device, but will be provided standard care through physiotherapist in acute cases, and no stretching exercises for chronic patients. Reassessment will be done at six weeks and 10 weeks.
3292326|NCT00527748|Experimental|Non-Measuring Ankle Exerciser|Subjects will train using only one combination of movement, dorsiflexion with inversion. This is done by manipulating the ring so that the medial and anterior ropes are taut. Subject will start with 3 minute warm-up. Subject will then manipulate the ring so that the foot moves into dorsiflexion with inversion until a point of tolerable discomfort is felt; subject will hold this position for 30 seconds. Stretch will be repeated 10 times, each day, for six weeks. Reassessment will be done at six weeks and 10 weeks.
3292327|NCT00527735|Experimental|Ipilimumab/ placebo + paclitaxel + carboplatin (concurrent)|
3292328|NCT00527735|Experimental|Ipilimumab/ placebo + paclitaxel + carboplatin (sequential)|
3292329|NCT00527735|Active Comparator|Ipilimumab placebo + paclitaxel + carboplatin|
3292330|NCT00527722|Experimental|Pleural Plug|Experimental lung plug after the lung biopsy.
3292331|NCT00527722|Active Comparator|No Pleural Plug|The standard lung biopsy without placement of the plug.
3292332|NCT00527696|Active Comparator|TVT SECURE|sling
3292333|NCT00527696|Active Comparator|TVT O|sling
3292334|NCT00527683|Active Comparator|A|Subjects will receive vigabatrin in escalating doses to 3 grams per day over three weeks, continued for 4 weeks and then tapered to zero over the next 2 weeks.
3292335|NCT00527683|Placebo Comparator|B|Orange juice and administration identical to Arm A.
3292336|NCT00527670||Normal Controls|Healthy patients undergoing laparoscopic surgery for cholelithiasis, appendicitis, and adrenalectomy.
3292337|NCT00527670||Recurrent Hernia|Patients presenting for laparoscopic repair of ventral or incisional hernias.
3292338|NCT00527657|Experimental|Lomustine + Temozolomide + Thalidomide|Lomustine starting dose 30 mg/m^2 by mouth daily on Day 1 and 29. Temozolomide 75 mg/m^2 by mouth daily on Days 1 to 42. Thalidomide 200 mg/m^2 by mouth daily.
3292339|NCT00527644|Other|Spring Clips|Subjects will undergo laparoscopic cholecystectomy with commercially available 5 mm spring clips utilized for the ligation of the cystic duct and artery.
3292340|NCT00527618|Active Comparator|Standard-dose acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
3292341|NCT00527618|Experimental|High-dose valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
3292342|NCT00527605|Experimental|A|dutasteride 0.5mg once daily orally
3292343|NCT00527605|Placebo Comparator|B|Placebo matched once daily orally
3292344|NCT00527592|Experimental|Travoprost|Travoprost assigned to one eye, with latanoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.
3292345|NCT00527592|Active Comparator|Latanoprost|Latanoprost assigned to one eye, with travoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.
3292346|NCT00527566|Experimental|Mepolizumab|Subjects will receive open-label mepolizumab
3292347|NCT00527553|Experimental|A|daily consumption of a regular egg
3292348|NCT00527553|Experimental|B|daily consumption of a lutein-enriched egg, eggs laid by chickens on a lutein-enriched feed.
3292349|NCT00527553|Experimental|C|daily consumtion of a zeaxanthin-enriched egg, eggs laid by chickens on a zeaxantin-enriched feed.
3292350|NCT00527553|Experimental|D|daily egg product from enriched eggs
3292351|NCT00527553|No Intervention|E|control subjects were not blinded as they did not receive any aditional supplementation. Only markers measured during the trial period as a control.
3292352|NCT00527527|Active Comparator|1|8 flexion distraction visits
3292353|NCT00527527|Active Comparator|2|12 flexion distraction visits
3292354|NCT00527527|Active Comparator|3|18 flexion distraction visits
3292355|NCT00527527|Placebo Comparator|4|8 placebo control visits
3292356|NCT00527514|Experimental|1|
3292357|NCT00527488|Experimental|Degarelix 16+16 mg|
3292358|NCT00527488|Experimental|Degarelix 32 mg|
3292359|NCT00527488|Experimental|Degarelix 32+32 mg|
3292360|NCT00527488|Experimental|Degarelix 64 mg|
3292361|NCT00527475|Active Comparator|Group I|Group I will receive 0.5 mg. ranibizumab intraocularly initially. This will be repeated monthly for 3 months total and then as needed over the period of one year.
3292529|NCT00525980|Experimental|Group 3: Computer Program + Promotora|Group 3 use the computer program with the guidance of a promotora.
3292362|NCT00527475|Experimental|Group II|Group II will receive Reduced Fluence-PDT (25 Joules) followed by 0.5 mg. of ranibizumab intraocularly on the same day. The second group will receive the combination of ranibizumab and RF-PDT as needed over a period of one year.
3292363|NCT00527423|Experimental|Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye)|
3292364|NCT00527410|Experimental|RTA 744|RTA 744 injection administered intravenously for a maximum of 18 cycles (54 weeks). Dose escalation based on four dose levels and occurance of dose limiting toxicity (DLT).
3292365|NCT00527397|Experimental|B|Type 2 Diabetes Mellitus (DM) who has not yet treated by Insulin
3292366|NCT00527397|Experimental|C|Type 2 DM who has already treated by Insulin
3292367|NCT00527397|Experimental|A|Type 1 DM
3292368|NCT00527371|Experimental|PVP|Photoselective vaporization of the prostate.
3292369|NCT00527371|Active Comparator|TURP|Transurethral resection of the prostate.
3292370|NCT00527358|Experimental|SAFER|"The intervention community will receive 4 services:~community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;~youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, and provide education about avoiding violence;~school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;~Youth drop-in center: will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training."
3292371|NCT00527358|No Intervention|2|Business as usual.
3292372|NCT00527345||1|children riding retrofitted school buses or private cars
3292373|NCT00527345||2|children riding old buses who will change to retrofitted buses during the first or second year of the study
3292374|NCT00527345||3|children who ride old diesel buses through the study
3292375|NCT00527332|Active Comparator|A|Spinal anesthesia combined with intrathecal morphine. Spinal anesthesia applied in intervertebral space L3/L4 or L2/L3 with hyperbaric bupivacaine 20 mg and morphine 0.2 mg intrathecally. Sedation with propofol.
3292376|NCT00527332|Active Comparator|B|General anesthesia. General anesthesia induced with propofol, fentanyl and rocuronium, and maintained with propofol and oxygen in air. Rocuronium and fentanyl repeated when needed.
3292377|NCT00527319|No Intervention|Group A, control group|Supportive care only
3292378|NCT00527319|Active Comparator|Group B, Low Dose VT-122|VT-122 (dose of etodolac: 400 mg/day) + supportive care
3292379|NCT00527319|Active Comparator|Group C, High Dose VT-122|VT-122 (dose of etodolac: 800 mg/day) + supportive care
3292380|NCT00527306|Experimental|I - Multivitamin|The multivitamin will contain 100% of the US reference daily intakes (recommended daily amounts) of vitamins A, B1, B2, B3, B5, B6, B9, B12, C, D, and E. It also contains several inactive ingredients including sodium bisulfite and gelatin.
3292381|NCT00527306|Placebo Comparator|II - Inactive Medication|The placebo will be a gelatin capsule filled with lactose.
3292382|NCT00527293|Experimental|MammoSite Brachytherapy|Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
3292383|NCT00527293|Experimental|3-dimensional conformal radiotherapy|3-dimensional conformal radiotherapy twice daily for 5-10 days.
3292384|NCT00527280|Experimental|1|
3292385|NCT00527267|Experimental|AMG 073|AMG 073
3292386|NCT00527267|Placebo Comparator|Placebo|Placebo
3292387|NCT00527254|No Intervention|Control group|
3292388|NCT00527254|Active Comparator|Telemedicine group|
3292389|NCT00527241|Experimental|1: A|
3292390|NCT00527241|No Intervention|2 B|wait-listed for intervention to begin in 6 months
3292391|NCT00527228|Active Comparator|A|After 6 months of treatment, and a 3-months wash-out, there is cross-over to Arm B
3292392|NCT00527228|Placebo Comparator|B|After 6 months of treatment, and a 3-months wash-out, there is cross-over to Arm A
3292393|NCT00527215|Experimental|darbepoetin alfa|
3292394|NCT00527202|Experimental|1|active treatment arm
3292395|NCT00527202|Placebo Comparator|2|
3292396|NCT00527150|Other|Cohort 1|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
3292397|NCT00527150|Other|Cohort 2|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
3292398|NCT00527150|Other|Cohort 3|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
3292399|NCT00527150|Other|Optional Cohort 4|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
3292400|NCT00527150|Other|Optional Cohort 5|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
3292401|NCT00527137|Active Comparator|rHuEPO|
3292402|NCT00527137|Experimental|darbepoetin alfa|
3292403|NCT00527124|Experimental|Arm I|Patients receive oral cediranib maleate once daily on days 1-21, docetaxel IV over 1 hour on day 1, and oral prednisone twice daily on days 1-21.
3292404|NCT00527124|Active Comparator|Arm II|Patients receive docetaxel and prednisone as in arm I.
3292405|NCT00527111|Experimental|Chemoradiotherapy plus Cetuximab|Pelvic irradiation plus 5-fluorouracil plus cetuximab
3292406|NCT00527111|Active Comparator|Chemoradiotherapy alone|Pelvic irradiation plus 5-fluorouracil
3292407|NCT00527085|Experimental|AMG 073|
3292408|NCT00527085|Placebo Comparator|Placebo|
3292409|NCT00527072|Experimental|001|infliximabOpen-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
3292410|NCT00527059|Experimental|1|patients with acute heart failure
3292411|NCT00527059|Active Comparator|2|standard therapy for heart failure
3292412|NCT00527033|Experimental|1|Oral
3292413|NCT00527033|Experimental|2|Oral
3292414|NCT00527033|Experimental|3|Oral
3292415|NCT00527033|Placebo Comparator|4|Oral
3292470|NCT00526474|Placebo Comparator|Placebo|1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.
3292530|NCT00525967|Active Comparator|1|Methadone plus Placebo
3292416|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort A|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
3292417|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort B|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
3292418|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort C|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
3292419|NCT00527020|Experimental|Part B: Subjects in 5 period crossover period|Eligible subjects (first 14 subjects) will be randomized to one of the following 14 sequences as a 5 period crossover with sequences; LMNOQ, MNOLQ, NOLMQ, OLMNQ, ONMLQ, NMLOQ, MLONQ, LONMQ, LNMOQ, NMOLQM MOLNQ, OLNMQ, OMNLQ and MNLOQ) (L= 80 milligrams GSK1018921 given in fasted state, M= 200 milligrams GSK1018921 given in fasted state, N= nicotine lozenge, O= placebo and Q= 80 milligrams GSK1018921 in fed state).
3292420|NCT00527020|Experimental|Part B: Subjects in 4 period crossover period|Eligible subjects (last 7 subjects) will be randomized to one of the following 7 sequences as a 4 period crossover with sequences; NLOM, LOMN, OLNM, LNMO, NMOL, MOLN, and MNLO.
3292421|NCT00527007|Experimental|A|
3292422|NCT00527007|No Intervention|B|
3292423|NCT00526994|Experimental|Screened|Screened w/4 questions on intimate partner violence; if positive, receives referral information
3292424|NCT00526994|Active Comparator|Universal education|all participants receive partner violence referral information
3292425|NCT00526994|No Intervention|Control|no screen and no referral
3292426|NCT00526981|Experimental|Treatment|Prone position + all conventional treatment.
3292427|NCT00526981|No Intervention|Control|Conventional treatment
3292428|NCT00526968|Experimental|1|EVT 101 8 mg capsule
3292429|NCT00526968|Experimental|2|EVT 101 15 mg capsule
3292430|NCT00526968|Placebo Comparator|3|Matching placebo capsule
3292431|NCT00526942|No Intervention|I|No contact control (NCC)
3292432|NCT00526942|Experimental|II|Computerized, SAAGE-designed, visual memory-based cognitive training
3292433|NCT00526929|Experimental|darbepoetin alfa|darbepoetin alfa (NESP)
3292434|NCT00526903|Experimental|Fiber|Fiber added to diet for a total of 6 weeks.
3292435|NCT00526903|Placebo Comparator|Placebo|Placebo powder taken for a total of 6 weeks.
3292436|NCT00526890|Experimental|CPSR|Concurrent Carboplatin, Paclitaxel and Selenomethionine in Combination with Radiation
3292437|NCT00526877|Experimental|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
3292438|NCT00526864||Elderly patients|
3292439|NCT00526864||HIV infected patients|
3292440|NCT00526864||Immunosuppressed patients|
3292441|NCT00526838|Experimental|1|once-weekly dosing
3292442|NCT00526838|Experimental|2|twice-weekly dosing
3292443|NCT00526812|Experimental|Group A (RTA 744)|Receive study drug for three consecutive days, Cycle repeated every 21 days.
3292444|NCT00526812|Experimental|Group C (RTA 744 Injection)|Receive study drug once a week for four consecutive weeks. Repeat cycle every 5 weeks.
3292445|NCT00526799|Experimental|Phase I|Topotecan 3.5 mg/m^2 + Sorafenib dose escalation:
3292446|NCT00526799|Experimental|Phase II|Topotecan 3.5 mg/m^2 + Sorafenib 400 mg po daily.
3292447|NCT00526773|Other|1|Telephone management plus a motivational intervention
3292448|NCT00526773|Other|2|Telephone management with standard patient education
3292449|NCT00526760|Experimental|Dexmedetomidine|
3292450|NCT00526747||Epo-resistant|Patients with CKD (estimated GFR < 60cc/min) not on hemodialysis who are receiving greater than or equal to 100IU/kg/week of epoetin alpha and/or 1mcg/kg/week darbepoetin to obtain target hemoglobin or hematocrit.
3292451|NCT00526747||Epo-responsive|Patients with CKD (estimated GFR < 60cc/min) not on hemodialysis who are requiring <100IU/kg/week of epoetin alpha and/or 1mcg/kg/week of darbepoetin to obtain target hemoglobin/hematocrit.
3292452|NCT00526682|Active Comparator|1|Comparison of actives for synergy
3292453|NCT00526656|Experimental|sunitinib malate|Drug
3292454|NCT00526643|Experimental|Arm B|combination chemotherapy
3292455|NCT00526643|Active Comparator|Arm A|monochemotherapy
3292456|NCT00526630|Active Comparator|1. MPD|Randomized to receive active Methylphenidate first. At cross-over, participants will receive placebo.
3292457|NCT00526630|Placebo Comparator|2. Placebo|Randomized to receive placebo first. At cross-over, participants will receive the active Methylphenidate.
3292458|NCT00526617|Experimental|Open Label|Within each dose level, subjects are treated with the same regimen/doses of ABT-888 and TMZ.
3292459|NCT00526604|Active Comparator|2|The control group will have an clinical examination and exercise and then return to general practitioner, which will take decision about sick leave or return to work.
3292460|NCT00526591|Experimental|Low-dose Cohort|Patients will receive 5.0mg P.O. daily continuously for 8 weeks
3292461|NCT00526591|Active Comparator|High-dose Cohort|Patients will receive 10mg P.O. daily continuously for 8 weeks
3292462|NCT00526578||Questionnaire|Pancreatic cancer patients or family member.
3292463|NCT00526565|Experimental|1|TAT (Tapas Acupressure Technique)
3292464|NCT00526565|Active Comparator|2|SS (Professionally facilitated social support groups)
3292465|NCT00526500|Experimental|P-T|
3292466|NCT00526500|Experimental|P- SAH|
3292467|NCT00526500|Experimental|P- A|
3292468|NCT00526500|Experimental|Control|
3292469|NCT00526487|Other|1|Endovascular Repair
3292531|NCT00525967|Experimental|2|Methadone plus Acetaminophen
3292471|NCT00526474|Experimental|Vorapaxar|one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.
3292472|NCT00526461|Experimental|PDT using HPPH|Patients receive HPPH IV over 1 hour on day 1. Patients then receive photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.
3292473|NCT00526448|Experimental|1|Peginterferon alfa-2a 180 mcg/week + ribavirin 2000 mg/day + epoetin beta 450 UI/week
3292474|NCT00526448|Active Comparator|2|Peginterferon alfa-2a 180 mcg/week + ribavirin 1000-1200 mg/day
3292475|NCT00526435|Experimental|Group WWE|Subjects will participate in a group-assisted 6 week WWE program.
3292476|NCT00526435|Experimental|Self-directed|Subjects will follow the self-directed WWE program.
3292477|NCT00526396|Active Comparator|A|standard fixed doses
3292478|NCT00526396|Experimental|B|toxicity adjusted dosing
3292479|NCT00526383|Experimental|A|antidepressant versus medical dispositive
3292480|NCT00526383|Placebo Comparator|B|
3292481|NCT00526370||A|Women with at least moderate dysplasia in biopsies from cervix uteri
3292482|NCT00526370||B|Women with only normal PAP-smears
3292483|NCT00526357|Other|A|Of the 24 asthmatic subjects, 12 will be enrolled who are taking beta2 agonists alone to treat their asthma
3292484|NCT00526357|Other|B|Of the 24 asthmatic subjects, 12 will be enrolled who are taking beta2 agonists and inhaled steroids to treat their asthma
3292485|NCT00526344||1|Subjects with complete remission of asthma
3292486|NCT00526344||2|Subjects with symptomatic remission of asthma
3292487|NCT00526344||3|Subjects with asthma
3292488|NCT00526344||4|Healthy controls
3292489|NCT00526331|Experimental|Study Group|FloTrac Sensor + Vigileo Monitor used to decide how much fluid to give during surgery.
3292490|NCT00526331|Experimental|Control Group|FloTrac Sensor + Vigileo Monitor only used for data collection during surgery; Standard of Care to decide fluid amount.
3292491|NCT00526292|Experimental|natural killer (NK) cells with salvage chemotherapy|This is a Phase II study, designed to determine the efficacy of natural killer (NK) cells isolated from HLA-haploidentical related donors when infused following a salvage chemotherapy regimen into patients who have relapsed or persistent leukemia following an allogeneic HLA-compatible HSCT and who are ineligible for a second HSCT.
3292492|NCT00526266|Experimental|1|
3292493|NCT00526266|Placebo Comparator|2|
3292494|NCT00526266|No Intervention|3|No Treatment
3292495|NCT00526253|Active Comparator|Low Dose|Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.
3292496|NCT00526253|Active Comparator|High Dose|Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.
3292497|NCT00526253|Placebo Comparator|Control|Patient will undergo biopsy of muscle tissue and biopsy tissue will be sent to lab.
3292498|NCT00526227|Experimental|1|Secura ICD implanted
3292499|NCT00526214|No Intervention|1|In the control group, patients will not take the drug. We do not use placebo drugs.
3292500|NCT00526214|Experimental|2|In the intervention group, patients will take celecoxib.
3292501|NCT00526201|Experimental|Exercise|Subjects will be randomized to exercise (12 week EnhanceFitness class) or a wait-list control group.
3292502|NCT00526201|Other|Control|Wait-list control group will receive intervention after 12-weeks.
3292503|NCT00526188|Experimental|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
3292504|NCT00526162|Experimental|1|
3292505|NCT00526136|Placebo Comparator|1|Placebo (b.i.d.)
3292506|NCT00526136|Experimental|2|Vernakalant (oral), 150 mg (b.i.d.)
3292507|NCT00526136|Experimental|3|Vernakalant (oral), 300 mg (b.i.d.)
3292508|NCT00526136|Experimental|4|Vernakalant (oral), 500 mg (b.i.d.)
3292509|NCT00526123|Active Comparator|1|symmetric tip catheter
3292510|NCT00526123|Active Comparator|2|conventional split-tip catheter
3292511|NCT00526110|Experimental|5-Fluorouracil + Docetaxel + Oxaliplatin|5-Fluorouracil 2.2 Gm/m^2 intravenously (IV) over 48 hours on Day 1. Docetaxel 20 mg/m^2 IV over 60 minutes. Oxaliplatin 85 mg/m^2 IV over 120 minutes on Day 1.
3292512|NCT00526097|Experimental|Bisacodyl 5 mg x 2 once daily|patient to receive two enteric-coated tablets containing 5 mg bisacodyl
3292513|NCT00526097|Placebo Comparator|Placebo|patient to receive two placebo-to-match enteric-coated tablets 5 mg bisacodyl
3292514|NCT00526071|Experimental|1|AT1001 dose group 1
3292515|NCT00526058|Other|A (Secura then Futura)|The Group Randomized first to the approved Plasmat® Secura apheresis system and then to the Plasmat® Futura apheresis system.
3292516|NCT00526058|Other|B (Futura then Secura)|The Group Randomized first to the approved Plasmat® Futura apheresis system and then to the Plasmat® Secura apheresis system.
3292517|NCT00526045|Experimental|Escalation|
3292518|NCT00526045|Experimental|HER2 Positive|
3292519|NCT00526045|Experimental|ER+ breast cancer|
3292520|NCT00526032||Spectroscopic Oblique-Incidence Reflectometry (OIR)|
3292521|NCT00526019||Complete remission of their asthma|Subjects in complete remission of their asthma Subjects in complete remission of their asthma: absence of respiratory symptoms, no rescue asthma medication need and an optimal pulmonary function and normal PC20 methacholine (>16 mg/ml) for more than two years (with no current treatment).
3292522|NCT00526019||Symptomatic remission ofasthma|Subjects in symptomatic remission of their asthma (No asthma symptoms in the last 2 years, no asthma medication, PC20 methacholine <16 mg/ml)
3292523|NCT00526019||Current asthma (mild asthma)|Subjects with current asthma (Mild asthma)
3292524|NCT00526019||Healthy controls|Healthy controls
3292525|NCT00525993|Experimental|A|
3292526|NCT00525993|Active Comparator|B|
3292527|NCT00525980|Experimental|Group 1: Written Materials|One group asked to read educational materials.
3292528|NCT00525980|Experimental|Group 2: Computer Program Only|Group 2 use an educational computer program to learn about breast cancer risk and genetic testing without guidance.
3292639|NCT00524940|Experimental|Study Group|
3292532|NCT00525915|Experimental|Arm A: Chemo with Radiation Treatment|For 5 weeks, Chemo of 5-FU 250 mg/m^2 intravenous (IV) over 24 hours for 5 days weekly with Oxaliplatin 40 mg/m^2 IV daily over 2 hours, and Radiation treatment every weekday; then surgery.
3292533|NCT00525915|Experimental|Arm B: Pre-Op Chemo + Chemo with Radiation Treatment|Pre-Operative Chemo 5-FU 2.2 mg/m^2 IV continuous infusion over 48 hours start on day 1 and 15, and Oxaliplatin 100 mg/m^2 IV on day 1 and 15; followed by Surgery + Chemo with Radiation Therapy (same as Arm A)
3292534|NCT00525902|Experimental|Adalimumab|
3292535|NCT00525889|Experimental|Rapamycin/IL-2 combination therapy|IL-2 (Proleukin) was administered at 4.5 3 106 IU s.c., three times per week for 4 weeks for a total of 12 doses. Rapamycin (Rapamune or Sirolimus) was administered without a loading dose at 2 mg/day, with adjustments to maintain trough blood levels of 5-10 ng/mL for 3 months.
3292536|NCT00525876|Experimental|Matched Sibling Transplant|Allogeneic Stem Cell Transplantation With Rituximab Containing Nonablative Conditioning Regimen: Cyclophosphamide 750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.
3292537|NCT00525876|Experimental|Allo MUD & MM|Allo MUD & MM = Allogeneic Stem Cell Transplantation, Matched unrelated donor or mismatched sibling donor transplantations: Cyclophosphamide 1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation. Alemtuzumab 15 mg per day given intravenously days 1 through 3 after transplantation.
3292538|NCT00525850|Other|1|high saturated fat diet
3292539|NCT00525850|Other|2|low calorie low saturated fat low trans fat high fiber diet
3292540|NCT00525837|Other|varenicline|open label varenicline
3292541|NCT00525811|Experimental|A|Interactive decision aid
3292542|NCT00525811|Active Comparator|B|Regular patient information
3292543|NCT00525798|Active Comparator|1|SMC021 - Oral Calcitonin
3292544|NCT00525798|Placebo Comparator|SMC021- Placebo|SMC021 - placebo
3292545|NCT00525785|Experimental|5-Fluorouracil + Folinic Acid + Oxaliplatin|"5-Fluorouracil 2.2 Gm/m^2 By Vein Over 48 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 300 mg/m2 a day Monday through Friday, by continuous infusion during radiation through an outpatient portable pump.~Folinic Acid 200 mg/m^2 by vein Over 30 Minutes On Days 1, 15, 29, and 43. Oxaliplatin 100 mg/m^2 By Vein Over 2 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 45 mg/m2 over 2 hours weekly for 5 weeks during radiation. (oxaliplatin should be administered on the first day of the radiation week).~Radiotherapy 45 Gy (1.8 Gy fx/day) Monday through Friday, 12 days after the last dose of 5FU plus oxaliplatin and no later than 28 days."
3292546|NCT00525772|Active Comparator|1|ciclesonide 50 and 200ug
3292547|NCT00525772|Active Comparator|2|ciclesonide 100ug and 400ug
3292548|NCT00525759|Active Comparator|A|Neoadjuvant chemotherapy alone
3292549|NCT00525759|Experimental|B|Neoadjuvant chemotherapy + zoledronic acid
3292550|NCT00525746||Cases|Patients with a confirmed diagnosis of AML or MDS (cases).
3292551|NCT00525746||Controls|Patients treated for a primary malignancy (controls).
3292552|NCT00525733|Active Comparator|3-drug standard therapy|FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ +ritonavir 100 mg QD
3292553|NCT00525733|Experimental|5-drug experimental therapy|FTC 200 mg/TDF 300 mg QD + darunavir 800 mg + ritonavir 100 mg QD + Raltegravir 400 mg BID + Maraviroc 150 mg BID
3292554|NCT00525720|Experimental|Brachytherapy - Participants with < 35% biopsy core|Brachytherapy implant procedure lasting 1-2 hours. Questionnaires taking 30 total minutes.
3292555|NCT00525720|Experimental|Brachytherapy - Participants with > 35% biopsy core|Brachytherapy implant procedure lasting 1-2 hours. Questionnaires taking 30 total minutes.
3292556|NCT00525707|Experimental|1|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
3292557|NCT00525707|Placebo Comparator|2|
3292558|NCT00525694|Other|1|glucose tolerance test solution
3292559|NCT00525694|Other|2|Diet Coke
3292560|NCT00525694|Other|3.|Coke Zero
3292561|NCT00525681|Other|CsA|Investigation of systemic exposure of cyclosporine before and after 2 moths of co-adminiastration of rimonabant.
3292562|NCT00525681|Other|Tac|Investigation of systemic exposure of tacrolimus before and after 2 moths of co-adminiastration of rimonabant.
3292563|NCT00525668|Active Comparator|verum|Sunphenon plus glatiramer acetate
3292564|NCT00525668|Active Comparator|placebo|placebo plus glatiramer acetate
3292565|NCT00525655|Experimental|Multimedia Intervention|
3292566|NCT00525642|Experimental|A|six cycles of adjuvant TAC
3292567|NCT00525642|Experimental|B|four cycles of T followed by 4 cycles of AC
3292568|NCT00525629|Experimental|Walnut Diet|48 Grams of Walnuts Daily
3292569|NCT00525629|Placebo Comparator|Control Diet|Isocaloric Diet with No Walnuts
3292570|NCT00525616|Experimental|Rituximab|Treatment consists of two slow intravenous infusions of rituximab 1000mg to 15 days apart with local corticosteroid .
3292571|NCT00525603|Experimental|CFAR|CFAR = Cyclophosphamide 200 mg/m^2/day 3-5 intravenous (IV) 5-30 minutes, Fludarabine 20 mg/m^2/day 3-5 IV 5-30 minutes, Alemtuzumab 30 mg 1, 3,5 IV 2-4 hours, and Rituximab 375 mg/m^2/day 2 IV 4-6 hours
3292572|NCT00525590|Experimental|1|
3292573|NCT00525577|Experimental|1:A|Placebo
3292574|NCT00525577|Experimental|2:B|AGI-1067 75 mg
3292575|NCT00525577|Experimental|3:C|AGI-1067 150 mg
3292576|NCT00525564|Placebo Comparator|A|Placebo diskus
3292577|NCT00525564|Active Comparator|B|Salmeterol diskus powder
3292578|NCT00525551|Active Comparator|1|
3292579|NCT00525551|Placebo Comparator|2|
3292580|NCT00525525|Experimental|Efficacy Group|Patients treated with the combination of radiation plus temozolomide (75 mg/m2 daily during radiotherapy) plus bevacizumab (10 mg/kg IV every two weeks during radiotherapy) plus tarceva (dose based upon use of EIAED, either 200 mg daily or 500 mg daily; given daily); all treatment begins at the start of radiotherapy and continues until tumor progression, death or excessive toxicity
3292638|NCT00524953|Experimental|I|10 patients after allogeneic BMT (non T-depleted).
3292640|NCT00524927|Active Comparator|A|
3292581|NCT00525525|Other|Safety Lead-in Group|"Fractionated radiotherapy in daily doses of 1.8-2.0 Gy delivered 5 days per week over ~6 weeks, to a total dose of 59.4 to 60 Gy.~Adjuvant temozolomide 200 mg/m^2/d x 5 d per 28-d cycle; Erlotinib 150-200 mg/d (or 500-600 mg/d for patients on enzyme-inducing antiepileptic drugs) on a continuous basis 7 days per week; Bevacizumab 10 mg/kg every 2 weeks"
3292582|NCT00525512|Experimental|tiotropium 18mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
3292583|NCT00525512|Placebo Comparator|Placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
3292584|NCT00525499|Placebo Comparator|1|Vehicle control cream applied topically to the face twice daily for 12 weeks
3292585|NCT00525499|Experimental|2|0.001% ASC-J9 cream applied topically to the face twice daily for 12 weeks
3292586|NCT00525499|Experimental|3|0.005% ASC-J9 cream applied topically to the face twice daily for 12 weeks
3292587|NCT00525499|Experimental|4|0.025% ASC-J9 cream applied topically to the face twice daily for 12 weeks
3292588|NCT00525486|Experimental|A|The treated group of pregnant women, after having successful treatment for PTL
3292589|NCT00525486|No Intervention|B|The no treatment arm of women treated with tocolysis for PTL.
3292590|NCT00525447|Experimental|1|
3292591|NCT00525434|Experimental|A|
3292592|NCT00525421|Experimental|Curcumin|Curcumin C3 Complex
3292593|NCT00525421|Placebo Comparator|Placebo|Placebo
3292594|NCT00525408|Experimental|2|Docetaxel+Mw
3292595|NCT00525408|Active Comparator|1|Docetaxel
3292596|NCT00525395|Experimental|A|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
3292597|NCT00525395|Active Comparator|B|Group B: 6 months non-stop treatment.
3292598|NCT00525356|Active Comparator|1|Anti-hypertensive medical treatment
3292599|NCT00525330|Experimental|KRP-104 120 mg QD|
3292600|NCT00525330|Experimental|KRP-104 60 mg BID|
3292601|NCT00525330|Placebo Comparator|Placebo|
3292602|NCT00525317|Active Comparator|Magnesium tablet suplementation (1)|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"
3292603|NCT00525317|Placebo Comparator|Placebo tablet suplementation (2)|Placebo (3 times daily for 2 weeks)
3292604|NCT00525304|Experimental|1|Participants will receive a self-management program for chronic illness
3292605|NCT00525304|No Intervention|Usaual Care|Usual Care; no additional intervention
3292606|NCT00525291|Experimental|EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
3292607|NCT00525291|Active Comparator|EMG-biofeedback alone|
3292608|NCT00525265|Experimental|1|OPC-41061
3292609|NCT00525265|Placebo Comparator|2|placebo
3292610|NCT00525252|Placebo Comparator|2|A total of 42 alcoholic patients with liver cirrhosis treated with placebo
3292611|NCT00525252|Active Comparator|1|a total of 42 alcoholic patients with liver cirrhosis treated by baclofen
3292612|NCT00525239|Experimental|1: Ritonaivr|Pre and post ritonavir, lopinavir/ritonavir or atazanavir/ritonavir
3292613|NCT00525226||1|Women who have experienced symptoms of depression or anxiety during pregnancy.
3292614|NCT00525213|Active Comparator|A|
3292615|NCT00525213|Active Comparator|B|
3292616|NCT00525213|Active Comparator|C|
3292617|NCT00525213|Placebo Comparator|D|
3292618|NCT00525200|Active Comparator|A|
3292619|NCT00525200|Experimental|B|
3292620|NCT00525174|Active Comparator|Patching|2 hours daily patching of the sound eye plus one hour near activities while patching
3292621|NCT00525174|Active Comparator|Bangerter filters|Bangerter filter worn on sound eye spectacles lens full time plus at least one hour near activities
3292622|NCT00525161|Experimental|Sorafenib & Endocrine Therapy|Sorafenib & Endocrine Therapy
3292623|NCT00525148|Experimental|BIBW 2992|Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop. Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs. After protocol amendment 2 (17 Dec 2008), the starting dose of BIBW 2992 was reduced to a medium dose, with 2 possible dose reductions if needed after discontinuation due to drug-related AEs.
3292624|NCT00525135|Other|1|If a patient exhibits increased radioiodine uptake on the Thyrogen scan post valproic acid therapy, patients will then prepare for ablative treatment and will remain on valproic acid for a total of 16 weeks, until receiving RAI ablation.
3292625|NCT00525135|Other|2|If no increased uptake is seen, patients will continue on valproic acid for 6 additional weeks at an increased dosage, totaling an overall treatment time of 16 weeks as well.
3292626|NCT00525122||1|Patients with hyperthyroidism who are will be treated with radioactive iodine.
3292627|NCT00525109||1|Single family cohort
3292628|NCT00525096|Placebo Comparator|Placebo|Aromasin + placebo in place of Celebrex
3292629|NCT00525096|Experimental|Celebrex|Aromasin + Celebrex
3292630|NCT00525057|Experimental|Group A:|Metastatic disease, myeloma, lymphoma - Dalteparin 5000 units subcutaneous injection once daily, for 7 - 10 days.
3292631|NCT00525057|Experimental|Group B:|Primary sarcoma of bone or soft tissue of the lower extremity - Dalteparin 5000 units subcutaneous injection once daily, for 7 - 10 days.
3292632|NCT00525031|Experimental|Temozolomide (TMZ)|Temozolomide = TMZ - 150 mg/m^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.
3292633|NCT00525031|Experimental|Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI)|"Temozolomide = TMZ and PGI = Pegylated Interferon-alpha 2b~Temozolomide 150 mg/m^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks. Pegylated Interferon-alpha 2b 0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks."
3292634|NCT00525005|Experimental|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
3292635|NCT00524979||Schizophrenia|People who are diagnosed as schizophrenic by DSM-IV
3292636|NCT00524979||Mental diseases|Patients who are deagnosed as having mental disease other then schizophrenia
3292637|NCT00524979||Mentally healthy|People who have no mental disease
3292641|NCT00524927|Placebo Comparator|B|
3292642|NCT00524914|Experimental|1|Apomorphine
3292643|NCT00524914|Placebo Comparator|2|Placebo
3292644|NCT00524901|Experimental|1|25 patients undergoing CABG for three vessel disease, receiving a single dose of erythropoietin periprocedural.
3292645|NCT00524901|Placebo Comparator|2|25 patients undergoing CABG for three vessel disease, receiving placebo (NaCl 0.9%) periprocedural.
3292646|NCT00524888|Active Comparator|1|suturing lacerations of the hand
3292647|NCT00524888|Active Comparator|2|using bioadhesive on lacerations of hand
3292648|NCT00524875|Experimental|1|Intravitreal bevacizumab injection 1-2 weeks before surgery
3292649|NCT00524875|Sham Comparator|2|Sham injection (needleless syringe pressed against conjunctiva)
3292650|NCT00524862|Other|1|
3292651|NCT00524862|Other|2|
3292652|NCT00524849|Active Comparator|conventional Zometa|Zometa 4mg IV q4w, in combination with other antitumor agents one month after the initial dosing.
3292653|NCT00524849|Experimental|weekly Zometa|Weekly Zometa in combination with other antitumor agents one month after the initial dosing.
3292654|NCT00524823|Case|1|10 diagnosed men in age 60 - 90 with Prostate Cancer
3292655|NCT00524823|Case|2|10 patients with benign growth
3292656|NCT00524823|Control|3|10 health volunteers
3292657|NCT00524823|Control|4|10 patients diagnosed with other cancer
3292658|NCT00524810|Experimental|Caelyx - Taxotere|
3292659|NCT00524797|Active Comparator|Main|50 patients will receive Profonycia 5 gr/day PO for 7 days
3292660|NCT00524784|Experimental|A|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses
3292661|NCT00524771||1|Users of NuvaRing
3292662|NCT00524771||2|Users of combined oral contraceptives
3292663|NCT00524758|Experimental|Ologen in Trabeculectomy|Ologen in Trabeculectomy
3292664|NCT00524758|Active Comparator|MMC in Trabeculectomy|MMC in Trabeculectomy
3292665|NCT00524745|Active Comparator|0,2,6 month vaccination schedule|
3292666|NCT00524745|Active Comparator|0,3,9 month vaccination schedule|
3292667|NCT00524745|Active Comparator|0,6,12 month vaccination schedule|
3292668|NCT00524745|Active Comparator|0,12,24 month vaccination schedule|
3292669|NCT00524732||1|18 to 30 months since last prior dose of TD/Td vaccine.
3292670|NCT00524732||2|30 to 42 months since last prior dose of TD/Td vaccine.
3292671|NCT00524732||3|42 to 54 months since last prior dose of TD/Td vaccine.
3292672|NCT00524732||4|54 to 66 months since last prior dose of TD/Td vaccine.
3292673|NCT00524732||5|66 to 78 months since last prior dose of TD/Td vaccine.
3292674|NCT00524732||6|78 to 90 months since last prior dose of TD/Td vaccine.
3292675|NCT00524732||7|90 to 102 months since last prior dose of TD/Td vaccine.
3292676|NCT00524732||8|102 to 114 months since last prior dose of TD/Td vaccine.
3292677|NCT00524732||9|Control - over 114 months since last prior dose of TD/Td vaccine.
3292678|NCT00524719|Active Comparator|Open, internal fixation volar plate|Open reduction and internal fixation (ORIF) with volar locked plate
3292679|NCT00524719|Active Comparator|Closed reduction with external fixator|Surgical procedure - Closed reduction and non-spanning external fixation (Ex-FIX)
3292680|NCT00524719|Active Comparator|Closed reduction percutaneous pinning|Surgical procedure - Closed reduction with percutaneous pinning (CRPP) and the application of a cast
3292681|NCT00524693|Active Comparator|1|4mg Singulair© sachets
3292682|NCT00524693|Placebo Comparator|2|
3292683|NCT00524680|Experimental|Arm I|Patients receive 4,000 IU of oral cholecalciferol (vitamin D3) once daily.
3292684|NCT00524680|Experimental|Arm II|Patients receive 6,000 IU of vitamin D3 once daily.
3292685|NCT00524680|Experimental|Arm III|Patients receive 8,000 IU of vitamin D3 once daily.
3292686|NCT00524680|Experimental|Arm IV|Patients receive 10,000 IU of vitamin D3 once daily.
3292687|NCT00524667|Experimental|1|
3292688|NCT00524615|Active Comparator|1|25 mg of Spironolactone oraly once daily
3292689|NCT00524615|Placebo Comparator|2|placebo oraly once daily
3292690|NCT00524589|Experimental|Dexamethasone and Calcitriol|Patients receive oral dexamethasone once on days 1 and 2 and calcitriol IV over 1 hour on day 2. Treatment repeats weekly.
3292691|NCT00524576|Experimental|Engerix 2 Doses + Challenge Dose|Subjects received 2 doses of Engerix™-B (Month 0 and 6) in the primary study and a single dose of Engerix™-B during the booster study.
3292692|NCT00524576|Experimental|Engerix 3 Doses + Challenge Dose|Subjects received 3 doses of Engerix™-B (Month 0, 1 and 6) in the primary study and a single dose of Engerix™-B during the booster study.
3292693|NCT00524537||Adalimumab (Humira) Treatment|Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.
3292694|NCT00524511|Experimental|1|Women receiving Dermabond for skin closure
3292695|NCT00524511|Active Comparator|2|Women receiving standard surgical skin staples
3292696|NCT00524498|Experimental|A|FAIT
3292697|NCT00524498|Active Comparator|B|BST
3292698|NCT00524485|Experimental|Arm 1 - ALA|Patients receive topical ALA topical (aminolevulinic acid) 2 hours before PDT.
3292699|NCT00524485|Experimental|Arm 2|Patients receive topical ALA topical (aminolevulinic acid) 4 hours before PDT
3292700|NCT00524485|Experimental|Arm 3|Patients receive topical ALA (aminolevulinic acid) 24 hours before PDT. Each anatomic area is divided into subunits (e.g., right and left arm, right and left side of the face). The subunits are randomized to receive 1 or 2 pulses of the laser treatment
3292701|NCT00524485|Experimental|Arm 4|Vbeam laser pulse (photodynamic therapy) is applied to the subunit
3292702|NCT00524485|Experimental|Arm 5|Vbeam laser pulses (photodynamic therapy) are applied to the subunit. Patients may receive up to 3 treatments (including pretreatment, ALA, and PDT) at least 1 month apart
3292703|NCT00524472|Experimental|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
3292704|NCT00524472|Other|Insulin at the standard of care levels|Group B will be administered insulin at the standard of care levels established by the participating institution.
3292842|NCT00523120|Active Comparator|2|dexotic
3292705|NCT00524446|No Intervention|ST-DI|Standard treatment - delayed intervention. Counselling on complementary feeding + Vitamin A (200,000 IU) every 6 months until 36 months + 1 kg maize / soy flour 2-weekly (71 g / day) between 18 and 30 months of age.
3292706|NCT00524446|Experimental|FSm|Fortified Spread (milk). Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
3292707|NCT00524446|Experimental|FSs|Counselling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
3292708|NCT00524446|Experimental|LP|Likuni Phala. Counseling + Vitamin A as for ST-DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
3292709|NCT00524433|Experimental|1|tezosentan
3292710|NCT00524433|Placebo Comparator|2|
3292711|NCT00524420|Experimental|Active rTMS|Active rTMS involves administration of real rTMS to the patient.
3292712|NCT00524420|Sham Comparator|Sham rTMS|Sham rTMS is a placebo or inactive form of rTMS for study control and comparison purposes.
3292713|NCT00524368|Experimental|DRV/rtv 800/100 mg once daily|Two 400 mg darunavir (DRV) ie, TMC114 tablets + one 100 mg ritonavir (rtv) capsule once daily.
3292714|NCT00524368|Experimental|DRV/rtv 600/100 mg twice daily|One 600 mg TMC114 tablet + one 100 mg capsule of rtv twice daily.
3292715|NCT00524342|Experimental|Oprelvekin, Interleukin 11, IL-11|25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
3292716|NCT00524316|Experimental|Sunitinib|oral sunitinib malate once daily on days 1-7 and 15-35 in course 1 and on days 1-28 in all subsequent courses
3292717|NCT00524303|Active Comparator|Arm 1|Trastuzumab alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles and Paclitaxel for 4 (21 day) cycles then continued trastuzumab until time of definitive surgery
3292718|NCT00524303|Experimental|Arm 2|Lapatinib alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued lapatinib until time of definitive surgery
3292719|NCT00524303|Experimental|Arm 3|Trastuzumab + Lapatinib for 2 weeks then added FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued trastuzumab + lapatinib until time of definitive surgery
3292720|NCT00524277|Experimental|Arm I|HLA-A2-positive patients receive GP2 peptide + GM-CSF vaccine intradermally (ID) every 3-4 weeks for a total of up to 6 inoculations.
3292721|NCT00524277|Active Comparator|Arm II|HLA-A2-positive patients receive GM-CSF ID every 3-4 weeks for a total of up to 6 inoculations.
3292722|NCT00524277|Experimental|Arm III|HLA-A2-negative patients receive AE37 peptide/GM-CSF vaccine ID every 3-4 weeks for a total of up to 6 inoculations.
3292723|NCT00524277|Active Comparator|Arm IV|HLA-A2-negative patients receive GM-CSF ID ID every 3-4 weeks for a total of up to 6 inoculations
3292724|NCT00524264|Experimental|1|
3292725|NCT00524264|Placebo Comparator|2|
3292726|NCT00524238|Other|1|11 hypothyroid patients, newly diagnosed, examined before and after treatment
3292727|NCT00524238|No Intervention|2|10 healthy controls
3292728|NCT00524225|Experimental|Neumega (Interleukin 11, IL-11)|Neumega (Oprelvekin, Interleukin 11, IL-11) 25 mcg/kg subcutaneously, given for 4 days preoperatively, and on day 5 preoperatively, and for up to 2 days postoperatively
3292729|NCT00524212||IE confirmed IE rejected|Prospective, controlled, blinded study of clinical/TEE criteria of IE compare to clinical/blood test criteria of IE.
3292730|NCT00524212||IE confirmed IE rejected|
3292731|NCT00524199|Placebo Comparator|Placebo|Saline IV infusion over five minutes at the beginning of dialysis.
3292732|NCT00524199|Active Comparator|Mesna|12 mg/kg mesna IV infusion over five minutes at the beginning of dialysis.
3292733|NCT00524186|Experimental|Oral Sunitinib|Patients receive oral sunitinib malate on day -7 and then once daily on days 2-28 in course 1 and on days 1-28 in all subsequent courses
3292734|NCT00524173|Active Comparator|Tenofovir only|Tenofovir 300mg by mouth daily for 192 weeks
3292735|NCT00524173|Experimental|Tenofovir & emtricitabine|Tenofovir 300mg in combination with emtricitabine 200mg by mouth daily for 192 weeks
3292736|NCT00524134|Experimental|1|Carvedilol-CR up to 80mg daily, used as a P-glycoprotein inhibitor to increase drug concentrations in specific regions of the brain.
3292737|NCT00524121|Experimental|Oral Erlotinib|Patients receive oral erlotinib hydrochloride once daily for 1 year
3292738|NCT00524095|No Intervention|1|standard of care
3292739|NCT00524095|Experimental|2|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
3292740|NCT00524095|Experimental|3|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
3292741|NCT00524056|Experimental|001|Carisbamate two 100 mg tablets twice per day
3292742|NCT00524056|Placebo Comparator|002|Placebo two placebo tablets twice per day
3292743|NCT00524043|Experimental|001|Paliperidone ER 1.5 mg tablet once daily for 6 weeks
3292744|NCT00524043|Active Comparator|002|Paliperidone ER 6 mg tablet once daily for 6 weeks
3292745|NCT00524043|Placebo Comparator|003|Placebo Once daily for 6 weeks
3292746|NCT00524030|Experimental|1|
3292747|NCT00524030|Experimental|2|
3292748|NCT00524017|Experimental|Arm I (treatment)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.
3292749|NCT00524017|No Intervention|Arm II (control)|Patients receive regular follow-up care
3292750|NCT00524004|Experimental|Anti-CsbD Bovine IgG|Anti CsbD Bovine Milk Immunoglobulin
3292751|NCT00524004|Experimental|Placebo|Lacto-free milk supplement
3292752|NCT00524004|Experimental|Anti-CS17 Bovin IgG|Anti-CS17 Bovin Milk Immunoglobulin
3292753|NCT00523991|Placebo Comparator|placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
3292754|NCT00523991|Experimental|tiotropium|Oral inhalation once daily of 18mcg tiotropium via handihaler
3292755|NCT00523978|Experimental|Experimental|Experimental subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci. If necessary, experimental subjects were allowed a previously failed Study Atrial Fibrillation Drug (AF Drug).
3294056|NCT00512941||7|Susceptible individuals
3292756|NCT00523978|Active Comparator|Control|Control Subjects were treated with an AF Drug (flecainide, propafenone, or sotalol) that they had not previously failed.
3292757|NCT00523965|Experimental|A|AmBisome 5 mg/kg iv infusion over 2 h x 1 day (single dose) + oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 7 days on day 2-8
3292758|NCT00523965|Experimental|B|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
3292759|NCT00523965|Experimental|C|oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
3292760|NCT00523965|Active Comparator|D|amphotericin B deoxycholate at 1 mg/kg every other day for 15 infusions
3292761|NCT00523952|Experimental|1|
3292762|NCT00523939|Experimental|Lymphomatous|Subjects with Lymphomatous Meningitis
3292763|NCT00523939|Experimental|Leukemic|Subjects with Leukemic Meningitis
3292764|NCT00523900|Experimental|Experimental|Malnourished adults who will be given a dietary supplement.
3292765|NCT00523848|Experimental|Arm 1|Patients receive low-dose oral thalidomide once a day on days 1-28, bortezomib IV on days 1, 4, 15, and 18, and doxorubicin hydrochloride liposome IV over 60-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity
3292766|NCT00523835|Case|KS|Patients with Klinefelter syndrome verified by chromosome analysis
3292767|NCT00523835|Control|Normal|Normal men Age matched to KS patients
3292768|NCT00523809|Experimental|Bevacizumab + Fludarabine + Melphalan|Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m^2 IV Daily over 5 Days; Melphalan 70 mg/m^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.
3292769|NCT00523770||Group A|Non-pneumococcal infected healthy elderly volunteers
3292770|NCT00523757|Experimental|1|Spironolactone
3292771|NCT00523757|Placebo Comparator|2|
3292772|NCT00523744|Experimental|Amlodipine(AML)+olmesartan, AML+valsartan, AML+valsartan+HCTZ|During the Treatment Phase 1, participants received 1 week of treatment with olmesartan 10 mg and amlodipine 5 mg once daily in free combination, followed by three weeks of treatment with olmesartan 20 mg plus amlodipine 10 mg once daily in free combination. During the treatment Phase 2 of the study participants received amlodipine 10 mg plus valsartan 160 mg for 4 weeks. During the Extension Phase, participants received 4 weeks treatment with amlodipine 10 mg plus valsartan 160 mg plus hydrochlorothiazide (HCTZ) 12.5 mg.
3292773|NCT00523718|Experimental|riluzole|Patients randomized to this arm will receive riluzole augmentation, at a standard, fixed dose (50 mg bid), in addition to the medication regimen they are on at enrollment
3292774|NCT00523718|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from riluzole, in addition to the medication regimen they are on at study enrollment.
3292775|NCT00523705|Experimental|escitalopram|Escitalopram 10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
3292776|NCT00523705|Placebo Comparator|placebo|Placebo tablets matched to drug.
3292777|NCT00523692|Experimental|1|Intensive therapy
3292778|NCT00523692|Active Comparator|2|Standard therapy
3292779|NCT00523666|Active Comparator|1|
3292780|NCT00523666|Placebo Comparator|2|
3292781|NCT00523640|Experimental|I|"Combination of gemcitabine, capecitabine, and bevacizumab~gemcitabine 1000 mg/m^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle"
3292782|NCT00523614||1: Cases|
3292783|NCT00523614||2: Controls|
3292784|NCT00523575|No Intervention|C|Usual nurse and dietetic care
3292785|NCT00523575|Experimental|I|Intensive nutritional support composed of oral dietary supplement combined with dietetic counselling.
3292786|NCT00523562|Experimental|normal weight male high fructose diet|"Effects of diet intervention  high fructose in normal weight subjects"
3292787|NCT00523562|Experimental|offsprings of T2DM high fructose diet|"Effect of diet intervention high fructose in healthy non-obese offsprings of patients with type 2 diabetes"
3292788|NCT00523562|Experimental|normal weight subjects high fat diet|"effects of diet intervention high fat in healthy male subjects"
3292789|NCT00523562|Experimental|Normal weight high fat+protein diet|"effect of diet intervention high fat + protein subjects in healthy male subjects"
3292790|NCT00523549|Experimental|Standard treatment regimen|(Valsartan + Amlodipine to target SBP of < 140 mmHg)
3292791|NCT00523549|Experimental|Intensive treatment regimen|(Valsartan + Amlodipine to target SBP < 130 mm Hg)
3292792|NCT00523536|Experimental|1|Patient navigator-nurse disease management intervention
3292793|NCT00523536|No Intervention|2|Usual clinical care
3292794|NCT00523523|Experimental|A|This group will complete a 2 week program of functional task practice with auditory rhythm cuing.
3292795|NCT00523523|Active Comparator|F|This group will complete a 2 week program of functional task practice without auditory rhythm cuing.
3292796|NCT00523510|Experimental|Feasibility Study|HIV positive women [and a smaller number of HIV negative/unknown status (1 for every 3 infected women)] to avoid stigmatizing home-based counseling will be recruited at 1-2 postpartum and provided enhanced home-based infant feeding counseling by community health workers to exclusively breastfeed for 6 months. Mothers will also be told about the option to Flash-heat breastmilk during and after the transition from exclusive breastfeeding. Mothers who choose to Flash-heat will be provided continued home-based counseling and support. Feasibility data will be collected during the time mothers Flash-heat.
3292843|NCT00523107|Experimental|PG2|PG2 500 mg / 500 ml normal saline will be given t.i.w for 8 weeks.
3292844|NCT00523107|Placebo Comparator|Placebo|500 ml normal saline will be given t.i.w 1-4 weeks, then PG2 500 mg / 500 ml normal saline will be given 5-8 weeks.
3292892|NCT00522678|Experimental|Cohort A|In Cohort A, subjects will be randomized (3:1) to receive once daily doses of GW685698X 400 microgram (mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
3294886|NCT00505531||Placebo|Diphenhydramine capsules Weeks 1-6- 25 mg/day
3292797|NCT00523510|Experimental|Pilot efficacy|We will collect infant health data to monitor and compare health outcomes among 3 groups of infants who had exclusive breast feeding (EBF) for the first months and then either: 1) fed Flash-heated breast milk and complementary foods (n=30), or 2) weaned to replacement foods and NO breast milk (n=15; per standard WHO recommendation for rapid cessation), or 3) continued feeding at the breast and providing other foods and/or fluids, i.e. mixed feeds (n=15; per WHO consensus that breastfeeding continue if replacement feeding is not AFASS94). We will collect infant growth and morbidity data. Infant health outcomes will be compared for the 3 groups noted above. These data will be collected primarily to pilot an efficacy trial.
3292798|NCT00523458|Active Comparator|1|Standard dose nevirapine (200 mg 2x daily) in combination with 2 nucleoside analogs
3292799|NCT00523458|Experimental|2|High dose nevirapine (400 mg in the morning, 200 mg in the evening) in combination with 2 nucleoside analogs
3292800|NCT00523458|Active Comparator|3|Standard dose efavirenz (600 mg at bedtime) in combination with 2 nucleoside analogs
3292801|NCT00523458|Experimental|4|High dose efavirenz (800 mg at bedtime) in combination with 2 nucleoside analogs
3292802|NCT00523445|Experimental|Varenicline|The effect of varenicline on cognitive function of Varenicline(Chantix) is being compared to that of placebo
3292803|NCT00523445|Placebo Comparator|Placebo|The effect of placebo comparator is being compared to that of varenicline
3292804|NCT00523432|Experimental|A|Arm A will consist of subjects without prior pelvic radiation or with radiation to a field smaller than the whole pelvis. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.
3292805|NCT00523432|Experimental|B|Arm A will consist of subjects with prior whole pelvic radiation. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.
3292806|NCT00523419|Experimental|Pemetrexed|Participants received pemetrexed 500 milligrams per square meter (mg/m^2) by intravenous (IV) infusion of 10 minutes on Day 1 of each 21-day cycle.
3292807|NCT00523406|Active Comparator|A|standard fluence photodynamic therapy and intravitreal triamcinolone combination
3292808|NCT00523406|Active Comparator|B|reduced fluence photodynamic therapy and intravitreal triamcinolone combination
3292809|NCT00523393|No Intervention|1|
3292810|NCT00523393|Experimental|2|
3292811|NCT00523393|Active Comparator|3|
3292812|NCT00523380|Experimental|A|
3292813|NCT00523367|No Intervention|esomeprazole|
3292814|NCT00523354|Experimental|1 (open-label)|prospective, open label, uncontrolled trial
3292815|NCT00523341|Experimental|Denosumab|Participants received a 60 mg subcutaneous injection of denosumab every 6 months for seven years.
3292816|NCT00523328|Experimental|BG9924|dosage administered as per Biogen-idec protocol
3292817|NCT00523302|Active Comparator|Active TMS|Since cortical stimulation can be performed non-invasively by active Transcranial Magnetic Stimulation (TMS), Participants in the active TMS group, receive five 20 minute active TMS treatment sessions per week for two weeks.
3292818|NCT00523302|Sham Comparator|Sham TMS|To prevent unwanted cortical activation, Sham TMS will be employed in the Sham TMS group. For the Sham TMS group, a specially designed sham TMS coil will be used for all sham conditions. This sham TMS coil produces auditory signals identical to active TMS coils but is shielded so that actual stimulation does not occur. This approach is currently the state-of-the-art approach to sham TMS procedures and is employed in high-quality clinical TMS trials. Participants in the sham TMS group receive five 20 minute Sham TMS treatment sessions per week for two weeks.
3292819|NCT00523289|Active Comparator|B|Arm number B corresponds to the Bupivacaine group.
3292820|NCT00523289|Active Comparator|R|Arm number R corresponds to the Ropivacaine group.
3292821|NCT00523276||HCWs|Who may/may not have contact with SARS patients
3292822|NCT00523276||Family/close contacts|No illness but household/close contact
3292823|NCT00523276||SARS subjects|Diagnosed with active disease
3292824|NCT00523263|Active Comparator|Dacron|Patients receiving polyester above-knee femoro-popliteal bypass
3292825|NCT00523263|Active Comparator|HUV|patients receiving HUV femoro-popliteal bypass
3292826|NCT00523250|Experimental|AR-102 0.003% Ophthalmic Solution|q.d. ocular
3292827|NCT00523250|Experimental|AR-102 0.005% Ophthalmic Solution|q.d. ocular
3292828|NCT00523250|Experimental|AR-102 0.01% Ophthalmic Solution|q.d. ocular
3292829|NCT00523250|Experimental|AR-102 0.03% Ophthalmic Solution|q.d. ocular
3292830|NCT00523250|Experimental|AR-102 Vehicle Ophthalmic Solution|q.d. ocular
3292831|NCT00523224|Experimental|single arm|open lable,single arm , intervention is Angiogenic Cell Precusors(ACPs)
3292832|NCT00523211|Experimental|Test Arm|Vicriviroc 30 mg QD
3292833|NCT00523211|Placebo Comparator|Placebo Control Arm|Placebo
3292834|NCT00523185|Active Comparator|2|
3292835|NCT00523185|Active Comparator|1|
3292836|NCT00523172|Active Comparator|Group A|"1) Group A will receive 9 manipulative therapy treatments (adjustments) to one area: the hip with pre-manipulative static and post active-assisted stretch of tight hip muscles. After the last (or 9th) treatment these patients will receive general advice and recommendations on managing HOA and how to gently and safely increase general exercise.~• Based on a previous trial, Group A treatment appears superior than placebo. There will be a 3, 6 and 9 month follow up."
3292837|NCT00523172|Active Comparator|Group B|2) Group B will receive 9 treatments with manipulative therapy treatments (adjustments) to the entire kinetic chain (five areas): the lumbosacral, sacroiliac, hip, knee, ankle and foot joints with pre-manipulative static and post active-assisted stretch of tight hip muscles. There will be a 3, 6 and 9 month follow up.
3292838|NCT00523172|Other|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
3292839|NCT00523159|Other|1|Pre-treatment with a single low dose of Cyclophosphamide followed by IMA901 vaccination plus GM-CSF as adjuvant
3292840|NCT00523159|Other|2|No pre-treatment with Cyclophosphamide before vaccination with IMA901 and GM-CSF as adjuvant
3292841|NCT00523120|Active Comparator|1|voltaren ophta
3292845|NCT00523081|Experimental|Experimental|Teens in the experimental group will meet with a research counselor for five to nine individual, 50-minute weekly sessions. They will learn ways to deal with stress and feel better. The study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
3292846|NCT00523081|Active Comparator|Active Control|
3292847|NCT00523068|Active Comparator|1|Tension Free Vaginal Tape
3292848|NCT00523068|Active Comparator|2|Tolterodine tartrate 4mg
3292849|NCT00523042|Experimental|A|
3292850|NCT00523042|Active Comparator|B|
3292851|NCT00523029|Experimental|1|Participants will receive a chronic disease self-management program
3292852|NCT00523016|Experimental|Electroacupuncture|Subjects will receive Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP) electroacupuncture protocol for 20 minutes per treatment session; a total of 13 treatments will be administered over 3-4 weeks.
3292853|NCT00523016|Sham Comparator|Sham acupuncture|Subjects will receive simulated acupuncture that includes insertion of acupuncture needles on the head. During each treatment session, needles will be stimulated with electricity for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
3292854|NCT00523003|Experimental|1,|2.2 g protein/kg LBM/day high protein diet
3292855|NCT00523003|Placebo Comparator|2, standard protein|1.1 g protein/kg LBM/day standard protein diet
3292856|NCT00522990|Experimental|1|Refractory Hematological Malignancies
3292857|NCT00522964|Experimental|Intervention|
3292858|NCT00522951|Experimental|Gadobutrol 0.1 mmol/kg bw|Participants received first injection (intravenous [i.v.]) of gadobutrol 0.1 mmol/kg body weight (bw), corresponding to a dose of 0.1 mmol/kg bw
3292859|NCT00522951|Experimental|Gadobutrol 0.2 mmol/kg bw|Participants received second injection (i.v.) of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min
3292860|NCT00522951|Experimental|Gadoteridol (ProHance)|Participants received two injections (i.v.) of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min
3292861|NCT00522925|Placebo Comparator|1|Matching Placebo
3292862|NCT00522925|Experimental|2|
3292863|NCT00522925|Experimental|3|
3292864|NCT00522912|Experimental|A|Immediate posterior lamella tarsal rotation surgery for minor trichiasis
3292865|NCT00522912|Active Comparator|B|Regular epilation by another person
3292866|NCT00522899|Experimental|Aerobic exercise|Study-specific group exercise classes include 10' warm-up, 30' cardio, 5' cool down, 15' stretching/toning. Target heart rate is 60-75% of maximum. Study participants attend classes 60 min/day, 3 days/week for 12 weeks.
3292867|NCT00522899|Active Comparator|Stretching/toning|Study-specific stretching/toning exercise classes include 10' warm-up, 40' stretching/toning, 10' relaxation. Participants attend classes 60 minutes/day, 3 days/week for 12 weeks.
3292868|NCT00522899|Experimental|Computer-based mental activity training|Computer-based visual and auditory stimulation training programs developed by Posit Science corporation. Participants perform assigned mental activity on computers in their homes for 60 minutes/day, 3 days/week for 12 weeks.
3292869|NCT00522899|Active Comparator|Educational DVD training|Watching and listening to in-depth, college-level lectures on art, history and science on the computer. Participants perform assigned mental activities 60 minutes/day, 3 days/week for 12 weeks.
3292870|NCT00522873|Experimental|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 13 cycles (28 days per cycle).
3292871|NCT00522873|Active Comparator|0.5mg NETA / 1.0mg E2 (Activella)|One capsule [0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)] per day taken orally for 13 cycles (28 days per cycle).
3292872|NCT00522860|Experimental|Vicryl Suture|Vicryl sutures, 5/0, 3/8 curved cutting needle
3292873|NCT00522860|Active Comparator|Silk Suture|Silk suture, 4/0, 3/8 curved cutting needle
3292874|NCT00522834|Active Comparator|1|Elesclomol (STA-4783) in Combination With Paclitaxel
3292875|NCT00522834|Other|2|Paclitaxel alone
3292876|NCT00522821|Other|Antibiotics|"A: co-trimoxazole prophylactically for 12 months followed by intravenous immunoglobulin treatment for 12 months.~Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given."
3292877|NCT00522821|Other|intravenous immunoglobulins|"B: intravenous immunoglobulin treatment for 12 months followed by co-trimoxazole prophylactically for 12 months.~Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given."
3292878|NCT00522795|Experimental|PPX with cisplatin and radiation|PPX 50mg/m2 wk and cisplatin 25mg/m2 wk for 6 weeks with 50.4 GY concurrent radiation
3292879|NCT00522782|Active Comparator|A|Nebulized budesonide
3292880|NCT00522769|Active Comparator|Delayed Intervention|1/2 of participants are randomized to immediate intervention that starts within a week of randomization. The other 1/2 of the participants are randomized to delayed intervention which starts 6 months after randomization.
3292881|NCT00522769|Experimental|Immediate intervention|Immediate intervention starts within two weeks of randomization. Delayed interventions starts 6 months after randomization.
3292882|NCT00522756|Experimental|Intervention|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
3292883|NCT00522756|Active Comparator|Control|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
3292884|NCT00522743|Experimental|1|GH & GNRHa treatment
3292885|NCT00522743|Active Comparator|2|GH treatment
3292886|NCT00522730|Experimental|1|Parenteral nutrition
3292887|NCT00522730|Active Comparator|2|Enteral nutrition
3292888|NCT00522717|Experimental|1|
3292889|NCT00522717|Active Comparator|2|
3292890|NCT00522691|Experimental|A: sacral first|Phase 1: sacral nerve stimulation crossover Phase 2 : sham stimulation
3292891|NCT00522691|Experimental|B: sham first|Phase 1: sham stimulation crossover Phase 2: sacral nerve stimulation
3293005|NCT00521612|Active Comparator|B|Isoflurane group, control group
3292893|NCT00522678|Experimental|Cohort B|In Cohort B, subjects will be randomized (3:1) to receive once daily doses of GW685698X (600 mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
3292894|NCT00522678|Experimental|Cohort C|InIn Cohort C, subjects will be randomized (3:1) to receive once daily doses of GW685698X (800 mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
3292895|NCT00522665|Active Comparator|Arm A: Irinotecan + Cetuximab +/- RAD001|
3292896|NCT00522665|Active Comparator|Arm B: Ironotecan + Cetuximab|
3292897|NCT00522652|Experimental|Investigational Drug|Dose Escalation
3292898|NCT00522626||Observational|Opioid exposed pregnancies
3292899|NCT00522587|Experimental|1|Fixed sevoflurane dose 1
3292900|NCT00522587|Experimental|2|Fixed sevoflurane dose 2
3292901|NCT00522587|Experimental|3|Fixed sevoflurane dose 3
3292902|NCT00522587|Experimental|4|Fixed sevoflurane dose 4
3292903|NCT00522587|Experimental|5|Fixed sevoflurane dose 5
3292904|NCT00522587|Experimental|6|Fixed sevoflurane dose 6
3292905|NCT00522587|Experimental|7|Fixed remifentanil dose 1
3292906|NCT00522587|Experimental|8|Fixed remifentanil dose 2
3292907|NCT00522587|Experimental|9|Fixed remifentanil dose 3
3292908|NCT00522587|Experimental|10|Fixed remifentanil dose 4
3292909|NCT00522587|Experimental|11|Fixed remifentanil dose 5
3292910|NCT00522587|Experimental|12|Fixed remifentanil dose 6
3292911|NCT00522561|Other|1|healthy volunteers
3292912|NCT00522548|Active Comparator|Enteric coated mycophenolate sodium|Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) at a target dose of 720 mg orally twice daily for 6 months after transplant.
3292913|NCT00522548|Active Comparator|Mycophenolate mofetil|Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent manufactured by Sandoz, at a target dose of 1000 mg orally twice daily for 6 months after transplant.
3292914|NCT00522535|Active Comparator|Open Surgical Repair|Open surgical repair of abdominal aortic aneurysm. All patient enrollment and 2-year follow-ups completed.
3292915|NCT00522535|Experimental|Endovascular Repair|"Endovascular treatment arm of 160 patients having suitable anatomy for the Aorfix™ AAA Flexible Stent Graft System. Use of stent grafts in aortic angles greater than 60° has not been approved for other devices available in the US. As a result, a minimum of 120 patients in this arm will have an aortic angle between 60° and 90°.~Patient recruitment completed; 5-year follow-up evaluations continue."
3292916|NCT00522535|Experimental|Continued Access|"Endovascular treatment arm of 50 patients maximum having suitable anatomy for the Aorfix™ AAA Flexible Stent Graft System. This Arm will provide active sites with ongoing device access while FDA reviews the PMA.~Patient recruitment completed; 5-year patient follow-ups continue."
3292917|NCT00522431|Experimental|1|2% testosterone gel
3292918|NCT00522418|Experimental|VNS Therapy|VNS Therapy + Best Medical Practice
3292919|NCT00522418|Active Comparator|Best Medical Practice|Best Medical Practice
3292920|NCT00522405|Active Comparator|1|Transarterial Chemoembolisation
3292921|NCT00522405|Active Comparator|2|TACE Plus oral chemotherapy
3292922|NCT00522392|Experimental|Arm A (VRD)|Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib, dexamethasone and lenalidomide. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11; fixed dose of lenalidomide at 15 mg orally on days 1-14; and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15. Aspirin 325 mg/day orally on days 1-21 of each cycle was required unless the patient was treated with alternate prophylaxis of either low molecular weight heparin or coumadin.
3292923|NCT00522392|Active Comparator|Arm B (VD)|Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib plus dexamethasone. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11 and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15.
3292924|NCT00522379|Experimental|Rotigotine 2 mg/24 hr|
3292925|NCT00522379|Experimental|Rotigotine 4 mg/24 hr|
3292926|NCT00522379|Experimental|Rotigotine 6 mg/24 hr|
3292927|NCT00522379|Experimental|Rotigotine 8 mg/24 hr|
3292928|NCT00522379|Placebo Comparator|Placebo|
3292929|NCT00522353|Active Comparator|1|Oligofructose
3292930|NCT00522353|Placebo Comparator|2|Placebo
3292931|NCT00522340|Experimental|Aerobic Exercise Program|
3292932|NCT00522340|No Intervention|Usual Care|
3292933|NCT00522327|Experimental|1|remote simult med interpret
3292934|NCT00522327|Active Comparator|2|Usual & Customary
3292935|NCT00522327|Other|3|comparison group
3292936|NCT00522314|Active Comparator|1|NIV & ACBT
3292937|NCT00522314|Placebo Comparator|2|Active cycle of breathing techniques
3292938|NCT00522301|Experimental|Oral Sorafenib (BAY43-9006)|Sorafenib is supplied as 200-mg tablets. Sorafenib will be administered as 400 mg orally daily x 28 days (continuous). One cycle = 28 days. There is no planned treatment interruption between cycles. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating). In the absence of intolerable toxicity, a patient may continue to receive treatment with sorafenib until disease progression, or until 24 months have elapsed.
3292939|NCT00522288|Experimental|Contact Lens|Soft contact lenses
3292940|NCT00522288|Active Comparator|Spectacle|Spectacles
3292941|NCT00522275|Experimental|Lacosamide|Up to 800 mg/day lacosamide (flexible dosing)
3292942|NCT00522262|Experimental|Exercise|Women randomized to the exercise intervention arm completed a one year aerobic exercise intervention of 225 minutes/week.
3292943|NCT00522262|No Intervention|Control|Women randomized to the control arm were asked to maintain their regular lifestyle which meant no changes to their exercise or dietary intake. Women eligible for this trial were inactive and hence were expected not to increase their levels of physical activity in the control arm.
3292944|NCT00522249|Experimental|1|One cycle of the combination therapy will be 42 days (6 weeks). All patients will receive PEG-Intron given subcutaneously on Day 1 each week. Patients will receive Sunitinib orally on Days 1-28 of each cycle. Patients will receive Tarceva orally on Days 1-42.
3292945|NCT00522236|Experimental|Arm 1|
3292946|NCT00522223||Questionnaire|Questionnaire
3292947|NCT00522210|Experimental|BID insulin with LA analogue|Treatment Group: BID Insulin Regimen with Long Acting Insulin Analogue (Detemir)
3292948|NCT00522210|Active Comparator|Standard TID insulin|Active Control Group: Usual TID Insulin Regimen (intermediate insulin- Humulin N or Novolin NPH)
3292949|NCT00522197|Active Comparator|ACAPHA|
3292950|NCT00522197|Placebo Comparator|Sugar Pill|
3292951|NCT00522184|Experimental|1|patient receiving etanercept intra-articular injection
3292952|NCT00522184|Active Comparator|2|patient receiving steroid intra-articular injection
3292953|NCT00522171||Electro Surgery|Electro Surgical instruments are used to cut and coagulate tissue using alternating electric current at the surgical site. In Electro Surgery, the patient is included in the circuit and current enters the patient's body.
3292954|NCT00522145|Experimental|Group 1|
3292955|NCT00522132|Active Comparator|cohort 1|2.4 mg/kg iv artesunate at 0, 12, 24, 48and 72 hours
3292956|NCT00522132|Experimental|cohort 2|4.0 mg/kg iv Artesunate at 0, 24 and 48 h
3292957|NCT00522106|Experimental|A|Behavioral graded activity
3292958|NCT00522106|Active Comparator|B|Exercise therapy
3292959|NCT00522067|Experimental|Arm 1|FLUAD
3292960|NCT00522054|Other|A|Single group study
3292961|NCT00522041|Experimental|Cellegesic (nitroglycerin 0.4%)|Participants applied Cellegesic 375 mg ointment containing approximately 1.5 mg of nitroglycerin anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
3292962|NCT00522041|Placebo Comparator|Placebo 375 mg|Participants applied placebo 375 mg ointment anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
3292963|NCT00522015|Active Comparator|1|patients take 6 mg rivastigmine daily, if well tolerable increase to 12 mg rivastigmine maximum daily
3292964|NCT00521989|Experimental|CRx-102 (2.7/90)|"2.7 mg prednisolone plus 90 mg dipyridamole~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
3292965|NCT00521989|Experimental|CRx-102 (2.7/180)|"2.7 mg prednisolone plus 180 mg dipyridamole~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
3292966|NCT00521989|Experimental|CRx-102 (2.7/360)|"2.7 mg prednisolone plus 360 mg dipyridamole~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
3292967|NCT00521989|Active Comparator|Prednisolone|"2.7 mg prednisolone~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM."
3292968|NCT00521989|Placebo Comparator|Placebo|"Placebo~Subjects were dose twice daily through day 98."
3292969|NCT00521976||Chest pain|Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).
3292970|NCT00521963|Experimental|E|
3292971|NCT00521950|Experimental|Intervention, TPMT genotyping|Pre-treatment TPMT genotyping to optimize initial thiopurine treatment dose. Intervention is based on the genotype.
3292972|NCT00521950|Active Comparator|control|Standard thiopurine treatment
3292973|NCT00521937|Experimental|A|Dermagen®
3292974|NCT00521937|Active Comparator|B|Conventional treatment
3292975|NCT00521924|Experimental|Infliximab + basic treatment|3 mg/kg infliximab plus basic treatment
3292976|NCT00521924|Active Comparator|Basic treatment (DMARDs)|Rheumatoid Arthritis basic therapy (disease modifying anti-rheumatic drugs [DMARDs])
3292977|NCT00521911|Active Comparator|1|Cognitive Behavioural Therapy
3292978|NCT00521911|No Intervention|2|Treatment as Usual
3292979|NCT00521898|Experimental|DMEK|DMEK as intervention
3292980|NCT00521885|Active Comparator|Arixtra (Fondaparinox) 2.5 mg SC Daily|Arixtra (Fondaparinox) 2.5 mg SC Daily
3292981|NCT00521885|Active Comparator|Lovenox 40mg SC Daily|Lovenox 40mg SC Daily
3292982|NCT00521859|Experimental|Cloretazine + Fludarabine|
3292983|NCT00521846||1|As part of their routine care, patient's will receive Biomet modular radial head replacement. This study is an observational, prospective study that monitors the patient's pain, functional ability, and patient-reported outcomes.
3292984|NCT00521833|Experimental|1|Temporal (right eye)
3292985|NCT00521833|Experimental|2|Nasal (Left eye)
3292986|NCT00521820|Experimental|Pioglitazone QD|
3292987|NCT00521820|Active Comparator|Glyburide QD|
3292988|NCT00521807|No Intervention|A 1|
3292989|NCT00521807|Experimental|A 2|Treatment group
3292990|NCT00521781|Experimental|1|Treatment will be Abraxane/hormonal therapy (LHRH Agonist) for four nine-week cycles, followed by Total androgen blockade therapy (LHRH Agonist+ Anti-androgen) for 2 years from the time the hormonal therapy was started.
3292991|NCT00521755|Experimental|A|
3292992|NCT00521742|Experimental|Pioglitazone 15 mg to 45 mg QD|
3292993|NCT00521742|Active Comparator|Glyburide 2.5 mg to 15 mg, QD|
3292994|NCT00521742|Experimental|Pioglitazone 15 mg or 30 mg QD|
3292995|NCT00521742|Active Comparator|Glyburide 5 mg or 10 mg, QD|
3292996|NCT00521716|Experimental|A|
3292997|NCT00521703|Experimental|1|group treated
3292998|NCT00521703|Placebo Comparator|2|control group
3292999|NCT00521677|Experimental|1|Procedure: Use of protocol that use special suction connected toothbrush to clean the teeth and the oral cavity, use of non alcoholic antiseptic solution and lubrication of the lips and the oral cavity.
3293000|NCT00521677|Active Comparator|2|The traditional method of oral care with cleaning of the oral cavity with a sponge soaked with antiseptic non alcoholic solution
3293001|NCT00521664|Active Comparator|1|Therapeutic platelet transfusion (TP) strategy versus prophylactic platelet transfusion (PP) strategy. In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
3293002|NCT00521664|Active Comparator|2|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
3293003|NCT00521638|Experimental|1|
3293004|NCT00521612|Experimental|A|Sevoflurane group, experimental group
3293006|NCT00521599|Experimental|MF DPI 2 x 100 mcg BID|2 inhalations of mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks
3293007|NCT00521599|Experimental|MF DPI 1 x 200 mcg BID|1 inhalation of mometasone furoate dry powder inhaler (MF DPI) 200 mcg plus 2 inhalations of placebo matching MF DPI 100 mcg twice daily (BID) for 8 weeks
3293008|NCT00521599|Placebo Comparator|Placebo|2 inhalations of placebo matching mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks
3293009|NCT00521586|Other|1|arm 1 = TIV +13vPnC at visit 1, placebo at visit 2 then 13vPnC at year 5
3293010|NCT00521586|Other|2|arm 2 = TIV + placebo at visit 1, then 13vPnC at visit 2 and at year 5
3293011|NCT00521560|Experimental|1|
3293012|NCT00521534||A|CRT programmed to VDD pacing mode
3293013|NCT00521534||B|CRT programmed to DDD with overdrive pacing based on first night average sinus rate.
3293014|NCT00521521|Active Comparator|docetaxel and cisplatin|
3293015|NCT00521521|Experimental|docetaxel|
3293016|NCT00521508|Other|1|Patient affected by Berger's disease confirmed by renal biopsy with increased rate of Ig A
3293017|NCT00521508|Other|2|Patient affected by Berger's disease with normal rate of Ig A
3293018|NCT00521508|Other|3|Healthy volunteers
3293019|NCT00521495|Experimental|A|Surface magnetic field strength at target 450 Gauss permanent magnet
3293020|NCT00521495|Experimental|B|Surface field strength at target 150 Gauss permanent magnet
3293021|NCT00521495|Active Comparator|C|
3293022|NCT00521482|Active Comparator|A|Temozolomide 75 mg/m2 daily for 21 days during each 28-day cycle until tumor progression.
3293023|NCT00521482|Experimental|B|Temozolomide 200 mg/m2 for 5 days during each 28-day cycle plus Thalidomide 100 mg for 2 weeks, thereafter 200 mg daily continuously until tumor progression.
3293024|NCT00521456|Experimental|1|
3293025|NCT00521456|Placebo Comparator|2|
3293026|NCT00521443|Control|Normal|Embryos derived from morphologically normal MII oocytes
3293027|NCT00521443|Case|Irregular Shapes|Embryos derived from irregularly shaped oocytes.
3293028|NCT00521443|Case|Large PVS|Embryos derived from oocytes with large perivitelline space.
3293029|NCT00521443|Case|Dark Zona|Embryos derived from oocytes with dark zona pellucida
3293030|NCT00521443|Case|Dark cytoplasm|Embryos derived from oocytes with dark cytoplasm
3293031|NCT00521443|Case|Vacuolar cytoplasm|Embryos derived from oocytes with vacuolated cytoplasm
3293032|NCT00521443|Case|Central granulation|Embryos derived from oocytes with centrally granulated cytoplasm
3293033|NCT00521443|Case|Double extra|Embryos derived from oocytes with double extracytoplasmic abnormalities
3293034|NCT00521443|Case|Double combined|Embryos derived from oocytes with any combination of one extracytoplasmic and one cytoplasmic anomaly
3293035|NCT00521443|Case|Double cytoplasmic|Embryos derived from oocytes with any two cytoplasmic anomalies
3293036|NCT00521443|Case|Triple extra|Embryos derived from oocytes with triple extracytoplasmic anomaly
3293037|NCT00521443|Case|Triple combined|Embryos derived from oocytes with triple combined anomalies
3293038|NCT00521417|Experimental|short-term dynamic therapy|Group therapy 20 sessions, give insight
3293039|NCT00521417|Active Comparator|long-term dynamic therapy|Group therapy 80 sessions, give insight
3293040|NCT00521404|Experimental|CS-1008 + gemcitabine|CS-1008 + gemcitabine
3293041|NCT00521391|Experimental|A|a tailored physical activity intervention involving moderate-intensity exercise
3293042|NCT00521391|No Intervention|B|
3293043|NCT00521365|Experimental|Quetapine 600 mg|
3293044|NCT00521352|Active Comparator|Active rTMS|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
3293045|NCT00521352|Sham Comparator|Sham rTMS|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
3293046|NCT00521339|Experimental|Apremilast 20 mg BID/ 30 mg BID|Apremilast 20 mg or 30 mg orally twice per day
3293047|NCT00521326|Case|A|Patients with an acute coronary syndrome that are candidates for coronary angiography. Doppler results will be compared to angiographic findings.
3293048|NCT00521300|Experimental|octreotide|6 months preoperative treatment with octreotide before transsphenoidal surgery for acromegaly
3293049|NCT00521300|Active Comparator|standard surgery|Standard transphenoidal surgery soon after the diagnosis of acromegaly
3293050|NCT00521287|Other|Early (E)|Early stage cancer
3293051|NCT00521287|Other|Advanced (A)|Advanced stage cancer (Stage IV without treatment)
3293052|NCT00521287|Other|Terminal (T)|Terminal stage cancer (Stage IV with chemotherapy)
3293053|NCT00521274|Experimental|1|"Patients randomized to Arm 1 will receive treatment cycles of Docetaxel and vaccine.~PI relocated, data not available."
3293054|NCT00521274|Active Comparator|2|"Patients randomized to Arm 2 will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over).~PI relocated, data not available."
3293055|NCT00521248|Active Comparator|Oral morphine solution|Oral morphine solution
3293056|NCT00521248|Experimental|Buprenorphine|Sublingual buprenorphine
3293057|NCT00521222|Active Comparator|Arg/Arg genotype on Advair (Fluticasone with Salmeterol) HFA|Asthma patients with the Arg/Arg genotype who are randomized to continue the combination therapy of a specific long-acting beta 2 agonist (salmeterol) and inhaled corticosteroid (fluticasone) in the form of Advair HFA.
3293058|NCT00521222|Active Comparator|Gly/Gly genotype on Advair (Fluticasone with Salmeterol) HFA|Asthma patients with the Gly/Gly genotype who are randomized to continue the combination therapy of a specific long-acting beta 2 agonist (salmeterol) and inhaled corticosteroid (fluticasone) in the form of Advair HFA.
3293059|NCT00521222|Experimental|Arg/Arg genotype on Fluticasone HFA|Asthma patients with the Arg/Arg genotype who are randomized to fluticasone (Flovent HFA) alone.
3293060|NCT00521222|Experimental|Gly/Gly genotype on Fluticasone HFA|Asthma patients with the Gly/Gly genotype who are randomized to fluticasone (Flovent HFA) alone.
3293061|NCT00521209|Experimental|Clinic 1 - intervention|Clinic 1 will feature the Self-Care Stimulating Disease Prevention Program (SCSDPP) intervention
3294943|NCT00505024|Experimental|IVRS Only|
3293062|NCT00521209|Other|Clinic 2 - no intervention|Clinic 2 will continue with standard procedures no intervention
3293063|NCT00521196|No Intervention|Baseline- 1 month|Subjects will be asked to maintain a migraine diary in which they will record the onset of each migraine, migraine-associated symptoms, migraine-associated pain, daily average pain, and daily average anxiety.
3293064|NCT00521196|Experimental|tDCS- 1 month|"There will be 10- twenty minute sessions of the tDCS intervention over a four week period. During each tDCS session, two electrodes are placed over selected areas of the brain. 2 mA of direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The subject may feel a slight itching on the scalp. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.~During this phase, participants will continue to maintain their migraine diary. In addition, the pain threshold of patients will be measured at the first, fifth, and tenth sessions via Thermal Sensory Analysis and Von Frey Hair tests."
3293065|NCT00521196|No Intervention|Follow Up- 4 months|During the follow up phase, subjects will meet with the study investigators a total of 5 times for follow up monitoring. Participants will continue to maintain their migraine diary during this time.
3293066|NCT00521196|Other|Active tDCS- 1 month|Participants randomized to sham tDCS (placebo) will be given the opportunity to receive the active intervention if the intervention is found to be safe and efficacious.
3293067|NCT00521183|Experimental|CldC + H4U|
3293068|NCT00521157|Experimental|intervention|Experimental group randomised after abstinence oriented treatment
3293069|NCT00521157|No Intervention|2|waiting list control
3293070|NCT00521144|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive obatoclax mesylate IV over 3 hours on day 1 OR days 1 and 3 and topotecan hydrochloride IV over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity
3293071|NCT00521118|Experimental|Treatment (second curettage)|Patients undergo a second curettage rather than standard treatment (immediate chemotherapy) within 14 days of registration.
3293072|NCT00521105|No Intervention|1|Participants will be seen every 3-4 months with a physician-only visit alternating with a multidisciplinary visit (MD, RN and RD). This is the current standard of practice.
3293073|NCT00521105|Experimental|2|Participants will be seen every 3-4 months with a phone contact, with the diabetes nurse educator, alternating with a multidisciplinary visit (MD, RN and RD).
3293074|NCT00521092|Experimental|Arm I|Patients receive oral sunitinib malate 50 mg once daily for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
3293075|NCT00521079|Experimental|vBloc|Subjects implanted with a functional Maestro System device that delivers therapy (Therapy ON).
3293076|NCT00521079|Sham Comparator|Placebo|Subjects implanted with a functional Maestro System device that does NOT deliver therapy (Therapy OFF).
3293077|NCT00521066||1|Prosima Pelvic Floor Repair System
3293078|NCT00521053|Experimental|PV-10|
3293079|NCT00521027|Other|Treatment|Debridement with Versajet Hydrosurgery system
3293080|NCT00521027|Other|Control|Conventional surgical debridement techniques
3293081|NCT00521014|Experimental|GM-CSF and Rituximab After Autologous Stem Cell Transplant|"GM-CSF: 250 mcg (flat dose) three times per week for 8 weeks, administered on alternate days. Thus, 24 doses of GM-CSF will be administered.~Rituximab: 375 mg/m2/week for 4 weeks, beginning within 3 days after the first dose of GM-CSF; rituximab. The second course of GM-CSF and rituximab will be administered approximately 22-26 weeks (day +154 to +182) after ASCT."
3293082|NCT00521001|Experimental|everolimus + temozolomide|"Patients receive oral everolimus once a day on days 1-5, 8-12, 15-19, 22-26, and 29-33 and oral temozolomide once a day on days 8-12 for course 1 only. For course 2 and all subsequent courses, patients receive oral everolimus once a day on days 1-5, 8-12, 15-19, and 22-26 and oral temozolomide once a day on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~All patients undergo blood sample collection periodically for correlative studies. Samples are analyzed for relative numbers of T, B, and NK cells via flow cytometry, quantitative immunoglobulin levels (IgG, IgM, and IgA), Tetramer/ELISPOT CTL frequencies to CMV/EBV immunodominant antigens, V beta T cell spectratyping, and VEGF levels via ELISA.~After completion of study treatment, patients are followed every 8 weeks."
3293083|NCT00520988|Experimental|1|Usual care plus use of Interactive Voice Recognition system
3293084|NCT00520988|No Intervention|2|Usual care
3293085|NCT00520975|Active Comparator|Arm A (chemotherapy and placebo)|"INDUCTION THERAPY: Patients receive trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22 and paclitaxel IV over 60 minutes with or without carboplatin IV over 60 minutes on days 1, 8, and 15. Patients also receive placebo IV over 30-90 minutes on day 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and placebo IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
3293086|NCT00520975|Experimental|Arm B (chemotherapy and bevacizumab)|"INDUCTION THERAPY: Patients receive trastuzumab and paclitaxel with or without carboplatin as in Arm A. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
3293087|NCT00520962|Case|1,2,3|"First degree relatives of patients with type 2 diabetes~Patients with cardiovascular disease and stroke~patients with heart valve disease"
3293088|NCT00520962|Control|4|Healthy controls
3293089|NCT00520949|Experimental|Quadruple Therapy|
3293090|NCT00520936|Experimental|Pemetrexed|
3293091|NCT00520923|Experimental|1|160mg of LY2140023, taken orally as 80mg twice daily, for up to 4 weeks.
3293092|NCT00520923|Experimental|2|80mg of LY2140023, taken orally as 40mg twice daily, for up to 4 weeks.
3293093|NCT00520923|Experimental|3|40mg of LY2140023, taken orally as 20mg twice daily, for up to 4 weeks.
3293094|NCT00520923|Experimental|4|10mg of LY2140023, taken orally as 5mg twice daily, for up to 4 weeks.
3293095|NCT00520923|Placebo Comparator|5|Placebo of LY2140023, taken orally twice daily, for up to 4 weeks.
3293096|NCT00520923|Active Comparator|6|Placebo, taken orally every morning, followed by Olanzapine 15mg taken orally every evening for up to 4 weeks.
3293097|NCT00520910|Experimental|1|Subject is given a 7.5 mg/kg dose of Polypodium leucotomos.
3293098|NCT00520910|No Intervention|2|Subject is not given any treatment.
3293099|NCT00520897|Experimental|MK0518 + cART|Raltegravir + standard of care combined antiretroviral therapy
3293100|NCT00520897|Placebo Comparator|Placebo + cART|Placebo + standard of care combined antiretroviral therapy
3293101|NCT00520884|Other|1|Healthy women
3293102|NCT00520884|Other|2|Frail women
3293103|NCT00520858|No Intervention|C|
3293104|NCT00520858|Active Comparator|RE|Resistance Exercise
3293105|NCT00520858|Active Comparator|AE|Aerobic Exercise
3293106|NCT00520858|Active Comparator|RAE|Resistance and Aerobic
3293107|NCT00520845|Experimental|Treatment Arm|Either docetaxel or pemetrexed given with celecoxib
3293108|NCT00520832|Experimental|MC-E|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
3293109|NCT00520832|Placebo Comparator|MC-P|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
3293110|NCT00520806|Placebo Comparator|Placebo|48 hour iv infusion of placebo
3293111|NCT00520806|Experimental|Relaxin|48 hour iv infusion of relaxin at 30 ug/kg/day
3293112|NCT00520780|Experimental|1|
3293113|NCT00520780|Placebo Comparator|2|
3293114|NCT00520767|Experimental|Melphalan, Dexamethasone, Bortezomib,|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22; Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23; Melphalan 9 mg/m2/day days 1-4
3293115|NCT00520741|Experimental|Lacosamide 400 mg/day|Lacosamide 400 mg/day
3293116|NCT00520741|Active Comparator|Lacosamide 300 mg/day|Lacosamide 300 mg/day
3293117|NCT00520728|Experimental|A|Experimental arm receives 12 week intervention along with standard care.
3293118|NCT00520715||Patients at hospital admission|Patients at hospital admission in medical wards on our tertiray care hospital (Hôpital Beaujon, Clichy, France).
3293119|NCT00520702|Active Comparator|3D CRT|3-Dimensional Conformal Radiation Therapy (3D CRT)
3293120|NCT00520702|Active Comparator|IMRT|Intensity-Modulated Radiation Therapy (IMRT)
3293121|NCT00520689|Active Comparator|1|
3293122|NCT00520689|Active Comparator|2|
3293123|NCT00520689|Active Comparator|3|
3293124|NCT00520689|Active Comparator|4|
3293125|NCT00520676|Experimental|pemetrexed plus carboplatin|"Drug: pemetrexed 500 milligrams per square meter (mg/m^2), intravenous (IV), every (q) 21 days x 6 cycles maximum~Drug: carboplatin Area Under the Curve (AUC) 5 milligram*minute/milliLiter (mg*min/mL), IV, q 21 days x 6 cycles maximum"
3293126|NCT00520676|Active Comparator|docetaxel plus carboplatin|"Drug: docetaxel 75 mg/m^2, IV, q 21 days x 6 cycles maximum~Drug: carboplatin AUC 5 mg*min/mL, IV, q 21 days x 6 cycles maximum"
3293127|NCT00520663|Experimental|Healthy male subjects|Each subject will receive a single oral dose of 14C-SB649868 (containing approximately 70 microcuries of radiocarbon and 30 milligrams of SB649868).
3293128|NCT00520624|Experimental|1|Treatment 1, for those with high degree of EIL
3293129|NCT00520624|Experimental|2|Treatment 2, for those with high degree of EIL
3293130|NCT00520624|No Intervention|3|Control group of those with high degree of EIL
3293131|NCT00520624|Experimental|4|Treatment 1, for those with low degree of EIL
3293132|NCT00520624|No Intervention|5|Control group of those with low degree of EIL
3293133|NCT00520611|Active Comparator|Lottery|Participants are entered into daily lotteries to win $10 or $100 every day their weight is at or below daily targets.
3293134|NCT00520611|Active Comparator|Deposit|Participants receive $3/day if they are at or below their daily weight goals, plus have opportunity to deposit up to $3/day of their own money, which is then matched 1:1 every day they are at or below their daily weight goals.
3293135|NCT00520611|No Intervention|Control|Participants would receive usual care from their providers and have monthly weigh ins.
3293136|NCT00520598|Active Comparator|1|Arm 1: 0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen.
3293137|NCT00520598|Experimental|2|Arm 2: 0.5 ml injection of V505 formulation 1 as 3 dose regimen.
3293138|NCT00520598|Experimental|3|Arm 3: 0.5 ml injection of V505 formulation 2 as 3 dose regimen
3293139|NCT00520598|Experimental|4|Arm 4: 0.5 ml injection of V505 formulation 2 as 2 dose regimen and 1 Pbo injection
3293140|NCT00520598|Experimental|5|Arm 5: 0.5 ml injection of V505 formulation 3 as 2 dose regimen and 1 Pbo injection
3293141|NCT00520572|Active Comparator|1|Etanercept 50mg, subcutaneous, once weekly
3293142|NCT00520572|Experimental|2|50mg oral, once daily
3293143|NCT00520572|Experimental|3|100 mg oral, once daily
3293144|NCT00520572|Experimental|4|200 mg oral, once daily
3293145|NCT00520572|Experimental|5|400mg once, daily
3293146|NCT00520572|Placebo Comparator|6|oral, once daily
3293147|NCT00520546|Experimental|1|Patients with prostate carcinoma confirmed by needle biopsy, age >50 years, planned radical prostatectomy with lymph-node dissection, fasting for >12 hours before FEC-PET and an interval between biopsy and PET >3 weeks.
3293148|NCT00520533|Experimental|On Study|"Treatment (cycle 1):~cG250 10mg/m² IV weekly x5 doses (1st & 5th doses trace-labelled with ¹²⁴I)~Sunitinib 50 mg/day orally x 4 weeks commencing day 8~Followed by two week break~Treatment (cycle 2 - investigator discretion):~cG250 10mg/m² IV weekly x4 doses~Sunitinib 50 mg/day orally x 4 weeks (commencing concurrently)~Followed by two week break"
3293149|NCT00520507|Experimental|1|
3293150|NCT00520507|Placebo Comparator|2|
3293151|NCT00520494|Experimental|Vivaglobin|Vivaglobin: 16% (160 mg/mL) liquid formulation of human IgG for SC use. Loading dose: 100 mg/kg for 5 consecutive days; maintenance dose: 100 mg/kg 1 to 2 times a week for 24 weeks.
3293256|NCT00519610||I|Patients will have charts reviewed for relevant medical information before and after surgery to assess patient outcome after placement of H-graft shunt for the treatment of portal hypertension.
3293257|NCT00519597|Experimental|I|Asymptomatic OSA (CPAP)
3293258|NCT00519597|No Intervention|II|Asymptomatic OSA (no CPAP)
3293259|NCT00519597|Active Comparator|III|Symptomatic OSA (OSAS)
3293152|NCT00520481|Experimental|IMC-A12|Thirty-one participants will receive IMC-A12 at 10 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). An additional 10 participants will receive IMC-A12 at a dose of 20 mg/kg every three weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Radiographic evaluation of response will be performed every 8 weeks for the participants treated with intravenous (i.v.) IMC-A12 at 10 mg/kg and every 9 weeks for the participants treated with i.v. IMC-A12 at 20 mg/kg.
3293153|NCT00520468|Experimental|Cytokine-Immunotherapy|Erythropoietin 40,000 units subcutaneously (SQ) weekly; G-CSF 300 mcg SQ twice a week; Prednisone 60 mg/Day for 7 days, taper over 1 month; Cyclosporin A 300 mg orally daily
3293154|NCT00520455|No Intervention|Control|Control participants were advised where they could obtain hormonal contraception on a sliding scale basis. Participants were also advised where they could obtain hormonal contraception on a sliding scale basis.
3293155|NCT00520455|Experimental|Intervention|Study subjects were prescribed levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and a package of 30 condoms provided via a commerical pharmacy at no cost to the study subject. The subject could refill this prescription as many times as they wanted for 12 months
3293156|NCT00520442|Experimental|Ibuprofen|
3293157|NCT00520442|Active Comparator|acetamin w codeine|
3293158|NCT00520429|Other|1|This study is an open pilot; therefore all participants were given the opportunity to receive treatment.
3293159|NCT00520416||1|There is no control or experimental group. The same patients undergoing endovascular AAA repair with serve as their own control
3293160|NCT00520403|Experimental|1|
3293161|NCT00520377|Experimental|1|MD05
3293162|NCT00520377|Active Comparator|2|Beta-TCP and autologous bone
3293163|NCT00520364||History of chemotherapy|IVF after chemotherapy
3293164|NCT00520364||IVF without history of chemotherapy|IVF without history of prior chemotherapy
3293165|NCT00520351|Active Comparator|1|
3293166|NCT00520351|Active Comparator|2|
3293167|NCT00520338|Placebo Comparator|2|"placebo~celecoxib"
3293168|NCT00520338|No Intervention|1|1 placebo
3293169|NCT00520325|Other|0.5 mg/kg|
3293170|NCT00520325|Other|1.0 mg/kg|
3293171|NCT00520299|Experimental|Cohort 1|Subjects received ADI-PEG 20 at a dose of 40 IU/m^2
3293172|NCT00520299|Experimental|Cohort 2|Subjects received ADI-PEG 20 at a dose of 80 IU/m^2
3293173|NCT00520299|Experimental|Cohort 3|Subjects received ADI-PEG 20 at a dose of 160 IU/m^2
3293174|NCT00520286|Active Comparator|Modafinil|Participants will receive a Modafinil 200 mg or 400 mg tablet one time per day for 12 weeks
3293175|NCT00520286|Placebo Comparator|Placebo|Participants will receive a matching Modafinil placebo 200 mg or 400 mg tablet one time per day for 12 weeks
3293176|NCT00520273|Experimental|A|
3293177|NCT00520260|Active Comparator|1|Active treatment arm bromfenac 0.09% BID for 6 weeks
3293178|NCT00520260|Active Comparator|2|ketorolac 0.4% BID for 6 weeks
3293179|NCT00520234|Active Comparator|1 prophylaxis|Caspofungin 50 mg Intravenous (IV) daily up to 28 days of therapy
3293180|NCT00520234|Placebo Comparator|2 placebo|Normal Saline 100 cc IV daily
3293181|NCT00520221|Treatment Comparison|2|"Minocycline group: 300 mg of minocycline hydrochloride was instilled into the pleural space through the catheter.~Control group consisted of 33 patients who had successful simple aspiration alone between January 2004 and December 2005."
3293182|NCT00520182|Active Comparator|1|ADA 2003 diet
3293183|NCT00520182|Active Comparator|2|Low Glycemic index (LGI) diet
3293184|NCT00520182|Active Comparator|3|MUFA diet
3293185|NCT00520169|Active Comparator|A|oral ketamine
3293186|NCT00520169|Experimental|B|intranasal ketamine
3293187|NCT00520169|Active Comparator|C|intravenous ketamine
3293188|NCT00520130|Experimental|A - Tacrolimus, methotrexate, sirolimus (TMS) Arm|TMS Arm
3293189|NCT00520130|Experimental|B - Cyclosporine (AC) Arm|AC Arm
3293190|NCT00520117||negative pap-smear|
3293191|NCT00520117||positive pap-smear|
3293192|NCT00520104|Experimental|A|intranasal ketamine
3293193|NCT00520104|Experimental|B|oxymetazoline plus intranasal ketamine
3293194|NCT00520104|Experimental|C|intranasal steroid plus intranasal ketamine
3293195|NCT00520091|Active Comparator|Cohort 1|Induction chemotherapy and chemoradiation without celecoxib
3293196|NCT00520091|Experimental|Cohort 2|Induction chemotherapy and chemoradiation with celecoxib
3293197|NCT00520065|Experimental|#1|Diabetes specific enteral product
3293198|NCT00520065|Active Comparator|#2|Standard enteral feeding
3293199|NCT00520052|Active Comparator|LHRH Group|Patients on LHRH agonists and zoledronic acid
3293200|NCT00520052|Active Comparator|Bicalutamide Group|Patients on Bicalutamide and zoledronic acid
3293201|NCT00520039|Experimental|Standard Care Plus OMM|Subjects will receive active intervention with osteopathic manipulative medicine (OMM) using a prescribed standardized treatment protocol which is age appropriate. Subjects will also receive standard care for otitis media from their referring physician.
3293202|NCT00520039|No Intervention|Standard Care Only|Subjects will receive standard care only for otitis media from their regular referring physician
3293203|NCT00520026|Active Comparator|1|Lithium treatment
3293204|NCT00520026|Placebo Comparator|2|Placebo treatment
3293205|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab then bevacizumab|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation (A): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 1 year."
3293260|NCT00519597|No Intervention|IV|Non-OSA
3293261|NCT00519584|Placebo Comparator|Ropivacaine/saline|Ropivacaine 30ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block and 0.9% saline 2 ml (systemic placebo) for intravenous injection with sedation for the block
3293484|NCT00517790|Experimental|ABT-869 0.25 mg/kg|Approximately half of the subjects were randomized to receive the high dose
3293206|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab then bevacizumab/erlotinib|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation (AE): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle and oral erlotinib 150mg daily for 1 year."
3293207|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation: None"
3293208|NCT00520000|Active Comparator|Weekly Arm|Carboplatin day 1, abraxane days 1, 8, 15 every 28 day cycle
3293209|NCT00520000|Experimental|Every 3 week Arm|Carboplatin day 1, abraxane day 1, every 21 day cycle
3293210|NCT00520000|Experimental|Arm C|Carboplatin day 1, abraxane day 1, 8 every 21 day cycle
3293211|NCT00519987|Experimental|Treatment A|intranasal ketamine
3293212|NCT00519961|Experimental|A|
3293213|NCT00519961|Experimental|B|
3293214|NCT00519935|Experimental|Multisystemic Therapy|In-home, intensive family therapy
3293215|NCT00519935|No Intervention|Standard Medical Care (TAU)|Standard medical care is provided at Children's Hospital of Michigan consistent with the standards for the care of children with T1D outlined by the American Diabetes Association.
3293216|NCT00519922|Experimental|1|KBA = Kinesthesia, Balance, Agility Exercise Training
3293217|NCT00519922|Active Comparator|2|Standard Lower Extremity Strength Training
3293218|NCT00519909|Other|1|Diet with high content of calcium and high content of fat
3293219|NCT00519909|Other|2|Diet with low content of calcium and high content of fat
3293220|NCT00519909|Other|3|Diet with high content of calcium and normal content of fat
3293221|NCT00519909|Other|4|Diet with low content of calcium and normal content of fat
3293222|NCT00519909|Other|5|Diet with high content of calcium fra supplement and high content of fat
3293223|NCT00519896|Experimental|Treatment (enzyme inhibitor therapy, antiangiogenesis therapy)|Patients receive sunitinib malate PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
3293224|NCT00519883|Active Comparator|A|Arm A: Standard Supportive Care (no supervised exercise)
3293225|NCT00519883|Experimental|B|Arm B: Exercise Intervention
3293226|NCT00519870|Active Comparator|I, II|I: nifedipine II: losartan
3293227|NCT00519857|Active Comparator|1|Tibolone
3293228|NCT00519857|Placebo Comparator|2|Placebo
3293229|NCT00519831|Experimental|Vinflunine + Cetuximab|Patients may receive more than 4 cycles of therapy if they continue to demonstrate response to therapy, have limited toxicity, and if the treating physician determines that they are deriving clinical benefit from the treatment. The decision of continuing therapy beyond 4 cycles must be discussed with the principal investigator.
3293230|NCT00519818|Experimental|Cortef and Chronocort|Cortef 3 times daily(total dose 30 mg)for minimum of 7 days followed by Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
3293231|NCT00519792|Experimental|1|Omega DUROS: Dose 25
3293232|NCT00519792|Experimental|2|Omega DUROS: Dose 50
3293233|NCT00519779|Placebo Comparator|2|Placebo oral Omega-3 fish oil supplementation
3293234|NCT00519779|Experimental|1|oral Omega-3 fish oil supplementation
3293235|NCT00519753|Experimental|DuoTrav|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
3293236|NCT00519727|Experimental|A|50 mg ISIS 325568 vs Placebo, s.c. injection
3293237|NCT00519727|Experimental|B|100 mg ISIS 325568 vs Placebo , s.c. injection
3293238|NCT00519727|Experimental|C|200 mg ISIS 325568 vs Placebo , s.c. injection
3293239|NCT00519727|Experimental|D|400 mg ISIS 325568 vs Placebo, s.c. injection
3293240|NCT00519727|Experimental|AA|50 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
3293241|NCT00519727|Experimental|BB|100 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
3293242|NCT00519727|Experimental|CC|200 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
3293243|NCT00519727|Experimental|DD|400 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
3293244|NCT00519714|Placebo Comparator|1|three placebo capsules PO three times daily.
3293245|NCT00519714|Active Comparator|2|1-MNA 90 mg daily: one active treatment capsule and two placebo capsules PO three times daily
3293246|NCT00519714|Active Comparator|3|1-MNA 270 mg daily: three active treatment capsules PO three times daily.
3293247|NCT00519701|Experimental|1|hydroxyurea
3293248|NCT00519688|Experimental|Thalidomide plus Tegafur/Uracil1|Thalidomide plus Tegafur/Uracil
3293249|NCT00519662|Experimental|Dose escalating cohorts of SNS-314|Sequential groups, starting at a dose of 30 mg/m2, will be escalated according to identification of dose limiting toxicities against various criteria. Doses escalated by doubling the dose until the first observation of clinically significant Grade 2 or greater toxicity related to SNS-314 injection. Results in dosing increments of 67%, 50%, 40%, 33%, and subsequently 25% based on modified Fibonacci schema.
3293250|NCT00519649|Experimental|Group Engerix|Subjects received a single challenge dose of Engerix™ (hepatitis-B [HBV] vaccine)
3293251|NCT00519636|Active Comparator|FFNS, FPNS|fluticasone furoate nasal spray, fluticasone propionate nasal spray
3293252|NCT00519636|Active Comparator|FPNS, FFNS|fluticasone propionate nasal spray, fluticasone furoate nasal spray
3293253|NCT00519636|Placebo Comparator|placebo FFNS, placebo FPNS|placebo nasal spray matching fluticasone furoate nasal spray, placebo nasal spray matching fluticasone propionate nasal spray
3293254|NCT00519636|Placebo Comparator|placebo FPNS, placebo FFNS|placebo nasal spray matching fluticasone propionate nasal spray, placebo nasal spray matching fluticasone furoate nasal spray
3293255|NCT00519623|Experimental|PassPort(R) Transdermal Insulin Delivery System|
3293476|NCT00517816|Experimental|3|
3293477|NCT00517816|Experimental|4|
3293478|NCT00517816|Experimental|5|
3293262|NCT00519584|Active Comparator|Ropivacaine/dex|Ropivacaine and local steroid: 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic and 0.9% saline 2ml (systemic placebo) for intravenous injection with sedation for the block;
3293263|NCT00519584|Active Comparator|bupivacaine/dex|bupivacaine and systemic steroid: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block plus dexamethasone 8 mg (2 ml) administered intravenously with sedation administered for the block.
3293264|NCT00519584|Placebo Comparator|bupivacaine/Saline|bupivacaine 30ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block and 0.9% saline 2 ml (systemic placebo) for intravenous injection with sedation for the block
3293265|NCT00519571|Experimental|1|
3293266|NCT00519545|Experimental|1|scripted prayer group (intervention group)
3293267|NCT00519545|No Intervention|2|no prayer intervention group (non-intervention group)
3293268|NCT00519532|Experimental|Rotigotine|Rotigotine Transdermal Patch
3293269|NCT00519519|Active Comparator|2|regular dose versus high dose
3293270|NCT00519493|Active Comparator|Suture|A keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
3293271|NCT00519493|Active Comparator|Clozex|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
3293272|NCT00519480|Placebo Comparator|Subjects receiving treatment P|Eligible subjects will receive placebo twice daily along with metformin twice daily for 13 days.
3293273|NCT00519480|Experimental|Subjects receiving treatment A|Eligible subjects will receive GSK189075 500 milligrams twice daily along with metformin twice daily for 13 days.
3293274|NCT00519480|Experimental|Subjects receiving treatment B|Eligible subjects will receive GSK189075 750 milligrams twice daily along with metformin twice daily for 13 days.
3293275|NCT00519454||Female Lupus patients|Females who are still childbearing age, not on hormones, with Systemic Lupus Erythematosus, still cycling.
3293276|NCT00519441|Other|I|All patients in the study will have pH studies done in order to determine the degree of reflux after laparoscopic Heller myotomies.
3293277|NCT00519428|Experimental|escitalopram + bupropion|escitalopram plus bupropion extra long (XL) as dual treatment (i.e., this is not a SINGLE treatment arm; all patients assigned this arm received both medications)
3293278|NCT00519428|Active Comparator|escitalopram|escitalopram monotherapy
3293279|NCT00519428|Active Comparator|bupropion|bupropion extra long (XL) monotherapy
3293280|NCT00519415|Experimental|A|
3293281|NCT00519415|Experimental|B|
3293282|NCT00519402||Partial Tonsillectomy|Patients who received a partial tonsillectomy
3293283|NCT00519402||Complete Tonsillectomy|Patients who received a complete tonsillectomy
3293284|NCT00519389|Experimental|Low dose H5N1 VLP Vaccine|
3293285|NCT00519389|Experimental|Mid dose H5N1 VLP Vaccine|
3293286|NCT00519389|Experimental|High dose H5N1 VLP Vaccine|
3293287|NCT00519389|Placebo Comparator|Placebo|
3293288|NCT00519376|Experimental|GW642444M 25mcg|
3293289|NCT00519376|Experimental|GW642444M 50mcg|
3293290|NCT00519376|Experimental|GW642444M 100mcg|
3293291|NCT00519376|Experimental|GW642444H 100mcg|
3293292|NCT00519376|Experimental|placebo|
3293293|NCT00519350||I|Liver surgery
3293294|NCT00519350||II|Colon surgery
3293295|NCT00519350||III|Femur Fracture
3293296|NCT00519337|Active Comparator|1|Ascorbic acid
3293297|NCT00519337|Placebo Comparator|2|Identical placebo
3293298|NCT00519324|Experimental|RAD001|
3293299|NCT00519311|Experimental|School based health intervention|Educational intervention based on health diary + health check
3293300|NCT00519311|No Intervention|Usual care|Normal school curriculum and usual medical care
3293301|NCT00519298|Experimental|1|
3293302|NCT00519298|Placebo Comparator|2|
3293303|NCT00519298|Active Comparator|3|
3293304|NCT00519285|Placebo Comparator|Placebo|Placebo added to standard chemotherapy with docetaxel plus prednisone or prednisolone
3293305|NCT00519285|Experimental|Aflibercept|Aflibercept added to standard chemotherapy with docetaxel plus prednisone or prednisolone
3293306|NCT00519272||Cervical Cancer Care Questionnaires|New cervical cancer patients through stage IVB presenting to the LBJ Gyn-Onc Clinic.
3293307|NCT00519246|Placebo Comparator|I|No drug was delivered.
3293308|NCT00519246|Active Comparator|II|Butorphanol tartrate 1mg was given intravenously.
3293309|NCT00519246|Active Comparator|III|Butorphanol tartrate 2 mg was given intravenously.
3293310|NCT00519246|Active Comparator|IV|Flurbiprofen Axetil 50 mg was given intravenously.
3293311|NCT00519246|Active Comparator|V|Flurbiprofen Axetil 100 mg was given intravenously.
3293312|NCT00519246|Active Comparator|VI|Tramadol Hydrochloride 10 mg was given intravenously.
3293313|NCT00519246|Active Comparator|VII|Tramadol Hydrochloride 20 mg was given intravenously.
3293314|NCT00519233|Experimental|1.AGS-1C4D4|
3293315|NCT00519220||I|Patients will answer symptom questionnaires and have their charts reviewed for relevant medical information.
3293316|NCT00519207|Active Comparator|1|This group will receive lidocaine and sucrose placebo (water).
3293317|NCT00519207|Active Comparator|2|This group will receive lidocaine placebo and sucrose.
3293318|NCT00519207|Active Comparator|3|This group will receive lidocaine and sucrose.
3293319|NCT00519194|Experimental|Epicor Cardiac Ablation|
3293320|NCT00519155|Experimental|1|Open flap debridement + MD05
3293321|NCT00519155|Active Comparator|2|Open flap debridement
3293322|NCT00519142|Placebo Comparator|1|metformin + placebo for mitiglinide
3293323|NCT00519142|Experimental|2|metformin + mitiglinide three times a day with meals
3293324|NCT00519142|Experimental|3|metformin + mitiglinide two times a day with morning and evening meal, placebo for mitiglinide with midday meal
3293325|NCT00519103|Experimental|1|Active resistive excercise for 7 weeks
3293326|NCT00519090|Experimental|Nilotinib (AMN107)|
3293327|NCT00519090|Active Comparator|Imatinib|
3293479|NCT00517816|Experimental|6|
3293480|NCT00517816|Experimental|7|
3293481|NCT00517816|Experimental|8|
3293328|NCT00519077|Experimental|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
3293329|NCT00519064|Active Comparator|Arm 1|
3293330|NCT00519064|Active Comparator|Arm 2|
3293331|NCT00519051|Active Comparator|control group|patients can receive pharmacotherapy and psychotherapy and specialized treatment
3293332|NCT00519038|Experimental|1|Patients treated according to clinical pathways
3293333|NCT00519038|Other|2|Patients treated according to usual care
3293334|NCT00519012|Active Comparator|Arm-1|Sertraline to Paroxetine
3293335|NCT00519012|Active Comparator|2|Paroxetine to Sertraline
3293336|NCT00518999|Other|1|Schizophrenia patients who performed earlier cognitive assessment as part of routine assessment for patients in the Shalvata Mental Health Center.
3293337|NCT00518986|Active Comparator|1|armodafinil 200 mg/day
3293338|NCT00518986|Placebo Comparator|2|Placebo
3293339|NCT00518947|Active Comparator|1|Continued-Lithium
3293340|NCT00518947|Experimental|2.|Verapamil
3293341|NCT00518947|Experimental|3.|Verapamil plus Lithium
3293342|NCT00518921|Experimental|Arm 1|
3293343|NCT00518921|Experimental|Arm 2|
3293344|NCT00518921|Experimental|Arm 3|
3293345|NCT00518921|Placebo Comparator|Arm 4|
3293346|NCT00518908|Experimental|Sevoflurane|Sevoflurane for pharmacological postconditioning
3293347|NCT00518908|Experimental|Propofol|Anesthesia maintenance with propofol instead of Sevoflurane postconditioning
3293348|NCT00518895|Experimental|A|Dacarbazine with Genasense
3293349|NCT00518895|Active Comparator|B|Dacarbazine with placebo
3293350|NCT00518882|Experimental|Liraglutide|Liraglutide 1.8 mg once daily + subject's own OAD treatment
3293351|NCT00518882|Active Comparator|Exenatide|Exenatide 10 mcg twice daily + subject's own OAD treatment
3293352|NCT00518869|Experimental|Treatment group|PG2 plus standard chemotherapies
3293353|NCT00518869|Placebo Comparator|Placeo group|Placebo plus standard chemotherapies
3293354|NCT00518856|Experimental|intervention|TBAs who receive training and supplies for the intervention
3293355|NCT00518856|Active Comparator|control|TBAs continuing with current standard of practice
3293356|NCT00518843|Experimental|FBT-BN|Family-based treatment
3293357|NCT00518843|Active Comparator|SPT|Individual Supportive Psychotherapy
3293358|NCT00518830|Experimental|PND-MCI|The multi-component intervention involved a psychoeducational group, treatment adherence support, and pharmacotherapy if needed
3293359|NCT00518830|Active Comparator|usual care|'Usual care' included all services normally available in the clinics, including antidepressant medication, brief psychotherapeutic interventions or referral for specialty treatment
3293360|NCT00518791|Experimental|I|Multidisciplinary Care
3293361|NCT00518791|Other|II|Usual Care
3293362|NCT00518765|Experimental|1|Various sequences of different doses of Aliskiren
3293363|NCT00518765|Experimental|2|Various sequences of different doses of Aliskiren plus placebo
3293364|NCT00518765|Experimental|3|Various sequences of different doses of Aliskiren
3293365|NCT00518765|Experimental|4|Various sequences of different doses of Aliskiren plus placebo
3293366|NCT00518752|Active Comparator|A|Standard Oral Care
3293367|NCT00518752|Experimental|B|Comprehensive Oral Care
3293368|NCT00518726|Experimental|Arm 1|
3293369|NCT00518713|Experimental|Clobazam Low Dose|
3293370|NCT00518713|Experimental|Clobazam Medium Dose|
3293371|NCT00518713|Experimental|Clobazam High Dose|
3293372|NCT00518713|Placebo Comparator|Placebo|
3293373|NCT00518687|Experimental|V710 60 µg|
3293374|NCT00518687|Placebo Comparator|Placebo|
3293375|NCT00518648|Experimental|I|Multifactorial fall prevention program
3293376|NCT00518648|Other|II|Usual care
3293377|NCT00518635|Experimental|A|Growth hormone or Placebo 0.1 mg/day self-administrated once a day.
3293378|NCT00518622|Experimental|1|25 mg b.i.d. MK7009
3293379|NCT00518622|Experimental|2|75 mg b.i.d. MK7009
3293380|NCT00518622|Experimental|3|250 mg b.i.d. MK7009
3293381|NCT00518622|Experimental|4|500 mg b.i.d. MK7009
3293382|NCT00518622|Experimental|5|700 mg b.i.d. MK7009
3293383|NCT00518622|Experimental|6|125 mg q.d. MK7009
3293384|NCT00518622|Experimental|7|600 mg q.d. MK7009
3293385|NCT00518622|Experimental|8|Placebo
3293386|NCT00518609||Indian Neonates|All hospitalized neonates (all live born infants <60 days of age, independent of birth weight and gestational age) brought to hospital, with the diagnosis of suspected sepsis.
3293387|NCT00518596|Experimental|Probiotic Arm|Newborn infants' ≥ 35 weeks of gestation and ≥1800g, given L. plantarum preparations orally once a day starting on day 1, 2, or 3 of life and continuing for seven days thereafter.
3293388|NCT00518596|Placebo Comparator|Control Arm|Newborn infants' ≥ 35 weeks of gestation and ≥1800g, receiving placebo preparations (a control solution of sterile 2.0 cc 5% dextrose-saline)orally once a day starting on day 1, 2, or 3 of life and continuing for seven days thereafter.
3293389|NCT00518570|Experimental|Open-Label treatment|Patients prospectively diagnosed with premenstrual dysphoric disorder.
3293390|NCT00518557|Experimental|1|All patients of this arm are treated by TACE together with Andostatin.
3293391|NCT00518557|Active Comparator|2|All patients of this arm are treated by TACE alone: only mixture of Epirubicin and Lipiodol is injected into the feeding arteries of the tumor, without injection of Andostatin.
3293392|NCT00518531|Other|Treatment Sequence B|When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment Sequences. Subjects randomized to treatment sequence B will receive 70 mg oral alendronate QW for 1-year (Treatment period 1) followed by denosumab 60 mg Q6M SC for 1 year (Treatment Period 2).
3293393|NCT00518531|Other|Treatment Sequence A|When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment sequences. Subjects randomized to treatment sequence A will receive 60 mg denosumab Q6M SC for 1-year (Treatment period 1) followed by oral alendronate 70 mg QW for 1 year (Treatment period 2).
3293394|NCT00518518|Active Comparator|1|
3293395|NCT00518518|Placebo Comparator|2|
3293396|NCT00518505|Other|I|This is a single arm study. All patients will be asked to complete questionnaires and have their medical charts reviewed.
3293397|NCT00518492|Experimental|Arm 1|Includes subjects from a trial involving experimental vaccine and an active comparator vaccine. Comparator is Twinrix (not a MnB vaccine) and thus is comparator for safety but not immunogencity
3293398|NCT00518479|Experimental|1|Neurohormonal stimulatory arm
3293399|NCT00518479|Experimental|2|Neurohormonal inhibitory arm
3293400|NCT00518466|Experimental|treatment 1|"One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Days 4 - 21 of Period 2."
3293401|NCT00518466|Experimental|treatment 2|"Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~One 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsules at Hour 0 on Days 4, 5, and 6 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules (Cardinal) and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2."
3293402|NCT00518466|Experimental|treatment 3|"Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsule at Hour 0 on Days 4, 5, and 6 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2."
3293403|NCT00518466|Experimental|treatment 4|"Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate IR tablet at Hour 0 on Days 1, 2, and 3 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and two 25 mg topiramate IR tablets at Hour 0 on Days 4, 5, and 6 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and three 25 mg topiramate IR tablets at Hour 0 on Days 7, 8, and 9 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Days 10 - 21 of Period 2."
3293404|NCT00518453|Experimental|Arm 1: Fluvirin|
3293405|NCT00518427|Experimental|1|insulin glargine
3293406|NCT00518414|Active Comparator|Marketed infant formula with DHA and ARA|Marketed milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA)
3293407|NCT00518414|Experimental|Milk-based infant formula with DHA and ARA|Experimental milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA)
3293408|NCT00518414|Experimental|Milk-based formula with DHA, ARA, prebiotics|Experimental milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA) and prebiotic blend
3293409|NCT00518388||Focus Group + Questionnaire|Participants that are self identified as Korean, Filipino, or Vietnamese.
3293410|NCT00518362|Experimental|immunosuppressor|Valsartan,160mg/d,TW 120mg/d
3293411|NCT00518349|Active Comparator|Prototype colonoscope|Colonoscopy using prototype colonoscope with passive bending function
3293412|NCT00518349|Placebo Comparator|Standard colonoscope|Colonoscopy using standard colonoscope with no passive bending function
3293413|NCT00518336|Experimental|Cervarix Group|Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.
3293414|NCT00518336|Placebo Comparator|Placebo Group|Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.
3293415|NCT00518323|Experimental|001|Paliperidone ER 1.5 mg tablet once daily for 6 weeks
3293416|NCT00518323|Experimental|002|Paliperidone ER 3 mg or 6 mg tablet once daily for 6 weeks
3293417|NCT00518323|Experimental|003|Paliperidone ER 6 mg or 12 mg tablet once daily for 6 weeks
3293418|NCT00518323|Placebo Comparator|004|Placebo Once daily for 6 weeks
3293419|NCT00518310|Placebo Comparator|0|Placebo
3293420|NCT00518310|Active Comparator|1|Azathiprine Prednisone
3293421|NCT00518297|Active Comparator|1|
3293422|NCT00518297|Active Comparator|2|
3293423|NCT00518297|Active Comparator|3|
3293424|NCT00518284|No Intervention|No Drug Treatment Control|Following revascularization, participants did not receive any study drug treatment.
3293425|NCT00518284|Experimental|Proximal to Lesion + IV|Participants received an initial intraarterial infusion (proximal to the lesion) of 45 mg/m^2 nanoparticle paclitaxel immediately following revascularization, and a follow-up intravenous injection of 45 mg/m^2 at 7 days.
3293426|NCT00518284|Experimental|During Flow Arrest|Participants received an initial intraarterial infusion (during flow arrest) of 45 mg/m^2 nanoparticle paclitaxel immediately following revascularization.
3293427|NCT00518284|Experimental|During Flow Arrest + IV|Participants received an initial intraarterial infusion (during flow arrest) of 45mg/m^2 nanoparticle paclitaxel immediately following revascularization and a follow-up intravenous injection of 45 mg/m^2 at 7 days.
3293428|NCT00518258||1|Patient Group
3293429|NCT00518258||2|Control Group
3293430|NCT00518245|Experimental|1|
3293431|NCT00518245|No Intervention|2|
3293432|NCT00518219|Experimental|immunosuppressor|TW 120mg/d，Valsartan,160mg/d
3293433|NCT00518206|Experimental|Cohort 1|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
3293434|NCT00518206|Experimental|Cohort 2|Cyclophosphamide (300 mg/m^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
3293435|NCT00518180|Experimental|MenACWY + Tdap + HPV|Subjects received MenACWY concomitantly with Tdap and HPV at study month 0 followed by two injections of HPV at month 2 and 6
3293436|NCT00518180|Experimental|MenACWY →Tdap → HPV|Subjects received MenACWY at study month 0 followed by one injection of Tdap at month 1, followed by three injections of HPV at months 2, 4, and 8
3293437|NCT00518180|Experimental|Tdap →MenACWY → HPV|Subjects received Tdap at month 0 followed by one injection of MenACWY at month 1, followed by three injections of HPV at months 2, 4, and 8
3293438|NCT00518167|Experimental|1|Intensive lifestyle intervention
3293439|NCT00518167|No Intervention|2|Standard counselling at baseline
3293440|NCT00518154|Experimental|A|Patients will be taking oral Pyridostigmine 30mg tid, as well as their usual antiretroviral treatment
3293441|NCT00518141|Experimental|1|FER
3293442|NCT00518141|No Intervention|2|FER
3293443|NCT00518141|Experimental|3|SET
3293444|NCT00518141|No Intervention|4|SET
3293445|NCT00518141|Experimental|5|DET
3293446|NCT00518141|No Intervention|6|DET
3293447|NCT00518128|Active Comparator|1|Surgical OSA Treatment Group: Moderate to Severe OSA patients who are unable to tolerate PAP (Positive Airway Pressure) and elect to proceed with surgical treatment (surgical cohort).
3293448|NCT00518128|Active Comparator|2|Positive Airway Pressure Therapy Comparison Group: Moderate to Severe OSA patients who tolerate PAP (Positive Airway Pressure).
3293449|NCT00518102||001|REGRANEX (becaplermin) A cohort of REGRANEX (becaplermin) users (ie patients treated with REGRANEX (becaplermin) a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
3293450|NCT00518102||002|REGRANEX (becaplermin) comparators A cohort of REGRANEX (becaplermin) nonusers (ie patients who are not treated with REGRANEX [becaplermin]) but are similar in characteristics to patients in the REGRANEX [becaplermin] user cohort)
3293451|NCT00518089|Experimental|Gatifloxacin 0.5% Eye Drops|Gatifloxacin 0.5% Eye Drops
3293452|NCT00518089|Placebo Comparator|Placebo Eye Drops|Placebo Eye Drops
3293453|NCT00518050||Specific Aim 1- Focus Group|"Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:~Screening, skin self-examination, sun protection, and other cancer preventive practices;~Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,~Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment"
3293454|NCT00518050||Specific Aim 2- Survey Study|A separate random sample of melanoma survivors will complete the pilot questionnaire. To enhance completion rates, survey instruments will be developed to be both self-administered and interviewer-administered. The survey will include questions from existing surveys, regarding demographics, sun sensitivity, eye and hair color, color of untanned skin, sun exposure, skin selfexamination, sun protection practices and frequency of sunburns, psychosocial/cognitive factors: skin cancer knowledge, skin awareness, cancer worry, perceived risk of recurrence, cancer risk and screening behaviors, and access to health care and insurance.
3293455|NCT00518037||1|nonmelanoma skin cancer patients
3293456|NCT00518024|Experimental|1|Bilateral theta burst stimulation to the secondary auditory cortex
3293457|NCT00518024|Experimental|2|Bilateral theta burst stimulation to the tertiary auditory cortex
3293458|NCT00518024|Sham Comparator|3|Bilateral theta burst stimulation to a non-cortical region
3293459|NCT00518011|Experimental|Erlotinib + Gemcitabine|Participants received Erlotinib 150 mg/day orally as a continuous schedule with Gemcitabine 1000 (mg/m^2)/day, IV on Days 1, 8, 15 and every 4 weeks for 6 cycles.
3293460|NCT00518011|Active Comparator|Gemcitabine|Participants received Gemcitabine 1000 (mg/m^2)/day, IV on Days 1, 8, 15 and every 4 weeks for 6 cycles.
3293461|NCT00517998|Experimental|Group1|Treatment will be administered in two sessions.
3293462|NCT00517998|Experimental|Group2|Treatment will be administered in a single session.
3293463|NCT00517959|Experimental|1|Stereotactic conformal radiotherapy (SCRT)
3293464|NCT00517959|Other|2|Conventional radiotherapy Patients in this arm will be treated with conventional radiotherapy techniques being used at the moment in the department. This involves patient being immobilised with a customised thermoplastic mask after which they will have a contrast enhanced planning CT scan. The radiation oncologist will draw the tumour on the appropriate CT slices and a margin of 1-2 cms grown for the planning target volume. Beam arrangement will be relatively simple and typically consist of 2-3 coplanar fields using 6 MV photons. Conventional planning optimisation will be carried out by the use of wedges, beam weightage and corner shields as appropriate. Radiotherapy doses, prescription and fractionation schedules will be identical to the SCRT arm
3293465|NCT00517933|Active Comparator|Sildenafil|20 mg of sildenafil 3 times a day (TID) for 12 weeks followed by 20 mg of sildenafil TID for an additional 12 weeks
3293466|NCT00517933|Placebo Comparator|Placebo / Sildanafil|20 mg of placebo TID for 12 weeks followed by 20 mg of sildenafil citrate TID for an additional 12 weeks
3293467|NCT00517920|Experimental|ABT-869|
3293468|NCT00517907|Experimental|1|6 steroid-resistant acute GVHD patients, post-matched BMT (serial)
3293469|NCT00517881|Experimental|C.E.R.A.|
3293470|NCT00517868|Other|Crossover|Placebo Treatment on Visit 1 followed by URG101 Treatment on Visit 2
3293471|NCT00517868|Other|Crossover 2|URG101 Treatment on Visit 1 followed by Placebo Treatment on Visit 2
3293472|NCT00517829|Active Comparator|1- Docetaxel plus Oxaliplatin|Docetaxel as an intravenous (IV) infusion over 1 hour, followed by oxaliplatin IV over 2 hours
3293473|NCT00517829|Active Comparator|2- Docetaxel plus oxaliplatin plus cetuximab|Docetaxel 60 mg/m2 as an IV infusion over 1 ho ur, followed by oxaliplatin 130 mg/m2 IV over 2 hours, followed by cetuximab 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
3293474|NCT00517816|Experimental|1|
3293475|NCT00517816|Experimental|2|
3293485|NCT00517790|Experimental|ABT-869 0.10 mg/kg|Approximately half of the subjects were randomized to receive the Low Dose
3293486|NCT00517777|Experimental|1|continuous positive airway pressure ventilation + dietary and life style recommendations
3293487|NCT00517777|Active Comparator|2|dietary and life style recommendations
3293488|NCT00517764|No Intervention|Healthy control|Healthy matched control, no intervention
3293489|NCT00517764|Active Comparator|Escitalopram|Depressed subjects receiving escitalopram
3293490|NCT00517764|No Intervention|subjects with major depression|Depressed subjects not receiving study treatment, but taking part in study measures.
3293491|NCT00517751|Experimental|X-STOP PEEK|In this arm, patients will undergo X-STOP PEEK surgery.
3293492|NCT00517738|Experimental|Physical training - No encephalopathy|Patients randomized to the physical training program and diet intervention
3293493|NCT00517738|Active Comparator|Control - No encephalopathy|Patients not allocated to exercise program, but undergoing diet intervention
3293494|NCT00517738|Experimental|Physical training - Early encephalopathy|Patients with early hepatic encephalopathy (minimal or clinical grade 1-2) randomized to the physical training program
3293495|NCT00517738|Active Comparator|Control - Early encephalopathy|Patients with early hepatic encephalopathy (minimal or clinical grades 1-2) not allocated to the physical training program, but undergoing diet intervention
3293496|NCT00517725|Active Comparator|Carvedilol|
3293497|NCT00517725|Active Comparator|Bisoprolol|
3293498|NCT00517725|Active Comparator|Nebivolol|
3293499|NCT00517712|Active Comparator|A|Duration of maintenance therapy with single agent ATO of 12 months
3293500|NCT00517712|Active Comparator|B|Duration of maintenance therapy with single agent ATO for 6 months
3293501|NCT00517699|Experimental|1|
3293502|NCT00517686|Experimental|1|The study will use automated databases and PHASE information systems to identify patients and incorporate feedback on a monthly basis into the ongoing reports used by program staff at facilities randomized to this intervention arm (n=4).
3293503|NCT00517686|No Intervention|2|Usual care facilities (n=4) will continue to use current PHASE reports that include information on recent risk factor levels and current use of selected medications but no treatment intensification information, and no information on medication adherence.
3293504|NCT00517673|Experimental|GSK945237|Active Study Drug
3293505|NCT00517673|Placebo Comparator|Sugar Pill|Placebo
3293506|NCT00517634|Experimental|Sequence 1: FP, SFC, Placebo|Fluticasone Propionate (FP) 100 micrograms (mcg) twice daily (BID) in the first treatment period: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID in the second treatment period: Placebo in the third treatment period
3293507|NCT00517634|Experimental|Sequence 2: Placebo, SFC, FP|Placebo in the first treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
3293508|NCT00517634|Experimental|Sequence 3: SFC, FP, Placebo|Salmeterol/Fluticasone Propionate 50/100 Combination mcg BID in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Placebo in the third treatment period
3293509|NCT00517634|Experimental|Sequence 4: SFC, Placebo, FP|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the first treatment period: Placebo in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
3293510|NCT00517634|Experimental|Sequence 5: FP, Placebo, SFC|Fluticasone Propionate 100 mcg BID in the first treatment period: Placebo in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
3293511|NCT00517634|Experimental|Sequence 6: Placebo, FP, SFC|Placebo in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
3293512|NCT00517582|Experimental|HOE-140|Administration of HOE-140 (icatibant) 30 mg at time 0 and at 6 hours
3293513|NCT00517582|Placebo Comparator|Placebo|Administration of placebo at time 0 and 6 hours
3293514|NCT00517569|Experimental|1|GX-12 combined with HAART
3293515|NCT00517556|Experimental|study group (CCOCP)|treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for 168 continuous days through six cycles
3293516|NCT00517556|Active Comparator|control group (traditional OCP)|treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for traditional (21 active days/7 inactive days) regimen through six cycles.
3293517|NCT00517530|Experimental|Phase I, NHL|Participants in this NHL arm received multiple ascending doses between 50 and 2000 mg via intravenous infusion of obinutuzumab.
3293518|NCT00517530|Experimental|Phase I, CLL|Participants in this CLL arm received multiple ascending doses between 400 and 2000 mg via intravenous infusion of obinutuzumab.
3293519|NCT00517530|Experimental|400/400 mg - Phase II, iNHL|Participants in this iNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
3293520|NCT00517530|Experimental|1600/800 mg - Phase II, iNHL|Participants in this iNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
3293521|NCT00517530|Experimental|400/400 mg - Phase II, aNHL|Participants in this aNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
3293522|NCT00517530|Experimental|1600/800 mg - Phase II, aNHL|Participants in this aNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
3293523|NCT00517530|Experimental|1000/1000 mg - Phase II, CLL|Participants in this CLL arm received an intravenous infusion of obinutuzumab 1000 mg on Days 1, 8, and 15 of Cycle 1 and obinutuzumab 1000 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
3293524|NCT00517530|Experimental|Retreated Participants|Participants who might benefit from retreatment who were allowed to be treated again via intravenous infusion of obinutuzumab at the request of the investigator.
3293525|NCT00517517|Experimental|1|Intramuscular injection of whole virion, Vero cell-derived influenza vaccine containing 7.5 µg of H5N1 HA antigen per 0.5 mL in a non-adjuvanted formulation
3293526|NCT00517517|Experimental|2|Intramuscular injection of whole virion, Vero cell-derived influenza vaccine containing 3.75 µg of H5N1 HA antigen per 0.25 mL in a non-adjuvanted formulation
3293527|NCT00517491|Experimental|1|
3293528|NCT00517465|Experimental|1|
3293529|NCT00517465|Experimental|2|
3293530|NCT00517465|Experimental|3|
3293531|NCT00517465|Placebo Comparator|4|
3293532|NCT00517452||Platelet Rich Plasma|Group received platelet rich plasma and observed over a period of 30 days or until wound closure
3293533|NCT00517452||Standard Wound Care|Group was treated as per standard care
3293534|NCT00517439|Experimental|Group 1|Group 1 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1000 po bid) plus PEGASYS (180 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
3293535|NCT00517439|Experimental|Group 2|Group 2 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (500 mg po bid) plus PEGASYS (180 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
3293536|NCT00517439|Experimental|Group 3|Group 3 will receive HCV polymerase inhibitor pro-drug 500mg po bid plus PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd for 24 weeks; after 24 weeks, those achieving a rapid virological response (RVR) will stop all medication, and non-RVR patients will remain on triple combination for an additional 24 weeks.
3293537|NCT00517439|Experimental|Group 4|Group 4 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1500 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
3293538|NCT00517439|Experimental|Group 5|Group 5 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1000 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
3293539|NCT00517439|Experimental|Group 6|Group 6 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (500 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
3293540|NCT00517439|Active Comparator|Group 7|Standard of care (SOC)
3293541|NCT00517426|Experimental|Active Acetazolamide|
3293542|NCT00517413|Experimental|C.E.R.A|Participants with chronic renal anaemia who were on dialysis and previously treated with intravenous (IV) or subcutaneous (SC) epoetin alfa, epoetin beta or darbepoetin alfa received monthly treatment with Continuous Erythropoietin Receptor Activator (C.E.R.A.) (methoxy polyethylene glycol-epoetin beta [Mircera]). The initial dose of C.E.R.A. was based on the last dose of the previous Erythropoiesis Stimulating Agent (ESA); 120, 200, or 360 micrograms (mcg) C.E.R.A., IV or SC, every 4 weeks for 48 weeks.
3293543|NCT00517400|Active Comparator|Exposure-Stimulation|
3293544|NCT00517400|Active Comparator|Sham exposure - Real stimulation|
3293545|NCT00517400|Active Comparator|Exposure - Sham Stimulation|
3293546|NCT00517387|Active Comparator|1|All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
3293547|NCT00517361|Experimental|Carboplatin + Avastin|
3293548|NCT00517335||1|Women who are healthy controls
3293549|NCT00517335||2|Women who have recovered from bulimia
3293550|NCT00517335||3|Women who have recovered from anorexia
3293551|NCT00517322|Experimental|1|treatment with ramipril
3293552|NCT00517322|Experimental|2|treatment with irbesartan
3293553|NCT00517296|Experimental|Adalimumab with EUS guided therapy|Patients will be randomized to adalimumab treatment with EUS guided therapy decisions. Colorectal surgeon will have access to EUS data prior to EUA with possible seton placement.
3293554|NCT00517296|Active Comparator|Adalimumab|Patients will be randomized to adalimumab treatment. Colorectal surgeon will not have access to EUS data prior to EUA with possible seton placement.
3293555|NCT00517283|Experimental|Sequence 1|Exenatide 5 mcg - Exentatide 10 mcg - Placebo
3293556|NCT00517283|Experimental|Sequence 2|Exenatide 10 mcg - Placebo - Exenatide 5 mcg
3293557|NCT00517283|Experimental|Sequence 3|Placebo - Exenatide 5 mcg - Exenatide 10 mcg
3293558|NCT00517257|Experimental|A|Atorvastatin 80 mg orally once daily for 24 weeks
3293559|NCT00517257|Placebo Comparator|P|Placebo tablet orally once daily for 24 weeks
3293560|NCT00517244||A|Primary anxiety disorder
3293561|NCT00517244||B|Primary obsessive compulsive disorder
3293562|NCT00517244||C|Healthy children with no previous history of an anxiety disorder
3293563|NCT00517166||A|Individuals on whom tourniquet was used.
3293564|NCT00517153|Experimental|1|OGT-918 - Zavesca (miglustat)
3293565|NCT00517153|No Intervention|2|Standard treatment
3293566|NCT00517127|Active Comparator|1|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
3293567|NCT00517127|Active Comparator|2|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
3293568|NCT00517088|Other|Other|Group Description
3293569|NCT00517075|Experimental|A|high frequency rTMS to the left infero-parietal lobe, active/sham condition randomized (2:1), double-blind
3293570|NCT00517075|Active Comparator|B|Active high frequency rTMS to the left dorsolateral prefrontal cortex
3293571|NCT00517075|Sham Comparator|C|Sham (placebo) high frequency rTMS to the left dorsolateral prefrontal cortex or left infero-parietal lobe, active/sham condition randomized (2:1), double-blind
3293716|NCT00515528|Experimental|1|4-peptide melanoma vaccine, ontak
3293717|NCT00515528|Experimental|2|ontak
3293572|NCT00517075|Experimental|Open cross over high frequency rTMS|Following the randomization phase with three arms, subjects who did not respond, have the possibility of receiving open active treatment to the target that they did not receive treatment to in the randomization phase. (i.e. randomized to IPL --> open phase DLPFC and vice versa)
3293573|NCT00517062|Active Comparator|A|Growth hormone
3293574|NCT00517062|Placebo Comparator|B|Placebo
3293575|NCT00517049|Experimental|1|
3293576|NCT00517036|Experimental|A|Participants will take EPA
3293577|NCT00517036|Experimental|B|Participants will take DHA
3293578|NCT00517036|Placebo Comparator|C|Participants will take placebo
3293579|NCT00517023|Active Comparator|ILR + Syncope Clinic|Patients will have ILR implanted and follow-up in Syncope Clinic
3293580|NCT00517023|Active Comparator|ILR Only|Patients will have ILR implanted and routine follow up.
3293581|NCT00517023|Active Comparator|Routine Mx + Syncope Clinic|Patients will receive routine care and management plus follow up in Syncope Clinic
3293582|NCT00517023|Active Comparator|Routine Mx|Patients will receive routine care and management
3293583|NCT00517010|Experimental|proton beam with ranibizumab|Intervention is 24Gy proton radiation in 2 fractions given within 6 weeks of first dose of intravitreal ranibizumab (0.5mg) drug combined with four monthly doses of intravitreal lucentis and monthly prn lucentis thereafter.
3293584|NCT00516984|Placebo Comparator|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
3293585|NCT00516984|Sham Comparator|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
3293586|NCT00516984|Active Comparator|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
3293587|NCT00516958|Experimental|1|Topical Dermacyn
3293588|NCT00516958|Active Comparator|2|Topical Dermacyn and levofloxacin
3293589|NCT00516958|Active Comparator|3|Topical saline and levofloxacin
3293590|NCT00516919|Experimental|1|Xenical + behavioral intervention
3293591|NCT00516919|Active Comparator|2|Placebo + behavioral intervention
3293592|NCT00516906|Placebo Comparator|Transparent Adhesive Dressing|Standard of Care Non-Antimicrobial Transparent Adhesive Dressing
3293593|NCT00516906|Experimental|CHG antimicrobial transparent dressing|Chlorhexidine gluconate antimicrobial transparent adhesive dressing
3293594|NCT00516893|Experimental|Natalizumab High Titer|natalizumab high titer 300 mg administered as intravenous (IV) infusion over 60 minutes once every 4 weeks for up to 9 doses
3293595|NCT00516867|Active Comparator|UVB 0.5%|
3293596|NCT00516867|No Intervention|Controls|
3293597|NCT00516867|Active Comparator|UVB 1.4%|
3293598|NCT00516841|Experimental|volociximab|15 mg/kg volociximab once weekly
3293599|NCT00516828|Experimental|Sorafenib and Cytarabine|Cytarabine: subcutaneously twice daily from day 1 - 10. Sorafenib: Days 2-28; at the dose level assigned at registration. Sorafenib will be given orally twice daily.
3293600|NCT00516802|Experimental|1|DTIC + KU-0059436
3293601|NCT00516737|Experimental|1|Active Drug
3293602|NCT00516737|Placebo Comparator|2|Matching Pbo Comparator
3293603|NCT00516724|Experimental|1|Carboplatin + KU-0059436
3293604|NCT00516724|Experimental|2.|Paclitaxel + KU-0059436
3293605|NCT00516724|Experimental|3.|Paclitaxel, Carboplatin + KU-0059436
3293606|NCT00516698||Group 1|"Patients undergo blood sample collection at baseline and at 1 year after initiation of aromatase inhibitor therapy (anastrozole or exemestane). Samples are analyzed for estrogen and testosterone levels and additional hormone levels and growth factors that have been previously linked with breast density and that could be altered by aromatase inhibitor use (i.e., sex hormone-binding globulin [SHBG], DHEA, DHEA sulfate, progesterone, prolactin, insulin-like growth factor-1 [IGF-1], and insulin-like growth factor binding protein 3 [IGF BP3]). Samples are also analyzed for anastrozole and exemestane levels by HPLC. Pharmacogenetic studies are also performed. Haplotype-tagged single nucleotide polymorphisms in genes in the aromatase pathway are examined.~Patients also undergo mammogram at baseline (≤ 6 months prior to study registration) and at 1 year after initiation of aromatase inhibitor therapy."
3293607|NCT00516685|Experimental|Vaccine Group|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
3293608|NCT00516685|No Intervention|Control Group|Patients in this arm will only receive Best Supportive Care.
3293609|NCT00516672|Experimental|Arm 1|Pazopanib monotherapy or in combination with lapatinib
3293610|NCT00516659|Active Comparator|Group 1|Group 1 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 37.5µg LT
3293611|NCT00516659|Placebo Comparator|Group 2|Group 2 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 0µg LT (placebo patch containing no LT)
3293612|NCT00516646|Active Comparator|1|ALT-711 200 mg bid
3293613|NCT00516646|Placebo Comparator|2|
3293614|NCT00516633|No Intervention|CG|The control group had regular individual information and support in connection with ordinary clinical follow-ups
3293615|NCT00516633|Experimental|IG|The intervention group had extra support and information in the form of four group discussions with parents
3293616|NCT00516620|Active Comparator|1|Participants receive Health Canada's Food Guide and Physical Activity guide.
3293617|NCT00516620|Active Comparator|2|Participants receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
3293618|NCT00516620|Active Comparator|3|Participants receive intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products.
3293619|NCT00516620|Active Comparator|4|Participants receive intensive dietary counseling for 6 months to decrease intake of sweetened soft drink.
3293620|NCT00516581||no HAART|Patients that no received HAART
3293621|NCT00516581||with HAART|Patients that received HAART
3293622|NCT00516555||A, 07, 001|Pregnant women at term with a baby in breech presentation who will have an external cephalic version.
3293623|NCT00516516|Experimental|I|Oral L-Carnitine, 1g PO twice daily
3293624|NCT00516516|Placebo Comparator|II|Placebo, similar in appearance to experimental drug, given orally twice daily.
3293625|NCT00516503|Experimental|Arm I|Patients apply 1 spoonful of baclofen-amitriptyline hydrochloride-ketamine gel> topically to each> area of pain,> numbness,> and/or tingling> on the> feet and/or hands twice daily> for> 4 weeks.
3293626|NCT00516503|Placebo Comparator|Arm II|Patients apply 1 spoonful of placebo gel topically to each area of pain, numbness, and/or tingling on the feet and/or hands twice daily for 4 weeks.
3293627|NCT00516490|Experimental|1|GnRH agonist administration
3293628|NCT00516490|Placebo Comparator|2|Sterile saline injection
3293629|NCT00516477|Experimental|dose cohort 1|1.5E10 vector genomes voretigene neparvovec-rzyl in 150 microliters administered subretinally
3293630|NCT00516477|Experimental|dose cohort 2|4.8E10 vector genomes voretigene neparvovec-rzyl in 150 microliters administered subretinally
3293631|NCT00516477|Experimental|dose cohort 3|1.5E11 vector genomes voretigene neparvovec-rzyl in 300 microliters administered subretinally
3293632|NCT00516451|Experimental|1|
3293633|NCT00516438|Experimental|1|Topotecan + KU-0059436
3293634|NCT00516412|Experimental|Everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3293635|NCT00516399|Experimental|I:|povidone-iodine 1.25% ophthalmic solution. The associated intervention descriptions contain sufficient information to describe the arm.
3293636|NCT00516399|Active Comparator|II|natamycin ophthalmic suspension, USP 5%. The associated intervention descriptions contain sufficient information to describe the arm.
3293637|NCT00516386|Experimental|Insulin like growth factor- 1 (IGF-1)|Adolescent girls with AN meeting inclusion criteria were administered recombinant human (rh) rhIGF-1 at a dose of 35-40 mcg/k twice daily by subcutaneous injections for a 7-10 day period.
3293638|NCT00516373|Experimental|KU-0059436|KU-0059436 administered orally twice daily
3293639|NCT00516360|Experimental|1|Chlorhexidien as the antibacterial agent used to cleanse the hub of neonatal central lines
3293640|NCT00516360|Active Comparator|2|Isopropyl alcohol as the antibacterial agent used to cleanse the hub of neonatal central lines
3293641|NCT00516295|Experimental|Arm I (Feasibility assessment of VTCB)|Patients receive bevacizumab IV over 30-90 minutes on day 1, vincristine sulfate IV on days 1, 8, and 15, and topotecan hydrochloride IV over 30 minutes and cyclophosphamide IV over 60 minutes on days 1-5. Treatment repeats every 21 days (except during weeks 14, 15 [course 5], 17, 18 [course 6], 26, 27 [course 9], 29, and 30 [course 10] when no chemotherapy is given) for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3293642|NCT00516295|Experimental|Arm II (VTCB)|Patients receive bevacizumab, vincristine sulfate, topotecan hydrochloride, and cyclophosphamide as in Arm I.
3293643|NCT00516295|Active Comparator|Arm III (CTC)|Patients receive vincristine, topotecan hydrochloride, and cyclophosphamide as in arm I.
3293644|NCT00516269|Experimental|Methylphenidate then Placebo|Methylphenidate 18 mg oral daily for 2 weeks then Placebo oral daily for 2 weeks
3293645|NCT00516269|Experimental|Placebo then Methylphenidate|Placebo oral daily for 2 weeks then Methylphenidate 18 mg oral daily for 2 weeks
3293646|NCT00516256|Experimental|CHESS System|CHESS System - Internet-based computer program for 6 months.
3293647|NCT00516256|Experimental|Cancer Information Mentor|Cancer Information Mentor - Phone calls to the patient for 6 months.
3293648|NCT00516256|Experimental|CHESS System + Cancer Information Mentor|CHESS System + Cancer Information Mentor
3293649|NCT00516243|Experimental|Arm I (defined green tea catechin extract)|Patients receive defined green tea catechin extract PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
3293650|NCT00516243|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
3293651|NCT00516217|Experimental|Galaximab|Induction: 500 mg/m^2 by IV over 60 minutes days 1, 8, 15 & 22 Extended Induction: 500 mg/m^2 by IV every 4 weeks until disease progression or unacceptable toxicity
3293652|NCT00516204||Patients at very high risk|
3293653|NCT00516204||Patients at high risk|
3293654|NCT00516204||Patients at medium risk|
3293655|NCT00516204||Patients at low risk|
3293656|NCT00516178|Placebo Comparator|Placebo|Saline (No lipid emulsion)
3293657|NCT00516178|Experimental|Fish oil emulsion|3 infusions of 0.2 g/kg omega-3 PUFA within 24 hours in cardiac surgery (continuous infusion post-PTCA)
3293658|NCT00516165|Experimental|RAD001|Patients will receive RAD001 10 mg/day orally (6 weeks/cycle). Patients will be continued on treatment until disease progression, limiting toxicity, patient withdrawal of consent, or death.
3293659|NCT00516139|Experimental|Lamotrigine|Open-label lamotrigine
3293660|NCT00516126||Point-of-Care managed|This arm includes all patients in which the hemostatic therapy is guided by POC devices e.g. MULTIPLATE (a platelet function analyzer) or ROTEM (thromboelastometry)
3293661|NCT00516126||Conventional hemostasis lab managed|This arm includes all patients in which the hemostatic therapy is guided by conventional hemostasis laboratory data e.g. INR, aPTT, fibrinogen concentration, platelet count but no POC devices e.g. MULTIPLATE (a platelet function analyzer) or ROTEM (thromboelastometry)
3293662|NCT00516113|Active Comparator|1|Paroxetine 20mg during the luteal phase of the menstrual cycle
3293663|NCT00516113|Placebo Comparator|2|Placebo during the luteal phase of the menstrual cycle
3293664|NCT00516087|Experimental|Patients|Patients with NPC in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV genome or antigens have been demonstrated in tissue biopsies.
3293665|NCT00516074|Experimental|Exenatide Arm|This arm will receive 5mcg exenatide for 4 weeks, and then 10mcg exenatide for the remaining 8 weeks of the study.
3293666|NCT00516074|Placebo Comparator|Placebo Arm|This arm will receive placebo injection (volume equivalent to the exenatide injection in the experimental arm).
3293667|NCT00516048|Experimental|Exenatide:Treatment-Emergent Antibody Negative|This arm will receive 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks.
3293668|NCT00516048|Experimental|Exenatide:Treatment-Emergent Antibody Positive|This arm will receive 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks.
3293762|NCT00515294|Experimental|1Caffeinated Alcoholic Beer|Caffeinated Alcoholic beer
3293763|NCT00515294|Active Comparator|2Non-Caffeinated Alcoholic Beer|Non-Caffeinated Alcoholic beer
3293669|NCT00516035|Experimental|1|0.50 ml (0.25 ml in each nostril) of Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca) administered by nasal spray at two timepoints (at study entry and between Weeks 4 and 8)
3293670|NCT00516022|Experimental|Investigator product|The patients randomized to this arm will receive the IP injections at home 3 times a week (the patients will inject the IP themselves).
3293671|NCT00516022|Other|Control|The patients randomized to this arm will continue to receive chemotherapy as usual without further treatment (unless prescribed by the Doctor).
3293672|NCT00516009|Experimental|1 TREATMENT GROUP|20 PATIENTS WILL RECEIVE DEXAMETHASONE 30 MG IV 3 DAYS AND 20 AND 10 MG FOR THE OTHER TWO DAYS
3293673|NCT00516009|Placebo Comparator|2|20 PATIENTS WILL RECEIVE PLACEBO FOR 5 DAYS
3293674|NCT00515996|Case|2|paroxetine treatment group vs. normal control group
3293675|NCT00515970|Experimental|1|Clinical or histologic diagnosis of nodular BCC
3293676|NCT00515970|Active Comparator|2|Clinical or histologic diagnosis of nodular BCC
3293677|NCT00515970|Experimental|3|Clinical or histologic diagnosis of superficial BCC
3293678|NCT00515970|Active Comparator|4|Clinical or histologic diagnosis of superficial BCC
3293679|NCT00515957|Experimental|Patients|Patients with Nasopharyngeal Carcinoma in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV-genome or antigens have been demonstrated in tissue biopsies
3293680|NCT00515931|Experimental|Radiotherapy|GIST patients who have progressing metastases will be treated with radiotherapy.
3293681|NCT00515918|Case|1|Iron deficient
3293682|NCT00515918|Control|2|Iron sufficient
3293683|NCT00515879|Experimental|CBT plus d-cycloserine|Participants will receive cognitive behavioral therapy plus D-cycloserine
3293684|NCT00515879|Placebo Comparator|CBT plus placebo|Participants will receive cognitive behavioral therapy plus pill placebo
3293685|NCT00515866|Experimental|1|Gemcitabine + KU-0059436
3293686|NCT00515840|Sham Comparator|1|equal time with health care professional (asthma nurse)
3293687|NCT00515827|Experimental|Raltegravir then Placebo (Arm A)|400 mg raltegravir (MK-0518) administered twice daily in addition to optimized background regimen (OBR) from entry to Week 12; halt raltegravir at Week 12 and add placebo twice daily for 12 weeks
3293688|NCT00515827|Experimental|Placebo then Raltegravir (Arm B)|Placebo administered twice daily in addition to OBR from entry until Week 12; halt placebo at Week 12 and add 400 mg raltegravir tablet twice daily for 12 weeks
3293689|NCT00515814|Experimental|1, 2|During measurement/test periods, investigator sets implant into ON or OFF condition without subjects knowledge of when device is active.
3293690|NCT00515801|Experimental|A|Glibenclamide 5 mg tablets
3293691|NCT00515801|Placebo Comparator|B|placebo capsules
3293692|NCT00515788|Experimental|DepoCyt + Temozolomide|DepoCyt Starting 50 mg Intrathecal Day 1 every 14 days for 12 weeks (6 treatments), then every 28 days for 40 weeks (10 treatments). Temozolomide 100 mg/m^2 by mouth daily for 7 days every 14 days.
3293693|NCT00515762|Experimental|1: scalp cooling|scalp cooling
3293694|NCT00515736|Experimental|AOX group|Treatment group - double dose (loading) for 48 hours then single dose (Se 270 mcg, Zn 30 mg, vit C 1.2 g, B1 100 mg, vit E 300 mg enteral)
3293695|NCT00515736|Placebo Comparator|0|Group receiving vehicle solution for 5 days (double dose for 48 hours)
3293696|NCT00515723|Active Comparator|1|Randomized switch from current antipsychotic treatment to either olanzapine, risperidone, ziprasidone, or quetiapine.
3293697|NCT00515710||1|Prior gene therapy study subjects receiving AAV2-hFIX16.
3293698|NCT00515697|Experimental|Ramucirumab|Intravenous infusion at 8 milligrams per kilogram (mg/kg) on day 1 of every 14-day cycle.
3293699|NCT00515671|Experimental|Arm 1_IMR|Illness Management and Recovery was offered in small groups (less than 8), co-facilitated by either an experienced masters level clinician or a doctoral level psychologist and by a doctoral student in clinical psychology. Facilitators used the IMR curriculum, incorporating psychoeducation, cognitive-behavioral approaches, relapse prevention, social skills training, and coping skills training. Facilitators worked with groups to set personal recovery goals and address progress towards those goals throughout the intervention. Home assignments helped participants apply newly learned skills and/or make progress on goals. Groups were open to rolling admission across the study period
3293700|NCT00515671|Placebo Comparator|Arm 2_PS|Problem Solving was the active control condition (also offered in groups weekly for 9 months). Participants were encouraged to discuss current concerns and receive group support; we did not use structured problem solving tasks. These groups were led by the same facilitators described above, who helped establish group expectations (attendance, confidentiality), encouraged participation, and provided process-oriented observations; there was no formal curriculum, goal setting, or homework assignments.
3293701|NCT00515645|Experimental|1|
3293702|NCT00515632|Experimental|Balaglitazone 10 mg per day|
3293703|NCT00515632|Experimental|Balaglitazone 20 mg per day|
3293704|NCT00515632|Active Comparator|Pioglitazone 45 mg per day|
3293705|NCT00515632|Placebo Comparator|Placebo|
3293706|NCT00515619|Experimental|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing
3293707|NCT00515580|Experimental|A|Pilot study of 5 patients, with an additional 20 patients with conditional approval by the IRB once the initial 5 patient's data is reviewed.
3293708|NCT00515554|Active Comparator|A|8 cycles BEACOPPesc
3293709|NCT00515554|Experimental|B|8 cycles BEACOPPesc plus rituximab
3293710|NCT00515554|Active Comparator|C|8 cycles BEACOPPesc
3293711|NCT00515554|Experimental|D|4 cycles BEACOPPesc
3293712|NCT00515541|Active Comparator|A|Patient is not on Aspirin, Clopidogrel, or Warfarin and is taking escalating doses of study drug.
3293713|NCT00515541|Active Comparator|B|Patient is on regular dose of Aspirin ( < or = 325mg). Patient is not taking Clopidogrel or Warfarin and is taking the escalating doses of Lovaza
3293714|NCT00515541|Active Comparator|C|Patient is taking regularly 75mg of clopidogrel daily and Aspirin (< or = 325mg) and not taking Warfarin and is taking the escalating doses of Lovaza
3293715|NCT00515541|Active Comparator|D|Patient is regularly taking Warfarin daily and Aspirin (< or = 325mg)and is not taking Clopidogrel and is taking the escalating doses of Lovaza
3293718|NCT00515502|Active Comparator|Seq 1: UMEC 250 µg, UMEC 500 µg, Tiotropium 18 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: umeclidinium bromide (UMEC) 250 micrograms (µg), UMEC 500 µg, Tiotropium 18 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
3293719|NCT00515502|Active Comparator|Seq 2: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
3293720|NCT00515502|Active Comparator|Seq 3: UMEC 250 µg, placebo, UMEC 500 µg, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, UMEC 500 µg and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
3293721|NCT00515502|Active Comparator|Seq 4: UMEC 250 µg, UMEC 500 µg, placebo, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, UMEC 500 µg, placebo and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
3293722|NCT00515502|Active Comparator|Seq 5: Placebo, UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, UMEC 250 µg, UMEC 500 µg and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
3293723|NCT00515502|Active Comparator|Seq 6: UMEC 250 µg, placebo, Tiotropium 18 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, Tiotropium 18 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
3293724|NCT00515502|Active Comparator|Seq 7: Placebo, Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, Tiotropium 18 µg, UMEC 250 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
3293725|NCT00515502|Active Comparator|Seq 8: Tiotropium 18 µg, placebo, UMEC 250 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, placebo, UMEC 250 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
3293726|NCT00515502|Active Comparator|Seq 9: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
3293727|NCT00515502|Active Comparator|Seq 10: Tiotropium 18 µg, UMEC 250 µg, placebo, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, UMEC 250 µg, placebo and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
3293728|NCT00515502|Active Comparator|Seq 11: Placebo, UMEC 250 µg, Tiotropium 18 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, UMEC 250 µg, Tiotropium 18 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
3293729|NCT00515502|Active Comparator|Seq 12: UMEC 250 µg, placebo, UMEC 500 µg, Tiotropium 18 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, UMEC 500 µg and Tiotropium 18 µg. Treatment periods were seperated by a washout period of at least 14 days.
3293730|NCT00515489||001|Risperidone as prescribed
3293731|NCT00515463|Experimental|Denosumab - Vial|Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.
3293732|NCT00515463|Experimental|Denosumab - Prefilled syringe|Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.
3293733|NCT00515450|Experimental|1|
3293734|NCT00515450|Active Comparator|2|
3293735|NCT00515437|Experimental|1|1500U Myobloc
3293736|NCT00515437|Experimental|2|2500U Myobloc
3293737|NCT00515437|Experimental|3|3500U Myobloc
3293738|NCT00515437|Placebo Comparator|4|pooled placebo
3293739|NCT00515411|Active Comparator|Arm A, - Modified DCF|"Drug Dose (mg/m2) Schedule~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Arm A is repeated every 2 weeks, and a cycle will be considered 6 weeks (eg 3 treatments)."
3293740|NCT00515411|Active Comparator|ARM B - Parent DCF with G-CSF|"Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17~* 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg"
3293741|NCT00515398||1|Group 1 (all subjects)
3293742|NCT00515385|Experimental|1a|Cohort 1 completed
3293743|NCT00515385|Placebo Comparator|1b|Cohort 1 placebo completed
3293744|NCT00515385|Experimental|2a|Cohort 2 completed completed
3293745|NCT00515385|Placebo Comparator|2b|Cohort 2 placebo completed
3293746|NCT00515385|Experimental|3a|Cohort 3 active
3293747|NCT00515385|Placebo Comparator|3b|Cohort 3 placebo
3293748|NCT00515385|Experimental|4a|Cohort 4 active
3293749|NCT00515385|Placebo Comparator|4b|Cohort 4 placebo
3293750|NCT00515385|Experimental|5a|Cohort 5 active
3293751|NCT00515385|Placebo Comparator|5b|Cohort 5 placebo
3293752|NCT00515372|Active Comparator|Intervention Group|Weekly phone calls lasting about 30 minutes. Lists of professional resources and referral recommendations will be provided.
3293753|NCT00515372|Other|Usual Care Group|Lists of professional resources and referral recommendations will be provided.
3293754|NCT00515359|Active Comparator|Dose Comparison|continuous versus intermittent bolus dosing
3293755|NCT00515333|Placebo Comparator|1|Placebo: 0 milligrams; t.i.d.
3293756|NCT00515333|Active Comparator|2|Treatment group: 30 milligrams; t.i.d.
3293757|NCT00515333|Active Comparator|3|Treatment group: 60 milligrams; t.i.d.
3293758|NCT00515333|Active Comparator|4|Treatment group: 100 milligrams; t.i.d.
3293759|NCT00515320|Experimental|Fluoxetine|
3293760|NCT00515320|Placebo Comparator|Placebo|
3293761|NCT00515307|Experimental|A|
3293764|NCT00515294|Active Comparator|3Caffeinated Non-Alcoholic Beer|Caffeinated Non-Alcoholic Beer
3293765|NCT00515294|Placebo Comparator|4Non-Caffeinated, Non-Alcoholic Beer|Non-Caffeinated, Non-Alcoholic Beer
3293766|NCT00515281|Experimental|INO Treatment|The treatment group will receive iNO, combined with O2 or room air, until 33 weeks corrected age.
3293767|NCT00515281|Placebo Comparator|INO Control|INO will be given to infants in the control group for the first 7 days of the study gas, then O2 or room air, as clinically appropriate, on the 8th day, until 33 weeks corrected age
3293768|NCT00515268|Experimental|Subjects receiving GSK256066|Eligible subjects will be randomized to receive GSK256066 with inhaled doses of 25 micrograms or 87.5 micrograms once daily for 7 days, administered via an ACCUHALER.
3293769|NCT00515268|Placebo Comparator|Subjects receiving placebo|Eligible subjects will be randomized to receive placebo for 7 days, administered via an ACCUHALER.
3293770|NCT00515242|Experimental|1|Therapeutic massage
3293771|NCT00515242|Active Comparator|2|Thermotherapy
3293772|NCT00515242|Placebo Comparator|3|Relaxation
3293773|NCT00515229|Active Comparator|1|Verum 1: Each individual capsule has a filling volume of 25 mg amitriptyline, given once an day in the evening over 28 days
3293774|NCT00515229|Active Comparator|2|Verum 1: Each individual capsule has a filling volume of 50 mg amitriptyline, given once an day in the evening over 28 days
3293775|NCT00515229|Active Comparator|3|Verum 3: Each individual capsule has a filling volume of 75 mg amitriptyline, given once an day in the evening over 28 days
3293776|NCT00515229|Placebo Comparator|0|Placebo: Each individual capsule has a filling volume of 25 mg placebo (corn starch), given once an day in the evening over 28 days
3293777|NCT00515216|Experimental|Oxaliplatin/Leucovorin/5-FU|"Good risk patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks."
3293778|NCT00515203|Placebo Comparator|II.|5 thrombocytopenic (as defined per protocol) subjects
3293779|NCT00515203|Experimental|I.|15 thrombocytopenic (as defined per protocol) subjects
3293780|NCT00515190|Active Comparator|A|(continuous):S-1 plus oxalipatin will be continued until disease progression, unacceptable toxicity or consent withdrawal.
3293781|NCT00515190|Active Comparator|B|(intermittent arm): Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles.
3293782|NCT00515177|Experimental|MBSR|A Mindfulness-Based Stress Reduction (MBSR) program that includes 8-weeks of group instruction in mindfulness meditation techniques followed by home practice and monitoring.
3293783|NCT00515177|Active Comparator|PCT Sleeping Pills|A pharmacotherapy control arm (PCT Sleeping Pills) consisting of a state-of-the-art prescription sedative hypnotic, eszopiclone - brand name LUNESTA(R), at a dose of one 3 milligram (mg) pill nightly for a duration of 8 weeks followed by use as needed (same dosage) for 3 months. This drug was approved by the Food and Drug Administration as a sedative for more than short term use.
3293784|NCT00515164|Experimental|Group 1|Treatment will be administered in 2 treatment sessions.
3293785|NCT00515164|Experimental|Group 2|Treatment will be administered in a single treatment session.
3293786|NCT00515151|Active Comparator|Oct/Alc|
3293787|NCT00515151|Active Comparator|Alc|
3293788|NCT00515125|Other|Dietary Advice|Dietary Advice
3293789|NCT00515125|Other|Oral Nutritional Supplements|Oral Nutritional Supplements
3293790|NCT00515112|Experimental|A|Twenty subjects will receive testosterone gel
3293791|NCT00515112|Placebo Comparator|B|Twenty subjects will receive the placebo
3293792|NCT00515099|Experimental|Antithymocyte globulin|This group received a total of 6.5 mg/kg of antithymocyte globulin (e.g., Thymoglobulin®) divided into four doses as follows: Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.
3293793|NCT00515099|Placebo Comparator|Placebo|This group received a saline solution to match the Thymoglobulin doses given to the active treatment group, on Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.
3293794|NCT00515086|Experimental|No Surgery (Everolimus 10 mg)|Participants with recurrent Glioblastoma Multiforme (GBM) not scheduled to undergo salvage surgical resection, received a daily oral dose of 10 mg Everolimus (RAD001) until evidence of disease progression or toxicity.
3293795|NCT00515086|Experimental|Everolimus 10 mg + Surgery|Participants scheduled to undergo salvage surgical resection received a daily oral dose of 10 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
3293796|NCT00515086|Experimental|Everolimus 5 mg + Surgery|Participants scheduled to undergo salvage surgical resection received a daily oral dose of 5 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
3293797|NCT00515086|Active Comparator|Everolimus 0 mg + Surgery|Participants scheduled to undergo salvage surgical resection received no treatment with Everolimus prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
3293798|NCT00515073|Experimental|Paclitaxel (Taxol) + Pelvic Radiation|"Paclitaxel (Taxol) 50 mg/m^2 intravenous (IV) weekly over 1 hour for 5 weeks. Radiation therapy to the pelvis daily for 25 treatments.~Both radiation therapy and paclitaxel chemotherapy on Day 1 or 2, followed by radiation alone for four days, repeated every week for a total of 5 weeks, giving a total dose of 45 Gy with external beam radiation to pelvis and 5 courses of paclitaxel 50 mg/m^2. Four-six weeks after pelvic radiation completed, 4 additional courses of paclitaxel 135 mg/m^2 alone given every 21 days. Vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for additional 3 days. No chemotherapy given with vaginal apex boost."
3293799|NCT00515060||Cancer Therapy-Induced Pain|Patients with advanced cancer entering chemotherapy or have reported pain as a result of cancer treatment.
3293800|NCT00515047||Eczema Herpeticum (EH)|Participants with AD who currently have or have had EH
3293801|NCT00515047||Non-EH|Participants with AD who do not have and have never had EH
3293802|NCT00515047||Healthy Controls|Healthy participants without a history of AD
3293803|NCT00515034|Experimental|001|Doripenem 1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
3293804|NCT00515034|Active Comparator|002|Imipenem/cilastatin 1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
3293805|NCT00515034|Experimental|003|Doripenem 1 gram infused over 4 hours at 8 hour intervals for patients with complicated intrabdominal infections (cIAI) for 5 to 14 days Vancomycin may be added as adjunctive therapy as per investigator discretion
3293806|NCT00515034|Active Comparator|004|Imipenem/cilastatin 1 gram infused over 1 hour at 8 hour intervals for patients with complicated intrabdominal infections (cIAI) for 5 to 14 days Vancomycin may be added as adjunctive therapy as per investigator discretion
3293807|NCT00515021|Experimental|1|Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 50mg, by mouth, daily, in the evening x 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks.
3293808|NCT00515008|Experimental|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi 18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
3293809|NCT00515008|Placebo Comparator|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
3293810|NCT00514995|Experimental|1|
3293811|NCT00514982|Other|1/Drug #1|Oral mesalamine will be used as initial therapy in patients who are not taking any medication or have not received any prior treatment for their IBD. Dosing will begin at 2.4 g PO QD and will be increased to 4.8 g QD within 2 weeks. Topical mesalamine (enema 4 g PR HS/BID or suppository 1 g PR HS/BID) may be added for patients with inflammation that is limited to the rectum (proctitis) or who have prominent complaints of urgency, incomplete evacuation or rectal bleeding.
3293812|NCT00514982|Other|1/Drug#2|Add oral corticosteroids (prednisone) to mesalamine. The standard induction dose will be 40 mg/day. After 1 week of therapy, if the total SCCAI score has decreased by greater than or equal to 2 points the patient will continue on another week of therapy. If the SCCAI has not decreased by greater than or equal to 2 points (indicative of a reduction in symptoms) at one week, then the dose will be increased to 60 mg/day. Patients on either dosage will have another SCCAI assessment done a week later (2 weeks after beginning corticosteroids), and if they are found to be in remission (SCCAI less than or equal to 2), a steroid-tapering schedule will be initiated.
3293813|NCT00514982|Other|1/Drug#3|Infliximab and 6-MP will be added to patients with a SCCAI greater than 2 at week 8. The first infusion of infliximab (5 mg/kg) will be given during that week. In addition, 6-MP will be initiated at doses of 1.0-1.5 mg/kg PO QD to reduce the incidence of infliximab antibody formation and facilitate steroid tapering (the target dose of 6-MP will be decreased accordingly if patients are found to have low TMPT levels/activity by genotypic or phenotypic testing). Also, steroids will also be rapidly tapered off at this time.
3293814|NCT00514982|Other|1/Drug#4|Infliximab and 6-MP will be added to patients with a SCCAI greater than 2 at week 8. The first infusion of infliximab (5 mg/kg) will be given during that week. In addition, 6-MP will be initiated at doses of 1.0-1.5 mg/kg PO QD to reduce the incidence of infliximab antibody formation and facilitate steroid tapering (the target dose of 6-MP will be decreased accordingly if patients are found to have low TMPT levels/activity by genotypic or phenotypic testing). Also, steroids will also be rapidly tapered off at this time.
3293815|NCT00514982|Other|1/Drug#5|Subjects with a SCCAI greater than 2 after 3 doses of infliximab will continue 6-MP, discontinue infliximab infusions and start adalimumab injections approximately 2 weeks after the 3rd dose of infliximab. Induction dosing will consist of a 160 Micro/g subcutaneous injection, followed by 80 Micro/g 2 weeks after.
3293816|NCT00514982|Other|1/Drug#6|Patients who have a SCCAI greater than 2 after 2 doses of adalimumab will continue 6-MP, discontinue adalimumab, and start therapy with tacrolimus 0.01 mg/kg PO BID approximately 2 weeks after the second dose of adalimumab.
3293817|NCT00514943|Experimental|BIBW 2992|once daily taken orally
3293818|NCT00514943|Active Comparator|Cetuximab|once every week by intravenous injection
3293819|NCT00514917|Experimental|Docetaxel+Leuprolide+Bicalutamide|Participants received docetaxel 75 milligram per square meter (mg/m^2) intravenous infusion over 1 hour every 3 weeks up to 10 cycles (3 week cycle) along with leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.
3293820|NCT00514917|Active Comparator|Leuprolide+Bicalutamide|Participants received leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.
3293821|NCT00514904|Experimental|Nimenrix Group|Subjects received 1 dose of Nimenrix vaccine at Month 0. Nimenrix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3293822|NCT00514904|Active Comparator|Mencevax ACWY Group|Subjects received 1 dose of Mencevax ACWY vaccine at Month 0. Mencevax ACWY vaccine was administered subcutaneously into the upper region of the non-dominant arm.
3293823|NCT00514891|Active Comparator|1|Vitamin A supplementation
3293824|NCT00514891|Placebo Comparator|2|Placebo
3293825|NCT00514878||1|Adult same-day outpatients scheduled for general anesthesia
3293826|NCT00514865|Experimental|E1|1-2 mg of ONO-2333
3293827|NCT00514865|Experimental|E2|5-10 mg of ONO-2333
3293828|NCT00514865|Placebo Comparator|P|placebo comparator
3293829|NCT00514852|Experimental|1|Carboxymethylcellulose and Glycerin based artificial tear
3293830|NCT00514852|Active Comparator|2|Carboxymethylcellulose
3293831|NCT00514839|No Intervention|C|Control group receiving a booklet on health behavior
3293832|NCT00514839|Experimental|MI|Counselling based on Motivational Interviewing plus individualized feedback
3293833|NCT00514813|Experimental|Dynepo (Epoetin delta)|Subjects received Dynepo (Epoetin delta) either twice weekly (BIW), once weekly (QW), once every 2 weeks (Q2W) or once every 4 weeks (Q4W) based on what is appropriate for the subject
3293834|NCT00514800|Experimental|Intervention|"Patients will be given a home blood pressure monitor and taught how to use it and how to respond to the readings using a standardised protocol and blood pressure targets. The study nurse will follow up patients at home after a month with additional telephone support according to a defined protocol. Patients will consult their own GP for medication changes when above target.~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings."
3293835|NCT00514800|Active Comparator|Control|
3293836|NCT00514774|Experimental|A|
3293837|NCT00514774|Experimental|B|
3293838|NCT00514774|Placebo Comparator|C|
3293839|NCT00514761|Active Comparator|1|Xeloda
3293840|NCT00514761|Experimental|2|AZD6244
3293841|NCT00514748|Active Comparator|1|Patients who receive breast reconstruction with bilateral DIEP flap based on bilateral vessel pedicles
3293842|NCT00514748|Experimental|2|Patient who receive breast reconstruction with vessel interconnected DIEP flap based on one vessel pedicle
3293843|NCT00514735|Experimental|1|Ablation Management
3293844|NCT00514735|Active Comparator|2|Medical Management
3293845|NCT00514709|Experimental|Group 1|DTaP-Hep B-PRP-T + OPV vaccine group
3293846|NCT00514709|Experimental|Group 2|Tritanrix-HepB/Hib™ + OPV vaccine group
3293847|NCT00514696|Experimental|GCS-100|GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
3293848|NCT00514683|Experimental|dose 1|low dose BIBF1120 once daily
3293849|NCT00514683|Experimental|dose 2|low dose BIBF 1120 twice daily
3293850|NCT00514683|Experimental|dose 3|intermediate dose BIBF 1120 twice daily
3293851|NCT00514683|Experimental|dose 4|high dose BIBF 1120 twice daily
3293852|NCT00514683|Placebo Comparator|placebo|placebo
3293853|NCT00514670|Experimental|1|Intervention classrooms received alcohol-based hand sanitizer and disinfecting wipes.
3293854|NCT00514670|No Intervention|2|No hand sanitizer or disinfecting wipes were used.
3293855|NCT00514657|Placebo Comparator|P|
3293856|NCT00514657|Experimental|L|low dose (0.03 %)
3293857|NCT00514657|Experimental|M|medium dose (0.1 %)
3293858|NCT00514657|Experimental|H|high dose (0.3 %)
3293859|NCT00514644|Experimental|Panorama to Ultrasound|100 asymptotic patients that have findings of calcifications in the area of the carotid arteries when examined with panorama. These persons are examined with carotid ultrasound.
3293860|NCT00514644|Experimental|Ultrasound to Panorama|100 patients with a known carotid stenosis seen on ultrasound will be examined with panorama before any intervention is made. These patients must undergo surgery to be finally included.
3293861|NCT00514618|Active Comparator|1|patients will be treated with misoprostol 50 mcg PO
3293862|NCT00514618|Placebo Comparator|2|patients will receive placebo (Vitamin C)
3293863|NCT00514592||All|All patients enter the same group
3293864|NCT00514579|Other|Myeloablative double unit UCBT|Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation
3293865|NCT00514566|Active Comparator|1|Surgical Patient undergoing midline laparotomy closure
3293866|NCT00514540|Experimental|Carboplatin + Docetaxel|Carboplatin area under the curve (AUC) = 5, intravenous (IV) over 30 minutes and Docetaxel 75 mg/m^2 IV over 60 minutes, Day 1 repeated every 3 weeks.
3293867|NCT00514527|Experimental|1|
3293868|NCT00514527|Experimental|2|
3293869|NCT00514527|Experimental|3|
3293870|NCT00514514|Active Comparator|CNI standard regimen|Myfortic, Sandimmun Optoral and corticosteroids
3293871|NCT00514514|Experimental|CNI free regimen|"CNI free regimen: comprising the following steps for switching treatment:~Step 1 at BL2 + 1 day: Myfortic, Certican 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, Certican 3 mg and corticosteroids"
3293872|NCT00514514|Active Comparator|CNI low regimen|"CNI low regimen: comprising the following steps for switching treatment:~Step 1 at BL2 + 1 day: Certican 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: Certican 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids"
3293873|NCT00514501|Experimental|Iodofiltic Acid I 123|
3293874|NCT00514462|Experimental|A|low level laser instrument (Painless Light PL-830, Advanced Chips & Products Crop., USA)
3293875|NCT00514449|Experimental|Valacyclovir|1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.
3293876|NCT00514449|Placebo Comparator|Sugar pill|2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.
3293877|NCT00514436|No Intervention|Usual care|Usual care consisted of referral back to primary care provider after index hospitalization
3293878|NCT00514436|Experimental|Behavioral|Asthma coaching, inperson contact followed by telephone contact
3293879|NCT00514423|Experimental|2|Psychoeducation by peer-moderators
3293880|NCT00514423|Experimental|1|Psychoeducation by professionals
3293881|NCT00514423|Experimental|3|Video-education
3293882|NCT00514423|Placebo Comparator|4|Control group
3293883|NCT00514410|Experimental|Folic Acid|
3293884|NCT00514410|Placebo Comparator|Placebo|
3293885|NCT00514371|Experimental|tanespimycin and bortezomib|A patient will receive a standard dose of bortezomib followed by a high dose of tanespimycin.
3294047|NCT00512967||IPF|15 IPF patients, partially treated
3293886|NCT00514371|Experimental|bortezomib and tanespimycin|A patient will receive a standard dose of bortezomib followed by a mid dose of tanespimycin.
3293887|NCT00514371|Experimental|bortezomib tanespimycin|A patient will receive a standard dose of bortezomib followed by a low dose of tanespimycin.
3293888|NCT00514358||gestational age|
3293889|NCT00514332|Experimental|A|primary surgery group
3293890|NCT00514306|Experimental|Schedule 1|OSI-906 days 1-3 every 14 days
3293891|NCT00514306|Experimental|Schedule 2|OSI-906 days 1-5 every 14 days
3293892|NCT00514306|Experimental|Schedule 3|OSI-906 days 1-7 every 14 days
3293893|NCT00514267|Experimental|1. HRPC|
3293894|NCT00514267|Experimental|2. Solid Tumors|
3293895|NCT00514254||case|Participants complete questionnaires about lifestyle factors and their usual diet and measure their waist and hips. Saliva or buccal specimens are collected for future research.
3293896|NCT00514254||control|Participants complete questionnaires about lifestyle factors and their usual diet and measure their waist and hips. Saliva or buccal specimens are collected for future research.
3293897|NCT00514241|Experimental|A|The arm utilizes the GPS™ II Platelet Concentrate Separation Kit.
3293898|NCT00514241|No Intervention|B|This arm utilizes standard leg wound closure procedures.
3293899|NCT00514228|Experimental|Continuous sunitinib treatment|
3293900|NCT00514215|Experimental|Sargramostim, Flow Cytometry, Biopsy. Cryosurgery|Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 & 32 Immunoenzyme technique-Days 1 & 32 CT guided biopsy-Days 1 & 32 Cryosurgery-Days 1 and 32
3293901|NCT00514202|Placebo Comparator|1|Placebo plus cognitive behavioral therapy
3293902|NCT00514202|Experimental|2|Dextroamphetamine SR (60 mg/kg) plus cognitive behavioral therapy
3293903|NCT00514189|Experimental|Autologous Dendritic Cells|
3293904|NCT00514163|Experimental|1|gemcitabine + S-1
3293905|NCT00514163|Active Comparator|2|S-1
3293906|NCT00514150|Active Comparator|1|1075 cc of 154 mEq/L solution of NaCl 0.9% , prepared by adding 75 cc of 154 mEq/L NaCl 0.9 % to 1000 cc of 154 mEq/L NaCl 0.9%
3293907|NCT00514150|Active Comparator|2|1075 cc fluid made by adding 75 cc of sodium bicarbonate 8.4% to 1000 cc of 154 mEq/ L NaCl 0.9%.
3293908|NCT00514137|Experimental|Treatment (kinase inhibitor therapy)|Patients receive 37.5 mg oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3293909|NCT00514111||HVC Patients|HVC patients attended in SAE e HD.
3293910|NCT00514072|Experimental|Arm I|Patients receive ONY-P1 vaccine with BCG intradermally on days 1 and 15. Patients then receive ONY-P1 vaccine alone on day 29 and then every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
3293911|NCT00514072|Placebo Comparator|Arm II|Patients receive placebo vaccine intradermally on days 1, 15, and 29 and then every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
3293912|NCT00514059|Other|1|
3293913|NCT00514046|Experimental|1|vandetanib daily
3293914|NCT00514033||Group A|PoliorixTM will be administered according to a 3-dose schedule at 2, 4, 6 months for primary vaccination followed by a booster dose between 4 to 6 years. For the primary vaccination course, 1 to 3 doses of the vaccine will be given depending on previous vaccination history with poliomyelitis vaccine.
3293915|NCT00514020|Experimental|Treatment|
3293916|NCT00514007|Experimental|OSI-906 QD|Once per day
3293917|NCT00514007|Experimental|OSI-906 BID|Twice per day
3293918|NCT00513994|Active Comparator|1|
3293919|NCT00513968|Experimental|I|HB-110 2mg, 4mg or 8mg combined with Adefovir
3293920|NCT00513968|Active Comparator|II|Adefovir
3293921|NCT00513955|Experimental|Bortezomib plus CHOP|"Patients receive bortezomib IV over 3-5 seconds on days 1 and 8; doxorubicin hydrochloride IV, cyclophosphamide IV, and vincristine IV on day 1; and oral prednisolone on days 1-5.~Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Patients complete quality of life questionnaires at baseline, prior to each treatment course, and then at 30 days after completion of treatment.~After completion of study treatment, patients are followed at 30 days and then every 12 weeks thereafter."
3293922|NCT00513942|No Intervention|A|These women will follow standard antenatal care according to the Norwegian Guidelines
3293923|NCT00513942|Active Comparator|B|Intervention group for Fetal Movement Counting
3293924|NCT00513929|Experimental|X: Zinc sulphate|
3293925|NCT00513916|Experimental|Arm I|"Participants partake in a high soy diet consisting of 2 daily soy servings (approximately 50mg isoflavones).~The choice of soy foods will include ½ cup of tofu, ¾ cup of soy milk, or ¼ cup of soy nuts. Replacement of currently consumed foods with soy foods will be encouraged."
3293926|NCT00513916|Active Comparator|Arm II|Participants will be asked to keep their soy intake below 3 servings per week. The participants will also receive general nutrition counseling.
3293927|NCT00513903|Active Comparator|Minimal intervention|Minimal intervention group patients will be seen by a clinical pharmacist in the hospital but will not receive followup after hospital discharge.
3293928|NCT00513903|Experimental|Enhanced intervention|Enhanced intervention patients will receive care from a clinical pharmacist during hospitalization and followup by phone after hospitalization.
3293929|NCT00513903|No Intervention|Control|Control arm patients will not be seen by the clinical pharmacist.
3293930|NCT00513877|Experimental|Bortezomib 1.6mg/m2|
3293931|NCT00513864|Active Comparator|CYP2D6-|This arm consists of subjects that are poor metabolizers (PM) and intermediate metabolizers (IM).
3293932|NCT00513864|Active Comparator|CYP2D6+|Extensive metabolizers (EM) of codeine
3293933|NCT00513851|Experimental|1|Once Daily Dosing
3293934|NCT00513851|Experimental|2|Twice Daily Dosing
3293935|NCT00513825|Active Comparator|1|1075 cc of 77 mEq/L solution of NaCl 0.45% , prepared by adding 75 cc of 77 mEq/L NaCl 0.45 % to 1000 cc of 77 mEq/L NaCl 0.45%
3293936|NCT00513825|Active Comparator|2|1075 cc fluid made by adding 75 cc of sodium bicarbonate solution 8.4% to 1000 cc of NaCl 0.45%.
3293937|NCT00513799|Active Comparator|1: Hygiene Education|"Intensive education on prevention of skin infections through improvements in personal hygiene (also serves as control group)"
3293938|NCT00513799|Active Comparator|2: Hygiene education + mupirocin|Application of mupirocin in the nasal mucosa alone
3293939|NCT00513799|Active Comparator|Education + mupirocin + chlorhexidine|A combination of nasal application of mupirocin and chlorhexidine showers
3293940|NCT00513799|Active Comparator|4: Education + mupirocin + bleach baths|A combination of nasal application of mupirocin and bathing in dilute bleach water
3293941|NCT00513786|Experimental|carboplatin/paclitaxel with bevacizumab|A regimen of Carboplatin and paclitaxel combined with bevacizumab given every 21 days in patients with advanced stage endometrial cancer for a maximum of 6 cycles.
3293942|NCT00513760|Experimental|1|Coingestion of 240 ml of grapefruit juice with 10 mg of montelukast.
3293943|NCT00513760|Active Comparator|2|Coingestion of 240 ml of orange juice with 10 mg of montelukast.
3293944|NCT00513760|Placebo Comparator|3|Coingestion of 240 ml of Gatorade with 10 mg of montelukast.
3293945|NCT00513747|Experimental|Arm I|Patients receive rituximab IV over 4 hours on days 1, 3, and 5 of week 1 and then on day 1 of weeks 5, 9, 13, 17, and 21. Patients also receive fludarabine phosphate IV over 30 minutes on days 1-5 of weeks 1, 5, 9, 13, 17, and 21. After completion of chemoimmunotherapy, patients are followed every 3 months until disease progression. At the time of disease progression, patients receive retreatment with chemoimmunotherapy as above or another treatment regimen.
3293946|NCT00513747|Active Comparator|Arm II|Patients are followed every 3 months until disease progression. At the time of disease progression, patients receive rituximab and fludarabine phosphate as in arm I. Patients are then followed every 3 months until second disease progression. Patients with a second disease progression receive retreatment with chemoimmunotherapy as above or another treatment regimen.
3293947|NCT00513734|Active Comparator|1|Geliperm Hydrogel Dressing
3293948|NCT00513734|Active Comparator|2|Lacrilube ointment
3293949|NCT00513721||III|Prostate specimens with positive surgical margins.
3293950|NCT00513708|No Intervention|Treatment As Usual (TAU)|"Treatment as Usual (TAU): Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during medically managed inpatient detoxification."
3293951|NCT00513708|Experimental|Motivational Enhancement Therapy (MET)|"Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during inpatient detoxification plus a 60-minute Motivational Enhancement Therapy (MET) session delivered by a trained professional."
3293952|NCT00513708|Experimental|Peer-delivered Twelve Step Facilitation|"Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during inpatient detoxification plus a 60-minute Peer-delivered Twelve Step Facilitation (P-TSF)session delivered by individuals from a common self-help program."
3293953|NCT00513695|Experimental|Treatment (neoadjuvant chemotherapy before surgery)|Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
3293954|NCT00513682|Experimental|Ultrase® MT20|
3293955|NCT00513669|Experimental|1 PEV301&302|The vaccine includes two antigens (CSP and AMA1- derived)in combination and formulated with virosomes
3293956|NCT00513669|Active Comparator|2 Influenza vaccine|Inflexal V is the comparator that includes 3 antigens from flu formulated in virosomes
3293957|NCT00513656|Active Comparator|Oxycodone Hydrochloride Tablets|
3293958|NCT00513656|Experimental|Oxycodone Naloxone Tablets|
3293959|NCT00513643|Experimental|1|6 U insulin aspart
3293960|NCT00513643|Experimental|2|12 U insulin aspart
3293961|NCT00513643|Experimental|3|24 U insulin aspart
3293962|NCT00513643|Active Comparator|4|6 IU human regular insulin
3293963|NCT00513643|Active Comparator|5|12 IU human regular insulin
3293964|NCT00513643|Active Comparator|6|24 IU human regular insulin
3293965|NCT00513630|Active Comparator|metformin|
3293966|NCT00513630|Active Comparator|glipizide|
3293967|NCT00513617|Active Comparator|Low Dose|0.05 g/kg/day Arginine
3293968|NCT00513617|Active Comparator|High Dose|0.10 g/kg/day Arginine
3293969|NCT00513617|Placebo Comparator|Placebo|No Arginine
3293970|NCT00513604|Experimental|Cohort 1 - NMA, TIL, aldesleukin|"Cohort 1 - Nonmyeloablative (NMA), tumor infiltrating lymphocytes (TIL), & high dose (HD) aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by bulk young tumor infiltrating lymphocytes and high dose aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. Bulk young TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 1 = unselected TIL"
3293971|NCT00513604|Experimental|Cohort 2 - NMA, CD4+ TIL, aldesleukin|"Cohort 2 - Nonmyeloablative (NMA), cluster of differentiation 4 (CD4+) depleted tumor infiltrating lymphocytes (TIL), aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by CD4+ depleted tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 2 = CD4+ depleted (selected) TIL"
3293972|NCT00513604|Experimental|Cohort 3 - NMA, total body irradiation|"Cohort 3 - Nonmyeloablative (NMA), total body irradiation (TBI):~Nonmyeloablative chemotherapeutic conditioning regimen and 2 gray units (Gy) of total body irradiation followed by cluster of differentiation 4 (CD4+) depleted tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL 2Gy (gray units) of total body irradiation (TBI) twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute using a linear accelerator in Radiation Oncology Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 3 = CD4 + depleted (selected) TIL + 600Gy radiation"
3294048|NCT00512967||COPD|15 COPD patients within 24 hours after their last exacerbation
3293973|NCT00513604|Experimental|Cohort 4 - NMA, young TIL, aldesleukin|"Cohort 4 - Nonmyeloablative (NMA), tumor infiltrating lymphocytes (TIL), aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by bulk young tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. Bulk young TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 4 = unselected TIL - it is the SAME as cohort 1"
3293974|NCT00513604|Experimental|Cohort 5 - NMA, CD4+TIL, HD aldesleukin|"Cohort 5 - Nonmyeloablative (NMA), cluster of differentiation 4 (CD4+) tumor infiltrating lymphocytes (TIL), high dose (HD) aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by CD4+ depleted tumor infiltrating lymphocytes and high dose aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 5 = CD4 + depleted TIL - it is the SAME as cohort 2"
3293975|NCT00513591||1|Women with lupus
3293976|NCT00513591||2|Health women who are matched to women with lupus by age and race
3293977|NCT00513591||3|Women with other autoimmune diseases
3293978|NCT00513565|Placebo Comparator|placebo arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
3293979|NCT00513565|Experimental|GSK561679 arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
3293980|NCT00513565|Active Comparator|lorazepam arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
3293981|NCT00513539|Active Comparator|Arm A|Biliary Stenting alone
3293982|NCT00513539|Experimental|Arm B|Photodynamic Therapy plus biliary stenting
3293983|NCT00513526|Experimental|Gardasil|Quadrivalent HPV Vaccine (types 6, 11, 16, 18) for intramuscular injection at study entry, week 8, week 24, and week 128.
3293984|NCT00513500|Experimental|1|Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on rapid diagnostic test. For pneumonia, give one half tablet (250mg amoxicillin) for children weighing (5-9.9kg) and one tablet for children weighing (10-20kg) three times a day for five days.
3293985|NCT00513500|Active Comparator|2|Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on clinical diagnosis. For pneumonia, refer to the nearest health facility
3293986|NCT00513474|Experimental|Rasburicase Group|Myeloablative (bone marrow depletion) conditioning protocol as per standard of care at the investigator's discretion followed by granulocyte colony-stimulating factor (GCSF)-mobilized human leukocyte antigen (HLA)-matched, related or unrelated donor allogeneic peripheral blood stem cells (unmanipulated), standard graft-versus-host disease (GVHD) prophylaxis as per standard of care at the investigator's discretion and rasburicase 0.20 mg/kg/day administered by intravenous infusion for 5 consecutive days. If after 5 days of rasburicase the participant's uric acid plasma level remains above 5 mg/dL, rasburicase may be continued for up to 7 days in total.
3293987|NCT00513474|Other|Control Group|Historical chart review of patients from the Blood and Marrow Transplant database who received myeloablative allogeneic stem cell/bone marrow transplantation followed by standard GVHD prophylaxis in the past 10 years. Participants received allopurinol per institutional guidelines.
3293988|NCT00513461|Experimental|Arm I (SAMe)|Patients receive SAMe PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
3293989|NCT00513461|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
3293990|NCT00513435|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO or by PEG tube QD on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
3293991|NCT00513422|Experimental|1|Glucosamine sulfate 1500mg and chondroitin sulfate 800mg (low molecular weight, bovine)
3293992|NCT00513422|Experimental|2|Glucosamine sulfate 1500mg
3293993|NCT00513422|Experimental|3|Chondroitin sulfate 800mg
3293994|NCT00513422|Placebo Comparator|4|Matching glucosamine/chondroitin placebo capsules
3293995|NCT00513409|Experimental|Synflorix Booster Group|Subjects previously primed with Synflorix™ and receiving in the current study Havrix™ co-administered with Infanrix™ hexa (Dose 1) and Synflorix™ (Dose 2).
3293996|NCT00513409|Experimental|Synflorix Catch-up Group|Subjects previously primed with Havrix™ co-administered with Infanrix™ hexa and receiving in the current study Synflorix™ co-administered with Infanrix™ hexa (Dose 1) and Synflorix™ (Dose 2).
3293997|NCT00513396|Experimental|1|
3293998|NCT00513396|Active Comparator|2|
3293999|NCT00513396|Placebo Comparator|3|
3294000|NCT00513383|Experimental|Part A|Determine the best dosing of panitumumab, chemotherapy and radiation.
3294001|NCT00513383|Experimental|Part B|Determine the best dosing of induction chemotherapy combined with panitumumab prior to receiving panitumumab and chemoradiotherapy.
3294002|NCT00513370|Experimental|1|
3294003|NCT00513357|Experimental|Melatonin|20 mg of Melatonin before going to sleep at night for a period of 4 weeks.
3294004|NCT00513357|Placebo Comparator|Placebo|20 mg of Placebo before going to sleep at night for a period of 4 weeks.
3294005|NCT00513344|Experimental|dark chocolate containing polyphenols|dark chocolate
3294006|NCT00513344|Experimental|Milk chocolate containing polyphenols|Bespoke milk chocolate
3294007|NCT00513344|Active Comparator|Control chocolate with no polyphenols|cocoa-free chocolate
3294008|NCT00513331||Algorithm #1|Patients without visable lesions
3294009|NCT00513331||Algorithm #2|Patients with a visable lesion that is less than 1cm
3294010|NCT00513331||Algorithm #3|Patients with a visable lesion greater than 1cm
3294049|NCT00512967||controls|25 healthy controls, matched for age and gender
3294050|NCT00512941||1|HBV: Carrier
3294051|NCT00512941||2|HBV: cure
3294052|NCT00512941||3|HBV: isolate anti-HBc
3294053|NCT00512941||4|HBV: vaccinated
3294054|NCT00512941||5|HCV: anti-HCV positive test
3294055|NCT00512941||6|HBV/HCV co-infection
3294011|NCT00513305|Active Comparator|Low-dose cytarabine plus arsenic trioxide|Cycle 1 cytarabine 10 mg/m^2 was administered subcutaneously (sc) twice daily (bid) on days 1-14. 0.25 mg/kg arsenic trioxide was administered intravenously (iv) on days 1-5 and days 8-12. Cycle 2 A second identical cycle of cytarabine and arsenic trioxide was given to patients with persistent disease. Patients who achieved complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine and arsenic trioxide with the doses and schedule identical to the initial cycle. A recovery period of up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of arsenic trioxide 0.25 mg/kg iv on days 1 and 4 and cytarabine 10 mg/m^2 sc bid on days 1 through 7 of a 28-day cycle.
3294012|NCT00513305|Active Comparator|Low-dose cytarabine alone|Cytarabine was administered at a dose of 10 mg/m^2 sc bid from days 1-14 of cycle 1. A second identical cycle of cytarabine was given to patients with persistent disease. Patients who achieved a complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine with the doses and schedule identical to the initial treatment cycle. Recovery period up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of cytarabine at 10 mg/m^2 sc bid on days 1-7 of a 28-day cycle. Patients started maintenance treatment within 42 days after platelet count recovery. Maintenance treatment continued for 2 years or until unacceptable toxicity or disease progression.
3294013|NCT00513292|Active Comparator|FEC-75 then Paclitaxel/trastuzumab|Patients receive FEC comprising fluoroucacil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks.
3294014|NCT00513292|Experimental|Paclitaxel/trastuzumab then trastuzumab/FEC-75|Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluoroucacil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I.
3294015|NCT00513279|Experimental|Cohort 1|Subjects in Cohort 1 will be randomized to one of the following sequences: ABDFH, BADFH, BDAFH, BDFAH and BDFHA in a 1:1:1:1:1 ratio where A = Placebo, B= GSK618334 dose 1 (2.5 mg), D = GSK618334 dose 3, F = GSK618334 dose 5, H = GSK618334 dose 7. On day 1, subjects will be administered a starting dose of 2.5 milligrams (mg) GSK618334. The planned doses of GSK618334 to be administered in Cohort 1 are 2.5, 25, 100 and 400mg. In each dosing period 2 subjects will receive placebo and 8 subjects will receive GSK618334. Subjects within a cohort will have a washout period of at least two weeks from last dose before receiving another dose.
3294016|NCT00513279|Experimental|Cohort 2|Subjects in Cohort 2 will be randomized to one of the following sequences: ACEGI, CAEGI, CEAGI, CEGAI, CEGIA in a 1:1:1:1:1 ratio where A = Placebo, C= GSK618334 dose 2, E = GSK618334dose 4, G = GSK618334 dose 6, I= GSK618334 dose 8. In each dosing period 2 subjects will receive placebo and 8 subjects will receive GSK618334. Subjects within a cohort will have a washout period of at least two weeks from last dose before receiving another dose.
3294017|NCT00513240|Experimental|EPO group|Patients randomized to receive the 3 doses of erythropoetin.
3294018|NCT00513240|Placebo Comparator|Control group.|Patients randomized to receive 3 doses of normal saline control.
3294019|NCT00513214|Active Comparator|XOMA 052|
3294020|NCT00513214|Placebo Comparator|Placebo|
3294021|NCT00513162|Experimental|Valproate + Etoposide|Valproate Starting Dose of 10 mg/kg By Mouth Daily. Etoposide 25 - 50 mg/m^2 By Mouth Daily.
3294022|NCT00513149|Active Comparator|c6|Clopidogrel 600 mg loading
3294023|NCT00513136|Active Comparator|I|10 week group-based mind body medicine intervention
3294024|NCT00513136|Experimental|II|Group-based mind body medicine intervention with a family focus
3294025|NCT00513123||Digital Colposcopy|Digital Colposcopy for Fluorescence (DCF)
3294026|NCT00513110|Experimental|1|Endotoxin and AMPD1 polymorphism
3294027|NCT00513110|Experimental|2|Endotoxin and intervention with caffeine
3294028|NCT00513110|Placebo Comparator|3|Endotoxin combined with placebo
3294029|NCT00513097|Experimental|Smoking Prevention & Cessation Program|
3294030|NCT00513084|Experimental|SDT Intervention|This arm will follow main experimental intervention, as described elsewhere
3294031|NCT00513084|No Intervention|Comparison Group|Comparison Group receiving standard care health promotion intervention
3294032|NCT00513071|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
3294033|NCT00513058|Experimental|lapatinib + vinorelbine|"starting with loading dose of lapatinib per os for 7 days~then, combining lapatinib (oral daily continuous) + vinorelbine (intravenous, day 1 and 8 every 3 weeks)"
3294034|NCT00513045|Experimental|IRT|Intervention based on Imagery Rehearsal Therapy
3294035|NCT00513045|Active Comparator|Exposure|Treatment based on exposure
3294036|NCT00513045|No Intervention|Nightmare diary|Recording nightmares in a diary
3294037|NCT00513045|No Intervention|Waiting list|Waiting list
3294038|NCT00513032|Case|methylene blue|
3294039|NCT00513032|Control|C|
3294040|NCT00513019|Active Comparator|1|Lamictal (lamotrigine)
3294041|NCT00513019|Placebo Comparator|2|Placebo
3294042|NCT00512993|Active Comparator|Treatment|Patients receive zoledronic acid (4mg) for 5 years. Additionally patients receive standard endocrine, radiologic and trastuzumab treatment, respectively
3294043|NCT00512993|No Intervention|Observation|Patients will be under observation and receive standard endocrine, radiologic and trastuzumab treatment, respectively
3294044|NCT00512980|Active Comparator|1|
3294045|NCT00512980|Active Comparator|2|
3294046|NCT00512967||sarcoidosis|21 onset patients, non-treated
3294057|NCT00512915|Active Comparator|1699T (Optisense)|Implantation of the Optisense Lead 1699T, programming of the shortest possible postventricular atrial blanking period (PVAB)
3294058|NCT00512915|Active Comparator|Standard lead|Implantation of a standard bipolar atrial pacing lead. Optimization of the postventricular atrial blanking period (PVAB) after implantation.
3294059|NCT00512902|Experimental|Group 1|SSc patients receiving Imatinib (Gleevec, up to 600 mg) QD PO for up to 1 year.
3294060|NCT00512889|Experimental|Cohort 1|Different dose of CTL
3294061|NCT00512889|Experimental|Cohort 2|Different dose of CTL
3294062|NCT00512889|Experimental|Cohort 3|Combination of CTL with GMCSF +/- radiation
3294063|NCT00512850|Other|Folic acid|Folic acid supplement 1g/day
3294064|NCT00512850|Other|Placebo|Placebo pill once per day
3294065|NCT00512837|Active Comparator|2|
3294066|NCT00512824|Placebo Comparator|1|
3294067|NCT00512824|Active Comparator|2|
3294068|NCT00512824|Active Comparator|3|
3294069|NCT00512824|Active Comparator|4|
3294070|NCT00512798|Experimental|Phase I|
3294071|NCT00512798|Experimental|Phase II|
3294072|NCT00512785|Experimental|E1|
3294073|NCT00512785|Experimental|E2|
3294074|NCT00512759|No Intervention|Standard of care|Standard of care of acute decompensated heart failure will be according to the current guidelines of the European Society of Cardiology (ESC).
3294075|NCT00512759|Experimental|Intervention|Early goal-directed preload and afterload decrement using a fixed therapy schedule including sublingual or nitrospray and transdermal nitrates together with hydralazine, followed by rapid up-titration of ACE-inhibitors , AT-receptor blockers or neprilysin inhibitors/AT-receptor blockers to achieve maximal vasodilatation with a target systolic blood pressure of 90-110 mmHg. All other elements of treatment will be according to the current guidelines of the European Society of Cardiology (ESC)
3294076|NCT00512746|Other|Surveillance|Screened arm
3294077|NCT00512746|Active Comparator|Control|Control arm
3294078|NCT00512707|Experimental|Active Testosterone Gel|Active Testosterone Gel and on demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
3294079|NCT00512707|Placebo Comparator|Placebo Gel|Placebo Gel and on demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
3294080|NCT00512668|Experimental|Treatment (hormone therapy, temsirolimus)|"Patients receive combined androgen ablation therapy comprising a luteinizing hormone-releasing hormone analogue (i.e., leuprolide acetate intramuscularly once monthly or goserelin subcutaneously every 3 months) and an oral anti-androgen drug (i.e., bicalutamide or nilutamide once daily or flutamide 3 times daily) on days 1-90.* Beginning on day 60 of hormonal therapy, patients receive temsirolimus IV over 30 minutes once weekly. Treatment with temsirolimus continues for up to 36 weeks in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients may receive no more than 3 months of hormonal therapy, including therapy initiated within 2 months of study entry."
3294081|NCT00512655|Experimental|1|Intervention: 5 week training program, 2 sessions per week (total of 10 sessions). Training includes both the patient and the caregiver. The training consists of two components: a cognitive and a physical component.
3294082|NCT00512655|No Intervention|2|Usual care.
3294083|NCT00512629|Experimental|Omegaven|Omegaven is a fish based intravenous fat emulsion
3294084|NCT00512629|Active Comparator|Intralipid|
3294085|NCT00512590|Experimental|Experimental|
3294086|NCT00512577|Active Comparator|A|Patients will not receive a pre-operative transfusion.
3294087|NCT00512577|Active Comparator|B|Patients will receive a pre-operative blood transfusion. Those presenting with an admission Hb of less than 9g/dL will receive a simple (also called a 'top-up') transfusion, those presenting with an admission Hb of more than or equal to 9g/dL will undergo a partial exchange transfusion.
3294088|NCT00512564||1|Patients suffering from Sickle cell disease
3294089|NCT00512551||Cervical cancer tumor biopsy + radiation therapy|Cervical cancer tumor biopsy + radiation therapy.
3294090|NCT00512525|Placebo Comparator|2|
3294091|NCT00512499|Placebo Comparator|Group 1|CONTROL GROUP (first year only; maximum 300 patients): patients seen by CHUS orthopedists at the Hotel-Dieu site, where no nurse coordinator is available for inclusion. This is random but not randomized.
3294092|NCT00512499|Active Comparator|Group 2|"MINIMAL INTERVENTION GROUP: 1/2 of patients, randomly selected.~INTERVENTION: A nurse coordinator will identify patients with fragility fractures and inform the patient about osteoporosis as the cause of the fracture, the benefit of treatment, and the options of treatment adapted to the individual patient. Written information will be sent to his/her family physician containing a presumed osteoporosis diagnosis, investigation to be performed, correct interpretation of any osteodensitometry results in the context of a fragility fracture, the options of treatment, and alternatives if the first prescriptions are not tolerated or stopped. Intervention"
3294093|NCT00512499|Experimental|Group 3|INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
3294094|NCT00512486|Active Comparator|1|MEDI-563
3294095|NCT00512473|Placebo Comparator|A|I.v. saline for 8 hours
3294096|NCT00512473|Experimental|GH|Growth hormone (0.5 mg s.c. at t = 0 hours)
3294097|NCT00512473|Experimental|Pegvisomant|Pegvisomant injection 30 mg 36 hours prior to the study
3294098|NCT00512460|Experimental|RTA 744|
3294099|NCT00512434|Active Comparator|Control in arm fields|Standard treatment Intervention no'Osteosynthesis'
3294944|NCT00505024|Experimental|IVRS + Symptoms Report|
3294100|NCT00512434|Experimental|IMOCA|Intervention 'Osteosynthesis' Percutaneous autologous bone-marrow grafting - surgical technique (ref: Hernigou Ph et al J Bone Joint Surg Am ,2006; 88 (sup 1 part 2): 322-327
3294101|NCT00512421||A|navigation technique
3294102|NCT00512421||B|conservative surgery
3294103|NCT00512421||C|Historical control
3294104|NCT00512408||A|
3294105|NCT00512408||B|
3294106|NCT00512395|Active Comparator|1|epidural analgesia
3294107|NCT00512395|No Intervention|2|traditional analgesia with opioids
3294108|NCT00512382||A|Babies and small children 1-24 months
3294109|NCT00512382||B|Children 2-18 years old
3294110|NCT00512356|Experimental|Investigational product group|"Anti-Adhesion Product was applied to the rectal stump and the incision line.~Like in the control group, surgical measures to prevent adhesions were also taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves."
3294111|NCT00512356|No Intervention|Control group|Only surgical measures to prevent adhesions were taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves. No specific additional treatment was applied.
3294112|NCT00512317|Experimental|ganaxolone|active experimental drug
3294113|NCT00512304|Experimental|Preoperative chemoradiotherapy|
3294114|NCT00512304|Experimental|Postoperative chemoradiotherapy|
3294115|NCT00512291|Experimental|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses
3294116|NCT00512278|Experimental|Infliximab|Infliximab: 48 weeks of therapy with the combination of PEG INF-2b/RBV plus adjuvant infliximab
3294117|NCT00512278|Placebo Comparator|Placebo|Placebo: 48 weeks of therapy with Placebo and PEG INF-2b/RBV
3294118|NCT00512265|Active Comparator|1|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
3294119|NCT00512265|Placebo Comparator|2|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
3294120|NCT00512252|Experimental|Phase I Dose Escalation|"AMD3100 SQ on days 0-5~Mitoxantrone on days 1-5~Etoposide on days 1-5~Cytarabine on days 1-5~Dose Level 1 AMD3100 dose = 80 mcg/kg/d~Dose Level 2 AMD3100 dose = 160 mcg/kg/d"
3294121|NCT00512252|Experimental|Phase II Dose Treatment|"AMD 3100 SQ on days 0-5~Mitoxantrone on days 1-5~Etoposide on days 1-5~Cytarabine on days 1-5~Dose Level 3 AMD3100 dose=240 mcg/kg/d (this was the Phase II dose)"
3294122|NCT00512239||EUPA cohort|Consecutive adult patients presenting to receive rheumatological care at the Sherbrooke University Hospital Centre (CHUS) with an immune-mediated inflammatory arthritis affecting at least 3 joints for a duration of more than 4 and less than 52 weeks.
3294123|NCT00512213|Active Comparator|1|Immunonutrition containing RNA, omega-3-FAs, arginine
3294124|NCT00512213|Active Comparator|2|Standard enteral nutrition: isocaloric and isonitrogeneous but w/o active ingredients
3294125|NCT00512200||Case|Patients aged 65 or older
3294126|NCT00512200||Control|Patients aged 20 to 40
3294127|NCT00512200||Control 2|Healthy volunteers aged 65 or older
3294128|NCT00512187|Experimental|first group|patients who adhered to a low-calorie diet associated to sub-optimal cyclosporine dose (2.5 mg/Kg/day)for 24 weeks
3294129|NCT00512148|Experimental|1|Receipt of autologous neo-bladder construct consisting of a device regenerated in the laboratory from the patient's own muscle and urothelial cells
3294130|NCT00512135|Experimental|IncobotulinumtoxinA (Xeomin) (20 units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
3294131|NCT00512122|Experimental|EN only|
3294132|NCT00512122|Active Comparator|EN plus early PN|
3294133|NCT00512096|Experimental|Cisplatin + Ifosfamide + Paclitaxel|Cisplatin 25 mg/m^2 IV Days 1-3; Ifosfamide 1200 mg/m^2 IV Days 1-3; Paclitaxel 175 mg/m^2 IV Day 1
3294134|NCT00512070|Experimental|IIA|0.3mg day melatonin
3294135|NCT00512070|Experimental|IIB|3.0 mg/day melatonin
3294136|NCT00512057|Experimental|1|
3294137|NCT00512057|Placebo Comparator|2|
3294138|NCT00512044|Active Comparator|A: general|general anesthesia: spinal and general
3294139|NCT00512044|Experimental|B: pudendal|local anesthesia: pudendal block
3294140|NCT00512018|Active Comparator|Isokinetic Exercise only|Individuals were asked to perform a 8-session training, twice a week, in which they trained the knee extensors muscles in an isokinetic dynamometer, 3 sets of 10 repetitions.
3294141|NCT00512018|Experimental|Isokinetic exercise + NMES|In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES).
3294142|NCT00511992|Experimental|Avastin|
3294143|NCT00511979|Experimental|Technosphere insulin inhalation system, 25 units|
3294144|NCT00511979|Experimental|Technosphere insulin inhalation system, 50 units|
3294145|NCT00511979|Experimental|Technosphere insulin inhalation system, 100 units|
3294146|NCT00511979|Active Comparator|Subcutaneous regular human insulin|
3294147|NCT00511966||001|
3294148|NCT00511966||002|
3294149|NCT00511953|Active Comparator|Gabapentin ER|Active drug, Gabapentin extended release
3294150|NCT00511953|Placebo Comparator|Sugar Pill|Comparator arm is Placebo
3294151|NCT00511940|Experimental|1|acamprosate
3294152|NCT00511940|Placebo Comparator|2|sugar pill
3294153|NCT00511927||GHD|Patients with Growth Hormone Deficiency
3294154|NCT00511927||non-GHD|Patients with CHF, without coexisting growth hormone deficiency
3294155|NCT00511914|Experimental|cTIV (Adults)|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
3294156|NCT00511914|Experimental|cTIV (Elderly)|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
3294157|NCT00511901|Placebo Comparator|Placebo & Niferex|Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks
3294158|NCT00511901|Active Comparator|epoetin alpha & Niferex|40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks
3294159|NCT00511875|Experimental|A|stratified equally to doxycycline monohydrate 50mg taken once daily for 24 months
3294160|NCT00511875|Placebo Comparator|Placebo|stratified equally to placebo taken once daily for 24 months
3294161|NCT00511862|Experimental|TheraSphere|Single arm, TheraSphere Yttrium 90 glass microspheres at 120 Gy +/- 10%; stratified by type of disease (colorectal cancer, neuroendocrine cancer, non-colorectal/non-neuroendocrine cancer
3294162|NCT00511849|Experimental|1|
3294163|NCT00511836|Experimental|VIVITROL 380 mg|
3294164|NCT00511836|Placebo Comparator|Placebo|
3294165|NCT00511823|Experimental|Subjects in Part A|Subjects will receive 100 milligrams (mg) of oral dolasetron once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 100 mg oral dolasetron once daily on days 1, 2 and 3 along with 150 mg oral casopitant on day 1 and 50 mg oral casopitant on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
3294166|NCT00511823|Experimental|Subjects in Part B|Subjects will receive 2 mg of oral granisetron once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 2 mg oral granisetron once daily on days 1, 2 and 3 along with 150 mg oral casopitant once daily on day 1 and 50 mg oral casopitant once daily on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
3294167|NCT00511823|Experimental|Subjects in Part C|Subjects will receive 4 mg of oral rosiglitazone once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 4 mg oral rosiglitazone once daily on days 1, 2 and 3 along with 150 mg oral casopitant once daily on day 1 and 50 mg oral casopitant once daily on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
3294168|NCT00511810|Experimental|Low Dose Fish Oil|Capsule omega-3 fatty acids 2.4g/day (4 capsules/day)
3294169|NCT00511810|Experimental|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
3294170|NCT00511797|Experimental|DRSP 1 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
3294171|NCT00511797|Experimental|DRSP 2 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
3294172|NCT00511797|Experimental|DRSP 3 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
3294173|NCT00511797|Placebo Comparator|Placebo|1 tablet per day placebo for 28 days in each 28-day cycle
3294174|NCT00511784||OrthoEvra(norelgestromin/ethinylestradiol contraceptive patch)|subjects in insurance claims database who used transdermal patch containing 6 milligrams norelgestromin and 0.75 milligram ethinyl estradiol worn for 1 week for 3 consecutive weeks; the fourth week was patch-free
3294175|NCT00511784||levonorgestrel-containing oral contraceptives|subjects in insurance claims database who were first time users of triphasic levonorgestrel-containing oral contraceptives with 30 micrograms ethinyl estradiol taken for 21 consecutive days followed by no pill or an inert pill for 7 days
3294176|NCT00511758||Digital Imaging Device|Patients with a diagnosis of cervical dysplasia that are scheduled for a colposcopy.
3294177|NCT00511745||001|
3294178|NCT00511732|Experimental|Technosphere Insulin|
3294179|NCT00511732|Placebo Comparator|Technosphere Inhalation Powder|
3294180|NCT00511719|Experimental|Technosphere Insulin|Technosphere Insulin Inhalation Powder
3294181|NCT00511719|Active Comparator|Actrapid|Subcutaneous regular human insulin
3294182|NCT00511706|Experimental|dexamethasone and ranibizumab|Intravitreal injection of dexamethasone 700 µg at Day 1; ranibizumab 500 µg at Day -30 and Day 7-14.
3294183|NCT00511706|Sham Comparator|sham and ranibizumab|Sham injection at Day 1; ranibizumab 500 µg at day -30 and Day 7-14.
3294184|NCT00511693|Experimental|1|hospitals randomly allocated to receive physician and patient osteoporosis recommendations from the regional coordinator
3294185|NCT00511693|Active Comparator|2|hospitals randomly allocated to receive falls prevention advice
3294186|NCT00511680|Experimental|Behavioral based In-home Intervention|This group will recieve up to 10 1-hour sessions over a 4 month period.
3294187|NCT00511667|Experimental|MK0941|
3294188|NCT00511667|Placebo Comparator|Placebo|
3294189|NCT00511654|Experimental|Subjects in Group 1 receiving GW823296|Subjects will receive single dose of GW823296 on Day 1 followed by a wash-out period of 1 week. The subjects will then be administered GW823296 for 28 days in the repeat dosing period.
3294190|NCT00511654|Placebo Comparator|Subjects in Group 1 receiving placebo|Subjects will receive single dose of placebo on Day 1 followed by a wash-out period of 1 week. The subjects will then be administered placebo for 28 days in the repeat dosing period.
3294191|NCT00511654|Experimental|Subjects in Group 2 and 3 receiving GW823296|Subjects will receive single dose of midazolam on Day 1 followed by wash-out period of one day. Further the subjects will be administered GW823296 on Day 3 of single dose period followed by a wash-out period of 1 week. The subjects will then be administered a single dose of GW823296 for 28 days (Day 1 to Day 28 of repeat dosing period) and a single dose of midazolam on Day 29 of repeat dosing period.
3294192|NCT00511654|Placebo Comparator|Subjects in Group 2 and 3 receiving placebo|Subjects will receive single dose of midazolam on Day 1 followed by wash-out period of one day. Further the subjects will be administered placebo on Day 3 of single dose period followed by a wash-out period of 1 week. The subjects will then be administered a single dose of placebo for 28 days (Day 1 to Day 28 of repeat dosing period) and a single dose of midazolam on Day 29 of repeat dosing period.
3294193|NCT00511641||Low Risk OVCA|Patient that is participating in an ovarian cancer (OVCA) screening program.
3294194|NCT00511628||001|Risperidone As prescribed
3294195|NCT00511615||1|Patients with cervical cancer scheduled to be treated with the LEEP procedure.
3294196|NCT00511602|Experimental|Technosphere Insulin Inhalation Powder|
3294197|NCT00511602|Placebo Comparator|Technosphere Inhalation Powder|
3294198|NCT00511576|Active Comparator|Part 1|In Part 1, cohorts of three to six subjects will receive doses of MGCD0103 administered orally three times per week (TIW) in combination with 60 mg/m2 IV docetaxel administered as a 1-hour infusion on Day 1 of each 3-week (21-day) cycle. The starting dose of MGCD0103 in Part 1 will be 50 mg (approximately 25 mg/m2).
3294199|NCT00511576|Active Comparator|Part 2|Part 2 will begin once the MTD for MGCD0103 in combination with 60 mg/m2 IV docetaxel has been determined and further evaluated in the expansion phase. In Part 2, cohorts of three to six subjects will receive escalating doses of MGCD0103 administered orally TIW in combination with 75 mg/m2 docetaxel administered as a 1-hour IV infusion on Day 1 of each cycle. The starting dose of MGCD0103 administered in combination with 75 mg/m2 IV docetaxel will be the MTD from Part 1 minus 25 mg.
3294200|NCT00511563|Experimental|GW876008 and GSK561679|GW876008 and GSK561679
3294201|NCT00511524|Experimental|Subjects receiving GW842166|Subjects will receive single oral dose of 400 milligram (mg) un-labeled GW842166X. After 2-5 hours subjects will receive [carbonyl-^11C]GW842166.
3294202|NCT00511498|Placebo Comparator|Placebo Arm|Placebo nightly
3294203|NCT00511498|Active Comparator|Drug|Sildenafil 50mg nightly
3294204|NCT00511485|Experimental|Etarfolatide + Vintafolide|Screening: After completion of all screening procedures and confirmation of eligibility, all participants receive a 1- to 2-mL injection of 0.1 mg etarfolatide labeled with 20 to 25 mCi of technetium-99m. Induction phase of treatment: Two 4-week cycles; if stable disease or better at (week 8) computed tomography (CT), participant may proceed into maintenance phase. Maintenance phase of treatment: 4-week cycles with CT every 8 weeks. Participants continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit.
3294205|NCT00511472|Experimental|MK-0941|
3294206|NCT00511472|Placebo Comparator|Placebo|
3294207|NCT00511459|Experimental|A|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 10 mg/kg IV QW
3294208|NCT00511459|Experimental|D|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + Open Label AMG 386 10 mg/kg IV QW
3294209|NCT00511459|Experimental|B|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 3 mg/kg IV QW
3294210|NCT00511459|Active Comparator|C|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 placebo IV QW
3294211|NCT00511446|Experimental|1|docetaxel, oxaliplatin, capecitabine
3294212|NCT00511433|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
3294213|NCT00511433|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
3294214|NCT00511420|Placebo Comparator|1|Cocoa and other ingredients (product type 1). This product is a control of type 2.
3294215|NCT00511420|Placebo Comparator|2|Cocoa plus hazelnuts and other ingredients (product type 2). This product is a control of type 3 and 4.
3294216|NCT00511420|Active Comparator|3|Cocoa plus hazelnuts and other ingredients (cocoa product type 3).
3294217|NCT00511420|Active Comparator|4|Cocoa, hazelnuts and other ingredients called LMN (cocoa product type 4).
3294218|NCT00511407|Experimental|I|RAD Treatment
3294219|NCT00511407|No Intervention|II|Conventional CVVHD
3294220|NCT00511394|Active Comparator|I|Infusion of 100 mL of 20% Albumin
3294221|NCT00511394|Placebo Comparator|II|100 mL Normal Saline
3294222|NCT00511368|Placebo Comparator|1|placebo
3294223|NCT00511368|Experimental|2|Bevirimat
3294224|NCT00511355|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
3294225|NCT00511355|Active Comparator|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets (LNG-EE), 150 mcg LNG and 30 mcg EE
3294226|NCT00511342|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic COC
3294227|NCT00511342|Active Comparator|LNG-EE|Levonorgestrel (LNG) and Ethinyl Estradiol (EE), 0.150 mg LNG and 0.030 mg EE monophasic COC
3294228|NCT00511329|Experimental|Somatropin|
3294229|NCT00511316|Experimental|Drug|20 mg montelukast daily for 6 months
3294230|NCT00511316|Placebo Comparator|Placebo|20 mg daily placebo
3294231|NCT00511238|Experimental|carfilzomib (A0)|
3294232|NCT00511238|Experimental|carfilzomib (A1)|
3294233|NCT00511225|Active Comparator|1|Will receive 10,000 IU of cholecalciferol weekly
3294234|NCT00511225|Placebo Comparator|2|Will receive a identical appearing placebo weekly
3294235|NCT00511199|Experimental|NOMAC-E2|"Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2~monophasic combined oral contraceptive"
3294236|NCT00511199|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
3294237|NCT00511186|Experimental|Bovine Intestinal AP|"Bovine Intestinal Alkaline Phosphatase (BIAP) Intravenous administration of 10 bolus (67,5U/kg) and 48h continuous infusion (132,5U/kg)"
3294238|NCT00511186|Placebo Comparator|2|"Placebo Intravenous administration of 10 bolus and 48h continuous infusion"
3294239|NCT00511173|Experimental|Clinician dosing of warfarin|Warfarin dose based on clinician dosing without the use of warfarin pharmacogenetics
3294240|NCT00511160|Active Comparator|S|Study arm: Cardiac surgery group
3294241|NCT00511160|Active Comparator|C|Routine cardiology group
3294242|NCT00511147|Experimental|IGIV3I Grifols 10% (All Subjects)|All subjects with Chronic ITP
3294243|NCT00511134|Experimental|Zyban + Lunesta|Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + Lunesta (3 mg qd x 6 weeks)
3294244|NCT00511134|Placebo Comparator|Zyban + Placebo|Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + placebo (1 pill per day x 6 weeks)
3294245|NCT00511108|Experimental|1|Arm 1: drug
3294246|NCT00511108|Active Comparator|2|Arm 2: active comparator
3294247|NCT00511108|Experimental|3|Arm 3: drug + active comparator
3294248|NCT00511108|Placebo Comparator|4|Arm 4: placebo comparator
3294249|NCT00511095|Experimental|HEPLISAV|3000ug 1018 ISS + 20ug HBsAg Intramuscular (IM) injection 0.5mL
3294250|NCT00511082|Experimental|Treatment group|
3294251|NCT00511056||HIVNAT 006|HIVNAT 006 is a long term follow up cohort. The primary objective of this study is to collect and evaluate the long-term clinical outcomes of HIV infected patients have participated in HIV-NAT studies. These subjects will be used to test our hypothesis.
3294252|NCT00511043|Experimental|All pts|PTK787
3294253|NCT00511017|Experimental|Doxercalciferol|
3294254|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole -STD|Standard therapy of DEC (300mg) and albendazole (400mg) yearly
3294255|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole- HD1|High dose of DEC (300mg) and albendazole (800mg) yearly
3294256|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole-HD2|High dose of DEC (300mg) and albendazole (800mg) twice yearly (every 6 months)
3294257|NCT00510991|Experimental|A|NIPPV
3294258|NCT00510978|Active Comparator|1|Bifidobacterium infantis 35624
3294259|NCT00510978|Active Comparator|2|Lactobacillus salivarius UCC118
3294260|NCT00510978|Placebo Comparator|3|Placebo
3294261|NCT00510965|Experimental|A|
3294262|NCT00510952|Experimental|Lispro|Insulin Lispro protamine suspension: Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
3294263|NCT00510952|Active Comparator|Glargine|Insulin glargine: Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
3294264|NCT00510887|Experimental|VR-FND|"Bortezomib (VELCADER) 1.6 mg/m2 IV days 1 and 8 Rituximab 375 mg/m2 IV on day 1 Fludarabine 25 mg/m2 IV on days 1,2,3 Mitoxantrone 10 mg/m2 IV on day 2 Dexamethasone 20 mg orally on days 1,2,3,4,5 On day 1 the sequence of drug administration will be Bortezomib followed by Fludarabine followed by Rituximab.~Each cycle will be repeated every 28 days for 8 cycles maximum."
3294265|NCT00510874|Experimental|Pumarix Formulation 1 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 1 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
3294266|NCT00510874|Experimental|Pumarix Formulation 2 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 2 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
3294267|NCT00510874|Experimental|Pumarix Formulation 3 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 3 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
3294268|NCT00510874|Experimental|Pandemrix Formulation A Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation A of Pandemrix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
3294269|NCT00510874|Experimental|Pandemrix Formulation B Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation B of Pandemrix ™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
3294270|NCT00510874|Experimental|Pumarix Formulation 4 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 4 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
3294271|NCT00510874|Experimental|Pumarix Formulation 5 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 5 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
3294272|NCT00510848|Experimental|1|Reconstruction with an autograft tendon (hamstrings)
3294273|NCT00510848|Experimental|2|Reconstruction with an allograft tendon (tibialis posterior)
3294274|NCT00510835|Experimental|1|Early Goal Directed Therapy (EGDT) - The study team will insert a central venous catheter (CVC) for continuous monitoring of the subjects' central venous pressure (CVP) and central venous oxygen saturation (Scv02). The study team will use this information to give fluid, blood, and heart medications in a structured fashion. The CVC is FDA approved and routinely used in hospitals.
3294275|NCT00510835|Experimental|2|Protocolized Standard Care (PSC)- The study team will monitor the subjects' blood pressure and blood oxygen level with routine equipment. The study team will use this information to give fluid and heart medications in a structured fashion. CVCs will only be used when standard IVs are unable to give the proper amount of fluids and medicines. Blood transfusions will be given according to currently recommended guidelines.
3294276|NCT00510835|Active Comparator|3|Usual Care - The attending physicians will treat the subjects according to their standard treatment plan and without any influence from the study team. A member of the study team will simply observe and record what happens.
3294277|NCT00510822|Placebo Comparator|Placebo|Placebo + Sertraline
3294278|NCT00510822|Experimental|Cimicoxib|Sertraline + Cimicoxib
3294279|NCT00510809|Active Comparator|1|Policosanol 20mg daily
3294280|NCT00510809|Placebo Comparator|2|
3294281|NCT00510809|Active Comparator|3|Policosanol 20mg daily Plus Statin Therapy Already In Use
3294282|NCT00510796||High Risk Group|Colon and/or Endometrial Cancer
3294283|NCT00510783|Active Comparator|Phenytoin/Fosphenytoin|Patients in the control arm will receive either IV Dilantin (1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals) or IV Fosphenytoin (1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals).
3294284|NCT00510783|Active Comparator|Levetiracetam|Patients in the intervention arm will receive IV Keppra (1 gram of Keppra added to 100 mL diluent infused over 15 minutes).
3294285|NCT00510757||Males|
3294286|NCT00510757||Females|
3294287|NCT00510744|Experimental|pancreatic enzyme supplementation|3 month supplementation in those gastric bypass patients shown to have a fat absorption less than 80%
3294288|NCT00510718|Experimental|1|MDV3100
3294289|NCT00510705|Other|1|Regular physical exercise training alone
3294290|NCT00510705|Other|2|Regular physical exercise training + metformin
3294291|NCT00510705|Other|3|Regular physical exercise training + glitazone
3294292|NCT00510705|No Intervention|4|Control
3294293|NCT00510692|Experimental|2g/day Eicosapentanoic Acid (EPA)|"Eicosapentanenoic Acid (EPA) as the free fatty acid 2 capsules twice daily for 6 months.~Endoscopy and biopsies taken as described under intervention."
3294294|NCT00510692|Placebo Comparator|Placebo|Medium chain triglycerides 2 capsules twice daily for six months. Endoscopy and biopsies taken as described under intervention.
3294295|NCT00510666|Experimental|1|Butorphanol basal infusion adjunct to morphine PCA
3294296|NCT00510666|Experimental|2|Saline infusion adjunct to morphine PCA
3294297|NCT00510666|Experimental|3|Premedication of Tramadol
3294298|NCT00510666|Experimental|4|Preemptive saline for morphine PCA
3294299|NCT00510653|Experimental|Imatinib Mesylate|600 mg/day orally for 6 Weeks
3294300|NCT00510640|Experimental|Sunitinib|Sunitinib will be administered orally daily for 4 weeks followed by a 2-week rest; the daily starting dose will be 50 mg with a provision for dose reduction based on tolerability. All patients will receive repeated cycles until disease progression or occurrence of severe toxicity.
3294301|NCT00510627|Experimental|A|Radiofrequency ablation in conjunction with chemotherapy
3294302|NCT00510627|Active Comparator|B|Standard of care chemotherapy regimen
3294303|NCT00510614|Active Comparator|A|1 gram tinidazole twice weekly for 12 weeks
3294304|NCT00510614|Placebo Comparator|B|Placebo twice weekly for 12 weeks
3294305|NCT00510601|Experimental|1|
3294306|NCT00510588|Other|1|regular physical exercise training
3294307|NCT00510588|Other|2|regular physical exercise training + metformin
3294308|NCT00510588|Other|3|regular physical exercise training + glitazon
3294309|NCT00510588|No Intervention|4|Control
3294310|NCT00510575|Active Comparator|1|Subjects in this arm will receive the 5.5mm stainless steel instrumentation rod.
3294311|NCT00510575|Active Comparator|2|Subjects in this arm will receive a 6.35mm stainless steel instrumentation rod.
3294312|NCT00510562|Experimental|1|Assessment for cranial strain patterns, followed by indirect osteopathic treatment of dysfunctions found on assessment, followed by reassessment.
3294313|NCT00510562|Sham Comparator|2|Assessment for cranial strain patterns, followed by laying on of hands, followed by reassessment.
3294314|NCT00510549|Active Comparator|1, PD|Peritoneal Dialysis
3294315|NCT00510549|Active Comparator|2, HD|Hemodialysis
3294316|NCT00510510|Experimental|NVA237 100 µg|
3294317|NCT00510510|Experimental|NVA237 200 µg|
3294318|NCT00510510|Placebo Comparator|Placebo|
3294319|NCT00510497|Experimental|Autologous HIV-1 ApB DC Vaccine|Subjects who will receive ApB Dendritic cell vaccine
3294320|NCT00510484|Experimental|A|
3294321|NCT00510484|Placebo Comparator|B|
3294322|NCT00510458|Other|LFIT™Femoral Heads With X3® Insert|LFIT™ Femoral Heads With X3® Insert
3294323|NCT00510445|Experimental|Single Arm Trial|Patients will be enrolled in the order of confirmation of eligibility. Dose cohorts will be filled sequentially with a minimum of 3 patients. Once assigned to a dose cohort, each patient will continue to be treated at the same dose level throughout the course of the study.
3294324|NCT00510432||s.c. anticoagulant therapy|All patients with s.c. anticoagulant therapy (UFH, LMWH, heparinoids, fondaparinux)
3294325|NCT00510406|Placebo Comparator|A|
3294326|NCT00510406|Active Comparator|B|
3294327|NCT00510406|Active Comparator|C|
3294328|NCT00510406|Active Comparator|D|
3294329|NCT00510406|Active Comparator|E|
3294330|NCT00510406|Active Comparator|F|
3294331|NCT00510406|Active Comparator|G|
3294332|NCT00510406|Active Comparator|H|
3294333|NCT00510393|Experimental|1|drug eluting stent
3294334|NCT00510393|Placebo Comparator|2|Bare Metal Stent
3294335|NCT00510380||growth-restricted Chinese pregnancies|
3294336|NCT00510380||appropriately-grown Chinese pregnancies|
3294337|NCT00510367|Experimental|Multimodality Treatment|"Multimodality (chemotherapy, surgery and radiation therapy) treatment:~5-Fluorouracil + Doxorubicin + Cyclophosphamide (FAC)"
3294338|NCT00510354|Experimental|RAD001 + Imatinib|
3294339|NCT00510341|Active Comparator|1|CMP program
3294340|NCT00510341|No Intervention|2|Control group
3294341|NCT00510315||Women treated with SCT/TBI|
3294342|NCT00510315||1:1 Matched group of women|"Current age + or - 2 years~Race and ethnicity~Cancer diagnosis~Interval from completion of cancer therapy to study + or - 2 years"
3294343|NCT00510302||Melanoma Risk-Reduction|Patients with melanoma, their spouses/partners, and first-degree relatives (FDRs).
3294344|NCT00510289|Experimental|all patients|sorafenib
3294345|NCT00510276|Experimental|Atomoxetine|
3294346|NCT00510276|Placebo Comparator|Placebo|
3294347|NCT00510263|Experimental|1|
3294348|NCT00510263|Experimental|2|
3294349|NCT00510263|Experimental|3|
3294350|NCT00510263|Placebo Comparator|4|
3294351|NCT00510250|Experimental|Cisplatin and Radiation in Combination with Sorafenib|
3294352|NCT00510237|Experimental|1|5-7 females per group at each of the four sites.
3294353|NCT00510237|Experimental|2|5-7 males per group at each of the four sites.
3294354|NCT00510224|Experimental|1|
3294355|NCT00510211||olanzapine coated tablet|
3294356|NCT00510211||olanzapine orodispersable tablet|
3294357|NCT00510198|Active Comparator|1|Standard of Care and Cardiac Compass with OptiVol
3294358|NCT00510198|Active Comparator|2|Standard of Care alone
3294359|NCT00510185|Experimental|1|Coronary angiography within 72h and revascularization as clinical indicated
3294360|NCT00510185|No Intervention|2|Initially conservative treatment with coronary angiography only for recurrent ischemia
3294361|NCT00510172|Active Comparator|1|Active treatment
3294362|NCT00510172|Placebo Comparator|2|Placebo
3294363|NCT00510146|Experimental|Olanzapine|During double-blind treatment, participants receive olanzapine at a dose of 5 milligram (mg) which is increased to 10 mg per day no later than 3-7 days after randomization (Baseline). Subsequent dose increases above 10 mg (up to a maximum of 20 mg per day) are permitted in 5 mg per day increments, based upon tolerability and symptoms. Dosing may be decreased by any number of decrements, however dosing below 5 mg requires study discontinuation.
3294364|NCT00510146|Placebo Comparator|Placebo|Matching placebo administered once daily, by mouth during double-blind treatment.
3294418|NCT00509600|Experimental|Etanercept|0.8 mg/kg subcutaneously weekly for 90 days
3294625|NCT00507923|Other|Usual Care|Option of participating in the Tibetan yoga program after completion of the study.
3294365|NCT00510146|Experimental|Olanzapine (open-label treatment period)|During open-label treatment, participants randomized to placebo in double-blind period will receive olanzapine 5 mg starting at Week 6. Participants randomized to olanzapine must be at a 5 mg olanzapine dose at Week 7. Those on higher doses will be reduced between Week 6 and Week 7 (10 mg reduced to 5 mg; 15 mg reduced to 10 mg and then to 5 mg at Week 7; 20 mg reduced to 15 mg and then 10 mg to dosing at 5 mg at Week 7). Dose increases beyond Week 7 are permitted and at the investigator's discretion.
3294366|NCT00510133|Experimental|GRNVAC1|Autologous dendritic cell vaccine
3294367|NCT00510120|Experimental|1|Participants will receive collaborative problem solving.
3294368|NCT00510120|Active Comparator|2|Participants will receive parent management training.
3294369|NCT00510120|Active Comparator|3|Participants assigned to waitlist control will receive one of the two treatments after a 10-weeks waitlist period.
3294370|NCT00510107|Active Comparator|1|Docetaxel 35 mg/m2 will be administered on days 1 and 8. Cisplatin 60 mg/m2 will be administered on day 1 every 3 weeks.
3294371|NCT00510107|Experimental|2|Docetaxel 35 mg/m2 will be administered on days 1 and 8. Oxaliplatin 120 mg/m2 will be administered on day 1 every 3 weeks.
3294372|NCT00510094|Experimental|1|Participants will receive the Friend to Friend program
3294373|NCT00510094|Active Comparator|2|Participants will receive the psychoeducational attention control intervention
3294374|NCT00510081|Experimental|1|subjects will receive filler injections
3294375|NCT00510068|Experimental|Everolimus 10 mg/day|Participants received 10 mg per day of Everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).
3294376|NCT00510068|Placebo Comparator|Placebo|Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).
3294377|NCT00510055|Experimental|A|scars receive subdermal manipulation ONLY
3294378|NCT00510055|Experimental|B|scars receive subdermal manipulation AND injection of a filler
3294379|NCT00510029|Other|GAP-134, IV and Oral|Experimental; Active Comparator; Placebo
3294380|NCT00510016|Experimental|Clonidine treatment|Infants intrauterine exposed to opioids (heroin or methadone) that demonstrate signs and symptoms of withdrawal with withdrawal scores (modified Finnegan score) greater than 9 on to consecutive scores taken 4 hours apart.
3294381|NCT00509977|Experimental|1|Light therapy
3294382|NCT00509977|Experimental|2|Laser Treatment
3294383|NCT00509964|Active Comparator|1|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
3294384|NCT00509964|Active Comparator|2|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and infusional 5-fluorouracil, on day 1 every 2 weeks.
3294385|NCT00509951|Active Comparator|1|One-session exposure treatment (OST)
3294386|NCT00509951|Experimental|2|Family-enhanced (augmented) OST
3294387|NCT00509938|Experimental|1|5mg hLF1-11, single dose iv
3294388|NCT00509925|Experimental|Treatment period 1|Insulin detemir for 16 weeks (treatment period 1) followed by insulin NPH treatment for 16 weeks (treatment period 2) in addition to meal-time insulin aspart
3294389|NCT00509925|Experimental|Treatment period 2|Insulin NPH for 16 weeks (treatment period 1) followed by insulin detemir treatment for 16 weeks (treatment period 2) in addition to meal-time insulin aspart
3294390|NCT00509899|Experimental|Ruxolitinib|All participants received oral ruxolitinib. Patients began treatment with either 10 mg twice a day (bid), 15 mg bid, 25 mg bid, 50 mg bid, 25 mg once a day (qd), 50 mg qd, 100 mg qd, or 200 mg qd, depending on the time period when they entered the study. The doses were titrated based on efficacy and safety to a maximum of 25 mg bid for patients who entered the study after sufficient dosing information had been obtained to define the maximum dose for patients in the study. Patients could continue receiving treatment indefinitely if receiving benefit at a dose that continues to maintain benefit but does not exceed a maximum dose of 25 mg BID.
3294391|NCT00509886|Experimental|1|ARMs were randomized. One side of the body received treatment with one antiperspirant and the contralateral side with a different antiperspirant.
3294392|NCT00509886|Experimental|2|ARMs were randomized. One side of the body received treatment with one antiperspirant and the contralateral side with a different antiperspirant.
3294393|NCT00509873|Experimental|Gatifloxacin 0.5% Eye Drops|Gatifloxacin 0.5% Eye Drops
3294394|NCT00509873|Placebo Comparator|Placebo Eye Drops|Placebo Eye Drops
3294395|NCT00509860|Experimental|Irinotecan|Irinotecan 16 mg/m2 by vein daily over 1 hour for 5 Days
3294396|NCT00509834|Experimental|hLF1-11|hLF1-11 0.5mg
3294397|NCT00509834|Placebo Comparator|Placebo|Placebo formulation is Similar to hLF1-11 iv formulation except for the active component
3294398|NCT00509821|Experimental|A|Enzastaurin before and concomitant with radiotherapy followed by Enzastaurin maintenance therapy
3294399|NCT00509808|Sham Comparator|electrostimulation|Use of device for predetermined length
3294400|NCT00509795|Active Comparator|ranibizumab 0.5mg Q4|
3294401|NCT00509795|Experimental|aflibercept injection 2.0mg Q4|
3294402|NCT00509795|Experimental|aflibercept injection 0.5mg Q4|
3294403|NCT00509795|Experimental|aflibercept injection 2.0mg Q8|
3294404|NCT00509782|Experimental|ZIO-101|
3294405|NCT00509769|Experimental|Trastuzumab emtansine 3.6 mg/kg|Patients received trastuzumab emtansine 3.6 mg/kg intravenously on Day 1 of each 21 day cycle for a maximum of 1 year. The total dose was dependent on the patient's weight on Day 1 of each cycle.
3294406|NCT00509756|Active Comparator|1|Drug: FXR-450
3294407|NCT00509756|Placebo Comparator|2|Placebo
3294408|NCT00509743|Experimental|A|Low dose Diclofenac
3294409|NCT00509743|Experimental|B|High dose Diclofenac
3294410|NCT00509717|Experimental|experimental|
3294411|NCT00509717|Active Comparator|control|
3294412|NCT00509691|Experimental|Single arm study|
3294413|NCT00509665|Experimental|Gemcitabine+doxorubicin|
3294414|NCT00509652|Experimental|Arm 1|Erythrocyte apheresis
3294415|NCT00509652|Active Comparator|Arm 2|Phlebotomy
3294416|NCT00509639|Experimental|Metronidazole 10% ointment|Metronidazole 10% ointment
3294417|NCT00509639|Placebo Comparator|Placebo ointment|Placebo ointment
3294835|NCT00505960|Experimental|1|
3294419|NCT00509587|Experimental|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3294420|NCT00509561|Active Comparator|Chemo-radiotherapy|
3294421|NCT00509561|Experimental|Chemo-radiotherapy plus cetuximab|
3294422|NCT00509548|Experimental|1|Dose 1
3294423|NCT00509548|Experimental|2|Dose 2
3294424|NCT00509496|Experimental|anti-gp100:154-162 TCR PBL + HD IL-2|"fludarabine phosphate-25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days~cyclophosphamide-60 mg/kg/day x 2 days intravenous~Anti-gp100:154-162 TCR-engineered peripheral blood lymphocyte (PBL) cell preparation - minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes.~aldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)"
3294425|NCT00509496|Experimental|anti-gp100:154-162 TCR TIL + HD IL-2|"fludarabine phosphate-25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days~cyclophosphamide-60 mg/kg/day x 2 days intravenous~Anti-gp100:154-162 TCR-engineered tumor infiltrating lymphocytes (TIL) cell preparation- minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes~aldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)"
3294426|NCT00509470|Active Comparator|telmisartan plus low-dose hydrochlorothiazide|12 week combination therapy with telmisartan plus low-dose hydrochlorothiazide
3294427|NCT00509470|Active Comparator|Amlodipine|Amlodipine is continuously administered.
3294428|NCT00509444|Active Comparator|Educational materials|
3294429|NCT00509444|Experimental|Educational materials, plus patient navigation|
3294430|NCT00509431|Experimental|Erlotinib + Sirolimus|This is an open-label,phase I single-arm dose-escalation and phase II study of continuous, once daily doses of erlotinib administered orally in combination with sirolimus in adult patients with malignant glioma at first, second or third recurrence
3294431|NCT00509418|Experimental|A|Viusid, a nutritional supplement, in combination with controlled diet and exercise
3294432|NCT00509418|Active Comparator|B|Controlled diet and exercise
3294433|NCT00509405|Placebo Comparator|Potassium citrate|
3294434|NCT00509392|Active Comparator|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation & ClosureFAST catheter
3294435|NCT00509392|Active Comparator|Endovenous Laser|Treatment invention of venous disease with an Endovenous Laser.
3294436|NCT00509379|Experimental|1|All patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
3294437|NCT00509366|Active Comparator|Cisplatin Sensitive (Post-Amendment)|"Assignment to Treatment Group based on histology and tumor genomics analysis:~Squamous Cell NSCLC-Cisplatin day 1, Gemcitabine days 1 & 8 Non-Squamous Cell NSCLC-Cisplatin day 1, Pemetrexed day 1~Per an amendment dated 1/25/2010, post-amendment treatment assignment refers to the further separation of patients into sub-groups, within the cisplatin sensitive arm, based on histology (squamous/non-squamous)."
3294438|NCT00509366|Active Comparator|Cisplatin Resistant (Post-Amendment)|"Assignment to Treatment Group based on histology and tumor genomics analysis:~Squamous Cell NSCLC-Docetaxel day 1, Gemcitabine days 1 & 8 Non-Squamous Cell NSCLC-Pemetrexed day 1, Gemcitabine days 1 & 8~Per an amendment dated 1/25/2010, post-amendment treatment assignment refers to the further separation of patients into sub-groups, within the cisplatin resistant arm, based on histology (squamous/non-squamous)."
3294439|NCT00509366|Active Comparator|Cisplatin Sensitive (Pre-Amendment)|"Assignment to Treatment Group based on tumor genomics analysis:~Cisplatin day 1, Gemcitabine days 1 & 8"
3294440|NCT00509366|Active Comparator|Cisplatin Resistant (Pre-Amendment)|"Assignment to Treatment Group based on tumor genomics analysis:~Pemetrexed day 1, Gemcitabine days 1 & 8"
3294441|NCT00509340|No Intervention|1|Participants will receive usual clinical care, which may or may not include mental health treatment
3294442|NCT00509340|Experimental|2|Participants will receive cognitive behavioral intervention
3294443|NCT00509327|Active Comparator|1|bisacodyl 10mg twice daily from one day preoperative to day three postoperative
3294444|NCT00509327|Placebo Comparator|2|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
3294445|NCT00509301|Experimental|1|1.5 mCi/cc
3294446|NCT00509301|Experimental|2|2.0 mCi/cc
3294447|NCT00509301|Experimental|3|2.5 mCi/cc
3294448|NCT00509288|Experimental|anti-MART-1 F5 TCR PBL + HD IL-2|Patients treated with peripheral blood lymphocytes (PBL)
3294449|NCT00509288|Experimental|anti-MART-1 F5 TCR TIL + HD IL-2|Patients treated with TIL (tumor infiltrating lymphocytes).
3294450|NCT00509275|Experimental|1|W0027
3294451|NCT00509275|Experimental|2|W0027
3294452|NCT00509275|Experimental|3|W0027
3294453|NCT00509275|Placebo Comparator|4|Placebo
3294454|NCT00509262|Experimental|Sitagliptin|Sitagliptin + Placebo for Glipizide
3294455|NCT00509262|Active Comparator|Glipizide|Glipizide + Placebo for Sitagliptin
3294456|NCT00509249|Experimental|Arm I|Patients will receive aflibercept IV at 4 mg/kg over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3294457|NCT00509236|Experimental|Sitagliptin 25 mg|
3294458|NCT00509236|Active Comparator|Glipizide 2.5 mg - 20 mg|
3294459|NCT00509223|Experimental|Group 1|Lifestyle counseling with Positive Airway Pressure (PAP) therapy
3294460|NCT00509223|Active Comparator|Group 2|Lifestyle counseling without Positive Airway Pressure (PAP) therapy
3294461|NCT00509197|Active Comparator|Active treatment group (A)|Intervention : treatment with inhaled corticosteroids (Fluticasone) will be administered to this group
3294462|NCT00509197|Placebo Comparator|Control group treated with placebo (B)|treatment with placebo
3294463|NCT00509171|Active Comparator|1-Standard reamer|Standard reamer
3294464|NCT00509171|Active Comparator|2-Use of the Reamer-Irrigator Aspirator|Use of the Reamer-Irrigator Aspirator
3294465|NCT00509145|Experimental|Laquinimod|Laquinimod 0.6 mg, oral
3294466|NCT00509145|Placebo Comparator|Placebo|Matching placebo
3294618|NCT00507936|Experimental|A|ABT-894 1 mg BID
3294467|NCT00509106|Experimental|Ceftaroline fosamil for injection|Ceftaroline fosamil was administered in two consecutive 300 mg IV infusions over 30 minutes, every 12 hours (q12h).
3294468|NCT00509106|Active Comparator|IV Ceftriaxone|Ceftriaxone was administered as a 1-g IV infusion over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h).
3294469|NCT00509093|Experimental|Imatinib Mesylate|
3294470|NCT00509067|Experimental|A|Participants assigned to receive galantamine and CDP-choline
3294471|NCT00509067|Placebo Comparator|B|Participants assigned to receive placebo
3294472|NCT00509041|Experimental|Dasatinib|Use of dasatinib in treatment of pts with previously treated malignant mesothelioma
3294473|NCT00509028|Experimental|BUD - Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
3294474|NCT00509028|Active Comparator|CONV - Conventional Asthma Therapy|Conventional Asthma Therapy - according to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
3294475|NCT00509015|Active Comparator|1|Sulphadoxine-pyrimethemine (day 1) artesunate (day 1-3) primaquine (day 3)
3294476|NCT00509015|Placebo Comparator|2|Placebo: lactose tablets (Albochin)
3294477|NCT00509002|Experimental|Adenoid Cystic Salivary Gland Carcinoma Group|Participants receive Gefitinib daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
3294478|NCT00509002|Experimental|Other Carcinoma of Salivary Gland Group|Participants receive Gefitinib daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
3294479|NCT00508989|Experimental|1|
3294480|NCT00508989|Placebo Comparator|2|
3294481|NCT00508976|Experimental|3|
3294482|NCT00508976|Experimental|2|
3294483|NCT00508976|Experimental|4|
3294484|NCT00508976|Active Comparator|1|
3294485|NCT00508950|Other|All subjects|All subjects
3294486|NCT00508937|Active Comparator|1|
3294487|NCT00508937|Experimental|2|
3294488|NCT00508937|Experimental|3|
3294489|NCT00508937|Experimental|4|
3294490|NCT00508937|Experimental|5|
3294491|NCT00508924|Experimental|ARG250|
3294492|NCT00508924|Experimental|ARG300|
3294493|NCT00508924|Experimental|ARG350|
3294494|NCT00508924|Placebo Comparator|Heparin|
3294495|NCT00508911|Experimental|Healthy female subjects|Each subject will be administered a monophasic combined oral contraceptive (COC) containing ethinylestradiol 30 micrograms and levonorgestrel 150 micrograms for two complete cycles (Day 8 to Day 28) in Session 1. The subjects will be administered COC on Day 8 to Day 28 and GW876008 125 milligrams on Days 1 to 35 in Session 2.
3294496|NCT00508898|Experimental|treatment group|Patients will receive calcitriol at a fixed dose of 1 mcg twice weekly.
3294497|NCT00508898|Active Comparator|control group|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
3294498|NCT00508885|Experimental|1|Niacinamide starting at 250 mg twice daily titrated up to 750 mg twice daily
3294499|NCT00508885|Placebo Comparator|2|Placebo
3294500|NCT00508872|Experimental|FOLFOX-B|FOLFOX-B: 5-Fluorouracil 400 mg/m^2 IV + Bevacizumab 5 mg/kg IV + Leucovorin 400 mg/m^2 IV + Oxaliplatin 85 mg/m^2 IV
3294501|NCT00508859|Experimental|Active, 1|sertraline
3294502|NCT00508859|Placebo Comparator|Placebo|placebo
3294503|NCT00508846||HNPCC Patients|
3294504|NCT00508820|Experimental|1|Romiplostim
3294505|NCT00508807|Experimental|RTA 402|5 mg PO daily x 21 days
3294506|NCT00508794|Experimental|Group 1 Yoga Program|3 sessions of yoga each week for 6 weeks. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
3294507|NCT00508794|Experimental|Group 2 Stretching Program|3 sessions of stretching each week for 6 weeks. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
3294508|NCT00508794|Other|Group 3 Waitlist Control Group|Option of participating in the yoga or stretching program after the study has ended. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
3294509|NCT00508755|Experimental|Arm 1|stroke
3294510|NCT00508742|Experimental|1|13 valent pneumococcal conjugate vaccine
3294511|NCT00508742|Active Comparator|2|7 valent pneumococcal conjugate vaccine
3294512|NCT00508716|No Intervention|A|Usual Care - Education about CHF by Primary Nurse on discharge. No teach-back is used in this arm.
3294513|NCT00508716|Experimental|B|"Tailored Intervention for patients with low health literacy and nurse-directed teachback: Educational leaflet which has been developed for low-health literacy patients. Adminstered by dedicated Nurse-educator. Nurse-educator asks Patient for teachback after Intervention. This means that the Patient repeats in his/her own words the Information received. Education ends once Patient has been able to repeat the Information back."
3294514|NCT00508703||CT Scan + IMRT Radiation Therapy|
3294515|NCT00508690|Active Comparator|IV|Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
3294516|NCT00508690|Active Comparator|Oral/IV|2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
3294517|NCT00508664|Experimental|A|TP + Radiation (TPF until Feb 2009)
3294518|NCT00508664|Experimental|B|TP + Cetuximab + Radiation (TPF until Feb 2009)
3294519|NCT00508651|Experimental|Cohort 1 MEDI-560|MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson^TM Luer slip tip syringes. Each 0.2 mL dose contained 10^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
3294520|NCT00508651|Placebo Comparator|Cohort 1 Placebo|Placebo was a frozen preparation filled into Becton Dickinson^TM Luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
3294521|NCT00508625|Other|C|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 of each 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
3294619|NCT00507936|Experimental|B|ABT-894 2 mg BID
3294620|NCT00507936|Experimental|C|ABT-894 4 mg BID
3294621|NCT00507936|Placebo Comparator|D|
3294622|NCT00507936|Active Comparator|E|Duloxetine 60 mg QD
3294522|NCT00508625|Experimental|E|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (20mg/kg) on days 1-2 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
3294523|NCT00508625|Experimental|B|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus AMG 951 (rhApo2L/TRAIL) (8mg/kg) for 5 days per 21 days cycle until disease progression, study drug intolerability or withdrawal of consent.
3294524|NCT00508625|Other|A|40 subjects will receive up to 6 cycles of Carboplatin (AUC = 6.0mg/ml.min) and Paclitaxel (200mg/m2) only
3294525|NCT00508625|Experimental|D|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (8mg/kg) on days 1-5 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
3294526|NCT00508612|Active Comparator|1|The 12-lesson Williams LifeSkills anger and stress management workshop (WLS) enhances awareness of thoughts and feelings in stressful situations, and provides training in evaluation, deflection, problem-solving, assertion, saying no, speaking, listening, empathy, and emphasizing positives.
3294527|NCT00508612|Placebo Comparator|2|Control group (will attend regular high school classes)
3294528|NCT00508599|No Intervention|1|Study 1 is the control arm in which participants continue with their normal activity.
3294529|NCT00508599|Experimental|2.|Study 2 consists of 48 hours of complete bed rest.
3294530|NCT00508586|Experimental|1|PTC299 with an aromatase inhibitor
3294531|NCT00508573||Lynch Syndrome Registry|Patient that has or is at risk for Lynch Syndrome.
3294532|NCT00508560|Experimental|Arm 1|Experimental
3294533|NCT00508560|Active Comparator|Arm 2|Active Comparator
3294534|NCT00508547||Infliximab|Participants will receive infliximab as prescribed by the physician according to standard of care for psoriasis.
3294535|NCT00508547||Ustekinumab|Participants will receive ustekinumab as prescribed by the physician according to standard of care for psoriasis.
3294536|NCT00508547||Biological Therapies|Participants will receive biological therapies other than infliximab, ustekinumab and guselkumab as prescribed by physician for psoriasis. Participants will not receive any intervention as a part of this study.
3294537|NCT00508547||Conventional Systemic Agents|Participants will receive conventional systemic agents as prescribed by physician for psoriasis. Participants will not receive any intervention as a part of this study.
3294538|NCT00508547||Guselkumab|Participants will receive guselkumab as prescribed by the physician according to standard of care for psoriasis.
3294539|NCT00508521|Experimental|FES and Motor Learning Training|participants <6 months after first stroke who presented with arm dysfunction were trained using FES and Motor Learning
3294540|NCT00508521|Other|Control group|Subjects in this arm will receive standard care as prescribed by their physician and covered by their insurance
3294541|NCT00508508|Experimental|1|Behavioral: IVR
3294542|NCT00508508|Experimental|2|Behavioral: Nurse-Led Group Visits
3294543|NCT00508495|Experimental|Test drug|
3294544|NCT00508495|Active Comparator|Reference drug|
3294545|NCT00508495|Placebo Comparator|Placebo|
3294546|NCT00508482|Experimental|deep needling group|Acupoints of bilateral Tianshu (ST25), which were located according to WHO Standardized Acupuncture Points Location, were used. After sterilizing the skin, needles of the size of 0.35×0.75mm were inserted into ST25 vertically and slowly without manipulation for about 20~60mm until piercing into the muscle layer. Paired alligator clips of the electric acupuncture (EA) apparatus were attached transversely to the needle holders of bilateral ST25. EA stimulation lasted for 30 minutes with a dilatational wave of 2/15Hz and current intensity of 0.1~1mA. Participant's abdominal muscle twitching mildly showed the proper dose. Patients were treated once a day, five times a week for continuous 4 weeks.
3294547|NCT00508482|Active Comparator|lactulose group|Lactulose Oral Solution was taken orally at the dose of 20~30ml once every morning after breakfast for continuous 4 weeks. Patients should take lactulose for another 3 months if no severe adverse effect was showed.
3294548|NCT00508482|Active Comparator|shallow needling group|Bilateral ST25, the same acupoints as deep needling group, were used. After skin disinfection, needles of the size of 0.30×25mm penetrated the skin uprightly for about 5~9mm into the fat layer without manipulation. The usage of EA apparatus and treatment course were the same as deep needling group.
3294549|NCT00508469|Experimental|Travalert with travoprost/timolol fixed combination|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
3294550|NCT00508469|Experimental|Travalert with travoprost and timolol|One drop travoprost in the study eye at 9 p.m. and one drop of timolol in the study eye twice daily (9 a.m. and 9 p.m.) for six months using a separate Travalert device for each medication.
3294551|NCT00508456|Experimental|Hominex®-2 + Temodar®|Dietary Methionine Restriction (Hominex®-2) Days 1-7 and 15-21 + Temodar® 150 mg/m^2 orally Days 8-15
3294552|NCT00508443|Experimental|Radiation Therapy|Radiation Therapy using CT-on-Rails or Trilogy procedure. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
3294553|NCT00508430|Experimental|1|Low dose group
3294554|NCT00508430|Experimental|2|Middle dose group
3294555|NCT00508430|Experimental|3|High dose group
3294556|NCT00508430|Placebo Comparator|4|
3294557|NCT00508404|Experimental|Panitumumab plus FOLFIRI|Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until diagnosed with radiographic disease progression.
3294558|NCT00508391|Experimental|Simultaneous 1st, Optimized 2nd|Lumax HF-T device programmed to simultaneous biventricular pacing first for 30 days, followed by optimized biventricular pacing for 30 days.
3294559|NCT00508391|Experimental|Optimized 1st, Simultaneous 2nd|Lumax HF-T device programmed to optimized biventricular pacing first for 30 days, followed by simultaneous biventricular pacing for 30 days.
3294560|NCT00508378||Interview & Questionnaires|
3294623|NCT00507923|Experimental|Tibetan Yoga Program|4 sessions of yoga over 12 weeks.
3294624|NCT00507923|Experimental|Stretching Group|4 sessions of simple stretching exercises for 12 weeks. Each session lasting 90 minutes.
3294561|NCT00508365|Experimental|Subjects receiving treatment sequence AB|Eligible subjects will receive treatment sequence AB; A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).
3294562|NCT00508365|Experimental|Subjects receiving treatment sequence BA|Eligible subjects will receive treatment sequence BA; B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).
3294563|NCT00508352|Experimental|Helical tomotherapy|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
3294564|NCT00508339||1|Patients with a diagnosis of soft tissue sarcoma.
3294565|NCT00508326|Experimental|HAI Paclitaxel|Paclitaxel via Hepatic Artery Infusion (HAI)
3294566|NCT00508313||With Lung Cancer|Patients with lung cancer.
3294567|NCT00508313||Healthy Participants|Healthy participants without cancer.
3294568|NCT00508300|Other|A|Epidural Analgesia (Th 8-9)
3294569|NCT00508300|Other|B|Patient controlled analgesia (morphine-based)
3294570|NCT00508287|Experimental|A|
3294571|NCT00508287|Active Comparator|B|
3294572|NCT00508287|Placebo Comparator|C|
3294573|NCT00508274|Experimental|lapatinib in combination with capecitabine|daily oral lapatinib (1250 mg/day) in combination with capecitabine (2000mg/m2/day on days1-14 every 21 days)
3294574|NCT00508261|Experimental|Group A|Meningococcal vaccine GSK134612 co-administered with Infanrix hexa™
3294575|NCT00508261|Experimental|Group B|Meningococcal vaccine GSK134612 followed one month later by Infanrix hexa™
3294576|NCT00508261|Active Comparator|Group C|Infanrix hexa™ followed one month later by Meningococcal vaccine GSK134612
3294577|NCT00508261|Active Comparator|Group D|Meningitec™ vaccination
3294578|NCT00508248|Active Comparator|A1|1 g omega 3 fatty acid supplements
3294579|NCT00508248|Placebo Comparator|A2|
3294580|NCT00508235||Quality of Friendships|Patients with Neurofibromatosis, type 1 (NF-1) between the ages of 8 and 18 years old.
3294581|NCT00508196|Experimental|A1|Dual chamber pacing with long AV delay
3294582|NCT00508196|Experimental|A2|Dual chamber pacing with long AV delay
3294583|NCT00508196|Experimental|A3|VVI pacing
3294584|NCT00508183|Active Comparator|single row fixation|
3294585|NCT00508183|Active Comparator|double row fixation|
3294586|NCT00508170||Patients with Oropharyngeal Cancer|
3294587|NCT00508170||Patients with Non-Oropharyngeal Cancer|
3294588|NCT00508157|Experimental|A|
3294589|NCT00508157|Active Comparator|B|
3294590|NCT00508144|Experimental|Alimta|Alimta 500 mg/m^2 by vein Once Over 10 Minutes Every 3 Weeks.
3294591|NCT00508131|Active Comparator|A|Milk fortified with, iron, zinc and vitamin C
3294592|NCT00508131|Placebo Comparator|B|Milk not fortified
3294593|NCT00508118|Experimental|1|Nicardipine
3294594|NCT00508118|Placebo Comparator|2|0.9% saline
3294595|NCT00508105|Active Comparator|tenotomy|
3294596|NCT00508105|Active Comparator|osteotomy|
3294597|NCT00508092|Active Comparator|A|lanz incision appendectomy
3294598|NCT00508092|Active Comparator|B|lanz incision appendectomy
3294599|NCT00508066|Experimental|Arm 1|Subjects in arm 1 will intraoperatively have a continuous infusion catheter placed in the paraspinal musculature of the posterior spinal wound. Post-operatively, the catheter will infuse 0.25 - 0.5% (according to patient's weight) Bupivacaine at a rate of 4ml/hr for 72 hours. This is in addition to the standardized PCA pain management.
3294600|NCT00508066|Placebo Comparator|Arm 2|Subjects in arm 2 will intraoperatively have a continuous infusion catheter placed in the paraspinal musculature of the posterior spinal wound. Post-operatively, the catheter will infuse normal saline at a rate of 4ml/hr for 72 hours. This is in addition to the standardized PCA pain management.
3294601|NCT00508053|Active Comparator|1|Mass closure
3294602|NCT00508053|Experimental|2|Small stitches
3294603|NCT00508040|Experimental|A|To analyse the potential therapeutic effect of Interferon alpha2a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
3294604|NCT00508040|Active Comparator|B|
3294605|NCT00508027|Other|Simvastatin, Dose Escalation|There are no arms in this study. Simvastatin will be given in a dose-escalating fashion to 3 sequential dosage groups (20 mg/day, 40 mg/day, 80 mg/day).
3294606|NCT00508014|Active Comparator|Control|usual care
3294607|NCT00508014|Experimental|Concurrent Peer Review Visit|See description of interventioin
3294608|NCT00508001|Placebo Comparator|1|Best Supportive Care + Placebo
3294609|NCT00508001|Experimental|2|Best Supportive Care + ZD6474 100 mg
3294610|NCT00508001|Experimental|3|Best Supportive Care + ZD6474 300 mg
3294611|NCT00507988|Experimental|A|Complex Problem Solving Training
3294612|NCT00507988|Active Comparator|B|Basic Cognitive Training
3294613|NCT00507975|Placebo Comparator|A|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
3294614|NCT00507975|Experimental|B|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
3294615|NCT00507962|Experimental|Cisplatin + Liposomal Doxorubicin|Cisplatin 100 mg/m^2 Intraarterial and Liposomal Doxorubicin starting dose 20 mg/m^2 by vein on Day 1 every 4 weeks
3294616|NCT00507949|Experimental|1|Megestrol acetate: sachets of granulated 160 mg. Dose: 160 mg/b.i.d. Duration 8 weeks
3294617|NCT00507949|Placebo Comparator|2|The placebo is the excipient of the experimental drug.
3294626|NCT00507897||A|Cohort: Patients with normal blood pressure scheduled to have thyroid nodules surgically removed
3294627|NCT00507897||A1|Patients from group A not receiving any drugs and who lack other pathology, gender and age matched group B1
3294628|NCT00507897||B|Cohort: Patients with increased blood pressure scheduled to have thyroid nodules surgically removed
3294629|NCT00507897||B1|Patients from group B not receiving any drugs and who lack other pathology, gender and age matched group A1
3294630|NCT00507884||3 Tesla MRI|Patients with renal tumors scheduled to have a CT scan of the kidneys and abdomen.
3294631|NCT00507858|Experimental|Pemetrexed|Starting dose 500 mg/m^2 IV once every 3 weeks
3294632|NCT00507858|Experimental|Pemetrexed + IV Dexamethasone|Pemetrexed Starting dose 500 mg/m^2 IV once every 3 weeks + Dexamethasone 20 mg intravenous (IV) Day 1.
3294633|NCT00507858|Experimental|Pemetrexed + Oral Dexamethasone|Pemetrexed starting dose 500 mg/m^2 IV once every 3 weeks + Dexamethasone 4 mg orally twice daily for 3 Days.
3294634|NCT00507832|Active Comparator|I|"Interindividual design:~active and comparator (one side each) applied twice daily"
3294635|NCT00507832|Active Comparator|II Hydrocortisone|Hydrocortisone, twice daily
3294636|NCT00507819|Active Comparator|Sildenafil, then Placebo|Sildenafil will be given at a dose of 20 mg three times-a-day for six weeks followed by a six week washout period followed by placebo for an additional six weeks.
3294637|NCT00507819|Active Comparator|Placebo, then Sildenafil|Placebo will be given for six weeks followed by a six week washout period followed by Sildenafil which will be given at a dose of 20 mg three times-a-day for six weeks
3294638|NCT00507767|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO or via PEG tube BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3294639|NCT00507754||Latent Tuberculosis Infection|Patients with cancer at risk for developing active tuberculosis (TB).
3294640|NCT00507741|Experimental|Ertafolide + Vintafolide|Screening: After completion of all screening procedures and confirmation of eligibility, all participants receive a 1- to 2-mL injection of 0.1 mg ertafolide labeled with 20 to 25 mCi of technetium-99m Part A: Induction phase of treatment: Two 4-week cycles; if stable disease or better at week 8 computed tomography (CT), participant may proceed into maintenance phase, comprised of 4-week cycles with CT every 8 weeks. Participants continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit. Part B: 4-week cycles with CT every 8 weeks. Participants continue until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit.
3294641|NCT00507728|Experimental|Bupropion|Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).
3294642|NCT00507728|Experimental|Varenicline|Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).
3294643|NCT00507728|Placebo Comparator|Placebo|Placebo by mouth for 12 weeks.
3294644|NCT00507715|Experimental|1|Plantago ovata husk
3294645|NCT00507715|Placebo Comparator|2|hemicellulose crystalline
3294646|NCT00507689|Experimental|FTC/TDF+HBIg|Participants received FTC/TDF+HBIg for up to 24 weeks in the pre-randomization period; those who completed 24 weeks of treatment were then randomized to receive FTC/TDF+HBIg in the randomized period.
3294647|NCT00507689|Experimental|FTC/TDF|Participants received FTC/TDF+HBIg for up to 24 weeks in the pre-randomization period; those who completed 24 weeks of treatment were then randomized to receive FTC/TDF in the randomized period.
3294648|NCT00507676||Group 1|One hundred and sixty healthy infants between 1 and 24 months of age will be evaluated. Subjects will be recruited so that there are 40 subjects within each of four subgroups: 1) Negative ETS exposure and Negative Fm Asthma, 2) Positive ETS exposure and Negative Fm Asthma, 3) Negative ETS exposure and Positive Fm Asthma and 4) Positive ETS exposure and Positive Fm Asthma. Equal numbers of males and females will be recruited. The ethnic composition will be approximately 80% Caucasian and 20% African-American in each of the four groups, which represents the distribution within the cities where infants will be evaluated. Subjects will be excluded if they were born prematurely (<37 weeks gestation), have a history of congenital cardio-respiratory disease, or have history of lower respiratory illness.
3294649|NCT00507676||Group 2|Eighty infants between 1 and 24 months of age scheduled for CT scans of the abdomen or chest will be evaluated. Subjects will be excluded if they are born prematurely (<37 weeks gestation), have history of congenital cardio-respiratory disease, or have history of recurrent wheezing.
3294650|NCT00507676||Group 3|Eighty infants with recurrent wheezing between 1 and 24 months of age will be evaluated when they are not acutely symptomatic for at least 3 weeks. Subjects will be recruited so that there are 20 subjects within each of four subgroups: 1) Negative ETS exposure and Negative Fm Asthma, 2) Positive ETS exposure and Negative Fm Asthma, 3) Negative ETS exposure and Positive Fm Asthma and 4) Positive ETS exposure and Positive Fm Asthma. Equal numbers of males and females will be recruited. Subjects will be excluded if they were born prematurely (<37 weeks gestation) or have history of congenital cardio -respiratory disease.
3294651|NCT00507663|Experimental|Atenolol|Atenolol given prior to and for up to 7 days after surgery
3294652|NCT00507663|No Intervention|routine care|routine clinical care
3294653|NCT00507650|Active Comparator|Prescribed|Fluid volume and type prescribed by MD or provider.
3294654|NCT00507650|Experimental|Supplemental|Fluid volume and type prescribed by physician or provider plus 10 ml/kg X 5 days.
3294655|NCT00507637|Experimental|NT 201 (IncobotulinumtoxinA/Xeomin®)|
3294656|NCT00507611|Other|Single-arm|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
3294657|NCT00507585|Experimental|Oxaliplatin + Fluorouracil + Leucovorin + Avastin|
3294658|NCT00507572||Pregnant Patients with Cancer|Patients that are or were pregnant when diagnosed with cancer.
3294659|NCT00507559|Experimental|AAA Repair System|
3294660|NCT00507546|Experimental|Ramelteon then placebo|8 mg nightly ramelteon for three weeks, followed by two weeks of nightly placebo (washout), then three weeks of nightly placebo (cross-over)
3294661|NCT00507546|Experimental|Placebo then ramelteon|placebo nightly for three weeks, followed by two weeks of nightly placebo (washout), then three weeks of 8 mg nightly ramelteon (cross-over)
3294662|NCT00507507|Experimental|Tenofovir DF|Participants were randomized to receive tenofovir DF plus placebo to match FTC once daily.
3294663|NCT00507507|Experimental|FTC+Tenofovir DF|Participants were randomized to receive FTC plus tenofovir DF once daily.
3294664|NCT00507455|Placebo Comparator|Placebo|Participants received once daily, oral doses of placebo matching solifenacin succinate and tamsulosin tablets for 12 weeks.
3294665|NCT00507455|Experimental|6 mg Solifenacin + 0.4 mg Tamsulosin|Participants received once daily, oral doses of 6 mg solifenacin succinate and 0.4 mg tamsulosin tablets for 12 weeks.
3294666|NCT00507455|Experimental|9 mg Solifenacin + 0.4 mg Tamsulosin|Participants received once daily, oral doses of 9 mg solifenacin succinate and 0.4 mg tamsulosin tablets for 12 weeks.
3294667|NCT00507442|Experimental|VDR|VELCADE (bortezomib), dexamethasone, and Revlimid (lenalidomide)
3294668|NCT00507442|Experimental|VDCR|VELCADE (bortezomib), dexamethasone, cyclophosphamide, Revlimid (lenalidomide)
3294669|NCT00507442|Experimental|VDC|VELCADE (bortezomib), dexamethasone, cyclophosphamide
3294670|NCT00507442|Experimental|VDC-mod|Modified dosing of VELCADE (bortezomib), dexamethasone, cyclophosphamide
3294671|NCT00507429|Experimental|Arm 1: CA4P + Carboplatin + paclitaxel|Six 21-day cycles: CA4P (60 mg/m2 on Days 1, 8, 15), carboplatin (AUC 6) + paclitaxel (200 mg/m2) on Day 2
3294672|NCT00507429|Active Comparator|Arm 2: Carboplatin + Paclitaxel|Six 21-day cycles of Carboplatin (AUC 6) + paclitaxel (200 mg/m2) given on Day 1
3294673|NCT00507416|Experimental|Bortezomib and Dexamethasone (VD)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
3294674|NCT00507416|Experimental|Bortezomib, Thalidomide, and Dexamethasone (VTD)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance) .
3294675|NCT00507416|Experimental|Bortezomib, Melphalan and Prednisone (VMP)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
3294676|NCT00507403|Active Comparator|Infliximab|Infliximab
3294677|NCT00507403|Experimental|Infliximab +methotrexate|Infliximab +methotrexate
3294678|NCT00507390|Active Comparator|A1|n-3 PUFAs
3294679|NCT00507390|Placebo Comparator|A2|olive oil capsules
3294680|NCT00507351||Cancer Pain Management|Patients receiving chemotherapy for breast, colon, lung, or prostate cancer.
3294681|NCT00507338|Experimental|ARC1779 low dose|0.1 mg/kg
3294682|NCT00507338|Experimental|ARC1779 mid dose|0.3 mg/kg
3294683|NCT00507338|Experimental|ARC1779 high dose|1.0 mg/kg
3294684|NCT00507338|Active Comparator|abciximab|labeled regimen for primary PCI
3294685|NCT00507325||Blood Sample + Tumor Sample|Blood samples will be collected. Tumor samples will be collected using a small needle, a punch knife, or a small surgery.
3294686|NCT00507312|Active Comparator|1|Healthy subjects (with no evidence of cardiovascular disease).
3294687|NCT00507312|Experimental|2|Patients with risk factors for heart failure
3294688|NCT00507312|Experimental|3|Patients with heart failure
3294689|NCT00507299|Experimental|Model Care (SEEK)|Residents in this group received special training on addressing pyschosocial problems. They then used a parent screening questionnaire, and addressed identified problems. A study social worker was also part of this intervention. Thus, this group provided enhanced pediatric primary care.
3294690|NCT00507299|Active Comparator|Standard pediatric primary care|This arm involved residents receiving the regular education through the program. They did not use the screening questionnaire to identify psychosocial problems, and did not have a dedicated social worker to assist them. Instead, residents in this group provided standard pediatric primary care
3294691|NCT00507273||GIST|Patients diagnosed with a gastrointestinal stromal tumor (GIST)
3294692|NCT00507260|Experimental|Control Group|Control Group (Food Record)
3294693|NCT00507260|Experimental|Treatment Group|Treatment Group (Food Record + Nutritional Consults)
3294694|NCT00507247|Experimental|Daptomycin|6mg/kg/day intravenous (IV) for 10 days
3294695|NCT00507221|Experimental|1|Arm 1 will receive an intensive regimen of anti-helminthic therapy consisting of albendazole every three months for two years and praziquantel at enrollment and at one year of follow up.
3294696|NCT00507221|Active Comparator|2|Arm 2 will receive symptomatic diagnosis and treatment of helminth infection as is current standard of care in Kenya.
3294697|NCT00507208|Experimental|Dynasplint|Participants randomized to this arm will be treated with the Dynasplint Trismus System
3294698|NCT00507208|Active Comparator|Control|Participants randomized to this arm will use tongue depressors for 3 months and if there is no improvement in their mouth opening at this timepoint, they will crossover to the Dynasplint Trismus System
3294699|NCT00507182|Experimental|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
3294700|NCT00507156|Experimental|Mek postcon|Re-opening of the infarcted coronary artery by several balloon inflations separated by reperfusion of the vessel.
3294701|NCT00507156|Active Comparator|Standard treatment|Standard treatment (primary PCI)
3294702|NCT00507130|Experimental|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
3294703|NCT00507130|Experimental|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
3294704|NCT00507130|Experimental|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
3294705|NCT00507130|Placebo Comparator|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
3294706|NCT00507117|Active Comparator|PSG|
3294707|NCT00507091|Experimental|ZD6474 (vandetanib) 100mg|
3294708|NCT00507091|Experimental|ZD6474 (vandetanib) 300mg|
3294709|NCT00507065|Experimental|Adderall XR (10 mg)|
3294710|NCT00507065|Experimental|Adderall XR (20 mg)|
3294711|NCT00507065|Experimental|Adderall XR (30 mg)|
3294712|NCT00507065|Experimental|Adderall XR (40 mg)|
3294713|NCT00507065|Placebo Comparator|placebo|
3294714|NCT00507039||grass allergy, bronchial challenge|subjects with known allergy against grass-pollen undergo bronchial challenges
3294715|NCT00507026|Experimental|A|DIC075V (IV diclofenac)
3294716|NCT00507026|Active Comparator|B|IV Ketorolac
3294717|NCT00507026|Placebo Comparator|C|Placebo
3294718|NCT00507013|Other|2|
3294719|NCT00507000|Active Comparator|A, Cholecalciferol|A Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
3294720|NCT00507000|Placebo Comparator|Vitamin D and Tuberculosis|B, Lactose
3294721|NCT00506987|Experimental|SCH 486757|
3294722|NCT00506987|Placebo Comparator|Placebo|
3294723|NCT00506961|Active Comparator|1|10 mg rosuvastatin for 4 weeks followed by 20 m rosuvastatin for another 8 weeks
3294724|NCT00506961|Active Comparator|2|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
3294725|NCT00506948|Experimental|Thymoglobulin + Sirolimus + MMF|Thymoglobulin 1.5 mg/kg intravenous (IV) days -4, -3, -2, -1 before Stem Cell Transplant (Day 0); Sirolimus 6 mg IV on day -2 followed by 2 mg daily to maintain therapeutic levels and Mycophenolate Mofetil (MMF) 15 mg/kg IV or orally every 12 hours starting on day 0 until day+27.
3294726|NCT00506935|Experimental|1|GVG
3294727|NCT00506935|Placebo Comparator|2|placebo
3294728|NCT00506922|Experimental|No Pentostatin|Group 1: No Pentostatin
3294729|NCT00506922|Experimental|Pentostatin 0.5|Group 2: Pentostatin 0.5 mg/m^2
3294730|NCT00506922|Experimental|Pentostatin 1|Group 3: Pentostatin 1 mg/m^2
3294731|NCT00506922|Experimental|Pentostatin 1.5|Group 4: Pentostatin 1.5 mg/m^2
3294732|NCT00506922|Experimental|Pentostatin 2|Group 5: Pentostatin 2 mg/m^2
3294733|NCT00506909|Experimental|Group 1|Group 1: 20 IU BID for the first week, 40IU BID for the following two weeks, 1 week washout, 3 week placebo trial.
3294734|NCT00506909|Experimental|Group 2|Group 2: 3 week placebo trial, 1 week washout, 20 IU BID for the first week, 40IU BID for the following two weeks.
3294735|NCT00506896|Active Comparator|1|
3294736|NCT00506883|Experimental|High Dose Colchicine|After confirmation of a gout flare, patients were to begin standard dosing of colchicine 4.8mg (two capsules (1.8mg) initially followed by additional one capsule doses (0.6mg) every hour for an additional 6 doses).
3294737|NCT00506883|Experimental|Low Dose Colchicine|Within 12 hours of a confirmed gout flare, patients were to begin the low dose colchicine regimen consisting of a total dose of 1.8 mg - two colchicine capsules initially (1.2 mg)followed an hour later by a single additional capsule of active drug(0.6 mg)then by 5 additional hourly doses of an identical looking placebo capsules
3294738|NCT00506883|Placebo Comparator|Placebo|
3294739|NCT00506870|No Intervention|1|Conventional follow-up of anticoagulation
3294740|NCT00506870|Experimental|2|Self-monitoring of anticoagulation
3294741|NCT00506857|Experimental|Busulfan + Fludarabine|Busulfan starting 0.8 mg/kg by vein (IV) every 6 hours for 12 doses; Fludarabine 30 mg/m^2 IV daily for 4 days.
3294742|NCT00506831|Experimental|Imatinib mesylate|100 mg daily and increase by 100mg daily every 2 weeks to a maximum of 400 mg daily as tolerated
3294743|NCT00506818|Active Comparator|2|Intensive risk factor intervention
3294744|NCT00506805|Experimental|Single Arm|
3294745|NCT00506792|Experimental|1|QAU145
3294746|NCT00506792|Placebo Comparator|2|Placebo
3294747|NCT00506779|Experimental|Paclitaxel + Imatinib Mesylate|Phase I, Phase II (Arm 2) = Paclitaxel + Imatinib Mesylate
3294748|NCT00506779|Experimental|Paclitaxel|Phase II, (Arm 1) = Paclitaxel
3294749|NCT00506753|Experimental|MI/CBT|Motivational Interviewing followed by Cognitive Behavior Therapy
3294750|NCT00506753|Experimental|RT/TU|Relaxation Training followed by Treatment as Usual
3294751|NCT00506740|Active Comparator|Electrocautery|Elesurgical instruments are used to cut and coagulate tissue using alternatig electric current focusing intense heat at the surgical site. In electrosurgery, the patient is included in the circuit and current enters the patient's body.
3294752|NCT00506727|Experimental|Adderall XR|
3294753|NCT00506727|Active Comparator|Atomoxetine hydrochloride|
3294754|NCT00506714|Experimental|Adult subjects with hip osteoarthritis|Walk with and without a single point cane at baseline and after four weeks
3294755|NCT00506714|No Intervention|Healthy Subjects|Healthy adults walking without a cane at baseline
3294756|NCT00506701|Experimental|Tadalafil treatment 40 mg|
3294757|NCT00506675|Active Comparator|Intensive|42 hours per week of patching combined with atropine (1%) once daily in the sound eye, with spectacle correction (if needed)
3294758|NCT00506675|Active Comparator|Weaning|For patients currently patching, reduce patching to two hours daily for four weeks, then no treatment thereafter except spectacle correction (if needed). For patients currently using atropine, reduce atropine to once weekly for 4 weeks, then no treatment thereafter except spectacle correction (if needed)
3294759|NCT00506662|Experimental|Insulin detemir|Individually adjusted dose of insulin detemir once daily
3294760|NCT00506662|Active Comparator|Insulin NPH|Individually adjusted dose of insulin NPH once daily
3294761|NCT00506597|Experimental|Erwinase|6 doses of 25,000 Units/m^2 Erwinase® intramuscular/subcutaneously every other day to replace each dose of Pegylated Asparaginase
3294883|NCT00505544||Questionnaire + Actigraphs|Questionnaires that ask about your sleep, symptoms, and mood. Wear actigraph to collect information on activity levels and sleep patterns for one week.
3294762|NCT00506584|Experimental|Group 1, arm 1|Human breast milk + Prolact20/Neo20 (as needed) + Prolact+4 (initiated when nutrition volume reaches 100 mL/kg/day, where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
3294763|NCT00506584|Experimental|Group1, Arm 2|Human breast milk + Prolact20/Neo20 (as needed) + Prolact+4 (initiated when nutrition volume reaches 40 mL/kg/day), where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
3294764|NCT00506584|Active Comparator|Group 1, Arm 3|Human breast milk + bovine-based human milk fortifier (initiated when nutrition volume reaches 100 mL/kg/day) + pre-term formula (as needed)
3294765|NCT00506584|Experimental|Group 2, Arm 1|Prolact20/Neo20 + Prolact+4 (initiated when nutrition volume reaches 100 mL/kg/day), where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
3294766|NCT00506584|Active Comparator|Group 2, Arm 2|Pre-term/term formula (minimum 20 cal/oz)
3294767|NCT00506558|Experimental|A|Ventral Decompression and Instrumented Fusion
3294768|NCT00506558|Active Comparator|B|Dorsal Decompression with or without fusion
3294769|NCT00506545|Experimental|SCH 619734|
3294770|NCT00506545|Placebo Comparator|Placebo|
3294771|NCT00506506|Experimental|1|N-acetylcysteine 1200 mg twice daily x 48 hours
3294772|NCT00506506|Placebo Comparator|2|
3294773|NCT00506480|Experimental|OD|patients artificially prepared for OD will undergo a mock cycle consisting of estrogen and later by progesterone. a pipelle sample will be taken after 6 days of progesterone supplementation.
3294774|NCT00506480|Experimental|IVF|A pipelle sample will be taken on day 21 of the cycle before administration of GNRHa. Exact timing will be performed by counting 7 days from the LH surge.
3294775|NCT00506467||VRI System|Vibration Response Imaging (VRI) System
3294776|NCT00506454|Active Comparator|Lipidose|Dosage of 1.5 mL/kg of Lipidose over a 2-hour period.
3294777|NCT00506454|Placebo Comparator|Placebo|Dosage of 1.5 mL/kg of Placebo over a 2-hour period.
3294778|NCT00506441|Experimental|1|
3294779|NCT00506441|Placebo Comparator|2|
3294780|NCT00506415|Experimental|Open label: Rivastigmine (5 cm^2 / 10 cm^2)|Rivastigmine 5 cm^2 transdermal patch once a day during the first 4 weeks of open label treatment followed by rivastigmine 10 cm^2 transdermal patch once a day from week 4 to week 24, 36 or 48.
3294781|NCT00506415|Experimental|Double blind: Rivastigmine (10 cm^2)|Rivastigmine transdermal patch 10 cm^2 and placebo to rivastigmine 15 cm^2 once daily for 48 weeks during the double blind period.
3294782|NCT00506415|Experimental|Double blind: Rivastigmine (15 cm^2)|Rivastigmine transdermal patch 15 cm^2 and placebo to rivastigmine 10 cm^2 once daily for 48 weeks during double blind period.
3294783|NCT00506415|Experimental|Extended open label Rivastigmine (10 cm^2)|Rivastigmine 10 cm^2 transdermal patch once a day during 48 weeks open label treatment running in parallel to the double blind period.
3294784|NCT00506402|Experimental|1|
3294785|NCT00506389|Experimental|Esmirtazapine 3.0 mg|Participants took placebo tablets on Days -7 and -6, esmirtazapine 3.0 mg tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
3294786|NCT00506389|Experimental|Esmirtazapine 4.5 mg|Participants took placebo tablets on Days -7 and -6, esmirtazapine 4.5 mg tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
3294787|NCT00506389|Placebo Comparator|Placebo|Participants took placebo tablets on Days -7 and -6, placebo tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
3294788|NCT00506376||Surgical Treatment Preferences|Assessment of patient's feelings toward risks associated with surgical treatment of cervical cancer.
3294789|NCT00506363|Experimental|A|pulsed dye laser and dynamic cooling device on the day of suture removal
3294790|NCT00506363|Active Comparator|B|pulsed dye laser and dynamic cooling device 2 months after suture removal
3294791|NCT00506363|Sham Comparator|C|dynamic cooling device
3294792|NCT00506350|Experimental|GSK1562902A non-AD F1 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
3294793|NCT00506350|Experimental|GSK1562902A non-AD F2 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
3294794|NCT00506350|Experimental|GSK1562902A non-AD F3 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
3294795|NCT00506350|Experimental|GSK1562902A non-AD F4 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
3294796|NCT00506350|Experimental|GSK1562902A AD F1 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
3294884|NCT00505531||Tramadol ER- 200mg|Tramadol Extended Release capsules Weeks 1 & 6- 100 mg/day Weeks 2-5- 200 mg/day
3294797|NCT00506350|Experimental|GSK1562902A AD F2 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
3294798|NCT00506350|Experimental|GSK1562902A AD F3 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
3294799|NCT00506350|Experimental|GSK1562902A AD Approved F4 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
3294800|NCT00506350|Experimental|Control Group|Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
3294801|NCT00506311|Experimental|Fibrin Sealant|
3294802|NCT00506311|No Intervention|No Fibrin Sealant|
3294803|NCT00506298|Experimental|A|CRx-401 (bezafibrate + diflunisal)
3294804|NCT00506298|Active Comparator|B|bezafibrate + placebo
3294805|NCT00506285|Experimental|A|This arm was 4 weeks long. Subjects were treated using Methylphenidate Transdermal System. Patients were seen weekly, phone contact was made between visits and dosing could be adjusted as a result of the phone contact. MTS was initiated using a 12.5 cm patch. The dose was increased during the first 2 weeks based on treatment response and side effects to the largest tolerated dose/patch size. It was held steady the last 2 weeks.
3294806|NCT00506285|Placebo Comparator|B|This arm was 4 weeks long. Placebo patch was initiated using a 12.5 cm patch and then increased to the largest tolerated patch size during the first 2 weeks and held steady the last two weeks. Subjects were seen weekly, phone contact was made between visits and dosing could be adjusted as a result of the phone visit.
3294807|NCT00506272|Experimental|Standard care|Patients admitted for elective surgery will receive standard diabetes care, including but not limited to finger stick blood glucose determinations, and insulin injections delivered by the nursing staff.
3294808|NCT00506272|Experimental|Patient administered care|Patients will self-monitor and record finger-stick blood glucose measurements, and self administer insulin at doses agreed upon with the consulting endocrinology in-patient service.
3294809|NCT00506246|Experimental|1|Propofol MCT/LCT
3294810|NCT00506246|Active Comparator|2|Propofol LCT
3294811|NCT00506233||Chronic Graft-Versus Host Disease (GvHD)|Participants with chronic graft-versus host disease (GvHD)
3294812|NCT00506194|Experimental|Insulin|Insulin therapy was initiated at a 75% total daily dose in the last day hospitalization with Insulatard. Two third of daily dose was administered before breakfast and the other was administered at bedtime. Insulin doses were titrated every 3 days to achieve target FPG and pre-supper blood glucose values between 90 and 130 mg/dl. Bedtime insulin doses were titrated based on FPG values and the pre-breakfast dose was titrated base on pre-supper blood glucose.
3294813|NCT00506194|Active Comparator|OAD|Subject in other OAD group was visited every two weeks in the two months and the every four weeks. The subjects will start with Gliclazide-MR 30mg before breakfast, The dosage was titrated based on the fasting blood glucose on the visiting day with the same target. Decreased by 30mg if blood glucose was <70mg /dl, decreased by 15 mg if blood glucose was 70-90mg/dl, no change if blood glucose was 90-130mg/dl, increased by 15 mg if blood glucose was 131-160 mg/dl, increased by 30 mg if blood glucose >160mg/dl. When the Gliclazide-MR dose each to the maximum dose of 60 mg twice daily, Metformin was added. The titration of Metformin was use 250mg for an adjust dosage with the same target.
3294814|NCT00506181|Active Comparator|X|receiving probiotics
3294815|NCT00506181|Placebo Comparator|Y|
3294816|NCT00506181|No Intervention|Z|
3294817|NCT00506155|Experimental|Neoadjuvant Chemotherapy with M-VAC + Avastin|Avastin 10 mg/kg by vein over 90 minutes. Cisplatin 70 mg/m^2 by vein over 4 hours. Doxorubicin 30 mg/m^2 by vein over 15 minutes. Methotrexate 30 mg/m^2 by vein over 30 minutes. Vinblastine Sulfate 3 mg/m^2 by vein over 30 minutes.
3294818|NCT00506142|Experimental|Cohort 1|Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.
3294819|NCT00506142|Experimental|Cohort 2|Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week
3294820|NCT00506129|Experimental|Fludarabine + Melphalan with PBPC|Fludarabine 25 mg/m^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant. Melphalan 70 mg/m^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant. Allogeneic transplant given by vein after completion of Fludarabine and Melphalan. Thymoglobulin 2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
3294821|NCT00506090|Experimental|A|pulsed dye laser and dynamic cooling device at 3 weeks intervals
3294822|NCT00506090|Active Comparator|B|pulsed dye laser and dynamic cooling device at 6 weeks intervals
3294823|NCT00506090|Sham Comparator|C|dynamic cooling device
3294824|NCT00506077|Experimental|MK0249|
3294825|NCT00506077|Placebo Comparator|Placebo|
3294826|NCT00506064|Experimental|Melatonin|0.15 mg/kg capsules by mouth daily
3294827|NCT00506064|Placebo Comparator|Placebo|Starch capsules by mouth daily
3294828|NCT00506051|Experimental|ZD6474 (vandetanib) 100mg|
3294829|NCT00506051|Experimental|ZD6474 (vandetanib) 300mg|
3294830|NCT00506025|Active Comparator|Cranberry 2xday|Cranberry juice (C) two times daily, a.m. and p.m.
3294831|NCT00506025|Active Comparator|Cranberry + Placebo|De-Activated Cranberry juice in the am, then placebo (P) in the pm
3294832|NCT00506025|Placebo Comparator|Placebo 2xday|Placebo in the form of juice two times daily in the a.m. and p.m.
3294833|NCT00506012|Experimental|1|T2000
3294834|NCT00505999||Questionnaire|Patients diagnosed with Multiple Myeloma and healthy controls.
3294836|NCT00505947|Active Comparator|A|"Infliximab 5 mg/Kg body weight by intravenous infusion on visit 1 (week 0), visit 2 (week 2), visit 3 (week 6)and visit 5 (week 14).~Afterwards, after a washout period of 2 weeks, arm A will receive placebo at visits 6 (week 16), visit 7 (week 18), visit 8 (week 22)and visit 30 (week 30)"
3294837|NCT00505947|Placebo Comparator|B|"Arm B will receive placebo at visit 1 (week 0), visit 2 (week 2), visit 3 (week 6)and visit 5 (week 14).~Afterwards, after a washout period of 2 weeks, group B will receive infliximab 5 mg/Kg body weight by intravenous infusion at visit 6 (week 16), visit 7 (week 18), visit 8 (week 22)and visit 30 (week 30)"
3294838|NCT00505934|Experimental|Levetiracetam|
3294839|NCT00505921|Experimental|Campath-1H|"3 mg in vivo Day 1; 10 mg Day 2; 30 mg Days 3 and 10 of chemotherapy treatment. Transplantation on Day 0.~Preparative Regimen For Autologous Stem Cell Transplantation: BEAM (BCNU 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice on day -5 to -2 (total 8 doses), and Melphalan 140 mg/m2 IV on day -1. Beginning on day +5 G-CSF 10 mg/kg sc (in a.m.) and GM-SCF 250 m/m2 on Day +5 (in p.m.)~Preparative Regimen For Allogenic Stem Cell Transplantation: Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy day 0."
3294840|NCT00505895|Experimental|Fludarabine + Melphalan + Stem Cell Infusion|"Fludarabine 30 mg/m^2 intravenous (IV) daily over 30 minutes for 4 Days (Beginning Day -4).~Melphalan 140 mg/m^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m^2 IV infused starting on day -5."
3294841|NCT00505895|Experimental|Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion|"Fludarabine 30 mg/m^2 intravenous daily over 30 minutes for 4 Days (Beginning Day -4).~Lower-Dose Melphalan 100 mg/m^2 intravenous over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m^2 intravenous infused starting on day -5."
3294842|NCT00505882|Active Comparator|Insulin|
3294843|NCT00505882|Experimental|Pramlintide|
3294844|NCT00505869||1|Health & Wellness Intervention + Questionnaire
3294845|NCT00505869||2|Mood Management Intervention + Questionnaire
3294846|NCT00505843|Other|1|7mg MK0657 capsules + >/=1.0 mg/kg/hr dose of levodopa.
3294847|NCT00505843|Other|2|7mg MK0657 Pbo capsules + >/=1.0 mg/kg/hr dose of levodopa.
3294848|NCT00505830|Case|1|50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ >85.
3294849|NCT00505830|Case|2|50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70<IQ<84.
3294850|NCT00505830|Control|3|50 adolescents with psychiatric disorders but no autism syndrom.
3294851|NCT00505830|Control|4|Sample of 50 healthy adolescents selected randomly from 200.
3294852|NCT00505804|Experimental|1|
3294853|NCT00505804|Active Comparator|2|
3294854|NCT00505791|Placebo Comparator|Sugar pill|Lactose, NF (monohydrate)
3294855|NCT00505791|Active Comparator|Nesiritide|Natrecor (nesiritide) is a commercially available B-type natriuretic peptide which is indicated for intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.
3294856|NCT00505778|Active Comparator|Mesalamine (Asacol) Once-Daily|an oral, once daily (QD) mesalamine regimen (1.6 - 2.4 g/day)
3294857|NCT00505778|Active Comparator|Mesalamine (Asacol) Twice-Daily|an oral, twice daily (BID) mesalamine regimen (1.6 - 2.4 g/day)
3294858|NCT00505765|Experimental|AL-108, 30 mg/day|AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
3294859|NCT00505765|Experimental|AL-108, 5 mg/day|AL-108, 5 mg/day- one spray in each nostril once per day
3294860|NCT00505765|Placebo Comparator|Placebo, 3 sprays BID|Placebo- 3 sprays in each nostril, twice per day
3294861|NCT00505765|Placebo Comparator|Placebo, 1 Spray Daily|Placebo- one spray in each nostril, once per day
3294862|NCT00505752|Experimental|AS900672-Enriched 50 mcg|
3294863|NCT00505752|Experimental|AS900672-Enriched 100 mcg|
3294864|NCT00505752|Experimental|AS900672-Enriched 150 mcg|
3294865|NCT00505752|Active Comparator|Follitropin alfa 150 IU|
3294866|NCT00505739|Experimental|Mifepristone|
3294867|NCT00505726||Confocal Microscopy|
3294868|NCT00505713|Experimental|1|Dose Level 1 of escalating doses of Rexin-G i.v.
3294869|NCT00505713|Experimental|3|Dose Level 3 of escalating doses of Rexin-G i.v.
3294870|NCT00505713|Experimental|4|Dose Level 4 of escalating doses of Rexin-G i.v.
3294871|NCT00505713|Experimental|5|Dose Level 5 of escalating doses of Rexin-G i.v.
3294872|NCT00505713|Experimental|2|Dose Level 2 of escalating doses of Rexin-G i.v.
3294873|NCT00505687|Experimental|Rotigotine|Rotigotine
3294874|NCT00505661|Experimental|Letrozole|2.5 mg by mouth (PO) daily
3294875|NCT00505635|Experimental|Biochemotherapy with Temozolomide|Temozolomide 250 mg/m^2 every 4 hours Day 1; Biochemotherapy of Velban 1.5 mg/m^2 intravenous (IV) Days 1-4; Cisplatin 20 mg/m^2 IV Days 1-4; + Interleukin-2 9 MIU/m^2 IV over 24 Hours for 4 Doses Days 1-4; Intron-A 5 mu/m^2 subcutaneously daily Days 1-5; + Oral Thalidomide 400 mg daily.
3294876|NCT00505622|Experimental|E2007|E2007 2 mg (one 2 mg tablet taken daily in the evening), or 4 mg (two 2 mg tablets daily in the evening).
3294877|NCT00505609|Experimental|A|The Institute for Reproductive Health trained health providers in teaching the Standard Days Method to study subjects and in study procedures. Providers counseled study participants in method use. Participants were followed for up to 13 cycles of method use.
3294878|NCT00505596|Experimental|Computerized decision aid|Participants instructed to view the updated PT Tool and told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study (Informed free choice). They also participate in a baseline pre-randomization interview and one follow-up telephone interview.
3294879|NCT00505596|No Intervention|Usual care|Control group, in which participants receive no intervention beyond a baseline pre-randomization interview and one follow-up telephone interview.
3294880|NCT00505570|No Intervention|Medical Management|
3294881|NCT00505570|Experimental|PFO Closure|
3294882|NCT00505544||Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
3294885|NCT00505531||Tramadol ER- 300mg|Tramadol Extended Release capsules Weeks 1 & 7- 100 mg/day Weeks 2 & 6- 200 mg/day Weeks 3-5- 300 mg/day
3294887|NCT00505505|Experimental|A|Insulin infusion rate titrated to maintain glycemia between 80 and 100 mg/dl
3294888|NCT00505505|Active Comparator|B|Insulin infusion rate titrated to maintain glycemia between 80 and 220 mg/dl
3294889|NCT00505492|Experimental|Radiation + Chemotherapy|Radiation with weekly Cisplatin 40 mg/m^2 intravenously (IV) Followed by Carboplatin (AUC 5 IV)/Paclitaxel (135 mg/m^2 IV) Chemotherapy every 28 days
3294890|NCT00505466||Pre-Test Genetic Counseling + Genetic Sample|
3294891|NCT00505440|Experimental|Computerized screening and referral|Computerized screening and referral: Intervention is a web-based screening and assessment tool completed by adolescents during primary care visits. Patient reported screening provided to primary care physicians in real time with recommendations for behavioral referrals.
3294892|NCT00505440|Active Comparator|Delayed feedback from screening|Active comparator is Usual pediatric care plus mailed screening results from computerized waiting room screens that arrive three days after screening.
3294893|NCT00505414|Placebo Comparator|Matching Placebo|Oral Tapentadol 100 mg to 250 mg twice daily. Followed by matching placebo in the maintenance (i.e. randomized withdrawal phase).
3294894|NCT00505414|Active Comparator|Morphine Controlled Release|Oral Morphine 45 mg to 90 mg twice daily.
3294895|NCT00505414|Experimental|Tapentadol Extended Release|Oral Tapentadol 100 mg to 250 mg twice daily.
3294896|NCT00505401|Other|A|Subjects were immunized subcutaneously with Tat, 3 dosage groups (7.5, 15 or 30 microgrammi), in association with Alum as adjuvant, or with Saline + Alum, as placebo.
3294897|NCT00505401|Other|B|Subjects were immunized intradermally with Tat, 3 dosage groups (7.5, 15 or 30 microgrammi), or with Saline, as placebo.
3294898|NCT00505375|Experimental|1|Intravenous infusions of CTLA-4 Ig
3294899|NCT00505375|Placebo Comparator|2|Intravenous infusions of placebo
3294900|NCT00505362|Active Comparator|Rectus muscle closure|Two-layer uterine closure, peritoneal closure, fascial and skin closure and reapproximation of the rectus muscles with three-interrupted sutures.
3294901|NCT00505362|No Intervention|Rectus muscle non-closure|Two-layer uterine closure, peritoneal closure, fascial and skin closure, and rectus muscles non-closure.
3294902|NCT00505349|No Intervention|No Intervention Arm|Phase I in this study will involve the evaluation of blood-derived neurotrophic factors in healthy, younger adults (18-30.) Individuals in this group will not undergo computerized, cognitive training.
3294903|NCT00505349|Experimental|Cognitive Training|Phase II of this study will involve an evaluation of the pre- and post- cognitive training levels of blood-derived neurotrophic factors in healthy, mature adults. Participants randomized to this arm will receive SAAGE-based computerized cognitive training.
3294904|NCT00505336|Experimental|1|Eplerenone
3294905|NCT00505336|Active Comparator|3|no additional treatment
3294906|NCT00505336|Experimental|2|Atorvastatin
3294907|NCT00505310|Experimental|Emotional Expression Writing|20 minutes of writing on different topics at four different times. Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
3294908|NCT00505310|Experimental|Neutral Writing|20 minutes of writing on different topics at four different times. Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
3294909|NCT00505297|Case|A|Subjects with potentiall rapidl progressing OA
3294910|NCT00505297|Control|B|Age-matched healthy subjects with no knee pain
3294911|NCT00505284|Placebo Comparator|Placebo|
3294912|NCT00505284|Active Comparator|Perampanel 2mg|
3294913|NCT00505284|Active Comparator|Perampanel 4mg|
3294914|NCT00505284|Active Comparator|Perampanel 6mg|
3294915|NCT00505284|Active Comparator|Perampanel 8mg|
3294916|NCT00505271|Experimental|1|Escalating doses of Rexin-G will be given two or three times a week for four weeks, with a 2 week rest period
3294917|NCT00505245||MDASI Validation|Surveys taking about 20 minutes to complete; collected at multiple time points for some patient populations.
3294918|NCT00505232|Experimental|Rituximab-HCVAD,Methotrexate/Cytarabine and Zevalin|Induction Treatment (Rituximab-HCVAD and Methotrexate/Cytarabine) followed by Consolidation Treatment (Rituximab and Y-90 Ibritumomab tiuxetan)
3294919|NCT00505219|Experimental|Ixmyelocel-T|The Treatment arm of the study will receive study cellular product.
3294920|NCT00505219|Active Comparator|Standard of Care Only|The Control arm of the study will receive standard of care therapy only.
3294921|NCT00505167|Active Comparator|1|Patients randomized to receive memantine
3294922|NCT00505167|Active Comparator|2|Patients randomized to receive donepezil
3294923|NCT00505154|Placebo Comparator|2|Placebo tablets
3294924|NCT00505154|Active Comparator|1|rosuvastatin
3294925|NCT00505128|Other|1|to test the interest of early bile duct decompression by endoscopic sphincterotomy after early non invasive diagnosis by endosonography or MR cholangiography
3294926|NCT00505102|Active Comparator|A|
3294927|NCT00505089|Experimental|1|ACZ885 10mg/kg subcutaneous
3294928|NCT00505089|Experimental|2|ACZ885 5mg/kg intravenous
3294929|NCT00505089|Experimental|3|ACZ885 2mg/kg subcutaneous
3294930|NCT00505089|Experimental|4|ACZ885 1mg/kg intravenous
3294931|NCT00505076|Experimental|MK-0777 8 mg|MK-0777 8 mg tablet by mouth twice daily for 4 weeks
3294932|NCT00505076|Experimental|MK-0777 3 mg|MK-0777 3 mg tablet by mouth twice daily for 4 weeks
3294933|NCT00505076|Placebo Comparator|Placebo|Placebo tablet by mouth twice daily for 4 weeks
3294934|NCT00505063|Other|A|Immunization Schedule patients <7 years.
3294935|NCT00505063|Other|B|Immunization Schedule patients > or = to 7 years and <11 years of age
3294936|NCT00505063|Other|C|Immunization Schedule patients > or = to 11 years of age
3294937|NCT00505050|No Intervention|1|Standard follow-up medical visits and treatment for control group were performed during the study period by the same cardiologist team that was not informed of the randomization.
3294938|NCT00505037|Experimental|ASP1585 dose #1|
3294939|NCT00505037|Experimental|ASP1585 dose #2|
3294940|NCT00505037|Experimental|ASP1585 dose #3|
3294941|NCT00505037|Placebo Comparator|Placebo|
3294942|NCT00505037|Active Comparator|Sevelamer hydrochloride|
3294945|NCT00504998|Experimental|1|Dose Level 1 of escalating doses of Rexin-G i.v.
3294946|NCT00504998|Experimental|2|Dose Level 2 of escalating doses of Rexin-G i.v.
3294947|NCT00504998|Experimental|3|Dose Level 3 of escalating doses of Rexin-G i.v.
3294948|NCT00504998|Experimental|4|Dose Level 4 of escalating doses of Rexin-G i.v.
3294949|NCT00504998|Experimental|5|Dose Level 5 of escalating doses of Rexin-G i.v.
3294950|NCT00504985||Fatigue in Emergency Center Patients|
3294951|NCT00504972|Experimental|Study Treatment|This study is a single arm study
3294952|NCT00504959|Experimental|1|ranibizumab
3294953|NCT00504946|Active Comparator|I|
3294954|NCT00504946|Active Comparator|II|
3294955|NCT00504946|Placebo Comparator|III|
3294956|NCT00504946|Active Comparator|A|
3294957|NCT00504946|Placebo Comparator|B|
3294958|NCT00504933|Experimental|A|Bilastine
3294959|NCT00504933|Active Comparator|B|Cetirizine
3294960|NCT00504933|Placebo Comparator|C|Placebo
3294961|NCT00504920||Symptom Assessment|Drawing blood samples and matching the test results with questionnaire responses for symptoms patients experience from transplant treatment.
3294962|NCT00504907|Experimental|Cohort A|Placebo or BTA9881 -10mg
3294963|NCT00504907|Experimental|Cohort B|Placebo or BTA9881 - 10mg
3294964|NCT00504907|Experimental|Cohort C|Placebo or BTA9881 - 25mg
3294965|NCT00504907|Experimental|Cohort D|Placebo or BTA9881 - 50mg
3294966|NCT00504907|Experimental|Cohort E|Placebo or BTA9881 - 100mg
3294967|NCT00504907|Experimental|Cohort F|Placebo or BTA9881 - 200mg
3294968|NCT00504907|Experimental|Cohort G|Placebo or BTA9881 - 400mg
3294969|NCT00504894|Placebo Comparator|Placebo|Placebo given in low dose to gauge subject's responses to visual stimuli.
3294970|NCT00504894|Active Comparator|Propofol|Propofol give at 0.90 μgml−1 to gauge subject's responses to visual stimuli.
3294971|NCT00504881|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
3294972|NCT00504881|Experimental|Brivaracetam|A flexible dose of Brivaracetam tablets, administered twice a day, starting with a dose of 20 mg/day and could increase to 50 mg/day, 100 mg/day or 150 mg/day
3294973|NCT00504855|Active Comparator|Gortex (Waterproof) Cast Padding|Randomized application of one of two cast padding materials
3294974|NCT00504855|Active Comparator|Cotton/Cotton-Poly Cast Padding|Randomized application of one of two cast padding materials
3294975|NCT00504829|Experimental|1|LCP-AtorFen
3294976|NCT00504829|Active Comparator|2|atorvastatin
3294977|NCT00504829|Active Comparator|3|fenofibrate
3294978|NCT00504816|Other|Brevicon|Oral contraceptive used to determine pharmacokinetics when given with GSK189075 to look for interaction.
3294979|NCT00504816|Experimental|GSK189075|Given in conjunction with Brevicon to see if GSK189075 interfered with Brevicon drug levels.
3294980|NCT00504803|Experimental|1|MSC co-infusion with either HLA-mismatched PBSC or cord blood
3294981|NCT00504790|Experimental|GSK923295|anti-mitotic compound under study
3294982|NCT00504777|Experimental|1|
3294983|NCT00504751|Experimental|Study Treatment|This is a single arm study
3294984|NCT00504725|Experimental|Ketamine|Single bolus 0.5mg/kg ketamine IV after induction of anesthesia
3294985|NCT00504725|Placebo Comparator|Placebo|0.9 % saline bolus of equivalent volume
3294986|NCT00504712|Experimental|ACTIVE|Testosterone 200 mg intramuscular every 2 weeks
3294987|NCT00504712|Placebo Comparator|PLACEBO|
3294988|NCT00504699|Experimental|letrozole|ovarian stimulation after breast cancer diagnosis and before breast cancer treatment
3294989|NCT00504699|No Intervention|control|No ovarian stimulation before breast cancer treatment
3294990|NCT00504686|Active Comparator|1|manual therapy - thoracic spine thrust manipulation
3294991|NCT00504686|Active Comparator|2|therapeutic exercise
3294992|NCT00504660|Active Comparator|1: Anaplastic Tumors|Anaplastic Tumors - 6-TG 80 mg/m^2 orally (PO) every 6 hours Day 1-3; Temozolomide 150 mg/m^2 PO daily Days 4-8, after 6 day rest Capecitabine 825 mg/m^2 and Celebrex 400 mg PO every 12 hours Day 14-27 for 28 day course.
3294993|NCT00504660|Active Comparator|2: Anaplastic Tumors|"Anaplastic Tumors - 6-TG 80 mg/m^2 PO every 6 hours Day 1-3, Lomustine 100 mg/m^2 PO on Day 4; Capecitabine 825 mg/m^2 PO every 12 hours Days 11-24, and Celebrex 400 mg PO every 12 hours Days 11-24.~Participants if previously received Temozolomide but not Lomustine (CCNU) will receive Lomustine; or if had Gliadel wafers and Temozolomide with radiotherapy (XRT) will receive Temozolomide."
3294994|NCT00504660|Active Comparator|3: Glioblastoma Multiforme|"Glioblastoma Multiforme - 6-TG 80 mg/m^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle.~Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide."
3294995|NCT00504634|Experimental|Bortezomib|1 mg/m^2 intravenous (IV) Days 1, 4, 8, and 11.
3294996|NCT00504621||sarcoidosis|Sarcoidosis known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009
3294997|NCT00504621||pulmonary fibrosis|Idiopathic pulmonary fibrosis (IPF) patients known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009
3294998|NCT00504595|Experimental|ACZ885|"Healthy Volunteers: Single administration of 600 mg of ACZ885 (Canakinumab) Intravenous (IV) on Day 1.~Rheumatoid Arthritis (RA) Patients: Dose of 600 mg of ACZ885 (Canakinumab) Intravenous (IV) on Day 1, Day 15, and Day 43."
3294999|NCT00504595|Placebo Comparator|Placebo|"Healthy Volunteers: Single administration of 600 mg of Placebo Intravenous (IV) on Day 1.~Rheumatoid Arthritis (RA) Patients: Dose of 600 mg of Placebo Intravenous (IV) on Day 1, Day 15, and Day 43."
3295000|NCT00504582|Experimental|Fibrin Sealant|Tisseel applied externally to the dissected axillary area.
3295001|NCT00504582|No Intervention|No Fibrin Sealant|
3295002|NCT00504556|Experimental|1|DU-176b 30mg tablet once daily
3295003|NCT00504556|Experimental|2|DU-176b 60mg once daily
3295004|NCT00504556|Experimental|3|DU-176b 30mg b.i.d.
3295005|NCT00504556|Experimental|4|DU-176b 60mg tablets two times a day
3295006|NCT00504556|Active Comparator|5|warfarin tablets
3295007|NCT00504543|Active Comparator|Neoral|
3295008|NCT00504543|Active Comparator|AEB071 high dose with Cetican reduced dose|
3295009|NCT00504543|Active Comparator|AEB071 low dose with Cetican standard dose|
3295010|NCT00504504|Experimental|Rituximab + ABVD Chemotherapy|Rituximab 375 mg/m^2 by vein (IV) over 3 to 8 hours weekly for 6 weeks in a row. ABVD Chemo: Adriamycin 25 mg/m^2 IV, Bleomycin 10 U/m^2 IV, Vinblastine 6 mg/m^2 IV, DTIC 375 mg/m^2 IV. Each but Rituximab over 3 hours every other week for a total of 12 treatments.
3295011|NCT00504491|Experimental|1|"Four Rituximab - CHOP courses will be given The courses will be given every 21 days Drug Dose Day Rituximab (Mabthera) 500mg/m2 1(*) (**) Cyclophosphamide 750mg/m2 1 Adriamycin 50mg/m2 1 Vincristine 1,4 mg/m2 1 Prednisone 60mg/m2 1 to 5~(**) 1st course, 375 mg/m2 (*) If lymphocyte count is > 30 X 10 9/l, dose will be split up in two, which will be given in days 0 and 1"
3295012|NCT00504478|Experimental|1|8-weeks of high complex carbohydrate diet
3295013|NCT00504478|Experimental|2|omega-3 fatty acids supplements
3295014|NCT00504439|Experimental|Cohort 1|Subjects in Cohort 1 will receive 20 milligrams (mg) of SB-656933-AAA once daily or matching placebo once daily for 14 days.
3295015|NCT00504439|Experimental|Cohort 2|Subjects will be administered 40 mg simvastatin on day 1 followed by a washout period of two days. From day 3, the subjects will receive 50 mg of SB-656933-AAA once daily or matching placebo once daily for 14 days. On day 17, subjects will be administered 40 mg simvastatin along with SB-656933-AAA to assess statin interaction.
3295016|NCT00504439|Experimental|Cohort 3|Subjects will be administered 100 mg SB-656933-AAA/ day or matching placebo for 14 days. Dosing will initiate after cohort I and II have completed dosing.
3295017|NCT00504426|Placebo Comparator|1|
3295018|NCT00504426|Active Comparator|2|
3295019|NCT00504426|Active Comparator|3|
3295020|NCT00504426|Active Comparator|4|
3295021|NCT00504400|Experimental|A|
3295022|NCT00504387||A: Patients|Patients with a primary burning mouth disorder Pain (VAS 0-10): 3<x<9 Patient understands and speaks german Age: >18 years
3295023|NCT00504387||B: Controls|Age and sex matched persons/patients who do not have any history of an oral burning sensation or a burning mouth disorder.
3295024|NCT00504374||Symptoms Questionnaire|Patients with lung cancer.
3295025|NCT00504361||1: Lung Disease|Individuals with at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) patients with diseases of organs with known association with lung disease; and (7) individuals suspected of history of lung diseased based on history and/or physical examination
3295026|NCT00504361||2: Normal Control|Individuals without a history of lung disease.
3295027|NCT00504348|Experimental|Prospective investigation group|Tacrolimus treatment is to be initiated at the starting dose of 0.075mg/kg/day, adjusted to maintain its whole blood trough levels between 5 and 10 ng/mL for 52 weeks. All patients are to receive glucocorticoids with the starting doses equivalent to between 0.6 and 1.0 mg/kg/day of prednisolone which are to be continued for the first 28 days after which be subsequently tapered according to a predefined guideline. Up to two courses of pulse intravenous glucocorticoid therapy are allowed during that period.
3295028|NCT00504335|Experimental|500 BIO 300 capsule|The first cohort will receive one 500 BIO 300 capsule and pharmacokinetic blood sampling will be conducted over the first 4 days in an outpatient setting
3295029|NCT00504335|Experimental|1000 BIO 300 capsule|the second cohort will be treated with 1000 mg BIO 300 using the same PK sampling program
3295030|NCT00504335|Experimental|1500 BIO 300 capsule|the third cohort will be treated with 1500 mg BIO 300using the same PK sampling program
3295031|NCT00504335|Experimental|2000 BIO 300 capsule|the forth cohort will be treated with 2000 mg BIO 300using the same PK sampling program
3295032|NCT00504322|Placebo Comparator|placebo|The placebo will be the salt water-sugar solution used as a vehicle for the vector.
3295033|NCT00504322|Active Comparator|AdcuCD40L|Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
3295034|NCT00504309|Experimental|4g P-OM3, then 1g P-OM3, then Placebo|4 g/day Dose Prescription Omega-3 acid ethyl esters (P-OM3)capsules(4) for first intervention (8 weeks), followed by 1g/day P-OM3 capsules(4) for 2nd intervention (8 weeks), followed by Placebo corn oil capsules, 4/day, for the 3rd intervention (8 weeks).
3295035|NCT00504309|Experimental|1g P-OM3, then 4g P-OM3, then Placebo|1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks,followed by 6-wk washout. Placebo capsules for 8-wks.
3295036|NCT00504309|Experimental|Placebo, then 4g P-OM3, then 1g P-OM3|Corn Oil placebo capsules for 8-wks, followed by 6-wk washout. 4g P-OM3 capsules for 8-wks, followed by 6-wk washout. 1g P-OM3 for 8-wks.
3295037|NCT00504309|Experimental|4g P-OM3, then Placebo, then 1g P-OM3|4g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 1g capsules for 8 wks.
3295038|NCT00504309|Experimental|1g P-OM3, then Placebo, then 4g P-OM3|1g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
3295039|NCT00504309|Experimental|Placebo, then 1g P-OM3, then 4g P-OM3|Corn oil placebo capsules for 8-wks, followed by 6-wk washout.1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
3295040|NCT00504270|Placebo Comparator|Placebo|po daily
3295041|NCT00504270|Experimental|RG3421 120mg|120mg po daily
3295042|NCT00504270|Experimental|RG3421 20mg|20mg po daily
3295131|NCT00503269|Active Comparator|1|30 ml of 1% Lignocaine with 1:10,000 Adrenaline
3295043|NCT00504257|Experimental|Avastin and Docetaxel|Combination Therapy: Immunotherapy (Avastin) and Chemotherapy (Docetaxel) as outlined in Intervention descriptions. Avastin: 15 mg/kg, In 100 ml normal saline (NS) IV infusion over 90 +/- 15 minutes, Day 1, every 21 day cycle. Docetaxel: 40 mg/m^2, In 250 ml 5% dextrose in pure water (D5W) or NS IV infusion over 1 hour in a non-pvc container and through a polyethylene-lined set, Day 1, 8, every 21 day cycle. Response assessment every 3 cycles (9 weeks).
3295044|NCT00504231|Experimental|0.3 mL Influenza Vaccine ID|60% dose - 0.3 mL delivered intradermally with needle and syringe
3295045|NCT00504231|Experimental|0.15 mL twice Influenza Vaccine ID|60% dose - 0.15 mL delivered twice intradermally with needle and syringe
3295046|NCT00504231|Active Comparator|0.5 mL Influenza Vaccine by IM|100% dose - 0.5mL delivered intramuscularly with needle and syringe
3295047|NCT00504231|Experimental|0.3 mL Influenza Vaccine IM|60% dose - 0.3 mL delivered intramuscularly with needle and syringe
3295048|NCT00504166|Active Comparator|alendronate sodium|alendronate sodium 70 mg tablet once a week for 24 months
3295049|NCT00504166|Placebo Comparator|placebo|placebo to match alendronate sodium
3295050|NCT00504153|Experimental|Treatment (tyrosine Kinase Inhibitor)|Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3295051|NCT00504140|Experimental|Interferon Alpha + Etoposide|Interferon Alpha 5x10^6 mu/m^2 subcutaneously and Etoposide 100 mg/m^2 intravenously, both daily for 5 days
3295052|NCT00504127|Experimental|naproxcinod 375 mg bid|
3295053|NCT00504127|Experimental|naproxcinod 750 mg bid|
3295054|NCT00504127|Active Comparator|naproxen 500 mg bid|
3295055|NCT00504127|Placebo Comparator|placebo|
3295056|NCT00504114||1|Healthy volunteers without knee pain.
3295057|NCT00504114||2|Patients with mild arthritic symptoms and radiographic changes (Kellgren Lawrence score of 1, 2)
3295058|NCT00504114||3|Patients with severe pain and functional limitations associated with knee arthritis (Kellgren Lawrence score of 3, 4).
3295059|NCT00504114||4|Patients with acute anterior cruciate ligament (ACL) injuries with associated osseous contusion.
3295060|NCT00504114||5|Patients with posttraumatic knee injury or degenerative condition and will have cartilage resurfacing procedures.
3295061|NCT00504075|Experimental|Gammaplex (intravenous immunoglobulin)|
3295062|NCT00504036|Experimental|Intra-gastric balloon|Patients will receive either an air-filled or water-filled intra-gastric balloon.
3295063|NCT00504036|No Intervention|Usual care|Usual care will be given to the patients.
3295064|NCT00504023|Experimental|imiquimod|This is a pilot study of the use of a topical immunomodulatory agent, imiquimod, for the treatment of recurrent Extramammary Paget's disease (EMPD).
3295065|NCT00504010|Active Comparator|1|arnica containing cream
3295066|NCT00504010|Placebo Comparator|2|carrier cream without arnica
3295067|NCT00503997|Experimental|drug therapy|
3295068|NCT00503984|Experimental|Phase 1 - Aza + Doc|Phase 1 Azacitidine (Aza) and Docetaxel (Doc) with dose escalation/de-escalation design, and Prednisone, with growth factor support; GADD45α methylation and expression analysis, with optional growth factor support (pegfilgrastim/filgrastim).
3295069|NCT00503984|Experimental|Phase 2 - Aza + Doc RPTD|Recommended Phase Two Dose (RPTD) of Azacitidine and Docetaxel; and Prednisone; with optional growth factor support (pegfilgrastim/filgrastim).
3295070|NCT00503971|Experimental|Vorinostat plus erlotinib|Vorinostat plus erlotinib
3295071|NCT00503932|Experimental|Proton Therapy + Capecitabine|Capecitabine 825 mg/m^2 by mouth twice daily on Proton Therapy (radiation) days.
3295072|NCT00503919|Experimental|MDC|Multi-spectral Digital Colposcopy for Fluorescence Spectroscopy
3295073|NCT00503906|Experimental|Abraxane, Avastin and Gemcitabine|"Each treatment cycle is 28 days. Participants will be treated until disease progression:~Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;~Abraxane: 150 mg/m2 IV over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;~Avastin: 10 mg/kg IV on days 1 and 15 of each cycle."
3295074|NCT00503893||Wilm's Tumor PO1|Familial and Sporadic Wilm's tumor, genitourinary anomalies, Beckwith-Wiedemann hemihypertrophy and/or aniridia.
3295075|NCT00503880|Experimental|Treatment|G-CSF 300 μg subcutaneously to begin one day prior to treatment and continued until ANC greater than 1.0 or recovers back to the patients baseline ANC for 3 days in a row subsequent to completion of chemotherapy (SOC) Low-dose Cytarabine 10 mg/m2 subcutaneously daily starting on day 1 for the first 5 consecutive days of the treatment course 2-4 hours following the end of the clofarabine infusion. (SOC) Clofarabine starting at dose level 0. Dose-10 mg/m2 IV over 1 hour daily starting on day 1 for the first 5 consecutive days of the treatment course The G-CSF and cytarabine doses are fixed. The dose of clofarabine is initially fixed. For the subsequent cohort, the dose of clofarabine will be advanced to the next dose level.
3295076|NCT00503854||Fatigue and Fever Assessment|
3295077|NCT00503841|Experimental|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
3295078|NCT00503828|Active Comparator|naproxen|Naproxen 500 mg/day for 4 weeks
3295079|NCT00503828|Experimental|Derris Scandens Benth|Derris Scandens Benth
3295080|NCT00503802|Active Comparator|1|Active RF treatment
3295081|NCT00503802|Sham Comparator|2|Sham RF treatment
3295082|NCT00503789|Active Comparator|1|cow-milk based infant formula
3295083|NCT00503789|Experimental|2|cow milk based infant formula with prebiotics
3295084|NCT00503789|Other|3|human milk reference group
3295085|NCT00503776|Active Comparator|Arm IA|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
3295086|NCT00503776|Active Comparator|Arm IB|Patients undergo SNT and low weight resistance training (LWRT).
3295087|NCT00503776|Experimental|Arm IIA|Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.
3295088|NCT00503776|Experimental|Arm IIB|Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.
3295089|NCT00503750|Active Comparator|Trastuzumab and Abraxane followed Trastuzumab and Vinorelbine|Patients will be treated sequentially with preoperative trastuzumab and dose-dense ABI-007 followed by trastuzumab in combination with vinorelbine. Trastuzumab will be administered as a one-time loading dose of 4 mg/kg as a 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as a 30 minute infusion. ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8). Growth factor support with pegfilgrastim (Neulasta®) is required 24 to 48 hours following completion of each cycle of ABI-007. Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20). As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52.
3295090|NCT00503737|Active Comparator|Colorectal Cancer Screening Toolkit|Toolbox includes tools and guides designed increase screening by primary care physicians
3295091|NCT00503737|No Intervention|Standard of Care Colorectal Cancer Screening|Primary Care physician will screen for colorectal cancer as per his/her standard practice
3295092|NCT00503711|Experimental|100 mg Vandetanib eod|100 mg Vandetanib every other day dosing
3295093|NCT00503711|Experimental|100 mg Vandetanib od|100 mg Vandetanib once daily dosing
3295094|NCT00503711|Experimental|300 mg Vandetanib od|300 mg Vandetanib once daily dosing
3295095|NCT00503698|Experimental|Somatropin|Somatropin once daily from week 0 to end of trial
3295096|NCT00503698|Placebo Comparator|Placebo|Placebo once daily to end of trial
3295097|NCT00503685|Experimental|IMC-A12|Administered every 2 weeks
3295098|NCT00503685|Experimental|IMC-A12 + cetuximab|Administered every 2 weeks
3295099|NCT00503685|Experimental|IMC-A12 + cetuximab [Kirsten rat sarcoma (K-ras) wild-type]|Participants who have experienced confirmed partial response (PR) or stable disease (SD) ≥ 24 weeks on a prior anti-EGFR-containing therapy followed by disease progression are enrolled in this arm.
3295100|NCT00503659|Active Comparator|A|Methacholine challenge, five-breath dosimeter protocol
3295101|NCT00503659|Active Comparator|B|Methacholine challenge five incremental dosages protocol
3295102|NCT00503594|Experimental|1|Comparative evaluation of the efficiency of a new protocol of the primitive LYMPHOME of the central nervous system ( LPSNC) to the old subject, associating Methotrexate and Temozolomide with regard to a standard protocol associating Methotrexate, Procarbazine, Vincristine and Cytarabine.
3295103|NCT00503594|Active Comparator|bras conventional|bras conventional
3295104|NCT00503581|Experimental|Regimen 1 (megestrol acetate, surgery)|Patients receive oral megestrol twice daily every day for 24 weeks. Approximately twelve weeks after treatment starts, clinical blood tests are obtained and research serum and plasma collected. Twenty-four weeks constitutes one course of treatment and a pill count is performed during the 12-week f/u visit and at the completion of the treatment course to determine compliance. After progestin therapy the patient has an induced-withdrawal bleed. Patients in this arm undergo a re-evaluation biopsy and hysterectomy a minimum of two weeks and a maximum of eight weeks after completing the megestrol treatment.
3295105|NCT00503581|Experimental|Regimen 2 (megestrol acetate, surgery)|Patients receive oral megestrol twice daily for two weeks continuously followed by no treatment for two weeks. This course is repeated for a total of 24 weeks. Approximately twelve weeks after treatment starts, clinical blood tests are obtained and research serum and plasma collected. Twenty-four weeks constitutes one course of treatment and a pill count is performed during the 12-week f/u visit and at the completion of the treatment course to determine compliance. After progestin therapy the patient has an induced-withdrawal bleed. Patients in this arm undergo a re-evaluation biopsy and hysterectomy a minimum of two weeks and a maximum of eight weeks after the megestrol treatment.
3295106|NCT00503581|Active Comparator|Regimen 3 (surgery/biopsy)|(Closed as of 6/3/2010) Patients do not receive megestrol. At the discretion of the managing physician, patients undergo the re-evaluation biopsy and hysterectomy anytime between 2-20 weeks after enrollment and randomization.
3295107|NCT00503568|Experimental|DS-1: gp96-ig Dose Schedule 1|Dose Schedule 1 (DS-1): Ad100-gp96Ig-HLA A1 Vaccine 4x10^7 cells bi-weekly, maximum 9 vaccines/patient;
3295108|NCT00503568|Experimental|DS-2: gp96-ig Dose Schedule 3|Dose Schedule 2 (DS-2): Ad100-gp96Ig-HLA A1 Vaccine 2X10^7 cells weekly, maximum 18 vaccines/patient;
3295109|NCT00503568|Experimental|DS-3: gp96-ig Dose Schedule 3|Dose Schedule 3 (DS-3): Ad100-gp96Ig-HLA A1 Vaccine 1x10^7 cells twice weekly, maximum 36 vaccines/patient
3295110|NCT00503542|Experimental|Intervention|Patients primarily with itching or irritation are treated for candidal vaginitis. Patients primarily with vaginal odor are treated for bacterial vaginosis. Patients who did not fit either of the previous groups are treated for both candidal vaginitis and bacterial vaginosis.
3295111|NCT00503542|Active Comparator|Control|Patient are examined and a wet mount is prepared. If a definitive diagnosis is made patient is treated for the condition diagnosed. If no diagnosis is made the clinician has the option of either foregoing treatment (watchful waiting) or following the protocol in the experimental group
3295112|NCT00503516|Experimental|1|Megestrol acetate 160 mg b.i.d. during 24 weeks
3295113|NCT00503516|Placebo Comparator|2|1 sachet of powder of placebo b.i.d. during 24 weeks
3295114|NCT00503490|Experimental|1|Inhaled Levofloxacin
3295115|NCT00503490|Placebo Comparator|2|Placebo
3295116|NCT00503451|Experimental|LBH589|
3295117|NCT00503438|Other|Salto Talaris Ankle|This is an Implant Registry of the approved Salto Talaris Ankle replacement device
3295118|NCT00503425|Experimental|1|
3295119|NCT00503399|Experimental|Teriparatide|Teriparatide 20 microgram (µg) subcutaneous (sc) injection once daily (QD).
3295120|NCT00503399|Active Comparator|Risedronate|Risedronate 35 milligrams (mg) oral (po) tablet once weekly (QW)
3295121|NCT00503347|Experimental|1|0.3 mg/kg
3295122|NCT00503347|Experimental|2|1 mg/kg
3295123|NCT00503347|Experimental|3|3 mg/kg
3295124|NCT00503347|Experimental|4|6 mg/kg
3295125|NCT00503334|Experimental|preOP booster|
3295126|NCT00503334|Placebo Comparator|preOP booster placebo|
3295127|NCT00503321|Experimental|Arm B|S-1 plus PSK group
3295128|NCT00503321|Active Comparator|Arm A|S-1 alone
3295129|NCT00503308|Experimental|Abbreviated Consenting|
3295130|NCT00503308|No Intervention|Standard Consenting|
3295132|NCT00503269|Active Comparator|2|Standard General anaesthesia with Enflurane and Propofol.
3295133|NCT00503256||CLL - Linkage Families|Gene identification related to Chronic lymphocytic leukemia (CLL) development
3295134|NCT00503230|Active Comparator|Standard Care Intervention (SCI)|
3295135|NCT00503230|Active Comparator|Culturally Tailored Intervention (CTI)|
3295136|NCT00503204|Experimental|1|Lomustine + Cediranib (AZD2171)
3295137|NCT00503191|Experimental|Intention-based therapy treatment for autism|NeuroModulation Technique
3295138|NCT00503178|Experimental|Patients undergoing imaging guided radiotherapy.|
3295139|NCT00503152|Experimental|benazepril|
3295140|NCT00503152|Experimental|valsartan|
3295141|NCT00503152|Experimental|benazepril/valsartan|
3295142|NCT00503113|Experimental|1|
3295143|NCT00503113|Experimental|2|
3295144|NCT00503113|Active Comparator|3|
3295145|NCT00503100||NICU full-term early pain group|
3295146|NCT00503100||NICU premature early pain group|
3295147|NCT00503100||NICU premature control group|
3295148|NCT00503100||Soroka- full-term control group|
3295149|NCT00503074|Experimental|1|Parents receive tailored health-behavior change messages designed to reduce their child's exposure to televised food commercials. Intervention is delivered by a case manager, by a website, and by periodic newsletters.
3295150|NCT00503074|Active Comparator|Control|Parents of children ages 2-5 receive behavioral-change counseling around toddler & preschooler safety and injury prevention.
3295151|NCT00503048||1|foster care children
3295152|NCT00503048||2|reference children (living with families)
3295153|NCT00503035|Experimental|Celecoxib|Celecoxib 400 mg orally twice daily for 6 months. Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure.
3295154|NCT00503009|Active Comparator|Arm 1|
3295155|NCT00503009|Active Comparator|Arm 2|
3295156|NCT00503009|Placebo Comparator|Arm 3|
3295157|NCT00502996|Experimental|Rituximab|Eligible participants receiving Rituximab (MabThera/Rituxan) 1 gram/dose (g/dose) intravenously (IV) on Day 1 and Day 15 followed by previous pre-medication (methylprednisolone 100 mg IV, antihistamine and antipyretic) and concomitant treatment of Methotrexate at least 15 mg per oris (PO) weekly were observed during the study period of 24 weeks. After treatment completion, participants were followed-up for safety up to 24 weeks.
3295158|NCT00502983||Interview|AML Patients & Healthy Controls
3295159|NCT00502970|Experimental|1|16 weeks Interferon Tiw with Ribavirin
3295160|NCT00502970|Active Comparator|2|24 weeks Interferon Tiw with Ribavirin
3295161|NCT00502944|Experimental|Counselor-based HIV screening|
3295162|NCT00502944|Active Comparator|Emergency staff member-based HIV screening|
3295163|NCT00502918||1|
3295164|NCT00502905|Experimental|Busulfan + Fludarabine|Once a day for four days, Busulfan 130 mg/m^2 through intravenous catheter over 3 hours immediately after Fludarabine 40 mg/m^2 over 1 hour.
3295165|NCT00502892|Experimental|Topotecan + Ifosfamide + Carboplatin|
3295166|NCT00502866||breastfed children|children, 6-15 months old, predominately breastfed for at least 6 months without supplemental vitamin D
3295167|NCT00502853|Experimental|1|
3295168|NCT00502840|Experimental|1|
3295169|NCT00502827|Other|Recommended Standard of Care|Recommended Standard of Care (RSOC) = Physician Advice + Written Materials
3295170|NCT00502827|Other|RSOC + Cell Phone Intervention|Recommended Standard of Care (RSOC) + Cell Phone Intervention
3295171|NCT00502814||1|Patients with Breast Cancer.
3295172|NCT00502801|Experimental|Doripenem|1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
3295173|NCT00502749|Experimental|Exercise program|Daily (Monday-Friday) 45-minute group physical exercise program during each hospital admission for three months or individual 20 minute session bedside.
3295174|NCT00502736|Experimental|1|
3295175|NCT00502723|Active Comparator|2|Radical laparoscopy prostatectomy
3295176|NCT00502723|Experimental|1|Radical retropubic prostatectomy
3295177|NCT00502710|Experimental|RO4876904 1|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
3295178|NCT00502710|Experimental|RO4876904 2|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
3295179|NCT00502710|Experimental|RO4876904 3|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
3295180|NCT00502710|Experimental|RO4876904 4|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
3295181|NCT00502710|Placebo Comparator|Placebo|Placebo po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
3295182|NCT00502697|Experimental|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic visits. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
3295183|NCT00502697|Other|Conventional prenatal/postpartum care|Women assigned to the control arm of the study received conventional prenatal and postpartum clinic care.
3295184|NCT00502684|Experimental|1|Peri-operative etodolac and propranolol as described in protocol
3295185|NCT00502684|Placebo Comparator|2|peri-operative placebo as described in protocol
3295186|NCT00502671|Experimental|1|
3295187|NCT00502632|Experimental|1|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
3295188|NCT00502632|Placebo Comparator|2|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~25ml normal saline, twice daily for 4 days"
3295920|NCT00494741|Experimental|mycophenolate mofetil|
3295189|NCT00502619|Experimental|Acupuncture plus Treadmill Exercise|Acupuncture plus Treadmill Exercise
3295190|NCT00502606||patients with provisional crowns|the same patient would serve as control and test
3295191|NCT00502593|Experimental|GSK1562902A-A Lot 1 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3295192|NCT00502593|Active Comparator|Fluarix-A 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3295193|NCT00502593|Experimental|GSK1562902A-A Lot 1 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3295194|NCT00502593|Active Comparator|Fluarix-A 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3295195|NCT00502593|Experimental|GSK1562902A-B Lot 2 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 2. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3295196|NCT00502593|Active Comparator|Fluarix-B 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3295197|NCT00502593|Experimental|GSK1562902A-B Lot 2 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 2. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3295198|NCT00502593|Active Comparator|Fluarix-B 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3295199|NCT00502593|Experimental|GSK1562902A-C Lot 3 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 3. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3295200|NCT00502593|Active Comparator|Fluarix-C 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3295201|NCT00502593|Experimental|GSK1562902A-C Lot 3 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 3. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3295202|NCT00502593|Active Comparator|Fluarix-C 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3295203|NCT00502580||1|Patients with lesions of the oral cavity mucosa.
3295204|NCT00502554|No Intervention|1|Observation with standard care (macrolides, exercise, oxygen therapy etc.) alone.
3295205|NCT00502554|Active Comparator|2|2-day cycles of photopheresis every 3 weeks for 3 months
3295206|NCT00502541|Experimental|Fluocinolone acetonide|Fluocinolone acetonide intravitreal implant
3295207|NCT00502541|Active Comparator|Standard of Care|Standard of care
3295208|NCT00502528|Placebo Comparator|1|Placebo
3295209|NCT00502528|Active Comparator|2|BQ-123
3295210|NCT00502515|Experimental|25 mg SSR180575|orally once daily for 24 weeks
3295211|NCT00502515|Experimental|100 mg SSR180575|orally once daily for 24 weeks
3295212|NCT00502515|Placebo Comparator|Placebo|orally once daily for 24 weeks
3295213|NCT00502502||Symptom-Related Cytokines Questionnaire|
3295214|NCT00502411|Experimental|Doxorubicin + Radiation Therapy|Doxorubicin 17.5 mg/m^2 IV bolus infusion, followed by continuous IV infusion on days 1-4. Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
3295215|NCT00502372|Experimental|Enriched product, dietary supplement|Subjects receiving enriched product compared to an unenriched product
3295216|NCT00502372|Active Comparator|1|Subjects not receiving enriched product
3295217|NCT00502320|Experimental|Ramelteon|8 mg
3295218|NCT00502320|Placebo Comparator|Placebo|
3295219|NCT00502307|Experimental|1|Tivozanib (AV-951) administered as a solid dosage form daily for three weeks per month
3295220|NCT00502307|Placebo Comparator|2|solid oral capsule containing excipients dosed daily for three weeks per month
3295221|NCT00502281|Active Comparator|Group A|COS followed by TI
3295222|NCT00502281|Active Comparator|Group B|COS followed by IUI
3295223|NCT00502268|Placebo Comparator|Group 1|Doxercalciferol administration by DOQI and 2nd Gen PTH assay
3295224|NCT00502268|Active Comparator|Group 2|Doxercalciferol administered by 1-84-7-84 ratio between 1.4-1.6
3295225|NCT00502255|Experimental|telemonitoring|Health Buddy in patients home situation
3295226|NCT00502255|Experimental|usual care|patients receive care as usual
3295227|NCT00502242|Active Comparator|A|Capsule - initial treatment is 5 mg (active)- oral - once per day
3295228|NCT00502242|Placebo Comparator|B|Capsule - initial treatment is 5 mg (placebo) - oral - once per day
3295229|NCT00502229|Active Comparator|Group A|Continuing treatment
3295230|NCT00502229|Active Comparator|Group B|Gonadotrophins
3295231|NCT00502216|Experimental|1|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
3295232|NCT00502216|Placebo Comparator|2|Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
3295233|NCT00502203|Experimental|Paclitaxel + Carboplatin|Paclitaxel 175 mg/m^2 intravenously (IV) over 3 hours and Carboplatin AUC 5 IV over 1 hour every 21 Days for 6 courses.
3295234|NCT00502190|Experimental|1|Silicon ring positioned in the vagina, around the cervix
3295235|NCT00502190|Experimental|2|Silicon ring positioned in the vagina, around the cervix
3295236|NCT00502177||Quality of Life Questionnaire|Patients undergoing continuous hyperthermic peritoneal perfusion with cisplatin and their parents/caregivers.
3295237|NCT00502138|Experimental|A|Interventional, continuous pramlintide infusion at 9 micrograms/hr plus 60 microgram meal bolus plus continuous insulin basal-bolus subcutaneous infusion
3295238|NCT00502125||Patients with oral lesions|
3295239|NCT00502112|Experimental|1|lintuzumab and lenalidomide
3295240|NCT00502099|Active Comparator|1|Pegylated interferon alpha 2a plus ribavirin
3295241|NCT00502099|Active Comparator|2|Pegylated interferon alpha 2b plus ribavirin
3295242|NCT00502086|Experimental|I|Viusid, three sachets daily during 96 weeks
3295243|NCT00502086|Placebo Comparator|2|Placebo three sachets daily during 96 weeks
3295244|NCT00502034|Experimental|A-immunotherapy|Immunotherapy with interferon-alpha and interleukin
3295245|NCT00502034|No Intervention|B-follow-up|Wait-and-see
3295246|NCT00502021|Experimental|1|Supplement of flaxseed powder (60 g/day)during 12 weeks
3295247|NCT00502021|Placebo Comparator|2|Placebo powder supplement 60 g/day during 12 weeks
3295248|NCT00502021|Experimental|3|Flaxseed oil 30 ml/day (10 g ALA)during 12 weeks
3295249|NCT00502021|Placebo Comparator|4|Safflower oil 30 ml/day (no ALA) during 12 weeks
3295250|NCT00501995|Experimental|IV Cyclophosphamide (50 mg/kg)|This is an open-labeled single arm study of Cyclophosphamide (50 mg/kg) administered intravenously over 1 hour daily for four consecutive days (200 mg/kg total) through a Hickman catheter .
3295251|NCT00501982|No Intervention|1|N Cpap in delivery room and than rescue curosurf in case of need
3295252|NCT00501982|Experimental|2|Poractant alfa (Curosurf) + N Cpap in delivery room
3295253|NCT00501969|Experimental|Rotigotine|Rotigotine
3295254|NCT00501956|Experimental|Intradialytic parenteral nutrition|Individually compounded intradialytic parenteral nutrition (IDPN) including glucose, amino acids, lipids, L-Carnitine, trace elements and water-soluable vitamins 3x / week over 16 weeks + 12 weeks postinterventional observation.
3295255|NCT00501956|No Intervention|Control Group|Observation over 28 weeks (16 + 12 weeks).
3295256|NCT00501943|Active Comparator|Riluzole|Riluzole + Avonex
3295257|NCT00501943|Placebo Comparator|Placebo|placebo + Avonex
3295258|NCT00501904|Active Comparator|Group A|Short protocol
3295259|NCT00501904|Active Comparator|Group B|Long protocol
3295260|NCT00501891|Experimental|Bevacizumab and Metronomic Temozolomide|Patients will receive up to 12 cycles of bevacizumab (Avastin) and metronomic temozolomide (Temodar), and each cycle is 28 days. Bevacizumab will be administered at 10 mg/kg every other week beginning a minimum of 7 days after a biopsy or 28 days after a craniotomy. Temozolomide will be dosed at 50 mg/m2 daily in a 28-day cycle.
3295261|NCT00501865|Experimental|Sequence AB|Subjects will be randomized to sequence AB, where A represents fasted state and B represents fed state. Subjects will be administered a single oral dose of GW273225 50 milligrams (mg) in the fasted state in dosing period 1. The subjects will receive a single oral dose of GW273225 50 mg immediately after a high fat breakfast in dosing period 2. There will be at least 21 days between doses for the fasted and fed treatment phases of the study.
3295262|NCT00501865|Experimental|Sequence BA|Subjects will be randomized to sequence BA, where A represents fasted state and B represents fed state. Subjects will be orally administered a single dose of GW273225 50 mg immediately after a high fat breakfast in dosing period 1. The subjects will receive a single oral dose of GW273225 50 mg in the fasted state in dosing period 2. There will be at least 21 days between doses for the fed and fasted treatment phases of the study.
3295263|NCT00501852|Experimental|NVA237 12.5 µg|12.5 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
3295264|NCT00501852|Experimental|NVA237 25 µg|25 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
3295265|NCT00501852|Experimental|NVA237 50 µg|50 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
3295266|NCT00501852|Experimental|NVA237 100 µg|100 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
3295267|NCT00501852|Placebo Comparator|Placebo|Placebo via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
3295268|NCT00501852|Active Comparator|Tiotropium 18 µg|18 µg od via Handihaler inhaler. Tiotropium was given open-label. At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
3295269|NCT00501839|Active Comparator|Group A|Cyclic progestogens for nine months
3295270|NCT00501839|Active Comparator|Group B|CC treatment for further three cycles at the same ovulating doses followed by six months of cyclic progestogens
3295271|NCT00501839|Active Comparator|Group C|CC administration at the same ovulating doses for nine cycles
3295272|NCT00501826|Experimental|Hyper-CVAD + Nelarabine|Intensive chemotherapy (hyper-CVAD therapy) includes combination of 7 chemotherapy drugs: Adriamycin (doxorubicin), cyclophosphamide, cytarabine (Ara-C), dexamethasone, methotrexate, nelarabine, and vincristine.
3295273|NCT00501813|Active Comparator|surgery|initial palliative hepatectomy followed by TACE and/or local regional treatment
3295274|NCT00501813|Experimental|no surgery|TACE combined with local regional treatment without hepatectomy
3295275|NCT00501800||Caucasian|
3295276|NCT00501800||African American|
3295277|NCT00501800||Chinese|
3295278|NCT00501800||Latina (Mexican or Central American)|
3295279|NCT00501800||Filipina|
3295280|NCT00501787|Active Comparator|Group B|Non-tailoring
3295281|NCT00501787|Active Comparator|Group A|Tailoring
3295282|NCT00501761||1: Endometrial Cancer Survivors|
3295283|NCT00501761||2: Healthy Participants|Healthy participants that have no history of invasive cancer.
3295284|NCT00501748|Experimental|Rituximab|
3295285|NCT00501696|Other|1|A randomized placebo-controlled, parallel-group study, crossover-design
3295286|NCT00501696|Other|2|A randomized placebo-controlled, parallel-group study, crossover-design
3295287|NCT00501670||Group A|Collection of lesion samples and blood sampling from subjects aged >=50 years with clinically diagnosed herpes zoster
3295288|NCT00501657|Experimental|Sitagliptin (100mg)|Active drug (sitagliptin)
3295289|NCT00501657|Placebo Comparator|Placebo (sugar pill)|Inactive drug (placebo)
3295290|NCT00501644|Experimental|Chemoimmunotherapy|GM-CSF Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy + rIFN-g (Interferon Gamma) 0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle) + Paraplatin (Carboplatin) AUC of 5 by 1 hour IV infusion every 28 days
3295291|NCT00501631|Active Comparator|VIVITROL 380 mg|Administered via intramuscular (IM) injection once every 4 weeks.
3295292|NCT00501631|Placebo Comparator|Placebo for VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
3295293|NCT00501618|Other|Fazaclo|open label switch from generic clozapine to Fazaclo
3295294|NCT00501592|Active Comparator|25 mg INT-747|
3295295|NCT00501592|Active Comparator|50 mg INT-747|
3295296|NCT00501592|Placebo Comparator|Placebo|
3295297|NCT00501540|Experimental|Lithium|Lithium carbonate will be dosed on a flat scale of mg/day and not by weight or body surface area (BSA). Lithium carbonate will be provided as a 300mg tablet and will be taken daily without breaks in treatment.
3295298|NCT00501527|Experimental|A: Biological vaccine|The first active arm will receive a dose that is 10x less than the dose of the other arm
3295299|NCT00501527|Experimental|B: biological vaccine|The first active arm will receive a dose that is 10x more than the dose of the other arm
3295300|NCT00501527|Placebo Comparator|C|
3295301|NCT00501462|Other|Mild renal impairmnent|
3295302|NCT00501462|Other|moderate renal impairment|
3295303|NCT00501462|Other|Normal renal function|
3295304|NCT00501449||Multiple Endocrine Neoplasia (MEN)|Patients with multiple endocrine neoplasia (MEN).
3295305|NCT00501410|Experimental|FOLFOX + Dasatinib + Cetuximab|5-FU 2400 mg/m^2 by vein over 46 Hours On Days 1 & 2. Cetuximab initial dose = 400 mg/m^2 by vein, then 250 mg/m^2 Weekly On Days 1 & 8. Dasatinib 100 mg by mouth daily on days 1-14. Leucovorin 400 mg/m^2 by vein on day 1. Oxaliplatin 85 mg/m^2 by vein on day 1.
3295306|NCT00501371|Active Comparator|MCS|Group A: MCS 30 mg/day for 12 weeks
3295307|NCT00501371|Placebo Comparator|Placebo|Placebo, 2 capsules per day
3295308|NCT00501345|Experimental|Aspirin|
3295309|NCT00501332|Active Comparator|2|
3295310|NCT00501319||1|Patients with Non-Small Cell Lung Cancer.
3295311|NCT00501293|Experimental|1|Methylphenidate Transdermal System
3295312|NCT00501280||MSF Women + their children|Blood and urine samples and interviews of Migrant or seasonal farmworker (MSF) woman + their children
3295313|NCT00501280||Non-MSF Women + their Children|Blood and urine samples and interviews of non-MSF women (women who have never worked in agriculture) and their children
3295314|NCT00501241|Placebo Comparator|1|placebo twice daily
3295315|NCT00501241|Experimental|2|20 mg ATI-7505, BID for 4 weeks
3295316|NCT00501241|Experimental|3|40 mg ATI, BID, 4 weeks
3295317|NCT00501241|Experimental|4|80 mg ATI-4505, BID for 4 weeks
3295318|NCT00501241|Experimental|5|120 mg ATI-7505, BID for 4 weeks
3295319|NCT00501228|Experimental|Filgrastim Injections|
3295320|NCT00501215|Experimental|Parathyroidectomy + Observation|
3295321|NCT00501215|Other|Observation Alone|
3295322|NCT00501202|Placebo Comparator|002|placebo twice daily for 4 weeks
3295323|NCT00501202|Experimental|001|RWJ-333369 (carisbamate) 200 mg tablet twice daily for 4 weeks
3295324|NCT00501189||1|Those getting Gardasil vaccination for low grade Pap abnormality.
3295325|NCT00501189||2|Historical group that did not get Gardasil.
3295326|NCT00501176|Active Comparator|plastic stent|Stent insertion
3295327|NCT00501176|Active Comparator|metalic stent|Stent inserttion
3295328|NCT00501137|Active Comparator|16-26 year olds 3 doses HPV Vaccine|Group 3 - 16-26 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0, 2, 6 mths
3295329|NCT00501137|Active Comparator|3 dose 9-13 HPV Vaccine|Group 2 - 9-13 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0,2,6 mths
3295330|NCT00501137|Active Comparator|2 dose 9-13 yrs HPV Vaccine|Group 1 9-13 year olds 2 doses HPV (Human Papillomavirus) Vaccine at 0 and 6 mths
3295331|NCT00501111|No Intervention|1|Placebo
3295332|NCT00501111|Active Comparator|2|donepezil
3295333|NCT00501111|Experimental|3|AZD3480
3295334|NCT00501098|Experimental|I|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned."
3295335|NCT00501085||LAP-BAND|Patients who receive the LAP-BAND AP Adjustable Gastric Banding System.
3295336|NCT00501072|Experimental|Open|Real-Time Continuous Glucose monitoring System (RT-CGMS) with alarm setting active and ability to view glucose trend profiles
3295337|NCT00501072|No Intervention|Blind|RT-CGMS is applied without alarm setting and without the ability to watch glucose trend profiles
3295338|NCT00501059|Experimental|Acetylsalicylic acid (Aspirin, BAYE4465)|Participants received 1 tablet of enteric-coated acetylsalicylic acid [100 milligram (mg)] orally once daily.
3295339|NCT00501059|Placebo Comparator|Placebo|Participants received 1 tablets of matching placebo orally once daily.
3295340|NCT00501046|Placebo Comparator|Placebo|
3295341|NCT00501046|Experimental|AST-120|
3295342|NCT00501007||Non-psychiatric smokers|Smokers not meeting criteria for Schizophrenia or Schizoaffective Disorder
3295343|NCT00501007||Smokers with Schizophrenia|Smokers meeting criteria for schizophrenia or schizoaffective disorder
3295344|NCT00500981|Experimental|Intravenous fluid bolus|Administration of 500 ml of 10% pentastarch
3295345|NCT00500968|Active Comparator|Stent|
3295346|NCT00500968|Active Comparator|conventional distal pancreatectomy|
3295347|NCT00500942||1|Patients having a standard procedure performed in Interventional Radiology.
3295348|NCT00500903|Experimental|1|MLN8237
3295349|NCT00500890|Experimental|Carboplatin + Etoposide + Vincristine|Carboplatin 350 mg/m^2 by vein, Over 2 Hours x 2 Days. Etoposide 100 mg/m^2 by vein, Over 1 Hour x 5 Days. Vincristine 1.5 mg/m^2 (by vein)IV Push Over 15 Minutes On Day 5. Radiation treatment over a period of about 6 weeks.
3295350|NCT00500890|Experimental|Cyclophosphamide + Etoposide + Vincristine|Cyclophosphamide 1 g/m^2 by vein, Over 1 Hour x 2 Days. Etoposide 100 mg/m^2 by vein, Over 1 Hour x 5 Days. Vincristine 1.5 mg/m^2 (by vein)IV Push Over 15 Minutes On Day 5. Radiation treatment over a period of about 6 weeks.
3295351|NCT00500877|Active Comparator|Mood Management Phone counseling|Mood management phone counseling for smoking cessation
3295352|NCT00500877|Placebo Comparator|Phone Counseling Standard|Phone counseling standard
3295353|NCT00500851|Active Comparator|1|In case of meeting clinical criteria for jejunal feeding, tubes are placed using CORTRAK (electromagnetic imaging).
3295354|NCT00500851|Active Comparator|2|Endoscopic placement of jejunal feeding tubes fulfilling clinical indication for jejunal feeding.
3295355|NCT00500838|Experimental|1|Transthoracic impedance device implanted.
3295356|NCT00500825||1|Patients successfully resuscitated after cardiac arrest undergoing therapeutic hypothermia
3295357|NCT00500812|Experimental|0.3 mg|Subjects Receiving 0.3 mg Cethrin
3295358|NCT00500812|Experimental|1 mg|Subjects receiving 1 mg Cethrin
3295359|NCT00500812|Experimental|3 mg|Subjects receiving 3 mg Cethrin
3295360|NCT00500812|Experimental|6 mg|Subjects receiving 6 mg Cethrin
3295361|NCT00500812|Experimental|9 mg|Subjects receiving 9 mg Cethrin
3295362|NCT00500786|Experimental|100 mcg CYT006-AngQb Healthy Volunteers|
3295363|NCT00500786|Experimental|100 mcg CYT006-AngQb Hypertensives|
3295364|NCT00500786|Experimental|300 mcg CYT006-AngQb Hypertensives|
3295365|NCT00500786|Placebo Comparator|Placebo Healthy Volunteers|
3295366|NCT00500786|Placebo Comparator|Placebo Hypertensives|
3295367|NCT00500760|Experimental|Panitumumab Plus Chemoradiation|Participants received standard radiation therapy for 7 weeks and cisplatin 75 mg/m^2 and panitumumab 9 mg/kg on Days 1, 22 and 43.
3295368|NCT00500760|Active Comparator|Chemoradiotherapy Alone|Participants received standard radiation therapy for 7 weeks and cisplatin 100 mg/m^2 on Days 1, 22, and 43.
3295369|NCT00500747|Experimental|Group C: 100 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 100 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
3295370|NCT00500747|Experimental|Group B: 20 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 20 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
3295371|NCT00500747|Experimental|Group A: 4 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 4 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
3295372|NCT00500734||Heart Disease Patients|
3295373|NCT00500695|Experimental|Motivational Interviewing|Motivational Interviewing
3295374|NCT00500695|Active Comparator|Psychoeducation|Psychoeducation
3295375|NCT00500682|Placebo Comparator|Placebo|
3295376|NCT00500682|Experimental|AST-120|
3295377|NCT00500669|Experimental|Betadine|
3295378|NCT00500669|Active Comparator|Saline|
3295379|NCT00500656|Experimental|Randomized controlled -Icatibant|"Subjects received S.C icatibant+ oral placebo~Icatibant Form: solution for injection, 3 mL, 10 mg/mL Single dose: 30 mg (3 mL)~Placebo Form: hard capsule Single dose: 2 capsules Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart"
3295380|NCT00500656|Active Comparator|Randomized controlled-Tranexamic acid|"Subjects received oral Tranexamic acid+ S.C. placebo~Tranexamic acid Form: over encapsulated film tablet Single dose: 1000 mg (2 capsules) Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart~Placebo Form: solution for injection, matched to icatibant for injection Single dose: 3 mL Frequency: one subcutaneous injection in the abdominal region"
3295381|NCT00500656|Experimental|Controlled Open-label / laryngeal attack|Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.
3295382|NCT00500656|Experimental|Untreated patients at the baseline|Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing were treated in the open label phase with icatibant
3295383|NCT00500617||segment 1|Gene discovery blood draw
3295384|NCT00500617||sement 2|Assay development blood draw
3295385|NCT00500617||segment 3|Assay validation blood draw
3295386|NCT00500617||segment 4|Additional assay testing blood draw (Note: post discovery diabetic subjects assigned to this group)
3295387|NCT00500604|Experimental|A|"period 1: Hydrochlorothiazide 12.5 mg for 3-5 weeks~period 2: One 150/12.5mg tablet every morning for 8 weeks.~period 3: One 300/12.5mg tablet every morning for 8 weeks.~period 4: Two 150/12.5mg tablets every morning for 8 weeks."
3295388|NCT00500604|Active Comparator|B|"period 1: Hydrochlorothiazide 12.5 mg for 3-5 weeks~period 2: One 80/12.5mg tablet every morning for 8 weeks.~period 3: One 160/12.5mg tablet every morning for 8 weeks.~period 4: Two 80/12.5mg tablets every morning for 8 weeks."
3295389|NCT00500591||Obese Women|
3295390|NCT00500578|Experimental|1: Standard Schedule - Ribavirin|Aerosolized Ribavirin 6 grams over 18 hours every 24 hours
3295391|NCT00500578|Experimental|2: Modified Schedule - Ribavirin|Aerosolized Ribavirin 2 grams over 3 hours every 8 hours
3295392|NCT00500565|Experimental|On-Q pump with Saline|On-Q Pump with Saline
3295393|NCT00500565|Experimental|On-Q Pump with Bupivicaine|On-Q Pump with bupivicaine
3295394|NCT00500526|Experimental|1 Singing Group|Patients who will receive singing classes
3295395|NCT00500526|Other|2 Control group|Patients who will attend hand craft classes
3295396|NCT00500513|Experimental|Implanted Markers + CT + RT|
3295397|NCT00500500|Experimental|EGb 761® (Tanakan®)|EGb 761® (Tanakan®)
3295398|NCT00500500|Placebo Comparator|Placebo|Placebo
3295399|NCT00500487|Experimental|1|
3295400|NCT00500487|Active Comparator|2|
3295401|NCT00500487|Active Comparator|3|
3295402|NCT00500461|Experimental|Subjects receiving GSK233705|Each subject will receive one or more ascending doses given as a constant rate IV infusion over 30 minutes and a single oral dose of 250 microgram GSK233705 solution. IV doses will include 30, 70, 110 microgram of GSK233705 at specified time points.
3295403|NCT00500448|No Intervention|No Treatment|No treatment was delivered to this arm. Participants went about activities of daily living
3295404|NCT00500448|Experimental|Electrical Stimulation|Neuromuscular electrical stimulation treatments 3 times per week for 4 weeks
3295405|NCT00500435||Laparoscopy Procedure|Laparoscopy procedure in abdomen to remove para aortic lymph nodes of patients diagnosed with cervical cancer.
3295406|NCT00500422|Experimental|Doxil + Gemcitabine + Velcade|Doxil Starting dose of 20 mg/m^2 intravenous (IV) over 2 hours on Day 1 and Gemcitabine 500 mg/m^2 IV over 30 minutes on Days 1 and 8; Velcade Starting dose of 0.7 mg/m^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles.
3295407|NCT00500409|Experimental|Drug Group|Osteoform
3295408|NCT00500409|Active Comparator|Control group|SHELCAL
3295409|NCT00500370|Experimental|Group A|
3295410|NCT00500370|Placebo Comparator|Group B|
3295411|NCT00500344|Other|1|
3295412|NCT00500331|Experimental|Arm 1|GSK189075
3295413|NCT00500331|Placebo Comparator|Arm 2|Placebo
3295414|NCT00500331|Other|Arm 3|pioglitazone (active control)
3295415|NCT00500318|Experimental|Aclidinium|
3295416|NCT00500318|Placebo Comparator|Placebo|
3295417|NCT00500292|Placebo Comparator|1|FOLFOX + Placebo vandetanib
3295418|NCT00500292|Experimental|2|FOLFOX + low dose vandetanib
3295419|NCT00500292|Experimental|3|FOLFOX + high dose vandetanib
3295420|NCT00500253|Active Comparator|1|children with asthma with FeNO monitored treatment (study group)
3295421|NCT00500253|Other|2|group of children with treatment monitored by GINA's grade of disease clinical control (control group)
3295422|NCT00500240|No Intervention|Conventional Care|Control Group: Conventional care using blood sugar management with regular human insulin.
3295423|NCT00500240|Other|Intensive Insulin|Intervention Group: Intense blood sugar management with Insulin Aspart + Insulin Glargine
3295424|NCT00500201|Experimental|Subjects in treatment sequence AB|In treatment sequence AB first subjects will be randomized to receive treatment A (two tablets of 60 milligram [mg] of SB-773812) and one placebo tablet. Then subjects will receive treatment B (one tablet of 120 mg of SB-773812) and two placebo tablets . There will be a wash-out period of 20 days between.
3295425|NCT00500201|Experimental|Subjects in treatment sequence BA|In treatment sequence BA first subjects will be randomized to receive treatment B (one tablet of 120 mg of SB-773812) and two placebo tablets. Then subjects will receive treatment A (two tablets of 60 mg of SB-773812) and one placebo tablet. There will be a wash-out period of 20 days between.
3295426|NCT00500188|Experimental|7 Days|Imatinib Mesylate 300 mg orally twice daily starting 7 days before surgery.
3295427|NCT00500188|Experimental|5 Days|Imatinib Mesylate 300 mg orally twice daily starting 5 days before surgery.
3295428|NCT00500188|Experimental|3 Days|Imatinib Mesylate 300 mg orally twice daily starting 3 days before surgery.
3295429|NCT00500162|Active Comparator|1|
3295430|NCT00500162|Active Comparator|2|
3295431|NCT00500149|Experimental|1|
3295432|NCT00500149|Placebo Comparator|2|
3295433|NCT00500110|Experimental|Hormonal Ablation, Imatinib + Docetaxel|Imatinib Mesylate 600 mg by mouth (PO) daily + Docetaxel 30 mg/m^2 by vein (IV) weekly + Hormonal Ablation (Goserelin Acetate or Leuprolide) injections every other month or every 3 months
3295434|NCT00500084|Experimental|Liprotamase|Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units) administered orally with each of three meals and two snacks daily for 12 months
3295435|NCT00500071|Experimental|1|
3295436|NCT00500058|Experimental|SB-485232+Rituximab|Rituximab 375 milligrams per square meter (mg/m^2) will be administered to subjects with CD20+ B cell lymphoma by intravenous (IV) infusion once a week for four consecutive weeks on Day 1 of Weeks 1 to 4. SB-485232 will be administered by IV infusion over a 2 hour period, at doses ranging from 1 microgram (μg)/kilogram (kg) to 100 μg/kg. SB-485232 will be given once a week for 12 consecutive weeks on Day 2 of Weeks 1 to 4 and Day 2 (± 1 day) of Weeks 5 to 12. SB-485232 will be infused at least 24 hours after the Rituximab infusion was started.
3295437|NCT00500045|Experimental|Treatment|Oral niacin
3295438|NCT00500032|Experimental|Arm 1|Active Comparator for all subjects enrolled in 6108A1-500
3295439|NCT00500019||1.|Elective Cesarean sections
3295440|NCT00500019||2.|Non-elective cesarean section
3295441|NCT00500006|Other|A|Arm A: Drug and comparator
3295442|NCT00500006|Other|B|Arm B: Drug and comparator
3295443|NCT00499967|Experimental|Cohort 1|GS-9191 0.01% ointment
3295444|NCT00499967|Experimental|Cohort 2|GS-9191 0.03% ointment
3295445|NCT00499967|Experimental|Cohort 3|GS-9191 0.1% ointment
3295446|NCT00499967|Active Comparator|Cohort 4|GS-9191 0.3%
3295447|NCT00499967|Active Comparator|Cohort 5|GS-9191 1.0%
3295448|NCT00499967|Placebo Comparator|Cohorts 1, 2, 3, 4 & 5|Placebo in all cohorts
3295449|NCT00499915|Experimental|Secondhand Smoke Reduction and Asthma Education|Parents of children in the experimental group will receive asthma education at NICU discharge as well as a secondhand smoke reduction program.
3295450|NCT00499915|Active Comparator|Asthma Education|Parents of children in the active comparator group will receive asthma education at NICU discharge.
3295451|NCT00499902|Other|2 stages|This is a two-stage study. The first stage is in a three-tier dose escalation format, followed by a second stage during which subjects will be randomized in an equal proportion to up to 3 qualifying dose arms.
3295452|NCT00499889|Experimental|Imatinib, Busulfan, Fludara + Antithymocyte Globulin|Oral Imatinib Mesylate 400 mg twice a day for 9 Days; Busulfan 130 mg/m^2 by vein (IV) daily for 2 Days; Fludara 40 mg/m^2 IV daily for 4 Days; Antithymocyte Globulin (ATG) 2.5 mg/kg IV daily for 3 Days; Tacrolimus levels maintained between 5-15 ng/dl, Day -2 to Day 180; Methotrexate 5 mg/m2 on days 1, 3, 6 and 11; and Donor bone marrow or blood stem cells infused on day 0 with possible donor lymphocyte infusion (DLI) for progressive disease.
3295453|NCT00499876|Active Comparator|A|
3295454|NCT00499876|Placebo Comparator|B|
3295455|NCT00499863|Experimental|Methylphenidate Transdermal System|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
3295456|NCT00499863|Placebo Comparator|2|Daily application of matching MTS Placebo Patch
3295457|NCT00499837|Experimental|80 mg/kg AAT inhaled|80 mg/kg AAT inhaled
3295458|NCT00499837|Placebo Comparator|Placebo inhaled|Placebo inhaled
3295459|NCT00500266|Experimental|1|13-valent Pneumococcal Conjugate Vaccine
3295460|NCT00499824|Experimental|1|Medical Practitioners who receive education on diabetes management following the guidelines of the International Diabetes Federation Western Pacific Region
3295461|NCT00499824|No Intervention|2|Medical practitioners who follow standard practice for management of their patients with type 2 diabetes
3295462|NCT00499811|Experimental|Treatment (enzyme inhibitor therapy)|"Vorinostat (SAHA) will be administered as a single oral dose on day -6 for all patients. Blood samples are obtained periodically on day -6 for pharmacokinetic studies.~One week later (day 1), the first course of oral vorinostat will be initiated on a continuous daily oral regimen. Each treatment course will consist of 21 days of therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
3295463|NCT00499798||patients on temozolimide for brain cancer|
3295464|NCT00499785||patients admitted with acute leukemia|
3295465|NCT00499746|Active Comparator|Tramadol|oral dose, once per day
3295466|NCT00499746|Placebo Comparator|Placebo|oral dose, once per day
3295467|NCT00499746|Active Comparator|hydromorphone|oral dose, once per day
3295468|NCT00499746|Active Comparator|methylphenidate|oral dose, once per day
3295469|NCT00499694|Experimental|Bevacizumab and Satraplatin|"Bevacizumab 10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)~Satraplatin 80 mg/m(2), Orally, Days 1-5, every 35 days"
3295470|NCT00499681|Experimental|Arm I|Patients receive Lapatinib and Letrozole once daily for two weeks, following tumor measurement patients receive Lapatinib and Letrozole once daily for 14 weeks.
3295471|NCT00499681|Experimental|Arm II|Patients receive Letrozole and placebo once daily for 2 weeks, following tumor measurement patients receive Letrozole and Lapatinib once daily for 14 weeks.
3295472|NCT00499668|Experimental|ARM A|
3295473|NCT00499668|Experimental|ARM B|
3295474|NCT00499655|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.
3295475|NCT00499655|Experimental|Arm II|Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily on days 1-28.
3295476|NCT00499629|Active Comparator|1|Arm 1: FXR 450
3295477|NCT00499629|Placebo Comparator|2|Placebo
3295478|NCT00499616|Experimental|Group 2 (chemotherapy, surgery)|2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.
3295479|NCT00499616|Experimental|Group 3 (chemotherapy, surgery)|4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
3295480|NCT00499616|Experimental|Group 4 (chemotherapy, surgery, antineoplastic therapy)|8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients < 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
3295481|NCT00499616|Experimental|Non-intermediate risk enrolled on intermediate risk trial|The no treatment group assignment patients may have received some treatment on ANBL0531 but they were not evaluable on this study due to being non-intermediate risk and hence did not receive a treatment assignment on ANBL0531.
3295482|NCT00499603|Experimental|Paclitaxel + FEC|Paclitaxel 80 mg/m^2 intravenously (IV) on day 1(+/- 2 days) of each week, followed by four cycles of combination 5-Fluorouracil at 500 mg/m^2, Epirubicin at 100 mg/m^2 and Cyclophosphamide at 500 mg/m^2 (FEC) on day 1 every 3 weeks (+/- 7 days).
3295483|NCT00499603|Experimental|Paclitaxel + RAD001 + FEC|Paclitaxel + RAD001 Followed by FEC (5-Fluorouracil + Epirubicin + Cyclophosphamide)
3295484|NCT00499590|Active Comparator|A|Lucentis® (0.5mg) every 4 weeks.
3295485|NCT00499590|Experimental|B|Bevasiranib (2.5mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
3295486|NCT00499590|Experimental|C|Bevasiranib (2.5mg) every 12 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
3295601|NCT00498212|Experimental|1018 ISS-HBsAg-Single|Single dose (3000 µg 1018 ISS + 20 µg rHBsAg)
3295602|NCT00498212|Experimental|1018 ISS-HBsAg-Double|Double dose (6000 µg 1018 ISS + 40 µg rHBsAg)
3295487|NCT00499577|Experimental|Group 1 (HLA-A2 positive)|Patients receive the following peptides emulsified in incomplete Freund's adjuvant VG: I) hTERT I540 peptide; ii) hTERT R572Y peptide; iii) hTERT D988Y peptide; iv) survivin Sur1M2 peptide ; and v) CMV control peptide N495 subcutaneously (SC). Patients also receive sargramostim (GM-CSF) SC and pneumococcal conjugate vaccine intramuscularly.
3295488|NCT00499577|Experimental|Group 2|Patients receive pneumococcal conjugate vaccine intramuscularly and GM-CSF subcutaneously.
3295489|NCT00499577|Experimental|Second group 1|On days 14, 42, and 90 post-transplant, patients receive peptides and GM-CSF subcutaneously and pneumococcal conjugate vaccine intramuscularly.
3295490|NCT00499577|Experimental|Second group 2|On day 14, 42, 90 post-transplant, patients receive pneumococcal conjugate vaccine intramuscularly and GM-CSF subcutaneously.
3295491|NCT00499525|Experimental|Arm I|Patients receive paclitaxel IV over 1 hour once weekly for 3 weeks. Patients also receive oral sorafenib tosylate twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3295492|NCT00499525|Active Comparator|Arm II|Patients receive paclitaxel as in arm I and oral placebo twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3295493|NCT00499512||Spirituality Questionnaire|Patients with newly diagnosed ovarian, primary peritoneal, or fallopian tube cancer.
3295494|NCT00499499|Experimental|1|
3295495|NCT00499486|Experimental|Sirolimus|Sirolimus 5mg. po QD continously (28 days=cycle)
3295496|NCT00499473|Experimental|Stratum 1 (kinase inhibitor therapy)|Non-EIAC patients receive oral sunitinib malate once daily for 4 consecutive weeks followed by 2 weeks of rest.
3295497|NCT00499473|Experimental|Stratum 2 (kinase inhibitor therapy)|EIAC & OSU patients receive oral sunitinib malate as in stratum 1. Patients receive escalating doses of oral sunitinib malate until the maximum tolerated dose (MTD) is determined.
3295498|NCT00499460|Other|Arm I|Two 30-day treatment periods separated by a washout of at least 4 weeks. In Period 1, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29. In Period 2, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
3295499|NCT00499460|Other|Arm II|Two 30-day treatment periods separated by a washout of at least 4 weeks. In Period 1, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29. In Period 2, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
3295500|NCT00499447|Experimental|Radiofrequency Ablation with External Beam Radiation|Radiofrequency Ablation (RFA)under computerized tomography guidance followed 3-4 weeks later with External Beam Radiation Therapy
3295501|NCT00499421||CT Scan|CT Scan with Fiducial markers + external beam radiation therapy
3295502|NCT00499382||PET/CT scan + NM cardiac scan|
3295503|NCT00499369|Experimental|Arm I (chemotherapy, cetuximab)|Patients receive single-agent irinotecan hydrochloride IV or FOLFIRI IV. They also receive cetuximab IV over 1-2 hours on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
3295504|NCT00499369|Experimental|Arm II (chemotherapy, cetuximab, bevacizumab)|Patients receive single-agent irinotecan hydrochloride or FOLFIRI AND cetuximab as in arm I. Patients also receive bevacizumab IV over 30 minutes on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
3295505|NCT00499369|Experimental|Arm III (closed to accrual as of 4/20/2009)|Patients receive single-agent irinotecan hydrochloride or FOLFIRI AND cetuximab as in arm I. Patients also receive a higher dose of bevacizumab (higher than in arm II) IV over 30 minutes on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
3295506|NCT00499343|Experimental|Rituximab + Ifosfamide + Etoposide + 2 Growth Factors|Growth Factors = granulocyte-colony stimulating factor (G-CSF) + granulocyte macrophage-colony stimulating factor (GM-CSF)
3295507|NCT00499343|Experimental|Rituximab + Ifosfamide + Etoposide + 1 Growth Factor|Growth Factor = granulocyte-colony stimulating factor (G-CSF)
3295508|NCT00499330|Other|Arm A|Patients undergo a standard operation for lung cancer called a lobectomy.
3295509|NCT00499330|Experimental|Arm B|Patents undergo a limited resection (segentectomy or wedge resection), which a smaller portion of the lung is removed.
3295510|NCT00499265|Active Comparator|Gemcitabine|
3295511|NCT00499265|Experimental|Gemcitabine plus 200 mg WX-671|
3295512|NCT00499265|Experimental|Gemcitabine plus 400 mg WX-671|
3295513|NCT00499252|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation (Abraxane®) IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3295514|NCT00499239|Experimental|GS-9219|Escalating doses of GS-9219 (5, 8, 11.5, 16, 22.5, 31.5, 44, and 61.5 mg/m^2) until determination of the maximum tolerated dose (MTD)
3295515|NCT00499200|Experimental|SRA-444 + Placebo|Experimental; Placebo
3295516|NCT00499187||Fanconi Cases|This cohort enrolled participants with evidence of protocol-defined Fanconi syndrome (confirmed creatinine clearance decline and evidence of proximal tubulopathy).
3295517|NCT00499187||Control Cases|This cohort enrolled participants with no evidence of protocol-defined Fanconi syndrome.
3295518|NCT00499174|No Intervention|Active Surveillance|Active surveillance with radical intervention at the time one or more of the following occur: Biochemical progression; Grade progression; Clinical progression
3295519|NCT00499174|Active Comparator|Radical Intervention|Radical prostatectomy or radiotherapy based on patient and physician preference
3295520|NCT00499161|No Intervention|1|Control group received usual care
3295521|NCT00499161|Experimental|2|Received intervention New model of nursing care
3295522|NCT00499135|Experimental|Schedule A|Patients receive sunitinib malate PO QD in weeks 1-4. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
3295523|NCT00499135|Experimental|Schedule B|Patients receive sunitinib malate PO QD in weeks 1, 2, 4, and 5. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
3295524|NCT00499122|Experimental|NOV-002 and Chemotherapy|"NOV-002:~Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart~Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration~Cycle 1 - 8, Days 2 - 21: 60 mg subcutaneous injections~Cyclophosphamide: 600 mg/m2 IV, Cycles 1 - 4, Day 1~Doxorubicin: 60 mg/m2 IV, Cycles 1 - 4, Day 1~Docetaxel: 100 mg/m2 IV, Cycles 5 - 8, Day 1"
3295525|NCT00499109|Experimental|E. Dual Agent Chemotherapy|"Experimental Arm E.~Patients received treatment according to gene expression strata with four doublet regimens.~Low ERCC1 and Low RRM1 Group - Gemcitabine (G) and Carboplatin (Cb): GCb Group.~Low RRM1 and High ERCC1 Group - Gemcitabine (G) and Docetaxel (D): GD Group.~High RRM1 and Low ERCC1 Group - Docetaxel (D) and Carboplatin (Cb): DCb Group.~High ERCC1 and High RRM1 Group - Vinorelbine (V) and Docetaxel (D): DV Group."
3295526|NCT00499109|Active Comparator|C. Standard of Care Control Arm|"Control Arm C: Gemcitabine and Carboplatin (GCb).~All patients in arm C were treated with GCb regardless of gene expression levels. Patients received up to 6 cycles, and no maintenance therapy was allowed."
3295527|NCT00499096|Experimental|Chronic Care Model for Bipolar Disorder|An intervention group of patients with bipolar disorder and 1 or more risk factor for cardiovascular disease; group will receive self-management group sessions, followed by phone contacts by the Care Manager. This is the chronic care model for bipolar disorder
3295528|NCT00499096|No Intervention|Enhanced Usual Care|A group of patients with bipolar disorder and one or more risk factors for cardiovascular disease will be randomized to receive enhanced usual care. This group will receive usual care, plus mailings on wellness topics (attention control), and their providers will receive information on guideline concordant care.
3295529|NCT00499083|Experimental|Vaccine|Patients with HER-2/neu negative tumors will receive IT DCs one week after the first three of four cycles of dose dense T therapy and then four cycles of dose dense AC therapy will be given (i.e. T-AC).
3295530|NCT00499057|Other|single arm study|single arm study
3295531|NCT00499044|Experimental|1|MATRICS Consensus Cognitive Battery
3295532|NCT00499044|Experimental|2|Cognitive Drug Research Computerized Cognitive Assessment System
3295533|NCT00499031|Experimental|Treatment (cetuximab)|Patients receive cetuximab IV over 120 minutes on day 1.
3295534|NCT00499018|Experimental|1|R-MegaCHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT
3295535|NCT00499018|Experimental|1 BIS|R-CHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT
3295536|NCT00499018|Experimental|2|R-MegaCHOP14 x 4 Restaging + R-MegaCHOP x 2
3295537|NCT00499018|Experimental|2 BIS|R-CHOP14 x 4 Restaging + R-CHOP14 x 4
3295538|NCT00499005|Active Comparator|Primi|
3295539|NCT00499005|Active Comparator|Multi|
3295540|NCT00498979|Experimental|recombinant interferon alfa-2b|recombinant interferon alfa-2b
3295541|NCT00498966|Experimental|Group A|Patients in group A will have previously failed a VEGF receptor inhibitor but not an mTOR inhibitor.Intervention: Perifosine.
3295542|NCT00498966|Experimental|Group B|Patients in group B will have failed both a VEGF receptor inhibitor and an mTOR inhibitor. Intervention: Perifosine.
3295543|NCT00498940|Active Comparator|Biventricular Pacing|After weaning from bypass, patients received temporary biventricular pacing for 24 hours. Values obtained from optimization testing determined pacemaker settings (AVD, VVD, heart rate).
3295544|NCT00498940|Active Comparator|Standard of Care|No continuous pacing occurred about surgery. Patients underwent optimization testing.
3295545|NCT00498927|Experimental|Temozolomide|Following diagnosis of tumor recurrence or progression, all patients will receive of daily low dose temozolomide given at 50mg/m2/d without interruption. Brain imaging will be performed at baseline and every 2 months (standard of care). The treatment will be administered until development of toxicity, evidence of progression of disease or death.
3295546|NCT00498914|Experimental|1|
3295547|NCT00498888|Active Comparator|1|Women were prescribed a 3 month supply of Tolterodine SR 4 mg (Detrusitol SR 4 mg, Pfizer Pharmaceuticals Israel LTD) . After the randomization she needs to get the first prescription from her doctor, and followed this protocol every three weeks. Her doctor how already knows this research were explained how to take the drug. After finished this protocol she get the money she pay after sending the receipts and the empty boxes.
3295548|NCT00498888|Active Comparator|2|The Bladder training protocol aims o to increase the time interval between voids, either by a mandatory or self-adjustable schedule, so that incontinence is ultimately avoided and continence regained. It is generally comprised of three components: 1) patient education that includes information about bladder and how continence is usually maintained, 2) scheduled voiding- a 'timetable for voiding' which may fixed or flexible to suit the participant's rate of increase in interval between voids, commonly the aim is to achieve an interval of three to four hours between voids and 3) positive reinforcement- - psychological support and encouragement is generally considered important and usually provided by health care professional . Frequency volume chart (FVC) records the time and volumes of voided for 24 hours by the women between the appointments. Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
3295549|NCT00498888|Active Comparator|3|The Pelvic floor muscle training (PFMT) protocol based on National Institute for health and clinical excellence (NICE clinical guideline 40, 2006), that the PFMT programs should comprise at least eight contractions performed three times per day, and the trial of supervised PFMT of at least 3 months' duration . Each appointment the women maid three sets of eight to 12 slow maximal contractions sustained for 6-8 second, and asked to made this protocol every day, and taught to contract these muscle to suppress urge filling. Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
3295550|NCT00498888|Active Comparator|4|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for pelvic floor muscle training and bladder training and lifestyle advice and information about good bladder and bowel habits.
3295551|NCT00498875||Questionnaire + Depression Intervention|
3295552|NCT00498784|Experimental|Arm 1|
3295603|NCT00498186|Experimental|Rotigotine|Rotigotine trans-dermal patch
3295604|NCT00498173|Experimental|Atomoxetine|Participants will receive flexibly dosed atomoxetine for 8 weeks. Dosage can be increased over the first 4 weeks of study participation and will then be held constant for the remainder of the 8-week trial.
3295659|NCT00497458|Active Comparator|Arimidex test 40mg|Arimidex 1mg and testosterone 40mg
3295921|NCT00494741|Experimental|azathioprine|
3295553|NCT00498771|Active Comparator|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
3295554|NCT00498771|No Intervention|Control - No Exercise Arm|No exercise will be performed in Control arm. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL) at baseline, 6 week, 6 and 12 month.
3295555|NCT00498719||CTP Group|One-on-one cognitive training
3295556|NCT00498719||Control Group|Standard educational support.
3295557|NCT00498706|Experimental|Telephone-administered CBT|Participants will receive telephone-administered cognitive behavioral therapy.
3295558|NCT00498706|Active Comparator|Face-to-face CBT|Participants will receive face-to-face cognitive behavioral therapy.
3295559|NCT00498680|Active Comparator|Viagra 100mg|
3295560|NCT00498680|Active Comparator|Levitra 20mg|
3295561|NCT00498680|Active Comparator|Viagra 50mg+ Levitra 10mg|
3295562|NCT00498667||PET/CT|all patients with aggressive lymphoma who had a baseline and interim pet/ct study
3295563|NCT00498628|Experimental|1|Quetiapine fumarate plus medical management
3295564|NCT00498628|Placebo Comparator|2|Medical management plus placebo comparator
3295565|NCT00498615|Experimental|Fasudil 80 mg|Subject is given a single dose of 80 mg of Fasudil ( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
3295566|NCT00498615|Experimental|40 mg Fasudil|Subject is given a single dose of 40 mg of Fasudil ( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
3295567|NCT00498615|Placebo Comparator|placebo|Subject is given a single dose of placebo( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
3295568|NCT00498602|Experimental|1|ACC-001
3295569|NCT00498602|Other|2|QS-21
3295570|NCT00498602|Other|3|Diluent: Phosphate Buffered Saline
3295571|NCT00498602|Experimental|4|ACC-001
3295572|NCT00498589|Placebo Comparator|1|Methotrexate IM or SC 25 mg/week vs placebo IM or SC for 24 weeks
3295573|NCT00498589|Placebo Comparator|2|1 IM or SC of placebo per week during 24 weeks
3295574|NCT00498576||1|kidney transplant with hypertension
3295575|NCT00498576||2|hypertensive patients with native kidneys
3295576|NCT00498576||3|healthy controls
3295577|NCT00498550|Experimental|Clozapine|Clozapine, Clozaril
3295578|NCT00498550|Active Comparator|Treatment as usual|Treatment as usual with any antipsychotic other than Clozapine.
3295579|NCT00498537|Other|1|
3295580|NCT00498537|Other|2|
3295581|NCT00498524||1|Sib who has received an ICD
3295582|NCT00498524||2|Sib who has not received an ICD
3295583|NCT00498485|Placebo Comparator|Placebo|Patients were randomized and these received placebo
3295584|NCT00498485|Active Comparator|Sodium Oxybate|Patients were randomized and these received the active drug
3295585|NCT00498472|Active Comparator|A|Pre-discharge NT-ProBNP based
3295586|NCT00498472|No Intervention|B|Discharge date and treatment not based on the knowledge of pre-discharge NT-proBNP levels
3295587|NCT00498459|Experimental|ICAPS|Promotion Physical Activity
3295588|NCT00498459|No Intervention|Control|No specific physical activity promotion Ususal school program
3295589|NCT00498433|Experimental|Aliskiren|"Part 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase (period 1) consisting of treatment with one tablet of placebo to aliskiren once daily (o.d.). This was followed by a 4 week treatment phase (period 2) consisting of treatment with 300 mg aliskiren o.d..~Part 2: Eligible randomized patients in this arm received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks."
3295590|NCT00498433|Active Comparator|Amlodipine|"Part 1: After aliskiren treatment (period 2), each patient was entered into a second washout period (4 weeks) during which blood pressure was required to be ≤ 140/90 mmHg. If blood pressure exceeded 140/90 mmHg on two consecutive days (home monitoring) and was confirmed at the study center, the patient was entered into the amlodipine treatment period (period 3). In period 3, all patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks.~Part 2: Eligible patients randomized to part 2 received amlodipine 5 mg o.d. and aliskiren placebo for 12 weeks"
3295591|NCT00498368|Experimental|Rituximab Plus ACE/ARB|Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement
3295592|NCT00498368|Active Comparator|ACE/ARB|ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement
3295593|NCT00498355|Experimental|Ranibizumab|0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
3295594|NCT00498316|Other|Cord Blood Infusion|"Cord blood transplantation performed on day 0. Busulfan 32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4.~Fludarabine 10 mg/m2 by vein on Days -7 to -4, 40 mg/m2 by vein on Days -6 to -3 or on Days -5 to -2.~Rituximab 375 mg/m2 by vein on Day -9. ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3, 1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2.~Cyclophosphamide 50 mg/kg by vein on Day -6. Clofarabine 30 mg/m2 by vein on Days -7 to -4. Total body irradiation (TBI) 200 cGy at 25 cGy/minute delivered on Day -3. Melphalan 140 mg/m2 by vein on Day -2. Tacrolimus 0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present."
3295595|NCT00498290|Experimental|A|received enhanced recovery after surgery (ERAS) protocol in colorectal surgery
3295596|NCT00498290|No Intervention|B|normal recovery protocol in colorectal surgery
3295597|NCT00498277||Spinal MRI|
3295598|NCT00498225|Experimental|1|Gemcitabine plus TS-1
3295599|NCT00498225|Experimental|2|TS-1
3295600|NCT00498225|Active Comparator|3|Gemcitabine
3295605|NCT00498173|Placebo Comparator|Placebo|Participants will receive blinded, matched placebo for 8 weeks. Dosage can be increased over the first 4 weeks of study participation and will then be held constant for the remainder of the 8-week trial.
3295606|NCT00498160|Experimental|Living or Deceased Donor Kidney Allograft|Recipients with the need for a living kidney allograft are treated with an enriched hematopoetic stem cell infusion from the same living donor. Recipients with the need for a deceased donor kidney allograft are treated with an enriched hematopoetic stem cell infusion from the same deceased donor
3295607|NCT00498147||ADEC <6months|Patients new to the ADEC program who will be provided the ADEC interventions (prospective study)
3295608|NCT00498147||ADEC >6months|Patients who have been with the ADEC program as early as 2002 (coincides with ADEC's EMR initiation date) who continue to be provided the ADEC interventions (combined retrospective/prospective study)
3295609|NCT00498121||VAP patient|
3295610|NCT00498069|Active Comparator|1|Injection of autologous bone marrow concentrate into ischemic tissues of the lower extremity
3295611|NCT00498069|Placebo Comparator|2|Injection of placebo into ischemic tissues of the lower extremity
3295612|NCT00498056|Experimental|1|Participants will receive a total of three injections of the DNA vaccine VRC-HIVDNA016-00-VP followed by one injection of the adenovirus vaccine VRC-HIVADV014-00-VP. Injections will occur at study entry and Weeks 4, 8, and 24.
3295613|NCT00498056|Placebo Comparator|2|Participants will receive a total of three injections of the DNA vaccine VRC-HIVDNA016-00-VP placebo followed by one injection of the adenovirus vaccine VRC-HIVADV014-00-VP placebo. Injections will occur at study entry and Weeks 4, 8, and 24.
3295614|NCT00498043|Experimental|R-CHOP-14|R-CHOP14 induction regimen
3295615|NCT00498043|Experimental|R-ACVBP14|R-ACVBP14 induction regimen
3295616|NCT00497978|Active Comparator|1|taurine will be given per capsule
3295617|NCT00497978|Placebo Comparator|2|placebo capsules containing microcrystalline cellulose will be given
3295618|NCT00497952|Experimental|Multiple Sclerosis Patients|Recipients treated with a hematopoetic stem cell infusion from a living donor
3295619|NCT00497926|Experimental|Living Kidney Allograft|Recipients with the need for a living kidney allograft are treated with an enriched hematopoietic stem cell infusion from the same living donor
3295620|NCT00497913|Active Comparator|A|
3295621|NCT00497913|Placebo Comparator|B|
3295622|NCT00497900|Experimental|1|Calcium and vitamin D
3295623|NCT00497900|Placebo Comparator|2|Calcium and placebo (cellulose)
3295624|NCT00497874|Experimental|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
3295625|NCT00497874|No Intervention|Usual care|Usual primary care treatment
3295626|NCT00497848|Active Comparator|motivational interviewing|
3295627|NCT00497848|Experimental|The System Orientated Intervention|
3295628|NCT00497809|Experimental|1|AVI-014 2.5mcg/kg
3295629|NCT00497809|Experimental|2|AVI-014 5.0 mcg/kg
3295630|NCT00497809|Experimental|3|AVI014 10.0 mcg/kg
3295631|NCT00497809|Active Comparator|4|Filgrastim 5.0 mcg/kg
3295632|NCT00497796|Experimental|1|
3295633|NCT00497796|Active Comparator|2|
3295634|NCT00497770||Caucasian|Caucasian patients receiving Alimta for 2nd line NSCLC
3295635|NCT00497770||African American|African American patients receiving Alimta for 2nd line NSCLC
3295636|NCT00497770||Asian American|Asian American patients receiving Alimta for 2nd line NSCLC
3295637|NCT00497770||Hispanic|Hispanic patients receiving Alimta for 2nd line NSCLC
3295638|NCT00497757|Experimental|Cardiac Failure Patients|Recipients treated with an enriched hematopoetic stem cell infusion from the heart donor's bone marrow
3295639|NCT00497653|Experimental|DCI|
3295640|NCT00497653|Placebo Comparator|Placebo|
3295641|NCT00497614|Other|No arm|
3295642|NCT00497601|Experimental|A|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 and 3
3295643|NCT00497601|Experimental|B|Amphotericin B in fat emulsion (Amphomul) 10 mg/kg on day 1 and 5 mg/kg on day 3
3295644|NCT00497601|Experimental|C|Amphotericin B in fat emulsion (Amphomul) 12.5 mg/kg on day 1 and 2.5 mg/kg on day 3
3295645|NCT00497601|Experimental|D|Amphotericin B in fat emulsion (Amphomul) 15 mg/kg in a single dose administration on day 1
3295646|NCT00497588|Active Comparator|radiotherapy|patients receive radiotherapy
3295647|NCT00497588|Experimental|surgery|Patients undergo surgery
3295648|NCT00497549|Active Comparator|1|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
3295649|NCT00497549|Active Comparator|2|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
3295650|NCT00497536|Active Comparator|1|≈ bolus protocol.
3295651|NCT00497536|Active Comparator|2|≈ CSII protocol
3295652|NCT00497536|Active Comparator|3|≈ CIII protocol.
3295653|NCT00497523|Experimental|Beclomethasone dipropionate|
3295654|NCT00497523|Experimental|Beclomethasone dipropionate/Salbutamol combination|
3295655|NCT00497523|Active Comparator|Salbutamol|
3295656|NCT00497497|Experimental|1|
3295657|NCT00497497|Experimental|2|
3295658|NCT00497458|Placebo Comparator|Arimidex|Arimidex 1 mg plus placebo
3295804|NCT00495833|Experimental|4|blood pressure personalization only
3295660|NCT00497458|Active Comparator|Arimidex plus test 80mg|Arimidex 1mg and testosterone 80mg
3295661|NCT00497445|Experimental|Angioplasty / surgery and exercise therapy|Angioplasty / surgery followed by supervised exercise therapy
3295662|NCT00497445|No Intervention|Angioplasty / surgery|Angioplasty / surgery alone
3295663|NCT00497393|No Intervention|Control|regular use of the 2-bed areas in the Emergency department
3295664|NCT00497380|Experimental|Arginine enriched nutrition|
3295665|NCT00497380|Placebo Comparator|Nutrition|
3295666|NCT00497367|Experimental|TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent|This arm received the TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent.
3295667|NCT00497341|Experimental|1|antibiotic is given before tourniquet inflation and before tourniquet release
3295668|NCT00497341|Placebo Comparator|2|antibiotic is given before tourniquet inflation
3295669|NCT00497328|Other|N-acetylcysteine Group (NAC)|"N-acetylcysteine Group (NAC)~Intravenous infusion 154mEq/L of sodium chloride (0.9% normal saline) at a rate of 1mL/kg/hour from 12 hours before till 6 hours after cardiac catheterization Oral NAC 1200mg dissolve in 250ml of water twice a day the day before to the day after the procedure (total 6 doses)"
3295670|NCT00497328|Other|Sodium Bicarbonate Group (SOB)|"Sodium Bicarbonate Group (SOB)~Intravenous infusion154meq/L sodium bicarbonate in 5% dextrose in water at a rate of 3 mL/kg/hour for 1 hour immediately before radiocontrast injection. For patients weighing more than 110 kg, the initial fluid bolus and drip will be limited to those doses administered to a patient weighing 110 kg.~Intravenous infusion154meq/L sodium bicarbonate in 5% dextrose in water at a rate of 1 mL/kg/hour during the contrast exposure and for 6 hours after the procedure"
3295671|NCT00497328|Other|Combination Group (COM: NAC and SOB)|"Combination Group (COM: NAC and SOB)~Intravenous infusion of 154 meq/l sodium bicarbonate at a rate of 3ml/kg/hour for 1 hour before cardiac catheterization and 1 ml/kg/hour till 6 hours after procedure Oral NAC 1200mg dissolve in 250ml of water twice a day the day before to the day after the procedure (total 6 doses). All patients will be monitored regularly for pulmonary congestion and hemodynamics compromise hourly after PCI for 6 hours and every 4 hour thereafter for 24 hours."
3295672|NCT00497315|Experimental|A|pemetrexed + cisplatin (3 cycles) followed by thoracic irradiation + pemetrexed
3295673|NCT00497315|Experimental|B|thoracic irradiation + pemetrexed followed by pemetrexed + cisplatin
3295674|NCT00497302|Experimental|1|receives housing based on drug abstinence
3295675|NCT00497302|Active Comparator|2|Usual care treatment at the Center for Addiction and Pregnancy
3295676|NCT00497289|Experimental|1|Lipidem 20 %
3295677|NCT00497289|Active Comparator|2|Lipofundin MCT/LCT 20%
3295678|NCT00497276|Experimental|I|Ultrasound guided placement of popliteal catheter
3295679|NCT00497276|Experimental|II|Nerve stimulation guided placement of popliteal catheter
3295680|NCT00497250|Other|1|Thoracic RT for patients will start from 54Gy, and then escalate dose at 2Gy increment to 60Gy. At each dose level, 8 patients are required to complete RT without dose limiting toxicity(DLT). Evaluation will be done after 8 patients have completed the treatment.If there are >=2 DLT in the first 8 patients, the maximum tolerated dose (MTD) is achieved. If there is a single DLT revealed, an additional 8 patients will be recruited to that dose level. Should there be severe complication occurred again be at least 1 more DLT, then MTD is thought to be achieved.Hence,MTD will be achieved if at least 2 out of the first 8 patients have a DLT,or if a further 8 patents are recruited, >=2 out of 16 patients have a DLT. Concurrent with RT, patients will be given gefitinib 250 mg/day PO as well as same dose PO for 60 days after the completion of RT.
3295681|NCT00497237|Experimental|1|Foster
3295682|NCT00497237|Active Comparator|2|Seretide
3295683|NCT00497224|Experimental|Erlotinib|
3295684|NCT00497198|Experimental|MCI-196|
3295685|NCT00497198|Placebo Comparator|Placebo|
3295686|NCT00497185|Other|A|Mindfulness-Based Cognitive Therapy
3295687|NCT00497185|No Intervention|B|Shared care: Treatment as usual augmented by psychiatric consultation intervention to optimise treatment in the present health care system.
3295688|NCT00497172|Experimental|1|drug-eluting stent
3295689|NCT00497172|Active Comparator|2|bare-metal stent
3295690|NCT00497159|Placebo Comparator|1|Placebo
3295691|NCT00497159|Experimental|2|Dimebon
3295692|NCT00497146|Experimental|Paricalcitol|Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.
3295693|NCT00497146|Placebo Comparator|Placebo|Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.
3295694|NCT00497107|Active Comparator|1|The Control Group (UFT + Calcium Folinate)
3295695|NCT00497107|Experimental|2|The PSK Group (UFT + Calcium Folinate + PSK)
3295696|NCT00497094|Active Comparator|1|Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin irrespective of the baseline cholesterol level) and clopidogrel (75mg daily). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations. Additionally patients will undergo carotid artery stenting using a filter wire protection device.
3295697|NCT00497094|No Intervention|2|Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin daily irrespective of the baseline cholesterol level) and clopidogrel (75mg daily). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations
3295698|NCT00497081|Active Comparator|Mirtazapine|mirtazapine 30 mg daily
3295699|NCT00497081|Placebo Comparator|Placebo|placebo 30 mg daily
3295700|NCT00497068|Experimental|tobacco abstinent contingent voucher|Tobacco abstinent contingent voucher condition
3295701|NCT00497068|Experimental|non-contingent|Participants receive vouchers non-contingent upon tobacco use status
3295702|NCT00497068|Other|no voucher|This is the standard care intervention
3295703|NCT00497055|Experimental|Aripiprazole|Aripiprazole 5mg daily for week one. Aripiprazole 10mg daily for week two. Aripiprazole 20mg daily for weeks three through twelve.
3295704|NCT00497055|Placebo Comparator|Placebo|Placebo (for Aripiprazole) 5mg daily for week one. Placebo (for Aripiprazole) 10mg daily for week two. Placebo (for Aripiprazole) 20mg daily for weeks three through twelve.
3295705|NCT00496990|Active Comparator|control|Participants in this group receive the opportunity to attend a support group
3295706|NCT00496990|Experimental|Enhanced care|Participants in this arm receive the opportunity to have detoxification or methadone treatment as well as receive vouchers contingent upon drug free urine samples and individualized counseling
3295707|NCT00496964|Experimental|1|Injection of Botulinum toxin A into vastus lateralis of study limb plus exercise program
3295708|NCT00496964|Placebo Comparator|2|Placebo injection + exercise
3295709|NCT00496938|Other|1|Observational cohort using an all-comers design
3295710|NCT00496899||1|Women in active labor
3295711|NCT00496873|Experimental|Cytoxan + Rituxan + Nipent|Cytoxan 600 mg/m^2 on Day 1 of 21-day cycle. Rituxan 375 mg/m^2 on Day 1 of 21 Day Cycle. Nipent 4 mg/m^2 on Day 1 of 21 Day Cycle.
3295712|NCT00496847|Experimental|Drug Group|PERIOGEN
3295713|NCT00496847|Active Comparator|Control group|Beta TCP alone
3295714|NCT00496834|Experimental|1|Losartan or Losartan/HCTZ
3295715|NCT00496834|Active Comparator|2|Carvedilol or Carvedilol/HCTZ
3295716|NCT00496808|Experimental|Herceptin|8 mg/kg intravenously (IV) Over 90 Minutes
3295717|NCT00496795|Other|epirubicin/docetaxel sequential|Epirubicin/docetaxel sequential, i.e. one arm study with Epirubicin 4 cycles 60 mg/m2 q2w, followed by docetaxel 4 cycles, 100 mg/m2 q2w. Each course with pegfilgrastim.
3295718|NCT00496782|Other|Single|
3295719|NCT00496769|Experimental|Apixaban|
3295720|NCT00496769|Active Comparator|Acetylasalicylic acid|
3295721|NCT00496756|Other|Sorafenib|
3295722|NCT00496730|Experimental|Vytorin®|simvastatin (+) ezetimibe 10/20 mg (Vytorin®) ; tablet, once daily, 8 Weeks
3295723|NCT00496730|Active Comparator|atorvastatin|atorvastatin 10 mg; tablet, once daily, 8 Weeks
3295724|NCT00496717||1|There is only one arm and all patients will have their aortic calcium scoring by CT scan.
3295725|NCT00496691|Experimental|1|Parent-child
3295726|NCT00496691|Active Comparator|2|Adolescent only intervention focusing on condom use skills and assertiveness training around sexual discussions
3295727|NCT00496691|Placebo Comparator|3|Health promotion intervention including general health promotion topics such as smoking, diet, exercise, etc.
3295728|NCT00496678|Experimental|Navigation|Navigation through the cancer care system is the intervention
3295729|NCT00496678|Active Comparator|Standard of Care|Cancer patient receives standard of care.
3295730|NCT00496665|Experimental|Vandetenib|Cyclophosphamide 50 mg daily, methotrexate 2.5 mg days 1-2 weekly, and daily vandetanib (zactima) in 3 dose-escalation cohorts (100mg=Cohort 1) (200mg=Cohort 2) (300mg=Cohort3)
3295731|NCT00496652|Active Comparator|1|Radiotherapy (+cisplatin to stage 3+4)
3295732|NCT00496652|Experimental|2|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4) + Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
3295733|NCT00496626|Experimental|1|V501 (Gardasil®)
3295734|NCT00496626|Placebo Comparator|2|Placebo
3295735|NCT00496613||1|Breast cancer survivors (2-6 years post-treatment) who were post-menopausal at the time of diagnosis and treated with a combination of chemotherapy and hormonal therapy, matched on age and education
3295736|NCT00496613||2|Breast cancer survivors (2-6 years post-treatment) who were post-menopausal at the time of diagnosis and treated with hormonal therapy only matched on age and education
3295737|NCT00496613||3|Healthy women matched on age and education
3295738|NCT00496587|Experimental|Capecitabine + Gemcitabine + Bevacizumab|Capecitabine 800 mg/m^2 By Mouth Twice Daily On Days 1-21. Gemcitabine 900 mg/m^2 By Vein Over 30 Minutes on Days 1 and 15. Bevacizumab 10 mg/kg By Vein On Days 1 and 15.
3295739|NCT00496574|Active Comparator|1|
3295740|NCT00496574|No Intervention|2|no intevention
3295741|NCT00496561|Active Comparator|1|subcutaneous immunotherapy (House Dust Mites)
3295742|NCT00496561|Placebo Comparator|2|placebo of subcutaneous immunotherapy (House Dust Mites)
3295743|NCT00496548|Experimental|1|Fecal calprotectin and urinary PGE-M levels will be tested on all participants.
3295744|NCT00496522|Other|Proton Beam Therapy|Proton Beam Therapy - A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
3295745|NCT00496509|Experimental|ZD6474 (vandetanib) 100mg|
3295746|NCT00496509|Experimental|ZD6474 (vandetanib) 300mg|
3295747|NCT00496483|Active Comparator|LCP-Tacro (tacrolimus)|Experimental: LCP Tacro; investigational product LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.
3295748|NCT00496470|Active Comparator|Symbicort+TIO|Symbicort Turbuhaler® (budesonide/formoterol) 320/9 mcg, one inhalation twice daily and Spiriva® (tiotropium) 18 mcg, one inhalation once daily
3295749|NCT00496470|Active Comparator|Spiriva® + Placebo Turbuhaler|Spiriva® (tiotropium) 18 mcg, one inhalation once daily and placebo Turbuhaler one inhalation once daily
3295750|NCT00496457|Experimental|1|TRO19622
3295751|NCT00496457|Placebo Comparator|2|
3295752|NCT00496444|Experimental|Azacitidine + Valproic Acid|
3295753|NCT00496431|Experimental|ITF2357|
3295754|NCT00496418|Experimental|Prophylactic stoma mesh|Mesh
3295755|NCT00496418|Active Comparator|No mesh prophylaxis|No mesh
3295756|NCT00496379|Experimental|ZK219477|
3295757|NCT00496366|Experimental|Capecitabine (Xeloda) + Lapatinib (Tykerb)|"Capecitabine for 2 weeks straight (Days 1-14) followed by 1 week without capecitabine (Days 15-21).~Lapatinib will be taken daily continuously for 21 days (Days 1- 21)."
3295805|NCT00495833|Experimental|5|no personalization
3295806|NCT00495833|Experimental|A|receives gift card in blood pressure (BP) kit
3295807|NCT00495833|Experimental|B|does not receive gift card in BP kit
3295808|NCT00495820|Experimental|Arm 1|Methylphenidate
3295809|NCT00495820|Placebo Comparator|Arm 2|Placebo
3295810|NCT00495807|No Intervention|1|No Words was delivered during the PCA management
3296228|NCT00491751|Experimental|Ascorbic Acid|Ascorbic Acid 500 mg/day
3295758|NCT00496340|Experimental|Conditioning Followed by HCT|"Pentostatin/Busulfan/Rituximab/Allogeneic Hematopoietic Cell Transplant (HCT).~Pre-conditioning therapy:~All participants will receive pentostatin 4 mg/m^2 on day -28. Patients may receive additional doses on days -21 & -14 depending on cell counts.~Conditioning:~Patients will receive anti-seizure prophylaxis with lorazepam 0.5 mg every 6 hours beginning day -6.~Intravenous Busulfan (1st dose) at a dose of 200mg/m^2 on day -4.~Patient will then receive pentostatin at a dose of 4 mg/m^2 by intravenous infusion over 1-2 hours on days -4, -3.~Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600.~Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.~Rituximab: Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m^2 according to prescribing and institutional guidelines."
3295759|NCT00496327|Experimental|1|Open label
3295760|NCT00496288|Experimental|prophylactic irradiation|prophylactic contralateral breast irradiation
3295761|NCT00496288|No Intervention|controls|Those that do not opt for prophylactic irradiation or mastectomy
3295762|NCT00496262|Experimental|Human Fibrinogen Concentrate|
3295763|NCT00496223|Experimental|1|
3295764|NCT00496197|Experimental|1.|Subjects receive anidulafungin IV followed by oral therapy with fluconazole or voriconazole.
3295765|NCT00496145|Experimental|treatment|Spanish Diabetes Self-Management Program
3295766|NCT00496145|No Intervention|control|usual-care control group
3295767|NCT00496132|Experimental|1|
3295768|NCT00496119|Experimental|70 Gray (Gy) Proton Beam Therapy|Participants treated to 70 cobalt Gray equivalent (CGE) only (the standard treatment).
3295769|NCT00496119|Experimental|Photon Beam Therapy|Proton beam therapy combined with photon radiation therapy where combination improves final dose distribution.
3295770|NCT00496106|Experimental|Control Arm|6 telephone counseling sessions
3295771|NCT00496106|Active Comparator|Usual Care Arm|6 telephone counseling sessions
3295772|NCT00496093|Experimental|Pneumococcal Vaccine, Polyvalent (23-valent)|Participants received one 0.5 mL dose of Pneumococcal Vaccine, Polyvalent (23-valent) by intramuscular (deltoid) injection on Day 1.
3295773|NCT00496080|Experimental|DUAO Device|Doppler-guided uterine artery occlusion device (Single-arm study)
3295774|NCT00496067|Experimental|1|DUAO Device
3295775|NCT00496054|Experimental|RotaTeq™ Vaccine (V260)|Evaluation of Safety, Tolerability and Immunogenicity of Vaccination with RotaTeq™ in Healthy Infants in India.
3295776|NCT00496041|Experimental|Smart Stent in the Superficial Femoral Artery .|
3295777|NCT00496028|Experimental|1|AZD0530 + Paclitaxel
3295778|NCT00496028|Experimental|2|AZD0530 + Carboplatin
3295779|NCT00496028|Experimental|3|AZD0530 + Carboplatin + Paclitaxel
3295780|NCT00496015|Experimental|Synflorix I Group|Subjects were vaccinated with 3 primary vaccination doses of Synflorix™ vaccine with prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa along with prophylactic antipyretic treatment.
3295781|NCT00496015|Experimental|Synflorix II Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment
3295782|NCT00496015|Experimental|Synflorix PRE Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study (before the implementation of the protocol amendment) at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment.
3295783|NCT00496015|Experimental|Synflorix POST Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study (after the implementation of the protocol amendment) at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment.
3295784|NCT00496015|Active Comparator|Mencevax + Infanrix Hexa Group|Age-matched pneumococcal vaccine unprimed group receiving a single dose of Mencevax™ vaccine co-administered with Infanrix™ hexa vaccine.
3295785|NCT00495950||Questionnaire|
3295786|NCT00495924||PD|Patients undergoing pancreaticoduodenectomy for pancreatic or peri-ampullary tumours.
3295787|NCT00495898|Experimental|1|CYPHER sirolimus-eluting stent
3295788|NCT00495898|Active Comparator|2|uncoated Bx VELOCITY balloon-expandable stent
3295789|NCT00495885|Experimental|Volinanserin|Volinanserin 2 mg for a maximum of 87 days
3295790|NCT00495885|Placebo Comparator|Placebo|Placebo for volinanserin for a maximum of 106 days
3295791|NCT00495872|Experimental|VN|Valproic Acid + Sorafenib
3295792|NCT00495872|Experimental|VS|Valproic Acid + Sunitinib
3295793|NCT00495872|Experimental|VD|Valproic Acid + Dasatinib
3295794|NCT00495872|Experimental|VT|Valproic Acid + Erlotinib
3295795|NCT00495872|Experimental|VL|Valproic Acid + Lapatinib
3295796|NCT00495872|Experimental|VR|Valproic Acid + Lenalidomide
3295797|NCT00495859|Active Comparator|1|Study group will receive formula enriched with arginine, ω-3 fatty acids, and nucleotides once daily
3295798|NCT00495859|Active Comparator|2|controls receive an isocaloric isonitrogenous non-specific nutritional support
3295799|NCT00495846|Experimental|A|"Patients with cirrhosis without HCC in all liver function classes already receiving specific therapy for cirrhosis who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study~Patients with cirrhosis with multifocal HCC and clinical and/or radiological signs of persistence or recurrence of HCC in presence or absence of trombosis of the portal vein, with a single nodule of >6 cm in size or multiple nodules of >3 cm in size who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study"
3295800|NCT00495846|Other|B|Historical controls
3295801|NCT00495833|No Intervention|1|
3295802|NCT00495833|Experimental|2|photo and blood pressure personalization
3295803|NCT00495833|Experimental|3|photo personalization only
3295811|NCT00495807|Active Comparator|2|Positive words was delivered as a positive control group during the therapy of the pain with PCA
3295812|NCT00495807|Active Comparator|3|Partially negative words was delivered during the PCA pain management
3295813|NCT00495807|Active Comparator|4|Totally negative words was delivered during the PCA pain management
3295814|NCT00495794|Experimental|Pharmacist management|Eligible patients assigned to - adherence counseling and medication management delivered by a clinical pharmacist trained in behavioral counseling approaches (motivational interviewing)
3295815|NCT00495794|No Intervention|Usual care|Eligible patients receive usual care
3295816|NCT00495755|Experimental|Campath (alemtuzumab)|
3295817|NCT00495729|Experimental|Cohort 1|Subjects in Cohort 1 will be randomized to receive 5 milligram (mg) of SB-649868 or Placebo along with 10 mg of simvastatin.
3295818|NCT00495729|Experimental|Cohort 2|Subjects in Cohort 2 will be randomized to receive two or three times higher than the starting dose of SB-649868 or Placebo along with 10 mg of simvastatin.
3295819|NCT00495729|Experimental|Cohort 3|Subjects in Cohort 3 will be randomized to dose higher than that administered in Cohort 2 of SB-649868 or Placebo along with 10 mg of simvastatin.
3295820|NCT00495716|Active Comparator|Episodic Treatment Arm|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
3295821|NCT00495716|Active Comparator|Suppressive Therapy Arm|400 mg acyclovir orally twice daily for 1 year
3295822|NCT00495703|Experimental|1|Exercise
3295823|NCT00495703|Active Comparator|2|Usual Care
3295824|NCT00495677|Active Comparator|PF-00232798 40 mg|
3295825|NCT00495677|Active Comparator|PF-00232798 300 mg|
3295826|NCT00495677|Active Comparator|PF-00232798 400 mg|
3295827|NCT00495677|Active Comparator|PF-00232798 5 mg|
3295828|NCT00495677|Active Comparator|PF-00232798 20 mg|
3295829|NCT00495677|Active Comparator|PF-00232798 150 mg|
3295830|NCT00495664|Experimental|TITANOX|Titanium-nitride-oxide coated stent
3295831|NCT00495664|Active Comparator|PES|Paclitaxel-eluting stent
3295832|NCT00495651|Active Comparator|I|Standard of care
3295833|NCT00495651|Experimental|II|Standard of care+Isoniazid Prophylaxis:
3295834|NCT00495651|Experimental|III|Early Antiretroviral therapy
3295835|NCT00495651|Experimental|IV|Early Antiretroviral therapy + Isoniazid prophylaxis
3295836|NCT00495625|Experimental|Sunitinib Malate (SUO11248) Treatment|
3295837|NCT00495612|Experimental|Omalizumab|Patients received omalizumab via subcutaneous injection either every 2 weeks or every 4 weeks for 16 weeks. The dose administered and the dosing interval were determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
3295838|NCT00495612|Placebo Comparator|Placebo|Patients received placebo as a subcutaneous injection either every 2 weeks or every 4 weeks for 16 weeks. Patients received injections at the same time intervals as the omalizumab group.
3295839|NCT00495586|Placebo Comparator|Placebo|Placebo pills t.i.d. for 8 days
3295840|NCT00495586|Active Comparator|Amoxycillin and clavulanic acid|Amoxycillin and clavulanate t.i.d. for 8 days
3295841|NCT00495573||1|HSV-2 seropositive subjects who will receive a 5-day course of acyclovir for treatment of a genital herpes recurrence.
3295842|NCT00495573||2|HSV-2 seropositive subjects who will be observed during a genital herpes recurrence but not receive acyclovir.
3295843|NCT00495521|Experimental|Active|4-Aminosalicylic acid extended release granules (as volume equivalent of active product), 50 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 50 mg/kg orally two times daily for 2 weeks
3295844|NCT00495521|Placebo Comparator|Placebo|Placebo granules identical in appearance to the active arm (as volume equivalent of active product), 0 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 0 mg/kg orally two times daily for 2 weeks
3295845|NCT00495495|Experimental|Ozone treatment|Ozone treatment of randomly selected study tooth for 60 seconds
3295846|NCT00495495|Placebo Comparator|Placebo, no ozone|Placebo treatment (no ozone) of randomly selected study tooth for 60 seconds.
3295847|NCT00495482||1|Patients receiving palliative care due to incurable illness
3295848|NCT00495469|Experimental|GSK189075|Participants will receive GSK189075 for 12 weeks
3295849|NCT00495469|Placebo Comparator|Placebo|Participants will receive GSK189075 matching Placebo for 12 weeks
3295850|NCT00495417|Active Comparator|1|
3295851|NCT00495417|Active Comparator|2|
3295852|NCT00495404|Other|Arm 1|
3295853|NCT00495404|Other|Arm 2|
3295854|NCT00495391|Active Comparator|1|Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if <75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
3295855|NCT00495391|Placebo Comparator|2|Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if <75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
3295856|NCT00495352|Active Comparator|High-dose NRT, Low-dose NRT, bupropion|
3295857|NCT00495339|Experimental|1|Levofloxacin
3295858|NCT00495326|Experimental|1|Nevirapine-based ART
3295859|NCT00495326|Active Comparator|2|Efavirenz-based ART
3295860|NCT00495313|Active Comparator|Cohort 1: doxycycline|Vibramycin plus metronidazole
3295861|NCT00495313|Active Comparator|Cohort 2|Oracea® delayed release plus metronidazole
3295862|NCT00495287|Active Comparator|A|"Remission induction arm A is with conventional chemotherapy cycle (ICE: idarubicin, standard-dose cytarabine, etoposide)"
3295863|NCT00495287|Experimental|B|Remission induction therapy with high-dose cytarabine sequential regimen (HD-Ara-C, idarubicin)
3295916|NCT00494767|Experimental|GW869682 1000 mg thrice daily (TID)|Subjects will be randomized to receive GW869682 1000 mg TID
3295917|NCT00494767|Experimental|GSK189075 250 mg TID|Subjects will be randomized to receive GSK189075 250 mg TID
3295918|NCT00494767|Placebo Comparator|GW869682-Placebo TID|Subjects will be randomized to receive Placebo matching GW869682 for TID
3295919|NCT00494767|Placebo Comparator|GSK189075-Placebo TID|Subjects will be randomized to receive Placebo matching GSK189075 for TID
3295864|NCT00495274|Experimental|Healthy male subjects|In Part A each subject will participate in six sessions and will be administered, in randomized order, single doses of five new formulations (formulation B, C, D, E and F) of SB-649868 30 milligrams (mg), in fasted state and a single dose of the original formulation (formulation A), after a standard Food and Drug Administration (FDA) High-Fat breakfast. All dosing sessions will be separated by a washout session of at least 5 ± 2 days after each dose. In Part B a single dose of the selected SB-649868 30 mg formulation will be administered after a standard FDA High-Fat breakfast.
3295865|NCT00495261|Experimental|1|
3295866|NCT00495261|Active Comparator|2|
3295867|NCT00495248|Experimental|1|
3295868|NCT00495248|Active Comparator|2|
3295869|NCT00495235||Endometrial Cancer Group|Participants who have had endometrial cancer (cases).
3295870|NCT00495235||Control Group|Participants who have not had endometrial cancer (controls).
3295871|NCT00495222|Experimental|Tissue plication|The Endoscopic Suturing System (ESS) is used for tissue apposition and reduction of the size of a dilated GJ anastomosis in subjects who are regaining weight after successful weight loss following gastric bypass
3295872|NCT00495209||Qigong|"Pre-surgical Qigong therapy for women with breast cancer~External Qi Therapy = EQT"
3295873|NCT00495196|Experimental|1|
3295874|NCT00495196|Active Comparator|2|
3295875|NCT00495183|Experimental|1|caffeine + placebo
3295876|NCT00495183|Experimental|2|caffeine + biperiden
3295877|NCT00495183|Placebo Comparator|3|Placebo+placebo
3295878|NCT00495170|Experimental|Concurrent proton and Chemotherapy|Proton Radiotherapy + Carboplatin + Paclitaxel
3295879|NCT00495157|Experimental|Symptom-based adjustment|Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
3295880|NCT00495157|Experimental|Biomarker-based adjustment|Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
3295881|NCT00495157|Experimental|Guideline-based adjustment|Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
3295882|NCT00495131|Active Comparator|Peginterfron and ribavirin (24 weeks)|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 24 weeks
3295883|NCT00495131|Active Comparator|Peginterferon and ribavirin (48 weeks)|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 48 weeks
3295884|NCT00495105|Experimental|Two Servings of Dairy Snacks|Intervention group received two servings of dairy food per day as a snack at school for 6 months as well as nutrition education.
3295885|NCT00495105|No Intervention|No Dairy Snacks|Control Group did not receive any snacks or education.
3295886|NCT00495092|Experimental|1|This study arm will receive caffeine+placebo
3295887|NCT00495092|Experimental|2|this study arm will receive Caffeine+Biperiden
3295888|NCT00495092|Placebo Comparator|3|this study arm will receive placebo+placebo
3295889|NCT00495079|Experimental|Marqibo|Eligible subjects received study drug at 2.25 mg/m^2 intravenously via peripheral or central venous access over 60 minutes (± 10 minutes).
3295890|NCT00495053|Active Comparator|hMaxi-K|
3295891|NCT00495053|Placebo Comparator|Placebo|
3295892|NCT00495040|Experimental|Proton Radiotherapy|Proton radiotherapy 87.5 CGE with 2.5 Gy/fraction for 35 treatments.
3295893|NCT00494975|Experimental|NB-UVB|Narrow band-Ultraviolet B phototherapy
3295894|NCT00494975|Placebo Comparator|UVA|Ultraviolet A Phototherapy
3295895|NCT00494949|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
3295896|NCT00494949|Active Comparator|Control|Ringer's lactate
3295897|NCT00494936||HIV/HCV|HIV and HCV coinfected
3295898|NCT00494936||HIV infected|HIV monoinfected
3295899|NCT00494936||HIV/HCV nonviremnic|HIV and HCV coinfected with HCV RNA less than 600 copies
3295900|NCT00494936||HCV infected|HCV monoinfected with HCV viremia
3295901|NCT00494910|Experimental|1|Meaning Centered Group Psychotherapy (MCGP)
3295902|NCT00494910|Active Comparator|2|standardized Supportive Group Psychotherapy
3295903|NCT00494871|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period
3295904|NCT00494871|Active Comparator|Warfarin|Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period
3295905|NCT00494858|Active Comparator|CBT-EF|Participants will receive cognitive behavioral therapy - focused
3295906|NCT00494858|Experimental|CBT-EB|Participants will receive cognitive behavioral therapy - broad
3295907|NCT00494845|Experimental|Intervention|8-week Mindfulness Program for chronic low back pain
3295908|NCT00494845|Active Comparator|Comparison|8-week health education program
3295909|NCT00494832|Active Comparator|Dexmedetomidine|Dexmedetomidine infusion
3295910|NCT00494832|Placebo Comparator|Placebo|Normal Saline infusion
3295911|NCT00494806|Experimental|Rocking Group|Patients rocked in a rocking chair in 10-20 minute increments for at least one hour per day beginning on the first day after surgery. Activity was increased each day and continued until passage of first postoperative flatus.
3295912|NCT00494806|No Intervention|Standard Care|Standard care group got out of bed and sat in a non-rocking chair and ambulated beginning the first day after surgery. Activity was increased each day and continued until passage of first postoperative flatus.
3295913|NCT00494793|Other|VAWC and mesh mediated fascial traction|This is a study aiming to evaluate one technique for temporary abdominal closure for open abdomen therapy in all patients applicable according to the inclusion criteria
3295914|NCT00494780|Active Comparator|Active Comparator 1|Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 500mg
3295915|NCT00494780|Active Comparator|Active Comparator 2|Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 1000mg
3295922|NCT00494728|Other|CBASP + ST|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) + Smoking Cessation Treatment (ST)
3295923|NCT00494728|Other|ST|Smoking Cessation Treatment (ST)
3295924|NCT00494715|Experimental|Benazepril|
3295925|NCT00494715|Experimental|valsartan|
3295926|NCT00494715|Experimental|benazepril/valsartan|
3295927|NCT00494702|Experimental|LOX|Low saturation group of premature infants that will be kept within preset limits of 85-89%
3295928|NCT00494702|Active Comparator|HOX|HOX group of premature infants will be kept within preset saturation limits of 90-93%
3295929|NCT00494676|Experimental|Real prism glasses first, then sham|Participants in this arm will receive high power (57 prism diopter) peripheral prism glasses in the first period of the crossover and low power sham peripheral prism glasses in the second period
3295930|NCT00494676|Experimental|Sham prism glasses first, then real|Participants in this arm will receive low power sham peripheral prism glasses in the first period of the crossover and high power (57 prism diopter) peripheral prism glasses in the second period
3295931|NCT00494663|Experimental|1|150mg DIO-902 + 10mg atorvastatin
3295932|NCT00494663|Experimental|2|300mg DIO-902 + 10mg atorvastatin
3295933|NCT00494663|Experimental|3|450mg DIO-902 + 10mg atorvastatin
3295934|NCT00494663|Placebo Comparator|4|DIO-902 Placebo + 10mg atorvastatin
3295935|NCT00494663|Experimental|5|150mg DIO-902 + atorvastatin placebo
3295936|NCT00494663|Experimental|6|300mg DIO-902 + atorvastatin placebo
3295937|NCT00494663|Experimental|7|450mg DIO-902 + atorvastatin placebo
3295938|NCT00494663|Placebo Comparator|8|DIO-902 placebo + atorvastatin placebo
3295939|NCT00494650|Experimental|1|Participants will receive cognitive behavioral therapy.
3295940|NCT00494650|Active Comparator|2|Participants will receive brief PTSD treatment.
3295941|NCT00494585|Experimental|CEP-701|80 mg orally twice a day for 30 days
3295942|NCT00494572|Sham Comparator|Sterile Water|Sterile water
3295943|NCT00494572|Active Comparator|Montelukast|10mg rapid dissolving granules in sterile water orally once
3295944|NCT00494559|Experimental|Actos|Actos group: pioglitazone 15mg or 30mg
3295945|NCT00494559|Placebo Comparator|Placebo|Placebo group: placebo without active medication
3295946|NCT00494520|Experimental|Errorful training condition|A type of anomia rehabilitation paradigm which allows for errors. The intervention involves providing minimal auditory cues to allow for errors in picture naming.
3295947|NCT00494520|Experimental|Errorless training condition|A type of anomia rehabilitation paradigm in which the situation surrounding the performance of the desired task (i.e., picture naming) is controlled to prevent errors. The intervention involves providing maximal auditory cues to prevent errors in picture naming.
3295948|NCT00494507|Active Comparator|HYP Dichlorphenamide|Hyperkalemic participants were randomized to Dichlorphenamide for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
3295949|NCT00494507|Placebo Comparator|HYP Placebo|Hyperkalemic participants were randomized to Placebo for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
3295950|NCT00494507|Active Comparator|HOP Dichlorphenamide|Hypokalemic participants were randomized to Dichlorphenamide for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
3295951|NCT00494507|Placebo Comparator|HOP Placebo|Hypokalemic participants were randomized to Placebo for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
3295952|NCT00494494|Active Comparator|Standard Treatment|topical antibiotic for 10 days and a topical corticosteroid for 1 month
3295953|NCT00494494|Experimental|Nepafenac|1 drop per study eye three times per day for 30 days in addition to standard care
3295954|NCT00494481|Placebo Comparator|1|Docetaxel + placebo vandetanib
3295955|NCT00494481|Experimental|2|Vandetanib + Docetaxel
3295956|NCT00494455|Active Comparator|1|Continuous subcutaneous glucose monitoring in patients without shock
3295957|NCT00494455|Active Comparator|2|continuous subcutaneous glucose monitoring in patients with shock
3295958|NCT00494442|Experimental|KU-0059436 (AZD2281) 100 mg BID|
3295959|NCT00494442|Experimental|KU-0059436 (AZD2281) 400 mg BID|
3295960|NCT00494429|Experimental|1|Gestational Age< 29 weeks will be administered a loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/hr.
3295961|NCT00494429|Experimental|2|Gestational Age>= 29 weeks will be administered a loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
3295962|NCT00494416|No Intervention|ANC approach|Passive health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.
3295963|NCT00494416|Other|advanced strategies SP|Joint with advanced strategies delivery approach (JAS). In addition to passive delivery of IPT/sulphadoxine pyrimethamine (SP) at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages, such as immunization, health promotion, and even ANC visits.
3295964|NCT00494416|Other|Community based|Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs). Each approach will be implemented in a zone constituted by the catchment area of a number of health centres to achieve the required sample size. The zones will be randomly assigned to a delivery approach. The main outcomes to be measured are: a) the coverage of IPT, b) compliance, c) infection prevalence, d) Hb level, e) difficulties and constraints of each approach, f) the acceptability to population and health staff and g) the performance of each approach to deliver IPT /SP. Coverage by 10%, each group should be composed of n = 3841 pregnant women.
3295965|NCT00494312|Experimental|Pioglitazone QD|
3295966|NCT00494312|Active Comparator|Glyburide QD|
3295967|NCT00494299|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose modification (delayed or reduced) was permitted due to toxicity.
3296286|NCT00490906||1|Patients receive Copaxone
3295968|NCT00494299|Placebo Comparator|Placebo|Sorafenib (Nexavar, BAY43-9006) matching placebo (2 placebo tablets) orally administered bid (twice daily).
3295969|NCT00494286|Experimental|AF-CBT|Participants will receive abused-focused cognitive behavioral therapy
3295970|NCT00494286|Active Comparator|TAU|Participants will receive treatment as usual
3295971|NCT00494260|Experimental|Social learning and cognitive behavioral therapy (SLCBT)|The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques.
3295972|NCT00494260|Active Comparator|Education Support (ES)|The ES condition focuses on education about GI system anatomy and function, information about the United States Department of Agriculture nutrition guidelines, and additional food-related information such as how to read food product labels. The ES condition was developed to provide a credible alternative condition that would control for therapist and patient time and attention.
3295973|NCT00494234|Experimental|KU-0059436 (AZD2281) 100 mg BID|
3295974|NCT00494234|Experimental|KU-0059436 (AZD2281) 400 mg BID|
3295975|NCT00494221|Active Comparator|FOLFOX + Cediranib 20 mg|FOLFOX + Cediranib 20 mg
3295976|NCT00494221|Active Comparator|FOLFOX + Cediranib 30 mg|FOLFOX + Cediranib 30 mg
3295977|NCT00494221|Placebo Comparator|FOLFOX + Placebo Cediranib|FOLFOX + Placebo Cediranib
3295978|NCT00494208|Active Comparator|1|
3295979|NCT00494208|Active Comparator|2|
3295980|NCT00494208|Active Comparator|3|
3295981|NCT00494208|Active Comparator|4|
3295982|NCT00494208|Active Comparator|5|
3295983|NCT00494195|Experimental|1|The first cohort will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml. The anatomical midline point of the muscle will be identified on the skin and two to six vector injections will be distributed in the direction of an X. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
3295984|NCT00494195|Experimental|2|The second cohort will receive the same dose of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
3295985|NCT00494182|Experimental|Sorafenib + Carboplatin + Paclitaxel|Sorafenib 400 mg orally twice daily on Day 2-19. Carboplatin 6 AUC intravenously (IV) over 30 Minutes on Day 1. Paclitaxel 200 mg/m^2 IV over 3 hours on Day 1.
3295986|NCT00494143|Active Comparator|Conventional Prosthetic foot|A conventional prosthetic foot that has limited energy storage and return capabilities. It is standardized and used by all subjects in the study.
3295987|NCT00494143|Active Comparator|Prescribed Prosthetic foot|the Prosthetic foot that the subject had prescribed for them by their clinical providers and was worn prior to study initiation
3295988|NCT00494143|Experimental|CESR foot|the experimental CESR, controlled energy storage prosthetic foot
3295989|NCT00494104|Active Comparator|200 IU/day Vitamin D|200 IU/day Vitamin D
3295990|NCT00494104|Experimental|400 IU/day Vitamin D|400 IU/day Vitamin D
3295991|NCT00494104|Experimental|600 IU/day Vitamin D|600 IU/day Vitamin D
3295992|NCT00494104|Experimental|800 IU/day Vitamin D|800 IU/day Vitamin D
3295993|NCT00494091|Experimental|A.|
3295994|NCT00494091|Experimental|B.|
3295995|NCT00494078|Active Comparator|1|Patients randomised to this arm are treated with intensive insulin therapy guided by the continuous glucose monitoring system.
3295996|NCT00494078|Active Comparator|2|intensive insulin therapy guided by an algorithm
3295997|NCT00494065|Experimental|1|Chiropractic Spinal Manipulative Therapy + Home exercise
3295998|NCT00494065|Active Comparator|2|Home exercise
3295999|NCT00494052|Experimental|1|Heart to Heart intervention
3296000|NCT00494052|No Intervention|2|Usual care
3296001|NCT00494026|Experimental|Pemetrexed + Carboplatin|
3296002|NCT00494013|Experimental|Insulin Lispro Protamine Suspension|Insulin Lispro Protamine Suspension: Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
3296003|NCT00494013|Active Comparator|Detemir|Detemir: Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
3296004|NCT00493987|Active Comparator|Testosterone enanthate|
3296005|NCT00493987|Placebo Comparator|Duatesteride|Duatesteride
3296006|NCT00493974|Active Comparator|Zileuton|Zileuton (Zyflo, 600 mg 4 times a day)
3296007|NCT00493974|Placebo Comparator|Placebo|Placebo
3296008|NCT00493922|Active Comparator|2|Microscopy for diagnosis of malaria
3296009|NCT00493922|Active Comparator|3|Clinical diagnosis for malaria
3296010|NCT00493922|Experimental|1|Rapid Diagnostic Test for Malaria
3296011|NCT00493909|Active Comparator|1|thoracic epidural analgesia
3296012|NCT00493909|Active Comparator|2|intrathecal opioids and thoracic paravertebral analgesia
3296013|NCT00493896|Experimental|Fondaparinux|Fondaparinux treatment - one standard of care option
3296014|NCT00493896|Active Comparator|2|Enoxaparin
3296015|NCT00493883|Other|TheraSphere|Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver
3296016|NCT00493870|Experimental|TC|docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2
3296017|NCT00493870|Active Comparator|TAC|doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 and docetaxel 75 mg/m2
3296018|NCT00493857|Experimental|2|Nimotuzumab 400mg every week or every two weeks
3296019|NCT00493844|Experimental|1|Discharge if clinical risk score <3 points + Nt-proBNP <110 ng/L
3296020|NCT00493844|Active Comparator|2|Discharge if negative exercise testing
3296021|NCT00493805|Experimental|Interventional Study arm (with insulin resistance)|"HOMA IR (homeostasis model assessment-estimated insulin resistance) of > 2~These participants received PEG-Intron 1.5 μg /kg subcutaneously (SC) once weekly plus weight based Rebetol 800-1400 mg by mouth (PO) administered twice daily (BID) for a variable period depending on their response to treatment."
3296022|NCT00493805|Experimental|Non interventional study arm (without insulin resistance)|"HOMA IR <= 2~These participants received PEG-Intron 1.5 μg /kg subcutaneously (SC) once weekly plus weight based Rebetol 800-1400 mg PO administered twice daily (BID) for 48 weeks. (Participants are treated according to~European labeling)."
3296023|NCT00493792|Other|1|Stryker Orthopaedics N2Vac Polyethylene when used with a Triathlon Posterior Stabilized total knee system. This is a fixed- bearing knee intended for use in patients undergoing cemented total knee arthroplasty.
3296024|NCT00493792|Other|2|X3 Polyethylene when used with a Triathlon Posterior Stabilized total knee system. This is a fixed- bearing knee intended for use in patients undergoing cemented total knee arthroplasty.
3296025|NCT00493779|No Intervention|1|Effect of Clopidogrel withdrawal on biomarkers will be assessed via blood draws
3296026|NCT00493766|Experimental|oral LBH589 alone|
3296027|NCT00493766|Experimental|oral LBH589 + IV docetaxel + oral prednisone|
3296028|NCT00493727|Other|1|
3296029|NCT00493714||Arm 1 (Patient)|Cancer patient who recently experienced confusion or restlessness.
3296030|NCT00493714||Arm 2 (Caregiver)|Caregivers of cancer patients who recently experienced confusion or restlessness.
3296031|NCT00493701|Other|Lifestyle|Measurement of body weight in a fown with light undercloting (30 minutes) and height.
3296032|NCT00493701|Other|DEXA Scanner|Low-dose X0rays to determine the amount of fat, bone and muscle in your body.
3296033|NCT00493688||Cardiopulmonary Exercise Testing (CPET)|
3296034|NCT00493649|Experimental|TC+H|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel (Taxotere) 75 mg/m2 IV (over 1 hour), plus cyclophosphamide (Cytoxan) 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab (Herceptin) 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter.
3296035|NCT00493636|Active Comparator|A (Sorafenib + Gemcitabine or Capecitabine)|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)
3296036|NCT00493636|Placebo Comparator|B (Placebo + Gemcitabine or Capecitabine)|Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)
3296037|NCT00493623|Experimental|1|
3296038|NCT00493623|Placebo Comparator|2|
3296039|NCT00493610|Other|1|
3296040|NCT00493584|Experimental|1|Primary PCI in patients with acute Non-STEMI
3296041|NCT00493584|Active Comparator|2|Standard medical treatment and coronary angiography after 3 days in patients with Non-STEMI.
3296042|NCT00493571|Experimental|Gimatecan|Gimatecan Starting dose: 0.6 mg capsules administered orally once daily.
3296043|NCT00493480|Active Comparator|carvedilol|
3296044|NCT00493480|Active Comparator|propranolol|Cirrhotic patients treated with propranolol
3296045|NCT00493467|Experimental|Zevalin|Ibritumomab Tiuxetan (Zevalin) + Rituximab
3296046|NCT00493454|Experimental|Ibritumomab tiuxetan + Rituximab|Rituximab 250 mg/m² intravenous (IV) Days 1 and 8, 111In Ibritumomab Tiuxetan (5mCi of 111In, 1.6 mg of Ibritumomab Tiuxetan) IV (over 10 minutes) on Day 1; and 90Y Ibritumomab Tiuxetan 0.3 or 0.4 mCi/kg IV (over 10 minutes) on Day 8 after the Day 8 of Rituximab.
3296047|NCT00493441|Experimental|Treatment|
3296048|NCT00493415|Experimental|1|nitroglycerine iv
3296049|NCT00493415|Placebo Comparator|2|nacl 0.9% 4 ml/h iv in the first 30 minutes, 2 ml/h iv in the next 23 hours and 30 minutes
3296050|NCT00493402|Experimental|combined chemotherapy with embolization|chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, with particle embolization.
3296051|NCT00493402|Experimental|combined chemotherapy without embolization|chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, without particle embolization.
3296052|NCT00493402|Experimental|single agent chemotherapy with embolization|chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
3296053|NCT00493363|Experimental|arm 1|
3296054|NCT00493363|Active Comparator|arm 2|
3296055|NCT00493350||1|Patients with newly diagnosed stage IV breast cancer scheduled to start systemic therapy.
3296056|NCT00493337|No Intervention|Control group|
3296057|NCT00493337|Experimental|Advanced counseling|
3296058|NCT00493337|Active Comparator|Compliance Card only|
3296059|NCT00493324|Experimental|1|
3296060|NCT00493311|Experimental|IV Acetaminophen|1 g of acetaminophen in 100 mL of intravenous solution
3296061|NCT00493311|Placebo Comparator|IV Placebo|100 mL of intravenous placebo solution
3296062|NCT00493298||natalizumab|According to the local prescribing information
3296063|NCT00493285|Active Comparator|1|MEDI-534 at 10^4 TCID50 at 0, 2, and 4 months (Nasal spray)
3296064|NCT00493285|Active Comparator|2|MEDI-534 at 10^5 TCID50 at 0, 2, and 4 months (Nasal Spray)
3296065|NCT00493285|Active Comparator|3|MEDI-534 at 10^6 TCID50 at 0, 2, and 4 months (Nasal Spray)
3296066|NCT00493272|Placebo Comparator|Placebo|Nacl
3296067|NCT00493272|Active Comparator|Fibrinogen|Fibrinogen
3296068|NCT00493246|Experimental|Intravenous (IV) Acetaminophen 15 milligrams/kilogram (mg/kg)|Intravenous Acetaminophen administered 15 milligrams/kilogram (mg/kg) every 8 hours (q8h) or every 6 hours (q6h) based age of subject
3296069|NCT00493246|Experimental|Intravenous (IV) Acetaminophen 12.5 (mg/kg)|Intravenous Acetaminophen administered 12.5 milligrams/kilogram (mg/kg) every 6 hours (q6h) or every 4 hours (q4h)
3296070|NCT00493233|Experimental|1|
3296071|NCT00493233|Placebo Comparator|2|
3296072|NCT00493220|Experimental|HYLENEX SC, Placebo SC, IV|subcutaneous HYLENEX and ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention
3296073|NCT00493220|Experimental|HYLENEX SC, IV, Placebo SC|subcutaneous HYLENEX and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention
3296287|NCT00490906||2|Patients receive interferons
3296074|NCT00493220|Experimental|Placebo SC, HYLENEX SC, IV|subcutaneous placebo and ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention
3296075|NCT00493220|Experimental|Placebo SC, IV, HYLENEX SC|subcutaneous placebo and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention
3296076|NCT00493220|Experimental|IV, HYLENEX SC, Placebo SC|IV ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention
3296077|NCT00493220|Experimental|IV, Placebo SC, HYLENEX SC|IV ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention
3296078|NCT00493181|Experimental|Interleukin-11|Starting dose 10 mcg/kg subcutaneously 3 times a week
3296079|NCT00493155|Experimental|1|
3296080|NCT00493142|Experimental|1|Usual care
3296081|NCT00493129|Experimental|Ontak|Ontak administered intravenously on Days 1-5 at the dose of 9 µg/kg/day, with a rest period from Days 6-21.
3296082|NCT00493116|Experimental|1|
3296083|NCT00493077|Experimental|1|
3296084|NCT00493064|Experimental|Prospective active treatment|Niacin 500mg TID PO for treatment of retinal vein occlusions.
3296085|NCT00493051|Other|1|Standardized Wound Care
3296086|NCT00493051|Placebo Comparator|2|Placebo 1 dose
3296087|NCT00493051|Placebo Comparator|3|Placebo 2 doses
3296088|NCT00493051|Active Comparator|4|Active 1 dose
3296089|NCT00493051|Active Comparator|5|Active 2 doses
3296090|NCT00493038|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg tablets once daily (OD) for 7 days and amoxicillin/clavulanate 1000 mg matching placebo tablets three times daily (TID)for 10 days
3296091|NCT00493038|Active Comparator|Amoxicillin/Clavulanate|Amoxicillin/clavulanate 1000 mg tablets three times daily (TID) for 10 days and moxifloxacin 400 mg matching placebo tablets once daily (OD) for 7 days
3296092|NCT00493012|Experimental|vitamin D oil|oil containing vitamin D (Vigantol oil)
3296093|NCT00493012|Placebo Comparator|placebo oil|oil not containg vitamin D (Migliol oil)
3296094|NCT00492999|Experimental|Group 1|Patients receive hepatic arterial infusion (HAI) therapy comprising floxuridine and dexamethasone continuously on days 1-14. Patients also receive oxaliplatin IV over 2 hours and irinotecan hydrochloride IV over 30 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3296095|NCT00492999|Experimental|Group 2|Patients receive HAI therapy as in group 1. Patients also receive irinotecan hydrochloride IV over 30 minutes and leucovorin calcium IV over 30 minutes on days 1 and 15 and fluorouracil IV continuously over 48 hours on days 1, 2, 15, and 16. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3296096|NCT00492986|Experimental|Arm 1|
3296097|NCT00492973|Active Comparator|Control|Patients in the active comparator group will receive intraoperative injections containing bupivacaine HCl, morphine, epinephrine, clonidine, cefuroxime, and normal saline, as per the surgeon's standard of care.
3296098|NCT00492973|Experimental|Corticosteroid|Patients in the Corticosteroid group will have the same medications as the Control Group with the addition of a corticosteroid (methylprednisolone acetate)
3296099|NCT00492960|Experimental|Larazotide acetate 1 mg|larazotide acetate 1 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
3296100|NCT00492960|Experimental|Larazotide acetate 4 mg|larazotide acetate 4 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
3296101|NCT00492960|Experimental|Larazotide acetate 8 mg|larazotide acetate 8 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
3296102|NCT00492960|Placebo Comparator|Placebo|placebo capsules TID + 900 mg gluten capsules TID for 6 weeks
3296103|NCT00492934|Active Comparator|1|Daily injections with a small dose of gonadotrophins from day 2 of the cycle
3296104|NCT00492934|No Intervention|2|No daily injections with hormones
3296105|NCT00492908|Active Comparator|Titanium Nitride Oxide Coated Stent|Stent
3296106|NCT00492908|Active Comparator|Zotarohlimus Eluting Stent|Stent
3296107|NCT00492895|Other|A|one arm only. Crossover study
3296108|NCT00492856|Experimental|Post-consolidation therapy arm I|Patients receive oral tretinoin twice daily on days 1-7, oral mercaptopurine once daily on days 1-14, and oral methotrexate on day 1. Treatment repeats every 2 weeks for up to 1 year.
3296109|NCT00492856|No Intervention|Post-consolidation therapy arm II|Patients receive no further chemotherapy. Patients are followed every 3 months for 1 year. (Randomization and observation arm closed as of 8/15/10)
3296110|NCT00492843|Experimental|A|Intravenous infusion of either 6mg Bondronat on three consecutive days
3296111|NCT00492843|Active Comparator|B|Intravenous infusion of 6mg Bondronat on one day
3296112|NCT00492817|Experimental|Single Session Stereotactic Body Radiotherapy (SBRT)|On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
3296113|NCT00492804|Other|Neurectomy|
3296114|NCT00492804|Other|Nerve preservation|
3296115|NCT00492791||Endoscopic Capsule|Patient enrolled for performing an endoscopic capsule
3296116|NCT00492778|Experimental|Arm I (brachytherapy, radiation therapy)|Patients undergo EBRT to the pelvis daily on days 1-5 for 5 weeks. After completion of EBRT, patients undergo intracavitary low-dose rate or high-dose rate brachytherapy or low-dose rate interstitial brachytherapy.
3296117|NCT00492778|Experimental|Arm II (brachytherapy, radiation therapy, cisplatin)|Patients undergo EBRT as in Arm I and receive cisplatin IV over 1-2 hours on days 1, 8, 15, 22, and 29. Patients then undergo brachytherapy as in Arm I.
3296118|NCT00492765|Experimental|1|interferon beta-1a and Simvastatin
3296119|NCT00492765|Placebo Comparator|2|Interferon beta-1a and Placebo
3296120|NCT00492752|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib was administered orally at a dose of 400 mg (2 x 200 mg tablets) bid (twice daily); 2 dose reductions to predefined levels of 400 mg (2 x 200 mg tablets) once daily (od) and 400 mg (2 x 200 mg tablets) every 2 days were permitted for treatment-emergent adverse events related to study treatment.
3296121|NCT00492752|Placebo Comparator|Placebo|Placebo tablets matching in appearance were orally administered bid (twice daily).
3296122|NCT00492739|Other|Varicella vaccine|2-3 doses of Varicella vaccine to seronegative patients two months apart
3296123|NCT00492726|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.
3296124|NCT00492726|Active Comparator|Ertapenem|Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.
3296125|NCT00492713|Active Comparator|1|Dark chocolate
3296126|NCT00492713|Active Comparator|2|Milk chocolate 1
3296127|NCT00492713|Active Comparator|3|Milk chocolate 2
3296128|NCT00492661|Experimental|Tacrolimus With Diet and Exercise Intervention|Participants on tacrolimus for immunosuppression (drug which suppresses the body's immune response, used in transplantation and diseases caused by disordered immunity) will be provided with intensive dietary advice and supervised progressive resistance training (PRT) for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
3296129|NCT00492648|Experimental|Group A|Subjects aged 18 to 30 years old
3296130|NCT00492648|Experimental|Group B|Subjects aged 50 to 70 years old.
3296131|NCT00492635|Experimental|Arm 1|
3296132|NCT00492635|Experimental|Arm 2|
3296133|NCT00492635|Placebo Comparator|Arm 3|
3296134|NCT00492622|Experimental|Immediate-release omeprazole release first|subjects receive immediate release omeprazole for 7 days then delayed release for 7 days
3296135|NCT00492622|Experimental|Delayed-release omeprazole first|subjects receive delayed release omeprazole for 7 days then immediate release for 7 days
3296136|NCT00492609||1|PATIENTS WITH COMPUTER-ASSISTED
3296137|NCT00492609||2|PATIENTS WITHOUT COMPUTER-ASSISTED
3296138|NCT00492596|Experimental|device|insertion of balloon system
3296139|NCT00492596|Sham Comparator|sham|cystoscopy with sham system
3296140|NCT00492583|Placebo Comparator|Placebo|Subjects were provided 4 fluid ounces (112 grams) administered orally per day of placebo drink.
3296141|NCT00492583|Experimental|Bifidobacterium lactis (BB-12)|Subjects were provided 4 fluid ounces (112 grams) administered orally per day of active drink.
3296142|NCT00492557|Experimental|13vPnC+TIV Followed by Placebo 1 month later|
3296143|NCT00492557|Active Comparator|Placebo+TIV Followed by 13vPnC 1 month later|
3296144|NCT00492544|Experimental|Cervarix|Subjects received 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) according to a 0, 1, 6-month schedule.
3296145|NCT00492531|Experimental|Sildenafil|There was a balancing of treatment group assignment across Tricuspid Regurgitant Jet velocity(TRV)measured on Echo.
3296146|NCT00492531|Placebo Comparator|Placebo|There was a balancing of treatment group assignment across Tricuspid Regurgitant Jet velocity(TRV)measured on Echo
3296147|NCT00492492|Other|trans-styloid and intrafocal pinning on the one side|trans-styloid and intrafocal pinning on the one side
3296148|NCT00492492|Other|volar fixed-angle plating on the other side|volar fixed-angle plating on the other side
3296149|NCT00492466|Experimental|1|
3296150|NCT00492453|Active Comparator|1|Laparoscopic cholecystectomy under spinal anesthesia
3296151|NCT00492453|Active Comparator|2|Laparoscopic cholecystectomy under general anesthesia
3296152|NCT00492440|Experimental|CYT107 (r-hIL-7)|
3296153|NCT00492427|Active Comparator|2|
3296154|NCT00492427|Experimental|1|
3296155|NCT00492401|Experimental|Treatment (chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3296156|NCT00492388|Experimental|A|PMI-150 (intranasal ketamine)
3296157|NCT00492388|Placebo Comparator|B|placebo
3296158|NCT00492362|Active Comparator|A|Ergometer during hemodialysis
3296159|NCT00492362|Active Comparator|B|Pedometer use outside of hemodialysis
3296160|NCT00492349|Experimental|1|Varenicline
3296161|NCT00492349|Placebo Comparator|2|Placebo
3296162|NCT00492336|Active Comparator|Rasagiline|Treatment with Rasagiline
3296163|NCT00492336|Placebo Comparator|Inactive pill|Treatment with Placebo
3296164|NCT00492323|Placebo Comparator|002|placebo twice daily for 4 weeks
3296165|NCT00492323|Experimental|001|carisbamate 200 mg tablet twice daily for 4 weeks
3296166|NCT00492310|Experimental|1|Cognitive-behavioral smoking cessation with yoga
3296167|NCT00492310|Active Comparator|2|smoking cessation with twice weekly wellness program
3296168|NCT00492297|Experimental|Sorafenib + Dacarbazine|Dacarbazine 1000 mg/m^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
3296169|NCT00492284|Experimental|1/4 Fluence Triple Therapy|Very low fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
3296170|NCT00492284|Experimental|1/2 Fluence Triple Therapy|Reduced-fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
3296171|NCT00492284|Experimental|1/2 Fluence Double Therapy|Reduced-fluence Visudyne followed by Lucentis double therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
3296172|NCT00492284|Experimental|Ranibizumab|Lucentis monotherapy administered on Day 0, Month 1 and Month 2, and then as required monthly thereafter
3296173|NCT00492271|Experimental|1|Experimental arm with increasing dosage
3296174|NCT00492232|Experimental|Ramelteon 8 mg QD and current Zolpidem therapy|Zolpidem therapy will be reduced by dose, frequency, or both for up to 10 weeks.
3296175|NCT00492232|Placebo Comparator|Placebo QD and current Zolpidem therapy|Zolpidem therapy will be reduced by dose, frequency, or both for up to 10 weeks.
3296176|NCT00492219|Active Comparator|1|Patients undergoing total knee replacement
3296177|NCT00492219|No Intervention|2|Healthy volunteers that are not undergoing knee replacement surgery
3296178|NCT00492219|Experimental|3|Patients undergoing partial knee replacement with the Oxford mobile bearing implant system
3296179|NCT00492219|Experimental|4|Patients undergoing partial knee replacement with the Vanguard M implant system
3296288|NCT00490854|Experimental|1|
3296180|NCT00492206|Experimental|Cetuximab|"Cetuximab 400 mg/m2 IV week 0 only~External beam radiation weeks 1 - 7~Cetuximab 250 mg/m2 IV weekly thereafter weeks 1 - 7~Cetuximab 250 mg/m2 IV weekly weeks 8 - 26~Carboplatin AUC = 6 IV Paclitaxel 200 mg/m2 IV Every 3 weeks x 3 Cycles"
3296181|NCT00492167|Experimental|Beta-Glucan and Monoclonal Antibody 3F8|"This is a dose-escalation study of beta-glucan. Patients receive oral beta-glucan once daily on days -4 to 12 and monoclonal antibody 3F8 IV over 30-90 minutes on days 1-5 and 8-12. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity and with a human antimouse antibody (HAMA) titer < 1,000 U/mL.~Cohorts of 3-6 patients receive escalating doses of beta-glucan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Patients undergo urine, bone marrow, and blood sample collection periodically for biological studies. Samples are analyzed for antibody-dependent cellular cytotoxicity, complement-mediated cytotoxicity, and serum HAMA response via immunohistochemistry.~After completion of study treatment, patients are followed periodica"
3296182|NCT00492141|Experimental|L9-NC + Temozolomide|Liposomal 9-nitro-20(S)-camptothecin (L9-NC) alone, total 10 ml of 0.4 mg/ml in aerosol reservoir once a day for 5 days in row each 2 weeks, followed by 2 weeks off; then in combination with Temozolomide 100 mg/m^2 oral/day for Cycle 2 Days 1-5.
3296183|NCT00492128|Experimental|Losartan/hydrochlorothiazide|Combination drug with losartan 50mg and hydrochlorothiazide 12.5mg
3296184|NCT00492128|Active Comparator|Losartan/amlodipine|Combination therapy with losartan 50mg and amlodopine 5mg
3296185|NCT00492115|Active Comparator|"therapeutic CPAP Treatment (6 weeks)"|The intervention is nightly therapeutic CPAP (continuous positive airway pressure) treatment for 6 weeks. Patients will use CPAP every night for the full duration of the study, i.e., 6 weeks
3296186|NCT00492115|Placebo Comparator|"Sham CPAP/therapetuic CPAP (6 weeks)"|"The intervention is placebo CPAP (continuous positive airway pressure) nightly for 3 weeks followed by therapeutic CPAP treatment nightly for 3 weeks.~Patients will use a sham CPAP (no real pressure) for 3 weeks and then will be switched to real CPAP for 3 weeks."
3296187|NCT00492102|Experimental|1|Nine VLBW pre-term infants older than 7 days will be enrolled in the study and receive one oral dose of Montelukast based on weight. Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.
3296188|NCT00492089|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
3296189|NCT00492089|Placebo Comparator|Arm II|Patients receive placebo IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
3296190|NCT00492076|Active Comparator|1|Pangramin Plus Dermatophagoides pteronyssinus 100%
3296191|NCT00492076|Placebo Comparator|2|Pangramin Plus placebo
3296192|NCT00492063|Experimental|Cell culture-derived influenza vaccine (cTIV)|
3296193|NCT00492063|Active Comparator|Egg-derived influenza virus vaccine (TIV)|
3296194|NCT00492050|Experimental|Bortezomib + Rituximab|Bortezomib 1.6 mg/m^2 IV Weekly on Days 1, 8, 15 and 22. Rituximab 375 mg/m^2 IV on Day 8 and 22. Valacyclovir 500 mg orally daily (or acyclovir 200 mg orally twice daily).
3296195|NCT00492024|Experimental|Moxifloxacin 400 mg|Moxifloxacin 400mg once daily for 5 days
3296196|NCT00492024|Placebo Comparator|Placebo|Matching placebo for 5 days
3296197|NCT00492011|Experimental|Ramelteon 1 mg QD|
3296198|NCT00492011|Experimental|Ramelteon 4 mg QD|
3296199|NCT00492011|Experimental|Ramelteon 8 mg QD|
3296200|NCT00492011|Placebo Comparator|Placebo|
3296201|NCT00491998|Experimental|2-hourly dosing|6 Doses of IMP at 2-hourly intervals
3296202|NCT00491998|Experimental|3-hourly dosing|4 doses of IMP at 3-hourly intervals
3296203|NCT00491998|Active Comparator|3-hourly dosing plus Entacapone|4 doses of IMP plus Entacapone at 3-hourly intervals
3296204|NCT00491985|Experimental|Study Group 1|Subjects aged 9 to 17 years
3296205|NCT00491985|Experimental|Study Group 2|Subjects aged 3 to 8 years
3296206|NCT00491985|Experimental|Study Group 3|Subjects aged 6 to 35 months
3296207|NCT00491894|Other|Patients with Chronic Drooling|Arm receiving study drug
3296208|NCT00491868|Experimental|1|
3296209|NCT00491868|Experimental|2|
3296210|NCT00491868|Active Comparator|3|
3296211|NCT00491868|Active Comparator|4|
3296212|NCT00491855|Experimental|Bevacizumab + Oxaliplatin + Paclitaxel|One cycle of treatment is 21 days. Bevacizumab starting dose level 2.5 mg/kg given intravenously on day 1. Oxaliplatin starting dose level 25 mg/m^2 given intraperitoneally on day 2. Paclitaxel starting dose level 110 mg/m^2 given continuous infusion on day 1 and 30 mg/m^2 given intraperitoneally on day 8.
3296213|NCT00491829|Experimental|flibanserin|50 mg qhs
3296214|NCT00491829|Experimental|flibanserin 100mg|100 mg qhs
3296215|NCT00491829|Placebo Comparator|placebo|placebo qhs
3296216|NCT00491816|Experimental|erlotinib with neoadjuvant chemotherapy|Study drug, erlotinib, is administered along with neoadjuvant chemotherapy. Adjuvant therapy given at discretion of treating physician. Once adjuvant therapy is completed, all patients will receive erlotinib 150 mg daily for 1 year.
3296217|NCT00491803|Active Comparator|1|Sildenafil 20mg
3296218|NCT00491803|Active Comparator|2|Sildenafil 40mg
3296219|NCT00491790|Sham Comparator|1|Sterile Water
3296220|NCT00491790|Active Comparator|Montelukast|Dissolved granules in sterile water
3296221|NCT00491764|Experimental|Posaconazole 100 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
3296222|NCT00491764|Experimental|Posaconazole 200 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
3296223|NCT00491764|Experimental|Posaconazole 400 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
3296224|NCT00491764|Experimental|Posaconazole 400 mg QD for 12 weeks.|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
3296225|NCT00491764|Active Comparator|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
3296226|NCT00491764|Placebo Comparator|Placebo|Placebo for 24 weeks.
3296227|NCT00491751|Experimental|Atorvastatin|Atorvastatin 40 or 80 mg/day
3296289|NCT00490854|Experimental|2|
3296229|NCT00491751|Placebo Comparator|Placebo|Placebo atorvastatin and Placebo ascorbic acid
3296230|NCT00491738|Experimental|1|
3296231|NCT00491738|Placebo Comparator|2|
3296232|NCT00491673|Active Comparator|Uncemented|Uncemented primary bipolar hemiarthroplasty of the hip
3296233|NCT00491673|Active Comparator|Cemented|Cemented primary bipolar hemiarthroplasty of the hip
3296234|NCT00491634|Experimental|1|treosulfan
3296235|NCT00491621|Other|1|surgery or biopsy of the kidney tumor
3296236|NCT00491608|Experimental|1|rThrombin
3296237|NCT00491582|No Intervention|Athletes, controls, patients|Sedentary controls: age, BMI, Gender and waist matched (to the growth hormone deficient patients) healthy control subjects Endurance trained athletes: minimal >50 mlO2/KG body weight
3296238|NCT00491556|Experimental|Experimental Arm|Subjects in the experimental group will begin HAART consisting of TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r upon entry or to begin treatment under current DHHS guidelines. Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
3296239|NCT00491556|Other|Standard Care Arm|Subjects randomized to the standard care arm will begin HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care and will be followed for a total of three years. Under these guidelines and under current clinical standards, subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur.
3296240|NCT00491530|Experimental|ABT-335 + rosuvastatin calcium|
3296241|NCT00491530|Experimental|ABT-335 + simvastatin|
3296242|NCT00491530|Experimental|ABT-335 + atorvastatin calcium|
3296243|NCT00491517|Experimental|Sirolimus|
3296244|NCT00491517|Active Comparator|conventional therapy|
3296245|NCT00491504|Experimental|Mometasone Furoate Nasal Spray (MFNS)|MFNS 200 mcg total dose (2 sprays each nostril)
3296246|NCT00491504|Placebo Comparator|Placebo|Placebo (2 sprays each nostril)
3296247|NCT00491491|Experimental|Z-BEAM|ibritumomab tiuxetan (zevalin) BEAM
3296248|NCT00491491|Active Comparator|standard BEAM|standard BEAM chemotherapy
3296249|NCT00491439||Corneal wounds after Epi-LASIK|Corneal wounds after Epi-LASIK
3296250|NCT00491439||penetrating keratoplasty|Corneal wound after penetrating keratoplasty
3296251|NCT00491439||corneal epithelial debridement|Corneal wound after pars plana vitrectioy with corneal epithelial debridement for diabetic retinopathy
3296252|NCT00491426||<26 weeks|Subjects <26 weeks gestational age
3296253|NCT00491426||26-29 weeks|Subjects 26-29 weeks gestational age
3296254|NCT00491426||30-32 weeks|Subjects 30-32 weeks gestational age
3296255|NCT00491400|Active Comparator|Fenofibrate First|Fenofibrate 145 mg/day for 8 weeks First and Atorvastatin 20 mg/day for 8 weeks Second
3296256|NCT00491400|Active Comparator|Atorvastatin First|Atorvastatin 20 mg/day for 8 weeks First and Fenofibrate 145 mg/day for 8 weeks Second
3296257|NCT00491387|Experimental|metoprolol succinate|Subjects will undergo I-123 MIBG testing before and after sustained-release beta-adrenergic blockade.
3296258|NCT00491374|Experimental|MFNS|
3296259|NCT00491374|Placebo Comparator|Placebo|
3296260|NCT00491322|Experimental|Ergocalciferol group|Ergocalciferol 50000 international units once a week for 12 weeks
3296261|NCT00491322|Placebo Comparator|Ergocalciferol Placebo group|Matching placebo once a week for 12 weeks
3296262|NCT00491309|Active Comparator|exercise training group|exercise and respiratory therapy with specific program for pulmonary hypertension (respiratory therapy, dumbbell training, ergometer training, mental training)
3296263|NCT00491309|No Intervention|Control group without exercise training|continuation of sedentary lifestyle without advice for specific exercise training
3296264|NCT00491257|Experimental|Study Group 1|Participants aged 18 to 60 years at enrollment
3296265|NCT00491257|Experimental|Study Group 2|Participants aged 61 years or older at enrollment.
3296266|NCT00491244|Experimental|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
3296267|NCT00491244|Experimental|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
3296268|NCT00491179|Experimental|Pegylated IFN + RBV for HCV genotype 1|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks for HCV genotype 1
3296269|NCT00491179|Experimental|Pegylated IFN + RBV for HCV genotype 2|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks for HCV genotype 2
3296270|NCT00491140||Observation|Colorectal cancer patients
3296271|NCT00491101||1|Children with asthma, both genders, from 7-18 years old.
3296272|NCT00491075|Experimental|Pemetrexed + Gemcitabine|Pemetrexed 500 mg/m^2 intravenous (IV) and Gemcitabine 1500 mg/m^2 IV on Day 1.
3296273|NCT00491062|Active Comparator|Control|
3296274|NCT00491062|Experimental|Parkinson stade 1|
3296275|NCT00491062|Experimental|Parkinson stade2|
3296276|NCT00491062|Experimental|Parkinson stade 3|
3296277|NCT00491036|Active Comparator|Intraaortic balloon pump|Patients in cardiogenic shock get an intraaortic balloon pump in the cath lab
3296278|NCT00491036|No Intervention|No intraaortic balloon pump|Patients in cardiogenic shock in this group get no intraaortic balloon pump
3296279|NCT00490997|Active Comparator|1|Ketamine only arm
3296280|NCT00490997|Active Comparator|2|Ketamine-Propofol arm
3296281|NCT00490971|Experimental|Paliperidone ER|
3296282|NCT00490971|Placebo Comparator|Placebo|
3296283|NCT00490971|Active Comparator|Olanzapine|
3296284|NCT00490919|Experimental|Double-blind BTDS 10 or 20|Buprenorphine transdermal system 10 or 20 mcg/h applied for 7-day wear
3296285|NCT00490919|Placebo Comparator|Double-blind Placebo TDS|Placebo transdermal system to match BTDS patches, applied for 7 days
3296290|NCT00490841|Experimental|RX Herculink Elite|To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.
3296291|NCT00490828|Placebo Comparator|A|
3296292|NCT00490828|Active Comparator|B|Stress doses of hydrocortisone
3296293|NCT00490815|Experimental|1|
3296294|NCT00490815|Experimental|2|
3296295|NCT00490802|Experimental|Intranasal Oxytocin|Subjects were given 24 IU intranasal oxytocin twice daily, in the morning and afternoon for 6 weeks.
3296296|NCT00490802|Placebo Comparator|Placebo|Subjects were given placebo twice daily, in the morning and afternoon for 6 weeks.
3296297|NCT00490776|Experimental|LBH589|
3296298|NCT00490763||Active Surveillance|Patients with low-risk prostate cancer who choose to undergo active surveillance.
3296299|NCT00490750|Active Comparator|Laparoscopic Dor fundoplication|Heller myotomy followed by Dor fundoplication
3296300|NCT00490750|Active Comparator|Laparoscopic Toupet fundoplication|Heller myotomy followed by Toupet fundoplication
3296301|NCT00490737|Experimental|Hemodialysis (HD) Participants|Participants will receive daptomycin 6 mg/kg by intravenous infusion (i.v.) at 48-hours intervals (with dialysis) for a total of 3 doses.
3296302|NCT00490737|Experimental|Continuous Ambulatory Peritoneal Dialysis (CAPD) Participants|Participants will receive daptomycin 6 mg/kg, i.v., at 48-hours intervals for a total of 3 doses.
3296303|NCT00490724|Experimental|Nesiritide (1+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
3296304|NCT00490724|Experimental|Nesiritide (2+0.005)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
3296305|NCT00490724|Experimental|Nesiritide (2+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
3296306|NCT00490698|Experimental|Zoledronate + Atorvastatin|Zoledronate 4 mg intravenous (IV) once every 4 Weeks + Atorvastatin 20 mg orally (PO) daily
3296307|NCT00490672|Other|Control Arm|Conventional Patient Management on Hypertension, Diabetes Mellitus and Hyperlipidaemia by Malaysian GP
3296308|NCT00490672|Active Comparator|CORFIS Arm|Community based Multiple Risk Factor Intervention Strategies
3296309|NCT00490646|Experimental|Arm A|trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.
3296310|NCT00490646|Active Comparator|Arm B|trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + docetaxel 100 mg/m^2 IV over 1 hour once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.
3296311|NCT00490633|Experimental|Facemask and hand hygiene|Facemask and hand hygiene provided for participants.
3296312|NCT00490633|Experimental|Facemask only|Facemask only provided for participants.
3296313|NCT00490633|No Intervention|Control|Control, no intervention.
3296314|NCT00490620|Placebo Comparator|1|blinded placebo control
3296315|NCT00490620|Active Comparator|2|Antiretroviral therapy
3296316|NCT00490581|Experimental|Study group|These patients are assigned to the intervention of early supportive housing with case management integrated into the medical system. These subjects are offerred respite care/interim housing upon discharge from enrolling hospitalizations, followed by stable housing within 90 days. They have a case manager at each stage (hospital, respite/interim housing, and stable housing)
3296317|NCT00490581|No Intervention|Usual Care|These patients receive usual social services for hospital discharge planning.
3296318|NCT00490568|Experimental|Rosiglitazone XR|Investigational drug
3296319|NCT00490555|Placebo Comparator|1|Placebo gel + Placebo pill + placebo injection
3296320|NCT00490555|Active Comparator|2|Testosterone 1% transdermal gel 10 g + placebo pill + placebo injection
3296321|NCT00490555|Active Comparator|3|Testosterone 1% transdermal gel 10 g + dutasteride 0.5 mg Orally + placebo injection
3296322|NCT00490555|Active Comparator|4|Testosterone 1% transdermal gel 10 g + placebo pill + DMPA 300 mg injection (IM)
3296323|NCT00490542|Placebo Comparator|Placebo arm|Participants were instructed by a physician to take a study drug daily. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone. Participants were not informed whether they were receiving sugar pills or Geodon. Participants in this study arm received sugar pills.
3296324|NCT00490542|Active Comparator|Geodon arm|Participants were instructed by a physician to take a study drug daily. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone. Participants were not informed whether they were receiving sugar pills or Geodon. Participants in this study arm received Geodon.
3296325|NCT00490529|Experimental|"CpG-MCL vaccine"|"Patients will initially receive three 'priming' CpG-MCL vaccinations in 21 days at 4-7 day intervals, followed by collection of primed T-Cells. Subsequently, within 72 hours of autologous hematopoetic cell transplant (AHCT)(standard of care procedure), the patient will receive his/her CpG-MCL vaccine and reinfusion of primed T cells (immunotransplant). At >/= 3 months after AHCT, when medically feasible, the patient will receive the final CpG-MCL vaccine. Regular follow-up research analysis of molecular residual disease will continue for 3 years or until disease progression."
3296326|NCT00490516|Experimental|1|
3296327|NCT00490516|Experimental|2|
3296328|NCT00490516|Placebo Comparator|3|
3296513|NCT00488319|Experimental|001|Paliperidone ER1.5 to 12 mg tablet once daily for 6 months
3296329|NCT00490503||MRI + MRS|Patients with newly diagnosed stage II A-B or III A-C breast cancers who are scheduled to start systemic chemotherapy.
3296330|NCT00490490|Experimental|Tositumomab + XRT + KI|Tositumomab + external beam radiotherapy (XRT) + potassium iodide (KI)
3296331|NCT00490477|No Intervention|CONVENTIONAL|
3296332|NCT00490477|Active Comparator|POLYMYXIN-B|an extracorporeal LPS removal
3296333|NCT00490451|Experimental|LY573636|
3296334|NCT00490412|Experimental|A: tenofovir/vitamin D|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Group A (who are already taking Tenofovir) once every four weeks during study visits.
3296335|NCT00490412|Placebo Comparator|B: tenofovir/placebo|A placebo will be administered orally to subjects in Group B (who are already taking Tenofovir).
3296336|NCT00490412|Experimental|C: no tenofovir/vitamin D|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Group C (who are not taking Tenofovir) once every four weeks during study visits.
3296337|NCT00490412|Placebo Comparator|D: no tenofovir/placebo|A placebo will be administered orally to subjects in Group D (who are not taking Tenofovir).
3296338|NCT00490334||Cancer patients|Children with cancer aged 8 to 16 years
3296339|NCT00490334||Control (non-cancer)|Normal children aged 8 to 16 years, age- and gender-matched to the cancer cohort
3296340|NCT00490295||newborn cardiac surgical study group|
3296341|NCT00490282|Experimental|Image-Guided Adaptive Radiotherapy|Intensity Modulated Radiotherapy (IMRT) + Adaptive Radiotherapy (ART)
3296342|NCT00490269|Active Comparator|Dronabinol|
3296343|NCT00490269|Placebo Comparator|Placebo|
3296344|NCT00490256|No Intervention|Control|Arm 1 is the control arm. This arm will receive the standard cardiopulmonary bypass circuit.
3296345|NCT00490256|Active Comparator|Experimental|This arm is the modified selective perfusion arm. This arm will receive the modified cardiopulmonary circuit.
3296346|NCT00490230|Experimental|WR 279,396|CL lesions treated with WR 279396
3296347|NCT00490230|No Intervention|Natural Healing|CL lesions healed naturally
3296348|NCT00490230|Placebo Comparator|vehicle control|CL lesions were treated with the vehicle alone
3296349|NCT00490152||1|Participants use Vivagel™, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
3296350|NCT00490152||2|Participants use VivaGel™ Placebo, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
3296351|NCT00490152||3|Participants use HEC Placebo Gel (HEC Gel), applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
3296352|NCT00490139|Active Comparator|Arm 1: Trastuzumab|"Design 1: Trastuzumab 8mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks for a total of 52 weeks.~Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab administered every 3 weeks (6mg/kg IV without loading dose) for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab (6mg/kg without loading dose) every 3 weeks for an additional 40 weeks (52 weeks total)."
3296353|NCT00490139|Experimental|Arm 2: Lapatinib|"Based on the IDMC results from 18 August 2011, any patient enrolled onto Arm 2 should be considered for a new treatment strategy based on discussion with their physician.~Design 1: Lapatinib 1500mg oral daily for a total of 52 weeks.~Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, oral lapatinib administered at 1500mg daily for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, the dose of lapatinib will be increased to 1500mg oral daily for an additional 40 weeks (52 weeks total)."
3296354|NCT00490139|Experimental|Arm 3: Trastuzumab followed by Lapatinib|"Design 1: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total).~Design 2: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks administered concomitantly and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles; followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) followed by a 6 week treatment-free interval followed by oral lapatinib 1500 mg daily for 28 weeks (52 weeks total)."
3296355|NCT00490139|Experimental|Arm 4: Lapatinib in combination with Trastuzumab|"Design 1: Oral lapatinib 1000 mg daily concurrent with trastuzumab 8 mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks (52 weeks total).~Design 2: Trastuzumab (4mg/kg loading dose followed by 2mg/kg IV weekly) concurrent with oral lapatinib 750 mg daily and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles (12 weeks). After completion of chemotherapy, the dose of lapatinib will be increased to 1000mg daily concurrently with trastuzumab every 3 weeks (6mg/kg without loading dose) for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concurrently with oral lapatinib 750mg plus weekly trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV. After the completion of chemotherapy, trastuzumab will be administered every 3 weeks (6mg/kg without loading dose) concurrent with lapatinib 1000mg daily for an additional 40 weeks (52 weeks total)."
3296356|NCT00490126||Laparoscopic Surgery Database|
3296357|NCT00490113|Experimental|1|
3296358|NCT00490100|Experimental|Treatment|Treatment
3296359|NCT00490087|Experimental|Hysteroscopic resection plus IUD|
3296360|NCT00490087|No Intervention|Hysteroscopic resection without IUD|
3296361|NCT00490074|Experimental|3 DNA-C + 1 NYVAC-C|
3296362|NCT00490074|Active Comparator|2 DNA-C + 2 NYVAC-C|
3296514|NCT00488293|Experimental|Arm 1|Store and forward teledermatology consult process
3296515|NCT00488293|No Intervention|Arm 2|Conventional consult process
3296363|NCT00490061|Experimental|Radiotherapy and Lapatinib with DCE-MRI|DCE-MRI will precede radiotherpy before and after Lapatinib loading. 1500mg/d once daily oral Lapatinib will be administration for seven days prior to and throughout radiotherapy. Radiotherapy will be delivered as Intensity Modulated Radio Therapy (IMRT) using a G.E. Healthcare 1.5T MR, systems revision 12.0 M5 for a total dose of 70Gy delivered in 2-2.12 Gy/ fraction over the course of 6.5-7 weeks.
3296364|NCT00490035|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
3296365|NCT00490035|Experimental|Brivaracetam 20 mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day
3296366|NCT00490035|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
3296367|NCT00490035|Experimental|Brivaracetam 100 mg/day|Brivaracetam 100 mg/day, 50 mg administered twice a day
3296368|NCT00490022|Active Comparator|1|DHT gel (70 mg/day) for one month
3296369|NCT00490022|Placebo Comparator|2|Placebo gel for one month
3296370|NCT00490009|Experimental|Bexxar + Total Body Irradiation (TBI)|Bexxar will be administered with pre-medications acetaminophen, diphenhydramine, and potassium iodide (KI).
3296371|NCT00489970|Experimental|Boostrix Group|Subjects received in the primary study Subjects who had received Boostrix vaccine in study NCT00346073 and will receive a second dose of Boostrix vaccine in this study at Year 9.
3296372|NCT00489970|Active Comparator|Adacel Group|Subjects who had received Sanofi Pasteurs' Adacel™ vaccine in study NCT00346073 and will receive a second dose of Boostrix in this study at Year 9.
3296373|NCT00489970|Active Comparator|Control group|Subjects in this group will receive the first dose of Tdap vaccine (Boostrix) in this study at Year 9.
3296374|NCT00489957||Normals|
3296375|NCT00489957||Cardiomyopathy|
3296376|NCT00489918|Placebo Comparator|Macroflux® placebo|Macroflux® placebo patch
3296377|NCT00489918|Experimental|Macroflux® 20 mcg|Macroflux® 20 mcg patch
3296378|NCT00489918|Experimental|Macroflux® 30 mcg|Macroflux® 30 mcg patch
3296379|NCT00489918|Experimental|Macroflux® 40 mcg|Macroflux® 40 mcg patch
3296380|NCT00489918|Active Comparator|FORTEO®|FORTEO® 20 mcg injection
3296381|NCT00489866|Experimental|Aripiprazole|
3296382|NCT00489866|Placebo Comparator|Placebo|
3296383|NCT00489853|Experimental|Symbicort then Formoterol then Placebo|Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
3296384|NCT00489853|Experimental|Formoterol then Symbicort then Placebo|Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
3296385|NCT00489853|Placebo Comparator|Placebo then Formoterol then Symbicort|Placebo, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily
3296386|NCT00489840|Experimental|anecortave acetate|
3296387|NCT00489827|Experimental|Intravenous glutamate|Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
3296388|NCT00489827|Placebo Comparator|Saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
3296389|NCT00489814||1|Patients who are planned to undergo local proton radiotherapy for biopsy-proven, untreated, prostate adenocarcinoma.
3296390|NCT00489801|Other|Exercise intervention|Exercise intervention and lifestyle counseling at centre or exercise intervention at home
3296391|NCT00489736|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets administered twice a day (bid) and matching over-encapsulated tablets of placebo of amiodarone 200mg
3296392|NCT00489736|Active Comparator|Amiodarone 600mg/200mg od|over-encapsulated tablets of amiodarone 200mg (600mg daily for 28 days then 200mg daily) administered once daily (od) and matching placebo of dronedarone 400mg tablets
3296393|NCT00489710|Experimental|Talabostat|Talabostat 600 mcg PO QD x 14 days (21 day cycle); 2 cycles
3296394|NCT00489697|Experimental|1 (single arm)|patient with histologically confirmed colorectal tumor treated in first line by a bevacizumab based chemotherapy
3296395|NCT00489671||pre cancerous condition (pancreatitis)|
3296396|NCT00489645|Placebo Comparator|1|Placebo, euglycemia
3296397|NCT00489645|Experimental|2|Pramlintide, euglycemia
3296398|NCT00489645|Placebo Comparator|3|placebo, hyperglycemia
3296399|NCT00489645|Experimental|4|pramlintide, hyperglycemia
3296400|NCT00489632||Questionnaire|Children with leukemia and their families/caregivers.
3296401|NCT00489593|Experimental|Olanzapine|Olanzapine 2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
3296402|NCT00489567||Group A|Children hospitalised with community-acquired severe RV GE and children acquiring nosocomial severe RV GE.
3296403|NCT00489554|Experimental|Synflorix Vaccine Group|Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.
3296404|NCT00489541|Experimental|TAXUS Element Stent System|
3296405|NCT00489515||patients with gastrointestinal cancer scheduled for surgery|
3296406|NCT00489489|Experimental|Teriflunomide 7 mg + IFN-β|Teriflunomide 7 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
3296407|NCT00489489|Experimental|Teriflunomide 14 mg + IFN-β|Teriflunomide 14 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
3296408|NCT00489489|Placebo Comparator|Placebo + IFN-β|Placebo (for Teriflunomide) once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
3296409|NCT00489476|Experimental|1.25 mg Staccato Loxapine|1.25 mg ADASUVE, single dose
3296410|NCT00489476|Experimental|2.5 mg Staccato Loxapine|2.5 mg ADASUVE, single dose
3296411|NCT00489476|Experimental|5 mg Staccato Loxapine|5 mg ADASUVE, single dose
3296412|NCT00489476|Experimental|Staccato Placebo|Staccato Placebo, 0 mg
3296413|NCT00489424|Experimental|Acetaminophen|2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
3296414|NCT00489424|Experimental|Fluvastatin|2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
3296415|NCT00489424|Placebo Comparator|Placebo|2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
3296416|NCT00489411|Experimental|Arm I/Group A (Duloxetine then Placebo)|Patients receive oral duloxetine hydrochloride once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive an oral placebo once or twice daily in weeks 8-13.
3296417|NCT00489411|Experimental|Arm II/Group B (Placebo then Duloxetine)|Patients receive an oral placebo once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive oral duloxetine hydrochloride once or twice daily in weeks 8-13.
3296418|NCT00489372|Placebo Comparator|Arm I (placebo)|Participants receive oral placebo on day 1.
3296419|NCT00489372|Experimental|Arm II (Se-methyl-seleno-L-cysteine)|Participants receive oral Se-methyl-seleno-l-cysteine (MSC) on day 1. Cohorts of 5 participants receive escalating doses of MSC until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 5 or 2 of 10 patients experience dose-limiting toxicity.
3296420|NCT00489359|Experimental|Pemetrexed/Carboplatin Phase 1|"Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion."
3296421|NCT00489359|Experimental|Pemetrexed/Carboplatin Phase 2|"Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion."
3296422|NCT00489307|Active Comparator|Dexamethasone|"Dexamethasone 4 mg orally two times a day for 14 days.~On day 15 [ ± 3 days], all patients receive dexamethasone 4 mg orally twice a day for 7 days, and then the dose of dexamethasone tapered to 2 mg orally twice a day between days 22 to 28."
3296423|NCT00489307|Placebo Comparator|Placebo|"Placebo by mouth (PO) twice daily for 14 days.~On day 15 [ ± 3 days], all patients receive dexamethasone 4 mg orally twice a day for 7 days, and then the dose of dexamethasone tapered to 2 mg orally twice a day between days 22 to 28."
3296424|NCT00489281|Experimental|Transplant - 200 cGy|Conditioning regimen with anti-thymocyte globulin, fludarabine, cyclophosphamide, and total body irradiation. Seizure prophylaxis with levetiracetam. Allogeneic bone marrow transplant infusion on Day 0. Graft-vs-host-disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and sirolimus.
3296425|NCT00489281|Experimental|Transplant - 400 cGy|Conditioning regimen with anti-thymocyte globulin, fludarabine, cyclophosphamide, and total body irradiation. Seizure prophylaxis with levetiracetam. Allogeneic bone marrow transplant infusion on Day 0. Graft-vs-host-disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and sirolimus.
3296426|NCT00489268|Active Comparator|Phase I: 6 J/cm2|Subjects randomized to the energy density group of 6 J/cm2 through the HALO Ablation System.
3296427|NCT00489268|Active Comparator|Phase I: 8 J/cm2|Subjects randomized to the energy density group of 8 J/cm2 through the HALO Ablation System.
3296428|NCT00489268|Active Comparator|Phase I: 10 J/cm2|Subjects randomized to the energy density group of 10 J/cm2 through the HALO Ablation System.
3296429|NCT00489268|Active Comparator|Phase I: 12 J/cm2|Subjects randomized to the energy density group of 12 J/cm2 through the HALO Ablation System.
3296430|NCT00489268|Active Comparator|Phase II|All Halo 360 treatments performed at 10 J/cm2 through the HALO Ablation System. All Halo 90 treatments performed at 12 J/cm2 through the HALO Ablation System.
3296431|NCT00489255|Experimental|Trimethobenzamide (Tigan®)|
3296432|NCT00489255|Placebo Comparator|Inactive substance|
3296433|NCT00489216|Experimental|Efalizumab|All patients on study will receive a total of 8 injections of efalizumab
3296434|NCT00489203|Experimental|Arm I|Patients receive oral beclomethasone dipropionate 4 times daily beginning at the start of the conditioning regimen and continuing through day 75 post-transplant. Patients also receive a standard immunosuppressive regimen comprising tacrolimus and methotrexate post-transplant.
3296435|NCT00489203|Active Comparator|Arm II|Patients receive oral placebo 4 times daily beginning at the start of the conditioning regimen and continuing through day 75 post-transplant. Patients also receive a standard immunosuppressive regimen comprising tacrolimus and methotrexate post-transplant.
3296436|NCT00489177|Active Comparator|A|QuickOpt
3296437|NCT00489177|Placebo Comparator|B|Usual care
3296438|NCT00489138|Experimental|1|Noradrenalin infusion
3296439|NCT00489138|No Intervention|2|No adrenalin infusion
3296440|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot A|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot A administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
3296441|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot B|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot B administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
3296442|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot C|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot C administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
3296443|NCT00489099|Active Comparator|V232 Current Process Hepatitis B Vaccine|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) current process administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
3296444|NCT00489086|Other|Tazarotene Cream|Open label
3296562|NCT00487773|Active Comparator|1|budesonide
3296563|NCT00487773|Active Comparator|2|D3 vitamin
3296445|NCT00489034||Index Participants|HIV-infected females, ages 13- 23 years, recruited from ATN sites in New York, Chicago, Miami, Los Angeles, and New Orleans will undergo quantitative interviewing. A sub-sample of the group will undergo ethnographic and/or gender interviewing.
3296446|NCT00489034||Network Participants|Closest friends of index participants s and parents/guardians of index participants who know the index participant's HIV status will undergo quantitative interviewing. A sub-sample of the group will undergo ethnographic interviewing.
3296447|NCT00489008|Experimental|Cohort 1|Stereotactic Body Radiation Therapy (SBRT) Stage I NSCLC
3296448|NCT00489008|Experimental|Cohort 2|Stereotactic Body Radiation Therapy (SBRT) Selective Stage II NSCLC
3296449|NCT00489008|Experimental|Cohort 3|Stereotactic Body Radiation Therapy (SBRT) Isolated Peripheral Lung Recurrent NSCLC
3296450|NCT00488982|Experimental|1|Docetaxel
3296451|NCT00488982|Experimental|2|Docetaxel and GM-CSF
3296452|NCT00488969|Active Comparator|Modified-release morphine then Placebo|up to a ceiling dose of 120 mg
3296453|NCT00488969|Placebo Comparator|Placebo then modified-release morphine|Matching placebo
3296454|NCT00488904|Experimental|a|
3296455|NCT00488904|Placebo Comparator|b|
3296456|NCT00488891||Paliperidone extended release (ER)|Drug: Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
3296457|NCT00488891||Atypical antipsychotics agent (AAP)|AAP includes quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
3296458|NCT00488878||Ovarian Cancer Data Collection|
3296459|NCT00488865|Other|Intravascular Filter Device|
3296460|NCT00488839|Other|IPX056 20 mg - OLE|A single dose of IPX056 20 mg, Placebo IPX056 40 mg and Placebo Baclofen Tablet (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
3296461|NCT00488839|Other|IPX056 40 mg - OLE|A single dose of IPX056 40 mg, Placebo IPX056 20 mg and Placebo Baclofen Tablet (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
3296462|NCT00488839|Other|Baclofen 20 mg - OLE|A single dose of Encapsulated Baclofen 20 mg, Placebo IPX056 20 mg and Placebo IPX056 40 mg (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
3296463|NCT00488839|Other|Placebo - OLE|A single dose of Placebo Baclofen Tablet, Placebo IPX056 20 mg and Placebo IPX056 40 mg (Part 1), 9 week Open label extension of IPX056 (flexible dose design,IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
3296464|NCT00488787|Experimental|A|Intranasal ketamine low dose
3296465|NCT00488787|Experimental|B|intranasal ketamine medium dose
3296466|NCT00488787|Experimental|C|intranasal ketamine high dose
3296467|NCT00488787|Placebo Comparator|D|placebo
3296468|NCT00488774|Placebo Comparator|Placebo|Matching placebo for golimumab, intravenous (IV) (through a vein in the arm) infusion administered at Week 0
3296469|NCT00488774|Experimental|Golimumab 1 milligram (mg) per kilogram (kg)|Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0.
3296470|NCT00488774|Experimental|Golimumab 2 mg per kg|Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0.
3296471|NCT00488774|Experimental|Golimumab 4 mg per kg|Golimumab 4 mg per kg, intravenous (IV) infusion administered at Week 0.
3296472|NCT00488748|Experimental|MST|Magnetic Seizure Therapy (MST)
3296473|NCT00488748|Active Comparator|ECT|Electroconvulsive Therapy (ECT)
3296474|NCT00488696|Experimental|Interventional|Endovascular Bifurcated Stent Graft: The investigational operation involves placing a stent-graft over the aortic aneurysm.
3296475|NCT00488683|Experimental|MenACWY-CRM and Routine Vaccines (Group 1)|Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 13 months), and 1 dose each of MMR and Hib (booster) at 13 months.
3296476|NCT00488683|Experimental|MenACWY-CRM and Routine Vaccines (Group 2)|"Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 12 months), and 1 dose each of MMR and Hib (booster) at 13 months.~This group had an additional blood draw at the time of enrollment."
3296477|NCT00488683|Experimental|MenACWY-CRM and Routine Vaccines (Group 3)|"Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 12 months), and 1 dose each of MMR and Hib (booster) at 13 months of age.~This group had an additional blood draw at 6-7 days after third dose of MenACWY-CRM."
3296478|NCT00488657|Experimental|1|In the ear device to provide altered auditory feedback
3296479|NCT00488644|Experimental|Levothyroxine + Liothyronine|Levothyroxine 75 mcg by mouth (PO) Daily for 8 Weeks + Liothyronine 15 mcg PO Daily for 8 Weeks
3296480|NCT00488631|Placebo Comparator|Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to placebo subcutaneous (under the skin) injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.
3296481|NCT00488631|Experimental|GLM-I-Rsp-Golimumab 50 mg Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 50 mg or 100 mg subcutaneous injections every 4 weeks through Week 52.
3296560|NCT00487825|Active Comparator|Methotrexate + placebo|Methotrexate (MTX) was given as variable dosing regimen of 7.5 mg-15 mg weekly. Intravenous (IV) Placebo Solution, given in the same mode of administration as the canakinumab solution.
3296909|NCT00484185||1|
3296482|NCT00488631|Experimental|GLM-I-Rsp-Golimumab 100 mg Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 100 mg or 200 mg subcutaneous injections every 4 weeks through Week 52.
3296483|NCT00488631|Placebo Comparator|Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance|Participants in clinical response to placebo at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized. Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.
3296484|NCT00488631|Experimental|PBO-I-nonRsp-Golimumab 100 mg Maintenance|Participants not in clinical response to placebo at Week 6 induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.
3296485|NCT00488631|Experimental|GLM-I-nonRsp-Golimumab 100 mg Maintenance|Participants not in clinical response to golimumab at Week 6 of induction study and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.
3296486|NCT00488618|Experimental|Cariprazine|Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
3296487|NCT00488618|Placebo Comparator|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
3296488|NCT00488605|Active Comparator|Treatment Arm A|
3296489|NCT00488605|Experimental|Treatment Arm B|
3296490|NCT00488592|Experimental|WTI: 126-134/ PRI|"Subjects were given 6 doses of PR1:169-177 in Montanide adjuvant and 6 doses of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
3296491|NCT00488579|Active Comparator|routine iron prophylaxis|giving 60 mg ferrous sulphate daily (+folic acid)
3296492|NCT00488579|Active Comparator|screening and therapy|doing Hb measurement on each visit, Hb>9g/dl giving only folic acid, Hb<9g/dl giving 60-120 mg of ferrous sulphate daily (+folic acid)
3296493|NCT00488566|Other|Part 1|Single dose escalation
3296494|NCT00488566|Other|Part 2|Pharmacodynamic assessment
3296495|NCT00488553||Cases|Participants of study with newly diagnosed lymphoma.
3296496|NCT00488553||Control|Participants of study from matched control group.
3296497|NCT00488540|Active Comparator|Paracetamol (Acetaminophen)|Paracetamol (Acetaminophen) given at 2 and 8 hours post birth, measurement of EDIN-Score on day one of life, measurement of stress response after Guthrie-test on day 4 of life.
3296498|NCT00488540|Placebo Comparator|Placebo|Placebo given at 2 and 8 hours post birth, measurement of EDIN-Score on day one of life, measurement of stress response after Guthrie-test on day 4 of life.
3296499|NCT00488527|Experimental|1|
3296500|NCT00488514|Other|Active Drug|Combination Tablet of Treximet (sumatriptan/naproxen sodium)
3296501|NCT00488488||A|
3296502|NCT00488475||Patients with Rheumatoid Arthritis|
3296503|NCT00488462|No Intervention|Control|Clinics will collect data on patients experiencing shock due to obstetrical hemorrhage. In the control arm, half of the study clinics will not use the NASG but the NASG will be available at the referral hospital for patients transported there.
3296504|NCT00488462|Other|Intervention|Clinics will collect data on patients experiencing shock due to obstetrical hemorrhage. In the intervention arm, half of the study clinics will use the NASG on patients before transporting to the referral hospital.
3296505|NCT00488423|Active Comparator|Lap-band|Patient undergoing Lap-band Bariatric Surgery
3296506|NCT00488423|Active Comparator|Gastric Bypass|Patient's undergoing Laparoscopic Roux-N Y Gastric Bypass surgery.
3296507|NCT00488397||1|
3296508|NCT00488384|Other|a|single arm only. Only open label treatment anticipated
3296509|NCT00488345|Experimental|A|0.75 mg/kg (up to a maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Escalation to next dose cohort will occur only after safety and tolerability at preceding dose have been established by sponsor (after tigecycline LDOT data are received) and if at least 5 of 6 PK samples per patient have been received by central laboratory in acceptable condition for 10 to 12 patients in cohort. Treatment period of tigecycline will be a minimum of 3 days (unless patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
3296510|NCT00488345|Experimental|B|1 mg/kg (up to a maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Escalation to next dose cohort will occur only after safety and tolerability at preceding dose have been established by sponsor (after tigecycline LDOT data are received) and if at least 5 of 6 PK samples per patient have been received by the central laboratory in acceptable condition for 10 to 12 patients in the cohort. Treatment period of tigecycline will be a minimum of 3 days (unless the patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
3296511|NCT00488345|Experimental|C|1.25 mg/kg (up to maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Treatment period of tigecycline will be a minimum of 3 days (unless patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
3296512|NCT00488332||OCT + FS + Questionnaire|Optical Coherence Tomography (OCT) + Fluorescence Spectroscopy (FS) and Questionnaire
3296516|NCT00488280|Experimental|Kids Step Study: Locomotor Training|All children who participate will be in the experimental cohort, KSS-#, and receive 60 sessions of daily locomotor training. This experimental cohort will also undergo clinical and neurophysiological testing pre, during, and post 60 sessions of locomotor training.
3296517|NCT00488267|Experimental|Thermoprofen|ThermoProfen™ (ketoprofen matrix/Controlled Heat Assisted Drug Delivery [CHADD™] patch)
3296518|NCT00488267|Placebo Comparator|Placebo Matrix|Placebo matrix with CHADD patch.
3296519|NCT00488267|Placebo Comparator|Ketoprofen matrix/placebo CHADD|Ketoprofen matrix with placebo CHADD patch (no heat)
3296520|NCT00488241|Active Comparator|1|Topically applied daily for 2 weeks
3296521|NCT00488228|Experimental|1|Participants in the behavioral self-regulation intervention will receive a modified standard treatment that incorporates daily weighing and training in self-regulation methods for weight loss. All treatment modules are adapted for a young adult age group.
3296522|NCT00488228|Experimental|2|Participants in the Standard group will receive a brief version of standard behavioral weight loss treatment with treatment modules tailored to better meet the needs of young adults.
3296523|NCT00488215|Active Comparator|1|Prucalopride
3296524|NCT00488215|Placebo Comparator|2|Placebo
3296525|NCT00488189|No Intervention|1|baseline, collecting rectal swab samples
3296526|NCT00488189|Active Comparator|2|use pipercill/tazobact to replace 3rd generation cephalosporin and collect rectal swab
3296527|NCT00488176|Active Comparator|1|monteluksat sodium
3296528|NCT00488176|Active Comparator|2|cetirizine
3296529|NCT00488176|Active Comparator|3|montelukast sodium and cetirizine
3296530|NCT00488176|Placebo Comparator|4|placebo
3296531|NCT00488163|Active Comparator|Atomoxetine|Atomoxetine 40 mg compounded into capsules.
3296532|NCT00488163|Placebo Comparator|Placebo|Inactive matching compounding of placebo capsules
3296533|NCT00488137|Active Comparator|1|Prucalopride 2 mg
3296534|NCT00488137|Placebo Comparator|3|Placebo
3296535|NCT00488137|Active Comparator|2|Prucalopride 4 mg
3296536|NCT00488111|Active Comparator|1|Participants were treated with normal Ringer's solution 15 min before the operation.
3296537|NCT00488111|Active Comparator|2|6% Starch was used 15min before operation followed epidural anesthesia.
3296538|NCT00488072|Experimental|Mirtazapine|Mirtazapine 15 mg by mouth (PO) daily for 15 days; Day 22-29, increased to 30 mg PO daily.
3296539|NCT00488072|Placebo Comparator|Placebo|One placebo tablet by mouth daily.
3296540|NCT00488059|Experimental|Phase I|Phase 1: ENF 90mg SC BID): In the first phase or cohort phase of day I-1 through Week I-12 of the trial all patients received enfuvirtide (ENF) 90 mg subcutaneously (SC) twice daily (BID) + Isentress® [raltegravir] (RAL) 400-mg orally (PO) BID + optimized background (OB) with at least 1 fully active antiretroviral (ARV) agent excluding nucleoside reverse transcriptase inhibitor (NRTIs).
3296541|NCT00488059|Experimental|Phase II|"In the randomized comparator Phase II of the trial- (Day II-1 through Week II-16): Virologic responders confirmed HIV-1 RNA ≤50 copies/mL from Phase I were randomized to 1 of 2 treatment arms of~(Phase II Arm A: Phase I then ENF 90mg SC BID): ENF 90 mg SC BID + RAL 400 mg PO BID + OB with at least 1 fully active ARV agent excluding NRTIs or (Phase II Arm B: Phase I then ENF 180mg SC QD): ENF 180 mg SC once daily (QD) + RAL 400 mg PO BID + OB with at least 1 fully active ARV agent excluding NRTIs."
3296542|NCT00488046|Experimental|1|Two, 0.5 ml doses of vaccine in nasal spray form administered at study entry and sometime between 4 and 8 weeks after initial vaccination
3296543|NCT00488033|No Intervention|1|Standard of Care
3296544|NCT00488033|Other|2|CT Angiography
3296545|NCT00488007|Experimental|Active Hearing aids|Active
3296546|NCT00488007|Placebo Comparator|Inactive Hearing aids|Hearing aids turned off
3296547|NCT00487994|Experimental|Lapaquistat Acetate 100 mg QD|
3296548|NCT00487994|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin 10 mg QD|
3296549|NCT00487994|Active Comparator|Atorvastatin 10 mg QD|
3296550|NCT00487981|Other|Spinal Cord Stimulation Group|Spinal Cord Stimulation (SCS) Treatment Group
3296551|NCT00487942|Active Comparator|50 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 50 mg/day armodafinil treatment arm for the double-blind treatment period of the study took one 50 mg armodafinil tablet plus three placebo tablets each morning.
3296552|NCT00487942|Active Comparator|100 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 100 mg/day armodafinil treatment arm for the double-blind treatment period of the study took two 50 mg armodafinil tablets plus two placebo tablets each morning. Subjects began taking 50 mg/day and then titrated to 100 mg/day on Day 2 of the first week of the double-blind treatment period.
3296553|NCT00487942|Active Comparator|200 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 200 mg/day armodafinil treatment arm for the double-blind treatment period of the study took four 50 mg armodafinil tablet and no placebo tablets each morning. Subjects were titrated to this dose by starting treatment at 50 mg/day (1 tablet) and increasing by 50 mg increments on days 2, 4, and 6 until they were taking 200 mg/day.
3296554|NCT00487942|Placebo Comparator|Placebo|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the placebo treatment arm for the double-blind treatment period of the study took four placebo tablets and no armodafinil tablets each morning.
3296555|NCT00487929|Experimental|CPAP|Continuous positive airway pressure
3296556|NCT00487929|Sham Comparator|Sham CPAP|Sham nasal continuous positive airway pressure
3296557|NCT00487851|Active Comparator|1|Endoscopic treatment strategy
3296558|NCT00487851|Active Comparator|2|Surgical treatment strategy
3296559|NCT00487825|Experimental|Canakinumab + Methotrexate|Canakinumab, human anti-interleukin-1beta monoclonal antibody plus Methotrexate (MTX). Intravenous (IV) Infusion of 600mg canakinumab on Day 1, 15 continuing every 4 weeks up to week 26. MTX was given as variable dosing regimen of 7.5 mg-15 mg weekly.
3296561|NCT00487786|Experimental|A|Each patient receives OGX-427
3296564|NCT00487773|Active Comparator|3|montelukast sodium
3296565|NCT00487773|Active Comparator|4|salbutamol
3296566|NCT00487747|Experimental|Peginterferon Alfa-2a|
3296567|NCT00487734|Experimental|1|Subjects in this arm will receive testosterone gel
3296568|NCT00487734|Placebo Comparator|2|
3296569|NCT00487721|Experimental|Silibin-Phytosome|Subjects in this group will take Silibin-Phytosome 13 grams daily, in three divided doses for 2-10 weeks.
3296570|NCT00487721|No Intervention|Control|Patients in this arm will not take any intervention.
3296571|NCT00487708|Experimental|1|ACZ885
3296572|NCT00487695|Active Comparator|CLE followed by standard EGD|Participants are randomized to have either confocal laser endomicroscopy (CLE) or standard endoscopy (EGD) first. Then 6 weeks later, they have the other procedure. This arm is for patients randomized to CLE followed by standard EGD
3296573|NCT00487695|Active Comparator|standard EGD followed by CLE|Patients are randomized to either have standard endoscopy (EGD)or confocal laser endomicroscopy (CLE) first. The second procedure is then completed 6 weeks later. This arm is for patients who had standard endoscopy first.
3296574|NCT00487682|Experimental|1|ASP2151 low dose
3296575|NCT00487682|Experimental|2|ASP2151 middle dose
3296576|NCT00487682|Experimental|3|ASP2151 high dose
3296577|NCT00487682|Active Comparator|4|
3296578|NCT00487669|Experimental|Paclitaxel Poliglumex with Pemetrexed|The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued.
3296579|NCT00487656|Experimental|ART-123|6 mg/ml ampule solution for injection
3296580|NCT00487656|Placebo Comparator|Placebo|6 mg/mlampule of solution for injection
3296581|NCT00487617|Experimental|fruit juice|300 mL of fruit juice
3296582|NCT00487617|Placebo Comparator|placebo|300 mL of fruit juice without polyphenols
3296583|NCT00487591||Simva+Omacor|
3296584|NCT00487591||Simva + Placebo|
3296585|NCT00487578|Active Comparator|A|Naratriptan 2.5 mg tablet bid x 30 days
3296586|NCT00487578|Placebo Comparator|B|placebo matching naratriptan 2.5 mg tablet
3296587|NCT00487565|Other|LCS Complete Posterior Stabilized knee implant|Total knee arthroplasty with a posterior stabilized implant
3296588|NCT00487552|Experimental|1|palliative treatment of gastric outlet obstruction
3296589|NCT00487539|Placebo Comparator|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
3296590|NCT00487539|Experimental|Golimumab 100 mg -> 50 mg|Golimumab 100 milligram (mg) subcutaneous injection administered at Week 0 and dose is decreased to 50 mg at Week 2.
3296591|NCT00487539|Experimental|Golimumab 200 mg -> 100 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 and dose is decreased to 100 mg at Week 2.
3296592|NCT00487539|Experimental|Golimumab 400 mg -> 200 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 and dose is decreased to 200 mg at Week 2.
3296593|NCT00487500|Experimental|Ultrabrief, Right Unilateral ECT|Right unilateral ECT administered with an ultrabrief pulse width (0.3 ms), at a dose 6 times the initial seizure threshold
3296594|NCT00487500|Experimental|Ultrabrief, Bilateral ECT (2.5 X ST)|Bilateral (frontotemporal) ECT with an ultrabrief pulse width with dosage 2.5 times the initial seizure threshold
3296595|NCT00487500|Active Comparator|Brief Pulse, Right Unilateral ECT|Right unilateral ECT, with a standard brief pulse (1.5 ms), with dosage 6 times the initial seizure threshold
3296596|NCT00487500|Active Comparator|Brief Pulse, Bilateral ECT|Bilateral (frontotemporal) ECT with a standard brief pulse (1.5 ms), with dosage 2.5 times the initial seizure threshold
3296597|NCT00487474|Experimental|Sculptra|
3296598|NCT00487461|Placebo Comparator|Control Group|Placebo tablet
3296599|NCT00487461|Experimental|Study Group #1|Simvastatin 40 mg
3296600|NCT00487461|Experimental|Study Group #2|Simvastatin 80 mg
3296601|NCT00487435|Experimental|001|Tapentadol (CG5503) Extended Release (ER) 100 150 200 250 mg oral tablet twice daily for 52 weeks
3296602|NCT00487422|Active Comparator|1|Prucalopride
3296603|NCT00487422|Active Comparator|2|Prucalopride
3296604|NCT00487422|Placebo Comparator|3|Placebo
3296605|NCT00487409|Other|Group A|Standard of Care
3296606|NCT00487409|Other|Group B|Standard of Care
3296607|NCT00487357||MATCh Parents' Supplemental Survey|Parent/Guardian Survey
3296608|NCT00487331|Experimental|Acupuncture|Acupuncture sessions 1-3 times per week. 2 pain questionnaires + satisfaction survey completed at beginning and end of treatment.
3296609|NCT00487318|Experimental|Arm 1 Plus statin|The addition of fluvastatin or rosuvastatin or other statins to the standard of care of peginterferon and ribavirin.
3296610|NCT00487318|Active Comparator|2|Administration of the standard of care for hepatitis C of peginterferon and ribavirin.
3296611|NCT00487305|Experimental|Biological/Vaccine|Biological/Vaccine: Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.
3296612|NCT00487279|Experimental|ICD Group|ICD (Implantable Cardioverter Defibrillator)
3296613|NCT00487279|Other|Control Group|Medial Therapy
3296614|NCT00487253|Active Comparator|Group 1|"Oral administration of Miltefosine, doses: 1,5mg to 2,5mg/kg/day, during 28 days.~presentation: capsulas 10mg and 50mg Miltefosine (Impavido®)"
3296615|NCT00487253|Active Comparator|Group 2|Administration of Parenteral meglumine antimoniate, Glucantime® Amp 5ml (83mg/ml). Dosage:20mg/kg/day, during 20 days.
3296616|NCT00487240|Experimental|Insulin Lispro Protamine Suspension|Insulin Lispro Protamine Suspension twice daily
3296617|NCT00487240|Active Comparator|Detemir|Insulin Levemir (detemir) subcutaneous (SC) twice daily.
3296618|NCT00487227|Placebo Comparator|Placebo|
3296619|NCT00487227|Experimental|2.5mg caffeine|
3296620|NCT00487227|Experimental|5mg caffeine|
3296621|NCT00487227|Experimental|10mg caffeine|
3296622|NCT00487188|Experimental|ENF + HAART|Participants received Enfuvirtide (ENF) 90 mg administered by subcutaneous injection twice a day for up to 48 weeks in addition to an oral highly active antiretroviral treatment (HAART) regimen for up to 48 weeks.
3296623|NCT00487188|Active Comparator|HAART|Participants received an oral highly active antiretroviral treatment (HAART) regimen, consisting of 3-5 antivirals for up to 48 weeks.
3296624|NCT00487162|Experimental|intensive glycemic control|In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R [Novo Nordisk]) in 50ml of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg / dL on two consecutive samples and will be adjusted to maintain the blood glucose level between 80 and 110 mg / dL. If the glucose level falls below 80 mg / dL, the insulin infusion will be tapered and discontinued.
3296625|NCT00487162|Active Comparator|conventional glycemic control|In this group if the subject's blood glucose level should exceed 200 mg/dL the subject will be treated with a continuous insulin infusion to maintain blood glucose levels between 180-200mg/dL
3296626|NCT00487136|Active Comparator|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
3296627|NCT00487136|Experimental|Warfarin plus ABT-335 plus Rosuvastatin|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
3296628|NCT00487136|Experimental|Warfarin plus ABT-335 mg plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
3296629|NCT00487097|Experimental|Study Group|Enteral Nutrition with Omega 3 (Eicosapentanoic acid, docosahexaenoic acid)
3296630|NCT00487097|No Intervention|Control Group|Patients in control group will receive nutritional support composed of a standard formula
3296631|NCT00487084|Experimental|morphine - 2CP-saline (MCS)|morphine will be administered 30 min prior to epidural anesthesia; 2CP will be used to achieve a T4 level; saline will be administered at skin incision
3296632|NCT00487084|Experimental|saline-2CP-morphine (SCM)|saline will be administered 30 min prior to epidural anesthesia; 2CP will be used to achieve a T4 level;morphine will be administered at skin incision
3296633|NCT00487084|Active Comparator|saline-lidocaine-morphine (SLM)|Saline will be administered 30 min prior to epidural anesthesia; lidocaine will be used to achieve a T4 level; morphine will be administered at skin incision
3296634|NCT00487071|Experimental|Anal fistula plug|
3296635|NCT00487045|Experimental|1|Hem-Avert Perianal Stabilizer, single use, disposable, sterile, individually packaged instrument
3296636|NCT00487045|No Intervention|2|
3296637|NCT00487032|Experimental|1|Prazosin 1mg challenge to block alpha 1 adrenoreceptors
3296638|NCT00487032|Placebo Comparator|2|Placebo to Prazosin
3296639|NCT00487019||1|Neonates aged <72 h and needing antibacterial therapy for early onset neonatal sepsis
3296640|NCT00487019||2|Same as group 1
3296641|NCT00487006|Active Comparator|At risk for CIH/with CIH|In hyperglycemic patients who will be starting insulin infusions to control hyperglycemia, blood will be drawn just prior to initiation of insulin infusion for the following levels: insulin, glucose, and C-peptide. These levels will be re-drawn upon achieving euglycemia, at 24 hours following that, then every three days. Levels will be again drawn once the insulin infusion is stopped/when CIH has resolved, and 24 hours following discontinuation of insulin infusion. At each timepoint the patient's clinical status will be documented and significant interval changes (intubation/extubation, change in pressor need), amount of dextrose (mg/kg/hour) supplied, and other concurrent medicines and doses will be recorded.
3296642|NCT00487006|Active Comparator|At risk for CIH/without CIH|"For comparative controls, insulin, C-peptide, and glucose levels will be drawn from ICU patients aged 2-12 years at similar risk (mechanical ventilation or vasoactive medications) but without CIH. The above labs will be drawn and data gathered near the time of risk, 24 hours later, then in 3 days following, for a total of three timepoints."
3296643|NCT00487006|Active Comparator|Not at risk for CIH/without CIH|"In addition, other ICU patients aged 2-12 years that are deemed NOT at risk for critical illness hyperglycemia will also be evaluated to serve as a group not at risk but admitted to the PICU as a further control population. Like Group B, the above labs will be drawn and data gathered at the time consent is obtained, 24 hours later, then in 3 days following, for a total of three timepoints"
3296644|NCT00486993||asuriesgo|unselected outpatient population
3296645|NCT00486954|Experimental|Paclitaxel plus Lapatinib|6 pills of lapatinib at 250 mg each once daily and infusion of paclitaxel at 80 mglm2 weekly
3296646|NCT00486954|Active Comparator|Paclitaxel alone|Infusion of paclitaxel at 80 mglm2 weekly
3296647|NCT00486928||AVR|All consecutive patients in the study period
3296648|NCT00486915|Active Comparator|Left Atrial Appendage Exclusion|
3296649|NCT00486915|No Intervention|Control|
3296650|NCT00486902|Experimental|Ketamine|Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.
3296651|NCT00486902|Placebo Comparator|Placebo|Subjects receive IV Saline 20 mL 5 minutes after infant delivery
3296652|NCT00486889|Experimental|alglucosidase alfa|
3296653|NCT00486876|Placebo Comparator|1|Placebo
3296654|NCT00486876|Experimental|2|100 mg BID
3296655|NCT00486876|Experimental|3|200 mg BID
3296656|NCT00486876|Experimental|4|300 mg BID
3296657|NCT00486863|Placebo Comparator|Control|Placebo at 12-16 weeks gestation.
3296658|NCT00486863|Experimental|Praziquantel|Praziquantel at 12-16 weeks gestation.
3296659|NCT00486837|Experimental|Group 1|Bronchial Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
3296660|NCT00486837|Experimental|Group 2|Peripheral Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
3296661|NCT00486824|Active Comparator|Indomethacin|50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
3296662|NCT00486824|Active Comparator|Nifedipine|30 mg Nifedipine initially followed by 10 mg every 6 hrs for 48 hrs.
3296663|NCT00486811|Placebo Comparator|Matching Placebo (twice daily)|The starting dose of placebo was matched with the active treatment arms taken twice daily for the first 3 days. The dose was then increased to match the active treatments for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days as in the active treatment arms. Dose decreases were allowed without time restrictions.
3296664|NCT00486811|Experimental|Tapentadol ER (100 to 250 mg twice daily)|The starting dose was tapentadol ER 50 mg twice daily for 3 days. The dose was then increased to 100 mg tapentadol ER twice daily for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days. Dose decreases were allowed without time restrictions.
3296665|NCT00486811|Active Comparator|Oxycodone CR (20 to 50 mg twice daily)|The starting dose was oxycodone CR 10 mg twice daily for 3 days. The dose was then increased to 20 mg oxycodone CR twice daily for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days. Dose decreases were allowed without time restrictions.
3296666|NCT00486785|Experimental|1|
3296667|NCT00486759|Experimental|Bevacizumab + rituximab + CHOP|Patients received bevacizumab 5 mg/kg/week on Day 1 of each cycle + rituximab 375 mg/m^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone).
3296668|NCT00486759|Active Comparator|Placebo + rituximab + CHOP|Patients received placebo to bevacizumab on Day 1 of each cycle + rituximab 375 mg/m^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone).
3296669|NCT00486746|Experimental|Lifestyle intervention|
3296670|NCT00486746|Active Comparator|General health counseling|
3296671|NCT00486733|No Intervention|Standard of Care|Standard of Care Treatment; no study treatment
3296672|NCT00486733|Experimental|Standard of Care plus Study Treatment|Standard of Care Treatment plus study treatment
3296673|NCT00486720|Experimental|1|vorinostat 400 mg
3296674|NCT00486720|Experimental|2|vorinostat 200 mg
3296675|NCT00486707||Patients with ovarian cancer|
3296676|NCT00486681||1|period I (warning of the Accu-Check Inform glucose meter on glucose levels not activated)
3296677|NCT00486681||2|period II (warning activated).
3296678|NCT00486668|Active Comparator|Group 1: AC then paclitaxel + trastuzumab|AC followed by paclitaxel plus trastuzumab
3296679|NCT00486668|Experimental|Group 2: AC then paclitaxel + lapatinib|AC followed by paclitaxel plus lapatinib
3296680|NCT00486668|Experimental|Group 3: AC then paclitaxel + trastuzumab + lapatinib|AC followed by paclitaxel plus trastuzumab plus lapatinib
3296681|NCT00486642|Experimental|Arm A (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28.
3296682|NCT00486642|Experimental|Arm B (pazopanib hydrochloride, bicalutamide)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Patients also receive bicalutamide PO QD on days 8-28 of course 1 and on days 1-28 in all subsequent courses.
3296683|NCT00486629|Experimental|Intervention|Lifestyle intervention
3296684|NCT00486629|No Intervention|Control|No internvetion
3296685|NCT00486577|Experimental|1|
3296686|NCT00486577|Experimental|2|
3296687|NCT00486538|Experimental|Single arm|One oral dose daily
3296688|NCT00486525|Experimental|Arm I: Yoga Therapy|Patients participate in a Hatha yoga session over 90 minutes twice weekly for 12 weeks. Patients are also encouraged to practice yoga at home using the appropriate DVD/video segments for the month.
3296689|NCT00486525|No Intervention|Arm II: Wait-List|Wait-listed women were told to continue performing their usual activities, and to refrain from beginning any yoga practice. After their final assessment they were offered the yoga classes.
3296690|NCT00486512|Experimental|1|aspirin, 1,25-dihydroxycholecalciferol, calcium
3296691|NCT00486512|Placebo Comparator|2|placebo to aspirin, 1,25-dihydroxycholecalciferol, calcium
3296692|NCT00486486|Active Comparator|Bimatoprost/Timolol AM therapy|
3296693|NCT00486486|Active Comparator|Bimatoprost/Timolol PM therapy|
3296694|NCT00486447|Experimental|Imaging|General imaging subjects receiving CT exams
3296695|NCT00486434|Active Comparator|1|SMC021 Oral Calcitonin
3296696|NCT00486434|Placebo Comparator|2|SMC021 Placebo
3296697|NCT00486421|Experimental|PRED & RITUX|
3296698|NCT00486408|Experimental|1|MRKAd5 HIV-1 gag/pol/nef vaccine administered as 1 ml in either deltoid at study entry and Weeks 4 and 26
3296699|NCT00486395|Active Comparator|1|Mechanical ventilation
3296700|NCT00486395|Experimental|2|CPAP
3296701|NCT00486382|Experimental|Low dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
3296702|NCT00486382|Experimental|Medium dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
3296703|NCT00486382|Experimental|High dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
3296704|NCT00486356|Experimental|Capecitabine, Epirubicin, and Carboplatin|
3296705|NCT00486343|Experimental|1|Zileuton CR
3296706|NCT00486343|Placebo Comparator|2|Placebo
3296707|NCT00486330|Other|Buprenorphine plus Tipranavir/Ritonavir|
3296708|NCT00486304|Experimental|Antioxidant-deficient diet (ADD)|
3296709|NCT00486304|Placebo Comparator|Placebo|
3296710|NCT00486291|Experimental|1|Phentermine 15mg/topiramate 100mg
3296711|NCT00486291|Placebo Comparator|2|Matched placebo
3296712|NCT00486278|Experimental|vatreptacog alfa 5 mcg/kg|
3296713|NCT00486278|Experimental|vatreptacog alfa 10 mcg/kg|
3296714|NCT00486278|Experimental|vatreptacog alfa 20 mcg/kg|
3296715|NCT00486278|Experimental|vatreptacog alfa 40 mcg/kg|
3296716|NCT00486278|Experimental|vatreptacog alfa 80 mcg/kg|
3296717|NCT00486278|Experimental|rFVIIa 90 mcg/kg|
3296718|NCT00486252||This is N/A due to the above description.|This is N/A due to the above description.
3296719|NCT00486226|Experimental|1 Endovascular|All patients implanted with an CORDIS ENTERPRISE Vascular Reconstruction Device.
3296720|NCT00486213|Active Comparator|Pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
3296721|NCT00486213|Placebo Comparator|Placebo|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
3296722|NCT00486200|Active Comparator|1|Oral administration of active comparator
3296723|NCT00486200|Placebo Comparator|2|Oral administration of placebo
3296724|NCT00486200|Experimental|3|Dosing regimen 1
3296725|NCT00486200|Experimental|4|Dosing regimen 2
3296726|NCT00486200|Experimental|5|Dosing regimen 3
3296727|NCT00486200|Experimental|6|Dosing regimen 4
3296728|NCT00486187|Experimental|1|"Treatment-naive subjects randomly assigned to rosiglitazone (4 mg/day force titrated to 8 mg/day).~Subjects taking metformin before randomization were randomly assigned to the addition of rosiglitazone (4 mg/day force titrated to 8 mg/day).~Subjects taking glyburide before randomization were randomly assigned to the addition of rosiglitazone (4 mg/day)."
3296729|NCT00486187|Active Comparator|2|"Treatment-naive subjects randomly assigned to metformin (250 mg twice per day [BID] titrated to 500 mg BID if baseline A1C ≥7.5% and ≤8.0%, or 500 mg BID titrated to 1 g BID if baseline A1C >8.0%).~Subjects taking metformin before randomization were randomly assigned to the addition of glyburide (2.5 mg BID titrated to 5 mg BID if baseline A1C ≥7.5% and ≤8.0%, or 5 mg BID titrated to 10 mg BID if baseline A1C >8.0%).~Subjects taking glyburide before randomization were randomly assigned to the addition of metformin (250 mg BID titrated to 500 mg BID if baseline A1C ≥7.5% and ≤8.0% or 500 mg BID titrated to 1 g BID if baseline A1C >8.0%)."
3296730|NCT00486174|Active Comparator|1|standard sepsis therapy plus Methylene Blue
3296731|NCT00486174|No Intervention|2|standard sepsis therapy
3296732|NCT00486148|No Intervention|"group S"|Breast milk
3296733|NCT00486148|No Intervention|"group A"|Control Infant formula
3296734|NCT00486148|Experimental|"group B"|Infant formula supplemented with 0.4 g/100 ml of oligosaccharides
3296735|NCT00486135|Experimental|1|Daily dosing for 21 days/7 days off
3296736|NCT00486135|Experimental|2|Continuous daily dosing
3296737|NCT00486135|Experimental|3|Continuous daily dosing
3296738|NCT00486044|Experimental|simvastatin|simvastatin 40 mg nightly for 1 month then 80 mg nightly for 8 months
3296739|NCT00486044|Placebo Comparator|Placebo|Matching placebo tablet nightly for 9 months
3296740|NCT00486031|Other|balsalazide disodium tablets,3.3 g BID,|
3296741|NCT00486018|Sham Comparator|Sham injection|
3296742|NCT00486018|Experimental|Ranibizumab injection 0.3 mg|
3296743|NCT00486018|Experimental|Ranibizumab injection 0.5 mg|
3296744|NCT00485979|Experimental|Arm A1|Cohort 1: Her2-ve breast cancer
3296745|NCT00485979|Active Comparator|Arm B1|Cohort 1: Her2-ve breast cancer
3296746|NCT00485979|Experimental|Arm A2|Cohort 2: Her2+ve breast cancer
3296747|NCT00485979|Active Comparator|Arm B2|Cohort 2: Her2+ve breast cancer
3296748|NCT00485953|Experimental|Active Medication Group|risedronate 35 mg weekly
3296749|NCT00485953|No Intervention|Placebo Group|Placebo
3296750|NCT00485940|Active Comparator|1|Prucalopride 2 mg
3296751|NCT00485940|Placebo Comparator|3|Placebo
3296752|NCT00485940|Active Comparator|2|Prucalopride 4 mg
3296753|NCT00485914|Experimental|On-site work evaluation|Participants will receive one-to-one contact with an occupational therapist and an individualized work plan
3296754|NCT00485914|Active Comparator|Educational material|Participants will receive educational materials to develop strategies to compensate for limitations caused by their condition
3296755|NCT00485888|Active Comparator|1|
3296756|NCT00485888|Placebo Comparator|2|
3296757|NCT00485836|Sham Comparator|Sham injection|
3296758|NCT00485836|Experimental|Ranibizumab injection 0.3 mg|
3296759|NCT00485836|Experimental|Ranibizumab injection 0.5 mg|
3296760|NCT00485784|Sham Comparator|control group|control group
3296761|NCT00485784|Experimental|prééclampsies group|prééclampsies group
3296762|NCT00485784|Experimental|RCIU group|RCIU group
3296763|NCT00485784|Experimental|MFIU group|MFIU group
3296764|NCT00485758|Other|1|Arm 1: One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study.
3296765|NCT00485758|Active Comparator|2|Arm 2: stable lipid-modifying regimen, adding Placebo ER niacin/laropiprant in week 4, for the duration of the study.
3296766|NCT00485732|Experimental|Cervarix Group|
3296767|NCT00485732|Placebo Comparator|Placebo Group|
3296768|NCT00485719|Experimental|1|Twice daily (bid) dosing
3296769|NCT00485719|Experimental|2|Once daily (qd) dosing
3296770|NCT00485693|Active Comparator|Bupivacaine HCl|Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000)
3296771|NCT00485693|Other|SKY0402|SKY0402 at various dosage levels. Single administration.
3296772|NCT00485667|Active Comparator|Moxifloxacin tablet|
3296773|NCT00485667|Experimental|Placebo tablet|
3296774|NCT00485667|Experimental|SKY0402 300mg|
3296775|NCT00485667|Experimental|SKY0402 450mg|
3296776|NCT00485667|Placebo Comparator|Placebo injection|
3296777|NCT00485615|Experimental|1|OMEGA 3
3296778|NCT00485589|Experimental|1|
3296779|NCT00485589|Placebo Comparator|2|
3296780|NCT00485485|Experimental|Imatinib Mesylate + Docetaxel|Imatinib 400 mg orally daily; Docetaxel 60 mg/m^2 by vein over 1 hour every 3 weeks
3296781|NCT00485472|Experimental|Lacosamide|lacosamide (LCM)
3296782|NCT00485472|Placebo Comparator|Placebo|Placebo
3296783|NCT00485433|Active Comparator|Bupivacaine HCl 105mg|Bupivacaine HCl given during hernia repair
3296784|NCT00485433|Experimental|SKY0402 low dose|SKY0402 low dose given during hernia repair
3296785|NCT00485433|Experimental|SKY0402 Middle dose|SKY0402 middle dose given during hernia repair
3296786|NCT00485433|Experimental|SKY0402 High dose|SKY0402 high dose given during hernia repair
3296787|NCT00485420|Active Comparator|Usual Care|Member with recurrent or chronic depression receives usual specialty mental health care
3296788|NCT00485420|Experimental|Internet-based disease managment program|Usual care is augmented with internet based education, self monitoring and clinical monitoring
3296789|NCT00485394|Experimental|1|OT-551 0.3% ophthalmic solution
3296790|NCT00485394|Experimental|2|OT-551 0.45% ophthalmic solution
3296791|NCT00485394|Placebo Comparator|3|vehicle placebo
3296792|NCT00485355|Active Comparator|1|Conventional Laparoscopic Hysterectomy
3296793|NCT00485355|Active Comparator|2|Robotic Assisted Laparoscopic Hysterectomy
3296794|NCT00485342|No Intervention|standard dose|"the reference strategy : Peg-interferon alpha 2a (180 µg/week) and ribavine (1000 mg/day if weight < 75 kg and 1200 mg/day if weight ≥ 75 kg)"
3296795|NCT00485342|Experimental|adjusted dose|individual dose adjustment of ribavirin dose at D7, based on ribavirin abbreviated AUC-0-4H , estimated itself by two independent methods: multiple linear regression and bayesien estimation based on three ribavirin concentration measurements obtained at 0.5H, 1H, 2H after the first intake of 600 mg at D0.
3296796|NCT00485329|Experimental|Low dose papain|Ratio of drug to placebo treated patients will be 4:1
3296797|NCT00485329|Experimental|Medium dose papain|Ratio of drug to placebo treated patients will be 4:1
3296798|NCT00485329|Experimental|High dose papain|Ratio of drug to placebo treated patients will be 4:1
3296799|NCT00485303|Experimental|Abiraterone|Abiraterone acetate 1000 milligram (mg) (4 oral tablets of 250 mg each) will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-days dosing cycle and will be continued until disease progression or unacceptable toxicity.
3296800|NCT00485264|Experimental|Cohort I|"Participants between the ages of 12 and 18 years; receiving raltegravir poloxamer film coated tablet:~Stage I starting dose: Weight based dose of ~6 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: 400-mg tablet taken orally twice daily."
3296801|NCT00485264|Experimental|Cohort IIA|"Participants between the ages of 6 and 11 years, receiving raltegravir poloxamer film coated tablet:~Stage I starting dose: Weight based dose of ~8 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants < 25 kg were switched to a weight-based dose of the chewable tablet."
3296802|NCT00485264|Experimental|Cohort IIB|"Participants between the ages of 6 and 11 years; receiving raltegravir chewable tablet:~Stage I starting dose: Weight based dose of ~8 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily."
3296803|NCT00485264|Experimental|Cohort III|"Participants between the ages of 2 and 5 years; receiving raltegravir chewable tablet:~Stage I starting dose: Weight based dose of ~6 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily."
3296804|NCT00485264|Experimental|Cohort IV|"Participants between the ages of 6 and 23 months; receiving raltegravir oral granules for suspension (20 mg/mL):~Stage I starting dose: Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data."
3296805|NCT00485264|Experimental|Cohort V|"Participants between the ages of 4 weeks and 5 months; receiving raltegravir oral granules for suspension (20 mg/mL):~Stage I starting dose: Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data."
3296806|NCT00485251|Active Comparator|1|hand assisted right hemicolectomy
3296807|NCT00485251|Active Comparator|2|laparoscopic right hemicolectomy
3296808|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 1|
3296809|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 2|
3296810|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 3|
3296811|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 4|
3296812|NCT00485186||1|
3296813|NCT00485186||2|
3296814|NCT00485173|Experimental|INFUSE® Bone Graft|In this arm, patients will receive implant with INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate.
3296815|NCT00485134|Experimental|Stage 1: Group A, Dolphin 240 µg|240 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of lipopolysaccharides (LPS). 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
3296816|NCT00485134|Experimental|Stage 1: Group B, Dolphin 480 µg|480 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
3296817|NCT00485134|Experimental|Stage 1: Group C, Dolphin 690 µg|690 Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
3296818|NCT00485134|Other|Stage 1: Group D, Pipette 240 µg|240 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. These subjects received 200 μL the vaccine via electronic pipette. This group is for lot bridging only, not included in dose-finding study.
3296819|NCT00485134|Other|Stage 2: Immunized / Challenge|The selected dose was to be administered with the Dolphin™ using the vaccination schedule from stage 1. Immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast.
3296820|NCT00485134|Placebo Comparator|Stage 2: Controls|A control was to be administered with the DolphinTM using the vaccination schedule from Stage 1. Non-immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast.
3296821|NCT00485108|Active Comparator|1|Prednisolone 1% eye drop
3296822|NCT00485108|Active Comparator|2|ketorolac 0.5% eye drop
3296823|NCT00485108|Placebo Comparator|3|Artificial Tears (methyl cellulose eye drop)
3296824|NCT00485069|Experimental|Ropinirole Hydrochloride|
3296825|NCT00485056|Placebo Comparator|Placebo|Crossover arm
3296826|NCT00485056|Active Comparator|Pioglitazone|Pioglitazone 45mgs daily
3296827|NCT00485030|Experimental|Cypher|sirolimus-eluting stent
3296828|NCT00485030|Active Comparator|Xience-V|everolimus-eluting stent
3296829|NCT00485017|Experimental|1|THR-4109: 115 mg orally in am, 115 mg orally in pm for 24 weeks
3296830|NCT00485017|Experimental|2|THR-4109: 100 mg orally in am, 100 mg orally in pm for 24 weeks
3296831|NCT00485017|Experimental|3|THR-4109: 15 mg orally in am, 15 mg orally in pm for 24 weeks
3296832|NCT00485017|Placebo Comparator|4|
3296833|NCT00485004|Experimental|Cutting balloon|Cutting balloon
3296834|NCT00485004|Active Comparator|Sirolimus-eluting stent|Sirolimus-eluting stent
3296835|NCT00484939|Experimental|Bevacizumab + capecitabine|Participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3-week treatment cycle. In addition, participants received capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 3-week treatment cycle.
3296836|NCT00484939|Active Comparator|Capecitabine|Participants received capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 3-week treatment cycle.
3296837|NCT00484926|Active Comparator|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
3296838|NCT00484926|Experimental|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
3296839|NCT00484874|Experimental|A Single Dose of I-131 Tositumomab|I-131 Tositumomab therapeutic regimen given to patients with relapsed/refractory Hodgkin's lymphoma who have or have not undergone transplant.
3296840|NCT00484822|Experimental|1|Brazo 1: Bemiparina Sódica 3.500 UI/día.
3296841|NCT00484822|Placebo Comparator|2|Brazo 2: Heparina Cálcica 10.000 UI/día.
3296842|NCT00484796||1|Patients undergoing carotid surgery
3296843|NCT00484783|Experimental|Prospective|Subjects scheduled to receive procedure
3296844|NCT00484783|Other|Historical|Chart review control group
3296845|NCT00484770|Other|Congestion Score Strategy|
3296846|NCT00484770|Other|BNP Strategy|
3296847|NCT00484744|Experimental|Acetaminophen|
3296848|NCT00484744|Experimental|Ibuprofen|
3296849|NCT00484744|Placebo Comparator|Avicel|
3296850|NCT00484731|Placebo Comparator|Injection with Saline|Injection with Saline instead of Bupivacain
3296851|NCT00484731|Active Comparator|Injection with Bupivacaine|Injection with Bupivacaine
3296852|NCT00484718|Active Comparator|A|
3296853|NCT00484718|Active Comparator|B|
3296854|NCT00484718|Placebo Comparator|C|
3296855|NCT00484705|Experimental|Low-frequency electro-acupuncture|
3296856|NCT00484705|Experimental|Physical exercise|
3296857|NCT00484705|Active Comparator|Untreated control|
3296858|NCT00484679|Experimental|1|Patients receiving Triamcinolone Acetonide 10 ml (Kenalog-10) intralesional injections.
3296859|NCT00484666|Active Comparator|Meds|
3296860|NCT00484614|Active Comparator|1 PEM|
3296861|NCT00484614|Active Comparator|2 MRI|
3296862|NCT00484575|Active Comparator|propofol|propofol for sedation minimum 2 hours in CTICU after CABG
3296863|NCT00484575|Experimental|sevoflurane|Sevoflurane via AnaConDa for minimum 2 hours in CTICU after CABG
3296864|NCT00484562|Active Comparator|Standard oxygen delivery system|Standard oxygen tank with pulse dose regulator
3296865|NCT00484562|Active Comparator|Homefill oxygen delivery system|Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.
3296866|NCT00484562|Active Comparator|Helios oxygen delivery system|Liquid oxygen portable system pre-filled from a larger liquid oxygen tank
3296867|NCT00484562|Active Comparator|FreeStyle oxygen system|portable battery-powered oxygen concentrator delivery system
3296868|NCT00484536|Experimental|CDP323 1000 mg/day|
3296869|NCT00484536|Experimental|CDP323 500 mg/day|
3296870|NCT00484536|Placebo Comparator|Placebo|
3296871|NCT00484510|Experimental|Ascorbic Acid|
3296872|NCT00484510|Placebo Comparator|Placebo|
3296873|NCT00484484|Experimental|1|Ketamine
3296874|NCT00484484|Experimental|2|Ketamine
3296875|NCT00484471|Experimental|1|
3296876|NCT00484471|Placebo Comparator|2|
3296877|NCT00484458|Experimental|1|Wallis Stabilization System
3296878|NCT00484458|Active Comparator|2|Total Disc Replacement
3296879|NCT00484432|Experimental|A: NGR-hTNF + doxorubicin|NGR-hTNF plus doxorubicin
3296880|NCT00484419|Experimental|colesevelam|colesevelam tablets 625 mg
3296881|NCT00484419|Active Comparator|rosiglitazone|rosiglitazone maleate 4mg
3296882|NCT00484419|Active Comparator|sitagliptin|sitagliptin phosphate tablets
3296883|NCT00484393|Experimental|Tetracaine|Tetracaine 4% gel 1g applied to injection site
3296884|NCT00484393|Placebo Comparator|Placebo|Placebo cream (Aquatain) 1g applied to inejction site
3296885|NCT00484367|Active Comparator|1 AGT|
3296886|NCT00484367|Active Comparator|2 TFT|
3296887|NCT00484354|Active Comparator|1|Bicarbonate administration
3296888|NCT00484354|Placebo Comparator|2|Normal saline administration
3296889|NCT00484341|Experimental|A: low-dose NGR-hTNF|0.8 mcg/m² of NGR-hTNF
3296890|NCT00484341|Experimental|B: high-dose NGR-hTNF|45 mcg/m² of NGR-hTNF
3296891|NCT00484341|Experimental|C: low-dose NGR-hTNF + doxorubicin|0.8 mcg/m² of NGR-hTNF + doxorubicin
3296892|NCT00484341|Experimental|D: high-dose NGR-hTNF + doxorubicin|45 mcg/m² of NGR-hTNF + doxorubicin
3296893|NCT00484328|Experimental|1|
3296894|NCT00484328|Experimental|2|
3296895|NCT00484315|Experimental|TAXUS Element|
3296896|NCT00484315|Active Comparator|TAXUS Express|
3296897|NCT00484302|Experimental|CapOpus|
3296898|NCT00484302|Active Comparator|Treatment as usual|
3296899|NCT00484289|Experimental|Arm 1: Participants from Phase I study (IM101-034)|
3296900|NCT00484289|Experimental|Arm 2: Participants from Phase II study (IM101-071)|
3296901|NCT00484289|Experimental|Arm 3: New Participants with Methotrexate (MTX) Intolerance|
3296902|NCT00484276|Experimental|A|
3296903|NCT00484263|Active Comparator|1|
3296904|NCT00484211|Experimental|A|
3296905|NCT00484198|Placebo Comparator|1|
3296906|NCT00484198|Experimental|2|Rivoglitazone 1.0 mg
3296907|NCT00484198|Experimental|3|Rivoglitazone 1.5 mg
3296908|NCT00484198|Active Comparator|4|Pioglitazone 45 mg
3296910|NCT00484159|Experimental|1|Radiofrequency lumbar facet joint denervation only if positive response to 2 diagnostic facet blocks.
3296911|NCT00484159|Experimental|2|Radiofrequency lumbar facet joint denervation if positive response to single facet joint block.
3296912|NCT00484159|Experimental|3|Radiofrequency lumbar facet denervation without a diagnostic facet block.
3296913|NCT00484120|Experimental|1|3% Diclofenac NE cream
3296914|NCT00484120|Placebo Comparator|2|
3296915|NCT00484094||Rapamune|
3296916|NCT00484055|Active Comparator|treatment|"Use of local CollagenGentamicin and enhanced sternal fixation according to the Clinical routine introduced 4 years earlier as a result of a previous RCT on 2000 patients. In that sense these patients did not receive any intervention but just the standard treatment introduced 4 years earlier.~The aim of the study was to PROSPECTIVELY include a defined number of patients to compare their complication rate with that from aControl Group of patients från a previous RCT to verify that the effect of the treatment was stable over time.~As the study did not include any intervention compared to the present standard treatment at that time ethical approval was Exempt."
3296917|NCT00484029|Experimental|1|Nasal Carbon Dioxide
3296918|NCT00484029|Placebo Comparator|2|Air
3296919|NCT00483977|Active Comparator|Oxycodone|
3296920|NCT00483977|Placebo Comparator|Placebo|
3296921|NCT00483977|Experimental|PF-00592379|
3296922|NCT00483964|Experimental|A|The group getting the study drugs, Bacopa monnieri and Nardostachys jatamansi
3296923|NCT00483964|Active Comparator|B|The group getting Olanzapine
3296924|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group A)|Participants with HCV RNA levels greater than (>) 15 international units per milliliter (IU/mL) at Week 4, HCV RNA greater than or equal to (>=) 15 IU/mL at Week 8, and either HCV RNA less than (<) 15 IU/mL or >=2 times logarithmic (2 log10) drop at Week 12, will receive pegylated-interferon alfa-2a (Pegasys) 180 micrograms (mcg) subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 milligrams (mg) orally daily for 48 weeks.
3296925|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group B)|Participants with HCV RNA levels >15 IU/mL at Week 4, HCV RNA >=15 IU/mL at Week 8, and either HCV RNA <15 IU/mL or >=2 log10 drop at Week 12, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 72 weeks, and ribavirin 1000 to 1400 mg orally daily for 72 weeks.
3296926|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group C)|Participants with HCV-RNA levels >15 IU/mL at Week 4, and HCV-RNA <15 IU/mL at Week 8, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 36 weeks, and ribavirin 1000 to 1400 mg orally daily for 36 weeks.
3296927|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group D)|Participants with HCV-RNA levels >15 IU/mL at Week 4, and HCV-RNA <15 IU/mL at Week 8, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
3296928|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group E)|Participants with HCV-RNA levels <15 IU/mL at Week 4, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 24 weeks, and ribavirin 1000 to 1400 mg orally daily for 24 weeks.
3296929|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group F)|Participants with HCV-RNA levels <15 IU/mL at Week 4, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
3296930|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group NR)|Participants who do not have any change in HCV-RNA levels at Weeks 4, 8, and 12 will not be randomized (NR) to any of the other groups. Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
3296931|NCT00483899|Experimental|Cohort 1: Part A|Subjects in Cohort 1 will be randomized to receive 0.5, 2 and 6 mg GW870086X and placebo.
3296932|NCT00483899|Experimental|Cohort 2: Part A|Subjects in Cohort 2 will be randomized to receive 3 mg GW870086X or placebo.
3296933|NCT00483899|Experimental|Part B|Subjects will be randomized to receive 1 and 3 mg of GW870086X or placebo.
3296934|NCT00483886|Active Comparator|1|Prucalopride 2 mg
3296935|NCT00483886|Placebo Comparator|3|Placebo
3296936|NCT00483886|Active Comparator|2|Prucalopride 4 mg
3296937|NCT00483860|Experimental|Topotecan|once a day
3296938|NCT00483808|Experimental|Denervation|Renal denervation using the Symplicty Catheter
3296939|NCT00483756|Active Comparator|1|Treatment Arm 1 will also receive standard of care medications
3296940|NCT00483756|Experimental|2|Treatment Arm 2 will also receive standard of care medications
3296941|NCT00483756|Experimental|3|Treatment Arm 3 will also receive standard of care medications
3296942|NCT00483743|Experimental|TPI 1020|TPI 1020 500 mcg BID x 42 days
3296943|NCT00483743|Active Comparator|Budosenide cortico|Budesonide 800 mcg BID x 42 days
3296944|NCT00483743|Placebo Comparator|Placebo|Placebo inhaler
3296945|NCT00483717|Placebo Comparator|Placebo|Intranasal Placebo
3296946|NCT00483717|Experimental|Ketorolac tromethamine|Intranasal ketorolac tromethamine
3296947|NCT00483704|Experimental|Telcagepant 140 mg|Telcagepant 140 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 140 mg or placebo.
3296948|NCT00483704|Experimental|Telcagepant 280 mg|Telcagepant 280 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 280 mg or placebo.
3296949|NCT00483704|Placebo Comparator|Control Group 1|Placebo, oral, tablet, across 3 migraine attacks (1st, 2nd, and 4th). Telcagepant 140 mg will be administered for the 3rd migraine attack. Participants will receive placebo for the optional second dose. For migraine attacks 2, 3, and 4, no study medication will be provided as an optional second dose.
3296950|NCT00483704|Placebo Comparator|Control Group 2|Placebo, oral, tablet, across 3 migraine attacks (1st, 2nd, and 3rd). Telcagepant 140 mg will be administered for the 4th migraine attack. Participants will receive placebo for the optional second dose. For migraine attacks 2, 3, and 4, no study medication will be provided as an optional second dose.
3296951|NCT00483678|Experimental|Intimacy-Enhancing Couples Therapy|Patients and their partners receive Intimacy-Enhancing Couples Therapy over 6 weeks comprising the following four 90-minute sessions: the Story of Cancer; Understanding the Couple, Ways of Relating and Key Influences; Intimacy; and Coping, Support, and Adaptation. Patients and their partners complete treatment satisfaction questionnaires after completion of study intervention.
3296952|NCT00483678|Active Comparator|standard psychosocial care|Patients and their partners receive standard psychosocial care. All participants complete questionnaires assessing psychological distress, intimacy, communication patterns, and overall relationship adjustment/satisfaction at baseline and at 1 month after completion of study intervention
3296953|NCT00483652|Placebo Comparator|Placebo|Placebo control
3296954|NCT00483652|Active Comparator|Fampridine-SR|10 mg b.i.d.
3296955|NCT00483600|Experimental|no arms/one group|
3296956|NCT00483574|Experimental|Group 1: Menactra® and Routine Pediatric Vaccines|Participants received Menactra® alone at age 9 months and Menactra® concomitantly with routine pediatric vaccines (measles-mumps-rubella-varicella [MMRV: ProQuad], pneumococcal conjugate [PCV], and hepatitis A [HepA]) at age 12 months.
3296957|NCT00483574|Other|Group 2: Routine Pediatric Vaccines|Participants received routine pediatric vaccines (measles-mumps-rubella-varicella [MMRV: ProQuad], pneumococcal conjugate[PCV], and hepatitis A [HepA]) at age 12 months.
3296958|NCT00483561|Experimental|Gefitinib plus Etoposide|"Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial.~Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple)."
3296959|NCT00483548|Experimental|Ziprasidone|Active treatment, double-blind, randomized treatment arm
3296960|NCT00483548|Placebo Comparator|Placebo|Inactive, placebo treatment, double-blind, randomized arm
3296961|NCT00483535|Experimental|Sequence ABC|All subjects will receive the treatment sequence ABC where A=combined oral contraceptive pill (COC), B=COC plus GW273225 and C=GW273225. COC will be administered in two cycles that is, cycle 1 (Days 1-21) and cycle 2 (Days 29-49) of the study. The cycles will be separated by a 7 day washout period. GW273225 will be administered at a dose of one 25 milligram tablet once daily on Days 29-75 of the study.
3296962|NCT00483522|Experimental|1|Scheduled telephone counseling over 2 years time.
3296963|NCT00483522|No Intervention|2|This control group will receive standard care after hospital rehabilitation discharge as directed by their physician.
3296964|NCT00483509|Experimental|A: NGR-hTNF + doxorubicin|NGR-hTNF plus doxorubicin
3296965|NCT00483496|Experimental|V0096CR actives and vehicle|"Each patient received each one of the 8 test products on their respective randomly allocated sites on grid (grid to be applied on the back skin; 1 product by grid window).~Single application of the test materials at the dosage of 2mg/cm² (total of 8 treated sites), prior to irradiation using a solar simulator."
3296966|NCT00483483|Experimental|1|Healthy Relationships Intervention (HRI)
3296967|NCT00483483|Active Comparator|Attention-control group|health education & support
3296968|NCT00483470|Experimental|1|
3296969|NCT00483470|Active Comparator|2|
3296970|NCT00483444|No Intervention|2|Control group were recruited in the emergency department after concussion and received standard care as directed by the ED physician and PCP.
3296971|NCT00483444|Experimental|1|Persons with concussion recruited in the emergency department received 5-6 scheduled telephone counseling calls focused on symptom management and self-management.
3296972|NCT00483431|Placebo Comparator|PLACEBO|MK7 dosage 0 mcg, 4 capsules, orally, daily for 12 weeks.
3296973|NCT00483431|Active Comparator|MK7_10|MK7 dosage 10 mcg, 1 capsule of 10 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
3296974|NCT00483431|Active Comparator|MK7_20|MK7 dosage 20 mcg, 2 capsules of 10 mcg and 2 placebo-capsules, orally, daily for 12 weeks.
3296975|NCT00483431|Active Comparator|MK7_45|MK7 dosage 45 mcg, 1 capsules of 45 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
3296976|NCT00483431|Active Comparator|MK7_90|MK7 dosage 90 mcg, 2 capsules of 45 mcg and 2 placebo-capsules, orally, daily for 12 weeks.
3296977|NCT00483431|Active Comparator|MK7_180|MK7 dosage 180 mcg, 4 capsules of 45 mcg, orally, daily for 12 weeks.
3296978|NCT00483431|Active Comparator|MK7_360|MK7 dosage 360 mcg, 1 capsule of 360 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
3296979|NCT00483405|Other|Single Arm Trial|Single Arm Trial
3296980|NCT00483379|Experimental|alglucosidase alfa 20 mg/kg every week|Participants were treated with alglucosidase alfa 20 mg/kg every week for 52 weeks. This was the 'frequent dose' arm.
3296981|NCT00483379|Experimental|alglucosidase alfa 40 mg/kg every other week|Participants were treated with alglucosidase alfa 40 mg/kg every other week for 52 weeks. This was the 'high dose' arm.
3296982|NCT00483366|Other|Imatinib/Gemcitabine/Capecitabine|"Patients will be accrued on cohorts of three per dose level starting at dose level 0. Accrual to higher dose levels will depend on toxicity occurrence.~Dose limiting toxicity (DLT) will be determined after cycle two for each patient.~Schema: Imatinib days 1 - 5 and days 8 - 12 Gemcitabine on days 3 and 10 Capecitabine on days 1 - 14~Doses: Imatinib 400 mg/d fixed dose Gemcitabine 450 mg/m2; 550 mg/m2; 675 mg/m2; 825 mg/m2; 1000 mg/m2 Capecitabine 500 mg/m2; 600 mg/m2 bid; 725 mg/m2; 850 mg/m2~Treatment cycle: 21-days~Treatment duration: Until disease progression or unacceptable toxicity defined in protocol."
3296983|NCT00483327|Experimental|Megestrol Acetate|80 mg (2 tablets) orally at breakfast, 80 mg at dinner for at least 12 weeks and up to 2 years.
3296984|NCT00483314|Experimental|1|
3296985|NCT00483262|Experimental|CCI779 and Bortezomib Phase I/II|In Phase I part, 15 or 25 mg temsirolimus (CCI-779)and 1·3 or 1·6 mg/m² bortezomib was given once a week.In Phase II, patients received intravenous temsirolimus once a week on days 1, 8, 15, 22, and 29 for a cycle of 35 days, and intravenous bortezomib once a week on days 1, 8, 15, and 22 for a cycle of 35 days, the MTD ascertained in the Phase I part.
3296986|NCT00483249|Experimental|Interventional|Endovascular Branched Stent-Graft: The investigational operation is done making small incisions in both groins and the right arm and placing a graft in the aorta through tubes that are inserted through the femoral and brachial arteries, than fastening it in position with metal springs(stents).
3296987|NCT00483223|Experimental|Single Arm|Cisplatin or carboplatin (1 arm, 2 cohorts)
3296988|NCT00483184|Placebo Comparator|1|(placebo)0 IU IFNa
3296989|NCT00483184|Experimental|2|(Veldona)500 IU IFNα bid
3296990|NCT00483184|Experimental|3|(Veldona)1000 IU IFNα bid
3296991|NCT00483171|Placebo Comparator|Placebo|
3296992|NCT00483171|Other|Non-pharmacological weight loss program (NPP)|
3296993|NCT00483171|Other|Low Calorie Diet|
3296994|NCT00483158|Placebo Comparator|A|Rising Single Dose
3296995|NCT00483158|Placebo Comparator|B|Rising Multiple Dose
3296996|NCT00483158|Experimental|C|Open Label H. pylori cohort
3296997|NCT00483145|Active Comparator|1|Long-pulsed dye laser (Candela)
3296998|NCT00483145|Active Comparator|2|Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)
3296999|NCT00483119|Active Comparator|Group A|IVIg alone (intravenous immunoglobulin)
3297000|NCT00483119|Experimental|Group B|IVIg with cyclophosphamide
3297001|NCT00483106|Placebo Comparator|Ritalin|
3297002|NCT00483106|Placebo Comparator|Placebo|
3297003|NCT00483093|Experimental|A|
3297004|NCT00483080|Experimental|A|
3297005|NCT00483067|Experimental|2-CdA + Ara-C + G-CSF|2-CdA 12 mg/m^2/day by vein (IV) Continuous Infusion and Ara-C 1 gm/m^2/day IV for 5 Days with G-CSF 5 mcg/kg/day subcutaneously starting Day 9
3297006|NCT00483054|Experimental|Efavirenz|Efavirenz 600 mg/day + stavudine +lamivudine
3297007|NCT00483054|Experimental|Nevirapine|Nevirapine 400 mg/day + stavudine +lamivudine
3297008|NCT00483041|Experimental|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
3297009|NCT00483041|Placebo Comparator|PLACEBO|Placebo administered as a single intravenous infusion
3297010|NCT00483002||Healthy smokers|
3297011|NCT00482989|Experimental|1|MEDI-545
3297012|NCT00482989|Other|2|Placebo
3297013|NCT00482963|Experimental|levonorgestrel, efavirenz|healthy HIV-negative women of reproductive age were given levonorgestrel, efavirenz
3297014|NCT00482924||Overweight/obese|"The cohort consists of age and sex matched normal weighted controls and overweight/obese persons.~Definition for overweight: BMI >90th and <97th percentile, if under 18 years of age, and BMI >25 and <29.9 kg/m2 if over 18 years of age.~Definition for obese: BMI >97th percentile, if under 18 years of age, and BMI >30kg/m2, if over 18 years of age."
3297015|NCT00482924||Interventional branch|A lifestyle intervention following a holistic schedule was done in a subgroup of obese juveniles.
3297016|NCT00482911|Experimental|Cohort 1-lenalidomide & cyclophosphamide|Participants first started on 2 Interventions (Dose A-QD) in Cycle 1, with 10 mg Lenalidomide (Len) once daily and 50 mg Cyclophosphamide (Cyc) once daily; 25 mg Sunitinib (Sun) was added once daily as a 3rd Intervention (Dose B-QD) from Cycle 2 onwards. Doses were adjusted in subsequent cycles depending on toxicity, including incremental step downs to 5/25/12.5 mg Len/Cyc/Sun once daily (Dose C-QD) or once every other day (Dose C-QOD).
3297017|NCT00482911|Experimental|Cohort 2-sunitinib & cyclophosphamide|2 participants started Cycle 1 with Dose B as described above and had adjusted-dosing as described for Cohort 1. The remaining 7 participants began Cycle 1 with 10 mg Len, 25 mg Cyc and 12.5 mg Sun once daily (Dose D-QD). Doses were adjusted in subsequent cycles depending on toxicity, including step up to 10/50/12.5 mg Len/Cyc/Sun once daily (Dose E-QD) and step down to Dose D once every other day (Dose D-QOD).
3297018|NCT00482846|Experimental|Palifermin & Melphalen|"Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is >40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3~Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. <60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
3297019|NCT00482833|Experimental|ARM A - ATO/ATRA|
3297020|NCT00482833|Active Comparator|ARM B - ATRA|
3297021|NCT00482820|Experimental|1|attention training away from threat
3297022|NCT00482820|Placebo Comparator|2|placebo attention training
3297023|NCT00482794||1|Individuals with APS who also have one or more of their family members affected specifically by APS
3297024|NCT00482794||2|Individuals with APS who also have one or more of their family members affected by another type of autoimmune disorder, such as lupus or rheumatoid arthritis.
3297025|NCT00482794||3|Individuals with APS and no family or no family affected with APS or another autoimmune disorder
3297026|NCT00482768|Experimental|1|Intervention clinics will receive practice facilitation visits at regular intervals over a 12-month period.
3297027|NCT00482768|No Intervention|2|Control clinics will deliver usual care for patients with diabetes.
3297028|NCT00482742|Other|Lifestyle counseling|
3297029|NCT00482742|Other|Metformin|
3297030|NCT00482729|Experimental|1|Arm 1: drug
3297031|NCT00482729|Active Comparator|2|Arm 2: active comparator
3297032|NCT00482703|Experimental|A|
3297033|NCT00482703|Experimental|B|
3297034|NCT00482677|Active Comparator|Temozolomide|Temozolomide and short course radiation
3297035|NCT00482677|Active Comparator|Radiation|Short course radiation alone
3297036|NCT00482664|Experimental|1 mg|
3297037|NCT00482664|Experimental|10 mg|
3297038|NCT00482664|Experimental|3 mg|
3297039|NCT00482664|Placebo Comparator|Placebo|
3297040|NCT00482651|Experimental|UAP, SAP|
3297041|NCT00482625|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.
3297042|NCT00482612|Experimental|Esmirtazapine 1.5 mg|Esmirtazapine 1.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
3297043|NCT00482612|Experimental|Esmirtazapine 3.0 mg|Esmirtazapine 3.0 mg tablet, oral administration in the evening, once daily, for 2 weeks
3297044|NCT00482612|Experimental|Esmirtazapine 4.5 mg|Esmirtazapine 4.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
3297045|NCT00482612|Placebo Comparator|Placebo|Placebo to esmirtazapine
3297046|NCT00482599|Active Comparator|Normal renal function|Org 25969 given to subjects with normal renal function
3297047|NCT00482599|Experimental|Impaired renal function|Org 25969 given to subjects with impaired renal function
3297048|NCT00482586||Image-guided Therapy|Patients undergoing Image-guided Therapy of Hepatic Neoplasms.
3297049|NCT00482573|Experimental|Group LE|Seventeen (54.8%) patients, composed group LE, were randomly assigned for the infusion of 1.8 mL (one cartridge) by the modified anesthesia into the periodontal ligament (PDLm injection) of 2% lidocaine solution with epinephrine 1:100,000. Their ages were ranging from 18 to 44 years (mean:29.6), they were diagnosed as having rheumatic valve disease, in a functional class I or II according to classification of the NYHA. Gestation age ranged from 28 to 36 weeks (mean:31.8), and the BMI from 18.7 to 32.9 (mean:23.8) kg/m2. All the patients had the restauration done in their inferior premolar and/or molar teeth.
3297050|NCT00482573|Active Comparator|Group LNE|Fourteen (45.2%) patients, composed group LNE, were randomly assigned for the infusion of 1.8 mL (one cartridge) by the modified anesthesia into the periodontal ligament (PDLm injection) of 2% lidocaine solution without epinephrine. Their ages were ranging from 22 to 33 years (mean:26.6), they were diagnosed as having rheumatic valve disease, in a functional class I or II according to classification of the NYHA. Gestation age ranged from 29 to 37 weeks (mean:32.1), and the BMI from 18.5 to 38.1 (mean:22.8) kg/m2. All the patients had the restauration done in their inferior premolar and/or molar teeth.
3297051|NCT00482547|Experimental|Silver-coated catheter|Bard Hydrogel Silver Salts Coated Latex Urinary Catheter System
3297052|NCT00482547|Placebo Comparator|Silicone-coated catheter|Bard silicone elastomer coated latex catheter system
3297053|NCT00482521|Experimental|CC-4047|
3297054|NCT00482482|Experimental|Yoga|Yoga was offered twice a week for 8 weeks, 1.5 hours per session
3297055|NCT00482482|Active Comparator|Psychoeducation|Psychoeducation was offered twice a week for 8 weeks, 1.5 hours per session
3297056|NCT00482443|Experimental|1|To assess the efficacy of a Diabetes Interactive Diary in Diabetes Management.
3297057|NCT00482443|Active Comparator|2|Control Arm. Patients will receive standard education programme.
3297058|NCT00482430|Other|1|MK0557 10mg tablet qd, crossing over to MK0557 Pbo tablet qd.
3297059|NCT00482430|Other|2|MK0557 Pbo tablet qd, crossing over to MK0557 10mg tablet qd.
3297060|NCT00482391|Experimental|AC, PACLITAXEL , TRASTUZUMAB & LAPATINIB|The regimen consists of AC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 4 with pegfilgrastim, followed by weekly paclitaxel (80 mg/m2) x 12 + trastuzumab (H) + lapatinib (L). Pegfilgrastim 6mg is given subcutaneously (SQ) on day # 2 of each AC. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion. Trastuzumab will be administered weekly starting with paclitaxel treatment # 1. Near the completion of all chemotherapy, patients may receive trastuzumab on a q 3-weekly schedule, starting as early as with paclitaxel cycle # 12. The total duration of trastuzumab from beginning to end is 52 weeks. Lapatinib will be given orally at 1000 mg daily, starting with trastuzumab for a total duration of 52 weeks. Hormonal therapy such as tamoxifen or an aromatase inhibitor will be given to patients with hormone receptor positive disease at the physician's discretion. Radiation therapy to the breast or chest is recommended to patients as appropriate.
3297061|NCT00482378|Experimental|Sm 153 lexidronam|
3297062|NCT00482352||Ancillary-Correlative (marker identification, molecular test)|Patients undergo blood collection and bone marrow biopsies at baseline and at the end of induction therapy for immunophenotyping for marker identification; molecular testing for translocations; trisomy analysis by fluorescence in situ hybridization (FISH); and DNA ploidy. Immunophenotype results obtained on this study are used to determine the patient's assignment to specific treatment clinical trials (consistent with acute lymphoblastic leukemia).
3297063|NCT00482313|Experimental|Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
3297064|NCT00482313|Placebo Comparator|Sugar pill|Placebo given orally once daily for 5 weeks.
3297065|NCT00482287|Other|1|Dose level 0.3 mg/kg with 6 active and 2 placebo
3297066|NCT00482287|Other|2|Dose level 0.6 mg/kg 6 patients active and 2 placebo
3297067|NCT00482287|Other|3|Dose level 1.2 mg/kg 6 active and 2 placebo
3297068|NCT00482287|Other|4|Dose level 2.4 mg/kg 6 active and 2 placebo
3297069|NCT00482261|Experimental|len-dex|Drug: Lenalidomide 15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards; Drug: dexamethasone 20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
3297070|NCT00482222|Active Comparator|OxMdG / IrMdG chemotherapy|OxMdG / IrMdG chemotherapy for 12 weeks Followed by surgery OxMdG / IrMdG chemotherapy for 12 weeks
3297071|NCT00482222|Experimental|OxMdG / IrMdG chemotherapy with cetuximab|OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks Followed by Surgery OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks
3297072|NCT00482209|Active Comparator|1|200mg mifepristone followed by 400mcg misoprostol
3297073|NCT00482209|Active Comparator|2|200mg mifepristone followed by 800mcg misoprostol
3297074|NCT00482170|Experimental|1|Arm 1: Enbrel 50 mg Prefilled Syringe
3297075|NCT00482170|Active Comparator|2|Arm 2 Enbrel 50 mg Autoinjector
3297076|NCT00482144|Active Comparator|Treatment: PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
3297077|NCT00482144|Active Comparator|Treatment: PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
3297078|NCT00482144|No Intervention|Control|The scar will be randomly divided into three equal fields. One third of the scar will not receive treatment
3297079|NCT00482105|Other|A|"This research study proposes to use a non-invasive method to capture superficial cells on pigmented skin lesions that are suspected of being early melanomas. This non-invasive biopsy technology has been developed and patented by DermTech International. RNA in skin cells captured by this method will be profiled in order to diagnose the nature of the lesion (i.e. malignant melanoma or not). A successful outcome of this proposal would create a candidate non-invasive diagnostic assay based on a gene expression profile for identifying early stage melanomas"
3297080|NCT00482092|Placebo Comparator|1|Placebo
3297081|NCT00482092|Active Comparator|2|Low dose (600 million cells total over four infusions in two weeks)
3297082|NCT00482092|Active Comparator|3|High dose (1200 million cells delivered in four infusions over two weeks)
3297083|NCT00482066|Active Comparator|1|Abatacept (Orencia)
3297084|NCT00482066|Placebo Comparator|2|saline placebo
3297085|NCT00482053|Experimental|Auto-HCT followed by Allo-HCT for Poor-risk DLBCL|"Participants will have peripheral blood stem cells (PBSC, aka progenitor / stem cells) mobilized to peripheral blood with rituximab, chemotherapy (cyclophosphamide or etoposide), and filgrastim; undergo apheresis to collect (self/autologous PBSC), and receive carmustine, etoposide, and cyclophosphamide as conditioning for PBSC infusion as a hematopoietic cell transplant (auto-HCT).~Then participants will receive allogeneic HCT (allo-HCT) transplant conditioning [total lymphoid irradiation (TLI) + anti-thymocyte globulin (ATG)] followed by allogenic PBSC (allo-HCT) obtained from a human leukocyte antigen (HLA)-matched or single mismatch filgrastim-mobilized donor. Participant allo-HCT transplant is to occur within 150 days of auto-HCT. Post-allo-HCT treatment includes cyclosporine + mycophenolate mofetil (MMF).~Subject's participation ends if donor is not identified within 150 days. Pre-medication includes acetaminophen; diphenhydramine; hydrocortisone; & methylprednisolone."
3297086|NCT00482027|Active Comparator|1 AAV-2 HIV Vaccine|64 volunteers receiving AAV-2 HIV vaccine tgAAC09 at 3 dosage levels, dose escalation and dose optimization
3297087|NCT00482027|Placebo Comparator|2|16 volunteers receiving formulation buffer consisting of a buffered salt solution with potassium phosphate, calcium chloride, magnesium chloride, and HEPES
3297088|NCT00482014|Experimental|A: Pemetrexed + Carboplatin|Pemetrexed + Carboplatin
3297089|NCT00482014|Experimental|B: Pemetrexed + Cisplatin|Pemetrexed + Cisplatin
3297090|NCT00482001|Experimental|1|
3297091|NCT00482001|Placebo Comparator|2|
3297092|NCT00481988|Active Comparator|transcranial direct current stimulation|The active group of patients will receive active Iomed II Phoresor transcranial direct current stimulation for the first two weeks followed by another two weeks of active transcranial direct current stimulation.
3297093|NCT00481988|Sham Comparator|sham tDCS|The patients in the sham arm receive active Iomed II Phoresor transcranial direct current stimulation for the second two weeks of the clinical trial only. For the first two weeks the Iomed II Phoresor constant current generator is turned on for 10 seconds to produce the tingling sensation on the scalp experienced by the patients in the active arm but the generator is then turned off and the patients receive no stimulation for the remainder of the 20 minute session.
3297094|NCT00481936|Experimental|Dose Escalating|"Patients will be treated with VB6-845 as a monotherapy IV infusion, once weekly in 4-week cycles. Patients will continue to receive treatment up until the treatment stopping criteria or patient withdrawal criteria are met.~Dose escalation will begin at a dose level of 1.00 mg/kg. Doses will be escalated according to the modified Fibonacci design with dose multipliers of 2.00, 1.67, 1.50, 1.40, and 1.33."
3297095|NCT00481884|Experimental|RadiaPlexRx Gel|RadiaPlexRx Gel for application to one half of irradiated breast skin, determined by a randomization process.
3297096|NCT00481884|Active Comparator|Aquaphor Gel|Aquaphor Gel for application to one half of irradiated breast skin, determined by a randomization process.
3297097|NCT00481871|Experimental|Pralatrexate & Gemcitabine - Sequential Days|
3297098|NCT00481871|Experimental|Pralatrexate & Gemcitabine - Same Day|
3297099|NCT00481845|Experimental|Vandetanib + Anastrozole|Vandetanib and Anastrozole as neoadjuvant therapy
3297100|NCT00481845|Active Comparator|Anastrozole|Anastrozole as neoadjuvant therapy
3297101|NCT00481832|Experimental|T & B Cell Mobilization Auto & Allo HCT|A transplant regimen that conditions the subjects using total lymphoid irradiation (TLI) and anti-thymocyte globulin(ATG) which will reduce acute graft-vs-host disease to negligible rates while maintaining the anti-tumor graft vs lymphoma GvL benefit. Along with TLI/ATG regiment; Solumedrol will be used as pre-medication and anti-emetic for any side effects. For stem cell mobilization, participants will be given either B Cell NLH or T Cell NHL. Before the filgrastim (G-CSF) mobilized PBPC infusion: acetaminophen, diphenhydramine and hydrocortisone will also be given as another set of pre-medications. BCNU, Etoposide, and Cyclophosphamide will be used as a preparative regimen. Cyclosporine and mycophenolate mofetil will be administered as an immunosuppressant after transplantation. Lastly, rituximab will be infused at the end of the transplantation regimen.
3297102|NCT00481819|Experimental|1|In combination with MMF and steroids
3297103|NCT00481819|Active Comparator|2|In combination with MMF and steroids
3297104|NCT00481767|Active Comparator|Cervarix Group|Healthy female subjects who received 3 doses of Cervarix at Months 0, 1 and 6, administered intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.
3297105|NCT00481767|Placebo Comparator|Placebo Group|Healthy female subjects who received 3 doses of placebo at Months 0, 1 and 6, administered intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.
3297106|NCT00481754||Females with ovarian cancer|Recruited from Magee Women's Hospital
3297107|NCT00481728|Experimental|Tolterodine|
3297108|NCT00481715|Experimental|1|Web-based weight loss program
3297109|NCT00481715|Experimental|2|Cash incentive weight loss program
3297110|NCT00481715|Experimental|3|Web-based program plus the cash incentive program
3297111|NCT00481715|No Intervention|4|No intervention
3297112|NCT00481676|Experimental|Omalizumab 75-375 mg|Omalizumab was dosed at 75 to 375 mg according to baseline IgE and body weight as described in dosing tables in the study protocol. Dosing occurred subcutaneously every 2 or 4 weeks depending on dose.
3297113|NCT00481676|Placebo Comparator|Placebo to omalizumab|Placebo to omalizumab was dosed at 75 to 375 mg according to baseline IgE and body weight as described in dosing tables in the study protocol. Dosing occurred subcutaneously every 2 or 4 weeks depending on dose.
3297114|NCT00481663|Experimental|Sitagliptin 25 mg once daily|Sitaglipin (MK-0431), 25 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
3297211|NCT00480571|Experimental|2|BL 1020 High Dose
3297212|NCT00480558|Active Comparator|1|Group 1: M. tb
3297115|NCT00481663|Experimental|Sitagliptin 50 mg once daily|Sitagliptin, 50 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
3297116|NCT00481663|Experimental|Sitaglipin 100 mg once daily|Sitagliptin, 100 mg, once daily for 158 weeks, orally
3297117|NCT00481663|Experimental|Sitagliptin 50 mg twice daily|Sitagliptin 50 mg, twice daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
3297118|NCT00481663|Placebo Comparator|Placebo to Sitagliptin → Metformin|Placebo to Sitagliptin, once daily, orally for 12 weeks. Participants randomized to the placebo treatment group during the base study were reallocated to treatment with metformin 850 mg twice daily (b.i.d., initiated with 850 mg q.d. for 4 weeks then force titrated to 850 mg b.i.d.) during either the first or initiation of the second extensions study periods.
3297119|NCT00481637||Cancer patients|SCLC and gynecological cancer patients and unrelated cancer patients with presence of PND-specific CTLs.
3297120|NCT00481637||Normal|Normal volunteers
3297121|NCT00481624|Experimental|Epoetin Alfa plus Iron|
3297122|NCT00481572|Experimental|1|Terlipressin
3297123|NCT00481572|Experimental|2|Vasopressin
3297124|NCT00481572|Active Comparator|3|titrated norepinephrine
3297125|NCT00481546|Experimental|Experimental|All clinical trial subjects received the same vector.
3297126|NCT00481520|Experimental|1|
3297127|NCT00481520|Placebo Comparator|2|
3297128|NCT00481507|Placebo Comparator|Placebo|
3297129|NCT00481507|Experimental|Kefir|
3297130|NCT00481481|Experimental|1|
3297131|NCT00481455|Experimental|1|
3297132|NCT00481429|Active Comparator|1|Rosiglitazone
3297133|NCT00481429|No Intervention|2|Diet control +/- metformin
3297134|NCT00481390||HIV-1 infected adults|HIV-1 infected adults
3297135|NCT00481364|Active Comparator|Statin|Atorvastatin 40 mg/day
3297136|NCT00481364|Placebo Comparator|Placebo|placebo
3297137|NCT00481351|Experimental|group1 ezetimibe|6 week wash out, followed by 06 week ezetimibe 10mg once a day e then 6 week ezetimibe 10mg plus sinvastatin 20mg for more 6 week.
3297138|NCT00481351|Active Comparator|group 2 simvastatin|6 week simvastatin 20mg once a day followed by 6 week simvastatin 80mg once a day.
3297139|NCT00481338|Experimental|Study specific procedure|X-rays, biological samples and medical information about osteoarthritis
3297140|NCT00481325|Experimental|A1|
3297141|NCT00481325|Active Comparator|A2|
3297142|NCT00481325|Placebo Comparator|A3|
3297143|NCT00481312|Active Comparator|1|Dexmedetomidine
3297144|NCT00481312|Active Comparator|2|Midazolam
3297145|NCT00481286|Experimental|Group Clinic|Patients in Group Clinic arm will meet every 3rd week for 12 weeks, for a total of 4 visits. At each visit, BP will be measured, home BP and glucose measurements collected. Each visit will include group-based education and feedback sessions, with an individualized process of selecting and modifying process of care goals for systolic BP, H1C, and LDL cholesterol. Short-term health behavior change goals will also be discussed.
3297146|NCT00481286|Placebo Comparator|Uusual Care|Older diabetes patients will attend regular clinician visits and one targeted primary care physician visit during the 12 weeks post-enrollment. They will be enrolled in a diabetes education class. Blood pressure, H1C and lipids will be measured at enrollment, 6 weeks , and 12 weeks.
3297147|NCT00481247|Experimental|Dasatinib|
3297148|NCT00481247|Active Comparator|Imatinib|
3297149|NCT00481221||1|Screened pregnant women
3297150|NCT00481195|Active Comparator|Armodafinil|
3297151|NCT00481195|Placebo Comparator|Placebo|
3297152|NCT00481156|Experimental|Patients: Cognitive Remediation|Patients in the cognitive REM condition attended up to 25 h of training in small groups over 4-6 weeks based on the approach to cognitive remediation described by Wexler and Bell (2005). Patients performed tasks designed to train attention and memory from the battery available within a computerized software package (CogPack Marker Software). This training protocol has been shown to improve memory and executive functioning in patients with schizophrenia (Sartory et al, 2005) and tasks chosen were designed to produce improved working memory and attention capacity in the treated group. In addition, patients in the REM group trained on the word N-back one to two times a week and on N-back tasks using a variety of other stimuli (such as faces) one to two times a week to support the generalization of working memory improvements.
3297153|NCT00481156|Active Comparator|Patients: Cognitive-Behavioral Social Skills Training|Patients in the CBSST group also attended up to 25 h of treatment but followed a manualized group therapy protocol (Granholm et al, 2005) using cognitive and behavioral therapy methods to increase patients' skills in symptom recognition, communication, problem solving, and relapse prevention. In both conditions, the facilitators interacted with the clients throughout small group (B4 patients) sessions: in the REM group, this mostly involved brief one-on-one discussions regarding task performance; in the CBSST condition, this interaction was in the context of the group milieu.
3297154|NCT00481156|Other|Controls: Retest control group|Estimate of normal brain functioning and retest effects
3297155|NCT00481143|Experimental|deferasirox|
3297156|NCT00481091|Experimental|Arm NA, Group is Applicable|Group/Cohort Number or Label is numerical and sequential starting with dose level 1
3297157|NCT00481078|Experimental|Arm I (vorinostat, paclitaxel, carboplatin)|Patients receive oral vorinostat (SAHA) at 400 mg once daily on days 1-14 and paclitaxel IV 200 mg/m2 over 3 hours and carboplatin IV dosed to achieve an area under the concentration versus time curve of 6 mg/mLXmin over 30 minutes on day 3.
3297158|NCT00481078|Active Comparator|Arm II (placebo, paclitaxel, carboplatin)|Patients receive an oral placebo once daily on days 1-14 and paclitaxel and carboplatin as in arm l.
3297159|NCT00481065|Experimental|Concomitant alone|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382.
3297160|NCT00481065|Experimental|Concomitant +Mixed|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
3297161|NCT00481065|Experimental|Concomitant +MF59-eH5N1|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
3297162|NCT00481065|Experimental|Mixed|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
3297163|NCT00481065|Experimental|Mixed and mixed|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382
3297164|NCT00481065|Experimental|Mixed+MF59-eH5N1|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
3297165|NCT00481065|Experimental|MF59-eH5N1+eTIV_a|1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
3297166|NCT00481065|Experimental|eTIV_a+MF59-eH5N1|1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
3297167|NCT00481039||1|Patients diagnosed as having abnormal hemoglobin like hemoglobin S and thalassemia in a bedouin village
3297168|NCT00481026|Sham Comparator|Placebo|Placebo tDCS
3297169|NCT00481026|Active Comparator|active tDCS|active tDCS
3297170|NCT00481013|Placebo Comparator|1a|For six months, half of patients are randomized into placebo . After 6 months, all patients are on treatment.
3297171|NCT00481013|Active Comparator|1b|Cohort 1b patients are randomized onto treatment. After 6 months, all patients are on drug.
3297172|NCT00481000|No Intervention|1|Waitlist; Treatment as usual
3297173|NCT00480987|Experimental|Oxaliplatin + Cytarabine + Fludarabine|Oxaliplatin 30 mg/m^2 intravenous (IV) days 1-4, Cytarabine 500 mg/m^2 by IV continuous infusion days 2-6, Fludarabine 30 mg/m^2 IV days 2-6
3297174|NCT00480974||1|Patients with Sickle cell anemia treated by Hydroxyurea
3297175|NCT00480948|Active Comparator|1|Infant formula with InFat™ oil(containing ~49% of C16:0 at sn-2 position).
3297176|NCT00480948|Placebo Comparator|2|Standard vegetable oil based infant formula
3297177|NCT00480935|Experimental|Sunitinib Malate (Sutent)|Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 2 week rest period to comprise a complete cycle of 6 weeks. Patients will then continue on Sutent for another cycle of 4 consecutive weeks
3297178|NCT00480922|Experimental|1|A low glycemic load diet
3297179|NCT00480922|Active Comparator|2|Low fat diet
3297180|NCT00480896|Experimental|1|
3297181|NCT00480896|Placebo Comparator|2|
3297182|NCT00480883|Active Comparator|1|injection meglumine antimoniate 20 mg/kg/day/intramuscular for 21 days.
3297183|NCT00480883|Experimental|2|injection meglumine antimoniate 10 mg/kg/day/intramuscular plus tablet allopurinol 1200 mg/day/6hourly divided doses.
3297184|NCT00480870|Experimental|A|Donepezil treated Alzheimer patients
3297185|NCT00480870|Placebo Comparator|B|Placebo treated Alzheimer patients
3297186|NCT00480857|Experimental|Docetaxel|
3297187|NCT00480844|Experimental|Sertindole|
3297188|NCT00480844|Active Comparator|Risperidone|
3297189|NCT00480831|Experimental|1|
3297190|NCT00480831|Placebo Comparator|2|
3297191|NCT00480792|Active Comparator|A|GenHevac-B 20 microgramme Intramuscular use at M0, M1, M6
3297192|NCT00480792|Experimental|B|GenHevac-B 40 microgramme Intramuscular use at M0, M1, M2, M6
3297193|NCT00480792|Experimental|C|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
3297194|NCT00480779|Other|GLB Group|The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study choose traditional GLB face-to-face group delivery or delivery via DVD. Group members met weekly and completed the program over a 12-15 week period. The face-to-face group meetings were led by a trained lifestyle coach, and participants were encouraged to self-monitor their eating and physical activity behaviors. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
3297195|NCT00480779|Other|GLB DVD|The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study choose traditional GLB face-to-face group delivery or delivery via DVD. Those who took part via DVD received an overview of the GLB program at the first session, as well as the materials needed for the program. They subsequently watched one session of the program each week, and received a telephone call from a trained lifestyle coach each week to review weight, physical activity minutes and questions/concerns regarding the program. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
3297196|NCT00480740|Experimental|Cardiac Transplant|diagnostic cardiac catheterization in children with a transplanted heart
3297197|NCT00480740|Experimental|Fontan procedure|diagnostic cardiac catheterization in children with a transplanted ventricle
3297198|NCT00480740|Other|Normal Physiology|diagnostic cardiac catheterization in children with normal cardiac physiology
3297199|NCT00480727|Placebo Comparator|Control|No fortnightly re-tensioning. Placebo treatment utilises the re-tensioning procedure, pt experiences clicking sensation, however, the pin is not tightened.
3297200|NCT00480727|Experimental|Treatment (Re-tensioning) Group|Pins are re-tensioned fortnightly back to initial fitting tension of 8lb/inch.
3297201|NCT00480701|Experimental|[123I]-IBVM|To assess [123I] IBVM and SPECT imaging
3297202|NCT00480675|Experimental|1|Trochanteric bursa injections done into the bursa under fluoroscopic guidance
3297203|NCT00480675|Active Comparator|2|Trochanteric bursa injection done with sham fluoroscopy using only landmarks as guidance.
3297204|NCT00480649|Active Comparator|Sal/FP 50/250mcg|SERETIDE 50/250
3297205|NCT00480649|Active Comparator|Sal/FP 50/500mcg|SERETIDE 50/500
3297206|NCT00480636||One cohort of patients treated with dalteparin.|About 100 patients with deep-vein thrombosis and with or without pulmonary embolism will be included in the study.
3297207|NCT00480610|Experimental|1|
3297208|NCT00480610|Placebo Comparator|2|
3297209|NCT00480584|Experimental|GemCap-T Dose Escalation|GemCap-T, capecitabine in combination with gemcitabine. Dose Escalation 6 Cycles @ 28 Days.
3297210|NCT00480571|Experimental|1|BL 1020 low dose
3297213|NCT00480558|Active Comparator|2|Group 2: HIV (not on antiretrovirals [ARV])
3297214|NCT00480558|Active Comparator|3|Group 3: M. tb and HIV (not on ARV)
3297215|NCT00480558|Active Comparator|4|Group 4: M. tb and HIV (on ARV)
3297216|NCT00480532|Experimental|Doxycycline 100bid x5 days|
3297217|NCT00480532|Placebo Comparator|placebo bid x 5 days|
3297218|NCT00480532|Experimental|Subantimicrobial doxycycline daily|
3297219|NCT00480532|Placebo Comparator|placebo daily|
3297220|NCT00480493|Experimental|Parent mentor contact|Parent mentor provides face-to-face social support
3297221|NCT00480493|Active Comparator|Control Arm|Parent is given a phone contact
3297222|NCT00480454|Active Comparator|1|Stage 1 would require 12 per group low dose and 12 per group high dose (total 72)
3297223|NCT00480454|Active Comparator|2|Stage 2 would require 48 per group (total 144)
3297224|NCT00480441|Active Comparator|1|Dronabinol+ BRENDA therapy
3297225|NCT00480441|Placebo Comparator|2|Placebo+BRENDA therapy
3297226|NCT00480402|Experimental|400 mg Progesterone|Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 400 mg Progesterone Group vaginal pessaries arm.
3297227|NCT00480402|Experimental|200 mg Progesterone Group|Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 200 mg Progesterone Group vaginal pessaries arm.
3297228|NCT00480402|Active Comparator|Placebo|Approximately one third of the bichoronic biamniotic twin pregnant women were randomized to the placebo vaginal pessaries arm.
3297229|NCT00480389|Experimental|Sorafenib|"All patients on study will be accrued to this arm. Sorafenib (200 mg tablets x 2) will be administered orally twice a day for 12 weeks (full daily dose of 800 mg). Patient visits for safety will be conducted at least every 4 weeks. Sorafenib dose reductions for drug-related toxicity will be applied based on considerable prior clinical experience. Surgery will be performed at the completion of the 13th week, allowing for a one-week washout period. Sorafenib will be continued post operatively (around 6 weeks post surgery or when complete wound healing has occurred) until patient progresses or unacceptable toxicity occurs."
3297230|NCT00480363|Experimental|1|Lenalidomide + Dexamethasone for 9 cycles and maintenance
3297231|NCT00480363|No Intervention|2|Observation
3297232|NCT00480324|Experimental|Rotarix Group|Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.
3297233|NCT00480324|Placebo Comparator|Placebo Group|Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.
3297234|NCT00480311||1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
3297235|NCT00480272|Experimental|group A|"adalimumab 40 mg subcutaneous injections every other week from baseline to month 12~methotrexate orally weekly at initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.~prednisone orally 50 mg daily, gradually tapered up to 6.25 mg at week 7 and stopped at month 6"
3297236|NCT00480272|Placebo Comparator|group B|"adalimumab 40 mg subcutaneous injections every other week from baseline to the end of month 12~methotrexate orally oweekly at an initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.~placebo orally, stopped at month 6"
3297237|NCT00480259|Active Comparator|Standard Nutrition|
3297238|NCT00480259|Experimental|Hyperprotein Nutrition|
3297239|NCT00480220|Experimental|1|Specific Intervention as Global care and support program
3297240|NCT00480220|No Intervention|2|'No specific intervention'
3297241|NCT00480207|Experimental|omega-3, folic acid, vitB12|folic acid (1600 mcg per day), and omega-3 (2000 mg per day: active docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA), proportion 1:1), vitamin B12 (1000 mcg per day)
3297242|NCT00480207|Experimental|omega-3, folic acid placebo, vit B12|omega-3,folic acid placebo (starch), vitamin B12 (1000 mcg per day)
3297243|NCT00480207|Experimental|omega-3 placebo, folic acid, vit B12|folic acid, omega-3 placebo(canola oil),vitamin B12 (1000 mcg per day)
3297244|NCT00480207|Experimental|omega-3 placebo, folic acid placebo, vit B12|omega-3 placebo (canola oil),folic acid placebo (starch), vitamin B12 (1000 mcg per day)
3297245|NCT00480181|Experimental|Active|
3297246|NCT00480181|Placebo Comparator|placebo|
3297247|NCT00480155|Active Comparator|1|FluMist
3297248|NCT00480155|Placebo Comparator|2|Placebo
3297249|NCT00480116|Active Comparator|1|
3297250|NCT00480116|Active Comparator|2|
3297251|NCT00480116|Active Comparator|3|
3297252|NCT00480090|Experimental|Cytarabine|
3297253|NCT00480077|Experimental|Access Arm|HF subjects managed with standard clinical assessment and using OptiVol® Fluid status monitoring with Cardiac Compass Report
3297254|NCT00480077|Active Comparator|Control arm|HF subjects managed with standard clinical assessment
3297255|NCT00480038|Other|1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
3297256|NCT00480025|Experimental|ASCI Group|
3297257|NCT00480025|Placebo Comparator|Placebo Group|
3297258|NCT00479986|Experimental|Pioglitazone|
3297259|NCT00479986|Active Comparator|placebo|
3297260|NCT00479973|Active Comparator|Cinnamonforce|Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.
3297261|NCT00479973|Placebo Comparator|Placebo|
3297262|NCT00479934|Experimental|1|6 month treatment with Imtinib 400mg/day
3297263|NCT00479934|Placebo Comparator|2|6 month treatment with Placebo 400mg/day
3297264|NCT00479895|Other|1|Occlusion with pre-oxygenated HBOC-201 followed by dry occlusion
3297265|NCT00479895|Other|2|Dry occlusion followed by occlusion with pre-oxygenated HBOC-201
3297266|NCT00479882|Experimental|Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg|After a 2-week placebo run-in, participants will receive MK-0524B (0.9 g/simvastatin 10 mg) for 4 weeks, then MK-0524B 1.8g /20 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 20 mg for 8 weeks.
3297329|NCT00479362|Other|4 No Antithrombotic Group|No antithrombotic treatment during operations
3297330|NCT00479349|Active Comparator|1|SAM 531 + placebo
3297331|NCT00479336|Placebo Comparator|1|
3297267|NCT00479882|Experimental|Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg|After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 10 mg for 4 weeks, then co-administered MK-0524A 2g +simvastatin 20 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/20 mg combination tablet for 8 weeks.
3297268|NCT00479882|Experimental|Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg|After a 2-week placebo run-in, participants will receive MK-0524B 0.9g/40 mg combination tablet for 4 weeks, then MK-0524B 1.8g /40 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 40 mg for 8 weeks.
3297269|NCT00479882|Experimental|Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg|After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 40 mg for 4 weeks, then co-administration MK-0524A 2g +simvastatin 40 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/40 mg combination tablet for 8 weeks.
3297270|NCT00479856|Experimental|Lapatinib plus Chemotherapy|Lapatinib is administered in combination with one of the following chemotherapies based on the discretion of the investigator : capecitabine, docetaxel or nab-paclitaxel.
3297271|NCT00479830||Group 1|South Asian, Subgroup: Asian Indian, population in the Greater Houston area.
3297272|NCT00479830||Group 2|South Asian, Subgroup: Bangladeshi, population in the Greater Houston area.
3297273|NCT00479830||Group 3|South Asian, Subgroup: Pakistani, population in the Greater Houston area.
3297274|NCT00479830||Group 4|South Asian, Subgroup: Sri Lankan, population in the Greater Houston area.
3297275|NCT00479817|Experimental|Arm A|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 10 mg/kg IV QW
3297276|NCT00479817|Experimental|Arm B|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 3 mg/kg IV QW
3297277|NCT00479817|Active Comparator|Arm C|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 placebo
3297278|NCT00479765|Experimental|1|OncoGel administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel
3297279|NCT00479752|Active Comparator|A|"FOLFOX4:~Oxaliplatin 85 mg/m² d1~Leucovorin 200 mg/m² d1+d2, followed by~Bolus 5FU 400 mg/m², followed by~Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks~Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m²."
3297280|NCT00479752|Active Comparator|B|"FOLFOX4:~Oxaliplatin 85 mg/m² d1~Leucovorin 200 mg/m² d1+d2, followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks~Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks."
3297281|NCT00479739|Experimental|Arm 1|
3297282|NCT00479713|Experimental|1|Arm 1: drug
3297283|NCT00479713|Active Comparator|2|Arm 2: active comparator
3297284|NCT00479687|Active Comparator|Supartz|Supartz
3297285|NCT00479687|Placebo Comparator|Phosphate Buffered Saline|Phosphate Buffered Saline
3297286|NCT00479674|Experimental|Abraxane, Carboplatin, Bevacizumab|Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15
3297287|NCT00479661|Experimental|1|Dexmedetomidine
3297288|NCT00479661|Active Comparator|2|Propofol
3297289|NCT00479648|Active Comparator|1|Inactivated trivalent influenza vaccine
3297290|NCT00479648|Experimental|2|CSL412 formulation
3297291|NCT00479648|Experimental|3|CSL412 formulation
3297292|NCT00479648|Experimental|4|CSL412 formulation
3297293|NCT00479635|Experimental|TPI 287|
3297294|NCT00479622|Experimental|1|
3297295|NCT00479622|Experimental|2|
3297296|NCT00479609|Placebo Comparator|1|Placebo gel
3297297|NCT00479609|Active Comparator|2|Transdermal testostrone therapy
3297298|NCT00479583|Active Comparator|A|
3297299|NCT00479583|Active Comparator|B|
3297300|NCT00479570|Experimental|Study period 1, 2 or 3|
3297301|NCT00479570|Placebo Comparator|Placebo Study period 1, 2 or 3|
3297302|NCT00479557|Active Comparator|1|arm 1: ACC-001 (Vanutide Cridificar)+ QS-21
3297303|NCT00479557|Active Comparator|2|arm 2: ACC-001
3297304|NCT00479557|Placebo Comparator|3|arm 3: QS-21
3297305|NCT00479557|Placebo Comparator|4|Drug: Phosphate Buffered Saline (PBS)
3297306|NCT00479505|Experimental|Active|
3297307|NCT00479505|Placebo Comparator|Placebo|
3297308|NCT00479492|Experimental|1|
3297309|NCT00479492|Experimental|2|
3297310|NCT00479492|Experimental|3|
3297311|NCT00479492|Placebo Comparator|4|
3297312|NCT00479479|Experimental|Cobalamin|An intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
3297313|NCT00479479|No Intervention|No intervention|No intervention
3297314|NCT00479466|Experimental|MK0893 80 mg|MK0893 tablets totaling 80 mg once daily.
3297315|NCT00479466|Experimental|MK0893 60 mg|MK0893 tablets totaling 60 mg once daily.
3297316|NCT00479466|Experimental|MK0893 40 mg|MK0893 40 mg tablet once daily.
3297317|NCT00479466|Experimental|MK0893 20 mg|MK0893 20 mg tablet once daily.
3297318|NCT00479466|Active Comparator|Metformin|Metformin HCL 500 mg tablet twice daily BID titrating up to 1000 mg twice daily over 3 weeks.
3297319|NCT00479466|Placebo Comparator|Placebo|PLA tablets. 12 week treatment period.
3297320|NCT00479427|Experimental|Overall study|overall study population
3297321|NCT00479401|Experimental|Pramipexole Extended Release (PPX ER)|
3297322|NCT00479401|Experimental|Pramipexole Immediate Release (PPX IR)|
3297323|NCT00479401|Placebo Comparator|Placebo|
3297324|NCT00479388|Other|1|One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
3297325|NCT00479388|Active Comparator|2|Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.
3297326|NCT00479362|Experimental|1 Warfarin Uninterrupted|Warfarin therapy is continued without interruption prior to cardiac pacing device implantation
3297327|NCT00479362|Active Comparator|2 Warfarin Interrupted|Warfarin therapy is discontinued 2 days prior to cardiac pacing device implantation
3297328|NCT00479362|Sham Comparator|3 Aspirin Group|Patients with aspirin therapy during implantation
3297335|NCT00479323|Other|1|Immunize healthy volunteers with pneumococcal vaccine (Pneumovax 23) to obtain a pool of hyperimmune sera in a quantity sufficient to generate reference sera.
3297336|NCT00479271|Active Comparator|Home Care|"A flexible home-care program tailored to the needs of the individual and the family. The components of the intervention will include:~Basic education about dementia (what is the disease, its course, its features etc)~Education about common behaviour problems and how they can be managed~Support to the carer, for example for an elderly carer living alone with the patient, in activities of daily living~Referral to specialists when behaviour problems are severe and warrant medication intervention (sedatives)."
3297337|NCT00479271|Other|Wait-list|This group will be put on a waiting list to receive the intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
3297338|NCT00479258|Experimental|Inhaled insulin (Exubera)|
3297339|NCT00479258|Active Comparator|Subcutaneous Insulin (subject's prescribed)|
3297340|NCT00479245|Other|1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
3297341|NCT00479232|Experimental|Cohort 1: Vorinostat (sequential)|"Vorinostat 400 mg capsules once daily given 7, 10 or 14 days in 28 day cycles. Up to 24 months of treatment.~Decitabine IV 20 mg/m^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment."
3297342|NCT00479232|Experimental|Cohort 2: Vorinostat (concurrent)|"Vorinostat 400 mg capsules once daily given 7 days, 14 days with 8 day break after first 7 days or 14 days without break, out of 28 day cycles.~Decitabine IV 20 mg/m^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment."
3297343|NCT00479219|Experimental|A|
3297344|NCT00479219|Placebo Comparator|B|
3297345|NCT00479193|Other|1|There is one arm to the study. The same subjects are their own control. One of the investigators will identify two sites that appear to be the same depth on each patient [1 site Polymen and 1 site bacitracin/xeroform )]. One site will be identified for bacitracin/xeroform and one site for Polymen. All burns will be initially debrided and cleaned according to burn unit protocol. Laser Doppler will be utilized to determine burn depth at both the trial and control sites. On each subsequent visit, patients will rate the pain of the dressing change on a 1-10 pain intensity scale.The study will end for each patient when the investigator determines that 95% of their burn has re-epithelized.
3297346|NCT00479180|Experimental|AVG1|Vascugel
3297347|NCT00479180|Placebo Comparator|AVG2|Gelfoam
3297348|NCT00479180|Experimental|AVF3|Vascugel
3297349|NCT00479180|Placebo Comparator|AVF4|Gelfoam
3297350|NCT00479154|Experimental|Botulinum Toxin A|Injection of onabotulinumtoxinA
3297351|NCT00479154|Placebo Comparator|Placebo (saline)|Injection of saline placebo
3297352|NCT00479141|Experimental|1|HIV infected participants and their families
3297353|NCT00479141|Experimental|2|Popular Opinion Leaders (POL) participants
3297354|NCT00479128|Experimental|Bortezomib + Gemcitabine + Doxorubicin|Starting dose of Bortezomib 0.8 mg/m^2 IV Over 3-5 Seconds. Starting dose of Gemcitabine 225 mg/m^2 IV Up to 90 Minutes. Starting dose of Doxorubicin 12.5 mg/m^2 IV Over 15-30 minutes.
3297355|NCT00479089|Active Comparator|Weekly Docetaxel|Docetaxel 25 mg/m^2 IV over 30 minutes for 4 weeks with premedication with Dexamethasone, followed by 2 weeks off therapy.
3297356|NCT00479089|Active Comparator|Weekly Docetaxel + ZD1839|Docetaxel 25 mg/m^2 IV over 30 minutes for 4 weeks with premedication with Dexamethasone, followed by 2 weeks off therapy. ZD1839 250 mg by mouth daily, without break.
3297357|NCT00479063||Cases|All subjects screened for this study were aged 30 to 50 years, had been referred to participating Radiology services, and underwent a lumbar MRI. Cases had been referred for a lumbar MRI for LBP lasting > 90 days.
3297358|NCT00479063||Controls|All subjects screened for this study were aged 30 to 50 years, had been referred to participating Radiology services, and underwent a lumbar MRI. Controls were headache patients who had been referred for a cranial MRI, which turned out to be normal, and who either had no history of LBP or had only experienced one episode in their life, which had lasted for less than 7 days.
3297359|NCT00479037|Active Comparator|PTH(1-84)|
3297360|NCT00479037|Active Comparator|Strontium Ranelate|
3297361|NCT00479024||observation|patients enrolled in previous trial IOP 104; collecting clinical outcome data on these same patients
3297362|NCT00478985|Experimental|1|Imatinib treatment ending
3297363|NCT00478972|Experimental|Rimonabant|Rimonabant 20 mg once daily in addition to diet and exercise
3297364|NCT00478972|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily in addition to diet and exercise
3297365|NCT00478959|Experimental|Lenalidomide|Lenalidomide given as a daily oral dose of 25 mg on days 1 - 21 followed by 7 days of no therapy of a 28 day cycle in the treatment of a population with relapsed or refractory Hodgkin's lymphoma.
3297366|NCT00478946|Experimental|1|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
3297367|NCT00478946|Active Comparator|2|FOLFOX Oxaliplatin 85 mg/m2, as a 2-hour infusion Leucovorin (400 mg/m2 in D5W) and Oxaliplatin. Leucovorin + oxaliplatin will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
3297368|NCT00478933|Experimental|ICD Therapy, blood sampling|Blood sampling Defibrillator, Dual Chamber ; Implantable
3297369|NCT00478881|Experimental|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
3297370|NCT00478881|Placebo Comparator|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
3297371|NCT00478842|Experimental|1|Deep brain stimulation
3297372|NCT00478816|Active Comparator|Group 1|Primed subject with pandemic Vaccine
3297373|NCT00478816|Active Comparator|Group 2|Non Primed subject with pandemic Vaccine
3297374|NCT00478803|Experimental|1, preservation|aortic valve surgery(Remodeling associated with a subvalvular aortic ring annuloplasty or double sub and supra valvular aortic annuloplasty)
3297375|NCT00478803|Sham Comparator|2, Bentall|Mechanical aortic valve replacement(isolated or composite valve and graft replacement);actual surgical standard for dystrophic aortic roots
3297524|NCT00477282|Experimental|Karenitecin|
3297525|NCT00477282|Active Comparator|Topotecan|
3297376|NCT00478790|Experimental|1|ologen™ collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy. After operation with ologen™ Collagen Matrix, anti-inflammatory eye-drops will be prescribed
3297377|NCT00478777|Experimental|lenalidomide plus dexamethasone|Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), dexamethasone was to be reduced to 40 mg QD for Days 1-4 of each 28 day-cycle.
3297378|NCT00478738|Other|GSK961081|GSK961081
3297379|NCT00478725|Experimental|Part A|Absorption, Distribution, Metabolism and Elimination of a Single Oral [14C] Labeled Dose of GW786034
3297380|NCT00478725|Experimental|Part B|characterize the pharmacokinetics of a single IV dose of GW786034
3297381|NCT00478712||Families with Hirschsprung Disease|Individuals with Hirschsprung disease and their affected and unaffected relatives.
3297382|NCT00478699|Active Comparator|1|
3297383|NCT00478699|Experimental|2|
3297384|NCT00478686||Severe Toxicity|Patients who experienced severe toxicity (at least one grade 4 side effect) with capecitabine chemotherapy
3297385|NCT00478686||Dose-Limiting Toxicity|Patients who experienced dose-limiting toxicity (at least one grade 3, or recurrent grade 2, side effect)with capecitabine chemotherapy
3297386|NCT00478686||Low/No Toxicity|Patients who have experienced low/no toxicity (none or only side effects at grade 1 & 2) with capecitabine chemotherapy.
3297387|NCT00478647|Experimental|GA-GCB (velaglucerase alfa)|
3297388|NCT00478634|Experimental|A1: RAD001 + cetuximab + irinotecan|RAD001 30mg weekly oral, 400mg/m2, loading i.v. (250mg/m2 for subsequent weekly dose i.v.), 350mg/m2 every 3 weeks i.v.
3297389|NCT00478634|Experimental|B1 dose: RAD001 + cetuximab + irinotecan|RAD001 30mg weekly oral, 400mg/m2 loading i.v (250mg/m2 for subsequent weekly dose i.v.), 250mg/m2 every 3 weeks i.v.
3297390|NCT00478621|Experimental|Group A|
3297391|NCT00478621|Experimental|Group B|
3297392|NCT00478621|Experimental|Group C|
3297393|NCT00478621|Experimental|Group D|
3297394|NCT00478621|Experimental|Group E|
3297395|NCT00478621|Active Comparator|Group F|
3297396|NCT00478595|Experimental|Rimonabant|Rimonabant 20 mg once daily
3297397|NCT00478595|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily
3297398|NCT00478569||Parathyroid Hormone (PTH) (1-84)|PTH(1-84) was prescribed in accordance with the terms of the marketing authorization. Participants were observed for 24 months.
3297399|NCT00478556|Active Comparator|1|Gastroview
3297400|NCT00478556|Experimental|2|Omnipaque
3297401|NCT00478543|Experimental|Diuretic|Furosemide
3297402|NCT00478504|Active Comparator|Clomiphene citrate|Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
3297403|NCT00478504|Active Comparator|Letrozole|Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
3297404|NCT00478491||1|Persons with a parent with Alzheimer's disease
3297405|NCT00478491||2|Persons whose parents survived to old age without memory problems
3297406|NCT00478491||3|Persons with diagnosed mild cognitive impairment
3297407|NCT00478491||4|Persons without memory problems
3297408|NCT00478478||Acute Ischemic Stroke patients|Patients presenting with signs and symptoms consistent with a diagnosis of Acute Ischemic Stroke, who are treated with the Merci Retrieval System during a Mechanical Thrombectomy procedure.
3297409|NCT00478452|Experimental|DC Ova|DC Ova vaccine administered day 2 and week 3,6,9
3297410|NCT00478452|Active Comparator|DC Ova with Cyclophosphamide|Cyclophosphomide administered at day 0 prior to administration of DC Ova vaccine administered day 2 and week 3,6,9
3297411|NCT00478439|Placebo Comparator|Placebo Comparator|
3297412|NCT00478426|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3297413|NCT00478400||Participants who have had a TBI|"(recruited by invitation only)~Must be between 1- and 6-years post-injury~Closed head injury~Evidence of loss of consciousness~Must have an informant (friend, spouse, child etc.)~Audit-C < 7, PCL < 65 and PHQ-9 < 15"
3297414|NCT00478400||Participants with No history of TBI|"(Recruited by invitation only)~No history of TBI~Must have an informant (friend, spouse, child etc.)"
3297415|NCT00478400||Veterans with History of TBI|"Must be between 1- and 6-years post-injury~Closed head injury~Evidence of loss of consciousness~Must have an informant (friend, spouse, child etc.)~Audit-C < 7, PCL < 65 and PHQ-9 < 15"
3297416|NCT00478400||US Veterans with No history of TBI|"No history of TBI~Must have an informant (friend, spouse, child etc.)"
3297417|NCT00478374|Experimental|1|
3297418|NCT00478361|Experimental|Gemcitabine, Paclitaxel and Doxorubicin|Paclitaxel 135 mg/m^2 intravenous (IV) over 1 hour; Gemcitabine 900 mg/m^2 IV over 90 min; Doxorubicin 40 mg/m^2 IV over 20 min; treatment may repeat every 2 weeks for up to nine courses. Injection of Pegfilgrastim on day 1.
3297419|NCT00478348|Other|Drain|
3297420|NCT00478348|Other|No drain|
3297421|NCT00478335|Experimental|Active Therapy|4-day treatment with hydrochlorothiazide/amiloride, indomethacin, calcitonin, sildenafil
3297422|NCT00478335|Placebo Comparator|Placebo Control|4-day treatment with hydrochlorothiazide/amiloride, indomethacin, placebo for calcitonin, placebo for sildenafil
3297423|NCT00478322|Experimental|INCB013739|
3297424|NCT00478322|Placebo Comparator|Matching Placebo|
3297425|NCT00478309|No Intervention|Arm I|Participants receive standard primary care.
3297426|NCT00478309|Experimental|Arm II|Participants receive standard primary care followed by the Genetic Epidemiology and Risk Assessment (GERA) intervention. Participants also participate in a discussion session regarding the GERA including the rationale behind methylenetetrahydrofolate reductase mutation detection and folate assessment and its relationship to colorectal cancer risk.
3297427|NCT00478270|Experimental|1|
3297428|NCT00478257|Active Comparator|1|Bright white light, the intervention, was administered via a light box made by Litebook Inc for 30 minutes each morning during four cycles of chemotherapy
3297863|NCT00473954|Experimental|EGEN-001|
3297429|NCT00478257|Active Comparator|2|Dim red light, the intervention, was administered via a light box made by Litebook Inc for 30 minutes each morning during four cycles of chemotherapy
3297430|NCT00478244|Experimental|Epidermolysis Bullosa (EB) Patients|Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant.
3297431|NCT00478231|Experimental|1|
3297432|NCT00478218|Experimental|Lenalidomide/Cyclophosphamide/Dexamethasone|
3297433|NCT00478205|Experimental|1|
3297434|NCT00478205|Experimental|2|
3297435|NCT00478192|Experimental|Regimen 1 Conivaptan QD|20 mg conivaptan once a day
3297436|NCT00478192|Experimental|Regimen 2 Conivaptan BID|20 mg conivaptan two times a day
3297437|NCT00478192|Placebo Comparator|Regimen 3 Placebo|
3297438|NCT00478140|Experimental|Trastuzumab|Participants receive trastuzumab loading dose 8 mg/kg intravenous (IV) over 30-90 minutes on day 1 and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3297439|NCT00478114|Experimental|1|Sorafenib
3297440|NCT00478088|Experimental|1|NeoDisc
3297441|NCT00478088|Active Comparator|2|ACDF
3297442|NCT00478062|Experimental|Cell vaccine after initial therapy for Hodgkin lymphoma|Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.
3297443|NCT00478049|Active Comparator|1|Docetaxel
3297444|NCT00478049|Experimental|2|Gefitinib
3297445|NCT00478036|Active Comparator|Acular LS|Acular LS - 1 drop in treated eye, 4 times a day, for 4 days
3297446|NCT00478036|Active Comparator|Pred Forte|Pred Forte - 1 drop in treated eye, 4 times a day, for 4 days
3297447|NCT00478036|Placebo Comparator|Refresh Tears|Refresh Tears - 1 drop in treated eye, 4 times a day, for 4 days
3297448|NCT00478023|Active Comparator|Morphine|
3297449|NCT00478023|Experimental|Tapentadol 50 mg immediate release|
3297450|NCT00478023|Experimental|Tapentadol 75 mg immediate release|
3297451|NCT00478023|Experimental|Tapentadol 100 mg immediate release|
3297452|NCT00478023|Placebo Comparator|Matched placebo|
3297453|NCT00477997|Placebo Comparator|1|Saline bolus + OGTT
3297454|NCT00477997|Other|2|GH-bolus and OGTT
3297455|NCT00477997|Other|3|GH-bolus
3297456|NCT00477984|Experimental|A|alcohol and placebo
3297457|NCT00477971|Active Comparator|Arm A|"Patients receive low-dose melphalan IV over 15-30 minutes on day~1 or orally once daily on days 1-7 and oral dexamethasone on days 1-4 and 22-25. Treatment repeats every 6 weeks for 10 courses.~Study treatment beyond one year is not allowed."
3297458|NCT00477971|Experimental|Arm B|Patients receive filgrastim (G-CSF) on days -7 to -3 and undergo autologous hematopoietic stem cell (HSC) collection. Patients receive high-dose melphalan IV over 1 hour on days -2 and -1 and undergo autologous HSC transplantation on day 0.
3297459|NCT00477958|Experimental|Geriatric Assessment Tool|
3297460|NCT00477919||Weekly assessment by E-MOSAIC|Patients complete a weekly assessment comprising visual analogue scales (VAS) of pain, fatigue, drowsiness, nausea, anxiety, depression, shortness of breath, loss of appetite, and overall well-being; up to 3 optional symptoms selected by the patient; and an estimated nutritional intake using an electronic tool for monitoring symptoms and syndromes associated with advanced cancer (E-MOSAIC). Nurses record the patient's weight, KPS score, body mass index, and assessment of current medication for pain (i.e., morphine-equivalent daily dose), fatigue, and anorexia/cachexia syndromes weekly. A Longitudinal Monitoring Sheet (LoMoS) is printed (comprising VAS of pain, pain medication, fatigue, KPS, medication for fatigue [i.e., methylphenidate hydrochloride or epoetin alfa], anorexia, weight change, nutritional intake, medication, supplements, counseling for anorexia, VAS of individually selected symptoms) and stored.
3297461|NCT00477919||Palm-based monitoring tool|Patients complete a weekly symptom assessment and nutritional intake using a Palm-based monitoring tool. Nurses record weight and Karnofsky performance status (KPS) scores weekly. A proof of electronic transfer sheet is printed and stored.
3297462|NCT00477906|Experimental|1|"MVax + BCG + cyclophosphamide + IL2~2:1 randomization - MVax:Control"
3297463|NCT00477906|Placebo Comparator|2|Placebo Vaccine + BCG + cyclophosphamide + IL2
3297464|NCT00477893|Placebo Comparator|Placebo|
3297465|NCT00477893|Active Comparator|Adalimumab|
3297466|NCT00477880|Experimental|Cetuximab|Cetuximab lV weekly at an initial loading dose of 400 ml/m2, followed by three weekly maintenance doses of 250 mg/m2. Four infusions of C225 will be defined as a course of therapy.
3297467|NCT00477854|Experimental|Visual Analogue Scale Ratings|Food intake data and its coefficients, including total food intake, food not eaten, duration of the meal, and bite rate. A mixed model analysis of variance will also be conducted on ratings of food cravings and eating atttudes. Changes in hunger and satiety ratings between, before, and after the meals will be compared for difference across treatment conditions.
3297468|NCT00477854|Experimental|Consuming less Lunch allows consumption of more dinner|Test whether chromium picolinate supplementation affects food cravings, eating attitudes, and satiety in healthy, overweight and/or obese, adult women who are determinded to be carbohydrate cravers. Whether participants who eat less at a lunch test meal consume more food at an ad lib dinner test meal with a diversity of foods.
3297469|NCT00477815|Experimental|Rituximab + Zevalin|Determine the dose level that is both tolerable and achieves the greatest B cell recovery in patients with multiple myeloma.
3297470|NCT00477802|Experimental|Botox|Randomized into receiving Botox first. At cross-over, patients will receive placebo.
3297471|NCT00477802|Placebo Comparator|Placebo|Randomized to receive placebo first. At cross-over, patients will receive the active Botox.
3297472|NCT00477776|Active Comparator|a|Mother with diet-controlled diabetes receive Metoclopramide 10 mg 3 times a day for the first 7 days, and 2 times a day for day 8 to 10, and once a day from day 11 to day 12
3297473|NCT00477776|Placebo Comparator|b|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, and once a day for day 11 to 12
3297474|NCT00477776|Active Comparator|c|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, and once a day from day 11 to 12
3297475|NCT00477776|Placebo Comparator|d|Placebo 10 mg 3 times a day for 7 days, 2 times a day for day 8 to 10; and once a day from day 11 to 12
3297476|NCT00477763|Active Comparator|1|
3297477|NCT00477763|Placebo Comparator|2|
3297478|NCT00477750|Experimental|Treatment (Lenalidomide, Melphalan, Prednisone)|"Intervention: Drug: lenalidomide Dose determined by Phase I treatment schedule. Taken orally days 1-21 every 28 days until progression~Intervention: Drug: melphalan Dose determined by Phase I treatment schedule. Taken orally days 1-4 every 28 days until progression~Intervention: Drug: prednisone 60mg/m^2, orally days 1-4 every 28 days until progression"
3297479|NCT00477724|Placebo Comparator|sedentary control group|patients are treated by conventional rehabilitation
3297480|NCT00477724|Active Comparator|exercise and respiratory therapy|rehabilitation with exercise and respiratory therapy
3297481|NCT00477711|Experimental|C225+Chemotherapy|
3297482|NCT00477685||OculusGen Collagen Matrix|OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
3297483|NCT00477672|Experimental|2|Pimavanserin tartrate (ACP-103), 10 mg, tablet, once daily by mouth, 6 weeks
3297484|NCT00477672|Experimental|3|Pimavanserin tartrate (ACP-103), 40 mg, tablet, once daily by mouth, 6 weeks
3297485|NCT00477672|Placebo Comparator|1|Placebo tablet, once daily by mouth, 6 weeks
3297486|NCT00477659|Experimental|Donepezil|
3297487|NCT00477646|Experimental|Prevention Care Management|Telephone support over 18 months from trained Prevention Care Managers, to help women overcome barriers to colon, breast, and cervical cancer screening
3297488|NCT00477646|No Intervention|Usual Care|Usual Care. A sample of patients receive a single telephone call to validate claims data and collect basic demographic information.
3297489|NCT00477633|Experimental|Norethindrone/ethinyl estradiol|1 tablet per day
3297490|NCT00477607|Experimental|Arm 1|Receiving alpha-lipoic acid during cisplatin treatment.
3297491|NCT00477607|Placebo Comparator|Arm 2|Receiving placebo during cisplatin treatment
3297492|NCT00477594|Experimental|Mipomersen 200 mg per week|Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.
3297493|NCT00477594|Experimental|Mipomersen 200 mg every other week|Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator's discretion after the first 52 weeks of the treatment period.
3297494|NCT00477581|Experimental|Sequence A|
3297495|NCT00477581|Experimental|Sequence B|
3297496|NCT00477529|Experimental|ABI-008|
3297497|NCT00477516|Experimental|1|
3297498|NCT00477503|Active Comparator|Group A|Ga-67 citrate injection alone for individuals with cancer cells in cerebral spinal fluid (CSF), no earlier treatment for disease.
3297499|NCT00477503|Active Comparator|Group B|Ga-67 + In 111 DTPA injection for individuals who have cancer cells in CSF, no earlier treatment for disease.
3297500|NCT00477503|Active Comparator|Group C|Individuals with tumors in the CSF that have been treated and are now cleared from the CSF, receive standard follow-up care (baseline injection of Ga-67 citrate and In-111 DTPA).
3297501|NCT00477490|Placebo Comparator|Placebo|Participants took a placebo 'melt' for 28 days to complete part 1 of the study. In part 2, placebo patients were randomized to one of the other 4 treatment arms based on assignments predetermined at the initial randomization, to receive active desmopressin melt for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
3297502|NCT00477490|Experimental|desmopressin melt 10 μg|Participants took desmopressin melt 10 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
3297503|NCT00477490|Experimental|desmopressin melt 25 μg|Participants took desmopressin melt 25 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
3297504|NCT00477490|Experimental|desmopressin melt 50 μg|Participants took desmopressin melt 50 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
3297505|NCT00477490|Experimental|desmopressin melt 100 μg|Participants will take desmopressin melt 100 μg for 28 days to complete part 1 of the study. Participants will continue on this dose in part 2 of the study for between 1-6 months (until the database for part 1 is locked and treatment is unblinded).
3297506|NCT00477477|Experimental|1|Low glycemic load diet
3297507|NCT00477477|Active Comparator|2|Low fat diet
3297508|NCT00477464|Experimental|Lapatinib+capecitabine|Lapatinib 1250mg once daily +capecitabine 2000mg/m^2 twice daily (14 days out of 21 days)
3297509|NCT00477451|Placebo Comparator|RCT Placebo|Subjects received inhaled placebo after 0.5 mg/kg doxapram IV in the randomized controlled trial
3297510|NCT00477451|Experimental|RCT Alprazolam 1 mg|Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the randomized controlled trial
3297511|NCT00477451|Experimental|Open Label Inhaled Alprazolam 1 mg|Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the open label dose validation
3297512|NCT00477451|Experimental|Initial Inhaled Alprazolam 2 mg|Subjects received 2 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the initial open label dose assessment
3297513|NCT00477412|Experimental|Bortezomib + Cyclophosphamide/Rituximab|1st Combination, Cycles 1,3,5 & 7 (if needed): Bortezomib + Rituximab + Cyclophosphamide + Doxorubicin + Vincristine; 2nd Combination, Cycles 2,4,6 & 8 (if needed): Rituximab + Methotrexate + Cytarabine.
3297514|NCT00477386|Experimental|Carboplatin combined with Decitabine|Decitabine at escalating dose levels will be given X 5 days followed by Carboplatin given on Day 8.
3297515|NCT00477373|Experimental|1|If the daily dose does not exceed 1000 mg, Depakine CHRONO can be administered once a day. If the dose is greater than 1000 mg/day, Depakine CHRONO will be administered in a bid regimen: one tablet in the morning and one tablet in the evening.
3297516|NCT00477360|Experimental|1|C.A.P
3297517|NCT00477347|Active Comparator|1|Manual administration
3297518|NCT00477347|Experimental|2|Closed-loop administration
3297519|NCT00477334|Experimental|1|Famciclovir 1000 mg; twice a day for one day.
3297520|NCT00477334|Placebo Comparator|2|Placebo; twice a day for one day.
3297521|NCT00477321|Experimental|CYT107|CYT107 vs Placebo (4:1 ratio)
3297522|NCT00477295|Active Comparator|Zonisamide|
3297523|NCT00477295|Active Comparator|Carbamazepine|
3297526|NCT00477269|Experimental|STI571|STI571
3297527|NCT00477269|Placebo Comparator|Placebo|Placebo
3297528|NCT00477269|Experimental|All Patients|Open label extension
3297529|NCT00477256||Child|Children between 6 and 17 years diagnosed with, and treated for, any type of cancer.
3297530|NCT00477256||Parent|Parent(s) or caregiver(s) of children with cancer.
3297531|NCT00477256||Medical Staff|Medical staff (i.e., physicians, nurse practitioners) involved in the children's medical decision-making.
3297532|NCT00477243||Palliative Care Clinic Patients|Department of Symptom Control and Palliative Care Center Patients
3297533|NCT00477230|Experimental|1|Single ablation procedure with Endoscopic Ablation System
3297534|NCT00477230|Active Comparator|2|Medication
3297535|NCT00477217|Other|1|
3297536|NCT00477204|Active Comparator|Simvastatin|Zocor(simvastatin)(20 mg)daily for 6 months along with Placebo (sugar pill)of active comparator (Vytorin [simvastatin] + Zetia [ezetimibe].
3297537|NCT00477204|Active Comparator|Ezetimibe/Simvastatin|Vytorin(simvastatin [Zocor} + ezetimibe [Zetia])(20 mg)daily for 6 months along with placebo (sugar pill)of comparator (Vytorin [simvastatin]).
3297538|NCT00477191|Experimental|Etanercept|Etanercept
3297539|NCT00477178||chronic non-malignant pain codeine|patients having chronic non-malignant pain, living in Trondheim or the four adjacent counties and treated at the Center for Pain and Complex Disorders at St. Olav University Hospital - on long-term codeine therapy
3297540|NCT00477178||chronic non-malignant pain|patients having chronic non-malignant pain, living in Trondheim or the four adjacent counties and treated at the Center for Pain and Complex Disorders at St. Olav University Hospital - NOT on long-term codeine therapy
3297541|NCT00477178||healthy|healthy controls
3297542|NCT00477165|Experimental|Citalopram|One 20mg capsule per day for 4 weeks, then 2 capsules per day (40mg) for 4 weeks
3297543|NCT00477165|Placebo Comparator|Placebo|Identical to citalopram 20mg capsule. One capsule per day for 4 weeks, then 2 capsules per day for 4 weeks
3297544|NCT00477152|Experimental|HYLENEX-augmented subcutaneous (SC ) rehydration|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
3297545|NCT00477126|Active Comparator|1|start generic product cross over to reference product
3297546|NCT00477126|Active Comparator|2|start reference product cross over to generic product
3297547|NCT00477100||IBC Registry|Blood & Tissue Collection + Interview
3297548|NCT00477087|Experimental|GM-CSF Plus Mitoxantrone|GM-CSF at 250 micrograms/ m² / day subcutaneously 3 x week for 3 weeks. Participants will also receive mitoxantrone 14 mg/m² on Day 1 of each cycle. Each cycle of therapy consists 21 days.
3297549|NCT00477048|Other|1|Replace Indinavir with SQV in patients with indinavir toxicity
3297550|NCT00477035|Experimental|Autologous Cytokine-induced Killer Cells|
3297551|NCT00477009|Experimental|1|Adjustable mandibular repositioning appliance
3297552|NCT00477009|Placebo Comparator|2|Placebo device in upper jaw
3297553|NCT00476996|Experimental|1|
3297554|NCT00476996|Experimental|2|
3297555|NCT00476996|Placebo Comparator|3|
3297556|NCT00476983|Experimental|1|SQV/r 1500/100 mg OD + Truvada OD
3297557|NCT00476970|Experimental|Patient Navigation Intervention|Participants randomized to this arm will receive language-concordant patient navigation in the form of an introductory letter with educational material followed by phone or in-person contact to provide individually tailored interventions.
3297558|NCT00476970|No Intervention|Usual Care|Participants randomized to this arm will receive no additional navigation beyond the usual care for the duration of the 9-month intervention. Participants will be offered navigation services after the completion of the intervention period.
3297559|NCT00476957|Active Comparator|1|Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System
3297560|NCT00476957|Active Comparator|2|Cordis Cypher® Sirolimus-eluting Coronary Stent
3297561|NCT00476931|Experimental|1|SB-509
3297562|NCT00476931|Placebo Comparator|2|
3297563|NCT00476905||Spectral-Diagnosis|Method for noninvasive detection of cutaneous malignancies
3297564|NCT00476892|Other|1|"It consists of five outpatient appointments (weeks 0, 2, 6, 11 and 16) with a local trial physiotherapist at a trial centre. At the first appointment a standardised history is taken from the woman, anatomy and function of the pelvic floor muscles are taught, and types of prolapse described, using diagrams and a model pelvis. Women are taught how to contract the muscles, and also how to contract and hold prior to an event that increases intra-abdominal pressure (the Knack). Pelvic floor muscles are assessed by vaginal examination and recorded on a dedicated form at each appointment thus determining the content of a single set of exercises for each woman. At least three sets of exercises daily is recommended. Women use an exercise diary to record compliance. Tailored advice is given on ways of reducing intra-abdominal pressure, e.g. advice on weight loss, chronic cough, heavy lifting and general exercise."
3297565|NCT00476892|No Intervention|2|Women allocated to the control group will be sent a lifestyle advice leaflet only, and will have no planned contact with the centre until their consultant review appointment at six months. The leaflet gives instructions on seeking advice where appropriate about weight loss, constipation, and avoidance of heavy lifting, coughing and high impact exercise, with a view to minimising increases in intra-abdominal pressure which may cause prolapse to worsen.
3297566|NCT00476879|Experimental|1|12 hours of fasting and a GH bolus
3297567|NCT00476879|Experimental|2|36 hours of fasting and a GH bolus
3297568|NCT00476879|Experimental|3|36 hours of fasting and Pegvisomant
3297569|NCT00476879|Experimental|4|36 hours of fasting and NaCl injection
3297570|NCT00476853|Active Comparator|1|NVP 400 mg
3297571|NCT00476853|Active Comparator|2|NVP 600 mg
3297572|NCT00476827|Active Comparator|Bevacizumab / Capecitabine|Bevacizumab 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle.
3297573|NCT00476827|Active Comparator|Bevacizumab / Docetaxel|Docetaxel (taxotere) 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
3297864|NCT00473941|No Intervention|1|Writing in a journal 15 minutes a day
3297574|NCT00476827|Active Comparator|Bevacizumab /Irinotecan (Camptosar®, CPT-11)|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
3297575|NCT00476827|Active Comparator|Bevacizumab / Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
3297576|NCT00476827|Active Comparator|Bevacizumab /Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle.
3297577|NCT00476827|Active Comparator|Bevacizumab / Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.
3297578|NCT00476801|Experimental|UVA1 irradiation|The dose and scheduling will be similar to those being successfully used in Germany: up to 130J/cm2 from a UVA1 Sellamed irradiation device (German manufactured UVA1 light emitting device) with irradiations up to 5 times per week for up to 14 weeks on one side of the face. Then a cross-over treatment an equal length of time.
3297579|NCT00476801|No Intervention|Control|No treatment on the opposite side of the face as the UVA1 treatment for up to 14 weeks. Then a cross-over treatment an equal length of time.
3297580|NCT00476788|Experimental|Omnipod Device|Patients will be placed on an Omnipod insulin pump
3297581|NCT00476775|Experimental|After school ethnic dance and home-based screen time reduction|After school ethnic dance classes and home-based screen time reduction intervention
3297582|NCT00476775|Active Comparator|Health and Nutrition Education|Health and nutrition education active placebo control intervention
3297583|NCT00476723||1|HIV/Hepatitis coinfected patients who use at least one hepatitis activity drug or medications
3297584|NCT00476710||Normal Glucose Metabolism|Overweight and obese individuals that have normal glucose metabolism and their response to Colesevelam HCl
3297585|NCT00476710||Impaired Glucose Tolerance|Overweight and obese individuals that have impaired glucose tolerance and their response to Colesevelam HCl
3297586|NCT00476710||Frank type 2 diabetes|Overweight and obese individuals that have frank type 2 diabetes and their response to Colesevelam HCl
3297587|NCT00476697|Experimental|UVA1 Irradiation|UVA1 irradiaton up to 5 times per week, for up to 16 weeks using German manufactured UVA1 emitting light system. UVA1 dose will be applied with up to 130 J/cm2.
3297588|NCT00476684|Experimental|radiofrequency neurotomy|Radiofrequency-neurotomy of the medial branch at 80 degr. C for 70 seconds, after diagnostic blocks
3297589|NCT00476684|Sham Comparator|sham controls|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
3297590|NCT00476671||1|HIV infected adults with viral load < 50 copies/ml on NNRTI based HAART
3297591|NCT00476645|Experimental|Fulvestrant|
3297592|NCT00476632||Control|Person with no history of cancer.
3297593|NCT00476619|Placebo Comparator|Erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
3297594|NCT00476606||Long-term pediatric cohort|Long-term follow-up cohort since 2003
3297595|NCT00476593|Experimental|Diclofenac|Preservative- free Diclofenac Na 0.1 % eye drops were applied in one consecutively assigned eye of healthy volunteers four times a day for three days, after which macular thichness was measured in both subjects' eyes with the OCT .
3297596|NCT00476593|Experimental|Dexamethasone|Benzalkonium-reserved Dexamethasone Sodium Phosphate 0.1% was applied in one consecutively assigned eye of healthy volunteers six times a day for three days, after which macular thickness was assessed in both subjects's eyes with the OCT.
3297597|NCT00476580||Sri Lankan Sinhalese|Sri Lankan Sinhalese adults (18 years of age or older) living in the greater Houston area, but born in Sri Lanka.
3297598|NCT00476580||Siblings or Cousins in Sri Lanka|Siblings or the first cousins of the study participants living in Sri Lanka of same sex and of an age plus or minus 10 years.
3297599|NCT00476567|Experimental|exercise|Regular exercise 45-60 minutes minimum three times per week
3297600|NCT00476567|Active Comparator|control|standard antenatal care
3297601|NCT00476554|Experimental|A|low dose
3297602|NCT00476554|Experimental|B|High dose
3297603|NCT00476541|Experimental|1|Gemtuzumab 5 mg / m2 two courses with three week interval
3297604|NCT00476541|No Intervention|2|No further therapy
3297605|NCT00476515|Experimental|Rituximab|this study has only one arm as treatment group.
3297606|NCT00476502||1|patients involved in structured interruption therapy
3297607|NCT00476476|Experimental|Erlotinib|Patients rcvd oral erlotinib 150 mg/day. Cohort 1 pts would have at least 28 days and no more than 42 days of therapy in advance of definitive therapy (surgery or chemoradiation). Cohort 2 pts continued on therapy (28 days per cycle) until disease progression, unacceptable toxicity or withdrawal of consent. Two potential dose reductions were prescribed to 100 and 50 mg/day.
3297608|NCT00476463|Active Comparator|1|AZT+FTC+EFV
3297609|NCT00476463|Active Comparator|2|TDF+FTC+EFV
3297610|NCT00476424|Active Comparator|1|400 mg EFV
3297611|NCT00476424|Active Comparator|2|600 mg EFV
3297612|NCT00476411|Experimental|1|HBV vaccine
3297613|NCT00476398|No Intervention|Diagnostic capsule endoscopy|Patient with non-cardiac chest pain will undergo capsule endoscopy
3297614|NCT00476385|Experimental|somatropine|
3297615|NCT00476372||Parkinson's disease|Pt with parkinsons disease
3297616|NCT00476359|Other|double-boosted PI|double-boosted protease inhibitor combination
3297617|NCT00476346|Active Comparator|Calcium|Daily calcium supplementation Intervention: Calcium 2000mg / daily
3297618|NCT00476346|Experimental|Vitamin D|Daily Calcium and Vitamin D supplementation Intervention: Vitamin D 800IU / daily
3297619|NCT00476294||Group 1: G + Placebo|G-CSF plus Placebo Arm (G + Placebo)
3297620|NCT00476294||Group 2: G + AMD3100|G-CSF plus AMD3100 Arm (G + AMD3100)
3297621|NCT00476281|Other|abnormal glucose tolerance|abnormal glucose tolerance
3297622|NCT00476268|Experimental|beclometasone /formoterol|beclomethasone dipropionate 100 µg plus formoterol 6 µg pMDI
3297865|NCT00473941|No Intervention|2|Control Writing in a journal 15 minutes a day
3297623|NCT00476268|Active Comparator|Beclomethasone|Beclomethasone dipropionate (BecotideTM) 250 µg/unit dose pMDI aerosol via CFC propellant.
3297624|NCT00476268|Active Comparator|Formoterol powder 12 µg/unit dose|Formoterol powder 12 µg/unit dose (Foradil™)
3297625|NCT00476255|Active Comparator|Enhanced Standard Care|Instructional materials
3297626|NCT00476255|Experimental|Motivational Intervention|Motivational interview
3297627|NCT00476242|Experimental|Memantine and Vivitrol|intramuscular injection of Vivitrol 380 mg and 20 mg bid Memantine (PO)
3297628|NCT00476242|Placebo Comparator|Placebo and Vivitrol|intramuscular injection of Vivitrol 380 mg and Placebo
3297629|NCT00476229|Experimental|Radiation + Chemotherapy + BSCT|Total Lymphoid Irradiation (2 times) at 80 cGy daily for five days + Thymoglobulin 1.5 mg/kg intravenous 5 days + Rituximab 375 mg/m^2 intravenous on 4 different days + Blood stem cell transplant (BSCT)
3297630|NCT00476216|Experimental|Combination of Arixtra with chemotherapy|Carboplatin 6 AUC q 21 days; Paclitaxel 200 mg/m2 q 21 days. Cohort I: Arixtra 2.5 mg SQ qd x 21 days; Cohort II: Arixtra weight-based dose (D1-2)followed by Arixtra 2.5 SQ q day (D3-21)
3297631|NCT00476203|Experimental|1|Immediate yoga classes offered
3297632|NCT00476203|Other|2|Delayed yoga classes (after 6 months) offered [wait list control group]
3297633|NCT00476190|Experimental|Arm A|Complete remission achieved after Induction Phase
3297634|NCT00476190|Experimental|Arm B|Failure to achieve complete remission after the Induction Phase
3297635|NCT00476164|Experimental|Rituximab|Infusion of 2 x 1g of rituximab, 14 days apart
3297636|NCT00476164|Sham Comparator|2|
3297637|NCT00476151|Placebo Comparator|placebo cream|vehicle cream
3297638|NCT00476151|Active Comparator|amitriptyline 4% ketamine 2% cream|active topical cream
3297639|NCT00476125|Experimental|3 day ketogenic diet|
3297640|NCT00476125|Experimental|12 day ketogenic diet|
3297641|NCT00476125|Experimental|16 hour fast|
3297642|NCT00476112|Experimental|1|Atrial flutter duration of 3 hours to <45 days
3297643|NCT00476099|Experimental|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|
3297644|NCT00476099|Active Comparator|Budesonide 200 µg plus formoterol 6 µg DPI|
3297645|NCT00476099|Active Comparator|Formoterol 12 µg DPI|
3297646|NCT00476086|Experimental|Oxaliplatin/ Gemcitabine Then Radiation|Patients rcvd IV chemotherapy on days 1 and 15 of a 4-week cycle: gemcitabine 1000 mg/m2 and oxaliplatin 65 mg/m2 for up to 3 cycles. Two dose reductions per study drug were permitted. On study, chemotherapy was followed by radiation therapy (RT) within 4-6 weeks of last chemotherapy. RT regimen was tumor-volume directed.
3297647|NCT00476060|Experimental|A|
3297648|NCT00476060|Placebo Comparator|B|
3297649|NCT00476047|Experimental|Treatment (monoclonal antibody therapy)|Patients receive tositumomab and iodine I 131 tositumomab IV over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.
3297650|NCT00476021|Experimental|Postplacental IUD insertion|immediate postplacental levonorgestrel-releasing IUD (Mirena) insertion
3297651|NCT00476021|Active Comparator|Delayed IUD insertion|delayed levonorgestrel-releasing IUD (Mirena) insertion (6-8 weeks after delivery)
3297652|NCT00476008|Placebo Comparator|Placebo|One tablet placebo morning and evening (BID) for 12 months
3297653|NCT00476008|Active Comparator|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months.
3297654|NCT00475982|Experimental|Arm 1: Weight Loss|Weight Loss Group
3297655|NCT00475982|Active Comparator|Arm 2: No Weight Loss|No Weight Loss Group
3297656|NCT00475956|Experimental|1|AZD2171 Monotherapy
3297657|NCT00475956|Experimental|2|AZD2171 + AZD0530
3297658|NCT00475930|Experimental|1|2% chlorhexidine gluconate impregnated cloths, self applied three times weekly
3297659|NCT00475930|Placebo Comparator|2|Comfort Bath cloths, self applied three times weekly
3297660|NCT00475917|Experimental|1|
3297661|NCT00475904|Active Comparator|amitriptyline 4% ketamine 2% cream, placebo capsules|Np-1 cream and placebo gabapentin
3297662|NCT00475904|Active Comparator|gabapentin capsules, placebo cream|gabapentin caps and placebo cream
3297663|NCT00475904|Placebo Comparator|placebo cream and capsules|placebo cream and capsules
3297664|NCT00475878|Placebo Comparator|placebo|
3297665|NCT00475878|Active Comparator|escitalopram|
3297666|NCT00475865|Placebo Comparator|Placebo + GA|Placebo (for teriflunomide) once daily concomitantly with glatiramer acetate (GA) for 24 weeks
3297667|NCT00475865|Experimental|Teriflunomide 7 mg + GA|Teriflunomide 7 mg once daily concomitantly with glatiramer acetate (GA) for 24 weeks
3297668|NCT00475865|Experimental|Teriflunomide 14 mg + GA|Teriflunomide 14 mg once daily concomitantly with glatiramer acetate (GA) for 24 weeks
3297669|NCT00475852|Experimental|001|Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
3297670|NCT00475852|Placebo Comparator|002|Placebo matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
3297671|NCT00475839|Active Comparator|Tension-free Vaginal Tape|
3297672|NCT00475839|Active Comparator|Monarc Sub-fascial hammock|
3297673|NCT00475787|Experimental|Spinal Manipulative therapy|Spinal manipulation involves high velocity low amplitude manipulation and flexion distraction and mobilization.
3297674|NCT00475787|Sham Comparator|Detuned Ultrasound|"Detuned Ultrasound involves utilizing an ultrasound machine that is set to 0 w/cm2 and US gel is applied to the spine for 11 minutes."
3297675|NCT00475735|Experimental|MK-0249|Total time in the study will be ~10 weeks.
3297676|NCT00475735|Active Comparator|Concerta|Total time in the study will be ~10 weeks.
3297677|NCT00475735|Placebo Comparator|Placebo|Total time in the study will be ~10 weeks.
3297678|NCT00475722|Active Comparator|1 Healthy Eating|Healthy People 2010 Diet using an exchange list
3297679|NCT00475722|Experimental|2 Mediterranean|Mediterranean Diet using an exchange list
3297680|NCT00475709|Experimental|Trifecta Aortic Heart Valve|All subjects enrolled into the study are implanted with the Trifecta Aortic Heart Valve.
3297681|NCT00475683|Sham Comparator|regular measurments|Mouth wash with chlorexidin
3297682|NCT00475683|Experimental|Curucmol|mouth wash with curcumol and mouth wash with chlorexidin
3297683|NCT00475670|Active Comparator|Trastuzumab Monotherapy|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose on Day 1, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death.
3297684|NCT00475670|Experimental|Trastuzumab, Taxane|Participant received an initial loading dose of 4 mg/kg trastuzumab i.v. on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death; and concomitant taxane, which is either 100 milligrams per square meter (mg/m2) docetaxel i.v. every 3 weeks, or 75 mg/m2 weekly or 175 mg/m2 every 3 weeks paclitaxel for at least 18 weeks, or more at the discretion of the investigator.
3297685|NCT00475657|Experimental|A|
3297686|NCT00475644|Experimental|Enzastaurin|enzastaurin: 1125 mg loading dose then 500 mg, oral daily, up to 3 years
3297687|NCT00475618|Experimental|Fluoride Varnish|Professional cleaning + education + fluoride vanish
3297688|NCT00475618|Active Comparator|Fluoride Toothpaste 500 ppm|Professional cleaning + education + fluoride toothpaste 500 ppm
3297689|NCT00475618|Active Comparator|No fluoride toothpaste|Professional cleaning + education + no fluoride toothpaste
3297690|NCT00475605||1. Protopic Exposure|Pediatric subjects whose ages are/were <16 years at the time of first tacrolimus ointment exposure
3297691|NCT00475592|Experimental|Capsule Endoscopy|
3297692|NCT00475592|Active Comparator|Upper Gastrointestinal Endoscopy|
3297693|NCT00475566|Other|1|This is a prospective, non-randomized, single-arm, multi-center study. A projected 100 patients will receive the stent(s) in this study at approximately 10-15 European sites. The primary objective is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral or proximal popliteal lesions.
3297694|NCT00475553|Other|Group 2|Subject will use the nuvaring and if they developed breakthrough bleeding or spotting for more than 5 days on the 6th day the ring would be removed and would leave it out for 3 full days and reinsert the same ring the next day. All subjects would be filling out a daily diary or calendar which would rate their blood flow, pelvic pain, headaches, moods, how many pain pills were taken and how many pads, liners or tampons would be used.
3297695|NCT00475553|Other|Group 1|Subject is using the nuvaring continuously and it would be changed out monthly. If she develops breakthrough bleeding or spotting she does not remove the ring until it is her time to change it. All subjects would be filling out a daily diary or calendar which would rate their blood flow, pelvic pain, headaches, moods, how many pain pills were taken and how many pads, liners or tampons would be used.
3297696|NCT00475540|Active Comparator|Prolift mesh|vaginal prolapse repair with mesh
3297697|NCT00475540|Active Comparator|Prolapse repair without mesh|vaginal prolapse repair without mesh
3297698|NCT00475527|No Intervention|iron only|Only iron therapy
3297699|NCT00475527|Experimental|iron + HP therapy|Iron + 'omeprazole,clarithromycin,amoxicillin (or metronidazole)
3297700|NCT00475501|Experimental|Arm 1|testosterone enanthate
3297701|NCT00475501|Experimental|Arm 2|finasteride
3297702|NCT00475501|Experimental|Arm 3|testosterone enanthate + finasteride
3297703|NCT00475501|Placebo Comparator|Arm 4|placebo
3297704|NCT00475488|Other|Group 1|Radial Artery versus Right Internal Thoracic Artery when used as a coronary conduit in patients undergoing multi-vessel coronary artery bypass grafting.
3297705|NCT00475488|Other|Group 2|Radial Artery versus Saphenous Vein when used as a coronary conduit in patients undergoing multi-vessel coronary artery bypass grafting.
3297706|NCT00475475|Experimental|1|Fructose-sweetened beverage Subjects will be asked to drink 4 servings of a beverage sweetened with 100% fructose per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
3297707|NCT00475475|Experimental|2|Glucose-sweetened beverage Subjects will be asked to drink 4 servings of a beverage sweetened with 100% glucose per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
3297708|NCT00475475|Placebo Comparator|3|Beverage sweetened with a non-caloric sweetener Subjects will be asked to drink 4 servings of a beverage sweetened with a non-caloric sweetener per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
3297709|NCT00475436|Experimental|Arm 1|
3297710|NCT00475423|Experimental|1|
3297711|NCT00475410|Experimental|ASCs|
3297712|NCT00475410|Experimental|ASCs+fibrin glue|
3297713|NCT00475410|Active Comparator|Fibrin glue|
3297714|NCT00475384|Experimental|Radiation+Chemotherapy+ Stem Cell Infusion|TBI (Total Body Irradiation) + Fludarabine + Thiotepa + SCT + Anergized cell infusion
3297715|NCT00475384|Experimental|Chemotherapy+Stem Cell Infusion|Melphalan + Thiotepa + Fludarabine + SCT + Anergized cell infusion
3297716|NCT00475371|Experimental|1|MKC253 Inhalation Powder
3297717|NCT00475319|Placebo Comparator|Placebo|0% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
3297718|NCT00475319|Experimental|1% OPC-12759 ophthalmic suspension|1% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
3297719|NCT00475319|Experimental|2% OPC-12759 ophthalmic suspension|2% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
3297720|NCT00475306|Active Comparator|Metoclopramide 20+diphenhydramine|Metoclopramide 20 mg + diphenhydramine, delivered intravenously over 15 minutes
3297721|NCT00475306|Active Comparator|Metoclopramide 20+placebo|Metoclopramide 20 mg + placebo, delivered intravenously over 15 minutes
3297722|NCT00475306|Active Comparator|Metoclopramide 10 + placebo|Metoclopramide 10mg + placebo, delivered intravenously over 15 minutes
3297723|NCT00475306|Active Comparator|Metoclopramide 10+diphenhydramine|Metoclopramide 10 mg + diphenhydramine 25 mg, delivered intravenously over 15 minutes
3297724|NCT00475293|Experimental|1|
3297725|NCT00475280|Other|Geriatric assessment|
3297726|NCT00475241|Experimental|Prolonged Exposure Therapy|Prolonged exposure therapy for PTSD
3297727|NCT00475241|Active Comparator|Present Centered Therapy|Present centered therapy for PTSD
3297728|NCT00475228|Experimental|Arm I|Levonorgestrel IUD will be inserted immediately after completion of D&E
3297729|NCT00475228|Active Comparator|Arm 2|Levonorgestrel IUD will be inserted at standard time post-procedure (3-6 weeks post D&E procedure)
3297730|NCT00475215|Experimental|1|Sugammadex 2.0 mg/kg
3297731|NCT00475215|Experimental|2|Sugammadex 4.0 mg/kg
3297732|NCT00475189|Active Comparator|1|
3297733|NCT00475189|Active Comparator|II|loestrin 1/20 given 1 tab 21/7
3297734|NCT00475176|Experimental|S-Adenosyl Methionine|
3297735|NCT00475150|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral cediranib maleate QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
3297736|NCT00475137|Experimental|Lamotrigine Plus Antidepressant|Subjects will be randomized to one of two study arms at baseline. Those in the first treatment arm will be prescribed lamotrigine in addition to the antidepressant medication they were prescribed prior to study entry.
3297737|NCT00475137|Active Comparator|2. Lamotrigine Monotherapy|Subjects in the second treatment arm will discontinue their antidepressants and will be prescribed lamotrigine monotherapy. Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily.
3297738|NCT00475124|Experimental|1|Home Monitoring ON
3297739|NCT00475124|Active Comparator|2|Home Monitoring OFF
3297740|NCT00475111|Experimental|1|People in Group 1 will participate in CBT for Pain (CBT-P), which will focus on altering thought processes as a way to cope more effectively with pain.
3297741|NCT00475111|Experimental|2|People in Group 2 will participate in Mindfulness Medication for Emotion Regulation (MM-ER), a type of CBT that focuses on being more aware of one's emotions and regulating them.
3297742|NCT00475111|Experimental|3|Group 3 participants will serve as controls and receive educational information on the causes of, course of, and treatment for RA.
3297743|NCT00475098|Active Comparator|A|
3297744|NCT00475098|Experimental|B|
3297745|NCT00475085|Active Comparator|Arm I|Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
3297746|NCT00475085|Experimental|Arm II|Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
3297747|NCT00475085|Active Comparator|Arm III|Patients receive palonosetron hydrochloride IV and dexamethasone IV once on day 1, oral aprepitant once daily on days 1-3, and oral dexamethasone once daily and oral placebo twice daily on days 2 and 3.
3297748|NCT00475085|Experimental|Arm IV|Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and oral dexamethasone once daily on days 2 and 3.
3297749|NCT00475072|Experimental|1|
3297750|NCT00475059|Experimental|1|patients who received cimétidine
3297751|NCT00475033|Experimental|1|
3297752|NCT00475033|Active Comparator|2|
3297753|NCT00475020|Experimental|Fludarabine + Busulfan + Thymoglobulin|Fludarabine 40 mg/m^2 by vein daily over 1 hour x 4 days. Busulfan test dose = 32 mg/m^2 by vein x 1 day; 100 mg/m^2 by vein daily over 3 hours x 4 days. Thymoglobulin 2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor.
3297754|NCT00475007|Experimental|1|The experimental group will have an investigational medical device implanted in their lungs with an instrument known as a bronchoscope. This procedure is done without an incision
3297755|NCT00475007|Sham Comparator|2|The sham comparator group will be tested, treated and followed in an identical manner as the experimental group, except that no valves will be placed during the diagnostic bronchoscopy, the sham procedure.
3297756|NCT00474994|Experimental|Group A|Vascular connective tissue neoplasms, leiomyosarcoma, dermatofibrosarcoma protuberans (DFSP), desmoid tumors. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
3297757|NCT00474994|Experimental|Group B|High grade undifferentiated pleomorphic sarcoma (includes the older designation malignant fibrous histiocytoma [MFH]) and other non-GIST connective tissue tumors; may include carcinosarcomas.Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
3297758|NCT00474994|Experimental|Group C|Chordomas. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
3297759|NCT00474981|Experimental|1|IMNCI
3297760|NCT00474981|No Intervention|2|Control
3297761|NCT00474968||Arm 1 - Experimental|e2 Cell Collector [SoftPAP(R)]
3297762|NCT00474968||Arm 2 - Control|Brush/spatula
3297763|NCT00474955|Experimental|Peginterferon Alpha-2a|Eligible participants will be administered peginterferon alpha-2a [Pegasys] (40 kilo Dalton), 180 micrograms as a subcutaneous injection, once in a week, for 48 weeks. Participants with a calculated glomerular filtration rate of <15 milliliter /minute will be administered a reduced dose of 135 mcg as a subcutaneous injection, once in a week, for 48 weeks.
3297764|NCT00474929|Experimental|Multiple Myeloma|Phase I: Dose level 0: Sorafenib 200 mg twice daily, RAD001 5mg every other day; Dose level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day; Dose level 2: Sorafenib 400 mg twice daily, RAD001 5mg every day; Dose level 3: Sorafenib 400 mg twice daily, RAD001 10mg every day; Phase II: Sorafenib 200 mg twice daily, RAD001 5mg every day;
3297765|NCT00474929|Experimental|Lymphoma|Phase I: Dose level 0: Sorafenib 200 mg twice daily, RAD001 5mg every other day; Dose level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day; Dose level 2: Sorafenib 400 mg twice daily, RAD001 5mg every day; Dose level 3: Sorafenib 400 mg twice daily, RAD001 10mg every day; Phase II: Sorafenib 200 mg twice daily, RAD001 5mg every day;
3297766|NCT00474916|Experimental|KRN5500|KRN5500 escalating dose of .6, 1.2, 1.8, or 2.2 mg/m2 in IV infusion of normal saline
3297767|NCT00474916|Placebo Comparator|Normal Saline|Placebo consists of IV infusion of normal saline
3297768|NCT00474903|Active Comparator|Arm I (placebo, esomeprazole magnesium)|Patients receive two oral placebos once daily and oral esomeprazole magnesium (40 mg, twice daily).
3298007|NCT00472381|Experimental|2|Insulin
3297769|NCT00474903|Experimental|Arm II (low-dose aspirin, esomeprazole magnesium)|Patients receive both an oral placebo and acetylsalicylic acid (81 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
3297770|NCT00474903|Experimental|Arm III (higher-dose aspirin, esomeprazole magnesium)|Patients receive both an oral placebo and acetylsalicylic acid (325 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
3297771|NCT00474851|Experimental|Norethindrone acetate + estrogens|Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + conjugated equine estrogens 0.625 mg by mouth daily for the 12 months of study participation.
3297772|NCT00474851|Placebo Comparator|norethindrone acetate + placebo|Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + a placebo capsule by mouth daily for the 12 months of study participation.
3297773|NCT00474838|Active Comparator|Oral AntiDiabetic Drug|glimepiride and metformin and/or once daily glargine
3297774|NCT00474838|Experimental|intensive insulin group|insulin glargine insulin glulisine
3297775|NCT00474825|Active Comparator|1|Hyperbaric Oxygen twice weekly (Monday & Friday) with Radiation and Chemotherapy
3297776|NCT00474825|Active Comparator|2|Hyperbaric Oxygen three times per week (Monday, Wednesday & Friday) with Radiation and Chemotherapy.
3297777|NCT00474825|Active Comparator|3|Hyperbaric Oxygen Five times per week (Monday through Friday) with Radiation and Chemotherapy
3297778|NCT00474812|Experimental|Dasatinib Treatment|Patients receive oral dasatinib twice daily on days 1-28.
3297779|NCT00474799|Experimental|A|MNS075 7.5mg q1h
3297780|NCT00474799|Experimental|B|MNS075 15mg q3h
3297781|NCT00474786|Experimental|1|
3297782|NCT00474786|Experimental|2|
3297783|NCT00474760|Experimental|1|
3297784|NCT00474747|Experimental|Fludarabine + Antithymocyte Globulin + Cyclophosphamide|Fludarabine 30 mg/m^2 IV over no less than 30 minutes daily x 4 days. Antithymocyte Globulin 3 mg/kg IV over no less than four (and preferably six) hours daily x 3 days. Cyclophosphamide starting maximum dose 50 mg/kg IV x 3 days (de-escalating doses follow). Total Body Irradiation (TBI) 200 cGy from a linear accelerator at 20 cGy/min on Day -1 (single dose). Infusion of matched unrelated donor marrow on Day 0.
3297785|NCT00474708|Experimental|1|1.Effexor XR Group
3297786|NCT00474708|Active Comparator|2|2.SSRI or Conventional Antidepressant Group
3297787|NCT00474695||1|Active approved treatment
3297788|NCT00474669|Experimental|Docetaxel|Intraperitoneal Docetaxel administered with heat
3297789|NCT00474630|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/ day with ancillary therapy
3297790|NCT00474630|Placebo Comparator|Placebo|Placebo with ancillary therapy
3297791|NCT00474617|Experimental|1|Org 25969 (sugammadex)
3297792|NCT00474604|Active Comparator|Participants without breast cancer|
3297793|NCT00474604|Experimental|Participants with breast cancer|
3297794|NCT00474552|Experimental|1|Experimental-Placebo Comparator
3297795|NCT00474539|Experimental|1|
3297796|NCT00474539|Active Comparator|2|
3297797|NCT00474526|Experimental|US1A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3297798|NCT00474526|Experimental|US1B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 13 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3297799|NCT00474526|Experimental|US2 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3297800|NCT00474526|Experimental|US3 (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3297801|NCT00474526|Experimental|US4A (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3297802|NCT00474526|Experimental|US4B (Infant Vaccines Only)|"Received vaccines:~MenACWY: 13 and 15 months DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3297803|NCT00474526|Experimental|US4C (Infant Vaccines Only)|"Received vaccines:~MenACWY: 18 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3297804|NCT00474526|Experimental|LA1A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months Pneumococcal, HAV, and MMR-V: 12 months"
3297805|NCT00474526|Experimental|LA1B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 6, and 13 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3297806|NCT00474526|Experimental|LA2 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3297807|NCT00474526|Experimental|LA3A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 16 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 16 months~Pneumococcal, HAV, and MMR-V: 12 months"
3297808|NCT00474526|Experimental|LA3B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 17 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 16 months~Pneumococcal, HAV, and MMR-V: 12 months"
3297809|NCT00474526|Experimental|LA4 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 15 months~Pneumococcal, HAV, and MMR-V: 12 months"
3297810|NCT00474526|Experimental|LA5 (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3297811|NCT00474526|Experimental|LA6A (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12, and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3297812|NCT00474526|Experimental|LA6B (Infant Vaccines Only)|"Received vaccines:~MenACWY: 13 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3297813|NCT00474526|Experimental|LA6C (Infant Vaccines Only)|"Received vaccines:~MenACWY: 18 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3297814|NCT00474487|Experimental|Novartis MenACWY Vaccine (19 to 55 Years)|Novartis meningococcal ACWY conjugate vaccine administered to subjects 19 years to 55 years
3297815|NCT00474487|Active Comparator|Licensed polysaccharide vaccine|Licensed meningococcal ACWY polysaccharide vaccine
3297816|NCT00474487|Active Comparator|Licensed Conjugate Vaccine|Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
3297817|NCT00474487|Experimental|Novartis MenACWY Vaccine (56 to 65 Years)|Novartis meningococcal ACWY conjugate vaccine administered to subjects 56 years to 65 years
3297818|NCT00474461|Experimental|Treatment group|Patients in this arm received intracoronary expanded autologous c-kit positive cardiac stem cells.
3297819|NCT00474461|No Intervention|Control group|Patients in this arm did not receive any intervention.
3297820|NCT00474383|Experimental|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) tablet or capsule will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study, along with prednisone/prednisolone 5 mg tablet orally twice daily or dexamethasone 0.5 mg tablet orally once daily.
3297821|NCT00474370|Experimental|Test Arm|Vicriviroc 30 mg QD
3297822|NCT00474370|Placebo Comparator|Placebo Control Arm|Placebo
3297823|NCT00474357|Experimental|1|Bipolar patients participating in psychoeducation intervention
3297824|NCT00474357|No Intervention|2|bipolar patients who do not participate in psychoeducation group
3297825|NCT00474357|No Intervention|3|Therapists will complete questionnaires regarding myths about bipolar patients, no intervention
3297826|NCT00474318||Adolescents with severe obesity|Adolescents and young adults with severe obesity
3297827|NCT00474266|Experimental|Group A|Meningococcal vaccine GSK134612 + Priorix-Tetra™, followed by the second dose of Priorix-Tetra™ 84 days later
3297828|NCT00474266|Experimental|Group B|Meningococcal vaccine GSK134612, followed by 2 doses of Priorix-Tetra™, respectively 42 and 84 days later
3297829|NCT00474266|Active Comparator|Group C|Priorix-Tetra™, followed by Meningitec™ 42 days later and the second dose of Priorix-Tetra™ 84 days later
3297830|NCT00474266|Active Comparator|Group D|Meningitec™, followed by 2 doses of Priorix-Tetra™, respectively 42 and 84 days later
3297831|NCT00474253|Experimental|1|rocuronium plus Org 25969
3297832|NCT00474253|Active Comparator|2|succinylcholine
3297833|NCT00474240|Placebo Comparator|1|
3297834|NCT00474240|Active Comparator|2|
3297835|NCT00474240|Experimental|3|
3297836|NCT00474240|Experimental|4|
3297837|NCT00474240|Experimental|5|
3297838|NCT00474240|Experimental|6|
3297839|NCT00474227|Experimental|A|behavioral intervention, group therapy including nutritional guidance and physical exercise
3297840|NCT00474227|No Intervention|B|comparison group, one time explanation of importance of proper nutrition. This group receives no group therapy or organized exercise sessions or nutritional guidance. They are wait listed for this program.
3297841|NCT00474201|Sham Comparator|Gemfibrozil PK without LPV/r|"Subjects received a single 600 mg dose of gemfibrozil without concurrent lopinavir-ritonavir 400mg/100mg; this is the control arm of a crossover study design."
3297842|NCT00474201|Experimental|Gemfibrozil PK after 2 weeks of LPV/r|Single dose (600 mg) Gemfibrozil pharmacokinetics (i.e. plasma concentrations collected over time to calculate area under the concentration vs. time curve) assessed after 14.5 days of lopinavir/ritonavir (400/100 mg twice daily) administration.
3297843|NCT00474188|Experimental|Single Arm|
3297844|NCT00474175|Placebo Comparator|1|Placebo control
3297845|NCT00474175|Active Comparator|2|10% benzocaine gel formulation
3297846|NCT00474175|Active Comparator|3|20% benzocaine gel formulation
3297847|NCT00474136|Experimental|1|
3297848|NCT00474136|Experimental|2|
3297849|NCT00474136|Active Comparator|3|
3297850|NCT00474123|Active Comparator|Simvastatin 80 mg|Patients were treated with simvastatin 80 mg for 6 weeks
3297851|NCT00474123|Active Comparator|Ezetimibe 10 mg / Simvastatin 20 mg|Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks
3297852|NCT00474110|Experimental|1|Ketamine and hydromorphone for patient-controlled relief in children's mucositis.
3297853|NCT00474058|Experimental|Rotigotine|Rotigotine transdermal patch
3297854|NCT00474058|Placebo Comparator|Placebo|Placebo transdermal patch
3297855|NCT00474045|Experimental|Insulin detemir|Individually adjusted insulin detemir injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn
3297856|NCT00474045|Active Comparator|Neutral Protamine Hagedorn (NPH) insulin|Individually adjusted NPH insulin injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn
3297857|NCT00474019|Experimental|1|Based on age and/or weight dose of esomeprazole IV qd in milligrams 20,40,10,20,10, 1.0 mg/kg, 0,5 mg/kg
3297858|NCT00474006|Active Comparator|arm I|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 45 mg/m2/d civ x 3 days
3297859|NCT00473980|Experimental|Drug|Treatment with indomethacin or celecoxib
3297860|NCT00473980|Sham Comparator|SHAM|Sham treatment
3297861|NCT00473967|Experimental|10 mcg Na-ASP-2/Alhydrogel|Na-ASP-2 Hookworm Vaccine
3297862|NCT00473967|Active Comparator|Butang hepatitis B vaccine|Hepatitis B Vaccine - comparator vaccine
3297866|NCT00473889|Experimental|1|vorinostat; IV paclitaxel; IV carboplatin
3297867|NCT00473889|Placebo Comparator|2|Placebo; IV paclitaxel; IV carboplatin
3297868|NCT00473876|Active Comparator|1|Receiving Metformin for 4 months
3297869|NCT00473876|Placebo Comparator|2|Matched Placebo for 4 months
3297870|NCT00473863|Experimental|intervention|Receives CCTA
3297871|NCT00473863|No Intervention|Control|
3297872|NCT00473837|Active Comparator|Treatment|Subjects initially treated with Co-arthemeter, and then continued on weekly chloroquine till day 90
3297873|NCT00473837|Placebo Comparator|Control|Subjects initially treated with Co-arthemeter, and then continued on weekly placebo till day 90
3297874|NCT00473824|Experimental|Civacir Treated|Hepatitis C Immune Globulin Intravenous (Human) 5% [Civacir], 18 infusions total, per schedule, of Civacir 300 or 400 mg/kg of body weight, with standard post-transplant site specific routine immunosuppressant therapy .
3297875|NCT00473824|No Intervention|Observational Control|Observation on standard post-transplant site specific routine immunosuppressant therapy without infusions of Hepatitis C Immune Globulin Intravenous (Human) 5% [Civacir].
3297876|NCT00473811|Active Comparator|ADA diet|Patients will be encouarged to consume foods consisted with ADA dietary recommendation
3297877|NCT00473811|Experimental|Low-GI|a low GI dietary education
3297878|NCT00473798||A|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
3297879|NCT00473798||A'|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
3297880|NCT00473798||B|Patients who have consented to participate in a randomized trial of optical spectroscopy.
3297881|NCT00473798||C|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
3297882|NCT00473798||D|Health care providers.
3297883|NCT00473772|Active Comparator|Cypher Stent|
3297884|NCT00473772|Experimental|DEBlue Stent|
3297885|NCT00473746|Experimental|Phase I Dose Escalation|
3297886|NCT00473746|Experimental|Phase II Dose Treatment|
3297887|NCT00473720|Experimental|satraplatin abraxane|Satraplatin and abraxane will be given in escalating cohorts on a 3 + 3 design from satraplatin 40mg/m2 and abraxane 80mg/m2
3297888|NCT00473707|Active Comparator|1|Active management of the third stage of labor- oxytocin infusion after delivery of fetus, gentle cord traction, and fundal massage
3297889|NCT00473707|Other|2|Expectant management of the third stage of labor
3297890|NCT00473694|Experimental|1|Sugammadex
3297891|NCT00473694|Active Comparator|2|neostigmine
3297892|NCT00473668|Experimental|TRITANRIX-HEPB/HIBERIX KFT. GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ Kft. vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
3297893|NCT00473668|Active Comparator|TRITANRIX-HEPB/HIBERIX LD GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ low-dose (LD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
3297894|NCT00473668|Active Comparator|TRITANRIX-HEPB/HIBERIX HD GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ high-dose (HD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
3297895|NCT00473642|Experimental|1|Standard Fluence Photodynamic Therapy combined with ranibizumab
3297896|NCT00473642|Experimental|2|Verteporfin at 50% fluence photodynamic therapy combined with ranibizumab
3297897|NCT00473642|Active Comparator|3|Ranibizumab monotherapy
3297898|NCT00473616|Experimental|1|AZD7762 monotherapy followed by AZD7762 + irinotecan
3297899|NCT00473603|Experimental|LHI|to perform an i.v. lipid heparin infusion for 4 h
3297900|NCT00473603|Sham Comparator|SHI|to perform an i.v. saline heparin infusion for 4 h
3297901|NCT00473590|Experimental|Bortezomib + bevacizumab|Participants received bortezomib 1.3 mg/m^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and bevacizumab 15 mg/kg administered by intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. After completion of 8 cycles, participants could continue to receive bevacizumab as monotherapy until disease progression.
3297902|NCT00473590|Active Comparator|Bortezomib + placebo|Participants received bortezomib 1.3 mg/m^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and placebo intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. At the completion of the 8-cycle treatment phase, participants entered the observation phase until disease progression.
3297903|NCT00473564|Experimental|TORS Candidates|Participants who consented to undergo transoral robotic-assisted surgery using the da Vinci® Robotic System
3297904|NCT00473551|Experimental|Anti-Third Party T Lymphocytes + Nonmyeloablative SCT|"Anti-Third Party CTL (Cytolytic T-lymphocytes) with Nonmyeloablative SCT (Stem Cell Transplantation)~Rituximab 375 mg/m^2 intravenously over several hours on Day -13, followed by 1000 mg/m^2 intravenously on Days -6, 1, and 8; + Cyclophosphamide 50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine; + Fludarabine 40 mg/m^2 intravenously over 30 minutes once per day for 4 days, starting Day -6; + Radiation 2Gy Total body radiation day before transplantation + Stem Cell Transplantation + Intravenous infusion of Anti-third Party CTLs."
3297905|NCT00473525|Placebo Comparator|Placebo|
3297906|NCT00473525|Experimental|PF-00734200 10 mg QD|
3297907|NCT00473525|Experimental|PF-00734200 20 mg QD|
3297908|NCT00473525|Experimental|PF-00734200 5 mg QD|
3297909|NCT00473525|Experimental|PF-00734200 2 mg QD|
3297910|NCT00473512|Experimental|Abiraterone acetate|Abiraterone acetate 250 mg up to a maximum of 2000 mg capsules will be given orally daily for 28-day treatment period to determine the MTD in Phase 1 of the study. Participants will receive MTD of abiraterone acetate for 12 cycles (28 day each) in Phase 2 of the study. Dexamethasone 0.5 mg will be given orally (If participants have disease progression) daily up to 12 cycles.
3297911|NCT00473499|Experimental|DEBlue stent|Paclitaxel coated balloon with CoCr stent mounted on it
3297912|NCT00473499|Active Comparator|Cypher stent|
3297913|NCT00473499|Placebo Comparator|Coroflex Blue stent|
3297914|NCT00473486|Active Comparator|1|Pemetrexed, Carboplatin plus Sorafenib in the first-line treatment of patients with stage IIIb or IV NSCLC
3297915|NCT00473486|Placebo Comparator|2|Pemetrexed, Carboplatin plus placebo in the first-line treatment of patients with stage IIIb or IV NSCLC
3297916|NCT00473473|Experimental|1|potassium bichromate
3297917|NCT00473473|Placebo Comparator|2|placebo
3297918|NCT00473460|Experimental|Arm 1|
3297919|NCT00473460|Placebo Comparator|Arm 2|
3297920|NCT00473434|Experimental|001|Paliperidone3mg or 6mg or 9mg or 12mg once daily for 52 weeks
3297921|NCT00473382|Experimental|Ranibizumab 0.3 mg|Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
3297922|NCT00473382|Experimental|Ranibizumab 0.5 mg|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
3297923|NCT00473382|Sham Comparator|Sham injection/ranibizumab 0.5 mg|Patients received a sham intravitreal injection monthly for 24 months. Patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
3297924|NCT00473356|Active Comparator|1|to receive amino acid supplement
3297925|NCT00473356|No Intervention|2|no amino acid supplement
3297926|NCT00473330|Experimental|Ranibizumab 0.3 mg|Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
3297927|NCT00473330|Experimental|Ranibizumab 0.5 mg|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
3297928|NCT00473330|Sham Comparator|Sham injection/ranibizumab 0.5 mg|Patients received a sham intravitreal injection monthly for 24 months. Patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
3297929|NCT00473317|Experimental|1|All subjects in this study will be in the active arm
3297930|NCT00473291||Patients with pleural effusion|Patients diagnosed with pleural effusion and presenting for treatment
3297931|NCT00473265|Experimental|PTH(1-84)|100mcg of PTH1-84 every other day, every day, or every three days
3297932|NCT00473252||Hemodialysis patients|
3297933|NCT00473252||Renal transplant patients|
3297934|NCT00473239|Experimental|cholecalciferol|A single dose of 100,000 IU vitamin D
3297935|NCT00473239|No Intervention|Control|No drug was given
3297936|NCT00473200|Active Comparator|S-adenosylmethionine|S-adenosylmethionine
3297937|NCT00473200|Placebo Comparator|Placebo|Placebo
3297938|NCT00473174|Active Comparator|1|Ramipril on awakening
3297939|NCT00473174|Active Comparator|2|Ramipril at bedtime
3297940|NCT00473148|Experimental|1|BNP-guided treatment (Furosemide)
3297941|NCT00473148|No Intervention|2|
3297942|NCT00473135|Experimental|1|Two subcutaneous vaccinations with rDEN1delta30 into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on Day 120.
3297943|NCT00473135|Experimental|2|Two subcutaneous vaccinations with rDEN1delta30 into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on Day 180.
3297944|NCT00473135|Placebo Comparator|3|Two subcutaneous vaccinations with placebo into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on either Day 120 or 180, depending on arm assignment.
3297945|NCT00473122|Other|Delayed-Immediate Breast Reconstruction|Delayed-Immediate Reconstruction: If radiation therapy (XRT) not needed, immediate reconstruction. If XRT is needed, delayed reconstruction until XRT complete.
3297946|NCT00473109|Experimental|Dialysis without systemic heparinization|Dialysis without systemic heparinization
3297947|NCT00473083|Experimental|Arm 1: Prophylactic Treatment|Participants will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
3297948|NCT00473083|Experimental|Arm 2: Reactive Treatment|"Pts will receive treatment at initiation of rash. Tx is dependent on grading of rash as follows:~Grade 1 or 2A: Topical clindamycin 2%, with hydrocortisone 1% in lotion base applied twice daily until resolution of rash by one grade~Grade 2B: Topical clindamycin 2%, with hydrocortisone 1% in lotion base applied 2x daily and oral minocycline 100mg 2x daily for a min. of 4 weeks and continuing thereafter, as required, until resolution of rash by 1 grade. Scalp lesions will be treated with a topical clindamycin 2%, triamcinolone acetonide 0.1% soln.~Grade 3: Pts will discontinue tx with erlotinib 150mg for 1 week and restart at 100mg once daily.~Tx with topical clindamycin 2%, with hydrocortisone 1% in lotion base applied 2x daily and oral minocycline 100mg 2x daily for a min. of 4 weeks and continuing thereafter, as required, until resolution of rash to Grade 1 or 2A. Scalp lesions will be treated with a topical clindamycin 2%, triamcinolone acetonide 0.1% soln."
3297949|NCT00473083|Experimental|Arm 3: No Treatment Unless Severe (Grade 3)|This is the control group. Patients will be treated only if grade 3 rash develops. For grade 3 rash, treatment will be in accordance with that of Grade 3 rash in Treatment Arm 2.
3297950|NCT00473031|Experimental|1|High Protein
3297951|NCT00473031|Active Comparator|2|Normal Protein
3297952|NCT00472966|Other|1|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
3297953|NCT00472953|Experimental|A|
3297954|NCT00472953|Active Comparator|B|
3297955|NCT00472862|Experimental|2|Cognitive training
3297956|NCT00472862|Active Comparator|1|OPUS psychosocial treatment alone
3297957|NCT00472849|Experimental|OFAR (Phase I)|Oxaliplatin starting dose 30 mg/m^2/day over 2 hours on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily intravenous (IV) over 30 minutes on days 2-3, 2-4, or 2-5 until maximum tolerated dose reached. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose (MTD) reached. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
3297958|NCT00472849|Experimental|OFAR MTD (Phase II)|Oxaliplatin 25 mg/m^2 IV per day MTD on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily IV over 30 minutes on days 2-4. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after fludarabine dose started, on days 2-4. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
3297959|NCT00472836|Experimental|Normal renal function|
3297960|NCT00472836|Experimental|Severe renal impairment|
3297961|NCT00472823|Experimental|vitamin D3 400 IU daily|vitamin D3 400 IU daily
3297962|NCT00472823|Experimental|vitamin D3 800 IU daily|vitamin D3 800 IU daily
3297963|NCT00472823|Experimental|vitamin D3 1600 IU daily|vitamin D3 1600 IU daily
3297964|NCT00472823|Experimental|vitamin D3 2400 IU daily|vitamin D3 2400 IU daily
3297965|NCT00472823|Experimental|vitamin D3 3200 IU daily|vitamin D3 3200 IU daily
3297966|NCT00472823|Experimental|vitamin D3 4000 IU daily|vitamin D3 4000 IU daily
3297967|NCT00472823|Experimental|vitamin D3 4800 IU daily|vitamin D3 4800 IU daily
3297968|NCT00472823|Placebo Comparator|placebo|matched to vitamin D tablet
3297969|NCT00472810|Experimental|1|20 patients will be recruited according to the enrollment acceptance criteria.Randomisation is performed using a sealed envelope system, where 40 shuffled envelopes designating the surgery to either trabeculectomy with mitomycin-C (MMC) and trabeculectomy with ologen™ Collagen matrix must be open before surgery. Then, patients are allocated and trabeculectomy is performed.If ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
3297970|NCT00472810|Active Comparator|2|Following ethics committee approval, 20 patients with uncontrolled glaucoma will be randomised to trabeculectomy with mitomycin -C. Randomisation is performed. Then, trabeculectomy is performed
3297971|NCT00472797|Active Comparator|1|Rebif New Formulation - Non Titrated
3297972|NCT00472797|Active Comparator|2|Rebif New Formulation - Titrated
3297973|NCT00472758|Active Comparator|1|MEDI 545
3297974|NCT00472758|Placebo Comparator|2|Placebo IV
3297975|NCT00472745|Experimental|WL|weight loss (WL) with nutrition/behavior modification counseling
3297976|NCT00472745|Active Comparator|WM|Weight Maintenance (WM)
3297977|NCT00472732||1|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD
3297978|NCT00472732||2|Healthy males or females without known medical or metabolic disorder (control group)
3297979|NCT00472719|Experimental|1|Participants in this group will receive an injection of the adenoviral vector vaccine VRC-HIVADV027-00VP at study entry and an injection of VRC-HIVADV038-00-VP at Month 3. There will be 9 study visits for this arm.
3297980|NCT00472719|Experimental|2|Participants in this group will receive an injection of VRC-HIVADV038-00-VP at study entry and an injection of VRC-HIVADV027-00-VP at Month 3. There will be 9 study visits for this group.
3297981|NCT00472719|Experimental|3|Participants in this group will receive an injection of the VRC-HIVDNA044-00-VP vaccine at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV027-00-VPat Month 6. There will be 13 study visits for this group.
3297982|NCT00472719|Experimental|4|Participants in this group will receive an injection of VRC-HIVDNA044-00-VP at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV038-00-VP at Month 6. There will be 13 study visits for this group.
3297983|NCT00472706|Active Comparator|1|Excision
3297984|NCT00472706|Active Comparator|2|Photodynamic therapy
3297985|NCT00472693|Experimental|Bevacizumab and ABI-007 (Abraxane)|Bevacizumab and ABI-007 (Abraxane)
3297986|NCT00472680|Experimental|1|High Dietary Protein
3297987|NCT00472680|Active Comparator|2|Normal Dietary Protein
3297988|NCT00472667|Experimental|1|Procalcitonin guided strategy
3297989|NCT00472654|Placebo Comparator|WL|
3297990|NCT00472654|Experimental|WL + D|
3297991|NCT00472654|Placebo Comparator|WM|
3297992|NCT00472654|Active Comparator|WM + D|
3297993|NCT00472641|Experimental|Ziprasidone/Geodon|Ziprasidone/Geodon up to 320 mg per day
3297994|NCT00472589||1|Healthy women
3297995|NCT00472589||2|Women with breast cancer
3297996|NCT00472576|Experimental|Placebo then MK-0657|Double-blind crossover administration of placebo then MK-0657 (4-8 mg/day)
3297997|NCT00472576|Experimental|MK-0657 then Placebo|Double-blind crossover administration of MK-0657 (4-8 mg/day) then placebo
3297998|NCT00472498||1|"Case:~Patients resuscitated after 2001"
3297999|NCT00472498||2|"Control:~Patients who suffer cardiac arrests after 2001."
3298000|NCT00472472|Placebo Comparator|1|PTA
3298001|NCT00472472|Active Comparator|2|PTA with Paccocath
3298002|NCT00472446|Experimental|cervical block before surgery|bilateral superficial cervical block, placed before surgery (just before skin incision)
3298003|NCT00472446|Placebo Comparator|placebo cervical block before surgery|placebo bilateral superficial cervical block with saline, placed before surgery (just before skin incision)
3298004|NCT00472446|Experimental|cervical block after surgery|bilateral superficial cervical block, placed after surgery (just after skin closure)
3298005|NCT00472446|Placebo Comparator|placebo cervical block after surgery|placebo bilateral superficial cervical block with saline, placed after surgery (just after skin closure)
3298006|NCT00472420|Experimental|1|
3298009|NCT00472329|No Intervention|Fludarabine and 400cGY TBI|
3298010|NCT00472303|Placebo Comparator|Matching Placebo after Tapentadol in Titration Phase|Oral Tapentadol 100 mg to 250 mg twice daily. Participants randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off the tapentadol dose they had received in the Titration Phase. From the 4th day (Day 18) all participants received matching placebo in the maintenance (i.e. randomized withdrawal) phase.
3298011|NCT00472303|Active Comparator|Morphine Controlled Release|Oral Morphine 40 mg to 100 mg twice daily. Capsule taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Maintenance phase: continuing on dose level established in titration phase.
3298012|NCT00472303|Experimental|Tapentadol Prolonged Release|Oral Tapentadol 100 mg to 250 mg twice daily. Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses.
3298013|NCT00472290|Experimental|Open Label Romiplostim (formerly AMG 531)|
3298014|NCT00472264||Single arm study (Healthy volunteers & COPD subjects)|A single arm study PET imaging is carried out twice during the first week of the study and again 4 weeks later in both Healthy volunteers and COPD subjects.
3298015|NCT00472238|Experimental|1, Training|Group for training therapy
3298016|NCT00472238|Active Comparator|2, Control|
3298017|NCT00472225|Experimental|1|Rituximab treatment arm
3298018|NCT00472212|Experimental|Spectacles|Spectacles with hyperopic lenses
3298019|NCT00472212|Placebo Comparator|Control|Spectacles with placebo lenses
3298020|NCT00472199|Experimental|Pramipexole|4 weeks of flexible dose-titration (to optimise efficacy and tolerability), starting at 0.125 mg once daily with the potential to increase or decrease the dose in steps to 0.25 mg, 0.5 mg and 0.75 mg, with the final dose level subsequently fixed for 22 weeks.
3298021|NCT00472199|Placebo Comparator|Placebo|4 weeks of flexible dose-titration as for the investigational product; with the dose subsequently fixed for 22 weeks.
3298022|NCT00472186|Experimental|1|Post-operative administration of Lansoprazole
3298023|NCT00472186|Placebo Comparator|2|Placebo
3298024|NCT00472173|Active Comparator|Calcium hydroxide|
3298025|NCT00472173|Experimental|MTA|
3298026|NCT00472160|Experimental|1|Non Invasive Ventilation
3298027|NCT00472134|Active Comparator|Bupivicaine via Elastomeric pump|Bupivicaine via elastomeric pump
3298028|NCT00472134|Placebo Comparator|Placebo via elastomeric pump|Placebo via elastomeric pump
3298029|NCT00472121||1: AMG|
3298030|NCT00472121||2: MMG|
3298031|NCT00472095|Experimental|diabetes fotonovela|spanish language comic book describing diabetes care and consequences
3298032|NCT00472095|Placebo Comparator|placebo fotonovela|
3298033|NCT00472082|Experimental|1|The study drug Efalizumab will be given as part of a triple drug regimen including mycophenolate mofetil and prednisone. A test dose of Efalizumab 0.7mg/kg will be given at the enrollment visit. Beginning with study visit 2, Efalizumab 1mg/kg will be administered subcutaneously by injection on a weekly basis for 1 year. Mycophenolate mofetil will be given at a dose of 2gm/day which is the same as the standard of care dose. If patient experiences drug toxicity with mycophenolate mofetil they may be reduced and resume a minimum of at least 1gram daily to continue in the study. Patients will be maintained at 10mg of prednisone daily, same as standard of care.
3298034|NCT00472069|Experimental|A|transplantation of the squeletic muscular cells
3298035|NCT00472056|Experimental|BEAM + Standard Rituximab|"Arm 1 BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + Standard Rituximab with Standard Rituximab for Cohort 1 or 2~Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Standard Rituximab: 375 mg/m^2 IV Days +1, +8 after Stem Cell Infusion on Day 0."
3298036|NCT00472056|Experimental|BEAM + High Rituximab|"BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + High Dose Rituximab~Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~High Dose Rituximab: 1000 mg/m^2 IV Days +1, +8 after Stem Cell Infusion on Day 0"
3298037|NCT00472030|Experimental|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
3298038|NCT00472030|Active Comparator|Prednisone|The control arm of the study will receive standard prednisone therapy to a maximum dose of 0.5 mg/kg/day.
3298039|NCT00472017|Experimental|Pediatric Diffuse Brainstem Glioma Patients|Patients with newly diagnosed diffuse brainstem gliomas receive vandetanib.
3298040|NCT00472004|Active Comparator|1|17B Estradiol (1mg) / (0.125 mg) Trimegestone (TMG) Continuous combined, 1 Daily, 1 year duration
3298041|NCT00472004|Active Comparator|2|Tibolone 2.5 mg 1 daily, 1 year duration
3298042|NCT00471991|Active Comparator|Arm 1|
3298043|NCT00471991|Experimental|Arm 2|
3298044|NCT00471965|Experimental|A|Oxaliplatin + 5-Fluorouracil/Leucovorin
3298045|NCT00471965|Active Comparator|B|Doxorubicin
3298046|NCT00471952|Experimental|1|Maxalt 10mg with Caffeine 75mg
3298047|NCT00471952|Active Comparator|2|Maxalt 10mg plus Placebo
3298048|NCT00471952|Placebo Comparator|3|Double placebo
3298049|NCT00471887|Experimental|Treatment-Single Arm|See intervention descriptions
3298050|NCT00471848|Experimental|Treatment Arm|Antithymocyte globuline with cyclosporin in first line treatment of patients with acquired severe aplastic anaemia and patients with non-severe aplastic anaemia who are transfusion dependent
3298051|NCT00471770||1|1.Core group: enrolled subjects who have isolated pneumococcal
3298052|NCT00471770||2|2.SPN group:enrolled subjects who have no isolated pneumococcal
3298053|NCT00471770||3|3.DCF group: Subjects screened but not enrolled
3298054|NCT00471718|Experimental|Phase I/II: Chemotherapy ABT-751|"Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21.~Phase II: Patients receive ABT-751 twice daily"
3298055|NCT00471705|Experimental|Miltefosine|Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
3298056|NCT00471705|Active Comparator|Glucantime®|Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
3298057|NCT00471705|Experimental|Thermotherapy|One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
3298058|NCT00471692|Placebo Comparator|placebo|Normal saline placebo
3298059|NCT00471692|Active Comparator|Ropivocaine|Ilioinguinal nerve block with ropivocaine
3298060|NCT00471679|Experimental|Ethanol-Lock Treatment|Ethanol instillation and removal will be carried out by one of the investigating physicians, a pediatric surgical nurse practitioner, or a dedicated research nurse. Syringes containing a 70% ethanol solution will be pre-filled in the PDH pharmacy and dispensed to the nurse caring for a particular patient. The volume of ethanol to be administered into each lumen of the central line will be specific to each patient's catheter and will be determined at enrollment.
3298061|NCT00471640|Active Comparator|1|dexamethasone
3298062|NCT00471640|Placebo Comparator|2|Placebo
3298063|NCT00471614|Experimental|1|NucleomaxX
3298064|NCT00471614|Placebo Comparator|2|Placebo
3298065|NCT00471601|Experimental|Interviews/Questionnaires|The primary intervention in part 1 includes the interview for item generation with 50 women and the pilot-testing with a separate group of n = 30 women. The primary intervention in part 2 and 3 is the administration of the questionnaire. In part 3, along with the questionnaire being developed, the Body Image Scale (BIS), the Life Orientation Test-Revised (LOT-R), and the upcoming MSKCC BREAST-Q will be given to determine convergent and discriminant construct validity. No other therapeutic or diagnostic agents will be administered.
3298066|NCT00471536|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3298067|NCT00471510|Experimental|1|NEOSH101 2%
3298068|NCT00471510|Experimental|2|NEOSH101 1%
3298069|NCT00471510|Experimental|3|NEOSH101 0.5%
3298070|NCT00471510|Placebo Comparator|4|
3298071|NCT00471497|Experimental|nilotinib 300mg bid (investigating arm)|
3298072|NCT00471497|Experimental|Nilotinb 400 mg bid (investigating arm)|
3298073|NCT00471497|Experimental|imatinib 400mg QD (control arm)|
3298074|NCT00471471|Experimental|Peptide Vaccine + GM-CSF + Pfizer 3512676 in-ISA Oil|"The water-in-oil emulsion will consist of peptide (100 mcg/0.1 mL), GM-CSF (80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water), Pfizer PF3512676 (0.6 mg/0.04 mL using 15mg/mL vial) and 0.20 mLl of sterile saline.~Vaccination will be given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year)."
3298075|NCT00471445|Experimental|ketamine/amitriptyline NP-H cream|Patients apply 4 grams amitriptyline (4%) and ketamine (2%) hydrochloride topical analgesic cream twice daily to areas of pain, numbness, or tingling in the hands and/or feet.
3298076|NCT00471445|Placebo Comparator|Placebo Cream|Patients apply a placebo cream twice daily to areas of pain, numbness, or tingling in the hands and/or feet.
3298077|NCT00471380|Active Comparator|Crossover group ABB|"3 period, 2 treatment cross-over model:~Participants received Treatment A, which was concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.) for period 1 for 8 weeks. Then participants received Treatment B, which was fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.) for Period 2 (8 weeks) and Period 3 (8 weeks)"
3298078|NCT00471380|Active Comparator|Crossover group BAA|"3 period, 2 treatment cross-over model:~Participants received Treatment B, which was fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.) for Period 1 (8 weeks). Then participants received Treatment A, which was concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.) for Period 2 (8 weeks) and Period 3 (8 weeks)."
3298079|NCT00471354|Experimental|Atomoxetine|0.5 mg/kg/day once a day (QD), by mouth (PO), starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
3298080|NCT00471328|Experimental|Nilotinib|400mg twice daily in core and extension phases of the study.
3298081|NCT00471328|Active Comparator|Control/cross-over to Nilotinib|"In core study phase, patients in this arm received Best Supportive Care (BSC) with or without imatinib or sunitinib at the last tolerated dose or at the investigator's choice until documented disease progression followed by cross-over to nilotinib arm.~Patients entering the extension study on this control arm were permitted to cross over to nilotinib arm only upon documented disease progression."
3298082|NCT00471315|No Intervention|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
3298083|NCT00471289|Experimental|1|PTA with primary placement of Drug (paclitaxel) Eluting Stent
3298084|NCT00471289|Active Comparator|2|PTA
3298085|NCT00471276|Experimental|1|
3298086|NCT00471237|No Intervention|Placebo|All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
3298087|NCT00471237|Active Comparator|Alendronate|All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
3298088|NCT00471237|Active Comparator|Teriparatide|Open-label arm. All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
3298089|NCT00471237|Experimental|Ronacaleret|4 arms, 100mg, 200mg, 300mg, 400mg. All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study.
3298090|NCT00471224||Patients who have received drug.|Patients who have received drug.
3298091|NCT00471185|Experimental|A|Subjects will receive progressively increasing doses of 10, 20 and 40 mg of oral acyline, on 3 occasions, each separated by 1 week
3298092|NCT00471146|Experimental|A|
3298093|NCT00471146|Active Comparator|B|
3298094|NCT00471133|Experimental|Xenogeneic Tyrosinase|
3298095|NCT00471120|Experimental|P2x7 Assay|Compare assay results with biopsy
3298096|NCT00471107|Sham Comparator|Sham TDCS|
3298097|NCT00471107|Experimental|Surface-anodal direct current|0.08 mA/cm2
3298098|NCT00471107|Active Comparator|Surface-cathodal direct current|0.08 mA/cm2
3298099|NCT00471094|Experimental|Ilaprazole 5 mg QD|
3298100|NCT00471094|Experimental|Ilaprazole 20 mg QD|
3298101|NCT00471094|Experimental|Ilaprazole 40 mg QD|
3298102|NCT00471094|Active Comparator|Lansoprazole 30 mg QD|
3298103|NCT00471081|Experimental|Group A|Single dose GSK134612.
3298104|NCT00471081|Experimental|Group B|Two doses of GSK134612.
3298105|NCT00471068|Experimental|Travatan|Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
3298106|NCT00471068|Active Comparator|Cosopt|treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
3298107|NCT00471055|Experimental|A|Capsaicin and placebo controlled,Cross-over design study
3298108|NCT00471055|Placebo Comparator|B|Capsaicin and placebo controlled,Cross-over design study
3298109|NCT00471003||Arm 1|
3298110|NCT00470977|Experimental|(Ranibizumab) Lucentis|(Ranibizumab)Lucentis 0.5%
3298111|NCT00470951|Active Comparator|open rectal resection|conventional open resection
3298112|NCT00470951|Active Comparator|laparoscopic rectal resection|laparoscopic rectal resection
3298113|NCT00470925|Experimental|Access [123I]MZINT and SPECT Imaging|
3298114|NCT00470899|Experimental|placental drainage|
3298115|NCT00470899|No Intervention|no drainage of fetal blood|
3298116|NCT00470886||Group 1|
3298117|NCT00470873||Group 1|
3298118|NCT00470847|Other|Lapatinib,Whole Brain Radiation,Herceptin|Lapatinib before and during Whole Brain Radiation Therapy (WBRT), then Herceptin 4mg/kg IV weekly
3298119|NCT00470834|Experimental|Arm 1|50 mg bicalutamide and 3.5 mg Dutasteride (IP)
3298120|NCT00470834|Placebo Comparator|Arm 2|50 mg bicalutamide and placebo
3298121|NCT00470821|Placebo Comparator|A - placebo|Identical tablets without the active principles. Each evening, nurses are requested to give 2 tablets at 8 PM and 12 PM
3298122|NCT00470821|Active Comparator|B - melatonin|Identical tablets containing melatonin 3 mg Nurses are requested to give two tablets daily, at 8 PM and 12 PM.
3298123|NCT00470795|Experimental|A|Acupuncture - 2 treatments weekly, 4 weeks (8 treatment)
3298124|NCT00470795|Placebo Comparator|B|Placebo/sham treatment; twice weekly for 4 weeks (total 8 treatments)
3298125|NCT00470756||evertors, invertors|
3298126|NCT00470743|Experimental|Ibuprofen|Compare ibuprofen
3298127|NCT00470743|Placebo Comparator|Normal saline|Compared against ibuprofen -- placebo
3298128|NCT00470704|Other|Lapatinib and Herceptin|1000 mg daily Lapatinib and 2 mg/kg weekly or the 6 mg/kg every 3 week dose of trastuzumab
3298129|NCT00470691|Experimental|complete plaster cast|reduction and a complete plaster cast,
3298130|NCT00470691|Active Comparator|dorsal plaster splint|reduction and a dorsal plaster splint.
3298131|NCT00470678|Experimental|1|Ranibizumab
3298132|NCT00470652||1|Pre-intervention patients admitted to our ED in the month prior to the intervention, before the 'computer-assisted decision support' is turned on (the intervention)
3298133|NCT00470652||2|Short-term post-intervention cohort of patients admitted in the month following the initiation of the 'computer-assisted decision support' for pain management
3298134|NCT00470652||3|long-term post-intervention cohort of patients admitted on the 6th month following the initiation of the 'computer-assisted decision support' for pain management
3298135|NCT00470626|Experimental|1|Vena Cava Filter
3298136|NCT00470613|Experimental|SGT-53|SGT-53 (2.4mg DNA/infusion) will be administered in a standard 3x3 dose escalation design in combination with docetaxel 40mg/m2 starting dose, cohort 1, cycle 1. This protocol will allow for both inter- and intra-patient dose escalations. SGT-53 will be administered weekly, day 1 except weeks 1, 4 & 7 when it will be administered biweekly on days 1 & 4. Docetaxel will be administered every 3 weeks (weeks 1, 4 & 7) on day 3. Patients completing cohort 1, cycle 1 without DLT at docetaxel 40mg/m2 will be allowed to dose escalate to 60mg/m2 in cycles 2 and 3. Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60mg/m2. Cohort 3 (3.6mg DNA/infusion; 75mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4mg DNA/infusion and docetaxel 75mg/m2. If necessary, the dose of docetaxel in cycle 2 and 3 may be reduced to 60mg/m2.
3298137|NCT00470600|Placebo Comparator|Normal Saline|250 milliliters normal saline as a placebo comparator was administered every 6 hours for a total of five doses over the first 24 hours. Those patients who received the initial five doses could continue to receive additional doses as needed every 6 hours through the 120-hour treatment period.
3298138|NCT00470600|Experimental|Intravenous ibuprofen|800 mg of intravenous ibuprofen diluted in 250 milliliters normal saline was administered every 6 hours for a total of five doses over the first 24 hours. Those patients who received the initial five doses could continue to receive additional doses as needed every 6 hours through the 120-hour treatment period.
3298139|NCT00470574|Experimental|Vaccine Therapy and QS21|"Patients receive sialyl Lewisª -keyhole limpet hemocyanin conjugate vaccine subcutaneously (SC) and QS21 immunoadjuvant SC once in weeks 1, 2, 3, 7, and 19 in the absence of disease progression or unacceptable disease.~Blood samples are collected periodically and evaluated for circulating tumor cells and reactivity against sialyl Lewisª antigen in ELISA and/or immunoprecipitation-western blot assays.~After completion of study treatment, patients are followed every 3 months"
3298140|NCT00470561|Active Comparator|Aspirin|
3298141|NCT00470561|Placebo Comparator|Placebo|
3298183|NCT00470106|Experimental|Social Cognitive Skills Training|social cognitive skills training
3298142|NCT00470548|Experimental|Phase I: Abraxane and Alimta|Three dose levels were tested. Pemetrexed 500mg/m2 day 1 and nab-paclitaxel day 1 at 180, 220, and 260 mg/m2 every 21 days.
3298143|NCT00470548|Experimental|Phase II: Abraxane and Alimta|Pemetrexed 500mg/m2 day 1 and nab-paclitaxel day 1 at 260 mg/m2 every 21 days.
3298144|NCT00470535|Experimental|Arm 1 - Oral Erlotinib hydrochloride|Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity
3298145|NCT00470496|Experimental|Treatment (intraoperative PDT)|Patients receive HPPH IV over 1 hour on day 1. Patients undergo surgery followed by laser light exposure to the entire tumor bed on day 2.
3298146|NCT00470483|Active Comparator|arm 1|Paroxetine treatment during 8 weeks
3298147|NCT00470483|Placebo Comparator|arm 2|Placebo treatment during 8 weeks
3298148|NCT00470470|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral imatinib mesylate twice daily for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
3298149|NCT00470444|Active Comparator|1|Liberal transfusion strategy
3298150|NCT00470444|Active Comparator|2|Restrictive transfusion strategy
3298151|NCT00470418|Other|NIC5-15|Subjects with Alzheimer's Disease
3298152|NCT00470418|Placebo Comparator|Placebo|Subjects with Alzheimer's Disease
3298153|NCT00470405|Experimental|Therapeutic Intervention|
3298154|NCT00470392|Other|Imiquimod|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
3298155|NCT00470392|Other|Clobetasol|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
3298156|NCT00470379|Experimental|Immunization with NY-ESO-1b|Efficacy of maximal dose of topical resiquimod as immune adjuvant to intradermally administered NY-ESO-1b peptide vaccine.
3298157|NCT00470366|Experimental|Paclitaxel, Ifosfamide, and Cisplatin|-Paclitaxel is administered first, 120 mg/m2 on days 1 and 2 every three weeks for four cycles. Cisplatin is administered at 20 mg/m2 over approximately 30 minutes daily for five days every three weeks for four courses. -The ifosfamide is given last with 1200 mg/m2 daily for five days every three weeks for four cycles.
3298158|NCT00470340|Experimental|1|Oxaliplatin, gemcitabine, cisplatin, lipiodol
3298159|NCT00470340|Experimental|2|Oxaliplatin, gemcitabine, cisplatin, lipiodol
3298160|NCT00470301|Experimental|Arm I|Tipifarnib plus sequential weekly paclitaxel followed by doxorubicin plus cyclophosphamide
3298161|NCT00470275|Experimental|Cytarbine|Cytarabine IV every 12 hours days 1-5 of 21 day cycle. Response evaluation after 6 cycles of therapy.
3298162|NCT00470262|Other|Fenofibrate 145 mg PO QD and Pioglitazone 45 mg PO QD|Treatment with pioglitazone and fenofibrate in subjects with pre diabetes
3298163|NCT00470262|Other|Fenofibrate 145 mg PO QD|Treatment with fenofibrate in subjects with pre diabetes
3298164|NCT00470236|Active Comparator|Arm 1 (Standard WB Fractionation)|Whole Breast RT alone - Standard fractionation schedule (50GY/25 Fractions/35days)
3298165|NCT00470236|Experimental|Arm 2 (Shorter WB Fractionation)|Whole Breast RT alone - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days)
3298166|NCT00470236|Active Comparator|Arm 3 (Standard WB fractionation+Boost)|Whole Breast RT + tumor bed boost - Standard fractionation schedule (50 Gy/25 fractions/35 days; Boost 16 Gy/8 fractions/10 days)
3298167|NCT00470236|Experimental|Arm 4 (Shorter WB fractionation + Boost)|Whole breast RT + tumour bed boost - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days; Boost 16 Gy/8 fractions/10 days)
3298168|NCT00470223|Experimental|Chemotherapy + zoledronicc acid|
3298169|NCT00470223|Active Comparator|chemotherapy|
3298170|NCT00470210|Experimental|1|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week Ribavirin (Copegus®) 1600 mg/day Epoetin β (450 UI/kg/week)
3298171|NCT00470197|Experimental|Arm I|Patients receive flavopiridol IV over 30 minutes on days 1, 2, and 3. Patients receive cytarabine IV continuously over 72 hours beginning on day 6 and mitoxantrone hydrochloride IV over 60-120 minutes on day 9.
3298172|NCT00470184|Experimental|Chemo|Oxaliplatin 85 mg/m2 will be administered IV on days 1, 15 and 29. Capecitabine 1250 mg/m2 will be administered in 2 divided daily doses P0 or via enteral tube, on radiation days only (Monday- Friday/ weekly). Capecitabine will be continued until the final dose of radiotherapy
3298173|NCT00470158|Experimental|combined iron and zinc|Iron and zinc together
3298174|NCT00470158|Experimental|Separate iron and zinc|Iron and zinc on separate days
3298175|NCT00470158|Experimental|iron alone|Iron
3298176|NCT00470158|Experimental|zinc alone|Zinc
3298177|NCT00470158|Placebo Comparator|placebo|
3298178|NCT00470119|No Intervention|Control|
3298179|NCT00470119|Other|Caloric Restriction|Nutritionist-delivered weight loss intervention though diet modification with an aim of 10% weightloss over a year long intervention based on the DPP and LookAHEAD interventions. Participants meet with a nutritionist individually and in small groups. Participants receive general information about diet and behavior strategies such as self-monitoring, goal-setting, stimulus-control, problem-solving, and relapse-prevention training. Participants learn to set a calorie goal and a fat gram goal and how to achieve the goal calorie reduction. Meetings are held weekly during the first 6 months of the diet program but taper off over the course of the study.
3298180|NCT00470119|Other|Exercise Intervention|Participants exercise 3 days per week under the supervision of a physiologist and 2 days per week independently at home, for a total of 5 exercise sessions (at least 45 minutes of moderate-intensity exercise per session) weekly over 12 months
3298181|NCT00470119|Other|Caloric Restriction AND Exercise Intervention|Combined caloric restriction & exercise intervention
3298182|NCT00470106|Active Comparator|Cognitive Remediation|cognitive remediation
3298386|NCT00467974|Active Comparator|2|TACE
3298184|NCT00470106|Active Comparator|Hybrid Intervention|combined social cognitive and cognitive remediation training
3298185|NCT00470106|Other|Skills Training|control training
3298186|NCT00470080|Experimental|1|venepuncture
3298187|NCT00470067|Experimental|Doxorubicin and carboplatin|Patients receive doxorubicin hydrochloride liposome IV over 1 hour on day 1 and carboplatin IV over 30 minutes on day 1
3298188|NCT00470054|Experimental|Treatment (dasatinib)|Patients receive oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3298189|NCT00470015|Experimental|MART1 Analog, gp100 and Survivin|
3298190|NCT00469963|Experimental|SIR-SPHERES|
3298191|NCT00469937|Experimental|Therapeutic Intervention|
3298192|NCT00469924|Experimental|Alerting system ON|Alerting system is ON
3298193|NCT00469924|No Intervention|Alerting system OFF|Alerting system is OFF
3298194|NCT00469898|Experimental|Therapeutic Intervention|Lung cancer patients will be treated for four 3-week cycles (12 weeks) in the absence of progressive disease, unacceptable toxicity, or withdrawal of patient consent. Up to two additional cycles may be administered at the discretion of the treating physician. If at treatment withdrawal the disease has responded or is stable, the patient will continue to be followed for efficacy (i.e. until progressive disease)at 8 week intervals. Following the diagnosis of progressive disease, patients will be followed every two months for survival.
3298195|NCT00469885|Other|1|Usual care
3298196|NCT00469885|Other|2|Reduction
3298197|NCT00469872|Active Comparator|Child Focused|Occupational and physical therapy focused on improving child's skills and abilities through rehabilitation to improve child functioning
3298198|NCT00469872|Experimental|Context Focused|Occupational and physical therapy focused on improving child's skills and abilities through rehabilitation to change the task or environment around a child
3298199|NCT00469859|Experimental|Group 1 (Lestaurtinib dose 50 mg/m2|"DOSE-FINDING PHASE:~COURSE 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2. Cohorts of 6 patients receive escalating doses of lestaurtinib until a TBAD is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by PIA assay.~COURSE 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Continued (see detailed description)"
3298200|NCT00469859|Experimental|Group 2 (Lestaurtinib: Dose 62.5 mg/m2|"DOSE-FINDING PHASE:~COURSE 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2. Cohorts of 6 patients receive escalating doses of lestaurtinib until a TBAD is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by PIA assay.~COURSE 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Continued (see detailed description)"
3298201|NCT00469833|Experimental|Arm 1|Intervention: Insulin glargine treatment. The study is designed as a within subjects comparison of insulin secretion in type 2 diabetic patients before and after 2 months of insulin treatment to reduce blood glucose. Insulin secretion will be determined with a hyperglycemic clamp using 20% dextrose, and ingestion of an oral glucose solution (75 g).
3298202|NCT00469781|Active Comparator|1|
3298203|NCT00469781|Other|2|
3298204|NCT00469768|Experimental|A|
3298205|NCT00469768|Experimental|B|
3298206|NCT00469768|Placebo Comparator|C|
3298207|NCT00469755|Active Comparator|1|Differin® Gel, 0.1% for 12 weeks
3298208|NCT00469755|Active Comparator|2|Tazorac® Cream, 0.1% for 12 weeks
3298209|NCT00469755|Active Comparator|3|Differin® Gel, 0.1% for 6 weeks switched to Tazorac® Cream, 0.1% for 6 weeks
3298210|NCT00469729|Experimental|StemEx|
3298211|NCT00469690|Other|1|
3298212|NCT00469690|Other|2|
3298213|NCT00469651|Experimental|1|15 microgramme candidate vaccine
3298214|NCT00469651|Active Comparator|2|Hepatitis B vaccine
3298215|NCT00469651|Experimental|3|30 microgramme MSP3 candidate malaria vaccine
3298216|NCT00469651|Active Comparator|4|Hepatitis B control vaccine
3298217|NCT00469638|Experimental|Agilis sheeth group|
3298218|NCT00469638|Active Comparator|Non-steerable sheeth group|
3298219|NCT00469612|Experimental|A|NeuroVision's NVC treatment for low myopia
3298220|NCT00469612|No Intervention|B|The subjects in this group will serve as controls and will be the no intervention group.
3298221|NCT00469599|Active Comparator|1|alfacalcidol 16 weeks, 6 weeks wash out, paricalcitol 16 weeks
3298222|NCT00469599|Active Comparator|2|paricalcitol ´16 weeks, 6 weeks wash out, alfacalcidol 16 weeks
3298223|NCT00469586|Experimental|A|
3298224|NCT00469586|Experimental|B|
3298225|NCT00469586|Active Comparator|C|
3298226|NCT00469573|Other|1.|
3298227|NCT00469560|Experimental|Deferasirox|
3298228|NCT00469547|Experimental|1|62% ethanol in emollient gel
3298229|NCT00469547|Placebo Comparator|2|15% ethanol in emollient gel
3298230|NCT00469508|Active Comparator|Modafinil|Modafinil 400mg oral dose taken daily for 12 weeks
3298231|NCT00469508|Placebo Comparator|Placebo|Modafinil 0mg (sugar pill) oral dose taken daily for 12 weeks
3298232|NCT00469482|Active Comparator|Sedation, RASS Targeted|Patient sedation utilizing standard of care methods (RASS Targeted)
3298233|NCT00469482|Active Comparator|Sedation,RASS Targeted plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring.
3298575|NCT00465608|Experimental|1|propranolol
3298234|NCT00469456|Active Comparator|1|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
3298235|NCT00469456|Placebo Comparator|2|Placebo oral administration twice daily for 12 weeks
3298236|NCT00469443|Experimental|1|FOLFIRI/Avastin
3298237|NCT00469443|Experimental|2|XELIRI/Avastin
3298238|NCT00469430|No Intervention|Op|traditional surgery
3298239|NCT00469430|Experimental|Ab|antibiotic treatment
3298240|NCT00469391|Experimental|GI Sleeve|medical device that mimics gastric bypass mechanism for weight-loss
3298241|NCT00469391|Sham Comparator|Sham Control|
3298242|NCT00469378|Experimental|firategrast|900 (females) or 1200 (males) mg twice daily for 24 weeks
3298243|NCT00469339||Mexican-American households|cohort of Mexican-American households
3298244|NCT00469326|Active Comparator|atorvastatin|atorvastatin pre-treatment group (80mg atorvastatin two days before PCI)
3298245|NCT00469326|No Intervention|control|PCI without atorvastatin pretreatment
3298246|NCT00469274|Active Comparator|Antibiotic PEP|Subjects who did receive PEP following pertussis exposure
3298247|NCT00469274|No Intervention|No PEP|Subjects who did not receive PEP following pertussis exposure
3298248|NCT00469261|Experimental|Doxycycline|Active drug 100 mg bid for seven days in pts with AMI treated with Primary PCI and current medical therapy
3298249|NCT00469261|Active Comparator|Standard Therapy|Pts with AMI treated with Primary PCI and current medical therapy
3298250|NCT00469235|Placebo Comparator|1|50ng dose group
3298251|NCT00469235|Placebo Comparator|2|200ng dose group
3298252|NCT00469209|Active Comparator|No Bortezomib|Arm 1: Melphalan 100 mg/m^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
3298253|NCT00469209|Active Comparator|Bortezomib 1.0 mg/m^2|Arm 2: Bortezomib (Level 1) 1.0 mg/m^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
3298254|NCT00469209|Active Comparator|Bortezomib 1.5 mg/m^2|Arm 3: Bortezomib (Level 2) 1.5 mg/m^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
3298255|NCT00469170|Experimental|A|vaginal ring first 12 weeks & observational safety last 12 weeks
3298256|NCT00469170|Experimental|B|observational safety first 12 weeks & vaginal ring last 12 weeks
3298257|NCT00469157|Other|1.|
3298258|NCT00469144|Experimental|Fixed-Dose Busulfan + Fludarabine|Busulfan Fixed Dose = 130 mg/m^2 IV Daily Over Three Hours x 4 Days. Fludarabine 40 mg/m^2 IV Daily Over 1 Hour x 4 Days.
3298259|NCT00469144|Experimental|Adjusted Dose Busulfan + Fludarabine|Busulfan Adjusted Dose = 32 mg/m^2 IV Over 2 Hours Test Dose x 1 Day. Fludarabine 40 mg/m^2 IV Daily Over 1 Hour x 4 Days.
3298260|NCT00469131|Active Comparator|1 Drug:|tacrolimus + steroid
3298261|NCT00469131|Active Comparator|2 Drug:|tacrolimus + mycophenolate mofetil
3298262|NCT00469118|Experimental|DRX Treatment|20 treatments of spinal decompression over a six week period. Each session lasts about 45 minutes and consists of a 28-minute treatment on the DRX9000™ machine followed by 15 minutes of cold therapy to the lumbar paravertebral muscles.
3298263|NCT00469118|No Intervention|Conservative Care|Conservative non surgical therapy for 6 weeks prior to beginning DRX9000 treatment
3298264|NCT00469105|Active Comparator|Control|Control Arm receives standard diabetes disease management
3298265|NCT00469105|Experimental|Intervention Arm|Receives numeracy/literacy sensitive diabetes management
3298266|NCT00469092|Experimental|BIAsp 30|
3298267|NCT00469092|Active Comparator|Glargine|
3298268|NCT00469079|Active Comparator|1|Nicotine gum or nicotine lozenge; Dosage: 2 or 4 mg; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
3298269|NCT00469079|Experimental|2|Taboka - oral tobacco product Dosage: 0.84 to 1.26 mg free nicotine per g dry weight; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
3298270|NCT00469079|Experimental|3|Camel Snus - oral tobacco product Dosage: 6.09 to 9.16 mg dry weight; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
3298271|NCT00469040|Experimental|GW642444M 25mcg|In Cohort 1 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 25 mcg.
3298272|NCT00469040|Experimental|GW642444M 50mcg|Subjects after randomization will receive two inhalations of 25 mcg GW642444M in Cohort 1.
3298273|NCT00469040|Experimental|GW642444M 100mcg|In Cohort 2 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 100 mcg.
3298274|NCT00469040|Experimental|GW642444M 200mcg|Subjects after randomization will receive two inhalations of 100 mcg GW642444M in Cohort 2.
3298275|NCT00469040|Experimental|GW642444M 400mcg|Subjects after randomization will receive two inhalations of 200 mcg GW642444M in Cohort 3.
3298276|NCT00469027|Experimental|eNOS transfected EPCs|eNOS transfected EPCs will be delivered by injection via a PA line, incremental doses over three days
3298277|NCT00469014|Active Comparator|Arm 1: Busulfan + Fludarabine (30 mg/m^2) + Clofarabine|Busulfan 30 mg/m^2 intavenous (IV) Daily + Fludarabine 30 mg/m^2 IV Daily; + Clofarabine 10 mg/m^2 IV Daily
3298278|NCT00469014|Experimental|Arm 2: Busulfan + Fludarabine (20 mg/m^2) + Clofarabine|Busulfan 20 mg/m^2 IV + Fludarabine 20 mg/m^2 IV Daily + Clofarabine 20 mg/m^2 IV Daily
3298279|NCT00469014|Experimental|Arm 3: Busulfan + Fludarabine (10 mg/m^2) + Clofarabine|Busulfan 10 mg/m^2 IV Daily + Fludarabine 10 mg/m^2 IV Daily + Clofarabine 30 mg/m^2 IV Daily
3298280|NCT00469014|Experimental|Arm 4: Busulfan + Clofarabine|Busulfan 40 mg/m^2 IV Daily + Clofarabine 40 mg/m^2 IV Daily
3298281|NCT00468949||1|Patients undergoing excision surgery for their dupuytren's contracture
3298282|NCT00468949||2|Patients not undergoing surgery for their excision surgery
3298283|NCT00468936|No Intervention|1|Usual medications (Cellcept)
3298284|NCT00468936|Active Comparator|2|Patients taking Myfortic
3298285|NCT00468923|Placebo Comparator|Rosuvastatin|Rosuvastatin 10 mg vs placebo
3298286|NCT00468923|Placebo Comparator|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 mg vs placebo
3298287|NCT00468910|Experimental|Arm I|Patients receive oral acetylsalicylic acid (aspirin) once daily.
3298288|NCT00468910|Placebo Comparator|Arm II|Patients receive oral placebo once daily.
3298334|NCT00468468|Experimental|CHESS Condition|Subjects who receive the CHESS (Comprehensive Health Enhancement Support System)
3298289|NCT00468897|Experimental|Treatment Arm AB|A will be a single tablet RSG XR 8 milligram (mg) manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm AB subject will receive A regimen in Period 1 and B regimen in Period 2.There will be wash-out period of 5 days between doses.
3298290|NCT00468897|Experimental|Treatment Arm BA|A will be a single tablet RSG XR 8 mg manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm BA subject will receive B regimen in Period 1 and A regimen in Period 2. There will be wash-out period of 5 days between doses.
3298291|NCT00468871|Experimental|Fluocinolone acetonide|Intravitreal fluocinolone acetonide implant
3298292|NCT00468871|Active Comparator|Standard care|Standard of Care
3298293|NCT00468858|Experimental|T-DEN-Post-Transfection F17|Post-Transfection F17, full dose
3298294|NCT00468858|Experimental|T-DEN-Post-Transfection F19|Post-Transfection F19, full dose
3298295|NCT00468858|Placebo Comparator|Placebo|Control
3298296|NCT00468845|Experimental|1|
3298297|NCT00468845|Experimental|2|
3298298|NCT00468845|Placebo Comparator|3|
3298299|NCT00468832||Ongoing Duchenne Muscular Dystrophy (DMD) Cohort|340 patients currently enrolled participants with DMD.
3298300|NCT00468832||New Young Duchenne Muscular Dystrophy (DMD) Cohort|Additional 100 confirmed DMD participants aged 4-7 years old to be recruited.
3298301|NCT00468832||Typically Developing Control Cohort|Up to 370 typically developing male children and adults aged 6-30 years old to be recruited.
3298302|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 2 to 6 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
3298303|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 7 to 11 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
3298304|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 12 to 17 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
3298305|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 2 to 17 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
3298306|NCT00468793|Active Comparator|2|Fluid therapy guided by blood pressure and urine production
3298307|NCT00468793|Experimental|1|ScvO2 guided fluid therapy
3298308|NCT00468767|Experimental|1|Atrial fibrillation (AF) duration of 3 hours to 7 days.
3298309|NCT00468767|Experimental|2|AF duration of >7 days to <45 days
3298310|NCT00468754|Experimental|A|
3298311|NCT00468754|Experimental|B|
3298312|NCT00468741|No Intervention|1|subjects receive internet access and computer
3298313|NCT00468741|Experimental|2|CHESS informational services only
3298314|NCT00468741|Experimental|3|CHESS social support and informational services
3298315|NCT00468741|Experimental|4|Full CHESS
3298316|NCT00468728|Active Comparator|1|Vancomycin
3298317|NCT00468728|Experimental|2|PAR-101/OPT-80
3298318|NCT00468715|Experimental|bicalutamide|This is a multicenter, open-label, phase II study to evaluate the antitumor activity and safety of bicalutamide administered orally daily to patients with ER(-)/PR(-)/AR(+) metastatic breast cancer. Eligible patients who have consented to trial participation will receive bicalutamide at a dose of 150mg PO daily.
3298319|NCT00468676|Active Comparator|B|Treatment as usual
3298320|NCT00468676|Experimental|A|Case management intervention
3298321|NCT00468650|Active Comparator|Open label|Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive Patrex® 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to Patrex® 100 mg PRN for the following four weeks.
3298322|NCT00468611|Experimental|1|
3298323|NCT00468611|Placebo Comparator|2|
3298324|NCT00468585|Experimental|1 Capecitabine and Bevacizumab|The Phase II trial has a Simon mini-max two-stage design. Twenty-seven patients will be enrolled to the first stage of the Phase II trial, with a target accrual of 40 patients. The treatment dose of capecitabine as determined in the Phase I portion of this trial will be administered orally in two divided doses daily on Days 1 through 7 and Days 15 through 21 in a 28 day cycle. Phase II patients will receive bevacizumab 10 mg/kg intravenously every 2 weeks concurrently with oral capecitabine. Patients will be evaluated for toxicity between Days 3 to 5 (complete blood count only), Day 8, Day 15, and Day 22 during cycle #1. Thereafter, toxicity will be assessed on Days 1 and 15. Efficacy will be assessed with every other week physical examination and radiographic scans of measurable disease every 12 weeks.
3298325|NCT00468572|Experimental|1|Participants will receive treatment with affectionate writing
3298326|NCT00468572|Active Comparator|2|Participants will receive treatment with meaningless writing
3298327|NCT00468559|Experimental|Open Label Esomeprazole|This is an open label, run-in phase. All patients received Esomeprazole.
3298328|NCT00468559|Experimental|Double Blind Esomeprazole|This is the double blind withdrawal phase. Patients are randomized to active drug or placebo.
3298329|NCT00468559|Placebo Comparator|Double Blind Placebo|This is the double blind withdrawal phase. Patients are randomized to active drug or placebo.
3298330|NCT00468546|Placebo Comparator|Placebo Plus Methotrexate|Participants will be administered placebo by intravenous infusion on Days 1 and 15 along with MTX 10-25 mg per os (p.o.) or parenterally once a week up to 24 weeks and will be followed up to Week 104.
3298331|NCT00468546|Experimental|Rituximab plus Methotrexate|Participants will be administered rituximab 1000 mg as intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to Week 24 and will be followed up to Week 104.
3298332|NCT00468481|Experimental|Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)|1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks
3298333|NCT00468481|Active Comparator|Drospirenone (DRSP)/Ethinylestradiol (EE)|1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks
3298385|NCT00467974|Experimental|1|TEA with LEM
3298335|NCT00468468|Experimental|Mentor Condition|Subjects who receive access to a Human Cancer Mentor only
3298336|NCT00468468|Experimental|CHESS + Mentor|Subjects who receive the CHESS system plus a Human Cancer Mentor
3298337|NCT00468468|No Intervention|Internet Only|Subjects receive routine care and nothing else
3298338|NCT00468442|Experimental|Allogeneic Pancreatic Islet Cells|Participants will receive up to three islet transplants and maintenance immunosuppressive therapy.
3298339|NCT00468403|Experimental|Allogeneic Pancreatic Islet Cells|Participants will receive up to three islet transplantations and continuous immunosuppressive therapy including belatacept
3298340|NCT00468338||BIS monitor used for all subjects|BIS monitor applied to all subjects
3298341|NCT00468325|Active Comparator|Multi-slice Computed Tomography|Patients admitted to the ED with chest pain and/or anginal equivalent symptoms are randomized to a multi-slice computed tomography arm where they will receive a CT scan of their heart.
3298342|NCT00468325|Active Comparator|Standard of Care|Patients admitted to the ED with chest pain and/or anginal equivalent symptoms are randomized to the Standard of Care arm and receive rest-stress nuclear myocardial perfusion imaging test.
3298343|NCT00468312|Experimental|Mometasone Furoate Nasal Spray (MFNS)|200 mcg daily
3298344|NCT00468312|Placebo Comparator|Placebo|Two sprays in each nostril in the morning
3298345|NCT00468299|Active Comparator|Misoprostol and placebo|Women in this arm receive placebo and misoprostol 800 mcg buccally
3298346|NCT00468299|Experimental|Mifepristone and misoprostol|Womwn in this group receive mifepristone 200 mg orally and misoprostol 800 mcg buccally
3298347|NCT00468286|Experimental|A|Treatment group A: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months.
3298348|NCT00468286|Experimental|B|Treatment group B: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months.
3298349|NCT00468273|Experimental|Intravenous Immune Globulin|Subjects with primary humoral immunodeficiency
3298350|NCT00468247|Active Comparator|1|Device , Navigator used for guiding haemodynamic care
3298351|NCT00468247|Placebo Comparator|2|Conventional care
3298352|NCT00468208|Experimental|1|Participants will receive abatacept intravenously at study visits on Days 1, 15, and 29, and then once a month thereafter.
3298353|NCT00468182||1|MS patients or patients with CIS (Clinically isolated syndrome) who decided to be treated with IFN-beta for 3 months (with the option to continue Rx)
3298354|NCT00468182||2|MS patients or patients with CIS(Clinically isolated syndrome)who decided to postpone the treatment with IFN-beta
3298355|NCT00468169|Experimental|1|The chemotherapy with radiation will consist of a combination of two drugs, cisplatin and cetuximab
3298356|NCT00468169|Experimental|2|The chemotherapy with radiation will consist of 5-FU, hydroxyurea and cetuximab
3298357|NCT00468156|Active Comparator|1|written materials only
3298358|NCT00468156|Experimental|2|written materials plus asked to form implementation intentions
3298359|NCT00468156|Experimental|3|same as arm 2 plus telephone support
3298360|NCT00468143|Experimental|Adderall Extended Release First|This group was treated with Adderall extended release, either during phase 2 of the trial, or during phase 3 (this subset received Adderall immediate release during phase 2 and then underwent a washout period). This was a counterbalanced crossover study, with a washout period in between treatment periods. Participants were randomized in a 1:1 ratio to one of two schedules Adderall IR followed by Adderall XR, or Adderall XR followed by Adderall IR.
3298361|NCT00468143|Experimental|Adderall Immediate Release First|This group was treated with Adderall immediate release, either during phase 2 of the trial, or during phase 3 (this subset received Adderall extended release during phase 2 and then underwent a washout period). This was a counterbalanced crossover study, with a washout period in between treatment periods. Participants were randomized in a 1:1 ratio to one of two schedules Adderall IR followed by Adderall XR, or Adderall XR followed by Adderall IR.
3298362|NCT00468130|Experimental|Aripiprazole|Subjects in the experimental group will receive Aripiprazole
3298363|NCT00468130|Placebo Comparator|Placebo|Subjects in the control group will receive placebo
3298364|NCT00468117|Experimental|Islet transplantation|Up to three separate islet transplants will occur and a regimen of immunosuppressive medications consisting of antithymocyte globulin (ATG) and etanercept throughout study.
3298365|NCT00468104|Active Comparator|Alteplase, Placebo- intapleural instillation|Either 25 mg of Alteplase or Placebo instilled daily. Response to therapy after three days. cross over to the other drug if no response was noted.
3298366|NCT00468104|Active Comparator|Placebo, Alteplase -2nd arm|If the first arm fails then the 2nd arm ( cross over to either Placebo or Alteplase not used in the first arm) instilled intrapleurally daily for three days
3298367|NCT00468091|Placebo Comparator|saline-saline|"saline IV~+ saline IV"
3298368|NCT00468091|Active Comparator|saline-exendin(9-39)amide|"saline IV~+ exendin(9-39)amide IV"
3298369|NCT00468091|Active Comparator|saline-atropine|"saline IV~+ atropine IV"
3298370|NCT00468091|Active Comparator|exendin(9-39)amide-atropine|"exendin(9-39)amide IV~+ atropine IV"
3298371|NCT00468078|Experimental|A|Parkinson's disease
3298372|NCT00468078|Active Comparator|B|ET+Normal
3298373|NCT00468065|Experimental|A|TO use Veinviewer to improve the effectiveness of IV starts in children
3298374|NCT00468065|No Intervention|B|Standard approach to placing IV s in children
3298375|NCT00468052|Active Comparator|fentanyl|fentanyl bolus 1ug.kg-1
3298376|NCT00468052|Experimental|dexmedetomidine|dexmedetomidine 2ug.kg-1 over 10 min followed by 0.7ug.kg-1.h-1
3298377|NCT00468039|Experimental|vildagliptin + metformin|
3298378|NCT00468013|Experimental|1|Computer-based exercises to be executed at home.
3298379|NCT00468013|Sham Comparator|2|Computer-based exercises to be executed at home.
3298380|NCT00468000|Experimental|Ixmyelocel-T|The treatment arm of the study will receive injections of the study cellular product.
3298381|NCT00468000|Placebo Comparator|Placebo|The control arm of the study will receive placebo injections.
3298382|NCT00467987|Experimental|androgel|androgel
3298383|NCT00467987|Placebo Comparator|placebo|placebo gel
3298384|NCT00467987|No Intervention|no treatment|eugonadal comparison arm
3298387|NCT00467961|Experimental|Miltenyi system transplant recipients|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach. Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. Determine appropriate level of post transplant immunosuppression
3298388|NCT00467896|Experimental|Iloprost|The study enrolled patients who were already using iloprost (10 µg/mL) standard dose (5 µg) delivered by I-neb® Adaptive Aerosol Delivery (AAD) System with Power Disc-6 (PD-6) without any safety or tolerability concerns, thereby facilitating a direct comparison with the Power Disc-15 (PD-15). The single arm design allowed each patient to serve as his/her own control.
3298389|NCT00467883|Experimental|amphotericin B|Treatment with high dosage of amphotericin B liposomal 10 mg/kg/day during 4 weeks
3298390|NCT00467870|Experimental|1|750 mg dose of testosterone undecanoate
3298391|NCT00467870|Experimental|2|1000 mg dose testosterone undecanoate
3298392|NCT00467857|Active Comparator|InteguSeal* and standard surgical preparation solutions|InteguSeal* microbial skin sealant was applied to surgical sites prior to incision after standard surgical skin preparation in patients undergoing coronary artery bypass graft (CABG) surgery
3298393|NCT00467857|Other|Standard surgical skin preparation alone|Prior to incision, standard surgical skin preparation in patients undergoing coronary artery bypass graft (CABG) surgery
3298394|NCT00467844|Experimental|1|1 mg GTx-024
3298395|NCT00467844|Experimental|2|3 mg GTx-024
3298396|NCT00467844|Placebo Comparator|3|Placebo
3298397|NCT00467831|Experimental|Multi-Drug Regimen|Losartan, 25 mg by mouth every night at bedtime; Zileuton, 1200 mg by mouth twice daily; N-acetylcysteine, 600 mg by mouth three times daily; Pravastatin, 20 mg by mouth every night at bedtime; Erythromycin, 333 mg by mouth three times daily.
3298398|NCT00467818|Experimental|Omega 3 fatty Acids|Omega 3 Fatty acids will be dispensed to subjects in the active experimental group of the study.
3298399|NCT00467818|Placebo Comparator|Placebo|The placebo will be dispensed to subjects in the control group
3298400|NCT00467779|Experimental|Stage 1: Cobimetinib Dose Escalation (21/7 Schedule)|Participants will receive cobimetinib (GDC-0973/XL518) at the starting dose of 0.05 mg/kg via solution or capsule, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment [21/7 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
3298401|NCT00467779|Experimental|Stage 1A: Cobimetinib Dose Escalation (14/14 Schedule)|Participants will receive cobimetinib at the starting dose of 60 mg via solution or capsule, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment [14/14 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
3298402|NCT00467779|Experimental|Stage 2: Cobimetinib Expansion (21/7 Schedule)|Participants will receive cobimetinib at the maximum tolerated dose (MTD) established in Stage 1, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment [21/7 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
3298403|NCT00467779|Experimental|Stage 2 A: Cobimetinib Expansion (14/14 Schedule)|Participants will receive cobimetinib at the MTD established in Stage 1A, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment [14/14 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
3298404|NCT00467779|Experimental|Stage 3: Cobimetinib+Midazolam+Dextromethorphan|Participants will receive a single dose of midazolam (2 mg of midazolam syrup) and dextromethorphan (30 mg tablet) on Cycle 1 Day 1, in the absence of cobimetinib. After a 2-day washout period, participants will receive 21 consecutive daily doses of cobimetinib (60-mg) followed by a 7-day washout period. Participants will receive another single dose of midazolam and dextromethorphan on Cycle 1 Day 15, in the presence of steady-state cobimetinib concentrations. In Cycle 2 and beyond participants will receive cobimetinib alone, administered as a 60-mg daily dose for 21 consecutive days in 28-day cycles (21/7 schedule).
3298405|NCT00467753|Experimental|Oxcarbazepine|Oxcarbazepine is the active drug to be given to subjects in the experimental arm
3298406|NCT00467753|Placebo Comparator|Sugar Pill|Patients are given either active or inactive intervention.
3298407|NCT00467727|Experimental|1|Phase Contrast Mammography Exam
3298408|NCT00467714|No Intervention|1|2.5 cm Cartilage as columella strut
3298409|NCT00467688|No Intervention|A,1|Real time access to current measured glucose values; hyperglycemic or hypoglycemic alerts
3298410|NCT00467688|No Intervention|A,2|Retrospective analysis of glucose values
3298411|NCT00467649|Experimental|Group A|
3298412|NCT00467649|Active Comparator|Group B|
3298413|NCT00467636|Experimental|Insulin Glulisine|Blood glucose monitoring and treatment of hyperglycaemia with insulin. Insulin to be with-held if pre meal blood glucose < 4 mmol/l.
3298414|NCT00467636|Active Comparator|2|Blood glucose monitoring for comparison with treatment arm (1)
3298415|NCT00467610|Experimental|Panhematin|
3298416|NCT00467597||Group 1|
3298417|NCT00467584|Active Comparator|High Dose Aspirin|High Dose Aspirin; 1300 milligrams of aspirin per day, taken by mouth as two tablets, twice per day for 8 weeks
3298418|NCT00467584|Active Comparator|Low Dose Aspirin|Low Dose Aspirin; 162 milligrams of aspirin per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
3298419|NCT00467584|Placebo Comparator|Placebo|Placebo tablets, matching the active aspirin tablets in appearance, taken by mouth twice per day for 8 weeks
3298420|NCT00467571|Experimental|I|Drug: lansoprazole, clarithromycin, amoxycillin
3298421|NCT00467558|Active Comparator|Naltrexone|Naltrexone 50mg-150mg by mouth per day.
3298422|NCT00467558|Placebo Comparator|Placebo|Placebo pills (1-3 pills daily) depending upon dose prescribed by study physician
3298423|NCT00467519|Experimental|Group 1|DAPTACEL primed participants
3298424|NCT00467519|Experimental|Group 2|Pentacel primed participants
3298425|NCT00467493|Experimental|Anastrozole - A|Treatment for 26 consecutive days
3298426|NCT00467493|Experimental|Anastrozole -B|Treatment for 7 consecutive days early in menstrual cycle
3298427|NCT00467493|Experimental|Anastrozoe - C|Treatment for 7 consecutive days mid follicular phase
3298428|NCT00467493|Experimental|Anastrozole - D|Treatment for 7 consecutive days - mid cycle
3298429|NCT00467493|Experimental|Anastrozole - E|Treatment for 7 consecutive days - luteal
3298430|NCT00467493|Placebo Comparator|Anastrozole - F|Treatment with placebo for 26 consecutive days
3298431|NCT00467454|Active Comparator|1|Naltrexone
3298432|NCT00467454|Placebo Comparator|2|Placebo
3298433|NCT00467402|Experimental|1|
3298434|NCT00467402|Experimental|2|
3298435|NCT00467402|Placebo Comparator|3|
3298436|NCT00467389|Experimental|Oral Placebo First|Three days of daily treatment with oral placebo, followed by three days of daily treatment with 5 mg of donepezil
3298437|NCT00467389|Experimental|Donepezil First|Three days of daily treatment with 5 mg of donepezil, followed by three days of daily treatment with oral placebo.
3298438|NCT00467376|Experimental|1|Administration of Insulin Glulisine
3298439|NCT00467376|Active Comparator|2|Administration of Lispro
3298440|NCT00467363|Active Comparator|Aspirin|81mg of low-dose aspirin plus 400micrograms of folic acid.
3298441|NCT00467363|Placebo Comparator|Placebo|400micrograms of folic acid.
3298442|NCT00467350|Active Comparator|enema|
3298443|NCT00467350|Active Comparator|PEG 3350|
3298444|NCT00467298|Experimental|Self-management|Novel intensive self-management education and exercise program of four weeks
3298445|NCT00467298|No Intervention|Usual care|Usual care- cardiac or pulmonary rehabilitation exercise program of 8 weeks duration
3298446|NCT00467285||Group 1|140 subjects with type 2 diabetes on pioglitazone.
3298447|NCT00467285||Group 2|140 subjects with type 2 diabetes not on pioglitazone.
3298448|NCT00467272|Experimental|Daptomycin|Daptomycin 6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria.
3298449|NCT00467259|Placebo Comparator|Placebo|28 cm² Placebo patch
3298450|NCT00467259|Experimental|Testosterone|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
3298451|NCT00467233|Experimental|1|Laser Treatment
3298452|NCT00467233|Experimental|2|Acid peel
3298453|NCT00467220|No Intervention|Control|Subjects will follow all study tasks but will not be required to follow a calorie-restricted meal plan.
3298454|NCT00467220|Other|Alternate Day Fasting Arm|Subjects in this arm will be asked to alternate between one day of eating as they wish versus one day on a calorie-restricted meal plan. Subjects will follow this alternating meal plan for 3 months.
3298455|NCT00467220|Other|Calorie Restriction|Subjects in this arm will be asked to follow a calorie-restricted meal plan, daily, for three months.
3298456|NCT00467207|Active Comparator|BoNT A|Botulinum toxin A injections in muscles of the arm (biceps brachii and brachialis)
3298457|NCT00467207|Experimental|Resistance training|8 weeks resistance training
3298458|NCT00467194|Experimental|Phase I study of rapamycin and bevacizumab|"Rapamycin (available as 1mg per tablet; Wyeth) will be given orally once in the morning before meal. The starting dose of rapamycin will be 1mg administered once daily. All doses of rapamycin will be preceded by an oral loading dose three times the maintenance dose on day 1. The dose of rapamycin will be increased at each dose level.~Bevacizumab (100mg/4ml; Roche) will start concurrently with rapamycin. It will be diluted in a total of 100ml of 0.9% sodium chloride given via intravenous injection. The first dose will be infused over 90 minutes. If the first infusion is tolerated without any adverse infusion-related events (fever and/or chills), the second infusion may be delivered over 60 minutes. If the 60- minute infusion is well tolerated, the subsequent doses may be delivered over 30 minutes."
3298459|NCT00467116|Experimental|Therapeutic Intervention|
3298460|NCT00467103||Chronic Stroke patients with Nonfluent Aphasia|patients with left hemisphere (LH) stroke who have chronic nonfluent aphasia
3298461|NCT00467077|Experimental|Gefitinib and PEG-IFNa Treatment|Gefitinib administered at a dose of 250 mg orally once daily for 12 weeks. PEG-IFNa at 4.0 µg/kg/wk administered subcutaneously once weekly for 6 weeks (cycle repeated once for a total of 2 cycles).
3298462|NCT00467064|Experimental|Arthritis self-management workshop|Comparison of two-week, lay led, scripted self-management workshop emphasizing action planning, problem-solving, and content specific to arthritis.
3298463|NCT00467064|Other|Delayed treatment control|After 4 month delay, participants in Control Group receive Experimental intervention.
3298464|NCT00467051|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously or IV once daily until blood count returns to normal. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
3298465|NCT00467038|Other|Dialectical Behavior Therapy|Dialectical Behavior Therapy
3298466|NCT00467038|No Intervention|Healthy Controls|Healthy controls
3298467|NCT00467025|Experimental|Arm A|
3298468|NCT00467025|Experimental|Arm B|
3298469|NCT00467025|Active Comparator|Arm C|
3298470|NCT00467012|Experimental|step 1|6 enrollment for 1 cycle(4 weeks)
3298471|NCT00467012|Experimental|step 2|114 enrollment through to meet the stopping criteria
3298472|NCT00466999|Active Comparator|surgery|standard surgical treatment (either dilation and curettage or manual vacuum aspiration)
3298473|NCT00466999|Active Comparator|misoprostol|400 mcg misoprostol
3298474|NCT00466973|Active Comparator|Dry bipolar radiofrequency (RF) clamp|used for ablation during surgical procedure
3298475|NCT00466973|Active Comparator|Unipolar microwave antenna|used for ablation during surgical procedure
3298476|NCT00466973|Active Comparator|Unipolar cryothermic probe|used for ablation during surgical procedure
3298477|NCT00466973|Active Comparator|Irrigated unipolar RF antenna|used for ablation during surgical procedure
3298478|NCT00466973|Active Comparator|Irrigated bipolar RF clamp|used for ablation during surgical procedure
3298479|NCT00466973|Active Comparator|Hi-intensity focused ultrasound wand|used for ablation during surgical procedure
3298480|NCT00466960|Experimental|Treatment (colony stimulating factor and chemotherapy)|"INDUCTION THERAPY: Patients receive GM-CSF SC once daily on days 16-26. Patients also receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 14 days after last GM-CSF injection, patients receive GM-CSF SC once daily on days 1-15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3298481|NCT00466947|Experimental|Synflorix Group|Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).
3298482|NCT00466947|Active Comparator|Control Group|Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.
3298483|NCT00466921|Experimental|Lenalidomide|
3298484|NCT00466895|Experimental|Stratum 1 Acute Leukemias|Patients must have a diagnosis of Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia(ALL)according to the WHO (World Health Organization) classification.
3298485|NCT00466895|Experimental|Stratum 2 Chronic lymphocytic leukemia|Patients must have diagnosis of B-Cell, Chronic Lymphocytic Leukemia(CLL) or Small Lymphocytic Leukemia (SLL) (including Waldenstrom's Macroglobulinemia) requiring therapy (see eligibility criteria for definition of this) and have previously received treatment with one or more prior chemotherapy regimens.
3298486|NCT00466882|No Intervention|Group 1 Inamed Lap-Band System|The LAPBAND is positioned laparoscopically around the stomach and requires an overnight hospitalization and an upper GI swallow the next morning. The device can be gradually adjusted to increase stomach constriction by the physician in an office setting so that the patient loses approximately 1-2 pounds per week over two years.
3298487|NCT00466856|Experimental|Sir-Spheres|
3298488|NCT00466843|Experimental|1|Participants will be treated with ATG
3298489|NCT00466817|Experimental|Valganciclovir|Six months of oral Valganciclovir.
3298490|NCT00466817|Placebo Comparator|Placebo|Six weeks of oral Valganciclovir followed by placebo to complete the six month time period.
3298491|NCT00466804||Heart Transplant Recipients|People who will have a heart transplant
3298492|NCT00466791|Active Comparator|Methylphenidate Transdermal System|Transdermal patch, 27.5mg, 41.3mg, 55mg, and 82.5mg, daily for 11 weeks
3298493|NCT00466791|Placebo Comparator|Placebo|Transdermal patch, 0mg, daily for 11 weeks
3298494|NCT00466765|Experimental|Single Arm|Use Brava system for pre-expansion of breast prior to fat grafting
3298495|NCT00466752|Experimental|Treatment (enzyme inhibitor) 48hr stop|Patients receive sorafenib tosylate PO BID on days 1-14. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 days after completion of sorafenib tosylate, patients undergo radical prostatectomy on approximately day 43.
3298496|NCT00466752|Experimental|Treatment (enzyme inhibitor) 24hr stop|tients receive sorafenib tosylate PO BID on days 1-14. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 day after completion of sorafenib tosylate, patients undergo radical prostatectomy on approximately day 43.
3298497|NCT00466687|Experimental|Therapeutic Intervention|"Tarceva and Avastin:~Tarceva: 150mg PO, days 1-28~Avastin: 10mg/kg, IV infusion, days 1,15 Regimen will be repeated every 28 days = 1 course"
3298498|NCT00466674|Experimental|Allogenic Transplant|
3298499|NCT00466661|Experimental|Acamprosate|666 mg p.o. TID
3298500|NCT00466661|Placebo Comparator|Placebo|Matching placebo
3298501|NCT00466622|Experimental|1|Metformin 1000mg x 2 daily. Orally. From Weifa
3298502|NCT00466622|Placebo Comparator|2|Placebo 2 tablets x 2 daily. Orally From Weifa
3298503|NCT00466609|Experimental|Quetiapine (fluoxetine plus quetiapine)|fluoxetine up to 40mg once a day plus Quetiapine up to 200mg once a day, during 12 weeks
3298504|NCT00466609|Active Comparator|Clomipramine (fluoxetine plus clomipramine)|Fluoxetine up to 40mg once a day plus clomipramine up to 75mg once a day, during 12 weeks
3298505|NCT00466609|Placebo Comparator|Placebo (fluoxetine plus placebo)|Fluoxetine up to 80 mg once a day plus placebo 3 pills once a day, during 12 weeks
3298506|NCT00466531|Experimental|Patients with CLL or indolent B-cell lymphoma|The first stage is a standard 3-step phase I dose escalation trial to assess the safety of 19-28z CAR expressing autologous T cells with or without prior conditioning chemotherapy.Step 1, a cohort of pts will receive the lowest planned dose of 19-28z+ modified T cells. Step 2, a cohort of pts will receive cyclophosphamide conditioning chemotherapy followed by the lowest planned dose of 19-28z+ modified T cells. If less than 33% of pts in the cohort experience unanticipated dose-limiting toxicity,Step 3, a cohort of pts will be treated with the investigator's choice conditioning chemotherapy followed by the higher dose of 19-28z+ modified T cells. If less than 33% of pts in the initial cohort (Step 3) experience unanticipated dose-limiting toxicity, the cohort in Step 3 may be expanded to include up to 15 pts. In Step 3, an additional cohort of Waldenstrom's Macroglobulinemia (WM) pts will be treated with the investigator's choice conditioning chemotherapy followed by 19-28z+ T cells.
3298507|NCT00466518|Experimental|1|
3298508|NCT00466505|Experimental|Therapeutic Intervention|
3298509|NCT00466492|Other|No sedatation intervention|The intervention group is the normal care in our institution, the control group is the golden standard
3298510|NCT00466466|Experimental|Daily dosing RAD001|
3298511|NCT00466466|Experimental|Weekly dosing RAD001|
3298512|NCT00466440|Experimental|A|
3298513|NCT00466440|Placebo Comparator|B|
3298514|NCT00466375||A|Patients with a hemangioma.
3298515|NCT00466375||B.|Patients with a vascular anomaly.
3298516|NCT00466323|Experimental|FMPO Condition|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
3298517|NCT00466323|Active Comparator|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
3298518|NCT00466310|Active Comparator|Aripiprazole for 4 weeks|Blood is drawn for baseline. 20 Subjects are randomly assigned to receive Aripiprazole for weeks weeks with a starting dose of 10mg/day and the dose will be titrated to a maximum of 30mg /day based on effectiveness and tolerability. After 4 weeks of treatment, blood will be drawn again for metabolomics.
3298519|NCT00466310|Active Comparator|Risperidone for 4 weeks|Blood will be drawn for baseline evaluation. 20 Subjects will be randomly assigned to receive risperidone at a starting dose of 2mg/day, and can be increased to 6mg/day based on response of the subject. After 4 weeks of medication, blood is drawn again.
3298520|NCT00466310|Other|Healthy volunteers|Fasting blood samples will be drawn from healthy volunteers to match age, race and gender with the research subjects for comparison.
3298521|NCT00466245|Experimental|A|Previously vaccinated for smallpox, 1x10-8 dose
3298522|NCT00466245|Experimental|B|Smallpox vaccine naive, 1x10-8 dose
3298523|NCT00466245|Experimental|C|Previous smallpox vaccination, 1x10-7 dose
3298524|NCT00466245|Experimental|D|Smallpox vaccine naive, 1x10-7 dose
3298525|NCT00466245|Experimental|E|Previous smallpox vaccination, 1x10-6 dose
3298526|NCT00466245|Experimental|F|Smallpox vaccine naive, 1x10-6 dose
3298527|NCT00466245|Experimental|G|Previous smallpox vaccination, placebo dose
3298528|NCT00466245|Experimental|H|Smallpox vaccine naive, placebo dose
3298529|NCT00466232|Experimental|1|Weekly Topetecan in combination with Sorafenib
3298530|NCT00466206|Experimental|3MP - Treatment Arm|Magnetic Mini-Mover Procedure using the Magnimplant and Magnatract
3298531|NCT00466193|Experimental|Zolpidem 3.5mg|
3298532|NCT00466193|Placebo Comparator|Placebo|
3298533|NCT00466167|Other|Pramipexole ER|
3298534|NCT00466167|Other|Pramipexole IR|
3298535|NCT00466167|Placebo Comparator|Placebo|
3298536|NCT00466102|Active Comparator|1|Patients with stable disease after 8 week run in randomized to RAD001 (blinded)
3298537|NCT00466102|Placebo Comparator|2|Patients with stable disease after 8 week run in receive placebo (blinded)
3298538|NCT00466089|Experimental|1|RT + Tarceva
3298539|NCT00466089|No Intervention|2|RT
3298540|NCT00466063||ICL670|ICL670
3298541|NCT00466024|Experimental|1|Health coach and 2 HEPA air cleaners
3298542|NCT00466024|Active Comparator|2|Standard asthma education and 2 HEPA air cleaners
3298543|NCT00466024|Active Comparator|3|Standard asthma education and delayed receipt of 2 HEPA air cleaners
3298544|NCT00465985|Experimental|Part I, Part II-arm1, & Part III|
3298545|NCT00465985|Placebo Comparator|Part II - arm 2|
3298546|NCT00465972|Placebo Comparator|Placebo|Placebo
3298547|NCT00465972|Active Comparator|2|Doxepin
3298548|NCT00465972|Active Comparator|3|Temazepam
3298549|NCT00465959|Experimental|400 mg TrIP|
3298550|NCT00465959|Experimental|800 mg TrIP|
3298551|NCT00465959|Placebo Comparator|Placebo|
3298552|NCT00465894|Active Comparator|Extended Release Tolterodine|
3298553|NCT00465894|Active Comparator|Intra Vaginal Estradiol Cream|
3298554|NCT00465855|Active Comparator|Hyperbaric Oxygen (HBO2) - 3 sessions|Subjects undergo 3 hyperbaric oxygen sessions within 24 hours following carbon monoxide poisoning.
3298555|NCT00465855|Sham Comparator|Hyperbaric Oxygen (HBO2) - 1 session|Subjects undergo 1 hyperbaric oxygen session and then 2 sham chamber sessions within 24 hours of carbon monoxide poisoning.
3298556|NCT00465816|Experimental|Nimenrix + Twinrix Group|Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.
3298557|NCT00465816|Active Comparator|Nimenrix Group|Subjects received 1 dose of Nimenrix™ vaccine at Month 0.
3298558|NCT00465816|Active Comparator|Twinrix Group|Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.
3298559|NCT00465803|Other|DuoTrav|One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months, as recorded by dosing aid
3298560|NCT00465803|Other|Travatan/Timolol|One drop Timolol in the study eye(s) once daily at 8 AM; one drop of Travatan in the study eye(s) once daily at 8 PM. Both products dosed for twelve months, as recorded by separate dosing aid for each product.
3298561|NCT00465764|Experimental|Protein formula|Feed as per HCP direction
3298562|NCT00465764|Active Comparator|Standard infant formula|Feed as per HCP instructions
3298563|NCT00465751|Active Comparator|A|chenodeoxycholic acid treatment
3298564|NCT00465751|Placebo Comparator|B|placebo treatment
3298565|NCT00465738|Experimental|incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 5.0 mL of sterile sodium chloride [NaCl] 0.9% solution without preservatives. Dilution with 5.0 mL resulted in a dose of 20 units per 1.0 mL."
3298566|NCT00465738|Active Comparator|incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 mL sterile of NaCl 0.9% solution without preservatives. Dilution with 2.0 mL resulted in a dose of 50 units per 1.0 mL."
3298567|NCT00465725|Experimental|1|two-period crossover, open label study in which a single dose (Cycle 1) of picoplatin will be given either IV or PO, followed 4 weeks later by a single dose (Cycle 2) of picoplatin given by the route not used for Cycle 1. Subjects subsequently may continue to receive IV picoplatin commencing with Cycle 3 in a Continuation Study.
3298568|NCT00465712|Experimental|A|Transabdominal amnioinfusion performed before external cephalic version
3298569|NCT00465712|No Intervention|V|Without transabdominal amnioinfusion
3298570|NCT00465686|Experimental|A|
3298571|NCT00465647|Experimental|≥ 28 Days to < 13 Months|infant and toddler
3298572|NCT00465647|Experimental|≥ 13 months to < 5 years|young child
3298573|NCT00465647|Experimental|≥ 5 years to < 12 years|older child
3298574|NCT00465647|Experimental|≥ 12 years to < 17 years|adolescent
3298576|NCT00465595|Experimental|Low Dose First, High Dose Second|The Low-Dose-1st Group received the low dose of psilocybin on the first session and the high dose on the second session
3298577|NCT00465595|Experimental|High Dose First, Low Dose Second|The High-Dose-1st Group received the high dose of psilocybin on the first session and the low dose on the second session
3298578|NCT00465569|Experimental|Active Treatment|Pre-measured doses of dry, nonfat powered milk prepared by the clinical research-registered dieticians
3298579|NCT00465569|Placebo Comparator|Placebo|
3298580|NCT00465556|Experimental|1|Dove Intervention
3298581|NCT00465556|Active Comparator|2|Intimate Partner Violence (IPV) Protocol
3298582|NCT00465543|Placebo Comparator|II|Arm 2 receives 4 weeks of placebo mint tea (consumed twice a day) followed by 4 weeks of washout and then a further 4 weeks of treatment with study mint tea (consumed twice a day).
3298583|NCT00465543|Placebo Comparator|I|Arm 1 receives 4 weeks of treatment with mint tea high in rosmarinic acid, consumed twice a day. Treatment is followed by a 4 week wash-out phase. Subjects then enter a 4 week phase of placebo mint tea (low in rosmarinic acid), to be consumed twice a day.
3298584|NCT00465530|Experimental|2|Saline plus Gentamycin
3298585|NCT00465530|Placebo Comparator|1|Saline
3298586|NCT00465517|Experimental|ganaxolone|
3298587|NCT00465517|Placebo Comparator|non-active drug|
3298588|NCT00465491|Experimental|1|Picoplatin
3298589|NCT00465491|Other|2|BSC
3298590|NCT00465465|Active Comparator|1|Dose of 1 x 10^7
3298591|NCT00465465|Active Comparator|2|Dose of 1 x 10^8
3298592|NCT00465426||1|HIV Positive men and women 18-65 years of age
3298593|NCT00465426||2|HIV negative men and women 18-65 years of age
3298594|NCT00465361|No Intervention|Baseline Performance|Observation of baseline performance
3298595|NCT00465361|Experimental|Post-intervention Performance|Observation of performance post-intervention
3298596|NCT00466388|Experimental|Cevimeline|Evoxac tid for xerostomia
3298597|NCT00466388|Placebo Comparator|Placebo|sugar pill
3298598|NCT00465283|Active Comparator|Donepezil|
3298599|NCT00465283|Placebo Comparator|placebo|
3298600|NCT00465270|Experimental|Device|AMPLATZER PFO Occluder
3298601|NCT00465270|Active Comparator|Standard or Care - Medical Management|Medical treatment with Aspirin alone, Coumadin alone, Clopidogrel alone, or Aspirin combined with dipyridamole.
3298602|NCT00465244|Experimental|1|Levetiracetam 1 g IV + Lorazepam 2 mg IV
3298603|NCT00465244|Other|2|Placebo + Lorazepam 3 mg IV
3298604|NCT00465231|Active Comparator|1|Epidural
3298605|NCT00465231|Placebo Comparator|2|Epidural - saline solution
3298606|NCT00465218||1|High dose aspirin (325 mg)
3298607|NCT00465218||2|Low dose aspirin (81 mgs) plus warfarin
3298608|NCT00465205|Experimental|I|
3298609|NCT00465179|Experimental|Sunitinib Malate|Sunitinib Malate 50 mg by mouth daily for 4 weeks, then 2 weeks off.
3298610|NCT00465166||1|Patients who had a documented, accidental dural puncture during placement of their labor epidural.
3298611|NCT00465153|Experimental|1|Flax oil
3298612|NCT00465153|Placebo Comparator|2|corn oil
3298613|NCT00465101|Other|GreenLight HPS|
3298614|NCT00465088|Experimental|1|
3298615|NCT00465088|Experimental|2|
3298616|NCT00465049|Experimental|primary closure|suture after I&D
3298617|NCT00465049|Placebo Comparator|SECONDARY CLOSURE|LEAVE TO HEAL BY SECONDARY INTENTIN AFTER I&D
3298618|NCT00465023|Experimental|Proton Beam Radiation|Proton radiation therapy
3298619|NCT00464984|Active Comparator|ILI-group|Intensive lifestyle intervention at a tertiary care rehabilitation center. Treatment included changes in both dietary habits (calori restriction) and physical activity with particularly high intensity the first 3 months.
3298620|NCT00464984|Active Comparator|MLI|Moderate lifestyle intervention at a secondary care outpatient center. Treatment included moderate changes in dietary habits (calori restriction) and physical activity.
3298621|NCT00464958|Experimental|Sublingual tizanidine|Once nightly dosing of 12 mg sublingual tizanidine tablet
3298622|NCT00464945|Experimental|1|
3298623|NCT00464945|Active Comparator|2|
3298624|NCT00464919|Experimental|A|
3298625|NCT00464893|Active Comparator|catumaxomab arm|Patients will get first the chemotherapeutic regimen (Epirubicin, Cisplatin and Capecitabine or 5-Fluorouracil) consisting of three 21-day cycles, starting on the weeks 1, 4 and 7. Four weeks after CTx the D2 surgery will take place. Treatment with catumaxomab will consist of an initial dose of 10µg given intraoperatively as in intraperitoneal bolus and of four postoperative ascending doses.
3298626|NCT00464841|Experimental|1|Tsui test for combined spinal-epidural
3298627|NCT00464841|Experimental|2|Tsui test for intrathecal catheter
3298628|NCT00464815|Experimental|Group A|Subjects of 11-17 years of age who will receive GSK134612
3298629|NCT00464815|Active Comparator|Group B|Subjects of 11-17 years of age who will receive MencevaxTM ACWY
3298630|NCT00464776|Experimental|1|Various sequences of 3 doses of Aliskiren plus placebo
3298631|NCT00464776|Experimental|2|Various sequences of 3 doses of Aliskiren plus placebo
3298632|NCT00464776|Experimental|3|Various sequences of 3 doses of Aliskiren plus placebo
3298633|NCT00464776|Experimental|4|Various sequences of 3 doses of Aliskiren plus placebo
3298634|NCT00464763|Experimental|Dexmedetomidine|
3298635|NCT00464763|Placebo Comparator|Placebo (PBO)|
3298636|NCT00464737|Placebo Comparator|Placebo|Placebo
3298637|NCT00464737|Experimental|Rotigotine 4 mg|4 mg/24 hrs
3298638|NCT00464737|Experimental|Rotigotine 8 mg|8 mg/24 hrs
3298639|NCT00464724|Experimental|3T MRSI Prostate|3T Magnetic Resonance Spectroscopic Imaging
3298640|NCT00464711|Other|Escitalopram|single arm
3298641|NCT00464698|Experimental|All Study Participants|Duloxetine 30mg: Dose level 1 (Week 1) Duloxetine 60mg: Dose level 2 (Wks 2-4) Duloxetine 120mg: Dose level 3 (Wks 3-7)
3298642|NCT00464685|Experimental|700 µg Dexamethasone Implant and Laser Photocoagulation|Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
3298643|NCT00464685|Sham Comparator|Sham Implant and Laser Photocoagulation|Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
3298644|NCT00464672|Experimental|Influenza virus vaccine|
3298645|NCT00464672|Active Comparator|Comparator influenza vaccine|
3298646|NCT00464659|Experimental|Effective CPAP treatment|Effective Continuous Positive Airway Pressure treatment (CPAP) applied for 6 weeks
3298647|NCT00464659|Sham Comparator|Sham CPAP treatment|Ineffective Continuous Positive Airway Pressure treatment (sham CPAP) applied for 6 weeks
3298648|NCT00464646|Experimental|1|"Cohort A: Women with unresected locally advanced breast cancer (clinical Stage IIIA, IIIB, and IIIC)~Cohort B: Women with resected pN2 or pN3 (pathologic Stage III) breast cancer"
3298649|NCT00464633|Experimental|Alvocidib|Cycles with 4-week treatment with alvocidib followed by 2-week rest period for up to a maximum of 6 cycles
3298650|NCT00464620|Experimental|Dasatinib, 70 mg, twice daily|Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
3298651|NCT00464555|Experimental|Islet Transfusion and LSF|Participants assigned to this group will receive an islet transfusion and an immunosuppressive medication regimen containing LSF.
3298652|NCT00464542|Other|Metronidazole|Observational before and after treatment Drug: Metronidazole 500 mg, taken by mouth, two times a day, 7 days
3298653|NCT00464516|Experimental|estetrol|
3298654|NCT00464516|Placebo Comparator|placebo|
3298655|NCT00464490|No Intervention|Standard Hospital Ventilation Weaning Protocol|Control. Hospital weaning protocol
3298656|NCT00464490|Experimental|Dexmedetomidine for Extubation|Dexmedomidine infusion to facilitate extubation
3298657|NCT00464464|Active Comparator|1|cognitive-behavioral therapy
3298658|NCT00464464|No Intervention|2|standard medical care
3298659|NCT00464451|Experimental|1|Dexmedetomidine sedated pediatric patients undergoing EEG study.
3298660|NCT00464451|Active Comparator|2|Chloral hydrate sedated pediatric patients undergoing sedated EEG study.
3298661|NCT00464438|Experimental|1|
3298662|NCT00464438|Active Comparator|2|
3298663|NCT00464425|Experimental|Electroacupuncture (EA)|EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles
3298664|NCT00464425|Sham Comparator|Sham Acupuncture (SA)|Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used
3298665|NCT00464425|No Intervention|No Acupuncture (NA)|Control
3298666|NCT00464386|No Intervention|POC Glucose Testing|Hourly blood glucose monitoring with point of care glucometer (i.e., current standard of care).
3298667|NCT00464386|Experimental|Continuous Glucose Monitoring|Continuous arterial glucose monitoring with Guardian sensor + hourly blood glucose monitoring with point of care glucometer (i.e., current standard of care).
3298668|NCT00464373|Experimental|1|Botulinum Toxin Type A 200 U in 4ml NaCl 0.9%
3298669|NCT00464373|Placebo Comparator|2|4ml NaCl 0.9%
3298670|NCT00464334|Experimental|Placebo to V950/IMX 0 mcg|Participants receive Placebo to V950/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3298671|NCT00464334|Experimental|Placebo to V950/IMX 16 mcg|Participants receive Placebo to V950/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3298672|NCT00464334|Experimental|V950 0.5 mcg/IMX 0 mcg|Participants receive V950 0.5 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3298673|NCT00464334|Experimental|V950 0.5 mcg/IMX 16 mcg|Participants receive V950 0.5 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3298674|NCT00464334|Experimental|V950 0.5 mcg/IMX 47 mcg|Participants receive V950 0.5 mcg/IMX 47 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3298675|NCT00464334|Experimental|V950 0.5 mcg/IMX 94 mcg|Participants receive V950 0.5 mcg/IMX 94 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3298676|NCT00464334|Experimental|V950 5 mcg/IMX 0 mcg|Participants receive V950 5 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3298677|NCT00464334|Experimental|V950 5 mcg/IMX 16 mcg|Participants receive V950 5 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3298678|NCT00464334|Experimental|V950 5 mcg/IMX 47 mcg|Participants receive V950 5 mcg/IMX 47 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3298679|NCT00464334|Experimental|V950 50 mcg/IMX 0 mcg|Participants receive V950 50 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3298680|NCT00464334|Experimental|V950 50 mcg/IMX 16 mcg|Participants receive V950 50 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3298681|NCT00464321|Experimental|Cohort A|Dose Group
3298682|NCT00464321|Experimental|Cohort B|Dose Group
3298683|NCT00464321|Experimental|Cohort C|Dose Group
3298684|NCT00464321|Experimental|Cohort D|Dose Group
3298685|NCT00464308|Active Comparator|001|Esomeprazole 40mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
3298686|NCT00464308|Active Comparator|002|Esomeprazole 20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
3298687|NCT00464308|Active Comparator|003|Rabeprazole 20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
3298688|NCT00464269|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period.
3298689|NCT00464269|Experimental|Brivaracetam 5 mg/day|Brivaracetam 5 mg/day, 2.5 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 5 mg /day in a double-blinded way for the 12-week Treatment Period.
3298690|NCT00464269|Experimental|BRV 20mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period.
3298691|NCT00464269|Experimental|BRV 50mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day, in a double-blinded way for the 12-week Treatment Period.
3298692|NCT00464243|Experimental|Volinanserin|2 mg volinanserin tablets orally once daily
3298693|NCT00464243|Placebo Comparator|Placebo|tablets orally once daily
3298694|NCT00464204|Experimental|Voluven® Arm|
3298695|NCT00464204|Active Comparator|0.9 % NaCl|
3298696|NCT00464178|Experimental|Bortezomilb and bevacizumab|Bortezomilb will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
3298697|NCT00464139||1|"The electronic files of all patients who consulted the LUFC since 2003 were searched to select women with at least 1 year of infertility, a regular cycle (variation 21 - 35 days), whose partner had normal sperm according to World Health Organization (WHO) criteria (n = 304).~After exclusion of 83 (27,3%) patients with a previous laparoscopic diagnosis of endometriosis before referral to our centre, 221 (72,7%) infertile women were included in our study."
3298698|NCT00464126|Active Comparator|Colloid|5% albumin for volume resuscitation
3298699|NCT00464126|Placebo Comparator|Crystalloid|Saline for volume resuscitation
3298700|NCT00464113|Experimental|1|once-weekly dosing
3298701|NCT00464113|Experimental|2|twice-weekly dosing
3298702|NCT00464087|Active Comparator|Heparin|Patients are switched from fondaparinux to heparin, receiving a dose of 60 U/Kg IV during the PCI
3298703|NCT00464087|Active Comparator|Bivalirudin|Patients switched from fondaparinux to bivalirudin, received a bolus of 0.75 mg/kg IV followed by infusion of 1.75 mg/g per hour infusion during the PCI.
3298704|NCT00464061|Experimental|Volinanserin|
3298705|NCT00464061|Placebo Comparator|Placebo|
3298706|NCT00464009|Active Comparator|A|Group A practices (n=39) received didactic training and course materials in oral health screening, referral, counseling and application of fluoride varnish.
3298707|NCT00464009|Active Comparator|B|Group B practices (n=41) received the same as Group A and were offered weekly conference calls providing advice and support.
3298708|NCT00464009|Active Comparator|C|Group C practices (n=41) received the same as Group B and were also offered in-office follow-up visits providing hands-on advice and support.
3298709|NCT00463983|Experimental|octreotide|octreotide SR 30 mg intra muscularly every 4 weeks
3298710|NCT00463970|Active Comparator|1|Brief Intervention
3298711|NCT00463970|Experimental|2|Cognitive Behavioural Therapy
3298712|NCT00463970|Experimental|3|Seal oil
3298713|NCT00463970|Placebo Comparator|4|Soy oil
3298714|NCT00463905|No Intervention|1|Current management for identifying postmenopausal women with osteoporotic vertebral fractures in primary care i.e. nothing
3298715|NCT00463905|Experimental|2|Intervention arm: simple clinical assessment to identify high risk 30% (approximately) who will then be offered lateral thoraco-lumbar X-rays
3298716|NCT00463853|Experimental|Arm 1|direct intramyocardial injection of cells as adjunct to CABG
3298717|NCT00463840|Experimental|Oxaliplatin+ 5FU+ radiation (RT) /surgery /FOLFOX 6|"Concurrent chemoradiation before surgery and FOLFOX6 regimen after surgery~Radiation (RT) 180cGy daily x 5 days/week x 5 weeks, then additional 540 cGy in 3 fractions over a half week to pancreatic portal;~Combined with :~5FU 200 mg/m^2 daily by continuous intravenous infusion (CIV) x 5 weeks and weekly Oxaliplatin 60 mg/m^2, IV for 5 weeks (in Phase I, 30, 40, 50, and 60 mg/m^2 Oxaliplatin were tested).~Observation for 2 weeks to assess dose-limiting toxicity (DLT)/Response. Surgery if deemed resectable.~Then modified FOLFOX 6 for 6 cycles (2 weeks/cycle):~Day 1 hour 0: Oxaliplatin 85 mg/m^2 intravenously (IV) + Leucovorin 350 mg IV over 2 hours; hour 2: 5FU 400 mg/m^2 IV bolus followed by 2400 mg/m^2 IV over 46 hours."
3298718|NCT00463827|Active Comparator|2|Atorvastatin 40
3298719|NCT00463827|Placebo Comparator|placebo|matched placebo
3298720|NCT00463814|Experimental|AZD6244|
3298721|NCT00463801|Experimental|Daptomycin|350 mg of Daptomycin was supplied as sterile lyophilized powder in glass vials. Each vial was to be reconstituted with 7 mL of normal saline or water for injection, to give a 50 mg/mL drug concentration. Daptomycin was to be administered as a 30-minute intravenous infusion, once daily for at least 7 days, at the dose of 4 mg/Kg, up to a maximum of 14 days.
3298722|NCT00463788|Experimental|cisplatin and cetuximab|
3298723|NCT00463788|Active Comparator|cisplatin|
3298724|NCT00463749|Active Comparator|1|High-dose N-Acetylcystein during percutaneous coronary intervention and for 2 days post intervention 2 x/day
3298725|NCT00463749|Placebo Comparator|2|Placebo (NaCl)
3298726|NCT00463736|Active Comparator|Magnesium sulfate|x 48 hours IV
3298727|NCT00463736|Placebo Comparator|Normal saline|x 48 hours IV
3298728|NCT00463697|Experimental|GW642444M 25mcg|Subject will inhale single dose of GW642444M 25 mcg via a DISKUS device in morning.
3298729|NCT00463697|Experimental|GW642444M 100mcg|Subject will inhale single dose of GW642444M 100 mcg via a DISKUS device in morning.
3298730|NCT00463697|Experimental|GW642444M 400mcg|Subject will inhale single dose of GW642444M 400 mcg via a DISKUS device in morning.
3298731|NCT00463697|Experimental|GW642444H 100mcg|Subject will inhale single dose of GW642444H 100 mcg via a DISKUS device in morning.
3298732|NCT00463697|Placebo Comparator|placebo|Subject will inhale single dose of Placebo via a DISKUS device in morning.
3298733|NCT00463658|Experimental|1|Subjects in the interdisciplinary group received home care services from a team of professional service providers (CCAC Case Manager, Registered Nurse, Occupational Therapist, Physiotherapist, Registered Dietician) with experience and training in falls prevention. The team provided a comprehensive, coordinated and evidence based approach to falls prevention through regular home visits, weekly case conferencing, a single accessible fall prevention plan,and joint client visits.
3298734|NCT00463658|No Intervention|2|Participants allocated to the control group received standard home care services arranged by the CCAC. These include routine follow-up by the CCAC case manager whose focus is on assessing client's eligibility for in-home health services, arrangement and coordination of professional (i.e. nursing, occupational therapy, physiotherapy, social work, speech-language pathology, nutrition) and non-professional HSS, information and referral to community agencies, and ongoing monitoring and evaluating the plan of care through in-home assessments with clients.
3298735|NCT00463606|Experimental|ABT-335 and Rosuvastatin Calcium|ABT-335 135mg in combination with rosuvastatin calcium 5mg administered orally, once daily for 12 weeks
3298736|NCT00463606|Active Comparator|ABT-335|ABT-335 135mg monotherapy administered orally, once daily for 12 weeks
3298737|NCT00463606|Active Comparator|Rosuvastatin Calcium|Rosuvastatin calcium 5mg monotherapy administered orally, once daily for 12 weeks
3299002|NCT00460551|Experimental|Zalutumumab 8 mg/kg|
3298738|NCT00463593||2|children enrolled in formal schools and children not enrolled in formal schools
3298739|NCT00463580|Experimental|infliximab (Remicade)|Infusion
3298740|NCT00463580|Placebo Comparator|Placebo|Normal saline
3298741|NCT00463567|Experimental|Indacaterol 150 µg (Continued Into Stage 2)|"In the morning, Indacaterol 150 µg once daily orally inhaled via a single dose dry powder inhaler (SDDPI) + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily Inhaled Corticosteroid (ICS) monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
3298742|NCT00463567|Experimental|Indacaterol 300 µg (Continued Into Stage 2)|"In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
3298743|NCT00463567|Active Comparator|Tiotropium 18 µg (Continued Into Stage 2)|"Tiotropium 18 µg dry powder capsules delivered (open label) via manufacturer's proprietary SDDPI, (Handihaler®). Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
3298744|NCT00463567|Placebo Comparator|Placebo (Continued Into Stage 2)|"In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
3298745|NCT00463567|Experimental|Indacaterol 75 µg (Not Continued into Stage 2)|"In the morning, Indacaterol 75 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
3298746|NCT00463567|Experimental|Indacaterol 600 µg (Not Continued Into Stage 2)|"In the morning, 2 capsules of Indacaterol 300 µg once daily orally inhaled via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
3298747|NCT00463567|Active Comparator|Formoterol 12 µg (Not Continued Into Stage 2)|"In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Formoterol 12 µg delivered via Aerolizer. In evening, Formoterol 12 µg delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
3298748|NCT00463541|Experimental|1|
3298749|NCT00463489|Active Comparator|Mail-based|Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
3298750|NCT00463489|Experimental|Individualized Lifestyle Intervention|Women randomized to the individualized lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
3298751|NCT00463450|Experimental|Arm 1|
3298752|NCT00463450|Active Comparator|Arm 2|
3298753|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany & Poland and Infanrix™ IPV Hib in Spain) and Wyeth's Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.
3298754|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany & Poland and Infanrix™ IPV Hib in Spain) and Baxter's Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.
3298755|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany & Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
3298756|NCT00463437|Active Comparator|Prevenar™ + Menitorix™|Subjects receiving a booster dose of Wyeth's pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany & Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
3298757|NCT00463398||Patients operated at the LUFc|All patients operated at the Leuven University Fertility Centre (LUFc) between september 2006 and August 2008.
3298758|NCT00463385|Experimental|Prednisone|"Participants received oral prednisone from Day 1-28 of each 28-day cycle for up to 3 cycles (84 days), 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day, and pomalidomide placebo tablets on Days 1-28 for up to 12 cycles in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants were discontinued from the study."
3298793|NCT00462865|Experimental|Gemcitabine and Capecitabine and Avastin|Avastin administered concurrently with chemotherapy (Gemcitabine + Capecitabine) for six cycles followed by single agent Avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
3298860|NCT00462020|Active Comparator|1|5 days of IV antibiotics after appendectomy
3298759|NCT00463385|Experimental|Pomalidomide|"Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and prednisone placebo tablets on Days 1-28 for the first 3 cycles in the Double-Blind Treatment Phase.~After the completion of Cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
3298760|NCT00463385|Experimental|Pomalidomide 2 mg + Prednisone|"Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
3298761|NCT00463385|Experimental|Pomalidomide 0.5 mg + Prednisone|"Participants received 0.5 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 0.5 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
3298762|NCT00463346|Experimental|Acamprosate|Acamprosate
3298763|NCT00463346|Placebo Comparator|placebo|placebo
3298764|NCT00463294|Active Comparator|On Pump Arm|
3298765|NCT00463294|Experimental|Off Pump Arm|
3298766|NCT00463268|Active Comparator|1|Alendronate 70 mg every 2 weeks
3298767|NCT00463268|Placebo Comparator|2|Alendronate 70 mg placebo tablet every 2 weeks
3298768|NCT00463242|Experimental|Agomelatine|Dosing for each subject in this extension study began with the same dose (25 mg or 50 mg of agomelatine orally once daily) the subject was receiving at the end of Week 8, the week before this study began.
3298769|NCT00463242|Active Comparator|2|
3298770|NCT00463242|Placebo Comparator|3|
3298771|NCT00463229|Experimental|Interprofessional Team Approach|Participants in the experimental group will receive home care services from a team of professional service providers [Community Care Access Centre (CCAC) Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist] and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
3298772|NCT00463229|No Intervention|Usual Home Care Services|Participants allocated to the control group received standard home care services arranged by the CCAC. These include routine follow-up by the CCAC case manager whose focus is on assessment and referral to community agencies, and ongoing monitoring and evaluating the plan of care through in-home assessment with clients.
3298773|NCT00463151|Placebo Comparator|1|0mg rebamipide
3298774|NCT00463151|Experimental|2|60mg rebamipide
3298775|NCT00463151|Experimental|3|150mg rebamipide
3298776|NCT00463151|Experimental|4|300mg rebamipide
3298777|NCT00463086|Experimental|1.Isoniazid (INH)|A self-administered daily dose of 5mg/kg of Isoniazid (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
3298778|NCT00463086|Placebo Comparator|2. Placebo|A self-administered daily dose of 5mg/kg of placebo for 12months (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
3298779|NCT00463060|Experimental|Treatment|Participants treated with chemotherapy and radiotherapy
3298780|NCT00463047|Experimental|Fentanyl Buccal Tablets (FBT)|This study includes a screening period, 2 open-label dose titration periods (in randomized order), and 2 double-blind treatment periods (in randomized order).
3298781|NCT00463047|Active Comparator|Oxycodone|This study includes a screening period, 2 open-label dose titration periods (in randomized order), and 2 double-blind treatment periods (in randomized order).
3298782|NCT00462995|Active Comparator|Erlotinib|Erlotinib 150mg once a day p.o
3298783|NCT00462982|Experimental|Sunitinib|Patients will be treated with 50 mg daily for four out of every six weeks.
3298784|NCT00462969|Experimental|1|pre-surgical SHG
3298785|NCT00462956|Experimental|lapatinib 1500mg daily|Subjects will self-administer lapatinib 1500 mg orally once daily.
3298786|NCT00462943|Experimental|OMA|"Omacetaxine mepesuccinate (OMA) Induction: 1.25mg/m^2 subcutaneously twice daily for 14 consecutive days, every 28 days for up to six cycles.~Omacetaxine mepesuccinate (OMA) Maintenance: 1.25mg/m^2 subcutaneously twice daily for 7 consecutive days, every 28 days for up to 24 months."
3298787|NCT00462917|Experimental|Pleiotropic info, in-person disclosure|Incidental pleiotropic risk information, in addition to AD risk information, is disclosed in-person during an APOE-based genetic risk assessment
3298788|NCT00462917|Experimental|AD-only info, phone disclosure|Alzheimer's disease risk information only is disclosed via telephone during an APOE-based genetic risk assessment
3298789|NCT00462917|Experimental|Pleiotropic info, phone disclosure|Incidental pleiotropic risk information, in addition to AD risk information, is disclosed via telephone during an APOE-based genetic risk assessment
3298790|NCT00462917|Active Comparator|AD-only info, in-person disclosure|Alzheimer's disease risk information only is disclosed in-person during an APOE-based genetic risk assessment
3298791|NCT00462891|Experimental|IT System|IT system to send reminder letters to patients overdue for breast cancer screening.
3298792|NCT00462891|No Intervention|Usual Care|
3298824|NCT00462462|Active Comparator|2|Ethanol solution
3298825|NCT00462449|No Intervention|1|Individuals randomized into this group will only receive specialized therapy associated with this population.
3298794|NCT00462839|Experimental|Calibrated drapes viewed first|Caregivers were shown calibrated drape demonstrating level of blood and asked to estimate amount of blood in collection bag. These same individuals were then crossed over and shown non-calibrated drapes and asked to estimate the amount of blood they contained.
3298795|NCT00462839|Active Comparator|Non-calibrated drapes viewed first|Standard vaginal delivery drape (non-calibrated) was shown to caregiver who was asked to estimate amount of blood. These same individuals were then crossed over and shown calibrated delivery drapes and asked to estimate the amount of blood they contained.
3298796|NCT00462826|Experimental|Treatment (aflibercept)|Patients receive VEGF Trap IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3298797|NCT00462787|Experimental|Clofarabine|This is a single arm phase I clinical trial to assess safety (morbidity and mortality) of a novel leukemia re-induction regimen. The first component of this trial is a phase I dose escalation study to determine the maximum tolerated dose (MTD) of the novel agent Clofarabine, when used in combination with topotecan, vinorelbine, thiotepa and dexamethasone. A total of three dose levels will be explored in this study.
3298798|NCT00462761|Experimental|AC220|Determine safety, tolerability and pharmacokinetic (PK) parameters of AC220
3298799|NCT00462748|Experimental|1|Arm 1: Drug
3298800|NCT00462748|Active Comparator|2|Arm 2: Active comparator
3298801|NCT00462748|Active Comparator|3|Arm 3: Active comparator
3298802|NCT00462735|Experimental|Advanced Head and Neck Cancer|Patients with stage IVA and IVB or high-risk stage III squamous cell carcinomas of the head and neck
3298803|NCT00462722|Placebo Comparator|Placebo pre and post exercise|placebo before and after musculoskeletal-loading exercise
3298804|NCT00462722|Experimental|Placebo pre and ibuprofen post exercise|placebo before and ibuprofen after musculoskeletal-loading exercise
3298805|NCT00462722|Experimental|Ibuprofen pre and placebo post exercise|ibuprofen before and placebo after musculoskeletal-loading exercise
3298806|NCT00462709|Experimental|Open-label C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 7 days.
3298807|NCT00462670|Placebo Comparator|1|0mg
3298808|NCT00462670|Experimental|2|15mg OPC-41061
3298809|NCT00462644|Active Comparator|Etomidate|Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications
3298810|NCT00462644|Active Comparator|Fentanyl-Midazolam|Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.
3298811|NCT00462631|Experimental|1|paclitaxel eluting balloon followed by bare metal stent
3298812|NCT00462631|Active Comparator|2|Paclitaxel eluting stent
3298813|NCT00462618|Active Comparator|CBT|
3298814|NCT00462605|Experimental|Arm I|Patients receive oral MS-275 on days 1, 8, 15, and 22. Patients also receive sargramostim (GM-CSF) subcutaneously once daily on days 1-42 in courses 3 and 5 and on days 1-35 in courses 1, 2, 4, and 6. Treatment repeats every 6 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. After completion of 2 courses of study therapy, patients who achieve a complete or partial response may receive an additional 4 courses. Patients who maintain stable disease for more than 2 months after completion of 6 courses of study therapy may receive an additional 6 courses at the time of disease progression, provided they meet original eligibility criteria.
3298815|NCT00462592|Active Comparator|1|montelukast - montelukast 5 mg ( < 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening
3298816|NCT00462592|Active Comparator|2|budesonide - inhaled budesonide turbuhaler 200ug (& matching placebo) taken 1 puff morning & 1 puff evening.
3298817|NCT00462592|Placebo Comparator|3|placebo
3298818|NCT00462592|Active Comparator|4|montelukast budesonide combination - montelukast 5mg ( < 15 years) or 10 mg (& matching placebo)will be taken 1 tab in the evening together with inhaled budesonide turbuhaler 200 ug (& matching placebo) taken 1 puff morning & 1 puff evening.
3298819|NCT00462553|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 OR on days 1, 8, and 15. Patients also receive oral sunitinib malate once daily on days 1-21 OR days 1-28. Treatment repeats every 21 days OR every 28 days in the absence of disease progression or unacceptable toxicity.
3298820|NCT00462501|Experimental|Chemotherapy and Bevacizumab With or Without Radiation|FOLFOX/Bevacizumab will be given for 4 cycles over 8 weeks; FOLFOLX6 without Bevacizumab will be given for an additional 2 cycles over 4 weeks. Oxaliplatin will be given on Day 1 of each cycle over 2 hours at 85 mg/m2 IV. Leucovorin will be given Day 1 of each cycle over 2 hours at 400 mg/m2 IV. Fluorouracil will be given on Day 1 of each cycle at 400 mg/m2 IVP, then Fluorouracil will be given at 1200 mg/m2 IVCI over Day 1 and 2. Bevacizumab will be given at 5mg/kg over 10 minutes on day 1. Patients will undergo re-staging within 3 weeks of completing their 6th cycle of FOLFOX. If the reassessment reveals that there has been no disease progression as compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection. If the surgical oncologist's reassessment is that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous infusional 5-fluorouracil.
3298821|NCT00462488|Active Comparator|Treatment Schedule A -|"Induction Phase is a single intravesical dose of Vicinium at 30 mg in 40 mL PBS once per week for 6 weeks. If free of disease at 12 weeks after the first instillation, the subject enters Maintenance dosing in which 30 mg of Vicinium is administered once per week for 3 weeks followed by 9 weeks of no therapy.~If the subject had histologically confirmed disease that is stage <T2, they repeat the Induction phase dosing. If the subject is free of disease, the subject enters the maintenance dosing phase of every 12 weeks (3 weeks of therapy followed by 9 weeks of no therapy until disease recurrence is confirmed by positive biopsy or up to a maximum of Week 51 (end-of-study [EOS])."
3298822|NCT00462488|Active Comparator|Treatment Schedule B|"Induction Phase is a single intravesical dose of Vicinium at 30 mg in 40 mL PBS once per week for 12 weeks followed by 1 week of no therapy.~If 13 weeks after the first instillation of Vicinium the subject is free of disease, they have a break from therapy before entering Maintenance dosing in which 30 mg of Vicinium is administered once weekly for 3 weeks followed by 9 weeks of no therapy. If the subject is free of disease, additional maintenance cycle(s) are repeated every 12 weeks (3 weeks of therapy followed by 9 weeks of no therapy until disease recurrence is confirmed by positive biopsy or up to a maximum of Week 57 (EOS)."
3298823|NCT00462462|Experimental|1|Ethanol gel
3298826|NCT00462449|Experimental|2|In addition to appropriate therapy, this group will receive the FES device and be given instruction on how to complete specialized exercises utilizing this device.
3298827|NCT00462423|Experimental|Single Arm, Open Label|Single Arm, Open Label trial of Abraxane and Avastin
3298828|NCT00462384|Experimental|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 micrograms per kilogram (mcg/kg) body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
3298829|NCT00462358|Experimental|ARRY-520|
3298830|NCT00462358|Experimental|ARRY-520 + G-CSF support|
3298831|NCT00462345|Experimental|Rituximab, Methotrexate|Participants received rituximab 1000 milligrams (mg), intravenously (IV), on Day 1 and Day 15. Participants also received methylprednisolone 100 mg, IV, 30 minutes before the infusion of rituximab. Participants also received methotrexate (MTX) 10 to 25 milligrams per week (mg/week), orally (PO) or parenterally, and folate greater than or equal to (≥) 5 mg/week, PO, folate greater than or equal to (≥) 5 mg/week, PO, either as a single dose or as divided daily doses from Day 1 through Week 24. Participants also received prednisone less than or equal to (≤) 10 milligrams per day (mg/day), PO, OR equivalent corticosteroid, OR non-steroidal anti-inflammatory drugs (NSAIDs), PO, from Day 1 through Week 24. Eligible participants who completed the first 24-week course were entered into a second course.
3298832|NCT00462332|Experimental|High risk patientes|Category of risk will be defined according to biological features.
3298833|NCT00462332|Experimental|Low risk patients|Category of risk will be defined according to biological features.
3298834|NCT00462306||Pregnant population|The study group consisted of pregnant women, presenting to Prentice Women's Hospital of Northwestern Memorial Hospital for spontaneous labor, induction of labor, and scheduled cesarean delivery.
3298835|NCT00462306||Non-Pregnant Population|The study group consisted of non-pregnant females, presenting to Northwestern Memorial Hospital for ambulatory surgery
3298836|NCT00462280|Experimental|Two matched nevi group - Lovastatin|Patients with two matched nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
3298837|NCT00462280|Placebo Comparator|Two Matched Nevi Group - Placebo|Patients with two matched nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
3298838|NCT00462280|Experimental|One large nevi group - Lovastatin|Patients who have one large nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
3298839|NCT00462280|Placebo Comparator|One Large Nevi Group - Placebo|Patients who have one large nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
3298840|NCT00462267|No Intervention|Usual care|
3298841|NCT00462267|Experimental|Enriched lifestyle intervention|
3298842|NCT00462254|Other|A|Day 1-3: placebo run-in - 8 mg of placebo orally 30 minutes before bedtime. Days 4-11: true drug - 8 mg of Ramelteon orally 30 minutes before bedtime. Days 12-14: crossover - 8 mg of placebo orally 30 minutes before bedtime. Days 15-22: continue placebo.
3298843|NCT00462254|Other|B|Day 1-3: Placebo run-in - 8 mg of placebo orally 30 minutes before bedtime. Days 4-11: continue placebo. Days 12-14: crossover - 8 mg of placebo orally 30 minutes before bedtime. Days 15-22: true drug - 8 mg of Ramelteon orally 30 minutes before bedtime.
3298844|NCT00462241|Experimental|chiropractic treatment|Individualised chiropractic treatment, pragmatic approach
3298845|NCT00462241|Sham Comparator|self-management|Self-management: Minimal intervention - practice as usual.
3298846|NCT00462228|Experimental|Memantine|Subjects will be titrated up to 20 mg of memantine per day for 12 weeks, followed by placebo for 12 weeks
3298847|NCT00462228|Placebo Comparator|Placebo|Subjects will be titrated up to 20 mg of placebo per day for 12 weeks, followed by memantine for 12 weeks
3298848|NCT00462215|Experimental|1|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
3298849|NCT00462215|Experimental|2|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
3298850|NCT00462215|Experimental|3|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
3298851|NCT00462215|Experimental|4|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
3298852|NCT00462215|Experimental|5|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
3298853|NCT00462215|Experimental|6|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
3298854|NCT00462202|Experimental|Sulodexide|Open label extension to original trial
3298855|NCT00462176||1|All women (n=45) who had undergone CO2 laser laparoscopic radical excision of deep infiltrating endometriosis with active involvement of the colorectal surgeon performing a bowel resection were selected retrospectively from the list of all patients (n=more than 400) operated at the Leuven University Fertility Centre (LUFc) between September 2004 and July 2006.
3298856|NCT00462137||1|control group
3298857|NCT00462137||2|hypnotic group
3298858|NCT00462098|Experimental|HBO|Subject receives 40 HBO sessions at 2 atmospheres of pressure over 4 weeks
3298859|NCT00462098|Active Comparator|Control|non-HBO comparison group
3298861|NCT00462020|Experimental|2|home on oral antibiotics to complete 7 days of treatment when tolerating PO's
3298862|NCT00462007|Experimental|1|Stalevo
3298863|NCT00461981|Experimental|FluMist, Influenza Virus Vaccine Live|FluMist, Influenza Virus Vaccine Live, Intranasal
3298864|NCT00461981|Active Comparator|TIV, Trivalent Inactivated Influenza Virus Vaccine|TIV, Trivalent Inactivated Influenza Virus Vaccine, Intramuscular
3298865|NCT00461955|Experimental|1|autologous peripheral blood stem cell transplantation
3298866|NCT00461903|Placebo Comparator|Placebo (for perindopril)|Sugar pill manufactued to mimic perindopril
3298867|NCT00461903|Active Comparator|Perindopril|Perindopril (coversyl) 4 mg tablets
3298868|NCT00461851|Experimental|Chemotherapy plus sorafenib|Gemcitabine 1000 mg/m2 weekly x 2 weeks plus carboplatin AUC (Area under curve) 5 every 3 weeks plus sorafenib x 6 cycles then maintenance sorafenib alone
3298869|NCT00461838||1|All women (n=56) who had undergone CO2 laser laparoscopic radical excision of deep infiltrating endometriosis with active involvement of colorectal surgeon and/or urologist were selected retrospectively from the list of all patients (n=more than 2000) operated at the Leuven University Fertility Centre (LUFc) between September 1996 and July 2004.
3298870|NCT00461812|Experimental|Mometasone|
3298871|NCT00461812|Experimental|Advair|
3298872|NCT00461786|Experimental|Pemetrexed|
3298873|NCT00461773|Active Comparator|1|brief exposure bevacizumab
3298874|NCT00461773|Active Comparator|2|brief exposure bevacizumab and letrozole
3298875|NCT00461760|Active Comparator|1|Women with normal cytology at recruitment will be recalled for their next routine screen at 2 years and if negative again, for their exit screen at 4 years, all according to current provincial guidelines.
3298876|NCT00461760|Active Comparator|2|Women with abnormal cytology at recruitment or at the 2 year screen will be followed according to provincial guidelines based on their cytology results.
3298877|NCT00461747|Active Comparator|A|"Four alternating cycles of VBMCP/VBAD + Velcade VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalán, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20. The interval between VBMCP and VBAD is 5 weeks and between VBAD and VBMCP is 4 weeks. The patients will received two cycles of VBMCP and two cycles of VBAD. After 4 weeks of last cycle of VBAD, patients will received two cycles of Velcade, 1,3 mg/ m2 iv twice a week (days 1, 4, 8 and 11), followed by 10 days without treatment"
3298878|NCT00461747|Experimental|B|"Six cycles of 4 weeks of Thalidomide/Dexamethasone. Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity < grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
3298879|NCT00461747|Experimental|C|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is < grade 2, the dose will be increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days."
3298880|NCT00461734|Active Comparator|RV Apex|
3298881|NCT00461734|Experimental|RV High Septum|
3298882|NCT00461708|Experimental|Rash, Grade <2|Participants with a rash graded less than (<) 2 according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version (v.) 3.0 received erlotinib, 100 milligrams (mg), orally (PO), once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg per (/) square meter (m^2), intravenously (IV), over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.
3298883|NCT00461708|Experimental|Rash, Grade ≥2|Participants with a rash graded greater than or equal to (≥) 2 according to the NCI-CTC v. 3.0 received erlotinib, 100 mg, PO, once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg/m^2, IV, over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.
3298884|NCT00461695|Other|CMV-seropositive|Cytomegalovirus-seropositive individuals at screening (week 0). Intervention: Intervention: Vaccination against tick-borne encephalitis by intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
3298885|NCT00461695|Other|CMV-seronegative|Cytomegalovirus-seronegative individuals at screening (week 0). Intervention: Vaccination against tick-borne encephalitis by intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
3298886|NCT00461643|Active Comparator|Strategy A|clomiphene followed by clomiphene plus metformin followed by gonadotropins
3298887|NCT00461643|Active Comparator|Strategy B|metformin followed by metformin plus clomiphene followed by gonadotropins
3298888|NCT00461643|Active Comparator|Strategy C|metformin plus clomiphene followed by gonadotropins
3298889|NCT00461630|Experimental|ER niacin/laropiprant|1 g ER niacin plus 20 mg laropiprant per tablet. 2 tablets orally per day. With either 40 mg simvastatin tablet or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily
3298890|NCT00461630|Active Comparator|Placebo|Placebo (for ER niacin/laropiprant) 2 tablets orally per day. With either 40 mg simvastatin tablet orally per day or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily
3298891|NCT00461617|Active Comparator|2|Nateglinide 120 mg TID
3298892|NCT00461591|Experimental|Apaziquone|TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
3298893|NCT00461591|Placebo Comparator|Placebo|TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT
3298894|NCT00461565|Active Comparator|Part A1|
3298895|NCT00461565|Placebo Comparator|Part A2|
3298896|NCT00461565|Experimental|Part B1|
3298897|NCT00461565|Placebo Comparator|Part B2|
3298898|NCT00461552|Active Comparator|Leptin ( still recruiting)|Leptin weight and gender based dose, sub-cutaneous, twice daily. Leptin versus placebo for entire 6 months double-blind.
3298899|NCT00461552|Placebo Comparator|Leptin Placebo|Placebo for Leptin, sub-Q injection twice daily.
3298900|NCT00461539|Active Comparator|2|Participants will receive treatment as usual
3298901|NCT00461539|Experimental|1|Participants will receive the behavioral health intervention
3298902|NCT00461526|Experimental|125 mg crofelemer|
3298903|NCT00461526|Placebo Comparator|placebo|
3298904|NCT00461513||Intervention|The PCDM intervention will include evaluation of CHF care by the collaborative care team, with diagnostic and therapeutic treatment recommendations based on current ACC/AHA national clinical practice guidelines, daily telemonitoring and patient self-care support utilizing the VA telemonitoring system, and screening and treatment for comorbid depression. The Collaborative Care (CC) team at each site will consist of a primary care provider, cardiologist, and psychiatrist, who are local opinion leaders, as well as a nurse site coordinator and pharmacist. For a given intervention patient, there will be an initial assessment of care by the CC team following the enrollment visit. Each intervention patient will be re-reviewed by the CC team a minimum of 2 additional times (at 6-weeks and 6 months). In addition, patients will have daily telemonitoring, and their care will be reviewed by the CC team if the telemonitoring data suggests clinical deterioration.
3298905|NCT00461513||Usual Care|Patients randomized to the usual care arm will continue to receive care at the discretion of their regular VA providers (for a given patient, this could include cardiology specialty care in addition to PCP care, participation in site-specific CHF programs such as CHF patient education classes, etc.), in direct continuity with the care they were receiving prior to enrollment. Patients in the usual care group will also be given information sheets that outline self-care for CHF, and will be provided with a scale, if needed, at the enrollment visit. Patients in the usual care group will have the same amount of interaction with the study team as the intervention patients (i.e. complete questionnaires at the same frequency; have the same study visits). PCPs of usual care patients will be notified of the results of all screening studies (patient survey results, lab tests) as we have done in previous studies.
3298906|NCT00461487|Experimental|1|Participants will receive sex education information during the physical exam
3298907|NCT00461487|Active Comparator|2|Participants will receive information on hygiene and nutrition during the physical exam
3298908|NCT00461487|No Intervention|3|Passive control participants will not receive any additional information during the physical exam
3298909|NCT00461448|Active Comparator|1 Potassium supplement|Patients received an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)
3298910|NCT00461448|Placebo Comparator|2 Grape Juice|Patients received same amount of grape juice for 28 days.
3298911|NCT00461422|Experimental|1|Standard Flexible antagonist protocol Addition of Ganirelix at first 3 days of the cycle
3298912|NCT00461422|No Intervention|2|Standard Flexible antagonist protocol
3298913|NCT00461409|Experimental|Open Lable Treatment with Levetiracetam|IV loading for persistent neonatal seizure after phenobarbital with levetiracetam 20 or 40 mg/kg bolus followed by 5-10 mg/kg/d
3298914|NCT00461396||Group 1|
3298915|NCT00461331|Active Comparator|Insulin 1|Either insulin Aspart or insulin Lispro were randomized to be insulin 1.
3298916|NCT00461331|Active Comparator|Insulin 2|Between insulin Aspart and insulin Lispro, the one that was not used as insulin 1 was then used as the second insulin for the second arm of the study.
3298917|NCT00461305|Experimental|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
3298918|NCT00461305|Experimental|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
3298919|NCT00461292|Experimental|1|botulinum toxin Type A (200U)
3298920|NCT00461292|Experimental|2|botulinum toxin Type A (300U)
3298921|NCT00461292|Other|3|placebo; botulinum toxin Type A (200U)
3298922|NCT00461292|Other|4|placebo; botulinum toxin Type A (300U)
3298923|NCT00461279|Other|1|
3298924|NCT00461279|Other|2|
3298925|NCT00461266|Experimental|1|
3298926|NCT00461266|Active Comparator|2|
3298927|NCT00461253||1|Breast Cancer Cases
3298928|NCT00461253||2|Matched Controls for Breast Cancer Cases
3298929|NCT00461240||acromegaly|
3298930|NCT00461240||growth hormone deficiency|
3298931|NCT00461175||1|Mirena®
3298932|NCT00461175||2|Copper IUD
3298933|NCT00461162|Experimental|1: i-DSMP|Internet Dyspnea Self-management Program (i-DSMP)
3298934|NCT00461162|Experimental|2: f-DSMP|Face-to-Face Dyspnea Self-management Program (f-DSMP)
3298935|NCT00461162|Active Comparator|3: AC|Attention Control (AC)
3298936|NCT00461123|Experimental|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
3298937|NCT00461123|Placebo Comparator|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
3298938|NCT00461110|Experimental|1|Active
3298939|NCT00461110|Experimental|2|Active
3298940|NCT00461097|Experimental|Egg Oral Immunotherapy (OIT)|Subjects ingest egg white solid (EWS) on Visit 1 (initial day dose escalation up to 50 mg), followed by a build-up phase (escalating daily egg doses every 2 wks, achieving a maintenance dose by 32-40 wks). Thereafter, subjects are on a maximally tolerated daily egg dose (306 mg to 2 gm) for ≥8 wks. After wk 44, subjects are given a 5 gm Oral Food Challenge (OFC) using EWS to identify desensitized [1] subjects. Subjects/study staff are unblinded following this OFC and either continue on their egg OIT maintenance dose of 2 gm/day or are allowed to attempt escalation up to 2 gm/day for the remainder of the study (1-3 years). A 10 gm OFC to identify desensitized [1] subjects occurs at specified intervals under prescribed conditions (yrs 2 - 4). Subjects who pass this 1st 10 gm OFC stop study therapy for 4-6 wks, then have a 2nd 10 gm OFC. Subjects that pass this 2nd 10 gm OFC are considered tolerant [2], stop EWS dosing and add egg to their diet.
3299000|NCT00460564|Active Comparator|Low-Dose BTX|
3299001|NCT00460564|Active Comparator|Low-Dose Placebo|
3298941|NCT00461097|Placebo Comparator|Control Group|Subjects ingest placebo (cornstarch) during Visit 1 (initial day of dose escalation up to 50 mg), followed by a build-up phase (escalating daily placebo doses every 2 wks, achieving a maintenance dose by 32-40 wks). Thereafter, subjects were on a maximally tolerated daily placebo dose (306 mg to 2 gm) for ≥8 wks. After wk 44, subjects were given a 5 gm Oral Food Challenge (OFC) using egg white solid to identify desensitized [1] subjects. Subjects/study staff were unblinded following this initial 5 gm OFC. After unblinding, subjects discontinued further placebo dosing and continued on an egg-restricted diet. A 10 gm OFC was administered under prescribed conditions to subjects if their egg-specific serum IgE level was below 2 kUA/L. They were followed in the study up to 2 years. [1] Desensitized: Subject does not react to egg during OFC while taking daily doses of therapy. [2] Tolerant: Subject does not react to egg during OFC 4-6 wks after abstinence from egg consumption.
3298942|NCT00461084||1|lymphoma follicular
3298943|NCT00461084||2|lymphoma non-follicular
3298944|NCT00461071|Active Comparator|Internet-based self-help|Internet-based self-help behavioural
3298945|NCT00461071|Active Comparator|Bibliotherapy|bibliotherapy
3298946|NCT00461058|Active Comparator|Actos|
3298947|NCT00461058|Experimental|Aleglitazar|
3298948|NCT00461045|Experimental|MRZ 0.5 mg/m^2|Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles
3298949|NCT00461032|Experimental|1|montelukast
3298950|NCT00461032|Placebo Comparator|2|Placebo
3298951|NCT00461019|Experimental|Implantation of the CardioFit system|
3298952|NCT00461006|Experimental|Aleglitazar|
3298953|NCT00461006|Active Comparator|Actos|
3298954|NCT00460993|Experimental|Group 1|Lunesta Active drug (eszopiclone) 1 mg during 1st week of active drug. If sleep efficiency does not improve does increases to 2 mg for 2nd week of active drug administration.
3298955|NCT00460993|Placebo Comparator|Group 2|"Sugar pill packaged and supplied by Sepracor. One pill weeks one and two of intervention.~Weeks 3 and 4 this Placebo group crosses over to active drug. 1 mg week 3 increasing to 2mg week 4 if sleep efficiency does not improve."
3298956|NCT00460980|Other|Virtual reality laparoscopic simulator|"Virtual reality laparoscopic simulator training:~Residents will participate in a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience."
3298957|NCT00460967|Experimental|1|Rheopheresis treatment
3298958|NCT00460967|Sham Comparator|2|Sham treatment
3298959|NCT00460941|Placebo Comparator|Placebo|sc weekly
3298960|NCT00460941|Experimental|Taspoglutide 20mg|sc weekly
3298961|NCT00460941|Experimental|Taspoglutide 20mg-30mg|sc weekly
3298962|NCT00460941|Experimental|Taspoglutide 20mg-40mg|sc weekly
3298963|NCT00460928|Experimental|intravenous immune globulin (IVIG)|
3298964|NCT00460902|Experimental|Deep TMS stimulation|
3298965|NCT00460902|Experimental|DTMS with positive cognitive-emotional provocation|
3298966|NCT00460902|Experimental|DTMS with negative cognitive-emotional provocation|
3298967|NCT00460850|Experimental|1|
3298968|NCT00460837|Active Comparator|1 A|gastrofin & Picolax
3298969|NCT00460837|Active Comparator|2|senna
3298970|NCT00460811|Active Comparator|72 ug linaclotide acetate|
3298971|NCT00460811|Active Comparator|145 ug linaclotide acetate|
3298972|NCT00460811|Active Comparator|290 ug linaclotide acetate|
3298973|NCT00460811|Active Comparator|579 ug linaclotide acetate|
3298974|NCT00460811|Placebo Comparator|Matching Placebo|
3298975|NCT00460798||Non-Interventional Study|
3298976|NCT00460759|Experimental|Moxifloxacin and Rifapentine|
3298977|NCT00460746|Experimental|001|TMC125, Darunavir; RitonavirTMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
3298978|NCT00460733|Experimental|1|
3298979|NCT00460733|Active Comparator|2|
3298980|NCT00460720||001|
3298981|NCT00460707|Experimental|Cohort 1|All subjects in Cohort 1 will receive ketoconazole 400 milligrams (mg) once daily on Day 1 to 9 and oral casopitant 150 mg on Day 4 and 50 mg on Day 5 and Day 6 of treatment period 1. After a washout period of 21 days, subjects will be administered oral casopitant 150 mg on Day 1 and 50 mg on Day 2 and Day 3 of treatment period 2.
3298982|NCT00460707|Placebo Comparator|Cohort 2, Group A|Subjects will receive placebo once daily on Day 1 to Day 3 in treatment period 1. Subjects will receive ketoconazole 400 mg once daily on Day 1 to Day 9 and oral placebo once daily on Days 4, 5 and 6 in treatment period 2. There will be a 14-day washout period between treatment periods 1 and 2.
3298983|NCT00460707|Experimental|Cohort 2, Group B|In treatment period 1, subjects will receive oral casopitant 150 mg on Day 1 and 50 mg on Days 2 and 3. In treatment period 2, they will be administered ketoconazole 400 mg once daily on Day 1 to Day 9 and oral casopitant 150 mg on Day 4 and 50 mg on Days 5 and 6. There will be a 14-day washout period between treatment periods 1 and 2.
3298984|NCT00460668|Experimental|Pulmonary rehabilitation post-thoracotomy|Pulmonary rehabilitation post-thoracotomy
3298985|NCT00460668|No Intervention|Control|Control
3298986|NCT00460655|Active Comparator|BTX|
3298987|NCT00460655|Placebo Comparator|Placebo|
3298988|NCT00460616||1|Patients already receiving treatment with cabergoline.
3298989|NCT00460616||2|healthy controls sex and age-matched with the patients
3298990|NCT00460603|Active Comparator|B|bevacizumab 5 mg/kg every 2 weeks + FOLFOX
3298991|NCT00460603|Experimental|C|AG-013726 5 mg bid+ bevacizumab 2 mg/kg every 2 weeks + FOLFOX
3298992|NCT00460603|Experimental|A|AG-013736 5 mg bid starting dose + FOLFOX
3298993|NCT00460590|Experimental|1|12 adults with prior BCG
3298994|NCT00460590|Experimental|2|12 adults without prior BCG
3298995|NCT00460590|Experimental|3|12 Adolescents
3298996|NCT00460577|Active Comparator|Formoterol (Foradil®)|Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.
3298997|NCT00460577|Active Comparator|Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg|Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.
3298998|NCT00460564|Active Comparator|High-Dose BTX|
3298999|NCT00460564|Placebo Comparator|High-Dose Placebo|
3299005|NCT00460525|Active Comparator|Rabies Vaccine|Rabies vaccine administered on Days 0, 30, and 60.
3299006|NCT00460525|Experimental|FMP2.1/AS02A|50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.
3299007|NCT00460512|Experimental|Paliperidone Extended Release (ER)|
3299008|NCT00460499|Active Comparator|B Low dose GIK|This group will have low doses of glucose and insulin
3299009|NCT00460499|Active Comparator|C High Dose GIK|This group will have high doses of insulin and glucose
3299010|NCT00460499|Active Comparator|A Insulin|This group will receive only an intravenous insulin infusion
3299011|NCT00460473|Experimental|Dexmedetomidine|
3299012|NCT00460473|Placebo Comparator|Placebo (PBO)|
3299013|NCT00460434|Experimental|1|Tension-free Vaginal Tape (TVT) surgery
3299014|NCT00460434|Sham Comparator|2|Sham Tension-free Vaginal Tape (TVT) surgery
3299015|NCT00460421|Experimental|Palifermin Dose Escalation|A 3 dose escalation design. Sucessive cohorts of patient (9 patients per group) will each be administered Palifermin as an IV bolus injection (40, 60 or 80 µg) once daily for 3 consecutive days before the start of conditioning regimen (chemotherapy and total body irradiation) and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).
3299016|NCT00460408||Observational study, no comparator|Observational study of patients with AMD treated with Macugen, no comparator
3299017|NCT00460369|Active Comparator|1|sulfadoxine-pyrimethamine
3299018|NCT00460369|Active Comparator|2|artemether-lumefantrine
3299019|NCT00460369|Active Comparator|3|amodiaquine-artesunate coformulation
3299020|NCT00460356||Ancillary-Correlative (glycoprotein and glycan profiling)|Primary and metastatic tumor specimens are collected during lymphadenectomy and used for tissue microarray analysis, mutational analysis of T-synthase and Cosmc, immunohistochemical staining of Tn antigen and sialyl Tn antigen, and customized gene expression array analysis of 400 genes associated with glycobiology. Pre-lymphadenectomy blood is collected from patients at baseline for customized glycan array analysis of 300 carbohydrates.
3299021|NCT00460343|Experimental|max|
3299022|NCT00460343|Active Comparator|min|
3299023|NCT00460317|Placebo Comparator|Arm B|All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and placebo 125mg QD orally
3299024|NCT00460317|Active Comparator|Arm A|All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and AMG 706 125mg QD orally.
3299025|NCT00460265|Active Comparator|ARM 2|Arm 2 consists of Cisplatin and 5-FU
3299026|NCT00460265|Experimental|ARM 1|ARM 1 Consists of Panitumumab plus Cisplatin and 5-FU
3299027|NCT00460239|Experimental|Placebo|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
3299028|NCT00460239|Experimental|Morphine 15|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
3299029|NCT00460239|Experimental|Morphine 30|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
3299030|NCT00460239|Experimental|Buprenorphine 8|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
3299031|NCT00460239|Experimental|Buprenorphine 16|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
3299032|NCT00460239|Experimental|Buprenorphine 32|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
3299033|NCT00460239|Experimental|Buprenorphine 48|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
3299034|NCT00460239|Experimental|Buprenorphine 60|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
3299035|NCT00460226||lamotrigine|there is only one group.
3299036|NCT00460213|Experimental|Valsartan|
3299037|NCT00460174|Experimental|Treatment Arm|Concurrent gemcitabine, bevacizumab, and radiation therapy
3299038|NCT00460161|Active Comparator|1|true acupuncture
3299039|NCT00460161|Placebo Comparator|2|placebo/sham acupuncture
3299040|NCT00460135|Experimental|RT|resistance training
3299041|NCT00460135|No Intervention|Routine care|General counseling on increasing physical exercise
3299042|NCT00460109|Experimental|rituximab + denileukin diftitox|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients also receive denileukin diftitox IV over 15-60 minutes on days 1-5. Treatment with denileukin diftitox repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3299043|NCT00460083|Active Comparator|Elidel(r)|
3299044|NCT00460083|Experimental|Epiceram(r)|
3299045|NCT00460057|Placebo Comparator|Alendronate, Placebo|All subjects were given 600 mg of calcium and 400 IU of vitamin D supplements. The subjects were randomized to receive weekly alendronate 20 mg (n = 31) or placebo (n = 32).
3299046|NCT00460031|Experimental|Ketoconazole Plus Lenalidomide|
3299047|NCT00460018|Experimental|Intervention|Women receiving the DEBI Intervention
3299048|NCT00460018|No Intervention|No intervention|Women receiving standard care
3299049|NCT00459979|Experimental|Sunitinib|
3299050|NCT00459953|Experimental|Extended treatment|extended cognitive behavioral treatment for smoking cessation; Participants receive an additional 9 sessions of cognitive behavior therapy
3299051|NCT00459953|No Intervention|Control group|Monthly follow-up phone calls for assessment purposes and to control for potential therapeutic effects associated with continued contact
3299052|NCT00459914|Active Comparator|1 CPAP|Nasal continuous positive airway pressure
3299053|NCT00459914|No Intervention|2|Pharmacological treatment alone
3299132|NCT00459030|Experimental|Electronic communication|Cancer screening educational information delivered via a password protected internet site.
3299054|NCT00459875|Experimental|Sunitinib|The treatment will include Sunitinib malate 50 mg self-administered orally, once daily in the evening, without regard to meals, for 4 consecutive weeks (28 days) followed by 2 weeks (14 days) off, to comprise a complete cycle of 6 weeks.
3299055|NCT00459862|Experimental|Arm I|Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
3299056|NCT00459823|Experimental|1|
3299057|NCT00459797|Active Comparator|Conventional Glidescope|
3299058|NCT00459797|Experimental|Single-use Glidescope|
3299059|NCT00459771|Placebo Comparator|Placebo|Placebo
3299060|NCT00459771|Active Comparator|Candesartan|Candasartan
3299061|NCT00459745|Active Comparator|Pravastatin|Pravastatin 40 mg
3299062|NCT00459745|Active Comparator|Fenofibrate|Fenofibrate 160 mg
3299063|NCT00459745|Experimental|Pravafen (Parvastatin and Fenofibrate)|Combined Therapy of Pravastatin 40 mg and Fenofibrate 160 mg.
3299064|NCT00459732|Placebo Comparator|Placebo Capsule|placebo capsule, similar in size, shape and color to zinc capsule, taken once daily for 18 months
3299065|NCT00459732|Active Comparator|Zinc (25 mg/d)|25 mg of elemental Zinc as zinc sulphate taken once daily for 18 months
3299066|NCT00459719|Experimental|1|In combination with steroids
3299067|NCT00459719|Active Comparator|2|In combination with steroids
3299068|NCT00459706|Experimental|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
3299069|NCT00459706|Experimental|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
3299070|NCT00459680|Experimental|Acupuncture|
3299071|NCT00459680|Experimental|Laser Acupoint|
3299072|NCT00459667|Experimental|IFNB-1b 500 mcg|Interferon beta 1b ([IFNB 1b] Betaseron) 500 mcg administered s.c. every other day (double blind)
3299073|NCT00459667|Experimental|IFNB-1b 250 mcg|Interferon beta 1b ([IFNB 1b] Betaseron) 250 mcg administered s.c. every other day (double blind)
3299074|NCT00459667|Experimental|IFNB-1b 250 mcg*|"Interferon beta 1b ([IFNB 1b] Betaseron) 250 mcg administered s.c. every other day~*(Subjects who were administered Copaxone and subjects who had prematurely discontinued medication during BEYOND study.)"
3299075|NCT00459654|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Each subject receives local filed external beam radiotherapy (EBR) and repeated injections of the investigational drug radium-223 (EBR+Radium-223)
3299076|NCT00459654|Placebo Comparator|Saline|Each subject receives local filed external beam radiotherapy (EBR) and repeated injections of saline (EBR+placebo)
3299077|NCT00459641|Experimental|1|I-040302 doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
3299078|NCT00459641|Active Comparator|2|Standard of care (bone marrow aspirate or steroids)
3299079|NCT00459628|Active Comparator|Conventional radiotherapy|Conventional Long schedule Radiotherapy Arm
3299080|NCT00459628|Experimental|Tomotherapy|Short course schedule by tomotherapy
3299081|NCT00459602||Laparoscopic incisional hernia repair|Subjects with an incisional, ventral, umbilical, or spigelian hernia no larger tham 15 cm at the largest measurement, who are candidates for laparoscopic repair of the hernia, and who are able to commit to long-term followup. Laparoscopic repair will proceed as per the standard technique, using polyester mesh.
3299082|NCT00459589|Experimental|1|nutritional intervention with dietician at each cycle of chemotherapy in 6 first cycles to maintain 30 kcal/kg/d and 1.2 protein/kg/d
3299083|NCT00459589|Active Comparator|2|
3299084|NCT00459563|Placebo Comparator|Placebo|
3299085|NCT00459563|Active Comparator|Cholecalciferol|Cholecalciferol
3299086|NCT00459563|Active Comparator|Calcitriol|Calcitriol
3299087|NCT00459550|Experimental|Part A|Part A will be a single-blind, single dose, placebo controlled, dose escalation study in up to five consecutive cohorts of Alzheimers Disease subjects. Each subject will receive a single infusion of GSK933776 or placebo. The dose for the first cohort will be 0.001 mg/kg. The proposed nominal doses for subsequent cohorts are 0.01, 0.1, 0.5 and 3 mg/kg, but these may be altered based on the outcome of the safety, tolerability, pharmacodynamic and pharmacokinetic data of the preceding group(s). The maximum possible dose will be 20 mg/kg, although the planned top dose is 18 mg/kg
3299088|NCT00459550|Experimental|Part B|"Part B will be a single-blind, repeat dose, placebo controlled dose escalation design. It is proposed that there will be initially 3 cohorts of AD subjects. However up to 5 cohorts may be recruited if required in order to characterise GSK933776 fully.Each cohort will consist of eight subjects (six active, two placebo) who will each receive a maximum of three infusions of GSK933776 or placebo. Dosing in Part B may proceed in parallel with Part A following satisfactory review of minimum data sets as below:~First cohort in Part B: at least 3 weeks' data from the Part A dose that is the same dose level as that planned for Part B Second cohort in Part B: at least 3 weeks PK data and 8 weeks safety data following the first dose from all the subjects on active treatment in the preceding Part B cohort plus a satisfactory outcome of the PIB Subsequent cohorts in Part B: at least 3 weeks PK data and 8 weeks safety data follow"
3299089|NCT00459537|Experimental|Terbinafine|10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.
3299090|NCT00459537|Active Comparator|Amorolfine|5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.
3299091|NCT00459524||Questionnaire|AML and MDS Patients
3299092|NCT00459485|Experimental|Zinc supplement (20 mg)|Daily intake of 20 mg supplementary zinc
3299093|NCT00459485|Experimental|Zinc supplement (10 mg)|Daily intake of 10 mg supplementary zinc
3299094|NCT00459485|Placebo Comparator|Placebo supplement|Daily intake of placebo supplement
3299095|NCT00459472|Other|Training|laparoscopic training curriculum: all general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
3299096|NCT00459433|Experimental|1|psychosocial intervention
3299097|NCT00459433|Active Comparator|2|Usual care
3299098|NCT00459420|Placebo Comparator|Placebo|
3299099|NCT00459420|Experimental|Caffeine|
3299100|NCT00459407|Experimental|Arm I (green tea catechin extract)|"Patients receive oral defined green tea catechin extract daily for 4-7 weeks.~All patients undergo surgery one day after the last dose of study agent."
3299101|NCT00459407|Placebo Comparator|Arm II (placebo)|"Patients receive oral placebo daily for 4-7 weeks.~All patients undergo surgery one day after the last dose of study agent."
3299102|NCT00459381|Experimental|Treatment (pazopanib hydrochloride)|"Patients receive oral pazopanib hydrochloride daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Other: laboratory biomarker analysis"
3299103|NCT00459368|Experimental|I|In this cluster-randomized trial physicians practicing at intervention clinic sites will receive adherence information on their patients with asthma who are currently taking an inhaled corticosteroid medication. This information will be available to them via our electronic prescribing software to discuss with patients at the time of the visit. Physicians at these sites also receive standardized training in how to interpret and intervene when poor adherence is identified.
3299104|NCT00459368|Active Comparator|II|Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
3299105|NCT00459355|Experimental|Home Safety Toolkit|Intervention group receives home safety tool-kit with education and self-efficacy materials to promote competence to make home safety modifications.
3299106|NCT00459355|No Intervention|Conventional Safety Checklist|Comparison group received a conventional home safety checklist
3299107|NCT00459342|Experimental|Arm I|Patients received oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3299108|NCT00459316|Experimental|Group 1|Participants ≤11 to <25 years of age with CD4% at screening ≥15%. All received Quadrivalent meningococcal conjugate vaccine at entry, those who were eligible were randomized at week 24, with Group 1B receiving a second Quadrivalent meningococcal conjugate vaccine at week 24. Those who were eligible received a booster dose of Quadrivalent meningococcal vaccine at 3.5 years.
3299109|NCT00459316|Experimental|Group 2|Participants ≤11 to <25 years of age with CD4% at screening <15%; All receiving Quadrivalent meningococcal conjugate vaccine at entry, with those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24 and 3 years.
3299110|NCT00459316|Experimental|Group 3|Participants >=2 to <11 years of age with CD4% at screening ≥ 25%; All received Quadrivalent meningococcal conjugate vaccine at entry, with those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24 and 3 years.
3299111|NCT00459303|Active Comparator|intraocular lens|patients with bilateral clinical significant cataract reisiceved cataract surgeries and recieved spherial intraocuar lens(SA60AT, Alcon) in one eye and aspherical intraocular lens(Tecnis Z9000, AMO)in the other respectively.
3299112|NCT00459290|Experimental|Mifepristone 200 mg PO daily|Mifepristone 200 mg PO daily administered on a continuous basis (every 4 weeks is considered one cycle) until disease progression or adverse effects prohibit further therapy.
3299113|NCT00459277|Experimental|Nasalfent, Fentanyl Citrate Nasal Spray|
3299114|NCT00459277|Placebo Comparator|Placebo Spray|
3299115|NCT00459264|Active Comparator|1|Folic Acid
3299116|NCT00459264|Placebo Comparator|2|Matching placebo for folic acid
3299117|NCT00459225|Active Comparator|1|The parent/guardian will be educated on the iron study and provided the opportunity to ask questions. If the parent/guardian chooses to participate in the study, the parent/guardian will give informed consent for the patient to be placed in either Group I or Group II, based upon guardian/parents' choice for participation in the iron arm of the study. Group I will be randomized in a 1:1 ratio in this open label trial to either receive or not receive iron. Group II will not receive iron but will be a participant in the study and follow the course of the non-iron randomized patients.
3299118|NCT00459225|No Intervention|2|Group II will not receive iron but will be a participant in the study and follow the course of the non-iron randomized patients.
3299119|NCT00459212|Experimental|Arm I|Patients receive GTI-2040 IV continuously on days 1-4 and 15-18.
3299120|NCT00459186|Experimental|RAD001 Followed by RAD001 + Docetaxel|RAD001 10 mg daily for 2 weeks, followed by RAD001 + Docetaxel at one of three doses: 5 mg RAD001 and docetaxel at 60 mg/m2, 10 mg RAD001 and docetaxel at 60 mg/m2, and 10 mg RAD001 and docetaxel at 70 mg/m2. RAD001 was given daily. Docetaxel was given every 3 weeks by intravenous infusion. Patients also received prednisone 5 mg by mouth twice daily.
3299121|NCT00459160|Experimental|Low MAP Group|Hypotensive Group with a target minimum MAP of 50 mmHg
3299122|NCT00459160|No Intervention|High MAP group|Non experimental group: These patients will have a target minimum MAP of 65 mm Hg
3299123|NCT00459134|Experimental|Arm I: ArginMax|ArginMax® 3 pills twice daily
3299124|NCT00459134|Placebo Comparator|Arm II: Placebo|Patients receive oral placebo 3 pills twice daily
3299125|NCT00459121|Experimental|Zactima, Paclitaxel, Carboplatin|"Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.~Neoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment."
3299126|NCT00459108|Experimental|Oral Dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3299127|NCT00459056|Experimental|Carvediolol CR + Lisinopril, then Lisinopril + HCTZ|Subjects were randomly assigned to Carvedilol CR + Lisinopril for three months, then had a washout period of one month, and then were given Lisinopril + HCTZ for the final three months.
3299128|NCT00459056|Active Comparator|Lisinopril + HCTZ, then Carvedilol CR + Lisinopril|Subjects were randomally assigned to Lisinopril + HCTZ for three months, then had a washout period for one month, and then were given Carvedilol CR + Lisinopril for the final three months.
3299129|NCT00459043|Active Comparator|1|Docetaxel Alone
3299130|NCT00459043|Active Comparator|2|Docetaxel with ZD6474
3299131|NCT00459030|Experimental|Print Communication|Cancer screening educational information mailed to patient's home one time after signing consent.
3299275|NCT00457119|Experimental|Step 2, Arm 2|30mg/week RAD001 + Carboplatin + Paclitaxel + Bevacizumab
3299133|NCT00459030|Active Comparator|No Health Communication|No additional cancer screening education information sent to patient.
3299134|NCT00458978|Experimental|Treatment (enzyme inhibitor)|Patients receive oral cediranib maleate once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3299135|NCT00458952|Experimental|Dose Escalation|Dosing of Ultratrace iobenguane I 131 began at 6.0 mCi/kg and escalated in 1.0 mCi/kg increments in order to establish the MTD. The MTD is the dose immediately below the level at which escalation stops due to dose-limiting toxicity (DLT). An additional 3 patients are to be treated at the MTD, for a total of 6.
3299136|NCT00458900|Experimental|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
3299137|NCT00458887||Ancillary/Correlative (ototoxicity assessment)|"Patients undergo hearing tests (conventional, otoscopy, ultrahigh frequency, and otoacoustic emission testing) for management of therapy complications before the first course of planned cisplatin, before each subsequent course of cisplatin, and 4 weeks after the last dose of cisplatin.~Patients who are scheduled to receive hematopoietic progenitor stem cell transplantation undergo hearing tests for management of therapy complications before the transplantation and 4 weeks after transplantation."
3299138|NCT00458874|Experimental|Receive CIMT Results (R-CIMT)|This group will receive visual feedback of their CIMT results on a weekly basis.
3299139|NCT00458874|No Intervention|Withhold CIMT Results (W-CIMT)|The W-CIMT group will not receive their CIMT results until the end of their study participation.
3299140|NCT00458861|Experimental|BG9924|Subcutaneous administration of BG9924 given every other week for 12 weeks
3299141|NCT00458861|Placebo Comparator|Placebo|Subcutaneous administration of placebo given every other week for 12 weeks
3299142|NCT00458822|Experimental|All Patients|All patients treated with Melphalan with Stem Cell Transplant and Adjuvant Bortezomib and Dexamethasone for Recently Diagnosed Untreated Patients with Systemic Light-Chain (AL) Amyloidosis
3299143|NCT00458809|Experimental|Hyperthermic Chemoperfusion with Oxaliplatin 200 mg/m2|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin 200 mg/m2
3299144|NCT00458809|Experimental|Hyperthermic Chemoperfusion with Oxaliplatin 250 mg/m2|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin 250 mg/m2
3299145|NCT00458783|Active Comparator|Prolonged RBC storage|Transfusion with oldest available matching RBCs.
3299146|NCT00458783|Active Comparator|Short RBC storage|Transfusion with youngest available matching RBCs.
3299147|NCT00458731|Experimental|Treatment (cediranib maleate and bevacizumab)|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral cediranib maleate once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of bevacizumab and cediranib maleate until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3299148|NCT00458705|Experimental|Combination therapy|Combination therapy with bortezomib, pegylated liposomal doxorubicin and dexamethasone (BDD) followed by either thalidomide and dexamethasone (TD) or bortezomib, thalidomide and dexamethasone in patients with symptomatic untreated high-risk or primary resistant multiple myeloma. Three cycles of BDD will be administered. Patients who respond after three cycles will receive two cycles of TD. Patients with stable or progressive disease after three cycles of BDD receive two cycles of bortezomib, thalidomide and dexamethasone. If at any point during the study a patient achieves a complete response (CR), the patient will be given the option to discontinue treatment on-study.
3299149|NCT00458679|Experimental|Vaccine|autologous B-CLL vaccine expressing CD40L and IL2
3299150|NCT00458653|Experimental|Group A|Post-transplant vaccination
3299151|NCT00458653|Experimental|Group B|Pre- and post-transplant vaccination
3299152|NCT00458601|Experimental|CDX-110 with GM-CSF|
3299153|NCT00458575|Experimental|CNTO 2476|Participants 1 to 4: advanced retinitis pigmentosa (RP) with light perception only (LP); Participant 5: combination visual acuity of LP in the treated eye and no better than hand motion (HM) in the fellow eye; and Participants 6 to 9: advanced RP with hand motion (HM) will receive different dose levels of CNTO 2476.
3299154|NCT00458562||HIV+, <CIN2|HIV positive women without CIN2-3 or worse
3299155|NCT00458562||HIV-, no >=CIN3 biopsy, HR HPV+|HIV negative women without biopsy-proven CIN3 or worse, and with high risk HPV infection
3299156|NCT00458562||HIV-, <=CIN1, HPV- at screening|HIV negative women who are <= CIN1 and HPV negative at screening
3299157|NCT00458549|Experimental|omega-3 fatty acids|omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
3299158|NCT00458549|Placebo Comparator|Corn Oil|Oral 8g once a day for 21 days prior to (biopsy) surgery
3299159|NCT00458510|Experimental|Fentanyl, Open-Label treatment|All patients take NasalFent at effective dose to treat up to four episodes of breakthrough cancer pain per day
3299160|NCT00458497|Experimental|1|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
3299161|NCT00458497|Placebo Comparator|2|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric.
3299162|NCT00458484|Experimental|Stereotactic radiosurgery|
3299163|NCT00458458|Active Comparator|NA alone|Norethindrone Acetate (NA) 5mg taken 1-3 tabs orally every night for duration of treatment
3299164|NCT00458458|Active Comparator|LD then NA|Lupron Depot(LD) given intramuscularly every 12 weeks for total of 24 weeks then switched to Norethindrone Acetate (NA) taken 1-3 tablets orally every night for remainder of treatment
3299165|NCT00458419|Placebo Comparator|A: naloxone; B: normal saline|Arm A: IV naloxone Arm B: IV normal saline
3299166|NCT00458406|Active Comparator|Bi-Flex|"Subjects randomized to this arm will undergo a clinical Bi-Flex sleep study. Following a baseline polysomnography, subjects in this arm will undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~In this randomized, double-blinded clinical trial, patients with obstructive sleep apnea will be randomized to Bi-Flex or CPAP, and repeat polysomnography will be performed on pressure at 3 months. Objective adherence data will be obtained at 1 and 3 months."
3299276|NCT00457015|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections.
3299167|NCT00458406|Active Comparator|CPAP|"Subjects randomized to this arm will undergo a clinical CPAP titration sleep study.~Subjects in this arm received standard continuous positive airway pressure (CPAP) therapy.~In this randomized, double-blinded clinical trial, patients with obstructive sleep apnea will randomized to CPAP or Bi-Flex, and repeat polysomnography will be performed on pressure at 3 months. Objective adherence data will be obtained at 1 and 3 months."
3299168|NCT00458393|Experimental|TDF/FTC|Drug. Daily oral tablet of co-formulated 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate (TDF/FTC).
3299169|NCT00458393|Placebo Comparator|Placebo|Drug. Daily oral placebo
3299170|NCT00458367||001|Open label risperidone long acting injectable intramuscular injections every 2 weeks for 26 weeks flexible dose 25 to 50 mg
3299171|NCT00458354|Experimental|Spinal Sealant|Dural repair with the Spinal Sealant System.
3299172|NCT00458354|Active Comparator|Standard Methods|Dural repair with standard methods such as the closing of the dura with stitches.
3299173|NCT00458302|Experimental|darunavir monotherapy|darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
3299174|NCT00458302|Experimental|darunavir + 2 NRTI|darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
3299175|NCT00458289|No Intervention|1|P-containing meal alone
3299176|NCT00458289|Active Comparator|2|P-containing meal AND single 1 g oral dose of chewed lanthanum carbonate
3299177|NCT00458289|Active Comparator|3|P-containing meal and single 1 g oral dose of lanthanum carbonate crushed into a fine powder
3299178|NCT00458276|Experimental|1|Tezosentan
3299179|NCT00458276|Placebo Comparator|2|Placebo
3299180|NCT00458263|Experimental|single arm|
3299181|NCT00458237|Experimental|Ph I: Everolimus L1 + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 5 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
3299182|NCT00458237|Experimental|Ph I: Everolimus L2 + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 10 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
3299183|NCT00458237|Experimental|PhII: Everolimus MTD + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus at the MTD by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
3299184|NCT00458224|Experimental|Parental counseling|Life style counseling
3299185|NCT00458211|Experimental|Experimental|Open label change to ziprasidone
3299186|NCT00458198|Experimental|1|Participants will receive integrated behavioral therapy
3299187|NCT00458198|Active Comparator|2|Participants will receive integrated behavioral therapy after a 12-week waitlist period
3299188|NCT00458159|Experimental|1|
3299189|NCT00458146|Experimental|1|MM-093
3299190|NCT00458146|Placebo Comparator|2|Placebo
3299191|NCT00458133|Experimental|1|We randomly assigned 72 individuals to an aerobic exercise training only group.
3299192|NCT00458133|Experimental|2|We randomly assigned 73 individuals to an resistance exercise training only group.
3299193|NCT00458133|Experimental|3|We randomly assigned 76 individuals to a combination of aerobic plus resistance training group.
3299194|NCT00458133|Placebo Comparator|4|We randomly assigned 41 individuals to a stretching and relaxation group.
3299195|NCT00458120|Experimental|1|Participants previously vaccinated with rDEN4delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN1delta30 vaccine into the deltoid region of either arm.
3299196|NCT00458120|Experimental|2|Participants previously vaccinated with rDEN4delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN2/4delta30(ME) into the deltoid region of either arm.
3299197|NCT00458120|Experimental|3|Participants previously vaccinated with rDEN2/4delta30(ME) will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN1delta30 vaccine into the deltoid region of either arm.
3299198|NCT00458120|Experimental|4|Participants previously vaccinated with rDEN1delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN2/4delta30(ME) vaccine into the deltoid region of either arm.
3299199|NCT00458120|Placebo Comparator|5|One subcutaneous vaccination with placebo into the deltoid region of either arm.
3299200|NCT00458094|Experimental|1|Participants will receive the peer-supported physical activity intervention
3299201|NCT00458094|Active Comparator|2|Participants will receive physical activity without peer support
3299202|NCT00458081|Experimental|Rimonabant|
3299203|NCT00458081|Placebo Comparator|Placebo|
3299204|NCT00458029|Experimental|1|integration of activities, events, and programs affecting total school food service environment, physical education class, behavior change, promotion, and communications
3299205|NCT00458029|No Intervention|2|observational control
3299206|NCT00458016|Experimental|1|
3299207|NCT00458016|Experimental|2|
3299208|NCT00458016|Experimental|3|
3299209|NCT00458016|Experimental|4|
3299210|NCT00458016|Placebo Comparator|5|
3299211|NCT00458003|Experimental|Phenylephrine|Subject will receive a phenylephrine infusion to prevent and to treat hypotension associated with spinal anesthesia
3299212|NCT00458003|Active Comparator|Ephedrine|Subject will receive an ephedrine infusion to prevent and to treat hypotension associated with spinal anesthesia
3299213|NCT00457977|Active Comparator|Pneumovax (PPSV23)|pneumococcal capsular polysaccharide vaccine (PPSV23) (Pneumovax)
3299214|NCT00457977|Active Comparator|Prevnar (PCV7)|diphtheria protein-conjugated vaccine (PCV7) (Prevnar) 1.0 mL dose
3299215|NCT00457964|Experimental|Administration of RAD001|
3299216|NCT00457951|Experimental|Open Label|Initial six subjects treated with ODSH open-label to confirm safety in subjects with an acute exacerbation of COPD; six additional patients will be enrolled following safety review.
3299217|NCT00457951|Placebo Comparator|0.9% Sodium Chloride|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride Solution bolus; dose of 0.375mg/kg/hr over 96 hours.
3299277|NCT00457015|Placebo Comparator|Placebo|Placebo, Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.
3299420|NCT00455182|Experimental|2|Acupuncture
3299218|NCT00457951|Active Comparator|Randomized, Blinded, ODSH Arm|Subjects will receive standard of care treatment. ODSH is administered in bolus doses estimated to inhibit inflammatory mediators randomized 1:1 to ODSH 8mg/kg or placebo. The continuous infusion dose will be 0.375 mg/kg/hr over 96 hours.
3299219|NCT00457938|Active Comparator|"Low fat diet is the drug"|Diet 10% fat versus 35% fat
3299220|NCT00457873|Experimental|A|0.9% saline in 5% dextrose (intravenous)
3299221|NCT00457873|Active Comparator|B|0.45% saline in 5% dextrose (intravenous)
3299222|NCT00457821|Experimental|Ivacaftor Group A|Subjects in Part 1 who first received 25 mg or 75 mg of ivacaftor every 12 hours (q12h) for 14 days, then crossed over to receive the alternate dose for another 14 days.
3299223|NCT00457821|Experimental|Ivacaftor Group B|Subjects in Part 1 who first received 75 mg or 150 mg of ivacaftor q12h for 14 days then crossed over to receive the alternate dose for another 14 days.
3299224|NCT00457821|Experimental|Ivacaftor Group C|Subjects in Part 2 who received 150 mg or 250 mg of ivacaftor q12h for 28 days.
3299225|NCT00457821|Placebo Comparator|Placebo|Subjects who received placebo in Part 1 and subjects who received placebo in Part 2.
3299226|NCT00457795|Experimental|brimonidine 0.1%|brimonidine 0.1%
3299227|NCT00457782|Experimental|I|Intravenous KW-2478 (ascending dose cohorts)
3299228|NCT00457769|Experimental|Aricept- A|Half of subjects are randomized to immediate treatment with donepezil 5mg orally daily following baseline testing, with retesting at 12 and 24 weeks.
3299229|NCT00457769|Experimental|A2-12-week waiting period|The remaining nine subjects are randomized to testing followed by a 12-week waiting period. After the 12 week wait, this group of subjects is retested and begins taking donepezil, 5 mg orally daily, with retesting at 24 weeks
3299230|NCT00457756|Active Comparator|I|Cohort I subjects will take supplement for 12 weeks
3299231|NCT00457756|Placebo Comparator|II|Cohort II will take placebo for 12 weeks
3299232|NCT00457743|Experimental|SU011248|25 , 50 or 75 mg/day of SU011248
3299233|NCT00457730|Experimental|Duloxetine|subjects will be randomized to study drug (Duloxetine) or Placebo. Subjects will take 30 mg (10 capsules) titrate up to 60 mg( 40 capsules) and titrate back down to 30 mg.
3299234|NCT00457730|Placebo Comparator|placebo|matched placebo medication
3299235|NCT00457691|Experimental|1|
3299236|NCT00457691|Placebo Comparator|2|
3299237|NCT00457652|Active Comparator|1|7 day treatment rosuvastatin
3299238|NCT00457652|Placebo Comparator|2|7 day treatment placebo
3299239|NCT00457639|Experimental|Cholic Acid active capsules|Cholic Acid weight based dose for 6 months double-blind
3299240|NCT00457639|Placebo Comparator|Placebo for Cholic Acid|Placebo for Cholic Acid for 6 months double-blind
3299241|NCT00457626|Experimental|Valsartan|
3299242|NCT00457509|Experimental|Group 1|Dose 1 with Adjuvant
3299243|NCT00457509|Experimental|Group 2|Dose 2 with adjuvant
3299244|NCT00457509|Experimental|Group 3|Dose 3 with adjuvant
3299245|NCT00457509|Experimental|Group 4|Dose 4 with adjuvant
3299246|NCT00457509|Active Comparator|Group 5|Control
3299247|NCT00457496|Active Comparator|A|
3299248|NCT00457457|Active Comparator|Comparator|Tamsulosin 0.4 mg prolonged release
3299249|NCT00457457|Experimental|Treatment Arm|There are 5 possible UK-369,003 arms as follows: UK-369,003 MR (10mg, 25mg, 50mg & 100mg), UK-369,003 IR (40mg),
3299250|NCT00457431|No Intervention|Control|Standard therapy as used in the hospital's ICU
3299251|NCT00457431|Active Comparator|Hypothermia|Standard therapy as used in the hospital's ICU plus Hypothermia
3299252|NCT00457418|Experimental|PEG-Intron|"6 ug/kg/week, SC (first 8 weeks)~3 ug/kg/week, SC (252 weeks [weeks 9-260], maintenance)"
3299253|NCT00457405|Active Comparator|1|first 7 day treatment with dipyridamol and at least two weeks later 7 day treatment with placebo
3299254|NCT00457405|Active Comparator|2|first 7 day treatment with placebo and at least two weeks later 7 day treatment with atorvastatin
3299255|NCT00457392|Experimental|1|
3299256|NCT00457392|Active Comparator|2|
3299257|NCT00457366|Active Comparator|1|Quetiapine
3299258|NCT00457366|Active Comparator|2|Cocktail (Haloperidol, Lorazepam, Cogentin)
3299259|NCT00457353|Active Comparator|1|Administration of oral rehydration therapy with Bacillus clausii probiotic strain (1 vial twice daily, each vial containing 2 billion spores of Bacillus clausii)
3299260|NCT00457353|Placebo Comparator|2|Administration of Oral rehydration therapy
3299261|NCT00457314|Experimental|1|Participants will partake in regular exercise training for 6 months. After 6 months, they will switch to no exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
3299262|NCT00457314|Experimental|2|Participants will not partake in regular exercise training for 6 months. After 6 months, they will switch to exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
3299263|NCT00457301|No Intervention|Control|
3299264|NCT00457249|Experimental|Adacel Vaccine Group|
3299265|NCT00457249|Active Comparator|DECAVAC Vaccine Group|
3299266|NCT00457223|Experimental|1Fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®)
3299267|NCT00457223|Active Comparator|2 Suture|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using continuous suture with nylon 10-0
3299268|NCT00457197|Placebo Comparator|Placebo|This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
3299269|NCT00457197|Active Comparator|Quetiapine|This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
3299270|NCT00457158|Experimental|1|ALN optional filter
3299271|NCT00457158|No Intervention|2|No ALN optional filter
3299272|NCT00457119|Experimental|Step 1 Arm 1|5mg/day RAD001 + Carboplatin + Paclitaxel
3299273|NCT00457119|Experimental|Step 1, Arm 2|30mg/week RAD001 + Carboplatin + Paclitaxel
3299274|NCT00457119|Experimental|Step 2, Arm 1|5mg/day RAD001 + Carboplatin + Paclitaxel + Bevacizumab
3299421|NCT00455182|Sham Comparator|3|Sham acupuncture
3299278|NCT00457002|Experimental|Arm 1|"While hospitalized, Apixaban plus Placebo~Apixaban (Tablets, Oral, 2.5 mg), Placebo (Syringes, SC)~After hospital discharge, Apixaban~Apixaban (Tablets, Oral, 2.5 mg)"
3299279|NCT00457002|Active Comparator|Arm 2|"While hospitalized, Enoxaparin plus Placebo~Enoxaparin (Syringes, SC, 40 mg), Placebo (Tablets, Oral)~After hospital discharge: Placebo~Placebo (Tablets, Oral)"
3299280|NCT00456989|Experimental|Taxotere and Doxil|Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively. Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
3299281|NCT00456963|Experimental|Diet, exercise and Enalapril|one Enalapril 10mg tablet and one Losartan placebo tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet and one Losartan placebo tablet once daily until the end of the randomized treatment phase. After this one Enalapril placebo tablet and one Losartan placebo tablet once daily for six months.
3299282|NCT00456963|Active Comparator|Diet, Exercise and Losartan|one Losartan 50mg tablet and one Enalapril placebo tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet and one Enalapril placebo tablet once daily until the end of the randomized treatment phase. After this one Losartan placebo tablet and one Enalapril placebo tablet once daily for six months.
3299283|NCT00456963|Placebo Comparator|Diet, exercise and Placebo|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
3299284|NCT00456885|Placebo Comparator|Exenatide First|Started on Exenatide, 3 week washout, start placebo
3299285|NCT00456885|Experimental|Placebo First|Started on placebo, 3 week washout, start exenatide
3299286|NCT00456872|Experimental|buffered lidocaine|Sodium bicarbonate is a buffering additive that decreases the pH of the solution allowing for decrease in pain upon filtration.
3299287|NCT00456872|Experimental|unbuffered lidocaine|lidocaine is injected without sodium bicarbonate added
3299288|NCT00456846|Experimental|ABI-007|100 mg/m^2 ABI-007 was administered by intravenous (IV) infusion over 30 minutes weekly for 3 weeks followed by 1 week rest. Therapy continued until disease progression or unacceptable toxicity.
3299289|NCT00456833|Experimental|RAD 5mg/day + erlotinib|
3299290|NCT00456833|Active Comparator|erlotinib 150mg/day|
3299291|NCT00456807|Experimental|Cervarix Group|Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).
3299292|NCT00456807|Placebo Comparator|Placebo Group|Subjects who received 3 doses of placebo during the primary study (NCT00294047).
3299293|NCT00456781|Experimental|Augmentation|Rotator Cuff Repair augmented with the Graft Jacket Device
3299294|NCT00456781|Active Comparator|No Augmentation|Rotator Cuff RFepair
3299295|NCT00456755|Active Comparator|Shi-Bi-Lin|Consist of 6 herbal. 7.5 g Xanthium sibiricum Patrin ex Widder (Asteraceae, Fructus), 20 g Angelica dahurica (Fisch. ex Hoffm.) Benth. (Apiaceae, Radix), 7.5 g Saposhnikovia divaricata (Turcz.) Schischk. (Apiaceae, Radix),15 g Magnolia biondii Pamp., (Magnoliaceae, Flos), 5 g Gentiana scabra Bunge (Gentianaceae, Radix) and 5 g Verbena officinalis L. (Verbenaceae, Herba).
3299296|NCT00456755|Placebo Comparator|Placebo|The placebo contained brown colored starch resembling the SBL powder
3299297|NCT00456703|Active Comparator|restriction|In this group, the fluids will be restricted compared to a standard procedure
3299298|NCT00456690|Experimental|1|Thalassemia Mayor Patients
3299299|NCT00456677|Experimental|Minocycline|Addition of minocycline 150 mg po twice daily to current asthma treatment regimen.
3299300|NCT00456677|Placebo Comparator|Placebos|Addition of placebo capsules po twice daily to current asthma treatment regimen
3299301|NCT00456638|Experimental|Depodur|Depodur arm
3299302|NCT00456638|Active Comparator|Traditional|traditional management
3299303|NCT00456625|Experimental|Group Engerix™-B|Subjects received a dose of Hepatitis B vaccine approximately 20 years after the primary neonatal vaccination
3299304|NCT00456612|Other|Cyberknife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
3299305|NCT00456599|Experimental|Oxaliplatin & gemcitabine with radiation|This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer.
3299306|NCT00456547||Postpartum hysterectomy|Women that require postpartum hysterectomy for post-delivery bleeding.
3299307|NCT00456547||Cesarean delivery case controls|Women that deliver by cesarean that presented with risk factors for bleeding but did not require post delivery hysterectomy
3299308|NCT00456521|Experimental|NB32|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day with intensive group lifestyle modification counseling
3299309|NCT00456521|Placebo Comparator|Placebo|Placebo with intensive group lifestyle modification counseling
3299310|NCT00456508|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) Patients were treated with DX-88 (ecallantide) when they experienced an HAE attack. 30 mg dose of ecallantide given via 3 SC injections; a second 30 mg dose can be administered if needed. Patients were to be assessed until 4 hrs post-dose. Patients were asked to return for 3 follow-up visits: 7 days, 28 days and 90 days post-dose.
3299311|NCT00456495|Experimental|Subconjunctival ranibizumab|Patients will receive subconjunctival ranibizumab every 2-4 weeks.
3299312|NCT00456482|Experimental|Fluocinolone Acetonide 0.59mg|Fluocinolone acetonide intravitreal implant 0.59mg
3299313|NCT00456482|Experimental|Fluocinolone Acetonide 2.1mg|Fluocinolone acetonide intravitreal implant 2.1mg
3299314|NCT00456482|No Intervention|No Intervention|Fellow eye
3299315|NCT00456378|Experimental|DIAM™ spinal stabilization system|Implantation of the DIAM Spinal Stabilization System
3299316|NCT00456378|Active Comparator|Conservative care|Conservative Care
3299317|NCT00456365|Experimental|Pravastatin|Pravastatin
3299318|NCT00456365|Placebo Comparator|Placebo|Placebo
3299319|NCT00456326||HIT Patients|Patients at Brigham and Women's Hospital diagnosed with Heparin Induced Thrombocytopenia.
3299320|NCT00456313|Active Comparator|arm 1|
3299321|NCT00456274|Other|1|
3299367|NCT00455741|Active Comparator|Older postmenopausal women|Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women..
3299368|NCT00455702|Experimental|D-cycloserine|50 mg d-cycloserine
3299322|NCT00456261|Experimental|Cohort A|Cohort A, will receive bevacizumab 10mg/kg by vein over 30-90 minutes followed by pemetrexed 500 mg/m2 by vein over 10 minutes followed by gemcitabine 1500 mg/m2 by vein over 30-60 minutes. This regimen will be given on day 1 and day 15 of each treatment cycle. Each cycle is 28 days long. As long as their disease does not worsen patients can receive up to a maximum of 6 cycles of this combination chemotherapy. Following that they can receive bevacizumab alone once every 2 weeks as long as their disease does not worsen.
3299323|NCT00456261|Experimental|Cohort B|Cohort B, will receive bevacizumab 15mg/kg by vein over 30-90 minutes followed by pemetrexed 500 mg/m2 by vein over approximately 10 minutes followed by carboplatin AUC=5 by vein over 30-60 minutes. This regimen will be given on day 1 of each treatment cycle. Each cycle is 21 days long. As long as their disease does not worsen patients can receive up to a maximum of 6 cycles of this combination chemotherapy. Following that they can receive bevacizumab alone once every 3 weeks as long as their disease does not worsen.
3299324|NCT00456248|Experimental|1|Infergen 15 ug QD plus RBV for 36 weeks
3299325|NCT00456248|Experimental|2|Infergen 15 ug QD plus RBV for 48 weeks
3299326|NCT00456248|Active Comparator|3|
3299327|NCT00456235|Experimental|adjument MMF|adjusting the dose according to the MMF AUC of mycophenolic acid
3299328|NCT00456235|Active Comparator|continued treatment|Continued treatment empirically usual
3299329|NCT00456222||Luteal|
3299330|NCT00456222||Follicular|
3299331|NCT00456144||Group 1|GnRH agonist for 24 months
3299332|NCT00456144||Group 2|GnRH agonist for 6 months
3299333|NCT00456131|Experimental|Intervention|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
3299334|NCT00456118||repeated miscarriages|60 womens for repeated miscarriages will be included
3299335|NCT00456118||Preeclampsia|70 women for pre-eclampsia will be included
3299336|NCT00456118||intervillites|20 women for intervillites will be included
3299337|NCT00456105|Active Comparator|1|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician, post operatively until hospital discharge and post discharge in the community.
3299338|NCT00456105|Experimental|2|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team post operatively until hospital discharge and post discharge in the community. The Diabetes Action team will consist of a nurse coordinator who is a Certified Diabetes Educator (CDE) and a team of physicians specialized in the management of diabetes.
3299339|NCT00456105|Placebo Comparator|3|Subjects without diabetes will have their blood glucose levels monitored while in the hospital.
3299340|NCT00456092|Experimental|Apremilast 20 mg|20mg CC-10004 orally twice a day (BID)
3299341|NCT00456092|Experimental|Apremilast 40 mg|40 mg CC-10004 orally every day (QD)
3299342|NCT00456092|Placebo Comparator|Placebo|Matching Placebo identical to CC-10004 orally BID or QD
3299343|NCT00456014|Experimental|1 - SSRI|Participants will receive standardized pharmacotherapy with the SSRI escitalopram over 8 weeks. Non-remitters after 8 weeks will be offered standardized pharmacotherapy with desipramine
3299344|NCT00455975|Experimental|Weekly Avastin|Bevacizumab 15mg/kg IV weekly until progressive disease or toxicity
3299345|NCT00455975|Experimental|Bi-weekly Avastin|Bevacizumab 15mg/kg IV every 2 weeks until progressive disease or toxicity
3299346|NCT00455962|Active Comparator|African American women 18-35 yo|intervention: estradiol steroid infusion and progesterone steroid infusion
3299347|NCT00455962|Active Comparator|Caucasian women 18-35 yo|intervention: estradiol steroid infusion intervention: progesterone steroid infusion
3299348|NCT00455936|Experimental|study arm|Gefitinib 250mg table/QD, daily every 3 weeks
3299349|NCT00455936|Active Comparator|control arm|gemcitabine 1250mg/m2 iv on D1 & D8 every 3 weeks Cisplatin 80mg/m2 iv on D1 every 3 weeks
3299350|NCT00455923|Experimental|Seretide|Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.
3299351|NCT00455923|Experimental|Flixotide|Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.
3299352|NCT00455897|Experimental|GMCSF-RCHOP|
3299353|NCT00455871|Active Comparator|Lucentis plus Reduced Fluence PDT same day|
3299354|NCT00455871|Active Comparator|Lucentis plus reduced fluence PDT 1-2 weeks later|
3299355|NCT00455858|Active Comparator|insulin detemir|
3299356|NCT00455845|Active Comparator|1 levonorgestrel IUD|
3299357|NCT00455845|No Intervention|2 control|
3299358|NCT00455793||1|HIV
3299359|NCT00455793||2|Non-HIV infected controls
3299360|NCT00455780|Experimental|MR-/REDE-|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy for weight loss maintenance.
3299361|NCT00455780|Experimental|MR+/REDE-|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy and use of meal replacements for weight loss maintenance.
3299362|NCT00455780|Experimental|MR-/REDE+|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy as well as Reduced Energy Density Education for weight loss maintenance.
3299363|NCT00455780|Experimental|MR+/REDE+|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy, as well as Reduced Energy Density Education and continued meal replacement use, for weight loss maintenance.
3299364|NCT00455767|Active Comparator|1|Depelestat
3299365|NCT00455767|Placebo Comparator|2|Placebo
3299366|NCT00455741|Active Comparator|Young postmenopausal women|Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women.
3299369|NCT00455702|Placebo Comparator|Placebo|50 mg placebo
3299370|NCT00455689|Experimental|Developed hot flashes|Subjects who developed hot flashes after receiving leuprolide acetate (3.75 mg intramuscular injection)
3299371|NCT00455689|Experimental|Did not develop hot flashes|Subjects who did not develop hot flashes after receiving leuprolide acetate (3.75 mg intramuscular injection)
3299372|NCT00455663|Experimental|Cognitive Adaptation Training|In home treatment using environmental supports such as signs, labels, alarms, checklists and the organization of belongings to bypass cognitive impairment, cue and sequence adaptive behavior and improve a wide range of functional outcomes.
3299373|NCT00455663|Experimental|Pharm-Cognitive Adaptation Training|Uses Supports from Cognitive Adaptation Training designed only to promote adherence to medication and treatment follow up.
3299374|NCT00455663|Active Comparator|Treatment As Usual|Medication follow up and limited case management provided by local mental health authority
3299375|NCT00455650|Active Comparator|Schizophrenia, Mecamylamine|
3299376|NCT00455650|Active Comparator|Schizophrenia, Varenicline|
3299377|NCT00455650|Placebo Comparator|Schizophrenia, Placebo|
3299378|NCT00455650|Active Comparator|Control, Mecamylamine|
3299379|NCT00455650|Active Comparator|Control, Varenicline|
3299380|NCT00455650|Placebo Comparator|Control, placebo|
3299381|NCT00455598|Placebo Comparator|A|Sulfonylurea + 100 mg/week ISIS 113715 or placebo
3299382|NCT00455598|Placebo Comparator|B|Sulfonylurea + 200 mg/week ISIS 113715 or placebo
3299383|NCT00455572|Experimental|Cohort 1|Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will receive chemo-and immunotherapy in parallel.
3299384|NCT00455572|Experimental|Cohort 2|Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will first receive chemotherapy and then immunotherapy
3299385|NCT00455572|Experimental|Cohort 3|Patients with resected stage IB, II or IIIA tumors who are not due for chemotherapy. These patients will receive immunotherapy only.
3299386|NCT00455572|Experimental|Cohort 4|Patients with unresectable stage III tumors, following standard chemotherapy and/or radiotherapy. These patients will receive immunotherapy only.
3299387|NCT00455559|Experimental|Perifosine 100 mg/d + imatinib mesylate|Perifosine 100 mg/d x 28 days Oral daily dose of perifosine 100 mg and oral daily dose of imatinib mesylate (current dose at time of progression of disease [PD] without interruption). Both drugs will be taken on a continuous basis and should be taken with food. Each cycle will be defined as 28 days.
3299388|NCT00455559|Experimental|Perifosine 900 mg/d + imatinib mesylate|Perifosine 900 mg/d (300 mg tid), 1 x weekly Oral once-weekly dose of perifosine 900 mg (300 mg tid) + oral daily dose of imatinib mesylate (current dose at time of PD without interruption). Perifosine will be taken on days 1, 8, 15, and 22 of a 28-day cycle. Both medications should be taken with food.
3299389|NCT00455533|Experimental|A|
3299390|NCT00455533|Active Comparator|B|
3299391|NCT00455520|Placebo Comparator|Placebo|placebo matching placebo twice daily for 12 weeks
3299392|NCT00455520|Experimental|CG5503|CG5503 100, 150, 200, 250mg twice daily given for up to 15 weeks
3299393|NCT00455507|Experimental|1|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
3299394|NCT00455507|Experimental|2|40mg KW-6002 per day (two 20 mg KW-6002 tablets orally once daily for 12 weeks)
3299395|NCT00455507|Placebo Comparator|3|Two placebo tablets once daily for 12 weeks
3299396|NCT00455455|Active Comparator|Optifree RepleniSH Multipurpose Disinfecting Solution|
3299397|NCT00455455|Active Comparator|ReNu Multiplus Multipurpose Solution|
3299398|NCT00455429|Placebo Comparator|Placebo|
3299399|NCT00455429|Experimental|JNJ-26113100 (50 mg) once daily|
3299400|NCT00455429|Experimental|JNJ-26113100 (100 mg) once daily|
3299401|NCT00455429|Experimental|JNJ-26113100 (100 mg) twice daily|
3299402|NCT00455429|Experimental|JNJ-26113100 (250 mg) twice daily|
3299403|NCT00455403|Experimental|1|Participants will receive 80 mg of chloroquine on a daily basis.
3299404|NCT00455403|Placebo Comparator|2|Participants will receive a placebo comparator tablet on a daily basis.
3299405|NCT00455351|Experimental|A I|Study drug
3299406|NCT00455325|Placebo Comparator|Placebo Comparator Limb 1|Chloroquine placebo one tablet daily for 3 weeks
3299407|NCT00455325|Active Comparator|Chloroquine Limb 2|80mg chloroquine or placebo tablet weekly for Weeks 1-3
3299408|NCT00455325|Active Comparator|Chloroquine Limb 3|80mg tablet daily for 3 weeks
3299409|NCT00455325|Active Comparator|Chloroquine Limb 4|250mg tablet daily for 3 weeks
3299410|NCT00455312|Experimental|Patients with DC|Patients with dyskeratosis congenita (DC). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, total body irradiation and stem cell transplantation.
3299411|NCT00455312|Experimental|Patients with SAA|Patients with severe aplastic anemia (SAA). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, antithymocyte globulin, total body irradiation and stem cell transplantation.
3299412|NCT00455299|Active Comparator|a|a: suture anchoring + tackers and approximation of defect
3299413|NCT00455299|Active Comparator|b|b: suture anchoring + tackers without approximation of defect
3299414|NCT00455299|Active Comparator|c|c: only tacker fixation and approximation of defect
3299415|NCT00455299|Active Comparator|d|d: only tacker fixation without approximation of defect
3299416|NCT00455221|Experimental|Peptide Vaccine|
3299417|NCT00455195|Experimental|Alglucosidase Alfa/Alglucosidase Alfa|Participants who received alglucosidase alfa during the double-blind study and, if they completed the double-blind study, continued that treatment during the extension study. Participants received an intravenous (IV) infusion of 20 mg/kg of alglucosidase alfa every other week (qow) until their participation in both the AGLU02704 (NCT00158600) and AGLU03206 studies combined equaled a minimum of 104 weeks.
3299418|NCT00455195|Experimental|Placebo/Alglucosidase Alfa|Participants given placebo during the double-blind study, completed the double-blind study (study AGLU02704, NCT00158600), and qualified to continue into the extension study on alglucosidase alfa. Participants received an intravenous (IV) infusion of 20 mg/kg of alglucosidase alfa every other week (qow) for up to 52 weeks. Only the alglucosidase alfa treatment experience is included in this extension study.
3299419|NCT00455182|Placebo Comparator|1|Standard medical care
3299424|NCT00455156|Experimental|150/15 NES/EE CVR|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
3299425|NCT00455143|Experimental|Dexmedetomidine|Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
3299426|NCT00455143|Placebo Comparator|Placebo|Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively or until discharge from the PACU.
3299427|NCT00455117|Placebo Comparator|1|placebo (2 ml normal saline) administered intravenously at dural closure during craniotomy
3299428|NCT00455117|Active Comparator|2|parecoxib 40 mg in 2 ml normal saline administered intravenously at dural closure during craniotomy
3299429|NCT00455104||National Registry|To maintain an established national registry which will collect information related to the identification and monitoring of all persons with Fabry disease in Canada.
3299430|NCT00455052|Experimental|XMT-1001|XMT-1001 is administered I.V. every 21 days. Groups of 3 patients are given one dose and the dose increases for each group. The first dose level is 17 mg/m^2, the next dose level is 30 mg/m^2, followed by dose levels: 50 mg/m^2, 80 mg/m^2, 120 mg/m^2, 150 mg/m^2, and 190 mg/m^2 until disease progressions or unacceptable side effects are experienced.
3299431|NCT00455026|Placebo Comparator|1|0 ng/ml target effect site concentration remifentanil
3299432|NCT00455026|Active Comparator|2|2 ng/ml target concentration remifentanil
3299433|NCT00455026|Active Comparator|3|4 ng/ml target effect site concentration remifentanil
3299434|NCT00455013|Experimental|belatacept, mycophenolate mofetil (MMF)|thymoglobulin 1.5mg/kg for 4 days;IV belatacept: 10 mg/kg Days 1 and 5, then every other week through Month 3 (Weeks 2,4,6,8,10,12), and then every 4 weeks through Month 6 (Weeks 16, 20, 24),after 6 months, 5 mg/kg every 4 weeks until 12 months; MMF 1g twice daily(bis in die, BID)
3299435|NCT00455013|Experimental|belatacept, sirolimus|thymoglobulin 1.5mg/kg for 4 days;IV belatacept: 10 mg/kg Days 1 and 5, then every other week through Month 3 (Weeks 2,4,6,8,10,12), and then every 4 weeks through Month 6 (Weeks 16, 20, 24),after 6 months, 5 mg/kg every 4 weeks until 12 months;sirolimus 5 mg/day on Day 1 (day of transplant)and continued through Day 2, dosing to be adjusted to keep pre-dose C0 levels at 7-12 ng/mL for first 6 months, followed by 5 - 10 ng/mL until 12 months.
3299436|NCT00455013|Other|tacrolimus, MMF|(IMPs as comparator regimen)thymoglobulin 1.5mg/kg for 4 days; oral tacrolimus 0.1 mg/kg/day in 2 divided doses with initial targeted trough level of 8-12 ng/mL for Days 1 - 30 with dose reduction to achieve 12 hour trough target of 5-10 ng/mL for 12 months; MMF (mycophenolate mofetil) 1g BID.
3299437|NCT00455000|Experimental|Active treatment|5 possible active doses
3299438|NCT00455000|Placebo Comparator|Placebo|
3299439|NCT00454987|Experimental|Group HibMenC|Previously primed in infancy with Hib-MenC and Infanrix-IPV and boosted with Hib-MenC (Priorix co-administered). All UK subjects received a booster dose of Infanrix IPV at 40 to 43 months of age. 3 doses of Meningitec: 2 administered by intramuscular injection (IM) in the right thigh and one in the deltoid; and one dose of Infnrix-IPV administered by IM in the left thigh.
3299440|NCT00454987|Active Comparator|Group LicMenC|Previously primed in infancy with Meningitec and Pediacel and boosted with Hib-MenC (Priorix co-administered). All UK subjects received a booster dose of Infanrix IPV at 40 to 43 months of age. 2 doses of Meningitec: one administered by IM injection in the right thigh and one in the deltoid; one dose of Pediacel administered by IM injection in the letf thigh; and one dose of Priorix administered subcutaneous in the left arm.
3299441|NCT00454987|Active Comparator|Group NoBoost|Previously primed (according to the routine UK immunisation schedule) with 3 doses of a MenC conjugate vaccine and a Hib containing vaccine before the age of 8 months without booster dose at 12 months of age (only for UK). All subjects received a booster dose of Infanrix IPV and Menitorix at 40 to 43 months of age. One dose of Infnrix-IPV administered by IM injection in the left thigh and one dose of Menitorix.
3299442|NCT00454922|Active Comparator|1|education
3299443|NCT00454922|Placebo Comparator|2|standard of care
3299444|NCT00454909|Experimental|Group A|Subjects aged 10 years (< 11 years) vaccinated with meningococcal vaccine GSK134612.
3299445|NCT00454909|Experimental|Group B|Subjects aged 11 to 25 years vaccinated with meningococcal vaccine GSK134612.
3299446|NCT00454909|Active Comparator|Group C|Subjects aged 11 to 25 years vaccinated with Menactra®.
3299447|NCT00454896|Experimental|1|
3299448|NCT00454896|Placebo Comparator|2|
3299449|NCT00454883||1 cohort of patients treated with ziprasidone|
3299450|NCT00454857||Patients with ITP|Participants with ITP and currently treated for ITP were followed prospectively for a period of 12 months.
3299451|NCT00454831|Active Comparator|HEP 400mg TID|HEP-40 400 mg three times a day
3299452|NCT00454831|Active Comparator|HEP 800mg BID|HEP-40 800 mg twice a day
3299453|NCT00454831|Active Comparator|HEP 800mg TID|HEP-40 800 mg three times a day
3299454|NCT00454831|Active Comparator|HEP 2400mg QD|HEP-40 2400 mg once a day
3299455|NCT00454831|Placebo Comparator|Placebo|Placebo, three times a day
3299456|NCT00454818|Experimental|MYDICAR Very Low Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1.4x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) only.
3299457|NCT00454818|Experimental|MYDICAR Low Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
3299458|NCT00454818|Experimental|MYDICAR Mid Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3x10e12 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study).
3299650|NCT00452608|Experimental|atorvastatina|atrovastatina 80 mg/d by mouth for 10 days
3299459|NCT00454818|Experimental|MYDICAR High Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1x10e13 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study).
3299460|NCT00454818|Placebo Comparator|Placebo infusion|A single dose of placebo (Sodium Chloride Injection, USP) administered by antegrade epicardial coronary artery infusion.
3299461|NCT00454805|Active Comparator|2|Fulvestrant Monotherapy
3299462|NCT00454805|Experimental|3|AZD2171 + Fulvestrant
3299463|NCT00454792|Active Comparator|Exercise and advise to stay active|The exercise group received exercises for the stabilising muscles in the low back and abdomen together with dynamic exercises, exercises for postural instability and light physical fitness training.
3299464|NCT00454792|Experimental|Rest and use of flexible lumbar belt|The rest group was instructed to avoid hard physical activity and to rest twice daily for one hour, by lying down
3299465|NCT00454779|Experimental|Arm 1|Panitumumab + Docetaxel + Cisplatin
3299466|NCT00454779|Other|Arm 2|control
3299467|NCT00454766||Questionnaire|Questionnaire Regarding Tailored Educational Materials
3299468|NCT00454740|Experimental|1|
3299469|NCT00454714|Active Comparator|A|Sildenafil arm
3299470|NCT00454714|Placebo Comparator|B|Placebo arm
3299471|NCT00454701||1. Amevive Exposure|Patients treated with alefacept for chronic plaque psoriasis
3299472|NCT00454688|Placebo Comparator|Placebo|
3299473|NCT00454688|Experimental|Asimadoline 0.15 mg|
3299474|NCT00454688|Experimental|Asimadoline 0.5 mg|
3299475|NCT00454688|Experimental|Asimadoline 1.0 mg|
3299476|NCT00454662|Active Comparator|1|olmesartan medoxomil, Calcium channel blockers (amlodipine, azelnidipine)
3299477|NCT00454662|Active Comparator|2|AT1 subtype angiotensin II receptor antagonist/low dose diuretic
3299478|NCT00454649|Experimental|Axitinib [AG-013736] + chemotherapy combination|"The following separate groups were included:~axitinib~plus carboplatin/paclitaxel in three different schedules~plus paclitaxel~plus docetaxel/carboplatin~plus docetaxel~plus capecitabine~plus gemcitabine/cisplatin~plus pemetrexed/cisplatin"
3299479|NCT00454636|Experimental|Cisplatin / Capecitabine|Cisplatin, 80 mg/m2/day, intravenous (IV), every 3 weeks; capecitabine, 1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks.
3299480|NCT00454636|Experimental|Epirubicin / Cisplatin / Capecitabine|Epirubicin, 50 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capecitabine, 625mg/m2, orally, twice daily per 3-week cycle. Study drugs were administered for at least 24 weeks.
3299481|NCT00454636|Experimental|Epirubicin / Oxaliplatin / Capecitabine|Epirubicin, 50 mg/m2/day, IV, every 3 weeks; oxaliplatin, 130 mg/m2/day, IV, every 3 weeks; capecitabine, 625mg/m2 orally, twice daily per 3-week cycle. Study drugs were administered for at least 24 weeks.
3299482|NCT00454636|Experimental|Docetaxel / Cisplatin / Capecitabine|Docetaxel, 60 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capecitabine, 825 mg/m2, orally, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks.
3299483|NCT00454584|Experimental|CNTO 1275 45 mg|Patients will receive CNTO 1275 45 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on Physician's Global Assessment (PGA) response at Week 12 and initial treatment assignment.
3299484|NCT00454584|Experimental|CNTO 1275 90 mg|Patients will receive CNTO 1275 90 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.
3299485|NCT00454584|Active Comparator|Etanercept 50 mg|Patients will receive Etanercept 50 mg twice weekly through Week 12. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.
3299486|NCT00454571|Experimental|Pazopanib|Patients receive pazopanib hydrochloride PO QD on days 1-28 after treatment with leuprolide acetate and goserelin acetate. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3299487|NCT00454571|Active Comparator|Observation|Patients undergo observation after treatment with leuprolide acetate and goserelin acetate.
3299488|NCT00454558|Experimental|Arm 1|
3299489|NCT00454519|Experimental|A|cytoreductive surgery, IPHC, cisplatin 20 mg/m2/L, Mitomycin C 4 mg/m2/L, postoperative chemotherapy.
3299490|NCT00454519|Active Comparator|B|cytoreductive surgery alone, postoperative chemotherapy.
3299491|NCT00454454||No treatment|
3299492|NCT00454389|Experimental|A|Epi-Rad90™ Ophthalmic System procedure + Lucentis
3299493|NCT00454389|Active Comparator|B|Lucentis only
3299494|NCT00454363|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3299495|NCT00454337|Experimental|Intensification arm|emtricitabine/TDF + efavirenz or lopinavir/ritonavir + enfuvirtide
3299496|NCT00454337|Active Comparator|Standard arm|emtricitabine/TDF + efavirenz or lopinavir/ritonavir
3299497|NCT00454324|Experimental|Arm A|Carboplatin + Abraxane (240mg/m2) on Day 1 of a 21 Day cycle, up to 6 cycles
3299498|NCT00454324|Experimental|Arm B|Carboplatin + Abraxane (80mg/m2)given on Days 1, 8 and 15 of a 21 Day Cycle, up to 6 cycles
3299499|NCT00454311|Active Comparator|One cell biopsy|
3299500|NCT00454311|Other|Two cell biopsy|
3299501|NCT00454298|Active Comparator|A|AGG-523 1800 mg QD PO (12 capsules) for 28 days
3299502|NCT00454298|Active Comparator|B|AGG-523 900 mg BID PO (12 capsules) for 28 days
3299503|NCT00454298|Placebo Comparator|C|Placebo QD PO (12 capsules) for 28 days
3299504|NCT00454298|Placebo Comparator|D|Placebo BID PO (12 capsules) for 28 days
3299505|NCT00454272|Active Comparator|1, Vancomycin|Vancomycin
3299506|NCT00454272|Active Comparator|2, Teicoplanin|Teicoplanin
3299507|NCT00454259|Experimental|1|0,5 µg/kg
3299508|NCT00454259|Experimental|2|0,05 µg/kg
3299509|NCT00454259|Experimental|3|0,005 µg/kg
3299510|NCT00454259|Placebo Comparator|4|NaCl 0,9 %
3299651|NCT00452582|Experimental|Sildenafil|Orally administered sildenafil in addition to usual care.
3299511|NCT00454246|Experimental|methoxy polyethylene glycol-epoetin beta|"120-360 micrograms methoxy polyethylene glycol-epoetin beta subcutaneous (sc) monthly starting dose, for a minimum of 5 months to a maximum of 18 months.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
3299512|NCT00454246|Active Comparator|Epoetin alfa|"Patients randomized to the reference arm continued to receive their standard of care dose and regimen of epoetin alfa subcutaneous once per week for a minimum of 5 months to a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
3299513|NCT00454246|Active Comparator|Darbepoetin alfa|"Patients randomized to the reference arm continued to receive their standard of care dose and regimen of darbepoetin subcutaneous once every two weeks for a minimum of 5 months and a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
3299514|NCT00454233|Experimental|1|Dose 1
3299515|NCT00454233|Experimental|2|Dose 2
3299516|NCT00454233|Experimental|3|Dose 3
3299517|NCT00454233|Experimental|4|Dose 4
3299518|NCT00454233|Active Comparator|5|
3299519|NCT00454233|Placebo Comparator|6|
3299520|NCT00454220|Placebo Comparator|Placebo|
3299521|NCT00454220|Experimental|0.01 mg MRrhTSH + 131-I arm|
3299522|NCT00454220|Experimental|0.03 mg MRrhTSH + 131-I arm|
3299523|NCT00454207|Experimental|sildenafil citrate (UK-92,480)|sildenafil citrate 20 mg TID
3299524|NCT00454194|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily on days 1-21 and pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3299525|NCT00454194|Active Comparator|Arm II|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3299526|NCT00454181|Experimental|IFN lozenges|500 IU Interferon-alpha lozenges for oral dissolution
3299527|NCT00454181|Placebo Comparator|placebo lozenges|200 mg lozenges containing anhydrous crystalline maltose
3299528|NCT00454168|Experimental|Arm I|Patients receive PR1 leukemia peptide vaccine and sargramostim (GM-CSF) subcutaneously.
3299529|NCT00454168|Active Comparator|Arm II|Patients receive placebo vaccine and GM-CSF subcutaneously.
3299530|NCT00454155|Experimental|Opebacan|
3299531|NCT00454142|Experimental|Treatment (pazopanib hydrochloride)|"Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Pharmacological study will be done on Day 1 and Day 28. Computed tomography will be done at baseline and day 28."
3299532|NCT00454116|Placebo Comparator|1|FOLFIRI + placebo vandetanib
3299533|NCT00454116|Experimental|2|FOLFIRI + low dose vandetanib
3299534|NCT00454116|Experimental|3|FOLFIRI + high dose vandetanib
3299535|NCT00454064|Active Comparator|1|cognitive-behavioral treatment
3299536|NCT00454064|Active Comparator|2|cognitive-behavioral treatment with biofeedback elements
3299537|NCT00454051|Active Comparator|Omalizumab|Omalizumab was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level.
3299538|NCT00454051|Placebo Comparator|Placebo|Placebo was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks.
3299539|NCT00454025||Glaucoma|Patients with Glaucoma
3299540|NCT00454025||Healthy Patients|Patients without glaucoma
3299541|NCT00453999|Experimental|Arm 1: Peramivir 200 mg|Peramivir 200 mg administered intravenously once daily for 5 days (5 doses)
3299542|NCT00453999|Experimental|Arm 2: Peramivir 400 mg|Peramivir 400 mg administered intravenously once daily for 5 days (5 doses)
3299543|NCT00453999|Experimental|Arm 3: Oseltamivir|Oseltamivir 75 mg oral suspension administered orally twice daily for 5 days (10 doses)
3299544|NCT00453986|Experimental|Nimenrix A Group|subjects received 1 dose of Nimenrix™ Lot A at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
3299545|NCT00453986|Experimental|Nimenrix B Group|subjects received 1 dose of Nimenrix™ Lot B at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
3299546|NCT00453986|Experimental|Nimenrix C Group|subjects received 1 dose of Nimenrix™ Lot C at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
3299547|NCT00453986|Active Comparator|Mencevax ACWY Group|subjects received 1 dose of Mencevax™ ACWY vaccine at Month 0. Mencevax™ ACWY vaccine was administered by subcutaneous injection in the non-dominant upper arm.
3299548|NCT00453986|Experimental|Nimenrix+Fluarix Group|subjects received 1 dose of Nimenrix™ Lot A co-administered with Fluarix™ vaccines at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm. Fluarix™ vaccine was administered by intramuscular injection in the deltoid region of the dominant arm.
3299549|NCT00453973|Experimental|Maintenance Switch in Dialysis Participants|"Participants were from a prior Affymax peginesatide treatment study conducted in participants who were on dialysis and had been on Epoetin at study entry, and who were switched to peginesatide (NCT00434330). This group is categorized as Maintenance Switch in Dialysis Participants regardless of dialysis status at the start of or during this study."
3299550|NCT00453973|Experimental|Treatment Initiation in Non-Dialysis Participants|"Participants were from a prior Affymax peginesatide treatment study conducted in participants who were not on dialysis and not on erythropoiesis stimulating agents (ESAs), and who received peginesatide (NCT00228436). This group is categorized as Initiation of Treatment in Non-Dialysis Participants regardless of dialysis status at the start of or during this study."
3299551|NCT00453960|Experimental|Genistein|Genistein 54 mg/day
3299552|NCT00453960|Active Comparator|Norethisterone Acetate|Norethisterone Acetate 10mg/day
3299553|NCT00453960|Placebo Comparator|Placebo|Placebo tablets, daily
3299554|NCT00453921|Placebo Comparator|1|Placebo Capsule and Placebo Memory and Attention Training (Placebo as both conditions)
3299555|NCT00453921|Active Comparator|2|Methylphenidate capsules and Memory and Attention Training (Active Med/Active therapy)
3299556|NCT00453921|Active Comparator|3|Methylphenidate capsules and Placebo Memory and Attention Training (Active Med/Placebo therapy)
3299557|NCT00453921|Active Comparator|4|Placebo capsules and Memory and Attention Training (Placebo Med/Active therapy)
3299558|NCT00453843|Experimental|proximal to distal training|
3299559|NCT00453843|Experimental|distal to proximal|
3299560|NCT00453843|Experimental|proximal and distal on alternate days|
3299561|NCT00453843|Experimental|proximal and distal same day|
3299562|NCT00453817|Experimental|Study subjects|One-arm observational study
3299563|NCT00453791|Experimental|Subjects receiving treatment sequence 1: Part 1|Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using Metered Dose Inhaler (MDI).
3299564|NCT00453791|Experimental|Subjects receiving treatment sequence 2: Part 1|Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.
3299565|NCT00453791|Experimental|Subjects receiving treatment sequence 1: Part 2|Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using MDI.
3299566|NCT00453791|Experimental|Subjects receiving treatment sequence 2: Part 2|Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.
3299567|NCT00453791|Experimental|Subjects receiving GW805858: Part 3|Eligible subjects will receive GW805858 1200 micrograms twice daily administered using MDI.
3299568|NCT00453791|Experimental|Subjects receiving placebo: Part 3|Eligible subjects will receive placebo administered using MDI.
3299569|NCT00453765|Experimental|A|montelukast
3299570|NCT00453765|Placebo Comparator|B|placebo
3299571|NCT00453687|Experimental|Arm 1|Drug
3299572|NCT00453674||Adrenocortical carcinoma|Adrenocortical carcinoma
3299573|NCT00453661||Intervention Group|Patient Navigator (PN) + Educational Materials + Annual Questionnaires
3299574|NCT00453661||Comparison Group|Educational Materials + Exit Questionnaire
3299575|NCT00453648|Placebo Comparator|White-fleshed Sweet Potato|0 ug retinol activity equivalents (RAE)/d as boiled white-fleshed sweet potatoes (WFSP) and a corn oil capsule, 6d/wk for 10 wk
3299576|NCT00453648|Experimental|Orange-fleshed Sweet Potato (boiled)|600 ug RAE/d as boiled orange-fleshed sweet potato and a corn oil capsule, 6d/wk for 10 wk
3299577|NCT00453648|Experimental|Orange-fleshed Sweet Potato (fried)|600 ug RAE/d as fried orange-fleshed sweet potato and a corn oil capsule, 6d/wk for 10 wk
3299578|NCT00453648|Active Comparator|White-fleshed Sweet Potato and retinyl palmitate capsule|0 ug RAE/d as white-fleshed sweet potato and 600 ug retinol/d as retinyl palmitate, 6d/wk for 10 wk
3299579|NCT00453635|Experimental|1|Docetaxel + Carboplatin + Herceptin (D/Carbo/Her)
3299580|NCT00453635|Experimental|2|Vinorelbine + Herceptin (VHer)
3299581|NCT00453570|Experimental|1|DTacP IPV// PRP~T combined vaccine at 2, 3 and 4 months of age, and a booster dose at 18-20 months of age.
3299582|NCT00453570|Experimental|2|DTacP-IPV// PRP~T combined vaccine at 3, 4 and 5 months of age and a booster dose at 18-20 months of age.
3299583|NCT00453570|Active Comparator|3|Control vaccines at 3, 4 and 5 months of age and a booster dose at 18-20 months of age
3299584|NCT00453544|Experimental|Enhanced consent - A|The intervention was an enhanced consent process, including a multimedia aid for a moderate risk hypothetical protocol
3299585|NCT00453544|Experimental|Enhanced consent - B|The intervention was an enhanced consent process, including multimedia aide for a higher risk hypothetical protocol
3299586|NCT00453544|Active Comparator|Routine consent - A|This was a comparison condition - a routine consent process, including a printed consent document, for a moderate risk hypothetical protocol
3299587|NCT00453544|Active Comparator|Routine consent - B|This was a comparison condition - a routine consent process, including a printed consent document, for a higher risk hypothetical protocol
3299588|NCT00453453|Experimental|Nesiritide|Subjects who come into the ED with CHF will be treated with nesiritide
3299589|NCT00453453|No Intervention|Standard care|Subjects who come into the ED with CHF will receive standard care treatment
3299590|NCT00453388|Experimental|Arm I (2 vs 2.5 vs 3 Gy TBI dose-escalation)|Patients with a history of hematologic malignancy and HLA-haploidentical donor receive fludarabine phosphate (FLU) intravenously (IV) over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF orally (PO) thrice daily (TID) on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
3299591|NCT00453388|Experimental|Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)|Patients with no history of hematological malignancy and HLA-haploidentical donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
3299592|NCT00453388|Experimental|Arm III (2 vs 2.5 vs 3 Gy TBI dose-escalation)|Patients with history of hematologic malignancy and HLA-matched unrelated donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
3299593|NCT00453388|Experimental|Arm IV (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)|Patients with no history of hematological malignancy and HLA-matched unrelated donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
3299594|NCT00453375|Experimental|1|BHT-3021
3299595|NCT00453375|Placebo Comparator|2|BHT-Placebo
3299596|NCT00453362|Experimental|Erlotinib|"Erlotinib 150 mg/day taken orally at approximately the same time of day with 200 mL (6-8 Ounces) of water on an empty stomach. Participants received Erlotinib for 1 year or until they developed progressive disease or intolerable toxicity.~After 14 days and after 56 days of treatment with Erlotinib participants underwent FDG-PET and FLT-PET scans."
3299597|NCT00453349|Experimental|Moxifloxacin|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
3299598|NCT00453349|Active Comparator|Levofloxacin plus Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
3299599|NCT00453336|Experimental|Single Arm|
3299600|NCT00453323|Experimental|study arm|
3299601|NCT00453310|Experimental|sunitinib malate|The dose of sunitinib malate will be a continuous daily dose of 37.5 mg administered orally for 6 weeks. The cycle of therapy is 42 days (or 6 weeks)
3299602|NCT00453271|Experimental|NB-002 0.25% BID|
3299603|NCT00453271|Experimental|NB-002 0.5% QD|
3299604|NCT00453271|Experimental|NB-002 0.5% BID|
3299605|NCT00453271|Sham Comparator|Vehicle control|
3299606|NCT00453258||Study Subject|Subjects receiving eye examination
3299607|NCT00453219||1|Women ages 18-35 years with regular ovulatory menstrual cycles
3299608|NCT00453219||2|Women ages 18-35 years with irregular or absent menstrual periods due to functional hypothalamic amenorrhea (FHA) also called stress-induced anovulation
3299609|NCT00453219||3|Women ages 18-35 years with irregular or absent menstrual periods due to polycystic ovary syndrome(PCOS).
3299610|NCT00453193|Experimental|Alemtuzumab + Pentostatin|Alemtuzumab 30 mg intravenous (IV) three times weekly; Pentostatin 4 mg/m^2 IV weekly for 4 weeks then every 2 weeks
3299611|NCT00453180|Experimental|1|Target dose for n-acetylcysteine is 60 mg/kg/day. Capsules available in 300 mg and 600 mg strengths.
3299612|NCT00453180|Placebo Comparator|2|Subjects randomized to placebo arm will receive capsules identical in size and appearance to those subjects receiving study drug. Placebo capsules contain inactive ingredients.
3299613|NCT00453167|Experimental|study arm|
3299614|NCT00453154|Experimental|Arm I (Combination Chemotherapy + Sunitinib Maintenance)|"Participants will receive the following combination chemotherapy for 4-6 cycles (21 days):~Cisplatin 80 mg/m^2 by IV over 1 hour on day 1 every cycle OR Carboplatin AUC = 5* by IV Etoposide 100 mg/m^2 by IV over 1 hour on days 1, 2, and 3 every cycle~Maintenance: Following 4-6 cycles of combination chemotherapy, start sunitinib at 150 mg on day 1, then 37.5 daily until disease progression."
3299615|NCT00453154|Active Comparator|Arm II (Combination Chemotherapy + Placebo Maintenance)|"Participants will receive the following combination chemotherapy for 4-6 cycles (21 days):~Cisplatin 80 mg/m^2 by IV over 1 hour on day 1 every cycle OR Carboplatin AUC = 5* by IV Etoposide 100 mg/m2 by IV over 1 hour on days 1, 2, and 3 every cycle~Maintenance: Following 4-6 cycles of combination chemotherapy, start placebo at 150 mg on day 1, then 37.5 daily until disease progression."
3299616|NCT00453115|Experimental|study arm|GemOx
3299617|NCT00453102|Experimental|Zevalin + Rituximab|Ibritumomab Tiuxetan (Zevalin) + Rituximab
3299618|NCT00453076|Experimental|Paclitaxel eluting covered metal stent|Paclitaxel eluting covered metal stent group
3299619|NCT00453076|Active Comparator|Control covered metal stent|Control covered metal stent group
3299620|NCT00453063|Experimental|MFNS 200 mcg QD|
3299621|NCT00453063|Placebo Comparator|Placebo|
3299622|NCT00453037|Active Comparator|group I (early intervention)|"We refer to the results of the DAFNE-study. This study showed the merits of an educational program in diabetics. In accordance to the protocol of DAFNE, we developed a design as follows: For each participating center patients are randomly assigned to two groups. Group I receives an early educational intervention at time of randomization, which should lead to better control of blood pressure after 6 months compared to the control group. The protocol design was chosen for proving an independent effect of the educational program despite optimal management by the GP. Group II is designated to receive the educational intervention 6 months after enrollment into the study.~for further details please see brief description section"
3299623|NCT00453037|Other|delayed education|"delayed educational intervention~for further details please see brief description section"
3299624|NCT00452985||1|"Injection of Docetaxel~3-hour gap~Injection of carboplatin"
3299625|NCT00452907|Experimental|1|Arsucam® (AS 50mg/Aq153mg),oad, per os, 3 days of treatment
3299626|NCT00452907|Active Comparator|2|Arsumax (AS 50mg) + Sulfadoxine-Pyrimethamine (SP=SDX 500mg/PYR 25mg), oad, per os
3299627|NCT00452907|Active Comparator|3|Coartem (arthemether 20mg+ lumefantrine 120 mg), bid, per os. Duration of treatment: 3 days
3299628|NCT00452881|Experimental|study arm|GemOx
3299629|NCT00452881|Active Comparator|control arm|GemCis
3299630|NCT00452868|Experimental|Donepozil|Donepezil 5 milligrams a day for 6 weeks
3299631|NCT00452829|Experimental|Study Group|5 mg folic acid (the standard UK supplement for pregnancies at high risk of NTD) and 1 g inositol,
3299632|NCT00452829|Placebo Comparator|Control Group|5 mg folic acid (the standard UK supplement for pregnancies at high risk of NTD)and 1 g placebo
3299633|NCT00452816|Experimental|Intervention|Intervention Group - Workplace Solutions Consulting
3299634|NCT00452816|Active Comparator|2|Delayed Intervention
3299635|NCT00452803|Active Comparator|study arm|pre-operative chemotherapy (Pac/Cis)
3299636|NCT00452803|Active Comparator|study arm 2|Pre-operative concurrent chemoradiation therapy
3299637|NCT00452790|Experimental|A|
3299638|NCT00452790|Active Comparator|B|
3299639|NCT00452777|Experimental|BVT.115959|Capsules containing 7 mg BVT.115959 administered orally three times daily
3299640|NCT00452777|Placebo Comparator|Placebo|Placebo capsules administered orally three times daily
3299641|NCT00452699|Active Comparator|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
3299642|NCT00452699|Active Comparator|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
3299643|NCT00452673|Experimental|50 mg BID dasatinib + 825 mg/m^2 BID capecitabine|Twice a day (BID) for 2 weeks of a 3-week cycle
3299644|NCT00452673|Experimental|70 mg BID dasatinib + 825 mg/m^2 BID capecitabine|BID for 2 weeks of a 3-week cycle
3299645|NCT00452673|Experimental|70 mg BID dasatinib + 1000 mg/m^2 BID capecitabine|BID for 2 weeks of a 3-week cycle
3299646|NCT00452673|Experimental|100 mg QD dasatinib + 1000 mg/m^2 BID capecitabine|2 weeks of a 3-week cycle
3299647|NCT00452660|Experimental|evaluating the effect of -Exjade|evaluating the effect of -Exjade (Deferasirox)_on oxidative stress parameters of blood cells in patients with Low risk Mylodysplastic syndrome ( MDS) with Iron over load
3299648|NCT00452634|Experimental|study arm|
3299649|NCT00452608|Placebo Comparator|amido pill|
3299652|NCT00452582|Active Comparator|Usual post-stroke care|Usual post-stroke treatment including physical, occupational, and speech therapy.
3299653|NCT00452569|Experimental|A|Oral thalidomide (100mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
3299654|NCT00452569|Experimental|B|Oral thalidomide (200mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
3299655|NCT00452569|Experimental|C|Oral thalidomide (400mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
3299656|NCT00452569|Active Comparator|D|High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
3299657|NCT00452556|Active Comparator|Standard Radiotherapy Sequence Arm|Standard sequence of radiotherapy = whole pelvic lymphatics, proximal seminal vesicles, prostate (or prostate bed) first, then prostate/prostate bed last
3299658|NCT00452556|Experimental|Experimental Radiotherapy Sequence Arm|Experimental sequence of radiotherapy = whole pelvic lymphatics, proximal seminal vesicles, prostate (or prostate bed) last, prostate/prostate bed first
3299659|NCT00452543|Experimental|Escitalopram plus acamprosate|
3299660|NCT00452543|Placebo Comparator|Escitalopram plus placebo|
3299661|NCT00452530|Experimental|Apixaban, 2.5 mg BID + Placebo|Participants received apixaban, 2.5-mg tablets twice daily (BID), plus a matching enoxaparin-placebo injection 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
3299662|NCT00452530|Active Comparator|Enoxaparin, 40 mg QD + Placebo|Participants received enoxaparin, 40-mg subcutaneous injection once daily (QD), plus a matching apixaban-placebo tablet 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
3299663|NCT00452491|Experimental|1|
3299664|NCT00452491|Active Comparator|2|
3299665|NCT00452478|Experimental|1|
3299666|NCT00452465|Experimental|Intervention|A research nurse will meet with participants, complete a detailed nursing assessment and develop of a care plan to help connect participants with resources to allow them to stay in their homes longer.
3299667|NCT00452465|No Intervention|Control|Usual Care
3299668|NCT00452452|Experimental|A|
3299669|NCT00452439|Active Comparator|Actonel|Actonel (Risedronate) + Vitamin D + Calcium
3299670|NCT00452439|Placebo Comparator|Placebo|Placebo + Vitamin D + Calcium
3299671|NCT00452426|Experimental|Sedation System|Computer-Assisted Personalized Sedation (CAPS) device used for delivery of sedation
3299672|NCT00452426|Active Comparator|Current Standard of Care|Site's current standard used for delivery of sedation
3299673|NCT00452413|Experimental|Enzastaurin and erlotinib combination therapy|"Enzastaurin:~Phase 1, Dose Level 1: 500 milligram (mg) oral loading dose Day 1, 250 mg oral, daily Day 2-28, 28-day cycle until disease progression~Phase 1, Dose Level 2: 1125 mg oral loading dose Day 1, 500 mg oral, daily until disease progression~Phase 2: Dose determined from Phase 1, oral, daily, 28-day cycles until disease progression~Erlotinib:~• 150 mg, oral, daily, 28-day cycles until disease progression"
3299674|NCT00452374|Experimental|Oxaliplatin, Fludarabine, Cytarabine + Rituximab|Starting dose oxaliplatin 17.5mg/m^2/day intravenous (IV) for 4 days; Fludarabine 30 mg/m^2 IV and Cytarabine 1 g/m^2 IV for two days, + Rituximab 375 mg/m^2 IV on Day 3, Cycle 1 then Day 1 following cycles.
3299675|NCT00452361|Experimental|1|Sirolimus therapy
3299676|NCT00452361|Active Comparator|2|Calcineurin Inhibitor therapy (either cyclosporine or tacrolimus)
3299677|NCT00452348|Active Comparator|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
3299678|NCT00452348|Active Comparator|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
3299679|NCT00452335|Experimental|Lubiprostone 12 mcg QD|Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (<6 years of age and able to swallow capsules) who are at least 12 kg body weight
3299680|NCT00452335|Experimental|Lubiprostone 12 mcg BID|Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight
3299681|NCT00452335|Experimental|Lubiprostone 24 mcg BID|Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight
3299682|NCT00452257|Experimental|A|
3299683|NCT00452244|Experimental|study arm|Iressa (gefitinib) + simvastatin
3299684|NCT00452244|Active Comparator|control arm|Iressa (gefitinib) only
3299685|NCT00452218|Experimental|Open|
3299686|NCT00452153|Experimental|Characterization Legionnella|Characterization Legionnella by polymerase chain reaction (PCR)
3299687|NCT00452127|Experimental|1|
3299688|NCT00452114|Experimental|In-Exsufflator Cough Assist Device|In-Exsufflator Cough Assist Device augments the expiratory flow and force of the patient's cough with the addition of a cycle of positive and negative inspiratory pressure when used daily
3299689|NCT00452114|Active Comparator|flutter valve device|flutter valve device delivers expiratory low-pressure vibratory pulse to the patient's airway when used daily
3299690|NCT00452088|Experimental|1|15 microgramme candidate vaccine group
3299691|NCT00452088|Active Comparator|2|Hepatitis B comprator group
3299692|NCT00452088|Experimental|3|30 microgrammes candidate vaccine group
3299693|NCT00452088|Active Comparator|4|Hepatitis B vaccine group
3299694|NCT00452075|Experimental|arm 1 medicine|erlotinib daily
3299695|NCT00452036||Minor head injury|patients with minor head injury
3299696|NCT00452036||minor head injury|patients with minor head injury
3299697|NCT00452023|Experimental|IFN-alpha2a|Starting dose 90 microgram (mcg) injection under the skin once a week.
3299698|NCT00452010|Experimental|1|transcutaneous electrical nerve stimulation
3299699|NCT00452010|Placebo Comparator|2|No transcutaneous electrical nerve stimulation
3299700|NCT00451997|Experimental|Gleevec + Low-Dose Ara-C|
3299747|NCT00451191|Active Comparator|1|100 units botulinum toxin type A (BoNT/A)
3299701|NCT00451958|Experimental|Degarelix 80 mg / Degarelix 80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.
3299702|NCT00451958|Experimental|Degarelix 160 mg / Degarelix 160 mg|"The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
3299703|NCT00451958|Experimental|Leuprolide 7.5 mg / Degarelix 80 mg|"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.~Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
3299704|NCT00451958|Experimental|Leuprolide 7.5 mg / Degarelix 160 mg|"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.~Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
3299705|NCT00451906|Experimental|Bevacizumab + Chemotherapy|Participants with advanced or recurrent NSCLC will be administered bevacizumab infusions at a dose of 7.5 milligram per kilogram (mg/kg) or 15 mg/kg (investigator's choice) on Day 1 and then every 3 weeks, intravenously (IV) for a maximum of 6 cycles in combination with the standard of care NSCLC first-line chemotherapy in line with the licensed national prescribing information, during the treatment period. The initial dose of bevacizumab will be administered following chemotherapy; all subsequent doses could be given before or after chemotherapy.
3299706|NCT00451893|Active Comparator|Heavy-weight|Lichtenstein operation performed with a heavy-weight mesh.
3299707|NCT00451893|Active Comparator|Light-weight|Lichtenstein operation performed with a light-weight mesh.
3299708|NCT00451880|Experimental|Arm 1|XL281 administered once a day
3299709|NCT00451880|Experimental|Arm 2|XL281 administered twice a day
3299710|NCT00451880|Experimental|Arm 3|XL281 administered once a day. Subjects in this arm will be dosed under fed conditions, fasted conditions, and with a concomitant single dose of 40 mg famotidine, during the second, third, and fourth week of the first cycle.
3299711|NCT00451867|Active Comparator|A|2000 mg per day of CellCept (MMF) divided into 2 equal doses.
3299712|NCT00451867|Placebo Comparator|B|Placebo
3299713|NCT00451841||1|Chronic cough caused by GERD
3299714|NCT00451841||2|Chronic cough without GERD
3299715|NCT00451776|Experimental|1|patients who received etomidate
3299716|NCT00451776|Active Comparator|2|patients who received propofol
3299717|NCT00451698|Placebo Comparator|3|acyanotic placebo
3299718|NCT00451698|Experimental|4|acyanotic erythropoietin
3299719|NCT00451646|Experimental|1|SMOFlipid
3299720|NCT00451646|Active Comparator|2|Intralipid
3299721|NCT00451620|Experimental|2.|GlucoNorm
3299722|NCT00451620|Experimental|1.|Glyburide
3299723|NCT00451568|Active Comparator|1|metformin
3299724|NCT00451568|Active Comparator|2|desorelle
3299725|NCT00451568|Active Comparator|3|desorelle + metformin
3299726|NCT00451555|Experimental|Enzastaurin/Fulvestrant|
3299727|NCT00451555|Placebo Comparator|Placebo/Fulvestrant|
3299728|NCT00451503|Experimental|1|surgery
3299729|NCT00451451|Experimental|BG00012 240 mg Twice Daily (BID)|Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
3299730|NCT00451451|Experimental|BG00012 240 mg 3 Times Daily (TID)|Participants received two 120 mg BG00012 capsules orally three times daily (TID)
3299731|NCT00451451|Placebo Comparator|Placebo|Participants received two placebo capsules orally three times daily (TID)
3299732|NCT00451451|Active Comparator|Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)|Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)
3299733|NCT00451425|No Intervention|control|standard maternity care
3299734|NCT00451412|Experimental|Certoparin|
3299735|NCT00451412|Active Comparator|Unfractionated Heparin|
3299736|NCT00451321|Experimental|otelixizumab|
3299737|NCT00451308|Experimental|1|Foley balloon wih 60cc fluid
3299738|NCT00451308|Active Comparator|2|Foley balloon with 30cc
3299739|NCT00451295|Placebo Comparator|1|
3299740|NCT00451295|Experimental|2|
3299741|NCT00451282|Experimental|Stepped Preventive Care|Receiving Stepped Preventive Care intervention - at least 2 brief assessments with nurse and/or social worker (1) during hospital admission , and (2) approximately 2 weeks post-discharge. Additional interventions provided as needed, based on manual.
3299742|NCT00451282|No Intervention|Treatment as usual|Medical and psychosocial care per usual hospital protocols, which may include social work support.
3299743|NCT00451217|Experimental|Sugammadex|
3299744|NCT00451217|Active Comparator|neostigmine|
3299745|NCT00451204|Active Comparator|Estriol plus Copaxone injections QD|Estriol Capsules (daily) plus Copaxone injections (daily). Progestin capsules given for 2 weeks every 3 months to avoid unopposed estrogens.
3299746|NCT00451204|Placebo Comparator|Placebo plus Copaxone injections QD|Placebo Capsules (daily) plus Copaxone injections (daily). A second placebo capsule given for 2 weeks every 3 months.
3299748|NCT00451191|Active Comparator|2|300 units botulinum toxin type A (BoNT/A)
3299749|NCT00451178|Experimental|A|
3299750|NCT00451178|Active Comparator|B|
3299751|NCT00451165||colon|
3299752|NCT00451165||rectum|
3299753|NCT00451152|Experimental|Anecortave Acetate Depot|
3299754|NCT00451152|Placebo Comparator|Anecortave Acetate Vehicle|
3299755|NCT00451100|Experimental|Sugammadex|2.0 mg/kg Org 25969 (sugammadex)
3299756|NCT00451100|Active Comparator|Neostigmine|50 ug/kg neostigmine
3299757|NCT00451087|Experimental|1|
3299758|NCT00451087|Active Comparator|2|
3299759|NCT00451048|Experimental|Arm I|Patients will receive sunitinib malate (SU11248) by mouth once a day. Treatment may continue for as long as benefit is shown.
3299760|NCT00451035|Experimental|1|
3299761|NCT00450970|Experimental|1|Prednisone and Satraplatin (INN / USAN), also known as JM-216, or OC-6-43-bis(acetato-O)ammine dichloro (cyclohexanamine)-platinum (IV), is a member of a novel class of platinum (IV) compounds that are absorbed by the oral route. The lipophilic properties of these compounds, and hence their absorption, are largely determined by the nature of the axial acetate ligands.
3299762|NCT00450970|Experimental|2|Prednisone (17 alpha, 21-dihydroxypregna-1, 4-diene-3, 11, 20-trione) is commercially formulated as the acetate salt (prednisone 21-acetate). It is a biologically inert glucocorticoid, which is converted to active prednisolone in the liver.
3299763|NCT00450957|Experimental|Arm I (high-dose lycopene)|Participants receive high-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive high-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days.
3299764|NCT00450957|Experimental|Arm II (low-dose lycopene)|Participants receive low-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive low-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days
3299765|NCT00450892|Other|arm 1|
3299766|NCT00450892|Other|arm 2|
3299767|NCT00450892|Experimental|arm 3|
3299768|NCT00450879|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD for 12-20 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgical resection of tumor between days 13 and 21 (24 hours after completion of pazopanib hydrochloride).
3299769|NCT00450866|Experimental|Epothilone B|
3299770|NCT00450853|Experimental|Granisetron SC-Granisetron IV|Granisetron SC followed by Granisetron IV
3299771|NCT00450827|Experimental|Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab|Patients will be administered a therapeutic doses of intravenous (IV) 131I-3F8 given in a single dose per the dose escalation regimen on day 0 of study. This will be followed by blood draws for pharmacokinetic and dosimetry studies and by gamma camera scan, where feasible. Bevacizumab will be administered at a fixed dose of 15mg/kg on days 1 and 15. Thyroid protection is commenced 10 days prior to administration of 131I-3F8 and continued for 28 days after the therapeutic dose of 131I-3F8. ASCR will be carried out if ANC < 500/ul on day 28 (blood radioactivity will be confirmed to be <1 uCi/ml prior to ASCR). ASCR will be carried out sooner in the case of life-threatening infection in the setting of neutropenia (ANC<500). G-CSF can be used to maintain ANC>500/ul but should not be used for 24 hours immediately before and after ASCR. Blood product support will be provided with platelet and red cell transfusions as required.
3299772|NCT00450814|Experimental|Stage 1 (MV-NIS alone)|Patients receive MV-NIS IV over 1 hour on day 1. (Closed to accrual on 12/17/2009 and reopened 10/13/2011)
3299773|NCT00450814|Experimental|Stage 2 (MV-NIS and cyclophosphamide)|Patients receive cyclophosphamide IV over 30 minutes and then MV-NIS IV over 1 hour 2 days later. (Temporarily closed to accrual on 10/13/11)
3299774|NCT00450801|Experimental|R-MACLO-IVAM-T|Rituximab, Methotrexate, Doxorubicin, Cyclophosphamide and Vincristine (cycle 1), followed by Rituximab, Ifosfamide (and Mesna), Etoposide and Cytarabine (cycle 2). These two cycles are repeated once, and patients achieving complete repose receive maintenance Thalidomide.
3299775|NCT00450775|Other|1|
3299776|NCT00450749|Placebo Comparator|Arm I (placebo)|Patients receive placebo PO QD for 4-7 weeks, and then undergo radical prostatectomy.
3299777|NCT00450749|Experimental|Arm II (low-dose lycopene)|Patients receive low-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy.
3299778|NCT00450749|Experimental|Arm III (high-dose lycopene)|Patients receive high-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy.
3299779|NCT00450736|Experimental|Single Arm|
3299780|NCT00450723|Experimental|Sentinel Lymph Node Biopsy|
3299781|NCT00450697||observation|
3299782|NCT00450684|Experimental|Group A|Implantation and testing of CRT
3299783|NCT00450684|Experimental|Group B|IImplantation and testing of CRT
3299784|NCT00450658|Experimental|1|HZT-501: Ibuprofen 800mg/Famotidine 26.6mg
3299785|NCT00450658|Active Comparator|2|Ibuprofen 800mg
3299786|NCT00450619|Experimental|Arm A -EDTMP Alone|Patients receive samarium Sm 153 lexidronam pentasodium 1 mCi/Kg intravenous (IV) over 1 minute on day 8. Treatment repeats every 12 weeks in the absence of disease progression or unacceptable toxicity.
3299787|NCT00450619|Experimental|Arm B - 153SmEDTMP with vaccine|Patients receive recombinant vaccinia-TRICOM vaccine 2 x 10^8 PFU subcutaneously (SC) on day 1. Patients also receive recombinant fowlpox-TRICOM vaccine 1 x 10^9 PFU SC on days 15 and 29 and sargramostim (GM-CSF)100 mcg/injection SC x 4 days. Treatment with recombinant fowlpox-TRICOM vaccine and GM-CSF* repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive samarium Sm 153 lexidronam pentasodium 1 mCi/Kg as in arm I.
3299788|NCT00450580|Experimental|Arm A|Fosamprenavir/ritonavir 1400mg/100mg QD + ABC/3TC FDC 600/300mg QD
3299789|NCT00450580|Active Comparator|Arm B|Fosamprenavir/ritonavir 700mg/100mg BID + ABC/3TC FDC 600/300mg QD
3299790|NCT00450541||Fatigue Questionnaire + Interview|
3299791|NCT00450515|Experimental|vinflunine + capecitabine|"Patients receive vinflunine IV over 20 minutes on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, every other course, and at the completion of study treatment.~After completion of study treatment, patients are followed periodically for up to 5 years."
3299965|NCT00448409|Experimental|1|TroVax alone
3299966|NCT00448409|Experimental|2|TroVax plus GM-CSF
3299792|NCT00450463|Active Comparator|A|Patients receive flutamide orally 3 times a day on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After 3 months of treatment, patients who do not develop clinical progression, but develop biochemical recurrence (e.g., rising PSA levels) without metastatic disease (as evidenced on scans), may receive vaccine treatment as defined in arm II beginning 4 weeks after flutamide therapy is discontinued.
3299793|NCT00450463|Experimental|B|Patients receive flutamide orally 3 times a day on days 1-28. Patients also receive recombinant vaccinia PSA vaccine subcutaneously (SC) on day 1 of course 1 only and recombinant fowlpox PSA vaccine SC on day 1 of all subsequent courses. Patients receive sargramostim (GM-CSF) SC on days 1-4. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After 3 months of treatment, patients who do not develop clinical progression, but develop biochemical recurrence (e.g., rising PSA levels), discontinue flutamide but may continue to receive vaccine treatment.
3299794|NCT00450450|Experimental|Arm I|Patients undergo filgrastim (G-CSF)-stimulated allogeneic bone marrow transplantation on day 0.
3299795|NCT00450450|Active Comparator|Arm II|Patients undergo conventional allogeneic bone marrow transplantation on day 0.
3299796|NCT00450437|Active Comparator|Licensed Meningococcal Vaccine|Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
3299797|NCT00450437|Experimental|Novartis MenACWY Conjugate Vaccine|Novartis meningococcal ACWY conjugate Vaccine
3299798|NCT00450424|No Intervention|Counseling|Participants will be given one of two counseling interventions regarding MSI testing: standard counseling or a CD-ROM intervention.
3299799|NCT00450411|Experimental|Brachytherapy|Prostate brachytherapy delivered using either 125-iodine (I-125) or 103-palladium (Pd-103)
3299800|NCT00450398|Experimental|1|YSPSL (rPSGL-Ig)
3299801|NCT00450398|Placebo Comparator|2|
3299802|NCT00450385|Experimental|R-CHOP|"Patients will receive R-CHOP for 6 to 8 cycles:~Rituximab 375 mg/m2 on day 1~Cyclophosphamide 750 mg/m2 IV on day 1~Doxorubicin 50 mg/m2 on day 1~Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1~Prednisone 100 mg orally days 1-5, repeated every 21 days."
3299803|NCT00450372|Experimental|ADI-PEG 20|
3299804|NCT00450333|Active Comparator|1|Erythropoietin(EPO)-naive BIW
3299805|NCT00450333|Active Comparator|2|EPO-naive QW
3299806|NCT00450333|Active Comparator|3|EPO QW
3299807|NCT00450333|Active Comparator|4|EPO Q2W
3299808|NCT00450320|Active Comparator|Rapamycin|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen.
3299809|NCT00450307|Experimental|3F8 and GM-CSF|One cycle has 5 days of 3F8 treatment. Each day, patients receive GM-CSF subcutaneously ~1.5 hr before the start 3F8 infusion. To limit side-effects, patients receive analgesics, antihistamines, and a small dose (IV, over ~5 minutes) of heat-modified 3F8. Cycles can be repeated after a 2-4 week interval, up to a total of two cycles.
3299810|NCT00450281||Male, Never-smokers|Male subjects who smoked less than 100 cigarettes during their lifetime.
3299811|NCT00450281||Male, Ever-smokers|Male subjects who have smoked at least 100 cigarettes during their lifetime.
3299812|NCT00450281||Female, Ever-smokers|Female subjects who have smoked less than 100 cigarettes during their lifetime.
3299813|NCT00450281||Female, Never-smokers|Female subjects who have smoked at least 100 cigarettes during their lifetime.
3299814|NCT00450255|Experimental|Arm I|Patients receive Aflibercept IV at 4 mg/kg over 1 hour on day 1. Treatment repeats every 14 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
3299815|NCT00450242|Experimental|5% Lidocaine cream|5% topical lidocaine cream.
3299816|NCT00450242|Placebo Comparator|Placebo cream|
3299817|NCT00450229|Experimental|Arm I|Patients receive low-dose, nutritional-grade oral diindolylmethane (DIM) twice daily for 21-28 days in the absence of disease progression or unacceptable toxicity. Treatment may continue for up to 60 days, if surgery is delayed.
3299818|NCT00450229|Experimental|Arm II|Patients receive high-dose, nutritional-grade oral DIM twice daily as in arm I.
3299819|NCT00450229|Placebo Comparator|Arm III|Patients receive oral placebo twice daily for 21-28 days in the absence of disease progression or unacceptable toxicity. Treatment may continue for up to 60 days, if surgery is delayed.
3299820|NCT00450216|Experimental|1|HZT-501: Ibuprofen 800mg/famotidine 26.6mg
3299821|NCT00450216|Active Comparator|2|Ibuprofen 800mg
3299822|NCT00450203|Experimental|ECX + Bevacizumab|ECX + Bevacizumab
3299823|NCT00450203|Active Comparator|Epirubicin, Cisplatin and Capecitabine|ECX chemotherapy
3299824|NCT00450203|Experimental|ECX + Lapatinib|ECX + Lapatinib
3299825|NCT00450190|Experimental|Saizen® E-Device|
3299826|NCT00450138|Experimental|1|Radiation + vandetanib
3299827|NCT00450138|Experimental|2|Radiation + cisplatin + vandetanib
3299828|NCT00450125||Six-Minute Walk Test|Two Six-minute walk tests where total distance walked measured. Tests performed within 15 days of an exercise stress test.
3299829|NCT00450099|Experimental|1|Epidural, bupivacaine
3299830|NCT00450086|Experimental|A|
3299831|NCT00450086|Experimental|B|
3299832|NCT00450086|Placebo Comparator|C|
3299833|NCT00450073|Active Comparator|Vitamin D3|Vitamin D3=cholecalciferol 50,000 IU weekly
3299834|NCT00450073|Active Comparator|vitamin D2|The intervention is an oral tablet of vitamin D2 (ergocaliferol 50,000 IU weekly) for 12 weeks.
3299835|NCT00450073|Active Comparator|Sunlamp|The intervention is the use of a Sunlamp (Sperti) to the skin 5 times a week for 12 weeks
3299836|NCT00450034|Experimental|1|
3299837|NCT00450008|Other|A|Combination therapy of GM-CSF, Thalidomide plus Docetaxel in patients with prostate cancer with a rising PSA
3299838|NCT00449969|Experimental|1. Extended feedback|
3299839|NCT00449969|Active Comparator|2. Limited feedback|
3299840|NCT00449956|Experimental|1|combination of dorzolamide hydrochloride and timolol maleate
3299841|NCT00449956|Active Comparator|2|Concomitant use of dorzolamide hydrochloride and timolol maleate
3299842|NCT00449956|Active Comparator|3|timolol maleate
3299843|NCT00449930|Experimental|1|Drug
3299844|NCT00449930|Active Comparator|2|Active comparator
3299967|NCT00448396|Experimental|Patupilone|
3299968|NCT00448383|Experimental|1|Open-label adalimumab
3299845|NCT00449904|Experimental|Liprotamase|Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units) administered orally with each of three meals and two snacks daily for 12 months.
3299846|NCT00449878|Experimental|Liprotamase|"Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units).~Open Label Period: Liprotamase administered orally with each of three meals and two snacks daily for 21 days.~Double Blind Treatment Period: Administered orally with each of three meals and two snacks daily for 6 days.~Second Open Label Period: Administered orally with each of three meals and two snacks daily for 7 days."
3299847|NCT00449878|Placebo Comparator|Placebo|Double Blind Treatment Period: Placebo (microcrystalline cellulose) administered orally with each of three meals and two snacks daily for 6 days.
3299848|NCT00449865|Placebo Comparator|Placebo|
3299849|NCT00449865|Active Comparator|creatine|
3299850|NCT00449852|Experimental|Interactive Voice Response Group|
3299851|NCT00449852|No Intervention|Usual Care Group|
3299852|NCT00449839|Other|A, CSII without bolus|Period A: A constant subcutaneous infusion rate of insulin aspart (0.5 U/hr) is given for 8 hours. Following 3 hours of blood sampling.
3299853|NCT00449839|Other|B; CSII with bolus|Period B: A constant subcutaneous infusion of insulin aspart (0.5 U/hr) is given for 8 hours and upon start a s.c.bolus (1.4 U)of insulin aspart is given. Hereafter follows 3 hours of blood sampling.
3299854|NCT00449839|Other|C; CSII with bolus, optional|A constant subcutaneous insulin aspart infusion is given for 8 hours and upon start a bolus of insulin aspart is given. The bolus in arm C is of a different size then arm B. After the 8 hours of constant infusion follows 3 hours of blood sampling. Period C are optional and it is evaluated if it will be conducted after period A and B has been performed.
3299855|NCT00449813|Active Comparator|1.|40 mg Pantoprazole
3299856|NCT00449787|Active Comparator|Sumatriptan|Sumatriptan 100 mg tablet
3299857|NCT00449787|Active Comparator|Naproxen|Naproxen 500 mg tablet
3299858|NCT00449774|Experimental|Subjects in Treatment regimen C|Subjects in treatment regimen C will receive 200 milligram (mg) orally disintegrating tablets (ODT) of lamotrigine disintegrate in mouth without water in fasting condition.
3299859|NCT00449774|Experimental|Subjects in Treatment regimen D|Subjects in treatment regimen D will receive 200 mg Immediate Release (IR) tablets of lamotrigine with water in fasting condition.
3299860|NCT00449774|Experimental|Subjects in Treatment regimen E|Subjects in treatment regimen E will receive 200 mg ODT disintegrate of lamotrigine in mouth without water in fed state.
3299861|NCT00449774|Experimental|Subjects in Treatment regimen F|Subjects in treatment regimen F will receive 200 mg ODT of lamotrigine, that subjects will swallow with water in fasting condition.
3299862|NCT00449761|Experimental|Panobinostat|
3299863|NCT00449748|Experimental|RAD001|Oral 10 mg daily for 30 days
3299864|NCT00449696|Experimental|Gel-200|
3299865|NCT00449696|Placebo Comparator|PBS|
3299866|NCT00449683|Experimental|terazosin|open-label treatment group
3299867|NCT00449670|Experimental|Group A|
3299868|NCT00449670|Experimental|Group B|
3299869|NCT00449670|Experimental|Group C|
3299870|NCT00449670|Experimental|Group D|
3299871|NCT00449670|Active Comparator|Group E|
3299872|NCT00449670|Active Comparator|Group F|
3299873|NCT00449644|Experimental|TMC207 Stage 1|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 weeks in addition to Background Regimen (BR) for multi-drug resistant tuberculosis (MDR-TB).
3299874|NCT00449644|Placebo Comparator|Placebo Stage 1|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 weeks in addition to BR for MDR-TB.
3299875|NCT00449644|Experimental|TMC207 Stage 2|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 22 weeks in addition to BR for MDR-TB.
3299876|NCT00449644|Placebo Comparator|Placebo Stage 2|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 22 weeks in addition to BR for MDR-TB.
3299877|NCT00449618|Active Comparator|1|Aspirin 100 mg on awakening
3299878|NCT00449618|Active Comparator|2|Aspirin 100 mg at bedtime
3299879|NCT00449618|Placebo Comparator|3|Placebo on awakening
3299880|NCT00449618|Placebo Comparator|4|Placebo at bedtime
3299881|NCT00449605|Experimental|Rimonabant|Rimonabant 20 mg once daily on top of metformin
3299882|NCT00449605|Active Comparator|Glimepiride|Glimepiride from 1 mg up to 6 mg once daily on top of metformin
3299883|NCT00449592|Experimental|1|Oral zinc therapy, intervention
3299884|NCT00449592|Placebo Comparator|2|oral placebo
3299885|NCT00449553||Pioglitazone 15 mg QD + Sulphonylurea|
3299886|NCT00449553||Pioglitazone 30 mg QD + Sulphonylurea|
3299887|NCT00449553||Pioglitazone 15 mg QD + Metformin|
3299888|NCT00449553||Pioglitazone 30 mg QD + Metformin|
3299889|NCT00449540|Active Comparator|Active Transcranial Magnetic Stimulation (TMS) Device|Both arms of participants receive identical looking devices and were instructed use the same treatment protocol. Participants in each group were instructed to treat with the device within one hour of onset of migraine aura.
3299890|NCT00449540|Sham Comparator|Sham TMS Device|Both arms of participants receive identical looking devices and were instructed use the same treatment protocol. Participants in each group were instructed to treat with the device within one hour of onset of migraine aura.
3299891|NCT00449488|No Intervention|Control|
3299892|NCT00449488|Active Comparator|Epoetin alfa|i.v bolus 60.000 IU epoetin alfa
3299893|NCT00449293|Active Comparator|1|
3299894|NCT00449293|Active Comparator|2|
3299895|NCT00449280|Experimental|A|Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken once a week until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.
3299896|NCT00449280|Experimental|B|Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.
3300218|NCT00445601|Experimental|Arm I|Patients receive intravesical gemcitabine hydrochloride over 1 hour.
3299897|NCT00449280|Experimental|C|Rapamycin once a week starting on Day 1. Beginning on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.
3299898|NCT00449280|Experimental|D|Rapamycin every day beginning on Day 1. Starting on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.
3299899|NCT00449267|Experimental|1|
3299900|NCT00449176|Experimental|001|tapentadol (CG5503) ER 50 100 150 200 250 mg twice daily for 15 weeks
3299901|NCT00449176|Active Comparator|002|oxycodone CR 10 20 30 40 50 mg twice daily for 15 weeks
3299902|NCT00449176|Placebo Comparator|003|placebo matching placebo twice daily for 15 weeks
3299903|NCT00449163|Experimental|Combination Chemotherapy and Bevacizumab|"Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:~Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;~Irinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;~Leucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;~Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29."
3299904|NCT00449150|Experimental|Treatment Group A: CET 78 mg + 78 mg|"Treatment course 1: Cetrorelix 78 mg + 78 mg~Week 0: 52 mg CET (2 injections)~Week 2: 26 mg CET (1 injection)~Treatment course 2:~Week 26: 52 mg CET (2 injections)~Week 28: 26 mg CET(1 injection)~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
3299905|NCT00449150|Experimental|Treatment Group B: CET 78 mg + 52 mg|"Treatment course 1: Cetrorelix 78 mg + 52 mg~Week 0: 52 mg CET (2 injections)~Week 2: 26 mg CET (1 injection)~Treatment course 2:~Week 26: 52 mg CET (2 injections)~Week 28: Placebo (1 injection)~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
3299906|NCT00449150|Placebo Comparator|Treatment Group C: Placebo|"Treatment course 1:~Week 0: placebo (2 injections)~Week 2: placebo (1 injection)~Treatment course 2:~Week 26: placebo (2 injections)~Week 28: placebo (1 injection)~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
3299907|NCT00449137|Experimental|Single Arm|
3299908|NCT00449124|Experimental|Part I-group 1|Part I/Group 1: Cycle 1-TG4040 10^6 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14; Cycle 3-Placebo days 0, 7 and 14.
3299909|NCT00449124|Experimental|Part IIa-group 1|Part IIa/Group 1: Cycle 1-TG4040 10^8 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14.
3299910|NCT00449124|Experimental|Part IIa-group 2|Part IIa/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^8 PFU days 0, 7 and 14.
3299911|NCT00449124|Experimental|Part I-group 3|Part I/Group 3: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14; Cycle 3-TG4040 10^8 PFU days 0, 7 and 14.
3299912|NCT00449124|Experimental|Part I-group 2|Part I/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^7 PFU days 0, 7 and 14; Cycle 3-Placebo days 0, 7 and 14.
3299913|NCT00449124|Experimental|Part IIb-group 1|Part IIb/Group 1: Cycle 1-TG4040 10^8 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14.
3299914|NCT00449124|Experimental|Part IIb-group 2|Part IIa/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^8 PFU days 0, 7 and 14.
3299915|NCT00449098|Experimental|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
3299916|NCT00449098|Active Comparator|MMC|Trabeculectomy with MMC
3299917|NCT00449072|Placebo Comparator|Placebo|"3 to 9 year old participants with Perennial Allergic Rhinitis (PAR) administered~Placebo in the baseline/screening period to demonstrate administration of investigational product (IP) with the nasal spray bottle~Placebo in the double-blind treatment period~All participants were provided Children's Claritin® Syrup as a rescue medication."
3299918|NCT00449072|Active Comparator|TAA-AQ|"3 to 9 year old participants with Perennial Allergic Rhinitis (PAR) administered~Placebo in the baseline/screening period to demonstrate administration of IP with the nasal spray bottle~Triamcinolone acetonide (TAA-AQ) in the double-blind treatment period~All participants were provided Children's Claritin® Syrup as a rescue medication."
3299919|NCT00449033|Experimental|Sorafenib (Nexavar, BAY43-9006) + GC|Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with sorafenib. Day 1: gemcitabine 1250 mg/ m^2 infusion (IV), followed by cisplatin 75 mg/ m^2 IV; Day 8: gemcitabine 1250 mg/ m^2 IV; Days 1-21: sorafenib 2 tablets (200 mg) taken orally (po) twice daily (bid). If the patient had radiological evidence of stable disease (SD) or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which sorafenib was administered 400 mg bid until criteria for withdrawal were met.
3299920|NCT00449033|Placebo Comparator|Placebo + GC|Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with placebo. Day 1: gemcitabine 1250 mg/ m^2 infusion (IV), followed by cisplatin 75 mg/ m^2 IV; Day 8: gemcitabine 1250 mg/ m^2 IV; Days 1-21: placebo 2 tablets po bid. If the patient had radiological evidence of SD or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which 2 placebo tablets were administered bid until criteria for withdrawal were met.
3299921|NCT00449007|Active Comparator|1|fluoxetine -- 6 months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention; patients will also be encouraged to attend daily Alcoholics Anonymous meetings
3299922|NCT00449007|Active Comparator|2|bupropion -- 6 months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention; patients will also be encouraged to attend daily Alcoholics Anonymous meetings
3299923|NCT00448929|Experimental|Trabeculectomy with Oculusgen|
3299924|NCT00448929|No Intervention|Trabeculectomy without Oculusgen or antifibrotic agents|
3299925|NCT00448916|Experimental|Pregabalin|Orally-administered pregabalin
3299926|NCT00448903|Experimental|A|Bemiparin
3299927|NCT00448903|Placebo Comparator|2|Placebo
3299928|NCT00448890|Experimental|GSK729327|Dose escalation from 1.0mg to 6 mg.
3299929|NCT00448890|Placebo Comparator|Placebo|
3299962|NCT00448435|Experimental|SFC|SFC (salmeterol/fluticasone propionate combination) 25/50mcg twice daily in Extension period (after cross-over period).
3299963|NCT00448422|Experimental|1|Tablet
3299964|NCT00448422|Placebo Comparator|2|Tablet
3299930|NCT00448864|Experimental|Ecallantide - Low Dose Regimen|Participants received a maximum of 15 milligrams (mg) ecallantide in stages. Intravenous (IV) infusion of 0.6 milligrams per milliliter (mg/mL) ecallantide was administered at 2.92 milliliters per minute (mL/min) for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of cardiopulmonary bypass (CPB), whichever came first. At the termination of the initial infusion, a second infusion of 0.4 mg/mL ecallantide was started at 38 milliliters per hour (mL/hr) for 4 hours.
3299931|NCT00448864|Experimental|Ecallantide - High Dose Regimen|Participants received a maximum of 91 mg ecallantide in stages. IV infusion of 0.6 mg/mL ecallantide was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, an infusion of normal saline was started at 38 milliliters per hour (mL/hr) for 4 hours.
3299932|NCT00448864|Placebo Comparator|Placebo|Participants received placebo in stages. IV infusion placebo was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, a second infusion of placebo was started at 38 mL/hr for 4 hours.
3299933|NCT00448851|Experimental|1|inhaled allergen challenge
3299934|NCT00448825|Experimental|Topiramate|Topiramate + Cognitive Behavioral Therapy
3299935|NCT00448825|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy
3299936|NCT00448786|Other|Arm C|Arm C - AMG 706 75 mg BID 5-days on and 2-days off
3299937|NCT00448786|Other|Arm B|Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
3299938|NCT00448786|Other|Arm A|Arm A = AMG 706 125 mg PO daily continuously
3299939|NCT00448760|Experimental|Neoadjuvant + Adjuvant Chemotherapy|
3299940|NCT00448747|Experimental|AEZS-130 ( formerly ARD-07)|A single oral administration of AEZS-130 (0.5 mg/kg po) as Growth Hormone Stimulation Test
3299941|NCT00448747|Active Comparator|L-ARG+GHRH|This trial was set up as a multi-center, randomized, cross-over study investigating AEZS-130 as a Growth Hormone Stimultation Tests in terms of safety and efficacy compared to L-ARG+GHRH. When GHRH became unavailable on the US market, this comparator arm was no longer available, which was addressed by Amendment No. 3 (version 27Ma 2010). Control subject enrolled under Amendment No. 3 were not randomized as there was no cross-over due to unavailability of L-ARG+GHRH. These control subjects received only AEZS-130
3299942|NCT00448734|Experimental|1|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
3299943|NCT00448734|Active Comparator|2|Docetaxel
3299944|NCT00448721|Experimental|Perifosine|Perifosine will be administered orally at 100mg PO daily with food. One treatment cycle will consist of 42 days (6 weeks).
3299945|NCT00448708|Experimental|Vascular Wrap and Graft|Lifespan® ePTFE Vascular Graft and Vascular WrapTM Paclitaxel-Eluting Mesh: The Lifespan® ePTFE Vascular Graft is implanted as an arteriovenous graft in an upper extremity to provide a hemodialysis access. The Vascular WrapTM Paclitaxel-Eluting Mesh is positioned on the vein and placed around the venous anastomosis to include both the toe and the heel of the anastomosis, and is sutured in place.
3299946|NCT00448708|No Intervention|Lifespan® ePTFE Vascular Graft|Lifespan® ePTFE Vascular Graft Only: The Lifespan® ePTFE Vascular Graft is implanted as an arteriovenous graft in an upper extremity to provide a hemodialysis access.
3299947|NCT00448682|Experimental|FUdR + Leucovorin + Oxaliplatin + Docetaxel (Taxotere)|"Treatment will be administered on an outpatient basis. Chemotherapy will be administered weekly, 3 out of 4 weeks, on days 1, 8 and 15:~Day 1 and Day 15 Chemotherapy Administration: Patients will be administered oxaliplatin (85 mg/m2) and docetaxel (25 mg/m2) followed by FUdR/Leucovorin (110 mg/kg//500 mg/m2) on Day 1 and Day 15 of each cycle.~Day 8 Chemotherapy Administration On Day 8, treatment will consist of docetaxel (25 mg/m2) followed by FUdR/Leucovorin (110mg/kg//500mg/m2).~There will be no treatment delivered week 4 (Day 22). For the purpose of this study, one cycle equals four weeks. There will be a maximum of 6 cycles."
3299948|NCT00448669|Active Comparator|TDF-FTC, condoms, risk counseling|Participants randomized to the active arm received daily oral TDF-FTC along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
3299949|NCT00448669|Placebo Comparator|Placebo, condoms, risk counseling|Participants randomized to the placebo arm received a daily oral placebo tablet along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
3299950|NCT00448643|Experimental|Whole-Abdominal Radiation Therapy and Chemotherapy|
3299951|NCT00448630||Atypical Antispychotics (or second generation antipsychotics)|Patients with schizophrenia who are currently receiving or are going to start a new treatment with atypical antipsychotics, ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, amisulpride.
3299952|NCT00448591|Experimental|1|
3299953|NCT00448539|Experimental|Extension Phase Rufinamide|
3299954|NCT00448539|Placebo Comparator|Placebo|
3299955|NCT00448513|Experimental|catechin|catechin capsule group
3299956|NCT00448461|Active Comparator|1|heparin
3299957|NCT00448461|Active Comparator|2|bivalirudin
3299958|NCT00448448|Active Comparator|Brace|This study involves full-time, rigid TLSO's only. Braced subjects are followed every six months with radiography, clinical exam and self-reported evaluations of health and functioning. Orthotic evaluations are conducted every 6 months as as necessary to maintain brace fit and function.
3299959|NCT00448448|Active Comparator|Observation|Observation. Observed subjects are followed every six months with radiography, clinical exam and self-reported evaluations of health and functioning.
3299960|NCT00448435|Active Comparator|SLM+FP First|SLM(salmeterol) 25mcg + FP(fluticasone propionate) 50mcg twice daily in first intervention period and SFC(salmeterol/fluticasone propionate) 25/50mcg twice daily in second intervention period and (after washout period).
3299961|NCT00448435|Active Comparator|SFC First|SFC (Salmeterol/Fluticasone propionate combination) 25/50mcg twice daily in first intervention period and SLM (Salmeterol) 25mcg + FP (Fluticasone Propionate) 50mcg twice daily in second intervention period (after washout period).
3299969|NCT00448357|Experimental|GVHD prophylaxis|"Subjects with matched-related donors (MRDs) were treated with tacrolimus and methotrexate with or without alemtuzumab for graft vs host disease prophylaxis Subjects also receive busulfan and fludarabine .~Matched unrelated donor (MUD) or mismatched related donor (MMRD) subjects receive GVHD prophylaxis with rabbit anti-thymocyte globulin (ATG) + Methotrexate Subjects also receive busulfan, fludarabine, and tacrolimus."
3299970|NCT00448344|Experimental|Arm 1|Family-supported smoking cessation
3299971|NCT00448344|Other|Arm 2|Standard smoking cessation
3299972|NCT00448331||positive screen, negative screen|Positive screens are those who received positive feedback regarding their answers to a mental illness screening assessment. Negative screens received feedback stating that they did not screen positive for any mental illness.
3299973|NCT00448305|Experimental|1|EndoTAG-1 + Paclitaxel
3299974|NCT00448305|Experimental|2|EndoTAG-1
3299975|NCT00448305|Active Comparator|3|Paclitaxel
3299976|NCT00448292|Experimental|1|PRX-00023 taken twice daily, escalating from 40 mg to 80 mg to 120 mg
3299977|NCT00448292|Placebo Comparator|2|Placebo taken twice daily, escalating from 40 mg to 80 mg to 120 mg
3299978|NCT00448279|Active Comparator|Chemotherapy Alone|Chemotherapy, schedule and dose at the investigator's discretion.
3299979|NCT00448279|Experimental|Chemotherapy, Trastuzumab|Trastuzumab, at the investigator's discretion, either 2 milligrams per kilogram (mg/kg) intravenous (i.v.) every 7 days or 6 mg/kg i.v. every 3 weeks. Chemotherapy, schedule and dose at the investigator's discretion.
3299980|NCT00448266|Experimental|2|1 course ddAc, 2 courses IAA with PBPC support
3299981|NCT00448266|Active Comparator|1|3 courses ddAC
3299982|NCT00448253|Experimental|1|Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA. And a Fourth Cohort at 840 units TNA with 2 additional product lots.
3299983|NCT00448253|Placebo Comparator|2|Saline (equal volume to 210 U, 420 U, or 840 U TNA dose)
3299984|NCT00448227|Experimental|Famciclovir|Famciclovir was administered orally as a suspension in OraSweet® on Day 1. Patients received a single, individualized dose between 25-200 mg based on body weight.
3299985|NCT00448214|Experimental|1|Low dose
3299986|NCT00448214|Experimental|2|Middle dose
3299987|NCT00448214|Experimental|3|High dose
3299988|NCT00448214|Active Comparator|4|
3299989|NCT00448201|Active Comparator|Methotrexate Only Arm|GVHD Prophylaxis with Methotrexate
3299990|NCT00448201|Active Comparator|2 Doses ATG + Methotrexate|GVHD prophylaxis with antithymocyte globulin (ATG) + Methotrexate
3299991|NCT00448201|Active Comparator|2 Doses ATG|GVHD prophylaxis with 2 doses ATG
3299992|NCT00448201|Active Comparator|3 Doses ATG|GVHD prophylaxis with 3 doses ATG
3299993|NCT00448175|Experimental|Urgent PC treatment arm|
3299994|NCT00448149|Experimental|1|To establish the maximally tolerated dose (MTD) of RAD001 in combination with Nexavar®
3299995|NCT00448136|Experimental|1|
3299996|NCT00448136|Experimental|2|
3299997|NCT00448123|Placebo Comparator|Placebo|Placebo
3299998|NCT00448123|Active Comparator|Tamsulosin|Intervention - Tamsulosin
3299999|NCT00448110|Experimental|A|intravenous diclofenac dosage level 1
3300000|NCT00448110|Experimental|B|intravenous diclofenac dosage level 2
3300001|NCT00448110|Active Comparator|C|intravenous ketorolac
3300002|NCT00448110|Placebo Comparator|D|placebo
3300003|NCT00448097|Other|Data not available PI relocated|No verifiable data available, PI relocated
3300004|NCT00448058|Experimental|GSK372475|flexible-dose design from GSK372475 1.0 mg/day to GSK372475 2.0 mg/day
3300005|NCT00448058|Active Comparator|Venlafaxine|Flexible- dose design from Venlafaxine XR 75 mg/day to Venlafaxine XR 225 mg/day
3300006|NCT00448058|Placebo Comparator|placebo|
3300007|NCT00448045|Experimental|Manual and mechanical assisted cough|Individuals will be given a pulse oximeter and taught both manually assisted and mechanically assisted coughing techniques to maximize their cough peak flow. Manually assisted coughing consists of air stacking to deep insufflations. An abdominal thrust is then applied upon glottic opening to augment the cough peak flow. Subjects will also have rapid access to a mechanical in-exsufflator (CoughAssistTM) and will be trained on how to access and use this device. Mechanically assisted coughing (MAC) involves the use of the CoughAssistTM to expand the lungs and then quickly reverse the pressure to rapidly empty the lungs with expiratory (cough) flows of 600 L/m. An abdominal (manual) thrust is applied in conjunction with the negative pressure (exsufflation) to further increase cough.
3300008|NCT00448045|Active Comparator|Incentive spirometry|The active control group will consist of individuals assigned to the oximetry with incentive spirometry group. These individuals will be given a pulse oximeter and an incentive spirometer (AirLife Company) and taught how to use them.
3300009|NCT00448019|Experimental|FCR + Bevacizumab|FCR = Fludarabine 25 mg/m^2 intravenous (IV) , Cyclophosphamide 250 mg/m^2 IV daily for 3 days, Rituximab 375 mg/m^2 IV Day 1, followed by 500 mg/m^2 IV. FCR daily for 3 days. Bevacizumab 10 mg/Kg IV on Day 3, course 1.
3300010|NCT00447993|Experimental|1 NT-501|High Dose Implant
3300011|NCT00447993|Experimental|2 NT-501|Low Dose Implant
3300012|NCT00447980|Experimental|1 NT-501 implant|High Dose
3300013|NCT00447980|Experimental|2 NT-501 implant|Low Dose
3300014|NCT00447967|Experimental|1|IOX
3300015|NCT00447967|Experimental|2|FLOX
3300016|NCT00447954|Experimental|1 high dose NT-501 implant|
3300017|NCT00447954|Experimental|2 low dose NT-501 implant|
3300018|NCT00447954|Sham Comparator|3 sham procedure|No implant
3300019|NCT00447915|Experimental|1|
3300020|NCT00447915|Experimental|2|
3300021|NCT00447915|Active Comparator|3|
3300022|NCT00447876|Experimental|Botulinum type A toxin (Dysport®)|
3300023|NCT00447876|Placebo Comparator|Placebo|
3300024|NCT00447837|Experimental|1|
3300025|NCT00447837|Experimental|2|
3300026|NCT00447837|Placebo Comparator|3|
3300072|NCT00447278|Active Comparator|OEST|Other Early Standard Treatment (OEST): any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
3300176|NCT00446134|Experimental|Group 2: Drug|Oral taribavirin tablet 25 mg/kg/day (Actual doses were 25-29 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
3300027|NCT00447798|Experimental|Prevention Care Advocate|Prevention Care Advocate (PCA) intervention contains elements based on cognitive-behavioral theories and strengths-based case management. Intervention arm participants will undergo an 8 session intervention comprised of three components: 1) An individual strengths-based case management approach aimed at motivating participants to seek or maintain their engagement with HIV primary care and drug treatment; 2) A cognitive-behavioral, skills-building approach to increase participants' risk reduction knowledge, skills, and perceived self-efficacy as well as intention to change high risk transmission behaviors; and 3) A community placement in which study participants will have the opportunity to practice their advocacy skills in prevention and care setting.
3300028|NCT00447798|No Intervention|Standard of Care|"Standard of Care (SOC) condition involves standard practice, consisting of usual inpatient/hospital services provided within normal clinical practice, plus a brief educational session consisting of the review of the topics in the Living with HIV brochure published by the Centers for Disease Control and Prevention (CDC)."
3300029|NCT00447772|Experimental|1|
3300030|NCT00447759|Experimental|Celecoxib|Drug
3300031|NCT00447759|Active Comparator|NSAID|Drug
3300032|NCT00447733|Experimental|Integrated treatment|Evidence-based psychosocial and pharmacological treatment of both the substance use disorder and the mental health disorder is provided at the same time and by the same therapists in a comprehensive way.
3300033|NCT00447733|Active Comparator|Treatment as usual|Non-manualized clinic-based treatment provided by therapists without formal training in integrated treatment of co-occurring disorders.
3300034|NCT00447720|Experimental|PATH counseling|These participants received the PATH intervention
3300035|NCT00447720|Active Comparator|Treatment as Usual|These individuals receive treatment as they normally would receive in the community
3300036|NCT00447694|Experimental|deferasirox every day for 77 weeks|participants will be given oral deferasirox 30mg/kg/day for 77 weeks.
3300037|NCT00447668|Experimental|1|
3300038|NCT00447668|Active Comparator|2|Exercise
3300039|NCT00447668|Active Comparator|3|Self-care book recommendations
3300040|NCT00447642|Experimental|LX201 0.50 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.50 inch in length
3300041|NCT00447642|Experimental|LX201 0.75 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.75 inch by length
3300042|NCT00447642|Placebo Comparator|Placebo 0.75 inch implant|Silicone implant not containing cyclosporine A, 0.75 inch in length
3300043|NCT00447603|Active Comparator|Losartan 50 mg|Losartan 50 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg once daily for 4 weeks
3300044|NCT00447603|Active Comparator|Losartan 100 mg|Losartan 100 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 100 mg/hydrochlorothiazide (HCTZ) 12.5 mg once daily for 4 weeks
3300045|NCT00447603|Experimental|Losartan 50 mg/HCTZ 12.5 mg|Losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 50 mg once daily for 4 weeks
3300046|NCT00447603|Experimental|Losartan 100 mg/HCTZ 12.5 mg|Losartan 100 mg/hydrochlorothiazide (HCTZ) 12.5 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 100 mg once daily for 4 weeks
3300047|NCT00447590|Experimental|LAP-BAND|All subjects who received the LAP-BAND System.
3300048|NCT00447577|Experimental|Zylet|Loteprednol etabonate and tobramycin ophthalmic suspension, 0.5%/0.3% (Zylet)
3300049|NCT00447577|Active Comparator|Tobradex|Tobradex (tobramycin and dexamethasone ophthalmic suspension, 0.3%/0.1%), US marketed product (Alcon) from commercial lots.
3300050|NCT00447564|Active Comparator|Group A|
3300051|NCT00447564|Placebo Comparator|Group B|
3300052|NCT00447551|Experimental|single group|
3300053|NCT00447525|Experimental|1|
3300054|NCT00447525|Active Comparator|2|
3300055|NCT00447499|Experimental|Somatuline Autogel (lanreotide acetate)|Somatuline Autogel (lanreotide acetate) Injection
3300056|NCT00447473|Other|A|GM-CSF given in combination with ketoconazole and mitoxantrone in patients with progressive prostate cancer despite androgen deprivation and prior taxane containing chemotherapy
3300057|NCT00447421|Experimental|A|
3300058|NCT00447408|Active Comparator|A|Education in the hemodialysis diet.
3300059|NCT00447408|Experimental|B|Education in the hemodialysis diet. Behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
3300060|NCT00447395||GROUP 1|Recurrent miscarriage, <40 year-old-men, < 38 year-old-women, normal or mild affected sperm, normal parents karyotype, no thrombophilia, normal uterus, no endocrinopathy
3300061|NCT00447395||GROUP 2|•Recurrent miscarriage, <40 year-old-men, < 38 year-old-women, oligozoospermia (1-5 mill/ml), normal parents karyotype, no thrombophilia, normal uterus, no endocrinopathy
3300062|NCT00447395||GROUP 3|•Oligozoospermia (1-5 mill/ml), < 40 year-old-men, no recurrent miscarriages
3300063|NCT00447395||GROUP 4|•Healthy young sperm donors
3300064|NCT00447382|Active Comparator|NN304|Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
3300065|NCT00447382|Experimental|NN729|Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
3300066|NCT00447343||Treatment group|"Patients with cervical myelopathy undergoing decompressive cervical spine surgery will have two scans (pre-operatively and 6 months post-operatively).~A blinded investigator will administer questionnaires at each time point."
3300067|NCT00447343||Control group|"Healthy Volunteers will have two scans 6 months apart.~A blinded investigator will administer questionnaires at each time point."
3300068|NCT00447330|Experimental|1|
3300069|NCT00447317|Experimental|A|Intervention
3300070|NCT00447317|Other|B|Attention control, standard dietary education
3300071|NCT00447278|Experimental|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
3300073|NCT00447265|Experimental|Etanercept|Participants in this group will self-administer 50 mg etanercept injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).
3300074|NCT00447265|Placebo Comparator|Placebo|Participants in this group will self-administer 50 mg placebo injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).
3300075|NCT00447226|Experimental|Lapatinib Oral Tablets|
3300076|NCT00447226|Placebo Comparator|Placebo Control|
3300077|NCT00447213|Experimental|1|
3300078|NCT00447213|Experimental|2|
3300079|NCT00447187|Experimental|LX201 0.50 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.50 inch in length
3300080|NCT00447187|Experimental|LX201 0.75 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.75 inch by length
3300081|NCT00447187|Placebo Comparator|Placebo 0.75 inch implant|Silicone implant not containing cyclosporine A, 0.75 inch in length
3300082|NCT00447174|Experimental|treatment|treatment manual
3300083|NCT00447174|No Intervention|control group|
3300084|NCT00447161|Experimental|1|Bacillus Clausii Multi ATB Resist
3300085|NCT00447161|Placebo Comparator|2|Placebo
3300086|NCT00447148|No Intervention|1|Paired comparison of 2 angiographic techniques
3300087|NCT00447122|Experimental|treatment|lapatinib, 1,500 mg/day, and Gemcitabine, 1 gm/m2/week for 3 weeks followed by 1 week off, until disease progression
3300088|NCT00447096|Experimental|Treatment Arm|Treatment arm will receive treatment 5 days a week for 6 weeks. Repetitive transcranial magnetic stimulation (rTMS) treatment.
3300089|NCT00447096|Sham Comparator|Sham Arm|Sham Arm will not receive any stimulation 5 days a week for 6 weeks. Sham transcranial magnetic stimulation.
3300090|NCT00447057|Experimental|Pemetrexed (Nonsquamous)|Group of participants with non-small cell lung cancer (NSCLC) of nonsquamous histology who were assigned to Pemetrexed arm
3300091|NCT00447057|Experimental|Pemetrexed + Erlotinib (Nonsquamous)|Group of participants with NSCLC of nonsquamous histology who were assigned to Pemetrexed + Erlotinib arm
3300092|NCT00447057|Experimental|Pemetrexed (Squamous)|Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed arm
3300093|NCT00447057|Experimental|Pemetrexed + Erlotinib (Squamous)|Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed + Erlotinib arm
3300094|NCT00447044|Experimental|2|Subjects drink essential amino acid supplement 3x day for 2 days.
3300095|NCT00447044|Placebo Comparator|1|Subjects receive inert substance versus protein supplement.
3300096|NCT00447044|Experimental|3|Resistance exercise.
3300097|NCT00447005|Experimental|Open|
3300098|NCT00446992|Experimental|Open Trial Group|The patients were newly diagnosed with psychosis and were recruited at their first clinical contact for psychosis.
3300099|NCT00446979|Experimental|1|UC 781 0.1% carbomer gel
3300100|NCT00446979|Experimental|2|UC 781 0.25% carbomer gel
3300101|NCT00446979|Placebo Comparator|3|Placebo vaginal gel
3300102|NCT00446966|Experimental|fish oil , corn oil|Highly purified pharmaceutical grade omega three polyunsaturated fatty acids
3300103|NCT00446953|Experimental|1|2x 12 mg betamethazone
3300104|NCT00446953|Placebo Comparator|2|no drugs
3300105|NCT00446901|Placebo Comparator|Placebo|Placebo
3300106|NCT00446901|Experimental|Selenium (selenized yeast)|Selenium (selenized yeast) tablets, 300 ug/day
3300107|NCT00446888|Active Comparator|1|"these subjects will get a standard protein supplement milkshake during thei study."
3300108|NCT00446888|Experimental|2|"these subjects will receive an enhanced protein supplement milkshake during their study. Product 4808."
3300109|NCT00446849|Experimental|MMX Mesalamine|
3300110|NCT00446836|Other|Single arm|Open label use of Xyotax
3300111|NCT00446810|Active Comparator|A1|Benfotiamine
3300112|NCT00446810|Active Comparator|A2|
3300113|NCT00446797|Active Comparator|Non-Selective NSAIDS|nsNSAIDs used in real-life standard practice for treatment of pain due to ankle sprain.
3300114|NCT00446797|Experimental|Celecoxib|
3300115|NCT00446758|Experimental|Zinc|zinc (as zinc sulphate) 12.5 mg orally per day (6.25 mg in children < 12 mo)
3300116|NCT00446758|Placebo Comparator|Placebo|
3300117|NCT00446745||Abdominal obesity|60 males were recruited according to waist circumference, from lean to obese values
3300118|NCT00446732|Active Comparator|1|
3300119|NCT00446732|No Intervention|2|
3300120|NCT00446693|Experimental|I|Use of EndoFast Reliant System
3300121|NCT00446680|Experimental|1|
3300122|NCT00446680|Placebo Comparator|2|
3300123|NCT00446667|Experimental|1|
3300124|NCT00446654|Experimental|CGC-11047 once every 2 weeks|16.5 mg CGC-11047 as a subconjunctival injection once every two weeks.
3300125|NCT00446654|Experimental|CGC-11047 once every four weeks|16.5 mg CGC-11047 as a subconjunctival injection once every four weeks.
3300126|NCT00446641|Experimental|1 Cilostazol|100mg of Cilostazol twice a day
3300127|NCT00446641|Placebo Comparator|Placebo|matching placebo to cilostazol
3300128|NCT00446628|Experimental|intervention|Five elementary school received intervention consistin of training in hand and respiratory hygiene, and access to hand sanitizer
3300129|NCT00446628|No Intervention|control|Five elementary school received no training or hand sanitizer.
3300130|NCT00446602|Experimental|001|Epoetin alfa Type=exact unit=units number=80 000 form=solution for injection route=subcutaneous use once every week or once every 2 weeks.
3300131|NCT00446589|Experimental|F|HD pts suffering from osteoporosis and adynamic bone disease who received teriparatide
3300132|NCT00446589|Experimental|I|Hemodialysis pts suffering from osteoporosis who received iv ibandronate
3300133|NCT00446563|Experimental|Amlodipine + Valsartan|Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
3300134|NCT00446563|Active Comparator|Losartan + Hydrochlorothiazide|Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
3300135|NCT00446550|Experimental|Afegostat Tartrate Treatment Regimen 1|For the first 2 weeks, afegostat tartrate was administered orally at a dose of 225 milligrams (mg) once daily (QD) for 7 consecutive days, followed by no study medication for 7 consecutive days. After 2 weeks, participants then took 225 mg afegostat tartrate QD for 3 consecutive days, followed by no study medication for 4 consecutive days. This 3-days-on/4-days-off treatment regimen was followed for 22 weeks.
3300136|NCT00446550|Experimental|Afegostat Tartrate Treatment Regimen 2|Afegostat tartrate was administered orally at a dose of 225 mg QD for 7 consecutive days, followed by no study medication for 7 consecutive days. This 7-days-on/7-days-off treatment regimen was followed for 24 weeks.
3300137|NCT00446524|Experimental|Valsartan + Amlodipine 80/5 mg|Valsartan 80 mg or Amlodipine 5 mg ---> Valsartan + Amlodipine 80 / 5 mg
3300138|NCT00446524|Experimental|Valsartan + Amlodipine 80/5 mg + Diuretic|Valsartan + Amlodipine 80 / 5 mg + Diuretic
3300139|NCT00446511|Experimental|CKD patients: Valsartan+enalapril|
3300140|NCT00446511|Active Comparator|CKD patients: Enalapril|
3300141|NCT00446511|Experimental|Non-CKD patients: Valsartan|
3300142|NCT00446511|Active Comparator|Non-CKD patients: Enalapril|
3300143|NCT00446485|Active Comparator|1|Ginkgo Biloba standardized extract 24/6
3300144|NCT00446485|Placebo Comparator|3|placebo
3300145|NCT00446472|Experimental|1|Randomized to Regranex gel
3300146|NCT00446472|Active Comparator|2|Placebo hydrogel will be used for a total of 16 weeks
3300147|NCT00446446|Experimental|Panitumumab|articipants received panitumumab as an intravenous infusion at a dose of 9 mg/kg every 21 days until disease progression, unacceptable toxicity, withdrawal of consent, death, or end of study.
3300148|NCT00446420|Active Comparator|1|These patients will only receive intravenous propofol which will be titrated to an OAA/S score of 3. They will not receive fentanyl, midazolam or any other drugs
3300149|NCT00446420|Active Comparator|2|These patients will receive propofol plus midazolam and/or fentanyl. Midazolam and fentanyl will be given in fixed doses first and propofol will be titrated to effect. All drugs will be given intravenously.
3300150|NCT00446407|Experimental|Collaborative Stepped Care|Screening, Antidepressants, Psychosocial interventions (psychoeducation, IPT, adherence management) by Health Counselor, support and supervision by Psychiatrist.
3300151|NCT00446407|Active Comparator|Enhanced Usual Care|
3300152|NCT00446394|Experimental|1|
3300153|NCT00446394|Active Comparator|2|
3300154|NCT00446381|Experimental|1|Patients with Proliferative Diabetic Retinopathy
3300155|NCT00446381|Experimental|2|Patients with Clinically Significant Macular Edema
3300156|NCT00446368|Experimental|RAD001|Subjects will take RAD001 (Everolimus) 10mg by mouth daily.
3300157|NCT00446342|Experimental|Dose-escalation of SNS-032 injection|Patients escalated to MTD starting in Cohort 1 of 15 mg/m2 of SNS-032 injection, with 1.5-fold increase each cohort and a maximum loading dose increase of 10 mg/m2. Each dose cohort will have a minimum of 3 patients each with advanced CLL or MM. Dose escalation continues in the absence of Cycle 1 DLT criteria until an MTD is achieved for each disease type to a maximum of 7 cohorts at a high dose of 70 mg/m2. Stage 2 tests at MTD in larger group.
3300158|NCT00446316|Experimental|Gleevec plus antacids|Gleevec® will be administered at a dose of 400 mg, and the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide). Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1.
3300159|NCT00446316|Experimental|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
3300160|NCT00446290|Experimental|Docetaxel, Capecitabine and Oxaliplatin|
3300161|NCT00446264|Experimental|islet transplantation|Each participant received up to three sequential fresh islet infusions within three months.
3300162|NCT00446238|Experimental|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
3300163|NCT00446238|Active Comparator|Standard of Community Care Treatment|Standard of Community Care Treatment
3300164|NCT00446225|Experimental|A|Erlotinib (Tarceva)150 mg /day
3300165|NCT00446225|Active Comparator|B|"4 cycles of Chemotherapy:~Cisplatin / Gemcitabine; Cisplatin /Docetaxel; Carboplatin / Gemcitabine; Carboplatin / Docetaxel."
3300166|NCT00446212|Active Comparator|1|Propofol based anaesthetic maintenance with propofol effect-site steered target-controlled infusion, in addition to fentanyl and non-opioid analgesics
3300167|NCT00446212|Active Comparator|2|Desflurane based anaesthetic maintenance with manually controlled administration in 100% oxygen in addition to fentanyl and non-opioid analgesics
3300168|NCT00446199|Experimental|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
3300169|NCT00446199|Experimental|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
3300170|NCT00446199|Experimental|Estradiol (E2 0.3mg)|One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).
3300171|NCT00446199|Placebo Comparator|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
3300172|NCT00446173|Experimental|Busulfan + Cyclophosphamide + G-CSF + GM-CSF|
3300173|NCT00446147|Placebo Comparator|Placebo|one tablet twice per day, which is identical to pyridoxine
3300174|NCT00446147|Experimental|Pyridoxine|100 mg twice per day
3300175|NCT00446134|Experimental|Group 1: Drug|Oral taribavirin tablet 20 mg/kg/day (Actual doses were 20-24 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
3300217|NCT00445614|Other|Poultry|150 g/d of poultry (for comparison)
3300177|NCT00446134|Experimental|Group 3: Drug|Oral taribavirin 30 mg/kg/day (Actual doses were 30-34 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
3300178|NCT00446134|Active Comparator|Group 4: Drug|Oral ribavirin 800 mg/day (body weight <65 kg), 1000 mg/day (body weight 65-84 kg), 1200 mg/day (body weight 85-104 kg) or 1400 mg/day (body weight greater than or equal to 105 kg) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
3300179|NCT00446095|Experimental|fostamatinib|
3300180|NCT00446082|Experimental|SOM230 LAR|
3300181|NCT00446069|Experimental|Egalet® morphine|
3300182|NCT00446069|Active Comparator|MST Continus®|
3300183|NCT00446030|Experimental|Stratum 1: TAC + Bevacizumab|"Human epidermal growth factor receptor-2 (HER2) negative participants stratified at registration, were administered chemotherapy with docetaxel, doxorubicin and cyclosphosphamide (TAC) + bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.~All participants were administered prophylactic recombinant Granulocyte Colony Stimulating Factor (G-CSF) during chemotherapy, based on a dose recommended by the manufacturer. For participants with estrogen receptor (ER) or progesterone receptor (PR) positive tumors, anti-estrogen therapy was recommended. Participants could receive radiation therapy at the discretion of the treating medical and radiation oncologist."
3300184|NCT00446030|Experimental|Stratum 2: TCH + Bevacizumab|"HER2 positive participants stratified at registration, were administered chemotherapy with docetaxel, carboplatin and trastuzumab (TCH) + bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks.~All participants were administered prophylactic recombinant Granulocyte Colony Stimulating Factor (G-CSF) during chemotherapy, based on a dose recommended by the manufacturer. For participants with estrogen receptor (ER) or progesterone receptor (PR) positive tumors, anti-estrogen therapy was recommended. Participants could receive radiation therapy at the discretion of the treating medical and radiation oncologist."
3300185|NCT00446004|Other|A|On an 18-day schedule, Omeprazole (PPI) once daily on days 10 through 16; and Gleevec® once daily on days 1 and 15 (i.e., Gleevec® alone on day 1, and combination of Gleevec® and PPI on day 15).
3300186|NCT00446004|Other|B|On an 18-day schedule, Omeprazole (PPI) once daily on days -4 through 1; and Gleevec® once daily on days 1 and 15 (i.e., combination of Gleevec® and PPI on day 1, Gleevec® alone on day 15).
3300187|NCT00445978|Experimental|6R-BH4|2.5, 5, 10, 20 mg/kg/day of 6R-BH4 during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks, with an optional extension phase at the highest tolerated dose for up to a total of 2 years.
3300188|NCT00445965|Experimental|131I-3F8|This is a phase II single-arm open-label study that will define responses to therapy with weekly intrathecal 131I-3F8 in patients with central nervous system/leptomeningeal GD2-expressing disease.
3300189|NCT00445939|Experimental|Adalimumab 160 mg/80 mg|
3300190|NCT00445939|Experimental|Adalimumab 80 mg/40 mg|
3300191|NCT00445939|Placebo Comparator|Placebo|
3300192|NCT00445913|Experimental|control dendritic cells|autologous dendritic cells that are not treated
3300193|NCT00445913|Experimental|AS ODN dendrtitic cells|autologous dendritic cells treated ex vivo with the mixture of the antisense oligonucleotides
3300194|NCT00445887|Experimental|Arm I (levonorgestrel)|Patients receive oral levonorgestrel once daily.
3300195|NCT00445887|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily.
3300196|NCT00445848|Experimental|Erlotinib and Bevacizumab|
3300197|NCT00445835|Other|BA :Active arm|A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
3300198|NCT00445835|Other|BC: Conservative arm|Conservative medical approach
3300199|NCT00445809||1|High Risk population for developing AKI during/after CABG surgery.
3300200|NCT00445809||2|Medium Risk population for developing AKI during/after CABG surgery.
3300201|NCT00445770|Experimental|1|
3300202|NCT00445770|Experimental|2|
3300203|NCT00445770|Active Comparator|3|
3300204|NCT00445744|Experimental|Treatment (cyclophosphamide, busulfan, transplant)|"CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11."
3300205|NCT00445718||Observational|Patients undergo an abdominal CT or MRI scan on weeks 0, 6, and 42 and an abdominal sonogram on weeks 0, 3, 6, 12, 18, 30, 42, 66, and 90. Urinary catecholamine levels are also measured on the same weeks as the abdominal sonogram. Patients with an increase in tumor volume or catecholamine levels undergo sonographic evaluation and urine catecholamine sampling every 3 weeks until stabilization. Patients with a continued increase in catecholamine levels or a 50% increase in tumor volume undergo surgical resection off protocol therapy.
3300206|NCT00445705|Placebo Comparator|Placebo|Part A: Placebo every 12 hours for 4 weeks
3300207|NCT00445705|Experimental|AGN 203818 3 mg|Part A: 3 mg AGN 203818 every 12 hours for 4 weeks
3300208|NCT00445705|Experimental|AGN 203818 20 mg|Part A: 20 mg AGN 203818 every 12 hours for 4 weeks
3300209|NCT00445705|Experimental|AGN 203818 60 mg|Part A: 60 mg AGN 203818 every 12 hours for 4 weeks
3300210|NCT00445692|Experimental|Treatment (clarithromycin, dexamethasone, lenalidomide)|"Patients receive clarithromycin orally (PO) twice daily and dexamethasone PO once a week. Treatment with clarithromycin and dexamethasone continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO once daily on days 1-14. Courses with lenalidomide repeat every 21 days in the absence of disease progression or unacceptable toxicity. Lenalidomide is taken 4 hours or more after last dose of daily clarithromycin.~NOTE: *After one year of treatment, dexamethasone is tapered for an additional 4 weeks."
3300211|NCT00445679|Experimental|A|DVS SR 50mg/day
3300212|NCT00445679|Experimental|B|DVS SR 100mg/day
3300213|NCT00445679|Experimental|C|DVS SR 200mg/day
3300214|NCT00445679|Active Comparator|D|Paroxetine 20mg/day
3300215|NCT00445614|Experimental|Marine trout|150 g/day of trout fed on marine based feed
3300216|NCT00445614|Experimental|Vegetable trout|150 g/d of trout fed on vegetable based feed
3300219|NCT00445601|Placebo Comparator|Arm II|Patients receive intravesical placebo over 1 hour.
3300220|NCT00445588|Experimental|Treatment|"Patients receive oral erlotinib hydrochloride 150mg once daily and oral sorafenib tosylate 400mg twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study"
3300221|NCT00445575|Experimental|1|treatment duration: 1 year
3300222|NCT00445575|Placebo Comparator|2|treatment duration: 1 year
3300223|NCT00445575|Experimental|3|duration treatment: 3 years
3300224|NCT00445575|Placebo Comparator|4|treatment duration: 3 years
3300225|NCT00445549|Experimental|Vandetanib treatment|300 mg daily oral dose, 28 day cycle
3300226|NCT00445523|Experimental|1|TroVax® alone
3300227|NCT00445523|Experimental|2|TroVax® plus IFN-α
3300228|NCT00445484|Experimental|Group 1|Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
3300229|NCT00445484|Experimental|Group 2|Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
3300230|NCT00445471|Other|A|Mifne Approach to PDD
3300231|NCT00445471|Other|B|Treatment as usual
3300232|NCT00445458|Experimental|HKI-272 dose level 1|Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 160 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
3300233|NCT00445458|Experimental|HKI-272 dose level 2|Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
3300234|NCT00445458|Experimental|HKI-272 expanded MTD cohort, arm A|Part 2: Subjects with metastatic breast cancer who have not received more than 1 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
3300235|NCT00445458|Experimental|HKI-272 expanded MTD cohort, arm B|Part 2: Subjects with metastatic breast cancer who have not received more than 3 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
3300236|NCT00445445||Patients|Histologically confirmed breast cancer that was diagnosed between the years 2002-2004
3300237|NCT00445445||Healthy participants|Healthy participant who is receiving routine medical care (e.g., screening mammograms. Healthy participants are frequency-matched by age (± 2 years) and ethnicity.
3300238|NCT00445432|Experimental|DB Adalimumab 40 mg eow|Subjects received double-blind (DB) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the DB treatment period lasting 52 weeks.
3300239|NCT00445432|Placebo Comparator|Placebo eow|Subjects received placebo subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
3300240|NCT00445432|Experimental|OL Adalimumab 40 mg eow|Subjects received open-label (OL) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
3300241|NCT00445367||Case|
3300242|NCT00445367||Control|
3300243|NCT00445341|Experimental|Flavopiridol in lymphoma patients|Flavopiridol 30 mg/m^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
3300244|NCT00445328|Active Comparator|B|
3300245|NCT00445328|Experimental|A|
3300246|NCT00445315|Experimental|2|
3300247|NCT00445315|Experimental|3|
3300248|NCT00445315|Experimental|1|
3300249|NCT00445315|Experimental|4|
3300250|NCT00445315|Placebo Comparator|5|
3300251|NCT00445302|Active Comparator|Normal renal function|Participants with normal renal function (creatinine clearance (CLcr) > 90 ml/min) who serve as the study control. Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
3300252|NCT00445302|Experimental|Mild renal impairment|Participants have mild renal impairment (creatinine clearance (CLcr) = 51 to 80 mL/min). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
3300253|NCT00445302|Experimental|Moderate renal impairment|Participants have moderate renal impairment (creatinine clearance (CLcr) = 31 to 50 mL/min). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
3300254|NCT00445302|Experimental|Severe renal impairment|Participants have severe renal impairment (creatinine clearance (CLcr) < 31 mL/min, not requiring dialysis). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
3300255|NCT00445263|Experimental|Early Invasive strategy|Tirofiban and coronarography within 6 hours
3300256|NCT00445263|Active Comparator|Delayed invasive strategy|Coronarography after 6 hours
3300257|NCT00445224|Experimental|Hip Progressive Resistive Exercises|Exercises targeting hip musculature such as hip abduction and hip external rotation that was progressed by increased resistance following typical progressive resistive exercise approach.
3300258|NCT00445224|Active Comparator|Quad Progressive Resistive Exercises|Exercises targeting quadriceps musculature such as quadriceps isometric setting, terminal knee extensions, and straight leg raises that was progressed by increased resistance following typical progressive resistive exercise approach..
3300259|NCT00445211|Active Comparator|Intra-Aortic balloon Pump with Heparin|Intra-Aortic Balloon Pump (IABP) with Heparin
3300260|NCT00445211|Active Comparator|Intra-Aortic balloon Pump without Heparin|Intra-Aortic balloon Pump (IABP) without Heparin
3300261|NCT00445198|Experimental|Phase 1 and Phase 2a|
3300262|NCT00445185|Experimental|1|Henogen Hepatitis B vaccine for uremic patients
3300263|NCT00445185|Active Comparator|2|Fendrix hepatitis B vaccine for uremic patients
3300264|NCT00445172|Experimental|1|
3300426|NCT00443560||Spontaneous Vaginal Delivery (SVD)|The control group consisted of parturients who had a spontaneous vaginal delivery (SVD)in the same 24 hour period who were case-matched for gravidity and parity.
3300427|NCT00443547|Other|1-level|Patients needing a single level cervical fusion
3300265|NCT00445146|Experimental|EVG+RTV|"EVG 85 mg or 150 mg + RTV + ARV regimen~Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their ARV regimen will receive EVG 85 mg and all other participants will receive EVG 150 mg.~Some participants may receive EVG 300 mg during the course of protocol amendment 2."
3300266|NCT00445120|Experimental|1|
3300267|NCT00445120|Placebo Comparator|2|
3300268|NCT00445081|Active Comparator|1|
3300269|NCT00445081|Active Comparator|2|
3300270|NCT00445068|Experimental|Panobinostat|
3300271|NCT00445055|Experimental|1|Intravenous injection of 0,625 mg Droperidol, 30 min before the end of anesthesia
3300272|NCT00445055|Experimental|2|Intravenous injection of 2,5 mg Droperidol, 30 min before the end of anesthesia
3300273|NCT00445055|Placebo Comparator|3|Intravenous injection of NaCl 9% (Placebo), 30 min before the end of anesthesia
3300274|NCT00445042|Experimental|A|Intrapatient dose escalation study of sorafenib
3300275|NCT00445003|Experimental|Sham injection plus laser|Sham injection at baseline and 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
3300276|NCT00445003|Experimental|0.5mg Ranibizumab plus laser|Intravitreal injections of 0.5mg Ranibizumab at baseline and at 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
3300277|NCT00445003|Active Comparator|4-mg Triamcinolone Acetonide plus Laser|4-mg Triamcinolone Acetonide at baseline and sham injection at 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
3300278|NCT00444977|Experimental|Case-management linkage intervention|"The intervention represents a brief, real world intervention that could easily be adopted by HIV care clinics to facilitate linkage and increase use of oral services by their HIV+ patients (if shown to be effective). We are seeking to compare this intervention to usual practice in these clinics."
3300279|NCT00444977|No Intervention|Standard of Care|Subjects will receive standard of care services.
3300280|NCT00444951|Experimental|Menactra® group|Have received previously a dose of an A, C, Y, W 135 and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, will receive a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.
3300281|NCT00444951|Experimental|Mencevax® group|Have received previously a dose of an A, C, Y, W 135 and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, will receive a booster dose of Mencevax ACWY (serogroups A, C, Y, W-135) polysaccharide meningococcal vaccine.
3300282|NCT00444951|Experimental|Control group|Participants have not previously received any meningococcal vaccine, will receive a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.
3300283|NCT00444925|Experimental|Fesoterodine|Tablets
3300284|NCT00444925|Placebo Comparator|Placebo|Tablets and capsules
3300285|NCT00444925|Active Comparator|Tolterodine|Capsules
3300286|NCT00444912|Experimental|G-CSF plus plerixafor|Participants with CD20- lymphoma
3300287|NCT00444912|Experimental|G-CSF plus plerixafor and rituximab|Participants with CD20+ lymphoma
3300288|NCT00444899|Experimental|Intensive treatment|Submitted to an intensive follow-up by the dietician.
3300289|NCT00444899|Active Comparator|Usual treatment|Subjects will remain under the care of their endocrinologist and/or general practitioner.
3300290|NCT00444886|Active Comparator|1|To assess the effect of BOTOX injection to the scalene muscles on the severity of pain from TOS.
3300291|NCT00444886|Active Comparator|2|To assess the effect of BOTOX injection on numbness and tingling and quality of life.
3300292|NCT00444873|Experimental|28 day dose interval|
3300293|NCT00444873|Experimental|42 day dose interval|
3300294|NCT00444873|Experimental|56 day dose interval|
3300295|NCT00444860|Experimental|1|Zostavax
3300296|NCT00444834|Experimental|1|Egalet carvedilol
3300297|NCT00444834|Active Comparator|2|Coreg
3300298|NCT00444821|No Intervention|Surveillance|
3300299|NCT00444821|Experimental|Early Endovascular Repair|
3300300|NCT00444795||1|patients diagnosed as GIST after disease progression on or intolerance to imatinib mesylate
3300301|NCT00444795||2|patients diagnosed as advanced RCC
3300302|NCT00444795||3|patients diagnosed as unresectable, well-differentiated advanced and/or metastatic pancreatic neuroendocrine carcinoma
3300303|NCT00444743|Active Comparator|1|
3300304|NCT00444743|Placebo Comparator|2|
3300305|NCT00444678|Experimental|Cetuximab, Capecitabine and Oxaliplatin|
3300306|NCT00444639|Experimental|1|triptorelin 11.25mg given 12 weekly by subcutaneous formulation
3300307|NCT00444639|Active Comparator|2|triptorelin 11.25mg given 12 weekly by intramuscular injection
3300308|NCT00444626|Experimental|DGE|Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. Participants who continued into the Repeat Treatment period were treated with DGE as an open-label treatment.
3300309|NCT00444626|Active Comparator|Restylane|Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period.
3300310|NCT00444613|Experimental|E0302 25 mg|
3300311|NCT00444613|Experimental|E0302 50 mg|
3300312|NCT00444613|Placebo Comparator|3|
3300313|NCT00444600|Experimental|0.5mg Ranibizumab plus laser|
3300314|NCT00444600|Experimental|0.5 mg Ranibizumab plus deferred laser|
3300315|NCT00444600|Experimental|4 mg Triamcinolone plus laser|
3300316|NCT00444600|Active Comparator|Sham plus laser|
3300317|NCT00444587|Experimental|Trastuzumab + 2nd Line Chemotherapy|
3300318|NCT00444587|Active Comparator|Only Chemotherapy|
3300319|NCT00444574|Active Comparator|Methylphenidate Transdermal System|Methylphenidate 2.7mg, 41.3mg, 55mg, and 82.5mg patches for 7 weeks
3300320|NCT00444574|Placebo Comparator|Placebo|Placebp matching MTS and Concerta for 7 weeks
3300321|NCT00444574|Active Comparator|Concerta|Methylphenidate HCL 18mg tablet 7 weeks
3300428|NCT00443547|Other|2-level|Patients needing cervical fusion at two consecutive levels
3300322|NCT00444561|Active Comparator|Pramlintide acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC administration. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
3300323|NCT00444535|Experimental|Oral lapatinib tablets in combination with IV bevacizumab|1500 mg oral lapatinib (once daily) plus 10 mg/kg intravenous bevacizumab (every two weeks)
3300324|NCT00444509|Experimental|Treatment 1|Subjects will receive GW685698X 800 microgram (mcg) single inhaled dose via a DISKUS inhaler. There will be a wash-out period of at least 5 days between doses.
3300325|NCT00444509|Experimental|Treatment 2|Subjects will receive GW685698X 800 mcg containing magnesium stearate inhaled dose via a DISKUS inhaler. There will be a wash-out period of at least 5 days between doses.
3300326|NCT00444470|Active Comparator|A|Active drug being tested in this study is Tranexamic Acid
3300327|NCT00444470|Placebo Comparator|B|Normal saline was used as the Placebo
3300328|NCT00444457|Experimental|1|
3300329|NCT00444457|Experimental|2|
3300330|NCT00444457|Experimental|3|
3300331|NCT00444457|Active Comparator|4|
3300332|NCT00444418|Experimental|1|Active medication (Naltrexone) combined with Modified Behavioral Self-Control Psychotherapy
3300333|NCT00444418|Experimental|2|Placebo combined with Modified Behavioral Self-Control Psychotherapy
3300334|NCT00444418|Experimental|3|Active medication (Naltrexone) combined with Brief Behavioral Compliance Enhancement Therapy
3300335|NCT00444418|Placebo Comparator|4|Placebo + Brief Behavioral Compliance Enhancement Therapy
3300336|NCT00444379|Active Comparator|PI-based HAART regimen|PI-based HAART regimen (lopinavir/ritonavir plus emtricitabine/tenofovir)
3300337|NCT00444379|Active Comparator|non-nucleoside reverse transcriptase inhibitor|non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART regimen (efavirenz plus emtricitabine/tenofovir)
3300338|NCT00444314|Experimental|A|
3300339|NCT00444314|Experimental|B|
3300340|NCT00444275|Experimental|Esomeprazole 20 mg Once Daily (initial phase)|
3300341|NCT00444275|Experimental|Esomeprazole 40 mg Once Daily (initial phase)|
3300342|NCT00444275|Experimental|Esomeprazole 20 mg Once Daily (Maintenance Phase)|
3300343|NCT00444275|Experimental|Esomeprazole 20 mg on Demand (Maintenance Phase)|
3300344|NCT00444275|Experimental|Antacid Treatment (Maintenance Phase)|
3300345|NCT00444262|Active Comparator|1|conventional treatment
3300346|NCT00444262|Experimental|2|stroke volume optimisation
3300347|NCT00444249|Active Comparator|1|White Alcon IOL
3300348|NCT00444249|Active Comparator|2|Yellow Alcon IOL
3300349|NCT00444249|Active Comparator|3|White Hoya IOL
3300350|NCT00444249|Active Comparator|4|Yellow Hoya IOL
3300351|NCT00444236|Active Comparator|1|
3300352|NCT00444236|Placebo Comparator|2|
3300353|NCT00444223|Experimental|fluorine F 18 FEQA + positron emission tomography|
3300354|NCT00444184|Active Comparator|Travoprost/Timolol therapy|24-hour pressure monitoring after 3 months of chronic dosing with travoprost/timolol drops
3300355|NCT00444184|Active Comparator|Travoprost therapy|24-hour pressure monitoring after 3 months of chronic dosing with travoprost drops
3300356|NCT00444145|Experimental|Patients with documented GERD or laryngopharyngeal reflux|Patients who have documented GERD as evidenced by erosive esophagitis or those patients who have newly diagnosed laryngopharyngeal reflux as diagnosed by endoscopy.
3300357|NCT00444106|Experimental|Artemether-lumefantrine (Coartem)|Artemether-lumefantrine (Coartem) tablets containing 20 mg artemether and 120 mg lumefantrine twice a day for 3 days, dosage dependent on body weight.
3300358|NCT00444106|Active Comparator|Atovaquone-proguanil (Malarone)|Atovaquone-proguanil (Malarone) tablets containing 250 mg atovaquone and 100 mg proguanil hydrochloride once daily for 3 days, dosage dependent on body weight.
3300359|NCT00444106|Active Comparator|Artesunate-mefloquine|Artesunate-mefloquine tablets containing 50 mg artesunate (Plasmotrim) and 250 mg mefloquine (Mephaquin). Artesunate 4 mg/kg/day (for 3 days) and mefloquine 25 mg/kg/day (days 2 and 3) total dose was given once daily dependent upon body weight.
3300360|NCT00444093|Experimental|Opii normata treatment|Treamtment with opii normata in case of diarrhea
3300361|NCT00444093|Experimental|Loperamid Treatment|Treatment with Loperamid in case of diarrhea
3300362|NCT00444080|Active Comparator|Control Arm|Subjects undergoing trabeculectomy with the use of Mitomycin C
3300363|NCT00444080|Experimental|Treatment Arm|Subjects undergoing Ex-PRESS Under Scleral Flap implantation procedure with the use of Mitomycin C
3300364|NCT00444067|Experimental|Spinal Sealant System|Spinal Sealant System
3300365|NCT00444067|Active Comparator|Standard of Care|Standard of care methods as an adjunct to sutured dural repair
3300366|NCT00444054|Experimental|Dietary modification|Patients are placed on a low carbohydrate diet (<30 grams/day) for 28 days.
3300367|NCT00444041|Experimental|Xelox, Bev|
3300368|NCT00444015|Experimental|Dose Escalation|
3300369|NCT00444002||Hepatitis C - Steatosis|Patients with chronic Hep C infection undergoing liver biopsy with >=5% steatosis on liver biopsy
3300370|NCT00444002||Hepatitis C - no steatosis|Patients with chronic Hep C infection without steatosis on liver biopsy (<5% of hepatocytes involved)
3300371|NCT00443976|Experimental|AT9283|
3300372|NCT00443924|Placebo Comparator|1|Arm 1
3300373|NCT00443924|Experimental|2|Arm 2
3300374|NCT00443924|Experimental|3|Arm 3
3300375|NCT00443924|Experimental|4|Arm 4
3300376|NCT00443924|Experimental|5|Arm 5
3300377|NCT00443898|Experimental|1|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks
3300378|NCT00443898|Placebo Comparator|2|vehicle (placebo) applied once daily for 48 weeks
3300379|NCT00443898|Experimental|3|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks
3300380|NCT00443898|Placebo Comparator|4|vehicle (placebo) applied once daily for 24 weeks
3300429|NCT00443547|Other|3-level|Patients needing cervical fusion at three consecutive levels
3300381|NCT00443872|Other|orally disintegrating selegiline|This is a one arm open label study of patients who are experiencing a dopamine agonist (DA) related adverse effects (AE) of either one or more of the following: excessive daytime sleepiness, hallucinations, pedal edema, impulse control disorder. All subjects received orally disintegrating selegiline.
3300382|NCT00443859||PPHN|Infants with persistent pulmonary hypertension (PPHN)
3300383|NCT00443846|Experimental|Group 1: Concomitant Administration|Participants received 2 concomitant doses of RotaTeq® and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age and a third dose of RotaTeq® at 24-25 weeks of age (and 28 to 42 days after the vaccine administration at 20-21 weeks of age).
3300384|NCT00443846|Active Comparator|Group 2: Sequential Administration|Participants received 3 doses of RotaTeq® at 6-7 weeks of age, 15-16 weeks of age, and 24-25 weeks of age (and 28 to 42 days after the MMC vaccine administered at 20-21 weeks of age), and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age.
3300385|NCT00443820|Experimental|1|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks
3300386|NCT00443820|Placebo Comparator|2|Vehicle (placebo) for 48 weeks
3300387|NCT00443820|Experimental|3|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks
3300388|NCT00443820|Placebo Comparator|4|Vehicle (placebo) for 24 weeks
3300389|NCT00443794|Experimental|1, POLYCAP|Combination of 3 anti hypertensives, lipid lowering agent and anti platelet agent
3300390|NCT00443794|Active Comparator|2 B|Diuretic antihypertensive
3300391|NCT00443794|Active Comparator|3 C|Thiazide plus Angiotensis converting enzyme inhibitor - combination antihypertensive.
3300392|NCT00443794|Active Comparator|4 D|Diuretic with Beta blocker combination antihypertensive
3300393|NCT00443794|Active Comparator|5, E|ACE inhibitor plus Beta blocker combination antihypertensive
3300394|NCT00443794|Active Comparator|6, F|Combination antihypertensive of ACE inhibitor, diuretic and beta blocker
3300395|NCT00443794|Active Comparator|7,G|Combination of ACE inhibitor, betablocker, diuretic and Antiplatelet
3300396|NCT00443794|Active Comparator|8,H|Lipid lowering agent
3300397|NCT00443794|Active Comparator|9,A|Antiplatelet
3300398|NCT00443781|Other|PD and F.A.D. diagnostic testing|
3300399|NCT00443768||1|
3300400|NCT00443768||2|
3300401|NCT00443755|Active Comparator|Insulin Sensitizer Therapy|Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily.
3300402|NCT00443755|Placebo Comparator|Placebo|Placebo tablets were used to match the active comparator drugs and dosing regimen.
3300403|NCT00443729|Experimental|1|Raltegravir & Placebo
3300404|NCT00443729|Active Comparator|2|Lopinavir (+) Ritonavir & Placebo
3300405|NCT00443703|Experimental|1|Arm 1: MK0518 (raltegravir) + placebo to KALETRA™ (lopinavir (+) ritonavir )
3300406|NCT00443703|Active Comparator|2|Arm 2: KALETRA™ (lopinavir (+) ritonavir) + placebo to MK0518 (raltegravir)
3300407|NCT00443690|Placebo Comparator|2|placebo control
3300408|NCT00443690|Experimental|1|KW-3902IV
3300409|NCT00443677|Active Comparator|abvd|
3300410|NCT00443677|Experimental|beacopp|
3300411|NCT00443677|Experimental|coppebvcad|
3300412|NCT00443651|Experimental|Rituximab 1000 mg (Stage I patients)|Stage I patients received 2 doses of rituximab 1000 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 1000 mg given 14 days apart. Concomitant non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
3300413|NCT00443651|Experimental|Rituximab 500 mg (Stage II patients)|Stage II patients received 2 doses of rituximab 500 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 500 mg given 14 days apart. Concomitant biological and non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
3300414|NCT00443638|No Intervention|Control Group|Control Group
3300415|NCT00443638|Experimental|Home visitation through pregnancy|Nurse home visitation through pregnancy
3300416|NCT00443638|Experimental|Home visitation through age 2|Nurse home visitation through child age 2.
3300417|NCT00443612|Experimental|1|"12 weeks on treatment 1~2 week washout period~12 weeks on treatment 2"
3300418|NCT00443612|Experimental|2|"12 weeks on treatment 2~2 week washout period~12 weeks on treatment 1"
3300419|NCT00443599|Experimental|Insulin|Insulin was infused to target a blood glucose concentration of 80-110 mg/dL
3300420|NCT00443599|Active Comparator|Usual Care|Insulin was infused according to the discretion of the treating clinical team.
3300421|NCT00443586|Active Comparator|Developmental Screening|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age.
3300422|NCT00443586|Active Comparator|Screening plus Transportation|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two).
3300423|NCT00443586|Active Comparator|Screening, Transport, Prenatal Visits|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy.
3300424|NCT00443586|Experimental|Screen, Transport, Prenatal/Inf Visits|Participants received regular sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy and through child age two.
3300425|NCT00443560||Instrumental Vaginal Delivery (IVD)|Instrumental vaginal delivery (IVD) is attempted to prevent fetal hypoxia if the second stage of labor is prolonged. It includes forceps and vacuum extractions.
3300430|NCT00443547|Other|4-level|Patients needing cervical fusion at four consecutive levels
3300431|NCT00443534|Experimental|1|
3300432|NCT00443469|Experimental|Magnetic Stimulation|
3300433|NCT00443469|Placebo Comparator|Magnetic Stimulation with tilted coil|Magnetic Stimulation with tilted coil
3300434|NCT00443456|Experimental|Single|
3300435|NCT00443430|Active Comparator|Methotrexate Arm|Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus placebo etanercept and placebo prednisolone
3300436|NCT00443430|Active Comparator|Methotrexate-Etanercept-Prednisolone Arm|Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus etanercept 0.8 mg/kg given by subcutaneous injection once per week, plus prednisolone by mouth daily with decreasing dose tapered over 16 weeks
3300437|NCT00443417|Placebo Comparator|1|
3300438|NCT00443417|Active Comparator|2|200mg qd
3300439|NCT00443417|Active Comparator|3|200mg bid
3300440|NCT00443417|Active Comparator|4|400mg qd
3300441|NCT00443404|Active Comparator|1|perioperative epidural analgesia
3300442|NCT00443404|Active Comparator|2|Iv PCA Fentanyl preoperative, Epidural analgesia postoperative
3300443|NCT00443404|Active Comparator|3|perioperative IV PCA Fentanyl, epidural anesthesia
3300444|NCT00443404|Active Comparator|4|perioperative IV PCA Fentanyl general anesthesia
3300445|NCT00443404|Placebo Comparator|5|IV PCA with saline 0.9% and sc saline 0.9%in the L3-L4 area. IM meperidine, po codeine/acetaminophen, IV acetaminophen and IV parecoxib
3300446|NCT00443391|Experimental|1|
3300447|NCT00443378|Experimental|1|"Arm 1, CARE+ arm is the study arm that receives the CARE+ computer intervention."
3300448|NCT00443378|No Intervention|2|Arm 2, the control arm, is the study arm that receives computerized risk assessment only.
3300449|NCT00443365|No Intervention|1|Coronary Artery Bypass Grafting with no Mitral Valve intervention
3300450|NCT00443365|Active Comparator|2|Coronary Artery Bypass Grafting + Mitral Annuloplasty
3300451|NCT00443352|Experimental|Duloxetine|Duloxetine 120mg daily for 12 weeks.
3300452|NCT00443326|Experimental|AMG 714|AMG 714 will be given as a multiple dose regimen
3300453|NCT00443300||Protective environment|Participants in a Protective environment
3300454|NCT00443300||Not a protective environment|Participants not in a protective environment
3300455|NCT00443287|Placebo Comparator|1|
3300456|NCT00443287|Experimental|2|dose level 1
3300457|NCT00443287|Experimental|3|dose level 2
3300458|NCT00443287|Experimental|4|dose level 3
3300459|NCT00443287|Active Comparator|5|
3300460|NCT00443274||NBIR placeholder|Once the US National Breast Implant Registry is established, subjects will be transferred to this database for follow up
3300461|NCT00443274||410 Arm|Anatomically shaped silicone gel-filled breast implants.
3300462|NCT00443274||BIFs|Round silicone gel-filled breast implants and saline-filled breast implants
3300463|NCT00443261|Experimental|1 (SCCHN)|Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Patients will receive Azacitidine and cisplatin.
3300464|NCT00443248|No Intervention|Not Specified|Not Specified
3300465|NCT00443235|Active Comparator|A|"One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
3300466|NCT00443235|Experimental|B|"One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity < grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
3300467|NCT00443209|Experimental|Telcagepant 280 mg/300 mg|Participants receive telcagepant 300 mg soft gel capsules or telcagepant 280 mg tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of telcagepant, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of telcagepant per month for up to 18 months.
3300468|NCT00443209|Active Comparator|Rizatriptan 10 mg|Participants receive rizatriptan tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of rizatriptan, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of rizatriptan per month for up to 18 months.
3300469|NCT00443196|Experimental|Experimental|
3300470|NCT00443183|Experimental|Brief Negotiation Interview|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
3300471|NCT00443183|Placebo Comparator|Discharge Instructions|Scripted discharge instructions to be read by emergency practitioner and designed to be less than 1 minute in length.
3300472|NCT00443131|Experimental|Group A|
3300473|NCT00443131|Experimental|Group B|
3300474|NCT00443131|Experimental|Group C|
3300475|NCT00443118|Active Comparator|Neopuff TM with PEEP|Newborns ventilated for neonatal resuscitation using Neopuff TM with PEEP
3300476|NCT00443118|Active Comparator|Self Inflating Bag with PEEP|Newborns ventilated for neonatal resuscitation using Self Inflating Bag with PEEP valve attached
3300477|NCT00443118|Active Comparator|Self Inflating Bag without PEEP|Newborns ventilated for neonatal resuscitationusing Self Inflating Bag without PEEP valve attached
3300478|NCT00443092|Experimental|1|proprietary tart cherry juice blend (8 oz., BID)
3300479|NCT00443092|Placebo Comparator|2|control juice (color matched kool aid blend),(8 oz., BID)
3300480|NCT00443053|Active Comparator|Fondaparinux 2.5mg|
3300481|NCT00443053|Placebo Comparator|Placebo|
3300482|NCT00443040|Placebo Comparator|Placebo|
3300483|NCT00443040|Active Comparator|Asimadoline 1.0 mg|Asimadoline 1.0 mg b.i.d.
3300484|NCT00443040|Active Comparator|Asimadoline 3.0 mg|Asimadoline 3.0 mg b.i.d.
3300485|NCT00443027|No Intervention|Not Specified|Not Specified
3300625|NCT00441636|Experimental|CPAP treatment|Continuous Positive Airway Pressure (CPAP)for 4 weeks
3300486|NCT00443014|Experimental|A Cognitive stimulation therapy|Patients with recently diagnosed dementia in five of the study municipality.
3300487|NCT00443014|No Intervention|B Care as usual|
3300488|NCT00442962|Experimental|EFV + FTC/TDF|Participants will efavirenz (600mg in pill form, taken orally, once daily) and emtricitabine/tenofovir disoproxil fumarate (200/300mg in pill form, taken orally, once daily), for 48 weeks
3300489|NCT00442949|Active Comparator|2|Catheterization immediate PCI
3300490|NCT00442949|Experimental|1|delayed PCI
3300491|NCT00442936|Experimental|Telcagepant 150 mg|Participants receive telcagepant 150 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 150 mg or placebo) or one dose of non-study rescue medication.
3300492|NCT00442936|Experimental|Telcagepant 300 mg|Participants receive telcagepant 300 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 300 mg or placebo) or one dose of non-study rescue medication.
3300493|NCT00442936|Active Comparator|Zolmitriptan 5 mg|Participants receive zolmitriptan 5 mg tablets, one tablet administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (placebo) or one dose of non-study rescue medication.
3300494|NCT00442936|Placebo Comparator|Placebo|Participants receive placebo matching capsules or tablets, one capsule or tablet administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (placebo) or one dose of non-study rescue medication.
3300495|NCT00442910|Active Comparator|3% SPL7013|Intravaginal application of 3.5 g SPL7013 gel twice daily for 14 days
3300496|NCT00442910|Placebo Comparator|Placebo for SPL7013 Gel|Intravaginal application of 3.5 g placebo gel twice daily for 14 days
3300497|NCT00442910|Placebo Comparator|HEC Placebo Gel|Intravaginal application of 3.5 g HEC placebo gel twice daily for 14 days
3300498|NCT00442897|Experimental|1|
3300499|NCT00442897|Active Comparator|2|
3300500|NCT00442871|Experimental|Eltrombopag|Eltrombopag 50 mg oral (single dose)
3300501|NCT00442832|Experimental|TD-1792|
3300502|NCT00442832|Active Comparator|Vancomycin|
3300503|NCT00442806|Placebo Comparator|Placebo|Placebo is injected
3300504|NCT00442806|Experimental|Treatment|ADRC's are injected
3300505|NCT00442793|Experimental|1|
3300506|NCT00442793|Active Comparator|2|
3300507|NCT00442780|Placebo Comparator|1|Dose Level A of BIIB014
3300508|NCT00442780|Placebo Comparator|2|Dose Level B of BIIB014
3300509|NCT00442780|Placebo Comparator|3|Dose Level C of BIIB014
3300510|NCT00442780|Placebo Comparator|4|Dose Level D of BIIB014
3300511|NCT00442767|Active Comparator|Rapid acting Insulin therapy - before meal|Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal
3300512|NCT00442767|Experimental|Pre-meal Pramlintide and Post-meal Insulin therapy|30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
3300513|NCT00442741|Experimental|Patupilone + Midazolam|
3300514|NCT00442741|Experimental|Patupilone + Omeprazole|
3300515|NCT00442702|Experimental|Mircera|Participants received Mircera by subcutaneous injection once every month during the dose titration (7 months) and evaluation period (2 months). The starting dose was based on the weekly dose of darbepoetin alfa administered prior to the switch to Mircera, and was either 120, 200 or 360 µg Mircera per month. The dose was then adjusted to maintain Hemoglobin levels within the defined target range and also according to the need for red blood cell transfusions (due to worsening anemia), or for toxicity related to Mircera.
3300516|NCT00442702|Active Comparator|Darbepoetin alfa|Participants continued to receive the same dose of darbepoetin alfa as before screening by subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling during the dose titration (7 months) and the evaluation period (2 months).
3300517|NCT00442689|Experimental|1|oral contraceptive (35 mg ethinyl estradiol)
3300518|NCT00442689|Experimental|2|Flutamide 250 mg twice daily
3300519|NCT00442689|Placebo Comparator|3|Placebo
3300520|NCT00442676|Experimental|1|Celecoxib, 200 mg/day
3300521|NCT00442676|Placebo Comparator|2|Placebo
3300522|NCT00442637|Experimental|1|observation
3300523|NCT00442637|Active Comparator|2|capecitabine plus bevacizumab
3300524|NCT00442624||1|Patients with chronic insomnia
3300525|NCT00442624||2|age, sex, bmi matched healthy controls
3300526|NCT00442611|Experimental|Abatacept|Abatacept (dosed based upon weight) administered intravenously (IV) on days 1, 15, 30 and monthly thereafter for a total of 7 doses.
3300527|NCT00442611|Placebo Comparator|IV fluid|Placebo to match abatacept (IV fluid) administered on days 1, 15, 30 and monthly thereafter for a total of 7 doses.
3300528|NCT00442598|Experimental|Glufosfamide q21 days|1-hour infusion of glufosfamide at a dose of 5,000 mg/m2 on Day 1 of a 21-day cycle
3300529|NCT00442598|Experimental|Glufosfamide q7 days low|1-hour infusion of glufosfamide at a dose of 1,660 mg/m2 on Days 1, 8 and 15 of a 21-day cycle
3300530|NCT00442598|Experimental|Glufosfamide q7 days high|1-hour infusion of glufosfamide at a dose of 2,500 mg/m2 on Days 1, 8 and 15 of a 21-day cycle
3300531|NCT00442572|Experimental|PEGASYS|Participants received 4 treatment cycles of continuous intermittent treatment with PEGASYS® (Peginterferon alfa-2a) . Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
3300532|NCT00442572|No Intervention|No Intervention|Participants were on non- specific anti-viral treatment.
3300533|NCT00442559|Experimental|Montelukast|Participants were treated for 12 months after randomization: Participants 2 to 5 years of age took one 4 mg chewable tablet and 6 to 14 years of age took one 5 mg chewable tablet daily in the evening. If participants had exacerbated from mild to moderate within 12 weeks, inhaled corticosteroids (ICS) was added to Montelukast and ICS, respectively and those participants were excluded in the efficacy evaluation at 12 weeks.
3300534|NCT00442559|Active Comparator|Inhaled Corticosteroids (ICS)|Participants were treated for 12 months after randomization: Each participant's physician selected the ICS agent, dose, and regimen. If participants had exacerbated from mild to moderate within 12 weeks, ICS was added to Montelukast and ICS, respectively and those participants were excluded in the efficacy evaluation at 12 weeks.
3300535|NCT00442546|Experimental|1|
3300536|NCT00442546|Experimental|2|
3300537|NCT00442546|Placebo Comparator|3|
3300538|NCT00442533|Experimental|Indium-111 pentetreotide|4 cycles of 500 mCi treatments every 10-12 weeks
3300539|NCT00442520||2|colorectal cancer patients
3300540|NCT00442520||3|head and neck cancer patients
3300541|NCT00442520||1|lung cancer patients
3300542|NCT00442507|Experimental|1|Patients will be treated with erlotinib 150 mg oral daily and Avastin 15 mg/kg intravenously each cycle of therapy (each cycle is 21 days or every 3 weeks). The first infusion of Avastin will be administered over 90 minutes. If tolerated, the second infusion will be given over 60 minutes and in 30 minutes for the subsequent treatments. Treatment will be administered until disease progression or intolerable side effects.
3300543|NCT00442494|Other|Study couldn´t start due to investigator|Study couldn´t start due to investigator
3300544|NCT00442468||All participants|This is a cross-sectional, non-interventional study. All enrolled subjects were asked to complete a questionnaire and pulmonary function test to assess the prevalence of airflow obstruction.
3300545|NCT00442455|Experimental|Erlotinib, radiotherapy.|There are three cohorts of patients in whom the dose of Erlotinib chlorhydrate(100 and 150 mg) and Cisplatin (30 and 40 mg / m2) will be increase, and the doses of Radiation therapy being fixed (63 Gy during 5 days a week during 7 weeks)
3300546|NCT00442442|No Intervention|1|No treatment control
3300547|NCT00442442|Active Comparator|2|LLIN Nets
3300548|NCT00442442|Experimental|3|Mosquito Coils
3300549|NCT00442442|Experimental|4|Mosquito coils & LLIN
3300550|NCT00442416|Experimental|RO0503821|Eligible participants will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) subcutaneously (SC) every month for eight months (6 months of titration period [TP] and two months of evaluation period [EP] and 15-days following the final study visit (9 months post randomization). The first dose of Mircera (120, 200, or 360 mcg) will be based upon the dose of epoetin alfa received 1 to 2 weeks prior to administration of study drug, while subsequent doses will be adjusted to maintain haemoglobin (Hb) concentrations within target of >=10.0 gram per decilitre (g/dL) and <=12.0 g/dL. Participants who self-administered/visited to clinics for erythropoiesis stimulating agent (ESA) dosing prior to randomization will continue to do so.
3300551|NCT00442416|Active Comparator|Epoetin Alfa|Eligible participants will be administered epoetin alfa SC as per the standard of care for eight months (TP and EP), and will be followed-up for 15 days following the final study visit. Participants who self-administered/visited to clinics for ESA dosing prior to randomization will continue to do so.
3300552|NCT00442364|Experimental|1|Polidocanol (1%) Microfoam (Varisolve)
3300553|NCT00442351|Experimental|Asmanex Twisthaler|
3300554|NCT00442351|Placebo Comparator|Placebo inhaler|
3300555|NCT00442338|Experimental|Montelukast 7 mg|Montelukast 7 mg IV administration
3300556|NCT00442338|Experimental|Montelukast 14 mg|Montelukast 14 mg IV administration
3300557|NCT00442338|Active Comparator|Aminophylline 250 mg|Aminophylline 250 mg IV drip administration
3300558|NCT00442286|Experimental|On|Subject will be randomized to a 2:1 allocation to the Rheos ON or OFF arms at the time of Rheos System activation (time point 0). After the six month follow up evaluation, all subjects will have therapy activated, though subjects and treating physicians will not be informed of randomized treatment assignment.
3300559|NCT00442286|Experimental|Off|Subject will be randomized to a 2:1 allocation to the Rheos ON or OFF arms at the time of Rheos System activation (time point 0). After the six month follow up evaluation, all subjects will have therapy activated, though subjects and treating physicians will not be informed of randomized treatment assignment.
3300560|NCT00442260|Experimental|Abraxane dose escalation + fixed dose DOXIL|Limited dose-escalation study of Abraxane and fixed dose of DOXIL in order to identify correct dose and side effect profile of the combination.
3300561|NCT00442169|Experimental|Group 1: WN02 Low Dose (Part 1)|Low Dose in healthy adults in Part 1 against a placebo control.
3300562|NCT00442169|Experimental|Group 2: WN02 Medium Dose (Part 1)|Medium dose level in part one healthy subjects against a placebo control.
3300563|NCT00442169|Experimental|Group 3: WN02 High Dose (Part 1)|High dose level in part one healthy subjects against a placebo control
3300564|NCT00442169|Placebo Comparator|Group 4: Placebo (Part 1)|Participants will receive a single dose of saline in Part 1 on Day 0
3300565|NCT00442169|Experimental|Group 5: WNO2 High Dose (Part 2)|Participants enrolled in Part 2 and received a single dose of West Nile Virus vaccine.
3300566|NCT00442169|Placebo Comparator|Group 6: Placebo (part 2)|Participants will receive a single dose of saline in Part 2 on Day 0
3300567|NCT00442156||Laser|People with diabetic macular edema involving the center of the macula (OCT central subfield thickness >250 microns), who were already intended to receive focal photocoagulation
3300568|NCT00442130|Experimental|GM-K562 Vaccine|"Biological/Vaccine: GM-K562 vaccine The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.~Procedure/Surgery: stem cell transplantation Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation"
3300569|NCT00442117|Experimental|MF-DPI|MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day)
3300570|NCT00442117|Active Comparator|BUD-DPI|Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day)
3300571|NCT00442104|Experimental|ganaxolone|
3300572|NCT00442091|Other|10 ml of dandelion juice twice daily|
3301269|NCT00435292|Active Comparator|flavocoxid 500 mg|flavonoid mixture
3300573|NCT00442065|Active Comparator|Open label, single arm|A prospective, open label, single-arm (non-randomized) multi-center, international clinical device investigation to collect safety and performance data concerning the Aorfix™ Stent Graft System in the treatment of abdominal aortic aneurysm and aorto-iliac aneurysm where a significant degree of vessel angulation exists
3300574|NCT00442039|Experimental|Lithium dosing 1|The starting dose of lithium was 300 mg for patients weighing < 20 kg [no patients were enrolled that weighed less than 20 kg] and 600 mg for patients weighing ≥ 20 kg.
3300575|NCT00442039|Experimental|Lithium dosing 2|The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patient‟s response and tolerability.
3300576|NCT00442039|Experimental|Lithium dosing 3|The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patient‟s response and tolerability.
3300577|NCT00442039|Placebo Comparator|Placebo|
3300578|NCT00442026|Experimental|1|DG
3300579|NCT00442026|Experimental|2|G
3300580|NCT00442013|Experimental|Lansoprazole|Participants in this group will receive lansoprazole on a daily basis for 6 months. There are two doses of Lansoprazole solutab provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
3300581|NCT00442013|Placebo Comparator|Matching placebo|Participants in this group will receive a matching placebo on a daily basis for 6 months. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
3300582|NCT00441974|Experimental|Single arm adefovir dipivoxil|adefovir dipivoxil once daily orally 10 mg
3300583|NCT00441935||Interstim Neuromodulation|Subjects undergoing implantation of an Interstim device for neuromodulation.
3300584|NCT00441922|Experimental|1|D
3300585|NCT00441922|Experimental|2|V
3300586|NCT00441909|Experimental|1A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 8 hours
3300587|NCT00441909|Placebo Comparator|1B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 8 hours
3300588|NCT00441909|Experimental|2A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 4 hours
3300589|NCT00441909|Placebo Comparator|2B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 4 hours
3300590|NCT00441909|Experimental|3A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 2 hours
3300591|NCT00441909|Placebo Comparator|3B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 2 hours
3300592|NCT00441909|Experimental|4A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 0 hours
3300593|NCT00441909|Placebo Comparator|4B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 0 hours
3300594|NCT00441896|Experimental|ganaxolone|
3300595|NCT00441896|Placebo Comparator|non-active drug|
3300596|NCT00441883|Experimental|PF-03187207 and Latanoprost Vehicle|One drop of each, once daily in study eye for 28 days
3300597|NCT00441883|Active Comparator|Latanoprost 0.005% and PF-03187207 Vehicle|One drop of each, once daily in study eye for 28 days
3300598|NCT00441792|Experimental|Etomidate|
3300599|NCT00441792|Experimental|midazolam|
3300600|NCT00441779||1|Traumatic injury
3300601|NCT00441779||2|Elective orthopedic surgery
3300602|NCT00441779||3|Burn injury
3300603|NCT00441766|Experimental|AGN 203818 3 mg|Part A: AGN 203818 3mg capsule every 12 hours for 4 weeks
3300604|NCT00441766|Experimental|AGN 203818 20 mg|Part A: AGN 203818 20mg capsule every 12 hours for 4 weeks
3300605|NCT00441766|Experimental|AGN 203818 60 mg|Part A: AGN 203818 60mg capsule every 12 hours for 4 weeks
3300606|NCT00441766|Placebo Comparator|Placebo|Part A: Placebo capsule every 12 hours for 4 weeks
3300607|NCT00441740|Experimental|1|VG
3300608|NCT00441740|Experimental|2|DG
3300609|NCT00441727|Experimental|Esomeprazole 40 mg|Esomeprazole 40 mg
3300610|NCT00441727|Experimental|Esomeprazole 20 mg|Esomeprazole 20 mg
3300611|NCT00441727|Placebo Comparator|Placebo|Placebo
3300612|NCT00441701|Experimental|Part 1: Navarixin 3 mg|Cohort 1: Participants receive navarixin 3 mg (three 1 mg capsules) once daily (QD) for up to 12 weeks
3300613|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 3 mg|Cohort 1: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
3300614|NCT00441701|Experimental|Part 1: Navarixin 10 mg|Cohort 2: Participants receive navarixin 10 mg (one 10 mg capsule and two placebo capsules) QD for up to 12 weeks
3300615|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 10 mg|Cohort 2: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
3300616|NCT00441701|Experimental|Part 1: Navarixin 30 mg|Cohort 3: Participants receive navarixin 30 mg (three 10 mg capsules) QD for up to 12 weeks
3300617|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 30 mg|Cohort 3: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
3300618|NCT00441701|Experimental|Part 2: Navarixin 3 mg|Cohort 4: Participants receive navarixin 3 mg (three 1 mg capsules) QD for up to 12 weeks
3300619|NCT00441701|Experimental|Part 2: Navarixin 10 mg|Cohort 4: Participants receive navarixin 10 mg (one 10 mg capsule and two placebo capsules) QD for up to 12 weeks
3300620|NCT00441701|Experimental|Part 2: Navarixin 30 mg|Cohort 4: Participants receive navarixin 30 mg (three 10 mg capsules) QD for up to 12 weeks
3300621|NCT00441701|Placebo Comparator|Part 2: Placebo to navarixin|Cohort 4: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
3300622|NCT00441688|Experimental|GI265235|
3300623|NCT00441675||Salmeterol/Fluticasone|Previous Salmeterol/Fluticasone treatment
3300624|NCT00441675||Fluticasone|Previous Fluticasone propionate treatment
3301273|NCT00435266|Experimental|1|Remote ischemic preconditioning
3300626|NCT00441636|No Intervention|No CPAP|routine psychiatric care for 4 weeks followed by CPAP titration and initiation after followup measures.
3300627|NCT00441636|No Intervention|Control group|No obstructive sleep apnea detected.
3300628|NCT00441610|Experimental|Gimatecan|
3300629|NCT00441597|Active Comparator|1|first 3 day treatment placebo and 4 weeks later three day treatment with atorvastatin 80 mg
3300630|NCT00441597|Active Comparator|2|first 3 day treatment atorvastatin 80 mg and 4 weeks later three day treatment with placebo
3300631|NCT00441597|No Intervention|3|3 days treatment with placebo twice
3300632|NCT00441584|Experimental|PegIntron plus Rebetol|PegIntron 1.5 μg/kg/week plus Rebetol 800-1400 mg/day administered for 48 weeks
3300633|NCT00441558|Experimental|flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
3300634|NCT00441545|Experimental|1|Fosrenol (Lanthanum carbonate)
3300635|NCT00441545|Active Comparator|2|Sevelamer hydrochloride
3300636|NCT00441480|Active Comparator|Plant sterol esters|plant sterols esterified to fish oil fatty acids
3300637|NCT00441480|Placebo Comparator|placebo|Corn oil
3300638|NCT00441467|Experimental|Glufosfamide|Glufosfamide
3300639|NCT00441454|Active Comparator|A|Retropubic Tension-free Vaginal Tape (TVT)
3300640|NCT00441454|Active Comparator|B|Transobturator Tension-free Vaginal Tape (TVT-O)
3300641|NCT00441441|Experimental|Fluticasone propionate/salmeterol 100/50 HFA|Fluticasone propionate/salmeterol 100/50 HFA (2 inhalations of 50/25mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate 100mcg HFA inhaler (2 inhalations) twice daily
3300642|NCT00441441|Experimental|Fluticasone propionate 100mcg HFA|Fluticasone propionate 100mcg HFA (2 inhalations of 50mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate/salmeterol 100/50 HFA inhaler (2 inhalations ) twice daily
3300643|NCT00441363|Active Comparator|Bromocriptine Mesylate|Bromocriptine mesylate 0.8 mg
3300644|NCT00441363|Placebo Comparator|Placebo|Bromocriptine mesylate 0.8 mg matching placebo
3300645|NCT00441350|Active Comparator|OM 40|Olmesartanmedoxomil (OM)40 mg tablets.
3300646|NCT00441350|Experimental|OM/HCTZ 40/12.5|Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets.
3300647|NCT00441337|Experimental|0.3 mg/kg MDX-1106 drug|0.3 milligrams (mg) MDX-1106 drug (nivolumab) per kilogram (kg) of body weight (mg/kg) was administered in a single intravenous (IV) infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
3300648|NCT00441337|Experimental|1 mg/kg MDX-1106 drug|1 mg MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
3300649|NCT00441337|Experimental|3 mg/kg MDX-1106 drug|3 mgs MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
3300650|NCT00441337|Experimental|10 mg/kg MDX-1106 drug|10 mgs MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
3300651|NCT00441311|Experimental|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
3300652|NCT00441311|No Intervention|Service-as-Usual|Control Arm
3300653|NCT00441298|Experimental|1|Tenofovir gel (a reverse transcriptase inhibitor)
3300654|NCT00441298|Placebo Comparator|2|Universal HEC placebo
3300655|NCT00441285|Active Comparator|I. ABZ + ABZ Placebo + PZQ|Albendazole 15 mg / kg / d (until 800 mg / d) + Placebo of Albendazole ( 7.5 mg / Kg / d )+ Praziquantel 50 mg / kg / d (until 3600 mg / d)
3300656|NCT00441285|Active Comparator|II.- ABZ + ABZ Placebo + PZQ Placebo|Albendazole 15 mg / kg / d ( until 800 mg / d ) + Placebo of Albendazole ( 7.5 mg / Kg / d ) + Placebo of Praziquantel ( 50 mg / kg / d )
3300657|NCT00441285|Active Comparator|III .- Albendazole + PZQ Placebo|"Albendazole 22.5 mg / kg / d (until 1200 mg / d) + Placebo of Praziquantel ( 50 mg / kg / d )~This arm was not used in the first substudy ( initial part and guide to the design of the parent study ) however it will be used henceforward."
3300658|NCT00441259|Experimental|JE-CV Group|Participants will receive Japanese encephalitis chimeric virus vaccine (JE-CV)
3300659|NCT00441259|Active Comparator|MBDV Group|Participants will receive the mouse brain-derived vaccine (MBDV)
3300660|NCT00441220||A|Patients must have lupus nephritis and previously had therapy with intravenous cyclophosphamide.
3300661|NCT00441220||B|Patients must have lupus nephritis and are currently receiving therapy with intravenous cyclophosphamide.
3300662|NCT00441168|Active Comparator|VAD Treatment|vincristine in combination with adriamycin and dexamethasone
3300663|NCT00441168|Experimental|PAD Treatment|bortezomib in combination with adriamycin and dexamethasone
3300664|NCT00441155|Experimental|Monotherapy: AMN107|initial dose of imatinib (dose level 1) was 400 mg bid was administered orally on a continuous daily schedule and was not escalated during the study
3300665|NCT00441155|Active Comparator|Combination Therapy: AMN107 + Imatinib|six possible doses of Nilotinib (100 mg once daily (qd), 200 mg qd, 400 mg qd, 200 mg bid, 300 mg bid, and 400 mg bid). four possible doses of Imatinib (0 mg, 400 mg qd, 600 mg qd, and 400 mg bid).the initial dose of nilotinib (dose level 1) was 200 mg qd and could have been escalated up to 400 mg bid
3300666|NCT00441142|Active Comparator|Phase II: Arm A (Control Group: RT + TMZ)|"The Induction Phase:~Temozolomide (75 mg/m2 daily for 6 weeks) with concurrent fractionated radiation therapy for approximately 6 weeks (XRT must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy), followed by 4-6 weeks rest.~Followed by the Maintenance Phase:~12 cycles of adjuvant temozolomide [at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle; if 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given]."
3300778|NCT00440219|Placebo Comparator|Placebo group|Placebo pill for 10 days immediately pre-operative
3301274|NCT00435266|No Intervention|2|
3300667|NCT00441142|Experimental|Phase I + Phase II: Arm B (RT + TMZ + Vandetanib)|"The Induction Phase:~ZD6474 (Vandetanib) daily (to begin 5-7 days prior to starting participant's RT) Temozolomide (75 mg/m2 daily for 6 weeks) with concurrent fractionated radiation therapy for approximately 6 weeks (XRT must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy), followed by 4-6 weeks rest.~Followed by the Maintenance Phase:~12 cycles of adjuvant temozolomide [at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle; if 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given].~ZD6474 (Vandetanib) daily for the twelve (12) 28-day cycles of adjuvant temozolomide, with the option to continue until participant experiences an unacceptable toxicity or his/her tumor progresses."
3300668|NCT00441116|Placebo Comparator|Dutasteride|Dutasteride
3300669|NCT00441103|Experimental|Rebif® New Formulation (IFN-beta-1a, RNF)|
3300670|NCT00441103|Placebo Comparator|Placebo/RNF|
3300671|NCT00441090|Experimental|Avatrombopag tablets|"2.5, 5, 10 or 20 mg tablets~1 tablet taken orally once daily for 28 days"
3300672|NCT00441090|Placebo Comparator|Placebo tablet|"2.5, 5, 10, or 20 mg tablets~1 tablet taken orally once daily for 28 days"
3300673|NCT00441064|Experimental|Diet Sequence Low/High Sodium|Patients on low sodium diet ( <= 100 mmol/day) for the first 4 weeks and high sodium (>= 200 mmol/day) diet for the next 4 weeks. [with Aliskiren 300 mg]
3300674|NCT00441064|Experimental|Diet Sequence High/Low Sodium|Patients on high sodium (>= 200 mmol/day) diet for the first 4 weeks and on low sodium diet ( <= 100 mmol/day) for the next 4 weeks. [with Aliskiren 300 mg]
3300675|NCT00441038|Active Comparator|1|Education on postural hygiene and handout of The Back Guide
3300676|NCT00441038|Active Comparator|2|Education on active management and handout of The Back Book
3300677|NCT00441038|Active Comparator|3|Education on cardiovascular and general health
3300678|NCT00441025|Active Comparator|1|1 Alemtuzumab
3300679|NCT00441012|Experimental|1|Modified process Hib/Hep B vaccine
3300680|NCT00441012|Active Comparator|2|COMVAX™
3300681|NCT00440973|Other|treatment arm|PI relocated, currently data is no longer available
3300682|NCT00440947|Other|Simplification|Atazanavir (ATV) 400 mg QD + abacavir (ABC) 600 mg/lamivudine (3TC) 300 mg fixed dose combination (FDC) QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.
3300683|NCT00440947|Other|Continuation|Atazanavir (ATV) 300 mg QD + ritonavir (/r) 100 mg QD + abacavir (ABC) 600mg/lamivuidine (3TC )300 mg FDC QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.
3300684|NCT00440895|Experimental|1 intracoronary + infusion|Bolus abciximab i.c. (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
3300685|NCT00440895|Active Comparator|2 intravenous|Bolus abciximab i.v. (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
3300686|NCT00440895|Placebo Comparator|3 Placebo|Bolus of placebo followed by 12 h infusion (placebo).
3300687|NCT00440869|Experimental|N-acetylcysteine|Active
3300688|NCT00440869|Placebo Comparator|placebo|placebo
3300689|NCT00440856|No Intervention|Control|
3300690|NCT00440856|Experimental|experimental|Participants are given their disc fragments following their operation
3300691|NCT00440843|Experimental|OLZ|
3300692|NCT00440843|Active Comparator|Typicals|
3300693|NCT00440830|Experimental|Smokers-nicotine|Smokers who were treated with nicotine
3300694|NCT00440830|Experimental|Nonsmokers-nicotine|Nonsmokers who were treated with nicotine
3300695|NCT00440830|Placebo Comparator|Smokers-placebo|Smokers who were treated with placebo
3300696|NCT00440830|Placebo Comparator|Nonsmokers-placebo|Nonsmokers who were treated with placebo
3300697|NCT00440817||Patients with lymphoma|Lymphoma Occurring in Patients with Rheumatoid Arthritis or Crohn's Disease
3300698|NCT00440778|Experimental|Gr 1 - intracoronary + infusion|abciximab bolus 0.25 mg/kg ic + 12 hrs iv infusion
3300699|NCT00440778|Experimental|Gr 2 - intracoronary|100% abciximab bolus dose 0.3 mg/kg ic
3300700|NCT00440778|Active Comparator|Gr 3 - intravenous|abciximab bolus dose 0.25 mg/kg iv + 12 hrs iv infusion
3300701|NCT00440778|Experimental|Gr 4 - intravenous|100% abciximab bolus dose 0.3 mg/kg iv
3300702|NCT00440765||001|bortezomib dose as determined (observational study) by treating physician
3300703|NCT00440752||AL|Cohort of study participants receiving treatment with artemether-lumefantrine
3300704|NCT00440739|Placebo Comparator|1|1=placebo
3300705|NCT00440739|Active Comparator|2|2= etoricoxib
3300706|NCT00440739|Active Comparator|3|3=falvoxate
3300707|NCT00440739|Active Comparator|4|etoricoxib and flavoxate
3300708|NCT00440700|Experimental|Patient-directed music|Patients select preferred music for listening through headphones whenever they like for as long as they like whenever feeling anxious, desire some rest and quiet time, or for listening enjoyment while mechanically ventilated in the ICU.
3300709|NCT00440700|Active Comparator|Headphones|Noise-canceling headphones only (no music) are applied by the patient to block out noise/sound in the ICU whenever desired.
3300710|NCT00440700|Other|Standard of Care|Patients receive usual care for the ICU and are encouraged to self-initiate rest periods twice daily.
3300711|NCT00440674|Experimental|1|Direct stenting technique
3300712|NCT00440674|Experimental|2|Conventional stenting with pre-dilatation strategy
3300713|NCT00440648|Other|1|sevelamer carbonate w(1-8) sevelamer hydrochloride w(9-16)
3300714|NCT00440648|Other|2|sevelamer hydrochloride w(1-8) sevelamer carbonate w(9-16)
3300715|NCT00440622|Experimental|1|GHer
3300716|NCT00440622|Experimental|2|CapHer
3300717|NCT00440609|Active Comparator|0.5mg transitioning to 2.0mg|Ranibizumab-intravitreal injection
3300718|NCT00440609|Active Comparator|1.0 mg transitioning to 2.0mg|Ranibizumab-intravitreal injection
3300719|NCT00440596|Experimental|MBSR|Mindfulness based stress reduction
3300720|NCT00440596|Active Comparator|PMR|Progressive Muscle Relaxation
3300779|NCT00440193|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants were to receive rivaroxaban 15 mg oral tablet twice daily for 3 weeks, followed by 20 mg once daily
3300721|NCT00440583|Experimental|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
3300722|NCT00440557|Experimental|TIW: Epoetin alfa 3 injections Weekly/Once Weekly|Participants will be administered with epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)
3300723|NCT00440557|Experimental|QW: Epoetin alfa once weekly|Participants will be administered with epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU).
3300724|NCT00440557|Experimental|Q2W: Epoetin alfa once every two weeks|Participants will be administered with epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU).
3300725|NCT00440544|Experimental|1|100 ug H1 antigen alone in BCG naive subjects
3300726|NCT00440544|Experimental|2|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
3300727|NCT00440544|Experimental|3|50 ug H1 antigen in BCG immunized subjects
3300728|NCT00440544|Experimental|4|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
3300729|NCT00440544|Experimental|5|100 ug H1 antigen in BCG immunized subjects
3300730|NCT00440544|Experimental|6|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
3300731|NCT00440531|Active Comparator|1|RECOMBIVAX HB™
3300732|NCT00440531|Experimental|2|Modified Process Hepatitis B Vaccine
3300733|NCT00440531|Active Comparator|3|ENGERIX-B™
3300734|NCT00440518|Placebo Comparator|Placebo|Placebo
3300735|NCT00440518|Experimental|Lacosamide 100mg|100mg lacosamide
3300736|NCT00440518|Experimental|Lacosamide 300mg|300mg lacosamide
3300737|NCT00440505|Placebo Comparator|Placebo|Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
3300738|NCT00440505|Experimental|Nicotine (5 mg)|Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
3300739|NCT00440505|Experimental|Nicotine (10 mg)|Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
3300740|NCT00440479||001|Bortezomib dose as determined (observational study) by treating physician
3300741|NCT00440466|Experimental|001|epoetin alfa Continue pre-study once weekly dose of epoetin alfa for 36 weeks
3300742|NCT00440466|Experimental|003|epoetin alfa Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
3300743|NCT00440466|Experimental|002|epoetin alfa Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
3300744|NCT00440453|No Intervention|1|Normal hospital food
3300745|NCT00440453|Experimental|2|Nutritional treatment
3300746|NCT00440440|Active Comparator|1|testosterone gel
3300747|NCT00440440|Placebo Comparator|2|placebo gel
3300748|NCT00440414|Experimental|1|Alimta
3300749|NCT00440414|Experimental|2|Tarceva
3300750|NCT00440401|Active Comparator|TachoSil®|
3300751|NCT00440401|Active Comparator|Standard Treatment|Standard Treatment of haemorrhage in cardiovascular surgery
3300752|NCT00440362|Active Comparator|T1|
3300753|NCT00440362|Active Comparator|T2|
3300754|NCT00440362|Active Comparator|T3|
3300755|NCT00440362|Active Comparator|T4|
3300756|NCT00440362|Active Comparator|T5|
3300757|NCT00440362|Active Comparator|T6|
3300758|NCT00440362|Active Comparator|T7|
3300759|NCT00440362|Active Comparator|T8|
3300760|NCT00440362|Placebo Comparator|C1|
3300761|NCT00440362|Placebo Comparator|C2|
3300762|NCT00440362|Placebo Comparator|C3|
3300763|NCT00440362|Placebo Comparator|C4|
3300764|NCT00440323|Experimental|ADBC sequence|In ADBC sequence A is Placebo, B is SB-649868 10 milligram (mg), C is SB-649868 30 mg, and D is Zolpidem 10 mg. Subject will receive placebo tablets, then two 5 mg tablets of SB-649868, then 25 mg and 5 mg tablet of SB-649868. There will be wash-out period of 7 days.
3300765|NCT00440323|Experimental|BACD sequence|In BACD sequence subject will receive SB-649868 two tablets of 5 mg each (10 mg, B), Placebo tablets (A), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), and Zolpidem 10 mg (D). There will be wash-out period of 7 days.
3300766|NCT00440323|Experimental|CBDA sequence|In CBDA sequence subject will receive SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), SB-649868 two tablets of 5 mg each (10 mg, B), Zolpidem 10 mg (D) and Placebo tablet (A). There will be wash-out period of 7 days.
3300767|NCT00440323|Experimental|DCAB sequence|In DCAB sequence subject will receive Zolpidem 10 mg (D), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), Placebo tablet (A), and SB-649868 two tablets of 5 mg each (10 mg, B). There will be wash-out period of 7 days.
3300768|NCT00440310|Experimental|Litx + Chemotherapy|
3300769|NCT00440310|Active Comparator|Chemotherapy alone|
3300770|NCT00440297|Experimental|Modified process hepatitis B vaccine|Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
3300771|NCT00440297|Active Comparator|ENGERIX-B™2|ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
3300772|NCT00440271|Other|Standard of Care (SoC)|Standard of Care (SOC) Arm = Tipranavir/ritonavir (TPV/r) capsules taken orally at a dose of 500 mg/200 mg twice a day (BID) plus optimized background regimen (OBR). No TPV/r dose changes were permitted.
3300773|NCT00440271|Other|Therapeutic Drug Monitoring (TDM)|Therapeutic Drug Monitoring (TDM) Arm = Patients began by receiving standard of care (SOC) tipranavir/ritonavir (TPV/r) capsules orally at a dose of 500 mg/200 mg twice a day (BID) plus optimized background regimen (OBR) followed, if needed, by TPV or ritonavir (RTV) dose adjustments at Week 4, 6, 10, 14, 18, 22, 26 and 30 based on viral response, phenotypic inhibitory quotient (IQ), and TPV trough concentrations.
3300774|NCT00440245|Other|salbutamol|There are two groups, asthma and COPD, which are being compared with respect to bronchoprotection from an active treatment (salbutamol).
3300775|NCT00440232|Experimental|Frovatriptan|5.0 mg of Frovatriptan given as single dose
3300776|NCT00440232|Placebo Comparator|placebo|
3300777|NCT00440219|Experimental|Prednisone group|Prednisone 50 mg daily for 10 days immediately pre-op
3300780|NCT00440193|Active Comparator|Enoxaparin/VKA|Participants were to receive 1.0 mg/kg enoxaparin twice daily (subcutaneous) for at least 5 days, plus vitamin K antagonist (VKA) (oral) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 to 3.0)
3300781|NCT00440180|Placebo Comparator|Group B|Placebo
3300782|NCT00440180|Experimental|Group A|Anastrozole
3300783|NCT00440167|Active Comparator|Arm A|
3300784|NCT00440167|Active Comparator|Arm B|
3300785|NCT00440154|Experimental|1|oral administration 5 mg breakfast timing
3300786|NCT00440154|Experimental|2|oral administration 25 mg breakfast timing
3300787|NCT00440154|Experimental|3|oral administration 50 mg breakfast timing
3300788|NCT00440154|Experimental|4|oral administration 100 mg breakfast timing
3300789|NCT00440154|Experimental|5|oral administration 25 mg dinner timing
3300790|NCT00440154|Placebo Comparator|6|oral administration
3300791|NCT00440154|Active Comparator|7|oral administration 10mg breakfast timing
3300792|NCT00440141|Experimental|1|
3300793|NCT00440141|Active Comparator|2|
3300794|NCT00440128|Active Comparator|Docetaxel|Docetaxel
3300795|NCT00440128|Experimental|Docetaxel/Casopitant|Docetaxel/Casopitant
3300796|NCT00440115|Experimental|High intensity disease management|High intensity disease management, free nicotine replacement therapy or bupropion
3300797|NCT00440115|Experimental|Low intensity disease management|Low intensity disease management, free nicotine replacement therapy or bupropion
3300798|NCT00440115|Other|Comparison group|Comparison group, free nicotine replacement therapy or bupropion
3300799|NCT00440102|Active Comparator|1|ketamine
3300800|NCT00440102|Active Comparator|2|Etomidate
3300801|NCT00440050|Experimental|1.|DHA
3300802|NCT00440050|Placebo Comparator|2.|Placebo
3300803|NCT00440037|Experimental|AMG 531|
3300804|NCT00440024|Experimental|Cell A|Study controlled daily skin care regimen during 'rest period' consisting of Dove Mild Cleanser, Dove Facial Moisturizer with SPF 15 followed by Tazorac
3300805|NCT00440024|Placebo Comparator|Cell B|Subject controlled normal skin care regimen during 'rest period, followed by study controlled daily skin care regime consisting of Dove Mild Cleanser, Dove Facial Moisturizer with SPF 15 followed by Tazorac
3300806|NCT00440011|Experimental|1|
3300807|NCT00440011|Active Comparator|2|
3300808|NCT00439985|Other|Behavioral: Cognitive Behavior Therapy|
3300809|NCT00439972|Active Comparator|Group 1|Visits 2-6: Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: extended use of Ortho Evra (R)
3300810|NCT00439972|Active Comparator|Group 2|Visits 2-6: Ortho Evra (R) Visits 6-11: extended use Ortho Evra (R) Visits 11-15: Ortho Cyclen (R)
3300811|NCT00439972|Active Comparator|Group 3|Visits 2-6: Ortho Cyclen (R) Visits 6-11: Ortho Evra (R) Visits 11-15: extended use of Ortho Evra (R)
3300812|NCT00439972|Active Comparator|Group 4|Visits 2-6: Ortho Cyclen (R) Visits 6-11: extended use of Ortho Evra (R) Visits 11-15: Ortho Evra (R)
3300813|NCT00439972|Active Comparator|Group 5|Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Evra (R) Visits 11-15: Ortho Cyclen (R)
3300814|NCT00439972|Active Comparator|Group 6|Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: Ortho Evra (R)
3300815|NCT00439946|Experimental|treprostinil|IV treprostinil continuous infusion via Crono Five infusion pump.
3300816|NCT00439920|Experimental|High-dose anthracycline|
3300817|NCT00439907|Active Comparator|End-to-end|End-to-end repair
3300818|NCT00439907|Active Comparator|Overlap|Overlap repair
3300819|NCT00439894||blood draw|One time blood draw
3300820|NCT00439868|Experimental|Treatment Group 1|Subjects in Period 1 of treatment group 1 will receive oral doses of extended release WELLBUTRIN XL tablets for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD. In Period 2 subject will receive placebo for 2 weeks.
3300821|NCT00439868|Experimental|Treatment Group 2|Subjects in Period 1 of Treatment group 2 will receive Placebo for 2 weeks and in Period 2 subject will receive oral doses of extended release WELLBUTRIN XL for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD.
3300822|NCT00439842|Experimental|HF group clinic appointments|HF group clinic appointments Heart failure multidisciplinary group clinic appointments (Arm 1 - HFcareGroup) includes 6 teaching sessions with patients led by nurse practitioner.
3300823|NCT00439842|No Intervention|Standard HF care|Standard HF care Standard heart failure education includes cardiologists instructions and hospital discharge information.
3300824|NCT00439829|Experimental|1|Initiation of ovarian stimulation therapy on day 1 (i.e., first day of menses)
3300825|NCT00439829|Active Comparator|2|Initiation of ovarian stimulation therapy on day 4 (day 1= first day of menses)
3300826|NCT00439816|Other|Arm 1|
3300827|NCT00439803|Active Comparator|T1|
3300828|NCT00439803|Placebo Comparator|C1|
3300829|NCT00439803|Active Comparator|T2|
3300830|NCT00439803|Placebo Comparator|C2|
3300831|NCT00439803|Active Comparator|T3|
3300832|NCT00439803|Placebo Comparator|C3|
3300833|NCT00439803|Active Comparator|T4|
3300834|NCT00439803|Placebo Comparator|C4|
3300835|NCT00439777|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)
3300836|NCT00439777|Active Comparator|Enoxaparin/VKA|Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)
3300837|NCT00439764|Active Comparator|1|Routine clinical practice and talk on general health
3300838|NCT00439764|Active Comparator|2|Talk on back health and handout of The Back Book
3300839|NCT00439764|Active Comparator|3|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
3300840|NCT00439751|Other|Immediate ADT|
3300841|NCT00439751|Other|Deferred ADT|
3300842|NCT00439738|Experimental|valsartan/HCTZ|
3300843|NCT00439738|Active Comparator|HCTZ +Amlodipine|
3300844|NCT00439725|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants were to receive rivaroxaban 20 mg oral tablet once daily
3300845|NCT00439725|Placebo Comparator|Placebo|Participants were to receive matching placebo oral tablet once daily
3300846|NCT00439712|Experimental|Treatment Group 1|
3300847|NCT00439712|Placebo Comparator|Treatment Group 2|
3300848|NCT00439699|Experimental|Memantine|Tremor reduction
3300849|NCT00439686|Experimental|Single Arm|
3300850|NCT00439647|Experimental|Zoledronic Acid|5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.
3300851|NCT00439647|Placebo Comparator|Placebo|100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The i.v. infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.
3300852|NCT00439634|Placebo Comparator|Placebo|
3300853|NCT00439634|Experimental|AVE1625 dose level 1|
3300854|NCT00439634|Experimental|AVE1625 dose level 2|
3300855|NCT00439634|Experimental|AVE1625 dose level 3|
3300856|NCT00439621|Experimental|1|
3300857|NCT00439621|Experimental|2|
3300858|NCT00439621|Experimental|3|
3300859|NCT00439621|Placebo Comparator|4|
3300860|NCT00439608|Experimental|Treatment|Cetuximab, paclitaxel, and carboplatin weekly for 6 weeks with 50.4 Gy radiation.
3300861|NCT00439595|Experimental|1|Hemocue 210 meter
3300862|NCT00439595|Experimental|2|Copack HBCS
3300863|NCT00439595|No Intervention|3|Control
3300864|NCT00439582|Experimental|1|
3300865|NCT00439582|Experimental|2|
3300866|NCT00439569|Experimental|Single Arm|Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first three subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The dosage of the next cohort was determined by the Modified Continual Re-assessment Method (MCRM) calculation and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage.
3300867|NCT00439556|Experimental|Bortezomib + Reduced Intensity Allo SCT|"Bortezomib + BEAM (Carmustine, Etoposide, Cytarabine and Melphalan) + Rituximab~Allo SCT = Allogeneic Stem Cell Transplantation"
3300868|NCT00439517|Experimental|1|UFOX + Cetuximab
3300869|NCT00439517|Active Comparator|2|FOLFOX4 + Cetuximab
3300870|NCT00439465|Other|Ex-vivo expanded effector cells|Infusing IL-2 and GM-CSF post-HCST
3300871|NCT00439452|Active Comparator|Telemedicine-Based Collaborative Care|Telemedicine-Based Collaborative Care - Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
3300872|NCT00439452|Active Comparator|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
3300873|NCT00439439|Sham Comparator|A|Sham Procedure
3300874|NCT00439439|Active Comparator|B|Verum Beamer ablation of heterotopic gastric mucosa
3300875|NCT00439426|Experimental|1|
3300876|NCT00439413|Active Comparator|Selegiline Transdermal Patch|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -4 week Screening/Baseline Phase.~During treatment, subjects received Selegiline Transdermal System, 6mg -20cm(2) patch, one time per day for 9 weeks~Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks"
3300877|NCT00439413|Placebo Comparator|Placebo|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -4 week Screening/Baseline Phase.~During treatment, subjects received matched placebo 20cm(2) patch transdermal patch one time per day for 9 weeks~Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks"
3300878|NCT00439400|Active Comparator|A|
3300879|NCT00439400|Placebo Comparator|B|
3300880|NCT00439374|Active Comparator|17 alpha-hydroxyprogesterone caproate|17 alpha-hydroxyprogesterone caproate
3300881|NCT00439361|Experimental|Bortezomib + ICE|"Bortezomib + ICE (Ifosfamide, Carboplatin, Etoposide):~Bortezomib 1.0 mg/m^2 intravenous (IV) over 5 Seconds on Days 1 and 4; + ICE (Ifosfamide 5 Gm/m^2 IV continuous infusion on Day 1, Carboplatin 5 AUC IV over 1 Hour Day 1, Etoposide 100 mg/m^2 IV over 2 Hours Days 1-3) + Mesna 5 mg/m^2 IV continuous infusion Day 1; 2 Gm/m^2 IV continuous infusion over 12 Hours."
3300882|NCT00439348|Experimental|Electronic prescription|Patients receive a prescription for specific over-the-counter medications.
3300883|NCT00439348|Active Comparator|Verbal advice|
3300884|NCT00439335|Experimental|H5 HA IM|Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.
3300885|NCT00439335|Experimental|H5 HA ID|Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.
3300886|NCT00439322||Group 1|
3300887|NCT00439309|Experimental|VascuSeal|Consists of two liquids that when mixed together in situ rapidly cross-link to form a biocompatible absorbable sealant that is tissue adherent. These liquids are sprayed onto tissues using the Dual Liquid Applicator. The formed Sealant remains intact for approximately 2 to 7 days. During this period the Sealant undergoes hydrolysis where it is absorbed into the circulatory system and is excreted through the kidneys.
3300922|NCT00438958|Active Comparator|Arm I|Patients undergo filgrastim (G-CSF)-mobilized sibling donor peripheral blood SCT on day 0.
3300888|NCT00439309|Active Comparator|GELFOAM/THROMBIN|GELFOAM/THROMBIN description - GELFOAM Sterile Compressed Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified porcine Skin Gelatin USP Granulates and Water for Injection, USP. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids. Although not necessary, GELFOAM can be used either with or without thrombin to obtain hemostasis.
3300889|NCT00439270|Active Comparator|Dasatinib, 50 mg + Docetaxel, 60 mg/m^2|Participants received dasatinib, 50 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 60 mg/m^2.
3300890|NCT00439270|Active Comparator|Dasatinib, 50 mg + Doxetaxel, 75 mg/m^2|Participants received dasatinib, 50 mg administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
3300891|NCT00439270|Active Comparator|Dasatinib, 70 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 70 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
3300892|NCT00439270|Active Comparator|Dasatinib, 100 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 100 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
3300893|NCT00439270|Active Comparator|Dasatinib, 120 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 120 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
3300894|NCT00439257||Group 1|
3300895|NCT00439244|Active Comparator|Zoledronic acid plus teriparatide|Zoledronic acid 5.0 mg/100 mL was administered via a peripheral intravenous site at Visit 2 (once at randomization) as a slow 15-minute infusion. Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. The pen device delivers 20 μg of teriparatide concurrently as daily subcutaneous injections for 52 weeks.
3300896|NCT00439244|Experimental|Zoledronic acid|Zoledronic acid 5.0 mg/100 mL was administered via a peripheral intravenous site at Visit 2 (once at randomization) as a slow 15-minute infusion.
3300897|NCT00439244|Active Comparator|Placebo zoledronic acid plus teriparatide|Placebo zoledronic acid 100 mL intravenous (i.v.) (once at randomization) plus teriparatide 20 μg (daily subcutaneous injections administered concurrently through 52 weeks). Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. The pen device delivers 20 μg of teriparatide concurrently as daily subcutaneous injections for 52 weeks.
3300898|NCT00439231|Experimental|Lenalidomide (Revlimid) subjects|Lenalidomide regimen testing to determine efficacy for CLL/ SLL subjects
3300899|NCT00439218|Experimental|Subject Enrollments|Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first three subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The dosage of the next cohort was determined by the Modified Continual Re-assessment Method (MCRM) approach and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage.
3300900|NCT00439205||MDM + FastEEM4|Multispectral digital microscope (MDM) + FastEEM4 Systems
3300901|NCT00439179|Experimental|Cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
3300902|NCT00439179|Experimental|Cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
3300903|NCT00439179|Experimental|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
3300904|NCT00439179|Experimental|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
3300905|NCT00439166|Experimental|1 AD combined doxycycline + rifampin|Doxycycline 100 mg b.i.d. plus rifampin 300 mg o.d. for 12 months.
3300906|NCT00439166|Experimental|2 AD Doxycycline only|Doxycycline 100 mg b.i.d. plus placebo matched to rifampin o.d. for 12 months.
3300907|NCT00439166|Experimental|3 Rifampin only|Rifampin 300 mg o.d. plus placebo matched to doxycycline b.i.d. for 12 months.
3300908|NCT00439166|Placebo Comparator|4 Double Placebo|Placebo matched to Doxycycline b.i.d. plus placebo matched to rifampin o.d. for 12 months.
3300909|NCT00439140|Experimental|botulinum toxin Type A 200U|Botulinum toxin Type A 200U injection into the detrusor on Day 1 followed by a repeat botulinum toxin Type A 200U injection after a minimum of 12 weeks (if applicable).
3300910|NCT00439140|Experimental|botulinum toxin Type A 300U|Botulinum toxin Type A 300U injection into the detrusor on Day 1 followed by a repeat botulinum toxin Type A 300U injection after a minimum of 12 weeks (if applicable).
3300911|NCT00439140|Other|Placebo/botulinum toxin Type A 200U|Placebo (Normal Saline) injection into the detrusor on Day 1 followed by a botulinum toxin Type A 200U injection after a minimum of 12 weeks (if applicable).
3300912|NCT00439140|Other|Placebo/botulinum toxin Type A 300U|Placebo (Normal Saline) injection into the detrusor on Day 1 followed by a botulinum toxin Type A 300U injection (200U after discontinuation of 300U) after a minimum of 12 weeks (if applicable).
3300913|NCT00439101|Experimental|1|
3300914|NCT00439101|Placebo Comparator|2|Placebo
3300915|NCT00439075|Experimental|CPAP|positive airway pressure
3300916|NCT00439075|Active Comparator|standard medical therapy|conventional oxygen therapy
3300917|NCT00439049||A|Cocaine Dependent Subjects
3300918|NCT00439036|Experimental|Behavior Therapy: Acceptance and Commitment Therapy|The Act-ODT intervention consists of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
3300919|NCT00439036|Active Comparator|Drug Counseling|The Drug Counseling intervention consists of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
3300920|NCT00438984|Experimental|Treatment (chemotherapy, immunosuppressive, lymphocytes)|"All patients receive high-dose cyclophosphamide IV on days -3 and -2 and autologous antigen-specific cytotoxic CD8+ T-lymphocyte clones IV over 30-60 minutes on day 0.~COHORT I: Beginning within 6 hours of T cell infusion, patients receive low-dose aldesleukin SC twice daily on days 0-14.~COHORT II: Beginning within 6 hours of T cell infusion, patients receive high-dose aldesleukin IV 3 times daily on days 0-5."
3300921|NCT00438971|Experimental|Duloxetine|
3300923|NCT00438958|Experimental|Arm II|Patients undergo G-CSF-mobilized sibling donor bone marrow transplantation on day 0.
3300924|NCT00438932|Active Comparator|Lanthanum Carbonate and Low Phosphorus Diet|25% of subjects will receive binders plus a phosphate restricted diet.
3300925|NCT00438932|Active Comparator|Lanthanum Carbonate and Unrestricted Phosphorus Diet|25% binders + unrestricted phosphate diet.
3300926|NCT00438932|Active Comparator|Placebo and Low Phosphorus Diet|25% placebo + phosphate restricted diet.
3300927|NCT00438932|Active Comparator|Placebo and Unrestricted Phosphorus Diet|25% placebo + unrestricted phosphate diet.
3300928|NCT00438919|Experimental|1|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
3300929|NCT00438893|Other|A portfolio of cholesterol-lowering foods|Dietary advice to consume a dietary portfolio of cholesterol-lowering foods
3300930|NCT00438880|Experimental|Arm I|See Detailed Description
3300931|NCT00438867|Experimental|1|
3300932|NCT00438867|Experimental|2|
3300933|NCT00438867|Placebo Comparator|3|
3300934|NCT00438854|Experimental|Dasatinib treatment|All patients were treated with dasatinib pills by mouth as treatment.
3300935|NCT00438828|Experimental|Dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
3300936|NCT00438815|Experimental|Open-label C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously. If there was no response to treatment 60 minutes after the first dose, a second 1,000 U dose could be administered.
3300937|NCT00438802|Experimental|alefacept|Determine both the maximum tolerated dose level as well as the optimal immunologic dose and toxicity.
3300938|NCT00438776|Active Comparator|olanzapine|active zyprexa (olanzapine)
3300939|NCT00438776|Placebo Comparator|sugar pill|Placebo (fake pill)
3300940|NCT00438763||1|Subjects using the neoprene splint.
3300941|NCT00438763||2|Subjects using the orthoplast splint.
3300942|NCT00438750|Experimental|Independent Home Exercises|Subjects who learn their therapy exercises from the surgeon and practice them independently at home.
3300943|NCT00438750|Experimental|Formal Therapy|Subjects who follow the conventional protocol of seeing a therapist to learn and guide them in their exercises.
3300944|NCT00438698|Experimental|Low Glycemic Index Diet|Diet with low glycemic index carbohydrates
3300945|NCT00438698|Active Comparator|High Fiber Diet|Diet with high cereal fibre choices
3300946|NCT00438672|Active Comparator|Dequervains|The de Quervain's injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and DeQuervain's is also fairly uncommon. Therefore, the trial wasn't feasible for this diagnosis.
3300947|NCT00438672|Active Comparator|Lateral Epicondylitis|
3300948|NCT00438672|Active Comparator|CMC Arthritis|The CMC Arthritis injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and it was decided that the trial wasn't feasible for this diagnosis.
3300949|NCT00438659|Experimental|Mometasone|Patients apply 2.5 mL mometasone furoate cream once daily to the treatment area (breast or chest wall) for the duration of planned radiotherapy.
3300950|NCT00438659|Placebo Comparator|Placebo|Patients apply 2.5 mL of an identical-appearing placebo cream to the treatment area as in arm I.
3300951|NCT00438633||1|Subjects who begin therapy immediately after diagnosis of injury.
3300952|NCT00438633||2|Subjects who delay therapy for 3 weeks after diagnosis of injury.
3300953|NCT00438607|Other|1|BIIB014 at MTD from Part A
3300954|NCT00438607|Other|2|BIIB014 at dose immediately below MTD from Part A
3300955|NCT00438607|Placebo Comparator|3|
3300956|NCT00438594|No Intervention|Control group|Control group
3300957|NCT00438594|Experimental|Paraprofessional home visits|home visitation by Paraprofessional
3300958|NCT00438594|Experimental|Nurse home visits|home visitation by Nurse
3300959|NCT00438568|Placebo Comparator|1|saline
3300960|NCT00438568|Experimental|2|10 Units
3300961|NCT00438568|Experimental|3|20 Units
3300962|NCT00438555|Experimental|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
3300963|NCT00438555|Experimental|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
3300964|NCT00438555|No Intervention|Control group|control group, no intervention, medical follow up only
3300965|NCT00438516|No Intervention|1|Control group
3300966|NCT00438516|Experimental|2|Nurse home visitation
3300967|NCT00438490|Experimental|recombinant human prolactin|Recombinant Human Prolactin 60 mcg/kg once daily subcutaneous injection
3300968|NCT00438490|Placebo Comparator|Placebo|Normal saline placebo subcutaneous injection
3300969|NCT00438477|Experimental|Injection Methods|One injection site with radioactive tracer intraparenchymal/peritumoral (around the tumor), and other subareolar (around the nipple)
3300970|NCT00438464|Experimental|Arm I (Finasteride)|Finasteride 5 mg once daily for 4-6 weeks, then undergo prostatectomy.
3300971|NCT00438464|Placebo Comparator|Arm II (Placebo)|Placebo once daily for 4-6 weeks, then undergo prostatectomy.
3300972|NCT00438451|Active Comparator|Levetiracetam|Levetiracetam
3300973|NCT00438451|Active Comparator|Carbamazepine|Carbamazepine
3300974|NCT00438451|Active Comparator|Lamotrigine|Lamotrigine
3300975|NCT00438425|Experimental|Intensive Portfolio|The portfolio dietary advice will conform to current therapeutic diets appropriate for hypercholesterolemic subjects (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal. Participants received 7 visits during a 6-month period with the study dietitian.
3301097|NCT00437229|Experimental|Subjects in Part B|In PART B, subjects received Regimen D: oral casopitant alone (150 mg QD Day 1, 50 mg QD Days 2 and 3); Regimen E: IV dexamethasone (8 mg single-dose Day 1 only) and oral ondansetron (8 mg BID Days 1 to 3); and Regimen F: oral casopitant regimen as in Regimen D, and IV dexamethasone and oral ondansetron as in Regimen E.
3301275|NCT00435253|Experimental|BLVR Treatment|BLVR Treatment
3300976|NCT00438425|Experimental|Routine Portfolio|The portfolio dietary advice will conform to current therapeutic diets appropriate for hypercholesterolemic subjects (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal. Participants received 2 visits during a 6-month period with the study dietitian.
3300977|NCT00438425|Active Comparator|Control|Advice focused on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
3300978|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 1|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Wash-out up to 8 weeks~Corticosteroid 1:~Dose or Concentration: Corticosteroid 1 Foam~Mode and Frequency of Administration:Twice daily, a golf-ball sized amount to be massaged into the affected area of the scalp~Duration of Treatment: 4 weeks as a maximum"
3300979|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 2|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 2:~Dose or Concentration: Corticosteroid 2 Lotion~Mode and Frequency of Administration: Twice daily, a thin film to be applied to the affected area of the scalp and massaged gently and thoroughly into the skin~Duration of Treatment: 4 weeks as a maximum"
3300980|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 3|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 3:~Dose or Concentration: Corticosteroid 3 Scalp application~Mode and Frequency of Administration: Twice daily, a thin film to be applied into the affected area of the dry scalp and rubbed gently into the scalp~Duration of Treatment: 4 weeks as a maximum"
3300981|NCT00438399|Active Comparator|Corticosteroid 1-Wash out-C. propionate|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 1:~Dose or Concentration: Corticosteroid 1 Foam~Mode and Frequency of Administration:Twice daily, a golf-ball sized amount to be massaged into the affected area of the scalp~Duration of Treatment: 4 weeks as a maximum"
3300982|NCT00438399|Active Comparator|Corticosteroid 2-Wash out-C. propionate|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 2:~Dose or Concentration: Corticosteroid 2 Lotion~Mode and Frequency of Administration: Twice daily, a thin film to be applied to the affected area of the scalp and massaged gently and thoroughly into the skin~Duration of Treatment: 4 weeks as a maximum"
3300983|NCT00438399|Active Comparator|Corticosteroid 3-Wash out-C. propionate|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 3:~Dose or Concentration: Corticosteroid 3 Scalp application~Mode and Frequency of Administration: Twice daily, a thin film to be applied into the affected area of the dry scalp and rubbed gently into the scalp~Duration of Treatment: 4 weeks as a maximum"
3300984|NCT00438360|Active Comparator|Cyclosporine A|Oral soft gelatin capsules of cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
3300985|NCT00438360|Placebo Comparator|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
3300986|NCT00438347||group 1|Intervention Group- aerobic exercise
3300987|NCT00438347||group 2|Control Group- stretching and toning
3300988|NCT00438321|Placebo Comparator|Placebo|Placebo injection, gel and pill
3300989|NCT00438321|Active Comparator|Testosterone only|Zoladex 3.6 mg IM injection Testosterone 7.5 g gel (AndroGel) transdermally daily Anastrozole 10 mg (Arimidex) orally daily
3300990|NCT00438321|Active Comparator|Testosterone and Estrogen|Zoladex 3.6 mg IM injection Testosterone 7.5 g gel (AndroGel) transdermally Placebo pill orally daily
3300991|NCT00438308||1|Subjects who begin therapy immediately after fracture.
3300992|NCT00438308||2|Subjects delay therapy for 3 weeks after injury.
3300993|NCT00438282|No Intervention|1|Control group
3300994|NCT00438282|Experimental|2|Paraprofessional home visits
3300995|NCT00438282|Experimental|3|Nurse home visitation
3300996|NCT00438256|Experimental|Group 1|10 Radiation Sessions over 2 weeks
3300997|NCT00438256|Experimental|Group 2|5 Radiation sessions: 3 in week 1 and 2 in week 2
3300998|NCT00438256|Experimental|Group 3|5 Radiation sessions: 4 in week 1 and 1 in week 2
3300999|NCT00438256|Experimental|Group 4|5 Radiation Sessions in one week
3301000|NCT00438243|Placebo Comparator|1|1 drop affected eye twice daily.
3301001|NCT00438243|Experimental|2|Bromfenac (Xibrom) 1 drop to affected eye twice a day.
3301002|NCT00438204|Experimental|Bevacizumab, gemcitabine hydrochloride|"Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days~Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed disodium every 14 days~Pemetrexed 400 mg/m2 intravenously over 10 minutes every 14 days."
3301003|NCT00438191||1|Subjects who wear the splint whenever the feel the need.
3301004|NCT00438191||2|Subjects who wear the splint whenever possible.
3301005|NCT00438165|No Intervention|1|Control group
3301006|NCT00438165|Experimental|2|Nurse home visits
3301007|NCT00438152|Active Comparator|Invirase® tablets|
3301008|NCT00438152|Active Comparator|Kaletra® tablets|
3301098|NCT00437216||1|Monotherapy - Subjects who are not currently being treated with anti-psoriatic medication and start using Clobex®
3301276|NCT00435227|Experimental|1|MEDI-524
3301009|NCT00438113|Active Comparator|Aggressive Blood Pressure control|"The experimental arm will receive open label therapy to achieve a target systolic blood pressure less than or equal to 120 mmHg.~If the average BP is found to be > 120 mmHg at the baseline, telephone or clinic followup visits, treatment will be recommended based on the following regimen (For details, please see Appendix 4):~Step 1 - Accupril, titrated to maximum tolerated dose, beginning at 20 mg po od followed by 40 mg successively Step 2 - combination of Accupril with Hydrochlorothiazide 12.5 mg po od. Step 3 - Addition of Atenolol 50 mg po od. Step 4 - Addition of Norvasc 2.5-10 mg po od. Step 5 - Addition of Terazosin 1 mg po od."
3301010|NCT00438113|No Intervention|Standard Blood Pressure control|Treatment will be carried out as per the CHEP guidelines. These patients may require ACEi or ARBs for their treatment. No changes to their drug regimen will be made as long as BP measurements are congruent with current guidelines. These modifications will be made as per standard practice by the physician who is primarily involved with their care (this may be a family physician or a specialist, depending on the patient). Patients with diabetes in the standard arm will be treated to a target BP of <130/80 as per the CHEP guidelines.
3301011|NCT00438100|Active Comparator|Capecitabine arm|Capecitabine (Xeloda): 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
3301012|NCT00438100|Experimental|S-1 arm|S-1: 80 mg/m2 orally bid daily for day 1 through day28 followed by 14-day washout; repeat this as a course.
3301013|NCT00438087|Placebo Comparator|2|placebo versus methylprednisolone
3301014|NCT00438087|Experimental|1|placebo versus methylprednisolone
3301015|NCT00438048|Active Comparator|a,b|Compare Pilocarpine and Artificial saliva
3301016|NCT00438022||1|Group 1 will include participants with AD, EH, and recurrent herpes simplex virus (HSV)
3301017|NCT00438022||2|Group 2 will include participants with AD and recurring HSV infections but without EH
3301018|NCT00438022||3|Group 3 will include participants with AD but without EH or HSV infection
3301019|NCT00438022||4|Group 4 will include participants in good general health without AD, EH, or HSV infection
3301020|NCT00438009|Experimental|CAVATAK|
3301021|NCT00437983|Active Comparator|PS-Omega3|Phosphatidylserine-Omega3, 300mg/day 15 wk
3301022|NCT00437983|Placebo Comparator|Placebo|Cellulose tainted with fishy odor, 3 capsules/day
3301023|NCT00437970|Active Comparator|A|Arm A- Metformin
3301024|NCT00437970|Active Comparator|B|Arm B- Pioglitazone
3301025|NCT00437957|Experimental|Temazolomide, Valproic Acid and Radiation|Temazolomide, Valproic Acid and Whole Brain Radiation Therapy
3301026|NCT00437931||A|patients with subclinical hypothyroidism
3301027|NCT00437931||B|patients with subclinical hyperthyroidism
3301028|NCT00437931||C|patient with normal thyroid function.
3301029|NCT00437892|Experimental|Atorvastatin and lipid lowering diet|
3301030|NCT00437892|Active Comparator|lipid lowering diet|
3301031|NCT00437840|Experimental|Treatment Arm A|In Arm A dosing subject will receive Placebo in Week 1, 10 milligram (mg) of GSK598809 in Week 2, 25 mg of GSK598809 in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
3301032|NCT00437840|Experimental|Treatment Arm B|In Arm B dosing subject will receive 10 mg of GSK598809 in Week 1, Placebo in Week 2, 25 mg of GSK598809 in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
3301033|NCT00437840|Experimental|Treatment Arm C|In Arm C dosing subject will receive 10 mg of GSK598809 in Week 1, 25 mg of GSK598809 in Week 2, Placebo in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
3301034|NCT00437840|Experimental|Treatment Arm D|In Arm D dosing subject will receive 10 mg of GSK598809 in Week 1, 25 mg of GSK598809 in Week 2, 75 mg of GSK598809 in Week 3, Placebo in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
3301035|NCT00437827|Active Comparator|1|Each subject in this arm will receive depression therapy similar to that used by the Star*D study - a major depression study conducted in the United States (Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Am J Psychiatry 2006; 163:1905-1917)
3301036|NCT00437827|Experimental|2|Each subject in this arm will receive therapy based upon an individualized rEEG report which provides one or more treatment options with the highest probability of success.
3301037|NCT00437762|Experimental|1|Botulinum Toxin A Injection
3301038|NCT00437762|Placebo Comparator|2|Placebo injection
3301039|NCT00437749|Active Comparator|CBT-1|
3301040|NCT00437749|Placebo Comparator|Placebo|
3301041|NCT00437736|Experimental|Single arm dose escalation|
3301042|NCT00437723|Experimental|1|
3301043|NCT00437723|No Intervention|2|
3301044|NCT00437684|Experimental|A|LPV/r: LPV/r monotherapy and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
3301045|NCT00437684|Active Comparator|B|LPV/r+ selected NUCS and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
3301046|NCT00437671|Experimental|Entered study|
3301047|NCT00437658|Active Comparator|DMPA-SC|
3301048|NCT00437658|Experimental|NBI-56418 150 mg|
3301049|NCT00437658|Experimental|NBI-56418 75 mg|
3301099|NCT00437216||2|Add-on therapy - Subjects who are taking some form of anti-psoriatic medication and add Clobex® treatment
3301100|NCT00437203|Experimental|1|
3301101|NCT00437190|Active Comparator|Anterior Cervical Discectomy Fusion|
3301270|NCT00435292|Active Comparator|naproxen|nonsteroidal antiinflammatory drug
3301271|NCT00435279|Experimental|Eszopiclone|
3301050|NCT00437645|Experimental|Valsartan/amlodipine 160/5 mg|Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.
3301051|NCT00437645|Active Comparator|Amlodipine 10 mg|Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.
3301052|NCT00437632|Experimental|Subjects in Cohort-1 of Section 1|Subjects will be randomized to receive either GSK598809 10 mg or Placebo.
3301053|NCT00437632|Experimental|Subjects in Cohort-2 of Section 1|Subjects will be randomized to receive either GSK598809 25 mg or Placebo.
3301054|NCT00437632|Experimental|Subjects in Cohort-3 of Section 1|Subjects will be randomized to receive either GSK598809 25 mg or Placebo.
3301055|NCT00437632|Experimental|Subjects in Cohort-4 of Section 1|Subjects will be randomized to receive either GSK598809 40 mg or Placebo.
3301056|NCT00437632|Experimental|Subjects in Cohort-5 of Section 2|Subjects will be randomized to receive either ascending doses of GSK598809 75, 120 and 175 mg or Placebo. There will be a washout period of 6 days between the doses.
3301057|NCT00437632|Experimental|Subjects in Cohort-6 of Section 3|Subjects will receive caffeine on day -1 and after randomization subject will either receive GSK598809 or Placebo on Day 1. After washout period of 1-week subject will either receive GSK598809 or Placebo for 28 days.
3301058|NCT00437619|Experimental|1|
3301059|NCT00437606|Experimental|1|
3301060|NCT00437606|Experimental|2|
3301061|NCT00437606|Experimental|3|
3301062|NCT00437567|Active Comparator|Prebiotics|Babies randomized to this arm will receive galacto-oligosaccharide supplements
3301063|NCT00437567|Placebo Comparator|Placebo|Babies randomized to this arm will receive placebo
3301064|NCT00437502|Experimental|tumor peptide vaccine|2 cohorts: High and low dose tumor peptide vaccine
3301065|NCT00437489|Active Comparator|Control|
3301066|NCT00437489|Experimental|Experimental|
3301067|NCT00437476|Experimental|A|LPV/r + selected NRTIs for 26 weeks, followed by LPV/r monotherapy and anti HCV drugs for 48 weeks. All the patients will be followed-up for 24 weeks after the end of anti-HCV drugs for the evaluation of SVR.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day . At the end of week 12 of combined therapy, only patients who will reach an early virological response will continue anti-HCV drugs.
3301068|NCT00437476|Active Comparator|B|LPV/r+ selected NRTIs for 24 weeks, followed by the same HAART and anti-HCV drugs for 48 weeks. At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decision. All the patients will be followed-up for 24 weeks after the end of anti-HCV drugs for the evaluation of SVR.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day . At the end of week 12 of combined therapy, only patients who will reach an early virological response will continue anti-HCV drugs.
3301069|NCT00437463|Experimental|1|Ramipril
3301070|NCT00437463|No Intervention|2|
3301071|NCT00437437|Experimental|1|
3301072|NCT00437424|Experimental|1|
3301073|NCT00437411|Experimental|Workshop|Affective Self Awareness intervention
3301074|NCT00437411|No Intervention|Control|Waiting-list control.
3301075|NCT00437398|Experimental|Islet Transplant|Subjects will receive standard intraportal transplantation or portal venous system infusion via laparotomy of purified pancreatic islets.
3301076|NCT00437385|Active Comparator|1|Continuation-Medication with Antidepressants (after WBS Guidelines)
3301077|NCT00437385|Experimental|2|Continuation-ECT with Antidepressants
3301078|NCT00437385|Experimental|3|"Continuation-Psychotherapy (Cognitive Behavioral Group Psychotherapy including the Situational Analysis of CBASP)"
3301079|NCT00437372|Experimental|Sunitinib plus Radiation|Sunitinib plus Radiation
3301080|NCT00437359|Other|Fareston|Toremifene citrate: 40-mg tablets by mouth once daily.
3301081|NCT00437359|Other|Arimidex|Anastrozole: 1-mg tablets by mouth once daily.
3301082|NCT00437346|Active Comparator|Group A|Patients is given thorough information based on the tests taken plus medical treatment.
3301083|NCT00437346|Active Comparator|Group B|Patients receive simple written information based on the tests taken plus medical treatment.
3301084|NCT00437320|Experimental|1|
3301085|NCT00437320|Placebo Comparator|2|
3301086|NCT00437307|Active Comparator|1|Topotecan: 0,75 mg/m²/d, Tage 1-3 und Carboplatin: AUC 5 (after Cockroft and Gault formula) am Tag 3 nach Topotecan, q 21d.
3301087|NCT00437307|No Intervention|2|Paclitaxel 175 mg/m2/d, day 1 and Carboplatin: AUC 5 (after Cockroft and Gault formula), day 1, q21d OR gemcitabine 1000 mg/m2/d, day 1 and 8 and Carboplatin AUC 4 (after Cockroft and Gault formula), day 1, q 21d.
3301088|NCT00437294|Experimental|A|
3301089|NCT00437294|Placebo Comparator|B|
3301090|NCT00437281|Placebo Comparator|Placebo|
3301091|NCT00437281|Experimental|Pregabalin|
3301092|NCT00437268|Experimental|A|
3301093|NCT00437268|Active Comparator|B|
3301094|NCT00437255|Active Comparator|1|Clobex® Spray
3301095|NCT00437255|Active Comparator|2|Taclonex® Ointment
3301096|NCT00437229|Experimental|Subjects in Part A|In PART A, subjects received Regimen A: oral casopitant alone (150 mg once daily [QD] Day 1, 50 mg QD Days 2 and 3); Regimen B: oral dexamethasone (20 mg QD Day 1 and 8 mg twice daily [BID] Days 2 and 3) and intravenous (IV) ondansetron (32 mg single-dose Day 1); and Regimen C: oral casopitant as in Regimen A, IV ondansetron as in Regimen B and a lower dose oral dexamethasone than in Regimen B (12 mg QD Day 1, 8 mg QD Days 2 and 3).
3301262|NCT00435383||Observational|Group 1 received a presurgical caudal block and group 2 received a intravenous narcotics.
3301102|NCT00437190|Experimental|BRYAN Cervical Disc Prosthesis|BRYAN Cervical Disc Prosthesis is a cervical intervertebral disc prosthesis designed to provide for motion like the normal cervical functional spinal unit.
3301103|NCT00437151|Active Comparator|1|More frequent than normal office visits
3301104|NCT00437151|Active Comparator|2|Electronic reminders (voice, e-mail, text messages)
3301105|NCT00437151|Active Comparator|3|Parental involvement / intervention reminders
3301106|NCT00437151|Active Comparator|4|No intervention or reminders
3301107|NCT00437125|Experimental|Duloxetine|Participants received duloxetine 30 milligram (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg orally QD for 11 weeks
3301108|NCT00437112|Experimental|1|"4 week pretreatment phase consists of continuation of usual OAM therapy~24 week treatment period with insulin glargine and OAM continuation followed by 24 week treatment period with HIIP and OAM continuation~8 week follow up period"
3301109|NCT00437112|Experimental|2|"4 week pretreatment phase consists of continuation of usual OAM therapy~24 week treatment period with HIIP and OAM continuation followed by 24 week treatment period with insulin glargine and OAM continuation~8 week follow up period"
3301110|NCT00437099|Experimental|1|subjects with BPD receiving Omacor 1.680 mg/d
3301111|NCT00437099|Experimental|2|BPD patients randomized to Omacor 3.360 mg/d
3301112|NCT00437099|Placebo Comparator|3|patients with BPD randomized to Placebo
3301113|NCT00437086|Experimental|PS-341|Designed to assess the toxicity and pilot response of PS-341 in patients with advanced myeloproliferative diseases.
3301114|NCT00437073|Experimental|lapatinib plus capecitabine|A total of 55 isubjects will be enrolled into this arm. Subjects with progression of CNS and/or non-CNS disease will be considered progressors. At the time of radiographically-documented CNS and/or non-CNS disease progression, a subject randomized to this arm will be allowed to cross over to the alternative arm.
3301115|NCT00437073|Experimental|lapatinib + topotecan|A total of 55 isubjects will be enrolled into this arm. Subjects with progression of CNS and/or non-CNS disease will be considered progressors. At the time of radiographically-documented CNS and/or non-CNS disease progression, a subject randomized to this arm will be allowed to cross over to the alternative arm.
3301116|NCT00437060||Ancillary/Correlative (neurocognitive assessment, biomarkers))|"Patients complete neurocognitive tests to assess thinking, memory, attention, and concentration. The baseline test is administered during the consolidation phase of chemotherapy and further tests are done at 1 year from baseline and 1 year after* the completion of study therapy.~Patients undergo blood and cerebrospinal fluid collection periodically for biomarker, genotypic polymorphisms, and pharmacokinetic analysis. Patients undergo MRI diffusion-tensor imaging to correlate imaging with neuropsychological outcomes."
3301117|NCT00437034|Experimental|Treatment (antiangiogenesis therapy)|Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3301118|NCT00437021|Active Comparator|Group C|Dryvax® vaccine or placebo on Day 0. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
3301119|NCT00437021|Experimental|Group D|Standard dose IMVAMUNE® vaccine or placebo on Day 0 and Dryvax® vaccine or placebo on Day 7. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
3301120|NCT00437021|Experimental|Group E|Dryvax® vaccine and standard dose IMVAMUNE® vaccine or 2 placebos on Day 0. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
3301121|NCT00437021|Experimental|Group F|Standard dose IMVAMUNE® vaccine or placebo on Day 0.
3301122|NCT00437021|Experimental|Group B|Standard dose IMVAMUNE® vaccine or placebo on Days 0 and 28.
3301123|NCT00437021|Experimental|Group A|Standard dose IMVAMUNE® vaccine or placebo on Days 0 and 7.
3301124|NCT00436995|Other|Single|
3301125|NCT00436982|Active Comparator|Cemented Triathlon total knee system|The Triathlon total knee system is the successor of the Duracon total knee system and was observed in a prospective randomised, parallel, double-blind study.
3301126|NCT00436982|Active Comparator|Cemented Duracon total knee system|The Duracon total knee system is the predecessor of the Triathlon total knee system and was observed in a prospective randomised, parallel, double-blind study.
3301127|NCT00436969|Active Comparator|Control|Subjects randomized to the control arm injection of prescribed anesthetic and corticosteroid, shall receive an equivalent volume (8 mL's).
3301128|NCT00436969|Experimental|Investigational|Subjects randomized to the active treatment in this study will receive a one-time dose of 8 mL's of Orthovisc derived from non-animal source bacterial fermentation, S. Equi.
3301129|NCT00436956|Experimental|AZD2171 in Prostate Cancer|Cohort 1 (n=35) received 20 mg AZD2171 (Cediranib) orally daily. Cohort 2 (n=23) received prednisone 10 mg orally daily with 20 mg AZD2171.
3301130|NCT00436943||A|Smokers
3301131|NCT00436930|Experimental|Arm I|Patients receive irradiated autologous tumor cells subcutaneously (SC) and sargramostim (GM-CSF) SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.
3301132|NCT00436930|Experimental|Arm II|Patients receive autologous dendritic cells loaded with irradiated autologous tumor cells SC and GM-CSF SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.
3301133|NCT00436917|Experimental|zoledronic acid|4 mg 15 minutes IV infusion. If creatinine clearance is ≤ 60, dosage should be adjusted as follows:CrCl 50-60: 3.5 mg; CrCl 40-49: 3.3 mg; CrCl 30-39: 3.0 mg.
3301134|NCT00436904|Experimental|Alemtuzumab + Rituximab|Alemtuzumab 30mg Monday, Wednesday, and Friday x 5 weeks, Rituximab 375/mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
3301135|NCT00436878|Experimental|Portion Size|Each experiment manipulated food portion size of beverages, entrees, and side dishes
3301136|NCT00436865|Other|PCOS|PCOS women receiving weight loss intervention
3301137|NCT00436865|Other|Control|Non-PCOS women receiving weight loss intervention
3301263|NCT00435370|Experimental|Tropisetron|Tropisetron (10mg/day) + risperidone(6mg/day)
3301264|NCT00435370|Placebo Comparator|Placebo|Placebo + risperidone (6mg/day)
3301265|NCT00435357|Experimental|mobile-bearing TKA|
3301266|NCT00435357|Active Comparator|fixed- bearing TKA|
3301138|NCT00436852|Experimental|Measurable disease by CT or MRI scan (ABT-751 chemotherapy)|Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.
3301139|NCT00436852|Experimental|Evaluable by I-MIBG scintigraphy (ABT-751)|Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.
3301140|NCT00436839|Experimental|1|Docetaxel 75mg/m² intravenously (day 1) every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle
3301141|NCT00436839|Active Comparator|2|Mitoxantrone 12mg/m² intravenously every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle
3301142|NCT00436826|Experimental|Cladribine 3.5 mg/kg, IFN-beta|
3301143|NCT00436826|Placebo Comparator|Placebo, IFN-beta|
3301144|NCT00436800|Experimental|1|Gemcitabine on Day 1 followed by Oxaliplatin on Day 2. The regimen is given every 2 weeks to a maximum of 12 cycles.
3301145|NCT00436748|Experimental|Darbepoetin Alfa QW|Participants received darbepoetin alfa once a week (QW) for 24 weeks. The initial dose was 0.45 μg/kg; thereafter, active doses were administered to achieve and then maintain hemoglobin levels within a target range of 10.0 to 12.0 g/dL. Participants not on dialysis or who were receiving peritoneal dialysis were administered darbepoetin alfa subcutaneously; participants receiving hemodialysis were administered darbepoetin alfa intravenously.
3301146|NCT00436748|Experimental|Darbepoetin Alfa Q2W|Participants received darbepoetin alfa every 2 weeks (Q2W) and a placebo every other 2 weeks to maintain the blind for 24 weeks. The initial dose was 0.75 μg/kg; thereafter, active doses were administered to achieve and then maintain hemoglobin levels within a target range of 10.0 to 12.0 g/dL. Participants not on dialysis or who were receiving peritoneal dialysis were administered darbepoetin alfa subcutaneously; participants receiving hemodialysis were administered darbepoetin alfa intravenously.
3301147|NCT00436696||Ancillary-correlative (SNP analysis)|DNA samples are derived from participants' banked blood or uninvolved bone marrow. A whole genome scan of DNA samples is employed to identify candidate single nucleotide polymorphisms (SNPs). The candidate SNPs are investigated, using a gene-centric haplotyping approach, to identify 10-20 true disease-associated alleles. The disease-associated alleles are again investigated, using a gene-centric haplotyping approach, to validate 5-10 disease-associated SNPs. SNPs are then analyzed for heritable predisposition.
3301148|NCT00436683|Experimental|1|Dose titration on active
3301149|NCT00436683|Active Comparator|2|Dose titration
3301150|NCT00436670|Experimental|AMG 317 75 mg|75 subjects
3301151|NCT00436670|Placebo Comparator|Placebo Arm|75 subjects
3301152|NCT00436670|Experimental|AMG 317 300 mg|75 subjects
3301153|NCT00436670|Experimental|AMG 317 150 mg|75 subjects
3301154|NCT00436657|Experimental|Surgery + CHPP of Escalating Cisplatin|Abdominal Surgery + CHPP of Escalating Cisplatin (Starting dose of 100 mg/m^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.)
3301155|NCT00436644|Experimental|Lapatinib + Topotecan|Assess biological effects of topotecan and lapatinib in patients with epithelial ovarian cancer and primary peritoneal carcinoma.
3301156|NCT00436631|Experimental|diet|
3301157|NCT00436618|Experimental|Relapsed aggressive non-Hodgkin lymphoma|Study 1. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
3301158|NCT00436618|Experimental|Relapsed indolent non-Hodgkin lymphoma|Study 2. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
3301159|NCT00436618|Experimental|Uncommon lymphomas|Study 3. Includes Hodgkin's lymphomas. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
3301160|NCT00436605|Experimental|Treatment (kinase inhibitor therapy)|Patients receive oral dasatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3301161|NCT00436592|Experimental|1|
3301162|NCT00436579|Experimental|Arm I (higher-dose enzyme inhibitor therapy)|Patients receive higher-dose oral sorafenib tosylate twice daily on days 15-36.
3301163|NCT00436579|Active Comparator|Arm II (standard-dose enzyme inhibitor therapy)|Patients receive standard-dose oral sorafenib tosylate three times daily on days 15-36.
3301164|NCT00436579|Active Comparator|Arm III (standard-dose enzyme inhibitor therapy)|Patients receive standard-dose oral sorafenib tosylate twice daily on days 15-36. (closed to accrual as of 4/29/2009)
3301165|NCT00436553|Experimental|Verteporfin With Standard Fluence Rate Plus Ranibizumab|Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin photodynamic therapy (PDT) with standard fluence (SF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.
3301166|NCT00436553|Active Comparator|Ranibizumab Monotherapy|Patients received monthly ranibizumab injections for 12 months and thereafter as needed based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. Retreatments were determined based on study specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA).
3301167|NCT00436553|Experimental|Verteporfin With Reduced Fluence Rate Plus Ranibizumab|Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT with reduced fluence (RF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.
3301168|NCT00436540|Active Comparator|1|clobetasol propionate (Clobex®) spray
3301169|NCT00436540|Active Comparator|2|clobetasol propionate (Olux®) foam
3301170|NCT00436527|Other|1|
3301171|NCT00436501|Experimental|Treatment (VEGF Trap, Docetaxel)|"Phase I (closed to accrual as of 3/14/2008): Patients receive VEGF Trap IV over 1 hour on day 1 of course 1. Patients then receive VEGF Trap IV over 1 hour and docetaxel IV over 1 hour on day 1 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of VEGF Trap until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 or 6 patients experience dose-limiting toxicity."
3301172|NCT00436501|Experimental|Phase II Treatment (VEGF Trap, Docetaxel)|Phase II (opened to accrual as of 5/9/2008): Patients receive VEGF Trap at the MTD determined in phase I and docetaxel as in phase I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3301173|NCT00436475|Other|1|Vitamin D3 2,000 IU daily plus Calcium Carbonate 400 mg twice daily
3301174|NCT00436475|Other|2|Vitamin D3 2,000 IU daily plus Calcium-Placebo twice daily
3301175|NCT00436475|Other|3|Vitamin D3-Placebo plus Calcium Carbonate 400 mg twice daily
3301176|NCT00436475|Other|4|Vitamin D3-Placebo plus Calcium-Placebo
3301177|NCT00436436|Experimental|O6-benzylguanine & Temozolomide in Glioblastoma|Patients receive O6-benzylguanine intravenous over 1 hour and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3301178|NCT00436423|Experimental|1|Gemcitabine with TS-1
3301179|NCT00436371|Experimental|1|Amisulpride 400-800mg per day on a twice-a-day regimen
3301180|NCT00436358||Group A|IS case deemed children
3301181|NCT00436358||Group B|LRTI-related post-neonatal deaths deemed Children
3301182|NCT00436358||Group C|A random sample of children from an annual birth cohort within the electronic IMSS dataset
3301183|NCT00436358||Group D|All children from a single annual birth cohort with IS identified in their electronic IMSS data
3301184|NCT00436358||Group E|A sample of children from the electronic IMSS dataset selected to match the selected IS cases on age, gender, and hospital of birth.
3301185|NCT00436345|Experimental|Remifentanil|remifentanil
3301186|NCT00436345|Active Comparator|Propofol|Propofol infusion
3301187|NCT00436332|Experimental|Erlotinib and Bevacizumab|
3301188|NCT00436319|No Intervention|1|In the control group (group 1) the initiation of the ovarian stimulation will be realized according to the typical long luteal protocol, two weeks after the initiation of the GnRH agonist administration.
3301189|NCT00436319|Other|2|In the study group (group 2) the initiation of the ovarian stimulation will be effectuated on the second day of the menstrual period.
3301190|NCT00436306|Experimental|Individualized Intervention: stage-matched/tailored counseling|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
3301191|NCT00436306|Placebo Comparator|Control: Enhanced usual care counseling|The Enhanced Usual Care arm was the control group. It provided computer-based information regarding contraceptive methods, but was not individualized or tailored to the participant stage of change.
3301192|NCT00436293|Experimental|1|Neo-adjuvant Taxotere followed by cisplatin and radiotherapy
3301193|NCT00436293|Active Comparator|2|Cisplatin and radiotherapy alone without neo-adjuvant chemotherapy
3301194|NCT00436280|Experimental|A|
3301195|NCT00436254|Experimental|Arm I|Patients receive pNGVL3-hICD vaccine admixed with GM-CSF intradermally once a month for 3 months in the absence of disease progression or unacceptable toxicity.
3301196|NCT00436241|Experimental|1|
3301197|NCT00436215|Experimental|BAY 43-9006 + Bevacizumab|BAY 43-9006 (sorafenib) + Bevacizumab
3301198|NCT00436176|Experimental|1|Intervention clinicians receive monthly performance reports, cultural competency training, and health navigation training
3301199|NCT00436176|No Intervention|2|Control clinicians function within the context of the generic chronic care model.
3301200|NCT00436163|Experimental|Peginterferon Alfa-2a|Participants received peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once per week for 48 weeks.
3301201|NCT00436150|Experimental|A|Participants will receive interpersonal therapy-based treatment
3301202|NCT00436150|Active Comparator|B|Participants will receive standard care
3301203|NCT00436137|Experimental|1|Patients will receive a mailing recommending colonoscopy, followed by a telephone outreach
3301204|NCT00436098|Experimental|1|physical training
3301205|NCT00436098|No Intervention|2|
3301206|NCT00436046|Active Comparator|Group 1: 0.6 ml of IVV|30 subjects to receive 0.6 ml of inactivated influenza virus vaccine (IVV).
3301207|NCT00436046|Experimental|Group 3: 0.7 ml of IVV + 10M units of IFN|30 subjects to receive 0.7 ml of IVV containing 10M units of interferon (IFN).
3301208|NCT00436046|Experimental|Group 2: 0.6 ml of IVV + 1M unit of IFN|30 subjects to receive 0.6 ml of IVV containing 1M units of interferon (IFN).
3301209|NCT00436033|Placebo Comparator|Placebo|
3301210|NCT00436033|Experimental|Minalcipran|
3301211|NCT00436020|Active Comparator|1|Active
3301212|NCT00436020|Placebo Comparator|2|Sham TMS
3301267|NCT00435331|Experimental|1|Open Label
3301268|NCT00435292|Experimental|flavocoxid 250 mg|flavonoid mixture
3301272|NCT00435279|Experimental|Placebo|
3301213|NCT00436007|Experimental|GSK 257049 1 Group|"Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib, Polio Sabin™ and GSK 257049 vaccines at Months 0, 1 and 2, and a single dose of Rouvax™ and Stamaril™ vaccines at Month 7.~The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. The Stamaril™ vaccine was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania."
3301214|NCT00436007|Experimental|GSK 257049 2 Group|Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib and Polio Sabin™ at Months 0, 1 and 2, 3 doses of GSK 257049 vaccine at Months 0, 1 and 7, and a single dose of Rouvax™ and Stamaril™ at Month 7. The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. Stamaril™ was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania.
3301215|NCT00436007|Active Comparator|Tritanrix™ HepB/Hiberix™ Group|Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib and Polio Sabin™ at Months 0, 1 and 2, and a single dose of Rouvax™ and Stamaril™ at Month 7. The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. The Stamaril™ vaccine was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania.
3301216|NCT00435994|Other|Infants with viral lower respiratory infections|Infants between the ages of 2-24 month, with viral lower respiratory infection defined as first episode of wheezing and shortness of breath preceded by an upper respiratory tract infection, including hospitalized infants
3301217|NCT00435994|Other|Healthy Control|Healthy infants between the ages of 2-24 month
3301218|NCT00435994|Other|Bronchiolitis-Nasal wash only|Infants 2 months to 24 months who were diagnosed with bronchiolitis received nasal wash only
3301219|NCT00435942|Experimental|1|Endovascular Treatment arm to be implanted with Relay device
3301220|NCT00435942|Active Comparator|2|Surgical Control, underwent open repair
3301221|NCT00435929|Experimental|1|
3301222|NCT00435929|Experimental|2|
3301223|NCT00435916|Experimental|1|
3301224|NCT00435890|No Intervention|1|No triage liaison physician
3301225|NCT00435864|Other|allogeneic donor from a file|
3301226|NCT00435864|Other|Registry geno-identical donor family|
3301227|NCT00435864|Other|transplantation of HSCs derived from placental blood|
3301228|NCT00435825|Experimental|peginterferon alfa-2a 90 μg_24 Weeks|Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.
3301229|NCT00435825|Experimental|peginterferon alfa-2a 180 μg_24 Weeks|Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.
3301230|NCT00435825|Experimental|peginterferon alfa-2a 90 μg_48 Weeks|Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.
3301231|NCT00435825|Experimental|peginterferon alfa-2a 180 μg_48 Weeks|Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.
3301232|NCT00435812|Experimental|HEPLISAV and/or Placebo|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
3301233|NCT00435812|Active Comparator|Engerix-B|1.0 mL Engerix-B
3301234|NCT00435799|Active Comparator|A|
3301235|NCT00435760|Active Comparator|Tiotropium|1 puff, 1 day treatment
3301236|NCT00435760|Placebo Comparator|Placebo|Tiotropium or Aclidinium Placebo, 1 day treatment
3301237|NCT00435760|Experimental|Aclidinium bromide|200 micrograms, once daily, 1 day treatment
3301238|NCT00435708|No Intervention|1|
3301239|NCT00435708|Experimental|2|5 portions fruit and vegetables/day
3301240|NCT00435695|Active Comparator|GSK163090|one infusion only
3301241|NCT00435643|Active Comparator|A|10 patients with severe OSAS (Apnea Hypopnea Index of more than 30 events per hour of sleep) were treated with nCPAP for three months and all mentioned measurements above were repeated.
3301242|NCT00435630|Other|1|Completing simulator training sessions
3301243|NCT00435617|Experimental|A|Hand Mentor
3301244|NCT00435591|Experimental|Dose Regimen 1|Placebo loading dose + 20mg/day continuous infusion conivaptan per ampoule
3301245|NCT00435591|Experimental|Dose Regimen 2|Conivaptan loading dose (20mg)+ 20mg/day continuous infusion conivaptan per ampoule
3301246|NCT00435591|Experimental|Dose Regimen 3|Placebo loading dose + 20mg/day continuous infusion conivaptan per premix bag
3301247|NCT00435591|Experimental|Dose Regimen 4|Conivaptan loading dose (20mg) + 20mg/day continuous infusion conivaptan per premix bag
3301248|NCT00435539|Experimental|ocriplasmin 75µg single injection|Ocriplasmin 75µg single injection versus sham injection
3301249|NCT00435539|Experimental|ocriplasmin 125µg single injection|Ocriplasmin 125µg single injection versus sham injection
3301250|NCT00435539|Experimental|ocriplasmin 175µg single injection|Ocriplasmin 175µg single injection versus sham injection
3301251|NCT00435539|Experimental|ocriplasmin 125µg multiple injections|Ocriplasmin 125µg multiple injections. Subjects who did not achieve resolution of VMT by the day 28 visit (i.e. non-responders) were given an open-label injection of ocriplasmin 125µg. Subjects who still did not achieve resolution of VMT by the day 56 visit were given a second open-label injection of ocriplasmin 125µg.
3301252|NCT00435539|Sham Comparator|sham injection|sham injection
3301253|NCT00435513||Transsexual group|Female-to-male and male-to-female transsexuals
3301254|NCT00435513||Controls|Healthy blood donors
3301255|NCT00435487|Experimental|A|
3301256|NCT00435487|Active Comparator|B|
3301257|NCT00435474|Active Comparator|1|Silver product
3301258|NCT00435474|Experimental|2|Honey product
3301259|NCT00435409|Experimental|A|
3301260|NCT00435409|Active Comparator|B|
3301261|NCT00435396|Experimental|Group A|
3301277|NCT00435227|Placebo Comparator|2|Placebo
3301278|NCT00435188|Experimental|Arm 1|Behavioral: Multi-component physical activity counseling program A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
3301279|NCT00435188|No Intervention|Arm 2|Usual care
3301280|NCT00435162|Experimental|Low Dose|
3301281|NCT00435162|Experimental|Medium Dose|
3301282|NCT00435162|Experimental|High Dose|
3301283|NCT00435149|Active Comparator|1|
3301284|NCT00435149|Active Comparator|2|
3301285|NCT00435123|Active Comparator|A|Patients are randomly assigned to receive either Active Comparator (ProStat 64) or placebo for the first 3 months. At the end of this, all patients receive open label ProStat64.
3301286|NCT00435123|Placebo Comparator|B|Patients are randomly assigned to Placebo Comparator or Active Comparator (ProStat 64). At the end of 3 months, all patients receive active ProStat 64
3301287|NCT00435084|Experimental|Single-arm mono therapy|APO866 will be administered by civ infusion at 0.126 mg/m2/hr for 4 consecutive days (96 hours). This constitutes 1 cycle.
3301288|NCT00435071|Active Comparator|1|
3301289|NCT00435071|Active Comparator|2|
3301290|NCT00435045|Active Comparator|atorvastatin arm|atorvastatin + placebo
3301291|NCT00435045|Experimental|Lovaza arm|Lovaza + atorvastatin
3301292|NCT00435032|Active Comparator|1|Early appendectomy
3301293|NCT00435032|Active Comparator|2|Interval appendectomy
3301294|NCT00435019|Experimental|insulin detemir|insulin detemir + insulin aspart
3301295|NCT00435019|Experimental|NPH insulin|NPH insulin + insulin aspart
3301296|NCT00434993|Active Comparator|Albuterol Sulfate|
3301297|NCT00434993|Placebo Comparator|Placebo|
3301298|NCT00434980|Experimental|Treatment|Participant and family take part in FCA treatment program.
3301299|NCT00434967|No Intervention|4|Placebo
3301300|NCT00434967|Active Comparator|2|Candesartan cilexetil
3301301|NCT00434967|Active Comparator|3|Hydrochlorothiazide (HCT)
3301302|NCT00434967|Experimental|1|Candesartan cilexetil + Hydrochlorothiazide Combination
3301303|NCT00434954|Experimental|Exenatide Twice Daily (BID)|
3301304|NCT00434954|Active Comparator|Premixed Insulin Aspart Twice Daily (BID)|
3301305|NCT00434941|Experimental|Radiotherapy + Capecitabine|Radiotherapy (for 25 days; Dose: 50 Gy) + Capecitabine (for 35 days; Dose: 825 mg/m2 twice per day p.o.)
3301306|NCT00434889||1|Memory problems
3301307|NCT00434889||2|No memory problems
3301308|NCT00434876|Experimental|1|Quetiapine XR
3301309|NCT00434876|Placebo Comparator|2|Placebo
3301310|NCT00434850|Experimental|Allogeneic Pancreatic Islet Cells|Participants in this study can receive up to three separate islet transplants. They will begin receiving antithymocyte globulin (ATG) and sirolimus 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant. Participants will continue taking sirolimus for the duration of the study. On the day of transplant, participants will receive DSG and etanercept, in addition to ATG and sirolimus. The DSG infusion will be administered over 3 hours and will immediately precede the islet transplant. Participants will continue receiving daily 3-hour infusions of DSG through Day 6 post-transplant. Etanercept will also be administered on Days 3, 7, and 10 post-transplant. Tacrolimus will be administered on Day 1 post-transplant and continued throughout the study.
3301311|NCT00434837|Experimental|Low-tension|Patients recruited to study the initial graft tension during ACL reconstruction surgery who were randomized to the Low-tension group will receive the low-tension treatment with initial graft tension set so that the anterior-posterior (A-P) displacement of the reconstructed knee is equal to that of the uninjured knee.
3301312|NCT00434837|Experimental|High-tension|Patients recruited to study the initial graft tension during ACL reconstruction surgery who were randomized to the High-tension group will receive the high-tension treatment with the initial graft tension set to reduce A-P displacement by 2 millimeters relative to that of the uninjured knee.
3301313|NCT00434837|No Intervention|Uninjured Control Group|Uninjured age, sex, and race matched control group
3301314|NCT00434824|Active Comparator|Arm 1|Oral testosterone undecanoate (Andriol)
3301315|NCT00434824|Placebo Comparator|Arm 2|Placebo
3301316|NCT00434811|Experimental|Islet Transplantation|Participants will receive up to three separate islet transplants and a regimen of immunosuppressive medications consisting of antithymocyte globulin (ATG), sirolimus, and low-dose tacrolimus.
3301317|NCT00434759|Active Comparator|SCP|SCP is a stepped-care program with a self-help module with minimal therapist contact (8 sessions) as first step, followed by therapist-guided intervention depending on status of remission (8 sessions up to a maximum of 16 sessions).
3301318|NCT00434759|Active Comparator|ST|A standard therapy which means a therapist-guided intervention with 16 sessions face-to-face therapy.
3301319|NCT00434655|Active Comparator|1 LAP BAND|
3301320|NCT00434655|Experimental|2 Sleeve gastrectomy|
3301321|NCT00434642|Experimental|Carboplatin and gemcitabine + bevacizumab|Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.
3301322|NCT00434642|Active Comparator|Carboplatin and gemcitabine + placebo|Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.
3301323|NCT00434616|Placebo Comparator|1|saline injections
3301324|NCT00434616|Active Comparator|2|autologous bone marrow transplantation into the ischemic leg
3301325|NCT00434590|Experimental|Full Dose Myfortic® and Reduced Dose Neoral®|The administration of gradual dose increased to reach 1440 mg/day (V4) of enteric-coated mycophenolate sodium (Myfortic®, EC-MPS) with simultaneous dose reduction of micro emulsion cyclosporine (Neoral®, CsA-ME) given to maintenance kidney transplant patients previously treated with reduced-dose mycophenolate mofetil (MMF) and standard dose CsA-ME
3301326|NCT00434590|Active Comparator|Standard Dose of Myfortic® and Standard Dose of CsA-ME|Patients received unchanged dose of Myfortic® (equimolar to the prior established dose MMF) and unchanged standard dose of CsA-ME.
3301327|NCT00434577|Active Comparator|Group A|Modified formulation of GSK1437173A vaccine (1st dose) followed by placebo (2nd dose).
3301328|NCT00434577|Experimental|Group B|Two doses of GSK1437173A low dose.
3301329|NCT00434577|Experimental|Group C|Two doses of GSK1437173A medium dose.
3301330|NCT00434577|Experimental|Group D|Two doses of GSK1437173A high dose.
3301331|NCT00434577|Placebo Comparator|Group E|Placebo (1st dose) followed by GSK1437173A high dose (2nd dose).
3301332|NCT00434551||1|Patients with suspected Crohn's disease
3301333|NCT00434525|Experimental|1 Sleeve gastrectomy with omentectomy|
3301334|NCT00434525|Active Comparator|2 Sleeve gastrectomy|
3301335|NCT00434512|Experimental|SB732461 adjuvanted_LD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, received two doses of the adjuvanted low-antigen dose [LD] SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
3301336|NCT00434512|Experimental|SB732461 adjuvanted_MD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, received two doses of the adjuvanted middle-antigen dose [MD] SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
3301337|NCT00434512|Experimental|SB732461 adjuvanted_HD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, received two doses of the adjuvanted high-antigen dose [HD] SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
3301338|NCT00434512|Experimental|SB732461 non-adjuvanted_LD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, received two doses of the non-adjuvanted low-antigen dose [LD] SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
3301339|NCT00434512|Experimental|SB732461 non-adjuvanted_MD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, received two doses of the non-adjuvanted middle-antigen dose [MD] SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
3301340|NCT00434512|Experimental|SB732461 non-adjuvanted_HD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, received two doses of the non-adjuvanted high-antigen dose [HD] SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
3301341|NCT00434499|Active Comparator|placebo first|placebo first then crossover to EGCG
3301342|NCT00434499|Active Comparator|EGCG first|EGCG first then crossover to placebo
3301343|NCT00434473|Placebo Comparator|Placebo|
3301344|NCT00434473|Experimental|A-001|
3301345|NCT00434460||1|Patients receiving invasive mechanical ventilation > 48 hours.
3301346|NCT00434447|Experimental|Zoledronic Acid|ZOL446
3301347|NCT00434434|Experimental|1|
3301348|NCT00434434|Experimental|2|
3301349|NCT00434434|Placebo Comparator|3|
3301350|NCT00434421|Experimental|German Cockroach Allergen Dosing Group|Glycerinated German Cockroach Allergenic Extract
3301351|NCT00434408|Experimental|1|4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth
3301352|NCT00434408|Experimental|2|4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth
3301353|NCT00434408|Active Comparator|3|dry cord care
3301354|NCT00434356|Experimental|1|
3301355|NCT00434356|Placebo Comparator|2|
3301356|NCT00434330|Experimental|Cohort 1, Q4W, SC, No Transition|
3301357|NCT00434330|Experimental|Cohort 2, Q4W, IV, No Transition|
3301358|NCT00434330|Experimental|Cohort 3, Q4W, SC, Transition|
3301359|NCT00434330|Experimental|Cohort 4, Q4W, IV, Transition|
3301360|NCT00434330|Experimental|Cohort 5, Q4W, SC, Transition|
3301361|NCT00434330|Experimental|Cohort 6, Q4W, IV, Transition|
3301362|NCT00434317|Experimental|ZOL446|
3301363|NCT00434304|Experimental|Ropinirole PR/XR|
3301364|NCT00434278|Placebo Comparator|Placebo|
3301365|NCT00434278|Experimental|Dornase alfa|
3301366|NCT00434252|Placebo Comparator|Carboplatin+Paclitaxel+Placebo|
3301367|NCT00434252|Experimental|Carboplatin+Paclitaxel+Bevacizumab|
3301368|NCT00434239|Experimental|Treatment: Lenalidomide and Ancestim|Drug: Lenalidomide + Ancestim Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
3301369|NCT00434226|Experimental|Bevacizumab + Carboplatin/Paclitaxel + Sunitinib|
3301370|NCT00434226|Placebo Comparator|Bevacizumab + Carboplatin/Paclitaxel|
3301371|NCT00434213|Experimental|Methylphenidate Transdermal System|To characterize the dermal reactions seen with the use of DAYTRANA
3301372|NCT00434174|Experimental|everolimus + Pemetrexed - daily|Daily treatment
3301373|NCT00434174|Experimental|everolimus + Pemetrexed - weekly|Weekly treatment
3301374|NCT00434161|Active Comparator|Palifermin before only|Subjects received palifermin before-high dose chemotherapy (total 3 doses) and matched placebo after-high dose chemotherapy (total 3 doses)
3301375|NCT00434161|Placebo Comparator|Placebo (suger pill)|Subjects received matched placebo before- and after-high dose chemotherapy
3301376|NCT00434161|Active Comparator|Palifermin before and after|Subjects received palifermin before- and after-high dose chemotherapy (total of 6 doses)
3301422|NCT00433641|Placebo Comparator|1|placebo tablet
3301423|NCT00433641|Experimental|2|sibutramine
3301424|NCT00433641|Experimental|3|sibutramine
3301425|NCT00433615|Experimental|1|
3301426|NCT00433615|Experimental|2|
3301427|NCT00433589|Active Comparator|Arm I (anthracycline-based)|"FEC 100~Canadian CEF~CAF~FAC~E-CMF"
3301377|NCT00434148|Experimental|Pasireotide 600 ug|At randomization, participants received 600 ug subcutaneously (sc) twice daily (bid). Participants continued at this dose until month 6 if their month 3 mean urinary free cortisol (mUFC) was <= 2 x the upper limit of normal (ULN) and the mUFC was below or equal to their baseline mUFC. Participants not meeting the mUFC criteria at month 3 were unblinded and required to increase their dose to 900ug bid on an open label basis. Participants had the option to continue in the extension phase as long as they did not meet any discontinuation criteria or until pasireotide was available commercially in their country.
3301378|NCT00434148|Experimental|Pasireotide 900 ug|At randomization, participants received 900 ug subcutaneously (sc) twice daily (bid). Participants continued at this dose until month 6 if their month 3 mean urinary free cortisol (mUFC) was <= 2 x the upper limit of normal (ULN) and the mUFC was below or equal to their baseline mUFC. Participants not meeting the mUFC criteria at month 3 were unblinded and required to increase their dose to 1200 ug bid on an open label basis. Participants had the option to continue in the extension phase as long as they did not meet any discontinuation criteria or until pasireotide was available commercially in their country.
3301379|NCT00434135|Experimental|A|Gemcitabine 1,250 mg/sqm days 1 and 8 + Alimta 500 mg/sqm day 8, every 3 weeks
3301380|NCT00434135|Active Comparator|B|Paclitaxel 120 mg/sqm days 1 and 8 + Gemcitabine 1,000 mg/sqm days 1 and 8, every 3 weeks
3301381|NCT00434122|Experimental|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
3301382|NCT00434122|Placebo Comparator|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
3301383|NCT00434109|Experimental|Sunitinib Malate and Hepatic Artery Embolizations|Sunitinib Malate and Selective Hepatic Artery Embolizations: Sunitinib malate (Sutent) at a dose of 37.5mg. 1-3 selective hepatic artery embolizations.
3301384|NCT00434096|Experimental|1|
3301385|NCT00434096|Placebo Comparator|2|
3301386|NCT00434057|Other|Biopsied Pigmented Skin Lesions|Pigmented skin lesions for which clinical management was prospectively determined to be biopsy of the lesion in toto
3301387|NCT00434018|Other|Wheelchair Skills Training Program|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs. The WSP is a set of assessment and training protocols related to wheelchair skills. The WSP includes the Wheelchair Skills Test (WST), the Wheelchair Skills Training Program (WSTP) and related materials.
3301388|NCT00434018|Other|Basic Health Education|Basic health educational training sessions: Five sessions are held with subjects to provide them additional information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
3301389|NCT00434005|Experimental|Diesel Exhaust|
3301390|NCT00434005|Sham Comparator|Filtered Air|
3301391|NCT00433992||ABC/3TC|HIV-infected subjects were given Abacavir-Lamuvidine
3301392|NCT00433992||TDF/FTC|HIV-infected patients were given tenofovir DF-emtricitabine
3301393|NCT00433966|Active Comparator|Pharmacology Arm|"To establish the safety and efficacy of the use of bivalirudin in patients with acute myocardial infarction undergoing a primary angioplasty strategy by showing that compared to unfractionated heparin plus routine use of GP IIb/IIIa inhibitors, bivalirudin (with use of GP IIb/IIIa inhibitors reserved for angioplasty complications) results in:~reduced rates of major bleeding events at 30 days~similar rates of major adverse ischemic cardiac events at 30 days~reduced rates of the composite of major adverse ischemic cardiac events + major bleeding at 30 days."
3301394|NCT00433966|Active Comparator|Stent Arm|"To establish the safety and efficacy of the paclitaxel-eluting TAXUS™ stent by showing that compared to an otherwise identical bare metal EXPRESS2™ stent, the TAXUS™ stent results in:~reduced rates of target lesion revascularization for ischemia at 1 year~similar rates of death, reinfarction, stroke or stent thrombosis at 1 year~lower rates of analysis segment binary angiographic restenosis at 13 months"
3301395|NCT00433940||Infantile Hemangioma Patients|Infants with infantile hemangioma being treated clinically with oral prednisolone sodium phosphate suspensions.
3301396|NCT00433927|Active Comparator|Arm A|FOLFIRI plus Cetuximab
3301397|NCT00433927|Active Comparator|Arm B|FOLFIRI plus Bevacizumab
3301398|NCT00433914|Experimental|rMenB|6-8 months-old infants received 3 doses of rMenB vaccine without OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
3301399|NCT00433914|Experimental|rMenB+OMV|6-8 months-old infants received 3 doses of rMenB vaccine with OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
3301400|NCT00433888|Experimental|1|
3301401|NCT00433888|Experimental|2|
3301402|NCT00433849|Experimental|1|
3301403|NCT00433849|Experimental|2|
3301404|NCT00433836|Experimental|Valsartan 80 mg|
3301405|NCT00433836|Experimental|Valsartan 160 mg|
3301406|NCT00433836|Experimental|Valsartan 320 mg|
3301407|NCT00433836|Active Comparator|Enalapril 10 mg|
3301408|NCT00433836|Active Comparator|Enalapril 20 mg|
3301409|NCT00433836|Active Comparator|Enalapril 40 mg|
3301410|NCT00433797|Experimental|1|Tomato
3301411|NCT00433797|Experimental|2|Multi-diet
3301412|NCT00433797|Active Comparator|3|Control
3301413|NCT00433771|Experimental|WallFlex Biliary Fully Covered stent|Single arm, biliary stenting, using WallFlex Biliary Fully Covered stent
3301414|NCT00433745|Experimental|WT1 Peptide Vaccine|WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
3301415|NCT00433719|Experimental|1|Combivir, efavirenz for 12 months
3301416|NCT00433719|Placebo Comparator|2|Placebo for 2 months followed by Combivir and efavirenz for 10 months
3301417|NCT00433706|Experimental|Control position by 3DOBI daily|
3301418|NCT00433706|Active Comparator|Standard imaging|
3301419|NCT00433693|Experimental|1|
3301420|NCT00433654|Active Comparator|MRI group|The MRI group underwent a one-hour MRI scan at the 9-12 weeks post-implant follow-up.
3301421|NCT00433654|Other|Control group|The control group waited for one hour (no MRI) at the 9-12 weeks post-implant follow-up.
3301584|NCT00432055|Experimental|I|Botox
3301428|NCT00433589|Experimental|Arm II (docetaxel and capecitabine)|"Docetaxel~Capecitabine"
3301429|NCT00433576|Experimental|Treatment (resveratrol, colorectomy)|"STAGE I: Patients undergo an colorectal endoscopy. Patients whose biopsies confirm colorectal adenocarcinoma histology and require surgical resection continue on study stage 2.~STAGE II: Patients receive oral resveratrol on days 1-8. Patients undergo colorectomy on day 9. A tumor biopsy is performed during endoscopy and colorectomy for research purposes."
3301430|NCT00433563|Experimental|Once daily radiotherapy|Once daily radiotherapy
3301431|NCT00433563|Active Comparator|Twice daily radiotherapy|Twice daily radiotherapy
3301432|NCT00433550|Experimental|Group 1 (6/6 UGT1A1 genotype)|Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 2-15
3301433|NCT00433550|Experimental|Group 2 (6/7 UGT1A1 genotype)|Patients receive irinotecan hydrochloride as in group 1. They also receive oxaliplatin and capecitabine as in group 1 but at lower doses.
3301434|NCT00433550|Experimental|Group 3 (7/7 UGT1A1 genotype)|Patients receive irinotecan hydrochloride, oxaliplatin, and capecitabine as in group 1 but at lower doses.
3301435|NCT00433537|Experimental|VcR-CVAD induction followed by maintenance rituximab|"VcR-CVAD induction: Patients receive VcR-CVAD comprising bortezomib IV over 3-5 seconds on days 1 and 4; rituximab IV over 3-4 hours on day 1; doxorubicin hydrochloride IV over 48 hours on days 1 and 2; cyclophosphamide IV over 3 hours every 12 hours on days 1-3; vincristine IV over 3-5 seconds on day 3; and dexamethasone IV or orally once daily on days 1-4. Patients also receive filgrastim (G-CSF) subcutaneously (SC) or IV once daily beginning on day 5 or 6 and continuing until blood counts recover OR pegfilgrastim SC on day 5 or 6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Maintenance rituximab: Beginning 4-8 weeks after completion of induction therapy, patients receive rituximab IV over 3-4 hours once weekly for 4 weeks. Treatment repeats every 6 months for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3301436|NCT00433537|Experimental|VcR-CVAD induction followed by ASCT|"VcR-CVAD induction: Patients receive VcR-CVAD comprising bortezomib IV over 3-5 seconds on days 1 and 4; rituximab IV over 3-4 hours on day 1; doxorubicin hydrochloride IV over 48 hours on days 1 and 2; cyclophosphamide IV over 3 hours every 12 hours on days 1-3; vincristine IV over 3-5 seconds on day 3; and dexamethasone IV or orally once daily on days 1-4. Patients also receive filgrastim (G-CSF) SC or IV once daily beginning on day 5 or 6 and continuing until blood counts recover OR pegfilgrastim SC on day 5 or 6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~ASCT: After completion of induction therapy, patients who are eligible may have the option to receive consolidation therapy for autologous stem cell transplantation (off-study). These patients undergo stem cell harvest during courses 4, 5, or 6 of induction therapy."
3301437|NCT00433511|Active Comparator|Arm I (chemotherapy, placebo)|Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV over 20-30 minutes, and placebo IV over 30-90 minutes on day 1. Treatment repeats every 2 or 3 weeks for 4 courses. Beginning 3 weeks later, patients then receive paclitaxel IV over 1 hour on days 1, 8, and 15 and placebo IV over 30-90 minutes on day 1. Treatment with paclitaxel and placebo repeats every 3 weeks for 4 courses.
3301438|NCT00433511|Experimental|Arm II (chemotherapy, bevacizumab)|Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 2 or 3 weeks for 4 courses. Beginning 3 weeks later, patients then receive paclitaxel as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment with paclitaxel and bevacizumab repeats every 3 weeks for 4 courses.
3301439|NCT00433511|Experimental|Arm III (chemotherapy, bevacizumab monotherapy)|Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I and bevacizumab as in arm II. Treatment repeats every 3 weeks for 4 courses. Beginning 3 weeks later, patients then receive paclitaxel as in arm I and bevacizumab as in arm II. Treatment with paclitaxel and bevacizumab repeats every 3 weeks for 4 courses. Beginning 2 months later, patients then receive bevacizumab IV over 30-90 minutes on day 1. Treatment with bevacizumab alone repeats every 3 weeks for 10 courses.
3301440|NCT00433498|Experimental|Carboplatin/cisplatin and Etoposide with Pravastatin|
3301441|NCT00433498|Placebo Comparator|Carboplatin/cisplatin and Etoposide with Placebo|
3301442|NCT00433472|Other|MRI -|"MRI scan to be complete to look at RSR13 on measurement of T2 and T2* on MRI~Procedure/surgery magnetic resonance imaging (MRI)"
3301443|NCT00433459|Active Comparator|COPP|procarbazine-containing consolidation chemotherapy arm
3301444|NCT00433459|Experimental|COPDAC|procarbazine-free consolidation chemotherapy arm
3301445|NCT00433446|Experimental|CNTO 328|
3301446|NCT00433433|Active Comparator|Favorable - Standard - any PET outcome|ABVDx3 cycles + Involved node RT (IN-RT) 30 Gy (+boost of 6Gy to residual lesions); FDG-PET after two cycles of ABVD for comparison with the experimental arm will be performed but no treatment adaptation will take place.
3301447|NCT00433433|Experimental|Favorable - Experimental - PET negative|"ABVDx2 cycles; then FDG-PET evaluation:~PET negative: ABVDx2 without further RT (total of 4 cycles!)"
3301448|NCT00433433|Experimental|Favorable - Experimental - PET positive|"ABVDx2 cycles; then FDG-PET evaluation:~PET positive: presumed poor-risk: switch to escalated BEACOPPx2 + INRT30Gy (+boost 6Gy to residual lesions)."
3301449|NCT00433433|Active Comparator|Unfavorable - Standard - Any PET outcome|ABVDx4 cycles + IN-RT 30Gy (+boost 6Gy to residual lesions). FDG-PET after two cycles of ABVD for comparison with the experimental arm will be performed but no treatment adaptation will take place.
3301450|NCT00433433|Experimental|Unfavorable - Experimental - PET negative|"ABVDx2 cycles; then FDG-PET evaluation:~PET negative: ABVDx 4 cycles, without RT (total of 6 cycles)"
3301451|NCT00433433|Experimental|Unfavorable - Experimental - PET positive|"ABVDx2 cycles; then FDG-PET evaluation:~PET positive: presumed poor-risk: switch to escalated BEACOPPx2 + INRT 30Gy (+boost 6Gy to residual lesions)."
3301452|NCT00433407|Experimental|trastuzumab|blood sample collected on different days from patients receiving trastuzumab
3301453|NCT00433394|Experimental|Stratum 1: No Consent for personal identification|Data to be collected for this stratum include histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries.
3301585|NCT00432055|Placebo Comparator|II|
3301875|NCT00428870|Experimental|Arthroscopic acromioplasty|Arthroscopic acromioplasty
3301454|NCT00433394|Experimental|Stratum 2: Consent for personal identification - No Contact|Data will be collected for this study include:child's name, parent's name, address, telephone number, child's date of birth, race, ethnicity, histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries. No contact for future to ask me to consider taking part in Research Network approved studies
3301455|NCT00433394|Experimental|Stratum 3: Consent for personal identification - Contact|Data will be collected for this study include:child's name, parent's name, address, telephone number, child's date of birth, race, ethnicity, histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries Someone from the Childhood Cancer Research Network may contact me in the future to ask me to consider taking part in Research Network approved studies
3301456|NCT00433381|Experimental|Arm I (bevacizumab and temozolomide)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral temozolomide once daily on days 1-21.
3301457|NCT00433381|Experimental|Arm II (bevacizumab and irinotecan hydrochloride)|Patients receive bevacizumab IV as in Arm I followed by irinotecan hydrochloride IV over 90 minutes on days 1 and 15.
3301458|NCT00433342|Experimental|I|Flucloxacillin
3301459|NCT00433342|No Intervention|II|
3301460|NCT00433329|Experimental|Bosentan|Oral bosentan 62.5 mg twice daily (BID) first 4 weeks, followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated, with the addition of sildenafil 20 mg thrice daily (TID) in patients who do not reach the 6-MWT distance threshold at Week 16
3301461|NCT00433316|Experimental|study|Receiving 10ml of 1% ropivacaine
3301462|NCT00433316|Placebo Comparator|Control|Receiving 10ml of saline
3301463|NCT00433290|Experimental|A|
3301464|NCT00433290|Placebo Comparator|B|
3301465|NCT00433212|Active Comparator|A|Non-invasive respiratory support via nasal intermittent positive pressure ventilation
3301466|NCT00433212|Active Comparator|B|Non-invasive respiratory support via nasal Continuous Positive Airway Pressure
3301467|NCT00433199|Placebo Comparator|Placebo|Placebo
3301468|NCT00433199|Experimental|T-Gel 1.62%|Testosterone (T) gel 1.62%
3301469|NCT00433186|Experimental|A|Mycophenolate
3301470|NCT00433173|Placebo Comparator|1|1) Group 1: Placebo
3301471|NCT00433173|Active Comparator|2|2) Group 2: Depot GnRH agonist (Zoladex) + Testosterone + placebo
3301472|NCT00433173|Active Comparator|3|3) Group 3: (Zoladex + Testosterone + aromatase inhibitor (anastrozole)
3301473|NCT00433160|Experimental|Teriparatide|20 micrograms for 104 weeks
3301474|NCT00433160|Placebo Comparator|Placebo|Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks
3301475|NCT00433147|Experimental|Afegostat tartrate 25 milligrams (mg) once per day|Afegostat tartrate was administered orally during the 4-week treatment period.
3301476|NCT00433147|Experimental|Afegostat tartrate 150 mg once per day|Afegostat tartrate was administered orally once per day during the 4-week treatment period.
3301477|NCT00433147|Experimental|Afegostat tartrate 150 mg once every four days|Afegostat tartrate was administered orally once every 4 days during the 4-week treatment period.
3301478|NCT00433147|Experimental|Afegostat tartrate 150 mg once every seven days|Afegostat tartrate was administered orally once every 7 days during the 4-week treatment period.
3301479|NCT00433121|Experimental|A|Discontinuation of neuroleptic or anti depressants
3301480|NCT00433069|Experimental|Intervention|Pioglitazone 15 mg QD + pegylated interferon Alfa-2a 180 μg QW + ribavirin 1000-1200 mg QD for 12 weeks, to be continued to a total of 48 weeks in case of complete early virological response, defined as undetectable serum HCV RNA after 12 weeks of triple therapy
3301481|NCT00433056|Experimental|1|STI
3301482|NCT00433056|Active Comparator|2|stable HAART, Any registered regimen containing NRTIs (AZT or D4T or 3TC or TDF or DDI), NNRTIs (EFV or NVP) or PIs (RTV-boosted ATV; IDV; LPV, fosAPV, SQV; unboosted ATV or NFV)is allowed according to international guidelines
3301483|NCT00433043|Active Comparator|1|CRT and b-blocker uptitration to target dose
3301484|NCT00433043|Active Comparator|2|CRT and continuation of entry b-blocker dose to 6 month evaluation
3301485|NCT00433017|Experimental|Verteporfin + Ranibizumab|Verteporfin (6 mg/m^2) photodynamic therapy (PDT) and ranibizumab (0.5 mg). Patients received three consecutive monthly ranibizumab injections starting on Day 1, and then as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).
3301486|NCT00433017|Active Comparator|Ranibizumab Monotherapy|Patients received three consecutive monthly ranibizumab injections starting on Day 1 and then as needed from Month 3 based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).
3301487|NCT00433004|No Intervention|1|No advance supply of emergency contraception
3301488|NCT00433004|Active Comparator|2|Advance supply of emergency contraception is given
3301489|NCT00432991|Placebo Comparator|Saline Placebo|Drug: Saline Placebo 0.5 mL, IM (in the muscle), one time
3301490|NCT00432991|Experimental|IM Ephedrine|Drug: Ephedrine [Synonyms: Ephedra, Ephedrinum] 25 mg, IM (in the muscle), one time
3301491|NCT00432965|Experimental|VAC Therapy|Treatment of Diabetic Foot Ulcers with VAC Therapy
3301492|NCT00432965|Active Comparator|Moist Wound Therapy|Moist Wound Therapy (standard of care)
3301870|NCT00428935|Experimental|Low Dose|Low dose cohort - 2.0E10 vg/kg
3301493|NCT00432926|Experimental|1|Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
3301494|NCT00432926|Experimental|2|Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
3301495|NCT00432926|Active Comparator|3|An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
3301496|NCT00432913|Active Comparator|1g EPA per day|
3301497|NCT00432913|Active Comparator|2g EPA per day|
3301498|NCT00432913|Placebo Comparator|Placebo|
3301499|NCT00432900|Experimental|Patient|Multiple Sclerosis Patients
3301500|NCT00432900|Active Comparator|Healthy Volunteer|Healthy Volunteers
3301501|NCT00432874|Experimental|1|"Anterior stromal hydration (Wong method)"
3301502|NCT00432874|Active Comparator|2|Traditional lateral wound hydration
3301503|NCT00432861|Active Comparator|1|Pancrecarb(R) MS-16 Capsules
3301504|NCT00432861|Placebo Comparator|2|
3301505|NCT00432835|Active Comparator|Gastric Stimulation Days1-4/Sham5-8|The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days
3301506|NCT00432835|Active Comparator|Sham1-4/Gastric Stimulation Days5-8|The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.
3301507|NCT00432809|No Intervention|Medical therapy|Intensive medical therapy for diabetes
3301508|NCT00432809|Active Comparator|Gastric Bypass|Procedure/Surgery: Bariatric surgery laparoscipic Roux-en-Y Gastric Bypass (RYGB) plus intensive medical therapy
3301509|NCT00432809|Active Comparator|Sleeve Gastrectomy|Procedure/Surgery: Bariatric surgery - laparoscopic sleeve gastrectomy plus intensive medical therapy
3301510|NCT00432796|Active Comparator|1|"patients are randomized post-operative to receive either active treatment or placebo.~Active treatment is Dalteparin injectable. Patients randomized to active treatment will receive Dalteparin 5,000 iu or 200 iu/kg once daily depending on the type of surgery they have had."
3301511|NCT00432796|Experimental|2|patients will be randomized post-operative to receive either active treatment or placebo
3301512|NCT00432744|Active Comparator|CoenzymeQ10|CoenzymeQ10: patients will be randomized to receive CoenzymeQ10 in either Period #1 (Months 0-6) or Period #2 (Months 7-12).
3301513|NCT00432744|Placebo Comparator|Placebo|Placebo: patients will be randomized to receive placebo either ion Period #1 (months 1-6) or Period #2 (months 7-12).
3301514|NCT00432679|Experimental|arm 1|study drug
3301515|NCT00432666|Experimental|IncobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection"
3301516|NCT00432666|Placebo Comparator|Placebo|
3301517|NCT00432640|Experimental|1|Endoscopic ultrasound staging
3301518|NCT00432640|Active Comparator|2|Surgical staging
3301519|NCT00432627|Experimental|Mild hepatic impaired|
3301520|NCT00432627|Experimental|Moderate hepatic impaired|
3301521|NCT00432627|Experimental|Severe hepatic impaired|
3301522|NCT00432627|Experimental|Healthy volunteers|Controlled group
3301523|NCT00432614|Experimental|Group 1|SR58611A 350mg twice daily with escitalopram 10mg once daily
3301524|NCT00432614|Active Comparator|Group 2|placebo with escitalopram 10mg once daily
3301525|NCT00432614|Placebo Comparator|Group 3|placebo
3301526|NCT00432601|Experimental|Arm 1|Patients will receive Michigan Cancer Consortium decision aid.
3301527|NCT00432601|Active Comparator|Arm 2|Patients will receive National Comprehensive Cancer Network decision aid.
3301528|NCT00432575|Placebo Comparator|1|
3301529|NCT00432575|Active Comparator|2|surinabant 2,5 mg/day
3301530|NCT00432575|Active Comparator|3|surinabant 5 mg/day
3301531|NCT00432575|Active Comparator|4|surinabant 10 mg/day
3301532|NCT00432510|Experimental|Single Dose|1,000 Units (U) of C1INH-nf administered intravenously (IV).
3301533|NCT00432510|Experimental|First Dose Followed by Second Dose|1,000 U of C1INH-nf administered IV, followed by a second 1,000 U dose 60 minutes later.
3301534|NCT00432484|Placebo Comparator|1|Placebo with Lingzhi(Granoderma Lucidum) and Sen Miao San
3301535|NCT00432471|Experimental|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
3301536|NCT00432458|Experimental|Arm I: Thal/ZLD|Thalidomide (Thal) + Zolendronic acid (ZLD)
3301537|NCT00432458|Experimental|Arm II: ZLD|Zoledronic acid (ZLD)
3301538|NCT00432445|Experimental|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks. Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
3301539|NCT00432432|Placebo Comparator|2|placebo with infliximab
3301540|NCT00432406|Active Comparator|1|infliximab
3301541|NCT00432406|Active Comparator|2|etanercept
3301871|NCT00428935|Experimental|High Dose|High Dose - 1.0E11 vg/kg
3301542|NCT00432380|Experimental|PLACEBO-ROTARIX-ROTARIX GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 2 oral doses of Rotarix™ liquid vaccine at Month 1 and Month 2, and a single oral dose of placebo at Day 0. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
3301543|NCT00432380|Experimental|ROTARIX-PLACEBO-ROTARIX GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 2 oral doses of Rotarix™ liquid vaccine at Day 0 and Month 2, and a single oral dose of placebo at Month 1. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
3301544|NCT00432380|Placebo Comparator|PLACEBO GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 3 oral doses of placebo at Day 0, Month 1 and Month 2. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
3301545|NCT00432367|Experimental|1|OptiMAL® antigen screening and treatment with SP plus LLIN
3301546|NCT00432367|Experimental|2|OptiMAL® antigen screening and treatment with AQ+AS plus LLIN
3301547|NCT00432367|Active Comparator|3|SP-IPTp plus LLIN
3301548|NCT00432341|Experimental|BOTOX®|Botulinum toxin type A (BOTOX®)
3301549|NCT00432341|Active Comparator|Dysport®|Botulinum toxin type A (Dysport®)
3301550|NCT00432315|Experimental|1|Resectable NSCLC
3301551|NCT00432315|Experimental|2|Unresectable NSCSC
3301552|NCT00432302|Experimental|Sagopilone|Subjects received 28 mg ZK 219477, containing 14 kBq/7.8 µg [14C]-ZK 219477 in the first infusion (Treatment course 1) followed by subsequent infusions (Treatment courses 2 to n [till disease progression]) of 16 mg/m2 ZK 219477 without radioactive label. Interval between the treatments was at least 21 days.
3301553|NCT00432276|Experimental|Alogliptin 25 mg + Pioglitazone 30 mg add-on to Metformin|Alogliptin 25 mg, tablets, orally, once daily; pioglitazone 30 mg, tablets, orally, once daily; and the maximum tolerated dose of metformin, tablets, orally, for up to 52 weeks.
3301554|NCT00432276|Active Comparator|Pioglitazone 45 mg add-on to Metformin|Alogliptin placebo-matching tablets, orally, once daily; pioglitazone 45 mg, tablets, orally, once daily; and the maximum tolerated dose of metformin, tablets, orally, for up to 52 weeks.
3301555|NCT00432237|Experimental|MK0974 50 mg|MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack
3301556|NCT00432237|Experimental|MK0974 150 mg|MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack
3301557|NCT00432237|Experimental|MK0974 300 mg|MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack
3301558|NCT00432237|Placebo Comparator|Placebo|Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack
3301559|NCT00432211|Placebo Comparator|1|Complete Scar Excision
3301560|NCT00432211|Placebo Comparator|2|Staged Excision of scar
3301561|NCT00432198|Experimental|1|Oral
3301562|NCT00432198|Experimental|2|Oral
3301563|NCT00432198|Placebo Comparator|3|Oral
3301564|NCT00432185|Active Comparator|1|One day treatment
3301565|NCT00432185|Active Comparator|2|Two day treatment
3301566|NCT00432172|Active Comparator|Group 1 (Luminal A) QT|Standard treatment
3301567|NCT00432172|Experimental|Group 1 (Luminal A) HT|Selective treatment
3301568|NCT00432172|Active Comparator|Group 2 (Basal) Standard treatment|Standard treatment
3301569|NCT00432172|Experimental|Group 2 (Basal) Selective treatment|
3301570|NCT00432159|Experimental|1-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at a single level of the cervical spine, C3 to C7 inclusive.
3301571|NCT00432159|Active Comparator|1-level ACDF with plate|Anterior Cervical Discectomy and Fusion with plate (ACDF with plate) using allograft spacer and the SLIM-LOC™ Anterior Cervical Plate System at a single level of the cervical spine, C3 to C7 inclusive.
3301572|NCT00432159|Experimental|2-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at two adjacent levels of the cervical spine, C3 to C7 inclusive.
3301573|NCT00432159|Active Comparator|2-level ACDF|Anterior Cervical Discectomy and Fusion with plate (ACDF with plate) using allograft spacer and the SLIM-LOC™ Anterior Cervical Plate System at two adjacent levels of the cervical spine, C3 to C7 inclusive.
3301574|NCT00432159|Experimental|Training: 1 & 2-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at a single level or multiple levels of the cervical spine, C3 to C7 inclusive. Training cohort.
3301575|NCT00432133|Experimental|1|Protection motivation theory-based tailored intervention to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
3301576|NCT00432133|Experimental|2|Environmental access and awareness intervention to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
3301577|NCT00432133|Experimental|3|Combination intervention combining protection motivation and environmental intervention components to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
3301578|NCT00432120|Active Comparator|A|"nonselective - clopidogrel 600 mg >6 hours before coronary angiography;"
3301579|NCT00432120|Active Comparator|B|"selective - clopidogrel 600 mg in the cath-lab after coronary angiography, only in case of percutaneous coronary intervention"
3301580|NCT00432107|Experimental|2-stage mono therapy of APO866|The treatment period consists of 3 consecutive 28 day cycles. Each cycle starts with a 4 day continuous infusion of the study medication followed by a 24 day break
3301581|NCT00432094|Experimental|2 Transplants|Patients with Germ Cell Tumors (GCT) treated with a second tandem autologous stem cell transplant (AuSCT) with non-cross-resistant conditioning regimens.
3301582|NCT00432094|Active Comparator|1 Transplant|Patients with Germ cell tumors who receive one transplant only.
3301583|NCT00432068|Experimental|Octreotide pamoate|
3301586|NCT00432042|Experimental|ProQuad® + Infanrix® hexa|Pediatric (12 to 23 months of age) participants received ProQuad® and Infanrix® hexa (booster dose) concomitantly on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
3301587|NCT00432042|Active Comparator|ProQuad®|Pediatric (12 to 23 months of age) participants received ProQuad® on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
3301588|NCT00432042|Active Comparator|Infanrix® hexa|Pediatric (12 to 23 months of age) participants received Infanrix® hexa (booster dose) on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
3301589|NCT00432029|Other|1|IDDM
3301590|NCT00432029|Other|2|Hypercholesterolemia and/or Hypertension
3301591|NCT00432029|Other|3|age/sex matched healthy control subjects
3301592|NCT00431964|Active Comparator|Active|azithromycin 250 mg tablets
3301593|NCT00431964|Placebo Comparator|Placebo|placebo tablets (matched to active drug in appearance)
3301594|NCT00431951|Experimental|ST-246|250 mg, 400 mg or 800 mg of ST-246 given once daily for 21 days
3301595|NCT00431951|Placebo Comparator|placebo|Placebo to match ST-246
3301596|NCT00431912|Experimental|Single-arm, trinomial 2-stage design|
3301597|NCT00431873|Experimental|1|MGCD0103 administered orally three times per week.
3301598|NCT00431847||Group 1|Soldiers with one or more severely injured, mangled or amputated limbs from the Iraq/Afghanistan war aggressively treated with regional anesthesia for pain control.
3301599|NCT00431847||Group 2|Soldiers with one or more severely injured, mangled or amputated limbs from the Iraq/Afghanistan war receiving standard treatment for pain control.
3301600|NCT00431821|Other|Arm 1|Home-based exercise prescriptions with weekly motivational telephone calls.
3301601|NCT00431821|Other|Arm 2|Stroke education program with matched attention phone calls
3301602|NCT00431808|Experimental|I, AMA1 vaccine|20 volunteers will receive 3 doses of the vaccine
3301603|NCT00431795|Experimental|1|Epi
3301604|NCT00431795|Experimental|2|Cael
3301605|NCT00431769|Experimental|Bortezomib|
3301606|NCT00431704|Experimental|vinorelbine, carboplatin, trastuzumab|
3301607|NCT00431691|Active Comparator|1|
3301608|NCT00431691|Placebo Comparator|2|
3301609|NCT00431678|Experimental|Arm 1|
3301610|NCT00431678|Active Comparator|Arm 2|
3301611|NCT00431639|Active Comparator|Treatment|The treatment condition will consist of a 20-minute visit by a therapy dog and its owner. Therapy dogowners will be instructed to limit conversation with the patient to topics of the therapy dog, thepatients pets, and pets in general.
3301612|NCT00431639|Active Comparator|Comparison|For the comparison condition, subjects will be asked to choose one of four topics that will be determined thatday with a recreational therapist for 20 minutes.
3301613|NCT00431626|Experimental|Laser TURP with dutasteride|Prior to and after standard treatment with laser TURP, dutasteride is applied to each patient
3301614|NCT00431626|Placebo Comparator|Laser TURP with placebo|Prior to and after standard treatment with laser TURP, placebo is applied to each patient
3301615|NCT00431613|Experimental|1|DG -> RT
3301616|NCT00431613|Experimental|2|DG -> RT -> DCarbo
3301617|NCT00431600|Experimental|1|12 healthy male subjects
3301618|NCT00431561|Experimental|AP 12009 10 µM|
3301619|NCT00431561|Experimental|AP 12009 80 µM|
3301620|NCT00431561|Active Comparator|Chemotherapy|
3301621|NCT00431496|Experimental|Cinacalcet|Cinacalcet was administered orally at a starting dose of 30 mg/day for 23 weeks. Possible sequential doses during the study were 30, 60, 90, 120, and 180 mg. Dose escalation of cinacalcet occurred if the intact parathyroid hormone (iPTH) level from the previous study visit was > 31.8 pmol/L (300 pg/mL) unless the participant had either reached the maximum dose (180 mg/day), the serum corrected total calcium was < 2.1 mmol/L (8.4 mg/dL), or the participant experienced an adverse event that precluded a dose increase.
3301622|NCT00431483|Other|Pharmaceutical counseling|
3301623|NCT00431457|Active Comparator|Implantation intracranial electrode with immediate stimulation|
3301624|NCT00431457|Placebo Comparator|Implantation intracranial electrode without stimulation|
3301625|NCT00431457|Active Comparator|Resective surgery: amygddohyppocampertomy|
3301626|NCT00431444|Active Comparator|Zoledronic Acid|Zoledronic acid 5 mg (single i.v. infusion) + daily oral placebo for 6 months (zoledronic acid group)
3301627|NCT00431444|Active Comparator|Raloxifene|Placebo (single i.v. infusion) + oral raloxifene 60 mg/day for 6 months (raloxifene group)
3301628|NCT00431431|Experimental|1|tibolone
3301629|NCT00431431|Active Comparator|2|raloxifene
3301630|NCT00431418|Active Comparator|1|Sildenafil oral solution.
3301631|NCT00431418|Placebo Comparator|2|Placebo oral solution.
3301632|NCT00431353|Experimental|1|
3301633|NCT00431353|Experimental|2|
3301634|NCT00431301||Case|PSP Cases
3301635|NCT00431301||Control|Healthy Controls
3301636|NCT00431275|Experimental|Commercial Formulation|Commercial Formulation
3301637|NCT00431275|Experimental|Current Formulation|Current Formulation
3301638|NCT00431249|Other|one|
3301639|NCT00431223|Active Comparator|Active Group|7 patients were assigned to Cognitive Remediation Therapy..
3301640|NCT00431223|No Intervention|Control Group|4 patients were assigned to Control group or no cognitive remediation therapy.
3301641|NCT00431210|Experimental|Biological/Vaccine|Epstein-Barr virus-specific adoptive T-cells immunotherapy given intravenously on Days 1 and 14
3301642|NCT00431184|Active Comparator|Pentazocine then Lorazepam|In the first leg of the study, pentazocine will be given to subjects randomly assigned to this group. On Day 1, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later. On Day 2, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two hours later.
3301643|NCT00431184|Active Comparator|Lorazepam then Pentazocine|In the first leg of the study, lorazepam will be given to subjects randomly assigned to this group. On Day 3, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two hours later. On Day 2, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later.
3301644|NCT00431158|Active Comparator|1|ARDSnet Protocol
3301645|NCT00431158|Active Comparator|2|OLA Protocol
3301646|NCT00431132|Experimental|Vagifem® 10 mcg|One 10 mcg (microgram) vaginal tablet of intravaginal estradiol (Vagifem®) once daily for two weeks followed by one 10 mcg vaginal tablet twice weekly for 50 weeks
3301647|NCT00431106|Active Comparator|1|Vinorelbine/Gemcitabine (VG)
3301648|NCT00431106|Active Comparator|2|Capecitabine (Cap)
3301649|NCT00431093|Experimental|1|tibolone
3301650|NCT00431093|Active Comparator|2|low-dose estradiol/noresterone
3301651|NCT00431080|Experimental|1|FEC -> TXT
3301652|NCT00431080|Experimental|2|FEC -> TXL
3301653|NCT00431067|Experimental|BIBW 2992|BIBW 2992 (Afatinib) once daily until progression
3301654|NCT00431054|Experimental|Perifosine + Docetaxel|
3301655|NCT00431041|Experimental|Solifenacin|Solifenacin succinate: 5 mg tablets, taken orally, once daily
3301656|NCT00431041|Active Comparator|Oxybutynin IR|Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day
3301657|NCT00431028|No Intervention|colirio|prednisolone 1% eye drops + ciprofloxacin 0,3% eye drops
3301658|NCT00430989|Other|N2O|N2O Group (FiO2 0.3)
3301659|NCT00430989|Other|2|N2O free group (FiO2 0.3)
3301660|NCT00430963|Placebo Comparator|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
3301661|NCT00430963|Experimental|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
3301662|NCT00430950|Experimental|1|olmesartan medoximil (OM)/ hydrochlorothiazide (HCTZ) 40/25 mg + OM/HCTZ 20/25 mg matching placebo
3301663|NCT00430950|Experimental|2|olmesartan medoximil (OM)/ hydrochlorothiazide (HCTZ)20/25 mg + OM/HCTZ 40/25 matching placebo
3301664|NCT00430937|Experimental|Daptomycin|4 mg/kg intravenous (i.v.) once daily
3301665|NCT00430937|Active Comparator|Pooled Comparator|
3301666|NCT00430924|Active Comparator|1|Eplerenone
3301667|NCT00430924|No Intervention|2|Control
3301668|NCT00430898|Placebo Comparator|1. Placebo|Placebo to mimic 40 mg of Simulect
3301669|NCT00430898|Experimental|2. 40 mg Simulect|40 mg of Simulect
3301670|NCT00430885|Placebo Comparator|Saline|
3301671|NCT00430885|Experimental|Octagam (IVIG)|Octagam (IVIg) is intravenous immunglobulin
3301672|NCT00430872||MDASI-Spine Tumor Module Survey|M. D. Anderson Symptom Inventory-Spine (survey) of patients with a tumor on the spine or spinal cord.
3301673|NCT00430859|Experimental|1|BIAP
3301674|NCT00430859|Placebo Comparator|Placebo|Placebo, saline
3301675|NCT00430846|Experimental|A|
3301676|NCT00430820||1|30 patients
3301677|NCT00430820||2|30 patients
3301678|NCT00430820||3|30 patients
3301679|NCT00430781|Experimental|Combination arm|Pazopanib plus lapatinib
3301680|NCT00430781|Active Comparator|Lapatinib monotherapy|Lapatinib
3301681|NCT00430781|Active Comparator|Pazopanib monotherapy|Pazopanib
3301682|NCT00430768|Experimental|Group 1 Low Dose|"rAAV1-CB-hAAT 6.9 x10e12 vector genomes (vg) administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
3301683|NCT00430768|Experimental|Group 2 Middle Dose|"rAAV1-CB-hAAT 2.2 x 10e13 vg administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
3301684|NCT00430768|Experimental|Group 3 High Dose|"rAAV1-CB-hAAT 6.0 x10e13 vg administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
3301685|NCT00430755|Other|Inpatients of hospital|"All patients who were admitted to the departments of nephrology or cardiology in a tertiary hospital in Germany.~The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition [history-taking] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
3301686|NCT00430742|Experimental|1|Arm 1: MK0364 0.5 mg capsule once daily
3301687|NCT00430742|Experimental|2|Arm 2: MK0364 1 mg capsule once daily
3301688|NCT00430742|Experimental|3|Arm 3: MK0364 2 mg capsule once daily
3301689|NCT00430742|Placebo Comparator|4|Arm 4: Pbo capsule once daily
3301690|NCT00430716|Experimental|Sildenafil High dose|
3301691|NCT00430716|Experimental|Sildenafil Low dose|
3301692|NCT00430716|Experimental|Sildenafil medium dose|
3301693|NCT00430716|Experimental|Sildenafil - Open label Phase|Open label extension from week 12 to week 24.
3301694|NCT00430703|Experimental|1|Patients with severe traumatic brain injury
3301695|NCT00430703|Experimental|2|Healthy volunteers
3301696|NCT00430690||1|Cocaine dependent subjects
3301697|NCT00430690||2|Healthy controls
3301698|NCT00430690||3|Siblings of cocaine dependent subjects
3301699|NCT00430677|Experimental|Abatacept 30 mg/kg+Corticosteroids+MMF|Short-term Period
3301700|NCT00430677|Experimental|Abatacept 10 mg/kg+Corticosteroids+MMF|Short-term Period
3301701|NCT00430677|Experimental|Placebo+Corticosteroids+MMF|Short-term Period
3301702|NCT00430677|Experimental|Abatacept 10mg/kg|Long-term Extension Period
3301703|NCT00430651|Experimental|1|Docetaxel + Carboplatin
3301704|NCT00430651|Experimental|2|Docetaxel
3301705|NCT00430638|Experimental|Treatment|Olmesartan medoxomil, plus hydrochlorothiazide, if necessary
3301706|NCT00430638|Placebo Comparator|Placebo|Placebo tablets were taken once daily for 12 weeks
3302212|NCT00424762|Placebo Comparator|Placebo|blinded matching placebo treatment
3301707|NCT00430625|Experimental|VPRIV®-45 U/kg, IV, every other week|VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB)
3301708|NCT00430625|Experimental|VPRIV®-60 U/kg, IV, every other week|VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase,GA-GCB)
3301709|NCT00430612||1|Non-voluntary registry of consecutive patients diagnosed as having a MI at each study site
3301710|NCT00430586|Experimental|20 U NT 201|
3301711|NCT00430586|Placebo Comparator|Placebo|
3301712|NCT00430586|Experimental|10 U NT 201|
3301713|NCT00430586|Experimental|30 U NT 201|
3301714|NCT00430573|Experimental|DCS-augmented CBT-IC|D-cycloserine-augmented CBT-IC
3301715|NCT00430573|Placebo Comparator|Placebo-augmented CBT-IC|Placebo-augmented CBT-IC
3301716|NCT00430560|Active Comparator|1|work therapy
3301717|NCT00430560|Experimental|2|work therapy plus cognitive remediation
3301718|NCT00430521|Experimental|Group A|Subjects received two doses of vaccine
3301719|NCT00430521|Experimental|Group B|Subjects received two doses of vaccine
3301720|NCT00430521|Experimental|Group C|Subjects received two doses of vaccine
3301721|NCT00430521|Experimental|Group D|Subjects received two doses of vaccine
3301722|NCT00430521|Experimental|Group E|Subjects received three doses of vaccine
3301723|NCT00430521|Experimental|Group F|Subjects received three doses of vaccine
3301724|NCT00430521|Experimental|Group G|Subjects received three doses of vaccine
3301725|NCT00430521|Experimental|Group H|Subjects received three doses of vaccine
3301726|NCT00430508|Experimental|4|olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
3301727|NCT00430508|Experimental|1|olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
3301728|NCT00430508|Experimental|3|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
3301729|NCT00430508|Experimental|2|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
3301730|NCT00430495|Experimental|Atacicept 25 mg|
3301731|NCT00430495|Experimental|Atacicept 75 mg|
3301732|NCT00430495|Experimental|Atacicept 150 mg|
3301733|NCT00430495|Placebo Comparator|Placebo|
3301734|NCT00430482|Experimental|1|Cognitive Behavioral Therapy
3301735|NCT00430482|Active Comparator|2|Individual Counseling
3301736|NCT00430456|Other|Arm 1|Higher Intensity, Shorter Duration Treadmill Training
3301737|NCT00430456|Active Comparator|Arm 2|Lower Intensity, Longer Duration Treadmill Training
3301738|NCT00430430|Experimental|High MUFA|high monounsaturated fat background diet to portfolio diet
3301739|NCT00430430|Active Comparator|Low MUFA|low monounsaturated fat background diet to portfolio diet
3301740|NCT00430417||3 groups|Group 1: post-partum breastfeeding women
3301741|NCT00430417||Group 2|Group 2: post-partum bottlefeeding women
3301742|NCT00430417||Group 3|Group 3: normal non-pregnant controls who are age and race-matched to Group 1
3301743|NCT00430404|No Intervention|Usual care (controlled group)|Usual care for management of depression
3301744|NCT00430404|Experimental|collaborative care (Intervention)|Collaborative care for management of depression for intervention group. We provided multidisciplinary groups of care from psychiatrist, psychologist, social counselor, general practitioners and case managers for intervention group.
3301745|NCT00430391|Experimental|DVD patient high risk|Patients with a diagnosis of schizophrenia/schizoaffective disorder randomized to the DVD, high risk version
3301746|NCT00430391|Experimental|DVD patient low risk|Patient with a diagnosis of schizophrenia/schizoaffective disorder randomized to DVD consent, low risk version
3301747|NCT00430391|Experimental|DVD normal high risk|Participants with no psychiatric diagnosis randomized to DVD consent, high risk version
3301748|NCT00430391|Experimental|DVD normal low risk|Participants with no psychiatric diagnosis randomized to DVD consent, low risk version
3301749|NCT00430391|Experimental|Routine control high risk|Participants with no psychiatric diagnosis randomized to routine consent, high risk version
3301750|NCT00430391|Experimental|Routine control low risk|Participants with no psychiatric diagnosis randomized to routine consent, low risk version
3301751|NCT00430391|Experimental|Routine patient low risk|Participants with schizophrenia/schizoaffective disorder randomized to routine consent, low risk version
3301752|NCT00430391|Experimental|Routine patient high risk|Participants with schizophrenia/schizoaffective disorder randomized to routine consent, high risk version
3301753|NCT00430378|Experimental|Acupuncture|Acupuncture Before the Radiation Treatment
3301754|NCT00430378|Experimental|Standard Care|Standard Care Without Acupuncture
3301755|NCT00430365|Placebo Comparator|placebo group|Administration of oral placebo
3301756|NCT00430365|Experimental|lenalidomide group|Administration of lenalidomide
3301757|NCT00430352|Experimental|1|
3301758|NCT00430313|Experimental|Electro-Stimulation (Active Site)|Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
3301759|NCT00430313|Experimental|Electro-Stimulation (Inactive Site)|"Electro-stimulation at a inactive site on the bottom of the foot (a placebo site)."
3301760|NCT00430300|Experimental|150mcg, 450mcg or 1350mcg|Active treatment given BID via a double pin monodose capsule inhaler device
3301761|NCT00430300|Placebo Comparator|Placebo|Placebo treatment given BID via a single pin monodose inhaler device
3301762|NCT00430287||1: Primary open angle glaucoma|Patients with a form of primary open angle glaucoma
3301763|NCT00430287||2: No known eye disease (controls)|Patients with no known eye disease (controls)
3301764|NCT00430248|Experimental|Febuxostat 40 mg QD|
3301765|NCT00430248|Experimental|Febuxostat 80 mg QD|
3301766|NCT00430248|Active Comparator|Allopurinol 200 mg or 300 mg QD|(dependent on renal function)
3301872|NCT00428922|Experimental|Trastuzumab, Bevacizumab, and Docetaxel|Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M²]
3301873|NCT00428909|Other|Drug-Drug interaction|
3301767|NCT00430183|Experimental|Arm A: docetaxel + LHRH agonist + surgical intervention|"Patients receive six cycles of docetaxel administered every 3 weeks combined with 18-24 weeks of androgen deprivation therapy. During each cycle of chemotherapy, all patients should undergo premedication with dexamethasone 8 mg orally prior to docetaxel. Dexamethasone may also be given intravenously according to institutional guidelines.~Patients will also receive androgen deprivation for 18-24 weeks of an LHRH agonist (eg, leuprolide acetate, goserelin acetate). Additional premedication and antiemetics may be given at the physician's discretion and as defined by the protocol.~Patients will undergo standard surgical intervention. The surgical procedures will be performed within 60 days of the completion of neoadjuvant therapy. Patients are allowed to receive adjuvant external beam radiation at the discretion of the treating physician and as defined per the protocol. It must be initiated within 6 months of the date of surgery."
3301768|NCT00430183|Other|Arm B: surgical intervention|All patients undergo standard surgical intervention. The surgical procedures will be performed within 60 days of randomization. Patients are allowed to receive adjuvant external beam radiation at the discretion of the treating physician and as defined per the protocol. Adjuvant radiation must be initiated within 6 months of the date of surgery.
3301769|NCT00430170|Active Comparator|1|dipyridamol during 7 days and before ischemic exercise caffeine 4mg/kg
3301770|NCT00430170|Placebo Comparator|2|dipyridamol during 7 days and before ischemic exercise placebo
3301771|NCT00430144|Experimental|CKD-602|
3301772|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction Prot III|
3301773|NCT00430118|Experimental|Induction Prot I/Pred - reinduction Prot III|
3301774|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction Prot II|
3301775|NCT00430118|Active Comparator|Induction Prot I/Pred - reinduction Prot II|
3301776|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 2x Prot III|
3301777|NCT00430118|Experimental|Induction Prot I/Pred - reinduction 2x Prot III|
3301778|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 3 HR courses + 3x Prot III|
3301779|NCT00430118|Experimental|Induction Prot I/Pred - reinduction 3 HR courses + 3x Prot III|
3301780|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 6 HR courses + Prot II|
3301781|NCT00430118|Active Comparator|Induction Prot I/Pred - reinduction 6 HR courses + Prot II|
3301782|NCT00430092|Experimental|Difluprednate 0.05% BID|Difluprednate 0.05% 1 drop BID for 14 days
3301783|NCT00430092|Experimental|Difluprednate 0.05% QID|Difluprednate 0.05% 1 drop QID for 14 days
3301784|NCT00430092|Placebo Comparator|Placebo|Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.
3301785|NCT00430079|Experimental|Diagnostic (etanidazole)|Patients receive etanidazole derivative EF5 IV over 1-2½ hours once within 1-2 days before surgical resection or biopsy. Tumor tissue, normal tissue, and/or tumor-infiltrated lymph node samples are collected during surgery and stained for biological markers. Fluorescent immunohistochemistry techniques are used to determine the presence, distribution, and levels of EF5 binding.
3301786|NCT00430066|Experimental|Imatinib Mesylate|400 mg/day by mouth for 6 months (+ 6 months in case of responsiveness)
3301787|NCT00430040|Experimental|carvedilol|carvedilol
3301788|NCT00430040|Active Comparator|lisinopril|lisinopril
3301789|NCT00430027|Experimental|Capecitabine, oxaliplatin, cetuximab, and radiation therapy|Patients enrolled on the trial will receive neoadjuvant combined capecitabine, oxaliplatin, cetuximab, and radiation therapy. This will be followed by surgical resection and adjuvant capecitabine, oxaliplatin, and cetuximab
3301790|NCT00430014|Experimental|Atiprimod|
3301791|NCT00429962|Experimental|A|intravitreal ranibizumab used in combination with verteporfin photodynamic therapy
3301792|NCT00429962|Active Comparator|B|intravitreal ranibizumab
3301793|NCT00429949|Experimental|Dasatinib|"Dasatinib will be administered continuously at an oral dose of 70 mg BID on Days 1-28 of each 28 day cycle.~In patients with stable disease after 8 weeks on therapy the dasatinib will be increased to 100 mg BID on Days 1-28 on each 28 day cycle."
3301794|NCT00429936|Active Comparator|100 mg fenretinide softgel capsules|Three (3) 100-mg fenretinide softgel capsules
3301795|NCT00429936|Active Comparator|Fenretinide and placebo softgel capsules|One (1) 100-mg fenretinide softgel capsule and two (2) placebo softgel capsules
3301796|NCT00429936|Placebo Comparator|Placebo softgel capsules|Three (3) placebo softgel capsules
3301797|NCT00429923|Experimental|Difluprednate 0.05% BID|Difluprednate 0.05% 1 drop BID for 14 days.
3301798|NCT00429923|Experimental|Difluprednate 0.05% QID|Difluprednate 0.05% 1 drop QID for 14 days.
3301799|NCT00429923|Placebo Comparator|Placebo|Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.
3301800|NCT00429871|Experimental|1|DF
3301801|NCT00429871|Experimental|2|DC
3301802|NCT00429806|Placebo Comparator|Placebo|Placebo suppository; once daily for 7 days.
3301803|NCT00429806|Experimental|DHEA 0.50%|DHEA 0.50% (6.5 mg) suppository; once daily for 7 days.
3301804|NCT00429806|Experimental|DHEA 1.0%|DHEA 1.0% (13 mg) suppository; once daily for 7 days.
3301805|NCT00429806|Experimental|DHEA 1.8%|DHEA 1.8% (23.4 mg) suppository; once daily for 7 days.
3301806|NCT00429793|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3301807|NCT00429780|No Intervention|Alum-ALM + BCG|Alum-ALM + BCG
3301808|NCT00429780|No Intervention|Placebo|BCG diluent
3301809|NCT00429754|Other|aprepitant|Aprepitant treatment
3301810|NCT00429715|Experimental|Alum-ALM + BCG|Alum-ALM + BCG
3301811|NCT00429715|Active Comparator|BCG|BCG
3301812|NCT00429715|Placebo Comparator|BCG diluent|Diluent
3301813|NCT00429702|Experimental|Benadryl® Ativan® Decadron® (BAD) Pump|Patients receive ondansetron hydrochloride IV twice daily and saline IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive diphenhydramine hydrochloride, lorazepam, and dexamethasone by continuous infusion pump.
3301814|NCT00429702|Active Comparator|Control Arm Saline|Patients receive ondansetron hydrochloride IV twice daily and dexamethasone IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive saline by continuous infusion pump.
3301815|NCT00429663|Other|IM Nails|Reamed, Interlocking Intramedullary Nail - Randomized treatment
3301816|NCT00429663|Other|Plate Fixation|Locking Periarticular Plate - Randomized Treatment
3301817|NCT00429650|Experimental|1|Increased amount of exercise to maintain weight loss.
3301818|NCT00429650|Experimental|2|Combination of Exercise and Diet to maintain weight loss
3301819|NCT00429650|Active Comparator|3|Use diet alone to maintain weight loss.
3301820|NCT00429585|Other|Randomized Treatment - Nail|Randomized Treatment - Nail
3301821|NCT00429585|Other|Randomized Treatment - Plate|Randomized Treatment - Plate
3301822|NCT00429572|Experimental|Allogeneic Transplantation|Intravenous Fludarabine 30 mg/m^2 daily on days 1-5, and Melphalan 70 mg/m^2 on days 4 and 5 followed by blood stem cell transplant on day 7.
3301823|NCT00429559|Experimental|A|
3301824|NCT00429546|Experimental|Intervention|Participants will receive a cognitive-behavioral intervention designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child
3301825|NCT00429546|Active Comparator|Control|Participants will receive treatment as usual
3301826|NCT00429507|Experimental|Samarium 153-EDTMP + Stem Cell Transplant|Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) by vein On Day 1. If enough study drug goes to bones, will receive a higher dose of 153 Sm-EDTMP, called a therapy dose, 7-14 days after the tracer dose. Stem Cell Transplant on Day 0, about 14-21 days after Samarium 153-EDTMP. Questionnaires taking about 15 minutes to complete.
3301827|NCT00429494|Experimental|Leuprolide Acetate|Leuprolide Acetate 22.5 mg intramuscular (IM) injection 2 months before hematopoietic stem cell transplantation (HSCT) transplant and 3 months post-transplant.
3301828|NCT00429455||Survey Participants|Female patients who had a hematopoietic stem cell transplantation between January 1987 and September 2004 at M. D. Anderson Cancer Center.
3301829|NCT00429442|Active Comparator|1|
3301830|NCT00429442|Placebo Comparator|2|
3301831|NCT00429429|Experimental|Peanut protein solution|Subjects receiving the peanut sublingual peanut protein drops. Sublingual Immunotherapy.
3301832|NCT00429416|Experimental|LLME to Decrease GVHD Following HSC T|To determine if an experimental agent, LLME, can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).
3301833|NCT00429403|Experimental|Goserelin|3.6 mg subcutaneously 1 week before chemotherapy, then once a month until 3 weeks after chemotherapy.
3301834|NCT00429403|No Intervention|No Goserelin|
3301835|NCT00429364|Active Comparator|Atenolol|Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.
3301836|NCT00429364|Active Comparator|Losartan|Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).
3301837|NCT00429338|Experimental|AIR-MRSI|Endorectal MRSI with Air
3301838|NCT00429338|Experimental|PFC-MRSI|Endorectal MRSI with PFC
3301839|NCT00429312|Experimental|Single Arm|Intratumoral injection(s) of Recombinant Vaccinia GM-CSF, JX-594
3301840|NCT00429299|Active Comparator|Arm A|Chemotherapy plus trastuzumab
3301841|NCT00429299|Experimental|Arm B|Chemotherapy plus lapatinib
3301842|NCT00429299|Active Comparator|Arm C|Chemotherapy plus trastuzumab plus lapatinib
3301843|NCT00429273|Active Comparator|Group 1: Guan-Guan+Placebo|weeks 1-4: Guanfacine weeks 5-8: Guanfacine + Placebo
3301844|NCT00429273|Active Comparator|Group 2: Placebo-Placebo+DMPH|weeks 1-4: Placebo weeks 5-8: Placebo+DMPH
3301845|NCT00429273|Experimental|Group 3: Guan-Guan+DMPH (Comb)|weeks 1-4: Guanfacine weeks 5-8: Guanfacine+DMPH
3301846|NCT00429247|Experimental|1|Her
3301847|NCT00429247|No Intervention|2|Follow up
3301848|NCT00429234|Experimental|Dasatinib + Gemcitabine|Dasatinib starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks. Gemcitabine starting dose of 800 mg/m^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
3301849|NCT00429182|Experimental|High-dose chemotherapy|Carboplatin + Cyclophosphamide + Thiotepa
3301850|NCT00429169|Active Comparator|Paroxetine|Participants will receive paroxetine for 8 weeks
3301851|NCT00429169|Active Comparator|Bupropion|Participants will receive bupropion for 8 weeks
3301852|NCT00429156|Active Comparator|1|Home non-invasive ventilation
3301853|NCT00429156|Sham Comparator|2|Home sham non-invasive ventilation with CPAP 5 cm H2O
3301854|NCT00429143|Experimental|Haploidentical Allogeneic Transplantation|Patients undergoing hematopoietic stem cell transplant from a partially matched related donor
3301855|NCT00429117||Survey|Physician members of the International Gynecologic Oncologists Society or the Society of Gynecologic Oncologists.
3301856|NCT00429104|Experimental|HER2+ Metastatic Breast Cancer|Herceptin 4 mg/kg IV Over 90 Minutes + GM-CSF 250 mcg/m^2 subcutaneously
3301857|NCT00429091|Placebo Comparator|1|
3301858|NCT00429091|Experimental|2|
3301859|NCT00429091|Active Comparator|3|
3301860|NCT00429026|Experimental|Fludarabine + Cyclophosphamide with ASCT|ASCT=Allogeneic Hematopoietic Stem Cell Transplantation
3301861|NCT00429026|Experimental|Fludarabine + Melphalan with ASCT|ASCT=Allogeneic Hematopoietic Stem Cell Transplantation
3301862|NCT00429013|No Intervention|2|no medical device
3301863|NCT00429013|Experimental|1|medical device
3301864|NCT00428974|Experimental|1|
3301865|NCT00428974|Experimental|2|
3301866|NCT00428974|Experimental|3|
3301867|NCT00428974|Placebo Comparator|4|
3301868|NCT00428948|Experimental|Tolvaptan|Participants received the highest tolerated split-dose regimen (upon awakening and 9 hours later) of tolvaptan 45/15 mg, 60/30 mg, or 90/30 mg orally for 36 months.
3301869|NCT00428948|Placebo Comparator|Placebo|Participants received placebo (upon awakening and 9 hours later) orally for 36 months.
3301874|NCT00428896|Experimental|1|ZD1839
3301876|NCT00428870|Placebo Comparator|Sham surgery|Shoulder arthroscopy without active treatment and subacromial arthroscopy without bursectomy, decompression or other active interventions
3301877|NCT00428870|Active Comparator|Conservative treatment|Standardized exercise rehabilitation (supervised by physiotherapist)
3301878|NCT00428844|Experimental|Daptomycin 6 mg/kg|Daptomycin (6 mg/kg every 24 hours [q24h]) as a 30 minute intravenous (IV) infusion for 6 weeks (± one week).
3301879|NCT00428844|Experimental|Daptomycin 8 mg/kg|Daptomycin (8 mg/kg q24h) as a 30 minute IV infusion for 6 weeks (± one week).
3301880|NCT00428844|Active Comparator|Comparator|Vancomycin was administered at 1 gram every 12 hours (q12h) as a 60-minute infusion and teicoplanin was administered 6 mg/kg q24h as a 30-minute infusion also for 6 weeks (±1 week). Semi-synthetic penicillin (nafcillin, oxacillin, or flucloxacillin) was administered according to standard of care for 6 weeks (±1 week).
3301881|NCT00428831||1|Patients with respiratory illnesses.
3301882|NCT00428805|Experimental|intervention 1|This transcommunity study has one intervention and one control group. The intervention, described elsewhere has 6 components--classroom curriculum, family component,grocery store component, health care provider component, training for Head Start food service workers,and training for Head Start teachers/aides.
3301883|NCT00428805|No Intervention|control 2|measurement only control arm
3301884|NCT00428792|Experimental|Very light breakfast (VLB) then standard breakfast (SB)|Very light breakfast (VLB) for one week then crossover to standard breakfast (SB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12.
3301885|NCT00428792|Experimental|Standard breakfast (SB) then very light breakfast (VLB)|Standard breakfast (SB) for one week then crossover to very light breakfast (VLB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12.
3301886|NCT00428779|Experimental|1|patients running during 24 hours without sleep
3301887|NCT00428779|Placebo Comparator|2|patients without sleep during 24 hours
3301888|NCT00428727|Experimental|1|Nitric oxide patches
3301889|NCT00428727|Placebo Comparator|2|Placebo patches
3301890|NCT00428714|Experimental|A|
3301891|NCT00428649|Experimental|1|20 µg selenium as selenomethionine
3301892|NCT00428649|Experimental|2|40 µg selenium as selenomethionine
3301893|NCT00428649|Experimental|3|60 µg selenium as selenomethionine
3301894|NCT00428649|Experimental|4|80 µg selenium as selenomethionine
3301895|NCT00428649|Experimental|5|100 µg selenium as selenomethionine
3301896|NCT00428649|Experimental|6|120 µg selenium as selenomethionine
3301897|NCT00428649|Placebo Comparator|7|placebo
3301898|NCT00428610|Experimental|LY573636|LY573636-sodium (LY573636) is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
3301899|NCT00428597|Experimental|A|
3301900|NCT00428597|Placebo Comparator|B|
3301901|NCT00428584|Experimental|1|interferon beta-1a
3301902|NCT00428584|Active Comparator|2|interferon beta-1b
3301903|NCT00428571|Placebo Comparator|Intensive Medical Management|Medical management of obesity including medication optimization and lifestyle and dietary advice.
3301904|NCT00428571|Active Comparator|Laparoscopic Gastric Bypass|
3301905|NCT00428571|Active Comparator|Laparoscopic Adjustable Gastric Band|
3301906|NCT00428558|Active Comparator|2|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
3301907|NCT00428558|Experimental|1|BRAS INDUCTION SEQUENTIAL
3301908|NCT00428545|Experimental|Bevacizumab + Bortezomib|Bevacizumab starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days. Bortezomib starting Dose 0.7 mg/m^2 By Vein On Days 1 and 8 Every 21 Days.
3301909|NCT00428519|Placebo Comparator|1|
3301910|NCT00428519|Active Comparator|2|
3301911|NCT00428519|Active Comparator|3|
3301912|NCT00428480|Experimental|1|Daily reinforcement of walking speed
3301913|NCT00428480|Active Comparator|2|No reinforcement of walking speed
3301914|NCT00428454|Experimental|Zotarolimus eluting stent|Zotarolimus eluting stent
3301915|NCT00428454|Active Comparator|Sirolimus eluting stent|Sirolimus eluting stent
3301916|NCT00428428|Placebo Comparator|1|Saline irrigation
3301917|NCT00428428|Active Comparator|2|ISO irrigation
3301918|NCT00428402||Focus Group|Participant is a 4th-8th grade student in select schools from Bastrop Independent School District (BISD).
3301919|NCT00428389|Experimental|Immediate Switch|Patients randomized to the immediate switch group continued treatment with donepezil through the evening prior to Day 8 of the study. On Day 8, all patients began open-label treatment with 5 cm^2 rivastigmine patch formulation. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm^2 patch and continued on their best tolerated dose for the remainder of the study.
3301920|NCT00428389|Experimental|Delayed Switch|Patients randomized to the delayed switch group were switched to 5 cm^2 rivastigmine patch formulation on Day 8, following a 7-day withdrawal period from donepezil. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm^2 patch and continued on their best tolerated dose for the remainder of the study.
3302213|NCT00424749|Experimental|Rituximab|375 mg/m^2/week for 4 weeks
3301921|NCT00428337|Experimental|1|Participants will receive one injection of DNA vaccine EP-1233 or placebo in each shoulder on Days 0 and 28 and one injection of MVA-mBN32 or placebo in each arm on Days 84 and 168
3301922|NCT00428337|Experimental|2|Participants will receive one injection of DNA vaccine EP-1233 or placebo in each shoulder on Days 0, 28, 84, and 168
3301923|NCT00428337|Experimental|3|Participants will receive one injection of MVA-mBN32 or placebo in each arm on Days 0, 28, 84, and 168
3301924|NCT00428298|Experimental|Active Treatment Valacyclovir|Subjects dispensed 500 mg capsules. Subjects take two 500 mg capsules twice daily for 16 weeks.
3301925|NCT00428298|Placebo Comparator|Placebo Treatment|Subjects dispensed 500 mg capsules. Subjects take two 500 mg capsules twice daily for 16 weeks.
3301926|NCT00428285|Experimental|Single Arm|
3301927|NCT00428272|Experimental|1|Lexatumumab alone dose escalation
3301928|NCT00428272|Experimental|2|Lexatumumab with interferon - dose escalation
3301929|NCT00428272|Other|3|Lexatumumab 10mg/kg with interferon expansion at
3301930|NCT00428246|Active Comparator|1|1 mcg paricalcitol
3301931|NCT00428246|Active Comparator|2|2 mcg paricalcitol
3301932|NCT00428246|Placebo Comparator|3|Placebo
3301933|NCT00428233|No Intervention|Leukemia Cell Harvest|Procedure/Surgery: Leukemia cell harvest Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
3301934|NCT00428220|Experimental|A|"Sunitinib will be administered in a continuous daily dose (oral, once per day). Starting dose will be 37.5 mg daily unless the patient was on a different dose (25 mg or 50 mg daily) on the previous trial. In that case, they will begin treatment on this study at the same dose used at the end of the previous study.~The protocol now allows for patients on dosing regimens other than only continuous dosing (e.g. 4/2, etc.) to be enrolled if eligible."
3301935|NCT00428207|Active Comparator|Insulin Aspart Versus Insulin Lispro|Insulin aspart will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Insulin aspart doses will be adjusted by the principal investigator as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Lispro).
3301936|NCT00428207|Active Comparator|Insulin Lispro Versus Insulin Aspart|Insulin lispro will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Dose will be adjusted as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Aspart).
3301937|NCT00428194|Experimental|Cohort 1|Erlotinib 100 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
3301938|NCT00428194|Experimental|Cohort 2|Erlotinib 125 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
3301939|NCT00428194|Active Comparator|Cohort 3|Erlotinib 150 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
3301940|NCT00428181|Active Comparator|1 Brief Intervention|The primary purpose of the proposed research is to compare the effectiveness of brief intervention, brief intervention plus a booster and treatment as usual for adult patients with an alcohol related injury.
3301941|NCT00428181|Active Comparator|2) Booster|The primary purpose of the proposed research is to compare the effectiveness of brief intervention, brief intervention plus a booster and treatment as usual for adult patients with an alcohol related injury.
3301942|NCT00428168|Experimental|Betahistine 24 mg|
3301943|NCT00428168|Placebo Comparator|Placebo|
3301944|NCT00428142|Experimental|Bortezomib + BCVP-R|BCVP-R - q 21 days x 4 cycles Bortezomib: 1.3 mg/m2 Days 1 & 8 Cyclophosphamide: 750 mg/m2 IV Day 1 Vincristine: 1.4 mg/m2 IV Day 1 (dose capped at 2 mg) Prednisone: 40 mg/m2 po Days 1-5 Rituximab: 375 mg/m2 IV Day 1
3301945|NCT00428129|Experimental|1|
3301946|NCT00428116|No Intervention|Interrupted HAART|After 24 months of treatment with HAART, half the eligible infants will be randomized to interrupted treatment and followed for 18 months.
3301947|NCT00428116|Active Comparator|Continued HAART|After 24 months of treatment with HAART, half the eligible infants will be randomized to continued treatment with HAART for 18 months.
3301948|NCT00428090|Experimental|Rosiglitazone|XR (extended release) oral tablets
3301949|NCT00428090|Other|Placebo|Placebo (Double-Dummy to Match)
3301950|NCT00428051||All eligible patients|
3301951|NCT00428038||1|"Group 1:~Infants born prematurely at a gestational age < 32 weeks with a diagnosis of chronic lung disease. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:~Oxygen requirements~Congenital heart disease"
3301952|NCT00428038||2|"Group 2:~Infants born prematurely at a gestational age < 32 weeks without a diagnosis of chronic lung disease. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:~Oxygen requirements~Congenital heart disease"
3301953|NCT00428038||3|"Group 3:~Infants born full term at a gestational age > 37 weeks. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:~Hospitalization for a respiratory illness~History of wheezing, asthma, or treatment with asthma medications~Congenital heart disease"
3301954|NCT00428025|Placebo Comparator|placebo suppository|
3301955|NCT00428025|Active Comparator|diclofenac suppository|
3301956|NCT00428012|Experimental|QOLT|Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions
3301957|NCT00428012|Active Comparator|ST|Supportive Therapy (ST) 8 weekly individual counseling sessions
3301958|NCT00428012|No Intervention|Standard Care|
3301959|NCT00427999|Experimental|STI571+ pioglitazone+ etoricoxib + dexamethasone + treosulfane|STI571 (imatinib) 400mg po daily + pioglitazone 60mg po daily + etoricoxib 60mg po daily + dexamethasone 1mg po daily + treosulfane 500mg po daily for 24 weeks
3301960|NCT00427973|Experimental|AZD2171|Patients will receive AZD2171 (cediranib maleate) 30mg by mouth once a day. Treatment may continue for as long as benefit is shown. Patients will undergo MRI and CT scan of the liver before beginning treatment, 3 days after the first dose of AZD2171, and after finishing course one. Patients will also undergo blood collection periodically for laboratory studies. Laboratory biomarker analysis, computed tomography, dynamic contrast-enhanced magnetic resonance imaging, and pharmacological study will be performed.
3301961|NCT00427960|Active Comparator|rosuvastatin|rosuvastatin 5 mg
3301962|NCT00427960|Active Comparator|atorvastatin|atorvastatin 10 mg
3301963|NCT00427947|Experimental|1|Continuous sciatic nerve bloc : ropivacaine infusion
3301964|NCT00427947|Placebo Comparator|2|Continuous sciatic nerve bloc : NaCl Infusion
3301965|NCT00427934|Placebo Comparator|2|
3301966|NCT00427934|Experimental|1|This study was divided into two components: safety/pharmacokinetic (PK) and proof-of-concept (POC). In the safety/PK component either 150 mg or 300 mg tablets of maraviroc was administered twice a day (BID) to 16 rheumatoid arthritis subjects for 4 weeks.
3301967|NCT00427921|Experimental|1|Open Label
3301968|NCT00427908|Experimental|Group A|All subjects received GSK Biolgicals' meningococcal vaccine 134612.
3301969|NCT00427908|Active Comparator|Group B|Subjects including and above two years of age received Mencevax™ ACWY, subjects below two years of age received Meningitec™.
3301970|NCT00427895|Experimental|13vPnC Cohort 1, Vaccination 1|Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.
3301971|NCT00427895|Active Comparator|23vPS Cohort 1, Vaccination 1|Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.
3301972|NCT00427895|Experimental|13vPnC Cohort 2, Vaccination 1|Participants aged 50-59 years given a 0.5 mL dose administered on day 1.
3301973|NCT00427895|Experimental|13vPnC Cohort 3, Vaccination 1|Participants aged 18-49 years given a 0.5 mL dose administered on day 1.
3301974|NCT00427895|Experimental|13vPnC Cohort 1, Vaccination 2|Participants aged 60-64 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.
3301975|NCT00427895|Active Comparator|23vPS Cohort 1, Vaccination 2|Participants aged 60-64 years who received 23vPS at vaccination 1 receive a 0.5 mL dose of 23vPS administered 3-4 years after dose 1.
3301976|NCT00427895|Experimental|13vPnC Cohort 2, Vaccination 2|Participants aged 50-59 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.
3301977|NCT00427856|Experimental|Obatoclax mesylate 40mg|40 mg over 3 hrs q/weekly for 12 weeks, 4 weeks combo with rituximab, another 8 weeks single-agent obatoclax
3301978|NCT00427856|Experimental|Obatoclax mesylate 60mg|60 mg obatoclax mesylate over 24 hours, q/weekly for 12 weeks, 4 weeks combo with rituximab, another 8 weeks single-agent obatoclax
3301979|NCT00427843|Experimental|Exercise Home-Based Program|Patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. The exercise program will be performed 3 times per week for 8 weeks.
3301980|NCT00427804|Experimental|Calcitriol|Calcitriol 0.25 mcg orally twice a day for 7 days or calcitriol 0.50 mcg orally twice a day for 7 days.
3301981|NCT00427791|Experimental|Etoposide + Total Body Irradiation + Rituximab|Etoposide 60 mg/kg intravenous (IV) Daily Over 4 Hours for 1 Day + Total Body Irradiation (TBI) 3 Gy Daily for 4 Days + Rituximab 375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks
3301982|NCT00427791|Experimental|Etoposide + Total Body Irradiation|Etoposide 60 mg/kg IV Daily Over 4 Hours for 1 Day + TBI 3 Gy Daily for 4 Days
3301983|NCT00427778|Experimental|Incontinence ring then no intervention|Participants first were fitted with an incontinence ring, which they wore continuously for 4 weeks. The ring wa then removed and a washout period of 2 weeks followed. Then the second 4-week period with no ring was completed.
3301984|NCT00427778|Experimental|No intervention then incontinence ring|Participants spend the first study 4-week period with no intervention. Then, a wasout period of 2 weeks followed. Participants were then fitted with an incontinence ring, which they wore continuously for 4 weeks.
3301985|NCT00427765|Experimental|Busulfan + Melphalan|Busulfan 32 mg/m^2 intravenous (IV) for 1 Day then 130 mg/m^2 IV for 4 Days; and Melphalan 70 mg/m^2 IV for 2 Days
3301986|NCT00427752|Experimental|Whipple|Patients with pancreatic cancer who will proceed to a Whipple procedure.
3301987|NCT00427739||CCT exam|
3301988|NCT00427700|Active Comparator|Clomiphene|Uso of 100mg of clomiphene citrate during days 5-9 of the menstrual cycle
3301989|NCT00427700|Experimental|Raloxifene|Use of 100mg of raloxifene during days 5-9 of the menstrual cycle
3301990|NCT00427674|Experimental|injection of 5 mCi of 123-I mZINT|
3301991|NCT00427661|Other|AHCT in High Risk SCD|Intervention: Busulfan; Fludarabine; cyclosporine A and MMF
3301992|NCT00427648|Active Comparator|1|xylocaine
3301993|NCT00427648|Placebo Comparator|2|normal saline
3301994|NCT00427609|Placebo Comparator|1|
3301995|NCT00427609|Active Comparator|2|
3301996|NCT00427583|Experimental|STI571|
3301997|NCT00427557|Experimental|Cellular Therapy with Cord Blood Cells|Fludarabine 30 mg/m^2 intravenous (IV) for 4 Days + Melphalan 140 mg/m^2 IV for 1 Day + Rituximab 375 mg/m^2 IV once weekly + Cord Blood Transplantation + Stem Cell Transplantation Infusion
3301998|NCT00427492|Active Comparator|Magnesia|Medical laxative
3301999|NCT00427492|Placebo Comparator|Placebo|Placebo
3302000|NCT00427440|Experimental|AMG 102 at 10 mg/kg Dose Level|Up to 40 subjects will be treated at this dose level based upon investigator assessment of responses observed.
3302001|NCT00427440|Experimental|AMG 102 at 20 mg/kg Dose Level|Up to 40 subjects will be treated at this dose level based upon investigator assessment of responses observed.
3302002|NCT00427414|Experimental|liposomal daunorubicin citrate|40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
3302003|NCT00427388|Experimental|Treatment|500 mg of methylprednisolone divided into two intravenous doses of 250 mg each, one during anesthetic induction and the other on CPB initiation
3302214|NCT00424710|Other|Single Arm study|"Single arm study:~Drug: ranibizumab intravitreal injection liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year"
3302004|NCT00427388|Placebo Comparator|Placebo|500 mg of matching placebo (normal saline solution) divided into two intravenous doses of 250 mg each, one during anesthetic induction and the other on CPB initiation
3302005|NCT00427375|Experimental|1|New surgical option in good responders after neoadjuvant treatment for low rectal cancer
3302006|NCT00427375|Active Comparator|2|Standard surgery
3302007|NCT00427349|Experimental|AMG 706+Octreotide|"Patients receive oral AMG 706 and octreotide acetate intramuscularly (IM) once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the morning. AMG 706 was taken daily without breaks in treatment.~One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles."
3302008|NCT00427336|Experimental|Fludarabine + Cyclophosphamide + ATG|Fludarabine 30 mg/m^2/day by vein (IV), Cyclophosphamide IV 300 mg/m^2/day, ATG (Antithymocyte Globulin) IV 3.75 mg/kg/day
3302009|NCT00427310|Experimental|Arm 1: Postoperative 5 FU + sodium heparin|Continuous portal vein infusion with 5 FU 600 mg/m2 + 5000 units sodium heparin per day given for a total of 7 consecutive days.
3302010|NCT00427310|Active Comparator|Arm 2: Postoperative observation|
3302011|NCT00427297|Experimental|NVP-containing|Infants randomized to this arm will receive nevirapine-containing HAART regimen
3302012|NCT00427297|Active Comparator|NVP-sparing|Infants randomized to this arm will receive nevirapine-sparing HAART
3302013|NCT00427219|Placebo Comparator|Placebo run-in phase|Eligible patients entered a placebo run-in phase in which placebo was administered twice over a 2 week period (Day -28 and Day -14) and patients were assessed to establish baseline values approximately 14 days following the second placebo injection
3302014|NCT00427219|Experimental|Ozarelix/Placebo|All patients completing the placebo run in period were randomized to enter the treatment phase of the study and received either placebo or ozarelix on Day 0 and Day 14
3302015|NCT00427206|Active Comparator|1|acetaminophen 4 g/day
3302016|NCT00427206|Placebo Comparator|2|placebo undistinguishable from active drug
3302017|NCT00427193|Experimental|1|25% caloric restriction
3302018|NCT00427193|Active Comparator|2|Ad libitum energy intake
3302019|NCT00427154|Active Comparator|A|
3302020|NCT00427154|Active Comparator|B|
3302021|NCT00427089|Experimental|1|2L gut cleansing solution
3302022|NCT00427089|Active Comparator|2|
3302023|NCT00427076|Experimental|A|Cotrimoxazole
3302024|NCT00427076|Active Comparator|B|Vancomycin
3302025|NCT00427037|Placebo Comparator|Placebo|Placebo
3302026|NCT00427037|Active Comparator|Cholecalciferol|D3
3302027|NCT00427011|Experimental|1|
3302028|NCT00426907|Experimental|1|Full postoperative weightbearing
3302029|NCT00426907|Active Comparator|2|Partial weightbearing 6 weeks postoperative
3302030|NCT00426881|Experimental|1|Twice weekly resistance training for 52 weeks.
3302031|NCT00426881|Experimental|2|Once weekly resistance training for 52 weeks.
3302032|NCT00426881|Experimental|3|Twice weekly balance and tone training for 52 weeks.
3302033|NCT00426868|Experimental|Treatment|
3302034|NCT00426868|Placebo Comparator|Placebo|
3302035|NCT00426855|Experimental|Bendamustine and Bortezomib|Combination Chemotherapy of Bendamustine and Bortezomib as described in the intervention section
3302036|NCT00426842|Experimental|Arm 1|Blood pressure response during HUT following administration of Midodrine Hydrochloride compared with no drug.
3302037|NCT00426829|Experimental|Proton Therapy + Bevacizumab|Proton Therapy + Bevacizumab
3302038|NCT00426816|Experimental|Crossover population|All study population receive placebo and doses of SB-649868 at 10mg, 30mg and 60mg in a crossover desing
3302039|NCT00426777|Active Comparator|risedronate|
3302040|NCT00426777|Placebo Comparator|placebo|
3302041|NCT00426764|Experimental|Romidepsin|Participants received romidepsin 14 mg/m^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.
3302042|NCT00426751|Active Comparator|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
3302043|NCT00426751|Experimental|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mcg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
3302044|NCT00426725|Experimental|A|This group uses the EasyLabour device according to the protocol
3302045|NCT00426725|No Intervention|Control|
3302046|NCT00426712|Experimental|1|Low dose
3302047|NCT00426712|Experimental|2|Middle dose
3302048|NCT00426712|Experimental|3|High dose
3302049|NCT00426712|Active Comparator|4|
3302050|NCT00426660|Experimental|1|
3302051|NCT00426647|Experimental|Buprenorphine|Norspan transdermal patch
3302052|NCT00426647|Active Comparator|Tramadol|Tramadol SR tablets
3302053|NCT00426621|Experimental|1|
3302054|NCT00426621|Placebo Comparator|2|
3302055|NCT00426608|Experimental|Session 1|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 gram per kilogram (g/kg) and Dose 2 of AEBCD sequence. In AEBCD sequence A is placebo, E Alprazolam, B GSK6561679 10 milligram (mg), C GSK6561679 50 mg and D GSK6561679 400 mg. Wash-out period will be of 7 days.
3302056|NCT00426608|Experimental|Session 2|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of BACED sequence. In BACED sequence B is GSK6561679 10 mg, A placebo, C GSK6561679 50 mg, E Alprazolam, and D GSK6561679 400 mg. Wash-out period will be of 7 days.
3302057|NCT00426608|Experimental|Session 3|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of CBEAD sequence. In CBEAD sequence C is GSK6561679 50 mg, B GSK6561679 10 mg, E Alprazolam, A placebo, and D GSK6561679 400 mg. Wash-out period will be of 7 days.
3302058|NCT00426608|Experimental|Session 4|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of ECABD sequence. In ECABD sequence E is Alprazolam, C is GSK6561679 50 mg, A placebo, B GSK6561679 10 mg and D GSK6561679 400 mg. Wash-out period will be of 7 days.
3302059|NCT00426608|Experimental|Session 5|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of GSK561679 400 mg and alprazopam placebo. Wash-out period will be of 7 days.
3302060|NCT00426582|Experimental|Patupilone only|Cycle 1 patupilone alone Cycle 2 and onward patupilone and carboplatin
3302061|NCT00426582|Active Comparator|Carboplatin alone|Cycle 1 Carboplatin alone Cycle 2 and onward patuilone and carboplatin
3302062|NCT00426556|Experimental|Phase I - RAD001 5mg + PT, daily|Daily dosing schedule of EPT = Paclitaxel & Trastuzumab verolimus 5mg plus Paclitaxel plus Trastuzumab.
3302063|NCT00426556|Experimental|Phase I - RAD001 10mg + PT, daily|Daily dosing schedule of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab
3302064|NCT00426556|Experimental|Phase I - RAD001 30mg + PT, weekly|Weekly dosing schedule of Everolimus 30mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab.
3302065|NCT00426556|Experimental|Phase II - RAD001 10mg + PT, daily|Daily dosing schedule of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab
3302066|NCT00426530|Experimental|RAD001 Daily Schedule|5mg or 10mg
3302067|NCT00426530|Experimental|RAD001 Weekly Schedule|30mg
3302068|NCT00426517|Other|Group 3|Sibling Donors for Group 1
3302069|NCT00426517|Other|Group 1|All Sibling BMT
3302070|NCT00426517|Other|Group 2|MUD or Cord Blood Unit BMT
3302071|NCT00426504|Experimental|radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
3302072|NCT00426491|Active Comparator|A|Four 200 ug tablets of Misoprostol
3302073|NCT00426491|Placebo Comparator|B|
3302074|NCT00426439|Experimental|1 Coartem|Treatment of documented malaria in children following the dosages recommended by the manufacturer.
3302075|NCT00426439|Active Comparator|2 Chloroquine|The antimalarial actually used in Guinea-Bissau is the dosage of 50 mg/kg given twice a day for 3 days.
3302076|NCT00426426|Active Comparator|Meta-Cognitive Therapy|first Meta-cognitive therapy then Cognitive Behaviour Therapy
3302077|NCT00426426|Active Comparator|Cognitive Behaviour Therapy|first Cognitive Behaviour Therapy then Meta-cognitive therapy
3302078|NCT00426426|Other|Waiting List|Waiting List
3302079|NCT00426413||1|Obese AA subjects with DKA or severe hyperglycemia
3302080|NCT00426413||2|obese nondiabetic subjects, age 19-65.
3302081|NCT00426413||3|Any subjects with recurrent DKA. Recurrent DKA is defined as more than one admission to Grady Memorial Hospital.
3302082|NCT00426361|Experimental|Cervarix Group|Subjects who received GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 0, 1 and 6.
3302083|NCT00426361|Experimental|Boostrix Polio → Cervarix Group|Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 1, 2 and 7.
3302084|NCT00426361|Experimental|Cervarix + Boostrix Polio Group|Subjects who received GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.
3302085|NCT00426348|Active Comparator|1|In arm 1,Valsartan(80-160mg/day) is given to patients in combination with Placebo
3302086|NCT00426348|Experimental|2|Valsartan(80-160mg/day) + Probucol(750mg/day)
3302087|NCT00426322|Active Comparator|1|small particles
3302088|NCT00426322|Active Comparator|2|large particles
3302089|NCT00426283|Experimental|1|Drug
3302090|NCT00426283|Placebo Comparator|2|
3302091|NCT00426270|Experimental|Octagam 10% 1 g/kg/day|Participants received Octagam 10% (human normal immunoglobulin) 1 g/kg intravenously once a day for 2 days.
3302092|NCT00426257|Experimental|1|Secondary debulking surgery with hyperthermic intraperitoneal chemotherapy
3302093|NCT00426257|Active Comparator|2|Secondary debulking surgery
3302094|NCT00426244|Sham Comparator|Placebo Ultrasound|"In addition to controlling for physician attention during the treatment visit, the SUT used a nonfunctional ultrasound therapy unit that was modified for research purposes to provide both visible and auditory cues that could potentially elicit a placebo response. The physician provided the SUT by placing the applicator head over the subject's clothing and applying sufficient pressure for tactile stimulation of the skin and underlying tissues in the same anatomical distributions as would generally be addressed if the subject were being treated with OMT.~The subjects assigned to the UOBC only group did not receive any study treatments beyond conventional obstetrical care; however, they were expected to complete data collection forms on the same schedule as all other trial subjects."
3302095|NCT00426244|Active Comparator|Osteopathic Manipulative Treatment|OMT is a complementary and alternative body-based treatment method in which the patient is evaluated and treated including the musculoskeletal system to improve physiologic functioning and remove impediments to optimal health and functioning.
3302096|NCT00426244|No Intervention|Standard Care|Subject only receives care from her OB provider. Subjects were allowed to receive conventional obstetrical care with the exception of OMT, massage therapy, physical therapy, chiropractic manipulation, or therapeutic ultrasound intended to treat musculoskeletal disorders.
3302097|NCT00426231|Experimental|Patient Navigator intervention|Patient Navigator intervention
3302098|NCT00426231|Active Comparator|Information control|Information control
3302099|NCT00426218|Experimental|1|ACZ885
3302100|NCT00426166|Experimental|1|Low Level Laser Therapy
3302101|NCT00426166|No Intervention|2|No Laser Therapy. Outcome Measures the same.
3302102|NCT00426153|Active Comparator|Octreotide|Participants received Octreotide LAR® Depot injections (up to 40 mg) intramuscularly every 28 days (+/- 5 days) for one year
3302103|NCT00426153|Placebo Comparator|Placebo|Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
3302104|NCT00426140|Experimental|EPO906|
3302105|NCT00426127|Experimental|Docetaxel and Liposomal Doxorubicin Combined with Enoxaparin|Docetaxel 75 mg/m^2 + Doxil 30 mg/m^2 + Enoxaparin 1.5 mg/kg
3302218|NCT00424619|Active Comparator|1|50 000 IU Vitamin D2
3302106|NCT00426101|Experimental|Etoposide, Dexamethasone, Cyclosporin A plus IT MTX & Steroids|"As compared to the HLH-94 treatment, the main changes are that~Cyclosporin A is administered from day 1 and~Intrathecal steroids are added to the intrathecal methotrexate.~Drugs, dosage, frequency and duration are described in the paragraph Interventions below."
3302107|NCT00426023|Experimental|1|this group of patients is treated with the experimental drug (Cyclosporine A 0,05% eye drops) 2 times daily
3302108|NCT00426023|Active Comparator|2|
3302109|NCT00426010|Active Comparator|1|overt then covert caffeine
3302110|NCT00426010|Active Comparator|2|covert then overt caffeine
3302111|NCT00426010|Active Comparator|3|overt then covert placebo
3302112|NCT00426010|Active Comparator|4|covert then overt placebo
3302113|NCT00425945|Placebo Comparator|Placebo|Placebo delivered as four tablets matching the active product once daily orally.
3302114|NCT00425945|Active Comparator|Pine Bark Extract|Flavangenol 200 mg Flavangenol is a brand of Pine Bark Extract manufactured by Toyo Shinyaku of Saga, Japan. Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day.
3302115|NCT00425932|No Intervention|Rituximab/Placebo|Patients will be randomized at Baseline to either Placebo or Rituximab. At Week 24 and up to Week 48 if patient DAS28 score is >2.6, patient will be retreated with open label Rituximab.
3302116|NCT00425932|Active Comparator|Open Label|At Week 24 or any time up to Week 48 if the Patient DAS 28 > 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
3302117|NCT00425906|Experimental|Nicotine inhaler|
3302118|NCT00425906|Placebo Comparator|Placebo inhaler|
3302119|NCT00425893|Active Comparator|1|health education
3302120|NCT00425893|Experimental|2|hand hygiene
3302121|NCT00425893|Experimental|3|masks and hand hygiene
3302122|NCT00425880||Pregnant Asthmatics|
3302123|NCT00425880||Pregnant Smokers|
3302124|NCT00425880||Healthy Pregnant Controls|
3302125|NCT00425854|Experimental|BIBW 2992|high dose once daily
3302126|NCT00425815|Experimental|Org 24448 250 mg|Two capsules (one Org 24448 250 mg capsule and one placebo capsule that is identical to the active treatment) will be ingested orally daily for eight weeks.
3302127|NCT00425815|Experimental|Og 244448 500 mg|Two capsules (two Org 24448 250 mg capsules) will be ingested orally daily for eight weeks.
3302128|NCT00425815|Placebo Comparator|Inactive Capsule|Two capsules (two placebo capsules that are identical to the active treatment) will be ingested orally daily for eight weeks.
3302129|NCT00425802|Other|treatment|This is a phase 2 study of a treatment regimen consisting of a non-myeloablative (NMA) conditioning regimen incorporating low dose chemotherapy and low dose radiation as well as peri-transplant Rituximab and the transplantation of peripheral blood stem cells (PBSC) or bone marrow if PBSC collection not possible from an HLA compatible related or unrelated donor in patients with B cell lymphoid malignancies including diffuse large cell (DLC) and mantle cell non-Hodgkin's lymphoma (NHL), indolent B cell NHL, or chronic lymphocytic leukemia (CLL).
3302130|NCT00425776|Active Comparator|Real acupuncture|
3302131|NCT00425776|Sham Comparator|Sham acupuncture|
3302132|NCT00425776|No Intervention|No intervention|
3302133|NCT00425763|Experimental|AQAS|
3302134|NCT00425750|Experimental|Treatment|"Docetaxel (40 mg/m2) IV Infusion over 30 minutes every 3 weeks (Day 1 and 8 of 21 day cycle)except the first dose is held on Day 1 of Cycle 1.~Bortezomib (1.6mg/m2) IV 3-5 second push every 3 weeks (Day 1 and 8 of 21 day cycle).Bortezomib is given as a single agent only on Day 1 of Cycle 1."
3302135|NCT00425711|Experimental|DUI Court Participants|Individuals enrolled in the DUI Court treatment site will be recruited for the 13 week open-label trial of acamprosate.
3302136|NCT00425698|Active Comparator|intravenous erythropoietin|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
3302137|NCT00425698|Placebo Comparator|intravenous placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
3302138|NCT00425672|Experimental|Arm I|Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3302139|NCT00425659|Active Comparator|3|
3302140|NCT00425659|Experimental|1|
3302141|NCT00425659|Other|2|usual practice
3302142|NCT00425620|Experimental|Amphotericin B|
3302143|NCT00425607|Experimental|Lonafarnib|All subjects initiated oral Lonafarnib twice daily at a dose of 115mg/m2 and escalated to 150 mg/m2. Two subjects de-escalated to 115mg/m2 following toxicity.
3302144|NCT00425555|Experimental|Previously treated with oral bexarotene|
3302145|NCT00425555|Experimental|No prior oral bexarotene treatmemt|
3302146|NCT00425542|Experimental|Outpatient treatment|
3302147|NCT00425542|No Intervention|Inpatient care|
3302148|NCT00425516|No Intervention|standard (A)|3 FEC100 followed 3 Taxotere
3302149|NCT00425516|Experimental|Modulated (B)|possibility treatments receive: 2 FEC100 followed by 4 Taxotere 4 FEC100 followed by 2 Taxotere 6 FEC 100
3302150|NCT00425464|Experimental|Synchrony® Dual Optic Intraocular Lens|
3302151|NCT00425464|Active Comparator|Standard Monofocal Intraocular Lens|
3302152|NCT00425451|Experimental|PerioChip Plus|
3302153|NCT00425451|Experimental|Flurbiprofen Chip|
3302154|NCT00425451|Active Comparator|PerioChip|
3302155|NCT00425451|Placebo Comparator|Placebo Chip|
3302156|NCT00425438|Experimental|Mycophenolate Mofetil|Participants received mycophenolate mofetil (MMF) 0.5 grams (g), orally (PO), twice daily (BID) from Day 0 to the end of Week 1, followed by 1.0 g, PO, BID from Weeks 2 through 24, and 0.75 g, PO, BID from Weeks 32 to 48. Participants also received prednisolone 0.75 to 1.0 milligrams per kilogram (mg/kg), PO, once per day, up to a maximum of 60 mg per day from Weeks 1 through 4, reduced by 10 mg per day every 2 weeks until dose reaches 40 mg per day, followed by a reduction of 5 mg per day every 2 weeks until dose reaches 10 mg per day up to Week 48.
3302215|NCT00424645|Experimental|Voraxaze|Voraxaze administered 50 units/kg intravenously (IV) repeated a maximum of 2 times in a given cycle of chemotherapy.
3302216|NCT00424645|Placebo Comparator|Placebo|Placebo administered IV following Voraxaze arm.
3302217|NCT00424632|Experimental|Single arm dose escalation|
3302157|NCT00425438|Active Comparator|Cyclophosphamide/Azathioprine|Participants received cyclophosphamide 0.75 grams per square meter (g/m^2), intravenously (IV), every 4 weeks from Weeks 1 through 4, and 0.5 to (-) 1.0 g/m^2, IV, to maintain a minimum white blood cell (WBC) count of greater than or equal to (≥) 2500 per cubic millimeter (mm^3) every 4 weeks from Weeks 5 through 24. Participants also received azathioprine 100 mg, PO, daily for participants with a body weight of 50 to 70 kg and 150 mg, PO, daily for subjects with a body weight of more than 70 kg from Weeks 25 through 48. Participants also received prednisolone 0.75 to 1.0 mg/kg, PO, once per day, up to a maximum of 60 mg per day from Weeks 1 through 4, reduced by 10 mg per day every 2 weeks until dose reaches 40 mg per day, followed by a reduction of 5 mg per day every 2 weeks until dose reaches 10 mg per day up to Week 48.
3302158|NCT00425386|Experimental|Erlotinib and Sunitinib|"Drug: erlotinib hydrochloride Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;~100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;~150 mg/day, continuous daily~Drug: sunitinib malate Will be administered at 50 mg daily, 4 weeks on, 2 weeks off"
3302159|NCT00425373|Experimental|Valsartan + amlodipine 40/2.5 mg|
3302160|NCT00425373|Experimental|Valsartan + amlodipine 40/5 mg|
3302161|NCT00425373|Experimental|Valsartan + amlodipine 80/2.5 mg|
3302162|NCT00425373|Experimental|Valsartan + amlodipine 80/5 mg|
3302163|NCT00425373|Active Comparator|Valsartan 40 mg|
3302164|NCT00425373|Active Comparator|Valsartan 80 mg|
3302165|NCT00425373|Active Comparator|Amlodipine 2.5 mg|
3302166|NCT00425373|Active Comparator|Amlodipine 5 mg|
3302167|NCT00425373|Placebo Comparator|Placebo|
3302168|NCT00425334|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
3302169|NCT00425334|Active Comparator|Control|Ringer's lactate
3302170|NCT00425321|Experimental|RWJ-445380 100 mg|
3302171|NCT00425321|Experimental|RWJ-445380 200 mg|
3302172|NCT00425321|Experimental|RWJ-445380 300 mg|
3302173|NCT00425321|Placebo Comparator|Placebo|
3302174|NCT00425308|Active Comparator|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|Everolimus dose has been adjusted to reach in Group 2, assessment of everolimus dose/trough level (C0), between 6 and 10 ng/ml plus Enteric-coated Mycophenolate Sodium (EC-MPS) 720 mg/d (360mg the morning and 360 mg the evening) plus steroids
3302175|NCT00425308|Active Comparator|Everolimus + Cyclosporine|Everolimus dose has been adjusted to reach in Group 1, assessment of everolimus dose/trough level (C0), between 3 and 8 ng/ml plus Cyclosporine in which Group 1 dose adjusted to reach, assessment of Cyclosporine dosage and blood concentration (C2), between 200 and 450 ng/ml plus steroids
3302176|NCT00425295|Active Comparator|1|
3302177|NCT00425295|Experimental|2|
3302178|NCT00425269|Experimental|Intervention|The intervention group was divided into nine subgroups of ten to twelve women who were offered six educational sessions, each lasting 2 h, during a 7 +- 1-month period. The main focus was on the physiological importance of blood glucose and its regulation by diet and physical activity, and on knowledge about the Pakistani lifestyle in Pakistan and Norway
3302179|NCT00425269|No Intervention|Control|One lesson recieved after post-test
3302180|NCT00425204|Experimental|Open Label|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
3302181|NCT00425191|Experimental|1|
3302182|NCT00425191|Experimental|2|
3302183|NCT00425191|Experimental|3|
3302184|NCT00425113|Experimental|Metronidazole|Metronidazole added to background TB treatment regimen during initial 2 months
3302185|NCT00425113|Placebo Comparator|Placebo|Placebo added to background TB treatment regimen during initial 2 months
3302186|NCT00425100|Experimental|Open Label-fesoterodine|Single treatment study arm.
3302187|NCT00425074|Experimental|SR-ASA|slow release acetylsalicylic acid 150 mg
3302188|NCT00425074|Active Comparator|ASA|normal release acetylsalicylic acid
3302189|NCT00425061|Experimental|1|
3302190|NCT00425061|Experimental|2|
3302191|NCT00425061|Placebo Comparator|3|
3302192|NCT00424983|Experimental|Zometa q 4 weeks|
3302193|NCT00424983|Active Comparator|Zometa q 12 weeks|
3302194|NCT00424970|Placebo Comparator|acetazolamide|acetazolamide 250mg /day oral administration, for 6 months
3302195|NCT00424944|Experimental|I, GMZ2 vaccine arm|20 volunteers will receive GMZ2 vaccine on days 0, 28, and 56
3302196|NCT00424944|Active Comparator|II, Rabies vaccine arm|20 volunteers will receive standard vaccine against rabies on the similar schedule on days 0, 28, and 56
3302197|NCT00424931|Experimental|001|JNJ-17216498 10mg one time
3302198|NCT00424931|Experimental|002|JNJ-17216498 50mg one time
3302199|NCT00424931|Active Comparator|003|Modafinil 200 mg X 2
3302200|NCT00424905|Experimental|1|Enterogermina® vials containing 2×109 spores of polyantibiotic resistant Bacillus clausii (test drug)
3302201|NCT00424905|No Intervention|2|No treatment (reference group)
3302202|NCT00424866|Placebo Comparator|Placebo|The dosing groups correspond to total doses of 0 µg/kg of FGF-1.
3302203|NCT00424866|Active Comparator|Human FGF-1|The dosing groups correspond to total doses of either 3, 10 or 30 µg/kg of FGF-1.
3302204|NCT00424853|Experimental|A|
3302205|NCT00424853|Experimental|B|
3302206|NCT00424840|Experimental|1|The primary objective of phase I study is to define the maximum tolerated dose (MTD) of weekly bortezomib in combination with carboplatin and bevacizumab. This is a pilot study to define the safety of this combination. Only three predefined cohorts of patients will be studied to define the maximum tolerated dose of bortezomib that could be safely administered with standard doses of carboplatin and bevacizumab.
3302207|NCT00424827|Experimental|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of Gemcitabine/Fluorouracil with External Beam Radiation in patients with non-metastatic, locally advanced pancreatic carcinoma.
3302208|NCT00424814|Experimental|1|Kaletra (lopinavir/ritonavir)
3302209|NCT00424814|Active Comparator|2|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)
3302210|NCT00424801|Experimental|Vasodilatory|Patients in this arm will receive intensive vasodilatory treatment to lower blood pressure
3302211|NCT00424762|Experimental|rosiglitazone|4mg titrated to 8mg daily
3302219|NCT00424619|Active Comparator|2|100 000 IU Vitamin D2
3302220|NCT00424619|Placebo Comparator|3|Placebo
3302221|NCT00424606|Experimental|1|
3302222|NCT00424606|Experimental|2|
3302223|NCT00424593|Experimental|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
3302224|NCT00424593|Placebo Comparator|Placebo|every day (QD), by mouth (PO), 13 weeks
3302225|NCT00424554|Experimental|Temozolomide treatment|
3302226|NCT00424554|No Intervention|No treatment|
3302227|NCT00424528|Active Comparator|Arformoterol 15 mcg twice daily|Arformoterol 15 mcg twice daily/Placebo Inhalation Powder
3302228|NCT00424528|Active Comparator|Tiotropium 18 mcg once daily|Tiotropium 18 mcg once daily/Placebo Inhalation Solution
3302229|NCT00424528|Experimental|Arformoterol /Tiotropium|Arformoterol 15 mcg twice daily/Tiotropium 18 mcg once daily
3302230|NCT00424515|Experimental|Treatment Arm|Imatinib
3302231|NCT00424502|Experimental|1|
3302232|NCT00424489|Experimental|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation will be performed after conditioning
3302233|NCT00424476|Placebo Comparator|Placebo|Placebo
3302234|NCT00424476|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg
3302235|NCT00424476|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg
3302236|NCT00424463|Experimental|1|
3302237|NCT00424463|Placebo Comparator|2|
3302238|NCT00424450||PAD patients|30 PAD patients
3302239|NCT00424398|Experimental|Bepreve|Bepotastine Besilate Ophthalmic Solution 1.5%
3302240|NCT00424398|Placebo Comparator|Placebo|sterile ophthalmic solution
3302241|NCT00424398|Experimental|Bepotastine Besilate|sterile ophthalmic solution 1.0%
3302242|NCT00424385|Experimental|Arm 1|Only 1 arm for the study - this arm gets both drugs, gleevec and sorafenib
3302243|NCT00424372|Experimental|pregabalin|
3302244|NCT00424346|Experimental|Canakinumab 600 mg IV + 300 mg q2wk|Participants received canakinumab 600 mg intravenous (IV) loading dose on Day 1 and 300 mg subcutaneous injections every 2 weeks (q2wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg every 4 weeks.
3302245|NCT00424346|Experimental|Canakinumab 300 mg q2wk|Participants received canakinumab 300 mg subcutaneous injections every 2 weeks (q2wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
3302246|NCT00424346|Experimental|Canakinumab 150 mg q4wk|Participants received canakinumab 150 mg subcutaneous injections every 4 weeks (q4wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
3302247|NCT00424346|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections every 2 weeks for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
3302248|NCT00424294|Active Comparator|Celecoxib|Celecoxib with placebo therapy.
3302249|NCT00424294|Other|Methotrexate|Background Methotrexate taken in both CP-195,543/Celecoxib and Celecoxib only arms.
3302250|NCT00424294|Experimental|CP-195,543|CP-195,543 and Celecoxib dual therapy.
3302251|NCT00424268|Active Comparator|Roflumilast|"Roflumilast 500 µg~underlying medication: tiotropium 18 µg, once daily, inhaled"
3302252|NCT00424268|Placebo Comparator|Placebo|"Placebo~underlying medication: tiotropium 18 µg, once daily, inhaled"
3302253|NCT00424255|Experimental|Lapatinib+Chemoradiation|"Adjuvant concurrent chemoradiotherapy plus lapatinib 1500 mg once daily for 6 to 7 weeks, followed by lapatinib 1500 mg once daily for one year.~Chemoradiotherapy=total dose of 66Gy over 6-7 weeks plus cisplatin 100mg/m2 on days 1,2 and 43 of the course of radiotherapy. Lapatinib is also given at 1500 mg once daily for 3-7 days prior to the start of chemoradiotherapy."
3302254|NCT00424255|Placebo Comparator|Placebo+Chemoradiation|"Adjuvant concurrent chemoradiotherapy plus placebo once daily for 6 to 7 weeks, followed by placebo once daily for one year.~Chemoradiotherapy = total dose of 66Gy over 6-7 weeks plus cisplatin 100mg/m2 on days 1,2 and 43 of the course of treatment. Placebo is also given once daily for 3-7 days prior to the start of chemoradiotherapy."
3302255|NCT00424242|Experimental|Escalating doses of Pemetrexed|Escalating doses of Pemetrexed beginning at 500 mg/m2
3302256|NCT00424203|Experimental|Myocet, Endoxan|
3302257|NCT00424190|Experimental|Ceftaroline for Injection|
3302258|NCT00424190|Active Comparator|IV Vancomycin and IV Aztreonam|
3302259|NCT00424177|Experimental|eltrombopag|
3302260|NCT00424164|Experimental|Tamoxifen-lapatinib|Tamoxifen alone at cycle 1 and as of cycle 2 in combination with Lapatinib.
3302261|NCT00424164|Experimental|Lapatinib-tamoxifen|Lapatinib will be given alone for 2 weeks during cycle 1. As of cycle 2, you will receive the combined treatment Lapatinib and Tamoxifen
3302262|NCT00424138|Experimental|Group A - 3 FDG-PET/CT Scans|Two FDG-PET/CT scans prior to 1st cycle of chemotherapy, plus 2 optional volumetric CT scans. One FDG-PET/CT after 1st cycle of chemotherapy, plus 1 optional volumetric CT scan.
3302263|NCT00424138|Experimental|Group B - 2 FDG-PET/CT + 1 Optional|One FDG-PET/CT prior to 1st cycle of chemotherapy; 1 FDG-PET/CT after the 1st cycle of chemotherapy; 1 optional FDG-PET/CT after the 2nd cycle of chemotherapy. All three with optional volumetric CT scans.
3302264|NCT00424138|Experimental|Group C - Test-Retest|Test-retest sequence for FDG-PET/CT; two scans with optional volumetric CT to be completed prior to 1st cycle of chemotherapy.
3302265|NCT00424125|Experimental|Enhanced Pharmacy Care|Received enhanced community pharmacy based services.
3302266|NCT00424099|Experimental|Group 1|Methylphenidate + Nursing Telephone Intervention
3302267|NCT00424099|Placebo Comparator|Group 2|Placebo + Nursing Telephone Intervention
3302268|NCT00424099|Experimental|Group 3|Methylphenidate
3302269|NCT00424099|Experimental|Group 4|Placebo
3302270|NCT00424047|Experimental|CC-5013 plus dexamethasone|Arm A: Oral CC-5013 is initiated on Day 1 of Cycle 1 at a dose of 25 mg daily for 21 days every 28 days. Therefore, the subject will take a placebo identical in appearance to the CC-5013 capsule for week 4 of every 28 days. Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral CC-5013 placebo capsules will be administered for 28 days of every cycle.
3302271|NCT00424047|Experimental|Dexamethasone plus placebo|Arm B: Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
3302272|NCT00424008|Experimental|MF/F MDI 200/10 mcg BID|Mometasone furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily.
3302273|NCT00424008|Active Comparator|F/SC DPI 250/50 mcg BID|Fluticasone propionate/salmeterol (F/SC) 250/50 mcg BID
3302274|NCT00423982|Active Comparator|Rifampicin-combination therapy|Cloxacillin or vancomycin in combination with Rifampicin. Treatment of early staphylococcal prosthetic joint infections in addition to debridement and retention of the prosthesis.
3302275|NCT00423982|Active Comparator|Monotherapy|Cloxacillin or vancomycin in the treatment of early staphylococcal prosthetic joint infections in addition to debridement and retention of the prosthesis.
3302276|NCT00423956|Sham Comparator|Sham Comparator|One side is experimental and the opposite side is Sham control.
3302277|NCT00423943|Experimental|D|modafinil
3302278|NCT00423943|Placebo Comparator|Placebo|placebo
3302279|NCT00423930|Experimental|IMRT + cisplatin + bevacizumab|This is a single-institution phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab.
3302280|NCT00423917|Experimental|fulvestrant + bevacizumab|"Patients receive fulvestrant intramuscularly on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, prior to every other course, and at the completion of study treatment.~After completion of study treatment, patients are followed every 3-6 months for 5 years."
3302281|NCT00423891|Experimental|Arm 1: Entecavir|
3302282|NCT00423878|Experimental|1|Participants will switch to aripiprazole with a cross-titration from the current antipsychotic over 3-4 weeks. Allowed final dosage range for aripiprazole was 5-30 mg/day
3302283|NCT00423878|Active Comparator|2|Participants will continue with their current antipsychotic treatment, either olanzapine 5-20 mg/day, quetiapine 200-1200 mg/day, or risperidone 1-16 mg/day.
3302284|NCT00423865|Experimental|cisplatin & RAD001|This will be a single institution phase I study of low dose weekly cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15) plus escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle) for patients with advanced solid tumors
3302285|NCT00423852|Experimental|chemotherapy with Stem Cell Support|This is a phase I/II trial of sequential accelerated chemotherapy cycles with paclitaxel/ifosfamide and paclitaxel/ifosfamide and carboplatin administered with G-CSF and PBSC support. During phase I, carboplatin, ifosfamide, and paclitaxel will be dose escalated to determine the MTD. Additional patients will be enrolled in the Phase II portion of the study following the determination of the MTD of Ifosfamide and paclitaxel, to bring the total possible number of patients treated at the MTD to 38.
3302286|NCT00423813|Placebo Comparator|1|
3302287|NCT00423813|Experimental|2|
3302288|NCT00423800|Experimental|Pegetron® - 24 Weeks|Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 16 weeks of treatment
3302289|NCT00423800|Active Comparator|Pegetron®- 48 Weeks|Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 40 weeks of treatment.
3302290|NCT00423787|Experimental|Ragweed MATA MPL|modified Ragweed pollen allergen absorbed to Tyrosine and containing MPL adjuvant
3302291|NCT00423787|Placebo Comparator|Placebo|4 injections of placebo 0.5 ml (2% tyrosine)
3302292|NCT00423735|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
3302293|NCT00423722|Experimental|Hydration: Normal Saline (salt water)|Group 1: 1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily
3302294|NCT00423722|Placebo Comparator|Placebo: Lower Saline|Group 2: Lower Amount of Normal Saline (salt water); 100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
3302295|NCT00423683|Experimental|1- Arixtra Alone|Arixtra Alone
3302296|NCT00423683|Active Comparator|2 Arixtra+ filter|Arixtra + filter
3302297|NCT00423670|Active Comparator|Arm 1. PEG +RBV for 48 Wks (Part I)|"Participants treated with PegIntron (1.5 μg/kg, once weekly [QW]) and Ribavirin (800 to 1400 mg/day) for 48 weeks.~Participants with detectable HCV-RNA levels after 24 weeks of treatment had the option of crossing over to receive 24 weeks of PegIntron (1.5 μg/kg, QW), Ribavirin (800 to 1400 mg/day), and boceprevir (800 mg three times daily [TID]) for 24 additional weeks. The participants that crossed over to receive boceprevir formed Arm 8. The total treatment duration was up to 54 weeks."
3302298|NCT00423670|Experimental|Arm 2. PEG + RBV + BOC for 28 Wks (Part I)|Participants receiving boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 28 weeks.
3302299|NCT00423670|Experimental|Arm 3. PEG + RBV + BOC (from Wk 4) for 24 Wks (Part I)|Participants receiving a lead-in treatment with PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks, followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 24 weeks.
3302300|NCT00423670|Experimental|Arm 4. PEG +RBV + BOC for 48 Wks (Part I)|Participants receiving boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 48 weeks.
3302301|NCT00423670|Experimental|Arm 5. PEG + RBV + BOC (from Wk 4) for 44 Wks (Part I)|Participants receiving a lead-in treatment with PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks, followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 44 weeks.
3302302|NCT00423670|Experimental|Arm 6. PEG + RBV + BOC for 48 Wks (Part II)|Participants receiving PegIntron (1.5 μg/kg QW), ribavirin (800 to 1400 mg/day) and boceprevir (800 mg TID) for up to 48 weeks during Part II of the study. Part II was initiated after participants were fully enrolled for Part I.
3302303|NCT00423670|Experimental|Arm 7. PEG +Low-dose RBV + BOC for 48 Wks (Part II)|Participants receiving PegIntron (1.5 μg/kg QW), low-dose ribavirin (400 to 1000 mg/day) and boceprevir (800 mg TID) for up to 48 weeks (Arm 7) during Part II of the study. Part II was initiated after participants were fully enrolled for Part I.
3302304|NCT00423670|Experimental|Arm 8. PEG + RBV + BOC (from Wk 24) for 48 Wks (Part I)|"Participants that started in Arm 1 and had detectable HCV-RNA levels after 24 weeks of treatment had the option of receiving boceprevir (800 mg TID) with~PegIntron (1.5 μg/kg QW), and ribavirin (800 to 1400 mg/day). Participants that took the option of crossing over to receive PegIntron, ribavirin, and boceprevir (800 mg TID) for 24 additional weeks constitute Arm 8. The total treatment duration was up to 54 weeks."
3302305|NCT00423657|Experimental|Ceftaroline fosamil for Injection|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
3302306|NCT00423657|Active Comparator|IV Vancomycin plus IV Aztreonam|Vancomycin 1 g administered over 60 minutes every 12 hours followed by aztreonam 1 g administered over 60 minutes every 12 hours.
3302307|NCT00423644|Experimental|Single Arm|
3302308|NCT00423631|Experimental|Standard Care and Web|Standard care plus a web site based on cognitive behavioral principals.
3302309|NCT00423631|Active Comparator|Standard Care|Subject recieve standard care from their primary care provider.
3302310|NCT00423618|Active Comparator|Control arm|Radiotherapy Conventional treatment arm A total of 33 fractions each of 2Gy should be given once a day for 5 days per week over 6 weeks and 3 days in week 7, totalling 66Gy. The first 50 Gy in 25 fractions will be given to CTV1 and subsequent 16 Gy in 8 fractions will be delivered to CTV2.
3302311|NCT00423618|Experimental|Research arm|Radiotherapy Research arm A total of 33 fractions each of 2Gy should be given once a day for 5 days per week over 6 weeks and 3 days in week 7, totalling 66Gy. The 66Gy in 33 fractions will be delivered to CTV2 alone. No attempt will be made to include drain/biopsy sites or the surgical scar.
3302312|NCT00423605|Experimental|1|
3302313|NCT00423579|Experimental|Ezetimibe/Simvastatin 10/20 mg + Simvastatin placebo|Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin 10/20 mg. The second tablet is simvastatin placebo. Subjects will receive a maximum of 6 weeks of treatment
3302314|NCT00423579|Active Comparator|Ezetimibe/Simvastatin placebo + Simvastatin 40 mg|Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin placebo. The second tablet is simvastatin 40 mg. Subjects will receive a maximum of 6 weeks of treatment.
3302315|NCT00423514|Experimental|cytoreduction regimen & stem cell transplant|This is a single arm phase I/II clinical trial to assess efficacy (the antileukemic potential and relapse rate), and safety (peri-transplant morbidity and mortality) of a novel cytoreduction regimen in preparation for allogeneic hematopoietic stem cell transplantation (HSCT).
3302316|NCT00423501|Experimental|1|
3302317|NCT00423501|Experimental|2|
3302318|NCT00423501|Experimental|3|
3302319|NCT00423501|Experimental|4|
3302320|NCT00423501|Experimental|5|
3302321|NCT00423501|Placebo Comparator|6|
3302322|NCT00423488|Experimental|Ezetimibe 10 mg + Simvastatin Placebo + Simvastatin 20 mg|Participants were instructed to take one 10-mg ezetimibe tablet and one simvastatin placebo tablet orally in the evening every day for six weeks in addition to their daily, oral, open-label, 20-mg simvastatin tablet.
3302323|NCT00423488|Active Comparator|Ezetimibe Placebo + Simvastatin 40 mg|Participants were instructed to take one ezetimibe placebo tablet and one simvastatin 20-mg tablet orally in the evening every day for six weeks in addition to their daily, oral, open-label, 20-mg simvastatin tablet.
3302324|NCT00423475|Active Comparator|I|Exclusive Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) in treating patients who have undergone surgery for recurent or refractory Prostate Cancer
3302325|NCT00423475|Experimental|II|Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) and GOSERELIN ACETATE in treating patients who have undergone surgery for recurent or refractory Prostate Cancer
3302326|NCT00423449|Experimental|Vorinostat + Gemcitabine + Platinum-based agent|
3302327|NCT00423436|Experimental|IVR Assessment Plus Triage|Interactive Voice Response Telephone System (IVR) Plus Triage (Participants report symptoms to telephone system and doctor/nurse notified when symptom is severe) + Questionnaire
3302328|NCT00423436|Experimental|IVR Assessment Only|IVR (Phone calls twice weekly) + Questionnaire
3302329|NCT00423410|Experimental|EPC2407 (crinobulin)|
3302330|NCT00423384|Experimental|1|Ibandronate
3302331|NCT00423384|Placebo Comparator|2|
3302332|NCT00423371|Experimental|EUFLEXXA™|
3302333|NCT00423371|Placebo Comparator|Placebo|
3302334|NCT00423358|Active Comparator|vitamin D|ergocalciferol 50,000 IU Twice monthly
3302335|NCT00423358|Placebo Comparator|placebo|matching placebo tablet
3302336|NCT00423332|Placebo Comparator|1|Cediranib placebo
3302337|NCT00423332|Experimental|2|Cediranib
3302338|NCT00423319|Active Comparator|Apixaban, 2.5 mg BID plus placebo|Participants received apixaban, 2.5 mg twice daily (BID), as oral tablets, and matching enoxaparin-placebo injection once daily (QD)
3302339|NCT00423319|Experimental|Enoxaparin, 40 mg QD plus placebo|Participants received enoxaparin, 40 mg QD subcutaneously, and matching apixaban-placebo tablets BID
3302340|NCT00423306|Experimental|Single Arm|
3302341|NCT00423293|Other|5-FU + Mitomycin + IMRT|5-FU + Mitomycin + IMRT
3302342|NCT00423280|Active Comparator|1|700mg/day 6R-BH4
3302343|NCT00423280|Active Comparator|2|400mg/day 6R-BH4
3302344|NCT00423280|Placebo Comparator|3|Placebo
3302345|NCT00423267|Experimental|Posaconazole|Eligible subjects will be stratified at Baseline by disease site (skeletal, lung, or soft tissue) and by immune status (immunocompromised or non-immunocompromised) and will then be randomly assigned to receive Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months.
3302391|NCT00422825|Experimental|Imatinib 800mg|
3302392|NCT00422825|Active Comparator|Imatinib 400mg|
3302346|NCT00423267|Active Comparator|Fluconazole|Eligible subjects will be stratified at Baseline by disease site (skeletal, lung, or soft tissue) and by immune status (immunocompromised or non-immunocompromised) and will then be randomly assigned to receive Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months. Fluconazole treatment or placebo only occurred during Period A.
3302347|NCT00423254|Experimental|Low Dose Cohort|
3302348|NCT00423254|Experimental|High Dose Cohort|
3302349|NCT00423241|Experimental|SEMPERFLO Pain Management System|
3302350|NCT00423241|Active Comparator|ON-Q PainBuster Post-Op Pain Relief System|
3302351|NCT00423228|Experimental|ZT-1|ZT-1 (investigational product)
3302352|NCT00423228|Active Comparator|Donepezil|Donepezil
3302353|NCT00423215||Patients with Type II diabetes|
3302354|NCT00423189|Active Comparator|Ranibizumab only|drug - intravitreal ranibizumab
3302355|NCT00423189|Experimental|40% fluence PDT/procedure|40% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab
3302356|NCT00423189|Experimental|20% fluence photodynamic therapy|20% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab
3302357|NCT00423176|Experimental|MFNS + Antibiotic|Mometasone furoate nasal spray (MFNS) twice daily (BID) for 29 days, plus antibiotic. Appropriate antibiotic therapy amoxicillin/clavulanic acid BID.
3302358|NCT00423176|Placebo Comparator|Placebo|Matching placebo nasal spray BID for 29 days, plus amoxicillin/clavulanic acid BID
3302359|NCT00423150|Experimental|Temozolomide|
3302360|NCT00423124|Experimental|A|
3302361|NCT00423098|Experimental|Standard dose|Mycophenolate sodium was administered orally in combination with a standard dose of corticosteroids (CS) administered as prednisone or prednisone equivalent (PRED). Mycophenolate sodium was administered in divided doses at a daily dose of 1440 mg during the first 2 weeks of the study and then at 2160 mg daily for the next 22 weeks. The dose of Prednisone was started at 1 mg per kg body weight and subsequently tapered according to the patient's weight. The planned treatment duration was 24 weeks.
3302362|NCT00423098|Active Comparator|Low dose|Mycophenolate sodium was administered in combination with a reduced dose of corticosteroids (CS) administered as prednisone or prednisone equivalent (PRED). Mycophenolate sodium was administered in divided doses at a daily dose of 1440 mg during the first 2 weeks of the study and then at 2160 mg daily for the next 22 weeks. The dose of Prednisone was started at 0.5 mg per kg body weight and subsequently tapered according to the patient's weight. The planned treatment duration was 24 weeks.
3302363|NCT00423085|Placebo Comparator|Placebo|Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
3302364|NCT00423085|Experimental|rivastigmine 5 cm^2|During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks and thereafter daily rivastigmine 5 cm^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
3302365|NCT00423085|Experimental|Rivastigmine 10 cm^2|During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks, rivastigmine 5 cm^2 patch for the next 4 weeks, rivastigmine 7.5 cm^2 patch for the next 4 weeks and then rivastigmine 10 cm^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
3302366|NCT00423072||1|children with cleft palate birth-24 months of age
3302367|NCT00423046|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals human papillomavirus [HPV]16/18 vaccine 580299 (CervarixTM) at Months 0, 1 and 6 and a dose of placebo at Month 2. All doses were administered by intramuscular injection in the deltoid muscle of the upper arm.
3302368|NCT00423046|Active Comparator|Gardasil Group|Subjects received 3 doses of Gardasil® (Merck's human papillomavirus [HPV] vaccine) at Months 0, 2 and 6 and a dose of placebo at Month 1. All doses were administered by intramuscular injection in the deltoid muscle of the upper arm.
3302369|NCT00423007|Experimental|Bromfenac|Ophthalmic Solution
3302370|NCT00423007|Placebo Comparator|Placebo|Vehicle ophthalmic solution
3302371|NCT00422981|Active Comparator|AL-108 5 mg|5 mg QD
3302372|NCT00422981|Active Comparator|AL-108 15 mg|15 mg BID
3302373|NCT00422981|Placebo Comparator|Placebo|Placebo
3302374|NCT00422968|Active Comparator|coronary artery bypass graft|coronary artery bypass graft
3302375|NCT00422968|Experimental|percutaneous coronary intervention|Using silorimus eluting stent
3302376|NCT00422955|Experimental|Arm 1|
3302377|NCT00422942|Experimental|1|
3302378|NCT00422929||chronic otitis media with effusion (OME)|history of chronic effusion (3 months if both ears, 6 months if one ear, or 3 episodes of effusion each lasting for 2 months or longer)
3302379|NCT00422929||recurrent AOM|recurrent acute otitis media (3 episodes in 6 months or 4 episodes in 1 year)
3302380|NCT00422929||no OM|no history of significant otitis media (i.e., does not meet criteria for chronic OME or recurrent AOM)
3302381|NCT00422916|Experimental|intervention arm|Lifestyle Intervention based on Nutrition Treatment, exercise Treatment and behavorial treatment
3302382|NCT00422916|No Intervention|waiting list|waiting 6 months for Intervention without any intervention
3302383|NCT00422903|Placebo Comparator|Letrozole plus placebo|Letrozole 2.5 mg administered orally fro 6 mos. plus placebo 1500 mg administered orally throughout the study until definitive surgery
3302384|NCT00422903|Experimental|Letrozole plus lapatininb|Letrozole 2.5 mg administered orally fro 6 mos. plus lapatinib 1500 mg administered orally throughout the study until definitive surgery
3302385|NCT00422877|Experimental|Taxoprexin|Starting dose of 500 mg/m2 (400 mg/m2 for patients with an elevated bilirubin at baseline) administered intravenously by a 1-hour infusion weekly for the first 5 weeks of a 6 week cycle.
3302386|NCT00422851||1|Normal tympanic membrane
3302387|NCT00422851||2|tympanosclerosis
3302388|NCT00422851||3|dimeric (atrophic)
3302389|NCT00422838||1|Chronic HCV Genotype 1 monoinfection, never had interferon and ribavirin treatment
3302390|NCT00422838||2|Chronic HCV Genotype 2 or 3 monoinfection,never had interferon and ribavirin treatment
3302393|NCT00422812|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo
3302394|NCT00422812|Experimental|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
3302395|NCT00422812|Experimental|Inhaled PCZ 7.5 mg|Inhaled Staccato Prochlorperazine 7.5 mg
3302396|NCT00422812|Experimental|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
3302397|NCT00422799|Experimental|bortezomib and rituximab|bortezomib and rituximab
3302398|NCT00422786|Experimental|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period.
3302399|NCT00422773|Experimental|Cetuximab+ FOLFOXIRI|Cetuximab and Irinotecan, Oxaliplatin, 5FU and Folinic acid
3302400|NCT00422747|Experimental|beclomethasondipropionate|2 x 100 ug dd for two months, via aerochamber
3302401|NCT00422734|Placebo Comparator|1|Placebo
3302402|NCT00422734|Active Comparator|2|5 mg tadalafil
3302403|NCT00422695||HIV +|Groups divided according to CD4 counts
3302404|NCT00422695||Healthy Controls|HIV -ve subjects
3302405|NCT00422682|Experimental|1|BSI-201 + topotecan
3302406|NCT00422682|Experimental|2|BSI-201 + temozolomide
3302407|NCT00422682|Experimental|3|bsi-201 + gemcitabine
3302408|NCT00422682|Experimental|4|bsi-201 + carboplatin/paclitaxel
3302409|NCT00422669|Active Comparator|RV Mid-Septal Pacing|Pacing lead is placed in the right ventricle at the middle of the muscle separating the right and left sides of the heart
3302410|NCT00422669|Active Comparator|RV Apical Pacing|Pacing lead is placed at the bottom of the right ventricle of the heart, in the right ventricular apex
3302411|NCT00422656|Experimental|Perifosine|Patients receive oral perifosine (150 mg) daily each cycle. Cycle duration is 28 days. After cycle 2, response is assessed and patients with stable or responding disease can continue for another 4 cycles or until disease progression (PD). Protocol treatment duration is 6 cycles but patients may receive perifosine maintenance per investigator discretion in absence of PD.
3302412|NCT00422630|Active Comparator|Average American Diet|
3302413|NCT00422630|Active Comparator|The DASH diet|
3302414|NCT00422630|Active Comparator|The Low Glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
3302415|NCT00422591|Experimental|Idarubicin + Cytarabine|Idarubicin 12 mg/m2 IV over 1 hour daily x 3 (days 1-3). Cytarabine 1.5 g/m2 IV over 24 hours daily on day 1-4 (age <60 years) or days 1-3 (age > 60 years).
3302416|NCT00422565|Experimental|Endeavor|Zotarolimus-eluting stent
3302417|NCT00422565|Active Comparator|Cypher|Sirolimus-eluting stent
3302418|NCT00422565|Active Comparator|Taxus|Paclitaxel-eluting stent
3302419|NCT00422513|Experimental|methoxy polyethylene glycol-epoetin beta|120-360 micrograms (iv) monthly, starting dose
3302420|NCT00422513|Active Comparator|Epoetin Alfa|As prescribed, (iv), 3 times weekly
3302421|NCT00422500||Chemotherapy Symptoms|Study participants with advanced-stage lung cancer.
3302422|NCT00422487|Experimental|MBX-2044 1.5 mg|
3302423|NCT00422487|Experimental|MBX-2044 4.5 mg|
3302424|NCT00422487|Experimental|MBX-2044 15 mg|
3302425|NCT00422487|Experimental|MBX-2044 30 mg|
3302426|NCT00422487|Experimental|MBX-2044 60 mg|
3302427|NCT00422487|Experimental|MBX-2044 90 mg|
3302428|NCT00422487|Placebo Comparator|Placebo|
3302429|NCT00422461|Experimental|PF-00489791 4 mg|
3302430|NCT00422461|Experimental|PF-00489791 10 mg|
3302431|NCT00422461|Experimental|PF-00489791 20 mg titrated to 40 mg|
3302432|NCT00422461|Placebo Comparator|Placebo|
3302433|NCT00422448|Experimental|Nevi from participants|Benign nevi dermoscopically sub-classified into 4 dermoscopic types (i.e., with globular, reticular, mixed pattern with globules in the center and mixed pattern with globules at the periphery) were excised from healthy volunteers for further genetical analysis
3302434|NCT00422435|Experimental|Drug eluting stent|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter
3302435|NCT00422422|Experimental|Brivaracetam|
3302436|NCT00422383|Experimental|1|
3302437|NCT00422383|Experimental|2|
3302438|NCT00422383|Experimental|3|
3302439|NCT00422344|Experimental|RAD001 AND SUNITINIB|RAD001 AND SUNITINIB IN METASTATIC RENAL CELL CARCINOMA PATIENTS
3302440|NCT00422305||1-Healthy Infants|"Group 1: The investigators will recruit 80 healthy infants born at > 37 weeks gestation, and between 2 and 36 months of age. Infants will be excluded for any of the following reasons:~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications~Small for gestational age at birth"
3302441|NCT00422305||2-Healthy Infants computerized Tomography|"Group 2: The investigators recruited 4 infants born at > 37 weeks gestation and they were evaluated between 2 and 36 months of age when scheduled for high resolution computed tomography (HRCT) imaging for non-respiratory medical problems. Subjects were enrolled and HRCT of the chest were obtained. Infants were excluded for the following reasons:~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications"
3302442|NCT00422305||3-Premature Infants|"Group 3: The investigators have recruited 45 infants born prematurely at 23-35 weeks gestation. Subjects were evaluated at corrected age at between 2 and 24 months. The subjects had no oxygen requirements, and were clinically stable outpatients when evaluated. Infants were excluded for any of the following reasons:~Congenital cardio-respiratory disease~Severe developmental delay"
3302443|NCT00422292|Experimental|Menactra® at 9 and 12 Months|Participants will received Menactra® vaccination at 9 and 12 months of age.
3302444|NCT00422292|Experimental|Menactra® at 9 Months and Menactra® + MMRV at 12 Months|Participants will receive Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV) vaccine at 12 months of age
3302445|NCT00422292|Experimental|Menactra® at 9 Months and Menactra® + PCV at 12 Months|Participants will receive Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age
3302702|NCT00419783|Experimental|2|Bilastine 100 mg
3302446|NCT00422292|Active Comparator|MMRV + PCV at 12 Months|Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age
3302447|NCT00422279|Experimental|supraalevolar|Bone inductive implant (Nobel Replace Tapered Groovy) placed in the supralveolar position
3302448|NCT00422279|Experimental|Other|Bone inductive implant (Nobel Replace Tapered Groovy) placed in extraction socket
3302449|NCT00422227|Active Comparator|1|Etanercept + Methotrexate
3302450|NCT00422227|Active Comparator|2|DMARD therapy Methotrexate + Sulfasalazine/Hydroxychloroquine/Leflunomide
3302451|NCT00422188|Experimental|Deoxycholic Acid Injection 0.5%|Participants received 0.5% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
3302452|NCT00422188|Experimental|Deoxycholic Acid Injection 1.0%|Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
3302453|NCT00422188|Experimental|Deoxycholic Acid Injection 2.0%|Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
3302454|NCT00422188|Experimental|Deoxycholic Acid Injection 4.0%|Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
3302455|NCT00422188|Placebo Comparator|Placebo|Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
3302456|NCT00422162|Experimental|Duloxetine Hydrochloride (60 mg)|"Up to Week 4: 60 milligrams (mg) every morning and placebo every evening, by mouth (PO).~Week 4 to Week 8: Responders continued on same dose as before; Nonresponders received 60 mg every morning and 60 mg every evening added to the placebo"
3302457|NCT00422162|Experimental|Duloxetine Hydrochloride (120 mg)|"Up to Week 4: 60 mg every morning and 60 mg every evening, PO.~Week 4 to Week 8: Responders continued on same dose as before; Nonresponders continued as before with a placebo capsule added to the evening dose"
3302458|NCT00422149|Active Comparator|1|SUBLIVAC® Grasses treatment
3302459|NCT00422149|Placebo Comparator|2|Placebo treatment
3302460|NCT00422097|Experimental|Ixabepilone, 5 mg/d|If none of first 3 participants experiences a dose-limiting toxicity (DLT) during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the maximum tolerated dose (MTD). If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
3302461|NCT00422097|Experimental|Ixabepilone, 10 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
3302462|NCT00422097|Experimental|Ixabepilone, 15 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
3302463|NCT00422097|Experimental|Ixabepilone, 20 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
3302464|NCT00422097|Experimental|Ixabepilone, 25 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
3302465|NCT00422097|Experimental|Ixabepilone, 30 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
3302466|NCT00422097|Experimental|Ixabepilone, 25 mg, with famotidine|Following identification of MTD, participants who completed Cycle 1 and treated at the ixabepilone MTD (25 mg/d) will crossover to Cycle 2 in which they receive famotidine, 40 mg on Day 1.
3302467|NCT00422097|Experimental|Ixabepilone, 25 mg, with food|Following identification of MTD, participants who completed Cycle 1 and treated at the ixabepilone MTD (25 mg/d) will crossover to Cycle 2 in which they receive a low-fat meal on Day 1.
3302468|NCT00422084|Experimental|1|Pyronaridine artesunate
3302469|NCT00422084|Active Comparator|2|Arthemether lumefantrine
3302526|NCT00421447||Breast Cancer patients|A group of women with breast cancer prescribed Anastrozole
3302527|NCT00421447||Healthy women wit no breast Cancer|A group of healthy women wit no breast cancer prescribed Anastrozole
3302470|NCT00422058|Placebo Comparator|Lira placebo/Lira 2.4 mg/Lira 3.0 mg|Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
3302471|NCT00422058|Experimental|Lira 1.2 mg/Lira 3.0 mg|Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
3302472|NCT00422058|Experimental|Lira 1.8 mg/Lira 3.0 mg|Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
3302473|NCT00422058|Experimental|Lira 2.4 mg/Lira 3.0 mg|Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
3302474|NCT00422058|Experimental|Liraglutide 3.0 mg|Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
3302475|NCT00422058|Active Comparator|Orlistat|Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)
3302476|NCT00422045|No Intervention|2|No Laser done. All outcome measures are the same.
3302477|NCT00422045|Experimental|1|Low Level Laser Therapy
3302478|NCT00422032|Experimental|15 mg/m^2 Clofarabine|Lower Dose Clofarabine Group A: 15 mg/m^2 intravenous (IV) over 1 hour daily for 5 days
3302479|NCT00422032|Experimental|30 mg/m^2 Clofarabine|Higher Dose Clofarabine Group B: 30 mg/m^2 IV over 1 hour daily for 5 days
3302480|NCT00422019|Experimental|AMG 102 at 20 mg/kg Dose Level|Up to 40 subjects will be treated at 20 mg/kg of AMG 102 Q2W (every 2 weeks) depending upon the stage of the study and number of responses observed.
3302481|NCT00422019|Experimental|AMG 102 at 10 mg/kg Dose Level|Up to 40 subjects will be dosed at 10mg/kg of AMG 102 Q2W (every two weeks) based upon the stage of the study and number of responses observed.
3302482|NCT00422006|Experimental|1|Non diabetic non dyslipidemic patient
3302483|NCT00422006|Experimental|2|Patient with metabolic syndrome
3302484|NCT00422006|Experimental|3|Patients with type II diabetes
3302485|NCT00422006|Experimental|4|Patient with a single lipidic anomaly
3302486|NCT00421993|Experimental|1|Adapalene/Benzoyl Peroxide Topical Gel
3302487|NCT00421993|Active Comparator|2|Adapalene Topical Gel
3302488|NCT00421993|Active Comparator|3|Benzoyl Peroxide Topical Gel
3302489|NCT00421993|Placebo Comparator|4|Topical Gel Vehicle
3302490|NCT00421967|Experimental|1|
3302491|NCT00421967|Active Comparator|2|
3302492|NCT00421954|Experimental|Ziprasidone|
3302493|NCT00421928|Experimental|001|tapentadol (CG5503) 50 100 150 200 250mg twice a day (BID) during 15 weeks
3302494|NCT00421928|Active Comparator|002|oxycodone 10 20 30 40 50mg twice a day (BID) during 15 weeks
3302495|NCT00421928|Placebo Comparator|003|placebo matching placebo twice a day (BID) during 15 weeks
3302496|NCT00421902|Experimental|Acupuncture|Acupuncture of the patients
3302497|NCT00421889|Experimental|Single arm|"Belinostat: 1000 mg/m2 days 1-5 in a 21 day cycle; IV Paclitaxel: Administered IV 2-3 hours after belinostat infusion on day 3 in a 21-day cycle~Carboplatin: Administered IV infusion after paclitaxel on day 3 in a 21-day cycle"
3302498|NCT00421863|Other|Intensive Strategy|
3302499|NCT00421863|Other|Usual Strategy|
3302500|NCT00421837||controls|household and other close contacts
3302501|NCT00421837||cases|elderly (>55) subjects hospitalized with Influenza
3302502|NCT00421824|Experimental|A|
3302503|NCT00421824|Experimental|B|
3302504|NCT00421759|Experimental|1|85 elderly individuals with somatosensory deficits
3302505|NCT00421759|Experimental|2|85 elderly individuals with recurrent falls
3302506|NCT00421733|Active Comparator|Paricalcitol 1 mcg|One paricalcitol 1 mcg capsule and one matching placebo capsule per dose
3302507|NCT00421733|Active Comparator|Paricalcitol 2 mcg|Two paricalcitol 1 mcg capsules per dose
3302508|NCT00421733|Placebo Comparator|Placebo|Two placebo capsules per dose
3302509|NCT00421707|Experimental|GW876008|GW876008
3302510|NCT00421707|Placebo Comparator|Placebo|Placebo
3302511|NCT00421681|Experimental|A|"Treatment Arm A will develop tailored/negotiated contracts with the exercise instructor to maintain post intervention exercise adherence at home or in the community. Half of the participants in this negotiated maintenance arm will be randomly assigned to receive telephone calls to reinforce adherence and half will be assigned to a no telephone calls group."
3302512|NCT00421681|Experimental|B|"Treatment Arm B will be mainstreamed into an ongoing facility-based exercise program for post intervention exercise adherence. Persons in this mainstream follow up arm will be randomly assigned such that half will receive regular telephone reinforcement follow up and half will not."
3302513|NCT00421668|Experimental|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate, and B12
3302514|NCT00421668|Experimental|Multivitamins + Zinc|Vitamins C, E, B1, B2, niacin, B6, folate and B12, and zinc
3302515|NCT00421668|Experimental|Zinc|zinc
3302516|NCT00421668|Placebo Comparator|Placebo|placebo
3302517|NCT00421655|Experimental|1|
3302518|NCT00421655|Placebo Comparator|2|
3302519|NCT00421603|Active Comparator|Adderall-XR and Topiramate|Adderall-XR (60 mg/day) and Topiramate (300mg/day)
3302520|NCT00421603|Placebo Comparator|Placebo|Placebo
3302521|NCT00421551|Experimental|1|
3302522|NCT00421551|Active Comparator|2|
3302523|NCT00421538|Active Comparator|LMWH|Therapeutic dose of Nadroparin
3302524|NCT00421538|Placebo Comparator|Placebo|Injectable placebo
3302525|NCT00421525|Active Comparator|Multiple Doses|Multiple Dose levels
3302528|NCT00421434|Experimental|Nitazoxanide-Peginterferon|One oral nitazoxanide 500 mg tablet with food twice daily for 12 weeks followed by 36 weeks of one oral nitazoxanide 500 mg tablet plus weekly injections of 180 µg peginterferon alfa-2a.
3302529|NCT00421434|Experimental|Nitazoxanide-Peginterferon-Ribavirin|One oral nitazoxanide 500 mg tablet with food twice daily for 12 weeks followed by 36 weeks of one oral nitazoxanide 500 mg tablet plus weekly injections of 180 µg peginterferon alfa-2a plus oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses.
3302530|NCT00421434|Active Comparator|Peginterferon-Ribavirin|Weekly injections of 180 µg peginterferon alfa-2a plus oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
3302531|NCT00421408|Experimental|Protein powder|Participants will receive a protein supplement daily (40 g whey protein supplement).
3302532|NCT00421408|Placebo Comparator|Placebo carbohydrate|Participants will receive a placebo supplement daily (40 g maltodextrin).
3302533|NCT00421395|Experimental|multi|escalating in increments of 2.5 mCi/m2
3302534|NCT00421343|Other|Treatment for osteoporosis and falls|calcium, vitamin D, a weekly oral bisphosphonate, and falls prevention measures. No comparator group. All participants received the same intervention
3302535|NCT00421330|Active Comparator|OR|Open Aneurysm Repair
3302536|NCT00421330|Experimental|EVAR|Endovascular Aneurysm Repair
3302537|NCT00421304|Experimental|1|MEDI-524 or Motavizumab
3302538|NCT00421304|Experimental|2|MEDI-524 or Motavizumab
3302539|NCT00421304|Placebo Comparator|3|Placebo
3302540|NCT00421278|Experimental|1|Arm 1: Drug
3302541|NCT00421252|Active Comparator|Clopidogrel 600 mg pre-treatment|Patients will receive 600 mg Clopidogrel load >2 hours pre-angiography with possibility for ad hoc PCI based on angiographic results
3302542|NCT00421252|Active Comparator|No clopidogrel 600 mg pretreatment|Patients will receive 600 mg Clopidogrel load after PCI, if performed
3302543|NCT00421252|Active Comparator|5Fr arterial access sheath|Patients will have angiography performed using 5Fr sheath. If PCI required, sheath will be upsized.
3302544|NCT00421252|Active Comparator|6Fr arterial access sheath|Patients will have angiography performed using 6Fr sheath
3302545|NCT00421239||A|
3302546|NCT00421239||B|
3302547|NCT00421213|Experimental|Single Arm|
3302548|NCT00421200|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
3302549|NCT00421200|Active Comparator|Control|Voluven (HES 130/0.4)
3302550|NCT00421187|Experimental|1|AmBisome® will be given on day 0 (10 mg/kg), day 2 (5 mg/kg), and day 5 (5 mg/kg)
3302551|NCT00421187|Active Comparator|2|AmBisome as a constant daily dose of 3 mg/kg for a maximum of 14 days or until the resolution of fever and neutropenia
3302552|NCT00421174|Experimental|Etanercept|Etanercept plus corticosteroids
3302553|NCT00421174|Active Comparator|Placebo|Placebo plus Corticosteroids
3302554|NCT00421148|Experimental|Arm 1|Sugammadex 0.5 mg/kg
3302555|NCT00421148|Experimental|Arm 2|Sugammadex 1.0 mg/kg
3302556|NCT00421148|Experimental|Arm 3|Sugammadex 2.0 mg/kg
3302557|NCT00421148|Experimental|Arm 4|Sugammadex 4.0 mg/kg
3302558|NCT00421148|Placebo Comparator|Arm 5|Placebo
3302559|NCT00421135|Experimental|Single Arm|ZIO-201
3302560|NCT00421122|Active Comparator|1|Bricasol®
3302561|NCT00421122|Experimental|2|Bricasol® + Pulmicort®
3302562|NCT00421122|Experimental|3|Bricasol® + Symbicort®
3302563|NCT00421109|Experimental|1|Bilastine 20 mg
3302564|NCT00421109|Active Comparator|2|Levocetirizine 5 mg
3302565|NCT00421109|Placebo Comparator|3|Placebo
3302566|NCT00421096|Experimental|patient with cervix cancer|will receive gemcitabine + cisplatin + radiotherapy
3302567|NCT00421070|No Intervention|Treatment as usual|Observational component
3302568|NCT00421070|Active Comparator|Intervention|Massage therapy adjunct comparator
3302569|NCT00421057||Exercise Group|Taught to perform a specific regimen for strength-training and walking exercises.
3302570|NCT00421057||Nonexercise Group|Follow usual routines of standard care but not taught to perform a specific regimen for strength-training and walking exercises; will keep record of any exercises done that are not a part of this study.
3302571|NCT00421044|Experimental|Arm A (Normal liver function)|
3302572|NCT00421044|Experimental|Arm B (Mild liver dysfunction)|
3302573|NCT00421044|Experimental|Arm C (Moderate liver dysfunction)|
3302574|NCT00421018|Sham Comparator|Symptom-guided group|Anti-inflammatory treatment is guided conventionally according to symptoms and beta-2-agonist use.
3302575|NCT00421018|Active Comparator|FeNO-guided group|Anti-inflammatory treatment is guided according to the level of exhaled nitric oxide
3302576|NCT00421005|Experimental|1|Fluvastatin 80mg
3302577|NCT00421005|Active Comparator|2|Fluvastatin 20, tapered up according to LDL concentration
3302578|NCT00420992|Experimental|ALO-01|Up to 80 mg twice a day (bid)
3302579|NCT00420992|Placebo Comparator|Placebo|Twice a day (bid)
3302580|NCT00420940|Experimental|90 Hz whole-body vibration|20-minute daily whole-body vibration at 90 Hz and 0.3g
3302581|NCT00420940|Experimental|30 Hz whole-body vibration|20-minute daily whole-body vibration at 90 Hz and 0.3g
3302582|NCT00420940|No Intervention|control|control group (receiving no vibration)
3302583|NCT00420927|Experimental|ADA+MTX/PBO+MTX (Arm 1)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2
3302584|NCT00420927|Experimental|ADA+MTX/ADA+MTX (Arm2)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2
3302585|NCT00420927|Experimental|ADA+MTX/OL ADA+MTX (Arm 3)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA + MTX during Period 2
3302586|NCT00420927|Experimental|PBO+MTX/PBO+MTX (Arm 4)|Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2
3302587|NCT00420927|Experimental|PBO+MTX/OL ADA+MTX (Arm 5)|Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2.
3302588|NCT00420888|Experimental|Safety group|6-12 patients
3302590|NCT00420888|Other|2|Standard treatment with IFN-alpha without add-on of ABR-217620/naptumomab estafenatox
3302591|NCT00420849|Experimental|Lenalidomide plus Dexamethasone|Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
3302592|NCT00420823|Placebo Comparator|Placebo pill|4 placebo pills daily for 3 months
3302593|NCT00420823|Experimental|Taurine 4g|Taurine 4g daily comprising four 1g pills
3302594|NCT00420784|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 24 weeks.
3302595|NCT00420784|Experimental|Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week|Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
3302596|NCT00420784|Experimental|Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week|Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.
3302597|NCT00420784|Placebo Comparator|PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
3302598|NCT00420771|Experimental|Gabapentin|gabapentin treatment 1200 mg three times daily
3302599|NCT00420771|Placebo Comparator|Placebo|Placebo condition received pills identical in appearance to experimental arm.
3302600|NCT00420758|No Intervention|Control|
3302601|NCT00420758|Experimental|LNS|Lipid-based nutrient supplement
3302602|NCT00420758|Experimental|CSB|Corn-soy blend supplement
3302603|NCT00420745|Experimental|Rotarix Group|All subjects received 2 oral doses of Rotarix vaccine, 1 dose at Day 0 and 1 dose at Month 1 or 2 depending on the country.
3302604|NCT00420745|Placebo Comparator|Placebo Group|All subjects received 2 oral doses of placebo, 1 dose at Day 0 and 1 dose at Month 1 or 2 depending on the country.
3302605|NCT00420732|Experimental|Vaccine Group|
3302606|NCT00420680|Experimental|Arm 1|Sugammadex 2.0 mg/kg
3302607|NCT00420680|Experimental|Arm 2|Sugammadex 4.0 mg/kg
3302608|NCT00420680|Placebo Comparator|Arm 3|Placebo
3302609|NCT00420654|Active Comparator|A1|
3302610|NCT00420654|Placebo Comparator|A2|
3302611|NCT00420654|Other|A3|
3302612|NCT00420641|Experimental|GSK372475 Arm|GSK372475 1.0- 1.5 mg/day
3302613|NCT00420641|Experimental|Paroxetine Arm|Paroxetine 20-30 mg/day
3302614|NCT00420641|Other|Placebo|Placebo to Match
3302615|NCT00420628|Experimental|Loteprednol/Tobramycin|0.5% loteprednol etabonate with 0.3% tobramycin opthalmic suspension
3302616|NCT00420628|Placebo Comparator|Vehicle|Vehicle
3302617|NCT00420615|Experimental|Patupilone and Omeprazole|patupiloe + omeprazole
3302618|NCT00420615|Experimental|patupilone + midalzolam|patupilone + midalzolam
3302619|NCT00420602|Other|Single Arm, Open Label|Single Arm, Open Label
3302620|NCT00420589|Placebo Comparator|1|Arm 1: MK0364 Pbo capsules once daily
3302621|NCT00420589|Experimental|2|Arm 2: MK0364 0.5 mg capsule once daily
3302622|NCT00420589|Experimental|3|Arm 3: MK0364 1 mg capsule once daily
3302623|NCT00420589|Experimental|4|Arm 4: MK0364 2 mg capsule once daily
3302624|NCT00420576|Experimental|1|Low Dose Danggui Buxue Tang (1.5g)
3302625|NCT00420576|Experimental|2|Middle Dose Danggui Buxue Tang(3g)
3302626|NCT00420576|Experimental|3|High Dose Danggui Buxue Tang (6g)
3302627|NCT00420563|Experimental|CYCLOPHOSPHAMIDE|
3302628|NCT00420563|Active Comparator|MEGESTROL|
3302629|NCT00420537|Active Comparator|mycophenolate|Mycophenolate mofetil with cyclosporine trough levels between 100 and 150
3302630|NCT00420537|Active Comparator|Everolimus|Everolimus with cyclosporine trough levels between 40 and 90 ng/ml
3302631|NCT00420524|Experimental|Arm A (Normal liver function)|
3302632|NCT00420524|Experimental|Arm B (Mild liver dysfunction)|
3302633|NCT00420524|Experimental|Arm C (Moderate liver dysfunction)|
3302634|NCT00420511|Experimental|Sitagliptin|Sitagliptin 100mg once a day (od) by mouth (po)
3302635|NCT00420511|Placebo Comparator|Placebo arm|Placebo once a day (od) by mouth (po)
3302636|NCT00420485|Experimental|Daily times five schedule|
3302637|NCT00420485|Experimental|Continuous schedule, twice daily|
3302638|NCT00420459|Experimental|Aripiprazole|
3302639|NCT00420433||1|Patients with breast cancer that has spread to the bones.
3302640|NCT00420420|Experimental|MK0249|
3302641|NCT00420420|Placebo Comparator|placebo|
3302642|NCT00420407|Experimental|I|Vasopressin
3302643|NCT00420407|Placebo Comparator|2|bolus of NS followed by continuous infusion of NS, no vasopressin added
3302644|NCT00420381|Experimental|A|
3302645|NCT00420355|Experimental|Arm A|Subjects on atazanavir/ritonavir will add lopinavir/ritonavir.
3302646|NCT00420355|Experimental|Arm B|Subjects on lopinavir/ritonavir will add atazanavir.
3302647|NCT00420342|Experimental|0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)|0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
3302648|NCT00420342|Experimental|2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)|2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
3302934|NCT00417274|Experimental|Quinacrine|Uncontrolled treatment arm
3302649|NCT00420342|Active Comparator|1.5 mg MPA / 0.3 mg CEE (Prempro)|1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
3302650|NCT00420316|Experimental|Rotarix Group|Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.
3302651|NCT00420316|Placebo Comparator|Placebo Group|Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.
3302652|NCT00420303|Experimental|A|
3302653|NCT00420303|Placebo Comparator|B|
3302654|NCT00420290|Active Comparator|Kineret|Interleukin-1 receptor antagonist
3302655|NCT00420290|Placebo Comparator|Placebo|
3302656|NCT00420277|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
3302657|NCT00420277|Active Comparator|Control|Voluven (HES 130/0.4)
3302658|NCT00420238|Experimental|A|
3302659|NCT00420238|Placebo Comparator|B|
3302660|NCT00420212|Placebo Comparator|Placebo|Participants received two placebo capsules orally three times daily (TID)
3302661|NCT00420212|Experimental|BG00012 240 mg Twice Daily (BID)|Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
3302662|NCT00420212|Experimental|BG00012 240 mg 3 Times Daily (TID)|Participants received two 120 mg BG00012 capsules orally three times daily (TID)
3302663|NCT00420199|Active Comparator|Abatacept + Methotrexate (Double-blind period)|
3302664|NCT00420199|Placebo Comparator|Placebo + Methotrexate (Double-blind period)|
3302665|NCT00420186|Experimental|1|
3302666|NCT00420173||Patients with CLE|
3302667|NCT00420160|Experimental|Exercise|3x/wk 50 minutes of moderate intensity walking on treadmills + health education videos
3302668|NCT00420160|Other|Health Education|Contact control group attending 3x/wk 50 minutes of health education videos
3302669|NCT00420147|Experimental|Wedged Orthosis|Subjects were given a wedged inshoe orthosis
3302670|NCT00420147|Placebo Comparator|Neutral Orthosis|Subjects were given a neutral inshoe orthosis.
3302671|NCT00420095|Active Comparator|1|Human insulin mix 30/70
3302672|NCT00420095|Experimental|2|Insulin lispro low mix
3302673|NCT00420082|Experimental|1|Bilastine 20 mg
3302674|NCT00420082|Active Comparator|2|Fexofenadine 120 mg
3302675|NCT00420082|Active Comparator|3|Cetirizine 10 mg
3302676|NCT00420082|Placebo Comparator|4|Placebo
3302677|NCT00420056|Experimental|PD-0332991|
3302678|NCT00420043|Experimental|imatinib 800mg|
3302679|NCT00420043|Active Comparator|imatinib 400mg|
3302680|NCT00420030|Active Comparator|1|Arm 1 - routine upfront administration of Reopro (Abciximab)
3302681|NCT00420030|Other|2|Reopro (Abciximab) only if needed - according to physician
3302682|NCT00420017|Experimental|Amiodarone|Intravenous amiodarone
3302683|NCT00420017|Other|Control|Control
3302684|NCT00420004|Experimental|LY2216684|"LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks.~For the first week of treatment, participants received a starting dose of 3 mg/day. Then, based on tolerability, for the next 7 weeks, the dose could remain at 3 mg/day; it could be increased 3 mg at a time (scheduled visit) to a maximum dose of 12 mg/day; or it could be decreased 3 mg at any time (scheduled or unscheduled visits) to a minimum dose of 3 mg/day.~All participants were required to take an equal number of tablets (2) and capsules (2) per day. Therefore, participants on 3 mg/day and 6 mg/day of LY2216684 also received 1 LY2216684-matching placebo tablet + 2 escitalopram-matching placebo capsules. Participants on 9 mg/day and 12 mg/day of LY2216684 also received 2 escitalopram-matching placebo capsules."
3302685|NCT00420004|Placebo Comparator|Placebo|Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks.
3302686|NCT00420004|Active Comparator|Escitalopram|"Escitalopram: flexible dose of 10 or 20 milligram (mg), capsules, administered orally, once daily for 8 weeks.~For the first week of treatment, participants received a starting dose of 10 mg/day. Then, based on tolerability, for the next 7 weeks, the dose could remain at 10 mg/day; it could be increased up to a maximum dose of 20 mg/day; or it could be decreased back to 10 mg/day.~All participants were required to take an equal number of tablets (2) and capsules (2) per day. Therefore, participants on 10 mg/day of escitalopram also received 1 escitalopram-matching placebo capsule + 2 LY2216684-matching placebo tablets. Participants on 20 mg/day of escitalopram also received 2 LY2216684-matching placebo tablets."
3302687|NCT00419991|No Intervention|1 Tigecycline|
3302688|NCT00419952|Experimental|Symbicort|Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
3302689|NCT00419952|Experimental|Budesonide|Budesonide HFA pMDI 160 ug x 2 actuations BID
3302690|NCT00419939||1|ab 10 patientsr with acquired severe brain injury (GCS 3 - 9), >18 år, PTA phase at the end (GOAT scoring), RLAS score at minimum 4 and informed consent in writing
3302691|NCT00419926|Experimental|Intensified Mycophenolate Sodium (Myfortic) dosing regimen|In patients randomized to the intensified Myfortic dosing regimen, the initial dose was 2-fold of the labeled dose (i.e. 2880 mg/day). The dosage was reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
3302692|NCT00419926|Active Comparator|Standard Mycophenolate Sodium (Myfortic) dosing regimen|In patients randomized to the standard Myfortic dosing regimen, the initial dose of 1440 mg/day had to be maintained throughout the whole study.
3302693|NCT00419913|Experimental|A|Dehydroepiandrosterone (DHEA) 25mg tid
3302694|NCT00419913|Placebo Comparator|B|
3302695|NCT00419861||Group 1|Adults >/= 50 years of age, hospitalized for respiratory illness in Davidson County, TN.
3302696|NCT00419848|Experimental|1|
3302697|NCT00419848|Active Comparator|2|
3302698|NCT00419822|Active Comparator|Acupuncture|
3302699|NCT00419822|Sham Comparator|Sham Acupuncture|
3302700|NCT00419822|Placebo Comparator|Standard of Care|
3302701|NCT00419783|Experimental|1|Bilastine 20 mg
3302703|NCT00419783|Active Comparator|3|Bilastine 20 mg + Ketoconazole 400 mg
3302704|NCT00419783|Active Comparator|4|Moxifloxacin 400 mg
3302705|NCT00419783|Placebo Comparator|5|Placebo
3302706|NCT00419770|Experimental|B|Deferasirox
3302707|NCT00419770|Placebo Comparator|A|
3302708|NCT00419757|Active Comparator|Symbicort|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
3302709|NCT00419757|Active Comparator|Budesonide|budesonide HFA pMDI 160 μg x 2 actuations twice daily
3302710|NCT00419731|Active Comparator|1|Bupropion+Placebo
3302711|NCT00419731|Experimental|2|Bupropion+Naltrexone
3302712|NCT00419705|Experimental|Transcranial Laser Therapy|
3302713|NCT00419705|Sham Comparator|Sham control procedure|
3302714|NCT00419692|Experimental|Sequence WAXBYZCDE|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), C: 1 x 6 mg CR-RLS (fasted), D: 1 x 6 mg CR-RLS (high fat fed) and E: 2 x 3 mg CR-RLS (fasted).
3302715|NCT00419692|Experimental|Sequence WAXBYZCED|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), C: 1 x 6 mg CR-RLS (fasted), E: 2 x 3 mg CR-RLS (fasted) and D: 1 x 6 mg CR-RLS (high fat fed).
3302716|NCT00419692|Experimental|Sequence WAXBYZDCE|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), D: 1 x 6 mg CR-RLS (high fat fed), C: 1 x 6 mg CR-RLS (fasted) and E: 2 x 3 mg CR-RLS (fasted).
3302717|NCT00419692|Experimental|Sequence WAXBYZDEC|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), D: 1 x 6 mg CR-RLS (high fat fed), E: 2 x 3 mg CR-RLS (fasted) and C: 1 x 6 mg CR-RLS (fasted).
3302718|NCT00419692|Experimental|Sequence WAXBYZECD|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), E: 2 x 3 mg CR-RLS (fasted),C: 1 x 6 mg CR-RLS (fasted) and D: 1 x 6 mg CR-RLS (high fat fed).
3302719|NCT00419692|Experimental|Sequence WAXBYZEDC|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), E: 2 x 3 mg CR-RLS (fasted), D: 1 x 6 mg CR-RLS (high fat fed) and C: 1 x 6 mg CR-RLS (fasted).
3302720|NCT00419666|Experimental|Calcitriol|
3302721|NCT00419653|Experimental|1|
3302722|NCT00419653|Active Comparator|2|
3302723|NCT00419653|Active Comparator|3|Haloperidol
3302724|NCT00419640|Experimental|LAS + DAO ON|The right atrial lead is placed in the low atrial septal position and the DAO algorithm is turned ON.
3302725|NCT00419640|Experimental|LAS + DAO OFF|The right atrial lead is placed in the low atrial septal position and the DAO algorithm is turned OFF.
3302726|NCT00419640|Experimental|RAA + DAO ON|The right atrial lead is placed in the right atrial appendage position and the DAO algorithm is turned ON.
3302727|NCT00419640|Active Comparator|RAA + DAO OFF|The right atrial lead is placed in the right atrial appendage position and the DAO algorithm is turned OFF.
3302728|NCT00419601|Active Comparator|2|Fentanyl
3302729|NCT00419601|Experimental|1|Remifentanyl
3302730|NCT00419588||1-Healthy Infants|"Group 1: We have recruited 50 healthy infants born >37 weeks gestation, and between 2 and 36 months of age. Infants were excluded for any of the following reasons.~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications for more than one time~Small for gestational age at birth~More than one respiratory illness~More than one episode of wheezing"
3302731|NCT00419588||3-Premature Infants|"Group 3: We will recruit 115 infants born prematurely, 23-35 weeks gestation. Subjects will be evaluated at the corrected age between 2 and 24 months. The subjects will have no oxygen requirements, and be clinically stable outpatients when evaluated. Infants will be excluded for any of the following reasons.~Congenital cardio-respiratory disease~Severe developmental delay"
3302732|NCT00419588||2-Healthy Infants CT|"Group 2: The investigators recruited 50 infants born at > 37 weeks gestation and they were evaluated between 2 and 36 months of age when scheduled for high resolution computed tomography (HRCT) imaging for non-respiratory medical problems. Subjects were enrolled and HRCT of the chest were obtained. Infants were excluded for the following reasons:~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications"
3302733|NCT00419562|Experimental|1|7.5 mg oral insulin capsules given before breakfast on a daily basis.
3302734|NCT00419562|Placebo Comparator|2|Placebo capsule designed to mimic appearance of treatment capsule
3302735|NCT00419549|Active Comparator|1|Valdecoxib
3302736|NCT00419549|Active Comparator|2|
3302737|NCT00419549|No Intervention|3|
3302738|NCT00419497|Active Comparator|Paleolithic diet vs Mediterranean diet|Prudent diets with or without grains and dairy
3302739|NCT00419471|Experimental|Escitalopram|
3302740|NCT00419471|Placebo Comparator|Placebo pill|
3302741|NCT00419445|Active Comparator|GTS21 25 mg tid/Placebo 25 mg tid|
3302742|NCT00419445|Active Comparator|GTS21 75 mg tid/Placebo 75 mg tid|
3302743|NCT00419445|Active Comparator|GTS21 150 mg tid/Placebo 150 mg tid|
3302744|NCT00419432|Active Comparator|Group A (standard pre-operative analysis)|
3302745|NCT00419432|Experimental|Group B (additional pre-operative analysis)|
3302746|NCT00419406|Experimental|A: UVA1|
3302747|NCT00419406|Experimental|B: NB UVB|
3302748|NCT00419393|Experimental|Keppra XR (Levetiracetam XR)|1000 - 3000 mg/day Keppra XR (Levetiracetam XR), flexible dosing, throughout the duration of the study (planned: approximately 6 months-3 years)
3302749|NCT00419380|Active Comparator|dornase alfa (Pulmozyme®)|dornase alfa - Pulmozyme®: 5 drops twice daily for 7 days to the affected ear.
3302750|NCT00419380|Active Comparator|Ofloxin|Ofloxin : 5 drops twice daily for 7 days to the affected ear.
3302751|NCT00419341|Experimental|IgPro20|Human Normal Immunoglobulin for Subcutaneous Administration (IgPro20) is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
3302752|NCT00419328|Experimental|A|
3302753|NCT00419315|Experimental|Alcohol Care Management|Care management for alcohol dependence delivered in primary care
3302754|NCT00419315|Active Comparator|Usual Care|Usual care included a referral to specialty addiction treatment
3302755|NCT00419276|Experimental|Prolonged infusion|At least 100 hours of femoral perineural ropivacaine infusion.
3302756|NCT00419276|Placebo Comparator|Standard-of-Care|Overnight femoral perineural ropivacaine infusion followed by a femoral perineural normal saline infusion (placebo) until postoperative day 4.
3302757|NCT00419263|Experimental|Peramivir 150 mg|
3302758|NCT00419263|Experimental|Peramivir 300 mg|
3302759|NCT00419263|Placebo Comparator|Placebo|
3302760|NCT00419250|Experimental|dose-escalation to 5 mg lenalidomide (len)|escalate up to 5 mg once daily / 28-day cycle
3302761|NCT00419250|Experimental|dose-escalation to 10 mg lenalidomide (len)|escalate up to 10 mg once daily / 28-day cycle
3302762|NCT00419250|Experimental|dose-escalation to 15 mg lenalidomide (len)|escalate up to 15 mg once daily / 28-day cycle
3302763|NCT00419250|Experimental|dose-escalation to 20 mg lenalidomide (len)|escalate up to 20 mg once daily / 28-day cycle
3302764|NCT00419250|Experimental|dose-escalation to 25 mg lenalidomide (len)|escalate up to 25 mg once daily / 28-day cycle
3302765|NCT00419237|Active Comparator|Healthy subjects|Subjects with normal liver function test will be administered a single oral inhaled dose of 400 micrograms (mcg) GW685698X in the morning of the study day. Each healthy subject will be matched as closely as possible for age, gender, bodyweight and race to a subject with impaired liver function.
3302766|NCT00419237|Experimental|Subjects with hepatic impairment|Subjects with Child Pugh B hepatic dysfunction will be administered a single oral inhaled dose of 400 mcg GW685698X in the morning of the study day.
3302767|NCT00419211|Experimental|Lifestyle counseling|Tailored exercise program
3302768|NCT00419211|No Intervention|No Intervention|Usual care group
3302769|NCT00419198|Experimental|1|Post-conditioning during angioplasty
3302770|NCT00419198|Active Comparator|2|standard angioplasty
3302771|NCT00419159|Experimental|Everolimus (RAD001) 70 mg/week|
3302772|NCT00419159|Experimental|Everolimus (RAD001) 10 mg/day|
3302773|NCT00419146|Experimental|Ethyl EPA (active) and Vitamins E + C (active)|
3302774|NCT00419146|Experimental|Ethyl EPA (active) and Vitamins E+C (placebo)|
3302775|NCT00419146|Experimental|Ethyl EPA (placebo) and Vitamins E+C (active)|
3302776|NCT00419146|Placebo Comparator|Ethyl EPA (placebo) and Vitamins E+C (placebo)|
3302777|NCT00419133|Experimental|1|Cholera Vaccine
3302778|NCT00419133|Placebo Comparator|2|Placebo
3302779|NCT00419120|Experimental|Neo-bladder construction|Surgical implantation of autologous neo-bladder construct
3302780|NCT00419094|Experimental|Keppra XR 1000 mg/day|1000 mg/day once daily for 18 weeks (administered as two levetiracetam XR tablets and two placebo tablets once daily)
3302781|NCT00419094|Experimental|Keppra XR 2000 mg/day|2000 mg/day once daily for 18 weeks (administered as four levetiracetam XR tablets once daily)
3302782|NCT00419055||1 Control|Patients are discharged the day after PCI
3302783|NCT00419055||2 Study group|Patients will be discharged 4-6 hrs after PCI
3302784|NCT00419029|Active Comparator|control|brief telephone check-in (no motivational interviewing)
3302785|NCT00419029|Experimental|telephone-administered motivational interviewing|motivational interviewing sessions
3302786|NCT00419003|Experimental|Lamotrigine Pre-Treatment|Patients who met enrolment criteria for phase 1 were randomly allocated to lamotrigine or placebo by a permuted block procedure consisting of blocks of two or four patients. The randomization list was created by a biostatistician with no patient contact. 300 mg of lamotrigine 2 hrs prior to ketamine infusion. Responders were randomized to one of two continuation pharmacotherapy groups, receiving either two capsules of riluzole 50 mg each (100 mg/d) or matching pill placebo under double-blind conditions.
3302787|NCT00419003|Placebo Comparator|Placebo Pre-Treatment|2 hours prior to ketamine infusion each patient received three capsules of placebo identical in size, weight, appearance, and taste to the lamotrigine tablets. Responders were randomized to one of two continuation pharmacotherapy groups, receiving either two capsules of riluzole 50 mg each (100 mg/d) or matching pill placebo under double-blind conditions.
3302788|NCT00418977|Experimental|Family Based Therapy|Participants will receive family based therapy (FBT)
3302789|NCT00418977|Active Comparator|Individual Supportive Psychotherapy|Participants will receive individual supportive psychotherapy (ISP)
3302790|NCT00418964|Experimental|Single bundle hamstring|
3302791|NCT00418964|Experimental|Double bundle hamstring|
3302792|NCT00418964|Active Comparator|Bone patellar tendon bone|
3302793|NCT00418951|Experimental|Liposomal amphotericin B: 3 mg/kg|3 mg/kg intravenously (IV) three times per week
3302794|NCT00418951|Experimental|Liposomal amphotericin B: 9 mg/kg|9 mg/kg IV once per week
3302795|NCT00418951|Experimental|Voriconazole: 400 mg|400 mg oral twice daily day 1 followed by 200 mg twice daily
3302796|NCT00418938|Experimental|Arm A|FOLFIRI + Panitumumab
3302797|NCT00418938|Experimental|Arm B|FOLFIRI + Bevacizumab
3302798|NCT00418899||GLIOGENE|International Multi-Center, Multidisciplinary Study Consortium
3302799|NCT00418886|Placebo Comparator|1|Placebo Vandetanib + Pemetrexed
3302800|NCT00418886|Experimental|2|Vandetanib + Pemetrexed
3302801|NCT00418873|Experimental|1. Zotepine|
3302802|NCT00418873|Active Comparator|2. Risperidone|
3302803|NCT00418860|Experimental|A|
3302804|NCT00418847|Experimental|1|
3302805|NCT00418834|Active Comparator|1|
3302806|NCT00418834|Active Comparator|2|
3302807|NCT00418782|Active Comparator|1|
3302808|NCT00418782|Experimental|2|
3302809|NCT00418782|Placebo Comparator|3|
3302810|NCT00418769|Experimental|Nilotinib Tablet Formulations|
3302811|NCT00418769|Active Comparator|Established Nilotinib Capsule Formulation|
3302812|NCT00418756|Experimental|Rifampin + nilotinib|
3302813|NCT00418730|Experimental|1|
3302814|NCT00418730|Active Comparator|2|
3302815|NCT00418730|Placebo Comparator|3|
3302816|NCT00418717|Experimental|1|Arm 1: Period A-25mg BW; Arm 1: Period B-50mg QW
3302817|NCT00418691|Active Comparator|Immediate Release (IR) Methylphenidate|10 mg by mouth (PO) twice daily for 4 Weeks
3302818|NCT00418691|Active Comparator|Sustained Release (SR) Methylphenidate|200 mg PO once daily for 4 Weeks
3302819|NCT00418691|Active Comparator|Modafinil|18 mg PO once daily for 4 Weeks
3302820|NCT00418665|Active Comparator|750 mcg AMG 531|750 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
3302821|NCT00418665|Placebo Comparator|Placebo Part B|Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
3302822|NCT00418665|Placebo Comparator|Placebo Part A|Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
3302823|NCT00418665|Active Comparator|500 mcg AMG 531|500 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
3302824|NCT00418665|Active Comparator|750 mcg AMG531 Part B|750 μg AMG 531 biweekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
3302825|NCT00418652|No Intervention|No TMS stimulation|The patients performed 2 tasks: a study and a control assignments with no TMS stimulation.
3302826|NCT00418652|Experimental|TMS over the dorsal stream|The patients performed 2 tasks: a study and a control assignments under TMS stimulation over the dorsal stream area (PO3 EEG site).
3302827|NCT00418652|Sham Comparator|TMS over the vertex|The patients performed 2 tasks: a study and a control assignments under TMS stimulation over the vertex area.
3302828|NCT00418626|Experimental|Nilotinib|
3302829|NCT00418613|Experimental|1|MK0633
3302830|NCT00418613|Placebo Comparator|2|Placebo
3302831|NCT00418600|Other|1|Hectorol capsules at 1.0 times current injection dose
3302832|NCT00418600|Other|2|Hectorol capsules at 1.5 times current injection dose
3302833|NCT00418600|Other|3|Hectorol capsules at 2.0 times current injection dose
3302834|NCT00418587|Experimental|1|800 IU oral daily dose level
3302835|NCT00418587|Experimental|2|2000 IU oral daily dose level
3302836|NCT00418587|Experimental|3|4000 IU oral daily dose level
3302837|NCT00418574|Experimental|Abagovomab|
3302838|NCT00418574|Placebo Comparator|Placebo|
3302839|NCT00418561|Experimental|rhASA|
3302840|NCT00418522|Active Comparator|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
3302841|NCT00418522|Experimental|Exubera|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
3302842|NCT00418496|Experimental|Aldekleukin Plus Dose Escalation Sorafenib|Patients will be admitted to a dedicated nursing unit for HD aldesleukin administration. Patients will receive bolus aldesleukin at a dose of 600,000 IU/Kg every eight hours on days 1-5 with a goal of 10-12 doses.
3302843|NCT00418483|Experimental|Plasmin (Human) 25 mg|Plasmin (Human) 25 mg
3302844|NCT00418483|Experimental|Plasmin (Human) 50 mg|Plasmin (Human ) 50 mg
3302845|NCT00418483|Experimental|Plasmin (Human) 75 mg|Plasmin (Human) 75 mg
3302846|NCT00418483|Experimental|Plasmin (Human) 100 mg|Plasmin (Human) 100 mg
3302847|NCT00418483|Experimental|Plasmin (Human) 125 mg|Plasmin (Human) 125 mg
3302848|NCT00418483|Experimental|Plasmin (Human) 150 mg|Plasmin (Human) 150 mg
3302849|NCT00418483|Experimental|Plasmin (Human) 175 mg|Plasmin (Human) 175 mg
3302850|NCT00418470|Experimental|A|Higher concentration of antibiotic in NS
3302851|NCT00418470|Experimental|B|Lower concentration of antibiotic in NS
3302852|NCT00418457|Active Comparator|General anesthesia and opioid|General anesthesia followed by opioid administration
3302853|NCT00418457|Active Comparator|Regional analgesia and propofol|Regional anesthesia and analgesia (either epidural or paravertebral) combined with propofol
3302854|NCT00418418|Active Comparator|A|Patient group receiving the stem cell injections during the CABG
3302855|NCT00418418|Placebo Comparator|B|The patient group receiving autologous serum injections during the CAGB operation
3302856|NCT00418392|Experimental|Minocycline group|After successful simple aspiration, minocycline pleurodesis will be performed.
3302857|NCT00418392|Placebo Comparator|Control group|After successful simple aspiration, nothing will be performed.
3302858|NCT00418379|Experimental|300 IR (4M)|300 IR grass pollen allergen extract tablet, treatment starting 4 months before the pollen season
3302859|NCT00418379|Experimental|300 IR (2M)|300 IR grass pollen allergen extract tablet, treatment starting 2 months before the pollen season
3302860|NCT00418379|Placebo Comparator|Placebo|Placebo tablet
3302861|NCT00418314|Experimental|QuickOpt (Treatment)|Frequent optimization using QuickOpt to optimize the AV/PV and VV Delays.
3302862|NCT00418314|Active Comparator|Control|Empiric programming or one-time optimization using a non-IEGM method.
3302863|NCT00418288|Active Comparator|A|
3302864|NCT00418288|Placebo Comparator|P|
3302865|NCT00418262|Experimental|Atomoxetine HCL (Strattera)|Teatment of children with fetal alcohol syndrome and ADHD with Atomoxetine HCL (Strattera)
3302866|NCT00418210|Experimental|Accelerated partial breast irradiation|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)
3302867|NCT00418184|Experimental|1|
3302868|NCT00418184|Placebo Comparator|2|
3302869|NCT00418145|Experimental|megadose oral methylprednisolone|1400 mg qd/5 days
3302870|NCT00418145|Experimental|IV methylprednisolone|1000 mg/qd/5 days
3302871|NCT00418132|Experimental|1|Participants will receive thalidomide.
3302872|NCT00418132|Placebo Comparator|2|Participants will receive placebo thalidomide.
3302873|NCT00418106||1|Mothers who are pumping breast milk and who are willing to kangaroo hold their infant.
3302935|NCT00417261|Experimental|1|ATF936
3302874|NCT00418093|Experimental|Chemotherapy|All patients received oxaliplatin, gemcitabine, and bevacizumab
3302875|NCT00418067|Active Comparator|Cypher|Sirolimus-eluting stent
3302876|NCT00418067|Active Comparator|Taxus Liberte|Paclitaxel-eluting stent
3302877|NCT00418067|Experimental|Endeavor|Zotarolimus-eluting stent
3302878|NCT00418028|Active Comparator|A Cint|Capecitabine will be administered orally at a dose of 1250 mg/m2 twice-daily (in the morning and in the evening, the equivalent of a total daily dose of 2500 mg/m2) for 14 days, in 3 week cycles with a resting period of 7 days,until disease progression or severe toxicity. Dose adjustments were made in patients with grade 3 or greater diarrhea or hand and food syndrome.
3302879|NCT00418028|Experimental|B Ccont|Capecitabine 800 mg/m2 orally twice-daily (in the morning and in the evening the equivalent of one dose of 1600 mg/m2) for 21 days, in 3 week cycles without resting period, until disease progression or severe toxicity. Dose adjustments were made in patients with grade 3 or greater diarrhea or hand and food syndrome.
3302880|NCT00418015||Labor analgesia|Labor analgesia receiving fentanyl labor analgesia
3302881|NCT00418015||Cesarean delivery analgesia|Cesarean delivery analgesia consisting of spinal fentanyl and morphine
3302882|NCT00417989|Experimental|722 sensor augmented pump|722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year
3302883|NCT00417989|No Intervention|Multiple Daily Injections (MDI)|MDI arm: Continue with current MDI therapy using Lantus and NovoLog/NovoRapid for 1 year
3302884|NCT00417976|Experimental|Bevacizumab|
3302885|NCT00417963|Experimental|stent placement in the carotid artery|placement of a bare metal stent for treatment of carotid artery stenosis
3302886|NCT00417937|Active Comparator|1|Azelaic acid 15 % gel once daily
3302887|NCT00417937|Active Comparator|2|Azelaic acid 15 gel twice daily
3302888|NCT00417911|Active Comparator|No treatment|
3302889|NCT00417911|Experimental|Bortezomib consolidation|Bortezomib consolidation : 20 injections starting 3 months after ASCT
3302890|NCT00417885|Experimental|A|sunitinib + exemestane
3302891|NCT00417859|Active Comparator|TKA mobile|TKA mobile
3302892|NCT00417859|No Intervention|TKA|TKA fix
3302893|NCT00417807|Experimental|Gleevec/Glivec|
3302894|NCT00417794|Active Comparator|1|Atomoxetine HCL (Strattera)
3302895|NCT00417794|Placebo Comparator|2|
3302896|NCT00417768|Active Comparator|Tissue Plasminogen Activator|tPA administered by drainage tube into abscess, allowed to dwell for one hour and then drained into drainage bag. Dose of tPA administered to be determined by the volume of drainage immediately post drain insertion. This intervention is done on day 0, 1 and 2.
3302897|NCT00417768|Sham Comparator|Instillation of Normal Saline|Insertion of abdominal drainage tube to drain intra-abdominal abscess. Normal Saline administered immediately post drain insertion. Normal Saline (10 cc) allowed to dwell for one hour, then allowed to drain into drainage bag.
3302898|NCT00417729|Active Comparator|acarbose, glibenclamide|acarbose vs. glibenclamide (background metformin therapy)
3302899|NCT00417690|Experimental|A|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
3302900|NCT00417690|Placebo Comparator|P|One packet of oral granules administered three times daily for 2 weeks followed by one packet two times daily for two weeks
3302901|NCT00417638|Experimental|1|Hypothermia using endovascular cooling with the Celsius Control System
3302902|NCT00417638|Active Comparator|2|Standard of care treatment
3302903|NCT00417612|Experimental|1|Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
3302904|NCT00417612|Placebo Comparator|2|Participants given placebo capsule to match for comparison
3302905|NCT00417599|Experimental|Lifestyle intervention|Behavioral lifestyle intervention versus control group. The Behavioral intervention consists of behavioral lessons delivered over the internet.
3302906|NCT00417599|Experimental|control|The intervention for the waiting list control group was usual care.
3302907|NCT00417560|Experimental|Influenza A/H5N1 Vaccine|Two 90ug Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine
3302908|NCT00417521|Experimental|Family therapy|
3302909|NCT00417508|Experimental|Nutritional supplement|2 packages/day with nutritional supplement containing a total of 600 kcal and 40 g protein
3302910|NCT00417508|Active Comparator|Dietary advice|ordinary dietary advice with a recommendation of four meals per day or similar dietary advice
3302911|NCT00417482|Other|Risperidone-risperidone|Risperidone for 16 weeks followed by risperidone for 16 weeks
3302912|NCT00417482|Other|Risperidone-Placebo|Risperidone for 16 weeks followed by placebo for 16 weeks
3302913|NCT00417482|Other|Placebo-Placebo|Placebo for 16 weeks followed by placebo for 16 weeks
3302914|NCT00417456|Active Comparator|1|Office Visits
3302915|NCT00417456|Experimental|2|Evisit
3302916|NCT00417417|Experimental|Rilonacept|Rilonacept 320 mg subcutaneous at each treatment visit
3302917|NCT00417417|Sham Comparator|Placebo|Normal saline subcutaneously at each treatment visit.
3302918|NCT00417404|Active Comparator|vitamin A|
3302919|NCT00417404|Sham Comparator|sham injection|
3302920|NCT00417391|Experimental|1 mg RR110|1 mg RR110
3302921|NCT00417391|Experimental|4 mg RR110|4 mg RR110
3302922|NCT00417378|Active Comparator|1|Intraaortic balloon counterpulsation (IABP)
3302923|NCT00417378|Experimental|2|Left Ventricular Assist Device (Impella LP2.5)
3302924|NCT00417339||hemodialysis, 4h, twice weekly|hemodialysis, four hours, twice weekly
3302925|NCT00417339||hemodialysis, 8h, twice weekly|hemodialysis, eight hours, twice weekly
3302926|NCT00417339||hemodialysis, 8h, every other day|hemodialysis, eight hours, every other day
3302927|NCT00417339||hemodialysis, 8h, six days per week|hemodialysis, eight hours, six days per week
3302928|NCT00417326|Placebo Comparator|P|
3302929|NCT00417326|Experimental|E|
3302930|NCT00417300|Experimental|1|Participants will receive prolonged exposure for adolescents
3302931|NCT00417300|Active Comparator|2|Participants will receive client centered therapy
3302932|NCT00417287|Active Comparator|High dose|128 mg/m2
3302933|NCT00417287|Active Comparator|Low dose|54 mg/m2
3302936|NCT00417261|Experimental|2|AXT914
3302937|NCT00417261|Placebo Comparator|3|Placebo
3302938|NCT00417248|Experimental|Investigational Treatment|Cisplatin/Etoposide/Radiotherapy followed by Sorafenib in patients with inoperable stage III non-small cell lung cancer
3302939|NCT00417235|Experimental|3-days dressing frequency/CHX sponge|"Interventions:~Device: 'Chlorhexidine Sponge (Biopatch TM)' on the insertion site"
3302940|NCT00417235|Experimental|7-days dressing frequency/CHX sponge|"Interventions:~Behavioural: 7-day catheter dressing frequency Device: 'Chlorhexidine Sponge (Biopatch TM)' on the insertion site"
3302941|NCT00417235|No Intervention|3-days dressing frequency/No CHX sponge|No intervention, classical protocol of dressing frequency every 3-days and no other device
3302942|NCT00417235|Experimental|7-days dressing change/No CHX sponge|Interventions:Behavioural: 7-day catheter dressing frequency
3302943|NCT00417222|Active Comparator|Olmesartan medoxomil|olmesartan medoxomil
3302944|NCT00417222|No Intervention|Standard therapy|Standard therapy
3302945|NCT00417209|Experimental|Larotaxel (XRP9881)|
3302946|NCT00417209|Active Comparator|5-Fluorouracil or capecitabine|Each Investigator must choose either IV 5-FU or oral capecitabine regimen before the first participant begins the study and has to consistently use the chosen regimen throughout the study for all participants treated at her/his site.
3302947|NCT00417170|Experimental|Aliskiren 300 mg|Eligible participants received oral Aliskiren 300 mg + Placebo Amlodipine once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed.
3302948|NCT00417170|Active Comparator|Amlodipine 5 mg|Eligible participants received oral Amlodipine 5 mg + Placebo Aliskiren once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed.
3302949|NCT00417118|Experimental|Saredutant 100 mg|Saredutant 100 mg once daily in the morning for a maximum of 8 weeks
3302950|NCT00417118|Active Comparator|Escitalopram 10 mg|Escitalopram 10 mg once daily in the morning for a maximum of 8 weeks
3302951|NCT00417118|Placebo Comparator|Placebo|Placebo for one week during the run in period and for a maximum of 8 weeks during the active period
3302952|NCT00417105||1|hemodialysis twice weekly 4 hours
3302953|NCT00417105||2|nocturnal dialysis twice weekly 8 hours
3302954|NCT00417105||3|nocturnal hemodialysis, 8 hours every other night
3302955|NCT00417105||4|nocturnal hemodialysis, 8 hours, six times per week
3302956|NCT00417079|Active Comparator|Mitoxantrone + Prednisone|Mitoxantrone + Prednisone
3302957|NCT00417079|Experimental|Cabazitaxel + Prednisone|Cabazitaxel + Prednisone
3302958|NCT00417040|Other|(Internet-based STAR database)|"Patients are registered into the STAR database, obtain a password, undergo STAR training, and complete a patient-STAR questionnaire after seeing their clinician (baseline self-report) on day 1 of course 2* of chemotherapy. Patients are reminded to complete online STAR questionnaire before seeing their clinician on day 1 of courses 3, 4, 5, and 6* of chemotherapy. Clinicians review these patient reports before creating their own assessment. Patients also complete a patient feedback survey on day 1 of course 4* of chemotherapy. Clinicians complete feedback survey at study completion.~NOTE: *All time points are based on scheduled therapy with clinical trial CALGB-90401, CALGB-30607, CALGB-30704, CALGB-40601, CALGB-40603, CALGB-40502, CALGB-70604, CALGB-80405, or CALGB-40503."
3302959|NCT00417027|Active Comparator|2.5 mL bolused every 15 minutes|
3302960|NCT00417027|Active Comparator|5ml bolused every 30 minutes|
3302961|NCT00417027|Active Comparator|10ml bolused every 60 minutes|
3302962|NCT00416975|Other|Breast Cancer Risk Assessment Screening|Counseling Intervention and Eduation Intervention
3302963|NCT00416949|Experimental|Patient-specific 3D-RD Dosimetry|Applied a patient-specific dosimetry calculation method to the imaging data collected to calculate tumor absorbed doses, using 3D-RD method.
3302964|NCT00416923|Experimental|intrathecal rituximab|3 dose levels of intrathecal rituximab, 10mg, 25mg, 50mg
3302965|NCT00416910|Active Comparator|FCM|Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) q28d, max. 6 cycles
3302966|NCT00416910|Experimental|FCM + G-CSF|Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) Filgrastim (G-CSF) s.c. (5 µg/kg/d beginning on day +6 until neutrophil recovery above 1500/µl.) q28d, max. 6 cycles
3302967|NCT00416884|Experimental|TBI, Campath, Fludarabine T-cell Deplete|(Campath) 30 mg on day -8 over 5-6 hours, Fludarabine 30 mg/m^2 on day -4 through day -2, Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0., Stem cells will be T cell depleted and given on day 0
3302968|NCT00416819|Experimental|methotrexate, leucovorin calcium, rituximab, and temozolomide|Determine the rate of toxicity, in terms of percentage of patients with grade 4 neurotoxicity, in patients with untreated primary CNS lymphoma treated with induction therapy comprising high-dose methotrexate, leucovorin calcium, rituximab, and temozolomide followed by consolidation therapy comprising cytarabine and etoposide phosphate.
3302969|NCT00416793|Experimental|Treatment|Patients receive bortezomib IV on days 1, 4, 8, and 11 and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3302970|NCT00416767|Experimental|FOLFIRI|
3302971|NCT00416741||1 Usual Care-Lifestyle counseling|Metabolic syndrome
3302972|NCT00416741||2 Intensive care-Lifestyle counseling|Metabolic Syndrome Implementation of guidelines
3302973|NCT00416715|Experimental|Treatment (letrozole)|Patients receive letrozole PO QD. Patients, who experience muscle pain, joint pain, or joint stiffness that requires an intervention and who are found to be vitamin D deficient, also receive calcium and vitamin D3 PO. Treatment continues for up to 28 weeks in the absence of disease progression or unacceptable toxicity.
3302974|NCT00416702|Experimental|1|QAB149
3302975|NCT00416689||Breast or lung CA pt undergoing chemoTx|
3302976|NCT00416663|Experimental|single arm|open label,single arm,intervention is Angiogenic Cell Precusors(ACPs)
3302977|NCT00416650|Experimental|Therapeutic Intervention|Patients will receive erlotinib (OSI-774) 150 mg daily by mouth. If specified toxicities occurs, the dose may be reduced.
3302978|NCT00416637|Experimental|Bevacizumab (Avastin)|Bevacizumab given and then BP checked and skin biopsies obtained.
3302979|NCT00416624|Experimental|Epoetin alfa - 40000 units|40,000 Units
3302980|NCT00416624|Experimental|Epoetin alfa - 80000 units|80,000 Units
3302981|NCT00416624|Experimental|Epoetin alfa - 120000 Units|120,000 Units
3302982|NCT00416624|Experimental|Darbepoetin alfa***|500 mcg
3302983|NCT00416598|Experimental|Treatment (chemotherapy, PBSC or bone marrow transplantation)|See Detailed Description.
3302984|NCT00416572|Experimental|Education Intervention|Participants attended 4 2-hr education sessions. The overall goal of the sessions was to provide information that would reduce participants' uncertainty about their illness and its treatment, to enhance coping in productive ways with the issues and problems confronting them, and to facilitate communication between the participants and their partners.
3302985|NCT00416572|Experimental|Nutrition Education Intervention|Participants attended 4 2-hr nutrition education sessions. Each session provided information and encouragement on setting and attaining measurable goals for healthy eating and on the benefits of thinking positively about dealing adaptively with problems in life and living a healthy lifestyle.
3302986|NCT00416572|No Intervention|Control Condition|Participants received care as usual.
3302987|NCT00416520|Experimental|1|
3302988|NCT00416520|Placebo Comparator|2|
3302989|NCT00416520|Active Comparator|3|
3302990|NCT00416494|Experimental|Initial Cohort|
3302991|NCT00416494|Experimental|Second cohort|
3302992|NCT00416481||Patient assessment|"Patients undergo assessments of cognition and performance status using the healthcare professional-rated Karnofsky performance scale. These assessments are performed by healthcare personnel. Body mass index and the percentage of unintentional weight loss and the number of falls in the past 6 months are also assessed.~Patients also complete self-administered questionnaires that measure level of functioning and need for services. It also includes questionnaires that measure higher levels of physical functioning, performance related to survival and clinically significant illness and measures of comorbidity and the impact on daily activities. Lastly, questionnaires are administered to measure the impact of cancer on patients' social functioning and perceived availability of social support.~Patients then begin planned treatment."
3302993|NCT00416455|Experimental|Treatment (diagnostic scans, surgery, chemotherapy, radiation)|Patients receive fludeoxyglucose F 18 (FDG) IV followed 60 minutes later by positron emission tomography (PET)/CT scanning on day 1. Patients also receive ferumoxtran-10 IV over 30-45 minutes on day 1 (or 24-36 hours before MRI) and undergo MRI on day 2. Patients undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy with pelvic and abdominal lymph node biopsy within 2 weeks after PET/CT scan. Patients diagnosed with metastatic disease prior to lymph node biopsy proceed directly to primary treatment. Patients with cervical cancer undergo chemoradiotherapy within 4 weeks of PET/CT scan.
3302994|NCT00416403|Experimental|Arm I|Patients receive oral fluvastatin sodium once daily for 3-6 weeks in the absence of disease progression or unacceptable toxicity.
3302995|NCT00416403|Experimental|Arm II|Patients receive oral fluvastatin sodium as in arm I at a higher dose.
3302996|NCT00416403|Experimental|Arm III|Patients do not receive fluvastatin sodium. breast Cancer surgery only
3302997|NCT00416364||1|
3302998|NCT00416364||2|
3302999|NCT00416364||3|
3303000|NCT00416364||4|
3303001|NCT00416351|Experimental|Clofarabine|Patients will receive intravenous clofarabine once daily for three consecutive days. Doses of clofarabine will start at 4 mg/m2/day and will be escalated to higher dose levels.
3303002|NCT00416312||Conventional & Patient-Specific Dosimetry|Tumor absorbed dose calculations determined using both conventional dosimetry and 3D-RD patient-specific dosimetry software.
3303003|NCT00416273|Experimental|Treatment group|Participants in the treatment group will receive Bortezomib at a dosage of 1.6 mg/m2.
3303004|NCT00416273|Experimental|Observation group|Participants in the observation group will not receive any consolidation therapy.
3303005|NCT00416260|Experimental|HFO-TGI|Patients with severe Acute Respiratory Distress Syndrome receiving sessions of high frequency oscillation and tracheal gas insufflation according to the study protocol
3303006|NCT00416260|No Intervention|CMV|Patients with severe Acute Respiratory Distress Syndrome receiving only conventional mechanical ventilation according to the study protocol
3303007|NCT00416234|Active Comparator|1|Laparoendoscopic Rendez vous (one stage management of cholelithiasis/choledocholithiasis)
3303008|NCT00416234|Active Comparator|2|preoperative ERCP and CBD clearance followed by lap cholecystectomy (two stage management of cholelithiasis/choledocholithiasis)
3303009|NCT00416208|Experimental|Bortezomib|Bortezomib 1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
3303010|NCT00416208|No Intervention|Observation|Observational arm
3303011|NCT00416195|Experimental|E2007|2 mg E2007 once daily for 2 weeks (Days 1 to 14), then 4 mg E2007 once daily for 2 weeks (Days 15 to 28), then 6 mg E2007 once daily for 2 weeks (Days 29 to 42), then 8 mg E2007 once daily for 2 weeks (Days 43 to 56), then 10 mg E2007 once daily for 2 weeks (Days 57 to 70), then 12 mg E2007 once daily for 6 weeks (Days 71 to 112).
3303012|NCT00416195|Placebo Comparator|Placebo|Matching placebo once daily for 16 weeks (Days 1 to 112)
3303013|NCT00416182|Experimental|Pulmozyme|2.5 mg Pulmozyme (dornase alfa) delivered intranasally once daily
3303014|NCT00416182|Placebo Comparator|placebo|2.5 mg/2mL placebo administered intranasally once daily
3303015|NCT00416130|Experimental|Vorinostat|A phase I portion that will determine the safety of 400mg Vorinostat once a day, continuously in the Asian population. A pre-determined dose reduction schema will be followed in the event of significant dose-limiting toxicities at this dose. Phase II will recruit additional patients at the determined dose with the goal of evaluating drug efficacy.
3303016|NCT00416078|Experimental|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
3303017|NCT00416078|Active Comparator|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
3303018|NCT00416039|Experimental|1|Midazolam and morphine
3303019|NCT00416039|Placebo Comparator|2|placebo, Nacl 0.9 %, morphine 0.5 mg/kg
3303061|NCT00415441|Placebo Comparator|Placebo physiotherapy|Manual therapy and home exercise program
3303062|NCT00415428||1.|Not Specified
3303063|NCT00415402|Placebo Comparator|placebo|non vitamin D containing sugar granules
3303064|NCT00415402|Experimental|Vitamin D3|vitamin D granules
3303020|NCT00415974|Other|Enhanced Usual Care|"Enhanced Usual Care Arm: This group will receive 2 face-to-face sessions with a health educator for dietary and health counseling in addition to an initial physician-patient visit. Educational materials that a patient might receive at his/her physician's office will also be provided at the initial health educator visit and monthly thereafter. This condition is called Enhanced Standard Care because it is, in fact, more than most obese adolescents currently receive in primary care offices in San Diego."
3303021|NCT00415974|Experimental|Stepped Care|"PACE-PC is a 1-year stepped-care intervention (subdivided into three 4-month blocks) utilizing multiple modalities including clinician and tailored health educator counseling, phone counseling, mailed content for overweight adolescents and their family to promote improved diet and physical activity behaviors aimed at weight loss and weight loss maintenance.~PACE-PC is designed to be based in the primary care setting and promotes involvement, management, and decision-making by the primary care provider about the level of PACE-PC step for each enrolled patient~Participants randomized to the PACE-PC condition will be enrolled in Step 1 (the most intensive) for the first 4 months. Depending upon response at the end of Step 1, for the next 4 months adolescents will be triaged to Step 2 (less intensive) or will repeat Step 1. At 8 months, again based upon treatment response, triage will occur to either Step 3 (least intensive) or repetition of the previous step."
3303022|NCT00415961|Experimental|1|CoStar Paclitaxel drug eluting stent
3303023|NCT00415909|Experimental|TALL-104 + IM|TALL-104 cells and imatinib mesylate (IM) therapy
3303024|NCT00415870|Experimental|PACE|Received text messages and counseling calls
3303025|NCT00415870|No Intervention|Control|
3303026|NCT00415857|Experimental|PR1 + Imatinib|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses. Continue receiving imatinib by mouth at the same dose received during the last 6 months. GM-CSF 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
3303027|NCT00415857|Experimental|PR1 + Imatinib + Interferon|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses. Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination. GM-CSF 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
3303028|NCT00415818|Experimental|Arm 1|MVA-MUC1-IL2 in combination with 1st line Chemotherapy
3303029|NCT00415818|Active Comparator|Arm 2|1st line Chemotherapy without a MVA-MUC1-IL2 combination
3303030|NCT00415805|Experimental|1|
3303031|NCT00415805|Active Comparator|2|
3303032|NCT00415766|Active Comparator|rHCG 250 ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
3303033|NCT00415766|Active Comparator|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
3303034|NCT00415766|Active Comparator|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
3303035|NCT00415701|Experimental|1|Etomidate as a single induction dose
3303036|NCT00415701|Active Comparator|2|Propofol as a single induction dose
3303037|NCT00415701|Other|3|Hydrocortisone substitution or placebo (50-50%) in etomidate-group
3303038|NCT00415675||Respiratory Tumor + Normal Tissue Motion|
3303039|NCT00415649|Experimental|A|DNA vaccine at baseline, Month 1, and Month 2, and the adenoviral vector vaccine at Month 6.
3303040|NCT00415649|Placebo Comparator|B|Placebo vaccine
3303041|NCT00415623|Active Comparator|Amlodipine 5mg|
3303042|NCT00415623|Experimental|Amlodipine 10mg|
3303043|NCT00415610|Other|Tier 1|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 170 to 200 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
3303044|NCT00415610|Other|Tier 2|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 140 to 170 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
3303045|NCT00415610|Other|Tier 3|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 110 to 140 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
3303046|NCT00415597|Experimental|ALO-01|Doses given once or twice daily
3303047|NCT00415545|Experimental|1|Fluid Watchers LITE program
3303048|NCT00415545|Experimental|2|Fluid Watchers PLUS program
3303049|NCT00415545|No Intervention|3|Usual care control group
3303050|NCT00415532|Experimental|Romiplostim|Romiplostim administered by subcutaneous injection once weekly at a starting dose of 3 μg/kg, adjusted to a maximum dose of 10 μg/kg to maintain a platelet count between 50 and 200 x 10^9/L for up to 52 weeks.
3303051|NCT00415532|Other|Standard of Care|Medical standard of care treatments were selected and prescribed by the investigator according to standard institutional practices or therapeutic guidelines and administered for up to 52 weeks.
3303052|NCT00415519|Experimental|1|
3303053|NCT00415519|Placebo Comparator|2|
3303054|NCT00415506|Experimental|Scleritis|Subjects with Scleritis
3303055|NCT00415506|Experimental|Orbital Inflammation|Subjects with Orbital Inflammation
3303056|NCT00415493|Experimental|Order 1|Cold-dry air provocation followed (on a separate day) by Warm-moist air provocation
3303057|NCT00415493|Experimental|Order 2|Warm-moist air provocation followed (on a separate day) by Cold-dry air provocation
3303058|NCT00415467|Experimental|GliaSite Radiation Therapy System (RTS)|Surgical removal of brain tumor followed by GliaSite RTS targeted brachytherapy to the specific brain tumor site
3303059|NCT00415454|Experimental|Gene therapy|Adenovirus injection followed by 3 weeks of 5-FC + vGCV prodrug therapy and a 6 week course of capecitabine-based chemoradiation
3303060|NCT00415441|Experimental|Active physiotherapy|Manual therapy and home exercise program
3303065|NCT00415389|Active Comparator|1|interactive educational program
3303066|NCT00415389|Active Comparator|2|usual medical care
3303067|NCT00415363|Experimental|A|
3303068|NCT00415363|Placebo Comparator|B|
3303069|NCT00415350|Active Comparator|Azithromycin treatment 1|
3303070|NCT00415350|Placebo Comparator|Placebo 2|
3303071|NCT00415324|Experimental|Arm 1|Patients receive eribulin mesylate IV over 5 minutes on days 1, 8, and 15 and cisplatin IV over 30-60 minutes on day 1.
3303072|NCT00415311|Other|0 mg/kg|
3303073|NCT00415311|Other|0.5 mg/kg|
3303074|NCT00415311|Other|1.0 mg/kg|
3303075|NCT00415259|Experimental|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
3303076|NCT00415259|Other|Flat control insoles|
3303077|NCT00415233|Experimental|1.1Gbq with rhTSH|Patients receive 1.1GBq dose of radioactive iodine and rhTSH
3303078|NCT00415233|Experimental|3.2 GBq with rhTSH|Patients receive 3.2GBq dose of radioactive idodine and rhTSH
3303079|NCT00415233|Experimental|1.1GBq without rhTSH|Patients only receive 1.1GBq dose of radioactive iodine and no rhTSH
3303080|NCT00415233|Experimental|3.2GBq without rhTSH|Patients only receive 3.2GBq dose of radioactive iodine and no rhTSH
3303081|NCT00415194|Experimental|Pemetrexed/Cisplatin|"Pemetrexed 500 milligrams per meter square (mg/m^2) administered intravenously (IV) plus cisplatin 75 mg/m^2 IV on Day 1 every 21 days. Pretreatment, Both Treatment Arms: Dexamethasone administered orally (po): 4 milligrams (mg) twice daily (BID) taken on the day before, the day of, and day after study treatment.~Vitamin B12 administered intramuscularly (im): 1000 micrograms (μg) taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks after last treatment dose. Folic Acid administered orally (po): 350 μg to 1000 μg taken 1 to 2 weeks before treatment and continue daily until 3 weeks after last treatment dose."
3303082|NCT00415194|Placebo Comparator|Placebo/Cisplatin|"Placebo (approximately 100 mL normal saline) administered intravenously (IV) plus cisplatin 75 mg/m^2 on Day 1 every 21 days.~Pretreatment - Both Treatment Arms: Dexamethasone administered orally (po): 4 milligrams (mg) twice daily (BID) taken on the day before, the day of, and day after study treatment. Vitamin B12 administered intramuscularly (im): 1000 micrograms (μg) taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks after last treatment dose.~Folic Acid administered orally (po): 350 μg to 1000 μg taken 1 to 2 weeks before treatment and continue daily until 3 weeks after last treatment dose."
3303083|NCT00415168|Experimental|Pemetrexed + Cisplatin|
3303084|NCT00415155|Experimental|A|
3303085|NCT00415142|Experimental|Saredutant 100 mg|Saredudant100 mg once daily for a maximum of 32 weeks
3303086|NCT00415142|Active Comparator|Escitalopram 10 mg|Escitalopram 10 mg once daily for a maximum of 32 weeks
3303087|NCT00415142|Placebo Comparator|Placebo|Placebo once daily for one week during screening phase and a maximum of 8 weeks during the acute phase
3303088|NCT00415129|Experimental|Study Group 1|Vaccine with adjuvant
3303089|NCT00415129|Experimental|Study Group 2|Vaccine without adjuvant
3303090|NCT00415103|Experimental|1|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days Palonosetrón: 0.25 mg iv every 48 horas starting day 1
3303091|NCT00415103|Active Comparator|2|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment.
3303092|NCT00415090|No Intervention|1|Follow with same ARV treatment
3303093|NCT00415090|Experimental|2|Switch one of ARV drugs to Nevirapine
3303094|NCT00415077|Active Comparator|2|LASEK- laser-assisted subepithelial keratectomy
3303095|NCT00415077|Active Comparator|3|Mitomycin C PRK
3303096|NCT00415077|Active Comparator|1|PRK- Photorefractive keratectomy
3303097|NCT00415051|Experimental|Single Group Assignment|RVF MP-12
3303098|NCT00415038|Experimental|Rostafuroxin 50 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
3303099|NCT00415038|Experimental|Rostafuroxin 150 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
3303100|NCT00415038|Experimental|Rostafuroxin 500 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
3303101|NCT00415038|Experimental|Rostafuroxin 1.5 mg capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
3303102|NCT00415038|Experimental|Rostafuroxin 5 mg capsule|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
3303103|NCT00414986|Experimental|1|Practice in this arm will receive the Chronic Care Improvement intervention
3303104|NCT00414986|Experimental|2|Practices in this arm will receive the standard CQI intervention. An in-practice CQI coordinator will assist the practices in implement a chronic disease registry.
3303105|NCT00414986|Active Comparator|3|Practice in this arm will have access to all chronic care tools, but will not have an in-practice change agent.
3303106|NCT00414973|Experimental|A|
3303107|NCT00414973|Active Comparator|B|
3303108|NCT00414960|Experimental|A|
3303109|NCT00414960|Placebo Comparator|B|
3303110|NCT00414934||metastatic bone lesion for patients with cancer|
3303111|NCT00414921|Active Comparator|1|clonidine
3303112|NCT00414921|Active Comparator|2|methylphenidate
3303113|NCT00414921|Active Comparator|3|methylphenidate and clonidine
3303114|NCT00414921|Placebo Comparator|4|
3303115|NCT00414908|Experimental|A|
3303116|NCT00414908|Placebo Comparator|B|
3303117|NCT00414869|Experimental|NCX-1000|Experimental drug under evaluation
3303118|NCT00414869|Placebo Comparator|Placebo|Placebo powder
3303158|NCT00414375|Experimental|2|appendectomy on presentation
3303159|NCT00414349|Experimental|1|
3303160|NCT00414349|Active Comparator|2|
3303161|NCT00414349|Experimental|3|
3303119|NCT00414817|Experimental|Automated Phone-Based Refill Reminders|Intervention Arm: Participants randomly assigned to this study arm may receive up to 8 automated phone calls from the BREATH EASY Medication Reminder Program over the course of the 19 month intervention period.
3303120|NCT00414817|No Intervention|Usual Care|"Usual Care: Participants randomly assigned to this arm received the same introductory letter as those in the intervention arm, giving them the opportunity to opt out, but were subsequently selected to be in the usual care study arm, and therefore, receive no intervention."
3303121|NCT00414804|Active Comparator|Spinal Cord Stimulation (SCS) Group|Spinal Cord Stimulation (SCS) Treatment Group
3303122|NCT00414804|Active Comparator|Nerve Blocks and PT|
3303123|NCT00414765|Experimental|Aldesleukin|
3303124|NCT00414726|Active Comparator|NBO (Normobaric Oxygen)|Oxygen, inhaled at 30-45L/min via a facemask for 8 hours
3303125|NCT00414726|Placebo Comparator|Room Air|Room Air, inhaled at 30-45L/min via a facemask for 8 hours
3303126|NCT00414713|Active Comparator|1|Regular transfusion
3303127|NCT00414713|Active Comparator|2|Restricted transfusion
3303128|NCT00414700|Experimental|ChondroCelect|
3303129|NCT00414700|Active Comparator|Microfracture|
3303130|NCT00414687|Experimental|Arm 1|
3303131|NCT00414661||Study group|All enrolled subjects
3303132|NCT00414648|Experimental|1|Participants will receive sirolimus daily for 1 year followed with serial pulmonary functional tests and 6-minute walk tests over a 2-year period.
3303133|NCT00414648|Placebo Comparator|2|Participants will receive placebo sirolimus daily for 1 year followed with serial pulmonary functional tests and 6-minute walk tests over a 2-year period.
3303134|NCT00414635|Other|Control Arm with Week 24 Crossover|Subjects randomized to the control arm will remain on daily dosing of the pre-study regimen of 600mg efavirenz and 1 coformulated tablet of 300mg tenofovir df + 200 mg emtricitabine by mouth daily, or the equivalent coformulated single tablet of 600mg efavirenz + 300mg tenofovir df + 200 mg emtricitabine by mouth daily for 24 weeks. After 24 weeks of daily therapy subjects on this arm may be eligible to cross over to the experimental arm regimen of the coformulated single tablet of 600 mg efavirenz +300 mg tenofovir df +200 mg of emtricitabine on the 5/2 intermittent dosing treatment schedule for the remainder of the study.
3303135|NCT00414635|Experimental|5/2 Intermitent Treatment Arm|Subjects randomized to the 5/2 intermittent dosing treatment schedule regimen will be prescribed the pre-study regimen of 600mg efavirenz and 1 coformulated tablet of 300mg tenofovir df + 200 mg emtricitabine by mouth daily, or the equivalent coformulated single tablet of 600mg efavirenz + 300mg tenofovir df + 200 mg emtricitabine by mouth daily, for 5 consecutive days per week followed by 2 days off of these medications, 600 mg efavirenz, 300 mg tenoforvir dt and 200 mg emtricitabine, for 48 weeks.
3303136|NCT00414609|Experimental|Aliskiren|"Core Study: Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for next 34 weeks orally once daily in the morning.~Extension Study: Patients from both the core arms who completed core study and signed informed consent form were included in this arm of extension study.~Patients received 150 mg aliskiren tablet orally once a day for two weeks. Patients were then up-titrated to 300 mg aliskiren orally once a day at the discretion of the principal investigator based on their clinical condition for the duration of the study."
3303137|NCT00414609|Placebo Comparator|placebo|Core study: placebo for 36 weeks once daily in the morning
3303138|NCT00414596|Experimental|DRX Group|Patients using the device DRX9000™.
3303139|NCT00414583||Observation|all adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology
3303140|NCT00414544|Experimental|CosmetaLife|Test Article was given at start and two week follow up if necessary, up to a maximum dose of 2 cc to achieve optimal correction as determined by investigator.
3303141|NCT00414544|Active Comparator|Restylane|Control Article was given at start and two week follow up if necessary, up to a maximum dose of 2 cc to achieve optimal correction as determined by investigator.
3303142|NCT00414531|Other|SIM|Patients diagnosed to have or not to have Statin induced Myopathy
3303143|NCT00414518|Experimental|Treatment interruption|Oral Tenofovir disoproxil fumarate/Emtricitabine and Lopinavir/Ritonavir for 12 weeks followed by treatment interruption if CD4 count is 450 mm^3 or higher. When CD4 count is less than 350 mm^3 on two separate, consecutive measurements during treatment interruption, therapy will be resumed.
3303144|NCT00414518|Experimental|CD4 T cell guided therapy|Anti Retroviral Therapy initiated when AIDS-defining illness occurs or if CD4 count is confirmed at less than 350 mm^3 at two separate, consecutive measurements
3303145|NCT00414479||children 9-12 years of age|Children with schistosomiasis, malaria and anaemia
3303146|NCT00414466|Placebo Comparator|Placebo (0mg/day)|Intraspinal Placebo delivered continuously for 29 days via an implantable infusion system
3303147|NCT00414466|Active Comparator|Gabapentin Low (1mg/day)|Intraspinal Gabapentin Low delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
3303148|NCT00414466|Active Comparator|Gabapentin Medium (6mg/day)|Intraspinal Gabapentin Medium delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
3303149|NCT00414466|Active Comparator|Gabapentin High (30mg/day)|Intraspinal Gabapentin High delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
3303150|NCT00414453|Active Comparator|Lidocaine 5% + placebo patch, ER and placebo pills|5% lidocaine patch used as intervention placebo patch used with extended release oxycodone or with placebo pills and placebo patches a randomized subjects given extended release oxycodone and placebo patches during this treatment placebo pills used with lidocaine 5% patch group and with placebo patch/placebo pill group period
3303151|NCT00414440|Experimental|Everolimus|Patients in the everolimus group initially received 5 mg/day everolimus divided in 2 equal doses (i.e. 2.5 mg b.i.d.). Dose adjustments were performed to achieve a blood trough level of 3-8 ng/mL (maximum daily dose: 10 mg/day [5 mg b.i.d.]).
3303152|NCT00414440|Placebo Comparator|Placebo|Placebo tablets equivalent to the dosage of everolimus 5 mg/day, divided in 2 equal doses.
3303153|NCT00414414|Active Comparator|prednisone|
3303154|NCT00414414|Placebo Comparator|placebo|
3303155|NCT00414401|Other|Arm 1|
3303156|NCT00414388|Experimental|Single agent Sorafenib|Oral Single agent Sorafenib 400mg twice daily
3303157|NCT00414375|Active Comparator|1|Drainage with interval appendectomy
3303162|NCT00414310|Experimental|Decitabine|Decitabine 20 mg/m^2 intravenous (IV) over 1 hour daily for 5 days.
3303163|NCT00414310|Experimental|Decitabine + Valproic Acid|Decitabine 20 mg/m^2 intravenous (IV) over 1 hour daily for 5 days. Valproic Acid 50 mg/kg orally daily for 7 days.
3303164|NCT00414297|Active Comparator|1 ECP|active ECP Therapy
3303165|NCT00414297|Placebo Comparator|2|Sham ECP Treatment
3303166|NCT00414206|Active Comparator|1% mecamylamine|
3303167|NCT00414206|Active Comparator|0.3% mecamylamine|
3303168|NCT00414206|Placebo Comparator|Placebo|
3303169|NCT00414167|Experimental|1|Bupropion
3303170|NCT00414167|Placebo Comparator|2|Placebo
3303171|NCT00414141|Experimental|1|Grass MATA MPL
3303172|NCT00414141|Placebo Comparator|2|
3303173|NCT00414128|Experimental|mycophenolate mofetil|Mycophenolate mofetil for 3-6 months until in stable remission, dose 2-3g/day
3303174|NCT00414128|Active Comparator|cyclophosphamide|pulsed intravenous cyclophosphamide 15mg/kg for 3-6 months (6-10 doses)until in stable remission
3303175|NCT00414102|Experimental|Ramelteon 8 mg QD|
3303176|NCT00414102|Placebo Comparator|Placebo QD|
3303177|NCT00414076|Active Comparator|Letrozole|Letrozole 2.5 mg Tablet By Mouth Daily for 12 Weeks.
3303178|NCT00414076|No Intervention|Standard of Care|Patients receive no treatment. Follow up every 3 months.
3303179|NCT00414050|Experimental|Modified Process Hepatitis B vaccine 5 μg|Infants received a primary series of 3 doses of experimental vaccine (5 μg per dose) at 2, 4 and 6 months of age.
3303180|NCT00414050|Active Comparator|RECOMBIVAX HB™ Hepatitis B Vaccine|Infants received a primary series of 3 doses of currently licensed vaccine (5 μg per dose) at 2, 4 and 6 months of age.
3303181|NCT00414050|Experimental|Modified Process Hepatitis B vaccine 10 μg|Infants received a primary series of 3 doses of experimental vaccine (10 μg per dose) at 2, 4 and 6 months of age.
3303182|NCT00414050|Active Comparator|ENGERIX-B®|Infants received a primary series of 3 doses of currently licensed vaccine (10 μg per dose) at 2, 4 and 6 months of age.
3303183|NCT00414037|Experimental|eszopiclone (Lunesta) 3mg|Subchronic (1-week) administration of 3mg Lunesta (eszopiclone)
3303184|NCT00414037|Placebo Comparator|Placebo|Placebo-treated group
3303185|NCT00414011|Experimental|Moxifloxacin|Moxifloxacin eye drops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
3303186|NCT00414011|Experimental|Gatifloxacin|Gatifloxacin eyedrops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
3303187|NCT00413998|Experimental|CABG + Mitral valve repair|
3303188|NCT00413998|Active Comparator|CABG only|
3303189|NCT00413972|Experimental|Vytorin 10/10|Ezetimibe 10 mg with Simvastatin 10 mg
3303190|NCT00413972|Experimental|Vytorin 10/20|Ezetimibe 10 mg with Simvastatin 20 mg
3303191|NCT00413972|Experimental|Vytorin 10/40|Ezetimibe 10 mg with Simvastatin 40 mg
3303192|NCT00413972|Placebo Comparator|Placebo|
3303193|NCT00413959|Experimental|Velcade, Rituximab,Cyclophosphamide & Decadron|Velcade 375 mg/m^2 given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
3303194|NCT00413946|Experimental|Erythropoietin|Three doses of rErythropoietin (3000 U/kg body weight) intravenously at 3, 12-18 and 36-42 hours after birth.
3303195|NCT00413946|Placebo Comparator|saline|Three doses of placebo (0.9% saline 1 ml/kg body weight) intravenously at 3, 12-18 and 36-42 hours after birth
3303196|NCT00413933|Experimental|Intrevention group|each subject in intervention group will get 15 weekly sessions (each session - 45 minutes) of specified exercise from a physical therapist that specializes in fall prevention and walking device recommendations. All subjects will get brochure for home exercise. It will be expected for intervention group to exercise twice daily, each time for 20 minutes in addition to the PT sessions
3303197|NCT00413933|No Intervention|Control group|"Those who agree to participate in the study will fill in questionnaire about falls (causes, circumstance, results). All will pass through: cognitive assessment by the Mini-Mental State Examination (MMSE), affective assessment by the 15-item Geriatric Depression Scale (GDS), functional assessment by Barthel Index (BI), visual assessment by Snellen charts and basic gait assessment by a Timed get Up and Go test (TU&G).~Participants that fulfill inclusion criteria will be randomly assigned to the intervention group or the control group"
3303198|NCT00413920|Experimental|Without Steroids|Patients received Enteric-coated Mycophenolate Sodium (EC-MPS), administered orally 2 times a day for 6 months. Patients also received cyclosporine and a dose of methylprednisolone immediately after transplantation, but did not subsequently receive oral corticosteroids for the remainder of the study.
3303199|NCT00413920|Active Comparator|With Steroids|Patients received Enteric-coated Mycophenolate Sodium (EC-MPS), administered orally 2 times a day for 6 months. Patients also received cyclosporine and a dose of methylprednisolone immediately after transplantation, and subsequently continued to receive daily oral prednisone.
3303200|NCT00413894|Experimental|1|
3303201|NCT00413881|Active Comparator|2|Conventional LASIK Enhancement
3303202|NCT00413881|Experimental|1|Wavefront guided LASIK Enhancement
3303203|NCT00413829|Other|1|
3303204|NCT00413803|Other|1|Four-hour dialysis session, blood flow rate 300-400 ml/min
3303205|NCT00413803|Active Comparator|2|Eight-hours dialysis session, blood flow rate 200-250 ml/min
3303206|NCT00413790|Experimental|1|Darifenacin
3303207|NCT00413790|Active Comparator|2|Tolterodine
3303208|NCT00413790|Placebo Comparator|3|Placebo
3303209|NCT00413777|Experimental|Tolvaptan 45/15 mg/day orally for up to 4 years|Participants received tolvaptan 45 mg orally in the morning and 15 mg orally 8 hours later for up to 4 years.
3303210|NCT00413777|Experimental|Tolvaptan 60/30 mg/day orally for up to 4 years|Participants received tolvaptan 60 mg orally in the morning and 30 mg orally 8 hours later for up to 4 years.
3303211|NCT00413764|Experimental|1|tibolone
3303212|NCT00413764|Active Comparator|2|transdermal continuous combined E2-NETA (estradiol-norethisterone)
3303213|NCT00413725|Experimental|1|Three doses of MRKAd5 HIV-1 gag/pol/nef vaccine
3303214|NCT00413725|Placebo Comparator|2|Placebo
3303215|NCT00413699|Experimental|Open-Label Active Treatment Enrolled from Phase 2|Patients enrolling from Phase 2 studies
3303216|NCT00413699|Experimental|Open-Label Active Treatment Enrolled from Phase 3|Patients enrolling from Phase 3 studies
3303217|NCT00413686|Experimental|1|AZD7762 monotherapy followed by AZD7762 + gemcitabine
3303218|NCT00413673|Experimental|1|PRK
3303219|NCT00413660|Experimental|CP 690,550 1 mg BID|
3303220|NCT00413660|Experimental|CP 690,550 10 mg BID|
3303221|NCT00413660|Experimental|CP 690,550 15 mg|
3303222|NCT00413660|Experimental|CP 690,550 3 mg BID|
3303223|NCT00413660|Experimental|CP 690,550 5 mg BID|
3303224|NCT00413660|Experimental|CP-690,550 20 mg QD|
3303225|NCT00413660|Placebo Comparator|Placebo|Dummy tablets
3303226|NCT00413647|Experimental|CardioPET|
3303227|NCT00413634|Experimental|1|
3303228|NCT00413608|Experimental|1|Clopidogrel
3303229|NCT00413608|Experimental|2|Clopidogrel
3303230|NCT00413595||Observation|Adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology and the genetic diagnosis (a-galactosidase defect) of Fabry disease
3303231|NCT00413582|Active Comparator|1|Epidural analgesia
3303232|NCT00413582|Experimental|2|IV narcotic analgesia
3303233|NCT00413556|Active Comparator|1|
3303234|NCT00413556|Placebo Comparator|2|
3303235|NCT00413543|Experimental|interventional, rehabilitation|'early pulmonary lung rehabilitation'
3303236|NCT00413543|No Intervention|control|"standard care"
3303237|NCT00413491|Experimental|1|Comparison of MR and mammography
3303238|NCT00413478|Experimental|5-Azacytidine|5-Azacytidine 75mg/m^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
3303239|NCT00413452|Experimental|50 mg|50 mg once weekly
3303240|NCT00413439|Experimental|Low dose isavuconazole intravenous solution|
3303241|NCT00413439|Experimental|High dose isavuconazole intravenous solution or oral capsules|
3303242|NCT00413413|Experimental|Valsartan/amlodipine 80/5 mg|
3303243|NCT00413413|Active Comparator|Valsartan 80 mg|
3303244|NCT00413413|Active Comparator|Valsartan 160 mg|
3303245|NCT00413400|Placebo Comparator|Placebo|
3303246|NCT00413400|Active Comparator|Etanercept|
3303247|NCT00413387|Experimental|1|chf1535
3303248|NCT00413387|Active Comparator|2|Symbicort
3303249|NCT00413374|Other|Enoxaparin|
3303250|NCT00413361|Placebo Comparator|A|placebo
3303251|NCT00413361|Experimental|B|versus hydroxychloroquine
3303252|NCT00413335|Active Comparator|1|Subject undergoes ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, NMR and DEXA scan. Subject then receives Rosiglitazone. Subjects are followed every 2 weeks. Imaging repeated at 2 months. 12 week follow up. And then all tests are repeated at 4 months.
3303253|NCT00413335|Placebo Comparator|2|Subject has ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, DEXA, NMR. Subject is randomized (double-blind) to placebo. Is followed every 2 weeks, repeats imaging at 2 months, is seen at 12 weeks and then repeats all tests at 2 months.
3303254|NCT00413322|Experimental|Single-arm dose escalation|
3303255|NCT00413296|Placebo Comparator|1|Tablets, no active ingredient, 1-6 tablets/day for 12 wks in the 2 nd phase of the trial.
3303256|NCT00413296|Active Comparator|2|Levetiracetam, 500mg (1-6 tablets /day) for 12 wks in the 2nd phase of the study.
3303257|NCT00413283|Placebo Comparator|Placebo|Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
3303258|NCT00413283|Experimental|Romiplostim 250 μg|Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
3303259|NCT00413283|Experimental|Romiplostim 500 μg|Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
3303260|NCT00413283|Experimental|Romiplostim 750 μg|Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
3303261|NCT00413257|Experimental|1|nefopam infusion will start before the surgical incision, at the induction time of anesthesia and will be continued until postoperative H48
3303262|NCT00413257|Experimental|2|nefopam administration will start at the end of the surgery and will be continued until postoperative H48
3303263|NCT00413257|Placebo Comparator|3|control group that will receive a placebo from the induction time of anesthesia until H48
3303264|NCT00413244|Experimental|Androgel treatment|"Androgel 5 grams~Androgel treatment - subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
3303265|NCT00413244|Placebo Comparator|Placebo|Placebo - will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
3303266|NCT00413231|Experimental|Valiant Thoracic Stent Graft System|"160 subjects were enrolled into the study, including 157 subjects treated with the study device and three subjects classified as intent-to-treat who did not receive the study device.~There were no other arms for this study."
3303326|NCT00412607|Experimental|NaviStar ThermoCool Catheter|
3303267|NCT00413218|Experimental|Isavuconazole (ISA)|Participants received 3 intravenous (IV) loading doses of 200 mg of isavuconazole on days 1 and 2, followed by an IV maintenance dose of 200 mg once daily from day 3 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV to oral therapy. Oral therapy consisted of 200 mg isavuconazole twice daily.
3303268|NCT00413218|Active Comparator|Caspofungin (CAS)/Voriconazole|Participants received 1 intravenous (IV) loading dose of 70 mg CAS on day 1, followed by an IV maintenance dose of 50 mg CAS from day 2 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV CAS to oral voriconazole comprising of a loading dose of 400 mg twice daily (BID) on the first day of oral therapy followed by standard dosing of 200 mg BID thereafter.
3303269|NCT00413205|Placebo Comparator|Placebo|po daily
3303270|NCT00413205|Experimental|RAR Gamma|5mg po daily
3303271|NCT00413192|Experimental|1|
3303272|NCT00413166|Experimental|Induction|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO)~ATRA 45 mg/m2 daily by mouth beginning day 1; ATO 0.15 mg/kg by vein daily beginning on day 1; Idarubicin 12 mg/m2 x 1 dose; Methylprednisolone 50 mg daily for 5 days starting on day 1."
3303273|NCT00413166|Experimental|Maintenance|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO)~ATO 0.15 mg/kg by vein over 2 hours Monday-Friday for 4 weeks, then a 4-week break. ATRA 45 mg/m2 by mouth every day for 2 weeks, followed by 2 additional weeks of no study drug. Continue ATRA until treatment with ATO complete."
3303274|NCT00413153|Active Comparator|1|Boosted Reyataz (300mg atazanavir + 100mg ritonavir)
3303275|NCT00413153|Active Comparator|2|Kaletra (pre-study dose)
3303276|NCT00413127|Experimental|1|Lidocaine i.v
3303277|NCT00413127|Active Comparator|2|intraoperatively lidocaine epidural postoperatively lidocaine i.v.
3303278|NCT00413127|Active Comparator|3|intraoperatively lidocaine i.v. postoperatively lidocaine epidural
3303279|NCT00413127|Active Comparator|4|lidocaine epidural
3303280|NCT00413127|Placebo Comparator|5|placebo i.v.
3303281|NCT00413114|Experimental|Obatoclax Mesylate|Obatoclax Mesylate 30mg
3303282|NCT00413101|Experimental|1|
3303283|NCT00413075|Experimental|oral belinostat|
3303284|NCT00413062|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
3303285|NCT00413062|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
3303286|NCT00413049|Experimental|Valsartan/amlodipine 80/5 mg|
3303287|NCT00413049|Active Comparator|Amlodipine 5 mg|
3303288|NCT00413036|Experimental|lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
3303289|NCT00413010|Placebo Comparator|Arm 2|
3303290|NCT00413010|Experimental|Arm 1|
3303291|NCT00412997|Experimental|LBH589|
3303292|NCT00412984|Active Comparator|1|
3303293|NCT00412984|Experimental|2|
3303294|NCT00412971|Active Comparator|Hexvix cystoscopy group|
3303295|NCT00412971|Other|White light|Standard White light cystoscopy
3303296|NCT00412958|Experimental|Ocriplasmin 25µg|25µg of ocriplasmin intravitreal injection
3303297|NCT00412958|Experimental|Ocriplasmin 75µg|75µg of ocriplasmin intravitreal injection
3303298|NCT00412958|Experimental|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
3303299|NCT00412958|Placebo Comparator|Placebo|Intravitreal injection of placebo
3303300|NCT00412893|Experimental|Isavuconazole|Participants received a loading dose of isavuconazole, 200 mg three times a day by intravenous infusion (IV) for the first 2 days followed by a maintenance dose from Day 3 of 200 mg once daily either IV or orally until they reached a treatment endpoint or for a maximum of 84 days.
3303301|NCT00412893|Active Comparator|Voriconazole|Participants received a loading dose of voriconazole, 6 mg/kg every 12 hours IV for the first 24 hours, followed by a maintenance dose of 4 mg/kg every 12 hours by IV on Day 2. Beginning on Day 3, participants received 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they reached a treatment endpoint or for a maximum of 84 days.
3303302|NCT00412867|Experimental|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
3303303|NCT00412841|Experimental|Atorvastatin|Atorvastatin 40mg
3303304|NCT00412841|Placebo Comparator|Placebo|Tablets identical to atorvastatin 40mg
3303305|NCT00412802|Experimental|1|dose adaptation of Enoxaparine at the renal deficient patients
3303306|NCT00412802|Active Comparator|2|No dose adaptation of Enoxaparine at renal normal patients
3303307|NCT00412789|Experimental|EPO906|
3303308|NCT00412776|Experimental|1|Proxinium plus Best Supportive Care
3303309|NCT00412776|No Intervention|2|Best Supportive Care
3303310|NCT00412750|Experimental|LdT+ PEG-INF|Telbivudine (LdT) 600 mg orally once a day for 104 weeks in combination with peginterferon alpha-2a (PEG-INF)180 μg subcutaneous injection once a week for 52 weeks.
3303311|NCT00412750|Experimental|LdT Monotherapy|Telbivudine (LdT) monotherapy: 600 mg orally once daily for 104 weeks.
3303312|NCT00412750|Active Comparator|PEG-INF Monotherapy|Peginterferon alpha-2a (PEG- INF) monotherapy: 180 μg subcutaneous injection once a week for 52 weeks.
3303313|NCT00412737|Experimental|Oseltamivir|
3303314|NCT00412737|Placebo Comparator|Placebo|
3303315|NCT00412698|Experimental|1|
3303316|NCT00412698|Placebo Comparator|2|
3303317|NCT00412685||TGA group|The TGA group consists of 15 patients treated withMustard or Senning procedures for surgical repaired of D-TGA atrial switch operation.
3303318|NCT00412685||TOF group|The TOF group consists of 15 patients with surgically corrected TOF.
3303319|NCT00412685||Control group|The control group C consists of 15 control subjects (AH) with normal Doppler Echocardiographic echocardiographic examinations.
3303320|NCT00412659|Active Comparator|Midline excision|Midline excision for pilonidal sinus disease.
3303321|NCT00412659|Active Comparator|Karydakis|Karydakis operation for pilonidal sinus disease.
3303322|NCT00412620|Placebo Comparator|Sugar Pill|
3303323|NCT00412620|Experimental|Group 1 Part 1 - ABT-925|
3303324|NCT00412620|Experimental|Group 1 Part 2 - ABT-925|
3303325|NCT00412620|Experimental|Group 2 - ABT-925|
3303327|NCT00412594|Experimental|2CDA + Rituximab|Cladribine (2CDA) 5.6 mg/m^2 by vein over 2 hours daily for 5 days; Rituximab 375 mg/m^2 by vein weekly times 8 starting on day 28 (plus or minus 4 days) following 2CDA treatment.
3303328|NCT00412581|Experimental|Lenalidomide + Dacarbazine|
3303329|NCT00412568|Active Comparator|1|PRK control group
3303330|NCT00412555|Experimental|1|
3303331|NCT00412542|Experimental|Thalidomide + CPT-11|Oral Thalidomide 100 mg daily for 8 weeks + CPT-11 125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest.
3303332|NCT00412529|Experimental|Telbivudine|
3303333|NCT00412529|Active Comparator|Entecavir|
3303334|NCT00412516|Other|Group 1|JE live attenuated SA 14-14-2 vaccine then measles vaccine after one month
3303335|NCT00412516|Experimental|Group 2|JE live attenuated SA 14-14-2 vaccine and measles vaccine concurrently
3303336|NCT00412516|Other|Group 3|Measles vaccine then JE live attenuated SA 14-14-2 vaccine after one month
3303337|NCT00412490||Smoking Behavior Group|Individuals Having Surgery for Oral Cavity Cancer.
3303338|NCT00412477|Experimental|Group 1 - LFn-p24 ISOug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
3303339|NCT00412477|Experimental|Group 2 - LFn-p24 300ug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
3303340|NCT00412477|Experimental|Group 3 - LFn-p24 450ug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
3303341|NCT00412451|Experimental|Ocriplasmin 25µg|25µg ocriplasmin intravitreal injection versus sham injection
3303342|NCT00412451|Experimental|Ocriplasmin 75µg|75µg ocriplasmin intravitreal injection versus sham injection
3303343|NCT00412451|Experimental|Ocriplasmin 125µg|125µg ocriplasmin intravitreal injection versus sham injection
3303344|NCT00412451|Sham Comparator|sham injection|Sham injection
3303345|NCT00412425|Active Comparator|2 Days Palonosetron|2 Days Palonosetron 0.25 mg intravenous (IV)
3303346|NCT00412425|Active Comparator|3 Days Palonosetron|3 Days Palonosetron 0.25 mg IV
3303347|NCT00412412|Experimental|A|Patients with HER2- Breast Cancer
3303348|NCT00412412|Experimental|B|Patients with HER2+ Breast Cancer
3303349|NCT00412386||BAV|patients with BAV
3303350|NCT00412386||Normal control|normal patients
3303351|NCT00412373|Experimental|001|Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
3303352|NCT00412373|Experimental|003|Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
3303353|NCT00412373|Placebo Comparator|002|Placebo for 6 weeks
3303354|NCT00412360|Experimental|Single Cord Blood Transplant|Unrelated donor, single umbilical cord blood unit transplant; conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil
3303355|NCT00412360|Experimental|Double Cord Blood Transplant|Unrelated donor, double umbilical cord blood unit transplant; Conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil
3303356|NCT00412334|Experimental|1|
3303357|NCT00412334|Experimental|2|
3303358|NCT00412334|Experimental|3|
3303359|NCT00412334|Experimental|4|
3303360|NCT00412321|Experimental|Cohort 1 (CNTO 328)|Patients will receive 4 administrations of 3 mg/kg CNTO 328 every 2 weeks till Day 43.
3303361|NCT00412321|Experimental|Cohort 2 (CNTO 328)|Patients will receive 4 administrations of 6 mg/kg CNTO 328 every 2 weeks till Day 43.
3303362|NCT00412321|Experimental|Cohort 3 (CNTO 328)|Patients will receive 3 administrations of 12 mg/kg CNTO 328 every 2 weeks till Day 43.
3303363|NCT00412321|Experimental|Cohort 4 (CNTO 328)|Patients will receive 7 administrations of 6 mg/kg CNTO 328 every week till Day 43.
3303364|NCT00412321|Experimental|Cohort 5 (CNTO 328)|Patients will receive 4 administrations of 12 mg/kg CNTO 328 every 2 weeks till Day 43.
3303365|NCT00412321|Experimental|Cohort 6 (CNTO 328)|Patients will receive 3 administrations of 12 mg/kg CNTO 328 every 3 weeks till Day 43.
3303366|NCT00412321|Experimental|Cohort 7a (CNTO 328)|Patients responding to CNTO 328 treatment will receive 9 mg/kg CNTO 328 every 3 weeks.
3303367|NCT00412321|Experimental|Cohort 7b (CNTO 328)|Patients responding to CNTO 328 treatment will receive 12 mg/kg CNTO 328 every 3 weeks as extended administration.
3303368|NCT00412243|Experimental|Clofarabine + Cyclophosphamide|Clofarabine 40 mg/m^2 daily for 3 Days + Cyclophosphamide starting 200 mg/m^2 every 12 hours for 3 days
3303369|NCT00412230||no treatment|
3303370|NCT00412230||2|
3303371|NCT00412217|Experimental|Erlotinib|Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive erlotinib tablets as 150 mg PO daily for 1 year until disease progression or intolerable toxicity.
3303372|NCT00412217|Placebo Comparator|Placebo|Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive placebo treatment for 1 year until disease progression or intolerable toxicity.
3303373|NCT00412204|Active Comparator|1|Tiotropium
3303374|NCT00412204|Placebo Comparator|2|Placebo
3303375|NCT00412191|Experimental|Subjects in treatment regimen A|Subjects in treatment regimen A will receive 100 and 200 mg lamotrigine XR in fasting condition.
3303376|NCT00412191|Experimental|Subjects in treatment regimen B|Subjects in treatment regimen B will receive 100 mg lamotrigine XR in fasting condition.
3303466|NCT00411229|Active Comparator|1|Capecitabine + Oxalipatin
3303377|NCT00412191|Experimental|Subjects in treatment regimen C|Subjects in treatment regimen C will receive 100 mg lamotrigine XR in fed condition.
3303378|NCT00412165|No Intervention|usual care|Usual care arm receives standard physical activity, nutrition and weight loss information from their primary care provider. The study offers and pays for a series of weight management sessions provided by Rady's Children's Hospital and Health Center's Nutrition Dept.
3303379|NCT00412165|Experimental|Intervention - Web|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition.
3303380|NCT00412165|Experimental|Intervention - Group|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition and has access to monthly group session with other teen and parent participants.
3303381|NCT00412165|Experimental|Intervention - Cell Phone|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition and are provided with cell phones to use during the program. The cell phone allows for the transfer of text messages from the study to the participant that are tailored to their health goals. In addition, self-monitoring and uploading capabilities to the program website are included.
3303382|NCT00412113|Active Comparator|Norvasc 5 mg|Blinded amlodipine 5 mg and amlodipine/atorvastatin single pill combination 5/20 mg placebo dosed once daily for 6 weeks.
3303383|NCT00412113|Experimental|Caduet 10/20mg|Blinded amlodipine/atorvastatin single pill combination 10/20 mg dosed once daily for 6 weeks and amlodipine besylate 10 mg placebo.
3303384|NCT00412113|Active Comparator|Norvasc 10 mg|Blinded amlodipine 19 mg and amlodipine/atorvastatin single pill combination 10/20 mg placebo dosed once daily for 6 weeks.
3303385|NCT00412113|Experimental|Caduet 5/20mg|Blinded amlodipine/atorvastatin single pill combination 5/20 mg and amlodipine besylate 5 mg placebo dosed once daily for 6 weeks .
3303386|NCT00412087|Experimental|Cholecalciferol 2000 IU|Women at 12-16 weeks' gestation are enrolled into the study to receive 2000 IU/day vitamin D3 for one month. After the run-in dose, the subjects are randomized to one of two treatment groups: either 2000 or 4000 IU/day to be taken throughout pregnancy until delivery.
3303387|NCT00412087|Experimental|Cholecalciferol 4000 IU|Women are randomized to one of 2 treatment groups: 2000 or 4000 IU vitamin D3/day
3303388|NCT00412074|Active Comparator|Control 400 IU vitamin D3|400 IU vitamin D3/day given to lactating women and 400 IU vitamin D3/day given as oral supplement to infant in dyad
3303389|NCT00412074|Experimental|2400 IU vitamin D3 (cholecalciferol)|2400 IU vitamin D3 given to lactating mother: 400 IU vitamin D3 from a prenatal vitamin and 2000 IU vitamin D3 and 0 IU vitamin D3 (placebo) given to her breastfeeding infant
3303390|NCT00412074|Experimental|6400 IU vitamin D3 (cholecalciferol)|6400 IU vitamin D3 given to lactating mother: 400 IU vitamin D3 from a prenatal vitamin and 6000 IU vitamin D3 and 0 IU vitamin D3 (placebo) given to her breastfeeding infant
3303391|NCT00412061|Experimental|Octreotide+ Everolimus|Everolimus was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity. Each treatment cycle lasted 28 days. Patients received their first dose of everolimus at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1, Day 1.
3303392|NCT00412061|Placebo Comparator|Octreotide+ Placebo|Matching placebo was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity; Each treatment cycle lasted 28 days. Patients received their first dose of matching placebo at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1 Day 1.
3303393|NCT00412048|Other|ALZHEIMER DISEASE|
3303394|NCT00412048|Other|MOLD COGNITIVE IMPAIRMENT|
3303395|NCT00412048|Other|CONTROLS|
3303396|NCT00412035|Active Comparator|Botox|Botulinum toxin A injection
3303397|NCT00412035|Placebo Comparator|Placebo|saline injection
3303398|NCT00412022|Active Comparator|A|Triptorelin 3.75 mg IM every 4 weeks and Tamoxifen 20 mg daily, for 5 years
3303399|NCT00412022|Active Comparator|B|Triptorelin 3.75 mg IM every 4 weeks and Letrozole 2.5 mg daily, for 5 years
3303400|NCT00412022|Experimental|C|Triptorelin 3.75 mg IM every 4 weeks and Letrozole 2.5 mg daily for 5 years + zoledronic acid 4 mg every 6 months.
3303401|NCT00411996|Active Comparator|1|IDV/r 600/100 mg + rifampicin
3303402|NCT00411957|Active Comparator|1|ATV/r 300/100 mg
3303403|NCT00411957|Active Comparator|2|ATV/r 200/100 mg OD
3303404|NCT00411892|Experimental|A|
3303405|NCT00411892|Active Comparator|B|
3303406|NCT00411879|Placebo Comparator|Control Group|Patients with refractory cardiac arrest (as defined in methods) treated according to the latest guidelines for resuscitation and receiving placebo instead of vasopressin and corticosteroids
3303407|NCT00411879|Experimental|Study Group|Patients with refractory cardiac arrest treated with combined vasopressin, epinephrine, and methylprednisolone during resuscitation. Patients receive stress-dose hydrocortisone for postresuscitation shock
3303408|NCT00411866|Experimental|Subjects receiving ketoconazole for 8 days|In Session 1, subjects will receive a single oral dose of SB-773812 20 milligrams (mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 8 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.
3303409|NCT00411866|Experimental|Subjects receiving ketoconazole for 14 days|In Session 1, subjects will receive a single oral dose of SB-773812 (20mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 12 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.
3303410|NCT00411827|Active Comparator|1|PRK
3303411|NCT00411827|Active Comparator|2|LASIK
3303412|NCT00411814|Placebo Comparator|Placebo|Saline
3303413|NCT00411814|Active Comparator|Active|GSK679586
3303461|NCT00411281|Experimental|Group I|Patients receive very low-dose cytarabine subcutaneously twice daily on days 1-7. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or complete or hepatic clinical remission undergo observation.
3303414|NCT00411801|Experimental|Uniplas|Participants will receive Uniplas intravenously in 4 cycles of 7 to 9 days each for 1 month. The first cycle will consist of 1.5 plasma volume exchanges (= 75 mL/kg) for 3 consecutive days, followed by a minimum of 4 and a maximum of 6 daily single volume plasma exchanges (= 50 mL/kg). Subsequent treatment will depend upon the response of the participant to the first cycle, as assessed by a blinded assessor.
3303415|NCT00411801|Active Comparator|Cryosupernatant plasma|Participants will receive cryosupernatant plasma intravenously in 4 cycles of 7 to 9 days each for 1 month. The first cycle will consist of 1.5 plasma volume exchanges (= 75 mL/kg) for 3 consecutive days, followed by a minimum of 4 and a maximum of 6 daily single volume plasma exchanges (= 50 mL/kg). Subsequent treatment will depend upon the response of the participant to the first cycle, as assessed by a blinded assessor.
3303416|NCT00411788|Experimental|sirolimus and trastuzumab|Patients received oral sirolimus 6 mg daily in combination with weekly trastuzumab administered intravenously with a loading dose of 4 mg/kg followed by 2 mg/kg weekly in a 28-day cycle. A subsequent amendment allowed trastuzumab to be administered every 3 weeks for patient convenience, with a loading dose of 8 mg/kg followed by a 6 mg/kg in a 21-day cycle. Sirolimus was administered at a 6 mg oral daily dose. Cycles were repeated on an every 21 or 28-day schedule until disease progression, unacceptable toxicity, or the development of any of the criteria for study removal. Doses were reduced or discontinued based on tolerability.
3303417|NCT00411762|Experimental|PHY906 Administration|PHY906 800mg, orally, twice a day for days 1-4 and capecitabine 1500mg/m^2 days 1-7 of a 14-day cycle
3303418|NCT00411749|Experimental|V501|"V501 vaccination Quadrivalent HPV (Types 6, 11, 16,~18) L1 VLP Vaccine Injection~cervix cancer exgenlesion Vaccination at Day 1, Month 2, and Month 6. Total 3 vaccinations. 0.5 mL intramuscular dose of V501 (HPV L1 Virus-Like Particle [VLP] Type 6,~Type 11, Type 16, Type 18) or placebo at Day 1, Month 2 and Month 6."
3303419|NCT00411749|Placebo Comparator|Placebo|Placebo vaccination, Placebo 0.5 ml injection in 3 dosing regimen
3303420|NCT00411736|Experimental|A|Stratification group: Age under 8 years, no CF siblings at home.
3303421|NCT00411736|Experimental|B|Stratification group: Age >/= 8 years, no CF siblings at home.
3303422|NCT00411736|Experimental|C|Stratification group: Age >/= 8 years, CF siblings at home.
3303423|NCT00411723|Experimental|1|
3303424|NCT00411723|Placebo Comparator|2|
3303425|NCT00411697|Experimental|Group A|
3303426|NCT00411671|Experimental|Sorafenib|Sorafenib 400 mg By Mouth Twice Daily for 28 Days.
3303427|NCT00411658|Experimental|Investigational Device|
3303428|NCT00411658|Active Comparator|Cryopreserved|
3303429|NCT00411645|Experimental|A|
3303430|NCT00411645|Placebo Comparator|B|
3303431|NCT00411632|Experimental|Bexarotene + Erlotinib|Bexarotene 400 mg/m^2 by mouth daily x 28 Days. Erlotinib 150 mg by mouth daily x 28 Days.
3303432|NCT00411619|Experimental|Everolimus|As this was a non-randomized, open-label, single arm study, all patients in the study received treatment with everolilmus
3303433|NCT00411606||1|Subjects with no allergies
3303434|NCT00411593|Experimental|Avastin® + Bortezomib|"Phase I - 3 * 3 design, enrolling patients to receive Avastin® at a fixed dose of 15 mg/kg every 3 weeks and Bortezomib dosed at 1.6 mg/m2 weekly for 2 weeks out of 3.~Phase II - The MTD for Bortezomib from the weekly schedule that is chosen will be combined with Avastin® to estimate the rate of progression-free survival."
3303435|NCT00411580|Experimental|1|CAD106
3303436|NCT00411580|Placebo Comparator|2|Placebo
3303437|NCT00411554|Experimental|Sitagliptin 50 mg QD|sitagliptin 50 mg orally once daily (QD=once daily)
3303438|NCT00411554|Active Comparator|Voglibose 0.2 mg TID|voglibose 0.2 mg orally three times daily (TID= three times daily)
3303439|NCT00411528|Experimental|1: 8 mg/m2 study drug + prednisone|Patupilone 8 mg/m2 + prednisone 5 mg bid daily
3303440|NCT00411528|Experimental|2: study drug + prednisone days 1 -8|Patupilone 10 mg/m2 + prednisone days 1 -8 at 25 mg bid, day 9 at 20 mg bid, day 10 at 15 mg bid, day 11 at 10 mg bid, day 12 - 21 at 5 mg bid
3303441|NCT00411528|Experimental|3: Study drug + prednisone days 1 - 4|Patupilone 10 mg/m2 + prednisone days 1 - 4 at 5 mg bid, days 5 -12 at 25 mg bid, day 13 at 20 mg bid, day 14 at 15 mg bid, day 15 at 10 mg bid, day 16 - 21 at 5 mg bid
3303442|NCT00411528|Active Comparator|4: Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 once every 3 weeks + prednisone 5 mg bid daily
3303443|NCT00411463|Experimental|Psychotherapy|Subjects randomized to the Psychotherapy arm will receive Interpersonal and Social Rhythm Therapy (IPSRT-BPII)
3303444|NCT00411463|Experimental|Medication|Subjects randomized to the medication arm will receive the FDA approved medication Seroquel (quetiapine)
3303445|NCT00411450|Experimental|Panitumumab plus FOLFIRI|Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until disease progression, intolerability, death, or study withdrawal.
3303446|NCT00411424|Experimental|1|
3303447|NCT00411424|Placebo Comparator|2|
3303448|NCT00411411|Placebo Comparator|Placebo|Placebo treatment, administered as tablets.
3303449|NCT00411411|Experimental|Januvia|Active treatment
3303450|NCT00411398|Experimental|Memantine 5-20mg/d flexible dose|Memantine tablets 5-20mg/d flexible dose
3303451|NCT00411385|Experimental|1|900 mcg alb-IFN every 2 weeks (12 doses) + Ribavirin 800 micrograms per day
3303452|NCT00411385|Experimental|2|1200 mcg alb-IFN every 2 weeks (12 doses) + Ribavirin 800 micrograms per day
3303453|NCT00411385|Active Comparator|3|180 mcg PEG-IFNx2a every 1 week (24 doses)+ Ribavirin 800 micrograms per day
3303454|NCT00411359|Experimental|Cardiac rehabilitation|8-week cardiac rehabilitation programme
3303455|NCT00411359|No Intervention|Monitoring|Carry on life as normal
3303456|NCT00411320|Active Comparator|Group 1|Smokers with asthma
3303457|NCT00411320|Active Comparator|Group 2|Ex-smokers with asthma
3303458|NCT00411320|Active Comparator|Group 3|Non-smokers with asthma
3303459|NCT00411320|No Intervention|Group 4|Non smokers without asthma
3303460|NCT00411320|No Intervention|Group 5|Smokers without asthma or COPD
3303462|NCT00411281|Other|Group II|Patients are observed. If symptoms of intermediate- or high-risk disease develop, patients may crossover to group I.
3303463|NCT00411242|Experimental|1|
3303464|NCT00411242|Experimental|2|
3303468|NCT00411216|Experimental|exercises for gaze stabilization|Experimental group performed vestibular adaptation and substitution exercises
3303469|NCT00411216|Placebo Comparator|Control exercises|Saccadic eye movements against a Ganzfeld to prevent retinal slip error signal; no head movements
3303470|NCT00411203|Active Comparator|Tamoxifen Citrate|
3303471|NCT00411203|Placebo Comparator|Placebo|
3303472|NCT00411190|Experimental|Session 1|Subjects will receive 500 mg acetaminophen on Day 1, 400 mg ibuprofen on Day 2, 40 mg atorvastatin on Day 3.
3303473|NCT00411190|Experimental|Session 2|Subjects will be randomized to receive relacatib 60 mg or 120 mg from Day 1-14. On Day 15 subjects will receive 500 mg acetaminophen, 400 mg ibuprofen on Day 16 and 40 mg atorvastatin on Day 17 with usual dose of relacatib.
3303474|NCT00411177|Active Comparator|Post-dilution on-line hemodiafiltration|Post-dilution on-line hemodiafiltration
3303475|NCT00411177|Other|High-flux hemodialysis|High-flux hemodialysis
3303476|NCT00411138|Active Comparator|Radiation Therapy|Pelvic Radiotherapy alone
3303477|NCT00411138|Experimental|Radiation Therapy and Chemotherapy|Pelvic Radiation plus 2 concurrent cycles cisplatin followed by 4 adjuvant cycles carboplatin and paclitaxel
3303478|NCT00411099|Experimental|1|
3303479|NCT00411099|Experimental|2|
3303480|NCT00411099|Placebo Comparator|3|
3303481|NCT00411086|Experimental|Rituximab + GM-CSF|Rituximab 375 mg/m^2 By Vein Weekly on Days 1, 8, 15, and 22. Sargramostim (GM-CSF) 250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
3303482|NCT00410982|Experimental|Gemcitabine + Busulfan + Melphalan + HCT|HCT = Hematopoietic Cell Transplantation
3303483|NCT00410956|Experimental|UNRESECTABLE PRIMARY HEPATIC MALIGNANCY|All patients enrolled in the study will receive HAI FUDR (0.16 mg/kg X pump volume / pump flow rate), Dexamethasone (1 mg/m2/day) and IV Bevacizumab at 5mg/kg. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days post surgical placement of HAI pump; patients will receive their first treatment with Bevacizumab no sooner than 28 days post surgical placement of HAI pump.
3303484|NCT00410904|Experimental|Arm I|Patients receive oral AZD2171 once daily on days 1-28 in course 1 and on days 1-21 in course 2 and all subsequent courses. Patients also receive pemetrexed disodium IV over 10 minutes on day 8 in course 1 and on day 1 in course 2 and all subsequent courses. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
3303485|NCT00410891|Experimental|topical antibiotic|topical gatifloxacin 4 times per day
3303486|NCT00410865|Experimental|INGN 201|INGN201 injection + oral rinse, day 1, courses 1-6. Twice-daily oral rinses, days 2-5, courses 1-6.
3303487|NCT00410852|Experimental|A|
3303488|NCT00410852|Experimental|B|
3303489|NCT00410852|Active Comparator|C|
3303490|NCT00410826|Experimental|Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer)|Patients receive cisplatin IV on days 1, 22, and 43 and undergo 3-dimensional conformal or intensity modulated radiotherapy once daily, 5 days per week, on days 1-47. Patients also receive erlotinib hydrochloride PO once daily on days -7 to 47.
3303491|NCT00410826|Active Comparator|Arm II (chemotherapy, radiotherapy)|Patients receive cisplatin and radiotherapy as in Arm I.
3303492|NCT00410813|Experimental|Arm I|Patients receive oral dasatinib once daily.
3303493|NCT00410813|Experimental|Arm II|Patients receive oral dasatinib twice daily.
3303494|NCT00410761|No Intervention|1|Placebo vandetanib
3303495|NCT00410761|Experimental|2|Vandetanib
3303496|NCT00410735|Placebo Comparator|P|
3303497|NCT00410735|Experimental|E|
3303498|NCT00410722|Experimental|Full-Dose Nut|Subjects will be given tree nuts (almonds, hazelnuts, pistachios, macadamia nuts, pecans, walnuts, and cashews) and peanuts (at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
3303499|NCT00410722|Experimental|Half-Dose Nut|Subjects will be given tree nuts (almonds, hazelnuts, pistachios, macadamia nuts, pecans, walnuts, and cashews) and peanuts as well as the control supplement (wheat bran muffin)(at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
3303500|NCT00410722|Active Comparator|Control|Subjects will be given a control supplement (wheat bran muffin)(at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
3303501|NCT00410696|Active Comparator|Filgrastim|Filgrastim administration starting 1 day after autologous stem-cell reinfusion up to hemopoietic reconstitution (defined as more than 500/mm3 for 2 days)
3303502|NCT00410696|Experimental|Pegfilgrastim|Pegfilgrastim administered the day after autologous stem-cell reinfusion
3303503|NCT00410683|Experimental|Radiotherapy|Beginning within 4-8 weeks after surgery or 2-6 weeks after chemotherapy, patients undergo adjuvant thoracic conformal radiotherapy once daily, 5 days per week, for 6 weeks.
3303504|NCT00410683|Active Comparator|No radiotherapy|Patients do not undergo adjuvant thoracic radiotherapy. After completion of study therapy, patients are followed periodically for up to 10 years.
3303505|NCT00410605|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3303506|NCT00410579||Patients treated in NSABP R-02, R-03, C-05, C-06 or C-07|Study population to be interviewed comprises patients who were treated at least 5 years ago for colon or rectal cancer in NSABP trials R-02, R-03, C-05, C-06 or C-07
3303507|NCT00410566|Experimental|1|
3303508|NCT00410566|Experimental|2|
3303509|NCT00410566|Experimental|3|
3303510|NCT00410566|Experimental|4|
3303511|NCT00410566|Experimental|5|
3303512|NCT00410553|Experimental|Treatment (combination chemotherapy)|Patients receive eribulin mesylate IV and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 OR on days 1 and 8. Courses repeat every 28 or 21 days* in the absence of disease progression or unacceptable toxicity.
3303513|NCT00410514|Placebo Comparator|Placebo|Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.
3303514|NCT00410514|Experimental|Mirabegron 50 mg|Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.
3303515|NCT00410514|Experimental|Mirabegron 100 mg|Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.
3303516|NCT00410488|Active Comparator|Palonosetron - 1 Dose|"Arm 1: Palonosetron 0.25 mg intravenous (IV) for 1 dose (day 0).~Dexamethasone: IV piggyback daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy. Chemotherapy treatment regimen: Zinecard: 750 mg/m2 as an IV bolus; Doxorubicin: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0. Mesna: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hours for days 0, 1, 2, and 3 (infusion completing on day 4); Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2); Vincristine: 2 mg IV by rapid administration on day 0 (for patients with small cell histology)."
3303517|NCT00410488|Active Comparator|Palonosetron - 3 Doses|"Arm 2: Palonosetron 0.25 mg IV for 3 doses (days 0, 2, 4).~Dexamethasone: IV piggyback daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy. Chemotherapy treatment regimen: Zinecard: 750 mg/m2 as an IV bolus; Doxorubicin: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0. Mesna: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hours for days 0, 1, 2, and 3 (infusion completing on day 4); Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2); Vincristine: 2 mg IV by rapid administration on day 0 (for patients with small cell histology)."
3303518|NCT00410436|Experimental|Resistance Training Group|Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM).
3303519|NCT00410436|Active Comparator|Control Group|Subjects will not be performing resistance exercise but will continue performing aerobic exercise at the same volume, duration and intensity as they did at baseline.
3303520|NCT00410423|Experimental|Bortezomib 0.7mg/m^2|Bortezomib in combination with mitoxantrone, etoposide and cytarabine
3303521|NCT00410423|Experimental|Bortezomib 1.0mg/m^2|
3303522|NCT00410423|Experimental|Bortezomib 1.3mg/m^2|
3303523|NCT00410410|Experimental|Abatacept (ABA)|"Induction Period; 3 arms for Cohort 1: ABA 30/~10 mg/kg (ABA administered at 30 mg/kg followed by ABA at ~10 mg/kg), ABA ~10 mg/kg, ABA 3 mg/kg~Induction Period; 2 arms for Cohort 2: ABA 30/~10 mg/kg and Second Cohort ABA ~10 mg/kg~1 arm for maintenance period (ABA ~10 mg/kg)"
3303524|NCT00410410|Placebo Comparator|Placebo|"1 arm for induction period~1 arm for maintenance period"
3303525|NCT00410410|Other|abatacept|1 arm for open-label extension phase (ABA ~10 mg/kg)
3303526|NCT00410397|Experimental|A|Osteopathic Manipulative Medicine
3303527|NCT00410397|Placebo Comparator|B|
3303528|NCT00410384|Placebo Comparator|Placebo|Placebo
3303529|NCT00410384|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg
3303530|NCT00410384|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg
3303531|NCT00410371|Experimental|GI267119|25 mg ODT tablet strength
3303532|NCT00410358|Experimental|LBQ707|
3303533|NCT00410345|Experimental|Pitocin|Treatment with Pitocin after mifegine
3303534|NCT00410345|Active Comparator|Cytotec|Treatment with cytotec after mifegine
3303535|NCT00410332|Active Comparator|A|TRAUMEEL S
3303536|NCT00410332|Placebo Comparator|B|
3303537|NCT00410306||Group 1|
3303538|NCT00410280|Other|1|
3303539|NCT00410241||A1|Self-referred individuals 45-65 at enrollment, 25% of whom had coronary artery disease
3303540|NCT00410241||A2|Individuals 45-65 at enrollment who self identified as African, African-American or Afro-Caribbean
3303541|NCT00410241||B|Family members of Group A1 or A2 participants
3303542|NCT00410215|Active Comparator|1|sodium phosphate
3303543|NCT00410215|Active Comparator|2|picosalax
3303544|NCT00410215|Active Comparator|3|picosalax plus bisacodyl
3303545|NCT00410202|Active Comparator|Entecavir|With the option of adding tenofovir at week 48. (This does not apply to Korea)
3303546|NCT00410202|Active Comparator|Adefovir + Lamivudine|
3303547|NCT00410202|Active Comparator|Entecavir + Adefovir|
3303548|NCT00410189|Experimental|ZD6474|ZD6474 300 mg by mouth daily for 28 Days.
3303549|NCT00410163|Active Comparator|Active Comparator 1|Each patient will receive a total of 6 infusions with ofatumumab every 4 weeks in combination with fludarabine and cyclophosphamide. The first infusion will be 300mg followed by 5 infusions of 500mg
3303550|NCT00410163|Active Comparator|Active Comparator 2|Each patient will receive a total of 6 monthly infusions with ofatumumab in combination with fludarabine and cyclophosphamide. The first infusion will be 300mg followed by 5 infusions of 1000mg
3303551|NCT00410150|Experimental|Group 1 (Heliox-powered albuterol)|Group 1 (Heliox-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 70:30 Heliox.
3303552|NCT00410150|Active Comparator|Group 2 (Oxygen-powered albuterol)|Group 2 (Oxygen-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 100% oxygen per usual standard of care.
3303553|NCT00410124|Experimental|RAD001 +BSC|The study drugs were self administered by the patients. Patients were instructed to take the study drug as specified in the protocol. Patients were instructed to take two tablets (5 mg each) by mouth every day. Tablets were to be taken one tablet after another with a glass of water, at the same time each day in a fasting state or with a light fat-free meal. If disease progression occurred, patients were unblinded and if they were receiving RAD001, they would discontinue the study. Otherwise, they would be given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
3303554|NCT00410124|Placebo Comparator|Placebo (plus BSC)|Patients received matching placebo of RAD001 tablets twice a day along with Best Supportive Care. With the documented disease progression, the investigator could unblind the patient. If unblinded patient was receiving placebo treatment, they were given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
3303555|NCT00410072|Experimental|TDF 0.5 mg|TDF=tenofovir
3303556|NCT00410072|Experimental|ETV 0.5 mg +TDF 300 mg|ETV=entecavir; TDF=tenofovir
3303557|NCT00410059|Experimental|Erlotinib|Erlotinib 150 mg by mouth daily x 28 days.
3303558|NCT00410046|Experimental|Etanercept (ETN)|Patients received ETN dose 50 mg once weekly or Sulphasalazine dose 3 g daily in study 402 for 16 weeks. Upon enrollment into study 405, all received subcutaneous injections of etanercept 50 mg once weekly for 36 weeks.
3304452|NCT00400387|Other|Multivitamin supplement|
3303559|NCT00410007|Other|Patients with ADPKD, HS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
3303560|NCT00410007|Other|Patients with ADPKD, LS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
3303561|NCT00410007|Other|Healthy Control Subjects, HS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
3303562|NCT00410007|Other|Healthy Control Subjects, LS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
3303563|NCT00409994|Experimental|Rapamycine|rapamycine 6 mg dd
3303564|NCT00409968||Screening Study|Screening study to find out if Patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body are eligible to take part in 1 of 4 different research studies.
3303565|NCT00409942|Experimental|1|Torasemide prolonged released
3303566|NCT00409942|Active Comparator|2|Furosemide
3303567|NCT00409916|Placebo Comparator|Standard Care Arm|In the Standard Care Arm, the treating clinician will adjust therapy according only to the clinical assessment of signs and symptoms of heart failure since the ICG information is blinded to the treating clinician.
3303568|NCT00409916|Active Comparator|ICG Arm|In the ICG Arm, the treating clinician will adjust therapy according to the clinical assessment of signs and symptoms of heart failure, in addition to the ICG hemodynamic information obtained from the printed report.
3303569|NCT00409864|Active Comparator|PTBD|percutaneous biliary drainage
3303570|NCT00409864|Active Comparator|Endoscopic stenting|ERCP and stenting
3303571|NCT00409838|Experimental|Abatacept and Methotrexate|
3303572|NCT00409838|Placebo Comparator|Placebo and Methotrexate|(standard of care)
3303573|NCT00409838|Experimental|Abatacept - Open Label|Open-label extension phase
3303574|NCT00409825|Experimental|Part 1|Part 1 done after 4 weekly 17-OHPC injections completed, between 20 6/7 to 24 6/7 weeks gestation. 10 cc blood drawn pre-5th injection. 10 cc blood drawn 12 hours post-dose and 7 consecutive days. 24-hour urine collected days 4-5 within 7 days post-injection. Part 2 done 31 0/7 to 34 6/7 or at 35 0/7 weeks. 10 cc blood drawn pre weekly injection, 12 hours post-dose, and 7 consecutive days. 24-hour urine collected between days 4-5 within 7 days post-injection. A subject in whom Part 2 is performed during the last scheduled injection of 17-OHPC (at or around 35 0/7 weeks) will have the option to participate in Part 3, in which 10 cc of blood will be drawn serially over 21 days after completing Part 2. Blood will be drawn on days 9, 11, 14, 17, 20, 24, 28 after the last injection. Part 4: At the time of labor and delivery, subject will have 10cc of blood removed from a maternal peripheral vein. 10cc of blood will be collected from the placenta/umbilical cord after delivery.
3303575|NCT00409799|Experimental|1|Experimental - high dose
3303576|NCT00409799|Experimental|2|Experimental - low dose
3303577|NCT00409799|Active Comparator|3|Autograft
3303578|NCT00409773|Other|1|Arm 1: drug + comparator + Placebo
3303579|NCT00409773|Other|2|Arm 2: drug + comparator + Placebo
3303580|NCT00409773|Other|3|Arm 3: drug + comparator + Placebo
3303581|NCT00409773|Other|4|Arm 4: drug + comparator + Placebo
3303582|NCT00409773|Other|5|Arm 5: drug + comparator + Placebo
3303583|NCT00409747|Experimental|Minocycline|
3303584|NCT00409734||Children with pyloric stenosis|Male or female children age two to nine weeks with history of vomiting and feeding intolerance, and abdominal sonogram showing presence of pyloric stenosis
3303585|NCT00409734||Children without pyloric stenosis|Male or female children age two to nine weeks without pyloric stenosis admitted to the hospital for other reasons
3303586|NCT00409721|Experimental|Memantine Low Dose|
3303587|NCT00409721|Experimental|Memantine High Dose|
3303588|NCT00409708|Active Comparator|1|
3303589|NCT00409708|Other|2|
3303590|NCT00409695|Experimental|High Dose Thymoglobulin (ATG)|High Dose Thymoglobulin (ATG): 1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
3303591|NCT00409695|Experimental|Low Dose Thymoglobulin (ATG)|Low Dose Thymoglobulin (ATG): 2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
3303592|NCT00409682|Active Comparator|Open-label adalimumab (Week 0 to Week 4)|All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
3303593|NCT00409682|Active Comparator|Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52)|Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
3303594|NCT00409682|Active Comparator|High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52)|Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
3303595|NCT00409617|Experimental|Open Label|
3303596|NCT00409604|Experimental|1|Standard PCI procedure + pacing post conditioning
3303597|NCT00409604|No Intervention|2|Standard PCI procedure
3303598|NCT00409591|Active Comparator|1|"NVP-NVP:~In women, one NVP 200 mg tablet at onset of labor;~In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours"
3303599|NCT00409591|Experimental|2|"PL-NVP:~In women, one placebo tablet at onset of labor;~In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours"
3303600|NCT00409591|Experimental|3|"LPV/r:~In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery"
3303601|NCT00409578|Placebo Comparator|Placebo|Placebo tablets and capsules
3303602|NCT00409578|Experimental|Aliskiren 300 mg|Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.
3303603|NCT00409578|Experimental|Valsartan 320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.
3303604|NCT00409578|Experimental|Aliskiren/valsartan 300/320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.
3303605|NCT00409565|Experimental|Cetuximab plus bevacizumab|Cetuximab plus bevacizumab
3303606|NCT00409552|Experimental|1|Virtual Reality with head display
3303607|NCT00409552|Active Comparator|2|Virtual Reality with flat projection display
3303608|NCT00409552|Active Comparator|3|non-interactive video with head display
3303609|NCT00409552|Active Comparator|4|non-interactive video with flat projection display
3303610|NCT00409552|No Intervention|5|No distraction
3303611|NCT00409539|Placebo Comparator|1|Placebo run-in phase. 2 week duration.
3303612|NCT00409539|Placebo Comparator|2|To be taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
3303613|NCT00409539|Experimental|3|20mg dose of SMP-986 to be taken once daily for 8 week duration.
3303614|NCT00409539|Experimental|4|40mg dose of SMP-986 to be taken for 8 week duration.
3303615|NCT00409539|Experimental|5|80mg dose of SMP-986 to be taken for 8 week duration.
3303616|NCT00409539|Experimental|6|120mg dose of SMP-986 to be taken for 8 week duration.
3303617|NCT00409487|Experimental|1|8 weeks of Valsartant treatment, 4 weeks of washout, 8 weeks of CPAP and 8 weeks of Valsartant plus CPAP treatments
3303618|NCT00409487|Experimental|2|8 weeks of CPAP , 4 weeks of washout, 8 weeks of Valsartant treatment and 8 weeks of Valsartant plus CPAP treatments
3303619|NCT00409448|Experimental|CAPS|Participants will receive the Internet-based counselor-assisted problem-solving group treatment
3303620|NCT00409448|Active Comparator|IRC|Participants will receive the Internet resource comparison group treatment
3303621|NCT00409435|Active Comparator|pyridostigmine|Active study drug
3303622|NCT00409435|Placebo Comparator|Placebo|Control
3303623|NCT00409409|Experimental|300 IR|300 IR grass pollen allergen extract tablet
3303624|NCT00409409|Placebo Comparator|Placebo|Placebo tablet
3303625|NCT00409396|Experimental|1|Fecal calprotectin and urinary PGEm levels will be tested on all participants.
3303626|NCT00409344|Placebo Comparator|1|Normal Saline
3303627|NCT00409344|Active Comparator|Dexmedetomidine|Dexmedetomidine is a highly specific a2 agonist with prominent central nervous system and cardiovascular effects. A postoperative sedative-hypnotic agent for intensive care patients for use up to 24 hours.
3303628|NCT00409331|Experimental|IMRT + Amifostine|Intensity-Modulated Radiation Therapy (IMRT) 2.0 to 2.2 Gy delivered in 30 fractions + Amifostine 500 mg, 2 divided doses subcutaneously 30-60 minutes prior to IMRT.
3303629|NCT00409318|Active Comparator|1|Etanercept
3303630|NCT00409318|Placebo Comparator|2|Placebo
3303631|NCT00409292|Experimental|RAD001|"RAD001 was administered continuously at a dose of 10 mg daily by mouth until disease progression, unacceptable toxicity, or withdrawal of consent.~Four weeks of study drug was considered to be one cycle of treatment."
3303632|NCT00409279|Experimental|1|multi-component psychosocial intervention
3303633|NCT00409279|No Intervention|2|
3303634|NCT00409253|Active Comparator|Urapidil|
3303635|NCT00409253|Active Comparator|Nicardipine|
3303636|NCT00409240|Experimental|MEDIC Intervention|Receives pharmacist-led behavioral and pharmacologic group intervention for cardiac risk reduction
3303637|NCT00409240|No Intervention|Usual Care|Patient continued on usual care
3303638|NCT00409227|Active Comparator|1|double blind placebo control
3303639|NCT00409227|Placebo Comparator|2|placebo control blinded arm
3303640|NCT00409188|Experimental|Tecemotide (L-BLP25)|
3303641|NCT00409188|Placebo Comparator|Placebo|
3303642|NCT00409175|Experimental|1.|Fx-1006A
3303643|NCT00409175|Placebo Comparator|2.|Placebo
3303644|NCT00409149|Experimental|CALM BP|dietary approach, education on cooking and food consumption choices, walking physical exercise, Qi Gong - a form of Chinese slow movement exercise combined with relaxation breathing and imagery and group therapy coaching in stress management techniques and mind-body balancing techniques.
3303645|NCT00409149|Active Comparator|DASH|standard dietary DASH approach in hypertensive patients
3303646|NCT00409136||Alert|Physicians alerted about their high risk patients who are not receiving any VTE prophylaxis.
3303647|NCT00409136||No Alert|Physicians not alerted about their high risk patients who are not receiving any VTE prophylaxis.
3303648|NCT00409084|Active Comparator|1|endoscopic variceal band ligation
3303649|NCT00409084|Active Comparator|2|subjects will receive nadolol (beta blocker) at 20mg/day with dose titration
3303650|NCT00409071|Experimental|1|cocculine
3303651|NCT00409071|Placebo Comparator|2|placebo
3303691|NCT00408551|Experimental|FOLFOX6|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continously over 46 hours beginning on day 1.
3303652|NCT00409058|Experimental|Teen Online Problem Solving|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
3303653|NCT00409058|Experimental|Internet Resources Comparison|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
3303654|NCT00409019|Experimental|1|Study cancelled: Withdrawn before enrollment of any participants
3303655|NCT00409019|Experimental|2|Study cancelled: Withdrawn before enrollment of any participants
3303656|NCT00409019|Experimental|3|Study cancelled: Withdrawn before enrollment of any participants
3303657|NCT00409006|Experimental|Pemetrexed/Cisplatin/Gefitinib|Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity.
3303658|NCT00409006|Experimental|Pemetrexed/Cisplatin|Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity.
3303659|NCT00408993|Experimental|Duloxetine|60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)
3303660|NCT00408993|Placebo Comparator|Placebo|Placebo every day (QD), by mouth (PO) for 12 weeks
3303661|NCT00408967|Experimental|Tucotuzumab celmoleukin (EMD 273066)|
3303662|NCT00408954|Placebo Comparator|Placebo|
3303663|NCT00408954|Active Comparator|UK-369,003|
3303664|NCT00408928|Experimental|Bortezomib for Treatment of GHVD|To determine if bortezomib (VELCADE®) will successfully inhibit T-cell responses in clinically acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
3303665|NCT00408902|Experimental|TandutinibTreatment|Patients receive oral tandutinib 500 mg twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3303666|NCT00408876|Experimental|Duloxetine 20 mg|duloxetine 20 mg once a day (QD), by mouth (PO) for 13 weeks
3303667|NCT00408876|Experimental|Duloxetine 60 mg|duloxetine 30 mg once a day (QD), by mouth (PO) for 1 week then duloxetine 60 mg QD, PO for 12 weeks
3303668|NCT00408876|Experimental|Duloxetine 120 mg|duloxetine 30 mg once a day (QD), by mouth (PO) for 1 week followed by duloxetine 60 mg QD, PO for 1 week, then duloxetine 120 mg QD, PO for 11 weeks
3303669|NCT00408876|Placebo Comparator|Placebo|placebo once a day (QD), by mouth (PO) for 13 weeks
3303670|NCT00408863|Active Comparator|Tibolone|Tibolone 2.5 mg/day
3303671|NCT00408863|Placebo Comparator|Placebo|Placebo
3303672|NCT00408850|Active Comparator|Pioglitazone|pioglitazone 15 mg for 6 weeks followed by 30 mg for 6 weeks
3303673|NCT00408850|Placebo Comparator|sugar pill|Placebo comparator
3303674|NCT00408785|Experimental|A|Injection
3303675|NCT00408785|Placebo Comparator|B|Injection
3303676|NCT00408772|Experimental|Unresectable colorectal liver mets|
3303677|NCT00408733|No Intervention|1|
3303678|NCT00408733|Experimental|2|Intervention
3303679|NCT00408694|Experimental|Treatment (bevacizumab, cisplatin, fluorouracil, IMRT, 3D-CRT)|"BEVACIZUMAB AND CHEMORADIOTHERAPY: Patients receive bevacizumab IV over 30-90 minutes and cisplatin IV over 20-30 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 1, patients also undergo three-dimensional conformal radiotherapy or intensity-modulated radiotherapy once daily 5 days a week for a total of 33 fractions.~ADJUVANT THERAPY: Beginning in week 10, patients receive fluorouracil IV continuously over 96 hours on days 1-4, cisplatin IV over 20-30 minutes on day 1 OR days 1 and 2, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
3303680|NCT00408681|Experimental|Arm I|Patients receive oral lithium carbonate once or twice daily. Treatment continues for up to 8 weeks in the absence of disease progression or unacceptable toxicity.
3303681|NCT00408655|Experimental|Arm I|"PART A: Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1 and temsirolimus IV over 30 minutes on days 8 and 15. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive paclitaxel and carboplatin as in part A. They also receive temsirolimus IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
3303682|NCT00408642|Experimental|1|enhanced adherence support for patients initiating antiretroviral therapy
3303683|NCT00408642|Active Comparator|2|standard adherence support
3303684|NCT00408629|Experimental|adalimumab group|
3303685|NCT00408629|Experimental|placebo group|
3303686|NCT00408616|Experimental|1|Grazax treatment
3303687|NCT00408616|Placebo Comparator|2|Grazax Placebo
3303688|NCT00408603|Experimental|All study patients|All patients will receive voreloxin injection
3303689|NCT00408590|Experimental|Experimental Arm|
3303690|NCT00408564|Experimental|Gemcitabine,Oxaliplatin and Cetuximab|"Gemcitabine will be given on day 1 of every 2 week cycle. Oxaliplatin will be given day 2 of every 2 week cycle. Cetuximab will be given every week for 12 weeks.~After chemotherapy, patient will be assessed for resectability. Patients will have either surgery or daily radiation and capceitabine Monday-Friday for a total of 5 and a half weeks."
3303692|NCT00408551|Experimental|FOLFIRI|Patients receive irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1.
3303693|NCT00408551|Experimental|FUDR|Patients receive floxuridine IV continuously on days 1-14.
3303694|NCT00408525|Experimental|1|Donepezil
3303695|NCT00408512|Active Comparator|Thiazides|Thiazidic diuretic
3303696|NCT00408512|Active Comparator|Non Tiazidic|Non tiazidic diuretic treatment: Any other therapy can be considered in this arm: example: CCB, BB, ACEi, ARB
3303697|NCT00408499|Experimental|Erlotinib + Cetuximab|Daily erlotinib combined with weekly cetuximab
3303698|NCT00408460|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive paclitaxel IV on days 3, 10, and 17 and imatinib mesylate PO QD on days 1-4, 8-11, and 15-18. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
3303699|NCT00408447|Other|SCD group|Sickle Cell Disease
3303700|NCT00408447|Other|BT group|Beta Thalassemia
3303701|NCT00408434|Experimental|CS-7017|CS-7017 from 0.05 to 3.2 mg bid
3303702|NCT00408421|Experimental|A|duloxetine 30 mg, daily (QD), by mouth (PO) for 1 week then duloxetine 60 mg QD, PO for 6 weeks then duloxetine 60 mg or 120 mg QD, PO for 6 weeks
3303703|NCT00408421|Placebo Comparator|B|placebo daily (QD), by mouth (PO) for 13 weeks
3303704|NCT00408408|Active Comparator|Arm 1A: Docetaxel then AC|Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
3303705|NCT00408408|Experimental|Arm 1B Docetaxel + Bev then AC + Bev|Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
3303706|NCT00408408|Experimental|Arm 2A: Docetaxel + Capecitabine then AC|Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
3303707|NCT00408408|Experimental|Arm 2B: Docetaxel + Cape + Bev then AC + Bev|Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
3303708|NCT00408408|Experimental|Arm 3A: Docetaxel + Gem then AC|Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
3303709|NCT00408408|Experimental|Arm 3B: Docetaxel + Gem + Bev then AC + Bev|Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
3303710|NCT00408395|Experimental|1: Trivalent Seasonal Influenza Vaccine|
3303711|NCT00408395|Experimental|2: Adjuvanted Trivalent Seasonal Influenza Vaccine|
3303712|NCT00408330|Active Comparator|1|azelaic acid 15%
3303713|NCT00408330|Placebo Comparator|2|Inactive 15% gel base
3303714|NCT00408317|Experimental|Ultrase® MT20|
3303715|NCT00408317|Placebo Comparator|Placebo|
3303716|NCT00408291||1|Winsta PH osteosynthesis device (Fischer Medical)for treatment of humeral fracture
3303717|NCT00408252|Experimental|Arm A|patients will receive SU011248 in monotherapy
3303718|NCT00408239|Experimental|1|Dose regimen 1
3303719|NCT00408239|Active Comparator|2|
3303720|NCT00408239|Experimental|3|Dose regimen 2
3303721|NCT00408226|Experimental|1|
3303722|NCT00408213|Experimental|1|
3303723|NCT00408213|Placebo Comparator|2|
3303724|NCT00408200|Other|AAD:YES|Subjects receive membrane-active anti-arrhythmic medication after ablation. See intervention list below.
3303725|NCT00408200|Other|AAD:NO|Subjects do not receive membrane-active anti-arrhythmic medications after ablation.
3303726|NCT00408187|Active Comparator|1.|
3303727|NCT00408187|Placebo Comparator|3.|
3303728|NCT00408187|Active Comparator|2.|
3303729|NCT00408161|Active Comparator|1|prize contingency management (CM) plus standard case management treatment -- patients earn the chance to win prizes by submitting negative breath samples and by complying with steps toward treatment goals
3303730|NCT00408161|Active Comparator|2|standard case management treatment
3303731|NCT00408148|Placebo Comparator|2|Administration of one rimonabant placebo tablet once daily in the morning
3303732|NCT00408148|Experimental|1|Administration of one tablet containing 20 mg of active rimonabant once daily in the morning
3303733|NCT00408096|Active Comparator|1|The Copeland uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact area used as a treatment for shoulder osteoarthritis
3303734|NCT00408096|Active Comparator|2|The Global Cap uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact area used as a treatment for shoulder osteoarthritis
3303735|NCT00408083|Experimental|1|MultiHance MRI contrast agent
3303736|NCT00408083|Active Comparator|2|Magnevist contrast agent for MRA
3303737|NCT00408070|Experimental|I|This is a single Arm study. Two of the study drugs used are non-experimental. One of the study drugs is experimental.
3303738|NCT00408031|Experimental|1|Randomization to 2 treatment groups. One group receives adjuvant treatment with D-cycloserine, up to 1 g/day. The second group receives adjuvant treatment with placebo, up to 1 g/day.
3303770|NCT00407797|Experimental|Pregabalin|
3303771|NCT00407745|Placebo Comparator|matched placebo|
3303772|NCT00407745|Experimental|pregabalin|flexible dosing over 4 weeks followed by 12 weeks maintenance and one week taper period
3303773|NCT00407732|No Intervention|SC|standard care
3303739|NCT00408005|Experimental|Group 0 Induction Therapy|All patients (T-ALL and T-LLy) receive cytarabine intrathecally (IT) on day 1; vincristine sulfate IV on days 1, 8, 15, and 22; prednisone IV or PO twice daily BID on days 1-28; pegaspargase IM (may give IV over 1 to 2 hours) on day 4, 5, or 6; daunorubicin hydrochloride IV on days 1, 8, 15 and 22; and methotrexate IT on days 8 and 29 (and days 15 and 22 for patients with CNS3 disease).
3303740|NCT00408005|Active Comparator|Group 1 Arm I (Consolidation chemotherapy)|Patients receive methotrexate IT on days 1, 8, 15, and 22; cyclophosphamide IV over 30 minutes on days 1 and 29; cytarabine IV over 15-30 minutes or SC on days 1-4, 8-11, 29-32, and 36-39; mercaptopurine PO on days 1-14 and 29-42; vincristine sulfate IV on days 15, 22, 43 and 50; and pegaspargase IM or IV over 1-2 hours on days 15 and 43. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 11-12, 15-19, and 22-26. (DS patients excluded as of 09/29/10.) Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT (1,200 cGy/dose) QD on days 15-21 and 22-28. Patients with low-risk disease do not undergo CRT. Patients with standard risk T-LLy received Arm I, and those with high risk T-LLy were randomized between Arm I and Arm II combination chemotherapy.
3303741|NCT00408005|Active Comparator|Group 1 Arm IV (Consolidation chemotherapy)|Patients receive nelarabine IV over 60 minutes on days 1-5 and 43-47; methotrexate IT on days 15, 22, 57, and 64; cyclophosphamide IV over 30 minutes on days 8 and 50; cytarabine IV over 15-30 minutes or SC on days 8-11, 15-18, 50-53 and 57-60; mercaptopurine PO on days 8-21 and 50-63; vincristine sulfate IV on days 22, 29, 64, and 71; and pegaspargase IM or IV over 1-2 hours on days 22 and 64. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 15, 22-26, and 29-33 (DS patients excluded as of 09/29/10). (Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT QD on days 22-28 and 29-35.
3303742|NCT00408005|Active Comparator|Group I Arm I (Delayed intensification chemotherapy)|Patients receive vincristine sulfate IV on days 1, 8, 15, 43, and 50; dexamethasone IV or PO BID on days 1-21 (for patients < 10 years of age) OR on days 1-7 and 15-21 (for patients >= 10 years of age and for patients with DS); doxorubicin hydrochloride IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6, AND day 43; methotrexate IT on days 1, 29, and 36; cyclophosphamide IV over 30 minutes on day 29; cytarabine IV over 15-30 minutes or SC on days 29-32 and 36-39; and thioguanine PO on days 29-42. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose (DS patients excluded as of 09/29/10). Standard risk T-LLy patients were assigned to Arm I and those with high risk were randomized between Arm I and Arm II.
3303743|NCT00408005|Active Comparator|Group I Arm I (Maintenance chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; prednisone PO BID on days 1-5, 29-33, and 57-61; mercaptopurine PO QD on days 1-84; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; and methotrexate IT on day 1. Treatment repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 119) (for girls with T-ALL), all patients with T-LLy, and 3 years from the start of interim maintenance therapy (approximately week 171) (for boys with T-ALL).
3303744|NCT00408005|Active Comparator|Group I Arm II (Consolidation chemotherapy)|Patients receive nelarabine IV over 60 minutes on days 1-5 and 43-47; methotrexate IT on days 15, 22, 57, and 64; cyclophosphamide IV over 30 minutes on days 8 and 50; cytarabine IV over 15-30 minutes or SC on days 8-11, 15-18, 50-53 and 57-60; mercaptopurine PO on days 8-21 and 50-63; vincristine sulfate IV on days 22, 29, 64, and 71; and pegaspargase IM or IV over 1-2 hours on days 22 and 64. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 15, 22-26, and 29-33 (DS patients excluded as of 09/29/10). (Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT QD on days 22-28 and 29-35. Patients with high risk T-LLy were either randomized to Arm I or Arm II. Patients with T-LLy who failed induction therapy were assigned to Arm II.
3303745|NCT00408005|Active Comparator|Group I Arm II (Delayed intensification chemotherapy)|Patients receive vincristine sulfate IV on days 1, 8, 15, and 50; dexamethasone IV or PO BID on days 1-21 (for patients < 10 years of age) OR on days 1-7 and 15-21 (for patients >= 10 years of age); doxorubicin hydrochloride IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6 AND day 50; methotrexate IT on days 1, 36, and 43; nelarabine IV over 60 minutes on days 29-33; cyclophosphamide IV over 30 minutes on day 36; cytarabine IV over 15-30 minutes or SC on days 36-39 and 43-46; and thioguanine PO on days 36-49.
3303746|NCT00408005|Active Comparator|Group I Arm III (Delayed intensification chemotherapy)|Patients receive vincristine sulfate IV on days 1, 8, 15, 43, and 50; dexamethasone IV or PO BID on days 1-21 (for patients < 10 years of age) OR on days 1-7 and 15-21 (for patients >= 10 years of age and for patients with DS); doxorubicin hydrochloride IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6, AND day 43; methotrexate IT on days 1, 29, and 36; cyclophosphamide IV over 30 minutes on day 29; cytarabine IV over 15-30 minutes or SC on days 29-32 and 36-39; and thioguanine PO on days 29-42. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose (DS patients excluded as of 09/29/10).
3303747|NCT00408005|Active Comparator|Group I Arm III (Interim maintenance chemotherapy)|Patients receive HDMTX IV over 24 hours and vincristine sulfate IV on days 1, 15, 29, and 43; mercaptopurine PO on days 1-56; and methotrexate IT on days 1 and 29. Beginning 42 hours after the start of HDMTX, patients also receive leucovorin calcium IV or PO once every 6 hours for 3 doses.
3303748|NCT00408005|Active Comparator|Group I Arm IV (Delayed intensification chemotherapy)|Patients receive vincristine sulfate IV on days 1, 8, 15, and 50; dexamethasone IV or PO BID on days 1-21 (for patients < 10 years of age) OR on days 1-7 and 15-21 (for patients >= 10 years of age); doxorubicin IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6 AND day 50; methotrexate IT on days 1, 36, and 43; nelarabine IV over 60 minutes on days 29-33; cyclophosphamide IV over 30 minutes on day 36; cytarabine IV over 15-30 minutes or SC on days 36-39 and 43-46; and thioguanine PO on days 36-49.
3303749|NCT00408005|Active Comparator|Group I Arm IV (Interim maintenance chemotherapy)|Patients receive HDMTX IV over 24 hours and vincristine IV on days 1, 15, 29, and 43; mercaptopurine PO on days 1-56; and methotrexate IT on days 1 and 29. Beginning 42 hours after the start of HDMTX, patients also receive leucovorin calcium IV or PO once every 6 hours for 3 doses.
3303774|NCT00407732|Experimental|INT|psychosocial intervention
3303775|NCT00407667|Experimental|1|patients receive 20 min of anodal transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
3303750|NCT00408005|Active Comparator|Group I Arm IV (Maintenance chemotherapy)|Patients receive vincristine sulfate, prednisone, mercaptopurine, methotrexate PO, methotrexate IT, and nelarabine in Cycles 1, 2 and 3. Patients then receive treatment (without nelarabine) as follows: vincristine, prednisone, mercaptopurine, methotrexate PO, and methotrexate IT as in arm II. Treatment (without nelarabine) repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 121) (for girls with T-ALL), and for those with T-LLY, and 3 years from the start of interim maintenance therapy (approximately week 173) (for boys with T-ALL).
3303751|NCT00408005|Active Comparator|Group I Arm I (Interim maintenance chemotherapy)|"Patients receive vincristine sulfate IV and escalating doses of methotrexate IV on days 1, 11, 21, 31, and 41; pegaspargase* IM or IV over 1-2 hours on days 2 and 22; and methotrexate IT on days 1 and 31. Patients with DS also receive leucovorin calcium PO 48 and 60 hours after each methotrexate IT dose (DS patients excluded as of 09/29/10).~Note: *Patients with an allergy to pegaspargase receive Erwinia asparaginase on days 2, 4, 6, 8, 10, 12, 22, 24, 26, 28, 30, and 32."
3303752|NCT00408005|Active Comparator|Group I Arm II (Interim maintenance chemotherapy)|"Patients receive vincristine sulfate IV and escalating doses of methotrexate IV on days 1, 11, 21, 31, and 41; pegaspargase* IM or IV over 1-2 hours on days 2 and 22; and methotrexate IT on days 1 and 31.~Note: *Patients with an allergy to pegaspargase receive Erwinia asparaginase on Monday, Wednesday and Friday for two consecutive weeks starting the day of asparaginase substitution."
3303753|NCT00408005|Active Comparator|Group I Arm II (Maintenance chemotherapy)|Patients receive vincristine sulfate, prednisone, mercaptopurine, methotrexate PO, methotrexate IT, and nelarabine in Cycles 1, 2 and 3. Patients then receive treatment (without nelarabine) as follows: vincristine sulfate, prednisone, mercaptopurine, methotrexate PO, and methotrexate IT as in arm II. Treatment (without nelarabine) repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 121) (for girls with T-ALL), and for those with T-LLY, and 3 years from the start of interim maintenance therapy (approximately week 173) (for boys with T-ALL).
3303754|NCT00408005|Active Comparator|Group I Arm III (Consolidation chemotherapy)|Patients receive methotrexate IT on days 1, 8, 15, and 22; cyclophosphamide IV over 30 minutes on days 1 and 29; cytarabine IV over 15-30 minutes or SC on days 1-4, 8-11, 29-32, and 36-39; mercaptopurine PO on days 1-14 and 29-42; vincristine sulfate IV on days 15, 22, 43 and 50; and pegaspargase IM or IV over 1-2 hours on days 15 and 43. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 11-12, 15-19, and 22-26. (DS patients excluded as of 09/29/10.) Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT (1,200 cGy/dose) QD on days 15-21 and 22-28. Patients with low-risk disease do not undergo CRT.
3303755|NCT00408005|Active Comparator|Group I Arm III (Maintenance chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; prednisone PO BID on days 1-5, 29-33, and 57-61; mercaptopurine PO QD on days 1-84; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; and methotrexate IT on day 1. Treatment repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 119) (for girls with T-ALL) and all patients with T-LLy, and 3 years from the start of interim maintenance therapy (approximately week 171) (for boys with T-ALL).
3303756|NCT00407992|Experimental|Occipital nerve stimulation ON|
3303757|NCT00407992|Other|Occipital nerve stimulation OFF|
3303758|NCT00407979||People with Atopic Dermatitis|
3303759|NCT00407979||People with Psoriasis|
3303760|NCT00407979||Generally healthy people|
3303761|NCT00407979||People with Atopic Dermatitis and Eczema Herpeticum|
3303762|NCT00407966|Experimental|Treatment (alvocidib, cytarabine, mitoxantrone hydrochloride)|"Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Beginning 35-63 days after completion of course 1, patients achieving complete or partial remission may receive a second course of treatment as above.~Patients age 50 and over with core binding factor acute myeloid leukemia (AML) (e.g., t[8;21], inv[16], or t[16;16]) achieving a complete remission after course 1 of treatment may receive 3-4 courses of consolidation therapy comprising high-dose cytarabine at the discretion of the investigator."
3303763|NCT00407914|Experimental|1|Aquamid
3303764|NCT00407914|Active Comparator|2|Restylane
3303765|NCT00407901||A, B|A: High functioning visually challenged (legally blind) B: Low-functioning visually challenged (legally blind)
3303766|NCT00407888|Experimental|Arm I|Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 week later, patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity.
3303767|NCT00407875|Active Comparator|Permanent interstitial prostate brachytherapy (PIPB)|patient will undergo permanent interstitial prostate brachytherapy (PIPB) using a transperineal approach to deliver 125Iodine Rapidstrand® seeds at the facilities of the British Columbia Cancer Agency (BCCA) by one or more of the certified prostate brachytherapists in the BCCA Prostate Brachytherapy Program. The minimum peripheral dose (MPD) to the prostate gland of the implant will be 144 Gy as per TG 43 protocol. A modified peripheral loading technique will be utilized in an effort to maintain the periurethral dose to < 150% of the MPD. Within 48 hours of the implant, the patient will undergo a day 0 CT scan of the pelvis to assess post implant dosimetry using the standard BCCA protocol.
3303768|NCT00407875|Experimental|Intensity modulated external beam radiation therapy (IMRT)|patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) to a volume encompassing the prostate gland. The total radiation dose will be 70 Gy delivered in 28 fractions, so that the minimum dose to the PTV is 70 Gy, with CT simulation used for planning the treatment. Prior to starting the course of IMRT, fiducial markers will be placed in the prostate to assist in localization of the prostate for planning and quality assurance during treatment.
3303769|NCT00407836|Experimental|Vaccination|One arm of open label T cell vaccination in which all participants will receive the T cell vaccine
3303776|NCT00407667|Experimental|2|patients receive 20 min of cathodal transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
3303777|NCT00407667|Sham Comparator|3|patients receive 20 min of sham transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
3303778|NCT00407654|Experimental|Arm I|Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
3303779|NCT00407641|Experimental|Tinzaparin|Patients will receive Tinzaparin as anticoagulant during the HD session.
3303780|NCT00407641|Active Comparator|Heparin|Patients will receive Heparin as an anticoagulant during the HD session
3303781|NCT00407602|Active Comparator|Implant of Argus II Retinal Prosthesis|This is a single group study where the status and performance of the implanted eye prior to surgery serves as the comparator.
3303782|NCT00407589|Experimental|BOL-303224-A|Systemic exposure of BOL-303224-A following single and multiple topical doses
3303783|NCT00407550|Experimental|Gemzar x2|Treat subjects with 2 dosings/cycle of Gemzar x6 cycles.
3303784|NCT00407550|Experimental|Gemzar x1|Treat subjects with 1 dosing/cycle of Gemzar x9 cycles.
3303785|NCT00407537|Experimental|Caduet|Open label caduet added to usual care regimen followed by investigators.
3303786|NCT00407511|Experimental|Pregabalin|
3303787|NCT00407485|Experimental|Treatment (ziv-aflibercept)|Patients receive 4 mg/kg VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
3303788|NCT00407381|Experimental|Ranibizumab|Ranibizumab (RBZ) intravitreal injection alone
3303789|NCT00407381|Active Comparator|Laser|Laser photocoagulation
3303790|NCT00407381|Experimental|Laser with Ranibizumab|Laser following intravitreal injection of RBZ
3303791|NCT00407355|Active Comparator|RBZ 0.3|RBZ at the 0.3 mg dose intravitreal injection
3303792|NCT00407355|Active Comparator|RBZ 0.5|RBZ dose level .5 for ITV injection
3303793|NCT00407303|Experimental|1|30mg obatoclax, 1.0mg/m2 bortezomib
3303794|NCT00407303|Experimental|2|obatoclax 30 mg, bortezomib 1.3 mg/m2
3303795|NCT00407303|Experimental|3|Obatoclax 45 mg, Bortezomib 1.3 mg/m2
3303796|NCT00407277|Experimental|1A|
3303797|NCT00407277|Placebo Comparator|1B|
3303798|NCT00407277|Experimental|2A|
3303799|NCT00407186|Experimental|1chemoradiotherapy|5 weeksadjuvant treatment; radiotherapy and concomitant chemotherapy with cisplatin and capecitabine.
3303800|NCT00407186|Active Comparator|2chemotherapy|3 adjuvant courses epirubicin, cisplatin, capecitabine.
3303801|NCT00407173|Experimental|1|HCV-796 1000mg single dose
3303802|NCT00407160||1|"Patients with ESRD and high PRA who randomise to the control group. These patients will get induction therapy prior to transplant with Thymoglobulin 1.5 mg/kg/day for 4 days to a total dose of 6mg/kg.~They will receive maintenance immunosuppression with three drugs : tacrolimus, cellcept and prednisone."
3303803|NCT00407160||2|Patients with ESRD and high PRA who randomise to the study group. These patients will get induction therapy prior to reperfusion of the kidney, during the transplant operation, with Campath (Alemtuzumab) 30mg, one dose. They will receive maintenance immunosuppression with tacrolimus alone (monotherapy).
3303804|NCT00407147|No Intervention|Control|Standard treatment
3303805|NCT00407147|Experimental|PCT|PCT guided arm
3303806|NCT00407095|Experimental|1|
3303807|NCT00407082|Experimental|Fluocinolone acetonide 0.59mg|Fluocinolone acetonide ocular implant 0.59mg
3303808|NCT00407082|Experimental|Fluocinolone acetonide 2.1mg|Fluocinolone acetonide ocular implant 2.1mg
3303809|NCT00407082|No Intervention|No intervention|Fellow eye
3303810|NCT00407069||Active Atopic Dermatitis (AD)|Pediatric and adult subjects who fulfill the criteria for AD, a chronic inflammatory skin disease.
3303811|NCT00407069||Inactive Atopic Dermatitis (AD)|Adult subjects with a prior history of active AD that has been quiescent for at least 1 year.
3303812|NCT00407069||Psoriatics|Adult subjects who fulfill the criteria for plaque psoriasis, a chronic inflammatory skin disease.
3303813|NCT00407069||Asthmatics (without a history of AD)|Adult subjects who fulfill the criteria for asthma (reactive airway disease) and have a negative history of skin disease.
3303814|NCT00407069||Eczema Herpeticum (EH|Pediatric and adult AD subjects with a history of EH.
3303815|NCT00407069||Healthy Volunteers|Healthy individuals with no history of skin or respiratory disease.
3303816|NCT00407030|Experimental|incobotulinumtoxinA (Xeomin) (240 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 240 units, total volume 4.8mL; Mode of administration: intramuscular injection"
3303817|NCT00407030|Experimental|incobotulinumtoxinA (Xeomin) (120 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 120 units, total volume 4.8 mL; Mode of administration: intramuscular injection"
3303818|NCT00407030|Placebo Comparator|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 4.8 mL; Mode of administration: intramuscular injection
3303819|NCT00406978|Experimental|MPTD|
3303820|NCT00406913|Experimental|Mupirocin ointment|
3303821|NCT00406913|Active Comparator|Standard of Care sterilization|
3303822|NCT00406848|Experimental|Duloxetine|
3303823|NCT00406848|Placebo Comparator|Placebo|
3303824|NCT00406809|Experimental|Phase 1a and 1b|Relapsed or refractory lymphoid malignancies
3303825|NCT00406809|Experimental|Arm A (Phase 2a)|Relapsed or refractory follicular lymphoma
3303826|NCT00406809|Experimental|Arm B (Phase 2a)|Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma
3303827|NCT00406809|Experimental|Extension Study|Relapsed or refractory follicular lymphoma or Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma
3303828|NCT00406796|Active Comparator|1|0.5mg Ranibizumab
3303829|NCT00406796|Active Comparator|2|0.3mg Ranibizumab
3303830|NCT00406783|Experimental|5-mg Desloratadine tablet|
3303831|NCT00406783|Placebo Comparator|Placebo tablet|
3303832|NCT00406757|Active Comparator|Pediatric Arm 1|"Cycle 1: Nelarabine 400mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.~Cycle 2 and subsequent Cycles: Nelarabine 650mg2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose."
3303833|NCT00406757|Active Comparator|Pediatric Arm 2|Cycle 1 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.
3303834|NCT00406757|Active Comparator|Adult Arm 1|"Cycle 1: Nelarabine 1000mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose."
3303835|NCT00406757|Active Comparator|Adult Arm 2|Cycle 1 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.
3303836|NCT00406757|Active Comparator|Pediatric Arm 3|Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
3303837|NCT00406718|Experimental|PharmCAT|Participants will receive PharmCAT in addition to Treatment as usual, Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
3303838|NCT00406718|Active Comparator|Med-eMonitor|Participants will receive Med-eMonitor™ in addition to treatment as usual. Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
3303839|NCT00406718|Active Comparator|Treatment as Usual|Participants will receive standard treatment as usual which is medication management and limited case management provided by the CMHC.
3303840|NCT00406692|Experimental|Zonisamide|In open-label non-placebo controlled trial subjects are treatment with zonisamide 400 mg during the maintenance phase of this study
3303841|NCT00406679|Experimental|1|
3303842|NCT00406679|Placebo Comparator|2|
3303843|NCT00406679|Active Comparator|3|
3303844|NCT00406653|Experimental|1|"4 arms for induction period~2 arms for maintenance period"
3303845|NCT00406653|Placebo Comparator|2|"4 arms for induction period~2 arms for maintenance period"
3303846|NCT00406653|Other|abatacept|1 arm for open-label extension phase
3303847|NCT00406640|Active Comparator|A|
3303848|NCT00406640|Active Comparator|B|
3303849|NCT00406614|Experimental|1|Literacy-focused high blood pressure intervention. The intervention group will receive the health literacy -focused hypertension management intervention that will be delivered through 6 weeks of highly interactive group sessions in a classroom setting, followed by telephone counseling once a month for 12 months. Also, the intervention group will concurrently use home blood pressure monitoring with telephone transmission for 12 months.
3303850|NCT00406614|Active Comparator|2|Wait-list control group will initially receive usual care from a regular medical provider. Participants in the control group will take part in the intervention once the study has been completed.
3303851|NCT00406588|Experimental|1|
3303852|NCT00406588|Placebo Comparator|2|
3303853|NCT00406575|Placebo Comparator|Placebo|Participants receive diluent via continuous IV infusion for 48 hours.
3303854|NCT00406575|Experimental|Low Dose rhRlx|Participants receive recombinant human relaxin (rhRlx) via continuous IV infusion for 48 hours at a rate of 100 µg/kg/day (corresponding to a dose of 4.2 µg/kg/hr).
3303855|NCT00406575|Experimental|High Dose rhRlx|Participants receive recombinant human relaxin (rhRlx) via continuous IV infusion for 48 hours at a rate of 500 µg/kg/day (corresponding to a dose of 21.0 µg/kg/hr).
3303856|NCT00406536|Active Comparator|1|
3303857|NCT00406536|Placebo Comparator|2|
3303858|NCT00406484|Experimental|1|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
3303859|NCT00406484|Active Comparator|2|Standard drug counseling
3303860|NCT00406471|Active Comparator|1|500 micrograms of ranibizumab
3303861|NCT00406471|Active Comparator|2|300 microgram ranibizumab
3303862|NCT00406458|Experimental|SB-509|60 mg SB-509 injected IM into lower limbs every 2 months
3303863|NCT00406458|Placebo Comparator|Normal Saline|Normal saline injected IM into lower limbs every 2 months
3303864|NCT00406432|Experimental|Subjects receiving paroxetine|Eligible subjects will receive single dose of paroxetine 25 milligrams controlled release formulation followed by wash-out period of 5 days. Subjects will receive multiple doses of paroxetine 25 milligrams for further 14 days.
3303865|NCT00406419|Experimental|1|
3303866|NCT00406419|Experimental|2|
3303867|NCT00406419|Placebo Comparator|3|
3303868|NCT00406393|Active Comparator|Tacrolimus/Methotrexate|Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.
3303869|NCT00406393|Experimental|Tacrolimus/Sirolimus|Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.
3303870|NCT00406367|Experimental|incobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to 50 Units per eye; Open-Label Extension Period: up to 5 injections, up to 50 Units per eye per injection session; Mode of administration: intramuscular injection"
3303909|NCT00405925|Experimental|Trizivir|patients who reach undetectable HIV-RNA within 24 weeks are randomized to switch to trizivir or continuation of combivir/kaletra
3303871|NCT00406367|Placebo Comparator|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
3303872|NCT00406354|Experimental|Atomoxetine Fast Titration|0.5 milligram per kilogram (mg/kg) daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 8 weeks
3303873|NCT00406354|Experimental|Atomoxetine Slow Titration|0.5 mg/kg daily dose taken orally for 1 week, then 0.8 mg/kg daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 7 weeks
3303874|NCT00406354|Placebo Comparator|Placebo|matching placebo daily dose taken orally
3303875|NCT00406315|Other|A1|atypical antipsychotic for the treatment of schizophrenia
3303876|NCT00406276|Experimental|RAD001+Docetaxel|RAD001 in combination with Docetaxel.
3303877|NCT00406250|Experimental|Bevacizumab|
3303878|NCT00406237|Experimental|1|
3303879|NCT00406133|No Intervention|Standard intensive glucose monitoring|Patients in the control group were given blood glucose meters and test strips and asked to perform home blood glucose monitoring at least four times daily.
3303880|NCT00406133|Active Comparator|Continuous Glucose Monitoring (CGM)|Patients in the CGM group were instructed to use the CGM device on a daily basis and to verify the accuracy of the glucose measurement with a home blood glucose meter (provided by the study) before making management decisions (as per the regulatory labeling of the devices).
3303881|NCT00406107|Active Comparator|Pegaptanib Sodium 0.3mg (Macugen)|Intravitreous injections of Macugen 0.3mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.
3303882|NCT00406107|Active Comparator|Pegaptanib Sodium 1 mg (Macugen)|Intravitreous injections of Macugen 1.0mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.
3303883|NCT00406094|Experimental|1|montelukast
3303884|NCT00406094|Placebo Comparator|2|placebo
3303885|NCT00406081||Participants with AD|Children with AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit (including a group of AD subjects with eczema herpeticum)
3303886|NCT00406081||Nonatopic controls|Children without AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit
3303887|NCT00406068|Experimental|Mycobacterial cell wall-DNA complex|Mycobacterial cell wall-DNA complex
3303888|NCT00406055||1|Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
3303889|NCT00406029|Experimental|Preladenant 1 mg BID|Participants received preladenant 1 mg twice daily (BID) during the 12-week treatment period.
3303890|NCT00406029|Experimental|Preladenant 2 mg BID|Participants received preladenant 2 mg BID during the 12-week treatment period.
3303891|NCT00406029|Experimental|Preladenant 5 mg BID|Participants received preladenant 5 mg BID during the 12-week treatment period.
3303892|NCT00406029|Experimental|Preladenant 10 mg BID|Participants received preladenant 10 mg BID during the 12-week treatment period.
3303893|NCT00406029|Placebo Comparator|Placebo BID|Participants received preladenant matching placebo BID during the 12-week treatment period.
3303894|NCT00406016|Experimental|1|
3303895|NCT00406003|Experimental|Subjects receiving treatment sequence ABC|Eligible subjects will receive treatment sequence ABC; A= paroxetine 12.5 milligrams, B= paroxetine 25 milligrams, and C= paroxetine 37.5 milligrams separated by a wash-out period of 10 days.
3303896|NCT00406003|Experimental|Subjects receiving treatment sequence BAC|Eligible subjects will receive treatment sequence BAC; B= paroxetine 25 milligrams, A= paroxetine 12.5 milligrams and C= paroxetine 37.5 milligrams separated by a wash-out period of 10 days.
3303897|NCT00406003|Experimental|Subjects receiving treatment sequence CBA|Eligible subjects will receive treatment sequence CBA; C= paroxetine 37.5 milligrams, B= paroxetine 25 milligrams and A= paroxetine 12.5 milligrams separated by a wash-out period of 10 days.
3303898|NCT00406003|Experimental|Subjects receiving treatment sequence BCA|Eligible subjects will receive treatment sequence BCA; B= paroxetine 25 milligrams, C= paroxetine 37.5 milligrams and A= paroxetine 12.5 milligrams separated by a wash-out period of 10 days.
3303899|NCT00406003|Experimental|Subjects receiving treatment sequence CAB|Eligible subjects will receive treatment sequence CAB; C= paroxetine 37.5 milligrams, A= paroxetine 12.5 milligrams and B= paroxetine 25 milligrams separated by a wash-out period of 10 days.
3303900|NCT00406003|Experimental|Subjects receiving treatment sequence ACB|Eligible subjects will receive treatment sequence ACB; A= paroxetine 12.5 milligrams, C= paroxetine 37.5 milligrams and B= paroxetine 25 milligrams separated by a wash-out period of 10 days.
3303901|NCT00405977|Placebo Comparator|Physiologic saline|
3303902|NCT00405977|Active Comparator|Magnesium sulphate|
3303903|NCT00405964|Experimental|5-mg Desloratadine tablet|
3303904|NCT00405964|Placebo Comparator|Placebo tablet|
3303905|NCT00405951|Experimental|Obatoclax Mesylate + Docetaxel|Obatoclax Mesylate 250mL in combination with Docetaxel
3303906|NCT00405938|Experimental|Bevacizumab/anastrozole|Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] and anastrozole (1 mg orally daily). Treatment will be given in 4-week cycles.
3303907|NCT00405938|Experimental|Bevacizumab/fulvestrant|Bevacizumab/fulvestrant (with trastuzumab in HER2+ patients). Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant). Treatment will be given in 4-week cycles.
3303908|NCT00405925|Active Comparator|combivir/kaletra|All patients started with combivir/Kaletra and were randomized if they reached undetectable viral load (2 times) within 24 weeks into continuation of the same regimen or Trizivir (2 arms)
3303910|NCT00405912|Placebo Comparator|Placeo|Placebo pill was identical in appearance to the active medication.
3303911|NCT00405912|Experimental|St. John's Wort-900 mg/day|St. John's Wort - 300 mg tablets, 3 times a day.
3303912|NCT00405912|Experimental|St. John's Wort-1800 mg/day|St. John's Wort - 600 mg 3 times per day
3303913|NCT00405899||Immunotherapy|Patients starting immunotherapy
3303914|NCT00405899||Non-immunotherapy|Patients being treated using methods other than immunotherapy
3303915|NCT00405886|Experimental|Neramexane 25mg/d|
3303916|NCT00405886|Experimental|Neramexane 50mg/d|
3303917|NCT00405886|Experimental|Neramexane 75mg/d|
3303918|NCT00405886|Placebo Comparator|Placebo|
3303919|NCT00405873|Experimental|AMT2003|
3303920|NCT00405821|Active Comparator|Acyclovir 400mg tablet twice daily|
3303921|NCT00405821|Placebo Comparator|Placebo tablet twice daily|
3303922|NCT00405808|Experimental|1|Administration of one tablet containing 20 mg of Rimonabant
3303923|NCT00405808|Placebo Comparator|2|Administration of one Rimonabant placebo tablet.
3303924|NCT00405782|Active Comparator|Immediate Exercise Group|Exercise Intervention begins immediately
3303925|NCT00405782|Active Comparator|Delayed Exercise Group|Exercise intervention delayed by 16 weeks
3303926|NCT00405769|Placebo Comparator|1|placebo control
3303927|NCT00405769|Active Comparator|2|red yeast rice
3303928|NCT00405756|Experimental|MPR+R|Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
3303929|NCT00405756|Experimental|MPR+p|Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
3303930|NCT00405756|Other|MPp+p|Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
3303931|NCT00405743|Experimental|Arm A|CP4055, 2 and 4 hour IV infusion
3303932|NCT00405743|Experimental|Arm B|CP-4055, Continuous IV infusion
3303933|NCT00405730|Experimental|Nepafenac|One drop in the study eye 3 times daily for 23 days
3303934|NCT00405730|Active Comparator|Ketorolac Trometamol|One drop in the study eye 3 times daily for 23 days
3303935|NCT00405730|Placebo Comparator|Nepafenac Vehicle|One drop in the study eye 3 times daily for 23 days
3303936|NCT00405704|Active Comparator|Trimethoprim-Sulfamethoxazole|Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
3303937|NCT00405704|Placebo Comparator|Placebo|Cherry-flavored liquid suspension matched to active comparator.
3303938|NCT00405678|Experimental|1|Subjects receiving chemo and exercise training
3303939|NCT00405678|Experimental|2|Subjects receiving chemo only
3303940|NCT00405665|Experimental|1|
3303941|NCT00405665|Experimental|2|
3303942|NCT00405652|Experimental|Enteric-coated Mycophenolate sodium|Enteric-coated Mycophenolate sodium (EC-MPS), administered orally twice a day to achieve a dose equimolar to the dose of Mycophenolate mofetil (MMF) the patient was taking at the time of study entry up to a maximum dose of 1440 mg.
3303943|NCT00405639|Active Comparator|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is >90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
3303944|NCT00405639|Placebo Comparator|Placebo|Subjects randomized to this arm will receive self administered SQ placebo (normal saline) injections to match those of the study drug group. That is, first dose on Day 1, second dose 12 hours after the first dose, third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
3303945|NCT00405600|Active Comparator|Device|Device used in surgery with or without instrumentation
3303946|NCT00405587|Experimental|PLX4032|Open-label, sequential dose escalation
3303947|NCT00405574|Experimental|High Dose|ATN-224 dose 300mg
3303948|NCT00405574|Experimental|Low Dose|ATN-224 dose: 30mg
3303949|NCT00405561|Experimental|AMT2003|
3303950|NCT00405548|Active Comparator|BNP (nesiritide)|BNP 10 micrograms/Kg twice per day given subcutaneously for 12 weeks
3303951|NCT00405548|Placebo Comparator|Placebo|Saline solution given subcutaneously twice per day for 12 weeks (packaged to match active comparator)
3303952|NCT00405535|Experimental|A|glycine powder
3303953|NCT00405535|Placebo Comparator|B|placebo powder
3303954|NCT00405522|Experimental|1|
3303955|NCT00405522|Experimental|2|
3303956|NCT00405509||Confirmed respiratory virus|
3303957|NCT00405509||Unconfirmed respiratory infection|
3303958|NCT00405483|Active Comparator|Minimally invasive exposure|Surgical technique, minimal incision
3303959|NCT00405483|Active Comparator|Standard exposure|Standard Incision
3303960|NCT00405470|Active Comparator|Medial Pivot|
3303961|NCT00405470|Active Comparator|Posterior Stabilized|
3303962|NCT00405457|Other|A|
3303963|NCT00405444|Experimental|1|
3303964|NCT00405444|Placebo Comparator|2|
3303965|NCT00405431|Active Comparator|1|Patients received restasis eyedrops during 6 month post-operative period
3303966|NCT00405431|Placebo Comparator|2|Patients receive artificial tears (Endura) during 6 month post-operative period
3303967|NCT00405418|Experimental|1|Insulin Glargine
3303968|NCT00405418|Active Comparator|2|Insulin Detemir
3303969|NCT00405405|Experimental|Treatment|A combination of Cisplatin, Docetaxel, Bevacizumab, Erlotinib, and Radiotherapy
3303970|NCT00405366|Other|Single Arm Study|
3303971|NCT00405340|Experimental|Drug|Rituximab
3303972|NCT00405327|Experimental|DC vaccine therapy|Tumor lysate-pulsed dendritic cell (DC) vaccine following HSCT
3303973|NCT00405301|Other|Arm 1|Arm 1: will receive Isoniazide(5mg/kg/day), Rifampicin(10mg/kg/day) and Pyrazinamide(25mg/kg/day) in full doses on day 1 and continued further
3303974|NCT00405301|Other|Arm 2|Arm 2 : will receive Rifampicin(10mg/kg/day) in full dose on day 1 and continued, Isoniazide(5mg/kg/day)in full dose on day 8 and continued, Pyrazinamide(25mg/kg/day)on day 15 and continued
3303975|NCT00405301|Other|Arm 3|Arm 3 will receive 100 mg/day of Isoniazide on day 1 which is gradually increased to maximum dose (5mg/kg/day) by day 4 and continued. Rifampicin is introduced on day 8 in a dose of 150 mg/day which is gradually increased to maximum dose (10mg/kg/day) by day 11 and continued. Pyrazinamide is introduced on day 15 in a dose of 500mg/day which is gradually increased to maximum dose (25mg/kg/day) by day 18 and continued.
3303976|NCT00405288||Proctofoam-HC®|Women in the third trimester of pregnancy prescribed Proctofoam-HC® aerosol foam canister for 36 applications for treatment of symptoms of hemorrhoids. One applicatorful is to be applied into the anus (or on the perianal area) two or three times daily and after bowel evacuation.
3303977|NCT00405288||Control|Control group of women in the third trimester of pregnancy who were not exposed to any teratogens during the course of the pregnancy, and to Proctofoam-HC any of its components, or any other topical corticosteroids or local anaesthetics during the course of their pregnancy.
3303978|NCT00405275|Active Comparator|Arm 1|Etanercept and Methotrexate. Participants also received placebo hydroxychloroquine and sulfasalazine
3303979|NCT00405275|Active Comparator|Arm 2|Hydroxychloroquine, sulfasalazine and methotrexate. Participants also received placebo etanercept.
3303980|NCT00405262|Active Comparator|1|
3303981|NCT00405262|Experimental|2|
3303982|NCT00405262|Experimental|3|
3303983|NCT00405080|Experimental|Treatment Period 1|Subject will receive single oral dose of 150 milligram (mg) of Casopitant. There will be wash out period of 7 days.
3303984|NCT00405080|Experimental|Treatment Period 2|Subjects will receive rifampin 600 mg once daily on Days 1 - 9. On Day 8 subjects will receive a single dose of oral casopitant 150 mg along with rifampin.
3303985|NCT00405054|Other|1|continuous infusion every 14 days
3303986|NCT00405041|Experimental|A|
3303987|NCT00405015|Experimental|1|Placebo first
3303988|NCT00405015|Experimental|2|Rosiglitazone first
3303989|NCT00405002||1|ALI/ARDS patients
3303990|NCT00404924|Placebo Comparator|1|Best Supportive Care
3303991|NCT00404924|Experimental|2|Vandetanib + Best Supportive Care
3303992|NCT00404911|Experimental|MFG therapy|Participants will receive multi-family group therapy
3303993|NCT00404911|Active Comparator|Standard of Care|Participants will receive standard care
3303994|NCT00404885|Placebo Comparator|Placebo|
3303995|NCT00404885|Active Comparator|LX211, 0.2 mg/kg|
3303996|NCT00404885|Active Comparator|LX211, 0.4 mg/kg|
3303997|NCT00404885|Active Comparator|LX211, 0.6 mg/kg|
3303998|NCT00404820|Experimental|Zoledronic acid 5 mg|Patients received zoledronic acid 5 mg in 100 ml solution in a 15 minute intravenous (iv) infusion once per year. The peripheral iv infusion was preceded by and followed by a 10 ml normal saline flush of the intravenous line. In addition to study therapy, all participants received 1200 mg elemental calcium and 800 IU of vitamin D daily. Calcium and vitamin D were supplied in a chewable tablet that was to be taken twice daily.
3303999|NCT00404820|Active Comparator|Alendronate 70 mg|Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal. Patients were to remain in an upright position for 30 minutes after swallowing the tablet. In addition to study therapy, all participants received 1200 mg elemental calcium and 800 IU of vitamin D daily. Calcium and vitamin D were supplied in a chewable tablet that was to be taken twice daily.
3304000|NCT00404781|Experimental|optimal antiplatelet|cilostazol in addition to aspirin and clopdidogrel for pts with clopidogrel resistance
3304001|NCT00404781|Active Comparator|standard antiplatelet|aspirin and clopidogrel for all patients
3304002|NCT00404768|Experimental|Treatment|GSK221149A
3304003|NCT00404768|Placebo Comparator|Placebo|Placebo
3304004|NCT00404755|Experimental|escitalopram|escitalopram 10 mg/d for 1 week, then increasing by 10 mg/week if tolerated and not remitted to maximal dose of 40 mg/d
3304005|NCT00404755|Experimental|bupropion|bupropion extended release (XL) 150 mg/d for a week, then 300 mg/d for a week and then 450 mg/d; all dose increases if tolerated and not remitted
3304006|NCT00404755|Experimental|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then by 50 mg/week to a maximum dose of 300 mg/d; all dose increases if tolerated and not remitted
3304007|NCT00404742|Placebo Comparator|Placebo|
3304008|NCT00404742|Active Comparator|LX211, 0.2 mg/kg|
3304009|NCT00404742|Active Comparator|LX211, 0.4 mg/kg|
3304010|NCT00404742|Active Comparator|LX211, 0.6 mg/kg|
3304011|NCT00404703|Experimental|1|
3304012|NCT00404690|Active Comparator|1|Operative attempt at closure
3304013|NCT00404690|Experimental|2|bedside silo
3304014|NCT00404677|Placebo Comparator|Standard|Methacholine challenges are performed using the standardized two minute tidal breathing method
3304015|NCT00404677|Active Comparator|Modified|Five deep inhalation maneouvers are incorporated into the standardized methacholine challenge
3304016|NCT00404651|Experimental|Group 1|Participants receive vaccine Batch A
3304017|NCT00404651|Experimental|Group 2|Participants receive vaccine Batch B
3304018|NCT00404651|Experimental|Group 3|Participants receive vaccine Batch C
3304019|NCT00404651|Active Comparator|Group 4|Participants receive Infanrix hexa™
3304020|NCT00404612|Placebo Comparator|Placebo|
3304021|NCT00404612|Active Comparator|LX211, 0.2 mg/kg|
3304022|NCT00404612|Active Comparator|LX211, 0.4 mg/kg|
3304023|NCT00404612|Active Comparator|LX211, 0.6 mg/kg|
3304453|NCT00400387|Experimental|Multivitamin supplement + dalteparin sodium|
3304024|NCT00404586|Experimental|Treatment period 1|In treatment period subjects will receive once daily 100 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
3304025|NCT00404586|Experimental|Treatment period 2|In treatment period subjects will receive once daily 200 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
3304026|NCT00404586|Experimental|Treatment period 3|In treatment period subjects will receive once daily 400 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
3304027|NCT00404586|Placebo Comparator|Treatment period 4|In treatment period subjects will receive once daily Placebo and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive Placebo and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
3304028|NCT00404547|Active Comparator|Alvesco|Alvesco 320mcg / Alvesco 640mcg
3304029|NCT00404547|Active Comparator|Usual Care|
3304030|NCT00404534|Experimental|1|Amoxicillin 1000 mg BID, clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
3304031|NCT00404534|Placebo Comparator|2|Placebo of Amoxicillin 1000 mg BID, placebo of clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
3304032|NCT00404521|Experimental|Arm 1|
3304033|NCT00404495|Experimental|Temozolomide + Irinotecan|
3304034|NCT00404469|Active Comparator|CORT|Peritendinous corticosteroid injections at 0 and 4 weeks. 12 weeks total
3304035|NCT00404469|Experimental|ECC|12 weeks of eccentric unilateral decline squats
3304036|NCT00404469|Experimental|HSR|Heavy slow resistance training. 3/week. 12 weeks
3304037|NCT00404443|Sham Comparator|1|arm 1: placebo needle
3304038|NCT00404430||Exacerbated COPD patients|Patients with exacerbated COPD
3304039|NCT00404430||Stable COPD patients|Patients with stable COPD
3304040|NCT00404417|Experimental|1|Botox/Placebo
3304041|NCT00404417|Experimental|2|Botox/Botox
3304042|NCT00404417|Experimental|3|Placebo/Botox
3304043|NCT00404417|Placebo Comparator|4|Placebo/Placebo
3304044|NCT00404391|Experimental|Arm 1: hydrocodone/acetaminophen extended release|
3304045|NCT00404391|Experimental|Arm 2: hydrocodone/acetaminophen extended release|
3304046|NCT00404391|Placebo Comparator|placebo|
3304047|NCT00404378|Experimental|Cohort 1 Treatment Period 1|Subjects will receive single oral dose of 100 milligram (mg) of Casopitant. There will be wash out period of 7 days.
3304048|NCT00404378|Experimental|Cohort 1 Treatment Period 2|Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 100 mg along with ketoconazole.
3304049|NCT00404378|Experimental|Cohort 2 Treatment Period 1|Subjects will receive single oral dose of 50 mg of Casopitant. There will be wash out period of 7 days.
3304050|NCT00404378|Experimental|Cohort 2 Treatment Period 2|Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 50 mg along with ketoconazole.
3304051|NCT00404365|Experimental|Arm I (control)|Arm I (control): Patients complete screening questionnaires about their mood and experience with lung cancer once before and once after a visit with their physician. Neither the patient nor physician receives the screening results before the visit.
3304052|NCT00404365|Experimental|Arm II|Arm II: Patients complete screening questionnaires as in arm I. Only the patient receives the screening results before their visit with the physician; the physician remains blinded to the results.
3304053|NCT00404365|Experimental|Arm III|Arm III: Patients complete screening questionnaires as in arm I. Only the physician receives the screening results before their visit with the patient; the patient remains blinded to the results.
3304054|NCT00404365|Experimental|Arm IV|"Arm IV: Patients complete screening questionnaires as in arm I. Both physician and patient receive the screening results before the visit.~All patients and physicians are notified of the screening results before the patient leaves the clinic. All patients are offered supportive counseling."
3304055|NCT00404352|Active Comparator|RNF 44 mcg three times weekly|
3304056|NCT00404352|Active Comparator|RNF 44 mcg once weekly and placebo twice weekly for blinding|
3304057|NCT00404352|Placebo Comparator|Placebo three times weekly|
3304058|NCT00404313|Experimental|1|MK0633 10 mg
3304059|NCT00404313|Experimental|2|MK0633 50 mg
3304060|NCT00404313|Experimental|3|MK0633 100 mg
3304061|NCT00404313|Placebo Comparator|4|placebo
3304062|NCT00404287|Active Comparator|fluvastatin|fluvastatin 80 mg
3304063|NCT00404287|Placebo Comparator|placebo|
3304064|NCT00404274|Experimental|Treatment regimen A|In treatment regimen A subject will co-administer casopitant and warfarin over three-day period (Day 1 150 milligram per day [mg/day], Day 2 50 mg/day, Day 3 50 mg/day) and from Days 4 to 10 subject will administer only warfarin.
3304065|NCT00404274|Experimental|Treatment regimen B|In treatment regimen B subject will co-administer casopitant 60 mg/day and warfarin for 14 days.
3304066|NCT00404274|Experimental|Treatment regimen C|In treatment regimen C subject will co-administer warfarin and casopitant 30 mg/day for 14 days.
3304067|NCT00404261|Other|Arm 1|Fluticasone/Salmeterol HFA MDI without counter
3304068|NCT00404261|Other|Arm 2|Fluticasone/Salmeterol HFA MDI with counter
3304069|NCT00404248|Active Comparator|Arm 1 + Enzyme-inducing antiseizure drugs (+EIASD)|"subjects on the +EIASD treatment arm were taking one of these antiseizure drugs: phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine.~Subjects will take terameprocol for 5 consecutive days each month by IV. Starting dose is 750mg/day. Dose escalation is 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, and 9300. NO intrasubject dose escalation.~PK (pharmacological study) data will be collected on day one of cycle one infusion"
3304170|NCT00403117|Experimental|Naltrexone (50mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (50 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3304454|NCT00400374|Experimental|Erlotinib, Celecoxib|
3304070|NCT00404248|Active Comparator|Arm 2 non enzyme-inducing antiseizure drugs (-EIASD)|"Subjects in the -EIASD group were either not being treated with antiseizure drugs or were taking ones that did not significantly induce hepatic enzymes such as gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine, topiramate, zonisamide and felbamate.~Subjects will take terameprocol for 5 consecutive days each month by IV. Starting dose is 750mg/day. Dose escalation is 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, and 9300. NO intrasubject dose escalation.~PK (pharmacological study) data will be collected on day one of cycle one infusion"
3304071|NCT00404235|Experimental|paclitaxel + carboplatin|"Patients receive paclitaxel albumin-stabilized nanoparticle formulation (ABI-007) IV over 30 minutes followed by carboplatin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for at least 8 courses in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected periodically to evaluate secreted protein acidic and rich in cysteine (SPARC) content of tumor tissue by immunohistochemistry and to explore the impact of therapy on immune homeostasis. Samples are also analyzed by immunoenzyme techniques for angiogenesis markers.~After completion of study treatment, patients are followed periodically for up to 2 years."
3304072|NCT00404222|Experimental|hydrocodone / acetaminophen extended release|
3304073|NCT00404222|Active Comparator|Hydrocodone/Acetaminophen Immediate Release (Norco ®)|
3304074|NCT00404222|Placebo Comparator|Placebo|
3304075|NCT00404183|Experimental|hydrocodone/acetaminophen extended release|
3304076|NCT00404183|Placebo Comparator|Placebo|
3304077|NCT00404170|Experimental|B-CIT and SPECT imaging|To assess B-CIT injection and SPECT scanning. Optional ongoing B-CIT SPECT imaging scans at follow-up visits
3304078|NCT00404144|Experimental|Drug Eluting Balloon|treatment of small vessel with drug eluting balloon
3304079|NCT00404092|Experimental|1st cohort|70mg caspofungin 1x/day
3304080|NCT00404092|Experimental|2nd cohort|100mg caspofungin 1x/day
3304081|NCT00404092|Experimental|3rd cohort|150mg caspofungin 1x/day
3304082|NCT00404092|Experimental|4th cohort|200mg caspofungin 1x/day
3304083|NCT00404079|Experimental|Glucosamine Sulphate|
3304084|NCT00404079|Placebo Comparator|Placebo|
3304085|NCT00404066|Experimental|Neoadjuvant Chemotherapy|Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles, followed by docetaxel + lapatinib for four 21-day cycles, followed by surgery. Dexamethasone was administered twice-a-day for 3 days, starting 24 hours before the docetaxel infusions. After surgery +/- radiation, participants may receive trastuzumab (Herceptin) for a year.
3304086|NCT00404014|Active Comparator|AL-208|1 dose of 300 mg
3304087|NCT00404014|Placebo Comparator|Placebo|
3304088|NCT00403949|Active Comparator|Azelaic acid 15% Gel|Azelaic acid 15%
3304089|NCT00403949|Placebo Comparator|Placebo|Non-active base from Azelaic acid 15% gel
3304090|NCT00403923||Patients with known lactose intolerance|
3304091|NCT00403897|Experimental|1|Ages 2 - 6: Day 1= 1 sachet/day; Day 3= 1 sachet BID; Day 5= 1 sachet TID Ages 7 - 11: Day 1= 1 sachet BID; Days 3 & 5 = 2 sachets BID;
3304092|NCT00403845|Experimental|Placebo-indacaterol 150μg-indacaterol 300μg-indacaterol 600μg|In treatment period, 1 patients received 2 placebo capsules; in treatment period 2, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; in treatment period 3, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; and in treatment period 4, patients received 2 indacaterol 300 μg capsules. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3304093|NCT00403845|Experimental|Indacaterol 150μg-indacaterol 600μg-placebo-indacaterol 300μg|In treatment period 1, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; in treatment period 2, patients received 2 indacaterol 300 μg capsules; in treatment period 3, patients received 2 placebo capsules; and in treatment period 4, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3304094|NCT00403845|Experimental|Indacaterol 300μg-placebo-indacaterol 600μg-indacaterol 150μg|In treatment period 1, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 2, patients received 2 placebo capsules; in treatment period 3, patients received 2 indacaterol 300 μg capsules; and in treatment period 4, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3304095|NCT00403845|Experimental|Indacaterol 600μg-indacaterol 300μg-indacaterol 150μg-placebo|In treatment period 1, patients received 2 indacaterol 300 μg capsules; in treatment period 2, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 3, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; and in treatment period 4 patients received 2 placebo capsules. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3304096|NCT00403806|Active Comparator|1|Intravenous dexamethasone 0.05 mg per kg bodyweight
3304097|NCT00403806|Active Comparator|2|Intravenous dexamethasone 0.15 mg per kg bodyweight
3304098|NCT00403806|Active Comparator|3|Intravenous dexamethasone 0.5 mg per kg bodyweight
3304099|NCT00403806|Placebo Comparator|4|Intravenous saline
3304100|NCT00403793|Active Comparator|Arm 1|etonogestrel with testosterone undecanoate
3304101|NCT00403793|Placebo Comparator|Arm 2|Placebo
3304102|NCT00403780|Active Comparator|A|Active intervention with pregabalin
3304103|NCT00403780|Placebo Comparator|B|placebo arm with capsule Lyrica Placebo
3304104|NCT00403767|Experimental|Rivaroxaban|
3304105|NCT00403767|Active Comparator|Warfarin|
3304171|NCT00403117|Experimental|Naltrexone (100mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (100 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3304455|NCT00400361|Experimental|1|
3304106|NCT00403754|Experimental|Placebo-Ind 150 μg-Ind 300 μg-Ind 600 μg-Salmeterol|"In treatment period 1: patients received 2 placebo capsules; in treatment period 2: patients received 1 indacaterol (Ind) 150 μg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 indacaterol 300 μg capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
3304107|NCT00403754|Experimental|Ind 150 μg-Ind 600 μg-Placebo-Ind 300 μg-Salmeterol|"In treatment period 1: patients received 1 indacaterol (Ind) 150 μg capsule + 1 placebo capsule; in treatment period 2: patients received 2 indacaterol 300 μg capsules; in treatment period 3: patients received 2 placebo capsules; and in treatment period 4: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
3304108|NCT00403754|Experimental|Ind 300 μg-Placebo-Ind 600 μg-Ind 150 μg-Salmeterol|"In treatment period 1: patients received 1 indacaterol (Ind) 300 μg capsule + 1 placebo capsule; in treatment period 2: patients received 2 placebo capsules; in treatment period 3: patients received 2 indacaterol 300 μg capsules; and in treatment period 4: patients received 1 indacaterol 150 μg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation, device on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
3304109|NCT00403754|Experimental|Ind 600 μg-Ind 300 μg-Ind 150 μg-Placebo-Salmeterol|"In treatment period 1: patients received 2 indacaterol (Ind) 300 μg capsules; in treatment period 2: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 placebo capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
3304110|NCT00403689|Experimental|x|capsules containing beta glycan
3304111|NCT00403689|Placebo Comparator|y|capsules containing placebo (waxy maize starch)
3304112|NCT00403676|Experimental|Follow up by nurse|Patient randomized for follow-up by a nurse
3304113|NCT00403676|Experimental|follow up by medical doctor|Patients randomized for follow up by a medical doctor
3304114|NCT00403650|Experimental|1|
3304115|NCT00403611|Active Comparator|Praziquantel 40mg/kg|Praziquantel (Distocide) 40mg/kg single oral dose
3304116|NCT00403611|Experimental|Praziquantel 60mg/kg|Praziquantel (Distocide) 60mg/kg single oral dose
3304117|NCT00403546|Experimental|High-Dose Ziprasidone|Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take ziprasidone oral capsule twice daily added to their regular open-label ziprasidone dose (total of 240 mg/d). After the first week, the study drug will be increased to a total ziprasidone dose of 320 mg/d for 7 weeks.
3304118|NCT00403546|Placebo Comparator|Placebo, Standard Treatment Ziprasidone|Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take matching placebo oral capsule twice daily added to their regular open-label ziprasidone dose of 160 mg/d. After the first week, the matching placebo will be increased to two capsules twice daily and their regular open-label ziprasidone will remain the same (160 mg/d) for 7 weeks.
3304119|NCT00403520|Experimental|Experimental 1|
3304120|NCT00403520|Placebo Comparator|Placebo Comparator|
3304121|NCT00403507|No Intervention|Clean Control|Probable Alzheimer's disease in the context of no excluding medical conditions.
3304122|NCT00403507|No Intervention|CoMorbid Control|Probable Alzheimer's disease in the context of well-controlled comorbid medical conditions.
3304123|NCT00403507|Experimental|Clean Exercise|Probable Alzheimer's disease in the context no comorbid medical conditions.
3304124|NCT00403507|Experimental|CoMorbid Exercise|Probable Alzheimer's disease in the context of well-controlled comorbid medical conditions.
3304125|NCT00403494|Experimental|6R-BH4|800 mg/day of 6R-BH4, divided into two doses each day, for 24 weeks
3304126|NCT00403494|Placebo Comparator|Placebo|Placebo to be administered in the same manner as that of the investigational product, 6R-BH4
3304127|NCT00403494|Experimental|6R-BH4 + Vitamin C|800 mg/day of 6R-BH4, divided into two doses, plus 1000mg/day Vitamin C, divided into two doses, for 24 weeks
3304128|NCT00403494|Placebo Comparator|Placebo + Vitamin C|Placebo to be administered in the same manner as that of the investigational product, plus 1000mg/day Vitamin C, divided into two doses
3304222|NCT00402597|Experimental|001|Rivaroxaban 1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
3304129|NCT00403481|Experimental|Active treatment|Blood pressure (BP) measurements were taken every three weeks for 12 weeks. In accordance with their BP results, participants either stayed on their current medication or were started on the next higher regimen at the 3, 6, or 9 week visits. All participants began at 20 mg olmesartan, once daily for 3 weeks. The next higher regimen was olmesartan 40 mg, followed by olmesartan 40 mg + 12.5 mg hydrochlorothiazide, followed by olmesartan 40 mg + 25 mg of hydrochlorothiazide.
3304130|NCT00403455|Other|Paroxetine Arm|This is a single arm, single site, open-label clinical trial to treat veterans with PTSD. It is a 12-week trial to investigate the efficacy of paroxetine in reducing PTSD symptoms, with the primary outcome measure using CAPS. Genetic information is included to understand why some respond and some do not respond to paroxetine treatment.
3304131|NCT00403429|Experimental|Capecitabine|
3304132|NCT00403416|Active Comparator|Mycophenolic Acid / tacrolimus|
3304133|NCT00403416|Experimental|AEB071 / tacrolimus arm 1|
3304134|NCT00403416|Experimental|AEB071 / tacrolimus arm 2|
3304135|NCT00403403|Placebo Comparator|Placebo+Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide
3304136|NCT00403403|Experimental|Bevacizumab+Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide
3304137|NCT00403390|Experimental|Brand name levothyroxine (Synthroid)|Dose previously demonstrated to normalize thyroid function given daily for 2 months
3304138|NCT00403390|Active Comparator|Generic formulation of Levothyroxine|Dosage previously determined to normalize thyroid function given daily for 2 months
3304139|NCT00403377|Experimental|Intervention|Phase II include two arms. In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
3304140|NCT00403377|No Intervention|Control|Phase II include two arms. In the control arm, a souvenir photograph is taken of the participants and they then receive product samples that are irrelevant to skin cancer risk reduction (e.g., skin moisturizer, hair gel, chewing gum). Participants also receive educational materials at the completion of the study.
3304141|NCT00403351||ARM-CAD 1|Cross-sectional analysis using coronary angiogram results
3304142|NCT00403351||ARM-CAD 2|Prospective cohort for incident cardiovascular events and mortality
3304143|NCT00403286|Experimental|C 10/1|
3304144|NCT00403286|Experimental|C 5/2|
3304145|NCT00403286|Experimental|C 5/1|
3304146|NCT00403286|Experimental|FP 1000|
3304147|NCT00403286|Experimental|FF 20|
3304148|NCT00403286|Active Comparator|AD 250/50|
3304149|NCT00403286|Placebo Comparator|Plc|
3304150|NCT00403286|Experimental|C 10/2|
3304151|NCT00403273|Experimental|A|Single Intra-articular Injection of 100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
3304152|NCT00403273|Placebo Comparator|B|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
3304153|NCT00403260|Experimental|1|Pyronaridine artesunate (180:60 mg tablets)
3304154|NCT00403260|Active Comparator|2|Mefloquine plus artesunate
3304155|NCT00403247|Experimental|A|vitamin capsule
3304156|NCT00403247|Placebo Comparator|B|placebo capsule
3304157|NCT00403234|Experimental|BTDS 10|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
3304158|NCT00403234|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
3304159|NCT00403234|Experimental|BTDS 30|Buprenorphine transdermal patch 30 mcg/h applied for 7-day wear
3304160|NCT00403234|Placebo Comparator|Placebo TDS|Placebo patches were similar to BTDS 10 and 20.
3304161|NCT00403169|Experimental|Lenalidomide for Advanced RCC|25 mg/day Lenalidomide for 21 days per cycle.
3304162|NCT00403130|Experimental|Phase II 3-drug regimen|Gemcitabine + Paclitaxel + Bevacizumab
3304163|NCT00403117|Placebo Comparator|Placebo, Marijuana (0% THC)|During each session, one capsule containing placebo was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3304164|NCT00403117|Experimental|Placebo, Marijuana (3.27% THC)|During each session, one capsule containing placebo was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3304165|NCT00403117|Experimental|Naltrexone (12mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (12 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3304166|NCT00403117|Experimental|Naltrexone (12mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (12 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3304167|NCT00403117|Experimental|Naltrexone (25mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (25 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3304168|NCT00403117|Experimental|Naltrexone (25mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (25 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3304169|NCT00403117|Experimental|Naltrexone (50mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (50 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3304223|NCT00402597|Experimental|002|Rivaroxaban/Placebo 1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
3304172|NCT00403117|Experimental|Naltrexone (100mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (100 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3304173|NCT00403104|Experimental|E|ONO-2506PO in the presence of Riluzole
3304174|NCT00403104|Placebo Comparator|P|Placebo in the presence of Riluzole
3304175|NCT00403091|Experimental|Intervention|
3304176|NCT00403091|Active Comparator|Control|
3304177|NCT00403052|Experimental|1|Low dose of 1018 ISS
3304178|NCT00403052|Experimental|2|Middle dose of 1018 ISS
3304179|NCT00403052|Experimental|3|High dose of 1018 ISS
3304180|NCT00403039|Other|Open-label ranibizumab|Subjects will receive open-label intravitreal injections of ranibizumab administered every 28 ± 7 days for a total of 3 injections. Thereafter they are to be evaluated monthly for re-treatment until Month 48.
3304181|NCT00403013|Experimental|1|lateral, head-down position during axillary plexus block
3304182|NCT00403013|Active Comparator|2|standard position during axillary plexus block
3304183|NCT00402987|Experimental|celecoxib 50 mg/50 mg|
3304184|NCT00402987|Experimental|celecoxib 100 mg/placebo|
3304185|NCT00402987|Experimental|celecoxib 100 mg/50 mg|
3304186|NCT00402987|Placebo Comparator|placebo|
3304187|NCT00402961|Active Comparator|1|Acupuncture is the insertion of needles at certain body points.
3304188|NCT00402961|Sham Comparator|2|sham acupuncture
3304189|NCT00402948|Experimental|TPI ASM8|ASM8 0.25mg
3304190|NCT00402948|Experimental|ASM8 as TPI ASM8|TPI ASM8 0.5mg
3304191|NCT00402896|Experimental|ZD6474|300 mg/day orally for 10 weeks.
3304192|NCT00402883|Experimental|Intervention|Induction treatment included: carboplatin AUC=5, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg each administered intravenously weeks 1 and 4. Radiation was administered concurrently at a dose of 1.8 Gy/d weeks 1 to 7 to a total of 61.2 Gy per institutional guidelines. Consolidative therapy, following an 8-week break from chemoradiotherapy, included carboplatin AUC=6, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg each administered intravenously on week 16, repeated weeks 19 and 22. Folic acid (350 to 1,000 ug or equivalent) supplementation was administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinued study therapy. Vitamin B12(1,000ug) was administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinued therapy.
3304193|NCT00402857|Experimental|1|Participants will receive the Incredible Years Program, a group parenting intervention
3304194|NCT00402857|Other|2|Participants assigned to the waitlist condition will receive the Incredible Years Program after a 1-year waiting period
3304195|NCT00402831|Experimental|Intramuscular ProQuad®|Participants will receive doses of ProQuad® by IM injection on Day 1 and Day 30 into the deltoid muscle perpendicular to the skin, with the first dose in the right arm and the second dose in the left arm.
3304196|NCT00402831|Active Comparator|Subcutaneous ProQuad®|Participants will receive doses of ProQuad® by SC injection on Day 1 and Day 30 in the deltoid area at a 45° angle to the skin, with the first dose in the right arm and second dose in the left arm.
3304197|NCT00402792|Experimental|Arm 1: hydrocodone / acetaminophen extended release|
3304198|NCT00402792|Experimental|Arm 2: hydrocodone / acetaminophen extended release|
3304199|NCT00402792|Placebo Comparator|Arm 3: Placebo|
3304200|NCT00402779|Experimental|Erlotinib|Balanced randomization: Erlotinib 150 mg continuous administration for 1 year.
3304201|NCT00402779|Placebo Comparator|Placebo|Balanced randomization: Placebo continuous administration for 1 year.
3304202|NCT00402766|Experimental|Cisplatin + Imatinib + Pemetrexed|Cisplatin 60 mg/m^2 by vein, Over 2 Hours. Imatinib 300 mg PO Daily. Pemetrexed 500 mg/m^2 by vein, Over 40 Minutes. Dexamethasone 20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
3304203|NCT00402753|Experimental|Group 1|Physical exercise group: Combined supervised physical activity: Endurance and Resistive strength
3304204|NCT00402753|No Intervention|Group 2|Usual care control group
3304205|NCT00402727|Experimental|Moxifloxacin|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
3304206|NCT00402727|Active Comparator|PIP/TAZ-AMC|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
3304207|NCT00402714|Active Comparator|1|Extracorporeal photopheresis, pentostatin and total body irradiation
3304208|NCT00402714|Active Comparator|2|Pentostatin and total body irradiation
3304209|NCT00402701|Experimental|1|Students in school with active walk-to-school promotion programs.
3304210|NCT00402701|No Intervention|2|Students in schools with access to standard school district transportation resources.
3304211|NCT00402688|Active Comparator|001|levofloxacin 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
3304212|NCT00402688|Active Comparator|002|levofloxacin 750mg tablet once daily for 3 weeks followed by 1 week of placebo.
3304213|NCT00402688|Active Comparator|003|levofloxacin 500mg tablet once daily for 4 weeks.
3304214|NCT00402675|Active Comparator|Immediate Intervention|Patients with NSTEMI undergo immediate invasive angiography (< 2 hours)
3304215|NCT00402675|Active Comparator|Early Intervention|Patients with NSTEMI undergo early invasive angiography (12-48 hours)
3304216|NCT00402675|Active Comparator|Selective invasive angiography|Patients with NSTEMI undergo selective invasive angiography
3304217|NCT00402649|Experimental|1|All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.
3304218|NCT00402636|Experimental|1|rapamycin plus 17beta estradiolvalerat-eluting stent
3304219|NCT00402636|Experimental|2|rapamycin-eluting stent
3304220|NCT00402623|Placebo Comparator|1|placebo
3304221|NCT00402623|Active Comparator|2|quercetin (food supplement)
3304224|NCT00402597|Placebo Comparator|003|Placebo 1 placebo tablet twice daily for 6 months.
3304225|NCT00402558|Experimental|Thymoglobulin + Busulfan + Fludarabine|"Thymoglobulin 1.5 mg/kg by vein for 3 days. Busulfan 130 mg/m^2 by vein for 4 days. Fludarabine 40 mg/m^2 by vein for 4 days. Alloreactive NK infusion from haploidentical donor on Day -8. Alloreactive NK cell infusion given at one of 4 dose levels 10e6, 5 x 10e6, 3 x 10e7 cells/kg and 3 x10e7 NK Cells plus systemic interleukin-2 treatment. The 4th dose level is 3 x 107 NK cells/kg plus systemic interleukin-2 at a dose of 0.5 million units per day subcutaneously starting on Day -8 (day of the NK cell infusion) to Day -4.~G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count is > 500 x 109/L for 3 consecutive days. Tacrolimus starting dose of 0.015 mg/kg daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present. Methotrexate 5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant."
3304226|NCT00402532|Active Comparator|Everolimus|
3304227|NCT00402532|Active Comparator|Mycophenolatmofetil|
3304228|NCT00402519|Experimental|APBI|Accelerated Partial Breast Irradiation with multicatheter brachytherapy
3304229|NCT00402519|Active Comparator|EBRT|Standard External Beam Whole Breast Irradiation
3304230|NCT00402493|Active Comparator|Latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
3304231|NCT00402493|Active Comparator|Brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
3304232|NCT00402493|Active Comparator|ibuprofen|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
3304233|NCT00402467|Experimental|Arm 6|
3304234|NCT00402467|Experimental|Arm 1|
3304235|NCT00402467|Experimental|Arm 2|
3304236|NCT00402467|Experimental|Arm 3|
3304237|NCT00402467|Experimental|Arm 4|
3304238|NCT00402467|Experimental|Arm 5|
3304239|NCT00402428|Active Comparator|1|180 mcg PEG-IFNx2a every 1 week (48 doses) + Ribavirin 1000 or 1200 mg/day
3304240|NCT00402428|Experimental|2|900 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
3304241|NCT00402428|Experimental|3|1200 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
3304242|NCT00402415|Experimental|1|
3304243|NCT00402389|Experimental|1|Participants assigned to take omega-3 fatty acids
3304244|NCT00402389|Placebo Comparator|2|Participants assigned to take placebo
3304245|NCT00402363|Experimental|omega-3-acid ethyl esters|
3304246|NCT00402363|Placebo Comparator|Placebo|
3304247|NCT00402350|Placebo Comparator|Placebo|Subjects (2) from each of the 4 dose escalation arms
3304248|NCT00402350|Experimental|25 mcg IV and Inhaled Crossover|Single dose crossover (IV vs Inhaled)
3304249|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 2|Inhaled Staccato fentanyl, 25 mcg x 2
3304250|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 4|Inhaled Staccato fentanyl, 25 mcg x 4
3304251|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 6|Inhaled Staccato fentanyl, 25 mcg x 6
3304252|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 12|Inhaled Staccato fentanyl, 25 mcg x 12
3304253|NCT00402337|Active Comparator|72 ug linaclotide acetate|
3304254|NCT00402337|Active Comparator|145 ug linaclotide acetate|
3304255|NCT00402337|Active Comparator|290 ug linaclotide acetate|
3304256|NCT00402337|Active Comparator|579 ug linaclotide acetate|
3304257|NCT00402337|Placebo Comparator|Matching Placebo|
3304258|NCT00402324|Experimental|1|olanzapine and divalproex
3304259|NCT00402324|Placebo Comparator|2|placebo and divalproex
3304260|NCT00402298|Experimental|1|Participants will receive an initial dose of 125 mg MDMNA followed 2.5 hours later by a supplemental dose of 62.5 mg MDMA during the course of two day-long psychotherapy sessions.
3304261|NCT00402298|Active Comparator|2|25 and 12.5 mg MDMA
3304262|NCT00402285|Active Comparator|lycopene supplement|Two 15mg lycopene capsules daily for 3 months.
3304263|NCT00402285|Active Comparator|fish oil supplement|1g fish oil capsule daily for 3 months.
3304264|NCT00402285|Placebo Comparator|placebo|placebos for lycopene and fish oil.
3304265|NCT00402272|Experimental|1|XIENCE V® Everolimus Eluting Coronary Stent System
3304266|NCT00402246|Experimental|Remote Arm|Remote Management
3304267|NCT00402246|Active Comparator|In-office Arm|In-Office Care
3304268|NCT00402233|Other|Placebo|
3304269|NCT00402233|Other|Pramipexole 0.5 mg Tid|Pramipexole 0.5 mg tid (three times a day)
3304270|NCT00402233|Other|Pramipexole 0.5 mg Bid|Pramipexole 0.5 mg bid (bis in die (two times a day))
3304271|NCT00402233|Other|Pramipexole 0.75 mg Bid|Pramipexole 0.75 mg bid (bis in die (two times a day))
3304272|NCT00402220|Active Comparator|1|active TMS
3304273|NCT00402220|Placebo Comparator|2|Sham TMS
3304274|NCT00402181|Experimental|Treatment Plan A|Siltuximab 6 milligram per kilogram (mg/kg) as intravenous (directly into the vein) infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days (if participant have complete or partial response) along with dexamethasone (starting from Cycle 2, If participant do not have complete or partial response) 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles.
3304275|NCT00402181|Experimental|Treatment Plan B|Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks along with dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles (duration of each cycle is 28 days) after that on Day 1 to 4 up to 12 cycles.
3304276|NCT00402168|Experimental|A: Belatacept|
3304277|NCT00402168|Active Comparator|B: calcineurin inhibitor (CNI)-based immunosuppressive regimen|
3304278|NCT00402155||1|Normal subjects
3304279|NCT00402155||2|Reading discomfort subjects
3304280|NCT00402142|Active Comparator|Pulsed dendritic cells untreated patients|Untreated patients receiving a dendritic cell based vaccine pulsed with autologous heat iactivated virus
3304281|NCT00402142|Placebo Comparator|non pulsed dendritic cells untreated patients|
3304380|NCT00401193|Placebo Comparator|3|
3304282|NCT00402142|Active Comparator|pulsed dendritic cell treated patient|treated patients will be immunized with a dendritic cell vaccine pulsed with heat inactivated autologous virus immediately before art interruption
3304283|NCT00402142|Active Comparator|pulsed dendritic cell in treated patients|patients will be immunized with a dendritic cell vaccine pulsed with heat inactivted autologous virus immediately after interruption of art
3304284|NCT00402142|Placebo Comparator|non pulsed dendritic cells|
3304285|NCT00402116|Experimental|A|
3304286|NCT00402103|Experimental|Aliskiren/Amlodipine|
3304287|NCT00402103|Experimental|Aliskiren/Amlodipine/HCTZ|
3304288|NCT00402077|Experimental|1|
3304289|NCT00402077|Experimental|2|
3304290|NCT00402077|Experimental|3|
3304291|NCT00402077|Placebo Comparator|4|
3304292|NCT00402051|Experimental|Pemetrexed + Cisplatin|
3304293|NCT00402051|Experimental|Pemetrexed + Carboplatin|
3304294|NCT00402038|Experimental|Arm 1|
3304295|NCT00402038|Placebo Comparator|Arm 2|
3304296|NCT00402025|Experimental|Talimogene Laherparepvec|Participants received 3 doses of talimogene laherparepvec administered by direct injection 3 weeks apart. At the discretion of the investigator, treatment with talimogene laherparepvec could continue beyond the third dose until week 15 in a regimen of at least 3 weeks between doses.
3304297|NCT00402012|No Intervention|1|
3304298|NCT00402012|Experimental|2|
3304299|NCT00401986||Alair Treatment|Alair Treated subject6s from PREDECESSOR STUDY
3304300|NCT00401973|Experimental|Olanzapine|olanzapine plus behavioral information
3304301|NCT00401973|Experimental|Olanzapine + Amantadine|Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information
3304302|NCT00401973|Experimental|Olanzapine + Metformin|Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information
3304303|NCT00401960|Experimental|Daptomycin adjunctive group|Patients with enterococcal endocarditis who elect to receive daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving
3304304|NCT00401960|No Intervention|standard of care|Patients with enterococcal endocarditis who elect to receive standard of care therapy as prescribed by their primary physician
3304305|NCT00401921|Placebo Comparator|Minocycline arm|Minocycline 100mg/Placebo 0mg Minocycline 100mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
3304306|NCT00401921|Placebo Comparator|Placebo arm|Placebo 0mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
3304307|NCT00401895|Active Comparator|1|patients treated with 10 mm stent
3304308|NCT00401895|Active Comparator|2|patients treated with 8 mm stent
3304309|NCT00401882|Active Comparator|Standard Of Care Drug Epinephrine|Additional doses of Epinephrine (1 mg) given as part of standard of care during cardiac arrest
3304310|NCT00401882|Active Comparator|IV Metoprolol instead Epinephrine|IV metoprolol 5 mg. up to 2 times (only) during cardiac arrest will be given instead of additional Epinephrine doses
3304311|NCT00401856|Experimental|1|This arm will receive eplerenone
3304312|NCT00401856|Placebo Comparator|2|This group will receive the placebo
3304313|NCT00401843|Experimental|Part 1: Siltuximab Plus Bortezomib|Siltuximab 6 milligram per kilogram (mg/kg) will be administered as intravenous infusion once every 2 weeks along with bortezomib 1.3 milligram per square meter (mg/m^2) during cycle 1.
3304314|NCT00401843|Experimental|Part 2: Bortezomib + Placebo|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period along with matching placebo administered as intravenous infusion once every 2 weeks during 42-day treatment phase. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) along with matching placebo once every 2 weeks during 35-day Maintenance Phase. Dexamethasone tablet will be administered at first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 milligram per day (mg/day) will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles.
3304315|NCT00401843|Experimental|Part 2: Bortezomib + Siltuximab|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period along with Siltuximab administered as intravenous infusion once every 2 weeks during 42-day treatment phase. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) along with Siltuximab administered as intravenous infusion once every 2 weeks for 35-day Maintenance Phase. Dexamethasone tablet will be administered at first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles.
3304316|NCT00401830|Placebo Comparator|Placebo|
3304317|NCT00401830|Experimental|Lacosamide|Lacosamide Tablet 400mg daily
3304318|NCT00401817|Experimental|Study Treatment Arm|Bevacizumab-R-CHOP therapy included bevacizumab administered at 15 mg/kg on day 1, and standard dose R-CHOP on day 3, for six 21-day cycles
3304319|NCT00401791|Experimental|1|
3304320|NCT00401791|No Intervention|2|
3304321|NCT00401778|Active Comparator|1|RAD001 5 mg/day for 21 days sequentially.
3304322|NCT00401778|Active Comparator|3|RAD001 10 mg/day for 21 days sequentially.
3304323|NCT00401778|No Intervention|Control|Patients who are eligible for the study but choose not to receive RAD001 treatment.
3304324|NCT00401765|Experimental|Cohort 1A (Docetaxel and CNTO 328)|In cohort 1A, 75 mg/m2 docetaxel will be administered in run-in phase and 75 mg/m2 docetaxel every 3 weeks and 6 mg/kg CNTO 328 every 2 weeks will be administered in the treatment phase.
3304325|NCT00401765|Experimental|Cohort 1B (Docetaxel and CNTO 328)|In cohort 1B, 6 mg/kg CNTO 328 will be administered in run-in phase and 75 mg/m2 docetaxel will be administered every 3 weeks plus 6 mg/kg CNTO 328 will be administered every 2 weeks in the treatment phase.
3304326|NCT00401765|Experimental|Cohort 2 (Docetaxel and CNTO 328)|In cohort 2, 75 mg/m2 docetaxel will be administered in run-in phase and 75 mg/m2 docetaxel plus 9 mg/kg CNTO 328 will be administered every 3 weeks in treatment phase.
3304408|NCT00400842|Placebo Comparator|P|
3304327|NCT00401765|Experimental|Cohort 3 (Doctaxel and CNTO 328)|In cohort 3, 75 mg/m2 docetaxel will be administered in the run-in phase and 75 mg/m2 docetaxel plus 12 mg/kg CNTO 328 will be administered every 3 weeks in treatment phase.
3304328|NCT00401739|Experimental|I|Treatment with CSL360
3304329|NCT00401674|Experimental|SINGLE ARM|
3304330|NCT00401661|Experimental|1|Alfuzosin for 24 weeks
3304331|NCT00401622|Experimental|OneTouch® Ultra®2 system|Test care group assigned to OneTouch® Ultra®2 system
3304332|NCT00401622|Active Comparator|Standard care|Control group receiving standard care with a traditional blood glucose monitoring system
3304333|NCT00401583|Experimental|Pazopanib receivers|During Days 1 and 2 subjects will be dosed with only probe drugs, and with no drugs on Days 3-5. During Days 6 to the end of the study, subjects will receive 800 mg daily pazopanib, and on Days 23-24 subjects will receive probe drugs in addition to pazopanib
3304334|NCT00401570|Experimental|Cohort 1|Volociximab (10 mg/kg every other week (qowk)) and Gemcitabine
3304335|NCT00401570|Experimental|Cohort 2|Volociximab (15 mg/kg weekly (qwk)) and Gemcitabine
3304336|NCT00401544|Experimental|Darbepoetin alfa 300 μg plus IV Iron|Darbepoetin alfa 300 μg subcutaneous injection plus intravenous (IV) iron 400 mg, every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
3304337|NCT00401544|Experimental|Darbepoetin alfa 300 μg|Darbepoetin alfa 300 μg subcutaneous injection every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
3304338|NCT00401544|Experimental|Darbepoetin alfa 500 μg|Darbepoetin alfa 500 μg subcutaneous injection every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
3304339|NCT00401544|Active Comparator|Darbepoetin alfa 500 μg plus IV Iron|Darbepoetin alfa 500 μg subcutaneous injection plus intravenous (IV) iron 400 mg, every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
3304340|NCT00401531|Experimental|Group 1: DTaP IPV Hep B PRP T + Prevnar™|
3304341|NCT00401531|Active Comparator|Group 2: Infanrix hexa™ + Prevnar™|
3304342|NCT00401518|Experimental|ACADIA®|Investigational surgical treatment using the ACADIA Facet Replacement system
3304343|NCT00401518|Active Comparator|Control Instrumented PLF|Control surgical treatment using an instrumented posterolateral fusion
3304344|NCT00401466|Experimental|1|Prolonged follow-up intervals every 12 months
3304345|NCT00401466|Active Comparator|2|Standard follow-up intervals of 3 months
3304346|NCT00401440|Active Comparator|A|400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
3304347|NCT00401440|Active Comparator|B|400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
3304348|NCT00401414|Experimental|Warfarin|We will develop a nomogram for warfarin dosing that uses rapid turnaround genetic testing and monthly nomogram modification (if necessary) to achieve effective and safe warfarin induction and maintenance. More than 70% of the time, we will maintain warfarin naïve patients within the target therapeutic range. The percent of time in the therapeutic range will be analyzed beginning 2 weeks after initiation of warfarin. Analyses will be stratified by the indication for anticoagulation.
3304349|NCT00401401|Experimental|Zalutumumab 4 mg/kg|Zalutumumab 8 weekly infusions
3304350|NCT00401401|Experimental|Zalutumumab 8 mg/kg|Zalutumumab 8 weekly infusions
3304351|NCT00401401|Experimental|Zalutumumab 12 mg/kg|Zalutumumab 8 weekly infusions
3304352|NCT00401401|Experimental|Zalutumumab 16 mg/kg|Zalutumumab 8 weekly infusions
3304353|NCT00401388|Experimental|Group A: chondrosarcoma|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of chondrosarcoma.~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
3304354|NCT00401388|Experimental|Group B: alveolar soft part sarcoma|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of alveolar soft part sarcoma.~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
3304355|NCT00401388|Experimental|Group C: extra-skeletal myxoid|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of extra-skeletal myxoid chondrosarcoma.~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
3304356|NCT00401375|Experimental|Arm 1|MNTX Active Treatment
3304357|NCT00401375|Experimental|Arm 2|MNTX Active Treatment
3304358|NCT00401375|Placebo Comparator|Arm 3|Placebo
3304359|NCT00401362|Experimental|Arm 1|
3304360|NCT00401362|Placebo Comparator|Arm 3|
3304361|NCT00401362|Experimental|Arm 2|
3304362|NCT00401336|Experimental|Magnetic Resonance Imaging|New magnetic resonance imaging multiecho gradient-echo sequence
3304363|NCT00401323|Experimental|docetaxel plus cisplatin|Taxotere 75 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by cisplatin 75 mg/m² administered as a 30-minute to 3-hour infusion on Day 1
3304364|NCT00401323|Active Comparator|cisplatin plus 5-FU|Cisplatin 100 mg/m², 30-minute to 3-hour infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 1000 mg/m²/day from Day 1 to Day 5
3304365|NCT00401323|Experimental|docetaxel plus 5-FU|"Taxotere 85 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 750 mg/m²/day from Day 1 to Day 5~Arm only in the phase II part of the study"
3304366|NCT00401310|Placebo Comparator|1|Placebo
3304367|NCT00401310|Experimental|2|MK0724
3304368|NCT00401258|Other|1|12-week, open-label trial of duloxetine in subjects with IBS.
3304369|NCT00401245|Active Comparator|A|
3304370|NCT00401245|Active Comparator|B|
3304371|NCT00401245|Active Comparator|C|
3304372|NCT00401245|Active Comparator|D|
3304373|NCT00401245|Active Comparator|E|
3304374|NCT00401245|Active Comparator|F|
3304375|NCT00401245|Active Comparator|G|
3304376|NCT00401245|Placebo Comparator|H|
3304377|NCT00401232|Other|Arm 1|
3304378|NCT00401193|Experimental|1|
3304379|NCT00401193|Experimental|2|
3304381|NCT00401154|Experimental|Intervention Stationary Cycling|Subjects receiving the intervention performed stationary cycling 3 times a week for 30 sessions over 12 weeks.
3304382|NCT00401115|Experimental|1|Subconjunctival injection
3304383|NCT00401115|Experimental|2|Intraocular injection
3304384|NCT00401102|Other|Interpersonal psychotherapy|All participants received interpersonal psychotherapy adapted for self-injury
3304385|NCT00401089|Experimental|Ginsana-115|Ginsana-115 (Panax Ginseng formulation obtained from Boehringer Ingelheim Pharmaton Inc. Switzerland )is available in oral dosage form of capsules. Two dosages of Ginsana-115 will be tested: 100 mg once daily oral dosage ( 1 100-mg Ginsana-115 capsule) and 200 mg once daily dosage ( 2 100-mg Ginsana-115 capsule). The total duration of each dosage is 8 weeks.
3304386|NCT00401089|Placebo Comparator|Sugar Pill|Placebo capsules formulated identical to the active drug: Ginsana-115 are to be obtained from Boehringer Ingelheim Pharmaton, Switzerland. Two dosages of Placebo capsules will be administered once daily for 8 weeks : a) Placebo 100 mg capsule: 1 placebo capsule daily; b) Placebo 200 mg capsule: 2 placebo-capsule daily
3304387|NCT00401076|Experimental|1|
3304388|NCT00401063|Other|Single arm|Acupuncture treatment
3304389|NCT00401024|Experimental|Treatment|Imatinib mesylate 600mg orally once a day for seven consecutive days prior to surgery with last dose taken one day prior to surgery
3304390|NCT00401011|Experimental|Phase II: Perifosine + Bortezomib|All patients will start with perifosine at bedtime daily and Bortezomib IV on days 1, 4, 8, and 11 q 21 days. Patients will be evaluated at q 3 weeks. If the patient has a CR, PR, MR or stable disease, they will continue treatment.
3304391|NCT00401011|Experimental|Phase II: Perifosine + Bortezomib + Dexa|If the patient shows progressive disease, dexamethasone 20 mg will be added on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
3304392|NCT00401011|Experimental|Phase I: Dose 1: Perifosine + Bortezomib|Perifosine 50 mg at bedtime and bortezomib 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks.
3304393|NCT00401011|Experimental|Phase I: Dose 2: Perifosine + Bortezomib|Perifosine 100 mg at bedtime and bortezomib 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
3304394|NCT00401011|Experimental|Phase I: Dose 3: Perifosine + Bortezomib|Perifosine 50 mg at bedtime and bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
3304395|NCT00401011|Experimental|Phase I: Dose 4: Perifosine + Bortezomib|Perifosine 100 mg at bedtime and bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
3304396|NCT00400998|Placebo Comparator|Vienna Challenge Chamber in season (Phase 3)|"Phase 3 will consist of two treatment periods each lasting 8 days, with a 10 day wash-out between each treatment period.~Subjects will administer 200micrograms (μg) fluticasone propionate or fluticasone propionate matched placebo nasal spray, once daily for 8 days. Dosing will be supervised on the first and last days of each treatment period (Day 1 and Day 8).~Immediately following the last dose received on Day 8 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy."
3304397|NCT00400998|Placebo Comparator|Vienna Challenge Chamber out of season (Phase 1)|"Phase 1 will consist of two treatment periods each lasting 8 days, with a 10 day wash-out between each treatment period.~Subjects will administer 200μg fluticasone propionate or fluticasone propionate matched placebo nasal spray, once daily for 8 days. Dosing will be supervised on the first and last days of each treatment period (Day 1 and Day 8).~Immediately following the last dose received on Day 8 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy.~An intermediate study follow-up visit will take place 7-14 days after the last dose is received in treatment period 2."
3304398|NCT00400998|Placebo Comparator|Park In Season (Phase 2)|"Phase 2 will consist of 2 treatment periods lasting either 8 to 14 days (D) (depending on out-door conditions). There will be a 10D wash-out between this treatment period in Phase 2 and that in Phase 3.~Subjects will administer 200μg fluticasone propionate (or fluticasone propionate matched placebo nasal spray, once daily up to 14D, with dosing supervised on the first and last days of each treatment period (D1 and either D8 or up to D14).~Immediately following the last dose received on either D8 or up to D14 baseline measures will be taken (time = 0). The subject is then taken by bus to the Park and the first measurement will be taken 15 minutes after the subjects leave the bus and enter the Park.~Immediately following the last dose received on D8 or up to D14 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy"
3304399|NCT00400946|Active Comparator|Intramuscular native E coli L-asparaginase (IM-EC)|Patients in this arm were randomized to intramuscular native E coli L-asparaginase 25 000 IU/m2 weekly for 30 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.
3304400|NCT00400946|Experimental|Intravenous PEG-asparaginase (IV-PEG)|Patients in this arm were randomized to intravenous PEG-asparaginase 2500 IU/m2 every 2 weeks for 15 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.
3304401|NCT00400933|Experimental|psycho-education|six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
3304402|NCT00400881|No Intervention|Continuous PAP (CPAP)|CPAP (continuous positive airway pressure). 5 cm H2O.
3304403|NCT00400881|Experimental|Automatic tube compensation (ATC)|ATC is a new mode of ventilation being compared with traditional one (CPAP). ATC is a mode of ventilation of the same device (mechanical ventilator), not a new device. The pressure in this modes varies according the mechanical parameters of the respiratory system that are automatically calculated by this mode. This is the intervention arm.
3304404|NCT00400868|Active Comparator|standard joint protection education|psycho-educational joint protection vs. usual care (standard joint protection education)
3304405|NCT00400855|Experimental|Arm 1|study drug
3304406|NCT00400842|Experimental|L|
3304407|NCT00400842|Experimental|H|
3304409|NCT00400829|Experimental|Arm I|Patients receive 1.4 mg/m2 eribulin mesylate IV over 1-2 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3304410|NCT00400816|Experimental|Temozolomide|Temozolomide, 150 mg/m2/d x days 1-7 and 15-21
3304411|NCT00400803|Experimental|Patients with Stage IIIb/IV Non-Small Cell Lung Cancer|Patients treated with Gemcitabine 2000mg/m^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
3304412|NCT00400764|Experimental|Phase Ib: Dulanermin 4 mg/kg|Participants received 4.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
3304413|NCT00400764|Experimental|Phase Ib: Dulanermin 8 mg/kg|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
3304414|NCT00400764|Active Comparator|Phase II: Rituximab|Participants received rituximab administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
3304415|NCT00400764|Experimental|Phase II: Combination Therapy|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
3304416|NCT00400764|Experimental|Phase II: Dulanermin|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles.
3304417|NCT00400738|Experimental|1|different dose per arm
3304418|NCT00400738|Experimental|2|different dose per arm
3304419|NCT00400738|Experimental|3|different dose per arm
3304420|NCT00400738|Experimental|4|different dose per arm
3304421|NCT00400725|Experimental|1|
3304422|NCT00400725|Placebo Comparator|2|
3304423|NCT00400712|No Intervention|Control|natural progression post-stroke
3304424|NCT00400712|Experimental|Intervention|two weeks of goal directed intensive physical rehabilitation therapy at 6 months (and one year)
3304425|NCT00400699|Other|REview|
3304426|NCT00400686|Experimental|Epoetin Alfa - 80,000 U sc|Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels
3304427|NCT00400673|Other|Chemotherapy|Risk-oriented chemotherapy for remission induction (application of sequential high-dose cytarabine course to patients unresponsive to standard chemotherapy course 1) and postremission consiolidation(standard risk: blood stem cell supported high-dose cytarabine course [x3]; high risk: allogeneic SCT)
3304428|NCT00400660|Experimental|Subjects receiving treatment sequence 1: Part 1|Eligible subjects will receive placebo followed by GSK615915A with a starting dose of 250 micrograms.
3304429|NCT00400660|Experimental|Subjects receiving treatment sequence 2: Part 1|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms followed by placebo.
3304430|NCT00400660|Experimental|Subjects receiving treatment sequence 1: Part 2|Eligible subjects will receive placebo followed by GSK615915A with a starting dose of 250 micrograms.
3304431|NCT00400660|Experimental|Subjects receiving treatment sequence 2: Part 2|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms followed by placebo.
3304432|NCT00400660|Experimental|Subjects receiving GSK615915A: Part 3|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms.
3304433|NCT00400660|Experimental|Subjects receiving placebo: Part 3|Eligible subjects will receive placebo.
3304434|NCT00400647|Experimental|EC MPS|Up to 1440mg taken in two doses
3304435|NCT00400647|Active Comparator|Mycophenolate mofetil|250 mg or 500 mg in two equal doses
3304436|NCT00400634|Experimental|1|Intracerebral administration of CERE-120
3304437|NCT00400634|Sham Comparator|2|Sham Neurosurgery
3304438|NCT00400595|Experimental|1|Polysporin tRIPLE ointment (topical ointment in widespread use for other skin lesions)
3304439|NCT00400595|Active Comparator|2|Mupirocin
3304440|NCT00400569|Experimental|Sunitinib Malate (SU011248) Treatment|Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks
3304441|NCT00400517|Experimental|GM-CSF Injections and Oral Thalidomide|taught to administer an injection of GM-CSF under your skin (subcutaneous injection) and will administer this medicine to yourself every Monday, Wednesday and Friday for 4 weeks at time. Thalidomide will be taken orally (by mouth) every evening at bed time. You will continue these injections 3 times a week and the daily oral medicine for up to 2 months if the therapy appears to be helping your disease.
3304442|NCT00400491|Experimental|1|
3304443|NCT00400491|Placebo Comparator|2|
3304444|NCT00400478|Active Comparator|A|Treatment
3304445|NCT00400478|No Intervention|B|Observation
3304446|NCT00400465|Active Comparator|Control group|Pressure dressing
3304447|NCT00400465|Experimental|Experimental group|Normal dressing
3304448|NCT00400439|Experimental|dalcetrapib (RO4607381)|
3304449|NCT00400439|Placebo Comparator|placebo|
3304450|NCT00400400|Experimental|Enteric-coated mycophenolate sodium|Enteric-coated mycophenolate sodium tablets taken orally twice a day (in the morning and in the evening) at a dose equimolar to the dose of mycophenolate mofetil the participant was taking prior to start of the study + Placebo to mycophenolate mofetil capsules taken orally twice a day for 30 days. Participants remained on their standard immunosuppressive regimen of calcineurin inhibitors (CNI) (Cyclosporin A or Tacrolimus) administered with or without corticosteroids throughout the study.
3304451|NCT00400400|Active Comparator|Mycophenolate mofetil|Mycophenolate mofetil capsules taken orally twice a day (in the morning and in the evening) at the dose the participant was taking prior to study start + Placebo to mycophenolate sodium tablets taken twice a day for 30 days. Participants remained on their standard immunosuppressive regimen of calcineurin inhibitors (CNI) (Cyclosporin A or Tacrolimus) administered with or without corticosteroids throughout the study.
3304456|NCT00400309|Experimental|REPEVAX® after REVAXIS®|REVAXIS® at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28).
3304457|NCT00400309|Active Comparator|REPEVAX® after Placebo|Placebo at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28).
3304458|NCT00400296|Experimental|1|
3304459|NCT00400257||1|People at high risk of heart failure.
3304460|NCT00400231|Active Comparator|1|Metformin
3304461|NCT00400231|Active Comparator|2|Fenofibrate
3304462|NCT00400231|Active Comparator|3|Fenofibrate and Metformin
3304463|NCT00400231|Placebo Comparator|4|
3304464|NCT00400205|Experimental|Recipients of Docetaxel, Cisplatin, 5-Fluorouracil|Participants with squamous cell carcinoma receiving chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil.
3304465|NCT00400179|Active Comparator|A|In Arm A, S-1 25 mg/m² was administered orally BID from Day 1 through Day 21 followed by a recovery period from Days 22 through Day 28. On Day 1, the morning dose of S-1 was administered before cisplatin 75 mg/m2 administration as a 1- to 3-hour IV infusion. This regimen was repeated every 4 weeks. S-1 was administered one hour before or one hour after a meal with a glass of water (approximately 100 mL).
3304466|NCT00400179|Active Comparator|B|In Arm B, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion (CIV) over 120 hours (on Days 1 through 5). This regimen was repeated every 4 weeks. 5-FU CIV followed cisplatin infusion on Day 1. All 5-FU used in this study was commercially available product.
3304467|NCT00400166|Experimental|1|Recovery Mentor: peer-based supportive care
3304468|NCT00400166|No Intervention|0|No Recovery Mentor, services as usual
3304469|NCT00400153|Experimental|COMBIVENT Respimat 20/100 mcg|
3304470|NCT00400153|Experimental|COMBIVENT CFC-MDI 36/206 mcg|
3304471|NCT00400153|Experimental|Ipratropium Respimat 20 mcg|
3304472|NCT00400140|Experimental|A|
3304473|NCT00400127|Experimental|amputee|
3304474|NCT00400114|Experimental|sunitinib|
3304475|NCT00400088|Experimental|lithium group|Start at 600 mg po hs. Dose titrated up to a serum level of between 0.6 and 1.1 mmol/l.
3304476|NCT00400088|Active Comparator|paroxetine group|Start dose at 20 mg po od. If no clinical improvement(<20% reduction in MADRS score) by week 4 dose to be increased to 40 mg po od.
3304477|NCT00400023|Experimental|1|"During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single dose of 50 mg S-1 (2 capsules of 25 mg) on Day 1 followed by a single dose of 800 mg FT (8 capsules of 100 mg) on Day 8~Sequence B: Single dose of 800 mg FT on Day 1 followed by a single dose of 50 mg S-1 on Day 8"
3304478|NCT00400023|Active Comparator|2|"During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single dose of 50 mg S-1 (2 capsules of 25 mg) on Day 1 followed by a single dose of 800 mg FT (8 capsules of 100 mg) on Day 8~Sequence B: Single dose of 800 mg FT on Day 1 followed by a single dose of 50 mg S-1 on Day 8"
3304479|NCT00400010|Experimental|Expert System Intervention|Computerized Expert System Intervention based on the Transtheoretical Model of Change: 1. Normative feedback and feedback on motivational variables during the first week of hospital stay 2. Ipsative feedback on drinking behavior and motivation to change after three months
3304480|NCT00400010|No Intervention|Control group|Controls received a brochure on health behavior
3304481|NCT00399984|Experimental|1|
3304482|NCT00399984|No Intervention|2|
3304483|NCT00399971|Experimental|Hemathera|Patients will receive cell-based immunotherapy.
3304484|NCT00399919|Experimental|PLC|Investigational drug
3304485|NCT00399919|Placebo Comparator|Placebo|
3304486|NCT00399906|Active Comparator|A1|10 mg
3304487|NCT00399906|Active Comparator|A2|30 mg
3304488|NCT00399906|Active Comparator|A3|100 mg
3304489|NCT00399906|Placebo Comparator|P1|10 or 100 mg
3304490|NCT00399893|Experimental|Octreotide|Octreotide to be administered by subcutaneous injection three times daily while on study
3304491|NCT00399893|Placebo Comparator|Placebo|Placebo to be administered by subcutaneous injection three times daily while on study
3304492|NCT00399880|Experimental|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
3304493|NCT00399880|No Intervention|Usual care|
3304494|NCT00399841|Active Comparator|1|Stimulation will occur at the T7 during the trial implant period
3304495|NCT00399841|Active Comparator|2|Stimulation will occur at the T8 level during the trial implant period
3304496|NCT00399802|Active Comparator|Single IV infusion of ZA 4 mg|Participants will receive a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks.
3304497|NCT00399802|Experimental|Odanacatib 5 mg|Participants will receive a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment.
3304498|NCT00399789|Active Comparator|Perifosine 150 mg qd|A daily dose of 150 mg to be given in one dose at bedtime. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 200 mg to be given in one dose at bedtime.
3304499|NCT00399789|Active Comparator|Perifosine 900 mg per week|A weekly dose of 900 mg to be divided into three doses of 300 mg each. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 1,200 mg divided into four doses of 300 mg.
3304500|NCT00399789|Active Comparator|Perifosine 50 mg tid|A daily dose of 150 mg to be divided into three doses of 50 mg each. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 200 mg divided into four doses of 50 mg.
3304501|NCT00399776||Group A|Adolescents taking haloperidol, risperidone, or olanzapine
3304502|NCT00399776||Group B|Healthy adolescents
3304503|NCT00399763|Placebo Comparator|1|placebo plus individual cognitive behavioral therapy
3304504|NCT00399763|Experimental|2|atomoxetine plus individual cognitive behavioral therapy
3304505|NCT00399685|Active Comparator|A|
3304506|NCT00399685|Active Comparator|B|
3304507|NCT00399685|Active Comparator|C|
3304508|NCT00399685|Active Comparator|D|
3304561|NCT00398970|Active Comparator|Traditional flouroscopy guided sampling|
3304562|NCT00398970|Experimental|Ultrasound guide sampling|
3304509|NCT00399672|Active Comparator|1|The 4 participating sites are designated either High Intensity or Low Intensity. High Intensity sites have access to: full time specialist physicians, access to full time nurses and counselors. All weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
3304510|NCT00399672|Active Comparator|2|The 4 participating sites are designated either High Intensity or Low Intensity. In the Low intensity group, all patients will have access to: full time primary care physicians, specialist physicians and access to part time nurse or counselor by appointment. Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
3304511|NCT00399607||Aim 1|Participants previously randomized for the parent study will be eligible for a portion of the adjunct biomarker study.
3304512|NCT00399607||All aims|Participants entering the parent study will be eligible for all sample collections of the adjunct biomarker study.
3304513|NCT00399594|Experimental|A|Targeted LV lead placement
3304514|NCT00399594|Active Comparator|B|Usual LV lead placement
3304515|NCT00399581|Experimental|HFOV-Lo|High Frequency Oscillatory Ventilation using lower mean airway pressures and higher FiO2s.
3304516|NCT00399581|Experimental|HFOV-Hi|High Frequency Oscillatory Ventilation using higher mean airway pressures
3304517|NCT00399568|Experimental|IV acetaminophen 1 g/100 mL solution|
3304518|NCT00399568|Placebo Comparator|IV Placebo 100 mL solution|
3304519|NCT00399555||One|Patients with HLHS that have had surgical palliation with the Norwood procedure (Stage I palliation) at Children's Healthcare of Atlanta after January 1, 2001. These patients must be between the ages of 2.5 years and 6 years of age.
3304520|NCT00399529|Experimental|Allo GM-CSF-secreting vaccine, Trastuzumab, Cyclophosphamide|"Allogeneic GM-CSF-secreting breast cancer vaccine : the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 10^8 cells for each patient and each vaccination cycle) given intradermally every 4-6 weeks for 3 cycles and then a 4th dose given 6-8 months after beginning the study.~Trastuzumab : An initial loading dose of 4 mg/kg for participants beginning treatment with Trastuzumab, otherwise 2 mg/kg given every week intravenously~Cyclophosphamide : 300 mg/m^2 given intravenously every 4-6 weeks for 3 cycles and then once 6-8 months after beginning the study"
3304521|NCT00399490|Experimental|1|
3304522|NCT00399477|Active Comparator|Rasagiline mesylate|
3304523|NCT00399477|Experimental|Rasagiline mesylate plus adjunct therapy|Rasagiline mesylate with one of three adjunct therapies
3304524|NCT00399438|Other|1|0 mg
3304525|NCT00399438|Other|2|25 mg
3304526|NCT00399438|Other|3|100 mg
3304527|NCT00399412||LQTS|Long QT syndrome
3304528|NCT00399412||HF|Heart Failure
3304529|NCT00399412||CRT|Cardiac Resynchronization Therapy
3304530|NCT00399412||Wide QRS|QRS > 120 milliseconds
3304531|NCT00399373||Quality Improvement Initiative|The initial step in the quality improvement initiative was a letter sent from JHHC Care Management Department to the quality improvement initiative group, inviting them to take advantage of the case management services that are part of their current benefits in the Priority Partners MCO. It is similar to the standard letter sent to PPMCO members who are appropriate for a JHHC disease or case management program. A substance abuse outreach staff initiated telephonic contact with the members in the intervention group. The staff member then refered to substance abuse treatment when possible and appropriate and refered to medical case management.
3304532|NCT00399373||Control group|No additional improvement modalities
3304533|NCT00399360|Placebo Comparator|Group 1|No Lifestyle Modification and Placebo
3304534|NCT00399360|Active Comparator|Group 2|Lifestyle Modification and Placebo
3304535|NCT00399360|Active Comparator|Group 3|No Lifestyle Modification and Metformin
3304536|NCT00399360|Active Comparator|Group 4|Lifestyle Modification and Metformin
3304537|NCT00399334||001|
3304538|NCT00399308|Active Comparator|Control|Multi-layer compression bandaging (Profore)
3304539|NCT00399308|Experimental|Celaderm, Bi-Weekly|Celaderm, bi-weekly applications, up to a maximum of four applications
3304540|NCT00399308|Experimental|Celaderm, Weekly|Celaderm, applied weekly, up to a maximum of four applications
3304541|NCT00399165|Active Comparator|1|Oral Testosterone enanthate in sesame oil, 400 mg po (orally), BID (twice daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once
3304542|NCT00399165|Active Comparator|2|Oral Testosterone sesame oil, 800 mg po (orally), qd (in am daily) + placebo sesame oil (in pm daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once
3304543|NCT00399152|Experimental|Perifosine+Sunitinib malate|
3304544|NCT00399087|Experimental|Perifosine D1 + Docetaxel|
3304545|NCT00399087|Experimental|Perifosine D1+ Docexatel+Prednisone|
3304546|NCT00399087|Experimental|Perifosine+ D1,8 and 15+Docetaxel+Prednisone|
3304547|NCT00399074|No Intervention|chloroquine|Weekly CQ
3304548|NCT00399074|No Intervention|Sulfadoxine-pyrimethamine|Monthly SP
3304549|NCT00399061|Active Comparator|1|Systane
3304550|NCT00399061|Active Comparator|2|Optive
3304551|NCT00399061|Placebo Comparator|3|Restasis
3304552|NCT00399035|Placebo Comparator|FOLFOX + placebo Cediranib|FOLFOX + placebo Cediranib
3304553|NCT00399035|Placebo Comparator|Xelox + placebo Cediranib|Xelox + placebo Cediranib
3304554|NCT00399035|Experimental|FOLFOX + Cediranib|FOLFOX + Cediranib
3304555|NCT00399035|Experimental|XELOX + Cediranib|XELOX + Cediranib
3304556|NCT00398996|Active Comparator|1 - Early integrated-therapy group|antiretroviral therapy to be initiated within 4 weeks of starting tuberculosis treatment
3304557|NCT00398996|Active Comparator|2 - Late integrated-therapy group|antiretroviral therapy to be initiated within 4 weeks of completing the intensive phase of tuberculosis treatment
3304558|NCT00398996|Active Comparator|3 - Sequential-therapy group|Antiretroviral therapy to be initiated within 4 weeks after completing tuberculosis treatment
3304559|NCT00398983|Experimental|Decitabine 20 mg/m^2|20 mg/m^2 intravenous (IV) daily for 5 days
3304560|NCT00398983|No Intervention|No Study Drug|Continue current therapy.
3304564|NCT00398918|Placebo Comparator|Placebo|
3304565|NCT00398905|Experimental|Arm 1|
3304566|NCT00398905|Experimental|Arm 2|
3304567|NCT00398905|Experimental|Arm 3|
3304568|NCT00398905|Experimental|Arm 4|
3304569|NCT00398905|Experimental|Arm 5|
3304570|NCT00398905|Active Comparator|Arm 6|
3304571|NCT00398892|Other|1|Crossover - placebo then active
3304572|NCT00398892|Other|2|Crossover - active then placebo
3304573|NCT00398879|Experimental|Arm 1: Perifosine + Capecitabine|Perifosine 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks until progression
3304574|NCT00398879|Placebo Comparator|Arm 2: Perifosine Placebo + Capecitabine|Perifosine Placebo 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks until progression
3304575|NCT00398866|Active Comparator|1|Bupivicaine (local anesthetic)
3304576|NCT00398866|Active Comparator|2|Corticosteroid (trimcinolone (Kenalog) 40 mg)
3304577|NCT00398866|Experimental|3|Synvisc
3304578|NCT00398853|Experimental|Chromium Picolinate|Chromium
3304579|NCT00398853|Other|Placebo|Placebo
3304580|NCT00398827|Experimental|Dexmedetomidine 0.5 mcg/kg load|
3304581|NCT00398827|Experimental|Dexmedetomidine 1 mcg/kg load|
3304582|NCT00398827|Placebo Comparator|Placebo|
3304583|NCT00398814|Experimental|Perifosine + Sorafenib|
3304584|NCT00398749||Epoetin alfa|Epoetin alfa 40 000 IU once weekly variable treatment length
3304585|NCT00398723|Experimental|Vitiligo|adult patients (age 18 or greater) with extensive vitiligo warranting treatment with whole body NB-UVB
3304586|NCT00398710|Experimental|Perifosine|Patients will receive perifosine orally at 150 mg daily after food for 28-d cycles.
3304587|NCT00398684|Experimental|1|One dose maternal NVP treatment at onset of labor, and one dose of infant NVP treatment 48-72 hours after birth (NVP-NVP)
3304588|NCT00398684|Experimental|2|One dose maternal NVP treatment at onset of labor, and one dose of infant placebo 48-72 hours after birth. (NVP-Placebo)
3304589|NCT00398684|Placebo Comparator|3|One dose maternal placebo at onset of labor, and one dose of infant placebo 48-72 hours after birth. This was the reference study arm. (Placebo-Placebo)
3304590|NCT00398645|Experimental|Arm 1|
3304591|NCT00398632|Experimental|Duloxetine|Duloxetine 60 mg, by mouth, once daily or twice daily (as needed to control symptoms of major depression)
3304592|NCT00398567|Experimental|Part 1 - dose level 1 (160 mg)|All subjects receiving HKI-272 dose level 1 in combination with trastuzumab
3304593|NCT00398567|Experimental|Part 1 - dose level 2 (240 mg)|All subjects receiving HKI-272 dose level 2 in combination with trastuzumab
3304594|NCT00398567|Experimental|Part 2 - expanded MTD cohort|All subjects receiving HKI-272 in combination with trastuzumab
3304595|NCT00398554|Experimental|VECOPA|dose and time intensified consoloditation chemotherapy cycle
3304596|NCT00398515|Experimental|Treatment (antiangiogenesis, chemotherapy, enzyme inhibitor)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3304597|NCT00398476|Active Comparator|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
3304598|NCT00398476|Active Comparator|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
3304599|NCT00398463|Experimental|1|Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus tirofiban infusion given at high bolus dose
3304600|NCT00398463|Placebo Comparator|2|Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus placebo
3304601|NCT00398411|Experimental|Moxifloxacin|moxifloxacin 400 mg tablets once daily
3304602|NCT00398411|Placebo Comparator|Placebo|identical appearing placebo
3304603|NCT00398398|Experimental|Capecitbine, oxaliplatin, cetuximab|Capecitbine, oxaliplatin and cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
3304604|NCT00398359|Experimental|1|
3304605|NCT00398333|Experimental|Eicosapentaenoic acid enriched nutritional supplement|
3304606|NCT00398333|No Intervention|No supplementation|
3304607|NCT00398320|Experimental|Bevacizumab (Avastin), Oxaliplatin (Eloxatin)|
3304608|NCT00398281|Experimental|Arm I|Patients receive oral dutasteride once daily on days 1-14.
3304609|NCT00398281|Placebo Comparator|Arm II|Patients receive oral placebo once daily on days 1-14.
3304610|NCT00398229|Active Comparator|A|receiving hCG injection
3304611|NCT00398229|Placebo Comparator|B|
3304612|NCT00398190|Active Comparator|Control|Students receive standard anti-tobacco education
3304613|NCT00398190|Experimental|Media Literacy|Students receive media literacy based anti-smoking education
3304614|NCT00398138|Experimental|vaccine|Six vaccinations of the WT-1 peptide (1.0 ml of emulsion) will be administered on weeks 0, 4, 6, 8, 10 & 12. Vaccinations will be administered subcutaneously with sites rotated among extremities. Injection sites will be pre-stimulated with Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 & -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) if they have been appropriately instructed on SQ injection administration. Patients will keep a logbook noting the time & placement of the injection. Note: during each vaccination, the Sargramostim (GM-CSF) & the vaccine emulsion will be administered to the same anatomical site. This site will be marked by the patient or treating healthcare professional by a permanent marker pen. For patients who have a clinical, molecular, or immunologic response & have not had disease progression, they may receive up to 6 more vaccinations administered approximately every month.
3304615|NCT00398112|Experimental|Arm I|Patients receive oral sunitinib malate daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3304616|NCT00398086|Experimental|100 mg/m^2|Participants received albumin-bound paclitaxel 100 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level one). Treatment continued until progressive disease or unacceptable toxicity.
3304693|NCT00397020|Experimental|1 Divalproex ER|Divalproex ER
3304617|NCT00398086|Experimental|125 mg/m^2|Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level two). Treatment continued until progressive disease or unacceptable toxicity.
3304618|NCT00398086|Experimental|150 mg/m^2|Participants received albumin-bound paclitaxel 150 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level three). Treatment continued until progressive disease or unacceptable toxicity.
3304619|NCT00398073|Experimental|mouse gp100 DNA via PMED|patients will be randomized to mouse gp100 DNA delivered via gold particles using the PowderMed delivery system (ND10, described above). Two actuations/day will be administered every two weeks for 4 months for a total of 16 actuations. Each actuation consists of 2 μg of plasmid DNA coated onto 1000 μg of gold. The total dose of plasmid DNA given will be 32 μg DNA on 16,000 μg gold.
3304620|NCT00398073|Experimental|mouse gp100 DNA injections intramuscularly|patients will be injected with 1000 μg of mouse gp100 plasmid DNA intramuscularly. Two injections/day will be administered every two weeks for 4 months (4000 ug of mouse gp100 plasmid/month) for 16 vaccinations.
3304621|NCT00398060|Experimental|A|
3304622|NCT00398047|Experimental|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine andHematopoietic Growth Factors
3304623|NCT00398008|Experimental|1|DC-HIV plus buprenorphine maintenance.
3304624|NCT00398008|Experimental|2|DC-HIV plus naltrexone maintenance
3304625|NCT00397982|Experimental|Treatment (enzyme inhibitor, monoclonal antibody)|Patients receive temsirolimus IV over 30 minutes on days 1 and 8 and bevacizumab IV over 30-90 minutes on day 8. Treatment repeats every 14 days for a maximum of 26 courses in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection on day 9 of course 2.
3304626|NCT00397943|Experimental|M72/AS01B Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of M72/AS01B vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
3304627|NCT00397943|Experimental|M72/AS02A Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of M72/AS02A vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
3304628|NCT00397943|Active Comparator|Mtb72F/AS02A Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the comparator Mtb72F/AS02A vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
3304629|NCT00397943|Active Comparator|Non-adjuvanted Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the comparator GSK Biologicals' candidate recombinant M. tuberculosis vaccine, non-adjuvanted, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
3304630|NCT00397943|Placebo Comparator|Control Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the adjuvant system alone, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
3304631|NCT00397930|Experimental|Yoga Intervention (YOCAS)|Standardized Yoga for Cancer Survivors (YOCAS)
3304632|NCT00397930|Experimental|Standard Care Control Condition|Standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses.
3304633|NCT00397917|Active Comparator|400 micrograms of folic acid|Blinded study with two arms one of 400ug in arm 1
3304634|NCT00397917|Active Comparator|4mg of folic acid|Second arm is 4mg of folic acid in arm 2
3304635|NCT00397904|Experimental|Cetuximab, Cisplatin, and Irinotecan|Cetuximab will be combined with weekly irinotecan and cisplatin. Patients will receive cetuximab 400 mg/m2 on day 1, week 1. Following this loading dose, patients will receive weekly cetuximab 250 mg/m2 (day 8, 15, 22, etc.) until disease progression or unacceptable toxicity. Patients will continue to receive irinotecan and cisplatin weekly on day 1 and day 8, on an every 21 day cycle. The standard maximum doses are irinotecan 65 mg/m2 and cisplatin 30 mg/m2.
3304636|NCT00397891|Experimental|1|bapineuzumab 0.15 mg/kg or placebo
3304637|NCT00397891|Experimental|2|bapineuzumab 0.5 mg/kg or placebo
3304638|NCT00397891|Experimental|3|bapineuzumab 1.0 mg/kg or placebo
3304639|NCT00397878|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3304640|NCT00397865|Experimental|A|
3304641|NCT00397839|Placebo Comparator|Placebo|
3304642|NCT00397839|Experimental|Ibandronate|
3304643|NCT00397826|Other|MK0733,simvastatin|20 patients with total cholesterol ≧ 240 mg/dL or LDL-C > 160 mg/dL for primary hypercholesterolemia; LDL-C ≧ 130 mg/dL for secondary hypercholesterolemia with identifiable risk factors will be enrolled into study to receive simvastatin 40 mg once daily for 12 weeks.
3304644|NCT00397813|Experimental|Treatment (low dose chemotherapy, TBI followed by PBSCT)|"NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
3304645|NCT00397787|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
3304646|NCT00397774|Active Comparator|Exercise|Physical exercise twice a week for 8 weeks, and best supportive care
3304647|NCT00397774|Other|No exercise|Best supportive care, no exercise
3304694|NCT00397020|Active Comparator|2 Quetiapine Fumarate|quetiapine fumarate
3304695|NCT00396994|Experimental|Low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz
3304696|NCT00396994|Placebo Comparator|2|10 minutes per day standing on sham low mechanical stimulation platform
3304697|NCT00396981|Active Comparator|Matrix 2® Coils|Matrix 2® Coils for endovascular aneurysm occlusion
3304648|NCT00397735|Experimental|N-Acetylcysteine|The subjects enrolled in our research protocol must have evidence of infection/inflammation at amniocentesis in order to receive N-acetylcysteine. Women with positive amniocentesis results The dose of N-acetylcysteine is the one recommended to be used in humans to prevent acetaminophen toxicity: 150 mg/kg loading dose (60 min), followed by 50mg/kg IV continuous infusion rate for 4 hours, and followed by 100 mg/kg IV continuous infusion rate for the following 16 hours. Acetadote (Cumberland Pharmaceuticals) is the only FDA-approved intravenous N-acetylcysteine formulation and will be used in our study.
3304649|NCT00397735|Placebo Comparator|Placebo|The subjects enrolled in our research protocol must have infection/inflammation in order to be randomized to receive N-acetylcysteine or placebo. Placebo-assigned patients will receive sodium chloride solution without N-acetylcysteine
3304650|NCT00397696|Experimental|[123I] 5-IA|To assess [123I] 5IA and SPECT imaging
3304651|NCT00397657|Active Comparator|Extended release niacin|
3304652|NCT00397657|Active Comparator|Ezetimibe|
3304653|NCT00397631|Experimental|1|sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.
3304654|NCT00397631|Active Comparator|2|sitagliptin 100 mg placebo q.d./pioglitazone 30 mg q.d.
3304655|NCT00397605|Experimental|Crossover|
3304656|NCT00397579|Experimental|SL-401|Patients will be treated with a maximum of five doses of approximately 15min IV infusions of DT388IL3/SL-401 over a ten day period at a maximum of once daily.
3304657|NCT00397553|Experimental|Insulin Glulisine|
3304658|NCT00397540|Active Comparator|percutaneous ethanol injection therapy|Patients with hepatocellular carcinoma who will be treated with PEIT (percutaneous ethanol injection therapy)
3304659|NCT00397540|Active Comparator|radiofrequency thermal ablation|Patients with hepatocellular carcinoma who will be treated with RFTA (radiofrequency thermal ablation)
3304660|NCT00397514||Congenital Heart Surgery Patients|Pacing protocol prior to patient's extubation with 20 min. of either conventional right ventricular (RV) or biventricular (BiV) pacing, preceded and followed by 10 min. of recovery time.
3304661|NCT00397501|Active Comparator|HER-2 positive subjects|HER-2 positive subjects treated with trastuzumab
3304662|NCT00397501|Active Comparator|HER-2 negative subjects|HER-2 negative subjects not treated with trastuzumab
3304663|NCT00397488|Experimental|Sunitinib|This is a phase II trial of Sunitinib in patients with metastatic urothelial carcinoma. Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks followed by a two-week rest period for the initial population. A second cohort of patients will be enrolled, who will receive 37.5 mg of sunitinib orally, on a continuous dosing schedule. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Re-staging imaging studies will be performed after every cycle of treatment during the first 4 cycles and subsequently after every other cycle. Patients may continue on study as long as they are tolerating therapy and in the absence of disease progression.
3304664|NCT00397462|No Intervention|Control|No change to usual behavior
3304665|NCT00397462|Experimental|Low dose|Request that calf muscle pump stimulation be used less than four hours per day
3304666|NCT00397462|Experimental|High dose|Request that calf muscle pump stimulation be used at least four hours per day
3304667|NCT00397449|Experimental|1, 2, 3|
3304668|NCT00397436|Experimental|1|Comparing irradiated skin to non irradiated skin.
3304669|NCT00397423|Active Comparator|1|1,G-CSF,intervention
3304670|NCT00397423|Placebo Comparator|2|2,NS,intervention
3304671|NCT00397384|Experimental|Treatment (cetuximab and erlotinib hydrochloride)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and erlotinib hydrochloride PO QD on days 8-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3304672|NCT00397345|Experimental|1|
3304673|NCT00397345|Placebo Comparator|2|
3304674|NCT00397254|Active Comparator|Clinical Limit|"Eligible patients were randomized to one of two treatment regimens in a 1:1 ratio. Those randomized to receive a clinical limit of study medication received Rizatriptan 10mg ODT: 27 tablets per month."
3304675|NCT00397254|Active Comparator|Formulary Limit|"Eligible patients were randomized to one of two treatment regimens in a 1:1 ratio. Those randomized to receive a formulary limit of study medication received Rizatriptan 10mg ODT: 9 tablets per month."
3304676|NCT00397228|Experimental|ALTROPANE®|ALTROPANE® dosing
3304677|NCT00397215|Experimental|GSK1562902A 1 Group|Subjects aged 61 years or older at the time of first vaccination received 1 dose of GSK1562902A adjuvanted vaccine at Day 0. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm.
3304678|NCT00397215|Experimental|GSK1562902A 2 Group|Subjects aged 61 years or older at the time of first vaccination received 1 dose of GSK1562902A non-adjuvanted vaccine at Day 0. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm.
3304679|NCT00397215|Experimental|GSK1562902A 3 Group|Subjects aged 61 years or older at the time of first vaccination received 2 doses of GSK1562902A adjuvanted vaccine at Days 0 and 21. The vaccine was administered in the deltoid region of each arm.
3304680|NCT00397215|Experimental|GSK1562902A 4 Group|Subjects aged 61 years or older at the time of first vaccination received 2 doses of GSK1562902A non-adjuvanted vaccine at Days 0 and 21. The vaccine was administered in the deltoid region of each arm.
3304681|NCT00397202|Active Comparator|The DivaCupTM|
3304682|NCT00397189|Experimental|Circadin|
3304683|NCT00397189|Placebo Comparator|placebo|
3304684|NCT00397163|Active Comparator|Remote preconditioning|Simultaneous inflation (5min) and deflation (5min) of cuffs placed on upper arm and thigh - cycle repeated 2 times
3304685|NCT00397163|Placebo Comparator|Placebo|Deflated cuffs placed on upperarm and thigh for 20 minutes
3304686|NCT00397150|Experimental|Intervention|Peer-support for exclusive breastfeeding
3304687|NCT00397150|No Intervention|No intervention|No intervention
3304688|NCT00397072|Experimental|ZK-EPO|administered iv for 3 h every 21 days; dose reductions to 12 or 9 mg/m2 ZK-EPO were allowed in order to manage any treatment-related toxicity.
3304689|NCT00397046|Experimental|Neratinib|
3304690|NCT00397033|Experimental|002|Paliperidone ER 12mg/day paliperidone er for 6 weeks
3304691|NCT00397033|Experimental|001|Paliperidone ER 6mg/day paliperidone er for 6 weeks
3304692|NCT00397033|Placebo Comparator|003|Placebo Placebo for 6 weeks
3304698|NCT00396981|Active Comparator|GDC® Coils|GDC® Coils for endovascular aneurysm occlusion
3304699|NCT00396877|Placebo Comparator|Placebo|
3304700|NCT00396877|Experimental|Clopidogrel 0.2 mg/kg/day|
3304701|NCT00396864|Experimental|NPI-0052|Advanced Solid Tumor Malignancies and Refractory Lymphoma
3304702|NCT00396825|Experimental|Active treatment|Subjects randomized to this arm will receive the Family Caregiver Kit composed of the Williams LifeSkills Family Caregiver Video and Workbook and will also receive telephone coaching
3304703|NCT00396825|No Intervention|Control|Subjects randomized to this arm will receive no intervention and serve as wait list controls. They will undergo the same evaluations as the Intervention arm subjects at comparable times. In a crossover design, once subjects have finished serving as controls, they will be given the video, workbook, and telephone calls from a social worker and tested one more time.
3304704|NCT00396812|Experimental|Rituximab|
3304705|NCT00396786|Experimental|Arm 1|
3304706|NCT00396786|Experimental|Arm 2|
3304707|NCT00396786|Experimental|Arm 3|
3304708|NCT00396786|Experimental|Arm 4|
3304709|NCT00396786|Experimental|Arm 5|
3304710|NCT00396786|Active Comparator|Arm 6|
3304711|NCT00396747|Active Comparator|A|Methotrexate
3304712|NCT00396747|Active Comparator|B|MTX + MP
3304713|NCT00396747|Active Comparator|C|MTX + IFX
3304714|NCT00396721|Active Comparator|A|
3304715|NCT00396721|Experimental|B|
3304716|NCT00396669|Experimental|Dopamine release|
3304717|NCT00396656|Experimental|Valsartan followed by atenolol + hydrochlorothiazide (HCTZ)|"After a 2-week washout period, patients were treated with valsartan for 20 weeks followed by one week in which it was tapered off. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. The valsartan dose was then tapered off to 80 mg for one week. Patients took valsartan film coated tablets orally once a day (od) in the morning.~After a second 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning."
3304718|NCT00396656|Experimental|Atenolol + hydrochlorothiazide (HCTZ) followed by valsartan|"After a 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks followed by one week in which atenolol was tapered off and HCTZ was discontinued. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning.~After a second 2-week washout period, patients were treated with valsartan for 20 weeks. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. Patients took valsartan film coated tablets orally once a day (od) in the morning."
3304719|NCT00396643|Experimental|A|
3304720|NCT00396643|Placebo Comparator|B|Coconut oil
3304721|NCT00396630|Experimental|Rotarix Group|"All subjects received 2 oral doses of Rotarix vaccine at Day 0 (Visit 1) and Week 7 (Visit 2).~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3)."
3304722|NCT00396630|Placebo Comparator|Placebo Group|"All subjects received 2 oral doses of placebo at Day 0 (Visit 1) and Week 7 (Visit 2).~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3)."
3304723|NCT00396591|Experimental|Aflibercept|Participants with advanced ovarian epithelial cancer (including fallopian tube and primary peritoneal adenocarcinoma) treated with Aflibercept every 2 weeks until a criterion for treatment discontinuation was met
3304724|NCT00396565|Experimental|ER OROS paliperidone|Extended Release (ER) Osmotic Controlled-Release Oral Delivery System (OROS) paliperidone
3304725|NCT00396565|Placebo Comparator|Placebo|
3304726|NCT00396565|Active Comparator|Olanzapine|
3304727|NCT00396552|Experimental|1|
3304728|NCT00396552|Sham Comparator|2|
3304729|NCT00396474||SGA patients|Infants born small for SGA who either received GH, no GH, or growth within normal ranges.
3304730|NCT00396461|Active Comparator|TPN A (Group I)|Emulsion based on 20% MCT/LCT (50:50 ratio)
3304731|NCT00396461|Experimental|TPN B (Group II)|Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides
3304732|NCT00396448|Experimental|CP-945,598 Treatment B|
3304733|NCT00396448|Experimental|CP-945,598 Treatment A|
3304734|NCT00396448|Placebo Comparator|Placebo|
3304735|NCT00396435|Experimental|Group A|High Hb target
3304736|NCT00396435|Active Comparator|Group B|Low Hb Target
3304737|NCT00396409|Experimental|Depigold+Omalizumab|Xolair® (Omalizumab, double-blind core study period only), Depigoid® (grass/rye pollen 50/50)
3304738|NCT00396409|Experimental|Depigoid+Placebo|Depigoid® (grass/rye pollen 50/50) + Placebo
3304739|NCT00396383|Experimental|Participants with Multiple Myeloma (MM)|Participants with MM who were eligible for autologous peripheral blood stem cell transplantation.
3304740|NCT00396370|Experimental|Group G: Connaught strain BCG ID|Primary vaccination: Connaught strain BCG ID; secondary vaccination (1 year later): none.
3304741|NCT00396370|Experimental|Group A: BCG ID/Placebo PO; Placebo ID/Placebo PO|Primary vaccination: BCG ID (Danish)/Placebo PO; secondary vaccination (1 year later): Placebo ID/Placebo PO.
3304742|NCT00396370|Experimental|Group E: BCG ID/BCG PO; Placebo ID/Placebo PO|Primary vaccination: BCG ID (Danish)/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/Placebo PO.
3304743|NCT00396370|Experimental|Group D: Placebo ID/BCG PO; Placebo ID/BCG PO|Primary vaccination: Placebo ID/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/BCG PO (Danish).
3304744|NCT00396370|Experimental|Group F: BCG ID/BCG PO; BCG ID/BCG PO|Primary vaccination: BCG ID (Danish)/BCG PO (Danish); secondary vaccination (1 year later): BCG ID (Danish)/BCG PO (Danish).
3304745|NCT00396370|Experimental|Group B: BCG ID/Placebo PO; BCG ID/Placebo PO|Primary vaccination: BCG ID (Danish)/Placebo PO; secondary vaccination (1 year later): BCG ID (Danish)/Placebo PO.
3304746|NCT00396370|Experimental|Group C: Placebo ID/BCG PO; Placebo ID/Placebo PO|Primary vaccination: Placebo ID/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/Placebo PO.
3304747|NCT00396357|Experimental|vildagliptin + metformin|
3304748|NCT00396357|Active Comparator|Metformin|
3304749|NCT00396344|Placebo Comparator|1|Saline control
3304750|NCT00396344|Experimental|2|
3304751|NCT00396344|Experimental|3|
3304752|NCT00396331|Experimental|G-CSF plus Plerixafor|
3304753|NCT00396318|Experimental|Tenecteplase|
3304754|NCT00396305|Experimental|Group 2, Control Double Dose|12 elderly and 6 young participants. This group will be vaccinated with a double dose of vaccine without booster on Day 0. These subjects will receive a double-dose of vaccine administered as 2 consecutive injections (2 injections of 0.5 mL) in the same deltoid. The control group for Group 2 is group 1, Cohort 2.
3304755|NCT00396305|Experimental|Group 3-Control late booster|12 elderly and 6 young participants. This group will be vaccinated with the standard dose of vaccine (0.5 mL) on Day 0 and with a booster dose of vaccine (0.5 mL) on Day 21. The control for Group 3 is Group 1, Cohort 3.
3304756|NCT00396305|Active Comparator|Group 1, Control|12 elderly and 8 young participants. Group 1 will be further divided into 4 equal cohorts (each containing 3 elderly and 2 young adults). Cohorts 2, 3, and 4 will receive the standard dose of vaccine and placebo (0.5 mL saline) on Day 0, 21, or 7 respectively. Cohort 1 will be vaccinated with the standard dose of vaccine without placebo/vaccine booster.
3304757|NCT00396305|Experimental|Group 4-Control early booster|12 elderly and 6 young participants. This group will be vaccinated with the standard dose of vaccine (0.5 mL) on Day 0 and with a booster dose of vaccine (0.5 mL) on Day 7. The control for Group 4 is Group 1, Cohort 4.
3304758|NCT00396292|Experimental|VIT-45|A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
3304759|NCT00396292|Active Comparator|Oral iron tablets|325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
3304760|NCT00396279|Experimental|Denosumab|Participants received denosumab 120 mg once every 4 weeks (Q4W), with an additional 120 mg doses on Days 8 and 15 of the first month of treatment. All participants were instructed to take daily supplements of at least 500 mg of calcium and 400 IU of vitamin D. Participants were to continue to receive denosumab until one of the following occurred: complete tumor resection, disease progression without clinical benefit, or decision by the participant to discontinue for any reason.
3304761|NCT00396266|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
3304762|NCT00396266|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
3304763|NCT00396253|Experimental|Tenecteplase|At each treatment, subjects had 2 mL (2 mg) of tenecteplase instilled into each lumen of their HD catheter. Subjects could receive up to three treatments with tenecteplase, the first two as part of the initial treatment course and one additional treatment as part of the retreatment (RT) course. The first treatment, followed by a 1-hour dwell time, was given to all subjects at Visit 1. At the end of hemodialysis at Visit 1, eligible subjects had a second treatment instilled for an extended dwell time until the start of Visit 2 (up to 72 hours).
3304764|NCT00396227|Experimental|1|Vildagliptin 100mg + Met
3304765|NCT00396227|Active Comparator|TZD|TZD + metformin
3304766|NCT00396214|Experimental|1|
3304767|NCT00396214|Experimental|2|
3304768|NCT00396214|Active Comparator|3|
3304769|NCT00396201|Experimental|Participants with Hodgkin's Disease (HD)|Participants with Hodgkin's Disease who were eligible for autologous peripheral blood stem cell transplantation.
3304770|NCT00396188||Normals|"Patients seeking initial laser vision correction that were screened to be good candidates for the procedure.~No history of refractive or other ocular surgery.~No corneal pathologies.~Normal corneal topography.~Contact lens wearers should discontinue use at least 2 weeks for hard contacts, and 3 days for soft lenses prior to imaging."
3304771|NCT00396188||Keratoconus|"An irregular cornea determined by distorted keratometry mires, distortion of the retinoscopic, or ophthalmoscopic red reflex (or a combination of these)~At least one of the following biomicroscopic signs: Vogt's striae, Fleischer's ring of >2 mm arc, or corneal scarring consistent with keratoconus.~Contact lens wearers should discontinue use preferably 1 day or at least half an hour prior to imaging."
3304772|NCT00396188||Myopic Laser Vision Correction|"Patients who have undergone myopic:~LASIK~PRK~LASEK"
3304773|NCT00396188||Hyperopic Laser Vision Correction|"Patients who have undergone hyperopic:~LASIK~PRK~LASEK"
3304774|NCT00396188||Orthokeratology|1. Patients using specially designed rigid contact lenses to reshape the cornea to temporarily reduce or eliminate refractive error.
3304775|NCT00396188||Others|1. Corneal conditions (diseases/ pathologies/surgeries) that can potentially affect the corneal surface that are not listed above (e.g. pellucid marginal degeneration; postoperative corneal transplant, intra-corneal ring segments, refractive keratotomy, conductive keratoplasty; peripheral ulcerative keratitis, Terrien's marginal degeneration; etc.).
3304776|NCT00396162|Placebo Comparator|Placebo pill|Placebo pills on same schedule as active intervention.
3304777|NCT00396162|Active Comparator|Probiotic|L. rhamnosus R0011 strain
3304778|NCT00396149|Placebo Comparator|Placebo|Placebo group
3304779|NCT00396149|Experimental|Active group|rBet v 1 tablets
3304780|NCT00396097|Active Comparator|Standard|Standard daily HGH treatment
3304781|NCT00396097|Active Comparator|Formula-based|Formula-based dose regimen
3304782|NCT00396084|Experimental|Linezolid once daily|10 subjects to receive linezolid 600 mg orally once daily for 7days.
3304783|NCT00396084|Experimental|Levofloxacin|10 subjects to receive levofloxacin 1000 mg orally once daily for 7days.
3304784|NCT00396084|Experimental|Moxifloxacin|10 subjects to receive moxifloxacin 400 mg orally once daily for 7 days.
3304845|NCT00395317|Experimental|Arm 5|SB-683699 1200 mg bid, male subjects only (4 x 300 mg tablets)
3304785|NCT00396084|Experimental|Linezolid every 12 hours|10 subjects to receive linezolid 600 mg orally every 12 hours daily for 7 days.
3304786|NCT00396084|Active Comparator|Isoniazid|20 subjects to receive isoniazid 300 mg orally once daily for 7days.
3304787|NCT00396084|Experimental|Gatifloxacin|10 subjects to receive gatifloxacin 400 mg orally once daily for 7 days.
3304788|NCT00396071|Experimental|1|Vildagliptin 100 mg qd
3304789|NCT00396071|Placebo Comparator|2|Matching placebo
3304790|NCT00396032|Experimental|1|
3304791|NCT00396032|Placebo Comparator|2|
3304792|NCT00395993|Experimental|Ferric Carboxymaltose (FCM)|Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
3304793|NCT00395993|Active Comparator|Ferrous Sulfate tablets|325 mg tablets TID on Days 0 through Day 42
3304794|NCT00395967|Experimental|All Patients|Patients who were predicted to be unable to mobilize a minimum number of cells (≥2*10^6 CD34+ cells/kg) in 3 apheresis days when given granulocyte colony-stimulating factor (G-CSF) alone and who were eligible for autologous peripheral blood stem cell transplantation.
3304795|NCT00395889|Experimental|Rehabilitation + Lifestyle Counseling|Multicomponent Pulmonary Rehabilitation Program including structured exercise training
3304796|NCT00395889|Active Comparator|Lifestyle Counseling|
3304797|NCT00395876|Placebo Comparator|Placebo + Tenecteplase + Tenecteplase (PTT)|
3304798|NCT00395876|Experimental|Tenecteplase + Tenecteplase + Placebo (TTP)|
3304799|NCT00395863|Active Comparator|MultiHance|0.5 M MultiHance at a single injection
3304800|NCT00395863|Active Comparator|Magnevist|0.5 M Magnevist at a single injection
3304801|NCT00395850|Placebo Comparator|1|microcrystalline cellulose
3304802|NCT00395850|Experimental|2|disulfiram at 250 mg/day
3304803|NCT00395850|Experimental|3|Disulfiram at 375 mg/day
3304804|NCT00395850|Experimental|4|Disulfiram at 500 mg/day
3304805|NCT00395772|Active Comparator|Arm 4|
3304806|NCT00395772|Experimental|Arm 1|
3304807|NCT00395772|Experimental|Arm 2|
3304808|NCT00395772|Experimental|Arm 3|
3304809|NCT00395746|Experimental|0.6 mg + SU|Liraglutide 0.6 mg + sulphonylurea
3304810|NCT00395746|Experimental|0.9 mg + SU|Liraglutide 0.9 mg + sulphonylurea
3304811|NCT00395746|Placebo Comparator|SU Mono - 1|Liraglutide placebo 0.6 mg + sulphonylurea
3304812|NCT00395746|Placebo Comparator|SU Mono - 2|Liraglutide placebo 0.9 mg + sulphonylurea
3304813|NCT00395733|Experimental|Gadobutrol, then Gadopentate dimeglumine|Period 1: Participant received Gadobutrol 1.0 M (iv: intravenous injection), at a dose of 0.2 mL/kg BW, up to 0.3 mL/kg BW if 3 Fields of View (FOVs) to be imaged; Period 2: Participant received Gadopentate 0.5 M (iv), at a dose of 0.4 mL/kg BW, up to 0.6 mL/kg BW if 3 FOVs to be imaged
3304814|NCT00395733|Experimental|Gadopentate, dimeglumine then Gadobutrol|Period 1: Participant received Gadopentate 0.5 M (iv), at a dose of 0.4 mL/kg BW, up to 0.6 mL/kg BW if 3 FOVs to be imaged; Period 2: Participant received Gadobutrol 1.0 M (iv: intravenous injection), at a dose of 0.2 mL/kg BW, up to 0.3 mL/kg BW if 3 Fields of View (FOVs) to be imaged
3304815|NCT00395720|Active Comparator|1|Group 1 (10 volunteers): 5 x 10^7 pfu
3304816|NCT00395720|Active Comparator|2|Group 2 (10 volunteers): 1 x 10^8 pfu
3304817|NCT00395707|Active Comparator|1|Lucentis 0.3mg/0.05 ml
3304818|NCT00395707|Active Comparator|2|Lucentis 0.5mg/0.05 ml
3304819|NCT00395694|Experimental|lamictal|
3304820|NCT00395681|Active Comparator|propofol|propofol 200 mg versus 350 mg
3304821|NCT00395681|Active Comparator|Propofol|Propofol 350 mg versus 200 mg
3304822|NCT00395642|Experimental|HM with weight and BP remote monitoring|Device based Home Monitoring and weight and blood pressure remote monitoring
3304823|NCT00395629|Experimental|ICL670 (Deferasirox)|Three dose cohorts: 5 mg/kg/day, 10 mg/kg/day, 15 mg/kg/day
3304824|NCT00395551|Active Comparator|ranibizumab|ranibizumab 0.5mg intravitreal injection
3304825|NCT00395538|Other|Biopsy|Subjects are randomized to have the second bone biopsy done 1,2, or 4 years after the start of PTH.
3304826|NCT00395512|Experimental|Alogliptin 25 mg QD|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
3304827|NCT00395512|Active Comparator|Pioglitazone 30 mg QD|Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
3304828|NCT00395512|Experimental|Alogliptin 25 mg QD+ Pioglitazone 30 mg QD|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
3304829|NCT00395512|Active Comparator|Alogliptin 12.5 mg QD + Pioglitazone 30 mg QD|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
3304830|NCT00395486|Experimental|Rosuvastatin|
3304831|NCT00395486|Active Comparator|Atorvastatin|
3304832|NCT00395460|Experimental|Gadobutrol 0.1 mmol/kg Body Weight (BW) (Gadavist, BAY86-4875)|Participant received 0.1 mmol/kg BW Gadobutrol (= 0.1 mL/kg BW by intravenous injection at a rate of 1.0 mL/sec)
3304833|NCT00395460|Active Comparator|GD 0.1 mmol/kg BW (Magnevist, BAY86-4882)|Participant received 0.1 mmol/kg BW Gadopentetate Dimeglumine (GD) (= 0.2 mL/kg BW by intravenous injection at a rate of 2.0 mL/sec
3304834|NCT00395447||Straight-forward Device Replacement|Subject with a straight-forward device replacement without lead revisions or additions.
3304835|NCT00395447||Device Replacement with Upgrade|Subjects with a device replacement and planned lead upgrade, revision, or addition.
3304836|NCT00395421|Experimental|A|NM283(200 mg QD)plus Peg-IFNα-2a (180 µg QW)
3304837|NCT00395382|Active Comparator|1|Alendronate
3304838|NCT00395382|Placebo Comparator|2|Placebo
3304839|NCT00395343|Experimental|1|sitagliptin
3304840|NCT00395343|Placebo Comparator|2|Placebo
3304841|NCT00395317|Placebo Comparator|Arm 1|placebo (4 tablets)
3304842|NCT00395317|Experimental|Arm 2|SB-683699 150 mg bid (1 x 150mg + 3 placebo tablets)
3304843|NCT00395317|Experimental|Arm 3|SB-683699 600 mg bid (2 x 300mg + 2 placebo tablets)
3304844|NCT00395317|Experimental|Arm 4|SB-683699 900 mg bid (3 x 300 mg + 1 placebo tablet)
3304846|NCT00395304|Experimental|Sequence #1|fluticasone propionate + montelukast, followed by fluticasone propionate, followed by fluticasone propionate + salmeterol
3304847|NCT00395304|Experimental|Sequence #2|fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol, followed by followed by fluticasone propionate
3304848|NCT00395304|Experimental|Sequence #3|fluticasone propionate + salmeterol, followed by fluticasone propionate, followed by fluticasone propionate + montelukast
3304849|NCT00395304|Experimental|Sequence #4|fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast, followed by fluticasone propionate
3304850|NCT00395304|Experimental|Sequence #5|fluticasone propionate, followed by fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast
3304851|NCT00395304|Experimental|Sequence #6|fluticasone propionate, followed by fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol
3304852|NCT00395291|Experimental|MK-0677 then Placebo|MK-0677 and Placebo - All subjects were given MK-0677 for a 30 +/- 7 days and then they were given a placebo for 30 +/- 7 days.
3304853|NCT00395291|Experimental|Placebo then MK-0677|MK-0677 and Placebo - All subjects were given Placebo for a 30 +/- 7 days and then they were given MK-0677 for 30 +/- 7 days.
3304854|NCT00395252|Experimental|one arm study|Cetuximab (Erbitux®) and Gemcitabine treatment over 6 months
3304855|NCT00395239|Experimental|1|
3304856|NCT00395226|Experimental|Zinc sulfate|220 mg of zinc sulfate
3304857|NCT00395226|Placebo Comparator|Lactose|270 mg lactose
3304858|NCT00395213||1|Children and adolescents with a pre-specified anxiety disorder, depressive disorder, eating disorder, or obsessive-compulsive disorder
3304859|NCT00395200|Experimental|MSC Treatment|
3304860|NCT00395174|Experimental|FluBlok|"Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2005-2006 formulation containing 45μg of each hemagglutinin derived from A/New Caledonia (H1N1), A/Wisconsin (H3N2) and B/Ohio~135μg total"
3304861|NCT00395174|Active Comparator|TIV (Fluzone)|"Licensed trivalent influenza vaccine (TIV): 2005-2006 formulation containing 15μg of each hemagglutinin derived from A/Wisconsin (H3N2), A/New Caledonia (H1N1) and B/Malaysia~45μg total~(Fluzone, sanofi pasteur)"
3304862|NCT00395161|Experimental|zinc selenium glutamine metoclopramide|metoclopramide, zinc, selenium, and glutamine
3304863|NCT00395161|Placebo Comparator|enteral whey protein and IV saline|saline, sterile water, whey protein
3304864|NCT00395135|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
3304865|NCT00395135|Placebo Comparator|Matching Placebo BID|Matching placebo tablet each morning and evening
3304866|NCT00395083|No Intervention|Group 1|Patients allocated to the control arm will receive standardized care that incorporates guide-line based recommendations including influenza vaccination, a short-acting bronchodilator, and either a long-acting bronchodilator or inhaled corticosteroid inhaler.
3304867|NCT00395083|Experimental|Group 2|The comprehensive group will receive an initial, intense education program with development of an action plan, and regular telephone contacts by a case manager in addition to standardized COPD care.
3304868|NCT00395070|Experimental|Treatment Arm|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
3304869|NCT00395070|Active Comparator|Control Arm|DTIC 1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR TMZ 150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
3304870|NCT00395057|Experimental|AGN 211745 Solution 1000 ug|AGN 211745 Solution 1000 ug
3304871|NCT00395057|Experimental|AGN 211745 Solution 300 ug|AGN 211745 Solution 300 ug
3304872|NCT00395057|Experimental|AGN 211745 Solution 100 ug|AGN 211745 Solution 100 ug
3304873|NCT00395057|Active Comparator|Ranibizumab 500 ug|Ranibizumab 500 ug
3304874|NCT00395044|Experimental|Gabapentin|1200 mg/daily of Gabapentin
3304875|NCT00395044|Placebo Comparator|Placebo|1200mg/d of Placebo
3304876|NCT00395031|Other|Ziprasidone|Open label
3304877|NCT00395018|Experimental|entecavir|
3304878|NCT00394992|Active Comparator|1 oxaliplatin+capecitabine|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
3304879|NCT00394992|Experimental|2 oxaliplatin+capecitabine+bevacizumab|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
3304880|NCT00394966|Experimental|SCH 619734 Dose 1|
3304881|NCT00394966|Experimental|SCH 619734 Dose 2|
3304882|NCT00394966|Experimental|SCH 619734 Dose 3|
3304883|NCT00394966|Experimental|SCH 619734 Dose 4|
3304884|NCT00394966|Placebo Comparator|Placebo|
3304885|NCT00394953|Experimental|MIRCERA|Eligible participants with anemia in CKD who were on hemodialysis will receive methoxy polyethylene glycol-epoetin beta (MIRCERA [RO0503821]) IV once every month up to 52 weeks. The starting dose of MIRCERA which will be administered during the treatment period will depend on the dose of darbepoetin alfa administered during screening period i.e., 120, 200 and 360 mcg for weekly darbepoetin alfa doses of <40, 40-80, and >80 mcg, respectively.
3304886|NCT00394953|Active Comparator|Darbepoetin Alfa|Eligible participants with anemia in CKD who were on hemodialysis will receive darbepoetin alfa (Aranesp) IV once every two weeks up to 26 weeks and darbepoetin alfa IV twice the dose than earlier, once every month from Week 27 up to Week 52.
3304887|NCT00394914|Experimental|Pleconaril|Participants will receive Pleconaril nasal spray 4 sprays per nostril twice daily (BID), 24 mg/day for 1 week during the Treatment Period for a total of 14 doses.
3304888|NCT00394914|Placebo Comparator|Placebo|Participants will receive placebo nasal spray 4 sprays per nostril BID for 1 week during the Treatment Period for a total of 14 doses.
3304889|NCT00394901|Placebo Comparator|Placebo|
3304890|NCT00394901|Experimental|Pregabalin 150mg/day|
3304891|NCT00394901|Experimental|Pregabalin 300mg/day|
3304892|NCT00394901|Experimental|Pregabalin 600mg/day|
3304893|NCT00394888|Other|Facial Hemangioma|Patients with large facial hemangioma.
3304894|NCT00394888|Other|Lumbosacral Hemangioma|Patients with lumbosacral hemangioma.
3304895|NCT00394888|Other|Multiple Hemangiomas|patients with multiple hemangiomas (>5)
3305170|NCT00391872|Experimental|Ticagrelor|Oral treatment
3304896|NCT00394849|Experimental|suture one tonsillar fossa|Intervention: one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
3304897|NCT00394849|No Intervention|One side not sutured|Intervention: one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
3304898|NCT00394810|Experimental|1|
3304899|NCT00394771|Experimental|Low Dose DR-1031|42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
3304900|NCT00394771|Experimental|Midrange Dose DR-1031|21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
3304901|NCT00394771|Experimental|High Dose DR-1031|21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
3304902|NCT00394771|Active Comparator|Seasonale|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.
3304903|NCT00394706|Experimental|1|Use of Impedance Threshold Device (ITD)
3304904|NCT00394706|Sham Comparator|2|Sham ITD
3304905|NCT00394706|Other|3|Analyze early. Upon EMS (emergency medical services) arrival at the scene of a non-traumatic cardiac arrest, the EMS providers assess the cardiac rhythm as soon as possible. Approximately thirty seconds of CPR (cardiopulmonary resuscitation) may be done prior to an assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
3304906|NCT00394706|Other|4|Analyze late. Upon the EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is done prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
3304907|NCT00394654|Experimental|MEDI528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
3304908|NCT00394654|Placebo Comparator|PLACEBO|Placebo administered as a single intravenous infusion
3304909|NCT00394602||Patients|Patients receiving chemoradiation for abdominal-pelvic tumors.
3304910|NCT00394602||Caregiver Controls|Healthy controls with no prior cancer diagnosis.
3304911|NCT00394589|Experimental|Increased Frequency|Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks
3304912|NCT00394589|Experimental|Increased Dose|3 mg/kg infliximab + 1 extra vial (100 mg) infliximab, every 8 weeks
3304913|NCT00394589|Active Comparator|Control|Continuation of infliximab 3 mg/kg every 8 weeks
3304914|NCT00394576|Experimental|1|usual care plus Internet-based nutrition module
3304915|NCT00394576|Active Comparator|2|usual care
3304916|NCT00394563|Experimental|1|monoclonal antibody
3304917|NCT00394563|Experimental|2|
3304918|NCT00394563|Experimental|3|
3304919|NCT00394563|Experimental|4|
3304920|NCT00394563|Experimental|5|
3304921|NCT00394563|Placebo Comparator|placebo|
3304922|NCT00394550|No Intervention|control|If laryngomalacia is found, then in the control group, no supraglottoplasty will be performed. Only the tonsils and adenoids will be removed.
3304923|NCT00394550|Experimental|Treatment|"If laryngomalacia is found, then in the Treatment group, a supraglottoplasty with laser will be performed, as well as removal of the tonsils and adenoids.~Intervention: supraglottoplasty with laser"
3304924|NCT00394524|Experimental|1|Glucommander computer assisted insulin infusion
3304925|NCT00394524|Active Comparator|2|Glulisine insulin infusion
3304926|NCT00394511|Experimental|Arm I|Radiotherapy. Irradiation of the prostatic bed using megavoltage equipment with effective photon energies of greater than 4 MV.
3304927|NCT00394511|No Intervention|Arm II|No further treatment.
3304928|NCT00394459|Active Comparator|A|Perifix Standard
3304929|NCT00394459|Experimental|B|Perifix New
3304930|NCT00394433|Experimental|Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA)|Patients received bevacizumab 10 mg/kg IV on day 1 every 3 weeks while on study. Additionally, they received docetaxel 30 mg/m2 IV over 30 minutes, followed by cisplatin 25 mg/m2 IV over 30 minutes, followed by irinotecan 50 mg/m2 IV over 30 minutes on days 1 and 8 of each 3-week cycle until disease progression or unacceptable toxicity. Dose reductions were not permitted for bevacizumab although treatment could be held up to 2 months. If bevacizumab was discontinued, treatment with other agents could continue. When docetaxel, cisplatin, or irinotecan was held on day 1 of a cycle, all agents were held.
3304931|NCT00394407|Active Comparator|sliding scale regular insulin|sliding scale insulin given acqhs
3304932|NCT00394407|Active Comparator|glargine insulin and glulisine insulin|glargine basal insulin once a day with prandial glulisine insulin tid
3304933|NCT00394381|Experimental|CIK infusion|Infusion of autologous CIK cells in study group. There is only one arm to this study
3304934|NCT00394355|Experimental|Group 1|MF DPI 400 mcg once a day (QD) in the evening (PM)
3304935|NCT00394355|Experimental|Group 2|MF DPI 200 mcg QD PM
3304936|NCT00394355|Active Comparator|Group 3|Fluticasone propionate (FP) metered dose inhaler (MDI) 250 mcg twice a day (BID)
3304937|NCT00394355|Active Comparator|Group 4|ML 10 mg QD PM
3304938|NCT00394329|Experimental|Daily ICS + Rescue ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) one puff bid + beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed + albuterol sulfate HFA (ProAir®™ 90 mcg Inhalation Aerosol) rescue puffs as needed
3304939|NCT00394329|Active Comparator|Daily ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) one puff bid + albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
3304940|NCT00394329|Experimental|Rescue ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed + albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
3304941|NCT00394329|Placebo Comparator|Placebo|Albuterol sulfate administered via a hydrofluoroalkane (HFA) inhaler (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
3304942|NCT00394303|Experimental|1|Intervention
3304943|NCT00394303|No Intervention|2|Control
3304944|NCT00394290|Experimental|PPC|Night time device for positive pulmonary pressure
3304945|NCT00394277|Experimental|PEG-IFN 180 µg + Ribavirin 1200 mg|
3304946|NCT00394277|Experimental|PEG-IFN 180 µg + Ribavirin 1400/1600 mg|
3304947|NCT00394277|Experimental|PEG-IFN 360/180 µg + Ribavirin 1200 mg|
3304948|NCT00394277|Experimental|PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg|
3304949|NCT00394251|Experimental|AC --> ABI-007|Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 260 mg/m^2 ABI-007 (Abraxane) plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
3304950|NCT00394251|Experimental|AC --> Taxol|Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 175 mg/m^2 Taxol plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
3304951|NCT00394212|Experimental|1|Transoral suturing of the dilated gastrojejunostomy
3304952|NCT00394212|Sham Comparator|2|Sham Endoscopy (suturing not performed)
3304953|NCT00394199|Experimental|1|FlutiForm 100/10ug
3304954|NCT00394199|Experimental|2|Fluticasone 100
3304955|NCT00394199|Active Comparator|3|Formoterol 10
3304956|NCT00394173|Experimental|1|
3304957|NCT00394173|Placebo Comparator|2|
3304958|NCT00394134|Other|Interview|Interviews to describe the sun exposure and sun protection practices of patients and their children.
3304959|NCT00394095|Experimental|Topiramate Group|Patients' initial dose of topiramate 25mg bid, which was titrated over 18 days to 150 mg bid (with flexibility to titrate to 200mg bid) as tolerated.
3304960|NCT00394095|Placebo Comparator|Placebo Group|Sugar pill
3304961|NCT00394082|Experimental|ABI-007 plus Bevacizumab|ABI-007 is administered on days 1, 8 and 15 at 125 mg/m^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If a patient develops intolerable toxicity to only one of the drugs, the other drug may be continued as single agent therapy in the absence of progression, as long as the treating physician feels this is in the best interests of the patient.
3304962|NCT00394069|Experimental|Montelukast sodium|Participants receive montelukast sodium for 14 days.
3304963|NCT00394056|Other|Period 1|
3304964|NCT00394056|Other|Period 2|
3304965|NCT00394056|Other|Period 3|
3304966|NCT00394043|Experimental|Osteopathic Manipulative Treatment|A protocol of specific osteopathic manipulative techniques was applied.
3304967|NCT00394043|Placebo Comparator|Placebo ultrasound|Sub-therapeutic ultrasound was applied.
3304968|NCT00394043|No Intervention|Standard Medical care|Subjects did not receive either study treatment, but continued to receive standard medical care.
3304969|NCT00394030|Experimental|Group A|In Group A healthy subjects will be randomized to receive 16 milligram (mg) of GSK716155 to abdomen.
3304970|NCT00394030|Experimental|Group B|In Group B healthy subjects will be randomized to receive 64 mg of GSK716155 to abdomen.
3304971|NCT00394030|Experimental|Group C|In Group C Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to abdomen.
3304972|NCT00394030|Experimental|Group D|In Group D Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to arm.
3304973|NCT00394030|Experimental|Group E|In Group E Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to leg.
3304974|NCT00394030|Experimental|Group F|In Group F Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to abdomen.
3304975|NCT00394030|Experimental|Group G|In Group G Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to arm.
3304976|NCT00394030|Experimental|Group H|In Group H Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to leg.
3304977|NCT00394017|Active Comparator|Intervention group|Reminder letters and usual implementations vs. usual implementation
3304978|NCT00394017|No Intervention|Control group|usual implementations
3304979|NCT00393991|Experimental|1|FlutiForm 100/10 μg
3304980|NCT00393991|Active Comparator|2|Fluticasone 100 μg
3304981|NCT00393991|Active Comparator|3|Formoterol 10 μg
3304982|NCT00393991|Placebo Comparator|4|Placebo
3304983|NCT00393978|Placebo Comparator|Quetiapine and Placebo|Quetiapine and Placebo
3304984|NCT00393978|Active Comparator|Quetiapine and Topiramate|Quetiapine and Topiramate
3304985|NCT00393952|Experimental|1|FlutiForm 250/10
3304986|NCT00393952|Active Comparator|2|FlutiForm 100/10
3304987|NCT00393952|Active Comparator|3|Fluticasone 250
3304988|NCT00393952|Active Comparator|4|Formoterol 10
3304989|NCT00393952|Placebo Comparator|5|Placebo
3304990|NCT00393939|Experimental|A|
3304991|NCT00393939|Active Comparator|B|
3304992|NCT00393913||Continuous Positive Airway Pressure (CPAP)|Participants will use a CPAP machine if they are found to have sleep apnea.
3304993|NCT00393900||1|Children with tympanostomy tubes for chronic OME
3304994|NCT00393887|Experimental|1|Biodesign IHM Graft placement
3304995|NCT00393887|Active Comparator|2|Polypropylene mesh placement
3304996|NCT00393874|Active Comparator|Medication|Treatment will be conducted under double blind conditions and will last a total of 8 weeks. Participants will also receive printed educational material about sleep hygiene developed by the American Academy of Sleep Medicine. Items include going to bed when drowsy, avoiding clock watching while awake in bed, avoidance of caffeine and alcohol, engaging in moderate exercise, and ensuring comfortable sleep environment. Clinical ratings will be obtained weekly throughout the trial.Medications will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose. The research pharmacy will prepare each dose in identical gelatin capsules to prevent identification.
3304997|NCT00393874|Active Comparator|Behavioral|"Participants randomized to BSI will receive the intervention aimed at reducing nightmares, insomnia, and sleep avoidance behavior. The treatment will be administered over 8 weeks. The intervention sessions will consist of two individual, 45-minute treatment sessions, delivered on Weeks 1 and 3. A 45-minute booster session will be conducted on Week 5. Thirty-minute face-to-face contacts will be scheduled on other weeks (i.e., Weeks 2, 4, 6, 7 and 8) to address any difficulty with the treatment instructions and techniques, to answer questions that may have occurred, and to complete weekly clinical ratings (CGI-I/SR and ASES)."
3304998|NCT00393874|Placebo Comparator|Placebo|Participants randomized to PLA will take 4 capsules each night, and capsule will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed. A placebo pill condition is included for several reasons. First, there is no approved treatment approach currently recognized as being effective for sleep disturbances associated with combat-related PTSD, and which is being withheld from subjects assigned to the placebo arm of the study. We will monitor subjects carefully and on a weekly basis.
3304999|NCT00393861|Experimental|oxaliplatin & bevacizumab|
3305000|NCT00393848|Experimental|Experiment 2 - Experimental Group|
3305001|NCT00393848|No Intervention|Experiment 1 - Standard of care Group|
3305002|NCT00393848|Experimental|Experiment 1 - Experimental Group|
3305003|NCT00393848|Placebo Comparator|Experiment 2 - Placebo Group|
3305004|NCT00393822|Experimental|Palifermin|50 subjects to receive palifermin 3 days prior to the first day (day 1) of each cycle of 5-FU/ LV chemotherapy.
3305005|NCT00393822|Placebo Comparator|Control Group|50 subjects to receive matched placebo 3 days prior to the first day (day 1) of each cycle of 5-FU/ LV chemotherapy.
3305006|NCT00393796|Active Comparator|SUTENT|Study participants randomized to received SUTENT will receive a dose of 50 mg PO (capsules) as a single agent to be taken once daily for four consecutive weeks followed by a two week rest period to form a complete cycle of six weeks.
3305007|NCT00393796|Placebo Comparator|Placebo|Study participants randomized to receive placebo will receive 50 mg/day PO (capsules) of an inactive substance to be taken once daily for four consecutive weeks followed by a two week rest period to form a complete cycle of six weeks.
3305008|NCT00393783|Experimental|1|HER2 ECD DNA.
3305009|NCT00393770|Experimental|L-acetylcarnitine|
3305010|NCT00393744|Experimental|1|
3305011|NCT00393744|Active Comparator|2|
3305012|NCT00393718|Experimental|Liraglutide|Liraglutide 0.9 mg + glibenclamide placebo
3305013|NCT00393718|Active Comparator|Glibenclamide|Glibenclamide 1.25-2.5 mg + liraglutide placebo
3305014|NCT00393705|Experimental|insulin lispro LM + insulin lispro MM|Three times per day subcutaneous injection of insulin lispro mid mixture (MM) with the possibility to change the evening injection of MM to insulin lispro low mixture (LM) if fasting blood glucose target is not achieved.
3305015|NCT00393705|Active Comparator|Insulin Biphasic Aspart 30/70 or Insulin Lispro LM|Twice daily subcutaneous injection of either insulin biphasic aspart 30/70 or insulin lispro low mixture (LM) (continuation of analogue formulation used before study enrollment).
3305016|NCT00393679|Experimental|1|AS-AQ
3305017|NCT00393679|Experimental|2|"DHAPQ~TO BE NOTED: since the batches of the study drug DHAPQ expire at the end of October 2008, and because of the unavailability of a new batch of DHAPQ from the manufacturer, the recruitment in the DHAPQ arm had to be discontinued on 30th October 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities."
3305018|NCT00393679|Experimental|3|AL
3305019|NCT00393679|Experimental|4|"Lapdap + AS~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008."
3305020|NCT00393640|Active Comparator|A|Breast pump given and used on regular intervals
3305021|NCT00393640|No Intervention|B|
3305022|NCT00393640|Active Comparator|c|Breast pump given to be used on regular interval
3305023|NCT00393640|No Intervention|D|
3305024|NCT00393627|Experimental|1|Sleep Education Program: The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
3305025|NCT00393627|Placebo Comparator|2|Routine medical care
3305026|NCT00393575|Experimental|Community Mobilization|The intervention population is defined as the community each site is attempting to mobilize.
3305027|NCT00393523|Active Comparator|5 µg Modified Process Hepatitis B Vaccine Booster (Group 1)|"Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine (Booster Dose)."
3305028|NCT00393523|Active Comparator|10 µg ENGERIX-B™ Booster (Group 2)|"Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a dose of 10µg/per 0.5 ml ENGERIX-B™ (Booster Dose)"
3305029|NCT00393523|Active Comparator|5 µg Modified Process Hepatitis B Vaccine Booster (Group 3)|"Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine, (Booster Dose)."
3305030|NCT00393523|Active Comparator|10 µg ENGERIX-B™ Booster (Group 4)|"Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 10µg/0.5 ml dose of ENGERIX-B™ (Booster Dose)."
3305031|NCT00393523|Experimental|5 µg Modified Process Hepatitis B Vaccine (Group 5)|"Participants did not receive a prior vaccination with a hepatitis B vaccine.~During the study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine."
3305032|NCT00393510|Active Comparator|Traditional Chinese Medicine|12 herbals formulation was given as an adjuvant therapy for the patients orally twice a day.
3305033|NCT00393510|Placebo Comparator|Placebo|Placebo was made with starch and colouring materials. Given to patient orally twice a day
3305034|NCT00393484|Experimental|Arm A|"Entecavir + Lamivudine placebo (0-96 weeks)~Entecavir (96-240 weeks)"
3305035|NCT00393484|Active Comparator|Arm B|"Lamivudine + Entecavir placebo (0-96 weeks)~Lamivudine (96-240 weeks)"
3305036|NCT00393458|Experimental|Indacaterol 300 μg plus placebo to formoterol|Patients inhaled indacaterol 300 μg once daily via a single-dose dry-powder inhaler (SDDPI), placebo to indacaterol once daily via a SDDPI, and placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Indacaterol, placebo to indacaterol, and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3305037|NCT00393458|Experimental|Indacaterol 600 μg plus placebo to formoterol|Patients inhaled indacaterol 600 μg (two 300 μg capsules) once daily via single-dose dry-powder inhalers (SDDPI) plus placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3305038|NCT00393458|Active Comparator|Formoterol 12 μg plus placebo to indacaterol|Patients inhaled formoterol 12 μg twice daily via the manufacturer's proprietary inhalation device (Aerolizer®) plus placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI). Formoterol and placebo to indacaterol were taken in the morning between 8:00 and 10:00 AM; formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3305039|NCT00393458|Placebo Comparator|Placebo to indacaterol plus placebo to formoterol|Patients inhaled placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI) plus placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Placebo to indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3305040|NCT00393445|Experimental|Intravenous infusion|intravenous infusion of test substances
3305041|NCT00393380|Experimental|Parathyroid Hormone (teriparatide)|Parathyroid hormone after double umbilical cord blood transplant.
3305042|NCT00393367|Placebo Comparator|Saline Placebo|All subjects will receive 3 albuterol sulfate doses, 2 ipratropium bromide doses, and systemic corticosteroids. All patients will receive both the systemic corticosteroids and one dose of a mixture of albuterol and ipratropium bromide while guardians are approached for consent. Patients randomized to this placebo comparator arm will then receive 2 nebulized albuterol doses mixed with 8mL of normal saline. Finally, all patients will receive the second nebulized ipratropium dose.
3305043|NCT00393367|Experimental|Budesonide Inhalaiton Suspension|All subjects will receive 3 albuterol sulfate doses, 2 ipratropium bromide doses, and systemic corticosteroids. All patients will receive both the systemic corticosteroids and one dose of a mixture of albuterol and ipratropium bromide while guardians are approached for consent. Patients randomized to this intervention arm will then receive 2 nebulized albuterol doses mixed with 8mL of budesonide inhalation suspension (BIS). Finally, all patients will receive the second nebulized ipratropium dose.
3305044|NCT00393341||Case|Women with breast cancer
3305045|NCT00393341||Control|Women without breast cancer
3305046|NCT00393328|Active Comparator|A|
3305047|NCT00393328|Active Comparator|B|
3305048|NCT00393302||1 & 2|"Retrospective chart review: HIV testing rates~Prospective cohort group: HIV testing rates"
3305049|NCT00393276|Experimental|A|HCV-infected defined as a positive result using polymerase chain reaction (PCR) without previous HCV-based therapy and without the presence of Child's B or C cirrhosis. These participants will be HIV-uninfected.
3305050|NCT00393276|Experimental|B|HIV-infected and ARV naive, with a CD4 cell count of 300 cells/mm3 or greater, with no prior or current opportunistic infection, and with no indication for HIV therapy. These participants will be HCV-uninfected.
3305051|NCT00393276|Experimental|C|HCV/HIV-coinfected as defined above in Arms A and B.
3305052|NCT00393263|Experimental|1|pimecrolimus
3305053|NCT00393263|Active Comparator|2|clobetasol
3305054|NCT00393198|Experimental|Arm 1|
3305055|NCT00393198|Placebo Comparator|Arm 2|
3305056|NCT00393198|Active Comparator|Arm 3|
3305057|NCT00393172|Experimental|exercise|5 days per week exercise for 4 months
3305058|NCT00393172|No Intervention|no exercise|
3305059|NCT00393120|Experimental|Treatment A - INCB009471 100mg IR|INCB009471, 100 mg IR orally once daily
3305060|NCT00393120|Experimental|Treatment B - INCB009471 300mg SR|INCB009471, 300 mg SR orally once daily
3305061|NCT00393120|Placebo Comparator|Treatment C - Placebo|Placebo matching INCB009471
3305062|NCT00393094|Experimental|Bevacizumab & Irinotecan Patients|Bevacizumab - 10 mg/kg intravenous injection Irinotecan - 125 mg/m^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
3305063|NCT00393068|Experimental|Treatment|"Prior to surgery study treatment will be given over a 6 weeks (Days 1-42) period. Beginning Day 1 and continuing through Day 35 patients will receive a continuous infusion of 5-FU by vein. A small portable pump will be used to administer this drug into a tube that has been surgically inserted into the patient's vein. On Day 1 and 22 patients will also receive the drugs paclitaxel, carboplatin and bevacizumab by vein. Erlotinib is given by mouth beginning on Day 1 and continuing through Day 45. Patients will receive radiation therapy daily, Monday through Friday, beginning Day 1-35 (approximately 5 weeks).~Surgery will be performed approximately 12-14 weeks after beginning this combined treatment."
3305064|NCT00393055|Experimental|xylitol lozenge|1g xylitol lozenge. Five/day, dissolved in mouth
3305177|NCT00391768|Experimental|oseltamivir (Tamiflu®)|
3305065|NCT00393055|Placebo Comparator|inactive lozenge|1g placebo lozenge. Five/day, dissolved in mouth
3305066|NCT00393042|Experimental|Focalin XR then Adderall XR|Subjects are given the Focalin XR first (dexmethylphenidate) for four weeks with a randomized placebo week followed by Adderall XR (mixed amphetamine salts) for four weeks with a randomized placebo week.
3305067|NCT00393042|Experimental|Adderall XR then Focalin XR|Subjects are given the Adderall XR (mixed amphetamine salts) for four weeks with a randomized placebo week followed by Focalin XR first (dexmethylphenidate) for four weeks with a randomized placebo week.
3305068|NCT00393029|Experimental|Patients with metastatic melanoma|Melanoma is a serious form of skin cancer that develops in the skin cells that make our skin color (melanocytes).
3305069|NCT00393029|Experimental|Patients with other metastatic cancers|
3305070|NCT00392990|Experimental|Alternating doxil/Magrath regimen & rituximab/Magrath regimen|Patients are stratified between high risk and low risk disease status. Low risk patients receive 3 cycles of rituximab (500 mg/m2) R-CODOX-M chemotherapy IV over 2-4 hours with intrathecal chemotherapy (Regimen A). High risk patients receive 1 cycle of R-CODOX-M chemotherapy IV followed by R-IVAC chemotherapy over 30 minutes(Regimen B); regimens A and B are then repeated.
3305071|NCT00392951|Experimental|Sirolimus treatment|Sirolimus treatment
3305072|NCT00392925|Experimental|Placebo and Metreleptin|Placebo-pramlintide 600 microliters (µL) twice a day (BID) and metreleptin (recombinant-methionyl human leptin) 5 milligram (mg) BID, 20 weeks
3305073|NCT00392925|Experimental|Pramlintide Acetate and Placebo|Lead-in period: 2 weeks pramlintide acetate 180 mcg BID, then 2 weeks pramlintide acetate 360 mcg BID Study period: Pramlintide acetate 360 mcg BID and placebo-metreleptin 1 mL BID, 20 weeks
3305074|NCT00392925|Experimental|Pramlintide Acetate and Metreleptin|Lead-in period: 2 weeks pramlintide acetate 180 mcg BID, then 2 weeks pramlintide acetate 360 mcg BID Study period: Pramlintide acetate 360 mcg BID and metreleptin (recombinant-methionyl human leptin) 5 mg BID, 20 weeks
3305075|NCT00392925|Other|Lead-In Period|During the Lead-In Period before a participant was randomized to a study arm, the participant received 180 mcg pramlintide acetate twice a day (BID) for 2 weeks, followed by 360 mcg pramlintide acetate BID for 2 weeks (total of 4 weeks in the Lead-In Period).
3305076|NCT00392899|Active Comparator|UFT adjuvant therapy group|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year. During protocol treatment, clinical findings and laboratory values are evaluated every month. After the completion of protocol treatment, patients are followed-up, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
3305077|NCT00392899|No Intervention|Observation group|Patients are followed-up without adjuvant treatment, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
3305078|NCT00392886|Experimental|Regimen C|Patients receive induction therapy of vincristine IV on days 1, 8, and 15 of courses 1-3, oral temozolomide once daily on days 1-5, and carboplatin IV over 4 hours on days 1 and 2. Patients also receive G-CSF SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients receive consolidation therapy of carboplatin IV over 4 hours on days -8 to -6 and thiotepa IV over 3 hours on days -5 to -3, undergo reinfusion of bone marrow or peripheral blood stem cells on day 0, and receive G-CSF SC beginning on day 1 and continuing until blood counts recover. Beginning within 6 weeks after transplantation, some patients undergo radiotherapy once daily 5 days a week for 4-6 weeks in the absence of disease progression or unacceptable toxicity and some patients undergo radiotherapy if there is evidence of tumor remaining after completion of induction chemotherapy.
3305079|NCT00392886|Experimental|Regimen D2|In courses 1, 3, and 5, patients receive cisplatin IV over 6 hours on day 1, cyclophosphamide IV over 1 hour and etoposide IV over 2 hours on days 2 and 3, high-dose methotrexate IV over 4 hours on day 4, vincristine IV on days 1, 8, and 15 (in courses1 and 3), and filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until blood counts recover. In courses 2 and 4, patients receive oral temozolomide once daily on days 1-5, oral etoposide once daily on days 1-10, cyclophosphamide IV over 1 hour on days 11 and 12, vincristine IV on days 1, 8, and 15 (in course 2), and G-CSF SC beginning on day 13 and continuing until blood counts recover. Patients receive consolidation therapy as in regimen C in combination with etoposide IV over 3 hours on days -5 to -3 and undergo autologous bone marrow or peripheral blood stem cell transplantation, receive G-CSF, and undergo radiotherapy as in regimen C.
3305080|NCT00392873|Experimental|EAMD+Calories|This group contains women with exercise-associated menstrual disturbances (EAMD) and receives an intervention of increased caloric intake during the 12-month intervention. The targeted increase in caloric intake is 20-30% of baseline energy expenditure.
3305081|NCT00392873|No Intervention|EAMD Control|This group contains women with exercise-associated menstrual disturbances (EAMD) and undergoes the same procedures as the EAMD+Calories group. However, this group is instructed to maintain exercise and eating habits.
3305082|NCT00392873|No Intervention|Heathy Control|This group contains exercising women with regular, ovulatory menstrual cycles. this group is instructed to maintain body weight and exercise and eating habits.
3305083|NCT00392860|Experimental|PalmRim Experimental|Participants will have PalmRim installed on their wheelchair.
3305084|NCT00392860|Experimental|Natural-Fix Experiment|Participants will have a Natural-Fit installed on their wheelchair.
3305085|NCT00392860|Placebo Comparator|Handrim Control|Participants in this arm had a new standard handrim installed on their wheelchair as a control.
3305086|NCT00392847|Active Comparator|2|The first group will receive routine follow-up as currently provided by national community health and social services.
3305087|NCT00392847|Experimental|1|will receive home visits by community workers. These visits will start during pregnancy and will continue up to the child's second birthday.
3305171|NCT00391859|Experimental|Health service provision|Health service provision within the first few months of diagnosis which includes physical examination, radiographs, education, exercise, weight loss, assistive devices and pharmacologic therapy.
3305172|NCT00391846|Other|Guided by NT-proBNP|Treatment guided by clinical symptoms and signs + NTproBNP
3305173|NCT00391846|Other|Not Guided by NT-proBNP|Treatment guided by clinical symptoms and signs
3305174|NCT00391807|Experimental|study drug|Norethindrone/Ethinyl Estradiol
3305088|NCT00392834|Experimental|Regimen A (R-CODOX-M chemotherapy)|Patients receive rituximab IV and doxorubicin hydrochloride IV over 15 minutes on day 1, cyclophosphamide IV over 30-60 minutes on days 1 and 2, pegfilgrastim SC on day 3, vincristine IV on days 1 and 8, high-dose methotrexate IV over 2-4 hours on day 15, and leucovorin calcium IV beginning 24 hours after the start of methotrexate and continuing every 6 hours until level is adequate. Patients receive CNS prophylaxis of methotrexate IT, cytarabine IT, and hydrocortisone IT on day 1. Patients with high-risk disease receive an additional dose of cytarabine IT on day 3. Patients also receive G-CSF SC once daily on days 3-9. Once the methotrexate levels drops below 50 nmol/L, patients resume G-CSF SC once daily beginning on approximately day 18 and continuing until blood counts recover.
3305089|NCT00392834|Experimental|Regimen B (rituximab and IVAC chemotherapy)|Patients receive rituximab IV on day 1, ifosfamide IV continuously and etoposide IV continuously over 24 hours on days 1-5, and high-dose cytarabine IV over 1-3 hours twice daily on days 1-2. Patients receive CNS prophylaxis comprising methotrexate IT and hydrocortisone IT on day 5. Patients also receive pegfilgrastim SC once 24-48 hours after completion of chemotherapy OR G-CSF SC beginning on day 6 and continuing until blood counts recover. Patients with CNS involvement (leptomeningeal and/or intraparenchymal) at diagnosis do not receive CNS prophylaxis as above. Instead, these patients receive a combination of sequential liposomal cytarabine and methotrexate IT or via an Ommaya reservoir on day 1 and then every 14 days as tolerated until completion of systemic chemotherapy.
3305090|NCT00392821|Experimental|RAD001 and Sorafenib|RAD001 and Sorafenib
3305091|NCT00392808|Experimental|MENC-CRM/MENC-CRM|Children primed with 3 doses of MenC-CRM vaccine, Intervention: boosted with one dose of MenC-CRM vaccine
3305092|NCT00392808|Experimental|MENC-CRM/MENC-TT|Children Primed with three doses of MenC-CRM vaccine. Intervention: boosted with one dose of MenC-TT
3305093|NCT00392808|Experimental|MENC-TT/MENC-CRM|Children primovacccinated with two MenC-TT vaccine doses. Intervention: boosted with one dose MenC-CRM vaccine
3305094|NCT00392808|Experimental|MENC-TT/MENC-TT|Children primovacccinated with two MenC-TT vaccine doses. Intervention boosted with one dose MenC-TT vaccine
3305095|NCT00392782|Experimental|Natural Killer Cell Kir Epitope|
3305096|NCT00392769|Experimental|Cetuximab|400 mg/m^2 intravenous (IV) over 120 Minutes, followed by weekly infusions at 250 mg/m^2 IV over 60 minutes.
3305097|NCT00392756|No Intervention|off treatment|Subjects undergo the baseline evaluation off treatment
3305098|NCT00392756|Experimental|GnRH Treatment|Subjects receive long term pulsatile GnRH therapy
3305099|NCT00392743||pet/spect scan|
3305100|NCT00392730||1|Preterm infants in NICU and age-matched controls
3305101|NCT00392730||2|Term infants in NICU and age-matched controls
3305102|NCT00392730||3|Children on home PN (to age 6) and age-matched controls
3305103|NCT00392704|Experimental|Intervention|"All patients initially received treatment with paclitaxel 200 mg/m2, 3 hour IV infusion days 1 and 22; carboplatin area under the curve (AUC) 6.0 IV, days 1 and 22; 5-fluorouracil (5-FU) 200 mg/m2 daily by 24-hour continuous IV infusion, days 1 to 43; bevacizumab 15 mg/kg IV infusion days 1 and 22.~One to three weeks after completing neoadjuvant therapy, patients began treatment with concurrent chemoradiation, bevacizumab, and erlotinib. Radiation therapy began on day 1, with 1.8-Gy single daily doses, Monday through Friday, to a total dose of 68.4 Gy. Paclitaxel 50 mg/m2 was administered by 1-hour IV infusion on days 1 and 22. Erlotinib 150 mg by mouth daily began concurrently with radiation therapy and continued daily during the 7-week course of radiation."
3305104|NCT00392691|Experimental|Zevalin, Rituximab, Melphalan|
3305105|NCT00392678|Placebo Comparator|Placebo|Placebo
3305106|NCT00392678|Active Comparator|Salsalate 3.0 g daily, divided|Salsalate 3.0 grams daily, divided
3305107|NCT00392678|Active Comparator|Salsalate 3.5 g daily, divided|Salsalate 3.5 g daily, divided
3305108|NCT00392678|Active Comparator|Salsalate 4.0 g daily, divided|Salsalate 4.0 g daily, divided
3305109|NCT00392665|Active Comparator|Erlotinib + Bevacizumab|erlotinib plus bevacizumab
3305110|NCT00392665|Active Comparator|Erlotinib + Sulindac|erlotinib plus sulindac
3305111|NCT00392652|Experimental|Arm I (low-dose oral diindolylmethane)|Participants receive low-dose oral diindolylmethane (BR-DIM) twice daily for 4 weeks.
3305112|NCT00392652|Experimental|Arm II (high-dose oral diinolylmethane)|Participants receive high-dose oral BR-DIM twice daily for 4 weeks.
3305113|NCT00392639|Experimental|1-2|Comparison of 2 cooling procedures
3305114|NCT00392574|Experimental|1|Prulifloxacin
3305115|NCT00392574|Placebo Comparator|2|Placebo
3305116|NCT00392561|Experimental|1|Selenium
3305117|NCT00392561|Experimental|2|Vitamin E
3305118|NCT00392561|Experimental|3|Vitamin E + Selenium
3305119|NCT00392561|No Intervention|Arm 4|
3305120|NCT00392509|Experimental|2|Unfractionated Autologous Mononuclear Bone Marrow
3305121|NCT00392496|Experimental|Arm I|This is a non-randomized, open-label, multicenter study. Patients receive sunitinib malate orally once daily on days 1-28. Treatment repeats every 4 weeks for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity.
3305122|NCT00392444|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
3305123|NCT00392392|Experimental|Intervention|Patients received treatment with nab-paclitaxel (100 mg/m2 IV days 1, 8, 15) and carboplatin (AUC 6 IV day 1) every 28 days for 6 cycles. Trastuzumab (4 mg/kg loading dose, followed by 2 mg/kg) and bevacizumab (5 mg/kg IV) were administered weekly for 23 weeks, beginning concurrently with chemotherapy. Patients then underwent either mastectomy or breast conserving surgery and pathologic treatment responses were assessed. After surgery, trastuzumab 6 mg/kg and bevacizumab 15 mg/kg were administered at 3 week intervals for a total of 52 weeks.
3305124|NCT00392379|Experimental|A|4 mg nicotine lozenges for 3 months
3305125|NCT00392379|Placebo Comparator|B|Placebo nicotine lozenges for 3 months
3305126|NCT00392353|Experimental|Treatment (azacitidine, vorinostat)|Patients receive azacitidine SC QD on days 1-7 and vorinostat PO 2-3 times daily on days 3-5, 3-9, or 3-16. Treatment repeats every 28 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
3305175|NCT00391794|Experimental|ESSG|eight weekly 90-minute sessions
3305176|NCT00391794|Active Comparator|ES|one 4-hour educational program
3305127|NCT00392327|Active Comparator|Arm A (chemoradiotherapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy QD five days a week for 6 weeks. Patients also receive vincristine sulfate IV over 1 minute once weekly for 6 weeks. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive cisplatin IV over 6 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 8, and cyclophosphamide IV over 1 hour on days 2 and 3. Patients also receive filgrastim SC or IV beginning on day 4 and continuing until blood counts recover (at least 10 days).~Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity."
3305128|NCT00392327|Experimental|Arm B (chemoradiotherapy)|"CHEMORADIOTHERAPY: Patients receive vincristine sulfate and undergo radiation therapy as in Arm A. Patients also receive carboplatin IV over 15 minutes on each day of radiation therapy. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive maintenance therapy as in Arm A."
3305129|NCT00392327|Experimental|Arm C (chemoradiotherapy, isotretinoin-CLOSED TO ACCRUAL)|"CHEMORADIOTHERAPY: Patients undergo chemoradiotherapy as in Arm A. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive isotretinoin PO BID on day 1 and days 16-28 and cisplatin, vincristine sulfate, cyclophosphamide, and filgrastim as in Arm A maintenance therapy. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive isotretinoin PO BID on days 15-28 every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3305130|NCT00392327|Experimental|Arm D (chemoradiotherapy, isotretinoin-CLOSED TO ACCRUAL)|"CHEMORADIOTHERAPY: Patients undergo chemoradiotherapy as in Arm B. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive maintenance therapy as in Arm C. Patients then proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive continuation therapy as in Arm C."
3305131|NCT00392314|Experimental|Early favorable|patients with early favorable disease Ia IIA will have a PET/CT following 2 cycles of ABVD
3305132|NCT00392314|Experimental|Early Unfavorable|Patients with early favorable disease Ia or IIa with risk factors :large mediastinal mass extra nodal disease elevated esr, three or more involved areas, age equal or >50 , lymphocytic depleted or mixed cellularity
3305133|NCT00392314|Experimental|advanced disease|patients with advanced disease low IPS score 0-2 will start chemotherapy with ABVD for 2 cycles followed by PET/CT further therapy will be given according to PET/CT results
3305134|NCT00392314|Experimental|advanced disease IPS 3-7|Patients with advanced disease IPS score 3-7 will start chemotherapy with escalated beacopp. following 2 cycles PET/CT will be carried out and according to results further chemotherapy will be given
3305135|NCT00392288|Placebo Comparator|Placebo MDI|double-blind
3305136|NCT00392288|Experimental|Ciclesonide MDI 40 µg BID|double-blind
3305137|NCT00392288|Experimental|Ciclesonide MDI 80 µg BID|double-blind
3305138|NCT00392236|Experimental|A|Participants will receive treatment as usual and a 2-way pager for 6 months
3305139|NCT00392236|Active Comparator|B|Participants will receive treatment as usual
3305140|NCT00392223|Experimental|Treatment Group A|
3305141|NCT00392223|Experimental|Treatment Group B|
3305142|NCT00392210|No Intervention|Spontaneous Fill|
3305143|NCT00392210|Active Comparator|Retrograde Fill|
3305144|NCT00392184|Experimental|APBI|Accelerated Partial Breast Irradiation with interstitial Brachytherapy
3305145|NCT00392171|Experimental|Temozolomide|Temozolomide will be administered at a dose of 50 mg/m^2 for cycles of 28 days for 12 months or until progression.
3305146|NCT00392145|Active Comparator|1|
3305147|NCT00392145|Experimental|2|
3305148|NCT00392106|Active Comparator|Control|Class I or III anti-arrhythmic drug for the treatment of AF
3305149|NCT00392106|Experimental|Treatment|Pulmonary vein ablation with HIFU
3305150|NCT00392080|Placebo Comparator|3|
3305151|NCT00392080|Experimental|1|75 mg BID
3305152|NCT00392080|Experimental|2|
3305153|NCT00392054|Experimental|Catheter Ablation|Pulmonary vein isolation performed by catheter ablation for the prevention of recurrence of symptomatic atrial fibrillation
3305154|NCT00392054|Active Comparator|Antiarrhythmic Drug Therapy|Conventional antiarrythmic drug therapy for the prevention of recurrence of symptomatic atrial fibrillation
3305155|NCT00392041|Experimental|Eszopiclone|
3305156|NCT00392041|Placebo Comparator|Placebo|
3305157|NCT00392015|Experimental|Dose-escalation|NMRC-M3V-Ad-PfCA
3305158|NCT00392015|Experimental|Regimen-comparison|NMRC-MV-Ad-PfC, NMRC-MV-Ad-PfA
3305159|NCT00391976|Experimental|Tobramycin 300 mg for 28 days|Patients inhaled tobramycin 300 mg bis in die (bid, twice a day) for 28 days using the PARI LC PLUS™ jet nebulizer and a suitable compressor. The 2 daily doses were taken approximately 12 hours apart and no less than 6 hours apart.
3305160|NCT00391976|Experimental|Tobramycin 300 mg for 56 days|Patients inhaled tobramycin 300 mg bis in die (bid, twice a day) for 56 days using the PARI LC PLUS™ jet nebulizer and a suitable compressor. The 2 daily doses were taken approximately 12 hours apart and no less than 6 hours apart.
3305161|NCT00391937|Experimental|1|ASR prosthesis placed using CAS
3305162|NCT00391937|Active Comparator|2|ASR prosthesis placed by conventional method
3305163|NCT00391911|Active Comparator|NAC and CRRT|N-Acetylcysteine and CRRT Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label,
3305164|NCT00391911|Other|NAC and non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
3305165|NCT00391911|Other|Placebo and CRRT|Patients are assigned to placebo treatment and CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT is open label.
3305166|NCT00391911|Other|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. This is the standard of care arm. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
3305167|NCT00391898|Experimental|Levodopa/carbidopa/entacapone|
3305168|NCT00391898|Active Comparator|Levodopa/carbidopa|
3305169|NCT00391872|Active Comparator|Clopidogrel|Oral treatment
3305178|NCT00391755|Active Comparator|1|ramelteon 8 mg po qhs with sleep and migraine journal
3305179|NCT00391755|Placebo Comparator|2|Placebo po qhs with sleep and migraine journal
3305180|NCT00391729|Placebo Comparator|1|
3305181|NCT00391729|Experimental|2|
3305182|NCT00391716|Experimental|gabapentin 900mg daily|900mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.
3305183|NCT00391716|Experimental|gabapentin 1800mg daily|1800 mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks
3305184|NCT00391716|Placebo Comparator|placebo daily|placebo capsules daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.
3305185|NCT00391703|Experimental|1|Quadriceps electrostimulation program, performed prior to an endurance retraining program using a cycloergometer
3305186|NCT00391703|Active Comparator|2|Usual sport activity, performed prior to an endurance retraining program using a cycloergometer
3305187|NCT00391677|Experimental|1|Participants will receive social skills training with attention shaping procedures
3305188|NCT00391677|Active Comparator|2|Participants will receive social skills training without attention shaping procedures
3305189|NCT00391651|Active Comparator|1|Nitrofurantoin 100mg BID x 5 days
3305190|NCT00391651|Active Comparator|2|TMP/SMX DS BID x 3 days
3305191|NCT00391638|Experimental|HIV antiretroviral therapy, TRUVADA , PEGASYS 180μg|Week-8 up Week0: HIV antiretroviral therapy Week 0 up Week 48: HIV antiretroviral therapy + TRUVADA + PEGASYS 180μg Week 48 up Week 72: HIV antiretroviral therapy + TRUVADA Week 72 up Week 144: HIV antiretroviral therapy
3305192|NCT00391625|Experimental|GA-GCB|15-60 U/kg every other week via intravenous infusion
3305193|NCT00391612|Sham Comparator|2|subject receives optimal medical management, supervised pulmonary rehabilitation therapy and undergoes bronchoscopy but no stents are placed
3305194|NCT00391612|Experimental|1|subject receives optimal medical management, supervised pulmonary rehabilitation therapy and undergoes bronchoscopy during which up to six Exhale drug-eluting stents are placed in the lungs
3305195|NCT00391599|Experimental|Study Group|a fleet enema (250 cc of sodium biphosphate 16 gr and sodium phosphate 6 gr per 100 cc) the night before cesarean section
3305196|NCT00391599|Active Comparator|Control Group|no preoperative intestinal preparation.
3305197|NCT00391586|Experimental|Erlotinib followed by chemotherapy|"Erlotinib: 150 mg orally once daily,~Platinum-based chemotherapy regimen selections include:~Carboplatin (Carbo) area under the curve (AUC) 6, or cisplatin (Cis) 60-100 mg/m2, day (D)1, administered with one of the following:~Docetaxel 75 mg/m2, D1~Docetaxel 35 mg/m2, D1,8,15~Paclitaxel 200-225 mg/m2, D1~Paclitaxel 80-100 mg/m2, D1,8,15~Carbo AUC 5-6, or Cis 60-100 mg/m2, D1, administered with one of the following:~Etoposide 100 mg/m2 D1-3~Etoposide 200 mg/m2 orally D1-3~Pemetrexed 500 mg/m2, D 1~Irinotecan 50 mg/m2 D1,8,15~Other regimens:~Gemcitabine 1000 mg/m2-1250 mg/m2, D1,8 + Carbo AUC 6, or Cis 60-100 mg/m2, D1 or 8~Vinorelbine 25 mg/m2 D1,8 + Carbo AUC 5, or Cis 80 mg/m2 D1"
3305198|NCT00391560|Experimental|Group 1 on Perifosine|"Patients with AML, MDS, CML-BP non-lymphoid, CMML, or Agnogenic Myeloid Metaplasia (AMM).~After a one-time loading dose of 600 mg (150 mg x 4 at least 4 hours apart) during the first cycle, perifosine will be given orally at 100 mg once a day continuously. Cycles are 28 days in length.~Intra-patient dose escalation for the maintenance dose to 150 mg daily will be done in the second cycle if no non-hematological toxicities beyond grade 0-1 occurred during the first cycle are observed."
3305199|NCT00391560|Experimental|Group 2 on Perifosine|"Patients with CLL, ALL, or CML-BP lymphoid. After a one-time loading dose of 600 mg (150 mg x 4 at least 4 hours apart) during the first cycle, perifosine will be given orally at 100 mg once a day continuously. Cycles are 28 days in length.~Intra-patient dose escalation for the maintenance dose to 150 mg daily will be done in the second cycle if no non-hematological toxicities beyond grade 0-1 occurred during the first cycle are observed."
3305200|NCT00391534|Experimental|Oxcarbazepine MR|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
3305201|NCT00391534|Active Comparator|Oxcarbazepine IR|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
3305202|NCT00391521|Active Comparator|1|Regimen 1
3305203|NCT00391521|Active Comparator|2|Regimen 2
3305204|NCT00391521|Active Comparator|3|Regimen 3
3305205|NCT00391469|No Intervention|control treatment|
3305206|NCT00391443|Experimental|Bosentan|Subjects receive bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg b.i.d (if body weight > 40 kg) or bosentan 62.5 mg b.i.d. (if body weight < 40 kg)
3305207|NCT00391443|Placebo Comparator|Placebo|Subjects receive placebo matching the bosentan treatment regimen
3305208|NCT00391430|No Intervention|Control|Participants assigned to the control condition will receive no treatment
3305209|NCT00391430|Active Comparator|Sertraline|Participants will receive treatment with sertraline
3305210|NCT00391430|Active Comparator|CBT|Participants will receive cognitive behavioral therapy
3305211|NCT00391404|Active Comparator|Alendronate|Oral alendronate 70 mg weekly
3305212|NCT00391404|Placebo Comparator|Placebo|Conventional drug treatment
3305213|NCT00391391|Experimental|1|Split, Inactivated, Trivalent Influenza Vaccine
3305214|NCT00391391|Experimental|2|Split, Inactivated, Trivalent Influenza Vaccine
3305215|NCT00391391|Active Comparator|3|Split, Inactivated, Trivalent Influenza Vaccine
3305216|NCT00391391|Active Comparator|4|Split, Inactivated, Trivalent Influenza Vaccine
3305217|NCT00391365||Group 1|Subjects undergoing ankle arthrodesis (fusion) for treatment of ankle arthritis
3305218|NCT00391365||Group 2|Subjects undergoing ankle arthroplasty (replacement) for treatment of ankle arthritis
3305219|NCT00391352||MS|MS patient is matched to healthy volunteer
3305220|NCT00391352||Control|
3305276|NCT00390780|Experimental|miconazole Lauriad|Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days
3305221|NCT00391287||erythropoietin treatment in CRF|Patients exposed to EPREX or other marketed erythropoietin products administered by the subcutaneous route of administration for the treatment of anemia of Chronic Renal Failure
3305222|NCT00391274|Experimental|Pemetrexed|
3305223|NCT00391274|Active Comparator|Docetaxel|
3305224|NCT00391235||BPD|Children with bipolar disorder
3305225|NCT00391235||HC|Healthy comparison children
3305226|NCT00391222|Experimental|001|Risperidone Long Acting Injectable (LAI) Intramuscular injections of risperidone LAI (25 37.5 or 50 mg) every 2 weeks and oral placebo daily
3305227|NCT00391222|Placebo Comparator|002|Placebo Intramuscular injections of placebo every 2 weeks and oral placebo daily
3305228|NCT00391222|Active Comparator|003|Olanzapine Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily
3305229|NCT00391209|Experimental|1|
3305230|NCT00391209|Experimental|2|
3305231|NCT00391196|Placebo Comparator|Placebo|
3305232|NCT00391196|Experimental|CP-945,598|
3305233|NCT00391196|Experimental|CP-945,598 Treatment B|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
3305234|NCT00391183|Active Comparator|Endoscopic stenting|patients with biliary obstruction will undergo endoscopic stenting.
3305235|NCT00391183|No Intervention|Best supportive care|
3305236|NCT00391170|Experimental|Active|Dexamethasone 0.01%
3305237|NCT00391170|Placebo Comparator|Placebo|Placebo oral rinse
3305238|NCT00391131|Experimental|Ig NextGen 16%|
3305239|NCT00391118|Experimental|A|
3305240|NCT00391118|Placebo Comparator|B|
3305241|NCT00391092|Experimental|1|
3305242|NCT00391092|Active Comparator|2|
3305243|NCT00391079|Experimental|A|
3305244|NCT00391079|Placebo Comparator|B|
3305245|NCT00391066|Active Comparator|1|"FCR~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
3305246|NCT00391066|Experimental|2|"FCR + Lumiliximab (L)~L (Lumiliximab): Day 2 50 mg/m2, Day 4 450 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks.~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
3305247|NCT00391053|Experimental|Study Group 1|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 1
3305248|NCT00391053|Experimental|Study Group 2|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 2
3305249|NCT00391053|Experimental|Study Group 3|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 3
3305250|NCT00391053|Active Comparator|Group 4|Participants will receive the Standard Fluzone® vaccine
3305251|NCT00391027|Active Comparator|Insulin Glargine (Lantus®)|
3305252|NCT00391027|Active Comparator|Inhaled Human Insulin (Exubera®)|
3305253|NCT00391014|Experimental|1|"AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.~If patient required ALO-TPH, the prophylaxis should be followed."
3305254|NCT00391001|Experimental|1|
3305255|NCT00391001|Placebo Comparator|2|
3305256|NCT00390936|No Intervention|1|4 dosages
3305257|NCT00390923|Experimental|1|
3305258|NCT00390923|Placebo Comparator|2|
3305259|NCT00390910|Experimental|Group A|Very pretem infants born after a gestation period of 27-30 weeks (189-216 days)
3305260|NCT00390910|Experimental|Group B|Mild pretem infants born after a gestation period of 31-36 weeks (217-258 days)
3305261|NCT00390910|Experimental|Group C|Infants born after a gestation period of more than 36 weeks (more than 258 days)
3305262|NCT00390884|Experimental|Fluzone®-Primed Group|Participants had received two doses of the 2005-2006 formulation of Fluzone® vaccine in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.
3305263|NCT00390884|Experimental|Fluzone®-Naive Group|Participants had never received Influenza vaccine and had received two doses of placebo in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.
3305264|NCT00390871|Active Comparator|Fentanyl/Propofol sedation|Patient sedated with fentanyl/propofol as needed to RASS Score 0 to -1
3305265|NCT00390871|Active Comparator|Fentanyl/Dexmedetomidine sedation|Patient sedated with fentanyl/dexmedetomidine as needed to RASS Score 0 to -1
3305266|NCT00390858|Experimental|Deferasirox|Initial dose of 10 mg/kg, dose modifications of ± 5 or 10 mg/kg were based on participant response.
3305267|NCT00390845|Experimental|SB681323|Patients with pain associated with peripheral nerve injury and/or compression will be recruited for this study.
3305268|NCT00390845|Experimental|Placebo|Patients with pain associated with peripheral nerve injury and/or compression will be recruited for this study.
3305269|NCT00390832|Active Comparator|A|recombinant human erythropoietin beta
3305270|NCT00390832|Placebo Comparator|B|0.9% NaCl solution
3305271|NCT00390806|Experimental|topotecan plus radiation|topotecan 1.1 mg/m2 followed by whole brain radiation 3 Gy/day for 10 days, followed by optional continuation therapy with topotecan 2.3 mg/m2 for 5 days Q21 days as monotherapy.
3305272|NCT00390806|Active Comparator|Whole brain radiation|Whole brain radiation 3 Gy/day for 10 days
3305273|NCT00390793|Experimental|Hyper-CVAD + Dasatinib|Odd-numbered courses (1, 3, 5, and 7), Cyclophosphamide intravenous (IV) Days 1-3, every 12 hours for 6 doses with MESNA CVC over 24 hours until 12 hours after last dose cyclophosphamide; Vincristine IV Days 4 and 11, over 30 minutes during hyper-CVAD therapy; Doxorubicin CVC Day 4 over 24-48 hours after last dose of Cyclophosphamide; Dexamethasone Days 1-4 & Days 11-14 PO or IV over 30 minutes during hyper-CVAD therapy.
3305274|NCT00390793|Experimental|Methotrexate + Ara-C|Even-numbered courses (2, 4, 6, and 8), Methotrexate IV Day 1; Ara-C IV Days 2 and 3 (over 2 hours every 12 hours for total of 4 doses each time)
3305275|NCT00390780|Active Comparator|Clotrimazole|Clotrimazole troches, 10 mg, 5 times per day for 14 days
3305499|NCT00388323|Experimental|1|
3305277|NCT00390767|Experimental|MultiGeneAngio|Escalating doses of MultiGeneAngio
3305278|NCT00390754|Experimental|Pregnancy Test Group|Group got free home pregnancy test kits
3305279|NCT00390754|No Intervention|2|Group did not receive free home pregnancy test kits
3305280|NCT00390741|Active Comparator|1|Home-based exercise program
3305281|NCT00390741|No Intervention|2|Usual care
3305282|NCT00390702|Experimental|VSD occluder|transcatheter implantation of a VSD occluder (Nitinol coil)
3305283|NCT00390689|Experimental|Pramipexole 0.25 mg once daily|Pramipexole 0.25 mg given once daily
3305284|NCT00390689|Experimental|Pramipexole 0.5 mg once daily|Pramipexole 0.5 mg given once daily
3305285|NCT00390689|Experimental|Pramipexole 0.75 mg once daily|Pramipexole 0.75 mg given once daily
3305286|NCT00390637|Experimental|1|Low Protein, Low GI Diet
3305287|NCT00390637|Experimental|2|Low Protein, High Glycemic Index Diet
3305288|NCT00390637|Experimental|3|High Protein, Low Glycemic Index diet
3305289|NCT00390637|Experimental|4|High Protein, High glycemic index diet
3305290|NCT00390637|Experimental|5|Control diet (current recommendations)
3305291|NCT00390611|Active Comparator|Paclitaxel/Carboplatin/Sorafenib|Paclitaxel 175 mg/m2 1-3 hour IV infusion, Day 1 Carboplatin AUC 6 infused over 20 minutes IV, Day 1 Sorafenib 400mg PO bid
3305292|NCT00390611|Active Comparator|Paclitaxel/carboplatin|Paclitaxel 175 mg/m2 1-3 hour IV infusion, Day 1 Carboplatin AUC 6 infused over 20 minutes IV
3305293|NCT00390598|Active Comparator|senna 36 mG + PEG 2L|Bowel preparation with senna tablets 36 mG and PEG 2L prior to colonoscopy.
3305294|NCT00390598|Active Comparator|4 L PEG|Bowel preparation with 4 L PEG prior to colonoscopy.
3305295|NCT00390585|Experimental|A|Iodixanol 320
3305296|NCT00390585|Active Comparator|B|Iomeprol 350
3305297|NCT00390572|Experimental|Sleep Specialty Consultation|Participants randomized to receive a one-time sleep consultation at beginning of study
3305298|NCT00390572|No Intervention|Treatment as Usual|Participants randomized to receive a one-time sleep consultation after completing study procedures (after 10 month study wait-list period).
3305299|NCT00390559|Experimental|ActiveP/ActiveC|21 mg patch/Nicotine-containing cigarette
3305300|NCT00390559|Experimental|PlaceboP/ActiveC|0 mg patch/nicotine-containing cigarette
3305301|NCT00390559|Experimental|Active P/PlaceboC|21 mg patch/no nicotine cigarette
3305302|NCT00390559|Experimental|PlaceboP/PlaceboC|0 mg patch/no nicotine cigarette
3305303|NCT00390546|Experimental|Propranolol|Single dose of 0.5 mg/kg per dose and increased to 1.0 mg/kg per dose ITD for the second and subsequent doses.
3305304|NCT00390546|Experimental|Digoxin|First 2 doses at 0.010 mg/kg per dose TID, then 0.0035 mg/kg per dose TID for the third and subsequent doses
3305305|NCT00390533|Experimental|Saredutant 30 mg|Saredutant 30 mg once daily for a maximum of 8 weeks
3305306|NCT00390533|Experimental|Saredutant 100 mg|Saredutant 100 mg once daily for a maximum of 8 weeks
3305307|NCT00390533|Placebo Comparator|Placebo|Placebo for saredutant once daily for one week during the screening phase and for a maximum of 8 weeks during the acute phase
3305308|NCT00390481|Other|Intervention|EC-IC Bypass
3305309|NCT00390481|No Intervention|Control|Best Medical Therapy
3305310|NCT00390468|Experimental|Tandutinib (MLN518)|500 mg twice daily, a small-molecule inhibitor of the type III receptor tyrosine kinases. Tandutinib (MLN518) previously known as CT53518.
3305311|NCT00390455|Experimental|Arm I (lapatinib)|Patients receive lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 and 15 of course 1 and on day 1 of each subsequent course. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3305312|NCT00390455|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28 and fulvestrant as in Arm I. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3305313|NCT00390429|Experimental|Phase I, Group I (completed)|Patients receive docetaxel IV over 1 hour on day 1 and oral erlotinib hydrochloride once on days 2, 9, and 16. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression. Patients may then continue to receive erlotinib hydrochloride alone in the absence of unacceptable toxicity or disease progression.
3305314|NCT00390429|Experimental|Phase I, Group II (completed)|Patients receive docetaxel as in group I and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression. Patients may then continue to receive erlotinib hydrochloride alone in the absence of unacceptable toxicity or disease progression.
3305315|NCT00390429|Experimental|Phase II|Patients receive docetaxel IV over 1 hour on day 1 and oral erlotinib hydrochloride at the MTD determined in group II of phase I once daily on days 2-16. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may then continue to receive erlotinib hydrochloride alone in the absence of disease progression or unacceptable toxicity.
3305316|NCT00390416|Experimental|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
3305317|NCT00390338|Experimental|peptide-pulsed type-1-polarized dendritic cells|intralymphatic vaccination with peptide-pulsed type-1-polarized dendritic cells (aDC1)
3305318|NCT00390338|Experimental|peptide-pulsed mature non-polarized dendritic cells (cDCs)|intralymphatic vaccination with peptide-pulsed mature non-polarized dendritic cells (cDCs)
3305319|NCT00390325|Experimental|Treatment (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID on days 1-56. Treatment repeats every 8 weeks in the absence of disease progression or unacceptable toxicity.
3305320|NCT00390312|Active Comparator|4|Intravenous morphine
3305321|NCT00390312|Experimental|1|Intranasal morphine 7.5 mg
3305322|NCT00390312|Experimental|2|Intranasal morphine 15 mg
3305323|NCT00390312|Active Comparator|3|Oral morphine 60 mg
3305324|NCT00390312|Placebo Comparator|5|Intranasal placebo
3305325|NCT00390312|Placebo Comparator|6|Oral placebo
3305326|NCT00390312|Placebo Comparator|7|Intravenous placebo
3305327|NCT00390299|Experimental|Arm A (resection cavity administration)|Patients undergo en block resection of their tumor (after confirming diagnosis) on day 1, followed by MV-CEA administered into the resection cavity.
3305328|NCT00390299|Experimental|Arm B (intratumoral and resection cavity administration)|Patients undergo stereotactic biopsy (to confirm the diagnosis) and placement of a catheter within the tumor, followed by MV-CEA IT through the catheter over 10 minutes on day 1. Patients then undergo en block resection of their tumor with computer-assisted stereotactic techniques on day 5, followed by MV-CEA administered around the tumor bed.
3305329|NCT00390234|Experimental|Treatment (ziv-aflibercept)|Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
3305330|NCT00390221|Placebo Comparator|Placebo|Participants will receive 3 subcutaneous (SC) injections of placebo every 4 weeks for up to 52 weeks.
3305331|NCT00390221|Experimental|150 mg DAC HYP|Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.
3305332|NCT00390221|Experimental|300 mg DAC HYP|Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.
3305333|NCT00390208|Other|Group 1|Combination triple therapy of Lucentis, Dexamethasone and Visudyne Therapy
3305334|NCT00390208|Other|Group 2|Monotherapy: One 0.5 mg intravitreal Ranibizumab injection
3305335|NCT00390195|Experimental|1. Daily|Taking orally the investigational drug daily
3305336|NCT00390195|Experimental|2. Weekly|Taking orally the investigational drug weekly
3305337|NCT00390182|Experimental|Single Arm|"Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.~Radiation: External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy."
3305338|NCT00390143|Experimental|Group A|Subjects previously primed with meningococcal vaccine 134612.
3305339|NCT00390143|Active Comparator|Group B|Subjects previously primed with Mencevax™ ACWY.
3305340|NCT00390130|Active Comparator|Pentacel|The subjects in this arm will be vaccinated with Pentacel
3305341|NCT00390130|Active Comparator|Prevnar|The subjects in this arm will be vaccinated with Prevnar
3305342|NCT00390117|Experimental|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
3305343|NCT00390078|Active Comparator|1|20 Subjects, 1x 10E8_TCID50 MVA-mBN32
3305344|NCT00390078|Placebo Comparator|2|10 Subjects 1x 10E8_TCID50 IMVAMUNE
3305345|NCT00390065|Experimental|Study group|Hypoxemic Respiratory Failure treated by Nitric Oxide;
3305346|NCT00390065|Placebo Comparator|Control|Hypoxemic Respiratory Failure control (Placebo);
3305347|NCT00390065|No Intervention|Reference|Reference (Non hypoxemic respiratory failure)
3305348|NCT00390052|Experimental|Arm I|Patients will receive a 2-hour infusion of 3-AP once in week 1. Beginning in week 2, they will receive 3-AP by mouth twice a day 3 days a week for 3 weeks. Treatment with 3-AP by mouth may repeat every 4 weeks for as long as benefit is shown.
3305349|NCT00390039|Experimental|A|MNS075 7.5mg
3305350|NCT00390039|Placebo Comparator|B|Placebo
3305351|NCT00390039|Active Comparator|C|IV Morphine
3305352|NCT00390039|Experimental|E|MNS075 15mg
3305353|NCT00390039|Placebo Comparator|D|Placebo
3305354|NCT00390039|Placebo Comparator|F|Placebo
3305355|NCT00390013|Active Comparator|Gabapentin|Gabapentin (Neurontin) titration and dosing for total of 8 weeks (Cross over)
3305356|NCT00390013|Placebo Comparator|Placebo oral capsule|Placebo titration and dosing for total of 8 weeks (Cross over)
3305357|NCT00390000|Experimental|Arm I|See Detailed Description
3305358|NCT00389974|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO daily for 4 weeks. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or PR may receive 2 courses after CR or PR is reached.
3305359|NCT00389935|Experimental|Treatment|
3305360|NCT00389922|Experimental|A (Daily Dosing)|"Oral lapatinib given daily for 28 days plus IV vinorelbine given weekly (3 out of 4 weeks)~Cohorts of 3-6 patients receive escalating doses of lapatinib ditosylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during course 1. At least 6 patients are treated at the MTD. Once the MTD of lapatinib has been determined, patients may be accrued to group B or to a separate pharmacokinetics cohort in group A."
3305361|NCT00389922|Experimental|B (Intermittent Dosing)|"Oral lapatinib given days 2-5, 9-12 and 16-25 plus IV vinorelbine given weekly (3 out of 4 weeks)~Cohorts of 3-6 patients receive escalating doses of lapatinib ditosylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during course 1. At least 6 patients are treated at the MTD. Once the MTD of lapatinib has been determined, patients may be accrued to group B or to a separate pharmacokinetics cohort in group A."
3305362|NCT00389909|Active Comparator|1|Treatment based on patient weight;
3305363|NCT00389909|Active Comparator|2|Treatment based on a chart taking into account weight, age and gender
3305364|NCT00389883|Active Comparator|1|propofol et remifentanil
3305365|NCT00389883|Experimental|2|sevoflurane et sufentanil
3305366|NCT00389857|Experimental|Influenza vaccine-naive group|Participants have never received Influenza virus vaccine in the past. They will receive a single dose of Fluzone vaccine on Day 0 and Day 28, respectively.
3305367|NCT00389857|Experimental|Influenza vaccine-primed group|Participants have received Influenza virus vaccine in the past. They will receive a single dose of Fluzone vaccine on Day 0.
3305368|NCT00389844|No Intervention|1|Routine care
3305369|NCT00389844|Active Comparator|2|Exercise only
3305370|NCT00389844|Active Comparator|3|Motivation only
3305371|NCT00389844|Experimental|4|Exercise plus motivation
3305372|NCT00389831|Placebo Comparator|Placebo|Subjects receiving a single dose of placebo nasal spray on all 4 treatment days
3305373|NCT00389831|Experimental|Rotigotine Nasal Spray|Subjects receiving doses of placebo nasal spray on Day 1 or Day 2, Rotigotine nasal spray 62µg on Day 1 or Day 2, Rotigotine nasal spray 124µg on Day 3, and Rotigotine nasal spray 247µg on Day 4
3305374|NCT00389818|Experimental|DR-COP|Single arm interventional study: all subjects receive DR-COP regimen.
3305375|NCT00389792|No Intervention|ATI-2042 200 mg|
3305376|NCT00389792|No Intervention|ATI-2042 400 mg|
3305377|NCT00389792|No Intervention|ATI-2042 600 mg|
3305378|NCT00389792|No Intervention|ATI-2042 Placebo|
3305379|NCT00389779|Experimental|Darusentan|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily for 14 weeks
3305380|NCT00389779|Active Comparator|Guanfacine|Placebo to match darusentan for 2-week placebo run-in period, followed by guanfacine 1 mg capsules administered orally once daily for 14 weeks
3305381|NCT00389779|Placebo Comparator|Darusentan Placebo|Placebo to match darusentan for 2-week placebo run-in period, followed by placebo to match darusentan administered orally once daily for 14 weeks
3305382|NCT00389675|Experimental|Darusentan|Darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily
3305383|NCT00389675|Active Comparator|Guanfacine|Guanfacine 1 mg capsules administered orally once daily
3305384|NCT00389636|Active Comparator|1|TheraGauze alone
3305385|NCT00389636|Active Comparator|2|Theragauze + Regranex
3305386|NCT00389610|Experimental|Stratum I|Patients receive booster vaccination comprised of an allogenic GM-CSF plasmid-transfected pancreatic tumor cell vaccine, given subcutaneously (SC). Treatment repeats every 6 months.
3305387|NCT00389610|Experimental|Stratum II|Patients receive priming vaccinations comprised of allogenic GM-CSF plasmid-transfected pancreatic tumor cell vaccine, given SC once a month for 3 months and then receive booster vaccinations as in stratum I.
3305388|NCT00389597|Experimental|1 Level|Cervical artificial disc (investigational device) at 1 level compared with control procedure (ACDF) at one level
3305389|NCT00389597|Experimental|2 Level|Cervical artificial disc (investigational device) at 2 levels compared with control procedure (ACDF) at two levels
3305390|NCT00389558|Active Comparator|2|Biseptine
3305391|NCT00389558|Active Comparator|1|Amukin
3305392|NCT00389532|Experimental|1|aged 19 to 59 years
3305393|NCT00389532|Experimental|2|aged ≥ 60 years
3305394|NCT00389519|Placebo Comparator|Placebo|once per day
3305395|NCT00389519|Experimental|ramipril low dose|0.3125, 0.625, or 1.25 mg once a day, based on subject weight
3305396|NCT00389519|Experimental|ramipril mid dose|1.25, 2.5, or 5 mg once a day, based on subject weight
3305397|NCT00389519|Experimental|ramipril high dose|5, 10, or 20 mg once a day, based on subject weight
3305398|NCT00389493|Active Comparator|1|Participants will receive treatment with risperidone
3305399|NCT00389493|Active Comparator|2|Participants will receive exposure and ritual prevention therapy (EX/RP)
3305400|NCT00389493|Placebo Comparator|3|Participants will receive treatment with the placebo
3305401|NCT00389480|Experimental|I|Dose escalating
3305402|NCT00389467|Active Comparator|1 Mechanical Embolectomy|Participants will be randomized to receive mechanical embolectomy treatment either with the Merci Retriever or Penumbra System and standard medical care or treatment with standard medical care alone.
3305403|NCT00389467|No Intervention|2|standard medical care
3305404|NCT00389441|Experimental|A|
3305405|NCT00389376|Other|Group 1|Placebo and 140 mg single dose + every 8 hours
3305406|NCT00389376|Other|Group 2|Placebo and 280 mg single dose
3305407|NCT00389376|Other|Group 3|Placebo and 280mg every 8 hours
3305408|NCT00389376|Other|Group 4|Placebo and 280 single dose + every 8 hours
3305409|NCT00389376|Other|Group 5|Placebo and 560 mg single dose + every 8 hours
3305410|NCT00389376|Other|Group 6|Placebo and 560 mg single dose + every 8 hours
3305411|NCT00389376|Other|Group 7|Placebo and 700 mg single dose + every 8 hours
3305412|NCT00389324|Experimental|Immune Globulin Intravenous (Human)|Immune Globulin Intravenous (Human), 10%, Caprylate/Chromatography Purified
3305413|NCT00389311|Active Comparator|Nonoxynol-9|Gynol-II, 2% N-9, 5 mL
3305414|NCT00389311|Other|Normosol-R|Normosol-R, 5 mL, single administration, negative control
3305415|NCT00389311|Experimental|Normosol with simulation, endoscopy and biopsy|Normosol-R, 5 mL following simulation, endoscopy and biopsy
3305416|NCT00389259|Experimental|A|IV Scopolamine 0.25mg in adults and 0.006mg/kg in children Q4h
3305417|NCT00389259|Placebo Comparator|B|IV Look alike drug Q 4h
3305418|NCT00389233|Experimental|1|2L gut cleansing solution
3305419|NCT00389233|Active Comparator|2|4L preparation
3305420|NCT00389220|Active Comparator|BioMatrix Flex stent|Coronary stent placement with Biolimus A9 coated stent with biodegradable polymer
3305421|NCT00389220|Active Comparator|Cypher Select stent|Coronary stent placement with Sirolimus coated stent with durable polymer
3305422|NCT00389207|Active Comparator|NVP bid|nevirapine (NVP) 200 mg BID in combination with emtricitabine (FTC) and tenofovir DF (TDF)
3305423|NCT00389207|Experimental|NVP qd|nevirapine (NVP) 400 mg QD in combination with emtricitabine (FTC) and tenofovir DF (TDF)
3305424|NCT00389207|Active Comparator|ATZ/r|ritonavir-boosted atazanavir in combination with emtricitabine (FTC) and tenofovir DF (TDF)
3305425|NCT00389181|Experimental|Medical management|Patients with unruptured BAVMs will receive symptomatic medical management alone.
3305426|NCT00389181|Active Comparator|Interventional therapy|Patients with unruptured BAVMs will receive symptomatic medical management with invasive therapies (any combination of surgery, endovascular embolization, or radiotherapy).
3305427|NCT00389168|Experimental|Irbesartan|Irbesartan per os titrated to 300 mg od, 48 weeks
3305428|NCT00389168|Active Comparator|Atenolol|Atenolol per os titrated to 100 mg od, 48 weeks
3305429|NCT00389155|Experimental|vinflunine and gemcitabine|solution for injection, IV, vinflunine: 280/320 mg/m2 + gemcitabine: 1000 mg/m2, every 3 wks, variable duration
3305430|NCT00389155|Placebo Comparator|placebo and gemcitabine|solution for injection, IV, placebo + gemcitabine, 1000 mg/m2, every 3 wks, variable duration
3305431|NCT00389116|Experimental|1|
3305432|NCT00389116|Placebo Comparator|2|
3305433|NCT00389103|Placebo Comparator|placebo|
3305434|NCT00389090|Experimental|Temozolomide + O6BG|
3305435|NCT00389077|Experimental|Perifosine Daily Dose|Daily dose perifosine 50 mg.
3305436|NCT00389077|Experimental|Perifosine Twice Daily Dose|Twice daily dose perifosine 50 mg.
3305437|NCT00389064|Experimental|Quetapine XR|Tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily.
3305438|NCT00389064|Placebo Comparator|Placebo|Matching placebo tablets orally administered once daily.
3305439|NCT00389038|Active Comparator|Coping Skills Training + Amitriptyline|Behavioral coping skills training--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.
3305440|NCT00389038|Active Comparator|Headache Education + Amitriptyline|Behavioral headache education
3305441|NCT00388999|Other|0 mg/kg|
3305442|NCT00388999|Other|0.5 mg/kg|
3305443|NCT00388999|Other|1.0 mg/kg|
3305444|NCT00388986|Experimental|1|
3305445|NCT00388986|Experimental|2|
3305446|NCT00388986|Experimental|3|
3305447|NCT00388960|Experimental|Amrubicin|Amrubicin 45mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
3305448|NCT00388960|Experimental|Amrubicin plus Cisplatin|Amrubicin 40mg/m<2> IV days 1, 2, 3 plus cisplatin 60mg/m<2> IV day 1 of each 21-day cycle until disease progression.
3305449|NCT00388960|Active Comparator|Cisplatin plus etoposide|Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 each 21-day cycle until disease progression.
3305450|NCT00388947||1|AMS Prolapse Product (AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family)
3305451|NCT00388934|Experimental|Drug eluting stent (Cypher)|Percutaneous coronary intervention with implantation of drug eluting coronary stent (Cypher)
3305452|NCT00388934|Experimental|Drug eluting stent (Taxus)|Percutaneous coronary intervention with implantation of drug eluting coronary stent (Taxus)
3305453|NCT00388908|Experimental|A|Multifaceted intervention
3305454|NCT00388908|Active Comparator|B|Usual Care
3305455|NCT00388843||Dose Increased|Patients presenting with symptoms of coronary artery disease or stroke/suspected stroke, with carotid plaque > 1.1 mm, and whose statin dose is increased to moderate to high dose by their clinicians.
3305456|NCT00388843||Dose Maintained|Patients presenting with symptoms due to coronary artery disease or stroke/suspected stroke, with carotid plaque > 1.1 mm, on no statins or whose statin dose was unchanged by their clinicians.
3305457|NCT00388804|Active Comparator|RT Group 1|Radiation Therapy (RT) over 8 1/2 weeks: 42 treatments, 5 days per week with 2 days rest in between.
3305458|NCT00388804|Active Comparator|RT Group 2 + Hormone Therapy|Radiation Therapy over 8 1/2 weeks; + Hormone Therapy (Bicalutamide 50 mg orally/day or Flutamide 250 mg orally 3 times daily on first 21-30 Days) + Leuprolide (22.5 mg Intramuscularly (IM)/every 3 months or 7.5 mg IM monthly) or Goserelin (10.8 mg subcutaneously every 3 months or 3.6 mg subcutaneously monthly)
3305459|NCT00388726|Experimental|1|
3305460|NCT00388726|Active Comparator|2|
3305461|NCT00388700|Experimental|GM-CT-01|
3305462|NCT00388674||A|
3305463|NCT00388674||B|
3305464|NCT00388661|Active Comparator|Melatonin|melatonin 3mg
3305465|NCT00388661|Placebo Comparator|Placebo|
3305466|NCT00388609|Experimental|T|5 mg (ST) to 50 mg (LT)
3305467|NCT00388609|Experimental|U|10 mg (ST) to 50 mg (LT)
3305468|NCT00388609|Experimental|V|25 mg (ST) to 50 mg (LT)
3305469|NCT00388609|Experimental|W|50 mg (ST and LT)
3305470|NCT00388609|Experimental|X|25 mg/d (X1 wk), 5 mg/d (X11 wks) (ST) to 50 mg (LT)
3305471|NCT00388609|Experimental|Z|"Open label: 50 mg/d (X 4 wks) 100 mg/wk (X8 wks) (ST) to 50 mg (LT)~Once daily (x 4 weeks), once daily (x 8 weeks)"
3305472|NCT00388609|Placebo Comparator|Y|0 mg (ST and LT)
3305473|NCT00388583|Experimental|Fluzone Intradermal (ID) Vaccine Group|Participants received a dose of Fluzone Intradermal (ID) Influenza Vaccine
3305474|NCT00388583|Active Comparator|Fluzone Intramuscular (IM) Vaccine Group|Participants received a dose of Fluzone Intramuscular (IM) Influenza Vaccine.
3305475|NCT00388557|Experimental|1|
3305476|NCT00388544|Experimental|1|
3305477|NCT00388544|Experimental|2|
3305478|NCT00388544|Experimental|3|
3305479|NCT00388544|No Intervention|4|Recreational activities are not tailored to either style of interest or function
3305480|NCT00388518|Active Comparator|Actos|
3305481|NCT00388518|Experimental|Aleglitazar 1|
3305482|NCT00388518|Experimental|Aleglitazar 2|
3305483|NCT00388518|Experimental|Aleglitazar 3|
3305484|NCT00388518|Experimental|Aleglitazar 4|
3305485|NCT00388518|Placebo Comparator|Placebo|
3305486|NCT00388505|Experimental|Tobramycin inhalation powder (TIP)|Participants received four 28 mg capsules of tobramycin inhalation powder (TIP) delivered with the T-326 inhaler twice daily for 28 days followed by 28 days off therapy (one cycle) for a total of three cycles.
3305487|NCT00388505|Active Comparator|Tobramycin solution for inhalation (TOBI)|Participants received one 300 mg (in 5 mL) ampoule of tobramycin solution for inhalation (TOBI) delivered with a nebulizer twice daily for 28 days followed by 28 days off therapy (one cycle) for a total of three cycles.
3305488|NCT00388453|Active Comparator|1|Healthy volunteers with no history of GERD or EERD or Proton Pump Inhibitor (PPI) use
3305489|NCT00388453|Experimental|2|subject is known to have GERD based on symptoms and previous positive response to PPI
3305490|NCT00388453|Experimental|3|subject is known to have EERD based on symptoms and previous positive response to PPI
3305491|NCT00388427|Other|Advanced Solid Malignancies|
3305492|NCT00388414|Placebo Comparator|Placebo - sugar pill|
3305493|NCT00388414|Experimental|Duloxetine|
3305494|NCT00388388|Experimental|1|Losartan treatment
3305495|NCT00388388|Active Comparator|2|Hydrochlorothiazide, 12.5-25 mg per day once a day for 6 months
3305496|NCT00388375|No Intervention|CVC Internal Jugular or Subclavian Vein|
3305497|NCT00388362|Experimental|Sirolimus Therapy|Administration of Sirolimus and Prednisone
3305498|NCT00388349|Experimental|Gemcitabine + Autologous HCT|Gemcitabine and high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue. Chemotherapy includes Gemcitabine + Vinorelbine + Carmustine + Etoposide + Cyclophosphamide.
3305500|NCT00388310|Active Comparator|Cephalexin|Cephalexin 250 mg PO q6h x5 days
3305501|NCT00388310|Active Comparator|Clindamycin|Clindamycin 300 mg PO q6h x5 days
3305502|NCT00388310|Active Comparator|trimethoprim/sulfamethoxazole|trimethoprim/sulfamethoxazole 160 mg/800 mg PO q12h x 5 days
3305503|NCT00388310|Placebo Comparator|Placebo|
3305504|NCT00388297|Experimental|Levothyroxine|Levothyroxine
3305505|NCT00388297|Placebo Comparator|Placebo for Levothyroxine|Placebo for Levothyroxine
3305506|NCT00388271|Active Comparator|1|xatral
3305507|NCT00388271|Placebo Comparator|2|standard treatment
3305508|NCT00388193|Experimental|1|
3305509|NCT00388167||1|Caspofungin
3305510|NCT00388154|Experimental|Gemcitabine + Cisplatin|Gemcitabine 900 mg/m^2 by vein (IV) over 1 hour on Day 1 and Day 8. Cisplatin 30 mg/m^2 by vein over 1 hour on Day 1 and Day 8.
3305511|NCT00388141|Experimental|NIDCAP|In the intervention NIDCAP group the staff has been introduced and trained in the principles of the NIDCAP-care, where main core is to see, organize and conduct the care of the preterm infant on behalf of the childs actually resources and competences
3305512|NCT00388128|Placebo Comparator|A|
3305513|NCT00388115|Experimental|RFA prior to surgery|
3305514|NCT00388076|Experimental|Part 1|pazopanib and paclitaxel
3305515|NCT00388076|Experimental|Part 2|pazopanib, paclitaxel, and carboplatin
3305516|NCT00388076|Experimental|Part 3|pazopanib, paclitaxel, and lapatinib
3305517|NCT00388050|Experimental|Diabetes Medication Choice decision aid|Patients in this arm will discuss diabetes medication for glucose control with the help of a decision aid that covers five commonly prescribed anti-hyperglycemic medications.
3305518|NCT00388050|Other|Usual Care|Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
3305519|NCT00388037|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3305520|NCT00388024||cancer patients about to be treated with radiation therapy|Patienta with histologically confirmed squamous cell or lymphoepithelioma of oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, or unknown primary of the head and neck about to be treated with radiation therapy
3305521|NCT00388011|Experimental|1|Intranasal morphine 3.75 mg
3305522|NCT00388011|Experimental|2|Intranasal morphine 7.5 mg
3305523|NCT00388011|Experimental|3|Intranasal morphine 15 mg
3305524|NCT00388011|Experimental|4|Intranasal morphine 30 mg
3305525|NCT00388011|Active Comparator|5|Intravenous morphine 7.5 mg
3305526|NCT00388011|Placebo Comparator|6|Intranasal placebo
3305527|NCT00387998|Experimental|Risk primer|"Booklet written by investigators know your chances"
3305528|NCT00387998|Active Comparator|Control booklet|AHRQ staying healthy booklet
3305529|NCT00387959|Experimental|Unrelated Donor Umbilical Cord Transplant|Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and the Transplantation of Unrelated Donor Umbilixal Cord Blood
3305530|NCT00387933|Experimental|Gleevec + PTK787/ZK 22584 + Hydroxyurea|Patients with recurrent or relapsing glioblastoma multiforme (GBM) will be given daily doses of Gleevec and PTK787/ZK 22584 orally in combination with fixed doses of hydroxyurea.
3305531|NCT00387920|Experimental|Treatment (enzyme inhibitor therapy)|"PART A: Patients receive oral sunitinib malate once daily on days 1-28 days. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive sunitinib malate capsule contents sprinkled over applesauce or yogurt once daily on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. After the first course, patients may switch to capsule formulation for convenience."
3305532|NCT00387907|Experimental|Larotaxel + Trastuzumab|
3305533|NCT00387894|Experimental|erlotinib hydrochloride (Tarceva)|During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
3305534|NCT00387881|Placebo Comparator|Placebo|
3305535|NCT00387881|Experimental|Treximet|
3305536|NCT00387868|Other|Registration|Cisplatin, Etoposide & concurrent radiotherapy
3305537|NCT00387868|Other|Surgical Resection|No distant Progression post Registration Arm
3305538|NCT00387868|Other|Post Resection|Assessment post surgical procedure to determine if at higher risk of recurrence or if complete resection could not be achieved.
3305539|NCT00387855|Experimental|1|receive SOS program
3305540|NCT00387829|Active Comparator|1|Use of DuraGen Plus Adhesion Barrier Matrix as an adhesion barrier in the spine
3305541|NCT00387829|No Intervention|2|Control arm is surgery alone (no adhesion barrier)
3305542|NCT00387790|Experimental|Arm I|Patients receive motexafin gadolinium IV over 5-10 minutes once daily (prior to radiotherapy) 5 days a week for 6 weeks. Patients undergo focal cranial radiotherapy once daily 5 days a week for 6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3305543|NCT00387764|Experimental|pazopanib arm|This was a single arm study, therefore no control arm.
3305544|NCT00387751|Experimental|Arm I|Patients receive oral sorafenib tosylate on days 1-5, 8-12, 15-19, and 22-26 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression.
3305545|NCT00387738|Experimental|1|TOLAMBA™ dose-intense regimen
3305546|NCT00387738|Experimental|2|TOLAMBA™ lower-dose regimen
3305547|NCT00387738|Placebo Comparator|3|
3305548|NCT00387725|Experimental|Group A|20ug Experimental
3305549|NCT00387725|Experimental|Group 2|60ug Experimental
3305550|NCT00387725|Experimental|Group 3|200ug Experimental
3305551|NCT00387725|Active Comparator|Group 4|Active comparator
3305591|NCT00387387|Experimental|FOLFOX 6 + Pazopanib|Subjects will receive escalating doses of Pazopanib in combination with FOLFOX 6.
3305552|NCT00387712|Experimental|Velocity based treadmill training|6 month of progressive treadmill walking with treadmill speed gradually progressed to meet the training heart rate goals for moderate intensity aerobic exercise, when hemiparetic gait velocity can no longer be safely progressed, incline is added to achieve the heart rate training goals.
3305553|NCT00387712|Experimental|Duration based treadmill training|6 month of progressive treadmill walking with duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress.
3305554|NCT00387686|Experimental|A|1.0 mg/mL rhBMP-2/CPM + surgical fixation
3305555|NCT00387686|Experimental|B|2.0 mg/mL rhBMP-2/CPM + surgical fixation
3305556|NCT00387686|Active Comparator|C|Buffer/CPM + surgical fixation Intervention
3305557|NCT00387686|Other|D|Standard of Care: Surgical fixation intervention
3305558|NCT00387673|Experimental|Arm 1|6 weeks of upper extremity training for 3 sessions/week, as follows: a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session);
3305559|NCT00387673|Active Comparator|Arm 2|a 6-week period of 2 hours somatosensory stimulation of the hand, without training
3305560|NCT00387673|Placebo Comparator|Arm 3|a 6-week period of 2 hours sham somatosensory stimulation of the hand, followed by 1 hour of activity-based training
3305561|NCT00387660|Experimental|Metastatic SCLC|Irinotecan 200 mg/m2, every 21 days (intravenous) + Carboplatin AUC = 5 mg/ml x min (intravenous), every 21 days for 6 cycles
3305562|NCT00387660|Experimental|Relapsed SCLC|Irinotecan 150 mg/m2 (intravenous), every 21 days + Carboplatin AUC = 5 mg/ml x min (intravenous, every 21 days for 6 cycles
3305563|NCT00387647|Experimental|Azacitidine Treatment|Azacitidine 50 mg/m^2 subcutaneously daily for 5 days (Monday through Friday) on days 1 through 5, every 28 days for 6-12 cycles.
3305564|NCT00387634|Active Comparator|Arm 1|Blood draw only, no vaccine
3305565|NCT00387634|Active Comparator|Arm 2|Blood draw only, no vaccine
3305566|NCT00387634|Active Comparator|Arm 3|Blood draw only, no vaccine
3305567|NCT00387634|Active Comparator|Arm 4|Blood draw only, no vaccine
3305568|NCT00387621|Experimental|Placebo First, then Nesiritide (Arm A)|In the first intervention period the subjects received subcutaneous placebo given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered. There was a 2 week washout period. In the second intervention period, the subjects received subcutaneous nesiritide given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered.
3305569|NCT00387621|Experimental|Nesiritide First, then Placebo (Arm B)|In the first intervention period the subjects received subcutaneous nesiritide given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered. There was a 2 week washout period. In the second intervention period, the subjects received subcutaneous placebo given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered.
3305570|NCT00387582|Experimental|I|Lucentis injections for the first three months of the study and then per the protocol for the duration of the trial.
3305571|NCT00387582|Active Comparator|II|Argon Laser treatment at enrollment and then per the protocol for the duration of the study.
3305572|NCT00387569|Experimental|Cohort 1|Experimental (20ug); Active Comparator/Placebo
3305573|NCT00387569|Experimental|Cohort 2|Experimental (60ug); Active Comparator/Placebo
3305574|NCT00387569|Experimental|Cohort 3|Experimental (200ug); Active Comparator/Placebo
3305575|NCT00387556|Experimental|Ketamine + Ondansetron|ketamine 1 mg/kg IV (maximum single dose 100 mg)+ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
3305576|NCT00387556|Placebo Comparator|Ketamine + Placebo|ketamine 1 mg/kg IV (maximum single dose 100 mg)+2 ml normal saline solution IV (placebo
3305577|NCT00387478|Experimental|1|modified Tree pollen allergen absorbed to Tyrosine and containing MPL adjuvant
3305578|NCT00387478|Experimental|2|modified Tree pollen allergen absorbed to Tyrosine
3305579|NCT00387478|Placebo Comparator|Placebo|4 injections of placebo 0.5 ml (2% tyrosine)
3305580|NCT00387465|Experimental|Treatment (azacitidine, entinostat)|Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3305581|NCT00387452|Active Comparator|1|
3305582|NCT00387452|Active Comparator|2|
3305583|NCT00387452|No Intervention|3|No intervention, only testing during 6 months.
3305584|NCT00387439|Experimental|standard medical treatment|standard medical treatment
3305585|NCT00387439|Experimental|standard medical treatment + anoperineal physiotherapy|standard medical treatment + anoperineal physiotherapy
3305586|NCT00387426|Experimental|Arm I|Patients receive oral sunitinib malate once daily for 6 weeks.
3305587|NCT00387413|Experimental|Treatment Arm A1|In treatment Arm A1 Period 1 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. In treatment Arm A1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2.
3305588|NCT00387413|Experimental|Treatment Arm A2|In treatment Arm A2 Period 1 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. In treatment Arm A2 Period 2 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. There will be a washout of approximately one week between periods 1 and 2.
3305589|NCT00387413|Experimental|Treatment Arm B1|In treatment Arm B1 Period 1 subject will receive 30 milligram (mg) Duloxetine plus GSK189254 Placebo in Week 1, in Week 2 60 mg Duloxetine plus GSK189254 Placebo and in Week 3 30 mg Duloxetine plus GSK189254 Placebo. In treatment Arm B1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2.
3305590|NCT00387413|Experimental|Treatment Arm B2|In treatment Arm B2 Period 1 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. In treatment Arm B2 Period 2 subject will receive 30 milligram (mg) Duloxetine plus GSK189254 Placebo in Week 1, in Week 2 60 mg Duloxetine plus GSK189254 Placebo and in Week 3 30 mg Duloxetine plus GSK189254 Placebo. There will be a washout of approximately one week between periods 1 and 2.
3307285|NCT00366444|Placebo Comparator|2|
3305592|NCT00387387|Experimental|CapeOx + Pazopanib|Subjects will receive escalating doses of Pazopanib in combination with CapeOx. CapeOx treatment consisted of IV oxaliplatin (130 mg/m^2) on Day 1 plus oral capecitabine (1000 mg/m^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment was administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine was reduced to 850 mg/m^2 twice daily.
3305593|NCT00387374|Experimental|Stratum I (radiotherapy, bevacizumab, chemotherapy)|Patients undergo prophylactic radiotherapy on days 1-5 and 8-12. Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 15. Patients also receive paclitaxel IV over 3 hours or carboplatin IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 36 (course 2).
3305594|NCT00387374|Experimental|Stratum II (radiotherapy, chemotherapy, bevacizumab)|Patients undergo prophylactic radiotherapy and receive paclitaxel and carboplatin as in stratum I. Patients also receive bevacizumab IV over 30-90 minutes on day 15 (course 1). In both strata, treatment with paclitaxel, carboplatin, and bevacizumab repeats every 21 days for 5-6 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response or stable disease may continue to receive single-agent bevacizumab every 21 days in the absence of disease progression or unacceptable toxicity.
3305595|NCT00387361|Experimental|1|
3305596|NCT00387361|No Intervention|2|
3305597|NCT00387348|Placebo Comparator|Placebo-Placebo|Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and placebo once daily for the second 4 weeks
3305598|NCT00387348|Other|Placebo-Escitalopram|Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and escitalopram oxalate 10 mg once daily for the second 4 weeks
3305599|NCT00387348|Other|Escitalopram-Placebo|Participants in this arm were randomzied to receive escitalopram 10 mg once daily for the first 4 weeks and placebo once daily for the second 4 weeks
3305600|NCT00387335|Experimental|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3305601|NCT00387322|Experimental|Group 1|Patients receive oral erlotinib hydrochloride once on days 2, 9, and 16 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of unacceptable toxicity or disease progression
3305602|NCT00387322|Experimental|Group 2|Patients receive oral erlotinib hydrochloride once daily on days 2-16 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of unacceptable toxicity or disease progression.
3305603|NCT00387270|Experimental|A|Dimebon
3305604|NCT00387244|Active Comparator|Precision for Spinal Cord Stimulation|Single arm Precision for Spinal Cord Stimulation
3305605|NCT00387205|Experimental|Arm 1|Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
3305606|NCT00387179|Experimental|Dim Light Melatonin and/or methylxanthine|Dim Light Melatonin and/or methylxanthine
3305607|NCT00387179|Experimental|Placebo and Dim Light or bright light|Placebo and Dim Light or bright light
3305608|NCT00387179|Experimental|Bright light melatonin and/or methylxanthine|Bright light, melatonin, and/or methylxanthine
3305609|NCT00387166||1|Mexican-American women, aged 40-65
3305610|NCT00387127|Experimental|Lapatinib|1500mg lapatinib orally daily
3305611|NCT00387127|Placebo Comparator|Placebo|orally daily
3305612|NCT00387088|Other|Tiotropium|Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
3305613|NCT00387088|Other|Placebo|Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
3305614|NCT00387075|Experimental|[123I]β-CIT and SPECT imaging|To Assess [123I]β-CIT and SPECT imaging
3305615|NCT00387049|Experimental|Anxiety-specific smoking cessation care|
3305616|NCT00387049|Active Comparator|Standard smoking cessation care|
3305617|NCT00387036|Other|1|Arm 1: drug, crossing over to Pbo comparator
3305618|NCT00387036|Other|2|Arm 2: Pbo comparator, crossing over to drug
3305619|NCT00387023|Experimental|Zevalin + Rituximab|Rituximab 250 mg/m^2 intravenous (IV) over 4-6 hours for 2 weeks, + Zevalin 5 millicurie (mCi)/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
3305620|NCT00387010|Experimental|fentanyl buccal tablets|Successful dose strength for each participant was determined during a titration period of no more than 10 days. Participants used the successful dose of 100, 200, 400, 600, or 800 mcg during the four week open-label treatment period.
3305621|NCT00386971|Active Comparator|1|L-carnitine
3305622|NCT00386971|Placebo Comparator|2|Placebo
3305623|NCT00386945|Other|1|Non-Experiment Intervention consisting of an intervention based on the Clinical Practice Guideline: Treating Tobacco Use and Dependence and modified for use in chiropractic settings.
3305624|NCT00386906|Other|Sentinel Lymph Node (SLN) Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
3305625|NCT00386893|Other|Treatment as usual|simultaneous EEG/fMRI
3305626|NCT00386880||Subjects with episodic migraine with allodynia|These are subjects with episodic migraine with allodynia
3305627|NCT00386880||Subjects with episodic migraine without allodynia|Subjects with episodic migraine without allodynia
3305628|NCT00386841|Active Comparator|A Escitalopram 10 mg|Escitalopram 10 mg
3305629|NCT00386841|Placebo Comparator|Placebo|Placebo
3305630|NCT00386776|Experimental|`Computer-based medical history|A computer-based medical history to take in their homes via the Internet. The history is divided into 24 modules— family history, social history, cardiac history, pulmonary history, and the like.
3305631|NCT00386724|Active Comparator|Precision Spinal Cord Stimulation|Single arm Precision Spinal Cord Stimulation System with Artisan Surgical Lead
3305632|NCT00386672|Experimental|Lite OJ with Ca and VitD|240ml of reduced energy (lite) OJ beverage fortified with 350mg Ca and 100U VitD, 3 times per day.
3305633|NCT00386672|Active Comparator|Lite OJ without Ca and VitD|240ml of reduced energy (lite) OJ beverage, 3 times per day.
3305634|NCT00386633|Other|1|Lower dosage: 10E7_TCID50
3305635|NCT00386633|Active Comparator|2|10E8_TCID50
3305851|NCT00384059|Active Comparator|2|7-valent pneumococcal vaccine
3305636|NCT00386620||Survey + ED|"Part 1: Survey + Electronic Diaries (ED)~Part 2: 3 Month, 6 Month Survey + ED"
3305637|NCT00386607|Experimental|Core Treatment|Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combination for 52-weeks, optional addition of Hydrochlorothiazide (HCTZ) 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (mean sitting Systolic Blood Pressure ≥ 140 and/or mean sitting Diastolic Blood Pressure ≥ 90 mmHg). The dose of Hydrochlorothiazide (HCTZ) 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.
3305638|NCT00386607|Experimental|Extension Treatment|"For patients entering into extension, those previously treated with Hydrochlorothiazide (HCTZ) 12.5 or 25 mg in addition to aliskiren 300 mg/valsartan 320 mg were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 25 mg in the extension. Those patients who had not received HCTZ during the core study were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 12.5 mg.~The HCTZ 12.5 mg dose could be increased to HCTZ 25 mg if the mean sitting Systolic Blood Pressure (msSBP) was ≥140 mmHg and/or the mean sitting Diastolic Blood Pressure (msDBP) was ≥90 mmHg for 2 consecutive visits."
3305639|NCT00386542|Experimental|ID-JI-0.1|"Group ID-JI-0.1 (n = 16) - reduced 0.1 mL INF doses administered intradermally (ID) by needle-free jet injector (JI) (Biojector® 2000 subcutaneous syringe no. 2 [green color code], with 2 cm investigational spacer, Bioject Medical Technologies, Inc., Portland, OR, USA)"
3305640|NCT00386542|Active Comparator|IM-NS-0.1|"Group IM-NS-0.1 (n = 16) - reduced 0.1 mL INF doses administered intramuscularly (IM) needle-syringe (NS) (via 22-25 gauge needle, minimum 25 mm/1-inch length)"
3305641|NCT00386542|Active Comparator|IM-NS-0.25 control|"Group IM-NS-0.25 (controls) (n = 16) - full 0.25 mL INF doses administered intramuscularly (IM) by needle-syringe (NS) (22-25 gauge needle, minimum 25 mm/1-inch length)"
3305642|NCT00386516|Experimental|GM-CT-01, 5-FU|GM-CT-01 (280 mg/m2) combined with 5-FU (600 mg/m2) given 4 consecutive days in a 28 days cycle until disease progression.
3305643|NCT00386490|Experimental|Larazotide acetate 0.25 mg|larazotide acetate 0.25 mg capsule TID for 10 days
3305644|NCT00386490|Experimental|Larazotide acetate 1 mg|larazotide acetate 1 mg capsule TID for 10 days
3305645|NCT00386490|Experimental|Larazotide acetate 4 mg|larazotide acetate 4 mg capsule TID for 10 days
3305646|NCT00386490|Experimental|Placebo|Placebo capsule TID for 10 days
3305647|NCT00386477|Experimental|Vag prep|Vagina cleansed prior to performing cesarean
3305648|NCT00386425|Experimental|Standard therapy|24 microgram/kilogram/hour (mcg/kg/hr) for 24 hours, followed by 24 mcg/kg/hr for an additional 72 hours
3305649|NCT00386425|Experimental|Alternative therapy:moderate protein C deficiency|24 mcg/kg/hr for 24 hours, followed by 24 mcg/kg/hr for an additional 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)
3305650|NCT00386425|Experimental|Alternative therapy:severe protein C deficiency|24 mcg/kg/hr for 24 hours, followed by 30 or 36 mcg/kg/hr for 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)
3305651|NCT00386399|Experimental|Arm 1|Patients with BRCA2 gene will be treated with Mitomycin-C (MMC) on Day 1 at a dose of 10mg/m2 intravenously. This will be repeated every 28 days, which is one cycle. Treatment will continue until disease progression, serious toxicity, patient withdrawal or maximum cumulative dose of 60 mg/m2
3305652|NCT00386386|Other|1|Subject receives two infusions: One by EASI Access and one by IV access, at different sites
3305653|NCT00386373|Experimental|Imatinib Mesylate|
3305654|NCT00386360|Placebo Comparator|Placebo|Placebo dose
3305655|NCT00386360|Experimental|Risedronate|35 mg risedronate, orally, once weekly
3305656|NCT00386334|Placebo Comparator|Placebo|Week -2 to day 0 single blind one tablet placebo in the evening. Double blind period: Day 1 to Week 12 double blind one tablet placebo in the evening. Follow up period: two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.
3305657|NCT00386334|Experimental|Eszopiclone|Week -2 to day 0 single blind one tablet placebo in evening. Double Blind period: Day 1 to Week 12 double blind one tablet 2 mg of eszopiclone in evening. Follow up period consists of two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.
3305658|NCT00386308|Experimental|1|
3305659|NCT00386308|Placebo Comparator|2|
3305660|NCT00386282|Other|mifepristone-misoprostol treatment|200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone
3305661|NCT00386256|Experimental|Health Buddy outpatient|Received home telehealth monitoring by Health Buddy
3305662|NCT00386256|Experimental|Telephone outpatient|
3305663|NCT00386256|Experimental|health buddy inpatient|
3305664|NCT00386256|Experimental|telephone inpatient|
3305665|NCT00386243|No Intervention|Usual Care|Study subjects randomized to this arm would receive usual care from their provider(s). No study intervention is undertaken on subjects in this arm. Participants in Usual Care would complete the same four outcome assessments (surveys) throughout the course of the study that members of the intervention complete.
3305666|NCT00386243|Experimental|Stepped Care|Study subjects randomized to this arm would receive stepped care for their pain. Stepped care involves FDA-approved analgesic therapy, a 12-week pain self-management program, and if pain does not improve, a 12-week cognitive behavioral therapy program.
3305667|NCT00386230|Experimental|1|Maternal ZDV treatment starting at 35 weeks Gestational Age (GA) and continuing through labor and delivery, and three days of infant ZDV treatment starting at birth (Smother-Sinfant)
3305668|NCT00386230|Experimental|2|Maternal ZDV treatment starting at 35 weeks Gestational Age (GA) and continuing through labor and delivery, and six weeks of infant ZDV treatment starting at birth (Smother-Linfant)
3305669|NCT00386230|Experimental|3|Maternal ZDV treatment starting at 28 weeks Gestational Age (GA) and continuing through labor and delivery, and three days of infant ZDV treatment starting at birth (Lmother-Sinfant)
3305670|NCT00386230|Active Comparator|4|Maternal ZDV treatment starting at 28 weeks Gestational Age (GA) and continuing through labor and delivery, and six weeks of infant ZDV treatment starting at birth (Lmother-Linfant). This study arm was the reference regimen.
3305671|NCT00386217||Telephone Survey|90 minute Telephone survey of female cancer survivors
3305672|NCT00386191|Experimental|1|50 mg
3305673|NCT00386191|Experimental|2|75 mg
3305674|NCT00386178|Experimental|1|Vitamin E supplement rich in gamma tocopherol
3305675|NCT00386165|Experimental|Larazotide acetate|Larazotide acetate capsules: 12 mg QD x 3 days
3305676|NCT00386165|Placebo Comparator|Placebo|Placebo capsules: QD x 3 days
3305677|NCT00386152|Experimental|epoetin alfa (120,000 Units)|epoetin alfa (PROCRIT) 120,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
3305678|NCT00386152|Experimental|epoetin alfa (80,000 Units)|epoetin alfa (PROCRIT) 80,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
3305679|NCT00386152|Active Comparator|darbepoetin alfa (500 mcg)|darbepoetin alfa (ARANESP) 500 mcg injected subcutaneously the skin once every 3 weeks for up to 13 weeks
3305680|NCT00386100|Placebo Comparator|Metformin|MET began at a total daily dose of 500 mg and could be increased up to a maximum dose of MET 2000 mg. The dose level was to be increased unless a tolerability issue existed at the current dose level.
3305681|NCT00386100|Active Comparator|Avandamet (Rosiglitazone maleate/metformin hydrochloride)|AVM began at a total daily dose of 4 mg/500 mg and could be increased up to a maximum dose of AVM 8 mg/2000 mg
3305682|NCT00386048||Standard of Care Observation Group|This group is randomized to continue their current medical management strategies for pain as recommended/prescribed by health care providers. Primary and secondary outcomes are collected at the same time intervals as the biopsychosocial intervention group.
3305683|NCT00386048||Biopsychosocial Intervention Group|This group continues all standard of care procedures for managing pain and adds to this additional cognitive-behavioral treatment (CBT) strategies for managing pain. The intervention explicitly frames the CBT strategies as added, complimentary pain management methods to add to the standard of care treatment.
3305684|NCT00386035||1: DC Group|HIV infected participants who will stop or defer ART until the CD4 cell count drops below 250 cells/mm3 and who discontinue ART when CD4 cell count reaches above 350 cells/mm3. Participants are followed by episodic ART based on CD4 cell count.
3305685|NCT00386035||2: VS Group|HIV infected participants who continue ART to keep viral loads as low as possible, regardless of CD4 cell count.
3305686|NCT00386022|Experimental|Young postmenopausal women|intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
3305687|NCT00386022|Experimental|Older postmenopausal women|intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
3305688|NCT00386009|Placebo Comparator|1|Placebo
3305689|NCT00386009|Active Comparator|2|tadalafil
3305690|NCT00385996|Experimental|Erlotinib|Erlotinib 150mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
3305691|NCT00385970|Active Comparator|1|UFT+LV Group: The group treated with UFT and LV
3305692|NCT00385970|Experimental|2|UFT+PSK Group: The group treated with of UFT and PSK
3305693|NCT00385944|Experimental|Prasugrel|Open label lead-in one time dose of Clopidogrel 900 mg oral tablets (a single or cumulative dose) and 250 mg to 500 mg aspirin loading dose (LD), either orally or intravenously. Patients are then assigned to maintenance dose (MD) prasugrel 10 mg and two placebo tablets, matched to clopidogrel, and 100 mg aspirin, all taken orally once a day for 14 days. Patients cross-over to MD of clopidogrel two 75 mg tablets and one placebo matched to prasugrel and 100 mg aspirin, all taken orally once a day for the next 14 days.
3305694|NCT00385944|Active Comparator|Clopidogrel|Open label lead-in one time dose of Clopidogrel 900 mg oral tablets (a single or cumulative dose) and 250 mg to 500 mg aspirin loading dose (LD), either orally or intravenously. Patients are then assigned to maintenance dose (MD) Clopidogrel two 75 mg and one placebo tablet, matched to prasugrel, and 100 mg aspirin, all taken orally once a day for 14 days. Patients cross-over to MD of prasugrel one 10 mg tablet and two placebo tablets matched to clopidogrel and 100 mg aspirin, all taken orally once a day for the next 14 days.
3305695|NCT00385918|Experimental|Lokomat training|Subjects will receive active exercise treatment in the Lokomat device 3 times per week for 3 months. Each session will last approximately 45 minutes.
3305696|NCT00385918|Active Comparator|Home stretching then Lokomat training|Patients will participate in a home stretching program for 3 months. They will then be crossed over to an active Lokomat treatment for a subsequent 3 months.
3305697|NCT00385866|Active Comparator|Comparison Group|The control or lesser intervention group, will receive cancer screening information on a quarterly basis, with no facilitation of services.
3305698|NCT00385866|Active Comparator|Intervention group|The intervention group are those participants who were randomly assigned to receive facilitation of services in the form of patient navigation for the duration of the study.
3305699|NCT00385853|Experimental|PTK787|Single arm study of PTK787
3305700|NCT00385840|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of re-vaccination, who previously received 1 dose of the Fluarix™ vaccine in study NCT00321763, received 1 dose of Fluarix™ vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3305701|NCT00385840|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of re-vaccination, who previously received 1 dose of the GSK1247446A vaccine in study NCT00321763, received 1 dose of adjuvanted GSK1247446A vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3305702|NCT00385827|Experimental|Mitoxantrone+Prednisone+Siltuximab (CNTO 328) (Part 1)|In Part 1, mitoxantrone 12 milligram per square meter (mg/m^2) will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with siltuximab 6 mg/kilogram (mg/kg) intravenously as a 2 hour-infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year; and prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
3305703|NCT00385827|Experimental|Mitoxantrone+Prednisone+Siltuximab (Part 2)|In Part 2, mitoxantrone 12 mg/m^2 will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with siltuximab 6 mg/kg intravenously as a 2-hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year; and prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
3305852|NCT00384046|Experimental|1|300mcg/day testosterone
3307286|NCT00366379|Experimental|1|
3305704|NCT00385827|Active Comparator|Mitoxantrone+Prednisone (Part 2)|In Part 2, mitoxantrone 12 mg/m^2 will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
3305705|NCT00385801|Placebo Comparator|Placebo|Identical placebo tablets and injections
3305706|NCT00385801|Active Comparator|risperidone consta|Risperidone 1-2 mg tablets and Risperidone 25 mg injections
3305707|NCT00385788|Experimental|Gemcitabine + Fludarabine + Melphalan|Gemcitabine 800 mg/m^2 intravenous (IV) over 30 minutes for one day; Fludarabine 33 mg/m^2 IV for 4 days; Melphalan 70 mg/m^2 IV over 30 minutes for 2 days. Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation. If receiving transplant from matched unrelated donor (not blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant, infusion of stem cells on Day 0. Tacrolimus 0.03 mg/kg by vein over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.
3305708|NCT00385788|Experimental|Fludarabine + Melphalan|Fludarabine 33 mg/m^2 IV for 4 days; Melphalan 70 mg/m^2 IV over 30 minutes for 2 days. Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation. If receiving transplant from matched unrelated donor (not blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant, infusion of stem cells on Day 0. Tacrolimus 0.03 mg/kg by vein over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.
3305709|NCT00385736|Experimental|Adalimumab 80/40|
3305710|NCT00385736|Experimental|Adalimumab 160/80/40|
3305711|NCT00385736|Placebo Comparator|Placebo|
3305712|NCT00385723|Experimental|1|1.25 g/d
3305713|NCT00385723|Experimental|2|2.496 g/d
3305714|NCT00385723|Placebo Comparator|3|
3305715|NCT00385710|Experimental|valproic acid|Depakine
3305716|NCT00385710|Placebo Comparator|Placebo|Placebo
3305717|NCT00385697|Experimental|1|
3305718|NCT00385697|Experimental|2|
3305719|NCT00385697|Experimental|3|
3305720|NCT00385697|Placebo Comparator|4|
3305721|NCT00385684|Experimental|A1: hydrocodone/APAP w placebo PRN|This is a fully crossed study, each participant serves as his own control. Phase A (closed label) has two arms: A1 is the experimental and A2 is the placebo comparator. Participants are randomized to either A1 for 1 week then A2 for 1 week OR A2 for 1 week then A1 for one week. A1: hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID, with liquid placebo available PRN. A2: liquid placebo TID with hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid PRN.
3305722|NCT00385684|Placebo Comparator|A2: placebo w hydrocodone/APAP PRN|This is a fully crossed study, each participant serves as his own control. Phase A: Participants are randomized to either A1 for 1 week then A2 for 1 week OR A2 for 1 week then A1 for one week. A1: hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID, with liquid placebo available PRN. A2: liquid placebo TID with hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid PRN.
3305723|NCT00385684|Active Comparator|B: Open label hydrocodone/acetaminophen|Phase B: If tolerated study medication during Phase A (i.e., the closed label, double-blind phase of the trial) then enter a six-week, open-label phase. Participants judged as responders during Phase A continue the same dose of study medication. Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
3305724|NCT00385671|Active Comparator|Pregabalin|Pregabalin (PGB) 50 milligram (mg) three times a day (TID) (US & Germany) or 75 mg twice daily (BID) (Canada), orally (PO) for 2 weeks, then PGB 100 mg TID (US & Germany) or 150 mg BID (Canada), PO for 10 weeks.
3305725|NCT00385671|Experimental|Duloxetine|Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then DLX 60 mg QD, PO for 11 weeks.
3305726|NCT00385671|Experimental|Gabapentin + Duloxetine|Stable Gabapentin (GAB) + Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then stable GAB + DLX 60 mg QD, PO for 11 weeks.
3305727|NCT00385632||1|Participants following a drug conservation (DC) regimen in which ART was stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count was at least 350 cells/mm3, and then followed by episodic ART based on CD4 cell count
3305728|NCT00385632||2|Participants following a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count
3305729|NCT00385580|Experimental|1|
3305730|NCT00385580|Experimental|2|
3305731|NCT00385541|Active Comparator|A|Patients receive morphine 1mg/dose PCA for postsurgical pain; max 10 mg/hr; lockout 6 minutes.
3305732|NCT00385541|Active Comparator|B|Patients receive hydromorphone 0.2mg/dose PCA for postsurgical pain; max 10mg/hr; lockout 6 minutes.
3305733|NCT00385515|Experimental|1|SNX-1012 (meclocyline sulfosalicylate) tablets dissolved in water for oral swish and expectorate; 30 mg 4 times daily for 10 days
3305734|NCT00385515|Placebo Comparator|2|placebo (matched to SNX-1012) tablets dissolved in water for oral swish and expectorate; 4 times daily for 10 days
3305735|NCT00385476||Patient Medication Knowledge Tool|Assessment of Cancer patients' knowledge of their medications in an outpatient acute care setting
3305736|NCT00385450|Experimental|Nelfinavir/placebo|
3305737|NCT00385411|Experimental|valproate|
3305738|NCT00385346|Experimental|A 1|Expressive writing
3305739|NCT00385268|Experimental|1|1998mg/day for 8 weeks
3305740|NCT00385268|Placebo Comparator|2|placebo pills for 8 weeks
3305741|NCT00385242|Active Comparator|PET guided Therapy|Patients will be randomized to undergo positron emission tomography aspart of their clinical work up
3305742|NCT00385242|Active Comparator|Standard care|Patients will be randomized to standard care will under go other types of imaging or work up for revascularization without PET imaging.
3305743|NCT00385229|Experimental|Induction|induction of labor at gestational age 289(41 weeks+2 days)
3305744|NCT00385229|No Intervention|expectant management|expectant management at gestational age 289(41 weeks+2 days)
3305745|NCT00385216|Active Comparator|Nicotine nasal spray|In one sitting the subject will receive a nicotine nasal spray, 3 mg, one application.
3305746|NCT00385216|Placebo Comparator|Placebo spray|In one sitting the subject will receive a placebo nasal spray (0 mg), one application.
3305747|NCT00385177|Experimental|A|SN2310 Injectable Emulsion
3305748|NCT00385138|Experimental|Cangrelor|cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion
3305749|NCT00385138|Active Comparator|Clopidogrel|placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion
3305750|NCT00385086|Experimental|TNF-alpha blocker|Treatment with TNF-alpha blocker
3305751|NCT00385086|Active Comparator|Placebo|Treatment with placebo
3305752|NCT00385047|Experimental|Group A|FMP 2.1 50 μg FMP2.1/AS01B
3305753|NCT00385047|Experimental|Group B|FMP 2.1 50 μg FMP2.1/AS02A
3305754|NCT00385008|Other|Arm 1|open-label active drug
3305755|NCT00385008|Other|Arm 2|open-label active drug
3305756|NCT00384995|Experimental|Bicarbonate|Bicarbonate solution infusion
3305757|NCT00384995|Active Comparator|Saline|Standard volume expansion
3305758|NCT00384982|Experimental|A, B, C, D|Early or late; percutaneous intracoronary or combined (intramyocardial and intracoronary) administration of BM-MNCs
3305759|NCT00384969|Experimental|1|RAD001 and Sorafenib
3305760|NCT00384956|Experimental|Azacitidine|Azacitidine 75 mg/m2 IV on days 1-5 of each 28 day cycle. Patients that do not respond after two cycles will have the dose increased to 100 mg/m2. Patients who achieve a CR will receive 3 additional 28 day cycles and then begin treatment on days 1-5 of a 56 day cycle. Individuals who demonstrate a loss of response will resume 28 day cycles.
3305761|NCT00384930|Placebo Comparator|1|placebo tablet
3305762|NCT00384930|Active Comparator|2|2.5 mg tadalafil tablet
3305763|NCT00384930|Active Comparator|3|5 mg tadalafil tablet
3305764|NCT00384930|Active Comparator|4|10 mg tadalafil tablet
3305765|NCT00384930|Active Comparator|5|20 mg tadalafil tablet
3305766|NCT00384904|No Intervention|A1|
3305767|NCT00384904|Experimental|A2|
3305768|NCT00384904|Experimental|A3|
3305769|NCT00384904|No Intervention|B1|
3305770|NCT00384904|Experimental|B2|
3305771|NCT00384904|Experimental|B3|
3305772|NCT00384891|Experimental|Synergo + MMC|Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
3305773|NCT00384891|Active Comparator|Bacillus Calmette-Guérin|Intravesical instillation with BCG (Bacillus Calmette-Guérin)
3305774|NCT00384865|Active Comparator|Aspirin 81 mg + Simvastatin 40 mg|"Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months~Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months"
3305775|NCT00384865|Active Comparator|Aspirin 81 mg + Placebo|"Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months~Placebo taken orally, once a day for 6 months"
3305776|NCT00384865|Active Comparator|Placebo + Simvastatin 40 mg|"Placebo taken orally, once a day for 6 months~Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months"
3305777|NCT00384865|Placebo Comparator|Placebo + Placebo|"Placebo taken orally, once a day for 6 months~Placebo taken orally, once a day for 6 months"
3305778|NCT00384852|Experimental|A|1.0 mg/mL rhBMP-2/CPM + SOC
3305779|NCT00384852|Experimental|B|2.0 mg/mL rhBMP-2/CPM + SOC
3305780|NCT00384852|Active Comparator|C|Buffer/CPM + SOC
3305781|NCT00384852|Other|D|Standard of Care Alone (SOC)
3305782|NCT00384839|Experimental|1|
3305783|NCT00384826|Experimental|1|
3305784|NCT00384826|Experimental|2|
3305785|NCT00384813|Experimental|1: Home-based family intervention|Home-based family intervention
3305786|NCT00384813|Active Comparator|2: ETAU|Enhanced Treatment As Usual (1 home visit)
3305787|NCT00384787|Experimental|1|Group 1 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost intramuscularly at Month 6.
3305788|NCT00384787|Experimental|2|Group 2 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost intradermally at Month 6.
3305789|NCT00384787|Experimental|3|Group 3 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost subcutaneously at Month 6.
3305790|NCT00384748|Experimental|Tele-visit Group|TR intervention targets safe functional mobility within a home environment and consists of: 1) exercise targeting underlying stroke-related impairment and 2) adaptive strategies targeting external factors to help compensate for disability. TR uses a combination of tele-video visits, an in-home messaging device, and telephone contact over a 3-month study period. A video camera is used in the home to provide visual and audio to a therapist located at the base hospital. An interactive, in-home messaging device is used to facilitate adherence with treatment recommendations and to screen for depression, falls, and difficulty with self-care. This allows evaluations of problem areas during tele-visits, rapid response to new functional problems.
3305791|NCT00384748|Active Comparator|Usual Care Group|Patients randomized to the Usual Care group receive routine VA care, as directed by their physicians. Therapy services are tracked via a weekly diary for the entire 6 month study period. In this weekly diary, patients in both the usual care and intervention group will record receipt of therapy. Usual Care group will be asked whether they exercised, and if so how frequently. They will be administered telephone interviews at baseline, 3-and 6-months. The interview outcome measures are FONEFIM, Late-Life Function and Disability Instrument, Falls Self Efficacy Scale and Stroke Specific Patient Satisfaction with Care. In addition, sociodemographics, stroke severity, length of time since stroke onset, and depression at baseline will be measured.
3305792|NCT00384735||1A|Intensive - 3 monthly follow up
3305793|NCT00384735||1B|Intensive - 6 monthly follow up
3305794|NCT00384735||IIA|Cost Effective - 3 monthly follow up
3305795|NCT00384735||IIB|Cost Effective - 6 monthly follow up
3305853|NCT00384046|Placebo Comparator|2|Placebo arm
3305854|NCT00384033|Experimental|Desvenlafaxine succinate sustained-release 50 mg|
3305796|NCT00384696||Smoking Cessation|Treatment to help quit smoking, including written self-help materials, counseling, and 4 week supply of nicotine patch plus 5 MD Anderson Visits.
3305797|NCT00384683||Endothelial Dysfunction|Participants are scheduled for major chest (lung or esophagus) surgery or are a healthy volunteer. A blood test will quantify the number of cells that are destined to become endothelial cells.
3305798|NCT00384670|Experimental|Dengue and Japanese Encephalitis vaccine|1 mL subcutaneous injection Dengue Vaccine Formulation 17 on Day 0 and Day 60. 0.5 mL subcutaneous injection Licensed Japanese Encephalitis (JE) Vaccine on months 7 and 7.5.
3305799|NCT00384657|Experimental|Group I|iv iron sucrose
3305800|NCT00384657|No Intervention|Group II|Patients will receive conventional treatment of Chronic Heart Failure.
3305801|NCT00384644||1|sepsis, septic shock ptients
3305802|NCT00384644||2|cardiogenic shock patients
3305803|NCT00384631|Sham Comparator|2|
3305804|NCT00384631|Experimental|1|
3305805|NCT00384605|Experimental|1|Arm 1: MK0364 2 mg capsule once daily
3305806|NCT00384605|Experimental|2|Arm 2: MK0364 1 mg capsule once daily
3305807|NCT00384605|Experimental|3|Arm 3: MK0364 0.5 mg capsule once daily.
3305808|NCT00384605|Placebo Comparator|4|Arm 4: Pbo capsule once daily.
3305809|NCT00384579|Experimental|1|Botulinum Toxin B
3305810|NCT00384579|Placebo Comparator|2|Placebo
3305811|NCT00384566|Experimental|1|
3305812|NCT00384566|Active Comparator|2|
3305813|NCT00384540|Other|Cardiovascular events vs Dobutamine stress echocardiography|
3305814|NCT00384527|Experimental|1|
3305815|NCT00384527|Active Comparator|2|
3305816|NCT00384462||1|Premature Infants (32-35 wks. GA) who are less than six months of age at start of RSV season and followed until May of the following year.
3305817|NCT00384462||2|Premature newborns (32-35 wks. GA) who are born during the current RSV season and discharged from the hospital after 01 Dec and followed until May of the next year.
3305818|NCT00384397|Experimental|Group 1: Menactra® Vaccine|Participants will receive Menactra® vaccine at age 9 months and 12 months, respectively.
3305819|NCT00384397|Experimental|Group 2: Menactra® + MMRV|Participants will receive Menactra® at age 9 months followed by Menactra® and Measles-Mumps-Rubella-Varicella (MMRV) vaccines at Age 12 Months
3305820|NCT00384397|Experimental|Group 3: Menactra® + PCV|Participants will receive Menactra® at age 9 months followed by Menactra® and Pneumococcal Conjugate (PCV) vaccines at Age 12 Months
3305821|NCT00384371|Experimental|1|Botulinum Toxin A
3305822|NCT00384371|Placebo Comparator|2|Placebo
3305823|NCT00384358|Experimental|A|1.0 mg/mL rhBMP-2/CPM + surgical fixation
3305824|NCT00384358|Experimental|B|2.0 mg/mL rhBMP-2/CPM + surgical fixation
3305825|NCT00384358|Other|C|Control: Surgical fixation
3305826|NCT00384332|Experimental|Arm 1|Orally disintegrating olanzapine
3305827|NCT00384332|Experimental|Arm 2|regular olanzapine
3305828|NCT00384293|Experimental|1|MK0524A
3305829|NCT00384293|Placebo Comparator|2|placebo
3305830|NCT00384267||Neonates|Inpatient
3305831|NCT00384254|No Intervention|1|Usual Care Control: Patients receive treatment as usual
3305832|NCT00384254|Experimental|2|"5 A Intervention Condition: Patients in this condition receive all five A components (Ask, Advise, Assess, Assist, Arrange) recommended in the Clinical Practice Guideline: Treating Tobacco Use and Dependence."
3305833|NCT00384254|Experimental|3|"3 A Condition: Patients receive Ask, Advise, Arrange intervention consisting of the first two A components recommended by the Clinical Practice Guideline: Treating tobacco Use and Dependence, plus Fax-to-Quit referral to a tobacco quit line."
3305834|NCT00384241||Children|Children age 15-19, self reported as African American of European Origin, healthy non-smoker, with normal blood pressure, exposed to an activity to that results in induced stress
3305835|NCT00384241||Parents|Collection of buccal swab Parent of participants in the Children Arm
3305836|NCT00384228|Experimental|Nilotinib|
3305837|NCT00384202|Experimental|1|
3305838|NCT00384189|Active Comparator|Ciclesonide 40 µg|Placebo-matching ciclesonide, inhaled via a metered-dose inhaler (MDI) with 1,1,1,2-hydrofluoroalkane (HFA)-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 40 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
3305839|NCT00384189|Active Comparator|Ciclesonide 80 µg|Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 80 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
3305840|NCT00384189|Active Comparator|Ciclesonide 160 µg|Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 160 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
3305841|NCT00384189|Placebo Comparator|Placebo|Placebo-matching Ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 2 to 4 week in the Baseline period followed by placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
3305842|NCT00384176|Active Comparator|1|Bevacizumab + FOLFOX
3305843|NCT00384176|Experimental|2|Cediranib + FOLFOX
3305844|NCT00384137|Experimental|1|
3305845|NCT00384111|Experimental|1|R-CVP plus Zevalin Therapeutic Regimen
3305846|NCT00384111|Active Comparator|2|R-CVP
3305847|NCT00384085|Experimental|Lantus/Apidra-3|Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.
3305848|NCT00384085|Experimental|Lantus/Apidra-1|Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.
3305849|NCT00384085|Experimental|Novolog Mix 70/30|Premixed insulin (Novolog® Mix 70/30) added to oral agents.
3305850|NCT00384059|Experimental|1|13-valent pneumococcal vaccine
3305855|NCT00384033|Experimental|Desvenlafaxine succinate sustained-release 100 mg|
3305856|NCT00384033|Placebo Comparator|Placebo|
3305857|NCT00384033|Other|Duloxetine 60mg|Active control to assess assay sensitivity
3305858|NCT00383994|Experimental|Immunotherapy with NK Cell, Rituximab + GM-CSF|"Immunotherapy in Non-myeloablative Allogeneic Stem Cell Transplantation~GM-CSF = Granulocyte-Macrophage Colony-Stimulating Factor"
3305859|NCT00383942|Active Comparator|Misoprostol|Patients randomized to this arm will receive 25 micrograms of misoprostol every four hours.
3305860|NCT00383942|Experimental|EASI Catheter|Patients randomized to this arm will receive extra amniotic saline infusion (EASI) administered via catheter
3305861|NCT00383929|Experimental|1|Candesartan Cilexetil (CC) /HCT 32/12.5mg
3305862|NCT00383929|Experimental|2|Candesartan Cilexetil (CC) /HCT 32/25mg
3305863|NCT00383929|Experimental|3|Candesartan Cilexetil monotherapy
3305864|NCT00383890|Experimental|Dexmedetomidine|Dexmedetomidine 1 mcg/kg load for 10 minutes and Dexmedetomidine Maintenance (0.7 mcg/kg/hr) for 15 min
3305865|NCT00383890|Placebo Comparator|Placebo (PBO)|Placebo load for 10 min and Placebo maintenance for 15 min
3305866|NCT00383799|Active Comparator|Group 1|IV procainamide (single dose: 10 mg/kg over 20 min)
3305867|NCT00383799|Active Comparator|Group 2|IV Amiodarone (single dose: 5 mg/kg over 20 min)
3305868|NCT00383786|Experimental|GR205171|selective neurokinin-1 receptor antagonist, fixed 5 mg dose every day, for 8 weeks.
3305869|NCT00383786|Placebo Comparator|placebo|sugar pill
3305870|NCT00383760|Experimental|Treatment (eribulin mesylate)|Patients receive E7389 IV on days 1 and 8.
3305871|NCT00383747|Active Comparator|Nicotine Patch|
3305872|NCT00383747|Placebo Comparator|Placebo Nicotine Patch|
3305873|NCT00383734|Experimental|1|newfill
3305874|NCT00383734|Experimental|2|Eutrophill
3305875|NCT00383721|Experimental|MF/F MDI 400/10 mcg BID|
3305876|NCT00383721|Experimental|MF/F MDI 200/10 mcg BID|
3305877|NCT00383721|Experimental|MF MDI 400 mcg BID|
3305878|NCT00383721|Active Comparator|Formoterol MDI 10 mcg BID|
3305879|NCT00383721|Placebo Comparator|Placebo MDI BID|
3305880|NCT00383708|Experimental|1|
3305881|NCT00383669|Active Comparator|Multiple RDA multivitamins|Multivitamins (including B, C, and E)
3305882|NCT00383669|Active Comparator|Single RDA Multivitamins|Multivitamins (including B, C, and E)
3305883|NCT00383656|Experimental|Pulsatile GnRH|All participants will be administered GnRH intravenously by means of a portable infusion pump that delivers boluses at specific intervals.
3305884|NCT00383643|Placebo Comparator|Placebo|Eligible subjects randomized to this arm received placebo as gelatin capsule and a liquid capsule to fully maintain the blind.
3305885|NCT00383643|Active Comparator|Zolpidem tartrate|Eligible subjects randomized to this arm received zolpidem as gelatin capsule and a placebo liquid capsule to fully maintain the blind.
3305886|NCT00383643|Active Comparator|Sodium oxybate|Eligible subjects randomized to this arm received placebo as gelatin capsule and a sodium oxybate capsule to fully maintain the blind.
3305887|NCT00383630|Experimental|Group 1|Intramyocardial injection of bone marrow mononuclaear cells + LVAD
3305888|NCT00383630|Experimental|Group 2|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells + LVAD
3305889|NCT00383630|Other|Group 3|LVAD alone
3305890|NCT00383578|Experimental|Vildagliptin|
3305891|NCT00383578|Active Comparator|Metformin|
3305892|NCT00383565|Experimental|Arm I|Patients receive FR901228 IV over 4 hours on days 1, 8, and 15.
3305893|NCT00383552|Experimental|MF/F MDI 100/10 mcg BID|
3305894|NCT00383552|Experimental|MF MDI 100 mcg BID|
3305895|NCT00383552|Experimental|F MDI 10 mcg BID|
3305896|NCT00383552|Placebo Comparator|Placebo BID|
3305897|NCT00383539|Experimental|1|Lot 1
3305898|NCT00383539|Experimental|2|Lot 2
3305899|NCT00383539|Experimental|3|Lot 3
3305900|NCT00383539|Active Comparator|4|Control
3305901|NCT00383526|Experimental|Study Group 1|
3305902|NCT00383526|Active Comparator|Study Group 2|
3305903|NCT00383513|Experimental|Epratuzumab|
3305904|NCT00383500|Experimental|Flexitouch device|Participants will self-administer lymphedema management via daily use of the Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump)
3305905|NCT00383500|Experimental|Manual Lymphatic Drainage (MLD)|Participants will self-administer lymphedema management via daily manual lymphatic massage therapy, using a Class 1 compression garment
3305906|NCT00383500|No Intervention|Observational Control (no intervention)|Control group, no intervention. No Flexitouch or manual massage therapy
3305907|NCT00383474|Experimental|Arm I|Patients will receive an infusion of bortezomib twice a week for 2 weeks. They will also receive tipifarnib by mouth twice a day for 2 weeks.
3305908|NCT00383448|Experimental|Treated Patients|Patients receiving chemotherapy (Hydroxyurea, Alemtuzumab, Clofarabine, Melphalan), Hematopoietic Stem Cell Transplantation and radiation therapy (Total body Irradiation) mycophenylate mofetil and cyclosporine A.
3305909|NCT00383435|Experimental|MF/F MDI 400/10 mcg BID|
3305910|NCT00383435|Experimental|MF/F MDI 200/10 mcg BID|
3305911|NCT00383435|Experimental|MF MDI 400 mcg BID|
3305912|NCT00383435|Active Comparator|Formoterol MDI 10 mcg BID|
3305913|NCT00383435|Placebo Comparator|Placebo MDI BID|
3305914|NCT00383422|Experimental|1|
3305915|NCT00383422|Active Comparator|2|
3305916|NCT00383370|Experimental|ITV-1|VEGF Trap formulation 1
3305917|NCT00383370|Experimental|ITV-2|VEGF Trap formulation 2
3305918|NCT00383370|Experimental|ITV-2 OL|VEGF Trap formulation 2 open label, higher concentration
3305919|NCT00383331|Experimental|A|
3305920|NCT00383331|Experimental|B|
3305921|NCT00383292|Experimental|Tasisulam|
3305922|NCT00383266|Experimental|Pemetrexed + Carboplatin|"Pemetrexed 500 mg/m^2 IV over 10 minutes~Carboplatin AUC 5 IV over 30 minutes on day 1 of each cycle~Each cycle will last 21 days."
3305923|NCT00383253|Experimental|10%|
3305924|NCT00383253|Experimental|25%|
3305925|NCT00383253|Experimental|50%|
3305926|NCT00383253|Placebo Comparator|Control|
3305927|NCT00383240|Experimental|MF/F MDI 200/10 mcg BID|
3305928|NCT00383240|Experimental|MF MDI 200 mcg BID|
3305929|NCT00383240|Experimental|F MDI 10 mcg BID|
3305930|NCT00383240|Placebo Comparator|Placebo BID|
3305931|NCT00383214|Active Comparator|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
3305932|NCT00383214|Placebo Comparator|Placebo|Intravenous
3305933|NCT00383188|Placebo Comparator|1|
3305934|NCT00383188|Experimental|2|
3305935|NCT00383188|Experimental|3|
3305936|NCT00383188|Experimental|4|
3305937|NCT00383188|Experimental|5|
3305938|NCT00383162|Other|Combination Product - Placebo|Combination product (sumatriptan and naproxen sodium) [Attack 1] followed by placebo [Attack 2]
3305939|NCT00383162|Other|Placebo - Combination Product|Placebo [Attack 1] followed by Combination Product (sumatriptan and naproxen sodium) [Attack 2]
3305940|NCT00383149|Experimental|Ixabepilone plus Cetuximab|All participants were administered ixabepilone at a starting dose of 32 mg/m^2 as a 3-hour intravenous (IV) infusion every 3 weeks. In addition, all participants were administered an initial dose of cetuximab (400 mg/m^2 IV over 2 hours) followed by a weekly lower dose (250 mg/m^2 IV over 1 hour).
3305941|NCT00383136|Experimental|1|Tirofiban
3305942|NCT00383136|Active Comparator|2|Abciximab
3305943|NCT00383123|Experimental|Fluarix Group|"Subjects in this group received Fluarix™ and will be further stratified by 3 age groups~1:1 in 6 months to < 36 months~1:1 in 3 to < 5 years~3:1 in 5 to < 18 years"
3305944|NCT00383123|Active Comparator|Fluzone Group|"Subjects in this group received Fluzone and will be further stratified by 3 age groups~1:1 in 6 months to < 36 months~1:1 in 3 to < 5 years~3:1 in 5 to < 18 years"
3305945|NCT00383110||Group 1|Adults (age 18 or older) with type 2 diabetes.
3305946|NCT00383084|Experimental|1|Group 1 participants will take part in 30 minutes total of self-selected lifestyle physical activity throughout the day, 5 to 7 days per week. Twice a month, they will attend group sessions designed to help participants develop and maintain a more physically active lifestyle. Goal setting, self-monitoring, and pain management will be discussed at these sessions.
3305947|NCT00383084|Active Comparator|2|Group 2 participants will attend monthly fibromyalgia educational sessions, which will focus on understanding the symptoms of FM, learning to manage pain and fatigue, and developing self-help strategies.
3305948|NCT00383071|Active Comparator|Cohort 1|H5N1 vaccine - 90 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
3305949|NCT00383071|Active Comparator|Cohort 2|H5N1 vaccine - 120 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
3305950|NCT00383071|Active Comparator|Cohort 3|H5N1 vaccine - 180 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
3305951|NCT00383071|Active Comparator|Cohort 4|H5N1 vaccine - 180 mcg IM every 4 weeks x 2 doses, injection site randomized to either deltoid or gluteus Apheresis - if HAI titer above 1:160
3305952|NCT00382993|Other|Combination Product - Placebo|Combination Product (sumatriptan and naproxen sodium) [Attack 1] followed by Placebo [Attack 2]
3305953|NCT00382993|Other|Placebo - Combination Product|Placebo [Attack 1] followed by Combination Product (sumatriptan and naproxen sodium) [Attack 2]
3305954|NCT00382980|Experimental|7.5-|7.5 mcg of vaccine without adjuvant administered on Days 0 and 28.
3305955|NCT00382980|Experimental|45-|45 mcg of vaccine without adjuvant administered on Days 0 and 28.
3305956|NCT00382980|Placebo Comparator|Placebo|Placebo administered on Days 0 and 28.
3305957|NCT00382980|Experimental|15+|15 mcg of vaccine with aluminum hydroxide adjuvant administered on Days 0 and 28.
3305958|NCT00382980|Experimental|7.5+|7.5 mcg of vaccine with aluminum hydroxide adjuvant administered on Days 0 and 28.
3305959|NCT00382980|Experimental|15-|15 mcg of vaccine without adjuvant administered on Days 0 and 28.
3305960|NCT00382967|Experimental|Datscan Product|
3305961|NCT00382967|No Intervention|Control|
3305962|NCT00382954|Experimental|Phase 1 escalation|
3305963|NCT00382928|No Intervention|Standard of Care Group|Patients will receive standard of care measures in case of cardiac arrest. They will not receive AECD monitoring or intervention
3305964|NCT00382928|Experimental|AECD Monitoring + Standard of Care Group|Patients will receive AECD monitoring and intervention in addition to standard of care in case of cardiac arrest during admission to the hospital. Defibrillation of pulseless VT/VF by AECD.
3305965|NCT00382915||1|Smokers with schizophrenia
3305966|NCT00382915||2|Smokers with bipolar disorder
3305967|NCT00382915||3|Smokers without any mental illness
3305968|NCT00382863|Experimental|Treatment|HeartNet and Optimal Medical/Device Therapy (e.g., medications and cardiac resynchronisation therapy)
3305969|NCT00382863|Active Comparator|Control|Optimal Medical/Device Therapy alone (e.g., medications and/or cardiac resynchronisation therapy) (Note: For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of angiotensin converting enzyme (ACE) inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as cardiac resynchronization therapy (CRT) or cardiac resynchronization therapy-defibrillator (CRT-D) for at least three months prior to study enrollment, when indicated.)
3305970|NCT00382850|Active Comparator|open nissen fundoplication|open repair through surgical midline incision
3305971|NCT00382850|Active Comparator|laparoscopic nissen fundoplication|use of laparoscope to do repair
3305972|NCT00382811|Experimental|1|Daily Phenoxodiol + weekly carboplatin
3305973|NCT00382811|Active Comparator|2|Daily phenoxodiol placebo + weekly carboplatin
3305974|NCT00382785|Experimental|moderated online support|12-week online support led by a healthcare professional
3305975|NCT00382785|Experimental|peer-led support|12-week online support group in a peer-led format
3305976|NCT00382720|Experimental|TE (Taxotere and Eloxatin)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin). Each chemotherapy cycle was repeated every 21 days.~Participants received either the optimal or non-optimal dose for Taxotere and Eloxatin. Participants who received the optimal dose for Taxotere and Eloxatin were analyzed in this study."
3306093|NCT00381407|No Intervention|3|Participants will receive wait list condition
3306094|NCT00381381|Experimental|1|
3307287|NCT00366379|Experimental|2|
3305977|NCT00382720|Experimental|TEF (Taxotere, Eloxatin and 5-FU)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and 5-FU (5-Fluorouracil). Each chemotherapy cycle was repeated every 14 days.~Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and 5-FU. Participants who received the optimal dose for Taxotere, Eloxatin and 5-FU were analyzed in this study."
3305978|NCT00382720|Experimental|TEX (Taxotere, Eloxatin and Xeloda)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and capecitabine (Xeloda). Each chemotherapy cycle was repeated every 21 days.~Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and Xeloda. Participants who received the optimal dose for Taxotere, Eloxatin and Xeloda were analyzed in this study."
3305979|NCT00382681|Experimental|FID 107027|Contact lens solution used as instructed for 90 days.
3305980|NCT00382681|Active Comparator|ReNu MultiPlus|Contact lens solution used as instructed for 90 days.
3305981|NCT00382668||A|
3305982|NCT00382668||B|
3305983|NCT00382668||C|
3305984|NCT00382642|Experimental|Ondansetron|Arm 1 = Ondansetron 4 mcg/kg b.i.d.+ Cognitive behavioral therapy
3305985|NCT00382642|Placebo Comparator|Placebo|Arm 2 = Placebo + Cognitive behavioral therapy
3305986|NCT00382590|Active Comparator|5-Aza + VPA|5-Azacytidine (5-Aza) 75 mg/m^2 subcutaneously daily + Valproic Acid (VPA) 50 mg/m^2 orally daily, each for 7 days
3305987|NCT00382590|Active Comparator|Ara-C|Low-Dose Ara-C 20 mg twice daily subcutaneously for 10 days.
3305988|NCT00382525||Patients with Cardiac Rhythm Management device|Patients receiving a Medtronic Cardiac Rhythm Device, worldwide
3305989|NCT00382499|Experimental|Lidocaine|IV lidocaine in OR as described in methods
3305990|NCT00382473|Experimental|exercise|
3305991|NCT00382447|Experimental|1|Standard nebulizer versus standard breath actuated nebulizer
3305992|NCT00382434||EPh Present|the emergency pharmacist is present in the ED when the medical care is provided
3305993|NCT00382408|Experimental|Vaccine|Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).
3305994|NCT00382408|Placebo Comparator|Placebo|Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).
3305995|NCT00382395|Experimental|1|SOLX Gold Shunt
3305996|NCT00382395|Active Comparator|2|Control Ahmed FP7 Shunt
3305997|NCT00382382|Other|Children with Autism|A diffusion tensor imaging (DTI) will be done to examine the integrity of the white matter pathways in high functioning austistic children.
3305998|NCT00382382|Other|Healthy Volunteers|A diffusion tensor imaging (DTI) will be done to examine the integrity of the white matter pathways in healthy volunteers.
3305999|NCT00382356|Experimental|study drug|Open label, single arm
3306000|NCT00382343|Experimental|sulfamethoxazole/trimethoprim|Antibiotic prophylaxis with sulfamethoxazole/trimethoprim [1-2 mg/kg trimethoprim and 5-10 mg/kg sulfamethoxazole once daily]; in case of intolerance (leucopoenia) and for children younger than 6 months: nitrofurantoin [2 mg/kg once daily]
3306001|NCT00382343|No Intervention|No prophylaxis|
3306002|NCT00382291|Experimental|Regular Titration|Regular titration of Sertraline plus cognitive behavioral therapy. The titration schedule used a flexible upward titration from 25 mg/day to 200 mg/day over 9 weeks unless higher doses were not tolerated, after which the dosage was adjusted as a function of tolerability. If tolerated, maximum dose could be achieved in 5 weeks.
3306003|NCT00382291|Placebo Comparator|Placebo|Placebo plus cognitive behavioral therapy
3306004|NCT00382291|Experimental|Slow Titration|Slow titration of Sertraline plus cognitive behavior therapy. The titration schedule utilized a slower titration schedule relative to the RegSert arm. Unless unable to tolerate higher doses, children remained on 25mg/day for the first two weeks, 50mg/day from weeks 3-4, 75mg/day for weeks 5-6, 100mg/day for week 7, 150mg/day for week 8, and 200mg/day for week 9 until the end of the study.
3306005|NCT00382265|Active Comparator|1|Tamsulosin 0.4mg PO
3306006|NCT00382265|Placebo Comparator|2|Placebo
3306007|NCT00382239|Experimental|Exenatide 5 mcg/exenatide 10 mcg|
3306008|NCT00382239|Experimental|Exenatide 5 mcg/exenatide 5 mcg|
3306009|NCT00382239|Experimental|Exenatide 2.5 mcg/exenatide 2.5 mcg|
3306010|NCT00382239|Placebo Comparator|Placebo/placebo|
3306011|NCT00382200|Experimental|Decitabine and All-Trans Retonoic Acid (Tretinoin)|Decitabine and All-Trans Retonoic Acid (Tretinoin)
3306012|NCT00382187|Experimental|MF59 adjuvant H5N1 influenza vaccine 7.5 micrograms|
3306013|NCT00382187|Experimental|MF59 adjuvant H5N1 influenza vaccine 15 micrograms|
3306014|NCT00382187|Experimental|non-adjuvanted influenza vaccine 15 micrograms of H5N1 antigen|
3306015|NCT00382174|Placebo Comparator|1|0.00% thymosin beta 4 w/w administered topically once daily for up to 84 days
3306016|NCT00382174|Active Comparator|2|3 doses of thymosin beta 4: 0.01% w/w, 0.02% w/w, and 0.1% w/w, administered topically once daily for up to 84 days
3306017|NCT00382148|Experimental|1|
3306018|NCT00382135|Placebo Comparator|1|placebo tablet
3306019|NCT00382135|Active Comparator|2|20 mg tadalafil tablet
3306020|NCT00382109|Experimental|Tacro-MTX/Sirolimus GVHD Prophylaxis Regimen|Preparative regimen of total body irradiation (TBI) 200 cGy BID days -8,-7, & -6, Thiotepa IV (dose 5 mg/kg/day on days -5 & -4) & cyclophosphamide IV (dose 60 mg/kg/day on days -3 & -2). Tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily on day -2 with a taper starting on day 42 - day 98 (patients undergoing matched sibling donor transplantation) OR tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily beginning on day -2 followed by a taper on day 100 through day 180 (patients undergoing other related, unrelated, or cord blood donor transplantation) in the absence of GVHD. Patients also receive methotrexate IV (5 mg/m2/dose) on days 1,3, & 6 (patients with matched sibling and umbilical cord blood donors) OR days 1,3 6, & 11 (patients with other related/unrelated bone marrow and peripheral blood stem cell donors) and oral sirolimus (dose 2.5mg/m2/day - 4 mg max starting dose) daily starting on day 0 followed by a taper starting on day 180 through day 207.
3306088|NCT00381485|Active Comparator|MF MDI 400 mcg BID|"Mometasone Furoate 400 mcg taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
3306089|NCT00381420|Experimental|1|sirolimus-coated Bx Velocity stent
3306090|NCT00381420|Active Comparator|2|uncoated Bx Velocity stent
3306021|NCT00382109|Active Comparator|Tacro-MTX GVHD Prophylaxis|Preparative regimen of total body irradiation (TBI) 200 cGy BID days -8,-7, & -6, Thiotepa IV (dose 5 mg/kg/day on days -5 & -4) & cyclophosphamide IV (dose 60 mg/kg/day on days -3 & -2). Tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally (when able) daily on day -2 with a taper starting on day 42 - day 98 (patients undergoing matched sibling donor transplantation) OR tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily beginning on day -2 followed by a taper on day 100 through day 180 (patients undergoing other related, unrelated, or cord blood donor transplantation) in the absence of GVHD. Patients also receive methotrexate IV (5 mg/m2/dose) on days 1,3, & 6 (patients with matched sibling and umbilical cord blood donors) OR days 1,3 6, & 11 (patients with other related/unrelated bone marrow and peripheral blood stem cell donors).
3306022|NCT00382096|Experimental|Vildagliptin + Metformin Dose 1|
3306023|NCT00382096|Experimental|Vildagliptin + Metformin Dose 2|
3306024|NCT00382096|Active Comparator|Vildagliptin|
3306025|NCT00382096|Active Comparator|Metformin|
3306026|NCT00382070|Experimental|Group 2 Letrozole|Patients receive oral letrozole once daily for up to 5 years.
3306027|NCT00382070|Placebo Comparator|Group 1 Placebo|Patients receive oral placebo once daily for up to 5 years.
3306028|NCT00382031|Active Comparator|zalutumumab|Zalutumumab in combination with Best Supportive Care
3306029|NCT00382031|Other|Control|Best Supportive Care
3306030|NCT00382018|Active Comparator|Group 1|Patients continue to receive regular treatment without change at the discretion of the physician. Patients are eligible for other first-line chemotherapy trials. No further blood is collected.
3306031|NCT00382018|Experimental|Group 2|Patients continue to receive their current chemotherapy regimen without change.
3306032|NCT00382018|Active Comparator|Group 3, Arm I|Patients continue with their current chemotherapy regimen without change.
3306033|NCT00382018|Experimental|Group 3, Arm II|Patients switch to a different chemotherapy regimen. Selection of a new chemotherapy regimen is made by the patient's doctor.
3306034|NCT00381979|Experimental|1|set
3306035|NCT00381966|Experimental|Robotic placement device|The intervention involves use of a robotic template to assist in placement of needles for prostate brachytherapy.
3306036|NCT00381953|Active Comparator|360 PEG IFN|360 mug peginterferon alfa-2a QW
3306037|NCT00381953|Active Comparator|9 MU + 180 PEG IFN|9 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
3306038|NCT00381953|Active Comparator|4,5 MU IFN + 180 PEG IFN|4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
3306039|NCT00381940|Experimental|Treatment (enzyme inhibitor therapy, chemotherapy)|"Patients receive ifosfamide IV continuously over days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, bortezomib IV on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy."
3306040|NCT00381914|Experimental|1|400 IU / day vitamin D
3306041|NCT00381914|Experimental|2|800 IU / day vitamin D
3306042|NCT00381914|Experimental|3|1200 IU / day vitamin D
3306043|NCT00381888|Experimental|Patients Treated with Fondaparinux|Patients treated with at least one dose of Fondaparinux (2.5 mg subcutaneous, Days 1-28 by mouth).
3306044|NCT00381862|Experimental|Aprepitant and Palonosetron|
3306045|NCT00381849|Active Comparator|Cystone then sugar pill|Subject will take Cystone for 6 weeks, then have a 1 week wash out period followed by the sugar pill for another 6 weeks
3306046|NCT00381849|Placebo Comparator|Sugar pill then Cystone|Subject will take sugar pill for 6 weeks, then a 1 week wash out followed by the Cystone for another 6 weeks
3306047|NCT00381849|Experimental|Open-label Cystone|All subjects will receive Cystone for 46 weeks in the open-label period.
3306048|NCT00381810|Experimental|Rituximab 1000 mg|Participants will receive rituximab 1000 mg intravenously twice, 14 days apart at study entry and again 6 months later. Participants will also receive methylprednisolone 100 or 125 mg IV, acetaminophen 1000 mg orally, and diphenhydramine 50 mg orally prior to study drug infusion.
3306049|NCT00381797|Experimental|Arm I|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and irinotecan hydrochloride IV over 90 minutes on day 16 or 17 for course 1. Patients receive bevacizumab and irinotecan hydrochloride on days 1 and 15 for all subsequent courses. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo MRIs of the brain, magnetic resonance perfusion/diffusion, and fludeoxyglucose F 18 positron emission tomography at baseline and periodically during treatment."
3306050|NCT00381784|Experimental|Community PROMISE|Community PROMISE is a community level HIV/STD prevention program that relies on role model stories and peer advocates from the community. Sites will adapt PROMISE for local use remaining faithful to the core elements.
3306051|NCT00381784|Experimental|Mpowerment|MPowerment is a community level HIV/STD prevention program that relies on peer advocates from the community to lead outreach activities including discussion groups (Mgroups), venue-based outreach, social events and a publicity campaign. Sites will adapt MPowerment for local use remaining faithful to the core elements.
3306052|NCT00381771||Objective salivary function|"Based on the salivary scintigraphy,~Objective salivary normo-function~Objective salivary dysfunction"
3306053|NCT00381732|Placebo Comparator|1|placebo tablet
3306054|NCT00381732|Active Comparator|2|2.5 mg tadalafil tablet
3306055|NCT00381732|Active Comparator|3|5 mg tadalafil tablet
3306056|NCT00381719|Experimental|1|3 mg
3306057|NCT00381719|Experimental|2|20 mg
3306058|NCT00381719|Experimental|3|60 mg
3306059|NCT00381719|Placebo Comparator|4|Placebo
3306060|NCT00381706|Experimental|Arm A (ECF + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab IV on days 1, 8 and 15. Patients receive epirubicin 50 mg/m^2 IV after cetuximab on day 1 followed by cisplatin 60 mg/m^2 IV over 60 minutes. On days 1-21, patients receive 5-fluorouracil 200 mg/m^2/day continuous IV infusion. Treatment repeats every 21 days in the absence of disease progression and unacceptable toxicity.
3306735|NCT00373113|Experimental|B|37.5 mg daily, continuous dosing
3306061|NCT00381706|Experimental|Arm B (IC + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab on days 1, 8 and 15. Patients receive cisplatin 30 mg/m^2 IV over 30 minutes on days 1 and 8 after cetuximab. Patients also receive irinotecan 65 mg/m^2 IV over 90 minutes on days 1 and 8 after receiving cisplatin.Treatment repeats every 21 days in the absence of disease progression and unacceptable toxicity.
3306062|NCT00381706|Experimental|ARM C (FOLFOX + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab on days 1 and 8. On Day 1, patients also receive oxaliplatin 85 mg/m^2 IV over 120 minutes and leucovorin 400 mg/m^2 IV over 120 minutes either concurrently with oxaliplatin via a separate infusion line or post oxaliplatin administration. Following leucovorin, patients will receive 5-fluorouracil 400 mg/m^2 IV bolus injection, then 5-fluorouracil 2400 mg/m^2 IV infusion over 46-48 hours. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
3306063|NCT00381680|Active Comparator|Regimen A: Standard vincristine dosing|See detailed description.
3306064|NCT00381680|Experimental|Arm B: Randomized High Dose Vincristine regimen|See detailed description. Closed to accrual as of 09/2010).
3306065|NCT00381667|Experimental|GW642444M 12.5|
3306066|NCT00381667|Experimental|GW642444M 100mcg|
3306067|NCT00381667|Experimental|GW642444M 400mcg|
3306068|NCT00381667|Experimental|GW642444H 100mcg|
3306069|NCT00381667|Experimental|Placebo|
3306070|NCT00381654|Experimental|A|Daily oral administration of AV-412
3306071|NCT00381641|Experimental|Sunitinib malate-Radioactive Iodine Refractory Subgroup|"Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity~This arm contains results for the Radioactive Iodine Refractory Thyroid Cancer Subgroup"
3306072|NCT00381641|Experimental|Sunitinib malate-Metastatic Medullary Subgroup|"Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity~This arm contains results for the Metastatic Medullary Thyroid Cancer Subgroup"
3306073|NCT00381628||Stable subjects with CF|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro.
3306074|NCT00381628||Exacerbating subjects with CF|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) at the beginning and end of treatment for a pulmonary exacerbation. These cells will be studied in vitro.
3306075|NCT00381628||Stable subjects with asthma|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro. This is the disease control group.
3306076|NCT00381628||Healthy volunteers|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro. This is the control group
3306077|NCT00381615|Experimental|rMenB|"Infants received 4 doses of recombinant meningococcal serogroup B (rMenB) vaccine without outer membrane vesicle (OMV-NZ) at 2, 4, 6 and 12 months of age.~Infants also received routine vaccines - 3 doses each of Diphtheria Tetanus Pertussis-Haemophilus influenzae type b-Inactivated Polio Vaccine (DTaP-Hib-IPV) (at 2, 3, and 4 months) and Heptavalent Pneumococcal Conjugate (PC7) (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and Measles Mumps Rubella (MMR) (at 13 months)."
3306078|NCT00381615|Experimental|rMenB+OMV|"Infants received 4 doses of rMenB vaccine with OMV-NZ at 2, 4, 6 and 12 months of age.~Infants also received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months)."
3306079|NCT00381615|Experimental|Routine|"Infants received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months).~Infants also received single dose of rMenB vaccine without OMV-NZ at 12 months of age."
3306080|NCT00381615|Experimental|Routine+OMV|"Infants received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months).~Infants also received single dose of rMenB vaccine with OMV-NZ at 12 months of age."
3306081|NCT00381589|Experimental|A|Random assignment to investigational spray
3306082|NCT00381576|Experimental|A|12 weeks of resistance training
3306083|NCT00381563|Other|Intervention to placebo|Participants will wear the patellofemoral realigning knee brace for 6 weeks, followed by the non-aligning knee brace for 6 weeks.
3306084|NCT00381563|Other|Placebo to intervetion|Participants will wear the non-aligning knee brace for 6 weeks, followed by the patellofemoral realigning knee brace for 6 weeks.
3306085|NCT00381550|Experimental|Arm I|Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3306086|NCT00381485|Experimental|MF/F MDI 400/10 mcg BID|"Mometasone Furoate 400 mcg and formoterol 10 mcg fixed dose combination taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
3306087|NCT00381485|Experimental|MF/F MDI 200/10 mcg BID|"Mometasone Furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
3306091|NCT00381407|Experimental|1|Participants will receive organizational skills training program
3306092|NCT00381407|Experimental|2|Participants will receive contingency management program
3306095|NCT00381342|Experimental|Exenatide 5 mcg/exenatide 5 mcg|Exenatide 5 mcg; then exenatide 5 mcg
3306096|NCT00381342|Experimental|Exenatide 5 mcg/exenatide 10 mcg|Exenatide 5 mcg, then exenatide 10 mcg
3306097|NCT00381342|Placebo Comparator|Placebo|Placebo in volumes equivalent to exenatide
3306098|NCT00381329|Active Comparator|1|Motivational Interviewing (MI)
3306099|NCT00381329|Active Comparator|2|Structured Brief Advice (SBA)
3306100|NCT00381316|Active Comparator|1|Thallous Chloride T1-201
3306101|NCT00381316|Active Comparator|2|Technetium Tc99m Tetrofosmin injections
3306102|NCT00381303|Experimental|001|darunavir 600mg bid for 48 wks,ritonavir 100mg bid for 48 wks
3306103|NCT00381290|Active Comparator|1|Participants will follow an exercise regimen
3306104|NCT00381290|Active Comparator|2|Participants will follow a calorie-restricted diet
3306105|NCT00381290|Active Comparator|3|Participants will follow a calorie-restricted diet and an exercise regimen
3306106|NCT00381238|Experimental|rosiglitazone|Extended Release Tablets
3306107|NCT00381225|Experimental|Ultra-sound guided radio-frequency ablation|
3306108|NCT00381212|Experimental|1|AGS-004 immunotherapeutic injections.
3306109|NCT00381173|Experimental|1|
3306110|NCT00381160|Experimental|1|Provision of non-caloric beverages to home
3306111|NCT00381160|No Intervention|2|
3306112|NCT00381121||Kidney disease cohort|Individuals with a clinically indicated biopsy are recruited and/or surplus tissue that remains from past clinical interventions is obtained.
3306113|NCT00381108|Experimental|Pomegranate Tablet|
3306114|NCT00381108|Placebo Comparator|Placebo Tablet|
3306115|NCT00381095|Experimental|1|flexible dosing
3306116|NCT00381095|Placebo Comparator|2|
3306117|NCT00381043|Active Comparator|1- Acamprosate|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
3306118|NCT00381043|Placebo Comparator|2 - Sugar Pill - Placebo|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
3306119|NCT00381004|Experimental|FCR + Sargramostim|Fludarabine + Cyclophosphamide + Rituximab (FCR) = Fludarabine - Course 1: 25 mg/m^2 IV Days 2-4; Course 2-6: 25 mg/m^2 IV Days 1-3. Cyclophosphamide - Course 1: 250 mg/m^2 intravenous (IV) Days 2-4; Course 2-6: 250 mg/m^2 Days 1-3. Rituximab - Course 1: 375 mg/m^2 IV over 2-6 hours Day 1; Course 2-6: 500 mg/m^2 IV Day 1. Sargramostim - Course 1: 250 mcg/m^2 subcutaneous (SQ) Days -1 and 5-11; Course 2-6: 250 mcg/m^2 SQ Days -1 and 4-10.
3306120|NCT00380978|Active Comparator|early analgesia:combined-spinal epidural|
3306121|NCT00380978|Active Comparator|late analgesia (systemic)|
3306122|NCT00380874|Experimental|1|flexible dosing
3306123|NCT00380874|Placebo Comparator|2|
3306124|NCT00380861|Active Comparator|PFC Sigma RP-F|PFC® Sigma™ RP-F knee implant is a posterior stabilized cemented component cemented that is implanted with a standard posterior stabilized surgical technique.
3306125|NCT00380861|Active Comparator|PFC Sigma RP|P.F.C.® Sigma™ Rotating Platform (RP) Cruciate Retaining Knee System has a special insert that helps the knee move more like it did before the knee replacement.
3306126|NCT00380809|Active Comparator|Rotational Atherectomy + PES|Elective lesion preparation with rotational atherectomy priot to stent implantation
3306127|NCT00380809|Active Comparator|Standard Treatment (PES without Rotational Atherectomy)|Stenting without prior rotational atherectomy, usually preceeded with balloon dilatation
3306128|NCT00380796||Cohort 1|
3306129|NCT00380770|Experimental|HAART alone|Arm 1. HAART These patients will be given one tablet twice daily of Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
3306130|NCT00380770|Active Comparator|Combination HAART and chemotherapy|Arm 2. CTX PLUS HAART. HAART will be given as above. In addition, CTX will be administered at 2 weekly intervals in the Oncology Dept at KEH VIII Hospital and will consist of:- Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
3306131|NCT00380757|Active Comparator|CPR 30:2|30 chest compressions to 2 ventilations
3306132|NCT00380757|Active Comparator|CPR 15:2|15 chest compressions to 2 ventilations
3306133|NCT00380744|Experimental|A|"Part A:2X Loading dose, then 0.1mg/kg/wk X 4wks, IV~Part B:2X Loading dose, then 0.02mg/kg/wk X 4wks, IV"
3306134|NCT00380744|Experimental|B|"Part A:2X Loading dose, then 0.3mg/kg/wk X 4wks, IV~Part B:2X Loading dose, then 0.15mg/kg/wk X 4wks, IV"
3306135|NCT00380744|Experimental|C|"Part A: 2X Loading dose, then 1.0mg/kg/wk X 4wks, IV~Part B: 2X Loading dose, then 1.0mg/kg/wk X 4wks, IV"
3306136|NCT00380744|Experimental|D|"Part A:2X Loading dose, then 2.5mg/kg/wk X 4wks, IV~Part B:2X Loading dose, then 2.5mg/kg/wk X 4wks, IV"
3306137|NCT00380744|Placebo Comparator|E|IV, QD, 4 weeks
3306138|NCT00380731|Experimental|1|Participants will receive immediate cognitive behavioral therapy
3306139|NCT00380731|Experimental|2|Participants will receive cognitive behavioral therapy with a 16-week delayed start
3306140|NCT00380718|Experimental|Pemetrexed|
3306141|NCT00380692|Experimental|Atomoxetine|atomoxetine 0.5 mg/kg/day every day (QD), by mouth (PO) for 1 week, atomoxetine 0.8mg/kg/day QD, PO for 1 week, 1.2mg/kg/day QD, PO for 6 weeks then atomoxetine 0.5-1.2 mg/kg/day QD, PO for up to 20 weeks
3306142|NCT00380692|Placebo Comparator|Placebo|"placebo every day (QD), by mouth (PO) for 8 weeks~Then patients can take atomoxetine 0.5-1.2 mg/kg/day QD, PO up to 20 weeks"
3306143|NCT00380640|Experimental|1|
3306144|NCT00380640|Experimental|2|
3306145|NCT00380601|Experimental|1|
3306146|NCT00380588|Experimental|Gemcitabine + Cisplatin|"Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.~Cisplatin: 25 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal."
3306206|NCT00379821|Experimental|CQ plus azithromycin|N=160: treat with CQ plus azithromycin.
3306147|NCT00380588|Experimental|Gemcitabine|Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1,8 and 15 every 28 days x 12 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.
3306148|NCT00380562|Experimental|Volunteer|High intensity volunteering (15 hours a week or greater) in Baltimore City Schools with children in grades K-3
3306149|NCT00380562|No Intervention|Control|Usual activities
3306150|NCT00380549|Active Comparator|CONSERVE® A-Class THA BFH|CONSERVE® A-Class Total Hip with BFH technology
3306151|NCT00380536|Experimental|1|Participants will participate in peer-led medical illness self-management group sessions.
3306152|NCT00380536|No Intervention|2|Participants will receive treatment as usual.
3306153|NCT00380497|Experimental|Pico-Salax|
3306154|NCT00380497|Active Comparator|PEGlyte|
3306155|NCT00380484|Experimental|1|Budesonide
3306156|NCT00380484|Active Comparator|2|Montelukast
3306157|NCT00380419|Experimental|1|Participants will receive 16 sessions of interpersonal psychotherapy
3306158|NCT00380406|Placebo Comparator|Placebo|Placebo
3306159|NCT00380406|Active Comparator|depot GnRHa (Leuprolide acetate (LA) 11.25 mg intramuscularly)|
3306160|NCT00380393|Experimental|GSK257049 Group|Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of GSK257049 vaccine administered intramuscularly in the left deltoid muscle at Days 0, 30 and 60.
3306161|NCT00380393|Active Comparator|Rabipur Group|Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine administered intramuscularly in the left deltoid muscle at Days 0, 30 and 60.
3306162|NCT00380367|Experimental|Quadrivalent HPV VLP Vaccine (Types 6, 11, 16, 18)|Participants who enroll receive a total of 3 intramuscular injections of Quadrivalent HPV VLP vaccine (types 6, 11, 16, 18) given on Day 1, Month 2 and Month 6.
3306163|NCT00380276|Other|Open Label Arm|Treatment is open-label
3306164|NCT00380250|Experimental|Lubiprostone|8 mcg capsule twice daily (BID)
3306165|NCT00380250|Placebo Comparator|Placebo|Matching placebo capsule twice daily (BID)
3306166|NCT00380237|Experimental|1|Two vaccinations with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops. The second vaccination will be given 4 to 12 weeks after the first.
3306167|NCT00380185||1|Subjects with no hemodynamically significant disease (NHSD) of the coronary or peripheral arteries
3306168|NCT00380185||2|Subjects with coronary artery disease only
3306169|NCT00380185||3|Subjects with both coronary artery disease and peripheral arterial disease
3306170|NCT00380146|Experimental|SP plus artesunate|SP (Fansidar®, Roche South Africa) at a dose of 25/1.25mg/kg of sulfadoxine/pyrimethamine respectively on day 0 only, and artesunate (Arsumax®, Sanofi-Aventis, South Africa) at a dose of 4mg/kg on days 0, 1, and 2
3306171|NCT00380133|Experimental|Randomised, double-blind, five-way crossover|A randomised, double-blind, double-dummy, placebo-controlled, five-way crossover study to assess the effects of single oral doses of SB-681323 (7.5 mg and 25 mg) and prednisolone (10 mg and 30 mg) on biomarkers in induced sputum and blood in COPD patients.
3306172|NCT00380120|Experimental|1|Tailoring the duration of anticoagulation according to the ultrasound persistence of residual vein thrombosis
3306173|NCT00380120|Active Comparator|2|Administering a fixed duration of anticoagulation (i.e., discontinue it at the time of randomization in patients with secondary DVT, and prolong it for 3 additional months in patients with idiopathic DVT)
3306174|NCT00380081|Experimental|placebo/zolpidem 3.5/zolpidem 1.75|
3306175|NCT00380081|Experimental|placebo/zolpidem 1.75/zolpidem 3.5|
3306176|NCT00380081|Experimental|zolpidem 3.5/placebo/zolpidem 1.75|
3306177|NCT00380081|Experimental|zolpidem 3.5/zolpidem 1.75/placebo|
3306178|NCT00380081|Experimental|zolpidem 1.75/placebo/zolpidem 3.5|
3306179|NCT00380081|Experimental|zolpidem 1.75/zolpidem 3.5/placebo|
3306180|NCT00380068|Experimental|Ambrisentan|
3306181|NCT00380055|Experimental|Screening Navigation|Individuals without a study cancer who receive services of a navigator.
3306182|NCT00380055|Experimental|Treatment Navigation|Individuals with a study cancer who receive navigation services.
3306183|NCT00380055|Active Comparator|Screening Education|Rather than receiving navigation, these participants receive general cancer education appropriate to Medicare enrollees.
3306184|NCT00380055|Active Comparator|Treatment Education|Rather than receiving navigation services, these participants receive cancer education appropriate to Medicare recipients.
3306185|NCT00380042|Active Comparator|Active Stimulation|
3306186|NCT00380042|Sham Comparator|Sham|
3306187|NCT00380029|Experimental|Erlotinib|erlotinib given before and after transurethral resection of a bladder tumor, TURBT
3306188|NCT00379990|Experimental|GW274150 60 mg once daily for 28 days|60 mg GW274150 taken once daily for 28 days
3306189|NCT00379990|Active Comparator|Prednisolone 7.5 mg once daily for 28 days|7.5 mg prednisolone taken once daily for 28 days
3306190|NCT00379990|Placebo Comparator|Placebo once daily for 28 days|Placebo taken once daily for 28 days
3306191|NCT00379951|Experimental|1|Arm 1: ertapenem sodium
3306192|NCT00379938|Experimental|1|25 micrograms + MF59 (n=26)
3306193|NCT00379938|Experimental|3|2.5 micrograms + MF59 (n=26)
3306194|NCT00379938|Placebo Comparator|4|saline (n=11)
3306195|NCT00379938|Experimental|2|25 micrograms alone (n=26)
3306196|NCT00379925|Experimental|Behavioral|Participants will take part in the Physical Activity and Dietary Health Promotion Program.
3306197|NCT00379912|Experimental|Investigational Arm A|Azacitidine + Erythropoietin
3306198|NCT00379912|Experimental|Investigational Arm B|Azacitidine
3306199|NCT00379899|Active Comparator|Control|Standard of care, without use of cinacalcet.
3306200|NCT00379847|Experimental|1|Lower dose
3306201|NCT00379847|Experimental|2|Higher dose
3306202|NCT00379834|Active Comparator|Cosopt|Cosopt twice daily in both eyes
3306203|NCT00379821|Experimental|CQ Monotherapy|N=160: treat with Chloroquine (CQ) alone.
3306204|NCT00379821|Experimental|CQ plus atovaquone proguanil|N=160: treat with CQ plus atovaquone proguanil.
3306205|NCT00379821|Experimental|CQ plus artesunate|N=160: treat with CQ plus artesunate.
3306207|NCT00379808|Placebo Comparator|Placebo|1 lactose-containing capsule daily for 1 month
3306208|NCT00379808|Active Comparator|Montelukast 10 mg|1 montelukast 10 mg tablet (masked by capsule) daily for 1 month
3306209|NCT00379795|Experimental|Ranibizumad 0.5 mg|Ranibizumab 0.5 mg intravitreal injection 0.5 mg in the study eye on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment.
3306210|NCT00379769|Experimental|rosiglitazone in addition to background metformin|Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
3306211|NCT00379769|Experimental|rosiglitazone in addition to background sulfonylurea|Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
3306212|NCT00379769|Active Comparator|Sulfonylurea in addition to background metformin|Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.
3306213|NCT00379769|Active Comparator|Metformin in addition to background sulfonylurea|Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
3306214|NCT00379756|Active Comparator|Levitra|10mg x 4 weeks, with option to increase to 20mg aat that time if desired
3306215|NCT00379756|Placebo Comparator|placebo|
3306216|NCT00379743|Active Comparator|2|Individuals randomized to this arm receive the following interventions: 1) educational materials on recommended cancer-preventive services, plus 2) a health coordinator (patient navigator) who helps the participant schedule and keep appointments for cancer screening and/or treatment.
3306217|NCT00379678||Information not available|
3306218|NCT00379665|Experimental|Cisplatin|1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
3306219|NCT00379652|Active Comparator|A|Patient-based intervention
3306220|NCT00379652|Active Comparator|B|Health center-based intervention
3306221|NCT00379652|Active Comparator|C|Combination of patient and health center-based intervention
3306222|NCT00379652|No Intervention|D|Control group: Neither patient-based nor center-based intervention
3306223|NCT00379639|Experimental|Romidepsin / Gemcitabine|Participants were to receive 7, 10 or 12 mg/m^2 of romidepsin intravenously on either Days 1, 8 and 15 (Schedule A) or Days 1 and 15 (Schedule B) of each 28-day cycle, followed by 800 or 1000 mg/m^2 of gemcitabine. Subsequent doses of both drugs were based on treatment-related toxicities. The planned duration of study therapy was 6 cycles or until disease progression occurred. Patients who responded could continue beyond 6 cycles until disease progression or until a withdrawal criterion was met.
3306224|NCT00379626|Experimental|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
3306225|NCT00379613|Placebo Comparator|1|rocuronium + 16.0 mg/kg Org 25969
3306226|NCT00379613|Experimental|2|rocuronium + 2.0 mg/kg Org 25969
3306227|NCT00379613|Experimental|3|rocuronium + 4.0 mg/kg Org 25969
3306228|NCT00379613|Experimental|4|rocuronium + 8.0 mg/kg Org 25969
3306229|NCT00379613|Experimental|5|rocuronium + 12.0 mg/kg Org 25969
3306230|NCT00379574|Experimental|Bortezomib + CHOP every 2 weeks|Bortezomib + CHOP(Cycloophosphamide, vincristine, doxorubicin,and predinisolone) every 2 weeks
3306231|NCT00379548|No Intervention|1|Control group- subjects are on the Asian diet for the entire duration of the study
3306232|NCT00379548|Experimental|2|Asian and Caucasian subjects switch from an Asian Diet to a Western Diet midway through the study.
3306233|NCT00379535|Experimental|1|Daily dose of 200 µg of potassium iodide
3306234|NCT00379535|Placebo Comparator|2|Daily dose of placebo
3306235|NCT00379522|Active Comparator|Vasopressin|Vasopressin, 10 I.U./4 ml, Solution for Injection
3306236|NCT00379522|Placebo Comparator|Saline|Saline placebo 4 ml, Solution for Injection
3306237|NCT00379509|Experimental|GW572016|
3306238|NCT00379483|Experimental|Arm 1|
3306239|NCT00379470|Active Comparator|Best Standard of Care|Patients randomized to the BSC group will be treated with one chemotherapy according to the BSC practiced at each center.
3306240|NCT00379470|Experimental|NovoTTF-100A|
3306241|NCT00379431|Experimental|Administration of rituximab and methylprednisolone|
3306242|NCT00379405|Experimental|A|Saquinavir (Invirase): 2 capsules (500 mg) / 12 hours
3306243|NCT00379405|No Intervention|2|IP o NNUCS + 2 NUCS as a HAART therapy .
3306244|NCT00379392|Experimental|Mental Imagery and CIT|Mental Imagery and Constraint Induced Therapy
3306245|NCT00379392|Active Comparator|Mental Imagery only|Mental Imagery only
3306246|NCT00379366|Active Comparator|1|14 Gy ionizing radiations
3306247|NCT00379366|No Intervention|2|
3306248|NCT00379353|Active Comparator|Group 1: Thalidomide|100 mg capsules orally, once a day for 14 days
3306249|NCT00379353|Placebo Comparator|Group 2: Placebo|Two placebo capsules orally, once a day for 14 days.
3306250|NCT00379340|Experimental|Stage IV and rapid complete response (RCR) of lung metastases|Stage IV and rapid complete response (RCR) of lung metastases continuously treated with DD4A after 6 weeks of DD4A
3306251|NCT00379340|Experimental|Stage IV and slow incomplete response (SIR) of lung metastases|Stage IV and slow incomplete response (SIR) of lung metastases treated with Regimen M after 6 weeks of DD4A
3306252|NCT00379340|Other|Stage III/IV with LOH 1p and 16q treated with Regimen M|Stage III/IV with LOH 1p and 16q treated with Regimen M
3306253|NCT00379340|Other|Stage IV with non-lung disease treated with Regimen M|Stage IV with non-lung disease treated with Regimen M
3306330|NCT00378378|Experimental|MFNS 100 mcg BID for subjects 6 to less than 12 years|
3306254|NCT00379340|Other|Stage IV with lung metastases|Stage IV with lung metastases treated with DD4A for less than 6 weeks and/or response inevaluable at week 6
3306255|NCT00379327|Experimental|Real Accupuncture|Acupuncture with a real needle that punctures the skin versus acupuncture needle that does not puncture the skin.
3306256|NCT00379327|Placebo Comparator|Non-puncturing Acupuncture|Acupuncture needle that touches but does not puncture the skin
3306257|NCT00379301|Active Comparator|Group 1|Pulmonary vein isolation (PVI) combined with ablation of documented non-PV triggers of atrial fibrillation --- (sites away from the pulmonary veins where consistent abnormal impulses that can trigger AF are identified during the procedure)
3306258|NCT00379301|Active Comparator|Group 2|PVI combined with ablation at documented sites of non-PV triggers, PLUS ablation at sites where non-PV triggers are commonly found
3306259|NCT00379301|Active Comparator|Group 3|PVI combined with ablation at documented sites of non-PV triggers and ablation at sites in the left atrium that demonstrate disorganized electrical impulses called complex fractionated electrograms (CFE).
3306260|NCT00379288|Experimental|MF/F 200/10 mcg BID|
3306261|NCT00379288|Experimental|MF/F 400/10 mcg BID|
3306262|NCT00379288|Active Comparator|F/SC 250/50 mcg BID|
3306263|NCT00379288|Active Comparator|F/SC 500/50 mcg BID|
3306264|NCT00379262|Experimental|1A|Concurrent-Adjuvant CRT using P-PF regimen and conventional fractionation radiotherapy
3306265|NCT00379262|Experimental|1B|Concurrent-Adjuvant CRT using P-PF regimen and accelerated fractionation radiotherapy
3306266|NCT00379262|Experimental|2A|Induction-Concurrent CRT using PF-P regimen and conventional fractionation radiotherapy
3306267|NCT00379262|Experimental|2B|Induction-Concurrent CRT using PF-P regimen and accelerated fractionation radiotherapy
3306268|NCT00379262|Experimental|3A|Induction-Concurrent CRT using PX-P regimen and conventional fractionation radiotherapy
3306269|NCT00379262|Experimental|3B|Induction-Concurrent CRT using PX-P regimen and accelerated fractionation radiotherapy
3306270|NCT00379236|Experimental|EUFLEXXA™ Double-blind|Each subject received 3 single-dose injections of EUFLEXXA™ into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
3306271|NCT00379236|Placebo Comparator|Placebo Double-blind|Each subject received 3 single-dose injections of placebo into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
3306272|NCT00379236|Experimental|EUFLEXXA™ Open Label|All patients who participated in the 26 week double-blind study (including participants randomized to the placebo treatment group) and elected to participate in the open label extension, received three injections of EUFLEXXA™ in the target knee. Injections were given once a week on weeks 26, 27 and 28.
3306273|NCT00379223|No Intervention|1|Standard treatment of central retinal vein occlusion : the rheologic correction
3306274|NCT00379223|Experimental|2|Standard treatment of central retinal vein occlusion : the rheologic correction and surgery associating pars plana vitrectomy and radial optic neurotomy
3306275|NCT00379210|Experimental|1|"Meditation training group-- received Mindfulness Based Stress Management from the Penn Program for Stress Management.~The meditation practice initially emphasized attention to a single focus. For most concentrative exercises, this focus was the breath. The sensations of breathing were to be examined closely, and when attention wandered it was to be redirected back to the breath. In other exercises, the focus of attention was to be directed to sensations within specific body parts (body scan exercise) and sensations of walking (walking meditation). During the 5th week of classes, the mindfulness training was expanded to include some explicit training in receptive attention."
3306276|NCT00379210|Active Comparator|2|"Nutrition education group~An active comparison condition involving nutrition education was offered. This course matched the mindfulness course in all dimensions including course duration, homework, psychosocial support, and teacher expertise. The course was taught by a nurse who had expertise in nutrition and offered a program described in the book, Nutrition for Life by Lisa Hark."
3306277|NCT00379197|Experimental|Naltrexone|Naltrexone 50 mg will be taken orally once a day every day of a 28 day treatment course (cycle 1) and continue for another identical 28 day treatment (cycle 2) . PET scan will be performed after cycle 1 and cycle 2 complete.
3306278|NCT00379184||A|Osteoarthritis patients scheduled for Total Knee Arthroplasty.
3306279|NCT00379184||B|Osteoarthritis patients not scheduled for Total Knee Arthroplasty.
3306280|NCT00379184||C|Healthy volunteers
3306281|NCT00379145|Experimental|Trabectedin|Trabectedin IV over 24 hours every 3 weeks
3306282|NCT00379106|Active Comparator|Group1|
3306283|NCT00379106|Experimental|Group 2|
3306284|NCT00379080|Experimental|Arm I - Feasibility|"Patients receive oral tandutinib twice daily for 7 days. Patients then undergo biopsy or surgery to remove the tumor. Within 2 weeks after biopsy or surgery, patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~conventional surgery~oral tandutinib~Pharmacological study~Tissue samples"
3306285|NCT00379080|Experimental|Arm 2 - Dose Escalation (Phase 1)|"Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.~the starting dose for tandtinib is 500mg BID~oral tandutinib~Pharmacological study~Tissue samples"
3306286|NCT00379080|Experimental|Arm 3 - Phase 2|"Patients receive tandutinib as in phase I at the MTD determined in phase I.~600mg was the determined MTD in Dose Escalation~oral tandutinib~Pharmacological study~Tissue samples"
3306287|NCT00379067|Active Comparator|1|Tamsulosin OCAS tablet
3306288|NCT00379067|Placebo Comparator|2|Placebo tablet
3306331|NCT00378378|Placebo Comparator|Placebo BID for subjects 6 to less than 12 years|
3306332|NCT00378378|Placebo Comparator|Placebo BID for subjects 12 to less than 18 years|
3306333|NCT00378365|Experimental|1|Arsenic trioxide
3306334|NCT00378352|Placebo Comparator|Dose Escalation Safety|The objective of the first phase is to evaluate the safety of escalating doses of Epoetin alfa in patients with STEMIs.
3306383|NCT00377663|Experimental|1|Participants will use the AsthmaNet web site.
3306289|NCT00379015|Experimental|HER2 over-expressing primary breast cancer group|"Patients receive epirubicin hydrochloride and cyclophosphamide in week 1-3. Treatment with epirubicin hydrochloride and cyclophosphamide repeats every 3 weeks for 4 courses. Patients then receive docetaxel in week 13 and trastuzumab (Herceptin®) in weeks 13-15. Treatment with docetaxel and trastuzumab repeats every 3 weeks for 4 courses.~Patients then undergo appropriate surgery. After surgery, patients with hormone receptor-positive disease receive trastuzumab once weekly and either tamoxifen with or without a luteinizing hormone-releasing hormone agonist or an aromatase inhibitor. Treatment continues for 40 weeks."
3306290|NCT00378989|Active Comparator|Intervention|A letter with personal feedback of the results of a health risk appraisal and invitation to a consultation at the occupational health services.
3306291|NCT00378989|No Intervention|Control|Care as usual
3306292|NCT00378976|Experimental|1|
3306293|NCT00378976|Placebo Comparator|2|
3306294|NCT00378950|Active Comparator|1|Participants will receive a 1-hour education session about CHF, symptom recognition, diet, exercise, and daily check ups.
3306295|NCT00378950|Experimental|2|Participants will receive a 1-hour education session about CHF, symptom recognition, diet, exercise, and daily check ups, as well as additional information on diuretic self adjustment. This group will then get several follow-up phone calls over the course of the year to reinforce these topics and help them master the knowledge and encourage behavior and lifestyle changes to align with these topics.
3306296|NCT00378911|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3306297|NCT00378898|Active Comparator|EGD with proximal BRAVO capsule|Subjects have a second BRAVO capsule placed 10cm proximal to prior BRAVO capsule placement. Fluoroscopy is used to confirm detachment of the monitor 7 days after investigational deployment.
3306298|NCT00378898|Sham Comparator|EGD with sham BRAVO capsule placement|Subjects have a EGD with BRAVO delivery introducer positioned 10cm proximal to prior BRAVO capsule placement with no BRAVO placed.
3306299|NCT00378781|Experimental|Arm I|Minocycline hydrochloride + Edetate Calcium Disodium (M-EDTA) flush solution into CVC once daily.
3306300|NCT00378781|Experimental|Arm II|Heparin flush solution into CVC once daily.
3306301|NCT00378729|Active Comparator|A|
3306302|NCT00378729|Active Comparator|B|
3306303|NCT00378716|Active Comparator|Group 1|5-FU + Leucovorin
3306304|NCT00378716|Experimental|Group 2|Uracil/Ftorarur + leucovorin
3306305|NCT00378703|Active Comparator|Arm A (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15.
3306306|NCT00378703|Experimental|Arm B (bevacizumab and temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and bevacizumab as in Arm A.
3306307|NCT00378703|Experimental|Arm C (bevacizumab and sorafenib tosylate)|Patients receive bevacizumab as in Arm A and sorafenib tosylate PO BID on days 1-5, 8-12, 15-19, and 22-26.
3306308|NCT00378703|Experimental|Arm D (sorafenib tosylate and temsirolimus)|Patients receive sorafenib tosylate PO BID on days 1-28 and temsirolimus as in Arm B.
3306309|NCT00378690|Active Comparator|Continuous Androgen Deprivation (CAD)|
3306310|NCT00378690|Experimental|Intermittent Androgen Deprivation (IAD)|
3306311|NCT00378664|Experimental|Intervention|All enrollees are included in the intervention - lumbar to sacral ventral nerve re-routing procedure surgical nerve re-routing procedure.
3306312|NCT00378612|Experimental|Cypher® sirolimus eluting coronary stent|All pts were given the Cypher sirolimus eluting coronary stent in this open-label, single-arm, non-randomized trial
3306313|NCT00378599|Experimental|PEG-Intron plus Rebetol (RBV)|PEG-Intron plus RBV treatment for up to 48 weeks with 24-week follow up. SCH 54031 PEG-Intron 1.5 ug/kg SC per week plus SCH 18908 REBETOL twice daily (BID) PO with food, dosed as followed: Weeks 1 and 2, RBV Dose 400 mg (2 capsules, 1 AM and 1 PM). At the end of Weeks 2 and 4 of Treatment (tx), a complete blood count (CBC) was performed. An increase in RBV dose was permitted only if the hemoglobin was >10 g/dL. At Weeks 3 and 4, RBV dose was 800 mg (4 capsules, 2 AM and 2 PM). From Weeks 5 to 48, RBV doses could be increased based on subject body weight. For subjects weighing <65 kg, maximum dose of RBV was to be 800 mg (4 capsules, 2 AM and 2 PM), for subjects weighing 65-85 kg, max dose of RBV was 1000 mg/day (5 capsules, 2 AM and 3 PM), for subjects weighing >85 kg, max dose of RBV was 1200 mg/day, 6 capsules, 3 AM and 3 PM).
3306314|NCT00378573|Experimental|docetaxel, gemcitabine and bevacizumab|Single arm treatment with docetaxel, gemcitabine and bevacizumab
3306315|NCT00378560|Placebo Comparator|1|Placebo
3306316|NCT00378560|Experimental|2|Vaccine
3306317|NCT00378547|Placebo Comparator|Paracetamol|Oral paracetamol 1 g + placebo + placebo
3306318|NCT00378547|Experimental|Paracetamol + Pregabalin|Oral paracetamol 1g + oral pregabalin 300 mg + placebo
3306319|NCT00378547|Experimental|Paracetamol + pregabalin + dexamethasone|Oral paracetamol 1g + oral pregabalin 300 mg + IV dexamethasone 8 mg
3306320|NCT00378534|Experimental|Miltenyi reagent system|"The protocol will evaluate survival at day +200 in subjects with hematological malignancies receiving myeloablative conditioning regimen of cyclophosphamidem fludarabine and total body irradiation followed by an infusion of a stem cell prodict prepared using the Miltenyi CliniMacs system for CD34 selection and a delayed T cell depletion add back as donor lymphocyte infusion (DLI) at day 90.~The objective is to determine the overall survival rate at day +200 following allogeneic peripheral blood stem cell allotransplantation (PBSCT)"
3306321|NCT00378508|Experimental|1|The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2 over a 14 day treatment period.
3306322|NCT00378508|Placebo Comparator|2|Normal saline infusion
3306323|NCT00378482|Experimental|1|Drug: CP-675,206 (Tremelimumab)
3306324|NCT00378404|Experimental|1|
3306325|NCT00378378|Experimental|MFNS 100 mcg QD for subjects 6 to less than 12 years|Mometasone Furoate nasal Spray (MFNS) 100 mcg once per day (QD) for subjects 6 to less than 12 years of age
3306326|NCT00378378|Placebo Comparator|Placebo QD for subjects 6 to less than 12 years|
3306327|NCT00378378|Experimental|MFNS 200 mcg QD for subjects 12 to less than 18 years|
3306328|NCT00378378|Experimental|MFNS 200 mcg BID for subjects 12 to less than 18 years|
3306329|NCT00378378|Placebo Comparator|Placebo QD for subjects 12 to less than 18 years|
3306645|NCT00374244|Placebo Comparator|1|placebo pimozide
3306335|NCT00378352|Placebo Comparator|Single Dose Efficacy|Single parenteral administration of 60000 U of epoetin alfa. The objectives of the second phase are to investigate the effects of the highest safe dose on infarct size, left ventricular remodeling and endothelial progenitor cells.
3306336|NCT00378326|Experimental|Tacrolimus|Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
3306337|NCT00378248|Experimental|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group- and individual psychotherapy
3306338|NCT00378248|Active Comparator|Outpatient individual psychotherapy|Eclectic individual psychotherapy in outpatient private practice
3306339|NCT00378209|Experimental|lenalidomide, dexamethasone, bortezomib combination|Participants took the study medication in the clinic on Cycle 1 day 1. Each treatment cycle lasted three weeks. They took the lenalidomide (capsules) every day for the first two weeks only (days 1-14). They took the dexamethasone (tablets) on Day 1, 2, 4, 5, 8, 9, 11 and 12 and came to the outpatient treatment center for intravenous bortezomib on Day 1, 4, 8 and 11. The third week of the cycle was a rest period and the participant did not take any study medication.
3306340|NCT00378196|Experimental|A|0.3 mg/0.05 ml dose of ranibizumab
3306341|NCT00378196|Experimental|B|0.5 mg /0.05 ml dose of ranibizumab
3306342|NCT00378144|Experimental|1|Pseudoephedrine/Paracetamol
3306343|NCT00378131|Placebo Comparator|1|
3306344|NCT00378131|Experimental|2|RC-1291 50mg
3306345|NCT00378131|Experimental|3|RC-1291 100mg
3306346|NCT00378105|Experimental|lenalidomide, dexamethasone, bortezomib combination|In this study each cycle will be 21 days and participants will begin the study medication in the clinic on Cycle 1 Day 1. Lenalidomide (capsules) will be taken daily for the first 2 weeks only (Day 1-14). Dexamethasone (tablets) will be taken on Day 1, 2, 4, 5, 8, 9, 11 and 12. Bortezomib will be given intravenously in the outpatient treatment clinic on Day 1, 4, 8 and 11. The third week is a rest period and no study medication will be given.
3306347|NCT00378092|Experimental|Risperidone Long-Acting Injection (RLAI) (Period 1)|Participants will receive 25 milligram (mg) to 50 mg of RLAI intramuscularly (into the muscle) which will be tapered and discontinued over a period of up to 6 weeks. Participants will be followed-up until their first disease relapse or maximum of 36 months.
3306348|NCT00378092|Experimental|Oral risperidone and RLAI (Period 2)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus (a muscle) for up to 24 months. Supplementation with oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injections becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
3306349|NCT00378079|Experimental|3|
3306350|NCT00378079|Active Comparator|1|
3306351|NCT00378079|Experimental|2|
3306352|NCT00378066|Active Comparator|Bevacizumab|Bevacizumab, capecitabine and oxaliplatin for metastatic colorectal cancer, 1st line treatment
3306353|NCT00378027||Stable Acute Pulmonary Embolism|Administer weight dosed Fondaparinux
3306354|NCT00378014|Experimental|Everolimus|Basiliximab plus everolimus-based immunosuppressive regimen following the reduction and cessation of initial CNI regimen plus optional steroids according to local best practice
3306355|NCT00378014|Active Comparator|Calcineurin Inhibitor (CNI)|Basiliximab plus CNI-based immunosuppressive regimen according to local best practice plus optional steroids according to local best practice
3306356|NCT00377988||001|Transdermal Contraceptive System In each 4-week period exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
3306357|NCT00377988||002|Norgestimate-containing oral contraceptives with EE NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days then no pill or a drug-free pill 7 days.
3306358|NCT00377962|Experimental|Everolimus + CNI reduction|Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level < 75 ng/mL or a tacrolimus trough level < 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice.
3306359|NCT00377962|Active Comparator|Control|CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.
3306360|NCT00377936|Active Comparator|1|Gemcitabine
3306361|NCT00377936|Experimental|2|EndoTag-1 + Gemcitabine
3306362|NCT00377936|Experimental|3|EndoTag-1 + Gemcitabine
3306363|NCT00377936|Experimental|4|EndoTag-1 + Gemcitabine
3306364|NCT00377910|Active Comparator|1, drug|Injections of polidocanol
3306365|NCT00377910|Placebo Comparator|2 drug|injections of lidocaine
3306366|NCT00377871|Active Comparator|1|Valve design 1
3306367|NCT00377871|Active Comparator|2|Valve design 2
3306368|NCT00377871|No Intervention|Control|Healthy control
3306369|NCT00377858|Experimental|Insulin Lispro Mid Mixture|Insulin lispro mid mixture (MM) up to three times a day (TID)
3306370|NCT00377858|Active Comparator|Insulin Glargine|Insulin glargine daily with insulin lispro at mealtime (up to 3 injections) as needed.
3306371|NCT00377832|No Intervention|1|
3306372|NCT00377832|Active Comparator|2|Acetaminophen 975 mg once
3306373|NCT00377819|Experimental|denosumab|
3306374|NCT00377819|Active Comparator|alendronate|
3306375|NCT00377793|Experimental|Arm 1|
3306376|NCT00377793|Placebo Comparator|Arm 2|
3306377|NCT00377780|Experimental|1|Myocet + docetaxel + trastuzumab
3306378|NCT00377741|Experimental|1|
3306379|NCT00377715|Experimental|Dimebon|Dimebon 20 mg three times a day x 26 weeks
3306380|NCT00377715|Placebo Comparator|Placebo|Placebo 20 mg three times a day x 26 weeks
3306381|NCT00377676|Experimental|Usual Diabetes Therapy plus placebo|Usual diabetes therapy plus placebo
3306382|NCT00377676|Experimental|Drug Cycloset|
3306384|NCT00377663|No Intervention|2|Participants will not use the AsthmaNet Web site.
3306385|NCT00377637|Experimental|Induction Phase: Mycophenolate mofetil|Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24 weeks of the Induction Phase.
3306386|NCT00377637|Active Comparator|Induction Phase: Cyclophosphamide|Participants received monthly infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.
3306387|NCT00377637|Experimental|Maintenance Phase: Mycophenolate mofetil|Participants received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.
3306388|NCT00377637|Active Comparator|Maintenance Phase: Azathioprine|Participants received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.
3306389|NCT00377598|Experimental|TAK-583 5 mg QD|
3306390|NCT00377598|Experimental|TAK-583 25 mg QD|
3306391|NCT00377598|Experimental|TAK-583 50 mg QD|
3306392|NCT00377598|Experimental|TAK-583 100 mg QD|
3306393|NCT00377598|Placebo Comparator|Placebo QD|
3306394|NCT00377572|Experimental|Omalizumab (Xolair) + Conventional Therapy|Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.
3306395|NCT00377572|Placebo Comparator|Placebo + Conventional Therapy|Placebo was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.
3306396|NCT00377559|Experimental|1.|Myocet+docetaxel
3306397|NCT00377520|Experimental|Pemetrexed|
3306398|NCT00377507|Experimental|catechin|mask containing catechins
3306399|NCT00377481|Experimental|1|
3306400|NCT00377481|Active Comparator|2|
3306401|NCT00377455|Experimental|Bosentan|
3306402|NCT00377455|Placebo Comparator|Placebo|
3306403|NCT00377442|Experimental|1|
3306404|NCT00377442|Experimental|2|
3306405|NCT00377442|Experimental|3|
3306406|NCT00377429|Experimental|catumaxomab|
3306407|NCT00377416|Experimental|1|rAAV2-CB-hAAT Gene Vector
3306408|NCT00377403|Experimental|Intervention Arm|Amoxicillin 500mg three times a day (tid) for 10 days in addition to symptomatic treatments
3306409|NCT00377403|Placebo Comparator|Symptomatic treatments only|Placebo for 10 days in addition to symptomatic treatments
3306410|NCT00377390||Cockroach sensitive|
3306411|NCT00377390||Control (cockroach insensitive)|
3306412|NCT00377364|Experimental|Acetaminophen|Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days.
3306413|NCT00377364|Placebo Comparator|Placebo|Participants will be given an identical appearing placebo (two 500 mg tablets) four times daily for 7 days.
3306414|NCT00377325|Experimental|1|Participants will receive full dose cyclosporin.
3306415|NCT00377325|Experimental|2|Participants will receive active drug full dose until cleared, then one dose every 4 days.
3306416|NCT00377325|Placebo Comparator|3|Participants will receive active drug full dose until clear, then full dose every 4 days with placebo on the intervening days.
3306417|NCT00377312|Experimental|Group 1|Parathyroid Hormone (PTH) (1-34) 2 picomols/kg/hr for one week.
3306418|NCT00377312|Experimental|Group 2|Parathyroid Hormone (PTH) (1-34)4 picomols/kg/hr for one week.
3306419|NCT00377299|Experimental|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
3306420|NCT00377299|Placebo Comparator|Placebo|Placebo matching active medication.
3306421|NCT00377286|Placebo Comparator|2|1500 mg of lite lemonade
3306422|NCT00377286|Active Comparator|1|1500 mg glucosamine in 16 oz lite lemonade 1 time daily for 6 months
3306423|NCT00377260|Experimental|Amoxicillin-clavulanate|Reconstituted amoxicillin-clavulanate at 90/6.4 mg/kg/day in 2 divided doses for 10 days.
3306424|NCT00377260|Placebo Comparator|Placebo|Reconstituted placebo in 2 divided doses for 10 days.
3306425|NCT00377247|Experimental|Dendritic Cells w/Tumor DNA|
3306426|NCT00377234|Experimental|1|
3306427|NCT00377234|Active Comparator|2|
3306428|NCT00377208|Active Comparator|Intervention Condition|Receives web-based feedback specific to their blood-pressure and other health-related conditions.
3306429|NCT00377208|No Intervention|Control Condition|The control group receives preventative feedback, general to the population.
3306430|NCT00377195|Experimental|1|
3306431|NCT00377182|Active Comparator|PEGASYS with COPEGUS|
3306432|NCT00377182|Experimental|RO5024048 1500mg in combination with PEGASYS|
3306433|NCT00377182|Experimental|RO5024048 3000mg in combination with PEGASYS|
3306434|NCT00377182|Experimental|RO5024048 in combination with PEGASYS and COPEGUS|
3306435|NCT00377156|Active Comparator|Arm I|Patients undergo stereotactic radiosurgery (SRS)
3306436|NCT00377156|Experimental|Arm II|Patients undergo SRS as in arm I. Within 14 days, patients then undergo whole-brain radiotherapy 5 days a week for 2.5 weeks.
3306437|NCT00377130|No Intervention|Arm I- Usual psychological care|Usual psychological care- no intervention
3306438|NCT00377130|Experimental|Self administered Stress Management|Self-Administered Stress Management Training Plus Usual Psychosocial Care
3306439|NCT00377104|Experimental|Treatment (chemotherapy)|Patients receive alvocidib IV over 30 minutes (loading dose), followed by alvocidib IV over 4 hours on days 1, 8, and 15. Treatment repeats every 5 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
3306440|NCT00377026|Experimental|lifestyle|participants receive lifestyle intervention
3306441|NCT00376961|Experimental|R-CHOP + Velcade|6 21-day cycles of standard R-CHOP with 1.3 mg/m^2 Bortezomib given on days 1 and 4 of each cycle. This is followed by 8 3-month cycles of maintenance with 1.3 mg/m^2 Bortezomib on days 1, 4, 8 and 11 of each cycle.
3306442|NCT00376948|Experimental|Novasoy®, Gemcitabine & Erlotinib|Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, & 15; Erlotinib 150 mg day 1 until day 28
3306443|NCT00376935|Placebo Comparator|1|Participants will receive palifermin placebo injection on Days 1, 2, and 3
3306444|NCT00376935|Experimental|2|Participants will receive palifermin 20 mcg/kg injection on Days 1, 2, and 3
3306445|NCT00376935|Experimental|3|Participants will receive palifermin 40 mcg/kg injection on Days 1, 2, and 3
3306446|NCT00376935|Experimental|4|Participants will receive palifermin 60 mcg/kg injection on Days 1, 2, and 3
3306447|NCT00376922|No Intervention|usual care|
3306448|NCT00376922|Experimental|Music therapy|
3306449|NCT00376909|Experimental|Intervention|Series of telephone support calls from a trained prevention care manager
3306450|NCT00376909|No Intervention|Usual Care|Usual care
3306451|NCT00376896|Experimental|GW876008 20mcg|GW876008 20mcg
3306452|NCT00376896|Experimental|GW876008 200mcg|GW876008 200mcg
3306453|NCT00376896|Placebo Comparator|Placebo|Placebo
3306454|NCT00376870|Active Comparator|Pioglitazone|Pioglitazone 30mg/d
3306455|NCT00376870|Placebo Comparator|Placebo|
3306456|NCT00376844|Active Comparator|External Beam Radiation Therapy|Postoperative pelvic radiotherapy
3306457|NCT00376844|Experimental|Vaginal Brachytherapy|Postoperative vaginal brachytherapy
3306458|NCT00376831|Active Comparator|0|fentanyl
3306459|NCT00376831|Active Comparator|1|ketamine
3306460|NCT00376805|Experimental|All Treated Patients|All patients with advanced metastatic breast cancer treated with natural killer cells after receiving fludarabine, cyclosphosphamide and total body irradiation.
3306461|NCT00376740|Experimental|Immediate zoledronic acid|Patients on this arm will receive zoledronic acid every 6 months during 2.5 years of letrozole therapy starting within 3 months of the start of letrozole therapy. (5 doses of zoledronic acid)
3306462|NCT00376740|Active Comparator|Delayed zoledronic acid|Patients on this arm will receive zoledronic acid during the 2.5 years of letrozole treatment only after the T-score on bone mineral density testing falls below minus 2.0.
3306463|NCT00376727|Experimental|Phase I dose escalation study|
3306464|NCT00376701|Experimental|1|Reduced fluence PDT plus intravitreal Kenalog (2 mg) plus intravitreal Avastin 1.25 mg
3306465|NCT00376701|Experimental|2|Reduced fluence PDT plus intravitreal Avastin
3306466|NCT00376701|Experimental|3|Intravitreal Avastin and sham reduced fluence PDT
3306467|NCT00376688|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3306468|NCT00376675|Experimental|Arm I|Patients receive oral methylphenidate hydrochloride daily on days 1-28.
3306469|NCT00376675|Placebo Comparator|Arm II|Patients receive oral placebo daily on days 1-28.
3306470|NCT00376597|Experimental|Arm I (lymphedema education)|Six weeks after surgery, patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction and written materials. Patients complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months. Patients are also contacted by telephone at 9 and 15 months.
3306471|NCT00376597|Experimental|Arm II (lymphedema education, physical therapy)|Description Patients receive lymphedema education and complete physical assessments and questionnaires as in Arm I. Patients also complete a personalized physical therapy intervention, receive a refrigerator magnet, and a 15-minute video that reinforces information and exercises.
3306472|NCT00376584|Placebo Comparator|Placebo → MK-0524A 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A Placebo for 5 days (drug holiday) followed by MK-0524A 2 g for the remainder of the study (7 days).
3306473|NCT00376584|Active Comparator|Placebo → Extended Release (ER)-Niacin 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A Placebo for 5 days (drug holiday) followed by ER-Niacin 2g for the remainder of the study (7 days)
3306474|NCT00376584|Experimental|MK-0524A 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A 2g for the remainder of the study (approximately 2 weeks).
3306475|NCT00376571|Experimental|Stenting of main vessel and side branch|Percutaneous coronary intervention
3306476|NCT00376571|Experimental|No side branch treatment|Percutaneous coronary intervention
3306477|NCT00376558|Active Comparator|Contingency Management w/ CRA|Cocaine users: Contingency management w/ Community Reinforcement Approach
3306478|NCT00376558|No Intervention|Healthy Control|A group of healthy matched comparison subjects with no DSM-IV axis I Disorder was included; they were matched for cigarette smoking, gender, and ethnicity.
3306479|NCT00376532||ICD pacing or shock event|Subjects who experienced a device treatment, defined as a pacing event or a shock event
3306480|NCT00376532||No ICD pacing or shock event|Subjects who did not experience a treatment defined as a pacing event or a shock event
3306481|NCT00376519|Experimental|Transplant with Treg Cells|Patients receive preparative therapy with Fludarabine, cyclophosphamide, total body irradiation and Treg infusion followed by umbilical cord blood transplantation.
3306482|NCT00376506|Experimental|Implanted Device|Implanted intramuscular neurostimulator device
3306483|NCT00376506|Active Comparator|External Device|External vibrotactile device
3306484|NCT00376493|Active Comparator|1|Use of antibiotics after hospital discharge
3306485|NCT00376493|Placebo Comparator|2|Use of placebo
3306486|NCT00376415|Experimental|Lessertia Fructescens|Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
3306487|NCT00376415|Placebo Comparator|Placebo|Participants received an identical placebo capsule twice daily for 3 months.
3306488|NCT00376363|Active Comparator|Ahmed implant,1|Ahmed glaucoma drainage implant for intraocular pressure control
3306646|NCT00374244|Active Comparator|2|active pimozide
3307288|NCT00366379|Experimental|3|
3306489|NCT00376363|Active Comparator|Baerveldt implant|Baerveldt glaucoma drainage implant for intraocular pressure control
3306490|NCT00376350|Experimental|High dose manipulation|High dose spinal manipulation + ultrasound
3306491|NCT00376350|Experimental|Moderate dose manipulation|Moderate dose manipulation + low dose massage + ultrasound
3306492|NCT00376350|Experimental|Low dose manipulation|low dose spinal manipulation + moderate dose massage + ultrasound
3306493|NCT00376350|Other|High dose masssage|high dose massage + ultrasound
3306494|NCT00376337|Active Comparator|1|infusion for 3-12 weeks
3306495|NCT00376337|Experimental|2|infusion for 3-12 weeks
3306496|NCT00376272|Experimental|1|
3306497|NCT00376272|Placebo Comparator|2|
3306498|NCT00376259|Experimental|Combination therapy|Combination therapy: 600 mg of telbivudine (LdT) by mouth plus 10 mg of adefovir (ADV) by mouth once daily for 96 weeks.
3306499|NCT00376259|Active Comparator|Adefovir monotherapy|Adefovir monotherapy: 10 mg of adefovir by mouth once daily for 96 weeks.
3306500|NCT00376220|Experimental|1|"Drug: Riluzole Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) < 12) the dose will not be increased further unless clinical symptoms recur.~Other Names:~• Rilutek"
3306501|NCT00376220|Placebo Comparator|2|Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS < 12) the dose will not be increased further unless clinical symptoms recur.
3306502|NCT00376181|Experimental|Pioglitazone 45 mg/Azilsartan 20 mg QD|
3306503|NCT00376181|Experimental|Pioglitazone 45 mg/Azilsartan 40 mg QD|
3306504|NCT00376181|Active Comparator|Pioglitazone 45 mg QD|
3306505|NCT00376168|Experimental|prGCD 30 Units/kg|
3306506|NCT00376168|Experimental|prGCD 60 Units/kg|
3306507|NCT00376129|Experimental|I|
3306508|NCT00376090|Experimental|Group I Vaccine|
3306509|NCT00376090|Placebo Comparator|Group I Placebo|
3306510|NCT00376090|Experimental|Group II Vaccine|
3306511|NCT00376090|Placebo Comparator|Group II Placebo|
3306512|NCT00376090|Experimental|Group III Vaccine|
3306513|NCT00376090|Placebo Comparator|Group III Placebo|
3306514|NCT00376090|Experimental|Group IV Vaccine|
3306515|NCT00376090|Placebo Comparator|Group IV Placebo|
3306516|NCT00376077|Active Comparator|Placebo and IVIG|"The trial site is blinded to the randomization process. Patients are assigned an arm by a research pharmacist. Patients on this arm receive an infusion of placebo (0.9% NaCl) over one hour. Immediately following this dosing, 1 g/kg IVIG (Gammunex ©) is infused over 2 - 3 hours. Following this treatment, complete blood counts are drawn at:~completion of IVIG infusion,~8 hours following the start of the placebo/solumedrol infusion~24 hours following the start of the placebo/solumedrol infusion~72 hours following the start of the placebo/solumedrol infusion~7 days post infusion~21 days post infusion"
3306517|NCT00376077|Experimental|Methylprednisolone and IVIG|"The trial site is blinded to the randomization process. Patients are assigned an arm by a research pharmacist.Patients on this arm receive IV Methylprednisolone 30 mg/kg (1 gram maximum) infused over one hour. Immediately following this dosing, 1 g/kg IVIG Gammunex © is infused over 2 - 3 hours. Following this treatment, complete blood counts are drawn at:~completion of IVIG infusion,~8 hours following the start of the placebo/solumedrol infusion~24 hours following the start of the placebo/solumedrol infusion~72 hours following the start of the placebo/solumedrol infusion~7 days post infusion~21 days post infusion"
3306518|NCT00376064|Experimental|SMS995 + Carbegolin, Somavert + SMS995|
3306519|NCT00376012|Active Comparator|1|2EHRZ3/4RH3
3306520|NCT00376012|Experimental|2|2EHRZ3/7RH3
3306521|NCT00375999|Experimental|docetaxel and epirubicin|salvage docetaxel and epirubicin
3306522|NCT00375973|Experimental|Duloxetine|Duloxetine po 60-120 mg/day for 12 weeks
3306523|NCT00375973|Placebo Comparator|Placebo|Placebo comparator to Duloxetine
3306524|NCT00375947|Experimental|1|Home-based hand exercise program
3306525|NCT00375947|Placebo Comparator|2|Sham hand cream
3306526|NCT00375934|Experimental|1|
3306527|NCT00375934|Placebo Comparator|2|
3306528|NCT00375895|Experimental|Ciclosporin|
3306529|NCT00375882|Other|cochlear implantation with mild hypothermia|
3306530|NCT00375869|Active Comparator|Darbopoeitin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
3306531|NCT00375869|Placebo Comparator|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
3306532|NCT00375856|No Intervention|1|DePuy P.F.C.® SigmaTM Posterior Cruciate Substituting Knee
3306533|NCT00375856|Experimental|2|Rotating Platform Knee
3306534|NCT00375843|Active Comparator|Level 1 Treatment: Escitalopram|Level 1 participants who are assigned to escitalopram
3306535|NCT00375843|Active Comparator|Level 2: Sertraline|Participants from Level 1 who do not achieve remission with escitalopram enter Level 2 and switch to sertraline
3307289|NCT00366379|Experimental|4|
3306536|NCT00375830|Experimental|Diagnostic (18F NaF/18F FDG PET/MRI)|Patients undergo a combined 18F NaF and 18F FDG PET/MRI scan over 45 minutes.
3306537|NCT00375791|Experimental|Perifosine daily|Patients will take three 50 mg tablets of perifosine daily at bedtime with food. Patients will be examined every three weeks. If patients have no progression it is allowed to receive 8 cycles of perifosine
3306538|NCT00375791|Experimental|Perifosine daily + Dexa twice per week|Patients will take three 50 mg tablets of perifosine daily at bedtime with food until progression. If progressive disease is confirmed by a second measurement at least one week later the patient will receive a combination of 20 mg twice per week dexamethasone (dexa) and 150 mg perifosine daily at bedtime.
3306539|NCT00375752|Active Comparator|Letrozole|Letrozole 2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvent treatment
3306540|NCT00375752|Experimental|Zolendronic Acid + Letrozole|2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvant treatment plus zoledronic acid 4 mg i.v. q4w
3306541|NCT00375726|Experimental|1|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^3 PFU dose) into the deltoid region of either arm.
3306542|NCT00375726|Experimental|2|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
3306543|NCT00375726|Experimental|3|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
3306544|NCT00375726|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
3306545|NCT00375713|Experimental|Levocetirizine|Levocetirizine + Cetirizine-Placebo + Standard Topical Steroid (1% hydrocortisone) Ointment for 14 days
3306546|NCT00375713|Active Comparator|Cetirizine|Cetirizine + Levocetirizine-Placebo + Standard Topical Steroid (1% hydrocortisone) Ointment for 14 days
3306547|NCT00375674|Experimental|A|
3306548|NCT00375674|Placebo Comparator|B|
3306549|NCT00375661|No Intervention|interferon|
3306550|NCT00375648|Experimental|zoledronate|
3306551|NCT00375609|Experimental|Betrixaban 15 mg|Betrixaban 15 mg oral twice daily for 10 to 14 days
3306552|NCT00375609|Experimental|Betrixaban 40 mg|Betrixaban 40 mg oral twice daily for 10 to 14 days
3306553|NCT00375609|Experimental|Enoxaparin|Enoxaparin 30 mg administered subcutaneously every 12 hours for 10 to 14 days
3306554|NCT00375570|Experimental|1|ME-609
3306555|NCT00375557|Active Comparator|1|Quetiapine
3306556|NCT00375557|Active Comparator|2|Divalproex ER
3306557|NCT00375518|Active Comparator|1|Atorvastatin
3306558|NCT00375518|Placebo Comparator|2|placebo
3306559|NCT00375505|Experimental|Zometa|Zoledronic acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).
3306560|NCT00375505|Placebo Comparator|Placebo|Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).
3306561|NCT00375492|Experimental|Group A|
3306562|NCT00375492|Placebo Comparator|Group B|
3306563|NCT00375466|Experimental|Tranexamic Acid|
3306564|NCT00375466|Placebo Comparator|placebo|
3306565|NCT00375453|Experimental|Arm 1|
3306566|NCT00375427|Experimental|Every 3 months|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every three months. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized patients will receive a maximum of 4 infusions in this group.
3306567|NCT00375427|Experimental|Every 4 weeks|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every 4 weeks. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Patients randomized to this group will receive up to 12 infusions.
3306568|NCT00375401|Experimental|CP-945,598 Treatment A|
3306569|NCT00375401|Experimental|CP-945,598 Treatment B|
3306570|NCT00375401|Placebo Comparator|Placebo|
3306571|NCT00375336||1|Patients with aortic stenosis (mean transvalvular aortic gradient ≥30 mm Hg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
3306572|NCT00375336||2|Patients with nonobstructive aortic sclerosis (mean gradient ≤10 mmHg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
3306573|NCT00375336||3|Patients with normal aortic valve plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
3306574|NCT00375310|Experimental|Gemcitabine + Sorafenib & radiotherapy|"Induction: Gemcitabine with Sorafenib for 4 weeks (1 cycle). Chemo-radiotherapy: Gemcitabine with Sorafenib and Radiotherapy for 5 weeks. Sorafenib will be given in escalating dose cohorts.~Sorafenib only: Sorafenib alone for 4 weeks. Consolidation: Gemcitabine with Sorafenib for 16 weeks (4 cycles). Maintenance: Sorafenib alone until disease progression."
3306575|NCT00375258|Experimental|1|Active
3306576|NCT00375258|Placebo Comparator|2|
3306577|NCT00375245|Experimental|Rapamycin + Grapefruit juice|
3306578|NCT00375219|Experimental|omacetaxine|Treatment was the same for all cohorts: induction therapy was subcutaneous (SC) administration of omacetaxine at 1.25 mg/m^2 twice a day (BID), administered for 14 consecutive days every 28 (±3) days for up to 6 cycles. Maintenance therapy was subcutaneous (SC) administration of omacetaxine at 1.25 mg/m^2 twice a day (BID), administered for 7 consecutive days every 28 (±3) days for up to 3 years.
3306579|NCT00375193|Experimental|1|Amrubicin 40mg/m<2> IV days 1, 2, 3 of each 21-day cycle until cycle 6 or no longer beneficial.
3306580|NCT00375102|Experimental|Acup|Acupuncture
3306581|NCT00375102|Experimental|RR|Relaxation Response
3306582|NCT00375102|No Intervention|UC|Usual Care
3306583|NCT00375089||Group 1|Individuals with Prader-Willi syndrome.
3306584|NCT00375089||Group 2|Individuals with Early-onset Morbid Obesity
3306585|NCT00375050|Experimental|Riluzole|
3306586|NCT00375050|Placebo Comparator|Placebo|
3306587|NCT00375037|Experimental|Hand hygiene|Hand hygiene promotion
3306588|NCT00375037|Active Comparator|Usual care|usual care
3306589|NCT00375024|Other|1: Patient Navigator|Patients will meet with a Patient Navigator regarding their treatment and any related concerns.
3306590|NCT00375024|Other|2: Without Navigator|Patient will work with existing clinic staff, which does not include a Patient Navigator.
3306591|NCT00374985|Experimental|one arm|
3306592|NCT00374972||combined contraceptives|combined contraceptives
3306593|NCT00374972||pregesterone only contraceptives|pregesterone only contraceptives
3306594|NCT00374946||A|THA. Bearing of Zirconia head and UHMWPE liner
3306595|NCT00374946||B|THA. Bearing of CO-Cr-Mo head and liner
3306596|NCT00374946||C|THA. Head og Zirconia head and UHMWPE moulded in shell (Asian)
3306597|NCT00374946||D|THA. Head and shell og Alumina ceramic
3306598|NCT00374933|Experimental|1|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
3306599|NCT00374907|Experimental|Saxagliptin (A)|Metformin 500-1500 mg (open-label, as needed for rescue in LT)
3306600|NCT00374907|Placebo Comparator|Placebo (ST) / Metformin (LT) (B)|Metformin 500-1500 mg (open-label, as needed for rescue in LT)
3306601|NCT00374881|Active Comparator|1|Morphine High Dose
3306602|NCT00374881|Placebo Comparator|2|Morphine Low Dose
3306603|NCT00374881|Placebo Comparator|3|Sorbitol Phenylephrine
3306604|NCT00374881|Experimental|4|Sorbitol high concentration+Phenylephrine+Morphine
3306605|NCT00374881|Experimental|5|Sorbitol low concentration+Phenylephrine+Morphine
3306606|NCT00374868|Experimental|Pemetrexed + Cisplatin|
3306607|NCT00374842|Experimental|GSK1247446A Formulation 1 Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the GSK1247446A vaccine adjuvanted with a full dose of adjuvant at Day 0. The adjuvanted GSK1247446A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3306608|NCT00374842|Experimental|GSK1247446A Formulation 2 Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the GSK1247446A vaccine adjuvanted with a half dose of adjuvant at Day 0. The adjuvanted GSK1247446A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3306609|NCT00374842|Active Comparator|Fluarix Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3306610|NCT00374803|Experimental|Mycophenolic Acid (Myfortic) Preload|Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter
3306611|NCT00374803|Active Comparator|Mycophenolic Acid (Myfortic) Standard|Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day).
3306612|NCT00374777|Experimental|1|
3306613|NCT00374777|Experimental|2|
3306614|NCT00374777|Active Comparator|3|
3306615|NCT00374777|Placebo Comparator|4|
3306616|NCT00374738|Experimental|GIFT Intervention|Guided Imagery for Trauma (GIFT)
3306617|NCT00374738|No Intervention|Music Control|Relaxing Music Audio control; same music used in guided imagery, with no narrative voice.
3306618|NCT00374673|Experimental|transcranial magnetic stimulation|repetitive transcranial magnetic stimulation of the motor cortex
3306619|NCT00374673|Sham Comparator|placebo stimulation|repetitive placebo stimulation of the motor cortex
3306620|NCT00374660|Experimental|1|
3306621|NCT00374634|Active Comparator|"Individual or standard rFSH dose"|"Patients were randomized to recieve individual (50, 75 or 100 IU/day) or standard (75 IU/day) rFSh dose. The individual dose was prescribed according to a dosage nomogram based on the patient's body weight (kg) and the total antral follicle count (Freiesleben NC et al., RBMOnline 2009;17:632-64)."
3306622|NCT00374634|Active Comparator|"Standard rFSH dose"|"Standard dose of rFSH"
3306623|NCT00374621|Active Comparator|Misoprostol|
3306624|NCT00374621|Active Comparator|Misoprostol with Isosorbide Mononitrate|
3306625|NCT00374569|Experimental|Gymnastics|Gymnasts stand on a computerized dynamic posturography Force Plate and Stability is measured and gymnastic routines performed
3306626|NCT00374569|Experimental|Non Gymnasts|Non Gymnasts stand on a computerized dynamic posturography Force Plate and Stability is measured and gymnastic routines performed
3306627|NCT00374556|Experimental|Eszoplicone|Eszoplicone 3mg capsules, once daily at bedtime for 12 weeks
3306628|NCT00374556|Placebo Comparator|Placebo|3mg placebo capsule, once daily at bedtime for 12 weeks
3306629|NCT00374543|Experimental|Ziprasidone|Ziprasidone will be dosed on a twice daily (BID) basis, with flexible dosing based on tolerability, with a total daily dose in the range of 40 to 160 mg/day, for 8 weeks. This time period reflects the rapid onset of effect seen in studies of atypical antipsychotics, but allows time for a potentially longer response for some anxiety symptoms.
3306630|NCT00374543|Placebo Comparator|Placebo Capsules|Identical placebo capsules will be dosed on a BID basis, with flexible dosing based on tolerability, with a total daily dose in the range of 40 to 160 mg/day.
3306631|NCT00374452|Experimental|ATHENA-CDS-HTN plus Guideline Link|ATHENA-CDS-HTN plus Guideline Link. ATHENA-CDS-HTN display on the cover sheet of electronic health record, plus link to the guidelines
3306632|NCT00374452|Other|Guideline Link Only|Guideline Link Only. Link to The Seventh Report of the Joint National Committee on Prevention Detection and Treatment of High Blood Pressure (JNC7) and to VA-Department of Defense (DoD) hypertension guidelines
3306633|NCT00374439|Experimental|Cognitive-behavioral|Participants in this arm received a cognitive-behavioral program
3306634|NCT00374439|Experimental|Interpersonal Therapy|Participants in this arm received a prevention program based on interpersonal therapy for depression
3306635|NCT00374439|No Intervention|No intervention|Participants in this arm did not receive an intervention, but complete assessments only
3306636|NCT00374413|Experimental|Kineflex-C|
3306637|NCT00374413|Active Comparator|ACDF|
3306638|NCT00374361||Caucasian Adolescents|Caucasian Adolescents
3306639|NCT00374361||African-American Adolescents|African-American Adolescents
3306640|NCT00374335|Other|infants with cutaneous hemangiomas|
3306641|NCT00374322|Placebo Comparator|Placebo|6 tablets daily for 12 months
3306642|NCT00374322|Experimental|Lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
3306643|NCT00374296|No Intervention|1|Elderly (≥65 years) untreated arm
3306644|NCT00374296|Experimental|2|Relapsed/Refractory Arm
3306647|NCT00374231|Experimental|Immunosuppression|All the patients who enroll in this study will receive the same medications (tacrolimus, mycophenolate mofetil, and a short course of steroids) to prevent rejection of the liver transplant. All participants will be gradually taken off prednisone if they are 90 days or longer post liver transplant and have not had a rejection in the last 30 days.
3306648|NCT00374205|Experimental|AL|Artemether plus Lumefantrine 6 dose 3 days treatment
3306649|NCT00374205|Active Comparator|ASAQ|Artesunate plus Amodiaquine
3306650|NCT00374192|Experimental|1|Eszopiclone
3306651|NCT00374192|Placebo Comparator|2|Placebo
3306652|NCT00374166|Experimental|SSR149415 - 250 mg|SSR149415 250 mg, twice daily for a maximum of 8 weeks
3306653|NCT00374166|Experimental|SSR149415 - 100 mg|SSR149415 100 mg and additional placebo capsules in order that all patients are being administered three capsules twice daily for a maximum of 8 weeks
3306654|NCT00374166|Active Comparator|Paroxetine|Paroxetine 20 mg and additional placebo capsules in order that all patients are being administered three capsules twice daily for a maximum of 8 weeks
3306655|NCT00374166|Placebo Comparator|Placebo|Placebo for a maximum of 9 weeks
3306656|NCT00374153|Experimental|1|Online personal feedback report.
3306657|NCT00374153|Experimental|2|In-person Motivational Interview with personal feedback report
3306658|NCT00374153|Experimental|3|In-person Motivational Interview only (without a personal feedback report)
3306659|NCT00374153|No Intervention|4|Assessment only
3306660|NCT00374153|No Intervention|5|Delayed Assessment
3306661|NCT00374140|Experimental|RAD001 (Everolimus)|RAD001 (Everolimus)10 mg by mouth daily without interruption
3306662|NCT00374127|Experimental|marijuana blunt|marijuana blunt (0%, 1.8%, or 3.6% THC)
3306663|NCT00374127|Experimental|marijuana cigarette|marijuana cigarette (0%, 1.8%, or 3.6% THC)
3306664|NCT00374088|Placebo Comparator|Placebo|These patients receive a placebo infusion of D5W prior to and after surgery
3306665|NCT00374088|Experimental|N-Acetylcysteine|These patients receive a loading dose of N-Acetylcysteine 100 mg/kg in D5W IV 1 hour prior to surgery. They receive a maintenance infusion of N-Acetylcysteine 10 mg/kg/hr in D5W IV for 24 hours after surgery.
3306666|NCT00374062|Experimental|I|relaxation tape 1
3306667|NCT00374062|Experimental|II|relaxation tape 2
3306668|NCT00374062|Placebo Comparator|III|relaxation tape 3
3306669|NCT00374049|Experimental|One|MUC1 vaccine in conjunction with GM-CSF and Poly-ICLC (Hiltonol)in Arm ONE
3306670|NCT00374036|Experimental|1|ECC
3306671|NCT00374036|Experimental|2|FOLFIRI
3306672|NCT00373958|Experimental|13vPnC vaccine|
3306673|NCT00373958|Active Comparator|7vPnC vaccine|
3306674|NCT00373932|Experimental|MOBILE-A|Coached exercise persistence intervention
3306675|NCT00373932|Active Comparator|MOBILE-B|Self-monitored exercise persistence intervention
3306676|NCT00373880|Experimental|Aripiprazole (15mg) + Cocaine|Aripiprazole (15 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg).
3306677|NCT00373880|Placebo Comparator|Placebo + Cocaine|Placebo (0 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg)
3306678|NCT00373867|Active Comparator|Standard|Standard treatment-based classification physical therapy
3306679|NCT00373867|Active Comparator|Graded exercise|Treatment-based classification physical therapy plus graded exercise
3306680|NCT00373867|Experimental|Graded exposure|Treatment-based classification physical therapy plus graded exposure
3306681|NCT00373789|Experimental|Botox A|up to two injections of 200 Units of intra-detrusor Botulinum Toxin A , which must be separated by at least eight weeks and no more than 52 weeks
3306682|NCT00373789|Placebo Comparator|Placebo|up to two injections of inactive injection (carrier saline), which must be separated by at least eight weeks and no more than 52 weeks
3306683|NCT00373750|Experimental|Family Spirit Intervention|The Family Spirit Intervention included 43 structured lessons and followed a culturally congruent format. Positive parenting lessons were focused on reducing behaviors (i.e., poor monitoring; coercive interactions;harsh, unresponsive, or rejecting parenting; and abuse/ neglect) associated with early childhood behavior problems, including externalizing, internalizing, and dysregulation problems.
3306684|NCT00373750|No Intervention|Optimized Standard Care Control Group|Optimized standard care consisted of transportation to recommended prenatal and well-baby clinic visits, pamphlets about child care and community resources, and referrals to local services. It also addressed access barriers to health care for young mothers and children, and it overcame concerns that home-visiting programs have operated in parallel, not in partnership, with pediatric care. Family health liaisons conducted the optimized standard care and were not trained in the Family Spirit intervention, to avoid contamination of the control condition.
3306685|NCT00373698|Experimental|Three Component Model|Three Component Model of Collaborative Care: Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
3306686|NCT00373698|No Intervention|Usual Care|"Patients randomized to Usual Care will receive care as usual by VA clinicians."
3306687|NCT00373685|Experimental|Celecoxib|dosing as per USPI label
3306688|NCT00373685|Active Comparator|NSAIDs|
3306689|NCT00373672|Active Comparator|1|armodafinil (Nuvigil) 150 mg
3306690|NCT00373672|Placebo Comparator|2|identical in appearance to active comparator
3306691|NCT00373633|Experimental|Continuous extra-pleural intercostal local anesthesia|intra-operatively placed extrapleural intercostal catheter
3306692|NCT00373633|Active Comparator|Thoracic Epidural|gold standard
3306693|NCT00373607|Experimental|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin, Hualijian Pharmaceutical Co. Ltd., Guangzhou, China). Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
3306694|NCT00373607|Active Comparator|Mefloquine + Artesunate (MAS3)|The MAS3 regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
3306695|NCT00373581|Experimental|Vigabatrin, cocaine|
3306696|NCT00373581|Placebo Comparator|placebo, cocaine|
3306733|NCT00373152|Experimental|RadioFrequency Ablation for Breast Cancer|
3306734|NCT00373113|Active Comparator|A|1250 mg/m^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
3306697|NCT00373529|Experimental|Clofarabine|Participants received an induction cycle of clofarabine 30 mg/m^2/day intravenous infusion for 5 consecutive days. Participants could then receive up to 5 additional cycles, repeated minimally every 28 days, of clofarabine 20 mg/m^2/day intravenous infusion for 5 consecutive days.
3306698|NCT00373503|Experimental|lofexidine, dronabinol, marijuana|lofexidine (.6 mg qid), dronabinol (20 mg tid)
3306699|NCT00373490|Experimental|Vorinostat 600 mg|600 mg daily (300 mg twice daily [b.i.d.]) for 3 consecutive days followed by 4 days of rest.
3306700|NCT00373490|Experimental|Vorinostat 400 mg|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
3306701|NCT00373451|Experimental|Abciximab+UFH|Abciximab and unfractionated heparin as bolus given during PCI and abciximab-perfusion for 12 hours after PCI
3306702|NCT00373451|Active Comparator|Bivalirudin|Bivalirudin given only during PCI
3306703|NCT00373438|No Intervention|A|
3306704|NCT00373438|Experimental|B|Fetoscopic tracheal occlusion
3306705|NCT00373425|Experimental|Erlotinib|Participants received 150 mg/day erlotinib orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.
3306706|NCT00373425|Placebo Comparator|Placebo|Participants received matching placebo tablets orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.
3306707|NCT00373399|Experimental|marijuana|
3306708|NCT00373399|Placebo Comparator|placebo|
3306709|NCT00373386|Experimental|Growth Hormone|Growth hormone treatment 0.3 mg/kg/min
3306710|NCT00373373|Placebo Comparator|A|Chemotherapy + Placebo
3306711|NCT00373373|Active Comparator|B|Chemotherapy + Sorafenib
3306712|NCT00373360|Experimental|1|
3306713|NCT00373334|Experimental|1|
3306714|NCT00373334|Experimental|2|
3306715|NCT00373334|Sham Comparator|3|
3306716|NCT00373295|Experimental|Baclofen 60 mg, Placebo, Baclofen 90 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
3306717|NCT00373295|Experimental|Baclofen 90 mg, Placebo, Baclofen 60 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
3306718|NCT00373295|Experimental|Baclofen 60 mg, Baclofen 90 mg, Placebo|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
3306719|NCT00373295|Experimental|Baclofen 90 mg, Baclofen 60 mg, Placebo|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
3306720|NCT00373295|Experimental|Placebo, Baclofen 90 mg, Baclofen 60 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
3306721|NCT00373295|Experimental|Placebo, Baclofen 60 mg, Baclofen 90 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
3306722|NCT00373269||Diabetic subject|Subjects with acute stroke, hyperglycemia and history of diabetes.
3306723|NCT00373269||Normoglycemic Control|Subjects with acute stroke and normal blood glucose.
3306724|NCT00373256|Experimental|A|
3306725|NCT00373256|Active Comparator|B|
3306726|NCT00373243|Experimental|Subjects receiving GW406381|Subjects will receive single oral dose of 20 milligram (mg) of GW406381.
3306727|NCT00373230|Experimental|1|Internet based telemedicine weight maintenance program
3306728|NCT00373230|Active Comparator|2|In person weight maintenance monthly consultations
3306729|NCT00373217|Experimental|Group 1|Patients in group one will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin in week 1. Treatment may repeat every 3 weeks for up to four courses. They will then undergo surgery to remove as much of the tumor as possible. Within 2 weeks after surgery, patients will receive an injection of the vaccine once a week for 3 weeks. Treatment may repeat every 14 weeks for two courses. After finishing the first course of vaccine therapy, patients will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin every 3 weeks for up to four courses.
3306730|NCT00373217|Experimental|Group 2|Patients in group two will undergo surgery to remove as much of the tumor as possible. Within 2 weeks after surgery, patients will receive an injection of the vaccine once a week for 3 weeks. Treatment may repeat every 14 weeks for two courses. After finishing the first course of vaccine therapy, patients will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin every 3 weeks for up to eight courses. Some patients may undergo a second surgery within 6 weeks after completing the fourth course of chemotherapy and undergo tumor and/or lymph node tissue collection.
3306731|NCT00373204|Experimental|Xcytrin® (motexafin gadolinium)|
3306732|NCT00373178|Active Comparator|Metformin,lifestyle counselling|
3306736|NCT00373100|Experimental|Zinc|Zinc acetate
3306737|NCT00373100|Placebo Comparator|Placebo|Placebo
3306738|NCT00373087|Active Comparator|L-dopa + entacapone|L-dopa + entacapone
3306739|NCT00373087|Experimental|L dopa / placebo|L dopa / placebo
3306740|NCT00373074|Active Comparator|15 cc|15 cc of blood used for Epidural Blood Patch
3306741|NCT00373074|Active Comparator|20 cc|20 cc of blood used for Epidural Blood Patch
3306742|NCT00373074|Active Comparator|30 cc|30cc of blood used for Epidural Blood Patch
3306743|NCT00373061||Pregnant Women Exposed to Xolair®|Women who are exposed to at least one dose of Xolair® within 8 weeks prior to conception or at any time during their pregnancy will be followed to completion of their pregnancies.
3306744|NCT00373048|Placebo Comparator|Placebo, tablet|
3306745|NCT00373048|Experimental|mefloquine, tablet|
3306746|NCT00373009|Experimental|Core stabilization and psychosocial education|A core stabilization exercise program (CSEP) is used in this group and has sound biomechanical and anatomical rationale. In addition, a psychosocial education program (PSEP) will be used for this group.
3306747|NCT00373009|Active Comparator|Core stabilization exercise only|A core stabilization exercise program (CSEP) is used in this group and has sound biomechanical and anatomical rationale.
3306748|NCT00373009|Active Comparator|Psychosocial education class only.|A psychosocial education program (PSEP) will be used in this group.
3306749|NCT00373009|Other|Traditional Army training|Traditional Army training will be used in this group.
3306750|NCT00372996|Experimental|1|CP-751,871 + exemestane Treatment until progression or toxicity
3306751|NCT00372996|Active Comparator|2|
3306752|NCT00372970|Active Comparator|Botulinum Toxin A|200 U of Botox injected endoscopically into pylorus
3306753|NCT00372970|Placebo Comparator|Placebo|saline into pylorus.
3306754|NCT00372957|Placebo Comparator|Placebo|Participants received two capsules of matching placebo orally once daily in the morning with 150 milliliter (mL) of water at least 15 minutes prior to breakfast for 7 Days.
3306755|NCT00372957|Experimental|GW823093C 15 mg|Participants received one 15 milligrams (mg) of GW823093C capsule and one placebo capsule orally once daily in the morning with 150 mL of water at least 15 minutes prior to breakfast for 7 Days.
3306756|NCT00372957|Experimental|GW823093C 30 mg|Participants received 30 mg (2x15 mg) of GW823093C capsules orally once daily in the morning with 150 mL of water at least 15 minutes prior to breakfast for 7 Days.
3306757|NCT00372944|Active Comparator|1|Xeloda
3306758|NCT00372944|Experimental|2|AZD6244
3306759|NCT00372918|Other|1|Transnasal Esophagoscopy
3306760|NCT00372905|Experimental|bortezomib, Ibritumomab tiuxetan, rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
3306761|NCT00372892|Active Comparator|A|Rituximab
3306762|NCT00372892|Placebo Comparator|B|Saline placebo iv infusion
3306763|NCT00372879|Experimental|Crossover group 1|Vitamin E first and placebo second
3306764|NCT00372879|Experimental|Crossover group 2|Placebo first then vitamin E
3306765|NCT00372853|Experimental|Arm A|
3306766|NCT00372853|Experimental|Arm B|
3306767|NCT00372840|Experimental|Arm I|Patients receive a specific print intervention manual entitled Facing Forward Series: Life After Cancer Treatment and a general print intervention fact sheet entitled The Cancer Information Service, Questions and Answers.
3306768|NCT00372840|Active Comparator|Arm II|Patients receive the general print intervention fact sheet entitled The Cancer Information Service, Questions and Answers.
3306769|NCT00372814|Experimental|Multisystemic Therapy (MST)|Adolescents receiving MST will receive Intensive Home-Based Family Therapy which will consist of home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their daily diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
3306770|NCT00372814|Active Comparator|Telephone Support Calls|Adolescents receiving Supportive Telephone Calls (TS) will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
3306771|NCT00372788|Active Comparator|1|Pemetrexed
3306772|NCT00372788|Experimental|2|AZD6244
3306773|NCT00372775|Experimental|Sunitinib|
3306774|NCT00372762|Active Comparator|Furosemide|Patients will be assigned to furosemide therapy (20mg to 80mg) orally, once or twice daily for an 8-week period.
3306775|NCT00372762|Active Comparator|Bumetanide|Patients will be assigned to bumetanide therapy at an equipotent dose to furosemide therapy (1mg bumetanide is equivalent to 40mg furosemide)for an 8-week period.
3306776|NCT00372697|Experimental|Octreotide 30 mg every 21 days|Patients received octreotide 30 mg every 21 days intramuscularly (im) for 6 months, a total of 8 doses. At each study visit, octreotide was administered only after completion of all scheduled efficacy and safety evaluations for that visit. Octreotide was injected im into the right or left gluteal regions. The injections were initially administered by a trained and authorized member of the investigational team. When no study visit at the investigational site was required, the injections were given by a trained nurse or the family doctor.
3306777|NCT00372697|Experimental|Octreotide 60 mg every 28 days|Patients received octreotide 60 mg every 28 days intramuscularly (im) for 6 months, a total of 6 doses. Octreotide mg was administered as two 30 mg injections. At each study visit, octreotide was administered only after completion of all scheduled efficacy and safety evaluations for that visit. Octreotide was injected im into the right or left gluteal regions. The injections were initially administered by a trained and authorized member of the investigational team. When no study visit at the investigational site was required, the injections were given by a trained nurse or the family doctor.
3306778|NCT00372684||1|with severe malaria hospitalized in ICU
3306779|NCT00372684||2|with uncomplicated malaria
3307290|NCT00366379|Experimental|5|
3306780|NCT00372645|Experimental|Diet|200 µg folate per day from folate-rich foods
3306781|NCT00372645|Experimental|Folic acid supplement|200 µg folate per day from supplemental folic acid
3306782|NCT00372645|Experimental|Metfolin supplement|200 µg folate per day from supplemental Metafolin®
3306783|NCT00372645|Placebo Comparator|Placebo|Placebo
3306784|NCT00372632|Placebo Comparator|placebo|
3306785|NCT00372632|Experimental|sulfadoxine-pyrimethamine|
3306786|NCT00372619|Experimental|Clofarabine 40 mg/m² to assess feasibility in ALL patients.|Clofarabine 40 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
3306787|NCT00372619|Experimental|Clofarabine 40 mg/m² to assess feasibility in AML patients.|Clofarabine 40 mg/m² to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
3306788|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess feasibility in ALL patients.|Clofarabine 52 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
3306789|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy in ALL patients.|Clofarabine 52 mg/m² to assess efficacy in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
3306790|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess feasibility in AML patients.|Clofarabine 52 mg/m² to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
3306791|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy in AML patients|Clofarabine 52 mg/m² to assess efficacy in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
3306792|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy - ambiguous lineage pt|Clofarabine 52 mg/m² to assess efficacy in acute leukemia of ambiguous lineage patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
3306793|NCT00372593|Active Comparator|Arm A: Standard Arm - No GMTZ, AML Pts w/out Down Syndrome|"Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9."
3306836|NCT00372112|Placebo Comparator|placebo|Twice daily
3306837|NCT00372073|Active Comparator|1|seliciclib
3306838|NCT00372073|Placebo Comparator|2|
3306839|NCT00372060|Experimental|1|MK0431 + pioglitazone
3306840|NCT00372060|Placebo Comparator|2|Placebo/MK0431 + pioglitazone
3307281|NCT00366470|Experimental|A|Vitamin D in doses of 100,000 IU
3306794|NCT00372593|Experimental|Arm B: Experimental - with GMTZ, AML Pts w/out Down Syndrome|Pts receive IT ARA-C at diagnosis or on day 1 of treatment or twice a week for up to six doses. They also receive an infusion of ARA-C on days 1-10; a 6-hr infusion of daunorubicin on days 1, 3, & 5; a 4-hr infusion of etoposide on days 1-5; and a 2-hr infusion of GMTZ - gemtuzumab ozogamicin (Mylotarg) on day 6. After 3 wks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5. After 3 wks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hr infusion of mitoxantrone hydrochloride on days 3-6. They also receive a 2-hr infusion of gemtuzumab on day 7. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9.
3306795|NCT00372593|Active Comparator|Arm A: Standard Arm - No GMTZ, AML Patients with Down Syndrome|"Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9."
3306796|NCT00372567|Experimental|A|
3306797|NCT00372567|Active Comparator|B|
3306798|NCT00372528|Experimental|pregabalin|open label treatment
3306799|NCT00372515|Experimental|High dose gefitinib|
3306800|NCT00372502|Active Comparator|1|
3306801|NCT00372502|Experimental|2|
3306802|NCT00372489|Experimental|Peginesatide|
3306803|NCT00372476|Experimental|Imatinib + Vinorelbine|
3306804|NCT00372437|Experimental|1|
3306805|NCT00372424|Experimental|1|Combination of SU011248 (37.5 mg once daily [Schedule 2/1]) with docetaxel (75 mg/m2 every 3 weeks) and trastuzumab (therapeutic dose)
3306806|NCT00372411|Experimental|Arm 1|Robot-Assisted Therapy - MIT-MANUS System
3306807|NCT00372411|Active Comparator|Arm 2|Intensive Comparison Therapy
3306808|NCT00372411|Other|Arm 3|Usual Care
3306809|NCT00372385|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
3306810|NCT00372385|Experimental|Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet orally thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks.
3306811|NCT00372385|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 12 weeks.
3306812|NCT00372385|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 12 weeks.
3306813|NCT00372294|Active Comparator|1|Classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon)
3306814|NCT00372294|Active Comparator|2|Intravitreal Clindamycin & Dexamethasone
3306815|NCT00372281|Experimental|Cliavist|
3306816|NCT00372268|Active Comparator|B|Administration of ropivacaïne 0,2% by direct intra-abdominal administration at the end of the surgery
3306817|NCT00372268|Active Comparator|C|Administration of ropivacaïne 0,75% by nebulization in the insufflated gas during all the surgical procedure with direct intra-abdominal administration of Nacl 0,9%
3306818|NCT00372268|Placebo Comparator|A|Administration of Nacl 0,9% by nebulization in the insufflated gas during all the surgical procedure with direct intra-abdominal administration of Nacl 0,9%
3306819|NCT00372268|Placebo Comparator|D|Administration of Nacl 0,9% by direct intra-abdominal administration at the end of the surgery
3306820|NCT00372229|Experimental|1|
3306821|NCT00372229|Active Comparator|2|
3306822|NCT00372216|Active Comparator|1|Pre-hospital loading dose of 600 mg Clopidogrel as early as possible (in addition to standard infarction therapy)
3306823|NCT00372216|No Intervention|2|Standard infarction therapy (without study-specific additions, no Clopidogrel before angiography)
3306824|NCT00372203|Experimental|Endobronchial ultrasound|
3306825|NCT00372190|Experimental|Mesh surgery|Trocar guided tension free vaginal mesh insertion by Prolift mesh kit
3306826|NCT00372190|Active Comparator|Conventional vaginal surgery|Classical vaginal prolapse surgery (fascia plication)
3306827|NCT00372177|Active Comparator|EP1645|Single-Dose
3306828|NCT00372151|Experimental|L-Theanine|
3306829|NCT00372151|Placebo Comparator|Placebo|
3306830|NCT00372138|Experimental|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
3306831|NCT00372125|Active Comparator|Norditropin SimpleXx|0.3 mg/day or 0.4 mg/day if bodyweight was below or above 100 kg,for 4 weeks, 0.6 mg/day or 0.8 mg/day, for 11 months.
3306832|NCT00372125|Placebo Comparator|Placebo|Placebo for 12 months
3306833|NCT00372112|Active Comparator|100 mcg GW642444H|Twice daily in the morning.
3306834|NCT00372112|Active Comparator|400 mcg GW642444H|Twice daily in the morning.
3306835|NCT00372112|Active Comparator|50 mcg salmeterol|Twice daily.
3307282|NCT00366470|Placebo Comparator|B|
3306841|NCT00371995|Experimental|1|"Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)"
3306842|NCT00371969|Active Comparator|1 - enhanced MI|Enhanced brief motivational interview (including an IVR component for alcohol self-monitoring purposes)
3306843|NCT00371969|Active Comparator|2- standard MI|The intervention consists of a standard motivational interview or viewing a DVD on HIV self-care.
3306844|NCT00371956|Active Comparator|1|raloxifene
3306845|NCT00371956|Placebo Comparator|2|placebo arm
3306846|NCT00371904|Experimental|1|
3306847|NCT00371904|Active Comparator|2|
3306848|NCT00371865|Active Comparator|Cognitive Behavioral Therapy|8 group-administered sessions of Cognitive-Behavioral Therapy
3306849|NCT00371865|Experimental|Acceptance-Based Therapy|8 group-administered sessions of Acceptance-based therapy
3306850|NCT00371839|Active Comparator|Mild Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz of 20-39 decibels hearing level (dBHL)
3306851|NCT00371839|Active Comparator|Moderate Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz of 40-49 decibels hearing level (dBHL)
3306852|NCT00371839|Active Comparator|Moderate-Severe Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz greater than 50 decibels hearing level (dBHL)
3306853|NCT00371826|Experimental|Calcineurin Inhibitor (CNI) Withdrawal|"Every randomized patient in this group received~Day 1 - Day 14: cyclosporine as Calcineurin Inhibitor (CNI) 5 mg/kg twice daily (b.i.d.), dose adjusted to achieve C2 target of 1,500 ng/mL (range 1,400-1,600 ng/mL) + mycophenolate sodium (MPA)720 mg b.i.d. + methylprednisone/prednisone 500 mg intra-operatively, 250 mg on day 1, then 10-30 mg/day prednisone~Day 15 - Day 60: everolimus 1.5 mg b.i.d. to achieve target 6-10 ng/mL + cyclosporine decrease dose as per protocol guideline + MPA 720 mg b.i.d. until everolimus trough >6 ng/mL, then MPA was stopped + prednisone 10-30mg/day~Day 61 - Day 120: everolimus dose adjusted to achieve target 6-10 ng/mL + cyclosporine 25% dose reduction per fortnight, to be discontinued by day 120 as per protocol (or commence reduction by day 120 at discretion of investigator, to be completed within 2 months of commencement) + prednisone 10-30mg/day Day 121 - Month 36: everolimus dose adjusted to achieve target 8-12 ng/mL + prednisone 5-10 mg/day"
3306854|NCT00371826|Experimental|Steroid Withdrawal|"Every randomized patient in this group received~Day 1 -14: cyclosporine 5 mg/kg b.i.d., dose adjusted to achieve C2 target as per protocol + mycophenolate sodium (MPA) 720 mg b.i.d. + methylprednisone/prednisone 500 mg intra-operatively, 250 mg on day 1, then 10-30 mg prednisone per day~Day 15 - 60: everolimus 1.5 mg b.i.d. to achieve target 6-10 ng/mL + cyclosporine decrease dose as per protocol guideline + MPA 720 mg b.i.d. until everolimus trough >6 ng/mL, then MPA was stopped + prednisone 10-30mg per day~Day 61 - 120: Everolimus dose adjusted + cyclosporine adjust dose according protocol guideline (or commence reduction by day 120 at discretion of Investigator, to be completed within 2 months of commencement) + gradual withdrawal of prednisone by 1 mg/week to be discontinued by Day 120.~Day 121 - Month 36: At Day 121, Month 7 and Month 13 Everolimus dose was adjusted to achieve target 6-10 ng/mL + Cyclosporine adjust dose to achieve C2 target as per protocol"
3306855|NCT00371826|Active Comparator|CNI+MPA+ Steroid|"Patients randomized to this group received:~Day 1 - Month 36: cyclosporine 5 mg/kg b.i.d., dose adjusted to achieve the protocol defined C2 Targets + mycophenolate sodium 720mg b.i.d. + Methylprednisone/prednisone 500mg intra-operatively, 250mg on day 1, 10-30mg prednisone per day until month 12 (as per local practice), 5-10mg/day months 13-36."
3306856|NCT00371787|Experimental|soft contact lens|
3306857|NCT00371787|No Intervention|non-lens wear|control group
3306858|NCT00371774||1|Dermatologic patients in Canada for which Amevive is clinically indicated
3306859|NCT00371761|Experimental|PegIntron|PegIntron, 1.5 micrograms/kg weekly, for up to 24 weeks followed by a 48-week observation phase
3306860|NCT00371761|Active Comparator|Adefovir|Adefovir, 10 mg daily, for up to 48 weeks followed by a 24-week observation phase
3306861|NCT00371748|Experimental|Arm 1|
3306862|NCT00371748|Other|Arm 2|Historical Comparator: control data derived from a TAXUS V de novo lesion and stent size-matched cohort randomized to receive a single, planned 2.25 mm DES
3306863|NCT00371748|Other|Arm 3|Historical Comparator: control data derived from a TAXUS V de novo lesion size-matched cohort randomized to receive a 2.25 mm or 2.5 mm BMS
3306864|NCT00371735|Experimental|Arm 1|
3306865|NCT00371709|Experimental|Arm 1|
3306866|NCT00371709|Other|Arm 2|Historical Comparator: control data derived from the TAXUS IV and TAXUS V studies
3306867|NCT00371683|Active Comparator|A1|+ placebo
3306868|NCT00371683|Experimental|A2|+ placebo
3306869|NCT00371644|Experimental|Arm 1|Participants receive 12 biweekly sessions of Cognitive Processing Therapy (CPT).
3306870|NCT00371644|Active Comparator|Arm 2|Participants receive 12 biweekly sessions of Present Centered Therapy (PCT).
3306871|NCT00371631|Other|Arm 1|insertion of E. coli coated catheter
3306872|NCT00371592|Experimental|1|Participants will receive acyclovir for 24 weeks
3306873|NCT00371592|Placebo Comparator|2|Participants will receive acyclovir placebo for 24 weeks
3306874|NCT00371566|Experimental|Lapatinib|
3306875|NCT00371566|Placebo Comparator|Placebo|
3306876|NCT00371540|No Intervention|I|Routine care in the clinic
3306877|NCT00371540|Experimental|II|Follow-up in clinic every 3 months, home visits monthly
3306878|NCT00371501|Active Comparator|treatment arm 1|
3306879|NCT00371501|Placebo Comparator|Treatment arm 2|
3306880|NCT00371501|Active Comparator|treatment arm 3|aspirin
3306881|NCT00371501|Placebo Comparator|treatment arm 4|placebo
3306934|NCT00370994|Active Comparator|Caudal epidural injection|Caudal epidural with placement of catheter in sacral canal with injection of 5 mL of 2% preservative-free lidocaine, followed by 6 mL of 0.9% sodium chloride solution and 6 mg of non-particulate Betamethasone and 1 mL of sodium chloride solution
3306935|NCT00370994|Active Comparator|Percutaneous adhesiolysis|Pecutaneous adhesiolysis and targeted placement of Racz catheter with injection of 5 mL of 2% preservative-free lidocaine, followed by 6 mL of 10% sodium chloride solution and 6 mg of non-particulate Betamethasone and 1 mL of sodium chloride solution
3306936|NCT00370981|Experimental|0.15 mg|
3306937|NCT00370981|Experimental|0.30 mg|
3306882|NCT00371488|Experimental|GW572016 in combination with trastuzumab|"Lapatinib:~A specified dose of lapatinib will be orally taken once daily, at least one hour before or one hour after the morning meal. Lapatinib should be taken at the same time of day wherever possible.~The starting dose of lapatinib should be 750 mg/day, which will be increased to 1000 mg/day (dose escalation group) according to the dose escalation criteria.~Trastuzumab:~Trastuzumab (4 mg/kg/day in the first week and 2 mg/kg/day for the 2nd and subsequent weeks) will be administered by intravenous infusion over at least 90 minutes immediately after administration of lapatinib. The fifth (Day 36) and subsequent doses may be administered up to 3 days after the scheduled date. In this case, however, the all following doses should be administered at one-week intervals."
3306883|NCT00371475|Experimental|Arm 1|
3306884|NCT00371475|Other|Arm 2|Historical Comparator: control data derived from the TAXUS IV and TAXUS V clinical trials
3306885|NCT00371462|Active Comparator|Arm 1|MOVE! level 2 group weight loss counseling, the VA standard of care alone (Standard Care);
3306886|NCT00371462|Experimental|Arm 2|MOVE! level 2 + Personal Digital Assistant decision support tool (PDA) (Treatment)
3306887|NCT00371449||hearing aid users|hearing aid users
3306888|NCT00371436|Active Comparator|Progressive Audiologic Tinnitus Management (PATM)|"The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment."
3306889|NCT00371436|Other|Usual Care (UC)|Typical audiologic care that would be received in a VA Audiology Clinic.
3306890|NCT00371423|Experimental|Arm 1|
3306891|NCT00371423|Other|Arm 2|Control data derived from ATLAS Workhorse Trial
3306892|NCT00371397|Experimental|Hatha yoga classes|Groups consisted of novices or experts. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
3306893|NCT00371397|Sham Comparator|Movement Control|Non-Hatha yoga gentle movement. Groups consisted of novices or experts. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
3306894|NCT00371397|No Intervention|Passive Video Control|Another control condition, a neutral video that did not include any music, allowed us to contrast the effects of yoga with no activity.The session included a sequence on how to design physics experiments for a high school classroom, as well as segments from two lectures on polymers and quantum mechanics. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
3306895|NCT00371384|Experimental|2|structural massage
3306896|NCT00371384|Experimental|1|relaxation massage
3306897|NCT00371371|Experimental|BM-MNC|autologous bone marrow-derived mononuclear cells
3306898|NCT00371371|Placebo Comparator|Placebo|Placebo
3306899|NCT00371345|Experimental|Dasatinib|Participants with either a Human epidermal growth factor (Her2/neu)-amplified tumor type or ER and/or PgR positive tumor types received oral dasatinib twice daily (BID).
3306900|NCT00371319|Active Comparator|Tacrolimus|Tacrolimus treatment
3306901|NCT00371319|Active Comparator|mycophenolate mofetil|mycophenolate mofetil
3306902|NCT00371293|Active Comparator|1|Participants will receive CPAP therapy.
3306903|NCT00371293|Active Comparator|2|Participants will take part in a weight loss program.
3306904|NCT00371293|Experimental|3|Participants will receive CPAP therapy and take part in a weight loss program.
3306905|NCT00371280|Active Comparator|1|Pegged unpegged hydroxyapatite orbital implantation
3306906|NCT00371280|Active Comparator|2|Unpegged hydroxyapatite orbital implantation
3306907|NCT00371267|Experimental|Arm 1: Telephone-delivered CBT|Telephone-delivered cognitive behavior therapy for pain management
3306908|NCT00371267|Active Comparator|Arm 2: Telephone patient education|Telephone-delivered patient education regarding management of chronic pain
3306909|NCT00371254|Experimental|1|
3306910|NCT00371254|Experimental|2|
3306911|NCT00371228|Experimental|1|Umbilical cord not cut until pulsation stops, in order to provide additional blood to newborn.
3306912|NCT00371228|No Intervention|2|Umbilical cord cut soon after birth without waiting for pulsing to stop.
3306913|NCT00371215|Experimental|1|rThrombin
3306914|NCT00371189|Experimental|Group C: Ad35.CS.01-10^10 vp/ml|15 subjects will receive dosage 10^10 vp/mL; 3 subjects will receive placebo.
3306915|NCT00371189|Experimental|Group D: Ad35.CS.01-10^11 vp/ml|15 subjects will receive dosage 10^11 vp/mL; 3 subjects will receive placebo.
3306916|NCT00371189|Experimental|Group A: Ad35.CS.01-10^8 vp/ml|15 subjects will receive dosage 10^8 vp/mL; 3 subjects will receive placebo.
3306917|NCT00371189|Experimental|Group B: Ad35.CS.01-10^9 vp/ml|15 subjects will receive dosage 10^9 vp/mL; 3 subjects will receive placebo.
3306918|NCT00371176|Experimental|D-Cycloserine|Brief imaginal exposure therapy plus DCS pill
3306919|NCT00371176|Placebo Comparator|Placebo|Brief imaginal exposure therapy plus Placebo pill
3306920|NCT00371163||Contact Dermatitis|Males or females with contact dermatitis
3306921|NCT00371163||Psoriasis|Males or females with psoriasis
3306922|NCT00371163||No skin disease|Males or females with no skin diseases
3306923|NCT00371163||Atopic Dermatitis|Males of females with atopic dermatitis
3306924|NCT00371150|Experimental|Arm1|
3306925|NCT00371137|Placebo Comparator|1|
3306926|NCT00371137|Experimental|2|
3306927|NCT00371111|Active Comparator|1|Intravitreal injection of Triamcinolone
3306928|NCT00371111|Active Comparator|2|Intravitreal injection of Avastin
3306929|NCT00371098|Experimental|active vaccine|patients received active influenza vaccine for season 2004/2005
3306930|NCT00371098|Placebo Comparator|placebo vaccine|patients received placebo influenza vaccine for season 2004/2005 containing all vaccine compounds except viral antigens
3306931|NCT00371085|Experimental|1|Video-based patient education on heart failure self care
3306932|NCT00371033|Active Comparator|1|Pregabalin
3306933|NCT00371033|Placebo Comparator|2|Placebo
3306938|NCT00370981|Experimental|0.60 mg|
3306939|NCT00370981|Placebo Comparator|PBO|
3307291|NCT00366353|Other|1|Sedation suring a spontaneous breathing trial.
3306940|NCT00370955|Active Comparator|High vacuum group|Those patients who underwent phacoemulsification using high hydrodynamic parameter: 400 mmHg vacuum and 40 ml/min flow rate.
3306941|NCT00370955|Active Comparator|Low vacuum group|Patients who underwent phacoemulsification using low hydrodynamic parameters: 200 mmHg vacuum and 20 ml/min flow rate.
3306942|NCT00370942|Placebo Comparator|GW823093C A|A=45 mg
3306943|NCT00370942|Placebo Comparator|GW823093C B|B=30 mg
3306944|NCT00370942|Placebo Comparator|GW823093C C|C=15 mg
3306945|NCT00370929|Experimental|Meditation|
3306946|NCT00370916|Experimental|Arm 1|Physician-initiated medication reconciliation
3306947|NCT00370916|Experimental|Arm 2|Pharmacist-initiated medication reconciliation
3306948|NCT00370916|No Intervention|Arm 3|No formal medication reconciliation
3306949|NCT00370890|Experimental|A|Adjuvant chemotherapy and then clinical follow-up and surveillance
3306950|NCT00370890|No Intervention|B|Clinical follow-up and surveillance only
3306951|NCT00370877|Active Comparator|Standard care for post-partum hemorrhage|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage.
3306952|NCT00370877|Experimental|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
3306953|NCT00370851|Experimental|1|Intravitreal injection of Avastin
3306954|NCT00370851|Sham Comparator|2|
3306955|NCT00370838|Experimental|Levetiracetam|"Levetiracetam (Keppra) is used in one phase of this cross-over study.~The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase."
3306956|NCT00370838|Active Comparator|Clonidine|"Clonidine is used in one phase of this cross-over study.~The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase."
3306957|NCT00370812|Active Comparator|A|AMT with conventional medical therapy
3306958|NCT00370812|Active Comparator|B|Medical treatment alone
3306959|NCT00370799|Active Comparator|local anesthetic|Group 1. local anesthetics only
3306960|NCT00370799|Active Comparator|Local anesthetic with generic Celestone|Group 2. local anesthetic with 6mg of non-particulate Celestone
3306961|NCT00370799|Active Comparator|Local anesthetic with Celestone|Group 3. local anesthetic with 6 mg of brand nameCelestone
3306962|NCT00370799|Active Comparator|Local anesthetic with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
3306963|NCT00370786|Experimental|1|
3306964|NCT00370760|Active Comparator|1|
3306965|NCT00370760|Placebo Comparator|2|
3306966|NCT00370747|Experimental|Ecabet|Ophthalmic solution in the Study eye four times daily for 90 days.
3306967|NCT00370747|Placebo Comparator|Placebo|Ophthalmic solution in the Study eye four times daily for 90 days.
3306968|NCT00370721|Experimental|I|
3306969|NCT00370695|Active Comparator|Precision Spinal Cord Stimulation System|Single arm Precision Spinal Cord Stimulation System.
3306970|NCT00370682|Experimental|T-DEN F17|Full Dose (0.5 mL) 0 and 6 months
3306971|NCT00370682|Experimental|T-DEN F19|Full Dose (0.5 mL) at 0 and 6 months
3306972|NCT00370682|Placebo Comparator|Placebo Comparator|0.5 mL sterile buffer at 0 and 6, subcutaneous injection
3306973|NCT00370604|Experimental|1|19g needle, 23g catheter
3306974|NCT00370604|Active Comparator|2|traditional =>18g needle
3306975|NCT00370591|Experimental|Arm 1|
3306976|NCT00370552|Experimental|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|
3306977|NCT00370552|Experimental|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|
3306978|NCT00370552|Active Comparator|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|
3306979|NCT00370513|Experimental|Pazopanib Arm|Different doses of oral pazopanib once daily for the duration of the study starting on Day 1 of Treatment Period 1. Treatment continues until disease progression or withdrawl from study.
3306980|NCT00370500|Experimental|A|There is only one arm in this study. All probands receive quetiapine.
3306981|NCT00370448|Experimental|1|Training gatekeeper recruited from students and tutors and counselors
3306982|NCT00370448|Active Comparator|2|
3306983|NCT00370448|No Intervention|3|
3306984|NCT00370409|Experimental|1|Cryotherapy
3306985|NCT00370409|Placebo Comparator|2|
3306986|NCT00370383|Experimental|Satraplatin|Satraplatin administered orally once daily for 5 consecutive days followed by erlotinib for 14 consecutive days
3306987|NCT00370383|Experimental|Erlotinib|Erlotinib administered orally once daily. Erlotinib - [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-y]- (3-ethynyl-phenyl)amine hydrochloride, molecular weight 393.4. This is a small molecule that competes with the binding of ATP to the intracellular tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and blocking downstream signal transduction.
3306988|NCT00370370|Active Comparator|1|Injection of intravitreal bevacizumab
3306989|NCT00370370|Active Comparator|2|Injection of bevacizumab + triamcinolone acetonide
3306990|NCT00370344|Active Comparator|Laparoscopic cholecystectomy|Operation by experts in laparoscopy.
3306991|NCT00370344|Active Comparator|Small-incision open cholecystectomy|Operation by experts in small-incision cholecystectomy.
3306992|NCT00370331|Experimental|Treatment arm plus standard of care|Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
3306993|NCT00370331|Placebo Comparator|placebo plus standard of care|Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
3307118|NCT00368901|Experimental|Single arm|Every other week dosing of Aranesp SC
3306994|NCT00370305|Experimental|Rosiglitazone treatment|Rosiglitazone will be given to the subjects. All subjects will be analyzed before and after treatment
3306995|NCT00370292|Experimental|Pemetrexed - Before Protocol Amendment|
3306996|NCT00370292|Experimental|Pemetrexed - After Protocol Amendment|
3306997|NCT00370279|Active Comparator|1|scleral buckling
3306998|NCT00370279|Active Comparator|2|Primary vitrectomy without encircling band
3306999|NCT00370279|Active Comparator|3|Primary vitrectomy with encircling band
3307000|NCT00370279|Active Comparator|4|Triamcinolone assisted vitrectomy
3307001|NCT00370253|Active Comparator|2|Terlipressin
3307002|NCT00370253|Experimental|1|Noradrenalin
3307003|NCT00370240|Experimental|Ropivacaïne|
3307004|NCT00370240|Placebo Comparator|placebo|
3307005|NCT00370149|Active Comparator|Antibiotic-impregnated Catheters (M/R)|Interventions is insertion intra-operatively of catheters impregnated with minocycline and rifampin to determine if their is a therapeutic difference between this catheter and the placebo (non-impregnated) catheter. The catheters are sized to accommodate children in different size ranges: Cook Inc. Double Lumen 4 Fr., 8 cm long, (C-UDLM-401J-ABRM-HC), 5 Fr., 8 cm long, (C-UDLM-501J-ABRM-HC), and 5 Fr., 12 cm long, (C-UDLMY-501J-RSC-ABRM-HC).
3307006|NCT00370149|Placebo Comparator|Non-impregnated Catheter (C/S)|Intervention is insertion intra-operatively of conventional, non-impregnated catheters. There are two sizes to accommodate children in different size ranges: Cook Incorporated Double Lumen Polyurethane Central Venous Catheters, 4 Fr., 8 cm long, (C-UDLM-401J), 5 Fr., 8 cm long, (C-UDLM-501J), and 5 Fr., 12 cm long (C-UDLM-501J-RSC).
3307007|NCT00370110|Experimental|Itopride|
3307008|NCT00370110|Other|Placebo|
3307009|NCT00370097|Experimental|Subjects receiving HFA|Subjects in Session 1 will receive two inhalations of placebo HFA by meter-dose inhaler (MDI) twice daily and in Session 2 subjects will receive two inhalations of fluticasone propionate (FP) HFA MDI 44 mcg twice daily
3307010|NCT00370084|Placebo Comparator|Placebo|
3307011|NCT00370084|Experimental|Itopride|
3307012|NCT00370071|Experimental|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
3307013|NCT00369967|Experimental|Quick start|Start contraceptive method (NuvaRing) day of enrollment
3307014|NCT00369967|Active Comparator|Traditional start|Start contraceptive method (NuvaRing) after next menses (per package insert)
3307015|NCT00369941|Experimental|MK-0518 400 mg b.i.d.|MK-0518 400 mg, which can be taken by mouth (PO) twice a day (b.i.d.) without regard to food, and placebo to efavirenz, which will be taken PO at bedtime (q.h.s.) on an empty stomach preferably at bedtime. All participants will take one tablet of TRUVADA® (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) with food, daily with the morning dose of MK-0518. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
3307016|NCT00369941|Active Comparator|Efavirenz 600 mg q.h.s.|Efavirenz 600 mg, which will be taken by mouth (PO) at bedtime (q.h.s.) on an empty stomach preferably at bedtime, and placebo to MK-0518, which will be taken PO twice a day (b.i.d.) without regard to food. All participants will take one tablet of TRUVADA® with food, daily with the morning dose of placebo. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
3307017|NCT00369928|Placebo Comparator|Placebo|Placebo, oral dose, BID
3307018|NCT00369928|Experimental|25 mg PG-760564|25 mg BID, of oral PG-760564
3307019|NCT00369928|Experimental|100 mg PG-760564|100 mg BID, of oral PG-760564
3307020|NCT00369915|Experimental|Plac/Scop|Placebo then scopolamine
3307021|NCT00369915|Experimental|Scop/Plac|Scopolamine then placebo
3307022|NCT00369850|Experimental|Tamoxifen for 5 years|Patients treated with tamoxifen for 5 years after randomisation.
3307023|NCT00369850|Experimental|Letrozole for 5 years|Patients treated with letrozole for 5 years after randomisation.
3307024|NCT00369850|Experimental|Tamoxifen 2 years plus letrozole 3 years|Patients treated with tamoxifen for 2 years and afterwards with letrozole for 3 years.
3307025|NCT00369850|Experimental|Letrozole 2 years plus tamoxifen 3 years|Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.
3307026|NCT00369837|Experimental|clevidipine|A patient-specific blood pressure target range (TR) of ≥20 mm Hg and ≤40 mm Hg SBP was prespecified by the investigator. Once established, clevidipine (0.5 mg/mL in 20% lipid emulsion) intravenous infusion was initiated at 2.0 mg/h and maintained for the first 3 minutes. Clevidipine was up-titrated, as tolerated by the patient, by doubling the dose every 3 minutes until the prespecified systolic blood pressure (SBP) target range was achieved and could continue to be titrated up or down to maintain the desired long-term SBP reduction.
3307027|NCT00369824|Experimental|Cervarix + Boostrix/Menactra Group|Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.
3307028|NCT00369824|Experimental|Cervarix + Menactra/Boostrix Group|Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.
3307029|NCT00369824|Experimental|Cervarix + Boostrix + Menactra Group|Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.
3307030|NCT00369824|Experimental|Boostrix/Cervarix Group|Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.
3307031|NCT00369824|Experimental|Menactra/Cervarix Group|Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.
3307032|NCT00369824|Experimental|Cervarix Group|Subjects received Cervarix at Months 0, 1 and 6.
3307033|NCT00369785|Experimental|Arm I - Donepezil|Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day
3307034|NCT00369785|Placebo Comparator|Arm II - Control|Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day
3307035|NCT00369759||1|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
3307036|NCT00369759||2|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
3307037|NCT00369759||3|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
3307038|NCT00369746||Alcohol and major depression, citalopram|Patients with alcohol use disorder and major depression, treated with citalopram tablets, 20-60 mg, once daily, for 12 weeks
3307039|NCT00369746||Major Depression, citalopram|Patients with major depression, treated with citalopram tablets 20-60 mg daily, for 12 weeks
3307040|NCT00369733|Experimental|Single arm|Aranesp adminsitered every other week for 52 weeks
3307041|NCT00369707|Experimental|Bortezomib and Rituximab|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
3307042|NCT00369694|Active Comparator|1|72 hours of Terlipressin
3307043|NCT00369694|Placebo Comparator|2|24 hours of Terlipressin & then next 48 hours of Dummy of Terlipressin
3307044|NCT00369681|Experimental|R-ABVD|ABVD (doxorubicin; vinblastine; bleomycin; dacarbazine) given as standard for 6-8 cycles. Rituximab given 375 mg/m^2 Cycle 1 Days -6, 1, 8, 15, and 22. Rituximab given 375 mg/m^2 Cycles 2, 4, and 6 Day 1.
3307045|NCT00369668|Experimental|High Intensity|Bilateral training moving both arms coupled with neuromuscular electrical stimulation; four 90-minute sessions/week for 2 weeks.
3307046|NCT00369668|Active Comparator|Low Intensity|Bilateral training moving both arms coupled with neuromuscular electrical stimulation; two 90-minute sessions/week for 2 weeks.
3307047|NCT00369668|Active Comparator|Control|Bilateral training moving both arms coupled with sham neuromuscular electrical stimulation
3307048|NCT00369655|Experimental|Treatment (ziv-afibercept)|Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3307049|NCT00369629|Experimental|Gemcitabine and Pemetrexed Disodium|
3307050|NCT00369616|Experimental|NicQb vaccine|
3307051|NCT00369616|Placebo Comparator|Placebo vaccine|
3307052|NCT00369603|Experimental|Razadyne ER|galantamine treatment group
3307053|NCT00369603|Experimental|Aricept|Aricept Treatment Group
3307054|NCT00369590|Experimental|All Study Patients|"Patients receive VEGF Trap (ziv-aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study; laboratory biomarker analysis."
3307055|NCT00369577|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo, single dose
3307056|NCT00369577|Experimental|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, single dose
3307057|NCT00369577|Experimental|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, single dose
3307058|NCT00369564|Experimental|Arm I Glutamic Acid|Patients receive oral glutamic acid 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).
3307059|NCT00369564|Placebo Comparator|Arm II Placebo|Patients receive oral placebo 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).
3307060|NCT00369551|Experimental|Treatment (paclitaxel, carboplatin, bevacizumab, radiation)|"Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, 36, and 43 and bevacizumab IV over 30-90 minutes on days 1, 15, 29, and 43. Patients also undergo chest radiotherapy 5 days a week for 7 weeks beginning on day 1.~Consolidation therapy: Beginning 4-5 weeks after completion chemoradiotherapy, patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 1 hour followed by bevacizumab IV over 30 minutes. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
3307061|NCT00369538|Active Comparator|1|losartan, hydrochlorothiazide
3307062|NCT00369538|Active Comparator|2|hydrochlorothiazide, losartan
3307063|NCT00369512|Experimental|Erlotinib|Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
3307064|NCT00369486|Active Comparator|1|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study (ETDRS) technique)
3307065|NCT00369486|Experimental|2|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
3307066|NCT00369486|Experimental|3|Anterior peribulbar injection of 20 mg triamcinolone
3307067|NCT00369486|Experimental|4|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
3307068|NCT00369486|Experimental|5|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
3307069|NCT00369473|Experimental|1|350
3307070|NCT00369473|Experimental|2|350
3307071|NCT00369447|Experimental|1|200 mg dose
3307072|NCT00369447|Placebo Comparator|2|
3307073|NCT00369408|Experimental|1|naltrexone (50 mg orally) for 12-week treatment period
3307074|NCT00369408|Placebo Comparator|2|placebo for 12-week treatment period
3307075|NCT00369395|Experimental|Volociximab|Volociximab 15 mg/kg
3307076|NCT00369382|Active Comparator|1|Group 1: Continuation of CNI regimen
3307077|NCT00369382|Experimental|2|Group 2: (CNI-Free) Conversion to SRL-based regimen
3307078|NCT00369356|Sham Comparator|1|Bare Metal Stenting
3307079|NCT00369356|Active Comparator|2|Stenting with DES
3307080|NCT00369356|Experimental|3|Bare metal stenting and administration of prednisone
3307081|NCT00369343|Experimental|A|
3307082|NCT00369343|Placebo Comparator|B|
3307083|NCT00369317|Experimental|Treatment (combination chemotherapy)|"INDUCTION THERAPY COURSE I: Patients receive cytarabine IT on day 1 and cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV continuously, and oral thioguanine BID on days 1-4. COURSE II: Patients receive high-dose cytarabine IV over 3 hours BID on days 1, 2, 8, and 9 and asparaginase (IM) on days 2 and 9.~COURSE III: Patients receive treatment as in course I. COURSE IV: Patients receive cytarabine IV, daunorubicin hydrochloride IV, and oral thioguanine as in course I~INTENSIFICATION THERAPY: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity."
3307084|NCT00369291|Experimental|CpG 7909|Patients treated with CpG 7909 oligodeoxynucleotides (ODNs) after autologous transplantation to enhance immune reconstitution.
3307283|NCT00366457|Other|Gemcitabine, Bevacizumab and Erlotinib|single-arm, no masking
3307085|NCT00369278|Experimental|Intensified Mycophenolate sodium|Enteric-coated mycophenolate sodium was given according to the following dosing regimen: Day 1-14: 2880 mg/day (2 x 1440 mg), then day 15-42: 2160 mg/day (2 x 1080 mg), then day 43-End of study (month 6): 1440 mg/day (2 x 720 mg). Total duration of treatment was 180 days.
3307086|NCT00369278|Active Comparator|Standard Mycophenolate sodium|Enteric-coated mycophenolate sodium was given according to the following dosing regimen: Day 1 - End of Study(month 6): 1440 mg/day (2 x 720 mg). Total duration of treatment was 6 months.
3307087|NCT00369265|Experimental|Lansoprazole|Lansoprazole 30 mg Twice Daily
3307088|NCT00369265|Placebo Comparator|Sugar pill|placebo
3307089|NCT00369226|Experimental|Bortezomib/Tacrolimus/Methotrexate post HSCT|
3307090|NCT00369200|Experimental|Arm I|"Patients receive AFP464 IV over 3 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.~Cohorts of 2-6 patients receive escalating doses of AFP464 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which ≤ 1 of 6 patients experience dose-limiting toxicity. An additional 10 patients whose tumor is amenable to biopsy are treated at the MTD.~Patients undergo blood collection periodically for pharmacokinetic and pharmacodynamic studies. Patients treated at the MTD also undergo tumor tissue biopsies periodically for additional pharmacodynamic and correlative biomarker studies.~After completion of study treatment, patients are followed for 4 weeks."
3307091|NCT00369174|Experimental|Treatment (rosiglitazone maleate)|Patients receive oral rosiglitazone once daily. Treatment continues for 12 weeks in the absence of unacceptable toxicity.
3307092|NCT00369161|Active Comparator|Very low dose tacrolimus|The first dose of everolimus was to be administered not later than 24 hours after transplantation with a starting dose of 1.5 mg bis in diem/twice a day (b.i.d.) thereafter adjusted to maintain the trough blood levels between 3 and 8 ng/ml. Tacrolimus was to be initiated within 24 hours after reperfusion of the graft with a starting dose of 0.1 mg/kg/day thereafter adjusted to maintain the trough blood levels between 4 and 7 ng/ml. Up to months three all patients received the same treatment and after three months patients in this arm received tacrolimus to reach a trough blood level between 1.5 and 3 ng/ml. All patients received two doses of 20 mg basiliximab, administered as an intravenous bolus injection. The first dose was given on the day of transplantation, with the second dose being administered on the fourth day post-transplant. Intravenous (i.v.) prednisone (or equivalent) was given pre- or intra-operatively according to center practice.
3307093|NCT00369161|Active Comparator|Low dose tacrolimus|The first dose of everolimus was to be administered not later than 24 hours after transplantation with a starting dose of 1.5 mg bis in diem/twice a day (b.i.d.) thereafter adjusted to maintain the trough blood levels between 3 and 8 ng/ml. Tacrolimus was to be initiated within 24 hours after reperfusion of the graft with a starting dose of 0.1 mg/kg/day thereafter adjusted to maintain the trough blood levels between 4 and 7 ng/ml. Up to months three all patients received the same treatment and after three months patients in this arm received tacrolimus to reach a trough blood level between 4 and 7 ng/ml. All patients received two doses of 20 mg basiliximab, administered as an intravenous bolus injection. The first dose was given on the day of transplantation, with the second dose being administered on the fourth day post-transplant. Intravenous (i.v.) prednisone (or equivalent) was given pre- or intra-operatively according to center practice.
3307094|NCT00369122|Experimental|Treatment (radiation therapy, bevacizumab, cisplatin)|"Patients undergo pelvic EBRT once daily, 5 days a week, for 5 weeks for a total of 45 Gy.~Some patients also undergo low-dose rate brachytherapy twice, 1-3 weeks apart, beginning >= 4 weeks after initiating EBRT or high-dose rate brachytherapy 5 times, >= 48 hours apart, beginning >= 2 weeks after initiating EBRT. EBRT and chemotherapy are halted on the day of high-dose rate brachytherapy. Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29 and cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, and 35."
3307095|NCT00369070|Experimental|A|AMG 706 125 mg once daily (QD) and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.
3307096|NCT00369070|Experimental|B|AMG 706 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.
3307097|NCT00369070|Active Comparator|C|Bevacizumab 15 mg/kg bevacizumab, delivered via intravenous (IV) infusion once every 3 weeks and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.
3307098|NCT00369031|Experimental|1|Human Immunodeficiency Virus glycoprotein 140 (vaccine)
3307099|NCT00369031|Active Comparator|2|Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant
3307100|NCT00369031|Active Comparator|3|Labile Toxin mutant LTK63 adjuvant
3307101|NCT00369018|Active Comparator|MAL 3|
3307102|NCT00369018|Active Comparator|MAL 12|
3307103|NCT00369018|Active Comparator|HAL 10, 3|
3307104|NCT00369018|Active Comparator|HAL 10, 12|
3307105|NCT00369018|Active Comparator|HAL 40, 3|
3307106|NCT00369018|Active Comparator|HAL 40, 12|
3307107|NCT00368992|Experimental|Treatment (cetuximab, paclitaxel, bevacizumab)|"INDUCTION THERAPY: Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive cetuximab IV over 1 hour on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
3307108|NCT00368979|Active Comparator|Dutasteride|
3307109|NCT00368979|Placebo Comparator|Placebo|
3307110|NCT00368966|Experimental|1|
3307111|NCT00368966|Active Comparator|2|
3307112|NCT00368953|Experimental|1|
3307113|NCT00368953|Active Comparator|2|
3307114|NCT00368940|Experimental|PATH|Participants will receive PATH for 12 weeks
3307115|NCT00368940|Active Comparator|ST-CI|Participants will receive ST-CI for 12 weeks
3307116|NCT00368927|Experimental|Arm I|Patients receive oral sulindac twice daily for 6 months.
3307117|NCT00368927|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 6 months.
3307284|NCT00366444|Experimental|1|
3307119|NCT00368875|Experimental|vorinostat, paclitaxel, bevacizumab|Vorinostat BID on days 1-3, 8-10, and 15-17, paclitaxel IV over 1 hour on days 2, 9, and 16, bevacizumab IV over 30-90 minutes on days 2 and 16, repeat every 28 days.
3307120|NCT00368849|Experimental|40 milligram twice a day atomoxetine|Participants received 40 milligram twice a day atomoxetine for 4 weeks.
3307121|NCT00368849|Placebo Comparator|Twice a day matching placebo|Participants received twice a day matching placebo for 4 weeks.
3307122|NCT00368836|Experimental|1|Breath Screen PE device + D-dimer
3307123|NCT00368784||1|Individuals ages 12-85 with an immune mediated skin disease, such as psoriasis, scleroderma, or mycosis fungoides. Peripheral blood and/or check swabs will be collected from participants ages 12- 85 years old. These samples will then be used to characterize the inflammatory cells as described above.
3307124|NCT00368784||2|Age-Matched Controls without immune mediated skin diseases. Peripheral blood and/or check swabs will be collected from participants ages 12- 85 years old. These samples will then be used to characterize the inflammatory cells as described above.
3307125|NCT00368771|Active Comparator|1|IBS Stress Management
3307126|NCT00368771|Active Comparator|2|IBS Symptom Management
3307127|NCT00368771|Active Comparator|3|IBS Educational Training
3307128|NCT00368745|Active Comparator|Pregabalin|Pregabalin treatment for GAD during 6 week taper/discontinuation from alprazolam treatment; followed by 6 weeks pregabalin treatment 'alprazolam free'.
3307129|NCT00368745|Placebo Comparator|Placebo|Placebo treatment of GAD during 6 week taper/discontinuation of alprazolam treatment followed by 6 weeks continuation of placebo treatment 'alprazolam free'.
3307130|NCT00368719|No Intervention|1|
3307131|NCT00368706|Experimental|1|
3307132|NCT00368706|Active Comparator|2|
3307133|NCT00368654|Active Comparator|A|Monotherapy with Raptiva alone
3307134|NCT00368654|Experimental|B|Combination therapy with both Raptiva and Methotrexate
3307135|NCT00368654|Experimental|C|Continue Raptiva, discontinue methotrexate
3307136|NCT00368654|Experimental|D|Continue combination therapy with both Raptiva and Methotrexate
3307137|NCT00368641|Experimental|Intervention|peritoneal dialysis
3307138|NCT00368641|No Intervention|Standard of Care|
3307139|NCT00368615||1|Subjects ages 18-85 years old with biopsy proven melanoma. Peripheral blood will be collected from adults ages 18-85 years old. These samples will then be used for PCR analysis and to generate melanoma-specific T cell clones. If the participant requires a palliative resection of a melanoma tumor(s) then tissue from the tumor will be used to characterize the melanoma's interaction with the immune system and to generate melanoma-specific cell lines. T cell clones isolated from participant's peripheral blood will then be assayed for in-vitro responsiveness to these cell lines. All experiments will be conducted in-vitro.
3307140|NCT00368615||2|Age-matched controls (no evidence of melanoma)
3307141|NCT00368602|Experimental|1|This group receives topical beta adrenergic antagonists (Timoptic) plus standard of care.
3307142|NCT00368602|Placebo Comparator|2|The group will be given standard of care with placebo medication.
3307143|NCT00368550|Experimental|1|Oral sertraline, cognitive-behavioral counseling to maintain abstinence from alcohol
3307144|NCT00368550|Placebo Comparator|2|Placebo, cognitive-behavioral counseling to maintain abstinence from alcohol
3307145|NCT00368537|Active Comparator|1|Arm 1: Tigecycline
3307146|NCT00368537|Active Comparator|2|Arm 2: Ampicillin-Sulbactam or Amoxicillin-Clavulanate plus or minus a glycopeptide
3307147|NCT00368511|No Intervention|1|Listening to music and posture changes
3307148|NCT00368472|Experimental|Perampanel|Participants previously receiving placebo/perampanel in the double blind study, were titrated to receive perampanel 2 mg to 12 mg, once daily during the OLE study
3307149|NCT00368459|Experimental|raloxifene|oral raloxifene 120 mg once daily
3307150|NCT00368459|Placebo Comparator|placebo|identical appearing oral placebo
3307151|NCT00368381|Active Comparator|Hydrocortision and fludrocortisone|Study is comparing hydrocortisone alone versus the combination of hydrocortisone and fludrocortisone in the treatment of adrenal insufficiency of septic patients.
3307152|NCT00368368|Experimental|1|
3307153|NCT00368368|Experimental|2|
3307154|NCT00368368|Experimental|3|
3307155|NCT00368355|Experimental|CLINIMACS Device|Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device
3307156|NCT00368355|Experimental|ISOLEX Device|Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device
3307157|NCT00368316|Experimental|S. sonnei conjugate vaccine|Shigella sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa
3307158|NCT00368316|Experimental|S. flexneri 2a conjugate vaccine|Shigella flexneri 2a O-specific polysaccharide covalently bound to recombinant exoprotein A of pseudomonas aeruginosa
3307159|NCT00368290|Experimental|1|modafinil plus CBT
3307160|NCT00368290|Placebo Comparator|2|placebo plus CBT
3307161|NCT00368277|Experimental|Aliskiren-based regimen|Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg
3307162|NCT00368277|Active Comparator|Ramipril-based regimen|Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg
3307163|NCT00368264|Experimental|1|azathioprine plus 4 infusions of infliximab (5 mg/kg)
3307164|NCT00368264|Placebo Comparator|2|azathioprine plus 4 placebo infusions
3307165|NCT00368251|Placebo Comparator|Placebo|Placebo Placebo twice a day (bid), 14 weeks (2 week Up-Titration Period + 12 week Maintenance Period)
3307166|NCT00368251|Experimental|Brivaracetam 5 mg/day|Brivaracetam (BRV) 5 mg/day 5 mg twice a day (bid) using 2.5 mg tablets for 12 weeks (after 2 week Up- Titration Period)
3307225|NCT00367380|Experimental|Group 2|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 414WRR
3307167|NCT00368251|Experimental|Brivaracetam 150 mg/day|Brivaracetam (BRV) 150 mg/day 150 mg twice a day (bid) using 25 mg and 50 mg tablets for 12 weeks (after 2 week Up-Titration Period)
3307168|NCT00368212|Experimental|1|"Participants will receive psychoeducational counseling (termed health care counseling)"
3307169|NCT00368212|Active Comparator|2|Participants will receive relaxation response training
3307170|NCT00368160|Experimental|1|eszopiclone 3 mg
3307171|NCT00368160|Placebo Comparator|2|Placebo tablet
3307172|NCT00368121|Experimental|Cetuximab + Dexamethasone|
3307173|NCT00368108|Experimental|2 mg perampanel|The Perampanel 2mg dosage was fixed for the entire double-blind study. Subjects taking perampanel 2mg were to take the dose orally once every day in the evening.
3307174|NCT00368108|Experimental|4 mg perampanel|The Perampanel 4mg group first were subjected to a 4 week titration period, followed by a maintenance period for the remaining weeks. Subjects taking perampanel 4mg had a titration period of 4 weeks, starting at 2mg per day adding 1mg of perampel every two weeks up to 4mg. The dosages were to be taken orally once every day in the evening.
3307175|NCT00368108|Placebo Comparator|placebo|The placebo dosage was a fixed dosage for the entire double-blind study. Subjects receiving the placebo were to take one dose orally once every day in the evening.
3307176|NCT00368082|Experimental|TGFbeta resistant LMP-specific CTLs|"CTLs be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~If patients with active disease have stable disease or a partial response at their 6 week or subsequent evaluations they will be eligible to receive up to 6 additional doses of CTLs at 1-2 monthly intervals-each of which will consist of the same cell number as their second injection."
3307177|NCT00368069|Experimental|Keppra® XR|Keppra® extended release formulation -XR
3307178|NCT00368069|Placebo Comparator|Placebo|placebo
3307179|NCT00368056|Experimental|1|eszopiclone 3 mg
3307180|NCT00368056|Placebo Comparator|2|Placebo tablet
3307181|NCT00368030|Experimental|A|Eszopiclone 3 mg QD
3307182|NCT00368030|Placebo Comparator|B|Placebo tablet
3307183|NCT00368017|Active Comparator|1|
3307184|NCT00368017|Placebo Comparator|2|
3307185|NCT00367991|Active Comparator|A|recombinant human erythropoietin 200 U/kg IV daily for 3 days
3307186|NCT00367991|Placebo Comparator|B|Normal saline volume to match active treatment IV daily for 3 days
3307187|NCT00367965|Experimental|1|eszopiclone 3 mg
3307188|NCT00367965|Placebo Comparator|2|placebo tablet
3307189|NCT00367952|Experimental|ATC 800mg BID|800mg ATC BID
3307190|NCT00367887|Active Comparator|1|
3307191|NCT00367887|Active Comparator|2|
3307192|NCT00367887|Active Comparator|3|
3307193|NCT00367861|Experimental|interruption of Glivec®|
3307194|NCT00367835|Experimental|SPD503 (Guanfacine hydrochloride)|
3307195|NCT00367835|Placebo Comparator|Placebo|
3307196|NCT00367809|Experimental|1|
3307197|NCT00367809|Active Comparator|2|
3307198|NCT00367809|No Intervention|3|
3307199|NCT00367770|Experimental|Tracleer|The starting dose for all patients will be 62.5 mg b.i.d. At the Week 4 visit, patients who were started on 62.5 mg b.i.d. will be uptitrated to 125 mg b.i.d. if the 62.5 mg b.i.d. dose was well-tolerated.
3307200|NCT00367757|Other|PVI group|Trigger-based ablation guided by pulmonary vein antrum isolation
3307201|NCT00367757|Other|CFAE group|Substrate-based ablation using an approach targeting CFAEs
3307202|NCT00367757|Other|Combined group|Combined trigger and substrate based approach
3307203|NCT00367744|Active Comparator|Rosigitazone arm|Rosiglitazone active 4 mg BID
3307204|NCT00367744|Placebo Comparator|Placebo arm|Matching Placebo BID
3307205|NCT00367705|Active Comparator|T|VSL-#3
3307206|NCT00367705|Placebo Comparator|P|
3307207|NCT00367679|Experimental|Single Arm|800 mg pazopanib oral daily
3307208|NCT00367666|Experimental|Patients Diagnosed with Breast Cancer|
3307209|NCT00367653|Experimental|1|
3307210|NCT00367653|Experimental|2|
3307211|NCT00367640|Experimental|100 IR|100 IR grass pollen allergen extract tablet
3307212|NCT00367640|Experimental|300 IR|300 IR grass pollen allergen extract tablet
3307213|NCT00367640|Experimental|500 IR|500 IR grass pollen allergen extract tablet
3307214|NCT00367640|Placebo Comparator|Placebo|Placebo tablet
3307215|NCT00367601|Experimental|1|Bevacizumab + erlotinib; if no progressive disease observed, combination or single-agent treatment will continue until unacceptable toxicity or progressive disease.
3307216|NCT00367484|Experimental|Rebif® (clone 484-39)|Rebif® 44 mcg, three times per week (tiw), subcutaneously (s.c.) During the first 4 weeks of the study, subjects underwent a dose titration regimen of 40% of Rebif® 22 mcg or 20% of Rebif® 44 mcg tiw (8.8 mcg per injection) in the first and second week followed by 100% of Rebif® 22 mcg or 50% of Rebif® 44 mcg (22 mcg per injection) in the third and fourth week. After 4 weeks, subjects received 44 mcg injected s.c. tiw.
3307217|NCT00367471|Active Comparator|Group A|Subjects in Treatment Group A (in cohorts of three) will receive oral lapatinib QD (Days 1 to 28). Following lapatinib administration on Day 1, paclitaxel will be administered intravenously over one hour followed immediately by an IV infusion of carboplatin over not less than 15 minutes. Carboplatin will be followed by an initial loading dose of trastuzumab by 90 minute IV infusion (first dose only) with subsequent IV doses of trastuzumab to be given weekly over 30 minute infusion.
3307218|NCT00367471|Active Comparator|Group B|Subjects in Treatment Group B (in cohorts of three) will receive oral lapatinib QD (Days 1 to 28). Following lapatinib administration on Day 1, paclitaxel will be administered intravenously over one hour followed immediately by a 15 minute intravenous infusion of carboplatin
3307219|NCT00367458|Active Comparator|A|STATIN 80 mg Atorvastatin daily
3307220|NCT00367458|Placebo Comparator|B|PLACEBO control
3307221|NCT00367432|Experimental|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
3307222|NCT00367406|Experimental|Treatment with a Gamma 3 nail.|
3307223|NCT00367393|Experimental|1|Pimecrolimus cream 1%
3307224|NCT00367380|Experimental|Group 1|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 413ABM
3307226|NCT00367380|Experimental|Group 3|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 418JAL
3307227|NCT00367341|Other|Escitalopram|
3307228|NCT00367341|Other|Cognitive Behavioral Therapy|
3307229|NCT00367328|Active Comparator|A|Oral Antibiotics in standard care vs. Laser treatment
3307230|NCT00367302|Experimental|1|Buprenorphine maintenance
3307231|NCT00367302|Active Comparator|2|Methadone maintenance
3307232|NCT00367276|Experimental|Arm 1|
3307233|NCT00367237|Experimental|Infliximab + methotrexate (IFX + MTX)|Remicade (infliximab [IFX]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week
3307234|NCT00367237|Active Comparator|Methotrexate (MTX)|Oral methotrexate (MTX) 15 mg/week
3307235|NCT00367198|Active Comparator|1|30 ml per serving
3307236|NCT00367198|Active Comparator|2|60 ml per serving
3307237|NCT00367198|No Intervention|3|chronic hemodialysis patients
3307238|NCT00367198|No Intervention|4|healthy subjects
3307239|NCT00367133|Active Comparator|1|Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
3307240|NCT00367133|Experimental|2|Intravitreal injection of 1mg of triamcinolone acetonide
3307241|NCT00367133|Experimental|3|Intravitreal injection of 4mg of triamcinolone acetonide
3307242|NCT00367042|No Intervention|1|
3307243|NCT00367029|Active Comparator|1|Print-based, individually tailored motivational program
3307244|NCT00367029|Experimental|2|Enhanced version of the print-based, individually tailored motivational program
3307245|NCT00367016|Placebo Comparator|A|The subjects will be randomized to a treatment group and a placebo group. Prior to Omalizumab administration, all subjects will undergo screening studies, including spirometry, blood test and skin test. Blood test includes comprehensive metabolic panel, CBC, and total and free IgE levels. Skin test will be done with a panel of 7 common allergens
3307246|NCT00367016|Active Comparator|B|The subjects will be randomized to a treatment group and a placebo group. Prior to Omalizumab administration, all subjects will undergo screening studies, including spirometry, blood test and skin test. Blood test includes comprehensive metabolic panel, CBC, and total and free IgE levels. Skin test will be done with a panel of 7 common allergens
3307247|NCT00367003|Experimental|DBS for Treatment Resistant Depression|Deep Brain Stimulation for Treatment Resistant Depression.
3307248|NCT00366990|Active Comparator|weight loss and sodium intake reduction|Behavioral and weight loss intervention, including a low sodium diet. Study goals are a 10% weight loss, 200 minutes of moderate physical activity a week, such as walking, and a 50% reduction in sodium intake.
3307249|NCT00366990|Placebo Comparator|weight loss and normal sodium intake|Behavioral and weight loss intervention, with regular sodium intake. Study goals are a 10% weight loss, 200 minutes of moderate physical activity a week, such as walking.
3307250|NCT00366964|No Intervention|Device|
3307251|NCT00366899|Experimental|1|13-valent pneumococcal conjugate vaccine
3307252|NCT00366899|Active Comparator|2|7-valent pneumococcal conjugate vaccine
3307253|NCT00366873|Active Comparator|1|cow-milk based infant formula
3307254|NCT00366873|Experimental|2|cow-milk based infant formula with prebiotics
3307255|NCT00366860|Experimental|Soy bread|Soy bread (75-100 mg isoflavone/day) for 12 weeks
3307256|NCT00366860|Active Comparator|Wheat bread|Wheat bread for 12 weeks
3307257|NCT00366834|Placebo Comparator|Control|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV on Day 1 + placebo
3307258|NCT00366834|Experimental|Single dose oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV + casopitant 150 mg on Day 1
3307259|NCT00366834|Experimental|3-day oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV + casopitant 150 mg on Day 1 + 50 mg on days 2 & 3
3307260|NCT00366834|Experimental|3-day IV/oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV on Day 1 + 90 mg IV casopitant on day 1 and 50 mg oral casopitant on days 2 & 3
3307261|NCT00366821||1|Examine the outcomes following cardiac surgery in those newborns with genetic abnormalities.
3307262|NCT00366821||2|Examine the outcomes following cardiac surgery in newborns without genetic abnormalities.
3307263|NCT00366795|Experimental|Satavaptan|
3307264|NCT00366795|Placebo Comparator|Placebo|
3307265|NCT00366782|Experimental|1|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to adults 18 to 49 years of age
3307266|NCT00366782|Experimental|2|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to HPIV3-seropositive children 15 to 59 months of age). This arm may enroll after Arm 1 depending on the effect of the vaccine on Arm 1.
3307267|NCT00366782|Experimental|3|One vaccination with rB/HPIV3 vaccine (at lower dose) given as nose drops to seronegative children or infants 6 to 36 months of age. This arm may enroll after Arm 2.
3307268|NCT00366782|Experimental|4|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to seronegative children or infants 6 to 36 months of age. This arm may enroll after Arm 2.
3307269|NCT00366782|Placebo Comparator|5|One vaccination with placebo vaccine given as nose drops to adults, HPIV3-seropositive children, or seronegative children or infants
3307270|NCT00366704|Experimental|A|
3307271|NCT00366704|Active Comparator|B|
3307272|NCT00366678|Experimental|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
3307273|NCT00366678|Active Comparator|7-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine
3307274|NCT00366639||001|
3307275|NCT00366626|Experimental|1.|Naltrexone one capsule a day
3307276|NCT00366626|Placebo Comparator|2|One capsule a day match to naltrexone
3307277|NCT00366548|Experimental|1|
3307278|NCT00366548|Active Comparator|2|
3307279|NCT00366535|Active Comparator|Placebo first, then Neurotropin (G-1)|Double blind cross-over study: receive Placebo for 12 weeks and then Neurotropin for 12 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
3307280|NCT00366535|Active Comparator|Neurotropin first, then Placebo (G-2)|Double blind cross-over study: receive Neurotropin for 12 weeks and then Placebo for 12 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others
3307292|NCT00366353|Other|2|No sedation during spontaneous breathing trial
3307293|NCT00366340|Experimental|1|13-valent pneumococcal conjugate vaccine
3307294|NCT00366340|Active Comparator|2|7-valent pneumococcal conjugate vaccine
3307295|NCT00366327|Experimental|A|
3307296|NCT00366301|Placebo Comparator|Placebo pill|Placebo pill
3307297|NCT00366301|Active Comparator|Metformin Pill|Metformin pill
3307298|NCT00366301|Active Comparator|Insulin Glargine plus placebo pill|Insulin glargine plus placebo pill
3307299|NCT00366301|Active Comparator|Insulin Glargine plus metformin pill|Insulin Glargine plus metformin pill
3307300|NCT00366288||1|
3307301|NCT00366288||2|
3307302|NCT00366288||3|
3307303|NCT00366288||4|
3307304|NCT00366288||5|
3307305|NCT00366288||6|
3307306|NCT00366288||7|
3307307|NCT00366275|Experimental|In vivo purging autotransplant|
3307308|NCT00366249|Active Comparator|A|
3307309|NCT00366249|Active Comparator|B|
3307310|NCT00366210|Experimental|Expanded CI therapy|3.5 hours of training for the more-affected arm set in the laboratory for 15 consecutive weekdays
3307311|NCT00366210|Placebo Comparator|Placebo Control|Stretching, movement exercises, and EMG biofeedback for the same duration as the experimental intervention.
3307312|NCT00366210|No Intervention|Usual & Customary Care Control|Treatments available to participants as part of their regular medical care, such as conventional physical or occupational therapy. For some participants, this would involve no treatment, since all participants were more than one year post stroke.f standard clinical care.
3307313|NCT00366158|Experimental|1|Ventricular Instrinsic Preference (VIP) turned ON
3307314|NCT00366158|Active Comparator|2|Ventricular Instrinsic Preference (VIP) turned OFF
3307315|NCT00366145|Active Comparator|1|Patients who receive standard of care plus treatment with ex vivo cultured adult human Mesenchymal Stem Cells
3307316|NCT00366145|Placebo Comparator|2|Patients who receive standard of care and do not receive treatment with ex vivo cultured adult human mesenchymal stem cells.
3307317|NCT00366093|Experimental|1|eszopiclone 3 mg
3307318|NCT00366093|Placebo Comparator|2|Placebo tablet
3307319|NCT00366041|Experimental|Cellularised LG002|Cellularised LG002
3307320|NCT00366041|Experimental|UnCellularised LG002|UnCellularised LG002
3307321|NCT00366028|Other|Organizational Model|Organizational Model: Participants in this arm of the study will receive information regarding the organizational model and work closely with the research team throughout the project to implement various aspects of the model. Participants in this arm of the study will be interviewed and participate in the data feedback portion of the study as well.
3307322|NCT00366028|Other|Data Feedback|Data Feedback Only: Participants in this arm will be interviewed periodically and participate in the data feedback portion of the study.
3307323|NCT00366002|Experimental|1|Darifenacin
3307324|NCT00365989|Experimental|1|
3307325|NCT00365976|Placebo Comparator|1|Placebo
3307326|NCT00365976|Active Comparator|2|Eszopiclone
3307327|NCT00365937|Experimental|Group A|The eight HLA-A2 peptides
3307328|NCT00365937|Experimental|Group B|The eight HLA-A2 peptides + immunological adjuvant Montanide ISA51
3307329|NCT00365937|Experimental|Group C|the eight peptides HLA-A2 + IMP321
3307330|NCT00365937|Experimental|Group D|The eight HLA-A2 peptides + the 2 immunological adjuvants (Montanides ISA 51 and IMP321)
3307331|NCT00365924|Other|Forteo|
3307332|NCT00365885|Experimental|1|electronic mail notifications to care managers about sentinel health events
3307333|NCT00365885|Experimental|2|feedback reports with notifications to clinic managers about sentinel health events
3307334|NCT00365885|Experimental|3|letters to patients with notifications about sentinel health events
3307335|NCT00365885|No Intervention|4|electronic mail notifications to care managers about sentinel health events -- generated but withheld
3307336|NCT00365885|No Intervention|5|feedback reports with notifications to clinic managers about sentinel health events -- generated but withheld
3307337|NCT00365885|No Intervention|6|letters to patients with notifications about sentinel health events -- generated but withheld
3307338|NCT00365872|Experimental|EBRT + DC Injection + Resection|Single Arm: EBRT + DC Injection + Resection. Prior to the fourth DC Injection, participants were assigned to 3 cohorts as outlined in that intervention.
3307339|NCT00365859|Experimental|De Novo|De novo participants (those who did not participate in protocol (CN138-178 [NCT00332241] or CN138-179 [NCT00337571]) assigned to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
3307340|NCT00365859|Experimental|Rollover Placebo|Participants who completed participation in protocol (CN138-178 [NCT00332241] or CN138-179 [NCT00337571]) on placebo treatment and continued to meet all of the inclusion criteria and none of the exclusion criteria. Assigned in this study to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
3307341|NCT00365859|Experimental|Rollover Aripiprazole|Participants who completed participation in protocol CN138-178 [NCT00332241] or CN138-179 [NCT00337571] on aripiprazole treatment and continued to meet all of the inclusion criteria and none of the exclusion criteria. Assigned in this study to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
3307342|NCT00365846|Experimental|Campath 1H induction w/ Sirolimus immunosuppression|Campath 1H at day -1 and 0 of kidney transplant followed by long term CNI free immunosuppressive therapy with Sirolimus,
3307343|NCT00365833||Recipients of Kidney Transplant|Patients Transplanted with Live or Deceased Donor's Kidney. Standard of Care treatment pre- and post-transplant.
3307344|NCT00365807|Active Comparator|Brief Family Intervention (Primarily education)|Behaviorally based family group intervention using standard education and nutrition counseling. Three hours of client contact
3307345|NCT00365807|Experimental|Positively Fit|12 week (90 minute per session) behavioral group intervention for children and their parents. Children and parent attend parallel group with identical (but developmentally appropriate) information presented.
3307346|NCT00365794|Experimental|Single arm|Open label treatment with each participant serving as his own control. Data is compared before and after treatment.
3307347|NCT00365768|Experimental|Arm I: Glutamine|Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.
3307348|NCT00365768|Placebo Comparator|Arm II: Placebo|Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.
3307349|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 1 received a 20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
3307350|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 2 received a 40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
3307351|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 3 received a 80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
3307352|NCT00365716|Experimental|Placebo (mcg) (Aluminum Adjuvant) 225|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 4 received placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
3307353|NCT00365716|Experimental|Placebo (mcg) (Aluminum Adjuvant) 450|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 5 received placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
3307354|NCT00365703|Experimental|1|Orogastric feeding tube.
3307355|NCT00365703|Experimental|2|Nasogastric feeding tube.
3307356|NCT00365690|Active Comparator|1|Participants will receive individual therapy upon request
3307357|NCT00365690|Active Comparator|2|Participants will receive telephone-administered supportive-expressive group therapy
3307358|NCT00365690|Experimental|3|Participants will receive telephone-administered coping improvement group therapy
3307359|NCT00365677|Experimental|Zyoptix Tissue Saving Aspheric|The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm is used for treatment with LASIK for the correction of myopia and myopic astigmatism.
3307360|NCT00365677|Active Comparator|Zyoptix Tissue Saving|The Bausch & Lomb Zyoptix Tissue Saving algorithm is used for treatment with LASIK for the correction of myopia and myopic astigmatism.
3307361|NCT00365599|Experimental|Vorinostat and Tamoxifen|As outlined in Intervention descriptions
3307362|NCT00365547|Experimental|Patients Treated With Topotecan and Avastin in NSCLC|Weekly topotecan hydrochloride and bi-weekly Avastin (bevacizumab) in patients with non-small cell lung cancer (NSCLC) who have failed prior systemic chemotherapy.
3307363|NCT00365508|Experimental|Arm I|Participants apply a transdermal nicotine patch at 3 different time periods during weeks 3-14; a higher-dose patch is applied for weeks 3-8, a medium-dose patch is applied for weeks 9-10, and a lower-dose patch is applied for weeks 11-14.
3307364|NCT00365508|Experimental|Arm II|Participants receive one oral nicotine lozenge every 1-2 hours in weeks 3-8 (≥ 9 lozenges per day), one lozenge every 2-4 hours in weeks 9-11 (≥ 5 lozenges per day), and 1 lozenge every 4-8 hours in weeks 12-14 (≥ 3 lozenges per day).
3307365|NCT00365469|Experimental|Probiotic|Commercially available cow's milk based infant formula with Bifidobacterium longum [BL999} and Lactobacillus rhamnosus [LPR]
3307366|NCT00365469|Placebo Comparator|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
3307367|NCT00365456|Experimental|PTH (1-84)|
3307368|NCT00365456|Active Comparator|Risedronate|
3307369|NCT00365391|Experimental|Treatment (monoclonal antibody, enzyme inhibitor)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory studies to determine EGFR and phosphorylated-EGFR protein levels using initial diagnostic biopsy specimens by IHC for correlation with clinical outcome. Levels of proteins through which EGFR signals, including Akt, phosphorylated-Akt, MAPK, and phosphorylated-MAPK, are also determined using initial diagnostic biopsy specimens by IHC and correlated with clinical outcome. Total and free serum vascular endothelial growth factor levels are determined at the start of study and prior to course 3 by ELISA.
3307370|NCT00365378|Experimental|1|HPV 16 L1 VLP vaccine
3307371|NCT00365378|Placebo Comparator|2|Placebo
3307372|NCT00365365|Experimental|Stratum 1 (AC->T + bevacizumab)|"HER2-negative participants administered~doxorubicin and cyclophosphamide (AC) + bevacizumab for 4 cycles followed by~docetaxel (T) + bevacizumab for 4 cycles followed by~bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
3307373|NCT00365365|Experimental|Stratum 2 (TAC + bevacizumab)|"HER2-negative participants administered~docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab for 6 cycles followed by~bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
3307374|NCT00365365|Experimental|Stratum 3 (TCH + bevacizumab)|"All HER2-positive participants administered~docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab for 6 cycles followed by~bevacizumab and trastuzumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
3307375|NCT00365352|Experimental|XP13512 600MG|XP13512 600MG ONCE DAILY
3307376|NCT00365352|Experimental|XP13512 1200MG|XP13512 1200MG ONCE DAILY
3307377|NCT00365352|Placebo Comparator|Placebo|PLACEBO ONCE DAILY
3307378|NCT00365339|Active Comparator|A|
3307379|NCT00365339|Experimental|B|
3307380|NCT00365339|Experimental|C|
3307381|NCT00365339|Experimental|D|
3307382|NCT00365339|Experimental|E|
3307383|NCT00365300|Active Comparator|Pantoprazole|
3307384|NCT00365300|Placebo Comparator|Placebo|
3307385|NCT00365274|Experimental|SGN-30 + Combination Chemotherapy|"Monoclonal antibody SGN-30 monotherapy: SGN-30 12 mg/kg weekly intravenously(IV) over 2 hours once weekly for 3 weeks.~SGN-30 and CHOP chemotherapy: Beginning 1 week after completion of monoclonal antibody SGN-30 monotherapy, SGN-30 12 mg/kg IV over 2 hours on day 1 and CHOP chemotherapy comprising cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, and vincristine IV over 15 minutes on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 6-8 courses."
3307386|NCT00365261|Active Comparator|eszopiclone|active drug
3307387|NCT00365261|Placebo Comparator|placebo|placebo
3307388|NCT00365222|Experimental|1|
3307389|NCT00365209|Experimental|2g (curcumin)|Patients receive 2 grams of oral curcumin once daily. Treatment continues for up to 30 days in the absence of unacceptable toxicity or disease progression.
3307390|NCT00365209|Experimental|4g (curcumin)|Patients receive 4 grams of oral curcumin once daily. Treatment continues for up to 30 days in the absence of unacceptable toxicity or disease progression.
3307391|NCT00365183|Experimental|Xcytrin® (motexafin gadolinium)|
3307392|NCT00365157|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 1-2 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3307393|NCT00365144|Experimental|Bevacizumab Plus Erlotinib Hydrochloride|"A treatment cycle is 21 days:~bevacizumab 15 mg/kg as a 60-90 min infusion once every 21 days, with erlotinib hydrochloride 150 mg by mouth daily"
3307394|NCT00365105|Active Comparator|Zoledronic acid|Zoledronic acid, vitamin D and calcium supplements.
3307395|NCT00365105|Experimental|Zoledronic acid + Radopharmaceuticals|Zoledronic acid, vitamin D and calcium supplements, plus Sr-89 or Sm-153.
3307396|NCT00365053|Experimental|Treatment (belinostat)|Patients receive PXD101 IV at 1000 mg/m2 over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3307397|NCT00365014||Blood disease patients|People with blood diseases presenting at Shanghai hospitals
3307398|NCT00365001|Experimental|1|
3307399|NCT00365001|Active Comparator|2|
3307400|NCT00364910|Experimental|Cognitive behavioral therapy (CBT)|Participants will receive cognitive behavioral therapy
3307401|NCT00364910|Active Comparator|Educational session and treatment as usual|Participants will receive an educational session and treatment as usual
3307402|NCT00364871|Experimental|1|Bupropion SR (400 mg/day) plus Naltrexone (48 mg/day)
3307403|NCT00364871|Experimental|2|Bupropion SR (400 mg/day) plus Naltrexone (16 mg/day)
3307404|NCT00364871|Active Comparator|3|Bupropion SR (400 mg/day)
3307405|NCT00364871|Active Comparator|4|Naltrexone (48 mg/day)
3307406|NCT00364871|Placebo Comparator|5|B-Placebo plus N-Placebo
3307407|NCT00364871|Placebo Comparator|6|B-Placebo plus N-Placebo
3307408|NCT00364871|Experimental|7|Bupropion SR (400 mg/day) plus Naltrexone (32 mg/day)
3307409|NCT00364858|Other|Q2 Cerezyme|Patients receiving Cerezyme one infusion every 2 weeks (Q2).
3307410|NCT00364858|Other|Q4 Cerezyme|Patients receiving Cerezyme one infusion every 4 weeks (Q4).
3307411|NCT00364845|Active Comparator|Darbepoetin alfa|Single-blind darbepoetin alfa administered by subcutaneous injection (SC) every other week until hemoglobin (Hgb) was stable (2 consecutive Hgb values between 120 and 135 g/L), then every month for up to 9 months.
3307412|NCT00364845|Placebo Comparator|Placebo|Single-blind placebo administered by subcutaneous injection (SC) every other week until week 16, then every month for up to 9 months.
3307413|NCT00364832|Experimental|Cohort A (0.4/150, 1x/ Week)|Eligible participant will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) SC using a dose conversion factor of 0.4/150 microgram (mcg)/ kilogram (kg) of the previous weekly erythropoiesis stimulating agents (ESA) dose, (equal to 50% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3307414|NCT00364832|Experimental|Cohort B (0.4/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.4/150 mcg/kg of the previous weekly ESA dose, (equal to 50% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3307415|NCT00364832|Experimental|Cohort C (0.4/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.4/150 mcg/kg of the previous weekly ESA dose, (equal to 50% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3307416|NCT00364832|Experimental|Cohort D (0.8/150, 1x/ Week)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3307417|NCT00364832|Experimental|Cohort E (0.8/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3307418|NCT00364832|Experimental|Cohort F (0.8/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3307419|NCT00364832|Experimental|Cohort G (1.2/150, 1x/ Week)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3307420|NCT00364832|Experimental|Cohort H (1.2/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3307421|NCT00364832|Experimental|Cohort I (1.2/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3307422|NCT00364819|Experimental|1|rituximab 1000 mg IV on days 1 and 15, given over 5 - 6 hours
3307423|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 3 months to < 6 months|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
3307424|NCT00364793|Experimental|EFV+ddI+FTC in patients >=6 months to < 2 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
3307425|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 2 years to < 3 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
3307426|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 3 years to <= 6 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
3307427|NCT00364780|Experimental|1|Patients received XL647 at an intermittent dosing schedule receiving drug for 5 days followed by 9 days without drug.
3307428|NCT00364780|Experimental|2|Patients received drug at a daily dosing schedule
3307429|NCT00364767|Experimental|A|Whiskey (32 gram of alcohol/day)
3307430|NCT00364767|Placebo Comparator|B|Water (0 gram alcohol/day)
3307431|NCT00364741|Active Comparator|A|Fraction of inspired oxygen (FiO2) = 0.30
3307432|NCT00364741|Active Comparator|B|FiO2 = 0.80
3307433|NCT00364676|Experimental|1|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
3307434|NCT00364676|Experimental|2|Patients are dosed on Day 1 of a 21-day cycle.
3307435|NCT00364650|Placebo Comparator|I|Placebo
3307436|NCT00364650|Experimental|II|Probiotic supplement
3307437|NCT00364637|Active Comparator|Total intravenous anesthesia|
3307438|NCT00364637|Experimental|sevoflurane|
3307439|NCT00364611|Experimental|Docetaxel and Bevacizumab|Stratum 1: HER2 Negative participants with metastatic breast cancer treated with DB (docetaxel and bevacizumab) intravenously (IV) every 3 weeks (q3w) until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met
3307440|NCT00364611|Experimental|Docetaxel, Bevacizumab and Trastuzumab|Stratum 2: HER2 Positive participants with metastatic breast cancer treated with DBT (docetaxel, bevacizumab, and trastuzumab) IV q3w until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met
3307441|NCT00364572|Placebo Comparator|1|Two injections of epidural saline 2 weeks apart
3307442|NCT00364572|Experimental|Epidural injection of etanercept|Two injections of epidural etanercept 2 weeks apart
3307443|NCT00364559|Experimental|B|A, Active B, Historical Register
3307444|NCT00364533|Placebo Comparator|003|Placebo Fixed Dose Matching placebo for 3 days
3307445|NCT00364533|Active Comparator|002|Oxycodone HCL IR Fixed Dose 10 mg BID for 3 days
3307446|NCT00364533|Experimental|001|Tapentadol IR (CG5503) Fixed Dose 50, 75, & 100 mg BID for 3 days
3307447|NCT00364533|Other|004|Tapentadol IR (CG5503) Flexible Dose q4-6 hr Tapentadol IR 50 & 100 mg BID for 9 days
3307448|NCT00364520||Shanghai Workers|Shanghai Workers
3307449|NCT00364442|Experimental|Arm 1|investigational drug
3307450|NCT00364416||001|
3307451|NCT00364403|Experimental|1|Low glycemic load diet
3307452|NCT00364403|Active Comparator|2|Low fat diet
3307453|NCT00364377|Active Comparator|Sitagliptin|People with impaired fasting glucose randomized to treatment with sitagliptin 100 mg once daily.
3307454|NCT00364377|Placebo Comparator|Placebo|People with impaired fasting glucose randomized to treatment with placebo once daily.
3307455|NCT00364351|Active Comparator|1|Erlotinib
3307456|NCT00364351|Experimental|2|Vandetanib
3307457|NCT00364325||001|
3307458|NCT00364286|Experimental|Dasatinib|Dasatinib 50mg Orally twice daily.
3307505|NCT00363805|Experimental|Polyphenon E|Patients receive placebo beverage and Polyphenon E capsules daily for 6 months.
3310586|NCT00321074|Experimental|2|
3307459|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 1|Eligible subjects will receive placebo, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms.
3307460|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, placebo, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms.
3307461|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, placebo, GSK159802 900 micrograms and GSK159802 1200 micrograms.
3307462|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, placebo and GSK159802 1200 micrograms.
3307463|NCT00364273|Experimental|Subjects receiving treatment sequence 5 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and placebo.
3307464|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 2|Eligible subjects will receive placebo, salmeterol, GSK159802 low dose (LD) and GSK159802 maximum tolerated dose (MTD).
3307465|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 2|Eligible subjects will receive salmeterol, GSK159802 MTD, placebo and GSK159802 LD.
3307466|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 2|Eligible subjects will receive GSK159802 LD, placebo, GSK159802 MTD and salmeterol.
3307467|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 2|Eligible subjects will receive GSK159802 MTD, GSK159802 LD, salmeterol and placebo.
3307468|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 3|Eligible subjects will receive placebo, salmeterol, GSK159802 300 micrograms and GSK159802 1200 micrograms.
3307469|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 3|Eligible subjects will receive salmeterol, GSK159802 1200 micrograms, placebo and GSK159802 300 micrograms.
3307470|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 3|Eligible subjects will receive GSK159802 300 micrograms, placebo, GSK159802 1200 micrograms and salmeterol.
3307471|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 3|Eligible subjects will receive GSK159802 1200 micrograms, GSK159802 300 micrograms, salmeterol and placebo.
3307472|NCT00364273|Experimental|Subjects receiving treatment sequence 5 : Cohort 3|Eligible subjects will receive GSK159802 1200 micrograms, salmeterol, GSK159802 300 micrograms and placebo.
3307473|NCT00364182|Experimental|A|
3307474|NCT00364182|Experimental|B|
3307475|NCT00364156|Experimental|Extended Patch Treatment|Participants in this treatment arm receive 24 weeks of 21mg nicotine patch in addition to 8 smoking cessation counseling sessions.
3307476|NCT00364156|Active Comparator|Standard Patch Treatment|Participants receive 8 weeks of 21mg nicotine patch followed by 16 weeks of placebo patch.
3307477|NCT00364130|Active Comparator|Active Low Magnitude Mechanical Stimulus|Active Low Magnitude Mechanical Stimulus
3307478|NCT00364130|Placebo Comparator|Inactive Low Magnitude mechanical Stimulus|Inactive, or placebo low magnitude mechanical stimulus
3307479|NCT00364104|Experimental|A|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
3307480|NCT00364104|Experimental|B|The 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
3307481|NCT00364104|Experimental|C|6-weeks of iron supplementation only plus 10-days of matching placebo of Hp infection eradication therapy
3307482|NCT00364104|Placebo Comparator|D|
3307483|NCT00364013|Experimental|FOLFOX + Panitumumab|Participants received panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.
3307484|NCT00364013|Active Comparator|FOLFOX|Participants received FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
3307485|NCT00364000|Active Comparator|I|Calcium acetate 670 mg tablets
3307486|NCT00364000|Experimental|II|label sevelamer (RenagelR) 800 mg tablets
3307487|NCT00363987|Experimental|1|
3307488|NCT00363987|Other|2|
3307489|NCT00363961|Experimental|1|resistance exercise
3307490|NCT00363961|Sham Comparator|2|flexibility exercises
3307491|NCT00363948|Placebo Comparator|P|
3307492|NCT00363948|Experimental|E|
3307493|NCT00363922|Experimental|1|Rehabilitation in institution
3307494|NCT00363922|Active Comparator|2|Rehabilitation at home
3307495|NCT00363909|Experimental|low-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in weeks 2-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
3307496|NCT00363909|Experimental|medium-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in week 2 and 2 tablets once daily in weeks 3-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
3307497|NCT00363909|Experimental|high-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in week 2, 2 tablets once daily in week 3, and 3 tablets once daily in weeks 4-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
3307498|NCT00363909|Placebo Comparator|placebo|"Patients receive 1-3 placebo tablets once daily in weeks 2-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
3307499|NCT00363896|Experimental|Aclidinium 200 μg once-daily|Aclidinium bromide 200 μg once-daily by inhalation
3307500|NCT00363896|Placebo Comparator|Placebo|Placebo once-daily via inhalation
3307501|NCT00363883|Experimental|Treatment (vorinostat)|Patients receive oral vorinostat (SAHA) twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3307502|NCT00363844|Experimental|E|
3307503|NCT00363831|Experimental|1|Oxaliplatin
3307504|NCT00363805|Experimental|Green Tea|Patients receive green tea beverage and placebo capsules for 6 months.
3307506|NCT00363805|Placebo Comparator|Placebo|Patients receive placebo beverage and placebo capsules daily for 6 months.
3307507|NCT00363779|Experimental|LGL Patients administered cyclosporine|Large Granular Lymphocyte Leukemia (LGL) is a low grade non-Hodgkins lymphoma characterized by tissue invasion of the marrow, spleen, and liver. Cyclosporine 5-10 mg/kg/day was administered as an oral preparation given every 12 hours. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml.
3307508|NCT00363766|Experimental|A|
3307509|NCT00363714|Experimental|1|Single intravitreal injection
3307510|NCT00363714|Experimental|2|Single intravitreal injection
3307511|NCT00363714|Experimental|3|Single intravitreal injection
3307512|NCT00363714|Experimental|4|Single intravitreal injection
3307513|NCT00363714|Experimental|5|Single intravitreal injection
3307514|NCT00363714|Experimental|6|Single intravitreal injection
3307515|NCT00363675|Experimental|All study participants|Children with hand burns
3307516|NCT00363649|Experimental|Arm I|Patients will receive injections of interferon alfa and GM-CSF once a day for 6 months. Some patients may receive treatment for up to 1 year. After 1 year, some patients may receive treatment as in arm II.
3307517|NCT00363649|Experimental|Arm II|Patients will receive an injection of GM-K562 cell vaccine every 3 weeks for at least 6 months. Some patients may receive treatment for up to 1 year. After 1 year, some patients may receive treatment as in arm I. NOTE: Study Arm B is not available to newly accrued and enrolled subjects based on the interim analysis directing all new subjects to the combination of Interferon + GM-CSF (Arm A).
3307518|NCT00363636|Experimental|1|
3307519|NCT00363636|Active Comparator|2|
3307520|NCT00363597|Experimental|A|
3307521|NCT00363545|Experimental|Liquid Rotarix Group|Healthy male and female infants, between and including 6-12 weeks of age, who received two oral doses of the liquid formulation of the Rotarix™ vaccine, according to a 0, 2 month schedule.
3307522|NCT00363545|Experimental|Lyophilized Rotarix Group|Healthy male and female infants, between and including 6-12 weeks of age, who received two oral doses of the lyophilized formulation of the Rotarix™ vaccine, according to a 0, 2 month schedule.
3307523|NCT00363519|Placebo Comparator|P|
3307524|NCT00363519|Experimental|E|
3307525|NCT00363480|Experimental|SFC 50/250 mcg|Participants received the combination product, fluticasone 250 microgram (mcg) plus salmeterol 50 mcg (SFC 50/250 mcg) for 12 weeks. Study treatment was received using DISKUS™ powder inhalers, one dose in morning and evening. Study medication was dispensed at visits 3, 4, and 5 for 30 days each. The participants were provided with salbutamol rescue medication if they developed acute asthmatic symptoms. This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol. Use of rescue medications was recorded in the participant's asthma diaries. Stable dosages of other concomitant medications were allowed if they had no impact on the outcome criteria.
3307526|NCT00363467|Other|Autologous Hematopoietic Progenitor Cell Transplantation|G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion
3307527|NCT00363454|Experimental|Dose Escalation|Phase I: Triciribine Phosphate Monohydrate
3307528|NCT00363428|Placebo Comparator|Control|Receive standard care and educational material on exercise and lifestyle choices of well-being
3307529|NCT00363428|Experimental|Lifestyle intervention|
3307530|NCT00363415|Experimental|A|
3307531|NCT00363415|Active Comparator|B|
3307532|NCT00363376|Experimental|Sugar pill|"olanzapine and placebo (sugar pill)"
3307533|NCT00363376|Experimental|Zonisamide|olanzapine and zonisamide (active drug)
3307534|NCT00363363|Experimental|1|
3307535|NCT00363363|Active Comparator|2|
3307536|NCT00363311|Active Comparator|Dutasteride|Dutasteride 0.5mg
3307537|NCT00363311|Placebo Comparator|Placebo|Matching placebo
3307538|NCT00363298|Experimental|d-amphetamine|dextro-amphetamine capsules, 15 mg per capsule, in Bottles A and B, dose: one from Bottle A each morning and 1 from Bottle B each morning
3307539|NCT00363298|Sham Comparator|Sham comparison|caffeine in capsules identical to those containing d-amphetamine, with 200 mg of caffeine in Bottle A capsules, and 100 mg of caffeine in Bottle B capsules, dose was 1 capsule from Bottle A and 1 capsule from Bottle B each morning
3307540|NCT00363272|Experimental|Arm I|Patients receive ispinesib IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
3307541|NCT00363246||Group 1|Older veterans who use a wheelchair for their primary means of mobility.
3307542|NCT00363194|Experimental|Lead-In cohort|In Part 1 of Lead-In cohort, subjects will be dosed with a single dose of pazopanib with a high-fat breakfast to establish safety and tolerability.
3307543|NCT00363168|Experimental|A|0.3 mg/0.05 ml dose of ranibizumab
3307544|NCT00363168|Experimental|B|0.5 mg/0.05 ml dose of ranibizumab
3307545|NCT00363142|Active Comparator|FPV/r200|Fosamprenavir/ritonavir (either 700/100mg BID or 1400/200mg QD)
3307546|NCT00363142|Experimental|FPV/r100|Fosamprenavir/ritonavir 1400/100mg QD
3307547|NCT00363129|Experimental|Arm I|Patients receive oral vitamin E twice daily beginning within 4 days of the start of chemotherapy course 1 and continuing until 1 month after completion of chemotherapy.
3307548|NCT00363129|Placebo Comparator|Arm II|Patients receive oral placebo twice daily beginning within 4 days of the start of chemotherapy course 1 and continuing until 1 month after completion of chemotherapy.
3307549|NCT00363116|Active Comparator|5 Dose Daclizbumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
3307550|NCT00363116|Active Comparator|2 Dose Daclizaumab|daclizumab 2 mg/kg/dose every 14 days for 2 doses
3307551|NCT00363116|Active Comparator|Control|no antibody induction
3307552|NCT00363077|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3307553|NCT00363077|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3307607|NCT00362518|Placebo Comparator|1|Study Arm A - Control: no vitamins (placebo only).
3307608|NCT00362518|Active Comparator|2|Study Arm B - Low Dose: Vitamin C 250 mg, Vitamin E 200 IU
3307554|NCT00363051|Experimental|Everolimus 10 mg|"Stratum 1 patients who were not receiving regular Octreotide Depot therapy. These patients were to receive everolimus monotherapy at 10 mg/day.~Stratum 2 patients who were to receive everolimus 10 mg/day in addition to continuing their entry dose of Octreotide Depot therapy.~Patients were instructed to take two 5 mg tablets of everolimus orally with a glass of water, once daily (preferably in the morning). Dosing was strongly recommended to occur at the same time every day."
3307555|NCT00363038|Experimental|Bruising|Bruises at three time points: immediate after bruise creating, and at 1 and 2 weeks.
3307556|NCT00362986|Experimental|sunscreen|"Patients apply sunscreen generously to the entire body twice daily for 4 weeks.~Patients complete self-reported questionnaires regarding their rash status at baseline and then weekly for 8 weeks.~After completion of study treatment, patients are followed for 8 weeks."
3307557|NCT00362986|Placebo Comparator|placebo|"Patients apply placebo generously to the entire body twice daily for 4 weeks.~Patients complete self-reported questionnaires regarding their rash status at baseline and then weekly for 8 weeks.~After completion of study treatment, patients are followed for 8 weeks."
3307558|NCT00362973||Hormone Receptor Positive Breast Cancer|Patients with hormone receptor positive primary, recurrent or metastatic breast cancer with a treatment plan that involves (neoadjuvant) administration of aromatase inhibitor and ovarian suppression (if premenopausal).
3307559|NCT00362973||HER-2/neu Positive Breast Cancer|Patients with HER-2/neu positive primary, recurrent or metastatic breast cancer with a treatment plan that involves (neoadjuvant) administration of trastuzumab.
3307560|NCT00362947|Placebo Comparator|A|A - Parnaparin 8.500 UI aXa od (therapeutic doses) for 10 days followed by placebo for 20 days
3307561|NCT00362947|Active Comparator|B|B - Parnaparin 8.500 UI aXa od for 10 days followed by 6.400 UI aXa once daily (intermediate therapeutic doses) for 20 days
3307562|NCT00362947|Active Comparator|C|C - Parnaparin 4.250 UI aXa od (prophylactic doses) for 30 days
3307563|NCT00362934|Experimental|1|
3307564|NCT00362934|Active Comparator|2|
3307565|NCT00362921|Experimental|Gliadel wafers in combination with O6-benzylguanine|
3307566|NCT00362908|Active Comparator|Group 1|"Subjects consume study diets in the following order:~Diet 1 (20% fat diet) for 1 month with all food provided,~American Heart Association Step I Diet for 1 month at home, and~Diet 2 (40% fat diet) for 1 month with all food provided and then continue to follow this diet for an additional 4 months at home."
3307567|NCT00362908|Active Comparator|Group 2|"Subjects consume study diets in the following order:~Diet 2 (40% fat diet) for 1 month with all food provided,~American Heart Association Step I Diet for 1 month at home, and~Diet 1 (20% fat diet) for 1 month with all food provided and then continue to follow this diet for an additional 4 months at home."
3307568|NCT00362895|Experimental|Tobradex AF|
3307569|NCT00362895|Active Comparator|TOBRADEX|
3307570|NCT00362882|Experimental|Arm 1|Patients receive docetaxel IV over 60 minutes on day 1 and bortezomib IV over 3-5 seconds on days 1 and 8.
3307571|NCT00362882|Experimental|Arm 2|Patients receive docetaxel as in arm I and bortezomib IV over 3-5 seconds on days 2 and 8.
3307572|NCT00362869|Experimental|1|Dosage 1X10^9 given orally in a sodium bicarbonate solution
3307573|NCT00362869|Experimental|2|Dosage 5X10^9 given orally in a sodium bicarbonate solution
3307574|NCT00362869|Placebo Comparator|5|Sodium bicarbonate placebo solution
3307575|NCT00362869|Experimental|4|Dosage 5X10^10 given orally in a sodium bicarbonate solution
3307576|NCT00362869|Experimental|3|Dosage 1X10^10 given orally in a sodium bicarbonate solution
3307577|NCT00362856|Placebo Comparator|Placebo + Gluten|placebo TID + gluten 800 mg TID administered orally in capsules
3307578|NCT00362856|Placebo Comparator|Placebo + Gluten placebo|placebo TID + gluten placebo TID administered orally in capsules
3307579|NCT00362856|Other|Larazotide acetate 8 mg + Gluten placebo|Safety Control Arm. Larazotide acetate 8 mg TID + gluten placebo TID administered orally in capsules
3307580|NCT00362856|Active Comparator|Larazotide acetate 0.25 mg + Gluten|Larazotide acetate 0.25 mg TID + gluten 800 mg TID administered orally in capsules
3307581|NCT00362856|Active Comparator|Larazotide acetate 1 mg + Gluten|Larazotide acetate 1 mg TID + gluten 800 mg TID administered orally in capsules
3307582|NCT00362856|Active Comparator|Larazotide acetate 4 mg + Gluten|Larazotide acetate 4 mg TID + gluten 800 mg TID administered orally in capsules
3307583|NCT00362856|Active Comparator|Larazotide acetate 8 mg + Gluten|Larazotide acetate 8 mg TID + gluten 800 mg TID administered orally in capsules
3307584|NCT00362830|Experimental|1|
3307585|NCT00362817|Experimental|Temozolomide & Intra-Arterial (IA) carboplatin|Patients will be administered Temozolomide orally once a day for 5 consecutive days and and will receive Intra Arterial Carboplatin
3307586|NCT00362778|Sham Comparator|Serum saline|
3307587|NCT00362765|Experimental|1|
3307588|NCT00362765|Active Comparator|2|
3307589|NCT00362765|Active Comparator|3|
3307590|NCT00362765|Placebo Comparator|4|
3307591|NCT00362752|Placebo Comparator|Placebo|
3307592|NCT00362752|Experimental|Norfloxacin 400 mg bid|
3307593|NCT00362739||1: Lung Disease|Individuals with at least one of the following: (1)symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) patients with diseases of organs with known association with lung disease; (7) individuals suspected of history of lung diseased based on history and/or physical examination
3307594|NCT00362739||2: Normal Controls|Individuals without a history of lung disease
3307595|NCT00362726|Active Comparator|A|
3307596|NCT00362726|Active Comparator|B|
3307597|NCT00362726|Active Comparator|C|
3307598|NCT00362726|Active Comparator|D|
3307599|NCT00362726|Active Comparator|E|
3307600|NCT00362713|Experimental|A|3 mg/kg or 10 mg/kg
3307601|NCT00362687|Experimental|1|Truvada 1 tablet once a day.
3307602|NCT00362687|Experimental|2|Emtricitabine 1 capsule once a day
3307603|NCT00362648|Experimental|1|RotaTeq™
3307604|NCT00362648|Placebo Comparator|2|Placebo
3307605|NCT00362609|Active Comparator|Low dose|
3307606|NCT00362609|Active Comparator|High dose|
3307609|NCT00362518|Active Comparator|3|Study Arm C - Medium Dose: Vitamin C 500 mg, Vitamin E 400 IU
3307610|NCT00362518|Active Comparator|4|Study Arm D - High Dose: Vitamin C 1000 mg, Vitamin E 800 IU.
3307611|NCT00362479|Experimental|1|
3307612|NCT00362466|Active Comparator|A|50-180 mg once daily (QD)
3307613|NCT00362466|Active Comparator|B|200-800 mg QD
3307614|NCT00362453|Experimental|Tai Chi|The Tai Chi program was based on the classical Yang Style. Patients participated in 60-minute Tai Chi sessions twice a week for 12 weeks. Each session included warm up and review of Tai Chi principles and techniques; Tai Chi exercises; breathing techniques; and various relaxation methods. The classes were taught by a Tai Chi master with over 20 years' experience conducting Tai Chi Mind-Body exercise programs. Several modifications were developed to achieve the physical and mental goals of the study for knee OA, accommodate knee OA symptoms and limit dropouts. Subjects were instructed to practice Tai Chi at least 20 minutes a day at home and encouraged to maintain their usual physical activities, but not to participate in additional new strength training other than their Tai Chi exercises.
3307615|NCT00362453|Placebo Comparator|Wellness Education and Stretching|The wellness education and stretching program provided an active control for the attention being paid to the Tai Chi group. The control group attended two 60-minute class sessions per week for 12 weeks. Each session started with 40 minutes of didactic lessons on OA knowledge, nutrition, and physical and mental health education. The final 20 minutes consisted of stretching exercises involving the upper body, trunk and lower body, each stretch being held for 10 to 15 seconds. Participants were also instructed to practice at least 20 minutes of stretching exercises per day at home. They were encouraged to maintain their usual physical activities, but not to participate in additional strength and mind-body exercise programs other than their stretching exercise.
3307616|NCT00362440|Experimental|Leptin|Leptin replacement therapy
3307617|NCT00362440|Placebo Comparator|Pioglitazone or metformin|Diabetes treatment therapy
3307618|NCT00362427|Experimental|Group A|
3307619|NCT00362427|Experimental|Group B|
3307620|NCT00362427|Active Comparator|Group C|
3307621|NCT00362414|Experimental|Dual Growth Factor|All patients received erythropoietin and beta-hCG. This was the only treatment arm in the study, i.e., all enrollees received active therapy.
3307622|NCT00362375|Experimental|Healthy Love Workshop|Single-session, small-group HIV prevention intervention
3307623|NCT00362375|Active Comparator|HIV101|Single-session, small-group intervention providing facts regarding HIV/AIDS
3307624|NCT00362349|Experimental|1|IVIg
3307625|NCT00362336|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|
3307626|NCT00362336|Experimental|Group 2: CombAct-HIB™ + OPV|
3307627|NCT00362336|Active Comparator|Group 3: DTaP-IPV-Hep B-PRP-T (ENGERIX B™ at birth)|
3307628|NCT00362323|Experimental|1|
3307629|NCT00362323|Active Comparator|2|
3307630|NCT00362297|Active Comparator|Standard dose|
3307631|NCT00362297|Experimental|High-dose|
3307632|NCT00362284|Experimental|NYUCI-AC group|Adult children in this arm received the NYUCI-AC intervention, which consisted of 6 individual and family counseling sessions, the offering of an adult child specific support group, and the provision of ad hoc, or ongoing, consultation throughout the duration of participation.
3307633|NCT00362284|No Intervention|Usual care control|Adult children randomly assigned to the usual care control did not receive the NYUCI-AC intervention. If they were in crisis or required support, the NYUCI-AC counselors provided information and referral on an as-needed basis.
3307634|NCT00362271|Other|1|
3307635|NCT00362232|Experimental|Rivaroxaban 10 mg Once Daily (OD) ((Xarelto, BAY59-7939))|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening plus placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
3307636|NCT00362232|Active Comparator|Enoxaparin 30 mg twice a day (bid)|Placebo tablet of rivaroxaban administered once daily in the evening plus syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
3307637|NCT00362219|Placebo Comparator|Placebo|Gel with no active ingredient
3307638|NCT00362219|Active Comparator|Morphine .25 mg|Gel with 0.25 mg morphine per 100cm2 square of wound
3307639|NCT00362219|Active Comparator|Morphine - .75 mg.|Gel with 0.75 mg morphine per 100cm2 square of wound.
3307640|NCT00362219|Active Comparator|Morphine 1.25 mg.|Gel with 1.25 mg morphine per 100cm2 square of wound.
3307641|NCT00362206|Experimental|1|
3307642|NCT00362206|Experimental|2|
3307643|NCT00362206|Active Comparator|3|
3307644|NCT00362180|Experimental|Cohort A: mipomersen|Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
3307645|NCT00362180|Placebo Comparator|Cohort A: placebo|Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
3307646|NCT00362180|Experimental|Cohort D: mipomersen|Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
3307647|NCT00362180|Placebo Comparator|Cohort D: placebo|Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
3307648|NCT00362180|Experimental|Cohort E: mipomersen|Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.
3307649|NCT00362180|Placebo Comparator|Cohort E: placebo|Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.
3307650|NCT00362180|No Intervention|Cohort F: no intervention|A reference group of participants with familial hypobetalipoproteinemia (FBHL) who did not receive a study intervention. Data gathered for 15 weeks.
3307651|NCT00362180|Experimental|Cohort G: mipomersen|Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.
3307711|NCT00361439|Active Comparator|Mometasone|Mometasone intranasal steroid therapy daily for 2 weeks
3307652|NCT00362180|Placebo Comparator|Cohort G: placebo followed by mipomersen|Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.
3307653|NCT00362115|Experimental|Azilsartan Medoxomil 5 mg QD|
3307654|NCT00362115|Experimental|Azilsartan Medoxomil 10 mg QD|
3307655|NCT00362115|Experimental|Azilsartan Medoxomil 20 mg QD|
3307656|NCT00362115|Experimental|Azilsartan Medoxomil 40 mg QD|
3307657|NCT00362115|Experimental|Azilsartan Medoxomil 80 mg QD|
3307658|NCT00362115|Active Comparator|Olmesartan 20 mg QD|
3307659|NCT00362115|Placebo Comparator|Placebo QD|
3307660|NCT00362089|Active Comparator|Marinol|Intervention group with Marinol D40 fish oil capsules
3307661|NCT00362089|No Intervention|Nutrition counseling|Control group
3307662|NCT00362063|Experimental|growth hormone|children with proven growth hormone deficiency
3307663|NCT00362063|No Intervention|healthy controls|No growth hormone is given
3307664|NCT00361985|Experimental|1|Nexium group
3307665|NCT00361972|Active Comparator|Lansoprazole therapy|Lansoprazole 30 mg orally twice daily
3307666|NCT00361972|Placebo Comparator|Placebo|placebo orally twice daily
3307667|NCT00361946||lean subjects|BMI <85th for age, normal glucose tolerance
3307668|NCT00361946||obese subjects|BMI> 95th for age normal glucose tolerance
3307669|NCT00361946||Type diabetes|BMI > 85th for age , history of Type 2 diabetes as per ADA criteria
3307670|NCT00361933|Experimental|1|
3307671|NCT00361907|Active Comparator|2|Diabetic patients who meet inclusion criteria will be enrolled to start Pulsatile Intravenous Insulin Therapy on a weekly basis. Baseline testing will be performed and measured against continued testing every twelve months.
3307672|NCT00361907|Placebo Comparator|1|Circulating blood markers will be performed on diabetic control patients at baseline and every twelve months to compare and measure against patients treated with Pulsatile intravenous insulin therapy
3307673|NCT00361894|Experimental|Arm 1|
3307674|NCT00361894|Active Comparator|Arm 2|
3307675|NCT00361881|Experimental|1|ME-609
3307676|NCT00361881|Active Comparator|2|Acyclovir in ME-609 vehicle
3307677|NCT00361881|Placebo Comparator|3|Vehicle
3307678|NCT00361868|Experimental|1|
3307679|NCT00361868|Active Comparator|2|
3307680|NCT00361803|Experimental|All treated subjects|All subjects received Topotecan, administered intravenously over 30 minutes at 4 milligrams per meter^2 weekly for 3 weeks every 28 days.
3307681|NCT00361790|Other|1|
3307682|NCT00361712|Experimental|Preemptive epidural analgesia|Parturients will receive epidural analgesia immediately upon arrival in the labor ward before onset of painful contractions (VAS<3).
3307683|NCT00361712|Active Comparator|Standard of care|Parturients with cervical dilatation and painful labor (VAS >5) will receive epidural analgesia as soon as possible
3307684|NCT00361699|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
3307685|NCT00361699|No Intervention|No intervention|Patient has no intervention.
3307686|NCT00361660|Experimental|1|Therapy is provided every other day 3 days per week (Monday, Wednesday, Friday).
3307687|NCT00361660|Active Comparator|2|The same therapy is provided daily Monday through Friday
3307688|NCT00361634|Experimental|Etanercept|Etanercept 50 mg administered by subcutaneous injection once weekly for up to 12 weeks.
3307689|NCT00361595|Experimental|open label|5 mg zoledronic acid in a single 15 minute IV
3307690|NCT00361569|Experimental|1|
3307691|NCT00361569|Experimental|2|
3307692|NCT00361569|Placebo Comparator|3|
3307693|NCT00361569|Placebo Comparator|4|
3307694|NCT00361556|Active Comparator|1|The Back Book
3307695|NCT00361556|Active Comparator|2|The Back Guide
3307696|NCT00361556|Active Comparator|3|General health book
3307697|NCT00361543|Active Comparator|1|Raloxifene Hydrochloride
3307698|NCT00361543|Placebo Comparator|2|placebo tablet
3307699|NCT00361530|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
3307700|NCT00361530|No Intervention|No intervention|Patient has no intervention.
3307701|NCT00361517|Experimental|GM test|Twice weekly blood draws from the patients in this arm for serial GM monitoring. They will be given standard antifungal prophylaxis but no antifungal therapy unless two consecutive GM readings are positive.
3307702|NCT00361517|No Intervention|no GM monitoring|in this arm the patients will not have any GM monitoring and they will be given standard antifungal prophylaxis and treatment according to the published guidelines.
3307703|NCT00361504|Experimental|Tapentadol (CG5503)|Tapentadol (CG5503) extended release (ER) 100 to 250 mg twice daily (BID) for up to one year.
3307704|NCT00361504|Active Comparator|Oxycodone|Oxycodone controlled release (CR) 20 to 50 mg twice daily (BID) for up to one year.
3307705|NCT00361478|Experimental|1|"Mother and Baby Program comprising exercise and education."
3307706|NCT00361478|Active Comparator|2|Education only
3307707|NCT00361465||Parkinsonian patients presenting of the dystonia|15 Parkinsonian patients presenting of the dystonia of ONE or OFF at the time of the phases of driving fluctuations. These patients must present a dystonia of the upper limb, mainly localised than the level of the segment brachial or in distality.
3307708|NCT00361465||patients carrying a primary education dystonia affecting|15 patients carrying a primary education dystonia affecting at least one of the two upper limbs, without excessive involuntary movements
3307709|NCT00361465||patients carrying a secondary dystonia|15 patients carrying a secondary dystonia (consecutive with a perinatal suffering) affecting at least one of the two upper limbs, without excessive involuntary movements
3307710|NCT00361465||pilot subjects|30 healthy pilot subjects paired in sex, age (± 5 years), dominant laterality and level of schooling (15 subjects paired with the Parkinsonian patients and 15 subjects paired with the patients dystonic
3307748|NCT00361036|Experimental|1|BeadBlock treatment arm
3307712|NCT00361439|Placebo Comparator|Placebo|2 puffs of placebo spray in each nostril once daily
3307713|NCT00361413|Experimental|1|Alefacept
3307714|NCT00361413|Placebo Comparator|2|
3307715|NCT00361374|Experimental|EPA|Eicosapentaenoic acid (EPA) Omega-3, 1g/day
3307716|NCT00361374|Experimental|DHA|Docosahexaenoic acid (DHA) Omega-3, 1g/day
3307717|NCT00361374|Placebo Comparator|Placebo|Placebo capsule (980mg soybean oil)
3307718|NCT00361348|Active Comparator|Palifermin|A single 60µg/kg IV bolus dose of palifermin on Day 1 of the treatment period
3307719|NCT00361348|Experimental|Palifermin + Heparin|A single 60µg/kg IV bolus dose of palifermin on Day 1 of the treatment period + unfractionated heparin for a 2 to 3 day heparin titation/maintenance period and continuing through a 3 day treatment period
3307720|NCT00361348|Active Comparator|Heparin|unfractionated heparin for a 2 to 3 day heparin titation/maintenance period and continuing through a 3 day treatment period
3307721|NCT00361335|Experimental|Group I: 2mg/kg Golimumab + MTX|Intravenous (IV) infusions of 2mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (an additional 2mg/kg IV infusion of golimumab) and dose regimen adjustment (switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of subcutaneous (SC) injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive methotrexate (MTX) at the same dose as that before study entry
3307722|NCT00361335|Experimental|Group II: 2mg/kg Golimumab only|IV infusions of 2mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX or switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules
3307723|NCT00361335|Experimental|Group III: 4mg/kg Golimumab + MTX|IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter for a minimum of 48 weeks followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive MTX at the same dose as that before study entry.
3307724|NCT00361335|Experimental|Group IV: 4mg/kg Golimumab only|IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules.
3307725|NCT00361335|Placebo Comparator|Group V: IV Placebo + MTX|IV infusions of placebo at Week 0 and Week 12 with early escape (switch to 4mg/kg IV golimumab) and dose regimen adjustment (switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (placebo plus golimumab) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition patients will receive MTX at the same dose as that before study entry. Participants still receiving placebo injections at Week 48 are not eligible to enter the Extension Study.
3307726|NCT00361309|Experimental|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks). Patients will be continued on treatment until disease progression, limiting toxicity, or patient withdrawal of consent.
3307727|NCT00361296|Experimental|GM-K562 cell vaccine|
3307728|NCT00361283|Other|atorvastatin|80mg of atorvastatin given once daily for 16 weeks
3307729|NCT00361270|Experimental|Arm 1 Hyp-8|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour hypnosis with hypnotherapist without audio recordings
3307730|NCT00361270|Experimental|Arm 2 Hyp-8 w recordings|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour hypnosis with hypnotherapist with audio recordings
3307731|NCT00361270|Experimental|Arm 3 Hyp-2 w recordings|Single-site study at MEDVA-Houston Behavioral: 2 weeks 1-hour hypnosis with hypnotherapist with audio recordings
3307732|NCT00361270|Active Comparator|Arm 4 BIO|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour EMG biofeedback without audio recordings
3307733|NCT00361257|Experimental|Arm 1: Minocycline|100 mg orally every 12 hours
3307734|NCT00361257|Placebo Comparator|Arm 2: Matching placebo|orally every 12 hours
3307735|NCT00361231|Experimental|Bevacizumab, Gemcitabine, Oxaliplatin|"The chemotherapy drugs are given twice every 28 days. This 28 day period is called a cycle of study treatment.~Bevacizumab will be administered by IV over 90 minutes on day 1 and day 15. Gemcitabine will be administered by IV over 1 hour and 40 minutes on days 1 and 15 of each cycle. Oxaliplatin will be administered by IV for 2 hours on days 1 and 15 of each cycle.~Participants will continue to receive cycles of study treatment as long as their disease does not progress and they are not experiencing any serious side effects."
3307736|NCT00361218|Other|open-label selective serotonin reuptake inhibitor (SSRI)|citalopram or escitalopram
3307737|NCT00361153|Active Comparator|1|Colesevelam hydrochloride
3307738|NCT00361153|Placebo Comparator|2|placebo
3307739|NCT00361140|Experimental|AUC 6000|"Busulfan AUC Level 1: 6000 +/- 600 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
3307740|NCT00361140|Experimental|AUC 7500|"Busulfan AUC Level 2: 7500 +/- 750 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
3307741|NCT00361140|Experimental|AUC 9000|"AUC Level 3: 9000 +/- 900 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
3307742|NCT00361127|Experimental|CMPD patients|Patients with CMPD with evaluation of ACE I/D polymorphism
3307743|NCT00361114|Active Comparator|A|SP in symptomatic children aged 6-59 months
3307744|NCT00361114|Experimental|B|SP to asymptomatic infected children aged 2-10 months
3307745|NCT00361114|Experimental|C|Chlorproguanil/dapsone in symptomatic 6-59 month old children
3307746|NCT00361088|Experimental|Phase I|
3307747|NCT00361088|Experimental|Phase II|
3308026|NCT00357721|Active Comparator|A2|
3307749|NCT00361036|Active Comparator|2|Embospheres control arm
3307750|NCT00360997|Other|Behavioural|Conventional UK physical therapy (Con UK PT)
3307751|NCT00360997|Experimental|Con UK PT + MTS|Con UK PT + 30/60 or 120 minutes MTS
3307752|NCT00360971|Experimental|Palifermin|Concurrent radiation therapy, cisplatin, and palifermin followed by neck dissection for indicated patients.
3307753|NCT00360971|Placebo Comparator|Placebo|Concurrent radiation therapy, cisplatin, and placebo followed by neck dissection for indicated patients.
3307754|NCT00360958|Experimental|Ultrafiltration|Ultrafiltration treatment
3307755|NCT00360958|Active Comparator|Usual treatment|Usual HF treatment
3307756|NCT00360919|Experimental|A|Cheese
3307757|NCT00360919|Placebo Comparator|B|Fruits and vegetables
3307758|NCT00360867|Other|1|Single Arm
3307759|NCT00360841|Experimental|A|The subjects in arms A and B will receive auricular acupuncture. The subjects in arms A will receive auricular acupuncture (at 2nd and 4th chemotherapy courses) as well as the sham auricular acupuncture (at the 3rd chemotherapy course).
3307760|NCT00360841|Sham Comparator|B|The subjects in arms A and B will receive auricular acupuncture. The subjects in arm B will receive the sham auricular acupuncture (at the 2nd and 4th chemotherapy courses) and auricular acupuncture (at the 3rd chemotherapy course).
3307761|NCT00360841|No Intervention|C|No treatment received.
3307762|NCT00360828|Experimental|Irinotecan Treatment|Participants were given irinotecan at a fixed dose: [350 mg/m2 in patients either not on anti-seizure drugs or on anti-seizure drugs which do not interfere with the metabolism of Irinotecan; 600 mg/m2 in patients on anti-seizure drugs which interfere with the metabolism of Irinotecan] once every 21 days. Depending on how many side effects were experienced with the first cycle [first 21 days], the dose of both drugs may remain the same or may be decreased to make the treatment better tolerated with less side effects. The irinotecan was given to through a vein over 90 minutes.
3307763|NCT00360802|Active Comparator|CBT|Cognitive Behavioral Treatment
3307764|NCT00360802|Active Comparator|MBSR|Mindfulness Based Stress Reduction
3307765|NCT00360776|Experimental|Arm I|"Patients will receive tipifarnib by mouth twice a day for 3 weeks. Treatment may repeat every 4 weeks for up to eight courses.~Patients will undergo blood collection periodically for laboratory studies. After finishing treatment, patients will be evaluated every 6 months for 5 years."
3307766|NCT00360737|Active Comparator|NP-018|Subjects received one or two vials of NP-018 administered intravenously.
3307767|NCT00360724|Experimental|duloxetine (cymbalta)|Duloxetine medication: a medication currently marketed in the USA that is reported to have pharmacological effects including reuptake blockage for serotonin and norepinephrine
3307768|NCT00360724|Placebo Comparator|Placebo treatment|placebo treatment: treatment with placebo capsules that match active medication capsules
3307769|NCT00360698|Other|insulin glulisine+insulin glargine+metformin+glimepiride|Bolus arm
3307770|NCT00360698|Other|insulin glargine+metformin+glimepiride|Control arm
3307771|NCT00360685|Other|TAC + MMF|Tacrolimus and Mycophenolate
3307772|NCT00360685|Other|TAC+MTX|Tacrolimus and Methotrexate
3307773|NCT00360672|Experimental|Revlimid|Revlimid 25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
3307774|NCT00360646||Subjects with liver injury|
3307775|NCT00360646||Subjects without liver injury|
3307776|NCT00360594|Experimental|1|Acamprosate
3307777|NCT00360594|Placebo Comparator|2|Placebo
3307778|NCT00360568|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants received LCIG, delivered through a percutaneous endoscopic gastrostomy with jejunal extension (PEG-J), administered for up to 12 months (52 weeks).~Starting dose of LCIG was based on the participant's optimized oral levodopa-carbidopa dose that the subject was receiving just prior to randomization in Study S187.3.001 (NCT00357994) or Study S187.3.002 (NCT00660387), administered in the morning of the first day following Study Day 86 of either of these 2 previous studies. The LCIG infusion was expected to infuse over approximately16 hours each day with a rate of infusion within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances."
3307779|NCT00360555|Experimental|flibanserin|flibanserin 25 mg b.i.d
3307780|NCT00360555|Experimental|flibanserin 50mg|flibanserin 50mg qhs/b.i.d
3307781|NCT00360555|Experimental|flibanserin 100mg|flibanserin 50mg b.i.d./100mg qhs
3307782|NCT00360555|Placebo Comparator|placebo|placebo comparator
3307783|NCT00360529|Experimental|fibanserin|flibanserin 50 mg q.h.s.
3307784|NCT00360529|Experimental|flibanserin|flibanserin 100 mg q.h.s.
3307785|NCT00360529|Placebo Comparator|placebo|placebo q.h.s.
3307786|NCT00360490|Experimental|Levonorgestrel Intrauterine System (LNG IUS) 20µg per 24 hours|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
3307787|NCT00360490|Active Comparator|Medroxyprogesterone acetate (MPA)|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
3307788|NCT00360477|Active Comparator|1|Floseal
3307789|NCT00360477|Active Comparator|2|Cope-Loop/Nephrostomy Tube
3307790|NCT00360477|Active Comparator|3|Fascial Stitch
3307791|NCT00360451|Experimental|1|Adolescent only Penn Resiliency Program
3307792|NCT00360451|Experimental|2|Adolescent plus parent Penn Resiliency Program
3307793|NCT00360451|No Intervention|3|Control
3307794|NCT00360438|Experimental|Rasburicase|
3307795|NCT00360412|Experimental|E2007|During the first two weeks of the study, Patients received 1 x 2mg E2007 tablet. At the week 2 visit, patients who tolerated the 2 mg/day dose were up-titrated to receive 4mg/day (2 x 2 mg E2007 tablets). Patients not tolerating the 4 mg dose were allowed to down titrate to 2 mg. Patients who did not tolerate the 2 mg dose were withdrawn from the study. Patients returned at week 4, if their tolerance to the 4 mg/day dose was acceptable they remained on this dose for the maintenance phase of the study. If at any time their tolerance declined, they were to return for an unscheduled visit and the daily dose was reduced to 2 mg. If at any stage, 2 mg day wass not tolerated, the patient was withdrawn from the study.
3307796|NCT00360399|Active Comparator|Escitalopram|Participants will receive treatment with escitalopram for 12 weeks
3307797|NCT00360399|Active Comparator|Duloxetine|Participants will receive treatment with duloxetine for 12 weeks
3308027|NCT00357721|Active Comparator|A3|
3307798|NCT00360399|Active Comparator|CBT|Participants will receive 16 one-hour sessions of cognitive behavioral therapy delivered over 12 weeks
3307799|NCT00360360|Experimental|Bevacizumab/Paclitaxel/Carboplatin/Erlotinib|Bevacizumab 15mg/kg IV infusion,Day 1 Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1 Carboplatin AUC 6.0 IV Day 1 Erlotinib 150 mg by mouth daily
3307800|NCT00360334|Experimental|1|
3307801|NCT00360334|Active Comparator|2|
3307802|NCT00360308|Placebo Comparator|Placebo|matching E2007 and matching entacapone
3307803|NCT00360308|Active Comparator|E2007|2 mg once daily in the evening, Weeks 0→2 (2 weeks) and 4 mg once daily in the evening, Weeks 2→18.
3307804|NCT00360308|Active Comparator|Entacapone|200 mg with each dose of Levodopa.
3307805|NCT00360282|Other|With Vertigo; Placebo - Rizatriptan|This group received placebo on visit 1 and Rizatriptan on visit 2.
3307806|NCT00360282|Other|With Vertigo; Rizatriptan - Placebo|These subjects received Rizatriptan on visit 1 and placebo on visit 2.
3307807|NCT00360282|Other|Without Vertigo; Placebo - Rizatriptan|This group received placebo on visit 1 and Rizatriptan on visit 2.
3307808|NCT00360282|Other|Without Vertigo; Rizatriptan-Placebo|This group received Rizatriptan on visit 1 and placebo on visit 2.
3307809|NCT00360269|Experimental|Active|Atomoxetine plus Motivational Enhancement Therapy
3307810|NCT00360269|Placebo Comparator|Placebo|Placebo plus Motivational Enhancement Therapy
3307811|NCT00360256||Control|
3307812|NCT00360256||Case group|
3307813|NCT00360243|Experimental|flibanserin 25 mg b.i.d|25 mg twice daily for 24 weeks
3307814|NCT00360243|Experimental|flibanserin 50mg qhs|50 mg taken once daily at bedtime for 24 weeks
3307815|NCT00360243|Experimental|flibanserin 50mg b.i.d.|50 mg twice daily for 24 weeks
3307816|NCT00360243|Placebo Comparator|placebo|twice daily for 24 weeks
3307817|NCT00360230|Experimental|SB257049 F2 0-1 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1-month schedule administered intramuscularly (IM) in the left deltoid muscle.
3307818|NCT00360230|Experimental|SB257049 F1 0-1 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1-month schedule administered intramuscularly (IM) in the left deltoid muscle.
3307819|NCT00360230|Experimental|SB257049 F2 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
3307820|NCT00360230|Experimental|SB257049 F1 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
3307821|NCT00360230|Experimental|SB257049 F2 0-1-7 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1, 7-month schedule administered intramuscularly (IM) in the left deltoid muscle.
3307822|NCT00360230|Active Comparator|SB257049 F1 0-1-7 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1, 7-month schedule administered intramuscularly (IM) in the left deltoid muscle.
3307823|NCT00360230|Active Comparator|Rabipur 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
3307824|NCT00360152|Active Comparator|Positive Axillary Ultrasound|Positive Axillary Ultrasound -> Fine Needle Aspiration Biopsy -> Cytopathology and Reverse Transcription-Polymerase Chain Reaction (RT-PCR) -> Positive Cyto=Axillary Lymph Node Dissection, Negative Cyto=Sentinel Lymph Node Biopsy -> Pathology
3307825|NCT00360152|Active Comparator|Negative Axillary Ultrasound|Negative Axillary Ultrasound -> Sentinel Lymph Node Biopsy/Fine Needle Aspiration Biopsy -> Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Pathology
3307826|NCT00360035|Experimental|GX15-070MS|Obatoclax mesylate 60mg
3307827|NCT00360022|Experimental|Joint Visits|Transition patients will have 2 joint visits performed with the pediatric GI specialist and the adult GI specialist as they transfer care to an adult GI provider.
3307828|NCT00360022|No Intervention|Control|Transition patients in the control group will transfer care to adult GI provider in typical manner.
3307829|NCT00360009|Active Comparator|STN DBS|Patients who underwent deep brain stimulation (DBS) of the subthalamic nucleus (STN) to treat Parkinson's disease (PD)
3307830|NCT00360009|Active Comparator|GPI DBS|Patients who underwent deep brain stimulation (DBS) of the globus pallidus interna (GPi) to treat Parkinson's disease (PD)
3307831|NCT00360009|No Intervention|no DBS|non-DBS PD patient control group
3307832|NCT00359996|Active Comparator|Health disparities collaborative|The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.
3307833|NCT00359996|Active Comparator|Control|No additional educational sessions added to usual care of patients.
3307834|NCT00359983|Experimental|MenHibrix 4-dose group|Subjects received in the primary study (NCT00129129) 3 doses of MenHibrix co-administered with Pediarix and Prevnar and a 4th dose of MenHibrix co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
3307835|NCT00359983|Active Comparator|ActHIB 4-dose group|Subjects received in the primary study (NCT00129129) 3 doses of ActHIB co-administered with Pediarix and Prevnar and a 4th dose of ActHIB co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
3307836|NCT00359983|Experimental|ActHIB 3-dose + MenHibrix 4th-dose group|Subjects received in the primary study (NCT00129129) 3 doses of ActHIB co-administered with Pediarix and Prevnar and a dose of MenHibrix co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
3307837|NCT00359970|Active Comparator|Azithromycin 500 mg plus Placebo|a single 500 mg dose of Azitrhomycin at the start of treatment; a single loading dose of placebo at the start of treatment and then a dose of placebo after each loose stool
3307838|NCT00359970|Active Comparator|Azithromycin 1000 mg plus Placebo|a single 1000 mg dose of Azitrhomycin at the start of treatment; a single loading dose of placebo at the start of treatment and then a dose of placebo after each loose stool
3307839|NCT00359970|Experimental|Azithromycin 500 mg plus Loperamide|a single 500 mg dose of Azitrhomycin at the start of treatment; a single 4 mg loading dose of Loperamide at the start of treatment and then 2 mg Loperamide after each loose stool
3307840|NCT00359957|Experimental|1|ADDED condition - behavioral intervention for modifying diet and physical activity, with greater emphasis on physical activity than the STANDARD condition
3307841|NCT00359957|Active Comparator|2|STANDARD condition - behavioral intervention for modifying diet, with little emphasis on physical activity
3307842|NCT00359944|Experimental|AC-3933|AC-3933, 5mg twice daily
3307843|NCT00359944|Experimental|AC-3933, 20 mg twice daily|AC-3933, 20 mg twice daily
3307844|NCT00359944|Placebo Comparator|Placebo|Sugar Pill twice daily
3307845|NCT00359918|Experimental|Prehospital facilitated PCI|
3307846|NCT00359918|Active Comparator|Primary PCI|
3307847|NCT00359905|Experimental|Silodosin|
3307848|NCT00359905|Active Comparator|Tamsulosin|
3307849|NCT00359905|Placebo Comparator|Placebo|
3307850|NCT00359892|Experimental|Obatoclax Mesylate|Obatoclax Mesylate 60mg
3307851|NCT00359879|Experimental|1 - exenatide before breakfast and dinner|
3307852|NCT00359879|Active Comparator|2 - exenatide before lunch and dinner|
3307853|NCT00359866|Experimental|Pelvic IMRT with Tomotherapy|"Helical tomotherapy will be used to plan and deliver the radiation treatment.~Treatment volume will include the upper third of the vagina and para-vaginal tissue and the common, external and internal iliac nodal regions.~External beam radiation will be delivered in 160-180 cGy daily fractions to a total dose of 4500-5120 cGY.~Receive treatment once a day for five days a week for approximately 6 weeks.~Treating physician will make determination if patient is to receive intracavitary brachytherapy.~Treating physician will make determination if patient is to receive chemotherapy (allowed but not mandated)."
3307854|NCT00359814|Experimental|1|Azathioprine administration: was stopped at day 0; Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily; Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
3307855|NCT00359801|Experimental|Exubera|
3307856|NCT00359801|Active Comparator|Usual Diabetes Care|
3307857|NCT00359762|Experimental|Exenatide|
3307858|NCT00359762|Active Comparator|Glimepiride|
3307859|NCT00359736|Experimental|Sildenafil|Sildenafil 20 mg tid orally
3307860|NCT00359736|Placebo Comparator|Placebo|Identical Placebo 20 mg tid orally
3307861|NCT00359684||Cystinosis|Patients with a diagnosis of cystinosis
3307862|NCT00359671|Experimental|1|Arm 1: study drug
3307863|NCT00359671|Other|2|Arm 2: study drug + comparator
3307864|NCT00359658|Experimental|1|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal; Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily; Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 mg/ml
3307865|NCT00359645|No Intervention|Control|Annual auto questionnaire
3307866|NCT00359645|Experimental|Screening|Annual screening of Head and Neck cancer
3307867|NCT00359632|Experimental|Linezolid|Subjects have received at least 6 weeks of linezolid therapy (600 mg BID). Continued duration of linezolid treatment is based on treating physician's benefit/risk assessment. A matching control who did not receive linezolid will be selected for each linezolid treated subject.
3307868|NCT00359632|Active Comparator|Matched control|Control subjects individually matched to linezolid subjects (on age, gender and type of infection) who received at least 6 weeks of antibiotics other than linezolid. Control group assessed only at baseline visit to assess presence of background abnormalities in the study test panel.
3307869|NCT00359619|Active Comparator|Cervarix Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3307870|NCT00359619|Experimental|Cervarix 1 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 1 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3307871|NCT00359619|Experimental|Cervarix 2 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 2 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3307872|NCT00359619|Experimental|Cervarix 3 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 3 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3307873|NCT00359619|Experimental|Cervarix 4 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 4 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3307874|NCT00359619|Experimental|Cervarix 5 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 5 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3307875|NCT00359619|Experimental|Cervarix 6 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 6 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3307876|NCT00359606|Experimental|Treatment (5-fluoro-2-deoxycytidine, tetrahydrouridine)|Patients receive tetrahydrouridine PO on day 1; 5-fluoro-2-deoxycytidine PO on days 1 and 8; tetrahydrouridine IV over 3 hours on days 2-5, 8, and 9-12; and 5-fluoro-2-deoxycytidine IV over 3 hours on days 2-5 and 9-12 of course 1. For all subsequent courses, patients receive tetrahydrouridine IV over 3 hours and 5-fluoro-2-deoxycytidine IV over 3 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3307877|NCT00359567|Experimental|1|palonosetron
3307878|NCT00359567|Active Comparator|2|granisetron hydrochloride
3307879|NCT00359476|Experimental|1|
3307880|NCT00359463|Active Comparator|Healthy subjects|Subjects will receive a single 50 mg oral dose of eltrombopag.
3307881|NCT00359463|Experimental|Subjects with hepatic impairment|Subjects with mild, moderate or severe hepatic impairment will receive a single 50 mg oral dose of eltrombopag.
3307882|NCT00359437|Experimental|Satavaptan|
3307883|NCT00359437|Placebo Comparator|Placebo|
3307884|NCT00359424|Active Comparator|intravenous (IV) rt-PA alone|Group one will receive the standard dose of intravenous (IV) rt-PA alone given over an hour.
3307885|NCT00359424|Experimental|Endovascular therapy|Group two will receive a lower dose or a standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose (based on the location and extent of the blood clot) a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery.
3307886|NCT00359398|Experimental|Platelet sequestration|Sequestration of platelet rich plasma before cardiopulmonary bypass
3307887|NCT00359398|No Intervention|Standard care|No platelet rich plasma sequestration undertaken before cardiopulmonary bypass (usual practice)
3307888|NCT00359385|Active Comparator|Alendronate 70mg weekly|Alendronate 70mg weekly
3307889|NCT00359385|Placebo Comparator|placebo of alendronate 70mg weekly|placebo of Alendronate 70mg weekly
3307890|NCT00359359|Experimental|Sagopilone and cisplatin|The study drug sagopilone was administered in combination with a fixed dose of cisplatin
3307891|NCT00359333|Experimental|Single Group|
3307892|NCT00359320|Experimental|Mucosa-to-jejunal mucosa technique of pancreaticojejunosto|Determine whether a duct mucosa-to-jejunal mucosa technique of pancreaticojejunostomy will improve the pancreatic fistula rate
3307893|NCT00359294|Experimental|Arm 1|
3307894|NCT00359255|Active Comparator|1|
3307895|NCT00359255|Experimental|2|
3307896|NCT00359242|Experimental|1|Soothing and Calming instructions given at 2 weeks of life
3307897|NCT00359242|Experimental|2|Repeated food exposure instructions given between 4 and 6 months of life
3307898|NCT00359242|Experimental|3|Receive both interventions: Soothing and Calming and Repeated food exposure
3307899|NCT00359242|No Intervention|4|Group receiving neither of the interventions.
3307900|NCT00359229|Experimental|1|For 3 weeks
3307901|NCT00359216|Experimental|Mometasone furoate nasal spray|
3307902|NCT00359216|Placebo Comparator|Placebo nasal spray|
3307903|NCT00359203|Placebo Comparator|Dual chamber pacemaker|Dual chamber pacemaker programmed ODO (switched OFF)
3307904|NCT00359203|Active Comparator|Dual chamber pacemeker|Medtronic dual chamber pacemaker programmed ON and with Rate Drope Response programmed ON
3307905|NCT00359190|Experimental|Lapatinib receivers|Subjects with treatment-naïve breast tumors will be administered lapatinib 1500 mg once daily, 1000 mg once daily, or 500 mg twice daily for a minimum of 9 days and maximum of 15 days prior to surgical resection..
3307906|NCT00359177|Experimental|Healthy subjects receiving GW679769|Healthy Subjects will receive single 100 milligram (mg) oral doses of GW679769 for five consecutive days.
3307907|NCT00359177|Experimental|Subjects with hepatic impairment receiving GW679769|Subjects with hepatic impairment will receive single 100 mg oral doses of GW679769 for five consecutive days.
3307908|NCT00359164|Active Comparator|1|Bevacizumab with verteporfin at Low Fluence Photodynamic Therapy.
3307909|NCT00359164|Active Comparator|2|Bevacizumab with verteporfin at Very Low Photodynamic Therapy.
3307910|NCT00359164|Sham Comparator|3|Bevacizumab with verteporfin with Sham Photodynamic Therapy.
3307911|NCT00359151|Experimental|Celecoxib|Celecoxib
3307912|NCT00359151|Placebo Comparator|Placebo|Placebo
3307913|NCT00359138|Experimental|Desloratadine 5 mg tablet + Levocetirizine placebo capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
3307914|NCT00359138|Active Comparator|Desloratadine placebo tablet + Levocetirizine 5 mg capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
3307915|NCT00359138|Placebo Comparator|Desloratadine placebo tablet + Levocetirizine placebo capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
3307916|NCT00359125|Active Comparator|1|RU-486, 600 mg/day for 1 week.
3307917|NCT00359125|Placebo Comparator|2|Placebo, 600 mg/day for 1 week
3307918|NCT00359086|Experimental|1|
3307919|NCT00359073|Active Comparator|Montelukast|montelukast (10 mg everyday)
3307920|NCT00359073|Placebo Comparator|Placebo|Placebo comparator
3307921|NCT00359047|Experimental|Documentation|Written educational material on osteoporosis for the participant and the physician.
3307922|NCT00359047|Experimental|Video|A 15-minute educational video on osteoporosis as well as written documentation on osteoporosis for the participant and the physician.
3307923|NCT00359021|Experimental|001|TMC125 200 mg twice daily until commercially available
3307924|NCT00359008||1|Intermediate AMD
3307925|NCT00359008||2|New untreated CNV subject
3307926|NCT00358995|Active Comparator|1|Cognitive Behavior Therapy (CBT) may include keeping a diary of significant events and associated feelings, thoughts and behaviors; questioning and testing cognitions, assumptions, evaluations and beliefs that might be unhelpful and unrealistic; gradually facing activities which may have been avoided; and trying out new ways of behaving and reacting and using relaxation and distraction techniques.
3307927|NCT00358995|Active Comparator|2|Stress Management Therapy (SMT) includes relaxation, interaction, biofeedback, exercises, such as muscle stretching exercises, yoga, meditation, time management techniques, and many more.
3307928|NCT00358982|Experimental|1|
3307929|NCT00358956|Experimental|1|
3307930|NCT00358917|Experimental|LPV/r 800/200 mg QD Tablet|
3307931|NCT00358917|Active Comparator|LPV/r 400/100 mg BID Tablet|
3307932|NCT00358878|Experimental|Satavaptan|
3307933|NCT00358878|Placebo Comparator|Placebo|
3307934|NCT00358852||Patients with Schizophrenia|
3307935|NCT00358826|Experimental|VIA-2291 25 mg|VIA-2291 25 mg
3307936|NCT00358826|Experimental|VIA-2291 50 mg|VIA-2291 50 mg
3307937|NCT00358826|Experimental|VIA-2291 100 mg|VIA-2291 100 mg
3307938|NCT00358826|Placebo Comparator|Placebo|Placebo
3307939|NCT00358813|Experimental|Subjects receiving casopitant|Eligible subjects will receive a 100 milligrams oral dose of casopitant once daily for five consecutive days.
3307940|NCT00358787|Active Comparator|1|Crossed K wire orientation for surgical management of a type III Supracondylar fracture.
3307941|NCT00358787|Active Comparator|2|Lateral K wire orientation for surgical management of a type III Supracondylar fracture.
3307942|NCT00358735|Experimental|ActiveCare CECT|The ActiveCare CECT device is a mobile compression device used to prevent venous thromboembolic events, used after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery.
3307943|NCT00358735|Active Comparator|LMWH (Enoxaparin)|Enoxaparin (LMWH) will be used, following a protocol that is considered a standard of care for this patient population. 40mg QD for the remainder of the 10 days.
3307944|NCT00358722|Experimental|Fermagate|
3307945|NCT00358670|Active Comparator|Maintenance Infliximab|Infliximab 5 mg/kg by body weight every 8 weeks
3307946|NCT00358670|Experimental|Intermittent Infliximab|Infliximab 5 mg/kg by body weight at Weeks 0, 2, 6 and 14 following a 50% reduction in Psoriasis Area and Severity Index (PASI) from the Study P04271 Baseline
3307947|NCT00358657|Experimental|Treatment (chemo, total-body irradiation, transplant)|See Detailed Description
3307948|NCT00358644|Experimental|1|
3307949|NCT00358579|Active Comparator|Adrenaline|
3307950|NCT00358579|Active Comparator|Vasopressin|
3307951|NCT00358566|Active Comparator|Gemcitabine|Gemcitabine alone treatment.
3307952|NCT00358566|Experimental|GV1001|GV1001 in sequential combination with Gemcitabine
3307953|NCT00358540|Experimental|Group B|Group B is a dose escalation phase designed to determine the optimal biological dose of eltrombopag in subjects with sarcoma who received chemotherapy treatment with Adriamycin and Ifosfamide
3307954|NCT00358540|Experimental|Group A|Group A will be used for further exploration of the optimal biological dose (as initially established by completion of Group B), by using 2 different dosing schedules of eltrombopag.
3307955|NCT00358527|Experimental|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray 200 mcg, once daily.
3307956|NCT00358527|Placebo Comparator|Matching placebo nasal spray|
3307957|NCT00358501|Experimental|Defibrotide|Defibrotide treatment
3307958|NCT00358501|No Intervention|Historical Control|Historical control group
3307959|NCT00358488|Experimental|GSK159797 (10, 15, and 20mcg)|GSK159797 (10, 15, and 20mcg)
3307960|NCT00358488|Experimental|salbutamol|salbutamol
3307961|NCT00358488|Experimental|salmeterol 50mcg|salmeterol 50mcg
3307962|NCT00358488|Placebo Comparator|placebo|placebo
3307963|NCT00358462|Active Comparator|Active azithromycin+placebo doxycycline|Active azithromycin (1g) and placebo doxycycline
3307964|NCT00358462|Active Comparator|Active doxycycline+placebo azithromycin|Active doxycycline and placebo azithromycin
3307965|NCT00358449|Experimental|Mepolizumab 0.55 mg/kg|Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
3307966|NCT00358449|Experimental|Mepolizumab 2.5 mg/kg|Participants received mepolizumab 2.5 mg/kg by IV infusion for 30 minutes on Day 1, Week 4 and Week 8.
3307967|NCT00358449|Experimental|Mepolizumab 10 mg/kg|Participants received mepolizumab 10 mg/kg by IV infusion for 30 minutes on Day 1, Week 4 and Week 8.
3307968|NCT00358436|Experimental|Aclidinium 200 μg once-daily|Aclidinium bromide 200 μg once-daily by inhalation
3307969|NCT00358436|Placebo Comparator|Placebo|Placebo by inhalation
3307970|NCT00358423|Experimental|A|
3307971|NCT00358423|Placebo Comparator|B|
3307972|NCT00358410|Experimental|GW679769|120mg once a day
3307973|NCT00358410|Placebo Comparator|Placebo|Placebo once a day
3307974|NCT00358397|Experimental|Treatment arm|
3307975|NCT00358384|Experimental|Subjects receiving treatment A|Eligible subjects will receive 0.1 percent pazopanib ointment.
3307976|NCT00358384|Experimental|Subjects receiving treatment B|Eligible subjects will receive 0.5 percent pazopanib ointment.
3307977|NCT00358384|Experimental|Subjects receiving treatment C|Eligible subjects will receive 1 percent pazopanib ointment.
3307978|NCT00358384|Placebo Comparator|Subjects receiving treatment D|Eligible subjects will receive pazopanib vehicle as negative control.
3307979|NCT00358384|Placebo Comparator|Subjects receiving treatment E|Eligible subjects will receive 0.1 percent betamethasone valerate ointment as steroid positive control.
3307980|NCT00358384|Placebo Comparator|Subjects receiving treatment F|Eligible subjects will receive 0.005 percent calcipotriol ointment as vitamin D agonist positive control.
3307981|NCT00358371|Experimental|Subjects receiving flucloxacillin 250 mg|Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
3307982|NCT00358371|Experimental|Subjects receiving flucloxacillin 500 mg|Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
3307983|NCT00358345||1|Intermediate AMD
3307984|NCT00358345||2|Newly diagnosed CNV
3307985|NCT00358332|Experimental|Group 1: FMP2.1/AS02A 10 mcg dose or rabies vaccine.|20 children will be randomized to receive either the 10 mcg dose of FMP2.1/AS02A (n=15) or rabies vaccine (n=5) on study days 0, 30 +/- 7, and 60 +/- 7.
3307986|NCT00358332|Experimental|Group 2: FMP2.1/AS02A 25 mcg dose or rabies vaccine.|40 children will be randomized to receive either the 25 mcg dose of FMP2.1/AS02A (n=30) or rabies vaccine (n=10) on study days 0, 30 +/- 7, and 60 +/- 7.
3307987|NCT00358332|Experimental|Group 3: FMP2.1/AS02A 50 mcg dose or rabies vaccine.|40 children will be randomized to receive either the 50 mcg dose of FMP2.1/AS02A (n=30) or rabies vaccine (n=10) on study days 0, 30 +/- 7, and 60 +/- 7.
3307988|NCT00358319|Experimental|Phase I|Dose escalation phase
3307989|NCT00358319|Experimental|Phase II|All patients enrolled in the Phase II will be treated with Valproic Acid (VPA) and Karenitecin using the dosing schedule determined to be the Maximum Tolerated Dose (MTD) in Phase I.
3307990|NCT00358306||a|those with previous history of Acute kidney injury
3307991|NCT00358267|Active Comparator|RFA|Radiofrequency Ablation (RFA) involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
3307992|NCT00358267|Active Comparator|PRIT|Partial Resection of Inferior Turbinate (PRIT) involves surgically removing a small piece off the turbinate, which also reduces its size.
3307993|NCT00358215|Experimental|Darbepoetin alfa|Starting dose of 0.75 µg/kg subcutaneously every 2 weeks until hemoglobin concentrations reach 13.0 g/dL on 2 consecutive visits, then monthly dosing, titrated to achieve hemoglobin target of 13.0 g/dL, not to exceed 14.5 g/dL.
3307994|NCT00358215|Placebo Comparator|Placebo|Participants received dose and administration schedule (every 2 weeks or once a month) changes that simulated the changes for participants receiving darbepoetin alfa.
3307995|NCT00358202|Active Comparator|1 cefepime|
3307996|NCT00358202|Active Comparator|2 ceftriaxone|
3307997|NCT00358150|Experimental|Eliglustat tartrate|
3307998|NCT00358072|Experimental|1|Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
3307999|NCT00358033|Experimental|group intervention|pharmacist-led group intervention in behavioral and pharmacologic therapy
3308000|NCT00358033|Active Comparator|individual|pharmacist-based individual clinic visits with behavioral and pharmacologic intervention for cardiac risk reduction
3308001|NCT00358033|No Intervention|usual care|usual care
3308002|NCT00358007|Experimental|Cone Beam CT|
3308003|NCT00357994|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG) + Placebo Capsules|Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
3308004|NCT00357994|Active Comparator|Placebo Gel + Levodopa-Carbidopa Capsules|Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.
3308005|NCT00357981|Experimental|ORTHO EVRA|"The approximate first two months of women's participation will be spent documenting baseline information about their health and well-being, work patterns and performance, and the economic impact of their menstruation. Subjects will then initiate two, two month intervals of continuous use of ORTHO EVRA.~Over this four month treatment period, subjects will document their health and well-being, work patterns and performance, and the economic impact of their menstruation while being treated with ORTHO EVRA. This will allow us to compare subjects' experiences pre- and post-treatment. The study's instruments will focus on eliciting information on the personal and economic costs of menstruation such as measuring time missed from work, changes in productivity and work satisfaction, and impact on quality of life."
3308006|NCT00357968|Experimental|Prasugrel to Clopidogrel|One time oral loading dose (LD) of 60-mg Prasugrel and placebo matched to clopidogrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 10-mg Prasugrel and placebo matched to clopidogrel taken orally once a day for 14 days. Patients cross-over to 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for the next 14 days.
3308007|NCT00357968|Active Comparator|Clopidogrel to Prasugrel|One time oral LD of 600 mg clopidogrel and placebo matched to prasugrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for 14 days. Patients cross-over to 10 mg prasugrel and placebo tablets matched to clopidogrel taken orally once a day for the next 14 days.
3308008|NCT00357955|Experimental|MEDIC|Multidisciplinary education and diabetes intervention for cardiac risk reduction
3308009|NCT00357955|No Intervention|usual care|usual care
3308010|NCT00357942|Experimental|C group I|Morphine mouthwash and placebo i.v.(24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
3308011|NCT00357942|Active Comparator|C group II|Placebo mouthwash and morphine i.v.(24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
3308012|NCT00357942|Placebo Comparator|C group III|Placebo mouthwash and placebo i.v. (24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
3308013|NCT00357903|Other|1|
3308014|NCT00357890|Experimental|Pump therapy (CSII)|Use of pump therapy
3308015|NCT00357890|Active Comparator|Multiple daily injections (MDI)|Use of MDI (basal bolus therapy with glargine)
3308016|NCT00357877|Placebo Comparator|Placebo Dental Coating|Dental coating with all ingredients except Chlorhexidine topically applied by dental professional supragingivally to the full dentition
3308017|NCT00357877|Active Comparator|Active Dental Coating|10% w/v chlorhexidine acetate coating FDA IND #45466. Dental coating with all ingredients including Chlorhexidine topically applied by dental professional supragingivally to the full dentition
3308018|NCT00357799|Active Comparator|VeinViewer Arm|Attempts at IV placement will be made with use of the VeinViewer Machine
3308019|NCT00357799|No Intervention|Conventional Method|IV attempted with conventional method
3308020|NCT00357786|Experimental|A|Enzyme replacement for Fabry's Disease
3308021|NCT00357760|Experimental|Arm A (higher dose of VEGF Trap)|Patients receive a higher dose of ziv-aflibercept (VEGF Trap) IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3308022|NCT00357760|Experimental|Arm B (lower dose of VEGF Trap)|Patients receive a lower dose of ziv-aflibercept (VEGF Trap) IV over 1 hour on day 1. In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. At the time of disease progression, the dose of ziv-aflibercept (VEGF Trap) may be escalated to the higher dose in Arm A.
3308023|NCT00357747|Experimental|AEG35156 plus docetaxel|
3308024|NCT00357734|Experimental|Gefitinib (ZD1839)|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
3308025|NCT00357721|Active Comparator|A1|
3308028|NCT00357708|Experimental|Treatment (decitabine, vorinostat)|"Patients receive decitabine IV over 1 hour on days 1-5 and oral vorinostat (SAHA) three times daily on days 6-19. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients receive escalating doses of decitabine and SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose."
3308029|NCT00357682|Experimental|Arm A|20mg Esomeprazole
3308030|NCT00357682|Experimental|Arm B|80mg Esomeprazole
3308031|NCT00357682|Experimental|Arm C|20mg Esomeprazole + 300mg Aspirin
3308032|NCT00357682|Experimental|Arm D|80mg Esomeprazole + 300mg Aspirin
3308033|NCT00357669|Placebo Comparator|Placebo|
3308034|NCT00357669|Experimental|Brivaracetam 50 mg/day|BRV 50 mg/day
3308035|NCT00357669|Experimental|Brivaracetam 150 mg/day|BRV 150 mg/day
3308036|NCT00357656|Experimental|BI|Bolus infusion of rAHF-PFM
3308037|NCT00357656|Experimental|CI|Continuous infusion of rAHF-PFM
3308038|NCT00357604|Active Comparator|A1|
3308039|NCT00357604|Experimental|A2|
3308040|NCT00357591|Active Comparator|Control|
3308041|NCT00357565|Experimental|Double Unit UCB Transplantation|Patients that receive 2 units of umbilical cord blood transplantation (UCBT).
3308042|NCT00357565|Experimental|Single Unit UCB Transplantation|Patients that receive one unit of umbilical cord blood transplantation (only if 2 adequate size and matched units are not available).
3308043|NCT00357552|Experimental|LPV/r monotherapy|Participants will receive lopinavir/ritonavir twice daily for up to 104 weeks. Upon confirmation of virologic failure, emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) once a day will be added to their regimen.
3308044|NCT00357500|Experimental|5-drug metronomic antiangiogenic regimen|Thalidomide: Start at 3 mg/kg (rounded to nearest 50 mg), increasing dose weekly by 50 mg as tolerated to 24 mg/kg (max 1,000 mg); Celecoxib: < 20 kg at 100 mg; 20-50 kg at 200 mg; > 50 kg at 400 mg; Fenofibrate: 90 mg/m2 (max 200 mg); Etoposide: 50 mg/m2; Cyclophosphamide: 2.5 mg/kg (max 100 mg); Patients receive oral etoposide once daily on days 1-21 and 43-63 (weeks 1-3 and 7-9) and oral cyclophosphamide once daily on days 22-42 (weeks 4-6). Patients also receive oral thalidomide once daily, oral celecoxib twice daily, and oral fenofibrate once daily in weeks 1-9. Treatment repeats approximately every 9 weeks for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients receive alternating etoposide and cyclophosphamide pulses (i.e., etoposide-cyclophosphamide-etoposide during courses 1 and 3 and cyclophosphamide-etoposide-cyclophosphamide during course 2).
3308045|NCT00357474|Active Comparator|chemotherapy|Transarterial chemoembolization (TACE)
3308046|NCT00357474|Active Comparator|ethanol|Percutaneous ethanol injection therapy (PEIT)
3308047|NCT00357448|Experimental|Arm I|Patients receive intraperitoneal denileukin diftitox over at least 15 minutes on days 1-3. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3308048|NCT00357422|Active Comparator|surgery|
3308049|NCT00357422|Active Comparator|local therapy|
3308050|NCT00357396|Experimental|Chemo followed by DSCT|"Myeloablative preparative regimen: Patients receive busulfan IV over 2 hours every 6 hours on days -8 to -6, melphalan IV over 20 minutes on days -5 to -3, and thiotepa IV over 4 hours on day -2.~Allogeneic hematopoietic stem cell transplant: Patients undergo allogeneic bone marrow or T-cell depleted peripheral blood stem cell transplantation on day 0.~Graft-vs-host disease (GVHD) prophylaxis: Patients receive treatment according to institutional guidelines and are given treatment against infection.~After completion of study treatment, patients are followed periodically for at least 3 years."
3308051|NCT00357370|Experimental|Cohort 1|20 mg
3308052|NCT00357370|Experimental|Cohort 2 - Arm 1|10 mg
3308053|NCT00357370|Experimental|Cohort 2 - Arm 2|20 mg
3308054|NCT00357370|Placebo Comparator|Cohort 2 - Arm 3|
3308055|NCT00357357|Placebo Comparator|Group1|4x 7 day rising dose
3308056|NCT00357357|Placebo Comparator|Group2|4x, 7 day rising dose
3308057|NCT00357357|Placebo Comparator|Group3|28 day fixed lower dose
3308058|NCT00357357|Placebo Comparator|Group4|28 day fixed upper dose
3308059|NCT00357331|Experimental|Potassium Citrate|Potassium Citrate 20 meq twice daily
3308060|NCT00357331|Placebo Comparator|Placebo|Placebo
3308061|NCT00357318|Experimental|Treatment (sunitinib malate, bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29 and oral sunitinib malate (SU11248) once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3308062|NCT00357305|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive oral SAHA two or three times daily on days 1-7 and cytarabine IV over 3 hours twice daily and etoposide IV over 1 hour once daily on days 11-14. Treatment repeats approximately every 6-7 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3308063|NCT00357279|Placebo Comparator|1|Placebo
3308064|NCT00357279|Experimental|2|
3308065|NCT00357240|Active Comparator|A1|
3308066|NCT00357240|Active Comparator|A2|
3308067|NCT00357240|Experimental|A3 I|
3308068|NCT00357240|Experimental|A3 II|
3308069|NCT00357240|Active Comparator|B1|
3308070|NCT00357240|Active Comparator|B2|
3308071|NCT00357240|Experimental|B3 I|
3308072|NCT00357240|Experimental|B3 II|
3308073|NCT00357214|Active Comparator|1|Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
3308074|NCT00357214|Active Comparator|Arm 2|Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
3308075|NCT00357214|Active Comparator|Arm 3|Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.
3308076|NCT00357214|Placebo Comparator|Arm 4|Participants will receive placebo is microcrystalline cellulose. This compound has no other name.
3308077|NCT00357188|Active Comparator|A|
3308078|NCT00357188|Active Comparator|B|
3308079|NCT00357162|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3308080|NCT00357149|Active Comparator|A|Cisplatin from day 1 to day 4 and 5-FU for 4 days starting immediately after the end of cisplatin infusion on day 1. Both drugs were administered during week 1 and 6 of irradiation, starting from day 1 of weekly radiotherapy.
3308081|NCT00357149|Experimental|B|Docetaxel followed by cisplatin and 5-FU from day 1 to day 4 starting after the end of cisplatin infusion. The cycle was repeated every 3 weeks up to a total of 3 cycles. After 3-6 weeks from the end of neoadjuvant chemotherapy, patients will receive with the same modality of arm A (reference arm).
3308082|NCT00357110|Active Comparator|1|Anastrozole monotherapy
3308083|NCT00357110|Experimental|2|Anastrozole + Fulvestrant
3308084|NCT00357032|Experimental|Treatment (belinostat)|Patients receive PXD101 IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 6-12 months in the absence of disease progression or unacceptable toxicity.
3308085|NCT00357006|Active Comparator|1|100 mcg Estradiol
3308086|NCT00357006|Active Comparator|2|200 mcg Estradiol
3308087|NCT00357006|Placebo Comparator|3|adjunctive transdermal placebo
3308088|NCT00356993|Experimental|NRT + Behavioural Support|Nicotine Replacement Therapy plus Behavioural Intervention
3308089|NCT00356941|Experimental|Chemoradiation Treated Patients|Patients receiving Docetaxel, Oxaliplatin and radiotherapy.
3308090|NCT00356928|Experimental|Cyclophosphamide + T cells|Conditioning regimen with cyclophosphamide followed by donor T cells on Day 0.
3308091|NCT00356915|Experimental|Itraconazole tablets|Itraconazole 200 mg tablets
3308092|NCT00356915|Active Comparator|Itraconazole capsules|Two Itraconazole 100 mg capsules were taken daily.
3308093|NCT00356915|Placebo Comparator|Placebo tablets|The itraconazole 200-mg tablets and placebo tablets exactly matched one another and were white to slightly grey in color, were oblong and biconvex in shape, and were melt-extrusion, film-coated.
3308094|NCT00356889|Experimental|Bevacizumab and Erlotinib Hydrochloride|"Patients receive 5 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15 and 150 mg oral erlotinib hydrochloride daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.~Tumor tissue and blood specimens are collected periodically for correlative studies. Specimens are examined by immunohistochemistry for epidermal growth factor receptor (EGFR) and P-EGFR protein levels; AKT p-AKT, mitogen-activated protein kinase (MAPK) and P-MAPK protein levels; and vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR-2 protein levels. EGFR mutations are detected by laser capture microdissection. Enzyme-linked immunosorbent assay is used to measure total and free serum VEGF levels."
3308095|NCT00356863|Experimental|Explanation on cardiac rehabilitation|Intervention: Increasing awareness to cardiac rehabilitation programs: Patients received a written and oral short explanation on the importance and benefits of cardiac rehabilitation (CR) participation, and information on available programs. They were telephoned 2 weeks after hospital discharge to encourage them to enroll at a cardiac rehabilitation program (CRP). In addition, physicians and nurses at the cardiothoracic units participated in a 1-hour seminar on CR. A recommendation to the general physician to refer the patient to CRP was added to the letter of discharge from hospital.
3308096|NCT00356863|No Intervention|Usual care with no intervention|Patients recruited to the study received the usual care without any additional explanation on cardiac rehabilitation, and no effort to increase their awareness or the ward's awareness to cardiac rehabilitation was done.
3308097|NCT00356837|Experimental|A|Those with extremity fractures.
3308098|NCT00356824||1|HIV-infected children in Uganda
3308099|NCT00356811|Experimental|Single arm|Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
3308100|NCT00356759|Sham Comparator|12-weekly INR|Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times
3308101|NCT00356759|No Intervention|Standard management|Dosing warfarin every 4 weeks, all INRs true values
3308102|NCT00356746||1|elective CABG only patients
3308103|NCT00356746||2|elective ICD replacement surgical patients requiring general anesthesia
3308104|NCT00356733|Experimental|EPO rise|EPO administration
3308105|NCT00356733|Experimental|EPO stable|EPO and stable Hemoglobin
3308106|NCT00356733|No Intervention|control|standard treatment
3308107|NCT00356707||1|This cohort comprises women from the Black Women's Health Study, a prospective study of African American women, who lived in the Los Angeles, New York, or Chicago metropolitan areas at the time of completion of the 1995, 1997, or 1999 questionnaires.
3308108|NCT00356681|Placebo Comparator|Arm A Placebo|Blinded AMG 706 placebo plus paclitaxel
3308109|NCT00356681|Experimental|Arm B Experimental|Blinded AMG 706 plus paclitaxel
3308110|NCT00356681|Active Comparator|Arm C Comparator|Open-label bevacizumab plus paclitaxel
3308111|NCT00356642|Experimental|Single dose 1 cohort|Subjects with body surface area (BSA) disease involvement between 10 and 15% will be included. Subjects will receive either 100 milligrams (mg) GW842470X or placebo in a ratio of 2:1.
3308112|NCT00356642|Experimental|Repeat dose 1 cohort|Subjects with BSA disease involvement between 10 and 15% will be included. Subjects will receive either 100-150 mg GW842470X or placebo in a ratio of 3:1
3308113|NCT00356642|Experimental|Repeat dose 2 cohort|Subjects with BSA disease involvement between 30 and 40% will be included. Subjects will receive either 300-400 mg GW842470X or placebo in a ratio of 3:1
3308114|NCT00356642|Experimental|Repeat dose 3 cohort|Subjects with BSA disease involvement >=50% will be included. Subjects will receive either 500-1000 mg GW842470X or placebo in a ratio of 2:1
3308115|NCT00356616|Experimental|A|Trizivir+ Tenofovir 2/day
3308116|NCT00356616|No Intervention|B|antiretroviral treatment optimizated by genotyp
3308117|NCT00356603|Experimental|Sumatriptan|Sumatriptan
3308118|NCT00356590|Other|1|
3308119|NCT00356525|Experimental|Less Than One Year: Pemetrexed|Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
3308120|NCT00356525|Experimental|Less Than One Year: Pemetrexed + Gemcitabine|Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
3308178|NCT00356057|Active Comparator|1|Biventricular pacing group with Closed Loop Stimulation rate adaptation (Protos CLS device)
3308121|NCT00356525|Experimental|One Year or Greater: Pemetrexed + Carboplatin|Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
3308122|NCT00356525|Experimental|One Year or Greater: Pemetrexed + Gemcitabine|Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
3308123|NCT00356486|Experimental|A|Peginterferon alfa-2a (40 KD) (270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (40 KD) (180 µg/week) + Ribavirin (1000-1200 mg/day) for 8 weeks
3308124|NCT00356486|Experimental|B|Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
3308125|NCT00356473|Placebo Comparator|Placebo|Placebo
3308126|NCT00356473|Experimental|Atorvastatin|Atorvastatin
3308127|NCT00356460|Experimental|1 - Part 1|Dose Group
3308128|NCT00356460|Experimental|2 - Part 1|Dose Group
3308129|NCT00356460|Experimental|3 - Part 1|Dose Group
3308130|NCT00356460|Experimental|4 - Part 1|Dose Group
3308131|NCT00356460|Experimental|5 - Part 1|Dose Group
3308132|NCT00356460|Experimental|6 - Part 1|Dose Group
3308133|NCT00356460|Experimental|1 (Part 2)|
3308134|NCT00356460|Experimental|2 (part 2)|
3308135|NCT00356447|Active Comparator|Arm 1|
3308136|NCT00356447|Placebo Comparator|Arm 2|
3308137|NCT00356434|Active Comparator|1|Patients will have the Kendall, A-V foot impulse pump, model 6060 applied to their lower extremities to prevent DVT
3308138|NCT00356434|Active Comparator|2|Patients will have the Kendall,sequential compression device, model 9525 applied to the lower extremities to prevent DVT
3308139|NCT00356421|Active Comparator|Control|
3308140|NCT00356421|Experimental|Experimental|
3308141|NCT00356408|Experimental|CDP870 400 mg|Certolizumab pegol (CDP870) 400 mg (2 injections of 1 mL) every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2
3308142|NCT00356369|Experimental|Nimenrix Group|Subjects receiving GSK Biologicals' meningococcal vaccine 134612
3308143|NCT00356369|Active Comparator|Mencevax Group|Subjects receiving Mencevax™ ACWY
3308144|NCT00356356|Experimental|All subjects|257 subjects
3308145|NCT00356343|Experimental|NMES Strengthening Group|Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
3308146|NCT00356343|No Intervention|Control Group|No Intervention Control Group
3308147|NCT00356343|Active Comparator|Volitional Strengthening|Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
3308148|NCT00356317|Experimental|1|Participants will receive a 15-week family therapy
3308149|NCT00356317|Active Comparator|2|Participants will receive a 3-week family therapy (treatment as usual)
3308150|NCT00356304|Experimental|1|Participants will receive motivational interviewing in addition to their antidepressant therapy
3308151|NCT00356304|Active Comparator|2|Participants will receive treatment as usual
3308152|NCT00356291|Experimental|1|Participants will receive Skill-Building and Motivational Interviewing.
3308153|NCT00356291|Active Comparator|2|Participants will receive Skill-Building.
3308154|NCT00356278|Experimental|A|Participants will receive VRE therapy and D-cycloserine
3308155|NCT00356278|Active Comparator|B|Participants will receive VRE therapy and alprazolam
3308156|NCT00356278|Placebo Comparator|C|Participants will receive VRE therapy and placebo
3308157|NCT00356265|Experimental|CKD|
3308158|NCT00356265|Active Comparator|Hypertension group|
3308159|NCT00356265|Active Comparator|Normotensive group|
3308160|NCT00356213|Experimental|A|laparoscopic sleeve gastrectomy
3308161|NCT00356213|Active Comparator|B|laparoscopic gastric bypass
3308162|NCT00356200|Experimental|Fluphenazine treated|Treated with fluphenazine
3308163|NCT00356200|Placebo Comparator|Placebo|Treated with Placebo
3308164|NCT00356187|Experimental|Propranol Treatment|
3308165|NCT00356187|No Intervention|Standard of Care|
3308166|NCT00356174||Children with food allergy|340 longitudinally followed children with egg and/or milk allergy without elevated peanut specific Immunoglobulin E (IgE), less than 5 kUA/L
3308167|NCT00356174||Full sibling controls for genetic studies|Approximately 250 not age matched full siblings (i.e., non-step siblings, non-half siblings) will be recruited as an additional control group for genetic studies.
3308168|NCT00356174||Full sibling controls for mechanistic studies|Approximately 50 not age matched full siblings (i.e., non-step siblings, non-half siblings) will be recruited as an additional control group for mechanistic studies. A subset of this cohort will be without food allergy,
3308169|NCT00356148|Active Comparator|Prophylaxis Group|patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis
3308170|NCT00356148|No Intervention|No Prophylaxis Group|Patients who are BMI over 25 and do not receive antibiotic prophylaxis
3308171|NCT00356135|Experimental|Prasugrel 10/10 mg|Open label (lead-in) dose of clopidogrel 75 milligram (mg) for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 10 mg and placebo, followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.
3308172|NCT00356135|Experimental|Clopidogrel 75/75 mg|Open label (lead-in) dose of clopidogrel 75 mg for 10 to 14 days. Upon completion, assignment to a single loading dose of clopidogrel 75 mg and placebo, followed by maintenance dose of clopidogrel 75 mg taken for 13 to 15 days.
3308173|NCT00356135|Experimental|Prasugrel 60/10 mg|Open label (lead-in) dose of clopidogrel 75 mg for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 60 mg and placebo followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.
3308174|NCT00356122|Experimental|Docetaxel/Oxaliplatin/Bevacizumab|Participants with advanced, recurrent, or metastatic Non Small Cell Lung Cancer (NSCLC), treated with the combination of docetaxel, followed by oxaliplatin, and then bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.
3308175|NCT00356109|Experimental|1|
3308176|NCT00356109|Active Comparator|2|
3308177|NCT00356083|Experimental|switch from morphine to methadon|
3308179|NCT00356057|Active Comparator|2|Biventricular pacing group with accelerometer based rate adaption (Stratos LV device)
3308180|NCT00356057|Active Comparator|3|Right Ventricular pacing group with accelerometer based rate adaption (Stratos LV device)
3308181|NCT00356031|Experimental|Bevacizumab, Radiation, and Surgery|Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)
3308182|NCT00356005|Experimental|Azithromycin + Artesunate|Azithromycin + Artesunate treatment
3308183|NCT00356005|Active Comparator|Artesunate|Artesunate treatment controls
3308184|NCT00355966|Active Comparator|A|In group A, immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
3308185|NCT00355966|Active Comparator|B|In Group B immediate induction of labour will be done by application of vaginal PGE2 gel 0.5 gm at an interval of 6 hours , a maximum of 2 doses.
3308186|NCT00355940|Experimental|1|
3308187|NCT00355940|Active Comparator|2|
3308188|NCT00355914|Active Comparator|Group 1 Without Steroids|Lumbar Facet Joint Nerve Block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin)
3308189|NCT00355914|Experimental|Group 2 With Steroids|Lumbar Facet Joint Nerve Block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin) and 0.15 mg of non-particulate betamethasone)
3308190|NCT00355888|Experimental|Open label study of MBP-426|Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
3308191|NCT00355862|Active Comparator|1|Center specific immunosuppressive regimen (mTOR inhibitor free)
3308192|NCT00355862|Experimental|2|Sirolimus containing regimen
3308193|NCT00355849|Experimental|1|Intensified Glargine
3308194|NCT00355849|Experimental|2|HIIP
3308195|NCT00355849|Experimental|3|Intensified Glargine plus HIIP
3308196|NCT00355810|Experimental|placebo followed by probiotic|placebo, then washout period, then Lactobacillus plantarum MF1298
3308197|NCT00355810|Experimental|probiotic followed by placebo|Lactobacillus plantarum MF1298, then washout period, then placebo
3308198|NCT00355797|Active Comparator|Closed Loop Stimulation (CLS)|Pacemaker programmed with Closed Loop Stimulation rate adaptive technology for long-term follow-up data collection.
3308199|NCT00355797|Active Comparator|Standard Rate Adaptive Technology (R)|Pacemaker programmed with standard rate adaptive technology (R, accelerometer) for long-term follow-up data collection.
3308200|NCT00355797|Active Comparator|Non-rate adaptive pacing (DDD)|Pacemaker programmed with no rate adaption (DDD mode) for long-term follow-up data collection.
3308201|NCT00355784|Other|Control|9 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and their plasma growth hormone concentration was allowed to decline naturally.
3308202|NCT00355784|Experimental|Growth Hormone Treatment|8 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and received exogenous growth hormone treatment administered in 4 daily injections to mimic physiological growth hormone secretion throughout the 2-week overeating period.
3308203|NCT00355784|Experimental|High Growth Hormone Treatment|5 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and received a relatively high daily dose of growth hormone.
3308204|NCT00355771|Experimental|Treatment Group 1|
3308205|NCT00355771|Placebo Comparator|Treatment Group 2|
3308206|NCT00355706|Active Comparator|Group I - without Steroids|Thoracic Facet Joint Nerve Blocks with Local Anesthetic(0.25% Bupivacaine)
3308207|NCT00355706|Active Comparator|Group II - with steroid|Thoracic Facet Joint Nerve Blocks with Local Anesthetic (0.25% Bupivacaine) and Sterioids(0.15 mg of non-particulate betamethasone)
3308208|NCT00355680|Experimental|1|Aurolab Green Laser
3308209|NCT00355680|Active Comparator|2|Available Green Laser
3308210|NCT00355667|Active Comparator|A|Patients with chronic heart failure with NYHA II or III are given furosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with furosemide 20-40 mg/day, without a placebo run-in period. The dose of each diuretic was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.
3308211|NCT00355667|Active Comparator|B|Patients with chronic heart failure with NYHA II or III are given azosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with azosemide 30-60 mg/day without a placebo run-in period. The dose of azosemide was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.
3308212|NCT00355654|Experimental|Group 1|Participants will receive PEDIACEL with Prevenar at Visit 1 and ENGERIX-B Kinder at Visit 2
3308213|NCT00355654|Active Comparator|Group 2|Participants will receive Infanrix hexa with Prevenar at Visit 1
3308214|NCT00355641|Experimental|Open Label|All subjects will receive ropinirole XR in this study. The total daily dose range of ropinirole XR will be 0.5mg to 6.0mg daily
3308215|NCT00355628|Experimental|1|KW-2246 (fentanyl citrate)
3308216|NCT00355615|Active Comparator|rosuva 5|rosuvastatin 5 mg
3308217|NCT00355615|Active Comparator|rosuva 10|rosuvastatin 10 mg
3308218|NCT00355615|Active Comparator|rosuva 20|rosuvastatin 20 mg
3308219|NCT00355615|Placebo Comparator|Placebo|Placebo
3308220|NCT00355615|Other|rosuva ol|rosuvastatin open label
3308221|NCT00355576|Experimental|Minocycline + Creatine|Minocycline 100 mg BID and Creatine 10 g BID
3308222|NCT00355576|Experimental|Celecoxib + Creatine|Celecoxib 400 mg BID and Creatine 10 g BID
3308223|NCT00355537|Experimental|Active|
3308224|NCT00355537|Placebo Comparator|Placebo|
3308225|NCT00355524|Experimental|Group A with >= 20 kg to < 30 kg body weight|300 milligram (mg) of TMC114 tablet with 50 mg (which is equivalent to 0.625 milliliter [mL]) of ritonavir liquid (80 milligram/milliliter [mg/ml]) will be administered orally twice daily.
3308226|NCT00355524|Experimental|Group A with >= 30 kg to < 40 kg body weight|300 mg of TMC114 tablet with 50 mg (which is equivalent to 0.625 milliliter [mL]) of ritonavir liquid (80 milligram/milliliter [mg/ml]) will be administered orally twice daily.
3308227|NCT00355524|Experimental|Group A with >= 40 kg to < 50 kg body weight|450 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
3308228|NCT00355524|Experimental|Group B with >= 20 kg to < 30 kg body weight|375 mg of TMC114 tablet with 50 mg (which is equivalent to 0.625 mL) of ritonavir liquid (80 mg/mL) will be administered orally twice daily.
3308229|NCT00355524|Experimental|Group B with >= 30 kg to < 40 kg body weight|450 mg of TMC114 tablet with 60 mg (which is equivalent to 0.75 mL) of ritonavir liquid (80 mg/mL) will be administered orally twice daily.
3308230|NCT00355524|Experimental|Group B with >= 40 kg to < 50 kg body weight|600 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
3308231|NCT00355524|Experimental|Participants with >= 50 kg body weight|600 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
3308232|NCT00355498||1|Controls
3308233|NCT00355498||2|Mild Cognitive Impairment
3308234|NCT00355498||3|Alzheimer's disease
3308235|NCT00355498||4|FTD
3308236|NCT00355485|Experimental|Microdermabrasion Treatment|Bilateral, split-face comparison in which one half of the face will be randomly assigned to receive the microdermabrasion treatment(s) while the other half of the face will not. Subjects will receive a series of microdermabrasion treatment sessions (up to 6) spaced one to two weeks apart. In all cases, microdermabrasion treatment parameters will be within those accepted in cosmetic work.
3308237|NCT00355472|Experimental|1|KW-0761
3308238|NCT00355394|Placebo Comparator|Placebo|Standard care including intravenous fluid, but no metoclopramide.
3308239|NCT00355394|Active Comparator|Metoclopramide|Standard care including intravenous fluid PLUS metoclopramide.
3308240|NCT00355368|Active Comparator|Succinylcholine|
3308241|NCT00355368|Active Comparator|Rocuronium|
3308242|NCT00355355|Experimental|Litx|Drug: Talaporfin Sodium (1 mg/kg iv), Device: Interstitial Light Emitting Diodes (200 J/cm) 3 treatments within 6 months
3308243|NCT00355355|Active Comparator|Standard Care|The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
3308244|NCT00355342|Experimental|Salmeterol 50 mcg BID|Participants randomized to this arm received salmeterol 50 microgram (mcg), formulated with lactose via the DISKUS™ inhaler one inhalation twice daily (BID) one inhalation in the morning and one inhalation in the evening for 156 Weeks. Each DISKUS contained 60 doses of study medication. Participant were provided with albuterol/salbutamol as relief medication. DISCUS is registered trademark product of GlaxoSmithKline.
3308245|NCT00355342|Experimental|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Participants randomized to this arm received Fluticasone propionate/salmeterol combination product 250/50 mcg, formulated with lactose via the DISKUS inhaler one inhalation BID, one inhalation in the morning and one inhalation in the evening for 156 Weeks. Each DISKUS contained 60 doses of study medication. Participant were provided with albuterol/salbutamol as relief medication.
3308246|NCT00355316|Experimental|Stage IV Breast Cancer|Blood draws at baseline before systemic therapy. Blood draw then every 6 weeks for approximately 12 weeks.
3308247|NCT00355316|Other|Healthy Volunteers|Baseline blood draw.
3308248|NCT00355303|Active Comparator|Misoprostol tablet, PGE2 gel|participants are assigned to one of two arms for the duration of the study In one group induction of labour is done by intravaginal misoprostol tablets at 4 hrly interval with maximum of five doses.In other group PGE2 gel is applied in poaterior fornix at six hourly interval.
3308249|NCT00355264|Experimental|Single Arm on Active Drug|5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
3308250|NCT00355251|Experimental|A|4 semanas manteniendo el tratamiento antirretroviral e iniciar atorvastatina 40 mg/día. A la semana 4 interrupción HAART y aumentar a 80 mg/día de atorvastatina hasta la semana 32 de seguimiento
3308251|NCT00355251|No Intervention|B|4 semanas manteniendo el tratamiento antirretroviral. A la semana 4 interrupción HAART hasta la semana 32 de seguimiento
3308252|NCT00355238|Experimental|1|no comparator to brivanib
3308253|NCT00355199|Experimental|R-HDS|R-HDS : Rituximab supplemented high-dose (Cyclophosphamide,Ara-C, Methotrexate, Etoposide, Cis-Platin) sequential chemotherapy with autografting.
3308254|NCT00355199|Active Comparator|R-CHOP|Rituximab-CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone).
3308255|NCT00355186|No Intervention|Control|
3308256|NCT00355186|Experimental|Early|
3308257|NCT00355186|Experimental|Late|
3308258|NCT00355147|Experimental|Arm 1 Secondary Risk Factor Management|Patient Secondary Stroke Risk Factor Program including Stroke Self Management and Stroke Peer Support and Physician Stroke Guideline Adherence
3308259|NCT00355147|Placebo Comparator|Attention Control Group|Received Phone Calls from Staff to Control for Attention
3308260|NCT00355134|Experimental|Fingolimod 1.25 mg|"Participants received 1.25 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 1.25 mg fingolimod orally once a day.~Note: Upon implementation of a protocol amendment all patients taking 1.25 mg fingolimod were switched to 0.5 mg fingolimod orally once a day."
3308261|NCT00355134|Experimental|Fingolimod 0.5 mg|Participants received 0.5 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 0.5 mg fingolimod orally once a day.
3308528|NCT00351533|Experimental|1|Enteral fish oil
3308262|NCT00355134|Experimental|Placebo|"Participants received placebo capsules orally once a day for up to 24 months during the core phase. In the Extension phase participants received either 1.25 or 0.5 mg fingolimod orally once a day.~Note: Upon implementation of a protocol amendment all patients taking 1.25 mg fingolimod were switched to 0.5 mg fingolimod orally once a day. Upon implementation of a protocol amendment, all patients taking placebo were switched to 0.5 mg fingolimod orally once a day."
3308263|NCT00355121|Experimental|Group 1|DAPTACEL® + IPOL on Day 0 and Menactra on Day 30
3308264|NCT00355121|Experimental|Group 2|DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30
3308265|NCT00355121|Experimental|Group 3|Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30
3308266|NCT00355095|Active Comparator|1|erythropoietin
3308267|NCT00355095|No Intervention|2|Placebo
3308268|NCT00355082|Experimental|lamotrigine 300|300 mg/day treatment
3308269|NCT00355082|Experimental|lamotrigine 250|250 mg/day treatment
3308270|NCT00355069|Experimental|1|Received the Basic Pediatric Chronic Care Model AND the Medication Assessment Prompt AND family education
3308271|NCT00355069|Experimental|2|Received the Basic Pediatric Chronic Care Model AND the Medication Assessment Prompt but NOT family education
3308272|NCT00355069|Experimental|3|Received the Basic Pediatric Chronic Care Model AND family education but NOT the Medication Assessment Prompt
3308273|NCT00355069|Placebo Comparator|4|Received the Basic Pediatric Chronic Care Model only (NO Medication Assessment Prompt and NO family education)
3308274|NCT00355056|Sham Comparator|1|
3308275|NCT00355056|Experimental|2|PFO device Closure
3308276|NCT00355030|Experimental|1|
3308277|NCT00355030|Experimental|2|
3308278|NCT00354991|Experimental|1|Losartan/HCTZ
3308279|NCT00354978|Experimental|FOLFIRI plus Bevacizumab|FOLFIRI [folinic acid (leucovorin) 400 mg/m^2 by vein (IV) Day 1; 5-FU 400 mg/m^2 IV injection Day 1 immediately followed by 2.4 g/m^2 IV over 46 hours over Days 1-3; Irinotecan 180 mg/m^2 IV on Day 1] + Bevacizumab 5 mg/kg over 90 minutes on Day 1 administered alone then 5 mg/kg IV on Day 1 of 14 day cycle.
3308280|NCT00354965|Experimental|ARM 1|
3308281|NCT00354926|Experimental|AME 133v|All subjects will receive weekly intravenous infusions of AME-133v. Each subject will receive a total of 4 infusions administered once a week for 3 consecutive weeks.
3308282|NCT00354913|Experimental|Imatinib mesylate+hydroxyurea|All patients receive imatinib mesylate and hydroxyurea orally on a daily, continuous basis. Dosing of imatinib mesylate is adjusted for patients who are also receiving p450-inducing anti-epileptic drugs.
3308283|NCT00354887|Experimental|Oxaliplatin + Capecitabine|Intravenous Oxaliplatin 130 mg/m^2, Day 1 + Oral Capecitabine 750 mg/m^2 twice daily Days 1-14.
3308284|NCT00354874|Experimental|GW642444 50mcg|
3308285|NCT00354874|Experimental|GW642444 100mcg|
3308286|NCT00354874|Experimental|GW642444 200mcg|
3308287|NCT00354874|Active Comparator|salmeterol 50mcg|
3308288|NCT00354874|Placebo Comparator|placebo|
3308289|NCT00354861|Experimental|A|IMP321
3308290|NCT00354861|Placebo Comparator|B|Saline
3308291|NCT00354861|Active Comparator|C|Engerix B
3308292|NCT00354835|Active Comparator|VAC|Patients receive VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
3308293|NCT00354835|Experimental|VAC Alternating with VI|Patients receive VAC chemotherapy alternating with VI chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 13, 22, 28, 34, and 40; cyclophosphamide IV over 1 hour on day 1 of weeks 1,10, 13, 22, 28, 34, and 40; and irinotecan hydrochloride IV over 1 hour on days 1-5 of weeks 4, 7, 16, 19, 25, 31, and 37. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
3308294|NCT00354770|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine
3308295|NCT00354770|Placebo Comparator|2|Placebo
3308296|NCT00354757|Active Comparator|2 arms|PPI 1
3308297|NCT00354757|Active Comparator|PPI|PPI 2
3308298|NCT00354744|Experimental|High Risk Rhabdomyosarcoma|Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20. Weeks 1-6: vincristine sulfate and irinotecan hydrochloride. Weeks 7-34: vincristine sulfate and irinotecan hydrochloride, Cyclophosphamide with MESNA, Doxorubicin hydrochloride, Etoposide, Ifosfamide with MESNA. Weeks 35-54: vincristine sulfate, Dactinomycin, irinotecan hydrochloride and Cyclophosphamide with MESNA and Filgrastim. Radiation therapy beginning at Week 20. Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients.
3308299|NCT00354731|Active Comparator|corticosteroid|Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
3308300|NCT00354731|Experimental|Pentoxifylline + corticosteroid|Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M + oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
3308301|NCT00354705||Colon Cancer Patients|Patients with colon cancer recently removed by surgery.
3308302|NCT00354692|Experimental|Experimental|
3308303|NCT00354679|Experimental|Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, & Surger|"Induction therapy: Patients receive cisplatin IV over 30 minutes and irinotecan hydrochloride IV over 30 minutes on days 1, 8, 22, and 29. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 22.~Combination therapy and radiotherapy: Patients receive cisplatin and irinotecan hydrochloride as in induction chemotherapy on days 43, 50, 64, and 71. Patients also receive bevacizumab IV over 30-90 minutes on days 43 and 64. Patients undergo external beam radiotherapy 5 days a week for 6 weeks beginning on day 43. Surgery: Patients undergo surgery 6-8 weeks after finishing combination therapy and radiotherapy.~Maintenance therapy: Approximately 6 weeks after surgery, patients receive bevacizumab IV over 30-90 minutes every 3 weeks for 6 months"
3308529|NCT00351533|Placebo Comparator|2|Enteral saline
3308304|NCT00354640|Experimental|Anastrozole and Simvastatin|This is a pharmacological study for women on anastrozole as adjuvant therapy for breast cancer to receive concurrent simvastatin for up to 14 days.
3308305|NCT00354627|Experimental|TMC125|TMC125 200 mg b.i.d. till commercially available.
3308306|NCT00354601|Experimental|Weekly Docetaxel and Capecitabine|Weekly Docetaxel and Capecitabine
3308307|NCT00354575|Experimental|A|Chinese Herb (CCH1)
3308308|NCT00354575|Placebo Comparator|B|Starch powder as placebo
3308309|NCT00354562|Active Comparator|A|Docetaxel + ABT-751
3308310|NCT00354562|Placebo Comparator|B|Docetaxel + placebo
3308311|NCT00354536|Active Comparator|albiglutide|albiglutide injection
3308312|NCT00354536|Placebo Comparator|albiglutide placebo|placebo injection
3308313|NCT00354523|Experimental|Capecitabine + Dacarbazine + Imatinib|Capecitabine starting Dose 500 mg/m^2 twice a day Days 1-14 of 21 Day Cycle. Dacarbazine starting Dose 250 mg/m^2 a day on Days 1-3 of 21 Day Cycle. Imatinib starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
3308314|NCT00354484|Experimental|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
3308315|NCT00354484|Active Comparator|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
3308316|NCT00354458|Placebo Comparator|1|
3308317|NCT00354458|Experimental|2|
3308318|NCT00354432|Active Comparator|Arm I - Placebo|Patients receive oral placebo pill and oral placebo powder once daily.
3308319|NCT00354432|Active Comparator|Arm II - Soy|Patients receive oral placebo pill and oral soy protein/isoflavones powder once daily.
3308320|NCT00354432|Experimental|Arm III - Venlafaxine|Patients receive oral Venlafaxine pill and placebo powder once daily.
3308321|NCT00354432|Placebo Comparator|Arm IV - Soy + Venlafaxine|Patients receive oral Venlafaxine pill and soy protein/isoflavones powder once daily.
3308322|NCT00354419|Experimental|Arm I|See Detailed Description
3308323|NCT00354406|Experimental|A|Patients in Arm A (Early abciximab arm) will receive abciximab at time of STEMI diagnosis, before transfer to the Cath Lab to undergo primary angioplasty.
3308324|NCT00354406|Active Comparator|B|Patients in Arm B (Late abciximab arm) will receive abciximab at time of primary angioplasty, directly in the Cath Lab.
3308325|NCT00354354|Experimental|1|Combivent
3308326|NCT00354354|Placebo Comparator|2|Saline Solution (0.9% NaCl)
3308327|NCT00354341|Experimental|Group 1 (Early Epoetin Beta)|Along with their standard treatment participants will receive epoetin beta at a starting dose of 2000 International Units (IU) subcutaneously (SC) once weekly to reach and maintain target hemoglobin (Hb) between 13 and 15 grams per deciliter (g/dL), for 15 months. Epoetin beta doses will be adjusted according to individual participant's Hb level. Standard treatment will be as per investigator discretion.
3308328|NCT00354341|Active Comparator|Group 2 (No/Late Epoetin Beta)|Participants will receive their standard treatment for 15 months but no treatment for anemia correction unless Hb level will be less than (<) 10.5 g/dL on 2 consecutive visits of 2 weeks interval or the Hb level will be <10 g/dL on a single determination. In such cases participants could receive epoetin beta at a starting dose of 2000 IU SC once weekly to reach and maintain a target Hb level of 10.5 to 11.5 g/dL. Standard treatment will be as per investigator discretion.
3308329|NCT00354315|Experimental|1|Immediate Continuous medical education (CME)
3308330|NCT00354315|No Intervention|2|control, 6 months delay CME intervention
3308331|NCT00354263|Placebo Comparator|A|PBS injected alone in step 1 or mixed with Aggripal in step 2
3308332|NCT00354263|Experimental|B|
3308333|NCT00354250|Experimental|Treatment (ispinesib)|Patients receive ispinesib (SB-715992) IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3308334|NCT00354237|Other|B|No intensive treatment
3308335|NCT00354237|Experimental|A|Intensive insulin treatment
3308336|NCT00354224|Experimental|Oxaliplatin + Capecitabine|Patients will receive Oxaliplatin 85 mg/m2/d on day 1, given as a 2-hour infusion in 250 mL of dextrose 5% repeated every 2 weeks. Capecitabine will be administered orally at a dose of 850 mg/m2 twice a day.
3308337|NCT00354211||1|FLOTRAC™ SYSTEM
3308338|NCT00354211||2|Control Group
3308339|NCT00354198|Active Comparator|corticosteroids|[intravenous pulse methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses
3308340|NCT00354198|Experimental|pentoxifylline + corticosteroids|[intravenous pulse methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses + intravenous infusion of pentoxifylline (0.33-0.66 mg/kg/h) x 7 days + oral pentoxifylline (400-800 mg/day) from days 8 to 90
3308341|NCT00354185|Experimental|Treatment (tanespimycin, belinostat)|"Patients receive 17-AAG IV over 2 hours on days 1, 4, 8, and 11 and PXD101 IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 17-AAG and PDX101 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD.~Patients undergo blood collection on days 1 and 4 of course 1 for pharmacokinetic studies."
3308342|NCT00354172|Experimental|Treated Patients|All patients receiving treatment with chemotherapy and radiation, along with natural killer cells, aldesleukin and umbilical cord blood transplant.
3308343|NCT00354159|Experimental|Treatment Arm|Physicians have access to device-based hemodynamic monitor information to guide patient management
3308344|NCT00354159|Placebo Comparator|Control Arm|Physicians do not have access to device-based hemodynamic monitor information to guide patient management
3308345|NCT00354133|Active Comparator|DBS treatment|Patients in this arm are treated with Deep Brain Stimulation (DBS) of the Nucleus subthalamicus with the device Kinetra and Soletra (neurostimulator, Medtronic) and addtionally get best medical treatment
3308346|NCT00354133|Active Comparator|BMT treatment|Patients in this arm get best medical treatment only.
3308347|NCT00354120|Experimental|1|Alentuzumab
3308348|NCT00354120|Active Comparator|2|Globulina antilinfocitaria
3308530|NCT00351468|Experimental|Eltrombopag|Open-label eltrombopag
3308349|NCT00354107|Experimental|Treatment (monoclonal antibody therapy, chemotherapy)|"Patients receive monoclonal antibody SGN-30 IV alone on day 1 in weeks 1-8. Beginning in week 5, patients receive ICE chemotherapy comprising ifosfamide IV over 2 hours on days 1-3, carboplatin IV over 1 hour on day 1, and etoposide IV over 1 hour on days 1-3. Treatment with ICE repeats every 3 weeks for 6 courses** in the absence of unacceptable toxicity. Patients also receive intrathecal therapy comprising methotrexate, cytarabine, and hydrocortisone once on day 29 (week 5).~Cohorts of 3-6 patients receive a pre-determined dose of monoclonal antibody SGN-30 with possible dose de-escalation to 1 dose level below in the event of ≥ 2 of 6 patients experience dose-limiting toxicity (DLT). The dose at which ≤ 1 of 6 patients experience DLT will be used in a phase II study."
3308350|NCT00354081|Active Comparator|1|folic acid (0.8 mg) plus vitamin B12 (0.4 mg) and vitamin B6 (40 mg)
3308351|NCT00354081|Active Comparator|2|folic acid (0.8 mg) plus vitamin B12 (0.4 mg)
3308352|NCT00354081|Active Comparator|3|vitamin B6 (40 mg)
3308353|NCT00354081|Placebo Comparator|4|placebo
3308354|NCT00354029|Placebo Comparator|Placebo|Saline 0,9%
3308355|NCT00354029|Active Comparator|S (+) Ketamine|
3308356|NCT00353977|Experimental|ALVAC-CMV (vCP260) Vaccinated group|Patients who were vaccinated with ALVAC-CMV (vCP260)
3308357|NCT00353938|Experimental|3,4-methylenedioxymethamphetamine 125 mg & Psychotherapy|3,4-methylenedioxymethamphetamine 125 and 62.5 m
3308358|NCT00353938|Active Comparator|3,4-methyelendioxymethamphetamine 25 mg & Psychotherapy|3,4-methylenedioxymethamphetamine 25 and 12.5 mg MDMA
3308359|NCT00353873|Active Comparator|Fluticasone propionate (FLIXOTIDE™)|Fluticasone propionate (FLIXOTIDE™) at a dose of 200μg twice daily
3308360|NCT00353873|Experimental|Fluticasone propionate/salmeterol (SERETIDE™)|Salmeterol/fluticasone propionate combination (SERETIDE™) at a dose of 50/100μg twice daily
3308361|NCT00353834|Active Comparator|Glargine insulin|Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve fasting blood glucose of 100 mg/dl and avoid hypoglycemia.
3308362|NCT00353834|Experimental|Exenatide|Exenatide 5ug twice daily for 4 weeks followed by 10 ug twice daily for 8 weeks.
3308363|NCT00353808|Experimental|s, s reboxetine|
3308364|NCT00353743|Active Comparator|1|Patients that receive up to 10 days of doxycycline 200mg/day and metronidazole 500mg/day
3308365|NCT00353743|Placebo Comparator|2|Patients that do not receive antibiotics, only placebo
3308366|NCT00353717|Experimental|1|
3308367|NCT00353704|Active Comparator|Pregabalin|150 mg Pregabalin per orally about one hour before surgery
3308368|NCT00353704|Placebo Comparator|Placebo|One capsule of saccharose (placebo) was administered orally about one hour before surgery.
3308369|NCT00353665|Experimental|1 - active|memantine + riluzole
3308370|NCT00353665|Placebo Comparator|2|riluzole + placebo
3308371|NCT00353652|Experimental|1A|
3308372|NCT00353652|Experimental|1C|
3308373|NCT00353652|Experimental|2|
3308374|NCT00353652|Experimental|3|
3308375|NCT00353613|Other|1|LBJ Hospital
3308376|NCT00353613|Other|2|Ben Taub Hospital
3308377|NCT00353587|Experimental|MBX-102 200 mg|MBX-102 200 mg once daily for 16 weeks
3308378|NCT00353587|Experimental|MBX-102 400 mg|MBX-102 400 mg once daily for 16 weeks
3308379|NCT00353587|Experimental|MBX-102 600 mg|MBX-102 600 mg once daily for 16 weeks
3308380|NCT00353587|Placebo Comparator|Sugar Pill|Placebo comparator once daily for 16 weeks
3308381|NCT00353587|Active Comparator|Actos|Actos 30 mg once daily for 16 weeks
3308382|NCT00353574|Experimental|Darusentan 50 mg|Darusentan 50 mg administered orally once daily
3308383|NCT00353574|Experimental|Darusentan 100 mg|Darusentan 100 mg administered orally once daily
3308384|NCT00353574|Experimental|Darusentan 300 mg|Darusentan 300 mg administered orally once daily
3308385|NCT00353561|Active Comparator|1, Boric acid|600 mg vaginal pessaries for 14 days
3308386|NCT00353561|Other|2, Fluconazole|
3308387|NCT00353548||1-Anorexia Nervosa|Women ages 16-50 who meet DSM-IV criteria for anorexia nervosa
3308388|NCT00353548||2-Bulimia Nervosa|Women age 16-50 who meet DSM-IV criteria for bulimia nervosa
3308389|NCT00353548||3-Binge Eating Disorder|Women with binge eating disorder
3308390|NCT00353548||4-Healthy Controls|Healthy control subjects ages 16-50 of normal weight
3308391|NCT00353548||5-Obese Controls|Healthy obese control subjects
3308392|NCT00353522|Experimental|Dalcetrapib|Dalcetrapib 900mg po daily for 24 weeks
3308393|NCT00353522|Placebo Comparator|Placebo|Placebo po daily for 24 weeks
3308394|NCT00353496|Experimental|lanreotide (Autogel formulation)|
3308395|NCT00353496|Placebo Comparator|Placebo|
3308396|NCT00353483||Tissue, blood, and bone marrow collection|"Undergo neoadjuvant systemic therapy~initial surgery for sentinel lymph node biopsy/portacath placement~definitive cancer surgery (if applicable)~when portacath is removed (1 year, if available)~if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis~Undergo Adjuvant Systemic Therapy~initial surgery for a sentinel lymph node biopsy/portacath placement~when portacath is removed (1 year, if available)~If metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis.~Undergone neoadjuvant systemic therapy~during definitive cancer surgery/portacath removal (if available)~if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis~An attempt to collect blood on all patients 1/year for 5 years from the time of enrollment"
3308397|NCT00353470|Experimental|1|Participants will receive panic focused psychodynamic psychotherapy for 12 weeks
3308398|NCT00353470|Active Comparator|2|Participants will receive cognitive behavioral therapy-panic control treatment for 12 weeks
3308399|NCT00353470|Active Comparator|3|Participants will receive applied relaxation training for 12 weeks
3308400|NCT00353431|Active Comparator|1|"Conventional insulin group:~In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician."
3308531|NCT00351442||1|Inidividuals who have been exposed to HIV but remain uninfected.
3308532|NCT00351442||2|HIV infected regular sexual partners of Group 1 participants.
3308401|NCT00353431|Experimental|2|"Intensive insulin therapy algorithm:~The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake."
3308402|NCT00353418|Experimental|PEG-IFN Alfa-2a 180 μg + Ribavirin 800 mg|
3308403|NCT00353418|Active Comparator|PEG-IFN Alfa-2a 180 μg + Ribavirin 1000 or 1200 mg|
3308404|NCT00353405|Experimental|1|Participants receiving social skills training and mass media messages
3308405|NCT00353405|Experimental|2|Participants receiving social skills training and no mass media messages
3308406|NCT00353405|Experimental|3|Participants receiving mass media messages and no social skills training
3308407|NCT00353405|Experimental|4|Participants receiving no social skills training and no mass media messages
3308408|NCT00353379|Experimental|guanfacine|Participants will take guanfacine.
3308409|NCT00353379|Placebo Comparator|placebo|Participants will take placebo.
3308410|NCT00353366||Cohort Group|Subjects received two oral doses of the Rotarix vaccine at the age of 6 weeks
3308411|NCT00353301|Experimental|Erlotinib and Sirolimus|"Erlotinib hydrochloride (Tarceva) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single-agent Tarceva, 150 mg/day.~Sirolimus (Rapamune) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day."
3308412|NCT00353275|Other|1|Strict glycemic control with a blood glucose target range of 80-110 mg/dL
3308413|NCT00353275|Other|2|Conventional glycemic control with blood glucose target range of 110-140 mg/dL
3308414|NCT00353262|Experimental|1|
3308415|NCT00353249|Experimental|1|Participants will receive adapted cognitive behavioral therapy treatment
3308416|NCT00353249|No Intervention|2|Participants will receive no treatment for the course of the study; they will be offered courtesy PTSD 5 weeks after the experimental intervention.
3308417|NCT00353223|Experimental|A|Participants will receive combined interpersonal and behavioral psychotherapy aimed at reducing depression in patients with heart failure.
3308418|NCT00353223|Active Comparator|B|Participants will receive the attention control condition.
3308419|NCT00353158|Active Comparator|A|Subjects currently on or previously on chronic voriconazole or subjects who are scheduled to begin voriconazole
3308420|NCT00353158|Experimental|B|100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
3308421|NCT00353145|Experimental|Gemcitabine + Oxaliplatin|Gemcitabine 1000 mg/m^2, infused at 10 mg/m^2/min on Day 1 and Oxaliplatin 100 mg/m^2 by vein infused on Day 2 over two hours. Repeated every 14 days (one cycle).
3308422|NCT00353119|Placebo Comparator|Placebo then etanercept|Patients randomized to initiate the study with placebo for the first 12 weeks - Group 1 then crossed over to etanercept 50mg twice weekly for weeks 12 to 24
3308423|NCT00353119|Active Comparator|Etanercept|Patients randomized to etanercept - Group 2. Patients received etanercept 50 mg subcutaneously twice weekly for 24 weeks
3308424|NCT00353106||Patients|Patients with chronic GVHD
3308425|NCT00353106||Content Expert Panel|Content expert panel with 5 years experience caring for patients with cGVHD.
3308426|NCT00353106||Caregivers|Caregivers of patients with cGVHD
3308427|NCT00353028|Experimental|F|
3308428|NCT00353028|Placebo Comparator|P|
3308429|NCT00353015|Experimental|Irinotecan plus Cisplatin|Irinotecan 65 mg/m2 and Cisplatin 25 mg/m2 intravenous (IV) days 1, 8 of a 21-day cycle
3308430|NCT00352976|Experimental|Treatment with TBI|Patients treated with total body irradiation, Fludarabine, Cyclophosphamide, Bone Marrow Transplantation, Mycophenolate Mofetil, and Sirolimus.
3308431|NCT00352911|Active Comparator|VGX-410 (Mifepristone)|150mg twice daily of VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of VGX-410 for 14 days
3308432|NCT00352911|Placebo Comparator|Placebo for VGX-410 (Mifepristone)|150mg twice daily of placebo for VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of placebo for VGX-410 for 14 days
3308433|NCT00352885|Experimental|A|Participants will receive escitalopram and IL-2 treatment
3308434|NCT00352885|Placebo Comparator|B|Participants will receive placebo and IL-2 treatment
3308435|NCT00352859|Experimental|Arm 1|
3308436|NCT00352859|Experimental|Arm 2|
3308437|NCT00352846|Experimental|Vitamin D + Calcium Carbonate|Oral Vitamin D 400 mg daily + Calcium 1200 mg daily
3308438|NCT00352846|Experimental|Vitamin D + Calcium Carbonate + Zoledronic Acid|Oral Vitamin D 400 mg daily and Calcium 1200 mg daily; Zoledronic Acid 4 mg/m^2 intravenous at baseline and 6 months.
3308439|NCT00352820||Interview + Questionnaire|
3308440|NCT00352794|Experimental|Lenalidomide + Prednisone|Lenalidomide oral 10 mg daily/days 1-21 of 28 day cycle. Prednisone starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
3308441|NCT00352781|Experimental|Nicotine Replacement + Behaviour Therapy|Nicotine Replacement Therapy as per monograph & behavioural intervention
3308442|NCT00352768|Experimental|F|
3308443|NCT00352768|Placebo Comparator|P|
3308444|NCT00352755|Experimental|Peritonectomy + IP5FU + FOLFOX|"Surgical debulking with peritonectomy~IP 5FU 600 mg/m^2 over 30-60 minutes with patient rotating every 15 minutes. Repeated every 2 weeks for a total of 9 cycles.~FOLFOX (oxaliplatin, 5FU, leucovorin) will follow IP therapy. Oxaliplatin 85 mg/m^2 over 2 hours with leucovorin at 400 mg/m^2 and IV 5-FU at 2400 mg/m^2 over 46 hours. Repeated every 2 weeks for a total of 8 cycles."
3308445|NCT00352742|Experimental|1|ATN-224 + bortezomib
3308446|NCT00352729|Active Comparator|A|
3308447|NCT00352703|Experimental|Kepivance (palifermin) 60 μg/kg/day IV|60 μg/kg/day IV for 3 consecutive days before the conditioning regimen and 3 consecutive days after the peripheral blood stem cell transplantation.
3308533|NCT00351442||3|HIV uninfected individuals or couples who have not been exposed to HIV.
3308448|NCT00352690|Other|Cohort 1 (first 12 eligible patients)|"Paclitaxel poliglumex 135 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.~Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.~Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.~Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.~Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles."
3308449|NCT00352690|Experimental|Cohort 2 (remaining patients)|"Paclitaxel poliglumex 175 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.~Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.~Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.~Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.~Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles."
3308450|NCT00352664|Active Comparator|Donepezil|Oral Donepezil 5 mg daily x 7 days
3308451|NCT00352664|Placebo Comparator|daily x 7 days|Placebo tablet daily x 7 days
3308452|NCT00352612|Placebo Comparator|cephalexin|
3308453|NCT00352612|Active Comparator|clindamycin|
3308454|NCT00352599|Active Comparator|Lovastatin|Lovastatin
3308455|NCT00352599|Placebo Comparator|Placebo pill|Placebo pill
3308456|NCT00352560|Active Comparator|A|
3308457|NCT00352560|Placebo Comparator|B|
3308458|NCT00352534|Experimental|Nephrectomy and re-evaluation (very low-risk disease)|Patients undergo nephrectomy only. If they meet criteria, they are then observed periodically for 5 years. Patients with recurrent disease undergo surgery (immediate or delayed) and receive chemotherapy as in stratum III. Patients with no metachronous renal disease receive radiotherapy. Patients with metachronous disease undergo renal-sparing surgery and chemotherapy as in stratum III, but no radiotherapy. Treatment continues for up to 25 weeks.
3308459|NCT00352534|Experimental|Nephrectomy, chemotherapy (standard-risk, stg I or II)|Patients undergo nephrectomy. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1, every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 doses of doxorubicin. Treatment continues for up to 25 weeks.
3308460|NCT00352534|Experimental|Nephrectomy/biopsy, chemotherapy (standard-risk, stage III)|Patients undergo nephrectomy, if feasible, or biopsy. For patients who undergo biopsy only, definitive surgery is undertaken at week 7 or 13. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1 every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 dose of doxorubicin hydrochloride. Patients undergo radiotherapy over 5-7 days after nephrectomy. Treatment continues for up to 25 weeks.
3308461|NCT00352521|Experimental|Bevacizumab and irinotecan|The bevacizumab will be dosed at 10 mg/kg every 14 days (days 1, 15 and 29) and the irinotecan on days 2, 15, and 29 of the first six week schedule. The irinotecan dose will depend on whether the patient is on an enzyme-inducing antiepileptic drug (EIAED). If the patient is on an EIAED, the patient will receive 340 mg/m2 on days 2, 15, and 29 of the first six week schedule. If the patient is not on an EIAED, the dose of irinotecan will be 125 mg/m2 on days 2, 15, and 29 of the first six week schedule. After the first cycle, the irinotecan and bevacizumab will be given on days 1, 15 and 29.
3308462|NCT00352495|Experimental|Vinblastine sulfate and carboplatin|The MTD of vinblastine in combination with a monthly dose of carboplatin will be determined during the first cycle of therapy. Each 4-week cycle will consist of carboplatin once every 4 weeks on day 1. Vinblastine will be given once a week for 3 weeks followed by a one week break. Doses of carboplatin and vinblastine sulfate will be assigned at study enrollment. Patients may receive eleven additional four week cycles, barring tumor progression or unacceptable toxicity. The total duration of therapy will be approximately 48 weeks.
3308463|NCT00352469|Placebo Comparator|2|Subjects will be randomized to receive either Seroquel SR or placebo
3308464|NCT00352443|Experimental|everolimus/lapatinib|Part 1, dose finding: everolimus and lapatinib at assigned dose daily Part 2, cohort A: Everolimus MTD from Part I: 5 mg PO 1-28 Daily Lapatinib MTD from Part I: 1,250 mg PO Cycle 1, Daily Days 8-28** Subsequent Cycles, Days 1-28 Part 2, cohort B: Lapatinib MTD from Part I: 1,250 mg PO 1-28 Daily Everolimus MTD from Part I: 5 mg PO Cycle 1, Daily Days 8-28** Subsequent Cycles, Days 1-28
3308465|NCT00352417|Experimental|VIA-2291|
3308466|NCT00352417|Placebo Comparator|Placebo|Matching Placebo
3308467|NCT00352391||Vanguard Study|Patients with Head and Neck or Non-Small Cell Lung Cancer who are Current or Former Smokers.
3308468|NCT00352378|Experimental|Adriamycin plus Cyclophosphamide|Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1.
3308469|NCT00352378|Experimental|Taxotere plus Xeloda|Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14
3308470|NCT00352365|Experimental|Treatment (lenalidomide)|"INDUCTION THERAPY: Patients receive oral lenalidomide once daily on days 1-14, 1-21, or 1-28 (course 1). Patients undergo bone marrow biopsy on day 28 or 35 to assess treatment efficacy. Patients with stable or improving disease (i.e., a decrease in blast percentage) without progressive disease proceed to maintenance therapy.~MAINTENANCE THERAPY: Beginning within 42 days after completion of induction therapy, patients receive oral lenalidomide once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3308471|NCT00352339|Experimental|Aripiprazole|switching group (from risperidone to aripiprazole)
3308472|NCT00352339|Active Comparator|Risperidone|Start with risperidone and keep it through the end of study
3308473|NCT00352339|Active Comparator|Abilify|Start with aripiprazole and keep it through the end of study
3308534|NCT00351429|Experimental|1|
3308535|NCT00351416|Experimental|Aromatase inhibitor EFP|"Letrozole administration (20 mg) on day 2-4 (EFP; early follicular phase) of cycle 2 and~Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted."
3308536|NCT00351416|Experimental|Aromatase inhibitor LFP|"Letrozole administration (20 mg daily x 2) at follicle size of > 16 mm (LFP; late follicular phase) in cycle 2.~Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted."
3308474|NCT00352326|Experimental|Children (with dystonia and controls)|"Participants sat in a chair or their own wheelchair in front of a table whose surface height was adjusted at the midpoint between the hip and the Xiphoid process. They placed the hand that was not used for the task on their lap.~An iPad® (Apple Inc, Cupertino, California) was located on the table in portrait mode in front of the participants at a distance that ranged between 40 and 55 cm. An adjustable metal bookstand supported the iPad® to allow the participants a comfortable screen view. The size of the screen was 19.5 × 14.6 cm. Custom software was developed for the experimental task (XCode 3.2 development environment, iOS 4.2 operating system; Apple Inc, Cupertino, California)."
3308475|NCT00352313|Experimental|Phase I|Patients receive ATN-161 IV over 10 minutes 3 times weekly in weeks 1-6 and carboplatin IV over 20 minutes in week 3 during course 1. Beginning in course 2, patients receive carboplatin IV over 20 minutes in week 1 and ATN-161 IV over 10 minutes 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
3308476|NCT00352313|Experimental|Phase II|Patients receive carboplatin IV in week 1 and ATN-161 IV, at the MTD determined in phase I, 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3308477|NCT00352300|Experimental|Treatment (carboplatin, paclitaxel, pegfilgrastim)|Patients receive carboplatin IV and paclitaxel IV over 3 hours on day 1. Patients also receive pegfilgrastim subcutaneously on day 2.
3308478|NCT00352196|Experimental|Magnetic Resonance Spectroscopy|Subjects will receive a baseline MRS prior to and within 7 day of completing 12 weeks of standard treatment with.
3308479|NCT00352196|Other|NO-MRS|Subjects will receive 12 weeks of standard treatment of risperidone 0.25 to 11 mg per day, or early termination. Dose titration will based on response and tolerability.
3308480|NCT00352183|Experimental|1|
3308481|NCT00352183|Active Comparator|2|
3308482|NCT00352170|Experimental|1|calcium supplementation
3308483|NCT00352170|Experimental|2|calcium and vitamin D3 supplementation
3308484|NCT00352170|Experimental|3|placebo
3308485|NCT00352144|Experimental|1|eszopiclone 3 mg tablet
3308486|NCT00352144|Placebo Comparator|2|Placebo tablet
3308487|NCT00352118|Experimental|Chemotherapy + Low Dose Radiation|Patients receiving chemotherapy and Low Dose (60 Gy) Radiation per protocol.
3308488|NCT00352105|Experimental|Concurrent Chemotherapy and ZD1839|
3308489|NCT00352079|Active Comparator|Intravesicle BCG|"Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months postrandomization (cycles 2 - 8)"
3308490|NCT00352079|Active Comparator|Iressa and Intravesicle BCG|"Intravesical BCG:~Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)~Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)"
3308491|NCT00352053|Experimental|OBR + Tenofovir DF|Tenofovir DF administered orally, one tablet daily without regard to meals
3308492|NCT00352053|Placebo Comparator|OBR + Tenofovir DF Placebo|Placebo to match tenofovir DF administered orally, one tablet daily without regard to meals
3308493|NCT00352027|Experimental|All Participants|Participants receive 12 weeks of Stanford V chemotherapy which includes Adriamycin®, Vinblastine, Nitrogen Mustard (or Cyclophosphamide), Vincristine, Bleomycin, Etoposide, Prednisone, and G-CSF. After completion of 12 weeks of Stanford V chemotherapy, participants receive radiotherapy.
3308494|NCT00352001|Experimental|Lenalidomide and Azacitidine|
3308495|NCT00351988||African American caregivers|African American caregivers for patients with advanced non-small cell lung cancer or breast cancer.
3308496|NCT00351988||Latino caregivers|Latino caregivers for patients with advanced non-small cell lung cancer or breast cancer.
3308497|NCT00351988||White non-Latino caregivers|White non-Latino caregivers for patients with advanced non-small cell lung cancer or breast cancer.
3308498|NCT00351975|Experimental|Arm I (chemotherapy)|Patients receive azacitidine SC on days 1-5.
3308499|NCT00351975|Experimental|Arm II (chemotherapy, enzyme inhibitor therapy)|Patients receive azacitidine as in arm I and belinostat at the MTD IV over 30 minutes on days 1-5.
3308500|NCT00351962|Experimental|Schedule I (10 fractions)|Subjects will receive a total of 10 stereotactic radiation treatments, given over 3 weeks.
3308501|NCT00351962|Experimental|Schedule II (4 fractions)|Subjects will receive a total of 4 stereotactic radiation treatments, given over 2 weeks.
3308502|NCT00351936|Active Comparator|Aripiprazole|aripiprazole 15mg/day
3308503|NCT00351936|Placebo Comparator|placebo|matched placebo for aripiprazole 15mg/day
3308504|NCT00351884|Experimental|vildagliptin am|
3308505|NCT00351884|Experimental|vildagliptin pm|
3308506|NCT00351884|Placebo Comparator|placebo|
3308507|NCT00351819|Active Comparator|Androgel (testosterone gel)|Testosterone replacement therapy
3308508|NCT00351819|Placebo Comparator|Placebo|Placebo gel
3308509|NCT00351806|Experimental|Chinese herbal medicine|
3308510|NCT00351806|Placebo Comparator|placebo|
3308511|NCT00351793||Combined Deformity <30 degrees|
3308512|NCT00351793||Combined Deformity >30 degrees|
3308513|NCT00351767|Experimental|1|
3308514|NCT00351767|Experimental|2|
3308515|NCT00351767|Experimental|3|
3308516|NCT00351767|Placebo Comparator|4|
3308517|NCT00351741|Experimental|High Frequency|Provide standard ventilatory support for burn patients utilizing high frequency percussive ventilation
3308518|NCT00351741|Active Comparator|Conventional|Standard ventilator support for non burned patients utilizing lung protective low tidal volume ventilation
3308519|NCT00351702|Active Comparator|Isoniazid|Isoniazid (300mg) daily for 36 months
3308520|NCT00351663|Active Comparator|IV by weight|intravenous dose of 0.5 mg/kg enoxaparin once daily
3308521|NCT00351663|Active Comparator|SC fixed dose|subcutaneous fixed dose of 40 mg enoxaparin once daily
3308522|NCT00351663|Active Comparator|SC by weight|subcutaneous dose of 0.5 mg/kg enoxaparin once daily
3308523|NCT00351624|Active Comparator|DHA|
3308524|NCT00351624|Placebo Comparator|placebo|
3308525|NCT00351611|Experimental|Active|Active drug
3308526|NCT00351611|Placebo Comparator|Placebo|placebo comparator
3308527|NCT00351598||1|Patients with loco-regional, NSCLC treated by definitive radiotherapy.
3308537|NCT00351403|Experimental|Individualized therapy|Lengh of therapy depends on time point when no HCV RNA is detectable in blood with Versant HCV Qualitative assay.
3308538|NCT00351403|Other|Historical control|48 week standard therapy
3308539|NCT00351390|Placebo Comparator|SOC|Standard of care HF therapy without NT-proBNP guidance
3308540|NCT00351390|Active Comparator|NT-proBNP arm|NT-proBNP plus standard HF management
3308541|NCT00351377|Experimental|Enteric-coated Mycophenolate Sodium|Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily in a dose that was equimolar to the dose of Mycophenolate mofetil the participant was taking at the time of study entry. The planned duration of treatment 6 to 8 weeks.
3308542|NCT00351364|Active Comparator|Montelukast sodium|Drug arm - Montelukast as a single dose 100 mg. To test the hypothesis of leukotriene inhibition.
3308543|NCT00351364|Placebo Comparator|2|No drug given - no placebo available. To compare with active drug.
3308544|NCT00351351|Experimental|A|Cyberwand
3308545|NCT00351351|Active Comparator|B|Currently available lithotripsy technology
3308546|NCT00351325|Experimental|dose escalation|
3308547|NCT00351299|Experimental|Infusion of dexmedetomidine|infusion 0.3-0.7 dexmedetomidine
3308548|NCT00351299|Other|Standard of Care|Standard of care per treating physician preference
3308549|NCT00351273|Active Comparator|Azithromycin and Rifampin|Participants received Azithromycin and Rifampin
3308550|NCT00351273|Active Comparator|Doxycycline and Rifampin|Participants received Doxycycline and Rifampin
3308551|NCT00351273|Placebo Comparator|received placebo|Participants received placebo
3308552|NCT00351143|Experimental|Interventional group: Period 2|Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training in Period 2
3308553|NCT00351143|Active Comparator|Control group: Period 2|Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg in treatment Period 2
3308554|NCT00351143|Experimental|Subjects receiving salmeterol/fluticasone propionate: Period 1|All subjects treated with salmeterol/fluticasone propionate 50/250 µg b.i.d without any other intervention will be included in Period 1
3308555|NCT00351117|Experimental|1|St. John's wort 300mg PO TID
3308556|NCT00351117|Placebo Comparator|2|Lactose in capsule matching the St. John's wort. 300mg PO TID
3308557|NCT00351078|Experimental|PTC124 PO|4-, 4-, and 8-mg/kg TID first 14 days of cycle 10-, 10-, and 20-mg/kg TID second 14 days of cycle 28 day study
3308558|NCT00351052|Experimental|1|Pimecrolimus
3308559|NCT00351052|Placebo Comparator|2|Vehicle
3308560|NCT00351039|Experimental|Bevacizumab, Erlotinib, Pemetrexed|Single Arm Phase II trial in elderly patients with advanced stage Non-Squamous Non-Small Cell Lung Cancer
3308561|NCT00351026|Active Comparator|1|25 HIV negative opiate dependent patients all treated with methadone
3308562|NCT00351026|Active Comparator|2|25 HIV positive opiate dependent patients all treated with methadone
3308563|NCT00351013|Experimental|1|
3308564|NCT00350987|Experimental|PCT|PCT guidance
3308565|NCT00350987|Active Comparator|Guidelines|enforced guidelines
3308566|NCT00350974||End-stage Renal Disease|on maintenance hemodialysis 3 x per week for more than 12 months
3308567|NCT00350974||No kidney disease|eGFR greater than 60 ml/Min
3308568|NCT00350974||Hypertensive group|Blood pressure greater than 130/80
3308569|NCT00350948|Experimental|Telcyta + Liposomal Doxorubicin|Telcyta at 1000 mg/m2 followed by Liposomal Doxorubicin at 50 mg/m2 on Day 1 of each four-week treatment cycle
3308570|NCT00350948|Active Comparator|Liposomal Doxorubicin|Liposomal Doxorubicin at 50 mg/m2 on Day 1 of each four-week treatment cycle
3308571|NCT00350935||Healthy volunteers|Healthy controls
3308572|NCT00350935||Patients|Patients with schizophrenia
3308573|NCT00350909|Experimental|1|One arm was a 2-session brief intervention with both sessions involving only the adolescent. Each session was a 60 minute individual session with the counselor.
3308574|NCT00350909|Active Comparator|2|The other arm was a 3-session brief intervention, with 2 sessions involving the adolescent and one session with the parent. Each of these individual sessions were 60 minutes.
3308575|NCT00350883|Other|Treatment as Usual|
3308576|NCT00350883|Experimental|Cognitive Therapy|
3308577|NCT00350870|Placebo Comparator|Placebo|Placebo (plus Cognitive Behavioral Therapy- CBT)
3308578|NCT00350870|Active Comparator|Disulfiram|Disulfiram (plus CBT)
3308579|NCT00350870|Placebo Comparator|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance (in addition to CBT).
3308580|NCT00350870|Active Comparator|Disulfiram plus Contingency Management|Disulfiram plus Contingency Management for cocaine abstinence and medication compliance (in addition to CBT).
3308581|NCT00350857|Active Comparator|Equetro active|
3308582|NCT00350844|Experimental|Hydroxyurea|
3308583|NCT00350818|Experimental|Azacitidine|Azacitidine after Allogeneic Transplantation
3308584|NCT00350805||Healthy volunteers|
3308585|NCT00350805||Patients|
3308586|NCT00350792|Experimental|Pemetrexed + Carboplatin|"Pemetrexed: 500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 6 cycles.~Carboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles."
3308587|NCT00350779|Experimental|1|Sitagliptin
3308588|NCT00350779|Placebo Comparator|2|Placebo
3308589|NCT00350766|Experimental|Treated Group|Intracoronary injection in the infarcted-related artery of 100 million bone marrow mononuclear cells resuspended in a 10 ml solution of saline with autologous serum.
3308590|NCT00350766|Placebo Comparator|Control Group|Intracoronary injection in the infarcted-related artery of placebo solution consisting of a saline containing autologous blood serum.
3308591|NCT00350753|Experimental|Erlotinib and bevacizumab|
3308592|NCT00350727|Experimental|Combination|Pazopanib and Lapatinib in combination. Subjects remain on treatment until disease progression or withdrawal from study.
3308593|NCT00350714|Experimental|MBT|C13 methacetin dissolved in water to be ingested after breath baseline collected. Metabolism to measured in real time.
3308594|NCT00350701|Experimental|androgel 5g|androgel 5g
3311352|NCT00310713|Experimental|Group 3|
3308595|NCT00350701|Experimental|androgel 10g|androgel 10g
3308596|NCT00350701|Placebo Comparator|placebo|placebo
3308597|NCT00350662|Experimental|Deferiprone + Desferrioxamine|
3308598|NCT00350662|Experimental|Deferiprone single agent|
3308599|NCT00350662|Active Comparator|Desferrioxamine single agent|
3308600|NCT00350649|Experimental|1|manualized delivery of CBT by trained clinicians
3308601|NCT00350649|Active Comparator|2|CBT with Contingency Management reinforcement for attendance and completing homework (CBT+CM/adherence)
3308602|NCT00350649|Experimental|3|Contingency Management for abstinence alone (CM/abstinence)
3308603|NCT00350649|Active Comparator|4|Contingency Management integrated with CBT (CM/abstinence+CBT)
3308604|NCT00350636|Experimental|Oxybutynin topical gel|Oxybutynin topical gel
3308605|NCT00350636|Placebo Comparator|Placebo topical gel|placebo topical gel
3308606|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
3308607|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
3308608|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
3308609|NCT00350610|Active Comparator|1|Standard treatment as usual (TAU) in a community based clinic consisting of individual and group therapy sessions and regular urine monitoring.
3308610|NCT00350610|Experimental|2|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping cocaine use and increasing coping skills twice weekly for 8 weeks.
3308611|NCT00350584|Experimental|Mindfulness Telehealth for PTSD|Participants receive two in-person sessions and 6 sessions over the phone. Participants are introduced to mindfulness concepts. CDs with guided meditation exercises are given to participants and they are asked to practice between sessions.
3308612|NCT00350584|Active Comparator|Psychoeducation Telehealth for PTSD|Participants receive two in-person sessions and six telehealth sessions with education about symptoms of PTSD and coping strategies. In addition, participants are asked to read short homework assignments and think about them during the week; these are discussed in weekly sessions.
3308613|NCT00350571|Active Comparator|Standard care follow up|Standard care counselor follow up care phone calls or letters.
3308614|NCT00350571|Experimental|Drop out reengagement motivational intervention|Single session office based or phone based motivational counseling session designed to promote participant re-engagement in standard treatment.
3308615|NCT00350545|Experimental|rituximab + prednisone arm|Rituximab will be given as an IV fusion as initial treatment, followed by predisone (given during registration) which will be continued through-out trial and tapered off by physician. Cyclosporine A and tacrolimus will be used if chances of new diagnosis of chronic GVHD occur. Both drugs have no interaction with Rituxan, but will be tapered off after predisone is completely tapered.
3308616|NCT00350532|Active Comparator|Neuropathic Pain Subjects|Chronic Pain Participants will be trained to accurately estimate pain by way of thermal heat testing. Next a small amount of spinal fluid will be withdrawn from each participant to measure the amounts of naturally-made chemicals in the participants' cerebrospinal fluid. Participants then will receive an injection of clonidine. After the injection, additional samples of spinal fluid will be taken to measure chemical changes in the fluid.
3308617|NCT00350532|Active Comparator|Healthy Subjects|Healthy Participants will be trained to accurately estimate pain by way of thermal heat testing. Next a small amount of spinal fluid will be withdrawn from each participant to measure the amounts of naturally-made chemicals in the participants' cerebrospinal fluid. Participants then will receive an injection of clonidine. After the injection, additional samples of spinal fluid will be taken to measure chemical changes in the fluid.
3308618|NCT00350519|Experimental|PROCRIT (epoetin alfa)|Participants will receive PROCRIT (epoetin alfa).
3308619|NCT00350519|Experimental|STANDARD THERAPY|Participants will receive standard of care.
3308620|NCT00350454|Active Comparator|A|Drug eluting stent using biodegradable polymer BP stent
3308621|NCT00350454|Active Comparator|B|polymer-free drug eluting stent PF stent
3308622|NCT00350454|Active Comparator|C|permanent polymer using stents PP stent
3308623|NCT00350415|Experimental|1|Asacol 2.4 g/day (400 mg tablet)
3308624|NCT00350415|Active Comparator|2|Asacol 4,8 g/day (800 mg tablet), oral, for 6 weeks
3308625|NCT00350402|Active Comparator|High Intensity Muscle Strength Training|This arm involved high intensity muscle strength training at 75% maximum inspiratory pressure (MIP). Training took place for 4 weeks, 5 days a week. Each daily session involved 5 sets of breathing exercises that required participants to take deep breaths (i.e., inspire) using use a breathing device. Settings on the breathing device were determined by obtaining the individual's maximal inspiratory pressure (MIP)using a specialized breathing gauge. The MIP was determined at the beginning of each week and the training device was adjusted and set at 75% MIP. Exercises took place in home setting, with weekly visit by staff. Participants kept daily exercise log.
3308626|NCT00350402|Sham Comparator|Sham MST|This arm (low intensity MST) was identical to the real intervention in all ways except that the training device was set at 5% maximum inspiratory pressure (MIP). Thus less muscle and breathing effort was required during this sham treatment.
3308627|NCT00350389|Experimental|1|Provision of single lens glasses, glasses aids, counselling, updated multifocal glasses if required
3308628|NCT00350389|No Intervention|2|Usual care, updated multifocal glasses if required
3308629|NCT00350363|Active Comparator|1 hour gatifloxacin|presence of conjunctival bacteria 1 hour after administration of topical gatifloxacin
3308630|NCT00350350||elderly people|elderly people over 70 years residents of old's people homes with symptoms of dry mouth
3308631|NCT00350298|Active Comparator|1|GS-CDA1 and MDX-1388
3308632|NCT00350298|Placebo Comparator|2|normal saline (0.9% sodium chloride)
3308633|NCT00350285|Experimental|1|Motivational enhancement therapy
3308634|NCT00350285|Active Comparator|2|Marijuana education
3308635|NCT00350285|No Intervention|3|Delayed treatment control condition
3308682|NCT00349479|Active Comparator|Intervention|
3308683|NCT00349479|No Intervention|Control|
3308636|NCT00350272|Experimental|Elvucitabine, Efavirenz,Tenofovir|"Elvucitabine (blinded) 10 mg/day in combination with open-label efavirenz 600 mg daily and open-label tenofovir 300 mg daily, all administered orally, over 12 weeks. Eligible subjects continued with an additional 84 weeks of open-label treatment (through Week 96).~Subjects who experienced at least a 2 log10 decrease in HIV-1 RNA from Baseline or who had an HIV-1 RNA level of less than 400 copies/mL at Week 10 and had not experienced any Grade 3 or 4 hematological toxicity as of the Week 10 measurement were considered eligible for an additional 84 weeks of open-label treatment after Week 12."
3308637|NCT00350272|Active Comparator|Lamivudine,Efavirenz,Tenofovir|"Lamivudine (blinded) 300 mg daily in combination with open-label efavirenz 600 mg daily and open-label tenofovir 300 mg daily, all administered orally, over 12 weeks. Eligible subjects continued with an additional 84 weeks of open-label treatment (through Week 96).~Subjects who experienced at least a 2 log10 decrease in HIV-1 RNA from Baseline or who had an HIV-1 RNA level of less than 400 copies/mL at Week 10 and had not experienced any Grade 3 or 4 hematological toxicity as of the Week 10 measurement were considered eligible for an additional 84 weeks of open-label treatment after Week 12."
3308638|NCT00350233|Experimental|ExAblate MRgFUS|
3308639|NCT00350220|Active Comparator|1|High Hemoglobin group; goal Hb >13g/dl. 10cc/kg RBCs are transfused for any hemoglobin value under 13g/dl regardless whether clinical indication for transfusion exists.
3308640|NCT00350220|Active Comparator|2|Low Hb transfusion group; goal to not transfuse unless the Hb <9.0 g/dl. 10cc/kg RBCs are transfused only if the Hemoglobin is under 9.0g/dl and clinical indications for transfusion exist.
3308641|NCT00350194|Placebo Comparator|1|Omega-3 fatty acid vs. placebo comparator
3308642|NCT00350142|Experimental|Stereotactic Body Radiotherapy|Patients will have a 4D pancreatic protocol CT and a FDG PET scan scan, both for planning purposes. An SBRT treatment plan will be developed based on tumor geometry and location. All patients will receive a single fraction of 25 Gy dose of Stereotactic Body Radiotherapy on Trilogy Linear Accelerator, followed by weekly Gemcitabine.
3308643|NCT00350129||1|healthy vasospastic subjects
3308644|NCT00350129||2|healthy non-vasospastic subjects
3308645|NCT00350051|Experimental|Arm 1|
3308646|NCT00350025|Other|Cetuximab alone|Cetuximab 250mg/m2 IV weekly during each 28 day cycle. Arm A closed to accrual June 11, 2009 for lack of efficacy
3308647|NCT00350025|Other|Cetuximab with Paclitaxel|Paclitaxel 80 mg/m2 IV weekly for every 28 day cycle. Cetuximab 250mg/m2 IV weekly for every 28 day cycle.
3308648|NCT00350012||1|Persons who have had a stroke
3308649|NCT00350012||2|Healthy volunteers
3308650|NCT00349999||1|18 males and non pregnant females, ages 18-45, with acute cholera.
3308651|NCT00349973|Experimental|1|Dipyridamole
3308652|NCT00349973|Active Comparator|2|Olanzapine
3308653|NCT00349947|Active Comparator|1|Participants will take part in an exercise program.
3308654|NCT00349947|No Intervention|2|Participants will take part in a usual activity group.
3308655|NCT00349934|Experimental|A|IMP321
3308656|NCT00349921|Active Comparator|clonidine first, then adenosine|clonidine given in first injection adenosine given in second injection
3308657|NCT00349921|Active Comparator|adenosine first, then clonidine|adenosine given in first injection clonidine given in second injection
3308658|NCT00349921|Placebo Comparator|clonidine given first, then placebo|placebo
3308659|NCT00349921|Placebo Comparator|adenosine given first, then placebo|placebo
3308660|NCT00349908|Experimental|Group 1: Atherosclerosis Arm|Implant of Cordis Neurovascular ENTERPRISE Self Expanding Stent System
3308661|NCT00349908|Active Comparator|Group 2: Aneurysm Arm|Implant of Cordis Neurovascular ENTERPRISE Self Expanding Stent System
3308662|NCT00349869|Experimental|1|8-week yoga program
3308663|NCT00349869|No Intervention|2|Usual care control
3308664|NCT00349856|Active Comparator|1|
3308665|NCT00349804|Other|Air cooled (COOL)|Subjects will complete the intermitent exercise protocol with cool dry air blown under the shoulder pads during the rest periods and recovery session
3308666|NCT00349791|Placebo Comparator|1|placebo patch replaced twice a week for two years
3308667|NCT00349791|Experimental|2|testosterone patch replaced twice a week for two years
3308668|NCT00349778|Experimental|High-Dose Sequential Therapy|Cyclophosphamide + Etoposide + Melphalan + Carmustine with Filgrastim
3308669|NCT00349752|Experimental|Certolizumab pegol 400 mg|Certolizumab pegol 400 mg
3308670|NCT00349752|Placebo Comparator|Placebo|Placebo
3308671|NCT00349726|Experimental|Inositol low volume|Single dose of intravenous inositol 5%, 60 mg/kg (1.2ml/kg) given over 20 minutes
3308672|NCT00349726|Experimental|Inositol high volume|Single dose of intravenous inositol 5%, 120 mg/kg (2.4ml/kg) given over 20 minutes
3308673|NCT00349726|Placebo Comparator|Placebo low volume|Placebo (5% glucose) at a volume equal to 60 mg/kg (1.2 ml/kg) given via IV over 20 minutes.
3308674|NCT00349726|Placebo Comparator|Placebo high volume|Placebo (5% glucose) at a volume equal to 120 mg/kg (2.4 ml/kg) given via IV over 20 minutes
3308675|NCT00349713|Experimental|Cohort 1: 25ug FMP2.1 / AS02A|20 subject to receive 25ug of FMP2.1 vaccine in 0.25mL of GSK Biologicals' adjuvant AS02A
3308676|NCT00349713|Experimental|Cohort 2: 50ug FMP2.1 / AS02A|20 subjects to receive 50ug of FMP2.1 vaccine in 0.5mL of GSK Biologicals' adjuvant AS02A
3308677|NCT00349713|Active Comparator|Cohorts 1 and 2: Rabies vaccine (RabAvert)|"20 subjects to receive Rabies vaccine (RabAvert). 10 subjects from Cohort 1 and 10 subjects from Cohort 2~Rabies vaccine (RabAvert): RabAvert Rabies vaccine"
3308678|NCT00349622|Active Comparator|Ceftriaxone|"Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day."
3308679|NCT00349622|Placebo Comparator|Placebo|"One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day."
3308680|NCT00349596|Experimental|Decitabine|Decitabine administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
3308681|NCT00349492|Active Comparator|EP|etoposide + cisplatin
3308684|NCT00349466|Experimental|1|CF101 1 mg given orally every 12 hours for 12 weeks
3308685|NCT00349466|Placebo Comparator|2|Placebo given orally every 12 hours for 12 weeks
3308686|NCT00349453|Experimental|Deferiprone (L1) monotherapy|Deferiprone (L1) monotherapy
3308687|NCT00349453|Experimental|Combination therapy|Deferiprone (L1) and desferrioxamine combination treatment
3308688|NCT00349440|Active Comparator|1|
3308689|NCT00349440|Placebo Comparator|2|
3308690|NCT00349427|Experimental|Rosiglitazone|4mg
3308691|NCT00349427|Placebo Comparator|Rosiglitazone placebo|4mg
3308692|NCT00349388|Experimental|Asacol once a day dosing|Asacol total dose in mg/kg given once a day
3308693|NCT00349388|Active Comparator|Asacol BID/TID dosing|Asacol total dose split BID or TID
3308694|NCT00349375|Experimental|1|
3308695|NCT00349375|Experimental|2|
3308696|NCT00349375|Active Comparator|3|
3308697|NCT00349362|Experimental|Testosterone|Testosterone injections- 200mg- every 2 weeks
3308698|NCT00349362|Placebo Comparator|Placebo|Normal saline injections- every two weeks
3308699|NCT00349349|Experimental|ofatumumab|Anti-CD20 antibody therapy
3308700|NCT00349336|Experimental|1|
3308701|NCT00349336|Experimental|2|
3308702|NCT00349271|Experimental|Stem Cell therapy|Stem Cell therapy
3308703|NCT00349271|Active Comparator|Standart therapy|Standart therapy
3308704|NCT00349219|Experimental|1|erlotinib followed at progression by gemcitabine and cisplatin
3308705|NCT00349219|Active Comparator|2|cisplatin and gemcitabine chemotherapy for 6 cycles, followed at progression by erlotinib
3308706|NCT00349206|Experimental|Arm 1|Patients receive temsirolimus IV over 30 minutes on days 1, 8,15, and 22 and oral sorafenib once or twice daily on days 1-28.
3308707|NCT00349193|Active Comparator|Laquinimod 0.3 mg|Laquinimod 0.3 mg
3308708|NCT00349193|Active Comparator|Laquinimod 0.6 mg|Laquinimod 0.6 mg
3308709|NCT00349193|Placebo Comparator|Placebo|Blinded Placebo
3308710|NCT00349167|Experimental|PR-104|PR104 was administered as a 1-hr IV infusion every 21 days at doses ranging from 135 to 1400 mg/m2
3308711|NCT00349102|Active Comparator|A|Free breathing during conformal radiation
3308712|NCT00349102|Experimental|B|Breath holding during conformal radiation
3308713|NCT00349089|Active Comparator|1|Cisplatin/Vinorelbine
3308714|NCT00349089|Experimental|2|Cisplatin/Pemetrexed
3308715|NCT00349076|Experimental|1|"Preoperative simultaneous radiochemotherapy: 5-Fluorouracil und Oxaliplatin:~Radiotherapy starts on day 1 of chemotherapy; 28 fractions; single dose: 1,8 Gy once per day, monday through friday; Total dose: 50,4 Gy; Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours; repeat day 15, 8 cycles"
3308716|NCT00349076|Active Comparator|2|"Preoperative simultaneous radiochemotherapy: 5-Fluorouracil Radiotherapy starts on day 1 of chemotherapy; 28 fractions; single dose: 1,8 Gy once per day, monday through friday; Total dose: 50,4 Gy; 5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
3308717|NCT00349050|Active Comparator|1|laboratory pain assessment
3308718|NCT00349050|Active Comparator|2|transcranial magnetic stimulation
3308719|NCT00348985|Experimental|PXD101 in Combination with Bortezomib (PS-341)|Patients receive PXD101 IV over 30 minutes on days 1-5 and bortezomib IV on days 1, 4, 8, and 11 (2, 5, 8, and 11 during course 1).
3308720|NCT00348946|Active Comparator|1|
3308721|NCT00348946|Placebo Comparator|2|
3308722|NCT00348933|Experimental|1|Participants will receive two daily doses of Metafolin, betaine, and creatine, and one daily dose of vitamin B12 for 12 months.
3308723|NCT00348920|No Intervention|1- General Anesthesia|General Anesthesia includes administration of a routine cardiac anesthetic as per institutional norms.
3308724|NCT00348920|Experimental|2- High Spinal and General Anesthesia|High Spinal and General Anesthesia includes a high dose intrathecal anesthetic administered prior to the induction of a standardized cardiac general anesthetic.
3308725|NCT00348907|Active Comparator|1|immediate thermal cure (1st year)
3308726|NCT00348907|Sham Comparator|2|late thermal cure (2 years)
3308727|NCT00348894|Experimental|Open Treatment|[S,S]-reboxetine
3308728|NCT00348894|Other|Standard Care|Standard Care
3308729|NCT00348881|Experimental|Group 1: DTaP-Hep B-PRP-T + OPV vaccine|Participants received 3 doses of the DTaP-Hep B-PRP-T concomitantly with OPV vaccine, 1 dose each at 6, 10, and 14 weeks of age.
3308730|NCT00348881|Active Comparator|Group 2: Tritanrix-HepB/Hib™ + OPV vaccine|Participants received 3 doses of the Tritanrix-HepB/Hib™ concomitantly with OPV vaccine, 1 dose each at 6, 10, and 14 weeks of age.
3308731|NCT00348868|Experimental|1|enhanced behavioral motivation counseling
3308732|NCT00348868|Active Comparator|2|
3308733|NCT00348855|Experimental|1|"Intervention with one day training, electronic device to measure bood pressure, leaflet with goals and drug strategies according to guidelines, six specific cardiovascular consultations during two years, feed back on results of the intervention group at inclusion, year 1 and year 2.~Specific consultations will be focused on goals to be reach, compliance, exercise and diet."
3308734|NCT00348855|No Intervention|2|
3308735|NCT00348829|Active Comparator|1|Surgical mitral valve reconstruction
3308736|NCT00348829|No Intervention|2|conservative treatment
3308737|NCT00348816|Experimental|Docetaxel (Single Arm)|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Prednisone 5mg twice a day Radical prostatectomy as standard of care Radiation therapy will be used as standard of care Post radiation Doxcetaxel
3308738|NCT00348790|Experimental|Vatalanib|"Patients will be treated with 500 mg of vatalanib, administered orally, twice a day for 28 days (1 cycle). Patients will start at a dose of 250 mg twice a day and increase by 250 mg per day every 7 days until 500 mg twice a day is reached.~Patients who are responding may remain on study treatment for 12 months."
3308739|NCT00348777|Active Comparator|1|group with 18 days thermal cure
3308796|NCT00347737|Experimental|1|Teriparatide
3308740|NCT00348777|Sham Comparator|2|group with no thermal cure but only access 3 days to watering place 6 months after inclusion
3308741|NCT00348738|Experimental|1|Patients assigned to this group are receiving Erythropoietin medication
3308742|NCT00348738|No Intervention|2|control group receiving no treatment
3308743|NCT00348712|Active Comparator|A|
3308744|NCT00348712|Active Comparator|B|
3308745|NCT00348699|Experimental|Treatment (AFP464)|Patients receive AFP464 IV over 3 hours on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3308746|NCT00348686|Experimental|Candesartan|Subjects were treated for 24 weeks with Candesartan 16mg once daily as initial dose. Subjects were modified investigational product dose to Candesartan 32mg, Candesartan 32mg + Felodipine 5mg, Candesartan 32mg + Felodipine 10mg, sequentially according to their blood pressures.
3308747|NCT00348673|Experimental|Stage 1|
3308748|NCT00348673|Experimental|Stage 2|
3308749|NCT00348621|Active Comparator|Visual impairment intervention program|enhanced access to eye care services
3308750|NCT00348621|No Intervention|Usual care|family and nursing home was apprised of ocular exam results; eye care services left to family/nursing home arrangements
3308751|NCT00348595|Active Comparator|1|5mg/day Arm: one 5 mg active Revlimid capsule and one 25 mg matched placebo capsules PO QAM (every morning) (at approximately the same time) days 1-21 days (28-day cycles).
3308752|NCT00348595|Active Comparator|2|25 mg/day Arm: one 25 mg active Revlimid capsule and one 5 mg matched placebo capsule PO QAM (every morning) (at approximately the same time) days 1-21 (28 day cycles).
3308753|NCT00348556|Experimental|Nesiritide|Subjects received an intrarenal infusion of nesiritide at 0.005 microgram/kg/min for 6 hours, 0.01 microgram/kg/min for 6 hours, 0.02 microgram/kg/min for 6 hours, and 0.03 microgram/kg/min for 6 hours.
3308754|NCT00348517|Experimental|Systane|
3308755|NCT00348517|Active Comparator|Refresh|
3308756|NCT00348439|Experimental|Plasmin Injection|human-derived plasmin
3308757|NCT00348439|Placebo Comparator|Vehicle|Plasmin formulation, without active ingredient.
3308758|NCT00348387|Experimental|Group 1|
3308759|NCT00348387|Active Comparator|Group 2|
3308760|NCT00348374|Active Comparator|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
3308761|NCT00348374|Experimental|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
3308762|NCT00348348|Active Comparator|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5%
3308763|NCT00348348|Experimental|Besifloxacin Suspension|Besifloxacin hydrochloride ophthalmic suspension 0.6%
3308764|NCT00348335|Active Comparator|1: Restasis|
3308765|NCT00348335|Active Comparator|2: Refresh Endura|
3308766|NCT00348309|Experimental|Arm 1|Rosiglitazone Extended Release 2mg OD
3308767|NCT00348309|Experimental|Arm 2|Rosiglitazone Extended Release 8mg OD
3308768|NCT00348309|Placebo Comparator|Arm 3|Placebo
3308769|NCT00348283|Placebo Comparator|Double Blind|Blinded study through Week 52. Adalimumab compared to placebo during blinded portion.
3308770|NCT00348283|Other|Open Label|Note: No comparator was used in Open-Label portion of study. From Week 8, subjects could have switched to open-label (OL) adalimumab 40mg administered subcutaneously (SC) every other week (eow)or OL adalimumab 40 mg SC every week (ew) dosing to treat disease flare or non-response. At Week 52, all remaining subjects were allowed to switch to the Open-Label portion of the study.
3308771|NCT00348205|Experimental|Technolas 217z Zyoptix System|Bausch & Lomb Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software.
3308772|NCT00348153|Experimental|Adalimumab + corticosteroids + immunosuppressive treatments|Adalimumab 40 mg eow, stable immunosuppression, corticosteroids in 1 mg/kg/Bodyweight (max. 80 mg) and taper
3308773|NCT00348153|Active Comparator|immunosuppressive treatment + corticosteroids|corticosteroids upped to 1mg/kg/Bodyweight and taper, stable immunosuppressive treatment
3308774|NCT00348140|Experimental|Arm 1|Rosiglitazone Extended Release 2mg OD
3308775|NCT00348140|Experimental|Arm 2|Rosiglitazone Extended Release 8mg OD
3308776|NCT00348140|Placebo Comparator|Arm 3|Placebo
3308777|NCT00348075|Experimental|Neurovision|
3308778|NCT00348036|Experimental|Group therapy|Participants will receive interpersonal group therapy.
3308779|NCT00348036|Active Comparator|Control|Participants will receive information only on PTSD.
3308780|NCT00347997|Experimental|LASIK|LASIK correction of myopia and myopic astigmatism
3308781|NCT00347958|Experimental|Adacel vaccine group|Participants 15 to 69 years of age who received a dose of Adacel vaccine in one of three previous studies (Td501, or Td502, or Td505), revaccinated in Study Td518.
3308782|NCT00347932|Experimental|ISV-403|0.6% ISV-403 ophthalmic suspension
3308783|NCT00347932|Placebo Comparator|Vehicle|Vehicle of ISV-403 ophthalmic suspension
3308784|NCT00347919|Experimental|monotherapy arm|1500 mg (6 x 250 mg tablets) oral lapatinib once daily
3308785|NCT00347919|Experimental|Cohort 1 combination arm|1000 mg (4 x 250 mg tablets) of oral lapatinib and 400 mg (4 x 100 mg tablets) of oral pazopanib taken together once daily
3308786|NCT00347919|Experimental|Cohort 2 combination arm|1500 mg (6 x 250 mg tablets) of oral lapatinib and 800 mg (1 x 500 mg tablets plus 3 x 100 mg tablets) of oral pazopanib taken together once daily
3308787|NCT00347854|Experimental|FID 105783|
3308788|NCT00347854|Active Comparator|Visine|
3308789|NCT00347854|Active Comparator|Refresh Liquigel|
3308790|NCT00347854|Active Comparator|Refresh Plus|
3308791|NCT00347776|Active Comparator|Control|topical tetracycline
3308792|NCT00347776|Active Comparator|Intervention 1|oral azithromycin, single 1g dose to subject
3308793|NCT00347776|Active Comparator|Intervention 2|single oral azithromycin dose to subject and immediate family members
3308794|NCT00347763|No Intervention|control|no active fly spray intervention
3308795|NCT00347763|Active Comparator|intervention|aerial spray of permethrin daily for two weeks and weekly as needed by assessment of fly density
3311353|NCT00310713|Experimental|Group 4|
3308797|NCT00347672|Experimental|1|Two vaccinations of H5N1 VN 2004/AA vaccine at the highest dose
3308798|NCT00347672|Experimental|2|One vaccination of H5N1 VN 2004/AA vaccine at a dose in-between the lowest and highest doses
3308799|NCT00347672|Experimental|3|One vaccination of H5N1 VN 2004/AA vaccine at the lowest dose
3308800|NCT00347659|Experimental|Single Treatment|Experimental Treatment
3308801|NCT00347646|Experimental|Plasmin|Human-derived plasmin reconstituted with sterile sodium chloride for intravitreal injection.
3308802|NCT00347594|Experimental|Next Generation Diagnostic Instrument|Next Generation Diagnostic Instrument (NGDI)
3308803|NCT00347594|Active Comparator|Zyoptix Diagnostic Workstation|Zyoptix Diagnostic Workstation (ZDW)
3308804|NCT00347555|Experimental|Group D|18 subjects 160 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
3308805|NCT00347555|Experimental|Group A|18 subjects 5 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
3308806|NCT00347555|Experimental|Group B|18 subjects 20 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
3308807|NCT00347555|Experimental|Group C|18 subjects 80 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
3308808|NCT00347438|Experimental|Capecitabine|Capecitabine will be given at 1000mg/m2 twice daily for 2 weeks x 8 cycles, with a one-week pause in-between cycles.
3308809|NCT00347425|Other|A|
3308810|NCT00347425|Other|B|
3308811|NCT00347412|Experimental|A|NOV-002 Injection in combination with Carboplatin and Paclitaxel
3308812|NCT00347412|Active Comparator|B|Paclitaxel and Carboplatin Alone
3308813|NCT00347386|Experimental|Zinc|Administration of zinc sulphate every day during illness
3308814|NCT00347386|Placebo Comparator|Placebo|Placebo tablet
3308815|NCT00347360|Experimental|lisinopril|lisinopril
3308816|NCT00347360|Experimental|carvedilol|carvedilol controlled release formulation
3308817|NCT00347321|Experimental|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
3308818|NCT00347269|Experimental|CALM Intervention|"Participant choice of:~Cognitive Behavioral Therapy (CBT) Psychotropic (anti-anxiety) medication optimization"
3308819|NCT00347269|Active Comparator|Treatment as Usual (TAU)|Participants assigned to TAU with their primary care provider (PCP)
3308820|NCT00347152|Active Comparator|2|Slow Progressive Divalproex DR to Divalproex ER switch
3308821|NCT00347152|Active Comparator|1|Immediate, Progressive Divalproex DR to Divalproex ER switch
3308822|NCT00347139|Experimental|GW642444|
3308823|NCT00347139|Active Comparator|Salmeterol|
3308824|NCT00347100|Experimental|1|Administration of Insulin Glargine and Sulfonylurea or Metformin
3308825|NCT00347100|Active Comparator|2|Administration of Sulfonylurea or Metformin + a second Oral Anti Diabetic (OAD) among Glyburide, Glyclazide,Glimiperide,Glipizide or Metformin
3308826|NCT00347048|Experimental|1|
3308827|NCT00347048|Placebo Comparator|2|
3308828|NCT00347022|Experimental|Xenetix|The patient receive one injection of Xenetix 300 (300 mg of iodine/ml)
3308829|NCT00347022|Active Comparator|Visipaque|The patient receive one injection of Visipaque 270 (270 mg of iodine/ml)
3308830|NCT00347009|Other|Adefovir Dipivoxil|10mg once daily in patients with CHB related advanced fibrosis/cirrhosis.
3308831|NCT00346996|Active Comparator|1|HUman Insulin
3308832|NCT00346996|Experimental|2|Analogue insulin
3308833|NCT00346983|Experimental|A|
3308834|NCT00346983|Placebo Comparator|B|
3308835|NCT00346970|Experimental|1|Extended-release Niacin
3308836|NCT00346970|Placebo Comparator|2|Placebo
3308837|NCT00346957|Experimental|Anecortave Acetate 30|
3308838|NCT00346957|Experimental|Anecortave Acetate 15|
3308839|NCT00346957|Experimental|Anecortave Acetate 3|
3308840|NCT00346957|Placebo Comparator|Anecortave Acetate Vehicle|
3308841|NCT00346944|Experimental|Treatment group|
3308842|NCT00346944|No Intervention|Reference group|
3308843|NCT00346918|Active Comparator|1|Treatment of hypertension, cyst infections and flank pain
3308844|NCT00346918|Active Comparator|2|Sirolimus plus Standard Treatment
3308845|NCT00346905|Experimental|Single Arm|Those receiving Enteryx treatment
3308846|NCT00346853|Experimental|1|
3308847|NCT00346853|Placebo Comparator|2|saline
3308848|NCT00346840|Experimental|MVI 25|Misoprostol vaginal insert 25 mcg
3308849|NCT00346840|Experimental|MVI 50|Misoprostol vaginal insert 50 mcg
3308850|NCT00346840|Experimental|MVI 100|Misoprostol vaginal insert 100 mcg
3308851|NCT00346840|Experimental|MVI 200|Misoprostol vaginal insert 200 mcg
3308852|NCT00346801|Experimental|CPT-11 + Celecoxib/Cisplatin with RT|CPT-11 + Celecoxib + Cisplatin + Radiation Therapy (RT)
3308853|NCT00346788|Experimental|MIS|minimally invasive incision
3308854|NCT00346788|Active Comparator|Standard|Standard incision length
3308855|NCT00346762||1|HIV infected former commercial blood donors (FBDs) in Fuyang, Anhui Province
3308856|NCT00346749|Experimental|Arm 1|
3308857|NCT00346697|Experimental|LOVAZA|4 g/d of omega-3 fatty acid esters, plus dietary counseling
3308858|NCT00346697|Placebo Comparator|Placebo|Corn oil placebo, plus dietary counselling
3308859|NCT00346671|Placebo Comparator|Supine Rest|30min supine rest listening to soft music
3308860|NCT00346671|Sham Comparator|Sham Reiki|30 min intervention by sham practitioner
3308861|NCT00346671|Experimental|Reiki|30 min session with Reiki practitioner
3308862|NCT00346632|Experimental|KW-2449|Treatment with ascending doses of KW-2449
3308863|NCT00346567|Active Comparator|1|AZT from week 28 or asap thereafter. Intrapartum AZT and 3TC + Single dose NVP Postpartum Combivir tail for 7 days twice daily
3308864|NCT00346567|Experimental|2|AZT from week 28 or asap thereafter. Intrapartum Single dose Truvada + Single dose NVP
3308865|NCT00346528|Experimental|NGOIS|
3308866|NCT00346528|Active Comparator|BSS Plus|
3308910|NCT00345865|Experimental|NHL with irradiation|Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
3309672|NCT00332774|Active Comparator|Acular|
3308867|NCT00346502|Experimental|Ointment|Treatment will consist of four weeks of daily application of 20% BA ointment to the dysplastic nevi, after which it will be removed surgically and examined. A similar dysplastic nevi will be removed as a control. Four groups of patients will be enrolled. The first group will apply the ointment once a day, the second twice a day, the third three times a day, and the fourth four times a day.
3308868|NCT00346476||Participants|Individuals in the Masiphumelele Township of Cape Town, South Africa, who have been potentially exposed to TB and/or HIV
3308869|NCT00346437|Experimental|1|Ad5FGF-4
3308870|NCT00346437|Experimental|2|Ad5FGF-4
3308871|NCT00346437|Placebo Comparator|3|Placebo
3308872|NCT00346398|Experimental|Oral mucosal immunoprophylaxis (OMIP)|Participants are administered oral mucosal immunoprophylaxis (OMIP) daily for 12 months.
3308873|NCT00346398|Placebo Comparator|Placebo|Participants are administered, via the same route as the experimental group, an oral placebo solution daily for 12 months.
3308874|NCT00346333|Experimental|Lutein plus 15,000 IU/d Vitamin A|Daily intake of 12mg of Lutein plus 15,000 IU/d of Vitamin A palmitate
3308875|NCT00346333|Placebo Comparator|Control plus 15,000 IU/d Vitamin A|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
3308876|NCT00346320|Experimental|Radiotherapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
3308877|NCT00346294|Other|Single-Arm|Open-lable Single Arm Study
3308878|NCT00346268|Active Comparator|Morphine plus Parecoxib|
3308879|NCT00346268|Active Comparator|Morphine and Placebo|
3308880|NCT00346229|Experimental|Thermodox|ThermoDox20-40mg/m2 every 21-35 days followed by Chest Wall Hyperthermia
3308881|NCT00346216|Experimental|celecoxib|subject receives celecoxib and dummy (placebo) ibuprofen and naproxen
3308882|NCT00346216|Active Comparator|ibuprofen|subject receives ibuprofen and dummy (placebo) celecoxib and naproxen
3308883|NCT00346216|Active Comparator|naproxen|subject receives naproxen and dummy (placebo) celecoxib and ibuprofen
3308884|NCT00346177|Active Comparator|1|Stem Cells
3308885|NCT00346177|Placebo Comparator|2|Placebo
3308886|NCT00346164|Experimental|Arm A: No adjuvant treatment|Patients with low-grade tumor with either negative or positive microscopic margins or high-grade tumor ≤ 5 cm (in maximum diameter) with negative microscopic margins are assigned to arm A: (observation only).
3308887|NCT00346164|Experimental|Arm B: Low risk; adjuvant radiotherapy|Patients with high-grade tumor ≤ 5 cm (in maximum diameter) with positive microscopic margins are assigned to arm B: (adjuvant radiotherapy). Beginning between 6-42 days after surgical resection, patients undergo a total of 31 fractions of adjuvant radiotherapy.
3308888|NCT00346164|Experimental|Arm C: Intermediate & High risk; adjuvant chemoradiotherapy|High risk [metastatic, resected, incompletely resected, or unresected disease] patients with high-grade, grossly resected primary tumor, with metastases are assigned to receive arm C: (adjuvant chemoradiotherapy). Patients receive ifosfamide IV; doxorubicin hydrochloride IV; beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy.
3308889|NCT00346164|Experimental|Arm D: Intermediate & High Risk; Neoadjuvant chemoradiotherapy|High risk [metastatic, resected, incompletely resected, or unresected disease] patients with unresected, high-grade metastatic tumor are assigned to receive treatment as in arm D: (neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy): Patients receive ifosfamide IV; doxorubicin hydrochloride IV. Beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy. Patients undergo surgical resection in week 13.
3308890|NCT00346151|Experimental|Belatacept|Immunosuppressive protocol consisting of belatacept, glucocorticoids, antithymocyte globulin (ATG), and sirolimus.
3308891|NCT00346125|Active Comparator|Preferred Standard Regimen|Subjects with soft tissue sarcoma who are receiving pegylated liposomal doxorubicin hydrochloride, Ifosfamide with mesna and pegfilgrastim - Repeat every 28 days for 4 cycles total
3308892|NCT00346125|Active Comparator|Alternative Treatment Regimen|Subjects with soft tissue sarcoma who are receiving Doxorubicin hydrochloride, Ifosfamide with mesna and pegfilgrastim - Repeat every 28 days for 4 cycles total
3308893|NCT00346073|Experimental|Boostrix Group|Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Boostrix® vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
3308894|NCT00346073|Experimental|Adacel Group|Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Adacel™ vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
3308895|NCT00346047|Placebo Comparator|0|
3308896|NCT00346047|Experimental|1|
3308897|NCT00346034|Experimental|1|
3308898|NCT00346021|Experimental|Sun Protection Intervention|School based sun protection education, provision of free hats.
3308899|NCT00346021|No Intervention|Control arm|Usual sun protection practices
3308900|NCT00345982|Experimental|A|Sertindole 16 mg
3308901|NCT00345982|Placebo Comparator|B|Placebo
3308902|NCT00345969|Active Comparator|Transdermal Testosterone gel (1%)|Transdermal testosterone 1% gel (Androgel) provided as 2.5 gm and/or 5 gm gel packets with dose titration and monthly dose adjustments to achieve and maintain serum total testosterone level between 500-900 mg/dL. Gel to be applied daily by participants. Participants are blinded to the contents of the gel packets. Participants in this arm also perform supervised exercise training for 6 months.
3308903|NCT00345969|Placebo Comparator|Placebo gel|Inactive topical gel identical in appearance to the active medication, provided in packets identical to the packaging for the active medication. Gel to be applied daily by participants. Participants are blinded to the contents of the gel packets. Participants in this arm also perform supervised exercise training for 6 months.
3308904|NCT00345943||Adolescents with Bulimia Nervosa or subclinical BN|Adolescents with Bulimia Nervosa or subclinical Bulimia Nervosa
3308905|NCT00345943||Healthy control adolescents|Healthy control adolescents
3308906|NCT00345930||2|Individuals without drug induced liver disease
3308907|NCT00345930||1|Individuals with drug induced liver disease
3308908|NCT00345878|Experimental|Cervarix Group|Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.
3308909|NCT00345878|Placebo Comparator|Placebo Group|Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.
3311354|NCT00310713|Experimental|Group 5|
3308911|NCT00345865|Experimental|HL without irradiation|Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
3308912|NCT00345865|Experimental|NHL without radiation and cyclosporine|Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
3308913|NCT00345839|Experimental|Cinacalcet|
3308914|NCT00345839|Placebo Comparator|Placebo|
3308915|NCT00345826|Experimental|Dasatinib|
3308916|NCT00345813|Experimental|Arm I|Patients receive oral soy supplementation daily for 4 weeks. Patients undergo radical prostatectomy within 21 days after completion of soy supplementation.
3308917|NCT00345813|Placebo Comparator|Arm II|Patients receive oral placebo supplementation daily for 4 weeks. Patients undergo radical prostatectomy within 21 days after completion of placebo supplementation.
3308918|NCT00345800|Experimental|Sodium Oxybate|Active Substance: Sodium Oxybate Pharmaceutical form: Oral Solution Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks Route of administration: Oral
3308919|NCT00345787|Placebo Comparator|0|
3308920|NCT00345787|Experimental|1|
3308921|NCT00345761|Experimental|Step 1|
3308922|NCT00345761|Experimental|Step 2|
3308923|NCT00345761|Experimental|Step 3|
3308924|NCT00345748|Active Comparator|Abatacept 2 mg/kg|
3308925|NCT00345748|Active Comparator|Abatacept 10 mg/kg|
3308926|NCT00345748|Placebo Comparator|Placebo|
3308927|NCT00345709||National Research Registry Enrollment|Patient, living or deceased, with a pathologically-confirmed diagnosis of Ovarian Cancer.
3308928|NCT00345683|Experimental|Menhibrix Group|Subjects received 3 doses of Menhibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course in the study NCT00345579 and a fourth dose of Menhibrix vaccine at 12-15 months of age in this study (study Month 10-13). Menhibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
3308929|NCT00345683|Active Comparator|ActHIB Group|Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course in the study NCT00345579 and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in this study (study Month 10-13). ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
3308930|NCT00345670|Experimental|1|MEDI-534
3308931|NCT00345670|Experimental|2|MEDI-534
3308932|NCT00345670|Experimental|3|MEDI-534
3308933|NCT00345644|Experimental|1|
3308934|NCT00345644|Placebo Comparator|2|
3308935|NCT00345631|Active Comparator|Manual Compression|Manual compression (MC)
3308936|NCT00345631|Experimental|Vascular Closure Device|Vascular Closure Device (VCD)
3308937|NCT00345618|Experimental|Idrabiotaparinux|"Idrabiotaparinux sodium, 3.0 mg, once-weekly for 3 or 6 months depending on the stratum, after enoxaparin, 1.0 mg/kg, every 12 hours for at least 5 days.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or over-dosage)."
3308938|NCT00345618|Active Comparator|Warfarin|"Warfarin, INR-adjusted dose, started 24 hours after the start of enoxaparin, 1.0 mg/kg, every 12 hours for at least 5 days, and continued for 3 or 6 months depending on the stratum.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or over-dosage)."
3308939|NCT00345605|Experimental|HDA|"High Dose Arm~Wash-out then 7 days of:~Arg 500 mg/kg/d or 10 g/m2 BSA Placebo instead of NaPBA"
3308940|NCT00345605|Experimental|LDA|"Low Dose Arm~Wash-out followed by 7 days of:~Arg 100 mg/kg/d or 2 g/m2 BSA NaPBA 500 mg/kg/d or 10 g/m2 BSA"
3308941|NCT00345592|Experimental|Device managed arm|Device-managed therapy arm. Shock therapy for atrial arrhythmias is delivered automatically from the device.
3308942|NCT00345592|Active Comparator|Traditional arm|Traditional therapy arm. In this arm, therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment. Therefore, patients who will experience symptoms at home, will refer to their center, eventually hospitalized and treated for atrial arrhythmias.
3308943|NCT00345579|Experimental|Menhibrix Group|Subjects received 3 doses of Menhibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of Menhibrix vaccine at 12-15 months of age in the study NCT00345683. Menhibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
3308944|NCT00345579|Active Comparator|ActHIB Group|Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
3308945|NCT00345553||1|Biliary atresia subjects who have their native liver
3308946|NCT00345553||2|Biliary atresia subjects who have had a liver transplant
3308947|NCT00345540|Experimental|NOV-002 plus Carboplatin|NOV-002 is given by IV bolus on lead-in day -1 at cycle 1, and on day 1 at subsequent cycles, followed by Carboplatin AUC 5. NOV-002 is then continued via daily SC injection, with 28 day cycles.
3308948|NCT00345514|No Intervention|1|
3308949|NCT00345514|Active Comparator|2|
3308950|NCT00345514|Active Comparator|3|
3308951|NCT00345501|Experimental|1|Iloprost
3308952|NCT00345501|Placebo Comparator|2|Placebo
3308953|NCT00345475||AED treatment|Women being treated with UCB AEDs while pregnant.
3308954|NCT00345397|Experimental|Subjects Receiving PEC Tube|Percutaneous Endoscopic Colostomy Tube (PEC) Placement
3309673|NCT00332774|Placebo Comparator|Vehicle|
3308955|NCT00345384|Placebo Comparator|Normal Saline|One group (placebo comparator) will receive a normal saline infusion, set at a rate as if it were the active drug.
3308956|NCT00345384|Active Comparator|Dexmedetomidine|The second group (the study group) will receive a continuous infusion of dexmedetomidine titrated from 0.1 - 0.5 mics/kg/h to control pain for up to 24 hours after they are admitted to an open nursing unit after discharge from the PACU or ICU
3308957|NCT00345371|Active Comparator|Topiramate|Subjects will receive topiramate (in tablet form) up to 200 mg/day for 13 weeks.
3308958|NCT00345371|Placebo Comparator|Placebo Oral Tablet|After randomization subjects will receive topiramate matched placebo (in tablet form), up to 200 mg/day for 13 weeks.
3308959|NCT00345358|Active Comparator|<6 Mo|Children of 9-12 weeks of age at the time of first vaccination receiving 3-dose primary vaccination of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix IPV/Hib) at 3-4-5 months of age and a booster dose at 12-15 months of age.
3308960|NCT00345358|Experimental|7-11 Mo|Children between 7 to 11 months of age at the time of first vaccination receiving 2-dose primary vaccination of pneumococcal conjugate vaccine GSK1024850A with at least 4 weeks interval and a booster dose at 12-15 months
3308961|NCT00345358|Experimental|12-23 Mo|Children between 12 to 23 months of age at the time of first vaccination receiving 2-dose primary vaccination of pneumococcal conjugate vaccine GSK1024850A with at least 8 weeks interval
3308962|NCT00345358|Experimental|>=24 Mo|Children between 24 months to 5 years of age at the time of first vaccination receiving single dose of pneumococcal conjugate vaccine GSK1024850A
3308963|NCT00345332|Placebo Comparator|1|Placebo
3308964|NCT00345332|Experimental|2|Botox
3308965|NCT00345319|Active Comparator|Group 1|
3308966|NCT00345319|Active Comparator|Group 2|
3308967|NCT00345293|Experimental|DC/PC3 vaccine|3 subcutaneous injections of ex vivo-generated autologous dendritic cell vaccine: 1) pulsed with apoptotic PC3 cells; 2) pulsed with apoptotic PC3-M1 cells, and 3) pulsed with keyhole limpet hemocyanin (KLH, control antigen)
3308968|NCT00345254|Experimental|severing cord|The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
3308969|NCT00345254|No Intervention|Untouched cord|The cord was untouched after delivery of the anterior shoulder and prior to extraction of the body.
3308970|NCT00345189|Other|Dosing Schedule 1|Starting dose of 25 mg, with dosing twice a week for 3 weeks out of a 4-week course (Schedule 1). Dosing for schedule 1 is currently closed.
3308971|NCT00345189|Other|Dosing Schedule 2|Starting dose of 600 mg, with dosing twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).
3308972|NCT00345176|Active Comparator|Lutein/Zeaxanthin|lutein (10mg)/zeaxanthin (2 mg)
3308973|NCT00345176|Active Comparator|DHA/EPA|DHA (350 mg)/EPA (650 mg)
3308974|NCT00345176|Active Comparator|Lutein/Zeaxanthin + DHA/EPA|lutein (10 mg)/zeaxanthin (2 mg) + DHA (350 mg)/EPA (650 mg)
3308975|NCT00345176|Placebo Comparator|Placebo/Control|Considered control because all participants received the AREDS formulation
3308976|NCT00345163|Experimental|1|
3308977|NCT00345163|Experimental|2|
3308978|NCT00345059|Active Comparator|docetaxel|single agent docetaxel
3308979|NCT00345059|Experimental|docetaxel + vinorelbine OR gemcitabine|docetaxel in combination with either vinorelbine or with gemcitabine
3308980|NCT00345059|Experimental|docetaxel + capecitabine|docetaxel in combination with capecitabine
3308981|NCT00345046|Active Comparator|Pred Forte 1%|Pred Forte 1% dosed four times daily decreasing to once daily over four weeks.
3308982|NCT00345046|Active Comparator|EconoPred Plus 1%|EconoPred Plus 1% dosed four times daily decreasing to once daily over four weeks.
3308983|NCT00345046|Active Comparator|Prednisolone Acetate 1%|Prednisolone Acetate 1% dosed four times daily decreasing to once daily over four weeks.
3308984|NCT00345033|Experimental|1|Participants will take aripiprazole 15mg/day for 8 weeks.
3308985|NCT00345033|Placebo Comparator|2|Participants will take placebo for 8 weeks.
3308986|NCT00344968|Experimental|1|
3308987|NCT00344968|Experimental|2|
3308988|NCT00344968|Sham Comparator|3|
3308989|NCT00344942|Experimental|1|
3308990|NCT00344942|Placebo Comparator|2|
3308991|NCT00344890|Experimental|Preservon|
3308992|NCT00344890|Active Comparator|Control|
3308993|NCT00344825||Group 1|
3308994|NCT00344786|Experimental|CNF2024|
3308995|NCT00344773|Experimental|Gefitinib|Gefitinib 250mg tablet once daily
3308996|NCT00344760|Active Comparator|Standard Treatment|Efavirenz 600mg once daily, Lamivudine 300mg once daily and Tenofovir 300mg once daily
3308997|NCT00344760|Experimental|Standard Treatment Plus Enfuvirtide|Efavirenz 600mg once daily, Lamivudine 300mg once daily, Tenofovir 300mg once daily and enfuvirtide 90mg subcutaneously twice a day until the viral load is less than 50copies for 2 consecutive visits or 12 weeks (whichever comes first).
3308998|NCT00344721|Active Comparator|EPA/DHA/flaxseed|Study patients in the active comparator arm will take four soft-gel capsules containing omega-3 fatty acids (a nutritional supplement) orally daily for 3 months. Each daily dose contains eicosapentaenoic acid (450 mg), docosahexaenoic acid (300 mg) and flaxseed oil (1000 mg).
3308999|NCT00344721|Placebo Comparator|Wheat germ oil|Study patients in the placebo arm will take four doses of soft-gel capsules containing wheat germ oil orally daily for 3 months.
3309000|NCT00344682|Experimental|memantine|memantine (5-20mg a day)
3309001|NCT00344682|Placebo Comparator|Placebo|placebo (5-20mg a day)
3309002|NCT00344656||Subjects and Controls|Patients with DSM-IV Anorexia Nervosa
3309003|NCT00344591|Experimental|Tailored SET program|tailored SET program for reducing sexual and drug-related HIV transmission risk factors and increasing HIV treatment adherence in HIV infected men who have recently been released from prison
3309004|NCT00344591|Active Comparator|Individually focused therapy|Individually focused therapy program for reducing sexual and drug-related HIV transmission risk factors and increasing HIV treatment adherence in HIV infected men who have recently been released from prison
3309005|NCT00344565|Placebo Comparator|Placebo|Placebo, was matched to modafinil up to 400 mg/day. Patients also receive motivational interviewing and Cognitive Behavioral Therapy—Relapse Prevention (CBT-RP)
3311784|NCT00305565|Other|Medium Dose|
3309006|NCT00344565|Active Comparator|Modafinil|Modafinil (Active comparator). Patients received motivational interviewing and Cognitive Behavioral Therapy--relapse prevention (CBT-RP)
3309007|NCT00344552|Experimental|1|
3309008|NCT00344539|Experimental|B|80 mcg AMA1-C1/Alhydrogel® with 368 mcg Aluminum and 500 mg CPG 7909.
3309009|NCT00344539|Experimental|C|80 mcg AMA1-C1/Alhydrogel® with 368 mcg Aluminum alone.
3309010|NCT00344539|Experimental|A|20 mcg AMA1-C1/Alhydrogel® with 377 mcg Aluminum and 500 mg CPG 7909.
3309011|NCT00344500|No Intervention|Usual Care|Usual Care
3309012|NCT00344500|Active Comparator|Lifestyle Balance|Behavioral Weight Loss Program
3309013|NCT00344487|Experimental|lopinavir/ritonavir (Kaletra)|lopinavir/ritonavir (Kaletra)400/100mg tablets by mouth twice a day for 48 weeks.
3309014|NCT00344474|Experimental|learning to cope with your impulsivity|cognitive behavioural intervention teaching high impulsive youth how to manage their impulsive thinking and behaviours
3309015|NCT00344474|Experimental|learning to cope with your sensation seeking|cognitive-behavioural intervention teaching high sensation seeking youth how to manage their need for stimulation and excitement
3309016|NCT00344474|Experimental|learning to cope with your anxiety sensitivity|cognitive behavioural intervention targeting catastrophic thinking in high anxiety sensitive youth
3309017|NCT00344474|Experimental|learning to manage your negative thinking|cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
3309018|NCT00344461|Experimental|Nevirapine, FTC, Tenofovir|Open Label Drugs- Nevirapine 200 mg twice a day, FTC 200 mg once a day and Tenofovir 300 mg once a day for 96 weeks.
3309019|NCT00344448|Experimental|Raptiva|At the beginning of the first (week 1) and second (week 13) phases, all patients will receive reduced dose of the study medication determined at 0.7 mg/kg/week. During all the subsequent administrations, all patients will receive full dose of the study medication determined at 1 mg/kg/week.
3309020|NCT00344448|Placebo Comparator|placebo|Weekly subcutaneous injection of a placebo (formulated to match the commercial vial of Raptiva in appearance and content except for the active ingredient) for the first 12 weeks of the study.
3309021|NCT00344370|Experimental|Pitavastatin|Pitavastatin 4 mg QD
3309022|NCT00344370|Active Comparator|Atorvastatin|Atorvastatin 40 mg
3309023|NCT00344318|Experimental|Group A|Receiving pneumococcal conjugate vaccine GSK1024850A
3309024|NCT00344318|Active Comparator|Group B|Receiving Prevenar
3309025|NCT00344305|Experimental|Cohort 1: Participants Between 6 to < 24 Months Age|Participants received a single, intranasal dose of 0.2 millilitre (mL) (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 fluorescent focus units (FFU) of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
3309026|NCT00344305|Experimental|Cohort 2: Participants Between 24 to < 60 Months Age|Participants received a single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 FFU of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
3309027|NCT00344253|Experimental|1|Interferon beta 3x weekly
3309028|NCT00344253|Active Comparator|2|Methotrexate sc 20 mg weekly
3309029|NCT00344214|Experimental|1|Participants will receive the tri-focal cognitive behavioral therapy - social skills training counseling program
3309030|NCT00344214|Active Comparator|2|Participants will receive the standard care comparison condition
3309031|NCT00344175|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
3309032|NCT00344175|Active Comparator|Simvastatin 40mg/80mg|Simvastatin 40 mg or 80 mg once daily
3309033|NCT00344149|Experimental|Rituximab|I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
3309034|NCT00344149|Placebo Comparator|Placebo|I.V infusion of NaCl 0.9%
3309035|NCT00344123|Other|Tipranavir/ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin.~Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
3309036|NCT00344045|Active Comparator|A|
3309037|NCT00344045|Placebo Comparator|B|
3309038|NCT00344032|Experimental|Cervarix|Subjects who received 3 doses of HPV-16/18 VLP/AS04 Vaccine (Cervarix TM) (at 0, 1, 6 months).
3309039|NCT00344032|Placebo Comparator|Placebo|Subjects who received 3 doses of Placebo (at 0, 1, 6 months).
3309040|NCT00344019|Active Comparator|atorvastatin 80 mg|80 mg atorvastatin on average of 2-4 hours pre angio/PCI for ACS
3309041|NCT00344019|Placebo Comparator|placebo oral tablet|placebo on average of 2-4 hours pre angio/PCI for ACS
3309042|NCT00344019|No Intervention|Screening|Patients signed consent if willing to participate. Patients will continue onto randomization if appropriate per inc/exc (i.e. stent placement) otherwise screen fail
3309043|NCT00344006|Experimental|Arm 1|
3309044|NCT00343980|Experimental|A|
3309045|NCT00343980|Active Comparator|B|
3309046|NCT00343928|Experimental|1|
3309047|NCT00343915|Experimental|2-Dose Engerix|subjects received 2 doses of adult (thiomersal-free) HBV formulation, one at 0 and 6 months, respectively and placebo (physiological saline) at 1 month.
3309048|NCT00343915|Active Comparator|3-Dose Engerix|subjects received 3 doses of paediatric (preservative-free) HBV formulation one at 0, 1 and 6 months, respectively.
3309049|NCT00343889|Experimental|Group 1: DTaP-Hep B-PRP-T + Oral Polio Vaccine (OPV) vaccine|Participants received 3 doses of the DTaP-Hep B-PRP~T concomitantly with Oral Polio Vaccine (OPV), 1 dose each at 6, 10, and 14 weeks of age.
3309050|NCT00343889|Active Comparator|Group 2: Tritanrix-HepB/Hib™ + OPV vaccine|Participants received 3 doses of Tritanrix-Hep B/Hib™ concomitantly with Oral Polio Vaccine (OPV) at 6, 10, and 14 weeks of age.
3309051|NCT00343863|Active Comparator|Dexamethasone + Ondansetron IV on Day 1|"All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.~Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)."
3309280|NCT00337870|Experimental|Treatment|50% randomized to receive distraction intervention during painful procedure
3309052|NCT00343863|Experimental|Dexamethasone + Palonosetron IV on Day 1|"All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.~Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)."
3309053|NCT00343824|Experimental|aquacel AG hydrofiber|
3309054|NCT00343824|Experimental|Acticoat burn dressing|
3309055|NCT00343798|Experimental|Treatment (umbilical cord blood transplant)|"MYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1.~TRANSPLANTATION : Patients undergo double-unit umbilical cord blood transplantation comprising unmanipulated umbilical cord blood unit IV over 20-30 minutes, and 4-6 hours later patients receive ex vivo-expanded umbilical cord blood cells IV over 30 minutes on day 0.~GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS: Patients receive cyclosporine IV every 8 or 12 hours on days -3 to 100, followed by a taper to at least day 180. Patients also receive MMF IV every 8 hours on days -3 to 5 and then PO, if tolerated, on days 6-30."
3309056|NCT00343785|Experimental|Treatment (conditioning regimen, transplant, GVHD prophylaxis)|Patients receive a conditioning regimen comprising cyclophosphamide IV on days -5 to -2 and anti-thymocyte globulin IV over 4-10 hours on days -4 to -2. Patients undergo allogeneic bone marrow transplantation on day 0. Patients then receive GVHD prophylaxis comprising methotrexate IV on days 1, 3, 6, and 11 and cyclosporine IV over 1 hour or PO twice daily on days -1 to 50, followed by a taper until 6 months after grafting.
3309057|NCT00343681|Experimental|1|
3309058|NCT00343642|Placebo Comparator|1|Time and attention + fructooligosaccharide placebo
3309059|NCT00343642|Active Comparator|2|Dietary therapy + fructooligosaccharide placebo
3309060|NCT00343642|Experimental|3|Time and attention + active fructooligosaccharide supplement.
3309061|NCT00343616|Experimental|Tamoxifen for 5 years|Patients treated with tamoxifen for 5 years after randomization.
3309062|NCT00343616|Experimental|Letrozole for 5 years|Patients treated with letrozole for 5 years after randomization.
3309063|NCT00343616|Experimental|Tamoxifen 2 years plus letrozole 3 years|Patients treated with tamoxifen for 2 years and afterwards with letrozole for 3 years.
3309064|NCT00343616|Experimental|Letrozole for 2 years plus tamoxifen for 3 years|Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.
3309065|NCT00343564|Experimental|Phase 1 Dose Escalation|Phase 1 dose escalation without and with GCSF support
3309066|NCT00343564|Experimental|Phase 2 Fixed Dose|Phase 2 fixed dose based on Phase I findings stratified by NHL type
3309067|NCT00343512|Experimental|Therapeutic Intervention|
3309068|NCT00343460|Active Comparator|Arm I|Patients receive palonosetron hydrochloride IV, placebo subcutaneously (SC), and dexamethasone IV on day 1 of chemotherapy course 1. Patients in the high-risk (level 5) stratum also receive oral dexamethasone on days 2-4 of all treatment courses.
3309069|NCT00343460|Experimental|Arm II|Patients receive APF530 SC, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
3309070|NCT00343460|Experimental|Arm III|Patients receive APF530 SC at a higher dose, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC (at the same higher dose) and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
3309071|NCT00343421|Experimental|Group 1|PEDIACEL co-administered with Prevenar
3309072|NCT00343421|Active Comparator|Group 2|Infanrix-IPV+Hib co-administered with Prevenar
3309073|NCT00343395|Active Comparator|Avandamet|AVANDAMET 2/500 mg
3309074|NCT00343395|Placebo Comparator|Placebo|
3309075|NCT00343382|Experimental|Arm I|Patients receive oral pilocarpine hydrochloride once a day for 3 days, twice a day for 3 days, three times a day for 3 days, and then 4 times a day for up to 6 weeks in the absence of unacceptable toxicity.
3309076|NCT00343382|Experimental|Arm II|Patients receive oral pilocarpine hydrochloride once a day for 3 days and then twice a day for up to 6 weeks in the absence of unacceptable toxicity.
3309077|NCT00343382|Placebo Comparator|Arm III|Patients receive oral placebo once a day for 3 days, twice a day for 3 days, three times a day for 3 days, and then 4 times a day for up to 6 weeks in the absence of unacceptable toxicity.
3309078|NCT00343382|Placebo Comparator|Arm IV|Patients receive oral placebo once a day for 3 days and then twice a day for up to 6 weeks in the absence of unacceptable toxicity.
3309079|NCT00343291|Active Comparator|Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)|"Cycles 1-6:~Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week~Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle~Paclitaxel 200 mg/m² on day 1 of every 3 week cycle~Carboplatin area under curve (AUC=6 min*mg/mL) on day 1 of every 3 week cycle~Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
3309080|NCT00343291|Active Comparator|Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)|"Cycles 1-6:~Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week~Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle~Cycles 1-3:~Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles~Carboplatin AUC=6 min*mg/mL on day 1 of each 3 week cycle for the first 3 cycles~Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
3309081|NCT00343265|Active Comparator|1|Progesterone gel
3309082|NCT00343265|Placebo Comparator|2|Vaginal gel with no medication
3309083|NCT00343252|Experimental|Teriparatide|Teriparatide 20 micrograms (ug)/day, subcutaneous, 18 months plus once weekly oral placebo
3309084|NCT00343252|Active Comparator|Risedronate|Risedronate 35 milligrams (mg)/once weekly, oral, 18 months plus daily subcutaneous injection placebo
3309085|NCT00343239|Experimental|Docetaxel/Cisplatin/Fluorouracil (DCF)|DCF combination for three 21-day cycles unless a disease progression is observed at the tumor assessment scheduled after the second cycle or due to patient intolerability
3309086|NCT00343200|Placebo Comparator|Placebo|
3309087|NCT00343200|Experimental|Sildenafil|Not Specified
3309088|NCT00343135|Experimental|ARM 1|
3311785|NCT00305565|Other|High Dose|
3309089|NCT00343109|Experimental|Arm I|Patients receive HER-2/neu intracellular domain peptide-based vaccine mixed with GM-CSF intradermally once monthly for 6 months in the absence of disease progression or unacceptable toxicity.
3309090|NCT00343083|Experimental|Cetuximab comparison for Head and Neck Cancer|"To report the mature data of a prospective Phase II trial designed to evaluate the efficacy of an epidermal growth factor receptor inhibitor cetuximab (CTX) added to the concurrent therapy of weekly paclitaxel/carboplatin (PC) and daily radiation therapy (RT).~Both chemotherapy and radiation will be given on a weekly basis (see interventions for details)."
3309091|NCT00343044|Experimental|Treatment|Subjects received standard topotecan with the addition of bevacizumab. Cycles were 28 days and continued until toxicity, progression or subject wish to discontinue treatment. Topotecan administered 4 mg/m2 IV on days 1, 8 and 15 and bevacizumab IV 10 mg/kg, days 1 and 15 of each cycle.
3309092|NCT00342862||1. Amevive Exposure|Pregnant women with psoriasis exposed to AMEVIVE® at any point within 8 weeks prior to conception, or at any time during pregnancy, where the outcome of the pregnancy is unknown prospectively
3309093|NCT00342849|Experimental|1|Scuccimer Treatment Group
3309094|NCT00342849|Placebo Comparator|2|In order to provide placebo with an odor comparable to that of succimer, the Drug Distribution Center will place a small canister containing 200 mg of active drug into each bottle of placebo drug. A canister containing 200 mg of placebo will be placed inside each bottle of succimer so that all bottles will appear the same.
3309095|NCT00342797||Retinoblastoma cohort|Retinoblastoma patients treated at two hospitals in New York and one hospital in Boston from 1914-2006 who survived at least one year after their retinoblastoma diagnosis.
3309096|NCT00342628|Experimental|Vi-rEPA plus DTP|Vi-rEPA and DTP at 2, 4, 6 months, and Vi-rEPA at 12 months
3309097|NCT00342628|Active Comparator|Hib-TT plus DTP|Hib-TT and DTP at 2,4 and 6 months, Hib-TT at 12 months
3309098|NCT00342628|Active Comparator|EPI|DTP at 2,4 and 6 months
3309099|NCT00342563|Experimental|Mecamylamine- Smoker|
3309100|NCT00342563|Placebo Comparator|Placebo-Smoker|
3309101|NCT00342563|Experimental|Mecamylamine- Non-Smoker|
3309102|NCT00342563|Placebo Comparator|Placebo-Non-Smoker|
3309103|NCT00342381|Active Comparator|3.4 diaminopyridine|Single dose 3,4 diaminopyridine
3309104|NCT00342381|Placebo Comparator|Placebo|Two tablets identical to active treatment
3309105|NCT00342368|Active Comparator|1|CPAP through an helmet
3309106|NCT00342368|No Intervention|2|O2 therapy with conventional face mask
3309107|NCT00342355|Active Comparator|AZT+DDI+EFV|Zidovudine,Didanosine,Efavirenz ( Zidovudine 600 mg once daily,Didanosine <60 kg/125 mg twice daily or >60kg/200 mg twice daily,Efavirenz 600 mg once daily)
3309108|NCT00342355|Active Comparator|AZT+DDI+r/LPV|Zidovudine,Didanosine,Lopinavir/Ritonavir(AZT 600 mg once daily,DDI 100 mg twice daily,r/LPV 400mg/100mg twice daily)
3309109|NCT00342355|Active Comparator|d4T+3TC+EFV|Stavudine,Lamivudine,Efavirenz(d4T 40 mg twice daily,3TC 300 mg once daily,EFV 600 mg once daily)
3309110|NCT00342355|Active Comparator|d4T+3TC+r/LPV|Stavudine,Lamivudine,Lopinavir/Ritonavir(d4T 40m mg twice daily,3TC 300 mg once daily,r/LPV 400mg/100mg twice daily)
3309111|NCT00342316|Experimental|Stem cell transplant (RICT)|Receiving intervention consisting of Reduced Intensity Conditioning Stem Cell Transplantation
3309112|NCT00342316|No Intervention|Control arm|Treatment according to standard of care, i.e. not undergoing RICT
3309113|NCT00342108|Experimental|1|Diagnosis: CP, moderate to severe MR and CVI
3309114|NCT00342108|Experimental|2|Diagnosis: CP, Moderate to severe MR, no visual impairment
3309115|NCT00341835||High risk lung cancer families|Individuals from families with a high risk of lung cancer, both affected and unaffected family members
3309116|NCT00341328|Experimental|1|In one arm the patient will receive intradermal Mycobacterium W Vaccine along with Category I ATT drugs according to RNTCP guidelines
3309117|NCT00341328|Placebo Comparator|2|In this Arm patient will receive Placebo along with Category I ATT drugs according to RNTCP guidelines
3309118|NCT00341237||polymorphisms|Specimens are available to investigators in coded form to anonymously screen for thepresence of single-nucleotide polymorphisms (SNPs) and other mutations in DNA.
3309119|NCT00341094||Main UkrArm|Subjects exposed to I131 before the age of 18 years
3309120|NCT00341094||Ukraine in utero|Subjects exposed to I131 in utero
3309121|NCT00340834|Experimental|Fingolimod 1.25 mg|
3309122|NCT00340834|Experimental|Fingolimod 0.5 mg|
3309123|NCT00340834|Active Comparator|Interferon β-1a 30 µg|
3309124|NCT00340704|Experimental|1. Low dose group|
3309125|NCT00340704|Experimental|2. Medium dose group|
3309126|NCT00340704|Experimental|3. High dose group|
3309127|NCT00340678|Experimental|Normoalbuminuria Losartan|Subjects with normal urinary albumin excretion were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
3309128|NCT00340678|Placebo Comparator|Normoalbuminuria Placebo|Subjects with normal urinary albumin excretion were treated with placebo corresponding to each dose of losartan.
3309129|NCT00340678|Experimental|Microalbuminuria Losartan|Subjects with microalbuminuria were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
3309130|NCT00340678|Placebo Comparator|Microalbuminuria Placebo|Subjects with Microalbuminuria were treated with placebo corresponding to each dose of losartan.
3309131|NCT00340379|Active Comparator|Ziprasidone|Subjects in this arm received ziprasidone with a placebo to maintain the blind
3309132|NCT00340379|Active Comparator|Sertraline/Haloperidol|Subjects in this arm received a combination of sertraline and haloperidol with a placebo to maintain the blind. Sertraline dosage was 150-200mg/day and haloperidol was 6-8mg/day based on tolerance.
3309133|NCT00340340||1|Newly diagnosed lung cancer cases
3309134|NCT00340340||2|Population-based controls
3309135|NCT00340210||Serum Bank Participants|The Columbia MO Serum Bank recruited 6915 women living in and around Columbia MO between 1977-1987 who were cancer-free except for non-melanoma skin cancer and at least 18 years of age.
3309136|NCT00339885||Fusion 1|Affected-sib pair (ASP) families and elderly controls
3309137|NCT00339885||Fusion 2|275 Replication ASP Families; Trios
3310424|NCT00322686|Experimental|Placebo followed by Oglemilast|
3309138|NCT00339885||Fusion 3|Siblings of FUSION1 families; Spouses, Offspring of 291 FUSION 1 families; Spouses, Offspring of Elderly Controls; Other F1 relatives
3309139|NCT00339885||Fusion 4/5|Spouses, Offspring of FUSION 1 and 2 Families
3309140|NCT00339885||AADM|Family and Population based individuals
3309141|NCT00339885||FINRISK 2002|Population based individuals; Test DNA
3309142|NCT00339885||Health-2000|Population based individuals
3309143|NCT00339885||Action-LADA|Population based individuals
3309144|NCT00339885||D2D 2004|Population based individuals
3309145|NCT00339885||FINRISK 1987|Population based individuals
3309146|NCT00339885||Savitaipale|Population based individuals
3309147|NCT00339885||DIAGEN (Dresden Biobank)|Population based individuals
3309148|NCT00339885||METSIM|Population based individuals
3309149|NCT00339885||HUNT 2|Population based individuals
3309150|NCT00339885||FUSION Finnish Groups|Family and Population based (including METSIM and DR's EXTRA): Tissue samples
3309151|NCT00339885||UEF - Laakso|Monogenic disease individuals and family members
3309152|NCT00339833|Experimental|Salsalate|Salsalate (3g/day) for 7 days
3309153|NCT00339833|Placebo Comparator|Placebo|Placebo
3309154|NCT00339768|Experimental|Vitamins|Supplement for 7 years; placebo controlled
3309155|NCT00339768|Experimental|Garlic|Supplement for 7 years; placebo controlled
3309156|NCT00339768|Experimental|Amox/omepr|2 weeks; placebo controlled
3309157|NCT00339690|Experimental|Test Kit Homes|Households assigned to use the in-home test kit.
3309158|NCT00339625|Experimental|1|low fat, high fiber, high fruit and vegetable eating plan
3309159|NCT00339625|No Intervention|2|Usual Diet
3309160|NCT00339495||Screening|Participants received trial-provided screening examinations for prostate, lung, colorectal, andovarian cancer
3309161|NCT00339495||Non-Screening|Participants received their usual care
3309162|NCT00339469|Other|2|Controlled feeding study.
3309163|NCT00339365|Experimental|1|Promoting first relationships group
3309164|NCT00339365|Active Comparator|2|Early education support group
3309165|NCT00339196|Experimental|1|5-azacytidine VALPROIC acid and ATRA
3309166|NCT00339183|Experimental|Panitumumab Plus FOLFIRI|Participants received panitumumab as an intravenous (IV) infusion at a dose of 6 mg/kg plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-fluorouracil (5-FU), leucovorin and irinotecan. Treatment was administered in cycles every two weeks.
3309167|NCT00339183|Active Comparator|FOLFIRI Alone|Participants received standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment is administered in cycles every two weeks.
3309168|NCT00339170|Experimental|1|Participants receive a 12-month cognitive enhancement training program plus a 12-month work therapy program.
3309169|NCT00339170|Active Comparator|2|Participants receive a 12-month work therapy program alone.
3309170|NCT00339144|Experimental|Dasatinib (100 mg)|
3309171|NCT00339144|Experimental|Dasatinib (150 mg)|
3309172|NCT00339144|Experimental|Dasatinib (200 mg)|
3309173|NCT00339092|Experimental|Treatment|Participants who receive storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals
3309174|NCT00339092|Active Comparator|Control|Participants who receive standard care
3309175|NCT00339079|Experimental|Cognitive Behavioral Therapy (CBT)|Patients in this arm only received Cognitive Behavioral Therapy (CBT). Six, 60 minute weekly sessions were followed by 4 bi-weekly sessions and 3 monthly booster sessions.
3309176|NCT00339079|Placebo Comparator|Placebo|Patients only received placebo pills accompanied by medication management supportive therapy; including non-specific encouragement, support and explanation similar to that provide in a physician's office.
3309177|NCT00339079|Experimental|Fluoxetine|Patients only received the SSRI Fluoxetine. Medication was adminstered on a fixed-flexible dosing regimen, beginning at 10mg/day for 2 weeks, then 20 mg/day for 2 weeks, 40 mg/day for two weeks, 60 mg/day for 2 weeks, and 80 mg/day (the target dose) thereafter. This was accompanied by medication management supportive therapy; including non-specific encouragement, support and explanation similar to that provide in a physician's office.
3309178|NCT00339079|Experimental|Combined CBT and Fluoxetine|Patients in this arm received both CBT and the fluoxetine medication. Both interventions were administered in the same way as when adminstered alone in the other arms.
3309179|NCT00339040|Active Comparator|Arm A: QHPV|QHPV at week 0, 8, 24, 96.
3309180|NCT00339040|Other|Arm B: Placebo/QHPV|Placebo at week 0, 8, 24; QHPV at week 96, 104, 120.
3309181|NCT00339014|Active Comparator|Group 1|Zonisamide SR 120 mg/day plus Bupropion SR 280 mg/day
3309182|NCT00339014|Active Comparator|Group 2|Zonisamide SR 120 mg/day plus Bupropion SR 360 mg/day
3309183|NCT00339014|Active Comparator|Group 3|Zonisamide SR 240 mg/day plus Bupropion SR 280 mg/day
3309184|NCT00339014|Active Comparator|Group 4|Zonisamide SR 240 mg/day plus Bupropion SR 360 mg/day
3309185|NCT00339014|Active Comparator|Group 5|Zonisamide SR 360 mg/day plus Bupropion SR 280 mg/day
3309186|NCT00339014|Active Comparator|Group 6|Zonisamide SR 360 mg/day plus Bupropion SR 360 mg/day
3309187|NCT00339014|Placebo Comparator|Group 7|
3309188|NCT00338988|Experimental|Capecitabine + Oxaliplatin|Combination of intravenous (IV) oxaliplatin 100 mg/m^2 Day 1 and oral (PO) capecitabine 750 mg/m^2 twice daily (total daily dose 1500 mg/m2) on Days 1-14.
3309189|NCT00338975|Experimental|1|Cognitive Behavioral Social Skills Training (CBSST)
3309190|NCT00338975|Active Comparator|2|Goal-Focused Supportive Contact (GFSC)
3309191|NCT00338962|Active Comparator|Paroxetine and naltrexone|Paroxetine was started at 10 mg per day and the dose was gradually increased over 2 weeks to 40 mg per day. Naltrexone was started at 25 mg the first day and 50 mg per day for the rest of the treatment.
3309192|NCT00338962|Active Comparator|paroxetine and placebo|Paroxetine was started at 10 mg per day and the dose was gradually increased over 2 weeks to 40 mg per day.
3309193|NCT00338962|Active Comparator|Desipramine and naltrexone|Desipramine was started at a dose of 25 mg per day. The dose was gradually increased over 2 weeks to 200 mg per day. Naltrexone was started at 25 mg the first day and 50 mg per day for the rest of the treatment.
3309281|NCT00337870|No Intervention|Control|50% RANDOMIZED TO RECEIVE NO INTERVENITON
3309194|NCT00338962|Active Comparator|Desipramine and placebo|Desipramine was started at a dose of 25 mg per day. The dose was gradually increased over 2 weeks to 200 mg per day.
3309195|NCT00338949|Active Comparator|Control|Participants on risperidone or olanzapine who will remain on risperidone or olanzapine and do not switch to ziprasidone
3309196|NCT00338949|Experimental|Switch|Participants who enter on risperidone or olanzapine and switch to ziprasidone
3309197|NCT00338923|Active Comparator|Treatment arm|One Arm - Active Compound (HO/03/03)
3309198|NCT00338884|Experimental|SUNITINIB MALATE.|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
3309199|NCT00338871|Experimental|study|home exercise
3309200|NCT00338871|No Intervention|control|regular therapy
3309201|NCT00338858|Active Comparator|1|TD
3309202|NCT00338858|Experimental|2|TBI
3309203|NCT00338858|Experimental|a|Cerebral palsy
3309204|NCT00338845|Experimental|1|Participants will receive the Share Safer Sex counseling program
3309205|NCT00338845|Active Comparator|2|Participants will receive a standard didactic safer-sex counseling session
3309206|NCT00338832|Experimental|1|Participants will receive the Physically Ready for Invigorating Movement Every Day program
3309207|NCT00338832|Active Comparator|2|Participants will receive the Program for Activity, Leisure Skills, and Socialization
3309208|NCT00338806|Experimental|Interpersonal Psychotherapy-Prevention|Participants will receive interpersonal psychotherapy for prevention with adolescents
3309209|NCT00338806|Active Comparator|Educational and Clinical Monitoring|Participants will receive educational clinical monitoring
3309210|NCT00338767|Experimental|Treatment|Participants receiving storefront directly observed therapy of anti-depressants (Fluoxetine)
3309211|NCT00338767|No Intervention|Control|Participants receiving referral to mental health follow-up with the UCSF AIDS Health Project
3309212|NCT00338741||1|Rebif exposed pregnancies
3309213|NCT00338741||2|Non-Rebif exposed pregnancies
3309214|NCT00338728|Experimental|Letrozole + Imatinib Mesylate|Oral Letrozole 2.5 mg daily + Oral Imatinib Mesylate 400 mg, twice a day (total daily dose 800 mg).
3309215|NCT00338715|Experimental|A|Prophylactic Pulmonary Vein Isolation in Addition to CABG for the prevention of postoperative Atrial Fibrillation
3309216|NCT00338689|Experimental|Lower protein formula|"Intervention: Infant formula with relatively low protein content (1.25 g/ 100 ml) during the first year of life; described as Lower protein formula"
3309217|NCT00338689|Placebo Comparator|Higher protein formula|"Intervention: Infant formula with a relatively high protein content (2.05 g/ 100 ml) during the first year of life; described as Higher protein formula"
3309218|NCT00338689|No Intervention|Breastfed reference group|Non-randomized breastfed group of infants at least 3 months exclusively breastfed
3309219|NCT00338598|Experimental|Glycine|Glycine, 0.8 gr per kg given in two daily doses
3309220|NCT00338598|Placebo Comparator|placebo|placebo will be administered.
3309221|NCT00338572|Active Comparator|1|12-week exercise program
3309222|NCT00338572|Experimental|2|12-week combined exercise and diet program
3309223|NCT00338572|No Intervention|3|Non-intervention group
3309224|NCT00338559||LMA group|Patients in which laryngeal mask airway (LMA) is used.
3309225|NCT00338559||ET group|Patients in which endotracheal tube (ET) is used.
3309226|NCT00338520||Healthy Controls (HC)|Healthy control children will be enrolled from out-patient well-baby visits.
3309227|NCT00338520||Uncomplicated Malaria (UM)|Febrile children admitted to the hospital with Plasmodium falciparum parasitemia, no other cause of fever identified, no evidence of severe malaria (as listed in Study Protocol, Section 5.2 under exclusion criteria for UM), and no co-infection with other malaria species will be enrolled in the UM group.
3309228|NCT00338520||Cerebral Malaria (CM)|Comatose children admitted to the hospitals will be evaluated by the house physician and/or member of the study team. If lumbar puncture is obtained, the parent or guardian will be approached for permission to enroll the child into the study. Parasitemic children with no other cause of coma identified will included in the CM group.
3309229|NCT00338520||Non-malaria CNS disease (NMC)|Children without parasitemia and diagnosed with a non-malaria cause of coma or CNS disease will be enrolled in the non-malaria CNS disease group.
3309230|NCT00338494|Experimental|1|
3309231|NCT00338481|Active Comparator|1|
3309232|NCT00338481|Active Comparator|2|
3309233|NCT00338455|Experimental|001|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min
3309234|NCT00338455|Placebo Comparator|002|Placebo+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min
3309235|NCT00338429|Experimental|Treatment: FHP Sleep Program|Stratified with or without behavior Disorder Diagnosis (ADHD): 50% randomized to receive Better Days, Better Nights- sleep distance intervention
3309236|NCT00338429|No Intervention|Control: Usual Care|Stratified with/without behavior diagnosis (ADHD): 50% randomized to receive usual care for sleep disorder
3309237|NCT00338390|No Intervention|1|Maintain antiretroviral treatment
3309238|NCT00338390|Experimental|2|Change tenofovir to abacavir and increase didanosine dose to 400 mg/day if weight is > 60 Kg. or to 250mg/day if weight is < 60 kg.
3309239|NCT00338390|Experimental|3|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
3309240|NCT00338377|Experimental|Group A: Chemotherapy + IL-2 plus T-cells|Cyclophosphamide 60 mg/kg/d by vein (IV) over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
3309282|NCT00337818|Experimental|Cervarix New Process|Subjects aged 15 to 25 years received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the new manufacturing process.
3309283|NCT00337818|Experimental|Cervarix Old Process Group|Subjects aged 15 to 25 years who received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the old manufacturing process.
3310789|NCT00318331|No Intervention|B|No enteral glutamine given
3309241|NCT00338377|Experimental|Group B: Chemotherapy + IL-2 plus T-Cells + Vaccine|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
3309242|NCT00338377|Experimental|Group C: Prior Treatment with BRAF Inhibitor|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
3309243|NCT00338377|Experimental|Group D: Leptomeningeal Disease|"T-cells: 5.0x109 TIL administered on Day 1 and 10x109 TIL on Day 15.~IL-2: 1.2 MIU of IL- 2 on Days 2, 4, 9, 11, 16 and 18 as tolerated. After this period, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks, patients switched to IL-2."
3309244|NCT00338364|Experimental|Treatment|50% randomized to receive distraction during painful procedure
3309245|NCT00338364|No Intervention|Control|50% randomized to receive no distraction during painful procedure
3309246|NCT00338325|Experimental|Treatment|50% randomized to receive treatment: reading pre-operatively
3309247|NCT00338325|No Intervention|Control|50% randomized to receive no intervention pre-operatively: no reading
3309248|NCT00338312|Placebo Comparator|1|Placebo patch
3309249|NCT00338312|Experimental|2|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
3309250|NCT00338286|Experimental|001|epoetin alfa + packed RBC transfusion 40 000 IU SC once a week.
3309251|NCT00338286|Other|002|Standard supportive care (packed RBC transfusion) Per doctor prescription
3309252|NCT00338273|Active Comparator|A1|
3309253|NCT00338273|Placebo Comparator|A2|
3309254|NCT00338234||Cardiac surgery|Successive cardiac surgery patients
3309255|NCT00338234||Surgical ICU|Successive patients admitted to the surgical ICU for more than 7 days, and experiencing anemia
3309256|NCT00338208|No Intervention|No training|Subjects will be fitted with low vision devices; no extra training will be provided.
3309257|NCT00338208|Experimental|Training in the Use of Low Vision Devices|Subjects will be fitted with low vision devices and will receive 6 training sessions with prescribed devices for up to 1 hour each time
3309258|NCT00338195|No Intervention|Delayed intervention control|
3309259|NCT00338182|Experimental|AZD1152|AZD1152 treatment given for 2 days every 14 days (2 treatment days followed by 12 days off treatment)
3309260|NCT00338130|Active Comparator|1|Temozolomide
3309261|NCT00338130|Experimental|2|AZD6244
3309262|NCT00338104|Experimental|40% Glargine|Patients will receive a dose of glargine insulin equal to 40% of insulin drip rate.
3309263|NCT00338104|Experimental|60% Glargine|Patients will receive a dose of glargine insulin equal to 60% of insulin drip rate.
3309264|NCT00338104|Experimental|80% Glargine|Patients will receive a dose of glargine insulin equal to 80% of insulin drip rate.
3309265|NCT00338065|Experimental|Subjects with autonomic dysfunction|"Subjects with known autonomic dysfunction diagnoses as defined by the General Clinical Research Center (GCRC) such as pure autonomic failure, Postural orthostatic tachycardia syndrome (POTS), and Multiple System Atrophy( MSA).~Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
3309266|NCT00338065|Experimental|Primary open-angle glaucoma subjects|"Subjects diagnosed with primary open-angle glaucoma following a glaucoma specialist's examination.~Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
3309267|NCT00338065|Experimental|Subjects with normal-pressure glaucoma|"Subjects with open-angle glaucoma damage following a glaucoma specialist's examination without ever an intraocular pressure recording greater than 21 mm Hg.~.1. Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~2. Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
3309268|NCT00338065|Active Comparator|Normal subjects|"Subjects without evidence of glaucoma or autonomic dysfunction.~..1. Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~2. Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
3309269|NCT00338039|Experimental|Chemotherapy + Chemoradation|Systemic chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. Cetuximab 500 mg/m^2 intravenous (IV)/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy. Induction Therapy Gemcitabine 1 gm/m^2 over 100 minutes every 2 weeks +/-1 day for 4 doses; Induction Chemotherapy Oxaliplatin 100 mg/m^2 over 120 minutes every 2 weeks +/-1 day for 4 doses. Capecitabine Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m^2 by mouth (PO) twice daily Monday-Friday throughout radiation. Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.
3309270|NCT00338026|Experimental|ECO-4601|
3309271|NCT00337974|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
3309272|NCT00337974|Active Comparator|Active Control|Educational DVDs
3309273|NCT00337974|No Intervention|No Contact Control|
3309274|NCT00337935|Experimental|Epoetin Alfa|
3309275|NCT00337935|Other|Group 2|Standard treatment of anemia excluding use of erythropoetin stimulating agents (ESAs).
3309276|NCT00337909|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
3309277|NCT00337909|Active Comparator|Active Control|Educational DVDs
3309278|NCT00337909|No Intervention|No Contact Control|
3309279|NCT00337896||observation|healthy adults ages 18-64 years, enrolled at Stanford University Hospital and participating in another clinical trial (DMID Protocol 04-062)
3314382|NCT00269360|Experimental|2|
3309284|NCT00337818|Experimental|Cervarix Young/Lot 1 Group|Subjects aged 10 to 14 years, who received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the new manufacturing process (Lot 1).
3309285|NCT00337805|Active Comparator|1 colloid|Boluses of fluids are a pentastarch (up to 1000 ml)
3309286|NCT00337805|Active Comparator|2. Crytalloid|Boluses are given as normal saline
3309287|NCT00337779|Active Comparator|glatiramer acetate 40 mg|
3309288|NCT00337779|Active Comparator|glatiramer acetate 20 mg|
3309289|NCT00337766|Active Comparator|Desmopressin (DDAVP)|
3309290|NCT00337766|Placebo Comparator|Placebo|
3309291|NCT00337753|Active Comparator|Cognitive Behavioral Therapy|Weekly Cognitive Behavior therapy
3309292|NCT00337753|Other|Wait-list|Subjects in wait-list for six-weeks
3309293|NCT00337727|Other|1|Arm 1: Day 1: aprepitant 125 mg capsule; ondansetron 8 mg capsule prior to chemotherapy and 1 8mg capsule 12 hrs after first dose; dexamethasone 12 mg tablets + 2 dexamethasone Pbo tablets. Day 2: Aprepitant 80 mg capsule; Ondansetron 8 mg capsule every 12 hours Day 3: Aprepitant 80 mg capsule Ondansetron 8 mg capsule every 12 hours.
3309294|NCT00337727|Other|2|Arm 2: Day 1: Aprepitant 125 mg Pbo capsule; Ondansetron 8 mg capsule prior to chemotherapy and 8 mg capsule 12 hours after first dose; Dexamethasone 20 mg tablets. Day 2: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours; Day 3: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours. 3 Day treatment period Optional cycle 2 is being offered to patients. Optional cycle 2 will substitute aprepitant with fosaprepitant dimeglumine 115 mg or Pbo on day 1. All other dosing regimen will remain the same as cycle 1.
3309295|NCT00337714|Placebo Comparator|A|in this arm conventional CVCs will be inserted
3309296|NCT00337714|Active Comparator|B|group B will receive medicated silver nanoparticles CVC
3309297|NCT00337701|Experimental|1|
3309298|NCT00337701|Experimental|2|
3309299|NCT00337675|Active Comparator|Arm 1: drug + episodic supplemental placebo|Montelukast once a day (qd) + episode driven supplemental placebo qd for 12 days for a 52-wk treatment period
3309300|NCT00337675|Active Comparator|Arm 2: placebo comparator + episodic supplemental drug|Placebo qd + episode driven supplemental Montelukast qd for 12 days for a 52-wk treatment period
3309301|NCT00337675|Placebo Comparator|Arm 3: placebo comparator + episodic supplemental placebo|Placebo qd + episode driven supplemental placebo qd for 12 days for a 52-wk treatment period
3309302|NCT00337662|Experimental|1|Olanzapine for Not Early Onset response (NEO) patients
3309303|NCT00337662|Active Comparator|2|Risperidone for Not Early Onset response (NEO) patients
3309304|NCT00337662|Active Comparator|3|Risperidone for Early Onset response (EO) patients
3309305|NCT00337649|Experimental|1|
3309306|NCT00337636|Experimental|HuCNS-SC|human central nervous system stem cells
3309307|NCT00337610|Experimental|sitagliptin 100 mg once a day (q.d.)/metformin ≥1500 mg a day|
3309308|NCT00337610|Placebo Comparator|sitagliptin 100 mg placebo q.d./ metformin ≥ 1500 mg/day|
3309309|NCT00337571|Experimental|A1|5 mg
3309310|NCT00337571|Experimental|A2|10 mg
3309311|NCT00337571|Experimental|A3|15 mg
3309312|NCT00337571|Placebo Comparator|B1|
3309313|NCT00337558|Experimental|1|Solifenacin succinate
3309314|NCT00337558|Experimental|2|Solifenacin succinate and simplified bladder training
3309315|NCT00337532|Active Comparator|paclitaxel-cisplatin combination regimen|
3309316|NCT00337519|Experimental|1|see detailed description
3309317|NCT00337493|Experimental|1|
3309318|NCT00337493|Experimental|2|
3309319|NCT00337493|Experimental|3|
3309320|NCT00337480|No Intervention|conventional|This arm is the conventional way of taking care of patients after an acute coronary syndrome
3309321|NCT00337480|Active Comparator|structured|This arm is an active way to monitor and educate patients after their acute coronary syndrome, with the intervention of health members in a House of Education
3309322|NCT00337467|Experimental|A1|
3309323|NCT00337454|Experimental|A1|
3309324|NCT00337454|Experimental|A2|
3309325|NCT00337454|Experimental|A3|
3309326|NCT00337454|Experimental|B1|
3309327|NCT00337454|Experimental|B2|
3309328|NCT00337454|Experimental|B3|
3309329|NCT00337428|Experimental|Group 1|Concomitant/CMF
3309330|NCT00337428|Experimental|Group 2|Non-Concomitant/CMF
3309331|NCT00337428|Experimental|Group 3|Concomitant/FMF
3309332|NCT00337428|Experimental|Group 4|Non-Concomitant/FMF
3309333|NCT00337389|Experimental|1|CoFactor, 5-FU, Avastin
3309334|NCT00337389|Active Comparator|2|Leucovorin, 5-FU, Avastin
3309335|NCT00337376|Experimental|1|
3309336|NCT00337350|Active Comparator|rosiglitazone|rosiglitazone 4mg/day
3309337|NCT00337350|Placebo Comparator|placebo|matched placebo for 4mg rosiglitazone
3309338|NCT00337298|Experimental|1|Crossover design. Arm is same all the way
3309339|NCT00337285|Experimental|1|
3309340|NCT00337272|Placebo Comparator|1 (Placebo)|Patients will take placebo 30 minutes before bedtime days 1-28 of treatment period.
3309341|NCT00337272|Active Comparator|2 (Ramelteon)|Patients will take 8 mgs of ramelteon 30 minutes before bedtime days 1-28 of treatment period.
3309342|NCT00337259|Experimental|Gemcitabine|"histologically confirmed marginal zone lymphoma~gemcitabine 1,250 mg/m2 on days 1 and 8 of each cycle, repeated every 3 weeks and continued for 6 cycles, until disease progression, withdrawal due to toxicity, or withdrawal of consent."
3309343|NCT00337207|Experimental|Avastin|
3309344|NCT00337194|Experimental|Arm I (SGN-30, chemotherapy)|"Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.~No prior stem cell transplant:~SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 20 mg/m^2 IV days 1 & 8, gemcitabine: 1000 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 & 8.~Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 15 mg/m^2 IV days 1 & 8, gemcitabine: 800 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 & 8."
3309383|NCT00336622|Experimental|Experimental|Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises
3309384|NCT00336622|Active Comparator|Control|Off-the-shelf splint
3309345|NCT00337194|Active Comparator|Arm II (placebo, chemotherapy)|"Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.~No prior stem cell transplant:~SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 20 mg/m^2 IV days 1 & 8, gemcitabine: 1000 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 & 8.~Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 15 mg/m^2 IV days 1 & 8, gemcitabine: 800 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 & 8."
3309346|NCT00337181||Vaccine Group|Received vaccination in RV144
3309347|NCT00337181||Placebo Group|Received placebo in RV144
3309348|NCT00337168|Experimental|Induc, ReInduc, Consol, clofarabine, cytarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
3309349|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 1|25 kBq/kg b.w., 3 times at 6 week intervals
3309350|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 2|50 kBq/kg b.w., 3 times at 6 week intervals
3309351|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 3|80 kBq/kg b.w., 3 times at 6 week intervals
3309352|NCT00337129|Experimental|eribulin mesylate|eribulin mesylate
3309353|NCT00337103|Experimental|1|
3309354|NCT00337103|Active Comparator|2|
3309355|NCT00337077|Experimental|Eribulin mesylate|Patients receive eribulin mesylate IV over 5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3309356|NCT00337051|Experimental|S|General Anesthesia with sevoflurane (inhalation) as hypnotic
3309357|NCT00337051|Active Comparator|P|General Anesthesia With Propofol TCI
3309358|NCT00336973|Experimental|1|
3309359|NCT00336960|Experimental|treatment intervention|
3309360|NCT00336934|Experimental|Arm I|Patients receive oral pomegranate extract daily.
3309361|NCT00336934|Placebo Comparator|Arm II|Patients receive oral placebo daily.
3309362|NCT00336921|Active Comparator|1|Alfuzosin 10mg
3309363|NCT00336921|Placebo Comparator|2|Placebo
3309364|NCT00336895|Experimental|Liver Transplant Subjects|All subjects in this study will receive Myfortic 360mg or 720 mg BID for 90 days.
3309365|NCT00336882|Active Comparator|1|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
3309366|NCT00336882|Experimental|2|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
3309367|NCT00336856|Experimental|IRINOTECAN AND CETUXIMAB|Cetuximab will be administered at the dose of 500 mg/m2 intravenously (IV) over 120 minutes, followed by 500 mg/m2 every 2 weeks, IV over 2 hours at an infusion rate not to exceed 5 ml/min. Followed immediately by Irinotecan administered at a dose of 180 mg/m2 IV over 60 minutes every two weeks.
3309368|NCT00336843|Experimental|Zevalin-BuCyE|histologically confirmed, relapsed or refractory CD20 positive B-cell NHL including diffuse large B-cell, follicular, mantle cell, and Burkitt lymphomas.
3309369|NCT00336830|Active Comparator|Usual Care|Comparator without MD endorsement of Cardiac Rehabilitation
3309370|NCT00336830|Experimental|MD Endorsment of CR|Provided with MD endorsement of participation in Cardiac Rehabilitation
3309371|NCT00336817|Active Comparator|Myfortic Group|Subjects in the Myfortic arm will receive Myfortic 360mg or 720 mg BID for 90 days
3309372|NCT00336817|Active Comparator|CellCept Group|Subjects in the CellCept arm will receive CellCept 500mg or 1000mg BID for 90 days
3309373|NCT00336791|Experimental|Paclitaxel + Additional FAC/FEC|"12 weekly Paclitaxel treatments 80 mg/m^2 by vein (IVPB) over 1 hour + 4 additional FAC or FEC combination chemotherapy treatments; FAC or FEC treatments given once every 3 weeks.~FAC Chemotherapy: 5-Fluorouracil 500 mg/m^2 intravenous (IV) day 1 & 4 + Doxorubicin 50 mg/m^2 IV day 1 over 72 hour continuous infusion or IV bolus + Cyclophosphamide 500 mg/m^2 IV day 1.~FEC Chemotherapy: 5-Fluorouracil 500 mg/m^2 IV day 1 + Epirubicin 100 mg/m^2 IV day 1 + Cyclophosphamide 500 mg/m^2 IV day 1."
3309374|NCT00336791|Active Comparator|FAC/FEC|"6 courses FAC or FEC Combination Chemotherapy~FAC Chemotherapy: 5-Fluorouracil 500 mg/m^2 intravenous (IV) day 1 & 4 + Doxorubicin 50 mg/m^2 IV day 1 over 72 hour continuous infusion or IV bolus + Cyclophosphamide 500 mg/m^2 IV day 1.~FEC Chemotherapy: 5-Fluorouracil 500 mg/m^2 IV day 1 + Epirubicin 100 mg/m^2 IV day 1 + Cyclophosphamide 500 mg/m^2 IV day 1."
3309375|NCT00336752|Active Comparator|1|Non operative treatment of Weber B ankle fracture. Use of cast, with no surgical intervention
3309376|NCT00336752|Active Comparator|2|Operative treatment of Weber B ankle fracture. Open reduction and internal fixation to repair a broken bones.
3309377|NCT00336713|Experimental|Saredutant 100 mg|Saredutant 100 mg once daily in the morning for a maximum of 64 weeks
3309378|NCT00336713|Placebo Comparator|Placebo|Placebo for Saredutant once daily in the morning during the maintenance phase for a maximum of 52 weeks
3309379|NCT00336700|Experimental|Gemcitabine and Erlotinib|Erlotinib (oral) 150 mg/day x 12 months Gemcitabine 1500 mg/m2 IV over 150 minutes q 2 weeks x 4 months
3309380|NCT00336674|Active Comparator|DV001|Recombinant human intranasal insulin formulation in a buffered solution of benzalkonium chloride and glycerol presented in multi-dose nasal spray devices with actuators (Pfeiffer) designed to deliver 100ul spray doses to nasal mucosa. The product is formulated at a dose strength of 1100 IU / mL (40mg/mL) manufacturing formulation. The product will be self administered by eligible participants as two 100 microlitre spray doses per nostril. Treatment will be administered daily for 7 consecutive days then on one day each week for 12 months. Participants will be followed until they develop diabetes or until 5 years after the last participant has been randomised (maximum period of follow up is expected to be 10 years.
3309381|NCT00336674|Placebo Comparator|Placebo|Placebo insulin carrier solution of benzalkonium chloride and glycerol presented in multi-dose nasal spray devices with actuators (Pfeiffer) designed to deliver 100ul spray doses to nasal mucosa. The product will be self administered by participants as two 100 microlitre spray doses per nostril. Treatment will be administered daily for 7 consecutive days then on one day each week for 12 months. Participants will be followed until they develop diabetes or until 5 years after the last participant has been randomised (maximum period of follow up is expected to be 10 years.
3309382|NCT00336648|Experimental|Gemcitabine + Avastin + Surgery|Gemcitabine plus Avastin-based chemoradiation followed by pancreaticoduodenectomy
3314383|NCT00269360|Active Comparator|3|
3309385|NCT00336583|Experimental|Oxaliplatin, response|relapsed or refractory non-Hodgkin's lymphoma
3309386|NCT00336557||Regularly Scheduled NAb Testing Arm|Subjects will be scheduled for 5 study visits over the course of 12 months and any NAbs test results will be available to the investigator during the study.
3309387|NCT00336557||Usual Care Arm|Subjects will be scheduled for 2 study visits over the course of 12 months and any NAbs test results will be unknown by the investigator until the conclusion of the subject's study participation.
3309388|NCT00336544|Experimental|Cethromycin|
3309389|NCT00336544|Active Comparator|Clarithromycin|
3309390|NCT00336505|Active Comparator|Clarithromycin|
3309391|NCT00336505|Experimental|Cethromycin|
3309392|NCT00336492|Experimental|002|infliximab infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
3309393|NCT00336492|Experimental|001|infliximab infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
3309394|NCT00336479|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
3309395|NCT00336479|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
3309396|NCT00336479|Experimental|Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks.
3309397|NCT00336479|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 12 weeks.
3309398|NCT00336453|Experimental|FluBlok-22.5 μg, 6-35 months old|6-35 months old, FluBlok-22.5 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
3309399|NCT00336453|Experimental|FluBlok-45 μg, 6-35 months old|6-35 months old, FluBlok-45 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
3309400|NCT00336453|Active Comparator|TIV-7.5 μg, 6-35 months old|6-35 months old, 2006-2007 formulation of Fluzone, (sanofi-pasteur, Swiftwater, PA)-7.5 μg of each hemagglutinin antigen: A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Malaysia/2506/2004 like viruses
3309401|NCT00336453|Active Comparator|TIV-15 μg, 36-59 months old|36-59 months old, 2006-2007 formulation of Fluzone (sanofi-pasteur, Swiftwater, PA)-15 μg of each hemagglutinin antigen: A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Malaysia/2506/2004 like viruses
3309402|NCT00336453|Experimental|FluBlok-45 μg, 36-59 months old|36-59 months old, FluBlok-45 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
3309403|NCT00336375|Experimental|1|All treatment doses accompanied with intake of fatty food
3309404|NCT00336375|Active Comparator|2|All treatment doses not-accompanied with intake of fatty food.
3309405|NCT00336362|Active Comparator|1|Participants will receive hydroxyurea pretreatment.
3309406|NCT00336362|No Intervention|2|Participants will not receive hydroxyurea pretreatment.
3309407|NCT00336336|Experimental|1|N-3PUFA
3309408|NCT00336336|Placebo Comparator|2|
3309409|NCT00336336|Experimental|3|Rosuvastatin
3309410|NCT00336336|Placebo Comparator|4|
3309411|NCT00336323|Active Comparator|1|Laser photocoagulation at baseline
3309412|NCT00336323|Experimental|2|1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks
3309413|NCT00336323|Experimental|3|2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks
3309414|NCT00336323|Experimental|4|1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
3309415|NCT00336323|Experimental|5|1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
3309416|NCT00336284|Active Comparator|Home Monitoring|Home Monitoring programmed on.
3309417|NCT00336284|Other|In-Office Conventional Follow-up|Home Monitoring programmed off.
3309418|NCT00336245|Experimental|Copper T Intrauterine Contraceptive Device|
3309419|NCT00336245|Active Comparator|Hormonal Contraception|
3309420|NCT00336232|Experimental|Diet Intervention|28 day diet low vitamin K, 28 day diet high vitamin K
3309421|NCT00336219|Active Comparator|1|Pantoprazole 40 mg
3309422|NCT00336193|Experimental|Home visitation|In the intervention condition, nurse home visitors receive enhanced training to improve delivery of parenting interventions to mothers
3309423|NCT00336180|Experimental|HW|The experimental group (HW) receives 18 classroom-based lessons on leisure motivation, life skills, and skills to avoid substance use and sexual risk.
3309424|NCT00336141|Experimental|Vorinostat|
3309425|NCT00336102||Group 1 Breast Cancer Patient Cases|"Patients between the ages of 25 and 75, diagnosed with primary, operable, stage I-III B breast cancer with planned chemotherapy regimen Adriamycin / Cytoxan (AC) plus a taxane are trial candidates.~Will have physiologic testing at baseline to assess thyroid function and fatigue assessment and management inventory. Will follow-up on management of therapy complications for thyroid disorder if one identified or until off study."
3314384|NCT00269321|Experimental|1|
3309426|NCT00336102||Group 2 Healthy Controls|"Controls will be women from the same general demographic area as Group 1 Cases, have no prior history of cancer and be within 5 years of the Group 1 case's age (+/- 5 years).~Will have physiologic testing at baseline to assess thyroid function and fatigue assessment and management inventory. Will follow-up on management of therapy complications for thyroid disorder if one identified or until off study."
3309427|NCT00336076||Participants evaluated for mastocytosis|Observational study of all patients referred for suspected mast cell disease. Collection of blood or bone marrow for analysis during diagnostic procedures.
3309428|NCT00336063|Experimental|Treatment (azacitidine, vorinostat)|Patients receive azacitidine SC on days 1-10 and vorinostat PO BID on days 1-14. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3309429|NCT00336024|Active Comparator|Arm I (induction+consolidation chemotherapy, autologous PBSC))|"Patients receive vincristine sulfate IV on days 1, 8, and 15; etoposide IV over 1 hour on days 1-3; cyclophosphamide IV over 1 hour on days 1 and 2; cisplatin IV over 6 hours on day 3. Treatment repeats every 3 weeks for 3 courses.~Within 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and filgrastim (G-CSF) IV or SC beginning on day 54 and continuing until blood counts recover. Patients also receive autologous PBSC IV on day 4. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity."
3309430|NCT00336024|Experimental|Arm II (induction+consolidation chemotherapy, autologous PBSC)|"Patients receive vincristine sulfate IV on days 1, 8, and 15; high-dose methotrexate IV over 4 hours on day 1; and leucovorin calcium IV or orally every 6 hours beginning on day 2 and continuing until methotrexate levels are in a safe range. Patients then receive etoposide IV over 1 hour on approximately days 4, 5, and 6, cyclophosphamide IV over 1 hour on approximately days 4 and 5, and cisplatin IV over 6 hours on approximately day 6. Treatment repeats every 3 weeks for 3 courses.~Within 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and filgrastim (G-CSF) IV or SC beginning on day 54 and continuing until blood counts recover. Patients also receive autologous PBSC IV on day 4. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity."
3309431|NCT00335998|Experimental|Treatment (triapine)|"Group 1: Patients undergo external-beam pelvic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33. Patients also receive 3-AP IV over 2 hours on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33 and cisplatin IV over 1½ hours on day 2, 9, 16, 23, and 30.~Group 2: Patients undergo external-beam pelvic radiotherapy and receive 3-AP as in group 1.~In both groups, patients undergo intracavitary or interstitial brachytherapy at least once weekly for 3-5 weeks during or after external-beam radiotherapy as per standard of care."
3309432|NCT00335985|Experimental|1|
3309433|NCT00335985|Placebo Comparator|2|
3309434|NCT00335972|Active Comparator|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
3309435|NCT00335972|Active Comparator|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
3309436|NCT00335959|Experimental|Chemotherapy, Chemoradiation, Surgery|"Chemotherapy: Oxaliplatin, 130 mg/m2, 2 hour IV infusion on Days 1 and 22; Capecitabine 850 mg/m2/dose, PO q 12 hours on Days 1-14 and 22-35 Chemoradiation: Capecitabine 650 mg/m2/dose, PO q 12 hours on days 43-77; Radiation therapy 180 cGy/day, 5 days/week beginning on Day 43.~Surgery: Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy"
3309437|NCT00335829|Experimental|single arm, received bevacizumab and TACE|
3309438|NCT00335816|Experimental|Group 1 (Closed to Enrollment)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil intravenously continuously over 24 hours 7 days a week for 6 weeks. Patients undergo standard surgical resection after completion of chemoradiation therapy..
3309439|NCT00335816|Experimental|Group 2 (Closed to Enrollment)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1-2. Treatment repeats every 14 days for 2 courses. After the last week of post-radiation chemotherapy, patients undergo standard surgical resection.
3309440|NCT00335816|Experimental|Group 3 (chemotherapy, FOLFOX, conventional surgery)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy as in group II. Treatment repeats every 14 days for 4 courses. After the last week of post-radiation chemotherapy, patients undergo standard surgical resection.
3309441|NCT00335816|Experimental|Group 4 (chemotherapy, FOLFOX, conventional surgery)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy as in group II. Treatment repeats every 14 days for 6 courses. After the last week of post- radiation chemotherapy, patients undergo standard surgical resection. Patients then receive 3 additional courses of FOLFOX-6 chemotherapy or other chemotherapy off study as directed by the physician.
3309442|NCT00335777|Experimental|Migranal treatment first treatment phase|All subjects were asked to treat one headache at 1 hour (early) and one headache at 4 hours after onset of throbbing (late). Dose of nasal spray constant for both time points. The subject could determine the order in which they could treat the headaches (early (first treatment phase) then late (second treatment phase), or late (first treatment phase) then early (second treatment phase).
3309522|NCT00334815|Experimental|Group 2 (cisplatin, etoposide, radiotherapy, bevacizumab)|Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 15, 36, and 57.
3310790|NCT00318292|Experimental|PLA|Active preemptive local analgesia.
3309443|NCT00335777|Experimental|Migranal second treatment phase|All subjects were asked to treat one headache at 1 hour (early) and one headache at 4 hours after onset of throbbing (late). Dose of nasal spray constant for both time points. The subject could determine the order in which they could treat the headaches (early (first treatment phase) then late (second treatment phase), or late (first treatment phase) then early (second treatment phase).
3309444|NCT00335764|Experimental|Group 1|Patients receive oral sorafenib tosylate twice daily and oral erlotinib hydrochloride once daily on days 1-28.
3309445|NCT00335764|Experimental|Group 2|Patients receive sorafenib tosylate as in group 1. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
3309446|NCT00335764|Experimental|Group 3|Patients receive sorafenib tosylate as in group 1. Patients also receive oral tipifarnib twice daily on days 1-21.
3309447|NCT00335751|Experimental|positron emission tomography computed tomography (PET/CT)|The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
3309448|NCT00335738|Experimental|Group 1 (identified by central review as high risk)|Includes patients who may or may not require chemotherapy. Patients who require chemotherapy receive vincristine IV and carboplatin IV over 1 hour on day 1 and etoposide IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity and patients who complete chemotherapy are followed after completion of therapy periodically for at least 5 years. Patients who do not require chemotherapy undergo observation periodically for at least 5 years.
3309449|NCT00335738|No Intervention|Group 2 (identified by central review as not high risk)|Patients undergo observation periodically for at least 5 years.
3309450|NCT00335725|Experimental|Fostimon|Fostimon is an highly purified FSH preparation.
3309451|NCT00335725|Active Comparator|Gonal-F|Gonal-F is a recombinant FSH preparation.
3309452|NCT00335686|No Intervention|1|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
3309453|NCT00335686|No Intervention|2|Nevirapine (Viramune): 1 comp (200mg)/12h
3309454|NCT00335595|Active Comparator|1|XELOXA
3309455|NCT00335595|Experimental|2|XELOXA-A
3309456|NCT00335556|Experimental|Surgery|Patients with completely resectable stage I-IV RCC undergo surgical resection. Patients with incompletely resectable stage III-IV RCC undergo treatment as per physician's choice.
3309457|NCT00335556|Experimental|Treatment (UH-1)|Patients receive combination chemotherapy comprising vincristine, doxorubicin hydrochloride, cyclophosphamide, etoposide, and carboplatin. Patients whose primary tumors were initially resected undergo radiotherapy once daily 5 days a week for 4-5½ weeks beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13. Patients with unresectable clear cell sarcoma of the kidney (CCSK) receive no further study therapy.
3309458|NCT00335556|Experimental|Treatment (window/UH-1)|Patients receive vincristine IV on days 1 and 8 and irinotecan hydrochloride IV over 30 minutes on days 1-5 and 8-12 (course 1). Patients with progressive disease (PD) are treated with regimen UH-1. Patients with stable disease (SD), partial response (PR), or complete response (CR) receive another course of irinotecan hydrochloride/vincristine window therapy beginning on day 22. After the second course, patients with SD or PD are treated with regimen UH-1 and patients with PR or CR are treated with regimen UH-2.
3309459|NCT00335556|Experimental|Treatment (UH-2)|Patients receive combination chemotherapy comprising vincristine, doxorubicin hydrochloride, cyclophosphamide, etoposide, carboplatin, and irinotecan hydrochloride. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 7. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 7.
3309460|NCT00335556|Experimental|Treatment (regimen I)|Patients receive vincristine, doxorubicin hydrochloride, cyclophosphamide, and etoposide. Patients whose primary tumors were initially resected (except those with stage I CCSK) undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13.
3309461|NCT00335556|Experimental|Treatment (regimen DD-4A)|Patients receive dactinomycin, vincristine, and doxorubicin hydrochloride. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13.
3309462|NCT00335517|Experimental|10mg Depodur|
3309463|NCT00335517|Experimental|15mg DepoDur|
3309464|NCT00335504|Experimental|Arm I (atorvastatin calcium)|Patients receive oral atorvastatin once daily.
3309465|NCT00335504|Experimental|Arm II (sulindac)|Patients receive oral sulindac twice daily.
3309466|NCT00335504|Experimental|Arm III (oligofructose-enriched inulin)|Patients receive oral oligofructose-enriched inulin (Raftilose Synergy 1) twice daily.
3309467|NCT00335504|Placebo Comparator|Arm IV (placebo)|Patients receive an oral placebo twice daily.
3309468|NCT00335478|Experimental|Daptomycin|
3309469|NCT00335452|Experimental|Clopidogrel high dose treatment regimen + ASA high dose|
3309470|NCT00335452|Experimental|Clopidogrel high dose treatment regimen + ASA low dose|
3309471|NCT00335452|Active Comparator|Clopidogrel standard treatment regimen + ASA high dose|
3309472|NCT00335452|Active Comparator|Clopidogrel standard treatment regimen + ASA low dose|
3309473|NCT00335374|Experimental|1|
3309474|NCT00335348|Experimental|Bortezomib and Dexamethasone|
3309475|NCT00335322|Active Comparator|1|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin efavirenz)
3309476|NCT00335322|Active Comparator|2|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)
3309477|NCT00335322|Experimental|3|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
3309575|NCT00333918|Experimental|1-bromfenac ophthalmic solution|sterile ophthalmic solution
3314385|NCT00269321|Experimental|2|
3309478|NCT00335309|Experimental|1|The Investigational arm is treated with sinus irrigation with normal saline 0.9% and intravenous antibiotics of Augmentin 1 gram 3 times a day for 4 days, and then per os (PO) Augmentin 875mg twice a day (BID) for another 10 days. The treatment is done while the patient is admitted to the otolaryngology - head and neck surgery department.
3309479|NCT00335309|Active Comparator|2|The control arm is treated with the same intravenous antibiotics of Augmentin 1 gram 3 times a day for 4 days, and then per os (PO) Augmentin 875mg twice a day (BID) for another 10 days. There is no sinus irrigation with normal saline for this arm. The treatment is done while the patient is admitted to the otolaryngology - head and neck surgery department.
3309480|NCT00335283|Active Comparator|Lansoprazole|
3309481|NCT00335283|Placebo Comparator|Sugar Pill|
3309482|NCT00335257||1|Users of OCs containing DRSP
3309483|NCT00335257||2|Users of OCs containing other progestins
3309484|NCT00335244|Experimental|1|Intravenous L-citrulline
3309485|NCT00335244|Placebo Comparator|2|Placebo of intravenous L-citrulline
3309486|NCT00335231|Experimental|gatifloxacin|one group will receive topical application of gatifloxacin prior to surgery,
3309487|NCT00335231|No Intervention|no eye drops|this group will receive no eye drops.
3309488|NCT00335218|Experimental|Arm 1|
3309489|NCT00335218|Placebo Comparator|Arm 2|
3309490|NCT00335192|Experimental|1|"Phase I: 3TC + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + LPV/rtv"
3309491|NCT00335192|Experimental|2|"Phase I: ABV + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: ABV + LPV/rtv"
3309492|NCT00335192|Experimental|3|"Phase I: 3TC + ABV + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + ABV + LPV/rtv"
3309493|NCT00335179|Active Comparator|Imiquimod cream|Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream Applied 3 times per week for 4 weeks
3309494|NCT00335179|Placebo Comparator|Vehicle cream|Vehicle cream 250 mg Applied 3 times per week for 4 weeks
3309495|NCT00335166|Experimental|1|
3309496|NCT00335166|Active Comparator|2|
3309497|NCT00335166|Placebo Comparator|3|
3309498|NCT00335153|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants were to receive LCIG, via the NJ tube during the nasojejunal (NJ) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.~The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the Post-PEG-J Long-Term Treatment Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour), in most instances."
3309499|NCT00335140|Experimental|Rituximab + standard chemotherapy|Rituximab + high dose methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine. Patients with meningeal involvement will receive additional methotrexate and leucovorin.
3309500|NCT00335075|Experimental|Temodal group|Subjects treated with temozolomide.
3309501|NCT00335075|Active Comparator|Semustine group|Subjects treated with semustine.
3309502|NCT00335049|Experimental|PAL|Progressive Addition Spectacle Lenses (PALs) with a +2.00 D add worn for first year off study. Single Vision Lenses worn for second year of study.
3309503|NCT00335049|Active Comparator|SVL|Single Vision Lenses (SVLs) worn both years of the study.
3309504|NCT00335036|Active Comparator|Thin leads|Thin (less than or equal to 7 French introducer) isodiametric ICD leads
3309505|NCT00335036|Active Comparator|Gore PTFE-coated|ICD lead with PTFE-coated coils
3309506|NCT00335023|Active Comparator|Red blood cell transfusion|At least one unit of red blood cells will be administered.
3309507|NCT00335023|No Intervention|Control|No red blood cell transfusion. Iron suppletion is allowed and can be administered according to local protocol. If suppletion is prescribed, the type and duration will be registered
3309508|NCT00334971|Other|1|Healthy Caucasian women 18-35 years old
3309509|NCT00334971|Other|2|Healthy African-American women 18-35 years old
3309510|NCT00334971|Other|3|Healthy Caucasian women 36-45 years old
3309511|NCT00334971|Other|4|Female fragile X premutation carriers 18-45 years old
3309512|NCT00334958|Placebo Comparator|Placebo|
3309513|NCT00334958|Active Comparator|Rufinamide|
3309514|NCT00334945||Growth Hormone|Patient ages 3-14 years receiving growth hormone for growth hormone deficiency or short stature
3309515|NCT00334945||Healthy Children|Children with normal stature ages 3-18 years.
3309516|NCT00334893|Experimental|Treatment (chemotherapy)|Patients receive eribulin mesylate IV over 15 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3309517|NCT00334867|Active Comparator|Arm I|Patients receive vincristine sulfate IV over 1 minute once a week on day 1 in weeks 1-3, 7-9, and 13-15; doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in weeks 1, 7, and 13; cyclophosphamide IV over 1 hour on day 1 in weeks 1, 7, and 13; and ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 in weeks 4, 10, and 16. Patients undergo local therapy comprising conventional surgery (surgical resection) in approximately week 18 and/or radiation therapy beginning in approximately week 19.
3309518|NCT00334867|Experimental|Arm II|Patients receive vincristine sulfate IV over 1 minute once a week on day 1 in weeks 1-3, 7-9, and 13-16; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 13; cyclophosphamide IV over 30 minutes on days 1-5 in weeks 1 and 13 and IV over 1 hour on day 1 in weeks 7 and 16; ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 in weeks 4 and 10; and doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in weeks 7 and 16. Patients also undergo local therapy comprising of conventional surgery (surgical resection) in approximately week 18 and/or radiation therapy beginning in approximately week 19. Patients then proceed to combination chemotherapy.
3309519|NCT00334828|Experimental|1|
3309520|NCT00334828|Placebo Comparator|2|
3309521|NCT00334815|Experimental|Group 1 (cisplatin, etoposide, radiotherapy)|Patients receive cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Patients undergo concurrent thoracic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47.
3309671|NCT00332774|Experimental|Nevanac|
3309523|NCT00334815|Experimental|Group 3 (cisplatin, etoposide, radiotherapy, bevacizumab)|Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 22, and 43.
3309524|NCT00334802|Experimental|A|
3309525|NCT00334789|Experimental|Treatment (belinostat, isotretinoin)|"Patients receive belinostat IV over 30 minutes on days 1-5 and isotretinoin PO QD on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of belinostat until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of therapy.~Once the MTD is determined, an expanded cohort of 10 patients are enrolled and treated at the MTD. These patients also undergo blood collection periodically during treatment for pharmacokinetic studies.~All patients undergo blood collection, buccal scrapings, and tumor biopsies periodically for biomarker, pharmacodynamic, gene expression, and laboratory studies."
3309526|NCT00334750||There is no intervention in this study|This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
3309527|NCT00334737|Experimental|Darbe|Darbepoetin 10 mics/kg/week x 10 weeks or until 35 completed weeks
3309528|NCT00334737|Active Comparator|Epo|Epo 400 units/kg three times a week SC x 10 weeks or until 35 completed weeks
3309529|NCT00334737|Placebo Comparator|placebo/control|Sham injection
3309530|NCT00334724|Active Comparator|1|Home blood pressure group
3309531|NCT00334724|Active Comparator|2|Office blood pressure group
3309532|NCT00334646|Experimental|Arm A|cyclophosphamide + dexamethasone + ondansetron
3309533|NCT00334646|Experimental|Arm B|cyclophosphamide + dexamethasone + ondansetron + GW679769
3309534|NCT00334633|Active Comparator|control|metronidazole 500 BID for 7 days
3309535|NCT00334633|Active Comparator|tinidazole 500|tinidazole 500 BID for 7 days
3309536|NCT00334633|Active Comparator|tinidazole 1 gm|tinidazole 1 gm BID for 7 days
3309537|NCT00334594|Active Comparator|No radiotherapy|
3309538|NCT00334594|Experimental|Radiotherapy|
3309539|NCT00334581|Experimental|1|Irbesartan 150mg
3309540|NCT00334581|Experimental|2|Irbesartan 300mg
3309541|NCT00334568|Experimental|Rosi XR|Rosi XR
3309542|NCT00334568|Placebo Comparator|Placebo|Placebo (matched)
3309543|NCT00334555|Active Comparator|usual care|patient told to refer her partner for treatment
3309544|NCT00334555|Active Comparator|partner delivered|patient given medication to deliver to her partners
3309545|NCT00334555|Active Comparator|field intervention|field intervention to find partners
3309546|NCT00334542|Experimental|Simvastatin|Simvastatin 40 mg for 24-28 weeks
3309547|NCT00334490|Active Comparator|1|Oral Sildenafil 12.5 mg
3309548|NCT00334490|Placebo Comparator|2|Placebo in 5 mls distilled water
3309549|NCT00334438|Other|Zevalin + Velcade Single Arm Study|Zevalin (Ibritumomab Tiuxetan) and Velcade (Bortezomib)
3309550|NCT00334373|Experimental|Post conditioning|Balloon inflations-deflations
3309551|NCT00334373|Placebo Comparator|Standard care|No balloon inflations
3309552|NCT00334360|Experimental|1|dexmedetomidine
3309553|NCT00334360|Experimental|2|Buspirone
3309554|NCT00334360|Experimental|3|Buspirone and dexmedetomidine
3309555|NCT00334360|Placebo Comparator|Control|No drug
3309556|NCT00334347|Active Comparator|Depakote ER|
3309557|NCT00334347|Active Comparator|Depakote DR|
3309558|NCT00334321|Experimental|IMRT with chemotherapy|"IMRT (upper third of vagina & para-vaginal tissue and the common, external and internal iliac nodal regions) 160-180 cGy daily fractions for a total dose of 4500-5120 cGy. Once a day treatment four to five days a week for approximately 6 weeks.~Intracavitary vaginal brachytherapy - some patients will be given this and it will be decided by the treating physician.~Carboplatin - AUC 6, IV over 30-60 minutes following completion of paclitaxel, given once every 3 weeks (3 weeks=1 cycles) for a total of 6 cycles~Paclitaxel - 175 mg/m2, 3 hour continuous IV infusion, administered prior to carboplatin, given once every 3 weeks (3 weeks=1 cycles) for a total of 6 cycles"
3309559|NCT00334282|Placebo Comparator|placebo arm|matching placebo (800 mg tablet) once daily
3309560|NCT00334282|Experimental|pazopanib arm|Oral pazopanib tablet 800 mg once daily continuously
3309561|NCT00334217|Experimental|1|PSS CogRehab exercises
3309562|NCT00334217|No Intervention|2|On-line computer games
3309563|NCT00334204|Other|Measure Platelet Function Analyser -100 (PFA-100)|measuring Platelet Function Analyser (PFA)-100 test (an in vitro platelet function test, in addition to the rest of the routine/uusal clinical care)
3309564|NCT00334139|Experimental|zoledronic acid|
3309565|NCT00334113|Experimental|Arm 1|Participants in this arm will meet with an exercise physiologist and obtain an exercise prescription for a walking program. In addition, they will recieve an intervention that will be delivered over an automated telephone system (TLC-PED). These automated phone calls with voice response and voice recognition capabilities will occur weekly over a 6 month period. During these calls, participants' physical activity will be monitored, new physical activities goals will be set, information about physical activity and the associated health benefits will be provided, and barriers to physical activity will be explored.
3309566|NCT00334113|No Intervention|Arm 2|"This is the treatment as usual condition. Participants in this condition will also have 2 sessions with an exercise physiologist and will receive an exercise prescription for a home based walking program. The will not receive the automated phone calls each week that are designed to motivate physical activity."
3309567|NCT00334100|Other|Arm 1|
3309568|NCT00334074|Experimental|Clofarabine and Cytarabine|Five consecutive days of clofarabine 40 mg/m^2 IVI over 1 hour followed 4 hours later by cytarabine 1000 mg/m^2 IVI over 2 hours
3309569|NCT00334022|Placebo Comparator|Did not receive enfuvirtide|patients were randomized to either receive enfuviratide or not receive it
3309570|NCT00334022|Active Comparator|enfuvirtide|enfuvirtide 1ml BID
3309571|NCT00333983|Experimental|Arm 1|Robot Exercise Group
3309572|NCT00333983|Active Comparator|Arm 2|Traditional Upper Extremity Exercise Group
3309573|NCT00333970|Experimental|cognitive remediation|cognitive remediation
3309574|NCT00333970|No Intervention|treatment as usual|treatment as usual
3309576|NCT00333918|Placebo Comparator|2-placebo comparator|sterile ophthalmic solution
3309577|NCT00333879|Other|Virtual Sound System|Efficacy of using a virtual sound system to simulate street crossing conditions.
3309578|NCT00333866|Experimental|1|
3309579|NCT00333866|Experimental|2|
3309580|NCT00333866|Experimental|3|
3309581|NCT00333866|Placebo Comparator|4|
3309582|NCT00333840|Experimental|imatinib (STI571)|In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injection for 10 days every month. Maximum study duration was 11.5 years.
3309583|NCT00333840|Active Comparator|IFN-a+Ara-C|In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.
3309584|NCT00333827|Active Comparator|Optimal Therapy|Optimal therapy for cardiac failure
3309585|NCT00333827|Experimental|cell therapy|stem cell
3309586|NCT00333814|Active Comparator|1|Dexamethasone 350 µg
3309587|NCT00333814|Active Comparator|2|Dexamethasone 700 µg
3309588|NCT00333814|Sham Comparator|3|Sham
3309589|NCT00333801|Active Comparator|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP). VRP is the treatment as usual, which mostly consisted of transitional work program (TWP) in which client is placed in a set-aside noncompetitive job for time-limited period and then pursues competitive employment at time of discharge from VRP. Limited integration with treatment team and limited follow-along supports that are time-limited.
3309590|NCT00333801|Experimental|Individual Placement and Support (IPS)|Inidividual Placement and Support (IPS). IPS Supported Employment involves an IPS specialists working with client to identify job preferences, rapidly begin community-based job search, engage in competitive employment, sustain employment via open-ended IPS follow-along supports, and integrate IPS within the PTSD treatment team.
3309591|NCT00333788|Experimental|Certolizumab pegol 400 mg|400 mg subcutaneous injection of certolizumab pegol every 2 (Q2W) or 4 (Q4W) weeks
3309592|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus placebo|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
3309593|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
3309594|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
3309595|NCT00333762|Experimental|SPAM and SWCS|Smart Power Assistance Module (SPAM) Smart Wheelchair Component System (SWCS)
3309596|NCT00333749|Experimental|1|55 children < 5 years with acute oral ulcer disease.
3309597|NCT00333749|Placebo Comparator|2|55 Children < 5 years with acute oral ulcer disease.
3309598|NCT00333710|Experimental|Individual face-to-face contact|Individual face-to-face contact treatment
3309599|NCT00333710|Experimental|Individual telephone contact|Individual telephone contact treatment
3309600|NCT00333710|No Intervention|Control condition/treatment as usual|Control condition/treatment as usual
3309601|NCT00333684|Active Comparator|receive bioalcamid at baseline|half subjects received bioalcamid at baseline
3309602|NCT00333684|Active Comparator|Receive bioalcamid at 24 weeks|other half of subjets received bioalcamid at 24 weeks
3309603|NCT00333658|Experimental|1|Intervention
3309604|NCT00333658|No Intervention|2|Work Services
3309605|NCT00333619|Experimental|Nonpharmacological sleep intervention|The intervention will combine: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies.
3309606|NCT00333619|Active Comparator|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
3309607|NCT00333580||Group 1|
3309608|NCT00333554|Experimental|DHA Treatment Group|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
3309609|NCT00333554|Placebo Comparator|Control Group|Placebo for DHA given to nursing mother (breast milk), study formula, or capsules (removing content and mixing with food)depending on age of child.
3309610|NCT00333541|Experimental|Treatment|follow-up via e-mail link to survey
3309611|NCT00333541|No Intervention|Control|standard follow-up by phone and in-person interview
3309612|NCT00333528|Experimental|1|Administration of one dose of the active drug (6 volunteers)
3309613|NCT00333528|Placebo Comparator|2|Administration of placebo (2 volunteers)
3309614|NCT00333515|Experimental|1|Administration of one of 3 doses (dose escalation) of the active drug (HuBChE). (Dose-escalation proceeds only after safety evaluation and after the previous dosage has been found to be acceptable by an independent Data Safety Monitoring Board.)
3309615|NCT00333515|Placebo Comparator|2|Administration of placebo
3309616|NCT00333502|Experimental|CRLX101 (formerly known as IT-101)|CRLX101 dosing per protocol dose escalation cohorts to MTD, then expansion cohort treated at MTD of CRLX101 15mg/m2
3309617|NCT00333463||Intervention group|The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
3309618|NCT00333463||Non-Intervention Group|The control group was told to take drops as prescribed and received no additional intervention.
3309619|NCT00333437|Experimental|Treatment|Mycophenolate Mofetil
3309620|NCT00333424|Placebo Comparator|Placebo|placebo containing diluent alone
3309621|NCT00333411|Experimental|BIRT 2584 XX high dose|
3309622|NCT00333411|Experimental|BIRT 2584 XX medium dose|
3309623|NCT00333411|Experimental|BIRT 2584 XX low dose|
3309624|NCT00333411|Placebo Comparator|Placebo|
3309625|NCT00333398|Experimental|1|250 subjects-Lot #1 multiple-dose vial (thimerosal-containing).
3309626|NCT00333398|Experimental|2|250 subjects-Lot #2 multiple-dose vial (thimerosal-containing).
3309627|NCT00333398|Experimental|3|250 subjects-Lot #3 multiple-dose vial (thimerosal-containing).
3309628|NCT00333398|Placebo Comparator|4|250 subjects-multiple-dose vial placebo (thimerosal-containing).
3309629|NCT00333398|Experimental|5|250 subjects-Prefilled Lot #1, #2, or #3 (TBD) (thimerosal-free).
3309630|NCT00333359|Experimental|XP13512 (GEn)|1200 mg XP13512, orally, once daily for 52 weeks
3309631|NCT00333333||SGA infants|Infants who are thought to be small for gestational age (SGA)
3309632|NCT00333333||Pre-eclampsia exposed|Infants who are born to mothers who had pre-eclampsia
3309633|NCT00333320|Placebo Comparator|- Control|
3309634|NCT00333320|Experimental|-postconditioning group|
3309635|NCT00333268|Experimental|NGOIS|
3309636|NCT00333268|Active Comparator|BSS Plus|
3309637|NCT00333229|Experimental|Zoledronic Acid|Patients randomized into the Zometa arm received a total of 8 study drug infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.
3309638|NCT00333229|Placebo Comparator|Placebo|Patients randomized into the Placebo Arm received a total of 8 placebo infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.
3309639|NCT00333216|Experimental|15 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 30 mg/mL, one injection of 0.5 mL in the study eye every 6 months for 48 months
3309640|NCT00333216|Experimental|30 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 60 mg/mL, one injection of 0.5 mL in the study eye every 6 months for 48 months
3309641|NCT00333216|Sham Comparator|Anecortave Acetate Vehicle|Anecortave Acetate Vehicle, one sham injection in the study eye every 6 months for 48 months
3309642|NCT00333203|Experimental|NGOIS|
3309643|NCT00333203|Active Comparator|BSS Plus|
3309644|NCT00333177|Experimental|1|Participants will receive cognitive remediation training plus injectable, long-acting risperidone.
3309645|NCT00333177|Active Comparator|2|Participants will receive health behavior training plus injectable, long-acting risperidone.
3309646|NCT00333177|Experimental|3|Participants will receive cognitive remediation training plus risperidone administered orally.
3309647|NCT00333177|Active Comparator|4|Participants will receive health behavior training plus risperidone administered orally.
3309648|NCT00333138|Experimental|Fingolimod (FTY720) 1.25 mg/day|Core study: patients received fingolimod 1.25 mg, once daily for 6 months. Extension: In dose -blind period and open label, fingolimod 1.25 mg once daily for 9-18 months (6 months to 24 months). Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
3309649|NCT00333138|Placebo Comparator|Placebo/Fingolimod (FTY720)|Core study: patients received placebo, once daily for 6 months. Extension: In dose-blind period patients were re-randomized into either fingolimod 1.25 mg or 5.0 mg once per day for 6-15 months. In open-label period patients received fingolimod 1.25 mg once per day for 15 to 24 months. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
3309650|NCT00333138|Experimental|Fingolimod (FTY720) 5.0 mg/day|Core study: patients received fingolimod 5.0 mg, once daily for 6 months. Extension: In dose-blind period fingolimod 5.0 mg once daily for 6-15 months. For open-label phase 15 to 24 months 1.25mg once daily. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
3309651|NCT00333125|Experimental|Travoprost/Timolol|
3309652|NCT00333125|Active Comparator|Dorzolamide/Timolol|
3309653|NCT00333112|Experimental|1|
3309654|NCT00333112|Placebo Comparator|2|
3309655|NCT00333099|Placebo Comparator|nutrition|study of immuno-modulating enteral nutrition
3309656|NCT00333073|Experimental|Bulkamid|Submucosal injection of Bulkamid into urethra
3309657|NCT00332969|Experimental|Sandostatin|
3309658|NCT00332956|Active Comparator|Group 1|Volunteers will be vaccinated with 80 mcg rF1V vaccine on Study Days 0 , 28, 182
3309659|NCT00332956|Active Comparator|Group 2|Volunteers will be vaccinated with 80 mcg of rF1V vaccine at Study Days 0, 56, 182
3309660|NCT00332956|Active Comparator|Group 3|Volunteers will be vaccinated with 160 mcg rF1V vaccine given on Study Days 0, 28, 182
3309661|NCT00332956|Active Comparator|Group 4|Volunteers will be vaccinated with 160 mcg rf1V vaccine on Study Days 0, 56, 182
3309662|NCT00332917|Experimental|1|
3309663|NCT00332904|Active Comparator|beta|patients with liver cirrhosis, treated with betablocker
3309664|NCT00332904|Active Comparator|spiron|patients with liver cirrhosis, treated with aldosterone antagonist
3309665|NCT00332904|No Intervention|control|patients with liver cirrhosis, no treatment
3309666|NCT00332878|Experimental|1|Stepping Stones
3309667|NCT00332878|Active Comparator|2|A 3 hour intervention on HIV and safer sex
3309668|NCT00332852|Experimental|Letrozole|
3309669|NCT00332839|Active Comparator|Calcineurin Inhibitor (CNI) group|Participants received Cyclosporine A (CsA) plus Enteric Coated Mycophenolate Sodium (EC-MPS) plus corticosteroids, or Tacrolimus A (CsA) plus Enteric Coated Mycophenolate Sodium (EC-MPS) plus corticosteroids.
3309670|NCT00332839|Experimental|Certican group|Participants were switched in a step-wise fashion from the CNI based regimen to Everolimus (RAD001).
3309674|NCT00332722|Active Comparator|Group 1- without steroid|Cervical Facet Joint Nerve block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin)
3309675|NCT00332722|Active Comparator|Group 2 - with steroid|Cervical Facet Joint nerve block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin) and 0.15 mg of non-particulate betamethasone)
3309676|NCT00332709|Experimental|Letrozole|Letrozole orally 2.5 mg/day for 3 years
3309677|NCT00332709|Experimental|Letrozole + Zoledronic Acid|Letrozole orally 2.5mg/day for 3 years; Zoledronic acid 4mg every 6 months by infusion
3309678|NCT00332696|Experimental|Octreotide|Participants received Octreotide long-acting release (LAR) 30 mg intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received immediate-release Octreotide 600 µg/day (administered subcutaneously 2 or 3 times a day or via continuous intravenous (IV) or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.
3309679|NCT00332696|Placebo Comparator|Placebo|Participants received physiologic saline solution intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received physiologic saline solution (administered subcutaneously 2 or 3 times a day or via continuous intravenous or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.
3309680|NCT00332683|Active Comparator|Control|Patients randomly assigned to this group will have no changes in the ETT during surgery
3309681|NCT00332683|Experimental|Treatment group|Patients in this group will undergo same surgery as control group but with a monitoring and manipulation of ETT pressure
3309682|NCT00332670|Active Comparator|1|10.000lux bright blue light 1hour every morning 1 hour after wake-up time during three weeks
3309683|NCT00332670|Placebo Comparator|2|50lux dim red light 1 hour every morning 1 hr after wake-up time during 3 weeks
3309684|NCT00332657|Experimental|Anecortave Acetate, 15 mg|One 0.5 mL injection of 30 mg/mL Anecortave Acetate Sterile Suspension into the posterior juxtascleral depot (PJD) at 6-month intervals for 42 months.
3309685|NCT00332657|Experimental|Anecortave Acetate, 30 mg|One 0.5 mL injection of 60 mg/mL Anecortave Acetate Sterile Suspension into the posterior juxtascleral depot (PJD) at 6-month intervals for 42 months.
3309686|NCT00332657|Sham Comparator|Anecortave Acetate Vehicle|One sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.
3309687|NCT00332644|Experimental|1|nicotine patch alone treatment
3309688|NCT00332644|Experimental|2|nicotine lozenge alone treatment
3309689|NCT00332644|Experimental|3|nicotine patch + lozenge combination treatment
3309690|NCT00332644|Experimental|4|bupropion alone treatment
3309691|NCT00332644|Experimental|5|bupropion + nicotine lozenge combination treatment
3309692|NCT00332644|Placebo Comparator|6|placebo control (no active medication) treatment
3309693|NCT00332605|Experimental|Naltrexone plus N-Acetyl Cysteine|"Naltrexone tablets~N-Acetyl Cysteine: 600mg tablets, daily"
3309694|NCT00332605|Placebo Comparator|Placebo|
3309695|NCT00332579|Active Comparator|A|Naltrexone
3309696|NCT00332579|Placebo Comparator|B|Placebo
3309697|NCT00332566|Experimental|Group A|
3309698|NCT00332566|Active Comparator|Group B|
3309699|NCT00332514|Other|Patients offered follow-up phone call|Patients offered follow-up telephone call
3309700|NCT00332488|Experimental|1|Technosphere Insulin
3309701|NCT00332488|Active Comparator|2|Metformin & Secretagogues
3309702|NCT00332488|Experimental|3|Technosphere & Metformin
3309703|NCT00332462|Experimental|Cyclosporine (Sandimmun®)|Period 1: Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days followed by Period 2: Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
3309704|NCT00332397|Active Comparator|A|Rapamycin-eluting Stent (Cypher)
3309705|NCT00332397|Active Comparator|B|Zotarolimus-eluting Stent (Endeavor)
3309706|NCT00332397|Active Comparator|C|Rapamycin-eluting Stent
3309707|NCT00332371|Experimental|1|
3309708|NCT00332371|No Intervention|2|
3309709|NCT00332332|Experimental|etanercept|Open label etanercept 50 mg twice weekly subcutaneously (SC) for 3 months followed by 50 mg twice a week week SC for 9 months, for a total treatment period of 12 months.
3309710|NCT00332306|Experimental|2|Didanosine + Lamivudine + Nevirapine
3309711|NCT00332306|Active Comparator|1|Didanosine + Lamivudine + Efavirenz
3309712|NCT00332293|Experimental|Moxifloxacin|
3309713|NCT00332293|Active Comparator|VIGAMOX|
3309714|NCT00332280|Experimental|AMT2003|
3309715|NCT00332254|Experimental|1|Intra-articular IL-1Ra
3309716|NCT00332254|Placebo Comparator|2|Intra-articular saline
3309717|NCT00332241|Experimental|A1|Active Abilify
3309718|NCT00332241|Placebo Comparator|A2|
3309719|NCT00332228|Active Comparator|CE plus oral +depot naltrexone|Compliance enhancement (CE), simulating standard treatment with oral naltrexone plus two depot naltrexone;
3309720|NCT00332228|Placebo Comparator|CE plus oral naltrexone+ placebo|CE with oral naltrexone plus two placebo injections
3309721|NCT00332228|Experimental|BNT plus Depot naltrexone|BNT plus two doses of depot naltrexone prior to hospital discharge
3309722|NCT00332228|Placebo Comparator|BNT plus PBO injection|BNT plus two placebo injections
3309723|NCT00332202|Experimental|A|
3309724|NCT00332202|Placebo Comparator|B|
3309725|NCT00332176|Experimental|1|
3309726|NCT00332176|Experimental|2|
3309727|NCT00332176|Active Comparator|3|
3309728|NCT00332163|Experimental|Pre-emptive Skin Treatment|Participants received either FOLFIRI and panitumumab 6 mg/kg once every 2 weeks (Q2W) or irinotecan and panitumumab 9 mg/kg once every 3 weeks (Q3W), and pre-emptive skin treatment which included skin moisturizer, sunscreen, 1% hydrocortisone cream, and an oral antibiotic for 6 weeks starting 24 hours prior to chemotherapy.
3309823|NCT00330798|Experimental|Nevanac|One drop, three times daily, in the assigned eye for the first three postoperative days
3314386|NCT00269321|Active Comparator|3|
3309729|NCT00332163|Experimental|Reactive Skin Treatment|Participants received either FOLFIRI and panitumumab 6 mg/kg Q2W or irinotecan and panitumumab 9 mg/kg Q3W. Participants were treated for each individual skin toxicity occurrence according to prespecified guidelines and based on the type and severity. Treatment could include emollient, sunscreen, topical or oral steroids, antibiotics, or antihistamines, as required.
3309730|NCT00332124|Placebo Comparator|1|Participants will take placebo
3309731|NCT00332124|Active Comparator|2|Participants will take choline
3309732|NCT00332098|Experimental|1|Family-Focused Treatment Plus Pharmacotherapy
3309733|NCT00332098|Active Comparator|2|Enhanced Care Plus Pharmacotherapy
3309734|NCT00332020|Experimental|Arm 1|
3309735|NCT00332020|Active Comparator|Arm 2|
3309736|NCT00332007|Experimental|1|Tonabersat 40 mg daily
3309737|NCT00332007|Placebo Comparator|2|
3309738|NCT00331994|Experimental|1|
3309739|NCT00331994|Active Comparator|2|
3309740|NCT00331955|Experimental|Treatment (vorinostat, doxorubicin hydrochloride)|Patients receive oral vorinostat twice daily for 5 doses on days 1-3, 8-10, and 15-17 and doxorubicin hydrochloride IV on days 3, 10, and 17. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 6 courses of treatment may continue to receive vorinostat alone in the absence of disease progression.
3309741|NCT00331929|Experimental|A|Cohort of school children that evaluated with questionnaire and spirometry with MINATO 500 JAPAN spirometer
3309742|NCT00331890|Experimental|Active|Receives active drug
3309743|NCT00331890|Placebo Comparator|Placebo|Receives a placebo
3309744|NCT00331864|Experimental|Ranibizumab|Ranibizumab-naïve (Non-ANCHOR) patients received up to 12 intravitreal injections (Month 0 through Month 11). The dose of 0.3 mg ranibizumab was administered monthly for three consecutive months. From Month 3 through Month 11, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab were injected as individually needed based on re-treatment criteria described in the protocol. For patients who had participated in the ANCHOR study, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab was injected if the patient met re-treatment criteria described in the protocol. Ranibizumab was administered no sooner than 14 days after the previous treatment.
3309745|NCT00331838|Experimental|Semuloparin 5 mg|Semuloparin sodium 5 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
3309746|NCT00331838|Experimental|Semuloparin 10 mg|Semuloparin sodium 10 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
3309747|NCT00331838|Experimental|Semuloparin 20 mg|Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
3309748|NCT00331838|Experimental|Semuloparin 40 mg|Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
3309749|NCT00331838|Experimental|Semuloparin 60 mg|Semuloparin sodium 60 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
3309750|NCT00331838|Active Comparator|Enoxaparin 40 mg|Enoxaparin sodium 40 mg + Placebo (for Semuloparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
3309751|NCT00331838|Experimental|Placebo pre-op / Semuloparin 20 mg|"Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,~Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery"
3309752|NCT00331838|Experimental|Placebo pre-op / Semuloparin 40 mg|"Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,~Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery"
3309753|NCT00331799|Active Comparator|1|Open label treatment with Duloxetine for 8 weeks with dosing from 30-60 mg.
3309754|NCT00331773|Active Comparator|Conventional 3D-CRT|Conventional 3D-CRT or IMRT to 73.8 Gy in 41 fractions
3309755|NCT00331773|Experimental|Hypofractionated 3D-CRT|Hypofractionated 3D-CRT or IMRT to 70 Gy in 28 fractions
3309756|NCT00331760|Other|Endometrial Cancer: IMRT|Endometrial Cancer patients receive Intensity Modulated Radiation Therapy (IMRT) 28 fractions over 5.5 weeks.
3309757|NCT00331760|Other|Cervical Cancer: IMRT + Chemotherapy (cisplatin)|Cervical patients receive Intensity Modulated Radiation Therapy (IMRT) 28 fractions over 5.5 weeks and concurrent weekly cisplatin 40 mg/m^2 for five weeks.
3309758|NCT00331721|Active Comparator|1|Enecadin
3309759|NCT00331721|Placebo Comparator|2|Placebo
3309760|NCT00331708|Experimental|Artesunate plus sulphadoxine-pyrimethamine|
3309761|NCT00331695|Experimental|1|17 alpha-hydroxyprogesterones caproate
3309762|NCT00331682|Experimental|Treatment (docetaxel and alvocidib)|Patients receive docetaxel IV over 30 minutes followed 4-6 hours later by flavopiridol IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3309763|NCT00331669|Placebo Comparator|1|device
3309764|NCT00331643|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.
3309765|NCT00331630|Experimental|Treatment arm|30 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3309766|NCT00331604|Experimental|A|
3309767|NCT00331604|Active Comparator|B|
3309768|NCT00331604|Active Comparator|C|
3309769|NCT00331565|Experimental|Surgery|Bariatric surgery
3309822|NCT00330824|Active Comparator|antibiotic / steroid (2 vials)|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having LASIK surgery
3309920|NCT00329563|No Intervention|control, standard of care|
3309770|NCT00331552|Experimental|Arm I|Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician.
3309771|NCT00331513|Active Comparator|Arm I (vorinostat, idarubicin)|Patients receive oral SAHA three times daily on days 1-14 and idarubicin IV over 15 minutes once daily on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy or who reach the maximum cumulative dose of idarubicin or an equivalent anthracycline and achieve clinical benefit may continue treatment with SAHA alone 3 times daily on days 1-14 of each course, in the absence of disease progression or unacceptable toxicity.
3309772|NCT00331513|Active Comparator|Arm II (vorinostat, idarubicin)|Patients receive oral SAHA three times daily and idarubicin IV over 15 minutes once daily on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy or who reach the maximum cumulative dose of idarubicin or an equivalent anthracycline and achieve clinical benefit may continue treatment with SAHA alone 3 times daily on days 1-14 of each course, in the absence of disease progression or unacceptable toxicity.
3309773|NCT00331500|Experimental|Olopatadine Hydrochloride 0.2%|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop in each eye, once-daily in the morning for 6 weeks
3309774|NCT00331500|Placebo Comparator|Vehicle|Olopatadine hydrochloride ophthalmic solution vehicle, 1 drop in each eye, once-daily in the morning for 6 weeks
3309775|NCT00331487|Experimental|Pioglitazone QD|
3309776|NCT00331487|Active Comparator|Rosiglitazone QD|
3309777|NCT00331435|Active Comparator|1|FA-guided PDT
3309778|NCT00331435|Experimental|2|ICG-guided PDT
3309779|NCT00331422|Experimental|Patients Who Received Treatment|All patients receiving treatment with Paclitaxel and Carboplatin followed by surgery to remove cancerous tissue.
3309780|NCT00331409|Experimental|Everolimus and Imatinib Mesylate|Everolimus: 2.5 mg daily by mouth Imatinib Mesylate: 600 mg daily by mouth
3309781|NCT00331344|Experimental|Treatment (combination chemotherapy)|Patients receive mitoxantrone hydrochloride IV over 30 minutes and ixabepilone IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
3309782|NCT00331279|Active Comparator|Cinnamon Extract|A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
3309783|NCT00331279|Placebo Comparator|Placebo|
3309784|NCT00331214|Sham Comparator|Placebo|placebo patch for 6 months
3309785|NCT00331214|Experimental|Testosterone|Testosterone patch
3309786|NCT00331162|Active Comparator|1|Alemtuzumab
3309787|NCT00331162|Active Comparator|2|Anti-Thymocyte Globulin
3309788|NCT00331136|Experimental|1|Pyronaridine artesunate 6:2 mg/kg
3309789|NCT00331136|Experimental|2|Pyronaridine artesunate 9:3 mg/kg
3309790|NCT00331136|Experimental|3|Pyronaridine artesunate 12:4 mg/kg
3309791|NCT00331123|Placebo Comparator|Placebo|Placebo patch
3309792|NCT00331123|Experimental|Testosterone Patch|
3309793|NCT00331097|Active Comparator|A|Standard chemotherapy with CMF
3309794|NCT00331097|Experimental|B|Weekly docetaxel
3309795|NCT00331084|Experimental|antibiotic steroid drops/single vial|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having cataract surgery
3309796|NCT00331084|Active Comparator|antibiotic steroids drops|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having cataract surgery
3309797|NCT00331071||001|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE worn for 1 week and replaced for 3 consecutive weeks fourth week is patch free
3309798|NCT00331071||002|Monophasic or triphasic Oral contraceptive tablet 35 mcg EE for 21 consecutive days followed by no or drug-free tablet for 7 days
3309799|NCT00331058|Other|healthy volunteers|control group not receiving prednisolone
3309800|NCT00331058|Other|asthmatic volunteers|receive prednisolone for 14-16 days
3309801|NCT00331045|Placebo Comparator|Placebo|
3309802|NCT00331045|Experimental|Alvimopan 0.25 mg/yday|
3309803|NCT00331045|Experimental|Alviompan 0.5 mg/day|
3309804|NCT00331045|Experimental|Alvimopan 1 mg/day|
3309805|NCT00331032|Experimental|1: 3% w/w SPL7013 Gel|40 subjects VivaGel™.
3309806|NCT00331032|Placebo Comparator|2: Placebo|20 subjects placebo.
3309807|NCT00331006|Experimental|Rituximab|Rituximab administered at a dose of 375 mg/m2 by slow intravenous infusion once per week for 4 weeks
3309808|NCT00330980|Experimental|1|Participants will receive 20 mg of simvastatin for 6 months.
3309809|NCT00330980|Experimental|2|Participants will receive 40 mg of pravastatin for 6 months.
3309810|NCT00330980|Placebo Comparator|3|Participants will receive placebo for 6 months.
3309811|NCT00330967||Group 1|healthy subjects
3309812|NCT00330967||Group 2|healthy subjects different from group 1
3309813|NCT00330928|Experimental|1|Subjects undergoing elective percutaneous coronary intervention
3309814|NCT00330915|Experimental|A|
3309815|NCT00330902|Active Comparator|1|Sulfadoxine pyrimethamine plus three daily doses of artesunate
3309816|NCT00330902|Experimental|2|Sulfadoxine pyrimethamine plus artesunate plus primaquine
3309817|NCT00330876|Experimental|Pitavastatin 2 mg QD|Pitavastatin 2 mg once daily
3309818|NCT00330876|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
3309819|NCT00330863|Experimental|Injectable|Participants assigned to receive long-acting injectable risperidone
3309820|NCT00330863|Active Comparator|Oral|"Participants assigned to receive oral atypical antipsychotic medication"
3309821|NCT00330824|Experimental|antibiotic steroid (single vial)|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having LASIK surgery
3311406|NCT00310063|Sham Comparator|Arm II|Sham wristband
3309824|NCT00330798|Placebo Comparator|Acular LS|One drop, three times daily, in the assigned eye for the first three postoperative days
3309825|NCT00330759|Active Comparator|zoledronic acid|denosumab placebo with active zoledronic acid
3309826|NCT00330759|Experimental|denosumab|active denosumab with zoledronic acid placebo
3309827|NCT00330746|Experimental|A|cetuximab and gemcitabine combination
3309828|NCT00330746|Experimental|B|gemcitabine followed by cetuximab (sequential)
3309829|NCT00330733|Placebo Comparator|Arm 1|Matching placebo
3309830|NCT00330733|Active Comparator|Arm 2|Salsalate
3309831|NCT00330694|Experimental|I|Implementation of ParkNet within 8 regions
3309832|NCT00330694|Other|II|Usual Care in 8 regions
3309833|NCT00330681|Experimental|1|MCI-186
3309834|NCT00330681|Placebo Comparator|2|Placebo of MCI-186
3309835|NCT00330629|Active Comparator|Standard Behavioral Treatment|"Goal setting: daily/weekly goals for calorie and fat consumption, exercise time, and behavior change.~Self-monitoring: systematically observing and recording one's behavior,45,46 which will be reviewed by the therapists, and written feedback will be provided to reinforce positive behaviors.~Feedback: therapists monitor the recorded behavior changes and provide feedback/encouragement."
3309836|NCT00330629|Active Comparator|SBT+LOV Group|In addition to SBT, participants will aim to eliminate all meat, poultry, and fish from their diet over the first 6 weeks, and will be taught how to select appropriate substitutes for these foods, such as low- or no-fat dairy products (cheeses, milk), and protein-containing vegetable sources (soy products, legumes). .
3309837|NCT00330564|Experimental|SU011248 (Sutent, Sunitinib Malate)|50 mg/day orally for 4 weeks
3309838|NCT00330551|Experimental|Long-acting injectible risperidone|Participants taking risperidone, administered in injectible long-acting form (Risperdal Consta), plus group skills training and case management
3309839|NCT00330551|Active Comparator|Oral risperidone|Participants taking daily oral risperidone, plus group skills training and case management
3309840|NCT00330499|Experimental|A|Synchronous chemo / radiation therapy
3309841|NCT00330499|Active Comparator|B|Radiation Alone
3309842|NCT00330473|Experimental|1|Treatment options available on the market plus the option of taking Human Insulin Inhalation Powder.
3309843|NCT00330473|Active Comparator|2|Treatment Options available on the market.
3309844|NCT00330460|Active Comparator|Alendronate|Subjects in this arm will receive active ALN and placebo denosumab
3309845|NCT00330460|Experimental|Denosumab|Subjects in this arm will receive active denosumab and placbo ALN
3309846|NCT00330447||Studygroup|Cancer in Pregnancy - all diagnoses and treatments Children born from mothers diagnosed with cancer during pregnancy
3309847|NCT00330447||Control group|Children from the general population
3309848|NCT00330421|Experimental|Group I (sarcomas of extremity, closed accrual as of 5/30/07)|Patients receive oral sorafenib twice daily on days 1-14. Patients undergo surgical resection of the tumor on approximately day 15. Once patients recover from surgery (and radiotherapy if indicated), patients who demonstrate a clinically and pathologically significant response (≥ 25% reduction in tumor size or ≥ 25% necrosis in the surgical specimen) may continue sorafenib as above for a maximum of 6 months in the absence of disease progression or unacceptable toxicity and at the discretion of the principal investigator. Biopsy tissue and blood samples are examined for biomarkers and interstitial fluid pressure (IFP) is measured at baseline and immediately before surgery.
3309849|NCT00330421|Experimental|Group II (metastatic or inoperable sarcomas)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for 2 courses. Patients with responding or stable disease may continue sorafenib in the absence of disease progression or unacceptable toxicity. Biopsy tissue and blood samples are examined for biomarkers and IFP is measured at baseline and on days 28 and 56.
3309850|NCT00330382|Experimental|Arm I (Bowman-Birk inhibitor concentrate)|Patients receive oral Bowman-Birk inhibitor concentrate twice daily for 6 months
3309851|NCT00330382|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo twice daily for 6 months
3309852|NCT00330369|Placebo Comparator|Darusentan Placebo|Placebo to match darusentan for 2-week placebo run-in period, followed by placebo to match darusentan administered orally once daily for 14 weeks
3309853|NCT00330369|Experimental|Darusentan 50 mg|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 50 mg administered orally once daily for 14 weeks
3309854|NCT00330369|Experimental|Darusentan 100 mg|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 100 mg administered orally once daily for 14 weeks
3309855|NCT00330369|Experimental|Darusentan 300 mg|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 300 mg administered orally once daily for 14 weeks
3309856|NCT00330343|Experimental|Naloxone|continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour
3309857|NCT00330317|Experimental|Letrozole|
3309858|NCT00330304|Experimental|Isoniazid preventive therapy|HIV infected children living in a high TB prevalence area receive isonaizid prophylaxis daily, together with cotrimoxazole prohpylaxis either 3 times a week or daily.
3309859|NCT00330304|Placebo Comparator|Placebo|HIV infected children living in a high TB prevalence area receive placebo once daily
3309860|NCT00330265|Experimental|1|KC-002
3309861|NCT00330265|Other|2|Conventional Wound Therapy
3309862|NCT00330252|Experimental|Alemtuzumab & Rituximab|"Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks)~Rituximab- Given intravenously on day 1 of every week for eight weeks (or 16 weeks)"
3309863|NCT00330226||Psychopharmacotherapy|patients under antipsychotic or mood stabilizer treatment
3309864|NCT00330174|Experimental|1|Acamprosate tablets
3309865|NCT00330174|Placebo Comparator|2|Matching placebo tablets
3309921|NCT00329550|Experimental|CZP 400 mg / Placebo|Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)
3309922|NCT00329550|Experimental|CZP 400 mg / CZP 200 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)
3315872|NCT00247741|Experimental|articaine|
3309866|NCT00330161|Experimental|Treatment (vorinostat)|"Patients receive oral vorinostat (SAHA) once daily on days 1-21. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (CR) after 4 courses receive an additional 3 courses. All other patients may continue treatment in the absence of disease progression or unacceptable toxicity.~Blood samples are taken on day 15 of course 1, day 1 of course 2, during the last week of course 4, and at completion of study treatment. Blood is examined for interleukin (IL)-6, IL-6 receptor, and gp130 levels."
3309867|NCT00330135|Experimental|1|Sodium hyaluronate 2.5 ml - 1 injection
3309868|NCT00330135|Placebo Comparator|2|Placebo injection - 1 injection
3309869|NCT00330096|Experimental|Hesperidin-rich food|
3309870|NCT00330096|Placebo Comparator|No intervention: Placebo|
3309871|NCT00330044|Experimental|Drug|Carboplatin and Pemetrexed
3309872|NCT00330018|Experimental|1|PO Valganciclovir
3309873|NCT00330018|Active Comparator|2|PO Acyclovir
3309874|NCT00329992|Experimental|Treatment group|16 sessions Brief Eclectic Psychotherapy
3309875|NCT00329992|Placebo Comparator|Control group|Minimal attention waitlist group
3309876|NCT00329979||1|Radial access
3309877|NCT00329979||2|Femoral access
3309878|NCT00329940|Experimental|Letrozole|to evaluate the rheumatological tolerability of Femara
3309879|NCT00329914|Placebo Comparator|Placebo|
3309880|NCT00329914|Active Comparator|Progesterone|
3309881|NCT00329901|Experimental|Tdap + MenACWY-CRM|Subjects received Tdap and MenACWY-CRM vaccines concomitantly, in separate arms
3309882|NCT00329901|Experimental|Tdap + saline|Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms
3309883|NCT00329901|Experimental|MenACWY-CRM + saline|Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms
3309884|NCT00329849|Experimental|MenACWY-CRM|Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)
3309885|NCT00329849|Active Comparator|MenACWY-PS|Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal polysaccharide (PS) vaccine (MenACWY-PS)
3309886|NCT00329836||Subjects with cluster headache|Subjects with both episodic and chronic cluster (as defined by the International Headache Society-IHS) were enrolled.
3309887|NCT00329810|Experimental|Switch|
3309888|NCT00329797|Experimental|Zoledronic Acid|Zoledronic acid q 6 months plus Vitamin D and calcium supplement for 3 years in addition to concurrent radiation therapy and LHRH therapy.
3309889|NCT00329797|Active Comparator|Control|Vitamin D and calcium supplement everyday for 3 years in addition to concurrent radiation therapy and LHRH therapy.
3309890|NCT00329784|Experimental|Peanut Consumption Group|Participants on this arm will consume peanut protein.
3309891|NCT00329784|No Intervention|Peanut Avoidance Group|Participants on this arm will avoid peanut as per United Kingdom (UK) public health recommendations.
3309892|NCT00329771||Episodic migraineurs|Eligible subjects with episodic migraine (with or without aura)
3309893|NCT00329758|Active Comparator|1|
3309894|NCT00329758|Placebo Comparator|2|
3309895|NCT00329745|Experimental|Rotarix Group|During the primary study (NCT00197210) subjects received two oral doses of Rotarix™ vaccine.
3309896|NCT00329745|Placebo Comparator|Placebo Group|During the primary study (NCT00197210) subjects received two oral doses of placebo.
3309897|NCT00329732|Active Comparator|Lidocaine/Bupivicaine|
3309898|NCT00329732|Placebo Comparator|saline|matching volume of saline injected
3309899|NCT00329719|Experimental|Group I (sorafenib tosylate, temsirolimus)|Patients receive sorafenib tosylate and temsirolimus as in Phase I.
3309900|NCT00329719|Experimental|Group II (sorafenib tosylate, temsirolimus, surgery)|Patients receive sorafenib tosylate PO BID on days 1-8 and temsirolimus IV over 30 minutes on day 1. Patients undergo surgery on day 8. After recovering from surgery, patients receive sorafenib tosylate and temsirolimus as in Phase I.
3309901|NCT00329719|Experimental|Group III (sorafenib tosylate, temsirolimus, anti-VEGF)|Patients who have received prior anti-VEGF therapy and are not undergoing surgery receive sorafenib tosylate and temsirolimus as in Phase I.
3309902|NCT00329706|Experimental|1|Experimental arm will have an immediate release of the PET report
3309903|NCT00329706|Active Comparator|2|Active Comparator arm will have a delayed release of 2 years
3309904|NCT00329693|Placebo Comparator|1|Daily Tablets Dosing
3309905|NCT00329693|Experimental|2|Daily Tablets Dose
3309906|NCT00329693|Experimental|3|Daily Tablets Dosing
3309907|NCT00329693|Experimental|4|Daily Tablets Dosing
3309908|NCT00329680|Experimental|1|Experimental arm will receive an enteral diet enriched with EPA, GLA and Antioxidant vitamins
3309909|NCT00329680|Placebo Comparator|2|"This arm will receive an enteral diet considered as a standard ICU diet, isocaloric to the control diet but not enhanced with EPA, GLA and antioxidant vitamins"
3309910|NCT00329654|Experimental|Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation.
3309911|NCT00329641|Experimental|Treatment (carboplatin, paclitaxel, sorafenib)|"Patients receive carboplatin IV and paclitaxel IV once on day 1 and oral sorafenib twice daily on days 2-19. Treatment repeats every 21 days for up to 6 courses.* After 6 courses, patients continue to receive oral sorafenib alone twice daily in the absence of disease progression or unacceptable toxicity.~[Note: *If sorafenib is discontinued prior to course 6, patients may continue to receive carboplatin and paclitaxel for up to 6 courses; if carboplatin and paclitaxel are discontinued prior to course 6, patients may continue to receive sorafenib alone twice daily on days 1-21 of each course in the absence of disease progression or unacceptable toxicity. ]"
3309912|NCT00329628|Experimental|Arm 1|
3309913|NCT00329628|Active Comparator|Arm 2|
3309914|NCT00329602|Placebo Comparator|Double-blind for 12 to 26 Weeks|Double-blind (Ropinirole:Placebo) for 12 to 26 weeks
3309915|NCT00329602|Other|Open-label ropinirole for 40-Weeks|Open label ropinirole for 40 weeks
3309916|NCT00329589|Experimental|CNS|Velcade (bortezomib)
3309917|NCT00329589|Experimental|Head and Neck|Velcade (bortezomib)
3309918|NCT00329589|Experimental|Cervix|Velcade (bortezomib)
3309919|NCT00329563|Experimental|Cold fluid|
3310076|NCT00327379|Experimental|Arm 1|
3309923|NCT00329550|Experimental|CZP 400 mg / CZP 400 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)
3309924|NCT00329537|Experimental|Arm 1|
3309925|NCT00329537|Placebo Comparator|Arm 2|
3309926|NCT00329524|Sham Comparator|Active versus Sham Treatment|Subjects randomly assigned to active and sham TMS separated by one week interval.
3309927|NCT00329511|Active Comparator|A|methyldopa
3309928|NCT00329511|Active Comparator|B|clonidine patch
3309929|NCT00329472|Experimental|Gem/Cis|neoadjuvant chemotherapy: gemcitabine 1250mg/m2 D1,D8 & cisplatin 70mg/m2 , 2 cycles
3309930|NCT00329472|No Intervention|no neoadjuvant chemotherapy|
3309931|NCT00329459|Experimental|arm 1|Treximet (sumatriptan/naproxen sodium)
3309932|NCT00329459|Placebo Comparator|arm 2|placebo to match
3309933|NCT00329433|Active Comparator|Heparin|Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
3309934|NCT00329433|Experimental|Desirudin (Iprivask™)|Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
3309935|NCT00329420|Experimental|CZP 400 mg / Placebo|Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)
3309936|NCT00329420|Experimental|CZP 400 mg / CZP 200 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)
3309937|NCT00329420|Experimental|CZP 400 mg / CZP 400 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)
3309938|NCT00329407|Active Comparator|Topiramate Treatment|In this open label non-placebo controlled trial all subjects received topiramate, the active medication. Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM & 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM & 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM & 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
3309939|NCT00329381|Placebo Comparator|1|Placebo will be compared to Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
3309940|NCT00329381|Experimental|2|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
3309941|NCT00329342|Experimental|1|
3309942|NCT00329342|No Intervention|2|
3309943|NCT00329238|Experimental|Dabigatran|Patient to receive 1 capsule containing dabigatran 150 mg twice daily plus placebo tablets for warfarin as decided by sham INR measurements
3309944|NCT00329238|Active Comparator|Warfarin (INR of 2.0-3.0)|Patient to receive warfarin tablets to target INR 2.0-3.0 plus placebo capsules for dabigatran twice daily
3309945|NCT00329108|Experimental|A|
3309946|NCT00329108|Active Comparator|B|
3309947|NCT00329082|Experimental|1|
3309948|NCT00329082|Experimental|2|
3309949|NCT00329082|Experimental|3|
3309950|NCT00329082|Experimental|4|
3309951|NCT00329082|Placebo Comparator|5|
3309952|NCT00329056|Experimental|1|40 mg MitoQ OD
3309953|NCT00329056|Experimental|2|80 mg MitoQ OD
3309954|NCT00329056|Placebo Comparator|3|Placebo
3309955|NCT00329043|Experimental|Sunitinib + Hormonal Ablation Before Prostatectomy|Sunitinib Malate 25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles. LHRH Agonist intramuscular injection either monthly for 3 months or in a single 3-month dose. Radical prostatectomy after completion of Sunitinib and LHRH agonist.
3309956|NCT00329030|Active Comparator|Rituxan/BEAM|Autologous transplantation using rituxan/BEAM
3309957|NCT00329030|Experimental|Bexxar/BEAM|Autologous transplantation using Bexxar/BEAM
3309958|NCT00329017||1|Post-menopausal women who are at increased risk for development of breast cancer on the basis of family or personal history.
3309959|NCT00329004|Experimental|1|
3309960|NCT00328965|Other|Lacidipine|All subjects who meet eligiblity criteria receive 2mg for the first 4 weeks in an open manner. If target systolic blood pressure is not ahcieved, subject can increase the dose to 4mg and then 6mg consequently.
3309961|NCT00328926|Active Comparator|Luveris® 75 IU|
3309962|NCT00328926|Active Comparator|Luveris® 25 IU|
3309963|NCT00328926|Placebo Comparator|Placebo|
3309964|NCT00328887|Experimental|CD40 Gene Transfer|Recruitment will be random from the referral base of the investigators from the popula¬tion of individuals with esophageal cancer defined by the protocol inclu¬sion/exclusion criteria.
3309965|NCT00328861|Experimental|NK Cells + IL-2: Melanoma|Melanoma (skin cancer). Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7. Fludarabine 25 mg/m^2 day intravenous on days -6 through -2. IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days. Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
3309966|NCT00328861|Experimental|NK Cells + IL-2: Renal Cell|Renal cell (kidney cancer). Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7. Fludarabine 25 mg/m^2 day intravenous on days -6 through -2. IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days. Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
3309967|NCT00328848|Experimental|Intervention care management|post dischsrge care management by a nurse care manager who performs in-home vistis and reports to a interdisciplinary team. Team generates care recommendations based on patient goals. PCP and care manager implement the care plan that is based on patient goals. Includes education, behavioral interventions, and coaching.
3309968|NCT00328822|Experimental|A|Quetiapine
3309969|NCT00328822|Placebo Comparator|B|Placebo
3309970|NCT00328809|Active Comparator|Spirnolactone|
3309971|NCT00328783|Experimental|Active Breathing Coordinator|Patients breathe through the ABC device
3309972|NCT00328770|Experimental|Sirolimus based immunosuppression|Sirolimus given intravenously or orally to achieve serum level of 12-20ug/l
3309973|NCT00328744|Experimental|1|Behavioral: Behavioral weight loss (Standard)
3309974|NCT00328744|Experimental|2|Behavioral: Behavioral weight loss (Limited Variety)
3309975|NCT00328692|Experimental|2|
3309976|NCT00328692|Placebo Comparator|1|
3309977|NCT00328679|Experimental|A|
3309978|NCT00328627|Placebo Comparator|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
3309979|NCT00328627|Experimental|Alogliptin 12.5 + Placebo|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
3309980|NCT00328627|Experimental|Alogliptin 25 + Placebo|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
3309981|NCT00328627|Active Comparator|Placebo + Pioglitazone 15|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
3309982|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 15|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
3309983|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 15|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
3309984|NCT00328627|Active Comparator|Placebo + Pioglitazone 30|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
3309985|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 30|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
3309986|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 30|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
3309987|NCT00328627|Active Comparator|Placebo + Pioglitazone 45|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
3309988|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 45|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
3309989|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 45|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
3309990|NCT00328614|Experimental|Samarium-153 (0.25 mCi/kg)|Cohort 1: Patients receive 0.25 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
3309991|NCT00328614|Experimental|Samarium-153 (0.5 mCi/kg)|Cohort 2: Patients receive 0.5 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
3309992|NCT00328614|Experimental|Samarium-153 (0.75 mCi/kg)|Cohort 3: Patients receive 0.75 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
3309993|NCT00328614|Experimental|Samarium-153 (1.0 mCi/kg)|Cohort 4: Patients receive 1.0 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
3309994|NCT00328614|Experimental|Samarium-153 (1.5 mCi/kg)|Cohort 5: Patients receive 1.5 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
3309995|NCT00328614|Experimental|Samarium-153 (2.0 mCi/kg)|Cohort 6: Patients receive 2.0 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
3309996|NCT00328588|Experimental|1|7 days continuous infusion
3309997|NCT00328575|Experimental|Intensity-Modulated Radiotherapy (IMRT)|Patients with brain metastases will be enrolled in one of three dose levels based on tumor size. For tumor size of 3 cm or less (maximum diameter in any dimension), doses of 47.5Gy, 52.5Gy, and 54.5Gy will be tested. For tumor size of greater than 3 cm (maximum diameter in any dimension), doses of 42.5Gy, 47.5Gy, and 52.5Gy will be tested.
3309998|NCT00328562|Experimental|Iressa and RT|"Iressa plus thoracic RT at the following dose levels:~Level 1: 42.0 Gy in 10 fractions of 4.2 Gy~Level 2: 50.4 Gy in 12 fractions of 4.2 Gy~Level 3: 63.0 Gy in 15 fractions of 4.2 Gy"
3309999|NCT00328510|Experimental|GTC Frame|Participant undergoes SRT using a GTC frame to immobilize the participant's heading during radiation therapy
3310000|NCT00328510|Experimental|BrainLab thermoplastic mask|Participant undergoes SRT using the BrainLab thermoplastic mask to immobilize the participant's head during radiation therapy
3310001|NCT00328497|Experimental|1|Panzem NCD will be dosed orally at a level of 1,000 mg, four times daily for 28 consecutive days and bevacizumab will be administered at a dose of 5 mg/kg as an intravenous bolus on Day 1 and Day 15 of the Treatment Period
3310002|NCT00328484|Experimental|1|Eleven month lifestyle activity program
3310003|NCT00328484|Active Comparator|2|Three month exercise program
3310004|NCT00328458|Experimental|Cohort 1 Brain Tumors|The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.
3310005|NCT00328458|Experimental|Cohort 2 Head and Neck Tumors|The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.
3310006|NCT00328445|No Intervention|Control|Business as usual
3310007|NCT00328445|Experimental|Treatment|Positive Action
3310008|NCT00328419|Experimental|1|photoprotected parenteral nutrition
3310009|NCT00328419|Active Comparator|2|Non-photoprotected parenteral nutrition
3310010|NCT00328393|Active Comparator|Pioglitazone|Pioglitazone 45 mg, 8 weeks
3310011|NCT00328393|Placebo Comparator|Placebo|Placebo
3310012|NCT00328367|Experimental|A|clozapine plus aripiprazole
3310013|NCT00328367|Placebo Comparator|B|clozapine plus placebo
3310014|NCT00328263|Experimental|1|Bio-K Cl1285 Bio-K Cl1285 contains 50 billion of live bacteria.
3310015|NCT00328263|Placebo Comparator|2|placebo devoid of bacteria
3310016|NCT00328250|Experimental|1|Participants will receive the online CBT intervention immediately and will use the online program for 8 weeks
3310017|NCT00328250|Active Comparator|2|Participants will receive the online CBT intervention after a 4-month waiting period
3310018|NCT00328211|Experimental|Bile Acid|To assess the role of bile acid pool size changes on cholesterol absorption, synthesis and intralumenal cholesterol solubilization.
3310077|NCT00327379|Placebo Comparator|Arm 2|
3311670|NCT00306917|Active Comparator|1|DuoFix HA
3310019|NCT00328211|Experimental|Cholesterol Absorption|To determine whether cholesterol absorption, synthesis and solubilization will be significantly altered by changes in phospholipid content, specifically sphingolipids and phosphatidylcholine in the intestinal lumen.
3310020|NCT00328211|Experimental|Pluronic F-68|To determine the effect of Pluronic F-68 on rodent and human cholesterol absorption, synthesis and intralumenal cholesterol solubilization, fat absorption and enterocyte appearance.
3310021|NCT00328211|Experimental|Intralumenal|To assess intralumenal solubilization and absorption of biliary and dietary cholesterol.
3310022|NCT00328198|Experimental|Dose escalation|Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated).
3310023|NCT00328198|Experimental|No escalation|Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered subcutaneously at alternating injection sites 3 times per week for up to 18 weeks.
3310024|NCT00328172|Placebo Comparator|Placebo|Placebo tablets matching BI 1356
3310025|NCT00328172|Experimental|BI 1356 0.5 mg|BI 1356 dose 1 once daily
3310026|NCT00328172|Experimental|BI 1356 2.5 mg|BI 1356 dose 2 once daily
3310027|NCT00328172|Experimental|BI 1356 5.0 mg|BI 1356 dose 3 once daily
3310028|NCT00328172|Active Comparator|Metformin|Metformin
3310029|NCT00328146||Observation of Sternal Re-entry|All subjects.
3310030|NCT00328107|Experimental|Low Dose|Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2004/05 formulation containing 45μg of each hemagglutinin derived from A/Wyoming/3/03(H3N2) and 15μg from A/New Caledonia/20/99(H1N1) and B/Jiangsu/10/03
3310031|NCT00328107|Experimental|Full Dose|Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2004/05 formulation containing 45μg of each hemagglutinin derived from A/Wyoming/3/03(H3N2), A/New Caledonia/20/99(H1N1) and B/Jiangsu/10/03
3310032|NCT00328107|Placebo Comparator|Placebo|0.9% Sodium Chloride
3310033|NCT00328094|Experimental|CII, Continuous Insulin Infusion|Continuous intravenous insulin infusion to control glucose to <150 mg/dL in patients undergoing open peripheral vascular bypass surgery
3310034|NCT00328094|Active Comparator|IIB, Intermittent insulin boluses|Intermittent intravenous insulin insulin boluses to a blood glucose target of <150mg/dL in patients undergoing peripheral vascular bypass surgery
3310035|NCT00328068||Back pain / peripheral arthritis|Patients with chronic back pain of unknown origin and onset of back pain <45 years of age or patients with peripheral arthritis / enthesitis / dactylitis of unknown origin and onset <45 years of age
3310036|NCT00328042|Experimental|Self-Management Workshop|
3310037|NCT00328042|Active Comparator|Information Only|
3310038|NCT00328016|Experimental|Device Guided Breathing|Individual breathing rate was determined from an expandable band around the torso connected to a commercially available device (RESPeRATE, Lod, Israel) that presented distinctive tones via earphones.
3310039|NCT00328016|Placebo Comparator|Control Group|Control group were instructed to sit in the same manner passively attend to their breathing, and silently repeat 'one' during each exhalation. If other thoughts came to mind, they were instructed to calmly attend to their breathing.
3310040|NCT00327964||study population|601 children enrolled in an on-going longitudinal antimalarial treatment efficacy trial in Kampala, Uganda.
3310041|NCT00327912|Experimental|1|Laparoscopic Biliopancreatic diversion with Duodenal switch
3310042|NCT00327912|Active Comparator|2|Laparoscopic Roux-en-Y Gastric Bypass
3310043|NCT00327873|Experimental|A|Oxygen
3310044|NCT00327873|Active Comparator|B|Medical Air
3310045|NCT00327860||Cohort 1|"Age between 1 and 16 years (before 17th birthday) and estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min|1.73m2"
3310046|NCT00327860||Cohort 2|"Age between 1 and 16 years (before 17th birthday), estimated GFR between 45 and 90 ml/min|1.73m2 based on the updated Schwartz formula, and an equal distribution of children with glomerular and non-glomerular causes of disease were enrolled (i.e., 150 within each) and the study placed an upper limit of 60% for the percent of enrolled with non-glomerular disease."
3310047|NCT00327860||Cohort 3|Age between 6 months and 16 years (before 17th birthday) with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled.
3310048|NCT00327808|Experimental|Inhaler|TPI 1020
3310049|NCT00327808|Active Comparator|Inhaler cortico.|Budesonide inhaler
3310050|NCT00327769|Active Comparator|1|Anastrozole
3310051|NCT00327769|Experimental|2|Anastrozole + Fulvestrant
3310052|NCT00327743|Experimental|larotaxel + Capecitabine|
3310053|NCT00327717|Experimental|Zonisamide 100 mg tablet|
3310054|NCT00327717|Placebo Comparator|Placebo|
3310055|NCT00327704|Active Comparator|Albumin|
3310056|NCT00327704|Placebo Comparator|Saline|
3310057|NCT00327665|Experimental|Group A|
3310058|NCT00327665|Experimental|Group B|
3310059|NCT00327665|Experimental|Group C|
3310060|NCT00327665|Active Comparator|Group D|
3310061|NCT00327665|Active Comparator|Group E|
3310062|NCT00327600|Experimental|imexon + DTIC|
3310063|NCT00327535|Experimental|Mircera 6.3 micrograms/kg|
3310064|NCT00327535|Experimental|Mircera 9 micrograms/kg|
3310065|NCT00327535|Experimental|Mircera 12 micrograms/kg|
3310066|NCT00327535|Active Comparator|Darbepoetin alfa|
3310067|NCT00327509||1-HTG|high tension glaucoma highest IOP > 21 mmHg
3310068|NCT00327509||2-NTG|normal tension glaucoma highest measured IOP < 21 mmHg
3310069|NCT00327509||3-PEX|pseudoexfoliation glaucoma PEX material visible
3310070|NCT00327509||4-Juvenile|juvenile glaucoma
3310071|NCT00327509||5-Control1|healthy subjects (age group 1)
3310072|NCT00327509||6-Control2|healthy subjects (age group 2)
3310073|NCT00327470|Experimental|Open Label|
3310074|NCT00327444|Placebo Comparator|Placebo|"Participants with advanced ovarian cancer administered placebo in the double-blind (DB) period.~In the open-label (OL) period, participants had the option to receive aflibercept or be withdrawn from the study."
3310075|NCT00327444|Experimental|Aflibercept|"Participants with advanced ovarian cancer administered aflibercept in the double-blind (DB) period.~In the open-label (OL) period, participants had the option to continue to receive aflibercept or be withdrawn from the study."
3310078|NCT00327340|Experimental|OGX-011 / mitoxantrone/prednisone|OGX-011 / mitoxantrone/prednisone: OGX-011 administered in combination with mitoxantrone and prednisone
3310079|NCT00327340|Experimental|OGX-011/docetaxel/prednisone|OGX-011/docetaxel/prednisone: OGX-011 administered in combination with docetaxel and prednisone
3310080|NCT00327288|Experimental|A|Docetaxel plus imexon
3310081|NCT00327223|Experimental|imexon|Dose escalation of imexon
3310082|NCT00327210|Experimental|BGATHome|Blood Glucose Awareness Training at Home Internet Intervention
3310083|NCT00327210|No Intervention|Control|No intervention
3310084|NCT00327197|Experimental|Intermittent mild steroid-naïve asthmatic group|Asymptomatic subjects receiving only beta-agonist inhaler with predicted FEV1 >=80% and normal peak expiratory flow between attacks will be included.
3310085|NCT00327197|Experimental|Mild to moderate persistent asthmatic group|Subjects with mild to moderate persistent asthma on low to moderate dose of inhaled corticosteroid (200-500 microgram fluticasone propionate daily or equivalent), an FEV1 >= 80% predicted (post-bronchodilator), and less than 20% variability in peak expiratory flow.
3310086|NCT00327197|Experimental|Severe asthma group|Subjects with severe persistent asthma. They will be on either: high inhaled corticosteroid (CS >=1000 microgram fluticasone daily or equivalent) or on high dose inhaled CS plus oral CS (no more than 20 milligrams predisolone a day). The subjects should have at least one ( if on oral steroids) or two (if only on inhaled steroids) of the following: 1) FEV1<80% and FEV1/FVC ratio <70% 2) more than 25% variability in peak expiratory flow 3) daily symptoms ± nocturnal symptoms 4) severe exacerbations of >= twice a year in at least one of the last two years.
3310087|NCT00327197|Placebo Comparator|Healthy subjects group|Non-asthmatic and non-smokers with FEV1 > 85% predicted, on no regular medication.
3310088|NCT00327184|Experimental|Group Hib-MenC|Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of Hib-MenC + Infanrix™ penta vaccines.
3310089|NCT00327184|Active Comparator|Group NeisVac-C|Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of NeisVac-C™ + Infanrix™ hexa vaccines.
3310090|NCT00327171|Experimental|Aflibercept 2.0 mg/kg|Participants with advanced ovarian epithelial adenocarcinoma administered 2.0 mg/kg Aflibercept.
3310091|NCT00327171|Experimental|Aflibercept 4.0 mg/kg|Participants with advanced ovarian epithelial adenocarcinoma administered 4.0 mg/kg Aflibercept.
3310092|NCT00327132|Experimental|Experimental Arm|
3310093|NCT00327106|Active Comparator|1|Exacyl
3310094|NCT00327106|Placebo Comparator|2|Physiologic serum
3310095|NCT00327093|Experimental|1|Bevacizumab
3310096|NCT00327093|Experimental|2|Cetuximab
3310097|NCT00327054|Experimental|Nigella sativa seed|
3310098|NCT00327054|No Intervention|Control|
3310099|NCT00327015|Experimental|Saxagliptin and Metformin (A)|PLUS open-label pioglitazone (as needed as rescue medication)
3310100|NCT00327015|Experimental|Saxagliptin and Metformin (B)|PLUS open-label pioglitazone (as needed as rescue medication)
3310101|NCT00327015|Experimental|Saxagliptin and Placebo (C)|PLUS open-label pioglitazone (as needed as rescue medication)
3310102|NCT00327015|Active Comparator|Metformin and Placebo (D)|PLUS open-label pioglitazone (as needed as rescue medication)
3310103|NCT00326989|Active Comparator|Low-dose shock wave treatment & Placebo|
3310104|NCT00326989|Active Comparator|low-dose shock-wave treatment & Cell therapy|
3310105|NCT00326989|Active Comparator|High-dose shock-wave treatment & Placebo|
3310106|NCT00326989|Active Comparator|High-dose shock-wave treatment & cell therapy|
3310107|NCT00326989|Active Comparator|Placebo shock-wave treatment & cell therapy|
3310108|NCT00326976|Experimental|1|400 mg injected in 2 divided boluses
3310109|NCT00326976|Placebo Comparator|2|Matching placebo
3310110|NCT00326963|Experimental|Enfuvirtide+PI+ARV's|"Eligible participants received Fuzeon® (enfuvirtide) 90 milligram (mg) subcutaneously (SC) two times a day (bid) for 24 weeks plus new protease inhibitor (PI) (darunavir/ritonavir) plus other investigator-choice antiretrovirals (ARVs). Participants selected their preferred injection device among the following three options: 27 gauge (G) ½ needle/syringe, 31G 8 millimeter (mm) needle/syringe or Biojector 2000 (B2000) needle-free injection device (NFID)."
3310111|NCT00326950|Experimental|1|
3310112|NCT00326924|Experimental|Biological|PRBCs that are less than 7 days old are considered 'fresh'.
3310113|NCT00326924|Experimental|Standard PRBCs|PRBCs 'stored' as per hospital policy.
3310114|NCT00326911|Experimental|cetuximab + bevacizumab + gemcitabine|Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks, and gemcitabine 1000 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks. All medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab, bevacizumab, and gemcitabine. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.
3310115|NCT00326911|Active Comparator|cetuximab + bevacizumab|Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks. Both medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab and bevacizumab. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.
3310116|NCT00326898|Experimental|Arm A (sunitinib + sorafenib placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive sunitinib malate PO QD for 4 weeks and placebo sorafenib tosylate PO QD or BID for 6 weeks.
3310117|NCT00326898|Experimental|Arm B (sorafenib + sunitinib placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive sorafenib tosylate PO QD or BID for 6 weeks and placebo sunitinib malate PO QD for 4 weeks followed.
3310118|NCT00326898|Placebo Comparator|Arm C (sunitinib placebo + sorafenib placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive placebo sorafenib tosylate as in Arm A and placebo sunitinib malate as in Arm B.
3310119|NCT00326885|Experimental|Catumaxomab|
3310294|NCT00324272|Experimental|Groin dissection: sealant used.|
3310295|NCT00324272|Active Comparator|Groin dissection: no sealant used.|
3310120|NCT00326872|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for 26 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue treatment beyond 26 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, prior to course 2, prior to course 4, and every 6 courses thereafter.
3310121|NCT00326820|Experimental|Ibandronic Acid|50mg tablet once daily over 96 weeks
3310122|NCT00326820|Active Comparator|Zoledronic Acid|4 mg via intravenous infusion (iv) over a minimum of 15 minutes in at least 100mls of saline every 4 weeks over 96 weeks
3310123|NCT00326781|Active Comparator|Nicotine Nasal Spray|
3310124|NCT00326781|Active Comparator|Transdermal Nicotine patch|
3310125|NCT00326716|Experimental|Treatment|
3310126|NCT00326664|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
3310127|NCT00326638|Other|Arm A: 3D-Conformal Radiation|"Intervention: Standard radiation treatment for high risk prostate cancer. Once daily Monday to Friday for 8 weeks.~3DCRT 7800 cGY/39 Fractions/ STD Technique*~Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23~Boost 6 F 3DCRT to Prostate 3,200 cGy/16"
3310128|NCT00326638|Experimental|Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy|"Intervention: Helical Tomotherapy Intensity Modulated Radiotherapy (IMRT) once daily Monday to Friday for 8 weeks.~IMRT using Helical Tomotherapy* 7800 cGY/39 Fractions Boost IMRT to Prostate 3,200 cGy/16"
3310129|NCT00326625|Experimental|40 mg glatiramer acetate (GA)|Pre-filled syringe of 40 mg glatiramer acetate (GA) for injection, administered subcutaneously once a day.
3310130|NCT00326625|Placebo Comparator|Placebo|Pre-filled syringe of matching placebo, administered subcutaneously once a day.
3310131|NCT00326612|Active Comparator|Intranasal Midazolam 0.2mg/kg|GIve once for seizure longer than 5 minutes
3310132|NCT00326612|Active Comparator|Rectal Diazepam 0.3-0.5 mg/kg|Given once for seizure longer than 5 minutes
3310133|NCT00326599|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and oral AZD2171 once daily on days 1-21. Treatment repeats every 21 days for up to 6 courses. Patients achieving stable disease, partial response, or complete response after 6 courses of therapy receive AZD2171 alone as above. Treatment with AZD2171 repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3310134|NCT00326599|Active Comparator|Arm II|Patients receive gemcitabine and carboplatin as in arm I. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3310135|NCT00326586|Experimental|1|
3310136|NCT00326534||Controls|Patients without sarcoidosis, but requiring a fiberoptic bronchoscopy
3310137|NCT00326534||Sarcoidosis patients|Patients with newly diagnosed sarcoidosis
3310138|NCT00326495|Experimental|BAY 43-9006 & Cetuximab|BAY 43-9006: Administered orally at a dose of 400 mg twice a day (BID). Cetuximab will be given intravenously (IV) at a dose of 400 mg/m^2 initially as a loading dose on week 2, followed by 250 mg/m^2 weekly starting on week 3
3310139|NCT00326469|Experimental|1|
3310140|NCT00326456|Experimental|carboplatin and liposomal doxorubicin|
3310141|NCT00326456|Active Comparator|carboplatin and paclitaxel|
3310142|NCT00326443|Experimental|1|14 subjects Oral CVD 909 with buffer on Day 0. Parental Vi polysaccharide vaccine on Day 21.
3310143|NCT00326443|Placebo Comparator|2|14 subjects oral buffer placebo. Parental Vi polysaccharide vaccine on Day 21.
3310144|NCT00326417|Experimental|Cyclophosphamide 150mg|Fludarabine plus 150 mg/kg Cyclophosphamide (total dose)
3310145|NCT00326417|Experimental|Cyclophosphamide 100mg|Fludarabine plus 100 mg/kg Cyclophosphamide (total dose)
3310146|NCT00326417|Experimental|Cyclophosphamide 50mg|Fludarabine plus 50 mg/kg Cyclophosphamide (total dose)
3310147|NCT00326417|Experimental|Fludarabine|Fludarabine only (no Cyclophosphamide administered)
3310148|NCT00326404|Experimental|1|
3310149|NCT00326404|Active Comparator|2|
3310150|NCT00326378|Active Comparator|CCRT arm without consolidation chemotherapy|Docetaxel 20mg/m2 & Cisplatin 20mg/m2 (D1,8,15,22,29,36) during radiotherapy
3310151|NCT00326378|Experimental|CCRT arm with consolidation chemotherapy|docetaxel 20mg/m2 & cisplatin 20mg/m2 (D1,8,15,22,29,36) during radiotherapy, and followed by consolidation chemotherapy with 3-weekly docetaxel 35mg/m2 & cisplatin 35mg/m2 (D1,8) every 3 weeks (#3).
3310152|NCT00326339|Experimental|1|R788 50 mg PO bid
3310153|NCT00326339|Experimental|2|R788 100 mg PO bid
3310154|NCT00326339|Experimental|3|R788 150 mg PO bid
3310155|NCT00326339|Placebo Comparator|4|Placebo PO bid
3310156|NCT00326287|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d
3310157|NCT00326287|Active Comparator|Ceftriaxone with or without Linezolid|Ceftriaxone 2g qd as 0.5h infusions with or without Linezolid 600mg q12h as 1h infusions, 7-14d
3310158|NCT00326248|Experimental|Arm 1|
3310159|NCT00326222|Experimental|1|Lifestyle counseling
3310160|NCT00326222|No Intervention|2|Usual care
3310161|NCT00326196|Active Comparator|PCI|Percutaneous coronary intervention
3310162|NCT00326196|Active Comparator|CABG|Coronary artery bypass graft (CABG)
3310163|NCT00326183|Active Comparator|1|Arm 1: vaccine
3310164|NCT00326183|Active Comparator|2|Arm 2: Active comparator
3310165|NCT00326170|Experimental|VPA + 5-aza + ATRA|Daily for 7 days, Valproic acid (VPA) starting dose 75 mg/m^2 subcutaneously in combination with 5-azacytidine (5-aza) 50 mg/kg orally; and all-trans retinoic acid (ATRA) 45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3.
3310166|NCT00326157|Experimental|1|AmBisome® will be administered for a duration of 8 weeks
3310167|NCT00326118|Active Comparator|Meningitec + Hiberix Group|Subjects received a single dose of Meningitec™ vaccine co-administered with Hiberix™ and Priorix™ vaccines. The Meningitec vaccine was administered intramuscularly in the left deltoid region, the Hiberix vaccine was administered intramuscularly in the left thigh region and the Priorix vaccine was administered subcutaneously in the right upper arm.
3310296|NCT00324272|Experimental|Axillary dissection: sealant used.|
3310297|NCT00324272|Active Comparator|Axillary dissection: no sealant used.|
3310168|NCT00326118|Experimental|Menitorix Group|Subjects received a single dose of Menitorix™ vaccine co-administered with Priorix™ vaccine. Menitorix vaccine was administered intramuscularly in the left deltoid region and the Priorix vaccine was administered subcutaneously in the right upper arm.
3310169|NCT00326079|Active Comparator|1|
3310170|NCT00326079|Active Comparator|2|
3310171|NCT00326066|Active Comparator|1|
3310172|NCT00326066|Placebo Comparator|2|
3310173|NCT00326040|Experimental|A|
3310174|NCT00326027|Active Comparator|1|Pantoprazole 20 mg
3310175|NCT00326027|Active Comparator|2|Pantoprazole 40 mg
3310176|NCT00326014|Experimental|A|
3310177|NCT00326001|Experimental|Gold tip catheter|Gold tip catheter
3310178|NCT00326001|Active Comparator|Platinum-iridium tip catheter|Platinum-iridium tip catheter
3310179|NCT00325949|Experimental|arm label (1) hydrocodone/acetaminophen extended release|
3310180|NCT00325949|Experimental|arm label (2) hydrocodone/acetaminophen extended release|
3310181|NCT00325949|Placebo Comparator|Arm label (3) placebo|
3310182|NCT00325936|Active Comparator|Nifedipine|parrallel design
3310183|NCT00325936|Experimental|Cilnidipine|
3310184|NCT00325897|Active Comparator|Azithromycin, 250 mg|Macrolide Antibiotic (Azithromycin)
3310185|NCT00325897|Placebo Comparator|Placebo|Inactive
3310186|NCT00325819|Active Comparator|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
3310187|NCT00325819|Placebo Comparator|Placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
3310188|NCT00325780|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
3310189|NCT00325754|Active Comparator|E-Cylinder|22-lb E-cylinder towed on a cart
3310190|NCT00325754|Active Comparator|Lightweight Cylinder|3.6-lb lightweight cylinder that can be carried
3310191|NCT00325728|Experimental|Ramelteon 8 mg QD|
3310192|NCT00325728|Placebo Comparator|Placebo|
3310193|NCT00325715|Experimental|1|
3310194|NCT00325715|Active Comparator|2|
3310195|NCT00325689|Active Comparator|Quetiapine or Risperidone + Aripiprazole|
3310196|NCT00325689|Placebo Comparator|Quetiapine or Risperidone + placebo|
3310197|NCT00325650|Experimental|Rimonabant|Rimonabant 20 mg once daily
3310198|NCT00325650|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
3310199|NCT00325637|Active Comparator|A,1,III|To compare the effect of cilnidipine (calcium channel blocker) and losartan (angiotension II receptor blocker) on CBF in patients with ischemic stroke
3310200|NCT00325598|Experimental|Cohort 1 (36 Gy)|36 Gy in 9 fractions BID x 4 1/2 treatment days
3310201|NCT00325598|Experimental|Cohort 2 (40 Gy)|40 Gy in 10 fractions BID over 5 treatment days
3310202|NCT00325572|Active Comparator|zinc and vitamin C supplementation|Participant will receive oral zinc and vitamin C supplementation based on the child's weight. Blood levels of zinc, copper, liver and renal function as well as blood counts will be measured. Copper to zinc ratio will be calculated at 6 and 16 weeks
3310203|NCT00325572|Placebo Comparator|2|Participant will receive placebo liquid with volume based on child's weight to match the amount given to participants in the experimental group.
3310204|NCT00325533|Experimental|Screening & Enhanced Intervention|After an intensive 10-week baselne screening, the enhanced intervention group barbers will be trained to measure blood pressure and deliver health messages related to blood pressure control during each customer's visit.
3310205|NCT00325533|Active Comparator|Screening|After the intensive 10-week baseline BP screening (an intervention in itself), the barbershops in the comparison arm received a continual supply of American Heart Association pamphlets on Hypertension in African Americans.
3310206|NCT00325520||Anorexia nervosa|Individuals with anorexia nervosa receiving inpatient treatment
3310207|NCT00325520||Healthy controls|
3310208|NCT00325494|Experimental|Cohort 1|MORAb-009 weekly dose of 12.5 mg/m^2
3310209|NCT00325494|Experimental|Cohort 2|MORAb-009 weekly dose of 25 mg/m^2
3310210|NCT00325494|Experimental|Cohort 3|MORAb-009 weekly dose of 50 mg/m^2
3310211|NCT00325494|Experimental|Cohort 4|MORAb-009 weekly dose of 100 mg/m^2
3310212|NCT00325494|Experimental|Cohort 5|MORAb-009 weekly dose of 200 mg/m^2
3310213|NCT00325494|Experimental|Cohort 6|MORAb-009 weekly dose of 400 mg/m^2
3310214|NCT00325468|Experimental|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
3310215|NCT00325442|Active Comparator|Active|Subjects assigned to active therapy with UT-15C 0.25, 0.5, 1, or 5 mg oral tablets.
3310216|NCT00325442|Placebo Comparator|Placebo Arm|Subjects assigned to placebo 0.25, 0.5, 1, or 5 mg oral tablets.
3310217|NCT00325416|Experimental|Age Group A - Melphalan and Topotecan plus Stem Cell Rescue|Participants 18 - 60 years of age. Intensive-Dose Melphalan and Topotecan (MT) followed by Stem Cell transplant.
3310218|NCT00325416|Active Comparator|Age Group B - Melphalan and Topotecan plus Stem Cell Rescue|Participants 61 years of age or older. Intensive-Dose Melphalan and Topotecan (MT) followed by Stem Cell transplant.
3310219|NCT00325403|Active Comparator|UT-15C (oral treprositnil)|Subjects receive UT-15C (oral treprostinil) twice daily.
3310220|NCT00325403|Placebo Comparator|Placebo|Subjects receive placebo (sugar pill) twice daily.
3310221|NCT00325364|Experimental|1|
3310222|NCT00325364|Active Comparator|2|
3310223|NCT00325351|Experimental|Arm 1|
3310224|NCT00325286|Experimental|1|Treatment with lithium and extended release carbamazepine
3310225|NCT00325273|Experimental|probiotics & allergy|"To understand the preventive effect of probiotics in neonatal peroid~To investate the possible mechanism"
3310226|NCT00325234|Experimental|Pemetrexed/Carboplatin|"Pemetrexed 600 mg/m^2 was administered intravenously over approximately 10 minutes on Day 1.~Carboplatin was given over approximately 30 minutes on Day 1 beginning after the end of the Pemetrexed infusion, consistent with a target of AUC (Area under the plasma drug concentration versus time curve) 5.0 mg*min/mL. The cycle of treatment was 21 days."
3310298|NCT00324259|Active Comparator|Arm 1 (6 mg estradiol)|6 mg of estradiol daily (2 mg tid).
3310227|NCT00325234|Active Comparator|Gemcitabine/Vinorelbine|Vinorelbine 30 mg/m^2 was given over approximately 6-10 minutes on Day 1 and Day 8. Gemcitabine 1200 mg/m^2 was given over approximately 30 minutes on Day 1 and Day 8 beginning after the end of the Vinorelbine infusion. The cycle of treatment was 21 days.
3310228|NCT00325221|Experimental|Home Monitoring On|Home Monitoring activated after implantation (Intervention HM On)
3310229|NCT00325221|Experimental|Home Monitoring Off|Home Monitoring activated 9 months after implantation (Intervention HM Off)
3310230|NCT00325195|Experimental|q2 wks|8 mg pegloticase every 2 weeks
3310231|NCT00325195|Experimental|q4 wks|8 mg pegloticase every 4 weeks (alternating with placebo every 4 weeks)
3310232|NCT00325195|Placebo Comparator|placebo|placebo every 2 weeks
3310233|NCT00325182|Experimental|Intervention: Levetiracetam|Levetiracetam dose schedule Days 1-4 250 mg bid Days 5- 19 500 mg bid Days 20 -70 1000 mg bid Days 71-78 500 mg bid Days 79-85 250 mg bid Days 86-91
3310234|NCT00325182|Placebo Comparator|Historical controls|Historical controls from COMBINE study who receive a placebo
3310235|NCT00325156|Experimental|Group A|
3310236|NCT00325143|Experimental|Infanrix Hexa Group|Healthy male or female subjects between and including 11 to 17 weeks of age, who were previously vaccinated with Rotarix™ in study 444563/028 (NCT00197210), additionally received 2 doses of Infanrix™-IPV/Hib vaccine (at 3 and 4 months of age), 2 doses of Rotarix™ vaccine (at 2 and 4 months of age) and one dose of Infanrix Hexa™ vaccine (at 5 months of age) as a primary vaccination course, followed by administration of a booster dose of Infanrix™-IPV/Hib vaccine (at 18 months of age). The Infanrix™-IPV/Hib and Infanrix Hexa™ vaccines were administered intramuscularly into the right antero-lateral thigh, while the Rotarix™ vaccine was given orally.
3310237|NCT00325130|Experimental|Group 1|Concomitant Administration
3310238|NCT00325130|Experimental|Group 2|Non-concomitant administration
3310239|NCT00325078|Experimental|Treatment|Study drug (TNFa inhibitor-infliximab or adalimumab) treated group.
3310240|NCT00325078|No Intervention|Observation|Subjects with IBD without TNFa inhibitor treatment
3310241|NCT00325039|Active Comparator|1|retropubic mid-urethral sling (TVT) The specific TVT used was the Tension-free Vaginal Tape (Gynecare)
3310242|NCT00325039|Active Comparator|2|"transobturator mid-urethral sling (TVT-O and the Monarc) Two transobturator slings were used: the Tension-free Vaginal Tape Obturator (Gynecare), which is placed starting inside the vagina and coming out through the obturator foramen (in-to-out) or the Monarc (American Medical System), which is placed starting in the groin area, passing through the obturator foramen, and then into the vagina (out-to-in)."
3310243|NCT00325013|Experimental|II|
3310244|NCT00324987|Experimental|Arm I (CLOSED TO ACCRUAL 10/1/2009) (imatinib and bevacizumab)|Patients receive imatinib mesylate PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3310245|NCT00324987|Active Comparator|Arm II (CLOSED TO ACCRUAL 10/1/2009) (imatinib)|Patients receive imatinib mesylate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3310246|NCT00324974|Experimental|Lansoprazole QD|
3310247|NCT00324974|Placebo Comparator|Placebo QD|
3310248|NCT00324961|Experimental|Single arm open label adefovir dipivoxil|adefovir dipivoxil once daily 10 mg orally
3310249|NCT00324922|Active Comparator|1|trimethoprim-sulfamethoxazole
3310250|NCT00324922|Active Comparator|2|vancomycin
3310251|NCT00324896|Experimental|eszopiclone|eszopiclone. Those under 65yo received 3mg of eszoplicone ( or randomized to matching placebo)and those 65yo or older received 2mg of eszoplicone ( or randomized to matching placebo)taken each night at bedtime
3310252|NCT00324896|Placebo Comparator|placebo|Those randomly assigned to matching placebo, took their dose each night at bedtime
3310253|NCT00324870|Experimental|Arm I|"Phase I: Patients receive oral SAHA twice daily on days 1-14 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.~Phase II: Patients receive SAHA at the MTD determined in phase I and bevacizumab as in phase I."
3310254|NCT00324857|Placebo Comparator|Arm 1/Attention Control|Subjects randomized to the attention control arm received a patient educational booklet about OA published by the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This booklet provides a brief educational program that summarizes how to live with knee OA but does not specifically mention joint replacement
3310255|NCT00324857|Active Comparator|Arm 2/Decision Aid (DA)|"Decision Aid Video: The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option."
3310256|NCT00324857|Active Comparator|Arm 3/ Motivational Interview (MI)|Motivational Interviewing: The research intervention will conduct the fact-to-face MI session with the participant. This was used as a mechanism to help patients confront their thoughts about TKR and how to engage their primary care doctors about knee pain
3310257|NCT00324857|Active Comparator|Arm 4/ DA and MI|"Decision Aid Video: The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option.~Motivational Interviewing: The research intervention will conduct the fact-to-face MI session with the participant. This was used as a mechanism to help patients confront their thoughts about TKR and how to engage their primary care doctors about knee pain"
3310299|NCT00324259|Active Comparator|Arm 2 (30 mg estradiol)|30 mg of estradiol. (10 mg tid)
3310300|NCT00324233|Active Comparator|SC|Speedicath (SC) catheter is a catheter for intermittent catherisation
3310301|NCT00324233|Experimental|SCCM|SpeediCath Compact Male (SCCM) is a compact catheter for intermittent catherisation to be used by males
3315976|NCT00246090|Experimental|1|
3310258|NCT00324805|Active Comparator|Arm I (chemotherapy)|"Patients receive one of the following. For all, treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~REGIMEN 1: Vinorelbine ditartrate 30 mg/m2 IV on days 1 and 8, cisplatin 75 mg/m2 IV over 60 minutes on day 1 REGIMEN 2: Docetaxel 75 mg/m2 IV and cisplastin 75 mg/m2 IV on day 1 REGIMEN 3: Gemcitabine hydrochloride 1200 mg/m2 IV on days 1 and 8, cisplatin 75 mg/m2 IV on day 1 REGIMEN 4 (non-squamous histology only): Pemetrexed disodium 500mg/m2 IV and cisplatin 75 mg/m2 IV on day 1"
3310259|NCT00324805|Experimental|Arm II (chemotherapy, bevacizumab)|Patients receive chemotherapy as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment with bevacizumab repeats every 21 days for up to 1 year.
3310260|NCT00324766|Active Comparator|1|levosimendan
3310261|NCT00324766|Placebo Comparator|2|Placebo, 1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
3310262|NCT00324753|Experimental|Arm 1|Communication sheet
3310263|NCT00324753|Other|Arm 2|Standard of care brochures
3310264|NCT00324740|Experimental|Treatment (vorinostat and isotretinoin)|Patients receive oral vorinostat (SAHA) twice daily and oral isotretinoin twice daily on days 3-5, 10-12, 17-19, and 24-26. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3310265|NCT00324727|Experimental|Arm I|"Patients undergo an isolated hepatic arterial infusion of melphalan over 30 minutes on day 1. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response undergo 2 additional courses~in the absence of ongoing or increasing toxicity."
3310266|NCT00324727|Active Comparator|Arm II|"Patients receive the best alternative therapy comprising supportive care, systemic or regional chemotherapy, hepatic artery (chemo)-embolization, or any other appropriate therapy at the National Cancer Institute or therapy at the discretion of their physician.~Patients may cross over to arm I if they have evidence of disease progression."
3310267|NCT00324701|Experimental|Telepsychology|therapy done at patients house
3310268|NCT00324701|Active Comparator|Face-to-face therapy|therapy delivered at the VAMC
3310269|NCT00324675|Active Comparator|Rosiglitazone|
3310270|NCT00324675|Placebo Comparator|placebo|
3310271|NCT00324649|Experimental|Truvada|Truvada + NNRTI or PI.
3310272|NCT00324649|Active Comparator|Zidovudine/lamivudine|Zidovudine/lamivudine + NNRTI or PI.
3310273|NCT00324623|Experimental|Lymphodepletion, vaccine, IMP321 adjuvant|
3310274|NCT00324558|Experimental|1|Bemiparin 3,500 IU
3310275|NCT00324558|No Intervention|Control|
3310276|NCT00324519|Active Comparator|Misoprostol Drug|This is the misoprostol drug.
3310277|NCT00324519|Experimental|The Foley Bulb|This is the experimental portion to test the Foley Bulb.
3310278|NCT00324506|Active Comparator|Cellcept and Avonex|
3310279|NCT00324480|Experimental|Treatment (chemotherapy, enzyme inhibitor)|Before beginning course 1 of study therapy, patients receive oral SAHA on days 1-3 in order to ensure tolerability of the drug. Beginning 1 week later, patients receive oral SAHA once daily on days 1-3 and 8-10 and fixed-dose alvocidib IV over 1 hour on days 2 and 9. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3310280|NCT00324467|Active Comparator|R-CHOP (Negative Mid-Treatment PET Scan)|"All participants will receive 4 cycles of standard dose R-CHOP chemotherapy administered at 3-weekly intervals. Non-progressing participants will undergo a mid-treatment PET scan along with routine restaging investigations after 4 cycles of R-CHOP. Patients with a negative mid-treatment PET scan (no evidence of abnormal 18F-FDG uptake) will complete therapy with two additional cycles of R-CHOP for a total of 6 cycles of chemotherapy. Patients with a mid-treatment PET scan interpreted to be indeterminate or equivocal will be recorded as such, but should be considered negative for the purpose of treatment planning and should not prompt a change in therapy."
3310281|NCT00324467|Active Comparator|R-ICE (Positive Mid-Treatment PET Scan|"All participants will receive 4 cycles of standard dose R-CHOP chemotherapy administered at 3-weekly intervals. Non-progressing participants will undergo a mid-treatment PET scan along with routine restaging investigations after 4 cycles of R-CHOP. Patients with a mid-treatment PET scan (abnormal 18F-FDG uptake) will be switched to R-ICE chemotherapy and receive 4 cycles of R-ICE for a total of 8 cycles of chemotherapy.~Following completion of R-ICE chemotherapy, patients will undergo a post-treatment PET scan along with routine restaging investigations. The post-treatment PET scan will be performed between days 28 and 35 following the final cycle of R-ICE. Patients with a negative post-treatment PET scan will undergo no further therapy. Patients with a positive post-treatment PET scan corresponding to persistent abnormalities on CT scan will be considered for radiation therapy to PET positive sites."
3310282|NCT00324428|Experimental|Transcranial Magnetic Stimulation (TMS)|This arm provides active 1Hz repetitive TMS (rTMS) applied to SII
3310283|NCT00324428|Sham Comparator|Transcranial Magnetic Stimulation Sham|This arm provides sham 1Hz repetitive TMS (rTMS) applied to SII
3310284|NCT00324415|Experimental|CMT with Radiation Therapy|"All patients will receive combined modality therapy (CMT) with 2 cycles of cisplatin and 5-FU chemotherapy, given concurrently with radiation therapy. CMT consists of:~Cetuximab 400 mg/m2 IV Day -7 (1 week before the cycle 1, Day 1 cisplatin/5-FU and RT), then 250 mg/m2 IV Days 1, 8, 15, 22, 29, 36 and 43 (a minimum of 6 and a maximum of 8 doses of cetuximab will be administered, including the loading dose).~Cisplatin 75 mg/m2 IV on Day 1 (cycle 1) and Day 29 (cycle 2)~5-FU 1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)"
3310285|NCT00324402||1|Healthy pregnant women, 18-40
3310286|NCT00324363|Experimental|Exenatide|Placebo lead-in; exenatide 5 mcg for 4 weeks; exenatide 10 mcg for 12 weeks
3310287|NCT00324363|Placebo Comparator|Placebo|Placebo in volume equal to exenatide
3310288|NCT00324350|Active Comparator|1|intensive glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level below 6.0%)
3310289|NCT00324350|Active Comparator|2|standard glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level of 7 to 7.9%)
3310290|NCT00324324|Active Comparator|moxifloxacin hydrochloride|Moxifloxacin 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
3310291|NCT00324324|Placebo Comparator|Sugar pill|Placebo 1 capsule orally once a day through D+100 after bone marrow transplant, then discontinue
3310292|NCT00324311|Experimental|DGD|
3310293|NCT00324311|Active Comparator|SOC|
3310302|NCT00324220|Experimental|1|MGCD0103 oral administration 3 times per week.
3310303|NCT00324194|Experimental|1|MGCD0103 oral dose 2 times per week.
3310304|NCT00324168|Active Comparator|1|
3310305|NCT00324168|Placebo Comparator|2|
3310306|NCT00324155|Experimental|Arm A: Ipilimumab and Dacarbazine|In Maintenance phase: Ipilimumab will be continued. Dacarbazine was given up to Week 22 and is not given in the Maintenance phase
3310307|NCT00324155|Active Comparator|Arm B: Placebo and Dacarbazine|
3310308|NCT00324129|Experimental|1|
3310309|NCT00324116|Experimental|Active|
3310310|NCT00324038|Experimental|buprenorphine transdermal system|Buprenorphine transdermal 7 day analgesic patch
3310311|NCT00324038|Active Comparator|codeine paracetamol tablets|codeine paracetamol combination tablets
3310312|NCT00324025|Experimental|1|Mycograb
3310313|NCT00324025|Active Comparator|2|biological
3310314|NCT00324012|Experimental|treatment|taxotere and cisplatin day one every three weeks
3310315|NCT00323973|Experimental|1|
3310316|NCT00323973|Placebo Comparator|2|Placebo
3310317|NCT00323960|Active Comparator|MPDN+PDN+CSA|MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A
3310318|NCT00323960|Active Comparator|MPDN+PDN+MTX|MPDN= methylprednisolone pulse PDN= prednisone or equivalent MTX= methotrexate
3310319|NCT00323960|Active Comparator|MPDN+PDN|MPDN+PDN MPDN= methylprednisolone PDN= prednisone or equivalent
3310320|NCT00323947|Active Comparator|1|Participants will take OROS-MPH then switch to placebo
3310321|NCT00323947|Placebo Comparator|2|Participants will take placebo then switch to OROS-MPH
3310322|NCT00323934|Experimental|1|MGCD0103 Oral 2 times weekly
3310323|NCT00323908||1|Women at high risk for developing breast cancer
3310324|NCT00323895|Experimental|1|group with intra-Cypher™ restenosis
3310325|NCT00323895|Active Comparator|2|group with intra-Taxus™ restenosis
3310326|NCT00323895|Active Comparator|3|group with intra-BMS restenosis
3310327|NCT00323882|Experimental|MDX-010|
3310328|NCT00323869|Experimental|Bevacizumab + carboplatin + gemcitabine|"Bevacizumab in combination with carboplatin and gemcitabine:~•Carboplatin, administered IV at area under the curve (AUC) of 5, every 3 weeks on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles.~Carboplatin was administered before the gemcitabine infusion:~•Gemcitabine, administered 1000 mg/m² IV on days 1 and 8 of each 3-week cycle (twice per cycle) for up to 6 cycles~Bevacizumab was administered 1 hour after end of all chemotherapy infusions:~•Bevacizumab was administered 15 mg/kg IV on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles in combination with chemotherapy, then continuing until evidence of progressive disease or significant treatment-related toxicity"
3310329|NCT00323856|Experimental|Coagulation factor VIII (Human)|Anti-Hemophilic coagulation factor VIII (Human) Alphanate SD/HT
3310330|NCT00323830|Experimental|capecitabine/cisplatin/radiotherapy|postoperative XP/RT
3310331|NCT00323830|Active Comparator|capecitabine/cisplatin|postoperative XP
3310332|NCT00323804|Experimental|Randomised PegIFN alfa 2b + ribavirin (RBV) arm|Combination of ribavirin capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
3310333|NCT00323804|Placebo Comparator|Randomised PegIFN alfa 2b + ribavirin-placebo arm|Combination of ribavirin-placebo capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
3310334|NCT00323739|Experimental|Bevacizumab and RAD001|Bevacizumab 10mg/kg, IV infusion, every 2 weeks RAD001 10 mg by mouth daily
3310335|NCT00323713|Experimental|VLPD diet|Adavnced CKD patients (stage 4-5) on a very low protein diet
3310336|NCT00323713|Active Comparator|LPD diet|Adavnced CKD patients (stage 4-5) on a low protein diet
3310337|NCT00323674|Active Comparator|Light Weight Mesh|
3310338|NCT00323674|Active Comparator|Polysoft Mesh|
3310339|NCT00323661|Experimental|1|Rate-adaptation by Closed Loop Stimulation
3310340|NCT00323661|Active Comparator|2|Accelerometer based pacing rate adaptation
3310341|NCT00323648|Experimental|postoperatively antibiotics|
3310342|NCT00323635|Experimental|Tolterodine|Tolterodine 4 mg q.d. X 8 weeks
3310343|NCT00323635|Placebo Comparator|Placebo|A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine
3310344|NCT00323622|Experimental|Cohort 1-RTS,S/AS02A <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
3310345|NCT00323622|Experimental|Cohort 1-RTS,S/AS02A ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
3310346|NCT00323622|Experimental|Cohort 2-RTS,S/AS02A <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
3310386|NCT00323271|Experimental|Arm 1|Behavioral: Cognitive-behavior therapy
3310387|NCT00323271|Active Comparator|Arm 2|Interventional: Educational intervention
3310458|NCT00322374|Experimental|25 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
3310583|NCT00321087|Experimental|2|Placebo followed by T2000 dose escalation
3311671|NCT00306917|Active Comparator|2|Porocoat porous coated
3310347|NCT00323622|Experimental|Cohort 2-RTS,S/AS02A ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 of the NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
3310348|NCT00323622|Active Comparator|Cohort 1-Prevnar-Hiberix <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 2 doses of Prevnar™ vaccine at Months 0 and 2 and 1 dose of Hiberix® vaccine at Month 1 in the Primary NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
3310349|NCT00323622|Active Comparator|Cohort 1-Engerix-B ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of Engerix®-B vaccine at Months 0, 1 and 2 in the Primary NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
3310350|NCT00323622|Active Comparator|Cohort 2-Prevnar- Hiberix <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 2 doses of Prevnar™ vaccine at Months 0 and 2 and 1 dose of Hiberix® vaccine at Month 1 in the Primary NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
3310351|NCT00323622|Active Comparator|Cohort 2-Engerix-B ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of Engerix®-B vaccine at Months 0, 1 and 2 in the Primary NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
3310352|NCT00323609|Active Comparator|Kyphoplasty|
3310353|NCT00323609|Active Comparator|Vertebroplasty|
3310354|NCT00323557|Experimental|Pneumococcal Vaccine + GM-CSF|Vaccine subcutaneously + GM-CSF (3 Doses of 250 mg subcutaneously) given either Pre Vaccine at Day -7, Day -1 and Day 0 (day of pneumococcal vaccine) or Post Vaccine given at Day 0, Day +3 and Day +7.
3310355|NCT00323557|Experimental|Pneumococcal Vaccine Alone|First vaccine dose subcutaneously, Day 0.
3310356|NCT00323531|Active Comparator|1|Video assisted thoracoscopic decortication
3310357|NCT00323531|Experimental|2|Fibrinolysis through the chest tube
3310358|NCT00323518|Placebo Comparator|1|placebo
3310359|NCT00323518|Experimental|2|30 mcg/kg velafermin
3310360|NCT00323518|Experimental|3|10 mcg/kg velafermin
3310361|NCT00323518|Experimental|4|60 mcg/kg velafermin
3310362|NCT00323492|Experimental|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization
3310363|NCT00323492|Active Comparator|Maintain Baseline Regimen|Maintain baseline regimen
3310364|NCT00323492|Experimental|Delayed Truvada|Truvada once daily with NNRTI or PI (participants from the comparator group who switched to Truvada during Study Phase 2)
3310365|NCT00323492|Experimental|All Truvada|Truvada once daily with NNRTI or PI (all participants who received Truvada during the study, i.e., participants in the Truvada and Delayed Truvada groups)
3310366|NCT00323466|Experimental|IMRT|
3310367|NCT00323453|Experimental|wound protection device|A wound protection device is utilized intraoperatively. Intervention is: Placement of intraoperative device.
3310368|NCT00323453|Placebo Comparator|no wound protection|procedure performed without wound protection device
3310369|NCT00323440||Group 1|FMF patients in remission
3310370|NCT00323440||Group 2|FMF patients during attack
3310371|NCT00323440||Group 3|FMF patients without colchicine in remission
3310372|NCT00323440||Group 4|FMF patients without colchicine in attack
3310373|NCT00323427|Experimental|Arm 1|Group Aural Rehabilitation session, two hours in length, approximately 6 participants plus Group Facilitator
3310374|NCT00323427|Active Comparator|Arm 2|Veterans receive new VA issued digital hearing aids per Standard VA Audiology Hearing Aid services
3310375|NCT00323414|Active Comparator|Polyunsaturated fatty acid (Opti-EPA)|Polyunsaturated fatty acid will consist of purified EPA:DHA (360 mg EPA and 240 mg DHA) 6 gelcaps-3 capsules by mouth 2x per day x 48 weeks
3310376|NCT00323414|Placebo Comparator|Placebo|Gelcaps containing corn oil as placebo 6 capsules 3 capsules by mouth 2 x per day for 48 weeks
3310377|NCT00323401|Experimental|Interventon|Antenatal classes for the parents
3310378|NCT00323401|No Intervention|Control|No programme are offered
3310379|NCT00323362|Experimental|Gemcitabine hydrochloride and imatinib mesylate|
3310380|NCT00323323|Experimental|Alemtuzumab/CHOP|For all patients enrolled, the study will begin with a stepped-up schedule of single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5. Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose
3310381|NCT00323310|Experimental|Gadobenate Dimeglumine|
3310382|NCT00323297|Placebo Comparator|placebo|
3310383|NCT00323297|Experimental|Active|
3310384|NCT00323284|Active Comparator|A--iStent plus Cataract Surgery|iStent plus Cataract Surgery
3310385|NCT00323284|Active Comparator|B--Cataract Surgery Only|Cataract Surgery only
3310388|NCT00323258|Experimental|Intervention|Patients enrolled in the intervention arm received inpatient education on the importance of medication and assessment of barriers to adherence. A pill box, pocket medication card, and tips for remembering to take medications were provided. The community pharmacist was notified of the subject's enrollment. The community pharmacist was asked to reinforce importance of evidence-based medications and assess the subject's medication adherence every 6 weeks for 6 months. If a problem was noted, the subject's health care team will be notified.
3310389|NCT00323258|Active Comparator|Usual Care|The usual care group received routine discharge counseling performed by the patient-care nurse and a letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations. Enrolled patients in the usual care arm were not disclosed to the community pharmacy until the end of the study period when refill records were requested.
3310390|NCT00323206|Experimental|Intra-tumoral Electroporation of pIL-12|Participants will receive intra-tumoral injection of pIL-12 followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid DNA into tumor cells. For each lesion selected for therapy, a total of three electroporation treatments will be performed.
3310391|NCT00323193|Experimental|Arm 1|The intervention group completes approximately 8 individual level sessions with a MOVE specialist as well as approximately 8 group level intervention sessions.
3310392|NCT00323193|No Intervention|Arm 2|The control group offers basic information about diet and exercise every month for six months.
3310393|NCT00323141|Active Comparator|Ventralex|
3310394|NCT00323141|Active Comparator|Leight Weight Vypro II prothesis|
3310395|NCT00323115|Experimental|Vaccine|
3310396|NCT00323089|Experimental|Surgical Arm|Preoperative CT-Guided Microcoil Localization (CTML) and Fluoroscopic-Guided Video-Assisted Thoracoscopic (VATS) Wedge Resection of Small Peripheral Pulmonary Nodules (SPPN)
3310397|NCT00323076|Experimental|1|18F-FAZA PET Imaging
3310398|NCT00323063|Active Comparator|Arm I (Gemcitabine Hydrochloride)|Patients receive gemcitabine hydrochloride IV on days 3 and 10.
3310399|NCT00323063|Experimental|Arm II (Gemcitabine Hydrochloride + Imatinib)|Patients receive gemcitabine hydrochloride IV on days 3 and 10 and oral imatinib mesylate once daily on days 1-5 and 8-12.
3310400|NCT00323037|Active Comparator|1|
3310401|NCT00323037|Active Comparator|2|
3310402|NCT00323011|Active Comparator|Arm A: 5-FU/LV/CPT-11/Bevacizumab|5-FU 400 mg/m2, days 1, 15, & 29 Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29
3310403|NCT00323011|Experimental|Arm B: 5-FU/LV/CPT-11/Bevacizumab + Dalteparin|5-FU 400 mg/m2, days 1, 15, & 29 5-FU 2400 continuous infusion days 1-2, 15-16, 29-30. Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29 Dalteparin 5000 IU subcutaneous starting cycle 2, days 1, 15, & 29
3310404|NCT00323011|Experimental|5-FU/LV/CPT-11/Bevacizumab+Dalteparin daily|5-FU 400 mg/m2, days 1, 15, & 29 5-FU 2400 continuous infusion days 1-2, 15-16, 29-30. Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29 Dalteparin 5000 IU subcutaneous starting cycle 2, daily
3310405|NCT00322972|Other|A|Annual mass treatment
3310406|NCT00322972|Other|B|Biannual mass treatment
3310407|NCT00322972|Experimental|C|Mass administration of antibiotic; treatment of children (1-10 years of age) only
3310408|NCT00322972|No Intervention|D|Delayed initiation of mass administration of antibiotic
3310409|NCT00322972|Other|F|One-time mass administration only
3310410|NCT00322972|Experimental|G|One-time mass administration of antibiotics, plus intensive latrine construction
3310411|NCT00322946|Experimental|1|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^5 PFU dose) into the deltoid region of either arm.
3310412|NCT00322946|Experimental|2|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^3 PFU dose) into the deltoid region of either arm. This arm will enroll after Arm 1.
3310413|NCT00322946|Experimental|3|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm will enroll after Arms 1 and 2.
3310414|NCT00322946|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
3310415|NCT00322881|Experimental|Carboplatin/Paclitaxel|Patients received chemotherapy on day 1 of a 21 day cycle for 6 cycles. Paclitaxel was given via peripheral or central IV catheter at the dose of 175 mg/m2 over 3 hours. IV carboplatin followed using a dose of Area Under the Curve (AUC) equal to 5 with creatinine clearance based on Jelliffe formula.
3310416|NCT00322868|Experimental|Pioglitazone|All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily Other names: Actos, Takeda
3310417|NCT00322855||Chart Review|patients diagnosed with soft tissue sarcoma
3310418|NCT00322842|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
3310419|NCT00322842|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
3310420|NCT00322777|Experimental|Spirituality Group|Arm where participants began the intervention (the Spirituality Teaching Program) upon recruitment for an 8 week period. Therefore, the program was initiated at week 1 of the trial.
3310421|NCT00322777|Active Comparator|Waitlist Control Group|Arm where participants began the intervention (the Spirituality Teaching Program) after an 8 week wait period. Therefore, the program was initiated at week 8 of the trial. Between week 1 and week 8, participants did not complete the program and were instructed to carry out their day to day activities as before.
3310422|NCT00322699|Experimental|A single arm, non-randomized Phase II Study|Non-Randomized Phase II,Single Arm Study evaluating the efficacy of whole bladder photodynamic therapy as an alternative to radical cystectomy.
3310423|NCT00322686|Experimental|Oglemilast followed by placebo|
3318184|NCT00208260|Experimental|D|FOLFOX-7
3310425|NCT00322621|Experimental|Duloxetine|All subjects receive 30 mg once daily (QD), by mouth (per os - PO) for 1 week followed by duloxetine 60 mg QD, PO for 7 weeks, then maintenance at 60 mg QD, PO for responders to 6 months and rescue at 120 mg QD, PO for non-responders to 6 months. Patients beginning maintenance at the 60 mg QD dose could be increased to the 120 mg QD level if they did not maintain appropriate level of response throughout the maintenance period.
3310426|NCT00322608|Experimental|Dose escalation|
3310427|NCT00322569|Experimental|1|Corio™ Pimecrolimus-Eluting Cobalt Chromium Coronary Stent System
3310428|NCT00322569|Experimental|2|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System
3310429|NCT00322569|Active Comparator|Control Arm|Costar ™ Paclitaxel-Eluting Coronary Stent System
3310430|NCT00322556|Experimental|IgPro10|See Intervention Description
3310431|NCT00322543|Experimental|Drug eluting stent|Corio™ Pimecrolimus-eluting stent
3310432|NCT00322530|Active Comparator|SLED|
3310433|NCT00322530|Active Comparator|CVVHD|
3310434|NCT00322517|Experimental|SU014813|
3310435|NCT00322491|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
3310436|NCT00322491|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
3310437|NCT00322478|Other|GlucoMON-ADMS enabled|Patients who are equipped with the automated technology vs. standard/conventional care
3310438|NCT00322465|Experimental|Doxycycline|Doxycycline 100 mg orally twice daily (2 pills/day = 200 mg/day) for 7 days plus placebo azithromycin orally single dose and placebo tinidazole.
3310439|NCT00322465|Experimental|Doxycycline + Tinidazole|Doxycycline 100 mg orally twice daily for 7 days plus placebo azithromycin single dose plus tinidazole 2 gm orally single dose (4 tablets at 500 mg each).
3310440|NCT00322465|Experimental|Azithromycin|Azithromycin 1 gram (gm) orally single dose (2 tablets at 500 milligrams (mg) each) plus doxycycline placebo twice daily for 7 days plus tinidazole placebo single dose.
3310441|NCT00322465|Experimental|Azithromycin + Tinidazole|Azithromycin 1 gm orally single dose (2 tablets at 500 mg each) plus doxycycline placebo twice daily for 7 days plus tinidazole single dose (4 tablets at 500 mg each).
3310442|NCT00322452|Experimental|1|gefitinib
3310443|NCT00322452|Active Comparator|2|Carboplatin/Paclitaxel
3310444|NCT00322439||Etanercept|Participants received etanercept (Enbrel) treatment at the dose and regimen determined by the investigator and were evaluated for up to 5 years at 6-month intervals. During this period, participants may have discontinued etanercept therapy, may have switched to another anti-psoriatic therapy, may have used etanercept in combination with other anti-psoriatic therapies, or may have discontinued any or all antipsoriatic treatments.
3310445|NCT00322400|Experimental|B1|AMG 706 50 mg daily + Docetaxel (100 mg/m2 D1 every 21 days)
3310446|NCT00322400|Experimental|A4|75 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8 and D15 every 28 days)
3310447|NCT00322400|Experimental|A1|AMG 706 50 mg daily + Paclitaxel (90 mg/m2 D1, D8, D15 every 28 days)
3310448|NCT00322400|Experimental|B4|75 mg AMG 706 daily + Docetaxel (100 mg/m2, D1 every 21 days)
3310449|NCT00322400|Experimental|B5|MTD of AMG 706 + Docetaxel (75mg/m2 D1 every 21 days)
3310450|NCT00322400|Experimental|B3|100 mg AMG 706 daily + Docetaxel (100 mg/m2 on D1 every 21 days)
3310451|NCT00322400|Experimental|B2|AMG 706 125 mg daily + Docetaxel (100 mg/m2 D1 every 21 days)
3310452|NCT00322400|Experimental|A2|AMG 706 125 mg daily + paclitaxel 90 mg/m2 D1, D8, D15 every 28 days
3310453|NCT00322400|Experimental|A3|100 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8, and D15 every 28 days)
3310454|NCT00322387|Experimental|Plerixafor PM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. After the first apheresis, plerixafor (240 µg/kg) was administered each evening (approximately 10pm) followed by apheresis 10 to 11 hours later for up to 4 consecutive days.~Called 'Cohort A' in protocol, study report and publications."
3310455|NCT00322387|Experimental|Plerixafor AM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. The morning of the second day after the first apheresis, plerixafor (240 µg/kg) was administered followed by apheresis 6 hours later. Plerixafor (240 µg/kg) was administered in the morning followed by apheresis 6 hours later for up to 4 consecutive days.~Called 'Cohort B' in protocol, study report and publications."
3310456|NCT00322387|Experimental|Low CD34+ Count/ Plerixafor PM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. If participants had a CD34+ count of >=10 cells/µL but <20 cells/µL on 2 consecutive days, plerixafor (240 µg/kg) was given in the evening. G-CSF was administered and apheresis performed in the morning. Plerixafor (240 µg/kg) administered in the evening followed by G-CSF and apheresis 10 to 11 hours later was repeated for up to 4 consecutive days.~Called 'Cohort C' in protocol, study report and publications."
3310457|NCT00322387|Experimental|Plerixafor After Chemo|"This investigational cohort evaluated the effect of administering plerixafor before white blood cell recovery.~Participants received mobilizing chemotherapy, followed by 5 consecutive days of G-CSF (10 µg/kg). Starting on the sixth day, participants received G-CSF (10 µg/kg) plus plerixafor (240 µg/kg) daily for up to 3 consecutive days. If CD34+ counts reached >= 20 cells/µL 6 hours after any of the 3 plerixafor doses, apheresis began. If not, G-CSF administration continued until the participant qualified for one of the other treatment arms.~Called 'Investigational Cohort' in protocol, study report and publications."
3310530|NCT00321737|Experimental|Dexlansoprazole MR 30 mg QD|
3310531|NCT00321737|Experimental|Dexlansoprazole MR 60 mg QD|
3310459|NCT00322374|Experimental|30 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
3310460|NCT00322374|Experimental|35 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 35 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
3310461|NCT00322361|Experimental|1|Modified Process Hepatitis B Vaccine
3310462|NCT00322361|Active Comparator|2|Recombivax HB™
3310463|NCT00322348|Experimental|ZOLADEX 10.8 mg|ZOLADEX (goserelin acetate) 10.8 mg intramuscular depot for injection every 12 weeks
3310464|NCT00322348|Experimental|ZOLADEX 3.6 mg|ZOLADEX (goserelin acetate) 3.6 mg intramuscular depot for injection every 4 weeks
3310465|NCT00322335|Experimental|Menitorix/Pediarix Group|Subjects were primed with 3 doses of Pediarix™ co-administered intramuscularly with Menitorix™ in the right and left thigh respectively in the primary study (NCT00352963) at 2, 4 and 6 months of age. This was followed by a booster dose of Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
3310466|NCT00322335|Active Comparator|Infanrix hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group|Subjects were either primed in the primary study (NCT00352963) with 3 doses of Infanrix™ hexa administered intramuscularly in the right thigh at 2, 4 and 6 months of age and 2 doses of NeisVac-C™ administered intramuscularly in the left thigh at 2 and 4 months of age or with Engerix-B at birth intramuscularly in the right thigh, Infanrix™ hexa intramusculary in the right thigh at 2 and 6 months of age and NeisVac-C™ intramuscularly in the left thigh at 2 and 4 months of age, Infanrix™ IPV/Hib was administered intramuscularly in the right thigh at 4 months of age. All subjects were boosted with Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
3310467|NCT00322335|Active Comparator|Infanrix hexa/Meningitec Group|Subjects were primed with Infanrix™ hexa co-administered intramuscularly with Meningitec™ in the right and left thigh respectively at 2, 4 and 6 months of age during the primary study (NCT00352963), followed by a booster dose of Infanrix™ hexa intramuscularly in the right thigh between 13 and 14 months of age in study (NCT00323050). No vaccines were administered during this long-term persistence phase of the study.
3310468|NCT00322322|Experimental|1|L-Carnitine
3310469|NCT00322309|Experimental|Mirtazapine|"Mirtazapine administration as follows:~Days 1-4 15mg of mirtazapine daily Days 5-9 30mg of mirtazapine daily Days 10-78 45mg of mirtazapine daily Days 79-81 30mg of mirtazapine daily Days 82-84 15mg of mirtazapine daily"
3310470|NCT00322309|Placebo Comparator|Placebo- Sugar pill|Matched Placebo given daily days 1-84
3310471|NCT00322283|Experimental|Oglemilast|
3310472|NCT00322283|Placebo Comparator|Placebo|
3310473|NCT00322257|Experimental|A|
3310474|NCT00322257|Active Comparator|B|
3310475|NCT00322231|Experimental|ZOSTAVAX™ / Placebo|Zoster vaccine live on Day 1 (Period 1), placebo on Week 4 (Period 2)
3310476|NCT00322231|Experimental|Placebo / ZOSTAVAX™|Placebo on Day 1 (Period 1), zoster vaccine live on Week 4 (Period 2)
3310477|NCT00322218|Experimental|1|Zevalin Therapeutic Regimen: Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
3310478|NCT00322218|Other|2|Observation
3310479|NCT00322179||Obese|
3310480|NCT00322179||Non-Obese|
3310481|NCT00322166|Active Comparator|Group A, Sunlight|Participants in this arm are required to sit in the sun most days of the week for 15 minutes
3310482|NCT00322166|Active Comparator|Group B, sunlight and calcium|Participants in this group receive sunlight and a calcium supplement
3310483|NCT00322166|No Intervention|Group C|Control group
3310484|NCT00322153|Placebo Comparator|Placebo|Oral administration, once daily.
3310485|NCT00322153|Active Comparator|Memantine ER|28mg, once daily. Oral administration for 24 weeks.
3310486|NCT00322114|Experimental|Arm I|Participants receive an oral tomato dietary supplement containing lycopene twice daily for 3 weeks.
3310487|NCT00322114|Experimental|Arm II|Participants receive an oral tomato dietary supplement containing lycopene at a higher dose twice daily for 3 weeks.
3310488|NCT00322114|Placebo Comparator|Arm III|Participants receive oral placebo twice daily for 3 weeks.
3310489|NCT00322101|Experimental|Arm I (Nonmyeloablative regimen)|"CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96."
3310490|NCT00322101|Experimental|Arm II (Myeloablative regimen)|"CONDITIONING: Patients are assigned to 1 of 2 treatment groups.~Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2.~Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4.~TRANSPLANTATION: Patients undergo PBSC infusion on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
3310491|NCT00322062|Experimental|1|"1 pack (contains 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets)= 2L NRL994 . 2 sachets (one of each) will be dissolved in 1L of water. Each litre will be drunk within 1 hour. Furthermore, at least 1000ml (or more) of any additional clear fluid (except milk) has to be drunk after the 2L of NRL994."
3310492|NCT00322062|Active Comparator|2|1 pack consists of 2 flasks of 45ml. Each flask has to be dissolved within 125ml of water. Each intake of NaP solution has to be preceded and followed by 250ml (or more if necessary)of clear liquids(excluding milk)and a delay of at least 12 hours between the intake of the 2 x 45ml of NaP solution has to be completed. In addition, 750ml more of clear liquids (excluding milk)or more if needed must be drunk between the 2 intakes.
3310532|NCT00321737|Placebo Comparator|Placebo|
3310584|NCT00321087|Experimental|3|Placebo followed by T2000 dose escalation
3310585|NCT00321074|Active Comparator|1|
3310493|NCT00322049|Experimental|Cohort A: Dengue Vaccine- Full Dose (T-DEN F17 )|"Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years;~DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection. All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection."
3310494|NCT00322049|Active Comparator|Cohort B: Control vaccines|Control vaccines: Hemophilus influenza type b (Hib) vaccine and varicella vaccine
3310495|NCT00322049|Experimental|Cohort C: Dengue Vaccine - 1/10 Dose (T-DEN F17 )|Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years
3310496|NCT00322036|Experimental|1|Oral 800 mg BID dosing
3310497|NCT00322036|Placebo Comparator|2|Oral BID dosing
3310498|NCT00322023|Experimental|A|Participants will receive treatment with D-serine
3310499|NCT00322010|Experimental|Early PT OT|Early PT/OT Therapy assessments to begin on the first day that consent is obtained. Therapy is delivered by a team consisting of a physical and occupational therapist and coordinated with daily sedative interruption.
3310500|NCT00322010|No Intervention|Standard Care|PT/OT delivered as ordered by the primary ICU team
3310501|NCT00321984|Experimental|Dexlansoprazole MR 30 mg QD|
3310502|NCT00321984|Experimental|Dexlansoprazole MR 60 mg QD|
3310503|NCT00321984|Placebo Comparator|Placebo|
3310504|NCT00321971|Experimental|PST-MCI/AD Caregiving|The experimental Intervention (PST-MCI/AD Caregiving) focuses on training in adaptive problem-solving attitudes and skills (Problem-Solving Therapy or PST). It was adapted from a manualized protocol for PST use in primary care. Our adaptation sought to enhance problem-solving skill levels of family caregivers as they began to face a variety of potential caregiving stressor.
3310505|NCT00321971|Active Comparator|NT-MCI/AD Caregiving|"The comparison Intervention (Caregiver Nutritional Training (NT-MCI/AD) was based on the United States Department of Health and Human Services (USDHHS) 2005 My Pyramid Dietary Guidelines for Americans over Age 50. We chose a nutrition-based comparison intervention because information about dietary practices is not likely to affect mental health outcomes. The NT intervention was matched to the PST-based intervention in terms of number and duration of sessions."
3310506|NCT00321932|Active Comparator|Arm I (control)|Patients receive oral cholecalciferol (vitamin D) and oral calcium once a day for 12 months.
3310507|NCT00321932|Experimental|Arm II (treatment)|Patients receive vitamin D and calcium as in arm I. Patients also receive zoledronic acid intravenously (IV) over 15-30 minutes at 28 days prior to stem cell transplantation and at 3 and 6 months after transplantation.
3310508|NCT00321919|Experimental|Early Epoetin Beta Therapy|Participants received immediate epoetin beta therapy starting at 2000 IU, subcutaneously once weekly up to four years to reach a target Hb level of 13-15 g/dL; with an individual Hb increase of at least 2 g/dL within approximately 3 months.
3310509|NCT00321919|Active Comparator|Late Epoetin Beta Therapy|Participants received epoetin beta treatment starting at 2000 IU, subcutaneously once weekly up to four years only when a decline in Hb levels to <10.5 g/dL had occurred in order to reach a target Hb of 10.5-11.5 g/dL.
3310510|NCT00321906|Active Comparator|Azathioprine|(tacrolimus,azathioprine/prednisone)
3310511|NCT00321906|Active Comparator|Sirolimus|tacrolimus/sirolimus/prednisone
3310512|NCT00321893|Experimental|Arm I: Budesonide|Inhaled Budesonide 800 ug twice daily for 1 year
3310513|NCT00321893|Placebo Comparator|Arm II: Placebo|Inhaled placebo twice daily for 1 year
3310514|NCT00321867|Active Comparator|1|Native tissue repair
3310515|NCT00321867|Experimental|2|Posterior repair with graft
3310516|NCT00321854|Experimental|Early Pramipexole|Patients were treated with pramipexole for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
3310517|NCT00321854|Experimental|Delayed Pramipexole|Patients were treated with placebo for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
3310518|NCT00321828|Experimental|Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab|Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab
3310519|NCT00321815|Experimental|A|Standard of Care chemotherapy plus experimental intervention (PF-3512676)
3310520|NCT00321815|Active Comparator|B|Standard of Care chemotherapy
3310521|NCT00321802|Experimental|1|Patients randomized to active drug, then AF burden and CRP values will be compared to those in placebo arm.
3310522|NCT00321802|Placebo Comparator|2|Patients take placebo once daily for 6 Months, then AF burden and CRP values will be compared to those in experimental arm.
3310523|NCT00321789|Experimental|Spouse-assisted intervention|Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse developed a plan to support patient goal achievement.
3310524|NCT00321789|No Intervention|Usual care|Couples assigned to this arm received educational materials at baseline and usual care thereafter, with no contact from the study interventionist.
3310525|NCT00321763|Experimental|GSK1247446A Lot 1 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3310526|NCT00321763|Experimental|GSK1247446A Lot 2 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3310527|NCT00321763|Experimental|GSK1247446A Lot 3 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3310528|NCT00321763|Experimental|GSK1247446A Pooled Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.
3310529|NCT00321763|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.
3310533|NCT00321724|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3310534|NCT00321711|Active Comparator|Dose level 1 500 AMG 531 (Part A - azacitidine)|500 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
3310535|NCT00321711|Active Comparator|Dose level 1 750 AMG 531 (Part B - decitabine)|750 mcg AMG 531 weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
3310536|NCT00321711|Active Comparator|Dose level 2 750 AMG 531 (Part A - azacitidine)|750 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
3310537|NCT00321711|Placebo Comparator|Placebo (Part A - azacitidine)|Placebo weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
3310538|NCT00321711|Placebo Comparator|Placebo (Part B - decitabine)|Placebo weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
3310539|NCT00321698|Experimental|Phase I Dose 1-4|"Group 1=radiation only; Group 2=Docetaxel IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=Docetaxel IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=Docetaxel IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
3310540|NCT00321698|Experimental|Phase II MTD Dose|"Phase II with no phase I dose-limiting toxicities=Docetaxel IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
3310541|NCT00321685|Experimental|Treatment (bevacizumab and chemoradiotherapy)|See Detailed Description
3310542|NCT00321672|Experimental|NGX-4010, 60 minutes|
3310543|NCT00321672|Experimental|NGX-4010, 30 minutes|
3310544|NCT00321672|Other|0.04% conc. capsaicin patch, 60 min.|
3310545|NCT00321672|Other|0.04% conc. capsaicin patch, 30 min.|
3310546|NCT00321659|Experimental|Aerobic and flexibility exercise|16 weeks of aerobic and flexibility exercise. Three days per week for 1 hour of walking and cycling.
3310547|NCT00321659|Experimental|Strength, aerobic, and flexibility|16 weeks of strength training, aerobic, and flexibility exercise (ST) intervention;
3310548|NCT00321659|Experimental|Fibromyalgia Self-Help Course|7 weeks of FSHC behavior change education
3310549|NCT00321659|Experimental|a Combination of ST and FSHC|16 wks of a combination of ST and FSHC (ST-FSHC) exercise and behavior change education
3310550|NCT00321646|Experimental|chemotherapy|docetaxel and bevacizumab prior to prostatectomy
3310551|NCT00321620|Active Comparator|zoledronic acid|
3310552|NCT00321620|Experimental|denosumab|
3310553|NCT00321594|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3310554|NCT00321555|Experimental|A|LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% NaCl and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
3310555|NCT00321516|Experimental|1|
3310556|NCT00321464|Active Comparator|zoledronic acid|
3310557|NCT00321464|Experimental|denosumab|
3310558|NCT00321451|Experimental|1|
3310559|NCT00321451|Sham Comparator|2|
3310560|NCT00321451|Active Comparator|3|
3310561|NCT00321412|Placebo Comparator|2|Celphere® CP-305, stained to match appearance of AST-120, in 2g sachets
3310562|NCT00321412|Experimental|1|AST-120, 2 gram sachets
3310563|NCT00321373|Experimental|GSK1247446A-AS03 Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3310564|NCT00321373|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3310565|NCT00321373|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3310566|NCT00321334|Active Comparator|Docetexel|Chemotherapy+Surgery
3310567|NCT00321308|Active Comparator|B|Standard of care chemotherapy
3310568|NCT00321308|Experimental|A|Standard of care chemotherapy plus experimental intervention (PF-3512676)
3310569|NCT00321269|Active Comparator|Single Illness Managment|This intervention includes standard disease self-management coaching for heart failure and helps patients set goals for fluid management, restricted salt-intake, and medication adherence.
3310570|NCT00321269|Experimental|Comorbid Illness Management|This intervention includes the same self-management coaching found in the comparator arm, but also includes discussion of ways to cope and manage mood.
3310571|NCT00321191|Experimental|N2O|
3310572|NCT00321191|Placebo Comparator|No N2O|
3310573|NCT00321178|Experimental|SR4/CR4|after 4 weeks of standard treatment with streptomycin and rifampicin, patients in the experimental arm switch to oral treatment consisting of rifampicin and clarithromycin
3310574|NCT00321178|Active Comparator|SR8|standard treatment consisting of 8 weeks of streptomycin and rifampicin
3310575|NCT00321152|Experimental|1|Deplin/Deplin = participants will receive 7.5 mg/day of Deplin (6(S)-5-MTHF)for the first 4 weeks, and then 15 mg/day of Deplin for the next 4 weeks.
3310576|NCT00321152|Experimental|2|placebo/Deplin = participants will receive placebo for the first 4 weeks, and then 7.5 mg/day of Deplin (6(S)-5-MTHF) for the next 4 weeks.
3310577|NCT00321152|Placebo Comparator|3|placebo/placebo = both tablets of study medication will be placebo during both phases of the study.
3310578|NCT00321113|Active Comparator|1|oral
3310579|NCT00321113|Experimental|2|oral
3310580|NCT00321100|Active Comparator|A|Cetuximab 250mg/m2 IVweekly of each 21 day cycle; Oxaliplatin 130mg/m2 IVday 1 of each 21 day cycle; Capecitabine 850mg/m2 PO days 1-14 of each 21 day cycle; Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
3310581|NCT00321100|Active Comparator|B|Cetuximab 250mg/m2 IV weekly for each 21 day cycle
3310582|NCT00321087|Experimental|1|T2000 dose escalation
3310587|NCT00321048|Experimental|Radiotherapy|Patients will receive radiation therapy at a dose of 180-200 cGy per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. Additional radiation to the lumpectomy bed or mastectomy scar is at the discretion of the treating physician. The total dose to the tumor bed or mastectomy scar cannot exceed 6600cGy. Treatments will be given Monday through Friday.
3310588|NCT00320814|Experimental|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
3310589|NCT00320801|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h, applied for 7-day wear
3310590|NCT00320801|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h, applied for 7-day wear
3310591|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q4|
3310592|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q12|
3310593|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q4|
3310594|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q12|
3310595|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 4.0mg q12|
3310596|NCT00320775|Experimental|Part A|Part A: An open label study in which six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye. The total volume of each injection will be 100 μL. Enrollment in new dose levels will not begin until all patients in the preceding dose level have completed Visit 5 (Day 15).
3310597|NCT00320775|Active Comparator|Part B|Part B: A controlled, prospective, randomized, double-masked study in which up to 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive a single ITV injection of2.0 mg/eye VEGF Trap (or the MTD if reached prior to 2.0 mg) followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later. Enrollment into Part B will begin 2 weeks after the last subject to receive the 2.0 mg/eye dose in Part A has been observed for 15 days and it has been determined that the safety profile of VEGF Trap at this dose level is adequate to support expansion of dosing at this dose level. The dose of pegaptanib sodium will be 0.3 mg, according to the package insert.
3310598|NCT00320775|Active Comparator|Part C|Part C: A controlled, prospective, randomized, double-masked study in which approximately 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap. Initiation of Part C is contingent upon the 4.0 mg dose being adequately tolerated in Part A.
3310599|NCT00320749|Experimental|capecitabine, docetaxel, gemcitabine|Dose escalation study of mGTX using three dose levels (DL1-3). Patients received docetaxel on days 1 and 8, gemcitabine on days 8 and 15, and capcitabine on days 8 through 21. Gemcitabine fixed dose at 750 mg/m2 over 75 min, capecitabine twice daily and escalated from 500 to 650 mg/m2 at DL2 and docetaxel increased from 30 to 36 mg/m2 at DL3.
3310600|NCT00320710|Experimental|Zoledronic acid every (q) 4 weeks|Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.
3310601|NCT00320710|Experimental|Zoledronic acid q 12 weeks|Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.
3310602|NCT00320710|Experimental|Placebo / zoledronic acid|Participants randomized to this arm received placebo but the arm was later dropped and participants in this arm were swithced to the zoledronic acid q 4 weeks according to a study amendment.
3310603|NCT00320697|Other|Bupropion + Nicotine patch + Nicotine gum or lozenges|Open label phase All enrolled subjects received weekly CBT group sessions, bupropion 300 mg/daily (if medically eligible), nicotine patch 21 mg/day, and up to 20 mg/day of nicotine gum or lozenge for prn use. Subjects set a quit date between weeks 3 and 4; a ½ hour individual CBT session to help prepare them for the quit date. The open phase groups consisted of 8 weekly CBT meetings.
3310604|NCT00320697|Active Comparator|Bupropion + Nicotine Patch|Randomized phase: Subjects who achieved 2 weeks continuous abstinence at the end of the open intervention and who are medically eligible for bupropion were eligible for the double blind, relapse prevention trial.Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
3310605|NCT00320697|Placebo Comparator|Placebo pill + placebo patch|Randomized phase: Subjects who achieved 2 weeks continuous abstinence at the end of the open intervention and who are medically eligible for bupropion were eligible for the double blind, relapse prevention trial. Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
3310606|NCT00320684||1|Women who have had anorexia nervosa but are now maintaining a healthy weight
3310607|NCT00320684||2|Women who have never had anorexia nervosa and are maintaining a healthy weight
3310608|NCT00320671|Experimental|Participants will take aripiprazole|Participants will take aripiprazole
3310609|NCT00320671|Experimental|Participants will take risperidone|Participants will take risperidone
3310610|NCT00320658|Experimental|A|3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm B.
3310611|NCT00320658|Experimental|B|3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel and CPG7909 given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm A.
3310612|NCT00320658|Experimental|C|3 vaccinations with a dose of 160 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm D after review of the results from Arms A and B.
3310613|NCT00320658|Experimental|D|3 vaccinations with a dose of 160 mcg MSP1 42-C1/Alhydrogel and CPG7909 given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm C after review of the results from Arms A and B.
3310614|NCT00320619|Experimental|1|Participants will receive either EACA.
3310615|NCT00320619|Placebo Comparator|2|Participants will receive placebo.
3310651|NCT00320203|Experimental|Anecortave Acetate 3 mg Depot|Single injection, anterior juxtascleral depot (AJD)
3310652|NCT00320203|Experimental|Anecortave Acetate 15 mg Depot|Single injection, anterior juxtascleral depot (AJD)
3310653|NCT00320203|Experimental|Anecortave Acetate 30 mg Depot|Single injection, anterior juxtascleral depot (AJD)
3310616|NCT00320606|Experimental|Immunosuppression Withdrawal|"Recipients of parental living donor liver transplants 4 or more years prior to trial enrollment, who also had stable allograft function during the preceding 6 months while taking a single immunosuppressive drug were permitted to undergo withdrawal of immunosuppression therapy. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.~Patients are carefully evaluated/monitored throughout the study by assessments including but not limited to liver biopsy, liver tests and clinic visits, alloantibodies, autoantibodies and quantitative immunoglobulin G test results."
3310617|NCT00320593|Active Comparator|Progressive addition lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
3310618|NCT00320593|Active Comparator|Single vision lenses (SVLs)|Single vision lenses
3310619|NCT00320580|Experimental|001|norelgestromin/ethinyl estradiol
3310620|NCT00320567|Experimental|001|norgestimate/ethinyl estradiol
3310621|NCT00320541|Active Comparator|paclitaxel plus bevacizumab (PB)|paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days
3310622|NCT00320541|Experimental|paclitaxel plus bevacizumab plus gemcitabine (PB+G)|paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by gemcitabine 1500 mg/m2 IV on days 1 and 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days
3310623|NCT00320528|Experimental|Pure ADHD|Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
3310624|NCT00320528|Experimental|ADHD+Internalizing Disorders|Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
3310625|NCT00320528|Experimental|ADHD+Externalizing Disorders|Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
3310626|NCT00320515|Experimental|A|
3310627|NCT00320489|Experimental|Olanzapine Pamoate Depot|Olanzapine pamoate depot
3310628|NCT00320489|Active Comparator|Olanzapine|Oral olanzapine
3310629|NCT00320411|Experimental|Lapatinb|Lapatinib 1500mg QD
3310630|NCT00320385|Experimental|Arm 1: Lapatinib plus Trastuzumab|Lapatinib 1000mg once daily in combination with trastuzumab 4mg/kg loading dose followed by 2mg/kg weekly
3310631|NCT00320385|Experimental|Arm 2: Lapatinib|Lapatinib 1500mg once daily
3310632|NCT00320372||1. 500 VNS Patients|VNS Patients - Treatment-resistant depression patients treated with VNS Therapy.
3310633|NCT00320372||2. 300 Non-VNS Patients|Non-VNS Patients - Treatment-resistant depression patients not receiving VNS Therapy.
3310634|NCT00320359|Active Comparator|Arm A|Cisplatin 75 mg/m2 i.v., day 1, Etoposide 100 mg/m2 i.v., days 1-3
3310635|NCT00320359|Experimental|Arm B|Topotecan 1 mg/ m2, i.v., days 1-5 Cisplatin 75 mg/m2 i.v., days 5
3310636|NCT00320281|Placebo Comparator|placebo|Normal saline injections were used for placebo injections. Injections were based on treatment plan determined in clinical setting by study PI and physical therapist. 25 cc syringe was used and amount of saline injected was unit based on muscles to be injected according to the treatment plan.
3310637|NCT00320281|Active Comparator|Botulinum toxin A|Botulism toxin A dosage was based on plan developed in clinical setting with study PI and physical therapist. Drug was dosed in 25 cc syringe,diluted with normal saline and injections occured based on treatment plan.
3310638|NCT00320255|Placebo Comparator|Cohort 1: Placebo|Participants received placebo tablets once daily
3310639|NCT00320255|Placebo Comparator|Cohort 1: Apixaban, 5 mg|Participants received apixaban as tablet, 5 mg, once daily
3310640|NCT00320255|Active Comparator|Cohort 1: Apixaban, 10 mg|Participants received apixaban as tablet, 10 mg, once daily
3310641|NCT00320255|Active Comparator|Cohort 1: Apixaban, 20 mg|Participants received apixaban as tablet, 20 mg, once daily
3310642|NCT00320255|Placebo Comparator|Cohort 2: Placebo|Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.
3310643|NCT00320255|Active Comparator|Cohort 2: Apixaban, 5 mg|Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.
3310644|NCT00320242|Active Comparator|1 mo baseline|1 mo baseline before visual cue: Cane or walker, no laserlight visual cue x 1 mo; + laserlight visual cue for 2nd mo
3310645|NCT00320242|No Intervention|2 month baseline|Cane or walker, no laserlight visual cue x 2 mo, + laserlight visual cue for 3rd mo
3310646|NCT00320216|Placebo Comparator|Group I (Placebo)|Patients in the placebo group will receive placebo at Weeks 0, 1, 2, 3, and 16. At week 20, all patients will receive a single dose of ustekinumab 90 mg.
3310647|NCT00320216|Experimental|Group II (Ustekinumab 45 mg)|Patients will receive single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.
3310648|NCT00320216|Experimental|Group III (Ustekinumab 90 mg)|Patients will receive 90 mg single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16 patients with PGA greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.
3310649|NCT00320216|Experimental|Group IV|Patients will receive 45 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.
3310650|NCT00320216|Experimental|Group V|Patients will receive 90 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16 patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.
3310654|NCT00320203|Other|Anecortave Acetate Vehicle|Single injection, anterior juxtascleral depot (AJD)
3310655|NCT00320190|Active Comparator|Dasatinib|Participants with chronic phase chronic myeloid leukemia (CML) who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.
3310656|NCT00320190|Active Comparator|Imatinib|Participants with chronic phase CML who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.
3310657|NCT00320164||Group A: Leukapheresis|Subject's peripheral blood mononuclear cells are collected via leukapheresis.
3310658|NCT00320164||Group B: Buffy Coats Collection|Subject's peripheral blood mononuclear cells are collected via the buffy coats from blood.
3310659|NCT00320138|Active Comparator|Acupuncture|
3310660|NCT00320138|No Intervention|Wait List|Usual Care
3310661|NCT00320125|No Intervention|1|Usual diet
3310662|NCT00320125|Active Comparator|2|Orange juice fortified with calcium
3310663|NCT00320125|Active Comparator|3|Dairy products
3310664|NCT00320112|Experimental|Reciprocal Diabetes Peer Support program|peers are paired during the group visit and are encouraged to speak with their partner at least once a week for the 6 month duration of the study.
3310665|NCT00320112|Other|Nurse Case Management|patients are not paired in the NCM arm. they are provided with educational session on diabetes management and informed of case management services.
3310666|NCT00320099|Active Comparator|1|Hydrocortisone and convention glycemic control
3310667|NCT00320099|Experimental|2|Hydrocortisone and fludrocortisone and conventional glucose control
3310668|NCT00320099|Experimental|3|Hydrocortisone and intensive insulin therapy
3310669|NCT00320099|Experimental|4|hydrocortisone, fludrocortisone and intensive insulin therapy
3310670|NCT00320073|Experimental|Arm A|Pemetrexed, Vinflunine, Folate, B12, Dexamethasone, Ondansetron, Midazolam
3310671|NCT00320073|Experimental|Arm B|Vinflunine, Erlotinib, Ondansetron, Midazolam
3310672|NCT00320047|Experimental|1|Participants will take baclofen for 10 weeks.
3310673|NCT00320008|Active Comparator|Standard Treatment Arm|This arm will at any time during the active intervention period follow treatment guidelines by the Danish Medical Association for the treatment of type 2 diabetes.
3310674|NCT00320008|Experimental|Intensive Treatment Arm|This arm will during the active intervention period be treated according to intensified multiple risk factor intervention following strict guidelines set out by the study protocol.
3310675|NCT00319982|Experimental|I- Diltiazem|Diltiazem- study medication
3310676|NCT00319982|Placebo Comparator|II- Placebo|Placebo Comparator
3310677|NCT00319969|Experimental|1|Amrubicin 40mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
3310678|NCT00319969|Active Comparator|2|Topotecan 1.5mg/m<2> IV, days 1, 2, 3, 4, 5 of each 21-day cycle until disease progression.
3310679|NCT00319956|Active Comparator|Azithromycin Group|Group receives azithromycin
3310680|NCT00319956|Placebo Comparator|Placebo Group|Group receives placebo
3310681|NCT00319917|Experimental|1|
3310682|NCT00319917|Placebo Comparator|2|
3310683|NCT00319878|Experimental|1|Participants will be treated with sirolimus and cyclosporine. In phase I, each dose cohort will initially enroll three patients. If no dose-limiting toxicity (DLT) is observed by Day 28 in any patient of a cohort, then 3 patients will be treated with the next highest sirolimus dose. If 1 out of 3 patients in any cohort experiences a DLT, then 3 more patients will be enrolled in that cohort. If no more patients have a DLT by Day 28, then sirolimus dose escalation will proceed. If one or more patients experience a DLT then that dose level will be considered to be the maximum tolerated sirolimus dose, and Phase II patients will be treated at the next lowest level. Cyclosporine will be given as a twice daily oral dose.
3310684|NCT00319852|Experimental|1|
3310685|NCT00319852|Active Comparator|2|
3310686|NCT00319839|Experimental|Abraxane plus Cetuximab|Drug: Abraxane-260 mg/m2 IV over 30 minutes every 3 weeks. Drug: Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles.
3310687|NCT00319826||1|Subjects with Staphylococcus Bacteremia
3310688|NCT00319826||2|Healthy (Non-infected) Control Subjects in the Nasal Carriage Group
3310689|NCT00319748|Experimental|Intent-To-Treat|Patients treated with at least one dose - 852A subcutaneous injection.
3310690|NCT00319748|Experimental|Evaluable Cohort|Patients who received all 24 doses of 852A per protocol.
3310691|NCT00319735|Experimental|Investigational Treatment|"Cetuximab 400 mg/m2 IV over 120 minutes Day -14 (Loading Dose)~Cetuximab 250 mg/m2 IV over 60 minutes Day -7~Cetuximab 250 mg/m2 IV over 60 minutes Days 1, 8, 15, 22, 29 and 36~Combined with radiation therapy for six weeks.~Surgery for esophageal resection after 6 to 8 week rest period.~Subjects who consent will provide tissue samples."
3310692|NCT00319696|Experimental|1|
3310693|NCT00319657|Experimental|Immune tolerance, kidney transplantation|Intervention: Participants will receive hematopoietic cell transplantation and Total lymphoid irradiation. The intervention is intended to induce immune tolerance in HLA-matched living donor kidney transplantation, to allow withdrawal of the immunosuppressive drugs. Immune tolerance is achieved through the development of donor/recipient mixed chimerism following combined kidney and hematopoietic stem cell transplantation from the living donor.
3310694|NCT00319644|Experimental|Minibal Arm|Using Mini bronchoalveolar lavage
3310695|NCT00319644|No Intervention|Tracheal Aspirates|standard of care for ICU.
3310696|NCT00319592|Experimental|ChimeriVax™-JE|Subjects received 2 injections of placebo (normal saline), 1 each on Days 0 and 7, and 1 injection of ChimeriVax™-JE on Day 28.
3310697|NCT00319592|Active Comparator|JE-VAX®|Subjects received 1 injection of JE-VAX® each on Days 0, 7, and 28.
3310698|NCT00319579||Observation|Living Kidney Donors with controls who have not donated a kidney and meet certain criteria at the time of the donor's donation (i.e. no hypertension, no kidney disease, etc.).
3310699|NCT00319553|Experimental|Adacel® Vaccine Group|
3310700|NCT00319553|Active Comparator|BOOSTRIX® Vaccine Group|
3310701|NCT00319527||Observation|Living Kidney Donors with controls who have not donated a kidney or had certain criteria at the time of the donor's donation (i.e. no hypertension, no kidney disease, etc.).
3318941|NCT00196092|Other|2|Surgical
3310702|NCT00319501|Placebo Comparator|Placebo|During the Double-blind Period, participants received a single, age- and weight-appropriate dose of placebo solution as a deep intramuscular injection in the mid to outer thigh. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of acute repetitive seizures (ARS).
3310703|NCT00319501|Experimental|Diazepam|During the Double-blind Period, participants received a single, age- and weight-appropriate dose of diazepam solution, ranging from 0.2 to 0.5 mg/kg, as a deep intramuscular injection in the mid to outer thigh. Additional doses were permissible during the Open-label Period. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of ARS.
3310704|NCT00319488|Active Comparator|1|Active ICS plus placebo LTRA plus albuterol inhalation treatments four times daily
3310705|NCT00319488|Active Comparator|2|Active LTRA plus placebo ICS plus albuterol inhalation treatment four times daily
3310706|NCT00319488|Placebo Comparator|3|Placebo ICS plus placebo LTRA plus albuterol inhalation treatments four times daily
3310707|NCT00319449|Experimental|Ezetimibe 10 mg|Participants treated with 10 mg/day ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.
3310708|NCT00319449|Placebo Comparator|Placebo 10 mg|Participants treated with 10 mg/day matching placebo to ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.
3310709|NCT00319436|Experimental|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
3310710|NCT00319436|Active Comparator|Standard Parent Education for Substance Using Mothers|This 12 session comparison intervention was designed to match the Maternal Mentalizing Therapy on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child care and child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
3310711|NCT00319423|Active Comparator|Patient education|Patient education according to Klassbo et al 2003
3310712|NCT00319423|Experimental|Patient education and supervised exercise|Patient education according to Klassbo et al 2003. Supervised exercise containing strengthening, functional and flexibility exercises.
3310713|NCT00319371||1|women with vasospasm and difficulties of initiating sleep
3310714|NCT00319371||2|women without vasospasm and no difficulties of initiating sleep
3310715|NCT00319358|Active Comparator|Antioxidants|Intervention was done with antioxidants
3310716|NCT00319358|Placebo Comparator|Placebo|
3310717|NCT00319280|Experimental|1|Minced Iliac Crest autograft in osteotomysite
3310718|NCT00319280|Experimental|2|Injectable calcium phosphate cement in osteotomysite
3310719|NCT00319280|Active Comparator|3|Local autograft in the osteotomysite serves as control
3310720|NCT00319267|Experimental|Bosentan|The initial dose of bosentan was 2 mg/kg b.i.d. for 4 weeks. After 4 weeks, the initial dose was up-titrated to the maintenance dose of 4 mg/kg b.i.d. up to the end of the study treatment at Week 12. If the maintenance dose was not well tolerated, the dose could be down-titrated to the initial dose.
3310721|NCT00319254|Experimental|Advanced breast cancer|
3310722|NCT00319228|Experimental|Antithrombin III|
3310723|NCT00319202|Experimental|1|
3310724|NCT00319202|Placebo Comparator|2|
3310725|NCT00319150|No Intervention|Standard of Care|Epo dose to remain constant throughout study
3310726|NCT00319150|Active Comparator|Dosage Decrease Arm|Arm 2 is to have an decrease of erythropoietin at regular intervals.
3310727|NCT00319124||Case|Patients with hip Osteoarthritis
3310728|NCT00319124||Control|Healthy controls without hip osteoarthritis
3310729|NCT00319111|Experimental|Bosentan|Open label bosentan treatment
3310730|NCT00319098|Experimental|GSK1562902A Group|Male and female subjects aged 18 or over received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm. The group was further stratified by age for analyses.
3310731|NCT00319098|Active Comparator|Fluarix+Placebo Group|Male and female subjects aged 18 or over received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm. The group was further stratified by age for analyses.
3310732|NCT00319046|Experimental|1|
3310733|NCT00319020|Experimental|Bosentan|Bosentan was administered at 4 mg/kg twice daily (b.i.d.) until the end of the study. It could be down-titrated to 2 mg/kg b.i.d. if not well tolerated.
3310734|NCT00318955|Experimental|Dexmedetomidine group|
3310735|NCT00318955|Active Comparator|Propofol group|
3310736|NCT00318942|Active Comparator|1|Crystalloids, any type of Crystalloids including isotonic or hypertonic saline, Ringer Lactates either modified or not
3310737|NCT00318942|Experimental|2|Colloids, including albumin, gelatines, starch any other synthetic colloids
3310738|NCT00318903|Experimental|Taxotere/Irinotecan|Taxotere and Irinotecan is given intravenously for 3 consecutive weeks with a one-week break before radiotherapy for 5-6 weeks. A combination of Taxotere and Irinotecan will then be administered simultaneously with the radiotherapy.
3310787|NCT00318357||CRT|In the CARE-HF study patients treated with standard medical treatment plus CRT were compared to patients treated with standard medical treatment.
3310739|NCT00318890|Experimental|Docetaxel + cisplatin followed by radiation|Docetaxel with cisplatin is given for three cycles, followed by concomitant therapy with weekly docetaxel for 4 weeks. Radiation therapy is given 5 days each week on Days 64-106 with a concomitant boost in the last 2 weeks of treatment. Amifostine is given as an injection on a daily basis during radiotherapy.
3310740|NCT00318877|Experimental|After school sports|After school team sports
3310741|NCT00318877|Active Comparator|Health and Nutrition Education|Health and Nutrition Education Active Placebo Control
3310742|NCT00318851|Experimental|Carotid Artery Stenting|
3310743|NCT00318838|Placebo Comparator|1|Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
3310744|NCT00318838|Experimental|2|125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
3310745|NCT00318812|Experimental|Heme Iron|Heme Iron Polypeptide 11mg PO tid for 6 months
3310746|NCT00318812|Active Comparator|Venofer|Venofer q month IV x 6 months
3310747|NCT00318799|Experimental|Arm 1|
3310748|NCT00318799|Active Comparator|Arm 2|
3310749|NCT00318760|Experimental|ARM 1|
3310750|NCT00318760|Placebo Comparator|ARM 2|
3310751|NCT00318721|Experimental|Intervention|
3310752|NCT00318721|No Intervention|control|
3310753|NCT00318708|Experimental|clarithromycin + fluticasone|clarithromycin 500 mg twice daily (Biaxin) + fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
3310754|NCT00318708|Active Comparator|placebo + fluticasone|placebo clarithromycin twice daily + fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
3310755|NCT00318695|Experimental|Probiotics|Bifidobacterium longum [BL999] and Lactobacillus rhamnosus [LPR]
3310756|NCT00318695|Placebo Comparator|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
3310757|NCT00318643|Experimental|Cohort 1: MMC plus Chemophase|On Day 1 of Week 1, all participants will receive mitomycin C (MMC) 40 milligrams (mg)/20 milliliter (mL) monotherapy via intravesical administration. In Weeks 2 through 6, participants will receive weekly intravesical administrations of a combination of MMC 40 mg/20 mL and 20,000 Units Chemophase.
3310758|NCT00318643|Experimental|Cohort 2: MMC plus Chemophase|On Day 1 of Week 1, all participants will receive MMC 40 mg/20 mL monotherapy via intravesical administration. In Weeks 2 through 6, participants will receive weekly intravesical administrations of a combination of MMC 40 mg/20 mL and 60,000 Units Chemophase.
3310759|NCT00318643|Experimental|Cohort 3: MMC plus Chemophase|On Day 1 of Week 1, all participants will receive MMC 40 mg/20 mL monotherapy via intravesical administration. In Weeks 2 through 6, participants will receive weekly intravesical administrations of a combination of MMC 40 mg/20 mL and 200,000 Units Chemophase.
3310760|NCT00318643|Experimental|Cohort 4: MMC plus Chemophase|On Day 1 of Week 1, all participants will receive MMC 40 mg/20 mL monotherapy via intravesical administration. In Weeks 2 through 6, participants will receive weekly intravesical administrations of a combination of MMC 40 mg/20 mL and 400,000 Units Chemophase.
3310761|NCT00318643|Experimental|Cohort 5: MMC plus Chemophase|On Day 1 of Week 1, all participants will receive MMC 40 mg/20 mL monotherapy via intravesical administration. In Weeks 2 through 6, participants will receive weekly intravesical administrations of a combination of MMC 40 mg/20 mL and 800,000 Units Chemophase.
3310762|NCT00318630|Experimental|Subjects receiving treatment 1|Eligible subjects will receive rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily administered orally for 28 days followed by placebo oral tablet.
3310763|NCT00318630|Experimental|Subjects receiving treatment 2|Eligible subjects will receive placebo oral tablet followed by rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily for 28 days.
3310764|NCT00318591|Experimental|SpeediCath|hydrophilic-coated intermittent catheter
3310765|NCT00318591|Experimental|Conveen Uncoated|uncoated urinary intermittent catheter
3310766|NCT00318565|Experimental|Navistar ThermoCool Catheter|
3310767|NCT00318487|Experimental|Bilateral sinus augmentation|
3310768|NCT00318474|Active Comparator|Mycophenolate Mofetil (MMF)|Dose is based on body size (between 25mg/kg/day and 36mg/kg/day with a maximum dose 1gm BID; initial dose to be used in the first 2 weeks of therapy will be approximately 1/2-2/3 of the full dose). Route of administration is oral. Frequency is daily. MMF will be administered up to 12 months.
3310769|NCT00318474|Placebo Comparator|MMF Placebo|Subjects receive MMF placebo.
3310770|NCT00318461|Experimental|Lira 0.6 + Met|Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
3310771|NCT00318461|Experimental|Lira 1.2 + Met|Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
3310772|NCT00318461|Experimental|Lira 1.8 + Met|Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
3310773|NCT00318461|Active Comparator|Met Mono|Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo
3310774|NCT00318461|Active Comparator|Met + Glim|Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo
3310775|NCT00318409|Active Comparator|Bupropion|buproprion XL 300mg daily
3310776|NCT00318409|Placebo Comparator|Placebo|placebo 300mg daily
3310777|NCT00318396|Experimental|Compaction|The bone is pressed very hard together before implantation of femoral component.
3310778|NCT00318396|Active Comparator|Conventional technique|The bone is broached before implantation of femoral component.
3310779|NCT00318383|Experimental|1|200 mcg NicVAX in each of 4 doses
3310780|NCT00318383|Experimental|2|200 mcg NicVAX in each of 5 doses
3310781|NCT00318383|Experimental|3|400 mcg NicVAX in each of 4 doses
3310782|NCT00318383|Experimental|4|400 mcg NicVAX in each of 5 doses
3310783|NCT00318383|Placebo Comparator|5|Placebo in 4 or 5 doses
3310784|NCT00318383|Experimental|6|200 mcg NicVAX formulation 2 in each of 5 doses
3310785|NCT00318370|Experimental|Far Only|Farletuzumab only (Far Only): farletuzumab, 100 milligrams (mg)/square meter (m2).
3310786|NCT00318370|Experimental|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
3310788|NCT00318331|Active Comparator|A|Will receive enteral glutamine
3318942|NCT00196092|Other|3|Standard Risk
3310791|NCT00318292|Placebo Comparator|Placebo|Placebo for preemptive local analgesia.
3310792|NCT00318266||patients with suerficial transitional cell carcinoma|
3310793|NCT00318240|Experimental|1|High Intensity Focused
3310794|NCT00318227|Active Comparator|Liberal Red cell transfusion arm|Transfusion if Hgb <100g/L
3310795|NCT00318227|Active Comparator|Restrictive Red Cell transfusion|Transfusion if Hgb <70g/L
3310796|NCT00318214|Experimental|1|
3310797|NCT00318214|Placebo Comparator|2|
3310798|NCT00318201|Experimental|1|Altered efficacy for drug to drug interaction of diltiazam with erythromycin
3310799|NCT00318188|Experimental|Intervention group|The patients in this group will do a personalized standardized rehabilitation program on the quality of life.
3310800|NCT00318188|No Intervention|Control group|Habitual care
3310801|NCT00318149|Experimental|Fluarix 18-40 Y Group|Subjects (aged 18-40 years [Y]) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
3310802|NCT00318149|Experimental|Fluarix ≥65 Y Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
3310803|NCT00318149|Experimental|Fluarix-AS25 Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.
3310804|NCT00318149|Experimental|Fluarix-AS50 Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.
3310805|NCT00318149|Experimental|Fluarix- AS01B Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.
3310806|NCT00318149|Experimental|Fluarix- AS01E Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.
3310807|NCT00318136|Experimental|Treated with Bevacizumab|
3310808|NCT00318123|Experimental|A|Abacavir 600mg + lamivudine 300mg in on table QD + efavirenz 600mg QD
3310809|NCT00318123|Experimental|B|Abacavir 600mg + lamivudine 300mg in ine tablet QD * lopinavir/ritonavir 400/100 mg BID
3310810|NCT00318110|Experimental|MUD treatment|NST using MUD for metastatic renal cell carcinoma
3310811|NCT00318097||MAS patients|patient with clinical diagnosis of MAS
3310812|NCT00318097||controls|age matched, tanner stage matched controls
3310813|NCT00318071|Experimental|Treatment|Treatment arm patients had at least one Merci Retriever deployed
3310814|NCT00318032|Other|Intensive Treatment|Frequent specialised diabetes clinician contact. DESMOND self-management programme
3310815|NCT00318019|Experimental|OPC Factor(TM)|
3310816|NCT00318019|Placebo Comparator|Placebo|
3310817|NCT00318006|Active Comparator|Spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
3310818|NCT00318006|Experimental|Irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
3310819|NCT00317980|Experimental|Low dose|Meglumine antimoniate 5 mg/kg/d for 20 days
3310820|NCT00317980|Active Comparator|Standard dose|Meglumine antimoniate 15 mg/kg/d for 20 days
3310821|NCT00317967|Experimental|1|Atorvastatin
3310822|NCT00317967|Placebo Comparator|2|Placebo
3310823|NCT00317941|Experimental|IFNB-1b 250 mcg (Betaseron) via Betaject|Interferon beta 1b ([IFNB-1b] Betaseron, BAY86-5046) 250 mcg (8 MIU) administered every other days by subcutaneous injection using Betaject
3310824|NCT00317941|Experimental|IFNB-1b 250 mcg (Betaseron) via Betaject light|Interferon beta 1b ([IFNB-1b] Betaseron, BAY86-5046) 250 mcg (8 MIU) administered every other days by subcutaneous injection using Betaject Light
3310825|NCT00317941|Active Comparator|IFNB-1a 44 mcg (Rebif) via Rebiject II|Interferon beta-1a ([IFNB-1a] Rebif) 44 mcg (12 MIU) three times per week by subcutaneous injection using Rebiject II
3310826|NCT00317889|Experimental|Compaction|Compaction technique for femoral bone preparation prior to cementless femoral stem insertion.
3310827|NCT00317889|Active Comparator|Broaching|Broaching technique for femoral bone preparation prior to cementless femoral stem insertion.
3310828|NCT00317837|Active Comparator|1|Patients treated with a cemented modular hemiarthroplasty, with a unipolar head
3310829|NCT00317837|Active Comparator|2|Patients treated with a modular cemented hemiarthroplasty with a bipolar head.
3310830|NCT00317772|Experimental|Topotecan + Gefitinib|"Phase I: Topotecan: 2.0, 3.0, or 4.0 mg/m^2 by vein Days 1, 8 and 15 of 28 day cycle.~Gefitinib: 250 mg by mouth daily.~Phase II: Topotecan starting dose: MTD from Phase I by vein Days 1, 8, and 15 of 28 day cycle.~Gefitinib: 250 by mouth daily for 28 Days."
3310831|NCT00317746|Placebo Comparator|Placebo|Placebo + PEG-interferon-alfa2b + ribavirin
3310832|NCT00317746|Experimental|Citalopram|Citalopram + PEG-interferon-alpha2b + ribavirin
3310833|NCT00317720|Experimental|Trastuzumab + RAD001|Trastuzumab loading dose is 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle. Starting RAD001 dose 10 mg by mouth daily.
3310834|NCT00317707|Experimental|N-3 PUFA|
3310835|NCT00317707|Placebo Comparator|Olive oil|
3310836|NCT00317694|Experimental|1|
3310837|NCT00317694|Placebo Comparator|2|
3310838|NCT00317642|Experimental|clofarabine (IV formulation) and cytarabine|"Participants received clofarabine (40 mg/m^2) administered as a 1-hour infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour infusion. Participants could receive up to 3 cycles of treatment (induction, re-induction, and consolidation)~Complete induction cycle = 5 consecutive days of treatment~Re-induction cycle = 5 consecutive days of treatment at the original or modified dose~Consolidation cycle = 4 consecutive days of treatment at the original or modified dose"
3311672|NCT00306904|Experimental|1|3.0 mg/eye dose group
3310839|NCT00317642|Experimental|placebo and cytarabine|Participants received placebo administered as a 1-hour infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour infusion. Patients could receive up to 3 cycles of treatment (induction, re-induction, and consolidation)
3310840|NCT00317629|Active Comparator|1|
3310841|NCT00317629|Experimental|2|
3310842|NCT00317603|Experimental|Vaccine|"Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately 1x10 7 , 4x10 6 ,~1x10 6 , or 1x10 5 depending on the final cell yield."
3310843|NCT00317512|Active Comparator|1|Voluven will be administered at 7.7 ml/min over 15 minutes,followed by Voluven at 7.7 ml/min over 15 minutes
3310844|NCT00317512|Active Comparator|2|HBOC-201 will be administered at 7.7 ml/min over 15 minutes,followed by Voluven at 7.7 ml/min over 15 minutes
3310845|NCT00317512|Experimental|3|HBOC-201 will be administered at 7.7 ml/min over 15 minutes,followed by HBOC-201 at 7.7 ml/min over 15 minutes
3310846|NCT00317499|Experimental|Etanercept|
3310847|NCT00317499|Placebo Comparator|Placebo|
3310848|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 10ug|Subject vaccinated with 10 ug of FMP1/AS02A on days 0, 29 and 57
3310849|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 25 ug|Subject vaccinated with 25 ug of FMP1/AS02A on days 14, 42, and 70
3310850|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 50 ug|Subject vaccinated with 50 ug of FMP1/AS02A on days 28, 56 and 84
3310851|NCT00317473|Active Comparator|Imovax Rabies Vaccine|Subject vaccinated with Imovax Rabies Vaccine on corresponding FMP1/AS021 vaccination days
3310852|NCT00317460|Active Comparator|1|Physician Management
3310853|NCT00317460|Experimental|2|Physician Management and counseling (drug counseling and medication adherence)
3310854|NCT00317395|Experimental|Otamixaban Dose 1|dosage regimen 1
3310855|NCT00317395|Experimental|Otamixaban Dose 2|dosage regimen 2
3310856|NCT00317395|Experimental|Otamixaban Dose 3|dosage regimen 3
3310857|NCT00317395|Experimental|Otamixaban Dose 4|dosage regimen 4
3310858|NCT00317395|Experimental|Otamixaban Dose 5|dosage regimen 5
3310859|NCT00317395|Active Comparator|UFH/Eptifibatide|
3310860|NCT00317382|No Intervention|No Ultrasound|Standard LP without ultrasound use
3310861|NCT00317382|Experimental|Ultrasound Use|Ultrasound used to assess spine and best location for lumbar puncture.
3310862|NCT00317304|Experimental|MBSR|
3310863|NCT00317278|Experimental|A,1|Massage therapy
3310864|NCT00317278|Sham Comparator|A,2|
3310865|NCT00317252|Experimental|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held >= 24 hours pre-cardiac catheterization and restarted post-catheterization after creatinine measurement (48-96 hours post)
3310866|NCT00317252|Other|Continue ACE1 or ARB|Randomized to continue on prescribed ACE1 or ARB
3310867|NCT00317239|Experimental|Ferric Carboxymaltose (FCM)|A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
3310868|NCT00317239|Active Comparator|Ferrous Sulfate tablets|325 mg/TID x 8 weeks
3310869|NCT00317226|Experimental|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
3310870|NCT00317200|Active Comparator|1|Paclitaxel + Devacizumab in patients with chemosensitive relapsed small cell lung cancer.
3310871|NCT00317187|Experimental|Hib-MenAC Lot 1 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 1 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
3310872|NCT00317187|Experimental|Hib-MenAC Lot 2 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 2 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
3310873|NCT00317187|Experimental|Hib-MenAC Lot 3 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 3 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
3310874|NCT00317187|Active Comparator|Hiberix Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB vaccine mixed extemporaneously with conjugate vaccine Hiberix at 2, 4 and 6 months of age as intramuscular injection in the anterolateral part of the thigh.
3310875|NCT00317148|Experimental|Placebo|
3310876|NCT00317148|Experimental|DHEA|
3310877|NCT00317135|Experimental|Hib-MenAC Lot 1 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 1 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
3310878|NCT00317135|Experimental|Hib-MenAC Lot 2 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 2 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
3310879|NCT00317135|Experimental|Hib-MenAC Lot 3 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 3 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
3310948|NCT00316264|Experimental|Palivizumab followed by motavizumab|2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)
3311673|NCT00306904|Experimental|2|1.5 mg/eye dose group
3310880|NCT00317135|Active Comparator|Hiberix Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB vaccine mixed extemporaneously with conjugate vaccine Hiberix at 2, 4 and 6 months of age as intramuscular injection in the anterolateral part of the thigh.
3310881|NCT00317109|Experimental|AC primed Group|
3310882|NCT00317109|Active Comparator|AC unprimed Group|
3310883|NCT00317096|Active Comparator|FCM|"All patients underwent a central randomization procedure. Randomization was done by a Computer program stratified for histology, Response to the preceding chemotherapy, and the number of previous chemotherapies using the method of permutuated blocks.~The FCM combination comprised:~25 mg/m2 fludarabine per day iv over 30 minutes, days 1 to 3 200 mg/m2 cyclophosphamide per day as a 4-hour-infusion, days 1 to 3 8 mg/m2 mitoxantrone per day iv over 30 minutes, day 1 4 treatment Cycles á 4 weeks per cycle In patients with peripheral lymphocyte Counts more than 20.000/mm3 and/or a large Tumor mass (ie, bulky disease more than 10 cm) a cytoreductive pre-phase could be performed, comprising cyclophosphamide at a dose of 200 mg/m2 as a 1-hour-infusion over 3 to 5 days."
3310884|NCT00317096|Experimental|R-FCM|"All patients underwent a central randomization procedure. Randomization was done by a Computer program stratified for histology, Response to the preceding chemotherapy, and the number of previous chemotherapies using the method of permutuated blocks.~The R-FCM combination comprised:~375 mg/m2 rituximab on the day before the respective FCM course. 25 mg/m2 fludarabine per day iv over 30 minutes, days 1 to 3 200 mg/m2 cyclophosphamide per day as a 4-hour-infusion, days 1 to 3 8 mg/m2 mitoxantrone per day iv over 30 minutes, day 1 4 treatment Cycles á 4 weeks per cycle In patients with peripheral lymphocyte Counts more than 20.000/mm3 and/or a large Tumor mass (ie, bulky disease more than 10 cm) a cytoreductive pre-phase could be performed, comprising cyclophosphamide at a dose of 200 mg/m2 as a 1-hour-infusion over 3 to 5 days."
3310885|NCT00317096|Other|Observation only|"Patients achieving a complete or partial remission after FCM or R-FCM underwent a subsequent randomization for 2 courses of rituximab to be given 3 and 6 months after completion of salvage therapy versus observation only.~This second randomization was stratified for the type of salvage therapy with FCM or R-FCM, the Response to this Treatment (CR or PR), and histology."
3310886|NCT00317096|Other|rituximab maintenance|"Patients achieving a complete or partial remission after FCM or R-FCM underwent a subsequent randomization for 2 courses of rituximab to be given 3 and 6 months after completion of salvage therapy versus observation only.~Courses of rituximab consisted of 4 doses of 375 mg/m2 per day given at 4 consecutive weeks.~This second randomization was stratified for the type of salvage therapy with FCM or R-FCM, the Response to this Treatment (CR or PR), and histology."
3310887|NCT00317070|Active Comparator|DMSO|Intravesical installation
3310888|NCT00317070|Experimental|Cocktail|
3310889|NCT00317044|Experimental|Esomeprazole 40 mg twice daily|
3310890|NCT00317044|Experimental|Esomeprazole 40 mg once daily|
3310891|NCT00317044|Placebo Comparator|Placebo|
3310892|NCT00317031|Active Comparator|1|Acamprosate
3310893|NCT00317031|Active Comparator|2|Naltrexone
3310894|NCT00317031|Placebo Comparator|3|Placebo
3310895|NCT00317018|Other|Arm 1|Implementation Group
3310896|NCT00317018|No Intervention|Arm 2|Control Group
3310897|NCT00316992|Experimental|Ramelteon 8 mg and Placebo|
3310898|NCT00316953|Experimental|Stratum 1 (solid tumors)|Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3310899|NCT00316953|Experimental|Stratum 2 (leukemia)|Patients receive dasatinib as in stratum 1. Cohorts of 3-12 patients receive escalating or de-escalating doses of dasatinib. The MTD is defined as the dose preceding that at which 7 of 12 patients experience DLT.
3310900|NCT00316914|Experimental|Ca/Mg|Patients receive calcium gluconate (Ca) and magnesium sulfate (Mg) IV over 30 minutes immediately before and after each oxaliplatin administration (once every 2 weeks) of their assigned chemotherapy regimen.
3310901|NCT00316914|Placebo Comparator|Placebo|Patients receive a placebo IV over 30 minutes immediately before and after each oxaliplatin administration (once every 2 weeks) of their assigned chemotherapy regimen.
3310902|NCT00316888|Experimental|Arm I (closed to accrual as of 11/3/2008)|Patients receive cisplatin IV over 60 minutes on days 1, 29, 57, and 85 and fluorouracil IV continuously over 96 hours on days 1-4, 29-32, 57-60, and 85-88. Patients also receive cetuximab IV over 120 minutes on day 50 and then IV over 60 minutes on days 57, 64, 71, 78, 85, 92, and 99 and undergo radiotherapy once daily 5 days a week for 5 weeks, beginning on day 57. Treatment continues in the absence of disease progression or unacceptable toxicity.
3310903|NCT00316888|Experimental|Arm II (open to accrual on 8/18/2009)|Patients receive cetuximab IV over 120 minutes on day 1 and then IV over 60 minutes on days 8, 15, 22, 29, 36, 43, and 50. Patients also receive cisplatin IV over 60 minutes on days 1 and 36, fluorouracil IV continuously over 96 hours on days 8-11 and 36-39, and undergo radiotherapy once daily 5 days a week for 5 weeks beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
3310904|NCT00316875|Experimental|Lapatinib Ditosylate and Doxil|
3310905|NCT00316862|Experimental|Treatment (chemotherapy, chemoradiotherapy, surgery)|"INDUCTION CHEMOTHERAPY (COURSES 1-2): Patients receive cisplatin intravenously (IV) over 30 minutes and irinotecan hydrochloride IV over 30-90 minutes on days 1 and 8 of courses 1 and 2. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CHEMORADIOTHERAPY (COURSES 3-4): Beginning 2 weeks after completion of induction chemotherapy, patients receive cisplatin and irinotecan hydrochloride as in induction chemotherapy on days 1 and 8 of courses 3 and 4 and undergo radiotherapy daily 5 days a week in course 3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Approximately 4-8 weeks after completion of chemoradiotherapy, patients undergo surgery to remove the tumor."
3310949|NCT00316264|Experimental|Motavizumab control|5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)
3310950|NCT00316225|Experimental|Pemetrexed|Pemetrexed 500 mg/m^2 intravenous (IV) every 21 days for 6 cycles
3310951|NCT00316199|Experimental|A|
3310952|NCT00316186|Experimental|Single arm, open label|
3310953|NCT00316173|Experimental|Single-arm|HYCAMTIN at a dose of 2.0 - 2.5mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1, every 21 days
3310954|NCT00316134||Pts scheduled to remove pleural fluid|
3310906|NCT00316849|Experimental|Treatment (temsirolimus, temozolomide, radiation therapy)|GROUP 1: (temsirolimus with radiation and temozolomide) Patients receive temsirolimus IV over 30 minutes once weekly. Beginning 7-10 days later, patients also receive oral temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients with stable or responding disease proceed to adjuvant therapy. GROUP 2: (radiation and temozolomide) Patients receive oral temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients with stable or responding disease proceed to adjuvant therapy. ADJUVANT THERAPY: Beginning 4-6 weeks after the completion of chemoradiotherapy patients receive oral temozolomide on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3310907|NCT00316836||Group 1|Patients complete a 10-minute questionnaire about factors that might affect changes in breast density at baseline and another questionnaire at 1 year and 2 years post registration. Blood samples are collected at baseline (before initiation of treatment ) and at 1 year post registration for hormone and drug level analysis. Mammograms taken prior to registration (within 12 months prior to enrollment) and at approximately 1 and 2 years post-registration to this study are retrieved and digitized for determination of percent breast density and dense area.
3310908|NCT00316810|Experimental|Campath|"Day 0: Before revascularisation patients are given 500 mg of Methylprednisolone i.v. followed by Campath 30 mg i.v. infusion over 3-6 hours.~Day 1: No treatment~Day 2: Initial dose of Tacrolimus 0.05 - 0.1 mg/kg/d orally.~till Month 6: Aim at blood level of 12-15 ng/ml (try to prevent the Tacrolimus trough level falling below 12 ng/ml in the first 6 months).~Month 7-12: Maintain the Tacrolimus blood level at 6-12 ng/ml after 6 months."
3310909|NCT00316810|Active Comparator|ATG|"Day 0: Prior to revascularisation patients are given 500 mg of Methylprednisolone i.v. followed by a single shot of a polyclonal antilymphocyte preparation. Tacrolimus will be given immediately after transplantation(0.05-0.1 mg/kg/d) orally. Preoperative loading dose MMF: 2 g orally.~From Day 1: Total initial daily dose of 0.05-0.1 mg/kg administered orally in 2 doses. Blood trough levels 12-15 ng/ml during the first 6 months and maintain blood levels 6-12 ng/ml after 6 months. Total daily dose of MMF is 2 g administered orally in 2 doses. Patients will receive Methylprednisolone 250 mg IV 12h post surgery and 125 mg of Methylprednisolone 24 h post transplantation.~Steroid taper (orally):~Day 2: 100 mg of Prednisolon Day 3: 80 mg of Prednisolon Day 4: 60 mg of Prednisolon Day 5: 40 mg of Prednisolon Day 6: 25 mg of Prednisolon Day 21: 20 mg of Prednisolon~Reduction by 5 mg in two week intervals/complete withdrawal by 3 months post-tx."
3310910|NCT00316797|Experimental|123-I INER|To assess 123-I INER
3310911|NCT00316771|Experimental|P38 Inhibitor (4) 150mg|
3310912|NCT00316771|Experimental|P38 Inhibitor (4) 25mg|
3310913|NCT00316771|Experimental|P38 Inhibitor (4) 300mg|
3310914|NCT00316771|Experimental|P38 Inhibitor (4) 50mg|
3310915|NCT00316771|Experimental|P38 Inhibitor (4) 75mg|
3310916|NCT00316771|Placebo Comparator|Placebo|
3310917|NCT00316758|Experimental|1|
3310918|NCT00316745|Active Comparator|1|mFOLFOX6 （ → IRIS ( Irinotecan and S-1) ）
3310919|NCT00316745|Experimental|2|IRIS ( Irinotecan and S-1 ) → mFOLFOX6
3310920|NCT00316719|Experimental|Adefovir Dipivoxil (ADV)|
3310921|NCT00316719|Active Comparator|Lamivudine (LAM)|
3310922|NCT00316706|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals' HPV-16/18 Vaccine (Cervarix™) during the primary study (NCT00196924). Subjects from this group continued the long-term follow-up study until Month 48.
3310923|NCT00316706|Active Comparator|Havrix Group|Subjects received 3 doses of Havrix™ (hepatitis A vaccine [HAV]) during the primary study (NCT00196924). Subjects from the this group completed the study at Month 24.
3310924|NCT00316693|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.
3310925|NCT00316693|Active Comparator|Aimmugen Group|Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.
3310926|NCT00316602|Experimental|1|
3310927|NCT00316602|Experimental|2|
3310928|NCT00316589|Experimental|Healthy subjects|Control group with (n=9) and without (n=88) a history of previous smallpox vaccination IMVAMUNE (MVA-BN)
3310929|NCT00316589|Experimental|HIV-infected, vaccinia-naive|Subjects without a history of previous smallpox vaccination (n=351), IMVAMUNE (MVA-BN)
3310930|NCT00316589|Experimental|HIV-infected, vaccinia-experienced|Subjects with a history of previous smallpox vaccination (n=100), IMVAMUNE (MVA-BN)
3310931|NCT00316563|Active Comparator|1|
3310932|NCT00316563|Placebo Comparator|2|
3310933|NCT00316524|Experimental|1|
3310934|NCT00316524|Experimental|2|
3310935|NCT00316524|Placebo Comparator|3|2x Placebo
3310936|NCT00316524|Experimental|4|1 immunization: 1x 10E8_TCID50
3310937|NCT00316355|Active Comparator|Traditional CBT|Cognitive-behavioral therapy (CBT) that incorporates exposure with ritual prevention (EX/RP)
3310938|NCT00316355|Experimental|Stepped-Care CBT|Stepped-care CBT
3310939|NCT00316316|Active Comparator|1|Participants will receive motivational interviewing plus exposure and response prevention
3310940|NCT00316316|Active Comparator|2|Participants will receive exposure and response prevention only
3310941|NCT00316303|Experimental|1|Participants will receive screening, testing, immunization, and risk reduction. Screening and testing will take place at study entry, immunization will occur at entry and after 3 and 6 months, and risk reduction will take place at study entry and after 3 and 6 months.
3310942|NCT00316303|Placebo Comparator|2|Participants will receive enhanced treatment as usual.
3310943|NCT00316290|Experimental|1|Participants will receive integrated parent training.
3310944|NCT00316290|Active Comparator|2|Parents will receive behavioral parent training.
3310945|NCT00316277|Experimental|Buprenorphine/Nx with EMM|
3310946|NCT00316277|Active Comparator|Buprenorphine/Nx with SMM|
3310947|NCT00316264|Experimental|Motavizumab followed by Palivizumab|2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)
3310955|NCT00316121|Experimental|1|
3310956|NCT00316121|Active Comparator|2|
3310957|NCT00316108|Experimental|Arm 1|
3310958|NCT00316082|Experimental|Saxagliptin 2.5 mg QAM (A)|PLUS open-label metformin (as needed as rescue medication)
3310959|NCT00316082|Experimental|Saxagliptin 2.5 mg titrated to 5 mg QAM (B)|PLUS open-label metformin (as needed as rescue medication)
3310960|NCT00316082|Experimental|Saxagliptin 5 mg QAM (C)|PLUS open-label metformin (as needed as rescue medication)
3310961|NCT00316082|Experimental|Saxagliptin 5 mg QPM (D)|PLUS open-label metformin (as needed as rescue medication)
3310962|NCT00316082|Placebo Comparator|Placebo (E)|PLUS open-label metformin (as needed as rescue medication)
3310963|NCT00316017|Experimental|1|7.5% hypertonic saline/6% Dextran-70 (HSD)
3310964|NCT00316017|Experimental|2|7.5% hypertonic saline (HS)
3310965|NCT00316017|Placebo Comparator|3|0.9% normal saline
3310966|NCT00316004|Experimental|7.5% hypertonic saline/6% dextran (HSD)|250 ml intravenous bolus administration of 7.5% saline/6% dextran 70
3310967|NCT00316004|Experimental|7.5% hypertonic saline (HS)|250 ml intravenous bolus administration of 7.5% hypertonic saline
3310968|NCT00316004|Placebo Comparator|0.9% normal saline (NS)|250 ml intravenous bolus administration of 0.9% saline
3310969|NCT00315991|Experimental|BGAT Intervention|Blood Glucose Awareness Training for Parents
3310970|NCT00315991|No Intervention|Control|Enter PDA data and complete questionnaires only. No intervention received.
3310971|NCT00315939|Experimental|Group A Order: SMBG, IBMF-1, IBMF-2|Group A performed routine self-monitored blood glucose (SMBG) alone (level 1), followed sequentially by Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1) level 2 and Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2) level 3. Each level continued for 3 months.
3310972|NCT00315939|Experimental|Group B Order: IBMF-1, IBMF-2, SMBG|Group B began with Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1) level 2, followed by level 3, Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2) and then level 1 (SMBG only). Each level continued for 3 months.
3310973|NCT00315926|Experimental|Melatonin|
3310974|NCT00315926|Placebo Comparator|Placebo|
3310975|NCT00315913|Experimental|IV Propranolol|IV dose propranolol
3310976|NCT00315913|Placebo Comparator|IV Placebo|IV Placebo of saline solution equal to propranolol in volume
3310977|NCT00315900|Experimental|Depakote ER|Depakote ER
3310978|NCT00315900|Active Comparator|Seroquel|Seroquel
3310979|NCT00315822|Placebo Comparator|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
3310980|NCT00315822|Active Comparator|80% oxygen|Subject undergoing surgery will receive supplemental oxygen
3310981|NCT00315757|Active Comparator|A|Bortezomib
3310982|NCT00315757|Experimental|B-10|Bortezomib and Mapatumumab 10 mg/kg
3310983|NCT00315757|Experimental|B-20|Bortezomib and Mapatumumab 20 mg/kg
3310984|NCT00315744|Experimental|Subjects receiving salmeterol/fluticasone|Eligible subjects will receive 60 individual doses of the salmeterol 50 microgram/ fluticasone 100 microgram combination. Subjects will also receive placebo.
3310985|NCT00315744|Active Comparator|Subjects receiving fluticasone|Eligible subjects will receive 60 individual fluticasone 100 microgram doses each.
3310986|NCT00315731|Experimental|tositumomab and iodine I 131 tositumomab|Subjects participating in this study will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I-131 tositumomab, immediately following an infusion of 450 mg of unlabeled tositumomab. Using the dosimetric data from three of the six imaging time points and the subject's weight, a patient-specific activity (mCi) of Iodine I-131 will be calculated to deliver the desired total body dose of radiation (75 cGy). All subjects will then receive an infusion of unlabeled tositumomab (450 mg) immediately followed by an infusion of the subject specific dose of tellurium-derived Iodine I-131 tositumomab (35 mg) to deliver a total body dose (TBD) of 75 cGy.
3310987|NCT00315705|Experimental|clofarabine, etoposide, cyclophosphamide|"Phase 1: escalating dosage of the three drugs delivered intravenously. Clofarabine dosage from 20-40 mg/m^2, etoposide dosage from 75-100 mg/m^2, cyclophosphamide dosage from 340-440 mg/m^2.~Phase 2: The recommended phase 2 doses (RP2D) were clofarabine 40 mg/m^2, etoposide 100 mg/m^2 and cyclophosphamide 440 mg/m^2 delivered intravenously"
3310988|NCT00315692||Premenopausal women|
3310989|NCT00315692||Postmenopausal women|
3310990|NCT00315640|Experimental|Anecortave Acetate 3 mg Depot|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
3310991|NCT00315640|Experimental|Anecortave Acetate 15 mg Depot|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
3310992|NCT00315640|Experimental|Anecortave Acetate 30 mg Depot|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
3310993|NCT00315640|Other|Anecortave Acetate Vehicle|
3310994|NCT00315627|Experimental|islet transplantation|Islet Alone Transplantation under Alentuzumab (Campath1H) induction.
3310995|NCT00315614|Experimental|Islet Transplantation and Bone Marrow|Administration of islets and infusion of CD34 enriched Bone Marrow cells in subjects with type 1 diabetes, impaired awareness of hypoglycemia and severe hypoglycemia.
3310996|NCT00315588|Experimental|Islet Transplantation|Islet Transplantation in subjects with a previous kidney transplant.
3310997|NCT00315575||1|Individuals with high risk for Alzheimer's disease
3310998|NCT00315575||2|Individuals with low risk for Alzheimer's disease
3310999|NCT00315562|Experimental|Early|Early
3311000|NCT00315562|Active Comparator|Delayed|Delayed
3311001|NCT00315458|Experimental|BTDS|Buprenorphine transdermal patches 10 or 20 mcg/h
3311002|NCT00315458|Placebo Comparator|Placebo|Placebo to match buprenorphine transdermal patch 10 or 20
3311003|NCT00315445|Placebo Comparator|Placebo|Placebo oxycodone (OXY)/acetaminophen (APAP) tablets and placebo transdermal patch (TDS) 5, 10, or 20
3311004|NCT00315445|Active Comparator|OXY/APAP|5 mg oxycodone/325 mg acetaminophen tablets
3311005|NCT00315445|Experimental|BTDS|Buprenorphine transdermal patch 5, 10, or 20 mcg/hour
3311006|NCT00315354|Experimental|1|Low glycemic index diet
3311007|NCT00315354|Active Comparator|2|Low fat diet
3311008|NCT00315354|Active Comparator|3|Very low carbohydrate diet
3311052|NCT00314782|Experimental|Part B (placebo)|Part B (randomised, placebo-controlled): Matching placebo oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
3311674|NCT00306904|Experimental|3|0.2 mg/eye dose group
3311009|NCT00315341|Experimental|Buprenorphine/Nx|For the BUP/NX group, all participants will receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg buprenorphine increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.
3311010|NCT00315341|Active Comparator|Methadone|For the MET group, all participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.
3311011|NCT00315328|Active Comparator|Patching|Patching 2 hours per day plus near activities for one hour while patching (with increase to 4 hours per day for moderate amblyopes and >4 hours per day for severe amblyopes at 5 weeks if acuity not improved at least 5 letters)
3311012|NCT00315328|Active Comparator|Atropine|Atropine 1% once each weekend day in the sound eye plus near activities for at least one hour every day (with increase to daily atropine at 5 weeks if acuity not improved by at least 5 letters)
3311013|NCT00315302|Active Comparator|Atropine|Atropine 1% once each weekend day in the sound eye
3311014|NCT00315302|Active Comparator|Atropine plus plano|Atropine 1% once each weekend day in the sound eye plus a plano lens for the sound eye
3311015|NCT00315250|Experimental|[123I]β-CIT|To assess B-CIT and SPECT imaging
3311016|NCT00315237|Experimental|1|
3311017|NCT00315237|No Intervention|2|best supportive care for 18 week duration
3311018|NCT00315211|Other|Arm A|Weekly intravenous topotecan with intravenous docetaxel
3311019|NCT00315198|Active Comparator|Near activities|2 hours of daily patching combined with near visual activities while patching
3311020|NCT00315198|Active Comparator|Distance activities|2 hours of daily patching combined with distance visual activities while patching
3311021|NCT00315159|No Intervention|No intervention|Patients with negative SLN will be followed on no intervention arm
3311022|NCT00315146|Placebo Comparator|Hypocaloric diet (and placebo)|
3311023|NCT00315146|Active Comparator|Hypocaloric diet, resist. training to maximize power, placebo|
3311024|NCT00315146|Active Comparator|Hypocaloric diet and a PPAR- γ agonist (pioglitazone/Actos™)|
3311025|NCT00315146|Active Comparator|Hypocaloric diet,resistance training, pioglitazone/Actos™|
3311026|NCT00315133|Experimental|Transplant arm|This is a single arm study. The intervention is immunosuppression and autologous stem cell transplantation.
3311027|NCT00315120|Other|A (Active OMT and active (UST)|Subjects in this group received active osteopathic manipulation and active ultrasound physical therapy
3311028|NCT00315120|Other|B (Sham OMT and active UST)|Subjects in this group received sham osteopathic manipulation and active ultrasound physical therapy
3311029|NCT00315120|Other|C (Active OMT and sham UST)|Subjects in this group received active osteopathic manipulation and sham ultrasound physical therapy
3311030|NCT00315120|Other|D (Sham OMT and sham UST)|Subjects in this group received sham osteopathic manipulation and sham ultrasound physical therapy
3311031|NCT00315094|Experimental|1|
3311032|NCT00315094|No Intervention|2|After a control period, this group crosses over to experimental interventions (Arm 1)
3311033|NCT00315055|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|Participants will receive 3 vaccinations with Diphtheria (D) and tetanus (T) toxoids, acellular pertussis (2-component) (aP), recombinant Hepatitis B surface antigen (HBsAg), inactivated poliomyelitis virus (IPV), and Hemophilus influenzae type b (Hib) polysaccharide conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T); One dose each at 2, 3, and 4 months of age.
3311034|NCT00315055|Active Comparator|Group 2: PENTAXIM™ and ENGERIX B® PEDIATRIC|Participants will receive 3 vaccinations with DTaP-IPV-PRP~T (PENTAXIM™ ) and recombinant Hepatitis B (ENGERIX® PEDIATRIC) vaccines. One dose each at 2, 3, and 4 months of age.
3311035|NCT00315029|Experimental|1|Receives combined patient centred intervention
3311036|NCT00315029|No Intervention|2|Standard treatment
3311037|NCT00315016|Placebo Comparator|1|placebo (double dummy)
3311038|NCT00315016|Active Comparator|2|eplerenone
3311039|NCT00315016|Active Comparator|3|doubling of fosinopril dose
3311040|NCT00314977|Experimental|A|Cycles 1-4 q 3 weeks: doxorubicin plus cyclophosphamide Cycles 5-8 q 3 weeks: docetaxel
3311041|NCT00314977|Experimental|B|Cycles 1-6 q 3 weeks: doxorubicin, cyclophosphamide and docetaxel
3311042|NCT00314951|Experimental|fidaxomicin|Participants receiving fidaxomicin 200 mg capsules orally two times daily (every 12 hours [q12h] regimen) with intermittent matching placebo to fidaxomicin
3311043|NCT00314951|Active Comparator|Vancomycin|Participants receiving vancomycin 125 mg capsules orally four times daily (every 6 hours [q6h] regimen).
3311044|NCT00314925|Experimental|1|
3311045|NCT00314847|No Intervention|Control|IABP, inotropic drugs, antiplatelet agents according to site habits.
3311046|NCT00314847|Experimental|Experimental|ECLS +/- IABP, inotropic drugs, antiplatelet agents according to site habits.
3311047|NCT00314808|Experimental|Dronabinol|
3311048|NCT00314795|Experimental|Peginesatide|Peginesatide dose administered subcutaneously once every 4 weeks. The frequency of each injection and the dose may be adjusted based on the participant's hemoglobin response and the ability to maintain a hemoglobin level in the range of 10.0-12.0 g/dL.
3311049|NCT00314782|Experimental|Part A|Part A (dose-finding): ZD4054 (Zibotentan) 10 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
3311050|NCT00314782|Experimental|Part A (ZD4054 (Zibotentan) 15 mg + docetaxel)|Part A (dose-finding): ZD4054 (Zibotentan) 15 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
3311051|NCT00314782|Experimental|Part B|Part B (randomised, placebo-controlled): ZD4054 (Zibotentan) Maximum Tolerated Dose (MTD), 15mg, oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
3311405|NCT00310063|Experimental|Arm I|Sea Band elastic acupressure wristband
3311053|NCT00314743|Active Comparator|Control (No aprepitant)|"Regimen #1 (BEAM; NHL and HL)~Carmustine 300 mg/m2 IV on day -7 (premedicate with ondansetron 32 mg IV and dexamethasone 20 mg IV)~Etoposide 100 mg/m2 IV Q 12 hours x 8 doses on days -6 to -3 (premedicate first daily dose ondansetron 32 mg IV and dexamethasone 20 mg IV)~Cytarabine 100 mg/m2 IV Q 12 hours x 8 doses on days -6 and -3 (no additional premedication)~Melphalan 140 mg/m2 IV on day -2 (premedicate with ondansetron 32 mg IV and dexamethasone 20 mg IV)~Regimen #2 (MM and Amyloidosis)~Melphalan 100 mg/m2 IV on days -3 and -2 (premedicate each dose with ondansetron 32 mg IV and dexamethasone 20 mg IV)"
3311054|NCT00314743|Experimental|Experimental (with aprepitant)|"Aprepitant 125 mg PO will be given 30 minutes prior to the first dose of chemotherapy followed by Aprepitant 80 mg PO QD for the remainder of chemotherapy and continuing for a total of 2 days after completing the regimen.~Regimen #1 (BEAM; NHL and HL)~Carmustine 300 mg/m2 IV on day -7 (premedicate with ondansetron 32 mg IV and dexamethasone 10 mg IV)~Etoposide 100 mg/m2 IV Q 12 hours x 8 doses on days -6 to -3 (premedicate first daily dose ondansetron 32 mg IV and dexamethasone 10 mg IV)~Cytarabine 100 mg/m2 IV Q 12 hours x 8 doses on days -6 and -3 (no additional premedication)~Melphalan 140 mg/m2 IV on day -2 (premedicate with ondansetron 32 mg IV and dexamethasone 10 mg IV)~Regimen #2 (MM and Amyloidosis)~Melphalan 100 mg/m2 IV on days -3 and -2 (premedicate each dose with ondansetron 32 mg IV and dexamethasone 10 mg IV)"
3311055|NCT00314626|Experimental|A|abacavir 600 mg + lamivudine (3TC) 300 mg in 1 tablet + efavirenz 600 mg 1/24h
3311056|NCT00314626|No Intervention|B|efavirenz + 2 NUCS
3311057|NCT00314574|Experimental|Xolair|"The subcutaneous dose of Xolair administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.~Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.~Participants were permitted to use albuterol as rescue medicine throughout the study."
3311058|NCT00314574|Placebo Comparator|placebo|"The subcutaneous dose of placebo administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.~Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.~Participants were permitted to use albuterol as rescue medicine throughout the study."
3311059|NCT00314548|Experimental|Cases|PGE1 drug
3311060|NCT00314548|Placebo Comparator|Placebo|normal saline via same nebulizer
3311061|NCT00314366|Active Comparator|Stem Cell Therapy|Subjects are randomized to receive Stem Cell Therapy (treatment) at the time of enrollment where cells are delivered after NOGA mapping and cells injected with the Myostar catheter.
3311062|NCT00314366|Placebo Comparator|Control|"Placebo patients will receive injections of plasma (control) instead of stem cells. Placebo patients are able to crossover and receive active treatment at 6 months if they meet the criteria.~At 6 months, subject is offered stem cell therapy and then followed for 12 months."
3311063|NCT00314353|Experimental|1|
3311064|NCT00314353|Experimental|2|
3311065|NCT00314340|Active Comparator|extended-release morphine|"Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity~On one of three study dates, subjects received ER morphine tablets, 45 mg (Mallinckrodt Pharmaceuticals, St. Louis, MO). The dose of ER morphine sulfate (45 mg) was selected because of its approximate equianalgesic effect to the dose of hydrocodone-acetaminophen (30/925 mg)."
3311066|NCT00314340|Active Comparator|hydrocodone|"Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity~On the day of the study session, patients received hydrocodone 30 mg plus N-acetyl-para-aminophenol 975 mg (APAP;Qualitest Pharmaceuticals Inc, Huntsville, AL)."
3311067|NCT00314340|Placebo Comparator|placebo|Subjects received a placebo pill if randomized to this arm. Both opioid medications and the placebo were administered in identical capsules.
3311068|NCT00314327|Experimental|long-acting injectable risperidone|One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.
3311069|NCT00314314|Experimental|1|
3311070|NCT00314314|Placebo Comparator|2|
3311071|NCT00314275|Experimental|ENDEAVOR|Drug Eluting Stent
3311072|NCT00314262|Experimental|Erlotinib & Celecoxib|
3311073|NCT00314249|Placebo Comparator|Placebo|Placebo, oral administration, twice daily for 12 weeks
3311074|NCT00314249|Experimental|Milnacipran|Milnacipran 100mg/day (50mg BID [twice a day])
3311075|NCT00314236|Experimental|Microfracture with BST-CarGel|BST-CarGel applied to a Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle
3311076|NCT00314236|Active Comparator|Microfracture without BST-CarGel|Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle
3311077|NCT00314171|Experimental|Brinzolamide + Timolol|
3311078|NCT00314171|Active Comparator|Dorzolamide + Timolol|
3311079|NCT00314158|Experimental|Brinzolamide +Timolol|
3311080|NCT00314158|Active Comparator|Brinzolamide|
3311081|NCT00314158|Active Comparator|Timolol|
3311082|NCT00314145|Experimental|ChimeriVax™-JE|Participants received dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine and saline placebo into different arms.
3311083|NCT00314145|Active Comparator|JE-VAX®|Participants received 1 dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a dose of saline placebo into a different arm on Day 30.
3311084|NCT00314132|Placebo Comparator|Placebo|All subjects received a single injection of placebo on Day 0.
3311085|NCT00314132|Experimental|ChimeriVax™ JE 4 log10 PFU Vaccine|All participants received a single injection of ChimeriVax™ JE 4 log10 Plaque-forming unit (PFU) Vaccine on Day 0.
3311131|NCT00313586|Experimental|Arm B (azacitidine, entinostat)|Patients receive azacitidine as in Arm A and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 6-24 courses in the absence of disease progression or unacceptable toxicity.
3311132|NCT00313560|Experimental|Arm I|Patients receive oral erlotinib hydrochloride once a day for 3-5 days. Patients then proceed to surgery.
3311086|NCT00314106|Experimental|TBI 1200 cGy + TIL +HD IL-2, prior IL-2|Patients that received prior interleukin 2 (IL-2) therapy will receive a myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x 2 days intravenous (IV)), fludarabine (25mg/m^2/day IV X 5 days) and 1200 cGy total body irradiation (TBI). Following the lymphodepleting regimen, patient will receive intravenous adoptive transfer of tumor reactive lymphocytes (minimum 3 X 10 (9) and up to a maximum of 3 X 10(11) lymphocytes) followed by high-dose intravenous (IV) IL-2 (720,000 IU/kg/dose every 8 hours for up to 15 doses).
3311087|NCT00314106|Experimental|TBI 1200 cGy + TIL +HD IL-2, no prior IL-2|Patients that have not received prior interleukin 2 (IL-2) therapy will receive a myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x 2 days intravenous (IV)), fludarabine (25mg/m^2/day IV X 5 days) and 1200 cGy total body irradiation (TBI). Following the lymphodepleting regimen, patient will receive intravenous adoptive transfer of tumor reactive lymphocytes (minimum 3 X 10 (9) and up to a maximum of 3 X 10(11) lymphocytes) followed by high-dose intravenous (IV) IL-2 (720,000 IU/kg/dose every 8 hours for up to 15 doses)
3311088|NCT00314067|Experimental|1|
3311089|NCT00314067|Experimental|2|
3311090|NCT00314067|Active Comparator|3|
3311091|NCT00314054|Experimental|1|HCV-796 1000mg single dose
3311092|NCT00314028|Active Comparator|1|Standard of care treatment
3311093|NCT00314028|Experimental|2|Educational program designed to motivate and provide information on the correct use of condoms
3311094|NCT00314015|Experimental|Patients with immediately loaded implants.|
3311095|NCT00313989|Experimental|Evaluation of implants of patients receiving radiotherapy.|
3311096|NCT00313976|Experimental|Arm 1|
3311097|NCT00313976|Experimental|Arm 2|
3311098|NCT00313963|Experimental|1|
3311099|NCT00313963|Placebo Comparator|2|
3311100|NCT00313950|Experimental|Group 1|
3311101|NCT00313950|Experimental|Group 2|
3311102|NCT00313950|Experimental|Group 3|
3311103|NCT00313911|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|
3311104|NCT00313911|Active Comparator|Group 2: Tritanrix-Hep B/Hib™+OPV|
3311105|NCT00313885|Experimental|1|1 mg daily
3311106|NCT00313885|Experimental|2|5 mg daily
3311107|NCT00313885|Placebo Comparator|3|
3311108|NCT00313872|Experimental|FOLFIRI|
3311109|NCT00313872|Experimental|DP|"D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr, D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr~D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan"
3311110|NCT00313846|Experimental|BTDS|Buprenorphine transdermal patch 5, 10 or 20 micrograms/hour (mcg/h)
3311111|NCT00313846|Placebo Comparator|Placebo|Placebo to match BTDS 5, 10 or 20 mcg/h
3311112|NCT00313820|Active Comparator|Pregabalin|The change from in pain scores from baseline to endpoint among stroke subjects receiving pregabalin will be compared to change in pain scores from baseline to endpoint among stroke subjects receiving matched placebo.
3311113|NCT00313820|Placebo Comparator|Placebo|The change in pain scores from baseline to endpoint will be compared among the two treatment groups- ie subjects receiving 12 weeks of pregabalin treatment vs subjects receiving 12 weeks of placebo treatment.
3311114|NCT00313807|Active Comparator|1|Intravenous saline infusion plus amino acid infusion
3311115|NCT00313807|Placebo Comparator|2|Intravenous saline infusion plus placebo infusion
3311116|NCT00313794|Experimental|1|single arm
3311117|NCT00313781|Experimental|A|For patients treated with docetaxel and prednisone only, who progress during treatment, CP-751,871 will be added to the regimen to test reversibility of chemoresistance.
3311118|NCT00313781|Active Comparator|B|
3311119|NCT00313768|Active Comparator|B|Standard of care chemotherapy
3311120|NCT00313768|Experimental|A|Standard of care chemotherapy plus experimental intervention (PF-3512676)
3311121|NCT00313729|Experimental|Temozolomide|Temozolomide
3311122|NCT00313716|Active Comparator|Epo1 and TT10|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, at 24 and 48 hrs after injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger of 10gm/dl
3311123|NCT00313716|Active Comparator|Epo1 and TT7|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, at 24 and 48 hrs after injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 7gm/dl
3311124|NCT00313716|Active Comparator|Epo2 and TT10|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 10gm/dl
3311125|NCT00313716|Active Comparator|Epo2 and TT7|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 7gm/dl
3311126|NCT00313716|Placebo Comparator|Placebo and TT10|Placebo administration and transfusion threshold 10 gm/dl
3311127|NCT00313716|Placebo Comparator|Placebo and TT7|Placebo administration and transfusion threshold 7 gm/dl
3311128|NCT00313612|Experimental|Treatment (oxaliplatin plus topotecan)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.
3311129|NCT00313599|Experimental|Lapatinib and Paclitaxel|Lapatinib will be self-administered orally on days 1 and 2 of weeks 1, 2, and 3 of a 4-week cycle. Lapatinib is the experimental therapy and is being administered using a dose escalation design guided by careful monitoring of toxicities. Abraxane will be administered IV weekly on day 3 of weeks 1, 2, and 3 of a 4-week cycle. Abraxane is being administered at the well tolerated and effective standard dose and schedule of 100mg/m2 weekly 3 out of 4 weeks as defined by previous phase I and II studies. Patients will continue on therapy as long as they are not experiencing toxicities and there is no evidence of disease progression.
3311130|NCT00313586|Experimental|Arm A (azacitidine)|Patients receive azacitidine SC QD on days 1-10. Treatment repeats every 28 days for 6-24 courses in the absence of disease progression or unacceptable toxicity.
3311133|NCT00313560|Placebo Comparator|Arm II|Patients receive oral placebo once a day for 3-5 days. Patients then proceed to surgery.
3318943|NCT00196092|Other|4|High Risk
3311134|NCT00313508|Experimental|A: Peptide-pulsed DC, ALI and Low Dose Fludarabine|Fludarabine: 5 mg/m^2/day, Auto Lymphocyte Infusion, DC Infusion
3311135|NCT00313508|Experimental|B: Peptide-pulsed DC, ALI and High Dose Fludarabine|Fludarabine: 25 mg/m^2/day, Auto Lymphocyte Infusion, DC Infusion
3311136|NCT00313443|Experimental|Amiodarone, long-term|Unique arm: all patients were taking amiodarone for more than 6 months and all patietns underwent amiodarone dosage in blood and fat tissue samplings
3311137|NCT00313430||Dialysis patients|
3311138|NCT00313430||with or wthout glucose added to dialysis fluid|
3311139|NCT00313417|Active Comparator|1|
3311140|NCT00313417|Placebo Comparator|2|
3311141|NCT00313404|Experimental|Norovirus in groundwater|We dosed volunteers with safety tested infectious norovirus in groundwater (that met EPA standards for drinking water). The length of time norovirus remained in groundwater varied by volunteer.
3311142|NCT00313378|Experimental|ketamine|This study compares two groups of patients undergoing thoracotomy for partial pneumonectomy, one receiving intravenous ketamine since the beginning of procedure and then during 48 hours, the other receiving inactive normal saline (placebo).
3311143|NCT00313378|Other|placebo|This study compares two groups of patients undergoing thoracotomy for partial pneumonectomy, one receiving intravenous ketamine since the beginning of procedure and then during 48 hours, the other receiving inactive normal saline (placebo).
3311144|NCT00313339|No Intervention|Control Group|A concurrent group meeting eligibility criteria but not receiving CD34+cells will be evaluated similar to the study group to assess the extent, if any, of significant improvement in cardiac perfusion/function without the CD34+cell product infusion.
3311145|NCT00313339|Experimental|Treatment Group|Intra-coronary infusion of an autologous bone marrow derived CD34+ stem cell product.
3311146|NCT00313313|Experimental|Saxagliptin 2.5 mg + Glyburide 7.5 mg (A)|Metformin 500-2500 mg (as needed)
3311147|NCT00313313|Experimental|Saxagliptin 5 mg + Glyburide 7.5 mg (B)|Metformin 500-2500 mg (as needed)
3311148|NCT00313313|Placebo Comparator|Placebo + Glyburide 7.5 mg (C)|Metformin 500-2500 mg (as needed)
3311149|NCT00313300|Active Comparator|A1|
3311150|NCT00313300|Experimental|A2|
3311151|NCT00313300|Placebo Comparator|A3|
3311152|NCT00313300|Experimental|A4|
3311153|NCT00313248|Experimental|Arm 1|
3311154|NCT00313248|Experimental|Arm 2|
3311155|NCT00313235|Experimental|DC Vaccine and Cyclophosphamide|"Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure."
3311156|NCT00313209|Active Comparator|Roflumilast|"Roflumilast 500 µg~underlying medication: salmeterol 50 μg, twice daily, inhaled"
3311157|NCT00313209|Placebo Comparator|Placebo|"Placebo~underlying medication: salmeterol 50 μg, twice daily, inhaled"
3311158|NCT00313196|No Intervention|1|
3311159|NCT00313196|Experimental|2|
3311160|NCT00313183|Experimental|1|single doses of pramlintide acetate or placebo, given in three different sequences to three cohorts of subjects
3311161|NCT00313170|Experimental|1|Fulvestrant 250 mg
3311162|NCT00313170|Experimental|2|Fulvestrant 250 mg (+ 250 mg loading regimen)
3311163|NCT00313170|Experimental|3|Fulvestrant 500 mg
3311164|NCT00313157|Active Comparator|Metoprolol|Treatment with Metoprolol 100 mg x 1 for three weeks
3311165|NCT00313157|Active Comparator|Diltiazem|Treatment with Diltiazem 360 mg x 1 for three weeks
3311166|NCT00313157|Active Comparator|Verapamil|Treatment with Verapamil 240 mg x 1 for three weeks
3311167|NCT00313157|Active Comparator|Carvedilol|Treatment with Carvedilol 25 mg x 1 for three weeks
3311168|NCT00313105|Experimental|Smokeless Tobacco|Smokeless Tobacco and individual visits
3311169|NCT00313105|Active Comparator|Nicotine tablets|Nicotine tablets
3311170|NCT00313105|Placebo Comparator|3|7-mg nicotine patch acts as placebo
3311171|NCT00313053|Experimental|Human mAb 216|
3311172|NCT00313014|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
3311173|NCT00313014|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
3311174|NCT00313014|Experimental|Oxycodone Immediate-Release|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
3311175|NCT00312975|Experimental|Arm A|
3311176|NCT00312975|Active Comparator|Arm B|
3311177|NCT00312962|Active Comparator|1|Participants will use commercially available computer games
3311178|NCT00312962|Experimental|2|Participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation
3311179|NCT00312949|Experimental|1|Participants will use the interactive website
3311180|NCT00312949|Active Comparator|2|Participants will read written materials and watch a video
3311181|NCT00312936|No Intervention|Wait List|
3311182|NCT00312936|Experimental|MBSR|8 week mindfulness based stress reduction
3311183|NCT00312923|Experimental|Policosanol|20 mg daily of policosanol
3311184|NCT00312923|Placebo Comparator|Placebo|20 mg of microcrystalline cellulose daily
3311185|NCT00312897|Placebo Comparator|corn oil|as stated
3311186|NCT00312897|Experimental|Omega 3 Fatty Acids|as stated
3311187|NCT00312884|Active Comparator|Usual Care|Recieved usual hospital and community care
3311188|NCT00312884|Experimental|Intervention Arm|Recieved telemonitoring
3311189|NCT00312858|Active Comparator|1|Arm 1: VAQTA™ 0.5 mL injection (2 doses 6 months apart), ProQuad™ 0.5 mL injection (2 doses 6 months apart), Prevnar™ 0.5 mL injection (one dose), all vaccines administered concomitantly. 28 weeks of study duration.
3311306|NCT00311376|Experimental|2|botulinum toxin Type A (300U)
3311307|NCT00311376|Other|3|placebo; botulinum toxin Type A (200U)
3311190|NCT00312858|Active Comparator|2|Arm 2: ProQuad™ 0.5 mL injection (2 doses ~8 months apart), Prevnar™ 0.5 mL injection (one dose), both administered concomitantly, VAQTA™ 0.5 mL injection (2 doses 6 months apart) administered alone. 34 weeks of study duration.
3311191|NCT00312845|Experimental|Bortezomib + Rituximab|
3311192|NCT00312845|Active Comparator|Rituximab|
3311193|NCT00312780|Experimental|Arm 1: XL784|
3311194|NCT00312780|Placebo Comparator|Arm 2: Placebo Gel capsules|
3311195|NCT00312728|Experimental|bevacizumab|
3311196|NCT00312702|Experimental|10µg dose FMP011|Falciparum Malaria Protein 11 with AS02A adjuvant
3311197|NCT00312702|Experimental|50µg dose FMP011|Falciparum Malaria Protein 11 with AS02A adjuvant
3311198|NCT00312663|Experimental|10ug dose FMP011|Falciparum Malaria Protein 11 with AS01B adjuvant
3311199|NCT00312663|Experimental|50ug dose FMP011|Falciparum Malaria Protein 11 with AS01B adjuvant
3311200|NCT00312598||aripiprazole|observational measures of metabolic parameters of subjects who are making clinically determined medication switch to aripiprazole
3311201|NCT00312585|Experimental|Acupuncture|
3311202|NCT00312585|Sham Comparator|Sham Acupuncture|
3311203|NCT00312585|No Intervention|Usual care only|
3311204|NCT00312572|Experimental|BTDS10/20|Initial doses (Level 1) of BTDS 10. Subjects were allowed to have their doses adjusted to BTDS 20 (Level 2) on or after day 4.
3311205|NCT00312572|Experimental|BTDS 20|Initial doses (Level 1) of BTDS 20.
3311206|NCT00312546|Experimental|2A|Discontinuation of VPA and enfuvirtide administered for 24 weeks. As of 05/20/08 this step was discontinued.
3311207|NCT00312546|Experimental|2B|Continuation of VPA for up to 96 weeks. As of 05/20/08 this step was discontinued.
3311208|NCT00312546|Experimental|3A|VPA may be added to enfuvirtide for 16 weeks. VPA and enfuvirtide will be continued for up to 96 weeks in responders, and the study will be discontinued in nonresponders.
3311209|NCT00312546|Experimental|3B|Enfuvirtide may be continued for up to 96 weeks. As of 05/20/08 this step was discontinued.
3311210|NCT00312494|Placebo Comparator|Placebo|
3311211|NCT00312494|Experimental|Ziprasidone 20-40mg twice a day (BID)|
3311212|NCT00312494|Experimental|Ziprasidone 60-80mg BID|
3311213|NCT00312481|Experimental|1|MOVIPREP
3311214|NCT00312481|Active Comparator|2|Picolax
3311215|NCT00312455|Experimental|1|Drug Treatment
3311216|NCT00312455|Placebo Comparator|2|Placebo treatment
3311217|NCT00312442|Experimental|WST 09|Treatment with WST09-mediated VTP
3311218|NCT00312403|Other|1|Patients with primary open angle glaucoma
3311219|NCT00312403|Other|2|Age- and sex-matched control subjects
3311220|NCT00312390|Other|Healthy Control Subjects|
3311221|NCT00312390|Other|Subjects with amblyopia|
3311222|NCT00312377|Active Comparator|1|Docetaxel monotherapy
3311223|NCT00312377|Experimental|2|Vandetanib + Docetaxel
3311224|NCT00312338|Experimental|Infected Patient treated with Vigamox|Conjunctivitis-Infected Patient receiving Vigamox 0.5% in both eyes three times daily for 7 days.
3311225|NCT00312338|No Intervention|Healthy Subjects|Healthy Subjects receiving no treatment
3311226|NCT00312299|Experimental|Arm 1 A - Square edge PMMA IOL|50 patientes will recieve square edge PMMA IOL
3311227|NCT00312299|Active Comparator|1B|In group 1, 50 eyes will receive round edge PMMA IOL
3311228|NCT00312299|Experimental|2A|In group 2, 50 eyes will receive square edge PMMA IOL
3311229|NCT00312299|Active Comparator|2B|In group 2, 50 eyes will receive acrysof IOL
3311230|NCT00312286|Experimental|1|
3311231|NCT00312286|Experimental|2|
3311232|NCT00312286|Experimental|3|
3311233|NCT00312286|Experimental|4|
3311234|NCT00312286|Experimental|5|
3311235|NCT00312286|Experimental|6|
3311236|NCT00312286|Experimental|7|
3311237|NCT00312286|Placebo Comparator|8|
3311238|NCT00312286|Placebo Comparator|9|
3311239|NCT00312286|Placebo Comparator|10|
3311240|NCT00312286|Placebo Comparator|11|
3311241|NCT00312260|Experimental|1|
3311242|NCT00312260|Active Comparator|2|
3311243|NCT00312247||Boys taking steroids|Boys who are taking prednisone or deflazacort
3311244|NCT00312247||Boys who are steroid naive|Boys who are not taking steroids for a variety of reasons
3311245|NCT00312221|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
3311246|NCT00312221|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
3311247|NCT00312221|Experimental|Oxycodone Immediate-Release (Oxy IR) 40 mg|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
3311248|NCT00312208|Experimental|1|Doxorubicin in combination with cyclophosphamide followed by docetaxel (AC -> T)
3311249|NCT00312208|Experimental|2|Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)
3311250|NCT00312195|Experimental|BTDS (5, 10 or 20)|Buprenorphine transdermal patch
3311251|NCT00312195|Placebo Comparator|Placebo to match BTDS|Placebo to match buprenorphine transdermal patch
3311252|NCT00312091|Experimental|A, Stage 1|Tablet containing d4T, 3TC, and NVP taken orally twice daily for the first 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for the final 4 weeks
3311253|NCT00312091|Experimental|A, Stage 2|Tablet containing d4T, 3TC, and NVP taken orally twice daily for 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 4 weeks
3311254|NCT00312091|Experimental|B, Stage 1|Liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 2 weeks, then tablet containing d4T, 3TC, and NVP taken orally twice daily for 2 weeks
3311255|NCT00312091|Experimental|B, Stage 2|Liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 4 weeks, then tablet containing d4T, 3TC, and NVP taken orally twice daily for 4 weeks
3311308|NCT00311376|Other|4|placebo; botulinum toxin Type A (300U)
3311309|NCT00311363|Experimental|GEn (XP13512) 1200 mg|GEn (XP13512) 1200 mg
3311310|NCT00311363|Placebo Comparator|Placebo|Placebo
3311311|NCT00311324|Experimental|Special Intervention|One individual counseling visit, twelve group sessions, three postcards, and twelve telephone calls.
3319386|NCT00187538|Active Comparator|1|
3311256|NCT00312065|Experimental|Patient|Once stabilized, a trimmed reflective shield to cover only the probe itself will be placed over the thermistor probe. Changes in measured skin temperature and warmer power output will be recorded non-invasively, as well as the time taken to reestablish baseline status. A full-sized reflective shield will then be placed over the thermistor probe and the same observations recorded, then repeated 15 minutes later. At the time of a subsequent routine change in thermistor position, the same procedure will be followed, but omitting the intermediate step of using the smaller trimmed shield. Continuous core temperatures will be monitored via a short rectal probe during the study periods.
3311257|NCT00312052|Experimental|E5555 50 mg|Participants received one 50 mg E5555 and two 100 mg placebo tablets, once orally daily for 24 weeks.
3311258|NCT00312052|Experimental|E5555 100 mg|Participants received one 50 mg placebo, one 100 mg E5555 and one 100 mg placebo tablets, once orally daily for 24 weeks.
3311259|NCT00312052|Active Comparator|E5555 200 mg|Participants received one 50 mg placebo and two 100 mg E5555 tablets were taken orally once daily for 24 weeks.
3311260|NCT00312052|Placebo Comparator|Placebo|Participants received one 50 mg placebo and two 100 mg placebo tablets, once orally daily for 24 weeks.
3311261|NCT00312039|Experimental|A|
3311262|NCT00312039|Active Comparator|B|
3311263|NCT00312013|No Intervention|No Nadroparin|Patients will receive all standard anticancer treatment. Patients in this arm will not receive nadroparin
3311264|NCT00312013|Experimental|Nadroparin|Patients will be randomized to receive standard anticancer treatment. Nadroparin patients will be treated with therapeutic doses of subcutaneous (s.c). nadroparin for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2-week periods of therapeutic doses of nadroparin will be given for a total of 6 cycles each separated by a 4-week wash-out. The study treatment period ends at week 46 regardless of number of cycles achieved at that moment.
3311265|NCT00312000|Active Comparator|1Capecitabine-irinotecan|1st line- 2nd line (3rd line oxaliplatin plus capecitabine)
3311266|NCT00312000|Experimental|2capecitabine plus irinotecan|1st line (2nd line oxaliplatin plus capecitabine)
3311267|NCT00311948|Active Comparator|Telephone counseling + interactive website|Teen has access to interactive website and receives tailored telephone counseling
3311268|NCT00311948|Other|Control with interactive website|Teen only has access to interactive website.
3311269|NCT00311922|Active Comparator|Control|Active Control Arm receives Comprehensive Diabetes Education
3311270|NCT00311922|Experimental|Intervention Arm|Receives comprehensive education that is literacy/numeracy sensitive
3311271|NCT00311896|Experimental|Bemiparin|
3311272|NCT00311896|Placebo Comparator|Placebo|
3311273|NCT00311831|Active Comparator|1|
3311274|NCT00311831|Experimental|2|
3311275|NCT00311805|Active Comparator|1|
3311276|NCT00311805|Active Comparator|2|
3311277|NCT00311805|Placebo Comparator|3|
3311278|NCT00311792|Experimental|1|Simulator training
3311279|NCT00311792|Active Comparator|2|Traditional Clinical education at operating room
3311280|NCT00311766|Placebo Comparator|1|Placebo comparator gel does not contain any active drug. Topical administration of 0.0% Thymosin Beta 4 gel, once a day (qd) up to 56 days
3311281|NCT00311766|Active Comparator|2|Topical Administration of 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel once a day (qd) up to 56 days
3311282|NCT00311753|Experimental|1|Certoparin
3311283|NCT00311753|Active Comparator|2|Heparin
3311284|NCT00311727|Experimental|Influenza A/H5N1|232 subjects receiving Influenza A/H5N1 vaccine.
3311285|NCT00311688||1|Individuals will follow the schedule of the study they are participating in
3311286|NCT00311675|Experimental|1|
3311287|NCT00311662|Experimental|1|Tonabersat 40mg
3311288|NCT00311662|Placebo Comparator|2|
3311289|NCT00311610|Experimental|SN-38 liposome|"Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 3 months for up to 3 years."
3311290|NCT00311597|Experimental|Single fractionated radiation adjusted for tumor size|Single fractionated radiation adjusted for volume of tumor tissue encompassed by desired isodose line
3311291|NCT00311584|Experimental|Disease measurable by CT or MRI scan (Irinotecan/Temozolomide)|Measurable by CT scan (Computed Tomography) or MRI scan (Magnetic Resonance Imaging). Patients receive irinotecan hydrochloride IV (10 mg/m2/dose) over 1 hour on days 1-5 and 8-12 and oral temozolomide (100 mg/m2/dose) on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3311292|NCT00311584|Experimental|Disease eval by bone marrow or MIBG (Irinotecan/Temozolomide)|Evaluation by bone marrow or MIBG scan (metaiodobenzylguanidine scan, a radiopharmaceutical). Patients receive irinotecan hydrochloride IV (10 mg/m2/dose) over 1 hour on days 1-5 and 8-12 and oral temozolomide (100 mg/m2/dose) on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3311293|NCT00311558|Experimental|SSG & INF|1 arm study: SSG & interferon
3311294|NCT00311545|Experimental|CNTO 328|CNTO 328, anti-IL-6 monoclonal antibody; 6 mg/kg, IV, q 2wks x 12 cycles (1 cycle = 2 wks)
3311295|NCT00311467|Active Comparator|Capecitabine and Interferon|Combined Chemo-Immunotherapy Chemotherapy: Mo-Fr Immunotherapy
3311296|NCT00311467|Active Comparator|Interferon|"Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups"
3311297|NCT00311415|Experimental|Group 1: 2+4 Months (2-doses)|
3311298|NCT00311415|Experimental|Group 2: 2 Months (1-dose)|
3311299|NCT00311415|Experimental|Group 3: 6 Months (1-dose)|
3311300|NCT00311415|Active Comparator|Group 4: 12-16 Months (1 dose in the second year of life)|
3311301|NCT00311402|Other|Aggrenox Capsule|
3311302|NCT00311402|Other|Acetylsalicylic Acid (ASA) 81 mg Tablet|
3311303|NCT00311389|Experimental|Travoprost/Timolol|1 drop in the affected eye(s) once daily in the morning for 12 months
3311304|NCT00311389|Active Comparator|Latanoprost/Timolol|1 drop in the affected eye(s) once daily in the morning for 12 months
3311305|NCT00311376|Experimental|1|botulinum toxin Type A (200U)
3311351|NCT00310713|Experimental|Group 2|
3311312|NCT00311324|Experimental|Delayed Intervention|"Direct mailing of two American Dietary Association pamphlets (Healthy Eating and Staying Alive) and three bimonthly newsletters providing general health information and study updates."
3311313|NCT00311311|Active Comparator|1|Tacrolimus + MMF + Steroids
3311314|NCT00311311|Experimental|2|Tacrolimus + MMF + Steroids with conversion from Tacrolimus to Sirolimus at 3-4 months post-transplant
3311315|NCT00311298|Placebo Comparator|No micronutrients|Biscuit without additional micronutrients
3311316|NCT00311298|Experimental|Micronutrients|Biscuit with additional micronutrients
3311317|NCT00311298|Active Comparator|1 biscuit|1 biscuit with micronutrients
3311318|NCT00311298|Experimental|6 biscuits|1 biscuit with micronutrients, plus 5 biscuits without additional micronutrients
3311319|NCT00311181|Experimental|2.5/3.5/4.5 ms defibrillation waveform|
3311320|NCT00311155|Experimental|1|"Olmesartan medoxomil oral tablets for 4 weeks followed by, if necessary:~Olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets for 8 weeks, followed by, if necessary:~Olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets + amlodipine oral tablets for 8 weeks"
3311321|NCT00311129|Experimental|Arm 1|
3311322|NCT00311129|Active Comparator|Arm 2|
3311323|NCT00311103|No Intervention|Care in the Control Group (CG)|Care in the Control Group (CG): was that provided by the General Practitioners, with basic diagnostic and therapeutic procedures without specified protocols.
3311324|NCT00311103|Experimental|Early Intervention Programa (IG)|Early Intervention Programa (IG): Patients assigned to the intervention group after the randomization were offered an immediate appointment. Patients, who voluntarily accepted, were attended by 2 rheumatologists. The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
3311325|NCT00311090|Experimental|Idrabiotaparinux|"Idrabiotaparinux sodium , 3.0 mg, once-weekly for 6 months.~In avidin sub-study, participants receive on Day 183, avidin 100 mg or placebo (for avidin) (4 hours after Idrabiotaparinux administration)"
3311326|NCT00311090|Active Comparator|Idraparinux|"Idraparinux sodium, 2.5 mg, once-weekly for 6 months~In avidin sub-study, participants receive on Day 183, placebo (for avidin) (4 hours after Idrabiotaparinux administration)"
3311327|NCT00310895|Experimental|Dose escalation|Treatment Schedule 3 will consist of dosing on Days 1, 4, 8, and 11 of each 21 day cycle (3 weeks equals 1 cycle) and Treatment Schedule 4 will consist of dosing on Day 1 of each 28 day cycle (4 weeks equals 1 cycle)
3311328|NCT00310869|Experimental|E|
3311329|NCT00310856|Experimental|MenACWY-CRM_6-12 M|Subjects received 2 doses of MenACWY-CRM (1 dose at 6 and 12 months of age). Subjects also received routine vaccines: 2 doses of PC7 (1 dose at 6 and 12 months of age), 1 dose of DTaP-Hib-IPV (at 6 months of age) and 1 dose of MMR+Varicella (at 13 months of age)
3311330|NCT00310856|Experimental|MenACWY-CRM_12 M|Subjects received 1 dose of MenACWY-CRM at 12 months of age. Subjects also received routine vaccines: 2 doses of PC7 (1 dose at 6 and 12 months of age), 1 dose of DTaP-Hib-IPV (at 6 months of age) and 1 dose of MMR+Varicella (at 13 months of age)
3311331|NCT00310856|Experimental|MenC-CRM_12 M_MenACWY-CRM_18 M|"Subjects received 1 dose of MenC-CRM (at 12 months of age) and 1 dose of MenACWY-CRM (at 18 months of age).~Subjects also received routine vaccines: 1 dose of PCV7 (at 12 months), MMR+Varicella (at 13 months) and DTaP-Hib-IPV (at 18 months)"
3311332|NCT00310843||All study population|
3311333|NCT00310830|No Intervention|1|
3311334|NCT00310830|Experimental|2|
3311335|NCT00310817|Experimental|MenACWY-CRM(Ad+) 12 to 35 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine with adjuvant (Ad+) on day 1 and second dose at 28 days or at 6 months or at 12 months after the first vaccination.
3311336|NCT00310817|Experimental|MenACWY-CRM(Ad-) 12 to 35 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine without adjuvant (Ad-) on day 1 and second dose either at 28 days or at 6 months or at 12 months after the first vaccination.
3311337|NCT00310817|Experimental|MenACWY-CRM(Ad-) 36 to 59 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine without adjuvant on day 1 and second dose on day 169 or day 337.
3311338|NCT00310817|Active Comparator|MenACWY-PS (36 to 59 Months)|Subjects received one dose of MenACWY polysaccharide (PS) vaccine on day 1 and second dose of MenACWY-CRM conjugate vaccine without adjuvant on day 169 or day 337.
3311339|NCT00310804|Experimental|cTIV_lot 1|
3311340|NCT00310804|Experimental|cTIV_lot 2|
3311341|NCT00310804|Experimental|cTIV_lot 3|
3311342|NCT00310804|Active Comparator|TIV group|
3311343|NCT00310791|Placebo Comparator|Sugar Pill|Placebo (sugar pill); identical to treatment medication capsule
3311344|NCT00310791|Experimental|DHEA + Hormone replacement therapy (estrogen/progestin)|Combined therapy of dehydroepiandrosterone (DHEA) and hormone replacement therapy (ERT). Patients randomized to the DHEA + HRT arm will receive micronized oral DHEA in a dose of 50 mg daily + HRT (0.3 mg Premarin, 1 tablet daily for 3 months, follow by Alesse (20 mg ethinyl estradiol + 0.1 mg levonorgestrel for 15 months). The estrogen/progestin component of the regimen has been chosen to maximize patient compliance, as patients with AN may experience bloating or nausea if higher estrogen doses (> 20 g) are initiated too rapidly. The DHEA capsule strength will be 50 mg, the total daily dose to be studied in combination with HRT. The micronized DHEA preparation achieves more constant DHEA and DHEA-S levels. Fifty milligrams appears to be a physiological replacement dose for these young women, determined both from our pilot (10) and longitudinal studies (7).
3311345|NCT00310778|Experimental|1|treatment
3311346|NCT00310765|Active Comparator|1|75-150 mg of pregabalin po BID
3311347|NCT00310765|Placebo Comparator|2|Placebo 75 or 150 mg po BID
3311348|NCT00310726|Experimental|Abrupt Weaning|Women were counseled to abruptly wean their child at 4 months of age.
3311349|NCT00310726|Active Comparator|Exclusive breastfeeding per WHO guidelines|Women were counseled to adhere to the WHO recommendations for duration of exclusive breastfeeding.
3311350|NCT00310713|Experimental|Group 1|
3311355|NCT00310661|Placebo Comparator|Placebo|Placebo hard gelatin capsules matching the investigational medication
3311356|NCT00310661|Experimental|Sarizotan HCI|Sarizotan HCI is administered at various doses ranging from 2-7mg.
3311357|NCT00310609|Experimental|Arm 1|
3311358|NCT00310596|Experimental|Arm 1|
3311359|NCT00310596|Experimental|Arm 2|
3311360|NCT00310596|Experimental|Arm 3|
3311361|NCT00310596|Experimental|Arm 4|
3311362|NCT00310596|Active Comparator|Arm 5|
3311363|NCT00310596|Placebo Comparator|Arm 6|
3311364|NCT00310557|Experimental|Arm 1|
3311365|NCT00310544|Experimental|Arm 2|
3311366|NCT00310544|Experimental|Arm 1|
3311367|NCT00310531|Experimental|Arm 1|
3311368|NCT00310531|Active Comparator|Arm 2|
3311369|NCT00310492|Active Comparator|Subcutaneous immunotherapy|Subcutaneous injections with ALK-depot SQ mites to 100,000 SQ-U
3311370|NCT00310492|Placebo Comparator|Subcutaneous injections|placebo injections
3311371|NCT00310466|Active Comparator|Sublingual immunotherapy|sublingual immunotherapy with drops applied once daily by single dose containers (200 STU per dose)
3311372|NCT00310466|Placebo Comparator|Placebo|placebo sublingual drops
3311373|NCT00310440|Experimental|Bone graft substitute|Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with P-15 synthetic osteoconductive bone substitute (investigational device).
3311374|NCT00310440|Active Comparator|Autologous Bone|Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with local autologous bone.
3311375|NCT00310427|Experimental|LY686017|Subjects received 50 mg of the NK1 antagonist LY686017 orally on a daily basis.
3311376|NCT00310427|Placebo Comparator|Placebo|Subjects received placebo orally on a daily basis
3311377|NCT00310401|Experimental|Albuterol|Albuterol sulfate 5 mg dissolved in normal saline administered every 4 hours by nebulization
3311378|NCT00310401|Placebo Comparator|Saline|Saline administered every 4 hours by nebulization
3311379|NCT00310388|Experimental|Retigabine (INN), Ezogabine (USAN)|Retigabine (Ezogabine): all subjects
3311380|NCT00310375|Experimental|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets - 50mg, 100mg or 300mg
3311381|NCT00310362|Experimental|Usual Care with nurse phone call|Usual Care--Nurses telephoned patients 7 days prior to appointment to remind patients about scheduled GI appointment and to answer any questions.
3311382|NCT00310362|Experimental|interactive voice response 3 days prior|IVR3-Interactive voice response system was used to remind patients 3 days before a scheduled appointment and to educate them about preparation procedures for the appointment
3311383|NCT00310362|Experimental|interactive voice response 7 days prior|IVR7-Interactive voice response system was used to remind patients 7 days before a scheduled appointment and to educate them about preparation procedures for the appointment
3311384|NCT00310323|Experimental|1|Children with OSAS identified via sleep study
3311385|NCT00310310|Placebo Comparator|Usual Care|Usual sleep apnea and cpap care
3311386|NCT00310310|Experimental|Self-Management|sleep apnea self-management program - 4 sessions, group-based
3311387|NCT00310219|Experimental|Arm 1|Two radiation oncologists are randomly assigned to develop either a 3DCRT plan using CT only, or a 3DCRT plan using fused PET/CT
3311388|NCT00310206|Experimental|ID injection-9 mcg|25 subjects to receive 9 mcg of inactivated influenza A/H5N1 vaccine intradermally on Days 0 and 28.
3311389|NCT00310206|Experimental|IM injection-15 mcg|25 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine intramuscularly on Days 0 and 28.
3311390|NCT00310206|Experimental|IM injection-45 mcg|25 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine intramuscularly on Days 0 and 28.
3311391|NCT00310206|Experimental|ID injection-3 mcg|25 subjects to receive 3 mcg of inactivated influenza A/H5N1 vaccine intradermally on Days 0 and 28.
3311392|NCT00310180|Experimental|Group 1 (Oncotype DX recurrence score =< 10)|Patients in this group receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.
3311393|NCT00310180|Experimental|Group 2, Arm I (experimental)|Patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.
3311394|NCT00310180|Active Comparator|Group 2, Arm II (standard)|Patients receive standard combination chemotherapy at the discretion of the treating physician. Within 4 weeks after the last dose of chemotherapy, patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.
3311395|NCT00310180|Experimental|Group 3 (Oncotype DX recurrence score >= 26)|Patients in this group receive combination chemotherapy followed by hormone therapy similar to the patients in group two who are assigned to receive both types of treatment.
3311396|NCT00310167|Experimental|4 Gy|4 Gy in 2 fractions
3311397|NCT00310167|Active Comparator|24 Gy|24 Gy in 12 fractions
3311398|NCT00310141|Active Comparator|Standard Care Group|Written self-help materials, counseling, and 6-week nicotine patch supply
3311399|NCT00310141|Active Comparator|Computer Treatment Group (CDT)|Written self-help materials, counseling, 6-week nicotine patch supply and 6 weeks of computer-delivered treatment
3311400|NCT00310141|Experimental|CDT Pilot|Written self-help materials, counseling, 6-week nicotine patch supply and 6 weeks of computer-delivered treatment
3311401|NCT00310115||Smoking Prevention Usual Care|Arm I (usual care): Self-help materials and brief relapse prevention advice based on Treating Tobacco Use and Dependence Clinical Practice Guideline.
3311402|NCT00310115||MRP|Arm II (motivational relapse prevention [MRP]): Same intervention as usual care, plus 30 minutes telephone counseling at 34 & 36 weeks gestation then at 2, 4, 7, & 16 weeks postpartum.
3311403|NCT00310115||Enhanced MRP +|Arm III (enhanced MRP [MRP+]): Same intervention as usual care and telephone counseling as MRP, plus 1 hour in-person counseling at 30-33 weeks gestation & 8 weeks postpartum.
3311404|NCT00310076|Experimental|Chemo therapy followed by thalidomide|After cytoreductive surgery with intraperitoneal hyperthermic chemotherapy, patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
3311407|NCT00310037|Experimental|Arm A maintenance therapy|Patients receive bortezomib 1.6 mg/m^2 IV on days 1, 8, 15, and 22 once daily for 4 weeks. There will be a 4 week rest period. One cycle is a total of 8 weeks. A total of 10 cycles of bortezomib will be given in the absence of disease progression or unacceptable toxicity.
3311408|NCT00310037|Experimental|Arm B consolidation therapy|Patients receive bortezomib 1.3 mg/m^2 IV on days 1, 4, 8, and 11 once daily for 3 weeks. One cycle is a total of 3 weeks. A total of 4 cycles of bortezomib will be given in the absence of disease progression or unacceptable toxicity.
3311409|NCT00310024|Experimental|Treatment (vorinostat, bortezomib)|"Patients receive bortezomib IV on days 1, 4, 8, and 11 followed by oral SAHA twice daily on days 4-11. Beginning in course 3, some patients may receive low-dose oral dexamethasone on days 4-8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional cohort of 10 patients receive treatment at the MTD.~Patients undergo blood collection and tumor biopsies periodically during study for pharmacologic and biomarker correlative studies."
3311410|NCT00309985|Experimental|Androgen-Deprivation Therapy and Docetaxel|Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone [LHRH] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3311411|NCT00309985|Active Comparator|Androgen-Deprivation Therapy alone|Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone [LHRH] agonist therapy, LHRH antagonist therapy, or surgical castration) alone.
3311412|NCT00309972|Active Comparator|Sequential arm (SEQ)|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
3311413|NCT00309972|Experimental|Experimental arm (CON)|Concurrent chemo-radiotherapy [55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20] followed by two cycles of cisplatinum/vinorelbine.
3311414|NCT00309959|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive ABI-007 IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3311415|NCT00309946|Experimental|Treatment (enzyme inhibitor therapy)|Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.
3311416|NCT00309907|Experimental|Etanercept and corticosteroid therapy|Patients receive etanercept IV (dose 0.4 mg/kg- max 25 mg) over 30 minutes on day 0 and subcutaneously (dose 0.4 mg/kg- max 25 mg) on days 3, 7, 10, 14, 17, 21, and 24. Treatment continues in the absence of an infectious pathogen, disease progression, or unacceptable toxicity. Patients also receive methylprednisolone (or corticosteroid equivalent) IV (dose 2.0 mg/kg/day) on days 0-2 and then orally with a taper beginning day 7. Dose on days 7-20 (1.0 mg/kg/day), days 21-34 (0.5 mg/kg/day), days 35-48 (0.25 mg/kg/day) and days 49-56 (0.25 mg/kg/every other day) discontinuing on day 56.
3311417|NCT00309855|Placebo Comparator|Double Placebo|(i.m. vehicle 0.5 mL weekly x three injections and oral placebo once daily x 21 days)
3311418|NCT00309855|Other|Testosterone IM and oral placebo|IM injections weekly x three injections and oral placebo once daily x 21 days
3311419|NCT00309855|Other|Testosterone and Oral Anastrozole|IM injections weekly x 3 injections and oral daily x 21 days
3311420|NCT00309855|Other|Testosterone and Dutasteride|IM injections weekly x 3 injections and oral once daily x 21 days
3311421|NCT00309842|Experimental|Unrelated UCBT for Blood Cancers|Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.
3311422|NCT00309777|Experimental|Pitavastatin 2 mg|Pitavastatin 2 mg once daily
3311423|NCT00309777|Active Comparator|Simvastatin 20 mg|Simvastatin 20 mg once daily
3311424|NCT00309777|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
3311425|NCT00309777|Active Comparator|Simvastatin 40 mg|Simvastatn 40 mg once daily
3311426|NCT00309751|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
3311427|NCT00309751|Active Comparator|Atorvastatin 20 mg QD|Atorvastatin 20 mg once daily
3311428|NCT00309738|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
3311429|NCT00309738|Active Comparator|Simvastatin 40 mg QD|Simvastatin 40 mg once daily
3311430|NCT00309699|Placebo Comparator|003|Placebo Daily for 3 weeks
3311431|NCT00309699|Active Comparator|002|Quetiapine 400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
3311432|NCT00309699|Experimental|001|Paliperidone ER 3 to 12 mg daily, flexibly dosed, for 12 weeks
3311433|NCT00309647|Experimental|H5N1 Formulation 1 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 1 vaccine at a 21-day interval
3311434|NCT00309647|Experimental|H5N1 Formulation 2 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 2 vaccine at a 21-day interval
3311435|NCT00309647|Experimental|H5N1 Formulation 3 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 3 vaccine at a 21-day interval
3311436|NCT00309647|Experimental|H5N1 Formulation 4 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 4 vaccine at a 21-day interval
3311437|NCT00309647|Active Comparator|H5N1 Formulation 5 Group|Subjects in this group received 2 doses of H5N1 formulation 5 vaccine at a 21-day interval
3311438|NCT00309647|Active Comparator|H5N1 Formulation 6 Group|Subjects in this group received 2 doses of H5N1 formulation 6 vaccine at a 21-day interval
3311439|NCT00309647|Active Comparator|H5N1 Formulation 7 Group|Subjects in this group received 2 doses of H5N1 formulation 7 vaccine at a 21-day interval
3311440|NCT00309647|Active Comparator|H5N1 Formulation 8 Group|Subjects in this group received 2 doses of H5N1 formulation 8 vaccine at a 21-day interval
3311441|NCT00309608|Experimental|Linagliptin low dose|Patients receive Linagliptin low dose tablets once daily
3319387|NCT00187538|Active Comparator|2|
3311442|NCT00309608|Experimental|Linagliptin medium dose|Patients receive Linagliptin medium dose tablets once daily
3311443|NCT00309608|Experimental|Linagliptin high dose|Patients receive Linagliptin high dose tablets once daily
3311444|NCT00309608|Placebo Comparator|Placebo|Patients receive tablets identical to those containing Linagliptin low, medium and high dose
3311445|NCT00309608|Active Comparator|Glimepiride|Patients receive Glimepiride tablets once daily
3311446|NCT00309595|Experimental|1|Cordis SMART™ nitinol self expandable stent
3311447|NCT00309595|Active Comparator|2|balloon
3311448|NCT00309556|Active Comparator|A (experimental group)|Epirubicin/Docetaxel/Capecitabine-containing chemotherapy ± trastuzumab in HER-2 positive disease
3311449|NCT00309556|Active Comparator|B (control group)|Epirubicin/Docetaxel-containing chemotherapy ± trastuzumab in HER-2 positive disease
3311450|NCT00309491|Experimental|Group I|Tamoxifen alone
3311451|NCT00309491|Experimental|Group II|Tamoxifen + Aminoglutethimide
3311452|NCT00309465|Experimental|1|Patients in Group 1 will administer 80% of their usual insulin glargine dose.
3311453|NCT00309465|Active Comparator|2|Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose.
3311454|NCT00309465|Experimental|3|Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
3311455|NCT00309452|Active Comparator|Treatment as usual|Referral to community providers.
3311456|NCT00309452|Experimental|STEP Care|Integrated and comprehensive treatment provided by a specialized team in a public mental health center.Interventions include pharmacotherapy, family education, cognitive behavioral group and individual psychotherapy and case management focused on vocational rehabilitation.
3311457|NCT00309413|Active Comparator|1|Cannabidiol/Placebo
3311458|NCT00309413|Placebo Comparator|2|Placebo/Cannabidiol
3311459|NCT00309387|Experimental|Centrum|multivitamin-mineral supplement. RDA dosage. 1 tablet a day for the whole study duration.
3311460|NCT00309387|Placebo Comparator|placebo|placebo pills. One tablet a day for the whole study duration.
3311461|NCT00309348|Experimental|Weekly measurement of graft flow|The surveillance group was measured with the FloMon instrument weekly, and all procedures related to their access-grafts recorded
3311462|NCT00309348|No Intervention|Control|The control group was questioned weekly with regard to their graft status and whether there had been any graft-related procedures
3311463|NCT00309296|Experimental|Longitudinal Care|One year of combined behavioral and pharamcological tobacco dependence treatment, with interim smoking reduciton for smokers who fail initial quit attempt.
3311464|NCT00309296|Active Comparator|Usual Care|Evidence based, state-of-the-science tobacco treatment; combined behavioral and pharmacological treatment for 8 weeks
3311465|NCT00309283|Experimental|somatostatin|
3311466|NCT00309283|Placebo Comparator|Saline solution|
3311467|NCT00309257|Experimental|ACE inhibitor, ATA II antagonists and Statins|
3311468|NCT00309244|Experimental|TI + Insulin glargine|Technosphere® Insulin Inhalation Powder + insulin glargine
3311469|NCT00309244|Active Comparator|BPR 70/30|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
3311470|NCT00309218|Active Comparator|A|Steroid withdrawal
3311471|NCT00309218|Placebo Comparator|B|continuos Steroid treatment
3311472|NCT00309179|Experimental|1|
3311473|NCT00309140|Experimental|A|
3311474|NCT00309114|Experimental|Interventions for Experimental Arm|Bacterial Interference with Escherichia coli 83972. Each bladder inoculation contains the study organism, E. coli 83972, suspended as a clear solution in sterile physiological saline.
3311475|NCT00309114|Placebo Comparator|Interventions for Control Arm|Each bladder inoculation contains sterile physiological saline that does not contain the study organism.
3311476|NCT00309101|Experimental|1. tacrolimus|
3311477|NCT00309088|Experimental|1|
3311478|NCT00309088|Placebo Comparator|2|
3311479|NCT00309075|Experimental|Arm 1|
3311480|NCT00309049|Active Comparator|A1|
3311481|NCT00309049|Active Comparator|A2|
3311482|NCT00309049|Active Comparator|A3|
3311483|NCT00309023|Experimental|dose escalation|
3311484|NCT00308997|Experimental|1|Active 1-hertz Repetitive Transcranial Magnetic Stimulation to Wernicke's area and right homologous area
3311485|NCT00308997|Sham Comparator|2|sham rTMS to Wernicke's area and a right homologous area
3311486|NCT00308971|Active Comparator|1|
3311487|NCT00308971|Placebo Comparator|2|
3311488|NCT00308945|Experimental|2|cross-over comparison of two substances
3311489|NCT00308945|Experimental|1|
3311490|NCT00308919|Experimental|WST 09|Treatment with WST09 Vascular Photodynamic therapy
3311491|NCT00308906||1|Hospitalized, untreated infants and children
3311492|NCT00308906||2|Aminoglycoside treated infants and children without renal injury
3311493|NCT00308906||3|Aminoglycoside treated infants with renal injury
3311494|NCT00308893|Experimental|Escitalopram|Treatment response after 3 and 6 weeks
3311495|NCT00308854|Active Comparator|1|PD P 506 A-PDT
3311496|NCT00308854|Placebo Comparator|2|Placebo-PDT
3311497|NCT00308789|Experimental|1|Biphasic NCPAP
3311498|NCT00308789|Active Comparator|2|Continuous CPAP
3311499|NCT00308776|Experimental|Cholecystokinin|Participants will receive intravenous saline plus cholescystokinin.
3311500|NCT00308776|Placebo Comparator|Saline|Participants will receive intravenous saline only.
3311501|NCT00308763|Active Comparator|1|Nicotine patch plus placebo sustained-release bupropion
3311502|NCT00308763|Active Comparator|2|Placebo nicotine patch plus sustained-release bupropion
3311503|NCT00308763|Active Comparator|3|Nicotine patch plus sustained-release bupropion
3311504|NCT00308750|Experimental|A|
3311505|NCT00308750|Experimental|B|
3311506|NCT00308750|Active Comparator|C|
3311507|NCT00308737|Experimental|TI Inhalation Powder|Technosphere® Insulin Inhalation Powder
3311508|NCT00308737|Other|Usual care|Usual care
3311509|NCT00308737|No Intervention|Non-diabetes|Subjects without abnormalities in glucose control (Note: Hypoglycemia and HbA1c were not reported for this group)
3311510|NCT00308724|Experimental|1|Cognitive Behavior Therapy
3311511|NCT00308724|Active Comparator|2|Usual Care
3311512|NCT00308711|Experimental|MVI 100|Misoprostol vaginal insert 100 mcg over 24h
3311513|NCT00308711|Experimental|MVI 50|Misoprostol vaginal insert 50 mcg over 24h
3311514|NCT00308711|Active Comparator|Cervidil 10 mg vaginal insert|Cervidil 10 mg over 24h
3311515|NCT00308685|Experimental|Albuterol HFA BAI|ProAir(TM) HFA, Breath Actuated Inhalation Aerosol
3311516|NCT00308685|Placebo Comparator|Placebo HFA BAI|Placebo
3311517|NCT00308620|Experimental|Chloroquine|Chloroquine 205mg or 500mg orally once daily (Results pooled)
3311518|NCT00308620|Placebo Comparator|Placebo|Placebo once daily for 8 weeks
3311519|NCT00308581|Experimental|Active 1|"Q4W regimen~- every 4 weeks: alternatively placebo and 400mg Certolizumab Pegol"
3311520|NCT00308581|Experimental|Active 2|"Q2W regimen~- every 2 weeks: 400 mg Certolizumab Pegol"
3311521|NCT00308555|Other|Cannabis|
3311522|NCT00308516|Experimental|Cohort A - Preoperative|"Each patient enrolled in the preoperative cohort received 5-fluorouracil (5-FU) 225 mg/m2 as a continuous infusion (IVCI) on days 1-42 through a portable infusion pump and central venous catheter. Bevacizumab 5 mg/kg was administered intravenously (IV) on days 1 and 15. Additionally these patients received radiation therapy to 50.4 Gy (1.8 Gy/day or 28 fractions) Monday through Friday during weeks 1-6.~At least 8 weeks after surgery, patients in cohort A began 4 months of chemotherapy and bevacizumab. This adjuvant treatment consisted of 5-FU 400 mg/m2 IV bolus over 2-4 minutes followed by 2400 mg/m2 IVCI over 46 hours, leucovorin 350 mg as a 2-hour infusion, oxaliplatin 85 mg/m2 IV (modified FOLFOX6) and bevacizumab 5 mg/kg IV all on days 1 and 15 of each cycle."
3311523|NCT00308516|Experimental|Cohort B - Combined Modality|"All patients enrolled in cohort B received 5-fluorouracil (5-FU) 225 mg/m2 IVCI on days 1-42. Bevacizumab was administered at 5 mg/kg IV on day 1 every 2 weeks. These patients also received radiation to 50.4 Gy (1.8 Gy/day or 28 fractions)Monday through Friday during weeks 1-6.~Six weeks after the completion of adjuvant 5-FU/radiation, patients began treatment with 5-FU 400 mg/m2 IV bolus over 2-4 minutes followed by 2400 mg/m2 IVCI over 46 hours, leucovorin 350 mg as a 2-hour infusion, oxaliplatin 85 mg/m2 IV (modified FOLFOX6) and bevacizumab 5 mg/kg IV all on days 1 and 15 of each cycle."
3311524|NCT00308503|Experimental|1|5 mg/day
3311525|NCT00308503|Placebo Comparator|2|
3311526|NCT00308438|Experimental|1|All subjects in the study dosed at 0.1 mg/kg teduglutide
3311527|NCT00308412|Experimental|1|Two 10^5 PFU doses of rHPIV3cp45 vaccine given as nose drops to healthy infants and children aged 6 to 36 months of age. The two doses are given 4 to 10 weeks apart.
3311528|NCT00308412|Placebo Comparator|2|Two placebo vaccinations given as nose drops to healthy infants and children aged 6 to 36 months of age. The two doses are given 4 to 10 weeks apart.
3311529|NCT00308334|Experimental|Domperidone|Domperidone
3311530|NCT00308334|Placebo Comparator|placeob- Sugar pill|
3311531|NCT00308308|Experimental|1|Technosphere Insulin
3311532|NCT00308308|Active Comparator|2|Rapid-acting analogue insulin plus basal insulin glargine
3311533|NCT00308282|Experimental|A|
3311534|NCT00308282|Placebo Comparator|B|
3311535|NCT00308269|Experimental|Vintafolide 1.2 mg IV Bolus|Vintafolide 1.2 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
3311536|NCT00308269|Experimental|Vintafolide 2.5 mg IV Bolus|Vintafolide 2.5 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
3311537|NCT00308269|Experimental|Vintafolide 4.0 mg IV Bolus|Vintafolide 4.0 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
3311538|NCT00308269|Experimental|Vintafolide 2.5 mg IV Infusion|Vintafolide 2.5 mg administered by a 1-hour IV infusion on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
3311539|NCT00308269|Experimental|Vintafolide 3.0 mg IV Infusion|Vintafolide 3.0 mg administered by a 1-hour IV infusion on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
3311540|NCT00308256|Experimental|Nurse counseling|Phone calls performed by nurse 15 days after each monthly visit
3311541|NCT00308256|No Intervention|Control|Normal monthly follow-up without phone calls
3311542|NCT00308230|Placebo Comparator|Normal Heart|Control Group with Normal Heart
3311543|NCT00308230|Active Comparator|Congenital Heart Disease|Tetralogy of Fallot, DTGA, CCTGA
3311544|NCT00308230|Active Comparator|Heart Failure|Left ventricular heart failure, no congestive heart disease
3311545|NCT00308165|Experimental|Topotecan|Once a plastic catheter is placed, within 24 hours of placement, the catheter will be connected to a small pump at the bedside, and the convection-enhanced delivery of the Topotecan will begin. The Topotecan will be infused for 4 to 5 days after which time the catheters will simply be pulled out. Patients will be monitored with blood tests and MRI scans during the treatment and at different time periods during the following months.
3311546|NCT00308152|No Intervention|Control|Observation only
3311547|NCT00308152|Active Comparator|Active|Infusion of 1 liter normal saline before sedated colonoscopy
3311548|NCT00308139|Experimental|Exenatide Once Weekly|Subcutaneous injection (SC), once a week of long acting release (LAR) exenatide.
3311549|NCT00308139|Active Comparator|Exenatide Twice Daily|"subcutaneous injection (SC), twice a day for the first 30 weeks, followed by exenatide LAR SC injection weekly for the remainder of the study.~Sub-study: Exenatide 2 mg subcutaneous injection, Administered Using the Exenatide Once Weekly Single-Dose Tray , once a week for 11 visits, switch to Exenatide 2 mg subcutaneous injection, Administered Using the Dual chamber pen device. Exenatide 2mg SC injection administered using the Dual chamber pen device."
3311550|NCT00308113|Active Comparator|1|CoenzymeQ10 taken once a day each morning by mouth.
3311551|NCT00308113|Active Comparator|2|Prednisone taken once a day each morning by mouth
3311552|NCT00308113|Active Comparator|3|CoenzymeQ10 and prednisone each taken once a day in the morning by mouth.
3311553|NCT00308113|No Intervention|4|Enhanced standard of care.
3311554|NCT00308100|Experimental|1|
3311555|NCT00308100|Active Comparator|2|
3311556|NCT00308087|Active Comparator|Rituximab|
3311557|NCT00308087|Experimental|Rituximab + Sargramostim|
3311781|NCT00305578|Placebo Comparator|Placebo|Placebo daily
3311558|NCT00308074|Experimental|Aripiprazole|aripiprazole monotherapy, begun at 2.5 mg or 5.0 mg based on clinical impression and severity of aggression and agitation. Dose to be adjusted in not more than 5 mg increments, weekly. The lowest effective dose will be used up to a maximum daily dose of 20 mg.
3311559|NCT00308061|Experimental|FMP1/AS02A Vaccine|500 uL of FMP1/AS02A is given to subject on days 0, 30+7, and 60+7 in the left deltoid muscle
3311560|NCT00308061|Active Comparator|Imovax Rabies Vaccine|1 mL of Imovax Rabies Vaccine is given to subject on days 0, 30+7, and 60+7 in the left deltoid muscle
3311561|NCT00308009|Active Comparator|1|Group I, Prolapse repair and TVT concomitantly
3311562|NCT00308009|Active Comparator|2|Group II, Prolapse repair and TVT 3 months afterwards if necessary
3311563|NCT00307931|Experimental|Certolizumab pegol|certolizumab pegol 400 mg
3311564|NCT00307905|Active Comparator|A|TRAUMEEL S
3311565|NCT00307905|Placebo Comparator|B|placebo remedy
3311566|NCT00307892|Active Comparator|A|TRAUMEEL S
3311567|NCT00307892|Placebo Comparator|B|comparable placebo remedy (injection and oral)
3311568|NCT00307866|Experimental|Arm 1|
3311569|NCT00307853|Active Comparator|1|TraumeelS
3311570|NCT00307853|Placebo Comparator|Placebo|
3311571|NCT00307827|Experimental|Arm 1|Visilizumab low dose level
3311572|NCT00307827|Experimental|Arm 2|Visilizumab middle dose level
3311573|NCT00307827|Experimental|Arm 3|Visilizumab high dose level
3311574|NCT00307801|Experimental|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|A blister consists of 28 tablets taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo.
3311575|NCT00307801|Placebo Comparator|Placebo|Matching placebo to be taken orally daily.
3311576|NCT00307762|Experimental|1|Gait trainer exercise actively for 20 minutes + 55 minutes other gait-oriented physiotherapy
3311577|NCT00307762|Active Comparator|2|Overground walking exercises actively for 20 minutes + 55 minutes other gait-oriented physiotherapy
3311578|NCT00307762|No Intervention|3|Control patients with ordinary therapy
3311579|NCT00307749|Placebo Comparator|1|
3311580|NCT00307749|Experimental|2|
3311581|NCT00307749|Experimental|3|
3311582|NCT00307749|Experimental|4|
3311583|NCT00307736|Experimental|Chemotherapy and radiation|Continuous infusion 5-fluorouracil 225 mg/M2/d, bevacizumab 5 mg/kg IV q 14 days, erlotinib 50-150 mg orally daily for duration of radiation.
3311584|NCT00307723|Experimental|Regimen Level 1|Radiation/Oxaliplatin/5-FU
3311585|NCT00307723|Experimental|Regimen Level 2|Radiation/Oxaliplatin/Bevacizumab/5-FU
3311586|NCT00307710|Experimental|A: Trivalent Subvirion Vaccine|Group A: Trivalent subvirion vaccine - standard inactivated influenza vaccine by intramuscular injection.
3311587|NCT00307710|Experimental|B: Vaccine 15 μg|Group B: Trivalent rHA0 vaccine 15 μg per rHA0 (total 45 μg rHA0)
3311588|NCT00307710|Experimental|C: Vaccine 45 μg|Group C: Trivalent rHA0 vaccine 45 μg per rHA0 (total 135 μg rHA0)
3311589|NCT00307710|Experimental|D: Vaccine 135 μg|Group D: Trivalent rHA0 vaccine 135 μg per rHA0 (total 405 μg rHA0)
3311590|NCT00307684|Experimental|001|open label PR OROS methylphenidate Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
3311591|NCT00307684|Experimental|002|double blind PR OROS methylphenidate 18 36 54 72 or 90 mg/day once daily for 4 weeks
3311592|NCT00307684|Placebo Comparator|003|double blind placebo matching placebo tablets once daily for 4 weeks
3311593|NCT00307671|Other|A|conventional treatment
3311594|NCT00307671|Experimental|B|reduction dose
3311595|NCT00307632|Experimental|Norelgestromine (NLGM)/Ethinyl Estradiol (EE)|
3311596|NCT00307593|Active Comparator|1|Rituximab
3311597|NCT00307593|Active Comparator|2|Infliximab
3311598|NCT00307528|Active Comparator|Group A|
3311599|NCT00307528|Experimental|Group B|
3311600|NCT00307528|Experimental|Group C|
3311601|NCT00307528|Experimental|Group D|
3311602|NCT00307528|Experimental|Group E|
3311603|NCT00307528|Experimental|Group F|
3311604|NCT00307515|Experimental|1|Fibrin Sealant 2 (FS2)
3311605|NCT00307515|Active Comparator|2|Oxidized Regenerated Cellulose (Surgicel)
3311606|NCT00307502|Experimental|NVP|Nevirapine
3311607|NCT00307502|Experimental|EFV|Efavirenz
3311608|NCT00307502|Experimental|INV|Indinavir/ritonavir
3311609|NCT00307502|Experimental|NFV|Nelfinavir
3311610|NCT00307502|Experimental|SQV|Saquinavir/ritonavir
3311611|NCT00307502|Experimental|LPV|Lopinavir/ritonavir
3311612|NCT00307502|Experimental|ATV|Atazanavir
3311613|NCT00307502|Experimental|ATV/rtv|Atazanavir/ritonavir
3311614|NCT00307502|Experimental|Fos-APV|Fos-amprenavir/ritonavir
3311615|NCT00307502|Experimental|TPV|Tipranavir/ritonavir
3311616|NCT00307502|Experimental|DRV|Darunavir/ritonavir
3311617|NCT00307489|Experimental|1|TDF
3311618|NCT00307489|Experimental|2|FTC/TDF
3311619|NCT00307463|Active Comparator|strict volume control policy|strict volume control policy: Antihypertensive medicine will be stopped and strict volume control policy will be applied.
3311620|NCT00307463|Other|antihypertensive drugs administration|antihypertensive drugs administration: Antihypertensive medicine will be continued. Target BP will be 130/80 mmHg in both groups.
3311621|NCT00307437|Placebo Comparator|Group I: Placebo|
3311622|NCT00307437|Experimental|Group II: Ustekinumab 45 mg|
3311623|NCT00307437|Experimental|Group III: Ustekinumab 90 mg|
3311624|NCT00307398|Experimental|AL-3789|One injection to the study eye by the posterior juxtascleral depot procedure at 6-month intervals for 42 months.
3311625|NCT00307398|Sham Comparator|Anecortave Acetate Vehicle|One sham injection to the study eye at 6-month intervals for 42 months. Syringe containing AA vehicle was not inserted into the eye.
3311626|NCT00307333|Experimental|1|Very low birth weight infants with their HRC index continuously displayed. Clinicians can utilize the HRC score to develop treatment plan.
3311675|NCT00306891|Experimental|Cediranib 45 mg Fed|Part A: Cediranib 45 mg Fed State
3311627|NCT00307333|No Intervention|2|Very low birth weight infants for whom the HRC index is not displayed. Infants receive standard of care treatment.
3311628|NCT00307320|No Intervention|1|
3311629|NCT00307320|Experimental|2|Relaxation techniques
3311630|NCT00307294|Experimental|thalidomide and doxil|Combination of Thalidomide and Doxil
3311631|NCT00307281||Registry|10 pack year tobacco smoking history required, current or former smokers accepted.
3311632|NCT00307216|Experimental|1|Participants will receive Graduated Recovery Intervention Program plus treatment as usual
3311633|NCT00307216|Active Comparator|2|Participants will receive treatment as usual
3311634|NCT00307203|Experimental|I|Experiment group received 300 mgs of bupropion, in addition to weekly CBT and nicotine replacement therapy
3311635|NCT00307203|Placebo Comparator|II|Placebo group received placebo, in addition to weekly CBT and nicotine replacement therapy
3311636|NCT00307190||Binge Eating Disorder|Women with Binge Eating Disorder
3311637|NCT00307190||Controls|Weight, age, and gender-matched control subjects
3311638|NCT00307177|Experimental|Arm D|25 subjects receive Recombinant rHA0 vaccine at 135 mcg per rHA0, via IM injection on Day 0
3311639|NCT00307177|Experimental|Arm C|25 subjects receive Recombinant rHA0 vaccine at 45 mcg per rHA0, via IM injection on Day 0
3311640|NCT00307177|Experimental|Arm B|25 subjects receive Recombinant rHA0 vaccine at 15 mcg per rHA0, via IM injection on Day 0
3311641|NCT00307177|Active Comparator|Arm A|25 subjects receive Standard TIV at 15 mcg HA per virus, in a total volume of 0.5 mL, by deep intramuscular (IM) injection on Day 0
3311642|NCT00307164|Active Comparator|NucleomaxX|Participants received NucleomaxX for 48 weeks
3311643|NCT00307164|Placebo Comparator|Placebo|Participants received NucleomaxX placebo for 48 weeks
3311644|NCT00307151|Experimental|Coh I: NVP|Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.
3311645|NCT00307151|Experimental|Coh I: LPV/r|Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.
3311646|NCT00307151|Experimental|Coh II: NVP|Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen
3311647|NCT00307151|Experimental|Coh II: LPV/r|Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen
3311648|NCT00307125|Experimental|Pilot Phase-Rituximab plus immunosuppression|"Enrollment into a Stage 2 pilot treatment study will occur after Stage 1. Adult Rituximab Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Rituximab Dosing (Subjects <\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
3311649|NCT00307125|Placebo Comparator|Pilot Phase-Placebo plus immunosuppression|"Adult Placebo Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Placebo Dosing (Subject <\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
3311650|NCT00307099|Experimental|Meropenem|Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.
3311651|NCT00307099|Active Comparator|Standard antibiotic therapy|Standard intravenous antibiotic therapy for a minimum of 8 days.
3311652|NCT00307086|Other|Autologous PBSCT|bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous peripheral blood stem cell transplant (PBSCT)
3311653|NCT00307047|Experimental|XIENCE V®|
3311654|NCT00307047|Active Comparator|TAXUS™ EXPRESS2™|
3311655|NCT00307034|Experimental|2-dose group|Subjects receiving GSK Biologicals' 10-valent pneumococcal conjugate vaccine at 2-4-11 months of age, co-administered with DTPa-combined vaccine (Infanrix hexa or Infanrix IPV/Hib) at 2-4-11 months of age.
3311656|NCT00307034|Experimental|Comparator group|Subjects receiving GSK Biologicals' 10-valent pneumococcal conjugate vaccine at 2-3-4-11 months of age, co-administered with DTPa-combined vaccine (Infanrix hexa or Infanrix IPV/Hib) at 2-4-11 months of age.
3311657|NCT00307021|Active Comparator|Group A|
3311658|NCT00307021|Experimental|Group B|
3311659|NCT00307008|Experimental|Group A|
3311660|NCT00306995|Experimental|SB218352_15 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
3311661|NCT00306995|Experimental|SB218352_8 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
3311662|NCT00306995|Experimental|SB218352_4 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
3311663|NCT00306995|Experimental|SB218352_2 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
3311664|NCT00306995|Experimental|SB218352_8AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
3311665|NCT00306995|Experimental|SB218352_4AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
3311666|NCT00306995|Experimental|SB218352_2AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
3311667|NCT00306956|Experimental|A|Recommendation to offer a pacifier to 15 days old newborn infants with successful breastfeeding
3311668|NCT00306956|Active Comparator|B|Recommendation not to offer a pacifier to normal newborn infant with successful breastfeeding at 15 days of age
3311669|NCT00306930|Other|A|Acetabular cup replacement with total hip arthroplasty
3311676|NCT00306891|Experimental|Cediranib 45 mg Fasted|Part A: Cediranib 45 mg Fasted State
3311677|NCT00306891|Experimental|Cediranib 45 mg Fixed Dose|Part B: Cediranib 45 mg Fixed Dose
3311678|NCT00306891|Experimental|Cediranib 30 - 90 mg Dose Escalation|Part B: Cediranib 30 - 90 mg Dose Escalation
3311679|NCT00306852|Active Comparator|Trabeculectomy|Trabeculectomy with mitomycin C
3311680|NCT00306852|Active Comparator|Implant|Baerveldt Implant
3311681|NCT00306839|Other|1|Tissel group
3311682|NCT00306839|Other|2|Suture group
3311683|NCT00306787|Experimental|Famciclovir|Patients received Famciclovir 1000 mg (2 x 500 mg tablets) twice a day for one day. The first dose was to be taken within 6 hours after onset of prodromal symptoms or genital herpes lesions and the second dose approximately 12 hours later. Patients also received 1 valacyclovir placebo capsule, beginning with the first famciclovir dose, twice a day for 3 days, each taken about 12 hours apart.
3311684|NCT00306787|Active Comparator|Valacyclovir|Patients received Valacyclovir 500 mg capsule twice a day approximately 12 hours apart for 3 consecutive days. The first dose was to be taken within 6 hours after onset of prodromal symptoms or genital herpes lesions. On the first day patients also received 2 famciclovir placebo tablets taken with the first 2 doses of Valacyclovir.
3311685|NCT00306774|Experimental|1|Participants will receive vitamin D (cholecalciferol)
3311686|NCT00306774|Placebo Comparator|2|Participants will receive a matched placebo
3311687|NCT00306735|Experimental|Palonosetron|
3311688|NCT00306709|Experimental|Teaching|
3311689|NCT00306670|Experimental|Rituximab|Patients will receive rituximab.
3311690|NCT00306670|Active Comparator|Oral cyclophosphamide|Patients will receive oral cyclophosphamide.
3311691|NCT00306644|Experimental|Arm 1|study drug
3311692|NCT00306631|Experimental|1|
3311693|NCT00306592|Experimental|Natalizumab|All study participants in 101-MS-322 (NCT00306592) and 101-MS-321 (NCT00297232) received open label 300 mg intravenous (IV) natalizumab 60-minute infusion once every 4 weeks (28 days ±7 days) for up to 48 weeks. After 48 weeks, participants from 101-MS-322 (NCT00306592) entering study 101-MS-321 (NCT 00297232; considered the Long-Term Treatment Period of 101-MS-322) were continued on treatment from Week 52 through Week 480.
3311694|NCT00306540|Active Comparator|1|Placebo Seroquel + existing therapy
3311695|NCT00306540|Experimental|2|Seroquel + existing therapy
3311696|NCT00306527|Active Comparator|cTIV\cTIV (adults)|Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.
3311697|NCT00306527|Active Comparator|cTIV\TIV (adults)|Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
3311698|NCT00306527|Active Comparator|cTIV\cTIV (elderly)|Subjects (≥61 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.
3311699|NCT00306527|Active Comparator|cTIV\TIV (elderly)|Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
3311700|NCT00306527|Active Comparator|TIV\TIV (adults)|Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
3311701|NCT00306527|Active Comparator|TIV\cTIV (adults)|Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.
3311702|NCT00306527|Active Comparator|TIV\TIV (elderly)|Subjects (≥61 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
3311703|NCT00306527|Active Comparator|TIV\cTIV (elderly)|Subjects (≥61 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.
3311704|NCT00306501|Other|Button Press|Training with button press
3311705|NCT00306501|Other|Vibtrotactile|Sensory Stimulation - Vibrotactile device with button press to initiate swallowing during retraining
3311706|NCT00306501|Other|Cortical Stimulation|Training with Cortical stimulation - cortical stimulation during training with button press
3311707|NCT00306501|Other|Combined|Combined vibrotactile and cortical stimulation with button press training
3311708|NCT00306488|Experimental|OT-551 antioxidant eye drop|The fellow eye was treated with OT-551 antioxidant eye drops over the course of the study.
3311709|NCT00306475|Active Comparator|1|
3311710|NCT00306475|Placebo Comparator|2|
3311711|NCT00306462|Active Comparator|1|Intravenous magnesium sulfate or placebo
3311712|NCT00306462|Active Comparator|2|Oral nifedipine or placebo
3311713|NCT00306397|Active Comparator|A|Rapamycin - MMF after 3 months
3311714|NCT00306397|Active Comparator|B|Low dose tacrolimus - MMF - Rapamycin after 3 months
3311715|NCT00306384|Experimental|Alogliptin 12.5 mg|Alogliptin 12.5 tablet, orally, once daily for up to 4 years.
3311716|NCT00306384|Experimental|Alogliptin 25 mg|Alogliptin 25 mg tablet, orally, once daily for up to 4 years.
3311717|NCT00306228|Active Comparator|bare-metal stent without tirofiban|implantation of a bare-metal stent with no tirofiban infusion after fibrinolysis
3311718|NCT00306228|Active Comparator|bare-metal stent with tirofiban|implantation of a bare-metal stent with tirofiban infusion after fibrinolysis
3311719|NCT00306228|Active Comparator|paclitaxel-eluting stent without tirofiban|implantation of a paclitaxel eluting-stent with no tirofiban after fibrinolysis
3311720|NCT00306228|Active Comparator|paclitaxel-eluting stent with tirofiban|implantation of a paclitaxel eluting-stent with tirofiban infusion after fibrinolysis
3311721|NCT00306215|Experimental|1|Blinded study arm
3311722|NCT00306215|Experimental|2|Blinded study arm
3311723|NCT00306215|Experimental|3|Blinded study arm
3311724|NCT00306215|Experimental|4|Blinded study arm
3311782|NCT00305578|Active Comparator|Memantine|Daily dose Memantine
3311783|NCT00305565|Other|Low Dose|
3311725|NCT00306202|Experimental|Stratum 1 (Ph+ CP-CML)|Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP)
3311726|NCT00306202|Experimental|Stratum 2/3 (Ph+ ALL or AP/BP-CML)|Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML)
3311727|NCT00306202|Experimental|Stratum 4 (Ph- ALL/AML)|Participants with second or subsequent relapse of Ph- ALL or Ph- AML
3311728|NCT00306189|Active Comparator|100 mg AMG 162|
3311729|NCT00306189|Active Comparator|60 mg AMG 162|
3311730|NCT00306189|Placebo Comparator|Placebo|
3311731|NCT00306189|Active Comparator|14 mg AMG 162|
3311732|NCT00306163|Active Comparator|1|Ciclesonide 160 µg
3311733|NCT00306163|Active Comparator|2|Fluticasone 100 µg
3311734|NCT00306150|Experimental|Arm 1|
3311735|NCT00306150|Placebo Comparator|Arm 2|
3311736|NCT00306137|Experimental|Arm 1|
3311737|NCT00306137|Placebo Comparator|Arm 2|
3311738|NCT00306111|Experimental|Pegfilgrastim|Pegfilgrastim for stem cell mobilization (single arm)
3311739|NCT00306098|Experimental|Islet transplantation|
3311740|NCT00306059|Experimental|patients having acute kidney injury|
3311741|NCT00306007||English prenatal|English speaking women recruited from the general OB/GYN clinic
3311742|NCT00306007||Spanish prenatal|Spanish speaking (monolingual) women recruited from the general OB/GYN clinic
3311743|NCT00306007||English abortion clinic|English speaking women recruited from the abortion clinic
3311744|NCT00306007||Spanish abortion clinic|Spanish speaking (monolingual) women recruited from the abortion clinic
3311745|NCT00305942|Experimental|1|"Topotecan 4mg/m2 IV on days 1, 8.~Carboplatin AUC=5 IV day 1 only .~- Cycles are repeated every 21 days for > 4 cycles of topotecan and carboplatin (maximum 6 courses). Restaging studies will be performed every 2 cycles (or 6 weeks.)"
3311746|NCT00305929|Experimental|1|Treatment with Tookad VTP
3311747|NCT00305916|Active Comparator|1|conventional coronary angiography
3311748|NCT00305916|Experimental|2|multislice spiral computed tomography coronary angiography
3311749|NCT00305890|Experimental|1|Participants will partake in a lifestyle behavioral weight management program for 24 weeks.
3311750|NCT00305890|Experimental|2|Participants will partake in pain-coping skills training for 24 weeks.
3311751|NCT00305890|Experimental|3|Participants will partake in lifestyle behavioral weight management program plus pain-coping skills training for 24 weeks.
3311752|NCT00305890|Active Comparator|4|Participants will receive standard care for 24 weeks.
3311753|NCT00305877|Experimental|Arm I (cetuximab, gemcitabine, capecitabine, radiation)|Patients receive cetuximab IV over 60-120 minutes on day 1, once weekly, in weeks 1-24; gemcitabine hydrochloride IV over 30 minutes on day 1, once weekly, in weeks 1-3, 13-15, 17-19, and 21-23; oral capecitabine twice daily on days 1-5, 5 days a week, in weeks 5-10. Patients also undergo radiotherapy once daily, 5 days a week, beginning in week 5 and continuing for approximately 5½ weeks (25 fractions).
3311754|NCT00305877|Experimental|Arm II (bevacizumab, gemcitabine, capecitabine, radiation)|Patients receive bevacizumab IV over 60-90 minutes on day 1 in weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23. Patients also receive gemcitabine hydrochloride and capecitabine and undergo radiotherapy as in arm I.
3311755|NCT00305864|Experimental|Phase I: MGd 3 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3311756|NCT00305864|Experimental|Phase I: MGd 4 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40.Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3311757|NCT00305864|Experimental|Phase I: MGd 5 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5.Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3311758|NCT00305864|Active Comparator|Phase II: MGd 5 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3311777|NCT00305643|Experimental|Arm I: Celecoxib + Capecitabine|Celecoxib 200 mg given orally twice/day along with standard capecitabine treatment (Initial dose of 750-1500 mg/m^2 orally twice/day).
3311778|NCT00305643|Placebo Comparator|Arm II: Placebo + Capecitabine|Placebo with standard capecitabine treatment (Initial dose of 750-1500 mg/m^2 orally twice/day)
3311779|NCT00305604|Active Comparator|1|sitagliptin
3311780|NCT00305604|Placebo Comparator|2|Placebo
3311759|NCT00305851|Experimental|"Low Dose Control Books on Tape"|Individuals randomly assigned to low-dose control group will have the same amount and timing of contacts as TMV group. A trained music therapist delivers the low-dose intervention (music therapy). Low-dose control group AYA initially choose up to three books-on-CD from a library selection of popular recordings. During the six sessions with the music therapist, AYA listens to the book and/or discusses their impressions and thoughts about he contents. Our rationale for having options of either listening to or discussing is to ensure the intervener has activities that will provide comparable contact time compared to the TMV group. As a parallel activity to the TMV protocol during which participants can work on their music video between sessions, AYA in the low-dose control group are provided with a portable CD player to listen to the books anytime during their hospitalization. As books ar e completed, or if the AYA changes their mind about the choice, the intervener offers other books.
3311760|NCT00305851|Experimental|"Experimental Music Video"|Intervention includes six 1-hour sessions (two sessions per week over 3 weeks) designed specifically for the pre-transplant and acute phase of treatment. The initial TMV session with the therapist occurs within 3 days of hospital admission. The phases of the intervention that require patient participation include song writing, recording the song with a digital accompaniment track, completing a video layout work sheet (determining the contents of the video), taking photos or making drawings for the video, and viewing clip art and pictures on a computer. The protocol concentrates many of these cognitive and active components to produce the video at the beginning, when patients experience less fatigue and malaise
3311761|NCT00305825|Experimental|Study intervention|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral letrozole once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3311762|NCT00305773|Experimental|Arm I (once daily vorinostat)|Patients receive oral vorinostat (SAHA) once a day on days 1-21. In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
3311763|NCT00305773|Experimental|Arm II (thrice daily vorinostat)|Patients receive oral SAHA three times a day on days 1-14. In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
3311764|NCT00305760|Experimental|Cyclophosphamide, Pancreatic Tumor Vaccine, Cetuximab|
3311765|NCT00305747|Experimental|BR-DIM|BR-DIM will be administered at a starting dose of 75 mg po twice daily. Patients will be instructed to take tablets twice daily with 8 ozs. of water, with/without food. A study calendar will be provided and patients will be asked to fill the appropriate boxes when they take their study capsules. One treatment cycle is 28 days.
3311766|NCT00305734|Experimental|Treatment (bortezomib, gemcitabine hydrochloride)|"Patients receive bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses of treatment with bortezomib.~Patients who experience disease progression on single-agent bortezomib and did not receive prior gemcitabine hydrochloride may begin combination therapy within 10-28 days of the last dose of bortezomib. Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and bortezomib IV on days 1, 4, 8, 11. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond the confirmed CR."
3311767|NCT00305695|Experimental|Arm I (zoledroic acid)|Beginning 60-90 days after surgery, patients receive zoledronate IV over 15 minutes once in months 3, 9, and 15.
3311768|NCT00305695|No Intervention|Arm II (clinical observation)|Patients are observed for 18 months after surgery.
3311769|NCT00305682|Active Comparator|Arm 1-Previous Autologous Transplant|Arm 1 - hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
3311770|NCT00305682|Active Comparator|Arm 2 - No Prior Autologous Transplant|Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
3311771|NCT00305682|Active Comparator|Arm 3 - Refractory Leukemia/Lymphoma|Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
3311772|NCT00305682|Active Comparator|Arm 4: MT2006-01 coenrolling patients|Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
3311773|NCT00305682|Active Comparator|Arm 5 - Previous Autologous Transplant|Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
3311774|NCT00305682|Active Comparator|Arm 6 - No prior autologous transplant|Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
3311775|NCT00305669|Experimental|GM-CSF before surgery|GM-CSF dose prior to surgery- Cohort 1-GM-CSF 250mcg/m2 for 2 weeks Cohort 2-GM-CSF 250mcg/m2 for 3 weeks Cohort 3-GM-CSF 250mcg/m2 for 4 weeks Cohort 4-GM-CSF 125mcg/m2 for 4 weeks
3311776|NCT00305656|Experimental|Arm I|Patients receive oral AZD2171 once daily on days 1-28.
3311786|NCT00305552|Experimental|1|THALIDOMIDE
3311787|NCT00305539|Active Comparator|1|
3311788|NCT00305539|Placebo Comparator|2|placebo
3311789|NCT00305461|Active Comparator|1|Ciclesonide 160µg
3311790|NCT00305461|Active Comparator|2|Ciclesonide 320µg
3311791|NCT00305448|Experimental|1|Fulvestrant 250 mg intramuscular injection
3311792|NCT00305448|Experimental|2|Fulvestrant 250mg (Plus 250mg Loading Regimen)
3311793|NCT00305448|Experimental|3|Fulvestrant 500 mg
3311794|NCT00305435|Experimental|romiplostim (AMG-531)|
3311795|NCT00305344|Active Comparator|Cord Blood|Umbilical Cord Blood
3311796|NCT00305279|Active Comparator|1|
3311797|NCT00305279|Active Comparator|2|
3311798|NCT00305279|Active Comparator|3|
3311799|NCT00305253|No Intervention|Pre-Intervention|The Pre-Intervention Phase served as the Control / Baseline group.
3311800|NCT00305253|Experimental|Post-Intervention|Intervention used in this phase and outcomes compared to the Pre-Intervention phase.
3311801|NCT00305227|Experimental|Lactin-V|Vaginal capsule containing Lactobacillus crispatus in high concentration. Self-administered once daily for 5 days during the 1st week. Self-administered once weekly for 10 weeks.
3311802|NCT00305227|Placebo Comparator|Placebo|Vaginal capsule - placebo. Self-administered once daily for 5 days during the 1st week. Self-administered once weekly for 10 weeks.
3311803|NCT00305188|Experimental|Xaliproden (SR57746A)|
3311804|NCT00305188|Placebo Comparator|Placebo|
3311805|NCT00305175||Patients With Prior Hydroxyurea|Patients who have received hydroxyurea therapy before entering the study.
3311806|NCT00305175||Patients Without Prior Hydroxyurea|Patients who have not received hydroxyurea before study entry.
3311807|NCT00305162|Experimental|Cangrelor|placebo capsules (to match) + cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + active clopidogrel (600mg) post infusion
3311808|NCT00305162|Active Comparator|Clopidogrel|clopidogrel capsules (600 mg) + placebo bolus & infusion (to match) + placebo capsules (to match) post infusion
3311809|NCT00305123||1|12,000 children 5 to 16 years of age attending the 4 public elementary schools in Djikoroni-para-Sébénikoro, Bamako, Mali.
3311810|NCT00305110|Experimental|2 mg IV hydromorphone|2 mg IV hydromorphone administered over 2-3 minutes
3311811|NCT00305097|Experimental|Caffeinated coffee|Caffeinated coffee
3311812|NCT00305097|Experimental|Decaffeinated coffee|Decaffeinated coffee
3311813|NCT00305097|Active Comparator|No coffee|
3311814|NCT00305084|Experimental|A|
3311815|NCT00305058|Experimental|Hydromorphone|0.0075 mg/kg IV hydromorphone
3311816|NCT00305058|Active Comparator|Morphine|0.05 mg/kg IV morphine
3311817|NCT00305045|Active Comparator|High-frequency Left (HFL)|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Subjects under age 65 will have treatment delivered at 100% of the RMT; those over age 65 will have treatment delivered at 120% of the RMT.~Site of Stimulation: left hemisphere of DLPFC.~Frequency: 10 Hz.~Duration: 29 - 5 second trains with 30 second inter-train interval."
3311818|NCT00305045|Active Comparator|Bilateral|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Subjects under age 65 will have treatment delivered at 100% of the RMT; those over age 65 will have treatment delivered at 120% of the RMT.~Sites of Stimulation: right and left hemispheres of the DLPFC.~Frequency: 1 Hz over the right DLPFC followed by 10 Hz over the left DLPFC.~Duration: i) low-frequency right: 4 trains of 100 second duration and one train of 65 second duration, with a 30 second inter-train interval, followed by ii) HFL: 15 - 5 second trains with 30 second inter-train interval."
3311819|NCT00305045|Sham Comparator|Sham Stimulation|Stimulation will occur over the site of active treatment, but with only the side-edge resting on the scalp. It will be administered as HFL for 17 minutes, with the coil angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
3311820|NCT00305032|Experimental|1|
3311821|NCT00305006|Experimental|A|CIMT
3311822|NCT00304954|Active Comparator|Intravenous Daclizumab|Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
3311823|NCT00304954|Active Comparator|Intravenous Infliximab|Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
3311824|NCT00304954|Active Comparator|Oral Rapamycin|Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
3311825|NCT00304954|Other|Observation|Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
3311826|NCT00304915|Experimental|Arm 1: Collaborative Care Intervention|HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received collaborative care intervention.
3311827|NCT00304915|No Intervention|Arm 2: Usual Care|HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received usual care.
3311828|NCT00304863|No Intervention|Arm 1|This are will not receive Lactobacillus
3311829|NCT00304863|Experimental|Arm 2|This arm will receive lactobacillus
3311830|NCT00304850|Experimental|R+ / K+|
3311831|NCT00304850|Experimental|R+ / K-|
3311832|NCT00304850|Experimental|R- / K+|
3311833|NCT00304850|Placebo Comparator|R- /K-|
3311834|NCT00304798|Experimental|Admission|Admission
3311835|NCT00304798|No Intervention|Discharge|Discharge
3311836|NCT00304772|Active Comparator|1|
3311837|NCT00304772|Active Comparator|2|
3311838|NCT00304759|Experimental|1|6000 cGy / 20 fractions in 4 weeks
3311839|NCT00304759|Active Comparator|2|7800 cGy / 39 fractions in 8 weeks
3311840|NCT00304746|Active Comparator|testosterone gel|AndroGel (1% testosterone transdermal gel), 2.5 g to 10 g daily
3311841|NCT00304746|Placebo Comparator|placebo gel|Placebo gel
3311842|NCT00304707|Experimental|2|participants in this arm receive bupropion
3311843|NCT00304707|Placebo Comparator|1|placebo
3311844|NCT00304603||Patients from previous topiramate obesity and diabetes studies|The patients from previous topiramate obesity and diabetes studies (PRI/TOP-INT-31 or PRI/TOP-INT-33 or a subset of patients with diabetes mellitus who were randomized within the PRI/TOP-INT-34 study at sites that also participated in the PRI/TOP-INT-31 study.
3311845|NCT00304564|Experimental|geriatric community|Subject will stand on a computerized posturography force plate and stability scores are measured
3311846|NCT00304551|Experimental|1|
3311847|NCT00304551|Experimental|2|
3311848|NCT00304551|No Intervention|3|
3311849|NCT00304525|Experimental|RAF265 - Arm 1|Patients received 10mg RAF265 as a once weekly dose until progressive disease was confirmed.
3311850|NCT00304525|Experimental|RAF265 - Arm 2|"RAF265 is given as a single PK run-in dose, a single loading dose on day 1 of cycle 1, followed by once daily maintenance doses."
3311851|NCT00304525|Experimental|RAF265 - Arm 3|Patients were treated with once weekly dosing of RAF265
3311852|NCT00304525|Experimental|RAF265 - Arm 4|Patients with locally advanced or metastatic melanoma will utilize a dose close to or at the MTD/RPTD of the liquid formulation that was determined in Arm 2.
3311853|NCT00304525|Experimental|RAF265 - Arm 5|RAF265 was administered as a continuous dose for 2 weeks followed by a dose holiday of 1 week.
3311854|NCT00304512|Experimental|Low Dose 50 mg|2 (25 mg) capsules (AT1001) every other day for 12 weeks and optional 36 treatment extension.
3311855|NCT00304512|Experimental|Middle Dose 150 mg|6 (25 mg) capsules (AT1001) every other day for 12 weeks and optional 36 treatment extension.
3311856|NCT00304512|Experimental|High Dose 250 mg|10 (25 mg) capsules (AT1001) every other day for 12 weeks and optional 36 treatment extension.
3311857|NCT00304434|Other|1|
3311858|NCT00304382|Experimental|PPV-PCV|Patients receive Pneumovax, and 6 months later Prevnar
3311859|NCT00304382|Experimental|PCV-PPV|Patients receive Prevnar, and 6 months later Pneumovax
3311860|NCT00304382|Experimental|PCV-PCV|Patients receive Prevnar, and 6 months later Prevnar again
3311861|NCT00304382|Experimental|PCV only|Patients receive Prevnar only
3311862|NCT00304356|Other|active drug|500 mg nitazoxanide bid given to patient
3311863|NCT00304317|Experimental|I|Celecoxib
3311864|NCT00304317|Placebo Comparator|II|Placebo
3311865|NCT00304304|Active Comparator|Intervention - asthma education|CCC received asthma education in the first 6 months of the study
3311866|NCT00304304|Placebo Comparator|Wait-list control|CCC received asthma education in second 6 months of study
3311867|NCT00304278|Experimental|RADPLAT and Tarceva|"All patients will receive RADPLAT and Tarceva:~Drug: Erlotinib (Tarceva)~150 mg daily X 7 weeks~Other Names:~Tarceva~Drug: Intra-arterial Cisplatin (PLAT)~1 dose (150 mg/sq) per week X 4 weeks~Other Names:~Cisplatin~Radiation: Radiation Therapy (RAD)~5 days per week X 7 weeks"
3311868|NCT00304265|Experimental|6th Dose Pertussis Vaccine Group|Participants received 6th dose of pertussis vaccine
3311869|NCT00304265|Experimental|5th Dose Pertussis Vaccine Group|Participants received 5th dose of pertussis vaccine
3311870|NCT00304200|Experimental|Single arm, Open Label|Single arm, Open Label Temodar and Sutent
3311871|NCT00304187|Experimental|Erythromycin|Subjects with Bulimia Nervosa will take erythromycin.
3311872|NCT00304187|Placebo Comparator|Placebo|Participants will take matched placebo.
3311873|NCT00304174||Subjects with bulimia nervosa|Participants with bulimia nervosa
3311874|NCT00304174||Controls between 80-120% of ideal weight|Controls without bulimia nervosa
3311875|NCT00304161|Active Comparator|Atomoxetine|Participants will receive 40-80mgs of atomoxetine orally once daily.
3311876|NCT00304161|Placebo Comparator|Placebo|Participants will receive placebo treatment once daily; the pill (taken orally) will resemble the atomoxetine pill but will not contain an active drug.
3311877|NCT00304148||CRIC Cohort|
3311878|NCT00304148||CRIC Subcohort|
3311879|NCT00304135|Active Comparator|Radio-chimiothérapie|Radio-chimiothérapie
3311880|NCT00304135|Experimental|GEMOX|GEMOX
3311881|NCT00304096|Experimental|Stratum 1: Receiving Hormone Therapy|Patients treated with 9 peptide vaccine who received hormone therapy
3311882|NCT00304096|Experimental|Stratum 2: Not receiving hormone therapy|Patients receiving 9 peptide vaccine who did not receive hormone therapy
3311883|NCT00304083|Experimental|Chemotherapy and local control by radiotherapy and surgery|Patients receive doxorubicin hydrochloride and ifosfamide (IA) chemotherapy. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity. Patients then receive etoposide and ifosfamide (IE) chemotherapy. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim (G-CSF) subcutaneously (SC) after each chemotherapy course. After recovery from chemotherapy, patients undergo radiotherapy and receive 2 more courses of IE during radiotherapy followed by 2 more courses of IA after completion of radiotherapy. Some patients may then undergo surgery.
3311884|NCT00304083|Experimental|Chemotherapy and local control by surgery|Patients receive 2 courses of IA followed by 2 courses of IE as above. After recovery from chemotherapy, patients undergo surgery. After recovery from surgery, patients receive 2 more courses of IA followed by 2 more courses of IE in the absence of disease progression or unacceptable toxicity.
3311885|NCT00304070|Experimental|Stratum I (surgery, observation)|Patients undergo conventional surgery (primary tumor resection and retroperitoneal lymph node sampling) followed by observation. Patients who have undergone prior surgery without nodal sampling undergo observation only.
3311886|NCT00304070|Experimental|Stratum II (exploratory surgery, observation)|Patients undergo conventional surgery (primary tumor resection and extended regional lymph node dissection) followed by observation. Patients who have undergone prior surgery with simple resection of the primary tumor undergo exploratory surgery with extended regional lymph node dissection followed by observation.
3311915|NCT00303771|Experimental|LV5FU2 simplifié+ irinotécan|LV5FU2 simplifié + irinotécan
3311916|NCT00303758|Active Comparator|LV5FU2 simplifié + cisplatine puis gemcitabine si progression|LV5FU2 simplifié + cisplatine puis gemcitabine si progression
3311961|NCT00303303|Experimental|1|Active initial and maintenance therapy
3311887|NCT00304070|Experimental|Stratum III (chemotherapy, surgery)|Patients receive combination chemotherapy with a total of 8 cycles of chemotherapy with cisplatin, etoposide and doxorubicin hydrochloride, filgrastim (G-CSF). The first 2 to 4 cycles are called the induction phase, followed by mitotane alone for an additional 2 months. Some patients undergo conventional surgery after chemotherapy course 2 or 4. Some patients undergo additional conventional surgery after finishing all chemotherapy.
3311888|NCT00304031|Active Comparator|Conventional adjuvant TMZ|Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.
3311889|NCT00304031|Experimental|Dose-dense adjuvant TMZ|Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.
3311890|NCT00304031|Other|No adjuvant TMZ (not randomized )|Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Not randomized to either adjuvant TMZ arm.
3311891|NCT00304018|Experimental|cord blood transplant|
3311892|NCT00303992|Experimental|Trastuzumab and Irinotecan|
3311893|NCT00303979||Cohort A (longitudinal)|Longitudinal Cohort: Approximately 15,000 patients followed at baseline, 12 months and 24 months
3311894|NCT00303979||Cohort B (6 Month)|6 Month Cohort: Approximately 10,000 patients reviewed at single time point
3311895|NCT00303979||Cohort C (18 Month)|18 Month Cohort: Approximately 10,000 patients reviewed at single time point
3311896|NCT00303966|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3311897|NCT00303953|Experimental|Arm I|"Patients will receive an infusion of PXD101 once a day for 5 days. Treatment may repeat every 3 weeks for up to 2 years. Some patients will also undergo core biopsy and blood collection for laboratory studies before and after treatment.~After finishing treatment, patients will be evaluated every 3-6 months for up to 3 years."
3311898|NCT00303901|Experimental|cryosurgery|cryoprobe is placed in the proper position using CT imaging guidance, and as internal tissue is being frozen, the physician avoids damaging healthy tissue by viewing the movement of the probe on CT images transmitted to a monitor similar to a television screen. Living tissue, healthy or diseased, cannot withstand extremely cold conditions.
3311899|NCT00303888|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on days 1, 8, and 15 and oral placebo three times daily on days 1-21.
3311900|NCT00303888|Experimental|Arm II|Patients receive oral phenoxodiol three times daily on days 1-21 and docetaxel IV over 1 hour on days 1, 8, and 15.
3311901|NCT00303875|No Intervention|Wait-list control|Wait-list control received diet & exercise counseling during year 2 as a courtesy
3311902|NCT00303875|Experimental|Lifestyle counseling|subjects randomized to receive diet & exercise counseling for one year
3311903|NCT00303862|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 4 weeks. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
3311904|NCT00303849|Experimental|Treatment (etoposide, mannitol, melphalan, carboplatin, STS)|Patients receive etoposide phosphate IV over 10 minutes, mannitol IA over 30 seconds, melphalan IA over 10 minutes, and carboplatin IA over 10 minutes on days 1 and 2. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Courses repeat every 4 to 6 weeks for up to 12 months.
3311905|NCT00303836|Experimental|Arm I|Patients undergo apheresis and in-vitro depletion of T-regulatory cells. Patients then receive a nonmyeloablative, lymphocyte-depleting preparative regimen comprising cyclophosphamide IV over 1 hour on days -8 and -7 and fludarabine IV over 15-30 minutes on days -6 to -2 followed by autologous T-regulatory-depleted lymphocytes IV over 20-30 minutes on day 0. Patients receive vaccination with gp100:209-217 (210M) and MART-1:27-35 peptides emulsified in Montanide ISA-51 subcutaneously (SC) on days 0-3, 20-23, 41-44, and 62-65. Patients also receive filgrastim (G-CSF) SC beginning on day 1 and continuing until blood counts recover.
3311906|NCT00303836|Experimental|Arm II|Patients receive treatment as in arm I. Patients also receive high-dose IL-2 IV over 15 minutes every 8 hours on days 0-4, beginning after the lymphocyte infusion. IL-2 treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3311907|NCT00303823|Experimental|Arm I|Patients receive oral green tea extract once daily for 16 weeks in the absence of unacceptable toxicity.
3311908|NCT00303823|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 16 weeks in the absence of unacceptable toxicity.
3311909|NCT00303797|Experimental|Treatment (bortezomib, sorafenib tosylate)|"GROUP I (solid tumors-dose-escalation group): Patients receive oral sorafenib twice daily on days 1-21 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of sorafenib and bortezomib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~GROUP II (multiple myeloma or chronic lymphocytic leukemia-maximum tolerated dose [MTD] group): Patients receive oral sorafenib at the MTD twice daily on days 3-21 of course 1 and on days 1-21 of each subsequent course. Patients also receive bortezomib IV over 3-5 seconds at the MTD on days 1, 4, 8, and 11.~Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3311910|NCT00303784|Active Comparator|LHRH agonists|"Patients randomised to the control arm will receive continuous treatment with LHRH agonists as per local practice. Treatment should continue for at least 3 years. LHRH antagonists, such as degarelix, are not allowed on the trial. The recommended anti-flare medication is bicalutamide and should be prescribed according to local practice. Control arm medication should be obtained from the hospital pharmacy or GP as per local practice."
3311911|NCT00303784|Experimental|Oestrogen Patches|Patients randomised to the investigational arm will receive transcutaneous oestrogen patches (100 micrograms/24 hours). Treatment should be planned to continue for at least 3 years. For patients prescribed bicalutamide or flutamide prior to randomisation, this treatment should be discontinued before treatment with the patches can commence (no washout period is needed).
3311912|NCT00303771|Active Comparator|LV5FU2 classique|LV5FU2 classique
3311913|NCT00303771|Experimental|LV5FU2 classique + irinotécan|LV5FU2 classique + irinotécan
3311914|NCT00303771|Active Comparator|LV5FU2 simplifié|LV5FU2 simplifié
3319388|NCT00187538|Active Comparator|3|
3311917|NCT00303758|Experimental|gemcitabine puis LV5FU2 simplifié + cisplatine si progression|gemcitabine puis LV5FU2 simplifié + cisplatine si progression
3311918|NCT00303732|Experimental|PTK787, RAD001|PTK787 (vatalinib) 1000 mg daily, RAD001 (everolimus) 5 mg daily
3311919|NCT00303719|Experimental|High Risk Patients|Nonmyeloablative conditioning using fludarabine, cyclophosphamide and low dose Total Body Irradiation with or without anti-thymocyte globulin followed by allogeneic hematopoietic stem cell transplantation, immunosuppressive cyclosporine and mycophenolate mofetil and post-transplant use of bone marrow-stimulating filgrastim.
3311920|NCT00303719|Experimental|Standard Risk Patients|Nonmyeloablative conditioning using fludarabine, cyclophosphamide and low dose Total Body Irradiation with or without anti-thymocyte globulin followed by allogeneic hematopoietic stem cell transplantation, immunosuppressive cyclosporine and mycophenolate mofetil and post-transplant use of bone marrow-stimulating filgrastim.
3311921|NCT00303667|Experimental|SCT w/Donor Natural Killer Cells - short schema|Patients with high risk myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation, receiving fludarabine phosphate (daily dose of 40mg/m^2), cyclophosphamide (administered on Day -15 only), cyclosporin A, total body irradiation, natural killer cells, aldesleukin, and thymoglobulin.
3311922|NCT00303667|Experimental|SCT w/Donor Natural Killer Cells - extended schema|Patients with high risk myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation, receiving fludarabine phosphate (daily dose of 35mg/m^2), cyclophosphamide (administered on Days -15 and -16), cyclosporin A, total body irradiation, natural killer cells, aldesleukin, and thymoglobulin.
3311923|NCT00303628|Active Comparator|Arm I|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 2 weeks for up to 12 courses.
3311924|NCT00303628|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive oxaliplatin, leucovorin calcium, and fluorouracil as in arm I.
3311925|NCT00303602|Experimental|A|Sublingual orally disintegrating olanzapine (SODO)
3311926|NCT00303602|Active Comparator|B|Oral olanzapine
3311927|NCT00303589|Experimental|1|
3311928|NCT00303589|Experimental|2|
3311929|NCT00303589|Active Comparator|3|
3311930|NCT00303563|Experimental|1|
3311931|NCT00303563|Experimental|2|
3311932|NCT00303563|Experimental|3|
3311933|NCT00303563|Placebo Comparator|4|
3311934|NCT00303524|Experimental|1|Zoladex 3-month depot
3311935|NCT00303524|Experimental|2|Zoladex 1-month depot
3311936|NCT00303498|Experimental|Sitaxsentan sodium|
3311937|NCT00303498|Placebo Comparator|Placebo|
3311938|NCT00303485|Experimental|Ibandronate|Participants received Ibandronate 150 mg tablet once-monthly along with a combination dietary supplement containing vitamin D 200 international units (IU) and elemental calcium 500 mg twice daily with meals for 6 months.
3311939|NCT00303485|Placebo Comparator|Placebo|Participants received a matching placebo tablet to Ibandronate once-monthly along with a combination dietary supplement containing vitamin D 200 IU and elemental calcium 500 mg twice daily with meals for 6 months.
3311940|NCT00303472|Experimental|Part A: 300 µg romiplostim|Cohort 1 in Part A, participants received romiplostim 300 µg subcutaneously once weekly for 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
3311941|NCT00303472|Experimental|Part A: 700 µg romiplostim|Cohort 2 in Part A, participants received romiplostim 700 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
3311942|NCT00303472|Experimental|Part A: 1000 µg romiplostim|Cohort 3 in Part A, participants received romiplostim 1000 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
3311943|NCT00303472|Experimental|Part A: 1500 µg romiplostim|Cohort 4 in Part A, participants received romiplostim 1500 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
3311944|NCT00303472|Experimental|Part B: 750 µg romiplostim SC QW|Part B participants received romiplostim 750 µg subcutaneously (SC) once weekly (QW) for 8 weeks. Participants who complete Part B could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
3311945|NCT00303472|Experimental|Part B: 750 µg romiplostim SC Q2W|Part B participants received romiplostim 750 µg subcutaneously every two weeks (Q2W) for 8 weeks. Participants who complete Part B could continue to receive injections of romiplostim for up to 1 year in the extension treatment phase.
3311946|NCT00303472|Experimental|Part B: 750 µg romiplostim IV Q2W|Part B participants received romiplostim 750 µg intravenously (IV) once every two weeks for 8 weeks. Participants who complete Part B could continue to receive romiplostim for up to 1 year in the extension treatment phase.
3311947|NCT00303459|Experimental|A|Bosentan
3311948|NCT00303459|Placebo Comparator|B|Placebo
3311949|NCT00303446|Active Comparator|Dutasteride|Dutasteride 0.5 mg/day
3311950|NCT00303446|Placebo Comparator|Placebo|Matched placebo
3311951|NCT00303420|Active Comparator|1|Alteplase used by normal dwell procedure
3311952|NCT00303420|Experimental|2|"Alteplase given by an new push protocol"
3311953|NCT00303381|Experimental|Interferon-beta-1a, 44 microgram|
3311954|NCT00303381|Experimental|Interferon-beta-1a, 66 microgram|
3311955|NCT00303381|Placebo Comparator|Placebo|
3311956|NCT00303342|Experimental|mind body treatment|regulation of attention, respiration and posture
3311957|NCT00303342|Active Comparator|desensitization|mentation on insomnia behaviors and cognitive activity
3311958|NCT00303329|Experimental|Deferasirox|Deferasirox daily oral dose between 5-40 mg/kg/day
3311959|NCT00303316|Experimental|DTacP IPV HepB PRP-T Combined Vaccine Group|Participant will receive a booster dose of PENTAXIM™ having received DTacP-IPV-HepB-PRP-T (primary series) in Study A3L02.
3311960|NCT00303316|Active Comparator|PENTAXIM™ and ENGERIX B® Vaccine Group|Participant will receive a booster dose of PENTAXIM™ having received ENGERIX B® and PEDIATRICO in Study A3L02 (Primary series)
3311962|NCT00303303|Experimental|2|Active initial therapy; placebo maintenance therapy.
3311963|NCT00303303|Placebo Comparator|3|Placebo initial and maintenance therapy.
3311964|NCT00303290|Experimental|PEG-Intron + ARA-C|Peg Interferon Alpha 2b (Peg Intron) 4.5 micrograms/kg once a week. ARA-C 10 mg under the skin daily.
3311965|NCT00303277|Active Comparator|1|simvastatin
3311966|NCT00303277|Active Comparator|2|pravastatin
3311967|NCT00303251|Experimental|TKI258|
3311968|NCT00303212|No Intervention|UC|Usual HF guideline-base care
3311969|NCT00303212|Experimental|TM|Telemonitoring group plus usual guideline-based HF care
3311970|NCT00303199|Experimental|Single Arm|
3311971|NCT00303108|Experimental|Arm 1|Patients will receive IV Doxil 30 mg/m2 and carboplatin AUC=5 on Day 1 of each cycle. A cycle consists of 28 days. In addition, HER2+ (IHC3+ and FISH+) patients only will receive a one-time loading dose of Herceptin 8 mg/kg IV on Day 1 of Cycle 1 and 4 mg/kg on Day 1 and Day 15 of every cycle thereafter.
3311972|NCT00303069|Experimental|V710 5 μg|V710 S. aureus vaccine
3311973|NCT00303069|Experimental|V710 30 μg|V710 S. aureus vaccine
3311974|NCT00303069|Experimental|V710 90 μg|V710 S. aureus vaccine
3311975|NCT00303069|Placebo Comparator|Placebo|Placebo
3311976|NCT00303043||1|
3311977|NCT00303030|Active Comparator|1. Anal injection|
3311978|NCT00303030|Active Comparator|2. Biofeedback|
3311979|NCT00303017|Experimental|flavocoxid|medical food
3311980|NCT00303017|Active Comparator|naproxen|NSAID
3311981|NCT00302952|Experimental|Lovastatin|Participants are randomized to take two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. For toxicity, the dose could either be adjusted to one 40 mg lovastatin tablet or treatment could be discontinued. In addition to the active ingredient lovastatin, each tablet contained the following ingredients: microcrystalline cellulose, lactose monohydrate, magnesium stearate, and pregelatinized starch. Butylated hydroxyanisole (BHA) was added as a preservative and D&C Yellow #10, FD&C Blue #1, and Yellow #6 were added as dyes.
3311982|NCT00302952|Placebo Comparator|Placebo|Participants are randomized to take two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. For toxicity, the dose could either be adjusted to one placebo tablet or treatment could be discontinued. The placebo tablets contained microcrystalline cellulose, NF (Avicel PH 102) and Supro AA Swedish Orange Opaque Capsule Shells, Color 4188.
3311983|NCT00302900|Experimental|1|Pre-donation water and muscle tension during donation
3311984|NCT00302900|Experimental|2|Pre-donation water
3311985|NCT00302900|Sham Comparator|3|Pre-donation muscle tension
3311986|NCT00302900|No Intervention|4|Standard donation
3311987|NCT00302848||Users of Drospirenone (DRSP)|
3311988|NCT00302848||Users of Levonorgestrel (LNG)|
3311989|NCT00302848||Users of other oral contraceptives (OCs)|
3311990|NCT00302822|Experimental|Intensification|lopinavir or efavirenz and emtricitabine/tenofovir and intensification with enfuvirtide (week 0 to 24)
3311991|NCT00302822|Active Comparator|Standard|lopinavir or efavirenz and emtricitabine/tenofovir
3311992|NCT00302796|Experimental|Group A, Antibiotic|1 antibiotic tablet 45 patients Group
3311993|NCT00302796|Placebo Comparator|Group B: 1 placebo|1 placebo tablet
3311994|NCT00302796|Experimental|Group C: Antibiotics|2 antibiotic tablets 45 patients
3311995|NCT00302796|Placebo Comparator|Group D, Placebo|2 placebo tablets 36 patients
3311996|NCT00302744|Other|1|Each subject functions as their own control (one placebo session/one active drug session)
3311997|NCT00302731|Active Comparator|1 equine estrogens m-progesteroneacetate|Menopausal women in first seven years of menopause randomized to arm 1 receive conjugated equine estrogens 0.45 mg combined with medroxyprogesteroneacetate 1.5 mg placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
3311998|NCT00302731|Experimental|2 estradiol estriol progesterone|Menopausal women in first seven years of menopause randomized to arm 2 estradiol .5mg, estriol 2.0mg, progesterone 100mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
3311999|NCT00302731|Experimental|4 estradiol progesterone|Menopausal women in first seven years of menopause randomized to arm 4 estradiol 0.5 mg, progesterone 100 mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
3312000|NCT00302731|Experimental|3 estriol progesterone|Menopausal women in first seven years of menopause randomized to arm 3 estriol 2.5mg, progesterone 100mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
3312001|NCT00302718|Experimental|Physician-level incentives|Examines the effect of physician-level financial incentives on hypertension quality of care
3312002|NCT00302718|Experimental|Practice-level incentives|Examines the effect of practice-level financial incentives on hypertension quality of care
3312003|NCT00302718|Experimental|Physician- and practice-level incentives|Examines the effect of physician- and practice-level financial incentives on hypertension quality of care
3312004|NCT00302718|No Intervention|No incentives (control)|Physician participants in this arm received only audit and feedback performance reports as did the participants in the intervention arms.
3312005|NCT00302705|Active Comparator|Valsartan|160 mg/day on awakening
3312006|NCT00302705|Active Comparator|Enalapril|10-20 mg/day on awakening
3312007|NCT00302666|Sham Comparator|Arm 1|
3312008|NCT00302666|Sham Comparator|Arm 2|
3312009|NCT00302653|Experimental|1|Rasburicase 0,20mg/Kg/Day once a day 3-7 days
3312010|NCT00302640|Active Comparator|Nitazoxanide|7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days
3312011|NCT00302640|Placebo Comparator|Placebo|7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days
3312012|NCT00302627|Experimental|Pamidronate, Vitamin D, and Calcium|"60mg or 90mg given at baseline, 6,12,18, and 24 months~vitamin D 800 units/day~calcium carbonate 1500 milligrams/day"
3312013|NCT00302601|Other|None relevant|Not relevant
3312014|NCT00302549|Active Comparator|FK506|
3312015|NCT00302536|Experimental|Tacrolimus|
3312016|NCT00302523|Active Comparator|FK506|
3312017|NCT00302510|Placebo Comparator|immunoadsorption|
3312018|NCT00302471|Experimental|1600 mg twice a day|MK0429
3312019|NCT00302471|Experimental|200 mg twice a day|MK0429
3312020|NCT00302471|Experimental|800 mg twice a day|MK0429
3312021|NCT00302471|Experimental|400 mg twice a day|MK0429
3312022|NCT00302458|Experimental|OROS-MPH + OROS-MPH|OROS-Methylphenidate Will be administered during the first part of the day, and again during the separate part of the day.
3312023|NCT00302458|Experimental|IR MPH + IR MPH|Immediate release methylphenidate will be administered in the first part of the day followed by Immediate release methylphenidate in the second part of the day.
3312024|NCT00302458|Placebo Comparator|Plabebo + Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
3312025|NCT00302458|Experimental|OROS MPH+ IR MPH|Concerta will be administered in the first part of the day, followed by Immediate Release Methylphenidate in the second part of the day.
3312026|NCT00302458|Experimental|IR MPH + OROS MPH|Immediate release Methylphenidate will be administered in the first part of the day, followed by Concerta in the second part of the day
3312027|NCT00302419|Experimental|1|Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given
3312028|NCT00302419|Active Comparator|2|Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed
3312029|NCT00302393|Active Comparator|IR-MPH|Immediate Release Methylphenidate administered before PET Scan
3312030|NCT00302393|Active Comparator|Concerta|OROS Methylphenidate (Concerta) administered before PET Scan
3312031|NCT00302380||un-medicated subjects with ADHD|
3312032|NCT00302380||subjects without ADHD|
3312033|NCT00302341|Experimental|1|pafuramidine maleate, oral tablet, 100 mg bid X 14 days
3312034|NCT00302341|Active Comparator|2|TMP/SMX oral tablet, 15 mg/kg, split tid X 21 days
3312035|NCT00302328|No Intervention|macular hole operation no peeling|
3312036|NCT00302328|Active Comparator|Macular hole operation ICG peeling|
3312037|NCT00302328|Experimental|Macular hole operation TB peeling|
3312038|NCT00302237||1|1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
3312039|NCT00302211|Experimental|Group A|Inhaled iloprost(5 μg) 6×/day + sildenafil ± bosentan
3312040|NCT00302211|Experimental|Group B|Inhaled iloprost (5 μg) 4×/day + sildenafil ± bosentan
3312041|NCT00302211|Placebo Comparator|Group C|Inhaled placebo 6×/day + sildenafil ± bosentan
3312042|NCT00302185|Active Comparator|Nurse-led supportive care|Visit with a Palliative Care nurse once weekly for 4 weeks
3312043|NCT00302185|Experimental|Acupuncture|Patients received acupuncture once a week for 4 weeks.
3312044|NCT00302172|Experimental|ARQ 197|
3312045|NCT00302159|Experimental|Valproic Acid|Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.
3312046|NCT00302133|Experimental|Naltrexone add on to valproate|Naltrexone hydrochloride 50 mg capsule daily for 12 weeks add on to valproate
3312047|NCT00302133|Placebo Comparator|Placebo add on to valproate|Placebo comparator one capsule daily for 12 weeks add on to valproate
3312048|NCT00302107|Active Comparator|Arm 1|Mirtazapine
3312049|NCT00302107|Placebo Comparator|Arm 2|Placebo
3312050|NCT00302081|Active Comparator|PEG2b 1.5/R (24 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg daily for 24 weeks
3312051|NCT00302081|Experimental|PEG 2b 1.0/R (24 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 24 weeks
3312052|NCT00302081|Experimental|PEG2b 1.5/R (16 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 16 weeks
3312053|NCT00302068|Experimental|1|Supervised aerobic exercise, three times per week for 16 weeks.
3312054|NCT00302068|Active Comparator|2|Sertraline (Zoloft), for 16 weeks.
3312055|NCT00302068|Placebo Comparator|3|Placebo control, for 16 weeks.
3312056|NCT00302055|Active Comparator|one-on-one lifestyle|Clinical referral to diabetes prevention lifestyle intervention at School of Medicine campus
3312057|NCT00302055|Experimental|group-based community lifestyle|Clinical referral to group diabetes prevention lifestyle intervention program in community
3312058|NCT00302042|Experimental|1: Brief Counseling Plus Group Lifestyle|Brief counseling plus group diabetes prevention in community
3312059|NCT00302042|Active Comparator|2: Brief Counseling Alone|Brief Counseling for pre-diabetes alone
3312060|NCT00302029||CMV positive|CMV +, N=500/167
3312061|NCT00302029||CMV negative|CMV -, N=500/167
3312062|NCT00302003|Experimental|Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim|Treatment consists of 3 cycles of Doxorubicin hydrochloride IV (25 mg/m2) days 1 & 2, Vincristine sulfate IV (1.4 mg/m2 [max 2.8 mg]) Days 1 & 8, Prednisone orally (40 mg/m2) Days 1-7, Cyclophosphamide IV (600 mg/m2) Days 1 & 2, Filgrastim by mouth or IV (5 micrograms/kg/dose) 24 hours after Cyclophosphamide complete. See detailed description for remainder of therapy.
3312063|NCT00301964|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
3312064|NCT00301951|Experimental|cord blood transplant|
3312065|NCT00301938|Experimental|Arm I (enzyme inhibitor, chemotherapy)|Patients receive a loading dose of oral perifosine every 6 hours on day 1 followed by a maintenance dose once daily on days 2-28 of course 1 and then once daily on days 1-28 in all subsequent courses. Patients also receive 7-hydroxystaurosporine IV over 3 hours on day 4. Cohorts of 3-6 patients receive escalating doses of 7-hydroxystaurosporine until the MTD is determined.
3312066|NCT00301938|Experimental|Arm 2 (enzyme inhibitor, chemotherapy)|Patients receive 7-hydroxystaurosporine IV over 3 hours on day 1 at the MTD determined in group I. Patients also receive oral perifosine as a loading dose every 6 hours on day 4 followed by a maintenance dose once daily on days 5-28 of course 1 and then once daily on days 1-28 in all subsequent courses.
3312067|NCT00301925|Active Comparator|Epi-CMF|
3312068|NCT00301925|Experimental|Accelerated Epi-CMF|
3312069|NCT00301925|Experimental|Epi-Capecitabine|
3312070|NCT00301925|Experimental|Accelerated Epi-Capecitabine|
3312071|NCT00301886|Experimental|zoledronate|zoledronate
3312072|NCT00301886|Experimental|ibandronate|ibandronate
3312073|NCT00301873|Experimental|IV Zometa|Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
3312074|NCT00301847|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3312075|NCT00301834|Experimental|Single arm - conditioning and transplant|Alemtuzumab 0.5 mg/kg (maximum 15 mg) daily for 3 days; Busulfan i.v. every 6 hours from day -9 to day -6 for 16 total doses; Fludarabine phosphate from day -5 for 4 days at 1.3 mg/kg (if patient was less than 12 kg) or 40 mg/m*2 per dose; Cyclosporine continuous infusion 3 mg/kg/Day beginning day -1 for GVHD prophylaxis; Methotrexate at 15 mg/m*2 on day +1, 10 mg/m*2 on days +3, +6, and (only for MUDs) day +11 also for GVHD prophylaxis; Methylprednisolone only as required for GVHD prophylaxis; allogeneic bone marrow transplantation or allogeneic hematopoietic stem cell transplantation or peripheral blood stem cell transplantation or umbilical cord blood transplantation.
3312076|NCT00301821|Experimental|Epratuzumab + Rituximab + CHOP|One arm open label.
3312077|NCT00301808|Experimental|Cisplatin, Docetaxel & Radiation Therapy|Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43; Docetaxel 75 mg/m2 on day 1 of each cycle; Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
3312078|NCT00301795|Experimental|Treatment (oblimersen sodium and rituximab)|"Induction therapy (month 1): Patients receive oblimersen IV continuously on days 1-7 and 15-21 and rituximab IV on days 3, 10, 17, and 24 in month 1.~Extended induction therapy (months 3, 5, 7, and 9): Patients receive oblimersen IV continuously on days 22-28 and rituximab IV on day 24 in months 3, 5, 7, and 9.~Treatment continues for 9 months in the absence of disease progression or unacceptable toxicity."
3312079|NCT00301769|Experimental|Arm I|Patients receive SJG-136 IV over 15 minutes on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients receive escalating doses of SJG-136 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD.
3312080|NCT00301756|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3312081|NCT00301652|Experimental|mycophenolate mofetil|
3312082|NCT00301613|Active Comparator|Mycophenolate mofetil|
3312083|NCT00301600|Active Comparator|Mycophenolate mofeti|
3312084|NCT00301561|Experimental|1|Simplify treatment follow-up
3312085|NCT00301561|Active Comparator|2|Standard treatment follow-up
3312086|NCT00301535|Experimental|1|
3312087|NCT00301535|No Intervention|2|
3312088|NCT00301522|Experimental|Arm 1|
3312089|NCT00301522|Active Comparator|Arm 2|
3312090|NCT00301483|Experimental|1|HBOC-201 followed by standard therapy
3312091|NCT00301483|Active Comparator|2|Standard Therapy
3312092|NCT00301457|Experimental|1|6 years adjuvant anastrozole therapy
3312093|NCT00301457|Experimental|2|3 years adjuvant anastrozole therapy
3312094|NCT00301418|Experimental|Tarceva (Erlotinib)|
3312095|NCT00301405|Active Comparator|Thalidomide|Open Label drug
3312096|NCT00301392|Other|Pitavastatin|Administration of Pitavastatin
3312097|NCT00301379||1|Patients with unresectable cholangiocarcinoma.
3312098|NCT00301366|Experimental|Alpha-1 Proteinase Inhibitor (Human), modified process|Study the safety and tolerability of weekly infusions of Alpha-1 Proteinase Inhibitor (Human), modified process (Alpha-1 MP, 60 mg/kg) over 20 weeks of therapy in adult Alpha-1 antitrypsin deficient subjects.
3312099|NCT00301210|Experimental|1|tramadol dose 1
3312100|NCT00301210|Experimental|2|tramadol dose 2
3312101|NCT00301184|Experimental|1A|One 0.3 mg dose of DNA HIV vaccine or placebo administered at study entry and Month 2, followed by one dose of 1x10^7 TCID50 MVA or placebo at Months 4 and 6
3312102|NCT00301184|Experimental|1B|One 3.0 mg dose of DNA HIV vaccine or placebo administered at study entry and Month 2, followed by one dose of 1x10^8 TCID50MVA or placebo administered at Months 4 and 6
3312103|NCT00301184|Experimental|2A|One MTD (determined in Part 1) of DNA HIV vaccine or placebo administered at study entry. One dose of placebo or MTD of MVA at Months 2 and 6
3312104|NCT00301184|Experimental|2B|One dose of placebo or MTD of MVA administered at study entry and Months 2 and 6
3312105|NCT00301119||lung cancer screening cohort|observational only. no intervention. current, former and never smokers over age 50 without history of cancer, except for non melanoma skin cancer, no previous treatment with chemotherapy.
3312106|NCT00301119||r/o lung cancer|observational only. no intervention. patients with CT findings suspicious for lung cancer who are undergoing bronchoscopy and/or surgery.
3312156|NCT00300495|Active Comparator|2 - Control|Control arm, standard care with no perioperative amiodarone
3312157|NCT00300482|Active Comparator|A|ABT-335 + 10 mg rosuvastatin
3312158|NCT00300482|Active Comparator|B|ABT-335 + 20 mg rosuvastatin
3312107|NCT00301106|Experimental|adenovirus-mediated human interleukin-12|starting dose of ADV-hIL12 - 1 x 10 to the 10th power vp (virus particles) per patient, escalating in half-log increments up to 1 x 10 to the 13th power vp per patient, after which dose escalation will be at lower increments of 2 x 10 to the 13th power vp, to a maximum of 3.0 x 10 to the 13th power vp per patient.
3312108|NCT00301080|Placebo Comparator|Placebo (original version)|Placebo administered orally twice per day for 4 weeks.
3312109|NCT00301080|Active Comparator|D-cycloserine 200mg|D-cycloserine administered orally at a dose of 200 mg twice per day for 12 weeks.
3312110|NCT00301080|Active Comparator|D-cycloserine 50 mg|D-cycloserine administered orally at a dose of 50 mg twice per day for 12 weeks.
3312111|NCT00301080|Active Comparator|D-cycloserine 250mg|This was the original active comparator arm (before the design was changed): D-cycloserine administered orally at a dose of 250 mg twice per day for 4 weeks.
3312112|NCT00301080|Placebo Comparator|Placebo (revised version)|Placebo administered orally twice per day for 12 weeks.
3312113|NCT00301067|Experimental|temozolomide|
3312114|NCT00301028|Experimental|Cetuximab + Carboplatin/Paclitaxel|Cetuximab beginning weekly dose 400 mg/m^2 intravenous (IV), and 250 mg/m^2 weeks 2-6; Weekly Carboplatin area under the curve (AUC) 2 and Paclitaxel 135 mg/m^2 for 6 courses.
3312115|NCT00301015|Experimental|1|Malaria diagnosis aided with rapid diagnostic test
3312116|NCT00301015|Active Comparator|2|Malaria diagnosis based on clinical judgement only
3312117|NCT00300976|Experimental|Intensive therapy|
3312118|NCT00300976|Active Comparator|Conventional therapy|
3312119|NCT00300950|Active Comparator|1|Gencitabine
3312120|NCT00300950|Experimental|2|Gemcitabine with GI-4000
3312121|NCT00300937|Experimental|A|
3312122|NCT00300898|Active Comparator|Nucleoplasty|Procedure/Surgery: Nucleoplasty
3312123|NCT00300898|Active Comparator|Percutaneous decompression|Procedure/Surgery: Percutaneous decompression
3312124|NCT00300898|Active Comparator|Electrothermal disc decompression (IDET)|Procedure/Surgery: Intervertebral electrothermal disc decompression (IDET)
3312125|NCT00300898|Experimental|Behavioral:Conservative treatment|Conservative treatment with oral medications, physical therapy, epidural steroid injections
3312126|NCT00300885|Experimental|Sorafenib + C/P|Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
3312127|NCT00300885|Active Comparator|Placebo + C/P|Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
3312128|NCT00300872|Active Comparator|1|Continuous positive airway pressure (CPAP)
3312129|NCT00300872|Sham Comparator|2|Sham Continuous positive airway pressure (CPAP)
3312130|NCT00300846|Active Comparator|A1|
3312131|NCT00300846|Placebo Comparator|A2|
3312132|NCT00300781|Experimental|Neratinib 240 mg, with prior trastuzumab|Neratinib administered with 80 mg capsules and 40 mg coated tablets taken orally in prescribed dose of 240 mg daily, as long as tolerated and disease does not worsen.
3312133|NCT00300781|Experimental|Neratinib 240 mg, no prior trastuzumab|Neratinib administered with 80 mg capsules and 40 mg coated tablets taken orally in prescribed dose of 240 mg daily, as long as tolerated and disease does not worsen.
3312134|NCT00300768|Experimental|2 mg moxidectin|2 mg moxidectin (Dose-escalation 1st step)
3312135|NCT00300768|Active Comparator|Ivermectin 150 mcg/kg|Active comparator arm (ivermectin 150 mcg/kg).
3312136|NCT00300768|Experimental|4 mg moxidectin|4 mg moxidectin (dose escalation second step)
3312137|NCT00300768|Experimental|8 mg moxidectin|8 mg moxidectin (dose escalation third step)
3312138|NCT00300755|Active Comparator|1|Arm 1- Low Dose pantoprazole
3312139|NCT00300755|Active Comparator|2|Arm 2- Medium Dose pantoprazole
3312140|NCT00300755|Active Comparator|3|Arm 3- High Dose pantoprazole
3312141|NCT00300742|Experimental|Topiramate|Drug: Topiramate Other Name for Topiramate: Topamax
3312142|NCT00300729|Active Comparator|Celecoxib|Four cycles of combination chemotherapy, usually with carboplatin + gemcitabine or carboplatin + vinorelbine, plus celecoxib 400 mg b.i.d. Treatment with celecoxib is continued after completion of chemotherapy. Maximum treatment duration is one year.
3312143|NCT00300729|Placebo Comparator|Placebo|Chemotherapy as in arm 1 plus placebo capsules, b.i.d.
3312144|NCT00300677|Experimental|voriconazole|voriconazole twice daily
3312145|NCT00300638||1- MRI and interviews|In our research, we are trying to understand where in the brain these emotional behaviors take place, and whether or not the brain functions differently for alcoholic and nonalcoholic individuals. We present emotional words and pictures on a computer screen, and using Magnetic Resonance Imaging (MRI) scans, we observe how the brain works when people purposefully respond to the words and pictures. Interviews, cognitive tests, and emotional measurements will also be done. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
3312146|NCT00300612|Experimental|vaccine group|
3312147|NCT00300599|Active Comparator|A|Continue positive airway pressure
3312148|NCT00300599|Placebo Comparator|B|Placebo
3312149|NCT00300586|Sham Comparator|A (supervision)|medical supervision, second line chemotherapy if progression
3312150|NCT00300586|Active Comparator|B (gemcitabicine)|Maintenance treatment (gemcitabicine 1250 mg/m² J1, J8 (repeated cycles every 21 days), second line chemotherapy if progression
3312151|NCT00300586|Experimental|C (Erlotinib)|Treatment by erlotinib 150 mg/day (sequential treatment), second line chemotherapy if progression
3312152|NCT00300573|Experimental|Dexelvucitabine (DFC)|200 mg once daily
3312153|NCT00300573|Active Comparator|lamivudine (3TC)|300 mg once daily
3312154|NCT00300534|No Intervention|Abbott Laboratories Determine test for syphilis|Abbott Laboratories Determine rapid test for syphilis
3312155|NCT00300495|Experimental|1 - Amiodarone|Perioperative amiodarone
3312159|NCT00300482|Placebo Comparator|C|ABT-335 monotherapy
3312160|NCT00300482|Placebo Comparator|D|10 mg rosuvastatin monotherapy
3312161|NCT00300482|Placebo Comparator|E|20 mg rosuvastatin monotherapy
3312162|NCT00300482|Placebo Comparator|F|40 mg rosuvastatin monotherapy
3312163|NCT00300469|Active Comparator|A|ABT-335 + 20 mg atorvastatin
3312164|NCT00300469|Active Comparator|B|ABT-335 + 40 mg atorvastatin
3312165|NCT00300469|Placebo Comparator|C|ABT-335 monotherapy
3312166|NCT00300469|Placebo Comparator|D|20 mg atorvastatin monotherapy
3312167|NCT00300469|Placebo Comparator|E|40 mg atorvastatin monotherapy
3312168|NCT00300469|Placebo Comparator|F|80 mg atorvastatin monotherapy
3312169|NCT00300456|Active Comparator|A|ABT-335 + 20 mg simvastatin
3312170|NCT00300456|Active Comparator|B|ABT-335 + 40 mg simvastatin
3312171|NCT00300456|Placebo Comparator|C|ABT-335 monotherapy
3312172|NCT00300456|Placebo Comparator|D|20 mg simvastatin monotherapy
3312173|NCT00300456|Placebo Comparator|E|40 mg simvastatin monotherapy
3312174|NCT00300456|Placebo Comparator|F|80 mg simvastatin monotherapy
3312175|NCT00300430|Active Comparator|A|20 mg drug and ABT-335
3312176|NCT00300430|Active Comparator|B|40 mg drug and ABT 335
3312177|NCT00300430|Active Comparator|C|40 mg drug and ABT-335
3312178|NCT00300391|Experimental|haloperidol|Once diagnosed as delirious, randomized to haloperidol 5 mg IV
3312179|NCT00300391|Placebo Comparator|placebo|once diagnosed as delirious, received 5 mg saline placebo
3312180|NCT00300365|Experimental|Active Pioglitazone + Open-Label Niacin|Intervention: Pioglitazone, initially 30mg, then titrated to 45mg + niacin ER 2.0 g/day + aspirin 325 mg/day
3312181|NCT00300365|Placebo Comparator|Placebo +Open-Label Niacin|Intervention: Pioglitazone Placebo + 2.0 g/day Open-Label Niacin + 325 mg/day Aspirin
3312182|NCT00300326|No Intervention|1|Using the same knee implant with a conventional surgical technique.
3312183|NCT00300326|Active Comparator|2|Using the same knee implant using a computer-assist surgery group is the comparator
3312184|NCT00300313|Active Comparator|1|
3312185|NCT00300313|Placebo Comparator|2|
3312186|NCT00300300|No Intervention|1|applying a patellar graft using conventional surgical technique.
3312187|NCT00300300|No Intervention|2|applying a hamstring graft using conventional surgical technique.
3312188|NCT00300300|Experimental|3|applying a patellar graft using a computer-assisted surgy technique.
3312189|NCT00300300|Experimental|4|hamstring graft CAOS
3312190|NCT00300274|Experimental|everolimus 1.5 mg|Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
3312191|NCT00300274|Experimental|everolimus 3.0 mg|"Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.~Randomization of new patients in this arm was prematurely stopped as of 27 March 2008 due to high mortality rate, as per Data Monitoring Committee."
3312192|NCT00300274|Active Comparator|mycophenolate mofetil|Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.
3312193|NCT00300261|No Intervention|1|receives home care
3312194|NCT00300261|Experimental|2|receives telehealth monitoring in addition to home care
3312195|NCT00300235||1|200 subjects ages 5 to 9.9 years with a diagnosis of HbSS/HbSβ0
3312196|NCT00300235||2|400 subjects ages 10 to 14.9 years with a diagnosis of HbSS/HbSβ0
3312197|NCT00300235||3|400 subjects ages 15 to 24.9 years with a diagnosis of HbSS/HbSβ0
3312198|NCT00300235||4|400 subjects over the age of 25 with a diagnosis of HbSS/HbSβ0
3312199|NCT00300235||5|250 subjects age 15 and older with a diagnosis of HbSC or HbSβ+
3312200|NCT00300196|Experimental|Intravenous ancrod|Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
3312201|NCT00300196|Placebo Comparator|Intravenous Placebo|Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.
3312202|NCT00300131||1|Bioabsorbable Vascular Solutions (BVS) Everolimus Eluting Coronary Stent System
3312203|NCT00300118|Experimental|A|
3312204|NCT00300118|Active Comparator|B|
3312205|NCT00300092|No Intervention|No antibioitcs|Group 1 received no antibiotics
3312206|NCT00300092|Active Comparator|Cephalexin|Group 2 received cephalexin at 50 mg/kg divided 3 times daily for 7 days
3312207|NCT00300040|Experimental|1|Hemoglobin glutamer 250 - bovine
3312208|NCT00300040|Active Comparator|2|6% Hydroxyethylstarch
3312209|NCT00299975|Experimental|MaZiRenWan (MZRW) Low dose|MaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks
3312210|NCT00299975|Experimental|MaZiRenWan (MZRW) Median dose|MaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks
3312211|NCT00299975|Experimental|MaZiRenWan (MZRW) High dose|MaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks
3312212|NCT00299962|Experimental|Dose level 4|
3312213|NCT00299962|Experimental|Dose level 5|
3312214|NCT00299962|Experimental|Dose Level 1|on Days 1 and 15
3312215|NCT00299962|Experimental|Dose Level 2|On Days 1 and 15
3312216|NCT00299962|Experimental|Dose Level 3|On Days 1 and 15
3312217|NCT00299884||1|Lipitor 20 mg
3312218|NCT00299884||2|Lipidil Supra 160 mg and Ezetrol 10 mg
3312219|NCT00299858|Active Comparator|Study Group|Patients will be given theophylline, titrated to optimal blood levels, for a period of 4 weeks.
3312220|NCT00299858|Placebo Comparator|Placebo group|Patients will receive placebo pills for a period of 4 weeks.
3312221|NCT00299819|Active Comparator|1|MEDI-545
3312222|NCT00299819|Active Comparator|2|MEDI-545
3312223|NCT00299819|Active Comparator|3|MEDI-545
3312224|NCT00299819|Active Comparator|4|MEDI-545
3312225|NCT00299819|Active Comparator|5|MEDI-545
3312226|NCT00299741|Experimental|1|Sunitinib
3312227|NCT00299702|Active Comparator|002|
3312228|NCT00299702|Experimental|001|
3312229|NCT00299689|Experimental|Intervention|Single-arm: Ontak
3312230|NCT00299676||001|Galantamine (Reminyl) Use of Reminyl according to approved NZ data sheet
3312231|NCT00299650|Placebo Comparator|A|
3312232|NCT00299650|Active Comparator|B|
3312233|NCT00299611|Active Comparator|1|Levetiracetam
3312234|NCT00299611|Placebo Comparator|2|there is no active ingredient in the pills.
3312235|NCT00299559|Other|1|cross over application of both specimen
3312236|NCT00299546|Placebo Comparator|Group 1: Placebo|Placebo Subcutaneous (SC) injections every 4 weeks (wks) thru Wk 20 (unless early escape at Wk 16); Golimumab - if early escape, 50 mg SC injections from Wk 16 up to 5 yrs; Golimumab - 50 mg SC injections beginning Wk 24 up to 5 yrs (unless early escape); Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-24 database lock.
3312237|NCT00299546|Experimental|Group 2: Golimumab 50 mg|Golimumab 50 mg SC injections every 4 wks from Wk 0 up to 5 yrs (unless early escape at Wk 16); Golimumab - if early escape, 100 mg SC injections every 4 wks beginning Wk 16 up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-24 database lock.
3312238|NCT00299546|Experimental|Group 3: Golimumab 100 mg|Golimumab 100 mg SC injections every 4 wks from Wk 0 up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50 mg. Duration of the blinded period will be until the week-24 database lock.
3312239|NCT00299507|Experimental|15 mg Anecortave Acetate, 3 month intervals|Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 3 month intervals (0, 3, 6, 9, 12, 15, 18 months).
3312240|NCT00299507|Experimental|15 mg Anecortave Acetate, 6 month intervals|Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months).
3312241|NCT00299507|Experimental|30 mg Anecortave Acetate, 6 month intervals|Anecortave Acetate Sterile Suspension, 60 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months).
3312242|NCT00299507|Sham Comparator|Anecortave Acetate Vehicle|One 0.5 mL sham injection of Anecortave Acetate Vehicle at 6 month intervals (3, 9, 15, 21 months).
3312243|NCT00299494|Experimental|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (FOLLICULAR)|Follicular
3312244|NCT00299494|Experimental|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (DLBCL)|Diffuse Large B-cell Lymphoma
3312245|NCT00299494|Experimental|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (REFRACTORY)|Refractory Aggressive NHL
3312246|NCT00299455|Experimental|1|Reconstituted amoxicillin-clavulanate at 40/5.7 mg/kg/day in 2 divided doses for 7 days.
3312247|NCT00299455|Placebo Comparator|2|Reconstituted placebo in 2 divided doses for 7 days.
3312248|NCT00299442|Experimental|1|Self-help Triple P Behavioural Family Intervention
3312249|NCT00299442|No Intervention|2|Wait-list control
3312250|NCT00299429|Active Comparator|MIDCAB Surgery|MIDCAB Surgery
3312251|NCT00299429|Experimental|PCI with drug-eluting stent|PCI with DES
3312252|NCT00299403|Active Comparator|1|Right frontal low frequency rTMS
3312253|NCT00299403|Active Comparator|2|electroconvulsive therapy (ECT). Right unilateral ECT 3 time a week in 3 weeks
3312254|NCT00299390|Experimental|Sagopilone|
3312255|NCT00299325|Experimental|Rimonabant|Rimonabant 20 mg once daily with mild hypocaloric diet
3312256|NCT00299325|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily with mild hypocaloric diet
3312257|NCT00299286|Experimental|Lapatinib|lapatinib oral 1500mg daily taken as 6 tablets as one dose 10-14 days presurgery
3312258|NCT00299286|Placebo Comparator|Lapatinib-Placebo|placebo comparator 6 tablets taken as one dose daily
3312259|NCT00299273|Experimental|Low calorie high fat/protein diet|Low calorie high fat/protein diet
3312260|NCT00299260|Active Comparator|vaccine|glycoprotein B plus MF59 adjuvant
3312261|NCT00299260|Placebo Comparator|placebo|normal saline
3312262|NCT00299234|Placebo Comparator|2|placebo
3312263|NCT00299234|Experimental|1|atomoxetine
3312264|NCT00299221|Active Comparator|Monotherapy|Tacrolimus alone
3312265|NCT00299221|Active Comparator|Combination therapy|tacrolimus with mycophenolate mofetil
3312266|NCT00299195|Experimental|1|sulindac
3312267|NCT00299195|Placebo Comparator|2|placebo
3312268|NCT00299182|Experimental|1 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
3312269|NCT00299182|Experimental|3 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
3312270|NCT00299182|Experimental|10 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
3312302|NCT00298909|Active Comparator|2|physical exercise
3312303|NCT00298909|Placebo Comparator|3|control
3312304|NCT00298896|Experimental|SNS-595|SNS-595; 48 mg/m2 administered IV once every 21 days for up to 6 cycles.
3312271|NCT00299182|Placebo Comparator|Placebo (Arm A & Arm B) with Chemotherapy|"Placebo Pre and Post (Arm A), or Post (Arm B) Chemotherapy~Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by placebo subcutaneously on days -5 and 5 (Arm A) or days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
3312272|NCT00299182|Experimental|1 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
3312273|NCT00299182|Experimental|3 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
3312274|NCT00299182|Experimental|10 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
3312275|NCT00299169|Experimental|1|N of 1 trials of statin therapy
3312276|NCT00299169|Other|2|usual care
3312277|NCT00299156|Experimental|Oral Clofarabine|10 mg (Group 1) or 20 mg (Group 2) tablets once a day for 5 days in a row and repeated every 4-8 week cycle.
3312278|NCT00299130|Active Comparator|Placebo + methotrexate (MTX)|"Participants received placebo intravenous infusion on Days 1 and 15. From Week 16 onwards, participants could switch to receive rituximab 0.5 g (on Days 1 and 15) every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Placebo and rituximab infusions were preceded with 100 milligrams (mg) intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of MTX and ≥ 5 mg/week folic acid for the duration of their participation in the study.~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
3312279|NCT00299130|Experimental|Rituximab 2 x 0.5 g + MTX|"Participants received 0.5 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.~Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
3312280|NCT00299130|Experimental|Rituximab 2 x 1.0 g + MTX|"Participants received 1.0 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.~Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
3312281|NCT00299104|Experimental|Rituximab (0.5 g x 2) + Methotrexate|Rituximab intravenously at a dose of 0.5 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
3312282|NCT00299104|Experimental|Rituximab (1.0 g x 2) + Methotrexate|Rituximab intravenously at a dose of 1.0 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
3312283|NCT00299104|Placebo Comparator|Placebo + Methotrexate|"Placebo intravenously on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.~From Week 104 participants were eligible to receive Rituximab 2 X 0.5 g or Rituximab 2 X 1.0 g every 24 weeks."
3312284|NCT00299091|No Intervention|Control|Efavirenz capsules 600 mg
3312285|NCT00299091|Experimental|Experimental|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
3312286|NCT00299052|Active Comparator|A|Bone reamings with 5cc of DMB putty
3312287|NCT00299052|Active Comparator|B|Bone reamings
3312288|NCT00299039|Active Comparator|1|
3312289|NCT00299039|Active Comparator|2|
3312290|NCT00299013|Active Comparator|1|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
3312291|NCT00299013|Experimental|2|COLAL-PRED 40mg oral capsule, once daily for 8 weeks.
3312292|NCT00299013|Experimental|3|COLAL-PRED 60mg oral capsule, once daily for 8 weeks.
3312293|NCT00299013|Experimental|4|COLAL-PRED 80mg oral capsule, once daily for 8 weeks.
3312294|NCT00299000|Other|Naglazyme, 1.0 mg/kg|Dose comparison
3312295|NCT00299000|Other|Naglazyme, 2.0 mg/kg|Dose Comparison
3312296|NCT00298987|Experimental|A1|
3312297|NCT00298974|Experimental|hydrocodone/acetaminophen extended release|
3312298|NCT00298974|Placebo Comparator|Placebo|
3312299|NCT00298922|Active Comparator|Azithromycin|participants taking 500 mg tablets orally thrice weekly for 24 weeks
3312300|NCT00298922|Placebo Comparator|Placebo|Participants taking 500 mg tablets orally thrice weekly for 24 weeks
3312301|NCT00298909|Experimental|1|niacin
3312305|NCT00298883|Experimental|Treatment|This is a single arm, interventional trial.
3312306|NCT00298870|Experimental|PGx-treatment|NAT2 genotype-guided treatment with stratified isoniazid dose (approx. 7.5 mg/kg b.w., patients homozygous for NAT2*4: rapid acetylators; 5 mg/kg, patients heterozygous for NAT2*4: intermediate acetylators; 2.5 mg/kg, patientes without NAT2*4: slow acetylators)
3312307|NCT00298870|Active Comparator|STD-treatment|Treatment with conventional standard isoniazid dose (approx. 5 mg/kg b.w.)
3312308|NCT00298831|Experimental|1|sugammadex
3312309|NCT00298792|Experimental|Individualized Assessment & treatment|Individualized treatment for alcohol dependent persons, based on momentary assessment of high-risk situations and recorded coping abilities.
3312310|NCT00298792|Active Comparator|Packaged Cognitive-Behavioral Treatment|Manualized cognitive-behavioral treatment for alcohol dependent persons.
3312311|NCT00298766|Experimental|1|VELCADE
3312312|NCT00298740|Experimental|Aventis U-400 Insulin|
3312313|NCT00298727|Active Comparator|1|SHIPS: Face-to-Face Workshop
3312314|NCT00298727|Active Comparator|2|ePBL: Online Problem-Based Course
3312315|NCT00298675|Experimental|Iniparib|
3312316|NCT00298675|Experimental|Iniparib/irinotecan|
3312317|NCT00298623|Placebo Comparator|Placebo|
3312318|NCT00298623|Experimental|XP13512 (GSK1838262)|
3312319|NCT00298610|Experimental|Artesunate and Malarone|Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
3312320|NCT00298558|Active Comparator|Memory Training|Memory training focused on verbal episodic memory. Participants were taught mnemonic strategies for remembering lists and sequences of items, text material, and main ideas and details of stories and other text-based information.
3312321|NCT00298558|Active Comparator|Reasoning Training|Reasoning training focused on the ability to solve problems that follow a serial pattern. Participants were taught strategies to identify the pattern or sequence required to solve a problem.
3312322|NCT00298558|Active Comparator|Speed of Processing Training|Speed of processing training focused on visual search and the ability to identify and locate visual information quickly in a divided attention format. Participants practiced increasingly complex speeded tasks on a computer.
3312323|NCT00298558|Placebo Comparator|Control|This group did not complete any cognitive training interventions
3312324|NCT00298545|Placebo Comparator|placebo and Calcitriol|placebo tablets together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
3312325|NCT00298545|Active Comparator|2|calcium together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
3312326|NCT00298532|No Intervention|standard therapy|"The use of a before-after controlled study design and 36-month time periods will mirror the approach of our Adult OPALS Study. The Control (before) Period represents the 36 months immediately prior to the introduction of ALS programs at each study community. The Intervention (after) Period is comprised of the 36 months immediately after each community has met all standards for a full ALS program, as defined below. Data will be pooled across communities but the start date for the periods will vary for each community as each will require different amounts of time to prepare their ALS program. A 6- to 36-month Run-in period will separate the Control and Intervention Periods and will allow for training and implementation of the ALS program. Data from the Run-in period will not be considered in the primary analysis. The study periods may be summarized as follows: a) Control (Before) Period b) Run-in Period c) Intervention (After) Period."
3312327|NCT00298506|Active Comparator|FK506+MMF|
3312328|NCT00298428|Other|SPACE group|
3312329|NCT00298415|Active Comparator|A|Chemotherapy (mono)
3312330|NCT00298415|Experimental|B|Chemotherapy (doublet)
3312331|NCT00298363|Experimental|Tenofovir DF|TDF 300 mg + FTC/TDF placebo + ETV placebo once daily (QD)
3312332|NCT00298363|Experimental|FTC/TDF|FTC 200 mg/TDF 300 mg + TDF placebo + ETV placebo QD
3312333|NCT00298363|Experimental|Entecavir|ETV 0.5 mg or 1 mg + TDF placebo + FTC/TDF placebo QD
3312334|NCT00298324|Active Comparator|Myfortic|Patients in this arm will receive Myfortic + Prednisone + Cyclosporine
3312335|NCT00298324|Other|Standard Care/ Placebo|In this arm patients will receive Prednisone + Cyclosporine + Placebo or Prednisone + Cyclosporine
3312336|NCT00298311|Experimental|mci guidance & peer social support|home visits to promote maternal-child interaction & social support
3312337|NCT00298311|Sham Comparator|peer social support|social support
3312338|NCT00298298|Experimental|1|5 million autologous, DNP-modified NSCLC cells
3312339|NCT00298298|Experimental|2|2.5 million autologous, DNP-modified NSCLC cells
3312340|NCT00298298|Experimental|3|0.5 million autologous, DNP-modified NSCLC cells
3312341|NCT00298272|Experimental|Double-blind/Open Label Rituximab|"The double-blind rituximab treatment group received rituximab 500 mg by intravenous (IV) infusion on Day 1 and Day 15. After 24 weeks (primary endpoint completion), participants continued post-treatment follow-up (PTFU) visits through Week 56, and entered a 48-week Safety Follow-Up (SFU). At any time between Week 24 and Week 40 of PTFU, eligible participants could enter the rituximab open label (OL) arm, and restart the 56-week treatment/follow-up schedule (rituximab 500 mg by IV infusion on Day 1 and Day 15) prior to the 48-week SFU.~Prior to rituximab infusion, participants were premedicated with methylprednisolone 100 mg IV. Participants received folate ≥5 mg weekly. Background therapy (stable dose for the duration of the study) included: a tumor necrosis factor (TNF) inhibitor; either etanercept 50 mg subcutaneous injection (SC) weekly or adalimumab 40 mg SC once every 2 weeks; methotrexate (MTX) 15 to 25 mg by mouth or by intramuscular injection (IM) weekly."
3312389|NCT00297479|Experimental|Mindfulness-Based Treatment Group (MBAT)|MBAT is 6 weeks of nicotine patch therapy; a Self-help guide; and In-person group therapy/counseling (8 sessions over 8 weeks) using a Mindfulness-Based Addiction Treatment for nicotine dependence.
3312390|NCT00297479|Active Comparator|Standard Care Group|Standard Care Group (ST) is 6 weeks of nicotine patch therapy, a Self-help guide and In-person group therapy/counseling (8 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
3312391|NCT00297479|Active Comparator|Usual Care Group|Usual Care (UC) is 6 weeks of nicotine patch therapy, a Self-help guide and In-person individual counseling (4 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
3319389|NCT00187538|Active Comparator|4|
3312342|NCT00298272|Other|Double-blind Placebo/Open Label Rituximab|"The double-blind placebo treatment group received saline solution IV on Day 1 and Day 15. After 24 weeks (primary endpoint completion), participants continued post-treatment follow-up (PTFU) visits through Week 56, and entered a 48-week Safety Follow-Up (SFU). At any time between Week 24 and Week 40 of PTFU, eligible participants could enter the rituximab open label (OL) arm, and restart the 56-week treatment/follow-up schedule (rituximab 500 mg by IV infusion on Day 1 and Day 15) prior to the 48-week SFU.~Prior to each infusion of placebo, participants were premedicated with methylprednisolone 100 mg IV. Participants received folate ≥5 mg weekly. Background therapy (stable dose for the duration of the study) included: a tumor necrosis factor (TNF) inhibitor; either etanercept 50 mg subcutaneous injection (SC) weekly or adalimumab 40 mg SC once every 2 weeks; methotrexate (MTX) 15 to 25 mg by mouth or by intramuscular injection (IM) weekly."
3312343|NCT00298259|Active Comparator|ORIF|open reduction internal fixation of fractured ribs in flail chest patients
3312344|NCT00298259|No Intervention|conservative management|current standard conservative management
3312345|NCT00298233|Active Comparator|Standard Dose oseltamivir adult cohort|All participants >= 15 years will receive standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
3312346|NCT00298233|Active Comparator|Double Dose oseltamivir Adult cohort|All participants >= 15 years will receive high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
3312347|NCT00298233|Active Comparator|Standard Dose Oseltamivir child cohort|All participants <15 years will receive standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
3312348|NCT00298233|Active Comparator|Double Dose Oseltamivir child cohort|All Participants <15 years will receive high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
3312349|NCT00298220|Active Comparator|training|tailored multi-component implementation program
3312350|NCT00298220|No Intervention|control|
3312351|NCT00298168|Experimental|1|
3312352|NCT00298168|Experimental|2|
3312353|NCT00298168|Placebo Comparator|3|
3312354|NCT00298155|Active Comparator|Group 1|Goserelin + dutasteride
3312355|NCT00298155|Active Comparator|Group 2|Bicalutamide for one week, begin goserelin plus dutasteride, continue bicalutamide for the full 12 weeks
3312356|NCT00298155|Active Comparator|Group 3|Begin bicalutamide for one week, goserelin injection; begin dutasteride, ketoconazole (and replacement hydrocortisone), continue bicalutamide for the full 12 weeks
3312357|NCT00298090||StO2 values|StO2 monitoring
3312358|NCT00298051|No Intervention|Early umbilical cord clamping (control)|"Umbilical cord was clamped immediately, or as close as possible, after delivery of the infant's shoulders. (This was standard practice in the study hospital, thus it served as the control group)."
3312359|NCT00298051|Experimental|Delayed umbilical cord clamping|Umbilical cord was clamped at 2 minutes after delivery of the infant's shoulder's with the infant held at the level of the mother's uterus.
3312360|NCT00298038|Placebo Comparator|placebo|
3312361|NCT00298025|Experimental|Cetrotide®|
3312362|NCT00298025|Active Comparator|Antagon ™|
3312363|NCT00297986||1|healthy subjects
3312364|NCT00297947|Experimental|600 mg/day quetiapine (Group B)|Patients qualifying for the Double Blind Phase will be randomly assigned to 600 mg quetiapine (Group B) daily and treated on the assigned dose in a double-blind fashion for 8 weeks
3312365|NCT00297947|Experimental|1200 mg/day quetiapine (Group A)|Patients qualifying for the Double Blind Phase will be randomly assigned to high dose 1200 mg quetiapine daily (Group A) on the assigned dose in a double-blind fashion for 8 weeks
3312366|NCT00297895|Active Comparator|Ultrasound observation + delayed CLND if recurrence detected|
3312367|NCT00297895|Active Comparator|CLND|
3312368|NCT00297882|Active Comparator|1 Artemether-Lumefantrine|
3312369|NCT00297882|Active Comparator|2 Amodiaquine-Artemether|
3312370|NCT00297869|No Intervention|1|
3312371|NCT00297869|Experimental|2|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
3312372|NCT00297856||Boostrix cohort|
3312373|NCT00297856||Historical Td cohort|
3312374|NCT00297830|Experimental|Active Zoledronic Acid & Placebo Alendronate|Group 1 will receive an infusion of active zoledronic acid 5 mg during the first 4 weeks after transplantation. Placebo alendronate 70 mg once weekly will be initiated at the same time as the first zoledronic acid infusion.
3312375|NCT00297830|Experimental|Placebo Zoledronic Acid & Active Alendronate|Group 2 will receive an infusion of placebo zoledronic acid during the first 5 weeks after transplantation. Active alendronate 70 mg once weekly will be initiated at the same time as the placebo infusion.
3312376|NCT00297817|Experimental|Arm 1: rMenB|
3312377|NCT00297817|Experimental|Arm 2: rMenB + OMV|
3312378|NCT00297817|Placebo Comparator|Arm 3: Placebo|
3312379|NCT00297804|Experimental|Arm 1|
3312380|NCT00297804|Active Comparator|Arm 2|
3312381|NCT00297791|Other|1|surgery (open or laparoscopic) and observation
3312382|NCT00297778|Experimental|pramipexole|A daily dose of pramipexole 0.125 mg t.i.d.; titration-to-response up to 1.0 mg t.i.d.
3312383|NCT00297778|Placebo Comparator|placebo|Placebo (matching) tablets
3312384|NCT00297648|Experimental|CDP870 400 mg|Certolizumab pegol (CDP870) 400 mg
3312385|NCT00297596|Experimental|Intervention|Patients with HER2 positive breast cancer received treatment with oxaliplatin 130 mg/m2 IV day 1 and trastuzumab 6 mg/kg (following 8 mg/kg loading dose during cycle 1). Cycles were repeated every 21 days.
3312386|NCT00297492|Experimental|Gradual reduction|Intervention: Reduction Phone Counseling. Intervention: Pre-Quit Nicotine Lozenges. Intervention: Post-Quit Nicotine Lozenges.
3312387|NCT00297492|Active Comparator|Abrupt cessation|Intervention: Abrupt Phone Counseling. Intervention: Post-Quit Nicotine Lozenges.
3312388|NCT00297492|Active Comparator|Minimal intervention|Intervention: Minimal Abrupt Phone Counseling. Intervention: Post-Quit Nicotine Lozenges.
3312392|NCT00297453|Experimental|Internet|Individual counseling + nicotine replacement. 6 sessions across a 3 month period.
3312393|NCT00297453|Experimental|Counseling|Individual counseling plus nicotine replacement treatment.
3312394|NCT00297453|Active Comparator|Self-Help|Self-help Manual plus nicotine replacment treatment.
3312395|NCT00297427|Experimental|Acupuncture|Subjects will 12 acupuncture treatments over 6 weeks; treatment sessions occur twice a week. A total of 12 acupuncture needles will be inserted bilaterally at two leg points and four back points. Needles are manually inserted through a standard guide tube contained within a fitted sheath and the basal ring secured to the skin by double-sided tape. The needles remain in place for 25 minutes and are manually stimulated twice during each treatment.
3312396|NCT00297427|Sham Comparator|Sham acupuncture|Subjects will receive 12 sham acupuncture treatments (delivered twice a week) over 6 weeks. The sham needle is blunted needle whose shaft telescopes into the handle when tapped. While the needle appears to have been inserted, it does not actually penetrate the skin. It is held in place by the same standard guide tube used in the true acupuncture group. The acupuncture points and duration of treatment are the same as for the true acupuncture group.
3312397|NCT00297414||Patients with mild cognitive impairment|Patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
3312398|NCT00297401|Experimental|1|
3312399|NCT00297401|Placebo Comparator|2|
3312400|NCT00297362||Galantamine hydrobromide|
3312401|NCT00297349||001|
3312402|NCT00297336||001|
3312403|NCT00297323||001|
3312404|NCT00297271||Mild cognitive impairment or dementia|Patients with mild cognitive impairment or dementia.
3312405|NCT00297232|Experimental|Natalizumab|300 mg intravenous (IV) infusions once every 4 weeks for up to 480 weeks
3312406|NCT00297219|Active Comparator|2|high dialysate calcium
3312407|NCT00297219|Active Comparator|1|low dialysate calcium
3312408|NCT00297206|Experimental|Cohort 1|Subjects in the age group of 2 to less than 6 years will be included
3312409|NCT00297206|Experimental|Cohort 2|Subjects in the age group of 1 to less than 2 years will be included
3312410|NCT00297206|Experimental|Cohort 3|Subjects in the age group of 6 months to less than 1 year will be included
3312411|NCT00297206|Experimental|Cohort 4|Subjects in the age group of 3 months to less than 6 months will be included
3312412|NCT00297206|Experimental|Cohort 5|Subjects in the age group of 1 month to less than 3 months will be included
3312413|NCT00297193|Experimental|Transplant Arm|Hematopoietic stem cell mobilisation followed, within 4 weeks, by high dose immunoablation and autologous stem cell transplantation
3312414|NCT00297193|Experimental|Delayed Transplant|Hematopoietic stem cell mobilisation followed, after 59 weeks, by high dose immunoablation and autologous hematopoietic stem cell transplantation
3312415|NCT00297167|Experimental|EUR-1008 (APT-1008) First, Then Placebo|
3312416|NCT00297167|Experimental|Placebo First, Then EUR-1008 (APT-1008)|
3312417|NCT00297141|Experimental|single arm (radiochemotherapy)|single arm study (capecitabine, oxaliplatin)
3312418|NCT00297128|Active Comparator|1|
3312419|NCT00297115|Active Comparator|Roflumilast|500 mcg, once daily, oral administration in the morning
3312420|NCT00297115|Placebo Comparator|Placebo|once daily
3312421|NCT00297102|Active Comparator|Roflumilast|500 mcg, once daily, oral administration in the morning
3312422|NCT00297102|Placebo Comparator|Placebo|once daily
3312423|NCT00297089|Active Comparator|A|Pemetrexed + ABT-751
3312424|NCT00297089|Placebo Comparator|B|Pemetrexed + placebo
3312425|NCT00297037|Active Comparator|1|"During the 6-week double-blind phase, all patients will be randomly assigned to receive either pimecrolimus 1% cream or its vehicle twice daily with occlusion on the affected areas. Topical application of pimecrolimus1% cream for oral erosive lichen planus for a duration of 6 weeks; ¼ gram of cream will be applied to each of the 2 sides of the mouth BID with a 2x2 gauze."
3312426|NCT00297037|Placebo Comparator|2|"During the 6-week double-blind phase, all patients will be randomly assigned to receive either pimecrolimus 1% cream or its vehicle twice daily with occlusion on the affected areas. Topical application of pimecrolimus1% cream for oral erosive lichen planus for a duration of 6 weeks; ¼ gram of cream will be applied to each of the 2 sides of the mouth BID with a 2x2 gauze."
3312427|NCT00297024|Experimental|MRI for brain mets|
3312428|NCT00296907|Experimental|Psychological Intervention|2-session psychological intervention
3312429|NCT00296894|Experimental|1|Drug - adalimimab sc
3312430|NCT00296894|Placebo Comparator|2|Placebo
3312431|NCT00296855|Experimental|Arm 1|
3312432|NCT00296816|Experimental|Oxaliplatin/Docetaxel/Bevacizumab|Participants with International Federation of Gynecology and Obstetrics (FIGO) stage IB through IV ovarian, primary peritoneal, or fallopian tube carcinoma treated with Oxaliplatin, Docetaxel, and Bevacizumab - 28 days after initial surgery
3312433|NCT00296777|Experimental|escitalopram|escitalopram 10 mg/d, increasing by 10 mg/week if tolerated and not remitted to maximum dose of 40 mg/d
3312434|NCT00296777|Experimental|bupropion|bupropion XL 150 mg/d, increasing by 150 mg/d if tolerated and not remitted to maximum dose of 450 mg/d
3312435|NCT00296777|Experimental|imipramine|imipramine 50 mg/d for 3 days, then 100 mg/d for 4 days, then 150 mg/d for 3 days then 200 mg/d for 4 days then 250 mg/d for a week and then 300 mg/d thereafter, all dose increases if tolerated and not remitted
3312436|NCT00296725|Experimental|fluoxetine|fluoxetine
3312437|NCT00296725|Experimental|imipramine|imipramine
3312438|NCT00296712|Experimental|escitalopram + bupropion|patients begin on escitalopram 10 mg/d, then bupropion 150 mg/d is added and each is alternately increased as tolerated to maximal dose of escitalopram of 40 mg/d and of bupropion of 450 mg/d
3312439|NCT00296686|Experimental|tranylcypromine|sequential tranylcypromine (TC) followed by TC + dextroamphetamine followed by TC + T3
3312440|NCT00296660||1|Proven acute HIV-1 infection
3312441|NCT00296660||1A|Sexual partners of members of Group 1
3312442|NCT00296660||2|Established HIV-infection
3312443|NCT00296660||3|HIV-1 uninfected
3312444|NCT00296647|Active Comparator|patch|
3312445|NCT00296647|Active Comparator|nicotine lozenge|
3312446|NCT00296647|Active Comparator|bupropion|
3312447|NCT00296647|Active Comparator|patch + lozenge|
3319843|NCT00180219||1|20 to 22 years
3312448|NCT00296647|Active Comparator|buproion + lozenge|
3312449|NCT00296634|Experimental|1|45 microgram dose Hemagglutinin (HA), 120 subjects receiving Aluminum hydroxide and 120 not receiving Aluminum hydroxide.
3312450|NCT00296634|Experimental|2|15 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
3312451|NCT00296634|Experimental|4|3.75 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
3312452|NCT00296634|Experimental|3|7.5 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
3312453|NCT00296621|Experimental|1|
3312454|NCT00296621|Placebo Comparator|2|
3312455|NCT00296608|Active Comparator|Radiotherapy|RT was delivered with photons from a linear accelerator with an energy level of 8MVor above.
3312456|NCT00296608|Experimental|Chemotherapy and radiotherapy|The first CT cycle was administered from days 1 to 5 of the RT treatment. LV 20 mg/m2/d was delivered intravenously immediately before administration of FU. FU 350 mg/m2/d was delivered during 20 minutes in 100 mL of saline infusion, 1 hour before RT. The second cycle was administered from days 29 to 33 of the RT treatment using the same schedule.
3312457|NCT00296595|Placebo Comparator|Placebo|Placebo capsules + 500 mL/day of placebo juice
3312458|NCT00296595|Experimental|Cranberry Juice|Placebo capsules + 500 mL/day of cranberry juice
3312459|NCT00296595|Experimental|Fish Oil|2 g/day of fish oil + 500 mL/day of placebo juice
3312460|NCT00296595|Experimental|Cranberry Juice + Fish Oil|2 g/day of fish oil + 500 mL/day of cranberry juice
3312461|NCT00296517|Placebo Comparator|Placebo|Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
3312462|NCT00296517|Experimental|Bupropion SR|Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
3312463|NCT00296491|Active Comparator|Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)|Fluticasone propionate/salmeterol DISKUS combination product (FSC) twice daily (BID) plus vehicle placebo nasal spray once daily (QD) plus montelukast capsule 10mg (MON) QD
3312464|NCT00296491|Active Comparator|Fluticasone Propionate/Salmeterol (FSC)|FSC BID plus vehicle placebo nasal spray QD plus placebo capsule QD
3312465|NCT00296491|Active Comparator|Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS)|Fluticasone propionate/salmeterol DISKUS combination product (FSC)100/50mcg BID plus fluticasone propionate aqueous nasal spray 200mcg (FPANS) QD plus placebo capsule QD
3312466|NCT00296491|Active Comparator|Montelukast (MON)|Placebo DISKUS BID plus vehicle placebo nasal spray QD plus MON QD
3312467|NCT00296478|Experimental|1|Endometrin 100mg BID
3312468|NCT00296478|Experimental|2|Endometrin 100mg TID
3312469|NCT00296478|Active Comparator|3|Crinone
3312470|NCT00296465|Experimental|Lutrepulse® 5mcg IV|5.0 mcg Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
3312471|NCT00296465|Experimental|Lutrepulse® 10 mcg IV|10.0 mcg Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
3312472|NCT00296465|Experimental|Lutrepulse® 20 mcg SC|20.0 mcg Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
3312473|NCT00296465|Placebo Comparator|Placebo IV|Placebo Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
3312474|NCT00296465|Placebo Comparator|Placebo SC|Placebo Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
3312475|NCT00296465|Active Comparator|Clomiphene Citrate/Placebo IV|Oral clomiphene citrate (over encapsulated) for 5 days and Placebo Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
3312476|NCT00296465|Active Comparator|Clomiphene Citrate / Placebo SC|Oral clomiphene citrate (over encapsulated) for 5 days and Placebo Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
3312477|NCT00296413||1|Valproate monotherapy
3312478|NCT00296413||2|Valproate monotherapy with combined oral contraceptive
3312479|NCT00296413||3|Lamotrigine monotherapy
3312480|NCT00296413||4|Lamotrigine monotherapy with combined oral contraceptive
3312481|NCT00296374|Experimental|1|Rosuvastatin 10 mg
3312482|NCT00296374|Experimental|2|Rosuvastatin 40 mg
3312483|NCT00296374|Active Comparator|3|Atorvastatin 80 mg
3312484|NCT00296361|Active Comparator|1|
3312485|NCT00296361|Experimental|2|
3312486|NCT00296348|Active Comparator|1|
3312487|NCT00296348|Experimental|2|
3312488|NCT00296335|Active Comparator|Mitomycin and doxifluridine|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
3312489|NCT00296335|Experimental|Mitomycin, doxifluridine and cisplatin|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
3312490|NCT00296322|Active Comparator|Mitomycin-C, Doxifluridine|Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)
3312491|NCT00296322|Active Comparator|Mitomycin-C, Doxifluridine, Cisplatin|iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)
3312492|NCT00296309|Active Comparator|1|
3312493|NCT00296309|Experimental|2|
3312653|NCT00294112|Experimental|2|Low dose: 2 million cells per kg body weight
3312494|NCT00296296|Active Comparator|Cyclosporin|Patients receive cyclosporin (dose-adjusted to pre-established targets) as immunosuppressive calcineurin inhibitor (CNI) and Diabetes Education / Management (therapeutic adjustment to target American Diabetes Association (ADA) criteria)
3312495|NCT00296296|Active Comparator|Tacrolimus|Patients receive tacrolimus (dose-adjusted to pre-established targets) as CNI and Diabetes Education / Management (therapeutic adjustment to target ADA criteria)
3312496|NCT00296244|Other|Steroid -free immunosuppression|Study group - Basiliximab, Tacrolimus, Enteric-coated Mycophenolic acid (EC-MPA)
3312497|NCT00296244|Other|Steroid containing immunosuppression|Control group- Basiliximab, Tacrolimus, EC-MPA, steroids
3312498|NCT00296231|Experimental|Nasal High Frequency Ventilation|Stable infants born at less than 1501 g who are at least 7 days old and undergoing nasal continuous positive airway pressure treatment.
3312499|NCT00296192|Placebo Comparator|Placebo 1|Placebo nasal spray 1 - 4 puffs
3312500|NCT00296192|Experimental|Rotigotine 1|Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)
3312501|NCT00296192|Experimental|Rotigotine 2|Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)
3312502|NCT00296192|Experimental|Rotigotine 3|Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)
3312503|NCT00296192|Experimental|Rotigotine 4|Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)
3312504|NCT00296153|Active Comparator|1|Omacor 1000mg x 4 / day
3312505|NCT00296153|Placebo Comparator|2|
3312506|NCT00296140|Other|self management of PSD symptoms|
3312507|NCT00296140|Other|screening and treatment of PSD|
3312508|NCT00296049|Active Comparator|vancomycin|
3312509|NCT00296049|Experimental|daptomycin|
3312510|NCT00296036|Experimental|Arm I (closed to accrual as of 10/24/2007)|Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily and oral pyridoxine once daily on days 1-21.
3312511|NCT00296036|Experimental|Arm II (closed to accrual as of 10/24/2007)|Patients receive topical urea/lactic acid-based cream as in arm I (closed to accrual as of 10/24/2007) and oral placebo once daily on days 1-21.
3312512|NCT00296036|Experimental|Arm III (closed to accrual as of 10/24/2007)|Patients receive placebo cream applied to palms and soles twice daily and pyridoxine as in arm I (closed to accrual as of 10/24/2007).
3312513|NCT00296036|Placebo Comparator|Arm IV (closed to accrual as of 10/24/2007)|Patients receive placebo cream as in arm III and oral placebo as in arm II (closed to accrual as of 10/24/2007).
3312514|NCT00296036|Experimental|Arm V|Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily on days 1-21.
3312515|NCT00296036|Placebo Comparator|Arm VI|Patients receive placebo cream applied to palms and soles twice daily on days 1-21.
3312516|NCT00296023|Experimental|stem cell transplant|
3312517|NCT00296010|Experimental|CASA-nil PLD|Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
3312518|NCT00296010|Active Comparator|CASA-Nil|No adjuvant therapy
3312519|NCT00296010|Experimental|CASA-CM PLD|Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
3312520|NCT00296010|Active Comparator|CASA-CM CM|Low-dose, metronomic cyclophosphamide and methotrexate (CM) for 16 weeks
3312521|NCT00295971|Experimental|Single arm of transplant|Receiving haplocompatible T cell depleted peripheral blood stem cell transplant
3312522|NCT00295945||PCA|Patient-controlled intravenous analgesia
3312523|NCT00295945||PCEA|Perioperative patient-controlled epidural analgesia
3312524|NCT00295932|Experimental|Arm I|Patients receive cyclophosphamide IV and rituximab IV on day 1, oral prednisone on days 2-6, and bortezomib IV (at the MTD determined in phase I) on days 2, 5, 9, and 12. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3312525|NCT00295932|Experimental|Arm II|Patients receive cyclophosphamide IV and rituximab IV on day 1, oral prednisone on days 2-6, and bortezomib IV (at the MTD determined in phase I) on days 2 and 8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3312526|NCT00295893|Active Comparator|Arm I|Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV, and docetaxel IV on day 1. Treatment repeats every 21 days for 6 courses.
3312527|NCT00295893|Experimental|Arm II|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; treatment repeats every 2 weeks for 4 courses. Patients then receive carboplatin IV on day 1 and paclitaxel IV on days 1, 8, and 15; treatment with carboplatin and paclitaxel repeats every 4 weeks for 3 courses.
3312528|NCT00295893|Experimental|Arm III|Patients receive chemotherapy as in arm II. They also receive trastuzumab (Herceptin®) IV weekly, beginning with the first doses of paclitaxel and carboplatin.
3312529|NCT00295880|Experimental|Transplant Patients|Patients receiving umbilical cord blood transplantation.
3312530|NCT00295867|Experimental|Zoledronic Acid|
3312531|NCT00295854|Experimental|MN-001|
3312532|NCT00295854|Placebo Comparator|MN-001 once daily|placebo tablets
3312533|NCT00295828|Active Comparator|1|Panretinal Photocoagulation (PRP)
3312534|NCT00295828|Active Comparator|2|Panretinal Photocoagulation and Macugen Intravitreal Injection
3312535|NCT00295815|Experimental|A|
3312536|NCT00295815|Active Comparator|B|
3312537|NCT00295802|Experimental|HIFU|Integrated Imaging High Intensity Focused Ultrasound using the Ablatherm Device
3312538|NCT00295802|Active Comparator|Cryotherapy|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)
3312539|NCT00295789|Active Comparator|1|Drug: chemotherapy: Paclitaxel/Cisplatin
3312540|NCT00295789|Experimental|2|Drug: chemotherapy: Paclitaxel/Carboplatin
3312541|NCT00295763|Other|1|
3312542|NCT00295750|Experimental|degarelix 240/160 mg|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.
3312543|NCT00295750|Experimental|degarelix 240/80 mg|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.
3312544|NCT00295750|Active Comparator|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5 mg IM (in the muscle) every 28 days starting at day 0.
3312545|NCT00295646|Active Comparator|AZ (Arimidex+Zoledronat)|Study Drugs Arimidex (Anastrozole), Zometa (Zoledronat; zoledronic acid)
3319844|NCT00180219||2|30 to 32 years
3312546|NCT00295646|Active Comparator|TZ (Tamoxifen+Zoledronat)|Study Drugs Nolvadex (Tamoxifen), Zometa (Zoledronat; zoledronic acid)
3312547|NCT00295646|Active Comparator|AC (Arimidex Control)|Study Drug Arimidex (Anastrozole)
3312548|NCT00295646|Active Comparator|TC (Tamoxifen Control)|Study Drug Nolvadex (Tamoxifen)
3312549|NCT00295633|Experimental|Saxagliptin plus open-label TZD (A)|"Saxagliptin PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)"
3312550|NCT00295633|Experimental|Saxagliptin plus open-label TZD (B)|"Saxagliptin PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)"
3312551|NCT00295633|Placebo Comparator|Placebo plus open-label TZD (C)|"Placebo PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)"
3312552|NCT00295620|Experimental|Arm A: Anastrozol|1 mg per day for 2 years
3312553|NCT00295620|Experimental|Arm B: Anastrozol|1 mg per day for 5 years
3312554|NCT00295607|Active Comparator|1|
3312555|NCT00295607|Experimental|2|
3312556|NCT00295594|Active Comparator|1|
3312557|NCT00295594|Experimental|2|
3312558|NCT00295542|Active Comparator|1|Treatment on awakening
3312559|NCT00295542|Active Comparator|2|Treatment at bedtime
3312560|NCT00295529|Experimental|Multifaceted Educational Intervention|Intervention group received an interactive workshop, portfolio of primary care appropriate genomics tools, and Gene Messengers
3312561|NCT00295529|No Intervention|No education|Educational materials at end of study
3312562|NCT00295503|Experimental|1|cisplatin, pemetrexed, and bevacizumab
3312563|NCT00295490|Experimental|240mg Devil claw|Sub clinical dose if the 3 doses employed
3312564|NCT00295490|Experimental|960mg Devil Claw|Active dose
3312565|NCT00295490|Experimental|1920 mg Devil claw|Active dose
3312566|NCT00295490|Placebo Comparator|Placebo|Comparator for all active intervention arms
3312567|NCT00295438|Experimental|Robot-Based Tele-Echography (TER)|ultrasound performed according to the method Tele-Echography
3312568|NCT00295438|Active Comparator|ultrasound method FAST|ultrasound performed according to the method FAST (Focused Assessment Sonography for Trauma)
3312569|NCT00295308|Experimental|Arm 1|
3312570|NCT00295308|Placebo Comparator|Arm 2|
3312571|NCT00295295|Experimental|Vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
3312572|NCT00295295|Active Comparator|Standing|Standing 10 min/day
3312573|NCT00295282|Experimental|1|patients will receive active MDX-1100
3312574|NCT00295191|Active Comparator|1|high-flux dialyser
3312575|NCT00295191|Active Comparator|2|low-flux dialyser
3312576|NCT00295191|Active Comparator|3|conventional dialysate
3312577|NCT00295191|Active Comparator|4|ultrapure dialysate
3312578|NCT00295165|Experimental|Arm 1|
3312579|NCT00295165|Placebo Comparator|Arm 2|
3312580|NCT00295139|Experimental|1|Behavioral Treatment for Substance Abuse in SPMI (BTSAS)
3312581|NCT00295139|Experimental|2|Behavioral Treatment for Substance Abuse in SPMI (BTSAS) + Critical Time Intervention (CTI)
3312582|NCT00295139|Active Comparator|3|Supportive Treatment in Addiction Recovery (STAR)
3312583|NCT00295061|Experimental|1 Alpha-1 MP|Sequential, blinded treatment periods of Alpha-1 MP (experimental), then crossed-over to Prolastin (active comparator), followed by open-label Alpha-1 MP
3312584|NCT00295061|Active Comparator|2 Prolastin|Sequential, blinded treatment periods of Prolastin (active comparator), then crossed-over to Alpha-1 MP (experimental), followed by open-label Alpha-1 MP
3312585|NCT00295022|Placebo Comparator|Placebo (PBO)|Placebo was administered orally on Days 1 and 2.
3312586|NCT00295022|Experimental|Montelukast (MLKT)|10 mg of Montelukast (MLKT) was administered orally on Days 1 and 2.
3312587|NCT00295022|Experimental|Levocetirizine (LCTZ)|5 mg of Levocetirizine (LCTZ) was administered orally on Days 1 and 2.
3312588|NCT00295009|Active Comparator|1-Level Fusion|Spinal fusion at a single lumbar level.
3312589|NCT00295009|Experimental|1-Level ProDisc|Total disc replacement with the ProDisc device at one spinal lumbar level.
3312590|NCT00295009|Active Comparator|2-Level Fusion|Spinal fusion at two adjacent lumbar levels.
3312591|NCT00295009|Experimental|2-Level ProDisc|Total disc replacement with the ProDisc device at two adjacent lumbar levels.
3312592|NCT00295009|Experimental|1-level ProDisc (non-randomized)|Total disc replacement with the ProDisc device for non-randomized subjects at one spinal lumbar level.
3312593|NCT00295009|Active Comparator|2-Level ProDisc (Continued Access)|Total disc replacement with the ProDisc device for non-randomized subjects at two spinal lumbar levels (only followed out to 24 months)
3312594|NCT00294970||PTSD|Patients with diagnosis of PTSD
3312595|NCT00294970||OCD|Patients with diagnosis of OCD
3312596|NCT00294970||PTSD/OCD|Patients with diagnosis of comorbid PTSD and OCD
3312597|NCT00294918|Experimental|Serostim® (1 mg)|
3312598|NCT00294918|Experimental|Serostim® (2 mg)|
3312599|NCT00294918|Experimental|Serostim® (4 mg)|
3312600|NCT00294892|Active Comparator|Carbamazepine|An oral dose of 400mg Carbamazepine is added to the 200mg oral dose Nevirapine intake prior delivery
3312601|NCT00294892|Placebo Comparator|Nevirapine|Standard therapy of 200mg Nevirapine oral prior to delivery
3312602|NCT00294866|Active Comparator|A|Receive Paricalcitol
3312603|NCT00294866|No Intervention|B|Paricalcitol on hold
3312604|NCT00294827|Experimental|Liver transplantation|
3312605|NCT00294762|Experimental|Erlotinib|150 mg erlotinib daily
3312606|NCT00294762|Experimental|Erlotinib + chemotherapy (intercalated)|carboplatin AUC 6 on Day 1 to 21 days, paclitaxel 200 mg/m2 on Day 1 to 21 days, erlotinib 150 mg Days 2-15 for 4 cycles then erlotinib 150 mg daily until progression, withdrawal of consent, or unacceptable toxicity
3312607|NCT00294736|Experimental|Arm A|Arm A (Tarceva MTD established in Part I)
3312608|NCT00294736|Experimental|Arm B|Arm B (150 mg Tarceva daily).
3312609|NCT00294723|Experimental|Lira 1.8|Liraglutide 1.8 mg once daily + glimepiride placebo 8 mg once daily, weeks 0-52 (double-blinded period) and open-label liraglutide 1.8 mg once daily in the extension periods (weeks 52-195).
3312610|NCT00294723|Experimental|Lira 1.2|Liraglutide 1.2 mg once daily + glimepiride placebo 8 mg once daily, weeks 0-52 (double-blinded period) and open-label liraglutide 1.2 mg once daily in the extension periods (weeks 52-195).
3312611|NCT00294723|Active Comparator|Glimepiride - 1|Glimepiride 8 mg once daily + liraglutide placebo 200 mcl, weeks 0-52 (double-blinded period) and open-label glimepiride 8 mg once daily in the extension periods (weeks 52-195).
3312612|NCT00294723|Active Comparator|Glimepiride - 2|Glimepiride 8 mg once daily + liraglutide placebo 300 mcl, weeks 0-52 (double-blinded period) and open-label glimepiride 8 mg once daily in the extension periods (weeks 52-195).
3312613|NCT00294684|Experimental|Corticosteroids|
3312614|NCT00294684|Placebo Comparator|Placebo|
3312615|NCT00294671|Active Comparator|Diflunisal|Diflunisal 250 mg po bid
3312616|NCT00294671|Placebo Comparator|Placebo|Placebo 1 po bid
3312617|NCT00294658|Active Comparator|Thymectomy plus prednisone|Procedure: Extended Transsternal Thymectomy plus prednisone treatment
3312618|NCT00294658|Placebo Comparator|Prednisone alone|Drug: prednisone alone protocol
3312619|NCT00294645|Active Comparator|Control|Transtelephonic monitoring at 2 month intervals
3312620|NCT00294645|Active Comparator|Remote|Medtronic CareLink® Network remote pacemaker interrogation at 3 month intervals
3312621|NCT00294632|Experimental|Lenalidomide + Rituximab|Lenalidomide Starting Dose 10 mg oral daily on Days 1-21 + Rituximab 375 mg/m^2 intravenous weekly for 4 weeks
3312622|NCT00294619|Experimental|LB03002|
3312623|NCT00294619|Placebo Comparator|Placebo|
3312624|NCT00294567|Active Comparator|1|Amlodipine
3312625|NCT00294567|Active Comparator|2|Azelnidipine
3312626|NCT00294554|Active Comparator|Active Memantine|Memantine tablets, formulated in appearance to match the placebo comparator, were initiated at 5 mg daily and advanced by 5mg /week to 20 mg/week by week 4 with dosing at 10 mg bid over the remaining 20 weeks of the trial. Over the 6 month duration of the trial, dosage could be titrated downward in increments of 5 mg to a minimum dose of 5mg/day in the event of intolerance.
3312627|NCT00294554|Placebo Comparator|Placebo Oral Tablet|Placebo tablets were formulated to match active 5mg memantine tablets. Dosing same as the active comparator with initiation at 5 mg daily and advancing by 5mg /week to 20 mg/week by week 4 with dosing at 10 mg bid over the remaining 20 weeks of the trial. Over the 6 month duration of the trial, dosage could be titrated downward in increments of 5 mg to a minimum dose of 5mg/day in the event of intolerance.
3312628|NCT00294515|Experimental|Valganciclovir up to 100 days|Valganciclovir for up to 100 days post kidney transplant
3312629|NCT00294515|Active Comparator|Valganciclovir up to 200 days|Valganciclovir for up to 200 days post kidney transplant
3312630|NCT00294437|Experimental|zoledronic acid|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
3312631|NCT00294437|No Intervention|no intervention|no reference therapy
3312632|NCT00294398|Other|Standard Asthma ED Discharge Therapy|Standard asthma therapy including oral corticosteroids, albuterol, education and discharge instructions.
3312633|NCT00294398|Experimental|ICS Prescription + Standard Asthma ED Discharge Therapy|"Subjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age:~1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily"
3312634|NCT00294385|Active Comparator|Gemcitabine, Docetaxel|Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
3312635|NCT00294385|Active Comparator|Docetaxel|Arm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
3312636|NCT00294320|Experimental|1|250mg of Imiquimod cream application once daily 3 times per week.
3312637|NCT00294320|Placebo Comparator|2|250mg vehicle cream for application once daily 3 times per week.
3312638|NCT00294307||Advanced Practice Nurse Care (APNC)|Hospital to Home
3312639|NCT00294307||Augmented Standard Care (ASC)|Hospital only
3312640|NCT00294307||Resource Nurse Care (RNC)|Hospital only
3312641|NCT00294281|Experimental|1|Participants will undergo surgical implantation of the VNS system. This will be followed by a 2-week recovery period, then a 2-week period of gradually increasing the electrical output of the VNS system, and finally a 12-week VNS treatment period during which the electrical output level will remain constant. Follow-up will occur until Month 24.
3312642|NCT00294268|Other|1|20 weekly sessions of CBT integrated with motivational enhancement strategies
3312643|NCT00294255|Experimental|Risperidone|patients will receive risperidone for up to 20 weeks
3312644|NCT00294203|Active Comparator|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
3312645|NCT00294203|Placebo Comparator|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
3312646|NCT00294190|Experimental|Topotecan|
3312647|NCT00294164|Experimental|Serostim® 4 mg daily|
3312648|NCT00294164|Experimental|Serostim® 4 mg alternate days|
3312649|NCT00294164|Placebo Comparator|Placebo|
3312650|NCT00294125|Experimental|1|Participants will receive daily flavocoxid for 12 weeks.
3312651|NCT00294125|Placebo Comparator|2|Participants will receive placebo for 12 weeks.
3312652|NCT00294112|Experimental|1|High dose (8 million cells per kg of body weight)
3319845|NCT00180219||3|40 to 42 years
3312654|NCT00294099|Experimental|2|120 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
3312655|NCT00294099|Experimental|3|60 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
3312656|NCT00294099|Experimental|4|60 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
3312657|NCT00294099|Experimental|8|60 subjects to receive 3.75 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
3312658|NCT00294099|Experimental|7|60 subjects to receive 3.75 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
3312659|NCT00294099|Experimental|1|120 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
3312660|NCT00294099|Experimental|5|60 subjects to receive 7.5 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
3312661|NCT00294099|Experimental|6|60 subjects to receive 7.5 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
3312662|NCT00294047|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
3312663|NCT00294047|Placebo Comparator|Aluminium Hydroxide Group|Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
3312664|NCT00294008||001|Risperdal Consta flexible dosage for 24 months
3312665|NCT00293956||1|Full-term and near-term infants with respiratory distress in the first 24 hours of life
3312666|NCT00293826|Experimental|1|196 subjects
3312667|NCT00293826|Experimental|3|196 subjects
3312668|NCT00293826|Experimental|2|196 subjects
3312669|NCT00293826|Placebo Comparator|4|196 subjects
3312670|NCT00293813|Placebo Comparator|3|Placebo for denosumab and placebo for alendronate
3312671|NCT00293813|Experimental|1|denosumab and placebo for alendronate
3312672|NCT00293813|Active Comparator|2|Placebo for denosumab and alendronate
3312673|NCT00293800|Experimental|Travoprost/Timolol|One drop Travoprost 0.004%/Timolol 0.5% in the study eye(s) each morning at 8 a.m. and one drop Timolol vehicle in the study eye(s) each evening at 8 p.m. for 3 months
3312674|NCT00293800|Active Comparator|Xalatan + Timolol 0.5%|One drop Timolol 0.5% in the study eye(s) each morning at 8 a.m. and one drop Xalatan in the study eye(s) each evening at 8 p.m. for 3 months
3312675|NCT00293787|Experimental|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5% in both eyes each morning at 8 a.m. and Timolol vehicle in both eyes each evening at 8 p.m. for 3 months
3312676|NCT00293787|Active Comparator|Xalatan + Timolol 0.5%|Timolol 0.5% in both eyes each morning at 8 a.m. and Xalatan in both eyes each evening at 8 p.m. for 3 months
3312677|NCT00293774||Standard|Standard hip replacement subjects (polyethylene)
3312678|NCT00293774||Alternative Bearing|Subjects with ceramic on ceramic total hip replacement or metal on metal hip resurfacing.
3312679|NCT00293761|Experimental|Travatan, Investigational|
3312680|NCT00293761|Active Comparator|Travatan|
3312681|NCT00293735|Active Comparator|1. Labetolol|
3312682|NCT00293735|Active Comparator|2. Magnesium Sulfate|
3312683|NCT00293722||Patients with Psoriatic Arthritis|
3312684|NCT00293709||Patients with Psoriatic Arthritis|
3312685|NCT00293644|Experimental|Pre-emptive Treatment Group|As soon as a patient becomes aware of the pregnancy, and before the Nausea and Vomiting of Pregnancy (NVP) starts, she will begin taking Diclectin®. When NVP starts, the dose will be adjusted to match symptoms.
3312686|NCT00293644|Active Comparator|Standard Treatment Group|Women randomised to this arm will not receive any Diclectin® before symptoms appear, and will be advised to commence treatment only at first sign of nausea. The starting dose of Diclectin® will be 20mg (2 tablets) at bedtime.
3312687|NCT00293644|No Intervention|Natural Course Group|A third group will be randomly matched from Motherisk NVP callers who did not participate in our pre-emptive intervention and experienced severe Nausea and Vomiting of Pregnancy/Hyperemesis Gravidarum (NVP/HG) in their previous pregnancy. This group will serve as a control group for the potential effect of the early counselling. (These women will have called for the first time after NVP symptoms (of any degree) started in the current pregnancy).
3312688|NCT00293618|Experimental|Intervention|Arm of anesthesiologists and senior residents who receive a patient's individual predicted PONV risk intraoperatively
3312689|NCT00293618|Active Comparator|Usual Care|Anesthesiologists and senior residents who provide usual care: they provide PONV prophylaxis as they always have
3312690|NCT00293605||1|C-stem implant
3312691|NCT00293605||2|Charnley Implant
3312692|NCT00293605||3|Exeter Implant
3312693|NCT00293592|Active Comparator|Dexamethasone|
3312694|NCT00293592|Placebo Comparator|Placebo|
3312695|NCT00293579|Experimental|Pemetrexed|pemetrexed 500 mg/m2 administered iv, every three weeks, for 6 cycles
3312696|NCT00293540|Active Comparator|A|Surgical oophorectomy in history-estimated mid-luteal phase of menstrual cycle plus Tamoxifen
3312697|NCT00293540|Active Comparator|B|Surgical oophorectomy in history-estimated mid-follicular phase of menstrual cycle plus Tamoxifen
3312698|NCT00293475|Experimental|Treatment (rituximab, mannitol, methotrexate, carboplatin)|Patients receive rituximab IV over 5 hours on day 1, mannitol IA, methotrexate IA over 10 minutes, and carboplatin IA over 10 minutes on days 2 and 3. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats monthly for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3312699|NCT00293462|Active Comparator|Arm I: GM-CSF Group (GG)|Arm I: Patients were randomized to receive oral sargramostim (GM-CSF) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving GM-CSF treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
3312700|NCT00293462|Active Comparator|Arm II: Salt & Soda Group (SS)|Arm II: Patients were randomized to receive salt and soda (SS) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving SS treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
3312748|NCT00292474|Placebo Comparator|Express Bare|
3312701|NCT00293462|Active Comparator|Arm III: Salt & Soda Switched to GM-CSF (SG)|Arm III: Patients were randomized to receive oral salt and soda (SS) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving GM-CSF treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
3312702|NCT00293423|Experimental|Vaccine with Chemotherapy|Single-arm,(HSPPC-96) administered in combination with temozolomide following standard treatment with radiation and temozolomide.
3312703|NCT00293397|Experimental|Drug-eluting bead transarterial chemoembolization (DEB-TACE)|Patients undergo DEB-TACE procedures utilizing LC Beads, polyvinyl alcohol microspheres with diameters of 100-300um or 300-500um, which are loaded with 100mg of doxorubicin hydrochloride and mixed with an equal volume of nonionic contrast media.
3312704|NCT00293384|Experimental|Aprepitant, Dexamethasone, Cytoxan & Kytril|"Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally, 1 hour prior to cyclophosphamide administration.~Cyclophosphamide 4gm/m2 I.V. over 90 - 120 minutes.~Days 2 & 3: Aprepitant 80 mg once daily in the morning."
3312705|NCT00293345|Experimental|Treatment (gemcitabine hydrochloride, triapine)|Patients receive 3-AP (TriapineÃÂ®) IV over 24 hours followed by gemcitabine hydrochloride IV over 100-125 minutes on days 1 and 8. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
3312706|NCT00293293|Active Comparator|Chemotherapy Alone|Patients receiving 6 cycles of taxane and platinum therapy for ovarian, fallopian tube or primary peritoneal cancer by their treating physician. Chemotherapy administration is not administered as part of this protocol.
3312707|NCT00293293|Experimental|Standard Chemotherapy + CAM|Patients receiving 6 cycles of taxane and platinum therapy for ovarian, fallopian tube or peritoneal cancer with additional complementary alternative medicine - CAM (healing touch, hypnosis and massage therapy). Chemotherapy administration is not administered as part of this protocol.
3312708|NCT00293267|Experimental|1|raltegravir potassium
3312709|NCT00293267|Placebo Comparator|2|Placebo
3312710|NCT00293254|Experimental|1|raltegravir potassium
3312711|NCT00293254|Placebo Comparator|2|Placebo
3312712|NCT00293241|Other|MVP ON|Managed Ventricular Pacing programmed on
3312713|NCT00293241|Other|MVP OFF|Managed Ventricular Pacing programmed off: conventional pacing
3312714|NCT00293228|Experimental|A|Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment.
3312715|NCT00293228|Active Comparator|B|B. Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.
3312716|NCT00293228|Experimental|C|C. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment
3312717|NCT00293228|Active Comparator|D|D. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.
3312718|NCT00293202|Active Comparator|A|Etanercept 25 mg injection twice a week
3312719|NCT00293202|Placebo Comparator|B|Saline injection twice a week
3312720|NCT00293176|Experimental|1|
3312721|NCT00293176|Placebo Comparator|2|
3312722|NCT00293150|Active Comparator|Eplerenone|Eplerenone 25mg daily for 2 weeks Titrated to Eplerenone 50mg daily
3312723|NCT00293150|Placebo Comparator|Placebo|Placebo dosed daily
3312724|NCT00293137||1|Patients enrolled into the trial must have left ventricular ejection fraction of <40% by echocardiogram within 6 months of enrollment
3312725|NCT00293085|Active Comparator|Docetaxel|"Docetaxel (Taxotere ) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
3312726|NCT00293085|No Intervention|Comparative arm|No chemotherapy will be administered. No specific salvage therapy after progression is defined.
3312727|NCT00293059|Experimental|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|A blister card consists of 28 pills taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo
3312728|NCT00293059|Placebo Comparator|Placebo|Matching placebo to be taken orally daily
3312729|NCT00293020|Experimental|1|BEMA Fentanyl
3312730|NCT00292981|Experimental|C1 Esterase Inhibitor|
3312731|NCT00292903|Experimental|A|
3312732|NCT00292903|Active Comparator|B|
3312733|NCT00292747|Experimental|drotaverine + Ibuprofen placebo|Drotaverine 80 mg plus ibuprofen placebo orally
3312734|NCT00292747|Active Comparator|Drotaverine placebo + ibuprofen|Drotaverine placebo plus ibuprofen 400 mg orally
3312735|NCT00292747|Active Comparator|Drotaverine + ibuprofen|Drotaverine 80 mg plus ibuprofen 400 mg orally
3312736|NCT00292721|No Intervention|Control|
3312737|NCT00292721|Active Comparator|Celecoxib|
3312738|NCT00292695|Experimental|chemoradiation|Chemoradiation: IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1
3312739|NCT00292591|Active Comparator|cholecalciferol-400 IU|Control group receiving 400 IU/day plus 0 IU vitamin D3 as placebo/day
3312740|NCT00292591|Experimental|cholecalciferol 2000 IU|Experimental group receiving 2000 IU total vitamin D3/day.
3312741|NCT00292591|Experimental|cholecalciferol 4000 IU|Experimental group receiving 4000 IU/day cholecalciferol
3312742|NCT00292552||COPD subjects|Subjects with GOLD stage II-IV COPD
3312743|NCT00292552||Smoker controls|Subjects with smoking history but normal lung function
3312744|NCT00292552||Non-smoker controls|Normal healthy non-smokers
3312745|NCT00292526|Experimental|enalapril arm|treatment with enalapril
3312746|NCT00292500|No Intervention|C-Port|Automated distal anastomotic device
3312747|NCT00292474|Experimental|TAXUS Express|
3312749|NCT00292461|Active Comparator|zonisamide|tablet
3312750|NCT00292461|Active Comparator|lamotrigine|tablet
3312751|NCT00292396|Active Comparator|1|Anti IL-12 monoclonal antibody/ABT-874, up to 12 weeks, 200 mg every week for 12 weeks
3312752|NCT00292396|Active Comparator|2|Anti IL-12 monoclonal antibody/ABT-874, 200 mg QOW for 12 weeks
3312753|NCT00292396|Active Comparator|3|Anti IL-12 monoclonal antibody/ABT-874, 100 mg QOW in 12 weeks
3312754|NCT00292396|Active Comparator|4|Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 4 doses in 12 weeks
3312755|NCT00292396|Active Comparator|5|Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 1 dose in 12 weeks
3312756|NCT00292396|Placebo Comparator|6|placebo, 12 doses
3312757|NCT00292370|Other|Arm 1: Open Label (OL) Paroxetine|Open-label Paroxetine In Phase I, eligible participants will take open-label (OL) Paroxetine (up to 60 mg) daily for 8 weeks. Participants who are refractory (less than 30% reduction in CAPS scores or a minimum CAPS of 50 at week 8) and have PTSD symptoms of at least moderate severity on CGI-S will be eligible for Phase II.
3312758|NCT00292370|Placebo Comparator|Arm 2 OL Paroxetine + DB Placebo|In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of placebo for 8 weeks in a double-blind (DB) fashion.
3312759|NCT00292370|Experimental|Arm 3: OL Paroxetine + DB Quetiapine|In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of quetiapine (up to 800 mg daily) for 8 weeks in a double blind fashion.
3312760|NCT00292318|Active Comparator|Arm 1|Control group of patients with fecal incontinence which would be given medical therapy and exercises to perform as treatment.
3312761|NCT00292318|Experimental|Arm 2|Study group of patients with fecal incontinence which would be given biofeedback therapy and exercises to perform as treatment.
3312762|NCT00292305|Experimental|T-crush stenting|Percutaneous coronary intervention with implantation of a stent
3312763|NCT00292305|Active Comparator|Culotte stenting|Percutaneous coronary intervention with stent
3312764|NCT00292292|Experimental|Kineflex Lumbar Artificial Disc|Treatment arm
3312765|NCT00292292|Active Comparator|Charite|
3312766|NCT00292279|Experimental|A|
3312767|NCT00292279|Active Comparator|B|
3312768|NCT00292266|Experimental|Rebif®|
3312769|NCT00292266|Active Comparator|Avonex®|
3312770|NCT00292253|Experimental|Rebif® with Rebiject™Mini|
3312771|NCT00292253|Active Comparator|Rebif® without Rebiject™Mini|
3312772|NCT00292227|Experimental|Rotigotine|Rotigotine Patch
3312773|NCT00292227|Placebo Comparator|Placebo|Placebo patch
3312774|NCT00292201|Experimental|1|Atorvastatin
3312775|NCT00292201|Placebo Comparator|2|Placebo Pill
3312776|NCT00292188|Experimental|Active|
3312777|NCT00292188|Placebo Comparator|Placebo|
3312778|NCT00292162|Active Comparator|medical therapy|Standard therapy for heart failure with angiotensin converting enzyme inhibitors(ACE) - (Ramipril, enalapril, lisinopril, captopril, perindopril), beta-blocker (BB) - (carvedilol, bisoprolol, metoprolol), Aldosterone antagonists (spironolactone) +/- diuretics and digoxin
3312779|NCT00292162|Active Comparator|Radiofrequency ablation (RFA)|Isolation of the pulmonary veins using radiofrequency ablation
3312780|NCT00292110|Experimental|Arm One|
3312781|NCT00292110|Active Comparator|ArmTwo|
3312782|NCT00292110|Active Comparator|Arm Three|
3312783|NCT00292110|Active Comparator|Arm Four|
3312784|NCT00292097|Experimental|1|Early conversion from endotracheal intubation to percutaneous tracheostomy for ventilator support of trauma patients with severe brain injury
3312785|NCT00292097|Active Comparator|2|Conventional conversion from endotracheal intubation to percutaneous tracheostomy for ventilator support of trauma patients with severe brain injury
3312786|NCT00292071|Other|1|IV caspofungin acetate (50 mg/m²/day)
3312787|NCT00292071|Other|2|IV caspofungin acetate (70 mg/m²/day)
3312788|NCT00292032||Cardiac Arrest Survivors or Post Mortem Unexplained Cardiac|Probands - Unexplained Cardiac Arrest Survivors and Post Mortem Unexplained Cardiac Arrest Cases
3312789|NCT00292032||First Degree Family Members|First Degree Family Members of those affected by Sudden Unexplained Cardiac Arrest
3312790|NCT00292019||Robotic prostatectomy|Patients who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robotics.
3312791|NCT00291980|Experimental|1|HB-AS02V vaccine
3312792|NCT00291980|Active Comparator|2|HBVAXPRO vaccine
3312793|NCT00291954|Experimental|1|Henogen hepatitis B vaccine
3312794|NCT00291954|Active Comparator|2|HBVAXPRO hepatitis B vaccine
3312795|NCT00291941|Experimental|1|Henogen HB vaccine
3312796|NCT00291941|Active Comparator|2|Fendrix vaccine
3312797|NCT00291928|Placebo Comparator|Dose ranging|A double-blind, placebo controlled, dose escalation part randomized within each of 3 sequential cohorts (Part A),
3312798|NCT00291928|Placebo Comparator|Parallel Arm RCT|a parallel group part with randomization into one of 4 treatment arms (Part B).
3312799|NCT00291876|Experimental|Havrix Group|Subjects who received during the primary study 2 doses of Havrix™ at Day 0 and at Month 12.
3312800|NCT00291733|Active Comparator|1|500mg levetiracetam for one week and 1000mg levetiracetam for one week
3312801|NCT00291733|Placebo Comparator|2|placebo
3312802|NCT00291733|Active Comparator|3|After crossover arm 3 equals arm 1
3312803|NCT00291733|Placebo Comparator|4|After crossover arm 4 equals arm 2
3312804|NCT00291720|Active Comparator|Spironolactone|25mg spironolactone daily
3312805|NCT00291720|Placebo Comparator|Placebo|matching placebo medication for the control group
3312806|NCT00291694|Active Comparator|1|Oral Celecoxib 400 mg twice daily for 12 months
3312807|NCT00291694|Placebo Comparator|2|Matched blinded placebo twice daily for 12 months
3312808|NCT00291668|Experimental|Certolizumab pegol 200 mg|Subjects received one subcutaneous (sc) injection of 200 mg CZP and one injection of Placebo to maintain the study blind on Weeks 0 (first dose), 2 and 4.
3312809|NCT00291668|Experimental|Certolizumab pegol 400 mg|Subjects received two subcutaneous (sc) injections of 200 mg CZP on Weeks 0 (first dose), 2 and 4.
3313029|NCT00288795|Other|3|Polarity Treatment
3312810|NCT00291668|Placebo Comparator|Placebo|Subjects received two subcutaneous (sc) injections of Placebo on Weeks 0 (first dose), 2 and 4.
3312811|NCT00291655|Experimental|Levetiracetam (LEV)|
3312812|NCT00291642|Placebo Comparator|Placebo (PBO)|A single dose of placebo was administered orally on Day 1.
3312813|NCT00291642|Experimental|Levocetirizine (LCTZ) 2.5 mg|A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.
3312814|NCT00291642|Experimental|Levocetirizine (LCTZ) 5 mg|A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.
3312815|NCT00291642|Experimental|Cetirizine (CTZ) 5 mg|A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.
3312816|NCT00291642|Experimental|Cetirizine (CTZ) 10 mg|A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.
3312817|NCT00291616|Active Comparator|1|Pegylated Interferon-alpha2a
3312818|NCT00291616|Active Comparator|2|Thymosin alpha1 & Pegylated Interferon-alpha2a
3312819|NCT00291577|Experimental|1|
3312820|NCT00291525|Experimental|AVR Low Risk without warfarin|AVR Low Risk without warfarin
3312821|NCT00291525|Active Comparator|AVR low risk with standard warfarin|AVR low risk with standard warfarin
3312822|NCT00291525|Experimental|AVR High risk with lower warfarin|AVR High risk with lower warfarin
3312823|NCT00291525|Active Comparator|AVR High Risk with standard warfarin|AVR High Risk with standard warfarin
3312824|NCT00291525|Experimental|MVR with lower warfarin|MVR with lower warfarin
3312825|NCT00291525|Active Comparator|MVR with standard warfarin|MVR with standard warfarin
3312826|NCT00291499|Active Comparator|Chondroitin 4&6 sulfate (Condrosulf)|
3312827|NCT00291499|Placebo Comparator|placebo|
3312828|NCT00291486|Experimental|Assigned Dose Level|
3312829|NCT00291343|Experimental|TRITANRIX™-HEPB/HIB-MENAC +MENCEVAX™ ACWY GROUP|Subjects previously primed with 3 doses of Tritanrix™-HepB/Hib-MenAC vaccine in study NCT00290303, were administered in the current study one booster dose of Tritanrix™-HepB/Hiberix™, intramuscularly in the left anterolateral thigh, at 15-24 months of age and one booster dose of Mencevax™ ACWY by subcutaneous injection in the upper region of the left arm, at 24-30 months of age.
3312830|NCT00291343|Active Comparator|TRITANRIX™-HEPB/HIBERIX™+MENCEVAX™ ACWY GROUP|Subjects previously primed with 3 doses Tritanrix™-HepB/Hiberix™ vaccine in study NCT00290303, were administered in the current study one booster dose of Tritanrix™-HepB/Hiberix™, intramuscularly in the left anterolateral thigh, at 15-24 months of age and one dose of Mencevax™ ACWY by subcutaneous injection in the upper region of the left arm, at 24-30 months of age.
3312831|NCT00291330|Experimental|dabigatran etexilate 150 mg|twice daily
3312832|NCT00291330|Active Comparator|warfarin (INR 2-3)|prn to maintain INR (2-3)
3312833|NCT00291317|Experimental|RT 300-P FES Cycle|Participants exercised using functional electrical stimulation cycling (FES) using the RT 300-P FES cycle (Restorative Therapies, Baltimore, MD).
3312834|NCT00291226|Experimental|Glycine|Glycine dosing was fixed at an initial dose of 0.2 g/kg q.h.s for 3 days, then 0.2 g/kg b.i.d. for 4 days, then 0.2 g/kg in the a.m. and 0.4 g/kg in the p.m. for 4 days, and finally 0.4 g/kg b.i.d. Subjects weighing > 100 kg were limited to a total daily dose of 80 g daily. Glycine was dispensed under IND 33,515 (DCJ).
3312835|NCT00291226|Placebo Comparator|Placebo Group|Placebo was dispensed as a proprietary formulations developed by Glytech, Inc, consisting of microencapsulated sucrose. Recommended administration of the sprinkles was to spoon them onto pudding or applesauce and swallow them with minimal chewing. Since earlier product testing by Glytech revealed that a few individuals did not like the somewhat granular texture of the sprinkles, subjects could switch to a second Glytech placebo formulation, consisting of proprietary pre-flavored sugar powders to be dissolved in 8 ounces of water.
3312836|NCT00291213|Experimental|Levetiracetram Administration|
3312837|NCT00291213|Placebo Comparator|Placebo|
3312838|NCT00291200||1|Participants with basic symptoms of psychosis
3312839|NCT00291200||2|Control participants
3312840|NCT00291187|Placebo Comparator|Placebo|Take orally 30 minutes prior to bedtime.
3312841|NCT00291187|Experimental|20 mg VEC-162|20 mg taken orally 30 minutes prior to bedtime.
3312842|NCT00291187|Experimental|50 mg VEC-162|50 mg taken orally 30 minutes prior to bedtime.
3312843|NCT00291187|Experimental|100 mg VEC-162|100 mg taken orally 30 minutes prior to bedtime.
3312844|NCT00291161|Experimental|Partners in Dementia Care|"PDC is telephone-based care consultation intervention jointly delivered by care consultants in the VA and local Alzheimer's Association. The steps in care consultation included 1) Assessment of medical and non-medical care needs; 2) Development of a care plan that addresses needs of patients and caregivers; 3) on-going monitoring of the status, progress, and barriers encountered; and 4) Reassessment of care needs for patients and caregivers.~PDC assisted families by: 1) providing disease-related education and information, 2) offering emotional support and coaching, 3) linking families to medical and non-medical services and resources, and 4) mobilizing and organizing the informal care network."
3312845|NCT00291161|No Intervention|Usual Care|Patients and caregivers at the three control VA settings were given a packet of educational materials on dementia and usual-care community resources.
3312846|NCT00291148|Active Comparator|Paroxetine|
3312847|NCT00291148|Active Comparator|pregabalin|
3312848|NCT00291135|Experimental|1|Oral Letrozole 2.5 mg daily for six months
3312849|NCT00291057|Experimental|1|MALG
3312850|NCT00291031|Experimental|IRT|Patients randomly assigned to the IRT condition receive Imagery Rehearsal Therapy after 4 weeks since the entrance into the trial next to their treatment as usual.
3312851|NCT00291031|No Intervention|TAU|Patients that are randomly assigned to the waiting list control condition get treatment as usual (TAU) and complete the daily nightmare logs for a period of three months. These patients get the IRT intervention after waiting for 6 months.
3312852|NCT00291018|Experimental|ProDisc-C|ProDisc-C total disc replacement device intended to treat single level SCDD in the cervical spine from C3-C7
3312853|NCT00291018|Active Comparator|Control|ACDF
3312854|NCT00290888|Active Comparator|ACR|Arthroscopic rotator cuff repair without acromioplasty
3312855|NCT00290888|Experimental|ACR-A|Arthorscopic rotator cuff repair with acromioplasty
3313030|NCT00288769|Other|2|
3313031|NCT00288730|Experimental|001|nesiritide
3312856|NCT00290875|Other|Arm 1|We randomly allocated sites to either intervention or control. At the intervention sites, active strategies were employed to implement the rule into practice, including education, policy, and real-time reminders on radiology requisitions.
3312857|NCT00290862|Experimental|CORTOSS|Patients prospectively randomized to be treated with Cortoss constitute treatment group.
3312858|NCT00290862|Active Comparator|PMMA|Patients prospectively randomized to be treated with PMMA constitute active control group.
3312859|NCT00290823|Experimental|1|Participants will receive 6 mg dexamethasone daily for 10 days Participants will also receive albendazole and omeprazole.
3312860|NCT00290823|Experimental|2|Participants will receive 6 mg dexamethasone daily for 10 days, then 8 mg dexamethasone daily for 4 weeks with a 2-week taper. Participants will also receive albendazole and omeprazole.
3312861|NCT00290810|Experimental|Treatment (monoclonal antibody therapy)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3312862|NCT00290771|Experimental|Imatinib 600 mg + hydroxyurea 1000 mg|Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.
3312863|NCT00290771|Experimental|Imatinib 1000 mg + hydroxyurea 1000 mg|Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.
3312864|NCT00290758|Experimental|Arm I (genistein)|Patients receive oral genistein once daily for up to 6 months.
3312865|NCT00290758|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily for up to 6 months.
3312866|NCT00290745|Active Comparator|tamoxifen or letrozole|tamoxifen or letrozole work in treating women with ductal carcinoma in situ
3312867|NCT00290732|Experimental|Intraductal arm|Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.
3312868|NCT00290732|Active Comparator|Intravenous arm|Participants receiving standard intravenous administration of pegylated liposomal doxorubicin prior to breast biopsy for drug concentrations.
3312869|NCT00290706|Experimental|Gemcitabine 800 mg/m2 + Bortezomib IVP over 3-5 seconds|Gemcitabine dose of 800 mg/m2 over 30 minutes followed by Bortezomib IVP given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
3312870|NCT00290693|Experimental|CapTere (Capecitabine + Docetaxel)|Capecitabine + Docetaxel (Taxotere)
3312871|NCT00290667|Active Comparator|Interventional: CHOP-14 + 8 x 2-weekly rituximab|Arm I (2-weekly rituximab): Patients receive rituximab IV 375 mg/m^2 (females) and 500 mg/m^2 (males) over 4 hours on days 0, 14, 28, 42, 56, 70, 84, and 98. Patients also receive pegfilgrastim subcutaneously on day 4 of each course.
3312872|NCT00290667|Active Comparator|Interventional: CHOP-14 + 8 x dose-dense rituximab|Arm II (pharmacokinetic-based dose-dense rituximab): Patients receive rituximab IV 375 mg/m^2 (females) and 500 mg/m^2 (males) over 4 hours on days -1, 0, 3, 7, 14, 21, 28, and 42. Patients also receive pegfilgrastim subcutaneously on day 4 of each course.
3312873|NCT00290654|Experimental|Lumpectomy with Brachytherapy|Patients with ductal carcinoma in situ (DCIS, a non-invasive form of breast cancer) treated with standard lumpectomy/brachytherapy following by radiation using the MammoSite (FDA approved a balloon-catheter device placed in the lumpectomy cavity through which high dose radiation is delivered). Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient.
3312874|NCT00290615|Experimental|Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab|"Capecitabine - oral administration of 850 mg/m2 every 12 hours on days 1-14. Oxaliplatin - IV administration of 130 mg/m2 over 2 hours on day 1 of a cycle. Bevacizumab- IV administration of 7.5 mg/kg over 30-90 minutes on day 1 of a cycle.~Cetuximab at an initial dose of 400 mg/m2 over 120 minutes and subsequently 250 mg/m2 over 60 minutes on day 1 of a cycle.~Cycles are 21 days."
3312875|NCT00290550|Other|1|MK-0457
3312876|NCT00290537|Experimental|Part One: ZD6474|First part of two part treatment, Part One: three 3-week cycles 300 mg of ZD6474 daily. Second part, Part Two: participants randomized to receive 300 mg of ZD6474 daily, or 100 mg of ZD6474 daily plus carboplatin AUC 6.0 intravenous (IV) over 15-30 minutes and paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 every 3 weeks.
3312877|NCT00290537|Experimental|Part Two A: ZD6474 300 mg|Second part of study where participants randomized to receive 300 mg of ZD6474 daily (group A)
3312878|NCT00290537|Experimental|Part Two B: ZD6474 100 mg + Carboplatin + Paclitaxel|Second part of study where participants randomized to receive 100 mg of ZD6474 daily plus carboplatin AUC 6.0 IV over 15-30 minutes and paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 every 3 weeks (group B).
3312879|NCT00290511|Experimental|R-FIND + Zevalin|Fludarabine 25 mg/m^2 intravenous (IV) over 5-30 minutes on Days 2-4. Mitoxantrone 10 mg/m^2 IV over 5-30 minutes on Day 2. Rituximab 375 mg/m^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total). Zevalin 0.3 mCi/kg IV after 4 cycles of R-FND. Dexamethasone 20 mg by mouth (PO) or IV daily on Days 2-6.
3312880|NCT00290498|Experimental|Arm A|R-HCVAD + R-MTX/Ara-C ((Rituximab-HCVAD (rituximab, doxorubicin, cyclophosphamide, vincristine, and dexamethasone) alternating with Rituximab-Methotrexate-Cytarabine))
3312881|NCT00290498|Active Comparator|Arm B|"R-CHOP ((Rituximab-CHOP (Rituximab, cyclophosphamide, vincristine, and prednisone))~No longer recruiting for this study arm."
3312882|NCT00290472|Experimental|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 8 weeks.
3312883|NCT00290433|Experimental|HCVIDDOXIL Regimen|"Cycle 1: Cyclophosphamide by vein two times a day on Days 1,2, and 3. Mesna by vein nonstop over Days 1 through 3. Pegylated liposomal doxorubicin by vein over 1 hour on Day 2. Vincristine by vein on Days 4 and 11. Dexamethasone by mouth on Days 1 through 4 and 11 through 14.~Cycle 2: Methotrexate by vein over 2 hours on Day 1 and over 22 hours on day 1. Cytarabine by vein twice a day on Days 2 and 3."
3312884|NCT00290420|Experimental|Chloroquine profilaxis|"Prevention: chloroquine profilaxis~Prevention of malaria attacks with chloroquine profilaxis taken once a week"
3312885|NCT00290420|No Intervention|No prevention|Treatment of malaria attack with chloroquine when they occur
3312886|NCT00290355|Experimental|Vaccine Group|
3312887|NCT00290355|Placebo Comparator|Placebo Group|
3312888|NCT00290342|Experimental|Group A|
3312889|NCT00290342|Active Comparator|Group B|
3312890|NCT00290329|Experimental|Group A|
3312891|NCT00290290|Active Comparator|povidone-iodine|preoperative skin preparation with povidone-iodine
3312892|NCT00290290|Experimental|chlorhexidine-alcohol|preoperative skin preparation with scrub and paint technique
3312893|NCT00290251|Active Comparator|ulipristal acetate -20 mg|20 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days in each study phase
3312894|NCT00290251|Active Comparator|ulipristal acetate - 10 mg|10 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days in each study phase
3312895|NCT00290251|Placebo Comparator|Placebo|Placebo taken daily for three menstrual cycles or up to 102 days in each study phase
3312896|NCT00290238|Experimental|PNT|
3312897|NCT00290238|Sham Comparator|TENS|
3312898|NCT00290199|Experimental|Transcervical Foley Catheter|
3312899|NCT00290199|No Intervention|No Foley|
3312900|NCT00290186|Experimental|Hyperbaric Oxygen Treatment (HBO)|100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
3312901|NCT00290186|Active Comparator|Hyperbaric Air Treatment (HBA)|14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
3312902|NCT00290147|Experimental|1.0 mg of D1ME100 vaccine|1.0 mg dose of DME100 vaccine delivered by Biojector IM injections at 0, 1 and 5 months
3312903|NCT00290147|Experimental|5.0 mg of D1ME100 vaccine|5.0 mg dose of DME100 vaccine delivered by Biojector IM injections at 0, 1 and 5 months
3312904|NCT00290121|Active Comparator|Olanzapine|
3312905|NCT00290082|Active Comparator|loxapine|agitated patients were randomly assigned either to loxapine, either to midazolam group
3312906|NCT00290082|Active Comparator|midazolam|midazolam is compared to loxapine in terms of efficacy and tolerance
3312907|NCT00289991|Active Comparator|Itraconazole|
3312908|NCT00289991|Experimental|Voriconazole|
3312909|NCT00289978|Experimental|Fingolimod 1.25 mg|
3312910|NCT00289978|Experimental|Fingolimod 0.5 mg|
3312911|NCT00289978|Placebo Comparator|Placebo|
3312912|NCT00289965|Active Comparator|1|in-person brief motivational intervention
3312913|NCT00289965|Active Comparator|2|Alcohol 101plus
3312914|NCT00289965|Active Comparator|3|AlcoholEdu (a Web-based tutorial).
3312915|NCT00289952|Experimental|Group 1|HAART + valproic acid for 16 weeks followed by HAART alone for 32 weeks.
3312916|NCT00289952|Experimental|Group 2|HAART alone for 16 weeks followed by HAART + valproic acid for 32 weeks.
3312917|NCT00289926|Experimental|dehydroepiandrosterone|50.0mg dehydroepiandrosterone capsule, by mouth, daily for 12 months
3312918|NCT00289926|Placebo Comparator|Placebo|Placebo capsule consists of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF manufactured to mimic dehydroepiandrosterone capsule
3312919|NCT00289913|Experimental|VAQTA™, PedvaxHIB™ and Infanrix™/VAQTA™ (Stage 1)|"Day 1: VAQTA™ (first dose), PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.~Week 24: The second dose of VAQTA™ was administered."
3312920|NCT00289913|Experimental|PedvaxHIB™ and Infanrix™/VAQTA™/VAQTA™ (Stage 1)|"Day 1: PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.~Week 4: The first dose of VAQTA™ was administered.~Week 28: The second dose of VAQTA™ was administered."
3312921|NCT00289913|Experimental|VAQTA™, PedvaxHIB™/VAQTA™ (Stage 1)|"Day 1: VAQTA™ (first dose) and PedvaxHIB™ were administered concomitantly at different injection sites.~Week 24: The second dose of VAQTA™ was administered."
3312922|NCT00289913|Experimental|PedvaxHIB™/VAQTA™/VAQTA™ (Stage 1)|"Day 1: PedvaxHIB™ was administered.~Week 4: The first dose of VAQTA™ was administered.~Week 28: The second dose of VAQTA™ was administered."
3312923|NCT00289913|Experimental|VAQTA™/VAQTA™ (Stage 2)|"Day 1: The first dose of VAQTA™ was administered.~Week 24: The second dose of VAQTA™ was administered."
3312924|NCT00289900|Experimental|MK-0524B 2g/20 mg|Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks
3312925|NCT00289900|Experimental|MK-0524B 2g/40mg|Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks
3312926|NCT00289900|Active Comparator|Atorvastatin 10 mg|Atorvastatin 10 mg, orally, once daily for 12 weeks
3312927|NCT00289900|Active Comparator|Atorvastatin 20 mg|Atorvastatin 20 mg, orally, once daily for 12 weeks
3312928|NCT00289900|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg, orally, once daily for 12 weeks
3312929|NCT00289900|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg, orally, once daily for 12 weeks
3312930|NCT00289887|Experimental|1|Losartan
3312931|NCT00289887|Placebo Comparator|2|Placebo
3312932|NCT00289874|Experimental|1|montelukast
3312933|NCT00289874|Placebo Comparator|2|placebo
3312934|NCT00289861|Active Comparator|risperdone|
3312935|NCT00289861|Placebo Comparator|placebo|
3312936|NCT00289848|Experimental|1|sitagliptin 100 mg
3312937|NCT00289848|Placebo Comparator|2|placebo
3312938|NCT00289835|Experimental|PCI-stenting|Stenting the moderate SVG lesion with the paclitaxel stent
3312939|NCT00289835|Other|Standard medical treatment|
3312940|NCT00289796|Active Comparator|Infanrix hexa Group|Subjects received a dose of hepatitis B vaccine at birth followed by immunization with 3 doses of Infanrix hexa™ (2, 4 and 6 months of age) and one booster dose of Infanrix hexa™ between 12 and 23 months of age. All vaccines were administered by deep intramuscular injection into the left anterolateral thigh.
3313081|NCT00288119||Cases|Patients with Barrett's esophagus undergoing surveillance or patients with esophageal adenocarcinoma and esophagogastric junctional adenocarcinoma undergoing EGD
3312941|NCT00289783|Experimental|Menhibrix A Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot A co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
3312942|NCT00289783|Experimental|Menhibrix B Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot B co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
3312943|NCT00289783|Experimental|Menhibrix C Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot C co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
3312944|NCT00289783|Experimental|Menhibrix Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot A, B or C co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
3312945|NCT00289783|Active Comparator|ActHIB Group|Subjects were primed with 3 doses of ActHIB co-administered with Pediarix and boosted with 1 dose of PedvaxHIB, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. ActHIB, PedvaxHIB vaccines were administered intramuscularly in the right upper thigh and Pediarix vaccine in the left upper thigh. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
3312946|NCT00289770|Experimental|Group A|Was vaccinated with Lot A in the primary study.
3312947|NCT00289770|Experimental|Group B|Was vaccinated with Lot B in the primary study.
3312948|NCT00289770|Experimental|Group C|Was vaccinated with Lot C in the primary study.
3312949|NCT00289757|Experimental|Havrix Group|"Subjects who received 2 doses of Havrix™ (lot A, B or C) in the primary study.~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Havrix Group for data analyses during the long term follow-up."
3312950|NCT00289744|Experimental|Twinrix Group|Subjects who received 2 doses (at Day 0 and Month 6) of Twinrix in the primary study (208127/076)
3312951|NCT00289744|Experimental|Engerix-B Additional Dose (Adult)|Subjects aged 16 years and above who received an additional dose of EngerixTM-B (adult dose).
3312952|NCT00289744|Experimental|Engerix-B Additional Dose (Pediatric)|Subjects under the age of 16 years who received an additional dose of EngerixTM-B (pediatric dose).
3312953|NCT00289731|Experimental|Group A|GSK Biologicals' combined Hepatitis A and B vaccine was administered.
3312954|NCT00289731|Active Comparator|Group B|GSK Biologicals' monovalent hepatitis A and hepatitis B vaccines were administered separately.
3312955|NCT00289731|Active Comparator|Group C|Aventis Pasteur's monovalent hepatitis A and hepatitis B vaccines were administered separately.
3312956|NCT00289718|Experimental|Twinrix Group|"Subjects who received 2 doses of Twinrix™ (lot A, B or C) in the primary study.~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Twinrix Group for data analyses during the long term follow-up."
3312957|NCT00289705|Experimental|Surgery|Laparoscopic gastric bypass
3312958|NCT00289705|No Intervention|2|Traditional treatment for obesity
3312959|NCT00289640|Experimental|1|
3312960|NCT00289640|Experimental|2|
3312961|NCT00289640|Experimental|3|
3312962|NCT00289627|Experimental|ipilimumab (MDX-010, BMS-734016)|
3312963|NCT00289536|Experimental|Low Dose|
3312964|NCT00289536|Experimental|Medium Dose|
3312965|NCT00289536|Experimental|High Dose|
3312966|NCT00289523||Escitalopram|
3312967|NCT00289523||Bupropion XL|
3312968|NCT00289523||Combination Therapy|Escitalopram and Bupropion XL
3312969|NCT00289471||Cognitive Screening|Cognitive screening
3312970|NCT00289458|Experimental|Aquatic Education|Exercise combined with education
3312971|NCT00289458|Experimental|Aquatic|
3312972|NCT00289458|Placebo Comparator|Control|
3312973|NCT00289432|Experimental|1|Behavioral: Psychoeducative intervention
3312974|NCT00289432|Active Comparator|2|The Hospitals standard follow-up support group
3312975|NCT00289419|Active Comparator|A|
3312976|NCT00289419|Experimental|B|
3312977|NCT00289380||Nutrition support|Nutrition support cohort means accept nutrition support，it was defined as ≥15kal/kg/d and < 30kal/kg/d of non-protein calories (carbohydrate and/or fat) and amino acids or protein≥1g/kg/d for 5~28 consecutive days.
3312978|NCT00289380||Without nutritional support|Group received only intravenous 5 to 10% glucose and electrolyte infusions
3312979|NCT00289341|Placebo Comparator|Placebo|12 patients in the placebo Arm for 8 weeks followed by DC/LNCAP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks.
3312980|NCT00289341|Experimental|DC/LNCaP|12 patients, receiving DC/LNCaP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks
3312981|NCT00289315|Experimental|Arm 1|Primary (Environmental) Prevention of Weight Gain
3312982|NCT00289315|Experimental|Arm 2|Primary (Envrironmental) and Secondary (Behavioral) Weight Gain Prevention Program
3312983|NCT00289315|Experimental|Arm 3|Control - no Environmental or Behavioral Program intervention
3312984|NCT00289289|Active Comparator|On-Off|Subjects have intervention pacing features turned On according to randomization assignment in the first crossover period then Off in the second period.
3312985|NCT00289289|Active Comparator|Off-On|Subjects have intervention pacing features turned Off according to the randomization assignment for the first crossover period and then On in the second period.
3312986|NCT00289289|No Intervention|Non-randomized|Subjects that did not have device recorded episodes of atrial tachycardia/atrial fibrillation during the 3 month observation period post-implant did not qualify for randomization but were continued to be followed in the study. There were no programming requirements and symptom activations were not collected.
3312987|NCT00289237|Experimental|High intensity intervention group|"Lifestyle intervention consisted of 15-30 minutes of individual lifestyle counselling + offer of participation in group-based lifestyle counselling (½ year). This offer was given at baseline to all participants in the group.~Persons at high risk of IHD: offer additionally given at 1- and 3-year follow-up"
3312988|NCT00289237|Experimental|Low intensity intervention group|"Lifestyle intervention consisted of 15-30 minutes of individual lifestyle counselling. This offer was given at baseline to all participants in the group.~Persons at high risk of IHD: offer additionally given at 1- and 3-year follow-up"
3312989|NCT00289237|No Intervention|Control group|"Questionnaires regarding lifestyle and general health were sent to all participants in this group.~The importance of healthy lifestyle was not mentioned, and no intervention was offered."
3312990|NCT00289224|Experimental|1|Cholera Vaccine
3312991|NCT00289224|Placebo Comparator|2|Placebo
3312992|NCT00289211|Experimental|C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously (IV). If there was no response to treatment 60 minutes after the first dose, a second 1,000 U dose could be administered.
3312993|NCT00289211|Placebo Comparator|Placebo|Matching placebo (saline) administered IV. If there was no response to treatment 60 minutes after the first dose, a second placebo (saline) dose could be administered.
3312994|NCT00289198|Experimental|Fluticasone furoate|Participants were instructed to administer two sprays into each nostril once daily every morning of fluticasone furoate 110 μg
3312995|NCT00289198|Placebo Comparator|Placebo|Participants were instructed to administer two sprays into each nostril once daily every morning of placebo
3312996|NCT00289185|Experimental|RTS,S/AS02D Group|Subjects aged between 6 and 10 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of the RTS,S/AS02D vaccine co-administered with the TETRActHib™ vaccine at Week 0, Week 4 (Month 1) and Week 8 (Month 2). The RTS,S/AS02D vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
3312997|NCT00289185|Active Comparator|Engerix-B Group|Subjects aged between 6 and 10 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of Engerix-B® vaccine co-administered with the TETRActHib™ vaccine at Week 0, Week 4 (Month 1) and Week 8 (Month 2). The Engerix-B® vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh..
3312998|NCT00289133|Active Comparator|GVF|Gamma Vacuum Foil polyethylene tibial insert
3312999|NCT00289133|Active Comparator|P.F.C.|Cross-linked polyethylene tibial insert
3313000|NCT00289120|Experimental|Cola beverage|Subjects will be given 500cc of Cola twice daily.
3313001|NCT00289120|Placebo Comparator|Deionized water|Subjects will be given 500cc of deionized water.
3313002|NCT00289107|Active Comparator|1|P.F.C.® Sigma™ Rotating Platform Cruciate Substituting Knee System
3313003|NCT00289107|Active Comparator|2|P.F.C.® Sigma™ Fixed Cruciate Substituting Knee System
3313004|NCT00289094|Active Comparator|1|P.F.C.® Sigma™ Rotating Platform (RP) Cruciate Retaining Knee System
3313005|NCT00289094|Active Comparator|2|P.F.C.® Sigma™ Fixed Cruciate Retaining Knee System
3313006|NCT00289081|Active Comparator|1|Rotating Platform Cruciate Retaining Knee implant
3313007|NCT00289081|Active Comparator|2|Rotating Platform Cruciate Substituting Knee implant.
3313008|NCT00289068||Phacoemulsification Sleeve 2.2mm|Phacoemulsification Sleeve setting 2.2 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
3313009|NCT00289068||Phacoemulsification Sleeve 2.8mm|Phacoemulsification Sleeve setting 2.8 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
3313010|NCT00289068||Phacoemulsification Sleeve 3.0mm|Phacoemulsification Sleeve setting 3.0 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
3313011|NCT00289055|Experimental|1|Cordis SMART™ Nitinol Stent
3313012|NCT00289055|Active Comparator|2|balloon angioplasty
3313013|NCT00289016|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec at an initial dose of 10⁶ plaque forming units (PFU)/mL injected into 1 or more tumors with maximum total volume of 4 mL (up to 2 mL per tumor). Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks for up to 15 weeks. After the initial 8 doses, if indications of biological activity were observed, treatment could continue for up to 16 additional doses.
3313014|NCT00288990||1|subjects who are NAb positive
3313015|NCT00288990||2|Subjects who are antibody negative
3313016|NCT00288990||3|subjects who are BAb positive
3313017|NCT00288977|Experimental|islet cell transplant|
3313018|NCT00288912|Active Comparator|Health Education Intervention|Health Education Intervention
3313019|NCT00288912|No Intervention|Usual Medical Care|Usual Medical Care
3313020|NCT00288912|Experimental|Osteoarthritis Self-Management|Osteoarthritis Self-Management
3313021|NCT00288899|Other|Arm 1|standard VA surgical iMedConsent process
3313022|NCT00288899|Experimental|Arm 2|enhanced version of VA surgical iMedConsent process (repeat-back)
3313023|NCT00288886|Experimental|Contracts, Prompts and Reinforcement arm|Participants were provided with contracting, prompting and reinforcement of continuing care attendance and substance use abstinence.
3313024|NCT00288886|Active Comparator|Control Arm|Participants were provided with routine care- they did not receive contracting, prompting and reinforcement of continuing care attendance and substance use abstinence.
3313025|NCT00288860|Experimental|Telephone Monitoring|Biweekly monitoring and support by telephone (up to 6 calls over 3 months) as augmentation to mental health care as usual.
3313026|NCT00288860|Active Comparator|Treatment-As-Usual|Mental health Treatment As Usual, potentially including case management, pharmacotherapy, and individual and/or group psychotherapy.
3313027|NCT00288795|No Intervention|1|Standard Care
3313028|NCT00288795|Other|2|Massage Treatment
3313032|NCT00288704|Placebo Comparator|Placebo|Some subjects were treated with Placebo in the Study. This occurred (if subject randomized to Placebo) either during the first 6 weeks of the study or during the randomized withdrawal (weeks 15-24).
3313033|NCT00288704|Active Comparator|rilonacept 160 mg|"If randomized to rilonacept, subjects received this treatment during the first 6 weeks of the study or during the randomized withdrawal (weeks 15-24). All subjects received rilonacept 160 mg during weeks 6-14 (between Parts A and B).~Study drug is administered as a 2.0 mL subcutaneous injection once a week. At baseline (week 0) subjects receive a loading dose of rilonacept 320 mg."
3313034|NCT00288704|Other|Open-Label rilonacept 160 mg|"After week 24 (the end of part B), all subjects went into weekly dosing of open label rilonacept 160 mg. During this phase of the study, adolescents aged 7 and above were entered into the study and rilonacept was dosed as 2.2 mg/kg injections, up to 160 mg, per week.~Study drug is administered as a 2.0 mL subcutaneous injection once a week."
3313035|NCT00288691|Experimental|Arm 1|
3313036|NCT00288691|Experimental|Arm 2|
3313037|NCT00288691|Experimental|Arm 3|
3313038|NCT00288691|Placebo Comparator|Arm 4|
3313039|NCT00288626|Experimental|MS Treatment|Autologous peripheral blood stem cell grafts were CD34+ selected; the participants then received high-dose treatment with carmustine, etoposide, cytarabine, and melphalan as well as rabbit antithymocyte globulin before autologous HCT.
3313040|NCT00288600|Experimental|Experimental group|Intravenous Immunoglobulin
3313041|NCT00288600|Placebo Comparator|CONTROL GROUP|Normal Saline solution
3313042|NCT00288587|Active Comparator|Ultrafiltration|Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
3313043|NCT00288587|Active Comparator|Usual & Customary|Patients treated with conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
3313044|NCT00288574|Experimental|fluoxetine|fluoxetine up to 80 mg per day
3313045|NCT00288574|Placebo Comparator|Placebo|Placebo
3313046|NCT00288444|Active Comparator|Docetaxel 36 mg/ m2 IV weekly and Lonafarnib 150 mg|Docetaxel 36 mg/ m^2 Intravenously weekly and Lonafarnib 150 mg by mouth twice a day daily.
3313047|NCT00288444|Active Comparator|Docetaxel 30 mg/ m2and Lonafarnib 150 mg|Docetaxel 30 mg/ m^2 Intravenously weekly and Lonafarnib 150 mg by mouth twice a day daily.
3313048|NCT00288444|Active Comparator|Docetaxel 36 mg/ m2 and Lonafarnib 100 mg|Docetaxel 36 mg/ m^2 Intravenously weekly and Lonafarnib 100 mg by mouth twice a day daily
3313049|NCT00288444|Active Comparator|Docetaxel 30 mg/m2 and Lonafarnib 100 mg|Docetaxel30 mg/m^2 Intravenously weekly and Lonafarnib 100 mg by mouth twice a day daily.
3313050|NCT00288431|Experimental|1|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
3313051|NCT00288418|Active Comparator|ARROWgard Blue® CVC|7-French x 20-cm, triple lumen, short-term CVC
3313052|NCT00288418|Experimental|Angiotech CVC|A 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
3313053|NCT00288366|Active Comparator|1|aripiprazole (Abilify)
3313054|NCT00288366|Active Comparator|2|ziprasidone (Geodon)
3313055|NCT00288353|Active Comparator|1|aripiprazole (Abilify)
3313056|NCT00288353|Active Comparator|2|ziprasidone (Geodon)
3313057|NCT00288340|Active Comparator|1,2|
3313058|NCT00288327|Experimental|1|Enhanced New Leaf Intervention
3313059|NCT00288327|Other|2|Minimum Intervention
3313060|NCT00288314||PTSD|
3313061|NCT00288314||CONTROLS|
3313062|NCT00288301|Experimental|1|Special Intervention
3313063|NCT00288301|Experimental|2|Delayed intervention
3313064|NCT00288288||1|Epicardial left ventricular lead placement during a clinically indicated open chest surgery
3313065|NCT00288288||2|Transvenous left ventricular lead implant during a clinically indicated CRT system implant
3313066|NCT00288249|Experimental|Arm 2|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
3313067|NCT00288249|Experimental|Arm 3|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
3313068|NCT00288249|Experimental|Arm 4|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
3313069|NCT00288249|Experimental|Arm 1|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
3313070|NCT00288223|Experimental|1|telithromycin
3313071|NCT00288184|Experimental|Allopurinol|Hypertensive children received both placebo and allopurinol in a cross over design.
3313072|NCT00288184|Placebo Comparator|Placebo|
3313073|NCT00288171|Experimental|Allopurinal|Hypertensive renal transplant recipients with elevated uric acid will the treated with allopurinol and placebo in an randomized cross over fashion. Subjects will serve as their own controls.
3313074|NCT00288171|Placebo Comparator|Placebo|
3313075|NCT00288158|Experimental|Allopurinol|
3313076|NCT00288158|Experimental|Probenecid|
3313077|NCT00288158|Active Comparator|Placebo|
3313078|NCT00288145|Active Comparator|T|Treatment arm comprises one worksite in a matched site pair; one site assigned to treatment, the other site assigned to comparison. Treatment site worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
3313079|NCT00288132|Active Comparator|Usual Care|
3313080|NCT00288132|Experimental|Intervention|
3313082|NCT00288119||EGD Screening|Patients scheduled for clinically indicated EGD for GERD who meet ACG criteria for BE screening
3313083|NCT00288119||Colon Screening|Patients scheduled for screening colonoscopy who have not had EGD and meet clinically indicated criteria for BE screening
3313084|NCT00288119||Controls|Patients scheduled for EGD who do not meet criteria for screening
3313085|NCT00288106||Long Term Follow-Up|Follow-up data collection study for men who developed prostate cancer after participation in SWOG-9217 (PCPT)
3313086|NCT00288093|Experimental|Treatment (triapine, radiation therapy)|Patients undergo radiotherapy once daily, 5 days a week, for approximately 5.5 weeks (a total of 28 fractions). Patients also receive 3-AP (Triapine) IV over 2 hours 3 days a week every other week for 5.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of 3-AP (Triapine) until the maximum tolerated dose (MTD) is determined.
3313087|NCT00288080|Active Comparator|Androgen suppression + Radiation Therapy|Androgen suppression (AS; LHRH agonist and oral antiandrogen) for 8 weeks followed by radiation therapy and concurrent AS. LHRH continues for 24 months after initiation of any treatment, oral antiandrogen discontinues at the end of radiation therapy (RT).
3313088|NCT00288080|Experimental|Androgen suppression + Radiation Therapy + Chemotherapy|Androgen suppression (AS; LHRH agonist and oral antiandrogen) for 8 weeks followed by radiation therapy and concurrent AS. LHRH continues for 24 months after initiation of any treatment, oral antiandrogen discontinues at the end of RT. Following completion of RT, 6 cycles of docetaxel (premedicated with dexamethasone) and prednisone are delivered concurrently with androgen suppression.
3313089|NCT00288067|Experimental|Treatment (fenretinide, rituximab)|"PHASE I: Patients receive fenretinide PO BID on days 1-5. Treatment repeats weekly for at least 4 weeks in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive fenretinide PO BID on days 1-5 in weeks 1-8 and rituximab IV once weekly in weeks 5-8. Treatment continues in the absence of disease progression or unacceptable toxicity."
3313090|NCT00288054|Experimental|Cetuximab + Radiotherapy (no Docetaxel)|
3313091|NCT00288054|Experimental|Cetuximab + Radiotherapy + Docetaxel|
3313092|NCT00288041|Experimental|Treatment (bortezomib, paclitaxel, carboplatin)|Patients will receive an infusion of bortezomib twice in week 1 and once in week 2. They will also receive a 3-hour infusion of paclitaxel and an infusion of carboplatin once in week 1. Treatment may repeat every 3 weeks for as long as benefit is shown.
3313093|NCT00288028|Experimental|Bortezomib|Bortezomib is administered as a 5 second IV bolus on days 1, 4, 8,11 or 1,8 and 15 of a 21-35 days cycle (Depending on the Dosing schedule). The dosage will be calculated based on actual weight of the patient unless the actual weight is greater than 40% above the ideal body weight. In this instance the dosage will be based on the adjusted ideal body weight. The Adjusted IBW (kg) = IBW + 0.25 x (actual body weight - IBW). The dosage will be adjusted based on the safety and toxicity profile, until a MTD is determined.
3313094|NCT00288015|Experimental|Bevacizumab|Bevacizumab treatment until disease progression or intolerance
3313095|NCT00287963|Experimental|Vinorelbine + topotecan|
3313096|NCT00287937|Experimental|Treatment (vorinostat, paclitaxel, carboplatin)|Patients receive oral SAHA once or twice daily on days 1-14* and paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have stable disease after the completion of 6 courses may receive single-agent SAHA at the discretion of the treating physician.
3313097|NCT00287911|Experimental|Combo Chemotherapy and Radiation|"Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36. Some patients may also undergo brachytherapy. Patients also receive cisplatin intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36 and topotecan IV continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3313098|NCT00287898|Experimental|Telephone Genetic Counseling|Participants randomized to this arm will receive all genetic counseling via telephone.
3313099|NCT00287898|Active Comparator|Usual Care|Participants randomized to usual care will receive standard in-person genetic counseling.
3313100|NCT00287885|Experimental|Metronomic Docetaxel|Docetaxel will be administered by daily injection via pre-filled syringes into the patient's accessed subcutaneous port.
3313101|NCT00287872|Experimental|Bortezomib and Thalidomide|The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.
3313102|NCT00287859|Experimental|Escalating Cohorts|"Patients receive topotecan intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 6 patients will be treated at the MTD."
3313103|NCT00287846|Experimental|Imatinib|400 to 800 mg/day for a maximal 12 months study duration.
3313104|NCT00287833|Experimental|Arm I (Bowman-Birk inhibitor concentrate)|Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
3313105|NCT00287833|Placebo Comparator|Arm II (placebo)|Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
3313106|NCT00287820|Active Comparator|1|olanzapine
3313107|NCT00287820|Active Comparator|2|risperidone
3313108|NCT00287768|Experimental|1|Docetaxel + S-1
3313109|NCT00287768|Active Comparator|2|S-1
3313110|NCT00287755|Experimental|1|
3313111|NCT00287729|Active Comparator|2403 mg/day pirfenidone|2403 mg/day pirfenidone dose group.
3313112|NCT00287729|Placebo Comparator|placebo|Placebo equivalent.
3313113|NCT00287716|Active Comparator|2403 mg/day pirfenidone|Active arm 1, 2403 mg/day pirfenidone dose group.
3313114|NCT00287716|Active Comparator|1197 mg/day pirfenidone|Active arm 2, 1197 mg/day pirfenidone.
3313115|NCT00287716|Placebo Comparator|placebo|Placebo equivalent.
3313116|NCT00287703|Experimental|1|Active Pulsating Electro Magnetic Fields (PEMF) treatment
3313117|NCT00287703|Sham Comparator|2|5 days a week for 5 weeks for 30 minutes Sham PEMF
3313118|NCT00287690|Experimental|Genistein|Supro drink once daily for 3 days
3313119|NCT00287690|Placebo Comparator|Placebo|Drink identical to Supro but containing no genistein, once daily for 3 days
3313120|NCT00287677|Experimental|A|growth hormone + vaccination + HAART
3313121|NCT00287677|Experimental|B|growth hormone + HAART
3313122|NCT00287677|Experimental|C|vaccination + HAART
3313123|NCT00287677|Active Comparator|D|control healthy HIV negative + vaccination
3313124|NCT00287651|Active Comparator|2|Patients with diagnosed Diabetic Retinopathy are enrolled as treated with pulsatile intravenous insulin or as a control patient with weekly treatment sessions. Baseline and quarterly fundus photography is performed to measure and monitor progress.
3313125|NCT00287651|No Intervention|1|Patients diagnosed with Diabetic Retinopathy are enrolled as control patients that do not receive the pulsatile intravenous insulin therapy. Control patients come into the center receive baseline fundus photography and quarterly fundus photography to measure progress and outcomes of diabetic retinopathy and are compared to the patients who receive pulsatile intravenous insulin therapy.
3313126|NCT00287638|Active Comparator|1|CPAP
3313127|NCT00287638|Placebo Comparator|2|no CPAP
3313128|NCT00287625|Active Comparator|1|PRP
3313129|NCT00287625|No Intervention|2|control
3313130|NCT00287612|Active Comparator|1|Arms:Lap. Fundo. with Mobilization of the Esophageal Junction
3313131|NCT00287612|Experimental|2|
3313132|NCT00287586|Active Comparator|Testosterone|Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
3313133|NCT00287586|Placebo Comparator|Placebo|Participants received placebo-matching testosterone gel daily for 3 years.
3313134|NCT00287573|Experimental|Arm 1|
3313135|NCT00287573|Active Comparator|Arm 2|
3313136|NCT00287534|Experimental|1|Anastrozole
3313137|NCT00287534|Active Comparator|2|Tamoxifen
3313138|NCT00287521|Experimental|AL-37807 Suspension|
3313139|NCT00287521|Active Comparator|Xalatan|
3313140|NCT00287521|Placebo Comparator|AL-37807 Vehicle|
3313141|NCT00287521|Experimental|Timolol Maleate|
3313142|NCT00287495|Experimental|A|Patients with AIDS-KS receiving ritonavir will be given 200 mg BAY 43-9006 once daily with dose escalation up to 400 mg twice daily
3313143|NCT00287495|Experimental|B|Patients with AIDS-KS not receiving ritonavir will be given 200 mg BAY 43-9006 once daily with dose escalation up to 400 mg twice daily
3313144|NCT00287378|Experimental|1|
3313145|NCT00287365|Experimental|1-ozone|Mildly asthmatic subjects with GSTM1 null genotype compared to GSTM1 sufficient subjects
3313146|NCT00287352|Placebo Comparator|Double-Blind Treatment|Olanzapine continuing with placebo
3313147|NCT00287352|Active Comparator|Olanzapine, Amantadine|Standard combine with Amantadine
3313148|NCT00287339|Experimental|1|40mg Esomeprazole BID
3313149|NCT00287339|Placebo Comparator|2|placebo capsules
3313150|NCT00287287|Experimental|Lenalidomide (Revlimid)|Treatment will be initated at 25 mg/day taken in the morning. Dose adjustments may be made to alleviate toxicities.
3313151|NCT00287261|Experimental|zometa|3-weekly infusion of zometa (zoledronic acid) 4 mg
3313152|NCT00287248|Experimental|Assess [123I] IMPY & SPECT Imaging|To assess [123I] IMPY & SPECT Imaging
3313153|NCT00287235|Experimental|Group 1: Standard Medical Therapy + MARS|Patients who were randomized to Group 1 received daily MARS treatments in addition to Standard Medical Therapy for 5 consecutive days.
3313154|NCT00287235|Active Comparator|Group 2: Standard Medical Therapy Only|Patients who were randomized to Group 2 received standard medical treatment only.
3313155|NCT00287222|Experimental|1 - Bevacizumab/Erlotinib|Subjects will be treated with bevacizumab and erlotinib
3313156|NCT00287196|Active Comparator|Post-operative RADIOTHERAPY|Immediate post-operative RADIOTHERAPY
3313157|NCT00287196|Experimental|Delayed Radiotherapy|OBSERVATION with delayed radiotherapy for relapse
3313158|NCT00287183|Active Comparator|PF-04494700 (TTP488)|
3313159|NCT00287183|Placebo Comparator|Placebo|
3313160|NCT00287118|Experimental|Efalizumab|
3313161|NCT00287105|Other|Good risk Ph+ALL|For protocols which adopt a steroid prephase: patients who are Prednisone-good responder and achieve CR after the induction course. For protocols which do not adopt steroid prephase: patients who have M1/M2 BM at day 15 or M1 BM at day 21 and achieve CR after the induction course. Expected stratification in this group: 70-75%.
3313162|NCT00287105|Other|Poor risk Ph+ALL|For protocols which adopt a steroid prephase: patients who are Prednisone poor-responders. For protocol which do not adopt a steroid prephase: patients who have M3 BM at day 15 or M2/M3 BM at day 21. For all protocols: patients who do not achieve CR after the induction course. Expected stratification: 25-30%.
3313163|NCT00287092|Experimental|Group 1|Participants will receive PEDIACEL vaccine
3313164|NCT00287092|Active Comparator|Group 2|Participants will receive Infanrix-IPV+Hib vaccines
3313165|NCT00287079|Experimental|Rebif®|
3313166|NCT00287079|Other|No Treatment|
3313167|NCT00287053|Experimental|Placebo|Divalproex Sodium
3313168|NCT00287053|Placebo Comparator|Placebo Comparator|Placebo Comparator
3313169|NCT00287040|No Intervention|1 - Usual Care|This arm looks at mammogram adherence in those individuals who at this time are not receiving booster mammogram interventions.
3313170|NCT00287040|Experimental|2. DVD Intervention|This arm will receive the initial information provided in usual care and will also receive booster mammography interventions via DVD.
3313171|NCT00287040|Experimental|3. Telephone Counseling|This arm will receive the initial information provided in usual care and receive boosters through tailored telephone counseling.
3313172|NCT00287001|Other|1|1= cool air cooling
3313233|NCT00286195|No Intervention|I|Consecutive patients, open label
3313173|NCT00286962|Experimental|CIPII|Intraperitoneal insulin infusion by means of an implanted insulin pump
3313174|NCT00286962|Active Comparator|CSII/ MDI|Optimized subcutaneous insulin infusion by means of continuous subcutaneous insulin infusion (CSII) or by multiple daily injections (MDI)
3313175|NCT00286949|Other|Atomoxetine (Strattera)|Open-Label Uncontrolled Active Drug Intervention, No comparator
3313176|NCT00286845||II|
3313177|NCT00286845||1|
3313178|NCT00286832||Single group study|
3313179|NCT00286819|Experimental|the FEC75 regimen|"Arm A: the FEC75 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles."
3313180|NCT00286819|Experimental|FEC90 regimen|"Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle."
3313181|NCT00286793|Experimental|SIngle Arm Study of AT-101 in combination with Docetaxel|
3313182|NCT00286780|Experimental|1|
3313183|NCT00286754|Experimental|Stage-matched intervention (SMI)|Stage-matched intervention (SMI)
3313184|NCT00286754|Active Comparator|Health Education Intervention (HEI)|Health Education Intervention (HEI)
3313185|NCT00286754|No Intervention|Usual Care (UC)|Usual Care (UC)
3313186|NCT00286741|Experimental|Medical group visits|Medical group visits
3313187|NCT00286741|No Intervention|Treatment as Usual control|control
3313188|NCT00286728|Experimental|Arm 1|Intensive referral to dual-focused self-help groups
3313189|NCT00286728|No Intervention|Arm 2|Usual care
3313190|NCT00286624|Experimental|1|Allogeneic islet transplantation with anti-thymocyte globulin induction and cyclosporine and RAD maintenance immunosuppression
3313191|NCT00286611||Amifostine|Those individuals enrolled who have received amifostine as part of standard care.
3313192|NCT00286598|Experimental|Feet First|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
3313193|NCT00286598|No Intervention|Control|Usual care
3313194|NCT00286585|Active Comparator|Inhalational anesthetic|Sevoflurane will be used as the main anesthetic in this arm, and no propofol will be administered
3313195|NCT00286585|Active Comparator|Intravenous anesthetic, propofol|Propofol will be used as the main anesthetic in this arm, and no inhalational anesthetic will be administered
3313196|NCT00286533|Experimental|Placed implants|
3313197|NCT00286507|Active Comparator|ILM peeling|Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with ILM peeling
3313198|NCT00286507|Active Comparator|No ILM peeling|combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas without ILM peeling
3313199|NCT00286494|Active Comparator|Placebo|
3313200|NCT00286494|Experimental|Alogliptin 12.5 mg QD|
3313201|NCT00286494|Experimental|Alogliptin 25 mg QD|
3313202|NCT00286481|Experimental|Lapaquistat Acetate 50 mg QD + Simvastatin|
3313203|NCT00286481|Experimental|Lapaquistat Acetate 100 mg QD + Simvastatin|
3313204|NCT00286481|Active Comparator|Simvastatin|
3313205|NCT00286468|Experimental|Alogliptin 12.5 mg QD|
3313206|NCT00286468|Experimental|Alogliptin 25 mg QD|
3313207|NCT00286468|Active Comparator|Placebo|
3313208|NCT00286455|Experimental|Alogliptin 12.5 mg QD|
3313209|NCT00286455|Experimental|Alogliptin 25 mg QD|
3313210|NCT00286455|Placebo Comparator|Placebo QD|
3313211|NCT00286442|Experimental|Alogliptin 12.5 mg QD|
3313212|NCT00286442|Experimental|Alogliptin 25 mg QD|
3313213|NCT00286442|Placebo Comparator|Metformin|
3313214|NCT00286429|Placebo Comparator|Insulin|
3313215|NCT00286429|Experimental|Alogliptin 12.5 mg QD|
3313216|NCT00286429|Experimental|Alogliptin 25 mg QD|
3313217|NCT00286325|Experimental|Treatment Rituximab|Open label study all subjects treated with rituximab
3313218|NCT00286299|Experimental|Aerobic interval training (AIT)|AIT is 4x4 minutes interval training on a treadmill at 85 to 95 % HRpeak interspersed with 3 min of active resting periods at a work load corresponding to 70 % HRpeak between each interval. Patients performed the intervals walking or running with a minimum of 5 % inclination.
3313219|NCT00286299|Active Comparator|Computer game training (CG)|36 minutes playing supervised computer games, Tetris, Xbox
3313220|NCT00286299|Experimental|Maximal strength training (MST)|MST is performed in a leg press machine. The weight is lowered in a controlled manner in the eccentric phase until the patient reached 90 degrees in the knee joint. Then the patients has a short stop (~0.5 second) before the weight is moved as rapidly as possible to complete extension. The training volume is 4 sets of 4RM (i.e. 85-90 % 1RM). The training load is increased with 2.5-5 kg each time patients managed to perform 4 sets with the determined load or each training session.
3313221|NCT00286273|Active Comparator|citrate|regional anticoagulation with citrate
3313222|NCT00286273|Active Comparator|nadroparin|nadroparin is a low molecular weight heparin
3313223|NCT00286234|Placebo Comparator|1|Dual placebo
3313224|NCT00286234|Experimental|2|niaspan
3313225|NCT00286234|Experimental|3|lovaza
3313226|NCT00286234|Experimental|4|combined therapy
3313227|NCT00286221|Experimental|Supratentorial PCA fentanyl|
3313228|NCT00286221|Active Comparator|Supratentorial PRN fentanyl|
3313229|NCT00286221|Experimental|Infratentorial PCA fentanyl|
3313230|NCT00286221|Active Comparator|Infratentorial PRN fentanyl|
3313231|NCT00286208|Active Comparator|Sublingual Misoprostol|400 mcg of sublingual misoprostol
3313232|NCT00286208|Active Comparator|Oral Misoprostol|Misoprostol administered orally
3320786|NCT00160381|Experimental|2|
3313234|NCT00286182|Experimental|Erythropoietin alpha|Subcutaneous erythropoietin will be administered once weekly to achieve a target hemoglobin of 13 g/dL. Subjects will be dosed with the study drug for 24 weeks. The administration of study drug will be performed according to a pre-specified treatment algorithm that adjust erythropoietin dosages based on the rate of rise of the hemoglobin.
3313235|NCT00286182|Placebo Comparator|Placebo|Placebo consists of saline injections.
3313236|NCT00286156|Experimental|1|Arm 1 Rapamune dose 2-6mg aimed at maintaining trough levels 5-8 ng/ml
3313237|NCT00286156|Experimental|2|Arm 2 Rapamune dose 2-6 mg aimed at maintaining trough levels of 2-5ng/ml
3313238|NCT00286156|No Intervention|3|Standard Care
3313239|NCT00286143|Active Comparator|A|Fentanyl added to Bupivacaine via epidural catheter.
3313240|NCT00286130|Active Comparator|FOLFOX 6|"FOLFOX 6:~Oxaliplatin 100 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
3313241|NCT00286130|Active Comparator|FOLFIRI|"FOLFIRI:~Irinotecan 180 mg/m² day 1 concurrent with~Leucovorin 400 mg/m² followed by~Bolus 5FU 400 mg/m², followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
3313242|NCT00286117|Experimental|1|Anastrozole
3313243|NCT00286117|Active Comparator|2|Tamoxifen
3313244|NCT00286104|Active Comparator|1|Bactiseal ventricular catheter (Rifampicin- and Clindamycin-impregnated)
3313245|NCT00286104|Placebo Comparator|2|Plain ventricular catheter
3313246|NCT00286091|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
3313247|NCT00286091|Experimental|Denosumb|Participants received 120 mg denosumab administered by subcutaneous injection every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
3313248|NCT00286078|Experimental|1|Stimulation on
3313249|NCT00286078|Sham Comparator|2|Sham Stimulation up to 12 weeks post-activation. Actual Stimulation from 12 weeks post-activation on.
3313250|NCT00286026|Experimental|Arm 1|Subjects residing in villages assigned to treatment arm 1 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0); will be treated with Azithromycin at Day 30; will be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60; and again at Day 360.
3313251|NCT00286026|Experimental|Arm 2|Subjects residing in villages assigned to treatment arm 2 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0), as well as receive an initial treatment with Azithromycin; will receive a second dose of Azithromycin at Day 30; will be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60; and again at Day 360.
3313252|NCT00285974|Experimental|hip prosthesis|
3313253|NCT00285935|Experimental|Treatment with SSRI|"Depressed participants will receive 8 weeks of treatment with one of the following serotonin-specific reuptake inhibitors:~fluoxetine (Prozac®), sertraline (Zoloft®), paroxetine (Paxil®), citalopram (Celexa®), escitalopram (Lexapro®)~The specific drug used for treatment will be selected by the study clinician based on clinical interviews and the participants preferences. Participants will be monitored for response and side effects by study clinician and will return after 8 weeks for a follow up study visit."
3313254|NCT00285896|Active Comparator|Active|GLP-1
3313255|NCT00285896|Placebo Comparator|Placebo|Placebo
3313256|NCT00285857|Experimental|Lovastatin 80 mg/day|Lovastatin 80 mg/day as 40 mg orally twice daily, for 6 months.
3313257|NCT00285844|Experimental|pioglitazone|IR and IS subjects will be randomized to pioglitazone 45 mg daily for 16 wks for comparison with dietary weight loss intervention
3313258|NCT00285844|Experimental|Dietary Weight Loss|IR and IS subjects will be randomized to dietary weight loss for 16 wks for comparison to pioglitazone intervention
3313259|NCT00285818|Active Comparator|Mifepristone|Patients receive mifepristone one day before and for 5 additional days after starting ECT
3313260|NCT00285818|Placebo Comparator|Placebo Oral Capsule|Patients receive a placebo capsule one day before and for 5 additional days after starting ECT
3313261|NCT00285805|Other|Rosiglitazone-placebo|
3313262|NCT00285805|Other|placebo-rosiglitazone|
3313263|NCT00285779|Placebo Comparator|Placebo injection|patients receive normal saline injection twice weekly for weeks 1-12
3313264|NCT00285779|Experimental|Etanercept|patients receive etanercept injection twice weekly for weeks 1-12.
3313265|NCT00285688||1|Gastroscope positive for H. pylori and resistant to clarithromycin
3313266|NCT00285688||2|Gastroscope positive for H. pylori and not resistant to clarithromycin
3313267|NCT00285662|Active Comparator|1|1 day Sulfadoxine/Pyrimethamine + 3 days Amodiaquine
3313268|NCT00285662|Active Comparator|2|1 day of Sulfadoxine/Pyrimthamine and 3 days of Artesunate
3313269|NCT00285662|Placebo Comparator|3|children of this gorup will receive only placebo dugs
3313270|NCT00285649|Experimental|HVLA-SM|HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
3313271|NCT00285649|Experimental|LVVA-SM|LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation
3313272|NCT00285649|Active Comparator|Usual Medical Care|Usual Medical Care, Active Comparator, advice, exercises and medications
3313273|NCT00285584|Active Comparator|Bupropion|Participants in this arm received bupropion.
3313274|NCT00285584|Placebo Comparator|Placebo|Participants in this arm received placebo that looked identical to the active comparator medication.
3313275|NCT00285558|Experimental|CBT with peer-enhanced activities|Cognitive behavioral treatment (CBT) with peer-enhanced adventure therapy. The peer intervention, ''adventure therapy,'' is based on the principles of Outward Bound and was expected to affect weight status through a positive effect on self-concept.
3313276|NCT00285558|Active Comparator|CBT with supervised aerobic exercise|Cognitive behavioral treatment (CBT) with supervised aerobic exercise. Activities for the supervised exercise intervention included use of treadmills, stationary bicycles, and other aerobic activities selected by participants, including dance videos and brisk walking within the clinic setting.
3313277|NCT00285545||Good blood flow|Group with normal blood flow to small intestine
3313278|NCT00285545||Poor blood flow|Group with partial ischemia to small intestine
3313279|NCT00285532||Home test kit|
3313280|NCT00285467|Experimental|Doxercalciferol|doxercalciferol 1 mcg capsule orally daily for 3 months. This is a form of vitamin D that does not require activation by enzymes in the liver and kidney.
3313281|NCT00285467|Active Comparator|Cholecalciferol|cholecalciferol 4000 IU capsule orally daily for one month, then 2000 IU capsule daily orally for 2 months. this form of vitamin D requires activation by cells of the body.
3313282|NCT00285428|Experimental|Dose level 1|120 mg/m2
3313283|NCT00285428|Experimental|Dose level 2|200 mg/m2
3313284|NCT00285428|Experimental|Dose Level 3|375 mg/m2
3313285|NCT00285428|Experimental|Dose level 1B|80 mg/m2
3313286|NCT00285415|Other|1|
3313287|NCT00285402|Experimental|A|
3313288|NCT00285402|Experimental|B|
3313289|NCT00285402|Placebo Comparator|C|
3313290|NCT00285389|Experimental|VAD Clorambucil Rituximab|
3313291|NCT00285376|Experimental|1|vilazodone
3313292|NCT00285376|Placebo Comparator|2|
3313293|NCT00285298|Experimental|Pentoxifylline|
3313294|NCT00285298|Placebo Comparator|Placebo|
3313295|NCT00285259|Experimental|VCL-CB01|
3313296|NCT00285259|Placebo Comparator|Placebo|PBS
3313297|NCT00285246||Group 1|Army Reserve and National Guard soldiers deploying to a hazardous deployment from Fort Dix, NJ and Camp Shelby, MS
3313298|NCT00285233|Experimental|1|
3313299|NCT00285207|Placebo Comparator|Placebo|Placebo administered topically to the cervix via intravaginal applicator for 5 consecutive days of a 28-day cycle for 2 cycles.
3313300|NCT00285207|Experimental|A007|0.25% A007 administered topically to the cervix via intravaginal applicator for 5 consecutive days of a 28-day cycle for 2 cycles.
3313301|NCT00285168||1 - Control|Usual Bone Density Report
3313302|NCT00285168||2 - Intervention|Bone Density Report with Absolute 10-year Fracture Risk Decision Aide
3313303|NCT00285090|Experimental|Early Treatment|
3313304|NCT00285090|Experimental|LateTreatment|
3313305|NCT00285090|Experimental|Total Treatment|
3313306|NCT00285090|Placebo Comparator|No Treatment|
3313307|NCT00285012|Placebo Comparator|placebo|
3313308|NCT00285012|Experimental|varenicline|
3313309|NCT00284986|Experimental|Prochymal|
3313310|NCT00284947|Experimental|Maintenance immunosuppression|"40mg Simulect i.v, once every 28 days for 24 weeks (treatment periods)~1g MMF or 720mg EC-MPS p.o twice daily~Oral corticosteroids"
3313311|NCT00284934|Active Comparator|Standard dose EC-MPS|Patients received 720 mg/day (360 mg twice a day (bid) orally) Enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus dose (twice a day orally) adjusted to maintain the trough blood level (C0) contained between 5.5 and 10 ng/mL. The randomization was stratified on 1 factor: treatment with or without steroids. Prednisone (or oral equivalent) was administrated to patients as before entering the study and as per center's standard practice, but at a dose of at least 5 mg/day.
3313312|NCT00284934|Experimental|High EC-MPS|Patients received 1440 mg/day (720 mg twice a day (bid) orally) Enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus dose (twice a day orally) tapered to reach a trough blood level target contained between 2 and 4.5 ng/mL within 15 days after randomization at the most. The randomization was stratified on 1 factor: treatment with or without steroids. Prednisone (or oral equivalent) was administrated to patients as before entering the study and as per center's standard practice, but at a dose of at least 5 mg/day.
3313313|NCT00284908|Experimental|I STU-Na|Cross-over study with escalating doses
3313314|NCT00284856|Experimental|1|Arm 1: Montelukast
3313315|NCT00284856|Active Comparator|2|Arm 2: Fluticasone
3313316|NCT00284856|Placebo Comparator|3|Arm 3: Placebo
3313317|NCT00284830|Active Comparator|1|dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
3313318|NCT00284830|No Intervention|2|conventional dual-chamber pacing
3313319|NCT00284817|Experimental|1|MEDI-522
3313320|NCT00284817|Experimental|2|MEDI-522
3313321|NCT00284817|Experimental|3|MEDI-522
3313322|NCT00284817|Experimental|4|MEDI-522
3313323|NCT00284817|Experimental|5|MEDI-522
3313324|NCT00284804|Experimental|MDX-060 plus standard of care|MDX-060 in combination with gemcitabine
3313325|NCT00284804|Active Comparator|Standard of care|Gemcitabine
3313326|NCT00284752|Experimental|ABI-007|
3313327|NCT00284739|Experimental|Alteplase|Multiple Alteplase injection into the abscess collection to improve percutaneous drainage
3313328|NCT00284739|Placebo Comparator|Saline|Multiple normal saline injection into the abscess collection to improve percutaneous drainage
3313329|NCT00284661|Experimental|FAST FIX|Inetrvention is Fast Fix repair of meniscal tear
3313330|NCT00284661|Experimental|Meniscal suturing|Intervention is Standard suturing of meniscal tear
3313331|NCT00284609|Experimental|1|
3313332|NCT00284609|Active Comparator|2|
3313333|NCT00284557|Experimental|Group-based behavioral intervention|"The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter."
3313334|NCT00284557|Active Comparator|Health education materials only|Those allocated to Group 2 were provided with a standardized packet of health education materials addressing the recommended items from the expert committee guidelines (e.g., dietary recommendations using the Food Guide Pyramid and the Traffic Light Diet, a general prescription to increase physical activity to 60 minutes daily). They were also given a community resource list that provides contact and program information for community-based obesity treatment activities in their area.
3313335|NCT00284518|Experimental|botulinum toxin Type A 300 U|Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.
3313336|NCT00284518|Experimental|botulinum toxin Type A 200 U|Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.
3313337|NCT00284518|Experimental|botulinum toxin Type A 100 U|Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.
3314094|NCT00273650|Active Comparator|A|Methyl-B12
3313338|NCT00284518|Placebo Comparator|Placebo (Normal Saline)|Placebo (Normal Saline) transperineal or transrectal injection on Day 1.
3313339|NCT00284492|Active Comparator|Lifestyle advice|
3313340|NCT00284492|Experimental|Lifestyle advice and acupuncture therapy|
3313341|NCT00284453||1|Forty(40)subjects that have received >2 appropriate ICD shock therapies
3313342|NCT00284453||2|Twenty(20)subjects that have received 1-2(low level)appropriate ICD therapies
3313343|NCT00284453||3|Ten(10)subjects that received inappropriate therapies from their ICD
3313344|NCT00284427|Experimental|1|Vitamin C
3313345|NCT00284310|Experimental|wrist surgery|
3313346|NCT00284297|Experimental|knee arthrodesis|
3313347|NCT00284258|Experimental|1|CPT-11 and TS-1
3313348|NCT00284258|Active Comparator|2|CPT-11, 5-FU and l-LV
3313349|NCT00284219|Active Comparator|Real high frequency rTMS|The patients will undergo a series of treatments of high frequency rTMS
3313350|NCT00284219|Sham Comparator|Sham high frequency rTMS|The patients will receive a series of sham treatments.
3313351|NCT00284193|Experimental|feiba-VIIa, hemophilia A-inhibitor therapy|COMBINED PATIENT- TAILORED THERAPY WITH CONCOMITANT ADMINISTRATION OF BOTH DRUGS , FOLLOWING EX VIVO THROMBIN GENERATION PREDICTING ASSAYS
3313352|NCT00284180|Experimental|HER2 Negative Intervention|Vinflunine 320 mg/m2 intravenously day 1 over 20 minutes, repeated every 21 days
3313353|NCT00284180|Experimental|HER2 Positive Intervention|Vinflunine 280 mg/m2 every 21 days with trastuzumab administered with a loading dose of 8 mg/kg, followed by 6 mg/kg IV on day 1 of each subsequent cycle, repeated every 21 days. If no grade 3/4 adverse events were encountered after the first cycle of vinflunine/trastuzumab, the dose of vinflunine could be escalated to 320 mg/m2.
3313354|NCT00284154|Experimental|Intervention|Patients received vinflunine 320 mg/m2 every 21 days as a 15- to 20-minute infusion.
3313355|NCT00284141|Experimental|aflibercept 4.0 mg/kg|Participants with metastatic non-small-cell lung adenocarcinoma administered 4.0 mg/kg Aflibercept every 2 weeks until a study withdrawal criterion was met.
3313356|NCT00284128|Experimental|ilepatril (2.5 mg ) once daily|AVE7688 oral administration
3313357|NCT00284128|Experimental|ilepatril (10 mg) once daily|AVE7688 oral administration
3313358|NCT00284128|Experimental|ilepatril (35 mg) once daily|AVE7688 oral administration
3313359|NCT00284128|Experimental|ilepatril (50 mg) once daily|AVE7688 oral administration
3313360|NCT00284128|Other|Losartan-potassium (100 mg) once daily|oral administration
3313361|NCT00284115|Experimental|Mechanical gait repetitive training|Body weight support treadmill training technique enabling nonambulatory patients to have the repetitive practice of a gate-like movement
3313362|NCT00284115|Active Comparator|Conventional rehabilitation program|Physiotherapeutic conventional rehabilitation program
3313363|NCT00284102|Experimental|1|ALI/ARDS patients
3313364|NCT00284089|Experimental|Group A: Ranibizumab 0.3 mg|In the single dose phase, all patients randomized in Group A received a single intravitreal injection of 0.3 mg of ranibizumab into the study eye. Those patients who successfully completed this phase entered the multiple dose phase, where they received an intravitreal injection of 0.3 mg of ranibizumab once a month for an additional 11 months. Subsequently patients enrolling in the extension phase received an intravitreal injection of 0.3 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.70 years.
3313365|NCT00284089|Experimental|Group A: Ranibizumab 0.5 mg|In the single dose phase, all patients randomized in Group A received a single intravitreal injection of 0.5 mg of ranibizumab into the study eye. Those patients who successfully completed this phase entered the multiple dose phase, where they received an intravitreal injection of 0.5 mg of ranibizumab once a month for an additional 11 months. Subsequently Group A patients enrolling in the extension phase received an intravitreal injection of 0.5 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.93 years.
3313366|NCT00284089|Experimental|Group B: Ranibizumab 0.3 mg|Group B patients received a total of 12 monthly intravitreal injections of 0.3 mg of ranibizumab into the study eye in the multiple dose phase of the study. Group B patients who enrolled in the extension phase received an intravitreal injection of 0.3 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.45 years.
3313367|NCT00284089|Experimental|Group B: Ranibizumab 0.5 mg|Group B patients received a total of 12 monthly intravitreal injections of 0.5 mg of ranibizumab into the study eye in the multiple dose phase of the study. Group B patients who enrolled in the extension phase received an intravitreal injection of 0.5 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.36 years.
3313368|NCT00284063|Active Comparator|Group 1: N; SPP; N|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
3313369|NCT00284063|Active Comparator|Group 2: N; SMT; N|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
3313370|NCT00284063|Active Comparator|Group 3: N; SMT; SP|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
3313371|NCT00284063|No Intervention|Group 4: N and SP|N = neutral MRI SP = side posture MRI SPP = side posture position SMT = side posture manipulation
3313372|NCT00284050|Experimental|Ranibizumab 0.3 mg|Participants received monthly intravitreal injections with 0.3 mg ranibizumab (6 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 0.6 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
3313373|NCT00284050|Experimental|Ranibizumab 0.5 mg|Participants received monthly intravitreal injections with 0.5 mg ranibizumab (10 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 1.0 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
3313374|NCT00284050|Sham Comparator|Sham injection|Participants in the control group received 12 monthly sham intravitreal injections. The evaluation was performed using the same criteria for dose doubling as in active treatment groups. The injection was a mimicked by an empty syringe without a needle. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
3313375|NCT00284011|Active Comparator|SAMe|Two 400 mg pills.
3313376|NCT00284011|Placebo Comparator|Placebo|Two placebo pills (identical in appearance to SAMe).
3313377|NCT00283959|Experimental|150 mg capsule|oral migalastat HCl (AT1001) administered every other day.
3313378|NCT00283946|Experimental|1|
3313379|NCT00283946|Active Comparator|2|
3313380|NCT00283933|Experimental|150 mg capsules|single dose, oral migalastat HCl (AT1001) administered every other day
3313381|NCT00283868||Telemedicine|Patients randomized to this group were evaluated using the digital observation camera and DICOM evaluations for telemedicine
3313382|NCT00283868||Telephone|Patients randomized to this group were evaluated using telephone only and no use of the digital observation camera or DICOM
3313383|NCT00283855|No Intervention|Control Group|No intervention
3313384|NCT00283855|Active Comparator|Online Self-Management|RAHelp.org
3313385|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 50mg|
3313386|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 100mg|
3313387|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 200mg|
3313388|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 400mg|
3313389|NCT00283842|Placebo Comparator|Placebo|
3313390|NCT00283829|Other|I|Docetaxel followed by IL-2
3313391|NCT00283816|Active Comparator|1|metformin
3313392|NCT00283816|Placebo Comparator|0|placebo
3313393|NCT00283803|Experimental|IAS and Exisulind|Patients will receive intermittent dosing of hormone therapy with commercially supplied luteinizing hormone-releasing hormone (LHRH) agonist and anti-androgen to be chosen by physician per standard of care. Exisulind will be started 3 months prior to the end of the second cycle of hormone therapy. Patients will continue treatment with Exisulind beyond the completion of the second cycle of hormone therapy until they meet criteria for discontinuation.
3313394|NCT00283738|Active Comparator|1|
3313395|NCT00283738|Placebo Comparator|2|Sham control
3313396|NCT00283725||Galantamine|
3313397|NCT00283725||No Alzheimer's disease (AD) treatment|
3313398|NCT00283712|Experimental|Infliximab|"Participants are randomized to receive intravenous infusions of infliximab (5mg/kg reconstituted in 10 mL of Sterile Water for Injection, USP ) at Weeks 0, 2, 6, and 14 over a time period of no less than two hours in a masked (blinded) fashion. Refer to section titled, Detailed Description for additional treatment information."
3313399|NCT00283712|Placebo Comparator|Placebo Comparator|"Participants are randomized to receive intravenous infusions of placebo (5 mg/kg comprised of a white lyophilized powder reconstituted in 10 mL of Sterile Water for Injection, USP) at Weeks 0, 2, 6, and 14 over a time period of no less than two hours in a masked (blinded) fashion. Refer to section titled, Detailed Description for additional treatment information."
3313400|NCT00283699|Active Comparator|1|"albendazole, 15 mg/kg/day for those less than 50 kg in weight. For those more than 50 kg, 800 mg was administered. All got standard symptomatic therapy~placebo plus standard symptomatic therapy"
3313401|NCT00283699|Placebo Comparator|2|
3313402|NCT00283686|Active Comparator|Study A, Arm 1|Lisinopril + Telmisartan (ACE-I + ARB) and standard blood pressure control of 120-130/70-80 mm Hg
3313403|NCT00283686|Active Comparator|Study A, Arm 2|Lisinopril + Telmisartan (ACE-I + ARB) and low blood pressure control of 95-110/60-75 mm Hg
3313404|NCT00283686|Placebo Comparator|Study A, Arm 3|Lisinopril + Placebo (ACE-I + Placebo) and standard blood pressure control of 120-130/70-80 mm Hg
3313405|NCT00283686|Placebo Comparator|Study A, Arm 4|Lisinopril + Placebo (ACE-I + Placebo) and low blood pressure control of 95-110/60-75 mm Hg
3313406|NCT00283660|Experimental|Active|Dietary Supplement: 10 mg zinc oxide
3313407|NCT00283660|Placebo Comparator|Placebo|Placebo (double blinded)
3313408|NCT00283621|Experimental|Growth Factors + Adriamycin/Ifosfamide|Growth Factors = Aranesp (Darbepoetin Alfa) and Pegfilgrastim (Neulasta)
3313409|NCT00283608||Anastrozole|Blood draws for baseline and six to twelve weeks.
3313410|NCT00283608||Exemestane|Blood draws for baseline and six to twelve weeks
3313411|NCT00283595|Active Comparator|1|Treatment with rHGH
3313412|NCT00283595|Placebo Comparator|2|Treatment with Placebo
3313413|NCT00283556|Experimental|Cohort #1|"Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes every (Q) 3 weeks x 15 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
3313414|NCT00283556|Experimental|Cohort #2|"Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
3313415|NCT00283556|Experimental|Cohort #3|"Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
3313416|NCT00283517||001|
3313417|NCT00283504|Experimental|all patients received Xolair/active drug|One arm:active drug
3313418|NCT00283491|Active Comparator|A|
3313419|NCT00283491|Placebo Comparator|B|
3313420|NCT00283452|Experimental|Intervention Group|Participation in phone/mail-based intervention to maintain physical activity.
3313421|NCT00283452|No Intervention|Control|No intervention; participation in surveys only
3313422|NCT00283439|Experimental|Single Arm: AMG 531 Dose-Escalating Cohort Study|
3313423|NCT00283413|Experimental|1|Symbiot Covered Stent System
3320787|NCT00160381|Placebo Comparator|3|
3313424|NCT00283413|Active Comparator|2|Commercially available bare metal stent
3313425|NCT00283400|Active Comparator|dosage tier 1|0.625 g/kg 25% human albumin
3313426|NCT00283400|Active Comparator|dosage tier 2|1.25 g/kg 25% human albumin
3313427|NCT00283400|Active Comparator|dosage tier 3|1.875 g/kg 25% human albumin
3313428|NCT00283400|Active Comparator|dosage tier 4|2.5 g/kg 25% human albumin
3313429|NCT00283387|Experimental|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral lactose placebo, in two doses daily, for 2 months.
3313430|NCT00283387|Placebo Comparator|Placebo|Subjects were randomly assigned to receive oral lactose placebo, in two doses daily, for 2 months. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
3313431|NCT00283335|Active Comparator|Gemfibrozil|1200 mg slow-release gemfibrozil (Lopid-SR) once per day
3313432|NCT00283335|Placebo Comparator|Placebo|Matching placebo tablets taken once per day
3313433|NCT00283322||Medical ICU patients|Patients admitted to a medical intensive care unit
3313434|NCT00283322||Surgical ICU patients|Patients admitted to a surgical-trauma intensive care unit
3313435|NCT00283322||Neuro ICU patients|Patients admitted to a neuro-trauma intensive care unit
3313436|NCT00283309|Active Comparator|Memantine|Memantine is used to determine if patients given pretreatment to corticosteroid therapy for inflammatory illnesses will show lesser declarative memory impairment than those receiving placebo. Baseline 10mg x 3 days, then 10mg BID x 4 days.
3313437|NCT00283309|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
3313438|NCT00283309|Active Comparator|Riluzole|Riluzole is given to patients receiving corticosteroid therapy for inflammatory illnesses pretreatment to determine if they show lesser declarative memory impairment than those receiving placebo. Baseline 50mg x 3 days, then 50mg BID x 4 days.
3313439|NCT00283296|Experimental|Endeavor Wheelchair|Participants will receive an introduction to the Endeavor wheelchair, and will complete the Activities of Daily Living Course with their own personal wheelchair and with the Endeavor chair.
3313440|NCT00283283|Experimental|Male, Age 18 -49, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
3313441|NCT00283283|Experimental|Male, Age 50 -64, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
3313442|NCT00283283|Experimental|Female, Age 18 - 49, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
3313443|NCT00283283|Experimental|Female, Age 18 - 49, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
3313444|NCT00283283|Experimental|Male, Age 18 - 49, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
3313445|NCT00283283|Experimental|Male, Age 50 -64, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
3313446|NCT00283283|Experimental|Female, Age 50 -64, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
3313447|NCT00283283|Experimental|Female, Age 50 -64, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
3313448|NCT00283244|Active Comparator|Arm A|Patients receive gemcitabine hydrochloride 1200mg/m2 IV on days 1 and 8. Patients with progressive disease may cross over to arm B.
3313449|NCT00283244|Experimental|Arm B|Patients receive oral erlotinib hydrochloride 150mg p.o. daily on days 1-21.
3313450|NCT00283244|Experimental|Arm C|Patients receive gemcitabine hydrochloride 1000mg/m2 IV on days 1 and 8 and erlotinib hydrochloride 100mg p.o. daily
3313451|NCT00283166|Experimental|A|Tailored Coaching and Education
3313452|NCT00283166|Other|B|Active Control
3313453|NCT00283153|Experimental|FAR|Facial affect recognition training (with computer assistance)
3313454|NCT00283153|Experimental|SEI|Stories of Emotional Inference
3313455|NCT00283114|Experimental|1|
3313456|NCT00283101|Experimental|1|SGN-40
3313457|NCT00283088|Active Comparator|Group 1|Groups 1 and 2: Parallel groups, randomized to hypothermia or no hypothermia. Both groups receive tPA as a part of standard of care.
3313458|NCT00283088|Active Comparator|Group 2|Groups 1 and 2: Parallel groups, randomized to hypothermia or no hypothermia. Both groups receive tPA as a part of standard of care.
3313459|NCT00283088|No Intervention|Group 3|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
3313460|NCT00283088|Active Comparator|Group 4|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
3313461|NCT00283088|Active Comparator|Group 5|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
3313462|NCT00283088|Active Comparator|Group 6|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
3313463|NCT00283075|Experimental|Cancer macrobeads|Cancer Macrobead placement in abdominal cavity
3313464|NCT00283062|Experimental|Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)|Participants administered docetaxel every three weeks (q3w) for 6 cycles in combination with leuprolide acetate every 3 months for 18 months immediately following prostatectomy.
3313465|NCT00283062|Active Comparator|Leuprolide Acetate - Immediate Treatment (I-HT)|Participants administered leuprolide acetate every 3 months for 18 months immediately following prostatectomy.
3313466|NCT00283062|Experimental|Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)|Participants in whom treatment was deferred from randomization until first progression - i.e. PSA progression and/or radiologically or histologically documented progression. Participants were treated with docetaxel every three weeks (q3w) for 6 cycles in combination with leuprolide acetate every 3 months for 18 months.
3320788|NCT00160355|Other|1|
3313467|NCT00283062|Active Comparator|Leuprolide Acetate - Deferred Treatment (D-HT)|Participants in whom treatment was deferred from randomization until first progression - i.e. PSA progression and/or radiologically or histologically documented progression. Participants were treated with with leuprolide acetate every 3 months for 18 months.
3313468|NCT00283049|Experimental|Insulins + Sulfonylurea (SU) + Thiazolidinedione (TZD)|Arm 1: Insulin glargine administered subcutaneously once daily plus a sulfonylurea and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
3313469|NCT00283049|Experimental|Insulins + Metformin (MET) + Thiazolidinedione (TZD)|Arm 2: Insulin glargine administered subcutaneously once daily plus metformin and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
3313470|NCT00283049|Experimental|Insulins + Metformin (MET) + Sulfonylurea (SU)|Arm 3: Insulin glargine administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added arms after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
3313471|NCT00283023|Experimental|A|Progenitor cells from the patinets with Craniotomy with V-P Shunt or ventriculostomy will be collected and cultured.
3313472|NCT00283010|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
3313473|NCT00283010|Active Comparator|Active Control|Educational DVDs
3313474|NCT00282984|Placebo Comparator|placebo|
3313475|NCT00282984|Experimental|varenicline|
3313476|NCT00282971|Experimental|Inhaled Insulin|Inhaled insulin plus oral therapy
3313477|NCT00282971|Other|Standard of Care|Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
3313478|NCT00282919|Experimental|Azithromycin plus chloroquine|Single Arm, Open label study
3313479|NCT00282906|Experimental|PET-CT|
3313480|NCT00282893|Experimental|pTBA|Prophylactic Transluminal Ballooning Angioplasty
3313481|NCT00282893|Active Comparator|Control|currently existing therapies for the treatment of vasospasm
3313482|NCT00282867|Active Comparator|tight control group|target glucose level 70-110 mg/dL
3313483|NCT00282867|Active Comparator|loose control group|target glucose level 70 - 200 mg/dL
3313484|NCT00282867|Active Comparator|usual care group|target level 70 - 300 mg/dL
3313485|NCT00282854||Group I: Cases|Children with rolandic epilepsy
3313486|NCT00282854||Group II: Controls|Individuals group matched to cases for ethnicity, sex and area of residence but lacking a primary brain disorder.
3313487|NCT00282841|Experimental|1|contrast-enhanced transcranial ultrasound to visualize the intracranial arteries
3313488|NCT00282828|Experimental|Sertraline & Clonazepam|"Phase I non-responders randomized to this group remained on sertraline at the same dose level as at entry into Phase 2 with the addition of clonazepam up to 3.0mg per day.~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 0.5mg of clonazepam per day in order to remain in the study."
3313489|NCT00282828|Experimental|Venlafaxine|"Phase I non-responders randomized to this group switched to venlafaxine with flexible titration up to 225 mg per day.~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 75 mg venlafaxine per day in order to remain in the study."
3313490|NCT00282828|Experimental|Sertraline & Placebo|"Phase I non-responders randomized to this group remained on sertraline at the same dose level as at entry into Phase 2 with the addition of placebo.~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 1 capsule of placebo per day in order to remain in the study."
3313491|NCT00282815|Active Comparator|1|CPAP
3313492|NCT00282815|Sham Comparator|2|sham CPAP (placebo)
3313493|NCT00282802||1|National Academy of Sciences/National Resource Council (NAS/NRC) World War II Veteran Twins Cohort
3313494|NCT00282776|Active Comparator|TAU|Participants will receive treatment as usual
3313495|NCT00282776|Experimental|DCM|Participants will receive care management for postpartum depression
3313496|NCT00282711||1|Standard Exercise treadmill test
3313497|NCT00282711||2|Exercise treadmill testing with nuclear imaging
3313498|NCT00282672|Sham Comparator|LGD Sham Procedure first then LGD Radiofrequency Ablation|"Sham procedure plus anti-secretory medication. Subjects with Low Grade Dysplasia (LGD) receive proton pump inhibitor (PPI) with dose of Esomeprazole 40 mg BID.~At 12 month, subjects crossover to receive radiofrequency ablation."
3313499|NCT00282672|Active Comparator|LGD:Radiofrequency ablation|Ablation System plus anti-secretory medication. Subjects with Low Grade Dysplasia (LGD) undergo an upper endoscopy with sizing of the esophageal diameter followed by radiofrequency ablation plus standard anti-secretory therapy (proton pump inhibitor, PPI-dose: Esomeprazole 40 mg BID.)
3313500|NCT00282672|Sham Comparator|HGD Sham Procedure first then HGD Radiofrequency Ablation|"Sham procedure plus anti-secretory medication. Subjects with High Grade Dysplasia (HGD) with proton pump inhibitor (PPI) dose: Esomeprazole 40 mg BID.~At 12 month, subjects crossover to receive radiofrequency ablation."
3313501|NCT00282672|Active Comparator|HGD:Radiofrequency ablation|Ablation System plus anti-secretory medication. Subjects with High Grade Dysplasia (HGD) undergo an upper endoscopy with sizing of the esophageal diameter followed by radiofrequency ablation plus standard anti-secretory therapy (proton pump inhibitor, PPI-dose: Esomeprazole 40 mg BID.)
3313502|NCT00282646|Active Comparator|1|intraarterial application of bone marrow mononuclear cells
3313503|NCT00282646|Placebo Comparator|2|intraarterial application of placebo
3313504|NCT00282581|Placebo Comparator|placebo|
3313505|NCT00282568|Experimental|Tacrolimus Modified Release|Participants were enrolled into the study on their stable twice-daily (bid) dose of tacrolimus on Day 1 and continued to receive a stable bid dose of tacrolimus through Day 7. Participants then converted to Tacrolimus Modified Release (MR), administered once daily at an equivalent dose to the patient's previous stable total daily dose of tacrolimus. Participants who completed the 4-week pharmacokinetic treatment period with tacrolimus MR could continue receiving tacrolimus MR as part of the extended treatment period of the study. Dose adjustments were allowed in order to maintain tacrolimus trough concentrations within the target range of 5 to 15 ng/mL and for clinical reasons.
3313506|NCT00282503|Active Comparator|methylprednisolone equivalent.|2mg/kg daily will be administered initially and may be tapered according to a tapering schedule provided in the protocol.
3313507|NCT00282503|Experimental|Uvadex+ECP|"Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:~Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),~Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days"
3313508|NCT00282464|Active Comparator|Ziprasidone 20 and 60mg|For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
3313509|NCT00282464|Placebo Comparator|Placebo|
3313510|NCT00282438|Experimental|Autologous hematopoietic stem cell transplantation|Autologous stem cells will be injected after conditioning
3313511|NCT00282438|Experimental|Allogeneic stem cell transplantation|Allogeneic stem cells will be injected after conditioning
3313512|NCT00282425|Experimental|Allogeneic Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation will be performed on eligible patients
3313513|NCT00282412|Experimental|Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation will be performed on eligible patients diagnosed with RA
3313514|NCT00282399|Experimental|DACO-019 2mg/m^2|DACO-019 2mg/m^2 twice daily (BID)
3313515|NCT00282399|Experimental|DACO-019 5mg/m^2|DACO-019 5mg/m^2 BID
3313516|NCT00282399|Experimental|DACO-019 10mg/m^2|DACO-019 10mg/m^2 BID
3313517|NCT00282347|Experimental|Rituximab|Participants received rituximab 1000 mg intravenously (IV) on Days 1, 15, 168, and 182. They also received mycophenolate mofetil, methylprednisolone, diphenhydramine, acetaminophen, and prednisone; see the Detailed Description for details.
3313518|NCT00282347|Placebo Comparator|Placebo|Participants received placebo intravenously (IV) on Days 1, 15, 168, and 182. They also received mycophenolate mofetil, methylprednisolone, diphenhydramine, acetaminophen, and prednisone; see the Detailed Description for details.
3313519|NCT00282334|Experimental|Home blood pressure telemonitoring|
3313520|NCT00282334|No Intervention|Conventional blood pressure monitoring|
3313521|NCT00282308|Experimental|Rituximab + methotrexate (Group A)|Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.
3313522|NCT00282308|Active Comparator|Methotrexate (Group B)|Patients received methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.
3313523|NCT00282295|Experimental|Boostrix + Menactra Group|Subjects, 11 through 18 years of age, received a booster dose of Boostrix® co-administered with Menactra™ at Day 0. The Boostrix® vaccine was administered intramuscularly into the left deltoid region and Menactra™ vaccine was administered intramuscularly into the right deltoid region.
3313524|NCT00282295|Experimental|Boostrix-Menactra Group|Subjects, 11 through 18 years of age, received one dose of Boostrix® vaccine at Day 0, followed by one dose of Menactra™ vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.
3313525|NCT00282295|Experimental|Menactra-Boostrix Group|Subjects, 11 through 18 years of age, received one dose of Menactra™ vaccine at Day 0 followed by one dose of Boostrix® vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.
3313526|NCT00282256|Experimental|Tacrolimus MR|Participants continued to receive their stable twice daily dose of tacrolimus twice daily on Day 1 through Day 7 and on Day 8 were converted to tacrolimus modified release (MR) once-daily in the morning for 7 days on a 1:1 (mg:mg) basis for their total daily dose. Patients who completed the 2-week pharmacokinetic treatment period were eligible to continue receiving tacrolimus MR as part of the extension treatment period of the study. The extended treatment period began on Day 15 and consisted of a single dose of tacrolimus MR once every morning through the end of the study.
3313527|NCT00282243|Experimental|Tacrolimus MR|"After enrollment in the pharmacokinetic period, patients were maintained on their usual dose of tacrolimus twice daily on Day 1 through Day 14 and on Day 15 were converted to tacrolimus modified release (MR) once-daily in the morning for 14 days, converted back to tacrolimus twice daily for 14 days and then converted back to tacrolimus MR formulation once-daily in the morning for 14 days, all based on a 1:1 mg for mg total daily dose conversion. The extended treatment period began on day 57 and consisted of a single dose of tacrolimus extended-release formulation once every morning through the end of the study.~Dose adjustments were allowed in order to maintain the target tacrolimus trough level within the range of 5 to 20 ng/mL and for clinical reasons."
3313528|NCT00282204|No Intervention|Control|Usual care control
3313529|NCT00282204|Experimental|Hypnosis + CD|Hypnosis plus audio cd on hypnosis
3313530|NCT00282204|Active Comparator|Audio CD on Hypnosis|Audio CD on hypnosis sessions weekly on three occasions after 34 weeks gestation
3313531|NCT00282178|Active Comparator|1|Candesartan 16-32 mg once daily
3313532|NCT00282178|Active Comparator|2|Hydrochlorothiazide 25-50 mg once daily
3313533|NCT00282178|Placebo Comparator|3|
3313534|NCT00282165|Placebo Comparator|placebo|four week double blind placebo treatment phase
3313535|NCT00282165|Active Comparator|naratriptan|four week double blind experimental treatment using daily naratriptan tablets
3313536|NCT00282152|Active Comparator|ODT|Optimal drug therapy: The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary.
3313537|NCT00282152|Experimental|DBS+ODT|"Subjects receive bilateral subthalamic nucleus (B-STN) DBS and continue to take optimal drug therapy as prescribed by their treating neurologist.~B-STN DBS: Deep brain stimulation (DBS) of both the right and left sub-thalamic nucleus (STN) is an FDA approved treatment for mid- and advanced PD. DBS is not approved for early stage PD. In mid- and advanced stage Parkinson's disease, using DBS in this area of the brain lessens symptoms and allows patients to take less drug to control the disease. Dosage and frequency are not applicable to the DBS. Once the DBS is placed, unless deemed necessary, it will not be removed.~Optimal drug therapy: The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary."
3313538|NCT00282126|Experimental|1|Participants will receive 90 meq of potassium citrate.
3313539|NCT00282126|Experimental|2|Participants will receive 60 meq of potassium citrate.
3313540|NCT00282126|Placebo Comparator|3|Participants will receive placebo.
3313541|NCT00282113|Active Comparator|ProBioPlus|
3313542|NCT00282113|Active Comparator|Culturelle|
3313543|NCT00282113|Placebo Comparator|Placebo|
3313544|NCT00282087|Other|gemcitabine/docetaxel then doxorubicin|Gemcitabine 900 mg/m2 IV over 90 minutes days 1 and 8 Docetaxel 75 mg/m2 IV day 8 (pre-medication dexamethasone 4-8 mg p.o. bid for 3 days, starting 12-24 hours prior to docetaxel). Doxorubicin 60 mg/m2 IVP every 21 days for 4 cycles (recommend use of central venous catheter access).
3313545|NCT00282048|Experimental|AG-013736 (axitinib)|AG-013736 single agent in continuous dosing until disease progression or unacceptable toxicity
3313546|NCT00282035|Experimental|APBI utilizing 3D-CRT radiation|Accelerated partial breast irradiation utilizing 3D-CRT
3313547|NCT00282035|Other|Whole breast irradiation|Whole breast irradiation
3313548|NCT00282009|Active Comparator|Basic Internet|Basic Internet
3313549|NCT00282009|Experimental|Enhanced Internet|Enhanced Internet
3313550|NCT00282009|Experimental|Enhanced Internet plus Phone|Enhanced Internet + proactive telephone counseling
3313551|NCT00281983|Experimental|Allogeneic stem cell transplantation|"Cytoreductive therapy for inducing a state of partial remission:~FC or FC-R or alternative salvage regimens (e.g. Alemtuzumab)~Conditioning regimen:~FC +/- ATG (Arm A) or FC/Busulfan +/- ATG (Arm C: refractory patients only)~allogeneic-PBSCT (from HLA-identical donor)~GVHD prophylaxis: CSA + MTX or MMF~+/- DLI (Donor lymphocyte infusions)"
3313552|NCT00281957|Experimental|Arm I (sorafenib, temsirolimus)|Patients receive oral sorafenib twice daily on days 1-28 and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
3313553|NCT00281957|Experimental|Arm II (sorafenib, tipifarnib)|Patients receive oral sorafenib as in arm I and oral tipifarnib twice daily on days 1-21
3313554|NCT00281944|Experimental|Treatment (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 followed by fluorouracil IV continuously over 46 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3313555|NCT00281918|Experimental|Fludarabine+Cyclophosphamide+Rituximab (FCR)|
3313556|NCT00281918|Active Comparator|Fludarabine+Cyclophosphamide (FC)|
3313557|NCT00281892|Experimental|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
3313558|NCT00281892|Active Comparator|fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
3313559|NCT00281879|Active Comparator|Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI)|
3313560|NCT00281879|Active Comparator|Busulfan and Cyclophosphamide (Cytoxan)|
3313561|NCT00281879|Active Comparator|BEAM Regimen|On the day of your admission, you will start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. Chemotherapy will begin on Day -6 with carmustine (BCNU), followed by etoposide (VP-16), cytosine arabinoside (ARA-C), and melphalan. This conditioning regimen is known as the BEAM regimen. The dose of this therapy is high enough to kill cancer cells but will also kill all of your normal blood forming cells. Subjects undergoing the BEAM regimen will not have total body irradiation (TBI).
3313562|NCT00281879|Active Comparator|Low-Dose Fludarabine and TBI(for second stem cell donation)|A conditioning regimen of low-dose fludarabine and TBI is used in the event that a second donation of hematopoietic stem cells is necessary. Chemotherapy with Fludarabine will begin 4 days prior to your transplant. This drug will be given through the catheter in your chest daily for 3 days. TBI (radiation) will be given to you on the day of your transplant. After your TBI, your donor's stem cells / bone marrow will be given to you through your catheter. The drugs cyclosporine and mycophenolate mofetil (MMF) will be given orally to help you accept your donor's cells.
3313563|NCT00281879|Active Comparator|Busulfan, Cyclophosphamide, and Fludarabine (Pediatric only)|On the day of your admission you will start to take a drug called Dilantin which is used to help prevent seizures while you receive your chemotherapy drugs. You will also start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. On the next day, you will then begin your conditioning therapy with a drug called busulfan. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm four times per day for four days. After the busulfan treatment, you will receive 4 doses each of two drugs, cyclophosphamide (also known as Cytoxan) and fludarabine, over 2 hours into your vein.
3313564|NCT00281879|Active Comparator|ATG For Cord Blood Transplants|If you are undergoing a pre-transplant conditioning regimen prior to undergoing a cord blood transplant, you will receive a drug called ATG to improve your chances of engraftment and decrease your risk of graft versus host disease. You may receive ATG 3 times during your transplant regimen on days -3 through days -1 in addition to your pre-transplant conditioning therapy. Methylprednisolone will also be given during each dose of ATG to help reduce any reactions during infusion.
3313565|NCT00281879|Active Comparator|DLI (Donor Leukocyte Infusion)|Donor Leukocyte Infusions: You will receive DLI from your original transplant donor. This will be given through a vein , usually in your arm. It will be similar to getting a platelet or blood transfusion. You may require more than one DLI. The decision to give you another infusion will be determined by your condition, relapse status, GVHD and how much DLI you were given before. You may need chemotherapy and/or radiation to improve your disease status prior to additional DLI's.
3313608|NCT00281489|Active Comparator|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
3313566|NCT00281879|Active Comparator|Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric only)|On the day after your admission, you will start receiving radiation therapy (TBI). Radiation will be given to you 2 times a day for 3 days. On the next day, you will then begin your chemotherapy with a drug called etoposide. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm for one day. After the etoposide treatment, on the next day you will receive cyclophosphamide (also known as Cytoxan) for 2 days. When you are given cyclophosphamide, you will also be given a medication called MESNA to help protect your bladder from damage. After you have completed the cyclophosphamide you will rest one day without any anti-cancer therapy. This allows your body time to remove and inactivate the chemotherapy. After a day of rest, you will be given your donor's cells.
3313567|NCT00281840|Experimental|bevacizumab with docetaxel and radiation therapy|
3313568|NCT00281827|Experimental|Treatment Arm|Chemotherapy treatment (carboplatin, gemcitabine and thalidomide) every 21 days for 3 courses.
3313569|NCT00281736|Experimental|Arm I|Patients receive HPPH IV over 1 hour on day 1. Approximately 24 hours later, the lesion is exposed to laser light endoscopically.
3313570|NCT00281736|Experimental|Arm II|Patients receive HPPH as in arm I, but at a higher dose, followed by laser light exposure.
3313571|NCT00281697|Experimental|Standard chemotherapy + bevacizumab|Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.
3313572|NCT00281697|Placebo Comparator|Standard chemotherapy + placebo|Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.
3313573|NCT00281684|Experimental|Placebo|Eligible participants received a single dose of SB705498 matching placebo capsules (4 placebo capsules) via oral route and were followed up to a maximum of 14 days.
3313574|NCT00281684|Experimental|SB705498 400 mg|Eligible participants received a single dose of SB705498 400 milligram (mg) capsules (2 x 200 mg capsules plus 2 placebo capsules) via oral route and were followed up to a maximum of 14 days.
3313575|NCT00281684|Experimental|SB705498 1000 mg|Eligible participants received a single dose of SB705498 1000 mg capsules (2 x 200 mg capsules plus 2 x 300 mg capsules) via oral route and were followed up to a maximum of 14 days.
3313576|NCT00281684|Experimental|Co-Codamol|Eligible participants received a single dose of Co-codamol capsules (2 x Paracetamol Ph Eur 500 mg, codeine phosphate hemihydrate Ph Eur 12.8 mg plus two placebo capsules) via oral route and were followed up to a maximum of 14 days.
3313577|NCT00281671|Other|1|In this crossover pilot study, patients are randomly assigned to receive either nesiritide or placebo infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.
3313578|NCT00281658|Experimental|Combination|Paclitaxel and Lapatinib (Blinded)
3313579|NCT00281658|Active Comparator|Paclitaxel|Paclitaxel and Placebo (Blinded)
3313580|NCT00281658|Other|Monotherapy Extension|Open-label monotherapy lapatinib
3313581|NCT00281632|Experimental|Pazopanib|800 mg GW786034 administered orally on a daily basis.
3313582|NCT00281619||Mycophenolic Acid (CellCept)|purpose of this study is to determine how fast children, who have had a recent kidney transplant, absorb, breakdown and eliminate mycophenolic acid (CellCept) following their prescribed dose
3313583|NCT00281606|Active Comparator|LPV/r (800/200 mg) 10 ml liquid|Once daily Lopinovir/ritonavir (800/200 mg) taken as a 10 ml liquid
3313584|NCT00281606|Active Comparator|LPV/r (800/200 mg) 6 gel capsules|Once daily Lopinavir/ritonavir (800/200 mg) as 6 gel capsules
3313585|NCT00281580|Placebo Comparator|Placebo|Placebo once daily for eight weeks
3313586|NCT00281580|Experimental|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
3313587|NCT00281580|Experimental|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
3313588|NCT00281580|Experimental|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
3313589|NCT00281580|Experimental|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
3313590|NCT00281580|Experimental|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
3313591|NCT00281580|Active Comparator|Amlodipine 10 mg|Amlodipine 5 mg for two weeks and forced titrated to amlodipine 10 mg for six weeks once daily
3313592|NCT00281580|Experimental|Telmisartan 20 / Amlodipine 2.5|Telmisartan 20/ Amlodipine 2.5 mg once daily for eight weeks
3313593|NCT00281580|Experimental|Telmisartan 20 / Amlodipine 5|Telmisartan 20 / Amlodipine 5 mg once daily for eight weeks
3313594|NCT00281580|Experimental|Telmisartan 20 / Amlodipine 10|Telmisartan 20 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
3313595|NCT00281580|Experimental|Telmisartan 40 / Amlodipine 2.5|Telmisartan 40 / Amlodipine 2.5 for eight weeks
3313596|NCT00281580|Experimental|Telmisartan 40 / Amlodipine 5|Telmisartan 40 / Amlodipine 5 for eight weeks
3313597|NCT00281580|Experimental|Telmisartan 40 / Amlodipine 10|Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
3313598|NCT00281580|Experimental|Telmisartan 80 / Amlodipine 2.5|Telmisartan 80 / Amlodipine 2.5 for eight weeks
3313599|NCT00281580|Experimental|Telmisartan 80 / Amlodipine 5|Telmisartan 80 / Amlodipine 5 mg for eight weeks
3313600|NCT00281580|Experimental|Telmisartan 80 / Amlodipine 10|Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
3313601|NCT00281554|Experimental|1|
3313602|NCT00281528|Experimental|260 mg/m^2 ABI-007 every 3 weeks|260 mg/m^2 every 3 weeks and 15 mg/kg bevacizumab every 3 weeks
3313603|NCT00281528|Experimental|260 mg/m^2 ABI-007 every 2 weeks|260 mg/m^2 ABI-007 every 2 weeks and 10 mg/kg bevacizumab every 2 weeks
3313604|NCT00281528|Experimental|130 mg/m^2 ABI-007 weekly|130 mg/m^2 ABI-007 weekly (without a week of 'rest') and 10 mg/kg bevacizumab every 2 weeks
3313605|NCT00281515|Experimental|Lonafarnib / Paclitaxel /Carboplatin|
3313606|NCT00281515|Other|Paclitaxel/Carboplatin|Standard Chemotherapy
3313607|NCT00281489|Experimental|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
3313812|NCT00278785|No Intervention|1|Control group to receive informational pamphlet on alcohol use and list of self referral agencies
3313609|NCT00281463|Experimental|Pushrim Activated Power Assist Wheelchair|Participants will be asked to propel both their own chair and a pushrim activated power assist wheelchair on a computer controlled wheelchair dynamometer.
3313610|NCT00281424|No Intervention|control|no pedometer
3313611|NCT00281424|Experimental|pedometer|given pedometer
3313612|NCT00281359|Experimental|With heat|heat applied to contracted tissues prior to using the active stretching orthosis.
3313613|NCT00281359|Placebo Comparator|Without heat|No heat applied to the contracted tissues prior to using the stretching orthosis
3313614|NCT00281346|Experimental|transthoracic Doppler echocardiography|
3313615|NCT00281320|Experimental|Asenapine 2-10 mg BID|Dose titration from 2 mg to 5 mg to 10 mg twice daily (BID)
3313616|NCT00281320|Experimental|Asenapine 5-10mg BID|Dose titration from 5 mg to 10 mg BID
3313617|NCT00281255|Experimental|allopurinol|
3313618|NCT00281255|Placebo Comparator|placebo|
3313619|NCT00281242||Research subjects|All participants undergo the same testing in this observational trial. There is no randomization, and no interventions other than blood drawing.
3313620|NCT00281203||healthy smokers|Must be free of serious diseases that might make it dangerous to undergo bronchoscopy.
3313621|NCT00281190||Healthy smokers|Smokers with normal pulmonary function
3313622|NCT00281190||COPD patients|COPD patients
3313623|NCT00281099|Active Comparator|VVI 40 pacing|Backup ventricular pacing (VVI) at 40 beats per minute
3313624|NCT00281099|Active Comparator|MVP pacing|Managed ventricular pacing (MVP) at 60 beats per minute
3313625|NCT00281073|Active Comparator|TEE and ICE|Serial use of TEE and ICE for comparative analysis
3313626|NCT00281073|Active Comparator|ICE or TEE|
3313627|NCT00281034||OASIS Study Group|
3313628|NCT00281021|Experimental|Erlotinib and Digoxin|Erlotinib plus Digoxin
3313629|NCT00281008|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
3313630|NCT00281008|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
3313631|NCT00281008|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
3313632|NCT00281008|Experimental|Cohort D|Loading doses followed by extended weekly maintenance doses
3313633|NCT00280995|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
3313634|NCT00280995|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
3313635|NCT00280995|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
3313636|NCT00280995|Experimental|Cohort D|Loading doses followed by extended weekly maintenance doses
3313637|NCT00280969|Experimental|atazanavir arm|Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
3313638|NCT00280969|Active Comparator|efavirenz arm|Patients are treated with efavirenz 300mg along with Epzicom.
3313639|NCT00280826|Experimental|Efalizumab|
3313640|NCT00280813|Active Comparator|Supportive Treatment in Alcohol Recovery (STAR)|
3313641|NCT00280800|Active Comparator|1|constant CPAP
3313642|NCT00280800|Experimental|2|automatic CPAP
3313643|NCT00280761||1|Single Arm Trial
3313644|NCT00280748|Other|Single Arm Study|Single Arm Study
3313645|NCT00280735|Other|Single Arm Trial|adjuvant carboplatin plus docetaxel carboplatin area under curve (AUC) = 6 IV on day 1 every 3 weeks for 4 cycles docetaxel 75 mg/m² IV on day 1 every 3 weeks for 4 cycles
3313646|NCT00280709|Active Comparator|1|Covered metal stent
3313647|NCT00280709|Active Comparator|2|Uncovered metal stent
3313648|NCT00280696|Experimental|Lev 0.5 g|Levetiracetam 0.5 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
3313649|NCT00280696|Experimental|Lev 1 g|Levetiracetam 1 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
3313650|NCT00280696|Experimental|Lev 2 g|Levetiracetam 2 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
3313651|NCT00280696|Experimental|Lev 3 g|Levetiracetam 3 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
3313652|NCT00280696|Placebo Comparator|Placebo|Placebo tablets as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
3313653|NCT00280683|Active Comparator|Arginine|Enrolled subjects will take L-arginine orally, at 0.1 g/kg/day. Subjects will take three to four 1 g capsules (based on weight) of L-arginine twice daily for three months. L-arginine capsules were obtained from Jarrow Pharmaceuticals.
3313654|NCT00280683|Placebo Comparator|Placebo|Enrolled subjects took three to four placebo capsules that matched color and size of the intervention twice daily for three months. Matching placebo capsules were obtained from Jarrow Pharmaceuticals.
3313655|NCT00280670|Experimental|Cognitive Behavioral Therapy|
3313656|NCT00280670|No Intervention|Waitlist|
3313657|NCT00280657|Experimental|Arm 1|
3313658|NCT00280657|Active Comparator|Arm 2|
3313659|NCT00280657|Placebo Comparator|Arm 3|
3313660|NCT00280631|Experimental|1|Dose Escalation Study of TLK199 Tablets From 200 mg Per day To 6000 mg Per Day
3313661|NCT00280592|Placebo Comparator|Placebo|
3313662|NCT00280592|Experimental|Cranberry|Cranberry
3313663|NCT00280579||Cases|Cases would have had their blood cyanide concentration measured
3313664|NCT00280566|Experimental|Ziprasidone|Active treatment, double-blind, randomized arm
3313665|NCT00280566|Placebo Comparator|Placebo|Placebo treatment, double-blind, randomized arm
3313666|NCT00280553|No Intervention|patient controlled analgesia (PCA) only|
3313667|NCT00280553|Other|PCA and pump with saline infusion for up to five days|
3313668|NCT00280553|Other|PCA and bupivicaine infusion for up to five days|
3313669|NCT00280501|Active Comparator|1|Quetiapine
3313670|NCT00280501|Active Comparator|2|Sulpiride
3313671|NCT00280501|Placebo Comparator|3|Placebo
3313813|NCT00278785|Experimental|2|Intervention group receives pamphlet on alcohol and self referral information in addition to brief motivational interview
3313672|NCT00280488|Active Comparator|1) MI with SO|Motivational Interviewing (MI), a brief, directive, non-confrontational intervention, with inclusion of a significant other (SO) in prolonged, intensive alcohol treatment.
3313673|NCT00280488|Active Comparator|2) MI with patient only|Motivational Interviewing (MI), a brief, directive, non-confrontational intervention, with the individual patient
3313674|NCT00280488|Active Comparator|3) Assessment only|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
3313675|NCT00280475|Active Comparator|1|Device: Whole brain radiation therapy arm
3313676|NCT00280475|Experimental|2|Device: Salvage stereotactic radiosurgery arm
3313677|NCT00280462|Active Comparator|1|Nifedipine
3313678|NCT00280462|Active Comparator|2|L-Arginin
3313679|NCT00280462|Placebo Comparator|3|Placebo
3313680|NCT00280397|Experimental|1|
3313681|NCT00280384|Active Comparator|E2014 (Botulinum toxin type B)|
3313682|NCT00280384|Placebo Comparator|E2014 (Botulinum toxin type B) Placebo|
3313683|NCT00280332||A|colonic adenoma
3313684|NCT00280332||B|colonic without adenoma
3313685|NCT00280319|Experimental|IPT arm|interpersonal psychotherapy for groups (IPT-G). this consists of psychotherapy provided to participants in a group format.
3313686|NCT00280319|Experimental|CP arm|Creative Play therapy consists of play activities provided to participants in groups.
3313687|NCT00280319|No Intervention|control|those who are wait-list controls
3313688|NCT00280293|Placebo Comparator|1|Placebo
3313689|NCT00280293|Active Comparator|2|LAmotrigine
3313690|NCT00280280|Experimental|1|This study will explore the safety and effectiveness of Botox versus baclofen in treatment subjects with upper-limb spasticity due to neurological damage or a stable neurological disorder. Subjects will be randomized to one of two treatment groups: intramuscular Botox plus oral placebo or intramuscular placebo plus oral baclofen.
3313691|NCT00280241|Experimental|FLUDARABINE, CYCLOSPHOSPHAMIDE AND RITUXIMAB|
3313692|NCT00280228|Experimental|1|Home Based Treatment
3313693|NCT00280228|Active Comparator|2|Treatment as Usual
3313694|NCT00280215|Active Comparator|1|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker. Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
3313695|NCT00280215|Placebo Comparator|2|Patients will take placebo for 24 months.
3313696|NCT00280150|Experimental|Cohort 1|Bevacizumab 10 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
3313697|NCT00280150|Experimental|Cohort 2|Bevacizumab 10 mg + Erlotinib 100 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
3313698|NCT00280150|Experimental|Cohort 3|Bevacizumab + Erlotinib 150 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
3313699|NCT00280150|Experimental|Phase II|Bevacizumab + Erlotinib 100 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
3313700|NCT00280111|Experimental|1|116E AGMK
3313701|NCT00280111|Experimental|2|I321 AGMK
3313702|NCT00280111|Placebo Comparator|3|Placebo
3313703|NCT00280098|Experimental|single group|
3313704|NCT00280059|Experimental|1|
3313705|NCT00280059|Active Comparator|2|
3313706|NCT00280033|Placebo Comparator|9|Saline administered on days 0 and 28.
3313707|NCT00280033|Experimental|8|45 mcg alone administered on days 0 and 28.
3313708|NCT00280033|Experimental|7|30 mcg plus aluminum hydroxide administered on days 0 and 28.
3313709|NCT00280033|Experimental|6|30 mcg alone administered on days 0 and 28.
3313710|NCT00280033|Experimental|5|15 mcg plus aluminum hydroxide administered on days 0 and 28.
3313711|NCT00280033|Experimental|4|15 mcg plus MF59 administered on days 0 and 28.
3313712|NCT00280033|Experimental|3|15 mcg alone administered on days 0 and 28.
3313713|NCT00280033|Experimental|2|7.5 mcg plus aluminum hydroxide administered on days 0 and 28.
3313714|NCT00280033|Experimental|1|7.5 mcg plus MF59 administered on days 0 and 28.
3313715|NCT00280020|Experimental|CBT|
3313716|NCT00280020|Experimental|TCC|
3313717|NCT00280020|Active Comparator|SS|
3313718|NCT00280007|Experimental|1|bevacizumab infusion evey 2 weeks
3313719|NCT00280007|Placebo Comparator|2|placebo infusion
3313720|NCT00279942|Active Comparator|Soy|A shake that contained 20 g of soy protein and 160 mg of soy isoflavone.
3313721|NCT00279942|Placebo Comparator|Placebo|A shake that contained 20 g of milk-based protein (casein) and no isoflavone.
3313722|NCT00279916|Active Comparator|Triamcinolone acetonide|"Triamcinolone acetonide nasal spray; Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms) for 6 weeks duration.~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms) for 6 weeks duration."
3313723|NCT00279916|Sham Comparator|Placebo|"Placebo nasal spray; Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily for 6 weeks duration.~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily for 6 weeks duration."
3313724|NCT00279903|Active Comparator|Cortisone|
3313725|NCT00279903|Experimental|Low Dose Btx-A|
3313726|NCT00279903|Experimental|High Dose Btx-A|
3313727|NCT00279877|Active Comparator|vertebroplasty|vertebroplasty
3313728|NCT00279877|Active Comparator|kyphoplasty|kyphoplasty
3313769|NCT00279409|Placebo Comparator|Sugar pill|"This treatment arm (also called the simple treatment arm) will consist of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus a placebo matching aripiprazole. Placebo pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis."
3313770|NCT00279318||General Population, First Degree Relative|Newborns with high risk HLA in the general population or having a first-degree relative affected with T1DM.
3313729|NCT00279825|Other|Sequence 1|Subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR.
3313730|NCT00279825|Other|Sequence 2|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo.
3313731|NCT00279825|Other|Sequence 3|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Third treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo.
3313732|NCT00279825|Other|Sequence 4|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo.
3313733|NCT00279812|Placebo Comparator|Placebo|Placebo
3313734|NCT00279812|Experimental|50ug selenium enriched yeast|50ug/d selenium enriched yeast (containing 60% selenomethionine)
3313735|NCT00279812|Experimental|100ug selenium enriched yeast|100ug/d selenium enriched yeast (containing 60% selenomethionine)
3313736|NCT00279812|Experimental|200ug selenium enriched yeast|200ug/d selenium enriched yeast (containing 60% selenomethionine)
3313737|NCT00279812|Experimental|Control onion|3 meals/wk containing un-enriched onions equivalent to 4ug/d Se
3313738|NCT00279812|Experimental|Enriched onion|3 meals/wk containing enriched onions equivalent to 50ug/d Se
3313739|NCT00279799|Experimental|Afiya group intervention + HIV prevention phone sessions|Afiya group-based intervention plus individually tailored HIV prevention phone sessions
3313740|NCT00279799|Active Comparator|Afiya group session + nutrition phone sessions|Afiya group-based intervention plus individually tailored nutrition phone sessions
3313741|NCT00279773|Experimental|TKI258 - dose escalation|Dose-Escalation
3313742|NCT00279773|Experimental|TKI258 - dose expansion|Dose-Expansion
3313743|NCT00279734|Experimental|Group 1|
3313744|NCT00279734|Active Comparator|Group 2|
3313745|NCT00279734|Active Comparator|Group 3|
3313746|NCT00279734|Active Comparator|Group 4|
3313747|NCT00279708|Active Comparator|Intervention Arm (Atorvastatin)|Atorvastatin: Subjects were assigned to the treatment intervention by way of double blind masking. Atorvastatin 80 mg/day was the initial treatment given, as tolerated for a 12 month period. During the study, a 50% dose reduction was applied for subjects meeting pre-specified criteria.
3313748|NCT00279708|Placebo Comparator|Control Arm (Placebo)|Placebo: In a double-blind fashion, subjects were assigned to receive the sham intervention which appeared the same as the intervention agent. For subjects meeting pre-specified criteria, a 50% dose reduction was applied during the 12 month treatment phase of the study: Placebo vs. Atorvastatin
3313749|NCT00279695||1|Subjects with glaucoma and age-matched normals
3313750|NCT00279695||2|normal volunteers, two age groups, one 18-25 years old, one 50 years and older.
3313751|NCT00279695||3|subjects with tumors of the iris and ciliary body
3313752|NCT00279695||4|subjects with age-related macular degeneration and age-matched normals
3313753|NCT00279630|Experimental|type of exericse|type of exercise
3313754|NCT00279617|Active Comparator|Levetricetam|open label treatment
3313755|NCT00279591|Active Comparator|Continuous Blood Pressure Monitoring|Patients received continuous blood pressure monitoring the entire time they were in med flight to the hospital.
3313756|NCT00279591|Placebo Comparator|Standard of care blood pressure monitoring|Patients received the normal standard of care for blood pressure monitoring during the course of the med flight to the hospital.
3313757|NCT00279500|Experimental|single arm study|Argus 16 Retinal Stimulation System-single arm study.
3313758|NCT00279487|Active Comparator|Arm 1|Patients will receive 1200mg gabapentin 1-2 hours prior to surgery.
3313759|NCT00279487|Placebo Comparator|Arm 2|Patients will receive placebo 1-2 hours prior to surgery.
3313760|NCT00279461|Experimental|A,|Arm A: Vitamin D 2,000 units daily all in one capsule for 6 months
3313761|NCT00279461|Placebo Comparator|B|Arm B: matching placebo one capsule daily for 6 months
3313762|NCT00279448|Experimental|A|
3313763|NCT00279448|Active Comparator|B|
3313764|NCT00279435|Placebo Comparator|placebo|
3313765|NCT00279435|Experimental|visilizumab|
3313766|NCT00279422|Placebo Comparator|placebo|
3313767|NCT00279422|Experimental|visilizumab|
3313768|NCT00279409|Active Comparator|aripiprazole|"This treatment arm (also called the combination arm) consists of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus augmentation with aripiprazole. Aripriprazole pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis. Dosing will start at 2.5 mg and will be titrated up to 5 mg by week 1, and up to 10 mg by week 2 and for the remainder of the trial."
3313814|NCT00278772|Experimental|1|Divalproex
3313771|NCT00279305|Experimental|Rituximab Intravenous Infusion|Participants will receive active rituximab (anti-CD20 monoclonal antibody) as an intravenous infusion, with 4 administrations at weeks 0, 1, 2, and 3 at a dose of 375mg/m2
3313772|NCT00279305|Placebo Comparator|Placebo Intravenous Infusion|Participants will receive placebo given as an intravenous infusion with 4 administrations at weeks 0, 1, 2, and 3.
3313773|NCT00279201|Active Comparator|Insulin glargine|Initiation Phase: Insulin glargine for 24 weeks Maintenance: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.
3313774|NCT00279201|Experimental|Lispro Low Mix|Initiation Phase: Lispro Low Mix (LM) for 24 weeks Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.
3313775|NCT00279201|Experimental|Lispro Mid Mix prior Lispro Low Mix addendum|Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.
3313776|NCT00279201|Experimental|Lispro Low Mix prior Glargine addendum|Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Low Mix for 24 weeks in the Intensification Addendum Phase
3313777|NCT00279201|Active Comparator|Basal bolus prior Lispro Low Mix addendum|Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.
3313778|NCT00279201|Active Comparator|Basal bolus prior Glargine addendum|Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.
3313779|NCT00279175|Experimental|BMC|Intracoronary infusion of autologous bone marrow derived cells
3313780|NCT00279175|Placebo Comparator|Placebo|Intracoronary infusion of Placebo medium
3313781|NCT00279149|Experimental|surgery|surgery
3313782|NCT00279110|Experimental|A|
3313783|NCT00279110|No Intervention|B|
3313784|NCT00279019|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive treatment sequence 1; GSK233705 20 micrograms, GSK233705 100 micrograms, tiotropium and placebo.
3313785|NCT00279019|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive treatment sequence 2; GSK233705 20 micrograms, Placebo, GSK233705 50 micrograms and tiotropium.
3313786|NCT00279019|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive treatment sequence 3; GSK233705 20 micrograms, tiotropium, Placebo and GSK233705 50 micrograms.
3313787|NCT00279019|Experimental|Subjects receiving treatment sequence 4|Eligible subjects will receive treatment sequence 4; GSK233705 20 micrograms, placebo, tiotropium and GSK233705 50 micrograms.
3313788|NCT00279019|Experimental|Subjects receiving treatment sequence 5|Eligible subjects will receive treatment sequence 5; Placebo, tiotropium, GSK233705 20 micrograms and GSK233705 50 micrograms.
3313789|NCT00279019|Experimental|Subjects receiving treatment sequence 6|Eligible subjects will receive treatment sequence 6; Placebo, GSK233705 20 micrograms, GSK233705 50 micrograms and tiotropium.
3313790|NCT00279019|Experimental|Subjects receiving treatment sequence 7|Eligible subjects will receive treatment sequence 7; tiotropium, GSK233705 20 micrograms, GSK233705 50 micrograms and Placebo.
3313791|NCT00279019|Experimental|Subjects receiving treatment sequence 8|Eligible subjects will receive treatment sequence 8; tiotropium, GSK233705 20 micrograms, Placebo and GSK233705 50 micrograms.
3313792|NCT00279019|Experimental|Subjects receiving treatment sequence 9|Eligible subjects will receive treatment sequence 9; GSK233705 20 micrograms, tiotropium, GSK233705 50 micrograms and Placebo.
3313793|NCT00279019|Experimental|Subjects receiving treatment sequence 10|Eligible subjects will receive treatment sequence 10; GSK233705 20 micrograms, GSK233705 100 micrograms, Placebo and tiotropium.
3313794|NCT00279019|Experimental|Subjects receiving treatment sequence 11|Eligible subjects will receive treatment sequence 11; Placebo, GSK233705 20 micrograms, tiotropium, and GSK233705 50 micrograms.
3313795|NCT00279019|Experimental|Subjects receiving treatment sequence 12|Eligible subjects will receive treatment sequence 12; Tiotropium, Placebo, GSK233705 20 micrograms and GSK233705 50 micrograms.
3313796|NCT00279019|Experimental|Subjects receiving treatment sequence 13|Eligible subjects will receive treatment sequence 13; Placebo, GSK233705 20 micrograms, GSK233705 50 micrograms and GSK233705 100 micrograms.
3313797|NCT00279019|Experimental|Subjects receiving treatment sequence 14|Eligible subjects will receive treatment sequence 14; GSK233705 20 micrograms, placebo, GSK233705 50 micrograms and GSK233705 100 micrograms.
3313798|NCT00279019|Experimental|Subjects receiving treatment sequence 15|Eligible subjects will receive treatment sequence 15; GSK233705 20 micrograms, GSK233705 100 micrograms, Placebo and GSK233705 50 micrograms.
3313799|NCT00279019|Experimental|Subjects receiving treatment sequence 16|Eligible subjects will receive treatment sequence 16; GSK233705 20 micrograms, GSK233705 100 micrograms, GSK233705 50 micrograms and Placebo.
3313800|NCT00278993|Active Comparator|1|With stratification
3313801|NCT00278954|Other|Gammaplex|Gammaplex
3313802|NCT00278915|Experimental|1|
3313803|NCT00278902|Experimental|ARRY-334543|
3313804|NCT00278889|Active Comparator|1|Bevacizumab + FOLFOX
3313805|NCT00278889|Experimental|2|AZD2171 + FOLFOX
3313806|NCT00278876|Experimental|imatinib mesylate|patients receiving adjuvant imatinib mesylate
3313807|NCT00278863|Active Comparator|S-1|
3313808|NCT00278863|Active Comparator|Capecitabine|
3313809|NCT00278837|Experimental|Mindfulness based meditation program|Meditation and Breast Cancer: Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress reduction and cognitive-affective-behavioral learning.
3313810|NCT00278824|Experimental|50 mcg/hr matrix fentanyl patch|active 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch (20 cm2)
3313811|NCT00278824|Placebo Comparator|Placebo Patch|placebo (20 cm2) will be indistinguishable in size, shape, and appearance to the active matrix fentanyl patch
3313815|NCT00278772|Placebo Comparator|2|
3313816|NCT00278746|Experimental|1|Zinc and ORS were promoted for treatment of diarrhea in underfive children
3313817|NCT00278746|Other|2|Promoted routine management of diarrhea in underfive with ORS
3313818|NCT00278694|Experimental|Chemoradiation|Neoadjuvant chemotherapy and chemoradiation
3313819|NCT00278681|Experimental|I|Zinc and ORS
3313820|NCT00278655|Experimental|Hematopoietic stem cell transplantation|All participants will undergo hematopoietic stem cell transplantation after receiving conditioning regimen.
3313821|NCT00278642|Experimental|stem cell transplantation|
3313822|NCT00278629|Experimental|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation will be performed after conditioning regimen
3313823|NCT00278590|Experimental|allogeneic stem cell transplantation|allogeneic stem cell transplantation will be performed
3313824|NCT00278577|Experimental|Autologous Hematopoietic Stem Cell Transplant|
3313825|NCT00278564|Experimental|Hematopoietic stem cell transplantation|Intervention as hematopoietic stem cells transplantation after conditioning regimen: Autologous hematopoietic stem cells will be injected after conditioning regimen
3313826|NCT00278551|Experimental|heatopoietic stem cell transplant|
3313827|NCT00278538|Experimental|hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation will be performed
3313828|NCT00278525|Experimental|stem cell trasplantation|intervention as stem cell transplantation after conditioning regimen
3313829|NCT00278525|Active Comparator|standard of care|medication as standard of care will be given
3313830|NCT00278512|Experimental|Autologous Stem Cell Transplant|Autologous Stem Cell Transplant will be performed on eligible patients
3313831|NCT00278512|Experimental|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant will be performed on eligible patients
3313832|NCT00278499||1|Female sex workers
3313833|NCT00278499||2|Female sex workers' clients (miners)
3313834|NCT00278486|Experimental|stem cell transplantation|
3313835|NCT00278473|Experimental|Meta-Cognitive Therapy|Cognitive behavioral group. Cognitive behavioral therapy focuses on changing patterns of thinking and behavior. Each group consists of 6 to 8 members and sessions are led by a psychologist.
3313836|NCT00278473|Active Comparator|Supportive Therapy|Social support problem-solving group. Social support problem-solving focuses on general support, problem solving, and information sharing. Each group consists of 6 to 8 members and sessions are led by a psychologist.
3313837|NCT00278447|Active Comparator|1) CDM|Chronic Disease Management
3313838|NCT00278447|Active Comparator|2) Standard care|Standard care
3313839|NCT00278434|Experimental|Zoledronate|"100 cc of saline with 4 mg of zoledronate intravenous (IV), over 20 minutes, for 3 doses one week apart~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.~After completion of study treatment, patients are followed at week 10 by telephone."
3313840|NCT00278434|Placebo Comparator|Saline|"100 cc of saline IV, over 20 minutes, for 3 doses one week apart~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.~After completion of study treatment, patients are followed at week 10 by telephone."
3313841|NCT00278421|Active Comparator|Interventional: 6 R-CHOP-21|Arm I: Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin hydrochloride IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 3 more courses of R-CHOP.
3313842|NCT00278421|Active Comparator|Interventional: 4 R-CHOP-21 + 2 x R|Arm II: Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 1 more course of R-CHOP followed by 2 courses of rituximab alone.
3313843|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-21|Arm I (R-CHOP-21): Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3313844|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-21 + radiotherapy|Arm II (R-CHOP-21 and radiotherapy): Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve a complete remission (CR) undergo radiotherapy 5 days a week for approximately 5½ weeks.
3313845|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-14|Arm III (R-CHOP-14): Patients receive R-CHOP as in arm I. Patients also receive filgrastim (G-CSF) subcutaneously once daily on days 4-13 or until blood counts recover. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3313846|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-14 and radiotherapy|Arm IV (R-CHOP-14 and radiotherapy): Patients receive R-CHOP as in arm I. Patients also receive G-CSF an in arm III. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve CR undergo radiotherapy as in arm II.
3313847|NCT00278395|Experimental|Arm I|Patients receive oral vorinostat (SAHA) twice daily on days 1-3, 8-10, 15-17, and 22-24. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may have the option of continuing treatment beyond 52 weeks at the discretion of the investigator.
3313848|NCT00278382|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily in the absence of disease progression or unacceptable toxicity.
3313849|NCT00278369|Experimental|A|6 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course
3313850|NCT00278369|Experimental|B|9 mcg/kg Denileukin Diftitox administered IV/daily on days -4 to -2 of standard interleukin 2 dose course
3313851|NCT00278369|Experimental|C|9 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course
3314095|NCT00273650|Placebo Comparator|B|Saline placebo
3313852|NCT00278343|Experimental|Treatment (cediranib maleate)|Patients receive cediranib maleate PO QD every 4 weeks in the absence of disease progression or unacceptable toxicity.
3313853|NCT00278330|Experimental|Arm I|Patients will receive a 1-hour infusion of flavopiridol on 5 days in week 1 and vorinostat by mouth three times a day in weeks 1 and 2. Treatment may repeat every 3 weeks for as long as benefit is shown.
3313854|NCT00278278|Experimental|Arm I|"Patients receive high-dose methotrexate IV over 24 hours on days 1 and 15 and leucovorin calcium IV every 6 hours on days 2-3 an 16-17. Four weeks later, patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.~Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Beginning seven days prior to completion of radiotherapy, patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5."
3313855|NCT00278278|Active Comparator|Arm II|"Patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.~Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Beginning seven days prior to completion of radiotherapy, patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5."
3313856|NCT00278265|Experimental|MTX followed by fludarabine|MTX is given with a dose of 10-20mg weekly Fludarabine is dosed with 25mg/m2 day 1-3 of 28 days, up to 4 cycles
3313857|NCT00278135|Active Comparator|1|
3313858|NCT00278135|Placebo Comparator|2|
3313859|NCT00278109|Experimental|Experimental|
3313860|NCT00278070|Active Comparator|1|
3313861|NCT00278070|Active Comparator|2|
3313862|NCT00278070|Active Comparator|3|
3313863|NCT00277888|Experimental|Femoral route|
3313864|NCT00277888|Experimental|Jugular route|
3313865|NCT00277862|Active Comparator|1|"Pegylated IFN- alpha 2b~Ribavirin for 24 weeks (patients with RVR)"
3313866|NCT00277862|Active Comparator|2|"Pegylated IFN- alpha 2b~Ribavirin for 36 weeks (patients with complete EVR)"
3313867|NCT00277862|Active Comparator|3|"Pegylated IFN- alpha 2b~Ribavirin for 48 weeks (patients with partial EVR)"
3313868|NCT00277862|Active Comparator|4|"Pegylated IFN- alpha 2b~Ribavirin for 48 weeks (control)"
3313869|NCT00277810|Experimental|A|
3313870|NCT00277810|Experimental|B|
3313871|NCT00277810|Experimental|C|
3313872|NCT00277797|Active Comparator|Biowave first|First Treatment: Biowave; Second Treatment: TENS
3313873|NCT00277797|Active Comparator|TENS first|First Treatment: TENS; Second Treatment: Biowave
3313874|NCT00277784||1|Individuals with age related macular degeneration
3313875|NCT00277758|Experimental|1|Interventions: 12 weeks of interleukin-2 administration, followed by 48 weeks of interleukin-2 + Ribavirin + interferon-alpha therapy, followed by 24 weeks off therapy
3313876|NCT00277758|Active Comparator|2|48 weeks of therapy with Ribavirin + interferon-alpha, followed by 24 weeks off therapy
3313877|NCT00277706|Experimental|FORTEO|
3313878|NCT00277706|Placebo Comparator|Placebo|
3313879|NCT00277654|Active Comparator|Risperidone|
3313880|NCT00277654|Placebo Comparator|Sugar pill|
3313881|NCT00277641|Experimental|1|lamotrigine
3313882|NCT00277641|Placebo Comparator|2|
3313883|NCT00277589|Experimental|1|
3313884|NCT00277589|Active Comparator|2|
3313885|NCT00277589|Active Comparator|3|
3313886|NCT00277589|Placebo Comparator|4|
3313887|NCT00277537|Experimental|1|
3313888|NCT00277537|Other|2|
3313889|NCT00277524||Overall|All patients enrolled in OMNI. Patient sub-groups include device type, history of atrial fibrillation (AF), history of investigate atrioventricular (AV) block, implant indication, and managed ventricular pacing (MVP) enabled.
3313890|NCT00277472|Experimental|valsartan HCTZ|
3313891|NCT00277472|Active Comparator|HCTZ|
3313892|NCT00277433||Atopic Dermatitis|
3313893|NCT00277433||Non-atopic control|
3313894|NCT00277394|Experimental|innohep®|innohep® 175 anti-Xa IU/kg once daily
3313895|NCT00277394|Active Comparator|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
3313896|NCT00277368||001|
3313897|NCT00277355|Experimental|Minocycline|Minocycline (3:1 randomization) 100 mg capsules taken by mouth twice daily, 200 mg per day total for 18 months treatment duration.
3313898|NCT00277355|Placebo Comparator|Matching placebo|Sugar pill manufactured to mimic minocycline, 1 capsule taken by mouth twice daily for 18 months treatment duration.
3313899|NCT00277238|Experimental|CPG10101 (0.2) + pegylated inteferon + ribavirin|
3313900|NCT00277238|Experimental|CPG10101 (0.5) + pegylated inteferon + ribavirin|
3313901|NCT00277238|Active Comparator|Pegylated interferon + ribavirin|
3313902|NCT00277238|Experimental|CPG10101 + pegylated interferon + ribavirin (rollover)|
3313903|NCT00277212|Experimental|A1|Phase 1: Single-Blind Treatment, Lamotrigine + Aripiprazole ; Phase 2 Double-Blind Treatment: Lamotrigine + Aripiprazole
3313904|NCT00277212|Placebo Comparator|A2|Phase 2 Double-Blind Treatment: Lamotrigine + Placebo
3313905|NCT00277186|Active Comparator|Intervention|Patients entering new care continuum
3313906|NCT00277186|Active Comparator|Control|Patient enter existing conventional approach
3313907|NCT00277160|Experimental|Treatment Group 1 (Primary Prophylaxis)|Neulasta 6mg single administration per cycle of chemotherapy starting with cycle 1
3313908|NCT00277160|Active Comparator|Treatment Group 2 (Secondary Prophylaxis)|Per Investigator's discretion
3313909|NCT00277095|Experimental|ProACT (Adjustable Continence Therapy)|Implantation with ProACT (Adjustable Continence Therapy), Single Arm
3313910|NCT00277043|Experimental|1 Test Dose|
3313911|NCT00277043|Active Comparator|2) Non test dose arm|
3313912|NCT00276991|Other|"Kallunk oxide (Immunotherapy)"|"The participants were received a daily regimen of Kallunk oxide(Immunotherapy) ."
3313913|NCT00276978|Experimental|Aripiprazole|Aripiprazol augmentation therapy
3313914|NCT00276965|Experimental|A|Participants will take lithium only.
3313915|NCT00276965|Experimental|B|Participants will take lithium and sertraline.
3313916|NCT00276965|Experimental|C|Participants will take sertraline only.
3313917|NCT00276939|Experimental|1|Low-fat, low-Glycemic Index, vegan diet
3313918|NCT00276939|Active Comparator|2|ADA diet
3313919|NCT00276874|Experimental|Aripiprazole|Subjects receive oral aripiprazole.
3313920|NCT00276874|Placebo Comparator|Placebo|Subjects receive oral placebo
3313921|NCT00276848|Active Comparator|Fludarabine plus Cyclophosphamide|
3313922|NCT00276848|Active Comparator|Fludarabine|
3313923|NCT00276835|Experimental|Genistein and Interleukin-2|
3313924|NCT00276783|Experimental|Treatment Arm|Pemetrexed 900 mg/m2 every 21 days until disease progression.
3313925|NCT00276744|Experimental|Arm 1|"PART A: Participants will have their tumors collected at the time of conventional surgery. Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Patients will then proceed to receive adjuvant treatment based on physician discretion and will be followed until disease progression.~Capecitabine 1,5 mmol/kg Oral gavage 1- 5 days x 2 weeks Cetuximab 500 mg IP Twice a week x 2 weeks Docetaxel 20 mg/kg IV Once at week x 4 weeks Erlotinib 75 mg/kg IP 1-5 days x 2 weeks Gemcitabine 100 mg/kg IP Twice a week x 4 weeks Irinotecan 50 mg/kg IV Twice a week Mitomycin C 5 mg/kg IP One dose Rapamycin 4 mg/kg IP 1-5 days x 2 weeks~PART B: At the time of progression, patients will be evaluated for Part B of the study and treated with the drug selected in Part A as the most active using approved doses and schedules of administration."
3313926|NCT00276640|Active Comparator|vincristine, carboplatin|standard chemotherapy group
3313927|NCT00276640|Active Comparator|vincristine, carboplatin, etoposide|intensified induction chemotherapy group
3313928|NCT00276640|Active Comparator|radiation|radiation therapy group
3313929|NCT00276640|No Intervention|Control|Control group: wait and see strategy
3313930|NCT00276627|Active Comparator|communication lecture|
3313931|NCT00276627|Experimental|lecture plus CD-ROM|
3313932|NCT00276614|Experimental|Velcade|Velcade IV twice a week for two weeks on Days 1, 4, 8 and 11 of each cycle. A 10 day-rest period (Days 12-21) with no Velcade will follow the 2 weeks of treatment in each cycle. one cycle = 21 days
3313933|NCT00276575|Experimental|Bevacizumab, Everolimus, and Erlotinib|"Dose Level Dose Bevacizumab (mg/kg q2wks) Everolimus (mg daily) Erlotinib (mg daily) -1 5 5 ---~10 5 ---~10 10 ---~10* 10* 75~10* 10* 150"
3313934|NCT00276549|Experimental|Gemcitabine and Docetaxel i|
3313935|NCT00276536|Experimental|Treatment|IFN weekly
3313936|NCT00276523|Active Comparator|Control|Control (no treatment), conventional surgery.
3313937|NCT00276523|Experimental|PEG-Intron 0.5 mg/kg|PEG-interferon alfa-2b 0.5 mg/kg subcutaneously (SQ) once a week for 3 weeks, plus surgery.
3313938|NCT00276523|Experimental|PEG-Intron 2.5 mg/kg|PEG-interferon alfa-2b 2.5 mg/kg SQ once a week for 3 weeks, plus surgery.
3313939|NCT00276523|Experimental|PEG-Intron 5.0 mg/kg|PEG-interferon Alfa-2b 5 mg/kg SQ once a week for 3 weeks, plus surgery.
3313940|NCT00276510|Experimental|1|
3313941|NCT00276510|Placebo Comparator|2|
3313942|NCT00276484|Active Comparator|1|Atorvastatin 80 mg
3313943|NCT00276484|Experimental|2|Atorvastatin 40 mg + ezetimibe 10 mg
3313944|NCT00276458|Active Comparator|1|Atorvastatin 40mg tablet + Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day).
3313945|NCT00276458|Experimental|2|Atorvastatin 40mg Pbo tablet + Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day).
3313946|NCT00276419|Experimental|Placebo First, then Diclofenac (Arm A)|Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks, then compounded topical Diclofenac cream applied to the skin three times daily for 10 weeks.
3313947|NCT00276419|Experimental|Diclofenac First, then Placebo (Arm B)|Compounded topical Diclofenac cream applied to the skin three times daily for 10 weeks, then placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks.
3313948|NCT00276406|Experimental|Pyridostigmine|Oral pyridostigmine, starting with 60 mg capsules three times per day (TID), increasing by 60 mg every third day (i.e., over 10 days) up to the maximum tolerated dose or 120 mg TID (a total of 360 mg per day). This dose was maintained for 7 days.
3313949|NCT00276406|Placebo Comparator|Placebo|Placebo (sham) capsules, matching the appearance of the active drug comparator and taken TID.
3313950|NCT00276380|Experimental|EGb761®|"EGb761® 240 milligrams (mg)/day for 6 months administered orally, in association with acetylsalicylic acid (325 mg/day).~The test treatment consists of 6 tablets/day. 2 tablets (each containing 40 mg EGb761®) taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch."
3313951|NCT00276380|Placebo Comparator|Placebo|"6 months, administered orally, in association with acetylsalicylic acid (325 mg/day).~The placebo consists of 6 tablets/day. 2 tablets taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch."
3313952|NCT00276302|Experimental|1|Schedule A: Doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration.
3313953|NCT00276302|Experimental|2|Schedule B: Doses occur on Days 1, 4, 8, 11, 15, and 18 (twice weekly for 3 weeks continuously).
3313954|NCT00276263|Experimental|1|
3313955|NCT00276250|Experimental|Efalizumab Followed by Abatacept Regimen|Participants with Type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years received efalizumab-based immunosuppression regimen after islet-cell transplantation. During the course of the study, efalizumab was withdrawn from the US market due to safety concerns. The protocol was subsequently amended to alter the immunosuppressive regimen to abatacept for these participants.
3313956|NCT00276250|Experimental|Abatacept Regimen|Participants with Type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years received abatacept immunosuppresion regimen after islet-cell transplantation.
3313957|NCT00276250|Experimental|Belatacept Regimen|Participants with Type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years received Belatacept immunosuppresion regimen after islet-cell transplantation.
3313958|NCT00276198|Experimental|1|Supplementation with daily sprinkle package
3314007|NCT00275275|Experimental|2|Conversion factor of Mirapex to Requip 24-Hour of 1:4
3320789|NCT00160342|Active Comparator|1|
3313959|NCT00276198|Active Comparator|2|Supplementation with Iron tonic 15mg, vitamins A 300 micrograms, vitamin D 10 micrograms. According to Ministry of Health routine recommendations.
3313960|NCT00276198|No Intervention|3|No intervention except for checking outcomes at approprite times.
3313961|NCT00276172|Experimental|Natalizumab|Open-label natalizumab
3313962|NCT00276159|Experimental|852A Treatment|Patients receiving at least one dose of 852A.
3313963|NCT00276094|Experimental|Ospemifene 30 mg/day and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of ospemifene 30 mg each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
3313964|NCT00276094|Experimental|Ospemifene 60 mg/day and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of ospemifene 60 mg each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
3313965|NCT00276094|Placebo Comparator|Placebo tablets and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of placebo each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
3313966|NCT00276055|Experimental|Cohort 1|1000mg/m2 gemcitabine
3313967|NCT00276055|Experimental|Cohort 2|1250 mg/m2 gemcitabine
3313968|NCT00276055|Experimental|Cohort 3|1500 mg/m2 gemcitabine
3313969|NCT00276016|Experimental|Phenylephrine, Pseudoephedrine, Placebo|"Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Placebo: Placebo capsules."
3313970|NCT00276016|Experimental|Pseudoephedrine, Placebo, Phenylephrine|"Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Placebo: Placebo capsules.~Phenylephrine: Immediate-release 12 mg capsules for oral administration."
3313971|NCT00276016|Experimental|Placebo, Phenylephrine, Pseudoephedrine|"Placebo: Placebo capsules.~Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration."
3313972|NCT00276016|Experimental|Phenylephrine, Placebo, Pseudoephedrine|"Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Placebo: Placebo capsules.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration."
3313973|NCT00276016|Experimental|Pseudoephedrine, Phenylephrine, Placebo|"Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Placebo: Placebo capsules."
3313974|NCT00276016|Experimental|Placebo, Pseudoephedrine, Phenylephrine|"Placebo: Placebo capsules.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Phenylephrine: Immediate-release 12 mg capsules for oral administration."
3313975|NCT00275990|Experimental|thrombectomy before stenting|thrombectomy before stenting
3313976|NCT00275990|Active Comparator|directing stenting alone|directing stenting alone
3313977|NCT00275951|Experimental|Cetuximab Plus P-HDFL|Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
3313978|NCT00275834|Experimental|A|Zonisamide 400 mg
3313979|NCT00275834|Experimental|B|Zonisamide 200 mg
3313980|NCT00275834|Placebo Comparator|C|matching placebo
3313981|NCT00275821|Experimental|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|
3313982|NCT00275821|Experimental|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|
3313983|NCT00275821|Active Comparator|Ranibizumab 0.3 mg monthly|
3313984|NCT00275756|Experimental|1|
3313985|NCT00275756|Experimental|2|
3313986|NCT00275756|Experimental|3|
3313987|NCT00275613|Experimental|Rituximab, IV infusion|The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
3313988|NCT00275574|Experimental|acupuncture|four acupuncture treatments over a period of two weeks
3313989|NCT00275561|Experimental|Fluticasone|Aerosolized swallowed fluticasone 880 mcg bid for 6 weeks
3313990|NCT00275561|Placebo Comparator|Placebo|Placebo inhaler swallowed bid for 6 weeks
3313991|NCT00275548|Other|The Preventative (Prophylaxis) Group:|This group of patients will receive study drugs for the treatment of recurring (or returning) hepatitis C before they actually develop clinical symptoms of hepatitis C.
3313992|NCT00275548|Other|The Observational Group:|This group of patients will receive the study drugs for the treatment of recurring hepatitis C only if they develop the clinical symptoms of hepatitis C infection.
3313993|NCT00275535|Active Comparator|Tacrolimus|Calcineurin inhibitor arm, consisting of treatment with tacrolimus, mycophenolate mofetil, and prednisone.
3313994|NCT00275535|Active Comparator|Sirolimus|Calcineurin inhibitor-free arm, consisting of treatment with rapamycin, mycophenolate mofetil, and prednisone.
3313995|NCT00275509|Experimental|Thymoglobulin|Thymoglobulin was administered as 1.5 mg/kg prior to reperfusion followed by 6 post-operative doses on days 1 through 6.
3313996|NCT00275509|Experimental|Daclizumab|Daclizumab was administered as 2 mg/kg prior to reperfusion followed by 1 mg/kg every other week for 8 weeks post-operatively (4 post-operative doses).
3313997|NCT00275496|Active Comparator|WEX only|
3313998|NCT00275496|Active Comparator|WEX + SLND|
3313999|NCT00275496|Active Comparator|WEX+SLND+CLND|
3314000|NCT00275392|Experimental|Vestibular Rehabilitation|vestibular exercises plus standard balance and gait exercises
3314001|NCT00275392|Placebo Comparator|Placebo|placebo exercises plus standard balance and gait exercises
3314002|NCT00275366|Other|1|
3314003|NCT00275301|Experimental|Open-label Olanzapine.|Open-label Olanzapine.
3314004|NCT00275288||Healthy Normal|
3314005|NCT00275288||Active Disease|
3314006|NCT00275275|Experimental|1|Conversion factor of Mirapex to Requip 24-Hour of 1:3. This was a switch study in which the conversion factor was being investigated to assist in the conversion from Mirapex to Requip PR. In this group, the dose of Requip PR was 3 times the dose of Mirapex.
3320790|NCT00160342|Experimental|2|
3314008|NCT00275275|Experimental|3|Conversion factor of Mirapex to Requip 24-Hour of 1:5
3314009|NCT00275262|Experimental|LAD 11.25 mg 3 Month Depot|Three intramuscular injections LAD 11.25 mg 3 Month treatment administered approximately 3 months apart.
3314010|NCT00275262|Placebo Comparator|Placebo Comparator|Three intramuscular injections of matched placebo administered approximately 3 months apart.
3314011|NCT00275171|Active Comparator|rhTSH|proceeded by 0.1 mg rhTSH
3314012|NCT00275171|Placebo Comparator|Placebo|1 ml isotonic saline
3314013|NCT00275145|Experimental|Resistance Training|8 months of Resistance Exercise Training
3314014|NCT00275145|Experimental|Aerobic Exercise|8 months of Aerobic Exercise Training
3314015|NCT00275145|Experimental|Combination RT & AT|8 months of Combined Aerobic and Resistance Exercise Training
3314016|NCT00275145|Experimental|Control|Control/sedentary intervention
3314017|NCT00275132|Experimental|Erlotinib|Tarceva (OSI-774, erlotinib) PO 150mg daily
3314018|NCT00275132|Placebo Comparator|Matched placebo|Matched placebo PO daily
3314019|NCT00275093|Experimental|Treatment (temsirolimus)|"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD."
3314020|NCT00275080|Experimental|Treatment (enzyme inhibitor, chemotherapy)|"Regimen 1 (sequential dosing): Patients receive oral vorinostat two or three times daily on days 6-21 or days 6-12 (patients with solid tumors or NHL only) and decitabine IV over 1 hour on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Regimen 2 (concurrent dosing): Patients receive oral vorinostat two or three times daily on days 1-21, days 1-14 (patients with hematological malignancies only), or two times daily on days 1-12 (patients with solid tumors or NHL only) and decitabine IV over 1 hour on days 1-5."
3314021|NCT00275067|Experimental|Radiation + temozolomide and arsenic trioxide|Radiation therapy followed by the combination of temozolomide and arsenic trioxide at the maximum tolerated dose determined in phase 1
3314022|NCT00275054|Experimental|Cohort I (FCR)|Patients with 2 or more risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) who are randomized into cohort I receive Fludarabine, Cyclophosphamide and Rituximab (FCR) chemoimmunotherapy.
3314023|NCT00275054|No Intervention|Cohort II (W&W)|Patients with 2 or more risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) who are randomized into cohort II receive no treatment at all (watch & wait).
3314024|NCT00275054|No Intervention|Cohort III (W&W)|Patients with less than 2 risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) are assigned directly to cohort III and receive no treatment at all (watch & wait).
3314025|NCT00275041|Experimental|cetuximab + irinotecan|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and irinotecan hydrochloride IV over 1½ hours on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed periodically for up to 5 years."
3314026|NCT00275028|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3314027|NCT00275015|Experimental|High dose therapy + autologous PBSCT|"Cytoreductive treatment: (preferentially) FC (2-4 cycles)~Mobilization: Dexa-BEAM + G-CSF (1-2 cycles)~Myeloablation:~fractionated TBI (e.g. 6x2Gy) + Cyclophosphamide (2 x 60 mg/kg; d -4 to -3)~autologous peripheral blood stem cell transplantation (PBSCT) (d 0)"
3314028|NCT00275002|Experimental|O6-BG and TMZ|O6-benzylguanine (O6-BG) and temozolomide (TMZ)
3314029|NCT00274989|Experimental|Bendamustine plus Rituximab|
3314030|NCT00274937|Experimental|Stratum I - AJCC Stages I-IIa|Patients undergo radiation therapy 5 days a week for 8 weeks. Patients also receive amifostine trihydrate subcutaneously on the same days they undergo radiation therapy.
3314031|NCT00274937|Experimental|Stratum II - AJCC Stages IIb-IV|Patients receive cisplatin IV over 6 hours on day 1 and fluorouracil IV continuously on days 1-4. Treatment repeats every 3 weeks for 3 courses. In weeks 10-18, patients undergo radiation therapy and receive amifostine trihydrate as in stratum I. Patients also receive 3 courses of cisplatin as before.
3314032|NCT00274924|Experimental|Group I (PET negative)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1, and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
3314033|NCT00274924|Experimental|Group II (PET positive)|Patients receive R-ICE comprising rituximab IV on day 1, ifosfamide IV continuously over 24 hours and carboplatin IV over 30 minutes on day 2, and etoposide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously once daily starting on day 4 and continuing until blood counts recover. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3314034|NCT00274846|Experimental|Intent-to-Treat|All patients treated with natural killer (NK) cells (at a dose of 1.5-8 x 10^7/kg.)
3314035|NCT00274833|Experimental|Radiation Therapy, Temozolomide, and Erlotinib|
3314036|NCT00274794|Other|Rituxan + Etoposide + G-CSF|
3314037|NCT00274794|Other|Etoposide + G-CSF|
3314038|NCT00274781|Experimental|ATO + GO|Arsenic Trioxide 0.25 mg/kg D1-5 Week 1/Twice Weekly W2-12 + Gemtuzumab Ozogamicin 3 mg/m^2 D8 for 1 or 2 Cycles of 12 Weeks each
3314039|NCT00274768|Experimental|Capecitabine|
3314040|NCT00274742|Experimental|Blinatumomab|Patients received blinatumomab as continuous intravenous infusion for 4 weeks. Participants with clinical benefit were permitted to continue for another 4 weeks for a total of 8 weeks. Participants with a clinical benefit 4 weeks after completion of the first cycle of treatment could also receive additional treatment approximately 3 months ater the end of infusion at the same dose level.
3314041|NCT00274716|Experimental|High BMI:MK-0736 2mg→Placebo|Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
3314042|NCT00274716|Experimental|High BMI:MK-0736 7mg→Placebo|Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
3314043|NCT00274716|Experimental|High BMI:MK-0916 6mg→MK-0916 6mg|Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
3314044|NCT00274716|Placebo Comparator|High BMI:Placebo→Placebo|Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
3314045|NCT00274716|Experimental|Low BMI:MK-0916 6mg→MK-0916 6mg|Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
3314046|NCT00274716|Placebo Comparator|Low BMI:Placebo→Placebo|Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
3314047|NCT00274677|Placebo Comparator|Placebo|
3314048|NCT00274677|Experimental|lamotrigine|
3314049|NCT00274651|Experimental|Arm A|PXD101 1000 mg/m2 once daily for 5 days every 21 days
3314050|NCT00274651|Experimental|Arm B|PXD101 1000 mg/m2 once daily for 5 days every 21 days
3314051|NCT00274625|Experimental|1|Surgisis Gold Graft
3314052|NCT00274625|Active Comparator|2|Control
3314053|NCT00274469|Experimental|1|Fulvestrant
3314054|NCT00274469|Active Comparator|2|Anastrozole
3314055|NCT00274456|Experimental|ABI-007 300 mg/m^2 q3w|ABI-007 300 mg/m^2 administered once every third week (q3w).
3314056|NCT00274456|Experimental|ABI-007 100 mg/m^2 weekly|ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest
3314057|NCT00274456|Experimental|ABI-007 150 mg/m^2 weekly|ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest
3314058|NCT00274456|Active Comparator|Docetaxel 100 mg/m^2, q3w|Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).
3314059|NCT00274443|Experimental|ABI-007 and Carboplatin|ABI-007 and Carboplatin in patients with Advanced Non-Small Cell Lung Cancer.
3314060|NCT00274287|Experimental|GM-CSF|Once patients have finished receiving the chemotherapy and no signs of disease progression they may receive GM-CSF as outlined in the protocol
3314061|NCT00274261|Experimental|A|C31G vaginal gel contains 35mg (1% concentration) of C31G in 3.5 mL volume of gel
3314062|NCT00274261|Active Comparator|B|Conceptrol® Vaginal gel contains 100mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
3314063|NCT00274209||IBD patients at risk for neoplasia|Patients with long-standing ulcerative colitis or Crohn's colitis at risk for neoplasia.
3314064|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ (vortex)|gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
3314065|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (vortex)|gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.
3314066|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in saline ID|gp100:209-217(210M) in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
3314067|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in saline ID + Imiquimod|gp100:209-217(210M) peptide in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of the injection daily for 5 days.
3314068|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ (2 Syringe)|gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
3314069|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (2 Syringe)|gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.
3314070|NCT00273858||etanercept|Patients already prescribed to receive etanercept for the first time for treatment of Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis according to the Summary of Product Characteristics (SmPC).
3314071|NCT00273845|Experimental|1|One session of motivational interviewing
3314072|NCT00273845|Experimental|2|Five sessions of strengths-based case management
3314073|NCT00273806|Experimental|1|Medical assistant identification and referral for behavioral risk factors.
3314074|NCT00273806|No Intervention|2|Usual care for behavioral risk factors.
3314075|NCT00273793|Experimental|1|Shaping intervention for hard-to-treat smokers
3314076|NCT00273793|Active Comparator|2|fixed criterion intervention for hard-to-treat smokers
3314077|NCT00273793|Other|3|Non contingent incentives available to hard to treat smokers
3314078|NCT00273793|Experimental|4|Ascending incentives values used in Smokers with Early Success
3314079|NCT00273793|Active Comparator|5|fixed value incentives are used in Smokers with Early Success
3314080|NCT00273793|Other|6|Non contingent incentives are available to Smokers with Early Success
3314081|NCT00273780|Active Comparator|Adherence counseling|
3314082|NCT00273780|Active Comparator|Alarm device|
3314083|NCT00273780|Active Comparator|Counseling and alarm|Participants in this arm will receive both education counseling and a pocket alarm device.
3314084|NCT00273780|No Intervention|Control|
3314085|NCT00273767|Experimental|1|epoetin beta
3314086|NCT00273767|Placebo Comparator|2|placebo of NaCl
3314087|NCT00273754|Placebo Comparator|Placebo|Saline
3314088|NCT00273754|Active Comparator|Caffeine|Caffeine benzoate
3314089|NCT00273741|Experimental|1|methylphenidate at 20mg per day during 7 days, at 20mg or 40mg per day during 7 days and 20, 40 or 60mg per day during 14 days
3314090|NCT00273741|Placebo Comparator|2|placebo capsules
3314091|NCT00273728|Active Comparator|HES, Septic shock, resuscitation|study group with HES 6%
3314092|NCT00273715|No Intervention|Staples|
3314093|NCT00273689|Other|I|This is a crossover trial- Patients get randomly assign to albuterol or singulair and then cross overed to the alternate active medication.
3314096|NCT00273624|Experimental|olanzapine|10 mg Olanzapine
3314097|NCT00273624|Placebo Comparator|placebo|Placebo
3314098|NCT00273611|Experimental|Pharmacist education|Pharmacist education about vitamin D
3314099|NCT00273611|No Intervention|Usual care|Usual care
3314100|NCT00273572|Active Comparator|Moderate lifestyle intervention|Moderate lifestyle intervention including two group sessions and one individual counselling session with a nutritionist, at recruitment. Individual sessions with a nutritionist after 6 and 12 months on follow-up.
3314101|NCT00273572|Experimental|Intensive lifestyle intervention|Intensive lifestyle intervention, including bi-monthly group sessions with a physical activity instructor; a monthly group session with a nutritionist, and a monthly individual session with a nutritionist.
3314102|NCT00273559||1|subjects who remain on steroids after discharge
3314103|NCT00273559||2|Subjects will be off steroids at the time of discharge
3314104|NCT00273364|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with Cyclophosphamide and rATG
3314105|NCT00273364|Active Comparator|Standard therapy for MS|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), Gilenya (fingolimod) or Dimethyl fumarate (Tecfidera or BG-12)
3314106|NCT00273351|Experimental|[123I]B-CIT|[123I]B-CIT and SPECT imaging
3314107|NCT00273312|Experimental|Patupilone|was administered at 10 mg/m2, as a single intravenous infusion over 20 minutes, once every 3 weeks
3314108|NCT00273286|Experimental|family diabetes management intervention|A trained health advisor will be responsible for interactions with parents and patients prior to each diabetes clinic visit (Preparation Phase), at the time of the diabetes clinic visit (Consolidation Phase) and by phone, e-mail, etc. after the clinic visit (Follow-up Phase). Using educational modules developed for the study, families will be engaged in problem identification and solving activities to improve shared parent-youth responsibility for diabetes management and foster increased adolescent's independent management capabilities.
3314109|NCT00273182||Cohort|Patients implanted with InSync Model 8040, InSync III Model 8042 , or Medtronic CRT-D system. A total of 1999 subjects were enrolled in the study. Of them, 1738 had successful post market implants of InSync Model 8040 (601 subjects), InSync III Model 8042 (512 subjects) and CRT-D devices (625 subjects). The rest 262 subjects came from two pre-market studies: the MIRACLE study added 141 subjects to InSync Model 8040, and the InSync III study added 121 subjects to the InSync III Model 8042. A total of 1014 subjects completed the study through 36 month follow up. Follow-up of 1000 subjects was required by the FDA to satisfy the conditions of approval.
3314110|NCT00273104|Active Comparator|Bariatric surgery|Bariatric surgery (gastric bypass) offered to patients after informed consent and shared decision. The surgical procedure was performed at Vestfold Hospital Trust by experienced bariatric surgeons.
3314111|NCT00273104|Active Comparator|Intensive lifestyle intervention|Intensive lifestyle intervention (1-year endurance) at a rehabilitation centre. The intervention consisted of motivation for behaviour change including calorie restriction and increased physical activity.
3314112|NCT00273052|Experimental|Carvedilol Phosphate modified release formulation|
3314113|NCT00273052|Active Comparator|metoprolol succinate|
3314114|NCT00273013|Experimental|Sequence 1|Subjects will receive Placebo in period 1, Singulair 10 milligrams (mg) in period 2 and GW274150 90 mg in period 3.
3314115|NCT00273013|Experimental|Sequence 2|Subjects will receive Placebo in period 1, GW274150 90 mg in period 2 and Singulair 10 mg in period 3.
3314116|NCT00273013|Experimental|Sequence 3|Subjects will receive Singulair 10 mg in period 1, Placebo in period 2 and GW274150 90 mg in period 3.
3314117|NCT00273013|Experimental|Sequence 4|Subjects will receive Singulair 10 mg in period 1, GW274150 90 mg in period 2 and Placebo in period 3.
3314118|NCT00273013|Experimental|Sequence 5|Subjects will receive GW274150 90 mg in period 1, Placebo in period 2 and Singulair 10 mg in period 3.
3314119|NCT00273013|Experimental|Sequence 6|Subjects will receive GW274150 90 mg in period 1, Singulair 10 mg in period 2 and Placebo in period 3.
3314120|NCT00272987|Experimental|Arm 1|Open label safety phase. All patients received paclitaxel + trastuzumab + lapatinib.
3314121|NCT00272961|Placebo Comparator|placebo|
3314122|NCT00272961|Experimental|ARM 1|
3314123|NCT00272961|Experimental|ARM 2|
3314124|NCT00272961|Experimental|ARM 3|
3314125|NCT00272961|Experimental|ARM 4|
3314126|NCT00272948|Experimental|Prophylaxis Arm|
3314127|NCT00272948|Active Comparator|Control Arm|
3314128|NCT00272935|Experimental|1|
3314129|NCT00272935|Placebo Comparator|2|
3314130|NCT00272909|Experimental|1|piclozotan IV infusion, low dose, for 72 hours.
3314131|NCT00272909|Experimental|2|piclozotan IV infusion, high dose, for 72 hours.
3314132|NCT00272909|Placebo Comparator|3|placebo (normal saline) IV infusion, for 72 hours.
3314133|NCT00272857|Experimental|Single arm|
3314134|NCT00272844|Experimental|Cholesterol supplementation|
3314135|NCT00272831|Active Comparator|Cilostazol|Cilostazol 100 mg twice daily
3314136|NCT00272831|Placebo Comparator|Placebo|
3314137|NCT00272792|Experimental|Sapropterin Dihydrochloride|Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
3314138|NCT00272792|Placebo Comparator|Placebo|Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
3314139|NCT00272779|Active Comparator|Atazanavir (ATV) + Ritonovir (RTV)|Participants were administered an oral dose of ATV 300 mg and RTV 100 mg once daily along with food on a background of fixed dose combination TDF 300 mg plus FTC 200 mg (TDF/FTC) once daily. Doses of ATV and RTV were taken 24 hours apart at the same time as the background TDF/FTC, up to 96 Weeks.
3314531|NCT00267098|Active Comparator|Right ventricular pacing|
3314140|NCT00272779|Active Comparator|Lopinavir (LPV) + RTV|Participants were administered an oral dose of LPV 400 mg and RTV 100 mg once daily along with food on a background of fixed dose combination TDF 300 mg plus FTC 200 mg (TDF/FTC) once daily. Doses of LPV and RTV were taken 24 hours apart at the same time as the background TDF/FTC, up to 96 Weeks.
3314141|NCT00272662|Experimental|Cohort 1|Peginesatide starting dose of 0.1 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 3 weeks (Q3W) for a total of 4 doses.
3314142|NCT00272662|Experimental|Cohort 2|Peginesatide starting dose of 0.15 mg/kg administered SC Q3W for a total of 4 doses.
3314143|NCT00272662|Experimental|Cohort 3|Peginesatide starting dose of 0.2 mg/kg administered SC Q3W for a total of 4 doses.
3314144|NCT00272662|Experimental|Cohort 4|Peginesatide starting dose of 0.05 mg/kg administered SC Q3W for a total of 4 doses.
3314145|NCT00272649|Experimental|Single Arm|Single Arm study
3314146|NCT00272597|Other|Risperidone LAI|"Subjects treated with any antipsychotic can be switched to Risperidone LAI.~If the subject is currently treated with an antipsychotic other than risperidone, the dosage will be tapered gradually and discontinued. Simultaneously, oral risperidone will be started at 2 mg/day and increased to no more than 6 mg/day. The subject will be treated with risperidone monotherapy for at least five days prior to entering the stabilization phase of the study.~On the other hand, if the patient has already been treated for more than 5 days with risperidone monotherapy then he/she may enter the stabilization phase of the study immediately."
3314147|NCT00272545|Experimental|1|Participants will receive the normalization of eating program
3314148|NCT00272545|Active Comparator|2|Participants will receive treatment as usual
3314149|NCT00272519|Experimental|Adolescent/caregiver dyads|Eight to ten adolescent/caregiver dyads
3314150|NCT00272493|Active Comparator|A|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
3314151|NCT00272493|Experimental|B|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
3314152|NCT00272467|Experimental|Rebamipide|"Dosage (1) The eradication therapy period (for all cases) Amoxicillin 2,000mg/day, clarithromycin 1,000 mg/day and omeprazole 40 mg/day. b.i.d. (morning and evening), oral administration. (2) The ulcer treatment period (on a double-blind basis) Rebamipide 100mg, t.i.d. (before breakfast, evening, before bed).~Drug period (1) The eradication therapy period: 1 week (2) The ulcer treatment period: 7 weeks"
3314153|NCT00272467|Active Comparator|Omeprazole|"Dosage (1) The eradication therapy period (for all cases) Amoxicillin 2,000mg/day, clarithromycin 1,000 mg/day and omeprazole 40 mg/day. b.i.d. (morning and evening), oral administration. (2) The ulcer treatment period (on a double-blind basis) omeprazole 20mg, once daily (before breakfast)~Drug period (1) The eradication therapy period: 1 week (2) The ulcer treatment period: 7 weeks"
3314154|NCT00272415|Experimental|1|
3314155|NCT00272402|Other|1|Simulated case-based learning
3314156|NCT00272402|Other|2|EMR clinical decision support tool.
3314157|NCT00272402|No Intervention|3|Control group
3314158|NCT00272337|Active Comparator|1|81 mg Aspirin
3314159|NCT00272337|Active Comparator|2|162 mg Aspirin
3314160|NCT00272337|Active Comparator|3|325 mg Aspirin
3314161|NCT00272337|Active Comparator|4|650 mg Aspirin
3314162|NCT00272337|Active Comparator|5|1300 mg Aspirin
3314163|NCT00272311|Active Comparator|1|81 mg Aspirin
3314164|NCT00272311|Active Comparator|2|162 mg Aspirin
3314165|NCT00272311|Active Comparator|3|325 mg Aspirin
3314166|NCT00272311|Active Comparator|4|650 mg Aspirin
3314167|NCT00272311|Active Comparator|5|1300 mg Aspirin
3314168|NCT00272285|Experimental|1|Intravenous (IV)
3314169|NCT00272285|Active Comparator|2|Intravenous (IV)
3314170|NCT00272272|Experimental|Balance and Music Listening|Music therapy
3314171|NCT00272220|Experimental|1|receive 6-week intervention of peer-delivered mDOT
3314172|NCT00272220|No Intervention|2|
3314173|NCT00272181|Experimental|Dose Determination|The recommended dose (RD) for Proxinium is to be determined based on the rate of Dose Limiting Toxicities (DLT) within each dose cohort. The RD is to be established as the highest dose at which one or fewer patients out of six within a dose cohort experienced a DLT. The initial dose level is 500 μg of Proxinium in PBS (the amount of PBS used will be based on the estimated volume of the target tumour). Doses are to be escalated to a maximum of 700 μg or de-escalated to a minimum of 260 μg according to the prescribed algorithm outlined in the study protocol.
3314174|NCT00272168|Experimental|Arm 1: MPROVE|The Maryland Program for Vocational Effectiveness (MPROVE)
3314175|NCT00272168|Active Comparator|Arm 2: Control|Supportive Treatment for SMI (control)
3314176|NCT00272116|Experimental|1|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children and Vitamin A 100,000 IU to infants and 200,000 IU to older children
3314177|NCT00272116|Placebo Comparator|2|
3314178|NCT00272064|Other|1|Telecare system
3314179|NCT00272064|Other|2|Self Monitoring Blood Glucose (SMBG)system.
3314180|NCT00272038|Experimental|Tarceva|Tarceva 150 mg QD
3314181|NCT00272025|Active Comparator|1|There is a 50% chance of being randomized to Escitalopram in addition to current atypical antipsychotic (minimum dose risperidone 3mg, olanzapine 10mg or seroquel 400mg) or mood stabilizer (lithium, epival or lamotrigine)
3314182|NCT00272025|Placebo Comparator|2|to be filled in
3314183|NCT00271999|Active Comparator|1|Three times a week conventional at home hemodialysis
3314184|NCT00271999|Experimental|2|Six times a week nocturnal home hemodialysis
3314185|NCT00271960|Active Comparator|Individual Care|Participants will receive usual care for their prenatal visits
3314186|NCT00271960|Active Comparator|CenteringPregnancy|Participants will receive CenteringPregnancy(R) group prenatal care
3314187|NCT00271960|Experimental|CenteringPregnancyPlus|Participants will receive CenteringPregancy with an HIV/STD prevention component
3314188|NCT00271947|Experimental|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after the conditioning regimen
3314189|NCT00271908||Cohort #1|Venue-tracking survey subjects recruited annually for 4 years: N= 320-640 (10-20 members of the population of focus per site, per year). The purpose of this cohort is to identify and track venues at which the population of focus congregates.
3314190|NCT00271908||Cohort #2|HIV-related risk survey subjects recruited annually for 4 years: N = 1280-2880 (20-30 members of the population of focus per 2-3 congregation venues, per site, per year). These subjects will complete a survey designed to assess HIV-related risk. In the fourth and final year only, HIV Antibody [Ab] assays will also be conducted with survey participants to assess HIV serostatus. The survey and HIVAb assay data will be used to evaluate the intervention within and across sites.
3314191|NCT00271856|Experimental|0|Mindfulness Based Stress Reduction (MBSR)
3314192|NCT00271856|Active Comparator|1|HIV education/self-management workshop
3314193|NCT00271817|Active Comparator|Part 1 - Arm 1|ezetimibe/simvastatin combination tablet + niacin (ER)
3314194|NCT00271817|Active Comparator|Part 1 -Arm 2|ezetimibe/simvastatin
3314195|NCT00271817|Active Comparator|Part 1 - Arm 3|Niacin (ER)
3314196|NCT00271817|Active Comparator|Part 2 - Arm 1|ezetimibe/simvastatin combination tablet + niacin (ER)
3314197|NCT00271817|Placebo Comparator|Part 2 - Arm 2|ezetimibe/simvastatin combination tablet + niacin (Pbo)
3314198|NCT00271791|Experimental|1|Prednisone
3314199|NCT00271791|Placebo Comparator|2|Placebo
3314200|NCT00271752|Experimental|PCT guided|Procalcitonin guided treatment of infections in the ICU. Intervention: Intensification of antibiotics, surgery, microbiologic testing and diagnostic imaging, when Procalcitonin levels are increasing
3314201|NCT00271752|Sham Comparator|Control|"These patients receive Standard of Care which is the recommended treatment in the given ICU"
3314202|NCT00271739|Experimental|Telemedicine case management|Telemedicine visits conducted by a registered nurse (RN) with remote monitoring of blood pressure (BP) and blood glucose through the use of a telemedicine home unit (HTU).
3314203|NCT00271739|Active Comparator|Usual care|usual care by primary care provider
3314204|NCT00271713|Active Comparator|ibandronate|150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily
3314205|NCT00271713|Placebo Comparator|2|placebo monthly plus 500mg calcium and 800 UI vitamin D daily
3314206|NCT00271635|Experimental|1|Ascorbic acid
3314207|NCT00271635|Placebo Comparator|2|Placebo
3314208|NCT00271609|Other|Anaplastic Glioma (AG)|Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic mixed oligoastrocytoma Malignant astrocytoma (not otherwise specified) 10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
3314209|NCT00271609|Other|Glioblastoma Multiforme (GBM)|Glioblastoma multiforme Gliosarcoma 10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
3314210|NCT00271596|Experimental|Citalopram|20mg daily citalopram
3314211|NCT00271596|Placebo Comparator|Placebo|Matching daily placebo
3314212|NCT00271570|Active Comparator|Second Dose of IVIG (2g/kg)|Subjects who did not respond to the first dose of IVIG received a 2nd dose of IVIG in this arm (2g/kg)
3314213|NCT00271570|Experimental|Infliximab (5mg/kg)|Remicade (5mg/kg) single dose
3314214|NCT00271544|Experimental|4196 Lead|Non-randomized study.
3314215|NCT00271531||1|150 subjects greater than 48 weeks post-conception and less than 18 years of age who are mechanically ventilated and have presumed bacterial pulmonary infection.
3314216|NCT00271518|Experimental|LB03002, sustained release human hGH|LB03002
3314217|NCT00271505|Experimental|Avastin + Docetaxel + Carboplatin|Avastin 15 mg/kg intravenously (IV) every 3 weeks. Docetaxel 75 mg/m2 IV every 3 weeks. Carboplatin AUC 6 IV every 3 weeks.
3314218|NCT00271492|Active Comparator|I|Qualifying patients took Atrasentan, 1 pill per day for 6 months, to determine if it had a favorable affect on patients who took it over those who were randomized to placebo.
3314219|NCT00271492|Placebo Comparator|2|placebo group to be compared to the actual medication
3314220|NCT00271440|Experimental|CHX 1.0%|1.0% CHX wiping
3314221|NCT00271440|Experimental|CHX 0.5%|0.5% Chlorhexidine
3314222|NCT00271440|Experimental|CHX 0.25%|chlorhexidine cleansing with pre-soaked pre-sealed wipe
3314223|NCT00271401|Experimental|Angioplasty With Abciximab Plus Low-Dose Heparin|Participants will receive conventional angioplasty/atherectomy along with bolus abciximab 0.25 milligram per kilogram (mg/kg) of body weight followed by a 0.125 microgram per kilogram per minute (mcg/kg/minute) infusion for 12 hours plus 7 unit per kilogram per hour (U/kg/hr) continuous infusion of heparin.
3314224|NCT00271401|Experimental|Intracoronary Stent With Reo Pro Plus Low Dose Heparin|Participants will receive intracoronary stent along with receive bolus abciximab 0.25 mg/kg of body weight followed by a 0.125 mcg/kg/minute infusion for 12 hours plus 7 U/kg/hr continuous infusion of heparin (low dose).
3314225|NCT00271401|Placebo Comparator|Intracoronary Stent With Placebo Plus Standard Dose Heparin|Participants will receive intracoronary stent along with bolus placebo followed by placebo infusion for 12 hours plus 10 U/kg/hr continuous infusion of heparin (standard dose).
3314226|NCT00271388|Experimental|Parameter Determination|Testing potential effects of GVS on the symptoms of neglect
3314227|NCT00271375|Experimental|Arm 1: Caring for you, Caring for me Educational Intervention|Educational Intervention
3314228|NCT00271375|Experimental|Arm 2: Caring for you, caring for me + social worker|Educational + Social Work Intervention
3314229|NCT00271375|Placebo Comparator|Arm 3: Control group usual care|Control group usual care
3314230|NCT00271362|Active Comparator|1|comparing 2 surgical procedures
3314231|NCT00271336|Placebo Comparator|A|
3314232|NCT00271336|Experimental|B|
3314233|NCT00271323|Experimental|1|Induction chemotherapy followed by concurrent chemoradiotherapy
3314234|NCT00271323|Active Comparator|2|Concurrent chemo-radiotherapy followed by consolidation chemotherapy
3314235|NCT00271284|Experimental|I|
3314236|NCT00271284|Active Comparator|II|
3314237|NCT00271245|Experimental|1|200 µg selenium as selenate
3314238|NCT00271245|Experimental|2|400 µg selenium as selenate
3314239|NCT00271245|Experimental|3|200 µg selenium as selenomethionine
3314240|NCT00271245|Placebo Comparator|4|placebo
3314241|NCT00271219|Experimental|Buprenorphine|Buprenorphine
3314242|NCT00271219|Active Comparator|Methadone|Methadone
3314243|NCT00271206|Active Comparator|Progesterone|200 mg to 400mg of progesterone
3314244|NCT00271206|Placebo Comparator|Sugar Pill|Will mirror active medication
3314245|NCT00271193|No Intervention|1|Control group, receives physician advice for weight loss and materials
3314246|NCT00271193|Active Comparator|2|Active treatment group, receives physician advice, materials, and brief weight loss counseling
3314247|NCT00271154|Placebo Comparator|CRT OFF|Cardiac Resynchronization Therapy (CRT) turned OFF in conjunction with optimal medical therapy
3314248|NCT00271154|Active Comparator|CRT ON|Cardiac Resynchronization Therapy (CRT) turned ON in conjunction with optimal medical therapy
3314249|NCT00271115|Other|Moms w/preterm infants|Mothers of preterm infants who are admitted to the newborn intensive care unit.
3314250|NCT00271102|Active Comparator|1|Anterior repair (colporrhaphy) for their cystocele
3314251|NCT00271102|Active Comparator|2|Abdominal paravaginal defect repair for their cystocele
3314252|NCT00271050|Experimental|1|
3314253|NCT00271024|Experimental|Male Naltrexone|50 mg Naltrexone tablet
3314254|NCT00271024|Experimental|Female Naltrexone|Females receiving either naltrexone (50 mg)
3314255|NCT00271024|Placebo Comparator|Male Placebo|Males receiving Placebo (sugar pill)
3314256|NCT00271024|Placebo Comparator|Female Placebo|Females receiving placebo (sugar pill)
3314257|NCT00271011|Experimental|Mitomycin C, Irinotecan and Cetuximab|"Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.~Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.~Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1*28 allele will receive irinotecan 110 mg/m2."
3314258|NCT00270998|Experimental|Intravaginal Pessary|Pessary restores continence by stabilization of the proximal urethra and urethrovesical junction, facilitating pressure transmission to the proximal urethra.
3314259|NCT00270998|Experimental|Behavioral Therapy|Pelvic floor muscle training and exercise which includes strong contraction of the pelvic floor muscles to prevent incontinence by occluding the urethra and regular practice can improve pelvic muscle support.
3314260|NCT00270998|Experimental|Pessary combined with behavioral therapy|Combination of the explanations above.
3314261|NCT00270985|Active Comparator|nut free diet|ADA recommended diabetes diet without any nuts
3314262|NCT00270985|Experimental|almond group|calorie controlled diet with prescribed daily amount of almonds
3314263|NCT00270959|Experimental|1|Stepped collaborative care (combination of behavioral therapy and drug therapy)
3314264|NCT00270959|Active Comparator|2|Standard care provided to injured trauma survivors
3314265|NCT00270907|Experimental|CT-2103 + Gemcitabine|CT-2103 135 mg/m^2 intravenous (IV) on Day 1. Gemcitabine 1000 mg/m^2 IV on Day 1 and 8.
3314266|NCT00270894|Experimental|Neoadjuvant therapy|Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments.
3314267|NCT00270855|Other|Arm Crank Ergometer|Upper body Cycle ergometer Exercise: 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
3314268|NCT00270855|Other|FESLCE|Functional Electrical Stimulation Leg Cycle Ergometer Exercise: 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
3314269|NCT00270842|Placebo Comparator|Education Control Group|Education group that is the control group for the study. Is a 10 week course with diverse health education topics.
3314270|NCT00270842|Experimental|Functional Balance Training|Exercise group that participated in functional balance training
3314271|NCT00270842|Experimental|Tai chi|Exercise Group that participated in tai chi training classes
3314272|NCT00270829|Experimental|1|Nesiritide given intrarenally
3314273|NCT00270829|No Intervention|2|No intrarenal drug administration
3314274|NCT00270816|Experimental|interferon beta cyclical administration|Interferon ß-1b Treatment by Cyclical Administration
3314275|NCT00270816|Active Comparator|Interferon ß-1b Treatment|Interferon ß-1b Treatment
3314276|NCT00270803|Placebo Comparator|A|Low nicotine cigarettes without THC
3314277|NCT00270790|Experimental|AMIFOSTINE +CARBOPLATIN, TAXOL +RT|EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.
3314278|NCT00270764||Full cohort|Adult ART patients at 3 treatment facilities in South Africa
3314279|NCT00270738|Experimental|1|TrA training group
3314280|NCT00270738|Active Comparator|2|PFMT group
3314281|NCT00270738|Active Comparator|3|control group (PFM exercise at home)
3314282|NCT00270712||Retrospective Cohort|537 transplant recipient records used retrospectively
3314283|NCT00270712||Prospective Cohort|3137 transplant recipients enrolled prospectively
3314284|NCT00270699|Experimental|1|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^5 PFU dose) into the deltoid region of either arm.
3314285|NCT00270699|Experimental|2|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^3 PFU dose) into the deltoid region of either arm. This arm will enroll after Arm 1.
3314286|NCT00270699|Experimental|3|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm will enroll after Arms 1 and 2.
3314287|NCT00270699|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
3314288|NCT00270647|Experimental|Vitamin E|Active or placebo vitamin E
3314289|NCT00270647|Experimental|Vitamin C|Active or placebo vitamin C
3314290|NCT00270647|Experimental|Multivitamin|Active or placebo multivitamin
3314291|NCT00270647|Experimental|Beta-carotene|Active or placebo beta-carotene
3314292|NCT00270634|Active Comparator|Low Dose Voclosporin|Low dose voclosporin
3314293|NCT00270634|Active Comparator|Mid Dose Voclosporin|Mid Dose Voclosporin
3314294|NCT00270634|Active Comparator|High Dose Voclosporin|High Dose Voclosporin
3314295|NCT00270634|Active Comparator|Tacrolimus|Standard Dose Tacrolimus
3314296|NCT00270621|Experimental|Treatment|FHP Night time Enuresis intervention
3314297|NCT00270621|No Intervention|Control|To receive standard/usual care for Nocturnal Enuresis- No FHP Night time Enuresis INtervention
3314298|NCT00270439|Experimental|single arm|Removed omentum of patients with type 2 diabetes
3314299|NCT00270413|Experimental|1|sutent
3314300|NCT00270413|No Intervention|2|
3314301|NCT00270400|Experimental|001|nesiritide
3314302|NCT00270387|Experimental|001|Natrecor (nesiritide)
3314303|NCT00270374|Experimental|001|nesiritide
3314304|NCT00270361|Experimental|001|nesiritide
3314305|NCT00270361|Experimental|002|nesiritide
3314306|NCT00270361|Active Comparator|003|usual long term cardiac medications
3314307|NCT00270335|Active Comparator|A|General anesthesia titrated according to a cerebral state monitor
3314308|NCT00270335|Active Comparator|B|General anesthesia titrated according to usual clinical criteria
3314309|NCT00270296|Experimental|Trizivir (TZV) Arm|Participants in the TZV Arm (Arm 1A) will be pregnant women who have CD4 counts of 200 cells/mm3 or more. As the intervention, they will receive TZV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
3314310|NCT00270296|Experimental|Kaletra Arm|Participants in the Kaletra Arm (Arm 1B) will be pregnant women who have CD4 counts of 200 cells/mm3 or more. As the intervention, they will receive Lamivudine/Zidovudine (3TC/ZDV) and Lopinavir/Ritonavir (LPV/RTV) twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
3314311|NCT00270296|Experimental|Nevirapine (NVP) Arm|Participants in the NVP Arm (Arm 2) will be pregnant women who have have CD4 counts less than 200 cells/mm3. These participants will receive NVP once daily for the first 14 days, then twice daily, and 3TC/ZDV twice daily; these women will be in the observational group.
3314312|NCT00270257|Experimental|Long term medication assisted treatment (LT-MAT)|Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52
3314313|NCT00270257|Experimental|Short term medication assisted treatment (ST-MAT)|Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.
3314314|NCT00270244|Active Comparator|1|Participants will receive treatment as usual
3314315|NCT00270244|Experimental|2|Participants will receive group interpersonal psychotherapy for depressed adolescents
3314316|NCT00270231|Active Comparator|Naltrexone|"All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.~Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg."
3314317|NCT00270231|Placebo Comparator|Placebo|"All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule."
3314318|NCT00270218|Experimental|1|Arm 1 participants will be given an injection of VRC-HIVADV014-00-VP vaccine on Days 0 and 168.
3314319|NCT00270218|Placebo Comparator|2|Arm 2 participants will be given an injection of final formulation buffer (FFB) on Days 0 and 168.
3314320|NCT00270218|Experimental|3|Arm 3 participants will be given an injection of VRC-HIVDNA009-00-VP vaccine on Days 0 and 28. Participants will also be given an injection of VRC-HIVADV014-00-VP on Day 168.
3314321|NCT00270218|Placebo Comparator|4|Arm 4 participants will be given an injection of phosphate buffered saline (PBS) on Days 0 and 28 and an injection of FFB on Day 168.
3314322|NCT00270205|Experimental|A: 0.1 mg DNA/participant vaccination at weeks 1,7,13|Participants receiving three separate low-dose vaccinations of LC002 (0.1 mg DNA/participant, 0.8 ml total, administered over two skin sites [on the left and right upper back] of 80 cm^2 each, 0.4 ml/site) at weeks 1, 7, and 13.
3314323|NCT00270205|Experimental|B|Participants receiving three separate vaccinations of LC002 placebo (0.8 ml total, administered over two skin sites [on the left and right upper back] of 80 cm^2 each, 0.4 ml/site) at weeks 1, 7, and 13.
3314324|NCT00270205|Experimental|C: 0.4 mg DNA/participant vaccination at weeks 1, 7, 13|Participants receiving three separate high-dose vaccinations of LC002 (0.4 mg DNA/participant, 3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at weeks 1, 7, and 13.
3314325|NCT00270205|Experimental|D|Participants receiving three separate vaccinations of LC002 placebo (3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at weeks 1, 7, and 13.
3314326|NCT00270205|Experimental|E: 0.4 mg DNA/participant vaccination at weeks 0,1,6,7,12,13|Participants receiving six separate high-dose vaccinations of LC002 (0.4 mg DNA/participant, 3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at study entry and weeks 1, 6, 7, 12, and 13.
3314327|NCT00270205|Experimental|F|Participants receiving six separate vaccinations of LC002 placebo (3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at study entry and weeks 1, 6, 7, 12, and 13.
3314328|NCT00270153|Placebo Comparator|enalapril|
3314329|NCT00269919|Experimental|Risperidone Long-Acting Injectable (RLAI)|The RLAI 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 2 years.
3314330|NCT00269906|Experimental|Abciximab (c7E3 Fab)|Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight abciximab as bolus intravenous injection followed by continuous infusion of abciximab at rate of 10 microgram per minute for at least 18 hours but not longer than 26 hours.
3314331|NCT00269906|Placebo Comparator|Placebo|Participants will receive matching placebo as bolus IV injection followed by continuous infusion of matching placebo for at least 18 hours but no longer than 26 hours.
3314380|NCT00269386|Placebo Comparator|2 (ii)|placebo tablets of identical size, colour and taste
3314332|NCT00269893|Placebo Comparator|Placebo|Participants will receive matching placebo solution bolus followed by matching placebo solution infusion up to 12 hours.
3314333|NCT00269893|Experimental|Abciximab and Placebo|Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight of abciximab (c7E3 Fab) bolus injection followed by followed by placebo solution infusion up to 12 hours.
3314334|NCT00269893|Experimental|Abciximab|Participants will receive 0.25 mg/kg of body weight of abciximab bolus followed by abciximab (c7E3 Fab) infusion up to 12 hours.
3314335|NCT00269880|Placebo Comparator|Placebo and Standard Dose of Heparin|Participants will receive bolus placebo followed by 12-hour infusion of placebo and bolus heparin at a dose of 100 units per kilogram of body weight.
3314336|NCT00269880|Active Comparator|Abciximab and Low Dose of Heparin|Participants will receive bolus abciximab at a dose of 0.25 milligram per kilogram (mg/kg) of body weight followed by 12-hour infusion of 0.125 microgram per kilogram per minute (mcg/kg/min) and bolus heparin at a dose of 70 units per kilogram of body weight.
3314337|NCT00269880|Active Comparator|Abciximab and Standard Dose Heparin|Participants will receive bolus abciximab at a dose of 0.25 mg/kg of body weight followed by 12-hour infusion of 0.125 mcg/kg/min and bolus heparin at a dose of 100 units per kilogram of body weight.
3314338|NCT00269867|Placebo Comparator|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
3314339|NCT00269867|Experimental|Infliximab 3 mg/kg every 8 weeks|Infliximab 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
3314340|NCT00269867|Experimental|Infliximab 3 mg/kg every 4 weeks|Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.
3314341|NCT00269867|Experimental|Infliximab 10 mg/kg every 8 weeks|Infliximab 10 mg/kg will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
3314342|NCT00269867|Experimental|Infliximab 10 mg/kg every 4 weeks|Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.
3314343|NCT00269854|Experimental|Infliximab 5 mg/kg|
3314344|NCT00269854|Experimental|Infliximab 10 mg/kg|
3314345|NCT00269854|Experimental|Infliximab 20 mg/kg|
3314346|NCT00269854|Placebo Comparator|Placebo|
3314347|NCT00269841|Experimental|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
3314348|NCT00269841|Experimental|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
3314349|NCT00269841|Placebo Comparator|Placebo|Matching placebo will be administered at Week 0, 2 and 6.
3314350|NCT00269815|Experimental|001|methylphenidate HCl
3314351|NCT00269802|Experimental|001|OROS methylphenidate HCl
3314352|NCT00269802|Active Comparator|002|Ritalin
3314353|NCT00269802|Placebo Comparator|003|Placebo
3314354|NCT00269789|Experimental|001|OROS Methylphenidate HCl
3314355|NCT00269789|Active Comparator|002|Ritalin
3314356|NCT00269789|Placebo Comparator|003|Placebo
3314357|NCT00269776|Experimental|001|OROS (methylphenidate HCl) Treatment A: 1 2 or 3 OROS methylphenidate 18-mg tablets + 0 1 or 2 OROS placebo tablets (3 tablets in total) once daily + 1 placebo capsule 3x/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
3314358|NCT00269776|Experimental|002|Ritalin (methylphenidate) Treatment B: 5 10 or 15-mg tablets (encapsulated/single capsule) 3 times a day + 3 OROS placebo tablets once daily for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
3314359|NCT00269776|Experimental|003|Placebo Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
3314360|NCT00269633|Placebo Comparator|Red Light Box 657 nm|Red Light Box 657 nm
3314361|NCT00269633|Active Comparator|Blue Light Box 467 nm|Blue Light Box 467 nm
3314362|NCT00269620|Experimental|2|OrthoEvra
3314363|NCT00269620|Experimental|1|NuvaRing
3314364|NCT00269581|Other|1|Educational CD-Rom
3314365|NCT00269581|Experimental|2|Headstrong CD-rom
3314366|NCT00269542|Experimental|1|
3314367|NCT00269542|Placebo Comparator|2|
3314368|NCT00269516|Experimental|1|
3314369|NCT00269516|Experimental|2|
3314370|NCT00269516|Experimental|3|
3314371|NCT00269516|Placebo Comparator|4|
3314372|NCT00269477|Experimental|Menactra® Vaccine Group 1|Participants had previously received a dose of Menactra® vaccine in Study MTA02,did not participate in Study MTA19 (NCT 00777790). They provided a pre-vaccination blood sample on Day 0, received one booster dose of Menactra® vaccine on Day 0 and provided 3 additional blood samples on Day 3, Day 7, and Day 28 post-vaccination.
3314373|NCT00269477|Experimental|Menactra® Vaccine Group 2|Participants had previously received a dose of Menactra® vaccine in Study MTA02,did not participate in Study MTA19 (NCT 00777790). They provided a pre-vaccination blood sample on Day 0, received one booster dose of Menactra® vaccine on Day 0 and provided 3 additional blood samples on Day 5, Day 14, and Day 28 post-vaccination
3314374|NCT00269477|Active Comparator|Meningococcal Vaccine-naive Group 3|Participants have never received Meningococcal vaccine and provided one blood sample pre-vaccination on Day 0, received a dose of Menactra® vaccine on Day 0, and provided 3 additional blood samples on Day 3, Day 7, and Day 28 post-vaccination.
3314375|NCT00269477|Active Comparator|Meningococcal Vaccine-naive Group 4|Participants have never received Meningococcal vaccine and provided one blood sample pre-vaccination on Day 0, received a dose of Menactra® vaccine on Day 0, and provided 3 additional blood samples on Day 5, Day 14, and Day 28 post-vaccination.
3314376|NCT00269425|Experimental|Mediterranean diet,|
3314377|NCT00269425|Experimental|American Heart Association Step 2 diet|
3314378|NCT00269425|No Intervention|Case controlled|
3314379|NCT00269386|Active Comparator|1 (i)|Clarithromycin S/R 1g od From April 2004, clarithromycin S/R (Klaricid XL) ceased to be available and subsequent patients will receive either standard clarithromycin 500mg bd or placebo tables of identical size, colour and taste
3314381|NCT00269360|Experimental|1|
3314387|NCT00269308|Experimental|1|Chiropractic Manual Treatment + Home Exercise
3314388|NCT00269308|Experimental|2|Supervised Rehabilitative Exercise + Home Exercise
3314389|NCT00269308|Active Comparator|3|Home Exercise
3314390|NCT00269295|Experimental|Cohort 1: Arm 1|12 subjects to receive vaccine dose 1: 5 X 10^7 cfu.
3314391|NCT00269295|Placebo Comparator|Cohort 1: Arm 2|6 subjects to receive placebo.
3314392|NCT00269295|Experimental|Cohort 2: Arm 1|12 subjects to receive vaccine dose 2: 5 X 10^8 cfu.
3314393|NCT00269295|Experimental|Cohort 3: Arm 1|12 subjects to receive vaccine dose 3: 5 X 10^9 cfu.
3314394|NCT00269295|Placebo Comparator|Cohort 3: Arm 2|6 subjects to receive placebo.
3314395|NCT00269295|Placebo Comparator|Cohort 2: Arm 2|6 subjects to receive placebo.
3314396|NCT00269282|Active Comparator|1|Self-Management (SM) (Standard Care Group)
3314397|NCT00269282|Experimental|2|Motivational Interviewing plus Self-Management Training (MI+SM)
3314398|NCT00269152|Experimental|A: Pemetrexed + Cisplatin|
3314399|NCT00269152|Experimental|B: Pemetrexed + Carboplatin|
3314400|NCT00269113|Experimental|1|
3314401|NCT00269113|Active Comparator|2|
3314402|NCT00269048|Experimental|Arm 1|SB-480848
3314403|NCT00269048|Placebo Comparator|Arm 2|placebo
3314404|NCT00269035|Experimental|Treatment Group 1|Subjects in group 1 will receive SB-773812 tablet once daily till still steady Cp
3314405|NCT00269035|Experimental|Treatment Group 2|Subjects in group 2 will receive SB-773812 tablets once daily over 6 weeks. Risperidone tablets 6 mg once daily from Days 1-7 two tablets of 3 mg and days 8 until stable Cp 6 mg tablets
3314406|NCT00268996|Experimental|Subjects with ACS and evidence of MN:SB-480848|Enrolled subjects (subjects with ACS and evidence of myocardial necrosis) will receive 160mg of SB-480848 once daily with food for 52 weeks
3314407|NCT00268996|Placebo Comparator|Subjects with ACS and evidence of MN: placebo|Enrolled subjects (subjects with ACS and evidence of myocardial necrosis) will receive SB-480848 matching placebo once daily with food for 52 weeks
3314408|NCT00268996|Experimental|Non-ACS and ACS subjects without evidence of MN: SB-480848|Enrolled subjects (non-ACS subjects and those ACS subjects without evidence of myocardial necrosis) will receive 160mg of SB-480848 once daily with food for 52 weeks
3314409|NCT00268996|Placebo Comparator|Non-ACS and those ACS subjects without evidence of MN: placebo|Enrolled subjects (non-ACS subjects and those ACS subjects without evidence of myocardial necrosis) will receive SB-480848 matching placebo once daily with food for 52 weeks
3314410|NCT00268983|Experimental|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes~Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes."
3314411|NCT00268983|Active Comparator|Rituximab|Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.
3314412|NCT00268957|Experimental|1|sevelamer carbonate powder
3314413|NCT00268957|Active Comparator|2|Sevelamer hydrochloride
3314414|NCT00268944|Experimental|1|
3314415|NCT00268931|No Intervention|True Control|This group is being enrolled as a true control group. This group will not participate in the movement training or social training however, they will be evaluated in the same way.
3314416|NCT00268931|Experimental|Social Training|This group underwent specific social interactions two times each day with their parents.
3314417|NCT00268931|Experimental|Movement Training|This group of preterm infants underwent movement training two times per day with their parents.
3314418|NCT00268918|Experimental|Docetaxel / PTK787|"Docetaxel: Lead In: Given intravenously on Day 1 and Day 14 Afer Lead in: Given intravenously on day 1, 8, 15, 22 of each 28-day cycle.~PTK787: Lead In: Given orally on day 4 and day 14 After Lead In: Given orally once a day."
3314419|NCT00268905|Experimental|1|
3314420|NCT00268905|Experimental|2|
3314421|NCT00268905|Experimental|3|
3314422|NCT00268892|Experimental|Degarelix 240/240@40(1-3-6-9)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (40 mg/mL) at months 1, 3, 6, and 9) in the extension study (240 mg (40 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
3314423|NCT00268892|Experimental|Degarelix 240/240@60(1-3-6-9)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (60 mg/mL) at months 1, 3, 6, and 9) in the extension study (240 mg (60 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
3314424|NCT00268892|Experimental|Degarelix 240/240@60(1-4-7-10)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (60 mg/mL) at months 1, 4, 7, 10) in the extension study (240 mg (60 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
3314425|NCT00268879|Placebo Comparator|1|Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
3314426|NCT00268879|Experimental|2|Renzapride 4 mg QD. Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
3314427|NCT00268879|Experimental|3|Renzapride 2 mg BID: Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
3314428|NCT00268853|Experimental|1|
3314429|NCT00268853|Active Comparator|2|
3314430|NCT00268840|Experimental|unique|Taxotère - Gemzar
3314431|NCT00268814|Experimental|MTF, Psycho-education, Heroin|Stratum: Methadone treatment failures (MTF) Intervention: Psycho-education and Counselling, Drug: Diacetylmorphine (i.v.)
3314432|NCT00268814|Experimental|MTF, Case management, Heroin|Stratum: Methadone treatment failures (MTF) Intervention: Case Management and Motivational Interviewing, Drug: Diacetylmorphine (i.v.)
3314433|NCT00268814|Active Comparator|MTF, Psycho-education, Methadone|Stratum: Methadone treatment failures (MTF) Intervention: Psycho-education and Counselling, Drug: Methadone (p.o.)
3314434|NCT00268814|Active Comparator|MTF, Case management, Methadone|Stratum: Methadone treatment failures (MTF) Intervention: Case Management and Motivational Interviewing, Drug: Methadone (p.o.)
3314435|NCT00268814|Experimental|NIT, Psycho-education, Heroin|Stratum: Not in treatment (NIT) Intervention: Psycho-education and Counselling, Drug: Diacetylmorphine (i.v.)
3314436|NCT00268814|Experimental|NIT, Case management, Heroin|Stratum: Not in treatment (NIT) Intervention: Case Management and Motivational Interviewing, Drug: Diacetylmorphine (i.v.)
3314437|NCT00268814|Active Comparator|NIT, Psycho-education, Methadone|Stratum: Not in treatment (NIT) Intervention: Psycho-education and Counselling, Drug: Methadone (p.o.)
3314438|NCT00268814|Active Comparator|NIT, Case management, Methadone|Stratum: Not in treatment (NIT) Intervention: Case Management and Motivational Interviewing, Drug: Methadone (p.o.)
3314439|NCT00268788|Active Comparator|1|Subcutaneous Ig given twice a week.
3314440|NCT00268788|Active Comparator|2|Intravenous Ig
3314441|NCT00268762|Experimental|Intervention|Argatroban IV Infusion 1 mcg/kg/min for 48 hours
3314442|NCT00268749|Experimental|1|
3314443|NCT00268723|Experimental|1|levalbuterol HFA MDI 90 mcg QID
3314444|NCT00268723|Placebo Comparator|2|Placebo MDI QID
3314445|NCT00268697|Experimental|Lapaquistat Acetate 100 mg QD|
3314446|NCT00268697|Experimental|Lapaquistat Acetate 100 mg QD + Ezetimibe|
3314447|NCT00268697|Active Comparator|Ezetimibe|
3314448|NCT00268593|Experimental|130 mg PI-88 + docetaxel|130 mg PI-88 7 days/week + docetaxel 75 mg/m2
3314449|NCT00268593|Experimental|250 mg PI-88 + docetaxel|250 mg PI-88 4 days/week + docetaxel 75 mg/m2
3314450|NCT00268580|Experimental|Intervention|Asthma care provided using care pathway
3314451|NCT00268580|No Intervention|Control|Standard of care provided
3314452|NCT00268528||Health service research (electronic pill monitoring system)|Patients receive an electronic pill monitoring system comprising an empty MEMS^? medication bottle with TrackCap? CR. The mercaptopurine prescription is filled using this system. Beginning on day 1 of the third or later course of maintenance therapy, patients take all doses of mercaptopurine from the MEMS^? medication bottle with TrackCap? CR for at least 169 days. The MEMS^? TrackCap? CR is mailed to the Coordinating Center at the end of study. Patients also receive methotrexate PO as indicated by their individual chemotherapy regimen.
3314453|NCT00268489|Experimental|pemetrexed + bevacizumab|"Patients receive pemetrexed disodium IV over 10 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed periodically for 5 years."
3314454|NCT00268476|Active Comparator|Arm A: Standard of Care|Androgen Deprivation Therapy [ADT] (plus Radiotherapy for newly-diagnosed non-metastatic disease, plus or minus Docetaxel, plus or minus Abiraterone)[Control]
3314455|NCT00268476|Experimental|Arm B: Zoledronic Acid|(ADT + zoledronic acid) NO LONGER RECRUITING
3314456|NCT00268476|Experimental|Arm C: Docetaxel|(ADT + docetaxel + prednisolone) NO LONGER RECRUITING
3314457|NCT00268476|Experimental|Arm D: Celecoxib|(ADT + celecoxib) NO LONGER RECRUITING
3314458|NCT00268476|Experimental|Arm E: Zoledronic Acid & Docetaxel|(ADT + zoledronic acid + docetaxel + prednisolone) NO LONGER RECRUITING
3314459|NCT00268476|Experimental|Arm F: Zoledronic Acid & Celecoxib|(ADT + zoledronic acid + celecoxib) NO LONGER RECRUITING
3314460|NCT00268476|Experimental|Arm G: Abiraterone|(ADT + abiraterone acetate + prednisolone) NO LONGER RECRUITING
3314461|NCT00268476|Experimental|Arm H: M1 RT|(ADT + radiotherapy to the prostate) NO LONGER RECRUITING
3314462|NCT00268476|Experimental|Arm J: Abiraterone * Enzalutamide|(ADT + abiraterone + enzalutamide + Prednisolone) NO LONGER RECRUITING
3314463|NCT00268476|Experimental|Arm K: Metformin|(ADT + Metformin) RECRUITING
3314464|NCT00268476|Experimental|Arm L: tE2|(Transdermal oestradiol) RECRUITING
3314465|NCT00268463|Active Comparator|Arm 1: Capecitabine + Oxaliplatin|Within 4-6 weeks after surgery and/or ablation, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
3314466|NCT00268463|Experimental|Arm 2: Floxuridine + Oxaliplatin + Capecitabine|Within 4-6 weeks after surgery and/or ablation, patients receive a continuous hepatic arterial infusion of floxuridine on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 42 days for 4 cycles in the absence of unacceptable toxicity. Beginning with cycle 5, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment with oxaliplatin and capecitabine repeats every 21 days for 4 cycles.
3314467|NCT00268450|Experimental|study intervention|Neo-adjuvant cisplatin, gemcitabine and bevacizumab followed by radical cystectomy. Patients without residual disease will enter follow up after surgery. Patients with residual disease will receive adjuvant therapy with bevacizumab and ciaplatin.
3314468|NCT00268437|Experimental|Pemetrexed/Carboplatin|Pemetrexed+Carboplatin+Radiation
3314469|NCT00268398|Active Comparator|FOLFOX4|
3314470|NCT00268398|Experimental|FOLFOX7 followed by FOLFIRI|
3314471|NCT00268385|Experimental|Treatment (vorinostat, temozolomide)|"PART I: Patients receive vorinostat PO QD or BID on days 1-7 and 15-21 OR QD or BID on days 1-7. Patients also receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Treatment may continue beyond 13 courses at the discretion of the investigator.~PART II: Patients receive vorinostat and temozolomide as in part I*.~[Note: Beginning in course 2, some patients may receive a higher dose of temozolomide.]"
3314472|NCT00268372|Active Comparator|cisplatin/RT alone|cisplatin and radiation therapy
3314473|NCT00268372|Experimental|induction chemo followed by cisplatin/RT|docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by surgery and/or cisplatin and radiation therapy
3314474|NCT00268346|Experimental|ZD1839|
3314475|NCT00268307|Experimental|Cell therapy|Intracoronary, one time infusion of autologous, unfractionated bone marrow mononuclear cells.
3314476|NCT00268242|Experimental|Gemcitabine + Mitoxantrone|Gemcitabine Hydrochloride as administered as a continuous intravenous infusion (I.V.) at 10mg/m^2/minute for 12 hours, starting on Day 1. Mitoxantrone Hydrochloride was given at a dose of 12mg/m^2/day I.V. on days 1, 2, and 3.
3314528|NCT00267111|Experimental|Amethocaine gel 4% Group|1 g of topical amethocaine gel 4%
3314529|NCT00267111|Placebo Comparator|Placebo Group|
3314530|NCT00267098|Experimental|Biventricular pacing|
3314477|NCT00267969|Experimental|ustekinumab 45 mg|Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.
3314478|NCT00267969|Experimental|ustekinumab 90 mg|Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.
3314479|NCT00267969|Placebo Comparator|Placebo|Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.
3314480|NCT00267956|Experimental|CNTO1275 (ustekinumab)|Group 1: Patients will receive CNTO 1275 63 mg at Weeks 0, 1, 2, and 3. At Weeks 12 and 16, patients will receive placebo to maintain the blind.
3314481|NCT00267956|Placebo Comparator|Placebo|Group 2: Patients will receive placebo at Weeks 0, 1, 2, and 3. At Weeks 12 and 16, patients will receive CNTO 1275 63 mg.
3314482|NCT00267930|Placebo Comparator|1|Tier 1: 1 placebo capsule b.i.d Tier 2: 2 placebo capsules b.i.d
3314483|NCT00267930|Experimental|2|Tier 1: Vernakalant (oral) 1 x 300 mg capsule b.i.d
3314484|NCT00267930|Experimental|3|Tier 2: Vernakalant (oral) 2 x 300 mg (600 mg) b.i.d
3314485|NCT00267865|Experimental|A|Induction treatment cycles with rituximab, high-dose methotrexate and leucovorin will be administered every 2 weeks for 6 cycles. Two additional consolidation cycles of high-dose methotrexate without rituximab will be administered at 4 weeks and 8 weeks following completion of the combined therapy.
3314486|NCT00267852||1.0|As per routinary clinical practice
3314487|NCT00267826|Experimental|1|Patients with atopic dermatitis.
3314488|NCT00267774|Experimental|FFR guided PCI|
3314489|NCT00267774|Active Comparator|Angio-guided PCI|
3314490|NCT00267748|Experimental|C|
3314491|NCT00267748|Experimental|A|
3314492|NCT00267696|Experimental|Gemcitabine/carboplatin/bevacizumab|A regimen consisting of gemcitabine(1000 mg/m2)/carboplatin(AUC 3) / bevacizumab(Avastin®)(10mg/kg) will be administered on day 1 and day 15 of a 28 day cycle.
3314493|NCT00267670|Experimental|Pentoxifylline|400mg PO TID
3314494|NCT00267670|Placebo Comparator|Placebo|1 pill PO TID
3314495|NCT00267644||Hydrated patients|Group 1 (n=63) were pediatric patiens that wer hydrated.
3314496|NCT00267644||Dehydrated Group|Group 2 (n=13) were pediatric patients that were dehydrated.
3314497|NCT00267631||At Risk Body Weight|Children with a BMI greater and equal to 85%
3314498|NCT00267631||Normal Body Weight|Children with a BMI of 25 to 75%
3314499|NCT00267618|Experimental|Treatment|50% randomized to receive FHP Pain intervention
3314500|NCT00267618|No Intervention|control|50% randomized to receive standard/usual care for recurrent headache/abdominal pain
3314501|NCT00267605|Experimental|Treatment|FHPADHD 50% randomized to receive Strongest Families (formerly Family Help Program): behavioural distance intervention
3314502|NCT00267605|Active Comparator|Control|ADHD Standard Care 50% randomized to receive standard/usual care for ADHD
3314503|NCT00267592|Experimental|enzyme-inducing antiseizure drug|A single-arm study with all subjects assigned to one treatment (radiation + temozolomide + talampanel) but subjects receiving concomitant anti-seizure drugs which could increase study drug elimination had a slightly modified dose/schedule of study drug. The primary endpoint is analyzed as a single group.
3314504|NCT00267579|Experimental|Treatment|50% randomized to receive Strongest Families (formerly Family Help Program): Behaviour treatment
3314505|NCT00267579|Active Comparator|Control|50% randomized to control group: standard/usual care for behaviour disorder
3314506|NCT00267566|Experimental|Treatment|50% random assignment to receive Family Help Anxiety Treatment
3314507|NCT00267566|Experimental|Control|50% random assignment to control group to receive usual/standard care for anxiety
3314508|NCT00267514|Other|1|sevelamer carbonate powder x 4 weeks then, sevelamer hydrochloride x 4 weeks
3314509|NCT00267514|Other|2|sevelamer hydrochloride x 4 weeks then, sevelamer carbonate powder x 4 weeks
3314510|NCT00267371|Active Comparator|Test Arm with Premere investigational|PFO Closure with Premere investigational device.
3314511|NCT00267371|Active Comparator|Medical management/current medications|Patients in the control group arm will not receive the medical device and will continue medical management.
3314512|NCT00267358|Active Comparator|RC-1291 HCl|50 mg
3314513|NCT00267358|Placebo Comparator|Placebo|
3314514|NCT00267319|Experimental|single group|
3314515|NCT00267293|Active Comparator|A|At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg)
3314516|NCT00267293|Experimental|B|At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) and an appropriate dose of Acetaminophen (15 mg/kg)
3314517|NCT00267293|Experimental|C|At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) and at time 3 hours is given an appropriate dose of Acetaminophen (15 mg/kg)
3314518|NCT00267241|Experimental|1|ALI/ARDS patients
3314519|NCT00267202|Placebo Comparator|Placebo|The dose of placebo was determined according to the omalizumab US product label using a dosing table nomogram that ensures patients receive at least 0.016 mg/kg/IgE (IU/ml) per 4 weeks. The study drug was administered by subcutaneous injection every 2 or 4 weeks according to the dosing table nomogram.
3314520|NCT00267202|Experimental|Omalizumab|The dose of omalizumab was determined according to the omalizumab US product label using a dosing table nomogram that ensures patients receive at least 0.016 mg/kg/IgE (IU/ml) per 4 weeks. The study drug was administered by subcutaneous injection every 2 or 4 weeks according to the dosing table nomogram.
3314521|NCT00267189|Active Comparator|Reduced CNI dose + everolimus ± steroids|Reduced CNI dose + everolimus (1.5 mg twice daily (b.i.d)) ± steroids
3314522|NCT00267189|Experimental|CNI continuation ± MPA/AZA ± Steroids|Standard CNI dose ± MPA/AZA ± steroids
3314523|NCT00267163|Experimental|1.|
3314524|NCT00267163|Placebo Comparator|2.|
3314525|NCT00267150|Experimental|1|
3314526|NCT00267124||1|elderly people who have normal cognition
3314527|NCT00267124||2|elderly people who have mild to moderate Alzheimer's disease
3320791|NCT00160342|Experimental|3|
3314532|NCT00267085|Experimental|CML Vaccine|Imatinib mesylate subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months
3314533|NCT00267059|Experimental|Lenalidomide|
3314534|NCT00267046|Experimental|Palifermin|"Palifermin + Chemotherapy (Adriamycin (Doxorubicin)+ Ifosfamide (AI) or Adriamycin (Doxorubicin) + Cisplatin (AP) Regimen); Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.~AP=Doxorubicin (Adriamycin) + Cisplatin:~Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0."
3314535|NCT00267046|Placebo Comparator|Placebo|"Placebo + Chemotherapy (AI or AP Regimen);~AI = Doxorubicin (Adriamycin) + Ifosfamide:~A single dose placebo prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.~AP=Doxorubicin (Adriamycin) + Cisplatin:~A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0."
3314536|NCT00267033|Experimental|1|injection of orthopaedic cement into vertebral bodies
3314537|NCT00267020|Experimental|A|
3314538|NCT00267020|Active Comparator|B|
3314539|NCT00267007|Experimental|001|PROCRIT 40 000 IU QW Epoetin alpha (PROCRIT) 40 000 IU every week (QW) for 18 weeks (IV or SC)
3314540|NCT00267007|Placebo Comparator|002|Placebo Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
3314541|NCT00266929||Surgical|Subjects receiving surgical treatment for Type II odontoid fracture per discretion of investigator (non-randomized allocation)
3314542|NCT00266929||Non-surgical|Subjects treated with non-operative treatment options
3314543|NCT00266877|Experimental|Prior Tarceva or Iressa With EGFR Mutation|HKI-272 administered to patients whose disease has progressed following > or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor with an EGFR mutation demonstrated at screening
3314544|NCT00266877|Experimental|Prior Tarceva or Iressa w/o EGFR Mutation|HKI-272 administered to patients whose disease has progressed following > or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor without an EGFR mutation demonstrated at screening
3314545|NCT00266877|Experimental|No Prior EGFR Tyrosine Kinase Inhibitor Treatment|HKI-272 administered to patients with no prior EGFR tyrosine kinase inhibitor treatment, adenocarcinoma, < or = 20 pack-year smoking history, and current non-smoker (no requirement for EGFR mutation)
3314546|NCT00266864|Experimental|Testosterone Replacement Therapy|Subjects with Low Testosterone (Hypogonadal) Receive Testosterone Transdermal System (Androderm 5 mg patch)
3314547|NCT00266864|No Intervention|No Intervention|Subjects with normal testosterone levels (eugonadal) participated in identical outcome measurements at parallel time points.
3314548|NCT00266851|Active Comparator|Azithromycin|Active adjunctive treatment
3314549|NCT00266851|Placebo Comparator|Placebo|Adjunctive placebo
3314550|NCT00266838|Placebo Comparator|Lacrystat|Lacrystat
3314551|NCT00266838|Active Comparator|Maxidex|Applying Maxidex
3314552|NCT00266825|Experimental|DHA capsules|DHA capsules
3314553|NCT00266825|Placebo Comparator|Placebo capsules|Placebo capsule
3314554|NCT00266812|Experimental|Chemotherapy with temozolomide and radiotherapy|
3314555|NCT00266812|Active Comparator|Radiotherapy alone|
3314556|NCT00266799|Experimental|Pegylated liposomal doxorubicin|
3314557|NCT00266799|Active Comparator|Capecitabine|
3314558|NCT00266786|Experimental|Intranasal Ketorolac Tromethamine|
3314559|NCT00266786|Placebo Comparator|Intranasal Placebo|
3314560|NCT00266773|No Intervention|1|Control - standard care only
3314561|NCT00266773|Experimental|2|Attention Control - standard care plus 6 months TIVR receiving minimal monthly feedback
3314562|NCT00266773|Experimental|3|Standard care plus 6 months TIVR receiving detailed monthly feedback
3314563|NCT00266708|Experimental|bisphosphonate arm|subjects received bisphosphonate for one year
3314564|NCT00266708|Placebo Comparator|subjects received placebo|subjects received placebo for 1 year
3314565|NCT00266695|Experimental|Ruboxistaurin|
3314566|NCT00266656|Experimental|Experimental 1 Control|"No drug administration in B9R-US-GDFG (NCT00406926).~Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given."
3314567|NCT00266656|Experimental|Experimental 2 Humatrope|Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given.
3314568|NCT00266630|Experimental|Olanzapine Monotherapy|"Olanzapine extension for Study BMAC patients who completed Visit 8.~Patients received olanzapine 5-20 mg for 18 weeks."
3314569|NCT00266630|Experimental|Olanzapine + Mood Stabilizer|"Olanzapine extension for Study BMAC patients who discontinued at Visit 4 or 5.~Patients received an initial dose of olanzapine 10 mg for 1 week and subsequent doses of olanzapine 5-20 mg for 17 weeks.~Patients received one (1) mood stabilizer (lithium, valproate or carbamazepine) for 18 weeks."
3314570|NCT00266565|Experimental|Anti-IL5 (Mepolizumab)|The purpose of the study is to assess the toxicity of anti-IL-5 (Mepolizumab), and to see whether it lowers eosinophils in peripheral blood and/or tissue and whether it has a steroid and/or interferon sparing effect.
3314571|NCT00266474||Cross sectional CF study|Multicentric study, including 187 CF patients of all age groupr in 5 CF centres.
3314572|NCT00266461|Experimental|TU-100 7.5g/day|Subjects will be randomized to TU-100 7.5g, 15g, or no active treatment group. Subjects will take a daily dose divided into 3 times a day.
3314573|NCT00266461|Experimental|TU-100 15g/day|Subjects will be randomized to TU-100 7.5g, 15g, or no active treatment group. Subjects will take a daily dose divided into 3 times a day.
3314574|NCT00266461|No Intervention|Water|Subjects will be randomized to TU-100 7.5g, 15g, or no active treatment group. Subjects will take a daily dose divided into 3 times a day.
3314575|NCT00266409|Experimental|Panic: Niravam+SSRI/SNRI|Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI
3314576|NCT00266409|Experimental|Panic: SSRI/SNRI alone|Panic Disorder: Newly prescribed SSRI or SNRI alone
3314577|NCT00266409|Experimental|GAD: Niravam+SSRI/SNRI|Generalized Anxiety Disorder: Niravam plus a newly prescribed SSRI or SNRI
3320792|NCT00160342|Active Comparator|4|
3314578|NCT00266409|Experimental|GAD: SSRI/SNRI alone|Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone
3314579|NCT00266396|Experimental|weight-bearing recommendation|Weight-bearing recommendation after THA and TKA
3314580|NCT00266331|Active Comparator|Group A, RayGel Topical Cream|RayGel Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
3314581|NCT00266331|Placebo Comparator|Arm B Placebo Topical Cream|Placebo Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
3314582|NCT00266305|Experimental|Fish oil|
3314583|NCT00266305|Placebo Comparator|Olive oil|Control group
3314584|NCT00266305|No Intervention|High fish|Reference group
3314585|NCT00266279|Experimental|Treatment with Study Drugs|Treatment with combination of oxaliplatin and capecitabine using study dose and schedule.
3314586|NCT00266253|Experimental|1|
3314587|NCT00266253|Experimental|2|
3314588|NCT00266253|Experimental|3|
3314589|NCT00266253|Experimental|4|
3314590|NCT00266253|Experimental|5|
3314591|NCT00266253|Active Comparator|6|
3314592|NCT00266240|Experimental|1|
3314593|NCT00266240|Experimental|2|
3314594|NCT00266240|Experimental|3|
3314595|NCT00266240|Experimental|4|
3314596|NCT00266240|Placebo Comparator|5|
3314597|NCT00266227|Experimental|Arm A: Rituximab Retreatment|1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.
3314598|NCT00266227|Placebo Comparator|Arm B: Placebo Retreatment|1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by retreatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/week methotrexate.
3314599|NCT00266214|Experimental|Lidocaine Patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.
3314600|NCT00266214|Placebo Comparator|Placebo|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.
3314601|NCT00266110|Experimental|Dendritic Cell Vaccine|Therapeutic autologous dendritic cells (Dendritic Cell Vaccine) i.d. injection, 20 x 106 DCs given per treatment Trastuzumab infusion Vinorelbine ditartrate infusion
3314602|NCT00266097|Experimental|Part I|Oxaliplatin + Gemcitabine + Radiation
3314603|NCT00266097|Experimental|Part II|Erlotinib + Oxaliplatin + Gemcitabine + Radiation
3314604|NCT00266058|Active Comparator|Lopinavir/ritonavir, artemethr/lumefantrine|Determination of the antimalarial drug levels artemether/lumefantrine in the absence and in the presence of co-administered antiretrovirals lopinavir and ritonavir.
3314605|NCT00266058|Active Comparator|efavirenz, artemether, lumefantrine|Determination of the antimalarial drug levels artemether/lumefantrine in the absence and in the presence of co-administered antiretroviral efavirenz.
3314606|NCT00266032|Experimental|Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
3314607|NCT00266032|Experimental|Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
3314608|NCT00266032|Active Comparator|Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
3314609|NCT00265993|Experimental|1|enoxaparin
3314610|NCT00265980|No Intervention|A: Baseline studies|Subjects undergo studies at their usual body weight which is used as a baseline against which to compare subjects following weight loss with or without tri-iodothyronine or leptin repletion.
3314611|NCT00265980|Placebo Comparator|B -1: Subcutaneous placebo|Subjects are studied while at a 10% reduced body weight and receiving twice daily doses of placebo for 5 weeks. Data from this phase of the study are compared to baseline arm (A) to examine the effects of weight loss without leptin repletion.
3314612|NCT00265980|Experimental|B-2: Leptin repletion|"Subjects are studied while at a 10% reduced body weight and receiving twice daily injections of replacement leptin for 5 weeks. Data from this phase of the study are compared to placebo arm (B-1) to examine the effects of of leptin repletion in weight-reduced subjects."
3314613|NCT00265980|Placebo Comparator|C-1: Oral placebo|Subjects are studied while at a 10% reduced body weight and receiving an oral placebo for 5 weeks. Data from this phase of the study are compared to baseline arm (A) to examine the effects of weight loss without thyroid repletion.
3314614|NCT00265980|Experimental|C-2: Tri-iodothyronine repletion|"Subjects are studied while at a 10% reduced body weight and receiving an oral replacement of tri-idothyronine for 5 weeks. Data from this phase of the study are compared to placebo arm (C-1) to examine the effects of of thyroid repletion in weight-reduced subjects."
3314615|NCT00265967|Experimental|1|Irbesartan
3314616|NCT00265954|Experimental|1|Individuals in this arm receive a 6 month behavioral weight loss intervention delivered on-line. Groups meet via a web chat weekly for 24 weeks and monthly for the following 12 months.
3314617|NCT00265954|Experimental|2|In-person; Individuals in the in-person condition attend weekly group behavioral weight loss sessions for 24 weeks and then monthly sessions for the following 12 months.
3314662|NCT00265395|Active Comparator|Standard therapy|Slow responders (defined as being polymerase chain reaction [PCR] positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to stop treatment at Week 48.
3314618|NCT00265954|Experimental|3|In-person+internet; Individuals in this condition receive a behavioral weight loss intervention over the internet weekly for 24 weeks and monthly for the following 12 months. Every month during the first 24 weeks and every third month during the following year they have an in-person meeting.
3314619|NCT00265941|Active Comparator|RT + cisplatin|Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin
3314620|NCT00265941|Experimental|RT + cisplatin + cetuximab|Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin plus cetuximab
3314621|NCT00265889|Experimental|Poor Risk|Primary progressive, recurrent, or resistant relapse patients
3314622|NCT00265889|Experimental|Good Risk|First recurrence patients
3314623|NCT00265863|Experimental|Patients with Malignant Ascites|Patients meeting protocol criteria enrolled with malignant ascites.
3314624|NCT00265850|Active Comparator|Arm A: FOLFOX or FOLFIRI + bevacizumab|Patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
3314625|NCT00265850|Experimental|Arm B: FOLFOX or FOLFIRI + cetuximab|Patients receive cetuximab 400mg/m^2 IV over 2 hours on the first day of treatment, then 250 mg/m^2 IV over 1 hour weekly thereafter. Patients also receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
3314626|NCT00265850|Experimental|Arm C: FOLFOX or FOLFIRI + cetuximab + bevacizumab|Patients receive cetuximab 400mg/m^2 IV over 2 hours on the first day of treatment, then 250 mg/m^2 IV over 1 hour weekly thereafter. Also, patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
3314627|NCT00265824|Active Comparator|bevacizumab alone|
3314628|NCT00265824|Experimental|Bevacizumab + erlotinib|
3314629|NCT00265811|Experimental|Folfox+Cetuximab|FOLFOX-4 Cetuximab alone every 2 weeks
3314630|NCT00265811|Active Comparator|Folfox|FOLFOX-4 alone every 2 weeks
3314631|NCT00265798|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3314632|NCT00265785|Experimental|Pemetrexed|pemetrexed
3314633|NCT00265759|Experimental|Arm I|Patients receive oral exemestane once daily for up to 16-18 weeks.
3314634|NCT00265759|Experimental|Arm II|Patients receive oral letrozole once daily for up to 16-18 weeks.
3314635|NCT00265759|Experimental|Arm III|Patients receive oral anastrozole once daily for up to 16-18 weeks.
3314636|NCT00265733|Experimental|paclitaxel + capecitabine|"Patients receive paclitaxel poliglumex IV (CT-2103; Xyotax™) over 10-20 minutes on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 6 months for up to 5 years."
3314637|NCT00265720|Placebo Comparator|Control|Written materials only
3314638|NCT00265720|Experimental|Reduced out-of-pocket expense|Reimbursed up to $500 out-of-pocket expense for colorectal cancer screening
3314639|NCT00265720|Experimental|One-on-one education|Individual education with a health educator on CRC screening
3314640|NCT00265720|Experimental|Group Education|Education on CRC screening in a small group with a health educator
3314641|NCT00265642|Experimental|group verum|Drug: Irbesartan
3314642|NCT00265642|Placebo Comparator|group placebo|
3314643|NCT00265629|Experimental|1|RF ablation
3314644|NCT00265616|Active Comparator|1|propofol, 2mg/kg as bolus, then titrated up to EEG burst-suppression as a continuous infusion; no maximum doses defined
3314645|NCT00265616|Active Comparator|2|thiopental/pentobarbital, 2mg/kg as bolus, then titrated up to EEG burst-suppression as a continuous infusion; no maximum doses defined
3314646|NCT00265603|Experimental|1 Arm|The investigators plan to have approximately 16 persons participate in the study of transimmunization. Transimmunization uses a device, called a UVAR-XTS instrument, to remove a portion of blood, part of which is returned, and part of which is incubated overnight before being returned to the bloodstream the next day
3314647|NCT00265564|Active Comparator|Arm 1|Seeking Safety is a manualized, empirically supported, cognitive behavioral therapy that treats substance use disorders and comorbid PTSD. Participants assigned to the Seeking Safety arm attend two one hour sessions of group therapy for 12 weeks.
3314648|NCT00265564|Active Comparator|Arm 2|Usual Care Condition. Patients randomized to usual care will receive standard outpatient SUD treatment.
3314649|NCT00265538|Other|Arm 1|Patient Intervention arms: pure control (no intervention letter); intervention control (patient does not receive intervention letter, but provider sees other patients who may bring in letter); group a (intervention letter only); group b (intervention, + 20$ incentive for discussion w/ provider and 6 month copay reimbursement); group c (intervention letter, 20$ incentive for discussion w/ provider + copay reimbursement, plus reminder phone call 1-3 days prior to primary care visit)
3314650|NCT00265525|Experimental|Cardio fit|
3314651|NCT00265525|No Intervention|Usual Care|
3314652|NCT00265512|Active Comparator|Arm 1|Telephone Case Monitoring Aftercare
3314653|NCT00265512|Active Comparator|Arm 2|Continuing Care as Usual
3314654|NCT00265473|Experimental|Allogeneic Islets of Langerhans|Islet infusion
3314655|NCT00265447|Active Comparator|Strength training|3 months of strength training
3314656|NCT00265447|Active Comparator|Aerobic conditioning|3 months of aerobic conditioning
3314657|NCT00265447|Other|Delayed exercise|delayed exercise control group
3314658|NCT00265434|Active Comparator|Dornase alfa|DBPC-cross over trial
3314659|NCT00265434|Placebo Comparator|isotonic saline|
3314660|NCT00265408|Experimental|aspirin|
3314661|NCT00265408|Experimental|warfarin|
3314846|NCT00263042|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
3314847|NCT00263029|Experimental|1|
3314663|NCT00265395|Experimental|Extended therapy|Slow responders (defined as being PCR positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to continue treatment to Week 72.
3314664|NCT00265382|Other|Open|
3314665|NCT00265356|Experimental|1|PET diagnostic imaging
3314666|NCT00265356|No Intervention|2|No PET
3314667|NCT00265343|Experimental|1|asenapine
3314668|NCT00265343|Active Comparator|2|olanzapine
3314669|NCT00265330|Experimental|Open|
3314670|NCT00265317|Experimental|A|
3314671|NCT00265317|Active Comparator|B|
3314672|NCT00265239|Active Comparator|1|Edaravone Group
3314673|NCT00265239|No Intervention|2|Placebo Group
3314674|NCT00265226|Experimental|1|In one arm the patient will receive intradermal Mycobacterium W Vaccine along with Category II ATT according to RNTCP guidelines
3314675|NCT00265226|Placebo Comparator|2|In this Arm patient will receive Placebo along with Category II ATT drugs according to RNTCP guidelines
3314676|NCT00265200|Experimental|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
3314677|NCT00265148|Experimental|Rosiglitazone|4 mg once a day for 1 month increasing to 8 mg once a day (Extended Released Tablets)
3314678|NCT00265148|Other|Placebo|Placebo dummy to match
3314679|NCT00265135|Experimental|Part 1 (CNTO 328)|In Part 1 of the study, 4 intravenous infusions (IV) [injection of a substance into a vein] of CNTO 328 will be administered to patients in 4 dose levels ranging from 1, 3, 6, and 12 mg/kg on days 1, 29, 43, and 57 to determine the maximum tolerated dose for Part 2 of the study.
3314680|NCT00265135|Experimental|Part 2 (CNTO 328)|In Part 2 of the study, 2 well tolerated dose levels of CNTO 328 from Part 1 of the study will be administered every 3 weeks as 4 IV infusions to patients.
3314681|NCT00265135|Experimental|Part 3 (CNTO 328)|In Part 3 of the study, CNTO 328 at a dose level of 6 mg/kg will be administered as IV infusion every 2 weeks for at least 6 doses.
3314682|NCT00265122|Experimental|Population 1: Placebo SC followed by ustekinumab SC|Placebo injected subcutaneously (SC) once a week for 4 weeks (Weeks 0-3) during Intervention Period 1 followed by ustekinumab 90 mg SC once a week for 4 weeks (Weeks 8-11) during Intervention Period 2.
3314683|NCT00265122|Experimental|Population 1: Ustekinumab SC followed by Placebo SC:|Ustekinumab 90 mg injected subcutaneously (SC) once a week for 4 weeks (Weeks 0-3) during Intervention Period 1 followed by ustekinumab 90 mg SC once a week for 4 weeks (Weeks 8-11) during Intervention Period 2.
3314684|NCT00265122|Experimental|Population 1: Placebo IV followed by ustekinumab IV|Placebo given as 1 intravenous (IV) infusion at Week 0 during Intervention Period 1 and ustekinumab 4.5 mg/kg given as one IV infusion at Week 8 during Intervention Period 2.
3314685|NCT00265122|Experimental|Population 1: Ustekinumab IV followed by Placebo IV:|Ustekinumab 4.5 mg/kg given as one intravenous(IV) infusion at Week 0 during Intervention Period 1 followed by placebo given as one IV infusion at Week 8 during Intervention Period 2.
3314686|NCT00265122|Experimental|Population 2: Ustekinumab SC|Ustekinumab 90 mg injected subcutaneously (SC) once a week at Weeks 0-3 during Intervention Period 1. No intervention given during Intervention Period 2.
3314687|NCT00265122|Experimental|Population 2: Ustekinumab IV|Ustekinumab 4.5 mg given as one intravenous (IV) infusion at Week 0 during Intervention Period 1. No intervention given during Intervention Period 2.
3314688|NCT00265109|Other|open label|Open-label trial; all participants received levetiracetam
3314689|NCT00265096|Experimental|002|golimumab 50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
3314690|NCT00265096|Experimental|001|Placebo; golimumab SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
3314691|NCT00265096|Experimental|003|golimumab 100 mg sc injections every 4 wks from wk 0 up to 5 yrs
3314692|NCT00265083|Experimental|003|golimumab 100 mg sc injections every 4 wks from wk 0 up to 5 yrs
3314693|NCT00265083|Placebo Comparator|001|Golimumab (CNTO 148); placebo SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
3314694|NCT00265083|Experimental|002|golimumab 50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
3314695|NCT00265044|Other|Arm 1|
3314696|NCT00265018|Active Comparator|Arm A|
3314697|NCT00265018|Experimental|Arm B|
3314698|NCT00265018|Experimental|Arm C|
3314699|NCT00265018|Experimental|Arm D|
3314700|NCT00265005|Experimental|All|All subjects receive active drug up to a total of 3 doses
3314701|NCT00264979|Other|1|Simultaneous surgery of colorectal cancer and synchronous liver metastases
3314702|NCT00264979|Other|2|Sequential surgeries of colorectal cancer and synchronous liver metastases
3314703|NCT00264953|Active Comparator|A|4x ABVD plus 30Gy IF-RT
3314704|NCT00264953|Experimental|C|4x BEACOPP baseline plus 30Gy IF-RT
3314705|NCT00264953|Experimental|B|4x ABVD plus 20Gy IF-RT
3314706|NCT00264953|Experimental|D|4x BEACOPP baseline plus 20Gy IF-RT
3314707|NCT00264875|Experimental|1|
3314708|NCT00264849|Experimental|OAT + Omalizumab|During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level.
3314802|NCT00263757|Other|Usual Care|Subjects randomized to this arm received medical management for 12 months as prescribed by their cardiologist.
3314803|NCT00263744|Experimental|1|MEDI517
3314804|NCT00263744|Active Comparator|2|Aluminum hydroxide
3314709|NCT00264849|Active Comparator|Optimized Asthma Treatment (OAT)|During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for 32 weeks.
3314710|NCT00264823|Experimental|1 - Experimental|
3314711|NCT00264823|No Intervention|2 - Control|
3314712|NCT00264810|Active Comparator|Treatment Group (stimulation ON)|Group of subjects that have undergone RNS® System implantation that are randomized to receive RNS® System responsive stimulation (i.e. responsive stimulation enabled or turned ON) during the Blinded Evaluation Period. Stimulation is enabled during the Stimulation Optimization Period (second month post-implant) and may continue throughout the subject's participation in the study.
3314713|NCT00264810|Sham Comparator|Sham Group (stimulation OFF)|Group of subjects that have undergone RNS® System implantation that are randomized to receive sham-stimulation (i.e. responsive stimulation disabled or turned OFF) during the Blinded Evaluation Period. Stimulation is enabled after transition into the Open Label Period (sixth month post-implant) and may continue for the remainder of the subject's participation in the study.
3314714|NCT00264797|Active Comparator|Methylphenidate|
3314715|NCT00264797|Placebo Comparator|Methylphenidate (Placebo)|
3314716|NCT00264758|Active Comparator|Conventional hemodialysis|Three times per week in-center hemodialysis
3314717|NCT00264758|Experimental|Frequent hemodialysis|Six times per week in-center hemodialysis
3314718|NCT00264745|Experimental|1|
3314719|NCT00264745|Active Comparator|2|
3314720|NCT00264732|Experimental|1|
3314721|NCT00264732|Experimental|2|
3314722|NCT00264732|Placebo Comparator|3|
3314723|NCT00264719|Active Comparator|A|Mothers with pre-term deliveries will receive metoclopramide 10 mg three times a day for the first 7 days and 2 times a day for the 8th to 10th day, and once a day for the 11th to 12th day
3314724|NCT00264719|Placebo Comparator|B|Mothers with pre-term deliveries will receive metoclopramide 10 mg 3 times a day, 2 times a day from 8th to 10th day and once a day from 11th to 12th day
3314725|NCT00264719|Active Comparator|C|Mothers with full term deliveries will receive 10 mg metoclopramide, 3 times a day for the first 7 days, 2 times a day from 8th to 10th day, and once a day for day 11 to 12
3314726|NCT00264719|Placebo Comparator|D|Mothers with full term deliveries will receive the placebo 10 mg three times a day, for 7 days, and two times a day from day 8 to day 10, and once a day from 11th to 12th day
3314727|NCT00264706|Other|Participant|Internal control study
3314728|NCT00264693||P - A|Prophylactic Dosage, GFR >= 60 mL/min/1.73m^2
3314729|NCT00264693||P - B|Prophylactic Dosage, GFR 30-59 mL/min/1.73m^2
3314730|NCT00264693||P - C|Prophylactic Dosage, GFR < 30 mL/min/1.73m^2
3314731|NCT00264693||P - CAPD|Prophylactic Dosage, CAPD
3314732|NCT00264693||T - A|Therapeutic Dosage, GFR >= 60 mL/min/1.73m^2
3314733|NCT00264693||T - B|Therapeutic Dosage, GFR 30-59 mL/min/1.73m^2
3314734|NCT00264693||T - C|Therapeutic Dosage, GFR < 30 mL/min/1.73m^2
3314735|NCT00264693||T - CAPD|Therapeutic Dosage, CAPD
3314736|NCT00264641|Experimental|High RAS activity|10 healthy men were characterized by having high basal RAS activity.
3314737|NCT00264641|Experimental|Low RAS activity|10 healthy men were characterized by having either a low basal RAS activity.
3314738|NCT00264602|Experimental|Near Infrared Imaging|The intervention to be administered is indocyanine green dye.
3314739|NCT00264589|Other|Study Population|"non-diabetic obese subjects and type 2 diabetic subjects~Intervention: 8 weeks individualized training program"
3314740|NCT00264576|Experimental|cTIV|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
3314741|NCT00264576|Active Comparator|TIV|Received one dose of egg-derived trivalent vaccine (TIV).
3314742|NCT00264563||Behavioral|The intervention is basically by letting the care givers to be aware that there is active recording of iatrogenesis
3314743|NCT00264550|Placebo Comparator|Group 1: Placebo + Methotrexate|Placebo subcutaneous (SC) injections every 4 weeks from Week 0 to Week 20 (early escape at Week 16); Methotrexate - 15 to 25mg weekly from Week 0 up to 5 yrs; Golimumab - if early escape, 50mg SC injections every 4 weeks from Week 16 up to 5 years; Golimumab - 50 mg SC injections every 4 weeks from Week 24 up to 5 yrs (unless early escape); Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
3314744|NCT00264550|Experimental|Group 2: Golimumab 100 mg + Placebo|Golimumab 100 mg SC injections every 4 weeks from Week 0 up to 5 yrs; Placebo - 7-10 capsules weekly during blinded period (or Week 16 if early escape); Methotrexate - if early escape, 15 to 25mg weekly from Week 16 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
3314745|NCT00264550|Experimental|Group 3: Golimumab 50 mg + Methotrexate|Golimumab 50 mg SC injections every 4 weeks from Week 0 up to 5 yrs (unless early escape at Week 16); Methotrexate - 15 to 25 mg weekly from Week 0 up to 5 years; Golimumab - if early escape, 100 mg SC injections every 4 weeks from Week 16 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to100mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
3314746|NCT00264550|Experimental|Group 4: Golimumab 100 mg + Methotrexate|Golimumab100 mg SC injections every 4 weeks from Week 0 up to 5 yrs; Methotrexate - 15 to 25 mg weekly from Week 0 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
3314747|NCT00264537|Experimental|Group 1: Placebo + Methotrexate|Placebo subcutaneous injections (SC) every 4 weeks from Week 0 for up to 5 years (unless early escape at week 28); Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - if early escape, 50 mg SC injections every 4 weeks from Week 28 up to 5 years; Golimumab - Dr's discretion after unblinding (in participants receiving methotrexate plus placebo), 50 mg SC injections every 4 weeks up to 5 years; Golimumab- Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
3314748|NCT00264537|Experimental|Group 2: Golimumab 100 mg + Placebo|Golimumab 100 mg SC injections every 4 weeks from Week 0 for up to 5 years; placebo capsules weekly from Week 0 for up to 5 years (unless early escape at Week 28); Methotrexate - if early escape, 10 to 20 mg weekly from Week 28 up to 5 years; Methotrexate - Dr's discretion after unblinding (in participants receiving golimumab plus placebo) 10 to 20 mg weekly for up to 5 years; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
3314749|NCT00264537|Experimental|Group 3: Golimumab 50 mg + Methotrexate|Golimumab 50 mg SC injections every 4 weeks from Week 0 for up to 5 years (unless early escape at week 28); Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - if early escape, 100 mg SC injections every 4 weeks from Week 28 for up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
3314750|NCT00264537|Experimental|Group 4: Golimumab 100 mg + Methotrexate|Golimumab 100 mg SC injections every 4 weeks from Week 0 for up to 5 years; Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
3314751|NCT00264511|Experimental|Hyperbaric oxygenation|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
3314752|NCT00264511|No Intervention|No hyperbaric oxygenation|Patients randomised to this group will receive standard trauma care.
3314753|NCT00264498|Active Comparator|1|Gemcitabine + Carboplatin
3314754|NCT00264498|Experimental|2|Gefitinib
3314755|NCT00264459|Placebo Comparator|Placebo|Placebo was given the same way as a sublingual preparation.
3314756|NCT00264459|Experimental|Liquid formulation of an extract of a 6 grass pollen mixture|"Sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter. Initial treatment was applied on the first day of treatment with a starting dose of 25% of the maintenance dose. Increasing doses of 50% were applied with the second and 100% with the third dose to give the maximum (=maintenance) dose. This was followed by a daily patient selfadministered treatment with the maintenance dose."
3314757|NCT00264420|Experimental|1|zoledronic acid plus radiation therapy
3314758|NCT00264394|Experimental|Updated CHD risk profiles|Provision of regularly updated CHD risk profiles
3314759|NCT00264394|Active Comparator|Guidelines|Physicians received guidelines only
3314760|NCT00264381|Active Comparator|Ibuprofen|Ibuprofen 800mg tid X 7 days + additional 7 days determined by protocol
3314761|NCT00264303|Experimental|Levocetirizine|Levocetirizine, once daily, 4 week duration
3314762|NCT00264303|Active Comparator|Desloratadine|Desloratadine, once daily, 4 week duration
3314763|NCT00264290|Experimental|Valganciclovir|900mg PO qd
3314764|NCT00264290|Placebo Comparator|Placebo|900mg PO qd
3314765|NCT00264264|Active Comparator|Direct Compression|
3314766|NCT00264264|Active Comparator|Closure Device|
3314767|NCT00264238|Experimental|Memantine open label|All subjects knowingly received (open label) memantine for up to 12 weeks with a target dose of 10 mg twice a day (20mg/d) taken orally.
3314768|NCT00264199|Active Comparator|1|
3314769|NCT00264199|Placebo Comparator|2|
3314770|NCT00264160|Experimental|AMN107|
3314771|NCT00264147|Experimental|Period I: 1|etoricoxib
3314772|NCT00264147|Experimental|Period I: 2|etoricoxib
3314773|NCT00264147|Experimental|Period I: 3|etoricoxib
3314774|NCT00264147|Experimental|Period I: 4|etoricoxib
3314775|NCT00264147|Placebo Comparator|Period I: 5|Placebo
3314776|NCT00264147|Experimental|Period II: 1|etoricoxib
3314777|NCT00264147|Active Comparator|Period II: 2|diclofenac
3314778|NCT00264108||1|Epoetin alfa 40 000 IU once weekly variable treatment length.
3314779|NCT00264108||2|Darbepoetin alfa Either 150 ug once weekly or 500 ug once every 3 wks variable treatment length.
3314780|NCT00264095||001|
3314781|NCT00264069||001|
3314782|NCT00264069||002|
3314783|NCT00264043|Experimental|1|AngioGuard™ device and Bx Velocity™ stent
3314784|NCT00264030|Other|1|PTCA
3314785|NCT00264030|Other|2|PTCA with angioguard
3314786|NCT00264004|Experimental|1|30 mg AZD2171
3314787|NCT00264004|Experimental|2|45 mg AZD2171
3314788|NCT00263939|Experimental|1 - In home intervention|In home (face to face) delivery of the study intervention, Homing in on Health
3314789|NCT00263939|Experimental|2 - Telephone intervention|Telephone delivery of the study intervention, Homing in on Health
3314790|NCT00263939|No Intervention|3 - Usual care|Patients receiving the care their usual health providers supply, without an study intervention
3314791|NCT00263887|Experimental|Group 1|Prolastin
3314792|NCT00263887|Placebo Comparator|Group 2|
3314793|NCT00263809|Experimental|1|Treatment, Mirasol-treated platelets
3314794|NCT00263809|No Intervention|2|Reference, Untreated platelets
3314795|NCT00263796|Experimental|Pitocin|
3314796|NCT00263796|Placebo Comparator|Placebo|
3314797|NCT00263783|Experimental|1|MEDI-522
3314798|NCT00263770|Other|Positive airway pressure (PAP)|which is air delivered by a mask worn over the nose during sleep
3314799|NCT00263770|Active Comparator|outpatient surgical procedure|where small fabric rods are inserted into the soft palate (the fleshy portion of the roof of the mouth) to stiffen the tissues.
3314800|NCT00263770|Sham Comparator|Sham surgery|an outpatient surgical procedure identical to #2 except that no rods are inserted into the soft palate.
3314801|NCT00263757|Experimental|Therapeutic Positive Airway Pressure|Subjects randomized to this arm received nightly Adaptive Servo-Ventilation during sleep for 12 months.
3314848|NCT00262990|Experimental|Patupilone|
3314805|NCT00263731||Group 1 (Experimental Group)|250 subjects with suspected or confirmed lung cancer undergoing surgical resection, will receive 13-C-glucose prior to surgery
3314806|NCT00263731||Group 2 (Control Group)|250 subjects with suspected or confirmed lung cancer undergoing surgical resection, will not receive 13-C-glucose prior to surgery
3314807|NCT00263731||Group 3 (Healthy Subjects)|250 healthy subjects (must be at least 30 years of age and have no prior history of diagnosed lung cancer) will provide 1 blood sample and 1 urine sample.
3314808|NCT00263705|Experimental|capecitabine|capecitabine 2000 mg/m² daily
3314809|NCT00263666|Experimental|Rotarix Group|Subjects received 3 dose of Rotarix vaccine co-administered with routine Tritanrix TM, HepB Hib and Polio Sabin TM vaccines.
3314810|NCT00263666|Placebo Comparator|Placebo Group|Subjects received 3 dose of placebo co-administered with routine Tritanrix TM, HepB Hib and Polio Sabin TM vaccines.
3314811|NCT00263640|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Children received lifestyle counselling.
3314812|NCT00263640|Experimental|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
3314813|NCT00263627|Placebo Comparator|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
3314814|NCT00263627|Experimental|Specific Immunotherapy|Subcutaneous injections with birch pollen allergoid were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
3314815|NCT00263601|Experimental|Allergovit 6-grasses immunotherapy|Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.
3314816|NCT00263601|Placebo Comparator|Placebo|Placebo injections was given the same way: Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.
3314817|NCT00263588|Experimental|single arm|750 mg laptinib administered orally twice daily
3314818|NCT00263575|Experimental|sublingual fentanyl tablet|
3314819|NCT00263484|Experimental|"dtZ regimen, Initial therapy"|"To test the efficacy of the dtZ regimen in previously untreated patients with multiple myeloma."
3314820|NCT00263458|Experimental|Integrated|Buprenorphine maintenance treatment delivered at an HIV primary care clinic
3314821|NCT00263458|Active Comparator|Non-integrated|Buprenorphine maintenance treatment delivered at a public health substance use disorder clinic
3314822|NCT00263432|Experimental|1|Implantation of fresh human allogenic chondrocytes
3314823|NCT00263393|Other|Algorithm-based care|An algorithm based approach to increase the identification of high-risk individuals in the community through encouraging opportunistic screening, and to increase the use of appropriate evidence based prevention strategies.
3314824|NCT00263393|Other|Health-promotion|The health promotion arm has been designed to increase knowledge of the causes of cardiovascular disease and enhance use of preventive behaviours in the general population
3314825|NCT00263367|Other|hyperbaric oxygen at 1.3 ATA|Hyperbaric Oxygen at 1.3 ATA for one hour followed by measurement of glutathione in the blood
3314826|NCT00263328|Active Comparator|Treatment group 1|Standard of care
3314827|NCT00263328|Experimental|Treatment group 2|Treatment group 2 also receives mycophenolate mofetil
3314828|NCT00263328|Experimental|Treatment group 3|Treatment group 3 does not receive mycophenolate mofetil
3314829|NCT00263276|Experimental|Arm 1|
3314830|NCT00263276|Experimental|Arm 2|
3314831|NCT00263276|Experimental|Arm 3|
3314832|NCT00263276|Experimental|Arm 4|
3314833|NCT00263276|Experimental|Arm 5|
3314834|NCT00263276|Placebo Comparator|Arm 6|
3314835|NCT00263276|Active Comparator|Arm 7|
3314836|NCT00263211|Experimental|Plavix and Aspirin|Patients will receive a 300 mg loading dose of Plavix on day 1, followed by 75 mg/day, and aspirin 81 mg per day starting day 1. Treatment will be continued until the treating physician elects to resume systemic therapy for the treatment of breast cancer or until unacceptable toxicity is observed. A pill diary will be collected monthly to monitor patients' compliance with the medication regimen.
3314837|NCT00263211|No Intervention|Observation only|Observation by treating physician
3314838|NCT00263198|Experimental|Letrozole + PTK787/ZK222584|"Letrozole 2.5 mg PO daily for 28 days (patients who have already been treated with letrozole for at least 28 days can skip this part)~Start cycle 1 with:~Letrozole 2.5 mg PO once daily~PTK787/ZK222584 250 mg BID PO for 1 week, then 500 mg BID PO for the 2nd week followed by 500 mg qAM and 750 mg QPM PO for the subsequent 2 weeks.~Subsequent cycles:~PTK787/ZK222584 500 mg qAM and 750 mg qPM PO daily~Letrozole 2.5 mg PO once daily"
3314839|NCT00263185|Experimental|Active Treatment Group|"Patients with baseline 25OH vitamin D level of 10-19 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Vitamin 50,000 IU/wk x 16 weeks and then once a month for a total of 6 months.~Patients with baseline 25OH vitamin D level of 20-29 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Vitamin 50,000 IU/wk x 8 weeks and then once a month for a total of 6 months."
3314840|NCT00263185|Placebo Comparator|Control Group|"Patients with baseline 25OH vitamin D level of 10-19 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Placebo once per week x 16 weeks and then once a month for a total of 6 months.~Patients with baseline 25OH vitamin D level of 20-29 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Placebo once per week x 8 weeks and then once a month for a total of 6 months."
3314841|NCT00263185|Other|Observational Group|"Patients with a baseline Vitamin D level below 10 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily."
3314842|NCT00263081|Experimental|Lapaquistat Acetate QD|(and current lipid-lowering treatment)
3314843|NCT00263081|Placebo Comparator|Current lipid-lowering treatment|
3314844|NCT00263068|Experimental|1|Up to 6.75 mg/day (optimal dosing)
3314845|NCT00263042|Experimental|Rimonabant|Rimonabant 20 mg once daily
3314849|NCT00262990|Active Comparator|doxorubicin|
3314850|NCT00262964|Experimental|NAFLD-Niacin|Subjects, having previously diagnosed with NAFLD, were given Niacin for 16 weeks. The dosage was 500mg/day for week 1, 1000mg/day for week 2, 1500mg/day for week three and 2000mg/day for weeks 4 through 16.
3314851|NCT00262964|No Intervention|Control|Subjects were found to have intrahepatic triglyceride levels below the threshold for Non-Alcoholic Fatty Liver Disease (NAFLD). For this study that threshold was set at 10% intrahepatic triglyceride content as determined by magnetic resonance spectroscopy. These control subjects did not participate in any intervention. Only baseline features were characterized for this arm.
3314852|NCT00262964|Experimental|NAFLD-fenofibrate|Subjects diagnosed with NAFLD were randomized to fenofibrate, an oral medication, nightly for eight weeks. Subjects will be given a dose of 200mg/day.
3314853|NCT00262964|Placebo Comparator|NAFLD-placebo|These subjects were diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD) and received an 8 week course of a placebo pill. Their baseline characteristics were averaged into the overall NAFLD baseline characteristics along with the baseline data for the two intervention groups.
3314854|NCT00262951|Experimental|Pancreatic Adenocarcinoma Patients|Pancreatic Adenocarcinoma Patients treated with chemotherapy regimen and radiation (and or surgery).
3314855|NCT00262938|Active Comparator|Lifestyle counseling|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling.Patients undergo quality of life, exercise, and clinical assessments at baseline and at 3, 6, and 12 months.
3314856|NCT00262938|Active Comparator|Without Counseling|Patients undergo quality of life, exercise, and clinical assessments at baseline and at 3, 6, and 12 months.
3314857|NCT00262925|Experimental|Treatment (chemotherapy, enzyme inhibitor therapy)|"INDUCTION THERAPY: Patients receive methotrexate IV; vincristine IV and asparaginase IM ; oral dexamethasone ; and alemtuzumab SC.~CONSOLIDATION THERAPY: Patients receive methotrexate IV and asparaginase IM.~CYTOREDUCTION THERAPY: Patients receive vincristine IV and methotrexate IV; leucovorin calcium IV; and oral dexamethasone.~MAINTENANCE THERAPY: Patients receive oral mercaptopurine; oral methotrexate; vincristine IV; and oral dexamethasone."
3314858|NCT00262899|Experimental|Rapid genetic counseling|Following randomization, participants will be informed about whether they are assigned to Usual Care (UC) or Rapid Genetic Counseling (RGC). Participants in the UC arm can schedule a genetic counseling appointment at any time during the study if they wish. Participants in the RGC agree to obtain genetic counseling as soon as possible, before they make a definitive surgery decision. RGC can be accomplished by telephone or in-person. The RGC intervention is delivered by highly experienced genetic counselors at each site. This counseling is identical to our standard genetic counseling procedure for newly diagnosed patients. Immediate DNA collection via blood or buccal cell collection is available following counseling. Phone counseling participants will be been mailed a kit for DNA collection or have the option of having the sample collected at at LCCC.
3314859|NCT00262899|No Intervention|Usual Care|Usual Care (UC) for newly diagnosed breast cancer patients does not typically include a pre-surgical genetic referral. These patients may obtain genetic counseling at their own discretion.
3314860|NCT00262873|Experimental|Bortezomib|
3314861|NCT00262860|Experimental|Bortezomib, Gemcitabine Hdrochloride|
3314862|NCT00262847|Active Comparator|Arm I (placebo, paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Beginning in course 2, patients also receive placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive placebo alone IV over 30-90 minutes on day 1. Treatment with placebo repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
3314863|NCT00262847|Experimental|Arm II (placebo, paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel and carboplatin as in arm I. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive placebo alone IV over 30-90 minutes on day 1. Treatment with placebo repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
3314864|NCT00262847|Experimental|Arm III (paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel and carboplatin as in arm I. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive bevacizumab alone IV over 30-90 minutes on day 1. Treatment with bevacizumab repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
3314865|NCT00262834|Experimental|Arm I|Patients receive oral vorinostat twice daily on days -3 to 0. Approximately 2 hours after the final dose of vorinostat, patients undergo conventional surgery of the tumor on day 0. After completion of study treatment, patients are followed for 30 days.
3314866|NCT00262821|Active Comparator|Arm I (cisplatin)|Patients receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6).
3314867|NCT00262821|Experimental|Arm II (cisplatin, tirapazamine)|Patients receive tirapazamine IV over 2 hours on days 1, 8, 10, 12, 15, 22, 24, 26, and 29 and cisplatin IV over 1 hour on days 1, 15, and 29.
3314868|NCT00262795|Experimental|F|Fludarabine
3314869|NCT00262795|Active Comparator|CLB|Chlorambucil
3314870|NCT00262782|Experimental|Fludarabine|
3314871|NCT00262782|No Intervention|watch & wait|
3314872|NCT00262769|Experimental|A - Gemcitabine|Gemcitabine alone
3314873|NCT00262769|Experimental|B - Gemcitabine and Cisplatin|Gemcitabine and Cisplatin
3314874|NCT00262743|Experimental|polyphenon E|Designed to assess toxicity, treatment response, and pertinent laboratory measurements in patients with previously untreated, asymptomatic, Rai Stage 0-II CLL.
3314875|NCT00262730|Experimental|Treatment Arm|"RT + TMZ 6wks, followed by~poly ICLC, temozolomide, radiation: radiation therapy"
3314876|NCT00262704|No Intervention|Group A|Control group
3314877|NCT00262704|Active Comparator|Group B|Simulated case-based customized learning
3314878|NCT00262704|Active Comparator|Group C|Simulated case based customized learning + leader feedback
3314879|NCT00262665|Experimental|Org 24448|ampa receptor potentiator for the treatment of MDD
3314880|NCT00262665|Placebo Comparator|Placebo|matching placebo pill
3314945|NCT00262028|Experimental|MenACWY-CRM (2-10 years)|Subjects received one dose of investigational MenACWY-CRM conjugate vaccine
3315155|NCT00258752|Experimental|1|Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST)
3314881|NCT00262639|Experimental|I|2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.
3314882|NCT00262639|Placebo Comparator|II|20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
3314883|NCT00262600|Active Comparator|Dabigatran dose 2|twice a day
3314884|NCT00262600|Active Comparator|Warfarin|once a day
3314885|NCT00262600|Active Comparator|Dabigatran dose 1|twice a day
3314886|NCT00262587|Placebo Comparator|Placebo|Placebo inhaler (sugar powder)
3314887|NCT00262587|Active Comparator|Seretide|Seretide inhaler
3314888|NCT00262561|Active Comparator|Aspirin|All participants get Aspirin, and platelet reactivity measurements are performed.
3314889|NCT00262522|Experimental|LPV/r 800/200 mg QD Tablet|
3314890|NCT00262522|Experimental|LPV/r 800/200 mg QD SGC (Through Week 8)|
3314891|NCT00262522|Active Comparator|LPV/r 400/100 mg BID Tablet|
3314892|NCT00262522|Active Comparator|LPV/r 400/100 mg BID SGC (Through Week 8)|
3314893|NCT00262509|Experimental|Egress Badge Performance|Blind subjects are walked into a building to a specific location, and then are asked to find their way out of the building.
3314894|NCT00262509|No Intervention|Baseline Egress Performance|Blind subjects are walked into a building to a particular location and then asked to find their way out of the building.
3314895|NCT00262470|Experimental|1|Acetazolamide
3314896|NCT00262470|Experimental|2|Atomoxetine
3314897|NCT00262470|Experimental|3|NO Drug
3314898|NCT00262470|Experimental|4|Clonidine
3314899|NCT00262470|Experimental|5|Entacapone
3314900|NCT00262470|Experimental|6|Indomethacin
3314901|NCT00262470|Experimental|7|Isosorbide Dinitrate
3314902|NCT00262470|Experimental|8|Mecamylamine
3314903|NCT00262470|Experimental|9|Memantine
3314904|NCT00262470|Experimental|10|Melatonin
3314905|NCT00262470|Experimental|11|Midodrine
3314906|NCT00262470|Experimental|12|Modafinil
3314907|NCT00262470|Experimental|13|Octreotide
3314908|NCT00262470|Placebo Comparator|14|Placebo (lactose tablet)
3314909|NCT00262470|Experimental|15|Propranolol
3314910|NCT00262470|Experimental|16|Sertraline
3314911|NCT00262470|Experimental|17|Normal Saline (0.9%) 1 liter
3314912|NCT00262470|Experimental|18|Drinking Water
3314913|NCT00262470|Experimental|19|Dead Space Breathing Device
3314914|NCT00262470|Experimental|Abdominal Binder|Abdominal binder with inflatable pressure over abdomen
3314915|NCT00262457|Other|Arm 1|
3314916|NCT00262431|Active Comparator|Early (A)|Patients of the EARLY group (A) will be submitted to tracheostomy on day 3-5 from oro/nasotracheal intubation.
3314917|NCT00262431|Active Comparator|Late (B)|Patients of the LATE group (B) will undergo tracheostomy on day 10-12 from oro/nasotracheal intubation.
3314918|NCT00262405|Experimental|zileuton|Zileuton
3314919|NCT00262405|Active Comparator|azathioprine/prednisone|azathioprine/prednisone
3314920|NCT00262392|Experimental|Pamidronate|Pamidronate
3314921|NCT00262392|Active Comparator|radiation|radiation
3314922|NCT00262379|No Intervention|Group A|HCV treatment with peginterferon plus ribavirin during 48 weeks
3314923|NCT00262379|Active Comparator|Groupb|HCV treatment with peginterferon plus ribavirin during 48 weeks plus epoetin beta under anemia conditions
3314924|NCT00262340|Experimental|1|This arm will have treatment changed based on measures of inflammation
3314925|NCT00262340|Active Comparator|2|Treatment will be changed on the basis of reported asthma symptoms
3314926|NCT00262301|Experimental|"100 IU/kg rhC1INH"|100 IU/kg recombinant human C1 inhibitor
3314927|NCT00262301|Placebo Comparator|Saline|Saline solution
3314928|NCT00262288|Experimental|Recombinant Human C1INH|
3314929|NCT00262223|Active Comparator|1) Seeking Safety + Sertraline|Seeking Safety + Sertraline
3314930|NCT00262223|Placebo Comparator|2) Seeking Safety + Placebo|Seeking Safety + Placebo;
3314931|NCT00262119|Active Comparator|Control Group|PM programming according to actual clinical practice
3314932|NCT00262119|Active Comparator|MVP Only|PM programming according to actual clinical practice + MVP algorithm ON
3314933|NCT00262119|Active Comparator|DDDRP|PM programming according to actual clinical practice + MVP algorithm ON + Atrial fibrillation therapies ON
3314934|NCT00262106|Placebo Comparator|Placebo|placebo
3314935|NCT00262106|Active Comparator|PRO 2000/5 Gel 0.5%|PRO 2000/5 Gel 0.5%
3314936|NCT00262080|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections.
3314937|NCT00262080|Placebo Comparator|Placebo|Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.
3314938|NCT00262067|Experimental|Bevacizumab + chemotherapy|Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle plus one of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
3314939|NCT00262067|Placebo Comparator|Placebo + chemotherapy|Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + 1 of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
3314940|NCT00262054|Experimental|A|bivalirudin is to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
3314941|NCT00262054|Active Comparator|B|UFH given as an intravenous bolus of 140 units/kg. Double blinding will be maintained by using a double-dummy technique consisting of identical UFH and bivalirudin syringes and bivalirudin or placebo infusion bags.
3314942|NCT00262041|Experimental|MenACWY-CRM(Ad+)|Subjects received one single dose of adjuvanted formulation of conjugate vaccine.
3314943|NCT00262041|Experimental|MenACWY-CRM(Ad-)|Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.
3314944|NCT00262041|Active Comparator|MenACWY- PS|Subjects received one single dose of the polysaccharide vaccine.
3314946|NCT00262028|Experimental|MenACWY-CRM (12-23 months)|Subjects received one dose of investigational MenACWY-CRM conjugate vaccine
3314947|NCT00262028|Active Comparator|MenACWY-PS (2-10 years)|Subjects received one dose of licensed comparator MenACWY polysaccharide (MenACWY-PS) vaccine
3314948|NCT00262028|Experimental|MenACWY-CRM+PnC (12-15 months)|Subjects received one dose of MenACWY-CRM vaccine alone or concomitantly with PnC
3314949|NCT00262028|Experimental|MenACWY-CRM+DTaP (16-23 months)|Subjects received one dose of MenACWY-CRM vaccine alone or concomitantly with DTaP
3314950|NCT00262002|Experimental|UK234+ (MenACWY Ad+ at 2, 3, 4 m)|Three doses of MenACWY Ad+ vaccine were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age in the UK group. A fourth dose of MenACWY Ad+ was given at 12 months of age.
3314951|NCT00262002|Experimental|UK24+ (MenACWY Ad+ at 2, 4 m)|Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.
3314952|NCT00262002|Experimental|UKMenC (Menjugate at 2, 4 m)|Two doses of Menjugate were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine was given at 12 months of age.
3314953|NCT00262002|Experimental|CA246+ (MenACWY Ad+ at 2, 4, 6 m)|Three doses of MenACWY Ad+ vaccine were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age of the Canadian group (Prevnar at 6 months was optional and was given if available).One subgroup of subjects was given a reduced dose (1/5) of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.
3314954|NCT00262002|Experimental|CA24+ (MenACWY Ad+ at 2, 4 m)|Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad+ vaccine or one reduced dose (1/5) of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.
3314955|NCT00262002|Experimental|UK24- (MenACWY Ad- at 2, 4 m)|Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.
3314956|NCT00262002|Experimental|CA24- (MenACWY Ad- at 2, 4 m)|Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.
3314957|NCT00261976||Patients in infliximab clinical studies|All patients enrolled in selected Centocor sponsored infliximab clinical studies.
3314958|NCT00261950|Experimental|Cinacalcet|All subjects were enrolled into the single arm to receive Cinacalcet. There was no comparator arm.
3314959|NCT00261924|Experimental|Intercept Platelets|Study patients receiving platelets that have been processed with the INTERCEPT pathogen inactivation system
3314960|NCT00261924|Active Comparator|Conventional Platelets|Study patients receiving platelets processed by standard method without the INTERCEPT pathogen inactivation system
3314961|NCT00261859|No Intervention|SCA|Standard Care with Assessment
3314962|NCT00261859|No Intervention|SCNA|Standard Care No Assessment
3314963|NCT00261859|Experimental|BNI|Brief Negotiated Interview
3314964|NCT00261859|Experimental|EBNI|Enhanced Brief Negotiated Interview
3314965|NCT00261846|Experimental|SKI-606|
3314966|NCT00261833|Experimental|Zemaira®|
3314967|NCT00261833|Placebo Comparator|Placebo|
3314968|NCT00261807|Other|Single ARM Study|It was a single arm study with daptomycin use at a higher dose for patients with severe skin and soft tissue infections.
3314969|NCT00261794|Experimental|1|computer-assisted cognitive remediation (CACR)
3314970|NCT00261794|Active Comparator|2|computer-based cognitive activity
3314971|NCT00261781|Experimental|Treadmill training|Home-based treadmill training
3314972|NCT00261781|No Intervention|Usual care|Control group
3314973|NCT00261768|Experimental|1|Noise reduction on
3314974|NCT00261755|Experimental|Acupuncture Group|Acupuncture treatment during labor
3314975|NCT00261755|Active Comparator|TENS Group|Transcutaneous Electric Nerve Stimulation (TENS treatment)during labor
3314976|NCT00261755|Active Comparator|Traditional Group|Traditional pain treatment during labor
3314977|NCT00261729|Experimental|1|paroxetine
3314978|NCT00261729|Placebo Comparator|2|placebo
3314979|NCT00261729|Experimental|3|prazosin
3314980|NCT00261716|Experimental|IPS and VOMI|Individual Placement and Support (IPS), a form of evidence-based supported employment with 4 sessions of manualized vocationally-oriented motivational interviewing (VOMI) prior to each course of job searching
3314981|NCT00261716|Active Comparator|IPS and IE|Individual placement and support (IPS), a form of evidence-based supported employment with 4 sessions of education about schizophrenia/schizoaffective disorder (IE), as appropriate, prior to each course of job searching
3314982|NCT00261703|Experimental|1|(Docetaxel + Cisplatin + 5-FU) + Cisplatin + Radiotherapy
3314983|NCT00261703|Experimental|2|(Cisplatin + 5-FU) + Cisplatin + Radiotherapy
3314984|NCT00261703|Experimental|3|Cisplatin + Radiotherapy
3314985|NCT00261690|Experimental|1|Virtual Reality distraction
3314986|NCT00261547|Experimental|Rituximab|this study has only one arm as the treatment group
3314987|NCT00261495|Active Comparator|Oxycodone|
3314988|NCT00261495|Experimental|OROS hydromorphone HCl|
3314989|NCT00261456||BRCA1/2 carriers|Carriers of a BRCA1 or BRCA2 mutation.
3314990|NCT00261456||BRCA1/2/non Carriers|Do not carry a mutation in either the BRCA1 or 2 genes that has been found in other members of the family.
3314991|NCT00261443|Placebo Comparator|A1|/Active Comparator
3314992|NCT00261443|Experimental|A2|
3314993|NCT00261365|Active Comparator|A1|
3314994|NCT00261365|Active Comparator|A2|
3314995|NCT00261326|Active Comparator|B|simvastatin tablets 80 mg daily
3314996|NCT00261326|Placebo Comparator|A|calcium tablets 80 mg
3314997|NCT00261313|Experimental|Aranesp|
3314998|NCT00261313|Experimental|Neulasta|
3314999|NCT00261300|Experimental|1|Pantoprazole 40 mg
3315156|NCT00258752|Experimental|2|Enhanced IPT-AST
3315000|NCT00261209|Experimental|Collagenase Injection|Injection of collagenase into adhesion restricting tendon gliding
3315001|NCT00261170|Active Comparator|1|bupropion and behavioral counseling
3315002|NCT00261170|Placebo Comparator|2|placebo medication
3315003|NCT00261118|Active Comparator|1 (i)|Rituximab 1g in 500 mls of 0.9% normal saline infused into a peripheral vein
3315004|NCT00261118|Placebo Comparator|2 (ii)|500 mls of 0.9% NORMAL SALINE INFUSED INTO A PERIPHERAL VEIN
3315005|NCT00261053|Other|1|Open-label i.v. administration of 100 U/kg rhC1INH
3315006|NCT00261040|Active Comparator|MIS|Minimally invasive hip surgery
3315007|NCT00261040|Active Comparator|Standard|Standard approach to hip surgery
3315008|NCT00261001|Experimental|Transcutaneous|
3315009|NCT00261001|Active Comparator|Intramuscular|
3315010|NCT00260988|Active Comparator|Dalteparin|Dalteparin 200 IU/kg/day for three days prior to surgery and dalteparin 5000IU daily for 3-5 days post-surgery
3315011|NCT00260988|Active Comparator|Tinzaparin|Tinzaparin 175 IU/kg/day for three days prior to surgery and Tinzaparin 4500 IU for 3-5 days post surgery
3315012|NCT00260975||Chemotherapy patients|Breast cancer patients treated with adjuvant chemotherapy of various types.
3315013|NCT00260975||Hormonal patients|Breast cancer patients treated with adjuvant hormonal therapy but not chemotherapy.
3315014|NCT00260962|Placebo Comparator|Placebo|Placebo and Treatment as usual (Day Hospital Program). After a 2-week baseline period, placebo was administered for 10 weeks (weeks 3-12 of the study). Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
3315015|NCT00260962|Experimental|Olanzapine Plus Day Hospital|After a 2-week baseline period, Olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of 10 mg/day. Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
3315016|NCT00260936||HIV-negative|HIV-infected and -uninfected males, ages 12 to 24 years, of Tanner Stage 4 or 5
3315017|NCT00260936||HIV-positive, has never been on ART|HIV-positive, has never been on ART
3315018|NCT00260936||HIV-positive, non PI containing NNRTI-based regimen|HIV-positive, currently on a non-PI-containing NNRTI-based regimen for at least 12 weeks. Must never have received a total of more than 6 months of PI-containing regimen, and at least one year must have passed since receipt of last PI-containing regimen
3315019|NCT00260936||HIV-positive, non-NNRTI-containing PI-based regimen|HIV-positive, currently on a non-NNRTI-containing PI-based regimen for at least 12 weeks. Must never have received a total of more than 6 months of NNRTI-containing regimen, and at least one year must have passed since receipt of last NNRTI-containing regimen.
3315020|NCT00260832|Experimental|A|Subject's choice of treatment with physician's advice. Subjects preselected their preference of supportive care (including IV fluids, nutrition, and antibiotics) or cytarabine. (These represent one intervention.)
3315021|NCT00260832|Active Comparator|B|
3315022|NCT00260819|Experimental|1|Experimental and Placebo Comparator administered in random order during to successive experimental phase
3315023|NCT00260819|Placebo Comparator|2|Experimental and Placebo Comparator administered in random order during to successive experimental phase
3315024|NCT00260806||1|Children perinatally infected with HIV with exposure to highly active anti-retroviral therapy (HAART).
3315025|NCT00260806||2|Children with perinatally acquired HIV infection enrolled on the P2C2 Study, not exposed to HAART therapy.
3315026|NCT00260728|Experimental|Arm 1|
3315027|NCT00260689|Experimental|Horse ATG/CsA taper|h-ATG (Anti-thymocyte globulin (horse)) + 6 months CsA (Cyclosporine) followed by an 18 month CsA taper
3315028|NCT00260689|Experimental|Rabbit ATG/CsA|r-ATG (Anti-thymocyte globulin (rabbit)) + 6 months CsA (Cyclosporine)
3315029|NCT00260689|Experimental|Alemtuzumab|Alemtuzumab administered for 10 days
3315030|NCT00260676|Other|conventional ventilation, protective ventilation|
3315031|NCT00260663|Other|Arm 1|
3315032|NCT00260650|Experimental|Arm 1|Heart PACT Program - patient activation intervention
3315033|NCT00260650|No Intervention|Arm 2|Usual Care
3315034|NCT00260611|Experimental|Oxaliplatin and Taxotere|Patients will receive both docetaxel and oxaliplatin, IV on day 1 of each cycle. Treatment will be repeated every 21 days for up to 6 courses in the absence of disease progression, unacceptable toxicity, or >50% increase in serum PSA.
3315035|NCT00260533|Experimental|1|Atomoxetine
3315036|NCT00260533|Placebo Comparator|2|Placebo
3315037|NCT00260494|Experimental|acupuncture|acupuncture to lower extremity postoperatively
3315038|NCT00260494|Sham Comparator|sham acupuncture|sham acupuncture at same sites.
3315039|NCT00260494|No Intervention|control|no acupuncture, otherwise the same care and measurements
3315040|NCT00260481|Placebo Comparator|Control Group|During the Infusion periods, participants in the placebo condition will receive pre-treatment with hydroxyzine (50mg) followed by placebo medications administered both orally and through infusion, as well as a second dose of hydroxyzine (50mg), delivered at the same rate and delivery system to match the active condition. All participants may receive daily multivitamins as determined appropriate by the study physician. Multivitamins are not considered active medications for the PROMETA pharmacotherapy, but may be provided to participants in both conditions at the same rates and delivery methods for the duration of the study. Because participants are treatment-seeking and use of a placebo condition is warranted, all participants will be provided with once weekly, manual-guided cognitive behavioral therapy sessions during all outpatient periods of the study.
3315086|NCT00259857|Experimental|1 Alendronate, Calcium, Vitamin D|Crossover study. Year-1, 10 participants will take study medication, calcium and vitamin D supplements and other 10 participants will take placebo, calcium and vitamin D supplements. Year-2, they will crossover to the second arm of the study. Those who took study medication and supplements in year-1, will take placebo and supplements in the year-2, and those 10 participants who took placebo and supplements in the year-1, will take study medications and supplements in the year-2.
3315157|NCT00258752|Active Comparator|3|Typical school counseling
3315158|NCT00258739|Experimental|1|Concomitant radiotherapy and carboplatin-docetaxel followed by docetaxel-gemcitabine
3320793|NCT00160342|Experimental|5|
3315041|NCT00260481|Active Comparator|Prometa|During the infusion periods, participants assigned to the PROMETA pharmacotherapy condition will receive pre-treatment with hydroxyzine (50mg) followed by intravenous flumazenil (2mg) over a 2-hour period. Before bedtime, patients will again take 50mg of hydroxyzine orally, as well as 300mg of oral gabapentin (participants will titrate up their dosage of gabapentin each day - 300mg on day 0, 600mg on day 1, 900mg on day 2). All participants may receive daily multivitamins as determined appropriate by the study physician. Multivitamins are not considered active medications for the PROMETA pharmacotherapy, but may be provided to participants in both conditions at the same rates and delivery methods for the duration of the study. Because participants are treatment-seeking and use of a placebo condition is warranted, all participants will be provided with once weekly, manual-guided cognitive behavioral therapy sessions during all outpatient periods of the study.
3315042|NCT00260442|Placebo Comparator|Placebo|< 200 mg/day dietary cholesterol, resistance training, sedentary
3315043|NCT00260442|Experimental|Average intake|400 mg/day dietary cholesterol, resistance training, sedentary
3315044|NCT00260442|Experimental|High intake|800 mg/day dietary cholesterol, resistance training, sedentary
3315045|NCT00260429|Experimental|AA4500 0.58 mg|
3315046|NCT00260429|Placebo Comparator|placebo|
3315047|NCT00260351|Experimental|Group 1|Participants on Thai Red Cross, TRC-ID regimen
3315048|NCT00260351|Experimental|Group 2|Participants on Zagreb-IM regimen
3315049|NCT00260351|Experimental|Group 3|Participants on Essen-IM regimen.
3315050|NCT00260338|Active Comparator|Mesenchymal stromal cell|Mesenchymal stromal cell
3315051|NCT00260273|Active Comparator|1|cognitive Behavioural Therapy
3315052|NCT00260273|No Intervention|2|supportive therapy
3315053|NCT00260234|Experimental|PEG Islet Cells|
3315054|NCT00260221|Experimental|1|Arm one uses Virtual Reality Hypnosis post hypnotic suggestions to reduce pain durng wound care procedures.
3315055|NCT00260221|Experimental|2|Arm two uses Virtual Reality distraction that is administered at times other than during burn care procedure to control for both for attention and high technology.
3315056|NCT00260221|Experimental|3|Arm three use Audio administered Hypnosis without the visual technology.
3315057|NCT00260208|Active Comparator|Cyclosporin A|"The first administration of Cyclosporin A (CsA) was within the first 24 hours post-transplantation at an initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout the study period. During the study, the dose of CsA was adjusted, as necessary, to achieve and maintain the C2 or C0 blood CsA concentration within the target ranges.~Before enrolling the first patient, each center chose the adjunct immunosuppressive (IS) regimen between:~Steroids administered and tapered as per local practice~interleukin-2 receptor (IL-2R) antagonists + mycophenolic acid (MPA): Induction with IL-2R antagonists; Dosages were as per center practice. Patients received mycophenolic acid (MPA) no later than 24 hours after reperfusion of the graft. Dosages were as per local practice.~The regimen selected by the center was to be given to all patients enrolled in the trial from this center."
3315058|NCT00260208|Active Comparator|Tacrolimus|"Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses (twice daily at 12-hour interval) either orally or via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout study period. Throughout the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain C0 tacrolimus concentrations within target ranges.~Before enrolling the first patient, each center chose adjunct immunosuppressive (IS) regimen between:~Steroids administered and tapered as per local practice~interleukin-2 receptor (IL-2R) antagonists + mycophenolic acid (MPA): Induction with IL-2R antagonists; Dosages were as per center practice. Patients received mycophenolic acid (MPA) no later than 24 hours after reperfusion of the graft. Dosages were as per local practice.~The regimen selected by center was to be given to all patients enrolled in trial from this center."
3315059|NCT00260195|Experimental|School-based cognitive behavioral support group|Ten group lessons facilitated by a teacher or school counselor that focuses on psycho-education, development of a trauma narrative, approaching trauma-related situations, social problem solving, and cognitive skills.
3315060|NCT00260195|No Intervention|Wait-list control group|Waiting list
3315061|NCT00260169|Experimental|1|Participants will receive collaborative care
3315062|NCT00260169|Active Comparator|2|Participants will receive enhanced usual care
3315063|NCT00260156|Experimental|vildagliptin|
3315064|NCT00260156|Placebo Comparator|Placebo|
3315065|NCT00260143|Experimental|Testosterone enanthate|300 mg of testosterone enanthate by intramuscular injection once weekly for 16 weeks
3315066|NCT00260143|Placebo Comparator|Placebo|Placebo (sesame oil) by intramuscular injection once weekly for 16 weeks
3315067|NCT00260130|Active Comparator|1|Consuming fruit and vegetable juice
3315068|NCT00260130|Active Comparator|2|Consuming whole fruits and vegetables
3315069|NCT00260091|Active Comparator|I.|Conventional infertility therapy
3315070|NCT00260091|Active Comparator|II.|Fast track to in vitro fertilization therapy
3315071|NCT00260078|Experimental|D|TDF and EFV or NVP throughout study
3315072|NCT00260078|Experimental|E|TDF and DRV with or without EFV throughout study
3315073|NCT00260078|Experimental|F|TDF and ATV and RTV with or without EFV throughout study
3315074|NCT00260065|Experimental|1|
3315075|NCT00260039|Active Comparator|1|Gardasil
3315076|NCT00260039|Experimental|2|HPV VLP vaccine -Dose regimen 1
3315077|NCT00260039|Experimental|3|HPV VLP vaccine -Dose regimen 2
3315078|NCT00260039|Experimental|4|HPV VLP vaccine -Dose regimen 3
3315079|NCT00259974|Experimental|1|Rituximab
3315080|NCT00259935|Experimental|All treated subjects|Subjects were randomized to receive 4 mg of a new formulation and current formulation of oral topotecan on Days 1 and 8 of Course 1.
3315081|NCT00259922|Placebo Comparator|Placebo|
3315082|NCT00259922|Experimental|Alvimopan 0.5 mg once daily|0.5 mg once daily (QD)
3315083|NCT00259922|Experimental|Alvimopan 0.5 mg twice daily|0.5 mg twice daily (BID)
3315084|NCT00259909||Subjects with COPD|Subject has a confirmed clinical diagnosis of COPD, with or without chronic bronchitis.
3315085|NCT00259883|Experimental|paroxetine|paroxetine 20 to 40mg/day
3315087|NCT00259857|Placebo Comparator|2 Placebo, Calcium and Vitamin D|Year-1, 10 participants will take Alendronate (study medication)and calcium and vitamin D supplement). Another 10 participants will take placebo, calcium and vitamin D. In year-2 they will crossover. Those who took alendronate in the first year, will take Placebo, calcium and vitamin D for 12 months and those who took Placebo in the first year, will take Alendronate, calcium and vitamin D in the second year (12 months).
3315088|NCT00259805|Experimental|IV Infusion|
3315089|NCT00259753|Experimental|1|0.2 mg/eye
3315090|NCT00259753|Experimental|2|1.5 mg/eye
3315091|NCT00259753|Experimental|3|3.0 mg/eye
3315092|NCT00259740|Experimental|Denosumab|
3315093|NCT00259727||1|
3315094|NCT00259714|Active Comparator|standard dialysate sodium|In the control phase of the study, the prescribed dialysate sodium is 140 mEq/L
3315095|NCT00259714|Experimental|dialysate sodium individualization|".Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized)."
3315096|NCT00259688|No Intervention|1|Women with gestational hypertension
3315097|NCT00259688|No Intervention|2|Women with uncomplicated pregnancies
3315098|NCT00259688|No Intervention|3|Re-test of women one to two years post-partum.
3315099|NCT00259610|Active Comparator|1|methotrexate (MTX) + etanercept
3315100|NCT00259610|Active Comparator|2|methotrexate (MTX) + sulfasalazine (SSZ)/hydroxychloroquine (HCQ)
3315101|NCT00259610|Active Comparator|3|methotrexate (MTX) or MTX + Etanercept
3315102|NCT00259610|Active Comparator|4|methotrexate (MTX) or MTX + sulfasalazine (SSZ)/hydroxychloroquine (HCQ)
3315103|NCT00259519|No Intervention|1|Expectant management
3315104|NCT00259519|Active Comparator|2|Induction of delivery
3315105|NCT00259428|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
3315106|NCT00259428|Placebo Comparator|Placebo|matching placebo tablets
3315107|NCT00259402|Experimental|Oxaliplatin|
3315108|NCT00259376|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
3315109|NCT00259376|Experimental|Placebo|matching placebo tablets
3315110|NCT00259337|Experimental|1|
3315111|NCT00259324|Experimental|1|Diet and Activity
3315112|NCT00259324|Experimental|2|Diet and Activity
3315113|NCT00259324|Placebo Comparator|3|Education
3315114|NCT00259298|Experimental|Teriparatide|Participants receive teriparatide 20 microgram once daily by subcutaneous injection for 18 months followed by 6 months off therapy
3315115|NCT00259285|Experimental|A|
3315116|NCT00259272|Experimental|A|
3315117|NCT00259220|Experimental|drug|erythromycine
3315118|NCT00259220|Other|2|gastric lavage alone
3315119|NCT00259220|Active Comparator|3|erythromycine and gastric lavage
3315120|NCT00259207|Active Comparator|classic surgery|classic surgery
3315121|NCT00259207|Experimental|medical surgery hybride|medical surgery hybride
3315122|NCT00259194|Active Comparator|Alternative Observation|Moving in bed during observation after coronary angiography
3315123|NCT00259194|Experimental|Standard Observation|No moving in bed during observation after coronary angiography
3315124|NCT00259129|Experimental|Arm 1|
3315125|NCT00259103|Experimental|7.5 µg/kg/d|Participants who received intravenous (IV) infusion of 7.5 µg/kg/d serelaxin, all during part A.
3315126|NCT00259103|Experimental|25 µg/kg/d|Participants who received intravenous (IV) infusion of 25 µg/kg/d serelaxin, all during part A.
3315127|NCT00259103|Experimental|75 µg/kg/d|Participants who received IV infusion of 75 µg/kg/d serelaxin, some during part A and others during part B.
3315128|NCT00259103|Experimental|Placebo|Participants who received IV infusion of placebo, some during part A and others during part B.
3315129|NCT00259090|Active Comparator|1|Anastrozole Monotherapy
3315130|NCT00259090|Experimental|2|Fulvestrant Monotherapy
3315131|NCT00259090|Experimental|3|Anastrozole + Fulvestrant
3315132|NCT00259064|Experimental|Gefitinib|ZD1839 + BSC (best supportive care)
3315133|NCT00259064|Placebo Comparator|Placebo|Placebo + BSC (best supportive care)
3315134|NCT00259038|Experimental|Experimental Drug|
3315135|NCT00259038|Placebo Comparator|Placebo|
3315136|NCT00259012|Active Comparator|Low dose|
3315137|NCT00259012|Active Comparator|High dose|
3315138|NCT00258934|Experimental|1|
3315139|NCT00258934|Active Comparator|2|
3315140|NCT00258895|Experimental|DAPTACEL Primed|Participants received Daptacel in Study P3T06.
3315141|NCT00258895|Experimental|Pentacel Primed|Participants received Pentacel in Study P3T06
3315142|NCT00258869||1|Emergency department patients with sepsis
3315143|NCT00258856|Experimental|Menactra® Group 1|Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 3 and Day 7 after booster vaccination.
3315144|NCT00258856|Experimental|Menactra® Group 2|Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 5 and Day 14 after booster vaccination.
3315145|NCT00258856|Experimental|Meningococcal Vaccine-naïve Group 3|Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 3 and Day 7 after Menactra® vaccination.
3315146|NCT00258856|Experimental|Meningococcal Vaccine-naïve Group 4|Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 5 and Day 14 after Menactra® vaccination.
3315147|NCT00258843|Experimental|Group 1|Children at 18 months of age
3315148|NCT00258843|Experimental|Group 2|Infants at 2 months of age
3315149|NCT00258830|Experimental|Age 18 to 59 years|Participants aged 18 to 59 years at enrollment.
3315150|NCT00258830|Experimental|Age 60 years and older|Participants aged 60 years and older at enrollment.
3315151|NCT00258817|Experimental|Influenza Virus Vaccine Naïve|Subjects have never received Influenza virus vaccine in the past
3315152|NCT00258817|Experimental|Influenza Virus Vaccine-primed|Subjects have received Influenza virus vaccine in the past
3315153|NCT00258765|Experimental|Zoledronic Acid|
3315154|NCT00258765|Active Comparator|Docetaxel|
3315159|NCT00258739|Experimental|2|docetaxel-gemcitabine followed by concomitant radiotherapy with carboplatin-docetaxel
3315160|NCT00258713|Active Comparator|1|
3315161|NCT00258713|Active Comparator|2|
3315162|NCT00258713|Active Comparator|3|
3315163|NCT00258687|Experimental|Treatment Arm A|GVAX for Sarcoma / Renal Cell Patients
3315164|NCT00258687|Experimental|Treatment Arm B|GVAX for Pediatric Melanoma Patients
3315165|NCT00258674|Active Comparator|Medicare Claims Feedback|Practices randomised to the Medicare Claims Feedback arm received period feedback on their performance on selected diabetes quality of care measures as reflected in the claims data for their diabetes patients.
3315166|NCT00258674|Experimental|Medicare Claims+Medical Record Feedback|Practices randomised to the Medicare Claims + Medical Record Review Feedback arm received periodic feedback on their performance on selected diabetes quality of care measures as reflected in both the Medicare claims for the diabetes patients AND review/audit of their diabetes patients' medical records.
3315167|NCT00258674|Experimental|Medicare Claims+Medical Chart Review+DRN|In addition to the performance data from both Medicare Claims data and from review of patients' medical records, practices randomised to the Medicare Claims + Medical Record review + Diabetes Resource Nurse (DRN) had a diabetes resource nurse assigned to them, who was available to provide diabetes education and care-coordination type services for their diabetes patients.
3315168|NCT00258661|Experimental|Osteopathic Manipulative Treatment|10-minute standardized OMT protocol + 5-minute nonstandardized component, twice daily for duration of hospitalization
3315169|NCT00258661|Sham Comparator|Light-touch Treatment|10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs, twice daily for duration of hospitalization
3315170|NCT00258661|No Intervention|Conventional Care Only|No intervention specific to the research study provided. Only conventional treatment as per attending physician orders.
3315171|NCT00258557|Experimental|002|TMC-114/RTV two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
3315172|NCT00258557|Active Comparator|001|LPV/RTV 400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
3315173|NCT00258518||1|ALI/ARDS patients
3315174|NCT00258479|Experimental|Modafinil|
3315175|NCT00258479|Placebo Comparator|Placebo|
3315176|NCT00258479|No Intervention|Nicotine Replacement Therapy|The effects of nicotine replacement therapy will be investigated - alone and in combination with modafinil - on nicotine withdrawal in nicotine-dependent adolescents.
3315177|NCT00258440|Active Comparator|Weekly Procrit (epoetin alfa) dosing|Weekly dosing schedule subjects will get the study drug once every week until the end of the study.
3315178|NCT00258440|Experimental|Interval Dosing (epoetin alfa) PK Group|Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week. Subjects who consented to pharmacokinetic testing
3315179|NCT00258440|Experimental|Interval Dosing (epoetin alfa) Non PK Group|Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week. Subjects who did not consent to pharmacokinetic testing.
3315180|NCT00258427|Experimental|transplant in fanconi anemia patients|Cytoreductive preparative regimen consisting of busulfan, cyclophosphamide, fludarabine phosphate, methylprednisolone, and antithymocyte globulin (ATG) followed by hematopoietic stem cell transplantation (HSCT) and post-transplant use of bone marrow-stimulating filgrastim.
3315181|NCT00258401|Active Comparator|low-residue diet|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.Patients are interviewed weekly for up to six weeks.
3315182|NCT00258401|Active Comparator|no dietary intervention|At the onset of diarrhea symptoms, patients undergo no dietary intervention but are interviewed weekly for up to six weeks.
3315183|NCT00258388|Active Comparator|OGX011, Docetaxel and Prednisone|
3315184|NCT00258388|Active Comparator|Docetaxel plus prednisone|
3315185|NCT00258362|Experimental|Patients with Endometrial Cancer|Patients with advanced or current endometrial cancer receiving treatment with induction docetaxel/carboplatin, radiation (Weekly, 5 days/week over 6-7 weeks, tailored 4500 cGy) and followed by 3 courses of consolidation docetaxel (75 mg/m^2 on Day 1 of each course) /carboplatin (Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles).
3315186|NCT00258349|Experimental|Arm I|Patients will receive vorinostat by mouth twice a day for 2 weeks. They will also receive a 90-minute infusion of trastuzumab in week 1.
3315187|NCT00258310|Experimental|Capecitabine|Surgery, chemotherapy and/or radiotherapy, prior to administration of Capecitabine 1000mg/day for one year.
3315188|NCT00258284|Experimental|Docetaxel & Capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
3315189|NCT00258245|Experimental|Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP d 1, 4, 8, 11; Arsenic Trioxide [AT] (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11; Thalidomide (Thalomid)- 50 mg/day by mouth (PO); Dexamethasone (Decadron)- 40 mg/d IVPB or by mouth (PO) d 1, 4, 8, 11; Ascorbic Acid (Vit C)- 1000 mg IVPB p Arsenic Trioxide (ATO) days 1, 4, 8, 11; Aspirin (ASA)- 325 mg by mouth (PO) every day
3315190|NCT00258206|Experimental|rituximab + cyclophosphamide|Rituximab 375 mg/m^2 on Days -10 and -7; Cyclophosphamide 50 mg/kg on days -3, -2, -1, and 0; Rituximab 375 mg/m^2 weekly x4 after platelet counts recover; For patients achieving at least stable disease, rituximab maintenance 375 mg/m^2 once each during months 3, 6, 9, and 12
3315191|NCT00258154|Experimental|1|RotaTeq/Infanrix Hexa
3315192|NCT00258154|Placebo Comparator|2|Placebo/Infanrix Hexa
3315193|NCT00258115|Active Comparator|salsalate|4.0 g/d divided dosing
3315194|NCT00258115|Placebo Comparator|placebo|placebo for salsalate
3315195|NCT00258076|Experimental|001|EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE
3315253|NCT00256932|Placebo Comparator|Placebo|
3315254|NCT00256932|Experimental|Alvimopan 0.5 mg once daily|
3315255|NCT00256932|Experimental|alvimopan 0.5 mg twice daily|
3315196|NCT00258050|Experimental|Subjects with cancer|"In Part 1 of the study, subjects will be randomized to one of four sequences. All subjects will receive oral or intravenous (IV) midazolam on Days 1, 3, 9 and 11 as per assigned randomization scheme. Starting on Day 4 through Day 11, subjects will receive a daily dose of 1500 milligrams (mg) of oral lapatinib.~In Part 2, which will begin on Day 12, the subjects will be required to take 1500 mg of lapatinib daily until removed from the study for disease progression, adverse events, withdrawal of consent, or transfer to another lapatinib study."
3315197|NCT00258011|Experimental|Aldurazyme (laronidase) treatment|Patients received weekly infusions of JC0498 (laronidase) at an intravenous dose of 100 Units/kg (0.58 mg/kg) body weight for up to 73 weeks.
3315198|NCT00257933|Active Comparator|1|High dose prednisolone
3315199|NCT00257933|Experimental|2|Lower dose prednisolone alternating with placebo
3315200|NCT00257920|Active Comparator|A|
3315201|NCT00257920|Active Comparator|B|
3315202|NCT00257894|Experimental|Baclofen condition|Baclofen taken orally for 12 days total up to 40 mg/day maximum, divided into 3 equal portions each day. Participants receive 12 mg/day the first 3 days, 30 mg/day the next 3 days, and 40 mg/day on Days 7, 8, 9. Testing is on day 10 after the first dose is taken, with downward titration days 10-12 of 30 mg on Day 10, 20 mg on Day 11 and 10 mg on Day 12.
3315203|NCT00257894|Placebo Comparator|Placebo condition|Placebo capsules identical to active medication, 3/day for 12 days.
3315204|NCT00257816|Experimental|Topotecan|Adding weekly topotecan to cisplatin in patients with primary, locally advanced carcinoma of the cervix receiving pelvic irradiation.
3315205|NCT00257803|Experimental|1|In the other group, the women will receive a small injection of oxytocin directly into the vein via their intravenous (bolus) after their baby is born.
3315206|NCT00257803|Placebo Comparator|2|In one group, women will receive a small injection of saline (salt water) directly into the vein via their intravenous (bolus) after their baby is born.
3315207|NCT00257738|Experimental|MAGE -A3 vaccine|for those individuals in which tumor tests positive for MAGE-A3
3315208|NCT00257738|Experimental|HPV 16 vaccine|for patients with HPV 16 positive tumor
3315209|NCT00257712|Experimental|1|
3315210|NCT00257712|Placebo Comparator|2|
3315211|NCT00257699|Placebo Comparator|I|Ciprofloxacin placebo and Metronidazole placebo
3315212|NCT00257699|Experimental|II|Ciprofloxacin 500 mg bid po Metronidazole - total daily dose dependent on body weight
3315213|NCT00257686|Experimental|Pitavastatin 1 mg|Pitavastatin 1 mg once daily
3315214|NCT00257686|Active Comparator|Pravastatin 10 mg|Pravastatin 10 mg once daily
3315215|NCT00257686|Experimental|Pitavastatin 2 mg|Pitavastatin 2 mg once daily
3315216|NCT00257686|Active Comparator|Pravastatin 20 mg|Pravastatin 20 mg once daily
3315217|NCT00257686|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
3315218|NCT00257686|Active Comparator|Pravastatin 40 mg|Pravastatin 40 mg once daily
3315219|NCT00257673|Experimental|A|Active 30 mg MEM 1003
3315220|NCT00257673|Experimental|B|90 mg MEM 1003
3315221|NCT00257673|Placebo Comparator|C|Placebo for MEM 1003
3315222|NCT00257660|Experimental|1|Drug: abobotulinumtoxinA (Dysport®)
3315223|NCT00257660|Placebo Comparator|2|Placebo
3315224|NCT00257608|Experimental|1|
3315225|NCT00257608|Placebo Comparator|2|
3315226|NCT00257556|Experimental|Menotrophin|
3315227|NCT00257556|Active Comparator|Follitropin alfa|
3315228|NCT00257543|Experimental|single arm study|this is a single arm study
3315229|NCT00257465|Experimental|A|'Autologous, DNP-modified vaccine (M-Vax)'
3315230|NCT00257465|Experimental|B|Autologous, DNP-Modified Vaccine (MVax)
3315231|NCT00257465|Experimental|C|Autologous, DNP-Modified Vaccine (MVax)
3315232|NCT00257465|Placebo Comparator|D|0 cells
3315233|NCT00257439||CKD|Elevated se-creatinine + proteinuria
3315234|NCT00257439||Healthy controls|Healthy controls, normal se-creatinine, no proteinuria
3315235|NCT00257400|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy
3315236|NCT00257400|Active Comparator|Individual Psychotherapy|Individual Psychotherapy
3315237|NCT00257322|Experimental|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) 250ug/m^2 SQ QD with a cap of 500mcg SQ QD
3315238|NCT00257309|Active Comparator|Thrombolysis|Weight adjusted tenecteplase bolus + Unfrationated heparin
3315239|NCT00257309|Active Comparator|Primary angioplasty|Primary angioplasty
3315240|NCT00257296|Experimental|Screening and Intervention|Use a computer-based screening tool for intimate partner violence and provide a multi-faceted intervention based on the needs of the woman and services should would like to utilize.
3315241|NCT00257296|Active Comparator|Usual Care|Use a computer-based screening tool for intimate partner violence and provide list of resources available. Also, all physicians were trained on intimate partner violence and were told they could help anyone regardless of randomization.
3315242|NCT00257205|Active Comparator|B|Choice of one or the other Dacarbazine or Temozolomide(CP-675,206) (choice)
3315243|NCT00257205|Experimental|A|
3315244|NCT00257192|Placebo Comparator|2.0|
3315245|NCT00257192|Active Comparator|1.0|
3315246|NCT00257166|Experimental|Ziprasidone oral capsules|
3315247|NCT00257166|Placebo Comparator|Placebo|
3315248|NCT00257127|Experimental|1|Patients will receive PCV, HBV, and MMR at study entry
3315249|NCT00257127|Experimental|2|Patients will receive PPV, HBV, and MMR at study entry
3315250|NCT00257010|Experimental|Almotriptan Malate|Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
3315251|NCT00256997|Experimental|Risperidone long-acting injection (LAI)|Risperidone LAI 25 milligram (mg), 37.5 mg or 50 mg intramuscular (injection of a substance into a muscle) injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following the dose increase. Duration of treatment will be 24 months.
3315252|NCT00256997|Active Comparator|Oral atypical Antipsychotic|Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
3320794|NCT00160342|Experimental|6|
3315256|NCT00256776|Experimental|Thal + Dex + Velcade|
3315257|NCT00256776|Active Comparator|Thal + Dex|Standard treatment
3315258|NCT00256750|Active Comparator|Cyclosporine (CsA)|
3315259|NCT00256750|Experimental|Belatacept LI (less intensive)|
3315260|NCT00256750|Experimental|Belatacept MI (more intensive)|
3315261|NCT00256724|Sham Comparator|Sham ITD|sham Impedance Threshold Device
3315262|NCT00256724|Active Comparator|active ITD|active impedance threshold device
3315263|NCT00256698|Active Comparator|1|Anastrozole
3315264|NCT00256698|Experimental|2|Anastrozole + Fulvestrant
3315265|NCT00256672|Active Comparator|1|High-dose Thoraco-Lumbar-Sacral Orthoses wear (>23hrs/day) will be compared to low-dose Thoraco-Lumbar-Sacral Orthoses wear (12hrs/day)
3315266|NCT00256672|Active Comparator|2|Low-dose Thoraco-Lumbar-Sacral-Orthoses wear (12hrs/day)
3315267|NCT00256646||Group 1|"Patients who are enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2."
3315268|NCT00256633||Group 1|enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2.
3315269|NCT00256607||coronary artery calcium (CAC)|Cohort from the VADT study, had baseline coronary atherosclerosis assessed by coronary artery calcium (CAC) measured by computed tomography. Participants were followed over the 7.5-year study for development of cardiovascular endpoints.
3315270|NCT00256568||Primary Care Practices|One hundred and three prescribers, managers, nurses and office staff at seven primary care practices in Vermont
3315271|NCT00256529||I|All subjects presenting in with dysphagia will be in this cohort.
3315272|NCT00256516|Experimental|Eco-Atkins diet|
3315273|NCT00256516|Active Comparator|NCEP diet|
3315274|NCT00256503|Experimental|Insomnia|Insomnia subjects who receive 8 session cognitive behavioral therapy for insomnia.
3315275|NCT00256503|No Intervention|Good Sleeper|Good sleeper controls who receive no intervention
3315276|NCT00256451|Experimental|ALC and NAL|alcohol and active naltrexone
3315277|NCT00256451|Active Comparator|placebo ALC and NAL|"sham alcohol and active naltrexone"
3315278|NCT00256451|Placebo Comparator|placebo pill and ALC|placebo naltrexone and alcohol
3315279|NCT00256451|Placebo Comparator|placebo pill and placebo ALC|placebo naltrexone and placebo (non-alcoholic) alcohol
3315280|NCT00256412|Placebo Comparator|1|
3315281|NCT00256412|Active Comparator|2|Low Dose
3315282|NCT00256412|Active Comparator|3|High Dose
3315283|NCT00256334|Experimental|Resveratrol|GM-CSF administration to all subjects in addition to chemotherapy treatment.
3315284|NCT00256308|Experimental|Oxaliplatin|Oxaliplatin-70mg/m2 IV over 120 min once a week during radiation. Radiation-200 centigray (cGy) per day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday.
3315285|NCT00256295|Experimental|Gemcitabine plus Oxaliplatin|Gemcitabine given 1000 mg/m2 IV over 100 minutes Every 21 days. Oxaliplatin given 65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days.
3315286|NCT00256282|Experimental|Docetaxel & Vinorelbine + Sargramostim|Docetaxel, Vinorelbine, and Sargramostim
3315287|NCT00256269|Experimental|Oxaliplatin plus Irinotecan|Drug: Oxaliplatin-40 mg/m2 IV over 60 minutes Every 21 days. Drug: Irinotecan-60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days.
3315288|NCT00256243|Experimental|Chemotherapy with GM-CSF|"Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Carboplatin/Paclitaxel with GM-CSF (day 2-6)~This regimen consists of intravenous administration of doxorubicin (Adriamycin) followed by cyclophosphamide (Cytoxan) every 14 days for a total of four cycles, unless stable disease or clinical progression is documented. Two weeks after completion of the last dose of AC, weekly Carboplatin/paclitaxel will be given for 3 weeks, followed by 1 week of rest, for a total of 12. Each clinic visit will last approximately 1 hour.~Patients who are her-2 overexpressors by FISH will also receive Trastuzumab with weekly carboplatin and paclitaxel as the combination has been found to be synergistic in advanced breast cancer with improved clinical outcome."
3315289|NCT00256230|Experimental|Disulfiram|
3315290|NCT00256217|Experimental|Anastrozole|
3315291|NCT00256204|Experimental|1mg rasagiline|1mg early start active treatment arm (72 weeks active)followed by 1mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active)
3315292|NCT00256204|Experimental|2mg rasagiline|2mg early start active treatment arm (72 weeks active)followed by 2mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active)
3315293|NCT00256204|Placebo Comparator|Placebo|Each arm is followed by 36 weeks of placebo
3315294|NCT00256178|Experimental|Lapaquistat Acetate 50 mg QD + Simvastatin|
3315295|NCT00256178|Experimental|Lapaquistat Acetate 100 mg QD + Simvastatin|
3315296|NCT00256178|Active Comparator|Simvastatin|
3315297|NCT00256152|No Intervention|AF Suppression OFF|
3315298|NCT00256152|Experimental|AF Suppression ON|
3315299|NCT00256126|Experimental|Turner Syndrome (TS)|
3315300|NCT00256126|Experimental|Growth Hormone Deficiency (GHD)|
3315301|NCT00256100|Active Comparator|One|Enoxaparin Sodium (Clexane ) is to be used in the control arm of the study
3315302|NCT00256100|Active Comparator|Two|Fondaparinux will be used as the anticoagulant in the sencond arm of the study
3315303|NCT00256087|Placebo Comparator|Standard Care|Two capsules containing placebo will be given 12 hourly
3315304|NCT00256087|Active Comparator|First active treatment|Two capsules containing probiotic lactobacillus fermentin given 12 hourly
3315305|NCT00256087|Active Comparator|Second active reatment|Two capsules containing probiotic lactobacillus acidiphilus given 12 hourly
3315306|NCT00256074|Other|Standard Therapy Group|Standard therapy group. Will receive high carbohydrate, low fat enteral feeding, (16.7% protein, 30% fat and 53.3% carbohydrate). The target rate is determined by the treating physician and dietician, for a minimum of 5 days following randomisation.
3315307|NCT00256074|Other|Alternative Therapy Group|2.Alternative therapy group will receive high-fat, low carbohydrate enteral feeding, (16.7% protein, 55.2% fat and 28.1% carbohydrates. At a target rate determined by the treating physician and dietician, for a maximum of 5 days following randomisation.
3315308|NCT00256048|No Intervention|Standard Care|Patients will receive enteral nutrition via a nasogastric tube as per standard feeding regime
3315309|NCT00256048|Active Comparator|Nasojejunal Arm|Patient will receive feeding via a nasojejunal feeding tube
3315310|NCT00256035|Other|Unstable coronary artery disease|Patients with unstable coronary artery disease will have daily IL6 levels
3315311|NCT00256035|Other|Coronary Angioplasty Patients|Patients having coronary angioplasty will have levels taken before and immediately after the proceedure and 24 hours post.
3315312|NCT00256035|Other|Coronary bypass grafts patients|Patients will have levels collected immediately after and 24 hours post procedure
3315313|NCT00256035|Other|Stable coronary Artery Diseaese Patients|Once the patients are commenced on treatment with statins and or angiotensin converting enzyme they will have twice weekly levels taken
3315314|NCT00256022|Active Comparator|Lactobacillus Acidophilus Arm|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
3315315|NCT00256022|Active Comparator|Lactobacillus Fermentum Arm|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
3315316|NCT00256022|Active Comparator|Lactobacillus Fermentum and Lactobacillus Acidophilus|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
3315317|NCT00256022|Placebo Comparator|Placebo|The placebo will be given to the patient 2 a day for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
3315318|NCT00255983|Experimental|1|faropenem medoxomil
3315319|NCT00255983|Placebo Comparator|2|
3315320|NCT00255970|Experimental|Regenafil graft|Regenafil
3315321|NCT00255970|Active Comparator|DFDBA|Demineralized Freeze Dried Bone Allograft
3315322|NCT00255944|Experimental|1|Participants will receive internet-based messages from the Youthnet program
3315323|NCT00255944|Active Comparator|2|Participants will receive internet-based messages from the control program
3315324|NCT00255931|Experimental|1|
3315325|NCT00255931|Placebo Comparator|2|
3315326|NCT00255931|No Intervention|3|Usual Care
3315327|NCT00255918|Experimental|Dimethoxybenzylidene anabaseine 75 mg|Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 75 mg)
3315328|NCT00255918|Placebo Comparator|Placebo|Participants will take placebo.
3315329|NCT00255918|Experimental|Dimethoxybenzylidene anabaseine 150 mg|Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 150 mg)
3315330|NCT00255892||Part A - Provider Interviews|The provider interviews will be comprised of participants who are clinical providers, mental health providers, and case managers with at least 1 year of experience working with HIV-positive youth; one from each category from all 15 ATN sites will be targeted for a total of 45 participants.
3315331|NCT00255892||Part B - Youth Focus Groups|"The focus groups will be comprised of 6-8 participants per group who are between the ages of 16 and 24, diagnosed HIV+ and aware of their HIV diagnosis for between 12-24 months, and receive services at three selected ATN sites or their community partners for a total of 36-48 participants.~For the purposes of this study, youth who acquired HIV perinatally will be excluded from participation in this study."
3315332|NCT00255840|Active Comparator|A|Study-specified Antiretroviral regimen under care of HIV-trained medical doctor
3315333|NCT00255840|Active Comparator|B|Study-specified Antiretroviral regimen under care of HIV-trained primary care nurse
3315334|NCT00255814|Other|Radiation therapy dose level II: 4.0 Gy/fx|Radiation therapy dose level II: 4.0 Gy/fraction
3315335|NCT00255814|Other|Radiation therapy dose level III: 4.5 Gy/fx|Radiation therapy dose level III: 4.5 Gy/fraction
3315336|NCT00255814|Other|Radiation therapy dose level IV: 5.0 Gy/fx|Radiation therapy dose level IV: 5.0 Gy/fraction
3315337|NCT00255801|Experimental|Doxil and Targretin® (bexarotene)|Patients will be treated with intravenous Doxil® every two weeks for 8 doses (16 weeks). Responses will be assessed. They will then receive Targretin® (bexarotene) orally for at least 16 weeks. Patients who achieve a CR or PR may continue on Targretin® (bexarotene) until relapse.
3315338|NCT00255762|Experimental|Treatment (carboplatin, paclitaxel, bevacizumab)|Patients receive carboplatin IV over 30 minutes on day 1, paclitaxel IV over 1 hour on days 1, 8, and 15, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3315339|NCT00255749|Experimental|early intervention epoietin alfa|Patients receive epoetin alfa subcutaneously on day 1. Treatment repeats every 21 days for up to 5 courses.
3315340|NCT00255749|Other|standard intervention epoietin alfa|Patients receive epoetin alfa as in arm I once their hemoglobin level is ≤ 10.5 g/dL.
3315341|NCT00255723|Experimental|Cytoreductive chemotherapy group 1|Patients receive ICE comprising ifosfamide IV and carboplatin IV once on day 2 and etoposide IV over 1 hour once daily on days 1-3. Patients then receive ifosfamide IV twice on day 15, carboplatin IV once on day 17 and etoposide IV over 1 hour twice daily on days 15-17.
3315342|NCT00255723|Experimental|Cytoreductive chemotherapy group 2|Patients receive ifosfamide IV twice on days 1 and 17, carboplatin IV once on days 3 and 19, and etoposide IV over 1 hour twice daily on days 1-3 and 17-19.
3315343|NCT00255684|Experimental|Conditioning therapy followed by TBI|Fludarabine, Cyclophosphamide; Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil
3315344|NCT00255658|Experimental|Treatment (sorafenib tosylate, temsirolimus)|"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. They also receive oral sorafenib* twice daily starting on day 8 of course 1. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.~NOTE: *On the days of the temsirolimus infusion, temsirolimus should be taken concurrently with the morning dose of sorafenib.~Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD."
3315397|NCT00254917|Experimental|2|Concommitant recombinant hepatitis B vaccine at 6, 10, and 14 weeks of age.
3320795|NCT00160342|Active Comparator|7|
3315345|NCT00255606|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on days 1 and 15 and oral prednisone once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3315346|NCT00255606|Experimental|Arm II|Patients receive docetaxel IV over 1 hour on day 1 and prednisone once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3315347|NCT00255580|Experimental|1|Active cannabis (1-8% THC by weight)
3315348|NCT00255580|Placebo Comparator|2|Placebo cannabis
3315349|NCT00255567|Active Comparator|1|Sodium Stibogluconate (30 days)
3315350|NCT00255567|Experimental|2|Paromomycin Sulphate (21 days)
3315351|NCT00255567|Experimental|3|Sodium Stibogluconate + Paromomycin Sulphate (17 days)
3315352|NCT00255515|Experimental|1|quetiapine fumarate
3315353|NCT00255515|Active Comparator|2|Conventional treatment for schizophrenia
3315354|NCT00255515|Experimental|3|quetiapine fumarate + Cognitive Remediation Therapy
3315355|NCT00255372|Experimental|1|
3315356|NCT00255372|Active Comparator|2|
3315357|NCT00255346|Experimental|Dasatinib|Dasatinib 70 mg orally twice daily.
3315358|NCT00255229|Active Comparator|1|Irinotecan, 5FU, Glutamine
3315359|NCT00255229|Placebo Comparator|2|Irinotecan, 5FU, Placebo
3315360|NCT00255190|Experimental|Dexlansoprazole MR 60 mg QD|
3315361|NCT00255190|Experimental|Dexlansoprazole MR 90 mg QD|
3315362|NCT00255177|Placebo Comparator|Placebo|
3315363|NCT00255177|Active Comparator|150 mg daily|
3315364|NCT00255177|Active Comparator|300mg daily|
3315365|NCT00255177|Active Comparator|300mg twice daily|
3315366|NCT00255164|Experimental|Dexlansoprazole MR 60 mg QD|
3315367|NCT00255164|Experimental|Dexlansoprazole MR 90 mg QD|
3315368|NCT00255164|Placebo Comparator|Placebo|
3315369|NCT00255151|Experimental|Dexlansoprazole MR 60 mg QD|
3315370|NCT00255151|Experimental|Dexlansoprazole MR 90 mg QD|
3315371|NCT00255151|Placebo Comparator|Placebo|
3315372|NCT00255125|Placebo Comparator|Arm Placebo|Placebo
3315373|NCT00255125|Experimental|Arm Soy Supplement|Soy Supplement
3315374|NCT00255112|No Intervention|1|The present study evaluates the efficacy of a family-based CBT treatment specifically tailored to children with SAD, developed at the University of Basel. The study consists of 40 participants (5-7 years old) with SAD and their families. Participants were randomly assigned to 12 weeks of SAD-specific family-based CBT treatment or to waitlist condition.
3315375|NCT00255112|Active Comparator|2|The present study evaluates the efficacy of a family-based CBT treatment specifically tailored to children with SAD, developed at the University of Basel in comparison to a global CBT treatment. The study consists of 60 participants (between 8 and 13 years old), randomly assigned to one of the two treatments.
3315376|NCT00255099|Active Comparator|001|TMC125 2 x 100 mg tablets b.i.d. / 96 weeks
3315377|NCT00255099|Placebo Comparator|002|Placebo 2 tablets b.i.d. / 96 weeks
3315378|NCT00255086|Experimental|Memantine|10mg Memantine
3315379|NCT00255086|Placebo Comparator|Control|10 mg Placebo pill
3315380|NCT00255047|Experimental|Study Group 1: DAPTACEL®, ActHIB®, and IPOL®|Participants will receive 3 doses of DAPTACEL®, ActHIB®, and IPOL® at Months 2, 4, and 6, respectively
3315381|NCT00255047|Experimental|Study Group 2: Pentacel®|Participants will receive 3 doses of Pentacel® at Months 2, 4, and 6, respectively
3315382|NCT00255047|Experimental|Study Group 3: DTaP-IPV and ActHIB®|Participants will receive 3 doses of DTaP-IPV and ActHIB® at Months 2, 4, and 6, respectively
3315383|NCT00255047|Experimental|Study Group 4: Pentacel®|Participants will receive 3 doses of Pentacel® at Months 2, 4, and 6, respectively
3315384|NCT00255034|Active Comparator|24 weeks of therapy|Genotype 3 HCV subjects with high viral load (at least 2 million copies/mL) treated for 24 weeks
3315385|NCT00255034|Experimental|48 weeks of therapy|Genotype 3 HCV subjects with high viral load (at least 2 million copies/mL) treated for 48 weeks
3315386|NCT00255021|Experimental|1|
3315387|NCT00255008|Active Comparator|Genotype 1 SEA PEG-IFN/RIB 48 w|Genotype 1 hepatitis C virus (HCV)-infected Southeastern Asian (SEA) subjects treated for up to 48 weeks with PEG-Intron (peginterferon alfa-2b; PEG-IFN) REDIPEN and REBETOL (ribavirin; RIB) combination therapy
3315388|NCT00255008|Active Comparator|Genotype 1 Caucasian PEG-IFN/RIB 48 w|Genotype 1 HCV-infected Caucasian subjects treated for up to 48 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
3315389|NCT00255008|Experimental|Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 24 w|Genotype 6, 7, 8, 9 HCV-infected SEA subjects randomized to treatment for 24 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
3315390|NCT00255008|Active Comparator|Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 48 w|Genotype 6, 7, 8, 9 HCV-infected SEA subjects randomized to treatment for 48 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
3315391|NCT00254995||Menactra Vaccine Recipients|Participants who received Menactra vaccine as part of routine medical care during the study period in Kaiser Permanente.
3315392|NCT00254995||Age-Matched Control|Each individual receiving Menactra vaccine served as their own control for evaluation of acute (Days 0-30) events (short-term surveillance). For the 6-month (long-term) surveillance, for each person receiving Menactra vaccine, a control matched on age (± 1 year), sex, and month of vaccination was selected who received a received tetanus and diphtheria toxoids (Td), hepatitis A, hepatitis B, or hepatitis A/hepatitis B combination vaccine as part of routine medical care during the same month 1 year earlier in Kaiser Permanente
3315393|NCT00254982|Experimental|Group 1 (high-need)|Adult participants with moderate to severe plaque psoriasis who were either not controlled by, or were intolerant to or had contraindications to at least two currently available systemic therapies (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).
3315394|NCT00254982|Experimental|Group II (low-need)|Adult participants with moderate to severe plaque psoriasis who had undergone pretreatment with no more than one currently available systemic therapy (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).
3315395|NCT00254969|Experimental|1|
3315396|NCT00254917|Experimental|1|Concommitant recombinant hepatitis B vaccine at 0, 6 and 14 weeks of age
3320796|NCT00160342|Active Comparator|8|
3315398|NCT00254904|Experimental|A|Standard of Care chemotherapy plus experimental intervention (PF-3512676)
3315399|NCT00254904|Active Comparator|B|Standard of Care chemotherapy
3315400|NCT00254891|Experimental|A|Standard of care chemotherapy plus experiment intervention (PF-3512676)
3315401|NCT00254891|Active Comparator|B|Standard of care chemotherapy
3315402|NCT00254852|Active Comparator|O|This treatment arm includes autograft harvested from local bone and / or the iliac crest, supplemented with a demineralized bone matrix (DBM) autograft extender, Optecure.
3315403|NCT00254852|Active Comparator|A|This treatment arm includes autograft harvested from local bone and / or the iliac crest.
3315404|NCT00254826|Other|YF-VAX® plus saline|Drug: YF-VAX® plus saline
3315405|NCT00254826|Experimental|17D YF Vaccine plus Ig|Drug: 17D YF Vaccine plus Ig; one vaccine on day 0
3315406|NCT00254800|Experimental|Sequence 1|Oral contraceptive 1 hour prior to exenatide/oral contraceptive 30 minutes after exenatide/oral contraceptive alone
3315407|NCT00254800|Experimental|Sequence 2|Oral contraceptive 30 minutes after exenatide/oral contraceptive alone/oral contraceptive 1 hour prior to exenatide
3315408|NCT00254800|Experimental|Sequence 3|Oral contraceptive alone/oral contraceptive 1 hour prior to exenatide/oral contraceptive 30 minutes after exenatide
3315409|NCT00254761|Experimental|1|High dose cannabis (7.5% THC by weight)
3315410|NCT00254761|Experimental|2|Low dose cannabis (3.5% THC by weight)
3315411|NCT00254761|Placebo Comparator|3|Placebo cannabis
3315412|NCT00254748|Placebo Comparator|1|Placebo
3315413|NCT00254748|Experimental|2|Flexible doses of 200 mg/day to 600 mg/day quetiapine fumarate
3315414|NCT00254722|Experimental|I|single arm study
3315415|NCT00254683|Experimental|PET/CT|Single arm study evaluating the use of PET/CT to assess rectal cancer response to neoadjuvant therapy
3315416|NCT00254657|Placebo Comparator|Placebo|
3315417|NCT00254657|Experimental|Levetiracetam|
3315418|NCT00254644||Dyslexia|adults from 18-35 ans.
3315419|NCT00254644||Control|adults from 18-35 ans.
3315420|NCT00254631|Active Comparator|study group|pre operative medication with 20 mg oxycontine PO
3315421|NCT00254631|Placebo Comparator|placebo group|pre operative medication with placebo tablet PO
3315422|NCT00254618|Experimental|30 mg|30 mg/kg/day mesalamine
3315423|NCT00254618|Experimental|60 mg|60 mg/kg/day mesalamine
3315424|NCT00254618|Experimental|90 mg|90 mg/kg/day mesalamine
3315425|NCT00254592|Experimental|AC with GM-CSF and Carboplatin/Nab-Paclitaxel|"Doxorubicin and cyclophosphamide (AC) administered intravenously every 14 days up to a total of 4 cycles, with GM-CSF on days 4-13, depending on tumor response.~Two weeks after the completion of AC, weekly doses of carboplatin/nab-paclitaxel will be given for 3 weeks, followed by 1 week of rest, for a total of 9-12 doses. Subjects who receive 4 cycles of AC will receive 9 doses of nab-paclitaxel and subjects who receive 2 cycles of AC will receive 12 weeks of nab-paclitaxel. In addition, subjects will receive trastuzumab weekly (12-16) doses if they are Her-2 positive and bevacizumab (6-8) doses every 2 weeks if they are Her-2 negative. Each clinic visit will last approximately ½ hour."
3315426|NCT00254579|Experimental|15 mg/kg CP-675,206|
3315427|NCT00254566|Experimental|1|
3315428|NCT00254566|Active Comparator|2|
3315429|NCT00254553|Active Comparator|Arm 1|Testim 1% (testosterone gel)
3315430|NCT00254553|Placebo Comparator|Arm 2|Placebo
3315431|NCT00254540|Experimental|SU-011248 capsule|
3315432|NCT00254501|Active Comparator|Usual Care plus out-of-pocket cost waiver|Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.
3315433|NCT00254501|Experimental|EMPOWER|Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.
3315434|NCT00254488|Experimental|Lithium (LI)|Participants will receive 9 weeks of treatment with lithium
3315435|NCT00254488|Experimental|Divalproex (DV)|Participants will receive 9 weeks of treatment with divalproex
3315436|NCT00254462|Experimental|atomoxetine and parent training|atomoxetine capsules, dose 0.5mg/kg/day to 1.8mg/kg/day administered once daily for 8 weeks
3315437|NCT00254462|Placebo Comparator|placebo and parent training|matching placebo capsules, dose 0.5mg/kg/day to 1.8mg/kg/day administered once daily for 8 weeks
3315438|NCT00254436|Experimental|Epoetin Alfa|
3315439|NCT00254423|Experimental|Dasatinib Daily (Arm A)|Dasatinib Daily Arm A: Starting dose 100 mg orally daily
3315440|NCT00254423|Experimental|Dasatinib Twice Daily (Arm B)|Dasatinib Twice Daily Arm B: Starting dose of 50 mg orally twice daily
3315441|NCT00254410|Experimental|FCM-R + Pegylated Filgrastim|Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6. Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6. Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6. Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6. Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
3315442|NCT00254397|Experimental|gp100 + Leuprolide|Group IA: HLA-A*0201 positive/HLA-DP4 negative treated with gp100 (1.0 ml subcutaneous injection in extremities) + Leuprolide (3-month 11.25 mg sustained-release formulation administrated intramuscularly then again 12 weeks later (2 injections)).
3315443|NCT00254397|Experimental|gp100 - No Leuprolide|Group IB: HLA-A*0201 positive/HLA-DP4 negative treated with gp100 (1.0 ml subcutaneous injection in extremities) - No Leuprolide
3315444|NCT00254397|Experimental|gp100 + MAGE-3 + Leuprolide|Group IIA: HLA-A*0201positive/HLA-DP4 positive treated with gp100 (1.0 ml subcutaneous injection in extremities) + MAGE-3 (1.0 ml subcutaneous injection in extremities) + Leuprolide (3-month 11.25 mg sustained-release formulation administrated intramuscularly then again 12 weeks later (2 injections)).
3315445|NCT00254397|Experimental|gp100 + MAGE-3 - No Leuprolide|Group IIB: HLA-A*0201positive/HLA-DP4 positive treated with gp100 (1.0 ml subcutaneous injection in extremities) + MAGE-3 (1.0 ml subcutaneous injection in extremities) - No Leuprolide
3315503|NCT00253643|Experimental|ArmII (FO placebo, GT catechin extract)|Patients receive a fish oil (FO) placebo 3/day and oral green tea (GT) extract 2/day
3320797|NCT00160342|Placebo Comparator|9|
3315446|NCT00254384|Experimental|Erlotinib + Cisplatin + Docetaxel|Erlotinib 150 mg by mouth daily for 1 year. Cisplatin 80 mg/m^2 IV over a 30 minutes - 1 hour infusion every 3 weeks (21 day cycle) for 3 cycles before surgery. Docetaxel 75 mg/m^2 IV over a 1 hour infusion every 3 weeks (21 day cycle) for 3 cycles before surgery.
3315447|NCT00254306||1|"ex-ecstasy users"
3315448|NCT00254306||2|control subjects
3315449|NCT00254293|Placebo Comparator|Group 1 (weight < 60 kg)|
3315450|NCT00254293|Placebo Comparator|Group 2 (weight < 60 kg)|
3315451|NCT00254293|Placebo Comparator|Group 3 (weight 60-100 kg)|
3315452|NCT00254293|Placebo Comparator|Group 4 (weight > 100 kg)|
3315453|NCT00254293|Placebo Comparator|Group 5 (weight > 100 kg)|
3315454|NCT00254293|Experimental|Abatacept|Long Term
3315455|NCT00254267|Experimental|Arm One|AMG 706 125mg, oral, once a day
3315456|NCT00254254|Experimental|Sequence 1|Exenatide 2.5 mcg - Exenatide 5 mcg - Placebo 0.02 mL
3315457|NCT00254254|Experimental|Sequence 2|Exenatide 2.5 mcg - Placebo 0.02 mL - Exenatide 5 mcg
3315458|NCT00254254|Experimental|Sequence 3|Placebo 0.02 mL - Exenatide 2.5 mcg - Exenatide 5 mcg
3315459|NCT00254176|Active Comparator|Cysteine|Subjects that receive cysteine
3315460|NCT00254176|Placebo Comparator|No-cysteine placebo|Subjects that do not receive cysteine but an isonitrogenous placebo
3315461|NCT00254163|Active Comparator|Fludarabine, Cyclophosphamide, and Rituximab|Fludarabine, Cyclophosphamide, and Rituximab (dosage based on day in cycle)
3315462|NCT00254163|Experimental|Pentostatin, Cyclophosphamide, and Rituximab|Pentostatin, Cyclophosphamide, and Rituximab (dosage depends on day in cycle)
3315463|NCT00254072|Active Comparator|Smaller Stapler|3.5 mm Circular Stapler
3315464|NCT00254072|Active Comparator|Larger Stapler|4.8 mm Circular Stapler
3315465|NCT00254046|Placebo Comparator|002|Placebo 2 tablets b.i.d.96 weeks
3315466|NCT00254046|Active Comparator|001|TMC125 2 X100 mg tablets b.i.d.96 weeks
3315467|NCT00253981|Experimental|Infrared Light Therapy|Intervention: The use of infrared light therapy for the treatment of tibial fracture. The treatment was assigned three times a week for four weeks.
3315468|NCT00253981|Placebo Comparator|Standard of Care|Standard of care was characterized by the use of standard medical treatment to include medication.
3315469|NCT00253968|Experimental|Eplivanserin|Eplivanserin 5 mg/day
3315470|NCT00253968|Placebo Comparator|Placebo|Placebo of Eplivanserin 5 mg /day
3315471|NCT00253955|Experimental|1|
3315472|NCT00253955|Active Comparator|2|
3315473|NCT00253916|No Intervention|Control Arm|No exercise measured
3315474|NCT00253916|Experimental|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
3315475|NCT00253916|Experimental|Resistance Exercise Program|Resistance Exercise Program
3315476|NCT00253903|Experimental|1|5 mg/day
3315477|NCT00253903|Placebo Comparator|2|
3315478|NCT00253890|Active Comparator|Trazodone|50-150mg (50mg capsules) at bedtime for 90 days
3315479|NCT00253890|Placebo Comparator|Placebo|1-3 capsules at bedtime for 90 days
3315480|NCT00253877|Active Comparator|Conserve Plus Hip Resurfacing|Conserve Plus Hip Resurfacing
3315481|NCT00253838|Active Comparator|Restoration HA Stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating
3315482|NCT00253838|Sham Comparator|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
3315483|NCT00253786|Experimental|Intensive multifactorial therapy (Protocol A)|Protocol A: serum creatinine <1.2 mg/dl in male and <1.0 mg/dl in female.
3315484|NCT00253786|Active Comparator|Standard therapy (Protocol A)|Protocol A: serum creatinine <1.2 mg/dl in male and <1.0 mg/dl in female.
3315485|NCT00253786|Experimental|Intensive multifactorial therapy (Protocol B)|Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.
3315486|NCT00253786|Active Comparator|Standard therapy (Protocol B)|Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.
3315487|NCT00253747|Active Comparator|Osmotic-Release Methylphenidate|
3315488|NCT00253747|Placebo Comparator|Placebo|
3315489|NCT00253734|Active Comparator|4|31 subjects to receive 15 mcg of TIV administered intramuscularly.
3315490|NCT00253734|Experimental|2|31 subjects to receive 6 mcg of TIV administered intradermally.
3315491|NCT00253734|Experimental|1|31 subjects to receive 9 mcg of TIV administered intradermally.
3315492|NCT00253734|Experimental|3|31 subjects to receive 3 mcg of TIV administered intradermally.
3315493|NCT00253734|Active Comparator|5|31 subjects to receive 9 mcg of TIV administered intramuscularly.
3315494|NCT00253734|Active Comparator|7|31 subjects to receive 3 mcg of TIV administered intramuscularly.
3315495|NCT00253734|Active Comparator|6|31 subjects to receive 6 mcg of TIV administered intramuscularly.
3315496|NCT00253721|Experimental|All subjects|
3315497|NCT00253708|Experimental|massage|"Patients received 3 massage therapy visits from massage therapists in initial week with a duration of 15-45 minutes.NOTE: Intervention 'management of therapy complications' has not been included in any Arm/Group Descriptions.~Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment"
3315498|NCT00253708|Active Comparator|no-touch control|Patients received 3 no-touch therapy visits from massage therapists who provided no-touch without healing intention.Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment
3315499|NCT00253708|No Intervention|Usual care|Patients did not receive visits from massage therapists. Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment
3315500|NCT00253682||1|HIV-uninfected infants born to HIV-infected women with in-utero exposure to HIghly Active Ani-Retroviral Therapy (HAART) who were enrolled in the Women and Infants Transmission Study (WITS).
3315501|NCT00253682||2|Historical cohort of HIV-uninfected infants born to HIV-infected women from the Pediatric Pulmonary and Cardiovascular Complications of HIV Study (P2C2 HIV) who were not exposed to HAART.
3315502|NCT00253643|Experimental|Arm I (FO, GT catechin extract)|Patients receive oral fish oil (FO) 3/day and oral green tea (GT) extract 2/day
3315504|NCT00253643|Experimental|Arm III (FO, GT placebo)|Patients receive oral fish oil (FO) 3/day and a placebo mimicking green tea (GT) catechins 2/day
3315505|NCT00253643|Placebo Comparator|Arm IV (FO placebo, GT placebo)|Patients receive a fish oil (FO) placebo mimicking fish oil 3/day and another placebo mimicking green tea (GT) catechins 2/day
3315506|NCT00253630|Experimental|Treatment (vorinostat)|Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3315507|NCT00253578|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3315508|NCT00253539|Experimental|Arm I|Participants receive oral tamoxifen once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
3315509|NCT00253539|Experimental|Arm II|Participants receive oral arzoxifene once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
3315510|NCT00253539|Placebo Comparator|Arm III|Participants receive an oral placebo once daily once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered treatment with arzoxifene for an additional 6 months.
3315511|NCT00253500|Experimental|Epirubicin|
3315512|NCT00253435|Experimental|All the patients enrolled in the study|"This is a single arm study. The following description applies to all the patients who are enrolled in the study:~On Day -21, patients receive 131I-MIBG infusion.~On Day -7, Day -6, Day -5, patients receive Carboplatin, Etoposide, Melphalan.~On Day -4, patients receive Carboplatin, Etoposide.~On Day -3, Day -2, Day -1, patients rest.~On Day 0, patients receive peripheral blood stem cell infusion.~Dosing of Carboplatin, Etoposide and Melphalan is based upon whole body dosimetry (cGy) estimates.~Filgrastim 5 micrograms/kg/day S.C. or IV will be given daily beginning on Day 0.~Local radiation therapy is to be given to previously non-irradiated primary and metastatic sites of disease."
3315513|NCT00253383|Experimental|ENABLE (concurrent palliative care)|telephone based ENABLE educational intervention
3315514|NCT00253383|Active Comparator|Usual Care|Supportive and palliative usual care services at DHMC, Behavioral
3315515|NCT00253370|Experimental|BAY 43-9006, docetaxel, cisplatin|Patients receive oral BAY 43-9006 400mg twice daily on days 1-21. Patients also receive docetaxel IV, 75 mg/m2 over 1 hour and cisplatin IV, 75 mg/m2 over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3315516|NCT00253318|Experimental|RAD001 + Docetaxel|RAD001 30 mg orally on Days 1 and 8. Docetaxel 40 mg/m^2 intravenous (IV) over 1 hour on Day 1. Dexamethasone 8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
3315517|NCT00253279||1|16 healthy subjects will be studied. Each patient will undergo one PET Scan to measure muscle protein synthesis rate.
3315518|NCT00253279||2|48 burn patients will be studied. Each patient will have a maximum of 3 PET Scans, which will be done at different times during the first 24 months after injury. A maximum of 2 of these scans will be done while they are inpatient; one after discharge.
3315519|NCT00253266|Experimental|Verum|Quetiapine augmentation
3315520|NCT00253266|Placebo Comparator|Placebo|"Placebo augmentation"
3315521|NCT00253110|Active Comparator|risperidone|
3315522|NCT00253110|Active Comparator|haloperidol|
3315523|NCT00253097|No Intervention|Control|Patients in the control group had the usual care provided at the stroke unit, that is counselling on avoiding risky health behavior, compliance with preventive medication, measurement of blood pressure and a 3 months' visit in the outpatient clinic
3315524|NCT00253097|Experimental|Intervention|Patienta allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
3315525|NCT00253084|Other|IPX054 - CD-LD IR|Subjects received IPX054 200 mg b.i.d and CD-LD IR Placebo q.i.d for 2 weeks and then received IPX054 Placebo b.i.d and CD-LD IR q.i.d for 2 weeks.
3315526|NCT00253084|Other|CD-LD IR - IPX054|Subjects received IPX054 Placebo b.i.d and CD-LD IR q.i.d for 2 weeks and then IPX054 200 mg b.i.d and CD-LD IR Placebo q.i.d for 2 weeks.
3315527|NCT00253071|Active Comparator|A,2|Standard treatment: treatment as usual at a community psychiatric center, private psychiatrist or general practitioner.
3315528|NCT00253071|Experimental|A, 1|"Behavioral: Prophylactic combined medical and psychological treatment~Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
3315529|NCT00253045|Experimental|Motivational group|Group counseling using motivational interviewing
3315530|NCT00252967|Placebo Comparator|Placebo|Placebo taken daily
3315531|NCT00252967|Experimental|Atorvastatin|Atorvastatin at a dose of 80 mg daily
3315532|NCT00252954|Placebo Comparator|1|
3315533|NCT00252928|Placebo Comparator|A|Placebo group does not receive Aquatabs.
3315534|NCT00252928|Experimental|B|Intervention arms receives Aquatabs.
3315535|NCT00252915|Experimental|Verum|GM-CSF therapy
3315536|NCT00252746|Experimental|ZD6474 100mg|Daily dose
3315537|NCT00252746|Experimental|ZD6474 200mg|daily dose
3315538|NCT00252746|Experimental|ZD6474 300mg|daily dose
3315539|NCT00252733|No Intervention|1|Placebo
3315540|NCT00252733|Experimental|2|candesartan cilexetil
3315541|NCT00252720|Experimental|candesartan|candesartan cilexetil 32 mg once daily
3315542|NCT00252720|No Intervention|placebo|control
3315543|NCT00252694|Experimental|candesartan|candesartan cilexetil 32 mg once daily
3315544|NCT00252694|No Intervention|placebo|control
3315545|NCT00252629|Active Comparator|Therapeutic nasal CPAP|Comparing change of veterans reported outcomes before and after 3 weeks treatment of therapeutic nasal CPAP with the change on sham nasal CPAP.
3315599|NCT00251745|Experimental|Dexlansoprazole MR 60 mg QD|
3315546|NCT00252629|Sham Comparator|Sham nasal CPAP|Comparing change of symptoms and veterans reported outcomes before and after treatment of 3 weeks on sham nasal CPAP with the change on therapeutic nasal CPAP
3315547|NCT00252616|Experimental|1|trophic feeds
3315548|NCT00252616|Active Comparator|2|Full-calorie feeds
3315549|NCT00252590|Experimental|Health Motivational Feedback|Personalized health-related feedback
3315550|NCT00252590|Active Comparator|Health Education|Non-personalized didactic health-related education
3315551|NCT00252590|Active Comparator|Control - treatment as usual|No added treatment control
3315552|NCT00252577||Group 1|Veterans with bipolar disorder
3315553|NCT00252564|Experimental|Arm A|"(Bev-FOLFOX): Bevacizumab, followed by oxaliplatin and LV given simultaneously via T connector over 2 hours, followed by bolus 5-FU followed by infusional 5-FU.~Bevacizumab --> oxaliplatin and LV --> bolus 5-FU --> infusional 5-FU~Dosing on Days 1 and 15 of each 28-day cycle"
3315554|NCT00252564|Experimental|Arm B|"(FOLF-CB): Cetuximab administered over 2 hours (first dose only; administer all other doses over 1 hour) followed by bevacizumab over 30 minutes, followed by LV over 30 minutes, followed by bolus 5-FU followed by infusional 5-FU.~Cetuximab --> bevacizumab --> LV --> bolus 5-FU --> infusional 5-FU"
3315555|NCT00252551|Experimental|1|osteosynthesis
3315556|NCT00252551|Active Comparator|2|Simple surgery
3315557|NCT00252538||Group 1|Research participants are: 1) male or female, 2) age 18 or older, 3) chronically infected with the hepatitis C virus, 4) candidates for interferon therapy, 4) not on antidepressant treatment , and 5) not currently abusing any substances such as alcohol or intravenous drugs, or having abused in the past 6 months
3315558|NCT00252525||Group 1|This is an observational study of patients who are enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2@.
3315559|NCT00252512|Experimental|Contingency Management|Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are negative, they receive a chance to draw tokens from a bowl. Some tokens are social reinforcement. Others have monetary value.
3315560|NCT00252512|Placebo Comparator|Placebo|Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
3315561|NCT00252499|Placebo Comparator|Placebo Arm|matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd
3315562|NCT00252499|Experimental|Rosiglitazone Arm|rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd
3315563|NCT00252499|Experimental|Fenofibrate Arm|micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid
3315564|NCT00252486|Placebo Comparator|Flax oil, placebo oil|
3315565|NCT00252421|Active Comparator|Nitroglycerin|Nitroglycerin ointment 15 mg/day daily for 24 month
3315566|NCT00252421|Placebo Comparator|Placebo|Placebo ointment daily for 24 month
3315567|NCT00252382|Experimental|Treatment with 48 mg/m2 of SNS-595|Patients are treated with 48 mg/m2 of the drug SNS-595 injection once every 21 days for up to 6 cycles as a second -line therapy to patients with advanced non-small cell lung cancer (NSCLC)
3315568|NCT00252317|Active Comparator|1|Captopril test dose and Trandolapril
3315569|NCT00252317|Placebo Comparator|2|
3315570|NCT00252304|Experimental|Zinc|Zinc sulphate 10 or 20 mg per day
3315571|NCT00252304|Placebo Comparator|Placebo|Placebo
3315572|NCT00252239|Active Comparator|1|tenecteplase
3315573|NCT00252239|Active Comparator|2|tissue plasminogen activator, tPA
3315574|NCT00252187|Active Comparator|B-type Natriuretic Peptide (BNP)|BNP (nesiritide) administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
3315575|NCT00252187|Placebo Comparator|Placebo|Placebo self-administered subcutaneously twice daily for 8 weeks.
3315576|NCT00252174|Experimental|Stage 1 Active methylenedioxymethamphetamine & psychotherapy|8 subjects will receive full or nearly full doses of MDMA in Stage 1 and do not continue to participate into Stage 2.
3315577|NCT00252174|Active Comparator|Stage 1 low dose methylenedioxymethamphetamine & Psychotherapy|4 individuals will receive sub-threshold to threshold minimal doses of MDMA in Stage I
3315578|NCT00252174|Experimental|Stage 2 Active methylenedioxymethamphetamine & Psychotherapy|The 4 subjects assigned in Stage I to the control arm will have the option to continue into Stage 2 to repeat the experimental procedures of Stage I but with open-label MDMA at the near-full to full dosage strength.
3315579|NCT00252161|Active Comparator|1|Procedure/Surgery: Gastrectomy with more than D2 dissection
3315580|NCT00252161|Experimental|2|Drug: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
3315581|NCT00252148|Active Comparator|ADMVA|ADMVA dosage escalation
3315582|NCT00252148|Placebo Comparator|Placebo|Placebo is 10mM TRIS HCl, 140mM NaCl, ph 7.7
3315583|NCT00252122|Experimental|1|Patients receiving ketamine are those patients, arm 1, that are sill experiencing pain after Morphine has been given.
3315584|NCT00252057|Experimental|Re-engineered hospital discharge|"Participants received the Re-Engineered Hospital Discharge, a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call 2-4 days after discharge by a clinical pharmacist."
3315585|NCT00252057|No Intervention|Standard hospital discharge|Participants received the routine, standard hospital discharge.
3315586|NCT00251927|Active Comparator|1|Surgery
3315587|NCT00251927|Experimental|2|Esomeprazole (NEXIUM) therapy
3315588|NCT00251862|Experimental|Decision aid plus YourDiseaseRisk|Patients viewed the decision aid and completed the Your Disease Risk risk assessment tool prior to visit with their primary care provider.
3315589|NCT00251862|Experimental|Decision aid alone|Patient's viewed decision aid only prior to a visit with their primary care provider.
3315590|NCT00251862|Sham Comparator|III|Standard care
3315591|NCT00251836||Left-sided donor nephrectomy|Left-sided laparoscopic hand-assisted donor nephrectomy
3315592|NCT00251836||Right-sided donor nephrectomy|Right-sided laparoscopic hand-assisted donor nephrectomy
3315593|NCT00251810||general anaesthesia|
3315594|NCT00251771|Experimental|I|
3315595|NCT00251771|No Intervention|II|
3315596|NCT00251758|Experimental|Dexlansoprazole MR 60 mg QD|
3315597|NCT00251758|Experimental|Dexlansoprazole MR 90 mg QD|
3315598|NCT00251758|Placebo Comparator|Placebo|
3320798|NCT00160316|Experimental|1|
3315600|NCT00251745|Experimental|Dexlansoprazole MR 90 mg QD|
3315601|NCT00251745|Placebo Comparator|Placebo|
3315602|NCT00251732|Active Comparator|Standard dose (PPI) plus low dose TCA|Standard dose Rabeprazole(PPI) plus low dose tricyclic antidepressant(TCA)
3315603|NCT00251732|Active Comparator|Double dose PPI|Double dose proton pump inhibitor plus placebo
3315604|NCT00251732|Placebo Comparator|Standard dose PPI plus placebo x 2|Standard dose 20 mg. once daily plus Placebo before dinner and placebo before bedtime
3315605|NCT00251719|Experimental|Dexlansoprazole MR 60 mg QD|
3315606|NCT00251719|Experimental|Dexlansoprazole MR 90 mg QD|
3315607|NCT00251719|Active Comparator|Lansoprazole 30 mg QD|
3315608|NCT00251693|Experimental|Dexlansoprazole MR 60 mg QD|
3315609|NCT00251693|Experimental|Dexlansoprazole MR 90 mg QD|
3315610|NCT00251693|Active Comparator|Lansoprazole 30 mg QD|
3315611|NCT00251680|Experimental|Lapaquistat Acetate 50 mg QD|(and stable lipid-lowering therapy)
3315612|NCT00251680|Active Comparator|Stable Lipid-lowering therapy|
3315613|NCT00251641|Experimental|Infliximab|
3315614|NCT00251641|Active Comparator|Methotrexate|
3315615|NCT00251628|Active Comparator|Group A|
3315616|NCT00251628|Active Comparator|Group B|
3315617|NCT00251628|Experimental|Group C|
3315618|NCT00251602|Experimental|1|II ACE genotype
3315619|NCT00251602|Experimental|2|ID ACE genotype
3315620|NCT00251602|Experimental|3|DD ACE genotype
3315621|NCT00251602|Placebo Comparator|4|II ACE genotype
3315622|NCT00251602|Placebo Comparator|5|ID ACE genotype
3315623|NCT00251602|Placebo Comparator|6|DD ACE genotype
3315624|NCT00251589|Experimental|Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 200 mg twice a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the study and determined to be the MTD and therefore the recommended Phase II dose. Of the 16 patients treated at this dose level, 4 were assigned to the Phase I portion of the study and 12 were assigned to the Phase II portion
3315625|NCT00251589|Experimental|Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 300 mg once a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the amended study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.
3315626|NCT00251589|Experimental|Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 300 mg twice a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.
3315627|NCT00251589|Experimental|Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 400 mg once a day for 21 out of 28 days + erlotinib 150 mg once a day was evaluated in the Phase I portion of the original study and exceeded MTD. This cohort was then amended (Amendment 1) to identify a more tolerable once daily vorinostat dosing regimen. All patients treated at this dose level were assigned to the Phase I portion of the study.
3315628|NCT00251433|Experimental|Phase I|The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
3315629|NCT00251433|Experimental|Phase II-A|Patients will receive OTR of lapatinib, docetaxel, trastuzumab dose determined in phase I.
3315630|NCT00251433|Active Comparator|Phase II-B|Patients will receive docetaxel and trastuzumab combination.
3315631|NCT00251407|Experimental|taxotere, cisplatin, irinotecan|
3315632|NCT00251355|Experimental|5-FU/gemcitabine/RT|
3315633|NCT00251316|Experimental|Lithium Carbonate|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive lithium capsules.
3315634|NCT00251316|Placebo Comparator|Placebo|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
3315635|NCT00251303|Experimental|riluzole|Active drug put into 10-mg capsule form,,prepared by Clinical Center Pharmacy. Dose up to 120 mg daily, divided. Brand name Rilutek.
3315636|NCT00251303|Placebo Comparator|placebo|Placebo Capsules designed to mimic active drug capsules
3315637|NCT00251264|Active Comparator|Open|
3315638|NCT00251264|Active Comparator|Arthroscopic|
3315639|NCT00251251|Active Comparator|1. Optimal Medical therapy plus ICD|
3315640|NCT00251251|Active Comparator|2. Optimal Medical Therapy plus CRT/ICD|
3315641|NCT00251238|Experimental|Ginkgo biloba extract EGb 761|Receiving daily Ginkgo biloba extract EGb 761
3315642|NCT00251238|Placebo Comparator|Placebo|Receiving daily placebo
3315643|NCT00251225|Experimental|Hormone Refractory Prostate Cancer|Gleevec + Docetaxel: Daily Oral Gleevec in Combination with Every-Three-Week Intravenous Docetaxel
3315644|NCT00251212|Active Comparator|1|Therapist delivered adapted motivational enhancement therapy and skills training
3315645|NCT00251212|Active Comparator|2|Computer delivered adapted motivational enhancement therapy and skills training
3315646|NCT00251212|No Intervention|3|3: Control brochure
3315647|NCT00251173|Active Comparator|Strengths Based Case Management Model (SBCM)|The Strengths Based Case Management Model (SBCM) consists of 5 case-management sessions designed to promote linkage and engagement in assessment and treatment services, while assisting with the patient's perceived needs, as well as personal strengths and barriers to linkage and engagement.
3315648|NCT00251173|Active Comparator|Motivational Enhancement Therapy (MET)|The MET therapist will conduct 2 motivational enhancement sessions to work through the content of an educational workbook targeting the participant's substance use/abuse with the goal of negotiating a 'contract' to: 1) link to services, with the eventual goal of seeking and receiving specialized substance treatment; or 2) provide a strategy to self-monitor substance use, consider consequences, and later seek assessment.
3315977|NCT00246051|Other|Sleep Hygiene Education|
3315649|NCT00251173|Active Comparator|Brief Informational Feedback (BIF) session|Subjects will receive brief informational feedback on the results of their alcohol screening and assessment and encouragement to seek treatment.
3315650|NCT00251160|Active Comparator|ETAC|
3315651|NCT00251160|Active Comparator|Open ICS|
3315652|NCT00251147|Active Comparator|Open Repair|
3315653|NCT00251147|Active Comparator|Mini-open Repair|
3315654|NCT00251134|Active Comparator|1|omega-3-acid ethyl ester 90
3315655|NCT00251134|Placebo Comparator|2|olive oil
3315656|NCT00251121|Experimental|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
3315657|NCT00251095|Active Comparator|Taxol|Taxol 80mg/m2/week
3315658|NCT00251095|Experimental|TOCOSOL|TOCOSOL Paclitaxel
3315659|NCT00251082|Experimental|A|
3315660|NCT00251082|Active Comparator|B|
3315661|NCT00251082|Placebo Comparator|C|
3315662|NCT00251056|Active Comparator|1|
3315663|NCT00251056|Active Comparator|2|
3315664|NCT00251056|Active Comparator|3|
3315665|NCT00251056|Active Comparator|4|
3315666|NCT00251043|Experimental|1|Participants will Psychotherapy weekly for 12 weeks
3315667|NCT00251043|Active Comparator|2|Parenting Education will include 45-minute weekly sessions for 12 week
3315668|NCT00251017|Active Comparator|Vancomycin|Effects of OCT2 genetic variation in renal elimination of Vancomycin
3315669|NCT00251004|Experimental|Low-dose Everolimus Group|"1.5 mg everolimus (one 0.75-mg tablet bis in diem/twice a day (bid)) + basiliximab + reduced-dose Cyclosporine A (CsA) ± corticosteroids.~The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
3315670|NCT00251004|Experimental|High-dose Everolimus Group|"3.0 mg everolimus (two 0.75-mg tablets bid) + basiliximab + reduced-dose CsA ± corticosteroids.~The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
3315671|NCT00251004|Active Comparator|Control Group|"1.44 g Mycophenolic Acid (two 360-mg tablets bid) + basiliximab + standard-dose CsA ± corticosteroids.~The CsA dose was adjusted to attain a C0 value within the following range for the time of the study: starting at the day 5 visit: 200-300 ng/mL, starting at the month 2 visit and thereafter: 100-250 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
3315672|NCT00250939|Experimental|1|
3315673|NCT00250926|Experimental|Bortezomib, Dexamethasone, Rituximab|A cycle of therapy consisted of bortezomib 1.3 mg/m(2) intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m(2) on day 11. Patients received four consecutive cycles for induction therapy and then four more cycles, each given 3 months apart, for maintenance therapy.
3315674|NCT00250835|Experimental|Chemotherapy, Celecoxib, and Radiation|"Oxaliplatin weekly at 50 mg/m2 given intravenously over two hours for the duration of radiation.~Capecitabine: on the days of radiation at 850 mg/m2 orally twice a day [1700 mg/m2/day] (Monday through Friday during radiation therapy).~Celecoxib at 200 mg orally twice a day throughout the duration of radiation without a break."
3315675|NCT00250796|Active Comparator|Arm 1|Thalidomide+alpha interferon
3315676|NCT00250796|Experimental|Arm 2|Thalidomide+interferon+Octreotide
3315677|NCT00250770||1|"Healthy postmenopausal and perimenopausal women with no history of endometrial carcinoma.~Women undergoing hysterectomy for benign conditions."
3315678|NCT00250744|Experimental|Arm A|
3315679|NCT00250744|Active Comparator|Arm B|
3315680|NCT00250731|Experimental|1|Telephone support and behavior change for couples
3315681|NCT00250731|Active Comparator|2|Telephone support and behavior change for individuals
3315682|NCT00250731|Placebo Comparator|3|Limited diabetes self-management education
3315683|NCT00250718|Experimental|Arm 1 Combination Treatment|"Treatment with combination therapy as follows:~VP-16 at 50 mg/day, orally for 14 days every 28 days; Chlorambucil at 0.1 mg/kg/day orally for 14 days every 28 days; Vincristine at 2 mg intravenously every 14 days; Dexamethasone at 200 mg intravenously every 24 days; Rituxan (rituximab) at 375 mg/m2 intravenously every 14 day; Levofloxacin at 500 mg orally daily; Diflucan at 200 mg orally daily~At least 2 courses, but no more than 8 courses total, will be administered to each patient"
3315684|NCT00250705|Other|Adolescent Conduct Disorder Males|All subjects were male and had a diagnosis of conduct disorder. All subjects were offered treatment with aripiprazole.
3315685|NCT00250679|Active Comparator|Formoterol 12 ųg 2x/day|
3315686|NCT00250679|Experimental|Arformoterol 15 ųg 2x/day|
3315687|NCT00250679|Experimental|Arformoterol 25 ųg 2x/day|
3315688|NCT00250640||Group 1|
3315689|NCT00250588|Experimental|Problem solving + care coordination|Problem solving skills training and asthma care coordination
3315690|NCT00250588|Experimental|Asthma care coordination|Asthma care coordination
3315691|NCT00250588|Active Comparator|Wait-list control|Usual care
3315692|NCT00250575|Experimental|1|
3315693|NCT00250549|No Intervention|HIV counselor|Patients who tested for HIV and consent to participate in the study receive a posttest educational session with an HIV counselor. Afterwards, patients complete an assessment tool concerning HIV prevention and transmission.
3315694|NCT00250549|Experimental|Post test video|Patients who tested for HIV and consent to participate in the study watch a a 15-minute HIV posttest educational video available in English/Spanish. Afterwards, patients complete an assessment tool concerning HIV prevention and transmission.
3315695|NCT00250523||Traumatic injury|ICU Patients with blunt or penetrating injury
3315696|NCT00250523||2|Healthy volunteers
3315697|NCT00250510|No Intervention|1|
3315698|NCT00250510|Experimental|2|EatRight Program inquirers with BMI's of 30 kg/m2 or greater were told that they would have the possibility of being reimbursed 50% ($150) of their initial fee ($300) if certain conditions were met.
3315699|NCT00250497|Experimental|New Moves Intervention Group|The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
3315700|NCT00250497|No Intervention|control group|Girls in the control group participated in an all-girls physical education class but did not receive additional components offered in the intervention such as individual coaching.
3315701|NCT00250484|Active Comparator|Transcranial Magnetic Stimulation|Active treatment with TMS for 10 days.
3315702|NCT00250484|Sham Comparator|Sham Transcranial Magnetic Stimulation|Patients will receive no active TMS/treatment.
3315703|NCT00250458|Experimental|1|Rizatriptan (MK0462)10 mg orally disintegrating tablet/oral lyophilisate
3315704|NCT00250458|Placebo Comparator|2|matching placebo
3315705|NCT00250432|Active Comparator|1|50 mg intravenous (IV) infusion (diluted with 9% saline) administered daily (following a 70-mg IV loading dose on Day 1), over the course of ~2 hrs. all patients should be treated with antifungal therapy for at least 14 days following both the improvement in clinical and radiographic signs of disease and the eradication of Candida from culture samples obtained from the invasive site of infection.
3315706|NCT00250432|Experimental|2|150 mg intravenous (IV) infusion (diluted with 9% saline) administered daily, over the course of ~2 hrs. all patients should be treated with antifungal therapy for at least 14 days following both the improvement in clinical and radiographic signs of disease and the eradication of Candida from culture samples obtained from the invasive site of infection.
3315707|NCT00250406|Active Comparator|1|Percuflex Plus Ureteral Stent
3315708|NCT00250406|Experimental|2|TRIUMPH stent (triclosan-eluting stent)
3315709|NCT00250341|Active Comparator|Advair|
3315710|NCT00250341|Experimental|QVAR|
3315711|NCT00250276|Experimental|Cervarix Lot1 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 1 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
3315712|NCT00250276|Experimental|Cervarix Lot2 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 2 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
3315713|NCT00250276|Experimental|Cervarix Lot3 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 3 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
3315714|NCT00250276|Experimental|Cervarix Low Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine manufactured lower scale-80L according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
3315715|NCT00250263|Placebo Comparator|1|Matching placebo- control arm (first year)
3315716|NCT00250263|Active Comparator|2|Drug Staloral (active group)
3315717|NCT00250237|Active Comparator|A|Patients receiving blinded medication (Haloperidol or Placebo)
3315718|NCT00250237|Placebo Comparator|B|Patients receiving blinded medication (Haloperidol or Placebo)
3315719|NCT00250224|Experimental|Stent|
3315720|NCT00250081|Active Comparator|Therapy Group|Therapy only
3315721|NCT00250081|Active Comparator|Surgery Group|surgical intervention
3315722|NCT00250081|Active Comparator|Botox Injections|botulinum toxin
3315723|NCT00249964|Experimental|Combination Treatment|"Paclitaxel at 175 mg/m2 + Carboplatin at area under the curve (AUC) 5 on day 1. Then, Temozolomide at the doses described under Interventions from day 2 to day 6 (a total of 5 days).~Cycle length is 21 days."
3315724|NCT00249912|Experimental|Lapaquistat Acetate 50 mg QD + Rosuvastatin|
3315725|NCT00249912|Experimental|Lapaquistat Acetate 100 mg QD + Rosuvastatin|
3315726|NCT00249912|Active Comparator|Rosuvastatin|
3315727|NCT00249899|Experimental|Lapaquistat Acetate 100 mg QD|(and stable statin therapy)
3315728|NCT00249899|Active Comparator|Stable statin therapy|
3315729|NCT00249873|Experimental|Clopidogrel + ASA|Clopidogrel 75 mg once daily (od) plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)
3315730|NCT00249873|Placebo Comparator|Placebo + ASA|Matching placebo of clopidogrel 75 mg od plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)
3315731|NCT00249860|Experimental|Interferon-beta-1a|
3315732|NCT00249860|Active Comparator|Ribavarin plus interferon-beta-1a|
3315733|NCT00249847|Experimental|Paroxetine|Paroxetine controlled-release (2-12.5 mg tablets, orally, every day for 4 weeks)
3315734|NCT00249847|Experimental|Conjugated equine estrogen|Conjugated equine estrogen (0.625 mg tablet, orally, every day for 4 weeks)
3315735|NCT00249834|Experimental|Gonal-f 112.5 IU|
3315736|NCT00249834|Experimental|Gonal-f 37.5 IU|
3315737|NCT00249834|Experimental|Gonal-f 75 IU|
3315738|NCT00249834|Experimental|Gonal-f 150 IU|
3315739|NCT00249834|Experimental|Gonal-f 187.5 IU|
3315740|NCT00249834|Experimental|Gonal-f 225 IU|
3315741|NCT00249834|Experimental|Gonal-f 262.5 IU|
3315742|NCT00249834|Experimental|Gonal-f 300 IU|
3315796|NCT00249015|Experimental|3|High Aerobic Exercise Group: perform three exercise sessions per week consisting of about 45-60 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.
3315743|NCT00249821|Experimental|Saizen® 0.057 mg/kg/day|Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.057 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the Height-Standard Deviation Score (H-SDS) at this time (less than [<] -2 SDS or greater than [>] -2 SDS)
3315744|NCT00249821|Experimental|Saizen® 0.035 mg/kg/day|Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.035 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the H-SDS at this time (< -2 SDS or > -2 SDS)
3315745|NCT00249808|Experimental|Efalizumab|
3315746|NCT00249795|Experimental|Irbesartan|150 mg for 2 weeks, then up-titrated to 300 mg up to final follow-up visit
3315747|NCT00249795|Placebo Comparator|Placebo|Matching placebo up to final follow-up visit
3315748|NCT00249756|Experimental|Re-entry Modified Therapeutic Community (Re-entry MTC)|
3315749|NCT00249756|Active Comparator|Parole Supervision and Case Management|
3315750|NCT00249704|Experimental|C|
3315751|NCT00249704|Experimental|B|
3315752|NCT00249704|Experimental|A|
3315753|NCT00249704|Placebo Comparator|D|
3315754|NCT00249691|Experimental|Topiramate|
3315755|NCT00249691|Placebo Comparator|Placebo|
3315756|NCT00249652|Experimental|TAP|MI-based phone intervention.
3315757|NCT00249652|Other|TAU|Treatment As Usual
3315758|NCT00249613|Experimental|Women-Only|Substance abuse treatment program for women only
3315759|NCT00249613|No Intervention|Mixed-Gender|Substance abuse treatment program for both women and men
3315760|NCT00249587|Experimental|1|Methadone plus behavioral counseling consisting of adherence, self-monitoring, and motivational interviewing
3315761|NCT00249587|Active Comparator|2|Methadone plus behavioral counseling consisting of adherence
3315762|NCT00249574|Experimental|pegInterferon|Open label, observational trial to determine the safety of HCV treatment in active IDUs stabilized on buprenorphine/naloxone
3315763|NCT00249561|Experimental|Recovery by Choice|A modified Therapeutic Community program.
3315764|NCT00249561|Active Comparator|Intensive Outpatient Program|Designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism.
3315765|NCT00249535|Experimental|1|standard treatment plus usual magnitude prize CM
3315766|NCT00249535|Experimental|2|standard treatment plus higher magnitude prize CM
3315767|NCT00249535|Experimental|3|standard treatment plus voucher CM
3315768|NCT00249496|Active Comparator|Employment Only|Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
3315769|NCT00249496|Experimental|Contingency Management|Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.
3315770|NCT00249483|Placebo Comparator|Placebo|Placebo
3315771|NCT00249483|Experimental|Venlafaxine|Venlafaxine 300mg daily
3315772|NCT00249470|Experimental|Abstinence & Work|Participants in the Abstinence & Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
3315773|NCT00249470|Other|Work Only|Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
3315774|NCT00249457|Experimental|Therapeutic Workplace|Contingency management. Invited to work in the Therapeutic Workplace. Completed monthly assessments.
3315775|NCT00249457|No Intervention|Usual Care Control Group|No intervention. Not invited to work int the Therapeutic Workplace. Completed monthly assessments.
3315776|NCT00249444|Active Comparator|Mirtazapine|Mirtazapine will be administered on a fixed-flexible schedule, with dose titrated up to 60 mg per day or the maximum tolerated dose.
3315777|NCT00249444|Placebo Comparator|Placebo|placebo
3315778|NCT00249431|Placebo Comparator|Placebo and Relapse Prevention|Patients will be treated with Relapse Prevention Therapy plus placebo
3315779|NCT00249431|Active Comparator|Sertraline and Relapse Prevention|Patients will be treated with Relapse Prevention Therapy plus Sertraline.
3315780|NCT00249405|Experimental|1|citalopram
3315781|NCT00249405|Placebo Comparator|2|Placebo
3315782|NCT00249379|Experimental|Acamprosate|Subjects randomized to receive acamprosate
3315783|NCT00249379|No Intervention|No medication|No medication intervention (subjects do not receive acamprosate), but do receive Building Social Networks counseling
3315784|NCT00249366|Active Comparator|Fixed-schedule treatment|Fixed-schedule administration of lorazepam for alcohol withdrawal
3315785|NCT00249366|Active Comparator|Symptom-triggered treatment|Symptom-triggered administration of lorazepam per protocol using the Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar)
3315786|NCT00249301|Experimental|1|MLN8054
3315787|NCT00249288|Experimental|Folate|Participants will receive a 2 mg/ day dose of folate, for 12 weeks
3315788|NCT00249288|Placebo Comparator|Placebo|Participants will receive a 2 mg/ day dose of placebo, for 12 weeks
3315789|NCT00249106|Experimental|HIV vaccine|dosage escalation of ADVAX
3315790|NCT00249106|Placebo Comparator|Placebo|Sodium phosphate
3315791|NCT00249054|Active Comparator|ASR hip prosthesis|DuPuy ASR hip prosthesis
3315792|NCT00249054|Active Comparator|ReCap hip prosthesis|Biomet ReCap hip prosthesis
3315793|NCT00249041|Experimental|Etanercept liquid|
3315794|NCT00249015|Experimental|1|Combined Aerobic and Resistance Exercise Program: perform three exercise sessions per week consisting of about 25-30 minutes of aerobic exercise at a moderate-to-vigorous intensity as well as some weight training consisting of two sets of 8-12 repetitions of 9-10 different exercises. For the aerobic exercise, participant can choose from different exercise equipment such as a treadmill or stationary bicycle.
3315795|NCT00249015|Active Comparator|2|Moderate Aerobic Exercise Group: perform three exercise sessions per week consisting of about 25-30 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.
3315797|NCT00249002|Experimental|ABI-007|ABI-007 35 mg/m^2 given intravenously (IV) into the arteriovenous (AV) graft within 96 hours after angioplasty, followed by repeat treatment during weeks 5, 13 and 21
3315798|NCT00248989|Experimental|Placebo|
3315799|NCT00248989|Experimental|DHEA|
3315800|NCT00248976|No Intervention|1|Control
3315801|NCT00248976|Experimental|2|This group received the experimental intervention. This is an intervention based on feedback of individualized risk profiles framed as the opportunity to reduce one's biologic age.
3315802|NCT00248911|Experimental|Mindfulness based meditation program|Meditation and Breast Cancer: Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
3315803|NCT00248885|Active Comparator|1|In this group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB.
3315804|NCT00248885|Experimental|2|In this group (High), the goal was to maintain MAP between 80-100 mm Hg during CPB.
3315805|NCT00248872|No Intervention|control group|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to adhere to their medication goal.
3315806|NCT00248872|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to engage adhere to their medication goal. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level.
3315807|NCT00248846|No Intervention|Control Group|This group received follow-up every 2-months for one year. Follow-up included questions about their heart disease progression and how well they had been able to engage in their doctor approved physical activity goal.
3315808|NCT00248846|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their heart disease progression and how well they had been able to engage in their doctor approved physical activity goal, which was the same as the control arm. Additionally, subjects in this arm were encouraged to use positive affect and self-affirmation techniques to motivate an increased level of participation in their physical activity goal. These subjects also received small token gifts to remind them of their study participation.
3315809|NCT00248807|Placebo Comparator|ARM 1|Head-up tilt maneuver without drug in subjects with spinal cord injury
3315810|NCT00248807|Placebo Comparator|ARM 3|Head-up tilt maneuver without drug in able-bodied controls
3315811|NCT00248807|Active Comparator|ARM 2|Head-up tilt maneuver with an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat) in subjects with spinal cord injury
3315812|NCT00248807|Active Comparator|ARM 4|Head-up tilt maneuver with an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat) in able-bodied controls.
3315813|NCT00248794|Experimental|CRT + Skills Training|"The intervention is call Cognitive Remediation Therapy (CRT) with a skill development group. Participants receive 15 weeks of cognitive training (with intake, 15 and 30 week assessment). This intervention is reliant upon didactic exchanges between trainer and participant, minimizing error, and behavioral modeling with the goal of developing better meta-cognitive skills. Procedures include paper and pencil activities (memory, planning and cognitive flexibility training) which are organized by difficulty. Sessions are organized to have a discussion between the trainer and the participant about the task and strategies, trainer modeling with articulation of strategy a participant attempts the task, talking aloud the steps, and finally the participant practices the task covertly. The trainer has the role of error catcher and model. All subjects randomized to this condition also are receiving the weekly skills group (SDG)offered to participants in all experimental conditions."
3315814|NCT00248794|Experimental|ICBCR and Skills Training|This intervention is Individualized Computer Based Cognitive Remediation (ICBCR) and skills development group (SDG). Participants receive 15 weeks of computerized training (with intake, 15 and 30 week assessments). This intervention relies upon intense, frequent, repetition of tasks being made incrementally more challenging. Computer tasks are organized so that the initial trials are easily completed and more challenging levels are then attempted. Parameters such as duration of task, task speed, and intra-task variables all be are manipulated. A trainer will be present at each session to help set up the computer tasks and answer questions. Besides the first two sessions that will be orientation sessions, the trainer has little involvement during the training sessions. The role of the trainer is to help organize, support, and provide feedback to each participant. All subjects randomized to this condition also are receiving the weekly skills group (SDG).
3315815|NCT00248794|Experimental|Skills Group Control|The control intervention is call the skills development group (SDG) and is augmented with up to five individual contacts with research staff. The Skills Group (SDG) control is standard care group which will receive 15 weeks of the skills development group (SDG) similar to that offered as a clinical service at the VA Medical Center. During the 15 weeks participants will attend 1.5 hours of skills group per week. The 15 sessions will include skills training related to: a) cooking and food preparation, b) negotiating the local transportation system, c) shopping, and d) planning leisure activities. The training activities are a blend of didactic learning, modeling and finally in vivo practice. Participants in this group will also be offered up to five weekly contacts with staff to balance out factors related to meeting with staff in the other conditions.
3315816|NCT00248781|Experimental|Arm 1|exercise
3315817|NCT00248781|Other|Arm 2|health education
3315818|NCT00248768|Other|Arm 1|
3315819|NCT00248703|Experimental|Docetaxel|Patients with presence of disseminated tumor cells in bone marrow after (no-taxane) epirubicin-containing adjuvant treatment receive 6 cycles of docetaxel (100 mg/m2) 3 qw.
3315820|NCT00248677|No Intervention|No Contact Control|
3315821|NCT00248677|Experimental|Behavior Family Intervention|
3315822|NCT00248677|Experimental|Behavioral Parent-Only Intervention|
3315823|NCT00248651|Active Comparator|Amitriptyline|Amitriptyline capsule (50 mg) plus a placebo escitalopram tablet will be taken at night half an hour before bedtime. To maximize patient tolerability, in the first 2 weeks the dose of amitriptyline will be 25 mg and then the dose will be increased to 50 mg, but the 25 mg and 50 mg capsules will be indistinguishable to maintain blinding.
3315870|NCT00247832|Experimental|3|Personal motivational interviewing
3315871|NCT00247741|Active Comparator|lidocaine|
3315824|NCT00248651|Active Comparator|Escitalopram|Escitalopram tablet (10 mg) plus a placebo amitriptyline capsule will be taken by mouth at night half an hour before bedtime for 12 weeks.
3315825|NCT00248651|Placebo Comparator|Placebo|Placebo escitalopram tablets and placebo amitriptyline capsules will be taken by mouth half an hour before bedtime for 12 weeks.
3315826|NCT00248638|Active Comparator|Glutamine dipeptide|Glutamine dipeptide supplemented nutrition to be given to participants.
3315827|NCT00248638|Placebo Comparator|standard|Participants given standard nutrition without glutamine dipeptide
3315828|NCT00248625|Active Comparator|N-acetylcysteine (NAC)|Eligible children were adaptively allocated by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) infused over 24 hours for up to 7 consecutive days
3315829|NCT00248625|Placebo Comparator|placebo|Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive 5% dextrose (D5W) infused over 24 hours for up to 7 consecutive
3315830|NCT00248612|Experimental|Venlafaxine & CBT|CBT is Cognitive Behavioral Treatment which will be tailored to participants. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
3315831|NCT00248612|Active Comparator|Placebo & CBT|CBT is Cognitive Behavioral Treatment which will be tailored to participants.For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
3315832|NCT00248612|Active Comparator|Venlafaxine & PMR|Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
3315833|NCT00248612|Placebo Comparator|Placebo & PMR|Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . For patients with co-morbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
3315834|NCT00248586|Experimental|Standard CBT (S-CBT)|
3315835|NCT00248586|Experimental|Minimal contact CBT (MC-CBT)|
3315836|NCT00248586|No Intervention|Control|
3315837|NCT00248560|Experimental|Gemcitabine hydrochloride, docetaxel|Gemcitabine hydrochloride given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine hydrochlorid.
3315838|NCT00248547|Active Comparator|Aprepitant|
3315839|NCT00248547|Placebo Comparator|sugar pill|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
3315840|NCT00248495|Experimental|Neoadjuvant chemotherapy|Patients receive pemetrexed disodium IV over 10 minutes followed by cisplatin IV over approximately 1 hour on day 1. Treatment repeats every 21 days for 3 courses
3315841|NCT00248482|Experimental|Irinotecan, Cisplatin & Gleevec™|"Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles~Gleevec™ 400 mg po BID (800mg/day)- for patients with objective response or stable disease.~Irinotecan 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles"
3315842|NCT00248365|Experimental|Low PDT intensity level|Theralux extracorporeal photochemotherapy PDT dose: TH9402 0.33μM
3315843|NCT00248365|Experimental|High PDT intensity level|Theralux extracorporeal photochemotherapy PDT dose: TH9402 1.32μM
3315844|NCT00248339|Active Comparator|1|PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD
3315845|NCT00248339|Active Comparator|2|PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
3315846|NCT00248339|Active Comparator|3|PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
3315847|NCT00248326||1|Patients of the Cardiovascular Institute with known cardiac conditions and no history of atrial fibrillation.
3315848|NCT00248326||2|Patients of the Cardiovascular Institute with known cardiac conditions and a history of atrial fibrillation.
3315849|NCT00248287|Active Comparator|Arm 1|irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle (Arm 1, ICb)
3315850|NCT00248287|Experimental|Arm 2|irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2 Week 1 and then 250 mg/m2 weekly thereafter, (Arm 2, ICb+Erbitux)
3315851|NCT00248235|Experimental|PRET|Progressive Resistance Exercise Training: upper extremity 6-8 exercises
3315852|NCT00248235|Active Comparator|Standard Care|Standard Care: physical therapy - range of motion, 6-8 strengthening exercises
3315853|NCT00248209|Placebo Comparator|Wellbutrin XL or placebo|1 arms - Wellbutrin XL or placebo
3315854|NCT00248170|Experimental|Letrozole|2.5 mg by mouth (p.o.) once daily
3315855|NCT00248170|Active Comparator|Anastrozole|1 mg p.o. once daily
3315856|NCT00248118|Active Comparator|Active medication|300mg bupropion HCL
3315857|NCT00248118|Placebo Comparator|Placebo|Placebo pill
3315858|NCT00248105|Experimental|PAM|
3315859|NCT00248105|No Intervention|PC|Participants not in the PAM group will be in the PC (physician counseling) group and will receive advice on lifestyle physical activity from their rheumatologist or primary care physician.
3315860|NCT00248053|Other|Lower GI|
3315861|NCT00248040|Experimental|reparixin continuous infusion|
3315862|NCT00248040|Experimental|reparixin intermittent infusion|
3315863|NCT00248040|Placebo Comparator|placebo infusion|
3315864|NCT00247962|Experimental|A|
3315865|NCT00247962|Active Comparator|B|
3315866|NCT00247936|Active Comparator|1|Combined Thoracoscopic and Laparoscopic Esophagectomy
3315867|NCT00247936|Active Comparator|2|Hand-Assisted Transhiatal Esophagectomy
3315868|NCT00247832|No Intervention|1|
3315869|NCT00247832|Experimental|2|Self-directed motivation
3315873|NCT00247715|Other|Step-up|"Stepwise treatment:~step1: antacid (+placebo proton pump inhibitor)~step2: H2-receptor antagonist~step3: proton pump inhibitor (+ placebo antacid)"
3315874|NCT00247715|Other|step-down|"Stepwise treatment:~step1: proton pump inhibitor (+placebo antacid)~step2: H2-receptor antagonist~step3: antacid (+proton pump inhibitor)"
3315875|NCT00247676|Experimental|A|
3315876|NCT00247663|Experimental|Letrozole|
3315877|NCT00247624|Experimental|A|Participants will receive treatment with eszopiclone and fluoxetine
3315878|NCT00247624|Active Comparator|B|Participants will receive treatment with placebo and fluoxetine
3315879|NCT00247611|Other|Control|Participants will receive the control condition
3315880|NCT00247611|Experimental|Intervention|Participants will receive the LifeWindows Intervention sessions
3315881|NCT00247416|Other|1 No Dex|No Dexamethasone
3315882|NCT00247416|Experimental|2 Dex|Dexamethasone
3315883|NCT00247403|Experimental|2DG|
3315884|NCT00247390|Experimental|Ramelteon 8 mg QD|
3315885|NCT00247390|Placebo Comparator|Placebo QD|
3315886|NCT00247377|Active Comparator|Laparoscopic Gastric Bypass|Subject undergoes Laparoscopic Gastric Bypass
3315887|NCT00247377|Active Comparator|LAP-BAND|Subject undergoes LAP-BAND procedure
3315888|NCT00247312|Active Comparator|125Gy prescription dose Pd-103|125Gy prescription dose Pd-103
3315889|NCT00247312|Active Comparator|110 Gy prescription dose Pd-103|110 Gy prescription dose Pd-103
3315890|NCT00247286|Experimental|a|Weighted vaginal cones used to perform pelvic floor exercises
3315891|NCT00247286|Active Comparator|b|Biofeedback
3315892|NCT00247273|Active Comparator|1|5 mg risedronate, once daily for 2 years
3315893|NCT00247273|Experimental|2|150 mg risedronate taken once a month for 2 years
3315894|NCT00247234|Experimental|schema therapy|
3315895|NCT00247234|Active Comparator|standard care|standard psychiatric out-patient care
3315896|NCT00247221|Experimental|1) MI/Family Check-Up|Brief integrated individual and family intervention -- the experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up
3315897|NCT00247221|Active Comparator|2) MI only|
3315898|NCT00247208|Active Comparator|1|Express 2 bare metal stent
3315899|NCT00247208|Experimental|2|Taxus, paclitaxel-eluting stent
3315900|NCT00247195|Experimental|Culturally congruent assessment and treatment|Outreach by phone to primary care patients interested in mental health referral. Engagement and evaluation approach conducted using the DSM-IV cultural formulation model. Same treatment choices as in control arm (medication, interpersonal psychotherapy, and combination treatment).
3315901|NCT00247195|Active Comparator|Usual referral and treatment|Usual referral procedure from primary care: PC clinician gives patient information on how to access mental health care at research site. Usual engagement and evaluation approach without using cultural formulation model. Same treatment choices (medication, interpersonal psychotherapy, and combination treatment) as in experimental arm.
3315902|NCT00247182|Other|Step 1|Minimal Intervention
3315903|NCT00247182|Active Comparator|Step 2-A|Brief motivational intervention (BMI)
3315904|NCT00247182|Active Comparator|Step 2-B|Assessment-only control
3315905|NCT00247130|Active Comparator|Omeprazole|Omeprazole (20 mg), intravenous, 2x /day
3315906|NCT00247130|Active Comparator|Ranitidine|Ranitidine (100 mg), intravenous drip infusion, 2x /day.
3315907|NCT00247078|Experimental|1|Patients with moderate or severe pain due to Black Widow envenomation
3315908|NCT00247078|Placebo Comparator|2|Patients with moderate to severe pain due to Black Widow envenomation
3315909|NCT00247052|Active Comparator|diclofenac|diclofenac
3315910|NCT00247052|Placebo Comparator|2|
3315911|NCT00247039|Experimental|Garlic extract|Garlic extract capsules
3315912|NCT00247039|Placebo Comparator|Placebo|Placebo capsules
3315913|NCT00246974|Active Comparator|1|Cisplatin + Gemcitabin
3315914|NCT00246974|Experimental|2|Cisplatin + Gemcitabin + Gefitinib
3315915|NCT00246805|Experimental|1. VRS ON|"Patients with permanent atrial fibrillation implanted with VVI(R) pacemaker Vitatron model C20 SSIR or T20 SSIR were randomized to Function Ventricular Rate Stabilization (VRS) ON or OFF.~This arm (1) is randomized to Function Ventricular Rate Stabilization ON."
3315916|NCT00246805|No Intervention|2. VRS OFF|"Patients with permanent atrial fibrillation implanted with VVI(R) pacemaker Vitatron model C20 SSIR or T20 SSIR were randomized to Function Ventricular Rate Stabilization (VRS)ON or OFF.~This arm (2) is randomized to Function Ventricular Rate Stabilization OFF."
3315917|NCT00246753|Other|Single Arm Trial|Single Arm Trial where each patient receives GW572016 (lapatinib ditosylate) at a dose of 1500mg daily initially until disease progression or unacceptable toxicity.
3315918|NCT00246740|Placebo Comparator|Placebo oral tablet|Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
3315919|NCT00246740|Experimental|Periostat|Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
3315920|NCT00246727|Placebo Comparator|Study 1: Chemotherapy plus SV or Placebo|For newly diagnosed patients who will be receiving or have received less than 4 weeks of a standard chemotherapy regimen.
3315921|NCT00246727|Placebo Comparator|Study 2: SV vs Placebo without chemotherapy|For those who have stopped or refuse standard chemotherapy but will receive best supportive care.
3315922|NCT00246701|Active Comparator|Simvastatin|Simvastatin + placebo
3315923|NCT00246701|Experimental|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
3315924|NCT00246688|Experimental|Sagopilone, 0.5 h infusion|Subjects received one infusion (for 0.5 h) of sagopilone every 3 weeks at a dose of 16 mg/m2 (maximum up to 32 mg) for approximately 18 weeks
3315925|NCT00246688|Experimental|Sagopilone, 3 h infusion|Subjects received one infusion (for 3 h) of sagopilone every 3 weeks at a dose of 16 mg/m2 (maximum up to 32 mg) for approximately 18 weeks
3315926|NCT00246675|Other|Standard Care|Patients will only receive frusemide as per the treating physicians treatment
3315927|NCT00246675|Other|Intervention|Patients will be given frusemide to achieve a study specified urine output target of 1-2mls/kg/hour
3315928|NCT00246662|Experimental|Sch A (18 mg/m2 vosaroxin initially)|Once weekly intravenous on days 1, 8, 15 up to 4 cycles
3315929|NCT00246662|Experimental|Sch B (9 mg/m2 vosaroxin initially)|Twice weekly intravenous administration on days 1, 4, 8, 11 up to 4 cycles
3315930|NCT00246636|Active Comparator|OM5/LOV111859 (double-blind study) - Antara|Antara (fenofibrate) + placebo
3315931|NCT00246636|Experimental|OM5X/LOV111860 (extension study) - Open-Label Antara + Lovaza|Open-label Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
3315932|NCT00246636|Experimental|OM5/LOV111859 (double-blind study) - Antara + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
3315933|NCT00246610|Experimental|Open-label|Non-randomized, open-label, single-arm
3315934|NCT00246571|Experimental|A|
3315935|NCT00246571|Active Comparator|B|
3315936|NCT00246532|Placebo Comparator|1: Placebo Pill|This arm contains placebo medication.
3315937|NCT00246532|Active Comparator|2: Morphine|Patients will receive oral morphine therapy.
3315938|NCT00246519|Experimental|Atenolol|atenolol 50 mg, then 100 mg if BP < 120/70, then add HCTZ 12.5 mg if BP < 120/70, then HCTZ 25 mg if BP < 120/70
3315939|NCT00246519|Experimental|Hydrochlorothiazide (HCTZ)|HCTZ 12.5 mg then HCTZ 25 mg if BP < 120/70, then add atenolol 50 mg if BP < 120/70, then atenolol 100 mg if BP < 120/70.
3315940|NCT00246506|Active Comparator|I.|Those randomized to have clomiphene/IUI treatments first will initiate therapy with two cycles of the fertility pill called clomiphene combined with (IUI) intrauterine insemination. If not pregnant after 2 IUI cycles, the couples will then proceed to IVF.
3315941|NCT00246506|Active Comparator|II.|Those randomized to have gonadotropins/IUI treatments first will initiate therapy with two cycles of the fertility injections called FSH or gonadotropins combined with (IUI) intrauterine insemination. If not pregnant after 2 IUI cycles, the couples will then proceed to IVF.
3315942|NCT00246506|Active Comparator|III.|Those couples randomized to (IVF) in vitro fertilization will bypass IUI treatments and start IVF therapy immediately.
3315943|NCT00246454||1|People with delayed sleep phase syndrome (DSPS).
3315944|NCT00246454||2|People with advanced sleep phase syndrome (ASPS).
3315945|NCT00246454||3|Control group (people with intermediate sleep patterns).
3315946|NCT00246441|Experimental|1|Paroxetine
3315947|NCT00246441|Placebo Comparator|2|Placebo
3315948|NCT00246428|Experimental|1|MI
3315949|NCT00246376|Placebo Comparator|1|Subjects receive lifestyle advice and placebos for Niaspan and Tricor
3315950|NCT00246376|Experimental|2|Diet, exercise, and two placebos
3315951|NCT00246376|Experimental|3|Diet, exercise, Niaspan, and placebo
3315952|NCT00246376|Experimental|4|Diet, exercise, placebo, and Tricor
3315953|NCT00246376|Experimental|5|Diet, exercise, Niaspan, and Tricor
3315954|NCT00246363|Experimental|Silymarin|Silymarin
3315955|NCT00246363|Placebo Comparator|Placebo|Placebo
3315956|NCT00246350|Active Comparator|1|8 light massage treatments
3315957|NCT00246350|Active Comparator|2|16 light massage treatments
3315958|NCT00246350|Experimental|3|8 spinal manipulation treatments
3315959|NCT00246350|Experimental|4|16 spinal manipulation treatments
3315960|NCT00246337|Placebo Comparator|Placebo|Placebo to match assigned treatment arm; one orally-administered dose, plus an optional second dose of active drug, per assigned treatment arm, to treat a single moderate-to-severe migraine headache.
3315961|NCT00246337|Experimental|MK0974 25 mg|MK0974 25 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
3315962|NCT00246337|Experimental|MK0974 50 mg|MK0974 50 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
3315963|NCT00246337|Experimental|MK0974 100 mg|MK0974 100 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
3315964|NCT00246337|Experimental|MK0974 200 mg|MK0974 200 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
3315965|NCT00246337|Experimental|MK0974 300 mg|MK0974 300 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
3315966|NCT00246337|Experimental|MK0974 400 mg|MK0974 400 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
3315967|NCT00246337|Experimental|MK0974 600 mg|MK0974 600 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
3315968|NCT00246337|Active Comparator|Rizatriptan 10 mg|Rizatriptan 10 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
3315969|NCT00246324|Experimental|Single Arm|Interferon beta 1a, oral doxycycline
3315970|NCT00246259|Experimental|Risperidone long-acting injection (LAI)|Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following initiation of Risperidone LAI, and for a maximum of 3 weeks following a dose increase.
3315971|NCT00246259|Active Comparator|Oral Antipsychotic|Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg. Participants will be switched to another oral therapy as per Investigator's discretion.
3315972|NCT00246194||Patients with schizophrenia|Long-acting injectable of risperidone given as per the prescription from the prescribing physician (Observational study).
3315973|NCT00246129|Active Comparator|1|Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy
3315974|NCT00246129|Experimental|2|Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy
3315975|NCT00246103|Experimental|Dose Escalation and Possible Expansion|Escalating doses of Valproic acid and one dose escalation step of epirubicin. Participants with breast cancer treated at the maximum tolerated dose, will also be treated with 5-fluorouracil and Cyclophosphamide.
3315978|NCT00246051|Other|Expert-Led Sleep Disorders Screening and Treatment|
3315979|NCT00246051|Other|Online Sleep Disorders Screening|
3315980|NCT00246025|Experimental|Dabigatran etexilate 110 mg|Dabigatran etexilate 110 mg capsule, once a day, oral administration
3315981|NCT00246025|Experimental|Dabigatran etexilate 150 mg|Dabigatran etexilate 150 mg capsule, once a day, oral administration
3315982|NCT00246025|Experimental|Dabigatran etexilate 220 mg|Dabigatran etexilate 110 mg capsule, 2capsules, once a day, oral administration
3315983|NCT00246025|Placebo Comparator|Placebo|matching placebo capsule, once a day, oral administration
3315984|NCT00246012|Experimental|Intetumumab 3 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). If after an evaluation of the preliminary single-dose pharmacokinetics, receptor saturation is not observed at the 3 mg/kg or 5 mg/kg dose level, that dose of intetumumab will be discontinued in Part 1 and participants will be treated at the highest, documented safe dose level at which receptor saturation is observed.
3315985|NCT00246012|Experimental|Intetumumab 5 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks until the occurrence of DLTs. If after an evaluation of the preliminary single-dose pharmacokinetics, receptor saturation is not observed at the 3 mg/kg or 5 mg/kg dose level, that dose of intetumumab will be discontinued in Part 1 and participants will be treated at the highest, documented safe dose level at which receptor saturation is observed.
3315986|NCT00246012|Experimental|Intetumumab 10 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks until the occurrence of DLTs.
3315987|NCT00246012|Experimental|Dacarbazine + intetumumab 5 mg/kg [Phase 1 (Part 2)]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with stable disease (SD) or better, they will be considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 milligram per meter-square (mg/m^2) intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
3315988|NCT00246012|Experimental|Dacarbazine + intetumumab 10 mg/kg [Phase 1 (Part 2)]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they will be considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 mg/m^2 intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
3315989|NCT00246012|Experimental|Dacarbazine + placebo [Phase 2]|Placebo will be administered intravenously over a period of 2 hr (±15 minutes). Commercially available dacarbazine will be administered at the dose of 1000 mg/m^2 intravenously over a period of 60 minutes (± 30 minutes) prior to placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue with 10 mg/kg intetumumab alone.
3315990|NCT00246012|Experimental|Intetumumab 5 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations.
3315991|NCT00246012|Experimental|Intetumumab 10 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations.
3315992|NCT00246012|Experimental|Dacarbazine + intetumumab 10 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 mg/m^2 intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
3315993|NCT00245960|Active Comparator|A|
3315994|NCT00245960|Active Comparator|B|
3315995|NCT00245895|Active Comparator|1|Aranesp
3315996|NCT00245882|Active Comparator|Care Coordination|Care Coordination with monthly follow-up by a diabetes nurse educator
3315997|NCT00245882|Active Comparator|Home Telemedicine|Active Care Management with Home Telemedicine
3315998|NCT00245856|Experimental|Treatment of Upper Extremity DVT|Participants received dalterparin followed by warfarin or received dalterparin monotherapy for the treatment of upper extremity DVT
3315999|NCT00245830|No Intervention|No Hepatic Ischemic Preconditioning|donor will act as a sham control.
3316000|NCT00245830|Experimental|Hepatic Ischemic Preconditioning|blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
3316001|NCT00245804||Adult dyslexia|Adult dyslexia
3316002|NCT00245804||Minor-Dyslexia|Minor-Dyslexia
3316003|NCT00245804||Adult-Control|Adult-Control
3316004|NCT00245804||Minor-Control|Minor-Control
3316005|NCT00245752|Active Comparator|A|in points bilaterally inBL 67, LI 4, SP6, one in GV20.
3316006|NCT00245752|Sham Comparator|2|sham acupuncture
3316007|NCT00245726|Active Comparator|1|Passive (Motor Assist) Cycle
3316008|NCT00245726|Active Comparator|2|
3316009|NCT00245726|Experimental|3|
3316010|NCT00245635|Experimental|Fluoxetine|Fixed/flexible dosing regimen of fluoxetine based on weight of subject and reaction to dosage, varying between 10mg and 80mg tablets once a day.
3316011|NCT00245635|Placebo Comparator|Placebo|Placebo tablets will be given 1/day for the duration of the study with a dosing schedule equivalent to that of the drug.
3316195|NCT00242710|Experimental|Arm 2|BZA 20mg/CE 0.45
3316012|NCT00245622|Experimental|Tovaxin Autologous T cell vaccine|2.0 mL subcutaneous formulated with 30-45 million autologous myelin reactive T cells
3316013|NCT00245622|Placebo Comparator|Placebo|2.0 mL subcutaneous injections without autologous myelin reactive T cells
3316014|NCT00245570|Experimental|1|Montelukast - Salmeterol - Placebo
3316015|NCT00245570|Experimental|2|Montelukast - Placebo - Salmeterol
3316016|NCT00245570|Experimental|3|Salmeterol - Montelukast - Placebo
3316017|NCT00245570|Experimental|4|Salmeterol - Placebo - Montelukast
3316018|NCT00245570|Experimental|5|Placebo - Montelukast - Salmeterol
3316019|NCT00245570|Experimental|6|Placebo - Salmeterol - Montelukast
3316020|NCT00245557|No Intervention|Healthy Controls|Healthy Controls undergo MRI and neuropsychological testing
3316021|NCT00245557|Experimental|Depressed|Depressed subjects receive experimental drug
3316022|NCT00245531||+IDU/+HIV or -HIV|
3316023|NCT00245531||-IDU and -HIV (controls)|
3316024|NCT00245518|Experimental|Isoflavone|Isoflavone
3316025|NCT00245518|Placebo Comparator|Placebo|
3316026|NCT00245492|Experimental|1|Chromocolonoscopy
3316027|NCT00245479|Other|1|
3316028|NCT00245466|Experimental|Degarelix 80/80 + 40|In the main study (FE200486 CS02; NCT00819247) loading doses of degarelix 80 mg were given on Days 0 and 3. Maintenance doses of 40 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
3316029|NCT00245466|Experimental|Degarelix 40/40 + 40|In the main study (FE200486 CS02; NCT00819247) loading doses of degarelix 40 mg were given on Days 0 and 3. Maintenance doses of 40 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
3316030|NCT00245466|Experimental|Degarelix 80 + 20|In the main study (FE200486 CS02; NCT00819247) one loading dose of degarelix 80 mg was given on Days 0. Maintenance doses of 20 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
3316031|NCT00245453|Active Comparator|1 Azithromycin|
3316032|NCT00245453|Active Comparator|2 Clarythromycin|
3316033|NCT00245453|Active Comparator|3 Telithromycin|
3316034|NCT00245440|Active Comparator|1|Subjects assigned Azithromycin
3316035|NCT00245440|Active Comparator|2|Subjects assigned Telithromycin
3316036|NCT00245427|Other|1 All macrolide antibiotics|
3316037|NCT00245427|Other|2 All beta lactam antibiotics|
3316038|NCT00245414|Experimental|1|Interferon (IFN)-Treated
3316039|NCT00245414|Experimental|2|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is positive at week 1
3316040|NCT00245414|Experimental|3|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is negative at week 1
3316041|NCT00245414|Experimental|4|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is negative at week 1
3316042|NCT00245349||FLT|Study group receiving FLT for imaging
3316043|NCT00245336|Experimental|1|rThrombin
3316044|NCT00245336|Active Comparator|2|bThrombin
3316045|NCT00245271|Experimental|1|OMS103 Irrigation Solution
3316046|NCT00245271|Placebo Comparator|2|Balanced Salt Solution (BSS)
3316047|NCT00245219|No Intervention|Health Tracking (control)|Participants assigned to the health-tracking condition received usual care and did not attend any meetings.
3316048|NCT00245219|Experimental|Peer support|The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another. Patients completed a weekly diary of critical experiences or current life problems as homework, and were then encouraged to share these experiences in the group meetings. The group facilitator encouraged participants to help one another with these issues, and share how they had dealt with similar problems.
3316049|NCT00245219|Experimental|Education|The education group meetings focused on providing patients with information about their disease as well as methods to manage their illness and its side effects. Facilitators emphasized the theme of perceived control during all sessions, discussing how participants are in control of their illness experience and can have more control of their lives. A different topic was addressed in each session. Weekly homework assignments asked patients to write down something new they had learned from the session regarding how to take control of their lives. Meeting topics were as follows: Overview of breast cancer, treatment types and side effects, nutrition and diet management, exercise, body image, communication issues, relationships, and sexuality.
3316050|NCT00245206|Experimental|1|Participants will take risperidal
3316051|NCT00245206|Experimental|3|Participants will take aripiprazole
3316052|NCT00245206|Experimental|4|Participants will take olanzapine
3316053|NCT00245180|No Intervention|control|Primary and secondary data collected as in intervention arm. Dental screenings will be done once a year as a service.
3316054|NCT00245154|Experimental|Arm I|Patients receive oral cediranib maleate once daily in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment with paclitaxel and carboplatin repeats every 21 days for 6-8 courses in the absence of disease progression or unacceptable toxicity.
3316055|NCT00245154|Active Comparator|Arm II|Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel and carboplatin as in arm I.
3316056|NCT00245102|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3316057|NCT00245063|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 28 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3316058|NCT00245050|Experimental|Pyridoxine|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine 100 mg twice daily on days 1-28.
3316059|NCT00245050|Placebo Comparator|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo twice 100 mg daily on days 1-28.
3316060|NCT00245037|Experimental|Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)|Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
3316061|NCT00245011|Experimental|Samarium-153|Cytoxan+Ifosfamide, Filgrastim pre samarium.'Sm-EDTMP (low dose). once counts recover, Sm-EDTMP (high dose) given. Peripheral blood stem cell transplantation is done 14 days later.
3316062|NCT00244985|Experimental|Arm 1: Rituximab and Doxorubicin HCI Liposome|Patients receive rituximab IV over 3-8 hours on day 1 and doxorubicin HCl liposome IV over 1-3 hours on day 3
3316063|NCT00244972|Experimental|Treatment (sorafenib tosylate, tipifarnib)|Patients receive sorafenib tosylate PO QD or BID on days 1-28 and tipifarnib PO QD or BID on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients may be allowed to continue the treatment after the 12 courses if there is continued clinical response or disease stabilization, and patients do not have significant toxicities.
3316064|NCT00244959|Experimental|Anastrozole|Anastrozole (1mg, orally, daily) for 12 months as adjuvant therapy for breast cancer
3316065|NCT00244946|Experimental|Autologous lymphocytes,carmustine,etoposide, melphalan, PBSCT|"minus Day 8 ADMIT for Hydration~minus Day 7 Carmustine 300 mg/m2 x 1 dose~minus Day 6 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 5 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 4 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 3 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 2 Melphalan 140 mg/m2 x 1 dose~minus Day 1 Day of Rest~Day 0 Transplant"
3316066|NCT00244933|Experimental|Gemcitabine, genistein (Novasoy), Tumor biopsy|Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
3316067|NCT00244907|Active Comparator|Genistein vs. Risedronate|Healthy post menopausal women who have been dosed with Ca41. Intervention, 100 mg Gensitein from soy protein isolate for 50 days. After a 50 day washout risedronate (Actonel- 5mg per day) for 50 days
3316068|NCT00244907|Active Comparator|Genistein dose and source|Healthy post menopausal women will consume 5 products containing varying quantities of genistein from different sources for 50 days each in a randomized order. Each intervention period is separated by a 50 day washout period. Intervention: A) 50 mg genistein from soy protein isolate, B) 100 mg genistein from soy protein isolate, C)50 mg genistein from Novasoy, D) 100 mg genistein from Novasoy, E) 100 ng genistein from 50% Novasoy and 50% soy protein isolate
3316069|NCT00244881|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3316070|NCT00244855|Other|No previous treatment|Patients received no previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
3316071|NCT00244855|Other|Previous treatment|Patients received previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
3316072|NCT00244842|Placebo Comparator|1|
3316073|NCT00244842|Active Comparator|2|
3316074|NCT00244842|Active Comparator|3|
3316075|NCT00244842|Active Comparator|4|
3316076|NCT00244803||HIV Positive FRAM 1 Participant|
3316077|NCT00244790|Experimental|low protein|
3316078|NCT00244764|Experimental|Pazopanib|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
3316079|NCT00244764|Placebo Comparator|Placebo|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
3316080|NCT00244751|Experimental|GI262570 0.5 mg|Participants received GI262570 0.5 milligrams (mg) tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.
3316081|NCT00244751|Experimental|GI262570 1.0 mg|Participants received GI262570 1.0 mg tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.
3316082|NCT00244751|Placebo Comparator|Placebo|Participants received matching placebo tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.
3316083|NCT00244738|Active Comparator|Intervention|Patients who received castor oil for labor induction
3316084|NCT00244738|Placebo Comparator|Control|Patients who received sunflower oil as a placebo
3316085|NCT00244712|Experimental|ABC/3TC|The intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo +lopinavir/ritonavir.
3316086|NCT00244712|Active Comparator|TDF/FTC|The intervention is a regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
3316087|NCT00244621|Experimental|1|0.05 mg/kg Atacand oral liquid dose
3316088|NCT00244621|Experimental|2|0.20 mg /kg Atacand oral liquid dose
3316089|NCT00244621|Experimental|3|0.40 mg /kg Atacand oral liquid dose
3316090|NCT00244517|Active Comparator|I|Isoflurane (only in part I)
3316091|NCT00244517|Active Comparator|II|Sevoflurane
3316092|NCT00244517|Active Comparator|III|Desflurane
3316093|NCT00244504|Active Comparator|I|moxonidine group
3316094|NCT00244504|Placebo Comparator|II|placebo group
3316095|NCT00244478|Experimental|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
3316096|NCT00244478|Placebo Comparator|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
3316097|NCT00244439|Experimental|1|MALG
3316098|NCT00244439|Active Comparator|2|Ovide
3316099|NCT00244439|Active Comparator|3|Permethrin 1%
3316100|NCT00244426|Experimental|1|
3316101|NCT00244426|Active Comparator|2|
3316102|NCT00244374|Experimental|AIC, Hepatitis A & B vaccine|Subjects randomized to a public health department clinic, the Adult Immunization Clinic (AIC), for administration of viral hepatitis immunizations at Month 1, 2, 6.
3316103|NCT00244374|Experimental|AIC, Outreach, Hepatitis A & B vaccine|AIC + outreach: Subjects randomized to a public health department clinic, the Adult Immunization Clinic (AIC)) for administration of viral hepatitis immunizations at Month 1, 2, 6, plus outreach worker adherence support to receive all immunizations
3316104|NCT00244374|Experimental|SEP, Hepatitis A & B vaccine|SEP only: Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6.
3316105|NCT00244374|Experimental|SEP, Outreach, Hepatitis A & B vaccine|Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6, plus outreach worker adherence support to receive all immunizations
3316106|NCT00244335||1|PTSD Subjects
3316107|NCT00244335||2|Trauma Controls: subjects who have experienced a trauma but never developed PTSD
3316108|NCT00244270|Experimental|1|totally implantable vascular access device
3316109|NCT00244257|Experimental|1|Cohort 1
3316110|NCT00244257|Experimental|2|Cohort 2
3316111|NCT00244257|Experimental|3|Cohort 3
3316112|NCT00244257|Experimental|4|Cohort 4
3316113|NCT00244257|Experimental|5|Cohort 5
3316114|NCT00244140|Experimental|Iopromide 370 mg I/mL|Iopromide (Ultravist 370 mg I/mL) administered intravenously
3316115|NCT00244140|Experimental|Iopromide 300 mg I/mL|Iopromide (Ultravist 300 mg I/mL) administered intravenously
3316116|NCT00244114||A|
3316117|NCT00244114||B|
3316118|NCT00244101|Active Comparator|PS Group|Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
3316119|NCT00244101|Experimental|NCPAP Group|Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
3316120|NCT00244101|Experimental|ISX Group|Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
3316121|NCT00244075|Active Comparator|1|nutrition supplementation, recombinant human growth hormone, and exercise
3316122|NCT00244075|Active Comparator|2|nutrition supplementation only
3316123|NCT00244049|Experimental|Brief clinician advice|
3316124|NCT00244023|Experimental|1|Testosterone gel (intervention)
3316125|NCT00244023|Placebo Comparator|2|one sachet of placebo gel once a day, possibly titrated to 2 sachets if insufficient efficacy
3316126|NCT00244010|Other|1|
3316127|NCT00243997|Active Comparator|1|Subjects receiving the Becoming Parents Program
3316128|NCT00243997|Placebo Comparator|2|Subjects not receiving the Becoming Parents Program
3316129|NCT00243932|Experimental|2,700 mg CoQ10|
3316130|NCT00243932|Placebo Comparator|placebo|
3316131|NCT00243932|Experimental|1,800 mg CoQ10|
3316132|NCT00243919|Active Comparator|Early Locomotor Training Program|body weight supported training program with treadmill
3316133|NCT00243919|Active Comparator|Late Locomotor Training Program|body weight supported training program with treadmill
3316134|NCT00243919|Active Comparator|Early Home Exercise Program|a non-specific low intensity exercise program
3316135|NCT00243893|Active Comparator|Brain AVMs|This trial is to investigate the use of minocycline or doxycycline as medical therapy, can minocycline or doxycycline induce biologically significant changes in the enzyme system thought to be related to spontaneous growth/rupture of these malformations. Finally, can patients safely tolerate these medications over an extended period of time.
3316136|NCT00243893|Active Comparator|Aneurysms|
3316137|NCT00243880|Experimental|lovastatin|lovastatin at escalating dosages: 1 mg/kg/day, 3 mg/kg/day, 6 mg/kg/day, 8 mg/kg/day, 10 mg/kg/day
3316138|NCT00243867|Experimental|Arm A|(Taxoprexin® + carboplatin)
3316139|NCT00243867|Active Comparator|Arm B- Paclitaxel and carboplatin|(Paclitaxel and carboplatin)
3316140|NCT00243841|Experimental|Radiation Treatment Arm :A|Patients with a score of Childs A Will receive 3 fractions of radiation over 5-10 days
3316141|NCT00243841|Experimental|Radiation Treatment Arm: B|Patients with a score of Childs B will receive 5 fractions of radiation over 2-6 weeks.
3316142|NCT00243789|Active Comparator|1|Pentoxifylline
3316143|NCT00243789|No Intervention|2|Placebo
3316144|NCT00243685|Experimental|II and III|
3316145|NCT00243659|Experimental|A|
3316146|NCT00243659|Experimental|B|
3316147|NCT00243646|Active Comparator|no hormones|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant with no hormones
3316148|NCT00243646|Active Comparator|9 months of hormone therapy|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant with a 9 month course of hormone therapy
3316149|NCT00243607|Experimental|immediate treatment group (SBG)|immediate start of hydrotherapy (self treatment) in immediate treatment group (SBG)
3316150|NCT00243607|No Intervention|waiting group (WG)|start of hydrotherapy (self treatment) after waiting period of 12 weeks
3316151|NCT00243529|Active Comparator|MHC Class I restricted epitopes|HLA-A2.1 patients are vaccinated with dendritic cells loaded with MHC Class I restricted epitopes of tumor antigens gp100 and tyrosinase
3316152|NCT00243529|Experimental|MHC Class I and II restricted epitopes|HLA-A2.1 and HLA-DR4 patients are vaccinated with dendritic cells loaded with MHC Class I and II restricted epitopes of tumor antigens gp100 and tyrosinase
3316153|NCT00243529|Experimental|mRNA transfected DC|HLA-A2.1 and/or HLA-DR4 patients are vaccinated with dendritic cells transfected with mRNA encoding tumor antigens gp100 and tyrosinase
3316154|NCT00243503|Experimental|A|
3316155|NCT00243477|Active Comparator|Treatment|Escitalopram given
3316156|NCT00243477|Placebo Comparator|Placebo|Placebo given
3316157|NCT00243438||1|Patients who have received a Vision stent and who have diabetes and/or complex lesions.
3316158|NCT00243412|Experimental|Arm A: 500 mg Rituximab|"Rituximab: 1000 mg intravenous (IV) on Days 1 and 15 of the first cycle; 500 mg IV on Days 1 and 15 of each subsequent 6-month cycle (Months 6, 12, and 18).~Corticosteroids: 100 mg IV methylprednisolone prior to each rituximab infusion.~Methotrexate: 15-25 mg/wk oral or parenteral (10-14 mg/wk if intolerant).~Folate: Minimum of 1 mg/day (or folinic acid 5 mg/wk)."
3316196|NCT00242710|Active Comparator|Arm 3|CE 0.45mg/MPA1.5mg
3316159|NCT00243412|Experimental|Arm B: 1000 mg Rituximab|"Rituximab: 1000 mg IV on Days 1 and 15 of each 12-month cycle (Rituximab cycles were administered at baseline and Month 12.) For the Month 6 and 18 cycles, rituximab or placebo was administered.~Corticosteroids: 100 mg IV methylprednisolone prior to each rituximab infusion For the Months 6 and 18 cycles, IV saline was administered prior to each rituximab or placebo infusion.~Methotrexate: 15-25 mg/wk oral or parenteral (10-14 mg/wk if intolerant).~Folate: Minimum of 1 mg/day (or folinic acid 5 mg/wk)."
3316160|NCT00243399|Experimental|Oxandrolone|
3316161|NCT00243386|Active Comparator|1|Standard prophylaxis
3316162|NCT00243386|Experimental|2|PK-driven prophylaxis
3316163|NCT00243334|Experimental|1|Decision Support integrated with Order Entry
3316164|NCT00243334|No Intervention|2|Decision Support Only (not integrated with order entry)
3316165|NCT00243321|Experimental|HDR brachytherapy -> IMRT|Radiotherapy
3316166|NCT00243282|No Intervention|1|Control (Support Group)
3316167|NCT00243282|Other|2|Intervention (Mindfulness Based Breathing Therapy)
3316168|NCT00243269|Sham Comparator|1|Expectancy neutral handout and expectancy neutral tape
3316169|NCT00243269|Experimental|2|Expectancy enhancing handout and expectancy neutral tape
3316170|NCT00243269|Experimental|3|Expectancy neutral handout and expectancy enhancing tape
3316171|NCT00243269|Experimental|4|Expectancy enhancing handout and expectancy enhancing tape
3316172|NCT00243243|Experimental|rFVIIa|intravenous administration of rFVIIa (Novoseven; 90 micrograms/kg, IV push, given at start of first surgical incision and again at 1 hr after start of surgery)
3316173|NCT00243243|Placebo Comparator|Control|intravenous administration of placebo (sterile water, IV push, given at first surgical incision and again at 1 hr after start of surgery)
3316174|NCT00243230|Experimental|Vicriviroc 20 mg|
3316175|NCT00243230|Experimental|Vicriviroc 30 mg|
3316176|NCT00243230|Placebo Comparator|Placebo|
3316177|NCT00243191|Other|imatinib mesylate|
3316178|NCT00243152|Active Comparator|Lamotrigine|The drug lamotrigine or placebo will be given for 9 weeks prior to imaging session 1. A rescue drug, Gabapentin, will be provided during both arms of the study for pain control. Patients will taper off the Gabapentin 2 weeks before each scan date. After a taper and washout period lamotrigine or placebo (cross over) will be administered. At the end of the trial (after imaging session 2), a taper for drug/placebo will be given. Patients will be required to maintain a pain diary during the study, documenting the perceived effects of the drug on the severity of their pain and keeping track of their subjective pain ratings day to day. Patients will also complete the McGill Pain Questionnaire at each visit.
3316179|NCT00243126|Experimental|Family-Based Risk Reduction Intervention|The intervention will be delivered in five, two-hour, small group sessions, across five weeks (group will meet once per week). Each of the 5 modules consists of 3 sessions: a one-hour session for the daughters meeting together with each other, a one-hour session for the mothers meeting together with each other; and a one-hour session in which the daughters and mothers meet together. Therefore, each week, the daughters will meet as a group for one hour of each module, while the mothers meet as a group for one hour, and for one hour the mothers and daughters will all meet together.
3316180|NCT00243126|No Intervention|No Treatment Control Group Condition|A no treatment control group condition will be utilized for this preliminary feasibility study. Participants in this condition, both mothers and adolescents will be assessed at baseline, immediate post-intervention, at 3-month follow-up and at 6-month follow-up.
3316181|NCT00243100|Experimental|Arm I|"Patients receive oral vorinostat (SAHA) once daily on days 1-14 and gemcitabine IV over 1-2 hours on days 3 and 10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA and gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD"
3316182|NCT00243074|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3316183|NCT00243061|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3316184|NCT00243035|Experimental|Treatment (bortezomib, tipifarnib)|"Phase I: Patients receive bortezomib IV on days 1, 4, 8, and 11 and oral tipifarnib twice daily on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tipifarnib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.~Phase II: Patients receive bortezomib as in phase I and tipifarnib as in phase I at the MTD."
3316185|NCT00243022|Experimental|Arm I (intervention)|Patients receive oral Boswellia serrata extract 4 times a day and oral cyanocobalamin (vitamin B 12) once a day for 6 months in the absence of unacceptable toxicity.
3316186|NCT00243022|Active Comparator|Arm II (control)|Patients in the control arm receive oral cyanocobalamin (vitamin B 12) once a day for 6 months.
3316187|NCT00242944|Active Comparator|1|Pitavastatin
3316188|NCT00242944|Active Comparator|2|Atorvastatin
3316189|NCT00242931|Experimental|Fludarabine, TBI, Cyclosporine, MMF|"Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0 For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop~For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181."
3316190|NCT00242892|Experimental|1|Intra coronary measures of pressure
3316191|NCT00242866|Experimental|Arm 1|GW274150 - 5mg or 30mg
3316192|NCT00242866|Placebo Comparator|Arm 2|Placebo to match GW274150
3316193|NCT00242723||1/Cohort 1|Subjects with potentially malignant or suspicious lesions, or biopsy proven thoracic cancers or thoracic metastases from cancers of non-thoracic origin
3316194|NCT00242710|Experimental|1|BZA 20mg/CE 0.625
3316197|NCT00242710|Placebo Comparator|Arm 4|Placebo
3316198|NCT00242684||Group 1|older patients admitted to a TCU unit
3316199|NCT00242658|Experimental|Tailored Physical Activity Intervention Group|Four feedback reports aimed to increase physical activity.
3316200|NCT00242658|No Intervention|No Tailored Physical Activity Intervention Group|General reports on preventive screening based on responses to preventive screening questions.
3316201|NCT00242632|Experimental|ApoE Non-Carriers|Subjects in this group did not carry the apolipoprotein E-epsilon 4 (apoE-e4) allele. During week 1 of the study, subjects were administered 5 mg of namenda once daily. During week 2 of the study, subjects were administered 5 mg of namenda in the morning and 5 mg in the evening (10 mg/day). During week 3 of the study, subjects were administered 10 mg in the morning and 5 mg in the evening (15 mg/day). During week 4 of the study, subjects were administered 10 mg in the morning and 10 mg in the evening (20 mg/day).
3316202|NCT00242632|Experimental|ApoE Carriers|Subjects in this group carried the apolipoprotein E-epsilon 4 (apoE-e4) allele. During week 1 of the study, subjects were administered 5 mg of namenda once daily. During week 2 of the study, subjects were administered 5 mg of namenda in the morning and 5 mg in the evening (10 mg/day). During week 3 of the study, subjects were administered 10 mg in the morning and 5 mg in the evening (15 mg/day). During week 4 of the study, subjects were administered 10 mg in the morning and 10 mg in the evening (20 mg/day).
3316203|NCT00242619|Experimental|Rosiglitzone|This group includes all 12 subjects who received rosiglitazone. Rosiglitazone was administered in addition to current antidepressant and/or mood-stabilizing medication at a dose of 4 mg/day for the first 4 weeks, with subsequent increase in dose to 9 mg/day for the remaining 8 weeks of the 12-week trial.
3316204|NCT00242606|Active Comparator|1|Levetiracetam 2000mg/day
3316205|NCT00242606|Active Comparator|2|Lamotrigine
3316206|NCT00242593|Experimental|A|oral rosiglitazone 4 mg twice daily for 18 months
3316207|NCT00242593|Placebo Comparator|B|placebo pill twice daily for 18 months
3316208|NCT00242580|Experimental|Verteporfin and Triamcinolone 1 mg|Participants received Verteporfin photodynamic therapy and 1 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 1 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
3316209|NCT00242580|Experimental|Verteporfin and Triamcinolone 4 mg|Participants received Verteporfin photodynamic therapy and 4 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 4 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
3316210|NCT00242580|Active Comparator|Verteporfin and Pegaptanib|Participants received Verteporfin photodynamic therapy and 0.3 mg Pegaptanib at the baseline visit. After the baseline visit, these participants received pegaptanib every 1.5 months up until and including the 10.5 month visit. After the baseline visit, these participants also received verteporfin at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. Starting from Month 12, if participants experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigator's discretion with available standard of care therapy.
3316211|NCT00242567|Experimental|Early Group|Zoledronic acid 4 mg i.v. infusion every 4 weeks, commencing at Baseline.
3316212|NCT00242567|Experimental|Delayed group|Zoledronic acid 4 mg i.v. infusion every 4 weeks, commencing no sooner than 12 months after their baseline visit, and not until they have had three rises in PSA level from Baseline, one of which must be a least 10 ng/mL greater than the baseline Serum Prostate-specific Antigen (PSA) level.
3316213|NCT00242541|Experimental|Octreotide acetate|
3316214|NCT00242502|Experimental|Bevacizumab + Erlotinib|Bevacizumab 10 mg/kg intravenous every 14 days, repeat cycle every 28 days; Erlotinib 150 mg orally every day continuous dosing.
3316215|NCT00242463|Experimental|nandrolone|Patients receive weekly injections of nandrolone
3316216|NCT00242463|Placebo Comparator|Placebo|
3316217|NCT00242424|Placebo Comparator|1|0.25 ml normal saline placebo given as injection to infants at 2 and 3 months of age
3316218|NCT00242424|Experimental|2|2005-6 Fluzone, pediatric formulation of trivalent inactivated influenza vaccine (sanofi pasteur) administered to infants at 2 and 3 months of age
3316219|NCT00242385|Experimental|ARALAST Fr. IV-1|60 mg/kg
3316220|NCT00242385|Active Comparator|ARALAST|60mg/kg
3316221|NCT00242320|Active Comparator|1|Roflumilast 500 µg
3316222|NCT00242320|Placebo Comparator|2|Placebo
3316223|NCT00242216|Active Comparator|Atazanavir oral once daily|HIV treatment
3316224|NCT00242216|Active Comparator|Fosamprenavir oral once daily|HIV treatment
3316225|NCT00242203|Experimental|Zometa|"Zometa 4 mg IV every 3 weeks for a total of 17 doses. The first treatment will be given at the time of the first chemotherapy treatment and will continue for approximately 1 year.~Neoadjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Docetaxel 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Surgery - modified radical mastectomy or breast conserving surgery with axillary lymph node dissection~Adjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 2 cycles~Docetaxel 75 mg/m2 IV every 21 days for 2 cycles~All patients who are found to be Her-2 overexpressing by 3+ by ICH for FSH will receive trastuzumab 6 mg/kg IV every 3 weeks for 1 year post surgery~Radiation therapy - 50-60 Gy in 1.8-2.0 Gy daily fractions to the breast or chest wall. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks"
3316255|NCT00241644|Experimental|Rotarix 3-Dose Group|Subjects received 3 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.
3316256|NCT00241644|Experimental|Rotarix 2-Dose Group|Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.
3316257|NCT00241644|Placebo Comparator|Placebo Group|Subjects received 3 doses of placebo given concomitantly with routine EPI vaccines.
3316258|NCT00241631|Active Comparator|1|
3316226|NCT00242203|Active Comparator|No Zometa|"Neoadjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Docetaxel 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Surgery - modified radical mastectomy or breast conserving surgery with axillary lymph node dissection~Adjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 2 cycles~Docetaxel 75 mg/m2 IV every 21 days for 2 cycles~All patients who are found to be Her-2 overexpressing by 3+ by ICH for FSH will receive trastuzumab 6 mg/kg IV every 3 weeks for 1 year post surgery~Radiation therapy - 50-60 Gy in 1.8-2.0 Gy daily fractions to the breast or chest wall. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks"
3316227|NCT00242112|Other|MRI - pathology|
3316228|NCT00241969|Experimental|Behavioral and Nutrition Treatment|The behavioral and nutrition treatment combines individualized nutritional counseling that targeted increasing energy and fat intake and parent training in behavioral child-management skills based on social learning theory to improve meal-time behaviors.
3316229|NCT00241969|Active Comparator|Education and Attention Control|The education and attention control treatment provides education and served as a behavioral placebo in terms of controlling for attention and contact frequency provided. Families are provided with information including general nutrition, enzyme therapy, respiratory infection control, and typical child development anticipatory guidance and safety for preschool- aged children.
3316230|NCT00241917|Experimental|Video|
3316231|NCT00241917|No Intervention|Control|
3316232|NCT00241904|Active Comparator|Comprehensive Intervention Group|The NP/CHW intervention focused on behavioral interventions to affect therapeutic lifestyle changes and adherence to medications and appointments as well as the prescription and titration of medications for one year. The NP and CHW worked as a team. The NP oversaw the initial assessment and, in collaboration with the CHW, tailored the intervention plan, conducted the intervention including lifestyle modification counseling and medication titration and prescription, consulted with the physician, and supervised the CHW. Specific algorithms for drug treatment of hyperlipidemia, hypertension (HBP), hyperglycemia, ACE, and β-blocker therapy were developed for this study based on current guidelines and standards of care.
3316233|NCT00241904|Active Comparator|Less Intensive Intervention Group|Participants will receive usual care from their physicians and a Less Intensive (LI) intervention of feedback on cardiovascular disease (CVD) risk factors and guidelines to patients and their physicians. Patients and their providers in the received the results of baseline lipids, BP, and HbA1c along with the recommended goal levels and a pamphlet on controlling risk factors published by the American Heart Association. In addition, providers received copies of the AHA/ACC Guidelines for Secondary Prevention.
3316234|NCT00241891|Other|Healthy Lifestyle (Active Intervention)|Parents and children in this program which will participate in a series of consultations and activities focused on multiple healthy interventions including healthy eating, drinking, and physical activity. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on healthy eating, drinking, and physical activity. In addition, your child will receive information on developing healthy interpersonal and social skills.
3316235|NCT00241891|Other|Healthy Drinks (Active Intervention)|Parents and children in this program will participate in a series of consultations and activities focused on a single intervention, the effects of beverage choices on diet, general health and teeth health. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on beverages and health. In addition, your child will receive information on healthy nutrition, physical activity, and interpersonal and social skills.
3316236|NCT00241891|Other|Social and Leadership Skills (Control Intervention)|Parents and children in this program will participate in a series of consultations that are designed to help your child learn strategies to make and keep friends, to express feelings appropriately, and to successfully decrease conflicts that often occur at school among children. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on these friendship making strategies. In addition, your child will receive information on healthy nutrition and physical activity. There is o intervention with regards to healthy weight.
3316237|NCT00241878|Experimental|1|Teacher-Delivered Weight Control Intervention
3316238|NCT00241878|Other|2|Teacher-Delivered General Health Intervention
3316239|NCT00241852|Experimental|Behavioral Intervention: Asthma: It's a Family Affair|Separate student and parent intervention groups.
3316240|NCT00241852|Active Comparator|Behavioral Control Group|Students and parents participate in an education only control group
3316241|NCT00241839|Active Comparator|A|Chlorthalidone 25 mg and Potassium Chloride 40-50meq were given daily for 5 weeks before baseline visit for testing. After baseline testing was completed, Allopurinol 300mg daily was added for 8-10 weeks at which time testing was repeated.
3316242|NCT00241839|Placebo Comparator|B|Chlorthalidone 25 mg and Potassium Chloride 40-50meq were given daily for 5 weeks before baseline visit for testing. After baseline testing was completed, a Placebo,matched in appearance to Allopurinol, was added daily for 8-10 weeks, at which time testing was repeated.
3316243|NCT00241813|Active Comparator|Health Education Control Program (CTL)|Health Education Control Program (CTL)
3316244|NCT00241813|Experimental|Mindfulness Meditation|Mindfulness Meditation (MM) Program
3316245|NCT00241813|Experimental|Lifeskills|Lifeskills Program (LP)
3316246|NCT00241813|Experimental|MM plus LP|Mindfulness Meditation (MM) Program plus Lifeskills Program (LP)
3316247|NCT00241774||NSHS95 samples|In 1995, our study participants enrolled in the Nova Scotia Health Study (NSHS95). At the time of enrollment, epidemiologic data as well as blood samples were obtained. The participants have since been followed prospectively for a variety of health outcomes. We plan to assay stored blood samples collected in 1995 for markers of inflammation and link these results to existing epidemiologic and outcomes data, specifically the 7- year incidence of CAD events.
3316248|NCT00241748||1|Rhabdomyolysis Case Subjects
3316249|NCT00241748||2|Heart and Vascular Health Study statin users - control group 1
3316250|NCT00241748||3|Cardiovascular Health Study statin users - control group 2
3316251|NCT00241722|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally twice daily (BID) for 12 months.
3316252|NCT00241722|Placebo Comparator|Placebo|Placebo was administered orally BID for 12 months.
3316253|NCT00241670|Experimental|5-aminolevulinic acid|
3316254|NCT00241670|No Intervention|Conventional resection|
3316259|NCT00241631|Placebo Comparator|2|
3316260|NCT00241449|Active Comparator|1|Tamoxifen
3316261|NCT00241449|Experimental|2|Fulvestrant
3316262|NCT00241423|Experimental|Exenatide|Exenatide and the subject's current oral antidiabetic agent regimen
3316263|NCT00241423|Placebo Comparator|Placebo|Placebo and the subject's current oral antidiabetic agent regimen
3316264|NCT00241410|Experimental|1|4 consecutive groups, dose escalation
3316265|NCT00241410|Placebo Comparator|2|4 consecutive groups
3316266|NCT00241384|Active Comparator|Pd-103 with 20Gy External Beam|Pd-103 with 20Gy External Beam
3316267|NCT00241384|Active Comparator|Pd-103 alone|Pd-103 alone
3316268|NCT00241371|Experimental|Clofarabine|4 mg/m2 IV over 1 hour on days 1-5 of each 28 day cycle.
3316269|NCT00241358|Active Comparator|Subcutaneous (SC) Treatment Plan - Donor|"Day 1: Mobilization with 240 mcg/kg SC AMD3100 and leukopheresis~If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3."
3316270|NCT00241358|Experimental|Intravenous (IV) Treatment Plan - Donor|"Day -3: Mobilization with 80-480 mcg/kg/day IV AMD3100 and PK analysis~Day 1: Mobilization with 240 mcg/kg/day SC AMD3100 and leukopheresis~If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3."
3316271|NCT00241358|Other|Recipients|"Conditioning Regimen~Cyclophosphamide 60mg/kg/day on Days -3 and -2~TBI 550cGy on Day -1~GVHD prophylaxis~*Cyclosporin 3.0mg/kg/day beginning on Day -1 then tapered through Day +100~PBSC transplant on Day 0"
3316272|NCT00241345|Experimental|Group A|IV ganciclovir (5mg/kg every 12 hours for 7 days followed by 5mg/kg every 24 hours for 7 days. If CMV viral load <5000 copies/ml after 14 days then 5mg/kg every 24 hours for a total of 21 total days of therapy. If CMV viral load >5000/ml but less than index viral load after 14 days then 5mg/kg every 24 hours for a total of 28 total days of therapy. If CMV viral load >= index viral load after 14 days then 5mg/kg every 12 hours for 7 days. If repeat CMV viral load is <= the previous CMV viral load then 5mg/kg every 12 hours for an additional 7 days.
3316273|NCT00241345|Experimental|Group B|PO valganciclovir (900 mg every 12 hours for 7 days followed by 900 mg every 24 hours for 7 days. If CMV viral load <5000 copies/ml after 14 days then 900 mg every day until 21 total days of therapy. If CMV viral load >5000 copies/ml after 14 days but less than the index viral load then 900 mg every day until 28 total days of therapy. If CMV viral load >= the index viral load 900 mg every 12 hours for 7 days, if CMV viral load <= to previous viral load then 900 mg every 12 hours for another 7 days.
3316274|NCT00241280|Active Comparator|Control|etafilcon A contact lens being worn 7 days/6 nights.
3316275|NCT00241280|Experimental|Test|galyfilcon A contact lens being worn 7 days/6 nights.
3316276|NCT00241254|Experimental|1|Cyclophosphamide
3316277|NCT00241254|Active Comparator|2|Methylprednisolone
3316278|NCT00241228|Experimental|High Volume|ultra filtration : High volume : 70 ml/kg/h
3316279|NCT00241228|Active Comparator|Medium Volume|Ultra filtration : conventional volume : 35 ml/kg/h
3316280|NCT00241189|Experimental|Rapamycin|Patients take oral rapamycin 6 mg daily (and dose adjusted to keep a serum trough level of 5-15 ng/ml) for one year
3316281|NCT00241189|Active Comparator|Methotrexate|Methotrexate 20 mg taken orally weekly for one year
3316282|NCT00241176|Experimental|Aripiprazole|
3316283|NCT00241111|Other|Zometa|
3316284|NCT00241059|Experimental|EC-MPS arm|
3316285|NCT00241020|Experimental|Octreotide|
3316286|NCT00240994|Experimental|Alemtuzumab (Campath)|In this open-label, single-arm trial , participants will be administered a 0.3 mg/kg dose of alemtuzumab (Campath) intravenously one day prior to kidney transplantation and one day post kidney transplantation. Participants will then receive a maintenance immunosuppressive regimen of tacrolimus and mycophenolate mofetil (MMF) for 8 to 12 weeks, followed by sirolimus and MMF until 24 months post transplantation.
3316287|NCT00240981|Experimental|Treatment|
3316288|NCT00240981|Placebo Comparator|Placebo|
3316289|NCT00240968|Experimental|3|Subjects will receive a single 45 mcg IM dose of the influenza A/H5N1 virus vaccine.
3316290|NCT00240968|Experimental|4|Subjects will receive a single 90 mcg IM dose of the influenza A/H5N1 virus vaccine.
3316291|NCT00240968|Experimental|1|Subjects will receive a single 7.5 mcg IM dose of the influenza A/H5N1 virus vaccine.
3316292|NCT00240968|Experimental|2|Subjects will receive a single 15 mcg IM dose of the influenza A/H5N1 virus vaccine.
3316293|NCT00240877|Experimental|1|Monovalent vaccine prior to the release of the trivalent vaccine (FluMist).
3316294|NCT00240877|Placebo Comparator|2|Placebo
3316295|NCT00240864|Experimental|001|acetaminophen
3316296|NCT00240864|Experimental|002|ibuprofen
3316297|NCT00240864|Placebo Comparator|003|placebo
3316298|NCT00240851|Experimental|001|acetaminophen extended release
3316299|NCT00240825|Experimental|001|Acetaminophen
3316300|NCT00240825|Experimental|002|Ibuprofen
3316301|NCT00240825|Placebo Comparator|003|Placebo
3316302|NCT00240799|Experimental|001|acetaminophen extended release
3316303|NCT00240799|Placebo Comparator|002|placebo
3316304|NCT00240773|Experimental|001|acetaminophen 4 grams daily for 12 months
3316305|NCT00240773|Active Comparator|002|naproxen 750 mg daily for 12 months
3316306|NCT00240773|Experimental|003|acetaminophen 4 grams daily for six months
3316307|NCT00240773|Active Comparator|004|naproxen 750 mg daily for six months
3316308|NCT00240682|Experimental|cetuximab|cetuximab
3316309|NCT00240630|Placebo Comparator|Arm 1|placebo to match
3316310|NCT00240630|Experimental|Arm 2|Treximet (sumatriptan/naproxen sodium)
3316311|NCT00240617|Active Comparator|arm 1|Treximet (sumatriptan/naproxen sodium) formerly known as TREXIMA
3316312|NCT00240617|Placebo Comparator|arm 2|placebo to match
3316313|NCT00240565|Experimental|Arm 1|Participants underwent two phases of treatment: an initial DD, followed by a therapeutic dose. The one-day DD comprised a 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with 185 MBq (5.0 mCi) of I 131. After 7 to 14 days, the one-day therapeutic dose comprised a second 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with I 131 with an administered activity (MBq or mCi) determined from the dosimetry calculation.
3316351|NCT00240032|Active Comparator|Copaxone® with Zyrtec|
3316314|NCT00240539|Experimental|HBsAg(+) & HBeAg(-) 4-dose Group|Newborns of anti-hepatitis B surface antigen positive [HBsAg(+)] and hepatitis B envelope antigen negative [HBeAg(-)] mothers, who received 4 doses of Engerix™ in the primary study.
3316315|NCT00240539|Experimental|HBsAg(+) & HBeAg(+) 4-dose Group|Newborns of anti-hepatitis B surface antigen positive [HBsAg(+)] and hepatitis B envelope antigen positive [HBeAg(+)] mothers, who received 4 doses of Engerix™ in the primary study.
3316316|NCT00240539|Experimental|HBsAg(+) & HBeAg(+) 5-dose Group|Newborns of anti-hepatitis B surface antigen positive [HBsAg(+)] and hepatitis B envelope antigen positive [HBeAg(+)] mothers, who received 5 doses of Engerix™ in the primary study.
3316317|NCT00240539|Experimental|HBsAg(-) & HBeAg(-) 4-dose Group|Newborns of anti-hepatitis B surface antigen negative [HBsAg(-)] and hepatitis B envelope antigen negative [HBeAg(-)] mothers, who received 4 doses of Engerix™ in the primary study.
3316318|NCT00240526|Experimental|Engerix 4D + HBIg Group|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.
3316319|NCT00240526|Experimental|Engerix 3D + HBIg Group|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.
3316320|NCT00240526|Experimental|Engerix 4D|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.
3316321|NCT00240526|Experimental|Engerix 3D Group|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6.
3316322|NCT00240513|Active Comparator|Minocycline 3 mo|Minocycline 3 mo
3316323|NCT00240513|Experimental|Minocycline plus Tretinoin|Minocycline plus Tretinoin for 3 months
3316324|NCT00240500|Experimental|HBV-1 Group|neonates born to HBsAg+ and HBeAg+ mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
3316325|NCT00240500|Experimental|HBV-2 Group|neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
3316326|NCT00240500|Experimental|HBV-3 Group|neonates born to HBsAg+ and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
3316327|NCT00240500|Experimental|HBV-4 Group|neonates born to HBsAg+ and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
3316328|NCT00240500|Experimental|HBV-5 Group|neonates born to HBsAg- and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
3316329|NCT00240500|Experimental|HBV-6 Group|neonates born to HBsAg- and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
3316330|NCT00240487|Active Comparator|Nitric oxide first|Subjects will be randomized to receive Nitric Oxide (NO) immediately after study entry, given at 10 parts per million (ppm) for the first 4 hours of study participation. Blood gases will be monitored once an hour for 4 hours. After the first 4 hours of study participation, the nitric oxide (NO) will be turned off and subjects will receive no intervention (no nitric oxide) for the next 4 hours of study participation. During this time, all subjects will receive standard clinical are. Blood gases will be monitored once an hour for 4 hours.
3316331|NCT00240487|Active Comparator|Delayed nitric oxide|Subjects will be randomized to receive no intervention (no nitric oxide) for he first 4 hours of study participation. During this time, all subjects will receive standard clinical care. Blood gases will be monitored once an hour for 4 hours. After the first 4 hours of study participation, the nitric oxide will be turned on and subjects will receive 10 ppm of nitric oxide for the next 4 hours of study participation. Blood gases will be monitored once an hour for 4 hours.
3316332|NCT00240461|Active Comparator|1|200 mg COLD-fX Natural health products 2 times daily for six months
3316333|NCT00240461|Active Comparator|Arm 2|Arm 2 - 400 mg COLD FX Natural health product - 2 times daily for 6 months
3316334|NCT00240461|Placebo Comparator|3|Inactive crystalline substance. This is the placebo arm in which subject receive 200 mg of the placebo 2 times daily for 6 months. Placebo is an inactive crystalline substance.
3316335|NCT00240331|Experimental|Rosuvastatin 10mg|
3316336|NCT00240331|Placebo Comparator|Placebo|matching Placebo
3316337|NCT00240253|Active Comparator|Pramlintide|
3316338|NCT00240227|Other|Placebo|Placebo no active medication
3316339|NCT00240227|Active Comparator|prazosin|Prazosin flexible dose titration up to 12 mg per day.
3316340|NCT00240214||1|sirolimus
3316341|NCT00240188|Other|1|
3316342|NCT00240162|Experimental|PTK787/ZK 222584|Initially patients will receive a dose of 500mg (2, 250mg tablets) in the morning and 250mg (1, 250mg tablet) in the afternoon for 2 weeks (cycle 1, days 1-14), then 500mg (2, 250mg tablets) bid for 2 weeks (cycle 1, days 15-28) and finally 750mg (3, 250mg tablets) in the morning and 500mg (2, 250mg tablets) in the afternoon for the remainder of treatment duration (cycle 2, day 1 and onwards). Each 28 days of drug administration will constitute one cycle of therapy.
3316343|NCT00240110|Placebo Comparator|Lithium carbonate add on Placebo|Lithium carbonate started and stabilized then participants randomized to placebo
3316344|NCT00240110|Experimental|Lithium carbonate add on Valproate|Lithium carbonate started and stabilized then participants randomized to Valproate
3316345|NCT00240097|Experimental|Irinotecan; Oxaliplatin; Neulasta|Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
3316346|NCT00240097|Experimental|Etoposide; Carboplatin; Neulasta|Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) area under the concentration curve (AUC) 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
3316347|NCT00240084|Experimental|Nesiritide infusion|Single arm study. 24-hour infusion of B-type Natriuretic Peptide at a dose of 0.01 mcg/kg/minute.
3316348|NCT00240071|Experimental|Avastin|The patient will continue the same hormonal therapy used prior to study enrollment but will combine it with Avastin.
3316349|NCT00240058|Other|phenylephrine infusion with and without nitric oxide clamp|Participants received phenylephrine infusion with saline followed by phenylephrine infusion with nitric oxide clamp
3316350|NCT00240045|Experimental|1|
3321047|NCT00156195|Experimental|2|
3316352|NCT00240032|Experimental|Copaxone® with placebo|
3316353|NCT00240006|Experimental|1|Shared Solutions®
3316354|NCT00240006|Experimental|2|Shared Solutions® and MS Center/Office Practice Partnership
3316355|NCT00239993|Experimental|1|skin reactions with the use of warm compress prior to performing a Copaxone® injection
3316356|NCT00239993|Experimental|2|skin reactions without the use of warm compress prior to performing a Copaxone® injection
3316357|NCT00239980|Active Comparator|A|50 IU/kg
3316358|NCT00239980|Active Comparator|B|100 IU/kg
3316359|NCT00239980|Active Comparator|C|150 IU/kg
3316360|NCT00239928|Experimental|EYE001|
3316361|NCT00239837|Experimental|Middle School Success Intervention (MSS)|Middle School Success Intervention (MSS): Participants receive the preventative intervention
3316362|NCT00239837|No Intervention|Foster Care Services as Usual|Foster Care Services as Usual: Participants continue with usual foster care
3316363|NCT00239824|Experimental|1|Strength training of the pelvic floor muscles with follow up instructions by a physiotherapist
3316364|NCT00239824|Active Comparator|2|Strength training of the pelvic floor muscles without follow up instructions
3316365|NCT00239746|Experimental|1|
3316366|NCT00239746|Placebo Comparator|2|
3316367|NCT00239733|Experimental|1|Participants will be given anti-D in an outpatient setting. Participants will be observed for any adverse effects for 1 hour postinfusion. Some participants may require additional doses of anti-D later in the study, depending on individual response to the drug; participants may receive 1 to 6 doses of anti-D.
3316368|NCT00239720|Experimental|hOKT3gamma1 (Ala-Ala)|Escalating dose of hOKT3gamma1 (Ala-Ala) given intravenously over 5 days of each 28 day cycle
3316369|NCT00239720|Placebo Comparator|Placebo|Intravenous dose of placebo given over 5 days of each 28 day cycle
3316370|NCT00239707|Experimental|Infusion 1|Normal Saline
3316371|NCT00239707|Placebo Comparator|Infusion 2|GIP or modified GIP
3316372|NCT00239707|Placebo Comparator|Infusion 3|GIP or modified GIP, opposite of Infusion 2
3316373|NCT00239694|Experimental|1|Previously vaccinated
3316374|NCT00239694|Experimental|2|Never vaccinated
3316375|NCT00239681|Experimental|Rosuvastatin|Rosuvastatin 20 mg once daily
3316376|NCT00239681|Placebo Comparator|Placebo|Placebo once daily
3316377|NCT00239642|Experimental|Venofer (0.5 mg/kg)|0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
3316378|NCT00239642|Experimental|Venofer (1.0 mg/kg)|1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
3316379|NCT00239642|Experimental|Venofer (2.0 mg/kg)|2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
3316380|NCT00239564|Experimental|Experimental: carbidopa and levodopa|Subjects receive IPX054 100 mg, IPX054 150 mg, IPX054 200 mg, IPX054 250 mg, or IPX054 300 mg to achieve optimum dosage and dosing frequency as directed by the Investigator for 5 weeks.
3316381|NCT00239551|Experimental|Prevacid|Effect of Prevacid at 8 weeks; EGD(esophagogastroduodenal endoscopy) at day 1 & EGD at 8 weeks
3316382|NCT00239356|Experimental|AI|
3316383|NCT00239239|Experimental|test treatment period|
3316384|NCT00239226|Experimental|1. IAS pacing - study group|"Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (1) includes patients with Delta CTos >50 ms and randomized IAS pacing.~IAS Pacing -Study Group: Patients with Delta CTos >50 ms (study group) at the electrophysiologic study and randomized Interatrial Septum Pacing"
3316385|NCT00239226|Experimental|2. IAS pacing-control group|"(Delta CTos<50ms)~Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (2) includes patients with Delta CTos <50 ms and randomized IAS pacing.~IAS Pacing -Control Group: Patients with Delta CTos <50 ms (control group) at the electrophysiologic study and randomized Interatrial Septum Pacing"
3316386|NCT00239226|Active Comparator|3. RAA Pacing - study group|"Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (3) includes patients with Delta CTos >50 ms and randomized Right Atrial Appendage pacing.~RAA Pacing -Study Group: Patients with Delta CTos >50 ms (study group) at the electrophysiologic study and randomized Right Atrial Appendage pacing"
3316387|NCT00239226|Active Comparator|4. RAA Pacing - control group|"Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (4) includes patients with Delta CTos <50 ms and randomized Right Atrial Appendage pacing.~RAA Pacing -Control Group: Patients with Delta CTos <50 ms (control group) at the electrophysiologic study and randomized Right Atrial Appendage pacing"
3316388|NCT00239083|Experimental|EC-MPS|
3316389|NCT00239031|Experimental|1|
3316390|NCT00239005|Active Comparator|Mycophenolate Mofetil (MMF)|250 mg capsules or 500 mg tablets of mycophenolate mofetil. Daily dose decided by physician, was taken morning and evening.
3316391|NCT00239005|Experimental|Enteric-Coated Mycophenolate Sodium (EC-MPS )|Oral film-coated gastroresistant tablets containing 360mg or 180mg of mycophenolate sodium. Daily dose decided by the physician, was taken morning and evening.
3316392|NCT00238953|Experimental|EC MPS|
3316393|NCT00238914|Active Comparator|CE plus oral naltrexone|Compliance enhancement plus oral naltrexone
3316394|NCT00238914|Active Comparator|BNT plus oral naltrexone|Behavioral naltrexone therapy plus oral naltrexone
3316395|NCT00238888|Experimental|Asthma control awareness|Multifaceted intervention to increase the patient awareness of the leve of asthma control
3316396|NCT00238888|Active Comparator|Usual care|Usual care
3316397|NCT00238875|Experimental|1|Procedure/Surgery: stereotactic body radiation therapy
3316398|NCT00238667|Active Comparator|Anti-platelet therapy|Aspirin, Dipyridamole, clopidogrel alone or in dual therapy
3316399|NCT00238667|Active Comparator|Anti-coagulant|Warfarin, unfractionated heparin, enoxaparin, dalteparin, tinzaparin aiming for an INR in range of 2-3. Local protocols for Heparin can be used
3316430|NCT00237978|Active Comparator|2|VIS, wIRA and Adapalen
3316431|NCT00237978|Active Comparator|3|Adapalen
3316432|NCT00237926|Experimental|1|aerobic exercise
3316400|NCT00238615|Experimental|Chemotherapy+Radiation+Surgery|"Concurrent weekly docetaxel at 20 mg/m2 and weekly carboplatin at an AUC of 2 with thoracic radiotherapy of 180-200cGy/day for 5/7 days to 45 Gy.~Complete surgical excision 3-6 weeks after completion of chemoradiotherapy.~No Surgery if patient is deemed unable to tolerate surgery, with completion to 61 Gy radiation~Consolidation after surgery: Docetaxel given at 75 mg/m2 every 3 weeks with carboplatin at AUC 6 every 3 weeks with concomitant growth factor support."
3316401|NCT00238459||Recently infected patients|Cohort 1)Patients elcted to be immediately treated with licensed drugs:21 patients Cohort 2) Or to delay treatment until clinically indicated:16 patieints
3316402|NCT00238459||A vaccine,HIV-1 immunogen was not provided for evaluation|In the intial design, acandiate HIV vaccine was to be evaluated, but in August 2007 the manufacturer refused to provide vaccine to allow this study to evaluate the effect of a vaccine on control of HIV. Therefore the study became an observational study of the effects of early versus delayed initiation of antiretrovral therapy on the preservation of anti-HIV immune responses and the ability of patients to control virus after a closely monitored discontinuation of therapy.
3316403|NCT00238433|Experimental|Filgrastim/Melphalan/Thiotepa|"Biological/Vaccine: filgrastim~5mcg/kg intravenous piggyback (IVPB) will be administered beginning on day +5 and continued until absolute neutrophil count (ANC) > 1500 for 2 consecutive days.~Drug: busulfan~3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.~Drug: melphalan~50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.~Drug: thiotepa~250 mg/m2/day/iv on days -3 and -2 Procedure/Surgery: bone marrow ablation with stem cell support~The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.~Procedure/Surgery: peripheral blood stem cell transplantation~Performed 36-48 hours following last chemotherapy dose."
3316404|NCT00238420|Experimental|Group I (paclitaxel, trastuzumab, radiation therapy)|Patients receive paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, and 43 and trastuzumab IV over 90 minutes on day 1 and then over 30 minutes on days 8, 15, 22, 29, 36, and 43. Patients also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, 43-47, and 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
3316405|NCT00238420|Experimental|Group II (paclitaxel, radiation therapy)|Patients receive paclitaxel and undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, 43-47, and 50.
3316406|NCT00238407|Active Comparator|Arm I|Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71. Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
3316407|NCT00238394|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR. Patients experiencing disease progression within 5 years after completion of study treatment may receive additional courses of study treatment.
3316408|NCT00238381|Other|Arm I|Patients undergo total mesorectal excision (TME) by standard methods or laparoscopically and side-to-end anastomosis rectal reconstruction.
3316409|NCT00238381|Other|Arm II|Patients undergo TME and colon-J-pouch anastomosis rectal reconstruction.
3316410|NCT00238381|Other|Arm III|Patients undergo straight coloanal anastomosis with/without temporary protective ileostomy
3316411|NCT00238355|Experimental|Voriconazole plus Caspofungin|
3316412|NCT00238316|Active Comparator|Letrozole|
3316413|NCT00238316|Placebo Comparator|Placebo|
3316414|NCT00238303|Experimental|Stratum 1 (not undergoing surgery)|Patients receive oral vorinostat (SAHA) twice daily for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3316415|NCT00238303|Experimental|Stratum 2 (undergoing surgery)|Beginning 3 days prior to surgery, patients receive oral SAHA once or twice daily for a total of 6 doses. Patients then undergo surgery to remove the tumor. Beginning within 1-4 weeks after surgery, patients receive oral SAHA twice daily for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3316416|NCT00238290|Active Comparator|Arm A|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
3316417|NCT00238264|Experimental|Treatment (radiotherapy)|Patients undergo reduced-field conformal radiation therapy 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
3316418|NCT00238251|Active Comparator|Arm I|Patients undergo whole-brain radiotherapy (WBRT) once daily on days 1-5 and 8-12 and receive oral gefitinib once daily on days 1-28. Gefitinib treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity
3316419|NCT00238251|Active Comparator|Arm II|Patients undergo WBRT as in arm I and receive oral temozolomide once daily on days 1-21. Temozolomide treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity
3316420|NCT00238238|Active Comparator|Arm I - rituximab|Patients receive rituximab IV on days 1, 8, 15, and 22.
3316421|NCT00238238|Experimental|Arm II - lenalidomide|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3316422|NCT00238238|Experimental|Arm III - lenalidomide and rituximab|Patients receive lenalidomide as in arm II. Patients also receive rituximab IV on days 8, 15, 22 and 29.
3316423|NCT00238212|Experimental|Treatment|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3316424|NCT00238121|Experimental|Treatment|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3316425|NCT00238108|Experimental|1|Melatonin (2,5 mg, by mouth, 1 per day, for 3-4 weeks)
3316426|NCT00238108|Placebo Comparator|2|Placebo
3316427|NCT00238030|Active Comparator|po thyroxine|placebo is iv
3316428|NCT00238030|Active Comparator|iv thyroxine|placebo is po
3316429|NCT00237978|Active Comparator|1|VIS and wIRA
3316433|NCT00237926|Experimental|2|Resistance Training
3316434|NCT00237913|Active Comparator|A1|
3316435|NCT00237913|Active Comparator|B1|
3316436|NCT00237809|Experimental|Drug and control CRT|D-serine/control
3316437|NCT00237809|Experimental|Drug and CRT|D-serine/cog rehab
3316438|NCT00237809|Experimental|Placebo Drug and Placebo CRT|Placebo/control
3316439|NCT00237809|Experimental|Placebo Drug and CRT|Placebo/cog rehab
3316440|NCT00237796|Experimental|ARM 1|Cognitive Behavioral Social Skills Training (CBSST)
3316441|NCT00237796|Active Comparator|ARM 2|Goal Focused Supportive Contact (GFSC)
3316442|NCT00237783|Active Comparator|standard dialysate sodium (140 mmol/L)|dialysate sodium (140 mmol/L)
3316443|NCT00237783|Experimental|individualized dialysate sodium|individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
3316444|NCT00237770|Placebo Comparator|Arm 1|Placebo control (normal saline) is employed on a separate visit during procedure.
3316445|NCT00237757|Experimental|Arm 1|The experimental arm consisted of a six month staff training period with an emphasis on effective team functioning to improve patient outcomes. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing
3316446|NCT00237757|Active Comparator|Arm 2|The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
3316447|NCT00237744|Experimental|Wrist/Hand FES + Whole Arm Motor Learning|Subjects > 6 months following first stroke with diminished upper limb strength, coordination and function, who received whole arm motor learning training and FES of the wrist/hand.
3316448|NCT00237744|Experimental|Shoulder/Elbow Robotics + Whole Arm Motor Learning|Subjects>6 months following first stroke with diminished upper limb strength, coordination and function, who received whole arm motor learning and shoulder/elbow robotics.
3316449|NCT00237744|Experimental|Whole Arm Motor Learning|Subjects>6 months following first stroke with diminished upper limb strength, coordination and function who received whole arm motor learning training without addition of FES or Robotics
3316450|NCT00237731|Experimental|1|morphine 0.05
3316451|NCT00237731|Active Comparator|2|morphine 0.10
3316452|NCT00237718|Active Comparator|ALA and Vitamin E|600 mg (2 pills 300 mg each) of alpha lipoic acid (ALA) and 666 IU (1 pill) of alpha, gamma, beta and delta (mixed) tocopherols (Vitamin E) taken orally on a daily basis for 6 months
3316453|NCT00237718|Placebo Comparator|Placebo|placebo for ALA (2 pills) and for Vitamin E (1 pill) taken orally on a daily basis for 6 months
3316454|NCT00237692|No Intervention|Arm 1|Control group - a group of hypertensive patient who receive usual care
3316455|NCT00237692|Experimental|Arm 2|Nurse Behavioral intervention with Home BP Telemonitoring Nurse-administered tailored behavior intervention
3316456|NCT00237692|Experimental|Arm 3|Nurse Medication Management with Home BP Telemonitoring -- Nurse administer medication management according to hypertension decision support system
3316457|NCT00237692|Experimental|Arm 4|Nurse Combined intervention with Home BP Telemonitoring - Combination of the nurse administered tailored behavioral & medication management interventions
3316458|NCT00237679|Active Comparator|Neuromuscular Electrical Stimulation|Subjects will receice Neuromuscular Electrical Stimulation (NMES)-stimulated swallowing combined with exercise therapy.
3316459|NCT00237679|Sham Comparator|Unstimulated|Subjects will receive sham (unstimulated) swallow therapy combined with exercise therapy.
3316460|NCT00237666|Experimental|Ziprasidone|Ziprasidone monotherapy, 20-60 mg BID.
3316461|NCT00237640|Placebo Comparator|1|
3316462|NCT00237640|Active Comparator|2|
3316463|NCT00237627|Experimental|Part 1|Doxil + PS-341
3316464|NCT00237627|Experimental|Part 2|Doxil + Velcade
3316465|NCT00237601||1|Women with the intention to give birth at home
3316466|NCT00237601||2|Women with the intention to give birth in a short-stay hospital setting
3316467|NCT00237549|Experimental|Intervention|The 334 general practices in Denmark, United Kingdom and the Netherlands have been randomised to screening for diabetes followed by routine care (RC group) according to national guidelines, or screening followed by multifactorial treatment (IT group).
3316468|NCT00237497|Experimental|Ramelteon 8 mg QD|
3316469|NCT00237497|Active Comparator|Zopiclone 7.5 mg QD|
3316470|NCT00237497|Placebo Comparator|Placebo QD|
3316471|NCT00237484|Experimental|Arm A|Remicade induction dose at Day -7 prior to initiation of PEGETRON treatment for up to 48 weeks
3316472|NCT00237484|Active Comparator|Arm B|PEGETRON treatment for up to 48 weeks
3316473|NCT00237458|Experimental|Lacosamide|Open-label active treatment
3316474|NCT00237393|Experimental|1|Quetiapine
3316475|NCT00237393|Placebo Comparator|2|
3316476|NCT00237224|Experimental|FEM345|
3316477|NCT00237211|Experimental|Letrozole|
3316478|NCT00237198|Experimental|Letrozole|
3316479|NCT00237185|Experimental|imatinib mesylate 400 mg|400 mg once daily
3316480|NCT00237185|Experimental|imatinib mesylate 600 mg|600 mg once daily
3316481|NCT00237172|Experimental|Imatinib Mesylate|400 mg once daily
3316482|NCT00237159|Experimental|ZOL446|
3316483|NCT00237146|Experimental|Zoledronic Acid|
3316484|NCT00237133|Experimental|Letrozole|
3316485|NCT00237107|Experimental|curettage|
3316486|NCT00237042|Active Comparator|Self Management|Dental hygienist-delivered pain self-management treatment
3316487|NCT00237042|Experimental|Targeted Self Management|Dental hygienist-delivered pain self-management treatment with a focus on menstrual cycle-related changes in pain and other symptoms
3316488|NCT00237042|Experimental|Continuous Oral Contraceptives|"Oral contraceptive (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months with no spacer pills."
3316489|NCT00237003|Active Comparator|1) assessment plus motivational interview|Participants are assigned, in this 6 month study, to an assessment-only condition or an assessment plus motivational interview condition. Two motivational interview sessions are conducted during the first month of study participation.
3316490|NCT00236990|Experimental|001|pentosan polysulfate sodium
3316491|NCT00236977|Experimental|Venofer|iron sucrose injection
3316492|NCT00236977|Active Comparator|Ferrous Sulfate|oral iron
3316493|NCT00236951|Active Comparator|Venofer + erythropoietin (responders)|
3316494|NCT00236951|Active Comparator|erythropoietin only (responders)|
3316495|NCT00236951|Active Comparator|Venofer+erythropoietin(non-responders)|
3316496|NCT00236951|Active Comparator|erythropoietin only (non-responders)|
3316497|NCT00236938|Experimental|Group A|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
3316498|NCT00236938|Active Comparator|Group B|Stable erythropoietin (EPO) dose and no supplemental iron.
3316499|NCT00236925|Active Comparator|Low dose Hydrocortisone|Low Dose Hydrocortisone
3316500|NCT00236925|Placebo Comparator|Placebo|Placebo
3316501|NCT00236899|Experimental|A: Docetaxel and Gemcitabine (Tri-weekly)|Docetaxel and Gemcitabine (Tri-weekly)
3316502|NCT00236899|Experimental|B: Paclitaxel and Gemcitabine (Tri-weekly)|Paclitaxel and Gemcitabine (Tri-weekly)
3316503|NCT00236899|Experimental|C: Docetaxel and Gemcitabine (Weekly)|Docetaxel and Gemcitabine (Weekly)
3316504|NCT00236899|Experimental|D: Paclitaxel and Gemcitabine (Weekly)|Paclitaxel and Gemcitabine (Weekly)
3316505|NCT00236379|Experimental|001|Risperidone Target oral dose of 6 milligrams per day for for 6 months
3316506|NCT00236379|Experimental|002|Olanzapine Target oral dose of 20 milligrams per day for 6 months
3316507|NCT00236301|Active Comparator|1|17 Beta-estradiol (2mg/day)and (1mg/day)
3316508|NCT00236301|Active Comparator|2|CLIMASTON
3316509|NCT00236301|Placebo Comparator|3|placebo
3316510|NCT00236275|Experimental|1|Fluoro-L-thymidine-(18F)
3316511|NCT00236223|Experimental|1|
3316512|NCT00236223|Placebo Comparator|2|
3316513|NCT00236210|Active Comparator|VIP program|Risk assessment, lifestyle counselling, exercise program
3316514|NCT00236210|No Intervention|Standard Care|
3316515|NCT00236197|Experimental|1|
3316516|NCT00236197|Placebo Comparator|2|
3316517|NCT00236184|Placebo Comparator|Placebo|Oral placebo tablet
3316518|NCT00236184|Experimental|Rabeprazole sodium 10 mg|oral rabeprazole 10 mg enteric-coated tablet
3316519|NCT00236158|Other|AAIR|
3316520|NCT00236158|Other|DDDR|
3316521|NCT00236119|Experimental|CEP-701 20mg|Patient Cohort 1
3316522|NCT00236119|Experimental|CEP-701 40mg|Patient Cohort 2
3316523|NCT00236119|Experimental|CEP-701 60mg|Patient Cohort 3
3316524|NCT00236119|Experimental|CEP-701 80mg|Patient Cohort 4
3316525|NCT00236080|Experimental|1|PROVIGIL 200 mg/day
3316526|NCT00236080|Experimental|2|Armodafinil 250 mg/day
3316527|NCT00236080|Experimental|3|Armodafinil 200 mg/day
3316528|NCT00236080|Experimental|4|Armodafinil 150 mg/day
3316529|NCT00236080|Placebo Comparator|5|Placebo
3316530|NCT00236002|Placebo Comparator|placebo|
3316531|NCT00235989|Active Comparator|ET: IFNB-1b 250 mcg => 250 mcg|Extension Treatment 250 mcg continued
3316532|NCT00235989|Experimental|ET: IFNB-1b 500 mcg => 250 mcg|Extension Treatment 500 mcg reduced to 250 mcg
3316533|NCT00235989|Experimental|ET: IFNB-1b 500 mcg => 500 mcg|Extension Treatment 500 mcg continued
3316534|NCT00235989|Experimental|ET: IFNB-1b 250 mcg => 500 mcg|Extension Treatment 250 mcg increased to 500 mcg
3316535|NCT00235898|Experimental|1|CoFactor, 5-FU
3316536|NCT00235898|Active Comparator|2|Leucovorin, 5-FU
3316537|NCT00235872|Experimental|Adalimumab 40 mg every other week (eow)|
3316538|NCT00235846|Active Comparator|Conventional vein harvest|Conventional open vein harvest from the lower leg
3316539|NCT00235846|Experimental|Endoscopic vein harvest|Endoscopic vein harvest from the calf
3316540|NCT00235833|Experimental|Adalimumab 40 mg eow|
3316541|NCT00235820|Active Comparator|A|
3316542|NCT00235820|Active Comparator|B|
3316543|NCT00235820|Placebo Comparator|C|
3316544|NCT00235807|Other|1|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
3316545|NCT00235807|Other|2|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
3316546|NCT00235807|Other|3|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
3316547|NCT00235755|Placebo Comparator|Placebo|
3316548|NCT00235755|Experimental|Retigabine 600 mg|
3316549|NCT00235755|Experimental|Retigabine 900 mg|
3316550|NCT00235729|Experimental|1|Lofexidine 0.8 mg QID
3316551|NCT00235729|Placebo Comparator|2|Placebo QID
3316552|NCT00235716|Experimental|Arm 1|2,000 IU per day of dl-alpha-tocopherol plus placebo for memantine
3316553|NCT00235716|Experimental|Arm 2|20 mg per day of memantine plus placebo for dl-alpha-tocopherol
3316554|NCT00235716|Experimental|Arm 3|Combination of 2,000 IU per day of dl-alpha-tocopherol and 20 mg per day of memantine
3316555|NCT00235716|Placebo Comparator|Arm 4|Matching placebos for dl-alpha-tocopherol and memantine
3316556|NCT00235690|Other|blood draws|all patients enrolled will have PK blood samples obtained around a colistin dosing
3316557|NCT00235573|Experimental|Vitamin B12 supplement|After taking a fasting blood sample, all subjects were given a light breakfast plus 9 micrograms of vitamin B12. Two more doses of vitamin B12 were administered 6 hours apart.
3321048|NCT00156182|Experimental|1|
3316558|NCT00235547|Active Comparator|contraception-Immediate start|contraception after abortion and before leaving the clinic, observed by clinic staff
3316559|NCT00235547|Active Comparator|Contraception-Delayed start|instructed to begin contraception the first Sunday after leaving the clinic
3316560|NCT00235534|Experimental|Immediate start|Initiate selected birth control method before leaving the clinic at the time of the abortion procedure.
3316561|NCT00235534|Active Comparator|Sunday start|Begin birth control the first Sunday after leaving the clinic
3316562|NCT00235508|Active Comparator|1|Escitalopram oxalate 10 mg at bedtime
3316563|NCT00235508|Active Comparator|2|Eszopiclone 3 mg at bedtime
3316564|NCT00235495|Experimental|1|Treatment with 25% Albumin, 2.0 g/kg
3316565|NCT00235495|Placebo Comparator|2|Treatment with same volume of normal saline
3316566|NCT00235456|Active Comparator|80% perioperative oxygen|Perioperative supplemental oxygen: Patients were randomly assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
3316567|NCT00235456|Placebo Comparator|30% perioperative oxygen|Standard oxygen: Patients were randomly assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
3316568|NCT00235443|Experimental|1|Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day
3316569|NCT00235404|Experimental|Intermediate community hospital|
3316570|NCT00235404|Active Comparator|Usual care|
3316571|NCT00235391|Experimental|Deferasirox|Deferasirox was administered orally once a day, 30 minutes prior to breakfast. Dosage was based on participant's body weight. Starting dose was determined by the frequency of blood transfusions and recommended initial daily dose of deferasirox is 20 mg/kg body weight for patients receiving blood transfusion, 10 mg/kg for patients receiving less frequent transfusion/exchange transfusion and 30 mg/kg for patients receiving more frequent blood transfusions.
3316572|NCT00235378||1|SLE patients
3316573|NCT00235378||2|Unaffected family members of SLE patients
3316574|NCT00235378||3|Control participants
3316575|NCT00235365|Experimental|meta-cognitive therapy|meta-cognitive therapy
3316576|NCT00235365|Active Comparator|waiting list|waiting list control
3316577|NCT00235339|Active Comparator|1|Standard exercise training rehabilitation at the hospital
3316578|NCT00235339|Experimental|2|Interval exercise training on treadmills, with high intensity
3316579|NCT00235326||2|Unexposed to gastroenteritis
3316580|NCT00235326||1|Exposed to gastroenteritis
3316581|NCT00235313|Experimental|1|adaptation of the nicotine patch with salivary cotinine
3316582|NCT00235313|Other|2|normal following with a nicotine patch
3316583|NCT00235300|Active Comparator|1 Control|Simulect (basiliximab)
3316584|NCT00235300|Experimental|2|Thymoglobulin (anti-thymocyte globulin (rabbit))
3316585|NCT00235287|Active Comparator|A,AIIA|24 weeks of treatment with Candesartan, where Enalapril is added in the last 8 weeks.
3316586|NCT00235287|Active Comparator|A, ACE-I|24 weeks of treatment with Enalapril, where Candesartan is added in the last 8 weeks.
3316587|NCT00235287|Active Comparator|C, AIIA|8 weeks of treatment with Candesartan, followed by 8 weeks of treatment with Enalapril. The treatment in the last 8 out of the 24 weeks is a combination of Candesartan and Enalapril.
3316588|NCT00235287|Active Comparator|C, ACE|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg) , followed by 8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg) . The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
3316589|NCT00235248|Experimental|Clopidogrel-aspirin|Clopidogrel-aspirin
3316590|NCT00235248|Active Comparator|Warfarin|Warfarin
3316591|NCT00235235||A|Doxorubicin 60 mg/m2 + Cyclophosphamide 600 mg/m2 day 2 of every 21-day cycle
3316592|NCT00235235||B|Capecitabine 1000mg/m2 bid days 1-14 of every 21-day cycle
3316593|NCT00235235||C|Vinorelbine 25 mg/m2 days 1, 8, 15 of every 28-day cycle
3316594|NCT00235235||D|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
3316595|NCT00235183|Active Comparator|Quarantined FFP|Quarantined FFP
3316596|NCT00235183|Active Comparator|Methylene blue FFP|Methylene blue FFP
3316597|NCT00235183|Active Comparator|Solvent detergent FFP|Solvent detergent FFP
3316598|NCT00235170|Experimental|1|Cypher Sirolimus-eluting Coronary stent
3316599|NCT00235157|Experimental|1|Sirolimus-eluting Palmaz Genesis peripheral stent
3316600|NCT00235144|Experimental|1|drug-eluting stent
3316601|NCT00235144|Active Comparator|2|bare-metal stent
3316602|NCT00235131|Experimental|1|Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
3316603|NCT00235131|Active Comparator|2|Bard® Luminexx™ 6F Vascular Stent
3316604|NCT00235079|Experimental|Colchicine|Colchicine 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
3316605|NCT00235079|Placebo Comparator|Placebo|Placebo 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
3316606|NCT00235066|Experimental|1|Cypher Sirolimus-Eluting Stent
3316607|NCT00235040|Other|1|Intervention
3316608|NCT00235040|No Intervention|2|Control
3316609|NCT00235027|Experimental|Adverse Drug Event Monitoring|In this intervention arm, clinicians received medication safety alerts when they prescribed medications in the electronic medical record.
3316610|NCT00235027|No Intervention|Care as Usual|In this arm, clinicians did not receive the medication safety alerts.
3316611|NCT00235014|Active Comparator|A-1, B-1|A-1 pertains to Phase 1; B-1 pertains to Phase 2
3316612|NCT00235014|Active Comparator|A-2, B-2|A2 pertains to Phase 1; B-2 pertains to Phase 2
3316613|NCT00235014|Placebo Comparator|A-3|
3316614|NCT00235014|Active Comparator|A-4|
3316615|NCT00235001|Experimental|1|
3316616|NCT00234988|Experimental|1|
3316617|NCT00234975|Active Comparator|HCV +|
3316618|NCT00234975|Active Comparator|HCV -|
3316619|NCT00234923|Active Comparator|1|Kaletra Monotherapy: lopinavir/ritonavir
3316620|NCT00234923|Active Comparator|2|Kaletra based triple therapy: lopinavir/ritonavir + lamivudine/zidovudine
3316621|NCT00234910|Experimental|A|2 drug arm
3316622|NCT00234910|Active Comparator|B|3 drug arm, SOC
3316623|NCT00234884||Adalimumab|RA patients in treatment with commercial adalimumab
3316624|NCT00234871|Active Comparator|1|
3316625|NCT00234871|Active Comparator|2|
3316626|NCT00234858|Active Comparator|1|
3316627|NCT00234858|Active Comparator|2|
3316628|NCT00234832|Experimental|Sibutramine|Subjects were randomized to receive sibutramine 10 mg once daily (QD) during the Treatment Period after a 6-week Lead-in Period
3316629|NCT00234832|Placebo Comparator|Placebo|Subjects were randomized to receive placebo QD during the Treatment Period after a 6-week Lead-in Period
3316630|NCT00234832|Experimental|Lead-in sibutramine|All subjects received 10 mg sibutramine QD during a 6-week Lead-in Period
3316631|NCT00234806|Experimental|Telemedicine intervention group|
3316632|NCT00234806|Placebo Comparator|Control group|
3316633|NCT00234754|Active Comparator|1|Trans-vaginal tape Surgery
3316634|NCT00234754|Experimental|2|Trans-obturator tape surgery
3316635|NCT00234702|Experimental|1|
3316636|NCT00234702|Placebo Comparator|2|
3316637|NCT00234676|Experimental|1|Premarin
3316638|NCT00234598|No Intervention|Control group, usual care|Usual care with no study interventions provided; no tooth brushing intervention and no chlorhexidine intervention. Usual care
3316639|NCT00234598|Active Comparator|Tooth brushing only|Tooth brushing by study personnel three times per 24 hours (TID) without chlorhexidine application.
3316640|NCT00234598|Active Comparator|Chlorhexidine only|Oral application of chlorhexidine 0.12% oral solution twice per 24 hours (BID) without tooth brushing.
3316641|NCT00234598|Active Comparator|Toothbrushing and chlorhexidine|Tooth brushing by study personnel three times per 24 hours (TID) and oral application of chlorhexidine 0.12% oral solution twice per 24 hours (BID)
3316642|NCT00234546|Experimental|1|Dysport
3316643|NCT00234546|Placebo Comparator|2|Placebo
3316644|NCT00234533|Experimental|NutropinAq 10 mg/2 mL (30 IU)|"Patients received daily subcutaneous (s.c.) injections of NutropinAq 10 milligrams (mg)/2 milliliters (mL) for 6 months. The therapeutic daily doses administered were as follows:~GHD patients: 0.025 - 0.035 mg/ kilogram (kg) bodyweight~TS patients: up to 0.05 mg/kg bodyweight~CRI patients: up to 0.05 mg/kg bodyweight~Patients visited the study clinic for a baseline visit and for 2 other visits every 3 months (Weeks 12 and 24). Additional home assessments were made at Weeks 21, 22 and 23.~The investigator determined the dose administered to each patient, and it was recommended to perform the injection in the evening."
3316645|NCT00234494|Experimental|Single Group Assignment|Cisplatin + Gemcitabine + Bevacizumab
3316646|NCT00234455|Other|1|stent in the main branch with balloon angioplasty by a kissing balloon technique in the side branch (stent/PTCA group)
3316647|NCT00234455|Other|2|stents in both the main and side branches (stent/stent group)
3316648|NCT00234299|Active Comparator|Group A|Enteric coated aspirin 325mg, one tablet orally every day for six months prior to prostate biopsy.
3316649|NCT00234299|Placebo Comparator|Group B|Enteric coated placebo, one tablet orally every day for six months prior to prostate biopsy.
3316650|NCT00234286|Experimental|Arm 1|Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
3316651|NCT00234273|Experimental|Therapeutic education combining dietary and rehabilitation|Therapeutic education combining dietary and rehabilitation (APA)
3316652|NCT00234273|Active Comparator|Therapeutic education primarily focused on dietary|Therapeutic education primarily focused on dietary
3316653|NCT00234221|Active Comparator|Strengths Based Case Management Model (SBCM)|The Strengths Based Case Management Model (SBCM) consists of 5 case-management sessions designed to promote linkage and engagement in assessment and treatment services, while assisting with the patient's perceived needs, as well as personal strengths and barriers to linkage and engagement.
3316654|NCT00234221|Active Comparator|Motivational Enhancement Therapy (MET)|The MET therapist will conduct 2 motivational enhancement sessions to work through the content of an educational workbook targeting the participant's alcohol use/abuse with the goal of negotiating a 'contract' to: 1) link to services, with the eventual goal of seeking and receiving specialized alcohol treatment; or 2) provide a strategy to self-monitor alcohol use, consider consequences, and later seek assessment.
3316655|NCT00234221|Active Comparator|Brief Informational Feedback (BIF) session|Subjects will receive brief informational feedback on the results of their alcohol screening and assessment and encouragement to seek treatment.
3316656|NCT00234208|Experimental|Medical thoracoscopy|
3316657|NCT00234208|Active Comparator|Simple chest tube drainage|
3316658|NCT00234156|Active Comparator|renal disease|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
3316659|NCT00234156|Active Comparator|normal|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
3316660|NCT00234143|Active Comparator|Aranesp and Neupogen|solution for subcutaneous injection , syringe 500 mcg and 300 mcg respectively
3316661|NCT00234143|Active Comparator|Aranesp|solution for subcutaneous injection, 500 mcg
3316662|NCT00234143|No Intervention|Best supportive care|Red cell transfusion support
3316663|NCT00234091|Active Comparator|1|Immediate treatment; individuals receive HAART on Day 1 of the study
3316664|NCT00234091|Active Comparator|2|Delayed treatment; individuals receive HAART if their CD4 percentage falls below 15 percentage OR if they develop a CDC category C illness
3321049|NCT00156156|Experimental|1|
3316665|NCT00234078|Experimental|0.5% OPC-12759|0.5% OPC-12759 (rebamipide) ophthalmic suspension
3316666|NCT00234078|Experimental|1% OPC-12759|1% OPC-12759 (rebamipide) ophthalmic suspension
3316667|NCT00234078|Experimental|2% OPC-12759|2% OPC-12759 (rebamipide) ophthalmic suspension
3316668|NCT00234078|Placebo Comparator|placebo|placebo of OPC-12759 (rebamipide) ophthalmic suspension
3316669|NCT00234065|Experimental|1|cilostazol
3316670|NCT00234065|Active Comparator|2|Aspirin
3316671|NCT00234052|Experimental|Treatment Arm|Carboplatin + pemetrexed + bevacizumab
3316672|NCT00234039|Experimental|Intravesical Gemcitabine|
3316673|NCT00234000|Experimental|Arm 1|see description in intervention
3316674|NCT00233987|Experimental|High-dose therapy plus tandem transplant|Regimen consists of 2 cycles of high-dose therapy, each followed by stem cell infusion. Cycle 1 consists of high-dose melphalan followed by infusion of approximately 1.5 million cluster of differentiation 34 positive (CD34+) cells. Cycle 2 consists of either TBI-based or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-based high-dose therapy followed by infusion of at least 2 million CD34+ cells.
3316675|NCT00233974|Experimental|PET negative|Traditional breast Surgery and full axillary dissection
3316676|NCT00233974|Experimental|PET positive|PET-probe-guided breast resection and full axillary dissection
3316677|NCT00233948|Experimental|Arm I|Patients receive oral nelfinavir mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3316678|NCT00233935|Experimental|Arm I (1 capsule)|Patients receive 1 capsule of defined green tea catechin extract PO BID for the next 6 months.
3316679|NCT00233935|Experimental|Arm II (2 capsules)|Patients receive 2 capsules of defined green tea catechin extract PO BID for the next 6 months.
3316680|NCT00233935|Experimental|Arm III (3 capsules)|Patients receive 3 capsules of defined green tea catechin extract PO BID for the next 6 months.
3316681|NCT00233935|Placebo Comparator|Arm IV (placebo)|Patients receive 1-3 capsules of placebo PO BID for the next 6 months.
3316682|NCT00233883|Experimental|1|
3316683|NCT00233883|Active Comparator|2|
3316684|NCT00233818|Other|1|
3316685|NCT00233805|Active Comparator|1|Bare metal Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system
3316686|NCT00233805|Experimental|2|Sirolimus coated modified Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system
3316687|NCT00233792|Other|1|sirolimus coated Bx VELOCITY stent - fast release
3316688|NCT00233792|Other|2|sirolimus coated Bx VELOCITY stent - slow release
3316689|NCT00233727|Active Comparator|HPV DNA Testing + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women."
3316690|NCT00233727|Active Comparator|VIA + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women."
3316691|NCT00233727|No Intervention|Delayed Evaluation and Treatment|Patients will undergo a similar screening process at entry, but will be randomized to have evaluation and treatment delayed until 6 months after screening.
3316692|NCT00233714|Active Comparator|1|Single-dose Sirolimus-Eluting Coronary stent
3316693|NCT00233714|Active Comparator|2|Double-dose Sirolimus-Eluting Coronary stent
3316694|NCT00233688|Experimental|1|QUANTUM LP™ STENT GRAFT SYSTEM
3316695|NCT00233688|Active Comparator|2|Surgical intervention
3316696|NCT00233571|Experimental|Adalimumab 40mg subcutaneous (SC) every other week (EOW)|Adalimumab 40mg subcutaneous (SC) every other week (EOW)
3316697|NCT00233532|Other|1|
3316698|NCT00233532|Other|2|
3316699|NCT00233532|Other|3|
3316700|NCT00233519|Experimental|Cohort 1- Two Escalating Doses of Iplex|0.5 and 1.0 mg/kg/day
3316701|NCT00233519|Active Comparator|Cohort 2 - Three Escalating Doses of Iplex|0.5, 1.0, and 2.0 mg/kg/day
3316702|NCT00233506|Experimental|CPG 7909 IV|Intravenous infusions will be administered with a standard infusion pump beginning at 125 cc/hr through an intravenous catheter (central or peripheral).
3316703|NCT00233506|Experimental|CPG 7909 SQ|Subcutaneous injections should be administered in the abdominal wall, upper arm, hip, or anterior thigh. If the volume of injection exceeds 1.5 ml, the volume should be divided into equal injections at a volume less than 1.5 ml and administered in different areas of the body. The maximum dose level on this trial may require 5 - 6 injections at an equal number of sites.
3316704|NCT00233480|Experimental|active treatment|atorvastatin 10mg QD x 3 months
3316705|NCT00233480|Placebo Comparator|placebo|matched placebo QD x 3 months
3316706|NCT00233454|Experimental|Midostaurin|100 mg midostaurin twice daily as oral capsules
3316707|NCT00233402|Active Comparator|Standard White Light Cystoscopy|
3316708|NCT00233402|Experimental|Standard White Light and Hexvix Fluorescence Cystoscopy|
3316709|NCT00233324|Experimental|Surfactant and Low Oxygen|Administration of surfactant by endotracheal tube and supplemental oxygen with target saturation of 85% to 89%
3316710|NCT00233324|Experimental|Surfactant and High Oxygen|Administration of surfactant by endotracheal tube and supplemental oxygen with target saturationof 91% to 95%
3316711|NCT00233324|Experimental|CPAP and Low Oxygen|Administration of continuous positive airway pressure (CPAP) and supplemental oxygen with target saturation of 85% to 89%
3316712|NCT00233324|Experimental|CPAP and High Oxygen|Administration of continuous positive airway pressure (CPAP)and supplemental oxygen with target saturation of 91% to 95%
3316713|NCT00233259|Active Comparator|1|Multiple risk factor intervention, that will include diet, physical activity, stress management, social support, and smoking cessation components
3316714|NCT00233259|Placebo Comparator|2|Control group
3316715|NCT00233220|Experimental|1|Patients and doctors will take part in a multicomponent, multi-level intervention.
3316716|NCT00233220|Active Comparator|2|Patients will receive usual care.
3316717|NCT00233194||Cohort 2|Children scheduled for adenotonsillectomy and healthy subjects, for comparison, not scheduled for such surgery.
3316718|NCT00233168|Experimental|1|Peer medication adherence counseling
3316719|NCT00233168|Active Comparator|2|Peer life skills counseling
3316720|NCT00233142|Experimental|Expressive writing|Expressive writing
3316721|NCT00233142|Sham Comparator|Neutral writing|Non-expressive writing
3316722|NCT00233129|Active Comparator|Standard Treatment|cognitive rehabilitation day treatment program
3316723|NCT00233129|Experimental|Top-Down|"cognitive rehabilitation day treatment program that incorporates systematic top down treatment of executive function deficits (problem solving and emotional regulation training), systematic treatment of attention deficits, and modular, contextual and embedded approaches to treatment."
3316724|NCT00233103|Experimental|Sertraline|Daily oral sertraline in doses starting at 25mg and increasing to therapeutic levels (up to 200mg).
3316725|NCT00233103|Placebo Comparator|Placebo|Placebo for 10 weeks.
3316726|NCT00233090|Experimental|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
3316727|NCT00233090|Placebo Comparator|Placebo|
3316728|NCT00233077|Experimental|Behavioral: Patient Assistance|Patient assistance programs
3316729|NCT00233077|Other|Control: Information only|Control patients will be sent a pamphlet about breast cancer & its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
3316730|NCT00233064|Active Comparator|1|Liquid Palivizumab
3316731|NCT00233064|Active Comparator|2|Lyophilized Palivizumab
3316732|NCT00232908|Experimental|1|
3316733|NCT00232882|Active Comparator|1|Candesartan 16 mg for 4 weeks followed by candesartan 16 mg and hydrochlorothiazide 12.5 mg for 4 weeks
3316734|NCT00232882|Active Comparator|2|Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
3316735|NCT00232882|Active Comparator|3|Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
3316736|NCT00232869|Experimental|1|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
3316737|NCT00232869|Active Comparator|2|SMART™ bare-metal stent
3316738|NCT00232856|Other|1|Cypher™ sirolimus-eluting stent
3316739|NCT00232843|Experimental|1|Cordis SMART™ nitinol self-expanding stent.
3316740|NCT00232843|Active Comparator|2|balloon angioplasty
3316741|NCT00232830|Experimental|1|Cypher Sirolimus-eluting Coronary Stent
3316742|NCT00232830|Active Comparator|2|Bare-metal stent
3316743|NCT00232817|Experimental|1|Propofol anesthetic with and without nicotine
3316744|NCT00232817|Experimental|2|isoflurane anesthetic with and without nicotine
3316745|NCT00232804|Other|1|
3316746|NCT00232791|Experimental|1|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
3316747|NCT00232791|Active Comparator|2|CYPHER™ Sirolimus-eluting Coronary Stent
3316748|NCT00232765|Experimental|1|Cypher Bx Velocity
3316749|NCT00232765|Active Comparator|2|Uncoated Bx Velocity
3316750|NCT00232752|Experimental|1|
3316751|NCT00232739|Experimental|1|
3316752|NCT00232687|Active Comparator|A1|
3316753|NCT00232687|Active Comparator|A2|
3316754|NCT00232622|Active Comparator|Standard infusion of streptokinase|Standard infusion of streptokinase
3316755|NCT00232622|Experimental|Accelerated infusion of streptokinase|Accelerated infusion of streptokinase
3316756|NCT00232596|Placebo Comparator|Placebo|
3316757|NCT00232596|Experimental|Retigabine|
3316758|NCT00232583|Active Comparator|Metfomin and Insulin|Metformin 1000mg/BID and Insulin Novolog 70/30 per protocol titration
3316759|NCT00232583|Active Comparator|Metformin, Pioglitazone and Glyburide|Metformin 1000mg/BID, Pioglitazone 45 mg and glyburide per protocol titration
3316760|NCT00232557|Experimental|TLC-Asthma|Telephone-based home education and asthma monitoring
3316761|NCT00232557|Active Comparator|TLC-health education|Telephone-based home education
3316762|NCT00232544|Experimental|TLC-CPAP|A telephone-linked communication (TLC) system for promoting adherence to continuous positive airway pressure (CPAP)
3316763|NCT00232544|Placebo Comparator|TLC-Control|A TLC system for providing general health education
3316764|NCT00232505|Experimental|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once a week. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients not responding to treatment may cross over to arm II.
3316765|NCT00232505|Experimental|Cetuximab and Carboplatin|Patients receive cetuximab as in arm I and carboplatin IV on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3316766|NCT00232492|Placebo Comparator|Placebo males|Saline physiological placebo males
3316767|NCT00232492|Active Comparator|Ketamine 0,1 mg/kg males|0,1 mg/kg ketamine males
3316768|NCT00232492|Active Comparator|Ketamine 0,3 mg/kg males|0,3 mg/kg ketamine males
3316769|NCT00232492|Active Comparator|Ketamine 0,5 mg/kg males|0,5 mg/kg ketamine males
3316770|NCT00232492|Placebo Comparator|Placebo females|Saline physiological as placebo females
3316771|NCT00232492|Active Comparator|Ketamine 0.1 mg/kg females|0,1 mg/kg ketamine females
3316772|NCT00232492|Active Comparator|Ketamine 0,3 mg/kg females|0,3 mg/kg ketamine females
3316773|NCT00232492|Active Comparator|Ketamine 0,5 mg/kg females|0,5 mg/kg ketamine females
3316774|NCT00232479|Experimental|arm 1|single arm study evaluating the efficacy of neoadjuvant taxotere, herceptin and carboplatin given in a dose dense fashion
3316775|NCT00232466|No Intervention|2|conservative therapy (no intervention)
3316776|NCT00232466|Active Comparator|1|Vertebroplasty
3316777|NCT00232349|Experimental|Intervention group|All subjects enrolled in study are in the intervention group.
3316778|NCT00232284|Active Comparator|Sertaline|8 week course of sertraline 50-100mg for those who fail to respond to CBT within first 4 weeks of study entry
3316779|NCT00232284|Placebo Comparator|Placebo|8 week course of placebo
3316780|NCT00232271|Active Comparator|clexane|patients received clexane
3316781|NCT00232271|No Intervention|non clexane|no clexane given
3316782|NCT00232245|Experimental|Fish oil|Patients prescribed 6g/day of fish oil containing total 1.8 g of EPA+DHA in a 1.5:1 ratio
3316783|NCT00232245|No Intervention|Control|No fish oil exposure
3316784|NCT00232232|No Intervention|Control|No fish oil
3316848|NCT00231153|Experimental|omiganan 1% gel|
3316785|NCT00232232|Experimental|Fish oil|Patients prescribed 6g/day of fish oil containing 1.8g EPA+DHA in a 1.5:1 ratio
3316786|NCT00232219|No Intervention|Control|No fish oil exposure
3316787|NCT00232219|Experimental|Fish oil|Patients given 6g/day of fish oil containing 1.8g/d of EPA+DHA in a 1.5:1 ratio.
3316788|NCT00232193||IFNβ+DS group|IFNβ+DS group received lyophilized Avonex 30mcg IM weekly plus dexamethasone 160 mg IV every 4 weeks for 52 weeks and was treated with Avonex 30mcg IM weekly from week 53 to 104
3316789|NCT00232193||IFNβ group|IFNβ group received lyophilized Avonex 30mcg IM weekly for 104 weeks
3316790|NCT00232180|Active Comparator|Eplerenone arm|Eplerenone administered on top of background standard heart failure therapy
3316791|NCT00232141|Experimental|1|
3316792|NCT00232141|Placebo Comparator|2|
3316793|NCT00232115|Experimental|1|Pimecrolimus
3316794|NCT00232115|Placebo Comparator|2|Vehicle
3316795|NCT00232011|Experimental|1|
3316796|NCT00231998|Experimental|1|
3316797|NCT00231985|Placebo Comparator|1|Participants will receive supportive psychotherapy.
3316798|NCT00231985|Active Comparator|2|Participants will receive habit reversal therapy.
3316799|NCT00231972|Experimental|Project Enhance|Participants will receive the risk reduction program, Project Enhance
3316800|NCT00231972|Active Comparator|Active Comparison Condition|Participants will receive standard prevention case management
3316801|NCT00231959|Placebo Comparator|Sugar pill|Placebo
3316802|NCT00231959|Experimental|Pramipexole|
3316803|NCT00231933|Active Comparator|1|Participants will receive standard care incorporating illness management recovery
3316804|NCT00231933|Experimental|2|Participants will receive illness management recovery plus person-centered planning
3316805|NCT00231933|Experimental|3|Participants will receive illness management recovery plus person-centered planning and community integration
3316806|NCT00231907|Active Comparator|Vaccine 1: TIV. Vaccine 2: TIV.|Vaccine 1: TIV. Vaccine 2: TIV.
3316807|NCT00231907|Experimental|Vaccine 1: LAIV. Vaccine 2: TIV.|Vaccine 1: LAIV. Vaccine 2: TIV.
3316808|NCT00231907|Experimental|Vaccine 1: LAIV. Vaccine 2: LAIV.|Vaccine 1: LAIV. Vaccine 2: LAIV.
3316809|NCT00231907|Experimental|Vaccine 1: TIV. Vaccine 2: LAIV.|Vaccine 1: TIV. Vaccine 2: LAIV.
3316810|NCT00231894|Active Comparator|Pioglitazone and life-style group|Pioglitazone (30-45 mg/daily) plus life-style diet group
3316811|NCT00231894|Placebo Comparator|Placebo and life style group|Placebo capsules daily plus life-style diet group
3316812|NCT00231868|Experimental|A|Drug:Carboplatin and Paclitaxel and Radiation: Pelvic Radiation Therapy
3316813|NCT00231842|Experimental|A|"Adjuvant Radiation Therapy Sandwiched between Ifosfamide in Patients with Mixed Mesodermal Tumors"
3316814|NCT00231816|Experimental|Concomitant|Zostavax concomitantly with influenza vaccine on Day 1, placebo at week 4
3316815|NCT00231816|Experimental|Nonconcomitant|Influenza vaccine and Zostavax placebo on Day 1, Zostavax at week 4
3316816|NCT00231790|Experimental|MK-0634 50 mg|All participants will receive placebo for the 1 week prior to randomization
3316817|NCT00231790|Experimental|MK-0634 125 mg|All participants will receive placebo for the 1 week prior to randomization
3316818|NCT00231790|Experimental|MK-0634 375 mg|All participants will receive placebo for the 1 week prior to randomization
3316819|NCT00231790|Placebo Comparator|Placebo|All participants will receive placebo for the 1 week prior to randomization
3316820|NCT00231777|Experimental|1|40 mg MK0517 IV
3316821|NCT00231777|Active Comparator|2|4 mg ondansetron IV
3316822|NCT00231673|Experimental|001|Topiramate Increasing dosing of topiramate gradually to 200 mg daily by mouth dose maintenance for 12 weeks then decreasing dose until stopped over 12 weeks
3316823|NCT00231582|Experimental|1|1
3316824|NCT00231569|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
3316825|NCT00231569|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
3316826|NCT00231569|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
3316827|NCT00231569|Experimental|Cohort D|Loading doses followed by weekly maintenance doses
3316828|NCT00231569|Experimental|Cohort E|Loading doses followed by weekly maintenance doses
3316829|NCT00231569|Experimental|Cohort F|Loading doses followed by extended weekly maintenance doses
3316830|NCT00231569|Experimental|Cohort G|Loading doses followed by extended weekly maintenance doses
3316831|NCT00231478|Experimental|1|
3316832|NCT00231478|Experimental|2|
3316833|NCT00231465|Experimental|Taxotere® (Docetaxel) + ZD1839 (IRESSA®)|"Patients will receive Taxotere at 75 mg/m2 given IV over 60 minutes on day 1 of a three week cycle.~ZD1839 will be administered orally at 250mg daily starting on day one, concurrently with the Taxotere."
3316834|NCT00231452|Experimental|Late exposure group|Participants received monthly Sulfadoxine-Pyrimethamine (SP) plus Artesunate (AS) from 2.5-4.5 months of age and monthly placebo from 5.5-9.5 months of age.
3316835|NCT00231452|Experimental|Early exposure group|Participants received monthly placebo from 2.5-4.5 months of age and monthly SP+AS from 5.5-9.5 months of age.
3316836|NCT00231452|Placebo Comparator|Control group|Participants received monthly placebo from 2.5 to 9.5 months of age.
3316837|NCT00231309|Other|single arm|
3316838|NCT00231296|Active Comparator|Treatment with CryoCor Cryoablation System|Intervention includes ablation therapy with the CryoCor catheter for the treatment of symptomatic PAF.
3316839|NCT00231296|Active Comparator|Treatment with standard medical therapy|Intervention includes treatment with ant-arrhythmic medications alone.
3316840|NCT00231283|Experimental|1|CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System
3316841|NCT00231257|Experimental|1|Cypher Bx Velocity
3316842|NCT00231257|Active Comparator|2|Brachytherapy
3316843|NCT00231244|Experimental|1|CYPHER Sirolimus-Eluting Coronary Stent
3316844|NCT00231179|Experimental|Home visiting Intervention|Home visiting intervention group.
3316845|NCT00231179|Placebo Comparator|Control|Control condition did not receive any services.
3316846|NCT00231166|Experimental|HCD122|
3316847|NCT00231153|Active Comparator|Povidone-Iodine 10%|
3316849|NCT00231114|Experimental|Alair|Treatment of airways with the Alair System
3316850|NCT00231114|Sham Comparator|Sham|Sham treatment of airways
3316851|NCT00230971|Active Comparator|A|
3316852|NCT00230971|Active Comparator|B|
3316853|NCT00230945|Experimental|1|Patient-oriented education and support intervention
3316854|NCT00230945|Experimental|2|Couple-oriented education and support intervention
3316855|NCT00230932||Group 1|outpatients selected from random visits in primary care, oncology, and cardiology clinics
3316856|NCT00230880|Experimental|Treatment|follow-up phone counseling
3316857|NCT00230880|No Intervention|Control|Usual care
3316858|NCT00230815|Experimental|Follitropin alfa injected by Pen device|
3316859|NCT00230802|Active Comparator|2 tablet increase|Patients will increase their current levothyroxine dose by 2 extra tablets per week (~29% increase)
3316860|NCT00230802|Active Comparator|3 tablet increase|Patients will increase their levothyroxine dosage by 3 extra tablets per week (~43%).
3316861|NCT00230763|Experimental|Active|
3316862|NCT00230763|Other|Procedure|
3316863|NCT00230750|Experimental|2|100 subjects to receive 90 mcg of inactivated influenza A/H5N1 vaccine on days 0, 28, and 6 months following the 1st vaccination.
3316864|NCT00230750|Placebo Comparator|3|40 subjects to receive saline placebo on days 0, 28, and 6 months following the 1st vaccination.
3316865|NCT00230750|Experimental|1|100 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine on days 0, 28, and 6 months following the 1st vaccination.
3316866|NCT00230737|Experimental|A|Melatonin 0.4 mg
3316867|NCT00230737|Experimental|B|Melatonin 4.0 mg
3316868|NCT00230737|Placebo Comparator|C|
3316869|NCT00230711|Experimental|Exercise Counseling|
3316870|NCT00230711|Placebo Comparator|Contact Control|
3316871|NCT00230659||HHT patients|Patients with hereditary haemorrhagic telangiectasia. Blood sample to be taken.
3316872|NCT00230659||Controls|People without hereditary haemorrhagic telangiectasia. Blood sample to be taken.
3316873|NCT00230607|Experimental|Agalsidase beta|Commercially available Fabrazyme treatment at prescribed dose and regimen as determined by their treating physician
3316874|NCT00230594|Active Comparator|1|desmopressin
3316875|NCT00230594|Placebo Comparator|2|placebo
3316876|NCT00230542|Experimental|Carboplatin / Pemetrexed|Single Arm Study Carboplatin AUC 5 Pemetrexed 500 mg/m2
3316877|NCT00230477|Active Comparator|Mono therapy|Hepsera
3316878|NCT00230477|Active Comparator|Combo therapy|
3316879|NCT00230438|Experimental|External Beam Radiation Therapy|
3316880|NCT00230321|Experimental|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously for 6 weeks. The dosage for the remaining treatment is dependent of patients response during the induction phase.
3316881|NCT00230282|Experimental|Fludarabine, cytoxan, then alemtuzumab|Fludarabine and cyclophosphamide days 1 to 3 for six 28-day cycles. Minimal residual disease positive responders continued on-treatment to receive alemtuzumab 30 mg weekly. MRD negative responders were observed.
3316882|NCT00230178|Experimental|Arm A|Rasburicase alone given as a single agent for 5 days
3316883|NCT00230178|Experimental|Arm B|Rasburicase alone given as a single agent from Day 1 through Day 3, followed by oral allopurinol given from Day 3 through Day 5 (Day 3 is an overlap)
3316884|NCT00230178|Active Comparator|Arm C|Oral allopurinol alone given as a single agent for 5 days
3316885|NCT00230165||Normal|Normal, healthy volunteers 18 years of age or older of either sex and any ethnic background
3316886|NCT00230165||Glanzmann thrombasthenia|Patients with Glanzmann thrombasthenia or their relatives, end stage renal disease, sickle cell disease or related disorders, inherited qualitative and/or quantitative platelet disorders, inherited disorders of white blood cells, inherited disorders of coagulation
3316887|NCT00230126|Active Comparator|A erlotinib 150 mg|erlotinib 150 mg/day cycles 1 - 3
3316888|NCT00230126|Experimental|B erlotinib modified according to weight|erlotinib Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to skin rash.
3316889|NCT00230113|Active Comparator|1|
3316890|NCT00230113|Placebo Comparator|2|
3316891|NCT00230100|Experimental|Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
3316892|NCT00230100|Active Comparator|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
3316893|NCT00230048|No Intervention|Assessment only|
3316894|NCT00230048|Experimental|Brief intervention|
3316895|NCT00230035|Experimental|1|high dose immunosuppressie therapy (HDIT) followed by HSCT (hemopoietic stem cell transplantation).
3316896|NCT00230035|Active Comparator|2|Currently available immunosuppressive/immunomodulatory therapy
3316897|NCT00230022|Experimental|Brief computer-delivered intervention|A 20-minute interaction with software designed to partially replicate the experience of a brief motivational intervention with a therapist or health care professional. Included decisional balance, normed feedback, and optional goal-setting.
3316957|NCT00229255|Active Comparator|twice-a -day meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks
3316898|NCT00230022|No Intervention|Assessment only|Participants in this arm only completed assessment section, same as intervention group, but then was done.
3316899|NCT00230009|No Intervention|Assessment only|
3316900|NCT00230009|Experimental|Brief intervention session|
3316901|NCT00229983|Experimental|Motivational Enhancement Therapy|Adolescents who are randomized to the experimental intervention will attend three 60-minute counseling sessions, delivered 2-4 weeks apart. The intervention will include a structured, developmentally appropriate, approach to identification of drug- and alcohol-related risks and problems, and establishment of goals for behavioral change.
3316902|NCT00229983|No Intervention|Enhanced Standard Care|Adolescents who are randomized to Enhanced Standard Care will receive the usual care at the outpatient adolescent substance abuse program. This will include an evaluation by pediatric and mental health staff and could include treatment in a group therapy program, urine drug testing, buprenorphine replacement therapy (for those dependent on opioids), and psychopharmacology evaluation and management.
3316903|NCT00229970|Experimental|1|Placebo
3316904|NCT00229970|Experimental|2|MK0476 7 mg injection
3316905|NCT00229970|Experimental|3|MK0476 14 mg injection
3316906|NCT00229957|Experimental|Intervention|Intervention
3316907|NCT00229957|No Intervention|Control|Control group received usual care in primary care.
3316908|NCT00229931|Active Comparator|Laser therapy|If randomized to laser therapy at time of cataract surgery, laser therapy will be performed one month after cataract surgery. If macular edema does not respond an additional laser therapy will be performed. If macular edema persists after 2 lasers, then IVTA will be administered as per standard of care.
3316909|NCT00229931|Active Comparator|Triamcinolone therapy|"At time of cataract surgery, will have IVTA injection. If macular edema does not show improvement at 1 month, then can have repeat IVTA injection. If the macular edema is stil not improved after 2nd injection, participant will be considered treatment failure and will be given the option to have laser therapy."
3316910|NCT00229801|No Intervention|MRI|
3316911|NCT00229736|Experimental|AAV-hAADC-2 (9x10^10 vector genomes)|
3316912|NCT00229736|Experimental|AAV-hAADC-2 (3x10^11 vector genomes)|
3316913|NCT00229723|Placebo Comparator|1|Radiation + cisplatin; followed by placebo as maintenance therapy
3316914|NCT00229723|Experimental|2|250 mg gefitinib + radiation + cisplatin; followed by placebo as maintenance therapy
3316915|NCT00229723|Experimental|3|500 mg gefitinib + radiation + cisplatin; followed by placebo as maintenance therapy
3316916|NCT00229723|Experimental|4|gefitinib 250 mg + cisplatin + radiotherapy; followed by gefitinib 250 mg as maintenance therapy
3316917|NCT00229723|Experimental|5|gefitinib 500 mg + cisplatin + radiotherapy; followed by gefitinib 500 mg as maintenance therapy
3316918|NCT00229723|Placebo Comparator|6|placebo + cisplatin + radiotherapy; followed by gefitinib 250 mg as maintenance therapy
3316919|NCT00229723|Placebo Comparator|7|placebo + cisplatin + radiotherapy; followed by gefitinib 500 mg as maintenance therapy
3316920|NCT00229697|Experimental|1|ZD1839 + Nolvadex
3316921|NCT00229697|Other|2|Nolvadex + placebo
3316922|NCT00229658||Type 1|Patients with type 1 diabetes
3316923|NCT00229658||Type 2|Patients with type 2 diabetes
3316924|NCT00229619|Experimental|Rituximab (Rituxan)|This is a non-randomized, off label, pilot study of humanized anti CD20 rituximab (Rituxan®) in patients with moderate aplastic anemia, pure red cell aplasia or Diamond-Blackfan anemia who have either failed to respond to at least one prior course of immunosuppressive therapy (PRCA/DBA patients only)or who have relapsed disease after prior immunosuppressive therapy (PRCA/DBA patients only).
3316925|NCT00229593|Active Comparator|1|100 mg Testosterone gel daily for 3 weeks
3316926|NCT00229593|Active Comparator|2|2 mg Nestorone gel daily for 3 weeks
3316927|NCT00229593|Active Comparator|3|4 mg Nestorone gel daily for 3 weeks
3316928|NCT00229593|Active Comparator|4|100 mg Testosterone gel + 2 mg Nestorone gel
3316929|NCT00229593|Active Comparator|5|100 mg Testosterone gel + 4 mg Nestorone gel
3316930|NCT00229593|Active Comparator|6|100 mg Testosterone Gel + 6 mg Nestorone Gel daily for 3 weeks
3316931|NCT00229593|Active Comparator|7|100 mg Testosterone Gel + 8 mg Nestorone gel daily for 3 weeks
3316932|NCT00229580|Experimental|1|Motivational feedback
3316933|NCT00229580|Active Comparator|2|treatment as usual
3316934|NCT00229554||Group 1|Male and female veterans age 50-75 who have had one or more primary care visits at a VA Medical facility in the past two years.
3316935|NCT00229541|Experimental|IG|intervention group, receives counselling on medical inpatient rehabilitation by statutory health insurance, is intended to apply for a 3-wek medical inpatient rehabilitation at the co-operating clinic (Bad Bramstedt)
3316936|NCT00229541|No Intervention|KG|control group, receives usual care
3316937|NCT00229515|Active Comparator|1|Patients will receive abciximab infusion at standard regimen prior undergoing percutaneous coronary intervention for STEMI followed by BMS implantation in the culprit lesion
3316938|NCT00229515|Experimental|2|Abciximab followed by implantation of sirolimus-eluting stent in the culprit lesion
3316939|NCT00229515|Experimental|3|tirofiban infusion followed by bare metal stent implantation
3316940|NCT00229515|Experimental|4|tirofiban and sirolimus-eluting stent
3316941|NCT00229502||1|Subjects receiving Avonex
3316942|NCT00229502||2|Subjects receiving Rebif
3316943|NCT00229502||3|Subjects receiving Copaxone
3316944|NCT00229502||4|Healthy controls
3316945|NCT00229437|Experimental|TAK-128 5 mg QD|
3316946|NCT00229437|Experimental|TAK-128 50 mg QD|
3316947|NCT00229437|Experimental|TAK-128 100 mg QD|
3316948|NCT00229437|Placebo Comparator|Placebo QD|
3316949|NCT00229424|Experimental|1|Lafutidine group
3316950|NCT00229424|Active Comparator|2|Famotidine group
3316951|NCT00229424|Placebo Comparator|3|Placebo group
3316952|NCT00229385|Active Comparator|1|
3316953|NCT00229385|Active Comparator|2|
3316954|NCT00229307|Active Comparator|1|
3316955|NCT00229307|Active Comparator|2|
3316956|NCT00229255|Active Comparator|high frequency meals group|High carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
3316958|NCT00229242|Active Comparator|1|Diuretic-Based Hypertension Therapy
3316959|NCT00229242|Active Comparator|2|Non-Diuretic-Based Hypertension Therapy
3316960|NCT00229229|Other|1|Low glycemic load diet
3316961|NCT00229229|Other|2|Canada Food Guide Diet
3316962|NCT00229229|Other|3|Low glycemic index diet
3316963|NCT00229229|Other|4|Low carbohydrate diet
3316964|NCT00229177|Placebo Comparator|P|
3316965|NCT00229177|Experimental|E1|
3316966|NCT00229177|Experimental|E2|
3316967|NCT00229151|Experimental|Sleep deprivation|Sleep deprivation and sleep phase advancement
3316968|NCT00229151|Active Comparator|usual treatment|
3316969|NCT00229138|Experimental|reduced Tacrolimus|
3316970|NCT00229138|Active Comparator|Reference Tacrolimus|
3316971|NCT00229047||Vein Stripping|Patients undergoing elective varicose vein stripping in our vascular OR. Observe circulation in the exposed soleus/gastrocnemius muscle.
3316972|NCT00229008|Experimental|001|ceftobiprole plus placebo ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
3316973|NCT00229008|Active Comparator|002|linezolid plus ceftazidime linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
3316974|NCT00228982|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q12h as 1h infusion, 7-14d
3316975|NCT00228982|Active Comparator|Vancomycin|Vancomycin 1g q12h as 1h infusion, 7-14d
3316976|NCT00228943|Experimental|Acute tryptophan depletion|Full-strength tryptophan depletion
3316977|NCT00228943|Active Comparator|Control|Half-strength tryptophan depletion drink used as a control
3316978|NCT00228917|Experimental|TRIANRIX-HEPB/HIB-MENAC-TT GROUP|Subjects vaccinated with 3 doses of Trianrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317135/ NCT00317187) were boosted in the current study with one dose of the same vaccines at 15 to 18 months (Philippines) and 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm.
3316979|NCT00228917|Experimental|TRIANRIX-HEPB/MENCEVAX+TRIANRIX-HEPB/HIBERIX GROUP|Subjects vaccinated with 3 doses of Trianrix-Hepb co-administrated with Mencevax vaccine in the primary study (NCT00317135/ NCT00317187) were boosted in the current study with one dose of Tritanrix™-HepB/Hiberix™ at 15 to 18 months (Philippines) and 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects were also administered one booster dose of Mencevax™ ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm.
3316980|NCT00228917|Experimental|TRITANRIX-HEPB/ HIBERIX +MENCEVAX GROUP|Subjects vaccinated with 3 doses of Tritanrix™-HepB/Hiberix™ vaccine in the primary study (NCT00317135/ NCT00317187) were boosted in the current study with one dose of Trianrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 18 months (Philippines) and 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects were also administered one booster dose of Mencevax™ ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm.
3316981|NCT00228917|Experimental|TRITANRIX-HEPB+MENCEVAX GROUP|Subjects vaccinated with 3 doses of Tritanrix™-HepB/Hiberix™ vaccine in the primary study (NCT00317135/ NCT00317187) were boosted in the current study with one dose of the same vaccine at 15 to 18 months (Philippines) and 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects were also administered one booster dose of Mencevax™ ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm.
3316982|NCT00228904|Placebo Comparator|1|Control patients with diagnosed diabetic neuropathy will receive baseline testing and testing every six months thereafter to compare and analyze results with patients treated with pulsatile intravenous insulin therapy.
3316983|NCT00228904|Active Comparator|2|Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after the start of pulsatile intravenous insulin therapy.
3316984|NCT00228891|Active Comparator|2|Patients with diagnosed diabetic neuropathy will receive objective baseline testing and follow up testing every six months after the start of Pulsatile intravenous insulin therapy to monitor and assess diabetic neuropathy.
3316985|NCT00228891|Placebo Comparator|1|Control patients with diabetic neuropathy will receive objective testing at baseline and every six months to compare and measure results with patients who are receiving pulsatile intravenous insulin therapy.
3316986|NCT00228878|Experimental|Effects of Pulsatile IV insulin on QoL|Effects of Pulsatile IV insulin on Diabetic Quality of Life
3316987|NCT00228865|Experimental|1|Testing performed on diabetic patients with decline in cognitive function at baseline and quarterly after the start of receiving pulsatile intravenous insulin therapy to assess continuing cognitive function ability.
3316988|NCT00228813|Other|Granulocyte Colony Stimulating Factor (G-CSF) stimulation|Participants will receive bone marrow from donors who undergo Granulocyte Colony Stimulating Factor (G-CSF) stimulation prior to bone marrow collection.
3316989|NCT00228696|No Intervention|screening|this is a screening study and no intervention.
3316990|NCT00228670||IPF-Clinic|Adult patients with idiopathic pulmonary fibrosis being followed in pulmonary clinic
3316991|NCT00228670||Controls - Clinic|Adult subjects with no underlying pulmonary disease who are the household partner of an IPF patient being followed in pulmonary clinic
3316992|NCT00228670||IPF-Transplant|IPF patient undergoing lung transplant
3316993|NCT00228670||Controls-Transplant|Lung tissue from organ donor
3316994|NCT00228631||Sickle Cell Disease Bone Marrow Transplant|Sickle Cell Disease Bone Marrow Transplant candidates
3316995|NCT00228579||Bariatric Surgery|Subjects will be recruited from patients undergoing bariatric surgery at Emory Bariatrics. The cost of surgical procedures will not be provided by the research study.
3316996|NCT00228553|Experimental|1|Armodafinil 100 to 250 mg/day
3316997|NCT00228449|Experimental|Cohort 1|Conversion from epoetin alfa to peginesatide with a conversion factor (CF) of 0.033: peginesatide dose administered intravenously once every 4 weeks (Q4W) for a total of up to 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
3316998|NCT00228449|Experimental|Cohort 2|Conversion from epoetin alfa to peginesatide with a CF of 0.041: peginesatide dose administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
3316999|NCT00228449|Experimental|Cohort 3|Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
3317000|NCT00228449|Experimental|Cohorts 4 and 9|Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
3317001|NCT00228449|Experimental|Cohort 5|Conversion from epoetin alfa to peginesatide with a CF of 0.066: peginesatide dose administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
3317002|NCT00228449|Experimental|Cohort 6|Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa . Doses were administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
3317003|NCT00228449|Experimental|Cohorts 7 and 8|Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa dose. Doses were administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
3317004|NCT00228449|Experimental|Cohorts 10 and 11|Conversion from epoetin alfa to peginesatide with fixed peginesatide starting doses of 4, 6, 12 or 16 mg based on total weekly doses of epoetin alfa. Doses were administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
3317005|NCT00228436|Experimental|Cohort 1|Peginesatide starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses.
3317006|NCT00228436|Experimental|Cohort 2|Peginesatide starting dose of 0.075 mg/kg administered SC Q4W for a total of 6 doses.
3317007|NCT00228436|Experimental|Cohort 3|Peginesatide starting dose of 0.025 mg/kg administered SC Q4W for a total of 6 doses.
3317008|NCT00228436|Experimental|Cohort 4|Peginesatide starting dose of 0.05 mg/kg administered intravenously (IV) Q4W for a total of 6 doses.
3317009|NCT00228436|Experimental|Cohort 5|Peginesatide starting dose of 0.025 mg/kg administered SC once every 2 weeks (Q2W) for a total of 12 doses.
3317010|NCT00228436|Experimental|Cohort 6|Peginesatide starting dose of 0.0375 mg/kg administered SC Q2W for a total of 12 doses.
3317011|NCT00228436|Experimental|Cohort 7|Peginesatide fixed starting dose of 4 mg administered SC Q4W for a total of 6 doses.
3317012|NCT00228436|Experimental|Cohort 8|Peginesatide fixed starting dose of 3 mg administered SC Q4W for a total of 6 doses.
3317013|NCT00228423|Active Comparator|75mg Clopidogrel|75mg clopidogrel. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.
3317014|NCT00228423|Placebo Comparator|Placebo|Water pill. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.
3317015|NCT00228384|Active Comparator|Gore VIABAHN Endoprosthesis|
3317016|NCT00228384|Active Comparator|Bare Nitinol Stent (BNS)|
3317017|NCT00228371|Other|1|The stimulator is switch ON during the first phase of the cross-over and switch OFF during the second phase
3317018|NCT00228371|Other|2|The stimulator is switch OFF during the first phase of the cross-over and switch ON during the second phase
3317019|NCT00228358|Experimental|Group A (cellular infusions after cyclophosphamide)|Patients receive low-dose cyclophosphamide IV on day -1 and 3 escalating doses of autologous ex vivo-expanded HER2-specific T cells IV over 30 minutes on days 1, 10, and 20.
3317020|NCT00228358|Experimental|Group B (cellular infusions after ONTAK conditioning)|Patients receive denileukin diftitox IV over 1 hour on day -1 and 3 escalating doses of autologous ex vivo-expanded HER2-specific T cells IV over 30 minutes on days 1, 10, and 20.
3317021|NCT00228319|Active Comparator|Standard of Care Group|carboplatin and paclitaxel chemotherapy
3317022|NCT00228319|Experimental|Standar of Care + Ascorbic Acid Group|carboplatin and paclitaxel chemotherapy, plus intravenous sodium ascorbate. In addition, participants will take a mix of vitamins including oral ascorbic acid, oral mixed natural carotenoids with vitamin A and oral vitamin E.
3317023|NCT00228306|Experimental|1|
3317024|NCT00228306|No Intervention|2|Control Group
3317025|NCT00228215|No Intervention|Usual care|
3317026|NCT00228215|Experimental|TIPS Intervention|
3317027|NCT00228189|Active Comparator|A|Dendritic cells pulsed with CEA-peptide
3317028|NCT00228189|Experimental|B|Dendritic cells electroporated with CEA-mRNA
3317029|NCT00228189|Experimental|C|Dendritic cells pulsed with CEA-peptide, in combination with oxaliplatin/capecitabine
3317030|NCT00228176|Experimental|Rimonabant|Rimonabant 20 mg once daily
3317031|NCT00228176|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
3317032|NCT00228163|Experimental|Teriflunomide 7 mg|
3317033|NCT00228163|Experimental|Teriflunomide 14 mg|
3317034|NCT00228020|Experimental|Basiliximab|Patients will be on a regimen of Basiliximab, MMF, cyclosporine and steroids
3317035|NCT00228020|Active Comparator|Basiliximab-free|Patients will be on a regimen of MMF, cyclosporine and steroids.
3317036|NCT00227994|Experimental|Galantamine|Galantamine for 12 weeks
3317037|NCT00227994|Experimental|Donepezil|Donepezil for 12 weeks
3317038|NCT00227942|Experimental|1|Participants will receive estrogen replacement therapy
3317039|NCT00227942|Experimental|2|Participants will receive treatment with zolpidem
3317040|NCT00227942|Placebo Comparator|3|Participants will receive treatment with placebo
3317041|NCT00227903|Experimental|MI-CBT|Motivationally-enhanced cognitive behavioral skills counseling
3317042|NCT00227903|Active Comparator|Brief Advice|Advice and education
3317043|NCT00227890|Experimental|1|Motivational Interviewing followed by Cognitive Behavior Therapy (MI/CBT)
3317044|NCT00227890|Experimental|2|Relaxation Training followed by Treatment as Usual (RT/TU)
3317045|NCT00227877|No Intervention|Control|"Control participants will receive care as usual from their provider"
3317046|NCT00227877|Experimental|Computer Screen & Brief Physician Advice|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking points which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
3317047|NCT00227864|Placebo Comparator|Treatment as Usual|Participants are administered assessments at baseline, 1, 3 and 6 months
3317048|NCT00227864|Experimental|Intervention|Participants complete assessments at baseline, 1, 3 and 6 months, and receive a 2-session behavioral intervention at the baseline and 1-month study appointments.
3317049|NCT00227760|Experimental|Treatment (cediranib maleate)|Patients receive cediranib maleate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3317050|NCT00227734|Active Comparator|Arm I|Patients receive oral capecitabine twice daily on days 1-15 and oxaliplatin IV over 2 hours on day 1.
3317051|NCT00227734|Active Comparator|Arm II|Patients receive capecitabine and oxaliplatin as in arm I and cetuximab IV over 1-2 hours on days 1 and 8
3317052|NCT00227721|Experimental|Docetaxel & Gemcitabine hydrochloride|Docetaxel, 40 mg/m2, 30 min IV infusion on Days 1 and 8, of a 21 day cycle Gemcitabine hydrochloride, 800mg/m2 30 min IV infusion on Days1 and 8, of a 21 day cycle
3317053|NCT00227695|Active Comparator|Arm A: Rituximab every 2 months x4|Rituximab 375 mg/m2 every 2 months x4
3317054|NCT00227695|Active Comparator|Arm B: Rituximab (5 years)|Rituximab 375 mg/m2 every 2 months for 5 years or until PD, relapse or unacceptable toxicity
3317055|NCT00227682|Experimental|Arsenic Trioxide|Arsenic Trioxide in Combination With Thalidomide, Dexamethasone, and Ascorbic Acid
3317056|NCT00227669|Active Comparator|Arm I: Gemcitabine|"Gemcitabine at Day 1, Day 8 and Day 15. No treatment at Day 22.~1 cycle = 28 days.~Treatment duration: 8 months"
3317057|NCT00227669|Experimental|Arm II: Gemcitabine + Docetaxel|"Gemcitabine at Day 1 and Day 8. No treatment at Day 15. Docetaxel at Day 8.~1 cycle = 21 days.~Treatment duration: 6 months"
3317058|NCT00227656|Experimental|Capecitabine + PEG-interferon alfa-2a|Capecitabine 1000 mg/m2 orally twice daily during the first 14 days of each 3-week cycle (2 weeks on, 1 week rest), and PEG-interferon alfa-2a subcutaneously beginning at 180 mcg per week for 21 days.
3317059|NCT00227617|Experimental|FOLFOX with Bevacizumab|"Starting on Day 1, administered every two weeks:~5-fluorouracil: 2400 mg/ m2 CIV; over 46-48 hours Leucovorin: 200 mg/ m2; over 2 hours Oxaliplatin : 85 mg/m2; over 2 hours Bevacizumab: 5 mg/kg IV over 30-90 minutes"
3317060|NCT00227591|Experimental|Treatment (lenalidomide, prednisone)|For courses 1 and 2, patients receive oral lenalidomide once daily and oral prednisone once daily on days 1-28. For course 3, patients receive oral lenalidomide once daily on days 1-28 and oral prednisone once on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Patients with stable or responding disease after course 3 receive oral lenalidomide alone once daily on days 1-28 for courses 4-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3317061|NCT00227565|Experimental|pemetrexed + carboplatin + radiation|"Patients receive pemetrexed disodium IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease in the CNS only may receive whole-brain radiotherapy and then continue chemotherapy after completion of whole-brain radiotherapy for up to 6 courses.~After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 4 years."
3317062|NCT00227539|Experimental|Neoadjuvant therapy, PET scan and surgery|
3317063|NCT00227513|Experimental|Arm I|"Patients receive oral vorinostat (SAHA) twice daily on days 1-14 in step A. Patients receive oral vorinostat (SAHA) twice daily on days 1-4 and 8-11 in Step B and bortezomib IV over 3-5 seconds on days 2, 5, 9, and 12 during the first course and on days 1, 4, 8, and 11 during subsequent courses in both steps A and B. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 6 additional patients receive bortezomib at the MTD. Subsequent cohorts of 3-6 patients receive escalating doses of SAHA until the MTD of that drug is determined."
3317064|NCT00227487|Other|Stool collection, Carbohydrate administration, Questionnaires|"A stool sample will be obtained~A carbohydrate solution (lactulose plus rhamnose dissolved in tap water) will be administered during a clinically indicated endoscopic procedure.~Five questionnaires will be completed by parent/guardian"
3317065|NCT00227461|Other|Wait control|Levitiracetam is started after a delay, with dosage and administration as described below.
3317066|NCT00227461|Experimental|Treatment first|Levitiracetam is started immediately after baseline data is collected; dosage and administration as described below.
3317067|NCT00227370|Active Comparator|1|Valganciclovir 900 mg QD for 9 months post lung transplant.
3317068|NCT00227370|Placebo Comparator|2|placebo for 9 months post lung transplant
3317069|NCT00227357||Buprenorphine|Study patients receiving buprenorphine treatment
3317070|NCT00227357||Comparison|Study patients receiving methadone or no agonist treatment
3317071|NCT00227344|Experimental|1|Catheter ablation
3317072|NCT00227344|Active Comparator|2|Antiarrhythmic drugs
3317073|NCT00227292|Placebo Comparator|A, 2, II|Placebo 10mg per day for the first week, then 20mg per day till the end of study.
3317074|NCT00227292|Experimental|A, 1|Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
3317075|NCT00227279|Experimental|1|
3317076|NCT00227279|Placebo Comparator|2|
3317077|NCT00227266|Placebo Comparator|Cohort 1a|Patients in Cohort 1a - Placebo Comparator, will be on a placebo for 6 months and then will switch to the active treatment. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor or equivalent placebo in the liquid form.
3317633|NCT00217919|No Intervention|2|Usual care
3321050|NCT00156156|Experimental|2|
3317078|NCT00227266|Active Comparator|Cohort 1b|Cohort 1b - Active Comparator will be on treatment throughout the study. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor in the liquid form.
3317079|NCT00227266|Experimental|Cohort 2|Cohort 2 pts are on open-label treatment throughout. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor or equivalent placebo in the liquid form.
3317080|NCT00227188||1|Children from 0-5 years of age evaluated for IPD
3317081|NCT00227162|Active Comparator|Group 1|Positive affect
3317082|NCT00227162|Active Comparator|Group 2|Self-Affirmation
3317083|NCT00227162|Active Comparator|Group 3|Positive Affect and self-affirmation
3317084|NCT00227162|No Intervention|Group 4|Control group
3317085|NCT00227123|Active Comparator|1|Quetiapine versus Risperidone
3317086|NCT00227110|Active Comparator|Pioglitazone|Pioglitazone 30 mg/d will be given for 8 weeks and titrated to 45 mg/d until the end of the 6-month study in a randomized, double-blind, study design.
3317087|NCT00227110|Placebo Comparator|Placebo|Placebo once daily is given following a randomized, double-blind, placebo-controlled study design.
3317088|NCT00227032|Experimental|Subjects receiving EIAEDs|Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)
3317089|NCT00227032|Experimental|Subjects NOT taking EIAEDs|Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)
3317090|NCT00227019|Experimental|bevacizumab+ pemetrexed|pemetrexed (500 mg/m² IV) + bevacizumab (15 mg/kg IV). In addition to Vitamin B12 + Folate + Dexamethasone
3317091|NCT00227006|Experimental|Taste-Based Goal Setting|6-month intervention (14 lifestyle counseling classes)
3317092|NCT00227006|Active Comparator|Smart Consumers|6-month intervention (14 lifestyle counseling classes)
3317093|NCT00227006|Active Comparator|Community Access|Can enroll in behavioral treatment programs available in the community that do not include medication or very-low calorie diets
3317094|NCT00226941|Experimental|Group 1 - Cetuximab + Capecitabine-800 + XRT + Oxaliplatin-100|"Cetuximab 250 mg/m² / week~Capecitabine 800 mg/m²~Radiotherapy (XRT)~Oxaliplatin 100 mg/m², Days 2 and 23"
3317095|NCT00226941|Experimental|Group 2 - Cetuximab + Capecitabine-700 + XRT + Oxaliplatin-85|"Cetuximab 250 mg/m² / week~Capecitabine 700 mg/m²~Radiotherapy (XRT)~Oxaliplatin 85 mg/m², Days 2 and 23"
3317096|NCT00226941|Experimental|Group A - Cetuximab + Capecitabine-800 + XRT|"Cetuximab 250 mg/m² / week~Capecitabine 800 mg/m²~Radiotherapy (XRT)"
3317097|NCT00226941|Experimental|Group B - Cetuximab + Capecitabine-1000 + XRT|"Cetuximab 250 mg/m² / week~Capecitabine 1000 mg/m²~Radiotherapy (XRT)"
3317098|NCT00226915|Active Comparator|1|Drug: Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
3317099|NCT00226915|Experimental|2|Drug: Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
3317100|NCT00226837|Placebo Comparator|1|0% nitrous oxide
3317101|NCT00226837|Active Comparator|2|33% nitrous oxide
3317102|NCT00226837|Active Comparator|3|66% nitrous oxide
3317103|NCT00226811|Experimental|A|50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
3317104|NCT00226772|Experimental|OMS103HP irrigation solution|Drug
3317105|NCT00226772|Placebo Comparator|vehicle irrigation solution|Vehicle
3317106|NCT00226759|Experimental|OMS103HP irrigation solution|Drug
3317107|NCT00226759|Placebo Comparator|vehicle irrigation solution|Vehicle
3317108|NCT00226746|Experimental|Paclitaxel and Gemcitabine|"Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions), Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36."
3317109|NCT00226733|Experimental|A|Interval exercise training with high intensity
3317110|NCT00226733|Active Comparator|B|Exercise training with moderate intensity
3317111|NCT00226720|Experimental|1|at the hospital
3317112|NCT00226720|Active Comparator|2|out of the hospital
3317113|NCT00226694|Active Comparator|Citalopram Group|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
3317114|NCT00226694|Placebo Comparator|Placebo Group|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
3317115|NCT00226681|Experimental|1|
3317116|NCT00226681|Active Comparator|2|
3317117|NCT00226668|Experimental|I|Patients will receive hCRf (XERECEPT) 2mg/day and dexamethasone 4 mg/day along with any open-label dexamethasone that they may be taking
3317118|NCT00226668|Placebo Comparator|II|Patients will receive placebo hCRF (XERECEPT) 2mg/day and dexamethasone 4 mg/day along with any open-label dexamethasone they may be taking
3317119|NCT00226655|Experimental|I|All patients will receive hCRF (XERECEPT) 2mg/day
3317120|NCT00226590|Experimental|Combined Therapy|In this trial we adopted the approach of using both induction and concurrent chemotherapy together with TRT planned conformally to a tumor dose of 74 Gy.
3317121|NCT00226577|Experimental|Pre-Surgery Chemotherapy|
3317122|NCT00226499|Experimental|Group A|
3317123|NCT00226499|Experimental|Group B|
3317124|NCT00226499|Active Comparator|Group C|
3317125|NCT00226486|Experimental|1|Identification of individual risk factors for falls and specified intervention aimed diminishing these risk factors in the individual.
3317126|NCT00226486|Placebo Comparator|2|Usual care
3317127|NCT00226434|Experimental|1|
3317128|NCT00226434|Active Comparator|2|
3317129|NCT00226356|Experimental|Supplements of L-methionine, betaine and folate|
3317130|NCT00226317|Experimental|Aripiprazole in depression treatment|
3317131|NCT00226291|Experimental|Synthesized evidence report|Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
3317132|NCT00226291|No Intervention|No evidence report|
3317133|NCT00226252|Experimental|Instruction Only (IO)|IO participants will train on the dynamometer for the same length of time as the Feedback Group. They will only be instructed to follow what they learned from the video presented at the beginning of the training session.
3317134|NCT00226252|Experimental|Instruction and Feedback Group (FB)|The FB group will receive video training, and real time feedback from the SMART Wheel as they push their wheelchair. A monitor displaying a random combination and amount of biomechanical feedback variables will be placed in front of subjects. Subjects will be instructed to adjust their stroke to optimize their biomechanics with feedback from the screen.
3317135|NCT00226252|No Intervention|Control Group|Wheelchair characteristics will be noted; however, no wheelchair manipulation or changes in equipment will be performed or recommended.
3317136|NCT00226239|Experimental|Head and neck cancer patients|Induction chemotherapy consists of 3 cycles of cisplatin 75 mg/m^2, on day 1, docetaxel 75 mg/m^2, on day 1, and cetuximab weekly days 1,8,15, repeated every 21 days (cetuximab dose is 400 mg/m^2 on day 1 and 250 mg/m^2 on subsequent weekly treatments). After 3 cycles of induction, patients receive standard radiation 70 Gy/200 cGy/daily, 5 days/week with concurrent weekly cisplatin 30 mg/m^2 and cetuximab 250 mg/m^2. After completing radiation therapy, patients receive cetuximab weekly as maintenance therapy for 6 months (see section 5 for detailed treatment plan and dose modifications)
3317137|NCT00226109|Active Comparator|A|
3317138|NCT00226031|Active Comparator|1|Usual care.
3317139|NCT00226031|Experimental|2|Mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the family physician and a letter and educational package for the women.
3317140|NCT00226018|Active Comparator|1|Acceleromyography with Hand Adapter on dominant arm
3317141|NCT00226018|Active Comparator|2|Acceleromyography with Hand Adapter on non-dominant arm
3317142|NCT00226018|Placebo Comparator|3|Acceleromyography without Hand Adapter on dominant arm
3317143|NCT00226018|Placebo Comparator|4|Acceleromygraphy without Hand Adapter on non-dominant arm
3317144|NCT00226005|Active Comparator|Vatalanib|Administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
3317145|NCT00225979|Experimental|SMS995|
3317146|NCT00225914|Experimental|1|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
3317147|NCT00225914|Placebo Comparator|2|Subjects then enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill
3317148|NCT00225784|Experimental|Cetuximab, Gemcitabine, RT|weekly cetuximab, twice-weekly gemcitabine and intensity modulated radiotherapy
3317149|NCT00225758|Experimental|1|Subjects will continue on their prior endocrine therapy with the addition of lapatinib at 1500 mg once daily for 26 weeks or longer.
3317150|NCT00225745||1|Pancreatic cancer patients
3317151|NCT00225745||2|Healthy controls
3317152|NCT00225732|Active Comparator|intravenous ibuprofen|
3317153|NCT00225732|Placebo Comparator|normal saline|
3317154|NCT00225641|Active Comparator|1 frequent control|Follow-up 6, 12, 18, 24 and 36 months after surgery
3317155|NCT00225641|Other|2 less frequent control|Follow-up 12 and 36 months after surgery
3317156|NCT00225576|No Intervention|1|Paper prescribing, 2005 and 2007
3317157|NCT00225576|Experimental|2|Paper prescribing 2005 vs. electronic prescribing 2007
3317158|NCT00225498|Experimental|1|ziprasidone
3317159|NCT00225498|Active Comparator|2|risperidone or olanzapine
3317160|NCT00225433|Active Comparator|1|Follitropin beta
3317161|NCT00225433|Active Comparator|2|Ganirelix acetate
3317162|NCT00225420|Other|Single Arm Intervention|Single Arm Intervention where after enrollment (or prior to enrollment but before starting radiotherapy) patients will initially receive leuprolide acetate (Lupron®) intramuscular (IM). Patients will begin adaptive external-beam radiation therapy 2-3 months following the initiation of hormonal therapy. Each patient receives a dose of docetaxel at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight weeks.
3317163|NCT00225381||metabolic gas exchange and cardiac output|
3317164|NCT00225381||mass spectrometer and anaerobic metabolism|
3317165|NCT00225381||metaboic gas exchange and type of anesthesia induction|
3317166|NCT00225381||metabolic gas exchange and PEEP|
3317167|NCT00225381||metabolic gas exchange and trendelenburg position|
3317168|NCT00225381||Patients requiring tourniquet during surgery|Patients undergoing orthopaedic surgeries requiring tourniquet intervention. Oxygen consumption and CO2 production were measured before, during and after tourniquet release.
3317169|NCT00225381||Patients prone to metabolic acidosis|Oxygen consumption and CO2 measurements taken during long surgeries prone to metabolic acidosis.
3317170|NCT00225277|Experimental|Pioglitazone QD|
3317171|NCT00225277|Active Comparator|Glimepiride QD|
3317172|NCT00225264|Experimental|Pioglitazone QD|
3317173|NCT00225264|Active Comparator|Glimepiride QD|
3317174|NCT00225251|Experimental|bupropion XL|Treatment with active medication (bupropion XL) dose ranging from 150 to 450 mg/day
3317175|NCT00225251|Placebo Comparator|Placebo|Placebo comparator, matching appearance with active medication, taken from 1 to 3 tablets per day
3317176|NCT00225225|Active Comparator|fixed calorie (500 kcal) Reduction|
3317177|NCT00225225|Placebo Comparator|Control (no diet change)|
3317178|NCT00225212|Experimental|Rituximab after ASCT|Rituximab 375 mg/m2 starting 6 weeks after ASCT transplant, and for the 5th and subsequent subjects, a second course at the same dose 6 months after ASCT.
3317179|NCT00225199|Experimental|Arm 1|
3317180|NCT00225199|Placebo Comparator|Arm 2|
3317181|NCT00225186|Experimental|Arm 1|
3317347|NCT00222326|Experimental|Pelvic floor muscle training|Pelvic floor muscle training: clinic and rooms exercise training
3318185|NCT00208260|Experimental|E|FOLFIRINOX
3317182|NCT00225173|Experimental|Treatment|"Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11~Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11~Cyclophosphamide 750 mg/m2 IV w 1, 5, 9~Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11~Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)~Bleomycin 5 u/m2 IV w 2,4,6,8,10,12~Gemcitabine 1250 mg/m2 IV w 13,15,17,19~Vinorelbine 25 mg/m2 IV w 13,15,17,19~Prednisone 40 mg/m2 PO qod w 1-10, taper"
3317183|NCT00225147|Experimental|100 IU/kg rhC1INH|100 IU/kg Recombinant human C1 inhibitor
3317184|NCT00225147|Experimental|50 IU/kg rhC1INH|50 IU/kg Recombinant human C1 inhibitor
3317185|NCT00225147|Placebo Comparator|Saline|
3317186|NCT00225121|Experimental|1|open label single arm trial
3317187|NCT00225095|Active Comparator|Arm 1|Chondrogen dose 1
3317188|NCT00225095|Active Comparator|Arm 2|Chondrogen dose 2
3317189|NCT00225095|Active Comparator|Arm 3|Control
3317190|NCT00225069|Experimental|1|T2 sympathectomy
3317191|NCT00225069|Experimental|2|T2-T3 sympathectomy
3317192|NCT00225017|Experimental|A|"ARM A: Switch current PI to atazanavir 400 mg once daily plus current > 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) for 24 weeks.~Subjects currently on ritonavir (RTV) (400 mg BID or greater) or RTV-boosted PI (<400 mg/day) , or tenofovir (TDF) as backbone NRTI therapy, will switch to ATV 300 mg boosted with RTV 100mg once daily."
3317193|NCT00225017|Active Comparator|B|ARM B: Continue current antiretroviral regimen (single or RTV-boosted PI plus > 2 NRTIs) for 24 weeks
3317194|NCT00224952||Patients receiving Carbamazepine or Valproic Acid|
3317195|NCT00224874|Experimental|Etanercept|Enroll within 48 hours of new onset acute GVHD and randomize to Etanercept
3317196|NCT00224874|Experimental|Mycophenolate Mofetil|Enroll within 48 hours of new onset acute GVHD and randomize to Mycophenolate Mofetil
3317197|NCT00224874|Experimental|Denileukin Diftitox|Enroll within 48 hours of new onset acute GVHD and randomize to Denileukin Diftitox
3317198|NCT00224874|Experimental|Pentostatin|Enroll within 48 hours of new onset acute GVHD and randomize to Pentostatin
3317199|NCT00224848|Experimental|ATP III|A novel practice-based intervention, based on the ATP III Clinical Practice Guideline, which includes the use of a personal digital assistant (PDA) based decision support tool.
3317200|NCT00224848|Active Comparator|JNC 7|A novel practice-based intervention, based on the JNC-7 blood pressure Clinical Practice Guideline, which includes the use of am automated blood pressure measurement device.
3317201|NCT00224835|Experimental|1|Mindfulness Based Stress Reduction Class
3317202|NCT00224835|Experimental|2|Cardiac Education Class
3317203|NCT00224783|Active Comparator|CAIV-T|CAIV-T contains 3 cold-adapted influenza virus strains (A/H1N1, A/H3N2, B) concentrated and refined by centrifugal separation from the chorioallantoic membrane of specific pathogen-free (SPF) eggs, containing SPG (sucrose-phosphate-glutamate), arginine, and acid hydrolyzed pig gelatin as stabilizers. Subjects were inoculated once with about 0.1 mL of investigational vaccine in each nasal cavity (a total of 0.2 mL) using a nebulizer.
3317204|NCT00224783|Placebo Comparator|Placebo|Placebo contained 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2). Subjects received about 0.1 mL (a total 0.2 mL) of the control drug using a nebulizer.
3317205|NCT00224770|No Intervention|Medical Management|Standard of care medical management as per American Heart Association (AHA) guidelines.
3317206|NCT00224770|Active Comparator|MISTIE Surgical Management|"Minimally invasive surgery (MIS) with clot lysis with recombinant tissue plasminogen activator (rt-PA).~MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo®) through the catheter once every eight hours for up to 72 hours, in addition to best medical care.~This includes 54 intent-to-treat patients, and excludes 27 pilots."
3317207|NCT00224770|Active Comparator|ICES Surgical Management|"Intraoperative stereotactic CT-Guided Endoscopic Surgery~Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative-targeting arm as MISTIE arm. Best medical care was provided, but no rt-PA was administered.~This includes 14 intent-to-treat patients, and excludes 4 pilots."
3317208|NCT00224757|Active Comparator|Aspirin|Ascal 100mg once daily
3317209|NCT00224757|Active Comparator|Coumarin derivates|Acenocoumarol or fenprocoumon
3317210|NCT00224744|Active Comparator|Classical surgical Inguinal curage|Classical Inguinal curage
3317211|NCT00224744|Experimental|Ultracision surgical Inguinal curage|
3317212|NCT00224718|Active Comparator|1|surgery - open repair
3317213|NCT00224718|Experimental|2|endovascular procedure
3317214|NCT00224640|Experimental|1|Iron chelating intervention
3317215|NCT00224575|Experimental|1|Diagnosis strategy and subsequent therapeutic reassessment All patients are in that arms. They all receive the diagnosis reassessment strategy.
3317216|NCT00224523|Experimental|Arm 1|
3317217|NCT00224484|Experimental|GD2-AS04 GROUP|Female subjects aged 10-17 years, who received 3 doses of gD2-AS04 vaccine, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
3317218|NCT00224484|Active Comparator|HAVRIX GROUP|Female subjects aged 10-17 years, who received 3 doses of Havrix™, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
3317219|NCT00224484|Placebo Comparator|SALINE GROUP|Female subjects aged 10-17 years, who received 3 doses of a saline solution, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
3317220|NCT00224471|Experimental|Group A|
3317221|NCT00224471|Experimental|Group B|
3317222|NCT00224471|Experimental|Group C|
3317223|NCT00224445|Experimental|Truvada + Ritonavir-boosted Atazanavir|All participants received Truvada plus ritonavir-boosted atazanavir
3317224|NCT00224419|Active Comparator|1 - CBT Counseling|Participants in this arm received a tailored CBT (TCBT) intervention that included: a written self-help guide, feedback about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session.
3317397|NCT00221299|Active Comparator|Group3-rhPTH-Placebo&Risedronate|First phase (year 1) - parathyroid hormone (rhPTH 1-34), placebo SC injections of normal saline daily and risedronate tablets (35mg/wk) tablets for one year Second phase (year 2) - continue on risedronate tablets (35mg/wk) for second year.
3317225|NCT00224419|Experimental|2 - Counseling + NRT|Women in this arm received the TCBT described in Arm 1, plus their choice of NRT. To minimize fetal exposure to nicotine for women in the TCBT+NRT arm, the dose of NRT are customized to the woman's current level of smoking. Women who smoke 5-10 cigarettes a day will be given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smokes per day. Those who smoke 11 cigarettes or more per day will be given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smokes per day, not to exceed 15 lozenges or pieces of gum per day.
3317226|NCT00280839|Active Comparator|topiramate|
3317227|NCT00280839|Placebo Comparator|placebo|
3317228|NCT00224289|Other|1|All participants will be taking Latanoprost; This study compares efficacy within age groups.
3317229|NCT00224237||A|Participants will be self-identified, adult Latino men and women from the community setting. The sample will comprise of a convenience sample from community-based organizations, including persons of Mexican, Puerto Rican, Cuban, Dominican, Central American, South American, or other Spanish-speaking culture.
3317230|NCT00224211||I|Stable premature infants
3317231|NCT00224198||Lung Disease|All study individuals will be males or females that are 18 years or older and are able to provide informed consent and have been diagnosed with lung disease.
3317232|NCT00224133|Experimental|Silodosin|Silodosin 8 mg per day with food
3317233|NCT00224120|Experimental|Silodosin|Silodosin 8 mg/Day with food
3317234|NCT00224120|Placebo Comparator|Placebo|Matching placebo capsule once daily with food
3317235|NCT00224107|Experimental|Silodosin|Silodosin 8 mg once daily with food
3317236|NCT00224107|Placebo Comparator|placebo|Matching Placebo capsule once daily with food
3317237|NCT00224094|Experimental|Sequence A|Oral ERT then transdermal ERT
3317238|NCT00224094|Experimental|Sequence B|Transdermal ERT then oral ERT
3317239|NCT00224081|Experimental|Ferric gluconate|
3317240|NCT00224081|No Intervention|standard of care|
3317241|NCT00224055|Experimental|IV iron|Sodium ferric gluconate
3317242|NCT00224055|Active Comparator|oral iron|ferrous sulfate
3317243|NCT00224042|Experimental|IV iron|
3317244|NCT00224042|Active Comparator|oral iron|
3317245|NCT00224029|Experimental|Oxybutynin transdermal system|Oxybutynin transdermal system 3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day dosing
3317246|NCT00224016|Experimental|Oxybutynin Transdermal System|Oxybutynin Transdermal System 1.3 mg/day, 2.6 mg/day, or 3.9 mg/day
3317247|NCT00224016|Active Comparator|Oral oxybutynin|5 to 15 mg/day immediate release or extended release tablets, or syrup
3317248|NCT00223977|Experimental|Sodium ferric gluconate complex 125 mg|125 mg sodium ferric gluconate weekly x 8 weeks
3317249|NCT00223977|Experimental|Sodium ferric gluconate complex 250 mg|250 mg sodium ferric gluconate complex weekly x 4 weeks
3317250|NCT00223977|Active Comparator|Oral iron|325 mg ferrous sulfate three times daily x 8 weeks
3317251|NCT00223964|Experimental|dose level 1|1.5 mg/kg
3317252|NCT00223964|Experimental|dose level 2|3 mg/kg
3317253|NCT00223938|Active Comparator|1|Oral Iron
3317254|NCT00223938|Experimental|2|sodium ferric gluconate
3317255|NCT00223938|Experimental|3|sodium ferric gluconate
3317256|NCT00223925|Placebo Comparator|Placebo|
3317257|NCT00223925|Experimental|Maribavir (100 mg twice daily)|
3317258|NCT00223925|Experimental|Maribavir (400 mg twice daily)|
3317259|NCT00223925|Experimental|Maribavir (400 mg once daily)|
3317260|NCT00223912|Other|1|Lower-extremity functional electrical stimulation
3317261|NCT00223899|Experimental|A|IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
3317262|NCT00223860|Other|1|
3317263|NCT00223847|Other|1|
3317264|NCT00223834|Other|1|Single session orientation to available services
3317265|NCT00223821|Active Comparator|Drug Therapy Aone|Oxybutynin chloride, extended-release, individually-titrated
3317266|NCT00223821|Experimental|Drug Therapy + Behavioral Training|Drug Therapy + Behavioral Training: Individually-titrated, extended-release oxybutynin chloride with management of side-effects. Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
3317267|NCT00223808|Experimental|Robot-Low|low-dose mechanically-assisted upper limb therapy
3317268|NCT00223808|Experimental|Robot-High|high-dose mechanically-assisted upper limb therapy
3317269|NCT00223808|Active Comparator|Control|additional traditional therapy
3317270|NCT00223795|Active Comparator|Single point cane|People with knee osteoarthritis underwent gait analysis with a cane
3317271|NCT00223795|No Intervention|No cane|Patients with knee osteoarthritis undergo gait analysis without a cane
3317272|NCT00223782|Other|1|
3317273|NCT00223756|Experimental|Arm 1|interdisciplinary, outpatient blind rehabilitation
3317274|NCT00223756|No Intervention|Arm 2|usual care
3317275|NCT00223743|Experimental|Zonisamide|Zonisamide administration and tremor assessment to assess efficacy in reducing essential tremor
3317276|NCT00223730|Experimental|citrulline|Patients randomized to receive oral citrulline at 3.8 gm/m2 in split BID dosing
3317277|NCT00223730|Placebo Comparator|Placebo|Patients randomized to receive oral diluent for citrulline in BID dosing
3317278|NCT00223717|Experimental|1: Active drug or intervention|Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt, aliskiren, local heat stress
3317279|NCT00223717|Placebo Comparator|2: Placebo|placebo pill or patch
3317280|NCT00223704|Experimental|HOE 140|Bradykinin receptor antagonist
3317281|NCT00223704|Active Comparator|Aminocaproic Acid|Antifibrinolytic
3317282|NCT00223704|Placebo Comparator|Placebo|Placebo
3317634|NCT00217893|Experimental|1|Combination of counseling, cotinine feedback, and contingent incentives.
3317283|NCT00223691|Experimental|1: active intervention|atomoxetine, pyridostigmine bromide, yohimbine, midodrine hcl, modafinil, octreotide, water intake, ranitidine hcl, diphenhydramine hydrochloride, tranylcypromine, ergotamine/ caffeine, celecoxib, pseudoephedrine, methylphenidate, indomethacin, ibuprofen, Oxymetazoline 0.05% nasal solution, acarbose, Rivastigmine tartrate, acetazolamide, carbidopa/levodopa, inflatable abdominal binder or bovril
3317284|NCT00223691|Placebo Comparator|2: Placebo or sham device|placebo pill or inflatable abdominal binder (sham)
3317285|NCT00223678|Active Comparator|1|pt will switch from calcineurin inhibitor (CYA, prograf) to Rapamycin
3317286|NCT00223678|No Intervention|2|Patient will remain on calcineruin inhibitor
3317287|NCT00223665|Experimental|Intermittent Androgen Suppression (IAS)|"Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.~Flutamide dosed as 250mg orally three times a day for 14 days prior to the initiation of Leuprolide Acetate.~Leuprolide Acetate dosed as 7.5mg intramuscular (IM) injections once per month for a total of 9 months."
3317288|NCT00223652|Experimental|Arm 1 - Telephone CBT|Telephone cognitive behavioral therapy
3317289|NCT00223652|No Intervention|Arm 2 - Treatment as Usual|Treatment as usual control.
3317290|NCT00223639|Experimental|Topiramate|
3317291|NCT00223639|Placebo Comparator|Placebo|
3317292|NCT00223626|Experimental|Topiramate|
3317293|NCT00223626|Placebo Comparator|Placebo|
3317294|NCT00223587|Experimental|A|1 week of treatment discontinuation
3317295|NCT00223496|Experimental|Aripiprazole|Aripiprazole open-label in doses ranging from 5-30mg QD adjunct to Divalproex 500-2500mg QD.
3317296|NCT00223444||1|Genotype group Pro/Pro
3317297|NCT00223444||2|Genotype group Pro/Ser
3317298|NCT00223405||metal-ceramic (D'Sign) o|Metal ceramic crown will be placed
3317299|NCT00223405||an all-ceramic crown (IPS Empress2, Eris EXC).|All ceramic crown will be placed
3317300|NCT00223353||Lower Limb Amputee|
3317301|NCT00223353||Amputee and Normals and Clinical Case Study|"Amputee:~Lower limb below/above knee amputee~Normals:~Health adult~Clinical Case Study:~Individual case studies"
3317302|NCT00223249|Active Comparator|Quetiapine|Quetiapine
3317303|NCT00223249|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
3317304|NCT00223236|Active Comparator|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
3317305|NCT00223236|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
3317306|NCT00223210|Active Comparator|Quetiapine|
3317307|NCT00223210|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
3317308|NCT00223171|Active Comparator|Arm 1 : 36 months AB + RT|Androgen blockade : 36 months of androgen blockade : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 12 Q 3 months + radiation therapy : pelvis 44 grays , prostate 70 grays (2 grays/fraction)
3317309|NCT00223171|Experimental|Arm 2 : 18 months AB + RT|Androgen blockade 18 months : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 6 Q 3 months + radiation therapy ( pelvis 44 grays , prostate 70 grays ,2 grays/fraction)
3317310|NCT00223145|Experimental|Arm 1|Androgen blockade for 6 months + Radiotherapy 70 Gy
3317311|NCT00223145|Experimental|Arm 2|Androgen blockade for 6 months + Radiotherapy 76 Gy
3317312|NCT00223145|Active Comparator|Arm 3|Radiotherapy alone with 76 Gy
3317313|NCT00223080|Active Comparator|II|
3317314|NCT00223080|Placebo Comparator|I|
3317315|NCT00223041|No Intervention|A (therapy with fluvastatin 80mg retard)|kidney transplants receive in addition fluvastatin 80mg retard for 3 years
3317316|NCT00223041|Placebo Comparator|B|no therapy with fluvastatin
3317317|NCT00223002|Experimental|1|PI
3317318|NCT00223002|Experimental|2|Chlorohex
3317319|NCT00222989|Other|no label study|1
3317320|NCT00222976|Experimental|1|A Naproxen PO + placebo PR
3317321|NCT00222976|Experimental|2|B Placebo PO + Naproxen PR
3317322|NCT00222937|Experimental|A|Patients are enrolled in Lessac-Madsen Resonant Voice Therapy.
3317323|NCT00222937|Experimental|B|Patients are enrolled in Casper Based Confidential Flow Therapy.
3317324|NCT00222872|Active Comparator|1 - PTHrP Group|Group receiving study drug: PTHrP(1-36)
3317325|NCT00222872|Placebo Comparator|2 - Single Blind Placebo Group|Receives placebo injections daily via subcutaneous injection
3317326|NCT00222846|Active Comparator|A|Attention control
3317327|NCT00222846|Experimental|B|Intervention
3317328|NCT00222755|Experimental|1|Behavioral Care Management
3317329|NCT00222755|No Intervention|2|Usual Care
3317330|NCT00222742|Experimental|A|Induced moderate hypothermia (32-33 C)
3317331|NCT00222729|Experimental|Pemetrexed & Bevacizumab|
3317332|NCT00222716|Experimental|Structured|Behavioral Intervention: Structured counseling behavioral intervention focused on problem solving.
3317333|NCT00222716|No Intervention|Usual Care|Control arm
3317334|NCT00222716|Experimental|Inidividualized|Behavioral Intervention: Individualized nurse counseling behavioral intervention focused on problem-solving
3317335|NCT00222612|Active Comparator|A or B with 2DI|3 or 4 drug induction plus 2 delayed intensifications
3317336|NCT00222612|Experimental|C plus 2DI|Intensified treatment including Capizzi maintenance
3317337|NCT00222612|Experimental|A or B with 1DI|Reduced intensity treatment
3317338|NCT00222534|Experimental|Acetazolamide|Acetazolamide 250 mg Three times a day for five days
3317339|NCT00222534|Placebo Comparator|Placebo|Placebo, one tablet Three times a day for five days
3317340|NCT00222469|Experimental|1|3-agent treatment group
3317341|NCT00222430|Active Comparator|A|Usual standard coronary angiographic procedure
3317342|NCT00222430|Experimental|B|Fluoroscopy-guided coronary angiography
3317343|NCT00222417||Myringoplasty|Patients subject to myringoplasty for tympanic membrane perforations.
3317344|NCT00222417||Otosclerosis|Patients subject to stapes surgery
3317345|NCT00222352||central laboratory cTnI test|Control Group
3317346|NCT00222352||Point of Care cTnL testing|Experimental Group
3318360|NCT00205075||Case|
3317348|NCT00222274|Experimental|1|RSA Biofeedback: RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.
3317349|NCT00222274|Active Comparator|2|EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
3317350|NCT00222261|Active Comparator|1, aspirin|Aspirin 160 mg
3317351|NCT00222261|Active Comparator|2, clopidogrel|Clopidogrel 75 mg
3317352|NCT00222144|Experimental|1|Gleevec and Taxotere
3317353|NCT00222131|Placebo Comparator|1|Placebo
3317354|NCT00222131|Active Comparator|2|Esomeprazole
3317355|NCT00222118|Experimental|1|intervention group
3317356|NCT00222118|Other|2|Attention control
3317357|NCT00222118|Other|3|Usual care
3317358|NCT00222105|Experimental|1|Doxil, Thalidomide, Dexamethasone
3317359|NCT00222066|Experimental|1|Fetal ovarian cyst aspiration performed as soon as possible
3317360|NCT00222066|No Intervention|2|Expectative
3317361|NCT00222053|No Intervention|1|No specific intervention
3317362|NCT00222053|Active Comparator|2|Biphosphonates
3317363|NCT00222053|Experimental|3|Thalidomide
3317364|NCT00222040|Experimental|1|Levovist
3317365|NCT00222040|No Intervention|2|No specific intervention
3317366|NCT00222014|Experimental|1|TIPS réalisé avec prothèse couverte de PTFE
3317367|NCT00222014|Active Comparator|2|Paracenthese and albumine perfusion
3317368|NCT00222001||HMO Patients|Measurement of telephone triage outcome.
3317369|NCT00221975|Active Comparator|Lithium + Divalproex + Lamictal|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL. Divalproex was then initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL. Patients meeting the criteria of being non-responsive to lithium plus divalproex were randomly assigned to receive lamotrigine or placebo. Patients randomized to the lamotrigine group were titrated up to a minimum dose of 150 mg and maximum dose of 200 mg per day.
3317370|NCT00221975|Placebo Comparator|Lithium + Divalproex + Placebo|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL. Divalproex was then initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL. Patients meeting the criteria of being non-responsive to lithium plus divalproex were randomly assigned to receive lamotrigine or placebo. Patients randomized to the placebo group were giving matching placebo.
3317371|NCT00221962|Other|Open label treatment with aripiprazole|After 1-3 week screening phase, entered six week open trial of aripiprazole initiated at 2.5mg/day. DOsing was increased weekly in 2.5mg increments in order to reach maximum dose of 10mg/d.
3317372|NCT00221923||Healthy individuals|
3317373|NCT00221923||Persons at risk for or with primary open angle glaucoma|
3317374|NCT00221897||Healthy individuals|
3317375|NCT00221897||Persons at risk for or with primary open angle glaucoma|
3317376|NCT00221845|Active Comparator|Conventional BP Control|Targeted 24-hour mean arterial pressure will be the 50th-95th percentile for age.
3317377|NCT00221845|Experimental|Intensified BP Control|Targeted 24-hour mean arterial pressure will be the 5th to 50th percentile for age.
3317378|NCT00221793|Experimental|1|Deep Brain Stimulation of the Subthalamic Nucleus
3317379|NCT00221793|Active Comparator|2|Later Deep Brain Stimulation of the Subthalamic Nucleus
3317380|NCT00221767|Experimental|1|Brindley technique (bladder system)
3317381|NCT00221767|No Intervention|2|Reference group
3317382|NCT00221715|Experimental|1|bypass by autologous saphenous vein
3317383|NCT00221715|Active Comparator|2|bypass by dacron or PTFE Prosthesis
3317384|NCT00221702|Experimental|A|Peg Intron 100 mcg SC/week for 36 months
3317385|NCT00221702|Active Comparator|B|Intron A 3 X 3 MIU, weekly, sc, for 18 months
3317386|NCT00221598|Experimental|hemodialysis|
3317387|NCT00221546|Active Comparator|DHA-rich supplement|
3317388|NCT00221546|Placebo Comparator|Placebo|
3317389|NCT00221468|Experimental|Quetiapine|Patients will begin 100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
3317390|NCT00221442|Active Comparator|zonisamide|zonegran (zonisamide)
3317391|NCT00221442|Placebo Comparator|Sugar pill|fake pill
3317392|NCT00221338|Experimental|Gabapentin|Double blind, placebo controlled
3317393|NCT00221325|Experimental|Rituximab Plus MTX|
3317394|NCT00221299|Active Comparator|Group1a-rhPTH&RIS-Placebo(Y1)&RIS(Y2)|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate placebo tablets for one year Second phase (year 2) - re-randomized to risedronate (35mg/wk) tablets for second year.
3317395|NCT00221299|Active Comparator|Group1b-rhPTH&RisendronatePlacebo|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate placebo tablets for one year Second phase (year 2) - continue on risedronate placebo tablets for second year.
3317396|NCT00221299|Active Comparator|Group2-rhPTH&Risedronate|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate tablets (35mg/wk) tablets for one year Second phase (year 2) - continue on risedronate tablets (35mg/wk) for second year.
3317398|NCT00221247|Active Comparator|Group 1|Intensely administered (5 times per week for 12wk) physical therapy, occupational therapy, and hydrotherapy with acupuncture
3318361|NCT00205075||Control|
3317399|NCT00221247|No Intervention|Group 2|Intensely administered (5 times per week for 12wk) physical therapy, occupational therapy, and hydrotherapy without acupuncture
3317400|NCT00221195|Other|On-demand first|Patients receive 6 months of on-demand therapy with study drug followed by 6 months of prophylaxis therapy with study drug
3317401|NCT00221195|Other|Prophylaxis first|Patients receive 6 months of prophylaxis therapy with study drug followed by 6 months on-demand therapy with study drug
3317402|NCT00221169|Other|surgical candidates|surgical candidates who underwent PET CT evaluation
3317403|NCT00221117|Active Comparator|Conventional Occupational Therapy (COT)|Conventional Occupational Therapy pertaining to hand function represents the current best practice activities against which the FET was compared. The COT included the following: (a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; (b) task-specific, repetitive functional training; (c) strengthening and motor control training using resistance to available arm motion to increase strength; (d) stretching exercises; (e) electrical stimulation applied primarily for muscle strengthening (this was neither FES nor FET, but electro muscular stimulation); (f) practice of activities of daily living (ADLs) including self-care where the upper extremities were used as appropriate; and (g) caregiver training.
3317404|NCT00221117|Experimental|Neuroprosthesis-FES Therapy|The FES Therapy began by designing stimulation protocols to generate power (circular grip and lateral pinch) and precision (opposition with 2 and 3 fingers) grasps on demand. The stimulation sequence (protocol) for power and precision grasps was developed for each patient individually using the Compex Motion electric stimulator. Compex Motion is a fully programmable transcutaneous (surface) stimulator that uses self-adhesive surface electrodes.
3317405|NCT00221104|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
3317406|NCT00221104|No Intervention|No intervention|Patient has no intervention.
3317407|NCT00221065|No Intervention|1|Control
3317408|NCT00221065|Experimental|2|CPAP
3317409|NCT00221039|Experimental|DRUG+ECP|UVVADEX +ECP will be administered to patients with CTCL.Duration of Treatment: The study will consist of 2 treatment periods, a 6-month initial period and a 6-month follow-up period where photopheresis therapy may continue.
3317410|NCT00221026|Experimental|drug|ECP + Uvadex given for 12 weeks.
3317411|NCT00221013|Experimental|Higher intensity CRRT regimen|
3317412|NCT00221013|Active Comparator|Lower intensity CRRT regimen|
3317413|NCT00220987|Experimental|Intensive Insulin therapy|Intensive Insulin therapy
3317414|NCT00220987|Active Comparator|Conventional Therapy|conventional insulin therapy
3317415|NCT00220961|Placebo Comparator|Placebo|Placebo tablet similar to pioglitazone tablet
3317416|NCT00220961|Active Comparator|Pioglitazone|Pioglitazone tablet similar to placebo tablet
3317417|NCT00220922|Experimental|1|injection site reactions with the use of alcohol wipes prior to performing the patients' daily Copaxone® injection
3317418|NCT00220922|Experimental|2|injection site reactions without the use of alcohol wipes prior to performing the patients' daily Copaxone® injection
3317419|NCT00220818|Experimental|Lansoprazole 1.0 mg/kg QD|
3317420|NCT00220818|Experimental|Lansoprazole 2.0 mg/kg QD|
3317421|NCT00220805|Experimental|Group 1|
3317422|NCT00220805|Placebo Comparator|Group 2|
3317423|NCT00220779|Experimental|Group 1|IGIV-C 0.2 g/kg bw/infusion (2 ml/kg bw)
3317424|NCT00220779|Experimental|Group 2|IGIV-C 0.4 g/kg bw/infusion (4 ml/kg bw)
3317425|NCT00220779|Placebo Comparator|Group 3|placebo (0.1% albumin) 4 ml/kg bw/infusion
3317426|NCT00220766|Experimental|Group 1|Infusion #1 (Week 0)Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min) ; Infusion #2 (Week 3-4)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min)
3317427|NCT00220766|Experimental|Group 2|Infusion #1 (Week 0)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min); Infusion #2 Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min)
3317428|NCT00220753|Active Comparator|Active air cleaner|Two Icleen IQAir air cleaners with active filters supplied
3317429|NCT00220753|Placebo Comparator|Placebo air cleaner|Two Icleen IQAir air cleaners with placebo filters supplied
3317430|NCT00220740|Experimental|Group 1|IGIV-C
3317431|NCT00220740|Placebo Comparator|Group 2|
3317432|NCT00220727|Experimental|Group 1|Infusion #1 (Week 0) IGIV-C (0.08 mL/kg/min); Infusion #2 (Week <6) IGIV-C (0.14 mL/kg/min)
3317433|NCT00220727|Experimental|Group 2|Infusion #1 (Week 0) IGIV-C (0.14 mL/kg/min); Infusion #2 (Week <6) IGIV-C (0.08 mL/kg/min)
3317434|NCT00220701|Experimental|escitalopram|Escitalopram (brand name Lexapro) is an antidepressant medication taken once per day, dosing from 10 to 20 milligrams per day.
3317435|NCT00220701|Placebo Comparator|Placebo|inactive comparator
3317436|NCT00220636|Experimental|Aripiprazole|Aripiprazole 5 to 30 mg/day
3317437|NCT00220584|Experimental|Open donepezil|open donepezil
3317438|NCT00220337|Experimental|1|Open label active treatment
3317439|NCT00220324|Experimental|Arm 1|
3317440|NCT00220311|Experimental|Arm 1|
3317441|NCT00220298|Experimental|Arm 1|
3317442|NCT00220285|Experimental|Arm 1|
3317443|NCT00220285|Experimental|Arm 2|
3317444|NCT00220038||Normal|700 healthy adult volunteers will be drawn from the New York City area
3317445|NCT00220025|Experimental|NBUVB|
3317446|NCT00219999||HCV infection|current HCV infection, including intravenous drug users
3317447|NCT00219999||cryoglobulinemia|cryoglobulinemia and without HCV infection
3317448|NCT00219999||chronic liver disease|chronic liver disease not due to hepatitis C virus infection
3317449|NCT00219999||Sustained Virologic responders|successfully treated for HCV infection
3317450|NCT00219999||normal|normal, healthy volunteers
3317451|NCT00219947||high risk|Blood draw from individuals known to be or at high risk for HIV-infection
3317452|NCT00219947||diagnosed|Blood draw f rom individuals diagnosed with HIV infection
3317453|NCT00219934||Group A|acute or early in the course of HIV-1 infection, independent of decisions regarding therapy with HAART.
3317601|NCT00218218|Experimental|2|Transdermal nicotine, 21 mg
3321861|NCT00141544|Experimental|1|
3317454|NCT00219934||Group B|subjects who were diagnosed with acute HIV-1 infection in the past and have been participating in an ADARC/Rockefeller University Hospital treatment protocol for acute HIV-1 infection, and currently have a viral load consistently less than 50 copies/ml on current treatment
3317455|NCT00219882|Experimental|1|standardized turmeric root extract
3317456|NCT00219856|Experimental|1|Anesthesic induction and maintenance with intravenous propofol.
3317457|NCT00219856|Active Comparator|2|Anesthesic induction with intravenous penthotal and maintenance with inhaled desflurane.
3317458|NCT00219830|Experimental|1 - home-based walking program|Based on medical record held in general practice, patients who had not attended a formal cardiac rehabilitation program after myocardial infarction and were enrolled in home-based walking programme
3317459|NCT00219830|No Intervention|2 - cardiac rehabilitation|Based on medical record held in general practice, patients who are identified as having attended a Cardiac Rehabilitation program following myocardial infarction - 'usual care'
3317460|NCT00219739|Experimental|Imatinib mesylate 400 mg|
3317461|NCT00219739|Experimental|Imatinib mesylate 600 mg|
3317462|NCT00219739|Experimental|Imatinib mesylate 400 mg +Peg interferon|
3317463|NCT00219739|Experimental|Imatinib mesylate 400 mg +Cytarabine|
3317464|NCT00219687|Active Comparator|1|When a 911 call is determined to be a cardiac arrest, the caller reporting the event who needs or desires instructions to perform CPR while waiting for EMS to arrive will receive dispatcher-assisted CPR instructions with chest compressions only
3317465|NCT00219687|Active Comparator|2|When a 911 call is determined to be a cardiac arrest, the caller reporting the event who needs or desires instructions to perform CPR while waiting for EMS to arrive will receive dispatcher-assisted CPR instructions with chest compressions and breaths
3317466|NCT00219674|Active Comparator|2|Group II
3317467|NCT00219674|Active Comparator|3|
3317468|NCT00219674|Active Comparator|4|
3317469|NCT00219674|Active Comparator|1|Group I
3317470|NCT00219557|Active Comparator|Gemcitabine|
3317471|NCT00219557|Experimental|Axitinib [AG-013736] plus gemcitabine|
3317472|NCT00219544|Experimental|1|
3317473|NCT00219544|Experimental|2|
3317474|NCT00219544|Experimental|3|
3317475|NCT00219544|Placebo Comparator|4|
3317476|NCT00219531||control|subjects with no irritable bowel syndrome or gastrointestinal complaints and regular menstrual cycle.
3317477|NCT00219531||IBS|women with IBS symptoms and normal menstrual cycle.
3317478|NCT00219466|Active Comparator|1|
3317479|NCT00219466|Active Comparator|2|
3317480|NCT00219440|Experimental|A|ACTOS plus standard diet
3317481|NCT00219440|Experimental|B|Actos plus structured diet
3317482|NCT00219440|Experimental|C|Metformin plus standard diet
3317483|NCT00219427||1|
3317484|NCT00219401|Experimental|Neonatal 7vPCV|Receive study vaccine (Prevnar) at birth, 1 and 2 months
3317485|NCT00219401|Experimental|Infant 7vPCV|Receive the study vaccine (Prevnar) at 1, 2 and 3 months
3317486|NCT00219401|Placebo Comparator|Control|Do not receive study vaccine (Prevnar)
3317487|NCT00219375|Experimental|E1|This arm is conducted as a separate study (12-601-0001)
3317488|NCT00219375|Experimental|E2|This arm is conducted as a separate study (12-603-0001).
3317489|NCT00219375|No Intervention|conventional therapy|This arm is conducted as a separate study (12-602-0001)
3317490|NCT00219362|Experimental|ALVAC-HIV 4 injections|Arm A: injection of ALVAC-HIV(vCP1452) for a total of 4 injections (W0, W4, W8, W20)
3317491|NCT00219362|Experimental|ALVAC-HIV 3 injections|Arm B: injection of ALVAC-HIV(vCP1452) for a total of injections (W4, W8, W20)
3317492|NCT00219362|Placebo Comparator|Placebo - 4 injections|Arm C1: injection of placebo for a total of 4 injections (W0, W4, W8, W20)
3317493|NCT00219362|Placebo Comparator|Placebo - 3 injections|Arm C2: injection of placebo for a total of 3 injections (W4, W8, W20)
3317494|NCT00219349|Experimental|Escitalopram|12 weeks of open label escitalopram, 10-20 mg/day (after 14 weeks of cognitive behavioral therapy
3317495|NCT00219336|Experimental|Self-motivational Choices|Students and nonstudents were mailed a brochure prepared as part of the PHC study intervention, Making Healthy Choices for a Healthy Baby in English or Mujeres y Salud Eligiendo Opciones Saludables in Spanish. This brochure allows women to make informed decisions about preventing an AEP. The MF materials included nonstigmatizing messages about drinking and contraception embedded among other health messages. Similar to Project CHOICES, this group also received a brochure on birth control practices.
3317496|NCT00219336|Active Comparator|Information Only|Students and nonstudents were mailed a brochure prepared by the CDC. The brochure (English: Think Before You Drink: You Can Hurt Your Unborn Baby; Spanish: Piénselo Antes de Beber: Puede Lastimar a Su Futuro Bebe), available at the CDC website, targets women of childbearing-age, discusses FAS and the negative effects of a mother's drinking on her unborn child, and recommends calling Alcoholics Anonymous or an alcohol treatment program for help to stop drinking. The CDC brochure did not contain information about how to contracept effectively.
3317497|NCT00219297|Experimental|Single Arm|
3317498|NCT00219284|Experimental|Immediate switch|Patients were switched the day after randomization from combined carbidopa/levodopa to combined carbidopa/levodopa/entacapone. Patients received the same doses of carbidopa (12.5, 25.0, or 37.5 mg) and levodopa (50, 100, or 150 mg) they were receiving prior to the switch, combined with 200 mg of entacapone. The frequency of doses per day prior to the switch remained the same after the switch.
3317499|NCT00219284|Active Comparator|Delayed switch|Patients were switched 4 weeks after randomization from combined carbidopa/levodopa to combined carbidopa/levodopa/entacapone. Patients received the same doses of carbidopa (12.5, 25.0, or 37.5 mg) and levodopa (50, 100, or 150 mg) they were receiving prior to the switch, combined with 200 mg of entacapone. The frequency of doses per day prior to the switch remained the same after the switch.
3317500|NCT00219271|Experimental|Zoledronic acid|4 mg IV infused over 15 minutes every 3 months
3317602|NCT00218218|Placebo Comparator|3|placebo patch
3317603|NCT00218179||Cases|Lung cancer cases diagnosed prior to 2007 among baseline smokers in the PLCO
3317604|NCT00218179||Controls|Subjects without lung cancer among smokers at baseline in the PLCO study
3317605|NCT00218166|No Intervention|A|Within subject design
3317501|NCT00219141|Experimental|Aliskiren 300 mg|Patients in this arm initially received 150 mg of aliskiren for two weeks and were then force-titrated up to 300 mg of aliskiren where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 1 tablet of aliskiren 150 mg, 1 tablet of aliskiren 150 mg placebo, and 1 capsule of losartan placebo. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg and 1 capsule of losartan placebo. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
3317502|NCT00219141|Active Comparator|Losartan 100 mg|Patients in this arm initially received 50 mg of losartan for two weeks and were then force-titrated up to 100 mg of losartan where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 2 tablets of aliskiren 150 mg placebo and 1 capsule of losartan 50 mg. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg placebo and 1 capsule of losartan 100 mg. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
3317503|NCT00219141|Experimental|Aliskiren/losartan 300/100 mg|Patients in this arm initially received 150 mg of aliskiren in combination with 50 mg of losartan for two weeks and were then force-titrated up to 300 mg of aliskiren in combination with 100 mg of losartan where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 1 tablet of aliskiren 150 mg, 1 tablet of aliskiren 150 mg placebo, and 1 capsule of losartan 50 mg. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg and 1 capsule of losartan 100 mg. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
3317504|NCT00218985|Experimental|exercise training|
3317505|NCT00218985|No Intervention|physician's advice|patients follow their physician's advice in regard to physical activity.
3317506|NCT00218972|Active Comparator|AIT: aerobic interval training|High intensity interval training on treadmill at > 90% of maximal HR for four bouts of four minutes with warm up, active pauses and cool down, three times per week for 12 weeks.
3317507|NCT00218972|Active Comparator|MIT, moderate intensity training|Moderate intensity treadmill continuous exercise at 70% of maximum heart rate for 47 minutes (in order to ensure isocaloric training amount), three times per week for 12 weeks.
3317508|NCT00218972|Active Comparator|Recommendation of regular exercise|No training intervention, general advice as prescribed in guidelines.
3317509|NCT00218959|Experimental|Narrative Exposure Therapy|carried out according to the manual as outlined by Schauer et al. (2005) (second revised edition 2011) 10 sessions of 90 min duration
3317510|NCT00218959|Active Comparator|treatment as usual|mainly help with such as sleep problems, depressive symptoms, problems related to asylum status, and other practical matters. Focus on everyday issues and the limited focus on the traumatic events, in line with reports from the National Center on Violence and Traumatic Stress.
3317511|NCT00218946|No Intervention|control|no fluid, no pacifier
3317512|NCT00218946|Experimental|water|water, no pacifier
3317513|NCT00218946|Experimental|sucrose|Sucrose, no pacifier
3317514|NCT00218946|Experimental|pacifier|No fluid, pacifier
3317515|NCT00218946|Experimental|water and pacifier|water, pacifier
3317516|NCT00218946|Experimental|sucrose and pacifier|sucrose, pacifier
3317517|NCT00218933|Active Comparator|moderate exercise training|
3317518|NCT00218933|Experimental|high intensity exercise training|
3317519|NCT00218933|No Intervention|controls|
3317520|NCT00218920|Experimental|strength training|Over a 12-week period, 13 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
3317521|NCT00218920|Experimental|continuous moderate-intensity aerobic training|Over a 12-week period, 13 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
3317522|NCT00218920|Experimental|high-intensity interval aerobic training|Over a 12-week period, 14 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
3317523|NCT00218894||post cataract surgery|
3317524|NCT00218868||skin scrape|
3317525|NCT00218855|Placebo Comparator|A|
3317526|NCT00218855|Active Comparator|B|
3317527|NCT00218842|Experimental|exercise group|individualized exercise
3317528|NCT00218842|No Intervention|control group|care as usal
3317529|NCT00218816|Experimental|1|
3317530|NCT00218816|Other|2|
3317531|NCT00218803|Experimental|1|
3317532|NCT00218803|Other|2|
3317533|NCT00218790|No Intervention|Control group|The control group received standard dialysis at a temperature of 37 degrees Celcius
3317534|NCT00218790|Experimental|Experimental group|Subjects in the experimental group received cool dialysate during treatment
3317535|NCT00218725|Other|Cognitive Therapy|The cognitive therapy intervention for suicide attempters has been designed to provide a brief, timely, flexible intervention that can be incorporated into general and psychiatric inpatient and outpatient services and applied to the population of patients who attempt suicide. A central feature of the intervention is the adaptation of cognitive therapy to the population of patients who attempt suicide. The focus of the intervention is the identification of core beliefs and key automatic thoughts that were elicited prior to and during the most recent suicide attempt. Once these beliefs and thoughts have been articulated, the counselor and patient develop more adaptive responses during an acute suicidal crisis.
3317606|NCT00218127|Experimental|1|LAAM WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day for 20 weeks
3317607|NCT00218127|Experimental|2|LAAM MaxEffect to 48 mg Adjust to effect (+/-)
3317608|NCT00218127|Experimental|3|LAAM Fixed Dose up to 48 mg 48 mg
3317635|NCT00217893|Active Comparator|2|Usual education program
3317536|NCT00218725|Other|Enriched Care|The Enriched Care condition will be used as the treatment comparison condition for this study. The Enriched Care condition consists of the usual care that patients may obtain in the community as well as the assessment and referral services provided by the case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health and substance abuse treatment in the community.
3317537|NCT00218712|Experimental|1|Participants will receive personalized cognitive counseling
3317538|NCT00218712|Active Comparator|2|Participants will receive standard counseling
3317539|NCT00218686|Experimental|1|behavioral social network risk reduction intervention
3317540|NCT00218686|Active Comparator|2|voluntary counseling and testing (VCT
3317541|NCT00218673|Experimental|experimental|social network
3317542|NCT00218673|No Intervention|control|testing and counseling
3317543|NCT00218660|Experimental|1|Nal + BRENDA
3317544|NCT00218660|Placebo Comparator|2|Placebo + BRENDA
3317545|NCT00218660|Experimental|3|Nal + CBT
3317546|NCT00218660|Placebo Comparator|4|Placebo + CBT
3317547|NCT00218634|Experimental|CBT-AD|Cognitive behavioral therapy for adherence and depression
3317548|NCT00218634|Active Comparator|ETAU|Enhanced treatment as usual
3317549|NCT00218608|Placebo Comparator|Placebo|Placebo (microcrystalline cellulose) was suspended in the methadone during weeks 3-14.
3317550|NCT00218608|Active Comparator|Disulfiram at 62.5 mg|Disulfiram at 62.5 mg was suspended in the methadone during weeks 3-14.
3317551|NCT00218608|Active Comparator|Disulfiram at 125 mg|Disulfiram at 125 mg/day was suspended in methadone during weeks 3-14.
3317552|NCT00218608|Active Comparator|Disulfiram at 250 mg|Disulfiram at 250 mg/day was suspended in methadone during weeks 3-14.
3317553|NCT00218595|Experimental|DBT|
3317554|NCT00218595|Active Comparator|I/GDC|
3317555|NCT00218582|Experimental|1|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
3317556|NCT00218582|Active Comparator|2|Standard psychiatric day treatment
3317557|NCT00218569|Experimental|1|Naltrexone
3317558|NCT00218569|Experimental|2|Placebo
3317559|NCT00218556|Experimental|Depression prevention|Cognitive behavioral treatment for depression.
3317560|NCT00218556|No Intervention|Control|Treatment as usual.
3317561|NCT00218543|Experimental|Atomoxetine|Atomoxetine
3317562|NCT00218517|Experimental|1|
3317563|NCT00218517|Placebo Comparator|2|
3317564|NCT00218491|Experimental|1|1200mg N-Acetylcysteine
3317565|NCT00218491|Experimental|2|2400mg N-Acetylcysteine
3317566|NCT00218491|Placebo Comparator|3|Matching Placebo
3317567|NCT00218465|Experimental|GW468816|Glycine Antagonist GW468816, 200 mg/day, for a 5-week trial
3317568|NCT00218465|Placebo Comparator|Placebo|Placebo, 200 mg/day, for a 5-week trial
3317569|NCT00218452|Experimental|Lifestyle counseling|
3317570|NCT00218439|Experimental|1|Active medication for 4 weeks followed by placebo for 4 weeks
3317571|NCT00218439|Experimental|2|Placebo for 4 weeks followed by active for 4 weeks
3317572|NCT00218426|Active Comparator|ON|Oral naltrexone
3317573|NCT00218426|Experimental|DNI|naltrexone implant
3317574|NCT00218426|Placebo Comparator|ONP|daily placebo oral naltrexone and placebo implant every 8 weeks
3317575|NCT00218413|Experimental|1|
3317576|NCT00218413|Experimental|2|
3317577|NCT00218413|Experimental|3|
3317578|NCT00218413|Experimental|4|
3317579|NCT00218413|Experimental|5|
3317580|NCT00218387|Experimental|1|200mg Modafinil
3317581|NCT00218387|Experimental|2|400mg Modafinil
3317582|NCT00218387|Placebo Comparator|3|Matching Placebo
3317583|NCT00218335|Experimental|Intervention Condition|Participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
3317584|NCT00218335|Active Comparator|Control Condition|The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.
3317585|NCT00218322|Placebo Comparator|1|Treatment with placebo or atomoxetine for 12 weeks.
3317586|NCT00218322|Experimental|2|
3317587|NCT00218296|Active Comparator|Usual Care Group|Usual care for cessation with immediate quit date scheduled and two weeks of nicotine patch supplied.
3317588|NCT00218296|Experimental|Reduction Group|Reduction in nicotine exposure for 6 weeks prior to quit date using medicinal nicotine lozenge or reduced nicotine smokeless tobacco.
3317589|NCT00218283|Experimental|1 - Nicotine Lozenge|Use of nicotine lozenge plus behavioral counseling to help reduce tobacco use prior to quit date.
3317590|NCT00218283|Placebo Comparator|2 Behavioral counseling|Use of behavioral counseling alone to help reduce tobacco use prior to quit date.
3317591|NCT00218270|Experimental|1|Reduction of tobacco use by substituting tobacco free snuff.
3317592|NCT00218270|Placebo Comparator|2|Reduction of tobacco use by using behavioral techniques.
3317593|NCT00218257|Active Comparator|Progesterone|200mg progesterone BID
3317594|NCT00218257|Placebo Comparator|placebo|Placebo BID
3317595|NCT00218244|Active Comparator|1 Controlled use|Reduction in tobacco toxicants by switching to a lower nicotine tobacco product under a controlled use condition.
3317596|NCT00218244|Active Comparator|2 Uncontrolled use|Reduction in tobacco toxicants by switching to a lower nicotine tobacco product under an uncontrolled use condition.
3317597|NCT00218244|Placebo Comparator|3 Behavioral|Reduction in smokeless tobacco use using behavioral techniques only.
3317598|NCT00218231|Experimental|1|300 mg/day bupropion-sr
3317599|NCT00218231|Placebo Comparator|2|0 mg bupropion-sr
3317600|NCT00218218|Experimental|1|Transdermal nicotine, 42 mg
3317609|NCT00218114|Experimental|1|Divalproex sodium (Depakote). This is a parallel groups design lasting a total of six weeks. Participants will be on a fixed-flexible dosing schedule. The dose of depakote will be raised to 750mgs or 1000mgs, depending on weight, in two weeks to achieve blood levels between 50-130 micrograms per milliliter. If a patient does not achieve this blood level on 750mgs or 1000 mgs, the dose may be raised during the second week.
3317610|NCT00218114|Placebo Comparator|2|This is a parallel groups design lasting a total of six weeks. Participants will be on matching placebo for 250 mgs divalproex sodium (Depakote).
3317611|NCT00218062|Experimental|D-Amphetamine 60mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. d-Amphetamine sustained release (SR) (Dexedrine Spansules) started at 15 mg (day 1-2), increased to 30mg (day3; 15mg, BID), 45mg (day4; 15mg, TID), and 60mg (day5; 15mg bid plus 30mg qd). A 5-day dose reduction schedule occurred at week 17.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
3317612|NCT00218062|Experimental|Modafinil 400mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. Modafinil started at 200mg (day1) and increased to 400mg (days2-5). A 5-day dose reduction schedule occurred at week 17.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
3317613|NCT00218062|Experimental|Modafinil 200mg + D-Amphetamine 30mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. For the combination condition, dosages of modafinil and d-amphetamine were escalated to one-half of that for the single medication conditions. A 5-day dose reduction schedule occurred at week 17.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
3317614|NCT00218062|Placebo Comparator|Placebo + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
3317615|NCT00218049|Experimental|1|50 mg of GBR 12909
3317616|NCT00218049|Experimental|2|75 mg of GBR 12909
3317617|NCT00218049|Experimental|3|100 mg of GBR 12909
3317618|NCT00218036|Experimental|1|Modafinil 200mg / Methadone Maintenance (1.2mg/kg)
3317619|NCT00218036|Experimental|2|Modafinil 400mg/ Methadone Maintenance (1.2mg/kg)
3317620|NCT00218036|Experimental|3|Citalopram 20/ Methadone Maintenance 1.2mg/kg
3317621|NCT00218036|Experimental|4|Citalopram 40/ Methadone Maintenance 1.2 mg/kg
3317622|NCT00218036|Placebo Comparator|5|Placebo given to methadone-maintained subjects (1.2mg/kg) for the duration of the 12-week study
3317623|NCT00218023|Experimental|Modafinil plus MI, CM, and CBT|"The modafinil dose began at 200 mg (day 1) and increased to the fixed dose of 200 mg twice daily (day 2) during the 12 weeks of Phase II.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
3317624|NCT00218023|Experimental|Levodopa/Carbidopa plus MI, CM, and CBT|"Levodopa-carbidopa, in the sustained-release formulation (Sinemet CR), began at a dose of levodopa/carbidopa 400/100 mg (day 1) and increased to the fixed dose of 400/100 mg twice daily (day 2) during the 12 weeks of Phase II.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
3317625|NCT00218023|Experimental|Naltrexone HCl plus MI, CM, and CBT|"Naltrexone hydrochloride (HCl) doses began at 25 mg (day 1) and increased to the fixed dose of 25 mg twice daily (day 2) during the 12 weeks of Phase II.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
3317626|NCT00218023|Placebo Comparator|Placebo plus MI, CM, and CBT|"Placebo capsules were identical in appearance to active drug capsules, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
3317627|NCT00218010||Methadone maintained lactating women|Methadone maintained women who chose to breastfeed their infants provided breast milk and plasma samples for this study.
3317628|NCT00217984|Experimental|Intensive intervention|Extended cognitive behavior therapy (16 sessions) plus nicotine patches and lozenges
3317629|NCT00217984|Other|Usual care|Referral to the smoking cessation clinic
3317630|NCT00217971|Active Comparator|Dronabinol|Dronabinol: 20mg bid for a daily maximum dose of 40mg.
3317631|NCT00217971|Placebo Comparator|Placebo|placebo
3317632|NCT00217919|Experimental|1|Health-Counselor Mediated Telephone Counseling Intervention
3317636|NCT00217867|No Intervention|1|Usual Care, defined as the usual hospital discharge process as delivered by nurses and doctors.
3317637|NCT00217867|Experimental|2|Use of animated computerized character to prepare subjects for discharge by reviewing information provided to subjects in a printed After Hospital Care Plan packet, followed by telephone system to reinforce the discharge.
3317638|NCT00217854|Other|Open label inhaled fluticasone|Patients are treated with open label high dose fluticasone for 30 days then discontinued. Comparisons are pre- and post- treatment single arm.
3317639|NCT00217776|Active Comparator|Open Airways Educational Intervention|Children in this arm will receive the Open Airways educational program which is an evidenced based asthma educational program for children, developed by the investigator.
3317640|NCT00217776|Active Comparator|Open Airways and Peer Asthma Action Intervention Education|Children in this arm will receive BOTH the Open Airways asthma education program and the Peer Asthma Action education program.
3317641|NCT00217776|No Intervention|Control Arm|Children in the Control Arm will be interviewed in person at baseline, 12 month and 24 months.
3317642|NCT00217737|Active Comparator|Arm A (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
3317643|NCT00217737|Experimental|Arm B (combination chemotherapy, bevacizumab)|Patients receive oxaliplatin, leucovorin calcium, and fluorouracil as in Arm A and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone for 12 additional courses in the absence of disease progression or unacceptable toxicity.
3317644|NCT00217737|No Intervention|Arm C (observation)|Patients undergo observation.
3317645|NCT00217724|Experimental|Glutamine Arm|Beginning on day 2 of course 1 of paclitaxel administration, patients receive oral glutamine three times daily for 4 days.
3317646|NCT00217724|Placebo Comparator|Placebo arm|Beginning on day 2 of course 1 of paclitaxel administration, patients receive oral placebo three times daily for 4 days.
3317647|NCT00217711|Active Comparator|Arm A|Oxaliplatin, Irinotecan, and Capecitabine
3317648|NCT00217672|Experimental|Bevacizumab + Docetaxel|"docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.~Bevacizumab: 15 mg/kg IV every 3 weeks. Subjects continue on study until disease progression, unacceptable toxicity, or withdrawal of patient consent."
3317649|NCT00217672|Active Comparator|docetaxel|docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
3317650|NCT00217646|Experimental|Arm I|Patients receive oral sorafenib once or twice daily on days 1-5, 8-12, and 15-19.
3317651|NCT00217646|Experimental|Arm II|Patients receive oral sorafenib once or twice daily on days 1-14.
3317652|NCT00217633|Experimental|Treatment (pelvic exenteration)|Patients undergo pelvic exenteration within 14 days after study entry.
3317653|NCT00217620|Experimental|sorafenib|sorafenib
3317654|NCT00217607|Experimental|Paclitaxel|"Paclitaxel 80 mg/m² Day 1, Day 8 and Day 15. No treatment on Day 22.~1 cycle = 28 days.~Treatment duration: 6 cycles (=6 months)"
3317655|NCT00217581|Experimental|Docetaxel, Oxaliplatin & Bevacizumab|Must be administered 1st before Docetaxel & Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
3317656|NCT00217542|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive azacitidine SC once daily on days 1-4 and 15-17 and recombinant interferon alfa-2b SC on days 8, 10, 12, 15, 17, 19, 22, 24, and 26 during course 1. Beginning in course 2 and for all subsequent courses, patients receive azacitidine SC once daily on days 1-3 and 15-17 and interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 12 total courses in the absence of disease progression or unacceptable toxicity.
3317657|NCT00217516|Experimental|Arm I|Patients receive oral selenium for 3-6 weeks.
3317658|NCT00217516|Placebo Comparator|Arm II|Patients receive oral placebo for 3-6 weeks.
3317659|NCT00217490|Experimental|Computer Only|Dietary Counseling delivered by interactive computer program, without the addition of individual counseling provided by a health counselor. This arm tested a completely automated counseling program that did not include personalized behavioral counseling provided by a study staff member.
3317660|NCT00217490|Experimental|Counseling only|In this arm, dietary counseling was delivered by nutritionist, and this counseling did not include use of an automated, computer program.
3317661|NCT00217490|Experimental|Combined|In this arm, participants received dietary counseling delivered using both the automated computer program and additional counseling by a study nutritionist. That is, this arm combined the intervention programs delivered in the other two active intervention arms.
3317662|NCT00217490|Active Comparator|Physical Activity-computer|Participants assigned to this arm did not receive nutrition counseling, but they were provided physical activity counseling delivered by computer only.
3317663|NCT00217477|Experimental|Paricalcitol IV in combination with Gemcitabine IV|Patients receive gemcitabine hydrochloride IV over 80 minutes on days 1, 8, and 15 and paricalcitol IV over 15 minutes on days 7 and 14 in course 1. Beginning in course 2, patients receive paricalcitol IV over 15 minutes on days 1, 8, and 15 and gemcitabine hydrochloride IV over 80 minutes on days 2, 9, and 16. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3317664|NCT00217464|Experimental|Fulvestrant|Fulvestrant will be provided as 250 mg in 5 mL as a pre-tilled syringe. Fulvestrant will be administered as 500 mg, that is, 2 injections of 5 mL, one into each buttock im on day 0. A single 250 mg in 5 mL injection will be administered on day 14 followed by a single 250 mg in 5 mL dose on day 28 and monthly thereafter.
3317693|NCT00216983||1|"Fasting condition to measure:~quantitative relationships among proline, ornithine and glutamate with an emphasis on evaluating the rate of proline disposal and its conversion to ornithine and glutamate in burn patients~Evaluating the rate of proline de novo synthesis from glutamate or ornithine in burn patients"
3317665|NCT00217438|Experimental|Arm I (high dose melphalan, amifostine trihydrate, transplant)|"INDUCTION THERAPY:~Patients receive amifostine IV over 3-5 minutes on days -3 and -2 followed by high-dose melphalan IV over 15-30 minutes on day 2.~AUTOLOGOUS OR SYNGENEIC PBSCT: At least 20 hours after completion of melphalan, patients undergo autologous or syngeneic PBSCT on day 0.~Patients undergo restaging of the disease between days 80-90. Patients with progressive disease are removed from the study. Patients who achieve a CR or near-CR can proceed to optional maintenance therapy. Patients who do not achieve a CR or near-CR may undergo additional induction therapy as in arm I followed by a second autologous or syngeneic PBSCT.~Patients again undergo restaging of the disease 80-90 days later. Patients with progressive disease are removed from the study. Patients without progressive disease can proceed to maintenance therapy."
3317666|NCT00217438|Active Comparator|Arm II (low dose melphalan, amifostine trihydrate, transplant)|"INDUCTION THERAPY:~Patients receive amifostine as in arm I and melphalan as in arm I at a lower dose.~AUTOLOGOUS OR SYNGENEIC PBSCT: At least 20 hours after completion of melphalan, patients undergo autologous or syngeneic PBSCT on day 0.~Patients undergo restaging of the disease between days 80-90. Patients with progressive disease are removed from the study. Patients who achieve a CR or near-CR can proceed to optional maintenance therapy. Patients who do not achieve a CR or near-CR may undergo additional induction therapy as in arm I followed by a second autologous or syngeneic PBSCT.~Patients again undergo restaging of the disease 80-90 days later. Patients with progressive disease are removed from the study. Patients without progressive disease can proceed to maintenance therapy."
3317667|NCT00217425|Experimental|Treatment (A-CHOP followed by MA)|Patients receive 6-8 cycles of bevacizumab and combination chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (A-CHOP) followed by 8 cycles of maintenance bevacizumab (MA), as outlined below. Bevacizumab 15 mg/kg is administered on day 1 over 90 min (first cycle), 60 min (second cycle) and 30 min for the subsequent cycles. CHOP (cyclophosphamide 750 mg/m 2 ; doxorubicin 50 mg/m 2 ; vincristine 1.4 mg/m2 [max. 2 mg]; prednisone 100 mg daily on days 1-5) is administered on day 1 of a 21-day cycle. Radiographic response is assessed after cycles 3, 6 and 8 of ACHOP and after cycle 8 of MA. Patients receive six cycles of ACHOP if they achieve a complete response (CR) after three cycles, eight cycles if they achieve a partial response (PR) after three cycles. Non-responders are removed from the study. ACHOP responders receive maintenance bevacizumab 15 mg/kg every 21 days for eight cycles.
3317668|NCT00217412|Experimental|Arm I|Group 1 (solid tumor or lymphoma patients): Patients receive oral SAHA once daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients may be treated at the MTD.
3317669|NCT00217412|Experimental|Arm II|Group 2 (leukemia patients): Patients receive SAHA as in group 1 at the MTD.
3317670|NCT00217412|Experimental|Arm III|Group 3 (select solid tumor patients): Patients receive oral isotretinoin twice daily on days 1-14. Patients also receive SAHA once daily on days 1-28 OR once on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.The MTD of SAHA is determined as in group 1. An additional 6 patients may be treated at the MTD.
3317671|NCT00217399|Experimental|Treatment|"PHASE I: Patients receive oral sorafenib twice daily and oral anastrozole once daily on days 1-28.~Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of sorafenib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD.~PHASE II: Patients receive sorafenib at the MTD and anastrozole as in phase I."
3317672|NCT00217373|Experimental|Arm I|"COURSE I: Patients receive recombinant vaccinia-CEA(6D)-TRICOM vaccine SC on day 1. Patients also receive sargramostim (GM-CSF) SC on days 1-4 and IFN-α-2b* SC on days 9, 11, and 13.~COURSES II-IV: Patients receive recombinant fowlpox-CEA(6D)-TRICOM vaccine SC on day 1. Patients also receive GM-CSF as in course 1 and IFN-α-2b* SC on days 1, 3, and 5.~NOTE: *The initial cohort of 6 patients does not receive IFN-α-2b.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients who do not have progressive disease or unacceptable toxicity may receive recombinant fowlpox-CEA (6D)-TRICOM vaccine, GM-CSF, and IFN-α-2b every 28 days for 2 more courses and then every 3 months for up to 2 years."
3317673|NCT00217308|Experimental|Lactobacillus|
3317674|NCT00217308|Placebo Comparator|Placebo capsules|
3317675|NCT00217269|Experimental|1|Endeavor Drug Eluting Stent
3317676|NCT00217269|Active Comparator|2|Taxus Drug Eluting Stent
3317677|NCT00217256|Experimental|1|Endeavor Drug Eluting Stent
3317678|NCT00217256|Active Comparator|2|Cypher Drug Eluting Stent
3317679|NCT00217243||Pain study Netherlands|20 healthy subjects 20 patients with a traumatic unilateral peripheral nerve injury 20 patients with CRPS I
3317680|NCT00217217|Experimental|Active EEP-MRSI treatment|20 minutes of active treatment with theEcho-Planar Magnetic Resonance Imaging (EP-MRSI)
3317681|NCT00217217|Sham Comparator|Sham comparator EP-MRSI|Sham treatment (20 minutes) with the Echo-Planar Magnetic Resonance Imaging (EP-MRSI).
3317682|NCT00217165|Placebo Comparator|1|cellulose
3317683|NCT00217165|Active Comparator|2|taurine
3317684|NCT00217100|Active Comparator|Multi Vitamin Formulation|
3317685|NCT00217100|Placebo Comparator|Sugar pill|
3317686|NCT00217087|Other|Endoscopic Mucosal Resection|Patients will undergo endoscopic mucosal resection at time of endoscopy if indicated.
3317687|NCT00217087|Other|Photodynamic Therapy|Patients will have endoscopic mucosal resection with photodynamic therapy.
3317688|NCT00217022|Active Comparator|Budesonide|9 mg daily
3317689|NCT00217022|Placebo Comparator|Placebo|three tablets daily
3317690|NCT00217009|Active Comparator|Narrowband Ultraviolet B (TL-01UVB) Therapy|treatments - 3x weekly for 15 months
3317691|NCT00217009|Active Comparator|Topical Psoralen plus ultraviolet A (PUVA)|Treatments - 3x weekly for 15 months
3317692|NCT00216996||Burn patients|Receiving standard TPN with or without glutamine enrichment
3317787|NCT00215553|Experimental|A.3 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
3321862|NCT00141544|Active Comparator|2|
3317694|NCT00216983||2|We will study the quantitative relationships among proline, ornithine and glutamate with an emphasis on evaluating the rate of proline disposal and its conversion to ornithine and glutamate in burn patients. When the patients are receiving regular TPN or TPN depleted with proline - arginine - glutamate.
3317695|NCT00216983||3|We wull evaluate the rate of proline de novo synthesis from glutamate or ornithine in burn patients when the patients are receiving regular TPN or TPN depleted proline-arginine-glutamate.
3317696|NCT00216970|No Intervention|1|"Patients will receive nutritional support in which the contents of arginine = 0, glutamate = 0 and proline = 0.~Stable isotope tracer studies will be conducted to investigate the whole body protein metabolism and the utilization of arginine in critically ill burn patients."
3317697|NCT00216970|No Intervention|2|In arm 2 patients will receive nutritional support which will provide glutamine 0.5g/kg/day. Stable isotope tracer studies will be conducted to investigate the whole body protein metabolism and the utilization of arginine in critically ill burn patients.
3317698|NCT00216944|Active Comparator|1|Premedication with atropine and morphine
3317699|NCT00216944|Active Comparator|2|Premedication with glycopyrronium, thiopental, suxamethonium and remifentanil
3317700|NCT00216853||Patients with Recurrent UTI|
3317701|NCT00216853||Healthy controls|
3317702|NCT00216749||Cilostazol|Cilostazol Treatment Patients who were in stable states after the occurrence of cerebral infarction (except cardiogenic cerebral embolism)
3317703|NCT00216736|Placebo Comparator|1|This group received intravenous phenothiazine treatment for migraine (dosing at physician discretion) plus placebo. Patients and clinicians were blinded.
3317704|NCT00216736|Experimental|2|This group received intravenous phenothiazine migraine treatment (dosage at physician discretion) plus oral dexamethasone 8mg at time of emergency department discharge. Patients and clinicians were blinded.
3317705|NCT00216710|Experimental|Home Visited Mothers|Mothers randomized to the home visited group received AK State-funded home visiting services. Frequency of home visits was determined by home visiting staff based on mothers' needs. Mothers could receive home visiting services until their child turned 3 years old
3317706|NCT00216710|No Intervention|Control Mothers|Mothers randomized to the control group did not receive home visiting services, but were offered referrals to other community-based services, as was usual protocol with home visiting agencies were operating at capacity.
3317707|NCT00216671|Experimental|001|early initiation of treatment with Risperdal Consta 25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at baseline. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
3317708|NCT00216671|Active Comparator|002|routine initiation of treatment with Risperdal Consta 25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at week 12. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
3317709|NCT00216619|Experimental|Open Label Phase|Topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening. Until Week 26
3317710|NCT00216619|Experimental|Double Blind and Roll Out Phase|the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26).
3317711|NCT00216580|Experimental|Risperidone, long-acting injectable|
3317712|NCT00216476|Experimental|001|Risperidone Long Acting Injectable (LAI) 25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.
3317713|NCT00216476|Active Comparator|002|Quetiapine Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
3317714|NCT00216476|Other|003|Aripiprazole 10-30 mg oral once daily for 104 weeks
3317715|NCT00216463|Experimental|A|Slow load with every other week maintenance
3317716|NCT00216463|Experimental|B|Slow load with every other week maintenance
3317717|NCT00216463|Experimental|C|No load; once weekly maintenance
3317718|NCT00216463|Experimental|D|No load; once weekly maintenance
3317719|NCT00216463|Experimental|E|No load; once weekly maintenance
3317720|NCT00216372|Experimental|1|
3317721|NCT00216372|Placebo Comparator|2|
3317722|NCT00216320|Experimental|WalkAide|Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
3317723|NCT00216320|Active Comparator|Ankle Foot Orthosis|Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
3317724|NCT00216320|Other|No Crossover|Subjects wear AFO for entire 12 weeks with no crossover
3317725|NCT00216281|Active Comparator|clozapine with AZT added|Clozapine augmented with Atomoxitine up to 40mg
3317726|NCT00216281|Placebo Comparator|placebo|Subjects will have a placebo pill added to their clozapine regimen.
3317727|NCT00216255|Experimental|Pagoclone|.15mg, .30mg, .60mg
3317728|NCT00216255|Placebo Comparator|Placebo|Placebo
3317729|NCT00216216|Active Comparator|1|Pemetrexed for patients with chemosensitive and chemoresistant relapsed small cell lung cancer.
3317730|NCT00216203|Experimental|Investigational Treatment|Pemetrexed + cetuximab for patients with recurrent non-small cell lung cancer.
3317731|NCT00216190|Experimental|Dexmedetomidine|
3317732|NCT00216190|Active Comparator|Midazolam|
3317733|NCT00216164|Experimental|1|Rituximab + Gemcitabine for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
3317734|NCT00216151|Active Comparator|A|Patients will be randomly assigned by study number to receive 4mg of zoledronic acid every three months.
3317735|NCT00216151|No Intervention|B|Patients will be randomly assigned by study number to observation only.
3317736|NCT00216138|Active Comparator|1|Docetaxel + Capecitabine
3318448|NCT00203476|Active Comparator|Statin with Ezitimibe|Ezitimibe 10mg (average 10mg)
3317737|NCT00216125|Other|Pre-Randomization|Prior to randomization patients received Cisplatin 50 mg/m^2 days 1,8,29,36 + Etoposide 50 mg/m^2 days 1-5, 29-33 + Radiation 5940 cGy (180 cGy/day). Patients with CR, PR or SD with manageable toxicity were randomized to either Docetaxel arm or Observation only arm.
3317738|NCT00216125|Active Comparator|Consolidation Docetaxel|Docetaxel 75 mg/m^2 q3wk X 3 cycles.
3317739|NCT00216125|No Intervention|Observation Only|Patients were followed for Observation.
3317740|NCT00216112|Experimental|Investigational Treatment|Imatinib Mesylate + Docetaxel
3317741|NCT00216099|Experimental|Investigational Treatment|"Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle~Oral Folic Acid, once per day for 7 days preceding pemetrexed dose, continued daily, and for 21 days after the last dose of pemetrexed.~Vitamin B12, 1000ug intramuscular injection 7 days preceding pemetrexed dose, and every three cycles thereafter on the same day of pemetrexed administration"
3317742|NCT00216086|Experimental|Investigational Treatment|"Irinotecan 200 mg/m2 IV, day 1~Capecitabine 1000* mg/m2 po bid day 1-14; repeat every three weeks for two cycles~For calculated creatinine clearance of 30-50 mL/min or patients > 70 years old, capecitabine starting dose is 825 mg/m2 po bid~EUS~Neoadjuvant Chemotherapy~Preoperative Radiation~Surgery~Adjuvant Chemotherapy (at discretion of treating physician)"
3317743|NCT00216073|Active Comparator|1|Capecitabine + Oxaliplatin + trastuzumab. Patients must be HER2 positive.
3317744|NCT00216060|Experimental|Experimental Arm|Daily oral risedronate combined with androgen deprivation
3317745|NCT00216060|Placebo Comparator|Placebo Arm|daily oral placebo combined with androgen deprivation
3317746|NCT00216047|Experimental|Single Group Assignment|Trastuzumab + PTK787 for HER2 positive patients
3317747|NCT00216034|Active Comparator|1|TS-1 Group: The group treated with TS-1 mono-therapy
3317748|NCT00216034|Experimental|2|TS-1+PSK Group: The group treated with combination therapy using TS-1 and PSK
3317749|NCT00216021|Experimental|Single Group Assignment|Capecitabine + Oxaliplatin
3317750|NCT00215995|Experimental|Cisplatin, Irinotecan and ZD1839|As outlined in Detailed Description.
3317751|NCT00215982|Experimental|Combination Therapy|Capecitabine in Combination with Irinotecan and Oxaliplatin
3317752|NCT00215956|Experimental|Dose Escalation and Radiation, Followed by Surgery|Preoperative treatment with radiation and oral topotecan for up to 5 weeks, followed by surgery.
3317753|NCT00215943|Active Comparator|VAD Treatment|"VAD (vincristine, adriamycin, dexamethasone). Vincristine and adriamycin was administered by continuous infusion via a venous catheter for 96 hours every 28 days. Each 28 days is considered one cycle of therapy. Patients were to receive 4 to 6 cycles of therapy. Dexamethasone was taken in pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4. Patients were randomized to receive zoledronic acid IV on either Day 1 or 15 of each cycle."
3317754|NCT00215943|Active Comparator|Thalidomide and Dexamethasone Treatment|Thalidomide was taken orally once every day in the evening for four to six months. The dexamethasone was taken in a pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4.
3317755|NCT00215930|Experimental|Double Agent Chemotherapy|Molecular Analysis-Directed Chemotherapy Assignment based on gene expression of ERCC1 and RRM1.
3317756|NCT00215904|Placebo Comparator|1|
3317757|NCT00215904|Experimental|2|
3317758|NCT00215878|Placebo Comparator|1|Adjuvant 6 weeks treatment with placebo (~2g /day)
3317759|NCT00215878|Experimental|2|Adjuvant 6 weeks treatment with D-serine (~2g /day)
3317760|NCT00215852|Active Comparator|1|500 IU
3317761|NCT00215852|Active Comparator|2|1000 IU
3317762|NCT00215852|Active Comparator|3|2000 IU
3317763|NCT00215826|Active Comparator|1|650 IU
3317764|NCT00215826|Active Comparator|2|1300 IU
3317765|NCT00215774|No Intervention|No antiarrhythmic treatment|Control group
3317766|NCT00215774|Experimental|B-Flecainide treatment|4 weeks treatment with flecainide
3317767|NCT00215774|Experimental|C-Flecainide treatment|6 months flecainide treatment
3317768|NCT00215735|Experimental|APC Treatment|wound debridement and treatment with APC
3317769|NCT00215683|Experimental|Degarelix 80 mg|Participants who completed the CS12 study in the Degarelix 80 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
3317770|NCT00215683|Experimental|Degarelix 120 mg|Participants who completed the CS12 study in the Degarelix 120 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
3317771|NCT00215683|Experimental|Degarelix 160 mg|Participants who completed the CS12 study in the Degarelix 160 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
3317772|NCT00215657|Experimental|Degarelix 120 mg (20 mg/mL)|Degarelix 120 mg (20 mg/mL)
3317773|NCT00215657|Experimental|Degarelix 120 mg (40 mg/mL)|Degarelix 120 mg (40 mg/mL)
3317774|NCT00215657|Experimental|Degarelix 160 mg (40 mg/mL)|Degarelix 160 mg (40 mg/mL)
3317775|NCT00215657|Experimental|Degarelix 200 mg (40 mg/mL)|Degarelix 200 mg (40 mg/mL)
3317776|NCT00215657|Experimental|Degarelix 200 mg (60 mg/mL)|Degarelix 200 mg (60 mg/mL)
3317777|NCT00215657|Experimental|Degarelix 240 mg (40 mg/mL)|Degarelix 240 mg (40 mg/mL)
3317778|NCT00215657|Experimental|Degarelix 240 mg (60 mg/mL)|Degarelix 240 mg (60 mg/mL)
3317779|NCT00215657|Experimental|Degarelix 320 mg (60 mg/mL)|Degarelix 320 mg (60 mg/mL)
3317780|NCT00215644|Active Comparator|1|
3317781|NCT00215644|Experimental|2|
3317782|NCT00215618|Experimental|1|Uterine Balloon Therapy with post procedure curettage
3317783|NCT00215618|Experimental|2|Uterine Balloon Therapy without post-procedure curettage
3317784|NCT00215605|Experimental|1|
3317785|NCT00215553|Experimental|A.1 Lucinactant|3 30-mL aliquots per bronchopulmonary segment using concentrations of 5, 5, and 10 mg/mL total phopholipids. One re-treatment at 48 hours.
3317786|NCT00215553|Experimental|A.2 Lucinactant|3 30-mL aliquots per bronchopulmonary segment using concentrations of 10, 10, and 10 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
3318449|NCT00203450|Experimental|Zonegran|Zonegran
3317788|NCT00215553|Experimental|A.4 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids (TPL). One re-treatment at 48 hours. One bolus re-treatment (20 mg/mL TPL) in another 48 hours. A second bolus re-treatment (20 mg/mL TPL) administered 48 hours later.
3317789|NCT00215553|Experimental|B.1 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
3317790|NCT00215553|Experimental|B.2 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids (TPL). One re-treatment at 48 hours. One bolus re-treatment (20 mg/mL TPL) in another 48 hours. A second bolus re-treatment (20 mg/mL TPL) administered 48 hours later.
3317791|NCT00215553|Other|B.3 SoC|Received standard ARDS management and ICU care (Standard of Care [SOC]). Included, but was not limited to, support with oxygen, conventional mechanical ventilation, sedations, and paralysis.
3317792|NCT00215540|Experimental|SURFAXIN High Dose|SURFAXIN (lucinactant) at 175 mg/kg
3317793|NCT00215540|Experimental|SURFAXIN Low Dose|SURFAXIN (lucinactant) at 90 mg/kg
3317794|NCT00215540|Placebo Comparator|Placebo|Sham air using 3.0 mL/kg volume of air
3317795|NCT00215527|Experimental|intrathecal laronidase|laronidase dose 1.74 mg, route intrathecal, frequency every 30 days, duration three months
3317796|NCT00215514|Experimental|ECF followed by 5-FU/RT followed by ECF|
3317797|NCT00215501|Experimental|Group A|Oral capecitabine
3317798|NCT00215501|Experimental|Group B|5-fluorouracil
3317799|NCT00215332||Training- CHARITE|Non-Randomized Training (TDR with CHARITE)
3317800|NCT00215332||CHARITE|Randomized Subjects treated by Lumbar Total Disc Replacment with CHARITE
3317801|NCT00215332||Control|Randomized Subjects treated by ALIF with BAK cage
3317802|NCT00215319|Experimental|TSM Cage|Lumbar I/F with cage and pedicle screws
3317803|NCT00215306|Experimental|Lumbar TDR|CHARITÉ Artificial Disc
3317804|NCT00215306|Active Comparator|ALIF|Anterior Interbody Fusion with BAK Cage
3317805|NCT00215293|Experimental|Cervical Cage|Cervical I/F Cage
3317806|NCT00215293|Active Comparator|Graft Spacer|Autograft or allograft with a plate, or autograft alone.
3317807|NCT00215150|Other|Open Label Treatment|8 weeks of open label treatment with sertraline
3317808|NCT00215150|Other|Randomization Ziprasidone|8 weeks of treatment with sertraline augmented with ziprasidone
3317809|NCT00215150|Other|Randomization Placebo|8 weeks of treatment with sertraline augmented by placebo
3317810|NCT00215137|Experimental|Open Label Escitalopram 10-20 mg/daily|Fourteen patients who met criteria for the study were enrolled in the open-label phase. Thirteen of these patients completed the open-label phase, while one patient was terminated early due to side effects.
3317811|NCT00215137|Placebo Comparator|Randomizationn Placebo 10-20 mg daily|Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I < 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).
3317812|NCT00215137|Active Comparator|Randomization Escitalopram 10-20 mg/daily|Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I < 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).
3317813|NCT00215111|Experimental|Low carbohydrate, reduced glycemic load, control diet|
3317814|NCT00215046|Experimental|Drug|no randomization, all patients receive experimental drugs
3317815|NCT00214968|Experimental|Modafinil|Subjects began taking Provigil at a dosage of 100 mg/day (1 tablet) and increased their dosage by 100 mg/day each week for up to 4 weeks
3317816|NCT00214916|Active Comparator|A|conventional insulin therapy (using Actrapid IV)
3317817|NCT00214916|Experimental|B|intensive insulin therapy (using actrapid IV)
3317818|NCT00214903||1|New users of oral continuous combined HRT containing drospirenone
3317819|NCT00214903||2|New users of oral continuous combined HRT containing other progestagens
3317820|NCT00214890|Active Comparator|Tenofovir|
3317821|NCT00214890|Active Comparator|Abacavir|
3317822|NCT00214825|Experimental|1|MR antagonist (Eplerenone) + placebo
3317823|NCT00214825|Placebo Comparator|2|Hydrochlorothiazide plus potassium
3317824|NCT00214786|Experimental|Islet Cell Transplantation|Allogenic islet cell transplantation
3317825|NCT00214773||Observational|No intervention. This is an observational program.
3317826|NCT00214760|Experimental|PGET|
3317827|NCT00214760|Active Comparator|PMMA|
3317828|NCT00214682|Experimental|Folic acid (400mcg) + Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
3317829|NCT00214682|Experimental|Mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
3317861|NCT00214305|Experimental|Range of Motion Therapy Program|The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
3317830|NCT00214682|Experimental|Mental health literacy|This MHL intervention comprised 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
3317831|NCT00214682|Placebo Comparator|Placebo tablet|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
3317832|NCT00214682|Active Comparator|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
3317833|NCT00214682|Active Comparator|Pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
3317834|NCT00214669|Experimental|1|"Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.~Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Lorig's chronic disease self-management programme.~Improved follow-up in primary care through appointment-booking by the specialist nurse."
3317835|NCT00214669|No Intervention|2|Usual Care
3317836|NCT00214539|Experimental|Treatment|Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
3317837|NCT00214539|Active Comparator|Control|Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
3317838|NCT00214526|Experimental|Alair Group|Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
3317839|NCT00214526|Active Comparator|Control Group|Conventional therapy with ICS+LABA.
3317840|NCT00214500|Experimental|25 mg, capsule|AT1001 (migalastat hydrochloride) administered twice a day for weeks 1 and 2.
3317841|NCT00214500|Experimental|100 mg, capsule|AT1001 (migalastat hydrochloride) administered twice a day for weeks 3 and 4.
3317842|NCT00214500|Experimental|250 mg, capsule|AT1001 (migalastat hydrochloride) administered twice a day for weeks 5 and 6.
3317843|NCT00214500|Experimental|50 mg, capsule|AT1001 (migalastat hydrochloride) administered daily for the remainder of the subjects participation.
3317844|NCT00214487|Experimental|Bifocal Contact Lenses|Use of bifocal contact lenses to control the progression of myopia
3317845|NCT00214487|Placebo Comparator|Control|Single vision soft contact lenses
3317846|NCT00214474|Active Comparator|ATSM Intervention|ATSM Intervention: Automated Telephone Self-Management Support
3317847|NCT00214474|Active Comparator|GMV Intervention|GMV Intervention: Group Medical Visits
3317848|NCT00214474|No Intervention|Usual Care|Usual Care: Standard care for diabetic patients
3317849|NCT00214461|Placebo Comparator|Placebo Vaccine Group|Participants will receive a dose of vaccine diluent (placebo) on Days 0, 28 and 56, respectively.
3317850|NCT00214461|Experimental|Low Dose Vaccine Group|Participants will receive a dose of vaccine containing of 2 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
3317851|NCT00214461|Experimental|Medium dose vaccine group|Participants will receive a dose of vaccine containing of 10 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
3317852|NCT00214461|Experimental|High dose vaccine group|Participants will receive a dose of vaccine containing of 50 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
3317853|NCT00214422|Experimental|1|5040cGy to lymph nodes
3317854|NCT00214422|Experimental|2|5400cGy to the lymph nodes
3317855|NCT00214422|Experimental|3|5900cGy to the lymph nodes
3317856|NCT00214383|Experimental|CHESS + Case Mgt|Case Management (with monthly support calls) and CHESS services were available for a 12 month intervention period. Support calls refer to check in calls by a nurse to the parents to see how the child is doing. CHESS services include access to a website with information on asthma management, discussion groups and a case manager. The website also include a management tool for asthma symptoms check in, and the case manager used the information entered to tailor the homepage to individual clients.
3317857|NCT00214383|No Intervention|Control|Control-usual care. Usual care refers to the manner in which clients generally manage their asthma.
3317858|NCT00214331||1|ciprofloxacin
3317859|NCT00214331||2|azithromycin
3317860|NCT00214331||3|gentamicin
3324187|NCT00107965|Placebo Comparator|8|
3317862|NCT00214305|Placebo Comparator|Postural Sensory Therapy Program|The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
3317863|NCT00214279|No Intervention|1|Remain on 3-drug standard of care immunosuppression including prednisone
3317864|NCT00214279|Experimental|2|Corticosteroid withdrawal / prednisone taper over 14 weeks
3317865|NCT00214266|Experimental|Campath-1H Induction Therapy Combined With CellCept® Therapy|Campath-1H Induction Therapy Combined With CellCept® Therapy
3317866|NCT00214253|Experimental|1|Thiazolidinedione therapy
3317867|NCT00214253|No Intervention|2|
3317868|NCT00214240|Experimental|1|Cytogam in addition to standard of care (IV ganciclovir therapy)
3317869|NCT00214240|No Intervention|2|Receive standard of care therapy (IV ganciclovir)
3317870|NCT00214201|No Intervention|1|Standard of Care CNI immunosuppression
3317871|NCT00214201|Experimental|2|Calcineurin inhibitor withdrawal
3317872|NCT00214175||patients|patients who will receive XRT
3317873|NCT00214175||matched volunteers|Spouse or sibling
3317874|NCT00214162|Other|1|internet access and computer for 1 year
3317875|NCT00214162|Experimental|2|computer and Full CHESS
3317876|NCT00214149|Experimental|1|breast brachytherapy to a dose of 34 Gy
3317877|NCT00214136|Experimental|1|prostate radiation to 70Gy, lymph nodes to 56Gy
3317878|NCT00214123|Experimental|Bin 1|bin assignment based on tumor volume
3317879|NCT00214123|Experimental|Bin 2|Bin assignment based on tumor volume
3317880|NCT00214123|Experimental|Bin 3|Bin assignment based on tumor volume
3317881|NCT00214123|Experimental|Bin 4|Bin assignment based on tumor volume
3317882|NCT00214123|Experimental|Bin 5|Bin assignment based on tumor volume
3317883|NCT00214097|Experimental|dose escalation|3 cohorts of dose escalations
3317884|NCT00214045|Active Comparator|Flexible Cystoscopy|Flexible Cystoscopy
3317885|NCT00214045|Active Comparator|Rigid Cystoscopy|Rigid Cystoscopy
3317886|NCT00214032|Experimental|1|pycnogenol daily
3317887|NCT00214032|Placebo Comparator|2|placebo daily
3317888|NCT00214019|Placebo Comparator|Placebo Diskus|Placebo comparator
3317889|NCT00214019|Experimental|Salmeterol Diskus 50 mcg twice per day|Salmeterol Diskus 50 mcg twice per day
3317890|NCT00214019|Experimental|Placebo diskus, fluticasone|placebo diskus, fluticasone MDI 88 mcg twice per day
3317891|NCT00214019|Experimental|Salmeterol, Fluticasone|Salmeterol diskus 50 mcg BID, fluticasone MDI 88 mcg twice per day
3317892|NCT00213993|Experimental|A|antiperspirant topically to one foot once daily
3317893|NCT00213980|No Intervention|Observation|Observation only for 12 months
3317894|NCT00213980|Active Comparator|Zoledronate|Zoledronate
3317895|NCT00213954|Other|interscalene block|Locoregional anesthesia selection
3317896|NCT00213954|Other|axillary block|Locoregional anesthesia selection
3317897|NCT00213954|Other|lumbar block|Locoregional anesthesia selection
3317898|NCT00213954|Other|parasacral plexus block|Locoregional anesthesia selection
3317899|NCT00213928|No Intervention|Control|
3317900|NCT00213928|Active Comparator|Horse Chestnut Seed Extract|Horse chestnut seed extract (escins, aesins)
3317901|NCT00213759|Active Comparator|groupe filigrastin|
3317902|NCT00213759|Placebo Comparator|groupe placebo|
3317903|NCT00213655||Daily instillation of BCG for 3 weeks then every 6 months|Effect of daily instillation of BCG (27 mg) for 3 weeks then one instillation of BCG (27 mg) every 6 months for 36 months on bladder tumor recurrence
3317904|NCT00213655||Daily instillation of BCG for 2 weeks then every 3 months|Effect of daily instillation of BCG (27 mg) for 2 weeks then one instillation of BCG (27 mg) every 3 months for 36 months on bladder tumor recurrence
3317905|NCT00213629|Other|no arm|no arm
3317906|NCT00213590|No Intervention|1|the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L
3317907|NCT00213590|Experimental|2|the low-exposure group the cyclosporine AUC0-12h target was 50% usual target or 2.2 (2.0 to 2.6, range) mg•h/L
3317908|NCT00213525||Patients With Scleroderma|Assessments of questionnary for environmental factors research
3317909|NCT00213525||Healthy Controls|Assessments of questionnary for environmental factors research
3317910|NCT00213421||1|
3317911|NCT00213421||2|
3317912|NCT00213291|Experimental|1|
3317913|NCT00213278|Experimental|1|
3317914|NCT00213265|Active Comparator|1|
3317915|NCT00213265|Experimental|2|
3317916|NCT00213252|Experimental|1|
3317917|NCT00213252|Active Comparator|2|
3317918|NCT00213239|Experimental|1|
3317919|NCT00213239|Experimental|2|
3317920|NCT00213148|Active Comparator|Clomiphene Citrate 50 Milligram (mg)|
3317921|NCT00213148|Active Comparator|Clomiphene Citrate 100 mg|
3317922|NCT00213148|Experimental|Anastrozole 1 mg|
3317923|NCT00213148|Experimental|Anastrozole 5 mg|
3317924|NCT00213148|Experimental|Anastrozole 10 mg|
3317925|NCT00213135|Experimental|Cladribine 5.25 mg/kg|
3317926|NCT00213135|Experimental|Cladribine 3.5 mg/kg|
3317927|NCT00213135|Placebo Comparator|Placebo|
3317928|NCT00212979||non intervention study|
3317929|NCT00212862||Patients with chemotherapy induced anemia|
3317930|NCT00212836|Experimental|Asenapine|
3317931|NCT00212836|Active Comparator|Olanzapine|
3317932|NCT00212797|Experimental|Org 34517_1|low dose Org 34517
3317933|NCT00212797|Experimental|Org 34517_2|high dose Org 34517
3317934|NCT00212797|Placebo Comparator|Placebo|
3317935|NCT00212784|Experimental|Arm 1|
3317936|NCT00212784|Active Comparator|Arm 2|
3317937|NCT00212771|Experimental|Arm 1|
3317938|NCT00212771|Active Comparator|Arm 2|
3318029|NCT00211263|Experimental|Enhanced Clinical Intervention|
3318030|NCT00211263|Active Comparator|Clinical Intervention|
3318450|NCT00203450|Placebo Comparator|Placebo|Placebo pill
3317939|NCT00212758|Active Comparator|Low- Standard GH dose|This arm will receive Low dose of growth hormone (GH) (Nutropin AQ), for 7 days in a cross over design. Low dose GH will be 0.025 mg/kg/day. This will be followed by 2 weeks of wash out, then subjects will receive and the standard dose of Nutropin AQ (GH) at 0.05 mg/kg/dose given subcutaneously for another 7 days. IGF-I levels are measured after 7 days of the Low and the Standard dose of GH. After that all subjects will be treated with the standard dose of GH therapy of 0.05 mg/kg/day for 6 months and re-evaluated. If growth is adequate then subjects will continue on standard dose of GH for another 6 months for a total of 12 months.
3317940|NCT00212758|Active Comparator|Standard-Low GH dose (7 Days)|This arm will receive Standard dose of growth hormone (GH) (Nutropin AQ), for 7 days in a cross over design. Standard dose GH will be 0.5 mg/kg/day. This will be followed by 2 weeks of wash out, then subjects will receive and the Low dose of Nutropin AQ (GH) at 0.025 mg/kg/dose given subcutaneously for another 7 days. IGF-I levels are measured after 7 days of the Low and the Standard dose of GH. After that all subjects will be treated with the standard dose of GH therapy of 0.05 mg/kg/day for 6 months and re-evaluated. If growth is adequate then subjects will continue on standard dose of GH for another 6 months for a total of 12 months.
3317941|NCT00212745|No Intervention|2|Receives only EEG and questionnaire testing, no behavioral intervention or meditative relaxation
3317942|NCT00212745|Experimental|1|Andrews/Reiter behavioral treatment for epilepsy and EEG and questionnaire testing
3317943|NCT00212576|Experimental|Building Blocks (0-3)|"Randomized at birth to receive Building Blocks Project from birth through 3 years of age.~Note: This arm not followed past 3 years of age; NOT re-randomized to any group at age 3."
3317944|NCT00212576|Experimental|VIP (0-3), VIP (3-5)|"Randomized at birth to receive Video Interaction Project from birth through 3 years of age.~Re-randomized at 3 years to receive Video Interaction Project from 3-5 years of age."
3317945|NCT00212576|Experimental|VIP (0-3), Control (3-5)|"Randomized at birth to receive Video Interaction Project from birth through 3 years of age.~Re-randomized at 3 years to receive care as usual (control) from 3-5 years of age."
3317946|NCT00212576|Experimental|Control (0-3), VIP (3-5)|"Randomized at birth to receive care as usual (control) from birth through 3 years of age.~Re-randomized at 3 years to receive Video Interaction Project from 3-5 years of age."
3317947|NCT00212576|No Intervention|Control (0-3), Control (3-5)|"Randomized at birth to receive care as usual (control) from birth through 3 years of age.~Re-randomized at 3 years to receive receive care as usual (control) from 3-5 years of age."
3317948|NCT00212550||TB diagnosis|
3317949|NCT00212498||TB diagnosis|
3317950|NCT00212472|Active Comparator|1|Low-dose treatment (50 FVIII u/kg three times a week).
3317951|NCT00212472|Active Comparator|2|High-dose treatment (200 FVIII u/kg per day).
3317952|NCT00212459|Experimental|1|Patients are contacted every two weeks after initial counseling to discuss completion of bleeding records.
3317953|NCT00212459|Active Comparator|2|After the initial counseling with regards to bleeding records, there are no more contacts made with the control patients.
3317954|NCT00212446|Experimental|Electrical Intervention|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
3317955|NCT00212407|Experimental|Umbilical cord blood unit(s) transplant|Transplantation of cryopreserved umbilical cord blood unit(s)
3317956|NCT00212381|Experimental|oral DIM (Active agent)|2mg/kg/day po of DIM
3317957|NCT00212381|Active Comparator|Red rice bran (Placebo)|this agent is not generally thought to be active but may be
3317958|NCT00212355|Experimental|NPC-02|zinc acetate
3317959|NCT00212342|Experimental|Norethisterone,Ethinylestradiol|
3317960|NCT00212342|Placebo Comparator|Sugar pill|
3317961|NCT00212303|Experimental|Exercise training|Exercise training, 3 times per week, for 6 months.
3317962|NCT00212303|No Intervention|Control|Usual care no active exercise intervention
3317963|NCT00212264|Experimental|Behavioral Therapy|Behavioral Therapy (Pelvic floor muscle training, bladder control strategies)
3317964|NCT00212264|Experimental|Behavioral Therapy Plus Technologies|Behavioral therapy plus technologies (home pelvic floor electrical stimulation and biofeedback)
3317965|NCT00212264|Placebo Comparator|Placebo Comparator|No treatment control
3317966|NCT00212251|Experimental|Lifestyle counseling|10 ActiveMoms classes, 8 Moms Time Out nutrition classes, 6 coaching calls, supportive materials
3317967|NCT00212212|Experimental|1|200 µg selenium as selenate
3317968|NCT00212212|Experimental|2|400 µg selenium as selenate
3317969|NCT00212212|Experimental|3|200 µg selenium as selenomethionine
3317970|NCT00212212|Placebo Comparator|4|placebo tablet
3317971|NCT00212160|Experimental|RYGB with omentectomy|Subjects undergoing RYGB will be randomized to also have the greater omentum removed at the time of surgery.
3317972|NCT00212160|No Intervention|RYGB without omentectomy|Subjects undergoing RYGB will be randomized to NOT have the greater omentum removed at the time of surgery.
3317973|NCT00212160|No Intervention|Normal body weight|Healthy normal weight subjects studied via hyperinsulinemic-euglycemic clamp to obtain reference values for insulin sensitivity and other metabolic parameters.
3317974|NCT00212160|No Intervention|Tissue samples|Tissue samples (omental fat, subcutaneous fat, muscle,and blood)are obtained from subjects of varying weights during abdominal surgery in order to compare various parameters, including inflammation, oxidative stress, and gene expression, among tissues across weight classes.
3317975|NCT00212147|Active Comparator|I|General anesthesia that includes nitrous oxide
3317976|NCT00212147|Active Comparator|II|General anesthesia not including nitrous oxide
3317977|NCT00212134|Active Comparator|aphakic contact lens|"Contact lens correction of aphakia~INTERVENTION: use of an external contact lens (CL) to correct the large hyperopic refractive error produced by surgically extracting the natural cataractous lens. As the eye grows, the refractive error changes and the power of the CL can be changed accordingly."
3318031|NCT00211237|Experimental|Balloon Kyphoplasty (BKP)|The subjects assigned to this group will undergo the treatment with Balloon kyphoplasty for their painful VCFs.
3317978|NCT00212134|Experimental|aphakic intraocular lens|"Intraocular lens implantation~INTERVENTION: At the time of surgery to remove the cataractous natural lens, an intraocular lens was implanted to correct the large hyperopic refractive error induced by the cataract surgery."
3317979|NCT00212121|Active Comparator|1|low dose boost (16 Gy)
3317980|NCT00212121|Experimental|2|high boost (26 Gy)
3317981|NCT00212108|Experimental|Celecoxib and ZD1839|Celecoxib and ZD1839 will be given twice a day and daily respectively for two consecutive weeks prior to further anti-cancer treatment.
3317982|NCT00212095|Experimental|docetaxel and ketoconazole|
3317983|NCT00212056|Active Comparator|ANP|
3317984|NCT00212056|Placebo Comparator|Control|
3317985|NCT00212030|Active Comparator|1|
3317986|NCT00212030|Placebo Comparator|2|
3317987|NCT00212017|Active Comparator|the voglibose group|Participants in the voglibose group were administered a voglibose tablet (0.2 mg) three times daily before meals.
3317988|NCT00212017|Active Comparator|the control group|Participants assigned to the control group were treated only with diet and exercise therapy.
3317989|NCT00212004|Active Comparator|Pioglitazone|Participants in the pioglitazone group were administered a pioglitazone tablet (15 mg) once a day. In the event of the side effects such as oedema, the dosage of pioglitazone was reduced to half or a quarter of the original dosage. Otherwise, we tried to increase the dose of pioglitazone to 30mg/day.
3317990|NCT00212004|Active Comparator|Control|Participants assigned to Control group were treated with diet and exercise therapy or sulfonylurea (SU) or other additional drugs than pioglitazone.
3317991|NCT00211978|Experimental|PhosLo|
3317992|NCT00211978|Placebo Comparator|placebo|
3317993|NCT00211965|Experimental|vaccine|single dose
3317994|NCT00211965|Placebo Comparator|placebo|single dose
3317995|NCT00211939|Experimental|1|PhosLo + atorvastatin
3317996|NCT00211939|Active Comparator|2|Sevelamer + atorvastatin
3317997|NCT00211926|Experimental|StaphVAX|
3317998|NCT00211926|Placebo Comparator|Placebo|
3317999|NCT00211913|Experimental|vaccine|single dose of StaphVAX®
3318000|NCT00211913|Placebo Comparator|placebo|single dose
3318001|NCT00211900|Experimental|vaccine|single dose of StaphVAX in hemodialysis patients
3318002|NCT00211887|Active Comparator|Interferon beta 1-a|"Active Interferon B1a Weekly vs. Placebo Glatiramer Acetate~Interferon b-1a (IFN) intramuscularly weekly"
3318003|NCT00211887|Active Comparator|glatiramer acetate|"Placebo Interferon B1a Weekly vs. Active Glatiramer Acetate~Glatiramer acetate 20mg daily"
3318004|NCT00211887|Active Comparator|IFN and GA|Active Interferon B1a Weekly and Active Glatiramer Acetate
3318005|NCT00211874|Experimental|Nurse-management|nurse-led intervention focused on specific management problems
3318006|NCT00211874|No Intervention|Usual Care|Usual care as control group
3318007|NCT00211835|Experimental|Treatment Arm 1|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
3318008|NCT00211835|Experimental|Treatment Arm 2|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
3318009|NCT00211822||Pathologic Gamblers|
3318010|NCT00211822||Obsessive Compulsive Disorder|
3318011|NCT00211822||Healthy Controls|
3318012|NCT00211809|Experimental|Body dysmorphic disorder|Participants with body dysmorphic disorder
3318013|NCT00211783||Autism|
3318014|NCT00211783||Control|
3318015|NCT00211757|Placebo Comparator|Placebo|Subjects in this arm will receive a placebo comparative to the study drug divalporex sodium.
3318016|NCT00211757|Experimental|Divalporex Sodium|Subjects will receive the study drug, divalproex sodium.
3318017|NCT00211692|Active Comparator|Group A consensus interferon+rbv 52 wks|Daily CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given 52 weeks (group A)
3318018|NCT00211692|Experimental|Group B CIFN variable duration|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for 52-72 weeks (from time of viral response +48 weeks) (group B)
3318019|NCT00211562|Active Comparator|Olanzapine|
3318020|NCT00211562|Active Comparator|Omega 3|
3318021|NCT00211562|Active Comparator|Vitamin E +C|
3318022|NCT00211536|Experimental|MiniMed Implantable insulin Pump (MIP)|The experimental group will receive intraperitoneally (IP) delivered insulin via the Medtronic MiniMed Implantable Pump (MIP). At the time of implant, the pump will be filled with Aventis HOE21PH U400 insulin and the subject will be treated with this insulin for the first 180 days post implant. During the refill procedure performed 180 days post implant, any insulin remaining in the pump will be removed and the pump will be refilled with Medtronic MiniMed Implantable Pump Human Recombinant Insulin.
3318023|NCT00211536|No Intervention|Subcutaneous insulin arm (SC)|The control group will remain on their current pre-study subcutaneous insulin therapy of either Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII - external insulin pump). The SC group will not be restricted to the type of insulin used, or be required to change or modify their current diabetes therapy for the purpose of the study.
3318024|NCT00211510|Experimental|Paradigm 722 sensor augmented pump|subjects will use the Paradigm 722 sensor augmented pump for infusion of insulin and continuous glucose monitoring
3318025|NCT00211510|Active Comparator|Paradigm 715 insulin pump|subjects will use the Paradigm 715 insulin pump which does not include sensor augmentation for infusion of insulin
3318026|NCT00211432|Experimental|Title: Treatment of Pseudovitellium Detachment|Open-Label Anecortave Acetate Sterile Suspension(15mg)
3318027|NCT00211393|Experimental|Drug: ketoconazole|"Drug: ketoconazole~Other Names:~ketoconazole~600mg. /day for 6 weeks"
3318028|NCT00211354|Experimental|anecortave acetate|anecortave acetate 15 mg. juxtascleral injection every 6 months for 24 months
3324188|NCT00107952|Experimental|Telavancin|
3318032|NCT00211237|Active Comparator|Non Surgical Management|The subjects in this group will undergo the non-operative treatments aimed at alleviation of back pain and restoration of decreased function associated with VCFs.
3318033|NCT00211185|Experimental|1|
3318034|NCT00211172|Experimental|Beta-blocker adherence after an AMI|Patients received two mailings about the importance of beta blocker use.
3318035|NCT00211172|No Intervention|Usual care|Patients received usual care.
3318036|NCT00211081|Experimental|Open Label|
3318037|NCT00211068||Epoetin alfa|Four control patients will be matched to each index patients enrolled in protocol EPO-IMU-301 identified as having chronic kidney disease and an immune-mediated cause of pure red cell aplasia (PRCA) indicated by the presence of anti-erythropoietin (EPO) antibodies in their serum at the time of loss of efficacy.
3318038|NCT00211042||Pure Red Cell Aplasia (PRCA)|This study will examine the relationship of the presence of anti-erythropoietin antibodies to the clinical course and outcome of participants currently or previously treated with recombinant human erythropoietin and who have PRCA identified from all notified reports (spontaneous postmarketing reports or from clinical trials reports).
3318039|NCT00211029||Participants Receiving Epoetin Alfa or Another Erythropoietin|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
3318040|NCT00210977||Erythropoietin receptor agonist|Participants with borderline serum anti erythropoietin (EPO) antibody (Ab) titers and who are treated with any erythropoietin receptor agonist (ERA) for any indication, having anti-EPO Ab identified by radioimmunoprecipitation (RIP), who are responding to ERA therapy, will be included in the study.
3318041|NCT00210964|Experimental|001|ceftobiprole plus placebo ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
3318042|NCT00210964|Active Comparator|002|linezolid plus ceftazidime linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
3318043|NCT00210951||Participants Receiving Epoetin Alfa or Another Erythropoietin|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
3318044|NCT00210899|Active Comparator|Vancomycin plus Ceftazidime|Vancomycin 1g q12h as 1h infusions plus Ceftazidime 1g q8h in 2h-infusions, 7-14d
3318045|NCT00210899|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d
3318046|NCT00210678||Group: 1|Men with premature ejaculation (PE)
3318047|NCT00210678||Group: 2|Men without PE
3318048|NCT00210652|Experimental|001|RWJ 333369: Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
3318049|NCT00210639||Levofloxacin-treated cohort|Participants receiveing levofloxacin in previous levofloxacin studies will be observed.
3318050|NCT00210639||Comparator-treated cohort|Participants receiveing comparator in previous levofloxacin studies will be observed.
3318051|NCT00210626|Active Comparator|PROCRIT|
3318052|NCT00210626|Placebo Comparator|Placebo|
3318053|NCT00210522|Experimental|001|RWJ 333369 Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
3318054|NCT00210470|Experimental|IRX-2 Regimen|The IRX-2 regimen is the combination of a 2-week course of IRX-2 itself, an initial dose of cyclophosphamide, and a 3-week course of indomethacin and zinc supplementation.
3318055|NCT00210418|Experimental|Preventive targeting|This arm targeted pregnant and lactating women as well as children 6-23.9 months of age to receive BCC and food assistance. A total of 27 months of enrollment in this program arm was possible.
3318056|NCT00210418|Active Comparator|Recuperative targeting|This arm targeted pregnant and lactating women as well as mothers of malnourished children (WAZ <-2 zscores) between 6 and 59 months of age. A total of 18 months of enrollment was possible in this program arm.
3318057|NCT00210405|Active Comparator|Food aid only|Children in this arm received fortified food aid commodities supplied through the maternal and child health and nutrition program implemented by World Vision. They received fortified corn-soy blend, which contained iron.
3318058|NCT00210405|Experimental|Micronutrient sprinkles + food aid|Children in this arm were enrolled in the food assisted program, and therefore received fortified food aid, as well as 60 sachets of a multiple micronutrient powder (Sprinkles) containing iron, zinc, vitamin A, vitamin C and folic acid
3318059|NCT00210353|Active Comparator|ARM A|chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment; two weeks rest; chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)
3318060|NCT00210353|Experimental|ARM B|rituximab 375 mg/m2 iv, d1, d8, d15, d22 chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment two weeks rest chlorambucil 6 mg/m2 os daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle
3318061|NCT00210353|Experimental|ARM C (Since April 2006)|rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140
3318062|NCT00210314|Active Comparator|High-dose methotrexate alone|
3318063|NCT00210314|Experimental|High-dose methotrexate associated with high dose cytarabine|
3318064|NCT00210275|No Intervention|Control|Usual practice; no additional information provided.
3318065|NCT00210275|Experimental|Printed Educational Message #1|Information about Angiotensin-converting enzyme inhibitors, hypertension treatment, and cholesterol lowering agents for diabetes
3318066|NCT00210275|Experimental|Printed Educational Message #2|Retinal screening for diabetes
3318067|NCT00210275|Experimental|Printed Educational Message #3|Diuretics for hypertension
3318068|NCT00210132|Experimental|Ropivacaine|
3318069|NCT00209898|Active Comparator|Rapid standard of care|Rapid standard of care treatment after screening
3318070|NCT00209898|Active Comparator|Ordinary standard of care|Subject put on ordinary waiting list for hcv treatment in Our outpatient clinic
3318071|NCT00209807|Experimental|1|subjects with MDD randomized to Escitalopram
3318072|NCT00209807|Active Comparator|2|MDD patients receiving reboxetine
3318073|NCT00209807|Other|3|Healthy volonteers
3318074|NCT00209742|Experimental|2|
3318075|NCT00209742|Experimental|3|
3318076|NCT00209742|Active Comparator|1|
3318077|NCT00209729|Experimental|1|Docetaxel plus S-1
3318078|NCT00209716|Experimental|1|
3318079|NCT00209690|Experimental|1|
3318080|NCT00209651|Experimental|1|Irinotecan and S-1
3318081|NCT00209612|Experimental|1|Paclitaxel+Irinotecan
3318082|NCT00209521|Experimental|fospropofol|
3318083|NCT00209521|Active Comparator|propofol|
3318084|NCT00209495|Placebo Comparator|A|
3318085|NCT00209495|Experimental|B|Pregabalin
3318086|NCT00209495|Experimental|C|Pregabalin + dexamethasone
3318087|NCT00209417|Active Comparator|Iodixanol 320-Arm 1|Iodixanol 320 mg I/mL
3318088|NCT00209417|Active Comparator|Iopamidol 300-Arm 2|Iopamidol 300 mg I/mL
3318089|NCT00209378|Active Comparator|heparin|Citrate regional anticoagulation is compared with standard systemic heparinization.
3318090|NCT00209378|Active Comparator|Citrate|regional anticoagulation with citrate containing replacement solution
3318091|NCT00209339|Experimental|MitraClip|Percutaneous mitral valve repair (MitraClip Implant)
3318092|NCT00209313|Other|1|Acyclovir 800 mg twice daily for 8 weeks, two week washout, 8 weeks placebo
3318093|NCT00209313|Other|2|8 weeks placebo, 2 week washout, 8 weeks 800 mg acyclovir twice daily
3318094|NCT00209274|Experimental|1|Percutaneous mitral valve repair using MitraClip implant. The calculated sample size was 186 patients in the device arm
3318095|NCT00209274|Active Comparator|2|Mitral valve repair or replacement surgery. The calculated sample size was 93 patients in the control arm.
3318096|NCT00209261|Active Comparator|1|
3318097|NCT00209261|Active Comparator|2|
3318098|NCT00209235|Experimental|Albright hereditary osteodystrophy natural history|Albright hereditary osteodystrophy: Natural history
3318099|NCT00209222|Active Comparator|1|induction: R-CHOP consoldiation : TBI/Cyclo
3318100|NCT00209222|Experimental|2|induction: R-CHOP/DHAP consolditaion: TBI/TAM
3318101|NCT00209209|Active Comparator|1|"randomisation: R-CHOP~randomisation: IFN maintenance"
3318102|NCT00209209|Experimental|2|"randomisation: R-FC~randomisation: Rituximab maintnenance"
3318103|NCT00209196||pediatric solid organ transplants|Adherence to medical regimens refers to what degree a patient chooses to follow the advice given by his/her healthcare provider.More recently, researchers have started to look at adherence with children who have undergone solid organ transplantation. This is because about 50% of these children are to some degree non-adherent with their medical regimen. This comes at a costly price as ongoing non-adherence in pediatric transplant can lead to the child's body rejecting the new organ and even death. This study has been designed to look at the reasons that pediatric patients may choose to be non-adherent.
3318104|NCT00209170|Experimental|Beating the Blues CBT + Escitalopram|Subjects with type 2 diabetes will be randomized to Beating the Blues (computerized cognitive behavioral therapy) with the selective serotonin reuptake inhibitor (SSRI) antidepressant, escitalopram (10 mg taken orally once or twice daily) for 6 months
3318105|NCT00209170|Active Comparator|Beating the Blues CBT + Placebo|Subjects with type 2 diabetes will be randomized to Beating the Blues (computerized cognitive behavioral therapy) with placebo (taken orally one to two tablets daily) for 6 months
3318106|NCT00209144|Experimental|Angioplasty with Insulin|Coming in with acute infarct and received angioplasty with intensive insulin therapy
3318107|NCT00209144|No Intervention|Angioplasty w/o Insulin|Coming in with acute infarct and received angioplasty
3318108|NCT00209131|Experimental|Flomax|Patients on this arm will be given 0.4mg of Flomax to be taken for one month following their shock wave lithotripsy procedure.
3318109|NCT00209131|Placebo Comparator|Sugar pill|Patients on this arm will be given a sugar pill to be taken for one month following their shock wave lithotripsy procedure.
3318110|NCT00209105||1|Participants who have experienced early-life trauma will undergo a series of diagnostic tests.
3318111|NCT00209092|Active Comparator|Sequential Therapy|Docetaxel will be given at 100mg/m^2 intravenous Day 1 every 3 weeks for 4 cycles followed by capecitabine 1000 mg/m^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) (total 24 weeks).
3318112|NCT00209092|Active Comparator|Concurrent Therapy|Docetaxel will be given at 50mg/m^2 Intravenous Day1 concomitantly with capecitabine 1000 mg/m^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
3318113|NCT00209079|Active Comparator|1|
3318114|NCT00209053|Experimental|Off Pump CABG|CABG without cardiopulmonary bypass.
3318115|NCT00209053|Active Comparator|On-Pump CABG|CABG with cardiopulmonary bypass.
3318116|NCT00209040||1|Subjects with posttraumatic stress disorder
3318117|NCT00209040||2|Healthy controls
3318118|NCT00209040||3|Combat controls
3318119|NCT00209027|Experimental|schizophrenia subjects|Patients to be switched from baseline medication to aripiprazole, and fMRI measured at baseline and after med switch.
3318120|NCT00209001|Sham Comparator|Sham acupuncture therapy|Sham acupuncture therapy
3318121|NCT00209001|Active Comparator|Acupuncture|Acupuncture
3318122|NCT00209001|No Intervention|Observation|Observation
3318123|NCT00208975|Active Comparator|Fludarabine and Mitoxantrome followed by GM-CSF and Rituximab|"Initial patients (n=9) received fludarabine (25 mg/m2 IV) and mitoxantrone (10 mg/m2 IV)with sequential administration of GM-CSF (500 mcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m2) on day 8.~After a change in the protocol, all additional patients (n=6) received fludarabine (25 mg/m2 IV) and cyclophosphamide (250 mg/m2 IV)with sequential administration of GM-CSF (500 mcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m2) on day 8. All patients received dditional doses of GM-CSF (days +8 through +14) were given for patients to reduce variability in neutropenic management."
3318124|NCT00208962|Active Comparator|1|
3318182|NCT00208260|Active Comparator|B|FOLFOX-4
3318183|NCT00208260|Experimental|C|FOLFIRI-HD
3318125|NCT00208949|Active Comparator|G-CSF(Granulocyte Colony-Stimulating Factor )|Single use of G-CSF(Granulocyte Colony-Stimulating Factor ) G-CSF 7.5 µg/kg twice a day
3318126|NCT00208949|Active Comparator|Granulocyte CSF+Granulocyte Macrophage CSF|Combined use of G-CSF(Granulocyte Colony-Stimulating Factor ) and GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) (G-CSF 7.5 µg/kg / GM-CSF 7.5 µg/kg.)
3318127|NCT00208923|Active Comparator|1|Chemotherapy-only conditioning regimen comprising busulfan (Bu), cyclophosphamide (Cy) and fludarabine (FLUDARA) followed by an allogeneic stem cell transplant.
3318128|NCT00208845||adult ED patients|
3318129|NCT00208806||congenital heart patients with congestive heart failure|20 effected patients with congestive heart failure patients total 50 patients
3318130|NCT00208793|Experimental|Calcium|Calcium 2,000 mg/day as calcium carbonate in two divided doses with food
3318131|NCT00208793|Experimental|Vitamin D3|Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
3318132|NCT00208793|Experimental|Calcium and vitamin D3 combined|Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with meals over 6 months
3318133|NCT00208793|Placebo Comparator|Placebo|
3318134|NCT00208780|Experimental|Dose-response of oral BH4|Eight subjects received 100 mg of oral BH4 twice a day and 8 received 200 mg twice daily.
3318135|NCT00208780|Experimental|Onset & duration of action of oral BH4|Eight hypertensive subjects were assigned to either 5 mg kg−1 day−1 (n=4) or 10 mg kg−1 day−1 (n=4) of BH4, given in two divided doses orally for 8 weeks.
3318136|NCT00208767|Active Comparator|Valsartan|Valsartan titrated up to 320 mg orally daily
3318137|NCT00208767|Placebo Comparator|Placebo|Patients received a placebo instead of Valsartan
3318138|NCT00208702|Experimental|sertraline + triiodothyronine|
3318139|NCT00208702|Placebo Comparator|sertraline + placebo|
3318140|NCT00208611|Experimental|Open-Label Treatment|Levodopa-treated Parkinson's Disease subjects with vitamin B12 < 200 pg/ml given oral vitamin B12 supplement
3318141|NCT00208559|Other|1 Open Label|Open Label
3318142|NCT00208546|Experimental|1Capecitabine + bevacizumab + oxaliplatin + cetuximab|
3318143|NCT00208546|Active Comparator|21Capecitabine + bevacizumab + oxaliplatin|
3318144|NCT00208533|Other|1 Open Label|Open Label Aripiprazole
3318145|NCT00208507|Active Comparator|Delta Ceramax Ceramic-on-Ceramic Acetabular Cup System|Total hip replacement with a 28 mm ceramic head and liner.
3318146|NCT00208507|Active Comparator|Pinnacle™ Acetabular Cup with Marathon® Polyethylene|Total hip replacement with 28 mm ceramic head with a polyethylene liner.
3318147|NCT00208494|Active Comparator|A|Ceramic-on-metal total hip implant
3318148|NCT00208494|Active Comparator|B|Metal-on-metal total hip implant
3318149|NCT00208468|Other|European Hip|A cementless femoral component for use in total hip replacement
3318150|NCT00208468|Active Comparator|Zweymüller|A cementless femoral component for use in total hip replacement
3318151|NCT00208468|Active Comparator|CLS Spotorno|A cementless femoral component for use in total hip replacement
3318152|NCT00208455|Other|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
3318153|NCT00208442|Active Comparator|Marathon™|Moderately cross-linked polyethylene liner in a modular acetabular component
3318154|NCT00208442|Active Comparator|Enduron™|Standard UHMWPE polyethylene liner in a modular acetabular component
3318155|NCT00208429|Other|Pinnacle Acetabular System|
3318156|NCT00208416|Active Comparator|1|DePuy MI System
3318157|NCT00208416|Active Comparator|2|Conventional surgical technique
3318158|NCT00208403|Active Comparator|1|Acryloc™ GHV
3318159|NCT00208403|Active Comparator|2|Palacos R
3318160|NCT00208390|Other|Summit Tapered Hip System|A cementless, tapered femoral component for use in total hip replacement
3318161|NCT00208377|Other|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
3318162|NCT00208364|Other|Pinnacle Acetabular Cup System|A cementless acetabular cup with metal liner for use in total hip replacement
3318163|NCT00208351|Active Comparator|1) Ultima LX Collared Stem - Non-Polished/Blasted Finished|A collared non-polished blasted finished cementless femoral component for use in total hip replacement.
3318164|NCT00208351|Active Comparator|2) Ultima LX Collared Stem - Polished Finished|A collared polished finished cementless femoral component for use in total hip replacement.
3318165|NCT00208351|Active Comparator|3) Ultima LX Collarless Stem - Non-Polished/Blasted Finished|A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
3318166|NCT00208351|Active Comparator|4) Ultima LX Collarless Stem - Polished Finished|A collarless polished finished cementless femoral component for use in total hip replacement.
3318167|NCT00208338|Experimental|1|Rotator cuff repair with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
3318168|NCT00208338|Active Comparator|2|Standard rotator cuff repair
3318169|NCT00208325|Other|PFC Sigma Fixed Bearing PCL Sacrificed|PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
3318170|NCT00208325|Active Comparator|PFC Sigma RP PCL Sacrificed|PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
3318171|NCT00208325|Other|PFC Sigma Fixed Bearing PCL Retained|PFC Sigma Fixed Bearing Total Knee System with PCL Retained
3318172|NCT00208325|Active Comparator|PFC Sigma RP PCL Retained|PFC Sigma Rotating Platform Total Knee System with PCL Retained
3318173|NCT00208312|Experimental|1|Regadenoson
3318174|NCT00208312|Active Comparator|2|Adenoscan
3318175|NCT00208299|Experimental|1|Regadenoson
3318176|NCT00208299|Active Comparator|2|Adenoscan
3318177|NCT00208286|Other|PFC Sigma Fixed Bearing|PFC Sigma Fixed Bearing system for use in total knee arthroplasty
3318178|NCT00208286|Active Comparator|PFC Sigma Mobile Bearing|PFC Sigma Mobile Bearing system for use in total knee arthroplasty
3318179|NCT00208273|Experimental|A|Letrozole 2.5 mg daily for 5 years started three weeks before the first day of adjuvant radiotherapy.
3318180|NCT00208273|Experimental|B|Letrozole 2.5 mg daily for 5 years started three weeks after the last day of adjuvant radiotherapy.
3318181|NCT00208260|Active Comparator|A|FOLFIRI
3318186|NCT00208247|Experimental|CBT|The cognitive behavioural treatment developed by Salkovskis, Warwick and co-workers was used, with adaptations for the specific setting.
3318187|NCT00208247|Experimental|STPP|The short-term psychodynamic psychotherapy (STPP).
3318188|NCT00208247|Experimental|Waiting List|Patients in the waiting-list group were asked to keep in touch with their GP, who had been informed of the trial in writing. The patients and their GPs were instructed not to begin any other treatment during the study period. After 6 months, the patients on the waiting list were re-evaluated for inclusion and exclusion criteria and, if they still met the criteria, re-randomized to CBT or STPP.
3318189|NCT00208234|Placebo Comparator|Control|Placebo
3318190|NCT00208234|Experimental|2|Omalizumab
3318191|NCT00208169|Experimental|1|Aripiprazole start dose at 5 mg/day by day 4-6 increase to 10 mg/da and day 7 and subsequent visits flexible dosing from 10 up to 30 mg/day.
3318192|NCT00208156|Experimental|mifepristone|
3318193|NCT00208117|Active Comparator|1|Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If AEs occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained. The psychiatry fellow will be responsible for drug administration and will see all patients weekly. All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess medical tolerance to the study medications, and ensure patient psychiatric safety. The study psychiatrist will be blinded to treatment allocation.
3318194|NCT00208117|Placebo Comparator|2|To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills. All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess the medical tolerance to the study medications (including placebo), and ensure patient psychiatric safety. The study psychiatrist will be blinded to treatment allocation.
3318195|NCT00208104|Experimental|Motivational Interview Condition|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
3318196|NCT00208104|No Intervention|Non-supportive Counseling|A non-supportive counseling session will consist of regular nurse-patient interaction.
3318197|NCT00208091|Experimental|Botulinum toxin, type B|Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
3318198|NCT00208078|No Intervention|Usual medical therapy|Usual CF care
3318199|NCT00208078|Experimental|Non-invasive ventilation|Pressure support ventilator (SAIME,AIROX)
3318200|NCT00208026|Experimental|Pimecrolimus 1% Cream|Treatment with drug/Elidel. Single arm-open-label treatment arm. A Pilot Study of the Efficacy and Safety of Pimecrolimus Cream 1% for the Treatment of Netherton Syndrome:
3318201|NCT00207948||Therapeutic Dose Adjustment|To adjust the doses of medications to meet target therapeutic concentrations
3318202|NCT00207883||Landmark|Procedure/Surgery: Use of landmarks for central line placement
3318203|NCT00207883||Ultrasound guided|Procedure/Surgery: Use of ultrasound for central line placement
3318204|NCT00207857||With and Without PFTs|
3318205|NCT00207831|Experimental|Tegafur uracile + radiotherapy|
3318206|NCT00207831|Active Comparator|radiotherapy|
3318207|NCT00207740|Experimental|CNTO 148 (golimumab)|
3318208|NCT00207740|Placebo Comparator|Placebo|
3318209|NCT00207714|Experimental|Golimumab (CNTO 148) with Methotrexate (MTX)|
3318210|NCT00207714|Experimental|Infliximab with MTX|
3318211|NCT00207714|Placebo Comparator|Placebo with MTX|
3318212|NCT00207688||Infliximab 5 mg/kg|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
3318213|NCT00207688||Infliximab 10 mg/kg|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
3318214|NCT00207688||Placebo|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
3318215|NCT00207441|Experimental|Arthritis self management program|
3318216|NCT00207441|Experimental|Chronic Disease Self Management Program|
3318217|NCT00207402|Active Comparator|rosiglitazone|Treatment with rosiglitazone 4 mg twice a day for 3 months prior to and during the course of 48 weeks of treatment with interferon alfacon-1 15mcg/0.5ml SQ daily and weight-based ribavirin.
3318218|NCT00207402|No Intervention|No Avandia|Monitoring period without rosiglitazone for 3 months prior to 48 weeks of interferon alfacon-1 15mcg/0.5ml SQ daily and weight-based ribavirin
3318219|NCT00207389||Laparoscopic gastric bypass|Patients undergoing Laparoscopic gastric bypass
3318220|NCT00207389||Open gastric bypass|Patients undergoing Open gastric bypass
3318221|NCT00207363|Experimental|Initial induction therapy|Receive Peg Intron 3.0mcg/kg/wk for 12 weeks followed by Peg Intron 1.5 mcg/kg/wk for 36 weeks
3318222|NCT00207363|Active Comparator|Standard of Care|Peg Inter 1.5mcg/kg/wk for 48 weeks
3318223|NCT00207350|Other|Brain tumor|Neurosurgical use of Interstitial Laser therapy
3318224|NCT00207311|Placebo Comparator|Xenical placebo|Xenical placebo PO three times daily with meals plus enrollment into the Xenicare program for 36 weeks followed by 48 weeks of therapy with Pegasys (180mcg/ml) plus weight based ribavirin for HCV genotype 1 or 4 and 24 weeks of therapy with Pegasys (180mcg/ml) plus 800mg ribavirin for HCV genotypes 2 and 3.
3318225|NCT00207311|Active Comparator|Xenical (orlistat)|Xenical (orlistat) 120mg PO three times daily with meals plus enrollment into the Xenicare program for 36 weeks followed by 48 weeks of therapy with Pegasys (180mcg/ml) plus weight based ribavirin for HCV genotype 1 or 4 and 24 weeks of therapy with Pegasys (180mcg/ml) plus 800mg ribavirin for HCV genotypes 2 and 3.
3318226|NCT00207285|Other|In Person Training|These firefighters received the sleep education and sleep disorders screening in person by one of our research staff.
3329370|NCT00050349|Experimental|EPO906|
3318227|NCT00207285|Other|Train the Trainer|These firefighters received the education and sleep disorder screening in person with someone taught by our research staff.
3318228|NCT00207285|Other|Online Group|These firefighters took the sleep disorder screening and education online.
3318229|NCT00207259|No Intervention|Control|Standard weekly treatments with radiation oncologist and nurse. All control patients offered intervention at end of 8-week course of radiotherapy.
3318230|NCT00207259|Experimental|Relaxation Therapy|Weekly relaxation therapy with PhD psychologist and home cognitive restructering practice
3318231|NCT00207259|Experimental|Reiki|Weekly Reiki therapy with a Reiki therapist, involves laying of the therapist's hands on the patient to rechannel energy, considered pleasant and calming
3318232|NCT00207233|Active Comparator|1|Will receive MCT study oil to supplement into liquid meal replacements.
3318233|NCT00207233|Placebo Comparator|2|Will receive LCT oil to supplement into their liquid meal replacements.
3318234|NCT00207220||3|subjects with heart failure and normal ejection fraction non-diabetic hypertensive controls hypertensive diabetic controls normotensive controls
3318235|NCT00207194|Active Comparator|Automated Telephone Program|The intervention was a totally automated, computer-based, interactive telephone counseling system called Telephone- Linked-Care, designed to monitor, educate, and counsel African-American adults with hypertension and to provide summary data regularly to the patient's primary care provider.
3318236|NCT00207194|Placebo Comparator|Health Behavior Education|The comparator group received health education relating to the management of hypertension. Members of this group also received standard primary medical care.
3318237|NCT00207155|Experimental|A|
3318238|NCT00207142|Active Comparator|Switch|ATV 400 mg + 2 NRTIs (TBD), ATV once daily, NRTIs (TBD)
3318239|NCT00207142|Active Comparator|Continuation|ATV 300 mg + RTV 100 mg + 2 NRTIs (TBD), ATV and RTV once daily, NRTIs (TBD)
3318240|NCT00207142|Other|Rescue|ATV 300 mg + RTV 100 mg + 2 NRTIs (TBD), ATV and RTV once daily, NRTIs (TBD)
3318241|NCT00207129|Experimental|A|
3318242|NCT00207129|Experimental|B|
3318243|NCT00207116|Experimental|A|
3318244|NCT00207103|Experimental|1|
3318245|NCT00207103|Experimental|2|
3318246|NCT00207103|Experimental|3|
3318247|NCT00207103|Experimental|4|
3318248|NCT00207103|Experimental|5|
3318249|NCT00207103|Experimental|6|
3318250|NCT00207090|Experimental|Ixabepilone + rifampin|
3318251|NCT00207077|Experimental|A|
3318252|NCT00207064|Experimental|1|
3318253|NCT00207051|Experimental|1|
3318254|NCT00206999|Experimental|1|
3318255|NCT00206986|Experimental|1|
3318256|NCT00206986|Experimental|2|
3318257|NCT00206960|Active Comparator|1|
3318258|NCT00206960|Active Comparator|2|
3318259|NCT00206947|Active Comparator|1|
3318260|NCT00206947|Placebo Comparator|2|
3318261|NCT00206934|Placebo Comparator|1|
3318262|NCT00206934|Placebo Comparator|2|
3318263|NCT00206843|Experimental|Results available|
3318264|NCT00206843|No Intervention|Results blinded|
3318265|NCT00206830|No Intervention|Control-Blinded from Results|
3318266|NCT00206830|Experimental|Access to Results|
3318267|NCT00206752|Experimental|unilateral radiation therapy|definitive external beam radiation in the ipsilateral neck.
3318268|NCT00206726|Experimental|Alemtuzumab plus Fludarabine|Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days.
3318269|NCT00206713|Experimental|Arm 1|
3318270|NCT00206713|Placebo Comparator|Arm 2|
3318271|NCT00206700|Experimental|Arm 1|
3318272|NCT00206687|Experimental|Arm 1|
3318273|NCT00206687|Sham Comparator|Arm 2|
3318274|NCT00206674|Experimental|Arm 1|
3318275|NCT00206674|Placebo Comparator|Arm 2|
3318276|NCT00206661|Experimental|Arm 1|
3318277|NCT00206661|Experimental|Arm 2|
3318278|NCT00206648|Experimental|Arm 1|
3318279|NCT00206648|Active Comparator|Arm 2|
3318280|NCT00206635||Group 1|
3318281|NCT00206622|Active Comparator|Arm 1|
3318282|NCT00206622|Active Comparator|Arm 2|
3318283|NCT00206622|Placebo Comparator|Arm 3|
3318284|NCT00206596|Experimental|Arm 1|
3318285|NCT00206596|Placebo Comparator|Arm 2|
3318286|NCT00206583|Experimental|EV/DNG (Qlaira, BAY86-5027)|Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral)
3318287|NCT00206544|Active Comparator|1|Tamoxifen 40 mg daily
3318288|NCT00206544|Active Comparator|2|Progesterone 20 mg daily
3318289|NCT00206544|Placebo Comparator|3|Placebo daily
3318290|NCT00206518|Experimental|A: Taxotere/Docetaxel|Chemotherapy In Arm A, patients will receive single agent Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. This will be followed by standard adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles. For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. This is done in order to minimize Adriamycin-induced cardiotoxicity.
3318291|NCT00206518|Experimental|B: AC Adriamycin/Cytoxan|In Arm B, patients will receive AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery. For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. This will be followed by 4 cycles of single agent Taxotere (100 mg/m2) every 3 weeks.
3318292|NCT00206492|Experimental|Iressa and Tamoxifen|Iressa and Tamoxifen
3318293|NCT00206466|Active Comparator|One|Taxotere
3318294|NCT00206440|Experimental|Esomeprazole|Patients receiving chemotherapy (anthracycline-based) will be randomized to esomeprazole for Cycle 1 Days 1-5 and Cycle 2 Days 1-5
3318295|NCT00206440|Placebo Comparator|Sugar pill|Subjects will be given placebo Cycle 1 Days 1-5 and Cycle 2 Days 1-5.
3318296|NCT00206427|Experimental|Intervention|Intervention/Lapatinib (GW572016)
3318571|NCT00201825|Experimental|Docetaxel and Capecitabine|
3330630|NCT00000304|Experimental|3|placebo
3318297|NCT00206414|Experimental|Iressa Day 1 with Arimidex and Faslodex|Subjects randomized to Iressa on Day 1 in combination with Arimidex and Faslodex.
3318298|NCT00206414|Active Comparator|Iressa Day 21 with Arimidex and Faslodex|Subjects randomized to Iressa Day 21 in combination with Arimidex and Faslodex
3318299|NCT00206388|Experimental|Zolendric acid with Cyclophosphamide|Zometa will be administered intravenously every 28 days beginning on day 0. Cyclophosphamide will be administered daily without interruption (unless toxicity supervenes) beginning day 0. Each course of therapy will be 28 days. On day 0 of each cycle, cyclophosphamide should be given first, followed by Zometa with a separation between the two drugs of at least one hour. All patients are required to take calcium and Vitamin D supplementation for the duration of study participation.
3318300|NCT00206375|No Intervention|1|Group 1 will be treated only with Synthroid.
3318301|NCT00206375|Experimental|2|Group 2 will be treated with Growth hormone, synthroid, and lupron.
3318302|NCT00206375|No Intervention|3|Group 3 will have acute hypothyroidism and will serve as controls.
3318303|NCT00206336|Experimental|topiramate|Topiramate open label
3318304|NCT00206323|Placebo Comparator|placebo/sugar pill|Placebo or sugar pill
3318305|NCT00206323|Active Comparator|Topiramate|Topiramate 25 mg to 200 mg
3318306|NCT00206232|Active Comparator|Spironolactone|Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.
3318307|NCT00206232|Placebo Comparator|Placebo|Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.
3318308|NCT00206102|Experimental|1|Quetiapine fumarate
3318309|NCT00206102|Active Comparator|2|Risperidone
3318310|NCT00206076|Experimental|1|mycophenolate mofetil monotherapy
3318311|NCT00206076|Active Comparator|2|mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
3318312|NCT00206011|Experimental|1|
3318313|NCT00206011|Other|2|
3318314|NCT00205946|Placebo Comparator|Placebo|
3318315|NCT00205946|Active Comparator|Bupropion|
3318316|NCT00205920|Experimental|single|BLVR Treatment
3318317|NCT00205907|Experimental|single|BLVR treatment
3318318|NCT00205881|Active Comparator|1|Bilaterally Implanted with HiRes 90K device.
3318319|NCT00205855|Experimental|Precision SCS|Precision SCS. Patients who receive Precision Spinal Cord Stimulator (SCS) Stimulus system
3318320|NCT00205829|Experimental|Active Therapy|Occipital nerve stimulation (ONS) therapy delivered to a subject implanted with a bion ONS device
3318321|NCT00205803|Experimental|13vPnC|
3318322|NCT00205803|Active Comparator|7vPnC|
3318323|NCT00205777|Active Comparator|A|
3318324|NCT00205777|Placebo Comparator|B|
3318325|NCT00205712|Placebo Comparator|Ketamine plue saline|Ketamine without dexmedetomidine
3318326|NCT00205712|Experimental|Ketamine plus dexmedetomidine|Ketamine infusion plus dexmedetomidine
3318327|NCT00205699|Active Comparator|aripiprazole|Participants in this group will be randomized to flexibly-dosed treatment with aripiprazole.
3318328|NCT00205699|Active Comparator|olanzapine|Participants in this group will be randomized to flexibly-dosed treatment with olanzapine.
3318329|NCT00205699|Active Comparator|risperidone|Participants in this group will be randomized to flexibly-dosed treatment with risperidone.
3318330|NCT00205660|Active Comparator|olanzapine|Subject's current use
3318331|NCT00205660|Active Comparator|ziprasidone|Subjects current use
3318332|NCT00205660|Active Comparator|risperidone|Subject's current use
3318333|NCT00205660|Active Comparator|quetiapine|Subject's current use
3318334|NCT00205569||1|Individuals with traumatic brain injury requiring inpatient rehabilitation.
3318335|NCT00205556|Other|1: low flux hemodialysis|standard treatment
3318336|NCT00205556|Active Comparator|2 on-line hemodiafiltration|
3318337|NCT00205543|Experimental|1|suture palate after resection
3318338|NCT00205543|Experimental|2|suture one side of palate afer resection
3318339|NCT00205543|Experimental|3|no sutures in palate after resection
3318340|NCT00205504|Active Comparator|Obese women with metabolic syndrome|
3318341|NCT00205504|Active Comparator|Obese women without metabolic syndrome|
3318342|NCT00205504|Active Comparator|lean women without metabolic syndrome|
3318343|NCT00205439||Fluorescence bronchosopy with sputum cytology|Patients undergo surgery with Fluorescence bronchosopy and sputum cytology.
3318344|NCT00205426|Experimental|Natrecor infusion|Nesiritide
3318345|NCT00205374|Active Comparator|Cidofovir|"Cidofovir (Vistide) is a commercially available agent approved by the FDA for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). The drug is not FDA approved for the treatment of RRP at this time. However, recent case reports have been encouraging with regard to the effectiveness of the agent in the treatment of RRP. The FDA has granted this study a safe to proceed designation with IND 58,481."
3318346|NCT00205374|Placebo Comparator|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
3318347|NCT00205361||1|well-nourished
3318348|NCT00205361||2|malnourished
3318349|NCT00205335|Other|glucose monitoring|Each participant received a Bayer Breeze Monitor and glucose test strips for monitoring blood sugar.
3318350|NCT00205179|Experimental|Active|100mg/day soy isoflavones
3318351|NCT00205179|Placebo Comparator|Placebo|100mg/day matching placebo
3318352|NCT00205166|Active Comparator|1|Caffeine 400 mg PO 1 hour before adenosine infusion
3318353|NCT00205166|Active Comparator|2|Caffeine 200 mg po one hour before adenosine infusion
3318354|NCT00205153|Experimental|TEAM Care|Intervention pharmacies implement 6-month TEAM program.
3318355|NCT00205153|No Intervention|Usual Care|"Control pharmacies provide usual care only."
3318356|NCT00205101||1|Triad allograft
3318357|NCT00205101||2|other anterior lumbar interbody fusion (ALIF)
3318358|NCT00205101||3|transforaminal lumbar interbody fusion (TLIF)
3318359|NCT00205101||4|posterior lumbar interbody fusion (PLIF)
3318362|NCT00205049|Experimental|Pentoxifylline/Placebo|All subjects will be randomized to receive either pentoxifylline 400mg orally or placebo 3 times daily for 28 days (20-40 treated, 1-20 placebo) with monthly follow up for 90 days.
3318363|NCT00205023|Experimental|A|
3318364|NCT00204997|Experimental|1|Laparoscopic Ovarian Transposition
3318365|NCT00204971|Experimental|1|Nutritional supplement
3318366|NCT00204971|Placebo Comparator|2|placebo
3318367|NCT00204932|Active Comparator|CLA treatment|The group randomized to Conjugated Linoleic Acid (CLA) treatment at 4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA; and 22% safflower oil for 6 months
3318368|NCT00204932|Placebo Comparator|Placebo|The group randomized to control received 4 g/d of safflower oil.
3318369|NCT00204919|Placebo Comparator|1|
3318370|NCT00204919|Active Comparator|2|
3318371|NCT00204867||A|In vivo surveillance of 6-9 mm polyps detected at CTC
3318372|NCT00204828||1.|Children with asthma
3318373|NCT00204828||2.|Children without asthma
3318374|NCT00204763|Active Comparator|2|Solid state catheter
3318375|NCT00204763|Experimental|A|
3318376|NCT00204750|Active Comparator|1|Bougie dilation
3318377|NCT00204750|Experimental|2|Needle-knife incision
3318378|NCT00204737|Active Comparator|Prednisone|Prednisone 20mg daily x 2 weeks
3318379|NCT00204737|Placebo Comparator|placebo|placebo
3318380|NCT00204698|Active Comparator|1|All subjects will be given active drug.
3318381|NCT00204594|Experimental|Antibody|
3318382|NCT00204568|Active Comparator|1|Adriamycin mono
3318383|NCT00204568|Experimental|2|Trofosfamide
3318384|NCT00204542|Active Comparator|A|Solaraze(R) 2x/day for 3 months
3318385|NCT00204542|Active Comparator|B|Solaraze(R) 2x/day for 6 months
3318386|NCT00204529|Experimental|PegIFN|pegylated interferon-alpha-2a
3318387|NCT00204529|Active Comparator|IFN|interferon-alpha-2a
3318388|NCT00204516|Experimental|mRNA Vacc|
3318389|NCT00204490|Experimental|1|soy isoflavones
3318390|NCT00204490|Placebo Comparator|2|carbohydrates (maltodextrin)
3318391|NCT00204477|Active Comparator|Soy milk|Subjects will consume two soy milk drinks from the content of 2 sachets (40 g isoflavone-free soy protein and 600 mg calcium) in place of a small meal, five days per week. Each sachet will contain 20 g soy protein and 300 mg calcium. Content of sachets will be mixed with ~1.6 liter of water for ingestion.
3318392|NCT00204477|Placebo Comparator|Cow's milk|Subjects will consume two cow's milk drinks from the content of 2 sachets (40 g cow's milk protein, casein, and 600 mg calcium) in place of a small meal, five days per week. Each sachet will contain 20 g cow's milk protein and 300 mg calcium. Content of sachets will be mixed with ~1.6 liter of water for ingestion. Casein is free of ovarian hormones.
3318393|NCT00204425|Experimental|1|exercise/soy isoflavone
3318394|NCT00204425|Experimental|2|exercise/isoflavone placebo
3318395|NCT00204425|Experimental|3|exercise placebo/soy isoflavone
3318396|NCT00204425|Placebo Comparator|4|exercise placebo/isoflavone placebo
3318397|NCT00204412|Experimental|1|flax lignan
3318398|NCT00204412|Placebo Comparator|2|placebo
3318399|NCT00204373|Experimental|single group|This is an open label, non-randomized, uncontrolled, single group study designed to treat patients with Zollinger-Ellison Syndrome and other hypersecretory conditions by controlling gastric acid production; to heal and prevent relapses of peptic ulcers and symptoms; to monitor the safety and efficacy of this treatment.
3318400|NCT00204308|Experimental|combination tenofovir-emtricitabine|
3318401|NCT00204308|No Intervention|control arm|
3318402|NCT00204243|Experimental|Naltrexone implant|Naltrexone implant (GoMedical Inc. 6 months implant)
3318403|NCT00204243|Active Comparator|Methadone|Methadone Maintenance Treatment
3318404|NCT00204061|Placebo Comparator|supportive management|needs-focused, unspecific supportive management
3318405|NCT00204061|Experimental|amisulpride|24 months amisulpride 50 to 800 mg, needs-focused, unspecific supportive management.
3318406|NCT00204022|Experimental|1|Mycophenolate mofetil (target dose 2g/day)
3318407|NCT00204022|Active Comparator|2|Azathioprine (target dose 2mg/kg/day)
3318408|NCT00203996|No Intervention|Aim 1: Placebo|One of the 3 treatment arms in Aim 1: Placebo. No subjects were randomized to this arm.
3318409|NCT00203996|Experimental|Aim 1: Pioglitazone|One of the 3 treatment arms in Aim 1: Pioglitazone. No subjects were randomized to this arm.
3318410|NCT00203996|Experimental|Aim 1: Leuprolide + Estrogen/Progestin|One of the 3 treatment arms in Aim 1: depot leuprolide plus estrogen/progestin replacement. No subjects were randomized to this arm.
3318411|NCT00203996|Experimental|Aim 2: PCOS + SDB|One of the 2 study groups in Aim 2: Women with polycystic ovary syndrome (PCOS) and sleep disordered breathing (SDB) were treated with 8 weeks of continuous positive airway pressure (CPAP).
3318412|NCT00203996|Experimental|Aim 2: Matched Controls|One of the 2 study groups in Aim 2: Women who were of similar age to those in the PCOS+SDB group were treated with 8 weeks of continuous positive airway pressure (CPAP). The recruitment of control subjects for this protocol was hindered by the difficulty in finding subjects who met both inclusion and exclusion criteria. As a consequence, the sample size of control subjects was insufficient to allow for any meaningful conclusions to be drawn. Statistical analyses were not possible due to insufficient sample size.
3318413|NCT00203996|Experimental|Aim 3: REM frag - SWS supp - Baseline|"Each subject was assessed under three experimental conditions in the following order.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~Slow wave sleep (SWS) suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention."
3318451|NCT00203424|Experimental|Erlotinib + Bevacizumab|Participants received Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
3318570|NCT00201838|Active Comparator|Arm II|Patients with pancreatic cancer for which treatment with gemcitabine as a single agent is planned will be asked to participate in this trial as a control group.
3318414|NCT00203996|Experimental|Aim 3: REM frag - Baseline - SWS supp|"Each subject was assessed under three experimental conditions in the following order.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed."
3318415|NCT00203996|Experimental|Aim 3: Baseline - REM frag - SWS supp|"Each subject was assessed under three experimental conditions in the following order.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed."
3318416|NCT00203996|Experimental|Aim 3: SWS supp - REM frag - Baseline|"Each subject was assessed under three experimental conditions in the following order.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention."
3318417|NCT00203996|Experimental|Aim 3: Baseline - SWS supp - REM frag|"Each subject was assessed under three experimental conditions in the following order.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed."
3318418|NCT00203957|Experimental|Group A|Patients who completed double-blind treatment studies 6002-US-013, 6002-US-013, 6002-US-018 immediately prior to entering this open-label trial and may have had an interuption of study drug of 14 days or less.
3318419|NCT00203957|Experimental|Group B|Patients who previously completed double-blind treatment studies 6002-US-013, 6002-US-018 or 6002-EU-007 or discontinued from open label study 6002-US-007 and have had an interuption of study drug greater than 14 days.
3318420|NCT00203944||international adopted infants|international adoptees making their first visit to international adoption clinic
3318421|NCT00203944||Control infants|
3318422|NCT00203931|Active Comparator|Cetuximab|Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes.
3318423|NCT00203931|Experimental|Cetuximab and Pemetrexed|Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes. Starting on day 15 and then subsequently on day 1 of each 21 day cycle, Pemetrexed 500 mg/m2.
3318424|NCT00203918||Prostate biopsies|Males undergoing prostate biopsies
3318425|NCT00203905|Active Comparator|A|Hydroxyurea at 500 mg PO q 12 hours x 6 days (11 total doses); Infusion of 5-FU (600 mg/m2/day x 5 days [120 hours]
3318426|NCT00203905|Experimental|B|Bevacizumab: 10 mg/kg will be given as a 90-minute infusion
3318427|NCT00203892|Experimental|A: CEA peptide 10mcg|Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
3318428|NCT00203892|Experimental|B: CEA peptide 100 mcg|Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
3318429|NCT00203892|Experimental|C: CEA peptide 1000mcg|Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
3318430|NCT00203879|Experimental|1|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
3318431|NCT00203879|Experimental|2|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 without IL-2
3318432|NCT00203788|Experimental|1|Individual Placement and Support Plus Workplace Fundamentals Module
3318433|NCT00203788|Active Comparator|2|Brokered Vocational Rehabilitation
3318434|NCT00203749|Experimental|1|Intervention communities will receive the community-based VCT intervention community mobilization, mobile VCT, and post-test support services), as well as standard clinic-based VCT
3318435|NCT00203749|Active Comparator|2|Comparison communities will receive standard clinic-based VCT
3318436|NCT00203645|Experimental|Brief self-directed treatment|self-help workbook plus motivational telephone intervention
3318437|NCT00203645|Experimental|Self-directed plus telephone support|Self-help workbook, motivational telephone intervention plus telephone booster calls
3318438|NCT00203645|Active Comparator|Workbook only|Workbook only
3318439|NCT00203645|No Intervention|Waitlist|Six week waitlist
3318440|NCT00203619|Experimental|1|Wireless capsule endoscopy
3318441|NCT00203619|Active Comparator|2|Standard care
3318442|NCT00203606|Experimental|Active Treatment|Active Treatment with Pegylated Interferon Alfa 2a (Pegasys, Roche) and ribavirin
3318443|NCT00203606|No Intervention|Observation|Observation with no active treatment for Hepatitis C. Observation period is based on standard treatment duration based on genotype of Hepatitis C. Active treatment offered to participants at conclusion of observation. (Protocol Amendment #1, October 30, 2001. Ethics approval Jan 19, 2004).
3318444|NCT00203567|Active Comparator|Equetro|Equetro
3318445|NCT00203502|Experimental|Intervention: Dtx Cyclophosphamide Bev|Docetaxel 75m/m2 Cyclophosphamide 500 mg/m2 Bevacizumab 15 mg/kg
3318446|NCT00203476|Active Comparator|Statin with Niacin|Niacin dose range of 500-1500mg (average 888mg)
3318447|NCT00203476|Active Comparator|Statin with Colestipol|Colestipol dose range 5-15gm (average 9.5gm)
3318452|NCT00203411|Experimental|Bevacizumab Plus Capecitabine|Bevacizumab 7.5 mg/kg every 3 weeks will be administered interavenously (IV) to the enrolled patients. Oral capecitabine 1000 mg/m^2 twice daily for 14 days followed by 7 days off every 21 days. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of patient consent.
3318453|NCT00203385|Experimental|Divalproex|Divalproex; oral up to 2000mg/d; open label
3318454|NCT00203372|Experimental|Bevacizumab 7.5 and TAC|one dose of Bevacizumab (7.5mg/kg) will be administered intravenously every 3 weeks followed by TAC.
3318455|NCT00203372|Placebo Comparator|Placebo 7.5 and TAC|Placebo7.5 will be administered intravenously every 3 weeks followed by TAC.
3318456|NCT00203372|Experimental|Bevacizumab 15 and TAC|one dose of Bevacizumab (15mg/kg) will be administered intravenously every 3 weeks followed by TAC.
3318457|NCT00203372|Placebo Comparator|Placebo 15 and TAC|Placebo 15mg/kg will be administered intravenously every 3 weeks followed by TAC.
3318458|NCT00203307|Other|Olanzapine then Placebo|Olazepam
3318459|NCT00203307|Other|Placebo then olanzapine|
3318460|NCT00203294|Active Comparator|Lidocaine 2%, Bupivicaine 0.5% and saline|Adult patients with CDH, and headache of at least moderate intensity at time of treatment, were randomized to receive bilateral GONB and trigger point injections in the cervical paraspinal and the trapezius muscles bilaterally.
3318461|NCT00203294|Active Comparator|Lidocaine 2%, Bupivicaine 0.5% and triamcinolone 40 mg|Adult patients with CDH, and headache of at least moderate intensity at time of treatment, were randomized to receive bilateral GONB and trigger point injections in the cervical paraspinal and the trapezius muscles bilaterally.
3318462|NCT00203268|Experimental|Treatment with dihydroergotamine mesylate (DHE-45)|Subjects who treated a moderate to severe migraine 2 and 4 hours after the onset of throbbing headache pain
3318463|NCT00203242|Experimental|Depacon IV and Depakote ER|Subjects will be treated in this single arm study with 2 consecutive days of IV Depacon followed by oral Depakote ER for a total of 1000 mg of Depacon and 1000 mg of Depakote ER each day.
3318464|NCT00203229|Placebo Comparator|Placebo|Dosing Schedule Morning Evening Daily Total Week 1-2 ---- 50mg 50mg Week 3-4 50mg 50mg 100mg Week 5 100mg 100mg 200mg Week 6 150mg 150mg 300mg Week 7 200mg 200mg 400mg Week 8 (if needed for pain) 200mg 300mg 500mg Week 9 (if needed for pain) 300mg 300mg 600mg Week 10 (if needed for pain) 300mg 400mg 700mg
3318465|NCT00203229|Active Comparator|Lamotrigine|Dosing Schedule Morning Evening Daily Total Week 1-2 ---- 50mg 50mg Week 3-4 50mg 50mg 100mg Week 5 100mg 100mg 200mg Week 6 150mg 150mg 300mg Week 7 200mg 200mg 400mg Week 8 (if needed for pain) 200mg 300mg 500mg Week 9 (if needed for pain) 300mg 300mg 600mg Week 10 (if needed for pain) 300mg 400mg 700mg
3318466|NCT00203216|Experimental|Levatiracetam|Subject titrated open-label study drug to maximally tolerated dose: maximum: 3000 mg. per date. (minimum allowed daily dose to remain in study: 1000)
3318467|NCT00203203|Experimental|Stem Cell Therapy|Subject is randomized to receive Stem Cell Therapy (intramyocardial injection of stem cells) via NOGA mapping.
3318468|NCT00203203|Other|Control, then Stem Cell Therapy|"Subject is randomized to receive a NOGA mapping and no injections at time of active enrollment.~At 6 months, subject is offered stem cell therapy."
3318469|NCT00203177|Experimental|Experimental 1|0.5 mg rasagiline mesylate oral once daily
3318470|NCT00203177|Experimental|Expermental 2|1.0 mg rasagiline mesylate oral once daily
3318471|NCT00203164|Experimental|rasagiline mesylate|rasagiline mesylate 1 mg oral once daily
3318472|NCT00203151|Experimental|1|
3318473|NCT00203151|Placebo Comparator|2|
3318474|NCT00203112|Active Comparator|Glatiramer Acetate injection with oral minocycline|Glatiramer Acetate 20mg with oral minocycline 100mg
3318475|NCT00203112|Experimental|Glatiramer Acetate with placebo|Glatiramer acetate injection 20mg with oral placebo
3318476|NCT00203099|Active Comparator|Glatiramer Acetate, N-Acetylcysteine|
3318477|NCT00203073|Active Comparator|Copaxone 20 mg|Copaxone 20 mg
3318478|NCT00203073|Active Comparator|Copaxone 20mg with Novantrone induction|Copaxone 20mg with Novantrone induction
3318479|NCT00203060|Experimental|A|Rasagiline treatment
3318480|NCT00203060|Placebo Comparator|B|placebo arm
3318481|NCT00203047|Active Comparator|GA + Placebo|Glatiramer acetate (GA) 10mg as a subcutaneous injection daily, plus a placebo to mimic prednisone given daily.
3318482|NCT00203047|Experimental|GA + Prednisone|Glatiramer acetate (GA) 20mg daily as a subcutaneous injection, plus 1250 mg of prednisone daily.
3318483|NCT00203034|Experimental|Experimental 1|0.5 mg rasagiline mesylate oral once daily
3318484|NCT00203034|Experimental|Experimental 2|1.0 mg rasagiline mesylate oral once daily
3318485|NCT00203034|Placebo Comparator|Placebo|Placebo Comparator
3318486|NCT00203021|Experimental|Glatiramer Acetate|Open label treatment
3318487|NCT00203008||Observational procedure|Patients will be examined and any suspicious skin abnormalities will be biopsied
3318488|NCT00202995|Experimental|1|Glatiramer Acetate 20 mg s.c. daily
3318489|NCT00202995|Active Comparator|2|Betaseron 250 ug every other day or Rebif 44 ug 3 times a week
3318490|NCT00202982|Active Comparator|glatiramer acetate 20 mg|glatiramer acetate 20 mg
3318491|NCT00202982|Active Comparator|glatiramer acetate 40 mg|glatiramer acetate 40 mg
3318492|NCT00202969|Experimental|1|S-1
3318493|NCT00202969|Active Comparator|2|S-1 plus CDDP
3318494|NCT00202969|Active Comparator|3|5-FU plus CDDP
3318495|NCT00202904|Experimental|Arm 1|
3318496|NCT00202904|Active Comparator|Arm 2|
3318497|NCT00202878|Experimental|ezetimibe/simvastatin|One Ezetimibe 10 mg/simvastatin 40 mg combination tablet and two simvastatin 40 mg placebo tablets once per day.
3318498|NCT00202878|Active Comparator|simvastatin|One simvastatin 40 mg tablet, one ezetimibe/simvastatin combination 10/40 placebo tablet and one simvastatin 40 mg placebo tablet once per day.
3318499|NCT00202865|Experimental|1|
3318500|NCT00202865|Placebo Comparator|2|
3318501|NCT00202852|Placebo Comparator|1|
3318502|NCT00202852|Experimental|2|
3318503|NCT00202839|Experimental|24-Week Treatment|Genotype 1 hepatitis C virus [HCV] subjects treated for a total of 24 weeks, during the pilot treatment program (immediately before randomization)
3318569|NCT00201838|Experimental|Arm I|Patients received entanercept 25 mg subcutaneously twice weekly with gemcitabine.
3318504|NCT00202839|Active Comparator|48-Week Treatment|Genotype 1 HCV subjects treated for a total of 48 weeks: 24 weeks during the pilot treatment program (immediately before randomization) plus 24 weeks during the extended treatment program (immediately after randomization)
3318505|NCT00202787|Experimental|1|FOLFOX-4+cetuximab
3318506|NCT00202787|Active Comparator|2|FOLFOX-4
3318507|NCT00202761|Experimental|PIH|Intensified training of children with CP. Functional training (motor, speech, executive function). Coaching of parents by psychologist, individually and in groups.
3318508|NCT00202735|Active Comparator|Immobilization in internal rotation|"Immobilization in internal rotation:All patients in this group are immobilized with the arm in internal rotation.~The arm is immobilized with a normal collar and cuff device."
3318509|NCT00202735|Experimental|Immobilization in external rotation.|Immobilization in external rotation (ER. All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling ER, 15˚ version.To control the position, a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed
3318510|NCT00202722|Active Comparator|Remifentanil IVPCA|Bolus dose steps of 0.15 microgr/kg, with a 2-min lock-out time
3318511|NCT00202709|Experimental|Thought Field Therapy (TFT)|Treatment with TFT, first one hour, then 1/2 hour.
3318512|NCT00202709|No Intervention|Wait list control|
3318513|NCT00202696|Experimental|1|Nalmefene 40 mg
3318514|NCT00202696|Experimental|2|Nalmefene 80 mg
3318515|NCT00202696|Other|3|Placebo
3318516|NCT00202670||1|SPECT
3318517|NCT00202670||2|dobutamine echocardiography
3318518|NCT00202644|Experimental|A|
3318519|NCT00202644|Active Comparator|B|
3318520|NCT00202475|Active Comparator|1|
3318521|NCT00202475|Active Comparator|2|
3318522|NCT00202449|Experimental|1|Prazosin
3318523|NCT00202449|Active Comparator|2|Paroxetine
3318524|NCT00202449|Placebo Comparator|3|Placebo
3318525|NCT00202436|Active Comparator|1|Phlebotomy
3318526|NCT00202436|Active Comparator|2|Erythrocytapheresis
3318527|NCT00202410|Placebo Comparator|physiologic solution|subcutaneous administration of physiologic solution
3318528|NCT00202410|Experimental|Bacille Calmette-Guèrin (BCG) Vaccine|Anti-Tubercular Vaccination
3318529|NCT00202397|Placebo Comparator|2|placebo bid for 8 weeks
3318530|NCT00202397|Experimental|1|Riluzole, capsule-shaped 50 mg tablets bid for 8 weeks
3318531|NCT00202358|Placebo Comparator|placebo|
3318532|NCT00202358|Experimental|atenolol|
3318533|NCT00202293|Experimental|Lithium and olanzapine|
3318534|NCT00202293|Active Comparator|Lithium and chlorpormazine|
3318535|NCT00202280|Placebo Comparator|Placebo pill|Placebo pill daily for 3 months
3318536|NCT00202280|Experimental|5mg folic acid, 0.4mg B12, 50mg B6|5mg folic acid, 0.4mg B12, 50mg B6 in one pill, daily for 3 months
3318537|NCT00202267|Active Comparator|1|Clients randomized to short-stretch bandaging application
3318538|NCT00202267|Active Comparator|2|Clients randomized to four-layer bandaging application
3318539|NCT00202228|Experimental|1|Individuals living with HIV who are naive to antiretroviral treatment, or who have been on a treatment interruption for at least six months
3318540|NCT00202228|Experimental|2|Individuals living with HIV who are on an antiretroviral regimen including one of D4T/ddI/ddC/AZT
3318541|NCT00202228|Experimental|3|Individuals living with HIV who are on an antiretroviral regimen including one of D4T/ddI/ddC/AZT and have liver disease.
3318542|NCT00202228|Experimental|4|HIV negative control group
3318543|NCT00202189|Experimental|1|Budesonide
3318544|NCT00202189|Placebo Comparator|2|Saline Solution (0.9% NaCl)
3318545|NCT00202176|Experimental|1|Ipratropium Bromide
3318546|NCT00202176|Placebo Comparator|2|Saline Solution (0.9% NaCl)
3318547|NCT00202137|Active Comparator|1|home blood pressure monitoring with automatic blood pressure device
3318548|NCT00202137|Active Comparator|2|physician monitoring of blood pressure by 3 monthly office visits
3318549|NCT00202098|Experimental|1|ALI/ARDS patients
3318550|NCT00202046||Patients with lymphedema|Identification of risk factors for lymphedema in women who have had axillary surgery for breast cancer.
3318551|NCT00202046||Control patients without lymphedema|Controls matched on type of axillary surgery and surgery date for comparison in quality of life (QOL) ratings from women who have lymphedema.
3318552|NCT00202033|Experimental|1|self monitor blood glucose 3 times a day per usual diabetes class curriculum
3318553|NCT00202033|Experimental|2|only self monitor blood glucose when fasting
3318554|NCT00202033|Experimental|3|no self monitoring of blood glucose
3318555|NCT00201981|Active Comparator|1|rebamipide 1%
3318556|NCT00201981|Active Comparator|2|Rebamipide 2%
3318557|NCT00201981|No Intervention|3|placebo
3318558|NCT00201968|Other|FES training|Arm 1 receives functional electrical stimulation while walking on body weight suspension training.
3318559|NCT00201968|Other|Control Group training|Aerobic and resistance training program
3318560|NCT00201916|Experimental|1|5250 cGy in 20 fractions over 28 days
3318561|NCT00201916|Active Comparator|2|6600 cGy in 33 fractions over 45 days
3318562|NCT00201890|Experimental|1|Standard of Care plus Lymphatic massage (Decongestive Lymphatic Therapy)
3318563|NCT00201890|No Intervention|2|Standard of Care
3318564|NCT00201877|Experimental|Velcade and Rituximab|"Rituximab 375 mg/m2 IV day 1 of weeks 4, 5, 7, 8, 10, 11, 13, and 14 prior to Velcade™ administration.~Velcade™ 1.3 mg/m2 IV days 1 and 4 of weeks 1, 2, 4, 5, 7, 8, 10, 11, 13, and 14"
3318565|NCT00201864|Experimental|single-arm study|Combination of daily exemestane 25 mg with monthly 250 mg Fulvestrant injection
3318566|NCT00201851|Active Comparator|Immediate surgery|Patient assigned to immediate surgical oophorectomy/mastectomy and Tamoxifen
3318567|NCT00201851|Experimental|Scheduled surgery|Patient scheduled for mid-luteal phase surgical oophorectomy/mastectomy plus Tamoxifen
3318568|NCT00201851|Other|Immediate Surgery - nonrandomized|Patient in mid-luteal phase at time of enrollment. Assigned to immediate surgical oophorectomy/mastectomy plus Tamoxifen without randomization
3318572|NCT00201799|Experimental|Infliximab|Patients will be treated with infliximab day 1 prior to starting myeloblative chemotherapy or radiotherapy. A total of 6 doses will be administered.
3318573|NCT00201786|Experimental|Pentostatin|Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS.
3318574|NCT00201773|Experimental|Exemestane & Celecoxib|Patients will receive exemestane 25 mg orally per day for 8 weeks. Starting in the 9th week, patients will receive celecoxib 400 mg orally twice per day for 8 weeks in addition to exemestane.
3318575|NCT00201760|Experimental|Arm 1 Gemcitabine/Cisplatin/Trastuzumab|Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Cisplatin 30 mg/m2 iv over 90 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not administered within the past 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be given on the first day of cycle 1 only).
3318576|NCT00201760|Active Comparator|Arm 2 Gemcitabine / Trastuzumab|Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not administered within the past 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be given on the first day of cycle 1 only).
3318577|NCT00201734|Experimental|Arm I|Patients receive paclitaxel IV over 60 minutes on days 1, 8, and 15, carboplatin IV over 1-2 hours on day 1, and capecitabine PO BID on days 8-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3318578|NCT00201708|Active Comparator|Arm A (Docetaxel before doxorubicin/cyclophosphamide)|"Docetaxel 75 mg/m2 every 2 weeks for 4 cycles followed by A (doxorubicin) 60 mg/m2 & C (cyclophosphamide) 600 mg/m2 every 2 weeks for 4 cycles."
3318579|NCT00201708|Active Comparator|Arm B (Docetaxel after doxorubicin/cyclophosphamide)|"A (doxorubicin) 60 mg/m2 & C (cyclophosphamide) 600 mg/m2 every 2 weeks for 4 cycles followed by Docetaxel 75 mg/m2 every 2 weeks for 4 cycles."
3318580|NCT00201682|Experimental|Arm I|Etanercept 25 mg administered sub-cutaneously twice weekly (Monday and Thursday) weeks 1-5 of therapy (total of 10 doses). The third dose of etanercept will be administered 1 hour prior to receiving rituximab. Rituximab: Patients will receive 375 mg/M2 of rituximab three times weekly for four weeks (a total of 12 doses of rituximab).
3318581|NCT00201669|Experimental|Arm I|
3318582|NCT00201656|Active Comparator|1 Retention of Cerclage|Group one = Subject whose Cerclage is retained after randomization.
3318583|NCT00201656|Active Comparator|2 - Removal of Cerclage|Group 2 = Subjects who will have cerclage removed after randomization
3318584|NCT00201643|Active Comparator|1 Test group|Receive 2nd Course = Study drug (betamethasone or dexamethasone)
3318585|NCT00201643|Placebo Comparator|2 - Control|Placebo group = received placebo course
3318586|NCT00201617||1|normal hearing sensitivity
3318587|NCT00201617||2|Unilateral deafness who are implanted with a Bone Anchored Hearing Aid
3318588|NCT00201539|Active Comparator|double dose once|double dose immediate-release oral morphine at bedtime in cancer patients, placebo after 4 hours
3318589|NCT00201539|Experimental|single dose twice|single dose immediate-release oral morphine at bedtime in cancer patients, second single dose after 4 hrs
3318590|NCT00201513|Experimental|TrA exercise|Isolated Transversus abdominis (TrA) exercises (low load)
3318591|NCT00201513|Experimental|sling exercise|Sling exercises (high load)
3318592|NCT00201513|Active Comparator|group exercise|Non-specific group exercises
3318593|NCT00201500||preeclampsia|women with preeclampsia
3318594|NCT00201500||controls|healthy pregnant women
3318595|NCT00201474||brief depressive periods|brief depressive periods together with other fluctuating psychiatric symptoms
3318596|NCT00201474||major depressive disorder|
3318597|NCT00201461|Active Comparator|1|Best medical therapy
3318598|NCT00201461|Experimental|2|STARFlex arm
3318599|NCT00201448|Active Comparator|Placebo (hepatitis A)|Placebo group
3318600|NCT00201448|Experimental|Towne vaccine|Towne vaccine given at 3000 pfu/subject
3318601|NCT00201422|Experimental|Omeprazole, Amoxicillin, Clarithromycin|Anti-H. pylori Therapy (Triple therapy)
3318602|NCT00201409|Experimental|1|Participants will be randomized to receive recombinant human GM-CSF (250 mcg/M2).
3318603|NCT00201409|Placebo Comparator|2|Participants will be randomized to receive placebo.
3318604|NCT00201396|Active Comparator|A arm|CCRT
3318605|NCT00201396|Experimental|B arm|Induction/CCRT
3318606|NCT00201266||Exacerbation resistant asthma|Control group
3318607|NCT00201266||Exacerbation prone asthma|Cases
3318608|NCT00201240|Experimental|CD34+ selection with CliniMACS device|T cell depletion using Miltenyi device
3318609|NCT00201227|Experimental|Practice Change|Enhancement of primary care practice performance and practice guideline adherence
3318610|NCT00201227|No Intervention|Control|Usual care
3318611|NCT00201201|Experimental|Education|PEP-NG targeted and tailored education intervention
3318612|NCT00201201|Other|Control|Control, intervention is care as usual.
3318613|NCT00201188|Experimental|1|Participants will receive feedback and peak flow monitoring reports from their doctors.
3318614|NCT00201188|No Intervention|2|Participants will receive usual care.
3318615|NCT00201162|Experimental|Intervention|dietary supplement soy protein containing isoflavones
3318616|NCT00201162|Placebo Comparator|Placebo|dietary supplement casein placebo
3318617|NCT00201149|Experimental|1|In one team of clinicians we will implement only the patient-centered counseling program.
3318618|NCT00201149|No Intervention|3|The control group will provide usual care
3318619|NCT00201149|Experimental|2|In a subset of those clinicians receiving the patient-centered counseling program intervention, we will augment it with cultural competency training.
3318620|NCT00201136|No Intervention|MD-C/PT-C|Physician and patient control group.
3318621|NCT00201136|Experimental|MD-I/PT-C|MD CQI-type intervention; Patient control
3318622|NCT00201136|Experimental|MD-C/Pt-I|MD control; patient behavioral intervention
3318623|NCT00201136|Experimental|MD-I/Pt-I|MD CQI-type intervention; Patient behavioral intervention
3318624|NCT00201123|Placebo Comparator|Standard Treatment|Isoniazid, Rifampin, Pyrazinamide Anti-Tuberculous Therapy
3318944|NCT00196092|Other|5|Compassionate Use
3318625|NCT00201123|Experimental|Aerosol Interferon-gamma|Aerosol Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide
3318626|NCT00201123|Experimental|Subcutaneous Interferon-Gamma|Subcutaneous Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide
3318627|NCT00201110|Experimental|1|Intensive Intervention: CVD Risk Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
3318628|NCT00201110|Active Comparator|2|Brief Intervention: CVD Risk Education (1 session) + Brief Health Problem-Solving Training (1 session)
3318629|NCT00201084|Active Comparator|1|Uncertainty reduction tools, at physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
3318630|NCT00201084|No Intervention|2|Usual primary care
3318631|NCT00201071||South Bronx, Harlem, Lower East Side|
3318632|NCT00201058|Experimental|1|Receives tailored web-based program
3318633|NCT00201058|Active Comparator|2|Control students receive existing web-based, generic asthma education
3318634|NCT00201045|Experimental|Intervention|Intervention patients receive care from a clinical pharmacist to improve blood pressure.
3318635|NCT00201045|No Intervention|Control|Control patients receive usual care and do not have a clinical pharmacist included in their care.
3318636|NCT00201019|Experimental|1|Active intervention participants receive a physician-pharmacist collaborative intervention.
3318637|NCT00201019|No Intervention|2|Control participants do not receive recommendations from a clinical pharmacist.
3318638|NCT00201019|No Intervention|3|Passive intervention participants receive care by the same physicians caring for participants in the active intervention arm but are not seen by a clinical pharmacist. They are not actively enrolled in the study and do not have study visits for measuring blood pressure.
3318639|NCT00201006|Experimental|Face-to-face counseling|26 biweekly face-to-face group counseling sessions
3318640|NCT00201006|Experimental|Telephone Counseling|26 biweekly telephone counseling sessions
3318641|NCT00201006|Active Comparator|Mail contact|26 biweekly newsletters with weight management advice
3318642|NCT00200967|Experimental|B16 Arg/Arg|B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone hydroflouroalkane (HFA), followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA
3318643|NCT00200967|Experimental|B16 Gly/Gly|B16 Gly/Gly genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA
3318644|NCT00200954|Placebo Comparator|placebo|placebo group
3318645|NCT00200954|Active Comparator|2|Probiotic bacteria group
3318646|NCT00200902|Active Comparator|1|venlafaxine XR
3318647|NCT00200902|Active Comparator|2|duloxetine (Cymbalta)
3318648|NCT00200902|Active Comparator|3|escitalopram (Lexapro)
3318649|NCT00200902|Placebo Comparator|placebo|
3318650|NCT00200902|No Intervention|ICI|Subjects assigned to the interpersonal clinical interaction (ICI) will undergo a one-week waiting period after the initial assessment. Visits will involve a session with a research nurse that will be approximately 20 minutes in length; visits at baseline, end of lead-in, and 1, 2, 4, and 8 weeks also will include a brief (5-10 minutes) meeting with a physician.
3318651|NCT00200889|Experimental|auricular tVNS|active and inactive auricular transcutaneous vagus nerve stimulation (tVNS)
3318652|NCT00200876|Active Comparator|pain challenge|
3318653|NCT00200876|Sham Comparator|non-painful control|
3318654|NCT00200863|Experimental|1|420 nm light
3318655|NCT00200863|Experimental|2|480 nm
3318656|NCT00200863|Experimental|3|507 nm
3318657|NCT00200863|Experimental|4|555 nm
3318658|NCT00200863|Experimental|5|620 nm
3318659|NCT00200863|Experimental|6|460 nm
3318660|NCT00200850|Active Comparator|1|Low dose SLIT
3318661|NCT00200850|Active Comparator|2|High dose SLIT
3318662|NCT00200850|Placebo Comparator|3|Placebo
3318663|NCT00200785|Active Comparator|Garlic powder in ambient water|high allicin
3318664|NCT00200785|Experimental|garlic powder in boiling water|no allicin
3318665|NCT00200746|Experimental|2|Moderate Arginine
3318666|NCT00200746|Sham Comparator|3|Polycose control arm
3318667|NCT00200746|Experimental|1|High Arginine
3318668|NCT00200720|Experimental|Atkins Diet|Participants randomized to this arm will consume a low carbohydrate diet as described by Dr. Robert Atkins in his book: Dr. Atkins' New Diet Revolution New York: Avon Books, 2002.
3318669|NCT00200720|Active Comparator|DASH Diet|Participants randomized to this arm will consume the Dietary Approaches to Stop Hypertension (DASH) diet as described here: http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/new_dash.pdf
3318670|NCT00200707|Experimental|The treatment group|Intracoronary Injection of Autologous Bone Marrow Mononuclear C
3318671|NCT00200707|No Intervention|the control group|
3318672|NCT00200577|Experimental|TIL+IL2|TIL + IL2
3318673|NCT00200577|No Intervention|control|Patients are not treated
3318674|NCT00200408||smokers|college students who smoke
3318675|NCT00200408||non smokers|college students who don't smoke
3318676|NCT00200356|Experimental|Edaravone|
3318677|NCT00200356|Active Comparator|Ozagrel|
3318678|NCT00200343|Experimental|Ursodeoxycholic acid 150mg / day|
3318679|NCT00200343|Experimental|Ursodeoxycholic acid 600mg / day|
3318680|NCT00200343|Experimental|Ursodeoxycholic acid 900mg / day|
3318681|NCT00200291|Experimental|1|Behavioral: hypocaloric low-fat diet
3318682|NCT00200291|Placebo Comparator|2|Behavioral: hypocaloric, low-fat diet
3318683|NCT00200265|Experimental|1|Behavioral: diet
3318684|NCT00200265|Experimental|2|Behavioral: diet
3318685|NCT00200265|Placebo Comparator|3|Behavioral: diet
3318686|NCT00200252|Active Comparator|group B|women in group B will receive 10 uts oxytocin IM
3318687|NCT00200252|Active Comparator|group C|women in group C will receive oxytocin 5 uts IV
3318688|NCT00200252|Active Comparator|group A|women in group A will receive oxytocin 5 uts IM
3318689|NCT00200239|Experimental|1|Behavioral: eating breakfast from portioned and unportioned foods
3318690|NCT00200239|Experimental|2|Behavioral: eating breakfast with portioned and unportioned foods
3318691|NCT00200226|Placebo Comparator|1|Vitamin B6
3318692|NCT00200226|Active Comparator|2|misoprostol
3318693|NCT00200200|Active Comparator|1|Bevacizumab in addition to HAI plus systemic chemotherapy
3318694|NCT00200200|Experimental|2|HAI plus systemic chemotherapy alone
3318695|NCT00200174|Active Comparator|A|Raloxifene followed by combination therapy
3318696|NCT00200174|Active Comparator|B|Exemestane followed by combination therapy
3318697|NCT00200161|Active Comparator|Metronomic Therapy Cohort|Concurrent temozolomide and radiotherapy plus lose dose of temozolomide
3318698|NCT00200161|Experimental|Dose-Dense Therapy Cohort|Concurrent temozolomide and radiotherapy plus high dose of temozolomide
3318699|NCT00200148|Experimental|1|For patients randomized to ANH
3318700|NCT00200148|Active Comparator|2|standard intraoperative management
3318701|NCT00200135||1|Treated and released from ED (minor injuries)
3318702|NCT00200135||2|Trauma, admitted to the hospital (injured)
3318703|NCT00200135||3|Fatalities reported by the coroner (deaths)
3318704|NCT00200135||4|Reported by the police (No medical treatment)
3318705|NCT00200109|Other|Group 1|See protocol
3318706|NCT00200109|Other|Group 2|See protocol
3318707|NCT00200109|Other|Group 3|See protocol
3318708|NCT00200109|Other|Group 4|See protocol
3318709|NCT00200096|Active Comparator|1|Acupuncture and questionnaires
3318710|NCT00200096|Sham Comparator|2|placebo acupuncture and questionnaires
3318711|NCT00200083|Active Comparator|A|"All subjects enrolled will be implanted with an IGS system. The active group are those randomized to on and will receive active stimulation for 12 months."
3318712|NCT00200083|Placebo Comparator|B|"All subjects enrolled will be implanted with an IGS system. The placebo group are those randomized to off and will receive no stimulation for 12 months."
3318713|NCT00200044|Sham Comparator|Sham|This arm of the study has the procedure but does not get the Gatekeeper prostheses. The Sham arm has the option to cross-over to the Treatment arm at the 6-month visit.
3318714|NCT00200044|Active Comparator|Treatment|The treatment arm has the Gatekeeper devices implanted.
3318715|NCT00200005|Experimental|InterStim therapy|Patients being treated with sacral neuromodulation with InterStim therapy.
3318716|NCT00199927|Active Comparator|standard therapy|Standard therapy
3318717|NCT00199927|Active Comparator|fluvastatin|40-80 mg/day
3318718|NCT00199914|Experimental|Shortwave diathermy|continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
3318719|NCT00199914|Sham Comparator|control|continuous sham shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
3318720|NCT00199901|Active Comparator|Vaccine|NY-ESO-1 ISCOMATRIX® vaccine
3318721|NCT00199901|Placebo Comparator|Adjuvant Alone|ISCOMATRIX® adjuvant alone
3318722|NCT00199862|Experimental|Radio-labeled huA33 Antibody|"Patients will receive a single I-V infusion of 4mCi-10mCi/10mg 124I-huA33 in 5-30 mL of 5% human serum albumin (HAS) in normal saline, over 5 minutes-4 hours. Patients will be studied with 124I-huA33 positron-emission tomography (PET) and ex-vivo quantitation of tumor uptake .~Blood samples will be obtained for pharmacokinetic analysis at 5, 15, 60, and 120 minutes after completion of IV, on and before or after PET scanning on subsequent days.~Surgery (or biopsy) will be scheduled to occur 8- 10 days after administration of 124I-huA33. The 8-10 day imaging session will be scheduled for the morning of surgery or biopsy, approximately 1-6 hours before the procedure."
3318723|NCT00199602|No Intervention|lack of drug prophylaxis|
3318724|NCT00199602|Experimental|HBPM 2500 UI anti Xa in one subcutaneous injection per day|
3318725|NCT00199602|Experimental|warfarine 1mg daily|
3318726|NCT00199563|Active Comparator|active drug|Viagra 100 mg / daily for 12 weeks.
3318727|NCT00199563|Placebo Comparator|Placebo|placebo/daily for 12 weeks
3318728|NCT00199550|Active Comparator|2|Bipolar Electrosurgical Unit
3318729|NCT00199550|Active Comparator|1|Monopolar Electrosurgical Unit
3318730|NCT00199524|Active Comparator|1|ureteroscopy with ureteral access sheath
3318731|NCT00199524|No Intervention|2|ureteroscopy without ureteral access sheath
3318732|NCT00199498|Experimental|Septal RV lead placement|patient randomized to Septal RV lead placement
3318733|NCT00199498|Active Comparator|Apical RV lead placement|patient randomized to Apical RV lead placement (current standard placement)
3318734|NCT00199485|Experimental|1|Angelica Sinensis
3318735|NCT00199485|Placebo Comparator|2|placebo
3318736|NCT00199381|Experimental|Single Arm|Treatment with oral istradefylline (KW-6002) 20 or 40 mg once daily.
3318737|NCT00199290|Placebo Comparator|P|
3318738|NCT00199290|Experimental|L|low dose (0.2 %)
3318739|NCT00199290|Experimental|M|medium dose (0.3 %)
3318740|NCT00199290|Experimental|H|high dose (0.4 %)
3318741|NCT00199134|Other|Letrozole|Letrozole 2.5 mg per day
3318742|NCT00198939|Active Comparator|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
3318743|NCT00198939|Experimental|Conitive Behavorial Therapy|The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
3318744|NCT00198939|Experimental|Family Therapy|Participants assigned to the Family Therapy arm received a family-centered intervention to support targeted adolescent behavior change. The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases.
3318745|NCT00198939|Experimental|Intergrated Family and Cognitve Behavioral Therapy|Participants assigned to the IFCBT arm received the Cognitive Behavioral Therapy and Family Therapy intervention components.
3318746|NCT00198874|Active Comparator|Psychoeducation|
3318747|NCT00198874|Experimental|Conitive Behavorial Therapy|
3318748|NCT00198874|Experimental|Family Therapy|
3318749|NCT00198874|Experimental|Intergrated Family|
3318802|NCT00198107|Active Comparator|2 Aripiprazole|Participants will take aripiprazole
3318939|NCT00196105|Active Comparator|10 mm Wallstent|10 mm Stainless Steel Wallstent
3318750|NCT00198861||Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors
3318751|NCT00198822|Experimental|1|Weekly oral supplement with 7000 µg retinol equivalents from early pregnancy through 12 weeks following termination of pregnancy
3318752|NCT00198822|Experimental|2|Weekly oral supplement with 42 mg of beta-carotene from early pregnancy through 12 weeks following termination of pregnancy
3318753|NCT00198822|Placebo Comparator|3|Weekly oral supplement with placebo from early pregnancy through 12 weeks following termination of pregnancy
3318754|NCT00198796|Experimental|H10407|H10407
3318755|NCT00198770|Experimental|Crossover design - 1 arm|Meat week followed by mushroom week, counterbalanced order
3318756|NCT00198718|Experimental|Infant vitamin A Mother vitamin A|Infant received 50,000 IU vitamin A, mother received 400,000 IU vitamin A
3318757|NCT00198718|Experimental|Infant vitamin A Mother placebo|Infant received 50,000 IU vitamin A, mother received placebo
3318758|NCT00198718|Experimental|Infant placebo, mother vitamin A|Infant received placebo, mother received 400,000 IU vitamin A
3318759|NCT00198718|Experimental|Infant received placebo, mother received placebo|Infant and mother received placebo
3318760|NCT00198666|Experimental|Treatment|Children with severe pneumonia were randomly assigned to receive supplementation with elemental zinc.
3318761|NCT00198666|No Intervention|Control|Children with severe pneumonia were randomly assigned to receive supplementation with placebo tablets.
3318762|NCT00198562|Active Comparator|1|target morning home blood pressure (below 130 mmHg vs 130-139 mmHg)
3318763|NCT00198562|Active Comparator|2|antihypertensive drug (amlodipine vs losartan)
3318764|NCT00198536|Experimental|Ecabet 2.83%|Ecabet ophthalmic solution One drop in study eye 4 times daily for 90 days.
3318765|NCT00198536|Experimental|Ecabet 3.70%|Ecabet ophthalmic solution One drop in study eye 4 times daily for 90 days.
3318766|NCT00198536|Placebo Comparator|Vehicle|One drop of vehicle in study eye 4 times daily for 90 days.
3318767|NCT00198523|Experimental|Prednisolone and Tobramycin|Prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension. One drop of test agent will be instilled in the inferior cul de sac of the operative eye prior to cataract extraction.
3318768|NCT00198523|Active Comparator|Prednisolone|Prednisolone acetate 1.0% ophthalmic suspension. One drop of test agent will be instilled in the inferior cul de sac of the operative eye prior to cataract extraction.
3318769|NCT00198510|Experimental|Vitrase|A single dose of 0.05 cc of Vitrase (hyaluronidase) for ophthalmic intravitreal injection is injected into the vitreous chamber.
3318770|NCT00198510|No Intervention|Observation|Observation only, no medication or intravitreal injection
3318771|NCT00198497|Experimental|Vitrase|Single Hyaluronidase ophthalmic intravitreal injection
3318772|NCT00198497|Placebo Comparator|Placebo|Single Saline solution intravitreal injection
3318773|NCT00198484|Experimental|Vitrase|ovine hyaluronidase injection 150 USP Units in 1 mL solution. Single dose of Vitrase will be administered as an adjuvant prior to ophthalmologic surgery
3318774|NCT00198471|Experimental|Vitrase|A single intravitreous injection of Vitrase 93 USP Units (75 IU) on Study Day 1.
3318775|NCT00198458|Experimental|Vitrase|A single intradermal dose of 4.5 USP units of Vitrase at one site and the same volume of saline at a distant site for comparative control.
3318776|NCT00198445|Experimental|Bromfenac|Topical bromfenac ophthalmic solution 0.1%
3318777|NCT00198445|Placebo Comparator|Placebo|Vehicle of bromfenac
3318778|NCT00198419|Experimental|Vitrase|a single intradermal dose of 3 USP Units of Vitrase (ovine hyaluronidase) at one site and the same volume of saline at a distant site for comparative control
3318779|NCT00198393|Experimental|A|Gefitinib
3318780|NCT00198393|Experimental|B|Gemcitabine
3318781|NCT00198393|Experimental|C|Docetaxel
3318782|NCT00198380|Experimental|1|
3318783|NCT00198367|Experimental|Cisplatin-Gemzar|Cisplatin-Gemzar
3318784|NCT00198367|Experimental|Cisplatin-Navelbine-Radiotherapy|Cisplatin-Navelbine-Radiotherapy
3318785|NCT00198367|Experimental|Carboplatin-Taxol-Radiotherapy|Carboplatin-Taxol-Radiotherapy
3318786|NCT00198354|Experimental|A: pre-operative chemotherapy|pre-operative chemotherapy (gemcitabine+cisplatine, 4 cycles)
3318787|NCT00198354|Experimental|B: pre-operative chemotherapy|pre-operative chemotherapy (paclitaxel+carboplatin, 4 cycles)
3318788|NCT00198354|Experimental|C: peri-operative chemotherapy|peri-operative chemotherapy (gemcitabine+cisplatine, 4 cycles)
3318789|NCT00198354|Experimental|D: peri-operative chemotherapy|peri-operative chemotherapy (paclitaxel+carboplatin, 4 cycles)
3318790|NCT00198341|Experimental|1|Radiological arm (Clinical Visit + X-Ray Chest)
3318791|NCT00198341|Experimental|2|Scan ARM : Clinical Visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous type)
3318792|NCT00198328|Active Comparator|Surgery Control|Patients receive surgical excision of their tumor.
3318793|NCT00198328|Experimental|MedPulser EPT|Patients receive electroporation with injection of Bleomycin Sulfate.
3318794|NCT00198315|Active Comparator|Surgery Control|Patients will receive standard of care surgical removal of their tumor.
3318795|NCT00198315|Experimental|MedPulser EPT with Bleomycin|Patients who are eligible for surgical excision will receive MedPulser electroporation with injection of bleomycin sulfate into the tumor treatment area.
3318796|NCT00198276|Experimental|Bleomycin|Bleomycin 4.0 U/mL at dose of 1 U/cm^3 of treatment area; Medpulser EP
3318797|NCT00198263|Experimental|Bleomycin|Bleomycin 4 USP Units/mL; intratumorally at dose of 0.25mL/cm^3
3318798|NCT00198133|Experimental|Pemetrexed|Pemetrexed infusion once every 21 days (one cycle).
3318799|NCT00198120|Experimental|1|Participants will receive D-Cycloserine for 8 weeks.
3318800|NCT00198120|Placebo Comparator|2|Participants will receive placebo for 8 weeks.
3318801|NCT00198107|Placebo Comparator|1 Placebo|Participants will take placebo
3318940|NCT00196092|Other|1|Roll-in
3318803|NCT00198107|Active Comparator|3 Aripiprazole + D-cycloserine|Participants first will take aripiprazole then will also take D-cycloserine
3318804|NCT00198081|Experimental|Surgical Candidate|COX-2 Inhibitor 6-8 weeks prior to surgery
3318805|NCT00198081|Experimental|Medical Candidate|COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
3318806|NCT00198068||Group 1: aPL+/SLE-|Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM >= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM >= 40 units; no SLE
3318807|NCT00198068||Group 2: aPL+/SLE+|Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM >= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM >= 40 units AND SLE defined as four or more American College of Rheumatology criteria for SLE.
3318808|NCT00198068||Group 3: aPL-/SLE+|No antiphospholipid antibodies; SLE defined as four or more American College of Rheumatology criteria for SLE.
3318809|NCT00198068||Group 4: aPL-/SLE-|Healthy controls: no antiphospholipid antibodies; no SLE
3318810|NCT00198055|Experimental|Aripiprazole|Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
3318811|NCT00198042|Experimental|Surgical Reconstruction of the ACL|
3318812|NCT00198029|Experimental|Pilot Study of Hylan G-F 20|32 Subjects have received Synvisc Injections and followed for 6 months.
3318813|NCT00197873|Active Comparator|Lactophilus|Lactophilus supplementation
3318814|NCT00197873|Placebo Comparator|Placebo|Placebo is administered during chemotherapy.
3318815|NCT00197808|Experimental|Vaccine schedule 1|Menjugate vaccine at 2 and 3 months
3318816|NCT00197808|Experimental|Vaccine schedule 2|Menjugate vaccine at 2 and 4 months
3318817|NCT00197808|Experimental|vaccine schedule3|Neissvacc at 2 and 3 months
3318818|NCT00197808|Experimental|vaccine schedule 4|Neissvacc at 2 and 4 months
3318819|NCT00197808|Experimental|Vaccine schedule 5|Meningitec at 2 and 3 months
3318820|NCT00197808|Experimental|Vaccine schedule 6|Meningitec at 2 and 4 months
3318821|NCT00197756||Vitamin A|Participants in the in the parent study who had been randomized to receive either Vitamin A alone or multivitamins including vitamin A.
3318822|NCT00197756||No Vitamin A|Participants in the parent study who were randomized to receive either multivitamins excluding vitamin A, or placebo.
3318823|NCT00197756||Multivitamins|Participants in the parent study who were randomized to receive multivitamins including vitamin A or multivitamins excluding vitamin A
3318824|NCT00197756||No Multivitamins|Participants from the parent study who had been randomized to vitamin A alone or placebo
3318825|NCT00197743|Active Comparator|Vitamin A|Vitamin A + Beta Carotene
3318826|NCT00197743|Active Comparator|Multivitamins|Vitamins B, C, and E
3318827|NCT00197743|Active Comparator|Vitamin A + Multivitamins|Vitamin A + Beta Carotene, Vitamins B, C, and E
3318828|NCT00197743|Placebo Comparator|Placebo|Placebo
3318829|NCT00197730|Experimental|Multivitamins|Vitamin E, Vitamin C, and Vitamin B complex
3318830|NCT00197730|Placebo Comparator|Placebo|Placebo
3318831|NCT00197704|Placebo Comparator|Placebo|Placebo
3318832|NCT00197704|Experimental|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium
3318833|NCT00197678|Experimental|Multivitamins-Single RDA|Multivitamins at doses resembling a single daily Recommended Dietary Allowance (RDA)
3318834|NCT00197678|Active Comparator|Multivitamins-Multiples of RDA|Multivitamin supplements at multiples of the Recommended Dietary Allowance (RDA)
3318835|NCT00197652||Diarrheal specimens from infants born to HIV infected mothers|400 diarrheal specimens will suffice to determine the prevalence of specific pathogens in the region. Of these, 300 specimens will be collected from infants born to HIV infected mothers, and 100 specimens will be collected from infants born to HIV uninfected mothers.
3318836|NCT00197652||Breast milk from HIV infected and HIV uninfected women|Breast milk from HIV infected and HIV uninfected women who are breastfeeding is collected at 2 days, 2 weeks, 2 months, and 5 months post-partum. This breast milk will be compared for in vitro functional quality of immunoglobulins to selected diarrheal and respiratory pathogens.
3318837|NCT00197587|Active Comparator|maternal nevirapine|
3318838|NCT00197587|Placebo Comparator|maternal placebo|
3318839|NCT00197561|Active Comparator|Selenium|Selenium (200 ug as selenomethionine)
3318840|NCT00197561|Placebo Comparator|Placebo|Placebo
3318841|NCT00197548|Active Comparator|Multivitamins|Multivitamins-vitamins B-complex, C, and E
3318842|NCT00197548|Placebo Comparator|Placebo|Placebo pill
3318843|NCT00197496|Experimental|BWSTT|Body weight supported treadmill training
3318844|NCT00197496|No Intervention|Usual care|Usual care
3318845|NCT00197444|Experimental|1|Chemoradiotherapy
3318846|NCT00197392|Experimental|Bactiseal TM EVD|Bactiseal External Ventricular Drainage System.
3318847|NCT00197392|Active Comparator|Standard EVD Catheter|Standard External Ventricular Device system
3318848|NCT00197236|Active Comparator|Havrix Group|Subjects received one dose of Havrix at Day 0 followed by a second dose of Havrix at Month 6-9.
3318849|NCT00197236|Experimental|Infanrix + ActHIB→Havrix Group|Subjects received Infanrix co-administered with ActHIB at Day 0, followed by one dose of Havix at Day 30 and a second dose of Havrix at Month 7-10.
3318850|NCT00197236|Active Comparator|Havrix + Infanrix + ActHIB Group|Subjects received one dose of Havrix co-administered with Infanrix and ActHIB vaccines at Day 0 followed by a second dose of Havrix at Month 6-9.
3318851|NCT00197184|Experimental|Twinrix Junior|Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).
3318852|NCT00197184|Active Comparator|Twinrix Adult|Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).
3318853|NCT00197145|Experimental|GW873140|
3318854|NCT00197119|Active Comparator|Group Twinrix Adult|Subjects received Twinrix™ Adult (720/20) in a 0, 6 month schedule in the primary study.
3318855|NCT00197119|Active Comparator|Group Twinrix Junior|Subjects received Twinrix™ Junior (360/10) in a 0, 1, 6 month schedule in the primary study.
3318938|NCT00196105|Experimental|10 mm Zilver|10 mm Nitinol Zilver Stent
3318856|NCT00197106|Active Comparator|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg
3318857|NCT00197106|Other|fluticasone propionate 2 x 100 mcg|fluticasone propionate 2 x 100 mcg
3318858|NCT00197028|Experimental|RTS,S/AS02D Group|Subjects aged between 6 and 12 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of RTS,S/AS02D at days 14, 44 and 74 and a 3-dose vaccination course of TETRActHib™ vaccine at days 0, 30 and 60. The RTS,S/AS02D vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
3318859|NCT00197028|Active Comparator|Engerix-B Group|Subjects aged between 6 and 12 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of Engerix-B® vaccine at days 14, 44 and 74 and a 3-dose of TETRActHib™ vaccine at days 0, 30 and 60. The Engerix-B® vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
3318860|NCT00197015|Active Comparator|HAV Group|Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)
3318861|NCT00197015|Experimental|HAV+MMR+V Group|Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9
3318862|NCT00197015|Active Comparator|MMR+V→HAV Group|Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)
3318863|NCT00197002|Active Comparator|Havrix Group|Healthy male or female subjects, 15 months of age, who received Havrix® vaccine administered intramuscularly in the right anterolateral thigh, at Day 0 and at Month 6-9.
3318864|NCT00197002|Experimental|Havrix+Prevnar Group|Healthy male or female subjects, 15 months of age, who received Havrix® and Prevnar™ vaccines co-administered intramuscularly in the right and left anterolateral thighs, respectively, at Day 0 and Havrix® vaccine administered intramuscularly in the right anterolateral thigh, at Month 6-9.
3318865|NCT00197002|Active Comparator|Prevnar Havrix Group|Healthy male or female subjects, 15 months of age, who received Prevnar™ vaccine administered intramuscularly in the left anterolateral thigh, at Day 0 and Havrix® vaccine, administered intramuscularly in the right anterolateral thigh, at Day 30 and at Month 7-10.
3318866|NCT00196976|Experimental|GSK134612A Form1 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
3318867|NCT00196976|Experimental|GSK134612A Form2 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
3318868|NCT00196976|Experimental|GSK134612A Form3 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
3318869|NCT00196976|Experimental|GSK134612A Form4 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
3318870|NCT00196976|Active Comparator|Control (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer`s Meningitec™ conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
3318871|NCT00196976|Experimental|GSK134612A Form1 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).
3318872|NCT00196976|Experimental|GSK134612A Form2 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).
3318873|NCT00196976|Experimental|GSK134612A Form3 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).
3318874|NCT00196976|Experimental|GSK134612A Form4 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm`s deltoid region, during this primary vaccination study (103533).
3318875|NCT00196976|Active Comparator|Control (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).
3318876|NCT00196976|Experimental|GSK134612A Form1 (T), Booster Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).
3318877|NCT00196976|Active Comparator|Control (T), Booster Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).
3318878|NCT00196976|Experimental|GSK134612A Form1 (C), Booster Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.
3318879|NCT00196976|Active Comparator|Control (C), Booster Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer`s Meningitec™ conjugate vaccine, did not receive any booster vaccination.
3318880|NCT00196937|Experimental|Cervarix (15-25 Years) Group|Women aged 15 to 25 years received 3 doses of Cervarix™ (human papillomavirus [HPV] vaccine) administered according to a 0, 1, 6-month schedule.
3318881|NCT00196937|Experimental|Cervarix (26-45 Years) Group|Women aged 26 to 45 years received 3 doses of Cervarix™ (HPV vaccine) administered according to a 0, 1, 6-month schedule.
3318882|NCT00196937|Experimental|Cervarix (46-55 Years) Group|Women aged 46 to 55 years received 3 doses of Cervarix™ (HPV vaccine) administered according to a 0, 1, 6-month schedule.
3318883|NCT00196872|Experimental|ETC-with Ibandronat|ETC follwoed by Ibandronat
3318884|NCT00196872|Experimental|ETC without Ibandronat|ETC not followed by Ibandronat
3318885|NCT00196872|Experimental|EC-TX with Ibandronat|EC-TX followed by Ibandronat
3318886|NCT00196872|Experimental|EC-TX without Ibandronat|EC-TX not followed by Ibandronat
3318887|NCT00196859|Active Comparator|A|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
3318888|NCT00196859|Experimental|B|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
3318889|NCT00196820|Experimental|A|Capecitabine 2000 mg/m2 orally day 1-14 q day 22 until progression, unacceptable toxicity, patient's request or withdrawal from study
3318890|NCT00196807|Experimental|Information plus DA at home|
3318891|NCT00196807|Active Comparator|UC Information at home|
3318892|NCT00196807|Experimental|Information plus decision aid at clinic|
3318893|NCT00196807|Active Comparator|UC Information at clinic|
3318894|NCT00196781|Experimental|the Information + Decision Aid group|
3318895|NCT00196781|Active Comparator|Information Only group|
3318896|NCT00196755|Experimental|Sevelamer Hydrochloride (Renagel®)|
3318897|NCT00196755|Active Comparator|Calcium acetate (PhosLo® )|
3318898|NCT00196716|Experimental|Fabrazyme|Open-label study. Patients received 1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months.
3318899|NCT00196573|Active Comparator|Shoulder bursectomy and acromioplasty|
3318900|NCT00196560|Experimental|exernal rotation|external rotation at 90 degrees
3318901|NCT00196404|Experimental|1|
3318902|NCT00196404|Experimental|2|
3318903|NCT00196404|Placebo Comparator|3|
3318904|NCT00196391|Experimental|1|
3318905|NCT00196391|Experimental|2|
3318906|NCT00196391|Experimental|3|
3318907|NCT00196391|Experimental|4|
3318908|NCT00196391|Experimental|5|
3318909|NCT00196391|Placebo Comparator|6|
3318910|NCT00196378|Experimental|1|
3318911|NCT00196378|Placebo Comparator|2|
3318912|NCT00196365|Experimental|1|
3318913|NCT00196365|Active Comparator|2|
3318914|NCT00196352|Experimental|1|
3318915|NCT00196339|Experimental|Cyproterone acetate 5 mg ( DR-2031)|1 tablet daily
3318916|NCT00196339|Experimental|Cyproterone acetate 15 mg ( DR-2031)|1 tablet daily
3318917|NCT00196339|Experimental|Cyproterone acetate 25 mg ( DR-2031)|1 tablet daily
3318918|NCT00196339|Placebo Comparator|Placebo|1 tablet daily
3318919|NCT00196326|Experimental|DR-1011|Participants were instructed to take, by mouth, one tablet daily for four 91-day cycles.
3318920|NCT00196313|Experimental|1 levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablet|
3318921|NCT00196313|Placebo Comparator|2|
3318922|NCT00196222|Experimental|1|RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
3318923|NCT00196222|Experimental|2|cryo energy ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
3318924|NCT00196209|Experimental|1|catheter ablation to treat persistent atrial fibrillation
3318925|NCT00196209|Experimental|2|cardioversion and drug prophylaxis to treat persistent atrial fibrillation
3318926|NCT00196183|Experimental|1|trigger-guided ablation of paroxysmal atrial fibrillation
3318927|NCT00196183|Experimental|2|trigger-+substrate guided ablation of paroxysmal atrial fibrillation
3318928|NCT00196170|Experimental|1|8mm tip ablation catheter for ablation of cavotricuspid isthmus
3318929|NCT00196170|Experimental|2|irrigated tip ablation catheter for ablation of cavotricuspid isthmus
3318930|NCT00196170|Experimental|3|cryo 10mm tip ablation catheter for ablation of cavotricuspid isthmus
3318931|NCT00196170|Experimental|4|Cryo 6.5mm tip ablation catheter for ablation of cavotricuspid isthmus
3318932|NCT00196157|Experimental|1|linear lesions to ablate persistent atrial fibrillation
3318933|NCT00196157|Experimental|2|focal electrophysiologically guided ablations to treat persistent atrial fibrillation
3318934|NCT00196144|Experimental|1|Optimization of the postventricular atrial blanking period to avoid far-field R-wave sensing.
3318935|NCT00196144|Experimental|2|Programming of the nominal setting for the post-ventricular atrial blanking period (100 ms)
3318936|NCT00196131|No Intervention|0|
3318937|NCT00196105|Experimental|6 mm Zilver|6 mm Nitinol Zilver Stent
3318945|NCT00196092|Other|6|Treatment for females.
3318946|NCT00196092|Other|7|Standard Risk Continued Access
3318947|NCT00196092|Other|8|High Risk Continued Access
3318948|NCT00195975||1|Children with FD
3318949|NCT00195975||4|Healthy controls
3318950|NCT00195910|Active Comparator|Morphine|"single dose of intravenous (IV) morphine, 0.1 mg/kg~intervention: 0.1 mg/kg IV morphine"
3318951|NCT00195910|Experimental|Hydromorphone|"single dose of intravenous (IV) hydromorphone, 0.015 mg/kg~intervention: 0.015 mg/kg IV hydromorphone"
3318952|NCT00195884|Experimental|Aerobic Group|Aerobic training is divided into three stages: the Starter phase (during the run-in period), the Progression phase, and the Maintenance phase. All aerobic activities are performed on a cycle ergometer, treadmill, elliptical exercise machine or stairclimber. Subjects are free to vary the machine(s) used from one visit to the next. Exercise intensity is standardized using Polar Heartminder heart rate monitors that display the subject's heart rate and emits a warming signal when heart rate is outside the prescribed training zone, thus guiding the subject in adjustment of the work load up or down to achieve the desired intensity.
3318953|NCT00195884|Experimental|Resistance Group|"Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row (back), seated biceps curls, supine bench press (chest), leg press, shoulder press (shoulders and neck); leg extension (quadriceps)~Group B: abdominal crunches, lat pulldown (back), sitting chest press (chest), leg press, upright row (shoulders and neck), triceps pushdown, leg curls (hamstrings).~Subjects are instructed to exhale while lifting a weight and inhale while lowering it, in order to minimize blood pressure excursions. Warm-up and cooldown are the same as for aerobic training."
3318954|NCT00195884|Experimental|Combined Aerobic and Resistance Training|Combined aerobic and resistance training. This group will perform both aerobic and resistance training programs, as described above. The aerobic and resistance components are performed on the same days, in varying orders.
3318955|NCT00195884|No Intervention|Control Group|Members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program.
3318956|NCT00195858|Active Comparator|Diet and Aerobic Exercise|
3318957|NCT00195858|Active Comparator|Diet and Resistane Exercise|
3318958|NCT00195858|Active Comparator|Diet and Combined Aerobic and Resistance Exercise|
3318959|NCT00195858|Other|Diet-only control group|
3318960|NCT00195845|Experimental|Double-Blind Galantamine vs Placebo|Double-Blinded, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction
3318961|NCT00195845|Placebo Comparator|Placebo Control Group|Placebo-Controlled Group
3318962|NCT00195819|Experimental|Adalimumab|
3318963|NCT00195819|Placebo Comparator|Placebo|
3318964|NCT00195728|Experimental|hydrocodone/acetaminophen extended release|
3318965|NCT00195702|Experimental|DB adalimumab 20 mg ew|Subjects received 20 mg adalimumab subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.
3318966|NCT00195702|Experimental|DB adalimumab 40 mg eow|Subjects received 40 mg adalimumab subcutaneously (SC) every other week (eow) and concomitant methotrexate (MTX) during the double-blind (DB) phase. Subjects received placebo injections SC and concomitant MTX on the alternate weeks during the DB phase.
3318967|NCT00195702|Placebo Comparator|DB placebo ew|Subjects received placebo subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.
3318968|NCT00195702|Experimental|DB adalimumab 20 mg ew/OL adalimumab 40 mg eow|Subjects received adalimumab 20 mg subcutaneously (SC) once weekly (ew) during the double-blind (DB) phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
3318969|NCT00195702|Experimental|DB adalimumab 40 mg eow/OL adalimumab 40 mg eow|Subjects received adalimumab 40 mg subcutaneously (SC) every other week (eow) with placebo on alternate weeks during the double-blind (DB) phase, then adalimumab 40 mg SC eow during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
3318970|NCT00195702|Experimental|DB placebo ew/OL adalimumab 40 mg eow|Subjects received placebo subcutaneously (SC) once weekly (ew) during the double-blind phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
3318971|NCT00195676|Other|Adalimumab|
3318972|NCT00195663|Experimental|Adalimumab|Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase and then adalimumab 40 mg every other week for up to 8 years in the open-label extension.
3318973|NCT00195663|Experimental|Adalimumab + methotrexate|Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.
3318974|NCT00195663|Experimental|Methotrexate|Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.
3318975|NCT00195650|Experimental|Adalimumab|Open-label adalimumab 40 mg
3318976|NCT00195494|Active Comparator|1a|Etanercept + Methorexate for Period 1 (first 12 months) and Period 2 (Second 12 months)
3318977|NCT00195494|Active Comparator|1b|Etanercept + Methotrexate for Period 1 (First 12 months) and Etanercept alone for Period 2 (Second 12 months)
3318978|NCT00195494|Active Comparator|2a|Methotrexate alone in Period 1 (First 12 months) and etanercept + Methotrexate in Period 2 (Second 12 months)
3318979|NCT00195494|Active Comparator|2b|Methotrexate alone in Period 1 (First 12 months) and Methotrexate alone in Period 2 (Second 12 months)
3318980|NCT00195442||A|Patients with Hemophilia A
3318981|NCT00195429|Experimental|Sirolimus + Tacrolimus|
3318982|NCT00195429|Active Comparator|Sirolimus + Prednisone|
3318983|NCT00195403||1|
3318984|NCT00195351|Active Comparator|A|
3318985|NCT00195351|Active Comparator|B|
3318986|NCT00195338||1|This is an open label, observational study.This is a post-marketing surveillance study in rheumatology practice patients in Luxemburg.Rheumatologists will be asked to document safety and adherence to therapy of Enbrel when given to adults with active rheumatoid arthritis.All patients initiated with Enbrel will be observed.
3318987|NCT00195273|Experimental|1|Sirolimus + Daclizumab + Mycophenolate + Corticosteroids
3318988|NCT00195273|Active Comparator|2|Cyclosporine + Mycophenolate + Corticosteroids
3318989|NCT00195260|Experimental|Dose escalation|Dose finding study of monotherapy bosutinib in patients with advanced solid tumors.
3318990|NCT00195260|Experimental|Colorectal Cancer|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
3318991|NCT00195260|Experimental|Pancreatic Cancer|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
3318992|NCT00195260|Experimental|Non-Small Cell Lung Cancer (NSCLC)|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
3318993|NCT00195195||1|Sirolimus
3318994|NCT00195182||1. No intervention|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to adhere to their medication goal.
3318995|NCT00195182||2. Experimental|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to engage adhere to their medication goal. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level.
3318996|NCT00195117|No Intervention|Control Group|This group received follow-up every 2-months for one year. Follow-up included questions about their asthma and how well they had been able to engage in their doctor approved physical activity goal.
3318997|NCT00195117|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their asthma and how well they had been able to engage in their doctor approved physical activity goal, which was the same as the control arm. Additionally, subjects in this arm were encouraged to use positive affect and self-affirmation techniques to motivate an increased level of participation in their physical activity goal. These subjects also received small token gifts to remind them of their participation in this study.
3318998|NCT00195104|Experimental|All Patients|Arsenic trioxide [TrisenoxTM Injection], 0.25mg/kg/dose administered intravenously over 1 to 4 hours
3318999|NCT00195091|Experimental|Tetrathiomolybdate (TM)|"Induction period - TM 40 mg is administered three x per day with meals and TM 60 mg at bedtime for a total of 4 doses (180 mg) per day.~Maintenance Period - Total TM dose per day will be in 20 mg increments to tailor the therapy to individualized patient needs to maintain the Cp level at 5-17mg/dL. Thus all dose modifications will be dependent on individual patient Cp levels. TM 40 mg p.o. BID with meals and TM 20 mg at bedtime. Subjects who have no evidence of disease (NED) and are receiving a benefit of TM can continue taking the drug for up to 120 months."
3319000|NCT00195039|Experimental|All patients|"Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min."
3319001|NCT00195013|Experimental|Glutamine|10 grams three times a day (orally) for four days and then stop
3319002|NCT00195013|Placebo Comparator|Placebo|10 grams three times a day (orally) for four days and then stop
3319003|NCT00194987|Experimental|3|
3319004|NCT00194922|Placebo Comparator|A|
3319005|NCT00194896|Active Comparator|rosiglitazone|Rosiglitazone is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. The rosiglitazone treatment group commenced therapy with 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved.
3319006|NCT00194896|Active Comparator|glyburide|Glyburide is a sulfonylurea. Glyburide therapy was initiated with 2.5 mg in the morning or the patient was maintained on the dose they had been receiving prior to starting the study. This starting dose was raised by 2.5 in the evening and further up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control.
3319007|NCT00194870|Other|Digital EEG|Digital EEG
3319008|NCT00194844|Experimental|1|Nurse Caring
3319009|NCT00194844|Experimental|2|Self Caring
3319010|NCT00194844|Experimental|3|Combined Caring
3319011|NCT00194844|No Intervention|4|This group is not treated and serves as control.
3319012|NCT00194818|Active Comparator|1|Asacol 6 tablets BID (4.8 grams/day)
3319013|NCT00194818|Active Comparator|2|Asacol 4 tablets TID (4.8 grams/day)
3319014|NCT00194805|Experimental|1|Subjects randomized into the treatment group received the computer treatment
3319015|NCT00194792|Experimental|Treatment (hormone therapy and chemotherapy)|See detailed description
3319016|NCT00194779|Experimental|Treatment (neoadjuvant therapy, adjuvant therapy)|See Detailed Description.
3319017|NCT00194766|Experimental|1|Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
3319018|NCT00194753|Experimental|1|Weekly doxorubicin (24 mg/m2 IV) with daily oral cyclophosphamide (60 mg/m2 PO) for 12 weeks with G-CSF support days 2 - 7 of each week followed by weekly paclitaxel (80 mg/m2 IV) for 12 weeks.
3319019|NCT00194740|Experimental|1|
3319020|NCT00194727|Experimental|1|Vinorelbine (20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle) and capecitabine (825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle). Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
3319021|NCT00194714|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID once per month for 6 months in the absence of disease progression or unacceptable toxicity.
3319022|NCT00194675|Active Comparator|Testosterone gel + oral placebo|Testosterone 1% gel 7.5 topical daily + placebo dutasteride orally daily
3319023|NCT00194675|Active Comparator|Testosterone gel + oral dutasteride|Testosterone 1% gel 7.5 topical daily + dutasteride 0.5 mg orally daily
3319024|NCT00194649|Experimental|1|100 mg Miglustat BID (twice daily) for six weeks
3319025|NCT00194610|Experimental|Botox injection|Subjects were injected with Botulinum toxin A in a mix of 50 U diluted in 2 cubic centimeters of normal saline. With the subjects in the dorsal lithotomy position, one injection of 25 international units was given into the bladder neck at the 3 o'clock position and another of 25 international units was given into the 9 o'clock position
3319026|NCT00194610|Placebo Comparator|Normal saline|Subjects were injected in the bladder neck with 1 cubic centimeter normal saline into the 3 o'clock and 6 o' clock positions in the perineum, while in the dorsal lithotomy position
3319027|NCT00194584|Experimental|1|
3319028|NCT00194584|No Intervention|0|
3319029|NCT00194545|Experimental|1|Medication diary
3319030|NCT00194545|No Intervention|2|Caregivers only receive counseling which is the standard of care
3319031|NCT00194532|Experimental|Cefpodoxime|Cefpodoxime 100mg twice a day(BID)for 3 days
3319032|NCT00194532|Active Comparator|Ciprofloxacin|Ciprofloxacin 250mg twice a day (BID)for 3 days
3319033|NCT00194519|Active Comparator|Acyclovir|
3319034|NCT00194519|Placebo Comparator|Placebo|
3319035|NCT00194493|Experimental|1|Patient's clinician receives graphical report of patient-reported symptoms and quality of life issues.
3319036|NCT00194493|No Intervention|2|
3319037|NCT00194480|Experimental|PegInterferon|Arm 1: 24 weeks of weekly injections of peginterferon Arm 2: control (no treatment)
3319038|NCT00194467|Experimental|1|
3319039|NCT00194467|Placebo Comparator|2|
3319040|NCT00194454|Experimental|1|Nine session psychosocial/behavioral counseling with homework
3319041|NCT00194454|Active Comparator|2|Usual clinic care with booklet describing depression following stroke
3319042|NCT00194441|Experimental|1|Highly visible continually updating color coded bar computer display of cerebral perfusion pressure.
3319043|NCT00194441|Placebo Comparator|2|Bedside computer display with a blank screen except for a message indicating that the program is running.
3319044|NCT00194428|Experimental|1|Almond enriched diet
3319045|NCT00194428|Active Comparator|2|Low-fat diet
3319046|NCT00194415|Other|1|HSV-2 antepartum testing
3319047|NCT00194415|Other|2|Subjects will receive safer-sex counseling during pregnancy
3319048|NCT00194402|Active Comparator|1|Atorvastatin 10 mg for 12 weeks followed by Slo-Niacin (titrated from 500 to 1500 mg over 8 weeks) taken with atorvastatin 10 mg for an additional 12 weeks
3319049|NCT00194402|Active Comparator|2|Slo-Niacin (titrated from 500 to 1500 mg over 8 weeks) for 12 weeks followed by atorvastatin 10 mg taken with Slo-Niacin 1500 mg for an additional 12 weeks
3319050|NCT00194311||pregnancy complications|prospective cohort study is to determine if maternal infection with Human papillomavirus (HPV) is associated with pregnancy complications including spontaneous preterm delivery (sPTD), severe preeclampsia (PE) (as per current ACOG: American College of Obstetrics and Gynecology criteria), and intrauterine growth restriction (IUGR).
3319051|NCT00194194|Active Comparator|moderate|moderate behavioral management
3319052|NCT00194194|Experimental|intensive|intensive behavioral management
3319053|NCT00194129|Experimental|Lithium plus Divalproex|Patients assigned to the combination group were continued on lithium and blinded divalproex.
3319054|NCT00194129|Placebo Comparator|Lithium plus placebo|Patients assigned to lithium monotherapy underwent divalproex-placebo substitution at a rate of 250 mg decrements every week until discontinued.
3319055|NCT00194116|Experimental|Divalproex Sodium ER|
3319056|NCT00194116|Placebo Comparator|Placebo|
3319057|NCT00194103|No Intervention|TAU|
3319058|NCT00194103|Active Comparator|Telephone Monitoring|
3319059|NCT00194103|Experimental|Telephone Monitoring and Counseling|
3319060|NCT00194077|Active Comparator|Aripiprazole|Phase I and Phase III are open label Abilify phases where all subjects receive active Abilify
3319061|NCT00194077|Placebo Comparator|Placebo|in Phase 2 subjects are randomized to either placebo or abilify for up to 72 weeks
3319062|NCT00194064|Experimental|Olanzapine|Subjects were be started on a standardized minimum first-day dose of 15 mg olanzapine. After the first day of therapy, the daily dose was either increased or decreased, as clinically indicated, by 5 mg, within an allowed range of 5 to 40 mg
3319063|NCT00194038|Experimental|1|
3319064|NCT00194025|Experimental|valproate|All participants received open-label, add-on valproate.
3319065|NCT00194012|Active Comparator|Aripiprazole-Randomized Phase|Patients randomly assigned to aripiprazole received medication in pill form with dosing at 2mg, 5mg, 7mg, 10mg, 12mg or 15mg depending on their response.
3319066|NCT00194012|Placebo Comparator|Placebo-Randomized Phase|Patients randomly assigned to placebo received pills/dosing made to look identical to the aripiprazole.
3319067|NCT00193973|Active Comparator|1|
3319068|NCT00193947||women initiating ARV therapy during pregnancy with neveripine|
3319069|NCT00193934||1|Cervical Cancer Patients
3319070|NCT00193921|Experimental|A|Vinorelbine + cisplatin + high-dose palliative radiotherapy
3319071|NCT00193921|Active Comparator|B|Gemcitabine + high-dose palliative radiotherapy
3319072|NCT00193908|Experimental|1|
3319073|NCT00193908|Experimental|2|
3319074|NCT00193895|Active Comparator|Radiotherapy alone|Radiotherapy alone (60Gy or 66Gy in 30-33 fractions 5-5/week)
3319075|NCT00193895|Experimental|Radiotherapy plus chemotherapy|Radiotherapy plus chemotherapy (Radiotherapy 60Gy or 66Gy in 30-33 fractions 5/week + Carboplatin (AUC 2) intravenously weekly)
3319076|NCT00193882|Active Comparator|A: Radiotherapy|Radiotherapy alone
3319077|NCT00193882|Experimental|B: Chemo-radiotherapy|Chemotherapy (Cisplatin + 5-Fluorouracil ) and Radiotherapy
3319078|NCT00193856|Active Comparator|A|LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 mths)
3319079|NCT00193856|Active Comparator|B|LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 months) + bisphosphonate therapy.
3319080|NCT00193856|Experimental|C|LH-RH analogue as for arm A, but continued for further 12 months (total 18 months)
3319081|NCT00193856|Experimental|D|LH-RH analogue as for arm A, but continued for further 12 months (total 18 months) + bisphosphonate therapy.
3319150|NCT00192322|Experimental|CAIV-T 10^5|a single intranasal 0.2 mL dose of liquid CAIV-T 10^5 (approximately 0.1 mL into each nostril)
3319082|NCT00193804||2|Patients with histologically proven, cervical cancer FIGO Stage IIB eligible will be invited for the study. The patients will recieve either 3D conformal radiation or IMRT external radiation with concomitant cisplatin chemotherapy followed by brachytherapy.
3319083|NCT00193791|No Intervention|Radiation (RT) Alone|Standard radical radiation therapy alone
3319084|NCT00193791|Experimental|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
3319085|NCT00193778|Experimental|Loco Regional Treatment Arm (LRT)|Surgery for breast cancer. (MRM/BCT)
3319086|NCT00193778|Active Comparator|No Loco-regional Treatment Arm|No surgery for Breast cancer
3319087|NCT00193765|Active Comparator|Wait and Watch|Therapeutic neck dissection on developing nodal relapse
3319088|NCT00193765|Experimental|Elective Neck dissection|Elective neck dissection in early oral cancer at the time of primary surgery
3319089|NCT00193739|Active Comparator|NACT followed by surgery|3 cycles of neoadjuvant chemotherapy (NACT) (Inj.Paclitaxel +Inj.Carboplatin) followed by surgery (radical abdominal hysterectomy Class III , bilateral pelvic lymphadenectomy & lower para aortic lymph node sampling)
3319090|NCT00193739|Active Comparator|Concurrent chemoradiotherapy|Radiation therapy will be administered to whole pelvis followed by intracavitary brachytherapy. Patients will be given chemotherapy (Inj.Cisplatin) concurrently with external beam radiotherapy.
3319091|NCT00193726|Experimental|Arm B- Experimental|Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
3319092|NCT00193726|Placebo Comparator|Arm A - Placebo|Tab Placebo once a day for 5 days prior to each cycle of chemotherapy
3319093|NCT00193674|Experimental|1|
3319094|NCT00193674|Placebo Comparator|2|
3319095|NCT00193648|Active Comparator|1|Avandia (rosiglitazone)
3319096|NCT00193648|Active Comparator|2|Humira (adalimumab)
3319097|NCT00193635|Active Comparator|1|oral MMF
3319098|NCT00193609|Experimental|Oxaliplatin/Capecitabine|All patients received treatment with oxaliplatin 130mg/m2, given intravenously on day 1 of each 21 day cycle. Capecitabine 1000mg/m2 by mouth twice daily was administered on days 1-14 of each cycle.
3319099|NCT00193596|Experimental|Regimen A|"Paclitaxel 200 mg/m2 by 1-hour IV infusion, day 1~Carboplatin area under the curve (AUC) 6.0 IV, day 1~Etoposide 50 mg alternating with 100 mg by mouth, days 1 and 10~Regimen A was repeated at a 21-day interval"
3319100|NCT00193596|Experimental|Regimen B|"Irinotecan 100 mg/m2 IV, days 1 and 8~Gemcitabine 1000 mg/m2 IV, days 1 and 8~Regimen B was repeated at a 21-day interval"
3319101|NCT00193492|Active Comparator|Rituximab|All patients will receive rituximab 375mg/m2 administered by slow IV infusion weekly for 4 consecutive weeks (days 1, 8, 15, and 22). Patients who have objective response or stable disease at week 12 reevaluation will receive 4 additional doses of rituximab (375 mg/m2) administered in months 3 (week 12), 5, 7, and 9.
3319102|NCT00193492|Experimental|Rituximab/Bevacizumab|All patients will receive rituximab 375mg/m2 administered by slow IV infusion weekly for 4 consecutive weeks (days 1, 8, 15, and 22). During the 4-week course of rituximab, all patients will receive 2 doses of bevacizumab 10mg/kg IV, given on Days 3 and 15. The first dose will be given on Day 3, following rituximab on Day 1. If both drugs are well tolerated during the first dose, rituximab and bevacizumab should be given on the same day for the Day 15 dose and all subsequent doses.
3319103|NCT00193479|Experimental|Cyclophosphamide/Vincristine/Rituximab +/- Mitoxantrone|All patients receive three courses of combination chemotherapy/rituximab followed by pegfilgrastim, administered at 21-day intervals. Treatment administered is as follows: cyclophosphamide 500mg/m2 IV day 1; mitoxantrone 10mg/m2 IV day 1; vincristine 1.0mg/m2 (maximum 2mg) IV day 1; prednisone 80mg PO days 1 - 5; rituximab 375mg/m2 IV day 1.
3319104|NCT00193453|Experimental|Intervention|Newly-diagnosed unresectable stage III/IV NSCLC patients were treated with docetaxel-30mg/m2 IV; gemcitabine-1000mg/m2 IV days 1, 8; cetuximab-400mg/m2 IV day 1, then 250 mg/m2 IV weekly. Patients received up to 6 cycles (21-d).
3319105|NCT00193427|Experimental|Intervention|Patients with potentially resectable clinical stage IB, II, and selected III NSCLC received gemcitabine 1000 mg/m2 days 1, 8 and docetaxel 30 mg/m2 days 1, 8 every 21 days for 3 cycles. Patients were restaged after treatment and resected 3-6 weeks later. If patients were inoperable, had incomplete resections or N2 disease, docetaxel 20 mg/m2 and carboplatin AUC = 1.5 weekly x 7 and radiation to 63 Gy was administered
3319106|NCT00193414|Experimental|Intervention|Chemotherapy-naïve patients with unresectable stage III/IV NSCLC received pemetrexed 500 mg/m2 IV and gemcitabine 1500 mg/m2 IV every 2 weeks for 8-12 cycles with restaging every 4 cycles. Patients also received supplemental folate/B12 therapy.
3319107|NCT00193375|Experimental|Intervention|Patients received carboplatin [area under the concentration-versus-time curve of 5 intravenously (IV) day 1 every 3 weeks x 4), irinotecan (50mg/m2 IV days 1 and 8 every 3 weeks x 4], and radiation (1.8 Gy daily to a total of 61.2 Gy beginning with the 3rd cycle). Cycles 3 and 4 were 28 days each; with restaging after 4 cycles. Patients without progressive disease received bevacizumab (10 mg/kg IV every 14 days x 10).
3319108|NCT00193258|Experimental|Intervention|"In the phase I portion:~Bevacizumab 10 mg/kg slow IV infusion on days 1 and 15 of each 28-day course~Erlotinib 150 mg orally daily~Imatinib 300 mg orally daily or 400 mg orally daily~In the phase II portion:~Bevacizumab 10 mg/kg 30-60 minute IV infusion on days 1 and 15 of every 28 day cycle~Erlotinib 150 mg orally daily~Imatinib 400 mg orally daily"
3319109|NCT00193219|Experimental|Intervention|"Bevacizumab 5 mg/kg IV~Cetuximab 400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8~5-Fluorouracil 400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)~Leucovorin 350 mg IV~Oxaliplatin 85 mg/m2 IV"
3319110|NCT00193206|Experimental|Intervention|Patients were treated with 6 doses of neoadjuvant gemcitabine 2000 mg/m2, epirubicin 50 mg/m2, and albumin-bound paclitaxel 175 mg/m2 intravenously administered at 14-day intervals. Following neoadjuvant chemotherapy, patients underwent either mastectomy or breast conservation surgery; pathologic response to treatment was assessed. Postoperatively, patients received 4 doses of gemcitabine 2000 mg/m2 with albumin-bound paclitaxel 220 mg/m2 at 14-day intervals. Pegfilgrastim 6 mg was administered subcutaneously on day 2 following each dose of chemotherapy.
3319151|NCT00192322|Experimental|CAIVT 10^7|A single intranasal 0.2 mL dose of liquid CAIV-T 10^7 (approximately 0.1 mL into each nostril)
3319152|NCT00192322|Placebo Comparator|Placebo|A single intranasal 0.2 mL dose of placebo
3319111|NCT00193180|Experimental|Intervention|All patients in this study received docetaxel 30 mg/m2 weekly for 3 consecutive weeks of each 28-day cycle, along with continuous imatinib mesylate. Initially, imatinib mesylate was given at a dose of 600 mg orally daily, beginning concurrently with the first dose of docetaxel; however, after the first 15 patients were treated it became evident that this imatinib dose was not tolerable, and subsequent patients received imatinib mesylate 400 mg orally daily.
3319112|NCT00193154|Experimental|OSI-774 & bevacizumab|OSI-774 (Tarceva) 150mb PO, days 1-28; bevacizumab (Avastin) 10mg/kg, IV infusion, days 1 and 15; Regimen will be repeated every 28 days.
3319113|NCT00193128|Experimental|Cohort 1|"An initial cohort of 10 patients was treated with oxaliplatin 40 mg/m2 intravenously (IV) over 2 hours and docetaxel 20 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, and 29. Radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).~Patients were to have esophageal resection after completion of preoperative therapy during weeks 9 to 12 and after all treatment-related side effects were resolved."
3319114|NCT00193128|Experimental|Cohort 2|"After completion of the first phase of the trial, the second cohort began treatment.~Oxaliplatin 40 mg/m2 intravenously (IV) over 2 hours and docetaxel 20 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, and 29. Capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35. Radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).~Patients were to have esophageal resection after completion of preoperative therapy during weeks 9 to 12 and after all treatment-related side effects were resolved."
3319115|NCT00193063|Experimental|Intervention|All patients entering this trial received treatment with a combination of gemcitabine and trastuzumab. Gemcitabine 1000 mg/m2 was administered intravenously on days 1, 8,and 15 of a 28-day cycle. Trastuzumab was administered as a 4 mg/kg intravenous loading dose on day 1 and subsequently at a dose of 2 mg/kg on a weekly basis.
3319116|NCT00193050|Experimental|Intervention|"In the neoadjuvant setting, patients were administered gemcitabine (800 mg/m2 IV days 1 and 8), epirubicin (75 mg/m2 IV day 1), and docetaxel (30 mg/m2 IV days 1 and 8)repeated every 21 days for 4 cycles~Patients then had either mastectomy or breast conservation surgery and pathologic treatment responses were assessed.~After surgery, 4 cycles of adjuvant gemcitabine (1000 mg/m2 IV days 1 and 8) and docetaxel (35 mg/m2 IV days 1 and 8) were administered at 21 day intervals.~After completion of chemotherapy, local regional radiation therapy and/or anti-estrogen therapy was administered per standard guidelines."
3319117|NCT00193037|Experimental|Liposomal Doxorubicin|Liposomal doxorubicin 40 mg/m2 by 1 hour IV infusion repeated every 28 days.
3319118|NCT00193037|Experimental|Docetaxel|Weekly docetaxel 36 mg/m2 by 30 minute IV infusion on days 1, 8, and 15 of the 28 day cycle
3319119|NCT00193011|Experimental|1|Docetaxel
3319120|NCT00193011|Experimental|2|Cyclophosphamide + Methotrexate + 5-fluorouracil
3319121|NCT00192699||Group 1: Cemented Bi-Metric femoral stem|Cemented Bi-Metric femoral stem
3319122|NCT00192647|Experimental|PEG-IFN alfa-2a+Ribavirin - Induction Treatment|Participants will receive 12 weeks of induction therapy with PEG-IFN alfa-2a (Pegasys), 360 micrograms (mcg) subcutaneous (SC) once weekly, along with ribavirin, 1000 or 1200 milligrams (mg) orally daily in divided doses. Thereafter, the dose of PEG-IFN alfa-2a will be reduced to 180 mcg SC once weekly and the ribavirin dose maintained for the remaining 36 weeks of treatment.
3319123|NCT00192647|Experimental|PEG-IFN alfa-2a+Ribavirin - Standard Treatment|Participants will receive 48 weeks of standard therapy with PEG-IFN alfa-2a, 180 mcg SC once weekly, along with ribavirin, 1000 or 1200 mg orally daily in divided doses.
3319124|NCT00192634|Active Comparator|1|Abacavir 600mg/Lamivudine 300mg
3319125|NCT00192634|Active Comparator|2|Tenofovir 300mg/emtricitabine 200mg
3319126|NCT00192608|Experimental|saquinavir at baseline|patients receiving NRTIs + saquinavir + ritonavir 1000/100 mg BID at entry switch from 200 mg SQV capsules to 500 mg SQV tablets following PK at day 0. After PK at day 8 NRTIs ceased and regimen changed to ATV/SQV/RTV 300/1500/100 QD using 500 mg SQV formulation and continued to week 48
3319127|NCT00192608|Experimental|other boosted PI at baseline|Patients receiving NRTIs + PI/RTV randomised at baseline to receive ATV/SQVRTV 300/1500/100 QD using 500 mg SQV formulation or ATV/SQV/RTV 300/1600/100 QD using 200 mg formulation. Following PK at day 7, SQV formulation switched with second PK assessment at day 15. Patients then receive ATV/SQV/RTV 300/1500/100 QD to week 48.
3319128|NCT00192595|Active Comparator|Arm 1:|Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)
3319129|NCT00192595|Experimental|Arm 2|Zidovudine (AZT), tenofovir (TDF), efavirenz (EFV)
3319130|NCT00192595|Experimental|Amr 3|Lamivudine (LAM), tenofovir (TDF), efavirenz (EFV)
3319131|NCT00192569|Experimental|Treated|Subjects will be treated for 24 weeks with PEG-IFN (HIV coinfected subjects will received RBV)
3319132|NCT00192569|No Intervention|Untreated|Subjects will be followed for natural history of newly acquired HCV
3319133|NCT00192543|Active Comparator|case|diet of fish and fruit addition compared to regular diet
3319134|NCT00192543|Placebo Comparator|control|regular diet
3319135|NCT00192517|Active Comparator|1|MEDI-522
3319136|NCT00192517|Placebo Comparator|2|Placebo
3319137|NCT00192491|Active Comparator|2|FluMist
3319138|NCT00192491|Placebo Comparator|3|Placebo
3319139|NCT00192491|Active Comparator|1|FluMist with other solution
3319140|NCT00192478|Active Comparator|1|MEDI-524
3319141|NCT00192465|Experimental|1|MEDI-524 (Numax-TM)
3319142|NCT00192465|Experimental|2|MEDI-524 (Numax-TM)
3319143|NCT00192465|Experimental|3|MEDI-524 (Numax-TM)
3319144|NCT00192465|Experimental|4|MEDI-524 (Numax-TM)
3319145|NCT00192465|Experimental|5|MEDI-524 (Numax-TM)
3319146|NCT00192413|Experimental|Cold-adapted influenza vaccine trivalent (CAIV-T)|A single 0.2 mL dose of 10^7 fluorescent focus units was administered intranasally.
3319147|NCT00192413|Active Comparator|Trivalent Inactivated Vaccine (TIV)|A single dose was administered by intramuscular injection.
3319148|NCT00192335|Active Comparator|1|CAIVT-The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
3319149|NCT00192335|Active Comparator|2|FluMist- The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
3319263|NCT00190060|Placebo Comparator|2|Matched transdermal placebo gel
3319153|NCT00192322|Active Comparator|Trivalent inactivated vaccine (TIV)|A single intramuscular injection of commercially available vaccine
3319154|NCT00192309|Experimental|Cold-adapted influenza vaccine (CAIVT)|A single intranasal dose of 10^7 fluorescent focus units.
3319155|NCT00192309|Active Comparator|Trivalent inactivated vaccine (TIV)|A single dose of commercially available Flushield was administered intramuscularly.
3319156|NCT00192309|Placebo Comparator|Placebo|The 0.2 mL administered intranasally.
3319157|NCT00192296|Experimental|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
3319158|NCT00192296|Experimental|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, IV dose
3319159|NCT00192296|Experimental|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, IV dose
3319160|NCT00192296|Experimental|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, IV dose
3319161|NCT00192283|Experimental|1|CAIV-T
3319162|NCT00192283|Placebo Comparator|2|Placebo
3319163|NCT00192270|Experimental|Cold-adapted influenza vaccine trivalent (CAIV-T)|All subjects were scheduled to receive 2 doses of CAIV-T.The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
3319164|NCT00192218|Experimental|1|FluMist
3319165|NCT00192179|Experimental|CAIV-T|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
3319166|NCT00192179|Placebo Comparator|Placebo|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
3319167|NCT00192140|Active Comparator|1|FluMist
3319168|NCT00192127|Active Comparator|1|FluMist
3319169|NCT00192127|Placebo Comparator|2|Placebo
3319170|NCT00192075|Experimental|A+FFG|Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid
3319171|NCT00192075|Active Comparator|A+FOLFOX 4|Avastin + Oxaliplatin + 5-Fluorouracil (5FU)/Folinic Acid
3319172|NCT00192036|Experimental|Gemcitabine + Cisplatin|"Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5).~Cisplatin: 80 mg/m2, IV, every 21 days x 5 cycles.~Radiation: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5."
3319173|NCT00192023|Experimental|Atomoxetine|atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO) for 1 week, 1.2 mg/kg/day QD, PO for 7 weeks, then 1.2 - 1.4 mg/kg/day QD, PO for up to 1.5 years or until atomoxetine receives marketing approval.
3319174|NCT00192023|Placebo Comparator|Placebo|placebo, daily (QD), by mouth (PO) for 8 weeks, then possibility to switch to atomoxetine at 0.5 mg/kg/day QD, PO for 1 week, then to 1.2 - 1.4 mg/kg/day QD, PO for up to 1.5 years or until atomoxetine receives marketing approval.
3319175|NCT00191984|Experimental|Pemetrexed + Irinotecan|
3319176|NCT00191945|Experimental|Atomoxetine|atomoxetine: 0.5 mg/kg/day every day (QD),by mouth (PO) for 2 weeks, 1.2 - 1.4 mg/kg/day QD, PO for 10 weeks, then 1.2 - 1.4 mg/kg/day QD, PO for up to 1 year
3319177|NCT00191945|Placebo Comparator|Placebo|placebo every day (QD), by mouth (PO) for 12 weeks,then possibility to switch to atomoxetine at 0.5 mg/kg/day QD, PO for 1 week, then to 1.2 - 1.4 mg/kg/day QD, PO for up to 1 year (open-label extension)
3319178|NCT00191906|Experimental|Atomoxetine first, then Placebo|Atomoxetine, 1.2 mg/kg/day, by mouth (PO) for 4 weeks, 2 week washout period and cross-over to placebo, every day (QD), PO for 4 weeks
3319179|NCT00191906|Experimental|Placebo first, then Atomoxetine|Placebo, every day (QD), by mouth (PO) for 4 weeks, 2 week washout period and cross-over to atomoxetine 1.2 mg/kg/day, PO for 4 weeks
3319180|NCT00191906|No Intervention|Normal Control|Normal controls were children selected from the general population. The normal control was matched (have same proportion) by sex (male/female) and by age (have same age range) as the study population.
3319181|NCT00191906|No Intervention|Reading Disordered Control|The reading disordered control group is comprised of children with reading disorder who receive standard remedial teaching therapy.
3319182|NCT00191854|Experimental|Gemcitabine + Paclitaxel|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.~paclitaxel: 150 mg/m2, IV, every 14 days x 8 cycles."
3319183|NCT00191854|Experimental|Gemcitabine + Carboplatin|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.~carboplatin: Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles."
3319184|NCT00191854|Experimental|Gemcitabine + Cisplatin|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.~cisplatin: 50 mg/m2, IV, every 14 days x 8 cycles"
3319185|NCT00191815|Experimental|Gemcitabine + Cisplatin|
3319186|NCT00191789|Experimental|Gemcitabine+Doxorubicin+Cisplatin+Surgery|"Gemcitabine: 1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8).~Doxorubicin: 60 mg/m^2, IV, every 21 days x 4 cycles (1-4). Cisplatin: 70 mg/m^2, IV, every 21 days x 4 cycles (5-8). Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision."
3319187|NCT00191724|Experimental|1|
3319188|NCT00191724|Experimental|2|
3319189|NCT00191724|Experimental|3|
3319190|NCT00191724|Experimental|4|
3319191|NCT00191724|Placebo Comparator|5|
3319192|NCT00191698|Experimental|A|Atomoxetine is administered at 1.2 mg/kg/day, PO for 8 weeks, followed by 1.2 or 2.4 mg/kg/day, PO for 4 weeks, open label administration can continue for up to one year
3319193|NCT00191698|Placebo Comparator|B|Placebo is administered by mouth, daily for 8 weeks. After 8 weeks, those randomized to placebo may be titrated to 1.2 mg/kg/day atomoxetine for the remainder of the study up to one year
3319194|NCT00191646|Experimental|Gemcitabine/Carboplatin|Gemcitabine 1000 milligrams per meter square (mg/m^2) Day 1 and Day 8, Carboplatin Area Under the Curve (AUC) 5 Day 1, six 21-day cycles
3319195|NCT00191646|Active Comparator|Paclitaxel/Carboplatin|Paclitaxel 175 milligrams per meter square (mg/m^2) administered intravenously (IV) Day 1 Carboplatin AUC 6 Day 1, six 21 day cycles
3319196|NCT00191477|Experimental|A|
3319197|NCT00191477|Placebo Comparator|B|
3319198|NCT00191451|Experimental|HER2+|Human Epidermal growth factor Receptor 2 positive (HER2+): Gemcitabine + Carboplatin + Herceptin.
3319328|NCT00188825|Placebo Comparator|placebo|
3319199|NCT00191451|Experimental|HER2- (Taxane-)|Human Epidermal growth factor Receptor 2 negative (HER2-): Gemcitabine + Carboplatin. (Taxane-naive patients).
3319200|NCT00191451|Experimental|HER2- (Taxane+)|Human Epidermal growth factor Receptor 2 negative (HER2-): Gemcitabine + Carboplatin. (Taxane-pretreated patients).
3319201|NCT00191386|Experimental|Atomoxetine|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
3319202|NCT00191334|Experimental|A|
3319203|NCT00191308|Experimental|Pemetrexed + Cisplatin|"Pemetrexed: 500 milligrams per square meter (mg/m^2) intravenous (IV) every 21 days (q 21 days) for 3 cycles unless disease progression occurs~Cisplatin: 75 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs"
3319204|NCT00191282|Experimental|1|Postprandial: Premeal insulin lispro +/- bedtime NPH
3319205|NCT00191282|Active Comparator|2|Fasting: NPH/insulin glargine or human insulin 30/70
3319206|NCT00191269|Experimental|A|Dose Level 1 - 1000 mg/m2
3319207|NCT00191269|Experimental|B|Dose Level 2 - 1250 mg/m2
3319208|NCT00191243|Experimental|A|
3319209|NCT00191243|Experimental|B|
3319210|NCT00191191|Experimental|Pemetrexed 500 mg/m2|Pemetrexed 500 mg/m2
3319211|NCT00191191|Experimental|Pemetrexed 1000 mg/m2|Pemetrexed 1000 mg/m2
3319212|NCT00191165|Experimental|1|Doubled dosage
3319213|NCT00191165|Active Comparator|2|In-label dosage
3319214|NCT00191152|Experimental|Gemcitabine + Docetaxel|
3319215|NCT00191152|Active Comparator|Capecitabine + Docetaxel|
3319216|NCT00191139|Experimental|Gemcitabine|
3319217|NCT00191139|Experimental|Gemcitabine plus Docetaxel|
3319218|NCT00191126|Other|A|
3319219|NCT00191126|Experimental|B|
3319220|NCT00191113|No Intervention|Control|Control arm; untreated with Humatrope. Ethinyl estradiol (escalating doses to 20 mcg daily) after age 13, and medroxyprogesterone acetate (10 mg tablets ten days monthly) after age 15. Subject continues until Core study completion criteria are met (protocol final height).
3319221|NCT00191113|Experimental|Humatrope|Humatrope (0.05 mg/kg/dose) by subcutaneous injection 6 times per week. Ethinyl estradiol (escalating doses to 20 mcg daily) after age 13, and medroxyprogesterone acetate (10 mg tablets ten days monthly) after age 15. Subject continues until Core study completion criteria are met (protocol final height).
3319222|NCT00191100|Experimental|1|"Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Gemcitabine 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks~Brachytherapy, 30-35 Gy over 1 week~Two week rest period with no chemotherapy or radiation~Cisplatin, 50 mg/m2, intravenous (IV), day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles"
3319223|NCT00191100|Active Comparator|2|"Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks~Brachytherapy, 30-35 Gy over 1 week"
3319224|NCT00190983|Experimental|Pemetrexed|
3319225|NCT00190775|Experimental|Atomoxetine|Atomoxetine 40 milligrams (mg) once daily (QD) for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
3319226|NCT00190775|Placebo Comparator|Placebo|Placebo is administered once daily (QD), orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
3319227|NCT00190749|Experimental|Olanzapine|
3319228|NCT00190749|Active Comparator|Risperidone|
3319229|NCT00190684|Experimental|Atomoxetine|Atomoxetine-naive patients will have an acute titration to a stable dose, atomoxetine experienced patients whose therapy has been interrupted with be rapidly titrated to their previously established stable dose, and atomoxetine patients on a known stable dose may continue treatment at that dose.
3319230|NCT00190671|Experimental|Pemetrexed 600 mg/m2|
3319231|NCT00190671|Experimental|Pemetrexed 1800 mg/m2|
3319232|NCT00190580|Experimental|1|
3319233|NCT00190580|Experimental|2|
3319234|NCT00190541|Active Comparator|1|Procedure/Surgery: Mesorectal excision with lateral lymph node dissection
3319235|NCT00190541|Experimental|2|Procedure/Surgery: Mesorectal excision without lateral lymph node excision
3319236|NCT00190528|Active Comparator|Surgery|
3319237|NCT00190528|Experimental|Chemotherapy + Surgery|
3319238|NCT00190515|Active Comparator|1|5-FU/l-LV
3319239|NCT00190515|Experimental|2|UFT/LV
3319240|NCT00190450|Experimental|1|Early Graft (Early G)
3319241|NCT00190450|Experimental|2|Late Graft (Late G)
3319242|NCT00190437|Experimental|1|Amoxicillin-clavulanic
3319243|NCT00190424|No Intervention|control|
3319244|NCT00190424|Experimental|CpG-ODN|
3319245|NCT00190411|Experimental|Treatment|Celiprolol
3319246|NCT00190398|Experimental|1|Carotid angioplasty and stenting with cerebral protection
3319247|NCT00190385|Active Comparator|A|
3319248|NCT00190372|Other|A|
3319249|NCT00190333|Active Comparator|A|
3319250|NCT00190307|Experimental|1|Aspirin:KARDEGIC
3319251|NCT00190294|Experimental|1|MIFEPRISTONE 200 mg and misoprostol 400 µg
3319252|NCT00190268|Experimental|3,4-diaminopyridine|3,4-diaminopyridine
3319253|NCT00190242|Experimental|group1:3 administrations of Havrix|group 1 received immunisation with Havrix (1440IU) at weeks S0, S4, S24
3319254|NCT00190242|Active Comparator|group2: 2 administrations of Havrix|group 2 received usual immunisation with Havrix (1440IU) at weeks S0 and S24
3319255|NCT00190229|Experimental|1|Cyclophosphamide
3319256|NCT00190216|Experimental|A|
3319257|NCT00190203|Experimental|A|HEMICRANIECTOMY
3319258|NCT00190190|Experimental|1|With Peeling of Limiting the Intern of the Retina
3319259|NCT00190190|Active Comparator|2|Traditional Procedure Without Peeling of Limiting
3319260|NCT00190164|Experimental|1|Macular hole surgery with alleviated positioning
3319261|NCT00190164|No Intervention|2|Macular hole surgery with no alleviated positioning
3319262|NCT00190060|Active Comparator|1|Transdermal testosterone gel (Testogel 1% )
3319264|NCT00189956|Active Comparator|Group 1|healthy, vaccinia naïve subjects 2 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
3319265|NCT00189956|Active Comparator|Group 2|healthy, vaccinia naïve subjects 5 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
3319266|NCT00189956|Active Comparator|Group 3|"healthy, vaccinia naïve subjects~1 x 10E8 TCID50 IMVAMUNE (MVA-BN), subcutaneous"
3319267|NCT00189930|Active Comparator|1|High dose
3319268|NCT00189930|Active Comparator|2|Low dose
3319269|NCT00189930|Placebo Comparator|3|
3319270|NCT00189878|Active Comparator|1 methotrexate|patient to receive methotrexate
3319271|NCT00189878|Placebo Comparator|2 Placebo|given placebo capsules
3319272|NCT00189852|Experimental|Docobo|telemonitoring at home system for heart failure
3319273|NCT00189852|No Intervention|Control|No telemonitoring system in place
3319274|NCT00189839|Active Comparator|1|
3319275|NCT00189839|Experimental|2|
3319276|NCT00189826|Active Comparator|1|
3319277|NCT00189826|Experimental|2|
3319278|NCT00189709|Experimental|1|
3319279|NCT00189709|Active Comparator|2|
3319280|NCT00189618|Placebo Comparator|1|
3319281|NCT00189618|Active Comparator|2|
3319282|NCT00189605|Active Comparator|1|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)
3319283|NCT00189605|Experimental|2|Percutaneous Disc Decompression of the lumbar level which is secondary to radicular pain
3319284|NCT00189592|Experimental|A|Percutaneous Fasciotomy
3319285|NCT00189592|Active Comparator|2|Standard Fasciotomy
3319286|NCT00189553|Active Comparator|Standard|Paclitaxel-Carboplatin
3319287|NCT00189553|Experimental|Experimental|Caelyx-Carboplatin
3319288|NCT00189540|Active Comparator|Active Group|4.0 mg AMG0001 via intramuscular injections on days 0, 14, and 28
3319289|NCT00189540|Placebo Comparator|Placebo Group|Placebo (saline) via intramuscular injections on days 0, 14, and 28
3319290|NCT00189527|Experimental|respiratory support|a mode of ventilation in comparison
3319291|NCT00189527|Active Comparator|Assist Control|an other mode of ventilation in comparison
3319292|NCT00189514|Experimental|1|
3319293|NCT00189514|Experimental|2|
3319294|NCT00189514|Experimental|3|
3319295|NCT00189514|Placebo Comparator|4|
3319296|NCT00189488|Experimental|Palifermin|Palifermin 60 μg/kg administered daily on 3 consecutive days prior to the day of start of the conditioning regimen and 180 μg/kg administered once prior to transplant and at least 96 hours from last palifermin dose of 60 μg/kg. Participants received conditioning therapy starting at least 24 hours after the last 60 μg dose of palifermin. Allogeneic stem cell transplant occurred on Day 0. Methotrexate dosing began at least 24 hours after the 180 μg/kg dose of palifermin on Days 1, 3, 6 and (planned) 11 administration (toxicity allowing) at doses of 15, 10, 10 and 10 mg/m^2 respectively.
3319297|NCT00189488|Placebo Comparator|Placebo|Placebo to palifermin 60 μg/kg administered daily on 3 consecutive days prior to the day of start of the conditioning regimen and placebo to palifermin 180 μg/kg once prior to transplant and at least 96 hours from previous placebo to palifermin 60 μg/kg dose. Participants received conditioning therapy starting at least 24 hours after the last 60 μg/kg dose of placebo to palifermin. Allogeneic stem cell transplant occurred on Day 0. Methotrexate dosing began at least 24 hours after the dose of placebo to palifermin 180 μg/kg on Days 1, 3, 6 and (planned) 11 administration (toxicity allowing) at doses of 15, 10, 10 and 10 mg/m^2 respectively.
3319298|NCT00189475|Active Comparator|Montelukast|Treated for 4 months with montelukast 4 mg per day
3319299|NCT00189475|Placebo Comparator|Placebo|Treated for 4 months with placebo
3319300|NCT00189462|Active Comparator|Montelukast|Treatment with montelukast for 4 months (4 mg per day)
3319301|NCT00189462|Placebo Comparator|Placebo|Treatment with placebo for 4 months
3319302|NCT00189436|Active Comparator|Treatment with Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
3319303|NCT00189436|Active Comparator|Usual care|Subject is treated with usual care as provided by the doctor. Usual care normally consists of treatment with albuterol with or without an oral steroid.
3319304|NCT00189423|Experimental|1|Active compression decompression cardiopulmonary resuscitation (ACD-CPR) with an impedance threshold device (ITD)
3319305|NCT00189423|Active Comparator|2|Conventional standard cardiopulmonary resuscitation (S-CPR)
3319306|NCT00189306|Experimental|Aldara|Aldara (imiquimod) cream 5% applied 7 times per week for 6 weeks
3319307|NCT00189293|Experimental|1|Imiquimod 5% cream
3319308|NCT00189293|Other|2|vehicle cream
3319309|NCT00189280|Experimental|imiqimod 5% cream|
3319310|NCT00189254||Imiquimod 5% cream|No investigational treatments were given during this study.
3319311|NCT00189228|Experimental|xolair|This is not a drug study examining differences of therapeutic outcomes. It uses Xolair as an intervention that might change the outcome of immunization.
3319312|NCT00189202|Experimental|Sirolimus, steroid avoidance arm|Thymoglobulin induction, sirolimus and no maintenance corticosteroid.
3319313|NCT00189176|Experimental|Tetrathiomolybdate|
3319314|NCT00189163|Active Comparator|Pioglitazone|30 mg, taken orally, once per day
3319315|NCT00189163|Placebo Comparator|Placebo|Sugar pill, taken orally, once a day
3319316|NCT00189137|Active Comparator|doxorubicin and ifosfamide|
3319317|NCT00189137|Experimental|gemcitabine and docetaxel|
3319318|NCT00189098|Placebo Comparator|placebo|
3319319|NCT00189098|Active Comparator|Sulfamethoxazole-trimethoprim|
3319320|NCT00189020|Experimental|2-dose|PCV7 at age 2 and 4 months
3319321|NCT00189020|Experimental|2+1-dose|PCV7 at age 2, 4 and 11 months
3319322|NCT00189020|No Intervention|Control|Control group
3319323|NCT00189007|Experimental|Allopurinol|500 mg allopurinol/ 50 mL water for injection intravenously
3319324|NCT00189007|Placebo Comparator|Placebo|500 mg mannitol/50 mL water for injection intravenously
3319325|NCT00188942|Active Comparator|Fluoxetine + Olanzapine|
3319326|NCT00188890||1|prior occupational exposure at least 20 years ago to ASBESTOS and / or documented pleural plaques on a chest x-ray Must be 30 years of age or older. NO prior cancers, except non-melanic skin cancers
3319327|NCT00188825|Experimental|basiliximab|
3319329|NCT00188721||1|Women with confirmed unilateral breast carcinoma or ductal carcinoma in situ (DCIS)
3319330|NCT00188721||2|Women without radiological suspicious lesions, matched to cases by age (± 2.5 years), date of screening mammogram, and screening center.
3319331|NCT00188708|Experimental|hypoxia measurement|Patients undergoing or planning to receive combined anti-androgen (Casodex) and radiotherapy
3319332|NCT00188630|Active Comparator|N-Acetylcysteine|IV NAC as a 100mg/kg bolus at the start of the surgical procedure (prior to the initiation of CPB), followed by a 10 mg/kg/hr infusion until 4 hours after completion of surgery
3319333|NCT00188630|Placebo Comparator|Placebo|The control arm will instead receive placebo (5% dextrose solution), both as a bolus and infusion.
3319334|NCT00188578|Experimental|IMRT Gynecological Cancers|
3319335|NCT00188539|Experimental|Pre-treatment tumour oxygen measurements (under anesthesia)|
3319336|NCT00188513|Experimental|Conformal intensity modulated radiotherapy (IMRT)|All patients shall receive a continuous course of intensity modulated conformal radiotherapy consisting of 66 Gy in 22 (3 Gy) fractions over 4.5 weeks.
3319337|NCT00188344|Active Comparator|1|pneumatic dilatation
3319338|NCT00188344|Active Comparator|2|Laparoscopic myotomy
3319339|NCT00188331||1|adjuvant/neoadjuvant chemotherapy
3319340|NCT00188331||2|non-chemotherapy group
3319341|NCT00188331||3|limited metastatic disease or localised recurrence to receive first line metastatic chemotherapy
3319342|NCT00188318|Experimental|Hyperfractionated Accelerated Radiotherapy|Hypofractionated Accelerated Radiotherapy with integrated neck surgery
3319343|NCT00188305|Experimental|1 In person|In person general health, colorectal cancer risk information and screening recommendations.
3319344|NCT00188305|Active Comparator|2 Telephone|Telephone general health counselling, colorectal cancer risk information and screening recommendations.
3319345|NCT00188305|Placebo Comparator|3 Control|Standard care for 2 months followed by summary letter with general health information, colorectal cancer risk information and screening recommendations.
3319346|NCT00188292||High-grade disease|Those who had histologic anal high-grade disease.
3319347|NCT00188292||Control|Those who had less than highgrade histologic anal disease
3319348|NCT00188279|Experimental|MnDCT|
3319349|NCT00188266|Experimental|5-Fluorouracil (5FU) and Cisplatin with Radiation|
3319350|NCT00188214|Other|CT perfusion scan|
3319351|NCT00188175|Experimental|IMRT for lower limb soft tissue sarcoma|
3319352|NCT00187941|Other|CellCept|CellCept + Prograf or Neoral + Steroids
3319353|NCT00187915|Other|CellCept + Prograf|Standard of Care Regime
3319354|NCT00187915|Other|CellCept + Neoral|Standard of Care Regime
3319355|NCT00187889|Active Comparator|Eplerenone|Eplerenone 25 mg (1 pill)daily for 1 week then uptitrated to 50 mg (2 pills)daily for 15 weeks.
3319356|NCT00187889|Placebo Comparator|Placebo or sugar pill|Placebo blinded as 25 mg tablet once daily for 1 week then uptitrated to 2 pills daily for 15 weeks.
3319357|NCT00187876|Active Comparator|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts.
3319358|NCT00187876|Experimental|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
3319359|NCT00187863||Exercise induced pain perception|
3319360|NCT00187863||Surgical pain perception|
3319361|NCT00187850|Experimental|PP|Partial pulpotomy
3319362|NCT00187850|Other|DPC|Direct pulp capping
3319363|NCT00187837|Experimental|SW intervention|Stepwise Excavation
3319364|NCT00187837|Other|DCE intervention|Control intervention Direct complete excavation. The updated terminology for completed excavation is non-selective excavation to hard dentin
3319365|NCT00187798|Other|Metformin|Metformin HCl
3319366|NCT00187746|Experimental|Age 18-25 years|African American subjects between the ages 18 to 25 years given Adefovir dipivoxil.
3319367|NCT00187746|Experimental|Age 48-55 years|African American subject between the ages 48 to 55 years given Adefovir dipivoxil.
3319368|NCT00187733||Fasting|Other: Fasting blood and urine collection
3319369|NCT00187720|Experimental|OCT2-variant Group|Subjects with OCT2-variant genotype will be given a single oral dose of 850 mg of metformin.
3319370|NCT00187720|Experimental|OCT2-reference Group|Subjects with OCT2-reference genotype will be given a single oral dose of 850 mg of metformin.
3319371|NCT00187707|Other|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
3319372|NCT00187681|Experimental|OCT1-variant Group|Subjects with OCT1-variant alleles will be dosed with 2 doses of Metformin
3319373|NCT00187681|Experimental|OCT1-reference Group|Subjects with OCT1-reference alleles will be dosed with 2 doses of Metformin
3319374|NCT00187668||African American|Must self identify as African American with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
3319375|NCT00187668||Cuacasian|Must self identify as Caucasian with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
3319376|NCT00187668||Hispanic|Must self identify as Hispanic with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
3319377|NCT00187668||Asian|Must self identify as Asian with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
3319378|NCT00187655|Other|Cefotaxime|Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
3319379|NCT00187629|Experimental|1|dietary phosphorus
3319380|NCT00187629|Active Comparator|2|other
3319381|NCT00187590|Experimental|Intervention|Phone call after an ER visit.
3319382|NCT00187590|No Intervention|Control|No phone call after an ER visit.
3319383|NCT00187577|Active Comparator|application to eyelid of latanoprost solution|Subject will apply latanoprost solution with applicator daily to affected eye lid(s)
3319384|NCT00187577|Active Comparator|Application of bimatoprost to eyelid|Subject will apply bimatoprost solution with applicator daily to affected eye lid(s)
3319385|NCT00187551|Experimental|interruption of enfuvirtide|enfuvirtide interruption
3319390|NCT00187486|Experimental|Temodar plus Tarceva plus Radiation Therapy|Single arm phase-2 experimental treatment of newly diagnosed patients with Glioblastoma with Temodar plus Tarceva plus Radiation Therapy
3319391|NCT00187460|Active Comparator|Early Feedback Arm|Hospital corporations randomized to receive early feedback in the form of a report card
3319392|NCT00187460|Active Comparator|Delayed Feedback Arm|Hospitals randomized to receive delayed feedback in the form of a hospital report cared, 21 months after the early feedback arm.
3319393|NCT00187421|No Intervention|1|Graft patency assessment by routine clinical assessment with/without intraluminal coronary probe
3319394|NCT00187421|Experimental|2|Graft patency assessment by indocyanine green angiography and transit-time flowmetry
3319395|NCT00187369|Other|Caesarean Section|delivery by CS
3319396|NCT00187369|Other|Vaginal Birth|delivery by VB
3319397|NCT00187356|Experimental|Surgical Conduit|The surgical arm will be composed of the experimental arm (the use of the radial artery) versus an active comparator (the use of the saphenous vein graft).
3319398|NCT00187317|Experimental|PERT|Perturbation-based balance training.
3319399|NCT00187317|Placebo Comparator|CON|Flexibility and relaxation training.
3319400|NCT00187278|Active Comparator|RV Pacing|Standard Pacemaker implant
3319401|NCT00187278|Experimental|Biventricular Pacing|Biventircular Pacemaker implant
3319402|NCT00187252|Experimental|1|CRT + AF Suppression turned ON
3319403|NCT00187252|Active Comparator|2|CRT + AF Suppression turned OFF
3319404|NCT00187239|Active Comparator|AICS On|Patients in this arm have Autointrinsic conduction search programmed ON.
3319405|NCT00187239|No Intervention|AICS Off|Patients assigned to this arm do not have Autointrinsic Conduction Search programmed on.
3319406|NCT00187226|Other|Stratum 1|Ependymoma, craniopharyngioma, low-grade glioma
3319407|NCT00187226|Other|Stratum 2|High-grade glioma
3319408|NCT00187200|Active Comparator|Simultaneous VV Pacing|Programmed to simultaneous biventricular pacing
3319409|NCT00187200|Active Comparator|Sequential VV Pacing|Programmed to sequential biventricular pacing
3319410|NCT00187187|Active Comparator|Implantable Defibrillator (ICD) VVI-40|The DAVID II Clinical Study evaluates the hypothesis that, in patients needing an ICD but without overt indications for pacing, AAI pacing with maximal concomitant drug therapy (AAI-70)will not increase the rate of the combined endpoint of mortality or hospitalization for new or worsened heart failure, compared to patients with ventricular backup pacing (VVI-40).
3319411|NCT00187187|Active Comparator|Implantable Defibrillator (ICD) AAI-70|The DAVID II Clinical Study evaluates the hypothesis that, in patients needing an ICD but without overt indications for pacing, AAI pacing with maximal concomitant drug therapy (AAI-70)will not increase the rate of the combined endpoint of mortality or hospitalization for new or worsened heart failure, compared to patients with ventricular backup pacing (VVI-40).
3319412|NCT00187174|Experimental|Phase 1|
3319413|NCT00187161|Experimental|A|"Group A: Resected Stage I and resected abdominal Stage II~Subjects will receive two courses (3 weeks apart) of COPAD."
3319414|NCT00187161|Experimental|B|"Group B: Other Stage II, Stage III, Stage IV or B-ALL M blast <70%; no CNS involvement.~Subjects in Group B will receive one week of treatment of COP."
3319415|NCT00187161|Experimental|C|"Group C: B-ALL with >70% BM blasts; CNS involvement, Group B COP failures i.e., <20% reduction Treatment Pre-Induction~Subjects will receive one week of treatment of COP."
3319416|NCT00187148|Other|1|
3319417|NCT00187135|Active Comparator|1|Fentanyl-1mcg/kg in 3 ml of Normal Saline
3319418|NCT00187135|Active Comparator|2|Fentanyl - 0.5 mcg/kg in 3 ml normal saline
3319419|NCT00187135|Placebo Comparator|3|normal saline
3319420|NCT00187122|Other|1|See Detailed Description section for description of treatment plan.
3319421|NCT00187096|Experimental|Stratum 1|"Stratum 1 (AML in complete remission)~Cyclophosphamide 60 mg/kg IV Day -7 Fludarabine 25 mg/m2/day IV Days -6 through -2 Donor pheresis Day -1 Start IL-2 on Day -1, then 3 times per week x 2 weeks NK Cell purification and infusion on Day 0"
3319422|NCT00187096|Experimental|Stratum 2|"Stratum 2 (AML that is refractory or relapsed or AML with increasing minimal residual disease)~Clofarabine 40 mg/m2 IV, days -6 through -2 Etoposide 100 mg/m2 IV, days -6 through -2 Cyclophosphamide 400 mg/m2 IV, days -6 through 02 Donor pheresis Day -1 Start IL-2 Day -1, and then 3 times per week x 2 weeks NK Cell purification and infusion on Day 0."
3319423|NCT00187083|Experimental|1|Native asparaginase
3319424|NCT00187083|Experimental|2|PEG-asparaginase
3319425|NCT00187070|Other|1|
3319426|NCT00187057|Other|1|Acute Lymphoblastic Leukemia (ALL) Low Risk
3319427|NCT00187057|Other|2|Acute Lymphoblastic Leukemia (ALL) - High Risk
3319428|NCT00187057|Other|3A|B-Cell Non-Hodgkins Lymphoma (Group A)
3319429|NCT00187057|Other|3B|B-Cell Non-Hodgkins Lymphoma (Group B)
3319430|NCT00187057|Other|4|Hodgkins Disease
3319431|NCT00187044|Other|1|
3319432|NCT00187031|Other|1|
3319433|NCT00187005|Other|1|
3319434|NCT00186992|Other|Treatment|Eligible patients will be accessioned at the time of irradiation and undergo a pre-radiotherapy evaluation, treatment planning, image-guided radiotherapy delivery and intra-and post-irradiation evaluations.
3319435|NCT00186979|Other|1|
3319436|NCT00186966|Other|FLAG|
3319437|NCT00186966|Other|FLAG and LP Dox|
3319438|NCT00186953|Other|1|
3319439|NCT00186940||1|
3319440|NCT00186927|Experimental|Participants|"Participants will be studied in three cohorts:~Healthy seropositive children 3 years up to 6 years~Healthy seropositive toddlers 12 months up to 24 months~Healthy seronegative toddlers 12 months up to 24 months.~Each cohort will receive Sendai virus vaccine."
3319441|NCT00186914|Other|1|
3319442|NCT00186901|Placebo Comparator|1A|Nutritional counseling + placebo
3319443|NCT00186901|Experimental|1B|Nutritional counseling + supplementation with calcium, 1000mg/day + vitamin D, 800 units/day, for a 2 year period
3319444|NCT00186888|Other|Stratum A|Patients with early bilateral or unilateral, or patients with bilateral that have already had the advanced eye enucleated. Treatment included vincristine and carboplatin for 8 courses, given at 3-4 week intervals. Focal therapies any time after second course can include cryotherapy, laser photocoagulation, thermotherapy, and plaque radiotherapy
3319445|NCT00186888|Other|Stratum B|"Patients with bilateral disease (at least one advanced stage eye), candidate for conservative management.~Treatment included window treatment with vincristine and topotecan, Followed by 3 more courses of vincristine-topotecan if they had a response to the window+ 6 courses of vincristine and carboplatin. If they do not respond to the window, they receive 6 courses of vincristine, carboplatin, and etoposide. Periocular injections of carboplatin are also given three times, depending on whether they respond to window."
3319446|NCT00186888|Other|Stratum C|"Patients with advanced unilateral advanced intraocular disease. First intervention is enucleation.~If enucleated eye does not have disease outside the retina (low risk), no additional treatment is given.~For patients whose enucleated eye shows tumor outside the retina (intermediate risk), they will receive 4 courses of vincristine, cyclophosphamide, and doxorubicin followed by G-CSF.~For patients with high risk disease (involvement of the sclera, optic nerve at the level of the cut-end), treatment after enucleation is 6 courses of alternating chemotherapy with vincristine, carboplatin, etoposide (VCE) to alternate with vincristine, cyclophosphamide, and doxorubicin (VCD). High risk patients also receive external-beam radiation therapy."
3319447|NCT00186875|Other|Treatment|Participants receive chemotherapy, intrathecal chemotherapy, steroid therapy, hematopoietic stem cell transplant, and natural killer cell transplant as outlined in the Interventions section, including etoposide, cytarabine, vincristine, dexamethasone, methotrexate, teniposide, PEG-asparaginase, mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine, L-asparaginase, erwinia asparaginase.
3319448|NCT00186862|Other|1|
3319449|NCT00186849|Other|1|
3319450|NCT00186823|Other|1|
3319451|NCT00186810|Other|1|
3319452|NCT00186771|Active Comparator|True Transcranial Magnetic Stimulation|True treatment with TMS over the temporoparietal cortex.
3319453|NCT00186771|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham treatment with rTMS over the temporoparietal cortex.
3319454|NCT00186758|Sham Comparator|1, Phase l, True or Sham|this treatment will be True or Sham (placebo) on one side of the head, phase I
3319455|NCT00186758|Active Comparator|2, phase ll, Sham or True|This treatment will be Sham(placebo)or True on the other side of the head phase II.
3319456|NCT00186745|Experimental|1|All patients in this cohort receive treatment with weight-adjusted, standard-dose tinzaparin for treatment of venous thromboembolism. Trough anti-Xa level measurements done on any 2 of days 3, 5 or 7 of treatment. Patients with a trough anti-Xa level > 0.5 IU/mL receive dose adjustment of the tinzaparin.
3319457|NCT00186628|Experimental|Prophylactic Rituximab|Rituximab will be infused after a non-myeloablative transplantation regimen of total lymphoid irradiation (TLI) + anti-thymoglobulin (ATG), with the intention of reducing chronic graft-vs-host disease (cGvHD)
3319458|NCT00186537|Active Comparator|fenofibrate|160 mg daily for 12 weeks
3319459|NCT00186537|Active Comparator|rosiglitazone|4 mg/daily 4 weeks followed by 4 mg 2 x daily for 8 weeks
3319460|NCT00186537|Active Comparator|calorie restricted diet|calorie restricted to achieve 0.5 kg weight loss/week x 12 weeks
3319461|NCT00186485|Experimental|Right Sided Low Frequency Unilateral TMS|1Hz unilateral TMS delivered to the right DLPFC using the MagStim device
3319462|NCT00186446|Experimental|Bupropion|
3319463|NCT00186342|Experimental|CIK cell|The initial dose utilized will be 1x107 expanded cells/kg. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD.
3319464|NCT00186186|Experimental|Depakote ER|Depakote ER up to 1500 mg/day
3319465|NCT00186173|Experimental|After school sports|After school team sports intervention designed specifically for overweight and obese children
3319466|NCT00186173|Active Comparator|After school health education|After school heath and nutrition education program
3319467|NCT00186147||Graft recipients and donors|
3319468|NCT00186121|Experimental|Anastrozole + Goserelin|Participants received goserelin 3.6 mg subcutaneously monthly. Beginning on Day 22 after the first dose of goserelin, participants began taking anastrozole 1 mg orally daily. No dose attenuation or escalation was allowed for either goserelin or anastrozole.
3319469|NCT00186082|Active Comparator|Cefotetan, Cefoxitin or Clindamycin|
3319470|NCT00186082|Placebo Comparator|Normal Saline|
3319471|NCT00186069|Active Comparator|Magnesium Sulfate|Magnesium Sulfate 4 gram bolus, followed by 2 grams per hour
3319472|NCT00186069|Placebo Comparator|Normal Saline|Normal Saline 4 gram bolus, followed by 2 grams per hour
3319473|NCT00186056|Experimental|Mifepristone|Patients received mifepristone for 6 days
3319474|NCT00186056|Placebo Comparator|placebo|Patients received placebo for 6 days
3319475|NCT00186043|Experimental|Quetiapine/Seroquel|Quetiapine/Seroquel up to 800 mg/day
3319476|NCT00186043|Placebo Comparator|Placebo|Placebo
3319477|NCT00186017|Experimental|Olanzapine/Zyprexa|Olanzapine/Zyprexa 2.5 mg up to 8 per day for 1 week
3319478|NCT00186017|Placebo Comparator|Placebo|Placebo was taken in the same manner as olanzapine with up to 8 per day for 1 week
3319479|NCT00185991|Active Comparator|Once daily Gentamicin|
3319480|NCT00185991|Active Comparator|Every eight hour Gentamicin|
3319481|NCT00185965|Experimental|Lymphoma, B-cell low-grade (BCL)|Recurrent low-grade B-cell lymphoma patients (at least one prior treatment failure)
3319482|NCT00185965|Experimental|Mycosis fungoides (MF)|"Mycosis fungoides patients must have failed or have been intolerant of at least 1 topical or 1 systemic treatment~Recurrent mycosis fungoides patients (at least one prior failure of topical or systemic treatment)"
3319483|NCT00185952|Active Comparator|Nifedipine|Maintenance tocolysis with nifedipine.
3319484|NCT00185952|Placebo Comparator|Placebo|Maintenance tocolysis with placebo tablets.
3319485|NCT00185900|Active Comparator|Magnesium Sulfate|Preterm labor treatment with Magnesium Sulfate.
3319486|NCT00185900|Active Comparator|Nifedipine|Preterm labor treatment with Nifedipine.
3319487|NCT00185887|Active Comparator|Terbutaline|
3319488|NCT00185887|Active Comparator|Nitroglycerine|
3319489|NCT00185848|Experimental|[18F]FHBG arm|
3319490|NCT00185796|Experimental|TLI/ATG conditioning|Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).
3319491|NCT00185757|Experimental|Cytokine-induced Killer Cells|The first cohort =1X10 7 cf expanded cells/kg. The second cohort = 5x10 7 expanded cells/kg. The second cohort = 1X10 8 expanded cells/kg.
3319492|NCT00185744|Experimental|Accelerated Partial Breast Irradiation|lumpectomy with accelerated partial breast irradiation
3319493|NCT00185744|Active Comparator|Standard Therapy|lumpectomy and whole breast irradiation
3319494|NCT00185731|Experimental|80 mg Atorvastatin|Atorvastatin, 80 mg tablet, will be taken orally by the patient daily, beginning on study day 1.
3319495|NCT00185692|Experimental|Transplantation of CD34+ cells|"Week #1: Total Lymphoid Inrradiation (TLI) 120 cGy + Anti-thymocyte Globulin (ATG) 1.5 mg/kg + Solumedrol 1.0 mg/kg Daily for 5 days.~Week #2: TLI 120 cGy (3 days a week, double on the 4th day) 5 days of CSP (oraly) one day after TLI was started. 3 days of MMF 4 days after TLI was started."
3319496|NCT00185679|Experimental|Haploidentical Allogeneic Transplant Using CliniMACS System|The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.
3319497|NCT00185640|Experimental|Non-myeloablative transplantation|Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil .
3319498|NCT00185614|Experimental|Auto- then Allo-HCT|Auto-HCT mobilization is cyclophosphamide 4 g/m2 + filgrastim 10 µg/kg/day for peripheral blood progenitor cell (PBPC) collection by apheresis. Transplant conditioning is high-dose melphalan 200 mg/m2, followed by PBPC infusion as melphalan rescue [ie, autologous hematopoietic cells transplant (Auto-HCT)]. Post-infusion support is filgrastim 5 µg/kg/day, starting 6 days after melphalan. Stable/responsive disease at 4 weeks continues to allogenic HCT (Allo-HCT) from sibling donor fully-matched for human leukocyte antigen (HLA). Allo-HCT conditioning is total body irradiation (TBI) 200 centigray (cGy) + cyclosporine (CSP) 6.25 mg/kg + mycophenolate mofetil (MMF) 15 mg/kg. Donor mobilization is filgrastim 16 µg/kg/day on day -4 to Day 0; apheresis collections on Day -1 & Day 0, to a target of > 5 x 10e6 CD34 cells/kg. Allo-HCT is infused to participant on Day 0, with premedication hydrocortisone 100 mg IV & diphenhydramine 50 mg IV. CSP tapering on Day 56 to Day 180, adjusted as needed.
3319499|NCT00185601|Other|on-line self management intervention|
3319500|NCT00185601|No Intervention|usual care control group|
3319501|NCT00185601|Experimental|on-line self management intervention with email reinforcement|
3319502|NCT00185588|Experimental|Stage 1 Dose Exploration 0 - Gemcitabine 700 + vatalanib 1250|Gemcitabine 700 mg/m2 + vatalanib 1250 mg daily
3319503|NCT00185588|Experimental|Stage 1 Dose Exploration 1 - Gemcitabine 850 + vatalanib 1250|Gemcitabine 850 mg/m2 + vatalanib 1250 mg
3319504|NCT00185588|Experimental|Stage 1 Dose Explrtion2 - Gemcitabine850+vatalanib 2x250/2x500|Gemcitabine 850 mg/m2 + vatalanib 250 mg Q12 hours x 1 week then 500 mg Q12 hours thereafter
3319505|NCT00185588|Experimental|Stage 2 Dose Expansion - Gemcitabine850+vatalanib 2x250/2x500|Gemcitabine 850 mg/m2 + vatalanib 250 mg Q12 hours x 1 week then 500 mg Q12 hours thereafter
3319506|NCT00185523||CML in first Chronic Phase or Accelerated Phase|Busulfan/cyclophosphamide Day -7: Busulfan 1.0 mg/kg IV q6 hrs** Day -6: Busulfan 1.0 mg/kg IV q6 hrs Day -5: Busulfan 1.0 mg/kg IV q6 hrs Day -4: Busulfan 1.0 mg/kg IV q6 hrs Day -3: Cyclophosphamide 60 mg/kg Day -2: Cyclophosphamide 60 mg/kg Day -1: rest Day 0: Allogeneic PBSC infusion
3319507|NCT00185523||AML and ALL in first or second remission|FTBI/VP-16 Day -7: FTBI 120 cGy x 3 fractions Day -6: FTBI 120 cGy x 2 fractions Day -5: FTBI 120 cGy x 3 fractions Day -4: FTBI 120 cGy x 3 fractions* Day -3: VP-16 at 60 mg/kg Day -2: rest Day -1: rest Day 0: Allogeneic PBSC infusion
3319508|NCT00185510|Experimental|Arm 1|
3319509|NCT00185510|Placebo Comparator|Arm 2|
3319510|NCT00185484|Experimental|Arm 1|
3319511|NCT00185458|Experimental|LNG IUS|Levonorgestrel Intrauterine System (LNG IUS) (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) Hormone-Replacement Therapy (HRT) Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by World Health Organization (WHO) guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
3319512|NCT00185445|Experimental|Arm 1|
3319513|NCT00185419|Active Comparator|Arm 1|
3319514|NCT00185419|Active Comparator|Arm 2|
3319515|NCT00185393|Experimental|Arm 1|
3319516|NCT00185393|Other|Arm 2|
3319517|NCT00185380|Experimental|LCS12|Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro
3319518|NCT00185380|Experimental|LCS16|Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro
3319519|NCT00185380|Active Comparator|IUS20 (Mirena)|Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro
3319520|NCT00185367|Experimental|Arm 1|
3319521|NCT00185367|Active Comparator|Arm 2|
3319522|NCT00185354|Experimental|Arm 1|
3319523|NCT00185354|Active Comparator|Arm 2|
3319524|NCT00185341|Experimental|CCR-1 Receptor Antagonist|Subjects received 600 mg (2 x 300 mg tablets) of CCR-1 Receptor Antagonist 3 times daily
3319525|NCT00185341|Placebo Comparator|Placebo|Subjects received placebo corresponding to verum
3319526|NCT00185328|Experimental|Arm 1|
3319527|NCT00185315|Experimental|Arm 1|
3319528|NCT00185302|Experimental|Histone Deacetylase Inhibitor, 3 mg|Subjects received 3 mg MS-275 orally biweekly (Days 1 and 15 of a 4 week cycle) or until disease progression or unacceptable toxicity
3319529|NCT00185302|Experimental|Histone Deacetylase Inhibitor, 7 mg|Subjects received 7 mg MS-275 orally weekly (Days 1, 8, and 15 of a 4 week cycle) until disease progression or unacceptable toxicity
3319530|NCT00185289|Experimental|Arm 1|
3319531|NCT00185276|Experimental|Arm 1|
3319532|NCT00185276|Experimental|Arm 2|
3319533|NCT00185263|Experimental|1|Ad5FGF-4
3319534|NCT00185263|Experimental|2|Ad5FGF-4
3319535|NCT00185263|Placebo Comparator|3|Placebo
3319536|NCT00185250|Experimental|Arm 1|
3319537|NCT00185250|Experimental|Arm 2|
3319538|NCT00185250|Placebo Comparator|Arm 3|
3319539|NCT00185250|Placebo Comparator|Arm 4|
3319540|NCT00185237|Experimental|Arm 1|
3319541|NCT00185237|Placebo Comparator|Arm 2|
3319542|NCT00185224|Experimental|Arm 1|
3319543|NCT00185224|Active Comparator|Arm 2|
3319544|NCT00185211|Experimental|Initial IFNB-1b (Interferon beta-1b)|Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
3319545|NCT00185211|Experimental|Initial Placebo|Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
3319546|NCT00185198|Active Comparator|Arm 1|
3319547|NCT00185198|Placebo Comparator|Arm 2|
3319548|NCT00185185|Experimental|1|olmesartan medoxomil
3319549|NCT00185185|Active Comparator|2|atenolol
3319550|NCT00185172|Placebo Comparator|1|2 week placebo run-in
3319551|NCT00185172|Experimental|2|Olmesartan medoxomil tablets for 8 weeks
3319552|NCT00185172|Experimental|3|Olmesartan medoxomil tablets, or olmesartan medoxomil tablets + hydrochlorothiazide tablets for 4 weeks
3319553|NCT00185159|Experimental|1|olmesartan medoxomil
3319554|NCT00185159|Placebo Comparator|2|placebo
3319555|NCT00184925|Active Comparator|subglottic drainage|suctioning of subglottis with cannula
3319556|NCT00184873|Active Comparator|Lifestyle counseling|Patients receiving lifestyle counseling
3319557|NCT00184873|No Intervention|Regular care|Patients receiving regular care
3319558|NCT00184795|Experimental|ALD 0.1|
3319559|NCT00184795|Experimental|ALD 0.25|
3319560|NCT00184795|Placebo Comparator|Placebo|
3319561|NCT00184717|Experimental|0.033 mg / NN-220|In the 156-week main period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
3319562|NCT00184717|Experimental|0.067 mg / NN-220|In the 156-week main period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
3319563|NCT00184717|No Intervention|No treatment|No somatropin (NN-220) treatment was given in the 52-week main period. Subjects was re-randomised to recive two dosing regimens (0.033 mg/kg/day or 0.067 mg/kg/day) in the 208-week extension period
3319564|NCT00184717|Experimental|No treatment --> 0.033 mg|In the 208-week extension period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period
3319565|NCT00184717|Experimental|No treatment --> 0.067 mg|In the 208-week extension period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period
3319566|NCT00184600|Experimental|Insulin detemir (basal insulin)|Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen.
3319567|NCT00184600|Active Comparator|Insulin aspart (prandial insulin)|Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen.
3319568|NCT00184600|Active Comparator|Biphasic insulin aspart 30 (biphasic insulin)|Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen.
3319569|NCT00184587|Experimental|candesartan|candesartan cilexetil 16 mg (one tablet/day) in week 1 and 32 mg (2 tablets/day) in week 3, provided for the study by AstraZeneca
3319570|NCT00184587|Placebo Comparator|placebo|placebo one tablet/day in week 1 and 2 tablets/day in week 3, provided for the study by AstraZeneca. Same size, weight, taste and appearance as experimental drug
3319571|NCT00184548|Experimental|rFVIIa, Blunt Trauma|
3319572|NCT00184548|Placebo Comparator|Placebo, Blunt Trauma|
3319573|NCT00184548|Experimental|rVIIa, Penetrating Trauma|
3319574|NCT00184548|Placebo Comparator|Placebo, Penetrating Trauma|
3319575|NCT00184522|Experimental|Aflurax|pectin-containing natural product
3319576|NCT00184522|Active Comparator|esomeprazole (Nexium)|esomeprazole (Nexium)
3319577|NCT00184496|Active Comparator|methadon|Morphine methadone stop and go switch
3319578|NCT00184496|Active Comparator|Methadone|Methadon morphine overlap switch
3319579|NCT00184483|Experimental|Lichtenstein's operation|Patients with a primary unilateral inguinal hernia are randomized to Lichtenstein's operation to repair their groin hernia
3319580|NCT00184483|Active Comparator|Prolene Hernia System|Patients with a primary unilateral inguinal hernia are randomized to Prolene Hernia System to repair their groin hernia
3319581|NCT00184444|Experimental|Hypoxic Interval training|4 x 4 minutes interval training with 100% oxygenated air
3319582|NCT00184444|Experimental|Normoxic interval training|4 x 4 minutes interval training in normoxic air
3319583|NCT00184431|Experimental|A|Intensive task specific balance training
3319584|NCT00184431|Active Comparator|B|Traditional physical therapy
3319585|NCT00184418||All patients admitted to a psychiatric acute ward|
3319586|NCT00184392|Experimental|debridement or saline irrigation|1 arm undergo debridement of the nose 1 week and 2 weeks after surgery the other arm rinse their nose with saline irrigation
3319587|NCT00184379|Experimental|1 S+E|Relatives of patients with schizophrenia, who receive education
3319588|NCT00184379|No Intervention|2 S-E|Relatives of patients with schizophrenia, who do not receive education
3319589|NCT00184379|Experimental|3 B+E|Relatives of patients with bipolar disorder, who receive education
3319590|NCT00184379|No Intervention|4 B-E|Relatives of patients with bipolar disorder, who do not receive education
3319591|NCT00184353||brain metastases|6 patients
3319592|NCT00184353||healthy|13 volunteers
3319593|NCT00184301|Experimental|inpatient treatment|inpatient treatment during 1 year
3319594|NCT00184301|Active Comparator|outpatient treatment|intensive outpatient treatment consisting of two-weekly group sessions during 1 year
3319595|NCT00184262|Active Comparator|ERP cognitive therapy|
3319596|NCT00184262|Experimental|ERP behavioral therapy|
3319597|NCT00184249|Experimental|Bipolar radiofrequency ablation|
3319598|NCT00184236|Active Comparator|Aerobic interval training|Aerobic interval training (AIT)
3319599|NCT00184236|Active Comparator|Multitreatment approach|multitreatment approach (MTG)
3319600|NCT00184223|Experimental|motivational interviewing|Manual guided motivational interviewing in addition to treatment as usual
3319601|NCT00184223|Other|control group|treatment as usual
3319602|NCT00184197|Experimental|Botox|
3319603|NCT00184197|Placebo Comparator|placebo|
3319604|NCT00184171|Experimental|Budesonide|Budesonide 9mg
3319605|NCT00184171|Experimental|bismuth|Bismuth mixture
3319606|NCT00184171|Sham Comparator|Fiber|Fiber preparation
3319607|NCT00184145|Experimental|EMDR|The experimental group was treated for animal phobia by EMDR, control group received an attention placebo (relaxation plus breathing exercises). Afterwards, both groups were treated by exposure therapy (therapy of choice for animal phobia).
3319608|NCT00184132|Experimental|Norwegian home style ward|The walls received wainscots, colourful wallpaper and paintings; the ceilings were lowered and had multiple lighting spots, the windows tasteful curtains; we put wardrobes, chairs, flowers and personal items in the patient rooms; and Italian ceramic tile covered the entire bathroom
3319609|NCT00184132|Active Comparator|sparsely furnished ward|traditional interior design and furnishings. The rooms had sparse furniture, walls in grey colours lacking pictures, no window curtains, single lamps in the ceiling 4 m high, bathroom with grey, laminated paint all over, and patient rooms with a single bed and a chair of metal tubes
3319610|NCT00184119|Experimental|Psychiatric Intensive Care Unit|
3319611|NCT00184119|Active Comparator|Whole acute unit|
3319612|NCT00184106|Active Comparator|Cognitive Therapy|Cognitive Therapy
3319613|NCT00184106|Active Comparator|Seroxat and SE|SSRI with Self exposure
3319614|NCT00184106|Active Comparator|Seroxat and Cognitive Therapy|Combination of Seroxat and Cognitive Therapy
3319615|NCT00184106|Placebo Comparator|Pill-Placebo|Pill Placebo
3319616|NCT00184093|Experimental|Gemcitabine weekly x 6 wks with concurrent external radiation|Gemcitabine 350 mg/m2 IV weekly x 6 weeks with concurrent external radiation
3319617|NCT00184067|Experimental|Peptide vaccine with Montanide ISA 51 + GM-CSF|Peptide vaccine with Montanide ISA 51 GM-CSF
3319618|NCT00184067|Active Comparator|Peptide vaccine with Montanide ISA 51|Peptide vaccine with Montanide ISA 51
3319619|NCT00184054|Experimental|Arsenic Trioxide (ATO) Plus Ascorbic acid|"Arsenic Trioxide (ATO) given at 0.25 mg/kg/day intravenously for 25 days over a 35-day period.~Ascorbic Acid given at 1000 mg/day intravenously every other day that ATO is given"
3319620|NCT00184041|Experimental|Intensified Post-Remission: MTX/LV/PEG-Asparaginase|Daunorubicin 60 mg/m2 iv on days 1, 2, 3 Vincristine 1.4 mg/m2 iv on days 1, 8, 15, 22 Peg-Asparaginase 2000 U/m2 iv on day 15 Prednisone 60 mg/m2 mg po on days 1-28 MTX 12 mg IT on days 8 & 15
3319621|NCT00184028|Experimental|Arm 1|On Day 1 of each day treatment cycle, patients receive Taxotere 60 mg/m2 as a 1-hour IV infusion, followed by the administration of oxaliplatin 100 mg/m2. Oxaliplatin will be administered IV over 2 hours at a rate of 10mg/m2/min. This treatment regimen will be repeated every 21 days.
3319622|NCT00184015|Experimental|Schedule A|
3319623|NCT00184015|Experimental|Schedule B|
3319624|NCT00184002|Experimental|DR-COP|"On cycle 1 patients receive Doxil 40 mg/m2 iv day 1 over a minimum of 60 min., Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min., Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum) and Prednisone 100 mg po days 1-5.~On cycle 2 until study completion patients receive Doxil 40 mg/m2 iv day 1, Rituxan 375 mg/m2 iv day 1, Cyclophosphamide 750 mg/m2 iv day 1, Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum) and Prednisone 100 mg po days 1-5~1 cycle = 21 days.~Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles."
3319625|NCT00183963|No Intervention|1|
3319626|NCT00183963|Active Comparator|2|Tamoxifen 20 mg
3319627|NCT00183963|Active Comparator|3|Fulvestrant 250mg
3319628|NCT00183963|Active Comparator|4|Fulvestrant 500mg IM
3319629|NCT00183937|Experimental|Bortezomib and Docetaxel|Bortezomib 1.6 mg/m2 Docetaxel 75 mg/m2
3319630|NCT00183898|Experimental|Oxaliplatin and Capecitabine|Oxaliplatin given every 21 days Capecitabine given daily x 14 days every 21 days
3319631|NCT00183885|Experimental|Cisplatin + Mitomycin-C|CDDP 60mg/m2 + Mitomycin-C 12mg/m2
3319632|NCT00183872|Experimental|Arm 1 - Irinotecan and Docetaxel|Irinotecan given day 1 and 8 every 21 days Docetaxel given day 1 and 8 every 21 days
3319633|NCT00183859|Experimental|A|Intraperitoneal Irinotecan
3319634|NCT00183833|Experimental|A|Xeloda plus gleevec
3319635|NCT00183820|Experimental|1|
3319636|NCT00183794|Experimental|Arm 1|Patients will receive Docetaxel 75mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8. Cycles will be repeated every 3 weeks.
3319637|NCT00183755||1|Control participants
3319638|NCT00183755||2|Participants with MDD
3319639|NCT00183729|Experimental|Memantine (1)|Memantine for 12 weeks
3319640|NCT00183729|Placebo Comparator|Placebo (2)|Placebo for 12 weeks
3319641|NCT00183716|Experimental|1|Participants will receive Trauma Recovery and Empowerment Model and usual care
3319642|NCT00183716|Active Comparator|2|Participants will receive usual care
3319643|NCT00183703||Qualitative Interview|Participants with rapid cycling bipolar disorder (RCBPD)
3319644|NCT00183690|Experimental|1|Participants receiving prolonged exposure therapy
3319645|NCT00183690|Active Comparator|2|Participants receiving active psychotherapy
3319646|NCT00183677|Experimental|Escitalopram|Participants will receive open treatment with escitalopram.
3319647|NCT00183651|Experimental|S-DBT|Participants receive standard dialectical behavior therapy
3319648|NCT00183651|Active Comparator|DBT-I|Participants receive individual dialectical behavior therapy plus activities group
3319649|NCT00183651|Active Comparator|DBT-S|Participants receive dialectical behavior therapy group skills plus case management
3319650|NCT00183638|Experimental|1|Participants will receive Internet-based tailored prevention messages
3319651|NCT00183638|Active Comparator|2|Participants will receive non-tailored messages containing information on reproductive health
3319652|NCT00183625|Active Comparator|Risperidone Plus Supported Employment|
3319653|NCT00183625|Active Comparator|Olanzapine Plus Supported Employment|
3319654|NCT00183625|Active Comparator|Risperidone+Supported Employment+Skills|
3319655|NCT00183625|Active Comparator|Olanzapine+Supported Employment+Skills|
3319656|NCT00183599|Experimental|1|
3319657|NCT00183599|Experimental|2|
3319658|NCT00183599|Experimental|3|
3319659|NCT00183586|Experimental|1|Participants will receive family-based treatment
3319660|NCT00183586|Active Comparator|2|Participants will receive individual adolescent focused therapy
3319661|NCT00183573|Experimental|1|Brief Motivational Intervention only
3319662|NCT00183573|Experimental|2|Brief Informational Intervention only
3319663|NCT00183573|Experimental|3|Brief Motivational Intervention + Intensive Informational Intervention
3319664|NCT00183573|Experimental|4|Brief Motivational Intervention + Intensive Information-Motivation-Behavioral Skills Intervention
3319665|NCT00183573|Experimental|5|Brief Informational Intervention + Intensive Informational Intervention
3319666|NCT00183573|Experimental|6|Brief Informational Intervention + Intensive Information-Motivation-Behavioral Skills Intervention
3319667|NCT00183560|Experimental|1|Participants will receive mindfulness based cognitive therapy
3319668|NCT00183560|Active Comparator|2|Participants will receive maintenance antidepressant pharmacotherapy
3319669|NCT00183560|Placebo Comparator|3|Participants will receive placebo plus clinical management
3319670|NCT00183547|Experimental|1|"Living in Harmony depression prevention program"
3319671|NCT00183547|Active Comparator|2|Depression-prevention education and support
3319672|NCT00183521|Experimental|1|Participants will receive raise-CO2 breathing regulation training
3319673|NCT00183521|Experimental|2|Participants will receive lower-CO2 breathing regulation training
3319674|NCT00183521|Active Comparator|3|Participants will receive no breathing regulation training
3319675|NCT00183508|Experimental|1 Cognitive behavioral therapy|
3319676|NCT00183508|Experimental|2 Psychoeducation|
3319677|NCT00183482|Experimental|Family Group Cognitive Behavioral|Family group cognitive behavioral program for families of parents with a history of depression to teach parenting skills to parents and coping skills to children.
3319678|NCT00183482|Active Comparator|Written Information Control|Provision of information about depression to parents with a history of depression and their children.
3319679|NCT00183469|Active Comparator|lamotrigine plus divalproex ER|Participants will take active lamotrigine and active divalproex ER
3319680|NCT00183469|Placebo Comparator|lamotrigine plus placebo divalproex ER|Participants will take active lamotrigine and placebo
3319681|NCT00183456|Experimental|Intervention Condition: CHAT|Participants received the program over the course of five small group sessions and one individual session based on a harm reduction philosophy. Participants were trained as Peer Mentors and were encouraged to talk to their family, friends, and sex partners about a range of sex risk reduction options.
3319682|NCT00183456|Active Comparator|Comparison Condition: Standard of Care|The comparison condition consisted of one group session. The session focused on HIV and STIs transmission and risk reduction information.
3319683|NCT00183456|No Intervention|Network Participants|Index participants generated a list of network members during their baseline visits and were asked to recruit eligible network members into the study. These network participants completed study interviews but did not participate in the intervention.
3319684|NCT00183456|No Intervention|Non-randomized Baseline index participants|This arm includes those index participants that did not show up for randomization or did not recruit a network member were thus not eligible to be randomized into a study condition.
3319685|NCT00183443|Placebo Comparator|DVP + placebo|Participants will receive divalproex ER at a therapeutic dose, plus placebo
3319686|NCT00183443|Active Comparator|DVP + Quetiapine|Participants will receive divalproex ER at a therapeutic dose, plus quetiapine up to 800 mg
3319687|NCT00183443|Active Comparator|DVP + Lithium|Participants will receive divalproex ER at a therapeutic dose, plus lithium at a therapeutic blood level
3319688|NCT00183430|Experimental|1|Participants will receive treatment with prazosin plus psychotherapy
3319689|NCT00183430|Placebo Comparator|2|Participants will receive treatment with placebo plus psychotherapy
3319690|NCT00183417|Experimental|1|Participants will receive cognitive behavioral therapy
3319691|NCT00183417|Active Comparator|2|Participants will receive supportive/expressive therapy
3319692|NCT00183417|Active Comparator|3|Participants will receive bibliotherapy
3319693|NCT00183417|No Intervention|4|Participants in the control condition will receive no treatment
3319694|NCT00183404|Experimental|Olanzapine|Participants will take open olanzapine for up to 20 additional weeks after phase 1.
3319695|NCT00183391|Active Comparator|Atomoxetine|Participants will receive treatment for ADHD with the non-stimulant atomoxetine
3319696|NCT00183391|Active Comparator|Methylphenidate|Participants will receive treatment for ADHD with the stimulant methylphenidate
3319846|NCT00180167|Active Comparator|Daunorubicin + Ara-C|
3319697|NCT00183378|Active Comparator|1|Routine medical care with education: therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support.
3319698|NCT00183378|Active Comparator|2|Walking: the therapist introduces a walking program and assists the caregiver in establishing a daily walking routine of 30 minutes for the study participant.
3319699|NCT00183378|Active Comparator|3|Light exposure: the therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
3319700|NCT00183378|Active Comparator|4|Combination: the therapist provides education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
3319701|NCT00183365|Experimental|1|Participants will receive the Protecting Families Program with individual parent training
3319702|NCT00183365|Active Comparator|2|Participants will receive parent training alone
3319703|NCT00183352||1|Women with bipolar disorder
3319704|NCT00183352||2|Women who are healthy controls
3319705|NCT00183339|Placebo Comparator|Placebo|Placebo, liquid solution flexible dose 0.5 to 5ml every morning (AM)
3319706|NCT00183339|Experimental|fluoxetine|Fluoxetine, 20mg/5ml solution, flexible dose 0.5 to 5ml every AM
3319707|NCT00183326|Experimental|1|Participants will receive trauma-focused cognitive behavioral therapy
3319708|NCT00183326|Active Comparator|2|Participants will receive child-centered supportive therapy
3319709|NCT00183313|Experimental|1|Participants will receive nurse case management intervention
3319710|NCT00183313|Active Comparator|2|Participants will receive usual care
3319711|NCT00183274|Active Comparator|Open-Label Group|6-month randomized phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d
3319712|NCT00183274|Active Comparator|Double-Blind Drug Group|6-month randomized, double-blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 6 - 12 of the study
3319713|NCT00183274|Placebo Comparator|Double-Blind Placebo Group|6-month randomized, double blind phase of placebo occurring between months 6 - 12 of the study
3319714|NCT00183274|Active Comparator|Double-Blind Drug-After-Drug Group|6-month randomized, double blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 13 - 19 of the study
3319715|NCT00183274|Placebo Comparator|Double-Blind Placebo-After-Drug Group|6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study
3319716|NCT00183274|Placebo Comparator|Double-Blind Placebo-After-Placebo Group|6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study
3319717|NCT00183261|Experimental|1|Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine at study entry and on Weeks 4 and 26
3319718|NCT00183261|Placebo Comparator|2|Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine placebo at study entry and on Weeks 4 and 26
3319719|NCT00183248|Experimental|DBMCs|Kidney transplantation, followed by immunotherapy given along with kidney donor Donor bone Bone marrow Marrow stem cell Cells (DBMCs) infusions
3319720|NCT00183248|Active Comparator|Control Group|Kidney transplantation, followed by immunotherapy
3319721|NCT00183209|Experimental|14 session behavioral intervention|7 sessions addressing problem alcohol and drug use and 7 session addressing parenting challenges (monitoring, negotiation, etc) based on based on Social Action Theory (Ewart, 1991) and Motivational Interviewing
3319722|NCT00183209|Active Comparator|Brief Video Intervention|Single session brief video intervention to build motivation to reduce or eliminate problem drinking/drug use
3319723|NCT00183196|Active Comparator|1|Naltrexone plus placebo
3319724|NCT00183196|Active Comparator|2|naltrexone + gabapentin
3319725|NCT00183196|Sham Comparator|3|Placebo plus placebo
3319726|NCT00183157|Active Comparator|1|Patients will receive an assessment, a brief motivational interview performed by a trained peer counselor, direct referrals to community-based resources for adolescents, and a 10-day follow-up phone call.
3319727|NCT00183157|Active Comparator|2|Patients will receive an assessment and a list of community resources
3319728|NCT00183157|Active Comparator|3|Patients will receive only the list of resources.
3319729|NCT00183092|Experimental|quinacrine|
3319730|NCT00183092|Placebo Comparator|placebo|
3319731|NCT00183079|Active Comparator|1|Brief, motivationally-focused alcohol intervention
3319732|NCT00183014|Experimental|1|discussion session and exercise class
3319733|NCT00183014|Active Comparator|2|exercise class only
3319734|NCT00182832|Experimental|1|
3319735|NCT00182832|Active Comparator|2|
3319736|NCT00182819|Other|radiotherapy|Radiotherapy (control arm), 50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
3319737|NCT00182819|Experimental|Temozolomide|Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles (experimental arm)
3319738|NCT00182793|Experimental|Arm I|Patients undergo stem cell collection. Patients receive high-dose melphalan IV with or without trastuzumab (Herceptin®). One day later, patients undergo autologous peripheral blood stem cell (PBSC) transplantation. No more than 7 weeks later, patients proceed to course 2. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.
3319739|NCT00182793|Experimental|Arm II|Patients undergo stem cell collection. Patients receive high-dose carboplatin, thiotepa, and cyclophosphamide IV continuously over 4 days followed by autologous PBSC transplantation. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.
3319786|NCT00181805||Controls with out GERD|Individuals that do not have a history of GERD or other GI problems prior to age 21 and whose date of birth are with in a year of a subjects
3319787|NCT00181766|Experimental|Strattera (atomoxetine)|
3319788|NCT00181753|Experimental|1|Burn Patients receiving at least 3 days of parenteral feeding on routine formula
3319789|NCT00181753|Experimental|2|Burn patients receiving at least 3 days on parenteral feeding on glutamine enriched formula.
3319740|NCT00182780|Experimental|Arm I - American ginseng (low dose)|"Patients receive oral American ginseng twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study.~Quality of life is assessed at baseline, every 2 weeks during treatment, and at the end of treatment.~PROJECTED ACCRUAL: A total of 280 patients (70 per treatment arm) will be accrued for this study within 35 months."
3319741|NCT00182780|Experimental|Arm II - American ginseng (mid-dose)|"Patients receive oral American ginseng at the mid-dose twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
3319742|NCT00182780|Experimental|Arm III - American ginseng (high-dose)|"Patients receive oral American ginseng at the high dose twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
3319743|NCT00182780|Other|Arm IV - Placebo|"Patients receive oral placebo twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
3319744|NCT00182767|Experimental|Treatment (ixabepilone and doxorubicin)|Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1.
3319745|NCT00182754|Experimental|Arm I|Patients receive octreotide subcutaneously (SC) once on day 1.
3319746|NCT00182754|Placebo Comparator|Arm II|Patients receive placebo SC once on day 1.
3319747|NCT00182728|Experimental|Intraoperative Radiation Arm|Intraoperative radiotherapy (radiation therapy) during surgery for tumor excision.
3319748|NCT00182702|Experimental|Treatment|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3319749|NCT00182689|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3319750|NCT00182663|Experimental|Treatment (immunomodulator, antiangiogenesis, steroid therapy)|Patients receive thalidomide PO QD dexamethasone PO once weekly, and clarithromycin PO BID. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Treatment with thalidomide continues in the absence of disease progression or unacceptable toxicity.
3319751|NCT00182637|Experimental|bortezomib|
3319752|NCT00182559|Active Comparator|Ciclosporin|Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.
3319753|NCT00182559|Active Comparator|Tacrolimus|Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.
3319754|NCT00182533|Experimental|1|Sertraline
3319755|NCT00182533|Placebo Comparator|2|Placebo
3319756|NCT00182520|Experimental|1|Topiramate
3319757|NCT00182520|Placebo Comparator|2|placebo
3319758|NCT00182468|Experimental|1|Women are screened for intimate partner violence prior to seeing a health care provider.
3319759|NCT00182468|No Intervention|2|Women see their health care provider without being asked about intimate partner violence.
3319760|NCT00182455|Experimental|1|Topiramate 25 - 400 mg/day x 12 weeks
3319761|NCT00182455|Placebo Comparator|2|Placebo
3319762|NCT00182338||Peritoneal Dialysis Patients|
3319763|NCT00182260|Active Comparator|Proton Pump Inhibitor|Patients randomized to medical therapy received optimized treatment with PPI using a standardized management protocol based on best evidence and published guidelines.
3319764|NCT00182260|Active Comparator|Laparoscopic Nissen Fundoplication|Surgical patients underwent LNF using previously published technique.
3319765|NCT00182156||1|conventional HD
3319766|NCT00182156||2|short daily HD
3319767|NCT00182156||3|PD
3319768|NCT00182143|Active Comparator|LMWH (Fragmin, dalteparin)|Placebo dose (normal saline) = AM dose LMWH (Fragmin, dalteparin) 5000IU daily = PM dose
3319769|NCT00182143|Active Comparator|2|Unfractionated Heparin 5000IU BID
3319770|NCT00182091|Active Comparator|AcroGHD Randomized to Growth Hormone|Subjects with a history of acromegaly who are now growth hormone deficient, randomized to growth hormone. This is an interventional arm.
3319771|NCT00182091|Placebo Comparator|AcroGHD Randomized to Placebo|Subjects with a history of acromegaly who are now growth hormone deficient, randomized to placebo. This is an interventional arm.
3319772|NCT00182091|No Intervention|AcroGHS|
3319773|NCT00182091|No Intervention|Active Acromegaly|
3319774|NCT00182078|Placebo Comparator|Placebo|Placebo was administered on a flexible fixed schedule and tapered at 12 weeks.
3319775|NCT00182078|Experimental|Sertraline|Sertraline was administered on a flexible fixed schedule beginning at 25 mg/day and increasing as high as 150 mg/day. At week 12, the medication was tapered at a rate of 25 mg every 3 days until it was discontinued.
3319776|NCT00182052|Active Comparator|Group 1|
3319777|NCT00182052|Placebo Comparator|Group 2|
3319778|NCT00182039|Experimental|A|metoprolol
3319779|NCT00182039|Placebo Comparator|B|placebo
3319780|NCT00182000|Active Comparator|Seromycin|
3319781|NCT00182000|Placebo Comparator|Placebo|
3319782|NCT00181883|Experimental|Quetiapine|"2.5 - 5.0mg/kg PO BID quetiapine~Other Names:~Seroquel"
3319783|NCT00181857||1|Children of Adults with ADHD NOS
3319784|NCT00181844|Experimental|Lamotrigine|
3319785|NCT00181805||Subject with History of GERD|Children and adolescents ages 12-17 years, inclusive, seen at Children's Hospital, Boston or Massachusetts General Hospital between 1977 and 1990 for symptoms of GERD and also had biopsies and / or a pH probe that was positive for GERD.
3319790|NCT00181753|Experimental|3|Burn patients receiving at least 3 days of enteral feeding on routine formula.
3319791|NCT00181753|Experimental|4|Burn patients receiving at least 3 days of enteral feeding on glutamine-enriched formula.
3319792|NCT00181714|Experimental|OROS MPH|Single arm- open treatment with extended duration methylphenidate (OROS MPH)
3319793|NCT00181649|Experimental|Recombinant human prolactin|
3319794|NCT00181623|Experimental|recombinant human prolactin treatment|Open label twice daily recombinant human prolactin
3319795|NCT00181610|Active Comparator|1|Placebo group normal saline twice per day
3319796|NCT00181610|Active Comparator|2|Recombinant human prolactin 60 mcg/kg every 12 hours
3319797|NCT00181610|Active Comparator|3|Recombinant human prolactin 60 mcg/kg alternating with normal saline placebo every 12 hours
3319798|NCT00181584|Active Comparator|Group 1|
3319799|NCT00181584|Placebo Comparator|Group 2|
3319800|NCT00181571|Active Comparator|1|Concerta
3319801|NCT00181571|Placebo Comparator|2|Placebo
3319802|NCT00181298|Active Comparator|1|
3319803|NCT00181298|Placebo Comparator|2|
3319804|NCT00181285|Sham Comparator|Sham high frequency chest wall oscillation|Sham high frequency chest wall oscillation
3319805|NCT00181285|Active Comparator|Active high frequency chest wall oscillation|Active high frequency chest wall oscillation
3319806|NCT00181181|Active Comparator|Atorvastatin|Atorvastatin for 3 months
3319807|NCT00181181|Placebo Comparator|Placebo|
3319808|NCT00181155|Experimental|Allopurinol|One time intravenous administration of Allopurinol 300 mg infused over approximately 20 minutes.
3319809|NCT00181155|Placebo Comparator|Placebo|One time intravenous administration of 50 ml dose of 5% dextrose infused over approximately 20 minutes.
3319810|NCT00180843|Placebo Comparator|saline control|nebulized saline
3319811|NCT00180843|Active Comparator|salbutamol and ipratropium bromide nebules|salbutamol 2.5 mg and ipratropium bromide 0.5 mg
3319812|NCT00180713|Placebo Comparator|1|Placebo tablet once daily
3319813|NCT00180713|Experimental|2|Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.
3319814|NCT00180687|Sham Comparator|Control|No intraperitoneal therapeutics (No nebulised Bupivacaine)
3319815|NCT00180687|Placebo Comparator|IP Aerosolized Normal Saline|Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)
3319816|NCT00180687|Experimental|Nebulised Bupivacaine intraperitoneally|Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)
3319817|NCT00180687|Active Comparator|Injected Bupivacaine intraperitoneally|Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)
3319818|NCT00180661||Severe Asthma|Patients under Steps 4/5 of Asthma Treatment - SIGN/BTS Guidelines
3319819|NCT00180661||Moderate Asthma|Asthma patients on steps 2/3 of Asthma treatment according to SIGN/BTS Guidelines
3319820|NCT00180661||Mild Asthma|Asthma patients on steps 1 of asthma treatment (steroid naive).
3319821|NCT00180583|Experimental|1|Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
3319822|NCT00180557|Experimental|Active fixation lead|Active fixation lead was implanted
3319823|NCT00180557|Active Comparator|Passive fixation lead|Passive fixation lead was implanted
3319824|NCT00180544|Other|1|Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
3319825|NCT00180518|Experimental|1|"To evaluate the safety and efficacy of the over-the-wire (OTW) ACCULINK (tm) System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA) To evaluate the efficacy of the OTW ACCUNET System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA).~To demonstrate equivalence in the safety and performance of the RX ACCULINK Carotid Stent System and RX ACCUNET Embolic Protection System and the corresponding OTW devices."
3319826|NCT00180505|Other|1|The purpose of the ASSESS Registry is to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries.
3319827|NCT00180479|Experimental|1|XIENCE V® Everolimus Eluting Coronary Stent System
3319828|NCT00180479|Active Comparator|2|TAXUS® EXPRESS2™Paclitaxel Eluting Coronary Stent System
3319829|NCT00180453|Experimental|1|Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System
3319830|NCT00180453|Active Comparator|2|Abbott Vascular MULTI-LINK VISION® BMS
3319831|NCT00180401||QRS 120-150 ms|Subjects with a QRS width between 120-150 ms
3319832|NCT00180401||QRS >150 ms|Subjects with a QRS width >150 ms
3319833|NCT00180388|Experimental|Endoscopic vein harvesting|Harvesting of vein for coronary artery bypass grafting using endoscopy to visualize the vein
3319834|NCT00180388|Active Comparator|Open Vein harvesting|Harvesting of vein for coronary artery bypass grafting without endoscopy
3319835|NCT00180323|Experimental|Renewal CRT (CRT ICD)|Single arm study only. All patients will undergo advanced echocardiographic examination pre-operative, pre-discharge after implantation and at 3 and 6-months follow-up. AV-delay optimization will be performed using aortic VTI (Velocity Time Integral) measured by continuous wave Doppler in a modified 4-chamber view. During optimisation aortic VTI will be measured at different heart rates reached by increasing atrial pacing 10, 20 and 30 beats above intrinsic heart rate (IHR).
3319836|NCT00180310|Experimental|1|XIENCE V® Everolimus Eluting Coronary Stent System
3319837|NCT00180310|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
3319838|NCT00180297|Experimental|Mid septal site location|RV lead is placed at mid septum.
3319839|NCT00180297|Active Comparator|Apical site location|RV lead is placed in apical position
3319840|NCT00180271|Experimental|CRT-D|CRT-D: Cardiac resynchronization therapy with defibrillation.
3319841|NCT00180271|Active Comparator|ICD|ICD: Implantable cardioverter defibrillator
3319842|NCT00180232||1|Patients starting an aminobisphosphonate therapy due to medical reasons Broca-index: between -20 and +25% who are willing and capable to confirm written consent to enrolment after ample information has been provided
3319847|NCT00180167|Experimental|Mitoxantrone + Ara-C|
3319848|NCT00180011|Experimental|omaluzimab|
3319849|NCT00179998|Active Comparator|1|once daily nebulized rhDNAse
3319850|NCT00179998|Placebo Comparator|2|once daily nebulized vehicle
3319851|NCT00179985||Training|Behavioral: Newborn Individualized Care and Assessment Program (NIDCAP)
3319852|NCT00179959|Active Comparator|Treatment|Intranasal mupirocin ointment and sodium hypochlorite (bleach) baths
3319853|NCT00179959|Placebo Comparator|Placebo|Intranasal petrolatum ointment treatment and plain water baths
3319854|NCT00179894|Experimental|1 Physician training|Physician participants will receive training in guidelines and medication monitoring
3319855|NCT00179894|No Intervention|2|Physician participants will provide usual care and no special intervention
3319856|NCT00179777|Experimental|Hydrolysed infant formula|Hydrolysed infant formula
3319857|NCT00179777|Placebo Comparator|Nonhydrolysed infant formula|Nonhydrolysed infant formula
3319858|NCT00179673|Experimental|Lenalidomide|Participants received single-agent lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed, lenalidomide treatment was discontinued for any reason, or the study was terminated.
3319859|NCT00179660|Experimental|Lenalidomide|Participants received single-agent lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed, lenalidomide treatment was discontinued for any reason, or the study was terminated.
3319860|NCT00179647|Other|Lenalidomide 5-25 mg, w/wo dexamethasone|single-arm, open-label, lenalidomide, 5-25 mg, 21/28 days, with/without dexamethasone
3319861|NCT00179634|No Intervention|1|Usual Care
3319862|NCT00179634|Experimental|2|Usual care and exposure to a visually enriched milieu (landscape photograph)
3319863|NCT00179634|Experimental|3|Usual care, exposure to a visually enriched milieu and audio taped guided visualization with healing suggestions.
3319864|NCT00179621|Placebo Comparator|Placebo|Placebo matching to active study arms.
3319865|NCT00179621|Experimental|Lenalidomide 5 mg|Lenalidomide 5 mg daily 28/28 days
3319866|NCT00179621|Experimental|Lenalidomide 10 mg|Lenalidomide 10 mg daily 21/28 days
3319867|NCT00179517|Experimental|depotestosterone plus anastrozole (T-A)|Each participant has biweekly intramuscular injections of 300 mg depotestosterone cypionate and takes an oral tablet of anastrozole 1 mg daily for the duration of the study. This group is referred to as the depotestosterone plus anastrozole (T-A) group.
3319868|NCT00179517|Placebo Comparator|depotestosterone plus placebo (T-P)|Each participant has biweekly intramuscular injections of 300 mg depotestosterone cypionate and takes 1 matching placebo oral tablet daily for the duration of the study. This group is referred to as the depotestosterone plus placebo (T-P) group.
3319869|NCT00179491|Active Comparator|Group 1|604 patients received intercessory prayer after being informed they may or may not receive prayers (Group 1)
3319870|NCT00179491|No Intervention|2|597 patients did not receive prayer after being informed they may or may not receive prayer (Group 2)
3319871|NCT00179491|Experimental|Group 3|601 patients received intercessory prayer after being informed they would receive it (Group 3).
3319872|NCT00179478|Experimental|Immediate Treatment Group|Initiation of treatment with Interferon Beta 1a IM once weekly immediately after onset of a first demyelinating syndrome in high risk individuals
3319873|NCT00179478|Active Comparator|Delayed Treatment Group|Delayed initiation of of Interferon beta-1a IM once weekly at diagnosis of clinically definite MS, at conclusion of initial CHAMPS study or during long term observation
3319874|NCT00179465|Active Comparator|Antipsychotic plus study drug|Half of the subjects will receive the study medications in addition to their ongoing antipsychotic regimen.
3319875|NCT00179465|Placebo Comparator|Antipsychotics plus placebo|Half of the subjects will receive placebo in addition to their antipsychotic regimen.
3319876|NCT00179452|Experimental|Intervention|Subjects invited to participate in yoga practice.
3319877|NCT00179413|Active Comparator|PEG-Intron|PEG-Intron 0.5mcg/kg once a week SC
3319878|NCT00179413|Active Comparator|Colchicine|0.6mg twice a day
3319879|NCT00179400|Active Comparator|Pioglitazone|
3319880|NCT00179400|Placebo Comparator|Placebo|
3319881|NCT00179387|Active Comparator|1|Psycho-educational / Stress Management group
3319882|NCT00179387|Active Comparator|2|Spiritual-Existential Support Group
3319883|NCT00179374|Experimental|1|Tailored telephone intervention plus mailed print educational materials
3319884|NCT00179374|Active Comparator|2|print intervention with no telephone component
3319885|NCT00179348|Experimental|Group I (yoga-based rehabilitation program)|Participants undergo a yoga-based rehabilitation program up to 5 days a week for 1.5 hours and practice at home at least once daily for 12 weeks.
3319886|NCT00179348|Active Comparator|Group II (standard care/control)|After a 3 month wait period, participants undergo a yoga-based rehabilitation program as in Group I.
3319887|NCT00179309|Experimental|Arm I - PANVAC + docetaxel|Patients receive vaccinia-carcinoembryonic antigen (CEA)- mucin-1 (MUC-1)- triad of costimulatory molecules (TRICOM) vaccine subcutaneously (SC) once and sargramostim, or granulocyte macrophage colony stimulating factor (GM-CSF) SC once daily for 4 days in week -2. Patients also receive fowlpox-CEA-MUC-1-TRICOM vaccine SC once and GM-CSF SC once daily for 4 days in weeks 1, 5, and 9. Patients also receive docetaxel intravenous (IV) over 30 minutes once weekly in weeks 1-3, 5-7, and 9-11. After week 12, patients with no disease progression continue with docetaxel once weekly for 3 weeks followed by 1 week of rest and fowlpox-CEA-MUC-1-TRICOM vaccine plus GM-CSF every 4 weeks until disease progression.
3319888|NCT00179309|Experimental|Arm II - Docetaxel alone|Patients receive docetaxel as in arm I. After week 12, patients with disease progression discontinue docetaxel and receive vaccinia-carcinoembryonic antigen (CEA)- mucin 1(MUC-1)-triad of costimulatory molecules (TRICOM) vaccine, fowlpox-CEA-MUC-1-TRICOM vaccine, and sargramostim, or granulocyte macrophage colony stimulating factor (GM-CSF) as in arm I until further disease progression. Patients with no disease progression after week 12 continue with docetaxel as in arm I until disease progression.
3319889|NCT00179218|Active Comparator|1|only protein supplementation
3319890|NCT00179218|Active Comparator|2|protein supplementation plus exercise
3319891|NCT00179205|Active Comparator|1|
3319892|NCT00179205|Placebo Comparator|2|
3319893|NCT00179192|No Intervention|1|control group
3319894|NCT00179192|Active Comparator|2|angioplasty intervention
3319895|NCT00179192|Active Comparator|3|surgery intervention
3319896|NCT00179179|Active Comparator|1|nutritional supplement plus resistance exercise
3319897|NCT00179179|Active Comparator|2|nutritional supplement only (resistance exercise will not be performed)
3319898|NCT00179166|Active Comparator|1|supplement contains protein content of 1.4 g/kg/day
3319899|NCT00179166|Active Comparator|2|supplement contains protein content of 2.0 g/kg/day
3319900|NCT00179153|Active Comparator|1|
3319901|NCT00179140|No Intervention|1|control period
3319902|NCT00179140|Active Comparator|2|protein supplementation plus resistance exercise
3319903|NCT00179140|Active Comparator|3|protein supplementation only
3319904|NCT00179127|Experimental|Glargine|0.3u/kg of glargine, subcutaneously, once
3319905|NCT00179127|Placebo Comparator|Placebo|0.3u/kg of saline, subcutaneously, once
3319906|NCT00179062|Active Comparator|1|
3319907|NCT00179062|Active Comparator|2|
3319908|NCT00179036||Good blood flow|Group without any ischemia to the small intestine
3319909|NCT00179036||Poor blood flow|Group with partial ischemia to the small intestine
3319910|NCT00179023|Other|Part 1|Estimation of resting energy expenditure and effect of autonomic blockade with trimethaphan infusion.
3319911|NCT00179023|Other|Part 2 (closed)|Estimation of autonomic function and effect of autonomic blockade with trimethaphan infusion.
3319912|NCT00179023|Other|Part 3|Estimation of energy metabolism and effect of sympathetic stimulation with pseudoephedrine.
3319913|NCT00179023|Other|Part 4a (closed)|Isoproterenol sensitivity in adipose and muscle tissue with and without systemic autonomic blockade with trimethaphan infusion.
3319914|NCT00179023|Other|Part 4b (closed)|Metabolic and hemodynamic response to submaximal exercise in adipose and muscle tissue with and without systemic autonomic blockade with trimethaphan infusion.
3319915|NCT00179010|Experimental|1|Intrarterial infusion of adenosine
3319916|NCT00179010|Experimental|2|Intrarterial infusion of AMP
3319917|NCT00178997||Good blood flow|Group without ischemia to the small intestine
3319918|NCT00178997||Poor blood flow|Groups that have partial ischemia to their small intestine
3319919|NCT00178984||poor blood flow|Group with partial ischemia to the small intestine
3319920|NCT00178984||Good blood flow|Group with normal blood flow, given different conditions to effect electrical currents in normal smooth muscle
3319921|NCT00178971|Active Comparator|1|buspirone 15-30 mg qd
3319922|NCT00178971|Placebo Comparator|2|placebo
3319923|NCT00178919|Experimental|Autonomic Failure Patients|To compare the effects of NO inhibition during intact and transient pharmacological blockade of the autonomic nervous system in Patients with Autonomic Failure.
3319924|NCT00178919|Experimental|Controls and hypertensives|To compare the effects of NO inhibition during intact and transient pharmacological blockade of the autonomic nervous system in normal volunteers and hypertensive subjects.
3319925|NCT00178880||Healthy volunteers|
3319926|NCT00178880||Depressed patients|
3319927|NCT00178802|Other|1|thermochemotherapy using fever-range whole-body thermal therapy combined with continuous infusion 5-fluorouracil, Doxil, and low-dose interferon-alpha.
3319928|NCT00178776|Experimental|Transtheoretical Model Group|
3319929|NCT00178776|Active Comparator|Education / Advice|
3319930|NCT00178763|Experimental|1|All protocol subjects are treated with fever-range whole-body thermal therapy combined in an optimized schedule with cisplatin + gemcitabine + metronomic low-dose interferon-alpha
3319931|NCT00178724||No Treatment Given|Any male or female 18 years or older admitted to a NACTN hospital, at the time of injury, with an initial (first time) spinal cord injury caused by trauma and has paralysis (muscle weakness) or loss of sensation (touch). The patient has not received medical or surgical care for this injury prior to admission to a NACTN hospital. Patient or family member must give consent to participate.
3319932|NCT00178711|Active Comparator|hypothermia|Induction and maintenance of moderate hypothermia to 33 degrees celsius achieved within 2.5 hours of injury and maintained for 48 hours.
3319933|NCT00178711|No Intervention|control|treated at normothermia
3319934|NCT00178698|Other|1|Thermochemotherapy
3319935|NCT00178659||1 healthy volunteers|Healthy volunteers to act as controls - Recruitment is complete for this cohort
3319936|NCT00178659||2 head trauma|Head trauma patients meeting enrollment criteria - Recruitment is complete for this cohort
3319937|NCT00178659||3 orthopedic injury|"The orthopedic injury cohort will include patients admitted to the ED able to provide informed consent with the following:~Fracture confirmed radiographically~No head trauma~No other known inflammatory process or infection~No history of neurological or psychiatric disorders or alcohol or drug dependency"
3319938|NCT00178659||4 Mild TBI|"The mild TBI patients will be defined as those admitted to the ED experiencing, - Recruitment is complete for this cohort~Non-penetrating head trauma manifesting one or more of the following:~Loss of consciousness~Post-traumatic amnesia~Altered mental status~Focal neurologic deficits, seizure~GCS> 12~No abnormalities on CT other than contusion~No operative Lesions~Length of hospital stay < 48 hrs~No other known inflammatory process or infection~No history of neurological or psychiatric disorders or alcohol or drug dependency"
3319939|NCT00178646|Active Comparator|1|Botox, 150 units prepared as 100 units/ml
3319940|NCT00178646|Active Comparator|2|Botox 150 units, prepared as 50 units/ml.
3319941|NCT00178646|Active Comparator|3|Botox 75 units, prepared as 25 units/ml.
3319942|NCT00178633||Bariatric Surgery|Procedures were not part of the trial. Patients already undergoing these clinical procedures agreed to analysis and follow-up for research purposes. All patients had one of two different types of procedures, but outcome analyses did not distinguish between the two procedures.
3319943|NCT00178620|Active Comparator|I|Retavase 10 U IV Bolus
3319944|NCT00178620|Other|II|
3319945|NCT00178503|Placebo Comparator|MPH Trial-Placebo|24 Participants with ASD-ADHD underwent 1 week of placebo in the MPH treatment phase
3319946|NCT00178503|Active Comparator|MPH Trial: Low Dose|24 Participants with ASD-ADHD underwent 1 week at a low dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
3319947|NCT00178503|Active Comparator|MPH Trial: Med Dose|24 Participants with ASD-ADHD underwent 1 week at a medium dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
3319948|NCT00178503|Active Comparator|MPH Trial: High Dose|24 Participants with ASD-ADHD underwent 1 week at a high dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
3319949|NCT00178490|Experimental|1|Children with high blood pressure who will receive treatment for high blood pressure
3319950|NCT00178490|No Intervention|2|Children with normal blood pressure who will undergo no treatment
3319951|NCT00178477|Experimental|Breath-holding|MRI with breath-holding
3319952|NCT00178464|Experimental|Aspirin|One-arm study
3319953|NCT00178412|Experimental|1|Treatment group
3319954|NCT00178412|Active Comparator|2|Comparison Group
3319955|NCT00178399|Experimental|Stereotactic body radiation therapy|
3319956|NCT00178373|Experimental|Modafinil|Modafinil 200 mg taken by mouth once a day. Subjects will take 2 100 mg tablets each morning.
3319957|NCT00178373|Placebo Comparator|placebo|Inactive sugar pill, 2 are taken once a day in the morning
3319958|NCT00178360|Experimental|Music Therapy|Subject will participate in one, individual, half-hour long music therapy session every other week and one hour-long group music therapy session each month, for a period of three months.
3319959|NCT00178360|No Intervention|Standard Care|During the Standard Care time period, participants will continue to receive all of the medical care that they would normally receive for the treatment of Huntington's Disease, without the addition of music therapy services.
3319960|NCT00178256|Experimental|1st dose cohort 15mg/m2 taxol plus RT|"15 mg/m2 Paclitaxel On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.~On Monday, Tuesday, Wednesday, Thursday, Friday Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible"
3319961|NCT00178256|Experimental|2nd dose cohort20 mg/m2 taxol plus daily RT|
3319962|NCT00178256|Experimental|3rd Dose Cohort --25mg/m2 taxol plus RT|
3319963|NCT00178256|Experimental|Phase II Arm --20mg/m2 taxol plus RT|
3319964|NCT00178217|Experimental|Music Therapy|The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
3319965|NCT00178217|No Intervention|Standard Care Control|Subjects will receive standard care at control condition sessions, which includes the use of television, books, CD's, a child life specialist (when available) or other activities to help cope with the procedure.
3319966|NCT00178191|Experimental|200 units Botox|200 units Botulinum-A toxin
3319967|NCT00178191|Experimental|300 units Botox|300 units Botulinum-A toxin
3319968|NCT00178191|Placebo Comparator|Placebo|Placebo
3319969|NCT00178178|Experimental|Drug: Bupivicaine 0.5% Intraaticulary Only|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%;Intraaticular Only~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) intraarticularly only via Breg Pain Care 3000 Catheter"
3319970|NCT00178178|Experimental|Drug: Bupivicaine 0.5% Patellar Tendon Site|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%;Patellar Tendon Site Only~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the patellar tendon harvest site via Breg Pain Care 3000 Catheter"
3319971|NCT00178178|Experimental|Drug: Bupivicaine 0.5% Intraarticular and Patellar Tendon|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%; Intraarticular and Patellar Tendon Sites~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the Patellar Tendon Harvest Site and Intraarticular infusion via Breg Pain Care 3000 Catheter"
3319972|NCT00178178|Placebo Comparator|Drug: Placebo|"Breg Pain Care 3000 Catheter with Placebo~Receive liquid with no pain medication (placebo) through a catheter in one part of the operative knee via Breg Pain Care 3000 Catheter"
3319973|NCT00178126|Active Comparator|Segmented Foam Cushion|Receive seating assessment, wheelchair and seat cushion representing the standard of care in nursing homes
3319974|NCT00178126|Experimental|Skin Protection Cushion|Receive seating assessment, wheelchair and cushion meeting CMS code for Skin Protection Wheelchair Cushion
3319975|NCT00177996|Active Comparator|Sertaline high dose titration|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of Sertraline hydrochloride. The doses and titration schedules used in this arm (Sertaline high dose titration) are consistent with recommended FDA guidelines.
3319976|NCT00177996|Active Comparator|Sertaline low dose titration|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of Sertraline hydrochloride. The doses and titration schedules used in this arm (Sertaline low dose titration) are consistent with recommended FDA guidelines.
3319977|NCT00177970|Active Comparator|IVIG|
3319978|NCT00177970|Placebo Comparator|Placebo|
3319979|NCT00177944||patients with funal infections|
3319980|NCT00177931||liver transplant patients in ICU|
3319981|NCT00177918||lung transplant patients|
3319982|NCT00177892|Experimental|1|non-OSAH/overweight individuals with the Metabolic Syndrome
3319983|NCT00177892|Experimental|2|non-OSAH/overweight individuals without Metabolic Syndrome
3319984|NCT00177892|Active Comparator|3|non-OSAH/normal weight without Metabolic Syndrome
3319985|NCT00177892|Experimental|4|OSAH patients with chronic positive airway pressure therapy
3319986|NCT00177892|Experimental|5|OSAH patients without chronic positive airway pressure therapy
3319987|NCT00177866|Active Comparator|A Placebo or Celebrex|either placebo PO BID for the first eight weeks or Celebrex 200 mg PO BID for the first eight weeks
3319988|NCT00177866|Placebo Comparator|B Placebo or Celebrex|either placebo PO BID for the last eight weeks or Celebrex 200 mg PO BID for the last eight weeks
3320061|NCT00176267|Experimental|1|
3319989|NCT00177853|Experimental|1|Celecoxib, Irinotecan and Concurrent Radiotherapy
3319990|NCT00177840|Experimental|1|True acupuncture using true needles
3319991|NCT00177840|Sham Comparator|2|sham acupuncture using sham needles
3319992|NCT00177671|Experimental|1|"escitalopram plus donepezil (DNP)in the experimental maintenance phase of the study.~For subjects failing to respond to escitalopram during the initial open phase of acute treatment we allowed the use of duloxetine or venlafaxine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation donepezil.~Participants remained on the same antidepressant medication and dosage throughout the 2 year maintenance phase of the study. In the event of a recurrence of major depression during maintenance treatment, dosages of antidepressant medication were raised, or the antidepressant was switched to venlafaxine or duloxetine.~For subjects failing to respond to escitalopram during the initial open phase of acute treatment, we allowed the use of duloxetine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation placebo."
3319993|NCT00177671|Placebo Comparator|2|"escitalopram plus placebo (PBO) in the experimental maintenance phase of the study.~For subjects failing to respond to escitalopram during the initial open phase of acute treatment, we allowed the use of duloxetine or venlafaxine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation placebo.~Participants remained on the same antidepressant medication and dosage throughout the 2 year maintenance phase of the study. In the event of a recurrence of major depression during maintenance treatment, dosages of antidepressant medication were raised, or the antidepressant was switched to venlafaxine or duloxetine.~For subjects failing to respond to escitalopram during the initial open phase of acute treatment, we allowed the use of venlafaxine or duloxetine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation placebo."
3319994|NCT00177645|Experimental|sodium bicarbonate|inhaled sodium bicarbonate
3319995|NCT00177541|Experimental|Biofeedback|Biofeedback assisted pelvic floor muscle therapy (3 visits)
3319996|NCT00177515|Experimental|1|Computerized counseling about Emergency Contraception
3319997|NCT00177515|Active Comparator|2|Computerized counseling about peri-conception folate
3319998|NCT00177489|Experimental|Treatment|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
3319999|NCT00177489|Other|Control|"Caregivers in the control group received 2 brief check-in telphone calls during the 6 month intervention."
3320000|NCT00177463|Experimental|L- Carnosine|an antioxidant and AGE inhibitor, 500 mg/day, increasing each week in titration reaching 2000 mg/day in 4 weeks and maintained for rest of trial
3320001|NCT00177463|Placebo Comparator|Placebo|Placebo
3320002|NCT00177424|Active Comparator|1|Sertraline
3320003|NCT00177424|Placebo Comparator|2|matching placebo
3320004|NCT00177411|Experimental|PTHrP group|Subjects receiving PTHrP in varying doses.
3320005|NCT00177372|Experimental|1|Mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
3320006|NCT00177346|Experimental|CAS with cerebral protection|
3320007|NCT00177346|Active Comparator|CAS without cerebral protection|
3320008|NCT00177307|Experimental|Oxaliplatin, Capecitabine, and Bevacizumab|
3320009|NCT00177294|Experimental|1|Participants who respond partially to 6 weeks of escitalopram 10mg daily then receive 16 weeks of extension therapy with escitalopram 20 mg daily, plus weekly interpersonal psychotherapy (IPT)
3320010|NCT00177294|Active Comparator|2|Participants who respond partially to 6 weeks of escitalopram 10mg daily then receive 16 weeks of extension therapy with escitalopram 20 mg daily, plus weekly depression care management(DCM) without interpersonal psychotherapy (IPT)
3320011|NCT00177268||I|Those subjects with cutaneous t-cell lymphoma and Sezary syndrome, atopic dermatitis, or eczema
3320012|NCT00177255|Experimental|Docetaxel + Capecitabine|"Docetaxel 30mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days. Premedication with dexamethasone will be given to all patients receiving weekly docetaxel therapy to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions. Cycle 2 will begin on day 22.~Capecitabine Capecitabine 825mg/m2 bid (total daily dose 1650mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days. Cycle 2 will begin on day 22."
3320013|NCT00177229|No Intervention|A|Enhanced usual care: 2 free, individual consultations with a nutritionist over first 6 months. Medical monitoring throughout study period.
3320014|NCT00177229|Experimental|B|
3320015|NCT00177216|Experimental|Zolpidem|The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or >). The dose was decreased to 5 mg if side effects occurred.
3320016|NCT00177216|Experimental|Excitalopram|The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
3320017|NCT00177216|Placebo Comparator|Placebo|A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
3320018|NCT00177177|Experimental|1|L Carnosine
3320019|NCT00177177|Placebo Comparator|2|Placebo
3320020|NCT00177164|Active Comparator|1|Oral Risperidone followed by Long acting Risperidone injections (Consta)
3320021|NCT00177164|Active Comparator|2|Oral second generation antipsychotic agents other than clozapine or risperidone (olanzapine, quetiapine, ziprasidone, aripiprazole)
3320022|NCT00177138|Active Comparator|Group 2|Tacrolimus/MMF/TMG
3320023|NCT00177138|Experimental|Group 1|Campath/MMF/TMG
3320024|NCT00177086|Experimental|Alfuzosin|
3320025|NCT00177086|Placebo Comparator|Placebo|
3320026|NCT00177047|Experimental|Chemotherapy and Transplant Treatment|Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.
3320027|NCT00176930|Experimental|Allogeneic stem cell transplant|Patients receiving cyclophosphamide and total body irradiation (TBI) and transplant, or cyclophosphamide, Busulfan and transplant.
3320028|NCT00176917|Experimental|Treatment Arm|All patients treated with chemotherapy and transplantation.
3320029|NCT00176904|Experimental|Treated Patients|All patients treated with protocol regimen (chemotherapy and surgery).
3320030|NCT00176891|Experimental|Laronidase ERT Treatment|Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.
3320031|NCT00176878|Experimental|Bone Marrow Failure Disorders|Patients with Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome
3320032|NCT00176865|Active Comparator|Arm 1 - Matched sibling donor|Stem Cell Transplant: human leukocyte antigen (HLA) genotypic matched sibling donor and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
3320033|NCT00176865|Active Comparator|Arm 2 - Matched unrelated donor|Stem Cell Transplant: HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
3320034|NCT00176865|Active Comparator|Arm 3 - Mismatched double cord donors|Stem Cell Transplant: two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord) and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
3320035|NCT00176852|Other|RIC Bu/Flu (A) (discontinued)|Full Preparative Regimen for subjects with matched donors using Busulfan on Day -8 and -7, Fludarabine on Day -6 through -2, antithymocyte globulin (ATG) on Day -2 through -1, total lymphoid radiation (TLI) on Day -1, stem cell infusion on Day 0.
3320036|NCT00176852|Experimental|MA Bu/Cy (B)|Myeloablative Preparative Regimen for subjects with HLA identical sibling donors consists of Busulfan on day -9 through -6, Cyclophosphamide on day -5 through -2, ATG on day -3 through -1, stem cell infusion on Day 0 and Granulocyte Colony Stimulating Factor on day -3 until ANC >2500 x 2 days.
3320037|NCT00176852|Experimental|RIC Cy/Flu/TBI (A2)|Patients with sickle cell disease or thalassemia who do not have an HLA-identical sibling donor or who has pre-existing organ dysfunction making myeloablative condition ineligible will receive Campath on day -10 through -6, Cyclophosphamide on day -7, Fludarabine on day -6 through -2, total body irradiation (TBI) on day -1, stem cell infusion on Day 0.
3320038|NCT00176839|Experimental|Treatment Arm|Patients treated with therapy plan consisting of Busulfan every 6 hours on days -7 through -4, Cyclophosphamide 60 mg/kg/day IV x 2 days, Melphalan 140 mg/m on day -1, antithymocyte globulin (ATG), G-CSF (granulocyte colony-stimulating factor) and stem cell transplantation on day 0.
3320039|NCT00176826|Experimental|Intent-To-Treat|Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
3320040|NCT00176800|Experimental|1|Paclitaxel is administered intravenously over 1 hour on Days 1, 8, 15, and 22. Cisplatin will then be administered intravenously over 1 hour on Days 1 and 22. Radiation treatments will be given twice/day, on Days 1-5, 8-12 and 15-19. The subject's esophagus will be surgically removed on approximately Day #50. Approximately 4-6 weeks after surgery, the subject will start taking Tetrathiomolybdate, for 2 years or until treatment is no longer working to control your cancer. The subject will have blood drawn weekly while he/she is receiving chemotherapy and radiation prior to their surgery. 4-6 weeks after their surgery (when the subject starts taking Tetrathiomolybdate), a blood test will be performed every other week for 2 times, and monthly thereafter. When the level of copper has been lowered sufficiently an additional blood test and a baseline chest x-ray will be obtained. Additional blood will be drawn and tested every 6 months for the first 2 years.
3320041|NCT00176748|Experimental|1|
3320042|NCT00176722||surgical|males & females undergoing spine surgery in the prone position
3320043|NCT00176683||All comers|capnography used for all consenting subjects
3320044|NCT00176644|Experimental|Transdermal estradiol|
3320045|NCT00176631|Experimental|licorice root extract and docetaxel|
3320046|NCT00176605|Experimental|Arm 1 (Etoposide + Cyclophosphamide)|Therapy will be divided into 4 cycles. Each cycle will be composed of 6 weeks of therapy. Total duration of therapy is 24 weeks. Administration of etoposide (50 mg po qd) and cyclophosphamide (50 mg po qd) will alternate in 21 day intervals. Starting with etoposide, patients will receive 21 days of therapy, upon completion of etoposide therapy patients will then receive 21 days of cyclophosphamide therapy. Therapy will continue in this alternating manner for 24 weeks. Week 1 of each cycle, begins with etoposide; Week 4 of each cycle, begins with cyclophosphamide.
3320047|NCT00176592|Active Comparator|Betaseron|Betaseron 250 micrograms SQ every other day
3320048|NCT00176592|Active Comparator|Copaxone|20 mg daily SQ
3320049|NCT00176501|Experimental|Irradiated allogeneic lymphocytes|
3320050|NCT00176488|Experimental|Sequential epirubicin/vinorelbine|For patients with stage IIB (T3N0), IIIA, or IIIB breast cancer, epirubicin and vinorelbine will be administered for up to 5 cycles. For patients with stage IV breast cancer, epirubicin and vinorelbine will be administered as long as there is evidence of continued response or stable disease and no evidence of cardiac or other serious toxicities.
3320051|NCT00176475|Experimental|Therapeutic allogeneic lymphocytes with rituximab|
3320052|NCT00176462|Experimental|Arm 1 Standard Risk|6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE METHOTREXATE Leucovorin
3320053|NCT00176462|Experimental|Arm 2 High Risk|6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE 6-THIOGUANINE CYTARABINE AMINOPTERIN CYCLOPHOSPHAMIDE ARABINOSIDE-C
3320054|NCT00176449|Active Comparator|Bupropion SR|
3320055|NCT00176449|Placebo Comparator|Placebo|
3320056|NCT00176436|Active Comparator|active|Atomoxetine titrated up to 120 mg/day by week 8 and continues at 120 mg/day through week 24. Diet support group, group counseling and exercise.
3320057|NCT00176436|Placebo Comparator|Placebo|Placebo medication, diet support group, group counseling and exercise
3320058|NCT00176306|Experimental|Levofloxacin|Patients receiving levofloxacin 750mg IV
3320059|NCT00176293|Experimental|1|dexamethasone
3320060|NCT00176293|No Intervention|2|
3320062|NCT00176254|Experimental|Induction chemotherapy and radiation|Induction chemotherapy with low dose radiation
3320063|NCT00176241|Experimental|1|
3320064|NCT00176228|Experimental|lamotrigine|The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg. Increasing the medication to final dose will take 8 weeks and the response on full and tolerable dose is further monitored for response over 6 weeks. Therefore, this is a 18-26 week trial (2 to 12 weeks=screening and wash out; 8 weeks=dosing; 6 weeks=acute trial period on full dose).
3320065|NCT00176202|Active Comparator|Risperidone|Risperidone is an antimanic medication and is a second generation antipsychotic
3320066|NCT00176202|Active Comparator|Divalproex sodium|Divalproex sodium is an antiepileptic medication and is a mood stabilizer
3320067|NCT00176124|No Intervention|1|storage and transfusion of autologous whole blood without leukocyte depletion : Control group
3320068|NCT00176124|Experimental|2|storage and transfusion of leukocyte depleted autologous whole blood : leukocyte depletion group
3320069|NCT00176085||healthy|healthy volunteers
3320070|NCT00176046|Experimental|viscum album pini|immediate start of treatment with Iscador P s.c.
3320071|NCT00176046|Active Comparator|waiting group|identical treatment with Iscador P s.c. after waiting period of 3 months
3320072|NCT00175929|Placebo Comparator|Placebo|Matching placebo tablets administered twice a day
3320073|NCT00175929|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
3320074|NCT00175929|Experimental|Brivaracetam 150 mg/day|Brivaracetam 150 mg/day, 75 mg administered twice a day
3320075|NCT00175916|Experimental|Brivaracetam|Flexible dosing, can up and down titrate as needed.
3320076|NCT00175903|Experimental|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
3320077|NCT00175903|Active Comparator|Older Antepileptic Drugs|Older AEDs consist of CBZ-CR 200 mg and 400 mg and VPA-ER 300 mg and 500 mg.
3320078|NCT00175890|Placebo Comparator|Placebo|Matching oral solution to Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
3320079|NCT00175890|Experimental|Levetiractem|10 % oral solution Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
3320080|NCT00175877|Experimental|Certolizumab Pegol|All patients received Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) every two weeks, given as two 1 ml injections of CZP for at least six months and then 200 mg of CZP sc every two weeks, given as one 1 ml injection.
3320081|NCT00175838|Active Comparator|Intermediate risk group|Intermediate risk patients are randomised to a either a group receiving Aspirin only, or a group receiving both Hydroxyurea and Aspirin.
3320082|NCT00175838|Active Comparator|Low risk group|Patients are given Aspirin only with observation.
3320083|NCT00175825|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
3320084|NCT00175825|Experimental|Brivaracetam 5 mg/day|Brivaracetam 5 mg/day, 2.5 mg administered twice a day
3320085|NCT00175825|Experimental|Brivaracetam 20 mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day
3320086|NCT00175825|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
3320087|NCT00175812|Experimental|ATRA plus valproic acid plus theophyllin|ATRA for 14 days, continuous treatment with valproic acid and theophyllin
3320088|NCT00175435|Experimental|1|2 doses of HPV vaccine 0.5 mL. given IM with Topical Immune Modulator in 9-13 year-olds.
3320089|NCT00175435|Active Comparator|2|3 doses of HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 9-13 year-olds.
3320090|NCT00175435|Active Comparator|3|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 16-26 year-olds.
3320091|NCT00175409|Active Comparator|1|Infants will be randomized to two interventions which will take place during two separate blood collections that are required for clinical management. For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
3320092|NCT00175409|Active Comparator|2|Infants will be randomized to two interventions which will take place during two separate blood collections that are required for clinical management. For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
3320093|NCT00175396|Active Comparator|1|
3320094|NCT00175396|Experimental|2|
3320095|NCT00175383|Experimental|Leuprolide preparations|One versus three-month Leuprolide preparations in patients otherwise suitable for our Brachytherapy Program
3320096|NCT00175357|Active Comparator|1|Oral methadone
3320097|NCT00175357|Experimental|2|Injected diacetylmorphine
3320098|NCT00175344|Experimental|A|Arm A: Self-administered massage of the postoperative scar after breast cancer surgery.
3320099|NCT00175227|Experimental|Intervention|Saline hydration + mannitol + furosemide
3320100|NCT00175227|Placebo Comparator|Controls|Saline hydration without mannitol or furosemide
3320101|NCT00175188|Active Comparator|Cemented PIP implant|Avanta PIP
3320102|NCT00175188|Active Comparator|Uncemented PIP implant|Avanta PIP
3320103|NCT00175162|Active Comparator|Osteopal G bone cement|
3320104|NCT00175162|Active Comparator|Refobacin-Palacos R bone cement|
3320105|NCT00175149|Active Comparator|1|Given alfacalcidiol. Dose adjusted after PTH level
3320106|NCT00175149|No Intervention|2|The untreated arm
3320107|NCT00175136|Active Comparator|I-beam|I-beam stem design of tibial component for Total Knee Arthroplasty.
3320108|NCT00175136|Active Comparator|wedge|Wedge stem design of tibial component for Total Knee Arthroplasty.
3320109|NCT00175097|Other|soybeans and products made thereof|Diet: soybeans and products made thereof (soynuts, soynut butter, soy flakes & grits)
3320110|NCT00175097|Other|soybean flour and products made thereof|Diet: soybean flour and products made thereof (textured soybean)
3320111|NCT00175097|Other|soybean milk|Diet: soybean milk (tofu, soybean yogurt, cheese, etc.)
3320112|NCT00175097|Other|animal protein based diet|Diet: animal protein based diet
3320113|NCT00175071|Experimental|Comparison of cooking oils|Postmenopausal women (50-85 y) with LDL cholesterol 120 mg/dL.
3320114|NCT00175058|No Intervention|1|Control - Patients with acute anterior myocardial infarction revascularized by means of PCI with stenting within 6 hours of onset of symptoms, no experimental intervention
3320115|NCT00175058|Experimental|2|AO Therapy group - anterior acute myocardial infarction patients revascularized by means of PCI with stenting within 6 hours of symptom onset, receiving adjunctive infusion of hyperoxemic blood into target coronary artery for 90 minutes post-PCI.
3320116|NCT00175045|Experimental|Lansoprazole IV 30 mg QD|
3320117|NCT00175045|Active Comparator|Lansoprazole Capsule 30 mg QD|
3320118|NCT00175032|Experimental|Lansoprazole 30 mg QD + Naproxen 500 mg BID|(and added aspirin)
3320119|NCT00175032|Active Comparator|Celecoxib 200 mg QD|(and added aspirin)
3320120|NCT00175019|Experimental|Febuxostat 80 mg QD|
3320121|NCT00175019|Experimental|Febuxostat 120 mg QD|
3320122|NCT00175019|Active Comparator|Allopurinol QD|
3320123|NCT00175006||Tophi Participants|
3320124|NCT00174993|Experimental|Pioglitazone QD|
3320125|NCT00174993|Placebo Comparator|Placebo QD|
3320126|NCT00174967|Placebo Comparator|Placebo QD|
3320127|NCT00174967|Experimental|Febuxostat 40 mg QD|
3320128|NCT00174967|Experimental|Febuxostat 80 mg QD|
3320129|NCT00174967|Experimental|Febuxostat 120 mg QD|
3320130|NCT00174954||1|Volumes/measurements of tophi determined by serial MRIs
3320131|NCT00174941|Experimental|1|
3320132|NCT00174941|Experimental|2|
3320133|NCT00174941|Experimental|3|
3320134|NCT00174928|Experimental|Lansoprazole 0.5 mg/kg QD|
3320135|NCT00174928|Experimental|Lansoprazole 1.0 mg/kg QD|
3320136|NCT00174915|Experimental|Febuxostat 80 mg QD|
3320137|NCT00174915|Experimental|Febuxostat 120 mg QD|
3320138|NCT00174915|Experimental|Febuxostat 240 mg QD|
3320139|NCT00174915|Active Comparator|Allopurinol QD|
3320140|NCT00174915|Placebo Comparator|Placebo QD|
3320141|NCT00174837|Experimental|Tirapazamine + Cisplatin|
3320142|NCT00174837|Active Comparator|Cisplatin|
3320143|NCT00174798|Placebo Comparator|Placebo|
3320144|NCT00174798|Experimental|SSR240600C|
3320145|NCT00174798|Active Comparator|Tolterodine|
3320146|NCT00174785|Experimental|Dronedarone 400mg bid|Dronedarone 400mg tablets twice daily (bid)
3320147|NCT00174785|Placebo Comparator|Placebo|matching placebo tablets
3320148|NCT00174772|Experimental|B|Concurrent chemoradiotherapy followed by consolidation chemotherapy
3320149|NCT00174772|Experimental|A|Induction chemotherapy followed by concurrent chemoradiotherapy
3320150|NCT00174707|Active Comparator|A|Sequential Epidoxorubicin followed by CMF: ciclophosphamide/Methotrexate/fluorouracile (±TAM: tamoxifen)
3320151|NCT00174707|Experimental|B|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
3320152|NCT00174707|Experimental|C|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
3320153|NCT00174668|Experimental|1|Mealtime insulin glulisine 3x daily and insulin glargine 1 x daily subcutaneously
3320154|NCT00174668|Active Comparator|2|Two daily injection conventional insulin therapy
3320155|NCT00174655|Active Comparator|A1|
3320156|NCT00174655|Active Comparator|A2|
3320157|NCT00174655|Experimental|B|
3320158|NCT00174655|Experimental|C|
3320159|NCT00174642|Experimental|1|Insulin Glargine + 3 bolus of Insulin Glulisine + Metformin
3320160|NCT00174642|Experimental|2|Insulin Glargine + 1 to 3 bolus of Insulin Glulisine + Metformin
3320161|NCT00174642|Experimental|3|Insulin Glargine + 1 to 3 bolus of Insulin Glulisine + Metformin + Insulin secretagogue
3320162|NCT00174629|Experimental|1|
3320163|NCT00174629|Active Comparator|2|
3320164|NCT00174616|Experimental|Single arm|
3320165|NCT00174499|Experimental|1|2 mg nicotine gum
3320166|NCT00174499|Experimental|2|4 mg nicotine gum
3320167|NCT00174460|Active Comparator|Treatment Arm|
3320168|NCT00174460|No Intervention|Control Arm|
3320169|NCT00174447|Experimental|A1|
3320170|NCT00174434|Experimental|A|
3320171|NCT00174382|Experimental|1|
3320172|NCT00174369|Experimental|PD0325901|15 mg BID
3320173|NCT00174291|Experimental|Somatropin|
3320174|NCT00174265|Experimental|asenapine|
3320175|NCT00174265|Active Comparator|olanzapine|
3320176|NCT00174252|Experimental|Genotonorm (Somatropin)|
3320177|NCT00174187|Experimental|Somatropin|
3320178|NCT00173888|Experimental|A|
3320179|NCT00173888|Active Comparator|B|
3320180|NCT00173875|Experimental|A|Iressa
3320181|NCT00173862|Experimental|A|
3320182|NCT00173537|Other|other|
3320183|NCT00173433||Culture-confirmed relapse of TB|Patients who have a recurrent episode of culture-confirmed TB after completion of treatment for the first episode of culture-confirmed TB
3320184|NCT00173108|No Intervention|Term group|
3320185|NCT00173108|No Intervention|Usual care program group|
3320186|NCT00173108|Experimental|Clinic-based interveniton program group|
3320187|NCT00173108|Experimental|Home-based interveniton program group|
3320188|NCT00172809|Active Comparator|1|Peginterferon alfa-2a (Pegasys, Hoffmann-LaRoche) 135 ug/week for 24 weeks
3320189|NCT00172809|Active Comparator|2|Interferon alfa-2a (Roferon, Hoffmann-LaRoche) 3 MU tiw for 24 weeks
3320190|NCT00172536|Other|Control|Received oral general education about proper diet, regular physcial activity and other medical care if necessary
3320191|NCT00172536|Experimental|Exercise training|Received a supervised structure treadmill training
3320192|NCT00172419|Experimental|Atorvastatin|
3320193|NCT00172380|Experimental|docetaxel and cisplatin|docetaxel 36mg/m2 and cisplatin 75mg/m2
3320194|NCT00172224||osteoporosis|
3320195|NCT00172185|Experimental|teduglutide 0.05 mg/kg/d|0.05 mg/kg/d teduglutide subcutaneous injection
3320196|NCT00172185|Experimental|teduglutide 0.10 mg/kg/d|0.10 mg/kg/d teduglutide subcutaneous injection
3320197|NCT00172172|Experimental|1|PTH 100 mcg and 700 mg calcium
3320198|NCT00172172|Experimental|2|PTH 100 mcg and placebo
3320199|NCT00172172|Placebo Comparator|3|Placebo and 700 mg calcium
3320200|NCT00172133|Experimental|1|All patients entering the study will receive 100mcg daily for up to 6 months, making their total exposure 24 months
3320201|NCT00172107|Placebo Comparator|1|Placebo drug injectable subcutaneously
3320202|NCT00172107|Experimental|2|50 mcg PTH(1-84)
3320203|NCT00172107|Experimental|3|75mcg PTH(1-84)
3320204|NCT00172107|Experimental|4|100 mcg PTH(1-84)
3320205|NCT00172094|Placebo Comparator|1|PLACEBO
3320206|NCT00172094|Experimental|2|400 mg 1776 powder
3320207|NCT00172094|Experimental|3|1776 (800 mg)
3320208|NCT00172081|Placebo Comparator|placebo|Daily subcutaneous injection into thigh or abdomen with 700 mg Calcium and 400 IU Vitamin D daily
3320209|NCT00172081|Experimental|PTH(1-84) 100 mcg|Subcutaneous injection of PTH(1-84) with 700 mg Calcium and 400 IU Vitamin D daily
3320210|NCT00172068|Experimental|Treatment Group|
3320211|NCT00172068|Active Comparator|Control Group|
3320212|NCT00172055|Experimental|ZOL446 (zoledronic acid)|
3320213|NCT00172042|Experimental|Zoledronic acid|Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 to 4 weeks for 24 months. Dosage was adjusted for participants with mild or moderate renal impairment.
3320214|NCT00172042|Other|Control|No investigational treatment. If a participant developed bone metastases, treatment was started with Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 to 4 weeks until 24 months from the date of study entry had elapsed.
3320215|NCT00172029|Experimental|ZOL446 Standard radiotherapy dosage|
3320216|NCT00172029|Experimental|ZOL446 Low radiotherapy dosage|
3320217|NCT00172016|Experimental|ZOL446 (zoledronic acid)|
3320218|NCT00172003|Experimental|Zoledronic acid|Zoledronic acid, dosage according to calculated creatinine clearance, administered as a 15 minute infusion every 3 weeks for 12 months. Study infusion visits should occur not earlier than the scheduled visit and no later than 3 days after the scheduled visit. The dose of zoledronic acid in patients with baseline creatinine clearance > 60 mL/min was recommended to be 4 mg infused over no less than 15 minutes.
3320219|NCT00171977|Experimental|Imatinib Mesylate|400 mg once per day
3320220|NCT00171964|Experimental|zoledronic acid + radiotherapy|zoledronic acid every 4 weeks in combination with radiotherapy
3320221|NCT00171951|Experimental|Pasireotide|
3320222|NCT00171925|Experimental|Zoledronic acid (ZOL446)|Participants received intravenous infusion of Zoledronic acid every 4 weeks for 48 weeks, and calcium and Vitamin D daily.
3320223|NCT00171925|No Intervention|Control|No treatment with study medication.
3320224|NCT00171912|Experimental|imatinib mesylate (STI571)|
3320225|NCT00171899|Experimental|STI571|
3320226|NCT00171886|Experimental|octrotide|
3320227|NCT00171873|Experimental|Octreotide LAR (Long Acting Release)|Octreotide LAR 30 mg intramuscularly every 28 days
3320228|NCT00171873|Placebo Comparator|Placebo|Placebo - Sodium chloride intramuscularly every 28 days
3320229|NCT00171860|Experimental|STI571|
3320230|NCT00171847|Experimental|A - HER-2 +ve patients with Femara alone|
3320231|NCT00171847|Experimental|B - HER-2 +ve patients with Femara + Herceptin|
3320232|NCT00171847|Experimental|C - HER-2 -ve patients with Femara alone|
3320233|NCT00171821|Experimental|ICL670 (Deferasirox)|
3320234|NCT00171808|Experimental|Letrozole|
3320235|NCT00171730|Experimental|Pasireotide s.c. (SOM230)|
3320236|NCT00171704|Experimental|Letrozole|2.5 mg once daily (q.d.)orally for 5 years
3320237|NCT00171704|Experimental|Tam-Let|20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.
3320238|NCT00171509|Active Comparator|BID cyclosporine|control group continuing with a BID administration of cyclosporine and C2 monitoring.
3320239|NCT00171509|Experimental|OAD cyclosporine|conversion to OAD administration of cyclosporine with the same daily dose as received prior to conversion
3320240|NCT00171509|Experimental|OAD cyclosporine reduced|OAD administration of cyclosporine with a daily dose adjusted to a reduced C2
3320241|NCT00171496|Experimental|Cyclosporine microemulsion|
3320242|NCT00171496|Active Comparator|Tacrolimus|
3320243|NCT00171340|Experimental|Upfront Zoledronic Acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.
3320244|NCT00171340|Experimental|Delayed Zoledronic Acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score <= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.
3320245|NCT00171314|Experimental|Upfront Zoledronic Acid|Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1
3320246|NCT00171314|Experimental|Delayed Zoledronic Acid|Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score <= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1
3320247|NCT00171301|Experimental|Deferasirox|Deferasirox was given orally once daily (10 to 20 mg/kg) to participants 2 years and older based on participant's body weight.
3320248|NCT00171249|Experimental|Gleevec/Glivec|
3320249|NCT00171223|Experimental|Gleevec/Glivec|
3320250|NCT00171210|Experimental|Deferasirox|All participants received Deferasirox (ICL670) orally once a day. Dosage based on body weight.
3320251|NCT00171184|Experimental|1|Darifenacin
3320252|NCT00171184|Placebo Comparator|2|Placebo
3320253|NCT00171171|Experimental|Deferasirox|
3320254|NCT00171158|Experimental|imatinib mesylate|
3320255|NCT00171145|Experimental|1|Darifenacin
3320256|NCT00171145|Placebo Comparator|2|Placebo
3320257|NCT00171054|Experimental|Valsartan 320 mg|
3320258|NCT00171054|Experimental|Amlodipine 10 mg|
3320259|NCT00170950|Experimental|Benazepril/amlodipine|Patients were instructed to take one capsule with water in the morning, except on the morning of their next office visit. On office visit days, study medication was taken after completion of the visit evaluations. Following randomization, all patients were treated at Dose Level 1 for 4 weeks, followed by a forced titration to Dose Level 2 for a subsequent 4 week period. Thereafter, patients were titrated as needed to Dose Level 3 to achieve a target blood pressure of < 140/< 90 mm Hg. For patients with diabetes or chronic kidney disease, investigators were encouraged to use a target blood pressure of 130/80 mm Hg.
3320260|NCT00170950|Active Comparator|Benazepril/hydrochlorothiazide|Patients were instructed to take one capsule with water in the morning, except on the morning of their next office visit. On office visit days, study medication was taken after completion of the visit evaluations. Following randomization, all patients were treated at Dose Level 1 for 4 weeks, followed by a forced titration to Dose Level 2 for a subsequent 4 week period. Thereafter, patients were titrated as needed to Dose Level 3 to achieve a target blood pressure of < 140/< 90 mm Hg. For patients with diabetes or chronic kidney disease, investigators were encouraged to use a target blood pressure of 130/80 mm Hg.
3320261|NCT00170846|Active Comparator|Group A: No RAD|Calcineurin Inhibitors (CNI) ± Mycophenolate Acid (MPA)/Azathioprine (AZA) ± Steroids
3320262|NCT00170846|Experimental|Group B : CNI Withdrawal|Initiation of everolimus (8-12 ng/mL) with discontinuation of CNI. Everolimus(RAD001) 4 mg initial daily dose.
3320263|NCT00170846|Experimental|Group C: CNI Reduction|Initiation of everolimus (3-8 ng/mL) with reduction by 70-90% in CNI blood levels. Everolimus (RAD001) 3 mg initial daily dose.
3320264|NCT00170768|Experimental|1|Darifenacin
3320265|NCT00170768|Active Comparator|2|Oxybutynin
3320266|NCT00170768|Placebo Comparator|3|Placebo
3320267|NCT00170755|Experimental|1|Darifenacin
3320268|NCT00170716|Active Comparator|Control|
3320269|NCT00170716|Experimental|Investigational|
3320270|NCT00170690|Experimental|1|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
3320271|NCT00170690|Experimental|2|Treosulfan 600 mg/m² p.o. on day 1-28, 57-84, etc
3320272|NCT00170677|Active Comparator|A|
3320273|NCT00170677|Experimental|B|
3320274|NCT00170664|Experimental|Paclitaxel, Carboplatin|
3320275|NCT00170625|Experimental|Hycamtin|
3320276|NCT00170612|Experimental|A|PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 18 months
3320277|NCT00170612|Experimental|B|PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 12 months and 18 months
3320278|NCT00170612|Experimental|C|PCV at 6 weeks and 14 weeks; PPS at 18 months
3320279|NCT00170612|Experimental|D|PCV at 6 weeks and 14 weeks; PPS at 12 months and 18 months
3320280|NCT00170612|Experimental|E|PCV at 14 weeks; PPS at 18 months
3320281|NCT00170612|Experimental|F|PCV at 14 weeks; PPS at 12 months and 18 months
3320282|NCT00170612|Experimental|G|No PCV; PPS at 12 months and 18 months
3320283|NCT00170612|Active Comparator|H|No PCV; PPS at 18 months
3320284|NCT00170573|Experimental|Caelyx|
3320285|NCT00170547|Experimental|Group 3|382 subjects will receive one 3 mcg dose of Fluzone intradermally using the Mantoux technique on Day 0,
3320286|NCT00170547|Experimental|Group 4|382 subjects will receive one 15 mcg dose Fluzone vaccine intramuscularly (IM) on Day 0,
3320287|NCT00170547|Experimental|Group 1|382 subjects will receive one 6 mcg dose of Trivalent inactivated influenza vaccine (TIV) intradermally (ID) with the BD ID System on Day 0,
3320288|NCT00170547|Experimental|Group 2|382 subjects will receive one 9 mcg dose of TIV intradermally (ID) with the BD ID System on Day 0,
3320289|NCT00170495||observation|male and female adults age 65 and older with acute respiratory illness (common colds, flu, bronchitis, pneumonia)
3320290|NCT00170469|Experimental|1|Low dose rPA vaccine
3320291|NCT00170469|Experimental|2|High dose rPA vaccine
3320292|NCT00170469|Active Comparator|3|Active vaccine control
3320293|NCT00170456|Active Comparator|1|Low dose rPA vaccine regime 1
3320294|NCT00170456|Active Comparator|2|Low dose rPA vaccine regime 2
3320295|NCT00170456|Active Comparator|3|High dose rPA vaccine regime 1
3320296|NCT00170456|Active Comparator|4|High dose rPA vaccine regime 2
3320297|NCT00170326|Active Comparator|Dual Chamber pacing|conventional dual-chamber pacemaker/ICD implantation with the ventricular lead in the right ventricular apex
3320298|NCT00170326|Experimental|Biventricular pacing|Biventricular pacing: dual-chamber biventricular pacemaker/ICD implantation with leads at the right ventricular apex and the left ventricle
3320299|NCT00170313|Experimental|Conducted AF-Response Algorithm (CAFR) On|"CAFR: On~Level medium~Max. Rate: 110ppm VSR: Off"
3320300|NCT00170313|Active Comparator|Conducted AF-Response Algorithm (CAFR) Off|CAFR: Off VSR: Off
3320301|NCT00170287|Experimental|1|ICD Therapy plus VT-Ablation
3320302|NCT00170287|Active Comparator|2|ICD Therapy only
3320303|NCT00170274|No Intervention|Control Arm|Algorithms for prevention and termination of AF not activated
3320304|NCT00170274|Active Comparator|Prevention and Therapy Algorithms on|Activation of preventive and therapeutic algorithms
3320305|NCT00170248|No Intervention|1|Physicians in this arm will be using the standard MOXXI electronic health record.
3320306|NCT00170248|Experimental|2|In addition to the standard MOXXI electronic health record, physicians in this arm will be using the computer-based decision support for asthma management
3320307|NCT00170235|Experimental|1|Prehabilitation (exercises pre surgery)
3320308|NCT00170235|Active Comparator|2|Usual care as provided by the institution
3320309|NCT00170209|Active Comparator|Isoniazid|The standard therapy will be daily self-administered INH, 10-15 mg/kg/day (max=300mg/day) for 9 months (9INH).
3320310|NCT00170209|Active Comparator|Rifampin|The experimental arm will be daily self-administered RIF 10-20 mg/kg/day for 4 months (4RIF).
3320356|NCT00169234|Experimental|0.1mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 0.1mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
3320357|NCT00169234|Experimental|0.5mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 0.5mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
3320311|NCT00170157|Experimental|Arm I|Patients receive either leuprolide acetate intramuscularly (IM) or goserelin subcutaneously (SC) on days 0, 28, and 56. Patients also receive oral flutamide three times daily or oral bicalutamide once daily. Treatment with antiandrogen (AA) therapy continues for 3 months (3-4 months for patients who initiated AA therapy <= 21 days prior to enrollment) in the absence of disease progression or unacceptable toxicity. Patients receive ipilimumab IV over 90 minutes on day 7 (within 7-28 days post-initiation of AA therapy for patients who initiated AA therapy <= 21 days prior to enrollment) of AA therapy.
3320312|NCT00170157|Active Comparator|Arm II|Patients receive AA therapy as in arm I. Patients may crossover to arm II in the case of disease progression.
3320313|NCT00170079|Experimental|Step care vs. regular care|Participants were randomized either to (1) Step care intervention, where smokers who failed to quit or who relapsed received increasingly intensive smoking cessation interventions; vs. (2) Regular care, where smokers who failed to quit or who relapsed received repeated intervention.
3320314|NCT00170001|Placebo Comparator|Sugar pill|
3320315|NCT00170001|Active Comparator|Active Comparator|
3320316|NCT00169910|Active Comparator|1|AUC monitored withdrawal of MMF
3320317|NCT00169910|Active Comparator|2|AUC monitored withdrawal of CNI
3320318|NCT00169897|Experimental|Hospital-based|This group has to go at the hospital 3 times per week to do the exercise program.
3320319|NCT00169897|Active Comparator|Home-Based|The group had to do the exercise program at home with indirect supervision (Polar watches and a phone call per week).
3320320|NCT00169845|Experimental|Alpha-Tocopherol and Beta-Carotene|Patients received a daily supplementation of alpha-tocopherol (one capsule of 400 IU dl-alpha-tocopherol) and beta-carotene (one capsule of 30 mg) for 3 years after the end of radiation therapy. Due to ethical concerns, the beta-carotene supplementation was stopped during the trial (after the randomization of 156 patients). See details in JNCI, 2005: 97 (7), 481-8.
3320321|NCT00169845|Placebo Comparator|Placebo|Patients received two capsules of placebos per day during 3 years. When the beta-carotene was stopped, they received only one capsule.
3320322|NCT00169832|Experimental|Rosiglitazone (Avandia)|
3320323|NCT00169832|Placebo Comparator|Placebo|
3320324|NCT00169806|Other|cohort|Subjects who are scheduled to undergo a percutaneous kidney stone removal who do not have complicated comorbidities
3320325|NCT00169793|Other|A|
3320326|NCT00169780||cohort|patients who require a CT scan prior to kidney stone surgery for diagnostic purposes
3320327|NCT00169767||A|Comparison study between KTP and HoLAP procedures for BPH
3320328|NCT00169754|Other|cohort|mapping and data collection
3320329|NCT00169741|Other|cohort|
3320330|NCT00169715|Other|A|
3320331|NCT00169702|Other|Standard|standard information
3320332|NCT00169702|Active Comparator|Intervention|weight management program, 12 sessions, 2 weekly, psychoeducational program, interactive topics like healthy food, diet behavior, physical activity, stress reduction.
3320333|NCT00169689|Sham Comparator|rTMS|sham coil system versus verum rTMS stimulation
3320334|NCT00169676||cohort|Registry and Database
3320335|NCT00169650||1|Registry and database of subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction
3320336|NCT00169559|Placebo Comparator|Arm 1|Placebo
3320337|NCT00169559|Active Comparator|Arm 2|Fenofibrate
3320338|NCT00169546|Experimental|Arm 1|
3320339|NCT00169533|Experimental|Arm 1|Lapatinib either 750, 1000, 1250 or 1500 mgs
3320340|NCT00169442|Experimental|Tritanrix-HepB/Hiberix Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine, received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
3320341|NCT00169442|Experimental|Tritanrix-HepB/Hiberix Kft. Ref Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ vaccine, received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
3320342|NCT00169442|Experimental|HB Tritanrix-HepB/Hiberix Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine (with HepB at birth), received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
3320343|NCT00169442|Experimental|Tritanrix-HepB Kft.+Hiberix Group|Healthy male and female infants who were primed with Tritanrix™-HepB Kft. and Hiberix™ vaccines, were boosted with Tritanrix™-HepB Kft. vaccine administered intramuscularly into the right upper thigh and Hiberix™ vaccine, administered intramuscularly into the left upper thigh, at 15-18 months of age.
3320344|NCT00169442|Experimental|PRP Tritanrix-HepB Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine, received plain Polyribosil-Ribitol-Phosphate (PRP) polysaccharide vaccine administered intramuscularly into the right upper thigh, at 10 months of age, followed by a booster dose of Tritanrix™-HepB Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
3320345|NCT00169442|Experimental|PRP Tritanrix-HepB Kft. Ref Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ vaccine, received plain Polyribosil-Ribitol-Phosphate (PRP) polysaccharide vaccine administered intramuscularly into the right upper thigh, at 10 months of age, followed by a booster dose of Tritanrix™-HepB Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
3320346|NCT00169390||pregnant smokers|
3320347|NCT00169390||pregnant non smokers|
3320348|NCT00169377|Active Comparator|Group A|Deep brain stimulation on followed by off
3320349|NCT00169377|Sham Comparator|Group B|No stimulation, deep brain stimulation off followed by on
3320350|NCT00169338|Experimental|deep brain stimulation|Paladin deep brain stimulation
3320351|NCT00169338|Placebo Comparator|sham deep brain stimulation|no stimulation
3320352|NCT00169273|Active Comparator|Weight loss only intervention|Structured group weight loss intervention
3320353|NCT00169273|Experimental|Combined intervention|Structured group program for weight loss and depression
3320354|NCT00169260|Experimental|1|Intervention
3320355|NCT00169260|Placebo Comparator|2|Control
3320461|NCT00167622|Experimental|2|Mechanical ventilation
3320462|NCT00167596|Experimental|1|Early goal directed therapy based on StO2 evaluation
3320358|NCT00169234|Experimental|1.0mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 1.0mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
3320359|NCT00169234|Experimental|2.0mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 2.0mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
3320360|NCT00169234|Experimental|0.5mL Pneumococcal Polysacc Vaccine|Participants in this group were randomized at enrollment to receive 0.5mL Pneumovax 23 at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
3320361|NCT00169221|Active Comparator|postop chemoradio with cisplatin|postoperative chemoradiotherapy with cisplatin
3320362|NCT00169221|Experimental|postop chemoradio (cisplatin)+gefitinib|postoperative chemoradiotherapy with cisplatin + gefitinib
3320363|NCT00169195|Experimental|R-GEMOX|Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)
3320364|NCT00169156|Experimental|Rituximab + CHOP|Rituximab + CHOP regimen Prednisone - Doxorubicine - Cyclophosphamide - Vincristine
3320365|NCT00169117|Experimental|1|Behavioural intervention: Songs/posters aimed at behaviour change to increase repair and maintenance of mosquito nets
3320366|NCT00169104|Active Comparator|1|Subjects will receive ten doses of G-CSF at a dose of 5 mcgm/kg daily Monday through Friday for the first two weeks of the trial. All patients will also receive trastuzumab at 4 mg/kg week 1, and 2 mg/kg week 2 during the first two weeks of the trial. All patients will then receive 12 weeks of trastuzumab at 2 mg/kg IV weeks 3 through 14, vinorelbine at 25 mg/m2 IV weekly weeks 3,4,6,7,9,10,12,13 and G-CSF at 5 mcgm/kg SQ daily Monday through Friday weeks 3-14.
3320367|NCT00169104|Placebo Comparator|2|Subjects will receive ten doses of a placebo injection SQ daily Monday through Friday for the first two weeks of the trial. All patients will also receive trastuzumab at 4 mg/kg week 1, and 2 mg/kg week 2 during the first two weeks of the trial. All patients will then receive 12 weeks of trastuzumab at 2 mg/kg weeks 3-14, vinorelbine at 25 mg/m2 IV weekly weeks 3,4,6,7,9,10,12,13, and G-CSF at 5 mcgm/kg SQ daily Monday through Fridays weeks 3-14.
3320368|NCT00169091|Experimental|Clozapine|Clozapine 12.5-300 mg taken orally per day for 12 weeks in the acute phase of the study and up to 130 weeks (total) in the Follow-up portion of the study.
3320369|NCT00169091|Active Comparator|Haloperidol|Haloperidol 2-12 mg taken orally per day for 12 weeks in the acute phase of the study and up to 130 weeks (total) in the Follow-up portion of the study.
3320370|NCT00169065|Active Comparator|Clozapine|Clozapine or olanzapine in treatment resistant schizophrenia
3320371|NCT00169065|Active Comparator|olanzapine|clozapine or olanzapine in treatment resistant schizophrenia
3320372|NCT00169000|Experimental|Capecitabine and Docetaxel|Escalating doses of capecitabine days 1-14 with a fixed dose of docetaxel on Day 8 of a 21 day cycle
3320373|NCT00168909|Experimental|1|alfacalcidol 1µg/d
3320374|NCT00168909|Placebo Comparator|2|placebo
3320375|NCT00168844|Other|Tiotropium Respimat 5mcg (Tio R5)|
3320376|NCT00168844|Other|Tiotropium Respimat 10mcg (Tio R10)|
3320377|NCT00168844|Other|Placebo|
3320378|NCT00168831|Other|Tiotropium Respimat 5mcg (Tio R5)|
3320379|NCT00168831|Other|Tiotropium Respimat 10mcg (Tio R10)|
3320380|NCT00168831|Other|Placebo|
3320381|NCT00168818|Experimental|dabigatran etexilate 75 mg|daily dose 150 mg once daily, half a dose on the day of surgery
3320382|NCT00168818|Experimental|dabigatran etexilate 110 mg|daily dose 220 mg once daily, half a dose on the day of surgery
3320383|NCT00168818|Active Comparator|enoxaparin|40 mg once daily
3320384|NCT00168805|Experimental|dabigatran etexilate 220 mg|220 mg once daily
3320385|NCT00168805|Experimental|dabigatran etexilate 150 mg|150 mg once daily
3320386|NCT00168805|Active Comparator|enoxaparin|40 mg once daily
3320387|NCT00168766|Experimental|1|interferon-beta-1a in combination with methylprednisolone
3320388|NCT00168766|Placebo Comparator|2|interferon-beta-1a in combination with placebo
3320389|NCT00168753|Experimental|1|
3320390|NCT00168714||Pregnant participants|Pregnant participants who were exposed to Avonex within approximately 1 week of conception or during the first trimester of pregnancy
3320391|NCT00168688|Active Comparator|FeFol|Iron (60 mg) and folic acid (400 ug), standard of care
3320392|NCT00168688|Experimental|MN1|"1 RDA of 15 micronutrients, including iron (30 mg) and folic acid (400 ug)~Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg"
3320393|NCT00168688|Experimental|MN2|"2 RDA of 14 micronutrients including iron (30 mg) and folic acid (800 ug)~Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg"
3320394|NCT00168558|Active Comparator|1|Standard titre Edmonston-Zagreb measles vaccine at 4½ and 9 months of age
3320395|NCT00168558|Active Comparator|2|Standard titre Schwarz measles vaccine at 9 months of age
3320396|NCT00168558|Active Comparator|3|Standard titre Edmonston-Zagreb measles vaccine at 9 months of age
3320397|NCT00168519|Active Comparator|1|
3320398|NCT00168493|Active Comparator|intervention|there is no sham or placebo control arm It is a single arm study
3320399|NCT00168480|Experimental|1|Botulinum Toxin Type A
3320400|NCT00168454|Placebo Comparator|Placebo|Placebo (normal saline) injected into detrusor on Day 1
3320401|NCT00168454|Experimental|BOTOX 50 U|botulinum toxin Type A 50 U injected into detrusor on Day 1
3320402|NCT00168454|Experimental|BOTOX 100 U|botulinum toxin Type A 100 U injected into detrusor on Day 1
3320403|NCT00168454|Experimental|BOTOX 150 U|botulinum toxin Type A 150 U injected into detrusor on Day 1
3320404|NCT00168454|Experimental|BOTOX 200 U|botulinum toxin Type A 200 U injected into detrusor on Day 1
3320405|NCT00168454|Experimental|BOTOX 300 U|botulinum toxin Type A 300 U injected into detrusor on Day 1
3320459|NCT00167635|No Intervention|3|Usual Care Control Group (UC). Following randomization the participants in the control group will receive two short phone calls to maintain contact during the comparable 9-week intervention in the treatment groups.
3320406|NCT00168428|Experimental|botulinum toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
3320407|NCT00168428|Placebo Comparator|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
3320408|NCT00168415|Experimental|1|Botulinum Toxin Type A
3320409|NCT00168389|Experimental|Dexamethasone 700 μg|700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
3320410|NCT00168389|Experimental|Dexamethasone 350 μg|350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
3320411|NCT00168389|Sham Comparator|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
3320412|NCT00168337|Experimental|Dexamethasone 700 μg|700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
3320413|NCT00168337|Experimental|Dexamethasone 350 μg|350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
3320414|NCT00168337|Sham Comparator|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
3320415|NCT00168324|Experimental|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.
3320416|NCT00168324|Experimental|350 µg Dexamethasone followed by 700 µg Dexamethasone|350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
3320417|NCT00168324|Sham Comparator|Sham Injection followed by 700 µg Dexamethasone|Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
3320418|NCT00168311|Experimental|Active Treatment|Bilateral high frequency (10 Hertz) rTMS
3320419|NCT00168311|Sham Comparator|Sham rTMS|Bilateral Sham rTMS
3320420|NCT00168298|Experimental|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.
3320421|NCT00168298|Experimental|350 µg Dexamethasone followed by 700 µg Dexamethasone|350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
3320422|NCT00168298|Sham Comparator|Sham Injection followed by 700 µg Dexamethasone|Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
3320423|NCT00168233||1|No antiretroviral therapy for 12 months
3320424|NCT00168233||2|Initiating ARV therapy with an NNRTI based regimen
3320425|NCT00168233||3|Initiating ARV therapy with a PI based regimen
3320426|NCT00168220||Drug hypersensitive group|HIV positive patients with a history of a Hypersensitivity Reaction to the antiretroviral medications Nevirapine, Abacavir or Efavirenz
3320427|NCT00168220||Drug tolerant group|HIV positive patients selected based on drug exposure greater than 2 weeks and tolerance to to Abacavir or Nevirapine.
3320428|NCT00168103|Experimental|C1-INH 10 U/kg bw|10 Units (U)/kg body weight (bw) dose
3320429|NCT00168103|Experimental|C1-INH 20 U/kg bw|20 U/kg bw dose
3320430|NCT00168103|Placebo Comparator|Placebo|
3320431|NCT00168064|Active Comparator|1 (PG - NM (MCH) 0.02%)|PG - mechlorethamine-MCH (nitrogen mustard) 0.02% gel To evaluate the tolerability and safety of topical mechlorethamine-MCH (nitrogen mustard) 0.02% ointment formulations in patients with stage I or IIA MF
3320432|NCT00168064|Active Comparator|2 (AP - MCH(NM) 0.02%)|AP - mechlorethamine-MCH (nitrogen mustard) 0.02% compounded in Aquaphor To evaluate the tolerability and safety of mechlorethamine-MCH (nitrogen mustard)0.02% ointment formulations in patients with stage I or IIA MF
3320433|NCT00168038|Experimental|IgPro10|
3320434|NCT00168025|Experimental|IgPro10|
3320435|NCT00167947|Active Comparator|A|
3320436|NCT00167947|Experimental|B|
3320437|NCT00167934|Placebo Comparator|Placebo|50% of participants will receive placebo
3320438|NCT00167934|Experimental|Experimental|50% of participants will receive Depakote ER
3320439|NCT00167856|Experimental|1|Venlafaxine HCL (extended release)
3320440|NCT00167856|Active Comparator|2|Benztropine Mesylate
3320441|NCT00167830|Experimental|Lifestyle Intervention|Dietary modification and exercise.
3320442|NCT00167804|Other|1|Present Centered Therapy focuses on the veterans problems in the here and now. It uses a problem solving approach and avoids discussion of war related traumatic events.
3320443|NCT00167778|Experimental|Arm 1|Novel prosthetic pylon
3320444|NCT00167778|Active Comparator|Arm 2|rigid pylon
3320445|NCT00167700|Experimental|Probiotics|
3320446|NCT00167700|Experimental|Probiotics + Dietary counseling|
3320447|NCT00167700|Experimental|Dietary counseling + placebo|
3320448|NCT00167700|Experimental|Prebiotics|
3320449|NCT00167700|Placebo Comparator|Placebo|
3320450|NCT00167700|No Intervention|Control|
3320451|NCT00167687|Placebo Comparator|2|
3320452|NCT00167674|Active Comparator|B|Combined short-course Zidovudine/Nevirapine
3320453|NCT00167674|Experimental|A|HAART during pregnancy and 6 months postpartum
3320454|NCT00167661|Experimental|1|Campath 1-H
3320455|NCT00167648|Active Comparator|A|Leuprolide 7.5 mg or Goserelin 3.6 mg
3320456|NCT00167648|Experimental|B|Transdermal estradiol 0.6 mg q 3 days
3320457|NCT00167635|Experimental|1|Face-to-Face Individualized Comprehensive Self-Management (CSM-FF) Group. Participants in the individualized CSM-FF group will be scheduled for 9 weekly sessions with the nurse therapist followed by post-intervention follow-up assessment.
3320458|NCT00167635|Experimental|2|Telephone Individualized Comprehensive Self-Management (CSM-TEL) Group. Participants in the individualized CSM-FTF group will initially have 2 face-to-face meetings with the nurse therapist, 6 sessions over the phone and the final session face-to-face at 9 weeks.
3320460|NCT00167622|Active Comparator|1|Physiotherapy, oxygen as needed
3320463|NCT00167596|Active Comparator|2|Early goal directed therapy
3320464|NCT00167583|Active Comparator|A Cyclosporin A|Cyclosporin A
3320465|NCT00167583|Active Comparator|B Interferon alpha|Interferon-alpha2a
3320466|NCT00167557|Experimental|Single Arm Study|
3320467|NCT00167544|Experimental|1|1. Tapering dose of hydrocortisone every 12 h over 7 day period
3320468|NCT00167544|Placebo Comparator|2|2. Identical-appearing saline placebo
3320469|NCT00167531|Experimental|Treadmill walking|30 minutes per day of treadmill walking with body weight support and assistance from one therapist
3320470|NCT00167531|Active Comparator|Overground walking|30 minutes per day of overground walking with assistance from one therapist
3320471|NCT00167505|Experimental|Risk Avoidance|The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes both classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
3320472|NCT00167505|Experimental|Risk Reduction|The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes both classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
3320473|NCT00167466|Experimental|A|4 week brushing with experimental Soladey-3 toothbrush followed by 4 week washout period followed by 4 week brushing with placebo Soladey-3 toothbrush
3320474|NCT00167466|Placebo Comparator|B|subjects to brush with Placebo Soladey-3 toothbrush for 4 weeks followed by a 4 week washout followed by 4 week brushing with experimental Soladey-3 toothbrush
3320475|NCT00167414|Experimental|Hypofractionated Stereotactic Body Radiation Therapy|Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.
3320476|NCT00167388|No Intervention|group 1|All babies <1250 gm at the time of the study are enrolled into this arm, and randomized to be NPO during the PRBC transfusion
3320477|NCT00167388|Active Comparator|group 2|Babies <1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
3320478|NCT00167388|No Intervention|group 3|All babies >1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
3320479|NCT00167388|Experimental|group 4|All babies <1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
3320480|NCT00167362|Experimental|1|Participants will receive cognitive enhancement therapy
3320481|NCT00167362|Placebo Comparator|2|Participants will receive enriched supportive therapy
3320482|NCT00167310|Experimental|1|Eicosapentaenoic acid (omega-3 fatty acid, 2 g in 4x500 mg softgels daily) + Antipsychotic drug (doctor's choice) treatment for baseline, 1 month, 2 months and 4 months duration.
3320483|NCT00167310|Placebo Comparator|2|Placebo (soy bean oil, 2 g in 4x500 mg softgels daily) + Antipsychotic drug (doctor's choice) treatment for baseline, 1 month, 2 months and 4 months duration.
3320484|NCT00167297|Experimental|Atomoxetine|Atomoxetine (Strattera) 25mg peroral (PO) each day for seven days, then up to 40mb bid 40mg PO each day for three days, then 80mg PO bid.
3320485|NCT00167271|Experimental|Experimental|Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.
3320486|NCT00167271|Active Comparator|Control|Subjects given pamphlets from the Arthritis Foundation
3320487|NCT00167245|Experimental|Group 1|topiramate
3320488|NCT00167245|Placebo Comparator|Group 2|
3320489|NCT00167232|Active Comparator|Naltrexone 150mg/day|
3320490|NCT00167232|Placebo Comparator|Placebo Sugar Pill|
3320491|NCT00167219|Experimental|Intent-to-Treat|Patients receiving study regimen.
3320492|NCT00167206|Experimental|HSCT Patients|Patients who received total body irradiation (450 cGy [centigray]) with thymic shielding prior to chemotherapy regimen and Hematopoietic Stem Cell Transplant (HSCT)
3320493|NCT00167180|Active Comparator|CML|Patients with Chronic Myelogenous Leukemia (CML) who have failed or refused Gleevec(TM) therapy and will receive Donor Lymphocyte Infusion.
3320494|NCT00167180|Active Comparator|Non-CML or CML that Relapsed after Donor Lymphocyte Infusion|Patients with non-CML or CML who have failed Donor Lymphocyte Infusion (DLI) and will receive induction chemotherapy plus DLI.
3320495|NCT00167167|Experimental|BMT patients|All patients treated.
3320496|NCT00167154|Experimental|risperidone|risperidone
3320497|NCT00167154|Placebo Comparator|placebo|placebo comparator
3320498|NCT00167141|Experimental|testosterone injections|injections of testosterone to normal men (arm 1) and two men with subnormal semen parameters (arm 2)
3320499|NCT00167102|Experimental|Alefacept|
3320500|NCT00167102|Placebo Comparator|Placebo|
3320501|NCT00166881|Experimental|A, 2, III|Weekly Docetaxel-Irinotecan for Inoperable Gastric Cancers After P-HDFL
3320502|NCT00166868|Experimental|Neomycin prescribed|Interventions: 10 cases received Neomycin for 6 months
3320503|NCT00166868|Experimental|Probiotics (Lactobacillus casei rhamnosus, Lcr35) prescribed|Interventions: 10 cases received Probiotics for 6 months
3320504|NCT00166868|No Intervention|control|10 cases without intervention were historical control.
3320505|NCT00166712|Active Comparator|Group 1: Alemtuzumab + TAC + MMF|Receive two doses of alemtuzumab (Campath-1H, 30mg) by intravenous (IV) infusion. One dose during kidney transplant surgery and the second dose on day 2 (post-surgery) to achieve peripheral T-cell depletion. IV glucocorticoids will be given prior to Campath administration to limit cytokine release syndrome in association with this monoclonal antibody. MMF on the day of surgery and continue taking it by mouth, twice daily. TAC started on the 1st day after surgery, and then taken by mouth twice daily.
3320506|NCT00166712|Active Comparator|Group 2: Alemtuzumab + Sirolimus + MMF|"Sirolimus will be taken by mouth before transplant surgery and will continue taking once daily after surgery. Group 2 will also receive 2 doses of Alemtuzumab: one during surgery and the second will be given on the second day after surgery. Mycophenolate mofetil will be give on the day of surgery and twice daily, by mouth, as instructed by the doctor.~If subjects do not experience kidney rejection after 6 months after surgery, they will be weaned off of the sirolimus and continue taking the mycophenolate mofetil."
3320507|NCT00166699|No Intervention|Palpation|Use of palpation to guide the the insertion site of combined spinal epidural needle in obese parturients
3320508|NCT00166699|Experimental|ultrasound|The use of ultrasound to guide the insertion of a combined spinal epidural needle
3320509|NCT00166543|Experimental|TAS-108 40 mg|
3320510|NCT00166543|Experimental|TAS-108 80 mg|
3320511|NCT00166543|Experimental|TAS-108 120 mg|
3320512|NCT00166530|Active Comparator|1|Arm 1: Active comparator
3320513|NCT00166530|Experimental|2|Arm 2: Drug
3320514|NCT00166517|Experimental|1|RotaTeq
3320515|NCT00166517|Placebo Comparator|2|Placebo
3320516|NCT00166504|Experimental|Vytorin|Ezetimibe 10 mg/Simvastatin 20 mg
3320517|NCT00166504|Active Comparator|Atorvastatin|Atorvastatin 10 mg
3320518|NCT00166413|Experimental|CC5013|Assess the proportion of confirmed hematologic responses (HCR, HPR) resulting from treatment with CC5013 after 3 months in patients with primary systemic amyloidosis.
3320519|NCT00166387||Phase I, II, III|Phase I consists of a brother pair with hemophilia, one or both of whom has a history of inhibitors, and their parents; Phase II consists of a person with hemophilia and an inhibitor, and both his parents; Phase III consists of an unrelated group of people with hemophilia.
3320520|NCT00166361|Experimental|Memokath 051 Ureteral Stent|Subjects assigned to this arm received a Memokath 051 Ureteral Stent.
3320521|NCT00166361|Active Comparator|JJ Stent|Subjects assigned to this arm received a JJ stent.
3320522|NCT00166296|Experimental|Escitalopram|Escitalopram, 15 mg/day
3320523|NCT00166296|Placebo Comparator|Placebo pill|Placebo
3320524|NCT00166283|Experimental|experimental group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for five weeks (10 training sessions).
3320525|NCT00166283|Placebo Comparator|placebo control group|The placebo control group will receive placebo memory exercises administered on a laptop computer twice a week for five weeks (10 placebo control sessions).
3320526|NCT00166270|Experimental|1|
3320527|NCT00166257|Active Comparator|Medical antitrhombotic treatment|
3320528|NCT00166257|Experimental|Device Implant|Percutaneous closure of patent foramen ovale
3320529|NCT00166244|Active Comparator|Fixed Dose|1 g MMF twice-daily (bid) for adults or 600 mg/m2 bid for paediatric patients. Treatment to be given orally unless it is not possible, in which case it is administered via intravenous (iv) infusion.
3320530|NCT00166244|Active Comparator|Concentration Controlled|1 g MMF bid for adults or 600 mg/m2 bid for paediatric patients. Thereafter, MMF doses will be adjusted to MPA AUC0-12 between 30-60mg.h/L based on 3-point abbreviated AUCs (taken at timepoints: 0, 30 min and 120 min always in fasted patients, except for pediatric patients on concomitant tacrolimus) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine MPA levels in plasma.
3320531|NCT00166231||Chest pain patients|
3320532|NCT00166231||Murmur group|
3320533|NCT00166205|Experimental|Gastric Band|Single-arm study, all subjects banded.
3320534|NCT00166192|Active Comparator|Chemical Peel|Split face treatment paradigm
3320535|NCT00166166|Experimental|Healthy Controls|Healthy subjects had venous occlusion plethysmography after intra-arterial infusions of saline, L-NG-monomethyl Arginine (L-NMMA), Tetraethylammonium (TEA), fluconazole, bradykinin, sodium nitroprusside and acetylcholine
3320536|NCT00166166|Experimental|Risk Factors|Non-hypertensive subjects with cardiovascular risk factors had venous occlusion plethysmography after intra-arterial infusions of saline, L-NG-monomethyl Arginine (L-NMMA), Tetraethylammonium (TEA), fluconazole, bradykinin, sodium nitroprusside and acetylcholine
3320537|NCT00166114|Active Comparator|Escitalopram|
3320538|NCT00166114|Active Comparator|Desipramine|
3320539|NCT00166088|Experimental|Mediterranean Diet Arm|
3320540|NCT00166088|Active Comparator|Mediterranean Dietary Supplement Arm|
3320541|NCT00166088|No Intervention|Control Arm|
3320542|NCT00166075||Female ED patients|All eligible African American female patients were approached in the ED waiting room during study periods. Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
3320543|NCT00166049|Placebo Comparator|Usual Care Attention Control|Usual care with provision of supplemental printed educational material on HF self care
3320544|NCT00166049|Experimental|Group 2 Patient Family Education PFE|Patient Family Education PFE Heart Failure Patients and family member dyads were provided with an educational and counseling session, and attended a 2 hour patient-family education session on heart failure self management with emphasis on dietary sodium and medication taking behaviors.
3320545|NCT00166049|Experimental|Group 3 Family Partnership Intervention|Patient and family member received one individual dyadic education/counseling session, and two group sessions focused on developing family approaches to HF self management. the emphasis of the two group sessions was on developing autonomy supportive approaches to family support.
3320546|NCT00166036|Experimental|Atorvastatin 10MG|
3320547|NCT00166036|Experimental|Pravastatin 80mg|
3320548|NCT00166010|Experimental|Nesiritide|
3320549|NCT00165958|Experimental|Punch excision|
3320550|NCT00165958|Active Comparator|Traditional excision|
3320551|NCT00165919||HCV+|No group or cohort; not a clinical trial
3320552|NCT00165841|Placebo Comparator|Placebo|
3320553|NCT00165841|Experimental|Rabeprazole 20 mg|
3320554|NCT00165828|Experimental|1|
3320555|NCT00165828|Experimental|2|
3320556|NCT00165802|Experimental|1|
3320557|NCT00165763|Experimental|1|
3320558|NCT00165750|Experimental|1|
3320559|NCT00165698|Active Comparator|1|
3320560|NCT00165698|Active Comparator|2|
3320561|NCT00165672|Experimental|1|
3320562|NCT00165672|Experimental|2|
3320563|NCT00165646|Experimental|1|
3320564|NCT00165646|Experimental|2|
3320565|NCT00165646|Placebo Comparator|3|
3320566|NCT00165633|Experimental|1|
3320567|NCT00165633|Experimental|2|
3320568|NCT00165633|Placebo Comparator|3|
3320569|NCT00165542||All patients|A PROTEIN levels in all patients and with all tumor types.
3320679|NCT00162656|Active Comparator|Standard LMB B|
3320570|NCT00165503|Experimental|Surgery+Heated Cisplatin+Sodium Thiosulfate+Adjuvant CT|Participants undergo surgery, Pleurectomy/Decortication, followed by heated cisplatin given as a one-hour lavage of the chest and abdominal cavity then sodium thiosulfate given intravenously over 6 hours. The adjuvant chemotherapy regimen beginning 6-10 weeks after surgery is a combination of cisplatin and Alimta each given day 1 of a 21-day cycle for 3 cycles.
3320571|NCT00165425|Experimental|Cardiac screening|"Interventions:~Participants will~meet with study cardiologist~undergo cardiac risk factors screening~undergo resting and stress echocardiogram (echo and stress echo)"
3320572|NCT00165308|Experimental|Tamoxifen|Single arm: Tamoxifen 20mg daily
3320573|NCT00165282|No Intervention|Usual Care|Normal standard of care
3320574|NCT00165282|Active Comparator|Nurse education|Meets with oncology nurse
3320575|NCT00165282|Experimental|Mindfulness training|Taught Mindfulness meditation
3320576|NCT00165256||Observation (omission of RT)|Wide excision of DCIS; no radiotherapy (RT).
3320577|NCT00165178|Experimental|Individualized ASP dose|
3320578|NCT00165178|Active Comparator|Fixed dose ASP|
3320579|NCT00165178|Experimental|Dexamethasone|
3320580|NCT00165178|Active Comparator|Prednisone|
3320581|NCT00165152|Active Comparator|Genetic Counseling|
3320582|NCT00165152|Active Comparator|Informed Consent Counseling|
3320583|NCT00165035|Experimental|1|CoStar™ Paclitaxel-Eluting Coronary Stent, a reservoir based DES
3320584|NCT00165035|Active Comparator|2|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
3320585|NCT00165009|No Intervention|DUAL THERAPY|DUAL THERAPY
3320586|NCT00165009|Experimental|'Resolution clip|'Resolution clip
3320587|NCT00164944||FDR of CRC patient|First degree relatives of patients having CRC
3320588|NCT00164944||FDR of normal colonoscopy|First degree relatives of patients having normal colonoscopy
3320589|NCT00164905|Active Comparator|Doppler ultrasound|
3320590|NCT00164905|No Intervention|No Doppler ultrasound|
3320591|NCT00164853|Active Comparator|Standard sphincterotomy (ES)|After deep cannulation, a pull-type sphincterotomy will be performed with a 25mm sphincterotome (eg clever cut, Olympus, Tokyo, Japan) with division of sphincter up to the duodenal wall. A complete sphincterotomy is defined by the free passage of a fully bowed sphincterotome with a 25m wire and spontaneous bile drainage.
3320592|NCT00164853|Active Comparator|Sphincterotomy plus balloon dilation (ESBD)|After complete sphincterotomy, a 3-cm long 15mm diameter CRE balloon is passed over a guidewire across the lower end of common bile duct. The contrast filled balloon is inflated to the size of the bile duct for around 30 seconds until waisting is abolished.
3320593|NCT00164788|Active Comparator|IV Nexium|Intravenous bolus injection of esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
3320594|NCT00164788|Active Comparator|Oral Nexium|Oral esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 40mg every 12 hours for 24 hours
3320595|NCT00164775|Active Comparator|Imipramine|Imipramine 25mg nocte for first 2 weeks then Imipramine 50 mg nocte for 10 weeks
3320596|NCT00164775|Placebo Comparator|Placebo|Placebo 1 tablet for first 2 weeks then Placebo 2 tablets for 10 weeks
3320597|NCT00164749|Placebo Comparator|Placebo|Color-matched placebo
3320598|NCT00164749|Experimental|1 gram|1 g/day curcumin
3320599|NCT00164749|Experimental|4 gram|4 g/day curcumin
3320600|NCT00164736|Active Comparator|Maternal ARVs & Nutrition Supplement|Extended maternal ARVs for prophylaxis (for the infant) & daily nutritional supplement given to the mother
3320601|NCT00164736|Active Comparator|Infant NVP & Nutrition Supplement|Extended infant nevirapine for prophylaxis & daily nutritional supplment given to the mother
3320602|NCT00164736|Active Comparator|Maternal ARVs & No Nutrition Supplement|Extended maternal ARVs for prophylaxis (for the infant) & no nutritional supplement given to the mother
3320603|NCT00164736|Active Comparator|Infant NVP & No Nutrition Supplement|Extended infant nevirapine for prophylaxis & no nutritional supplment given to the mother
3320604|NCT00164736|Active Comparator|No Drugs & Nutrition Supplement|"No extended maternal ARV prophylaxis nor infant nevirapine prophylaxis & daily nutritional supplement given to the mother.~Note: As of March 2008, the third arm of the antiretroviral intervention, in which neither mother nor infant received drugs beyond enhanced standard of care, was stopped based on recommendations of a Data and Safety Monitoring Board review of interim efficacy results and safety data after 77% participants had received treatment assignment."
3320605|NCT00164736|No Intervention|No Drugs & No Nutrition Supplement|"No extended maternal ARV prophylaxis nor infant nevirapine prophylaxis & no nutritional supplement given to the mother.~Note: As of March 2008, the third arm of the antiretroviral intervention, in which neither mother nor infant received drugs beyond enhanced standard of care, was stopped based on recommendations of a Data and Safety Monitoring Board review of interim efficacy results and safety data after 77% participants had received treatment assignment."
3320606|NCT00164723|Other|NSAID|patients taking NSAID will undergo capsule endoscopy
3320607|NCT00164723|Other|Aspirin|patients taking Aspirin will undergo capsule endoscopy
3320608|NCT00164723|Other|Non-user|patients didn't take NSAID or ASA will undergo capsule endoscopy
3320609|NCT00164697|Experimental|1|Parenting group
3320610|NCT00164697|No Intervention|2|"Families in this usual care comparison group were not prevented from utilizing any service that would otherwise be available to them, even if the service was similar to the services received in the intervention arm of the study."
3320611|NCT00164619|Experimental|1|Standard STD clinic services and the VOICES/VOCES intervention
3320612|NCT00164619|Active Comparator|2|Standard STD clinic services
3320613|NCT00164515|No Intervention|Arm 1: Physical activity awareness|The awareness group received a physician-recommendation to exercise an informational brochure, and pedometer.
3320614|NCT00164515|Experimental|Arm 2: Lower Support|The lower support group received arm 1 plus monthly newsletter, weekly personalized exercise support via telephone.
3320615|NCT00164515|Experimental|Arm 3: Higher support|The higher support group received arm 1 plus arm 2 plus a face-to-face monthly exercise support group.
3320616|NCT00164463|Experimental|Moxifloxacin|Moxifloxacin 400 mg po qd given 5 of 7 days per week
3320617|NCT00164463|Active Comparator|Isoniazid|Isoniazid 300 mg po qd given 5/7 days per week
3320618|NCT00164281|Experimental|Continuous vs limited isoniazid|The placebo arm will receive 6 months of open label isoniazid before beginning placebo (as a coded medication). The treatment (experimental arm) will receive 6 months of open label isoniazid before beginning coded medication (isoniazid).
3320619|NCT00164203|Experimental|Cognitive Behavioral Therapy|School-based, 12-session protocol, weekly
3320620|NCT00164203|Active Comparator|activity control condition|Structured games and activities, weekly for 12 weeks
3320621|NCT00164138|Experimental|Pelvic Floor Training Group|Pelvic floor training, biofeedback.
3320622|NCT00164021||Cystic Fibrosis|Patients with cystic fibrosis
3320623|NCT00164021||Control|
3320624|NCT00163865||Clinical Group|clinical adolescent group
3320625|NCT00163865||Community Group|community adolescent group
3320626|NCT00163826||Trauma Patients|Major trauma patients
3320627|NCT00163761|Active Comparator|Commence VGF treatment|Drug. Vinorelbine, gemcitabine and filgrastim 21 day cycle
3320628|NCT00163761|Active Comparator|Commence F-GIV treatment|Drug. Gemcitabine, ifosfamide, Vinorelbine and filgrastim 21 day cycle
3320629|NCT00163722|Active Comparator|Standard diagnostic strategy of culture and histology|The standard-diagnostic strategy was designed to be consistent with the 2002 guidelines for antimicrobial use in neutropenic patients with cancer. When an invasive fungal infection was suspected (e.g. persistent fevers) cultures of blood, urine, sputum (if available) and faeces (if clinically indicated), and HRCT scans of chest were performed. Bronchoscopy and biopsies were performed according to institutional protocols. Empiric antifungal therapy was recommended whilst undergoing these investigations and was continued, de-escalated to prophylaxis, or changed to treatment of invasive aspergillosis or other IFD according to test results.
3320630|NCT00163722|Experimental|Aspergillus galactomannan and PCR directed|Results of once to twice weekly testing with Aspergillus galactomannan and PCR directed the timing of CT scan performance and whether antifungal therapy was given
3320631|NCT00163670||Motor vehicle accident|
3320632|NCT00163670||Control|
3320633|NCT00163657|Active Comparator|tacrolimus and cyclosporine|immunosuppressant treatment regimens the intervention is antirejection treatment with the above labeled drugs tacrolimus and cyclosporine
3320634|NCT00163657|Active Comparator|MMF, tacrolimus and cyclosporine|immunosuppressant treatment regimensthe intervention is antirejection treatment with the above labeled drugs MMF tacrolimus and cyclosporine
3320635|NCT00163657|Active Comparator|daclizumub, MMFand tacrolimus|immunosuppressant treatment regimens
3320636|NCT00163644|Active Comparator|Aerobic exercise plus resistance|Aerobic exercise plus resistance exercise for 6 weeks
3320637|NCT00163644|Active Comparator|Aerobic exercise|Aerobic exercise for 6 weeks
3320638|NCT00163644|Other|Control|No formal exercise and weekly phone calls
3320639|NCT00163566|Placebo Comparator|Placebo gel|Placebo gel twice per day
3320640|NCT00163566|Active Comparator|0.7% DHT gel, Dose 1|0.7% DHT gel twice per day, 35 mg/day
3320641|NCT00163566|Active Comparator|0.7% DHT gel, Dose 2|0.7% DHT gel twice per day, 70 mg/day
3320642|NCT00163553|Experimental|P|Epidural pethidine group
3320643|NCT00163553|Placebo Comparator|N|placebo group
3320644|NCT00163449|Active Comparator|1|Ciclesonide 40 µg
3320645|NCT00163449|Active Comparator|2|Ciclesonide 80 µg
3320646|NCT00163449|Active Comparator|3|Ciclesonide 160 µg
3320647|NCT00163449|Placebo Comparator|4|Placebo
3320648|NCT00163293|Placebo Comparator|Placebo|
3320649|NCT00163293|Active Comparator|Ciclesonide 100 µg|Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.
3320650|NCT00163293|Active Comparator|Ciclesonide 200 µg|Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.
3320651|NCT00163280|Experimental|1|ATL-104 50mg
3320652|NCT00163280|Experimental|2|ATL-104 100mg
3320653|NCT00163280|Experimental|3|ATL-104 150mg
3320654|NCT00163280|Placebo Comparator|4|Placebo
3320655|NCT00163267|Placebo Comparator|ASS + Placebo|control arm
3320656|NCT00163267|Active Comparator|ASS + Plavix|active drug
3320657|NCT00163215|Experimental|Somatropin|
3320658|NCT00163189|Experimental|Somatropin|
3320659|NCT00163137|Experimental|Lasofoxifene 0.25 mg|lasofoxifene 0.25 mg/day
3320660|NCT00163137|Active Comparator|raloxifene|raloxifene 60 mg/day
3320661|NCT00163137|Placebo Comparator|Placebo|Placebo
3320662|NCT00163046|Experimental|Gabapentin|
3320663|NCT00163046|Placebo Comparator|Placebo|
3320664|NCT00163020|Active Comparator|1 Test Group (170HP)|Test Group will receive weekly doses of 170HP via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
3320665|NCT00163020|Placebo Comparator|2 - Control (Normal Saline)|Control Group will receive weekly doses of placebo (NS) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
3320666|NCT00162981|Experimental|Clobazam Low Dose|
3320667|NCT00162981|Experimental|Clobazam High Dose|
3320668|NCT00162955|Experimental|ARB administration|80mg/day from the day of the start of 1st CHOP until the completion of all the evaluations
3320669|NCT00162955|No Intervention|non-administration|ARB non-administration group
3320670|NCT00162942|Active Comparator|Adacolumn|Adacolumn, ten apheresis sessions within 9 weeks
3320671|NCT00162942|Sham Comparator|Sham|Sham, ten apheresis sessions within 9 weeks
3320672|NCT00162916|Placebo Comparator|1|
3320673|NCT00162916|Experimental|2|
3320674|NCT00162890||Patient with degenerative cervical disease|
3320675|NCT00162773|Placebo Comparator|Placebo|water injection
3320676|NCT00162773|Experimental|Omalizumab|"Other Names:~Xolair 150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE."
3320677|NCT00162682|Active Comparator|1|* VL-S, the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
3320678|NCT00162682|Experimental|2|CD4-S, the alternative CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
3320680|NCT00162656|Experimental|LMB B without COPADM3|
3320681|NCT00162656|Experimental|LMB B with half cyclophosphamide|
3320682|NCT00162656|Experimental|LMB B without COPADM3 and with half cyclophosphamide|
3320683|NCT00162656|Active Comparator|LMB C standard|
3320684|NCT00162656|Experimental|LMB C with mini CYVE and without 3 maintenance courses|
3320685|NCT00162565|Experimental|1|bbloquant treatment
3320686|NCT00162552|Active Comparator|1|Patients with severe cirrhosis treated with Pentoxifylline
3320687|NCT00162552|Placebo Comparator|2|Patients with severe cirrhosis treated with a placebo
3320688|NCT00162474|Experimental|Warfarin|
3320689|NCT00162461|Experimental|Phenytoin|
3320690|NCT00162448|Experimental|A1|
3320691|NCT00162448|Placebo Comparator|A2|
3320692|NCT00162435|Experimental|Genetic|
3320693|NCT00162435|Experimental|Control|
3320694|NCT00162383|Experimental|Cocktail|
3320695|NCT00162370|Experimental|Definity|All patients will undergo a gray scale baseline unenhanced imaging session (apical 2- or 4 chamber view), as well as a DEFINITY (Perflutren Lipid Microsphere Injectable Suspension)-enhanced rest and a DEFINITY enhanced exercise or dobutamine stress echocardiography imaging session. The unenhanced and DEFINITY-enhanced rest and stress echocardiography imaging sessions will be performed on the same day. For the DEFINITY-enhanced imaging sessions all patients will receive diluted DEFINITY intravenously (IV). Diluted DEFINITY will be prepared by mixing 1 mL of activated DEFINITY® with 9 mL of normal saline in a 10 mL syringe.
3320696|NCT00162318|Experimental|A|
3320697|NCT00162305|Active Comparator|1|
3320698|NCT00162305|Active Comparator|2|
3320699|NCT00162305|Active Comparator|3|
3320700|NCT00162305|Placebo Comparator|4|
3320701|NCT00162266|Experimental|Abatacept (10 mg/Kg) - Open Label|
3320702|NCT00162266|Experimental|Abatacept (2 mg/kg) - Double blind|
3320703|NCT00162266|Experimental|Abatacept (10 mg/kg) - Double blind|
3320704|NCT00162266|Experimental|Placebo - Double blind|
3320705|NCT00162214|Active Comparator|1|
3320706|NCT00162201|Experimental|1|
3320707|NCT00162149|No Intervention|A1|
3320708|NCT00162149|Experimental|A2|
3320709|NCT00162149|Experimental|A3|
3320710|NCT00162149|No Intervention|B1|
3320711|NCT00162136|Experimental|A1|
3320712|NCT00162123|Experimental|First reinduction: Ipilimumab, 0.3 to 10 mg/kg|Participants who initially received ipilimumab, 0.3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
3320713|NCT00162123|Experimental|First reinduction: Ipilimumab, 3 to 10 mg/kg|Participants who initially received ipilimumab, 3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
3320714|NCT00162123|Experimental|First reinduction: Ipilimumab, 10 to 10 mg/kg|Participants who initially received ipilimumab, 10 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
3320715|NCT00162123|Experimental|Extended maintenance: Ipilimumab, 0.3 mg/kg|Participants who received ipilimumab, 0.3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (0.3 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
3320716|NCT00162123|Experimental|Extended maintenance: Ipilimumab, 3 mg/kg|Participants who received ipilimumab, 3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (3 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
3320717|NCT00162123|Experimental|Extended maintenance: Ipilimumab, 10 mg|Participants who received ipilimumab, 10 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (10 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
3320718|NCT00162123|No Intervention|Follow-up|Participants did not receive any additional study treatment in current study but continued follow-up for the collection of survival data.
3320719|NCT00162110|Active Comparator|1|
3320720|NCT00162097|Experimental|EFV600mg Participants With Mild Hepatic Impairment|
3320721|NCT00162097|Experimental|EFV600mg Participants With Moderate Hepatic Impairment|
3320722|NCT00162097|Experimental|EFV600mg Participants With Severe Hepatic Impairment|
3320723|NCT00162097|Active Comparator|EFV600mg Participants With Normal Hepatic Function|
3320724|NCT00162032|Other|Children (Ages 4-11)|Children 4-11 years of age, intervention Sestamibi
3320725|NCT00162032|Other|Adolescents (Ages 12-16)|Adolescents 12-16 years of age, intervention Sestamibi
3320726|NCT00161616|Active Comparator|A|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage +surgical fixation
3320727|NCT00161616|Other|B|Standard of Care: Surgical fixation only
3320728|NCT00161577|Other|A|Group A = Ketorolac
3320729|NCT00161577|Placebo Comparator|B|
3320730|NCT00161486|Placebo Comparator|1|Placebo acyline injections every two weeks (2 doses) + placebo testosterone gel daily for 4 weeks
3320731|NCT00161486|Active Comparator|2|Acyline 300 μg/kg every two weeks (2 doses) + placebo Testosterone gel daily for 4 weeks
3320732|NCT00161486|Active Comparator|3|Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks + Testosterone gel 100 mg daily for 4 weeks
3320733|NCT00161473|Active Comparator|prazosin|
3320734|NCT00161473|Placebo Comparator|placebo (inert substance)|
3320735|NCT00161460|Active Comparator|1|Study nurse contacts subjects who enroll in the intervention to provide detailed education about screening tests, to assess their risk for colorectal cancer, and to facilitate screening.
3320736|NCT00161460|No Intervention|2|Patients who do not enroll receive usual care from their primary care providers.
3320737|NCT00161447|Active Comparator|1|Testosterone (T) gel for 6 months + DMPA (injected into muscle once)on Day 0 and at Month 3
3320738|NCT00161447|Active Comparator|2|Testosterone (T) gel for 6 months + DMPA (injected into muscle on Day 0 & at month 3) + Acyline (SQ) every two weeks for the first 12 weeks
3320739|NCT00161434|Experimental|1|
3320740|NCT00161434|Placebo Comparator|2|
3320741|NCT00161421|Experimental|1|Lupron injection at Day -14 with load of dutasteride (24.5 mg) followed by 13 days of Dutasteride. On day 0, 11, 0.5 mg Dutasteride taken daily for next 11 days. Day 1 Oral Testosterone (T) 200mg without food, Day 2 Oral T 400 mg without food, Day 3 Oral T 400 mg with food. During the 2nd week of the study, we will repeat the testosterone doses, with a 2nd formulation of testosterone (Day8, 9, & 10.
3320742|NCT00161395|Active Comparator|1|Preconception advice.
3320743|NCT00161395|Experimental|2|Instruction in the Creighton Model Fertility Care System.
3320744|NCT00161382|Experimental|Intervention Group|HIV, STD, and pregnancy prevention curriculum
3320745|NCT00161382|Experimental|Control Group|Standard sexual education curriculum
3320746|NCT00161343|Experimental|1|Small interactive groups on preventing HIV infections using an Information-Behavioral Skills-Motivational model
3320747|NCT00161343|Placebo Comparator|2|Small interactive groups on general health-promotion topics using an Information-Behavioral Skills-Motivational model
3320748|NCT00161265||1|women with breast cancer
3320749|NCT00161213|Experimental|Gemcitabine and Imatinib|
3320750|NCT00161187|Experimental|Treatment|Biological/Vaccine: therapeutic allogeneic lymphocytes The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
3320751|NCT00160979|Experimental|hypoxia and RT in prostate cancer|
3320752|NCT00160966|Active Comparator|1|Immunosuppression with Ciclosporin and Mycophenolate-mofetil; Ciclosporin treatment being started at the latest at day 4 after transplantation with 7 mg/kg body weight daily administered every 8 hours until the target trough level of 300 µg/l was reached. Then it was administered twice daily with daily monitoring of trough levels. The target trough level was lowered to 200 µg/l 1 month after transplantation. Thereafter dosage and target trough levels were adjusted at the investigators discretion. Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once ciclosporin was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted at the investigators discretion.
3320753|NCT00160966|Active Comparator|2|Immunosuppression with Tacrolimus and Mycophenolate-mofetil Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once tacrolimus was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted to clinical signs of overimmunosuppression (infections) or intolerance (mainly gastrointestinal side effects) or rejections.
3320754|NCT00160966|Active Comparator|3|Immunosuppression with Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus after completion of posttransplant wound healing
3320755|NCT00160875|Experimental|Cisplatin, Irinotecan|
3320756|NCT00160784|Active Comparator|Arthroscopic Manipulation|Manipulation of Shoulder performed during arthroscopy
3320757|NCT00160784|Active Comparator|Home exercise program|Shoulder exercise program performed at home to increase shoulder function
3320758|NCT00160771||Joint Motion Analysis|Joint motion will be recorded for analysis.
3320759|NCT00160732|Experimental|Transplant|
3320760|NCT00160706|Experimental|Certolizumab Pegol|3-dose induction regimen of Certolizumab Pegol 400 mg at Weeks 0, 2, 4. Subsequently continue on 4-weekly treatment with Certolizumab Pegol 400 mg until Week 360.
3320761|NCT00160693|Experimental|Certolizumab Pegol|
3320762|NCT00160667|Placebo Comparator|Placebo|Matching placebo tablets administered twice a day
3320763|NCT00160667|Experimental|Brivaracetam 200 mg/day|Brivaracetam 200 mg/day (100 mg administered twice a day)
3320764|NCT00160667|Experimental|Brivaracetam 400 mg/day|Brivaracetam 400 mg/day (200 mg administered twice a day)
3320765|NCT00160641|Experimental|Certolizumab Pegol|All patients received Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) every two weeks, given as two 1 ml injections of CZP for at least six months and then 200 mg of CZP sc every two weeks, given as one 1 ml injection.
3320766|NCT00160563|Experimental|LCTZ-LCTZ|Levocetirizine after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ-LCTZ)
3320767|NCT00160563|Placebo Comparator|LCTZ-PLC|Placebo after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ - PLC)
3320768|NCT00160563|Placebo Comparator|PLC-PLC|Placebo after having been randomized to Placebo in the preceding A00309 trial - NCT00152464 (PLC-PLC)
3320769|NCT00160524|Experimental|Certolizumab Pegol|400 mg subcutaneous injection every 4 weeks from Week 2 to Week 362.
3320770|NCT00160485|Experimental|1|Glyburide,gestational diabetes, maternal complications, neonatal complications
3320771|NCT00160485|Active Comparator|2|Insulin, gestational diabetes, maternal complications, neonatal outcomes
3320772|NCT00160459|Experimental|1|
3320773|NCT00160459|Experimental|2|
3320774|NCT00160459|Experimental|3|
3320775|NCT00160459|Placebo Comparator|4|
3320776|NCT00160446|Experimental|1|
3320777|NCT00160446|Experimental|2|
3320778|NCT00160446|Experimental|3|
3320779|NCT00160446|Placebo Comparator|4|
3320780|NCT00160433|Experimental|1|
3320781|NCT00160433|Experimental|2|
3320782|NCT00160433|Experimental|3|
3320783|NCT00160433|Placebo Comparator|4|
3320784|NCT00160420|Experimental|1|
3320785|NCT00160381|Experimental|1|
3320799|NCT00160290|Experimental|A|Lactulose Group
3320800|NCT00160290|Active Comparator|B|Plantago Group
3320801|NCT00160251|Active Comparator|Arm 1A: PegIntron (PEG) + Ribavirin (RBV)|A single dose of PEG is given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA is undetected, PEG + RBV will continue for another 36 weeks.
3320802|NCT00160251|Active Comparator|Arm 1B: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400|A single dose of PEG is given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA is detectable, BOC 400 mg TID will be added for 36 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
3320803|NCT00160251|Experimental|Arm 2: PegIntron (PEG) + Boceprevir (BOC) 100 (48 weeks)|A single dose of PEG is given first, followed 1 week later by PEB + BOC 100 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
3320804|NCT00160251|Experimental|Arm 3: PegIntron (PEG) + Boceprevir (BOC) 200 (48 Weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 200 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
3320805|NCT00160251|Experimental|Arm 4: PegIntron (PEG) + Boceprevir (BOC) 400 (48 weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 400 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
3320806|NCT00160251|Experimental|Arm 5: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400|A single dose of PEG is given first, followed 1 week later by PEG + RBV + BOC 400 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
3320807|NCT00160251|Experimental|Arm 6: PegIntron (PEG) + Boceprevir (BOC) 400 (24 Weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 400 for 24 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
3320808|NCT00160251|Experimental|Arm 7: PegIntron (PEG) + Boceprevir (BOC) 800|By first protocol amendment to P03659, this non-randomized arm is added. A single dose of PEG is given first, followed 1 week later by PEG + BOC 800 for 24 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
3320809|NCT00160251|Experimental|Arm 8: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 800|By second protocol amendment to P03659, participants from all arms except Arm 1A will be rolled over into PEG + RBV + BOC 800 for the remainder of the treatment period.
3320810|NCT00160199|Experimental|1|
3320811|NCT00160199|Active Comparator|2|
3320812|NCT00160186|Experimental|1|
3320813|NCT00160186|Placebo Comparator|2|
3320814|NCT00160147|Experimental|1|
3320815|NCT00160147|Placebo Comparator|2|
3320816|NCT00160069|Experimental|Arm 1|
3320817|NCT00160069|Experimental|Arm 2|
3320818|NCT00160069|Experimental|Arm 3|
3320819|NCT00160056|Other|Hypoglycemia|Intrerfvention is a hypoglycemic stimulus
3320820|NCT00160043|Experimental|Arm 1|
3320821|NCT00160043|Experimental|Arm 2|
3320822|NCT00160030|Experimental|1|
3320823|NCT00160030|Active Comparator|2|
3320824|NCT00160017||Collaborative group|Participants (i.e. profesionals) participate in a Breakthrough Collaborative intervention to improve diabetes care so that patients are provided more often with diabetes care as described in guidelines
3320825|NCT00160017||usual care group|Participants are offered no intervention and care is provided as usual
3320826|NCT00159991|Experimental|A|Total arterial revascularization
3320827|NCT00159991|Active Comparator|B|Conventional revascularization
3320828|NCT00159965|Active Comparator|sertraline|flexible dose sertraline, 25 to 200mg titration as tolerated, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES
3320829|NCT00159965|Placebo Comparator|placebo|flexible dose placebo, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES
3320830|NCT00159952|Active Comparator|1|
3320831|NCT00159939|Active Comparator|prone position|prone positioning
3320832|NCT00159939|No Intervention|supine position|
3320833|NCT00159926|Experimental|1|With cell saver
3320834|NCT00159926|Active Comparator|2|Without cell saver
3320835|NCT00159913|Experimental|Sildenafil Low dose|
3320836|NCT00159913|Experimental|Sildenafil Medium dose|
3320837|NCT00159913|Experimental|Sildenafil High dose|
3320838|NCT00159913|Placebo Comparator|Placebo|
3320839|NCT00159874|Experimental|Sildenafil high dose|As per Protocol Amendment 8 (Aug 2011), all doses in the high dose treatment group were discontinued. Subjects who were receiving these doses and continued in the study were requested to down titrate.
3320840|NCT00159874|Experimental|Sildenafil Low dose|
3320841|NCT00159874|Experimental|Sildenafil medium dose|As per Protocol Amendment 8 (August 2011), the dose 40 mg TID in the medium dose treatment group was discontinued. Subjects who were receiving this dose and continued in the study were requested to down titrate.
3320842|NCT00159822|Experimental|1|
3320843|NCT00159796|Experimental|Arm 1|Asenapine
3320844|NCT00159796|Active Comparator|Arm 2|Olanzapine
3320845|NCT00159796|Placebo Comparator|Arm 3|Placebo
3320846|NCT00159783|Experimental|Asenapine|Asenapine 5-10 mg twice daily for 40 weeks
3320847|NCT00159783|Active Comparator|Olanzapine|Olanzapine 5-20 mg once daily for 40 weeks
3320848|NCT00159744|Active Comparator|Arm 1|Asenapine
3320849|NCT00159744|Active Comparator|Arm 2|Olanzapine
3320850|NCT00159744|Placebo Comparator|Arm 3|Placebo
3320851|NCT00159601||outpatients in Child and Adolescent Mental Health Service|
3320852|NCT00159601||youth from general population|
3320853|NCT00159588|Active Comparator|1|Use of preventive drugs from the start without abrupt withdrawal
3320854|NCT00159588|No Intervention|2|Device: Abrupt withdrawal
3320855|NCT00159588|No Intervention|3|Active control: No instruction for abrupt withdrawal or prophylactic treatment
3320856|NCT00159575|Experimental|M: Metformin P: Placebo|
3320857|NCT00159562|Experimental|group education|Bipolar 1 and 2 patients in a stable euthymic phase will receive group education in 10 weekly sessions and then a session every third month for two years. Symptoms, admittances to hospital and function will be followed for two years.
3320858|NCT00159562|Active Comparator|individual education|Bipolar 1 and 2 patients in a stable euthymic phase will receive three individual sessions of education.
3320859|NCT00159536|Experimental|Metformin|Metformin 1000mg x 2 daily
3320860|NCT00159536|Placebo Comparator|placebo|Placebo x 2 daily
3320861|NCT00159523|Experimental|probiotic|
3320862|NCT00159523|Placebo Comparator|placebo|
3320863|NCT00159510|No Intervention|Control|The control group with neither nitric oxide nor methylene blue used
3320864|NCT00159510|Active Comparator|MB alone|Single methylene blue used
3320865|NCT00159510|Active Comparator|NO alone|Nitric oxide alone used
3320866|NCT00159510|Active Comparator|MB+NO|Both nitric oxide and methylene blue used
3320867|NCT00159497|Active Comparator|1|Standard porouscoated Trilogy Cup
3320868|NCT00159497|Experimental|2|HA coated Trilogy cup
3320869|NCT00159484|Experimental|A|EPO906, celecoxib
3320870|NCT00159432|Experimental|Oxaliplatin, followed by Bevacizumab with Capecitabine|oxaliplatin 85 mg/m2 q 14 days, followed by bevacizumab 5 mg/kg q 14 days, with capecitabine 750 mg/m2 bid daily
3320871|NCT00159419|Active Comparator|Alendronate|1 mg/kg po qd rounded to nearest 10 or 20 mg dose
3320872|NCT00159419|Active Comparator|Pamidronate|3 mg/kg IV q4 months
3320873|NCT00159406||cohort|Registry and Database
3320874|NCT00159289|Experimental|1|Inhalation of LPS
3320875|NCT00159289|Placebo Comparator|2|PLacebo
3320876|NCT00159224|Experimental|Lopinavir/ritonavir monotherapy|Patients with undetectable viral load while on 1st line ARV therapy will be randomized to the expermental arm: Lopinavir/ritonavir monotherapy
3320877|NCT00159224|Active Comparator|Lopinavir/Ritonavir plus 2 NRTIs|Patients randomized to this arm will continue with standard of care triple therapy, based on Lopinavir/Ritonavir plus 2 NRTIs
3320878|NCT00159211|Active Comparator|1|UMULINE NPH at bed time
3320879|NCT00159211|Experimental|2|pioglitazone 30 mg
3320880|NCT00159198||1|Patients with frontotemporal dementia and amyotrophic lateral sclerosis
3320881|NCT00159198||2|Relatives (first and second degree) of patients presenting an association of frontotemporal dementia with amyotrophic lateral sclerosis
3320882|NCT00159146|Active Comparator|A|Venlafaxine and pindolol
3320883|NCT00159146|Placebo Comparator|B|Venlafaxin and placebo
3320884|NCT00159133|Experimental|1|Early intervention with benzodiazepines in case of prodromal symptoms of an impending relapse
3320885|NCT00159133|Active Comparator|2|Early intervention with antipsychotics in case of prodromal symptoms of an impending relapse
3320886|NCT00159120|Active Comparator|1|further maintenance antipsychotic treatment and prodrome-based early intervention
3320887|NCT00159120|Experimental|2|stepwise drug discontinuation (after 1 year maintenance antipsychotic treatment) and prodrome-based early intervention
3320888|NCT00159107|Experimental|2|Placebo +Integrative behavior therapy
3320889|NCT00159107|Experimental|3|Acamprosate + treatment as usual
3320890|NCT00159107|Experimental|1|Acamprosate + Integrative behavior therapy
3320891|NCT00159081|Experimental|1|Maintenance antipsychotic treatment with risperidone
3320892|NCT00159081|Active Comparator|2|Maintenance antipsychotic treatment with haloperidol in low-dose
3320893|NCT00158925|Experimental|EASYTRAK EPI Lead|Subjects in this arm will be implanted or attempted with the EASYTRAK EPI lead.
3320894|NCT00158886|Experimental|Subjects with rectal cancer|Subjects will be administered topotecan along with concomitant radiation for five days per week for five weeks. Topotecan doses will start at 0.25 milligrams per square meter (mg/m˄2) and will be escalated 0.15 mg/m˄2 for subsequent cohorts. To advance to the next dose level of topotecan, at least two subjects will have to complete therapy with oral topotecan without experiencing grade 3 or 4 toxicity for three weeks after the oral topotecan treatment.
3320895|NCT00158860|Experimental|Arm 1|
3320896|NCT00158782|Experimental|Cohort 1|Subjects will receive GW786034 500 milligrams and lapatinib 750 milligrams.
3320897|NCT00158782|Experimental|Cohort 2|Subjects will receive GW786034 250 milligrams and lapatinib 750 milligrams.
3320898|NCT00158782|Experimental|Cohort 3|Subjects will receive GW786034 250 milligrams and lapatinib 1000 milligrams.
3320899|NCT00158782|Experimental|Cohort 4|Subjects will receive GW786034 500 milligrams and lapatinib 1000 milligrams.
3320900|NCT00158782|Experimental|Cohort 5|Subjects will receive GW786034 250 milligrams and lapatinib 1250 milligrams.
3320901|NCT00158782|Experimental|Cohort 6|Subjects will receive GW786034 400 milligrams and lapatinib 1250 milligrams.
3320902|NCT00158782|Experimental|Cohort 7|Subjects will receive GW786034 200 milligrams and lapatinib 1500 milligrams.
3320903|NCT00158782|Experimental|Cohort 8|Subjects will receive GW786034 400 milligrams and lapatinib 1500 milligrams.
3320904|NCT00158782|Experimental|Cohort 9|Subjects will receive GW786034 400 milligrams and lapatinib 1000 milligrams.
3320905|NCT00158782|Experimental|Cohort 10|Subjects will receive GW786034 800 milligrams and lapatinib 1500 milligrams.
3320906|NCT00158769|Experimental|Subjects with moderate hepatic impairment|Subjects with moderate hepatic impairment as defined by a Child-Pugh score of 7-9 will be included. Subjects will be given GR270773 as a loading infusion of 25 milligram per kilogram per hour (mg/kg/hr) for 2 hours followed by a maintenance infusion of 5 mg/kg/hr for 70 hours.
3320907|NCT00158769|Experimental|Healthy subjects|Subjects will be matched as closely as possible to the group of moderate hepatic subjects for gender, age and body mass index (BMI). Subjects will be administered 25 mg/kg/hr GR270773 as a loading dose for 2 hours followed by a maintenance infusion of 5 mg/kg/hr for 70 hours. Following a washout period of 21 days, the subjects will then receive a loading dose of 75 mg/kg/hr for 2 hours followed by a maintenance dose of 12.5 mg/kg/hr of GR270773 for 70 hours.
3320908|NCT00158756|Experimental|Tritanrix™-HepB+Rotarix™ Group|Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.
3320909|NCT00158756|Experimental|Tritanrix™-HepB+Placebo Group|Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.
3320910|NCT00158756|Active Comparator|Zilbrix™+Rotarix™ Group|Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.
3320911|NCT00158756|Active Comparator|Zilbrix™+Placebo Group|Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.
3320912|NCT00158756|Active Comparator|Triple Antigen™+Engerix™-B Group|Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.
3320913|NCT00158743|Active Comparator|Digoxin immune fab|Digibind treatment plus standard of care
3320914|NCT00158743|Placebo Comparator|placebo (sodium chloride)|
3320915|NCT00158678|Active Comparator|1|Conventional RT 70Gy + concomitant cisplatin
3320916|NCT00158678|Experimental|2|IMRT 75Gy + concomitant cisplatin
3320917|NCT00158665|Experimental|Subjects receiving vaccine|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine 4 weeks apart.
3320918|NCT00158652|Active Comparator|1|
3320919|NCT00158652|Experimental|2|
3320920|NCT00158652|Experimental|3|
3320921|NCT00158600|Active Comparator|alglucosidase alfa|Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
3320922|NCT00158600|Placebo Comparator|Placebo|Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.
3320923|NCT00158574|Placebo Comparator|Placebo|IPTi placebo
3320924|NCT00158574|Experimental|Sulphadoxine-pyrimethamine|IPTi SP
3320925|NCT00158574|Experimental|Mefloquine|
3320926|NCT00158574|Experimental|Chlorproguanil dapsone|
3320927|NCT00158522|Experimental|1|
3320928|NCT00158431|Active Comparator|Arthroscopy plus Medical Management|Arthroscopic Surgery of the Knee plus the optimized medical management including physiotherapy, education, medication, etc
3320929|NCT00158431|No Intervention|Medical Management|Optimized Medical management including physiotherapy, education, medication, etc
3320930|NCT00158379|Experimental|Paclitaxel|
3320931|NCT00158366|Experimental|1|Phase 1 participants who will receive behavioral training for 14 weeks
3320932|NCT00158366|Active Comparator|2|Phase 1 participants who will receive social skills training for 14 weeks
3320933|NCT00158366|Experimental|3|Participants in the Phase 1 behavioral training group who have a 4% or more weight loss and will be enrolled in weekly behavioral training alone for 24 months in Phase 2
3320934|NCT00158366|Experimental|4|Participants in the Phase 1 behavioral training group who have a 4% or more weight loss and will be enrolled in weekly behavioral training plus biweekly booster treatments for 24 months in Phase 2
3320935|NCT00158353|Experimental|1|GirlPOWER! mentoring program
3320936|NCT00158353|Active Comparator|2|Big Brothers Big Sisters community-based mentoring program
3320937|NCT00158340|Experimental|1|Participants will receive guided self-help cognitive behavioral therapy
3320938|NCT00158340|Active Comparator|2|Participants will receive treatment as usual
3320939|NCT00158327|Experimental|1|Participants will receive telephone-based collaborative care
3320940|NCT00158327|Active Comparator|2|Participants will receive usual care
3320941|NCT00158301|Experimental|1|Continuation phase cognitive behavioral therapy and drug therapy for 6 more months following acute treatment response
3320942|NCT00158301|Active Comparator|2|Continuation phase drug therapy only for 6 more months following acute treatment response
3320943|NCT00158275|Experimental|Integrated Intervention|Participants will receive cognitive behavioral therapy for back pain and antidepressants and/or problem solving therapy for depression. Study visits will initially occur once a week and then taper to once every 2 weeks for the 6-month duration.
3320944|NCT00158275|No Intervention|Standard of Care|Participants will receive care as usual from their health care provider.
3320945|NCT00158262|Experimental|Propranolol|Following the occurrence of an acute psychologically traumatic event, an initial dose of short-acting propranolol 40 mg orally then one hour later, long-acting propranolol 60 mg capsule orally on Day 1 followed by a 19-day course of long-acting propranolol starting with 120 mg every morning and evening for 10 days, and then tapering to 120 mg in the morning and 60 mg in the evening for 3 days, then 60 mg in the morning and 60 mg the evening for 3 days, then 60 mg in the morning for 3 days.
3320946|NCT00158262|Placebo Comparator|Placebo|Following the occurrence of an acute psychologically traumatic event, an initial dose of placebo-matching short-acting propranolol 40 mg orally then one hour later, placebo-matching long-acting propranolol 60 mg capsule orally on Day 1 followed by a 19-day course of placebo-matching long-acting propranolol starting with 120 mg every morning and evening for 10 days, and then tapering to 120 mg in the morning and 60 mg in the evening for 3 days, then 60 mg in the morning and 60 mg the evening for 3 days, then 60 mg in the morning for 3 days.
3320947|NCT00158249|Placebo Comparator|placebo|matched capsules
3320948|NCT00158249|Experimental|citicoline|2 gm/day
3320949|NCT00158223|Placebo Comparator|placebo|Participants will receive encapsulated placebo made to match active drug
3320950|NCT00158223|Experimental|pimozide|Participants will receive pimozide flexible dosing
3320951|NCT00158197|Experimental|continuous voucher schedule|Those in the continuous condition will receive a contingency management voucher each time they test negative for methamphetamine. The initial voucher value will be $2.50. Each consecutive instance of abstinence will increase the magnitude of the voucher by $1.50. Three consecutive abstinences will result in the delivery of a $10.00 bonus. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again. All participants will provide observed urine samples three times a week (e.g., M, W, & F) for twelve weeks and will complete study-related measures one time per week.
3320996|NCT00157209|Experimental|Tecemotide (L-BLP25) plus Best Supportive Care (BSC)|
3320952|NCT00158197|Experimental|intermittent predictable schedule|Those in the intermittent predictable condition will earn a contingency management voucher when they provide three consecutive methamphetamine-negative urine tests. Participants in the intermittent predictable condition will receive $22.00 for the provision of their first three consecutive methamphetamine-negative urine samples, $35.50 for the provision of their second set of three consecutive instances of methamphetamine-negative urine samples, and so forth. There are no bonuses for consecutive instances of abstinence in the intermittent predictable condition. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again. All participants will provide observed urine samples three times a week (e.g., M, W, & F) for twelve weeks and will complete study-related measures one time per week.
3320953|NCT00158197|Experimental|intermittent unpredictable schedule|Those in the intermittent unpredictable condition will be eligible to receive a contingency management voucher on one day a week. Participants in this group will receive a voucher for $22.00 following their first 3 methamphetamine-negative urine tests. They will then be eligible to receive a voucher one day a week if all of their urine tests since the receipt of their last voucher were methamphetamine negative. They will receive a voucher for $35.50 for the provision of their second set of 3 consecutive instances of methamphetamine-negative urine samples, $49.00 for their third set of 3 consecutive instances, and so forth. The day of the week on which the voucher will be available will be randomly selected for each week and the participants will not know which day of the week they will be eligible to receive a voucher until they have provided their urine test. All participants will provide observed urine samples M, W, & F for 12 wks and complete measures 1x/wk.
3320954|NCT00158197|No Intervention|standard|Participants assigned to the standard condition will not receive vouchers for the provision of clean urines. All participants will provide observed urine samples three times a week (e.g., M, W, & F) for twelve weeks and will complete study-related measures one time per week.
3320955|NCT00158184|Active Comparator|Rx Opioid Abusers|Recreational users of prescription opioids. Participants in this arm received the 3 interventions (0, 15, and 30 mg oxycodone) at random.
3320956|NCT00158184|Active Comparator|Rx Opioid Non-Abusers|Participants with a history of prescription opioid use, but who did not abuse them. Participants in this arm received the 3 interventions (0, 15, and 30 mg) at random.
3320957|NCT00158171|Experimental|1|Nicotine patch
3320958|NCT00158171|Experimental|2|Nicotine gum
3320959|NCT00158171|Placebo Comparator|3|Folic acid
3320960|NCT00158158|Placebo Comparator|1|Usual care
3320961|NCT00158158|Experimental|2|Reduction in smoking
3320962|NCT00158132|Experimental|Propranolol|Propranolol 100mg/day in 3 divided doses
3320963|NCT00158132|Experimental|Amantadine|Amantadine 100mg three times daily
3320964|NCT00158132|Experimental|Propranolol and Amantadine|Propranolol 100mg/day in 3 divided doses and Amantadine 100mg 3X's daily
3320965|NCT00158132|Placebo Comparator|Placebo|Identical Placebo pills
3320966|NCT00158054|Experimental|Intervention Condition (INT)|Enhanced depression care: Participants assigned to INT condition will be given an information brochure describing the intervention. This description will include an overview of the two elements of treatment (Problem Solving Therapy (PST), pharmacotherapy), the choice that the participant has for which element of treatment they will receive, and the stepped care aspect of treatment.
3320967|NCT00158054|Other|Usual Cardiologic Care Condition (UCC)|Referred depression care: Participants assigned to the usual cardiologic care condition (UCC) condition will be scheduled for their next follow-up visit and thanked for their time.
3320968|NCT00158028|Experimental|Risperidone|starting dose 0.25mg/day, titrated upward to 2mg/day over 9 weeks
3320969|NCT00158028|Placebo Comparator|Placebo|placebo match in identical tablets
3320970|NCT00157950|Experimental|Gardasil™|Gardasil™ 3 dose regimen
3320971|NCT00157950|Placebo Comparator|Placebo|Gardasil™ matching placebo 3 dose regimen
3320972|NCT00157924|Experimental|1|1. simvastatin/ezetimibe 10/20mg
3320973|NCT00157924|Active Comparator|2|2. atorvastatin 10mg
3320974|NCT00157846|Experimental|BiV Pacing|Biventricular pacing for 3 months, subsequently right ventricular pacing for 3 months
3320975|NCT00157846|Active Comparator|RV Stimulation|Right ventricular pacing for 3 months, subsequently biventricular pacing for 3 months
3320976|NCT00157820|Active Comparator|SC true|Single chamber Implantable Cardioverter Defibrillator programmed as a Single Chamber.
3320977|NCT00157820|Experimental|SC sim|Dual chamber ICD initially programmed as single chamber (SC simulated) ICD (''SC sim arm'')
3320978|NCT00157820|Experimental|DC true|Dual chamber ICD initially programmed as a DDED (''DC true arm'').
3320979|NCT00157807|No Intervention|No Ablation|
3320980|NCT00157807|Other|bipolar radiofrequency ablation of persistent and permanent AF|intra operative bipolar RF ablation of persistent and permanent AF
3320981|NCT00157690|Active Comparator|1|Alendronate
3320982|NCT00157690|Placebo Comparator|2|Placebo
3320983|NCT00157677|Experimental|1|Selective D-Dimer use
3320984|NCT00157677|Active Comparator|2|Uniform D-Dimer use
3320985|NCT00157651|Active Comparator|1|Receiving warfarin
3320986|NCT00157651|Placebo Comparator|2|Receiving matching placebo
3320987|NCT00157573|Experimental|GM-CSF, Sargramostim Cohort 1|GM-CSF, Sargramostim 250 μg/m^2 subcutaneous injection daily on days 1 to 14 in a 28-day cycle until disease progression or unacceptable toxicity for a median of 3 cycles.
3320988|NCT00157573|Experimental|GM-CSF, Sargramostim Cohort 2|GM-CSF, sargramostim 150 μg/m^2 subcutaneous injection daily for 28 days in a 28-day cycle until disease progression or unacceptable toxicity fora median of 3 cycles. GM-CSF, sargramostim dose escalation was permitted up to 250 μg/m^2 per day if applicable based on toxicity and white blood cell count.
3320989|NCT00157339|Experimental|1|
3320990|NCT00157339|Active Comparator|2|
3320991|NCT00157300|Experimental|Epoetin beta|
3320992|NCT00157248|Experimental|dabigatran etexilate, 150 mg once daily|dosage used at study start
3320993|NCT00157248|Experimental|dabigatran etexilate, 150 mg twice daily|dosage used at study start
3320994|NCT00157248|Experimental|dabigatran etexilate, 300 mg once daily|dosage used at study start
3320995|NCT00157248|Experimental|dabigatran etexilate, 300 mg twice daily|dosage used at study start
3320997|NCT00157209|Active Comparator|Best Supportive Care (BSC) Alone|
3320998|NCT00157196|Experimental|Tecemotide(L-BLP25)+Cyclophosphomide+best standard of care|
3320999|NCT00157157|Experimental|Single Arm - All Participants|
3321000|NCT00157131|Experimental|FS 4IU VH S/D|"FS 4IU VH S/D was administered intraoperatively to the wound bed by spray application using the TISSOMAT and Spray Set. Only the DUPLOJECTvii system and Spray Set (connection tube with sterile filter and spray head) device was used for simultaneous spray application of the study product. A thin layer of FS 4IU VH S/D was applied to the wound bed using a painting motion from side to side to achieve coverage. The recommended dosing volume was 2.0 to 4.0 mL/100 cm2. One 2-mL pack (4 mL total volume) of FS 4IU VH S/D applied using the TISSOMAT and Spray Set was sufficient to coat a wound bed of 100-200 cm2."
3321001|NCT00157131|Active Comparator|Staples|Staples are the current standard of care in burn surgery and are well accepted as the control in this type of study.
3321002|NCT00157027|Active Comparator|1|"Photopheresis (or extracorporeal photoimmunetherapy [ECP]) is a process developed by THERAKOS, Inc., a Johnson and Johnson Company. During the process of ECP, whole blood is drawn from the patient over several cycles, centrifuged and separated into the components of plasma, white cells (or buffy coat), and red blood cells. A portion of the white cells and the plasma are saved in a separate compartment. The remaining plasma and red blood cells are immediately returned to the patient.~The saved buffy coat (white blood cells) and plasma are inoculated with the photosensitizing agent UVADEX. Photoactivation begins when the suspension is exposed to a prescribed amount of ultraviolet-A light. After photoactivation is complete, the treated suspension is returned to the patient."
3321003|NCT00157014|Experimental|Tacrolimus - Adult|Adults: 0.05 - 0.10 mg/ kg/ day in 2 divided doses starting within 10 days of transplant
3321004|NCT00157014|Active Comparator|Cyclosporine - Adult|Adults: 3-5 mg/ kg/ day in 2 divided doses starting within 10 days of transplant
3321005|NCT00157014|Experimental|Tacrolimus - Pediatric|Pediatrics: 0.05 - 0.30 mg/ kg/ day in 2-3 divided doses starting within 10 days of transplant
3321006|NCT00157014|Active Comparator|Cyclosporine - Pediatric|Pediatrics: 6 - 10 mg/ kg/ day in 2-3 divided doses starting within 10 days of transplant
3321007|NCT00156962|Active Comparator|Epoetin alfa RB|
3321008|NCT00156962|Experimental|Epoetin alfa DT|
3321009|NCT00156949|Experimental|Epoetin alfa DT|
3321010|NCT00156936|Experimental|Medisorb naltrexone 380 mg (VIVITROL)|
3321011|NCT00156936|Experimental|Oral naltrexone to Medisorb naltrexone 380 mg (VIVITROL)|
3321012|NCT00156923|Experimental|Medisorb naltrexone 380 mg|
3321013|NCT00156923|Experimental|Medisorb naltrexone 190 mg|
3321014|NCT00156910|Experimental|botulinum toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
3321015|NCT00156910|Placebo Comparator|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
3321016|NCT00156819|Active Comparator|Fluticasone|Participants continued fluticasone (100 microgram twice daily) treatment.
3321017|NCT00156819|Experimental|Montelukast|Participants were changed to Montelukast (5 or 10 mg each night).
3321018|NCT00156819|Experimental|Fluticasone plus salmeterol|Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.
3321019|NCT00156715|Experimental|Quetiapine|After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.
3321020|NCT00156702|Active Comparator|1|
3321021|NCT00156702|No Intervention|2|
3321022|NCT00156676|Experimental|Arm 1|Cross over from body-weight support treadmill to Lokomat
3321023|NCT00156676|Experimental|Arm 2|Cross over from Lokomat to body-weight support treadmill
3321024|NCT00156663|Other|Arm 1|
3321025|NCT00156650|Active Comparator|1|Testosterone (T) gel for 6 months + DMPA (Depo-Medroxyprogesterone) (injected into muscle Day 0 & at Month 3)
3321026|NCT00156650|Active Comparator|2|T gel for 6 months + DMPA (Day 0 & Month 3) + Acyline 300 mcg/kg twice monthly for 12 weeks
3321027|NCT00156637|Other|Arm 1|
3321028|NCT00156637|Active Comparator|Arm 2|Dosing & Side Effect Monitoring
3321029|NCT00156533|Placebo Comparator|Placebo|QHS dosing with placebo (i.e. nightly dose)
3321030|NCT00156533|Active Comparator|QHS Zolpidem|QHS dosing with 10mg of zolpidem (i.e. nightly dose)
3321031|NCT00156533|Experimental|Intermittant Zolpidem|Intermittent dosing with 10mg of zolpidem (3-5 pills per week as needed
3321032|NCT00156533|No Intervention|Control|Monitor only condition (no placebo, no drug).
3321033|NCT00156507|Experimental|1|Parents of children in the experimental group receive asthma education prior to NICU discharge.
3321034|NCT00156416|Experimental|Meditation group|Participants received 8 weeks of mindfulness meditation instruction and support
3321035|NCT00156416|Active Comparator|Education group|Participants received 8 weeks of healthy living instruction
3321036|NCT00156390|Experimental|1|echo-guided LV lead placement
3321037|NCT00156390|Other|2|LV lead placement as per standard of care (without echo-guidance)
3321038|NCT00156338|Experimental|1|volume and sodium restriction
3321039|NCT00156338|Active Comparator|2|volume restriction
3321040|NCT00156338|Active Comparator|3|liberal fluid management
3321041|NCT00156299|Experimental|Dexamethasone plus Choline Magnesium Trisalicylate|Dexamethasone plus Choline Magnesium Trisalicylate
3321042|NCT00156299|Experimental|Choline Magnesium Trisalicylate|Choline Magnesium Trisalicylate
3321043|NCT00156247|Experimental|etanercept with acitretin|open-label
3321044|NCT00156208|Experimental|1|
3321045|NCT00156208|Experimental|2|
3321046|NCT00156195|Experimental|1|
3321051|NCT00156130||1|Accelerated whole breast irradiation
3321052|NCT00156130||2|Conventional whole breast irradiation
3321053|NCT00156117|Experimental|1|asenapine 5 mg BID and 10 mg BID
3321054|NCT00156117|Placebo Comparator|2|Placebo against olanzapine and asenapine
3321055|NCT00156117|Active Comparator|3|olanzapine 15 mgQD
3321056|NCT00156104|Experimental|1|Asenapine 5 mg BID
3321057|NCT00156104|Experimental|2|Asenapine 10 mg BID
3321058|NCT00156104|Active Comparator|3|Haloperidol 4m mg BID
3321059|NCT00156104|Placebo Comparator|4|placebo
3321060|NCT00156091|Active Comparator|1|Olanzapine 20 mg QD
3321061|NCT00156091|Experimental|2|Asenapine 5 or 10 mg BID
3321062|NCT00156091|Other|3|Double-Blind subjects randomized to only placebo medication for 6 weeks in the short-term 041021 or 041022 asenapine trials, were randomized (double-blind) Into the long-term 041512 asenapine extension trial and received asenapine 5 mg BID for Week 1. After Week 1, subjects received asenapine (either 5 mg BID or 10 mg BID) for the remainder of the 52 week trial.
3321063|NCT00156065|Active Comparator|Haloperidol/Haloperidol|Haloperidol in original study (NCT00156104) and in current long-term extension.
3321064|NCT00156065|Experimental|Asenapine/Asenapine|Asenapine in original study and asenapine in current long-term extension.
3321065|NCT00156065|Experimental|Placebo/Asenapine|Double-Blind subjects randomized to only placebo medication for 6 weeks in the short-term 041023 asenapine trial, were randomized (double-blind) into the long-term 041513 asenapine extension trial and received asenapine 5 mg BID for Week 1. After Week 1, subjects received asenapine (either 5 mg BID or 10 mg BID) for the remainder of the 52-week trial.
3321066|NCT00156052|Experimental|Hypofractionated whole breast radiation|Subjects treated with 4250 cGY in 16 fractions
3321067|NCT00156052|Active Comparator|Conventional whole breast radiation|Subjects treated with 5000 cGY in 25 fractions
3321068|NCT00156026|Experimental|1|Immediate Treatment - LEEP - Loop electrosurgical excision procedure
3321069|NCT00156026|No Intervention|2|Colposcopic Follow-up
3321070|NCT00156013|Experimental|1|Clofarabine 4 mg/m^2 days 1-5 of every cycle for a maximum of 6 cycles.
3321071|NCT00155558|Experimental|A|
3321072|NCT00155545|No Intervention|Metformin|
3321073|NCT00155454|Experimental|Study group|Group 1 had intravitreal long acting gas (10% C3F8) injection in the vitreous cavity at the end of surgery
3321074|NCT00155454|Sham Comparator|Control group|Group 2 did not receive intravitreal long acting gas (10% C3F8)
3321075|NCT00155402|Experimental|1|Use of fibrin glue after corneal surgery or transplantation
3321076|NCT00155389|Active Comparator|H pylori eradication|All enrolled subjects received chemoprevention with Helicobacter pylori eradication
3321077|NCT00155311|Experimental|days after treatment|different days after orthodontic treament, samples will be taken.
3321078|NCT00155259|Experimental|A|
3321079|NCT00154882|Experimental|A|
3321080|NCT00154843|Experimental|A|Lycopene 15 mg/day
3321081|NCT00154843|Experimental|B|Lycopene 30 mg/day
3321082|NCT00154804|Experimental|A|
3321083|NCT00154778|Experimental|A|
3321084|NCT00154687|Experimental|A|
3321085|NCT00154622|No Intervention|pain/ disability survey|
3321086|NCT00154466|Experimental|cardiac rehabilitation|Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2.
3321087|NCT00154466|No Intervention|postinfarction patients|those in the nontraining group continued their usual lifestyle
3321088|NCT00154466|Placebo Comparator|healthy controls|Age-, weight-, and height-matched subjects without cardiovascular risk factors were selected as healthy controls.
3321089|NCT00154375|Experimental|Imatinib mesylate + hydroxyurea (HU)|Imatinib was supplied as 100 mg and 400 mg tablets. Patients in the combination arm were instructed to take a daily oral imatinib dose of 600 mg (600 mg at lunch time) and a daily oral hydroxyurea (HU) dose of 1000 mg (500 mg twice daily; in the morning and at bed time). Every 6 weeks after randomization based on assessment of therapeutic response, either patients continued with above mentioned dosing regimen or switched to receive a daily dose of 800 mg imatinib with 1000 mg HU. Patients were instructed to split the intake, taking 400 mg imatinib with 500 mg HU in the morning, then the same in the evening.
3321090|NCT00154375|Active Comparator|Hydroxyurea alone|1500 mg/day of HU given as 500 mg 3 times daily. Every 6 weeks after randomization and based on assessment of therapeutic response, the patients were either switched to combination arm or continued in monotherapy arm of hydroxyurea.
3321091|NCT00154349|Experimental|imatinib mesylate|
3321092|NCT00154336|Active Comparator|Imatinib 400mmg OD +MTX|
3321093|NCT00154336|Placebo Comparator|Imatinib Placebo + MTX|
3321094|NCT00154310|Experimental|Everolimus + Mycophenolate sodium|Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL and enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day. Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5 mg prednisolone or equivalent and had to be continued throughout the first year. Cyclosporine withdrawal started from Month 4.5 post-transplant.
3321095|NCT00154310|Active Comparator|Cyclosporine + Mycophenolate sodium|Cyclosporine tablets orally twice a day to achieve protocol specific target levels and enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day. Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
3321096|NCT00154297|Active Comparator|Immediate Everolimus|Patients received Everolimus starting within 48 hours of kidney transplant through to the end of the study, administered orally twice a day. Dose was adjusted in order to maintain a trough level between 3-8 ng/mL.
3321097|NCT00154297|Experimental|Delayed Everolimus|Patients received Everolimus 4 weeks after kidney transplant until the end of the study, administered orally twice a day. The dose was adjusted in order to maintain a trough level between 3-8 ng/mL. Patients received mycophenolic acid until everolimus was initiated.
3321145|NCT00153673|Active Comparator|1|Celecoxib + Famotidine
3321146|NCT00153673|Active Comparator|2|Dologesics + Famotidine
3321147|NCT00153660|Active Comparator|NSAID #1|Celecoxib and Naproxen Placebo
3321148|NCT00153660|Active Comparator|NSAID #2|Naproxen and Celecoxib Placebo
3321098|NCT00154284|Active Comparator|Everolimus (Certican) with Cyclosporine (Neoral) Continuation|Patients were treated with everolimus and cyclosporine for 3 months post-transplantation. Everolimus (Certican) was administered orally, in two divided doses (b.i.d), and at the same time as Cyclosporine (Neoral). Everolimus (Certican) dose was adjusted in order to maintain a trough level between 3 and 8 ng/mL until randomization. After randomization the target trough range remained at 3 - 8 ng/mL in the cyclosporine (Neoral) continuation groups for a period of 9 months. Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
3321099|NCT00154284|Experimental|Everolimus (Certican) with Cyclosporine (Neoral) Withdrawal|Patients were treated with everolimus and cyclosporine for 3 months post-transplantation. Everolimus (Certican) was administered orally, in two divided doses (b.i.d), and at the same time as Cyclosporine (Neoral). Everolimus (Certican) dose was adjusted in order to maintain a trough level between 3 and 8 ng/mL until randomization. Therefore, patients were randomized to cyclosporine withdrawal over a period of 1 month (±1 week) in study A2419 (NCT00154284) and over 3 months (±1 week) in study A2423 (NCT00170807). After randomization, final target trough range for everolimus was 8 - 12 ng/mL. Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
3321100|NCT00154258|Experimental|1|
3321101|NCT00154193|Active Comparator|Cyclosporine|
3321102|NCT00154180|Active Comparator|Arm 1|CEE 0.45 mg w/ Prometrium 200 mg patch 0.05 mg w/ Prometrium 200 mg
3321103|NCT00154180|Placebo Comparator|Arm 2|Placebo patch, placebo CEE, placebo Prometrium
3321104|NCT00154154|Active Comparator|A|General Psychiatric Management
3321105|NCT00154154|Experimental|2|Dialectal Behaviour Therapy
3321106|NCT00154115|Experimental|1|Levosimendan
3321107|NCT00154115|Placebo Comparator|2|
3321108|NCT00154102|Experimental|Cetuximab Plus FOLFIRI|
3321109|NCT00154102|Active Comparator|FOLFIRI Alone|
3321110|NCT00154089|Experimental|EM-1421|"Administration of EM-1421 intravaginally once per week for 3 weeks~Dose level of 45 mg/application (1% w/w) or 90 mg/application (2% w/w)"
3321111|NCT00154076|Experimental|1|
3321112|NCT00154076|Active Comparator|2|
3321113|NCT00154063|Placebo Comparator|Placebo|During the Titration Phase, placebo was initiated at a dose of 1.0 mg/day for the first 2 weeks, increased to 1.5 mg/day for the next 2 weeks, and then further increased to 2.0 mg/day for 10 weeks (last 2 weeks of the Titration Phase continuing into the 8-week Maintenance Phase).
3321114|NCT00154063|Experimental|E2007|During the Titration Phase, perampanel was initiated at a dose of 1.0 mg/day for the first 2 weeks, increased to 1.5 mg/day for the next 2 weeks, and then further increased to 2.0 mg/day for 10 weeks (last 2 weeks of the Titration Phase continuing into the 8-week Maintenance Phase).
3321115|NCT00153998|Active Comparator|1|Cetuximab and FOLFIRI
3321116|NCT00153998|Active Comparator|2|Cetuximab and FOLFOX
3321117|NCT00153972|Active Comparator|Levodopa|Levodopa 300 mg per day orally.
3321118|NCT00153972|Active Comparator|Cabergoline|Cabergoline 3 mg per day orally.
3321119|NCT00153946|Active Comparator|A|The patients who are allocated to Argatroban monotherapy
3321120|NCT00153946|Active Comparator|B|The patients who are allocated to Edaravone-Argatroban combination therapy
3321121|NCT00153933|Experimental|CC-5013 in combination with bortezomib|Participants will receive bortezomib intravenously on day 1,4,8 and 11 followed by 10 days of rest. CC-5013 will be given orally on days 1-14 followed by 7-days of rest. One cycle lasts 21 days.
3321122|NCT00153920|Experimental|bortezomib|Participants received intravenous bortezomib on a 3-week dosing cycle: 1.3 mg/m2 on days 1, 4, 8 and 11 followed by 10 day rest period for up to 8 cycles or for 2 cycles beyond complete response. Participants with progressive disease or unacceptable toxicity discontinued treatment.
3321123|NCT00153894|Active Comparator|Group A|Immediate Exercise
3321124|NCT00153894|Active Comparator|Group B|Delayed Exercise (delay by 16 weeks)
3321125|NCT00153881|Experimental|1|Docetaxel/Carboplatin every 3 weeks for 2 cycles then concommitant chemotherapy and radiation Docetaxel weekly for 5 doses without premedication, then Capecitabine will be given orally, one dose prior to each fraction or irradiation (28 cycles).
3321126|NCT00153868|Active Comparator|1|Darbepoetin alfa 200 mcg with escalation to 300 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 2 weeks for 12 weeks (weeks 1, 3, 5, 7, 9, and 11)
3321127|NCT00153868|Active Comparator|2|darbepoetin alfa 300 mcg with escalation to 500 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 3 weeks for 12 weeks (weeks 1, 4, 7, and 10)
3321128|NCT00153842|Experimental|1|Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).
3321129|NCT00153816|Experimental|Full Factorial Placebo|subjects in 2X2 factorial design; randomized to daily placebo
3321130|NCT00153816|Experimental|Full Factorial Calcium|subjects in 2X2 factorial design; randomized to daily 1200 mg as calcium carbonate
3321131|NCT00153816|Experimental|Full Factorial Vitamin D|Subjects in 2X2 factorial design; randomized to daily 1000 IU vitamin D3
3321132|NCT00153816|Experimental|Full Factorial Calcium Plus Vitamin D|Subjects in 2X2 factorial design; randomized to daily 1200 mg as calcium carbonate and 1000 IU vitamin D3
3321133|NCT00153816|Experimental|Two Arm Placebo|Women choosing to take daily 1200 mg as calcium carbonate randomized to daily placebo
3321134|NCT00153816|Experimental|Two Arm Vitamin D|Women choosing to take daily 1200 mg as calcium carbonate randomized to daily 1000 IU vitamin D3
3321135|NCT00153803|Experimental|1|Tarceva 150mg
3321136|NCT00153803|Placebo Comparator|2|Matched Placebo
3321137|NCT00153764|Placebo Comparator|multivitamin|1 tablet morning and evening
3321138|NCT00153751|Experimental|Traditional Chinese Medicine|They are Common peony root, other herbs.
3321139|NCT00153751|Active Comparator|Holopon|Holopon
3321140|NCT00153751|Placebo Comparator|placebo|Placebo
3321141|NCT00153712||Non NSAID non-Hp|Patient of history of peptic ulcer bleeding with Hp-ve and without prior history of taking NSAID or Aspirin within 30 days
3321142|NCT00153712||Helicobacter pylori +ve|Patient with Hp+ve at peptic ulcer bleeding
3321143|NCT00153686|Experimental|Capsule Endoscopy|Capsule Endoscopy examination of small intestine
3321144|NCT00153686|Other|Mesenteric Angiogram|Mesenteric Angiogram of the small intestine
3321149|NCT00153647|Active Comparator|1|Cap-assisted Colonoscopy
3321150|NCT00153647|Placebo Comparator|2|Regular Colonoscopy
3321151|NCT00153634|Experimental|1|Antibiotic regimen assignment based on biofilm susceptibility test results
3321152|NCT00153634|Active Comparator|2|Antibiotic regimen assignment based on conventional susceptibility test results
3321153|NCT00153530|Active Comparator|1|1 chemotherapy with radiotherapy
3321154|NCT00153530|Experimental|2|chemotherapy without radiotherapy
3321155|NCT00153504|Experimental|Housing and Health Study housing rental assistance|
3321156|NCT00153504|Active Comparator|Standard local practice housing assistance|
3321157|NCT00153426|Experimental|lifestyle counseling|Women assigned to lifestyle change intervention arm for nutrition and physical activity with print-based tailored health communications and a computer-based interactive nutrition program targeting health behaviors of diet and physical activity. Women in a control group did not receive the intervention.
3321158|NCT00153231|Experimental|Infracoccygeal sacropexy|Intervention: IVS
3321159|NCT00153231|Active Comparator|Sacrospinofixation|Intervention: Sacrospinofixation
3321160|NCT00153205|Placebo Comparator|Introduction of A Clinical Pharmacist|
3321161|NCT00153205|Experimental|Technological|
3321162|NCT00153179|Active Comparator|1|
3321163|NCT00153179|Placebo Comparator|2|placebo
3321164|NCT00153166|Experimental|Patients with PAD (Including diabetics)|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
3321165|NCT00153166|Active Comparator|PAD (Excluding Diabetics)|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
3321166|NCT00153166|Active Comparator|Healthy Controls|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
3321167|NCT00153062|Placebo Comparator|Aggrenox, Clopidogrel placebo, Micardis|Aggrenox (25mg/200mg) bid, clopidogrel placebo qd, Micardis (80mg) qd
3321168|NCT00153062|Placebo Comparator|Aggrenox placebo, clopidogrel,, Micardis|Clopidogrel (75mg) qd; Aggrenox placebo bid, Micardis (80mg) qd
3321169|NCT00153062|Placebo Comparator|Aggrenox, clop placebo, micardis placebo|Aggrenox (25mg/200mg) bid, clopidogrel placebo qd, Micardis placebo qd
3321170|NCT00153062|Placebo Comparator|Aggrenox plcebo, clop, micardis placebo|Clopidogrel (75mg) qd, Aggrenox placebo bid, Micardis placebo qd.
3321171|NCT00152971|Experimental|Dabigatran Dose 1|low dose regimen taken once daily
3321172|NCT00152971|Experimental|Dabigatran Dose 2|high dose regimen taken once daily
3321173|NCT00152971|Active Comparator|Enoxaparin|30 mg subcutaneously twice daily
3321174|NCT00152906|Experimental|Stereotactic RT or highly conformal RT|
3321175|NCT00152893|Experimental|Chromium|400 μg (200 μg pills, twice per day) of Cr-nicotinate
3321176|NCT00152893|Placebo Comparator|Placebo|Identical looking placebo (di-calcium phosphate)
3321177|NCT00152867|Active Comparator|1|Dexamethasone
3321178|NCT00152867|Placebo Comparator|2|Placebo
3321179|NCT00152854|Active Comparator|A, 1, acetaminophen|acetaminophen
3321180|NCT00152854|Placebo Comparator|B placebo|placebo PO qid
3321181|NCT00152828|Experimental|Celecoxib|Celecoxib
3321182|NCT00152815|Experimental|Vitamin E|alpha-tocoperol, capsules, 2 per day
3321183|NCT00152776|Placebo Comparator|Group I|ovaria comp 10 Globuli 3 times per day 24 weeks - Placebo 12 weeks
3321184|NCT00152776|Placebo Comparator|Group II|Placebo 12 weeks - ovaria comp 10 globuli 3 times per day 24 weeks
3321185|NCT00152776|Placebo Comparator|Group III|ovaria comp 10 globuli 3 times per day 12 weeks - Placebo 12 weeks - ovaria comp 10 globuli 3 times per day 12 weeks
3321186|NCT00152763|Experimental|Cognitive Behavior Therapy - males|Eight telephone sessions of cognitive behavior therapy tailored to psychological adaptation to an ICD, plus a psycho-educational booklet for participants and a therapist manual. This arm included the males.
3321187|NCT00152763|Experimental|Cognitive Behavior Therapy - females|Eight telephone sessions of cognitive behavior therapy tailored to psychological adaptation to an ICD, plus a psycho-educational booklet for participants and a therapist manual. This arm included the females.
3321188|NCT00152763|Active Comparator|Usual Cardiac Care - Males|The UCC was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed. This arm was just for males randomized.
3321189|NCT00152763|Active Comparator|Usual Cardiac Care - females|The UCC was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed. This arm was for females randomized.
3321190|NCT00152698|Active Comparator|Irbesartan|
3321191|NCT00152698|Placebo Comparator|Placebo|
3321192|NCT00152633|Active Comparator|Losartan|Treatment with Losartan.
3321193|NCT00152633|Active Comparator|Betablocker|Treatment with Metoprolol.
3321194|NCT00152568|Experimental|Child Passenger Safety Technician services|
3321195|NCT00152542|Experimental|Inhaled nitric oxide|
3321196|NCT00152542|Placebo Comparator|Placebo|
3321197|NCT00152516|Experimental|Levetiracetam|
3321198|NCT00152477|Experimental|Carboplatin/Paclitaxel|Carboplatin and paclitaxel alone.
3321199|NCT00152477|Experimental|Carboplatin/Paclitaxel/CDP791 10mg|Carboplatin and paclitaxel plus CDP791 10mg/kg
3321200|NCT00152477|Experimental|Carboplatin/Paclitaxel/CDP791 20mg|Carboplatin and paclitaxel plus CDP791 20mg/kg
3321201|NCT00152438|Experimental|1|Oral micronized progesterone
3321202|NCT00152438|Placebo Comparator|2|Placebo
3321203|NCT00152360|Experimental|Xenical (Orlistat)|Investigating the effectiveness of Xenical on cardiovascular risk factors in the patients of St. Paul's Hospital Lipid Clinic
3321204|NCT00152321|Experimental|A|Multifaceted intervention
3321205|NCT00152321|Active Comparator|B|Usual Care
3321206|NCT00152295|Experimental|1|
3321207|NCT00152282|Experimental|1|
3321208|NCT00152282|Experimental|2|
3321209|NCT00152282|Experimental|3|
3321210|NCT00152282|Placebo Comparator|4|
3321211|NCT00152269|Experimental|1|
3321212|NCT00152269|Experimental|2|
3321213|NCT00152269|Placebo Comparator|3|
3321214|NCT00152256|Experimental|1|
3321215|NCT00152256|Experimental|2|
3321216|NCT00152256|Placebo Comparator|3|
3321217|NCT00152243|Experimental|1|UFT (uracil, tegafur)
3321218|NCT00152243|Other|2|Surgery alone
3321219|NCT00152230|Experimental|1|UFT (uracil, tegafur)
3321220|NCT00152230|Other|2|Surgery alone
3321221|NCT00152217|Experimental|1|TS-1 (S-1)
3321222|NCT00152217|Other|2|Surgery alone
3321223|NCT00152204|Experimental|1|Doses of IPTi with SP delivered alongside doses 2 & 3 of DTP/HB vaccination and alongside measles vaccination
3321224|NCT00152204|No Intervention|2|
3321225|NCT00152191|Experimental|1|UFT (uracil, tegafur)
3321226|NCT00152191|Active Comparator|2|CMF(cyclophosphamide, methotrexate, and fluorouracil)
3321227|NCT00152178|Experimental|1|UFT (uracil, tegafur) and tamoxifen
3321228|NCT00152178|Active Comparator|2|CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen
3321229|NCT00152139|Other|1|
3321230|NCT00152126|Other|1|
3321231|NCT00152113|Other|1|
3321232|NCT00152009|Experimental|SPD503 (Guanfacine HCl) (2 mg)|
3321233|NCT00152009|Experimental|SPD503 (3 mg)|
3321234|NCT00152009|Experimental|SPD503 (4 mg)|
3321235|NCT00152009|Placebo Comparator|Placebo|
3321236|NCT00151996|Experimental|Methylphenidate + SPD503|
3321237|NCT00151996|Experimental|Amphetamine + SPD503|
3321238|NCT00151983|Active Comparator|Methylphenidate Transdermal System|Methylphenidate 27.5mg, 41.3mg, 55mg, and 82.5mg patches applied daily for 8 weeks
3321239|NCT00151983|Placebo Comparator|Placebo patch|Placebo patch applied daily for 8 weeks
3321240|NCT00151970|Active Comparator|Methylphenidate Transdermal System|The duration of MTS patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
3321241|NCT00151970|Placebo Comparator|Placebo|The duration of placebo patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
3321242|NCT00151970|Active Comparator|Concerta|CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
3321243|NCT00151957|Experimental|Methylphenidate transdermal system|MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
3321244|NCT00151892|Experimental|SPD476|Mesalazine
3321245|NCT00151892|Active Comparator|Asacol|
3321246|NCT00151827|Experimental|Olmesartan medoxomil|Olmesartan oral tablets 20 mg or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
3321247|NCT00151827|Experimental|Losartan|Losartan over encapsulated tablets 50 mg and 100 mg plus olmesartan placebo.
3321248|NCT00151814|Experimental|Olmesartan|Children less than 6 years old received 0.3 mg/kg. Children 6 years old or older received 40 mg, if they weighed 35 kg or more; 20 mg if they weighed less than 35 kg.
3321249|NCT00151775|Experimental|Period 2|"For Cohorts A and B, olmesartan medoxomil suspension 2.5 mg to 40 mg in patients 6-16 years old, depending on weight.~For Cohort C, olmesartan medoxomil suspension 0.3 mg/kg to in patients 1-5 years old."
3321250|NCT00151775|Experimental|Period 3|Cohorts A, B, C - olmesartan medoxomil suspension or placebo taken once daily. Olmesartan medoxomil dose continued as in previous period.
3321251|NCT00151775|Experimental|Period 4|"Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg"
3321252|NCT00151736|Experimental|Chlorambucil|Regime A
3321253|NCT00151736|Experimental|R-etodolac with chlorambucil|Regime B
3321254|NCT00151671|Experimental|1|Perioperative Oral Nutritional Supplementation
3321255|NCT00151671|Placebo Comparator|2|Placebo of Perioperative Oral Nutritional Supplementation
3321256|NCT00151632|Experimental|MMF+FK|Low doses of tacrolimus in association with mycophenolate mofetil
3321257|NCT00151632|Active Comparator|FK|Full recommended doses of tacrolimus
3321258|NCT00151593|Experimental|1|Celsior preservation solution
3321259|NCT00151580|Experimental|1|Ribavirin maintenance treatment
3321260|NCT00151580|Placebo Comparator|2|
3321261|NCT00151567|Experimental|1|Tamsulosin
3321262|NCT00151567|Placebo Comparator|2|Placebo
3321263|NCT00151554|No Intervention|Control group|
3321264|NCT00151554|Experimental|Intervention group|
3321265|NCT00151515|Experimental|1|Topical 5% minoxidil foam formulation used twice daily
3321266|NCT00151476||Celecoxib - Routine Medical Care|800 mg total daily dosing
3321267|NCT00151476||Control Group - Routine Medical Care|Observation of subjects treated with routine medical care
3321268|NCT00151424|Experimental|1|asenapine 5-10mg BID
3321269|NCT00151424|Placebo Comparator|2|Placebo
3321270|NCT00151424|Active Comparator|3|olanzapine 10-20 mg QD
3321271|NCT00151411|Experimental|Metformin|Metformin
3321272|NCT00151411|Placebo Comparator|Placebo|Placebo
3321273|NCT00151398|Experimental|A|
3321274|NCT00151398|Experimental|B|
3321275|NCT00151398|Experimental|C|
3321276|NCT00151398|Active Comparator|D|
3321277|NCT00151372|Experimental|Treatment Adherence Intervention|In the Treatment Adherence Intervention group, a study therapist regularly meets with subjects in order to identify obstacles to depression and chronic obstructive pulmonary disease treatment adherence and to help the participant overcome those obstacles.
3321278|NCT00151372|Active Comparator|Enhanced Care|In the Enhanced Care group, physicians providing aftercare will be informed in writing of the patients' diagnosis but will receive no clinical instructions by the research team.
3321279|NCT00151346|Active Comparator|CSE|"Subjects assigned to this group will receive combined spinal-epidural (CSE) to relieve pain during labor. For CSE, subjects receive a small amount of a local anesthetic and a small amount of a narcotic pain killer directly into the spinal canal (a smaller amount than is given for traditional epidural), followed by a small amount of both of these medications that is continuously infused into the epidural space through a catheter that is left in place. CSE is not experimental."
3321280|NCT00151346|Active Comparator|Traditional Epidural|"Subjects assigned to this group will receive traditional epidural to relieve pain during labor. For the traditional epidural, subjects receive a small amount of a local anesthetic and a small amount of a narcotic pain killer into the epidural space, followed by a small amount of both of these medications that is continuously infused into the epidural space through a catheter that is left in place. The traditional epidural is not experimental."
3321281|NCT00151320|Experimental|Arm 1|"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles~Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by a dose escalation schedule."
3321282|NCT00151281|Experimental|Study Treatment Arm|
3321283|NCT00151242|Active Comparator|1|
3321284|NCT00151242|Experimental|2|
3321285|NCT00151229|Active Comparator|strict control|systolic blood pressure control: less than 140 mm Hg
3321286|NCT00151229|Active Comparator|moderate control|systolic blood pressure control: 140 mm Hg to 149 mm Hg
3321287|NCT00151216|Experimental|Group A-Severe Stages of LINCL|"Group A will include n= 5 children with a total disability score of 0 to 4 (the severe forms of the disease; the staging based on a modification of the scale of Steinfeld et al.~All subjects will receive 3x10^12 particle units of the AAV2CUhCLN2 vector."
3321288|NCT00151216|Experimental|Group B-Moderate Stages of LINCL|"Group B will include n=6 children with a total disability score of 5 to 6, a moderate stage of the disease.~All subjects will receive 3x10^12 particle units of the AAV2CUhCLN2 vector."
3321289|NCT00151177|Experimental|A|treatment with three nights of CPAP ventilation starting the first night of admission
3321290|NCT00151177|No Intervention|B|usual Stroke Unit care
3321291|NCT00151125|Experimental|A|rhIL-11 (Interleukin-11, Neumega) 25 mcg/kg subcutaneously daily for 7 days
3321292|NCT00151125|Experimental|B|rhIL-11 (interleukin-11, Neumega) 50 mcg/kg subcutaneously daily for 7 days
3321293|NCT00151125|Experimental|C|rhIL-11 (Interleukin-11, Neumega) 10 mg/kg subcutaneously daily for 7 days
3321294|NCT00151112|Experimental|1|combination of lateral position and 20° Trendelenburg Position
3321295|NCT00151112|Active Comparator|2|standard positioning
3321296|NCT00151086|Experimental|Estramustine and Vinorelbine|Treatment will consist of 28-day cycles with estramustine at a dose of 140mg orally 3 times per day on days 1-3 and 8-10 and vinorelbine orally on days 2 and 9 beginning at dose 50mg/m^2.
3321297|NCT00151073|Experimental|Zoledronate Alone|Zoledronate is given alone for the first cycle. All subsequent cycles consist of Docetaxel (70mg/m^2) given on day 2, Estramustine (280mg) given orally three times per day on days 1-3, and Zoledronate (4mg) given intravenously on day 2.
3321298|NCT00151073|Experimental|Docetaxel and Estramustine|Docetaxel and Estramustine are given for the first cycle of therapy. All subsequent cycles consist of Docetaxel (70mg/m^2) given on day 2, Estramustine (280mg) given orally three times per day on days 1-3, and Zoledronate (4mg) given intravenously on day 2.
3321299|NCT00151060|Experimental|Estramustine, Etoposide and Paclitaxel|
3321300|NCT00151047|Experimental|Docetaxel and Capecitabine|
3321301|NCT00151034|Experimental|Herceptin|"Herceptin - 4mg/kg day 1 of cycle 1; 2mg/kg day 8 and 15 of cycle 1 and subsequent cycles.~Paclitaxel - 200mg/m^2 on day 1 Carboplatin - AUC 5 on day 1 Gemcitabine - 800 mg/m^2 on day 1 and 8"
3321302|NCT00150995|Experimental|Tetrathiomolybdate|Patients will be started on a dose of 60mg Tetrathiomolybdate at bedtime and 40mg 3 times per day.
3321303|NCT00150969|Experimental|phyloquinone|5 mg Vitamin K1
3321304|NCT00150969|Placebo Comparator|placebo|
3321305|NCT00150878|Other|12 Gy/Cyclophosphamide|Standard intensity conditioning
3321306|NCT00150878|Experimental|8 Gy /Fludarabine|Reduced-intensity conditioning
3321307|NCT00150839|Active Comparator|1|Probands receive mirtazapine and venlafaxine
3321308|NCT00150839|Placebo Comparator|2|Patients receive mirtazapine and placebo
3321309|NCT00150826|Active Comparator|Quinapril|This arm will receive quinapril which will be started at 40mg daily and titrated to 80mg daily by the end of the first week. After treatment on the maximum tolerated dose for 16 weeks, patients will be reevaluated with coronary angiogram with coronary flow reserve measurements and assessment of angina using the Seattle Angina Questionnaire.
3321310|NCT00150826|Placebo Comparator|Placebo|This arm will receive placebo for 16 weeks and will be reevaluated with coronary angiogram with coronary flow reserve measurements and assessment of angina using the Seattle Angina Questionnaire.
3321311|NCT00150800|Experimental|Brivaracetam|Brivaracetam used as adjunctive treatment, flexible dosing up to 200 mg /day in b.i.d (twice daily) administration. Dose increase or decrease can be made in increments of maximum 50 mg/day on a weekly basis.
3321312|NCT00150748|Experimental|Levetiracetam|Subjects received treatment up to 1764 days during the Evaluation Period. Up to 4000 mg/day (or 80 mg/kg/day for children and adolescents less than 50 kg). Oral tablets of 166, 250, or 500 mg Levetiracetam twice daily (b.i.d.).
3321313|NCT00150670|Experimental|1|TS-1 and cisplatin
3321314|NCT00150670|Active Comparator|2|TS-1
3321315|NCT00150644|Experimental|1|
3321316|NCT00150644|Experimental|2|
3321317|NCT00150644|Placebo Comparator|3|
3321318|NCT00150631|Placebo Comparator|active (candesartan)|12 mo treatment with candesartan
3321319|NCT00150631|Placebo Comparator|placebo|12 mo placebo treatment
3321320|NCT00150618|Experimental|SPD503 (Guanfacine HCl) (1 mg)|
3321321|NCT00150618|Experimental|SPD503 (2 mg)|
3321322|NCT00150618|Experimental|SPD503 (3 mg)|
3321323|NCT00150618|Experimental|SPD503 (4 mg)|
3321324|NCT00150618|Placebo Comparator|Placebo|
3321325|NCT00150592|Experimental|SPD503 (Guanfacine HCl)|
3321326|NCT00150592|Placebo Comparator|Placebo|
3321327|NCT00150488|Experimental|1|Uracyst®
3321328|NCT00150462|Experimental|CFZ 1.2 mg/m²|Participants received carfilzomib (CFZ) 1.2 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
3321329|NCT00150462|Experimental|CFZ 2.4 mg/m²|Participants received carfilzomib 2.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
3321330|NCT00150462|Experimental|CFZ 4.0 mg/m²|Participants received carfilzomib 4.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
3321331|NCT00150462|Experimental|CFZ 6.0 mg/m²|Participants received carfilzomib 6.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
3321332|NCT00150462|Experimental|CFZ 8.4 mg/m²|Participants received carfilzomib 8.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
3321333|NCT00150462|Experimental|CFZ 11.0 mg/m²|Participants received carfilzomib 11.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
3321334|NCT00150462|Experimental|CFZ 15.0 mg/m²|Participants received carfilzomib 115.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
3321335|NCT00150462|Experimental|CFZ 20.0 mg/m²|Participants received carfilzomib 20.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
3321336|NCT00150462|Experimental|CFZ 27.0 mg/m²|Participants received carfilzomib 27.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
3321337|NCT00150462|Experimental|CFZ 20/27 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles.
3321338|NCT00150462|Experimental|CFZ 20/27 mg/m² + DEX|Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles. Participants also received 20 mg dexamethasone (DEX) administered before each dose of carfilzomib (i.e. 40 mg weekly).
3321339|NCT00150345|Experimental|Early treatment|Voriconazole starts within 18 hours of onset of fever intravenously with a loading dose of 6 mg/kg q12h for the first two doses followed by 4 mg/kg q12h (maintenance dose). Switched to oral treatment (200 mg BID) is possible after at least four days. Treatment will be ended if the patient is afebrile (< 38.0 °C) for 7 days with neutrophil counts < 500/µL, or if the patient is afebrile (< 38.0 °C) for 2 days with neutrophil counts > 500/µL.
3321340|NCT00150345|Other|Deferred treatment|"Treatment with voriconazole (for dosage see early treatment arm) is initiated only if a patient is persistently febrile on day 5 after the onset of fever despite antibiotic treatment."
3321341|NCT00150176|Experimental|asenapine|
3321342|NCT00150176|Placebo Comparator|placebo|
3321343|NCT00150124|Experimental|block-replacement therapy|BRT regimen until 3 months after 131I therapy
3321344|NCT00150124|Active Comparator|methimazole|methimazole stopped 8 days before 131I therapy
3321345|NCT00150098|Experimental|lifestyle counselling|Education
3321346|NCT00150072|Experimental|imatinib|
3321347|NCT00149994|Experimental|Cyclosporine A|Cyclosporine A was given in a twice-daily schedule at 12-hour intervals. It was administered within the first 4 hours post-operatively (study day 1), at an initial dose of 10-15mg/kg/day in two doses, as close as possible to 15mg/kg/day. After the first oral administration, the dose of Cyclosporine A was adjusted to bring the sample taken 2 hours after oral dose (C-2h) level into the target range by Days 3-5 post-transplantation. C-2h target ranges post-transplantation: 0-3 months: range of 800-1200 ng/ml with midpoint of 1000 ng/ml; 4-6 months: range of 700-900 ng/ml with midpoint of 800 ng/ml; > 6 months: range of 500-700 ng/ml with midpoint of 600 ng/ml is recommended. During the course of the study, the dose of Cyclosporine A was adjusted as necessary to achieve and maintain the C-2h blood Cyclosporine A (CsA) concentrations within the target ranges.
3321348|NCT00149994|Active Comparator|Tacrolimus|Tacrolimus was given on a twice-daily schedule at 12-hour intervals which had to be maintained throughout the study period. Tacrolimus was administered within the first 24 hrs postoperatively (Study Day 1) at an initial dose of 0.1-0.15 mg/kg/day in two divided oral doses either by mouth or via an enteral feeding tube until the patient can swallow. The initial dosing level was determined by the patient's overall post-operative condition. During the course of the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain the pre-dose blood concentration (C-0h) (trough) tacrolimus concentrations. C-0h target ranges post-transplantation: 0-3 months: 10-15 ng/ml; 4-6 months: 5-10 ng/ml; > 6 months: range of 5-10 ng/ml is recommended.
3321349|NCT00149981|Experimental|everolimus (RAD)|Everolimus according to local practice
3321350|NCT00149968|Experimental|Myfortic|
3321351|NCT00149916|Experimental|Mycophenolate sodium (enteric coated)|
3321352|NCT00149890|Experimental|With Intraoperative Steroids|Intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was <35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab was administered as an intravenous bolus injection within 8 hours after reperfusion of the graft.
3321353|NCT00149890|Active Comparator|Without Intraoperative Steroids|No intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was <35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab and the first dose of steroids had to be administered within 8 hours after reperfusion of the graft and basiliximab was given as an intravenous bolus injection.
3321354|NCT00149838|Experimental|1|Phase I participants receiving rTMS
3321355|NCT00149838|Placebo Comparator|2|Phase I participants receiving sham stimulation
3321356|NCT00149838|Experimental|3|Phase II participants
3321357|NCT00149838|Experimental|4|Phase III participants
3321358|NCT00149825|Experimental|MED+CBTI|Escitalopram plus Cognitive Behavioral Therapy for Insomnia
3321359|NCT00149825|Active Comparator|MED+CTRL|Escitalopram plus Pseudo-desensitization Therapy for Insomnia
3321360|NCT00149812|Experimental|Intervention|"Intervention: Keeping Families Strong Cognitive Behavioral and Communication intervention with mothers recovering from depression and their children, 9 years and older."
3321361|NCT00149799|Experimental|Escitalopram|In Phase I, all participants received open-label escitalopram for 14 weeks (at a dosage of 10 mg/d in weeks 1-3, 20 mg/d weeks 4-6, and 30 mg/d thereafter). Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to continue with escitalopram for Phase II of the study (Weeks 16-40)
3321362|NCT00149799|Placebo Comparator|Placebo|Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to receive a placebo for Phase II of the study (Weeks 16-40)
3321363|NCT00149786|Experimental|1|Those adolescents receiving family based therapy
3321364|NCT00149786|Active Comparator|2|Those adolescents receiving individual therapy
3321365|NCT00149773|Experimental|Cognitive Therapy + Enriched Usual Care|"The cognitive therapy intervention consists of approximately 12 (1-hour) sessions over the course of a 4-month period. The main therapy components include:~Using problem-solving and cognitive restructuring techniques to target hopelessness, reasons for living and dying, coping with loss, and perceived medical comorbidity that lead to suicidal ideation.~Improving social resources.~Improving adherence to medical regimen.~Targeting Suicidal Cognitions."
3321366|NCT00149773|No Intervention|EnrichedUsual Care Condition|"The Enriched Care (EC) condition will be used as the treatment comparison for this study. EC consists of usual care patients may obtain in the community as well as the assessment and referral services provided by the study case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health treatment in the community.~The primary role of the study case manager is to establish a strong relationship with patients in order to retain the patients in the study for the duration of the study period."
3321367|NCT00149760|Active Comparator|Augmented Standard Medical Care|Participants will receive standard medical care augmented by a psychiatric consultation letter sent to the participants' primary care physician.
3321368|NCT00149760|Experimental|Cognitive-Affective Behavior Therapy|Participants will receive individually administered cognitive-affective behavior therapy as well as augmented standard medical care.
3321369|NCT00149747|Experimental|Exercise training|Group based exercise training. Two weekly classes including aerobic endurance physical activity and strength and flexibility training, and up to three home-based sessions of similar composition of aerobic endurance, strength and flexibility training.
3321370|NCT00149747|Placebo Comparator|2|Attention-control of exposure to study staff. Weekly general health education classes conducted in group sessions.
3321371|NCT00149734|Experimental|Ondansetron followed by placebo|Participants will take ondansetron then placebo plus an atypical antipsychotic drug
3321372|NCT00149734|Experimental|Placebo followed by Ondansetron|Participants will take placebo then ondansetron plus an atypical antipsychotic drug
3321373|NCT00149669|No Intervention|Work Plus Naltrexone Prescription|Participants were prescribed naltrexone, but were not be required to ingest it to work. Participants could work and earn money, independent of whether or not they continued to take naltrexone.
3321374|NCT00149669|Experimental|Work Plus Naltrexone Contingency|Participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose (employment-based reinforcement of naltrexone ingestion).
3321375|NCT00149656|Placebo Comparator|1|
3321376|NCT00149656|Experimental|2|Multivitamins
3321377|NCT00149656|Experimental|3|Multivitamins with Selenium
3321378|NCT00149656|Experimental|4|Selenium
3321379|NCT00149643|Active Comparator|Fluoxetine|Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
3321380|NCT00149643|Placebo Comparator|Placebo|Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.
3321381|NCT00149630|Experimental|Disulfiram, Methadone (w/lactose) & CBT|Participants are randomly assigned to receive a daily dose of 250 mg of disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving study medication at week 14, at which point they will undergo a 4-week methadone detoxification period.
3321382|NCT00149630|Active Comparator|Placebo, Methadone (w/lactose) & CBT|Participants are randomly assigned to receive a daily dose of a sugar pill to mimic the experimental drug disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving all medication at week 14, at which point they will undergo a 4-week methadone detoxification period.
3321383|NCT00149552|Active Comparator|Zinc gluconate|Zinc supplementation
3321384|NCT00149552|Placebo Comparator|Placebo|Placebo
3321385|NCT00149513|Experimental|1|Targeted nurse case management
3321386|NCT00149513|Active Comparator|2|Usual Care
3321387|NCT00149500|Experimental|Coaching group for lifestyle changes|Patients received monthly phone calls with coaching for lifestyle changes over 2 years.
3321388|NCT00149500|No Intervention|Routine pediatric care|This group receives routine care with their pediatrician.
3321389|NCT00149461|Experimental|Written Asthma Action Plan Group|Participants randomized to the written asthma action plan group received an asthma action plan form along with asthma education from their specialist physician.
3321390|NCT00149461|No Intervention|No Written Instructions Group|Participants randomized to the usual care group received no written instructions other than prescriptions from their specialist physician.
3321391|NCT00149422|Active Comparator|NT-proBNP guided treatment group|In this group, management was guided by an individually set NT-proBNP, defined by the lowest level at discharge or 2 weeks thereafter. If NT-proBNP levels were elevated above the individually set NT-proBNP interventions were performed according to the ESC heart failure guidelines.
3321392|NCT00149422|Placebo Comparator|Clinically guided arm|Heart failure treatment guided by clinical assessment.
3321393|NCT00149409|Placebo Comparator|Placebo|4 gelatine capsules/d
3321394|NCT00149409|Active Comparator|1g/d Omacor|
3321395|NCT00149409|Active Comparator|4g/d Omacor|
3321460|NCT00148174|Experimental|Phone calling|Phone calling to encourage improved adherence
3321461|NCT00148122|Experimental|Arm 1|Docetaxel (1000mg PO BID days 5-18 of each Cycle) and Capecitabine (30mg/m2/week IV days 1, 8, &15)
3321540|NCT00146900|Experimental|SSRI (escitalopram)|Twenty milligrams daily of escitalopram (blinded capsules)
3321396|NCT00149396|Experimental|Safety and antitumor effects of NV1020|"Stage 1: Four escalating dose cohorts of NV1020 3x10^6 pfu, 1x10^7 pfu, 3x10^7 pfu, and 1x10^8 pfu administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy.~Stage 2: Expansion of one dose cohort from Stage 1 of optimal NV1020 dose administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy."
3321397|NCT00149383|Placebo Comparator|2|
3321398|NCT00149383|Experimental|1|
3321399|NCT00149357||1, 2 ,3|Group 1 Women with unprovoked VTE and No Known Thrombophilia Group 2 Women who are investigated for VTE and are negative (Control) Group 3 Women with unprovoked VTE who have Thrombophilia
3321400|NCT00149318||Patients with Fabry disease|
3321401|NCT00149305||Patients with gouthy diathesis|
3321402|NCT00149305||Healthy subjects|
3321403|NCT00149227|Active Comparator|Non-ARB|'Non-ARB' was defined as Conventional anti-hypertensive treatment except for ARB and ACEIs
3321404|NCT00149227|Experimental|Valsartan|Valsartan add-on treatment
3321405|NCT00149214|Experimental|A: Pemetrexed Plus Doxorubicin, Followed by Docetaxel|
3321406|NCT00149214|Active Comparator|B: Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel|
3321407|NCT00149175||Neurodegenerative disorders with cognitive impairment|
3321408|NCT00149175||Control|
3321409|NCT00149175||At risk reactive|
3321410|NCT00149162|Active Comparator|1|Patients treated by Proleukin
3321411|NCT00149162|No Intervention|2|Without Proleukin
3321412|NCT00149110|Experimental|A|Sleep deprivation in combination with light and duloxetine
3321413|NCT00149110|Active Comparator|B|Exercise and duloxetine
3321414|NCT00149071|Active Comparator|A|rTMS
3321415|NCT00149071|Sham Comparator|B|sham rTMS
3321416|NCT00148954|Active Comparator|Implantable Cardioverter Defibrillator - Boston Scientific|VITALITY 2 ICD
3321417|NCT00148954|Active Comparator|Implantable Cardioverter Defibrillator - Medtronic|Selected Medtronic family ICD
3321418|NCT00148915|Experimental|Ibandronate|Participants will receive 150 milligrams (mg) ibandronate tablet orally once monthly for one year.
3321419|NCT00148915|Placebo Comparator|Placebo|Participants will receive ibandronate matched placebo tablet orally once monthly for one year.
3321420|NCT00148902|Experimental|All treated subjects|All subjects received Lapatinib in Combination with Docetaxel (Taxotere)
3321421|NCT00148889|Sham Comparator|2|Sham-stimulation
3321422|NCT00148889|Active Comparator|1|Active GPI-DBS
3321423|NCT00148876|Active Comparator|Capecitabine|Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression and discontinuation of Trastuzumab.
3321424|NCT00148876|Experimental|Capecitabine and Trastuzumab|Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression + Trastuzumab 6 mg/kg body weight every 3 weeks i.v. as a 90 min infusion until progression
3321425|NCT00148798|Experimental|Cetuximab plus chemotherapy|cetuximab + cisplatin + vinorelbine
3321426|NCT00148798|Active Comparator|Chemotherapy alone|cisplatin + vinorelbine alone
3321427|NCT00148759|Active Comparator|adult male subjects|LPV/r 800/200 mg once daily
3321428|NCT00148759|Experimental|Adult female subjects|LPV/r 800/200 mg once daily
3321429|NCT00148733|Experimental|Zinc|Zinc sulphate 10 or 20 mg (elemental zinc) per day. Intervention and placebo given perorally mixed with approximately 5 mL of breastmilk or clean water
3321430|NCT00148733|Placebo Comparator|Placebo|Placebo
3321431|NCT00148694|Experimental|Intervention single arm|Cisplatin 75mg/m2 q21 days x 4 pre-surgery
3321432|NCT00148681|Experimental|Lower Risk Regimen|
3321433|NCT00148681|Experimental|Higher Risk Regimen|
3321434|NCT00148668|Active Comparator|Arm 1|Herceptin/navelbine
3321435|NCT00148668|Active Comparator|Arm 2|Taxotere/carboplatin/herceptin
3321436|NCT00148642|Experimental|1|silver salts coated endotracheal tube
3321437|NCT00148642|Placebo Comparator|2|uncoated endotracheal tube
3321438|NCT00148616|Active Comparator|1|
3321439|NCT00148616|Placebo Comparator|Placebo|
3321440|NCT00148590|Active Comparator|1|
3321441|NCT00148590|Placebo Comparator|Placebo|
3321442|NCT00148564|Active Comparator|Olanzapine|
3321443|NCT00148564|Active Comparator|Zpirasidone|
3321444|NCT00148538|Active Comparator|1|exercise
3321445|NCT00148525|Experimental|social cognitive theory|This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory and delivered by an automated telephone system.
3321446|NCT00148525|Experimental|Goal Systems Theory|This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory.
3321447|NCT00148525|No Intervention|Comparison group|comparison group
3321448|NCT00148369||Observational Group|Subjects previously administered GDNF and have discontinued the drug.
3321449|NCT00148356|Experimental|1|ZoMaxx™ Drug-Eluting Stent System
3321450|NCT00148356|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
3321451|NCT00148343|Experimental|ODFS|Odstock Dropped-Foot Stimulator (ODFS)
3321452|NCT00148343|Active Comparator|Standard of Care (inc. AFO)|Conventional Standard of Care (which may include a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) [Traditional Physical Therapy Treatment]
3321453|NCT00148317|Experimental|Treatment Arm|
3321454|NCT00148304||Group 1|
3321455|NCT00148278|Experimental|1|norepinephrine plus dobutamine
3321456|NCT00148278|Active Comparator|2|epinephrine
3321457|NCT00148239|Experimental|Caregiver Only|A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.
3321458|NCT00148239|Experimental|Dual Treatment|Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention
3321459|NCT00148239|Active Comparator|Control|Participants are provided with written materials at beginning of study; nothing thereafter
3321462|NCT00148109|Active Comparator|EGFR positive|The EGFR positive group will be conducted in a 2-stage minimax trial design to determine the rate of four-month progression free survival in this patient population treated with cetuximab
3321463|NCT00148109|Active Comparator|EGFR Negative|The EGFR negative group will help us explore the possibility of benefit of cetuximab in a patient whose tumor does not express or minimally expresses EGFR. If benefit in progression-free survival or in another surrogate such as tumor response or a molecular event is seen in this group it would provide rationale to study this group further in subsequent trials
3321464|NCT00148096|Placebo Comparator|1|Mechanical heat recovery ventilation units installed but not fully functional
3321465|NCT00148096|Active Comparator|2|Mechanical heat recovery ventilation unit installed and active
3321466|NCT00148031|Experimental|1|On-site (MMT Clinic) HCV evaluation and treatment
3321467|NCT00148031|Active Comparator|2|Off-site (GI Clinic) HCV evaluation and treatment
3321468|NCT00147992|Experimental|implants|
3321469|NCT00147979|Experimental|1|PTFE with bounded heparin
3321470|NCT00147979|Active Comparator|2|PTFE without bounded heparin
3321471|NCT00147966|Experimental|ritxumab|all patients get treatment
3321472|NCT00147914|Active Comparator|1|cefdinir
3321473|NCT00147914|Active Comparator|2|amoxicillin/clavulanate
3321474|NCT00147901|Experimental|FCCam|After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
3321475|NCT00147836|Active Comparator|CSII|Patients in continuous subcutaneous insulin infusion group received Human Insulin (Novolin-R, Novo Nordisk) with an insulin pump (H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland);
3321476|NCT00147836|Active Comparator|MDI|Patients in MDI group were treated with pre-meal Novolin-R, and Human Insulin NPH (Novolin-N, Novo Nordisk) at bedtime. Initial insulin doses were 0.4-0.5 IU/kg and total daily doses were divided into 50% of basal and 50% of bolus injection in CSII group and 30%-20%-20%-30% in multiple daily insulin injection group
3321477|NCT00147836|Active Comparator|OHA|In oral hpoglycemic agents group, the patients with 20 kg/m2<BMI≤25kg/m2 were initiated with Gliclazide (Diamicron, Servier) 80mg Bid (maximum to 160mg Bid), the patients with 25kg/m2<BMI≤35kg/m2 were initiated with Metformin (Glucophage, BMS) 0.5 Bid (maximum to 2.0g/d), the combination of Diamicron and Glucophage was used in patients who could not achieve glycaemic control goal with one OHA or with FPG≥11.1mmol/l at randomization
3321478|NCT00147823|Experimental|Vitoss with bone marrow aspirate|Addition of Vitoss to the bone marrow aspirate
3321479|NCT00147823|Active Comparator|Vitoss Alone|vitoss alone
3321480|NCT00147797||Pravastatin group|Patients in the pravastatin group were consecutively recruited in four department of infectious diseases if they fulfilled the following criteria : (1) HIV-infected treated with HAART for > 12 months 2) with dyslipidemia, defined as fasting serum LDL cholesterol > 160 mg/dL before initiation of pravastatin, (3) treated with pravastatin > 12 months and one more coronary risk factor.
3321481|NCT00147797||COotrol group|The patients in the control group were selected consecutively in the same departments among 1) HIV-infected patients treated with HAART > 12 months 2) fasting serum LDL cholesterol > 160 mg/dL 3) without lipid-lowering drugs and one more coronary risk factor. Cases and control patients were matched for age, gender and tobacco consumption.
3321482|NCT00147771|Experimental|1|
3321483|NCT00147745|Experimental|1|colesevelam 3.8g administered daily for 12 weeks
3321484|NCT00147745|Placebo Comparator|2|Colesevelam matching placebo for 12 weeks
3321485|NCT00147745|Active Comparator|3|open-label Insulin Glargine for 12 weeks
3321486|NCT00147732|Active Comparator|1|Accelerated radiotherapy
3321487|NCT00147732|Experimental|2|ARCON
3321488|NCT00147550|Experimental|1|
3321489|NCT00147537|Experimental|Phase 2 (Arms A & B)|CP-751,871 + paclitaxel + carboplatin
3321490|NCT00147537|Experimental|Phase 1b|"Phase 1b Dose Escalation /Expansion: CP-751,871 + paclitaxel + carboplatin~Phase 1b Erlotinib Extension: CP-751,871 + paclitaxel + carboplatin + erlotinib"
3321491|NCT00147498|Experimental|5 mg BID|CP 690,550 5 mg BID
3321492|NCT00147498|Experimental|15 mg BID|CP 690,550 15 mg BID
3321493|NCT00147498|Experimental|30 mg BID|Oral tablets administered at a dose of 30 mg BID for 6 weeks
3321494|NCT00147498|Placebo Comparator|Placebo|Placebo
3321495|NCT00147485|Experimental|1|
3321496|NCT00147472|Other|PET|All patients receive PET scan and conventional CT imaging.
3321497|NCT00147459|Active Comparator|booster|no antibody and boosted
3321498|NCT00147446|Experimental|Individual Stress Management|Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
3321499|NCT00147446|Other|Wait List Control|Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
3321500|NCT00147381|Experimental|Campath-1H 20 mg|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 20 mg IV infusion over 3-6 hours.~Day 1: Same protocol of Campath-1H and methylprednisolone as on Day 0.~Day 2: No treatment~Day 3: Initial dose of Tacrolimus 0,1 mg/kg/d (0,05 mg/kg/bid)~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
3321538|NCT00146900|Experimental|Prolonged Exposure (CBT)|Twelve 1.5 hours weekly sessions of Prolonged Exposure cognitive behavioral therapy
3321539|NCT00146900|Active Comparator|Cognitive Therapy|Twelve 1.5 hours weekly sessions of Cognitive Therapy without exposure to traumatic reminders.
3321501|NCT00147381|Active Comparator|Tacrolimus|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 30 mg IV infusion over 3-6 hours.~Day 1: No treatment~Day 2: Initial dose Tacrolimus 0.1 mg/kg/d (0.05 mg/kg.bid).~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
3321502|NCT00147381|Experimental|Campath-1H 30 mg|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 30 mg IV infusion over 3-6 hours.~Day 1: No treatment.~Day 2: Initial dose Tacrolimus 0.1 mg/kg/d (0.05 mg/kg.bid).~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
3321503|NCT00147355|Other|A|Ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
3321504|NCT00147355|Other|B|Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
3321505|NCT00147355|Other|D|metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
3321506|NCT00147355|Other|C|metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
3321507|NCT00147316|Experimental|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
3321508|NCT00147303|Experimental|group L|25mg sarpogrelate
3321509|NCT00147303|Experimental|group M|50mg sarpogrelate
3321510|NCT00147303|Experimental|group H|100mg sarpogrelate
3321511|NCT00147290|Experimental|BiV|ATP therapies are delivered in both the ventricles
3321512|NCT00147290|Active Comparator|RV|ATP delivered only in the right ventricle
3321513|NCT00147277|Active Comparator|8 pulses|8 pulses Anti-Tachycardia Pacing (ATP) delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)
3321514|NCT00147277|Experimental|15 pulses|15 pulses Anti-Tachycardia Pacing (ATP) delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)
3321515|NCT00147238|Experimental|Ferumoxtran-10 MRI|MR lymphangiography using Ferumoxtran-10 contrast agent.
3321516|NCT00147238|Active Comparator|MRI|MR lymphangiography before injecting Ferumoxtran-10 contrast agent.
3321517|NCT00147225|Experimental|1 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 1 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~Adriamycin - Ifosfamide (AI) regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
3321518|NCT00147225|Experimental|3 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 3 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
3321519|NCT00147225|Experimental|10 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 10 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
3321520|NCT00147225|Experimental|10 mcg/kg Pre/Post Chemotherapy|"Cycle 1, Chemotherapy (Control Cycle); Beginning Cycle 2, 10 mcg/kg AMG 531 subcutaneously on Day -5 (pre dose) and on day after chemotherapy (post dose) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
3321521|NCT00147225|Experimental|5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 5 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
3321522|NCT00147225|Experimental|10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy|"10 mcg/kg AMG 531 + Pre/Pre/Post/Post Chemotherapy Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 10 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
3321523|NCT00147212|Experimental|1|ET-743
3321524|NCT00147199|Experimental|Inhaled treprostinil|0.9 mg/mL treprostinil for inhalation supplied in 2.9mL ampoules for use in ultra sonic nebulizer
3321525|NCT00147199|Placebo Comparator|Placebo|Placebo inhalation solution for use in ultrasonic nebulizer
3321526|NCT00147134|Active Comparator|1|Procedure/Surgery: open colectomy
3321527|NCT00147134|Experimental|2|Procedure/Surgery: laparoscopic colectomy
3321528|NCT00147121|Active Comparator|1|Rituximab+Standard CHOP
3321529|NCT00147121|Experimental|2|Rituximab+bi-Weekly CHOP
3321530|NCT00147082||COPD|Patients with COPD - no intervention
3321531|NCT00147082||Smokers without COPD|Smokers without COPD - no intervention
3321532|NCT00147082||Non-smokers|Non-smokers with no history of respiratory disease - no intervention
3321533|NCT00147056|Experimental|ExAblate transcranial system|MR Guided Focused Ultrasound
3321534|NCT00147030|Active Comparator|cooled|Whole body mild induced hypothermia for 72 hours, starting by 6 hours of age, in addition to standard intensive care. After 72 hours of cooling, rewarming by a maximum of 0.5 degree C / hour to normothermia.
3321535|NCT00147030|No Intervention|non-cooled|Standard intensive care
3321536|NCT00147004|Experimental|1|hydrocortisone sodium succinate
3321537|NCT00147004|Placebo Comparator|2|Placebo
3321541|NCT00146900|Placebo Comparator|Placebo|Two concealed placebo pills resembling 10mg escitalopram tablets
3321542|NCT00146900|No Intervention|Waiting List|Twelve weeks of waiting list no intervention group
3321543|NCT00146848|Active Comparator|DDD-40|DDD-40 for this trial is the comparator arm. Even though patients are receiving a CRT-D device, atrial support pacing in this arm will be limited as the device will not pace unless the rate falls below 40 bpm.
3321544|NCT00146848|Active Comparator|DDDR-40|DDDR-40 programming will initiate atrial support pacing if the rate falls below 40 bpm or if atrial support is needed in response to increased activity.
3321545|NCT00146848|Active Comparator|DDD-70|Atrial support pacing in this arm will be delivered when the rate falls below 70 bpm.
3321546|NCT00146835||Cohort A|The primary study cohort includes all infants from SCKP who have begun their primary course of vaccine with PEDIARIX co-administered with Prevnar and for whom at least one dose of PEDIARIX was administered prior to the infant's 9-month birthday and safety follow-up information is available.
3321547|NCT00146835||Cohort B|This Historical cohort includes age-, gender- and area-matched infants who received at least one dose of DTaP vaccine co-administered with 7Pn between 1 January 2002 and 29 April 2003.
3321548|NCT00146835||Cohort C|"This delayed Pediarix use clinics cohort includes all infants who, during the enrollment period for Cohort A, begin their primary course of vaccination with a DTaP vaccine co-administered with 7Pn. It is age-, gender-, and area-matched in a similar manner to Cohort B."
3321549|NCT00146770|Active Comparator|Placebo/Aldurazyme|Patients received placebo for 26 weeks in the Double-Blind Study then received 182 weeks of Aldurazyme (0.58 mg/kg every week) in this Extension Study; patients received a total of 182 weeks of Aldurazyme.
3321550|NCT00146770|Active Comparator|Aldurazyme/Aldurazyme|Patients received 26 weeks of Aldurazyme in the Double-Blind Study and then received 182 weeks of Aldurazyme in this Extension Study; patients received a total of 208 weeks of Aldurazyme.
3321551|NCT00146757|Experimental|Aldurazyme (rhIDU) 100 U/kg ONLY every week|Patients received Aldurazyme (recombinant human alpha-L-iduronidase (rhIDU)) once per week at a dose of 100 Units/kg (approximately 0.58 mg/kg) for up to 52 weeks - labeled dose.
3321552|NCT00146757|Experimental|Aldurazyme (rhIDU) 100-200 U/kg every week|After receiving 100 Units/kg dose of Aldurazyme (rhIDU) for the first 25 weeks, patients enrolling after January 1, 2004 were eligible to receive an increased dose of 200 Units/kg from Week 26 onwards if the patient's urinary glycosaminoglycan (uGAG) levels were >200µg/mg creatinine at Week 22.
3321553|NCT00146679|Placebo Comparator|Usual Care (UC)|Usual Care provided by providers
3321554|NCT00146679|Active Comparator|Psychoeducational Telephone CounselingTC|Education and Counseling for ICD patients provided through Telephone Contact
3321555|NCT00146679|Active Comparator|Psychoeducation through Groups (SG)|Education and Counseling for ICD patients provided in a group setting with other ICD Patients
3321556|NCT00146653||Xa|An additional 20 patients will be enrolled to address the validation of heparin concentrations calculated by the Hepcon machine with laboratory-measured heparin concentrations. These patients will not be randomized and therefore will not receive an intervention. .
3321557|NCT00146640|Experimental|MR Prednisone|Participants will receive MR prednisone at bed time and placebo matching to IR prednisone in the morning. Total duration of double blind treatment will be 12 weeks.
3321558|NCT00146640|Active Comparator|IR Prednisone|Participants will receive IR prednisone in the morning and placebo matching to MR prednisone at bed time. Total duration of double blind treatment will be 12 weeks.
3321559|NCT00146575|Experimental|1|randomized patients get sirolimus stent
3321560|NCT00146575|Experimental|2|randomized patients get paclitaxel stent
3321561|NCT00146523|Experimental|mifepristone 600 mg|
3321562|NCT00146523|Placebo Comparator|matching placebo|
3321563|NCT00146471|Active Comparator|2|
3321564|NCT00146471|Placebo Comparator|1: Diazepam plus Placebo|
3321565|NCT00146328|Experimental|Group 1|Patients With Varying Degrees of Tipranavir Treatment Experience
3321566|NCT00146328|Experimental|Group 2|Highly Tipranavir Treatment Experienced Patients
3321567|NCT00146328|Experimental|Group 3|Tipranavir Treatment Naive Patients
3321568|NCT00146315|Active Comparator|Control|Secondary prevention program for coronary heart disease
3321569|NCT00146315|Experimental|Supervised exercise|
3321570|NCT00146250|Experimental|Nitrous oxide|Nitrous oxide 70% as balance gas in inspired mixture
3321571|NCT00146250|Experimental|Nitrogen|Nitrogen instead of nitrous oxide 70% as balance gas in inspired mixture
3321572|NCT00146224|Active Comparator|Epoetin alfa RB|
3321573|NCT00146224|Experimental|Epoetin alfa DT|
3321574|NCT00146172|Experimental|Neratinib|
3321575|NCT00146159|Experimental|1|1st group: 12 mg Mitoxantrone/m²
3321576|NCT00146159|Experimental|2|2nd group: 9mg Mitoxantrone/m²
3321577|NCT00146159|Experimental|3|3rd group: 5mg Mitoxantrone/m²
3321578|NCT00146107|No Intervention|1|
3321579|NCT00146107|Experimental|2|Weight loss
3321580|NCT00146107|Experimental|3|Exercise
3321581|NCT00146107|Experimental|4|Weight loss and exercise
3321582|NCT00146081|Experimental|A|Family Program: Participants who have identified at least 1 family member or friend to enroll in SHARE with them, who are randomly assigned to program A, are invited to bring their enrolled family member or friend (co-participant) with them to the study intervention group sessions as their supportive team member.
3321583|NCT00146081|Active Comparator|B|Coach Program: Participants who identify 1 or 2 family members or friends to enroll in SHARE with them, who are randomly assigned to program B, are invited to attend the study intervention group sessions without their enrolled family or friend (co-participants). The co-participants receive the same written materials, but act as supportive team members outside of the group sessions only. They are invited to attend special field workshops and personal counseling sessions with their co-participants.
3321584|NCT00146081|Experimental|C|Team Program: Participants who do not identify 1 or 2 family or friend co-participants, and are randomly assigned to program C, are paired with other unrelated enrollees in their group sessions as supportive team members.
3321585|NCT00146081|Active Comparator|D|Individual Program: Participants who do not identify 1 or 2 family members or friends to enroll in SHARE with them, and are randomly assigned to program D, attend group sessions as individuals.
3321586|NCT00145977|Experimental|Alendronate|All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal. This group will also receive alendronate 70 mg once weekly, according to standard recommendations.
3321587|NCT00145977|Active Comparator|Control|All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal.
3321588|NCT00145951||1|
3321589|NCT00145951||2|
3321590|NCT00145951||3|
3321591|NCT00145925|Placebo Comparator|Blood pressure|Perindopril indapamide vs placebo
3321592|NCT00145925|Other|Glucose control|Standard versus intensive glucose control
3321593|NCT00145912|Experimental|Intrinsic Motivation|PCP motivational interview + Internet program
3321594|NCT00145912|Active Comparator|Extrinsic Motivation|PCP breif advice + Internet Program
3321595|NCT00145886|Experimental|rhPTH|Subjects will be treated rhPTH for 12 months
3321596|NCT00145847|Active Comparator|Naltrexone|Naltrexone 50 mg per day, directly administered as 100 mg on Mondays, 100 mg on Wednesdays and 150 mg on Fridays
3321597|NCT00145847|Placebo Comparator|Lactose pill|
3321598|NCT00145795|Experimental|Kaletra + Current Dual NRTI Backbone|Patients in this arm received Kaletra in addition to their current Dual NRTI Backbone.
3321599|NCT00145795|Active Comparator|Current Regimen|Patients in this study arm continued their current regimen.
3321600|NCT00145769|Active Comparator|Short Course Radiotherapy|Short Course (SC) pre-operative radiotherapy, followed by surgery and adjuvant chemotherapy
3321601|NCT00145769|Active Comparator|Long Course Radiotherapy|Long Course (LC) radiotherapy delivered with concurrent chemotherapy, followed by surgery and adjuvant chemotherapy
3321602|NCT00145769|Active Comparator|Surgery|Patients will receive initial surgery followed by post-operative management according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Adjuvant therapy for rectal cancer.
3321603|NCT00145743|Experimental|1|Patient's reported questionaire, profile in 10 dimensions (EORTC) and referees' report with treatment recommendations
3321604|NCT00145743|Experimental|2|Patient's reported questionaire; no recommendations given
3321605|NCT00145704|Active Comparator|Growth Hormone only|No bisphosphonate therapy given, participants will take Vitamin D 400 IU daily for 18 months, as well as calcium carbonate 500 mg twice a day for 18 months.
3321606|NCT00145704|Experimental|Growth Hormone & Bisphosphonate Therapy|Bisphosphonate Therapy-Risedronate 35 mg once a week for 18 months, Vitamin D 400 IU daily for 18 months and calcium carbonate 500 mg twice daily for 18 months
3321607|NCT00145678|Experimental|dynamic deconstructive psychotherapy|weekly individual psychotherapy of 50 minute duration lasting 12-18 months
3321608|NCT00145678|Active Comparator|optimized community care|eclectic weekly individual and group psychotherapy, as well as drug and alcohol rehabilitation
3321609|NCT00145639|Other|1|
3321610|NCT00145626|Experimental|Study Participants|"Participants who meet the eligibility criteria for this study. Donor cells will be obtained using the Miltenyi Biotec CliniMACS device.~Interventions: Chemotherapy and antibodies, allogeneic stem cell transplantation."
3321611|NCT00145613|Other|1|
3321612|NCT00145600|Experimental|Unfavorable Risk, Group 2|Unfavorable risk (group 2) arm in patients with Hodgkin's disease (n=146)
3321613|NCT00145600|Experimental|Favorable Risk|Favorable Risk arm in patients with Hodgkin's Disease (n=91).
3321614|NCT00145600|Experimental|Intermediate Risk|Intermediate Arm in patients with Hodgkins's disease (n=46).
3321615|NCT00145600|Experimental|Unfavorable Risk, Group 1|Unfavorable risk group 1 closed early due to excessive number of adverse events (n=13).
3321616|NCT00145587|Other|1|
3321617|NCT00145574|Experimental|high dose colesevelam|colesevelam HCl 3.750 g
3321618|NCT00145574|Experimental|Low dose colesevelam|Low dose colesevelam 1.875 g
3321619|NCT00145574|Placebo Comparator|placebo|placebo comparator
3321620|NCT00145535|Experimental|1|Titanium sapphire laser treatment
3321621|NCT00145535|Active Comparator|2|Argon laser treatment
3321622|NCT00145522|Experimental|1|
3321623|NCT00145522|Active Comparator|2|
3321624|NCT00145509|Active Comparator|Asenapine|Asenapine
3321625|NCT00145509|Placebo Comparator|Placebo|Placebo
3321626|NCT00145496|Experimental|asenapine|
3321627|NCT00145496|Active Comparator|olanzapine|
3321628|NCT00145470|Experimental|1|Asenapine (Org 5222)
3321629|NCT00145470|Placebo Comparator|2|Placebo
3321630|NCT00145418|Experimental|1|Oxaliplatin + Docetaxel as first line therapy of Stage IV or IIIB unresectable non-small cell lung cancer. The primary objective of the trial is to determine the response rate by RECIST criteria to the combination of oxaliplatin and docetaxel in patients with previously untreated NSCLC.
3321631|NCT00145379|Experimental|Metformin|
3321632|NCT00145379|Placebo Comparator|Placebo comparator|
3321633|NCT00145327|Experimental|Zoledronic Acid 6|Patients who received Zoledronic acid for 3 years in the core study (CZOL446H2301; NCT00049829) received a single intravenous infusion of 5 mg Zoledronic acid once a year for 3 years (at Months 36, 48 and 60) in this extension study for a total of 6 years of treatment.
3321634|NCT00145327|Placebo Comparator|Zoledronic Acid 3 Placebo 3|Patients who were treated with Zoledronic acid for 3 years in the core study received a single intravenous matching Placebo infusion once a year for 3 years in this extension study.
3321635|NCT00145327|Experimental|Placebo 3 Zoledronic Acid 3|Patients who were treated with placebo for 3 years in the core study received 5 mg Zoledronic acid in a single intravenous infusion once a year for 3 years (at Months 36, 48 and 60) in this extension study.
3321636|NCT00145314|Active Comparator|A|FLOX: 5-fluorouracil/folinic acid/oxaliplatin; Nordic Regimen; given continuosly
3321637|NCT00145314|Experimental|B|FLOX: 5-fluorouracil/folinic acid/oxaliplatin and cetuximab
3321638|NCT00145314|Experimental|C|FLOX given intermittently and maintenance cetuximab
3321639|NCT00145249|Active Comparator|Standard Therapy|Amphotericin B 0.7 mg/kg for 14 day followed by fluconazole 400 mg daily for 8 weeks. For subjects in the standard therapy arm whose Amphotericin B dose is continued beyond 14 days, fluconazole initiation will be delayed.
3321863|NCT00141531|Active Comparator|Apaziquone|
3321640|NCT00145249|Experimental|Fluconazole Low Dose|Amphotericin B 0.7 mg/kg and the randomized dose of fluconazole at 400 mg/day for the first 14 days, then the randomized dose of fluconazole at 400 mg/day respectively for an additional 8 weeks.
3321641|NCT00145249|Experimental|Fluconazole High Dose|Amphotericin B 0.7 mg/kg and the randomized dose of fluconazole at 800 mg/day for the first 14 days, then the randomized dose of fluconazole at 800 mg/day respectively for an additional 8 weeks.
3321642|NCT00145197|Experimental|Improving the Delivery of Effective Care to Minorities|
3321643|NCT00145184|Placebo Comparator|Placebo|Placebo
3321644|NCT00145184|Experimental|Multivitamins|Multivitamin supplement containing the following vitamins: B1, B2, Niacin, B6, Folate, B12, C, and E
3321645|NCT00145041|Experimental|VSLI|Single armed study; all subjects received VSLI
3321646|NCT00144989|Active Comparator|1|Etoposide and cisplatin after chemoradiotherapy
3321647|NCT00144989|Experimental|2|Irinotecan and cisplatin after chemoradiotherapy
3321648|NCT00144963|Experimental|VSLI|Vincristine Sulfate Liposomes Injection (VSLI)
3321649|NCT00144911|Experimental|Arm 1|
3321650|NCT00144898|Experimental|Sentinel Node Resection|Sentinel Node Resection
3321651|NCT00144898|Other|Conventional Axillary Dissection|Conventional Axillary Dissection
3321652|NCT00144885|No Intervention|1|
3321653|NCT00144872|Experimental|Subjects receiving lamotrigine|Eligible subjects will receive chewable dispersible tablets of lamotrigine with a starting dose of 0.3 milligrams per kilogram administered orally.
3321654|NCT00144846|Other|Arm 1|
3321655|NCT00144807|Experimental|R-AC|rituximab + doxorubicin + cyclophosphamide + autologous stem cell transplantation
3321656|NCT00144781|Active Comparator|1|0.58 mg Aldurazyme/kg of body weight (100 U/kg) administered every week (labeled dose). Final Visit is Week 27 for patients randomized to every week regimen.
3321657|NCT00144781|Active Comparator|2|1.2 mg Aldurazyme/kg of body weight (200 U/kg) administered every week. Final Visit is Week 27 for patients randomized to every week regimen.
3321658|NCT00144781|Active Comparator|3|1.2 mg Aldurazyme/kg of body weight (200 U/kg) administered every 2 weeks. Final Visit is Week 26 for patients randomized to every 2 week regimen.
3321659|NCT00144781|Active Comparator|4|1.8 mg Aldurazyme/kg of body weight (300 U/kg) administered every 2 weeks. Final Visit is Week 26 for patients randomized to every 2 week regimen.
3321660|NCT00144755|Active Comparator|R-CHOP21|8 cycles of R-CHOP21
3321661|NCT00144755|Experimental|R-CHOP21, Darbepoetin alfa|8 cycles of R-CHOP21 + prophylactic darbepoetin alfa
3321662|NCT00144755|Experimental|R-CHOP14|8 cycles of R-CHOP14
3321663|NCT00144755|Experimental|R-CHOP14, Darbepoetin alfa|8 cycles of R-CHOP14 + prophylactic darbepoetin alfa
3321664|NCT00144664|Experimental|1|MRA(Tocilizumab)
3321665|NCT00144651|Experimental|1|
3321666|NCT00144625|Experimental|1|
3321667|NCT00144612|Experimental|1|
3321668|NCT00144599|Experimental|1|
3321669|NCT00144599|Placebo Comparator|2|
3321670|NCT00144586|Experimental|1|
3321671|NCT00144547|Experimental|1|
3321672|NCT00144534|Experimental|1|
3321673|NCT00144521|Experimental|1|
3321674|NCT00144521|Active Comparator|2|
3321675|NCT00144508|Experimental|1|
3321676|NCT00144508|Other|2|continue current treatment
3321677|NCT00144495|Experimental|1|patient whose ΔHb is less than 1.0g/dL on the day of 7th administration
3321678|NCT00144495|Experimental|2|patient whose ΔHb is 1.0g/dL or above on the day of 7th administration
3321679|NCT00144482|Experimental|1|
3321680|NCT00144482|Placebo Comparator|2|
3321681|NCT00144456|Experimental|1|
3321682|NCT00144456|Active Comparator|2|
3321683|NCT00144417|Active Comparator|HRZE|isoniazid, rifampin, pyrazinamide, ethambutol, moxifloxacin-placebo
3321684|NCT00144417|Experimental|MRZE|moxifloxacin, rifampin, pyrazinamide, ethambutol, isoniazid-placebo
3321685|NCT00144391|Experimental|Transdermal Testosterone Gel|Transdermal Testosterone Gel (2 mg per pump), 2 pumps per day for 6 months
3321686|NCT00144391|Placebo Comparator|Placebo|Placebo 2 pumps per day for 6 months
3321687|NCT00144300|Active Comparator|Mirapex|Mirapex tablets three times daily (TID) dosing according to manufacturer's guidelines
3321688|NCT00144300|Active Comparator|Requip|Requip tablets three times daily (TID) dosing according to manufacturer's guidelines
3321689|NCT00144170|Other|Tipranavir(TPV)/low dose ritonavir(r)|
3321690|NCT00144170|Other|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
3321691|NCT00144040|Other|Arm 1|
3321692|NCT00144027|No Intervention|Control|The control group will receive treatment as usual; meaning patients in the control group will not receive the medication adherence intervention.
3321693|NCT00144027|Experimental|Antipsychotic adherence intervention|Antipsychotic Medication Adherence Intervention which included the Barriers, Facilitators, and Motivators Checklist summary and Adherence tips provided in hard copy to patient and electronic copy to mental health provider.
3321694|NCT00144014|Experimental|V10153, 1.0 mg/kg|Single acute intravenous bolus dose
3321695|NCT00144014|Experimental|V10153, 2.5 mg/kg|Single acute intravenous bolus dose
3321696|NCT00144014|Experimental|V10153, 5.0 mg/kg|Single acute intravenous bolus dose
3321697|NCT00144014|Experimental|V10153, 7.5 mg/kg|Single acute intravenous bolus dose
3321698|NCT00144014|Experimental|V10153, 10 mg/kg|Single acute intravenous bolus dose
3321699|NCT00144001||Group 1|
3321700|NCT00143988||Treadmill Test exertion females|
3321701|NCT00143988||Treadmill test exertion males|
3321702|NCT00143988||Sexual activity exertion females|
3321703|NCT00143988||Sexual activity exertion males|
3321704|NCT00143936|Active Comparator|Low Carb|Low Cabohydrate Diet: 20 week of weekly group behavior modification, 20 weekly bi-weekly, bi-monthly to finish
3321705|NCT00143936|Active Comparator|Low Calorie|Low Calorie Diet: 20 weeks of weekly behavior modification, 20 weekly of bi-weekly, bimonthly to finish 2 years
3321706|NCT00143923|Active Comparator|1|Intervention: 6 months of individualized advice regarding Nutrition, Exercise, Stress Management Counseling for participants who are at intermediate or high Framingham risk for CVD and are randomized to Arm 1
3321707|NCT00143923|Placebo Comparator|2|Intervenition: 6 months of Usual care for participants who are at intermediate or high Framingham risk for CVD and are randomized to Arm 2. No active Nutrition, Exercise, Stress Management Counseling
3321708|NCT00143923|No Intervention|3|No intervention for all participants who are at low Framingham risk for CVD or have preexisting CVD prior to study entry/ No active Nutrition, Exercise, Stress Management Counseling
3321709|NCT00143910||Renal transplant recipient|Recipients of successful renal transplant
3321710|NCT00143845|Experimental|Immunosuppression Taper|Reduced intensity conditioning consisting of Busulfan and Fludarabine(fludarabine 150 mg/m2 IV, busulfan 6 mg/kg IV, total lymphoid irradiation 2 Gy), followed by a rapid immunosuppressive taper of Tacrolimus (0.06 mg/kg q12h, PO, Days -7 to +28), Methotrexate (5 mg/m2, IV, Days +1, +3, +6, +11) and Mycophenolate Mofetil (10 mg/kg every 8 hours, PO, Days -6 to +7).
3321711|NCT00143819|Active Comparator|1|bilateral comparison
3321712|NCT00143819|Placebo Comparator|2|bilateral comparison
3321713|NCT00143741|Other|Lipitor|
3321714|NCT00143715|Experimental|1|Low dose oral vitamin K + warfarin cessation
3321715|NCT00143715|Placebo Comparator|2|
3321716|NCT00143689|Experimental|Lopinavir/ritonavir, Zidovudine, Lamivudine|"Participants will be randomly assigned to receive one of the following drug combinations:~lopinavir/ritonavir (Kaletra) and nevirapine (Viramune) twice a day;~Combivir (Zidovudine (AZT) plus lamivudine (3TC)) and nevirapine twice a day;~Combivir and lopinavir/ritonavir twice a day."
3321717|NCT00143676|Experimental|Lapaquistat Acetate 50 mg QD + Atorvastatin|
3321718|NCT00143676|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin|
3321719|NCT00143676|Active Comparator|Atorvastatin|
3321720|NCT00143663|Experimental|Lapaquistat Acetate 100 mg QD|
3321721|NCT00143663|Placebo Comparator|Placebo QD|
3321722|NCT00143637|Experimental|2|Office dust with added glucan
3321723|NCT00143637|Experimental|1|Clean air exposures in climate chamber
3321724|NCT00143624|Experimental|1|The first group will receive 8 mg of the study drug (rosiglitazone).
3321725|NCT00143624|Placebo Comparator|2|The second group will be given a placebo.
3321726|NCT00143611|Experimental|Resatorvid 1.2 mg/kg/day|
3321727|NCT00143611|Experimental|Resatorvid 2.4 mg/kg/day|
3321728|NCT00143611|Placebo Comparator|Placebo|
3321729|NCT00143598|Active Comparator|Active ECS|Active Elastic Compression Stockings (ECS) 30-40 mm Hg compression at the ankle.
3321730|NCT00143598|Placebo Comparator|Placebo ECS|Placebo stockings with identical appearance to Active ECS and with < 5 mm Hg compression at the ankle.
3321731|NCT00143572|Other|1|
3321732|NCT00143559|Other|1|
3321733|NCT00143533|Other|1|
3321734|NCT00143507|Experimental|Ivabradine|
3321735|NCT00143507|Placebo Comparator|Placebo|
3321736|NCT00143494|Experimental|1|Critically hill, mechanically ventilated patients
3321737|NCT00143468|Experimental|1|ALI/ARDS patients and healthy subjects
3321738|NCT00143455|Experimental|B|
3321739|NCT00143455|Experimental|A|
3321740|NCT00143403|Experimental|1|
3321741|NCT00143403|Active Comparator|2|
3321742|NCT00143390|Experimental|1|
3321743|NCT00143390|Experimental|2|
3321744|NCT00143312|Experimental|1|
3321745|NCT00143273|Experimental|Lasofoxifene Dose 1|0.05 mg
3321746|NCT00143273|Experimental|Lasofoxifene Dose 2|0.25 mg
3321747|NCT00143273|Experimental|Lasofoxifene Dose 3|0.5 mg
3321748|NCT00143273|Placebo Comparator|Placebo|0 mg
3321749|NCT00143247|Experimental|Exubera® (inhaled insulin)|Open label, no comparator
3321750|NCT00143182|Experimental|1|Asenapine
3321751|NCT00143182|Active Comparator|2|Olanzapine
3321752|NCT00143130|Experimental|Single Arm|
3321753|NCT00143039||NIH/SSIUGR fetuses|Group 1 includes pregnancies complicated by a fetus with either Non-Immune Hydrops or Severe Symmetrical IUGR.
3321754|NCT00143039||Control-Normal fetus|Group 2 includes all normally appearing fetuses on U/S who will be having a diagnostic amniocentesis as part of their routine care.
3321755|NCT00142961|Experimental|1|Atomoxetine prescribed daily
3321756|NCT00142961|Placebo Comparator|2|placebo controlled arm
3321757|NCT00142948|Experimental|Naltrexone|Naltrexone Oral 50 mgs daily
3321758|NCT00142948|Placebo Comparator|Placebo|1 to 1 comparison of Naltrexone to placebo
3321759|NCT00142935|Experimental|Pre-Release Initiation MMT|Participants assigned to this arm will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
3321760|NCT00142935|Experimental|Post Release Initiation of MMT|Participants assigned to this arm will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
3321761|NCT00142935|Active Comparator|Standard of Care Plus|Participants assigned to this arem will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
3321762|NCT00142922|Experimental|1|Attended Breaking Down Barriers program
3321763|NCT00142922|Active Comparator|2|Attention control group
3321764|NCT00142922|Active Comparator|3|Indivdual attention control group
3321854|NCT00141687|Active Comparator|Delayed External Cephalic Version Group|Delayed external cephalic version (ECV) procedure performed at or after 37 weeks and 0/7 days of gestation
3321855|NCT00141661|Experimental|Low Dose Arm|
3321856|NCT00141661|Experimental|High Dose Arm|
3321765|NCT00142909|Experimental|Drug: Lofexidine|"Lofexidine: Study medication~Participants will receive daily lofexidine and the dosing will be initiated at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject."
3321766|NCT00142909|Placebo Comparator|Drug: Placebo|"Placebo pill.~Participants will receive daily placebo and will follow the same scheduled delivery as those in the intervention for 12 weeks."
3321767|NCT00142883|Active Comparator|pregabalin|pregabalin compared to placebo
3321768|NCT00142883|Placebo Comparator|Placebo|Placebo compared to pregabalin
3321769|NCT00142870|Placebo Comparator|A|
3321770|NCT00142844|Experimental|Naltrexone|Naltrexone
3321771|NCT00142844|Experimental|Disulfiram|Disulfiram
3321772|NCT00142844|Experimental|Naltrexone and Disulfiram|Naltrexone and Disulfiram
3321773|NCT00142844|Placebo Comparator|Placebo|Placebo
3321774|NCT00142831|Experimental|1|Bupropion-SR, 150 mg/day x 3 days, then 300 mg/day for 13 weeks
3321775|NCT00142831|Placebo Comparator|2|Identical Placebo
3321776|NCT00142818|Experimental|1|Nal + Mod
3321777|NCT00142818|Experimental|2|Nal
3321778|NCT00142818|Experimental|3|Mod
3321779|NCT00142818|Placebo Comparator|4|Placebo
3321780|NCT00142792|Active Comparator|A. Cyclic stim|"Preprogrammed cycles of finger and thumb flexor and extensor stimulation (and flexor stimulation if deemed necessary by the PI) repeatedly and automatically close and open the hand without any effort or voluntary intent required by the subject.~Subject instructed to relax, not attempt to assist the stimulation, and not to move the contralateral arm/hand during stimulation~Uses NMES device with EMG-triggered and Cyclic capabilities"
3321781|NCT00142792|Active Comparator|B. Sensory stim|"Sensory-only electrical stimulation. The stimulation will be cyclic in nature but intensity will be set to a level that can be felt by the patient but not sufficient to cause muscle contraction.~Uses NMES device with EMG-triggered and Cyclic capabilities"
3321782|NCT00142792|Active Comparator|C. EMG-Triggered|"EMG-Triggered electrical stimulation. Subjects in this group will attempt to extend their affected wrist and fingers in response to an audio cue. They will be rewarded with stimulation to cause full hand opening once they have generated EMG sufficient to reach a preset threshold level.~Uses NMES device with EMG-triggered and Cyclic capabilities"
3321783|NCT00142753|Active Comparator|A1: ATN 024 Energix-B Standard Adult Dose|
3321784|NCT00142753|Experimental|A2: ATN 024 Engerix-B Increased Adult Dose|
3321785|NCT00142753|Active Comparator|A3: ATN 024 Twinrix Standard Adult Dose|
3321786|NCT00142753|Experimental|B1: ATN 025 Recombivax|
3321787|NCT00142753|Experimental|B2: ATN 025 Twinrix|
3321788|NCT00142740||1 - HIV Positive|Participant in parent study ATN 024, aged 12-24 years, testing HIV positive. All eligible youths must be negative for HBV core antibody, HBV surface antigen, and HBV surface antibody at the time of enrollment in to ATN 024.
3321789|NCT00142740||2 - HIV Negative|Participant in parent study ATN 025, aged 12-24 years and testing negative for HIV infection. All eligible youths must be negative for HBV core antibody, HBV surface antigen, and HBV surface antibody at the time of enrollment in to ATN 025.
3321790|NCT00142688|Experimental|1|Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
3321791|NCT00142688|Active Comparator|2|Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
3321792|NCT00142623|Experimental|1|"Use of five tailored take-home DVDs aimed at reducing exposure to ETS"
3321793|NCT00142623|No Intervention|2|Usual care
3321794|NCT00142610|Experimental|vitamin|500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks
3321795|NCT00142610|Placebo Comparator|Placebo|
3321796|NCT00142597|Active Comparator|Traditional Acupuncture|Acupuncture sites will be used for active intervention.
3321797|NCT00142597|Sham Comparator|Sham Treatment|Sham acupuncture is used.
3321798|NCT00142584|Experimental|1-NEB|Nebivolol
3321799|NCT00142584|Active Comparator|2-MET|Metoprolol
3321800|NCT00142532|Experimental|1|At the time of pre-op preparation, 18 semi-permanent intradermal acupuncture studs will be placed at acupuncture points in the back, two will be placed in the legs and two in the ear. All studs will be replaced when the epidural is removed or, for patients without epidurals, shortly before discharge. The new leg and auricular studs will then be removed at eleven days; the new back studs will be removed at the three week post-discharge consult.
3321801|NCT00142532|Placebo Comparator|2|"The treatment is the same as for the true acupuncture group, with the following exceptions. The studs in the back will be dummy studs have no needle and that have been used in previous research at MSKCC. The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (~1.25cm) from the spine. The leg studs will be placed at 2 cun (~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (~ 5cm) proximal and 3 cun (~ 5cm) medial to the midpoint of the antecubital crease.~Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory"
3321802|NCT00142519|Active Comparator|1|methadone
3321803|NCT00142519|Experimental|2|methadone and morphine
3321804|NCT00142506|Active Comparator|1|radiotherapy with hormones, questionaire assessments
3321805|NCT00142506|Placebo Comparator|2|radiotherapy without hormones, questionaire assessments
3321806|NCT00142493|Experimental|1|
3321807|NCT00142493|Experimental|2|
3321808|NCT00142493|Experimental|3|
3321809|NCT00142493|Experimental|4|
3321810|NCT00142493|Placebo Comparator|5|
3321857|NCT00141661|Placebo Comparator|Placebo Control|
3321858|NCT00141648|Experimental|1|Chemotherapy followed by radiotherapy to begin 3 weeks after the last cycle.
3321811|NCT00142480|Experimental|Capecitabine, Oxaliplatin, Bevacizumab|There are two phases of study treatment. Phase I includes all patients and will last 6 weeks. During this phase, oxaliplatin will be given intravenously (IV) on days 1, 8, 22, and 29; bevacizumab will be given IV on days 1, 15, and 29; capecitabine will be administered orally on days 1-14 and 22-35. Radiation therapy will be given once daily for 5 days (Monday-Friday) per week for a total of 28 treatments. Phase II has two groups: 1) patients who had tumors removed prior to entering study and 2) patients who entered the study with advanced disease. Patients who had their tumors removed prior to entering the study will be treated with the above 6-week regimen twice for a total of 12 weeks of treatment. Patients who were unresectable prior to entering the study but then were deemed resectable after treatment on trial will undergo resection. Following surgical recovery (8-10 weeks) they will be treated again with the above 6-week regimen twice for a total of 12 weeks of treatment.
3321812|NCT00142467|Experimental|Bevacizumab, Gemcitabine, Oxaliplatin|For cycle 1 (14 days), bevacizumab 10 mg/kg was administered alone on day 1. For cycle 2 and beyond (28 days/cycle), bevacizumab 10 mg/kg was administered on days 1 and 15, gemcitabine 1,000 mg/m2 was administered as a dose rate infusion at 10 mg/m2/min followed by oxaliplatin at 85 mg/m2 on days 2 and 16. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
3321813|NCT00142428|Experimental|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
3321814|NCT00142415|Experimental|Cohort 1, 30 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 30 mCi/m^2 of 177-Lu.
3321815|NCT00142415|Experimental|Cohort 2, 40 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 40 mCi/m^2 of 177-Lu.
3321816|NCT00142415|Experimental|Cohort 3, 50 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 50 mCi/m^2 of 177-Lu.
3321817|NCT00142415|Experimental|Cohort 4, 60 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 60 mCi/m^2 of 177-Lu.
3321818|NCT00142415|Experimental|Cohort 5, 70 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 70 mCi/m^2 of 177-Lu.
3321819|NCT00142415|Experimental|Cohort 6, 65 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 65 mCi/m^2 of 177-Lu.
3321820|NCT00142246|Experimental|1|Intermittent preventive treatment with antimalarial drug combination(SP and amodiaquine)
3321821|NCT00142246|Placebo Comparator|2|Dual placebo comparator
3321822|NCT00142207|Active Comparator|1|Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine
3321823|NCT00142207|Active Comparator|2|Device: Insecticide-treated mosquito bed net
3321824|NCT00142207|Active Comparator|3|"Combination of Drug + Device:~Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine Device: Insecticide-treated mosquito bed net"
3321825|NCT00142181|Experimental|Campath-1H|30 mg IV three times a week, 6-12 weeks.
3321826|NCT00142168|Experimental|CC-5103 (Lenalidomide) and Rituximab|Intended therapy consisted of 48 weeks of CC-5103 (lenalidomide)(25 mg/d for 3 weeks and then 1 week off) along with rituximab (375 mg/m(2)/wk) dosed on weeks 2 to 5 and 13 to 16.
3321827|NCT00142116|Experimental|Thalidomide and Rituximab|"Thalidomide 200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks~Rituximab Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later."
3321828|NCT00142103|Experimental|CPG10101|
3321829|NCT00142103|Experimental|CPG10101 + pegylated interferon|
3321830|NCT00142103|Experimental|CPG10101 + ribavirin|
3321831|NCT00142103|Experimental|CPG10101 + pegylated interferon + ribavirin|
3321832|NCT00142103|Active Comparator|Pegylated inteferon + ribavirin|
3321833|NCT00142103|Experimental|CPG10101 + pegylated interferon + ribavirin (rollover)|
3321834|NCT00142090|Experimental|2|3% Hypertonic saline
3321835|NCT00142090|Placebo Comparator|1|Normal saline
3321836|NCT00142051|Experimental|1|inhaled NO
3321837|NCT00142051|Placebo Comparator|2|room air inhalation
3321838|NCT00141986|Experimental|Vitamin D—higher dose|Vitamin D 2000 IU per os once daily
3321839|NCT00141986|Active Comparator|Vitamin D—lower dose|Vitamin D 400 IU per os once daily
3321840|NCT00141921|Experimental|Etanercept|Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
3321841|NCT00141908|Placebo Comparator|Placebo progesterone injection|Placebo IM injections
3321842|NCT00141908|Active Comparator|Progesterone injections|17-hydroxyprogesterone caproate weekly injections
3321843|NCT00141895|Active Comparator|A|Vaginal Cytotec at doses of 400 microgram every 4 hours until delivery
3321844|NCT00141895|Active Comparator|B|Sublingual Cytotec at doses of 400 microgram every 4 hours until delivery
3321845|NCT00141856|Other|1|
3321846|NCT00141778|Placebo Comparator|Placebo|matched placebo pills daily beginning 4-7 days before surgery and continuing through discharge
3321847|NCT00141778|Experimental|Ramipril|Ramipril daily (2.5mg, increased to 5mg) beginning 4 to 7 days before surgery and continuing through discharge
3321848|NCT00141778|Experimental|Spironolactone|Spironolactone 25mg daily beginning 4 to 7 days before surgery and continuing through discharge
3321849|NCT00141765|Experimental|Myeloablative Chemotherapy with Stem Cell Rescue|Myeloablative Chemotherapy, followed by stem cell rescue
3321850|NCT00141739|Experimental|GVHD prophylaxis|GVHD prophylaxis with etanercept
3321851|NCT00141726|Experimental|etanercept treatment|Etanercept for lung injury
3321852|NCT00141713|Experimental|1|etanercept treatment for GVHD
3321853|NCT00141687|Experimental|Early External Cephalic Version Group|Early external cephalic version (ECV) procedure performed between 34 weeks and 0/7 days and 35 weeks and 6/7 days of gestation
3321859|NCT00141557|Experimental|1|
3321860|NCT00141557|Active Comparator|2|
3321864|NCT00141518|Experimental|Duodopa Naïve|Duodopa-naïve participants titrated to receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL [100-200 mg levodopa]); the continuous maintenance dose (usually 2-6 mL/hour [40-120 mg levodopa/hour]); and extra bolus doses, adjusted individually.
3321865|NCT00141518|Experimental|Duodopa Non-naïve < 2 Years|Duodopa non-naïve participants treated with Duodopa for < 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL [100-200 mg levodopa]); the continuous maintenance dose (usually 2-6 mL/hour [40-120 mg levodopa/hour]); and extra bolus doses, adjusted individually.
3321866|NCT00141518|Experimental|Duodopa Non-naïve ≥ 2 years|Duodopa non-naïve participants treated with Duodopa for ≥ 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL [100-200 mg levodopa]); the continuous maintenance dose (usually 2-6 mL/hour [40-120 mg levodopa/hour]); and extra bolus doses, adjusted individually.
3321867|NCT00141453|Experimental|1|Olmesartan medoxomil tablets 10mg to 40 mg
3321868|NCT00141453|Placebo Comparator|2|Matching placebo tablets
3321869|NCT00141440|Experimental|1|COPD patients
3321870|NCT00141323|Experimental|lasofoxifene 0.5 mg/day|
3321871|NCT00141323|Placebo Comparator|placebo|
3321872|NCT00141323|Experimental|lasofoxifene 0.25 mg/day|
3321873|NCT00141297|Experimental|PD-0332991|
3321874|NCT00141271|Active Comparator|20-40mg BID arm|
3321875|NCT00141271|Active Comparator|60-80mg bid arm|
3321876|NCT00141271|Placebo Comparator|Placebo|
3321877|NCT00141219|Experimental|1|
3321878|NCT00141219|Placebo Comparator|2|
3321879|NCT00141193|Placebo Comparator|A|
3321880|NCT00141115|Experimental|Levetiracetam|Levetiracetam 1500 mg BID
3321881|NCT00141102|Experimental|A|
3321882|NCT00141102|Active Comparator|B|
3321883|NCT00141037|Active Comparator|Steroid-Based Immunosuppression|Subjects will receive prednisone immunosuppression (10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing <40kg and 1.5 mg/kg/day in subjects weighing >40 kg) and proceed with a prednisone taper according to the trial's protocol.
3321884|NCT00141037|Experimental|Steroid-Free Immunosuppression|Subjects will receive extended daclizumab induction until the sixth month post-transplant (2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11 and months 4, 5, and 6).
3321885|NCT00141024|Experimental|1|Group 1 will receive 4 vaccinations of the EP-1043 vaccine or placebo. Vaccinations will be given at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
3321886|NCT00141024|Experimental|2|Group 2 will receive 4 vaccinations of the EP-1043 vaccine or placebo. Vaccinations will be given at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
3321887|NCT00141024|Experimental|3|In Part B, Group 3 will receive 4 vaccinations of either the EP-1043 vaccine or placebo. Vaccinations will occur at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
3321888|NCT00141024|Experimental|4|In Part B, Group 4 will receive 4 vaccinations of either the DNA vaccine EP-HIV-1090 or placebo. Vaccinations will occur at Months 0, 1, 3, and 6.
3321889|NCT00141024|Experimental|5|In Part B, Group 5 will receive 4 vaccinations of either the protein vaccine EP-1043 plus DNA vaccine EP-HIV- 1090 or placebo. Vaccinations will occur at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
3321890|NCT00141011|Experimental|Intravenous ancrod|Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
3321891|NCT00141011|Placebo Comparator|Intravenous Placebo|Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.
3321892|NCT00140907|Placebo Comparator|1|Placebo
3321893|NCT00140907|Active Comparator|2|Losartan
3321894|NCT00140842||Obese girls|The inclusion criteria will be girls 12-18 years of age. According to the Centers for Disease Control and Prevention, the definition of obesity is a BMI higher than the 95th percentile for age and sex, and that of overweight is a BMI between the 85th and 95th percentiles. Cases will be defined as having a body mass index (BMI) greater than the 95th percentile for age according to the 2000 Centers for Disease Control and Prevention growth charts.
3321895|NCT00140842||Normal-weight girls|
3321896|NCT00140790|Active Comparator|Valsartan 40mg|Standard Dose valsartan
3321897|NCT00140790|Active Comparator|Valsartan 160mg|High Dose valsartan
3321898|NCT00140751|Experimental|Simplification|The patients included in this arm are on Monotherapy of Kaletra (Lopinavir/ritonavir)during 48 weeks
3321899|NCT00140751|No Intervention|Continued|The patients included in this arm continue their treatment without any changes
3321900|NCT00140738|Experimental|Group A|"Patients receive study vaccinations in 3 consecutive cycles:~In Cycle 1 each patients will receive six vaccinations at two-week intervals followed by evaluation.~In Cycle 2, subjects will patients six vaccinations at two-week intervals followed by evaluation.~In Cycle 3, subjects will patients six vaccinations at three-week intervals."
3321901|NCT00140738|Experimental|Group B|Patients receive study vaccinations as second-line therapy
3321902|NCT00140712|Experimental|Ropinirole|single dose .25mg of IR formulation, .05mg of RLS controlled release
3321903|NCT00140660|Experimental|R-ACVBP|addition of rituximab to standard ACVBP chemotherapy
3321904|NCT00140660|No Intervention|ACVBP|standard ACVBP chemotherapy
3321905|NCT00140621|Experimental|Agalsidase Beta|Agalsidase beta 1 milligram per kilogram (mg/kg) intravenously once every 2 weeks up to 156 weeks.
3321906|NCT00140582|Experimental|A : rituximab maintenance|Maintenance with rituximab for 2 years
3321907|NCT00140582|No Intervention|B : no maintenance|No further treatment
3321908|NCT00140556|Experimental|ChemoRadiotherapy|Radiation Therapy concurrent with cisplatin chemotherapy, Avastin and Tarceva
3321909|NCT00140530|Experimental|1|Due to randomisation patients got a Paclitaxel-eluting stent
3321954|NCT00139490|Placebo Comparator|C|Usual Care group
3321910|NCT00140530|Experimental|2|Due to randomization patients got a Rapamycin-eluting stent.
3321911|NCT00140504|Experimental|MedCheck|Electronic medication safety queries via PatientSite portal
3321912|NCT00140504|No Intervention|Usual care|No electronic medication safety messages via PatientSite portal
3321913|NCT00140465|Active Comparator|1|75 mg Clopidogrel Maintenance Doses
3321914|NCT00140465|Active Comparator|2|150 mg Clopidogrel Maintenance Doses
3321915|NCT00140426|Placebo Comparator|placebo|double blind study of risperidone for anorexia nervosa. this is the subject group that receives placebo.
3321916|NCT00140426|Active Comparator|risperidone|Study is double blind, placebo controlled. This is the subject group on active medication
3321917|NCT00140413|Experimental|Treatment Group 1: Receiving GH Treatment|Treatment group assignment was based on subject's stature SDS relative to the mid-parental target height (MPTH) at baseline and subsequent classification as growth deceleration or normal growth. Subjects with growth deceleration were assigned to the GH treatment group in accordance with standard of care. Subjects with normal growth were randomized to treatment or to control (no intervention). The intervention was Nutropin AQ. The starting dose was calculated as 0.3 mg/kg/wk and subsequently modified based on observed length/height velocity and serum IGF-I levels.
3321918|NCT00140413|No Intervention|Treatment Group 2: Control|Treatment group assignment was based on subject's stature SDS relative to the mid-parental target height (MPTH) at baseline and subsequent classification as growth deceleration or normal growth. Subjects with normal growth were randomized to treatment or to control. The control group received no intervention; however, control subjects were switched (crossed over) to the GH replacement group if, during the course of the study, they met criteria for growth deceleration.
3321919|NCT00140244|Active Comparator|r-MetHuLeptin|r-MetHuLeptin SubQ once daily
3321920|NCT00140244|Placebo Comparator|Placebo|SubQ once daily
3321921|NCT00140231|Active Comparator|Metreleptin|r-metHuLeptin self-administered subcutaneously
3321922|NCT00140231|Placebo Comparator|Placebo|Placebo, administered in same method as active arm.
3321923|NCT00140140|Experimental|Part 1: 80 mg ABI-007 + 15 mg vinorelbine|Weekly intravenous infusion of 80 mg/m^2 ABI-007, followed by an infusion of 15 mg/m^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. No G-CSF support was planned.
3321924|NCT00140140|Experimental|Part 2: 80 mg ABI-007 + 15 mg vinorelbine|Weekly intravenous infusion of 80 mg/m^2 ABI-007, followed by an infusion of 15 mg/m^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. G-CSF support was given.
3321925|NCT00140140|Experimental|Part 2: 90 mg ABI-007 + 20 mg vinorelbine|Weekly intravenous infusion of 90 mg/m^2 ABI-007, followed by an infusion of 20 mg/m^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. G-CSF support was given.
3321926|NCT00140114|Other|A|A: Vaginal misoprostol (cytotec)
3321927|NCT00140114|Other|B|Sublingual misoprostol (Cytotec)
3321928|NCT00140101|Experimental|1|ZoMaxx™ Drug-Eluting Stent System
3321929|NCT00140101|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
3321930|NCT00140075|Experimental|B|"ET (8 cycles)~T = docetaxel or paclitaxel"
3321931|NCT00140075|Experimental|A|"EC (4 cycles) followed by T (4 cycles) for a total of 8 cycles~T = docetaxel or paclitaxel"
3321932|NCT00140010|Experimental|A|30,000 units of erythropoietin beta in one vial; 3 vials as one set per patient
3321933|NCT00139997|Experimental|LED phototherapy device|Litebook treatment devices: LED phototherapy device, used for 30 min before 8 am
3321934|NCT00139997|Placebo Comparator|Inactivated Negative Ion Generator|Equivalent exposure to inactivated negative ion generator
3321935|NCT00139958||1|
3321936|NCT00139958||2|
3321937|NCT00139841|Experimental|1|bendamustine
3321938|NCT00139828|Other|A|The amount of Nonafact® to be administered and the frequency of treatment is based on the SmPC and should always be determined on the basis of the clinical effectiveness in the individual patient
3321939|NCT00139815|Active Comparator|Enoxaparin|
3321940|NCT00139815|Experimental|Fondaparinux|
3321941|NCT00139776|Active Comparator|Celecoxib - Continuous use|
3321942|NCT00139776|Active Comparator|Celecoxib - Intermittent use|
3321943|NCT00139659|Experimental|Inhaled Insulin|
3321944|NCT00139659|Active Comparator|Subcutaneous Insulin|
3321945|NCT00139594|Experimental|licarbazepine|
3321946|NCT00139581|Experimental|1|Pimecrolimus b.i.d.
3321947|NCT00139581|Experimental|2|Pimecrolimus o.d. and placebo o.d.
3321948|NCT00139542|Active Comparator|CONTROL|AED Treatment protocol following AHA Guidelines 2000 recommendations for cardiac arrest resuscitation.
3321949|NCT00139542|Experimental|STUDY|AED treatment protocol with prolonged CPR intervals, single shocks, fewer rhythm analysis and pulse checks.
3321950|NCT00139529|Experimental|1|Participants will receive an educational intervention during pregnancy combined with a motivational interviewing program using telephone counseling to prevent postpartum relapse to tobacco use.
3321951|NCT00139529|Active Comparator|2|Participants will receive an educational intervention during pregnancy.
3321952|NCT00139490|Experimental|A|The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
3321953|NCT00139490|Active Comparator|B|"The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay."
3321955|NCT00139477|Experimental|Diet/Exercise only, then Diet/Exercise plus Metformin|Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period).
3321956|NCT00139477|Active Comparator|Diet/Exercise plus Metformin, then Diet/Exercise only|Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period).
3321957|NCT00139451|Active Comparator|Nutrition and Growth Hormone|
3321958|NCT00139451|Active Comparator|Observation and Growth Hormone|
3321959|NCT00139399|Active Comparator|Saphenous vein coronary artery bypass graft|Radial artery coronary artery bypass graft versus active comparator of long saphenous vein coronary artery bypass graft
3321960|NCT00139399|Experimental|Radial artery coronary artery bypass graft|
3321961|NCT00139386|Active Comparator|Candesratan|
3321962|NCT00139386|No Intervention|Non-candesartan|
3321963|NCT00139360|Experimental|1|Active drug
3321964|NCT00139256|Experimental|Betamethasone|Betamethasone injection
3321965|NCT00139256|Placebo Comparator|Placebo|Placebo injection
3321966|NCT00139152|Placebo Comparator|Placebo|Saline placebo
3321967|NCT00139152|Experimental|Xolair|Xolair treatment
3321968|NCT00139113|Experimental|HAVRIX 6 and 12 mos; mother antibody pos|HAVRIX administered to infants born to anti-HAV positive mothers at ages 6 and 12 months
3321969|NCT00139113|Active Comparator|HAVRIX age 6, 12 mos; mom antibody neg|HAVRIX administered to infants born to anti-HAV negative mothers at ages 6 and 12 months
3321970|NCT00139113|Experimental|HAVRIX ages 12, 15 mos; mom antibody +|HAVRIX administered to infants born to anti-HAV positive mothers at ages 12 and 15 months
3321971|NCT00139113|Active Comparator|HAVRIX ages 12, 15 mos; mom antibody-|HAVRIX administered to infants born to anti-HAV negative mothers at ages 12 and 15 months
3321972|NCT00139113|Experimental|HAVRIX ages 15,21 mos; mom antibody +|HAVRIX administered to infants born to anti-HAV positive mothers at ages 15 and 21 months
3321973|NCT00139113|Active Comparator|HAVRIX ages 15,21 mos; mom antibody -|HAVRIX administered to infants born to anti-HAV negative mothers at ages 15 and 21 months
3321974|NCT00139074|Active Comparator|1|quetiapine fumarate monotherapy
3321975|NCT00139074|Experimental|2|Quetiapine + sodium valproate
3321976|NCT00138944|Placebo Comparator|1|Placebo
3321977|NCT00138944|Active Comparator|2|Eplerenone
3321978|NCT00138853|Active Comparator|Tantalum knee|Tantalum Tibial component, uncemented
3321979|NCT00138853|Active Comparator|Titanium Knee|Titanium Tibial Component, screw fixed
3321980|NCT00138736|Experimental|A|MBL until the patient's absolute neutrophil count (ANC) is above 500/microL blood.
3321981|NCT00138684|Experimental|Venesection therapy|
3321982|NCT00138684|No Intervention|no venesection therapy|
3321983|NCT00138671|Active Comparator|Subcutaneous Insulin|
3321984|NCT00138671|Experimental|Inhaled Insulin|
3321985|NCT00138645|Experimental|MicroDiet|Participants randomized to the MicroDiet group (1200 kcal/day) will be instructed by a Registered Dietitian to consume (one shake and 3 cookies; 240 kcal) for two meals each day for Months 1 through 3. They will be provided with meal plans for the meal that they do not replace with MicroDiet. During Months 4 through 6, participants in the MicroDiet group will be instructed to replace one meal per day with MD (the energy content of the meal plan will still be 1200 kcal/day). Participants will also be encouraged to eat or drink MD for snacks. The rest of the diet will consist of healthy foods, as outlined above. To help participants adhere to the MicroDiet regimen, they will meet with a registered dietitian for one hour at Week 0 and 30 minutes at Weeks 2 and 4, and every month thereafter.
3321986|NCT00138645|Active Comparator|Healthy Diet|Participants randomized to the Healthy Diet group will be prescribed a traditional food-based diet that contains the same number of kilocalories (1200/day) as the MicroDiet. The Healthy Diet will consist of the same foods that are used in the meal plans for the MicroDiet group. The Healthy Diet group will be instructed not to use meal replacements such as shakes (e.g., Slim Fast®), nutrition bars (e.g., Balance Bar®), or portion-controlled meals (e.g., Healthy Choice entrees).
3321987|NCT00138632|Experimental|1|
3321988|NCT00138632|Experimental|2|
3321989|NCT00138632|Placebo Comparator|3|
3321990|NCT00138554|Experimental|vildagliptin 50 mg qd + pioglitazone 45 mg qd|vildagliptin 50 mg qd + pioglitazone 45 mg qd for 28 weeks
3321991|NCT00138554|Experimental|vildagliptin 50 mg bd+ pioglitazone 45 mg qd|vildagliptin 50 mg bd + pioglitazone 45 mg qd for 28 weeks
3321992|NCT00138476|Experimental|Group 4: 0.48 RT-PCR units or Placebo|Group 4: dosage group of 10 subjects will receive 0.48 RT-PCR units of Lot 42399 NV or placebo control (8 subjects will receive NV and 2 subjects will receive placebo control).
3321993|NCT00138476|Experimental|Group 3: 4.8 RT-PCR units or Placebo|Group 3: dosage group of 12 subjects will receive 4.8 RT-PCR units of Lot 42399 NV or placebo control (10 subjects will receive NV and 2 subjects will receive placebo control).
3321994|NCT00138476|Experimental|Group 2: 48 RT-PCR units or Placebo|Group 2: dosage group of 12 subjects will receive 48 RT-PCR units of Lot 42399 NV or placebo control (10 subjects will receive NV and 2 subjects will receive placebo control).
3321995|NCT00138476|Experimental|Group 1: 4800 RT-PCR units or Placebo|Group 1: dosage group of 11 subjects will receive 4800 reverse transcription polymerase chain reaction (RT-PCR) units of Lot 42399 Norwalk Virus (NV) or placebo control (9 subjects will receive NV and 2 subjects will receive placebo control).
3321996|NCT00138476|Experimental|Validation Group: 4.8 and 0.48 RT-PCR units|Validation Group: dosage group of 12 subjects, 4 will receive 4.8 RT-PCR units and 8 will receive 0.48 RT-PCR units of Lot 42399 NV. No placebo control.
3321997|NCT00138463||West Nile Virus (WNV) Neuroinvasive Disease Cohort|Fever (temperature > 38 C) documented by a health care provider AND: at least one of the following, as documented by a health care provider and in the absence of a more likely clinical explanation: acutely altered mental status; other acute signs of central or peripheral neurologic dysfunction; or cerebrospinal fluid (CSF) pleocytosis associated with illness clinically compatible with meningitis.
3321998|NCT00138463||West Nile Virus Fever Cohort|Temperature > 38 C as documented by a health care provider.
3321999|NCT00138437||Leprosy Patients (Group 1)|All leprosy patients
3322000|NCT00138437||Household Contacts (Group 2)|Household contacts with known contact with leprosy patients
3322001|NCT00138437||Healthy Individuals (Group 3)|Healthy persons with no known contact with leprosy patients
3322002|NCT00138424|Experimental|Cidofovir|32 subjects will be randomized to 1 of 3 possible cohorts. Cohort I will receive dose 0.25 mg/kg; Cohort II will receive 0.5 mg/kg, Cohort III will receive 1.0 mg/kg. Maximum tolerated dose is to be determined.
3322003|NCT00138424|Placebo Comparator|Placebo|16 subjects to receive placebo.
3322004|NCT00138294|Experimental|Intervention Cities|Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) with be offered live attenuated or inactivated influenza vaccines through a school-based research vaccination program.
3322005|NCT00138294|Active Comparator|Comparison Cities|Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites will received their influenza vaccines (live attenuated or inactivated influenza vaccines) by the local healthcare providers.
3322006|NCT00138216|Experimental|Oral Irinotecan, temozolomide and vincristine sulfate|see detailed description
3322007|NCT00138203|Experimental|Treatment (vorinostat)|Patients receive oral suberoylanilide hydroxamic acid once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3322008|NCT00138177|Experimental|Treatment (vorinostat, mFOLFOX)|"Patients receive oral SAHA once or twice daily on days 1-3. Patients also receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 4 followed by fluorouracil IV over 46 hours on days 4-5. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD."
3322009|NCT00138151|Experimental|Paclitaxel, 13-cis Retinoic Acid, and Interferon Alpha-2b|"Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle~Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle~Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days"
3322010|NCT00138125|Experimental|Arm I|see intervention description for details
3322011|NCT00138073|Experimental|Web-based waveform interpretation guide|The arm has access to the Web-based waveform interpretation guide.
3322012|NCT00138034|Active Comparator|Percutaneous coronary intervention (PCI)|Stenting of the culprit lesion of the infarct related artery and aspirin and clopidorgel for at least 6 months
3322013|NCT00138034|Other|Dual antiplatelet therapy|Aspirin and clopidogrel for at least 6 months
3322014|NCT00138008|Active Comparator|1|Drug: endocrine therapy
3322015|NCT00138008|Experimental|2|Procedure/Surgery: radiotherapy
3322016|NCT00137995|Experimental|R-ICE|R-ICE + R-BEAM /ASCT Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna BCNU, Etoposide, Cytarabine, Melphalan Autologous Stem Cell Transplantation
3322017|NCT00137995|Experimental|R-DHAP|R-DHAP + R-BEAM /ASCT Rituximab, Cisplatine, Cytosine Arabinoside, Dexamethasone BCNU, Etoposide, Cytarabine, Melphalan Autologous Stem Cell Transplantation
3322018|NCT00137969|Experimental|Rituximab 1000 mg + prednisone|Participants will receive rituximab 1000 mg intravenously on Days 1, 15, 168, and 182. Participants will also receive an initial dose of prednisone (0.5, 0.75, or 1.0 mg/kg orally once a day) with tapering beginning at Day 16 for 10 weeks to a dose of ≤ 10 mg/day. Participants will also receive acetaminophen 1000 mg orally and diphenhydramine 50 mg orally prior to study drug infusion.
3322019|NCT00137969|Placebo Comparator|Placebo + prednisone|Participants will receive placebo intravenously on Days 1, 15, 168, and 182. Participants will also receive an initial dose of prednisone (0.5, 0.75, or 1.0 mg/kg orally once a day) with tapering beginning at Day 16 for 10 weeks to a dose of ≤ 10 mg/day. Participants will also receive acetaminophen 1000 mg orally and diphenhydramine 50 mg orally prior to study drug infusion.
3322020|NCT00137865|Experimental|EGEN-001|
3322021|NCT00137852|Experimental|Cisplatin/CPT-11/Celecoxib/XRT/Surgery|Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
3322022|NCT00137787|Experimental|1|
3322023|NCT00137787|Active Comparator|2|
3322024|NCT00137735|Active Comparator|1|Gabapentin
3322025|NCT00137735|Placebo Comparator|2|Placebo
3322026|NCT00137631|Experimental|Many Men, Many Voices (3MV) Intervention|Receive 6-session intervention immediately after baseline assessment and randomization
3322027|NCT00137631|No Intervention|Wait list comparison|Receive intervention after 6-month delay (wait list control group)
3322028|NCT00137605|Experimental|Pneumovax/immediate|
3322029|NCT00137605|Experimental|Pneumovax/delayed|
3322030|NCT00137605|Experimental|Prevnar/immediate|
3322031|NCT00137605|Experimental|Prevnar/delayed|
3322032|NCT00137592|Experimental|Lifestyle counseling|Behavioral: small media, group education (multicomponent)
3322033|NCT00137566|Experimental|1 Paracetamol|Paracetamol as per protocol
3322034|NCT00137566|Placebo Comparator|2 Placebo|Inactive placebo as per protocol.
3322035|NCT00137501|Other|A|High dose Nifedpine arm
3322036|NCT00137501|Other|B|Low dose Nifedipine arm
3322037|NCT00137449|Experimental|A|
3322038|NCT00137436|Experimental|A|SU011248 in combination with docetaxel and prednisone
3322039|NCT00137423|Experimental|SU011248 (sunitinib)|Single-arm study
3322040|NCT00137306|Other|Arm 1|
3322041|NCT00137280|Experimental|Collaborative Chronic Illness Care Model|Collaborative Chronic Illness Care Model: A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
3322042|NCT00137280|No Intervention|Usual Care|Usual Care
3322043|NCT00137267|Experimental|Arm 1|This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
3322094|NCT00136565|Experimental|Experimental|Velcade, Doxorubicine, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
3322095|NCT00136474|Active Comparator|Group 1|Amifostine plus radiation therapy
3322096|NCT00136474|Active Comparator|Group 2|Radiation therapy alone
3322044|NCT00137267|Active Comparator|Arm 2|This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
3322045|NCT00137254|Active Comparator|A|
3322046|NCT00137241||Group 1|
3322047|NCT00137215|Active Comparator|A|
3322048|NCT00137202|Active Comparator|2|
3322049|NCT00137189|Experimental|Music therapy|See published study protocol
3322050|NCT00137189|Other|Standard care|See published study protocol
3322051|NCT00137176|Experimental|Rebif + Lipitor|
3322052|NCT00137111|Other|1|
3322053|NCT00137111|Other|2|
3322054|NCT00137046|Active Comparator|Subcutaneous Insulin|
3322055|NCT00137046|Experimental|Inhaled Insulin|
3322056|NCT00136955|Experimental|irinitecan/cisplatin|experimental arm consists of patients who receive irinotecan/cisplatin
3322057|NCT00136916|Experimental|Inhaled Insulin|Inhalable short-acting insulin
3322058|NCT00136916|Active Comparator|Subcutaneous insulin|
3322059|NCT00136903|Active Comparator|Prochymal - 2 million cells|Prochymal - 2 million cells/kg actual body weight, intravenously on study Days 1 and 4 plus daily methylprednisolone 2 mg/kg intravenously or prednisone 2.5 mg/kg orally. Subjects will also continue cyclosporine, tacrolimus, and/or MMF at full therapeutic doses
3322060|NCT00136903|Active Comparator|Prochymal - 8 million cells|Prochymal - 8 million cells/kg actual body weight intravenously on study Days 1 and 4 plus daily methylprednisolone 2 mg/kg intravenously or prednisone 2.5 mg/kg orally. Subjects will also continue cyclosporine, tacrolimus, and/or MMF at full therapeutic doses
3322061|NCT00136890|No Intervention|1|Conventional Staging
3322062|NCT00136890|Experimental|2|PET Imaging
3322063|NCT00136864|Experimental|1|PET Imaging
3322064|NCT00136864|No Intervention|2|Standard Imaging
3322065|NCT00136838|Experimental|Neutral Cue first, then Active Cue|"Each participant receives two consecutive interventions.~Neutral Cue: during this phase of treatment participants were presented with neutral (sham) cue~Cigarette cue: during this phase of treatment participants were presented with active cigarette cue."
3322066|NCT00136838|Experimental|Active Cue first, then Neutral Cue|"Each participant receives two consecutive interventions.~Cigarette cue: during this phase of treatment participants were presented with active cigarette cue.~Neutral Cue: during this phase of treatment participants were presented with neutral (sham) cue"
3322067|NCT00136825|Placebo Comparator|2|Identical appearing placebo pill containing lactose powder, packaged to have similar odor as N-Acetylcysteine in capsule form
3322068|NCT00136825|Experimental|1|N-Acetylcysteine
3322069|NCT00136812|No Intervention|enhanced usual care control|NRT during hospitalization with brief advice to stay quit once discharged
3322070|NCT00136812|Experimental|stage-tailored intervention|NRT during hospitalization with brief advice to stay quit once discharged plus a computer-delivered stage-tailored smoking cessation intervention with manual and counseling plus 10-weeks of nicotine patch available post-hospitalization
3322071|NCT00136786|Placebo Comparator|Intervention 1|"Each participant receives three consecutive interventions.~Placebo~Bupropion~Memantine"
3322072|NCT00136786|Placebo Comparator|Intervention 2|"Bupropion~Memantine~Placebo"
3322073|NCT00136786|Placebo Comparator|Intervention 3|"Memantine~Placebo~Bupropion"
3322074|NCT00136760|Experimental|1|Contingent reinforcement plus bupropion
3322075|NCT00136760|Experimental|2|Contingent reinforcement plus placebo
3322076|NCT00136760|Experimental|3|Non-contingent reinforcement plus bupropion
3322077|NCT00136760|Placebo Comparator|4|Non-contingent reinforcement plus placebo
3322078|NCT00136747|Experimental|BUPROPION|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
3322079|NCT00136747|Experimental|placebo|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
3322080|NCT00136747|Experimental|memantine|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
3322081|NCT00136734|Experimental|1|methylphenidate
3322082|NCT00136734|Placebo Comparator|2|placebo
3322083|NCT00136708|Experimental|NRP Training (Intervention)|Training in AAP neonatal resuscitation training program
3322084|NCT00136708|Other|Control|
3322085|NCT00136695|Experimental|anastrozole|anastrozole
3322086|NCT00136695|Placebo Comparator|placebo|placebo
3322087|NCT00136682|Active Comparator|(PCEA)|patient-controlled epidural analgesia PCEA involves having an epidural catheter placed before surgery.The epidural catheter will be used during surgery to give drugs, such as morphine and a local anesthetic bupivacaine, which will help control pain. After surgery, a constant flow of pain-reducing medicine, such as morphine, will be given through the catheter. This is controlled by the patient.
3322088|NCT00136682|Active Comparator|PCA|patient-controlled intravenous analgesia (PCA) PCA involves placing a tube into the patient's vein after surgery. The tube is connected to a pump that is controlled by the patient. The pump holds a medicine, such as morphine, that eases pain.
3322089|NCT00136656|Active Comparator|1|cefixime antibiotic treatment by oral route
3322090|NCT00136656|Sham Comparator|2|ceftriaxone antibiotic treatment by venous infusion and cefixime antibiotic treatment by oral route during six days
3322091|NCT00136591|Active Comparator|A|Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle. Subjects in this treatment arm will receive a total of 8 cycles of treatment,
3322092|NCT00136591|Experimental|B|
3322093|NCT00136578|Experimental|Subjects receiving carboplatin and SB-715992|Subjects will receive carboplatin on Day 1 as an intravenous (IV) infusion over 30 minutes followed by 1-hour IV infusion of SB-715992 once every 21 days.
3322097|NCT00136435|Other|Only Arm for this study|Only Arm for this study
3322098|NCT00136409|Experimental|Mono-Therapy Gleevec|Gleevec administered orally at a pre-determined dose once daily.
3322099|NCT00136370|Experimental|1|Chlorhexidine Vaginal Wipe
3322100|NCT00136370|Placebo Comparator|2|Sterile water external genital wipe
3322101|NCT00136357|Experimental|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
3322102|NCT00136357|No Intervention|Delayed Intervention|Comparison group not receiving intervention until after the initial intervention was completed.
3322103|NCT00136318|Active Comparator|Escitalopram|After the preobservation period,patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram.
3322104|NCT00136318|Placebo Comparator|Placebo|After the preobservation period, patients received placebo. After 2 weeks of antidepressant pretreatment, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of placebo.
3322105|NCT00136305|Experimental|Pictorial Asthma Action Plan|
3322106|NCT00136305|Active Comparator|Written Asthma Action Plan|
3322107|NCT00136279|Experimental|School plus parent|Adolescents receive school-based curriculum (either Project TNT or Making a Difference) and mothers receive the Linking Lives curriculum
3322108|NCT00136279|Active Comparator|School-only|Adolescents receive school-based curriculum and parents received a control curriculum on helping their child choose a high school
3322109|NCT00136279|Experimental|Parent-Only|In the sex risk reduction portion of the study only, a second experimental group consisted of parents receiving the Linking Lives intervention and adolescents receiving no in-school intervention
3322110|NCT00136227|Experimental|Lifestyle counseling|Behavioral: small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention
3322111|NCT00136214||Interferon Treated Group|Group treated with PEG-Interferon and ribavirin and undergoing MR brain and neuropsychiatric tests
3322112|NCT00136214||Non-treated cohort control|Group undergoing MR brain and neuropsychiatric tests
3322113|NCT00136201|Experimental|1|armDesc1
3322114|NCT00136175|Experimental|Arm I|Patients with clinical stage T2 with hydronephrosis or T3 bladder cancer will receive 3 cycles of chemotherapy (200mg/m^2 paclitaxel on day 1, carboplatin on day 1, and 800 mg/m^2 gemcitabine on days 1 and 8 of each 21 day cycle).
3322115|NCT00136175|Experimental|Arm II|Patients with T4 or lymph node positive disease will receive up to 6 cycles of paclitaxel, carboplatin, and gemcitabine.
3322116|NCT00136149|Experimental|Immediate implants|
3322117|NCT00136136||Normal healthy term newborn|Normal healthy term newborns
3322118|NCT00136136||Ill term newly born without brain damage|Ill term newly borns without brain damage
3322119|NCT00136136||Preterm newly born without brain damage|Preterm newly borns without brain damage
3322120|NCT00136123|Experimental|Implants|
3322121|NCT00136084|Experimental|HDAC (High-Dose Cytarabine)|Since limited characters are allowed in this passage, please see detailed Description for HDAC.
3322122|NCT00136084|Experimental|LDAC (Low-Dose Cytarabine)|Since limited characters are allowed in this passage, please see detailed Description for LDAC.
3322123|NCT00136032|Active Comparator|1|
3322124|NCT00136032|Placebo Comparator|2|
3322125|NCT00135954|Other|late intervention|cyclophosphamide and steroids started at time of renal insufficiency
3322126|NCT00135954|Experimental|early intervention|immediate start of cyclophosphamide and steroids
3322127|NCT00135941|Experimental|1|Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
3322128|NCT00135941|Experimental|2|Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
3322129|NCT00135811|Active Comparator|1|Cyclosporin
3322130|NCT00135811|Active Comparator|2|MMF and Dexamethasone
3322131|NCT00135798|Experimental|LADR Treatment, Genotypes 1,4,6|Subjects randomized to low accelerating dose regimen (LADR) treatment
3322132|NCT00135798|No Intervention|Standard care|Subjects randomized to Standard Care group, Genotypes 1,4,6
3322133|NCT00135798|Experimental|LADR treatment, Genotypes 2,3|Subjects randomized to low accelerating dose regimen (LADR) treatment.
3322134|NCT00135785|Active Comparator|1|Bupropion
3322135|NCT00135785|Placebo Comparator|2|Placebo
3322136|NCT00135759|Placebo Comparator|Group 1|Drug
3322137|NCT00135759|Experimental|2|experimental
3322138|NCT00135759|Experimental|3|experimental
3322139|NCT00135733|Active Comparator|A|Amevive
3322140|NCT00135733|Placebo Comparator|B|Placebo
3322141|NCT00135707|Active Comparator|Vitamins|Vitamins C & E
3322142|NCT00135707|Placebo Comparator|Placebo|Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell
3322143|NCT00135694|Experimental|Immunosuppression Withdrawal|Subjects may randomize to this group at 12 to 24 months after transplantation. This is followed by tapered withdrawal of calcineurin inhibitor-based immunosuppression therapy over the course of 1 year.
3322144|NCT00135694|Active Comparator|Immunosuppression Maintenance|Liver transplant, followed by maintenance doses of continuous calcineurin inhibitor-based immunosuppression therapy.
3322145|NCT00135668|Active Comparator|1|Nitroprusside infusion 0.3 mcg/kg/min
3322146|NCT00135668|Active Comparator|2|nitroprusside infusion 1 mcg/kg/min
3322147|NCT00135668|Active Comparator|3|nitroprusside infusion 2 mcg/kg/min
3322148|NCT00135668|Active Comparator|4|nitroprusside 3 mcg/kg/min
3322898|NCT00125385|Experimental|Cohort 5|Dose Group
3322149|NCT00135603|Active Comparator|A|appendectomy, actual usual treatment
3322150|NCT00135603|Active Comparator|B|antibiotic therapy
3322151|NCT00135590|Experimental|1|Protein pulse-feeding
3322152|NCT00135590|Active Comparator|2|Spread diet
3322153|NCT00135577|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally once in the morning and once in the evening.
3322154|NCT00135577|Experimental|Alvimopan 1 mg Once Daily (QD)|"Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg in the morning and received placebo in the evening.~Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan in the morning and placebo in the evening for 3 days, then 1 mg of alvimopan in the morning and placebo in the evening for the remaining 3 weeks."
3322155|NCT00135577|Experimental|Alvimopan 1 mg Twice Daily (BID)|"Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg once in the morning and once in the evening.~Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan once in the morning and once in the evening for 3 days, then 1 mg of alvimopan once in the morning and once in the evening."
3322156|NCT00135577|Placebo Comparator|Placebo|Placebo was administered orally once in the morning and once in evening.
3322157|NCT00135551|Active Comparator|angiotensin receptor blockers|benidipine+angiotensin receptor blockers, titlation scheme
3322158|NCT00135551|Active Comparator|β-blockers|benidipie+β-blockers, titlation scheme
3322159|NCT00135551|Active Comparator|thiazide diuretics|benidipine+thiazide diuretics, titlation scheme
3322160|NCT00135525|Experimental|Paroxetine|"Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.~Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan."
3322161|NCT00135525|Placebo Comparator|Placebo|
3322162|NCT00135499|Experimental|R-ACVBP|Rituximab, Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
3322163|NCT00135499|Active Comparator|R-CHOP|Rituximab, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone
3322164|NCT00135447||A|
3322165|NCT00135421|Experimental|A1|
3322166|NCT00135421|Active Comparator|A2|
3322167|NCT00135421|Placebo Comparator|A3|
3322168|NCT00135408|Active Comparator|A1|
3322169|NCT00135408|Active Comparator|A2|
3322170|NCT00135395|Active Comparator|A|
3322171|NCT00135395|Active Comparator|B|
3322172|NCT00135356|Active Comparator|Switch arm|
3322173|NCT00135356|Active Comparator|Control Arm|
3322174|NCT00135343|Experimental|A|
3322175|NCT00135343|Experimental|B|
3322176|NCT00135330|Experimental|Exenatide Arm|
3322177|NCT00135330|Experimental|Exenatide plus Rosiglitazone Arm|
3322178|NCT00135330|Experimental|Rosiglitazone Arm|
3322179|NCT00135304|Experimental|Cinacalcet and low-dose Vitamin D|Cinacalcet and low-dose IV Vitamin D
3322180|NCT00135304|Active Comparator|Vitamin D alone|Escalating doses of IV Vitamin D alone
3322181|NCT00135278|Other|CSF Drainage|
3322182|NCT00135278|Other|No CSF Drainage|
3322183|NCT00135226|Active Comparator|Aspirin + Omega-3-Ethyl Esters|Participants receive 100mg of aspirin once daily and 1g of omega-3-Ethyl Esters once daily.
3322184|NCT00135226|Active Comparator|Aspirin + Placebo Omega-3-Ethyl Esters|Participants receive 100mg of aspirin once daily and placebo omega-3-Ethyl Esters once daily.
3322185|NCT00135226|Active Comparator|Placebo Aspirin + Omega-3-Ethyl Esters|Participants receive placebo aspirin once daily and 1 g of omega-3-Ethyl Esters once daily.
3322186|NCT00135226|Active Comparator|Placebo Aspirin + Placebo Omega-3-Ethyl Esters|Participants receive placebo aspirin once daily and placebo omega-3-Ethyl Esters once daily.
3322187|NCT00135200|Experimental|Bexxar therapeutic|"The Bexxar therapeutic regimen is delivered in two sets of intravenous infusions given 7-14 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body. A trace amount of radioactive Iodine 131 Tositumomab is initially given to enable physicians to evaluate the clearance of radiation from the subject's body with gamma camera scans. Calculations made on the basis of these individualized radiation clearance rates allow the therapeutic dose (given 7-14 days after the dosimetric infusion) to be tailored for each patient. The therapeutic dose contains Tositumomab labeled with the amount of Iodine 131 tositumomab specifically calculated based on the scans performed following the dosimetric dose."
3322188|NCT00135161|Experimental|Intensity modulated radiation therapy (IMRT).|
3322189|NCT00135135|Other|1|
3322190|NCT00135122|Placebo Comparator|2|Placebo in six days
3322191|NCT00135096|Experimental|1|PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
3322192|NCT00135096|Experimental|2|POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
3322193|NCT00135083|Experimental|1|"Once daily:~Insulin glulisine Dosing: Supper, Lunch, Breakfast~Monitoring Needed at: Bedtime,Pre-Supper, Pre-Lunch"
3322194|NCT00135083|Experimental|2|"Twice daily:~Insulin glulisine Dosing: Supper & Lunch, Lunch & Breakfast, Breakfast & Supper~Monitoring Needed at: Bedtime & Pre-Supper, Pre-Supper & Pre-Lunch, Pre-Lunch & Bedtime"
3322195|NCT00135083|Experimental|3|"Twice daily:~Insulin glulisine Dosing: Supper, Lunch, Breakfast~Monitoring Needed at: Bedtime, Pre-Supper, Pre-Lunch"
3322196|NCT00135005|Experimental|AMN107 + STI571|
3322197|NCT00134966|Experimental|1|
3322198|NCT00134966|Active Comparator|2|
3322199|NCT00134901|Experimental|Memantine|Memantine
3322200|NCT00134901|Placebo Comparator|Placebo|Placebo
3323002|NCT00124020|Active Comparator|Vancomycin|
3322201|NCT00134823|Experimental|dosing decision support|weight based dosing decision support
3322202|NCT00134823|No Intervention|no decision support|no weight based dosing decision support
3322203|NCT00134784|Experimental|Assess [123I]B-CIT SPECT imaging|To assess[123I]B-CIT SPECT imaging in early Parkinson's disease subjects on placebo compared to early verses later Levodopa. Subjects on Levodopa 150mg/day, Levodopa 300 mg/day, and Levodopa 600 mg/day will be assessed.
3322204|NCT00134758|Experimental|1|"Ursodeoxycholic acid during 2 years :~between 40 and 50 kg : 500 mg/day~between 51 and 75 kg : 750 mg/day~between 76 and 100 kg : 1000 mg/day"
3322205|NCT00134758|Placebo Comparator|2|
3322206|NCT00134745|Active Comparator|4 mg estradiol|
3322207|NCT00134745|Placebo Comparator|2 mg estradiol|
3322208|NCT00134719|Experimental|MenHibrix Group|Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.
3322209|NCT00134719|Active Comparator|ActHIB + Meningitec Group|Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.
3322210|NCT00134719|Active Comparator|ActHIB/PedvaxHIB Group|Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.
3322211|NCT00134680|Experimental|Letrozole & Trastuzumab|Letrozole 2.5 mg tablets daily and Trastuzumab 2 mg/kg by IV weekly
3322212|NCT00134654|Active Comparator|Group A|Premarin once a day
3322213|NCT00134654|Active Comparator|Group B|Premarin 3 times a day
3322214|NCT00134628|Active Comparator|A|Hyperbaric Oxygen Therapy
3322215|NCT00134628|Sham Comparator|B|Normal Air
3322216|NCT00134615|Experimental|RQP-MH|These participants receive the RQP-MH intervention
3322217|NCT00134563|Experimental|Teriflunomide 7 mg|Teriflunomide 7 mg once daily for 108 weeks
3322218|NCT00134563|Experimental|Teriflunomide 14 mg|Teriflunomide 14 mg once daily for 108 weeks
3322219|NCT00134563|Placebo Comparator|Placebo|Placebo (for teriflunomide) once daily for 108 weeks
3322220|NCT00134537|Experimental|1|Interspinous process and dynamic stabilization
3322221|NCT00134537|Active Comparator|2|Conservative Care
3322222|NCT00134420|Active Comparator|Growth Hormone Treatment|Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, and Neuropsychological Testing was done 1st for eligibility and this group received GH (growth hormone) (Nutropin AQ) 0.3 mgs per kg per week (standard dosing for GH)immediately after randomization
3322223|NCT00134420|Other|GH treatment delayed by one year|Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, and Neuropsychological Testing was done first for eligibility and this group received growth hormone (Nutropin AQ) 0.3 mgs per kg per week (standard dosing for GH)after one year of observation
3322224|NCT00134381|Active Comparator|active drug|bilateral comparison of green tea constituent
3322225|NCT00134381|Placebo Comparator|placebo|bilateral comparison of placebo vehicle
3322226|NCT00134355|Experimental|PTK787|"PTK787:~250 mg orally twice daily x 2 wks, then 250 mg orally am, 500 mg orally pm x 1 wk, then 500 mg orally twice daily"
3322227|NCT00134303|Experimental|NASH|
3322228|NCT00134277|Active Comparator|Infragenual dilatation with stenting|
3322229|NCT00134277|Active Comparator|Infragenual dilatation with cutting balloon|
3322230|NCT00134277|Active Comparator|Laser therapy|
3322231|NCT00134277|Placebo Comparator|Infragenual dilatation|
3322232|NCT00134160|Active Comparator|1|High-dose ARB monotherapy
3322233|NCT00134160|Active Comparator|2|Combination therapy of ARB with Calcium Channel Blocker
3322234|NCT00134069|Experimental|Treatment (sorafenib, irinotecan, cetuximab)|Patients will receive sorafenib by mouth once or twice a day and a 1- to 2-hour infusion of cetuximab once a week for 8 weeks. They will also receive a 1½-hour infusion of irinotecan once a week in weeks 3-6. Patients will then receive sorafenib by mouth once or twice a day and a 1- to 2-hour infusion of cetuximab once a week for 6 weeks. They will also receive a 1½-hour infusion of irinotecan once a week in weeks 1-4. Treatment may repeat every 6 weeks for as long as benefit is shown.
3322235|NCT00134056|Active Comparator|Arm I: placebo|Patients receive docetaxel and prednisone as in arm I. Patients also receive oral placebo once daily on days 1-21. Treatment repeat every 21 days for up to 12 courses. Patients with stable or responding disease after course 12 may register for continued oral placebo treatment for up to 52 weeks.
3322236|NCT00134056|Experimental|Arm II: atrasentan hydrochloride|Patients receive docetaxel IV over 1 hour on day 1. Patients also receive oral atrasentan and oral prednisone once daily on days 1-21. Treatment repeats every 21 days for up to 12 courses. Patients with stable or responding disease after course 12 may register for continued oral atrasentan treatment for up to 52 weeks.
3322237|NCT00134043|Experimental|Arm I|Patients receive oral suberoylanilide hydroxamic acid (SAHA) twice daily on days 1-14. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients are then evaluated for disease response. Patients achieving a complete response receive an additional 2 courses of SAHA. Patients achieving stable disease or a partial response receive 4 additional courses of SAHA.After completion of study treatment, patients are followed within 4 weeks.
3322238|NCT00134030|Active Comparator|Maintenance therapy group 1 arm I|Patients receive doxorubicin IV continuously over 48 hours on days 1-2 in weeks 12, 17, 22, and 26 and cisplatin IV over 4 hours on days 1 and 2 in weeks 12 and 17. Patients also receive high-dose MTX IV over 4 hours on day 1 in weeks 15, 16, 20, 21, 24, 25, 28, and 29.
3322239|NCT00134030|Experimental|Maintenance therapy group 1 arm II|Patients receive doxorubicin, cisplatin, and high-dose MTX as in arm I. Patients than receive PEG-interferon alfa-2b subcutaneously once daily on day 1 in weeks 30-104.
3322240|NCT00134030|Active Comparator|Maintenance therapy group 2 arm I|Patients receive doxorubicin, cisplatin, and high-dose MTX as in group 1 arm I.
3322291|NCT00133471|Experimental|Group 2B: 7.5 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 7.5 mcg A/H9N2 plus MF59 adjuvant.
3322292|NCT00133471|Experimental|Group 3A: 15 mcg A/H9N2 no adjuvant|12 subjects to receive 15 mcg A/H9N2 with no adjuvant.
3322845|NCT00126126|No Intervention|Wait List Control|Wait List Control Group
3322241|NCT00134030|Experimental|Maintenance therapy group 2 arm II|Patients receive doxorubicin IV continuously over 48 hours on days 1-2 in weeks 12, 20, 28, and 36 and cisplatin IV over 4 hours on days 1 and 2 in weeks 12 and 28. Patients also receive high-dose MTX IV over 4 hours on day 1 in weeks 15, 19, 23, 27, 31, 35, 39, and 40. Patients receive ifosfamide IV over 4 hours on days 1-5 in weeks 16, 24, and 32 and on days 1-3 in weeks 20 and 36 and etoposide IV over 1 hour on days 1-5 in weeks 16, 24, and 32.
3322242|NCT00134017|Experimental|Bone marrow transplant|Myeloablative bone marrow transplant with a busulfan (Bu), cyclophosphamide (Cy), preparative regimen and post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis
3322243|NCT00134004|Experimental|Mini-haplo Transplant|Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.
3322244|NCT00133978|Experimental|Glutamine|Glutamine supplementation
3322245|NCT00133978|Experimental|Antioxidants|Antioxidant supplementation
3322246|NCT00133978|Experimental|Glutamine + Antioxidants|Glutamine and antioxidant supplementation
3322247|NCT00133978|Placebo Comparator|Placebo|Non-isonitrogenic, iso-caloric placebo solution
3322248|NCT00133965||1|Dignity Psychotherapy
3322249|NCT00133965||2|Supportive Psychotherapy
3322250|NCT00133965||3|Standard Palliative Care
3322251|NCT00133952|Experimental|Ruboxistaurin|32 mg taken orally daily for up to 48 months
3322252|NCT00133952|Placebo Comparator|Placebo|Taken orally daily for up to 48 months
3322253|NCT00133913||Cohort|Patients with measurable metastatic colorectal cancer about to start a new line of chemotherapy.
3322254|NCT00133900||Cohort|Metastatic Hormone Refractory Prostate Cancer Patients
3322255|NCT00133887|Experimental|1|patients receiving Rapamycin
3322256|NCT00133887|Active Comparator|2|patients receiving anticalcineurin treatment
3322257|NCT00133809|Experimental|Islet Transplant|All subjects who are found eligible and who can be matched to an appropriate donor will receive/have received an islet transplant
3322258|NCT00133796|Experimental|Heceptin|Herceptin administered to enrolled subjects
3322259|NCT00133770|Experimental|IV pantoprazole|The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
3322260|NCT00133744|Active Comparator|A, 1|
3322261|NCT00133744|Experimental|A, 2|
3322262|NCT00133744|Experimental|A, 3|Multiple micronutrient supplement
3322263|NCT00133718|Other|Structured multi intervention|Structured multi intervention to reach predefined glycemic and blood pressure goals as well as activity and weight goal
3322264|NCT00133718|Other|Standard of care|Standard care with or without structured care according to national guidelines
3322265|NCT00133705|Experimental|Mifepristone|Mifepristone 5 MG capsule taken once daily by mouth
3322266|NCT00133705|Placebo Comparator|Inert capsule|Placebo (for Mifepristone) capsule of nearly identical color, size, and weight taken once daily by mouth
3322267|NCT00133679|Experimental|1|Sildenafil x 45 days
3322268|NCT00133679|Placebo Comparator|2|Placebo x 45 d
3322269|NCT00133666|Experimental|1|
3322270|NCT00133666|Active Comparator|2|
3322271|NCT00133601|Experimental|1|CBT-1
3322272|NCT00133601|No Intervention|2|Control Group
3322273|NCT00133575|Experimental|Group E: ACAM3000 MVA 10^7 ID|10 subjects to receive ACAM3000 MVA dose 10^7 TCID50 via intradermal route on days 0 and 28; 2 subjects to receive placebo via intradermal route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
3322274|NCT00133575|Experimental|Group F: ACAM3000 MVA 10^8 IM|10 subjects to receive ACAM3000 MVA dose 10^8 TCID50 via intramuscular route on days 0 and 28; 2 subjects to receive placebo via intramuscular route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
3322275|NCT00133575|Experimental|Group D: ACAM3000 MVA 10^8 SC|10 subjects to receive ACAM3000 MVA dose 10^8 TCID50 via subcutaneous route on days 0 and 28; 2 subjects to receive placebo via subcutaneous route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
3322276|NCT00133575|Experimental|Group B: ACAM3000 MVA 10^7 IM|10 subjects to receive ACAM3000 MVA dose 10^7 TCID50 via intramuscular route on days 0 and 28; 2 subjects to receive placebo via intramuscular route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
3322277|NCT00133575|Experimental|Group A: ACAM3000 MVA 10^6 ID|10 subjects to receive ACAM3000 MVA dose 10^6 tissue culture infectious dose 50 (TCID50) via intradermal (ID) route on days 0 and 28; 2 subjects to receive placebo via intradermal route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
3322278|NCT00133575|Experimental|Group C: ACAM3000 MVA 10^7 SC|10 subjects to receive ACAM3000 MVA dose 10^7 TCID50 via subcutaneous (SC) route on days 0 and 28; 2 subjects to receive placebo via subcutaneous route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
3322279|NCT00133549|Experimental|2|Vaccine dose 1: CRM-PS; Vaccine dose 2 (month 4): CRM-PS; Vaccine dose 3 (month 8): PS.
3322280|NCT00133549|Experimental|1|Vaccine dose 1: CRM-PS; Vaccine dose 2 (month 4): saline placebo; Vaccine dose 3 (month 8): PS.
3322281|NCT00133549|Active Comparator|3|Vaccine dose 1: PS; Vaccine dose 2 (month 4): saline placebo; Vaccine dose 3 (month 8): saline placebo.
3322282|NCT00133536|Experimental|1|100 subjects 45 mcg of influenza A/H5N1.
3322283|NCT00133536|Placebo Comparator|2|20 subjects saline placebo.
3322284|NCT00133523|Placebo Comparator|Group 4: Placebo: Intramuscular|N=165 subjects administered placebo intramuscularly.
3322285|NCT00133523|Placebo Comparator|Group 3: Placebo: Nasal|N=165 subjects administered placebo intranasally.
3322286|NCT00133523|Experimental|Group 1: FluMist™|N=825 subjects administered live attenuated vaccine intranasally.
3322287|NCT00133523|Experimental|Group 2: Fluzone®/Fluvirin|N=825 subjects administered inactivated vaccine intramuscularly.
3322288|NCT00133497|Experimental|20 mcg CMV gB + MF59|200 subjects will receive vaccine CMV gB + MF59.
3322289|NCT00133497|Placebo Comparator|Saline|200 subjects will receive saline placebo.
3322290|NCT00133471|Experimental|Group 1A: 3.75 mcg A/H9N2 no adjuvant|12 subjects to receive 3.75 mcg A/H9N2 with no adjuvant.
3322293|NCT00133471|Experimental|Group 3B: 15 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 15 mcg A/H9N2 plus MF59 adjuvant.
3322294|NCT00133471|Experimental|Group 4B: 30 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 30 mcg A/H9N2 plus MF59 adjuvant.
3322295|NCT00133471|Experimental|Group 4A: 30 mcg A/H9N2 no adjuvant|12 subjects to receive 30 mcg A/H9N2 with no adjuvant.
3322296|NCT00133471|Experimental|Group 2A: 7.5 mcg A/H9N2 no adjuvant|12 subjects to receive 7.5 mcg A/H9N2 with no adjuvant.
3322297|NCT00133471|Experimental|Group 1B: 3.75 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 3.75 mcg A/H9N2 plus MF59 adjuvant.
3322298|NCT00133445|Experimental|Group A|Group A will receive DTaP-HepB-IPV (Pediarix™) vaccine along with other required vaccines at birth, 2 and 6 months of age.
3322299|NCT00133445|Active Comparator|Group B|Group B will receive the monovalent HepB vaccine (Engerix-B) at birth, the DTaP-HepB-IPV (Pediarix™) vaccine with other vaccines at 2, 4 and 6 months of age.
3322300|NCT00133406|Experimental|a|oral glutamine with juice for 10 days
3322301|NCT00133406|Experimental|b|PO vit A q 4 mo for 1 year plus zinc placebo
3322302|NCT00133406|Active Comparator|c|Zinc 40 mg twice weekly Plus Vitamin A Placebo for one year
3322303|NCT00133406|Placebo Comparator|d|oral glycine with juice daily for 10 days
3322304|NCT00133406|Placebo Comparator|e|Vitamin A Placebo plus Zinc Placebo for one year
3322305|NCT00133406|Experimental|f|Vitamin A q 4 months and PO Zinc for 1 year
3322306|NCT00133354|Active Comparator|Arimidex and Growth Hormone|
3322307|NCT00133354|Placebo Comparator|Placebo and Growth Hormone|
3322308|NCT00133276|Active Comparator|1|
3322309|NCT00133276|Placebo Comparator|2|
3322310|NCT00133263|Experimental|1|
3322311|NCT00133263|Active Comparator|2|
3322312|NCT00133250|Experimental|A|Abciximab
3322313|NCT00133250|Placebo Comparator|B|Heparin Sodium
3322314|NCT00133237|Active Comparator|A|Sirolimus-eluting stent (Cypher)
3322315|NCT00133237|Active Comparator|B|Paclitaxel-eluting stent (Taxus)
3322316|NCT00133224|Experimental|1|
3322317|NCT00133224|Other|2|
3322318|NCT00133211|Active Comparator|1|Antiarrythmic drug treatment
3322319|NCT00133211|Experimental|2|
3322320|NCT00133172|Experimental|1|Steroid rapid 5-day withdrawal
3322321|NCT00133172|Active Comparator|2|Standard steroid maintenance
3322322|NCT00133094|Other|Arm 1|
3322323|NCT00133068|Other|1|Control
3322324|NCT00133068|Experimental|2|Reduction of financial barrier
3322325|NCT00133068|Experimental|3|Computer Intervention
3322326|NCT00133068|Experimental|4|Reduction of financial barrier and Computer Intervention
3322327|NCT00133055|Experimental|Treatment booklet and telephone coaching|
3322328|NCT00133055|Other|Usual Care|
3322329|NCT00133003|Active Comparator|1|
3322330|NCT00133003|Placebo Comparator|2|
3322331|NCT00132964|Active Comparator|Immobilizaton device|Below Knee walking cast
3322332|NCT00132964|Experimental|Immobilization device|Removable ankle brace
3322333|NCT00132899|Active Comparator|Methotrexate|Methotrexate and infliximab combination
3322334|NCT00132899|Placebo Comparator|Placebo|Placebo plus infliximab combination
3322335|NCT00132834||Asthma/no ICS|Asthmatic children who are not currently taking ICS
3322336|NCT00132834||Asthma/ICS|Asthmatic children on ICS
3322337|NCT00132834||Non-asthmatic children|Children without asthma
3322338|NCT00132821|Active Comparator|A|Bupropion
3322339|NCT00132821|Active Comparator|B|Transdermal nicotine patch
3322340|NCT00132821|Placebo Comparator|C|
3322341|NCT00132821|Placebo Comparator|D|
3322342|NCT00132808|Experimental|Zoledronic Acid 2x5 mg|Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12
3322343|NCT00132808|Experimental|Zoledronic Acid 1x5 mg|Zoledronic acid 5 mg intravenous (i.v.) given at randomization and placebo at Month 12
3322344|NCT00132808|Placebo Comparator|Placebo|Placebo given at randomization and Month 12
3322345|NCT00132795|Experimental|1 Therapeutic Phone System|patients assigned to this condition will have unlimited access to the therapeutic telephone system for 4 months.
3322346|NCT00132795|Active Comparator|2 Standard care|Standard post-CBT care (i.e., no formal relapse prevention or professional treatment).
3322347|NCT00132769|Experimental|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
3322348|NCT00132769|Placebo Comparator|Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
3322349|NCT00132743|Active Comparator|1|Optimal Medical Care
3322350|NCT00132743|Active Comparator|2|Optimal Medical Care and Supervised Exercise
3322351|NCT00132743|Active Comparator|3|Optimal Medical Care and Stent
3322352|NCT00132730|Experimental|MK-0873 2.5 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
3322353|NCT00132730|Experimental|MK-0873 1.25 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
3322354|NCT00132730|Experimental|MK-0873 0.75 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
3322355|NCT00132730|Placebo Comparator|Placebo|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)
3322356|NCT00132730|Experimental|MK-0873 2.5 mg + Usual Care|Participants receive MK-0873 2.5 mg tablets once daily plus usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks during Periods IV and V (EXT2)
3322357|NCT00132730|Active Comparator|Usual Care|Participants receive usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks during Periods IV and V (EXT2)
3322895|NCT00125385|Experimental|Cohort 2|Dose Group
3322358|NCT00132704||A|The experiments in Group A will be conducted in order to determine if human tumor microvascular endothelium displays similar dose parameters as mouse tumor endothelium, and if the microvascular endothelium of tumors of different types behaves in a similar fashion in its response to IR.
3322359|NCT00132704||B|The experiments in Group B will be conducted in order to determine if tumor endothelium isolated to near homogeneity demonstrates dose parameters similar to those used in single dose radiotherapy of brain tumors.
3322360|NCT00132691|Active Comparator|1|Immunosuppressant medication implant
3322361|NCT00132691|Active Comparator|2|Systemic corticosteroids with immunosuppressant drugs as needed
3322362|NCT00132678|Experimental|001|Risperdal Consta 12.5 25 37.5 or 50mg intramuscular (IM) injection every 2 weeks
3322363|NCT00132678|Placebo Comparator|002|Placebo Matching placebo intramuscular (IM) injection every 2 weeks
3322364|NCT00132665|Active Comparator|1|Procedure/Surgery: A: Radiotherapy alone
3322365|NCT00132665|Experimental|2|Drug: B: CBDCA and Radiotherapy
3322366|NCT00132639|Experimental|1|Preoperative docetaxel-cisplatin combination chemotherapy
3322367|NCT00132639|Active Comparator|2|Preoperative docetaxel monotherapy
3322368|NCT00132613|Active Comparator|1|Procedure/Surgery: Observation alone after pericardial drainage
3322369|NCT00132613|Experimental|2|Drug: Pericardial instillation of bleomycin after drainage
3322370|NCT00132522|Experimental|Arm 1|
3322371|NCT00132509|Experimental|DFIL|
3322372|NCT00132509|Active Comparator|NINDS|
3322373|NCT00132483|Experimental|Intervention arm|
3322374|NCT00132483|No Intervention|Control|
3322375|NCT00132444|Active Comparator|1|0.25% gel
3322376|NCT00132444|Active Comparator|2|0.1% gel
3322377|NCT00132444|Placebo Comparator|3|
3322378|NCT00132418|Placebo Comparator|Placebo|placebo
3322379|NCT00132418|Experimental|Enbrel|Enbrel
3322380|NCT00132379|Experimental|1|
3322381|NCT00132314|Experimental|Arm 1|long-acting injectable risperidone
3322382|NCT00132314|Active Comparator|Arm 2|oral antipsychotic medication
3322383|NCT00132301|Active Comparator|Arm 1: Docetaxel and Prednisone|Chemotherapy after radical prostatectomy
3322384|NCT00132301|No Intervention|Arm 2: Standard of care|Standard of care
3322385|NCT00132262|Experimental|1|Patients randomized to this arm received an intervention based in the motivational interviewing style
3322386|NCT00132262|Active Comparator|2|Patients randomized to this arm received standard hospital care
3322387|NCT00132249||Head Injured|The Vietnam Head Injured Subjects
3322388|NCT00132249||Head Uninjured|Uninjured Vietnam Veteran Control Subjects
3322389|NCT00132158|Other|1|
3322390|NCT00132145|Other|Intervention|Behavioural
3322391|NCT00132132|Experimental|Intervention|This is a long term randomized controlled study looking at the effect of a Behavioral program on BMI in a population 10-20years old with a BMI greater than or equal to 85%. The intervention is a Behavioral education program which meets monthly for 4 hour session and includes exercise, education, empowerment and incentives. Both groups are referred to a dietician. The primary outcome is change in BMI and the secondary outcome is improvement in fasting metabolic parameters (lipid panel, insulin, glucose).
3322392|NCT00132132|No Intervention|Standard of Care/Control|Education on physical activity and nutrition in a primary care office setting
3322393|NCT00132119|Experimental|1|Nalmefene HCl 20 mg
3322394|NCT00132119|Experimental|2|Nalmefene HCl 40 mg
3322395|NCT00132119|Placebo Comparator|3|Placebo
3322396|NCT00132080|Placebo Comparator|1|Patients with acute Kawasaki disease
3322397|NCT00132067|Experimental|Treatment (vorinostat)|Patients receive oral vorinostat twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3322398|NCT00132028|Experimental|Treatment (vorinostat)|Patients receive oral vorinostat twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR.
3322399|NCT00132002|Experimental|Treatment (vorinostat)|Patients receive oral suberoylanilide hydroxamic acid twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3322400|NCT00131989|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-14 or 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR may be considered for retreatment with sorafenib for up to an additional 6 courses upon disease recurrence provided the duration of CR is longer than 1 month.
3322401|NCT00131963||Regimen 1|Patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.
3322402|NCT00131963||Regimen 2|Patients receive doxorubicin and cyclophosphamide as in regimen 1. Patients then receive paclitaxel IV over 1 hour once weekly for 12 weeks.
3322403|NCT00131937|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3322404|NCT00131911|Experimental|Group A (patients with carcinoid tumors)|Patients receive 400 mg oral sorafenib twice daily on days 1-28.
3322405|NCT00131911|Experimental|Group B (islet cell and other neuroendocrine tumors)|Patients receive 400 mg oral sorafenib twice daily on days 1-28.
3322406|NCT00131885|Placebo Comparator|Levonorgestrel 1.5 with Placebo Herb|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a placebo herb daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg
3322407|NCT00131885|Active Comparator|Levonorgestrel 1.5 with SJW 900 mg|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took St. John's Wort (SJW) 900 mg a Day orally for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg
3322408|NCT00131885|Active Comparator|Levonorgestrel 2.25 with SJW 900 mg|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a St. Johns's Wort 300 mg capsules three times daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 2.25 mg
3322409|NCT00131885|Active Comparator|Levonorgestrel 1.5 with SJW 1500 mg|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a St. Johns's Wort 300 mg capsules five times daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg
3322410|NCT00131846|Active Comparator|1|Diuretics use
3322411|NCT00131846|Active Comparator|2|No diuretics use
3322412|NCT00131677|Active Comparator|active immediate|participants in this arm start study product immediately upon enrollment
3322413|NCT00131677|Placebo Comparator|placebo immediate|participants in this arm start study product immediately upon enrollment
3322414|NCT00131677|Active Comparator|active delayed|persons in this arm start study product 9 months after enrollment
3322415|NCT00131677|Placebo Comparator|placebo delayed|participants in this arm start study product nine months after enrollment
3322416|NCT00131664|Active Comparator|Avandamet|Avandamet 2 mg / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily over 6 months
3322417|NCT00131664|Active Comparator|Avandia and Amaryl|Avandia + Amaryl 4 mg + 1 mg once daily titration up to 8 mg + 2 mg once daily over 6 months
3322418|NCT00131664|Active Comparator|Metformin|Metformin 500 mg twice daily titration up to 1000 mg twice daily over 6 months
3322419|NCT00131638|Experimental|Palifermin|Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
3322420|NCT00131638|Placebo Comparator|Placebo|Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
3322421|NCT00131573|Experimental|1|Stimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on.
3322422|NCT00131573|Sham Comparator|2|No stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on.
3322423|NCT00131560|Other|A|
3322424|NCT00131547|No Intervention|1|Usual Clinical Care
3322425|NCT00131547|Experimental|2|Behavioral (e.g., Counseling)
3322426|NCT00131508|Experimental|2|Glutamine
3322427|NCT00131508|Placebo Comparator|1|
3322428|NCT00131495|Placebo Comparator|1|Placebo patch
3322429|NCT00131495|Experimental|2|Testosterone patch (300mcg/day, changed twice a week for one year
3322430|NCT00131482|Experimental|10 micrograms|
3322431|NCT00131482|Experimental|30 micrograms|
3322432|NCT00131482|Placebo Comparator|Placebo|
3322433|NCT00131482|Experimental|3 micrograms|
3322434|NCT00131482|Experimental|1 microgram|
3322435|NCT00131469|Active Comparator|Teriparatide (FORTEO)|Once daily SQ administration of Teriparatide (FORTEO) 20 ug for 18 months
3322436|NCT00131469|Placebo Comparator|Placebo|Daily SQ placebo for 18 months
3322437|NCT00131456|Active Comparator|Venlafaxine|Venlafaxine
3322438|NCT00131456|Placebo Comparator|Placebo|Placebo
3322439|NCT00131404|Placebo Comparator|Phase A/B: Arm 1|"Phase A: Arm 1: MK0364 Pbo capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 1: MK0364 Pbo capsule once daily."
3322440|NCT00131404|Experimental|Phase A/B: Arm 2|"Phase A: Arm 2: MK0364 2 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 2: MK0364 2 mg capsule once daily."
3322441|NCT00131404|Experimental|Phase A/B: Arm 3|"Phase A: Arm 3: MK0364 4 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 3:~MK0364 4 mg capsule once daily."
3322442|NCT00131404|Experimental|Phase A/B: Arm 4|"Phase A: Arm 4: MK0364 6 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 4:~MK0364 6 mg capsule once daily."
3322443|NCT00131404|Experimental|Phase A/B: Arm 5|Phase A: Arm 5: MK0364 6 mg capsule once daily. 52 week treatment period. Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 5: MK0364 6 mg capsule once daily.
3322444|NCT00131391|Placebo Comparator|Phase A/B; Arm 1|Phase A: Arm 1: MK0364 Pbo capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 1: MK0364 Pbo capsule once daily.
3322445|NCT00131391|Experimental|Phase A/B: Arm 2|Phase A: Arm 2: MK0364 4 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 2: MK0364 4 mg capsule once daily.
3322446|NCT00131391|Experimental|Phase A/B: Arm 3|Phase A: Arm 3: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 3: MK0364 Pbo capsule once daily.
3322447|NCT00131391|Experimental|Phase A/B: Arm 4|Phase A: Arm 4: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 4: MK0364 2 mg capsule once daily.
3322448|NCT00131391|Experimental|Phase A/B: Arm 5|Phase A: Arm 5: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 5: MK0364 4 mg capsule once daily.
3322449|NCT00131391|Experimental|Phase A/B: Arm 6|Phase A: Arm 6: MK0364 6 mg once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 6: MK0364 6 mg capsule once daily.
3322450|NCT00131378|Experimental|Male on GH|"Participants received growth hormone replacement therapy. The starting dose was 2 micrograms/kg per day and they were titrated within the normal range based on blood levels.~Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months."
3322451|NCT00131378|Placebo Comparator|Male on Placebo|"Participants received placebo.~Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months."
3322452|NCT00131378|Experimental|Female on GH|"Participants received growth hormone replacement therapy. The starting dose was 4 micrograms/kg per day and they were titrated within the normal range based on blood levels.~Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months."
3322453|NCT00131378|Placebo Comparator|Female on Placebo|"Participants received placebo.~Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months."
3322454|NCT00131365|Experimental|ExAblate MRgFUS|
3322455|NCT00131352|Experimental|Synvisc|Participants with symptomatic primary osteoarthritis (OA) of the knee received a single injection of 6 mL hylan G-F 20 (Synvisc).
3322456|NCT00131352|Placebo Comparator|Saline Control|Participants (control group) with symptomatic primary osteoarthritis (OA) of the knee received a single injection of 6 mL phosphate buffered saline.
3322457|NCT00131248|Other|Anti-reflux Medications, then Placebo (group 1)|"3-day course of anti-reflux medications, followed by 7-day course placebo, followed by 4-day course anti-reflux medications.~All study medication administered via nipple or orogastric (OG) tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes."
3322458|NCT00131248|Other|Placebo, then Anti-reflux Medications|"3-day course placebo, followed by 7-day course anti-reflux medication, followed by 4-day course placebo.~All study medication administered via nipple or OG tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes."
3322459|NCT00131235|Placebo Comparator|Control|Standard antenatal care as described in intervention
3322460|NCT00131235|Experimental|Monthly SP|Standard antenatal care + monthly intermittent presumptive treatment of malaria with sulfadoxine pyrimethamine, as described in intervention
3322461|NCT00131235|Experimental|AZI-SP|Standard antenatal care + monthly intermittent presumptive treatment of malaria with sulfadoxine pyrimethamine + two presumptive treatments of sexually transmitted infections and malaria with azithromycin, as described in intervention
3322462|NCT00131144|Experimental|Octreotide Acetate in Microspheres 20 mg|20 mg will be administered im once every 4 weeks
3322463|NCT00131144|Experimental|Octreotide Acetate in Microspheres 30 mg|30 mg will be administered im once every 4 weeks
3322464|NCT00131144|Placebo Comparator|Placebo|
3322465|NCT00131131|Experimental|Exercise|The intervention was an exercise program of moderate to vigorous intensity. The intervention started with 30-minute sessions three times per week, with the ultimate goal to have participants exercise four to five times per week for 45 to 60 minutes per session.
3322466|NCT00131131|No Intervention|Control|Women in the control group did not attend instructional sessions with the exercise interventionist and did not receive the motivational mailings
3322467|NCT00131079|Experimental|PEPAF|General Practitioner's assessment of physical activity level and minimal advice in routine clinical practice supplemented by physical activity prescription to those who accepted an additional 15 minutes appointment.
3322468|NCT00131079|Active Comparator|Control|
3322469|NCT00131053|Experimental|A|
3322470|NCT00131027|Experimental|A|HD-MTX
3322471|NCT00131027|Active Comparator|B|ID-MTX
3322472|NCT00131014||Next of Kin of deceased subj by lymphoma|Next of Kin of deceased subject by lymphoma
3322473|NCT00131014||Subject unaffected by lymphoma|Subject unaffected by lymphoma
3322474|NCT00131014||Subject affected by lymphoma|Subject affected by lymphoma
3322475|NCT00130923|Experimental|Risperidone Long Acting|Risperidone Long Acting; aka Risperdal Consta; injectable form
3322476|NCT00130923|Active Comparator|Oral Risperidone|Oral Risperidone; aka Risperdal; oral form
3322477|NCT00130910|Experimental|1|Albendazole
3322478|NCT00130910|Placebo Comparator|2|
3322479|NCT00130845|Experimental|Octreotide Acetate in Microspheres|
3322480|NCT00130845|Placebo Comparator|Placebo|
3322481|NCT00130832|Experimental|1|RotaTeq and OPV concomitantly
3322482|NCT00130832|Experimental|2|RotaTeq and OPV on staggered schedule
3322483|NCT00130819|Experimental|1|Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
3322484|NCT00130819|Active Comparator|2|Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
3322485|NCT00130793|Experimental|zoster vaccine live (Oka/Merck) refrigerated formulation|ZOSTAVAX™ with phosphate-gelatin-sucrose-urea (PGSU) stabilizer (~45,000 plaque-forming units [PFU]), 1 subcutaneous 0.65-mL injection
3322486|NCT00130793|Active Comparator|zoster vaccine live (Oka/Merck) frozen formulation|ZOSTAVAX™ with phosphate-gelatin-sucrose (PGS) stabilizer (~57,000 PFU), 1 subcutaneous 0.65-mL injection
3322487|NCT00130780|Active Comparator|A|Pre-surgical Treatment with Bevacizumab plus Chemotherapy
3322488|NCT00130780|Active Comparator|B|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
3322489|NCT00130754|Experimental|1|Thymo
3322490|NCT00130754|No Intervention|2|
3322491|NCT00130728|Experimental|erlotinib HCl + bevacizumab|oral erlotinib HCl 150 mg/day orally + intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
3322492|NCT00130728|Placebo Comparator|erlotinib HCl + placebo|oral erlotinib HCl 150 mg/day orally + intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
3322493|NCT00130702|Experimental|Gefitinib (Iressa)|All patients will receive Gefitinib (Iressa) at a dose of 750 mg orally (three 250 mg tabs) each day.
3322494|NCT00130689|Other|Cetuximab|Patients received cetuximab at an initial dose of 400 mg/m2 administered IV over 120 min, followed by weekly infusions at 250 mg/m2 administered IV over 60 min. Once cycle was 4 weeks of therapy. Patients received treatment until disease progression or unacceptable toxicity.
3322495|NCT00130676|Experimental|mifepristone 600 mg|
3322496|NCT00130676|Placebo Comparator|matching placebo|
3322497|NCT00130637|Experimental|Daclizumab|IV daclizumab
3322498|NCT00130611|Placebo Comparator|BNP blinded therapy|Clinical treatment without knowledge of BNP levels
3322499|NCT00130611|Experimental|BNP guided therapy|Clinical treatment based on clinical examination and BNP-levels
3322560|NCT00129766|Active Comparator|palivizumab|15 mg/kg administered intramuscularly for 5 monthly doses
3322500|NCT00130598|Active Comparator|1|control group: patients receive a preventive hydration with 154mEq/l saline at an ongoing rate of 1ml/kg per hour of at least 12 hours prior and after the procedure.
3322501|NCT00130598|Active Comparator|2|7h-sodium bicarbonate (according to the regimen used in a recently published study (slightly modified)14): before contrast a bolus of 3ml/kg NaHCO3 166mEq/l for one hour, followed by an infusion of NaHCO3 166mEq/l with a rate of 1ml/kg per hour until 6h after contrast.
3322502|NCT00130598|Active Comparator|3|short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg; patients with a body weight above 100kg 300ml) as a bolus 20 minutes before contrast; additionally ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl of San Pellegrino® non-sparkling mineral water at the start of the infusion. Ingestion of 500ml San Pellegrino® non-sparkling mineral water in the first 6 hours after contrast.
3322503|NCT00130546|Active Comparator|1|Cypher Stent
3322504|NCT00130546|Active Comparator|2|Taxus Stent
3322505|NCT00130533|Experimental|Xeloda (capecitabine)|1000 mgrs/m2 twice a day, tablets, 8 cycles
3322506|NCT00130533|No Intervention|Observation|Observation. No intervention.
3322507|NCT00130520|Experimental|open label|
3322508|NCT00130507|Active Comparator|Arm A|VX (vinorelbine and capecitabine)
3322509|NCT00130507|Experimental|Arm B|Vinorelbine and capecitabine plus trastuzumab(VXH)
3322510|NCT00130442|Experimental|1|PI-88 190 mg daily by subcutaneous injection and dacarbazine 1000 mg/m2 on day 1 of each 21 day cycle
3322511|NCT00130442|Active Comparator|2|dacarbazine 1000 mg/m2 on day 1 of every 21 day cycle by intravenous infusion
3322512|NCT00130390|Experimental|1|One nitazoxanide 500 mg tablet twice daily for 28 days
3322513|NCT00130390|Placebo Comparator|2|One placebo tablet twice daily for 28 days
3322514|NCT00130377|Experimental|cell therapy|Patient receiving active biologic
3322515|NCT00130377|Placebo Comparator|control|Patient receiving placebo or standard of care
3322516|NCT00130364|Experimental|1|Pimecrolimus
3322517|NCT00130364|Placebo Comparator|2|Pimecrolimus vehicle cream
3322518|NCT00130325|Active Comparator|A|Isoniazid arm
3322519|NCT00130325|Placebo Comparator|B|Placebo of Isoniazid tablet 300mg
3322520|NCT00130312|Experimental|Sulodexide|Also known as KRX-101. These patients are also on standard of care ACEs and ARBs.
3322521|NCT00130312|Placebo Comparator|Placebo|These patients were on standard of care ACEs and ARBs.
3322522|NCT00130286|Experimental|rhGH + rosi|Recombinant human growth hormone + rosiglitazone
3322523|NCT00130286|Experimental|rhGH placebo + rosi|Placebo for recombinant human growth hormone + rosiglitazone
3322524|NCT00130286|Experimental|rhGH + rosi placebo|Recombinant human growth hormone + placebo for rosiglitazone
3322525|NCT00130286|Placebo Comparator|Double placebo|Placebo for recombinant human growth hormone + placebo for rosiglitazone
3322526|NCT00130273|Experimental|1|Participants will receive managed problem solving for 12 months
3322527|NCT00130273|Active Comparator|2|Participants will receive standard of care for 12 months
3322528|NCT00130260|Experimental|vaccine, schedule 1|3rd and 4th dose of vaccine, on original schedule
3322529|NCT00130260|Experimental|vaccine, schedule 2|3rd and 4th dose of vaccine on modified schedule
3322530|NCT00130260|Placebo Comparator|placebo, schedule 1|3rd and 4th dose of placebo, on original schedule
3322531|NCT00130260|Placebo Comparator|placebo, schedule 2|3rd and 4th dose of placebo on modified schedule
3322532|NCT00130247|Experimental|2EHRZ/2HR arm|Daily treatment with isoniazid (INH), rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks.
3322533|NCT00130247|Active Comparator|2EHRZ/4HR arm|Daily treatment with Isoniazid (INH), rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks.
3322534|NCT00130208|Experimental|Sulodexide|Also known as KRX-101. All patients will be on standard of care ACE or ARBs.
3322535|NCT00130208|Placebo Comparator|Placebo|All patients will be on standard of care ACE or ARBs.
3322536|NCT00130195|Experimental|A|
3322537|NCT00130169|Experimental|1|
3322538|NCT00130156|Experimental|1|
3322539|NCT00130156|Experimental|2|
3322540|NCT00130117|Experimental|r-metHuLeptin|r-metHuLeptin administered subcutaneously.
3322541|NCT00130117|Placebo Comparator|Oral Contraceptive Pills (OCPs)|PLACEBO
3322542|NCT00130104|Experimental|MCB|randomized to receive the metacarpal block for anesthesia
3322543|NCT00130091|Experimental|Clonidine|administer with local anesthetic
3322544|NCT00130091|Placebo Comparator|Local anesthetic|Local anesthetic without clonidine
3322545|NCT00130039|Experimental|cilostazol|cilostazol 100mg bid plus placebo of clopidogrel
3322546|NCT00130039|Active Comparator|Clopidogrel|clopidogrel 75mg qd and matching placebo of cilostazol
3322547|NCT00130026|Placebo Comparator|I|Saline placebo
3322548|NCT00129961|Experimental|1|Conversion to a sirolimus-based regimen
3322549|NCT00129961|Active Comparator|2|Continuation of a CNI-based regimen
3322550|NCT00129935|Active Comparator|EC followed Docetaxel|Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.
3322551|NCT00129935|Experimental|ET followed Capecitabine|Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.
3322552|NCT00129922|Active Comparator|Fluorouracil+Epirubicin+Cyclophosphamide|5-FU+4-Epirubicin+Cyclophosphamide
3322553|NCT00129922|Experimental|FEC followed by Paclitaxel|5-FU+4-Epirubicin+Cyclophosphamide
3322554|NCT00129896|Experimental|Myocet+Taxotere+Herceptin|Myocet 50 mg/m2; Taxotere 60 mg/m2; Herceptín 4 mg/Kg (first dose) and in the following cycles 2 mg/Kg
3322555|NCT00129805|Experimental|MCI-9042|
3322556|NCT00129805|Active Comparator|Aspirin|
3322557|NCT00129792|Experimental|1|Has 100% expectation of receiving supplement
3322558|NCT00129792|Sham Comparator|2|Has 50% expectation of receiving supplement
3322559|NCT00129792|Other|3|Has 0% expectation of receiving supplement.
3322896|NCT00125385|Experimental|Cohort 3|Dose Group
3322561|NCT00129766|Experimental|motavizumab (MEDI-524)|15 mg/kg of motavizumab was administered intramuscularly for 5 monthly doses
3322562|NCT00129753|Experimental|Alemtuzumab|
3322563|NCT00129740|Experimental|Nilotinib|400 mg orally twice daily
3322564|NCT00129727|Experimental|Phase II|Paclitaxel carboplatin bevacizumab
3322565|NCT00129714|No Intervention|wait and see|
3322566|NCT00129714|Experimental|collar|
3322567|NCT00129714|Experimental|physiotherapy|
3322568|NCT00129675|Experimental|[123I]ß CIT|To assess [123I]ß CIT and SPECT imaging
3322569|NCT00129662|Experimental|Intervention arm|Pictorial action plan
3322570|NCT00129623|Experimental|1|
3322571|NCT00129623|Placebo Comparator|2|
3322572|NCT00129545|Experimental|WATCHMAN|Implant of WATCHMAN Left Atrial Appendage Closure Technology
3322573|NCT00129545|Active Comparator|Warfarin control|Subjects are treated with current standard of care Oral Anticoagulation Therapy with Warfarin
3322574|NCT00129545|Other|Roll-in|Implant of WATCHMAN Left Atrial Appendage Closure Technology. Up to 3 non-randomized subjects per site, these subjects were not included in the primary analysis.
3322575|NCT00129519|Active Comparator|Imiquimod cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
3322576|NCT00129493|Other|Arm 1|
3322577|NCT00129480|Experimental|Assistance with Pain Treatment|Care management intervention including assessment, decision support, patient activation, education and followup, provider education, feedback to providers
3322578|NCT00129480|No Intervention|Treatment as usual|Treatment as usual
3322579|NCT00129467|Experimental|methylphenidate + SSRI|During the 18-day blind treatment period, subjects will be prescribed methylphenidate 5-10 mg twice per day and selective serotonin reuptake inhibitor (SSRI). Subjects already receiving a SSRI when they begin the study, will continue on the recommended dose of that SSRI; subjects not receiving a SSRI will be prescribed 10-20 mg per day Citalopram. Subjects who respond to methylphenidate treatment will have the option of continuing on methylphenidate, up to 15 mg bid, and an antidepressant in the 6 week open label portion of the study.
3322580|NCT00129467|Placebo Comparator|Placebo + SSRI|During the 18-day blind treatment period, subjects will be prescribed placebo 1-2 capsules twice per day and selective serotonin reuptake inhibitor (SSRI). Subjects already receiving a SSRI when they begin the study, will continue on the recommended dose of that SSRI; subjects not receiving a SSRI will be prescribed 10-20 mg per day Citalopram.
3322581|NCT00129454|Experimental|Telemedicine treatment|Psychotherapy delivered by telephone
3322582|NCT00129454|Active Comparator|In-Person treatment|Psychotherapy delivered in-person
3322583|NCT00129454|No Intervention|Assessment only|No intervention
3322584|NCT00129441|Experimental|Merck L-830982|
3322585|NCT00129441|Placebo Comparator|Sugar pill|
3322586|NCT00129428|Experimental|UVB Irradiation|A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
3322587|NCT00129415|Experimental|UVA1 Irradiation|UVA 1 Irradiation (Sellemed UVA1 light source) up to 130 J/cm2
3322588|NCT00129415|Experimental|UVB Irridiation|UVB Irradiation maximum dose of 4000 mJ/cm2
3322589|NCT00129402|Experimental|Pooled subjects who received ezetimibe with simvastatin|Pooled subjects who received ezetimibe 10 mg plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg
3322590|NCT00129402|Active Comparator|Pooled subjects who received simvastatin monotherapy|Pooled subjects who received ezetimibe matching placebo plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg
3322591|NCT00129389|Active Comparator|1|FAC X 6
3322592|NCT00129389|Experimental|2|FAC X 4 + 8 Taxol
3322593|NCT00129376|Experimental|Doxorubicin+cyclophosphamide - Docetaxel|Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles. Later, docetaxel (36 mg/m2) was administered an intravenous infusion, weekly for six weeks followed by a 2-week resting period (8-week cycle).
3322594|NCT00129337|Experimental|1|0.1 mg/kg
3322595|NCT00129337|Experimental|2|0.3 mg/kg
3322596|NCT00129337|Experimental|3|1 mg/kg
3322597|NCT00129337|Experimental|4|3 mg/kg
3322598|NCT00129324|Other|Lead Reduction Arm|random assignment to receive lead hazard control intervention. Assessing lead hazards in the home. Reducing lead hazards by cleaning, painting, covering, and/or replacing/repairing interior and exterior components of the home.
3322599|NCT00129324|Other|Injury Reduction Arm|random assignment to receive injury hazard control intervention. Assessing home for potential injury hazards. Controlling hazards by 1) installing safety equipment such as stairway gates, cabinet locks, smoke & CO detectors, etc. 2) removing the hazards from the reach of a child and/or 3) restricting access to the hazards.
3322600|NCT00129311|Experimental|1|Selegiline
3322601|NCT00129311|Placebo Comparator|2|Placebo
3322602|NCT00129298|Experimental|1|Tiagabine
3322603|NCT00129298|Placebo Comparator|2|Matching placebo
3322604|NCT00129285|Experimental|Low Dose Modafinil|Low Dose Modafinil 200 mg daily
3322605|NCT00129285|Experimental|High Dose Modafinil|High dose modafinil 400 mg daily
3322606|NCT00129285|Placebo Comparator|Placebo|Placebo
3322607|NCT00129272|Active Comparator|Bupropion (Wellbutrin-SR)|Using a double-blind, randomized, placebo-controlled design, smokers received active treatment with Bupropion-SR (150 mg. twice daily) in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
3322608|NCT00129272|Placebo Comparator|Matching Placebo|Using a double-blind, randomized, placebo-controlled design, smokers received treatment with a matching placebo (to Bupropion-SR 150 mg) twice daily in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
3322626|NCT00129116|Experimental|Menitorix/Infanrix-penta Group|Subjects received Menitorix vaccine and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menitorix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
3322897|NCT00125385|Experimental|Cohort 4|Dose Group
3322609|NCT00129259|Experimental|Anti-CD3 mAb Plus Diabetes Standard of Care Treatment|"Subjects receive 1.) a 14-day course of anti-CD3 monoclonal antibody (mAb) intravenously (IV) comprised of daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 days of 826 µg/m2 [Cycle 1] and, when eligible per protocol, receipt of a second 14-day course after a 12-month interval (at month 13)[Cycle 2]. Note: Prior to May 2007, the course of IV daily doses of anti-CD3 mAb were: 57 µg/m2, 115 µg/m2, 230 µg/m2, 460 µg/m2, and 10 days of 919 µg/m2 and, when eligible per protocol, a second course after a 12-month interval (at month 13). 2.) and intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.~Iron supplementation initiated status post treatment randomization."
3322610|NCT00129259|Active Comparator|Diabetes Standard of Care Treatment|"Subjects receive intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.~Iron supplementation initiated status post treatment randomization."
3322611|NCT00129246|Active Comparator|Bupropion only|The placebo comparator was a group of matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen in a similar 7-week study investigation compared to naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day).
3322612|NCT00129246|Experimental|Naltrexone +Bupropion|The active comparator in this 7-week open label study investigation was naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day) compared to matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen (bupropion only).
3322613|NCT00129233|Active Comparator|Valsartan|Valsartan group treated with 80-160mg daily valsartan without Ca channel blockers or ACE inhibitors.
3322614|NCT00129233|Active Comparator|Amlodipine|Amlodipine group treated with 5-10mg daily amlodipine without ACE inhibitors or angiotensin receptor blockers.
3322615|NCT00129220|Experimental|Olanzapine|olanzapine: 5 to 20 mg per day for 6 weeks
3322616|NCT00129220|Active Comparator|Haloperidol|haloperidol: 2.5 to 10 mg per day for 6 weeks
3322617|NCT00129220|Placebo Comparator|Placebo|placebo for 3 weeks, then olanzapine 5 to 20 mg per day for 3 weeks
3322618|NCT00129129|Experimental|MenHibrix Group|Subjects in the Group were followed during the entire study period, from Day 0 up to study end 6 months post fourth dose vaccinationDuring Primary Phase (Study 101858), subjects in this group, aged 6-12 weeks at enrolment, received 3 doses of Menhibrix™ co-administered with Pediarix™ and Prevnar™ (at Day 0 and Months 2 and 4). During Fourth-Dose Phase (Study 102015), subjects primed with 3 doses of Menhibrix™ during the Primary Phase received one dose of Menhibrix™ and one concomitant dose of Prevnar™ at Month 10-13. During Primary Phase, Menhibrix™ was administered intramuscularly (IM) in the right upper thigh, and Pediarix™ and Prevnar™ IM in the left upper and lower thighs, respectively. During Fourth-Dose Phase, Menhibrix™ was administered by the same route and at the same site as during Primary Phase, and Prevnar™ was administered IM in the left upper thigh.
3322619|NCT00129129|Active Comparator|ActHIB Group|During Primary Phase (Study 101858), subjects in this group, aged 6-12 weeks at enrolment, received 3 doses of ActHIB™ vaccine co-administered with the Pediarix™ and Prevnar™ vaccines (at Day 0 and Months 2 and 4). Subjects in this Group were followed from Day 0 up to Month 10-13 solely. During Fourth-Dose Phase (Study 102015), these subjects were followed as subjects either in the ActHIB/MenHibrix Group or in the ActHIB/ActHIB Group, receiving then one dose of either Menhibrix™ or ActHIB™ concomitantly with one dose of Prevnar™. During Primary Phase, ActHIB™ was administered intramuscularly (IM) in the right upper thigh, and the Pediarix™ and Prevnar™ vaccines IM in the left upper and lower thighs, respectively.
3322620|NCT00129129|Active Comparator|Menomune Group|Subjects in the Group were followed solely during the period of Primary Phase (Study 101858), up to Month 10. Subjects in the Group, aged 3-5 years at enrolment, received one dose of Menomune™ at Day 0. Menomune™ was administered subcutaneously in the left deltoid region.
3322621|NCT00129129|Experimental|ActHIB/Menhibrix Group|Subjects in the Group were followed solely during the period of the Fourth-Dose Phase of the study (Study 102015), from Month 10-13 to Month 11-14. Subjects in this Group had been primed with ActHIB™ during Primary Phase (study 101858) and received at Month 10-13 a fourth dose of Menhibrix™ and a concomitant fourth dose of Prevnar™. Menhibrix™ and Prevnar™ were administered intramuscularly in the right and left upper thighs, respectively.
3322622|NCT00129129|Experimental|ActHIB/ActHIB Group|Subjects in the Group were followed solely during the period of the Fourth-Dose Phase of the study (Study 102015), from Month 10-13 to Month 11-14. Subjects in this Group had been primed with ActHIB™ during Primary Phase of the study (study 101858) and received at Month 10-13 a fourth dose of ActHIB™ and a concomitant fourth dose of Prevnar™. ActHIB™ and Prevnar™ were administered intramuscularly in the right and left upper thighs, respectively.
3322623|NCT00129116|Experimental|Menhibrix F1/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 1 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
3322624|NCT00129116|Experimental|Menhibrix F2/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 2 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
3322625|NCT00129116|Experimental|Menhibrix F3/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 3 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
3322765|NCT00127231|Active Comparator|2 Standard Care Arm|
3322627|NCT00129116|Active Comparator|Menjugate/Infanrix-hexa Group|Subjects received Menjugate vaccine and Infanrix-hexa vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menjugate and Infanrix-hexa vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
3322628|NCT00129090|Experimental|R-CHOEP14 with 12x Rituximab|8 cycles of standard CHOP with etoposide in 14-day intervals. Patients with CD20+ lymphoma receive 12 doses of Rituximab (day 0,1,4,8 of cycle 1, day 1 and 8 of cycle 2, day1 of cycle 3-8 )
3322629|NCT00128921|Experimental|Velcade, Cohort A|Treatment: 1.3 mg/m^2
3322630|NCT00128921|Experimental|Velcade, Cohort B|Treatment: 1.0 mg/m^2
3322631|NCT00128921|Experimental|Velcade, Cohort C|Treatment: 0.7 mg/m^2
3322632|NCT00128908|Active Comparator|Continuous triple-class therapy|Patients will be treated with a regimen containing antiretroviral agents from 3 different classes
3322633|NCT00128908|Experimental|Alternating therapy|Patients will be assigned to weekly alternating dual-class regimen
3322634|NCT00128895|Active Comparator|azathioprine, standard|standard azathioprine maintenance upto one year after diagnosis, subsequently tapering of azathioprine with 25 mg per 3 months
3322635|NCT00128895|Experimental|azathioprine, longterm|longterm maintenance with azathioprine upto four years after diagnosis, subsequently azathioprine will be tapered with 25 mg per 3 months
3322636|NCT00128856|Experimental|Gemcitabine + Adriamycine + Paclitaxel|Neoadjuvant chemotherapy consisted of adriamycine 40 mg/m2, administered on day 1 as an i.v. infusion. Paclitaxel 150 mg/m2 was administered on day 2 as an i.v infusión followed by gemcitabine 2000 mg/m2 as an i.v. infusion. The three drugs were administered every two weeks for 6 cycles.
3322637|NCT00128843|Experimental|Exemestane|25mg/day per VO until progression disease, after this progression the patient could receive the another drug (comparator arm) ie Anastrozole by investigator decision
3322638|NCT00128843|Active Comparator|Anastrozole|1mg/day per VO until progression disease, after this progression the patient could receive the another drug (experimental arm) ie Exemestane by investigator decision
3322639|NCT00128830|Experimental|Etravirine + 2 antiretrovirals|
3322640|NCT00128817|Experimental|1|Concurrent Chemoradiation
3322641|NCT00128817|Active Comparator|2|Laryngectomy + adjuvant radiotherapy/chemoradiotherapy
3322642|NCT00128765|Active Comparator|usual care|usual care, i.e. COPD care at patient's own initiative, mostly for medical help during exacerbations
3322643|NCT00128765|Experimental|monitoring controls|regular COPD care (monitoring) provided by practice nurse according to current COPD guidelines
3322644|NCT00128765|Experimental|self-management|disease specific self-management program 'Living Well with COPD'
3322645|NCT00128713|Active Comparator|1|Lower Dose Prophylactic Platelets
3322646|NCT00128713|Active Comparator|2|Medium Dose Prophylactic Platelets
3322647|NCT00128713|Active Comparator|3|Higher Dose Prophylactic Platelets
3322648|NCT00128687|Experimental|Immediate Intervention|Participants in both arms continue to receive usual medical care throughout the study period. In addition, participants randomized to Immediate Intervention receive intensive case management for Coronary heart disease (CHD) risk reduction for 15 months and then a maintenance program for a minimum of 12 months to assess the durability of initial intervention changes.
3322649|NCT00128687|Placebo Comparator|Delayed Intervention|Participants randomized to Delayed Intervention serve as control for Immediate Intervention patients for the first 15 months and then receive intensive case management for 15 months. The switching-over design not only addresses ethical concerns about withholding treatment from half the study sample, but will also enable us to assess whether the intervention had equal impact whether provided to a naïve population or to a group followed in usual care for 15 months.
3322650|NCT00128661|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
3322651|NCT00128661|Active Comparator|Havrix Group|Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
3322652|NCT00128622|Experimental|Denileukin Diftitox plus vaccine|This is a single arm Phase I safety study.
3322653|NCT00128518|Experimental|Group A : T1+P2 ● P1+P2 ● T2+P1 ● P1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
3322654|NCT00128518|Experimental|Group B : P1+P2 ● T1+P2 ● P1+P2 ● T2+P1|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
3322655|NCT00128518|Experimental|Group C : T2+P1 ● P1+P2 ● T1+P2 ● P1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
3322656|NCT00128518|Experimental|Group D : P1+P2 ● T2+P1 ● P1+P2 ● T1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
3322657|NCT00128505|Experimental|mifepristone|
3322658|NCT00128479|Experimental|mifepristone 300 mg|
3322659|NCT00128479|Placebo Comparator|placebo|
3322660|NCT00128479|Experimental|mifepristone 600 mg|
3322661|NCT00128479|Experimental|mifepristone 1200 mg|
3322662|NCT00128453|Placebo Comparator|Placebo|Conventional therapy plus placebo
3322663|NCT00128453|Active Comparator|Colchicine|Conventional therapy plus colchicine
3322664|NCT00128414|Placebo Comparator|Placebo|Placebo Comparator
3322665|NCT00128414|Experimental|Colchicine|Colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 6 month in patients ≥70 kg, and halved doses for patients <70 kg or intolerant to the highest dose.
3322666|NCT00128401|Active Comparator|D-Cycloserine|An antibiotic, d-cycloserine (DCS) was given to one group and the group is evaluated to see if the drug boosts the effectiveness of cognitive behavior therapy (CBT) for social anxiety.
3322667|NCT00128401|Placebo Comparator|Placebo|Another group was given the placebo and tested for effectiveness of cognitive behavior therapy (CBT) for social anxiety.
3322668|NCT00128388|Experimental|1 PFPP|Panic Focused Psychodynamic Psychotherapy
3322669|NCT00128388|Active Comparator|2 ART|Applied Relaxation Training
3322766|NCT00127218|Experimental|1|any statin plus niacin
3322670|NCT00128362|Experimental|Radio guided Sentinle node biopsy|The radiolabeled Tc-99 colloid or phytate (500 Mbq) will be injected into the primary tumor 2 hours before surgery. A localized scintiscan will then be performed to confirm the radiolabeling of the sentinel node before surgery and for documentation. Isosulphan blue dye will be injected subdermal (0.5ml) over the tumor and intraparenchymal (3-4ml) towards the axilla 10-15mins before incision.
3322671|NCT00128336|Active Comparator|Nurse support|
3322672|NCT00128336|Experimental|Intensive support|
3322673|NCT00128336|Active Comparator|High carbohydrate diet|
3322674|NCT00128336|Experimental|High mono-unsaturated fat diet|
3322675|NCT00128284||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
3322676|NCT00128284||Gastroparesis|Subjects with documented gastroparesis
3322677|NCT00128258|Experimental|open|open treatment
3322678|NCT00128219|Experimental|GBS III-TT|A single dose of GBS III-TT vaccine administered intramuscularly (IM) containing 50 mcg of GBS III capsular polysaccharide and 32 mcg of tetanus toxoid.
3322679|NCT00128219|Active Comparator|Td|The control group will receive a single dose of Tetanus and Diphtheria Toxoids (Td) vaccine.
3322680|NCT00128206|Active Comparator|B|isoniazid (INH) (900 mg orally) given twice weekly for 9 months
3322681|NCT00128206|Active Comparator|A|rifampin (600 mg orally) given daily for 4 months
3322682|NCT00128193|Experimental|A1-Ramping (MLSA-LAM)|5 subjects to receive: 1.0 mcg of MLSA-LAM, 0.1 mcg of MLSA-LAM, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
3322683|NCT00128193|Experimental|C1-Target Population|80 subjects to receive: 1.0 mcg of MLSA-LAM, 1.0 mcg of MLCwA and 2TU Purified Protein Derivative/RT-23.
3322684|NCT00128193|Experimental|C-1b-Target Population (Low Dose)|80 subjects to receive: 0.1 mcg MLSA-LAM, 0.1 mcg MLCwA, 2 TU Purified Protein Derivative/RT-23.
3322685|NCT00128193|Experimental|B2-Full-Scale (MLCwA)|45 subjects to receive: 1.0 mcg of MLCwA, 0.1 mcg of MLCwA, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
3322686|NCT00128193|Experimental|B1-Full-Scale (MLSA-LAM)|45 subjects to receive: 1.0 mcg of MLSA-LAM, 0.1 mcg of MLSA-LAM, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
3322687|NCT00128193|Experimental|A2-Ramping (MLCwA)|5 subjects to receive: 1.0 mcg of MLCwA, 0.1 mcg of MLCwA, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
3322688|NCT00128180|Active Comparator|Active|Methylprednisolone
3322689|NCT00128180|Placebo Comparator|Placebo|Placebo
3322690|NCT00128141|No Intervention|1|
3322691|NCT00128141|Experimental|2|tactile stimulus
3322692|NCT00128128|Active Comparator|Arm 1|Cranberry Juice Cocktail- 4 ounces
3322693|NCT00128128|Active Comparator|Arm 2|Cranberry Juice Cocktail-8 ounces
3322694|NCT00128128|Placebo Comparator|Arm 3|Placebo- 4 ounces
3322695|NCT00128128|Placebo Comparator|Arm 4|Placebo- 8 ounces
3322696|NCT00128102|Experimental|Vorinostat|Vorinostat
3322697|NCT00128102|Placebo Comparator|Placebo|Placebo
3322698|NCT00128076|Active Comparator|1|All-arthroscopic repair
3322699|NCT00128076|Active Comparator|2|Mini-open repair
3322700|NCT00128050|Active Comparator|1|Patients treated with recombinant FVIIa
3322701|NCT00128050|Placebo Comparator|2|Patients with spontaneous supratentorial ICH included in this arm will be treated with placebo
3322702|NCT00128024|Active Comparator|Statins|
3322703|NCT00128024|No Intervention|No statins|
3322704|NCT00127985|Experimental|Active|IV 6-methyl-prednisolone
3322705|NCT00127985|Placebo Comparator|Comparator|IV Placebo
3322706|NCT00127946|Active Comparator|AMNIOECHANGE|The AMNIOECHANGE consists of a transabdominal infusion of saline.They will be repeated every 15 days from 30 week of amenorrhea.
3322707|NCT00127946|No Intervention|placebo|This will be done at the same place and under the same aseptic conditions a AMNIOECHANGE true.
3322708|NCT00127933|Experimental|HER2-NEU Positive|
3322709|NCT00127933|Experimental|HER2-NEU Negative|
3322710|NCT00127920|Experimental|Single Arm|Paclitaxel, Carboplatin and Avastin on day1 every 21 days
3322711|NCT00127881|Experimental|Zanolimumab|
3322712|NCT00127868|Active Comparator|1|oral griseofulvin and selenium sulfide shampoo 1%
3322713|NCT00127868|Active Comparator|2|oral griseofulvin and ciclopirox shampoo
3322714|NCT00127868|Active Comparator|3|oral griseofulvin and ketoconazole shampoo 2%
3322715|NCT00127868|Placebo Comparator|4|oral griseofulvin and baby shampoo
3322716|NCT00127855|Experimental|MenHibrix Formulation 1 Group|Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
3322717|NCT00127855|Experimental|MenHibrix Formulation 2 Group|Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
3322718|NCT00127855|Experimental|MenHibrix Formulation 3 Group|Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
3322719|NCT00127855|Active Comparator|Menjugate Group|Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
3322720|NCT00127855|Active Comparator|ActHIB Group|Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
3322721|NCT00127842|Other|Etanercept|Open-label etanercept administered by subcutaneous injection at a dose of 50 mg/week for 24 months.
3322722|NCT00127829|Experimental|1|Gefitinib (IRESSA®)
3322767|NCT00127218|Placebo Comparator|2|any statin plus placebo
3322723|NCT00127803|Placebo Comparator|Placebo|Participants will receive a dose of vaccine diluent (placebo) on Days 0, 28, and 56, respectively.
3322724|NCT00127803|Experimental|Low dose vaccine|Participants will receive a 2 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively.
3322725|NCT00127803|Experimental|Medium dose vaccine|Participants will receive a 10 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively
3322726|NCT00127803|Experimental|High dose vaccine|Participants will receive a 50 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively
3322727|NCT00127790|Active Comparator|CBT for Insomnia (CBT-I)|Cognitive-Behavioral Therapy for Insomnia (CBT-I)consisting of 10 individual sessions and including sleep education, sleep restriction therapy, stimulus control therapy, sleep hygiene, cognitive therapy, relaxation training and relapse prevention.
3322728|NCT00127790|Active Comparator|CBT for Pain (CBT-P)|Cognitive-Behavioral Therapy for Pain (CBT-P)consisting of 10 individual sessions and including pain education, pacing strategies, problem solving, goal setting, cognitive therapy, relaxation training and relapse prevention.
3322729|NCT00127790|Experimental|CBT for Insomnia & Pain (CBT-I/P)|Combined Cognitive-Behavioral Therapy for Insomnia & Cognitive-Behavioral Therapy for Pain (CBT-I/P)over 10 individual sessions.
3322730|NCT00127790|No Intervention|Wait-List Control (WL)|Waitlist Control condition (WL) with no contact during the intervention period.
3322731|NCT00127712|Experimental|Amiodarone|Amiodarone 1050 mg via continuous intravenous infusion for 24 hours followed by 400 mg orally twice daily for 6 days
3322732|NCT00127712|No Intervention|No treatment|Patients in this group receive no intervention
3322733|NCT00127673|Active Comparator|1|Participants will receive no choice cognitive behavioral therapy
3322734|NCT00127673|Active Comparator|2|Participants will receive choice cognitive behavioral therapy
3322735|NCT00127673|Active Comparator|3|Participants will receive no choice sertraline
3322736|NCT00127673|Active Comparator|4|Participants will receive choice sertraline
3322737|NCT00127660|Experimental|Menu: calories=yes, value pricing=no|There were calories listed on the menu, but no value pricing was in place.
3322738|NCT00127660|Experimental|Menu: calories=yes, value pricing = yes|There were calories listed on the menu, AND value pricing was in place.
3322739|NCT00127660|Experimental|Menu: calories=no, value pricing = no|Calories were not listed on the menu, and value pricing was not in place.
3322740|NCT00127660|No Intervention|Menu: calories=no, value pricing = yes|CONTROL CONDITION: calories were not listed on the menu, and value pricing WAS in place.
3322741|NCT00127647|Experimental|1|montelukast sodium 5 mg, QD 2-weeks
3322742|NCT00127647|Experimental|2|montelukast sodium 10 mg QD 2-weeks
3322743|NCT00127647|Active Comparator|3|Pranlukast 225 mg BID 2-weeks
3322744|NCT00127634|Experimental|1|
3322745|NCT00127634|Active Comparator|2|
3322746|NCT00127530|Placebo Comparator|Placebo- sugar pill|Placebo control
3322747|NCT00127530|Experimental|Fampridine-SR|10 milligram (mg) tablet b.i.d.
3322748|NCT00127491|Experimental|EPVent|All patients will have an esophageal balloon placed for the purpose of obtaining transpulmonary pressure measurements. The intervention group will undergo transpulmonary pressure-directed controlled mechanical ventilation using parameters directed by the initial balloon measurements. Driving pressures will be adjusted to maintain a transpulmonary plateau pressure of less then 30. The PEEP setting will be set to achieve a transpulmonary end expiratory pressure of 0. Repeat PES measurements will be done at 24, 48 and 72 hours following the initial measurements. Additional measurements will be taken as clinically indicated. Ventilator management by PES measurements will continue for a period of 72 hours.
3322749|NCT00127491|Active Comparator|Control|All patients will have an esophageal balloon placed for the purpose of obtaining transpulmonary pressure measurements. The control group will be managed using the low tidal volume strategy laid out by the NIHBLI ARDSnet study. These recommendations include a set tidal volume of 6 ml/ kg. Respiratory rate and PEEP are set to maintain adequate ventilation and oxygenation. These settings will be continued for a period of 72 hours.
3322750|NCT00127452|Experimental|EPA + DHA|Margarine spread that yields 400 mg of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) per day for average margarine use of 20 grams per day
3322751|NCT00127452|Experimental|ALA|Margarine spread that yields 2 grams of alpha-linolenic acid (ALA) per day for average margarine use of 20 grams per day
3322752|NCT00127452|Experimental|EPA + DHA plus ALA|Margarine spread that yields 400 mg of EPA + DHA per day plus 2 grams of ALA per day, for average margarine use of 20 grams per day
3322753|NCT00127452|Placebo Comparator|Placebo|Margarine spread that contains no EPA, DHA or ALA (exchanged for oleic acid)
3322754|NCT00127439|Experimental|Robotic Assisted Locomotor Training|A robotic stepping device in concert with a body weight support system and treadmill is used by a physical therapist and trainers for the participant with spinal cord injury to intensely practice task-specific standing and stepping to advance retraining the capacity to step. The robotic device provides the appropriate kinematics associated with standing and stepping.
3322755|NCT00127439|Experimental|Manually Assisted Locomotor Training|A body weight support system and treadmill is used by a physical therapist and trainers for the participant with spinal cord injury to intensely practice task-specific standing and stepping to advance retraining the capacity to step. Therapists and trainers promote the appropriate kinematics associated with standing and stepping.
3322756|NCT00127413|Experimental|Cognitive Behavioral Therapy - Pain|Cognitive Behavioral Therapy targeting chronic pain
3322757|NCT00127413|Experimental|Cognitive Behavioral Therapy-Integrated|Integrated treatment for comorbid chronic pain and PTSD
3322758|NCT00127413|Experimental|Cognitive Processing Therapy - PTSD|Cognitive Processing Therapy for PTSD
3322759|NCT00127413|Other|Treat as Usual|Participants received care for pain and PTSD as usual from their Primary care provider
3322760|NCT00127335|Placebo Comparator|1|
3322761|NCT00127335|Active Comparator|2|statin administration
3322762|NCT00127270|Experimental|1|Darifenacin
3322763|NCT00127270|Other|2|Darifenacin in combination with Behavioral Modification Programme for Symptoms of Overactive Bladder
3322764|NCT00127231|Experimental|1 Brief Intervention|The brief intervention will include two sessions that review drinking patterns and behavior change strategies as well as two telephone calls to reinforce session content.
3322768|NCT00127205|Experimental|Arm I|Patients receive zoledronate IV over 15 minutes once a month for 6 months and then once every 3 months for 2.5 years.
3322769|NCT00127205|Active Comparator|Arm II|Patients receive oral clodronate once daily for 35 months.
3322770|NCT00127205|Experimental|Arm III|Patients receive oral ibandronate once daily for 35 months.
3322771|NCT00127192|Placebo Comparator|1|Placebo QD 12-week
3322772|NCT00127192|Experimental|2|25 mg QD 12-week
3322773|NCT00127192|Experimental|3|50 mg QD 12-week
3322774|NCT00127192|Experimental|4|100 mg QD 12-week
3322775|NCT00127192|Experimental|5|200 mg QD 12-week
3322776|NCT00127166|Experimental|Montelukast/Salmeterol|Period I - Montelukast 5 milligrams (mg) oral tablet once daily and Salmeterol matching placebo dry powder inhaler (DPI) twice daily for 4 weeks followed by a 2-week washout period (salmeterol matching placebo + montelukast matching placebo). Period II - Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 micrograms (mcg) twice daily for 4 weeks. Inhaled Fluticasone 100 mcg twice daily throughout the study.
3322777|NCT00127166|Experimental|Salmeterol/Montelukast|Period I - Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 mcg twice daily for 4 weeks followed by a 2-week washout period (salmeterol matching placebo + montelukast matching placebo). Period II - Montelukast 5 mg oral tablet once daily and Salmeterol matching placebo DPI twice daily for 4 weeks. Inhaled Fluticasone 100 mcg twice daily throughout the study.
3322778|NCT00127140|Experimental|Vorinostat|Participants received (Cycle 1) once-daily vorinostat at assigned dose (100 or 200 mg) on Days 1 and 17 and twice-daily on Days 3-16. Thereafter, participants remaining on study received the same dose level therapy twice-daily for 14 consecutive days followed by 7 days of rest.
3322779|NCT00127127|Experimental|1|1. level 1: 100 mg BID 14-day, level 2: 200 mg BID 14-day, level 3: 400 mg QD 14 day, level 5: 500 mg QD 14-day
3322780|NCT00127114|Experimental|Amantadine|
3322781|NCT00127114|Placebo Comparator|Placebo|
3322782|NCT00127101|Experimental|Cohort 1|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter[2] daily x 7 days per week
3322783|NCT00127101|Experimental|Cohort 2|Vorinostat 300 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter[2] daily x 7 days per week
3322784|NCT00127101|Experimental|Cohort 2a|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 225 milligrams/meter[2] daily x 7 days per week
3322785|NCT00127101|Experimental|Cohort 2b|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 300 milligrams/meter[2] daily x 7 days per week
3322786|NCT00127101|Experimental|Cohort 6|Vorinostat 400 milligrams daily for 7 days per week + Bexarotene 150 milligrams daily for 7 days per week
3322787|NCT00127101|Experimental|Cohort 7|Vorinostat 400 milligrams daily for 7 days per week + Bexarotene daily for 7 days per week [150 milligrams (Cycle 1) 225 milligrams (Cycle 2-6)
3322788|NCT00127075|Experimental|NOMA + estradiol|Oral NOMA (LUTENYL® 10 mg/day) combined with transdermal Estradiol (DERMESTRIL SEPTEM® 75 mcg, once a week),
3322789|NCT00127075|Placebo Comparator|placebo|Matching placebo treatments
3322790|NCT00127062||Asthma|Asthma patients ranging from mild to severe
3322791|NCT00127062||Healthy Non-Smokers|
3322792|NCT00127036|Experimental|XELOX + Bevacizumab|Arm A: Anticipated 75 Patients - Drug: XELOX (which is Capecitabine + Oxaliplatin) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression
3322793|NCT00127036|Experimental|XELIRI + Bevacizumab|Arm B: Anticipated 75 Patients - Drug: XELIRI (which is Capecitabine + Irinotecan) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression
3322794|NCT00126984|Experimental|Group A|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation A
3322795|NCT00126984|Experimental|Group B|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation B
3322796|NCT00126984|Experimental|Group C|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation C
3322797|NCT00126984|Experimental|Group D|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation D
3322798|NCT00126984|Active Comparator|Group E|Subjects of 12-14 months of age who will receive Meningitec and subjects of 3-5 years of age who will receive Mencevax ACWY.
3322799|NCT00126880|Experimental|600mg BID ATC|600mg BID ATC
3322800|NCT00126880|Experimental|800mg BID ATC|800mg BID ATC
3322801|NCT00126880|Active Comparator|150mg BID 3TC|150mg BID 3TC
3322802|NCT00126789|Experimental|ZR-02-01|ZR-02-01 matrix transdermal fentanyl patch
3322803|NCT00126776|Active Comparator|1|CAse/self management for COPD
3322804|NCT00126776|Other|2|usual care
3322805|NCT00126763|Experimental|Matrix Transdermal Fentanyl Patch|
3322806|NCT00126750|Other|Arm 1|
3322807|NCT00126737|Active Comparator|Arm 1|Group assigned to both a Weight Control Nutritional Program and home-based exercise program (Ex+WC).
3322808|NCT00126737|Active Comparator|Arm 2|Group assigned to a Weight Control Nutritional Program (WC).
3322809|NCT00126737|Active Comparator|Arm 3|Group assigned to a home-based exercise program (Ex).
3322810|NCT00126737|No Intervention|Arm 4|Usual care and non- specific health information (C).
3322811|NCT00126724|Active Comparator|1|1x10^11 DRP/mL tgAAC94
3322812|NCT00126724|Active Comparator|2|1x10^12 DRP/mL tgAAC94
3322813|NCT00126724|Active Comparator|3|1x10^13 DRP/mL tgAAC94
3322814|NCT00126724|Placebo Comparator|4|
3322815|NCT00126659|Experimental|Group I (cytoreductive nephrectomy and sorafenib tosylate)|"Patients undergo cytoreductive nephrectomy on day 1. Patients then receive oral sorafenib twice daily on days 15-84.~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
3322816|NCT00126659|Experimental|Group II (sorafenib tosylate and cytoreductive nephrectomy)|"Patients receive oral sorafenib twice daily on days 1-7. Patients undergo cytoreductive nephrectomy on day 8. Patients then receive oral sorafenib twice daily on days 22-84.~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
3322817|NCT00126659|Experimental|Group III (sorafenib tosylate and cytoreductive nephrectomy)|"Patients receive oral sorafenib twice daily on days 1-28. Patients undergo cytoreductive nephrectomy on day 29. Patients then receive oral sorafenib twice daily on days 43-84.~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
3322818|NCT00126620|Experimental|OSI-774 erlotinib) and Bay 43-9006 (Sorafenib)|Sorafenib administered alone for a 1-week run-in period, and then both drugs e given together continuously, with every 28 days considered as a cycle. Three dose levels assessed.
3322819|NCT00126607|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3322820|NCT00126594|Experimental|Sorafenib Tosylate|Arm I: Oral Sorafenib 400 mg twice daily on days 1-28.
3322821|NCT00126594|Experimental|Sorafenib Tosylate, Recombinant interferon alfa-2b|Arm II: Sorafenib as in Arm I and low-dose Interferon alfa-2b 0.5 million units subcutaneously twice daily on days 1-28.
3322822|NCT00126581|Experimental|Arm I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3322823|NCT00126581|Experimental|Arm II (erlotinib hydrochloride, paclitaxel, carboplatin)|Patients receive erlotinib hydrochloride as in arm I. Patients also receive paclitaxel IV over 1-3 hours and carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses of treatment, patients may continue to receive erlotinib hydrochloride alone as above.
3322824|NCT00126568|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3322825|NCT00126555|Experimental|Stratum I (Gefitinib, Radiotherapy, Surgery)|"Resectable Strata: Induction Gefitinib (60 days), Surgery followed 3-6 weeks later by daily Radiotherapy 5 days a week for approximately 6-7 weeks then after 4 weeks restart Maintenance Gefitinib for up to additional 12 months post radiation.~Gefitinib Induction Phase starting dose 250 mg/day, possible doubling to 500 mg/day for no response Day 15; Maintenance dose post radiation starts at same dose level as last dosing of Induction Phase."
3322826|NCT00126555|Experimental|Stratum II (Gefitinib, Radiotherapy/Surgery)|"Unresectable Strata: Concomitant Radiation/Gefitinib and post-radiation (or post-surgery if surgery is indicated) Gefitinib. Daily Radiotherapy 5 days a week for approximately 6-7 weeks concurrent with Maintenance Gefitinib dose daily up to 12 months.~Gefitinib Induction Phase starting dose 250 mg/day, possible doubling to 500 mg/day for no response Day 15; Maintenance dose post radiation starts at same dose level as last dosing of Induction Phase."
3322827|NCT00126542|Experimental|Treatment (bevacizumab, erlotinib hydrochloride)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral erlotinib once daily on days 1-21. Treatment repeats every 21 days for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to 1 of the study drugs may continue treatment with the remaining study drug alone in the absence of disease progression or unacceptable toxicity.
3322828|NCT00126516|Active Comparator|1|Angiotensin II Receptor Antagonists group
3322829|NCT00126516|Active Comparator|2|Angiotensin-converting Enzyme Inhibitors group
3322830|NCT00126503|Experimental|Treatment (bevacizumab and sorafenib tosylate)|"Phase I: Patients receive sorafenib PO twice daily on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of sorafenib and bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.~Phase II: Patients receive sorafenib PO once daily on days 1-28 and bevacizumab IV over 90 minutes on days 1 and 15 at the MTD in the absence of disease progression or unacceptable toxicity."
3322831|NCT00126490|Experimental|Treatment (bevacizumab, aldesleukin)|Patients receive bevacizumab IV over 30-90 minutes on day 1 in weeks 1, 3, 5, 7, 9, and 11. Patients also receive interleukin-2 subcutaneously on days 1-5 in weeks 5-10. Treatment repeats every 12 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease then receive bevacizumab alone in weeks 1, 3, 5, 7, 9, and 11. Courses with bevacizumab alone repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
3322832|NCT00126438|Experimental|123I-mIBG (meta-iodobenzylguanidine)|Single dose
3322833|NCT00126425|Experimental|123I-mIBG (meta-iodobenzylquanidine|Single dose
3322834|NCT00126373|Placebo Comparator|Sugar pill|Placebo (sugar) pill with identical look to bupropion
3322835|NCT00126373|Experimental|buproprion|bupropion pill
3322836|NCT00126334|Active Comparator|1|Liberal transfusion threshold
3322837|NCT00126334|Experimental|2|Conservative transfusion threshold
3322838|NCT00126308|Experimental|Immediate|poly-L-lactic acid injections
3322839|NCT00126308|Active Comparator|Delayed|poly-L-lactic acid injections
3322840|NCT00126217|Experimental|1|
3322841|NCT00126217|No Intervention|2|
3322842|NCT00126191|Experimental|Low Risk|"Low-risk patients receive 3 cycles of regimen A.~Regimen A:~Rituximab (375 mg/m^2) on Days 1 and 3. Cyclophosphamide (800 mg/m^2) on days 1 and 2. Vincristine (1.4 mg/m^2) on days 1 and 10. Doxorubicin (50 mg/m^2) on Day 1. Methotrexate (3000 mg/m^2) on Day 10. Intrathecal Cytarabine (50mg) will be given on Day 1 and intrathecal methotrexate (12mg) will be given on Days 1 and 10.~Leucovorin on days 11 and 12.~Rituximab is given on Days 1 and 3 in cycle 1, and on Day 1 of all other cycles."
3322843|NCT00126191|Experimental|High Risk|"High-risk patients receive 4 alternating cycles of regimens A and B (A-B-A-B).~Regimen A (as described earlier).~Regimen B:~Rituximab (375mg/m^2) on Day 1. Ifosfamide (1500mg/m^2) on Days 1-5. Mesna (275 mg/m^2) on Days 1-5. Etoposide (60mg/mg^2) on Days 1-5. Cytarabine (2 gm/m^2) twice a day on Days 1 and 2. Intrathecal methotrexate (12mg) on Day 5, and intrathecal methotrexate (50mg) on Day 3 (also on Day 1 for patients with central nervous system involvement)."
3322844|NCT00126126|Experimental|EBAR Program|Evidence Based Amputee Rehabilitation Program (rehabilitation program based on performance of the Amputee Mobility Predictor
3322846|NCT00126113|Experimental|PPT-based Counseling|Counseling based on Performance-Perceptual Discrepancy (PPDIS) consisting of explanation of hearing tests plus recommendations based on PPDIS
3322847|NCT00126113|Other|Standard Educational Counseling|Standard educational counseling consisting of explanation of hearing tests
3322848|NCT00126100|Experimental|1|Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
3322849|NCT00126100|Placebo Comparator|2|Patients were randomly assigned to receive subcutaneously a daily dose of placebo for 5 days.
3322850|NCT00126048|Active Comparator|1|Oral atorvastatin 40mg
3322851|NCT00126048|Placebo Comparator|2|Placebo
3322852|NCT00125970|Experimental|1|DNA HIV vaccine administered at study entry and at Months 1 and 2 and adenoviral vector HIV vaccine administered at Month 6
3322853|NCT00125970|Placebo Comparator|2|DNA HIV vaccine placebo administered at study entry and at Months 1 and 2 and adenoviral vector HIV vaccine placebo administered at Month 6
3322854|NCT00125957|Experimental|Wellbutrin first, then Placebo|Subjects randomly assigned to the Wellbutrin then Placebo group will receive 100mg BID of Wellbutrin at the first visit following intake (Week 0).Subjects will be increased to 150mg Wellbutrin BID at Week 1 unless moderate/severe side effects are reported. If subject and rater classify 1+ symptom as severe or 2+ symptoms as moderate, subject will continue on 100mg of bupropion qAM. If subject and rater classify 1+ symptom as moderate or 2+ mild as moderate, subject will continue on Wellbutrin 100mg BID. At Week 4, subjects will cross-over to placebo and will continue to take placebo until Week 8.
3322855|NCT00125957|Experimental|Placebo first, then Wellbutrin|Subjects randomly assigned to the Placebo then Wellbutrin group will receive placebo until Week 4 when they will cross-over to active drug. At Week 4, subjects will be assigned 100mg Wellbutrin BID. At Week 5, Subjects will be increased to 150mg Wellbutrin BID unless moderate/severe side effects are reported. If subject and rater classify 1+ symptom as severe or 2+ symptoms as moderate, subject will continue on 100mg of Wellbutrin qAM. If subject and rater classify 1+ symptom as moderate or 2+ mild as moderate, subject will continue on bupropion 100mg BID. Subject will continue on the assigned dosage until Week 8 of study.
3322856|NCT00125931|Experimental|Pentazocine/Talwin|Talwin NX
3322857|NCT00125918|Placebo Comparator|1|Placebo
3322858|NCT00125918|Active Comparator|2|2.5 mg tadalafil
3322859|NCT00125918|Active Comparator|3|10 mg tadalafil
3322860|NCT00125918|Active Comparator|4|20 mg tadalafil
3322861|NCT00125918|Active Comparator|5|40 mg tadalafil
3322862|NCT00125879|Experimental|1|
3322863|NCT00125853|Experimental|atenolol 25mg daily|atenolol 25mg daily
3322864|NCT00125853|Active Comparator|nebivolol 2.5mg daily|nebivolol 2.5mg daily
3322865|NCT00125827|Experimental|1|Single-arm, dose escalation
3322866|NCT00125788|Experimental|investigational product|L-glutamine
3322867|NCT00125788|Placebo Comparator|placebo|maltodextrin
3322868|NCT00125775|Active Comparator|1|Engerix-B 40 mcg dose
3322869|NCT00125775|Active Comparator|2|Engerix-B 80 mcg dose
3322870|NCT00125762|Experimental|Single Arm undergoing FibroScan|Single arm active comparison of biopsy to vibration controlled elastography
3322871|NCT00125723|No Intervention|No Intervention|
3322872|NCT00125723|Other|Intervention|PI Discretion
3322873|NCT00125658|Active Comparator|Control|FTP: 30 sessions (90 minute sessions, 3 times per week, 10 weeks) followed by POWER: 30 sessions (90 minute sessions, 3 times per week, 10 weeks)
3322874|NCT00125658|Experimental|Experimental|POWER: 30 sessions (90 minute sessions, 3 times per week, 10 weeks) followed by FTP: 30 sessions (90 minute sessions, 3 times per week, 10 weeks)
3322875|NCT00125645|Experimental|Irbesartan|Tablet Irbesartan 150 mg once daily
3322876|NCT00125619|Active Comparator|Arm 1: Therapist assisted|Therapist assisted locomotor training (partial body-weight supported)
3322877|NCT00125619|Experimental|Arm 2: Robot-assisted|Robot-assisted locomotor training (partial body-weight supported)
3322878|NCT00125606|Active Comparator|conditioning therapy with 12 Gy TBI / cyclophosphamide 120|
3322879|NCT00125606|Experimental|conditioning therapy with 8 Gy TBI / fludarabine 120|
3322880|NCT00125593|Placebo Comparator|Placebo|Placebo = Arm 1. A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with all Arm 1 patients taking 2 tablets (placebo simvastatin plus ezetimibe tablet with a placebo simvastatin tablet) during the first year. After the first year, all Arm 1 patients took one tablet (placebo simvastatin plus ezetimibe tablet).
3322881|NCT00125593|Active Comparator|Simvastatin 20mg plus Ezetimibe 10mg|Simvastatin 20mg plus ezetimibe 10mg = Arm 2. A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with all Arm 2 patients taking 2 tablets during the first year (active simvastatin plus ezetimibe tablet with a placebo simvastatin tablet). After the first year, all Arm 2 patients took one tablet (active simvastatin 20mg plus ezetimibe 10mg tablet).
3322882|NCT00125593|Other|Simvastatin 20mg|Simvastatin 20mg alone = Arm 3. After 1 year, those initially allocated to Arm 3 were re-randomized to simvastatin 20mg plus ezetimibe 10mg (Arm 3b) daily or placebo (Arm 3a). A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with Arm 3 patients taking 2 tablets (a placebo simvastatin plus ezetimibe tablet with an active simvastatin tablet) during the first year. After the first year, all Arm 3a and Arm 3b patients took one tablet (active or placebo simvastatin plus ezetimibe tablet).
3322883|NCT00125567|Experimental|1|Stalevo (levodopa/carbidopa/entacapone)
3322884|NCT00125567|Active Comparator|2|Levodopa/carbidopa
3322885|NCT00125528|Experimental|1|D-cycloserine 50mg bid/100mg bid/200 mg bid
3322886|NCT00125528|Placebo Comparator|2|placebo
3322887|NCT00125515|Placebo Comparator|Placebo|Placebo plus oral naltrexone
3322888|NCT00125515|Active Comparator|Memantine 30 mg bid|Memantine 30 mg bid plus oral naltrexone
3322889|NCT00125515|Active Comparator|Memantine 15 mg bid|memantine 15 mg bid plus oral naltrexone
3322890|NCT00125502|Experimental|I|n=200; 20 micrograms gB with MF59
3322891|NCT00125502|Placebo Comparator|II|n=200; placebo (normal saline)
3322892|NCT00125450|Experimental|A|Chest Physiotherapy with Forced Expiratory Technique
3322893|NCT00125450|Active Comparator|B|Aspiration
3322894|NCT00125385|Experimental|Cohort 1|Dose group
3322899|NCT00125372|Experimental|Erlotinib and Bexarotene|Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy.
3322900|NCT00125359|Experimental|1|All eligible patients will receive continuous daily oral erlotinib 150mg with daily bexarotene oral capsules 400mg.
3322901|NCT00125268|Active Comparator|MIRE|Subjects randomized to this arm will receive treatment with monochromatic near infrared photo energy (MIRE).
3322902|NCT00125268|Sham Comparator|Sham|Subjects randomized to this arm will receive treatment with the sham device, which is non-active but otherwise identical to the study device.
3322903|NCT00125255|Experimental|S-Caine Peel|
3322904|NCT00125255|Placebo Comparator|Placebo Peel|
3322905|NCT00125242|Experimental|Semantic Feature Analysis (SFA)|Word retrieval treatment for aphasia.
3322906|NCT00125242|No Intervention|Participants for Stimuli Development|Non-brain-injured participants provided data for development of treatment stimuli.
3322907|NCT00125216|Other|Arm 1|Single subject design - participant receives three administrations of the same treatment
3322908|NCT00125164|No Intervention|Untreated|Observational Group
3322909|NCT00125164|Experimental|40 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 40 μg/kg BID. Per protocol amendment these subjects were reassigned to receive 120 μg/kg BID. Due to the dose change, the efficacy results for these subjects were analysed in a separate subanalysis. For all outcome measures, mean and standard deviations were not calculated for this arm.
3322910|NCT00125164|Experimental|80 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 80 μg/kg BID
3322911|NCT00125164|Experimental|120 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 120 μg/kg BID
3322912|NCT00125138|Experimental|Melperone HCl - 20 mg|
3322913|NCT00125138|Experimental|Melperone HCl - 40 mg|
3322914|NCT00125138|Experimental|Melperone HCl - 60 mg|
3322915|NCT00125138|Placebo Comparator|Placebo|
3322916|NCT00125047|Experimental|1|Typhoid Vi polysaccharide vaccine
3322917|NCT00125047|Active Comparator|2|Inactivated Hepatitis A vaccine
3322918|NCT00125034|Experimental|Cetuximab Plus FOLFOX-4|
3322919|NCT00125034|Active Comparator|FOLFOX-4 Alone|
3322920|NCT00125008|Experimental|1|Typhoid Vi vaccine
3322921|NCT00125008|Active Comparator|2|Hepatitis A vaccine
3322922|NCT00124982|Experimental|Open-label Abatacept (ABA)-Previous User|In participants who have had an inadequate efficacy response or intolerance on previous TNF-antagonist therapy (off therapy for at least 2 months), open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing < 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing > 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
3322923|NCT00124982|Experimental|Open-label ABA-Current User|In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing < 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing > 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
3322924|NCT00124982|Experimental|Long-term ABA|Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.
3322925|NCT00124969|Active Comparator|1|Amlodipine
3322926|NCT00124969|Placebo Comparator|2|Placebo
3322927|NCT00124943|Experimental|10 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 10 mg/m^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesion) or balloon angioplasty (in-stent restenosis lesions).
3322928|NCT00124943|Experimental|22 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 22 mg/m^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
3322929|NCT00124943|Experimental|35 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 35 mg/m^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
3322930|NCT00124943|Experimental|45 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 45 mg/m^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
3322931|NCT00124917|Experimental|1|Radiation to tumor area as per protocol
3322932|NCT00124878|Active Comparator|Arm 1 Male circumcision|Men receive circumcision after randomization; procedure is generally provided within two weeks. A man randomized to the intervention arm who then declines circumcision for 6 or more months is considered a cross over.
3322933|NCT00124878|No Intervention|Arm 2|Men wait for two years of follow up before being offered male circumcision
3322934|NCT00124852|Placebo Comparator|High Oleic Sunflower Oil|
3322935|NCT00124852|Active Comparator|400 mg EPA+DHA/day|low dose fish oil
3322936|NCT00124852|Active Comparator|1800 mg EPA+DHA/day|high dose fish oil
3322937|NCT00124839|Other|1|Blinded sequential administration: naltrexon 50 mg (3 weeks)- placebo (3 weeks)- placebo (1 week)
3322938|NCT00124839|Other|2|Blinded sequential administration: 200mg naltrexone (3 weeks) - placebo (3 weeks)- placebo (1 week)
3322939|NCT00124839|Other|3|Blinded sequential administration: placebo (3 weeks) - 200mg naltrexone (3 weeks) - placebo (1 week)
3322940|NCT00124839|Other|4|Blinded sequential administration: placebo (3 weeks) - 50mg naltrexone (3 weeks) - placebo (1 week)
3322941|NCT00124787|Experimental|Dimenhydrinate|dimenhydrinate PO x 4 doses
3322942|NCT00124787|Placebo Comparator|Placebo|placebo PO x 4 doses
3322943|NCT00124761|Other|Surgery + Whole Brain Radiotherapy|
3322944|NCT00124761|Experimental|RadioSurgery + Whole Brain Radiotherapy|
3323003|NCT00123981|Active Comparator|CCABG|Coronary artery bypass surgery using cardiopulmonary bypass
3323004|NCT00123981|Experimental|OPCAB|Coronary artery bypass surgery NOT using cardiopulmonary bypass
3322945|NCT00124748|Experimental|Imatinib 400 mg|Oral dose of 400mg Imatinib once daily. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted, reduced, or escalated based on guidelines defined in protocol.
3322946|NCT00124748|Experimental|imatinib 800 mg|Patients randomized to receive 800 mg Imatinib were to receive 400 mg twice daily (b.i.d.) oral administration, in the morning and the evening. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted or reduced based on guidelines defined in protocol.
3322947|NCT00124735|Experimental|Rocuronium bolus maintenance|Rocuronium bolus maintenance
3322948|NCT00124735|Experimental|Rocuronium continuous infusion maintenance|Rocuronium continuous infusion maintenance
3322949|NCT00124722|Experimental|0.45 mg/kg Zemuron|0.45 mg/kg Zemuron
3322950|NCT00124722|Active Comparator|0.6 mg/kg Zemuron|0.6 mg/kg Zemuron
3322951|NCT00124722|Experimental|1.0 mg/kg Zemuron|1.0 mg/kg Zemuron
3322952|NCT00124709|Experimental|1|Pimecrolimus
3322953|NCT00124709|Active Comparator|2|Corticosteroid
3322954|NCT00124683|Experimental|1|Nicotine Patch + Bupropion
3322955|NCT00124683|Placebo Comparator|2|Nicotine patch + placebo
3322956|NCT00124657|Experimental|Patients with High-Grade/Low-Grade Glioma|Patients with newly diagnosed high-grade glioma (excluding those originating in the brain stem) and unfavorable low-grade glioma who are ≥ 3 years and <26 years of age. Patients receiving enzyme-inducing anticonvulsants (EIACs) are not eligible for this study. Patients with spinal cord tumors will be eligible for the Phase I and Phase II component of this study, but they will not be taken into consideration to estimate PFS in the Phase II component of this trial because of their notoriously worse prognosis. Patients receive erlotinib hydrochloride.
3322957|NCT00124618|Experimental|cetuximab/Radiation|Cetuximab (C225) and Radiation
3322958|NCT00124605|Experimental|Treatment (pamidronate disodium and arsenic trioxide)|Patients receive pamidronate IV and over 2 hours on days 1 and 15 and arsenic trioxide IV over 2 hours on days 1-5 and 15-19. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3322959|NCT00124579|Experimental|bortezomib with thalidomide and dexamethasone|bortezomib with thalidomide and dexamethasone
3322960|NCT00124566|Experimental|1|Irofulven + prednisone
3322961|NCT00124566|Experimental|2|Irofulven + capecitabine + prednisone
3322962|NCT00124566|Active Comparator|3|Mitoxantrone + prednisone
3322963|NCT00124540|Placebo Comparator|1|placebo resembling misoprostol
3322964|NCT00124540|Experimental|2|misoprostol
3322965|NCT00124514|Experimental|Triptorelin Vs Placebo (Normal Saline)|Placebo (Normal Saline) vs triptorelin Pamoate
3322966|NCT00124501|Active Comparator|SMT|Standard Medication Treatment
3322967|NCT00124501|Experimental|BART|Biofeedback-assisted Relaxation Training plus SMT
3322968|NCT00124462|Other|Realignment to Placebo|Realigning knee brace and custom orthodic- A valgus brace, customized functional orthotic for neutral foot position and motion control footwear.
3322969|NCT00124462|Other|Placebo to Realignment|Non realigning knee brace and flat orthodic- A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole
3322970|NCT00124449|Active Comparator|1|
3322971|NCT00124449|Placebo Comparator|2|
3322972|NCT00124345|Experimental|1|
3322973|NCT00124319||1|Incoming cadets at the U.S. Naval, Air Force, or Military Academies
3322974|NCT00124306|Active Comparator|1|Amitryptiline
3322975|NCT00124306|Placebo Comparator|2|Placebo will be dosed exactly as active arm.
3322976|NCT00124293||Factor VII|
3322977|NCT00124280|Experimental|previously treated with chemotherapy only|patients previously treated with chemotherapy only (at most 2 prior regimens one of which must have been platinum-based) and no EGFRI
3322978|NCT00124280|Experimental|previously treated with chemotherapy + small|patients previously treated with chemotherapy (at most 2 prior regimens one of which must have been platinum-based) and with one small molecule EGFRI
3322979|NCT00124254|Experimental|1|Surgical group undergoing SMPA
3322980|NCT00124254|Active Comparator|2|Nosurgical group
3322981|NCT00124228|No Intervention|1|Antibiotic following hospital Protocols according the cause of the infection .
3322982|NCT00124228|Active Comparator|2|Antibiotic following hospital Protocols according the cause of infection plus albumin
3322983|NCT00124202|Placebo Comparator|a fatty meal vs normal saline|Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
3322984|NCT00124189|Other|open label|Sequential dose cohort, open label, escalation trial evaluating one infusion duration of 2 hours
3322985|NCT00124176|Experimental|1|Nebulized levalbuterol 10mg/hr given continuously
3322986|NCT00124176|Active Comparator|2|Racemic albuterol 20mg/hr given continuously
3322987|NCT00124150|Experimental|M|Intravenous magnesium sulfate infusion for 14 days.
3322988|NCT00124150|No Intervention|S|Saline infusion without additional magnesium sulfate.
3322989|NCT00124124|Experimental|1|KLH and peptide pulsed DCs
3322990|NCT00124124|Experimental|2|KLH, peptides plus Montanide
3322991|NCT00124072|Active Comparator|Simvastatin 20 mg + folic acid and B12|Participants received 20 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily
3322992|NCT00124072|Active Comparator|Simvastatin 80 mg + folic acid and B12|Participants received 80 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily
3322993|NCT00124072|Active Comparator|Simvastatin 20 mg + placebo|Participants received 20 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily
3322994|NCT00124072|Active Comparator|Simvastatin 80 mg + placebo|Participants received 80 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily
3322995|NCT00124059|Experimental|Type A SERO|
3322996|NCT00124059|Experimental|Type B SERO|
3322997|NCT00124059|Placebo Comparator|Type A PLA|
3322998|NCT00124059|Placebo Comparator|Type B PLA|
3322999|NCT00124046|Active Comparator|Surgical|
3323000|NCT00124046|Active Comparator|Medical Treatment|
3323001|NCT00124020|Experimental|Telavancin|
3323005|NCT00123968|Experimental|1A|Participants will receive a low dose of the adenovirus-vectored HIV vaccine or placebo at study entry
3323006|NCT00123968|Experimental|1B|Participants will receive a higher dose of the adenovirus-vectored HIV vaccine or placebo at study entry
3323007|NCT00123968|Experimental|1C|Participants will receive the DNA plasmid vaccine or placebo at study entry and Days 28 and 56. They will also receive either a low dose of the adenovirus-vectored HIV vaccine or placebo at Day 168.
3323008|NCT00123968|Experimental|1D|Participants will receive the DNA plasmid vaccine or placebo at study entry and Days 28 and 56. They will also receive either a higher dose of the adenovirus-vectored HIV vaccine or placebo at Day 168.
3323009|NCT00123968|Experimental|2A|Participants will receive the DNA plasmid vaccine at study entry and Days 28 and 56. They will also receive a low dose of the adenovirus-vectored HIV vaccine at Day 168.
3323010|NCT00123968|Experimental|2B|Participants will receive the DNA plasmid vaccine placebo at study entry and Days 28 and 56. They will also receive a the adenovirus-vectored HIV vaccine placebo at Day 168.
3323011|NCT00123955|Experimental|1|Spironolactone
3323012|NCT00123955|Placebo Comparator|2|Placebo
3323013|NCT00123929|Active Comparator|1|doxorubicin
3323014|NCT00123929|Other|2|docetaxel
3323015|NCT00123916|Experimental|Benznidazole|60 days treatment with benznidazol
3323016|NCT00123916|Placebo Comparator|Placebo|60 days treatment with matching placebo
3323017|NCT00123838|Experimental|Single Group Assignment|Calypso® 4D Localization System
3323018|NCT00123682|Experimental|Arm 1 - proactive, intensive counseling|Proactive outreach to counseling; multi-session counseling from California Smokers' Helpline
3323019|NCT00123682|Experimental|Arm 2 - reactive, intensive counseling|Reactive outreach to counseling; multi-session counseling from California Smokers' Helpline
3323020|NCT00123682|Experimental|Arm 3 - proactive, self-help|Proactive outreach to engage smoker in treatment; mailed self-help materials
3323021|NCT00123682|Experimental|Arm 4 - reactive, self-help|Reactive approach to engaging smoker in treatment; mailed self-help materials
3323022|NCT00123669|No Intervention|Control|Patient will not receive Inj Progesterone 500 mg
3323023|NCT00123669|Experimental|Treatment|An intramuscular injection of 500mg depot hydroxy-progesterone 5-14 days prior to surgery.
3323024|NCT00123656|Active Comparator|1|fluticasone
3323025|NCT00123656|Active Comparator|2|esomeprazole
3323026|NCT00123643|Experimental|Rosiglitazone|
3323027|NCT00123643|Active Comparator|Glyburide|
3323028|NCT00123630|Placebo Comparator|placebo|placebo group
3323029|NCT00123630|Experimental|omalizumab|Xolair group
3323030|NCT00123617|Experimental|Phase III cardiac rehabilitation|Phase III group-based cardiac rehabilitation classes, weekly
3323031|NCT00123617|No Intervention|Monitoring|Normal daily living, no extra visits to study centre
3323032|NCT00123604|Experimental|Carvedilol|Carvedilol, orally, 25 mg, twice daily for five months
3323033|NCT00123604|Active Comparator|Metoprolol|Metoprolol, orally, 200 mg, twice daily for five months.
3323034|NCT00123578|Experimental|Lorazepam|Lorazepam for the treatment of mild GHB withdrawal.
3323035|NCT00123578|Active Comparator|Pentobarbital|Pentobarbital for the treatment of mild GHB withdrawal.
3323036|NCT00123552|Experimental|1|
3323037|NCT00123552|Experimental|2|
3323038|NCT00123552|Experimental|3|
3323039|NCT00123526|Experimental|1|Worksite intervention
3323040|NCT00123526|No Intervention|2|Receive no intervention
3323041|NCT00123513|Experimental|1|Worksite intervention for obesity prevention
3323042|NCT00123513|No Intervention|2|Control group
3323043|NCT00123500|Active Comparator|1|Worksite Intervention
3323044|NCT00123500|Placebo Comparator|2|Control Group
3323045|NCT00123487|Experimental|dasatinib Twice a Day (BID)|70 mg dasatinib twice a day (BID)
3323046|NCT00123487|Experimental|dasatinib Once a Day (QD)|140 mg dasatinib once a day (QD)
3323047|NCT00123474|Experimental|1|
3323048|NCT00123474|Experimental|2|
3323049|NCT00123474|Experimental|3|
3323050|NCT00123474|Experimental|4|
3323051|NCT00123435|Active Comparator|Arm 1|5-session nutritional counseling program
3323052|NCT00123435|Experimental|Arm 2|5-session nutritional counseling program + simple pedometer feedback
3323053|NCT00123435|Experimental|Arm 3|5-session nutritional counseling program + simple pedometer feedback + enhanced pedometer feedback web-based feedback
3323054|NCT00123422|Experimental|Breathing retraining|Exercise training with computerized training program
3323055|NCT00123422|Experimental|Heliox|Exercise training with helium oxygen combination
3323056|NCT00123422|Active Comparator|Exercise|Exercise training
3323057|NCT00123409|Experimental|Telephone Disease Management|Telephone based disease management or counseling used to promote a reducution in alcohol misuse
3323058|NCT00123409|Placebo Comparator|Usual Care|Usual Care
3323059|NCT00123396|Experimental|Arm 1|Test the effectiveness of the BioCASES teaching modules by way of a randomized controlled trial of VAMCs using the BioTESTS to evaluate their effectiveness for increasing and sustaining VA clinician knowledge, skills, and ability to respond to bioterrorism events.
3323060|NCT00123357||Group 1|
3323061|NCT00123318|Experimental|1|Single-arm, non-randomised feasibility study to evaluate new regimen of adjuvant chemoradiotherapy (Epirubicin, Cisplatin, 5-Fluorouracil + radiotherapy)
3323062|NCT00123305|Experimental|1|
3323063|NCT00123305|Experimental|2|
3323064|NCT00123305|Experimental|3|
3323065|NCT00123305|Placebo Comparator|4|
3323066|NCT00123292|Experimental|1|
3323067|NCT00123292|Experimental|2|
3323068|NCT00123292|Experimental|3|
3323069|NCT00123292|Experimental|4a|
3323070|NCT00123292|Experimental|4b|
3323071|NCT00123279|Experimental|1|
3323072|NCT00123279|Experimental|2|
3323073|NCT00123279|Experimental|3|
3323074|NCT00123279|Experimental|4|
3323075|NCT00123279|Experimental|5|
3323076|NCT00123279|Experimental|6|
3323077|NCT00123266|Experimental|Active|
3323458|NCT00117884|Experimental|9|
3323078|NCT00123240|Active Comparator|High Fat/Protein Diet|
3323079|NCT00123240|Active Comparator|High Carbohydrate Diet|
3323080|NCT00123188|Experimental|Ultrasound and Biopsy|Transvaginal Ultrasound and Endometrial Biopsy
3323081|NCT00123162|Experimental|Sildenafil Citrate|A single vaginal dose of Viagra 100 mg.
3323082|NCT00123162|Placebo Comparator|Placebo|A single vaginal dose of placebo.
3323083|NCT00123123|Placebo Comparator|Placebo (Vehicle Control)|Delivered Twice a day
3323084|NCT00123123|Experimental|0.12% chlorhexidine gluconate oral rinse|Delivered twice a day
3323085|NCT00123123|Experimental|0.12% chlorhexidine oral rinse|Delivered once a day, placebo once a day
3323086|NCT00123110|Experimental|1|metformin plus placebo injection
3323087|NCT00123110|Experimental|2|leuprolide plus placebo pill
3323088|NCT00123110|Placebo Comparator|3|placebo pill plus placebo injection
3323089|NCT00123097|Experimental|Chlorinated polyethylene elastomer first|Patient receives prosthetic made from CPE then the SOC, silicon.
3323090|NCT00123097|Active Comparator|Silicon first|Patient receives prosthetic made from the SOC, silicon, followed by the CPE,Chlorinated polyethylene elastomer.
3323091|NCT00123084|Experimental|Voice/Respiratory Treatment|4 Days a week for 4 weeks with focus on high intensity voice exercises
3323092|NCT00123084|Experimental|Articulation Treatment|4 days a week for 4 weeks with focus on high intensity articulation tasks
3323093|NCT00123084|No Intervention|Subjects with PD in a no treatment group|Subjects do not receive therapy during experimental phases, and will be offered therapy at the end of the study enrollment period.
3323094|NCT00123084|No Intervention|Healthy Control Subjects|Subjects are without Parkinson disease and will not receive therapy.
3323095|NCT00123058|Experimental|Nurse administered|"Nurse Administered Intervention:~Subject received nurse administered behavioral intervention every 8 weeks via telephone for 24 months."
3323096|NCT00123058|Experimental|Nurse & BP monitor|Subjects received both a nurse administered behavioral intervention via telephone every 8 weeks for 24 months and a study provided home BP monitor. Subject recorded home BP 3 times per week for 24 months.
3323097|NCT00123058|No Intervention|Usual Care|Subjects received neither home BP monitor nor nurse phone intervention.
3323098|NCT00123058|Experimental|Home BP Monitor|Subject received study provided home BP monitor. Subject recorded home BP 3 times per week for 24 months.
3323099|NCT00123032|Experimental|1|This group will focus on improving their diet and increasing physical activity at home and at school.
3323100|NCT00123032|No Intervention|2|A control group will not receive any intervention.
3323101|NCT00123019|Active Comparator|1|Minimal intervention; annual weight/waist assessment, questionnaire, and advice
3323102|NCT00123019|Experimental|2|Intensive intervention. All arm 1 activities plus ongoing environmental and group interventions in worksite for two years.
3323103|NCT00123006|Active Comparator|1|Dietary Approaches to Stop Hypertension (DASH)
3323104|NCT00123006|Placebo Comparator|2|Control diet
3323105|NCT00122993|Experimental|1|Multi-component environmental intervention to prevent excess weight gain among bus drivers
3323106|NCT00122993|No Intervention|2|Control group
3323107|NCT00122980|Active Comparator|1|Hydroxyurea and phlebotomy
3323108|NCT00122980|Active Comparator|2|Transfusion and chelation
3323109|NCT00122954|Experimental|Fish oil concentrate|Fish oil concentrate
3323110|NCT00122954|Placebo Comparator|Placebo oil|Placebo oil
3323111|NCT00122928|Experimental|High intensity environmental intervention|Intense intervention
3323112|NCT00122928|Experimental|Moderate intensity environmental intervention|Moderate intervention
3323113|NCT00122928|No Intervention|Individual intervention only|Control
3323114|NCT00122772|Experimental|EBR plus 2 HDBT fractions|External Beam Radiotherapy High Dose Brachytherapy (2 fractions of 9Gy)
3323115|NCT00122772|Active Comparator|EBR plus 4 fractions HDBT|External Beam Radiotherapy High Dose Brachytherapy (4 fractions of 7Gy)
3323116|NCT00122772|Experimental|EBR/2 HDBT fractions/Chemotherapy|"External Beam Radiation~High Dose Brachytherapy (2 fractions of 9Gy)~Cisplatin"
3323117|NCT00122772|Experimental|EBR/4 fractions HDBT/chemotherapy|"External Beam Radiation~High Dose Brachytherapy (4 fractions of 7Gy)~Cisplatin"
3323118|NCT00122746|Active Comparator|Radiotherapy alone|EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A
3323119|NCT00122746|Experimental|Radiotherapy plus Chemotherapy|EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
3323120|NCT00122681|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.
3323121|NCT00122681|Active Comparator|Havrix Group|Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrix™-based investigational formulation) at Months 0, 1 and 6.
3323122|NCT00122642|Experimental|1|The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes for patients not in the hospital.
3323123|NCT00122642|Placebo Comparator|2|The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
3323124|NCT00122616|Active Comparator|Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy|Day0 to week 96:Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy
3323125|NCT00122616|Placebo Comparator|HIV antiretroviral therapy|Day0 to week 96: HIV antiretroviral therapy
3323126|NCT00122603|Experimental|Group 1|Atazanavir + Fosamprenavir + ritonavir
3323127|NCT00122603|Experimental|group 2|Atazanavir + saquinavir + ritonavir
3323128|NCT00122460|Experimental|Cetuximab Plus Chemotherapy|
3323129|NCT00122460|Active Comparator|Chemotherapy alone|
3323130|NCT00122447|Active Comparator|Anti-inflammatory agent|Aspirin (ASA)
3323131|NCT00122447|Active Comparator|Angiotensin receptor blocker (ARB)|Olmesartan (ARB)
3323132|NCT00122447|Active Comparator|Antioxidant|Alpha lipoic acid (ALA)
3323133|NCT00122447|Placebo Comparator|Placebo|Aspirin placebo once a day Olmesartan placebo once a day Alpha lipoic acid placebo twice a day
3323459|NCT00117884|Experimental|10|
3323134|NCT00122421|Active Comparator|pharmacist recommendation|recommendations based on chart review by pharmacist, given to pcp at time of visit
3323135|NCT00122421|No Intervention|usual care|usual care
3323136|NCT00122408|Active Comparator|1|
3323137|NCT00122408|Placebo Comparator|2|
3323138|NCT00122382|Active Comparator|ABA + MTX|abatacept 10 mg/kg intravenous (IV) + methotrexate
3323139|NCT00122382|Active Comparator|Placebo (PLA) + MTX|placebo IV + methotrexate
3323140|NCT00122369|Experimental|Self-hypnotic Relaxation|A research assistant displayed defined behaviors of empathic attention and read to the patient a self-hypnotic relaxation script. Patients also received lidocaine as local anesthetic which is the standard care approach and not considered a unique intervention in terms of the trial.
3323141|NCT00122369|No Intervention|Standard Care|Patients received the routine standard treatment which included application of lidocaine as local anesthetic. This is not considered a unique intervention in terms of the trial. Omitting local anesthetic actually would have been an intervention deviating from routine care.
3323142|NCT00122369|Active Comparator|Empathic Attention|A research assistant displayed defined behaviors of empathic attention. Patients also received lidocaine as local anesthetic which is the standard care approach and not considered a unique intervention in terms of the trial.
3323143|NCT00122356|Other|Anastrozole and alendronate|Patients will receive anastrozole for 5 years and alendronate for 3 years or anastrozole and alendronate treatment for 5 years.
3323144|NCT00122343|Experimental|1|AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
3323145|NCT00122317|Experimental|Eculizumab|600 mg intravenous infusion every week x 4 then 900 mg iv every two weeks
3323146|NCT00122187|Experimental|Electronic Consult System|A new consult system designed to automatically send a gastroenterology consult request for patients with positive fecal occult blood testing (FOBT+) results
3323147|NCT00122187|No Intervention|Usual Care|The usual and customary procedures for addressing FOBT+ results: primary care physicians continued to be responsible for follow up of FOBT+ results.
3323148|NCT00122174|Other|Arm 1|
3323149|NCT00122161|Other|Arm 1|
3323150|NCT00122148|Other|1|
3323151|NCT00122135|No Intervention|Patients without Values Inventory (VI)|Clinic encounter w/physician & patient and/or surrogate - Patients who did not receive the VI prior to their physician clinic encounter
3323152|NCT00122135|Experimental|Patients with Values Inventory (VI)|Clinic encounter w/physician & patient and/or surrogate - Patients who completed the VI prior to their physician clinic encounter
3323153|NCT00122122|Other|Arm 1|
3323154|NCT00122109|Experimental|Videoteleconferencing AMT|"The experimental arm is the group condition that received the AMT treatment intervention via a videoteleconferencing modality as compared to the control condition which is the traditional face-to-face modality.~Behavioral: 12 sessions Anger Management Therapy. Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills."
3323155|NCT00122109|Active Comparator|Face to Face AMT|"The control arm is the group condition that received the AMT treatment intervention via a traditional face-to-face modality as compared to the experimental condition which is the videoteleconferencing modality.~Behavioral: 12 sessions Anger Management Therapy. Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills."
3323156|NCT00122070|Experimental|A|Quetiapine at dosage of 50 to 150 mg
3323157|NCT00122031|Experimental|DBS|
3323158|NCT00122018|Experimental|NAC|N-acetylcysteine started day prior to surgery, continued through night of surgery
3323159|NCT00122018|Experimental|fenoldopam|fenoldopam started at surgery continued for 24 hours
3323160|NCT00122018|Experimental|NAC and fenoldopam|Both N-acetylcysteine and fenoldopam as above
3323161|NCT00122018|Placebo Comparator|Control|Placebo
3323162|NCT00121940|Experimental|Guided Care|
3323163|NCT00121940|No Intervention|Usual Care|
3323164|NCT00121875||Turner syndrome|Girls, aged 7-14, with short stature due to Turner syndrome and eligible for growth hormone therapy
3323165|NCT00121875||Control / idiopathic short stature|Girls, aged 7-14, with idiopathic short stature and eligible for growth hormone therapy
3323166|NCT00121836|Experimental|1|
3323167|NCT00121810|Experimental|1|
3323168|NCT00121810|Active Comparator|2|
3323169|NCT00121784|Experimental|1|1
3323170|NCT00121745|Experimental|1|
3323171|NCT00121745|Experimental|2|
3323172|NCT00121745|Experimental|3|
3323173|NCT00121745|Experimental|4|
3323174|NCT00121732|Experimental|A|
3323175|NCT00121732|Experimental|B|
3323176|NCT00121719|Experimental|1|
3323177|NCT00121693|Experimental|Music Listening 1|Intervention: Listen to Music type 1
3323178|NCT00121693|Experimental|Music Listening 2|Intervention: Listen to Music type 2
3323179|NCT00121693|Experimental|Music LIstening 3|Intervention: Listen to Music type 3
3323180|NCT00121693|No Intervention|Control|Intervention: Listen to White noise
3323181|NCT00121680|Experimental|1|
3323182|NCT00121667|Experimental|Saxagliptin + Metformin (A)|Pioglitazone 15-45 mg (as needed for rescue)
3323183|NCT00121667|Experimental|Saxagliptin + Metformin (B)|Pioglitazone 15-45 mg (as needed for rescue)
3323184|NCT00121667|Experimental|Saxagliptin + Metformin (C)|Pioglitazone 15-45 mg (as needed for rescue)
3323185|NCT00121667|Placebo Comparator|Placebo+ Metformin (D)|Pioglitazone 15-45 mg (as needed for rescue)
3323186|NCT00121654|Active Comparator|1|paresthesic SCS
3323187|NCT00121654|Active Comparator|2|subliminal SCS (75-80% of paresthesic threshold)
3323460|NCT00117884|Experimental|11|
3323188|NCT00121654|Sham Comparator|3|low stimulation, consisting of an hour of SCS a day at 0.05 mV intensity, which does not have any significant stimulator effect (sham stimulation)
3323189|NCT00121641|Experimental|Saxagliptin 2.5 mg (A)|Metformin 500-2000 mg (as needed for rescue)
3323190|NCT00121641|Experimental|Saxagliptin 5 mg (B)|Metformin 500-2000 mg (as needed for rescue)
3323191|NCT00121641|Experimental|Saxagliptin 10 mg (C)|Metformin 500-2000 mg (as needed for rescue)
3323192|NCT00121641|Placebo Comparator|Placebo (D)|Metformin 500-2000 mg (as needed for rescue)
3323193|NCT00121641|Experimental|Open-Label Treatment Cohort (Direct Enrollees) (E)|"Saxagliptin 10 mg~Metformin 500-2000 mg (as needed for rescue)"
3323194|NCT00121602|Active Comparator|Roller bottle|
3323195|NCT00121602|Experimental|Serum free|
3323196|NCT00121550|Experimental|Clarithromycin|Clarithromycin is a lipophilic semi-synthetic macrolide antibiotic. The lipophilic nature of the drug allows it to easily penetrate into body fluids and tissues and accumulate intracellularly. Side effects are few, apart from trivial gastrointestinal complaints, and severe side effects are rarely observed during standard treatment.
3323197|NCT00121550|Placebo Comparator|Placebo|Placebo comparator
3323198|NCT00121524|Experimental|IV yes|Intravenous needle Epinephrine q 3 min during CPR Atropine 3 mg in initial asystole Amiodarone 300 mg iv after repeated failed defibrillation attempts
3323199|NCT00121524|No Intervention|IV no|The patient will not have an intravenous needle placed or given any drugs during CPR. If patient obtains spontaneous circulation, an intravenous needle is placed and patient can receive any drugs that are appropriate during the following treatment.
3323200|NCT00121485|Experimental|HeartMate II|Implantation of HeartMate II LVAS
3323201|NCT00121485|Active Comparator|HeartMate XVE|Implantation of HeartMate XVE LVAS
3323202|NCT00121394|Experimental|Chlorhexidine|
3323203|NCT00121381|Experimental|1|Pimecrolimus 1 % cream plus topical corticosteroid (TCS)
3323204|NCT00121381|Placebo Comparator|2|Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
3323205|NCT00121316|Experimental|1|Pimecrolimus
3323206|NCT00121316|Placebo Comparator|2|Matching vehicle cream (placebo)
3323207|NCT00121303|Active Comparator|Arm A low dose Dauno|Induction 45 mg Dauno
3323208|NCT00121303|Experimental|ARM B high dose Dauno|Induction 90 mg Dauno
3323209|NCT00121303|No Intervention|Arm 1 no further treatment|
3323210|NCT00121303|Experimental|Arm 2 Mylotarg|Post induction treatment with Mylotarg
3323211|NCT00121290|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes once daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3323212|NCT00121277|Experimental|SAHA (Suberoylanilide Acid) with Capecitabine|
3323213|NCT00121264|Experimental|Treatment (sorafenib tosylate, tanespimycin)|Patients receive oral sorafenib twice daily on days -14 to 28 in course 1 and on days 1-28 in all subsequent courses. Patients also receive 17-AAG IV over 3 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3323214|NCT00121251|Experimental|Arm I|Patients receive sorafenib* PO BID on days 1-21, gemcitabine IV over 30 minutes on days 1 and 8, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for at least 3 courses in the absence of unacceptable toxicity or disease progression.
3323215|NCT00121238|Experimental|Experimental treatment: cilengitide|Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity. After 3 courses, patients undergo evaluation. Patients achieving a complete prostate-specific antigen (PSA) response (i.e., PSA < 0.2 ng/mL) receive 2-3 additional courses of therapy. Patients with partial PSA response or stable disease continue treatment indefinitely in the absence of disease progression or unacceptable toxicity. Patients demonstrating disease progression by CT scan, MRI, or bone scan are removed from the study.
3323216|NCT00121225|Experimental|Arm I|Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
3323217|NCT00121212|Active Comparator|Surgery - Negative PET scan|If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is negative, the patient will receive the curative therapy and be followed for recurrence.
3323218|NCT00121212|Experimental|Surgery - Positive PET scan|If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is positive, the patient will receive the curative therapy and be followed for recurrence or receive alternative therapy.
3323219|NCT00121212|Active Comparator|Radiation therapy Negative or Positive PET scan|If patient is candidate for radiation therapy with curative intent, he will be enrolled. If PET scan is negative he will receive curative therapy and be followed for PSA recurrence. If PET scan is positive he may receive confirmatory studies and then if negative, not indicated, or refused he will receive curative therapy be followed for PSA recurrence. If PET scan is positive and received positive confirmatory studies he will receive curative therapy and followed for recurrence.
3323220|NCT00121199|Experimental|Treatment (CHOP, rituximab, bevacizumab)|Patients receive rituximab IV, bevacizumab IV over 30-90 minutes, cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1. Patients also receive oral prednisone on days 1-5. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
3323221|NCT00121186|Experimental|Nonmyeloablative allogeneic stem cell transplant|Patients are given fludarabine 30 mg/m^2 on days -6 to -2 and melphalan 70 mg/m^2 on days -3 and -2, then transplanted with donor peripheral blood stem cells or harvested bone marrow stem cells on day 0. Patients are then given post-transplant immunosuppression consisting of tacrolimus 0.06 mg/kg/day on days -3 to 100 and methotrexate 5 mg/m^2 on days 1, 3, and 7.
3323222|NCT00121173|Experimental|Low dose|"3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals.~Genetic (recombinant DNA vaccine)"
3323223|NCT00121173|Experimental|Intermediate dose|3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)
3323224|NCT00121173|Experimental|High dose|3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)
3323225|NCT00121134|Experimental|Group A|Bevacizumab Alone
3323226|NCT00121134|Experimental|Group B|Bevacizumab with cyclophosphamide and methotrexate
3323227|NCT00121134|Experimental|Group C|capecitabine, 14 days on/7 days off scheduling, and bevacizumab
3323228|NCT00121134|Experimental|Group D|capecitabine 7 days on/7 days off scheduling, and bevacizumab
3323229|NCT00121108|Placebo Comparator|2|Placebo
3323230|NCT00121108|Active Comparator|1|MEDI-524
3323231|NCT00121095|Other|1|
3323232|NCT00120965|Experimental|1|Autopulse device
3323233|NCT00120965|Active Comparator|2|Manual CPR
3323234|NCT00120874|Experimental|Group 1|Individualized Management including caregiver training and Memantine
3323235|NCT00120874|Active Comparator|Group 2|Only Memantine
3323236|NCT00120796|Active Comparator|1|Lamivudine alone
3323237|NCT00120796|Experimental|2|Lamivudine + Vaccine
3323238|NCT00120627|Experimental|Arm 1: Mantram + Usual Care|Mantram Repetition Program for PTSD delivered in this study as 6-week, 90-minute per week that targeted PTSD symptoms. It was offered as an adjunct to usual care consisting of medication and case-management.
3323239|NCT00120627|Active Comparator|Arm 2: Usual Care alone|Usual care alone is defined as receiving 6 weeks of medication and case management, as needed by each patient. No group meetings.
3323240|NCT00120523|Experimental|1|Pimecrolimus
3323241|NCT00120523|Active Comparator|2|Topical corticosteroids
3323242|NCT00120510|Experimental|A|Randomly assigned group who will start an ART regimen of 3TC/ZDV and EFV twice daily at study entry
3323243|NCT00120510|Active Comparator|B|Randomly assigned group who will delay beginning ART regimen of 3TC/ZDV and EFC twice daily until they develop clinical AIDS or their CD4 count drops below 200 cells/mm3
3323244|NCT00120471|Experimental|1|Pregnant participants will receive a single dose of TDF during active labor. These participants will be hospitalized at the delivery facility through Day 3 postpartum.
3323245|NCT00120471|Experimental|2|Pregnant participants will not receive TDF. Participants will be hospitalized at the delivery facility through Day 7 postpartum. Their infants will receive TDF at birth and on Days 3 and 5 after birth.
3323246|NCT00120471|Experimental|3|Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum. They will receive TDF during active labor and their infants will receive TDF at birth and on Days 3 and 5 after birth.
3323247|NCT00120471|Experimental|4|Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum. Mothers will receive TDF during active labor and their infants will receive TDF at birth and daily for 7 days after birth.
3323248|NCT00120458|Experimental|1|Anxiolytic Therapy
3323249|NCT00120458|Placebo Comparator|2|Anxiolytic Therapy
3323250|NCT00120445|Active Comparator|2|air vs perfluoropropane gas in pneumatic retinopexy
3323251|NCT00120432|Active Comparator|A|single dose vs three doses of 1%tropicamide and 10%phenylephrine
3323252|NCT00120406|Experimental|1|Zilver® PTX™ Drug Eluting Vascular Stent
3323253|NCT00120406|Active Comparator|2|Angioplasty
3323254|NCT00120393|Active Comparator|G1|
3323255|NCT00120393|Active Comparator|G2|
3323256|NCT00120380|Active Comparator|Aerosolized Iloprost|
3323257|NCT00120380|Placebo Comparator|Bosentan monotherapy|
3323258|NCT00120315|No Intervention|esomeprazole|Long-term users continue antisecretory medication
3323259|NCT00120315|Placebo Comparator|placebo drug|Long-term users are treated with placebo
3323260|NCT00120302|Experimental|1|Pimecrolimus
3323261|NCT00120302|Placebo Comparator|2|Vehicle
3323262|NCT00120289|Experimental|Combination Therapy|Extended release niacin plus simvastatin
3323263|NCT00120289|Active Comparator|Monotherapy|Simvastatin alone
3323264|NCT00120250|Experimental|Eszopiclone|Subjects received 3mg eszopiclone nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of placebo, followed by another 1 week washout.
3323265|NCT00120250|Placebo Comparator|Placebo|Subjects received placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of 3mg eszopiclone, followed by another 1 week washout.
3323266|NCT00120211|Experimental|Radiotherapy: 6 Fractions|
3323267|NCT00120211|Active Comparator|Radiotherapy: 5 fractions|
3323268|NCT00120120|Experimental|1|
3323269|NCT00120120|Experimental|2|
3323270|NCT00120081|Experimental|Low dose|10 mcg Na-ASP-2/Alhydrogel
3323271|NCT00120081|Experimental|Medium dose|50 mcg Na-ASP-2/Alhydrogel
3323272|NCT00120081|Experimental|High dose|100 mcg Na-ASP-2/Alhydrogel
3323273|NCT00120081|Placebo Comparator|Saline placebo|Saline placebo
3323274|NCT00120068|Other|Arm 1|
3323275|NCT00120042|No Intervention|1|No specific oxytocic to assist in placental delivery
3323276|NCT00120042|Active Comparator|2|Intramuscular oxytocin injection
3323277|NCT00120042|Active Comparator|3|Oral misoprostol to assist in placental delivery
3323278|NCT00120016|Experimental|1|Mediterranean diet
3323279|NCT00120016|No Intervention|2|non-intervention diet
3323280|NCT00120003|Experimental|Candesartan Cilexetil|Candesartan Cilexetil
3323281|NCT00120003|Placebo Comparator|Placebo|Placebo
3323282|NCT00119977|Active Comparator|1|
3323283|NCT00119925|Active Comparator|minimal intervention|professional audit and feedback on current practice
3323284|NCT00119925|Active Comparator|maximal intervention|multi-faceted intervention consisting of professional and patient elements
3323285|NCT00119912|Active Comparator|A 1 Intervention arm Flex Sig|Randomised from the population registry, age 50-64 years and invited for Flexible Sigmoidoscopy (Flex Sig) screening. Half of invitees are additionally invited to provide a stool sample for fecal occult blood testing (Intervention arm A 2). They are drawn directly from the population registry without prior consent to be randomized - approved by Regional Ethics Committees of South-East Norway..
3323286|NCT00119912|No Intervention|B Control arm|"No screening group randomised from population age 50-64 years. As for the active intervention arm, the control group was not informed about being randomized to 'no screening' since 'no screening' was the current usual care (and still is in 2015) in Norway - approved by Regional Ethics Committees of South-East Norway."
3323287|NCT00119912|Active Comparator|A 2 Intervention arm Flex Sig + iFOBT|Randomised from the population registry, age 50-64 years and invited for Flexible Sigmoidoscopy (Flex Sig) screening plus an immunochemical test for fecal occult blood (iFOBT). As for arms A 1 and B, they are drawn directly from the population registry without prior consent to be randomized.
3323288|NCT00119847|Experimental|PCI+MED|Percutaneous Coronary Intervention (PCI) with angioplasty and stenting of the infarct-related artery and optimal medical therapy
3323289|NCT00119847|Experimental|MED|Optimal medical therapy alone
3323290|NCT00119821|Experimental|I|Behavioral Weight Reduction
3323291|NCT00119821|Other|II|Exercise
3323292|NCT00119821|Other|III|Smoking Cessation
3323293|NCT00119795|Active Comparator|Health education control|This is an education program for older adults entitles, successful aging.
3323294|NCT00119795|Experimental|Exercise Only|Structured exercise 150 min/wk
3323295|NCT00119795|Experimental|Weight Loss|Behavioral weight loss; goal of 7%
3323296|NCT00119782|Experimental|1|Comprehensive worksite intervention
3323297|NCT00119782|Experimental|2|Delayed intervention control group
3323298|NCT00119769|Placebo Comparator|1|
3323299|NCT00119769|Active Comparator|2|
3323300|NCT00119730|Experimental|Fludarabine, Mitoxantrone, Rituximab, Zevalin|Drug: Fludarabine Given on days 1-3 of each 28-day cycle Drug: Mitoxantrone Given on day 1 of each 28-day cycle Drug: Rituximab Given on day 1 of each 28-day cycle Drug: Zevalin Given after two cycles if there is no disease progression.
3323301|NCT00119717|Experimental|1|
3323302|NCT00119717|Active Comparator|2|
3323303|NCT00119691|Experimental|Nesiritide + standard of care|Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
3323304|NCT00119691|Active Comparator|Standard of care|Standard of care until adequate diuresis achieved
3323305|NCT00119678|Active Comparator|Abatacept + Prednisone|Double Blind Period
3323306|NCT00119678|Placebo Comparator|Placebo + Prednisone|Double Blind Period
3323307|NCT00119678|Experimental|Abatacept|Open Label
3323308|NCT00119639|Experimental|Arm 1|
3323309|NCT00119613|Experimental|Group 1 - darbepoetin alfa|Darbepoetin alfa 300 mcg QW for the first 4 weeks, followed by Q3W dosing commencing on week 5 for the remainder of the treatment period.
3323310|NCT00119613|Placebo Comparator|Group 2 - Placebo|Placebo QW for the first 4 weeks, followed by Q3W dosing commencing on week 5 for the remainder of the treatment period.
3323311|NCT00119574|Other|Arm 1|
3323312|NCT00119561|Experimental|Arm 1|Telephone support groups
3323313|NCT00119561|No Intervention|Arm 2|Usual VA care
3323314|NCT00119548|Other|Arm 1|Randomized, controlled trial with three intervention models: Model A (traditional counseling/testing);
3323315|NCT00119548|Other|Arm 2|Model B (nurse-initiated screening, traditional counseling/testing);
3323316|NCT00119548|Other|Arm 3|Model C (nurse-initiated screening, streamlined counseling/rapid testing).
3323317|NCT00119535|Other|Arm 1|
3323318|NCT00119522||Group 1|cohort is of individuals with a spinal cord injury who use a wheelchair as their primary means of mobility
3323319|NCT00119496|Active Comparator|Group 1|Inhaled beclomethasone (400mcg/day)
3323320|NCT00119496|Active Comparator|Arm 2|Rosiglitazone
3323321|NCT00119496|Active Comparator|Arm3|Oral theophylline
3323322|NCT00119496|Active Comparator|Arm 4|Oral theophylline and inhaled beclomethasone
3323323|NCT00119444|Other|periacetabular osteotomy|
3323324|NCT00119392|Experimental|Treatment (90Y ibritumomab tiuxetan, hematopoietic transplant)|See Detailed Description
3323325|NCT00119379|Experimental|uridine supplementation|NucleomaxX 36 grams TID every other day
3323326|NCT00119379|Active Comparator|Switch to Tenofovir|Switch of AZT or d4T to Tenofovir Disoproxil Fumarate
3323327|NCT00119366|Experimental|Treatment (radiolabeled monoclonal antibody, TBI, chemo, PBSC)|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
3323328|NCT00119262|Experimental|Arm I (combination chemotherapy, 18 courses of bevacizumab)|See detailed description.
3323329|NCT00119262|Active Comparator|Arm II (combination chemotherapy, 22 courses of bevacizumab)|See detailed description.
3323330|NCT00119249|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3323331|NCT00119236|Experimental|Arm I|Patients receive irinotecan IV over 30 minutes followed by 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)* IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable or improved disease after course 2 may receive additional courses of treatment.
3323332|NCT00119210|Placebo Comparator|Placebo|Sugar pill
3323333|NCT00119210|Experimental|Bupropion SR|
3323334|NCT00119197|Experimental|1|Killed Whole Cell Oral Cholera Vaccine
3323335|NCT00119197|Placebo Comparator|2|Heat-killed E. coli
3323336|NCT00119184|Experimental|External cephalic version with spinal anesthesia|External cephalic version with spinal anesthesia
3323337|NCT00119184|Active Comparator|External cephalic version without spinal anesthesia|External cephalic version without spinal anesthesia
3323338|NCT00119158|Placebo Comparator|placebo|Placebo cream
3323339|NCT00119158|Active Comparator|pimecrolimus cream|
3323340|NCT00119106|Active Comparator|Tenofovir|Tenofovir
3323341|NCT00119106|Placebo Comparator|Placebo|Placebo
3323342|NCT00119067|Active Comparator|AVA 8-SQ|receive 8 injections of AVA SQ
3323343|NCT00119067|Experimental|AVA 8-IM|receive 8 injections of AVA IM
3323344|NCT00119067|Experimental|AVA 7-IM|receive 7 injections of AVA IM
3323345|NCT00119067|Experimental|AVA 5-IM|receive 5 injections of AVA IM
3323346|NCT00119067|Experimental|AVA 4-IM|receive 4 injections of AVA IM; months 0, 2, 6 and a booster at month 42
3323347|NCT00119067|Placebo Comparator|Saline placebo IM or SQ|
3323348|NCT00119054|Other|Arm 1|
3323349|NCT00119041|Experimental|Telemedicine CBOC|"Designated CBOC's were involved in the intervention phase where their Diabetes Mellitus (DM) patients were asked to participate in a telemedicine visit.~The Behavioral: The Diabetes Treatment Satisfaction Questionnaire given during this phase along with the Behavioral: Diabetes Empowerment Scale and the Behavioral: CBOC's undergo half-day joint-clinics via teleconference."
3323350|NCT00119041|No Intervention|Control CBOC|The CBOC's not involved in the intervention phase had their patients not be involved in the telemedicine visit, but traditional education.
3323351|NCT00119041|No Intervention|Provider Interviews|Qualitative interviews with providers
3323352|NCT00119028|Other|Arm 1|Non-experimental QI intervention - No comparator
3323353|NCT00119015|Placebo Comparator|Fluticasone propionate + Placebo|"Fluticasone propionate nasal spray - 2 sprays in each nostril once a day for 2 weeks (200 micrograms daily)~Placebo - 10 mg po daily for 2 weeks"
3323354|NCT00119015|Active Comparator|Fluticasone propionate + Montelukast|"Fluticasone propionate nasal spray - 2 sprays in each nostril once a day for 2 weeks (200 micrograms daily)~Montelukast - 10 mg po daily for 2 weeks"
3323355|NCT00119002|Active Comparator|Dexamethasone|1mg of Dexamethasone/kg
3323356|NCT00119002|Placebo Comparator|Placebo|1mg/kg placebo
3323357|NCT00118989|Placebo Comparator|PLACEBO|placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
3323358|NCT00118989|Experimental|Curcuminoids C3 Complex® to be taken orally via caps|Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
3323359|NCT00118963|Active Comparator|3|BIAsp30 plus Metformin plus Placebo-Repaglinide. Double-Masked and randomized. Duration: 12 months.
3323360|NCT00118963|Active Comparator|2|BIAsp30 plus Repaglinide plus Placebo-Metformin. Double-masked and randomized. Duration: 12 months.
3323361|NCT00118963|Other|1|Run-in period of four months duration with Repaglinide 6 mg daily plus Metformin 2000 mg daily. No masking of interventions.
3323362|NCT00118950|Active Comparator|4|Metformin plus placebo-Repgalinide. Double-masked, randomized. Duration: Four months.
3323363|NCT00118950|Active Comparator|2|Repaglinide plus Placebo-Metformin. Double-masked, randomized. Duration: Four months.
3323364|NCT00118950|Other|1|Run-in period: Treatment: Diet-only. Duration: One month.
3323365|NCT00118950|Other|3|Wash-out period: Treatment: Diet-only: Duration: One month.
3323366|NCT00118937|Placebo Comparator|1|Single-blind placebo run-in period. Duration one month.
3323367|NCT00118937|Active Comparator|2|Metformin 2000 mg, double-masked randomized during 12 months.
3323368|NCT00118937|Placebo Comparator|3|Placebo, double-masked randomized during 12 months.
3323369|NCT00118924|Experimental|1|One subcutaneous vaccination with a 10^3 PFU dose of LGT(TP21)/DEN4 vaccine given in the deltoid region of either arm. A second booster vaccination will be given 6 months after the first vaccination.
3323370|NCT00118924|Experimental|2|One subcutaneous vaccination with a 10^5 PFU dose of LGT(TP21)/DEN4 vaccine given in the deltoid region of either arm. A second booster vaccination will be given 6 months after the first vaccination. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
3323371|NCT00118924|Placebo Comparator|3|One subcutaneous vaccination with a placebo vaccine given in the deltoid region of either arm. A second placebo vaccination will be given 6 months after the first vaccination.
3323372|NCT00118911|Experimental|Cognitive-Behavioral Therapy|Participants will receive cognitive-behavioral therapy following our protocol.
3323373|NCT00118911|Active Comparator|Relaxation with Educational Support|Applied relaxation plus educational support (RES).
3323374|NCT00118898|Experimental|EFV, FTC/TDF, and placebo ABC/3TC|Participants will receive EFV, FTC/TDF, and placebo for ABC/3TC for at least 96 weeks
3323375|NCT00118898|Experimental|EFV, ABC/3TC and placebo FTC/TDF|Participants will receive EFV, ABC/3TC, and placebo for FTC/TDF for at least 96 weeks
3323376|NCT00118898|Experimental|RTV-boosted ATV, FTC/TDF, and placebo ABC/3TC|Participants will receive RTV-boosted ATV, FTC/TDF, and placebo for ABC/3TC for at least 96 weeks
3323377|NCT00118898|Experimental|RTV-boosted ATV, ABC/3TC, and placebo FTC/TDF|Participants will receive RTV-boosted ATV, ABC/3TC, and placebo for FTC/TDF for at least 96 weeks
3323378|NCT00118872|Active Comparator|LGG yogurt|Lactobacillus (LGG) containing yogurt
3323379|NCT00118872|Placebo Comparator|Placebo yogurt|Regular yogurt, NOT containing LGG
3323380|NCT00118846|Experimental|1|25 gm soy protein administered twice daily in equivalent dosages (12.5 gm)
3323381|NCT00118846|Placebo Comparator|2|Matching placebo
3323382|NCT00118755|Experimental|1|
3323383|NCT00118755|Active Comparator|2|
3323384|NCT00118742|Experimental|CellCept + CNI (tacrolimus or cyclosporine)|
3323385|NCT00118742|Active Comparator|CellCept + sirolimus|
3323386|NCT00118729|Experimental|Arm 1|
3323387|NCT00118638|Experimental|Darbepoetin alfa 500 mcg - Group A|
3323388|NCT00118638|Active Comparator|Darbepoetin alfa 2.25 mcg/kg - Group B|
3323389|NCT00118573|Experimental|EVAR|AAA repair with endografting
3323390|NCT00118573|Active Comparator|Surveillance|Not AAA repair; surveillance
3323391|NCT00118560|Experimental|1|treadmill walking and calf exercise
3323392|NCT00118547|Other|1|
3323393|NCT00118534|Experimental|Arm 1|Integration of smoking cessation therapy with PTSD therapy.
3323394|NCT00118534|Active Comparator|Arm 2|Per standard of care, patients are referred to a smoking cessation clinic for their smoking cessation therapy.
3323395|NCT00118508|Placebo Comparator|A|Group A will receive active study drug
3323396|NCT00118482|Experimental|fludrocortisone acetate|
3323397|NCT00118482|Placebo Comparator|Placebo|
3323398|NCT00118456|Experimental|1|Continuous daily dosing
3323399|NCT00118456|Experimental|2|Monday, Wednesday, Friday Dosing
3323400|NCT00118430|Experimental|Stepped Care|Stepped care group
3323401|NCT00118430|Active Comparator|Usual Care|Treatment as usual group
3323402|NCT00118430|No Intervention|No Treatment|Participants without depression group
3323403|NCT00118417|Experimental|1|Participants in phase II will receive sertraline, or an equivalent medication, up to 100 mg plus a placebo pill. Participants in phase III will receive the same medication with cognitive behavioral therapy.
3323404|NCT00118417|Experimental|2|Participants in phase II will receive sertraline, or equivalent medication, up to 200 mg. Participants in phase III they will receive the same medication with flexible clonazepam augmentation.
3323405|NCT00118404|Experimental|1|Participants received acute phase and continuation phase cognitive therapy
3323406|NCT00118404|Placebo Comparator|2|Participants received acute phase cognitive therapy and continuation phase pill placebo
3323407|NCT00118404|Active Comparator|3|Participants received acute phase cognitive therapy and continuation phase fluoxetine
3323408|NCT00118378|Experimental|Modafinil|Participants will take modafinil for 4 weeks.
3323409|NCT00118378|Placebo Comparator|Placebo|Participants will take placebo for 4 weeks.
3323410|NCT00118365|Placebo Comparator|Arm II (placebo)|Patients receive oral double placebo once daily. In both arms, treatment continues for 36 months in the absence of unacceptable toxicity or the development of an invasive malignancy.
3323411|NCT00118365|Experimental|Arm I (eflornithine and sulindac)|Patients receive oral eflornithine (DFMO) and oral sulindac once daily. In both arms, treatment continues for 36 months in the absence of unacceptable toxicity or the development of an invasive malignancy.
3323412|NCT00118352|Experimental|Treatment (chemotherapy, TBI, transplant)|"NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive alemtuzumab IV over 6 hours once daily on days -6, -5, and -4 OR days -5 and -4 and fludarabine phosphate IV over 30 minutes on days -4, -3, and -2. Patients also undergo low-dose TBI on day 0.~ALLOGENEIC PBSCT: After completion of TBI, patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV every 12 hours on days -3 to 180 followed by a taper until day 365 in the absence of GVHD. Beginning 4-6 hours after completion of allogeneic PBSCT, patients receive mycophenolate mofetil PO every 8 hours on days 0 to 100 followed by a taper until day 156 in the absence of GVHD."
3323413|NCT00118287|Experimental|Treatment (chemotherapy, chemoprotection)|Patients receive etanercept SC twice weekly during weeks 1 and 2 and azacitidine SC or IV over 10-40 minutes on days 1-7. Treatment repeats every 28 days for at least 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
3323414|NCT00118274|Experimental|Arm I|Patients receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
3323415|NCT00118274|Experimental|Arm II|Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
3323416|NCT00118274|Experimental|Arm III|Patients receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
3323417|NCT00118274|Experimental|Arm IV|Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
3323418|NCT00118261|Experimental|Erlotinib, modified FOLFOX6, and bevacizumab|
3323419|NCT00118248|Experimental|Treatment (chemotherapy)|Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3323420|NCT00118235|Experimental|Treatment (cisplatin, irinotecan hydrochloride, bevacizumab)|Patients receive cisplatin IV over 60 minutes and irinotecan IV over 90 minutes on days 1 and 8. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3323421|NCT00118222|Active Comparator|Low light dose during surgery|Arm I: During surgery, patients receive low light dose photodynamic therapy.
3323422|NCT00118222|Active Comparator|High light dose during surgery|Arm II: During surgery, patients receive high light dose photodynamic therapy.
3323423|NCT00118209|Active Comparator|Arm A - R-CHOP|"Patients receive the following treatment:~Rituximab 375 mg/m^2 IV infusion on Day 1 prior to CHOP chemotherapy~Cyclophosphamide 750 mg/m^2 IV on Day 1~Doxorubicin 50 mg/m^2 IV on Day 1~Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1~Prednisone 40 mg/m^2/day PO on Days 1-5~filgrastim or pegfilgrastim as defined in the protocol~Required ancillary medications is administered during all cycles as defined in the protocol.~Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6."
3323424|NCT00118209|Experimental|Arm B - DA-EPOCH-R|"Patients receive the following treatment:~Cycle 1 Doses:~Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy~Doxorubicin 10 mg/m^2/day CIVI on Days 1-4~Etoposide 50 mg/m^2/day CIVI on Days 1-4~Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours)~Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions)~Prednisone 60 mg/m^2 PO BID on Days 1-5~Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC > 5000 after the nadir (nadir usually between Days 10-12) or for 10 days (Days 6-15) if the ANC is not being monitored, during every cycle.~Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle.~Required ancillary medications are administered during all cycles as defined in the protocol.~Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6."
3323425|NCT00118183|Experimental|Arm I|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and cetuximab IV over 1-2 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 4 courses receive cetuximab alone as above in the absence of disease progression or unacceptable toxicity.
3323510|NCT00117312|Experimental|Degarelix 80 mg|Degarelix 80 mg (20 mg/mL)
3323511|NCT00117312|Experimental|Degarelix 120 mg|Degarelix 120 mg (30 mg/mL)
3323426|NCT00118183|Experimental|Arm II|Patients receive docetaxel as in arm I and bortezomib IV over 3-5 seconds on days 1, 8, and 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 4 courses receive bortezomib alone as above in the absence of disease progression or unacceptable toxicity.
3323427|NCT00118170|Experimental|Treatment (sorafenib tosylate)|"Patients receive oral sorafenib once on day 1 and then once daily, twice daily, or every other day beginning on day 8 and continuing for 3 months. Patients are re-evaluated at 3 months. Patients with responding disease may continue study treatment in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients (per treatment cohort) receive escalating doses of sorafenib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD."
3323428|NCT00118157|Experimental|Treatment (lapatinib, tamoxifen)|Patients receive lapatinib ditosylate PO daily and tamoxifen citrate PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3323429|NCT00118144|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1 and 8.
3323430|NCT00118131|Experimental|Docetaxel and Cisplatin|"A cycle is defined as an interval of 28 days.~Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2).~Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2).~Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15."
3323431|NCT00118105|Experimental|Chemotherapy + Surgery + Chemotherapy|"Preoperative Neoadjuvant Chemotherapy~Bevacizumab, 7.5 mg/kg, IV, Day 1 of cycles 1,2,3~Oxaliplatin, 130 mg/m^2, IV, Day 1 of cycles 1,2,3,4~Capecitabine, 1,700 mg/m^2/day divided, PO at 12 hr intervals, Days 1-14 of cycles 1,2,3,4~Conventional surgery: After 4 cycles of chemotherapy~Postoperative Neoadjuvant Chemotherapy~Bevacizumab, 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4~Oxaliplatin, 130 mg/m^2, IV, Day 1 of cycles 1,2,3,4~Capecitabine, 1,700 mg/m^2/day divided, PO at 12 hr intervals, Days 1-14 of cycles 1,2,3,4"
3323432|NCT00118092|Experimental|Treatment (tanespimycin)|Patients receive 17-N-allylamino 17-demethoxygeldanamycin (17-AAG) IV over 2-6 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses of treatment beyond documentation of CR.
3323433|NCT00118066|Experimental|Arm I|Patients receive oral calcitriol once daily for 8 weeks. Treatment repeats every 8 weeks for 2 courses. After completion of course 2 (week 16), patients undergo biopsy. Patients continue to receive calcitriol for up to 3 additional weeks while the biopsy is being evaluated. Patients with persistent high-grade prostatic intraepithelial neoplasia (HGPIN) by biopsy receive 2 additional courses of calcitriol.
3323434|NCT00118066|Other|Arm II|Patients undergo observation for 16 weeks. At week 16, patients undergo biopsy. Patients with persistent HGPIN by biopsy receive 2 courses of calcitriol as in arm I.
3323435|NCT00118053|Experimental|Docetaxel, Carboplatin and Trastuzumab|"A total of six cycles of TCH [(Taxotere® (75 mg/m2) + Carboplatin (AUC = 6) + Herceptin® (2 mg/kg weekly after a 4 mg/kg load on Day 1)] will be administered every 3 weeks.Three weeks after receiving the sixth cycle of TCH, all patients will be restaged.~Those determined to have localized and operable disease (as determined by surgical consultation) will undergo a modified radical mastectomy or lumpectomy and axillary node dissection. After recovery from surgery, the patients will receive whole breast or chest wall irradiation (as determined by radiologist) with concurrent Herceptin® (6 mg/kg). Following radiation, patients will continue Herceptin® (6 mg/kg) every 3 weeks until they have been on study for a total of 52 weeks.~If patients are staged and are negative they will continue Herceptin® (6 mg/kg)every 3 weeks until they have been on study for a total of 52 weeks."
3323436|NCT00118040|Experimental|Arm I (lower dose genistein)|Patients receive oral genistein twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
3323437|NCT00118040|Experimental|Arm II (higher dose genistein)|Patients receive oral genistein as in arm I but at a higher dose. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
3323438|NCT00118040|Placebo Comparator|Arm III (placebo)|Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
3323439|NCT00117988|Experimental|Arm I|Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1 hour on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease regression after completion of 8 courses may receive 2 additional courses of treatment beyond their maximal response. After completion of study treatment, patients are followed every 3 months until disease progression.
3323440|NCT00117962|Experimental|Std Tx + Pemetrexed|Patients receive pemetrexed disodium IV over 10 minutes followed by carboplatin IV over 30 minutes on days 1, 22, 43, and 64. Patients also undergo thoracic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47.
3323441|NCT00117962|Experimental|Std Tx + Pemetrexed and Cetuximab|Patients receive pemetrexed disodium, carboplatin, and thoracic radiotherapy as in arm I. Patients also receive cetuximab IV over 2 hours on day 1 and then IV over 1 hour on days 8, 15, 22, 29, 36, and 43.
3323442|NCT00117949|Experimental|Degarelix 40 mg|Degarelix 40 mg (10 mg/mL)
3323443|NCT00117949|Experimental|Degarelix 80 mg|Degarelix 80 mg (20 mg/mL)
3323444|NCT00117949|Experimental|Degarelix 120 mg|Degarelix 120 mg (30 mg/mL)
3323445|NCT00117949|Experimental|Degarelix 160 mg|Degarelix 160 mg (40 mg/mL)
3323446|NCT00117936|Experimental|1|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141)
3323447|NCT00117936|Experimental|2|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141)
3323448|NCT00117936|Experimental|3|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141)
3323449|NCT00117936|Placebo Comparator|4|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141)
3323450|NCT00117884|Experimental|1|
3323451|NCT00117884|Experimental|2|
3323452|NCT00117884|Experimental|3|
3323453|NCT00117884|Experimental|4|
3323454|NCT00117884|Experimental|5|
3323455|NCT00117884|Experimental|6|
3323456|NCT00117884|Experimental|7|
3323457|NCT00117884|Experimental|8|
3323461|NCT00117845|Experimental|Denileukin Diftitox in ATL|Denileukin Diftitox in adult T-cell leukemia (ATL) Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
3323462|NCT00117819|Experimental|[123I]ß CIT and SPECT imaging|To assess [123I]ß-CIT and SPECT imaging
3323463|NCT00117806|Experimental|Arm 1|SCI-VIP: Supported employment implemented for veterans with spinal cord injury
3323464|NCT00117806|Placebo Comparator|Arm 2|Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
3323465|NCT00117793|Active Comparator|Arm 1|Current clinical practice
3323466|NCT00117793|Experimental|Arm 2|Novel socket system
3323467|NCT00117767|Experimental|1|Terbinafine
3323468|NCT00117767|Active Comparator|2|Griseofulvin
3323469|NCT00117741|Experimental|Dialectical Behavior Therapy|Participants receive standard dialectical behavior therapy and suboxone
3323470|NCT00117741|Active Comparator|Drug Counseling|Participants receive standard individual and group counseling and suboxone.
3323471|NCT00117689|Experimental|1|Standard (tacrolimus based standard therapy without induction)
3323472|NCT00117689|Active Comparator|2 Standard of Care|Thymoglobulin with tacrolimus and corticosteroid sparing maintenance therapy
3323473|NCT00117676|Experimental|TDF-TDF|TDF plus ADV placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.
3323474|NCT00117676|Active Comparator|ADV-TDF|ADV plus TDF placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of FTC/TDF FDC tablet) to their treatment regimen in the open-label period.
3323475|NCT00117650|Active Comparator|Low Dose|2 x 10^9 vp (viral particles)
3323476|NCT00117650|Active Comparator|Middle Dose|2 x 10^10 vp
3323477|NCT00117650|Active Comparator|High Dose|2 x 10^11 vp
3323478|NCT00117650|Placebo Comparator|Placebo|(PBS + 10% sucrose + 0.02% polysorbate 80)
3323479|NCT00117637|Experimental|First Sorafenib (Nexavar, BAY43-9006) 400 mg then 600 mg|Subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (bid) (ie 12-hourly) orally until progression (= first intervention period, 5.7 months [median] ) and 3 tablets of Sorafenib twice daily (ie 12-hourly) orally until the following progression (= second intervention period, 3.6 months [median]) on a continuous basis.
3323480|NCT00117637|Active Comparator|First Interferon then Sorafenib (Nexavar, BAY43-9006) 400 mg|Interferon (IFN) α-2a was administered at a dose of 9 million international units(MIU) subcutaneously three times a week until progression (= first intervention period, 5.6 months [median]). Subjects initially started with a single dose of 3 MIU IFN and increased the dose as rapidly as possible to 9 MIU IFN three times a week within 1 or 2 weeks in first intervention period.After first progression, subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (BID) (ie 12-hourly) until the next progression (=second intervention period, 5.3 months [median]).
3323481|NCT00117611|Active Comparator|1|Xolair administered subcutaneously, once or twice monthly (dose dependent on subject weight and serum IgE level)
3323482|NCT00117611|Placebo Comparator|2|placebo administered subcutaneously once or twice monthly
3323483|NCT00117598|Experimental|A|
3323484|NCT00117598|Experimental|B|
3323485|NCT00117598|Active Comparator|C|
3323486|NCT00117585|Other|Treatment Phase 1|Stepped intervention consisting of treatment phase 1, 2 and 3. Subjects whose orthostatic hypotension is resolved after treatment phase 1 will not receive new treatments (phase 2 and 3)
3323487|NCT00117572|Active Comparator|Induction plus chemoradiotherapy|"Induction therapy: Two 21-day cycles of chemotherapy consisting of docetaxel (75 mg/m2, day 1), cisplatin (75 mg/m2, day 1), and 5-fluorouracil (750 mg/m2/day, days 1-5). Total duration of 6 weeks.~Chemoradiotherapy: Five 14-day cycles of docetaxel (25 mg/m2, day 1), 5-fluorouracil (600 mg/m2/day, day 0-4), and hydroxyurea (500 mg PO q 12 hours x 6 days (11 doses)) with twice daily radiation (150 cGy given bid, days 1-5). Total duration of 10 weeks."
3323488|NCT00117572|Active Comparator|Chemoradiotherapy|Chemoradiotherapy: Five 14-day cycles of docetaxel (25 mg/m2, day 1), 5-fluorouracil (600 mg/m2/day, day 0-4), and hydroxyurea (500 mg PO q 12 hours x 6 days (11 doses)) with twice daily radiation (150 cGy given bid, days 1-5). Total duration of 10 weeks.
3323489|NCT00117559|Experimental|TEL-CBT|Telehealth, problem solving based treatment provided over the telephone
3323490|NCT00117559|No Intervention|Treatment as Ususal|Control group, no treatment provided
3323491|NCT00117507|Experimental|20mg/kg/day deferasirox|Deferasirox will be administered orally once per day for 12 months. Surrogate marker findings, including serum ferritin, and LIC in the context of the study results will be monitored on a regular basis for any indications of clinically important over- or under-chelation.
3323492|NCT00117481|Experimental|1|
3323493|NCT00117481|Experimental|2|
3323494|NCT00117481|Placebo Comparator|3|
3323495|NCT00117468|Experimental|1|
3323496|NCT00117468|Active Comparator|2|
3323497|NCT00117442|Experimental|Pegfilgrastim 18 mg|Pegfilgrastim 18 mg given once for mobilization
3323498|NCT00117442|Active Comparator|Filgrastim|Filgrastim given daily for mobilization
3323499|NCT00117442|Experimental|Pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for mobilization
3323500|NCT00117442|Experimental|Pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for mobilization
3323501|NCT00117403|Experimental|1|vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals, plus two placebo wafers three times per day with meals
3323502|NCT00117403|Experimental|2|CoQ 400 mg, compounded as a wafer, two wafers three times per day with meals, plus one placebo capsule three times per day with meals
3323503|NCT00117403|Placebo Comparator|3|two placebo wafers three times per day with meals, plus one placebo capsule three times per day with meals
3323504|NCT00117377|Experimental|1|Pimecrolimus
3323505|NCT00117377|Placebo Comparator|2|Placebo control twice daily application
3323506|NCT00117338|Placebo Comparator|1|Placebo
3323507|NCT00117338|Active Comparator|2|montelukast sodium
3323508|NCT00117325|Experimental|GW685698X|GW685698X
3323509|NCT00117312|Experimental|Degarelix 40 mg|Degarelix 40 mg (10 mg/mL)
3323512|NCT00117312|Experimental|Degarelix 160 mg|Degarelix 160 mg (40 mg/mL)
3323513|NCT00117299|Experimental|A|PTK/ZK o.d. 1250 mg p.o.
3323514|NCT00117286|Experimental|Degarelix (60 mg to 160 mg)|Participants who completed the CS14 study in the Degarelix 60 mg (20 mg/mL) arm continued that dose into the CS14A extension study. A protocol amendment in March 2006 changed the dosage to 160 mg (40 mg/mL) for all study participants.
3323515|NCT00117286|Experimental|Degarelix (80 mg to 160 mg)|Participants who completed the CS14 study in the Degarelix 80 mg (20 mg/mL) arm continued that dose into the CS14A extension study. A protocol amendment in March 2006 changed the dosage to 160 mg (40 mg/mL) for all study participants.
3323516|NCT00117273|Experimental|1|
3323517|NCT00117273|Active Comparator|2|
3323518|NCT00117273|Active Comparator|3|
3323519|NCT00117208|Experimental|1|
3323520|NCT00117208|Active Comparator|2|DNase daily for 12 weeks
3323521|NCT00117208|Other|3|combination
3323522|NCT00117195||PD/PS|
3323523|NCT00117156|Experimental|Fludarabine and Rituximab|"Fludarabine:~25 mg/m2 on days 1-5 of 28 day cycle up to 6 cycles~Rituximab:~375 mg/m2 on day 1 of 28 day cycle up to 6 cycles Rituximab dose was split between days 1 and 3 for patients with absolute lymphocyte counts > 10x10^9/L~Patients received three cycles of therapy followed by re-staging with chest/ abdomen/ pelvic CT scan. Patients with progressive disease discontinued treatment. Patients with stable or responding disease continued therapy for another 3 cycles."
3323524|NCT00117052|Active Comparator|During dialysis visit|Cinacalcet is given during the dialysis visit
3323525|NCT00117052|Active Comparator|Post-dialysis meal|Cinacalcet is administered with a post-dialysis meal
3323526|NCT00117026|Experimental|Benfotiamine|Benfotiamine 300mg/day
3323527|NCT00117026|Placebo Comparator|Placebo|Placebo for benfotiamine
3323528|NCT00116987|Other|1|Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
3323529|NCT00116987|Other|2|Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
3323530|NCT00116974|Experimental|1|
3323531|NCT00116974|Placebo Comparator|2|
3323532|NCT00116935|Active Comparator|1|1 year of adjuvant imatinib mesylate 400 mg/day orally
3323533|NCT00116935|Experimental|2|3 years of adjuvant imatinib mesylate 400 mg/day orally
3323534|NCT00116922|Active Comparator|A|Avandamet [ Rosuglitazone 2 and Metformin 500]
3323535|NCT00116883|Experimental|Arm 1|
3323536|NCT00116857|Active Comparator|Sertraline/omega-3 supplement|
3323537|NCT00116857|Placebo Comparator|Sertraline/corn oil|
3323538|NCT00116844|Experimental|Sequence 1: VALTREX 1 g once daily, Placebo|VALTREX 1 g once daily, Placebo
3323539|NCT00116844|Experimental|Sequence 2: Placebo, VALTREX 1 g once daily|Placebo, VALTREX 1 g once daily
3323540|NCT00116831|Active Comparator|Glipizide|oral anti-diabetic medication
3323541|NCT00116831|Experimental|rosiglitazone maleate|oral anti-diabetic medication
3323542|NCT00116818|Experimental|Arm 1|
3323543|NCT00116805|Experimental|TDF-TDF|TDF plus ADV placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.
3323544|NCT00116805|Active Comparator|ADV-TDF|ADV plus TDF placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of FTC/TDF FDC tablet) to their treatment regimen in the open-label period.
3323545|NCT00116779|Experimental|Degarelix 60mg|Initial dose of 200 milligrams (40 milligrams per milliliter) of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams (20 milligrams per milliliter) of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.
3323546|NCT00116779|Experimental|Degarelix 80mg|Initial dose of 200 milligrams (40 milligrams per milliliter) of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams (20 milligrams per milliliter) of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.
3323547|NCT00116753|Active Comparator|Degarelix 240@40/240@40 (1,3,6,9)|240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (40 mg/mL) at months 1, 3, 6 and 9.
3323548|NCT00116753|Active Comparator|Degarelix 240@40/240@60(1,3,6,9)|240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 3, 6 and 9.
3323549|NCT00116753|Active Comparator|Degarelix 240@40/240@60(1,4,7,10)|240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 4, 7 and 10.
3323550|NCT00116727||Drug|etanercept 50 mg/wk SC
3323551|NCT00116714||Observation|
3323552|NCT00116688|Experimental|Romiplostim|Romiplostim weekly subcutaneous dosing based on screening weight and platelet count. Starting dose of 1 µg/kg up to a maximum dose of 10 µg/kg.
3323553|NCT00116649|Experimental|Aldara 5%|Aldara® (imiquimod) cream, 5% supplied in 250 mg single-use packets.
3323554|NCT00116584|Other|heliox|heliox-driven nebulizations for children with moderate to severe bronchiolitis
3323555|NCT00116558|Experimental|intervention group|NIPPV
3323556|NCT00116558|No Intervention|Nutrition|
3323557|NCT00116493|Other|1|Standard of care (Iron-folic acid + Deworming)
3323558|NCT00116493|Experimental|2|
3323559|NCT00116493|Experimental|3|
3323560|NCT00116493|Experimental|4|
3323561|NCT00116480|Experimental|Misoprostol|three tablets of active misoprostol (600 mcg) given sublingually
3323562|NCT00116480|Placebo Comparator|Placebo|three tablets resembling misoprostol given sublingually
3323563|NCT00116454|Experimental|lipiocis group|intra-arterial hepatic administration, one 2200 MBQ dose, duration of treatment 1 week
3323564|NCT00116454|No Intervention|control group|group untreated
3323565|NCT00116428|Experimental|NAVISTAR® THERMOCOOL® Catheter|
3323566|NCT00116428|Active Comparator|Antiarrhythmic drug|
3323567|NCT00116402|Active Comparator|1|will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID
3323568|NCT00116402|Active Comparator|2|salmeterol 50 mcg BID then crossover to combination therapy with fluticasone 220 mcg BID
3323569|NCT00116376|Experimental|AEE788 + non EIACD|
3323570|NCT00116376|Experimental|AEE788 + EIACD|
3323571|NCT00116350|Experimental|Misoprostol|800 mcg sublingual misoprostol
3323572|NCT00116350|Active Comparator|Oxytocin|40 IU Oxytocin IV
3323573|NCT00116337|Experimental|1|Procedure/Surgery: spinal cord stimulation
3323574|NCT00116272||Etanercept-Exposed|Pregnant women with a current diagnosis of rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis (AS), psoriatic arthritis (PsoA) or psoriasis (PsO) who used etanercept in the first trimester of pregnancy for any length of time.
3323575|NCT00116272||Diseased Controls|Pregnant women with a current diagnosis of RA, JRA, AS, PsA, or PsO who did not use etanercept or any tumor necrosis factor (TNF) antagonist during pregnancy.
3323576|NCT00116272||Non-Diseased Historical Comparison|Pregnant women not diagnosed with RA, JRA, AS, PsoA, or PsO who did not use etanercept or any TNF antagonist at any time in pregnancy and were not exposed to any known human teratogen during pregnancy. This cohort consists of historical controls enrolled in other pregnancy outcome studies selected to match pregnant women in the exposed cohort.
3323577|NCT00116220|Active Comparator|Treatment 1|External beam radiation therapy + 6 months total androgen ablation
3323578|NCT00116220|Active Comparator|Treatment 2|External beam radiation therapy
3323579|NCT00116207|Experimental|ORAL ANTIOXIDANT|Allopurinol (300mg daily), ALA (600mg twice daily) nicotinamide (750 mg twice daily) Given orally These drugs were given together as a combination and not as individual treatment.
3323580|NCT00116207|Placebo Comparator|Placebo|Placebo administered twice daily.
3323581|NCT00116181|Experimental|continuous therapy|Subjects will receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24.
3323582|NCT00116181|Active Comparator|intermittent therapy|Subjects who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24.
3323583|NCT00116168|Experimental|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
3323584|NCT00116168|Experimental|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, SC dose
3323585|NCT00116168|Experimental|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, SC dose
3323586|NCT00116168|Experimental|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, SC dose
3323587|NCT00116142|Other|1|Androgen Suppression Therapy and Radiation therapy
3323588|NCT00116142|Experimental|2|Docetaxel plus androgen suppression therapy and radiation therapy
3323589|NCT00116129|Placebo Comparator|Placebo|Placebo
3323590|NCT00115960|Experimental|1|Group 1 will receive 3 vaccinations of the HIV-1 gag DNA vaccine, or placebo. Vaccinations will be given at Months 0, 1, and 3.
3323591|NCT00115960|Experimental|2|Group 2 will receive 3 vaccinations of either the HIV-1 gag DNA vaccine with a low dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
3323592|NCT00115960|Experimental|3|Group 3 will receive 3 vaccinations of either the HIV-1 gag vaccine with a medium dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
3323593|NCT00115960|Experimental|4|Group 4 will receive 3 vaccinations of either the HIV-1 gag vaccine with a high dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
3323594|NCT00115960|Experimental|5|In Part B, Group 5 will receive 5 vaccinations of either the HIV-1 gag vaccine plus IL-15 DNA, or placebo. Vaccinations will occur at Months 0, 1, 3, 6, and 9.
3323595|NCT00115960|Experimental|7|In Part B, Group 7 will receive 3 vaccinations of the HIV-1 gag vaccine with a high dose of IL-15 adjuvant (maximum tolerated dose from Part A) followed by 2 vaccinations of the gag DNA vaccine with IL-12 DNA adjuvant. Some participants will receive placebo instead of this vaccine regimen. For Group 7, the HIV-1 gag vaccine with IL-15 adjuvant vaccinations will be given at Months 0, 1, and 3, and booster vaccinations will be given at Months 6 and 9.
3323596|NCT00115934|Active Comparator|MBTS|Blalock-Taussig pulmonary artery shunt
3323597|NCT00115934|Active Comparator|RVPAS|Right ventricular to pulmonary artery shunt
3323598|NCT00115895|Experimental|Radioactive iodine 1,1 GBq|Low activity of radioiodine, 1,1 GBq
3323599|NCT00115895|Other|Radioactive iodine 3,7 GBq|Routine activity of radioiodine, 3,7 GBq
3323600|NCT00115882|Experimental|1|proactive smoking-cessation telephone counseling
3323601|NCT00115882|No Intervention|2|no-intervention control
3323602|NCT00115869|No Intervention|No-intervention control|
3323603|NCT00115869|Experimental|Social influences school-based smoking prevention curriculum|
3323604|NCT00115856|No Intervention|Subjects studied|Single arm exploratory feasibility safety and efficacy study of MRI to image atherosclerosis in arteries
3323605|NCT00115804|Experimental|Fluoxetine|All eligible patients were started on Fluoxetine at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily.
3323606|NCT00115791|Experimental|1|
3323607|NCT00115791|Placebo Comparator|2|
3323608|NCT00115765|Active Comparator|Oxaliplatin and bevacizumab without panitumumab|Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone.
3323609|NCT00115765|Experimental|Irinotecan and bevacizumab plus panitumumab|Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W
3323610|NCT00115765|Active Comparator|Irinotecan and bevacizumab without panitumumab|Irinotecan-based chemotherapy and Bevacizumab Q2W alone
3323611|NCT00115765|Experimental|Oxaliplatin and bevacizumab plus panitumumab|Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W
3323612|NCT00115739|Experimental|Imatinib|Patients will be treated with Imatinib (Gleevec) 400 mg two times a day for eight weeks after which radiologic imaging will be obtained to assess response. Patients who attained a complete response will be treated with four additional weeks of Imatinib. Patients who attain a partial response or stable disease will be treated until a complete response is attained, or until disease progression. All patients with progression of disease will be taken off the study. Patients continuing on the study, will undergo radiologic imaging every eight weeks following their initial response assessment. All patients will be followed until death.
3323613|NCT00115726|Experimental|1|furosemide
3323614|NCT00115726|Placebo Comparator|2|placebo
3323615|NCT00115700|Experimental|Radiotherapy+ Chemotherapy|Involved field Radiotherapy (RT) 30-36 GY plus Cyclophosphamide, Vincristine and Prednisolone (CVP) + rituximab × 6 cycles
3323616|NCT00115700|Active Comparator|Radiotherapy alone|Involved field Radiotherapy (30-36 GY) alone
3323617|NCT00115687|Placebo Comparator|A|placebo
3323618|NCT00115687|Experimental|B|2 mg nicotine gum
3323619|NCT00115648|Active Comparator|A|Single dose NVP + ZDV daily for the first week.
3323620|NCT00115648|Experimental|C|Arm A plus NVP + ZDV daily to age 14 weeks.
3323621|NCT00115648|Experimental|B|Arm A plus oral NVP daily to age 14 weeks.
3323622|NCT00115596|Experimental|Intervention Arm|"'Formal Curriculum; Low-Fidelity Simulation'~Residents randomized to the intervention arm will receive the study skills training curriculum (the intervention)."
3323623|NCT00115596|No Intervention|Control|Residents randomized to the control arm will receive standard pediatric training.
3323624|NCT00115570|Experimental|Insulin Glulisine|Insulin Glulisine (100UI/ml), at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine for a maximum of 26 weeks
3323625|NCT00115570|Active Comparator|Insulin Lispro|Insulin Lispro (100UI/ml) Subcutaneous (SC) injection , at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine ) for a maximum of 30 weeks
3323626|NCT00115557|Experimental|1|Performance feedback, academic detailing, practice facilitation, IT support
3323627|NCT00115557|Active Comparator|2|Performance feedback only
3323628|NCT00115544|Experimental|1|stannsoporfin 0.75mg/kg
3323629|NCT00115544|Experimental|2|stannsoporfin 1.5mg/kg
3323630|NCT00115544|Placebo Comparator|3|saline injection
3323631|NCT00115531|Experimental|Arm 1|Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
3323632|NCT00115531|Experimental|Arm 2|High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
3323633|NCT00115505||Ancillary-Correlative (QOL, employment, informal care cost)|Patients complete the QOL Assessments comprising the Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form; Employment and Informal Care Cost Assessments; and Peripheral Neuropathy of the FACT-NTX subscale at baseline, 29-42 and 57-70 days, and at 9 and 18 months. Patients meeting the cut-off score for peripheral neuropathy on the FACT-NTX subscale at 18 months complete the Symptoms in Relation to Patient Functioning Survey, FACT-NTX subscale, the EORTC QLQ-C30, EORTC QLQ-BR23, and the Medications Used for Treating Peripheral Neuropathy at 24, 36, 48, and 60 months.
3323634|NCT00115453|Experimental|A|Active treatment arm.
3323635|NCT00115440|Experimental|A|Active treatment arm.
3323636|NCT00115388|Other|Deferred screening control group|Samples from women in the control group were stored and tested at the end of the trial
3323637|NCT00115349|Experimental|L1/DFO|Deferoxamine (DFO) and deferiprone (L1) combination therapy
3323638|NCT00115349|Active Comparator|DFO|Deferoxamine (DFO) monotherapy
3323639|NCT00115336|Active Comparator|1|Intravenous ketorolac and oral placebo
3323640|NCT00115336|Active Comparator|2|Intravenous placebo and oral ibuprofen
3323641|NCT00115323|Active Comparator|1|Problem solving intervention
3323642|NCT00115323|Active Comparator|2|Attention control intervention
3323643|NCT00115297|Experimental|Montelukast|Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.
3323644|NCT00115297|Placebo Comparator|Placebo|Participants who are 2 to 3 years old received 5-mg montelukast placebo tablets and participants who are 12 months to 2 years old received 4-mg montelukast placebo granules.
3323645|NCT00115258|Experimental|parenteral nutrition titrated to measured REE|parenteral nutrition titrated to measured REE
3323646|NCT00115258|No Intervention|standard of care|
3323647|NCT00115232||1|Children without family history of early atherosclerosis
3323648|NCT00115232||2|Children with family history of early atherosclerosis.
3323649|NCT00115232||3|Parents of children without family history of early atherosclerosis
3323650|NCT00115232||4|Parents of children with family history of early atherosclerosis
3323651|NCT00115193|Active Comparator|Arm A|Pegfilgrastim
3323652|NCT00115193|Active Comparator|Arm B|Pegfilgrastim
3323653|NCT00115180||Hispanic|Hispanic patients with long bone fractures no intervention
3323654|NCT00115180||White|White patients with long bone fractures no intervention
3323655|NCT00115180||African-American|African-American patients with long bone fracture no intervention
3323656|NCT00115167|Experimental|Darbepoetin alfa|
3323657|NCT00115167|Placebo Comparator|Placebo|
3323658|NCT00115128||Filgrastim|Normal donors being treated with filgrastim for PBPC mobilization and collection
3323659|NCT00115076|Experimental|psoriasis|moderate to severe plaque psoriasis
3323660|NCT00115063|Experimental|1|"Intensive Medical Intervention including Low Calorie Liquid Diet, Weight loss medications, Group Behavioral Therapy and a Tool Box approach"
3323661|NCT00115063|Active Comparator|2|Access to Weight Loss Informational Website sponsored by the Mayo Clinic
3323662|NCT00115037|Experimental|P1|In phase 1, all participants on open-label naltrexone with MM.
3323663|NCT00115037|Experimental|P2RA|Phase 2: Naltrexone and TAU for phase 1 responders.
3323664|NCT00115037|Experimental|P2RB|Phase 2: Naltrexone and telephone counseling for phase 1 responders.
3323665|NCT00115037|Experimental|P2NA|Phase 2: naltrexone, MM and CBI for phase 1 non-responders.
3323666|NCT00115037|Placebo Comparator|P2NB|Phase 2: placebo, MM and CBI for phase 1 non-responders.
3323667|NCT00114972|Experimental|PCI with DES|
3323668|NCT00114972|Active Comparator|CABG (coronary artery bypass graft)|Coronary Artery Bypass Graft
3323739|NCT00113828|Experimental|Transplantation|T-cell depleted HLA-matched peripheral blood stem cell transplantation
3323740|NCT00113815|Experimental|003|topiramate 25 mg/kg/day
3323741|NCT00113815|Experimental|002|topiramate 15 mg/kg/day
3323742|NCT00113815|Experimental|001|topiramate 5 mg/kg/day
3323669|NCT00114959|Experimental|Homoharringtonine + Imatinib Mesylate|Participants are administered homoharringtonine (omacetaxine) 2.5 mg/m^2 by continuous 24-hour intravenous infusion daily on Days 1-5 of each 4 week treatment cycle, and imatinib mesylate (Gleevec) by mouth with a daily dose of 400 mg for participants in the chronic phase of chronic myeloid leukemia (CML) or 600 mg for participants in the accelerated or blast phase of CML.
3323670|NCT00114894|Experimental|Safe Sea|
3323671|NCT00114894|Sham Comparator|Placebo|Coppertone® SPF15 (Schering-Plough)
3323672|NCT00114881||Inner-city children with asthma|Children at high risk for developing allergic diseases and asthma, on the basis of a parental history of asthma, allergic rhinitis or atopic dermatitis, and residence in the inner city
3323673|NCT00114868|Active Comparator|Vitamin A|48,000 IU vitamin A oral dose spread over 2 days as soon as possible after birth.
3323674|NCT00114868|Placebo Comparator|Placebo|placebo
3323675|NCT00114790|Experimental|BNCT.|Boronophenylalanine-based BNCT.
3323676|NCT00114777|Active Comparator|Cyclosporin A|
3323677|NCT00114777|Experimental|Belatacept Less Intensive Regimen (LI)|
3323678|NCT00114777|Experimental|Belatacept More Intensive Regimen (MI)|
3323679|NCT00114764|Experimental|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
3323680|NCT00114764|Active Comparator|filgrastim|Filgrastim given daily after induction chemotherapy
3323681|NCT00114738|Experimental|EPOCH-R + Bortezomib|Combo chemo etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH)-Rituxan (R) + Bortezomib (B)
3323682|NCT00114738|Experimental|"Bortezomib window"|Bortezomib alone
3323683|NCT00114738|Active Comparator|Bortezomib maintenance|Bortezomib maintenance
3323684|NCT00114738|Other|Observation|At the beginning of part C patients are randomized to receive bortezomib maintenance or observation without bortezomib.
3323685|NCT00114634|Experimental|Egg yolk preparation with cholesterol|Dietary cholesterol in the form of liquid egg yolk
3323686|NCT00114634|Placebo Comparator|Egg yolk preparation without cholesterol|"No dietary cholesterol supplementation (egg substitute) Papetti Foods Better 'n Eggs egg substitute"
3323687|NCT00114608|Experimental|1|Electrical foot stimulation
3323688|NCT00114543|Active Comparator|Aggressive ELBW|In Aggressive group 1, infants with birth weights 501-750g.
3323689|NCT00114543|Active Comparator|Aggressive VLBW|In the Aggressive group 2, infants with birth weights 751-1000g.
3323690|NCT00114543|Active Comparator|Conservative ELBW|In the Conservative group 1, infants with birth weights 501-750g.
3323691|NCT00114543|Active Comparator|Conservative VLBW|In the Conservative group 2, infants with birth weights 751-1000g.
3323692|NCT00114530|Experimental|mHSCT|Myeloablative Hematopoietic Stem Cell Transplant (mHSCT) Participants will first have hematopoietic stem cells removed from their blood. They then will receive high doses of chemotherapy and radiation to eliminate their developed and presumably abnormal immune system, followed by autologous stem cell transplantation to reintroduce the purified stem cells to re-establish their immune system.
3323693|NCT00114530|Experimental|cyclophosphamide|"Cyclophosphamide (CY) Participants will receive high doses of intravenous cyclophosphamide. The dose being used in this study is about 50% higher than that commonly used by most physicians to treat many other autoimmune diseases.~Administration of 12 monthly pulses of high-dose intravenous cyclophosphamide (an initial dose of 500 mg/m^2, followed by 11 doses of 750 mg/m^2)."
3323694|NCT00114517|Active Comparator|17B-estradiol|Oral 17B-estradiol 1 mg daily
3323695|NCT00114517|Placebo Comparator|Placebo|Matched placebo oral 17B-estradiol daily
3323696|NCT00114504|Experimental|Simvastatin group|Patients with FDG-positive plaque who received simvastatin and diet therapy
3323697|NCT00114504|No Intervention|Control group|Patients FDG-positive plaque who received diet therapy alone
3323698|NCT00114465|Experimental|VSL#3|Probiotic
3323699|NCT00114465|Placebo Comparator|Placebo|Placebo
3323700|NCT00114452|Active Comparator|Provacel|ex vivo cultured adult mesenchymal stem cells
3323701|NCT00114413|Active Comparator|Reference Strategy|Participants in the reference strategy group will undergo the eNO procedure but will follow NAEPP guidelines alone for asthma treatment without eNO measurements for the rest of the study.
3323702|NCT00114413|Experimental|Biomarker Strategy|Participants in the biomarker strategy group will follow NAEPP treatment guidelines, as well as eNO measurements, to determine asthma treatment at each study visit.
3323703|NCT00114361|Active Comparator|1|Ribavirin + Peg IFN
3323704|NCT00114361|Active Comparator|2|Peg IFN + Placebo
3323705|NCT00114348|Active Comparator|R-Blöcke|Blocktherapie
3323706|NCT00114348|Experimental|Prot-II-Ida|a
3323707|NCT00114309|Experimental|1|3 Dose Regimen
3323708|NCT00114309|Experimental|2|6 Dose Regimen
3323709|NCT00114283|Experimental|Treatment (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3323710|NCT00114257|Experimental|Arm I|"Patients receive decitabine IV over 1 hour on days 1-5 and 8-12 and FR901228 (depsipeptide) IV over 4 hours on days 5 and 12 OR days 5, 12, and 19. Treatment repeats every 4-6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing complete remission for 1 year are removed from the study.~Cohorts of 6 patients receive escalating doses of decitabine and FR901228 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
3323711|NCT00114244|Experimental|Arm I (sorafenib tosylate)|Patients receive 400 mg oral sorafenib twice daily on days 1-28. Patients experiencing disease progression cross over to Arm II.
3323712|NCT00114244|Experimental|Arm II (sorafenib tosylate, gemcitabine hydrochloride)|Patients receive 400 mg oral sorafenib as in Arm I and 1000 mg/m2 gemcitabine IV over 100 minutes on days 1, 8, and 15.
3323743|NCT00113815|Experimental|004|placebo placebo
3323744|NCT00113789|Active Comparator|Pegfilgrastim|
3323745|NCT00113789|Placebo Comparator|Placebo|
3323786|NCT00113269|Active Comparator|Conventional Low-Risk Patients|Basiliximab, tacrolimus, mycophenolate mofetil and steroids; Low risk patients: Panel reactive antibody < 20% and first transplant and non-African American
3323787|NCT00113230|Experimental|Avastin|Capecitabine, Avastin (RHUMAB VEGF/Bevacizumab) And Radiotherapy
3323713|NCT00114231|Experimental|Treatment (capecitabine, oxaliplatin, radiotherapy, surgery)|"Patients undergo high-dose external beam radiotherapy once daily and receive capecitabine PO BID on days 1-5, 8-12, 15-19, 22-26, and 29-33. Patients also receive oxaliplatin IV over 2 hours on days 1, 8, 22, and 29.~Approximately 4-8 weeks after completion of chemoradiotherapy, patients undergo local excision of the tumor. Patients with T3 disease or positive resection margins after local excision undergo radical resection of the rectum and receive additional chemotherapy and/or radiotherapy at the discretion of the physician."
3323714|NCT00114218|Experimental|Treatment (gemcitabine hydrochloride, docetaxel)|Patients receive gemcitabine IV over 30 minutes followed by docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
3323715|NCT00114179|Experimental|Treatment (capecitabine, radiation, bevacizumab, gemcitabine)|"Chemoradiotherapy and bevacizumab: Patients receive oral capecitabine twice daily and undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-38. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29. Patients undergo reevaluation 3-4 weeks after completion of chemoradiotherapy and bevacizumab.~Patients with no evidence of disease progression proceed to maintenance therapy. Patients with a marked response may undergo surgery at the discretion of the attending surgeon and then proceed to maintenance therapy approximately 4-8 weeks later.~Maintenance therapy: Beginning within 4-7 weeks after completion of chemoradiotherapy and bevacizumab, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30 minutes on days 1 and 15 provided that blood counts have returned to normal. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3323716|NCT00114166|Active Comparator|Topotecan 1.25 mg/m2 IV days 1-5 of a 21 day cycle|Topotecan 1.25 mg/m2 IV days 1-5 of a 21 day cycle until disease progression or adverse effects prohibit further therapy
3323717|NCT00114166|Active Comparator|Topotecan 4.0 mg/m2 IV day 1, 8 and 15 of a 28 day cycle|Topotecan 4.0 mg/m2 IV day 1, 8 and 15 of a 28 day cycle until disease progression or adverse effects prohibit further therapy
3323718|NCT00114140|Experimental|Temozolomide + Radiation Therapy (RT)|Daily temozolomide plus concurrent radiotherapy followed by temozolomide
3323719|NCT00114127|Placebo Comparator|Duloxetine 60mg + Placebo for 18 Weeks|In Phase 2 participants were randomized to 60mg Duloxetine + Placebo or 120mg Duloxetine.
3323720|NCT00114127|Active Comparator|Duloxetine 120mg for 18 Weeks|In Phase 2 participants were randomized to 60mg Duloxetine + Placebo or 120mg Duloxetine.
3323721|NCT00114127|Active Comparator|Duloxetine 60mg/day for 6 Weeks|In Phase 1 all participants entered an open trial.
3323722|NCT00114114|Experimental|1: Men age 20-50|"Goserelin acetate (Zoladex) plus testosterone (or placebo) in men age 20-50. This arm is complete and no longer recruiting.~Men were assigned to 1 of 6 groups: G1= Zoladex plus placebo T; G2= Zoladex plus 1.25 gm T gel/day; G3: Zoladex plus 2.5 gm T gel/day; G4: Zoladex plus 5 gm T gel/day; G5: Zoladex plus 10 gm T gel/day; G6: Placebo Zoladex plus placebo T gel."
3323723|NCT00114114|Experimental|2: Men age 20-50|"Goserelin acetate (Zoladex) plus testosterone (or placebo) plus anastrazole in men age 20-50.~This arm is complete and no longer recruiting. Men were assigned to 1 of 6 groups: G1= Zoladex plus placebo T; G2= Zoladex plus 1.25 gm T gel/day; G3: Zoladex plus 2.5 gm T gel/day; G4: Zoladex plus 5 gm T gel/day; G5: Zoladex plus 10 gm T gel/day; G6: Placebo Zoladex plus placebo T gel. In addition, all men received anastrozole 1 mg/day."
3323724|NCT00114114|Experimental|3: Men age 60-75|Goserelin acetate (Zoladex) plus testosterone (or placebo) in men age 60 to 75. This arm is complete and no longer recruiting. Men are assigned to 1 of 6 groups: G1= Zoladex plus placebo T; G2= Zoladex plus 1.25 gm T gel/day; G3: Zoladex plus 2.5 gm T gel/day; G4: Zoladex plus 5 gm T gel/day; G5: Zoladex plus 10 gm T gel/day; G6: Placebo Zoladex plus placebo T gel.
3323725|NCT00114101|Experimental|Arm I (melphalan, autologous PBSCT, lenalidomide)|Beginning between day 100-110, patients receive lenalidomide PO once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
3323726|NCT00114101|Placebo Comparator|Arm II (melphalan, autologous PBSCT, placebo)|Beginning between day 100-110, patients receive placebo PO once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
3323727|NCT00114075|Experimental|Gait analysis|Gait analysis report is available for treatment planning
3323728|NCT00114075|Active Comparator|Control|Subject has gait analysis test, but report is not available for treatment planning
3323729|NCT00113919|Experimental|Busulfan|study-specific treatment: Busulfex according to study design: Level I 3.2 mg/kg over 6 hours x 2 days Level II 3.2 mg/kg over 6 hours x 3 days Level III 3.2 mg/kg over 6 hours x 4 days Level IV 4.3 mg/kg over 6 hours x 3 days Level V 5.6 mg/kg over 6 hours x 2 days Level VI 6.4 mg/kg over 6 hours x 2 days
3323730|NCT00113893|Experimental|Scio-469 30 Milligram (mg)|SCIO-469 tablet will be administered orally at a dose of 30 mg thrice daily (90 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
3323731|NCT00113893|Experimental|Scio-469 60 mg|SCIO-469 tablet will be administered orally at a dose of 60 mg thrice daily (180 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
3323732|NCT00113893|Experimental|Scio-469 90 mg|SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
3323733|NCT00113893|Experimental|Scio-469 120 mg|SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
3323734|NCT00113880||1|5-8 years of age, estimated to be approximately 4,000 new FluMist vaccinees per season
3323735|NCT00113880||2|9-17 years of age, estimated to be approximately 5,000 new FluMist vaccinees per season
3323736|NCT00113880||3|18-49 years of age, estimated to be approximately 6,000 new FluMist vaccinees per season.
3323737|NCT00113841|Experimental|Curcumin|Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.).
3323738|NCT00113841|Experimental|Curcumin + Bioperine|Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.) and Bioperine 5 mg orally twice daily.
3323746|NCT00113763|Experimental|Panitumumab plus best supportive care|Panitumumab will be administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants develop progressive disease or are unable to tolerate study drug. Participants will also receive best supportive care (BSC) as judged appropriate by the investigator and according to institutional guidelines.
3323747|NCT00113763|Other|Best Supportive Care|Best supportive care will be defined in this study as the best care available as judged appropriate by the investigator and according to institutional guidelines and will include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any symptomatic therapy as clinically indicated. For the purpose of this study, best supportive care will not include anti-neoplastic chemotherapy.
3323748|NCT00113698|Placebo Comparator|1|
3323749|NCT00113698|Active Comparator|2|Ace inhibition (enalapril)
3323750|NCT00113672|Experimental|A|Increase healthy eating and increase healthy activity
3323751|NCT00113672|Experimental|B|Increase healthy eating and decrease unhealthy activity
3323752|NCT00113672|Experimental|C|Decrease unhealthy eating and increase healthy activity
3323753|NCT00113672|Experimental|D|Decrease unhealthy activity and decrease unhealthy eating
3323754|NCT00113659|Active Comparator|1|Participants in this arm will receive Lactobacillus GG.
3323755|NCT00113659|Placebo Comparator|2|Participants in this arm will receive a placebo.
3323756|NCT00113633|No Intervention|Control Subjects|These subjects will receive standard discharge instructions that recommend follow-up with a PCP within 3-5 days.
3323757|NCT00113633|Experimental|Intervention Subjects|As part of the intervention, the family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups. For children reporting persistent asthma symptoms, a letter will be given to the family to bring to their PCP stating that screening revealed symptoms that may require further treatment with controller medications. A mailed reminder to schedule a follow-up appointment will be sent to the family.
3323758|NCT00113607|Experimental|DOXIL + trabectedin|Combination arm - Trabectedin + DOXIL: DOXIL 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks. patients will be premedicated with 20 mg dexamethasone or its equivalent IV infusion over 30 minutes prior to the DOXIL infusion.
3323759|NCT00113607|Active Comparator|DOXIL|Monotherapy arm - DOXIL: 50 mg/m2 IV infusion over 90 minutes every 4 weeks.
3323760|NCT00113568|Experimental|XP12B (tranexamic acid tablets)|
3323761|NCT00113555|Experimental|Experimental|Open Label Study, ACT (Adjustable Continence Therapy)
3323762|NCT00113529|Experimental|Sunitinib + Gefitinib|"Phase 1 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib; 50 mg Sunitinib + 250 mg Gefitinib~Phase 2 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib"
3323763|NCT00113516|Experimental|1|
3323764|NCT00113503|Active Comparator|Azathioprine weight-based dose|
3323765|NCT00113503|Experimental|Azathioprine individualised dose|
3323766|NCT00113490|Experimental|motavizumab (MEDI-524) 15 mg/kg|A single IM injection every 30 days beginning at Day 0 for a total of 4-5 injections determined by when in the RSV season a child was enrolled.
3323767|NCT00113490|Active Comparator|palivizumab 15 mg/kg|A single IM injection every 30 days beginning at Day 0 for a total of 4-5 injections determined by when in the RSV season a child was enrolled.
3323768|NCT00113438|Experimental|45 mg/m2 Combretastatin A-4 Phosphate|
3323769|NCT00113438|Experimental|60 mg/m2 Combretastatin A-4 Phosphate|
3323770|NCT00113425|Experimental|Laser Therapy|V-Beam laser, Candela Corp., 595 nm wavelength
3323771|NCT00113425|No Intervention|Control|Untreated
3323772|NCT00113399|Other|Radiotherapy and chemotherapy|Radiotherapy/paclitaxel/cisplatin/filgrastim
3323773|NCT00113399|Other|Chemotherapy|Cisplatin/fluorouracil/paclitaxel/docetaxel
3323774|NCT00113386|Other|Induction chemotherapy, surgery, consolidation chemotherapy|Induction/surgery/consolidation
3323775|NCT00113386|Other|Chemotherapy and radiation, surgery, consolidation ch|Induction/radiation/surgery/cosolidation
3323776|NCT00113373|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3323777|NCT00113360|Experimental|RAD001 plus Depot Octreotide|RAD001 at 5 or 10 milligrams orally once a day plus Octreotide Depot 30 milligrams intramuscularly once every 28 days.
3323778|NCT00113347|Experimental|Erlotinib + Docetaxel|Erlotinib 100, 125, or 150 mg orally daily except days receive Docetaxel 15 mg/m^2 or 20 mg/m^2 intravenously with Concomitant Boost Radiation to Head/Neck
3323779|NCT00113334|Experimental|ABT-510 (Thrombospondin)|Fixed dose level of thrombospondin 100 mg subcutaneously twice daily.
3323780|NCT00113321|Experimental|Decitabine|20 mg/m2 by vein (IV) over 1 hour daily x 5 days.
3323781|NCT00113295|Active Comparator|Paroxetine CR and Placebo|Eleven individuals were randomized to plaecbo augmentation of continued paroxetine CR at the week 10 dose level. In the first phase of the study, individuals started at 12.5 mg/day of paroxetine and flexibly titrated up to a maximum of 62.5 mg/day by week 10. Individuals who did not achieve remission and were randomized into the placebo group received placebo augmentation of continued paroxetine CR at the week 10 dose level.
3323782|NCT00113295|Experimental|Quetiapine and continued paroxetine CR|Eleven individuals were randomized to quetiapine augmentation of continued paroxetine CR at the week 10 dose level. In the first phase of the study, individuals started at 12.5 mg/day of paroxetine and flexibly tirated up to a maximum of 62.5 mg/day by week 10. Individuals who did not receive remission and were randomized to receive quetiapine started at 25 mg at bedtime for the first week, then flexibly dosed based on response and tolerability to a maximum of 200 mg BID by week 16.
3323783|NCT00113269|Experimental|Alemtuzumab High-Risk Patients|Alemtuzumab, tacrolimus, mycophenolate mofetil and steroids; High risk patients: Panel reactive antibody ≥ 20% or re-transplant or African American
3323784|NCT00113269|Active Comparator|Conventional High-Risk Patients|Rabbit anti-thymocyte globulin, tacrolimus, mycophenolate mofetil and steroids; High risk patients: Panel reactive antibody ≥ 20% or re-transplant or African American
3323785|NCT00113269|Experimental|Alemtuzumab Low- Risk Patients|Alemtuzumab, tacrolimus, mycophenolate mofetil and steroids; Low risk patients: Panel reactive antibody < 20% and first transplant and non-African American
3323788|NCT00113217|Experimental|Bevacizumab|10 mg/kg intravenous (IV) Day 1 of 14-day cycle.
3323789|NCT00113139|Experimental|Telephone-based coping skills|Telephone-based coping skills intervention
3323790|NCT00113139|Active Comparator|Usual Care|
3323791|NCT00113087|Active Comparator|Enalapril|Enalapril (angiotensin converting enzyme inhibitor)
3323792|NCT00113087|Placebo Comparator|Placebo|Placebo (Ora-Plus and Ora-Sweet)
3323793|NCT00113074|Active Comparator|1|Weight management and BP control program
3323794|NCT00113074|Active Comparator|2|Self-help materials targeting lifestyle modification
3323795|NCT00113035||Patients with late onset Pompe Disease|
3323796|NCT00113022|Experimental|Org 24448|Blinded, active experimental compound
3323797|NCT00113022|Placebo Comparator|Placebo|Blinded placebo
3323798|NCT00112996|Experimental|Arm I: Alpha-Lipoic Acid|Oral alpha-lipoic acid three times daily for at least 24 weeks in the absence of unacceptable toxicity.
3323799|NCT00112996|Placebo Comparator|Arm II: Placebo|Oral placebo three times daily for at least 24 weeks in the absence of unacceptable toxicity.
3323800|NCT00112957|Experimental|rV- and rF-NY-ESO-1|Patients received a single intradermal injection of rV-NY-ESO-1 (3.1 × 10^7 PFU) on Day 1, followed by subcutaneous injections of rF-NY-ESO-1 (7.41 × 10^7 PFU) on Days 29, 57, 85, 113, 141, and 169 or until observation of treatment-related ≥ grade 3 toxicity or disease progression.
3323801|NCT00112931|Active Comparator|Watch and Wait|Watch and Wait - no treatment
3323802|NCT00112931|Experimental|Arm C Rituximab 4 and Rixuximab Maintenance|4 infusions - 375mg/m2 every 2 months. A single dose of rituximab (375mg/m2 will then be given at 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92 and 100 weeks
3323803|NCT00112918|Active Comparator|FOLFOX4|"Weeks 1-24: Oxaliplatin was administered as an 85 mg/m^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).~Weeks 25-48: Observation only."
3323804|NCT00112918|Experimental|FOLFOX4 + Bv|"Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).~Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks)."
3323805|NCT00112918|Experimental|XELOX+Bv|"Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m^2 twice daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).~Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks)."
3323806|NCT00112905|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-56. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
3323807|NCT00112866|Experimental|Group I (high-dose cilengitide) 2000mg|"Preoperative Treatment: Patients receive high-dose cilengitide IV over 1 hour on days -8, -4, and -1. (High dose 2000mg)~Resection: All patients undergo tumor resection on day 0.~Postoperative Treatment: Beginning within 2 weeks after surgery, all patients receive high-dose cilengitide IV over 1 hour twice weekly for 4 weeks. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity."
3323808|NCT00112866|Experimental|Group II (low-dose cilengitide) 500mg|"Preoperative Treatment: Patients receive low-dose cilengitide IV over 1 hour on days -8, -4, and -1. (500mg)~Resection: All patients undergo tumor resection on day 0.~Postoperative Treatment: Beginning within 2 weeks after surgery, all patients receive high-dose cilengitide IV over 1 hour twice weekly for 4 weeks. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity"
3323809|NCT00112853|Experimental|Treatment (tipifarnib, etoposide)|"Patients receive oral tipifarnib twice daily on days 1-14 OR 1-21 and oral etoposide once daily on days 1-3 and 8-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a CR may receive up to 5 additional courses of therapy beyond documentation of CR.~Cohorts of 3-6 patients receive escalating doses of tipifarnib and etoposide until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 14 additional patients receive treatment at the MTD."
3323810|NCT00112840|Experimental|CCI-779 and bevacizumab|Patients receive CCI-779 IV on days 1, 8, 15, and 22 and bevacizumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of CCI-779 and bevacizumab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Phase II patients receive CCI-779 and bevacizumab as in phase I at the MTD determined in phase I. After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years after study entry.
3323811|NCT00112827|Experimental|Arm I|See Detailed Description
3323812|NCT00112749|Experimental|Study Arm|Please see intervention description
3323813|NCT00112736|Experimental|Phase 1 (erlotinib & temsirolimus)|"PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (dose escalation). Every 28 days until disease progression or unacceptable toxicity.~pharmacological study: Correlative studies"
3323888|NCT00111917|Experimental|Infliximab|infusion: 3:1 infliximab:placebo ratio administered at 0, 2, 6, 12, 18 and 24 weeks.
3323890|NCT00111865|Experimental|Exercise|Aerobic Exercise Training
3323814|NCT00112736|Experimental|Phase 2 temsirolimus MTD & erlotinib|"Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 at MTD phse I. Every 28 days until disease progression or unacceptable toxicity.~PHASE II (preoperative component): Patients who are surgical candidates may opt to undergo surgical resection of the tumor. Beginning 5-7 days before surgery, these patients receive oral erlotinib once daily until surgery. Patients also receive temsirolimus IV over 30 minutes at the MTD and then undergo surgical resection of the tumor 3-24 hours later. Beginning 2-4 weeks after surgery, patients receive temsirolimus at the MTD and erlotinib as in phase I.~therapeutic conventional surgery: Undergo surgical resection~laboratory biomarker analysis: Correlative studies"
3323815|NCT00112723|Experimental|Treatment (alvocidib)|"PHASE I: Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I."
3323816|NCT00112684|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive alvocidib IV over 4½ hours once weekly in weeks 1-4. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3323817|NCT00112671|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3323818|NCT00112593|Experimental|Treatment (allogeneic hematopoietic stem cell transplantation)|"CONDITIONING REGIMEN: Patients receive fludarabine IV over 2 hours on days -4, -3, and -2. Patients undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic bone marrow or peripheral blood stem cell transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV or PO 2 to 3 times daily on days -3 to 99 with taper beginning on day 100 and continuing until day 177 in the absence of GVHD. Beginning within 6 hours after transplantation, patients also receive mycophenolate mofetil IV or PO 3 times daily on days 0 to 40 followed by a taper in the absence of GVHD."
3323819|NCT00112554|Experimental|Induction therapy arm I|Patients receive cytarabine IV continuously on days 1-3 and VNP40101M IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
3323820|NCT00112554|Active Comparator|Induction therapy arm II|Patients receive cytarabine as in arm I and placebo IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
3323821|NCT00112528|Experimental|gemcitabine + bevacizumab + oxaliplatin|"Patients receive gemcitabine IV over 100 minutes and bevacizumab IV over 30-90 minutes on days 1 and 15. Patients also receive oxaliplatin IV over 120 minutes on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses of therapy beyond CR.~After completion of study treatment, patients are followed every 3-6 months for up to 5 years."
3323822|NCT00112502|Active Comparator|Arm I: TMZ|Oral Temozolomide (TMZ) 150 mg/m^2 once daily on days 1-7 and 15-21.
3323823|NCT00112502|Experimental|Arm II: TMZ + Thalidomide|Temozolomide as in arm I and oral Thalidomide (Thal) once daily on days 1-28 (starting dose 200 mg).
3323824|NCT00112502|Experimental|Arm III: TMZ + Isotretinoin|Temozolomide as in Arm I and oral Isotretinoin 40 mg/m^2 twice daily on days 1-21.
3323825|NCT00112502|Experimental|Arm IV: TMZ + Celecoxib|Temozolomide as in arm I and oral Celecoxib 400 mg twice daily on days 1-28.
3323826|NCT00112502|Experimental|Arm V: TMZ + Thalidomide + Isotretinoin|Temozolomide as in arm I, Thalidomide as in arm II, and Isotretinoin as in arm III.
3323827|NCT00112502|Experimental|Arm VI: TMZ + Thalidomide + Celecoxib|Temozolomide as in Arm I, Thalidomide as in Arm II, and Celecoxib as in Arm IV.
3323828|NCT00112502|Experimental|Arm VII: TMZ + Isotretinoin + Celecoxib|Temozolomide as in Arm I, Isotretinoin as in Arm III, and Celecoxib as in Arm IV.
3323829|NCT00112502|Experimental|Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib|Temozolomide as in Arm I, Thalidomide as in Arm II, Isotretinoin as in Arm III, and Celecoxib as in Arm IV.
3323830|NCT00112489|Experimental|Taxol-Carbo|Paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC = 6 IV over 30 minutes every 21 days until disease progression or adverse effects prohibit further therapy
3323831|NCT00112476|Experimental|Treatment (bryostatin, temsirolimus)|Patients receive bryostatin 1 IV over 1 hour on days 1, 8, 15, and 22 and temsirolimus IV over 30 minutes once on days 8, 15, and 22 during course 1. On subsequent courses patients receive bryostatin 1 and temsirolimus once on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3323832|NCT00112463|Experimental|Treatment (single-agent depsipeptide)|Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.
3323833|NCT00112437|Placebo Comparator|Placebo|
3323834|NCT00112437|Experimental|Odanacatib 3 mg|
3323835|NCT00112437|Experimental|Odanacatib 10 mg|
3323836|NCT00112437|Experimental|Odanacatib 25 mg|
3323837|NCT00112437|Experimental|Odanacatib 50 mg|
3323838|NCT00112398|Active Comparator|Standard (paramedic) prehospital care|
3323839|NCT00112398|Experimental|Physician prehospital care|
3323840|NCT00112385|Active Comparator|Etanercept|Subjects randomized to Etanercept will be provided with syringes contain 50 mg and will be injected subcutaneously once a week for 52 weeks.
3323841|NCT00112385|Placebo Comparator|Placebo|Subjects will be given syringes containing placebo. Injections will be given subcutaneously, one time per week for 52 weeks.
3323842|NCT00112372|Experimental|Ridaforolimus|10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.
3323843|NCT00112359|Placebo Comparator|Placebo three times a day (TID)|
3323844|NCT00112359|Experimental|AZLI 75 mg three times a day (TID)|
3323845|NCT00112346|Active Comparator|A|
3323846|NCT00112346|Active Comparator|B|
3323847|NCT00112320|Active Comparator|1|Standard PVR
3323848|NCT00112320|Experimental|2|PVR plus RV remodeling
3323889|NCT00111917|Placebo Comparator|Placebo|infusion: 3:1 infliximab:placebo ratio administered at 0, 2, 6, 12, 18 and 24 weeks.
3323849|NCT00112294|Active Comparator|Cetuximab+Taxane+Carboplatin (C/T/C)|Cetuximab was administered at an initial dose (Week 1) of 400 mg/m^2 intravenous (IV) infusion (infused over 120 minutes) and a weekly maintenance dose of 250 mg/m^2 IV infusion (infused over 60 minutes). A cycle of therapy was defined as 3 weeks. Taxane was paclitaxel 225 mg/m^2 infused over 180 minutes on Day 1 and subsequently every 3 weeks or docetaxel 75 mg/m^2 infused over 60 minutes on Day 1 and subsequently every 3 weeks. Carboplatin was infused over 30 minutes on Day 1 and subsequently every 3 weeks.
3323850|NCT00112294|Active Comparator|Taxane+Carboplatin (T/C)|A cycle of therapy was defined as 3 weeks. Taxane was paclitaxel 225 mg/m^2 infused over 180 minutes on Day 1 and subsequently every 3 weeks or docetaxel 75 mg/m^2 infused over 60 minutes on Day 1 and subsequently every 3 weeks. Carboplatin was infused over 30 minutes on Day 1 and subsequently every 3 weeks.
3323851|NCT00112242|Experimental|1|Montanide + Melan-A analogue peptide
3323852|NCT00112242|Experimental|2|Montanide + Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide
3323853|NCT00112242|Experimental|3|Montanide + CpG-7909/PF-3512676+Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide
3323854|NCT00112242|Experimental|4|Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide
3323855|NCT00112242|Experimental|5|Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide + low dose IL-2
3323856|NCT00112229|Experimental|group 1|Melan-A analog peptide + CpG + Montanide
3323857|NCT00112229|Experimental|group 2|Melan-A natural peptide + CpG + Montanide
3323858|NCT00112229|Experimental|group 3|Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
3323859|NCT00112229|Experimental|group 4|Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
3323860|NCT00112151|Experimental|LowT+Resistance Training|"Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)~1 year standard Progressive Resistance Training(PRT) program"
3323861|NCT00112151|Experimental|LowT+No Resistance training|"Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)~No exercise program"
3323862|NCT00112151|Experimental|HighT+Resistance Training|"High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)~1 year standard Progressive Resistance Training(PRT) program"
3323863|NCT00112151|Experimental|HighT+No Resistance Training|"High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)~No exercise program"
3323864|NCT00112151|Active Comparator|Placebo+Resistance Training|"Placebo Group applies two 2.5 gm placebo packets~1 year standard Progressive Resistance Training(PRT) program"
3323865|NCT00112151|Placebo Comparator|Placebo+No Resistance Training|"Placebo group applies two 2.5 gm placebo packets~No exercise program"
3323866|NCT00112125|Experimental|Optimizer System + Optimal medical treatment|Optimizer System implanted and cardiac contractility modulation therapy activated.
3323867|NCT00112125|No Intervention|Optimal medical treatment|
3323868|NCT00112112|Active Comparator|FluMist|The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.
3323869|NCT00112112|Placebo Comparator|Placebo|Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
3323870|NCT00112099|Active Comparator|1|Procedure/Surgery: Surgery: Splenectomy
3323871|NCT00112099|Experimental|2|Procedure/Surgery: Surgery: Spleen-preservation
3323872|NCT00112073|Experimental|0.15 mg/kg active bapineuzumab|
3323873|NCT00112073|Placebo Comparator|0.15 mg/kg placebo|
3323874|NCT00112073|Experimental|0.5 mg/kg active bapineuzumab|
3323875|NCT00112073|Placebo Comparator|0.5 mg/kg placebo|
3323876|NCT00112073|Experimental|1.0 mg/kg active bapineuzumab|
3323877|NCT00112073|Placebo Comparator|1.0 mg/kg placebo|
3323878|NCT00112073|Experimental|2.0 mg/kg active bapineuzumab|
3323879|NCT00112073|Placebo Comparator|2.0 mg/kg placebo|
3323880|NCT00112047|Active Comparator|EFV+CBV|Participants in this group received EFV 600 mg once daily + Combivir ([CBV]; the fixed dose combination pill containing lamivudine 150 mg + zidovudine 300 mg) taken twice daily from the start of the study until Week 144. At Week 144 all participants who opted to roll over into the additional 96-week study extension received Atripla ([ATR]; the fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg) taken once daily until the end of the study (Week 240). At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.
3323881|NCT00112047|Experimental|EFV+FTC+TDF|Participants in this arm received 3 component drugs: efaviren (EFV; 600 mg) + emtricitabine (FTC; 200 mg) + tenofovir disoproxil fumarate (tenofovir DF [TDF]; 300 mg) as 3 separate pills once daily from the start of the study. At 96 weeks Truvada ([TVD] the fixed-dose combination pill containing FTC/TDF [200/300 mg] once daily) replaced the 2 component drugs FTC + TDF; participants continued to receive EFV 600 mg once daily. At Week 144 all participants who opted to roll over into the further 96-week study extension received ATR. At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.
3323882|NCT00112021|Experimental|Pramlintide Acetate|
3323883|NCT00112021|Placebo Comparator|Placebo|
3323884|NCT00112008|Experimental|darbepoetin alfa|
3323885|NCT00111982|Experimental|Liatermin|Bilateral continuous infusion of liatermin for up to 24 months.
3323886|NCT00111956|Experimental|Etanercept|
3323887|NCT00111956|Placebo Comparator|Placebo|
3323891|NCT00111865|No Intervention|Usual Care|
3323892|NCT00111852|Experimental|Desmoteplase, low dose|Desmoteplase 90 mcg/kg, intravenous administration.
3323893|NCT00111852|Experimental|Desmoteplase, high dose|Desmoteplase 125 mcg/kg, intravenous administration.
3323894|NCT00111852|Placebo Comparator|Placebo|Dose-Match Placebo, intravenous administration.
3323895|NCT00111839|Active Comparator|Pemetrexed Alone|Participants will receive pemetrexed 50 milligrams per square meter (mg/m^2) intravenous (IV) infusion every 3 weeks until disease progression (PD) or the occurrence of unacceptable toxicity.
3323896|NCT00111839|Experimental|Pemetrexed Plus Matuzumab 800 mg per Week|Participants will receive pemetrexed 50 mg/m^2 IV infusion every 3 weeks in combination with matuzumab 800 milligrams (mg) IV infusion once every week. Treatment will continue until PD or the occurrence of unacceptable toxicity.
3323897|NCT00111839|Experimental|Pemetrexed Plus Matuzumab 1600 mg Every 3 Weeks|Participants will receive pemetrexed 50 mg/m^2 IV infusion every 3 weeks in combination with matuzumab 1600 mg IV infusion every 3 weeks. Treatment will continue until PD or the occurrence of unacceptable toxicity.
3323898|NCT00111813|Experimental|vorinostat 200 mg + bortezomib 0.7 mg/m^2|Vorinostat capsules given twice daily (b.i.d.); bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
3323899|NCT00111813|Experimental|vorinostat 200 mg + bortezomib 0.9 mg/m^2|Vorinostat capsules given b.i.d.; bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
3323900|NCT00111813|Experimental|vorinostat 300 mg + bortezomib 1.3 mg/m^2|Vorinostat given once daily (q.d.); bortezomib given on Days 1, 4, 8, and 11 of each cycle.
3323901|NCT00111813|Experimental|vorinostat 400 mg + bortezomib 0.9 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
3323902|NCT00111813|Experimental|vorinostat 400 mg + bortezomib 1.1 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
3323903|NCT00111813|Experimental|vorinostat 400 mg + bortezomib 1.3 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
3323904|NCT00111800|Placebo Comparator|Placebo|Participants received oral dose of matching placebo capsule to denagliptin (DEN) once daily in the morning, 30 minutes (min) prior to breakfast during the main phase 12-weeks treatment period. Participants who were randomized to placebo in the main phase 12-weeks treatment period received oral dose of DEN 2.5 milligram (mg) once daily in the morning, 30 min prior to breakfast during the extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of placebo to the participants.
3323905|NCT00111800|Experimental|DEN 2.5 mg|Participants received oral dose of DEN 2.5 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 2.5 mg to the participants.
3323906|NCT00111800|Experimental|DEN 7.5 mg|Participants received oral dose of DEN 7.5 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 7.5 mg to the participants.
3323907|NCT00111800|Experimental|DEN 15 mg|Participants received oral dose of DEN 15 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 15 mg to the participants.
3323908|NCT00111800|Experimental|DEN 30 mg|Participants received oral dose of DEN 30 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 30 mg to the participants.
3323909|NCT00111800|Experimental|DEN 45 mg|Participants received oral dose of DEN 45 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 45 mg to the participants.
3323910|NCT00111787|Experimental|Overall study|A Single arm study with 2 cohorts of participants. Cohort A consists of participants with tumors overexpressing HER2 and/or EGFR. Cohort B consists of participants with tumors expressing EGFR without overexpressing HER2.
3323911|NCT00111761|Experimental|Part 1: Panitumumab + IFL|Panitumumab (2.5 mg/kg once weekly for up to 48 weeks or until disease progression, intolerable adverse event or other reason for discontinuation) in combination with irinotecan, 5-fluorouracil (5-FU)and leucovorin (IFL chemotherapy regimen)
3323912|NCT00111761|Experimental|Part 2: Panitumumab + FOLFIRI|Panitumumab (2.5 mg/kg once weekly until disease progression, intolerable adverse event or other reason for discontinuation) in combination with irinotecan/5-FU/leucovorin chemotherapy (the FOLFIRI regimen)
3323913|NCT00111748|Active Comparator|1|"Stratification:~CA13/hypodiploidy at diagnosis versus no CA13/hypoploidy at diagnosis~Prior Velcade vs. No prior Velcade~TREATMENT:VTD Velcade 1.0 mg/m2 Days 1,4, 8,11 Thalidomide 100 mg Daily qhs Dexamethasone 20 mg Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg Days 1-14 Every 21 days"
3323914|NCT00111748|Active Comparator|2|"Stratification:~CA13/hypodiploidy at diagnosis versus no CA13/hypoploidy at diagnosis~Prior Velcade vs. No prior Velcade~TREATMENT:~VATD Velcade 1.0 mg/m2 Days 1,4, 8,11 Thalidomide 100 mg Daily qhs Dexamethasone 20 mg Days 1, 2, 4,5, 8, 9, 11, 12 Adriamycin 2.5 mg/m2 Days 1-4 & Days 9-12 Lovenox 40 mg Days 1-14 Every 21 days"
3323915|NCT00111696|Experimental|MEDI-522|Drug
3323916|NCT00111683|Experimental|MK-0457|Participants receive MK-0457 as a continuous intravenous infusion (CIV) at assigned dose and duration
3323917|NCT00111670|Experimental|1|
3323918|NCT00111670|Experimental|2|
3323919|NCT00111670|Experimental|3|
3323920|NCT00111670|Experimental|4|
3323921|NCT00111670|Placebo Comparator|5|
3324094|NCT00109473|Active Comparator|Cortecosteroids alone|Cortecosteroid therapy as prescribed by the referring gastroenterologist
3323922|NCT00111657|Experimental|pegloticase|"All study participants received intravenous pegloticase at dose of 8 mg, administered every 21 days for a maximum of 5 doses.~There was no control group for this open label study."
3323923|NCT00111644|Experimental|1|
3323924|NCT00111644|Experimental|2|
3323925|NCT00111644|Active Comparator|3|
3323926|NCT00111631|Experimental|1|
3323927|NCT00111631|Experimental|2|
3323928|NCT00111631|Experimental|3|
3323929|NCT00111631|Placebo Comparator|4|
3323930|NCT00111605|Experimental|1|HIV gag DNA vaccine or placebo on Days 0, 28, and 84
3323931|NCT00111605|Experimental|2|HIV gag DNA vaccine plus 100 mcg of IL-12 or placebo on Days 0, 28, and 84
3323932|NCT00111605|Experimental|3|HIV gag DNA vaccine plus 500 mcg of IL-12 or placebo on Days 0, 28, and 84
3323933|NCT00111605|Experimental|4|HIV gag DNA vaccine plus 1,500 mcg of IL-12 or placebo on Days 0, 28, and 84
3323934|NCT00111605|Experimental|5|HIV gag DNA vaccine or placebo on Days 0, 28, 84, 168, and 273
3323935|NCT00111605|Experimental|6|HIV gag DNA vaccine plus IL-12 or placebo on Days 0, 28, and 84 plus CTL MEP/RC529-SE/GM-SCF booster vaccine on Days 168 and 273
3323936|NCT00111605|Experimental|7|HIV gag DNA vaccine plus IL-12 DNA adjuvant or placebo on Days 0 and 84
3323937|NCT00111592|Active Comparator|1|current usual care
3323938|NCT00111592|Experimental|2|treatment protocol with clear indications for therapy
3323939|NCT00111579|Active Comparator|1|CAIV-T
3323940|NCT00111579|Other|2|TIV
3323941|NCT00111566|Active Comparator|18 Hour infusion|
3323942|NCT00111566|Experimental|4 hour infusion|
3323943|NCT00111540|Experimental|Exenatide|Exenatide 5 mcg for 4 weeks (transition) then 10 mcg to study termination
3323944|NCT00111527|Active Comparator|1|Normal RV pacing
3323945|NCT00111527|Experimental|2|Echo-guided optimization of pacing
3323946|NCT00111501|Experimental|Targeted Internet Intervention|Web-based self help intervention developed to include specific cultural tailoring relevant to the LGBT community
3323947|NCT00111501|Active Comparator|Standard Intervention|Standard self-help internet-based intervention with no LGBT relevant information included
3323948|NCT00111436|Experimental|50 mg|50 mg once weekly
3323949|NCT00111436|Experimental|100 mg|50 mg twice weekly
3323950|NCT00111358|Active Comparator|Lifestyle Modification|Goals derived from the AACE and NCEP-ATP III guidelines and the Diabetes Prevention Program are as follows: <35% calories from fat, < 7% calories from saturated fat, up to 10% calories from polyunsaturated fat, reduction of trans fatty acid intake, up to 20% calories from monounsaturated fat, and 25-35g of fiber per day. 3 hrs of physical activity/week at moderate intensity, >10,000 steps in daily activity, measured by pedometer. The curriculum is modeled after the Diabetes Prevention Program. Subjects will complete lifestyle sessions in the offices of the Program in Nutritional Metabolism or in the Clinical Research Center at MGH with protocol study staff trained to implement the curriculum.
3323951|NCT00111358|Placebo Comparator|Control|
3323952|NCT00111345|Experimental|1|Daunoxome, standard risk
3323953|NCT00111345|Active Comparator|2|Idarubicin, standard risk
3323954|NCT00111345|Experimental|3|Daunoxome, high-risk, 2-CDA
3323955|NCT00111345|Active Comparator|4|Idarubicin, high-risk, nothing
3323956|NCT00111254|Experimental|1|In group I, acute effect group, each subject will undergo microdermabrasion of the hip/buttock. Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device). 4mm punch biopsies will be performed in the treated area at 4hrs, 8hrs, and 24hrs post-treatment. In addition, one 4mm punch biopsy will be obtained from adjacent untreated skin.
3323957|NCT00111254|Experimental|2|In group II, chronic effect group, each subject will undergo microdermabrasion of the face at weekly intervals for six weeks. Treatment will consist of 3 passes in different directions with the microdermabrasion handpiece (horizontal, vertical, and oblique). Aluminum oxide abrasion and negative pressure will be increased as tolerated by the patient. Two 2mm punch biopsies will be obtained prior to the first treatment and one week following the sixth treatment.
3323958|NCT00111189|Experimental|001|Paliperidone Palmitate 25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
3323959|NCT00111189|Placebo Comparator|002|Placebo Placebo every 4 wk up to 24 mo
3323960|NCT00111176|Other|1|Endovascular Repair
3323961|NCT00111176|Other|2|Surgical
3323962|NCT00111137|Active Comparator|rHuEPO|
3323963|NCT00111137|Experimental|Darbepoetin alfa|
3323964|NCT00111098|Experimental|darbepoetin alfa|
3323965|NCT00111085|Experimental|Clazosentan 1 mg/h|intravenous clazosentan at 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
3323966|NCT00111085|Experimental|Clazosentan 5 mg/h|intravenous clazosentan at 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
3323967|NCT00111085|Experimental|Clazosentan 15 mg/h|intravenous clazosentan at of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
3323968|NCT00111085|Placebo Comparator|Placebo|intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
3323969|NCT00111020|Experimental|Arm 1|
3323970|NCT00111007|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg orally, 2 tablets (200 mg each) bid (bis in die [twice daily]) on Study Days 2 to 19 + Paclitaxel (225 mg/m^2 iv [Intravenous]) and Carboplatin (AUC [area under the curve] 6 iv) on Study Day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
3323971|NCT00111007|Active Comparator|Carboplatin/Paclitaxel (C/P)|Placebo, 2 tablets bid on Study Days 2-19 + Paclitaxel (225 mg/m^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
3324189|NCT00107952|Active Comparator|Vancomycin|
3323972|NCT00110994|Experimental|Sorafenib (Nexavar, BAY43-9006) + Dacarbazine|Sorafenib, 2 tablets (200 mg each) orally twice daily (bid) on study days 1-21 + Dacarbazine, 1000 mg/m^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
3323973|NCT00110994|Active Comparator|Placebo + Dacarbazine|Placebo, 2 tablets orally twice daily on study days 1-21 + Dacarbazine, 1000 mg/m^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
3323974|NCT00110981|Experimental|Single-arm|
3323975|NCT00110955|Experimental|Darbepoetin alfa - Group A|
3323976|NCT00110955|Placebo Comparator|Placebo- Group B|
3323977|NCT00110942|Active Comparator|Minor sub-study AMG 108|N = 15
3323978|NCT00110942|Placebo Comparator|Minor sub-study placebo|N = 15
3323979|NCT00110942|Active Comparator|Main sub-study AMG 108|N = 73
3323980|NCT00110942|Placebo Comparator|Main sub-study placebo|N = 73
3323981|NCT00110916|Experimental|Anakinra|anakinra
3323982|NCT00110916|Placebo Comparator|placebo|placebo
3323983|NCT00110890|No Intervention|Standard of care|Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
3323984|NCT00110890|Other|Cinacalcet|Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg. Dose escalation of cinacalcet may occur based on iPTH values.
3323985|NCT00110877|Experimental|002|LPV/rtv One 400mg LPV tablet twice daily with 100mg RTV
3323986|NCT00110877|Experimental|001|TMC114/rtv Two 300mg TMC114 tablets twice daily with 100mg RTV
3323987|NCT00110812|No Intervention|No IL-2|Participants will receive no aldesleukin or HAART
3323988|NCT00110812|Experimental|IL-2 without ART|Participants will receive aldesleukin under the skin twice daily for 5 consecutive days every 8 weeks for 3 cycles, then as needed to maintain CD4 counts at or above a goal level. Some Group 2 participants may take part in additional cycles of aldesleukin if they meet certain study criteria.
3323989|NCT00110812|Experimental|IL-2 with pericycle HAART|Participants will receive aldesleukin under the skin twice daily for 5 consecutive days every 8 weeks for 3 cycles, then as needed to maintain CD4 counts at or above a goal level; Group 3 participants will also take HAART for 3 days prior to the start of each aldesleukin cycle, throughout the 5-day aldesleukin cycle, and for 2 days after the end of each aldesleukin cycle (for a maximum of 10 days with each aldesleukin cycle). Some Group 3 participants may take part in additional cycles of aldesleukin if they meet certain study criteria. HAART is not supplied by the study, and choice of drugs is left to the participant and physician. The HAART regimen should include at least one protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors.
3323990|NCT00110799|Active Comparator|Arm B|SB-497115-GR 30mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
3323991|NCT00110799|Active Comparator|Arm C|SB-497115-GR 50mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
3323992|NCT00110799|Active Comparator|Arm D|SB-497115-GR 75mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
3323993|NCT00110799|Placebo Comparator|Arm A|Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
3323994|NCT00110773|Experimental|S-Caine Peel|
3323995|NCT00110773|Placebo Comparator|Placebo Peel|
3323996|NCT00110760|Experimental|S-Caine Peel|
3323997|NCT00110760|Placebo Comparator|Placebo Peel|
3323998|NCT00110747|Experimental|S-Caine Peel|
3323999|NCT00110747|Placebo Comparator|Placebo Peel|
3324000|NCT00110695|Experimental|A|
3324001|NCT00110669|Active Comparator|High Dose Prednisone|"Subjects who are randomized to the high-dose prednisone arm of the study will receive the following starting dose:~•Prednisone at 10.0 mg/kg/wk (divided into two doses given on Saturday and Sunday)"
3324002|NCT00110669|Active Comparator|Daily Prednisone|"Subjects who are randomized to the daily prednisone arm of the study will receive the following starting dose:~•Prednisone at 0.75 mg/kg/d"
3324003|NCT00110656||Kidney Transplant|All patients entered into the study will have received a kidney transplant.
3324004|NCT00110617|Experimental|Deferasirox (ICL670)|Deferasirox (ICL670) 20 mg/kg orally once daily for 104 weeks.
3324005|NCT00110617|Experimental|Deferoxamine (DFO) then ICL670|Deferoxamine (DFO) subcutaneously for a weekly dose of 175 mg/kg for 24 weeks then crossed over to receive Deferasirox (ICL670) orally 20 mg/kg for a total of 104 weeks on therapy.
3324006|NCT00110591|Placebo Comparator|Placebo|Intravenous placebo for PRO 140
3324007|NCT00110591|Experimental|PRO 140 dose 1|0.1 mg/kg PRO 140 by intravenous infusion
3324008|NCT00110591|Experimental|PRO 140 dose 2|0.5 mg/kg PRO 140 by intravenous infusion
3324009|NCT00110591|Experimental|PRO 140 dose 3|2.0 mg/kg PRO 140 by intravenous infusion
3324010|NCT00110591|Experimental|PRO 140 dose 4|5.0 mg/kg PRO 140 by intravenous infusion
3324011|NCT00110552|Experimental|1|Sage capsules taken by mouth
3324012|NCT00110552|No Intervention|2|No intervention, no-pill as control
3324013|NCT00110526|Experimental|Ad.hIL-12|
3324014|NCT00110513|Experimental|Recombinant Human Antithrombin (rhAT) Infusion|Intravenous infusion of rhAT.
3324015|NCT00110461|Active Comparator|1|Aripiprazole 10 mg tablet
3324016|NCT00110461|Active Comparator|2|Aripiprazole 30 mg tablet
3324017|NCT00110461|Placebo Comparator|3|Placebo
3324018|NCT00110448|Active Comparator|1|Aspirin use
3324019|NCT00110448|Active Comparator|2|No aspirin use
3324020|NCT00110422|Experimental|A1|
3324021|NCT00110422|Active Comparator|B1|
3324022|NCT00110409|Experimental|1|Intervention participants will receive information focusing on asthma self-management, education, self-efficacy, and social support while in the hospital emergency room. Telephone reinforcement will occur for 8 weeks following study entry.
3324023|NCT00110409|Active Comparator|2|Participants in the control group will receive standard emergency room education about asthma.
3324024|NCT00110396|Experimental|Rebif New Formulation Cohort|
3324025|NCT00110383|Experimental|1|Supervised therapy
3324026|NCT00110383|No Intervention|2|Inhaled steroid use as usual care
3324027|NCT00110357|Active Comparator|Group A|1-12 years old
3324028|NCT00110357|Active Comparator|Group B|13-18 years old
3324029|NCT00110344|Experimental|Arm 1|
3324030|NCT00110344|Placebo Comparator|Arm 2|
3324031|NCT00110305|Experimental|TMC278 25 mg|Participants will receive TMC278 25 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
3324032|NCT00110305|Experimental|TMC278 75 mg|Participants will receive TMC278 75 mg once daily up to Week 144. Later on, participants will receive TMC278 25 mg once daily up to Week 240.
3324033|NCT00110305|Experimental|TMC278 150 mg|Participants will receive TMC278 150 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
3324034|NCT00110305|Active Comparator|Efavirenz|Participants will receive efavirenz 600 mg once daily up to Week 96. Later on, participants will have an option to continue on efavirenz until Week 144 or until Week 240.
3324035|NCT00110279|Experimental|1|One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops.
3324036|NCT00110279|Experimental|2|One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops. This Arm will enroll 4 weeks after Arm 1. Enrolled volunteers must have participated in Arm 1.
3324037|NCT00110266|Experimental|ICL670|Evaluate the safety and tolerability of deferasirox 20 mg/kg/day over one year in patients with MDS
3324038|NCT00110253|Experimental|S-Caine Peel|
3324039|NCT00110227|Experimental|Tai Chi|12-week tai chi program
3324040|NCT00110227|Active Comparator|Heart Health Education|12-week attention control
3324041|NCT00110214|Experimental|Arm I|Patients receive docetaxel IV over 1 hour and placebo IV over 30-90 minutes on day 1. Patients also receive oral prednisone once daily on days 1-21.
3324042|NCT00110214|Experimental|Arm II|Patients receive docetaxel and prednisone as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1.
3324043|NCT00110188|Experimental|Ridaforolimus|50 mg of ridaforolimis intravenously over 30 minutes, weekly
3324044|NCT00110149|Experimental|Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan|Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
3324045|NCT00110136|Experimental|St. John's Wort|Patient given one 300mg St. John's Wort tablet three times per day
3324046|NCT00110110|Experimental|CEV Chemo + Cyclosporine & Focal Therapy|Systemic carboplatin (28 mg/kg/dose), etoposide (12 mg/kg/dose) and vincristine sulfate (0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated) chemotherapy given with cyclosporin A (33 mg/kg/dose). Following 4-6 cycles CEV chemotherapy (depending on tumor stage) given every 3 weeks, focal laser therapy and/or cryosurgery are applied for tumor consolidation. Filgrastim is given after each chemotherapy cycle to prevent severe neutropenia.
3324047|NCT00110084|Experimental|Nab-paclitaxel/Gemcitabine|
3324048|NCT00110071|Experimental|Treatment (chemoradioimmunotherapy)|Patients receive a dosimetric dose of iodine I 131 tositumomab IV over 40-60 minutes on day -24 followed by gamma camera imaging over the next 6 days. Patients then receive a therapeutic dose of iodine I 131 tositumomab via central line over 40-60 minutes on day -14. Patients also receive fludarabine phosphate IV QD on days -11 to -9 OR days -11 or -7. Patients undergo autologous or syngeneic peripheral blood stem cell transplantation on day 0.
3324049|NCT00110032|Experimental|Group 1 (fluorine F 18 EF5, PET)|Patients receive fluorine F 18 EF5 (^18F-EF5) IV followed by whole brain and whole body PET scanning OR whole body PET scanning only. Patients then receive nonradioactive EF5 IV over 1-2 ½ hours.
3324050|NCT00110032|Experimental|Group 2 (EF5, PET)|Patients receive nonradioactive EF5 IV over 1-2½ hours followed by ^18F-EF5 IV. Patients then undergo whole brain and whole body PET scanning.
3324051|NCT00110032|Experimental|Group 3 (EF5, PET)|Patients receive nonradioactive EF5 and ^18F-EF5 as in group 2. Patients then undergo whole brain PET scanning.
3324052|NCT00110019|Experimental|Arm I (paclitaxel, carboplatin, sorafenib tosylate)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients also receive sorafenib tosylate PO BID (approximately every 12 hours) on days 2-19.
3324053|NCT00110019|Active Comparator|Arm II (carboplatin, paclitaxel, placebo)|Patients receive paclitaxel and carboplatin as in Arm I. Patients also receive placebo PO BID (approximately every 12 hours) on days 2-19.
3324054|NCT00109967|Experimental|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and on day 1 only of courses 3, 5, 7, 9, and 11. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of course 3, patients undergo reevaluation. Patients achieving a CR or an unconfirmed CR (CRu) receive 2 additional courses of treatment for a total of 5 courses. Patients achieving a PR or stable disease continue study treatment as outlined above for up to 12 courses. Patients achieving a PR or stable disease who subsequently achieve a CR or CRu between courses 3 and 10 receive 2 additional courses of treatment.
3324055|NCT00109941|Experimental|metenkephalin, OGF-opioid growth factor|DRUG All subjects treated with met-enkephalin (also called OGF) 250 ug/kg iv weekly over 45 minutes
3324056|NCT00109928|Experimental|PEGS Treatment|VP-16 (Etoposide) 40 mg/m2 IV Days 1-4 Methyl Prednisolone 250 mg IV Days 1-4 Cisplatin 25 mg/m2 IV Days 1-4 Gemcitabine 1,000 mg/m2 IV Day 1
3324057|NCT00109889|Other|MRI and PET|Magnetic resonance imaging and positron emission tomography
3324058|NCT00109876|Experimental|Treatment (RFA therapy)|A radiofrequency electrode is placed by CT guidance into the target tumor. Patients undergo RFA directly to the tumor for up to 12 minutes to obtain an intratumoral temperature > 60° C. Patients may receive 3 RFA treatments (a total of 36 minutes) to obtain the target temperature.
3324059|NCT00109863|Experimental|Hu14.18-IL2 Treatment|Hu14.18-IL2 will be given on days 1, 2, and 3 of each course of therapy as a 4 hour continuous IV infusion at a daily dose of 6 mg/m2. Treatment courses will be repeated every 28 days at the same dose.
3324060|NCT00109850|Experimental|Treatment|Cetuximab+Cisplatin+Irinotecan followed by radiation therapy (RT) in Cycle 3.
3324061|NCT00109837|Experimental|Induc x2, Consol, Maint|Induc 1: Allopurinol; Daunorubicin; Vincristine; Prednisone; asparaginase; Bactrim Induc 2: Allopurinol; cytarabine; Dexamethasone; filgrastim; mitoxantrone; Methotrexate; leucovorin Consol: Cyclophosphamide; cytarabine; 6-mercaptopurine; Methotrexate; filgrastim Maint:Course 1: 6-mercaptopurine; Methotrexate Course 2: Vincristine; doxorubicin; Dexamethasone Course 3: Cyclophosphamidee; thioguanine; cytarabine Course 4: 6-mercaptopurine; methotrexate
3324062|NCT00109824|Experimental|Arm I|Patients receive decitabine IV over 1 hour on days 1-5 or 1-10. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3324063|NCT00109824|Experimental|Arm II|Patients receive decitabine as in stage 1 and valproic acid PO TID on days 5-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3324064|NCT00109811|Experimental|Treatment|Patients receive PSA peptide vaccine (PSA-3A; PSA: 154-163 [155L]) emulsified in Montanide ISA-51 subcutaneously once in weeks 0, 2, 4, 6, 10, 14, and 18 in the absence of disease progression or unacceptable toxicity.
3324065|NCT00109798|Experimental|Temozolomide, Topotecan|Patient will take on days 1-5 of a 28-days schedule. Take Topotecan on days 2-6 of the 28 day schedule
3324066|NCT00109785|Experimental|PET Scans|The first group of positron emission tomography (PET) scans is performed within 2 weeks before the first dose of chemotherapy. The second group of PET scans occur no more than 7 weeks after chemotherapy and prior to local therapy, either surgery or radiation therapy. The PET scan before initiation of chemotherapy consists of 4 imaging sessions. There is one iodine I-124 iododeoxyuridine (IUdR) PET scan (3 imaging sessions) at 1, 4-8, and 24 hours after IUdR infusion, followed by one fludeoxyglucose (FDG) PET scan (1 imaging session) 45 minutes after FDG infusion.
3324067|NCT00109772|Experimental|lenalidomide|10 mg/day lenalidomide orally for up to 12 weeks in the double-blind treatment period. Participants who completed double-blind treatment had the option of continuing on lenalidomide in the open-label extension period for as long as benefit was derived from the drug or until study closure.
3324068|NCT00109772|Placebo Comparator|Placebo|Placebo orally for up to 12 weeks in the double-blind treatment period. Participants who completed double-blind treatment had the option of crossing over to lenalidomide 10mg in the open-label extension period for as long as benefit was derived from the drug or until study closure.
3324069|NCT00109746|Active Comparator|Chromium Picolinate|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
3324070|NCT00109746|No Intervention|Placebo|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
3324071|NCT00109733|Experimental|Standard dose group|0.005 mg/kg/day recombinant human growth hormone (r-hGH) for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
3324072|NCT00109733|Experimental|High dose group|0.010 mg/kg/day recombinant human growth hormone for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
3324073|NCT00109720|Experimental|1|Patients in the experimental group received the services of a Diabetes Self-Management Consultant (DSC)
3324074|NCT00109720|Active Comparator|2|This Arm was a Enhanced Usual Care Control group who continued with their usual care but also they and their physicians received the results of all metabolic assessments obtained during the study.
3324075|NCT00109707|Experimental|Arm 1|Relapsed / refractory Ph+ ALL patients
3324076|NCT00109707|Experimental|Arm 2 - Group A and Group B|Imatinib-resistant / intolerant Ph+ CML-BC patients
3324077|NCT00109707|Experimental|Arm 3 - Group A and Group|Imatinib-resistant / intolerant Ph+ CML-AP patients
3324078|NCT00109707|Experimental|Arm 4 - Group A and Group B|Imatinib-resistant / intolerant Ph+ CML-CP patients
3324079|NCT00109707|Experimental|Arm 5|Hypereosinophilic syndrome and chronic eosinophilic leukemia patients
3324080|NCT00109707|Experimental|Arm 6|Systemic Mastocytosis patients
3324081|NCT00109655|Experimental|1|
3324082|NCT00109590|Experimental|Arm A: LPV/r x 7d|NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and BID for 7 days postpartum, ddI 250 mg orally daily (if body weight <60 kg) or 400 mg orally twice daily (if body weight >= 60 kg) at the onset of labor, during labor, and for 7 days postpartum, LPV/r 400/100mg orally twice daily at the onset of labor, during labor and for 7 days postpartum.
3324083|NCT00109590|Experimental|Arm B: no LPV/r|NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and twice daily for 7 days postpartum , ddI 250 mg orally daily (if body weight <60 kg) or 400 mg orally daily (if body weight >= 60 kg) at the onset of labor, during labor, and for 30 days postpartum.
3324084|NCT00109590|Experimental|Arm C: LPV/r x 30d|NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and twice daily for 7 days postpartum , ddI 250 mg orally daily (if body weight <60 kg) or 400 mg orally daily (if body weight >= 60 kg) at the onset of labor, during labor, and for 30 days postpartum,LPV/r 400/100mg orally twice daily at the onset of labor, during labor and for 30 days postpartum.
3324085|NCT00109577|Placebo Comparator|2|Placebo comparator, 6 placebo capsules three times a day
3324086|NCT00109577|Experimental|1|nutritional supplement intervention, 6 nutritional supplement capsules three times a day; the nutritional supplement is a 36-ingredient micronutrient supplement (primarily vitamins and minerals) and is referred to as MCN36, because it contains 36 nutrients.
3324087|NCT00109538|Experimental|Lonafarnib|Lonafarnib 200 mg twice daily, oral, continuously
3324088|NCT00109538|Placebo Comparator|Placebo|Placebo, BID, oral
3324089|NCT00109512|Placebo Comparator|placebo|
3324090|NCT00109512|Experimental|NBI-56418 75 mg|
3324091|NCT00109512|Experimental|NBI-56418 150 mg|
3324092|NCT00109486|Experimental|Arm 1|
3324093|NCT00109473|Experimental|Growth Hormone plus cortecosteroid|Growth Hormone (nutropin AQ 0.075 mg/kg/day subcutaneously daily)
3324190|NCT00107926|Experimental|licarbazepine|
3324095|NCT00109421|Experimental|Experimental arm|In the experimental condition, the intervention group will receive the half-day Project ÒRÉ intervention. All participants will complete pre-, post- and 3-month follow-up self-administered questionnaires. A subset of groups will participate in a process evaluation focus group immediately following the program.
3324096|NCT00109421|No Intervention|Attention control group|The attention control group will receive a standard health promotion control program which has been used previously with similar populations. All participants will complete pre-, post- and 3-month follow-up self-administered questionnaires.
3324097|NCT00109408|Experimental|1|
3324098|NCT00109408|Active Comparator|2|
3324099|NCT00109395|Active Comparator|Lorazepam Intermittent bolus|lorazepam administered by intermittent bolus
3324100|NCT00109395|Active Comparator|lorazepam continuous infusion|lorazepam administered by continuous infusion
3324101|NCT00109395|Active Comparator|midazolam continous infusion|midazolam administered by continous infusion
3324102|NCT00109369|Experimental|Active|Provider and patient receive Diabetes Information System services
3324103|NCT00109369|No Intervention|Control|Usual Care
3324104|NCT00109343|Experimental|1|Group 1: ProQuad™ (V221) + PREVNAR™ (pneumococcal 7-valent conjugate vaccine) followed by ProQuad™ (Day 91)
3324105|NCT00109343|Experimental|2|Group 2: PREVNAR™ followed by ProQuad™ (Day 43) followed by ProQuad™ (Day 133)
3324106|NCT00109343|Experimental|3|Group 3: ProQuad™ followed by PREVNAR™ (Day 43), followed by ProQuad™ (Day 91)
3324107|NCT00109291|Placebo Comparator|Placebo|Single injection of placebo administered intravenously
3324108|NCT00109291|Experimental|Peginesatide 0.025 mg/kg|Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.
3324109|NCT00109291|Experimental|Peginesatide 0.05 mg/kg|Single peginesatide dose of 0.05 mg/kg administered intravenously.
3324110|NCT00109291|Experimental|Peginesatide 0.10 mg/kg|Single peginesatide dose of 0.10 mg/kg administered intravenously.
3324111|NCT00109213|Active Comparator|1|Lumbar Laminectomy without Fusion
3324112|NCT00109213|Active Comparator|2|Lumbar Laminectomy with Pedicle Screw Instrumented Fusion
3324113|NCT00109031|Active Comparator|Palifermin 60 µg/kg for 3 days|Palifermin 60 µg/kg plus placebo to match the total volume equivalent to a 180 µg/kg dose on the 3 days prior to fractionated total body irradiation (fTBI) and palifermin 60 µg/kg on Days 0, 1 and 2 after peripheral blood progenitor cell transplantation (PBPC). Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
3324114|NCT00109031|Experimental|Palifermin 180 μg/kg on Day −1|Palifermin 180 μg/kg on Day −1 and matched placebo on Days −2 and −3 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC. Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
3324115|NCT00109031|Experimental|Palifermin 180 μg/kg on Day −2|Palifermin 180 μg/kg on Day −2 and placebo on Days −1 and -3 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC. Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
3324116|NCT00109031|Experimental|Palifermin 180 μg/kg on Day −3|Palifermin 180 μg/kg on Day −3 and placebo on Days −1 and −2 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC. Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
3324117|NCT00109005|Experimental|Cohort 1 - 25 mg lenalidomide (Revlimid)|oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks
3324118|NCT00109005|Experimental|Cohort 2 - 5 mg lenalidomide (Revlimid)|oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks
3324119|NCT00108953|Experimental|Sorafenib + Doxorubicin|"Sorafenib + Doxorubicin -- combination therapy: Sorafenib (Nexavar, BAY43-9006) 200 mg tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)"
3324120|NCT00108953|Active Comparator|Placebo + Doxorubicin|"Placebo + Doxorubicin -- monotherapy: Sorafenib (Nexavar, BAY43-9006) matching placebo tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)"
3324121|NCT00108901|No Intervention|Control|Children were not provided with an after-school exercise intervention. They were free to do their usual activities. Families were offered a monthly healthy lifestyle class.
3324122|NCT00108901|Experimental|Low Dose|This group was assigned to receive a 20 min/day aerobic exercise program offered 5 days/week after school. Families were offered a monthly healthy lifestyle class.
3324123|NCT00108901|Experimental|High dose|This group was assigned to receive a 40 min/day aerobic exercise program offered 5 days/week after school. Families were offered a monthly healthy lifestyle class.
3324124|NCT00108862|Experimental|Immediate ART|The intervention is the strategy of initiating antiretroviral therapy (ART) after approximately 2 weeks of tuberculosis (TB) treatment.
3324125|NCT00108862|Active Comparator|Deferred ART|The intervention is the strategy of initiating ART after 8 to 12 weeks of TB treatment.
3324126|NCT00108810|Experimental|Transdermal Ketoprofen Patch with CHADD|
3324127|NCT00108810|Placebo Comparator|Placebo patch and a dummy heating unit|
3324128|NCT00108771|Experimental|ZR-02-01 matrix fentanyl Patch|ZR-02-01 matrix fentanyl patch
3324129|NCT00108771|Placebo Comparator|Placebo Patch|
3324130|NCT00108745|Experimental|Arm I (paclitaxel poliglumex)|Patients receive polyglutamate paclitaxel IV over 10-20 minutes on day 1.Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3324131|NCT00108745|Active Comparator|Arm II (paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3324132|NCT00108745|Other|Arm III (observation)|Patients receive no further anticancer treatment until evidence of disease progression.
3324177|NCT00107991|Experimental|Treatment arm|Open-label treatment with etanercept 50 mg/week subcutaneous injection
3324178|NCT00107978|Experimental|Telavancin|
3324179|NCT00107978|Active Comparator|Vancomycin|
3324180|NCT00107965|Experimental|1|
3324181|NCT00107965|Experimental|2|
3324182|NCT00107965|Experimental|3|
3324183|NCT00107965|Placebo Comparator|4|
3324184|NCT00107965|Experimental|5|
3324133|NCT00108732|Experimental|Treatment (vaccine therapy)|"Patients receive vaccinia-PSA-TRICOM vaccine SC on day 1 and sargramostim (GM-CSF) SC on days 1-4 during weeks 1-4. Beginning in week 5, patients receive fowlpox-PSA-TRICOM vaccine SC on day 1 and GM-CSF SC on days 1-4. Treatment with fowlpox-PSA-TRICOM vaccine and GM-CSF repeats every 4 weeks for 3 courses (weeks 5-16). Beginning in week 17, patients receive fowlpox-PSA-TRICOM vaccine and GM-CSF as above every 12 weeks in the absence of clinical or biochemical disease progression or unacceptable toxicity.~Patients with biochemical or clinical disease progression receive androgen ablation therapy comprising oral bicalutamide once daily for 1 month and goserelin SC once every 4 weeks in addition to fowlpox-PSA-TRICOM vaccine and GM-CSF. Treatment continues in the absence of further clinical or biochemical disease progression."
3324134|NCT00108628|Experimental|Arm 1|Imagery Rehearsal Therapy
3324135|NCT00108628|Active Comparator|Arm 2|Sleep and Nightmare Management
3324136|NCT00108615|Experimental|1|pioglitazone
3324137|NCT00108615|Active Comparator|2|metformin
3324138|NCT00108602|Other|1|
3324139|NCT00108576|Placebo Comparator|Arm 1|Look-a-like placebo
3324140|NCT00108576|Experimental|Arm 2|Divalproex
3324141|NCT00108550|Experimental|1|Gabapentin 300 mg orally three times daily up to a maximum of 1200 mg orally three times daily for 12 weeks
3324142|NCT00108550|Sham Comparator|2|Inert placebo capsules identical in size and shape to the experimental capsules, one to three capsules taken orally three times daily for 12 weeks
3324143|NCT00108524|Experimental|Low Carbohydrate Ketogenic Diet|Participants receive dietary counseling over 48 weeks aimed at helping them to lower starch and sugar intake.
3324144|NCT00108524|Active Comparator|Low-Fat Diet plus Orlistat|Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake, and additionally receive Orlistat taken 3 times daily.
3324145|NCT00108485|Active Comparator|Extended release niacin|Extended release niacin 1500-2000 mg daily versus placebo comparator
3324146|NCT00108485|Placebo Comparator|Placebo|Placebo tablets
3324147|NCT00108407|Experimental|1|Integrated Cognitive Behavioral Therapy
3324148|NCT00108407|Experimental|2|Twelve Step Facilitation Therapy
3324149|NCT00108381|Experimental|Arm 1|Standard and Tailored Conditions
3324150|NCT00108355|Active Comparator|Albumin (Control group)|"After LVP, patients in this group received:~Intravenous albumin (25%) at 8 g/liter of ascitic fluid removed, one time dose; Intramuscular injection of 5 cc saline (Octreotide LAR placebo), every 30 days ; Oral tablet 3 times a day (Midodrine placebo)"
3324151|NCT00108355|Experimental|Vasoconstrictor (Study Group)|"After LVP, patients in this group received:~Octreotide LAR intramuscular injection 20 mg, every 30 days; Midodrine tablet, 10 mg three times a day; Intravenous saline infusion (Albumin placebo), one time dose"
3324152|NCT00108342|Active Comparator|Nicotine Replacement Treatment (NRT) Sampling|"Sampling = 3 minute testing of each of 6 NRTs (3 forms x 2 dosages)~2 mg and 4 mg nicotine gum; 2 mg and 4 mg nicotine lozenges; frequent and infrequent puffing on a nicotine inhaler (can yield 4 mg from 10 mg device)."
3324153|NCT00108342|Sham Comparator|NRT Computer Learning|Computer learning: learning about 6 NRTs (3 forms x 2 dosages) by computer only
3324154|NCT00108316|Other|Arm 1|
3324155|NCT00108303||Diagnostic|A diagnostic was performed
3324156|NCT00108277|Experimental|Raise CO2|Raise CO2 - biofeedback-assisted breathing training to raise baseline pCO2
3324157|NCT00108277|Active Comparator|Lower CO2|Lower CO2 - biofeedback-assisted breathing training to lower baseline pCO2
3324158|NCT00108277|No Intervention|Waitlist|Waitlist - treatment as usual
3324159|NCT00108251|Placebo Comparator|1|placebo tablet
3324160|NCT00108251|Experimental|2|eplerenone tablets
3324161|NCT00108225|Active Comparator|Arm 1|30% carbohydrate, 30% protein, 40% fat
3324162|NCT00108225|Placebo Comparator|Arm 2|55% carbohydrate, 15% protein, 30% fat
3324163|NCT00108186|Other|Arm 1|Celecoxib is an FDA approved drug for other indications such as osteoarthritis. It is not FDA approved for non-small cell lung cancer.
3324164|NCT00108173|Other|Arm 1|
3324165|NCT00108160|Active Comparator|Mupirocin Ointment [Treatment]|Treatment arm or active comparator [mupirocin 2% polyethylene glycol (PEG) ointment] will be compared with its placebo comparator [polyethylene glycol (PEF) in patients with a prior history of S. aureus infection. Drug or placebo will be applied topically to nares and/or wounds twice daily for 14 days at 3 month intervals for up to 18 months
3324166|NCT00108160|Placebo Comparator|Polyethylene Glycol Ointment [Placebo]|Treatment arm or active comparator [mupirocin 2% polyethylene glycol (PEG) ointment] will be compared with its placebo comparator [polyethylene glycol (PEF) in patients with a prior history of S. aureus infection. Drug or placebo will be applied topically to nares and/or wounds twice daily for 14 days at 3 month intervals for up to 18 months
3324167|NCT00108147|Experimental|1|Circuit Training
3324168|NCT00108147|Active Comparator|2|Cardiac Rehabilitation
3324169|NCT00108147|Active Comparator|3|Flexibility and toning
3324170|NCT00108108|Experimental|HCD122|
3324171|NCT00108082|Experimental|Carvedilol CR|Carvedilol controlled release (CR) 20 to 80 mg once daily (OD) plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study. (In the protocol, carvedilol CR was referred to as carvedilol modified-release [MR].)
3324172|NCT00108082|Experimental|Atenolol|Atenolol 50 to 100 mg OD plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study.
3324173|NCT00108082|Experimental|Lisinopril|Lisinopril 10 to 40 mg OD plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study.
3324174|NCT00108069|Experimental|GBM (Glioblastoma multiforme)|
3324175|NCT00108069|Experimental|AG (Anaplastic glioma)|
3324176|NCT00108004|Experimental|Pramlintide|"Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection.~It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43-mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative"
3324185|NCT00107965|Experimental|6|
3324186|NCT00107965|Experimental|7|
3324191|NCT00107926|Placebo Comparator|Placebo|
3324192|NCT00107900|Experimental|15mg BID|15mg edoxaban administered twice daily (BID)
3324193|NCT00107900|Experimental|30mg QD|30mg edoxaban administered once daily (QD)
3324194|NCT00107900|Experimental|30mg BID|30mg edoxaban administered twice daily (BID)
3324195|NCT00107900|Experimental|60mg QD|60mg edoxaban administered once daily (QD)
3324196|NCT00107900|Experimental|60mg BID|60mg edoxaban administered twice daily (BID)
3324197|NCT00107900|Experimental|120mg QD|120mg edoxaban administered once daily (QD)
3324198|NCT00107887|No Intervention|1|Subjects in clinics that have not received the intervention
3324199|NCT00107887|Experimental|2|Subjects at clinics that have received the intervention
3324200|NCT00107835|Experimental|S-Caine Peel|
3324201|NCT00107783|No Intervention|Control|No treatment
3324202|NCT00107783|Experimental|Nitisinone-treated|Subjects received nitisinone 2 mg orally, once daily.
3324203|NCT00107770|Other|1|ALS patient
3324204|NCT00107744|Active Comparator|Soy protein-milk protein-carbohydrate|Participants received 40 grams of soy protein daily for 8 weeks, 40 grams of milk protein daily for 8 weeks, and 40 grams of carbohydrate daily for 8 weeks.
3324205|NCT00107744|Active Comparator|Milk protein-carbohydrate-soy protein|Participants received 40 grams of milk protein daily for 8 weeks, 40 grams of carbohydrate daily for 8 weeks, and 40 grams of soy protein daily for 8 weeks.
3324206|NCT00107744|Active Comparator|Carbohydrate-soy protein-milk protein|Participants received 40 grams of complex carbohydrate daily for 8 weeks, 40 grams of soy protein daily for 8 weeks, and 40 grams of milk protein daily for 8 weeks.
3324207|NCT00107653|Experimental|Latino|Participants received peginterferon alfa-2a 180 microgram (mcg)/0.5 mL by subcutaneous injection once a week in combination with ribavirin 1000 or 1200 mg per day, which was taken orally in split doses for 48 weeks. Participants with <75 kg (165 lbs) of body weight received 1000 mg/day (400 mg in the morning and 600 mg in the evening). Participants with >=75 kg (165 lbs) of body weight received 1200 mg/day (600 mg in the morning and 600 mg in the evening).
3324208|NCT00107653|Experimental|Non-Latino White|Participants received peginterferon alfa-2a 180 mcg/0.5 mL by subcutaneous injection once a week in combination with ribavirin 1000 or 1200 mg per day which was taken orally in split doses. Participants with <75 kg (165 lbs) of body weight received 1000 mg/day. Participants with >=75 kg (165 lbs) of body weight received 1200 mg/day for 48 weeks.
3324209|NCT00107640|No Intervention|Usual care|Patients not assigned to the experimental condition received usual care, which may or may not have included alcohol education.
3324210|NCT00107640|Experimental|Patient-provider education|Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
3324211|NCT00107627|Active Comparator|1|Skin staples;
3324212|NCT00107627|Active Comparator|2|Monocryl subcuticular sutures.
3324213|NCT00107627|Active Comparator|3|Caprosyn subcuticular sutures.
3324214|NCT00107614|Experimental|DT PACE/auto transplant/maint therapy|
3324215|NCT00107588|Experimental|Reinforcement for homework completion|
3324216|NCT00107588|Active Comparator|Reinforcement for Abstinence|
3324217|NCT00107588|Active Comparator|Case Management|
3324218|NCT00107575|Active Comparator|Standard treatment (ST)|Standard smoking cessation treatment (ST)
3324219|NCT00107575|Experimental|ST-BI|Standard treatment plus a brief alcohol intervention
3324220|NCT00107562|Experimental|Intervention|The cohort will be comprised of up to 4 index participants and from 1-4 of their network members for a possible range of 8-16 subjects in each cohort (average of 12 per cohort). The vast majority of the intervention will be delivered to both females and males together, but it would be beneficial, and appropriate for this adolescent population, to deliver certain exercises with the two genders separated.
3324221|NCT00107549|Experimental|1|All participants in this study will receive two injections of the rMVA-HIV vaccine and the rFPV-HIV vaccine
3324222|NCT00107536|Experimental|Arm I|Patients receive oral lapatinib ditosylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324223|NCT00107510|Experimental|docetaxel + carboplatin + pegfilgrastim + surgery|"Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Patients also receive pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~No more than 6 weeks after completion of chemotherapy, patients undergo definitive surgery.~After completion of study therapy, patients are followed every 6 months until disease progression and then annually for up to 5 years. Patients who do not complete all 4 courses of chemotherapy or do not undergo surgery are followed every 6 months for up to 5 years."
3324224|NCT00107471|Experimental|Dose Level I (0.5 mg/m^2)|Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n)
3324225|NCT00107471|Experimental|Dose Level 2 (0.6 mg/m^2)|Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n.)
3324226|NCT00107458|Experimental|Treatment 1|VPA Target Trough Concentration 75-100 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid
3324227|NCT00107458|Experimental|Treatment 10|VPA Target Trough Concentration 100-150 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid
3324228|NCT00107458|Experimental|Treatment 20|VPA Target Trough Concentration 150-200 mcg/mL
3324229|NCT00107445|Experimental|Treatment (EF5)|Patients receive EF5 IV over 1-2½ hours on day 1. Approximately 1-2 days later, patients undergo tumor resection or biopsy. Patients' tumor tissue samples undergo immunohistochemistry and flow cytometry to detect EF5 binding levels. Patients' blood is drawn immediately before and 30-60 minutes and 1-2 days after receiving EF5 to measure systemic EF5 binding levels.
3324230|NCT00107432|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324231|NCT00107419|Experimental|pemetrexed|pemetrexed
3324329|NCT00106080|No Intervention|Control|Usual care
3324474|NCT00103935|Experimental|Group B|Exenatide lead-in followed by exenatide LAR 0.8 mg weekly
3324475|NCT00103935|Experimental|Group C|Exenatide lead-in followed by exenatide LAR 2.0 mg weekly
3324232|NCT00107380|Experimental|R-CHOP x 8 with I-131 Tositumomab|"Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 IV Day 1 Prednisone 100 mg PO Days 1-5 Rituximab 375 mg/m2 IV Day 1 Q 21 Days x 6 cycles~Unlabeled Anti-B1 Antibody 450 mg IV Day 170 Dosimetric dose 35 mg IV Day 170~Unlabeled Anti-B1 Antibody 450 mg IV Day 177 Therapeutic dose 35 mg IV Day 177"
3324233|NCT00107341|Experimental|bortezomib + paclitaxel + carboplatin|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, and 8 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years."
3324234|NCT00107315|Experimental|Arm 1|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral capecitabine twice daily on days 1-7
3324235|NCT00107289|Experimental|Radiation|
3324236|NCT00107276|Experimental|cyclophosphamide and capecitabine|cyclophosphamide orally days 1-14 and capecitabine orally days 15-21 for 8 cycles of 21 days each
3324237|NCT00107263|Experimental|Arm I: letrozole + zoledronate|"Patients receive oral letrozole once daily. Patients also receive zoledronate IV over 15 minutes once every 6 months.~Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity."
3324238|NCT00107263|Experimental|Arm II: letrozole + zoledronate|"Patients receive oral letrozole once daily. Patients with radiologic evidence of bone loss after 1 year of letrozole therapy receive zoledronate as in arm I.~Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity."
3324239|NCT00107237|Experimental|AEE788 200 mg + RAD001 5 mg|AEE788 200 mg qd, RAD001 5 mg qd
3324240|NCT00107237|Experimental|AEE788 150 mg + RAD001 5mg|AEE788 150 mg qd, RAD001 5 mg qod
3324241|NCT00107198|Experimental|Surgery or combination chemotherapy, with/without radiotherapy|"Patients receive doxorubicin hydrochloride 50 mg/m2 IV over 10-30 minutes and cyclophosphamide 800 mg/mg2 IV over 1 hour on day 1, vincristine sulfate 1.4 mg/m2 IV (2.8 mg maximum) over 1 minute on days 1 and 8, and prednisone 40 mg/m2/day PO or IV two or three times daily on days 1-7. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve CR after 3 courses of therapy proceed to follow-up. Patients who do not achieve a CR proceed to involved-field radiation therapy (IFRT).~IFRT: Beginning within 3 weeks after completion of combination chemotherapy, patients undergo IFRT once daily, 5 days a week for 2.8 weeks (14 treatments)."
3324242|NCT00107185|Experimental|Vaccine|
3324243|NCT00107172|Active Comparator|Arm I|Patients undergo open or thoracoscopic sublobar resection comprising either a wedge resection or anatomical segmentectomy.
3324244|NCT00107172|Experimental|Arm II|Patients undergo surgery as in arm I. Patients also undergo intraoperative brachytherapy comprising an iodine I 125 implant at the resection margin.
3324245|NCT00107120|Experimental|Escitalopram|Escitalopram 10mg once daily for three weeks, 10-20mg once daily for up to the remaining 5 weeks
3324246|NCT00107120|Placebo Comparator|2|Placebo once daily for up to 8 weeks
3324247|NCT00107107|Active Comparator|Pramlintide Acetate|Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
3324248|NCT00107081|Active Comparator|Standard|Continued inpatient i.v. antibiotics
3324249|NCT00107081|Experimental|Experimental|Switch to outpatient p.o. antibiotics
3324250|NCT00107042|Active Comparator|1|Participants receive doses of Recombivax at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.
3324251|NCT00107042|Experimental|2|Participants receive doses of Twinrix at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.
3324252|NCT00107016|Experimental|RAD001 + letrozole 2.5mg|
3324253|NCT00107016|Active Comparator|Letrozole 2.5mg|
3324254|NCT00106964|Active Comparator|1|Standard dose (20 mcg) of Hepatitis B vaccine.
3324255|NCT00106964|Active Comparator|2|40 mcg of Hepatitis B vaccine
3324256|NCT00106964|Active Comparator|3|20 mgc of Twinrix
3324257|NCT00106938|Active Comparator|1|"CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).~Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years."
3324258|NCT00106938|Active Comparator|2|"CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).~Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years."
3324259|NCT00106899||1|Mild Cognitive Impairment (MCI); scans performed at screening/baseline, 6, 12, 18, 24, and 36 months
3324260|NCT00106899||2|Early Alzheimer's disease (AD); scans performed at screening/baseline, 6, 12, and 24 months
3324261|NCT00106899||3|Unaffected/normal controls; scans performed at baseline/screening, 6, 12, 24, and 36 months
3324262|NCT00106782|Other|1|Real TEP
3324263|NCT00106782|Other|2|Sham Stimulation
3324264|NCT00106704|Experimental|Sitagliptin|Sitagliptin 10 mg tablet daily for 54 weeks
3324265|NCT00106704|Placebo Comparator|Placebo/ Pioglitazone|Placebo tablet daily for 24 weeks followed by Pioglitazone tablet daily for 30 weeks
3324266|NCT00106691|Experimental|toremifene 20mg|
3324267|NCT00106691|Placebo Comparator|Placebo|
3324268|NCT00106678||Infected through risk behaviors|
3324269|NCT00106678||Infected perinatally or through blood/blood products.|
3324270|NCT00106639|Experimental|CP-690,550 15 mg BID|
3324271|NCT00106639|Experimental|CP-690,550 30 mg BID|
3324272|NCT00106639|Active Comparator|tacrolimus|
3324273|NCT00106626|Experimental|1|vorinostat (Suberoylanilide Hydroxamic Acid [SAHA])
3324274|NCT00106613|Experimental|FK228 (romidepsin)|13 mg/m2 of romidepsin
3324275|NCT00106574|Experimental|1|
3324276|NCT00106574|Placebo Comparator|2|
3324277|NCT00106548|Experimental|1|
3324278|NCT00106548|Experimental|2|
3324279|NCT00106548|Placebo Comparator|3|
3324476|NCT00103922|Experimental|Arm 1|
3324280|NCT00106535|Experimental|Tocilizumab 4 mg/kg + Methotrexate|Tocilizumab 4 mg/kg IV every 4 weeks plus MTX 10-25 mg (oral or parenteral) weekly for 52 weeks. From Week 16 participants with < 20% improvement in swollen and tender joints counts were eligible for escape therapy with tocilizumab. After Week 52 participants were able to switch to open label treatment with tocilizumab 8 mg/kg every 4 weeks for 12 months in year 2 (except patients who had a >70% improvement in both swollen and tender joint counts who remained on blinded treatment). Participants who completed year 2 of the study were eligible to enter an optional open-label long-term extension period (Year 3 to 5) and received Tocilizumab 8 mg/kg every 4 weeks.
3324281|NCT00106535|Experimental|Tocilizumab 8 mg/kg + Methotrexate|Tocilizumab 8 mg/kg IV every 4 weeks plus MTX 10-25 mg (oral or parenteral) weekly for 52 weeks. From Week 16 participants with < 20% improvement in swollen and tender joints counts were eligible for escape therapy with tocilizumab. After Week 52 participants were able to switch to open label treatment with tocilizumab 8 mg/kg every 4 weeks for 12 months in year 2 (except patients who had a >70% improvement in both swollen and tender joint counts who remained on blinded treatment). Participants who completed year 2 of the study were eligible to enter an optional open-label long-term extension period (Year 3 to 5) and received Tocilizumab 8 mg/kg every 4 weeks.
3324282|NCT00106535|Placebo Comparator|Placebo + Methotrexate|Placebo intravenously (IV) every 4 weeks plus methotrexate (MTX) 10-25 mg (oral or parenteral) weekly for 52 weeks. From Week 16 participants with < 20% improvement in swollen and tender joints counts were eligible for escape therapy with tocilizumab. After Week 52 participants were able to switch to open label treatment with tocilizumab 8 mg/kg every 4 weeks for 12 months in year 2 (except patients who had a >70% improvement in both swollen and tender joint counts who remained on blinded treatment). Participants who completed year 2 of the study were eligible to enter an optional open-label long-term extension period (Year 3 to 5) and received Tocilizumab 8 mg/kg every 4 weeks.
3324283|NCT00106522|Experimental|1|
3324284|NCT00106522|Experimental|2|
3324285|NCT00106522|Placebo Comparator|3|
3324286|NCT00106496|Experimental|1A|
3324287|NCT00106496|Active Comparator|1B|
3324288|NCT00106496|Experimental|2|Open label
3324289|NCT00106496|Experimental|3A|
3324290|NCT00106496|Placebo Comparator|3B|
3324291|NCT00106496|Experimental|4|Open label
3324292|NCT00106483||Coronary Artery Risk Development in Young Adults|There were no interventions.
3324293|NCT00106418|Experimental|Romidepsin|13 mg/m^2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
3324294|NCT00106392|Experimental|Tacrolimus|Preoperatively: Tacrolimus 2 mg oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Tacrolimus 3 mg oral daily at time of hospital discharge through 6 months of follow up.
3324295|NCT00106392|Placebo Comparator|Placebo|Preoperatively: Matching placebo oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Matching placebo oral daily at time of hospital discharge through 6 months of follow up.
3324296|NCT00106353|Experimental|1.0|
3324297|NCT00106340|Experimental|Vildagliptin|
3324298|NCT00106340|Active Comparator|Glimepiride|
3324299|NCT00106327|Experimental|1|6-month supervised treadmill exercise program
3324300|NCT00106327|Experimental|2|6-month supervised lower extremity progressive resistance training program
3324301|NCT00106327|Active Comparator|3|Diet/nutrition control group
3324302|NCT00106301|Experimental|FK228 (romidepsin)|romidepsin
3324303|NCT00106288|Experimental|1|
3324304|NCT00106288|Active Comparator|2|
3324305|NCT00106249|Active Comparator|Active rTMS|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
3324306|NCT00106249|Sham Comparator|Sham rTMS|Placebo Repetitive Transcranial Magnetic Stimulation (rTMS)
3324307|NCT00106223|Experimental|1|Group receiving immediate treatment with cognitive behavioral therapy
3324308|NCT00106223|Active Comparator|2|Waitlist control group to begin CBT 3 months after other CBT group begins treatment
3324309|NCT00106210|Experimental|1|Behavioral Intervention (experimental)
3324310|NCT00106210|Active Comparator|2|Behavioral Intervention 2
3324311|NCT00106197|Experimental|1|Participants will receive bupropion in the sleep study
3324312|NCT00106184|Experimental|Adult Study Group 1|Refractory adult polymyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
3324313|NCT00106184|Experimental|Adult Study Group 2|Refractory adult polymyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
3324314|NCT00106184|Experimental|Adult Study Group 3|Adult dermatomyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
3324315|NCT00106184|Experimental|Adult Study Group 4|Adult dermatomyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
3324316|NCT00106184|Experimental|JDM Study Group 1|Refractory juvenile dermatomyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
3324317|NCT00106184|Experimental|JDM Study Group 2|Refractory juvenile dermatomyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
3324318|NCT00106171|Experimental|1|Participants will receive HAART for 1 year
3324319|NCT00106171|No Intervention|2|Participants will receive no treatment
3324320|NCT00106145|Experimental|Part I - Arm 1|
3324321|NCT00106145|Experimental|Part II - Arm 1|
3324322|NCT00106145|Experimental|Part III - Arm 1|
3324323|NCT00106145|Experimental|Part IV - Arm 1|
3324324|NCT00106145|Experimental|Part V - Arm 1|
3324325|NCT00106119|Active Comparator|Liothyronine and Levothyroxine|Hypothyroid patients treatment with Levothyroxine and Liothyronine in 2 crossover, randomized phases
3324326|NCT00106106|Placebo Comparator|Placebo|For subjects randomized to placebo control, placebo doses were given every 8 hours.
3324327|NCT00106106|Experimental|Acamprosate|For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
3324328|NCT00106080|Experimental|Intervention|Audit and Feedback
3324330|NCT00106067|Experimental|Arm 1|In the intervention arm, Patients and their family caregivers have access to a coping and communication support practitioner (CCSP) (see intervention description) in addition to receiving the usual care in the site.
3324331|NCT00106067|No Intervention|Arm 2|In the control arm, Patients are receiving the usual care in the site.
3324332|NCT00106041|Other|Arm 1|Palliative Care Nurse Case Management
3324333|NCT00106028|Placebo Comparator|Placebo Daily|placebo tablet, once a day for one year then for two years open label risedronate
3324334|NCT00106028|Experimental|Risedronate Daily|risedronate tablet, once a day for one year then for two years open label risedronate once a day
3324335|NCT00106002|Experimental|A|
3324336|NCT00105989|Experimental|A|duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks
3324337|NCT00105989|Placebo Comparator|B|duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks
3324338|NCT00105950|Experimental|Lapatinib|Single arm study of lapatinib with no comparator arm.
3324339|NCT00105911|Other|Arm 1|
3324340|NCT00105898|Experimental|Arm 1|Intervention group
3324341|NCT00105898|Active Comparator|Arm 2|Comparator
3324342|NCT00105898|Sham Comparator|Arm 3|Comparator
3324343|NCT00105885|Experimental|Arm 1|Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinical visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval.
3324344|NCT00105885|No Intervention|Arm 2|Patients randomized to receive routine care will be scheduled to see their psychiatric medication provider at the recommended interval.
3324345|NCT00105872|Other|Arm 1|
3324346|NCT00105859|Other|1|
3324347|NCT00105846|Other|Arm 1|
3324348|NCT00105833|Experimental|Arm 1|Multifaceted collaborative intervention for depression based in primary care
3324349|NCT00105833|No Intervention|Arm 2|Treatment as usual
3324350|NCT00105820|Other|Arm 1|
3324351|NCT00105807|Other|Arm 1|
3324352|NCT00105794|Other|Arm 1|
3324353|NCT00105781|Other|Arm 1|
3324354|NCT00105768|Other|Arm 1|
3324355|NCT00105755|Other|Arm 1|
3324356|NCT00105742|Other|Arm 1|
3324357|NCT00105729|Other|Arm 1|
3324358|NCT00105716|Other|Arm 1|
3324359|NCT00105703|Other|Arm 1|
3324360|NCT00105690|Other|Arm 1|
3324361|NCT00105677||Group 1|
3324362|NCT00105664|Other|Arm 1|
3324363|NCT00105651|Other|Arm 1|
3324364|NCT00105638|Other|Arm 1|
3324365|NCT00105625||Group 1|
3324366|NCT00105599|Other|Arm 1|
3324367|NCT00105586|Experimental|Escitalopram (1)|Escitalopram
3324368|NCT00105586|Placebo Comparator|Placebo (2)|Placebo
3324369|NCT00105573|Experimental|Interpersonal Psychotherapy|Participants will receive interpersonal psychotherapy for depression.
3324370|NCT00105573|Experimental|Interpersonal psychotherapy/child-parent psychotherapy|Participants will receive interpersonal psychotherapy for depression plus 1 year of in-home, child-parent psychotherapy.
3324371|NCT00105573|Active Comparator|Enhanced community standard|Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
3324372|NCT00105560|Experimental|Radiation therapy|This is a single arm study of radiation therapy with protons to standard doses.
3324373|NCT00105547|Experimental|1|800 mg BID
3324374|NCT00105547|Placebo Comparator|2|BID dosing
3324375|NCT00105534|Experimental|AzaSite|
3324376|NCT00105534|Sham Comparator|Vehicle|
3324377|NCT00105521|Placebo Comparator|Placebo|Participants will receive placebo matched to sarizotan tablet orally twice daily up to Week 12.
3324378|NCT00105521|Experimental|Sarizotan 2 milligrams per day (mg/day)|Participants will receive sarizotan 2 milligrams (mg) per day (given in 2 divided daily doses) up to Week 12.
3324379|NCT00105521|Experimental|Sarizotan 4 mg/day|Participants will receive sarizotan 4 mg/day (given in 2 divided daily doses) up to Week 12.
3324380|NCT00105521|Experimental|Sarizotan 10 mg/day|Participants will receive sarizotan 10 mg/day (given in 2 divided daily doses) up to Week 12.
3324381|NCT00105508|Experimental|Sarizotan|
3324382|NCT00105508|Placebo Comparator|Placebo|
3324383|NCT00105482|Experimental|Naltrexone, Transdermal Nicotine|Arm 1 (Experimental) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Naltrexone 25 mg oral capsule once per day
3324384|NCT00105482|Placebo Comparator|Placebo Naltrexone, Transdermal Nicotine|Arm 2 (Placebo Comparator) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Placebo Naltrexone 25 mg oral capsule once per day
3324385|NCT00105469|Experimental|AzaSite|1.0% azithromycin in DuraSite
3324386|NCT00105469|Active Comparator|Tobramycin|0.3% tobramycin
3324387|NCT00105443|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.
3324388|NCT00105443|Placebo Comparator|Placebo|Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.
3324389|NCT00105365|Placebo Comparator|walking shoes|walking shoes
3324390|NCT00105365|Experimental|walking shoes + shoe insert|walking shoes + shoe insert
3324430|NCT00104845|Experimental|mouse gp100 DNA vaccine|Patients receive mouse gp100 DNA vaccine IM once in weeks 1, 4, and 7. Patients then receive human gp100 DNA vaccine IM once in weeks 10, 13, and 16
3324431|NCT00104767|Experimental|celecoxib|
3324626|NCT00101894|Experimental|100 mg QD AMG 706 + FOLFOX-4|100 mg QD AMG 706 + FOLFOX-4
3324796|NCT00099008|Placebo Comparator|Arm II|Placebo
3324391|NCT00105339||Illustration Style Preference Group|Ten participants at each site will be invited to attend a focus group to determine their comfort with and preference for one of four styles of illustration. The same two concepts will be presented in each of the four styles and ratings will be obtained from all participants. Detailed information on why participants rated each of the styles the way they did will also be obtained by reviewing comments on the rating sheets and audiotapes of the groups. Groups will be run by the study coordinator at the Florida and New York sites, and by Dannie Hoffman, protocol coordinator, in Los Angeles, using a focus group script developed by Dr. Murphy.
3324392|NCT00105339||Review of Draft Focus Group|Lori Perez will travel to each site from Westat and conduct Review of Draft Focus Groups with adolescents and young adults (n per site = approximately 10 - 15) to collect final feedback on the adolescent friendly version (present key pieces of the adolescent friendly version and obtain feedback on the wording and the illustrations). Based on the focus group feedback, the research team will finalize the adolescent friendly materials.
3324393|NCT00105339||Comprehension/Recall Assessment|The assessment will be read to the participants to preclude reading problems. Responses will be recorded by the interviewer on the assessment instrument.
3324394|NCT00105235|Experimental|Alemtuzumab|Liver transplant, with two in-patient infused doses of alemtuzumab; followed by maintenance immunotherapy with cyclosporine, mycophenolate mofetil, and/or tacrolimus; with possible immunosuppression withdrawal
3324395|NCT00105196|Experimental|A1|
3324396|NCT00105196|Placebo Comparator|A2|
3324397|NCT00105183|Active Comparator|EZ-2053|Anti-human-T-lymphocyte Immune Globulin, Rabbit (EZ-2053)
3324398|NCT00105183|Placebo Comparator|Placebo|USP 0.9% sodium chloride solution
3324399|NCT00105183|Active Comparator|EZ-2053 5mg/kg|Anti-human-T-Lymphocyte Immune Globulin, Rabbit
3324400|NCT00105157|Experimental|1|MK0518 200 mg
3324401|NCT00105157|Experimental|2|MK0518 400 mg
3324402|NCT00105157|Experimental|3|MK0518 600 mg
3324403|NCT00105157|Placebo Comparator|4|Placebo
3324404|NCT00105144|Experimental|1|lower dose
3324405|NCT00105144|Experimental|2|higher dose
3324406|NCT00105144|Active Comparator|3|
3324407|NCT00105079|Experimental|saquinavir/ritonavir|saquinavir mesylate 1000 mg twice daily (BID) + ritonavir 100 mg BID + emtricitabine/tenofovir disoproxil fumarate 200/300 mg orally every day for 48 weeks.
3324408|NCT00105079|Active Comparator|lopinavir/ritonavir|lopinavir/ritonavir 400/100 mg BID + emtricitabine/tenofovir disoproxil fumarate 200/300 mg orally every day for 48 weeks.
3324409|NCT00105066|Placebo Comparator|Placebo|placebo
3324410|NCT00105066|Experimental|Metformin|Metformin 850 mg twice daily
3324411|NCT00105053|Experimental|vaccine group|
3324412|NCT00105040|Experimental|Levetiracetam (LEV)|Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
3324413|NCT00105040|Placebo Comparator|Matching Placebo (PBO)|Oral tablets and oral solution.
3324414|NCT00105027|Active Comparator|CRVO Observation|
3324415|NCT00105027|Active Comparator|CRVO 1 mg dose triamcinolone acetonide|
3324416|NCT00105027|Active Comparator|CRVO 4 mg dose triamcinolone acetonide|
3324417|NCT00105027|Active Comparator|BRVO standard care|
3324418|NCT00105027|Active Comparator|BRVO 1 mg dose triamcinolone acetonide|
3324419|NCT00105027|Active Comparator|BRVO 4 mg dose triamcinolone acetonide|
3324420|NCT00105001|Active Comparator|Arm I (MMF and tacrolimus)|Patients receive tacrolimus IV or PO every 12 hours on days -3 to 180 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-96 with taper beginning on day 40 in the absence of GVHD.
3324421|NCT00105001|Experimental|Arm II (MMF and tacrolimus alternate schedule)|Patients receive tacrolimus IV or PO every 12 hours on days -3 to 150 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-180 with taper beginning on day 150 in the absence of GVHD.
3324422|NCT00105001|Experimental|Arm III (MMF, tacrolimus, and sirolimus)|Patients receive tacrolimus and MMF as in arm II. Patients also receive sirolimus PO once daily on days -3 to 80.
3324423|NCT00104988|Experimental|Thalidomide and Temozolomide|Patients receive oral thalidomide once daily on days 1-56 and temozolomide once daily on days 1-42. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
3324424|NCT00104962|Experimental|Treatment (lenalidomide)|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3324425|NCT00104910|Experimental|Treatment (brachytherapy, radiation, cetuximab, cisplatin)|Patients receive cetuximab IV over 1-2 hours and cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6). Patients also undergo external beam radiotherapy to the para-aortic and pelvic lymph nodes OR whole pelvis once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33 (weeks 1-5). Patients then receive either 1 or 2 applications of low-dose rate brachytherapy in weeks 6-8 OR 5 applications of high-dose rate (HDR)* brachytherapy once weekly in weeks 4-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
3324426|NCT00104884|Experimental|Depsipeptide|Depsipeptide is administered as a 4-hour IV infusion weekly in doses of 13 mg/m^2 for 3 weeks. Repeat cycle every 28 days until unacceptable toxicity or disease progression.
3324427|NCT00104871|Experimental|Bortezomib|Bortezomib 1.3 mg/m^2 intravenous (IV) at over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for at least 4 courses.
3324428|NCT00104858|Experimental|Treatment (chemotherapy and rituximab followed by HCT)|"Patients receive a conditioning regimen comprising fludarabine IV on days -4 to -2 and rituximab IV on days -3, 10, 24, and 38.~Patients undergo single fraction low-dose TBI on day 0. After completion of TBI, patients undergo allogeneic hematopoietic stem cell transplantation on day 0. Patients then receive rituximab IV on days 10, 24, and 38.~Patients receive an immunosuppressive regimen comprising cyclosporine PO BID on days -3 to 56 followed by a taper to day 180 (related recipients) or on days -3 to 100 followed by a taper to day 180 (unrelated recipients). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related recipients) or TID on days 0-40 followed by a taper to day 96 (unrelated recipients)."
3324429|NCT00104845|Experimental|human gp100 DNA vaccine|Patients receive human gp100 DNA vaccine intramuscularly (IM) once in weeks 1, 4, and 7. Patients then receive mouse gp100 DNA vaccine IM once in weeks 10, 13, and 16.
3324432|NCT00104754|Experimental|liposomal SN-38|"Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete or partial response or patients with stable disease (SD) who were previously treated before study enrollment receive up to 4 additional courses of treatment. Patients with CNS-only disease progression receive whole brain radiotherapy (WBRT). After completion of WBRT, these patients also receive up to 4 additional courses of treatment. Patients with disease progression to sites other than the CNS or patients with SD who were previously untreated before study enrollment are removed from the study.~Quality of life is assessed at baseline, before each treatment course, and then annually for 3 years.~After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 2 years."
3324433|NCT00104728|Experimental|Neoadjuvant ZD1839 Preoperative Therapy|"The ZD1839 250-mg tablet will be taken once a day, every day about the same time. It can be taken with or without food.~At the time of surgery, investigators will collect tissue from the participant's tumor once it has been removed. This tissue will be used to study the effect of ZD1839 on tumor growth."
3324434|NCT00104702|Experimental|Concentrated and Focalized Radiotherapy|
3324435|NCT00104676|Active Comparator|Arm I|Patients receive 4 courses of bleomycin, etoposide, and cisplatin (BEP).
3324436|NCT00104676|Experimental|Arm II|Patients receive 1 course of bleomycin, etoposide, and cisplatin (BEP). Patients then receive dose-dense sequential combination chemotherapy comprising cisplatin, etoposide, bleomycin, paclitaxel, oxaliplatin, and ifosfamide.
3324437|NCT00104650|Active Comparator|IV Bisphosphonates q 4 weeks|This is an open-label randomization to receive IV bisphosphonate (administered per package insert) every 4 weeks during the treatment phase. If subjects are enrolled into the extension phase, they will receive AMG 162 180mg (SC) every 4 weeks.
3324438|NCT00104650|Experimental|180 mg AMG 162 (SC) q 12 weeks|This is an open-label randomization to receive 180 mg AMG 162 (SC) every 12 weeks during the treatment phase. If subjects are enrolled into the extension phase, they will continue to receive 180 mg AMG 162 (SC) every 12 weeks.
3324439|NCT00104650|Experimental|180 mg AMG 162 (SC) q 4 weeks|This is an open-label randomization to receive 180 mg AMG 162 (SC) every 4 weeks during the treatment phase. If subject is enrolled into the extension phase, they will continue to receive 180 mg AMG 162 (SC) every 4 weeks.
3324440|NCT00104637|Active Comparator|Sildenafil / Placebo|Sildenafil first, followed by washout, followed by placebo
3324441|NCT00104637|Placebo Comparator|Placebo / Sildenafil|Placebo first, followed by washout, followed by Sildenafil
3324442|NCT00104611|Active Comparator|TMS|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 6 weeks
3324443|NCT00104611|Placebo Comparator|Placebo|Treatment 5 days/week for up to 6 weeks
3324444|NCT00104598|Active Comparator|Gain Framed Absitnence Program|Gain framed video and printed messages encouraging smoking abstinence with Bupropion.
3324445|NCT00104598|Active Comparator|Loss Framed Abstinence Program|Loss framed video and printed messages encouraging smoking abstinence with Bupropion.
3324446|NCT00104585||1|People with young onset Parkinson's disease and their family members
3324447|NCT00104572|Experimental|1|17 participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months
3324448|NCT00104572|Experimental|2|14 participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months
3324449|NCT00104572|Placebo Comparator|3|13 participants will receive a placebo tablet and placebo gel daily for 12 months
3324450|NCT00104559|Experimental|1|Participants will receive the computer-based tutorial for VT and then the standard paper consent form for AT
3324451|NCT00104559|Experimental|2|Participants will receive the standard paper consent form for VT and then the computer-based tutorial for AT
3324452|NCT00104559|Experimental|3|Participants will receive the computer-based tutorial for AT and then the standard paper consent form for VT
3324453|NCT00104559|Experimental|4|Participants will receive the standard paper consent form for AT and then the computer-based tutorial for VT
3324454|NCT00104520|Placebo Comparator|Placebo (pooled two times a day [BID]/three times a day [TID])|
3324455|NCT00104520|Experimental|AZLI (pooled two times a day [BID]/three times a day [TID])|
3324456|NCT00104494|Experimental|1|CF, Zinc acetate
3324457|NCT00104494|Experimental|2|CF, Placebo
3324458|NCT00104494|No Intervention|3|Controls
3324459|NCT00104416|Placebo Comparator|Placebo|
3324460|NCT00104416|Experimental|lamotrigine (LAMICTAL) extended-relesase|
3324461|NCT00104312||1|Participants with symptomatic knee osteoarthritis
3324462|NCT00104312||2|Participants without symptomatic knee osteoarthritis, age-matched as controls
3324463|NCT00104299|Experimental|Rituximab|
3324464|NCT00104299|Active Comparator|Control Group|
3324465|NCT00104234|Other|rhASB/rhASB|N-acetylgalactosamine 4-sulfatase
3324466|NCT00104234|Other|Placebo/rhASB|
3324467|NCT00104104|Experimental|15 Minute Infusion|Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 15-minute infusion time, but increasing to a 30-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12 weeks
3324468|NCT00104104|Experimental|30 Minute Infusion|Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 30-minute infusion time, but increasing to a 45-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12-weeks.
3324469|NCT00104091|Experimental|1|40 mL of TP-38 at a 100 nanograms/mL concentration
3324470|NCT00104052|Experimental|PEG-Intron alfa 2b (PEG2b) plus REBETOL (RBV)|PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) and RBV 400-1200 mg/day by mouth divided in 2 daily doses (administered twice daily with food, dosed 12 hours apart) for 48 weeks. Subjects treated up to 48 weeks and followed for additional 24 weeks after the end of treatment (total of 72 weeks study participation).
3324471|NCT00103961||1|Treatment-naive and treatment-experienced HIV-infected adults
3324472|NCT00103935|Placebo Comparator|Group A1|Placebo lead-in followed by placebo equivalent volume to 0.8 mg exenatide LAR
3324473|NCT00103935|Placebo Comparator|Group A2|Placebo lead-in followed by placebo equivalent volume to 2.0 mg exenatide LAR
3324477|NCT00103896||HIV Infected Youth in Treatment/Care|HIV infected youth in treatment/care will be interviewed using Audio Computer-Assisted Self-Administered Interview ACASI technology to reveal possible venues where youth at high risk for acquiring the disease may be found (N = 20-30 individuals per ATN site).
3324478|NCT00103896||BVI Individuals|Additional data will be gathered on potential recruitment venues by administering a brief venue interview (BVI) to individuals who appear to be between 12 and 24 years old (N = unlimited individuals during 3-5 assessment periods per venue each lasting 5 hours).
3324479|NCT00103896||HIV Serosurvey Individuals|HIV Serosurvey Individuals Anonymous structured interview using ACASI technology and an anonymous HIV antibody assay will be administered to 20-30 young women at 2-3 targeted locations and 20-30 young men at 2-3 targeted locations whose HIV status is unknown (N = 160-360 individuals per ATN site)..
3324480|NCT00103883||HIV Infected Teens -ATN Clinical Sites|HIV infected teens who are referred to or engaged in care at any of the 15 ATN clinical sites during the course of the study.
3324481|NCT00103883||HIV Positive - ATN Clinical Sites|Youth who test HIV positive at ATN-managed or ATN-affiliated HIV Counseling and Testing Sites (CTS) during the course of the study.
3324482|NCT00103883||HIV Positive - BCHD STD Clinic|Youth who test HIV positive at the BCHD STD Clinic during the course of the study.
3324483|NCT00103857|Experimental|1|MK0431 100 mg q.d.
3324484|NCT00103857|Active Comparator|2|Metformin 500 mg b.i.d.
3324485|NCT00103857|Active Comparator|3|Metformin 1000 mg b.i.d.
3324486|NCT00103857|Experimental|4|Coadministration of MK0431 and Metformin 50/500 mg b.i.d.
3324487|NCT00103857|Experimental|5|Coadministration of MK0431 and Metformin 50/1000 mg b.i.d.
3324488|NCT00103857|Placebo Comparator|6|Placebo/Metformin 1000 mg b.i.d.
3324489|NCT00103857|Experimental|7|Non-Randomized, Open-Label: Coadministration MK0431 and Metformin 50/1000 mg b.i.d.
3324490|NCT00103844|Experimental|1|Active Comparator
3324491|NCT00103844|Experimental|2|Active Comparator
3324492|NCT00103792|Experimental|1|mycophenolate and steroids as remission induction, followed by azathioprine maintenance therapy
3324493|NCT00103792|Active Comparator|2|cyclophosphamide
3324494|NCT00103779|Experimental|1|
3324495|NCT00103740|Experimental|Zoledronic acid and placebo to risedronate|Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
3324496|NCT00103740|Active Comparator|Risedronate and placebo to zoledronic acid|Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
3324497|NCT00103727|Experimental|talnetant|200mg, 400mg, 600mg) twice a day
3324498|NCT00103727|Placebo Comparator|placebo|placebo
3324499|NCT00103727|Active Comparator|risperidone|3mg twice a day
3324500|NCT00103701|Experimental|1|
3324501|NCT00103662|Experimental|G-CSF plus plerixafor|
3324502|NCT00103662|Placebo Comparator|G-CSF plus placebo|
3324503|NCT00103610|Experimental|G-CSF plus plerixafor|
3324504|NCT00103610|Placebo Comparator|G-CSF plus placebo|
3324505|NCT00103532|Experimental|Healthy Choices - Motivational Enhancement Intervention|Motivational enhancement intervention
3324506|NCT00103532|Active Comparator|Standard Care|Standard care/individualized referrals
3324507|NCT00103519|Experimental|DITPA 180 mg/day|DITPA 180 mg/day BID
3324508|NCT00103519|Experimental|DITPA 360 mg/day|DITPA 360 mg/day BID
3324509|NCT00103519|Placebo Comparator|Placebo|Placebo BID
3324510|NCT00103506|Active Comparator|VELCADE (bortezomib) monotherapy|Bortezomib (VELCADE) 1.3 milligram per meter square (mg/m^2) by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
3324511|NCT00103506|Experimental|DOXIL/CAELYX in combination with VELCADE (bortezomib)|Bortezomib (VELCADE) 1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
3324512|NCT00103454|Experimental|Arm 1|
3324513|NCT00103389|Active Comparator|docetaxel|treated with docetaxel alone
3324514|NCT00103389|Experimental|PI-88+docetaxel|treated with docetaxel and PI-88
3324515|NCT00103337|Experimental|Arm I (500 mg cilengitide)|Patients receive lower dose cilengitide IV over 1 hour twice a week for 6 weeks.
3324516|NCT00103337|Experimental|Arm II (2000 mg cilengitide)|Patients receive higher dose cilengitide IV over 1 hour twice a week for 6 weeks.
3324517|NCT00103324|Experimental|Treatment|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324518|NCT00103311|Experimental|Arm I|Patients receive SB-715992 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324519|NCT00103311|Experimental|Arm II|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3324520|NCT00103285|Experimental|Group 0 Induction Therapy|All patients receive cytarabine intrathecally (IT) on day 1; vincristine IV on days 1, 8, 15, and 22; dexamethasone IV or orally (PO) twice daily (BID) on days 1-28; pegaspargase intramuscularly (IM) (may give IV over 1 to 2 hours) on day 4, 5, or 6; and methotrexate IT on days 8 and 29 (and days 15 and 22 for patients with CNS3 disease). Patients with Down syndrome (DS) receive leucovorin calcium PO at 48 and 60 hours after each dose of methotrexate IT. Patients are assessed for response on day 29. Patients with M1 bone marrow AND minimal residual disease (MRD) < 0.1% OR MRD >= 0.1% and < 1% proceed to therapy in part II. Patients with M2 bone marrow OR M1 bone marrow AND MRD >= 1% proceed to extended induction therapy. Patients with M3 bone marrow are removed from the study.
3324535|NCT00103181|Experimental|Group 2: PBI|Patients undergo partial-breast irradiation (PBI) twice daily on 5 days over a period of 5-10 days. This may be delivered by intracavitary brachytherapy, MammoSite or other single-entry intracavitary device, or 3-dimensional conformal accelerated partial breast irradiation.
3324521|NCT00103285|Active Comparator|Group 1-SR-low ALL, Arm I-combination chemotherapy|Patients receive standard consolidation therapy (vincristine sulfate, mercaptopurine and methotrexate. Patients with Down syndrome (DS) receive leucovorin calcium), standard interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine and methotrexate. Patients with DS receive leucovorin calcium), and standard delayed intensification (DI) therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and methotrexate. Patients with DS receive dexamethasone, leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
3324522|NCT00103285|Experimental|Group 1-SR-low ALL, Arm II-combination chemotherapy|Patients receive experimental consolidation therapy (vincristine sulfate, mercaptopurine, MTX, leucovorin calcium and pegaspargase), experimental interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine, MTX and pegaspargase), and standard DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and MTX), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
3324523|NCT00103285|Active Comparator|Group 2-SR-avg ALL, Arm I-combination chemotherapy|Patients receive standard consolidation therapy (vincristine sulfate, mercaptopurine and methotrexate. Patients with Down syndrome (DS) receive leucovorin calcium), standard interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine and methotrexate. Patients with DS receive leucovorin calcium), and standard delayed intensification (DI) therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and methotrexate. Patients with DS receive dexamethasone, leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
3324524|NCT00103285|Experimental|Group 2-SR-avg ALL, Arm II-combination chemotherapy|Patients receive standard consolidation therapy (vincristine sulfate, mercaptopurine and MTX. Patients with Down syndrome (DS) receive leucovorin calcium), augmented interim maintenance therapy (vincristine sulfate, MTX and pegaspargase. Patients with DS receive leucovorin calcium), augmented DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine, MTX. Patients with DS receive dexamethasone and leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
3324525|NCT00103285|Active Comparator|Group 2-SR-avg ALL, Arm III-combination chemotherapy|Patients receive intensified consolidation therapy (cyclophosphamide, cytarabine, mercaptopurine and vincristine sulfate, pegaspargase, MTX. Patients with DS receive oral leucovorin calcium), standard interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine and MTX. Patients with DS receive leucovorin calcium), and standard DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and MTX. Patients with DS receive dexamethasone, leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
3324526|NCT00103285|Experimental|Group 2-SR-avg ALL, Arm IV-combination chemotherapy|Patients receive intensified consolidation therapy (cyclophosphamide, cytarabine, mercaptopurine and vincristine sulfate, pegaspargase, MTX. Patients with DS receive oral leucovorin calcium), augmented interim maintenance therapy (vincristine sulfate, MTX and pegaspargase. Patients with DS receive leucovorin calcium), and augmented DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine, MTX. Patients with DS receive dexamethasone and leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
3324527|NCT00103285|Experimental|Group 3-SR-high ALL, combination chemotherapy|Patients receive intensified consolidation therapy (cyclophosphamide, cytarabine, mercaptopurine and vincristine sulfate, pegaspargase, methotrexate. Patients with DS receive oral leucovorin calcium), augmented interim maintenance therapy (2 courses - vincristine sulfate, methotrexate and pegaspargase. Patients with DS receive leucovorin calcium), and augmented DI therapy (2 courses - vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine, methotrexate. Patients with DS receive dexamethasone and leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
3324528|NCT00103272|Experimental|Treatment (17-AAG and bortezomib)|"Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1-6 hours on days 1, 4, 8, and 11 and bortezomib IV over 3-5 seconds on days 4, 8, and 11 of course 1 and on days 1, 4, 8, and 11 of all subsequent courses.~Treatment repeats every 21 days for 3-12 courses provided patient is receiving clinical benefit. Patients achieving objective response may discontinue therapy to undergo stem cell transplantation."
3324529|NCT00103259|Experimental|Arm I (bortezomib, irinotecan hydrochloride)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and irinotecan IV over 90 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
3324530|NCT00103259|Experimental|Arm II (bortezomib)|Patients receive bortezomib as in arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may cross over to arm I.
3324531|NCT00103220|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324532|NCT00103207|Experimental|Cetuximab|Cetuximab was given as a weekly intravenous (IV) infusion (over 60 minutes) at 250 mg/m2 from week 2 onwards after an initial loading dose of 400 mg/m2 (over 120 minutes) on week 1 until disease progression or unacceptable toxicity. The infusion rate of cetuximab could not exceed 5 mL/min. Each cycle will be 28 days in length. To prevent a hypersensitivity reaction, all patients were premedicated with diphenhydramine hydrochloride 50 mg (or an equivalent antihistamine) by IV (over 30-60 minutes) prior to the first dose of cetuximab. Premedication might be administered prior to subsequent doses, but at the investigator's discretion, the dose of diphenhydramine (or a similar agent) was reduced.
3324533|NCT00103194|Experimental|Treatment (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324534|NCT00103181|Active Comparator|Group 1: WBI|Patients undergo whole breast irradiation (WBI) once daily, 5 days a week for 5-7 weeks.
3324536|NCT00103168|Experimental|Imatinib mesylate|400 mg/day for 2 years
3324537|NCT00103168|No Intervention|Control|
3324850|NCT00098111|Active Comparator|Azathioprine 0.5 mg/kg body weight|
3324538|NCT00103142|Experimental|PANVAC-V + PANVAC-F + DC|Patients undergo leukapheresis to obtain leukocytes for generation of autologous dendritic cells (DC). Patients then receive autologous DC loaded with vaccinia-CEA-MUC-1-TRICOM (PANVAC-V) vaccine subcutaneously (SC) and intradermally (ID) on day 1 and autologous DC loaded with fowlpox-CEA-MUC-1-TRICOM (PANVAC-F) vaccine SC and ID on days 28, 56, and 84.
3324539|NCT00103142|Experimental|PANVAC-V + PANVAC-F + GM-CSF|Patients receive PANVAC-V SC on day 1 and PANVAC-F SC on days 28, 56, and 84. Patients also receive sargramostim (GM-CSF) SC into the same injection site once daily on days 0-3, 28-31, 56-59, and 84-87.
3324540|NCT00103116|Experimental|Autologous dendritic cell cancer vaccine|Open label nonrandomized
3324541|NCT00103090|Experimental|Fenretinide + Lonafarnib|Lonafarnib daily for 21 days each cycle and with Fenretinide daily on days 1-7 only. On day 1 of cycle 1, Fenretinide only then beginning Lonafarnib on day 2 of cycle 1.
3324542|NCT00103038|Experimental|Diagnostic (ferumoxytol, gadolinium, DCE-MRI, DSC-MRI)|Patients receive ferumoxytol non-stoichiometric magnetite IV beginning approximately 15 seconds after start of 3T DSC-MRI and GBCA IV approximately 1 minute and 50 seconds after start of 3T DCE-MRI on day 1. Patients also undergo MRI without contrast at baseline and on day 2. Imaging with ferumoxytol, GBCA and without contrast repeats every 3 weeks for a total of 6 more imaging sessions over up to 5 years.
3324543|NCT00103012|Experimental|Effect of G. Biloba on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Ginkgo Biloba).
3324544|NCT00103012|Experimental|Effect of Echinacea on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Echinacea purpurea).
3324545|NCT00103012|Experimental|Effect of P. ginseng on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Panax ginseng).
3324546|NCT00102973|Experimental|TLK286 in Combination with Carboplatin|
3324547|NCT00102973|Active Comparator|Doxorubisin HCl Liposome Injection|
3324548|NCT00102960|Experimental|1A|For participants with a CD4 count of at least 25%, ART deferred until necessary
3324549|NCT00102960|Experimental|2A|For participants with a CD4 count of at least 25%, receive 40 weeks of ART until first birthday
3324550|NCT00102960|Experimental|3A|For participants with a CD4 count of at least 25%, receive ART for 96 weeks until second birthday
3324551|NCT00102960|Experimental|1B|For participants with a CD4 count less than 25%, receive continuous ART
3324552|NCT00102934|Experimental|1|Participants will receive enfuvirtide for 6 months
3324553|NCT00102908|Experimental|1|Participants will receive zoledronate at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis
3324554|NCT00102908|Placebo Comparator|2|Participants will receive zoledronate placebo at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis
3324555|NCT00102804|Experimental|Pemetrexed and Best Supportive Care|
3324556|NCT00102804|Placebo Comparator|Placebo and Best Supportive Care|
3324557|NCT00102726|Active Comparator|Arm 1|SB-497115-GR 50mg. administered orally daily on days 2 through 11 for each 21-day cycle.
3324558|NCT00102726|Active Comparator|Arm 2|SB-497115-GR 75 mg administered orally dailey on days 2-11 of each 21-day cycle.
3324559|NCT00102726|Active Comparator|Arm 3|SB-497115 100mg administered orally daily on days 2 through 11 of each 21-day cycle.
3324560|NCT00102726|Placebo Comparator|Placebo Arm|Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
3324561|NCT00102687|Experimental|Aza-5|Azacitidine administered subcutaneously at 75mg/m^2 for 5 days on a 28 day cycle.
3324562|NCT00102687|Experimental|Aza-5-2-2|Azacitidine administered subcutaneously at 75mg/m^2 for 5days with 2 days off, then for an additional 2 days, on a 28 day cycle.
3324563|NCT00102687|Experimental|Aza-5-2-5|Azacitidine administered subcutaneously at 50mg/m^2 for 5 days with 2 days off, then for an additional 5 days, on a 28 day cycle.
3324564|NCT00102687|Experimental|Maintenance Aza 5 days q 4 weeks|Azacitidine administered subcutaneously at 75mg/m^2 for 5 days every 4 weeks.
3324565|NCT00102687|Experimental|Maintenance Aza 5 days q 6 weeks|Azacitidine administered subcutaneously at 75mg/m^2 for 5 days every 6 weeks.
3324566|NCT00102661|Experimental|CAMPATH-1H|15 mg infused daily for continuous infusion x 7 days; starting day 10, CAMPATH-1H 30 mg subcutaneously three times weekly for 11 additional weeks.
3324567|NCT00102648|Experimental|Sarasar + Temodar|"Sarasar Starting Dose: 100 mg by mouth twice a day, with water, for 7 consecutive days (Days 8-14 and Days 22-28). Cycle is 28 days.~Temodar 150 mg/m^2 by mouth once a day, after fasting one hour, for 7 consecutive days (Days 1-7 and Days 15-21). Cycle is 28 days."
3324568|NCT00102635|Experimental|4-HPR + FTI|SCH66336 daily for 21 days each cycle and with 4-HPR daily on days 1-7 only. On day 1 of cycle 1, 4-HPR only beginning SCH66336 on day 2 of cycle 1.
3324569|NCT00102622|Experimental|Arm 1: Paclitaxel + tgDCC-E1A|80 mg/m^2 intravenous Paclitaxel and intraperitoneal (IP) tgDCC-E1A starting dose 1.8 mg DNA/m^2 weekly for six treatments every 7 days.
3324570|NCT00102622|Active Comparator|Arm 2: Paclitaxel Alone|Weekly single agent intravenous Paclitaxel 80 mg/m^2 for six treatments every 7 days.
3324571|NCT00102609|Experimental|Trabectedin and doxorubicin|Doxorubicin (50 to 75 mg/m2) administered intravenously on Day 1 followed by trabectedin (0.9 to 1.3 mg/m2) administered intravenously on Day 1 every 3 weeks for up to 6 cycles. Dexamethasone 20 mg administered intravenously will be given within 1 hour before the start of doxorubicin. Patients may receive filgrastim for unmanageable neutropenia.
3324572|NCT00102544|Experimental|prostate biopsy|Patients with prostate cancer. Patients will be defined and the benefit will be characterized within specific subset populations, such as in patients with prior negative biopsies, anterior targets, or PSA in specific ranges
3324573|NCT00102544|Experimental|percutaneous biopsy and ablation|Patients with other cancers.
3324574|NCT00102531|Experimental|Cisplatin liposomal 24 mg/m2|Inhaled liposomal cisplatin was administered over 1 day in a 14-day treatment cycle by inhalation for a maximum of 6 cycles.
3324625|NCT00101894|Experimental|75 mg QD AMG 706 + FOLFOX-4|75 mg QD AMG 706 + FOLFOX-4
3324575|NCT00102531|Experimental|Cisplatin liposomal 36 mg/m2|The study allowed for a dose escalation of liposomal cisplatin to 36 mg/m2 if no adverse events of Grade 3 or higher occurred after at least 3 cycles of drug administration at 24 mg/m2
3324576|NCT00102518|Experimental|NCT00102063 and NCT00110461 Subjects|All subjects had either completed or had withdrawn from the double-blind extension phase of study NCT00110461 (OPDC 31-03-240) and study NCT00102063 (OPDC 31-03-239).
3324577|NCT00102466|Experimental|Vildagliptin|
3324578|NCT00102466|Active Comparator|Gliclazide|
3324579|NCT00102453|Experimental|Solution|All enrolled participants were give pentoxifylline in this pilot protocol.
3324580|NCT00102440|Experimental|Febuxostat 80 mg QD|
3324581|NCT00102440|Experimental|Febuxostat 120 mg QD|
3324582|NCT00102440|Active Comparator|Allopurinol 300 mg QD|
3324583|NCT00102388|Experimental|vildagliptin|
3324584|NCT00102388|Active Comparator|Gliclazide|
3324585|NCT00102336|Experimental|AMG 531|Active investigational product
3324586|NCT00102336|Placebo Comparator|Placebo|
3324587|NCT00102323|Placebo Comparator|Placebo|
3324588|NCT00102323|Experimental|AMG 531|Active Investigational Product
3324589|NCT00102141|Experimental|Arm 1|
3324590|NCT00102141|Experimental|Arm 3|
3324591|NCT00102141|Experimental|Arm 4|
3324592|NCT00102141|Placebo Comparator|Arm 5|
3324593|NCT00102141|Experimental|Arm 2|
3324594|NCT00102063|Active Comparator|Aripiprazole 10 mg/day Group|Dose was titrated to a target dose of 10 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5; one dose reduction to 5 mg/day allowed after Day 25
3324595|NCT00102063|Active Comparator|Aripiprazole 30 mg/day Group|Dose was titrated to a target dose of 30 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5, 15 mg/day on Day 7, 20 mg/day on Day 9, and 30 mg/day on Day 11; one dose reduction to 15 mg/day allowed after Day 25
3324596|NCT00102063|Placebo Comparator|Placebo Group|Participants were given a single pill administered once daily
3324597|NCT00102011|Experimental|Study I- Arm I|Participants undergo baseline screening colonoscopy
3324598|NCT00102011|Other|Study I- Arm II|Participants receive standard care
3324599|NCT00102011|Experimental|Study II- Arm I|Participants undergo baseline screening colonoscopy. Participants are given individualized recommendations for further surveillance based on the results of the colonoscopy.
3324600|NCT00102011|Active Comparator|Study II- Arm II|Participants undergo a baseline fecal occult blood test (FOBT). Participants are given individualized recommendations for further surveillance based on the results of the FOBT. Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT.
3324601|NCT00101998|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally BID for 3 weeks.
3324602|NCT00101998|Experimental|Alvimopan 1 mg Once Daily (QD)|"0.5 mg of alvimopan was administered orally QD for 3 days, then 1 mg of alvimopan QD for the remaining 3 weeks. Placebo was administered orally QD to maintain the blind.~A protocol amendment dropped this arm because another study had demonstrated 1 mg QD treatment to have similar efficacy but a less favorable gastrointestinal-related safety profile compared with 0.5 mg BID treatment."
3324603|NCT00101998|Experimental|Alvimopan 1 mg Twice Daily (BID)|0.5 mg of alvimopan was administered orally BID for 3 days, then 1 mg of alvimopan BID for the remaining 3 weeks.
3324604|NCT00101998|Placebo Comparator|Placebo|Placebo was administered orally BID for 3 weeks.
3324605|NCT00101972|Experimental|RAV12|
3324606|NCT00101933|Experimental|1|Active Stimulation
3324607|NCT00101933|Sham Comparator|2|No Stimulation
3324608|NCT00101920|Experimental|ABX-EGF|Open-label, single arm panitumamab monotherapy
3324609|NCT00101907|Experimental|Panitumumab + Gem/Cis|Panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
3324610|NCT00101907|Experimental|50 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 50 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
3324611|NCT00101907|Experimental|75 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 75 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
3324612|NCT00101907|Experimental|100 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 100 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
3324613|NCT00101907|Experimental|125 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 125 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
3324614|NCT00101907|Experimental|75 mg BID AMG 706 + panitumumab + Gem/Cis|AMG 706 75 mg administered orally twice daily (BID) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
3324615|NCT00101894|Experimental|Part 2 AMG 706 (MTD) + FOLFOX-4|Maximum Tolerated Dose of AMG 706 established in Part 1b + FOLFOX-4
3324616|NCT00101894|Experimental|125 mg QD AMG 706 + FOLFOX-4|125 mg QD AMG 706 + FOLFOX-4
3324617|NCT00101894|Experimental|50 mg QD AMG706 + panitumumab + FOLFIRI|50 mg QD AMG706 + panitumumab + FOLFIRI
3324618|NCT00101894|Experimental|Part 2 AMG 706 (MTD) + FOLFIRI|Maximum Tolerated Dose of AMG 706 established in Part 1b + FOLFIRI
3324619|NCT00101894|Experimental|100 mg QD AMG 706 + FOLFIRI|100 mg AMG 706 + FOLFIRI
3324620|NCT00101894|Experimental|75 mg QD AMG 706 + panitumumab + FOLFOX-4|75 mg QD AMG 706 + panitumumab + FOLFOX-4
3324621|NCT00101894|Experimental|75 mg BID AMG 706 + panitumumab + FOLFIRI|75 mg BID AMG 706 + panitumumab + FOLFIRI
3324622|NCT00101894|Experimental|125 mg QD AMG 706 + panitumumab + FOLFIRI|125 mg QD AMG 706 + panitumumab + FOLFIRI
3324623|NCT00101894|Experimental|125 mg QD AMG 706 + FOLFIRI|125 mg QD AMG 706 + FOLFIRI
3324624|NCT00101894|Experimental|100 mg QD AMG 706 + panitumumab + FOLFIRI|100 mg QD AMG 706 + panitumumab + FOLFIRI
3324627|NCT00101894|Experimental|50 mg QD AMG 706 + panitumumab + FOLFOX-4|50 mg QD AMG 706 + panitumumab + FOLFOX-4
3324628|NCT00101894|Experimental|75 mg QD AMG706 + panitumumab + FOLFIRI|75 mg QD AMG706 + panitumumab + FOLFIRI
3324629|NCT00101881|Active Comparator|Monophasic Shock|Administration of monophasic waveform defibrillation
3324630|NCT00101881|Active Comparator|Biphasic Shock|Administration of biphasic waveform defibrillation
3324631|NCT00101868|Experimental|Discharge communication software|Computerized-Physician-Order-Entry software application to facilitate communication at time of hospital discharge to patients, retail pharmacists, community physicians. Software had required fields, pick lists, standard drug doses, alerts, reminders, online reference information. Software prompted discharging physician to enter pending tests, order tests after discharge. Hospital physicians used software on day of discharge to generate four documents automatically: personalized letter to outpatient physician, legible prescriptions, and legible discharge order
3324632|NCT00101868|Active Comparator|Usual care discharge process|Hospital physicians and ward nurses completed handwritten discharge forms on the day of discharge. The forms contained blanks for discharge diagnoses, discharge medications, medication instructions, post discharge activities and restrictions, post discharge diet, post discharge diagnostic and therapeutic interventions, and appointments. Patients received handwritten copies of the forms, one page of which also included medication instructions and prescriptions
3324633|NCT00101829|Experimental|Rituximab Treatment|Participants will receive rituximab at study entry and at Week 2
3324634|NCT00101816|Experimental|1|
3324635|NCT00101790|Active Comparator|1|
3324636|NCT00101725|Experimental|125 mg crofelemer|
3324637|NCT00101725|Experimental|250 mg crofelemer|
3324638|NCT00101725|Experimental|500 mg crofelemer|
3324639|NCT00101725|Placebo Comparator|placebo|
3324640|NCT00101712|Experimental|Vildagliptin|
3324641|NCT00101712|Placebo Comparator|Placebo|
3324642|NCT00101686|Experimental|Modified Bolus 5-FU/LV with Irinotecan|
3324643|NCT00101686|Experimental|FOLFIRI + bevacizumab|
3324644|NCT00101686|Experimental|miFL + bevacizumab|
3324645|NCT00101686|Experimental|Infusional 5-FU/LV with Irinotecan|
3324646|NCT00101686|Other|Oral Capecitabine with Irinotecan|
3324647|NCT00101660|Experimental|Dasatinib, 70 mg twice daily (BID)|Dasatanib, 70 mg twice daily (BID), with dose escalation to 90 mg BID was allowed for participants who showed evidence of progression or lack of response. Up to 2 dose reductions were allowed for intolerance.
3324648|NCT00101647|Experimental|1|
3324649|NCT00101608|Experimental|1|
3324650|NCT00101595|Experimental|1|
3324651|NCT00101582|Experimental|Palifermin|Participants received a single intravenous dose of palifermin at 180 μg/kg three days before the start of radiotherapy, and then 7 once weekly palifermin doses at the same dose level during a 7-week radiotherapy/chemotherapy course.
3324652|NCT00101582|Placebo Comparator|Placebo|Participants received a single IV dose of placebo three days before the start of radiotherapy, and then 7 once weekly placebo doses during a 7-week radiotherapy/chemotherapy course.
3324653|NCT00101569|Experimental|A1|
3324654|NCT00101569|Experimental|A2|
3324655|NCT00101491|Experimental|1|
3324656|NCT00101491|Other|2|Attention Control Comparator
3324657|NCT00101452|Experimental|S-adenosyl-l-methionine (SAMe)|A natural substance
3324658|NCT00101452|Active Comparator|2. Escitalopram|A selective serotonin reuptake inhibitor (SSRI)
3324659|NCT00101452|Placebo Comparator|3. placebo|Sugar pill- contains no active ingredients
3324660|NCT00101439|Experimental|Ezetimibe→Placebo|After a 2-week single- blind placebo run-in, participants will receive ezetimibe 10 mg once daily for 4 weeks and then receive placebo once daily for 4 weeks.
3324661|NCT00101439|Experimental|Placebo→ Ezetimibe|After a 2-week single- blind placebo run-in, participants will receive placebo once daily for 4 weeks and then receive ezetimibe10 mg once daily for 4 weeks.
3324662|NCT00101413|Experimental|Sorafenib|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (bid, bis in die) X 28 day cycles
3324663|NCT00101400|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg administered twice daily (b.i.d.)
3324664|NCT00101387|Experimental|Lumbar PENS + exercise|Lumbar PENS twice a week for six weeks combined with general conditioning and aerobic exercise
3324665|NCT00101387|Active Comparator|Lumbar PENS|Lumbar PENS twice a week for 6 weeks
3324666|NCT00101387|Placebo Comparator|Control PENS|Control lumbar PENS twice a week for 6 weeks
3324667|NCT00101387|Active Comparator|Control PENS + exercise|Control PENS twice a week for 6 weeks along with general conditioning and aerobic exercise
3324668|NCT00101361|Active Comparator|1|oxandrolone
3324669|NCT00101361|Placebo Comparator|2|placebo
3324670|NCT00101348|Experimental|Treatment (erlotinib hydrochloride, cetuximab, bevacizumab)|"Part 1: Patients receive oral erlotinib once daily on days 1-28. Patients also receive cetuximab IV over 3 hours on day 1 and over 1 hour on days 8, 15, and 22.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Part 2: Patients receive erlotinib as in part 1 at the MTD and cetuximab as in part 1. Patients also receive bevacizumab IV over 1½ hours on day 1 and over 1 hour on day 15.~Cohorts of 3-6 patients receive escalating doses of bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~In both groups, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression."
3324671|NCT00101296|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-7 and 15-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients achieving a CR receive 2 additional courses beyond CR. Patients experiencing relapse after previously achieving CR may receive additional tipifarnib at the current dose level for newly registered patients.
3324672|NCT00101283|Experimental|Pemetrexed/Carboplatin|Pemetrexed disodium 500 mg/m2 IV over 10 minutes and carboplatin to area under the curve (AUC) 5 IV over 30 minutes on day 1 of a 21-day cycle.
3324673|NCT00101283|Experimental|Pemetrexed/Gemcitabine|Pemetrexed disodium 500 mg/m2 IV over 10 minutes on day 1 and gemcitabine 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle.
3324674|NCT00101270|Experimental|Treatment (irinotecan hydrochloride, oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
3324675|NCT00101244|Experimental|Treatment (ispinesib)|"Patients receive SB-715992 IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SB-715992 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 10 additional patients are treated at the MTD."
3324676|NCT00101231|Experimental|Treatment (flavopiridol)|Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression.
3324677|NCT00101205|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3324678|NCT00101179|Experimental|Arm I|"Patients receive azacitidine subcutaneously on days 1-10 and oral MS-275 on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses* of MS-275 until the maximum tolerated dose (MTD) is determined. Patients receive adjusted doses of azacitidine based on clinical response. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 9 additional patients are treated at the MTD."
3324679|NCT00101166|Experimental|Vaccine Therapy|Treatment consisted of intradermal vaccine injections at 28-day intervals for a total of 3 immunizations. Injections were performed on Days 1, 29, and 57.
3324680|NCT00101153|Experimental|Tipifarnib with conventional induction and consolidation|
3324681|NCT00101114|Experimental|Treatment (sorafenib tosylate, interferon alpha-2b)|Patients receive oral sorafenib twice daily on days 1-28 and interferon alfa subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324682|NCT00101101|Experimental|Vaccine and Conventional Therapy|"Patients were treated with 3-6 cycles of chemotherapy +/- rituximab, with type and duration at the discretion of the individual clinician.~Chemotherapy: 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.~Patients who achieve a partial or complete response after completion of chemotherapy proceed to autologous tumor cell-based vaccine therapy.~Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2.~Treatment continues in the absence of disease progression or unacceptable toxicity."
3324683|NCT00101088|Experimental|Treatment (imatinib mesylate, temsirolimus)|Patients receive temsirolimus IV over 30 minutes once on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression
3324684|NCT00101075|Experimental|XELOX|"Oxaliplatin 130 mg/m2 day 1 every 3 weeks~Capecitabine 1700 mg/m2/day days 1-14 every 3 weeks. -- Patients will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
3324685|NCT00101036|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324686|NCT00101010|Experimental|Rituximab - Combination Chemotherapy|Rituximab intravenous (IV), cyclophosphamide IV over 1-1½ hours, pegylated doxorubicin HCl liposome IV over 1 hour, and vincristine IV on day 1, and oral prednisone on days 1-5. Patients also receive filgrastim (G-CSF) subcutaneously (SC) once daily beginning on day 6 and continuing until blood counts recover OR pegfilgrastim SC once on day 6 (24 hours after the completion of chemotherapy). Treatment repeats every 21 days for up to 8 courses
3324687|NCT00100945|Experimental|gefitinib|"Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease recurrence or unacceptable toxicity.~Quality of life is assessed at baseline, 4 weeks, every 12 weeks during study treatment, and then at the end of study treatment.~Patients are followed every 3 months for up to 5 years."
3324688|NCT00100932|Experimental|1|E7389 28 day cycle
3324689|NCT00100932|Experimental|2|E7389 21 day cycle
3324690|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Dose Level A|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
3324691|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Dose Level B|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
3324734|NCT00100048|Experimental|200 mg combo therapy|MK0518 200 mg + tenofovir + lamivudine
3324735|NCT00100048|Experimental|100 mg combo therapy|MK0518 100 mg + tenofovir + lamivudine
3324736|NCT00100048|Active Comparator|EFV combo therapy|efavirenz + tenofovir + lamivudine
3324737|NCT00099983|Active Comparator|Risperidone|1 mg/day tablet for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day to a maximum of 4 mg/day allowed after a minimum of 4 weeks at the target dose 3 mg/day
3324692|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Level C|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
3324693|NCT00100893|Experimental|Dietary Supplement: grape seed proanthocyanidin extract|Administered orally.
3324694|NCT00100880|Experimental|Treatment (lenalidomide)|"Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 2-3 patients receive escalating doses of lenalidomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which an estimated 25% of patients experience dose-limiting toxicity."
3324695|NCT00100854|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily on days 1-28. Courses repeat every 28 days.
3324696|NCT00100854|Experimental|Arm II|Patients receive erlotinib hydrochloride as in arm I and fulvestrant intramuscularly on days 1, 15, and 29, and then every 28 days thereafter.
3324697|NCT00100841|Experimental|Treatment (combination chemotherapy)|Patients receive cetuximab IV over 60-120 minutes on day 1 in weeks 1-8. Patients also receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 48 hours on days 1 and 2 of weeks 1, 3, 5, and 7. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
3324698|NCT00100828|Experimental|Irinotecan|
3324699|NCT00100802|Experimental|Surgery, Chemoradiotherapy, Rest, Maintenance, FUP|Patients must begin therapy within 31 days of surgery. Chemoradiotherapy = Radiation Therapy Dose: 54.0 Gy with a Boost of 5.4 Gy Temozolomide 90mg/m2/day daily for 42 days. Maintenance consists of 6 treatment cycles of combo chemotherapy with lomustine and temozolomide. Maintenance will begin 4 weeks following radiation. Five days of temozolomide (day 1 - 5) and one dose of lomustine (day 1) followed by 36 days of rest = 1 treatment cycle.
3324700|NCT00100789|Experimental|gemcitabine paclitaxel combination|
3324701|NCT00100750|Experimental|Treatment (gemcitabine hydrochloride, tipifarnib)|Patients receive tipifarnib PO BID on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3324702|NCT00100698|Active Comparator|1|recombinant human growth hormone subcutaneously once a day
3324703|NCT00100698|Placebo Comparator|2|placebo subcutaneously once a day
3324704|NCT00100685|Experimental|Arm 1|Volociximab administered intravenously at a dose of 10 mg/kg qowk
3324705|NCT00100685|Experimental|Arm 2|Volociximab administered intravenously at a dose of 15 mg/kg qwk
3324706|NCT00100659|Active Comparator|Pegylated interferon/ribavirin|"Pegasys - 180 mcg per 1.73 meter squared body surface area subcutaneously once weekly.~Ribavirin - 15 mg per kg orally twice daily using 100-mg tablets."
3324707|NCT00100659|Placebo Comparator|Pegylated interferon/placebo|Placebo tablets were supplied in the same dosing regimen as ribavirin, using the same number of tablets that would be given if ribavirin were being administered (eg, 3 placebo tablets twice daily for a 40-kg child who would receive 3 100-mg RV tablets twice daily).
3324708|NCT00100646|Experimental|1|Highly active antiretroviral therapy (HAART) consisting of lamivudine, lopinavir/ritonovir, and stavudine for 16 weeks with three structured treatment interruptions for 2, 4, and 8 weeks each; rabies vaccine at Weeks 16, 17, 22 and 92.
3324709|NCT00100646|Active Comparator|2|Continuous HAART consisting of lamivudine, lopinavir/ritonovir, and stavudine throughout the study; rabies vaccine at Weeks 16, 17, 22 and 92.
3324710|NCT00100568|Experimental|1|All participants will be given an ARV regimen of lamivudine/zidovudine and efavirenz at study entry. If toxicity or treatment failure occurs, some participants may require changes in their ARV regimens.
3324711|NCT00100542||1|All HIV infected and uninfected participants and their caregivers.
3324712|NCT00100477|Other|Arm 1|
3324713|NCT00100308|Experimental|1|Standard treatment plus unfractioned heparin low-dose continuous infusion
3324714|NCT00100308|Placebo Comparator|2|Standard treatment plus placebo
3324715|NCT00100295|Experimental|A|Herbal treatment
3324716|NCT00100295|Placebo Comparator|B|
3324717|NCT00100256|Experimental|Arm 1|
3324718|NCT00100230|Experimental|1.|Oral Docosahexaenoic acid, dosage based on body weight
3324719|NCT00100230|Placebo Comparator|2|corn/soy oil placebo; oil not containing DHA...dosage based on body weight
3324720|NCT00100178|Experimental|MMF and DBZ|DZB given by intravenous infusion (1 mg/kg)at baseline and 2 weeks later, and MMF given orally at dose of 600 mg/m2 (2000 mg/day maximum) in 2-3 divided doses for 2 years.
3324721|NCT00100178|Experimental|MMF Alone|MMF given orally at dose of 600 mg/m2 (2000 mg/day maximum) in 2-3 divided doses for 2 years and saline intravenous infusions given at baseline and two weeks later.
3324722|NCT00100178|Placebo Comparator|Placebo|Placebo pills given daily for two years and saline intravenous infusions given at baseline and two weeks later.
3324723|NCT00100165|Experimental|Arm 1: Experimental Drug|Experimental Drug
3324724|NCT00100165|Placebo Comparator|Arm 2: Placebo|Placebo
3324725|NCT00100061|Active Comparator|Cranberry Juice|Cranberry Juice provided by Ocean Spray
3324726|NCT00100061|Placebo Comparator|Placebo cranberry juice|Taken orally
3324727|NCT00100048|Experimental|600 mg monotherapy|MK0518 600 mg twice daily
3324728|NCT00100048|Experimental|400 mg monotherapy|MK0518 400 mg twice daily
3324729|NCT00100048|Experimental|200 mg monotherapy|MK0518 200 mg twice daily
3324730|NCT00100048|Experimental|100 mg monotherapy|MK0518 100 mg twice daily
3324731|NCT00100048|Placebo Comparator|placebo monotherapy|Placebo to MK0518 twice daily
3324732|NCT00100048|Experimental|600 mg combo therapy|MK0518 600 mg + tenofovir + lamivudine
3324733|NCT00100048|Experimental|400 mg combo therapy|MK0518 400 mg + tenofovir + lamivudine
3324738|NCT00099983|Placebo Comparator|Sugar Pill|Placebo 1 mg/day tablet for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day to a maximum of 4 mg/day allowed after a minimum of 4 weeks at the target dose 3 mg/day
3324739|NCT00099944|Experimental|LAF237 50 mg qd + glimepiride 4 mg qd|LAF237 50 mg qd + glimepiride 4 mg qd
3324740|NCT00099944|Experimental|LAF237 50 mg bid + glimepiride 4 mg qd|LAF237 50 mg bid + glimepiride 4 mg qd
3324741|NCT00099944|Placebo Comparator|LAF237 placebo + glimepiride 4 mg qd|LAF237 placebo + glimepiride 4 mg qd
3324742|NCT00099866|Experimental|Vildagliptin|
3324743|NCT00099866|Active Comparator|Metformin|
3324744|NCT00099853|Experimental|Vildagliptin 50 mg qd + pioglitazone 45 mg qd|Vildagliptin 50 mg qd + pioglitazone 45 mg qd for 24 weeks
3324745|NCT00099853|Experimental|Vildagliptin 50 mg bid + pioglitazone 45 mg qd|Vildagliptin 50 mg bid + pioglitazone 45 mg qd for 24 weeks
3324746|NCT00099853|Placebo Comparator|Vildagliptin placebo + pioglitazone 45 mg qd|Vildagliptin placebo + pioglitazone 45 mg qd for 24 weeks
3324747|NCT00099788|Experimental|1|Ranolazine
3324748|NCT00099788|Placebo Comparator|2|Placebo
3324749|NCT00099736|Experimental|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids,|
3324750|NCT00099736|Experimental|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids|
3324751|NCT00099736|Experimental|MMF 2 g + full-dose Neoral (FDN) + corticosteroids|
3324752|NCT00099658|Experimental|1|HIV-uninfected infants born to HIV-uninfected mothers
3324753|NCT00099658|Experimental|2|HIV-infected infants in CDC Disease Category 1 who were randomly assigned to the delayed therapy arm (Arm 1) of CIPRA SA-Project 2
3324754|NCT00099658|Experimental|3|HIV-infected infants in CDC Disease Category 1 who were randomly assigned to the first early therapy arm (Arm 2) of CIPRA SA-Project 2
3324755|NCT00099658|Experimental|4|HIV-infected infants in CDC Disease Category 2 or 3 who were randomly assigned to the second early therapy arm (Arm 3) of CIPRA SA-Project 2
3324756|NCT00099658|Experimental|5|HIV-uninfected infants born to HIV infected mothers
3324757|NCT00099632|Experimental|7-day 3TC/ZDV|SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.
3324758|NCT00099632|Experimental|21-day 3TC/ZDV|SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.
3324759|NCT00099632|Experimental|7-day FTC/TDF|SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.
3324760|NCT00099632|Experimental|21-day FTC/TDF|SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.
3324761|NCT00099632|Experimental|7-day LPV/r|SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.
3324762|NCT00099632|Experimental|21-day LPV/r|SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r
3324763|NCT00099619|Experimental|exenatide/insulin glargine|Arm that first receives exenatide, then crosses over to insulin glargine
3324764|NCT00099619|Experimental|Insulin glargine/exenatide|Arm that first receives insulin glargine, then crosses over to exenatide
3324765|NCT00099606|Experimental|A1|
3324766|NCT00099580|Experimental|1|
3324767|NCT00099580|Placebo Comparator|2|
3324768|NCT00099515|Experimental|A|
3324769|NCT00099515|Experimental|B|
3324770|NCT00099502|Experimental|Arm 1|
3324771|NCT00099502|Experimental|Arm 2|
3324772|NCT00099502|Active Comparator|Arm 3|
3324773|NCT00099437|Experimental|1|Fulvestrant 500 mg
3324774|NCT00099437|Experimental|2|Fulvestrant 250 mg
3324775|NCT00099372||Abdominal Sacral Colpopexy with no Burch colposuspension|
3324776|NCT00099372||Abdominal Sacral Colpopexy with Burch Colposuspension|
3324777|NCT00099359|Experimental|A|Standard of care ( Zidovudine only)
3324778|NCT00099359|Experimental|B|Standard of care (Zidovudine) plus Nevirapine
3324779|NCT00099359|Experimental|C|Standard of Care (Zidovudine) plus 2 weeks of Epivir and Nelfinavir
3324780|NCT00099333|Experimental|Exenatide|The subjects will discontinue their insulin and substitute it with exenatide. Subjects will remain on their existing oral diabetic therapy.
3324781|NCT00099333|Active Comparator|Insulin|The subjects will remain on their current insulin therapy. Subjects will also remain on their existing oral diabetic therapy.
3324782|NCT00099320|Experimental|Exenatide|After a 2-week placebo lead-in period, exenatide will be given in an esclating dose along with the subject's current therapy regimen
3324783|NCT00099320|Placebo Comparator|Placebo|After a 2-week placebo lead-in period, subjects will be given placebo (in equivalent amounts to exenatide) in addition to their current therapy regimen.
3324784|NCT00099268|Experimental|Carbidopa/levodopa/entacapone|Patients received Carbidopa/levodopa/entacapone tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks.
3324785|NCT00099268|Active Comparator|Immediate release carbidopa/levodopa|Patients received Immediate release carbidopa/levodopa tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks.
3324786|NCT00099203|Experimental|1|
3324787|NCT00099203|Active Comparator|2|
3324788|NCT00099177|Experimental|1|
3324789|NCT00099177|Active Comparator|2|
3324790|NCT00099125|Experimental|RT with chemotherapy + post-radiation chemotherapy|Radiation therapy (RT) with concurrent chemotherapy + post-radiation chemotherapy
3324791|NCT00099086|Experimental|Experimental Arm|
3324792|NCT00099047|Experimental|Arm I (celecoxib)|Patients receive celecoxib PO BID for 6 months in the absence of unacceptable toxicity or progression to malignancy.
3324793|NCT00099047|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 6 months in the absence of unacceptable toxicity or progression to malignancy.
3324794|NCT00099021|Experimental|Prevention (pioglitazone hydrochloride)|Patients receive pioglitazone hydrochloride PO QD for 12 weeks in the absence of disease progression, unacceptable toxicity, or the development of carcinoma.
3324795|NCT00099008|Experimental|Arm I|Genistein
3324797|NCT00098956|Experimental|Treatment (topotecan hydrochloride, UCN-01)|Patients receive topotecan IV over 30 minutes on days 1-5 and UCN-01 IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or PR receive 2 additional courses beyond CR or PR.
3324798|NCT00098891|Experimental|Treatment (entinostat, isotretinoin)|Patients receive oral MS-275 once on days 1, 8, and 15 and oral isotretinoin twice daily on days 1-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
3324799|NCT00098865|Experimental|Thalidomide and Temozolomide|"Thalidomide:~Oral thalidomide on days 1-28 of a 28 day cycle initiated at 3 mg/kg and increased to maximum dose of 24 mg/kg or 1000 mg as tolerated.~Temozolomide:~Oral temozolomide on days 1-5 of 28 day cycle given at 200 mg/m2 or 150 mg/m2 for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal radiation.~Patients were treated for 6 cycles unless disease progression or excessive toxicity. Treatment could continue beyond 6 cycles if absent disease progression"
3324800|NCT00098839|Experimental|Reinduction Chemoimmunotherapy with Epratuzumab once weekly|Four weekly doses of epratuzumab (360 mg/m2/dose) IV days 1, 8, 15, 22. Also received vincristine sulfate, prednisone, pegaspargase, doxorubicin hydrochloride, dexrazoxane hydrochloride, etoposide, cyclophosphamide, filgrastim, high-dose (HD) methotrexate with Leucovorin calcium rescue, L-asparaginase, cytarabine, IT cytarabine, IT methotrexate (CNS-negative), Intrathecal triple therapy (ITT) (methotrexate, cytarabine, therapeutic hydrocortisone for CNS-positive) during the 3 blocks of reinduction therapy.
3324801|NCT00098839|Experimental|Reinduction Chemoimmunotherapy with Epratuzumab twice weekly|Eight 8 twice-weekly doses of epratuzumab (360 mg/m2/dose) IV days 1, 4, 8, 11, 15, 18, 22 & 25. Also received vincristine sulfate, prednisone, pegaspargase, doxorubicin hydrochloride, dexrazoxane hydrochloride, etoposide, cyclophosphamide, filgrastim, high-dose (HD) methotrexate with Leucovorin calcium rescue, L-asparaginase, cytarabine, IT cytarabine, IT methotrexate (CNS-negative), Intrathecal triple therapy (ITT) (methotrexate, cytarabine, therapeutic hydrocortisone for CNS-positive) during the 3 blocks of reinduction therapy.
3324802|NCT00098826|Experimental|Treatment (ispinesib)|"Induction chemotherapy: Patients receive SB-715992 IV over 1 hour on days 1-3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Consolidation chemotherapy: Patients achieving CR, PR, or SD after induction chemotherapy receive up to 4 additional courses of SB-715992 beyond CR, PR, or SD.~Cohorts of 3-6 patients receive SB-715992 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 9 patients are treated at the MTD."
3324803|NCT00098813|Experimental|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of unacceptable toxicity or disease progression.
3324804|NCT00098787|Experimental|Arm A (High TS, IROX/bev)|Patients with high TS who are randomized to Arm A receive irinotecan and oxaliplatin plus bevacizumab (IROX/bev). The combination regimen is administered by giving bevacizumab IV over 30-90 minutes followed by oxaliplatin IV over 2 hours and irinotecan IV over 90 minutes on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
3324805|NCT00098787|Experimental|Arm B (High TS, FOLFOX/bev)|Patients with high TS who are randomized to Arm B receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev). The combination regimen is administered by giving bevacizumab and oxaliplatin as in Arm A, leucovorin calcium IV over 2 hours, and fluorouracil IV over 5 minutes and then continuously over 46 hours on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
3324806|NCT00098787|Experimental|Arm C (Low or intermediate TS, FOLFOX/bev)|Patients with low or intermediate TS receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev) as in Arm B.
3324807|NCT00098774|Experimental|Intensive Combination Chemo & Immunotherapy|"Induction Cycles 1-3: Methotrexate 8gm/m^2 days 1 & 15; Leucovorin 100 mg/m^2 days 2 & 16; Rituximab 375 mg/m^2 days 3, 10, 17 & 24 of cycle 1, days 3 & 10 of cycle 2; Temozolomide 150 mg/m^2/day PO days 7-11~Induction Cycle 4: Temozolomide 150 mg/m^2/day PO days 7-11; Methotrexate 8gm/m^2 day 15; Leucovorin 100 mg/m^2 day 16~Consolidation Cycle 5: Methotrexate 8gm/m^2 days 1; Leucovorin 100 mg/m^2 days 2; Temozolomide 150 mg/m^2/day PO days 7-11~Consolidation Cycle 6: Cytarabine 2 g/m^2 (x 8 doses) days 1-4; Etoposide 5 mg/kg (x 8 doses) days 1-4; G-CSF 5 mcg/kg/day or GM-CSF 250 mcg/m^2/day starting day 14 until ANC recovers (>= 500 for 2 consecutive days or >= 1500 for one day)"
3324808|NCT00098748|Experimental|1|
3324809|NCT00098748|Experimental|2|
3324810|NCT00098748|Experimental|3|
3324811|NCT00098722|Experimental|1|
3324812|NCT00098722|Placebo Comparator|2|
3324813|NCT00098722|Experimental|3|
3324814|NCT00098670|Experimental|Treatment (alemtuzumab, rituximab, fludarabine phosphate)|"Patients receive induction therapy comprising rituximab IV over 4 hours on days 1, 3, and 5 of course 1 and day 1 of all subsequent courses and fludarabine IV over 30 minutes on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression.~Approximately 4 months after completion of induction therapy, patients achieving a partial response, nodular partial response, or stable disease receive consolidation therapy comprising alemtuzumab subcutaneously on days 1-3. Treatment repeats weekly for up to 6 courses in the absence of disease progression."
3324815|NCT00098631|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324816|NCT00098618|Experimental|Treatment (sorafenib tosylate and recombinant interferon alfa)|Patients receive oral sorafenib twice daily and interferon alfa subcutaneously three times a week for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity
3324817|NCT00098605|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324851|NCT00098111|Active Comparator|Azathioprine 2.5 mg/kg body weight|
3324852|NCT00098111|Active Comparator|Azathioprine 3.5 mg/kg body weight|
3324853|NCT00098059|Experimental|Famciclovir, pediatric oral formulation|single-arm
3324854|NCT00098020|Experimental|Isotretinoin|Subjects will be treated with Isotretinoin.
3324855|NCT00097981|Active Comparator|Thalidomide + dexamethasone|
3324856|NCT00097981|Experimental|Thalidomide + dexamethasone + DOXIL|
3324818|NCT00098579|Experimental|Treatment (chemotherapy)|Patients receive doxorubicin hydrochloride IV over 5-10 minutes and alvocidib IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients reaching a cumulative doxorubicin dose of 600 mg/m^2 or experiencing cardiotoxicity may receive alvocidib alone at the discretion of the investigator. Cohorts of 3-6 patients receive escalating doses of alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Ten additional patients receive treatment at the MTD. Patients are followed every 3 months for 1 year.
3324819|NCT00098553|Experimental|everolimus|"Patients receive oral everolimus once daily for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months until disease progression and then every 4 months for up to 5 years after registration."
3324820|NCT00098540|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324821|NCT00098527|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324822|NCT00098514|Experimental|Dose Level 1a|10 mg/m2 dose of PT523 administered day 1 of a 28-day cycle as a 5 minute IV infusion (IV bolus)
3324823|NCT00098514|Experimental|Dose Level 1b|5 mg/m2 dose of PT523 administered days 1 and 8 of a 28-day cycle as a 5 minute IV infusion
3324824|NCT00098514|Experimental|Dose Level 1c|3.33 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
3324825|NCT00098514|Experimental|Dose Level 2|5 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
3324826|NCT00098514|Experimental|Dose Level 3|7.5 mg/m2 dose (or 6.7 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
3324827|NCT00098514|Experimental|Dose Level 4|11.25 mg/m2 dose (or 9 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
3324828|NCT00098514|Experimental|Dose Level 5|17 mg/m2 dose (or 12 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
3324829|NCT00098501|Experimental|Arm I|Patients receive oral EKB-569 on days 1-28 and oral CCI-779 on days 1-7 and 15-21.
3324830|NCT00098488|Experimental|Treatment (17-AGG and rituximab)|Patients receive 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15 and 18 (course 1). Patients achieving ≥ 25% reduction in measurable disease after course 1 receive an additional course of single-agent 17-AAG approximately 10 days later in the absence of disease progression or unacceptable toxicity and provided absolute lymphocyte count continues to decrease. Patients failing to achieve a 25% reduction in measurable disease after course 1 OR with disease progression after courses 1 or 2 of single-agent 17-AAG proceed to combination therapy comprising 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15, 18, and 22; and rituximab IV over 4 hours on days 1 and 2 and over 1 hour on days 4, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.
3324831|NCT00098475|Active Comparator|Arm I (lenalidomide, dexamethasone)|Patients receive lenalidomide PO QD on days 1-21 and standard-dose dexamethasone PO QD on days 1-4, 9-12, and 17-20.
3324832|NCT00098475|Experimental|Arm II (lenalidomide, low-dose dexamethasone)|Patients receive lenalidomide and acetylsalicylic acid as in Arm I and low-dose dexamethasone PO QD on days 1, 8, 15, and 22.
3324833|NCT00098475|Active Comparator|Arm III (thalidomide, dexamethasone)|Patients with no response after treatment on Arm I: Patients receive thalidomide PO QD on days 1-28 and standard-dose dexamethasone PO QD on days 1-4, 9-12, and 17-20
3324834|NCT00098475|Experimental|Arm IV (thalidomide, low-dose dexamethasone)|Patients with no response after treatment on Arm II: Patients receive thalidomide as in arm III and low-dose dexamethasone PO QD on days 1, 8, 15, and 22.
3324835|NCT00098423|Experimental|Treatment (chemotherapy)|"Patients receive induction therapy comprising cytarabine IV continuously on days 1-5 and tanespimycin IV over 1 hour on days 3 and 6.~Patients achieving a morphologic complete response with CRi or partial response may be eligible to receive a second induction course of therapy after day 21 at the discretion of the principal investigator. Patients achieving a CR receive up to 4 courses of consolidation therapy with cytarabine and tanespimycin. Consolidation therapy repeats approximately every 60 days in the absence of disease progression or unacceptable toxicity. Patients who achieve CR and remain in remission for â¥ 6 months may be retreated with cytarabine and tanespimycin (at the current dose level or the MTD) at the time of relapse. Cohorts of 3-6 patients receive escalating doses of tanespimycin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed at 3 months."
3324836|NCT00098397|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324837|NCT00098371|Experimental|Treatment (alvocidib)|Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving at least a partial remission (PR) and whose PR lasts for > 6 months after completion of treatment may receive 6 additional courses of flavopiridol.
3324838|NCT00098345|Experimental|Caprelsa (vandetanib) 300 mg|Daily oral dose of Caprelsa (vandetanib) 300mg
3324839|NCT00098306|Experimental|1|
3324840|NCT00098306|Experimental|2|
3324841|NCT00098306|Experimental|3|
3324842|NCT00098293|Experimental|1|
3324843|NCT00098293|Active Comparator|3|
3324844|NCT00098293|Experimental|2|Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz
3324845|NCT00098254|Experimental|BAY 43-9006 (Sorafenib)|Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
3324846|NCT00098163|Experimental|1|
3324847|NCT00098163|Placebo Comparator|2|
3324848|NCT00098137|Experimental|Olmesartan|Olmesartan tablet, 1 in the morning
3324849|NCT00098137|Placebo Comparator|Placebo|Placebo tablets, 1 in the morning
3324857|NCT00097903|Experimental|1|Karenitecin IV/ Karenitecin tablet
3324858|NCT00097838|Experimental|1 x 10^5 IU dose|Vaccine dose of 1 x 10^5 IU per injection
3324859|NCT00097838|Experimental|1 x 10^6 IU dose|Vaccine dose of 1 x 10^6 IU per injection
3324860|NCT00097838|Experimental|1 x 10^7 IU dose|Vaccine dose of 1 x 10^7 IU per injection
3324861|NCT00097838|Experimental|1 x 10^8 IU dose|Vaccine dose of 1 x 10^8 IU per injection
3324862|NCT00097838|Placebo Comparator|Placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
3324863|NCT00097786|Experimental|Valsartan 160 mg + nateglinide 60 mg|For the first 2 weeks of treatment, patients took the combination of nateglinide 30 mg (3 times daily, ante cibum [ac] before meals) and valsartan 80 mg (once daily [od] in the morning). After 2 weeks, patients were up-titrated to nateglinide 60 mg ac and valsartan 160 mg od.
3324864|NCT00097786|Experimental|Valsartan 160 mg + nateglinide placebo|For the first 2 weeks of treatment, patients took valsartan 80 mg capsules (once daily [od] in the morning). After 2 weeks, patients were up-titrated to 160 mg valsartan od. Patients also received nateglinide placebo tablets (3 times daily, ante cibum [ac] before meals).
3324865|NCT00097786|Experimental|Nateglinide 60 mg + valsartan placebo|For the first 2 weeks of treatment, patients took nateglinide 30 mg tablets (3 times daily, ante cibum [ac] before meals). After 2 weeks, patients were uptitrated to 60 mg nateglinide ac. Patients also received valsartan placebo capsules (once daily [od] in the morning).
3324866|NCT00097786|Placebo Comparator|Placebo|Patients took 3 nateglinide placebo tablets (3 times daily, ante cibum [ac] before meals) and 1 valsartan placebo capsule (once daily [od] in the morning).
3324867|NCT00097773|Placebo Comparator|Cycled TOBI & placebo|Tobramycin inhalation solution and oral placebo for six consecutive quarterly cycles
3324868|NCT00097773|Active Comparator|Cycled TOBI & oral ciprofloxacin|Tobramycin solution for inhalation and oral ciprofloxacin for six consecutive quarterly cycles.
3324869|NCT00097773|Placebo Comparator|Culture based TOBI & placebo|Tobramycin solution for inhalation and oral placebo administered only when quarterly respiratory cultures are found positive for Pa.
3324870|NCT00097773|Active Comparator|Culture based TOBI & oral cipro|Tobramycin solution for inhalation and oral ciprofloxacin administered only when quarterly respiratory cultures are found positive for Pa.
3324871|NCT00097760|Experimental|Group 1|Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.
3324872|NCT00097760|Placebo Comparator|Group 2|Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
3324873|NCT00097747|Placebo Comparator|Placebo|Single injection administered intravenously
3324874|NCT00097747|Experimental|Peginesatide 0.025 mg/kg|Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.
3324875|NCT00097747|Experimental|Peginesatide 0.05 mg/kg|Single peginesatide dose of 0.05 mg/kg administered intravenously.
3324876|NCT00097747|Experimental|Peginesatide 0.10 mg/kg|Single peginesatide dose of 0.10 mg/kg administered intravenously.
3324877|NCT00097721|Experimental|E7389|
3324878|NCT00097695|Experimental|Icatibant- Randomized|Patients who were randomized to icatibant in the controlled phase after they had an eligible first in-study attack.
3324879|NCT00097695|Placebo Comparator|Placebo-Randomized|Patients who were randomized to placebo in the controlled phase after they had an eligible first in-study attack.
3324880|NCT00097695|Experimental|Controlled Open-label / laryngeal attack|Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.
3324881|NCT00097695|Experimental|Untreated Patients at the baseline|Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing (they were not treated during the Controlled phase but treated with icatibant during the Open Label Extension Phase (OLE) )
3324882|NCT00097656|Experimental|Periodontal Treatment|maternal periodontal therapy
3324883|NCT00097604|Experimental|Valerian|This study used a cross-over design with valerian compared to placebo. Group 1 received valerian first followed by placebo after washout and cross-over; group 2 received placebo first followed by placebo after wash-out and cross-over.
3324884|NCT00097604|Placebo Comparator|Placebo|This study used a cross-over design with valerian compared to placebo. Group 1 received valerian first followed by placebo after washout and cross-over; group 2 received placebo first followed by placebo after wash-out and cross-over.
3324885|NCT00097591|Experimental|Prasugrel|Oral loading dose of six 10 mg prasugrel tablets and four placebo tablets matched to clopidogrel, followed by an oral maintenance dose of prasugrel one 10 mg tablet and one placebo tablet matched to clopidogrel once daily
3324886|NCT00097591|Active Comparator|Clopidogrel|Oral loading dose of four 75 mg clopidogrel tablets and six placebo tablets matched to prasugrel, followed by an oral maintenance dose of one 75 mg clopidogrel tablet and one placebo tablet matched to prasugrel once daily
3324887|NCT00097539||Participants With Growth Disorders|Participants initiating therapy with Genentech GH products: Protropin (somatrem for injection), Nutropin (somatropin for injection), Nutropin AQ (somatropin for injection), and Nutropin Depot (somatropin for injectable suspension) for the treatment of pediatric growth disorders as determined by their physician and who have consented to participate in the NCGS will be enrolled in the study and will be followed throughout their course of treatment, or until withdrawal from the NCGS.
3324888|NCT00097500|Experimental|Exenatide Arm|Exenatide and Metformin
3324889|NCT00097500|Active Comparator|Insulin Glargine Arm|Insulin Glargine and Metformin
3324890|NCT00097474|Experimental|Hydrocortisone|Upon morning arrival at the new destination, volunteers take 20 mg hydrocortisone and at the target bedtime of (10 pm to midnight local time) theywill take placebo for four days.
3324891|NCT00097474|Experimental|Melatonin|Upon morning arrival at the new destination, volunteers take 20 mg placebo and at the target bedtime of (10 pm to midnight local time) they willtake 5 mg of melatonin for four days.
3324892|NCT00097474|Experimental|HC/Melatonin|Upon morning arrival at the new destination, volunteers take 20 mg hydrocortisone and at the target bedtime of (10 pm to midnight local time) theywill take 5 mg of melatonin for four days.
3324893|NCT00097474|Placebo Comparator|Placebo|Upon morning arrival at the new destination, volunteers take placebo and at the target bedtime of (10 pm to midnight local time) they will take placebo for four days.
3324894|NCT00097448|Other|1|Nineteen days of oral prednisone
3324895|NCT00097448|Experimental|2|Four doses of methylprednisolone sodium succinate delivered by injection to the middle ear over 2 weeks
3324896|NCT00097370|Experimental|mepolizumab|750mg Intravenous, monthly and individual dosing schedule
3324897|NCT00097357|Experimental|A1|"Apixaban: 2.5 mg, BID~PLUS~Enoxaparin Placebo"
3324898|NCT00097357|Experimental|A2|"Apixaban: 5 mg, BID~PLUS~Enoxaparin Placebo"
3324899|NCT00097357|Experimental|A3|"Apixaban: 10 mg, BID~PLUS~Enoxaparin Placebo"
3324900|NCT00097357|Experimental|A4|"Apixaban: 5 mg, QD~PLUS~Enoxaparin Placebo"
3324901|NCT00097357|Experimental|A5|"Apixaban: 10 mg, QD~PLUS~Enoxaparin Placebo"
3324902|NCT00097357|Experimental|A6|"Apixaban: 20 mg, QD~PLUS~Enoxaparin Placebo"
3324903|NCT00097357|Active Comparator|E1|"Enoxaparin: 30 mg~PLUS~Apixaban Placebo"
3324904|NCT00097357|Active Comparator|W1|Warfarin: 5 mg tablets dose titrated to a targeted INR of 1.8 to 3.0
3324905|NCT00097292||Annual Monitoring|Participants will be monitored annually for risk of type 1 diabetes.
3324906|NCT00097292||Semi-annual Monitoring|Participants will be monitored every six months for risk of type 1 diabetes
3324907|NCT00097266|Placebo Comparator|A|
3324908|NCT00097266|Experimental|B|
3324909|NCT00097266|Active Comparator|C|
3324910|NCT00097253|Experimental|Lavender|
3324911|NCT00097253|Experimental|Citrus|
3324912|NCT00097253|Placebo Comparator|Water|
3324913|NCT00097227|Active Comparator|Arm A (3-week cycle)|"Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~Paclitaxel 225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks.~Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks."
3324914|NCT00097227|Active Comparator|Arm B (4-week cycle)|"Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~Paclitaxel 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.~Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks."
3324915|NCT00097214|Experimental|1|"Cetuximab 400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8. Carboplatin AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.~Therapy will continue for four cycles (12 weeks)for combination therapy"
3324916|NCT00097058||1|Continue current hormone therapy
3324917|NCT00097058||2|Taper off hormone therapy
3324918|NCT00096993|Placebo Comparator|Placebo + gemcitabine|Participants received placebo intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). In addition, participants received gemcitabine 800 mg/m^2 intravenously on Days 1 and 8 of every 3 week cycle for up to 1 year (up to 17 treatment cycles).
3324919|NCT00096993|Active Comparator|Pertuzumab + gemcitabine|Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). Participants received pertuzumab at a loading dose of 840 mg in Cycle 1 followed by a dose of 420 mg in Cycles 2 and beyond. In addition, participants received gemcitabine 800 mg/m^2 intravenously on Days 1 and 8 of every 3 week cycle for up to 1 year (up to 17 treatment cycles
3324920|NCT00096954|Experimental|Omalizumab|Omalizumab (Xolair) administered in this study was either a minimum of 0.008 mg/kg/IgE [IU/mL] every 2 weeks or a minimum of 0.016 mg/kg/IgE [IU/mL] every 4 weeks.
3324921|NCT00096954|Placebo Comparator|Placebo|Placebo administered in this study was either a minimum of 0.008 mg/kg/IgE [IU/mL] every 2 weeks or a minimum of 0.016 mg/kg/IgE [IU/mL] every 4 weeks.
3324922|NCT00096941|Experimental|Pertuzumab|Participants received the same dose of pertuzumab that they received in their parent Phase II trial, either 420 mg or 1050 mg, intravenously on Day 1 of every 3 week cycle until disease progression.
3324923|NCT00096915|Experimental|darbepoetin alfa|
3324924|NCT00096863|Placebo Comparator|A - placebo|per oral pill
3324925|NCT00096863|Active Comparator|B|Ziprasidone
3324926|NCT00096863|Active Comparator|C|Haloperidol
3324927|NCT00096850|Experimental|1|From Days 1 to 8, participants will receive 600 mg RIF every 24 hours. From Days 9 to 19, participants will receive 300 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours. From Days 20 to 27, participants will receive 400 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours.
3324928|NCT00096824||1|Participants will undergo neurological examinations and neuropsychological assessments at entry to both steps of ACTG A5175 and before the administration of the new antiretroviral regimen, then every 24 weeks until they discontinue ACTG A5175. Physicians will make targeted diagnoses at each study visit.
3324929|NCT00096785|Active Comparator|A1|
3324930|NCT00096785|Active Comparator|A2|
3324931|NCT00096746||A1|HIV infected individuals on first line ATV based HAART with presence of I50L mutation.
3324932|NCT00096746||A2|HIV infected PI naïve on failed NNRTI based regimen.
3324933|NCT00096733||Donors|Living liver donors. This label may also refer to those evaluated for liver donation who did not go on to donate, i.e., potential living liver donors.
3324934|NCT00096733||Recipients|Liver transplant recipients (either living or deceased donor). This label may also refer to those who were evaluated for liver transplantation, but never received a transplant, i.e., potential recipients.
3324935|NCT00096668|Experimental|TOCOSOL Paclitaxel|TOCOSOL Paclitaxel administered weekly at 120mg/mm2
3324936|NCT00096629|Experimental|human PSMA|Patients will receive a total of 6 vaccinations via the intramuscular route. Sites of injection should have intact lymphatic drainage. Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
3324937|NCT00096629|Experimental|mouse PSMA|Patients will receive a total of 6 vaccinations via the intramuscular route. Sites of injection should have intact lymphatic drainage. Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
3325015|NCT00095498|Experimental|Denosumab 180 mg|Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
3327022|NCT00071812|Experimental|Belimumab 1 mg/kg plus SOC|
3324938|NCT00096538|Experimental|valganciclovir|Patients receive oral valganciclovir twice daily for 3 weeks and then once daily for 21 weeks in the absence of disease progression or unacceptable toxicity. All patients are followed for 1 month after completion of therapy. Patients with responding disease are followed monthly for up to 1 year.
3324939|NCT00096512|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324940|NCT00096499|Experimental|Treatment (ispinesib)|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3324941|NCT00096486|Experimental|Gefitinib and Everolimus (RAD001)|"Phase I: Patients receive oral everolimus once on day 1. Beginning on day 8, patients receive oral gefitinib once daily. Beginning on day 22, patients receive oral everolimus once daily. Both drugs are then given concurrently for the rest of the treatment. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of everolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.~Phase II: Patients receive oral everolimus at the MTD determined in phase I and oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity."
3324942|NCT00096460|Active Comparator|Autologous Transplant|Cyclophosphamide and Rituximab with Filgrastim conditioning and chemotherapy or radiation therapy prior to autologous Hematopoietic Stem Cell Transplant (HSCT). Rituximab maintenance therapy following HSCT.
3324943|NCT00096460|Active Comparator|Allogeneic Transplant|Non-myeloablative conditioning regimen followed by allogeneic Hematopoietic Stem Cell Transplant (HSCT). Graft-versus-Host Disease (GVHD) Prophylaxis therapy following HSCT.
3324944|NCT00096447|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324945|NCT00096434|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324946|NCT00096408|Active Comparator|1|Total Abdominal Hysterectomy
3324947|NCT00096408|Experimental|2|Total Laparoscopic Hysterectomy
3324948|NCT00096395|Experimental|Treatment (sorafenib tosylate, gemcitabine hydrochloride)|"Course 1 (56 days): Patients receive oral sorafenib twice daily on days 1-56 and gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43.~Course 2 and all subsequent courses (28 days): Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3324949|NCT00096382|Other|TBI 200cGy + TIL +HD IL-2, prior IL-2|"Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.~Lymphocytes that that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient."
3324950|NCT00096382|Other|TBI 200cGy + TIL +HD IL-2, No prior IL-2|"Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.~Lymphocytes that that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient."
3324951|NCT00096356|Active Comparator|Arm 1 - CoQ10 & Vitamin E|CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day.
3324952|NCT00096356|Placebo Comparator|Arm 2 - Placebo & Vitamin E|Placebo-Vitamin E 100 mg/day in 3 doses
3324953|NCT00096343|Experimental|Paclitaxel IV followed by Carboplatin IV|paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3324954|NCT00096291|Active Comparator|Sequence Doxorubicin followed by Paclitaxel|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
3324955|NCT00096291|Other|Sequence of neoadjuvant CT: Paclitaxel followed by Doxorubicin|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
3324956|NCT00096278|Active Comparator|Arm I (mFOLFOX6)|Patients receive adjuvant chemotherapy comprising concurrent oxaliplatin and leucovorin calcium IV over 2 hours on day 1. Patients also receive adjuvant fluorouracil IV over 2-4 minutes on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3324957|NCT00096278|Experimental|Arm II (bevacizumab, mFOLFOX6)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive adjuvant oxaliplatin, leucovorin calcium, and fluorouracil as in arm I. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of adjuvant chemotherapy, patients continue to receive bevacizumab alone every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
3324958|NCT00096265|Active Comparator|Arm I|Patients undergo whole brain radiotherapy (WBRT) once daily on days 1-5, 8-12, and 15-19. Within 14 days after completion of WBRT, patients undergo stereotactic radiosurgery.
3324959|NCT00096265|Experimental|Arm II|Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral temozolomide once daily on days 1-21. Beginning 4 weeks after completion of WBRT, patients may receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3324960|NCT00096265|Experimental|Arm III|Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral erlotinib once daily for up to 6 months.
3324961|NCT00096226|Experimental|Chemoradiation, Surgery, Chemotherapy|Induction paclitaxel(50 mg/m2 I.V. in a one-hour infusion) and induction carboplatin (AUC 2.0 I.V. in a thirty-minute infusion): 1x/week for 6 weeks. Concurrent radiation therapy (RT): 1.8 Gy/day, 5 fx/week, for a total of 50.4 Gy in 28 fractions plus a boost of 1.8 Gy/day, 5 fx/week, for a total of 10.8 Gy in 6 fractions. Followed by an assessment to determine whether patient will undergo a resection or not. Followed by consolidation paclitaxel (200 mg/m2 I.V. over three hours) and consolidation carboplatin (AUC 6.0 over one hour) q 21 days x 2.
3324962|NCT00096213|Other|surgery|intralesional resection
3325550|NCT00088764|Experimental|2|Writing: Either emotional disclosure writing or health behavior writing
3324963|NCT00096200|Experimental|Arm I (closed to accrual 10/10/2008)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression crossover to arm II
3324964|NCT00096200|Experimental|Arm II|Patients receive oral sorafenib twice daily on days 2-19. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3324965|NCT00096174|Experimental|Cisplatin, C225, Radiation|"Cetuximab therapy: Patients receive an initial loading dose of cetuximab intravenously (IV) over 2 hours on day 1. Patients then receive cetuximab IV over 1 hour on days 8, 15, 22, 29, 36, 43, 50, and 57.~Chemoradiotherapy: Beginning on day 15 of cetuximab therapy, patients undergo radiotherapy once daily, 5 days a week, for at least 7 weeks. Patients also receive cisplatin IV over 1-2 hours on days 15, 36, and 57.~Cetuximab maintenance therapy: After the completion of chemoradiotherapy, patients continue to receive cetuximab IV over 1 hour once weekly for 6-12 months."
3324966|NCT00096161|Experimental|pentostatin, DLI, mycophenolate mofetil, cyclosporine|"Group I (pentostatin, DLI): Patients receive pentostatin IV over 20-30 minutes on day -2 and DLI over 15-30 minutes on day 0. Treatment may repeat once beginning with an escalated or same CD3-dose at least 4 weeks if persistent donor T-cells are documented, no GvHD has developed, and the chimerism status worsens or, if chimerism status is unchanged after at least 8 weeks with two subsequent tests of chimerism 4 weeks apart.~Group II (pentostatin, DLI, mycophenolate mofetil, cyclosporine): Patients receive treatment as in group I. Patients also receive cyclosporine PO BID on days -3 to 56 and mycophenolate mofetil PO QD on days 0 to 27. Treatment continues in the absence of GvHD."
3324967|NCT00096148|Experimental|Arm I (idarubicin, cytarabine)|"Arm I: Patients receive idarubicin IV over 1 hour on days 1-3 and cytarabine IV continuously over 24 hours on days 1-4.~Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.~Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24 hours on days 1-4."
3324968|NCT00096148|Experimental|Arm II (idarubicin, cytarabine, bevacizumab)|"Patients receive idarubicin and cytarabine as in arm I. Patients also receive bevacizumab* IV over 30-90 minutes on day 1. Patients who do not achieve complete remission (CR) after the first induction course may receive a second induction course approximately 28 days* later. Patients who do not achieve CR after 2 courses are removed from the study.~NOTE: *Patients in arm II receive bevacizumab, independently of chemotherapy administration schedule, once every 21 days for 1 year from CR date.~Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.~Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24 hours on days 1-4."
3324969|NCT00096135|Experimental|CNS Patients-Treatment (combination chemotherapy)|All patients receive common induction (vincristine sulfate, dexamethasone, daunorubicin hydrochloride & intrathecal triple therapy (ITT: MTX, therapeutic hydrocortisone and cytarabine)), consolidation (cytarabine, pegaspargase, filgrastim, re-induction (vincristine, dexamethasone, daunorubicin), and intensification chemotherapy (MTX, leucovorin calcium, mercaptopurine, etoposide, cyclophosphamide & ITT.
3324970|NCT00096135|Experimental|Testicular Relapse Patients (Combination chemotherapy)|All patients receive common induction (vincristine sulfate, dexamethasone, daunorubicin hydrochloride & intrathecal triple therapy (ITT: MTX, therapeutic hydrocortisone and cytarabine)), consolidation (cytarabine, pegaspargase, filgrastim, testicular radiation therapy, re-induction (vincristine, dexamethasone, daunorubicin), and intensification chemotherapy (MTX, leucovorin calcium, mercaptopurine, etoposide, cyclophosphamide & ITT.
3324971|NCT00096122|Experimental|Arm I|See Detailed Description
3324972|NCT00096109|Experimental|Treatment (tanespimycin)|Patients receive tanespimycin IV over 1-6 hours on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3324973|NCT00096083|Active Comparator|Melphalan Administration PHP|
3324974|NCT00096070|Experimental|Arm I|Patients undergo radiotherapy once daily, 5 days a week, for 5.5 weeks. Beginning concurrently with radiotherapy, patients receive oxaliplatin IV over 2 hours on days 1, 15, and 29 and fluorouracil IV continuously for 5.5 weeks. Beginning 4-6 weeks after the completion of chemoradiotherapy, patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment with gemcitabine repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3324975|NCT00096044|Experimental|Oral Lenalidomide|Patients receive oral lenalidomide (CC-5013) once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity
3324976|NCT00096031|Experimental|Cetuximab|250 mg/m^2 on days 1, 8, 15, and 22 of every 28-day cycle.
3324977|NCT00096018|Experimental|Dose escalation|Thalidomide (100 mg/day, 200 mg/day, or 300 mg/day) on Day 1 followed by Fludarabine 25 mg/m2/day for 5 days starting on Day 7 (cycle = 28 days
3324978|NCT00096005|Experimental|Treatment (chemotherapy and enzyme inhibitor therapy)|"Patients receive tanespimycin IV over 1-2 hours and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of tanespimycin and bortezomib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 12 additional patients are treated as above* at the MTD.~NOTE: *Bortezomib is not administered on day 1 of course 1 only. Patients are followed at 3 months."
3324979|NCT00095979|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3324980|NCT00095966|Experimental|Treatment (sorafenib tosylate and gemcitabine hydrochloride)|Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3325016|NCT00095498|Experimental|Denosumab 60 mg|Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
3325017|NCT00095498|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections on Day 1 and at Month 6.
3325018|NCT00095420|Experimental|1|Participants with autism will receive social skills training targeting children with autism
3324981|NCT00095940|Experimental|Treatment (surgery, lapatinib)|"Molecular Biology Phase: Patients randomized to receive lapatinib prior to surgery receive oral lapatinib twice daily for 7-14 days. Surgery is performed after 7-14 days of lapatinib treatment. For patients randomized to not receive lapatinib, surgery is performed within 3 weeks of registration. After surgical resection, all molecular biology participants start lapatinib treatment within 10 days post-surgery. The first dose of lapatinib post-surgery initiates course 1. Patients receive oral lapatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity.~Lapatinib Continuation/Phase II: Patients receive oral lapatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity."
3324982|NCT00095927|Active Comparator|Arm A Amifostine|"Patients with newly diagnosed, locally advanced stage ill or IV SCCHN received;~4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m 2) concurrently with concomitant boost radiation consisting of 72 grays in 42 fractions over 6 weeks (every day for 18 days, twice a day for 12 days) (grading determined according to the TNM staging system).~Subcutaneous daily amifostine at a dose of 500 mg"
3324983|NCT00095927|Experimental|Arm B No-Amifostine|"Patients with newly diagnosed, locally advanced stage ill or IV SCCHN~- 4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m 2) concurrently with concomitant boost radiation consisting of 72 grays in 42 fractions over 6 weeks (every day for 18 days, twice a day for 12 days) (grading determined according to the TNM staging system)."
3324984|NCT00095901|Experimental|Capecitabine|Capecitabine (Xeloda 4:14. ) 150 mg and 500 mg tablets. Capecitabine will be administered at a dose of 1000 mg/m2 twice daily, for a total daily dose of 2000 mg/m 2. Capecitabine will administered P.O. or per G-tube B.I.D. for 14 days, followed by a one-week rest period in 3-week cycles.
3324985|NCT00095888|Experimental|Treatment (triapine, gemcitabine hydrochloride)|Patients receive 3-AP (Triapine®) IV over 2 hours followed by gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324986|NCT00095875|Experimental|Arm I|Patients receive induction chemotherapy comprising docetaxel, cisplatin, and fluorouracil. Treatment repeats every 21 days for 3 courses. Patients achieving a pathologic complete response at the primary site and a clinical complete response in the neck then receive carboplatin once weekly and undergo concurrent radiotherapy once daily, 5 days a week, for 7 weeks. Patients with a partial response at the primary site (i.e., positive biopsy), stable disease, or radiographic evidence of persistent disease in the neck receive docetaxel once weekly for 4 weeks and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 6 weeks.
3324987|NCT00095875|Experimental|Arm II|Patients receive cisplatin IV on weeks 1 and 4 and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 6 weeks.
3324988|NCT00095836|Experimental|Gefitinib 250mg|
3324989|NCT00095823|Placebo Comparator|A1|
3324990|NCT00095823|Active Comparator|A2|
3324991|NCT00095823|No Intervention|A3|
3324992|NCT00095810|Experimental|A|
3324993|NCT00095797|Experimental|Treatment (XK469R)|Patients receive XK469R IV over 30-60 minutes on days 1, 3, and 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3324994|NCT00095784|Experimental|Treatment (decitabine)|Patients receive decitabine SC on days 1-5 and 8-12. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.
3324995|NCT00095758|Placebo Comparator|A1|
3324996|NCT00095758|Active Comparator|A2|
3324997|NCT00095745|No Intervention|Antidepressant + Aripiprazole|
3324998|NCT00095732|Experimental|Low Liprotamase Dose|Liprotamase in a fixed combination of lipase (5,000 units), protease (5,000 units) and amylase (750 units) administered orally (one Size 5 capsule of liprotamase and five Size 2 capsules of placebo) with each of three meals and two snacks daily for 28 days
3324999|NCT00095732|Experimental|Mid Liprotamase Dose|Liprotamase in a fixed combination of lipase (25,000 units), protease (25,000 units) and amylase (3,750 units) administered orally (one Size 5 capsule of liprotamase, one Size 2 capsule of liprotamase, and four Size 2 capsules of placebo) with each of three meals and two snacks daily for 28 days
3325000|NCT00095732|Experimental|High Liprotamase Dose|Liprotamase in a fixed combination of lipase (100,000 units), protease (100,000 units) and amylase (15,000 units) administered orally (one Size 5 capsule of placebo and five Size 2 capsules of liprotamase) with each of three meals and two snacks daily for 28 days
3325001|NCT00095719|Active Comparator|A1|
3325002|NCT00095719|Placebo Comparator|B1|
3325003|NCT00095693|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib tosylate twice daily for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 8 additional weeks of therapy beyond CR.
3325004|NCT00095680|Experimental|001|SCIO-469 two 30-mg capsules three times daily
3325005|NCT00095680|Active Comparator|002|SCIO-469 and bortezomib The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
3325006|NCT00095667|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
3325007|NCT00095628|Experimental|Treatment (ispinesib)|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3325008|NCT00095576|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef|Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.
3325009|NCT00095576|Placebo Comparator|Placebo|Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.
3325010|NCT00095563|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
3325011|NCT00095550|Experimental|A1|
3325012|NCT00095550|Active Comparator|A2|
3325013|NCT00095550|Active Comparator|A3|
3325014|NCT00095537|Experimental|Phase 1 MTD Study|
3325019|NCT00095420|Experimental|2|Participants without autism will receive social skills training to increase acceptance of peers with autism
3325020|NCT00095420|Experimental|3|Participants with and without autism will receive a combination treatment of social skills/education about autism
3325021|NCT00095420|Active Comparator|4|Participants with and without autism will receive usual training provided by their school district
3325022|NCT00095394|Experimental|A1|
3325023|NCT00095394|Active Comparator|A2|
3325024|NCT00095329|Experimental|sirolimus|
3325025|NCT00095316|Placebo Comparator|Placebo|Subjects receive placebo intravenously daily for 28 days
3325026|NCT00095316|Experimental|Caspofungin|Subjects receive 50mg/day caspofungin intravenously (IV) for 28 days
3325027|NCT00095303|Experimental|Brief Strategic Family Therapy (BSFT)|"BSFT is a family therapy approach that consists of 12 to 16 sessions (each 1 to 1.5 hours long) over a 4-month period during the Main Study, and up to 8 booster sessions. Interventions are delivered to adolescents and relevant family members in non-restrictive community settings (e.g., clinics, homes, school)."
3325028|NCT00095303|Active Comparator|Treatment as Usual (TAU)|TAU varies depending on site, however each will offer services that include at least 1 therapy session (individual or group therapy) per week during the Main Study, as well as participation in ancillary services (e.g., case management, self help groups, etc.) over a four month period.
3325029|NCT00095290|Experimental|A1|
3325030|NCT00095290|Placebo Comparator|A2|
3325031|NCT00095251|Active Comparator|Dexmedetomidine group|Patients in the dexmedetomidine arm will receive a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. The patient's managing physician will have the option of beginning the dexmedetomidine infusion without a bolus in circumstances where the patient's sedation level is adequate at enrollment or in the presence of baseline bradycardia /hypotension. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
3325032|NCT00095251|Active Comparator|Lorazepam group|Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
3325033|NCT00095238|Active Comparator|1|
3325034|NCT00095238|Placebo Comparator|2|
3325035|NCT00095212|Active Comparator|1 Transdermal Testosterone (Patch)|300 micrograms applied twice a week
3325036|NCT00095212|Placebo Comparator|2 Placebo Patch (identical in appearance)|placebo patch (0 micrograms of testosterone)applied twice a week
3325037|NCT00095199|Experimental|Cetuximab & Pemetrexed|
3325038|NCT00095199|Active Comparator|Pemetrexed|
3325039|NCT00095199|Experimental|Cetuximab & Docetaxel|
3325040|NCT00095199|Active Comparator|Docetaxel|
3325041|NCT00095173|Active Comparator|Abatacept|Double Blind Period
3325042|NCT00095173|Placebo Comparator|Placebo|Double Blind Period
3325043|NCT00095173|Experimental|Abatacept - Open Label|
3325044|NCT00095147|Active Comparator|Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB])|Days 1-365
3325045|NCT00095147|Active Comparator|Infliximab + MTX (DB)|Days 1-365
3325046|NCT00095147|Placebo Comparator|Placebo + MTX (DB)|Days 1-197
3325047|NCT00095147|Experimental|Placebo + MTX switched to abatacept + MTX (DB)|Participants received placebo plus methotrexate for days 1-197, and abatacept plus methotrexate for days 198-365
3325048|NCT00095147|Experimental|Abatacept (open-label)|Days 365 to 729 All participants receive Active Drug
3325049|NCT00095121|Placebo Comparator|Placebo (PLB)|Participants randomized to receive placebo received placebo during the first 48 weeks of treatment (double-blind phase) and then all eligible participants were administered open-label ADV for the remainder of the study.
3325050|NCT00095121|Experimental|Adefovir Dipivoxil (ADV)|Participants randomized to receive ADV received ADV during the first 48 weeks of treatment (double-blind phase) and then all eligible participants were administered open-label ADV for the remainder of the study.
3325051|NCT00095056|Experimental|Sitagliptin|Participants in the Sitagliptin treatment sequence will receive sitagliptin in Phase A and placebo to glipizide in Phase B.
3325052|NCT00095056|Placebo Comparator|Placebo|Participants in the Placebo treatment sequence will receive placebo to sitagliptin in Phase A and glipizide in Phase B.
3325053|NCT00094965|Experimental|1|
3325054|NCT00094926|Experimental|001|
3325055|NCT00094926|Placebo Comparator|002|
3325056|NCT00094900|Experimental|IL-1 Trap|
3325057|NCT00094887|Experimental|1|Inhaled nitric oxide
3325058|NCT00094887|Placebo Comparator|2|Nitrogen gas
3325059|NCT00094861|Placebo Comparator|Placebo|"Participants received a single intravenous (IV) dose of placebo administered 3 days before the initiation of concurrent chemo/radiotherapy, then once weekly during Weeks 1 through 6, typically for a total of 7 doses. Concurrent radio/chemotherapy was given as follows:~standard radiotherapy 2 Gy once daily x 30 to 33 fractions (6 to 7 weeks) for a total target dose of 60 to 66 Gy~paclitaxel 50 mg/m^2 intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy)~carboplatin dosed at an area under the curve (AUC) 2.0 IV on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy).~Participants subsequently received two 21-day cycles of consolidation chemotherapy with paclitaxel 225 mg/m^2 and carboplatin dosed at AUC 6.0."
3325060|NCT00094861|Experimental|Palifermin|"Participants received a single IV dose of palifermin at 180 μg/kg administered 3 days before the initiation of concurrent chemo/radiotherapy, then once weekly during Weeks 1 through 6, typically for a total of 7 doses. Concurrent radio/chemotherapy (administered for 6 to 7 weeks) was given as follows:~standard radiotherapy 2 Gy once daily x 30 to 33 fractions (6 to 7 weeks) for a total target dose of 60 to 66 Gy~paclitaxel 50 mg/m^2 IV infusion on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy)~carboplatin dosed at an area under the curve (AUC) 2.0 IV on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy).~Participants subsequently received two 21-day cycles of consolidation chemotherapy with paclitaxel 225 mg/m^2 and carboplatin dosed at AUC 6.0."
3325132|NCT00093847|Experimental|1 Oral SAMe Tosylate|Participants receiving the oral SAMe tosylate
3325133|NCT00093847|Placebo Comparator|2 Oral Placebo Pill Twice Daily|Participants receiving placebo
3325551|NCT00004193|Experimental|ISIS 2503|patients who have metastatic and/or locally recurrent colorectal cancer
3325061|NCT00094835|Experimental|Paclitaxel + Carboplatin + Motesanib|Chemotherapy naïve participants received paclitaxel 200 mg/m^2 and carboplatin chemotherapy administered by intravenous (IV) infusion on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. The initial dose of motesanib was 50 mg once daily administered in the initial cohort and up to 125 mg once daily was used in subsequent cohorts. A cycle was defined as the 3 weeks plus the time to recover from toxicity, if encountered.
3325062|NCT00094835|Experimental|Panitumumab + Motesanib|Participants with no more than one prior chemotherapy regimen for NSCLC received panitumumab administered by IV at 9.0 mg/kg on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. The initial dose of motesanib was 50 mg once daily administered in the initial cohort, up to 125 mg once daily was used in subsequent cohorts.
3325063|NCT00094835|Experimental|Panitumumab + Paclitaxel + Carboplatin + Motesanib|"Chemotherapy naïve participants received panitumumab administered by IV at 9.0 mg/kg on Day 1 of each 21-day cycle, paclitaxel 200 mg/m^2 and carboplatin chemotherapy administered by IV infusion on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter.~Participants were enrolled in this arm once a safe and tolerable dose of motesanib was established."
3325064|NCT00094822||Pegfilgrastim|
3325065|NCT00094822||PLACEBO|
3325066|NCT00094809|Active Comparator|Pegfilgrastim|6 mg pegfilgrastim
3325067|NCT00094809|Placebo Comparator|Placebo|6 mg placebo
3325068|NCT00094770|Experimental|Sitagliptin 100 mg|Sitagliptin 100 mg oral tablets of sitagliptin once daily.
3325069|NCT00094770|Active Comparator|Glipizide|Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
3325070|NCT00094757|Experimental|Sitagliptin 100 mg|Sitagliptin 100 mg
3325071|NCT00094757|Experimental|Sitagliptin 200 mg|Sitagliptin 200 mg
3325072|NCT00094757|Placebo Comparator|Placebo/Pioglitazone|Placebo/Pioglitazone
3325073|NCT00094744|Active Comparator|6hrs daily patching|6 hours per day of patching in the sound eye
3325074|NCT00094744|Active Comparator|Full-time daily patching|Patching of the sound eye all but one waking hour
3325075|NCT00094718|Experimental|1|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^3 PFU dose) into the deltoid region of either arm.
3325076|NCT00094718|Experimental|2|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^4 PFU dose) into the deltoid region of either arm. This arm may enroll after the results from Arm 1 are analyzed.
3325077|NCT00094718|Experimental|3|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after the results from Arm 2 are analyzed.
3325078|NCT00094718|Placebo Comparator|4|One subcutaneous vaccination with placebo vaccine into the deltoid region of either arm.
3325079|NCT00094705|Experimental|1|One subcutaneous vaccination with a 10^3 PFU dose of rDEN2/4delta30(ME) vaccine given in the deltoid region of either arm.
3325080|NCT00094705|Experimental|2|One subcutaneous vaccination with a 10^5 PFU dose of rDEN2/4delta30(ME) vaccine given in the deltoid region of either arm.
3325081|NCT00094705|Placebo Comparator|3|One subcutaneous vaccination with a placebo vaccine given in the deltoid region of either arm.
3325082|NCT00094679|Active Comparator|2hrs daily patching|2 hours patching per day to cover the sound eye
3325083|NCT00094679|Active Comparator|6hrs daily patching|6 hours per day patching to cover the sound eye
3325084|NCT00094653|Active Comparator|1|Melanoma Peptide Vaccine (MDX-1379) (gp100) + Placebo
3325085|NCT00094653|Experimental|2|MDX-010 (ipilimumab) + MDX-1379 (gp100) (Melanoma Peptide Vaccine)
3325086|NCT00094653|Active Comparator|3|MDX-010 (ipilimumab) + Placebo
3325087|NCT00094575|Active Comparator|Arm 1|Standard Open Repair of Abdominal Aortic Aneurysm
3325088|NCT00094575|Active Comparator|Arm 2|Endovascular Repair of Abdominal Aortic Aneurysm
3325089|NCT00094536|Experimental|Extended Treatment Regimen|Extended treatment regimens using the Her Option Endometrial Cryotherapy System to more effectively ablate the endometrial lining, reducing menstrual levels to normal or less.
3325090|NCT00094523|Experimental|Treatment Arm A|Subjects switched their baseline PI for fosamprenavir (± ritonavir) while maintaining their baseline regimen of two nucleoside or nucleotide reverse transcriptase inhibitors for 48 weeks.
3325091|NCT00094523|Experimental|Treatment Arm B|Subjects continued baseline regimen for first 24 weeks with the option of switching their initial PI for fosamprenavir (± ritonavir) while maintaining their baseline nucleoside or nucleotide reverse transcriptase inhibitor regimen for another 24 weeks
3325092|NCT00094497|Active Comparator|EDP-M|etopodide, doxorubicin, cisplatin and mitotane
3325093|NCT00094497|Active Comparator|Sz-M|streptozotocin and mitotane
3325094|NCT00094458|Experimental|003|infliximab (IFX) infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
3325095|NCT00094458|Experimental|001|infliximab (IFX) placebo infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
3325096|NCT00094458|Experimental|002|infliximab infusion; AZA placebo caps Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
3325097|NCT00094445|Experimental|Curcumin|8 gm per day
3325098|NCT00094432|Active Comparator|A1|
3325099|NCT00094432|Placebo Comparator|A2|
3325134|NCT00093821|Experimental|Treatment (tanespimycin)|"Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11 (for patients with solid tumors) OR days 1, 4, 8, 11, 15, and 18 (for patients with leukemia). Courses for all patients repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tanespimycin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 15 patients are treated at the MTD."
3325243|NCT00092222|Active Comparator|C|EPOCH chemotherapy with rituximab may be utilized to rescue such patients, with the intent of stabilizing such patients
3325244|NCT00092222|Active Comparator|D|Patients not responding to high-dose zidovudine and valganciclovir alone may be treated with botezomib plus high-dose zidovudine and valganciclovir
3325100|NCT00094380|Experimental|Dose-escalation portion: Low dose CTLA4-IgG4m (RG2077)|Three patients will receive a single intravenous infusion of 0.2 mg/kg CTLA4-IgG4m following the scheduled cyclophosphamide infusion on the same day. If one or more dose-limiting toxicities (CTC grade 3 or higher adverse event in the first 28 days after CTLA4-IgG4m administration that is possibly, probably, or definitely related to CTLA4-IgG4m (RG2077)). are observed, enrollment in the trial will be suspended pending DSMB review. If no dose-limiting toxicity is observed in the 0.2mg/kg dose, three patients will receive a single intravenous infusion of 2 mg/kg of CTLA4-IgG4m following the scheduled cyclophosphamide infusion on the same day. If one or more dose-limiting toxicities are observed, enrollment will be suspended pending review by the Data Safety and Monitoring Board (DSMB).If no dose-limiting toxicity is observed in the 2 mg/kg dose, treatment of patients with 10 mg/kg of CTLA4-IgG4m in combination with cyclophosphamide will proceed.
3325101|NCT00094380|Experimental|Part IIA: CTLA4-IgG4m|Participants randomized to the CTLA4-IgG4m Arm will receive a single intravenous infusion of 10 mg/kg CTLA4-IgG4m (RG2077) following the scheduled cyclophosphamide infusion on the same day
3325102|NCT00094380|Experimental|Part IIA: Control Group|Participants randomized to the control group will not receive treatment with CTLA4-IgG4m (RG2077); these participants will undergo all study evaluations with the exception of the CTLA4-IgG4m (RG2077) pharmacokinetic evaluations and immunogenicity evaluations.
3325103|NCT00094354||1|HIV-infected FPDs
3325104|NCT00094354||2|Family members of HIV-infected FPDs
3325105|NCT00094354||3|Local healthcare workers
3325106|NCT00094354||4|Villagers not related to an HIV-infected individual
3325107|NCT00094328|Other|Bicalutamide with Anastrozole|Bicalutamide in combination with Anastrozole
3325108|NCT00094302|Placebo Comparator|Placebo|Placebo of spironolactone
3325109|NCT00094302|Experimental|Spironolactone|Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
3325110|NCT00094276|Experimental|1|Breathmobile intervention combined with a Facilitated Asthma Communication intervention (FACI)
3325111|NCT00094276|Active Comparator|2|FACI intervention
3325112|NCT00094276|Active Comparator|3|Breathmobile intervention
3325113|NCT00094276|No Intervention|4|Control group
3325114|NCT00094185||General|No intervention
3325115|NCT00094172|Experimental|Atorvastatin|80 mg/day
3325116|NCT00094172|Placebo Comparator|Placebo|Once daily.
3325117|NCT00094107|Experimental|Axitinib [AG-013736]|
3325118|NCT00094094|Experimental|Axitinib|AG-013736 is a vascular endothelial growth factor [VEGF] inhibitor
3325119|NCT00091468|Placebo Comparator|Placebo Group|Placebo for first six months of study; moved to open-label active nicotine for second six months
3325120|NCT00091468|Experimental|Active Nicotine Group|Blinded active nicotine for first six months of study; open-label active nicotine for second six months
3325121|NCT00094055|Experimental|Axitinib [AG-013736]|
3325122|NCT00093977|Experimental|darbepoetin alfa SF|
3325123|NCT00093964|Experimental|1|
3325124|NCT00093964|Experimental|2|
3325125|NCT00093925|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of postoperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
3325126|NCT00093925|Active Comparator|nicardipine|Nicardipine (NIC) was initiated after insertion of an arterial line upon the occurrence of postoperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
3325127|NCT00093912|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
3325128|NCT00093912|Active Comparator|sodium nitroprusside|Sodium nitroprusside (SNP) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
3325129|NCT00093886|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
3325130|NCT00093886|Active Comparator|nitroglycerin|Nitroglycerin (NTG) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
3325131|NCT00093873|Experimental|AMG 706|AMG 706 QD
3327023|NCT00071812|Experimental|Belimumab 4 mg/kg plus SOC|
3325135|NCT00093808|Experimental|capecitabine + vinorelbine + trastuzumab|"Patients receive oral capecitabine twice daily on days 1-14, vinorelbine IV over 6-10 minutes on days 1 and 8, and trastuzumab (Herceptin^®) IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years."
3325136|NCT00093795|Active Comparator|Group 1: TAC X 6|Doxorubicin, cyclophosphamide, and docetaxel.
3325137|NCT00093795|Active Comparator|Group 2: AC X 4 then P X 4|Doxorubicin, cyclophosphamide, and paclitaxel
3325138|NCT00093795|Experimental|Group 3: AC X 4 then PG X 4|Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine
3325139|NCT00093782|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a CR or PR receive 2 additional courses beyond CR or PR.
3325140|NCT00093769|Experimental|bortezomib + rituximab|"Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.~Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients in either arm may crossover to the other arm if treatment is found to be ineffective."
3325141|NCT00093756|Experimental|Treatment (bortezomib, paclitaxel, carboplatin)|"PHASE I: Cohorts of 3-6 patients receive escalating doses of study medications until the maximum tolerated dose (MTD) is determined. PHASE II: Patients receive as in phase I at the MTD. Patients also undergo radiotherapy as in phase I.~3-dimensional conformal radiation therapy bortezomib: Given IV paclitaxel: Given IV carboplatin: Given IV"
3325142|NCT00093743|Experimental|Treatment (allogeneic bone marrow or PBSC transplantation)|"NON-MYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2, cyclosporine IV every 8-12 hours on days -3 to 0, and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic bone marrow or PBSC transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV every 8-12 hours on days 1-100 with taper to day 177, and mycophenolate mofetil PO or IV every 8 hours on days 0-40 with taper to day 96."
3325143|NCT00093730|Experimental|BMS-59926|
3325144|NCT00093704|Experimental|Bortezomib + ganciclovir|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
3325145|NCT00093626|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3325146|NCT00093613|Experimental|Treatment (sorafenib tosylate)|"Patients receive oral sorafenib twice daily on days 1-28 (once daily on day 1 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients per stratum receive escalating doses of sorafenib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 3 of 6 patients experience dose-limiting toxicity."
3325147|NCT00093600|Experimental|PKC412 administered sequentially|twice daily oral dosing of PKC412 administered sequentially
3325148|NCT00093600|Experimental|PKC412 administered concomitantly|PKC412 administered concomitantly with standard induction daunorubicin and cytarabine therapy followed by high-dose consolidation therapy with cytarabine
3325149|NCT00093509|Experimental|Magnetic Resonance Based Thermometry|"Patients will receive hyperthermia throughout the course of radiotherapy delivered once weekly for a total of 5 treatments. Each treatment will last 1-2 hours with a goal of delivering a cumulative thermal dose of 10-100 CEM 43˚T90. Interstitial temperature measurements will be taken by placing a single (less than or equal to) 15 gauge thermometry catheter into the tumor.~In addition to hyperthermia treatment and radiation therapy all patients will receive conventional surgery for the removal of their tumors. Some patients will also receive chemotherapy if their treating physician thinks it is the their best interested (including the possibility of doxorubicin hydrochloride or ifosfamide and mesna)."
3325150|NCT00093496|Experimental|Treatment (chemotherapy)|Patients are stratified according to gemcitabine hydrochloride therapy (gemcitabine hydrochloride-naive/no prior exposure to gemcitabine hydrochloride vs gemcitabine hydrochloride-resistant/prior exposure to gemcitabine hydrochloride as a single agent with disease progression while on treatment). Patients receive tanespimycin IV over 2 hours on days 1 and 8 during course 1 and days 2 and 9 during subsequent courses and gemcitabine hydrochloride IV over 30 minutes on day 7 during course 1 and days 1 and 8 during subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years.
3325151|NCT00093470|Experimental|Arm A (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3325152|NCT00093470|Other|Arm B (clinical observation)|Patients undergo observation only.
3325153|NCT00093418|Experimental|Arm I|Arm I: Patients receive oral tipifarnib twice daily on days 1-21. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
3325154|NCT00093418|Experimental|Arm II|Patients receive oral tipifarnib twice daily on days 1-7 and 15-21. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
3325155|NCT00093418|Experimental|Arm III|Patients receive tipifarnib as in arm I, but at a lower dose. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
3325240|NCT00092235||Cohort 4|Patients who have undergone an allogeneic stem cell transplant and are not diagnosed withcGVHD
3325156|NCT00093418|Experimental|Arm IV|Patients receive tipifarnib as in arm II, but at a lower dose. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
3325157|NCT00093379|Experimental|Capecitabine + Oxaliplatin + XRT|Capecitabine (825 mg/m^2 twice a day, Monday-Friday during weeks 1, 2, 4, and 5) and Oxaliplatin (50 mg/m^2, Days 1, 8, 22, 29) during the duration of radiation therapy only. Radiotherapy once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. Participants with T3-4 lesions undergo radiotherapy once daily on days 43 and 44. The final dose of radiation therapy determined by the T stage of the primary tumor. Radiotherapy = XRT.
3325158|NCT00093262|Experimental|clevidipine|Clevidipine was administered in a blinded fashion intravenously, starting with an infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/hr), titrating upward, as tolerated by the patient, in doubling increments approximately every 90 seconds up to an infusion rate of 3.2 μg/kg/min (16 mg/hr) to achieve the desired blood pressure-lowering effect. Up-titration to infusion rates above 3.2 μg/kg/min could be used, guided by the patient's response, by increasing the infusion rate in serial increments of 1.5 μg/kg/min, up to the maximum recommended clevidipine infusion rate of 8.0 μg/kg/min. Clevidipine was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
3325159|NCT00093262|Placebo Comparator|placebo|Placebo consisted of 20% lipid emulsion (the same lipid vehicle used for clevidipine) administered in a blinded fashion intravenously following the same study drug administration guidelines as with clevidipine study drug administration guidelines. As with clevidipine, placebo was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
3325160|NCT00093249|Experimental|clevidipine|Clevidipine was administered in a blinded fashion by intravenous (IV) infusion, starting at a rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/hr) and titrating upward, as tolerated, in doubling increments approximately every 90 seconds to achieve the desired blood pressure-lowering effect. Up-titration to 3.2 μg/kg/min (16 mg/hr) was allowed. Infusion rates above 3.2 μg/kg/min could be used, guided by the patient's response, by increasing in serial increments of 1.5 μg/kg/min up to the maximum recommended clevidipine infusion rate of 8.0 μg/kg/min. Clevidipine was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
3325161|NCT00093249|Placebo Comparator|placebo|Placebo consisted of 20% lipid emulsion (the same lipid vehicle used for clevidipine) administered in a blinded fashion intravenously following the same study drug administration guidelines as with clevidipine study drug administration guidelines. As with clevidipine, placebo was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
3325162|NCT00093236|Experimental|Early Periodontal Treatment|Subjects will receive scaling, root planing and if needed periodontal surgery
3325163|NCT00093236|Active Comparator|Usual Dental Hygiene|Subjects will receive routine oral hygiene
3325164|NCT00093223|Experimental|1|35mg/m^2 infusion time is 3.5 minutes
3325165|NCT00093223|Experimental|2|2 doses of 35mg.m^2 with the second dose given 2 months later
3325166|NCT00093197|Experimental|A1: KAI-9803|
3325167|NCT00093197|Experimental|A2: KAI-9803|
3325168|NCT00093197|Experimental|A3: KAI-9803|
3325169|NCT00093197|Experimental|A4: KAI-9803|
3325170|NCT00093197|Placebo Comparator|A5: Placebo|
3325171|NCT00093145|Experimental|Albumin-bound paclitaxel, Carboplatin + Herceptin|Participants received albumin-bound paclitaxel, 100 mg/m^2 weekly every 3 out of 4 weeks, carboplatin at an area under the curve (AUC) = 6 every 4 weeks and Herceptin weekly, 4 mg/kg the first week and 2 mg/kg on all subsequent weeks by intravenous (IV) infusion for up to 6 cycles in the absence of disease progression or intolerable toxicity. Participants could continue treatment with chemotherapy beyond 6 cycles at the discretion of the investigator, but Herceptin therapy was to continue to be administered weekly (2 mg/kg) until intercurrent illness, disease progression, unacceptable toxicity, patient withdrawal or administration of any non-protocol anti-cancer treatment.
3325172|NCT00002524|Experimental|Regimen A|Regimen A: 5-Drug Combination Chemotherapy followed by Radiotherapy.
3325173|NCT00002524|Experimental|Regimen B|Regimen B: 4-Drug Combination Chemotherapy alternating with 3-Drug Combination Chemotherapy followed, as indicated, by Radiotherapy
3325174|NCT00002524|Experimental|Regimen C|Regimen C: 2-Drug Combination Chemotherapy with Drug Modulation followed, as indicated, by Radiotherapy.
3325175|NCT00093132|Experimental|Satraplatin|Satraplatin
3325176|NCT00093080|Experimental|Ridaforolimus|12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
3325177|NCT00093054|Active Comparator|1|Cranberry juice
3325178|NCT00093054|Placebo Comparator|2|Placebo juice
3325179|NCT00093041|Experimental|Zalutumumab 0.15 mg/kg|
3325180|NCT00093041|Experimental|Zalutumumab 0.5 mg/kg|
3325181|NCT00093041|Experimental|Zalutumumab 1 mg/kg|
3325182|NCT00093041|Experimental|Zalutumumab 2 mg/kg|
3325183|NCT00093041|Experimental|Zalutumumab 4 mg/kg|
3325184|NCT00093041|Experimental|Zalutumumab 8 mg/kg|
3325185|NCT00093015|Active Comparator|Active|
3325186|NCT00093015|Placebo Comparator|Placebo|
3325187|NCT00093002|Experimental|1|250 mg fulvestrant
3325188|NCT00093002|Experimental|2|500 mg fulvestrant
3325189|NCT00092989|Experimental|Montelukast 7 mg|Participants receive montelukast 7 mg intravenously (IV) until until a decision is made for one of the following: (1) discontinuation from the study, (2) discharge from the study site, or (3) admission to the hospital. All randomized participants will receive systemic corticosteroids (60 mg prednisone OR 50 mg prednisolone) orally immediately after the completion of the study drug administration. In addition, all participants will continue to receive standardized treatment in addition to study drug. Standardized treatment may consist of: (1) β-agonist administration beginning 20 minutes after study drug infusion, and every 20 minutes thereafter, as needed; (2) oxygen therapy; and (3) inhaled ipratropium every 60 minutes as needed.
3325241|NCT00092222|Active Comparator|A|Treatment with rituximab and liposomal doxorubicin for patients where targeted oncolytic virotherapy seems suboptimal
3325242|NCT00092222|Active Comparator|B|Single agent sirolimus for patients where targeted oncolytic virotherapy seems suboptimal
3325190|NCT00092989|Placebo Comparator|Placebo|Participants receive placebo IV until until a decision is made for one of the following: (1) discontinuation from the study, (2) discharge from the study site, or (3) admission to the hospital. All randomized participants will receive systemic corticosteroids (60 mg prednisone OR 50 mg prednisolone) orally immediately after the completion of the study drug administration. In addition, all participants will continue to receive standardized treatment in addition to study drug. Standardized treatment may consist of: (1) β-agonist administration beginning 20 minutes after study drug infusion, and every 20 minutes thereafter, as needed; (2) oxygen therapy; and (3) inhaled ipratropium every 60 minutes as needed.
3325191|NCT00092833|Experimental|1|Ezetimibe
3325192|NCT00092729|Experimental|1|etoricoxib
3325193|NCT00092729|Placebo Comparator|2|Placebo to match etoricoxib
3325194|NCT00092729|Active Comparator|3|naproxen sodium
3325195|NCT00092677|Experimental|EZ/Simva 10/40 mg|Ezetimibe 10 mg + Simvastatin 40 mg
3325196|NCT00092677|Placebo Comparator|Placebo|
3325197|NCT00092547|Experimental|qHPV Vaccine in Base Study|Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6.
3325198|NCT00092547|Placebo Comparator|Placebo in Base Study|Represents participants who were randomized into the Placebo Group, who received three 0.5 mL intramuscular injections of placebo at Day 1, Month 2, and Month 6.
3325199|NCT00092547|Experimental|qHPV Vaccine in Extension Study|Represents participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.
3325200|NCT00092534|Experimental|Quadrivalent Human Papillomavirus (HPV) Vaccine|The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
3325201|NCT00092534|Placebo Comparator|Placebo|The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
3325202|NCT00092521|Experimental|1|V501
3325203|NCT00092521|Placebo Comparator|2|Placebo
3325204|NCT00092521|Experimental|3|HPV 16 Monovalent Vaccine
3325205|NCT00092495|Experimental|1|100% Formulation qHPV Vaccine
3325206|NCT00092495|Experimental|2|60% Formulation qHPV Vaccine
3325207|NCT00092495|Experimental|3|40% Formulation qHPV Vaccine
3325208|NCT00092495|Experimental|4|20% Formulation qHPV Vaccine
3325209|NCT00092456|Experimental|RotaTeq™ Lot 1|~8.81 X 10^7 IU/Dose of RotaTeq™
3325210|NCT00092456|Experimental|RotaTeq™ Lot 2|~8.01 X 10^7 IU/Dose of RotaTeq™
3325211|NCT00092456|Experimental|RotaTeq™ Lot 3|~6.91 X 10^7 IU/Dose of RotaTeq™
3325212|NCT00092456|Placebo Comparator|Placebo|
3325213|NCT00092443|Experimental|RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)|"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent)~administered 28 to 70 days apart."
3325214|NCT00092443|Placebo Comparator|Placebo matching RotaTeq™|Placebo matching RotaTeq™ administered 28 to 70 days apart.
3325215|NCT00092417|Experimental|1|Higher Potency Dose
3325216|NCT00092417|Experimental|2|Lower Potency Dose
3325217|NCT00092391|Active Comparator|Control Group|M-M-R(TM) II at current release potency
3325218|NCT00092391|Experimental|Mumps Expiry Group 1|M-M-R(TM) II at intermediate expiry potency
3325219|NCT00092391|Experimental|Mumps Expiry Group 2|M-M-R(TM) II at expiry potency
3325220|NCT00092001|Experimental|1|
3325221|NCT00092131|Experimental|1|Montelukast - Placebo
3325222|NCT00092131|Experimental|2|Placebo - Montelukast
3325223|NCT00092118|Experimental|1|Montelukast
3325224|NCT00092118|Placebo Comparator|2|Placebo
3325225|NCT00092092|Experimental|Montelukast→Placebo|Participants receive one montelukast 5 mg chewable tablet once daily (QD) for 3 weeks. After a 2-week washout period, participants receive one placebo chewable tablet QD for 3 weeks.
3325226|NCT00092092|Experimental|Placebo→Montelukast|Participants receive one placebo chewable tablet QD for 3 weeks. After a 2-week washout period, participants receive one montelukast 5 mg chewable tablet QD for 3 weeks.
3325227|NCT00092092|Active Comparator|Budesonide→Placebo|Participants receive budesonide 200 mcg inhalation powder twice daily (BID) for 3 weeks. After a 2-week washout period, participants receive placebo inhalation powder BID for 3 weeks.
3325228|NCT00092092|Active Comparator|Placebo→Budesonide|Participants receive placebo inhalation powder BID for 3 weeks. After a 2-week washout period, participants receive budesonide 200 mcg inhalation powder BID for 3 weeks.
3325229|NCT00092053|Placebo Comparator|Placebo|Participants will receive 3 placebo tablets once a month, for 3 months, on the first day of each treatment cycle.
3325230|NCT00092053|Experimental|ibandronate 100 mg|Participants will receive 2 ibandronate 50 mg tablets and 1 placebo tablet once a month, for 3 months, on the first day of each treatment cycle.
3325231|NCT00092053|Experimental|ibandronate 150 mg|Participants will receive 3 ibandronate 50 mg tablets once a month, for 3 months, on the first day of each treatment cycle.
3325232|NCT00092014|Experimental|Alendronate 70 mg|Alendronate sodium, 70 mg, orally once weekly for up to 24 months
3325233|NCT00092014|Active Comparator|Risendronate 35 mg|Risendronate, 35 mg, orally once weekly for up to 24 months
3325234|NCT00091962|Experimental|Depressed Intervention|Telephone-based, nurse-delivered Collaborative Care program for depression; Involving: Psychoeducation; workbook for depression self-care; initiation or adjustment of antidepressant pharmacotherapy prescribed under their PCPs' direction; referral to mental health specialist
3325235|NCT00091962|Active Comparator|Depressed Usual Care|"Usual care for depression; feedback of the depression finding by the study team"
3325236|NCT00091962|No Intervention|Non-Depressed Control Group|Non-depressed control group
3325237|NCT00092235||Cohort 1|Patients who have undergone an allogeneic stem cell transplant and are diagnosed withcGVHD
3325238|NCT00092235||Cohort 2|Pediatric patients who have undergone an allogeneic stem cell transplant and arediagnosed with cGVHD
3325239|NCT00092235||Cohort 3|Patients who have undergone an allogeneic stem cell transplant and choose to submitbiopsy, blood and urine samples only
3325245|NCT00092222|Active Comparator|E|Rituximab with liposomal doxorubicin (R-Dox) followed by consolidation or maintenance therapy with dose escalating interferon-alpha
3325246|NCT00091988|Experimental|Lifestyle & Behavioral Change Program|
3325247|NCT00091988|Other|Structured Education Program|
3325248|NCT00091949|Active Comparator|Pioglitazone|pioglitazone
3325249|NCT00091949|Placebo Comparator|Placebo|inactive substance
3325250|NCT00091858|Experimental|Darbepoetin alfa 6.75 mcg/kg Q4W|
3325251|NCT00091858|Placebo Comparator|Placebo Q4W|
3325252|NCT00091832|Experimental|Denosumab 60 mg every 12 weeks|Denosumab 60 mg by subcutaneous injection once every 12 weeks (Q12W) for 25 weeks.
3325253|NCT00091832|Experimental|Denosumab 120 mg every 4 weeks|Denosumab 120 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
3325254|NCT00091832|Experimental|Denosumab 180 mg every 4 weeks|Denosumab 180 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
3325255|NCT00091832|Active Comparator|IV bisphosphonates every 4 weeks|Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion for 25 weeks.
3325256|NCT00091832|Experimental|Denosumab 180 mg every 12 weeks|Denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W) for 25 weeks.
3325257|NCT00091832|Experimental|Denosumab 30 mg every 4 weeks|Denosumab 30 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
3325258|NCT00091819|Experimental|Telavancin|
3325259|NCT00091819|Active Comparator|Vancomycin|
3325260|NCT00091806|Experimental|Cohort 1|6mg/kg of panitumumab administered once every 2 weeks until subjects develop disease progression or are unable to tolerate the study drug
3325261|NCT00091806|Experimental|Cohort 2|Panitumumab 9 mg/kg administered once every 3 weeks until subjects develop disease progression or are unable to tolerate the study drug.
3325262|NCT00091793|Experimental|AMG 162|60 mg/mL denosumab given day 1, month 6, month 12 and month 18
3325263|NCT00091793|Placebo Comparator|Placebo|Placebo given day 1, month 6, month 12 and month 18
3325264|NCT00091897|Experimental|Rituximab or placebo|Rituximab or placebo is administered through intravenous access on day 1 and again on day 15 (+/- 2 days)
3325265|NCT00091715|Experimental|1|62.5 mg table twice a day for 4 weeks followed by 125 mg tablet twice a day for 6 months followed by an open label period until end of study.
3325266|NCT00091715|Placebo Comparator|2|placebo for 6 months followed by an open label period
3325267|NCT00091676|Experimental|ID-KLH + GM-CSF|
3325268|NCT00091676|Active Comparator|KLH + GM-CSF|
3325269|NCT00091637|Placebo Comparator|1|Placebo infusion
3325270|NCT00091637|Experimental|2|Pexelizumab infusion
3325271|NCT00004195|Active Comparator|Oral eniluracil 20 mg twice daily|20 mg of eniluracil given twice daily for duration of the study. This subject may have surgery IF tumor is amenable to resection
3325272|NCT00004195|Placebo Comparator|Placebo|20 mg placebo that will be given for the duration of the study. This subject may have surgery IF tumor is amenable to resection
3325273|NCT00004184|Experimental|Arm I|Patients receive human anti-idiotypic monoclonal antibody vaccine (4B5) in sargramostim (GM-CSF) subcutaneously (SQ) on days 0, 14, 28, and 42. Patients receive GM-CSF alone SQ at vaccination site on days 2, 3, and 4 following immunization.
3325274|NCT00004184|Experimental|Arm II|Patients receive 4B5 plus alum SQ on days 0, 14, 28, and 42. Cohorts of 5 patients receive treatment every 2 weeks for up to 4 courses in the absence of unacceptable toxicity.
3325275|NCT00091572|Experimental|A|"temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (7 days on / 7 days off continuously)"
3325276|NCT00091572|Active Comparator|B|dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks
3325277|NCT00003858|Experimental|Mitoxantrone|Patients receive mitoxantrone IV over 10-30 minutes every 21 days. Treatment continues for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for the first 3 years, and then every 6 months for the next 3 years or until disease progression.
3325278|NCT00003714|Experimental|Pyrazoloacridine|
3325279|NCT00091507|Experimental|1 -- GIK|GIK = glucose-insulin-potassium; In one-liter: Dextrose 30% + 80 mEq Potassium Chloride + 50 units Regular Insulin; infused at 1.5 ml/kg/hour for a total of 12 hours.
3325280|NCT00091507|Placebo Comparator|2 -- Placebo|Dextrose 5%, infused at 1.5 ml/kg/hour for total of 12 hours.
3325281|NCT00091442|Experimental|DOXIL and docetaxel combination therapy|DOXIL and docetaxel combination therapy: DOXIL 30 mg/m2 solution administered by intravenous infusion, followed by docetaxel 60 mg/m2 administration by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
3325282|NCT00091442|Active Comparator|Docetaxel monotherapy|Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
3325283|NCT00003671|Experimental|Chemotherapy Treatment|See detailed description.
3325284|NCT00003666|Experimental|HMAF|treatment of refractory or relapsed NSCLC with HMAF
3325285|NCT00003625|Experimental|Stratum 1|Concomitant irradiation and vincristine sulfate in esc dose beginning with 0.8 mg/m2, etoposide and Cyclosporine A given over 6 weeks, then monthly maint courses over 6 mths, with no clinical and radiologic progression. Stable disease indicates continuation of therapy. Clinical deterioration within 4 months of completion of radiation therapy must be confirmed to be PD by imaging. Clinical progression even in the absence of imaging changes will be accepted as reflecting disease progression. Steroids dexamethasone (Decadron) given as clinically indicated and tapered as tolerated. Steroids may decrease capillary permeability to chemotherapeutic agents and antagonise the effect of cyclosporin A. Also contributes to the syndrome of seizures and white matter changes seen with cyclosporine in the post BMT period. If steroid use is required, the recommended schedule of Decadron dosing during the 6 week induction course is 8 mg/m2 divided q 6-8 hours.
3325286|NCT00003599|Experimental|Arm I|Alpha-tocopherol (AT) orally and isotretinoin orally daily (arm I)
3325287|NCT00003599|Experimental|Arm II|Isotretinoin orally plus AT placebo orally daily (arm II).
3325288|NCT00003591|Experimental|Pacilitaxel + External Beam Radiation Therapy (PXRT)|Paclitaxel 50 mg/m2 given on Days 1, 8, 15, 22, 29 and 36. Radiation therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day in 5.5 weeks.
3325380|NCT00090363|Experimental|ZD4054 15 mg|ZD4054 15 mg oral tablet once daily, with best supportive care
3327024|NCT00071812|Experimental|Belimumab 10 mg/kg plus SOC|
3325289|NCT00003587|Experimental|carboplatin/gemcitabine/paclitaxel|IV carboplatin AUC=5.5 day 1 every 21 days X 3 IV gemcitabine 1,000 mg/m^2/day, days 1 and 8 every 21 days X3 IV paclitaxel 225 mg/m^2/day, day 1 every 21 days X 3
3325290|NCT00003587|Experimental|cisplatin/vinorelbine/docetaxel|IV cisplatin 100 mg/m^2 day 1 every 21 days X 3 IV vinorelbine 25 mg/m^2/day, days 1 and 8 every 21 days X 3 IV docetaxel 75 mg/m^2 day 1 every 21 days X 3
3325291|NCT00003564|Experimental|Arm I (Procarbazine + Isotretinoin)|Arm I: Oral procarbazine once daily on days 1-14 every 28 days, and Oral isotretinoin every 12 hours on days 15-28 every 28 days; 6 courses of combined therapy, then continue oral isotretinoin alone on days 15-28 of each 28 day course.
3325292|NCT00003564|Experimental|Arm II (Procarbazine Alone)|Arm II: Oral Procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses of treatment.
3325293|NCT00003546|Experimental|gemcitabine + radiation|Patients receive radiation therapy 5 days per week for 5 1/2 weeks and gemcitabine IV over 30 minutes not greater than 2 hours prior to radiation therapy twice weekly. This combination radiation therapy and chemotherapy is followed by 2 weeks of rest. Patients with stable or responding disease receive a higher dose of gemcitabine IV over 30 minutes weekly for 3 weeks followed by 1 week of rest. This 4 week course is repeated 3 more times for a total of 16 weeks of gemcitabine therapy alone. Patients are followed every 2 months for the first year and then every 3 months for the next 2 years or until disease progression. Upon documentation of disease progression, patients are followed every 3 months for survival and secondary malignancy.
3325294|NCT00003451|Experimental|Arm I|Cohorts of 3 patients receive interleukin-12 IV push on day 1, followed by escalating doses of interferon alfa by subcutaneous injection at 24, 48, 72, 96 and 120 hours. Courses repeat every 2 weeks for 6 months (12 courses total) in the absence of unacceptable toxicity and disease progression. Patients achieving partial response or stable disease at the completion of 6 months of therapy may receive additional courses of therapy for up to 24 months. Dose escalation of interferon alfa continues in subsequent cohorts in the absence of dose limiting toxicity (DLT). If 1 of 3 patients experiences DLT at a dose level, then 3 additional patients are entered at that dose level. If 2 of 6 patients experience DLT, then dose escalation stops. The maximum tolerated dose is defined as 1 level below that dose at which 2 or more of 6 patients experience DLT. Patients are followed every 3 months for 1 year and then every 6 months thereafter.
3325295|NCT00003441|Experimental|Irofulven|6-hydroxymethylacylfulvene (MGI-114) IV over 5 minutes daily for 5 consecutive days every 28 day cycle.
3325296|NCT00003288|Experimental|Arm I|See arm description.
3325297|NCT00003248|Experimental|Arm I|"Patients receive fludarabine and chimeric anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab) induction. Rituximab is administered IV over 4 hours on day 1, on day 3, and over 1 hour on day 5 of week 1. Subsequent doses are given over 1 hour on day 1 every 4 weeks for a total of 6 courses. Fludarabine IV is administered over 10-30 minutes daily for 5 days during weeks 1, 5, 9, 13, 17, and 21 for a total of 6 courses. Following the sixth course of fludarabine, patients undergo clinical staging and are then observed for an additional 2 months, after which they undergo repeat clinical staging, including bone marrow aspiration. Patients achieving a complete or partial response or stable disease then proceed to consolidation therapy consisting of weekly intravenous infusions of rituximab once weekly for 4 weeks.~Patients are followed every 3 months for 1 year, and then every 6 months thereafter."
3325298|NCT00003248|Experimental|Arm II|Patients receive fludarabine induction. Patients receive fludarabine IV over 10-30 minutes daily for 5 days during weeks 1, 5, 9, 13, 17, and 21 for a total of 6 courses. Patients then proceed as in arm I. Patients are followed every 3 months for 1 year, and then every 6 months thereafter.
3325299|NCT00003223|Experimental|treatment|Fenretinide 200 mg PO days 1-25, q 28 days x 6 cycles.
3325300|NCT00091390|Experimental|EBRT and HDR brachytherapy boost|External beam radiation therapy (EBRT) and high dose rate (HDR) brachytherapy boost.
3325301|NCT00091377|Experimental|Arm A|Phenoxodiol IV 3 mg/kg combined with cisplatin 40 mg/m2 on Day 2 6 week cycles
3325302|NCT00091377|Experimental|Arm B|Phenoxodiol IV 3 mg/kg combined with paclitaxel 80 mg/m2 on Day 2 6 week cycles
3325303|NCT00091351|Experimental|surgery|"Patients undergo surgery.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed at 28 days, 4 months, every 6 months for 5 years, and then annually for 5 years."
3325304|NCT00091351|Experimental|radiation + surgery|"Patients undergo preoperative radiotherapy once daily, 5 days a week, for 5.5 weeks. Within 28-63 days after the completion of radiotherapy, patients undergo surgery.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed at 28 days, 4 months, every 6 months for 5 years, and then annually for 5 years."
3325305|NCT00091299|Experimental|warfarin|
3325306|NCT00091260|Experimental|revlimid|lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
3325307|NCT00091247|Experimental|tetracycline|"Patients receive oral tetracycline twice daily. Treatment continues for 4 weeks in the absence of unacceptable toxicity.~Quality of life is assessed at baseline and then weekly for 8 weeks.~Patients are followed at weeks 4 and 8."
3325308|NCT00091247|Placebo Comparator|placebo|"Patients receive oral placebo twice daily. Treatment continues for 4 weeks in the absence of unacceptable toxicity.~Quality of life is assessed at baseline and then weekly for 8 weeks.~Patients are followed at weeks 4 and 8."
3325309|NCT00091195|Experimental|Treatment (single-agent depsipeptide)|Patients receive depsipeptide (romidepsin) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3325310|NCT00091182|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
3325311|NCT00091169|Experimental|Arm I|Patients receive oral levocarnitine (L-carnitine) twice daily on weeks 1-4.
3325312|NCT00091169|Placebo Comparator|Arm II|Patients receive oral placebo twice daily on weeks 1-4.
3325313|NCT00091130|Experimental|Arm I (SGN-00101)|Patients receive SGN-00101 vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.
3325314|NCT00091130|Placebo Comparator|Arm II (placebo)|Patients receive placebo vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.
3325315|NCT00091117|Experimental|Treatment|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3325316|NCT00091091||All patients|Self report/Medical record review/ clinical eval
3325317|NCT00091078|Experimental|Treatment (oblimersen sodium and imatinib mesylate)|Patients receive oblimersen IV continuously on days 1-14. Patients also receive oral imatinib mesylate on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3325318|NCT00091026|Experimental|Arm I (cetuximab, gemcitabine hydrochloride, bevacizumab)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, and 22; gemcitabine IV over 30 minutes on days 1, 8, and 15; and bevacizumab IV over 30-90 minutes on days 1 and 15.
3325319|NCT00091026|Experimental|Arm II (gemcitabine hydrochloride, bevacizumab, erlotinib)|Patients receive gemcitabine and bevacizumab as in arm I. Patients also receive oral erlotinib once daily on days 1-5, 8-12, and 15-26.
3325320|NCT00090987|Experimental|Imatinib mesylate|Imatinib mesylate (Gleevec) taken 400 mg orally once a day for up to 6 months
3325321|NCT00090961|Experimental|12-week exercise program + education|A 12-week supervised exercise program consisting of 3 days a week on a stationary bike or treadmill. In addition, at the time of enrollment patients are provided educational materials focusing on breathing and energy conservation.
3325322|NCT00090961|Other|Education|At the time of enrollment patients are provided educational materials focusing on breathing and energy conservation.
3325323|NCT00090896|Experimental|CTLA4-Blocking Monoclonal Antibody|
3325324|NCT00090870|Experimental|PEG-Intron, BM-CSF and thalidomide|
3325325|NCT00090857|Experimental|Letrozole|Participants in this arm received 2.5 mg of letrozole per day for a duration of 12 months; followed by an optional 4 years. Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, ductal carcinoma in situ, or any non-breast primary cancer.
3325326|NCT00090857|Placebo Comparator|Placebo|Participants in this arm received 1 tablet per day which contained the inert ingredients from the letrozole tablet, for a duration of 12 months; followed by an optional 5 years of letrozole.Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, ductal carcinoma in situ, or any non-breast primary cancer.
3325327|NCT00090844|Experimental|triptorelin|GnRH analogue (triptorelin) during chemotherapy
3325328|NCT00090844|No Intervention|no triptorelin|No GnRH analogue (triptorelin) during chemotherapy
3325329|NCT00090779|Active Comparator|IT arm|IT (immediate treatment) arm participants received emtricitabine/tenofovir disoproxil fumarate once daily and lopinavir/ritonavir twice daily
3325330|NCT00090779|No Intervention|DT arm|DT (deferred treatment) arm participants received no treatment
3325331|NCT00090766|Experimental|Valganciclovir Age Group <= 2 Years|Eligible participants aged <= 2 years received valganciclovir up to maximum of 900 milligrams (mg) once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * body surface area (BSA) * creatinine clearance (CrCLS).
3325332|NCT00090766|Experimental|Valganciclovir Age Group >2 to <12 Years|Eligible participants aged >2 to <12 years received valganciclovir up to maximum of 900 mg once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * BSA * CrCLS.
3325333|NCT00090766|Experimental|Valganciclovir Age Group >= 12 Years|Eligible participants aged >= 12 years received valganciclovir up to maximum of 900 mg once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * BSA * CrCLS.
3325334|NCT00090753|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Patients received the same weekly dose of methoxy polyethylene glycol-epoetin beta via the same route of administration (iv or sc) as they received in the Phase II or Phase III study that qualified the patient for participation in this study. Methoxy polyethylene glycol-epoetin beta was administered every 2 or every 4 weeks in the initial 104-week treatment period. Patients on a 4-week dosing interval were switched to once-monthly administration in the 24-month extension phase. The dose of methoxy polyethylene glycol-epoetin beta was adjusted to maintain the patient's hemoglobin (Hb) within a target range of 11 to 13 g/dL.
3325335|NCT00090753|Active Comparator|Comparator ESA|Patients received the same comparator ESA [epoetin alfa, epoetin beta, or darbepoetin alfa] at the same weekly dose and dosing interval via the same route of administration (iv or sc) as they received in the Phase III study that qualified the patient for participation in this study. The dose of the comparator drug was adjusted to maintain the patient's Hb within a target range of 11 to 13 g/dL. Of the 480 patients in the comparator drug group, 170 received darbepoetin alfa, 134 received epoetin alfa, and 176 received epoetin beta.
3325336|NCT00090740||Asthmatics|People who have asthma
3325337|NCT00090740||Controls|People who do not have asthma
3325338|NCT00003217|Experimental|Treatment|See detailed description.
3325339|NCT00003170|Experimental|glutamine|Beginning the first or second day of radiotherapy, patients receive oral glutamine twice daily, including the days that they do not receive radiotherapy. Patients continue on treatment throughout radiotherapy and continue 2 weeks postradiotherapy or until grade 3 diarrhea occurs. Patients are followed weekly for 4 weeks, then at 12 months, and then at 24 months after radiotherapy.
3325340|NCT00003170|Placebo Comparator|placebo|Beginning the first or second day of radiotherapy, patients receive placebo twice daily, including the days that they do not receive radiotherapy. Patients continue on treatment throughout radiotherapy and continue 2 weeks postradiotherapy or until grade 3 diarrhea occurs. Patients are followed weekly for 4 weeks, then at 12 months, and then at 24 months after radiotherapy.
3325341|NCT00003139|Experimental|Pilocarpine hydrocloride|5mg pilocarpine hydrochloride tablets commencing 3 days prior to irradiation
3325342|NCT00003139|Placebo Comparator|Placebo|Placebo tablets commencing 3 days prior to irradiation
3325343|NCT00003134|Experimental|Arm I: irinotecan|"Patients receive irinotecan IV over 90 minutes on days 1, 8, 15, and 22. This is followed by a 2 week rest and continues for a maximum of 6 courses. Patients who received prior nitrosoureas, also receive reduced starting doses of irinotecan. The dosages may be increased once per patient after the first course if toxic effects are acceptable.~Patients are followed every 3 months for the first year, every 6 months for the next 4 years, then annually until death."
3326064|NCT00002707|Experimental|Group 3|doxorubicin and cyclophosphamide followed by surgery followed by taxotere plus tamoxifen
3325344|NCT00003134|Experimental|Arm II: irinotecan|"Patients receive irinotecan on day 1 every 3 weeks for up to 12 courses. Patients who received prior nitrosoureas receive reduced starting doses of irinotecan. The dosages may be increased once per patient after the first course if toxic effects are acceptable.~Patients are followed every 3 months for the first year, every 6 months for the next 4 years, then annually until death."
3325345|NCT00003088|Experimental|Sequential chemotherapy 21 days|Patients received doxorubicin 60 mg/m^2 every 3 weeks for four cycles followed by paclitaxel 175 mg/m^2 every 3 weeks for four cycles followed by cyclophosphamide 600 mg/m^2 every 3 weeks for four cycles.
3325346|NCT00003088|Experimental|Concurrent chemotherapy 14 days|Patients received doxorubicin 60 mg/m^2 plus cyclophosphamide 600 mg/m^2 every 2 weeks for four cycles followed by paclitaxel 175 mg/m^2 every 2 weeks for four cycles with filgrastim days 3 to 10 of each cycle at 5 µg/kg rounded to either 300 or 480 µg total dose.
3325347|NCT00003088|Experimental|Sequential chemotherapy 14 days|Patients received doxorubicin 60 mg/m2 every 2 weeks for four cycles followed by paclitaxel 175 mg/m2 every 2 weeks for four cycles followed by cyclophosphamide 600 mg/m2 every 2 weeks for four cycles, with filgrastim days 3 to 10 of each cycle (a total of seven doses) at 5 µg/kg, which could be rounded to either 300 or 480 µg total dose.
3325348|NCT00003088|Experimental|Concurrent chemotherapy 21 days|Patients received doxorubicin 60 mg/m^2 plus cyclophosphamide 600 mg/m^2 every 3 weeks for four cycles followed by paclitaxel 175 mg/m^2 every 3 weeks for four cycles.
3325349|NCT00003048|Experimental|Amifostine|Amifostine IV 2 weeks, followed by 2 weeks rest (4 week cycle)
3325350|NCT00003039|Experimental|Arm I|Patients receive treatment on an outpatient basis. Flavopiridol is administered as a continuous infusion over 72 hours every 2 weeks. Patients receive a minimum of 4 cycles of therapy unless unacceptable toxicity or disease progression occurs.
3325351|NCT00003005|Experimental|deoxycoformycin and cordycepin|Dose escalation for deoxycoformycin and cordycepin
3325352|NCT00002946|Experimental|Arm I|atients enrolled on the bioavailability portion of this study receive one dose of IV penclomedine over 1 hour followed by 2 weeks of rest. At the end of two weeks, they receive oral penclomedine for 5 days every 28 days. The starting dose is determined by a single primary patient who has been administered oral penclomedine and observed for dose limiting toxicity (DLT). [Bioavailability portion completed as of 3/98.] Those not on the bioavailability portion of study start on a standard design dose escalating schedule in which patients enroll in cohorts of 3. Patients are administered oral penclomedine daily for 5 days. This treatment repeats every 4 weeks. The MTD is defined as the dose immediately below that at which 2 patients experience DLT. Treatment repeats for 6 courses or until severe toxicity or tumor progression is observed.
3325353|NCT00002942|Active Comparator|Peripheral Blood Progenitor Cells|
3325354|NCT00002942|Experimental|Autologous Bone Marrow Collection|
3325355|NCT00002805|Experimental|Treatment|Induction will consist of one course of cytarabine and mitoxantrone. Patients achieving a complete or partial response by the end of induction will start intensification. Intensification will consist of one course of chemotherapy (Cytarabine (Ara-C), Etoposide (VP-16), Filgrastim (G-CSF)). Patients who do not attain a CNS remission following the completion of intensification therapy, or who develop recurrence of CNS disease and have not previously received radiation therapy involving the central nervous system should receive craniospinal radiotherapy. Continuation Therapy: cladribine (2CdA), Etoposide.
3325356|NCT00002744|Experimental|Arm I|Therapy defined in description.
3325357|NCT00002744|Experimental|Arm 2|Therapy defined in description.
3325358|NCT00002744|Experimental|Arm 3|Therapy defined in description.
3325359|NCT00002744|Experimental|Arm 4|Therapy defined in description.
3325360|NCT00002735|Experimental|Treatment arm|induction chemotherapy followed by chemoradiation
3325361|NCT00090610|Experimental|Arm 1 - Combination Therapy|Docetaxel 30mg/m2 mg IV on Days 1 and 8, in combination with carboplatin AUC 6 IV on Day 1, repeated every 21 days X 6 cycles or until disease progression
3325362|NCT00090610|Experimental|Arm 2 - Sequential Therapy|Docetaxel 30mg/m2 IV on Days 1 and 8, repeated every 21 days for 6 cycles until disease progression. Once subjects have completed 6 cycles of docetaxel, they receive carboplatin AUC 6 IV every 21 days for 6 cycles or until disease progression.
3325363|NCT00090584|Experimental|Combination therapy|Women randomly assigned to this condition receive 10 weeks of anti-cholinergic medication (tolterodine) and behavioral training.
3325364|NCT00090584|Active Comparator|Drug therapy alone|Women assigned to this arm received 10 weeks of anti-cholinergic medication (tolterodine), only.
3325365|NCT00090519|Experimental|Ruboxistaurin|32 milligrams (mg) once daily (QD) oral for up to 36 months
3325366|NCT00090519|Placebo Comparator|Placebo|QD oral for up to 36 months
3325367|NCT00090493|Experimental|MAGE-A3 and NY-ESO-1 Immunotherapy|Treatment will consist of receiving peptide vaccinations as a shot just under the skin (subcutaneous). Peptides are small pieces of proteins. We have chosen to vaccinate with peptides derived from cancer proteins found in myeloma and other cancers. The purpose is to generate anti-myeloma T-cells which will kill myeloma cells and nothing else.
3325368|NCT00090480|Experimental|Vaccine group|
3325369|NCT00002622|Active Comparator|Talc slurry via chest tube|talc slurry via chest tube
3325370|NCT00002622|Active Comparator|Talc via insufflation|4 to 5 grams talc via insufflation through direct or videoscopic thoracoscopy, one time
3325371|NCT00002593|Active Comparator|5-FU/Leucovorin/Levamisole|levamisole hydrochloride: 50 mg every 8 hours x 3 days, PO, repeat every 14 days for 6 months; leucovorin calcium: 20 mg/m^2/day, IV, Days 1-5 of each cycle; 5-fluorouracil: 425 mg/m^2/day, IV, Days 1-5 of each cycle;
3325372|NCT00002593|Active Comparator|Infusional 5-FU + Levamisole|levamisole hydrochloride : 50 mg every 8 hours x 3 days, PO, repeat every 14 days for 6 months; 5-fluorouracil: 250 mg/m^2/day, continuous infusion, daily for 56 days x 3 cycles of 8 weeks.
3325373|NCT00002570|Active Comparator|Fluorouracil and folinic acid|
3325374|NCT00002570|No Intervention|Observation|
3325375|NCT00002527|Experimental|Aspirin|325 mg/day PO
3325376|NCT00002527|Placebo Comparator|Placebo|
3325377|NCT00090571||Sib Pairs|Two or more biological siblings affected with JIA.
3325378|NCT00090363|Placebo Comparator|Placebo|Matching placebo oral tablet once daily, with best supportive care
3325379|NCT00090363|Experimental|ZD4054 10 mg|ZD4054 10 mg oral tablet once daily, with best supportive care
3325381|NCT00004029|Experimental|Arm I|atients in cohorts of 3-6 receive 3 vaccinations with rV-PSA at 4-week intervals (days 1, 29, 57, and 85) in the absence of disease progression or unacceptable toxicity. Response assessment is performed at eight weeks. Patients who discontinue therapy prior to eight weeks are considered unevaluable for response. If dose limiting toxicity is observed in 2 of 6 patients entered at a dose level, no further patients are entered at that level and the MTD is defined as the preceding dose level. Ten additional patients are treated at the MTD and receive granulocyte-macrophage colony-stimulating factor (GM-CSF) administered subcutaneously on day -1 through day 2 of each cycle. Patients who are HLA-A2 positive, have received all 3 rV-PSA vaccinations without unacceptable toxicity, and have been off study for at least 30 days due to disease progression may continue treatment with rV-PSA at the highest dose level and the addition of GM-CSF.
3325382|NCT00090545|Experimental|First Stage - disease progression|"The first stage was to rule out the probability of 4 month progression free survival.~Patients were given 400 mg BAY 43-9006 orally twice daily in 28 day cycles."
3325383|NCT00090545|Experimental|Second Stage - increased accrual|"Due to prostatic specific antigen and radiographic discordance during the first stage, the protocol was amended to allow accrual to a second stage.~Patients were given 400 mg BAY 43-9006 orally twice daily in 28 day cycles."
3325384|NCT00090428|Experimental|1|Participants will follow a gluten-free and casein-free diet for 18 weeks. The compliance with the diet was monitored with 24 hour dietary recall and nutritional sufficiency with diet diary analysis.
3325385|NCT00090428|Active Comparator|2|After established on a gluten free and casein free diet for at least 6 weeks, participants received double blind, placebo controlled challenges containing gluten, casein, gluten+casein, or placebo in a random order. Data was collected on behavioral and physiologic responses relative to the challenges. Children remained on the gluten free and casein free diet throughout this period.
3325386|NCT00090415|Experimental|1|Child participants with autism will undergo intensive behavioral therapy.
3325387|NCT00090415|No Intervention|2|Child participants without autism will receive no treatment and will undergo assessments to determine brain functioning only.
3325388|NCT00090285|Experimental|qHPV Vaccine|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6. Follow-up for the Base Study encompassed Month 7 through Month 36.
3325389|NCT00090285|Placebo Comparator|Placebo|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6. Follow-up for the Base Study encompassed Month 7 through Month 36.
3325390|NCT00090259|Experimental|Losartan 50 mg|50-mg losartan tablet administered daily with 1 tablet of 100-mg losartan placebo beginning Week 1 and continuing to end of study (up to 4 years)
3325391|NCT00090259|Experimental|Losartan 150 mg|Titrated losartan administration up to daily 150-mg losartan: Week 1, daily 50-mg losartan tablet coadministered with 100-mg losartan placebo; Week 2, daily 50-mg losartan placebo coadministered with 100-mg losartan; Week 3 to end of study (up to 4 years), daily 50-mg losartan tablet coadministered with 100-mg losartan
3325392|NCT00090233|Experimental|1|RotaTeq
3325393|NCT00090233|Placebo Comparator|2|Placebo
3325394|NCT00090220|Experimental|qHPV Vaccine in Base Study|Participants received blinded qHPV vaccination at Day 1, Month 2, and Month 6 of the Base Study
3325395|NCT00090220|Placebo Comparator|Placebo in Base Study|Participants received blinded placebo at Day 1, Month 2, and Month 6 in the Base Study. They were eligible to receive open-label qHPV vaccine in Extension 1
3325396|NCT00003778|Experimental|Arm I|Patients receive dolastatin 10 IV over 10 minutes. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3325397|NCT00090402|Placebo Comparator|Fish Oil Placebo & Lipoic Acid Placebo|Three 1-gram placebo-fish oil capsules (2 in the morning, 1 evening) plus one 600 milligram placebo-lipoic acid per day. Placebo fish oil capsules consisted of soybean oil flavored with lemon flavor and 5% fish oil to match fish oil capsules. LA placebo contained no LA and the following excipients: lactose, hypromellose, silicon dioxide, microcrystalline cellulose, polyethylene glycol, povidone, corn starch, talc, and magnesium stearate.
3325398|NCT00090402|Active Comparator|Fish Oil Only|Three 1-gram fish oil concentrate capsules in triglyceride form (675 milligrams DHA and 975 milligrams EPA), 2 in the morning and 1 in the evening, plus one 600 milligram placebo-lipoic acid (containing no LA and the following excipients: lactose, hypromellose, silicon dioxide, microcrystalline cellulose, polyethylene glycol, povidone, corn starch, talc, and magnesium stearate) per day.
3325399|NCT00090402|Experimental|Fish Oil Plus Lipoic Acid|Three 1-gram placebo-fish oil capsules (2 in the morning, 1 evening) plus one 600 milligram lipoic acid (LA) capsule in the racemic form per day.
3325400|NCT00090337|Experimental|Arm I|Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks.
3325401|NCT00090337|Active Comparator|Arm II|Patients undergo standard of care for 4 weeks.
3325402|NCT00090194|Experimental|Low Dose|0.5 gm/kg at 5 days pre-transplant and 7 days post-transplant
3325403|NCT00090194|Experimental|Middle Dose|1.0 gm/kg at 5 days pre-transplant and 7 days post-transplant
3325404|NCT00090194|Experimental|High Dose|2.0 gm/kg at 5 days pre-transplant and 7 days post-transplant
3325405|NCT00090142|Experimental|1|Montelukast - Placebo
3325406|NCT00090142|Experimental|2|Placebo - Montelukast
3325407|NCT00090129|Experimental|Onercept|
3325408|NCT00090129|Placebo Comparator|Placebo|
3325409|NCT00090103|Active Comparator|dutasteride|dutasteride 0.5mg once daily
3325410|NCT00090103|Experimental|Combo|Combination of dutasteride (0.5mg) and tamsulosin (0.4mg), once daily
3325411|NCT00090103|Active Comparator|tamsulosin|tamsulosin 0.4mg once daily
3325412|NCT00003588|Experimental|Arm I|Patients undergo laparoscopy for p53 assessment and catheter placement. Patients receive daily intraperitoneal injections of adenovirus p53 (Ad-p53) for 5 days every 3 weeks. Treatment is repeated every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each are treated at each dose level of Ad-p53. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity.
3325413|NCT00090064|Experimental|1|Participants will receive 125 mg MDMA followed 2 to 2.5 hours later by 62.5 mg MDMA during course of each of two day-long psychotherapy sessions plus a third open-label MDMA-assisted session.
3327315|NCT00067873|Experimental|Diet plus aerobic exercise|
3325414|NCT00090064|Placebo Comparator|2|Participants will receive an initial dose of placebo orally followed 2 to 2.5 hours later by a second dose of placebo during the course of each of two experimental sessions.
3325415|NCT00090051|Active Comparator|Fludarabine+Cyclophosphamide (FC)|
3325416|NCT00090051|Experimental|Fludarabine+Cyclophosphamide+Rituximab (FCR)|
3325417|NCT00003224|Experimental|Group 1: peptide 946 plus QS-21|100 mcg peptide gp100 [280-288] plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant
3325418|NCT00003224|Experimental|Group 2. p946 plus IFA|100 mcg peptide gp100 [280-288] plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant
3325419|NCT00003224|Experimental|Group 3: p946 plus Tet-p plus QS-21|100 mcg peptide gp100 [280-288],190 mcg tetanus peptide, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant
3325420|NCT00003224|Experimental|Group 4. p946, Tet-p plus IFA|100 mcg peptide gp100 [280-288], 190 mcg tetanus peptide, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant
3325421|NCT00003224|Experimental|Group 5: p946/Tet-p plus QS-21|282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant
3325422|NCT00003224|Experimental|Group 6. p946/Tet-p plus IFA|282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant
3325423|NCT00090038|Experimental|1|Rituximab
3325424|NCT00090038|No Intervention|2|No drug
3325425|NCT00003147|Experimental|Arm I|Patients receive adenovirus p53 construct by percutaneous injection to a maximum of two lesions on day 1. Treatment is repeated every 28 days for up to 6 courses. In the absence of dose-limiting toxicity (DLT) in the first cohort of 6 patients treated, subsequent cohorts of 6 patients each receive escalating doses of the drug on the same schedule. If DLT occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and that dose is declared the maximum tolerated dose. Study treatment may continue in the absence of disease progression and unacceptable adverse events.
3325426|NCT00003136|Experimental|Arm A|Cyclophosphamide (40mg/kg/day on days -6, -5 and -4), Carboplatin (1600, 1700 or 1800 mg/m2 on days -6, -5, -4 and -3), Amifostine (910 mg/m2 on days -6, -5, -4 and -3), Peripheral blood stem cell transplantation (day 0), G-CSF (beginning day 4)
3325427|NCT00002879|Experimental|cladribine|Patients receive cladribine (2-chlorodeoxyadenosine; 2-CdA) daily for 5 days every 4 weeks for a maximum of 6 courses; response is assessed after every 2 courses. Patients in complete remission or with stable disease discontinue treatment and are followed; those with disease progression at any time are removed from study. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and annually for 2 years.
3325428|NCT00090025|Experimental|becatecarin|becatecarin
3325429|NCT00090025|Active Comparator|5-FU Plus Leucovorin (LV)|5-Fluorouracil (5-FU) Plus Leucovorin (LV)
3325430|NCT00089973|Experimental|SB-715992|Females with advanced or metastatic breast cancer were administered Ispinesib
3325431|NCT00089960|Other|Arm|AMG 125 mg daily continuously
3325432|NCT00089921|Experimental|001|SCIO-469 30 mg capsule three times daily for 12 weeks
3325433|NCT00089921|Experimental|002|SCIO-469 60 mg capsule three times daily for 12 weeks
3325434|NCT00089921|Experimental|003|SCIO-469 100 mg tablet once daily for 12 weeks
3325435|NCT00089921|Placebo Comparator|004|Placebo 2 capsules three times daily and one tablet daily
3325436|NCT00004136|Experimental|Heat Therapy|
3325437|NCT00089908|Experimental|1|One subcutaneous vaccination with rDEN1delta30 vaccine (10^3 PFU dose) into the deltoid region of either arm.
3325438|NCT00089908|Experimental|2|One subcutaneous vaccination with rDEN1delta30 vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the effect of the vaccine on subjects in Arm 1.
3325439|NCT00089908|Placebo Comparator|3|One subcutaneous vaccination with placebo into the deltoid region of either arm.
3325440|NCT00089895|Experimental|Eptifibatide|Eptifibatide in addition to standard of care such as standard doses of aspirin, unfractionated heparin or low-molecular-weight heparin.
3325441|NCT00089895|Placebo Comparator|Placebo|Placebo in addition to standard of care such as standard doses of aspirin, unfractionated heparin or low-molecular-weight heparin.
3325442|NCT00089856|Other|2|Standard of care - chemotherapy
3325443|NCT00089856|Experimental|1|Immunotherapy
3325444|NCT00089843|Active Comparator|2|Placebo Actonel (risedronate) and active testosterone patch
3325445|NCT00089843|Active Comparator|3|Active Actonel (risedronate) and active testosterone patch
3325446|NCT00089843|Active Comparator|4|Active Actonel (risedronate) and placebo testosterone
3325447|NCT00089843|Placebo Comparator|1|Placebo testosterone patch and placebo Actonel (risedronate)
3325448|NCT00089804|Active Comparator|1|300 mg (three 2 mL vials of abetimus sodium plus six 2 mL vials of normal saline) administered i.v (in the vien) weekly
3325449|NCT00089804|Active Comparator|2|900 mg (nine 2 mL vials of abetimus sodium) administered i.v. (in the vein) weekly
3325450|NCT00089804|Placebo Comparator|3|A volume of 18 mL (Nine 2 mL vials) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly
3325451|NCT00003686|Active Comparator|Pilocarpine|
3325452|NCT00003686|Placebo Comparator|Placebo|
3325453|NCT00003556|Experimental|Arm I|Patients receive ALVAC-hB7.1 alone or combined with ALVAC-hIL-12 intratumorally on days 1, 4, 8, and 11. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at each dose level of ALVAC-hB7.1. The maximum tolerated dose is defined as the dose of ALVAC-hB7.1 at which no more than 1 of 5 patients experiences dose limiting toxicity.
3325454|NCT00089791|Placebo Comparator|Placebo|Placebo administered subcutaneously once every 6 months for 3 years.
3325455|NCT00089791|Experimental|Denosumab 60 mg Q6M|Denosumab 60 mg administered subcutaneously once every 6 months (Q6M) for 3 years.
3325456|NCT00089752|Active Comparator|Active Treatment|Continuous Positive Airway Pressure Treatment
3325457|NCT00089752|Placebo Comparator|Sham/Placebo Treatment|Ineffective sham continuous positive airway pressure device with leak in interface to <1.0 cm H2O and resistance in motor to simulate normal operating noise and no compensation for leak.
3325497|NCT00089414|Experimental|1|Treatment arm # 1 consists of the continuous administration of Yasmin oral contraceptive (a combination of 30 µg of ethinyl estradiol and 3 mg of drospirenone) for 15 weeks starting on day 2 to 5 of the first menstrual cycle.
3325458|NCT00089778|Experimental|Grp A-Measurable metastatic disease (no immediate aldesleukin)|"Patients who do not need or are ineligible for treatment with interleukin-2 (IL-2) and patients who have previously had IL-2 therapy.~A3 FGF-5 (Fibroblast growth factor 5): 172-176/217-220 peptide - two 1 ml injections in the anterior thigh deep subcutaneous tissue within 2c of each other."
3325459|NCT00089778|Experimental|Grp B - Measurable metastatic disease that require aldesleukin|"Patients who require immediate treatment with IL-2. A2 FGF-5: 117-126 peptide + HD (high dose) IL-2 (prior cycle 1)- two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.~720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses)."
3325460|NCT00089778|Experimental|Grp C - High-risk loco-regional disease|"Patients whose cancer has been surgically removed but who are at risk for recurrence and local disease and who are seeking experimental adjuvant therapy.~A2 FGF-5: 117-126 peptide (adjuvant); A3 FGF-5: 172-176/217-220 peptide (adjuvant)"
3325461|NCT00003200|Experimental|Taxotere|"After the screening procedures confirm participation in the research study:~Taxotere-Administered weekly for 1 hour (6 doses)~Radiation Therapy (XRT) -5 days a week for 6 weeks~Exam under anesthesia~Neck Dissection (if indicated)"
3325462|NCT00003058|Experimental|Troglitazone|Patients received troglitazone 800 mg oral once-daily. Treatment continued as long as patient was responding or in stable disease clinically and ended if patient experienced progression or unacceptable toxicity.
3325463|NCT00089674|Experimental|AMG 162|
3325464|NCT00089674|Placebo Comparator|Placebo|
3325465|NCT00089661|Experimental|AMG 162 / Denosumab|
3325466|NCT00089661|Placebo Comparator|Placebo|
3325467|NCT00089648|Experimental|1|
3325468|NCT00089635|Experimental|ABX-EGF|Open-label, single arm
3325469|NCT00002909|Experimental|Arm I|All patients receive oral phenylbutyrate three times daily. Groups of 4 or more patients receive escalating doses of phenylbutyrate until the maximum tolerated dose (MTD) is determined. Treatment continues until disease progression or unacceptable toxicity intervenes.
3325470|NCT00089583|Experimental|2 - 18 yrs old (FPV/RTV BID)|Cohort 1B - 2 - less than 6yrs old (FPV/RTV BID) Cohort 2 - 6 to less than 12 yrs old (FPV/RTV BID) Cohort 3 - 12 - 18 yrs old (FPV/RTV BID) Cohort 4 - 2 - 18 yrs (FPV/RTV BID)
3325471|NCT00089583|Experimental|2 - less than 6yrs old (FPV BID)|Cohort 1A - 2 - less than 6yrs old (FPV BID)
3325472|NCT00005626|Experimental|Irinotecan Treatment|Patients receive irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed for survival.
3325473|NCT00002574|Experimental|Arm I|Single-Agent Chemotherapy plus Biological Response Modifier Therapy. Homoharringtonine, HH, NSC-141633; plus Interferon alfa (Schering), IFN-A, NSC-377523.
3325474|NCT00089609|Experimental|Main cohort - Prostate Cancer|Docetaxel 75 mg/m^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days. Thalidomide 200 mg by mouth daily throughout the cycle. Prednisone 10 mg by mouth daily throughout the cycle. Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.
3325475|NCT00089609|Experimental|Expansion cohort - Prostate Cancer|Docetaxel 75 mg/m^2 intravenously over 60 minutes and Bevacizumab 15 mg/kg intravenously was given for 2 cycles. After two cycles Prednisone 10 mg by mouth daily and Thalidomide 200 mg by mouth daily was added.
3325476|NCT00089570|Experimental|Terlipressin|Terlipressin
3325477|NCT00089570|Placebo Comparator|Placebo|Placebo
3325478|NCT00089544|Experimental|Cohort A (chemotherapy, radiation, thalidomide, surgery)|Patients receive doxorubicin, ifosfamide, and dacarbazine IV continuously on days 1-3, 22-24, and 43-45. Patients receive G-CSF subcutaneously beginning on days 4, 25, and 46 and continuing until blood counts recover. Patients undergo radiotherapy once daily on days 7-11, 14-18, 21, 28-32, 35-39, and 42. Patients receive oral thalidomide once daily on days 7-21 and 26-42. Patients undergo surgical resection between days 84 and 98. Beginning 2 weeks after surgery, patients receive oral thalidomide once daily for 12 months in the absence of unacceptable toxicity.
3325479|NCT00089544|Experimental|Cohort B (thalidomide, radiation, surgery)|Patients receive oral thalidomide once daily beginning on day 1 and continuing until 1 week before surgery. Patients undergo radiotherapy once daily, 5 days a week, on weeks 1-5. Patients undergo surgical resection between days 77 and 91. Beginning 2 weeks after surgery, patients receive oral thalidomide once daily for 6 months in the absence of unacceptable toxicity.
3325480|NCT00005076|Experimental|EgFR antibody|
3325481|NCT00089505|Experimental|NVP/NVP|For participants who had SD NVP exposure prior to study entry. FTC, TDF, and NVP daily the first 14 days, then twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV twice daily plus two more NRTIs.
3325482|NCT00089505|Experimental|NVP/LPV_r|For participants who had SD NVP exposure prior to study entry. FTC and TDF daily and LPV/RTV twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily for 14 days before taking it twice daily. plus 2 more NRTIs.
3325483|NCT00089505|Experimental|NoNVP/NVP|For participants who did NOT have SD NVP exposure prior to study entry.FTC, TDF, and NVP daily the first 14 days, then twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV twice daily plus two more NRTIs.
3325484|NCT00089505|Experimental|NoNVP/LPV_r|For participants who did NOT have SD NVP exposure prior to study entry. FTC and TDF daily and LPV/RTV twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily for 14 days before taking it twice daily. plus 2 more NRTIs.
3325485|NCT00089492|Experimental|1|
3325486|NCT00089492|Active Comparator|2|
3325487|NCT00089479|Experimental|1|
3325488|NCT00089479|Active Comparator|2|
3325489|NCT00089466|Experimental|A|200 mg AMD11070 every 12 hours
3325490|NCT00089466|Experimental|B|400 mg AMD11070 every 12 hours
3325491|NCT00089466|Experimental|C|600 mg AMD11070 every 12 hours
3325492|NCT00089466|Experimental|D|800 mg AMD11070 every 12 hours
3325493|NCT00089466|Experimental|E|1000 mg AMD11070 daily
3325494|NCT00089466|Experimental|F|1500 mg AMD11070 daily
3325495|NCT00089466|Experimental|G|1000 mg AMD11070 every 12 hours
3325496|NCT00089466|Experimental|H|2000 mg AMD11070 daily
3325498|NCT00089414|Active Comparator|2|Treatment arm # 2 (interrupted Yasmin administration) will be identical to arm # 1 with the exception that the continuous administration of Yasmin will be interrupted by the substitution of placebo for Yasmin for one week during weeks 3, 8, and 14 of the study. The women participating in this treatment arm will experience episodes of menstruation after Yasmin withdrawal (when they are on placebo).
3325499|NCT00089414|Active Comparator|3|Yasmin oral contraceptive; CDB 2914 progesterone antagonist. Treatment arm # 3 is identical to treatment arm # 1 with the exception that the continuous administration of Yasmin will also include the administration of progesterone antagonist CDB-2914 during weeks 3, 8, and 14. Menses is anticipated to occur within 2-3 days of CDB-2914 administration. Women in treatment arms # 3 and # 1 will be exposed to continuous levels of Yasmin, but due to the local effects of the progesterone antagonist on the endometrium, women in arm # 3 will experience menses.
3325500|NCT00089388|Experimental|Arm I (low dose cilengitide)|Patients receive cilengitide IV at a lower dose over 1 hour twice weekly for 4 weeks.
3325501|NCT00089388|Experimental|Arm II (higher dose cilengitide)|Patients receive cilengitide IV at a higher dose over 1 hour twice weekly for 4 weeks.
3325502|NCT00089362|Experimental|Treatment (alvespimycin hydrochloride)|"Patients receive alvespimycin hydrochloride IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-2 patients receive accelerated escalating doses of alvespimycin hydrochloride until at least 1 of 2 patients experience DLT. Cohorts are then expanded to 3-6 patients who receive escalating doses (in a standard manner) of alvespimycin hydrochloride until MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. Once the MTD is determined, 10 additional patients are treated at that dose."
3325503|NCT00089349|Experimental|Arm I|"Course 1: Patients receive alemtuzumab IV over 2 hours on days 1-5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission (CR), partial remission (PR), or cytolytic PR at day 29, or patients with CNS disease that achieve a CNS 1 or CNS 2 status, proceed to course 2.~Courses 2 and 3: Patients receive alemtuzumab IV over 2 hours on days 1, 8, 15, and 22; methotrexate IV continuously over 24 hours on day 1 and then orally once daily on days 8, 15, and 22; and oral mercaptopurine once daily on days 1-28. Patients with a CR or PR at day 29 proceed to course 3. In course 3, patients receive alemtuzumab, methotrexate, and mercaptopurine as in course 2.~CNS prophylaxis*: Patients receive methotrexate intrathecally on day 1 of courses 2 and 3 on day 1 of courses 2 and 3.~NOTE: * CNS-negative patients receive methotrexate intrathecally on day 15 of course 1 and day 1 of courses 2 and 3."
3325504|NCT00089323|Other|1: Bone Marrow Aspiration|
3325505|NCT00089310|Experimental|Sentinal node mapping|
3325506|NCT00089297|Experimental|Cetuximab/Paclitaxel/Carboplatin|"Induction: Cetuximab (C225) 400 mg/m2 at wk 1 then 250 mg/m2 for 5 weeks. Paclitaxel (P) 90 mg/m2 IV and carboplatin (C) AUC = 2 IV were given weekly.~Restaging biopsy of primary site scheduled at wk 7. Concurrent chemoradiation: Radiation therapy at 200cGy/d/5 wks for a total of 50Gy and C225 at 250 mg/m2/wk. P following C225 at 30 mg/m2/wk and C following P at AUC = 1/week. Patients with a negative biopsy continued concurrent therapy to complete radiation (68-72Gy).~Restaging biopsy of primary site: Patients with positive biopsy at wk 7 or patients without a clinical complete response at the primary site after induction therapy had re-biopsy at wk 14. If the biopsy was negative, the patients continued concurrent therapy to complete radiation (68-72 Gy). If positive, resection of the primary site was done.~Additional concurrent chemoradiation: C225 at 250mg/m2/wk IV followed by P 30mg/m2/wk IV followed by C AUC = 1/wk and RT for 3 wks."
3325507|NCT00089284|Experimental|Rituxan and 90Yttrium-Zevalin plus MGd|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
3325508|NCT00089271|Experimental|Treatment (alvespimycin hydrochloride)|Patients receive 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) IV over 1-6 hours on days 1-3 or 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3325509|NCT00089245|Experimental|Radiolabeled Monoclonal Antibody Therapy|This is a Phase I trial designed to evaluate the Maximally Tolerated Dose (MTD) of intrathecal 131I-8H9. In order to find the MTD, a dose escalation scheme will be employed with patients entering in cohorts of 3 at each dose level from 10 mCi to 60 mCi and a cohort of 6 at each dose level from 70 mCi to 100 mCi.
3325510|NCT00089219|Experimental|Arm A. 6MHP vaccine 200 mcg|vaccine containing 6 melanoma helper peptides, at 200 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
3325511|NCT00089219|Experimental|Arm B. 6MHP vaccine 400 mcg|vaccine containing 6 melanoma helper peptides, at 400 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
3325512|NCT00089219|Experimental|Arm C. 6MHP vaccine 800 mcg|vaccine containing 6 melanoma helper peptides, at 800 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
3325513|NCT00089180|Experimental|Arm I (liposomal T4N5 lotion)|Patients apply T4N5 liposomal lotion topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.
3325514|NCT00089180|Placebo Comparator|Arm II (placebo)|Patients apply placebo topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.
3325515|NCT00089154|Experimental|Treatment (apolizumab)|Patients receive apolizumab IV over 2-4 hours on days 1, 2, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity.
3325516|NCT00089141|Active Comparator|Mycophenolate mofetil|Patients receive oral mycophenolate mofetil twice daily.
3325517|NCT00089141|Placebo Comparator|Placebo|Patients receive oral placebo twice daily
3325518|NCT00089128|Experimental|Gemcitabine and Irnotecan|
3325519|NCT00089102|Experimental|Gemcitabine + Irinotecan|
3325520|NCT00089089|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 1 hour on days 1-5 or on days 1-5 and 8-12. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients receive escalating doses of decitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
3325521|NCT00089076|Experimental|Treatment (ipilimumab)|"PHASE I: Patients receive MDX-010 IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients from each group receive escalating doses of MDX-010 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.~PHASE II: Patients receive MDX-010 as in phase I at the MTD."
3325522|NCT00089063|Experimental|Arm I (vaccine therapy)|Patients receive vaccination comprising tyrosinase peptide, gp100 antigen, and MART-1 antigen emulsified with Montanide ISA-51 and ISA-51 VG SC on day 1 of weeks 0, 26, 52, 78, and 104 (total of 5 vaccinations).
3325523|NCT00089063|Experimental|Arm II (vaccine therapy, sargramostim)|Patients receive vaccination comprising tyrosinase peptide, gp100 antigen, and MART-1 antigen emulsified with Montanide ISA-51 and ISA-51 VG as in arm I. Patients also receive sargramostim (GM-CSF) SC on days 1-5 of weeks 0, 26, 52, 78, and 104.
3325524|NCT00089011|Experimental|Arm I (nonmyeloablative conditioning with fludarabine and TBI)|Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.
3325525|NCT00089011|Experimental|Arm II (nonmyeloablative conditioning with TBI)|Patients undergo TBI on day 0. All patients then undergo allogeneic peripheral blood stem cell transplantation on day 0 and receive tacrolimus PO every 12 hours on days -3 to 180, with taper on day 56, or tacrolimus IV if unable to tolerate PO; and mycophenolate mofetil PO every 12 hours on days 0-27 or mycophenolate mofetil IV if unable to tolerate PO.
3325526|NCT00088998|Experimental|docetaxel + bevacizumab + capecitabine|"Patients receive docetaxel IV over 1 hour and bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.~Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years."
3325527|NCT00088985|Experimental|Dendritic Cell Vaccine|Dendritic Cells: Dosage: 20 x 106 dendritic cells (DCs) given per treatment Vinorelbine:25 mg/m2 will be administered i.v biweekly Trastuzumab: 6mg/Kg administered by i.v. biweekly
3325528|NCT00088972|Experimental|Arm I - Celecoxib|Patients receive oral celecoxib twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.
3325529|NCT00088972|Placebo Comparator|Arm II - Placebo|Patients receive oral placebo twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.
3325530|NCT00088959|Experimental|Treatment (erlotinib hydrochloride, celecoxib)|Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
3325531|NCT00088946|Experimental|Arm 1|Polyphenon E plus erlotinib placebo daily for 12 months.
3325532|NCT00088946|Experimental|Arm 2|Erlotinib and Polyphenon E placebo daily for 12 months.
3325533|NCT00088946|Placebo Comparator|Arm 3|Erlotinib placebo and Polyphenon E placebo daily for 12 months.
3325534|NCT00088933|Experimental|Arm I|Three weeks after treatment with vaccinia-CEA-TRICOM vaccine, patients receive fowlpox-CEA-TRICOM vaccine SC on day 1 and GM-CSF SC into each vaccination site on days 1-4.
3325535|NCT00088933|Experimental|Arm II|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and lower-dose docetaxel IV over 30 minutes on days 1 and 8.
3325536|NCT00088933|Experimental|Arm III|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and standard-dose docetaxel IV over 30 minutes on days 1 and 8.
3325537|NCT00088933|Experimental|Arm IV|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and full-dose docetaxel IV over 1 hour on day 1.
3325538|NCT00088933|Experimental|Arm V|Patients receive full-dose docetaxel IV over 1 hour on day 1, fowlpox-CEA-TRICOM vaccine SC on day 8, and GM-CSF SC into each vaccination site on days 8-11.
3325539|NCT00088933|Experimental|Arm VI|Patients receive full-dose docetaxel as in arm V, fowlpox-CEA-TRICOM vaccine SC on day 15, and GM-CSF SC into each vaccination site on days 15-18.
3325540|NCT00088907|Active Comparator|Arm I (docetaxel and placebo)|Patients receive docetaxel intravenously (IV) over 30-60 minutes on days 1, 8, and 15 and oral placebo once daily on days 1-28.
3325541|NCT00088907|Experimental|Arm II (docetaxel and gefitinib)|"Patients receive docetaxel as in arm I and oral gefitinib once daily on days 1-28.~ZD1839 (Iressa, gefitinib) will be given at a dose of 250 mg (one tablet) orally each day starting on day 1 and continuing for days 1 to 28 of each cycle until progression.~In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression."
3325542|NCT00088894|Experimental|Arm I (gemcitabine hydrochloride, bevacizumab)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15.
3325543|NCT00088894|Active Comparator|Arm II (gemcitabine hydrochloride, placebo)|Patients receive gemcitabine IV as in arm I and placebo IV over 30-90 minutes on days 1 and 15.
3325544|NCT00088881|Experimental|Treatment|"R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone): Patients receive R-CHOP every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response after 2 courses receive 2 additional courses. Patients achieving a partial response, uncertain CR, or stable disease receive 4 additional courses. Patients with progressive disease go off study.~Zevalin™Radioimmunotherapy: Beginning no more than 9 weeks after the last course of R-CHOP, patients receive rituximab IV on day 1 followed by indium In 111 ibritumomab tiuxetan IV over 10 minutes for imaging studies. Patients then receive rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8.~Radiation therapy: Patients with residual disease by CT scan or positron emission tomography (PET) scan after 12 weeks after radioimmunotherapy undergo conventional involved-field radiotherapy."
3325545|NCT00088855|Experimental|Treatment (bortezomib and pegylated liposomal doxorubicin)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 4. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3325546|NCT00088829|Experimental|Paclitaxel|Paclitaxel given before surgery
3325547|NCT00088777|Experimental|MET|
3325548|NCT00088777|Experimental|CSE|
3325549|NCT00088764|Experimental|1|Education: Either coping skills training or arthritis education interventions
3325552|NCT00004162|Experimental|Dose group 1 - dose 1 of Doxorubicin HCL Liposome|Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
3325553|NCT00004162|Experimental|Dose group 2 - dose 2 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
3325554|NCT00004162|Experimental|Dose Group 3 - dose 3 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
3325555|NCT00004162|Experimental|Dose group 4 - dose 4 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
3325556|NCT00004162|Experimental|Dose group 5 - dose 5 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
3325557|NCT00004162|Experimental|Dose group 6 - dose 6 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
3325558|NCT00004162|Experimental|Dose group 7 - dose 7 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
3325559|NCT00004162|Experimental|MTD group|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
3325560|NCT00003892|Experimental|ISIS 5132|ISIS 5132 x 21 days IV infusion
3325561|NCT00003828|Experimental|vinorelbine|vinorelbine 30 mg/m2/week IV bolus over approximately 6-10 minutes
3325562|NCT00003786|Experimental|Arm A|MGI-114 (11mg/m2/day x 5 days every 28 days)
3325563|NCT00003416|Experimental|treatment|"Ind:~dexamethasone 40 mg/d PO D1-4,9-12,17-20 q35 days x 3 cycles~SC Collection:~cyclophosphamide 1.5gm/m2 IV q3 hrs x 2 mesna 3 gm/m2 conIV start with cyclo GCSF 5mcg/kg/d SQ start 1 day after cyclo until WBC > 50,000/mcg~Trans (x2):~melphalan 100 mg/m2/d IV D-1,-2 PBSC infusion D0~Maint:~interferon 3 million units/m2 SQ 3x/wk"
3325564|NCT00088634|Experimental|Lurasidone|80 mg AM dosing once daily
3325565|NCT00088634|Placebo Comparator|Placebo|
3325566|NCT00088621|Experimental|Lurasidone 80 mg tablet|Lurasidone 80mg oral tablet taken once a day
3325567|NCT00088595|Experimental|Pasireotide|
3325568|NCT00088582|Experimental|Sandostatin s.c. (Octreotide)|
3325569|NCT00088582|Experimental|Pasireotide (SOM230)|
3326065|NCT00002707|Active Comparator|Group 1|doxorubicin and cyclophosphamide plus tamoxifen
3325570|NCT00003256|Experimental|Arm I|Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects may receive a dose escalation.
3325571|NCT00003213|Experimental|Oral Granisetron + Dexamethasone|"1 mg Granisetron in the morning~1 Metoclopramide placebo in the afternoon~1 mg Granisetron in the evening 4 mg Dexamethasone in the morning"
3325572|NCT00003213|Experimental|Metoclopramide + Dexamethasone|20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening) 4 mg Dexamethasone in the morning
3325573|NCT00088556|Experimental|Triplet Combination of TLK286 Carboplatin & Paclitaxel|Experimental
3325574|NCT00088543|Experimental|1 Low dose|total dose 4.5 mg/kg Thymoglobulin
3325575|NCT00088543|Experimental|2 High dose|total dose 8.5 mg/kg Thymoglobulin
3325576|NCT00002921|Experimental|Suramin|
3325577|NCT00002833|Experimental|Group 1A|"Group 1A - With or Without Remission + Failing Fludarabine therapy:~Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3 with Cladribine continuous infusion for 5 days, beginning 4 hours before Ara-C first dose. Idarubicin IV Days -6, -5 and -4. Cells infused on day 0. Cyclosporine via continuous IV infusion, oral cyclosporine administered for 6 months postinfusion (tapered 10% weekly until discontinued). Methylprednisolone begins 5 days after infusion then gradually tapered."
3325578|NCT00002833|Experimental|Group 1B|"Group 1B: With or Without Remission, No previous Fludara Therapy~Fludarabine IV over 30 minutes daily on days -6, -5, -4 and -3. Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours. Idarubicin IV Days -6, -5 and -4. Cells infused on day 0. Cyclosporine via continuous IV infusion, oral cyclosporine administered for 6 months postinfusion (tapered 10% weekly until discontinued). Methylprednisolone begins 5 days after infusion then gradually tapered."
3325579|NCT00088530|Experimental|1|
3325580|NCT00088530|Active Comparator|2|
3325581|NCT00002832|Experimental|Decitabine + Stem Cell Transplantation|
3325582|NCT00002831|Experimental|Deoxyazacytidine + Busulfan + Cyclophosphamide|Deoxyazacytidine + Busulfan + Cyclophosphamide With Allogeneic Stem Cell Transplantation
3325583|NCT00002784|Active Comparator|Standard chemotherapy|EC/AC x 4 followed by CMF x 3 and tamoxifen to 5 years after randomization.
3325584|NCT00002784|Experimental|Dose-intensive EC|High-dose EC x 3 supported by peripheral blood progenitor cells and tamoxifen to 5 years after randomization.
3325585|NCT00002779|Experimental|fludarabine + octreotide|Patients receive fludarabine IV over 10-30 minutes on days 1-5. Patients not currently receiving octreotide, receive a test dose of octreotide subcutaneously on day 1 during course 1 only and then receive octreotide intramuscularly monthly on day 1. Treatment repeats every 28 days for 4-6 courses. Patients then receive octreotide alone for 6-8 courses. Some patients may then receive another 12 courses of octreotide alone, for a total of 2 years of treatment. Patients are followed every 3 months for 5 years or until disease progression.
3325586|NCT00002618|Active Comparator|Regimen A|Patients begin radiotherapy (5 days a week for 4.5 weeks) to residual tumor on day 1 of maintenance.
3325587|NCT00002618|Active Comparator|Regimen B|Patients receive whole brain irradiation (5 days a week for 3.1 weeks) beginning on day 1 of maintenance. Patients are followed monthly for 6 months, every 3 months for 18 months, every 6 months for 3 years, and annually thereafter.
3325588|NCT00002529|Experimental|AC with concurrent tamoxifen|AC for 4 cycles with concurrent tamoxifen for 5 years
3325589|NCT00002529|Experimental|AC followed by tamoxifen|AC for 4 cycles followed by tamoxifen to 5 years from randomization.
3325590|NCT00002529|Experimental|Tamoxifen alone|Tamoxifen alone for 5 years.
3325591|NCT00002529|Experimental|AC with concurrent toremifene|AC for 4 cycles with concurrent toremifene for 5 years.
3325592|NCT00002529|Experimental|AC followed by toremifene|AC for 4 cycles followed by toremifene to 5 years from randomization.
3325593|NCT00002529|Experimental|Toremifene alone|Toremifene alone for 5 years.
3325594|NCT00088465|Experimental|Intramuscular Olanzapine Depot|Intramuscular (IM) olanzapine depot flexible dosing and flexible interval
3325595|NCT00088452|Active Comparator|1|ethosuximide
3325596|NCT00088452|Active Comparator|2|lamotrigine
3325597|NCT00088452|Active Comparator|3|valproic acid
3325598|NCT00088413|Experimental|Core|Patients receive 2 x 108 pfu PANVAC-V (vaccinia) subcutaneously on Day 1, followed by (1 x 109) pfu PANVAC-F (fowlpox) or about days 15, 29, and 43
3325599|NCT00088413|Experimental|Extention|An optional provision of up to 12 additional monthlyboosting immunizations.
3325600|NCT00088413|Experimental|Maintenance|Patients who have completed the extension phase without evidence of progressive disease maycontinue vaccination every 3 months.
3325601|NCT00088374|Experimental|Von Hippel-Lindau (VHL) associated renal tumors|
3325602|NCT00088257||Mother-child pairs|Subset of mother-child pairs enrolled in Project Viva, a cohort study of pregnant women and their offspring. 411 mother-child pairs with measures of lymphocyte proliferation in their cord blood samples make up the subset for this study.
3325603|NCT00005624|Experimental|CI-994 Treatment|Patients receive CI-994 orally daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for 30 days and then every 2 months.
3325604|NCT00005614|Experimental|Gemcitabine Treatment|Patients receive gemcitabine IV over 1 hour weekly for 7 consecutive weeks in an 8 week course. Treatment then continues weekly for 3 consecutive weeks in 4 week courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed prior to treatment and then every 12 weeks. Patients are followed every 3 months for 2 years, then every 6 months until year 5, and then annually thereafter.
3325605|NCT00004875||Standard Heparin|
3325606|NCT00004875||Enoxaprin|
3325607|NCT00004263|Experimental|Cytarabine + UCN-01|
3325608|NCT00088231|Experimental|PTK 787 + Imatinib|For 1 week prior to receipt of study combination regimen, all patients will receive single agent PTK 787 at dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels. Patients should not have a grade 3 or 4 PTK 787-related adverse events in order to begin study combination therapy with a imatinib on day 8. On Day 8, PTK 787 250 mg by mouth every day and imatinib 600 mg by mouth every day (for Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia- blastic phase (CML-BP) and imatinib 400 mg by mouth every day (for Agnogenic Myeloid Metaplasia (AMM). Length of therapy is four courses; each course equals 28 days. Patients assessed for response after each course.
3325609|NCT00088231|Experimental|PTK 787 (vatalanib) Alone|For 1 week prior to receipt of study combination regimen, all patients will receive single agent PTK 787 at dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels. Patients should not have a grade 3 or 4 PTK 787-related adverse events in order to begin study combination therapy with a imatinib on day 8. PTK 787 250 mg by mouth for Days 1 - 7.
3325610|NCT00088218|Active Comparator|Clofarabine|Clofarabine intravenous (IV) 30 mg/m^2 daily times 5 days
3325611|NCT00088218|Active Comparator|Clofarabine Plus Ara-C|Clofarabine IV 30 mg/m^2 daily times 5 days + Ara-C 20 mg/m^2 subcutaneously daily times 14 days.
3325612|NCT00088205|Experimental|A|
3325613|NCT00088166|Experimental|I|Patients will take hCRF (XERECEPT) 2mg/day and open label-dexamethasone they are currently taking.
3325614|NCT00088166|Placebo Comparator|II|Patient will receive placebo hCRF and any open-label dexamethasone that they are currently taking
3325615|NCT00003812|Experimental|chemotherapy + radiation therapy|Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 1. Filgrastim (G-CSF) is administered subcutaneously every day starting on day 6 until blood counts recover. The course is repeated once beginning on day 22. After restaging, patients begin thoracic radiotherapy daily, five days per week, for 6-7 weeks. On the same day that radiotherapy begins, patients receive carboplatin IV over 1 hour (day 43) and etoposide IV over 1 hour daily for 3 days (days 43-45). The consolidation chemotherapy is repeated every 21 days for a total of 3 courses. Patients with stable or responding disease undergo prophylactic cranial irradiation. Patients are followed at least every 3 months for 2 years, every 6 months for 3 years, and then at least every year.
3325616|NCT00003748|Experimental|irinotecan hydrochloride|One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
3325617|NCT00003677|Experimental|Dolastatin 10|Dolastatin 10 IV bolus once every 21 days.
3325618|NCT00003675|Experimental|Oral Topotecan 5 days|Patients receive intervention twice daily for 5 days
3325619|NCT00003675|Experimental|Oral Topotecan 10 days|Patients receive intervention once daily for 10 days
3325620|NCT00003610|Experimental|capsaicin + radiation therapy|Patients receive one lozenge orally of capsaicin four times daily. Treatment begins within the first 3 days of radiation therapy and continues during and for two weeks after radiation therapy is completed.
3325621|NCT00003610|Placebo Comparator|placebo + radiation therapy|Patients receive one lozenge orally of placebo four times daily. Treatment begins within the first 3 days of radiation therapy and continues during and for two weeks after radiation therapy is completed.
3325622|NCT00003557|Experimental|Arm A|Dolastatin-10 (400 mcg/m2 IV every 3 weeks)
3325623|NCT00088153|Experimental|Physiologic estrogen replacement|"Mature girls with anorexia nervosa (AN) (bone age 15 or greater): Transdermal estradiol (100 mcg) with cyclic progesterone (days 1-10 of each month).~Immature girls with AN (bone age less than 15 years): Ethinyl estradiol (3.75 mcg daily for the first 6 months, 7.5 mcg daily for the next 6 months, and 11.25 mcg daily for the final 6 months of the study"
3325624|NCT00088153|Placebo Comparator|Placebo|Placebo patches or pills
3325625|NCT00088140|Placebo Comparator|Placebo|
3325626|NCT00088140|Active Comparator|IDN-6556 5 mg twice a day (BID)|
3325627|NCT00088140|Active Comparator|IDN-6556 25mg twice a day (BID)|
3325628|NCT00088140|Active Comparator|IDN-6556 50 mg twice a day (BID)|
3325629|NCT00003225|Experimental|Ethyol plus Irinotecan|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. 10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.
3325630|NCT00088010|Experimental|1|
3325631|NCT00088010|Placebo Comparator|2|
3325632|NCT00087984|Experimental|MB-002-003|
3325633|NCT00087880|Active Comparator|Brief Treatment|Participants will start with a 21 mg nicotine patch, tapering to 14 mg patch and finally tapering to 7 mg patch. The nicotine patch will be administered on Week 3 of the program. Participants will meet with medical staff during Weeks 1, 2, 5, and 11. Five group counseling sessions must be attended by the participants. Assessments will be conducted on Weeks 12, 24, 36, 52, 64, and 104.
3325634|NCT00087880|Active Comparator|Extended Bupropion/Low Contact|Participants will receive the Brief Treatment followed by ongoing Bupropion treatment through Week 52. Participants will meet with medical staff once a month.
3325635|NCT00087880|Placebo Comparator|Extended Placebo/Low Contact|Participants will receive the Brief Treatment followed by placebo medication (sugar-pill) through Week 52 and meet with medical staff once a month.
3325636|NCT00087880|Active Comparator|Extended Bupropion/High Contact|Participants will receive Brief Treatment followed by ongoing bupropion treatment through Week 52. Participants will attending counseling session 20-40 minutes in duration and will be scheduled at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52. The contents of these sessions will introduce additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal. Subjects will be contact by phone between counseling sessions (at Weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, 48) for a brief check-in.
3325637|NCT00087880|Placebo Comparator|Extended Placebo/High Contact|Participants receive the Brief Treatment followed by a placebo medication through Week 52 and meet with medical staff once per month. Participants will attending counseling session 20-40 minutes in duration and will be scheduled at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52. The contents of these sessions will introduce additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal. Subjects will be contact by phone between counseling sessions (at Weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, 48) for a brief check-in.
3325638|NCT00087867|Experimental|001|SCIO-469 two 30-mg capsules three times daily
3325639|NCT00087867|Other|002|SCIO-469 and bortezomib In addition to SCIO-469 patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1 4 8 and 11 of a 21-day cycle followed by a 10-day rest period
3325640|NCT00005632|Experimental|Vaccine|Patients sequentially will receive glycosylated MUC-1-KLH vaccines at 3ug per vaccination.
3325641|NCT00004160|Experimental|Dose 1 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
3326132|NCT00082433|Active Comparator|B|
3325642|NCT00004160|Experimental|Dose 2 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
3325643|NCT00004160|Experimental|Dose 3 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
3325644|NCT00004160|Experimental|Dose 4 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
3325645|NCT00004160|Experimental|Dose 5 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
3325646|NCT00003196|Experimental|Treatment (irradiation, transplant, immunosuppression, DLI)|"CYTOREDUCTION: If necessary, patients with advanced malignancies undergo cytoreductive chemotherapy to reduce tumor size at discretion of primary physician and study investigators.~CONDITIONING REGIMEN: Patients undergo low-dose total-body irradiation followed by allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV BID on days -1 to 0 and then PO BID on days 1-35 with taper to day 56. Patients also receive mycophenolate mofetil PO BID on days 0-27.~POST-TRANSPLANT DLI: Patients with mixed chimerism on day 56 and no evidence of GVHD undergo DLI over 30 minutes on day 65 and may receive up to 3 additional infusions in the absence of GVHD and disease progression or persistence. Patients who have not achieved mixed chimerism at day 56 undergo DLI if complete response is not obtained after a 2 month monitoring period."
3325647|NCT00002998|Experimental|gemcitabine + cisplatin|Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 1 hour on days 1, 8, and 15 every 28 days. Patients with complete response may receive an additional 2 courses after attainment of complete response status. Treatment continues in the absence of disease progression or unacceptable toxicities for a maximum of 8 courses. Patients are followed every 3 months for 2 years and then at 3 years after treatment.
3325648|NCT00002994|Experimental|Monoclonal antibody + interleukin 2|"Cycle 1: low dose IL2 days 1-7; MoAb day 7; intermediate dose IL-2 days 8-10; Low dose IL2 days 11-20.~Cycle 2 & all subsequent cycles: MoAb day 1; intermediate dose IL2 days 1-3; low dose IL2 days 4-14"
3325649|NCT00002956|Experimental|infusions of EBV specific cytotoxic T lymphocytes|Donors undergo leukapheresis, and Epstein-Barr virus (EBV) specific cytoxic T lymphocytes are cultivated in vitro. Patients receive infusions of EBV specific cytotoxic T lymphocytes over 5 to 10 minutes on weeks 0, 2, and 4. Patients with stable disease and those achieving partial remission are followed weekly for signs of disease progression
3325650|NCT00002925|Active Comparator|ADE|
3325651|NCT00002925|Experimental|ADEP|
3325652|NCT00002862|Experimental|Arm I|Groups of 3-6 patients receive escalating doses of oral perillyl alcohol three times per day until the maximum tolerated dose or recommended phase II dose is determined. Treatment at the assigned dose continues until disease progression or unacceptable toxicity intervenes. Patients with stable disease after 8 weeks of treatment are removed from study.
3325653|NCT00002760|Other|Antiandrogen withdrawal|"antiandrogen therapy withdrawn; patient who progress will be crossed over to Arm 1A: 400 mg ketoconazole PO tid and hydrocortisone 30 mgs PO q am and 10 mgs PO qhs until treatment is no longer effective"
3325654|NCT00002760|Active Comparator|Antiandrogen withdrawal + therapy|Ketoconazole and hydrocortisone
3325655|NCT00002495|Experimental|Nodal RT|subtotal nodal irradiation will consist of mantle and periaortic/spleen fields treated sequentially. Total dose 3600-4000 cGy over 20 fractions.
3325656|NCT00002495|Experimental|Chemotherapy + Nodal RT|3 cycles (28 days each) of chemotherapy (doxorubicin 25 mg/m^2 on days 1 and 15, vinblastine 6 mg/m^2 on days 1 and 15). Four weeks after last cycle, subtotal nodal irradiation (total dose 3600-4000 cGy over 20 fractions) will be given as described for the Nodal RT arm.
3325657|NCT00087802|Active Comparator|Stratum 1|Subjects will be randomized in a 1:1 allocation to either GEMOX or CP after signed consents and baseline evaluations are completed, allowing for safe entry into the study. In order to avoid an unbalanced distribution by baseline characteristics, randomization will be stratified by one factor: disease stage (in a 1:4 proportion for Stage IIIb vs. Stage IV or relapsed disease). Randomization schedules will be produced for each stratum, and treatment allocation will be carried out centrally
3325658|NCT00087802|Active Comparator|Stratum 2|Subjects will be randomized in a 1:1 allocation to either GEMOX or CP after signed consents and baseline evaluations are completed, allowing for safe entry into the study. In order to avoid an unbalanced distribution by baseline characteristics, randomization will be stratified by one factor: disease stage (in a 1:4 proportion for Stage IIIb vs. Stage IV or relapsed disease).
3325659|NCT00087711|Experimental|A|
3325660|NCT00087711|Active Comparator|B|
3325661|NCT00087698|Experimental|A|chemotherapy, surgery then chest radiation x 54 gray (Gy)
3325662|NCT00003873|Experimental|Arm I|Patients receive fluorouracil IV as a continuous infusion for 28 days.
3325663|NCT00003873|Experimental|Arm II|Patients receive eniluracil/fluorouracil orally twice a day for 28 days.
3325664|NCT00087685|Experimental|RAD001|RAD001 10 mg by mouth Daily
3325665|NCT00087672|Experimental|CC-5013|
3325666|NCT00087646|Experimental|1|
3325667|NCT00087646|Experimental|2|
3325668|NCT00087646|Experimental|3|
3325669|NCT00087646|Active Comparator|4|
3325670|NCT00087633|Experimental|1|
3325671|NCT00087633|No Intervention|2|
3325672|NCT00087607|Experimental|Peginterferon Alfa-2a + Ribavirin|Participants received Peginterferon alfa-2a (40 kD) [Pegasys] at a dosage of 180 microgram (μg), subcutaneously (SC), once a week plus Ribavirin [Copegus] 1000 or 1200 milligram (mg)/day), orally, [according to body weight, lesser than or greater than/equal to (< or >/=) 75 kilogram (kg), respectively] twice daily during the randomized treatment period for 12 weeks. Participants who completed the randomized treatment period of 12 weeks and wished to continue therapy were given Peginterferon alfa-2a 180 μg SC once weekly plus Ribavirin 1000 or 1200 mg/day orally (< or >/=75 kg body weight, respectively twice daily for an additional 36 weeks to complete a full 48-week treatment course. After treatment completion, participants were followed-up for safety for 24 weeks.
3325793|NCT00003995|Experimental|Arm I|Patients receive a loading dose of trastuzumab IV over 90 minutes on week 1, and over 30-90 minutes weekly thereafter. Patients receive irinotecan IV over 90 minutes following trastuzumab weekly for 4 weeks. Courses are repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.
3325673|NCT00087607|Active Comparator|Peginterferon Alfa-2b + Ribavirin|Participants received Peginterferon alfa-2b (12 kD) [PEG-Intron] at a dosage of 1.5 μg/kg SC once weekly plus Ribavirin [Rebetol] 1000 or 1200 mg/day orally (< or >/=75 kg body weight, respectively) twice daily during the randomized treatment period for 12 weeks. Participants who completed the randomized treatment period of 12 weeks and wished to continue therapy were given Peginterferon alfa-2a 180 μg SC once weekly plus Ribavirin 1000 or 1200 mg/day orally (< or >/=75 kg body weight, respectively) twice daily for an additional 36 weeks to complete a full 48-week treatment course. After treatment completion, participants were followed-up for safety for 24 weeks.
3325674|NCT00087594|Experimental|Direct Observed Therapy|Participants will receive the peginterferon alfa-2a plus ribavirin at the clinic as: subcutaneous peginterferon alfa-2a 180 microgram (mcg) (once in a week) for 24 weeks for Genotype 2 or 3 (G2/3), and for 48 weeks for Genotype 1 (G1); oral ribavirin 800 milligram (mg)/day (twice in a day) for 24 weeks for G2/3, and 1000 or 1200 mg/day (twice in a day) for 48 weeks for G1.
3325675|NCT00087594|Experimental|Self-Administration Therapy|Participants will receive the peginterferon alfa-2a plus ribavirin at home as: subcutaneous peginterferon alfa-2a 180 mcg (once in a week) for 24 weeks for G2/3, and for 48 weeks for G1; oral ribavirin 800 mg/day (twice in a day) for 24 weeks for G2/3, and 1000 or 1200 mg/day (twice in a day) for 48 weeks for G1.
3325676|NCT00087581|Experimental|Group A: Monitored MMF + Reduced CNI|Group A will receive concentration-controlled/monitored MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or intravenous (IV) form. The initial dose will be at least 1 gram twice a day (BID) in adults and 600 milligrams per meter-squared (mg/m^2) in pediatrics. Subsequent doses will be adjusted to maintain blood mycophenolic acid (MPA) levels greater than or equal to (≥) 1.3 micrograms per milliliter (μg/mL) with cyclosporine or ≥1.9 μg/mL with tacrolimus. The selected CNI will be dosed to maintain reduced blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 nanograms per milliliter (ng/mL); Days 30-90, 125-165 ng/mL; Days 90 through end of study, 95-145 ng/mL. Tacrolimus target concentrations areas follows: Days 1-30, 8-12 ng/mL; Days 30-90, 4-6 ng/mL; Days 90 through end of study, 3-5 ng/mL.
3325677|NCT00087581|Experimental|Group B: Monitored MMF + Full CNI|Group B will receive concentration-controlled/monitored MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The initial dose will be at least 1 gram BID in adults and 600 mg/m^2 in pediatrics. Subsequent doses will be adjusted to maintain blood MPA levels ≥1.3 μg/mL with cyclosporine or ≥1.9 μg/mL with tacrolimus. The selected CNI will be dosed to maintain standard/full blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 250-270 ng/mL; Days 90 through end of study, 190-220 ng/mL. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 8-10 ng/mL; Days 90 through end of study, 6-8 ng/mL.
3325678|NCT00087581|Experimental|Group C: Fixed MMF + Full CNI|Group C will receive fixed-dose MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The dose will be at least 1 gram BID in adults and 600 mg/m^2 in pediatrics. Subsequent doses are not to be adjusted, except in the case of unacceptable toxicity. The selected CNI will be dosed to maintain standard/full blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 250-270 ng/mL; Days 90 through end of study, 190-220 ng/mL. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 8-10 ng/mL; Days 90 through end of study, 6-8 ng/mL.
3325679|NCT00087568|Experimental|Non-Responders|Participants will receive Pegasys 180 micro grams (µg or mcg) subcutaneously (SC) once a week and ribavirin 1000 or 1200 milligrams per day [(mg/day), < or >=75 kilogram (Kg) body weight, respectively], orally in divided doses for 60 weeks.
3325680|NCT00087568|Experimental|Non-Tolerators|Participants will receive Pegasys 180 µg subcutaneously (SC) once a week and ribavirin 1000 or 1200 mg/day (< or >=75 kg body weight, respectively) orally in divided doses for 36 weeks.
3325681|NCT00087555|Experimental|2|Sodium oxybate 6.0 g per day.
3325682|NCT00087555|Placebo Comparator|3|Placebo (one of two doses matching active treatment by volume).
3325683|NCT00087555|Experimental|1|Sodium oxybate 4.5 g per day.
3325684|NCT00087529|Experimental|1|
3325685|NCT00087529|Placebo Comparator|2|
3325686|NCT00087516|Active Comparator|Sitagliptin 100 mg/100 mg|Phase A and B: Oral tablets of sitagliptin 100 mg Once a Day (q.d )
3325687|NCT00087516|Active Comparator|Sitagliptin 200 mg/200 mg|Phase A and B: Oral tablets of sitagliptin 200 mg q.d
3325688|NCT00087516|Placebo Comparator|Placebo/Sitagliptin 100 mg|Phase A: Oral tablets of placebo matching sitagliptin 100 mg q.d. Phase B: Oral tablets of sitagliptin 100 mg q.d.
3325689|NCT00087516|Placebo Comparator|Placebo/Sitagliptin 200 mg|Phase A: Oral tablets of placebo matching sitagliptin 200 mg q.d. Phase B: Oral tablets of sitagliptin 200 mg q.d.
3325690|NCT00086645|Experimental|citalopram hydrobromide|citalopram hydrobromide, up to 20 mg daily
3325691|NCT00086645|Placebo Comparator|placebo|placebo, up to equivalent of 20 mg of active comparator daily
3325692|NCT00087438|Experimental|Stereotactic body radiation therapy (SBRT)|20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy
3325693|NCT00087412|Experimental|Treatment|Patients receive oral erlotinib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3325694|NCT00087399|Experimental|gabapentin + antidepressant|"Patients continue to receive the same antidepressant (as before study entry) on weeks 1-5. During weeks 2-5, patients also receive oral gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity.~Patients complete a hot flash diary at baseline and then daily during study treatment."
3325695|NCT00087399|Experimental|gabapentin|"Patients receive gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity. Patients are tapered off their antidepressant over 7-10 days and remain on gabapentin alone.~Patients complete a hot flash diary at baseline and then daily during study treatment."
3325696|NCT00087386|Experimental|Treatment (tanespimycin)|Patients receive tanespimycin IV over 1-6 hours once weekly for 6 weeks. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
3327316|NCT00067873|Experimental|Diet plus resistance exercise|
3325697|NCT00087373|Experimental|Treatment (recombinant fowlpox-TRICOM vaccine)|Patients receive fowlpox-TRICOM intratumorally on day 1 of weeks 1, 4, and 7 (maximum of 3 injections for a single lesion) (course 1). After 3 injections (course 1), patients with stable or responding disease receive additional injections into new lesions following the same schedule as above. Treatment repeats every 9 weeks for a maximum total of 9 injections (3 injections total into a maximum of 3 different tumors) (total of 3 courses) in the absence of disease progression or unacceptable toxicity
3325698|NCT00087295|Experimental|Treatment|Depsipeptide
3325699|NCT00087269|Experimental|Treatment (erlotinib)|Patients receive oral erlotinib once daily on days 1-14 or days 1-21 in the absence of unacceptable toxicity. Patients then undergo surgical resection on the last day of study drug administration (day 14 or day 21). Patients may receive chemotherapy and/or radiotherapy after surgical resection at the discretion of the primary physician.
3325700|NCT00087256|Placebo Comparator|Arm 1: placebo|one placebo capsule taken orally twice a day for 3 years
3325701|NCT00087256|Experimental|Arm 2: celecoxib|one 400 mg capsule taken orally twice a day for 3 years
3325702|NCT00087217|Experimental|Treatment (tanespimycin, paclitaxel)|Patients receive 17-AAG IV over 1 hour on days 1*, 4, 8, 11, 15 and 18 and paclitaxel IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3325703|NCT00087204|Experimental|Treatment (becatecarin)|Patients receive rebeccamycin analogue (XL119) IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 1 additional course beyond CR. Patients achieving a PR or HI receive 2 additional courses beyond PR or HI. Cohorts of 3-6 patients receive escalating doses of XL119 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
3325704|NCT00087191|Experimental|Diagnostic (EF5, motexafin lutetium)|Patients receive EF5 IV over 1-2.5 hours on day 1 and motexafin lutetium IV over 10-15 minutes on day 2. Patients undergo definitive surgical resection approximately 3 hours after motexafin lutetium administration. Hypoxia and motexafin lutetium levels in the resected tumors are evaluated. Tumor to normal tissue ratios are also determined.
3325705|NCT00087178|Active Comparator|Arm 1: adriamycin + cyclophosphamide|Patients receive adriamycin IV over 15 minutes followed by cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.
3325706|NCT00087178|Experimental|Arm 2: fluorouracil + epirubicin + cyclophosphamide|Patients receive fluorouracil IV, epirubicin IV over 15 minutes, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.
3325707|NCT00087152|Experimental|Imatinib Mesylate & Capecitabine|
3325708|NCT00087139|Experimental|Arm I|"Patients are stratified according to prior chemotherapy (none vs 1 prior taxane-containing regimen vs 2 prior cytotoxic regimens).~Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3325709|NCT00087126|Experimental|Topotecan|Topotecan weekly
3325710|NCT00087074|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses beyond CR.
3325711|NCT00087035|Experimental|Taxotere plus Tarceva|"Patients receive Tarceva 150 mg daily for 21 consecutive days (one treatment cycle). In addition, all patients will receive single agent Taxotere 60 mg/m2 IV over 1 hour infusion every 21 ± 2 days and have it administered on day 1.~Taxotere + Tarceva to be taken for three cycles past maximal response or until one of the following occurs: 1) a drug-related toxicity requiring discontinuation, 2) disease progression, or 3) for a maximum of 9 cycles.~Upon completion of 9 cycles of Taxotere plus Tarceva, patients showing evidence of objective response (CR, PR or stable disease) may continue in the extension phase of the study and receive treatment with Tarceva alone. Treatment response evaluated after four cycles of Tarceva treatment(immediately prior to cycle 14). Patients with progression of disease will be taken off study. Responding and stable disease patients will remain on study for up to 8 extension-phase cycles for a total of 17 cycles."
3325712|NCT00087022|Experimental|Arm I|Patients receive monoclonal chimeric antibody cG250 (WX-G250) IV over 15 minutes once weekly for 24 weeks.
3325713|NCT00087022|Placebo Comparator|Arm II|Patients receive placebo IV over 15 minutes once weekly for 24 weeks.
3325714|NCT00087009|Experimental|Group I|Patients receive rituximab IV on days 1, 8, 15, and 22 and oral beta-glucan once daily on days 1-28 (days 8-28 of course 1). Treatment repeats every 42 days for 4 courses.
3325715|NCT00087009|Experimental|Group II|Patients receive rituximab IV on days 1, 4, 8, 15, and 22 and oral beta-glucan once daily on days 8-28. Beginning on day 42, patients with responding disease may receive monthly rituximab prophylaxis.
3325716|NCT00086996|Experimental|Chemo Plus RT, Surgery, Chemo|neoadjuvant fluorouracil, oxaliplatin and radiation therapy followed by conventional surgery and adjuvant fluoruracil and oxaliplatin
3325717|NCT00086983|Experimental|Treatment (becatacarin, oxaliplatin)|"Patients receive rebeccamycin analogue IV over 1 hour on days 1-5 and oxaliplatin IV over 2 hours on day 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue and oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD."
3325718|NCT00086970|Experimental|Arm I (ifosfamide)|Patients receive high-dose ifosfamide IV continuously over 72 hours on days 1-3.
3325719|NCT00086970|Experimental|Arm II (O6-benzylguanine, ifosfamide)|Patients receive a bolus dose of O6-benzylguanine (BG) IV over 1 hour on day 1 followed by BG IV continuously and high-dose ifosfamide IV continuously over 72 hours on days 1-3.
3325720|NCT00086957|Experimental|ZD1839, Trastuzumab and Docetaxel|
3325721|NCT00086944|Experimental|Treatment (genase, combination chemotherapy)|See detailed description.
3325722|NCT00086840|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving an objective response may receive 3 consolidation courses of therapy.
3326133|NCT00082381|Experimental|Exenatide Arm|exenatide subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
3325723|NCT00086827|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have continuing tumor response or stable disease after 6 courses receive 2 additional courses beyond best response.
3325724|NCT00086801|Experimental|doxorubicin + vinblastine + gemcitabine|"Patients receive doxorubicin IV over 3-5 minutes, vinblastine IV over 3-5 minutes, and gemcitabine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo fludeoxyglucose F 18 positron-emission tomography (PET) scanning and CT scan before treatment and after courses 2 and 6 of therapy to assess response. Patients with a positive PET scan after completion of study therapy may undergo biopsy. A PET scan is performed 3 months later if biopsy is negative or biopsy is unable to be performed.~Patients are followed every 3 months for 1 year, every 4 months for 2 years, every 6 months for 2 years, and then annually for 5 years."
3325725|NCT00086762|Experimental|MR Therapy|Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. A CD with the mindfulness relaxation technique recorded on it will be given to participant. Participant to listen to the recording for about 30 minutes before receiving chemotherapy and during the time they are receiving chemotherapy. In addition to the mindfulness relaxation technique, they will also receive general information about how to manage symptoms that develop due to the chemotherapy they are receiving.
3325726|NCT00086762|Experimental|Relaxing Music (RM) Therapy|Arm II: Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment.
3325727|NCT00086762|Active Comparator|Standard Symptom Management|Arm III: Participants receive standard symptom management education.
3325728|NCT00086749||Tamoxifen group|
3325729|NCT00086736|Experimental|Arm I|Patients receive oral eflornithine and oral bicalutamide once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
3325730|NCT00086736|Experimental|Arm II|Patients receive oral eflornithine and oral bicalutamide placebo once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
3325731|NCT00086736|Experimental|Arm III|Patients receive oral eflornithine placebo and oral bicalutamide once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
3325732|NCT00086736|Experimental|Arm IV|Patients receive oral eflornithine placebo and oral bicalutamide placebo once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
3325733|NCT00086684|Experimental|Pentosan polysulfate sodium 100 mg once a day|One 100 mg pentosan polysulfate sodium capsule in the morning and 1 matching placebo capsule in the afternoon and evening for 24 weeks
3325734|NCT00086684|Experimental|Pentosan polysulfate sodium 100 mg three times a day|One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning afternoon and evening) for 24 weeks
3325735|NCT00086684|Placebo Comparator|Placebo|Placebo One placebo capsule 3 times a day (morning afternoon and evening) for 24 weeks
3325736|NCT00086671|Experimental|ABT-874 200 mg weekly|
3325737|NCT00086671|Placebo Comparator|Placebo|
3325738|NCT00086671|Experimental|ABT 874 QOW|
3325739|NCT00086619|Experimental|constant dose|Participants will receive synthetic human parathyroid hormone fragment 1-34 (hPTH 1-34) once-daily in a constant dose of 30 mcg/day.
3325740|NCT00086619|Experimental|ascending dose|Participants will receive synthetic human parathyroid hormone fragment 1-34 (hPTH 1-34) once-daily in a dose that ascends at 6 month intervals (20-30-40 mcg/day).
3325741|NCT00086580|Experimental|Combination Arm (FluCAM)|
3325742|NCT00086580|Active Comparator|Fludarabine Alone|
3325743|NCT00086411|Experimental|1: Bup+MM|bupropion and MM counseling with placebo patch
3325744|NCT00086411|Experimental|2 Bup+Mayo|bupropion and Mayo counseling with placebo patch.
3325745|NCT00086411|Placebo Comparator|3 Patch+MM|patch and MM counseling with placebo pills
3325746|NCT00086411|Experimental|4 Patch+Mayo|patch and Mayo counseling with placebo pills
3325747|NCT00086385|Active Comparator|Brief Treatment|"Pharmacological Treatment - Subjects received 12 weeks of bupropion treatment and 10 weeks of nicotine replacement treatment (NRT)~Brief Counseling - The counseling intervention consisted of five 90-minute group meetings.~There was no further treatment during Weeks 12-52."
3325748|NCT00086385|Experimental|Extended NRT|"Pharmacological Treatment - Following completion of the Brief Treatment, subjects assigned to this condition would continue receiving NRT for up to 52 weeks. Subjects in this condition would be encouraged to continue NRT through Week 24. If a subject terminated NRT and resumed smoking, before Week 50, would be instructed to set a quit date and resume NRT.~Counseling Treatment - This is identical to the Brief Counseling described above."
3325749|NCT00086385|Experimental|Tailored/No Extended NRT|This condition was identical to the Tailored/NRT condition except that no NRT was available after completion of the Brief Treatment.
3325750|NCT00086385|Experimental|Extended Tailored Counseling + NRT|Tailored Counseling Treatment- The primary goal of the extended treatment was to prevent relapse. Secondary goal was to encourage initiation of abstinence for those who have not attained it by Week 12, and re-initiation of abstinence after slips. Subjects would participate in the Brief Treatment followed by individual sessions. The first extended treatment counseling session would occur at Week 10. Additional sessions would be held every two weeks then every four weeks, and finally at Weeks 44 and 52. Each session would be 20-30 minutes long. Between sessions subjects would be contacted by phone for brief check-ins (5-10 minutes).
3325751|NCT00086515|Experimental|Sitagliptin 100 mg|The Sitagliptin 100 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin 100 mg during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin 100 mg and glipizide-matched placebo.
3326023|NCT00006001|Experimental|Arm I|Patient receive SU5416 IV over 60 minutes twice weekly for 4 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
3325752|NCT00086515|Placebo Comparator|Placebo / Glipizide 5 mg|The Placebo/Glipizide 5 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin-matched placebo during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin-matched placebo 100 mg and glipizide 5 mg which was allowed to be uptitrated, in a blinded fashion, to a maximum dose of 15 mg/day.
3325753|NCT00086502|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg
3325754|NCT00086502|Placebo Comparator|Placebo|Placebo
3325755|NCT00086489|Experimental|10 mg/kg|pts treated at 10 mg/kg dose level on a monthly regimen
3325756|NCT00086489|Experimental|15 mg/kg|pts treated at 15 mg/kg dose level on a quarterly regimen
3325757|NCT00086450|Active Comparator|Coronary Artery Bypass Graft|Coronary Artery Bypass Graft
3325758|NCT00086450|Experimental|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
3325759|NCT00086346|Active Comparator|A|
3325760|NCT00086346|Active Comparator|B|
3325761|NCT00086359|Experimental|A|One pill of abacavir/lamivudine/zidovudine twice daily
3325762|NCT00086359|Experimental|B|One pill of zidovudine/lamivudine and four pills of lopinavir/ritonavir twice daily.
3325763|NCT00086281|Experimental|1|Xyrem 9 grams given in a divided dose: 4.5 g at bedtime and 4.5 g given 2.5 to 4 hours later
3325764|NCT00086281|Active Comparator|2|Zolpidem 10 mg + placebo were given at bedtime and placebo given 2.5 to 4 hours later.
3325765|NCT00086281|Experimental|3|Xyrem 9 g + modafinil 200 mg (Xyrem 9 g was given in a divided dose: 4.5 g at bedtime and 4.5 g given 2.5 to 4 hours later; modafinil was given at 8 am on the morning of Xyrem treatment).
3325766|NCT00086281|Placebo Comparator|4|Placebo was given at bedtime and again 2.5 to 4 hours later.
3325767|NCT00086268|Experimental|Zometa®|4mg monthly for 12 months from date of first chemotherapy dose
3325768|NCT00086268|No Intervention|no further treatment|Control arm; no further treatment. Follow-up monthly for 12 months from date of first chemotherapy dose
3325769|NCT00002837|Experimental|Doxorubicin, Paclitaxel + Cyclophosphamide with PBPC|
3325770|NCT00002804|Experimental|Chemotherapy Regimen|Induction (Weeks 1-6) Vincristine sulfate (1.5 mg/m2) day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Weeks 2 and 3 - Vincristine sulfate (1.5 mg/m2) IV day 1, week 5 no chemotherapy. Evaluate for response. Local Control (Weeks 7-13) Conventional surgery and radiation therapy. Vincristine sulfate (1.5 mg/m2) IV day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Treatment continues per protocol.
3325771|NCT00002705|Experimental|Arm I|Single-Agent Chemotherapy. Topotecan, TOPO, NSC-609699.
3325772|NCT00002704|Experimental|Arm I|Single Agent Chemotherapy. TSPA or DTC101. 3-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. DM/DNR/VCR; plus TIT. 2-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. ARA-C/ASP; plus TIT. 4-Drug Combination Chemotherapy with Leucovorin Rescue plus Triple Intrathecal Therapy. CTX/MP/MTX/VP-16; with CF; plus TIT. 3-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. DM/DNR/VCR; plus TIT. 6-Drug Combination Chemotherapy with Leucovorin Rescue plus Triple Intrathecal Therapy. ARA-C/ASP/CTX/MP/MTX/VP-16; with CF; plus TIT. Radiotherapy plus 3-Drug Combination Chemotherapy. Craniospinal irradiation using x-rays with energies of 4-6 MV (electrons acceptable for spinal cord irradiation); plus ASP/DM/VCR. 2-Drug Combination Chemotherapy Alternating with 2-Drug Combination Chemotherapy. MP/MTX; alternating with CTX/VCR.
3325773|NCT00086307|Active Comparator|Pramipexole|Patients receive pramipexole and placebo. The dosage of pramipexole is 0.125 milligrams (mg) three times per day in the first week, 0.250 mg three times per day in the second week, 0.5 mg three times per day in the third week, and 0.75 mg three times per day in the fourth week and thereafter.
3325774|NCT00086307|Active Comparator|Escitalopram|Patients receive escitalopram and placebo. The dosage of escitalopram is 10 milligrams (mg) per day.
3325775|NCT00086307|Experimental|Escitalopram and Pramipexole|Patients receive escitalopram and pramipexole. The dosage of escitalopram is 10 milligrams (mg) per day. The dosage of pramipexole is 0.125 mg three times per day in the first week, 0.250 mg three times per day in the second week, 0.5 mg three times per day in the third week, and 0.75 mg three times per day in the fourth week and thereafter.
3325776|NCT00002642|Experimental|chemoradiotherapy followed by surgery|chemoradiotherapy followed by surgery and post-surgery boost chemotherapy
3325777|NCT00002565|Experimental|Arm I|"Sequential 4-, 5-, and 3-Drug Combination Chemotherapy. IdSHAP: IDA/CDDP/ARA-C/MePRDL; followed by BIdCOS: BLEO/IDA/CTX/VCR/MePRDL; followed by MINE: Mesna/IFF/DHAD/VP-16.~Alternating triple therapy (ATT) of IdSHAP (idarubicin, cisplatin, cytarabine, methylprednisolone), BIdCOS (idarubicin, vincristine, bleomycin, cyclophosphamide, methylprednisolone), and MINE (mesna, ifosfamide, mitoxantrone, etoposide)."
3325778|NCT00002565|Experimental|Arm II|4-Drug Combination Chemotherapy. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone): CTX/DOX/VCR/PRED.
3325779|NCT00086190|Active Comparator|paroxetine|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
3325780|NCT00086190|Active Comparator|venlafaxine extended release|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
3325781|NCT00086190|Placebo Comparator|placebo|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
3325782|NCT00086177|Active Comparator|1|Progesterone 8% vaginal gel
3325783|NCT00086177|Placebo Comparator|2|Placebo Vaginal Gel
3325784|NCT00086138|Experimental|1|Participants will receive sertraline at a target dose of 100mg daily.
3325785|NCT00086138|Placebo Comparator|2|Participants will receive placebo matched to sertraline
3325786|NCT00086125|Experimental|1|AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
3325787|NCT00005975|Active Comparator|Megestrol Acetate/Placebo 20 mg/day|Double blinded Megestrol Acetate 20 mg/day or Megestrol Acetate Placebo 20 mg/day taken for 3 months
3325788|NCT00005975|Active Comparator|Megestrol Acetate/Placebo 40 mg/day|Double blinded Megestrol Acetate 40 mg/day or Megestrol Acetate Placebo 40 mg/day taken for 3 months
3325789|NCT00086099|Experimental|1|Idarubicin plus amifostine
3325790|NCT00086099|Experimental|2|Idarubincin
3325791|NCT00005613|Experimental|Autologous Transplant|autologous hematopoietic progenitor cell transplant
3325792|NCT00005613|Experimental|Allogeneic Transplant|allogeneic hematopoietic progenitor cell trasnplant
3325794|NCT00003762|Experimental|Arm I: docetaxel + gemcitabine|"Patients receive docetaxel IV over 1 hour on day 1 followed by gemcitabine IV over 30 minutes on days 1, 8, and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
3325795|NCT00003762|Experimental|Arm II: docetaxel + gemcitabine|"Patients receive docetaxel IV over 1 hour and gemcitabine IV over 30 minutes on days 1 and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
3325796|NCT00003762|Experimental|Arm III: docetaxel + gemcitabine|"Patients receive docetaxel IV on day 1 and gemcitabine IV on days 1, 8, and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
3325797|NCT00003723|Experimental|Gemcitabine/Cisplatin|Gemcitabine 1000 mg/m^2 days 1, 8 15 (q 28 days) cisplatin 30 mg/m^2 days 1, 8, 15 (q 28 days)
3325798|NCT00003369|Experimental|tirapazamine/cisplatin|tirapazamine and cisplatin given Day 1 of each 21-day treatment cycle
3325799|NCT00003317|Active Comparator|Surgery + paclitaxel + carboplatin|Four to eight weeks after surgery, all patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on days 1, 22, 43, and 64. Following completion of four courses of chemotherapy, patients are followed at least every 4 months for 2 years, then every 6 months thereafter.
3325800|NCT00003317|Experimental|Surgery + paclitaxel + carboplatin + radiotherapy|Four to eight weeks after surgery, all patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on days 1, 22, 43, and 64. Following completion of four courses of chemotherapy, patients receive radiotherapy 5 days a week for 5 weeks to the mediastinum, beginning 2.5 to 4 weeks after completion of chemotherapy. Patients are followed at least every 4 months for 2 years, then every 6 months thereafter.
3325801|NCT00003127|Experimental|carbo, taxol, amifostine|carbo, taxol, amifostine
3325802|NCT00086060|Experimental|1 - Relaxation Training|Participants will receive relaxation training and standard care for FM
3325803|NCT00086060|Experimental|2 Exercise Regimen|Participants will receive an exercise regimen and standard care for FM
3325804|NCT00086060|Active Comparator|3 Standard Care|Participants will receive standard of care for FM
3325805|NCT00086060|No Intervention|4 Health Controls|Health participants will act as a control
3325806|NCT00086047|Experimental|Coping Skills|Patients will receive 8 weeks of behavioral training in pain coping strategies
3325807|NCT00086047|Active Comparator|Education|Patient will receive 8 weekly sessions of education about fibromyalgia syndrome.
3325808|NCT00002844|Experimental|Cyclophosphamide + TBI + BMT|TBI = Total Body Irradiation and BMT = Bone Marrow Transplantation (allogeneic or autologous bone marrow)
3325809|NCT00002816|Experimental|EARLY # CNS RELAPSE with BM DONOR|Induction (Etoposide, Ifosfamide with Mesna Uroprotection,Ifosfamide, Dexamethasone, Vincristine sulfate, PEG, ITT (methotrexate, cytosine arabinoside and therapeutic hydrocortisone), and leucovorin calcium then Intensification (4 courses of 6 weeks, ITT, dexamethasone, vincristine, methotrexate, leucovorin, 6-Thioguanine, cytarabine (Ara-C), Etoposide, pegaspargase, Ifosfamide with Mesna) and Idarubicin and CXRT.
3325810|NCT00002816|Experimental|LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR|Induction (Etoposide, Ifosfamide with Mesna Uroprotection,Ifosfamide, Dexamethasone, Vincristine sulfate, pegaspargase, ITT (methotrexate, cytosine arabinoside and therapeutic hydrocortisone), and leucovorin calcium then Intensification (4 courses of 6 weeks, ITT, dexamethasone, vincristine, methotrexate, leucovorin, 6-Thioguanine, cytarabine (Ara-C), Etoposide, PEG, Ifosfamide with Mesna) and Idarubicin), and Maintenance (4 x 12 courses) of ITT, Vincristine, Methotrexate, T-thioguanine.
3325811|NCT00002725|Experimental|Arm I|Single-Agent Chemotherapy/Differentiation Therapy. Bryostatin 1, BRYO, NSC-339555.
3325812|NCT00085969|Placebo Comparator|A1 - Placebo 0.04 mL twice daily|
3325813|NCT00085969|Placebo Comparator|A2 - Placebo 0.04 mL once daily|
3325814|NCT00085969|Placebo Comparator|A3 - Placebo 0.08 mL once daily|
3325815|NCT00085969|Experimental|B - Exenatide 10 mcg twice daily|
3325816|NCT00085969|Experimental|C - Exenatide 10 mcg once daily|
3325817|NCT00085969|Experimental|D - Exenatide 20 mcg once daily|
3325818|NCT00006214|Experimental|flutamide|"Patients receive oral flutamide once daily.~Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before study, at 1, 6, and 12 months, and then annually therafter. Patients are followed annually for up to 10 years."
3325819|NCT00006214|Other|placebo|"Patients receive an oral placebo once daily.~Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before study, at 1, 6, and 12 months, and then annually therafter. Patients are followed annually for up to 10 years."
3325820|NCT00002657|Experimental|Immumosuppression, IFN-a, ProMACE-CytaBOM|Doses and schedules of immunosuppressive drugs (cyclosporin (or FK506), prednisone, and acyclovir) will depend on whether patients are judged to have clinically urgent disease or not. Patients who do not have a CR after initial immunosuppression will receive 3 cycles (28 days each) Interferon alpha 2b at 3.0 x 10^6 IU/m^2 on days 1-28. Patients who have a CR will then receive 6 additional cycles with 3 doses per week, then go onto observation. Patients who do not have a CR will then receive a maximum of 6 21-day cycles of chemotherapy, consisting of: cyclophosphamide 650 mg/m^2 on day 1, adriamycin 25 mg/m^2 on day 1, etoposide 120 mg/m^2 on day 1, prednisone 60 mg/m^2 on days 1-14, cytosine arabinoside 300 mg/m^2 on day 8, bleomycin 5 mg/m^2 on day 8, vincristine 1.4 mg/m^2 on day 8, methotrexate 120 mg/m^2 on day 8, leucovorin 25 mg/m^2 q 6 hours on days 8-9, G-CSF 5 ug/kg/day on days 2-14, and one double strength tablet trimethoprim-sulfamethoxazole 3 times per week.
3327669|NCT00062491|Experimental|1|Karenitecin (BNP1350)
3325821|NCT00085930|Experimental|EBV specific CTLs w/out lymphodepletion|Escalating doses of 14g2a.zeta chimeric receptor transduced autologous EBV specific cytotoxic T-lymphocytes (EBV-CTL) and 14g2a.zeta transduced autologous peripheral blood T-cells administered to patients with Neuroblastoma.
3325822|NCT00005829|Experimental|gemcitabine|Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 4 weeks for a minimum of 3 courses. Patients achieving clinical complete remission, complete remission, nodular partial remission, or partial remission following 3 courses of therapy, receive 2 additional courses of therapy. Patients achieving complete remission or further improvement following the 2 additional courses of therapy, receive another 2 courses of therapy. Patients are followed every 3 months until disease progression or relapse. Patients achieving complete remission are followed every 6 months for 1 year.
3325823|NCT00004929|Experimental|Vaccine|Patients receive vaccination with glycosylated MUC-2 antigen with keyhole limpet hemocyanin conjugate subcutaneously (SQ) plus immunological adjuvant QS21 SQ on weeks 1-3, 7, 15, and 27 for a total of 6 vaccinations. Patients are followed every 3 months for 1 year or until disease progression.
3325824|NCT00085917|Active Comparator|Standard dose arm|Pegylated interferon alfa -2a STANDARD DOSE Pegasys 180ug/week
3325825|NCT00085917|Experimental|Double dose arm|Double dose pegylated interferon with weight based Ribavirin
3325826|NCT00085852|Experimental|Single|Treatment with BLVR
3325827|NCT00085839|Experimental|Erlotinib|Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
3325828|NCT00085839|Active Comparator|Standard Chemotherapy|Paclitaxel 200 mg/m^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
3325829|NCT00085787|Experimental|ARRY-142886|
3325830|NCT00085774|Experimental|Albuterol HFA BOI|
3325831|NCT00085774|Experimental|Albuterol HFA MDI|
3325832|NCT00085774|Placebo Comparator|Placebo|
3325833|NCT00004251|Experimental|Letrozole|Letrozole 2.5 mg po daily
3325834|NCT00003996|Experimental|chemotherapy + carmustine + etoposide + cisplatin + radiation|Patients receive pre-irradiation chemotherapy consisting of carmustine IV over 1 hour on days 1-3 and oral etoposide on days 1-21 and 29-49 immediately followed by cisplatin IV over 1-2 hours on days 1-3 and 29-31. Treatment repeats every 8 weeks for 2 courses. Patients receive concurrent cranial radiotherapy daily over 8 weeks during course 2. Patients then receive carmustine IV over 1-2 hours every 8 weeks for 4 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before the study, prior to each treatment course, every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients are followed every 4 months for 1 year, every 6 months for 4 years, annually for 5 years, and then for survival.
3325835|NCT00085735|Experimental|Arm I (3-7 years of age, LDCSI, IFRT)|See Detailed Description (Arm I)
3325836|NCT00085735|Experimental|Arm II (3-7 years of age, LDCSI, PFRT)|See Detailed Description (Arm II)
3325837|NCT00085735|Experimental|Arm III (3-7 years of age, SDCSI, IFRT)|See Detailed Description (Arm III)
3325838|NCT00085735|Active Comparator|Arm IV (3-7 years of age, SDCSI, PFRT)|See Detailed Description (Arm IV)
3325839|NCT00085735|Experimental|Arm V (8-21 years of age, SDCSI, IFRT)|See Detailed Description (Arm V)
3325840|NCT00085735|Active Comparator|Arm VI (8-21 years of age, SDCSI, PFRT)|See Detailed Description (Arm VI)
3325841|NCT00085722|Experimental|Dextrose|Subjects in Group 1 receive PrT with 15% and 25% dextrose solution, as it is generally practiced in the US today.
3325842|NCT00085722|Placebo Comparator|Normal saline|Subjects in Group 2 will receive the same treatment as Group 1, except that a 0.9% 'normal' saline solution with no known benefit will be used instead of dextrose.
3325843|NCT00085722|Other|Exercise|At-home physical therapy exercises as a non-injection control
3325844|NCT00085709|Experimental|Post-consolidation GO|Patients receive gemtuzumab ozogamicin IV over 2 hours on day 1. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
3325845|NCT00085709|Other|Post-consolidation observation|Patients receive no additional therapy. Patients are observed at days 30 and 60 after randomization.
3325846|NCT00085709|Active Comparator|Induction 7+3|Standard induction regimen of 7 days of Ara-C (cytosine arabinoside) and 3 days of daunomycin
3325847|NCT00085709|Active Comparator|Induction 7+3+GO|Gemtuzumab (GO) added to the standard induction regimen of 7 days of Ara-C and 3 days of daunomycin
3325848|NCT00085644|Experimental|Adalimumab|
3325849|NCT00085644|Placebo Comparator|Placebo|
3325850|NCT00003847|Experimental|Treatment|
3325851|NCT00003829|Experimental|fludarabine + cyclophosphamide|Patients receive alternating courses of fludarabine and cyclophosphamide. Fludarabine is administered IV over 10-30 minutes on days 1-5 of courses 1, 3, and 5. Cyclophosphamide is administered IV over 30-60 minutes on day 1 of courses 2, 4, and 6. Treatment repeats every 4 weeks. Patients achieving clinical complete remission (CCR) after 6 courses of chemotherapy receive 2 additional courses (one course of each drug). Patients achieving partial remission after 6 courses of chemotherapy also receive 2 additional courses. If these patients then achieve CCR, they receive another 2 courses. Patients are followed every 3 months.
3325852|NCT00003254|Experimental|776C85 + 5-FU|776C85, 10mg/m2/dose, PO, Days 1-28 (BID), q 5 wk; 5-FU, 1.0mg/m2/dose, PO, Days 1-28 (BID), q 5 wk.
3325853|NCT00003143|Experimental|DHAP + amifostine|Patients are randomized to receive salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP) with or without amifostine. Patients receive cisplatin IV over 3 hours followed by cytarabine IV for 2 doses. Patients also receive dexamethasone orally or IV. Treatment repeats every 3-4 weeks for 2-6 courses. Arm I: Patients receive amifostine IV over 15 minutes prior to all courses of DHAP, as a 15 minute infusion, beginning 30 minutes prior to cisplatin administration. Arm II: Patients do not receive amifostine. On day 3 of the last DHAP course, patients receive filgrastim (G-CSF) until the last day of progenitor stem cell (PSC) mobilization. PSC transplant continues daily for 4-10 days.
3325918|NCT00084630|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily on days 1-56. Treatment repeats every 56 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with documented tumor progression and no serious side effects may continue therapy at a higher dose for another 6 courses.
3326810|NCT00075114|No Intervention|2 Control Group|Participants randomized to this arm did not receive any interventions.
3325854|NCT00003143|Other|DHAP|Patients are randomized to receive salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP) with or without amifostine. Patients receive cisplatin IV over 3 hours followed by cytarabine IV for 2 doses. Patients also receive dexamethasone orally or IV. Treatment repeats every 3-4 weeks for 2-6 courses. Arm I: Patients receive amifostine IV over 15 minutes prior to all courses of DHAP, as a 15 minute infusion, beginning 30 minutes prior to cisplatin administration. Arm II: Patients do not receive amifostine. On day 3 of the last DHAP course, patients receive filgrastim (G-CSF) until the last day of progenitor stem cell (PSC) mobilization. PSC transplant continues daily for 4-10 days.
3325855|NCT00003099|Active Comparator|Arm 1 Tamoxifen + Fenretinide|Tamoxifen + Fenretinide daily for 14-28 days
3325856|NCT00003099|Placebo Comparator|Arm 2 Placebo|Placebo daily for 14-28 days
3325857|NCT00002949|Experimental|Arm A|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2), Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy) Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
3325858|NCT00002864|Active Comparator|Octreotide|
3325859|NCT00002864|Active Comparator|Tamoxifen|
3325860|NCT00002838|Experimental|Combination Chemotherapy + PSCT|PSCT = Peripheral Stem Cell Transplantation
3325861|NCT00002740|Experimental|Treatment - Carboplatin Chemotherapy|See detailed description.
3325862|NCT00085631|Experimental|Arm I|Patients received cisplatin IV and concurrently underwent hyperthermia treatment over 60-90 minutes on day 1. Patients also underwent external beam radiation therapy once daily on days 1-5. Treatment repeated weekly for 5-6 weeks in the absence of disease progression or unacceptable toxicity. After completion of chemoradiotherapy and hyperthermia, patients underwent brachytherapy to the cervix for 2-3 days.
3325863|NCT00085631|Active Comparator|Arm II|Patients received cisplatin and undergo external beam radiation therapy (and brachytherapy) as in arm I.
3325864|NCT00085566|Experimental|Everolimus (RAD-001) and Gefitinib|"•Phase I: Patients receive oral everolimus on day 1 and oral gefitinib once daily on days 8-21. Beginning on day 22, patients receive oral everolimus once weekly and oral gefitinib once daily. Treatment with the combination continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of everolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~•Phase II (prostate cancer patients only) (closed to accrual as of 10/19/2006): Patients receive oral everolimus (at the MTD determined in phase I) once weekly and oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity."
3325865|NCT00085553|Experimental|Treatment (erlotinib hydrochloride, tipifarnib)|Patients receive erlotinib hydrochloride PO QD on days 1-28 (days 8-28 of course 1 as of 11/4/2013) and tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. (Closed to accrual as of 2/2/06)
3325866|NCT00085540|Experimental|Phase 1 Dose Escalation - Romidepsin|"Patients receive FR901228 (romidepsin) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Dose escalation two dose levels:~Romidepsin (depsipeptide): 13.3mg/m2 and 17.7mg/m2~Pharmacokinetics"
3325867|NCT00085540|Experimental|Phase 2 Dose from Phase 1 - Romidepsin|"Patients receive FR901228 (romidepsin) as in phase I at dose level 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity~Romidepsin (depsipeptide): 13.3mg/m2"
3325868|NCT00085527|Experimental|depsipeptide|Depsipeptide administered on Days 1, 8, and15 of a 28-day cycle.
3325869|NCT00085501|Active Comparator|1|
3325870|NCT00085501|Active Comparator|2|
3325871|NCT00085449|Experimental|Regimen A + B|"Conditioning regimen A: Patients receive alemtuzumab IV over 2 hours on days -14 to -12; fludarabine IV over 30 minutes on days -7 to -3; and melphalan IV over 20-30 minutes on day -2.~Conditioning regimen B: Patients receive oral or IV cyclosporine twice daily and oral or IV mycophenolate mofetil twice daily on days -15 to 0. Patients also receive alemtuzumab, fludarabine, and melphalan as in conditioning regimen A. Patients undergo low-dose total body irradiation twice daily on days -2 and -1.~All patients undergo allogeneic, T-cell-depleted, CD34-positive peripheral blood stem cell transplantation on day 0. Patients receive sargramostim (GM-CSF) subcutaneously beginning on day 1 and continuing until blood counts recover.~Patients are followed every 3 months for 1 year and then every 6 months for 5 years."
3325872|NCT00085436|Experimental|Vaccine, Aldesleukin-2, Interferon-a|All patients will be treated with autologous tumor cell vaccine administered into inguinal lymph nodes via ultrasound guidance in addition to systemic IL-2 and recombinant interferon alfa. Two cycles of induction IL-2/IFNα-2a followed by 3 cycles of maintenance IL-2 + IFNα-2a.
3325873|NCT00085423|Experimental|IL-2, CTX, fludarabine, GM-CSF|Aldesleukin (IL-2), cyclophosphamide, fludarabine phosphate, sargramostim
3325874|NCT00085410|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.
3325875|NCT00085397|Experimental|Arm I|Patients undergo surgical harvesting of tumor cells for subsequent fusion. Patients receive vaccination comprising dendritic cells (DC) fused with autologous tumor cells subcutaneously on day 1. Treatment repeats every 21 days for 3 courses. Patients who achieve a partial (PR) or complete response (CR) may receive an additional 3 courses.
3325876|NCT00085397|Experimental|Arm II|Patients receive vaccination comprising DC pulsed with gp100 antigen IV on day 1. Treatment repeats every 21 days for 6 courses. Patients who achieve a PR or CR may receive an additional 6 courses.
3325877|NCT00085384|Experimental|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b (PEG IFN-α) subcutaneously (SC) on days 1, 8, 15, and 22.
3325878|NCT00085384|Experimental|Arm II|Patients receive PEG IFN-α SC (at a higher dose than in arm I) on days 1, 8, 15, and 22.
3325879|NCT00085384|Experimental|Arm III|Patients receive PEG IFN-α SC (at a higher dose than in arm II) on days 1, 8, 15, and 22.
3325880|NCT00085371|Experimental|Treatment (triapene)|Patients receive triapene IV over 2 hours on days 1-4 and 15-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3325919|NCT00084617|Experimental|Treatment (oxaliplatin, irinotecan, capecitabine)|Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on days 1, 8, 15, and 22 and oral capecitabine twice daily on days 1-5, 8-12, 15-19, and 22-26. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3325881|NCT00085358|Experimental|Treatment (carboplatin, paclitaxel, docetaxel, bevacizumab)|"Patients receive IP carboplatin on day 1, and paclitaxel IV over 3 hour (part A) or docetaxel IV over 1 hour (Part B) on day 1, and IP paclitaxel on day 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients receive IP carboplatin on day 1, paclitaxel IV on day 1, and IP paclitaxel on day 8 in course 1 as in part A dose-escalation phase. Beginning in course 2 and all subsequent courses, patients receive IP carboplatin on day 1, IV paclitaxel on day 1, and IP paclitaxel on day 8 as in the dose-escalation phase, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity."
3325882|NCT00085306|Experimental|Recombinant interferon beta|
3325883|NCT00085293|Experimental|Treatment|Starting dose 6 mg/m^2 Decitabine intravenous (IV) over 1 hour on days 1-5 and 8-12 of weeks 1 and 2 (course 1). Week 3, Iodine I 131 (131I) scanning using thyrotropin alfa injections. Participants whose scan do not demonstrate iodine uptake continue suppressive thyroid hormone therapy but no further study therapy; these participants who do show uptake undergo thyroid hormone withdrawal on weeks 4-8 and second course of decitabine (as in course 1) on weeks 7 and 8, with 131I therapy on week 9.
3325884|NCT00085280|Experimental|Treatment (erlotinib hydrochloride)|"Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients complete the Smoking Status Survey, a questionnaire regarding smoking habits, at baseline, and then every 3 months during study treatment."
3325885|NCT00085254|Experimental|Arm 1 (Safety Run In)|"INITIATION COURSE: Patients receive cilengitide IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Doses of cilengitide: 500mg, 1000mg and 2000mg~Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
3325886|NCT00085254|Experimental|Phase II (Arm1-500mg)|"INITIATION COURSE: Patients receive cilengitide (500mg) IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV (500mg) on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~cilengitide, Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
3325887|NCT00085254|Experimental|Phase II (Arm 2 -2000mg)|"INITIATION COURSE: Patients receive cilengitide (2000mg) IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV (2000mg) on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~cilengitide,Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
3325888|NCT00085202|Experimental|Stratum 1 (high-risk group)|"Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks. Six weeks after the completion of radiotherapy, patients receive high-dose chemotherapy followed by autologous stem cell transplantation (SCT) and filgrastim (G-CSF) with post-transplantation vincristine. High-dose chemotherapy and autologous SCT repeat every 4 weeks for 3 additional courses in the absence of unacceptable toxicity.~Interventions: vincristine, cisplatin, cyclophosphamide, autologous hematopoietic stem cell transplantation, filgrastim, radiation therapy"
3325889|NCT00085202|Experimental|Stratum 2 (average-risk group)|"Patients undergo craniospinal radiotherapy as in stratum 1, but at a lower dose. Patients receive high-dose chemotherapy, autologous SCT, G-CSF, and post-transplantation vincristine as in stratum 1.~Interventions: vincristine, cisplatin, cyclophosphamide, autologous hematopoietic stem cell transplantation, filgrastim, radiation therapy"
3325890|NCT00085189|Experimental|Cohort I (melanoma peptide vaccine, Montanide ISA-51)|Patients receive multi-epitope peptide melanoma peptide vaccine with incomplete Freund's adjuvant and agatolimod sodium SC at 0, 2, 4, 6, 8, 10, 14, 18, 22, 26, 38, and 50 weeks and then every six months for two years for up to 16 vaccinations in the absence of disease progression or unacceptable toxicity.
3325891|NCT00085189|Experimental|Cohort II (melanoma peptide vaccine, Montanide ISA 51 VG)|Patients receive multi-epitope peptide melanoma peptide vaccine with Montanide ISA 51 VG and agatolimod sodium SC at 0, 2, 4, 6, 8, 10, 14, 18, 22, 26, 38, and 50 weeks and then every six months for two years for up to 16 vaccinations in the absence of disease progression or unacceptable toxicity.
3325892|NCT00085124|Experimental|Arm I|"Remission induction therapy: Patients receive oblimersen IV continuously on days 1-10, cytarabine IV continuously on days 4-10, and daunorubicin IV on days 4-6.~Patients who achieve CR proceed to consolidation therapy. Patients who do not achieve CR receive a second course of induction therapy.~Second remission induction therapy: Patients receive oblimersen IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.~Patients who achieve CR proceed to consolidation therapy.~Consolidation therapy: Patients receive oblimersen IV continuously on days 1-8 and high-dose cytarabine IV over 3 hours on days 4-8. Patients with a continuing CR receive a second course of consolidation therapy."
3325893|NCT00085124|Experimental|Arm II|"Remission induction therapy: Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3.~Patients who achieve CR proceed to consolidation therapy. Patients who do not achieve CR receive a second course of induction therapy.~Second remission induction therapy: Patients receive cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1 and 2.~Patients who achieve CR proceed to consolidation therapy.~Consolidation therapy: Patients receive high-dose cytarabine IV over 3 hours on days 1-5. Patients with a continuing CR receive a second course of consolidation therapy."
3325894|NCT00085111|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3325895|NCT00085098|Experimental|Regimen A (radiotherapy only)|Within 52 days of surgery, patients will undergo standard-dose radiation therapy 5 days a week for approximately 5-6 weeks.
3326018|NCT00006083|Experimental|Fragmin|Fragmin at 5000 IU injected subcutaneously daily
3326019|NCT00006083|Placebo Comparator|placebo|placebo injected subcutaneously daily
3325896|NCT00085098|Experimental|Regimen B (chemotherapy plus radiotherapy)|"Courses 1 and 2: Patients receive carboplatin IV over 1 hour on days 1 and 2 and etoposide IV over 2 hours on days 1-3. Treatment repeats every 21 days for 2 courses.~Within 3 weeks of completing chemotherapy, patients with CR undergo low-dose radiation therapy 5 days a week for 5 weeks. Patients with MRD, a PR, or SD receive chemotherapy courses 3 and 4 as outlined below.~Courses 3 and 4: Patients receive cisplatin IV over 6 hours on day 1, cyclophosphamide IV over 1 hour on days 2 and 3, and filgrastim (G-CSF), subcutaneous (SC) or IV beginning on day 4 and continuing until blood counts recover.~Treatment repeats every 21 days for 2 courses. Patients achieving a CR or MRD proceed to reduced-dose radiotherapy. Patients with a PR, SD, or progressive disease (PD) are restaged and may undergo standard radiation therapy as in regimen A. Reduced-dose radiation therapy: Within 6 weeks of starting course 4, patients undergo lower-dose radiation therapy once daily on days 1-5 for 5 weeks"
3325897|NCT00084981|Experimental|Treatment (decitabine, valproic acid)|"Patients receive decitabine IV over 1 hour on days 1-10 and oral valproic acid three times daily on days 5-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine and valproic acid until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. After the MTD is determined, an additional 6 patients are treated at that dose."
3325898|NCT00084929|Experimental|CT Colonography|CT colonography conducted during the same assessment as colonoscopy.
3325899|NCT00084916|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3325900|NCT00084903|Experimental|Fluorescence Spectroscopy|
3325901|NCT00084877|Experimental|Treatment (triapine, irinotecan hydrochloride)|"Patients receive irinotecan IV over 1 hour on day 1 and 3-AP (Triapine®) IV over 2 hours on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of irinotecan and 3-AP (Triapine®) until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 6 additional patients are treated at that dose."
3325902|NCT00084864|Experimental|Stage 1, Arm I|Patients receive oral dexamethasone once daily on days 1-4 and oral calcitriol once daily on days 2-4 weekly for 4 weeks before surgery.
3325903|NCT00084864|Experimental|Stage 1, Arm II|No study drugs before surgery.
3325904|NCT00084864|Experimental|Stage 1 Arm 3|Patients receive oral dexamethasone once daily on days 1-4.
3325905|NCT00084864|Experimental|Stage 1, Arm 4|Patients receive oral calcitriol once daily on days 2-4.
3325906|NCT00084838|Experimental|Multi-agent Intrathecal and Systemic CT with RT (mod IRS III)|"Pre-irradiation induction therapy (wks 1-6); Chemoradiation induction therapy (wks 7-12); Post-radiation induction therapy (wks 13-18); Maintenance therapy (wks 19-44); Continuation therapy (wks 45-51)~Induction Chemotherapy: CT backbone of the IRS-III regimen [vincristine, dactinomycin, cyclophosphamide (specifically, in combination), cisplatin, doxorubicin, and imidazole carboximide (DTIC)] was modified to incl temozolomide in lieu of DTIC. Pts w/ M0 dz (and initially positive CSF cytology) rcvd intrathecal (IT) CT (alt btwn intralumbar and intraventricular routes) w/ methotrexate, cytarabine, and hydrocortisone, coinciding with a cycle of CT.~Radiation Therapy: Pts w/ M0 dz OR M+ dz aged <3y received focal RT (3D conformal or intensity-modulated delivery). Pts >3y w/ M+ dz rcvd craniospinal irradiation.~Continuation Therapy: Pts treated with either non-doxorubicin or doxorubicin dose therapy if receiving CSI or mediastinal radiotherapy or not, respectively."
3325907|NCT00084825|Experimental|Docetaxel + Imatinib Mesylate|Docetaxel intravenous (IV) over 1 hour on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-42. Courses repeat every 42 days.
3325908|NCT00084812|Experimental|Safingol and Cisplatin|"Patients receive safingol IV over 1 hour and cisplatin IV over 1 hour on day 1. Courses repeat every 21 days* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients receive safingol on days 1 and 8 and cisplatin on day 8 for course 1 only; course 1 is 28 days in duration.~Cohorts of 3-6 patients receive escalating doses of safingol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose level."
3325909|NCT00084773|Experimental|Cetuximab, Fluorouracil, and Pelvic Irradiation|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64 and fluorouracil IV continuously on days 1-42. Patients undergo whole-pelvic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Treatment continues in the absence of disease progression or unacceptable toxicity.~Approximately 1-3 weeks after completion of study treatment, patients undergo surgical resection followed by adjuvant chemotherapy off-study.~Patients are followed for up to 5 years."
3325910|NCT00084747|Experimental|bortezomib|
3325911|NCT00084695|Experimental|Regimen A|Patients undergo total body irradiation (TBI) two times daily on days -7 to -4. Patients receive cyclophosphamide IV over 30-60 minutes on days -3 and -2 and anti-thymocyte globulin (ATG) IV over at least 6 hours on days -3 to -1.
3325912|NCT00084695|Experimental|Regimen B (patients who do not receive TBI)|Patients receive oral busulfan 4 times daily on days -8 to -5, and ATG IV over at least 6 hours and melphalan IV over 15-20 minutes on days -4 to -2.
3325913|NCT00084695|Experimental|Regimen C (patients with Fanconi's anemia/related disorders)|Patients undergo TBI on day -6. Patients receive ATG IV over at least 6 hours and methylprednisolone IV on days -5 to -1 and fludarabine IV over 30 minutes and cyclophosphamide IV over 30-60 minutes on days -5 to -2.
3325914|NCT00084695|Experimental|Regimen D|Patients receive oral or IV busulfan 4 times daily on days -9 to -5, ATG IV over at least 6 hours on days -5 to -3, and cyclophosphamide IV over 30-60 minutes on days -5 to -2.
3325915|NCT00084682|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3325916|NCT00084656|Experimental|Arm 1|
3325917|NCT00084643|Experimental|Treatment (GTI-2040, capecitabine, oxaliplatin)|Patients receive GTI-2040 IV continuously on days 1-14, oral capecitabine twice daily on days 2-15, and oxaliplatin IV over 2 hours on day 2 of the first course. In all subsequent courses, capecitabine is administered on days 1-14, oxaliplatin is administered on day 1, and GTI-2040 is administered as in course 1. Courses repeat every 21 days in the absence of disease progression and unacceptable toxicity.
3325920|NCT00084604|Experimental|Treatment (bevacizumab, cisplatin, irinotecan)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive cisplatin IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3325921|NCT00084552|Active Comparator|Arm I|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
3325922|NCT00084552|Experimental|Arm II|Patients undergo IMRT with dose restriction to erectile tissue once daily 5 days a week for approximately 7.5 weeks.
3325923|NCT00084539|Experimental|Radiation therapy|"Radiation Therapy~Daily 5 days per week for 4 weeks~45 Gy in 20 fractions whole breast~56 Gy in 20 fractions to boost volume"
3325924|NCT00084487|Experimental|Treatment (becatecarin)|Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3325925|NCT00084461|Experimental|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses beyond CR.
3325926|NCT00084435|Experimental|chemoRT after surgery|chemoRT with cisplatin and docetaxel after surgery
3325927|NCT00084409|Experimental|Arm I|Patients receive oral iloprost twice daily for 6 months in the absence of unacceptable toxicity.
3325928|NCT00084409|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 6 months in the absence of unacceptable toxicity.
3325929|NCT00084396|Experimental|Letrozole/Surgery|
3325930|NCT00084383|Experimental|GVAX pancreatic cancer vaccine|"5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth booster vaccination, six months following the fourth vaccination"
3325931|NCT00084370|Experimental|Group 1|Group I: Patients receive oral celecoxib twice daily for 3 months and then undergo prophylactic oophorectomy.
3325932|NCT00084370|Experimental|Group II|Group II: Patients undergo immediate prophylactic oophorectomy.
3325933|NCT00084318|Experimental|RT + cisplatin + cetuximab|Loading dose of cetuximab followed by radiation therapy with weekly cisplatin and cetuximab.
3325934|NCT00084318|Experimental|RT + docetaxel + cetuximab|Loading dose of cetuximab followed by radiation therapy (RT) with weekly docetaxel and cetuximab.
3325935|NCT00084266|Experimental|1|Subjects receiving linezolid for the treatment phase of the study
3325936|NCT00084266|Active Comparator|2|Subjects receiving vancomycin for the treatment phase of the study
3325937|NCT00084253|Active Comparator|1|
3325938|NCT00084253|Active Comparator|2|
3325939|NCT00002682|Experimental|Antibiotic Treatment|
3325940|NCT00002676|Experimental|CHOD + BVAM + WBRT|Patients 70 years old and younger with newly diagnosed, biopsy-proven PCNSL received one cycle of CHOD followed by two cycles of BVAM. Patients then received WBRT, 30.6 Gy, if a complete response was evoked, or 50.4 Gy if the response was less than complete; both doses were given in 1.8-Gy daily fractions.
3325941|NCT00002670|Active Comparator|Radiation therapy|Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week)
3325942|NCT00002670|Experimental|Radiation therapy plus cisplatin|Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week) plus Cisplatin-100 mg/m2 i.v. on days 1,22 and 43 with radiation therapy.
3325943|NCT00002656|Experimental|Pyrazoloacridine|Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.
3325944|NCT00002625|Experimental|Arm I|Radiosensitization plus Radiotherapy. Topotecan hydrochloride, TOPO, NSC-609699; plus external-beam irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons acceptable for the boost field).
3325945|NCT00002551|Experimental|Bolus 5-FU, Pelvic XRT + PVI 5-FU, Bolus 5-FU|Bolus 5-FU (fluorouracil) (500mg/m2/day on days 1-5, 29-33), Pelvic XRT + PVI 5-FU, Bolus 5-FU (450mg/m2/day for 5 days beginning 28 days after RT, for 2 cycles on days 1-5 of a 28 days cycle).
3325946|NCT00002551|Experimental|PVI 5-FU+Pelvic XRT+PVI 5-FU+PVI 5-FU|5-FU (fluorouracil) 300mg/m2/day for 42 days followed by 2 week interruption, Day 57 through XRT will receive 225mg/m2/day of 5-FU followed by 1 month interruption, 4 weeks after completion of XRT 1 8wk cycle of 5-FU 300mg/m2/day.
3325947|NCT00002551|Experimental|Bol 5-FU+LV+LEV+Pel XRT+Bol 5-FU+LV Bol 5-FU + LV + LEV|5-FU (fluorouracil) 425/mg/m2/day Days 1-5,29-33; LV (leucovorin calcium) 20mg/m2/day Days 1-5,29-33; LEV (levamisole hydrochloride) 150mg/day (50mg TID) for 3 days every 14 days starting after each course of 5-FU. During RT: 5-FU and LV 4 days on wk 1 and wk 5 of RT. LV 20 mg/m2/day IV bolus within 2hrs after completion of that day's radiation therapy, for four days in each cycle. Followed immediately by 5- FU 400 mg/m2/day IV bolus. Treatment will be given on days 57 - 60 and 85 - 88.Treatment post-RT-chemotherapy 28 days after completion of RT consist of 5 days of chemotherapy in 28 day cycles. 5-FU, 380 mg/m2/day on days 1 - 5 and LV given at a dose of 20 mg/m2/day on days 1 - 5 with the 5-FU given immediately after the LV. For 2 post-radiation cycles on days 1 - 5 of a 28 day cycle. Levamisole will be given orally at a dose of 150 mg/day (50 mg tid) for 3 days every 14 days during the 1st 3 days of each cycle of 5-FU, and again 14 days after starting each course of 5-FU.
3325948|NCT00006251|Experimental|Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)|"CONDITIONING REGIMEN : Patients receive fludarabine phosphate IV on days - 4 to -2 and undergo low-dose TBI on day 0. (Note: Patients who have had an autologous transplant within 90 days prior to day 0 will not receive fludarabine phosphate.)~PBSC INFUSION: Patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 35 with a taper to day 56. Patients receive mycophenolate mofetil PO BID on days 0-27.~POST TRANSPLANT DLI: Patients with stable mixed chimerism on day 56, and without evidence of GVHD, undergo DLI IV over 30 minutes on day 65. Patients without a complete response, full donor chimerism, and GVHD after 2 months undergo further DLI at higher cell numbers. Up to 6 DLIs may be given 65 days apart."
3326020|NCT00006079|Experimental|Arm I|Arm I-II: Patients receive one of two different doses of oral eflornithine daily. Treatment continues for 28 days.
3326021|NCT00006079|Experimental|Arm II|Arm I-II: Patients receive one of two different doses of oral eflornithine daily. Treatment continues for 28 days.
3325949|NCT00003992|Experimental|Arm I|Patients receive paclitaxel IV over 3 hours immediately followed by trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Paclitaxel repeats every 3 weeks for 4 courses and trastuzumab (Herceptin) repeats weekly for 10 courses. At 3 weeks following paclitaxel and trastuzumab (Herceptin), patients receive doxorubicin IV and cyclophosphamide IV over 1 hour every 3 weeks for 4 courses. Following chemotherapy, estrogen receptor (ER) positive and/or progesterone receptor (PR) positive patients receive oral tamoxifen twice daily for 5 years.
3325950|NCT00003992|Experimental|Arm II|Patients receive same therapy as in Arm I, except for additional trastuzumab (Herceptin) IV weekly beginning within 3 weeks following completion of chemotherapy and local therapy and continuing for 1 year. ER and/or PR positive patients receive tamoxifen as in Arm I but may be concurrent with trastuzumab (Herceptin). Following completion of doxorubicin and cyclophosphamide, post lumpectomy and post mastectomy patients may receive local radiotherapy daily for 5-6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3325951|NCT00084149|Experimental|A|Arm A will receive one tablet of ABC/3TC/AZT twice daily, 3 capsules or 2 tablets of LPV/r twice daily, and liquid CsA (dose determined by weight) twice daily. At Week 5, Arm A patients will stop CsA but continue both ABC/3TC/AZT and LPV/r.
3325952|NCT00084149|Experimental|B|Arm B will receive one tablet of ABC/3TC/AZT twice daily and 3 capsules or 2 tablets of LPV/r twice daily for all 48 weeks
3325953|NCT00084136|Experimental|ZDV/3TC+EFV|ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz
3325954|NCT00084136|Experimental|ddI+FTC+ATV|ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine
3325955|NCT00084136|Experimental|TDF/FTC+EFV|TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz
3325956|NCT00084123|Experimental|Healing Touch|Healing Touch Therapy
3325957|NCT00084123|Active Comparator|Relaxation Therapy|Relaxation Therapy
3325958|NCT00084123|Placebo Comparator|Standard Care|Standard Care
3325959|NCT00084084|Experimental|Agalsidase alfa (Cohort 1)|Cohort 1: Patients who completed TKT023.
3325960|NCT00084084|Experimental|Agalsidase Alfa (Cohort 2)|Cohort 2: Treatment-naive patients.
3325961|NCT00084032|Experimental|1|In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will continue taking ARV therapy for 16 weeks and then stop ARVs for 64 weeks.
3325962|NCT00084032|Experimental|2|In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will stop ARVs for 4 weeks, take ARVs for 8 weeks, stop ARVs for 4 weeks, take ARVs for 8 weeks, and then stop ARVs for 56 weeks.
3325963|NCT00083980|Active Comparator|active antidepressant drug comparator|Venlafaxine ER
3325964|NCT00083980|Placebo Comparator|Sugar pill|Inert placebo pills as duble dummy - up to 4 per day for kava and 3 per day for venlafaxine
3325965|NCT00083980|Experimental|Herbal treatment kava|Kava
3325966|NCT00083915|Active Comparator|Auto Transplant w/ High Dose Melphalan|Autologous transplant with High Dose Melphalan alone
3325967|NCT00083915|Active Comparator|Auto Transplant w/ Melphalan + DT Pace|Melphalan plus Dexamethasone, Thalidomide, CisPlatinum, Adriamycin, Cyclophosphamide, and Etoposide
3325968|NCT00083889|Active Comparator|2|
3325969|NCT00083889|Experimental|1|
3325970|NCT00083863||Framingham Heart Study Offspring|
3325971|NCT00083863||FHS Gen 3|
3325972|NCT00083824|Placebo Comparator|Sugar Pill|Placebo
3325973|NCT00083824|Experimental|Estrogens, Conjugated (USP)|Conjugated Equine Estrogen 0.625 mg/day for 3 years, drug
3325974|NCT00083824|Experimental|Medroxyprogesterone 17-acetate|Conjugated Equine Estrogen 0.625 mg/day plus Medroxyprogesterone Acetate 2.5 mg/day
3325975|NCT00005032|Experimental|Arm A|G3139 (3 mg/kg/day continuous IV infusion over 7 days every 21 days), Paclitaxel (150 mg/m2, 3 hr IV infusion on Day 6 of every 21 day cycle)
3325976|NCT00005030|Experimental|SCH 66336|Starting dose of preoperative oral SCH 66336 100 mg twice daily for 7-14 days prior to exploratory laparotomy and/or resection of hepatic metastases with surgery between days 8-15.
3325977|NCT00005030|No Intervention|No Treatment|Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization.
3325978|NCT00004161|Experimental|Arm I|Patients receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients then receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients are followed every 3 months.
3325979|NCT00004161|Experimental|Arm II|Patients receive oral placebo daily (except days 1-3 each month) for 6 months. Patients then receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients are followed every 3 months.
3325980|NCT00004146|Experimental|Treatment (RT and CAI)|"Patients receive induction therapy consisting of radiotherapy once daily 5 days a week plus oral carboxyamidotriazole once daily for 6 weeks followed by carboxyamidotriazole alone daily for 4 weeks. Patients continue on oral carboxyamidotriazole once daily as maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for survival.~Other: pharmacological study, radiation therapy"
3325981|NCT00004070|Experimental|IL-12 Injection 3mg/ml [Phase I]|The dosing schedule will consist of eight injections 3 mg/ml of formulated plasmid over a seven week period.
3325982|NCT00004070|Experimental|IL-12 Injection 6mg/ml [Phase I]|The dosing schedule will consist of eight injections 6mg/ml of formulated plasmid over a seven week period.
3325983|NCT00004070|Experimental|IL-12 Injection MTD [Phase II]|The dosing schedule will consist of eight injections over a seven week period of formulated plasmid at the MTD established in the phase I portion.
3325984|NCT00083772|Experimental|1|Nesiritide
3325985|NCT00083759|Active Comparator|natalizumab|
3325986|NCT00083759|Placebo Comparator|placebo|
3325987|NCT00004055|Experimental|topotecan + paclitaxel + filgrastim|Patients receive oral topotecan on days 1-5 followed by paclitaxel IV over 3 hours on day 5. Beginning 24-48 hours after chemotherapy, patients receive filgrastim (G-CSF) subcutaneously daily for up to 10 days until blood counts recover. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression. Patients who develop CNS progressive disease only should receive whole brain radiotherapy before continuing study treatment.
3326022|NCT00006079|Placebo Comparator|Arm III|Arm III: Patients receive oral placebo daily. Treatment continues for 28 days.
3326811|NCT00075101|Experimental|Study Cycle|
3325988|NCT00003997|Experimental|Arm I|Patients receive 6-hydroxymethylacylfulvene (HMAF) IV over 5 minutes on days 1-5. Treatment repeats every 3-4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3 patients receive escalating doses of HMAF. The maximum tolerated dose is defined as the dose at which dose limiting toxicity occurs in at least 40% of patients.
3325989|NCT00003850|Experimental|Arm I|Patients receive 4-20 capsules of oral thalidomide once daily. Dose is escalated in individual patients on a weekly basis for the first 5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity, or for 12 months past complete response.
3325990|NCT00003787||Intervention|high fiber, high vegetable, low-fat diet
3325991|NCT00003787||Control|NCI-recommended diet
3325992|NCT00003249|Experimental|Arm I|Patients receive oral carboxyamidotriazole (CAI) as a test dose on day 1. Patients receive oral ketoconazole on day 7, followed by CAI plus ketoconazole on day 8. CAI and ketoconazole are administered in combination on day 1 and days 3-28 of the first course. Ketoconazole is administered alone on day 2 of the first course. Subsequent courses begin at 28 day intervals in the absence of disease progression or unacceptable toxic effects. Cohorts of 3 patients are evaluated at each dose level prior to dose escalation. If one of three patients within a cohort experiences dose limiting toxicity (DLT), that dose level is expanded to incorporate six patients. If two or more patients experience DLT, the next lower dose is declared to be the maximum tolerated dose.
3325993|NCT00083720|Experimental|cetuximab|Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes
3325994|NCT00083616|Experimental|Panitumumab|Participants received panitumumab 6 mg/kg once every 2 weeks weeks administered by intravenous (IV) infusion until progressive disease, inability to tolerate the investigational product, or discontinuation of treatment for other reasons.
3325995|NCT00083603|Experimental|1|rFPV-HIV vaccine administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, and 196
3325996|NCT00083603|Placebo Comparator|2|Empty TBC-FPV vector administered as two separate 1-mL intramuscular injections, one into each deltoid at Days 0, 28, 84, 140, and 196
3325997|NCT00083603|Experimental|3|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
3325998|NCT00083603|Placebo Comparator|4|Empty TBC-MVA vector administered in each deltoid on Days 0, 28; empty TBC-FPV vector administered in each deltoid on Days 84, 140, and 196
3325999|NCT00083603|Experimental|5|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
3326000|NCT00083603|Placebo Comparator|6|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
3326001|NCT00083603|Experimental|7|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
3326002|NCT00083603|Placebo Comparator|8|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
3326003|NCT00083603|Experimental|9|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, 196
3326004|NCT00083603|Placebo Comparator|10|Empty TBC-MVA vector administered in each deltoid Days 0, 28, 84, 140, 196
3326005|NCT00083603|Experimental|11|rFPV-HIV vaccine administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, and 196
3326006|NCT00083603|Placebo Comparator|12|Empty TBC-FPV vector administered as two separate 1-mL intramuscular injections, one into each deltoid at Days 0, 28, 84, 140, and 196
3326007|NCT00083603|Experimental|13|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
3326008|NCT00083603|Placebo Comparator|14|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
3326009|NCT00083603|Experimental|15|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, 196
3326010|NCT00083603|Placebo Comparator|16|Empty TBC-MVA vector administered in each deltoid Days 0, 28, 84, 140, 196
3326011|NCT00083551|Active Comparator|Thalidomide|Thalidomide 400 qod during induction.100 mg qd between transplants, post transplant pat. 200 mg qd. During year one of maintenance therapy pt will take 100mg of Thal qod and 50 mg of thal qod during second year of maintenance
3326012|NCT00083551|Active Comparator|No Thalidomide|During induction, consolidation, and maintenance steps patient receives no thalidamide
3326013|NCT00003075|Experimental|Fenretinide|
3326014|NCT00003075|Placebo Comparator|Placebo|
3326015|NCT00083460|Active Comparator|1|
3326016|NCT00083460|Active Comparator|2|
3326017|NCT00006222|Experimental|Arm I|Patients receive EMD 121974 IV twice a week for four weeks. Courses repeat every 4 weeks in the absence of disease progression. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.
3326024|NCT00005942|Experimental|Treatment (liposomal danorubicin citrate, semaxanib)|Patients receive daunorubicin liposomal IV over 6 hours on days 1-3 and SU5416 IV twice a week for 2 months. The second course is administered for 1 month, then treatment continues every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
3326025|NCT00005640|Experimental|Mapping and Biopsy|Lymph node mapping and sentinel lymph node biopsy. Patients undergo preoperative endoscopy with injection of technetium Tc 99m sulfur colloid around tumor followed by celiotomy and intraabdominal exploration. At 30 minutes following injection, patients undergo lymphatic mapping with a gamma probe and biopsy of the sentinel lymph node(s). Following biopsy and mapping, patients undergo resection of primary tumor.
3326026|NCT00005578|Experimental|Arm 1|Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin hydrochloride and etoposide on days 0 and 1, bleomycin sulfate and vincristine sulfate on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Patients assigned to arm I receive only these drugs.
3326027|NCT00005578|Experimental|Arm 2|Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin hydrochloride and etoposide on days 0 and 1, bleomycin sulfate and vincristine sulfate on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Dexrazoxane hydrochloride on days 0, 1, and 7
3326028|NCT00005059|Experimental|carboplatin + paclitaxel|"Following completion of the Lubben Social Network Scale and Frailty Questionnaire, patients receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, and 15.~Treatment repeats every 28 days for 2 courses. Patients with complete response receive 2 additional courses of therapy. Patients with partial response or stable disease may receive additional courses of therapy at investigator's discretion. Patients are followed every 3 months for 5 years or until disease progression."
3326029|NCT00002923|Experimental|KRN5500|
3326030|NCT00002829|Experimental|Bone Marrow Transplantation|
3326031|NCT00002827|Experimental|Treatment #1 (Without Zinecard)|"All patients undergoing a splenectomy must receive penicillin or erythromycin prophylaxis twice a day. Pneumocystis prophylaxis:TMP/SMZ 150mg/m2(maximum 300 mg) of TMP in 2 divided doses on 3 consecutive days each week. Aerosolized Pentamidine (200mg/m2/dose - maximum dose 300 mg) should be substituted monthly for patients who cannot tolerate TMP/SMZ therapy. Continue pneumocystis prophylaxis for 6 months after stopping therapy.~Doxorubicin hydrochloride 25mg/m2/day IV push over 15 minutes days 1 and 15 Bleomycin sulfate 10 IU/m2/day IV push over 10 minutes on days 1 and 15 Vincristine sulfate 1.5mg/m2/day IV push (maximum 2mg) days 1 and 15 Etoposide 10mg/m2/day 1-5. IV drip ( < 0.4mg/ml) over 1 hour. Monitor blood pressure every 15 minutes during infusion. G-CSF (filgrastim) 5 mcg/Kg/day start on day 6 (24-36 hrs after 5th dose of VP16) and continued through day 13 (total 8 days)."
3326032|NCT00002827|Experimental|Treatment #2 (with Zinecard)|Zinecard (DZR) 250 mg/m2 IV push on days 1 and 15 before administration of doxorubicin and bleomycin sulfate. Give bleomycin sulfate and doxorubicin within 30 minutes of Zinecard (dexrazoxane hydrochloride). Bleomycin 10 IU/m2/day IV push over 10 minutes on days 1 and 15 Doxorubicin hydrochloride 25mg/m2/day IV push over 15 minutes days 1 and 15 Vincristine Sulfate 1.5mg/m2/day IV push (maximum 2mg) days 1 and 15
3326033|NCT00002806|Experimental|procarbazine + lomustine + vincristine + radiation|PCV followed by external-beam cranial irradiation using at least 6 MV photons.
3326034|NCT00002721|Experimental|Prostate cancer patients|Prostate cancer patients that have not responded to hormon therapy
3326035|NCT00002602|Experimental|Group 1|Clinical stages T1b-c or T2a-b with PSA + ([Gleason -6] x 10) is ≤ 15. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
3326036|NCT00002602|Experimental|Group 2|Clinical stages T1b-c or T2a-b with PSA + ([Gleason -6]x10)>15. Any clinical T2c with PSA < 70. Must be lymph node negative. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
3326037|NCT00002602|Experimental|Group 3|Clinical stage T3 with PSA < 70. Must be lymph node negative. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
3326038|NCT00083512||Patients|Patients receiving radiation therapy for Glioblastoma multiforme (GBM).
3326039|NCT00004190|Experimental|gemcitabine + oxaliplatin|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 immediately followed by oxaliplatin IV over 2 hours on day 1. Treatment repeats every 3 weeks. Patients achieving stable disease, partial response, or regressive disease continue with therapy. Patients achieving complete response for two consecutive evaluations receive an additional 2 courses of therapy. Phase I (closed as of 7/5/00): Cohorts of 3-6 patients receive escalating doses of gemcitabine and oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. Phase II: Patients receive the MTD of gemcitabine and oxaliplatin as in phase I. Patients are followed every 3 months for 1 year, and then every 6 months for 4 years.
3326040|NCT00004139|Experimental|Gemcitabine + Irinotecan|
3326041|NCT00004139|Experimental|Gemcitabine + Docetaxel|
3326042|NCT00003846|Experimental|Treatment|See detailed description.
3326043|NCT00083382|Experimental|Thalidomide + Bisphosphonate|200 mg/day Thalidomide + 90 mg Pamidronate OR 4 mg Zometa every 2 weeks for 2 months and then every 4 weeks as maintenance therapy
3326044|NCT00003098|Experimental|fat reduction increased fiber|Patients are randomized to dietary fat reduction with increased fiber). All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
3326062|NCT00002787|Experimental|Treatment (vaccine therapy)|Patients receive autologous immunoglobulin idiotype-KLH conjugate vaccine combined with sargramostim SC in weeks 0, 2, 6, and 10 and sargramostim SC QD for three days following each vaccine injection. Some patients also receive aldesleukin SC daily from weeks 2-14.
3326045|NCT00003098|Experimental|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber). All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
3326046|NCT00003084|Experimental|Arm I (Estramustine + Etoposide)|Arm I: Oral Estramustine 3 x day + oral Etoposide 2 x day on days 1-14 + Paclitaxel IV over 1 hour Day 2, repeats every 21 days.
3326047|NCT00003084|Experimental|Arm II (Chemotherapy + Ketoconazole)|Arm II: Doxorubicin IV Days 1, 15, and 29, Vinblastine IV Days 8, 22, and 36, Oral Ketoconazole 3 x day on Days 1-7, 15-21, + 29-35, and Oral Estramustine 3 x day on Days 8-14, 22-28, and 36-42; 6 weeks of alternating chemotherapy and 2 weeks rest, for 8 week course.
3326048|NCT00003056|Active Comparator|Unselected peripheral blood haemopoietic stem cells (PBSC)|Unselected PBSC together with control graft versus host disease (GVHD) prophylaxis - Control
3326049|NCT00003056|Experimental|CD34+ cells isolated from PBSC|CD34+ cells isolated from PBSC using the Isolex 300i system together with cyclosporine
3326050|NCT00002924||Source of patient samples|The CALGB conducted a phase III study (CALGB 9583) in which 260 men with AiPC were randomly assigned to antiandrogen withdrawal together with simultaneous ketoconazole and hydrocortisone versus antiandrogen withdrawal alone, followed by sequential ketoconazole and hydrocortisone. Metastatic disease with progression despite castrate levels of testosterone, prior antiandrogen therapy for a minimum of 4 weeks, and a minimum PSA level of 5 ng/mL were required; treatment with sequential antiandrogens was allowed. No prior chemotherapy was allowed. Bone marrow biopsies were obtained from 164 patients enrolled on CALGB 9583 and from 20 patients enrolled on CALGB chemotherapy trials (CALGB 9480, 9680, 9780).
3326051|NCT00002875|Experimental|Regimen A|Following surgery, craniospinal irradiation followed by a boost to the primary tumor. Beginning within 1 week after initiation of radiotherapy, patients receive vincristine sulfate weekly for 8 doses. Beginning 6 weeks after the completion of radiotherapy, patients receive adjuvant lomustine/vincristine sulfate/cisplatin every 6 weeks for a total of 8 courses.
3326052|NCT00002875|Experimental|Regimen B|Following surgery, craniospinal irradiation plus vincristine sulfate, followed by adjuvant cyclophosphamide/vincristine sulfate/cisplatin every 6 weeks for a total of 8 courses.
3326053|NCT00002734|Experimental|Arm I|Patients receive interferon alfa subcutaneously on days 1, 3, 5, and 7; paclitaxel intraperitoneally (IP) on day 4 or topotecan IP on day 6; and 177Lu-CC49 IP on day 6. Treatment continues every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-5 patients receive escalating doses of paclitaxel and decreasing doses of 177Lu-CC49 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 5 patients experience dose limiting toxicity. Once the MTD of paclitaxel is determined, the dose of 177Lu-CC49 is escalated. Once the MTD of 177Lu-CC49 is determined, 90Y-CC49 is substituted. The MTD of 90Y-CC49 is then determined when administered with paclitaxel. Topotecan is then substituted for paclitaxel (administered with the MTD of 177Lu-CC49 and interferon alfa only) and escalated until the MTD is determined.
3326054|NCT00002664|Experimental|Treatment|
3326055|NCT00002571|Experimental|ProMACE-CytaBOM + G-CSF|6 cycles of 21 days each of ProMACE-CytaBOM (cyclophosphamide 490 mg/m^2 on day 1, doxorubicin 19 mg/m^2 on day 1, etoposide 90 mg/m^2 on day 1, cytarabine 225 mg/m^2 on day 8, bleomycin 5 u/m^2 on day 8, methotrexate 90 mg/m^2 on day 8, leucovorin 25 mg/m^2 q 6 hours on days 8-9, vincristine 1.4 mg/m^2 on day 8, prednisone 60 mg/m^2 on days 1-14, allopurinol 300 mg on days 1-21 of cycle 1 and days 1-8 of cycle 2 only) plus 1 double strength tablet TMP/SMX 3 days a week plus G-CSF 5 ug/kg on days 9-20. Patients also receive intrathecal cytarabine 30 mg/m^2 (BM positive: 5 doses spaced evenly during 1st 2 cycles, then on day 1 of cycles 3-6; CSF cytology positive: 5 doses spaced evenly during 1st cycle, then on day 1 of cycles 2-6; BM and CSF negative: 5 doses spaced evenly within 1 month of completion of cycle 6). All patients with CR or PR after systemic therapy and IT cytarabine receive 2400 cGy RT to the whole brain in 12 fractions.
3326056|NCT00005648|Experimental|001|Gemcitabine with R115777 R115777 200 mg oral twice daily at 12-hour intervals throughout the study coadministered with gemcitabine 1000 mg/m2 iv every week for the first 7 weeks followed by 1 week rest and then every 3 out of 4 weeks thereafter for up to 5 years
3326057|NCT00005648|Placebo Comparator|002|Gemcitabine with Placebo Placebo oral twice daily at 12-hour intervals throughout the study coadministered with gemcitabine 1000 mg/m2 iv every week for the first 7 weeks followed by 1 week rest and then every 3 out of 4 weeks thereafter for up to 5 years
3326058|NCT00004126|Experimental|Arm A|Paclitaxel 175 mg/m2 : administered by 1-hour constant rate IV infusion through a pump on day 1 of each cycle. Oxaliplatin 130 mg/m2 : On Day 1 of each 21-day treatment cycle, patients receive oxaliplatin diluted in 250-500 mL Dextrose 5% in Water infused intravenously over 2 hours.
3326059|NCT00003724|Experimental|surgery|"Patients undergo open resection (thoracotomy, median sternotomy, or bilateral sternothoracotomy).~Patients with isolated recurrence in the chest should have the recurrence(s) resected if feasible. The original resection approach (open versus VATS) should be the preferred method for the second resection, but is not required.~Quality of life is assessed prior to randomization and then at 30 days, 3 months, and 6 months. Patients are followed every 3 months for 1 year and then every 6 months thereafter."
3326060|NCT00003724|Experimental|video-assisted surgery|"After spiral CT showing pulmonary nodules are amenable to video-assisted thoracic surgery (VATS) resection with curative intent, patients undergo minimally-invasive video-assisted resection.~Patients with isolated recurrence in the chest should have the recurrence(s) resected if feasible. The original resection approach (open versus VATS) should be the preferred method for the second resection, but is not required.~Quality of life is assessed prior to randomization and then at 30 days, 3 months, and 6 months. Patients are followed every 3 months for 1 year and then every 6 months thereafter."
3326061|NCT00002880|Experimental|Etoposide|Oral etoposide for relapsed or refractory non-Hodgkin's lymphoma
3326063|NCT00002707|Experimental|Group 2|doxorubicin and cyclophosphamide plus Taxotere prior to surgery plus tamoxifen
3326885|NCT00074269|Experimental|treatment|
3326066|NCT00012350|Experimental|Oral FTI (R115777) Treatment|"Patients will be administered oral FTI (R115777) at a dose of 300-mg by mouth (PO) twice a day (BID). Drug will be taken without regard to meals.~The study regimen will consist of 3 weeks of treatment followed by one week off for a total cycle duration of 4 weeks."
3326067|NCT00006220|Experimental|Phase I|Starting dose of arsenic trioxide of 0.15 mg/kg/day
3326068|NCT00006220|Experimental|Phase II|MTD of arsenic trioxide
3326069|NCT00006220|Experimental|Treatment Failure|Arsenic trioxide and tretinoin
3326070|NCT00004156|Experimental|Vaccine: MUC1-KLH vaccine/QS21|Patients receive glycosylated MUC-1 antigen containing MUC-1(106) or MUC-1(33) with keyhole limpet hemocyanin conjugate subcutaneously (SQ) plus immunological adjuvant QS21 SQ on weeks 1-3, 7, and 19 for a total of 5 vaccinations. Patients are followed every 3 months.
3326071|NCT00004056|Experimental|Chemo + STEM cell|See detailed description.
3326072|NCT00004038|Experimental|Arm I|Patients undergo biopsy of one of their skin nodules prior to any treatment. Patients receive the Ad-p53 gene therapy in one nodule and injection of a second nodule with Dulbecco's phosphate buffered saline. The next day, patients begin chemotherapy, which may be given weekly and continues every 21-28 days for up to 6 courses. On day 3, patients return for biopsy of injected nodules. Biopsies are only performed during the first course. Patients may receive further injections of the Ad-p53 gene with subsequent courses of chemotherapy, for up to six courses.
3326073|NCT00003700|Experimental|Daunorubicin, ara-C, & MTX Therapy|daunorubicin during induction, increasing doses of cytarabine during consolidation followed by methotrexate in place of cranial irradiation for treatment of ALL
3326074|NCT00003575|Experimental|Arm I|All patients receive ifosfamide IV by continuous infusion for 2 days, etoposide IV over 2 hours daily on days 1 and 2, and filgrastim (G-CSF) subcutaneously (SC) daily on days 4-13. Courses are repeated every 21 days. Patients who have complete or partial remission after a minimum of 4 courses of chemotherapy receive maintenance therapy consisting of interleukin-12 SC twice weekly beginning on day 28 of the final chemotherapy course and continuing for 6 months or until disease progression. All patients also receive combination antiretroviral therapy during study.
3326075|NCT00003439|Experimental|Arm I|Cohorts of 3-6 patients each receive escalating doses of intraperitoneal recombinant human interleukin-12 (rhIL-12) administered weekly for 9 weeks. If a patient tolerates rhIL-12 and shows evidence of objective response or stable disease, patient may receive up to 9 additional weeks of treatment. Treatment continues in the absence of unacceptable toxicity or disease progression. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which no more than 1 of 6 patients experiences dose limiting toxicity.
3326076|NCT00003330|Experimental|Arm I|See detailed description.
3326077|NCT00003255|Experimental|topotecan + carboplatin|Patients receive continuous intravenous infusions of topotecan and carboplatin for 5 days. Treatment repeats every 3-4 weeks during induction (two courses) and every 6-10 weeks during consolidation. No more than four courses of treatment are given. Patients are followed every 6 months for 5 years.
3326078|NCT00083304|Experimental|Efaproxiral + WBRT + Supplemental Oxygen|
3326079|NCT00083304|Active Comparator|WBRT + Supplemental Oxygen|
3326080|NCT00082888|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3326081|NCT00082875|Experimental|Arm I|"Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11*, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: *For the first course only, treatment is omitted on day 11"
3326082|NCT00082875|Experimental|Arm II|Patients receive cilengitide as in arm I at a higher dose.
3326083|NCT00082810|Experimental|Treatment (tipifarnib, fulvestrant)|Patients receive fulvestrant intramuscularly on day 1 and oral tipifarnib twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity*.
3326084|NCT00082784|Experimental|Treatment|Patients receive bortezomib IV over 3-5 seconds followed by flavopiridol IV over 1 hour on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3326085|NCT00082758|Experimental|Disease Measurable by Standard Criteria(hu14.18-interleukin-2)|"Patients with residual/refractory neuroblastoma and readily measurable residual/refractory disease using standard radiographic criteria. Standard radiographic criteria for CT/MRI Lesions will use the definitions of measurable disease from the Response Evaluation Criteria In Solid Tumors (RECIST) from the National Cancer Institute.~hu14.18-Interleukin-2 fusion protein : Given IV"
3326086|NCT00082758|Experimental|Disease Eval by MIBG or BM Histology (hu14.18-interleukin-2)|"Patients with residual/refractory neuroblastoma with disease that is not measurable by standard radiographic criteria, but is evaluable by meta-iodobenzylguanidine (MIBG) scanning and/or by bone marrow (BM) histology.~hu14.18-Interleukin-2 fusion protein : Given IV"
3326087|NCT00082758|Experimental|Disease Identified by BM Immunohistochemistry Only|"Patients with residual/refractory neuroblastoma that do not have disease that is measurable by standard radiographic techniques or evaluable by meta-iodobenzylguanidine (MIBG) scanning or bone marrow (BM) histology, however, disease is identified and quantified by BM immunohistochemistry (>5 neuroblastoma cells per 1,000,000 nucleated marrow cells).~hu14.18-Interleukin-2 fusion protein : Given IV"
3326088|NCT00082745||Ancillary-Correlative (genetic analysis)|DNA from peripheral blood or buccal sample of patients is analyzed for the presence of polymorphisms in candidate genes associated with an increased risk of late-occurring complications.
3326089|NCT00082732|Experimental|Arm I: Dietary Intervention|Nutritional counseling on a low-fat, high-fiber, soy supplemented diet and behavior-based activities, such as goal-setting, contracting, and stimulus control, once weekly for 6 weeks, every 3 weeks for 33 weeks, and then at weeks 44, 48, and 52.
3326090|NCT00082732|No Intervention|Arm II: Observation|Observation every 6 weeks for 36 weeks and then every 8 weeks for 18 weeks.
3326091|NCT00082719|Experimental|Arm I|Low-dose interferon alfa subcutaneously (SC) twice daily.
3326092|NCT00082719|Experimental|Arm II|Interferon alfa as in arm I at a higher dose.
3326093|NCT00082719|Experimental|Arm III|Interferon alfa SC once daily.
3326094|NCT00082719|Experimental|Arm IV|Interferon alfa as in arm III at a higher dose.
3326134|NCT00082381|Active Comparator|Insulin Glargine Arm|subcutaneous injection, once daily; forced titration to target blood glucose level
3326095|NCT00082706|Experimental|5-FU, Leucovorin, Gemcitabine + Cisplatin|5-FU continuous infusion over Days 1 - 5; Leucovorin once a day as a short infusion on Days 1 - 5; Cisplatin infusion over a few hours (usually 2-4 hours) once a day on Days 1 - 5; Gemcitabine infusion over 30 minutes on Days 1 & 5 only.
3326096|NCT00082641|Experimental|Arm I|Patients receive vaccination comprising p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients with stage III disease), and at 6 and 12 weeks after completion of radiotherapy (for a total of 4 vaccinations).
3326097|NCT00082641|Experimental|Arm II|Patients receive vaccination comprising p53-infected autologous dendritic cells SC at 6, 8, 10, and 12 weeks after completion of radiotherapy.
3326098|NCT00003118|Experimental|Chemotherapy + Radiation + Surgery|
3326099|NCT00003118|Active Comparator|Surgery|
3326100|NCT00003117|Experimental|Paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 of each course. Treatment is repeated every 21 days for 6 courses in the absence of tumor progression or unacceptable toxicity. Quality of life assessments are conducted before treatment and at 2, 6, 9, and 12 months. Patients are followed every 3 months for 2 years, then every 6 months until disease progression or death.
3326101|NCT00003117|Experimental|Paclitaxel + Carboplatin|Patients receives paclitaxel as in Arm I, followed by carboplatin IV over 1 hour. Treatment is repeated every 21 days for 6 courses in the absence of tumor progression or unacceptable toxicity. Quality of life assessments are conducted before treatment and at 2, 6, 9, and 12 months. Patients are followed every 3 months for 2 years, then every 6 months until disease progression or death.
3326102|NCT00003095||bone marrow transplant|bone marrow transplant
3326103|NCT00003095||standard chemotherapy|standard chemotherapy
3326104|NCT00002961|Active Comparator|Total body irradiation|Total body irradiation 1200 centigray
3326105|NCT00002961|Active Comparator|Busulfan|Busulfan 16 doses
3326106|NCT00083226|Experimental|Treatment (doxorubicin+bortezomib)|Patients receive doxorubicin IV over 5-15 minutes on days 1 and 8. Patients also receive bortezomib at a dose of 1.3 mg/m^2 IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with no disease progression may continue to receive bortezomib alone in the absence of disease progression or unacceptable toxicity.
3326107|NCT00083174|Other|Exemestane|one 25 mg tablet daily in am
3326108|NCT00083161|Experimental|Oral cyclophosphamide plus standard cisplatin with etoposide|"Etoposide 120 mg/m2 IV Days 1-3 or Etoposide 120 mg/ m2 IV Day1 followed by Etoposide 120 mg/ m2 PO BID Days 2-3~Cisplatin 60 mg/m2 IV Day 1 Every 21 days x 4 cycles~Cyclophosphamide 25 mg PO BID Days 8-19 of each cycle"
3326109|NCT00083122|Experimental|Group 1|Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3326110|NCT00083122|Experimental|Group 2|Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3326111|NCT00083109|Experimental|Treatment (suramin and fluorouracil)|"PHASE I: Patients receive suramin IV over 30 minutes and fluorouracil IV on days 1, 8, 15, 22, 29, and 36. Cohorts of 3-6 patients receive escalating doses suramin and fluorouracil until the dose level allowing 10-50 uM of suramin into the patient's blood is determined without 2 or more of 6 patients experiencing dose-limiting toxicity.~PHASE II: Patients receive suramin and fluorouracil (at the dose level determined in phase I) as in phase I.~In both phases, courses repeat every 8 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
3326112|NCT00083070|Experimental|Temozolomide Therapy|
3326113|NCT00082966|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of rapid disease progression or unacceptable toxicity.
3326114|NCT00082628|Placebo Comparator|Period I: Placebo|Subjects will receive placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.
3326115|NCT00082628|Experimental|Period I: Serostim® 4 mg|Subjects will receive Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.
3326116|NCT00082628|Experimental|Period II: Serostim® 4 mg to Placebo|All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive placebo matched to Serostim® on alternate days for 24 weeks in Period II.
3326117|NCT00082628|Experimental|Period II: Serostim® 4 mg to Serostim® 2 mg|All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive Serostim® 2 mg on alternate days for 24 weeks in Period II.
3326118|NCT00082628|Experimental|Period II: Placebo to Placebo/Serostim® 4 mg|All subjects who will be initially randomized to Placebo arm in Period I continue receiving placebo matched to Serostim® on alternate days for 12 weeks followed by Serostim® 4 mg daily 12 weeks.
3326119|NCT00082498|Placebo Comparator|1|Group 1 will receive placebo
3326120|NCT00082498|Experimental|2|Group 2 will receive 5 mg vicriviroc daily
3326121|NCT00082498|Experimental|3|Group 3 will receive 10 mg vicriviroc daily
3326122|NCT00082498|Experimental|4|Group 4 will receive 15 mg vicriviroc daily
3326123|NCT00082485|Active Comparator|1|
3326124|NCT00082485|Placebo Comparator|2|
3326125|NCT00082446|Experimental|E|Subject will receive an SC dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of placebo by scarification.
3326126|NCT00082446|Active Comparator|D|Subject will receive a SC dose of placebo on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
3326127|NCT00082446|Experimental|C|Subject will receive a SC dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
3326128|NCT00082446|Experimental|B|Subjects will receive a SC dose of MVA 5x10^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
3326129|NCT00082446|Experimental|A|Subjects will receive a SC dose of MVA 2x10^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
3326130|NCT00082446|Experimental|F|Subject will receive an IM dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
3326131|NCT00082433|Experimental|A|
3326135|NCT00002677|Experimental|Arm I|Patients receive oral tributyrin every 8 hours for 3 weeks. Treatment continues every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease may receive additional courses at the discretion of the protocol chairperson. Cohorts of 3-6 patients receive escalating doses of tributyrin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
3326136|NCT00002587|Experimental|Arm I|"Patients receive paclitaxel IV over 3 hours on day 1 followed 2-6 hours later by topotecan IV continuously on days 1-14. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan and paclitaxel until the maximum tolerated dose (MTD) of each drug is determined. The MTD is defined as the highest dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
3326137|NCT00082407|Experimental|Exenatide Arm|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks
3326138|NCT00082407|Active Comparator|Biphasic Insulin Aspart Arm|subcutaneous injection, twice daily; titration to target blood glucose level
3326139|NCT00082368|Experimental|PET (positron emission imaging) Imaging with Tc-94m Sestamibi|PET sestamibi scans followed by tariquidar and repeat imaging
3326140|NCT00082355|Experimental|Alteplase (r-tPA)|Patients with DVT of lower extremity will receive up to 4 treatments low dose (<10 mg/day) intraclot injections of alteplase. Intention is to evaluate safety and efficacy of this treatment, and durability of outcomes (for 6 months)in 25 patients.
3326141|NCT00082342|Active Comparator|real transcranial direct current stimulation (tDCS)|
3326142|NCT00082342|Sham Comparator|sham transcranial direct current stimulation (tDCS)|
3326143|NCT00082329|Experimental|AMD 3100 (Mozobil plerixafor)|Healthy volunteers will be administered AMD 3100 (Mozobil plerixafor) and granulocyte colony stimulating factor (G-CSF) to determine cytokine polarization status of cluster of differentiation (CD 4) T-cells collected by apheresis
3326144|NCT00082290|Experimental|a massage|About 45 minute massage
3326145|NCT00082290|Experimental|visit with a volunteer|45 minute visit
3326146|NCT00082290|Experimental|period of quiet time|45 minutes of quiet time
3326147|NCT00082277|Experimental|1|High-Risk Fragility Fracture-Open-Label, Non-Comparative Stratum
3326148|NCT00082277|Experimental|2|Moderate-Risk of Fragility Fracture-Randomised, Double-Blind Stratum
3326149|NCT00082277|Experimental|3|Low-Risk of Fragility Fracture - Open-Label, Non-Comparative Stratum
3326150|NCT00082238|Experimental|Cystic fibrosis (CF)|
3326151|NCT00082238|Active Comparator|Healthy volunteers|
3326152|NCT00082225|Experimental|EBV specific T cells|"Patients receiving CTLs as therapy for relapsed Lymphoma or who are at high risk for relapse or patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.~A fixed dose of CD45 MAb (400ug/kg over 4 hours daily times 4 given over 2 daily IV infusions) will be used."
3326153|NCT00082212|Experimental|1|400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
3326154|NCT00082199|Active Comparator|A1|
3326155|NCT00082199|Placebo Comparator|A2|
3326156|NCT00082186|Experimental|1|Oral bosentan tablets
3326157|NCT00082173|Experimental|1|INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks
3326158|NCT00082173|Placebo Comparator|2|INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks
3326159|NCT00005988|Experimental|in vitro-treated bone marrow transplantation|"Donor bone marrow will be harvested on Day -2~Bone Marrow incubated with irradiated recipient cells and anti-B7.1 and anti-B7.2 for 36 hours.~Bone marrow will be infused intravenously~Cyclophosphamide will be administered IV once daily~Total Body Irradiation (TBI) will be delivered per institutional practice~Methylprednisolone will be administered IV as 4 doses separated by 12 hours,"
3326160|NCT00005594|Experimental|ISIS 2503|All patients will begin treatment at a dose of 6 mg/kg/day of ISIS 2503. ISIS 2503 at the assigned dose will be given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. No drug will be administered during the third week of each treatment cycle.
3326161|NCT00004893|Experimental|IL12 Therapy|Patients begin therapy no sooner than 3 weeks and no later than 6 weeks since last chemotherapy dose. Patients receive interleukin-12 subcutaneously twice a week. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed at least every 3 months for 1 year. If no progression after 1 year, may be followed as needed for new signs or symptoms and survival for 5 years.
3326162|NCT00004893|No Intervention|Observation|Patients are observed for 6 months. If disease progresses during first 6 months, patients may receive interleukin-12 as in arm I. Patients without disease progression within first 6 months may also then receive interleukin-12 as in arm I. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for toxicity only until interleukin-12 is discontinued.
3326163|NCT00004246|Experimental|RT + Fludarabine|Radiotherapy (RT) on Days 1-5 for 7 weeks + Fludarabine IV, 3-4 hours prior to daily RT, Days 1-5 of weeks 6 and 7 of RT
3326164|NCT00004101|Experimental|Arm I|Patients receive monoclonal antibody Hu1D10 IV over 2-4 hours on days 1, 8, 15, and 22. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of monoclonal antibody Hu1D10 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose limiting toxicity. Once the MTD is determined, an additional cohort of 3-6 patients receive Hu1D10 IV over 2-4 hours on days 1-5.
3326165|NCT00003968|Experimental|Arm I|Patients receive bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment continues every 4 weeks in the absence of unacceptable toxicity or disease progresssion.
3326166|NCT00003900|Experimental|irinotecan + docetaxel|Patients receive irinotecan IV over 90 minutes immediately followed by docetaxel IV over 60 minutes on day 1. Treatment is repeated every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 5 years or until death.
3326167|NCT00003849|Experimental|rituximab|Patients receive rituximab IV over 4-6 hours on day 1 weekly for 4 weeks. Patients are followed at 1, 3, 6, 9, and 12 months, then every 6 months for 3 years, then annually thereafter.
3326223|NCT00002772|Experimental|chemo with autologous stem cell support|conventional chemotherapy with doxorubicin and cyclophosphamide followed by autologous stem cell support
3327670|NCT00062478|Experimental|1|Karenitecin for intravenous use
3326168|NCT00003726|Experimental|Lepirudin|Dose level 1: 10 mg once daily -> (total dose, 10 mg/d) Dose level 2: 15 mg once daily -> (total dose, 15 mg/d) Dose level 3: 10 mg twice daily -> (total dose, 20 mg/d) Dose level 4: 15 mg twice daily -> (total dose, 30 mg/d) Dose level 5. 20 mg twice daily -> (total dose, 40 mg/d) Dose level 6: 25 mg twice daily -> (total dose, 50 mg/d)
3326169|NCT00003622|Experimental|paclitaxel + vinorelbine|
3326170|NCT00082147|Experimental|Biopsy|Biopsy
3326171|NCT00082095|Experimental|Group 1 (doxorubicin)|Pegylated liposomal doxorubicin 40 mg/m2 administered intravenously on Day 1 of each cycle. Cycle is repeated every 28 days, up to one year.
3326172|NCT00082095|Active Comparator|Group 2 (capecitabine )|Capecitabine administered orally at a dosage of 2000 mg/m2/day (1000 mg/m2 BID) for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
3326173|NCT00003563|Experimental|WBRT|3 Gy of WBRT daily for a total of 10 days
3326174|NCT00003563|Experimental|MGd|IV does of 5.0 mg/kg MGd plus WBRT
3326175|NCT00003276|Experimental|irinotecan|Patients receive a 90 minute continuous infusion of irinotecan on days 1, 8, 15, and 22 for 4 weeks, followed by a 2 week rest period. Courses of treatment are repeated every 42 days. Patients continue treatment in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months for the next 4 years.
3326176|NCT00003239|Experimental|Chemotherapy with Cytarabine + Homoharringtonine|Interferon alfa and cytarabine daily by subcutaneous injection. Homoharringtonine is administered by continuous infusion on days 1-5.
3326177|NCT00003019|Experimental|Chemotherapy Treatment|Patients receive vinblastine sulfate (5 mg/m2) IV and methotrexate (30 mg/m2) IV weekly for 26 weeks, then every 2 weeks for an additional 26 weeks. Treatment continues for a maximum of 1 year in the absence of unacceptable toxicity or disease progression. Patients with a complete response receive an additional 8 doses of chemotherapy. Patients are followed every 6 months for 4 years and then annually thereafter.
3326178|NCT00081939|Experimental|Study Treatment|Two cycles of VDTPACE induction (Velcade days 1, 4, 8, and 11; DTPACE days 4-7) with interim thalidomide (50 mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle. Induction followed by single or tandem MEL200 transplant (MEL140 mg/m2 for subjects > 70 years of age) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each transplant. Transplants followed by two cycles of VDTPACE consolidation (Velcade days 1, 4, 8, and 11; DTPACE days 1-4) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle of VDTPACE. Consolidation followed by 3 years of maintenance therapy with VDT (velcade 1.0 mg/m2 days 1, 4, 8, 11 q 28 days; Thal 100 mg QD; and Dex 20mg days 1-4 and 8-11 q 28 days) during Year 1 and TD (Thal 100 mg QD and Dex 20 mg days 1-4, q 28 days) or VTD (velcade 1.0 mg/m2 weekly, Thal 100 mg QD, and Dex 20 mg weekly) during Years 2 and 3.
3326179|NCT00006483|Experimental|aerosolized sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) by nebulizer over 10-15 minutes twice daily on days 1-7 and 14-21. Treatment repeats every 28 days in the absence of disease progression or unaceptable toxicity.~Patients are followed for disease progression and then every 3 months thereafter."
3326180|NCT00002939|Experimental|Paclitaxel in combination with Irinotecan|The first study cohort will receive 60 mg/m2 of paclitaxel on cycle days 1, 8, and 15 as a 1 hr infusion. Immediately following paclitaxel, 30 mg/m2 irinotecan will be administered as a 90 minute intravenous infusion. Irinotecan doses will be administered in an identical infusion schedule on days 8 and 15 of each treatment cycle.
3326181|NCT00002912|Experimental|Arm I|Patients undergo induction therapy consisting of etoposide IV and mitoxantrone IV on days 1-5. Patients then receive PSC-833 IV over 124 hours beginning on day 2. A second course is administered no sooner than 21 days from the start of the first course if the marrow is hypocellular after the first course. Patients with persistent disease after 2 induction courses are removed from the study. Patients receive a total of 3 courses of etoposide/mitoxantrone. Patients who achieve complete remission after 1 induction course receive 2 courses of etoposide/mitoxantrone with PSC-833 as consolidation, beginning within 4 weeks of attainment of complete remission. Patients who achieve complete remission after 2 induction courses receive 1 course of etoposide/mitoxantrone with PSC-833 as consolidation. Cohorts of 3-6 patients receive escalating doses of PSC-833 until the maximum tolerated dose is determined. Patients are followed every 6 months.
3326182|NCT00002590|Experimental|Regimen A|See detailed description.
3326183|NCT00082043|Experimental|1|Dutasteride 2.5 mg by mouth daily for one month
3326184|NCT00082043|Placebo Comparator|2|Placebo oral capsule for two months
3326185|NCT00082017|Experimental|UCN-01 for T-cell lymphomas - Cohort 1 - Every 28 days|"Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2~Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 28 days."
3326186|NCT00082017|Experimental|UCN-01 for T-cell lymphomas - Cohort 2 -Every 21 days|"Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2~Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 21 days."
3326187|NCT00081900|Experimental|DENSPM|
3326188|NCT00005969|Experimental|Liposomal Tretinoin|Liposome by vein (IV) over 30 minutes every other day for 28 days and Chemotherapy.
3326189|NCT00005796|Experimental|Single arm|PCV therapy
3326190|NCT00004933|Experimental|Homoharringtonine|
3326191|NCT00004933|Active Comparator|Hydroxyurea|
3326192|NCT00004604|Experimental|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
3326193|NCT00003953|Experimental|Doxorubicin and Docetaxel|
3326194|NCT00081887|Experimental|Weekly Clofarabine|
3326195|NCT00081874|Experimental|RAD001|"Phase I: Participants initially treated with 5 mg RAD001 by mouth daily for 28 days.~Phase II: The MTD (either 5mg or 10mg) administered daily until intolerance or failure or lack of response after 4 cycles of therapy. For assessment purposes, each cycle will comprise a 28-day period."
3326196|NCT00081861|Experimental|Avastin + Rituximab|Avastin 10 mg/kg given intravenously every 2 weeks for 4 doses, and Rituximab 375 mg/m^2 intravenously weekly for 8 doses.
3326197|NCT00003950|Experimental|CPT-11 with Cyclosporine|Each cycle lasts 6 weeks. Administration of cyclosporine and CPT-11 weekly for 4 weeks followed by a 2 week 'rest' period with no drug given. Cyclosporine is given by IV infusion at a dose of 5 mg/kg. CPT-11 is given by IV infusion at a dose of 60 mg/m2.
3326198|NCT00003835|Experimental|Arm I (leucovorin calcium and fluorouracil)|Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV beginning 1 hour into leucovorin calcium infusion weekly for 6 weeks. Treatment is repeated every 8 weeks for 4 courses.
3326199|NCT00003835|Experimental|Arm II (leucovorin calcium, fluorouracil, irinotrcan)|Patients receive irinotecan IV over 90 minutes, followed by leucovorin calcium IV, then followed by fluorouracil IV weekly for 4 weeks. Treatment is repeated every 6 weeks for 5 courses
3326200|NCT00003819|Experimental|vaccine|This is a dose escalation study. Patients receive TF(c)-KLH conjugate with adjuvant QS21 subcutaneously weekly for 3 weeks, then once during weeks 7 and 19. Cohorts of 5 patients each receive escalating doses of TF(c)-KLH vaccine until the optimal dose, based on antibody response, is reached. Patients are followed monthly for 6 months, then every 3 months for 1 year.
3326201|NCT00003783|Experimental|Complete Response and no CNS 3|See detailed description.
3326202|NCT00003783|Experimental|Complete Response and CNS 3|See detailed description.
3326203|NCT00003765|Experimental|Arm I|Patients receive O6-benzylguanine IV over 1 hour, then, 1 hour later, carmustine IV is administered over 1 hour. Treatment is repeated every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each receive escalating doses of carmustine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose level at which fewer than 2 of 6 patients experience dose limiting toxicity (DLT). If myelosuppression is the DLT, stratum 1 is closed and patients are accrued to stratum 2. If neutropenia is the DLT in stratum 2, patients receive filgrastim (G-CSF) subcutaneously beginning on day 2 and continuing until blood counts recover.
3326204|NCT00003270|Experimental|Arm 1|Patients eligible to undergo total body irradiation (TBI) first receive cyclophosphamide IV over 2 hours on days -5 and -4, then undergo TBI twice a day on days -3 to -1. Patients also receive antithymocyte globulin (ATG) IV over 10 hours on days -3 to -1. Cord blood is infused on day 0
3326205|NCT00006463|Experimental|Therapy ECTEINASCIDIN 743 (1100 ug/m2 )|
3326206|NCT00006463|Experimental|ECTEINASCIDIN 743 (1300 ug/m2)|
3326207|NCT00005849|Experimental|Arm A|Paclitaxel (90 mg/m2, days 1, 8 and 15 of every 28 day cycle), Bryostatin-1 (50 mcg/m2, days 2, 9 and 16 of every 28 day cycle)
3326208|NCT00005842|Experimental|Arm I|Patients receive trastuzumab (Herceptin) IV over 90 minutes on days 1, 8, 15, and 22 plus oral R115777 twice daily for 3 weeks. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R115777 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.
3326209|NCT00005832|Experimental|R115777|300mg/dose BID, PO, Days 1-21, q 28days
3326210|NCT00002485||Stratum 1|Not Enrolled / No IRB Applied
3326211|NCT00002485||Stratum 2|Not Enrolled / IRB Approved
3326212|NCT00081822|Other|Clofarabine + Ara-C|An initial dose escalation of clofarabine with a fixed standard dose of Ara-C in phase I will be used to determine an optimal phase II dose.
3326213|NCT00005092|Experimental|Chemo, RT + PSCT|Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation
3326214|NCT00003735|Experimental|Stratum 1 - Stage 1|Topotecan hydrochloride (0.8 mg/m²/day) by mouth for 21 days. Bone marrow will be obtained on approximately Day 28 of Course 1 and 2 and in any course where the CBC suggests that a relapse has occurred. One additional course may be given if the blood is cleared of blasts and the bone marrow is M1, M2 or M3. The patient is off protocol therapy if blasts are still present in the blood and the marrow is M3. Subsequent courses of topotecan may be given only if the bone marrow after Course 2 is M1 or M2. If the bone marrow is M2 on Day 28 of any course, another bone marrow aspirate will be done at the end of the next course. If the patient is in CR, a bone marrow aspirate will be required only every other course unless the peripheral blood suggests that a relapse has occurred. Each subsequent course should begin within six weeks of the start of the previous course.
3326215|NCT00003735|Experimental|Stratum 2 - Stage 2|Topotecan hydrochloride (0.8 mg/m²/day) by mouth for 21 days. Bone marrow will be obtained on approximately Day 28 of Course 1 and 2 and in any course where the CBC suggests that a relapse has occurred. One additional course may be given if the blood is cleared of blasts and the bone marrow is M1, M2 or M3. The patient is off protocol therapy if blasts are still present in the blood and the marrow is M3. Subsequent courses of topotecan may be given only if the bone marrow after Course 2 is M1 or M2. If the bone marrow is M2 on Day 28 of any course, another bone marrow aspirate will be done at the end of the next course. If the patient is in CR, a bone marrow aspirate will be required only every other course unless the peripheral blood suggests that a relapse has occurred. Each subsequent course should begin within six weeks of the start of the previous course.
3326216|NCT00003621|Experimental|carmustine + etoposide + cisplatin + radiation therapy|Patients receive carmustine IV over 1 hour on days 1-3, oral etoposide on days 1-21 and 29-49, and cisplatin IV over 1-2 hours on days 1-3 and 29-31. Treatment repeats every 8 weeks for 3 courses. Patients receive radiotherapy concurrently with the third course of chemotherapy. Quality of life is assessed every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients are followed every 3 months for 5 years and then annually thereafter.
3326217|NCT00081770|Experimental|PegIntron 1.5 ug/kg/wk plus REBETOL|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up
3326218|NCT00081770|Experimental|PegIntron 1.0 ug/kg/wk plus REBETOL|PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up
3326219|NCT00081770|Active Comparator|PEGASYS 180 ug/wk Plus COPEGUS|PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up
3326220|NCT00003018|Experimental|Chemotherapy|dipyridamole: 75mg/dose, PO, Days 1-28 of 5 week cycle; fluorouracil: 200 mg/m^2/day, continuous IV, Days 1-28 of 5 week cycle; leucovorin calcium: 30 mg/m^2/day, IV, Days 1,8,15,22 of 5 week cycle; mitomycin C: 10 mg/m^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
3326221|NCT00002952|Experimental|Arm A|Melan-A peptide loaded PBMCs (sc, q3wk x 3), rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
3326222|NCT00002772|Experimental|High dose chemo|sequential high dose chemotherapy with doxorubicin, paclitaxel and cyclophosphamide with filgrastim support
3328168|NCT00053625|Active Comparator|SA #1 Arm 2: Unilateral DBS in STN|
3326224|NCT00002768|Experimental|Autologous stem cell transplantation|Patients receive consolidation chemotherapy followed by autologous stem cell transplantation
3326225|NCT00002745|Experimental|aminocamptothecin|aminocamptothecin
3326226|NCT00002583|No Intervention|Observation|Observation only
3326227|NCT00002583|Active Comparator|Chemotherapy|Cisplatin and Vinorelbine
3326228|NCT00002501|Experimental|cyclophosphamide + filgrastim|Patients receive cyclophosphamide IV over 90 minutes on day 1 and filgrastim (G-CSF) subcutaneously beginning on day 3 and continuing until blood counts recover. Treatment continues every 2 weeks for 4 courses in the absence of disease progression or stable disease. Patients who achieve complete remission (CR) after completion of course 4 receive 2 additional courses. Patients who achieve partial remission (PR) after completion of course 4 receive 2 additional courses, and those who achieve CR after completion of course 6 receive 2 additional courses. Patients are followed every 2 months for 6 months, every 6 months for 2 years, and then annually thereafter.
3326229|NCT00002463|Experimental|Combination Chemotherapy|Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine
3326230|NCT00081731|Active Comparator|Optimal Medical Therapy|Optimal anti-hypertensive therapy
3326231|NCT00081731|Experimental|Stenting|Stent procedure plus optimal anti-hypertensive therapy
3326232|NCT00081653|Experimental|1|
3326233|NCT00081653|Active Comparator|2|
3326234|NCT00005950|Experimental|Treatment|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3326235|NCT00005828|Experimental|green tea extract|Patients receive oral green tea extract six times daily for 4 months. Patients with a 50% decline in PSA, complete or partial response, or stable disease after 4 months continue treatment in the absence of disease progression or unacceptable toxicity. Patients with disease progression after 4 months receive no further treatment. Patients are followed every 3 months for 5 years or until disease progression. If disease progression, patients are followed every 6 months for 5 years.
3326236|NCT00081588|Experimental|001|TMC114600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
3326237|NCT00005810|Experimental|Estramustine + docetaxel + carboplatin+ filgrastim|Patients receive oral estramustine 3 times daily on days 1-5. Patients receive docetaxel IV over 1 hour followed by carboplatin IV over 1 hour on day 2. Filgrastim (G-CSF) SC is administered beginning on day 6 and continuing until hematopoietic recovery. Treatment continues every 21 days in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for a maximum of 2 years.
3326238|NCT00005080|Experimental|Nelarabine|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive up to 8 courses of therapy.
3326239|NCT00004229|Experimental|Arm I|Patients undergo a biopsy during prestudy and after the second course of treatment. Patients receive endostatin IV daily for 4 weeks. Patients on dose level 1-6 receive endostatin over 20 minutes. Patients on dose level 7 receive endostatin over 40 minutes, with no treatment on day 2 of the first course only. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of endostatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
3326240|NCT00081510|Experimental|Lonafarnib plus Anastrozole|Participants receive lonafarnib 200 mg orally (PO) twice per day (BID) beginning on Day 1 Cycle 1 and continuing until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole 1 mg, PO, once per day (QD) for as long as the participant is receiving lonafarnib
3326241|NCT00081510|Active Comparator|Placebo plus Anastrozole|Participants receive placebo to lonafarnib PO BID beginning on Day 1 Cycle 1 until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole, 1mg PO QD for as long as the participant is receiving placebo
3326242|NCT00081497|Experimental|Fabrazyme 1.0 mg/kg every 2 weeks|This is an open-label extension study to AGAL-008-00 (NCT00074984) and all patients received Fabrazyme treatment.
3326243|NCT00081484|Experimental|1|
3326244|NCT00081484|Active Comparator|2|
3326245|NCT00081471|Experimental|1|
3326246|NCT00081471|Active Comparator|2|
3326247|NCT00081523||Patients|patients who meet eligibility criteria.
3326248|NCT00004010|Experimental|BEACOPP therapy|"Patients receive 4 cycles of BEACOPP therapy. Drugs utilized in this regimen include Bleomycin (B), Etoposide (E), Doxorubicin (A), Cyclophosphamide (C), Vincristine (O), Prednisone (P) and Procarbazine (P). Each cycle lasts 21 days and is characterized by intravenous pulses of Etoposide (Days 0-2), Doxorubicin (Day 0), Cyclophosphamide (Day 0), Bleomycin (Day 7), Vincristine (Day 7). Seven days of oral procarbazine (Days 0-6) and 14 days of oral prednisone (Days 0-13) are given during each cycle.~Growth factor support with Filgrastim (G-CSF) is given by subcutaneous injection daily beginning Day 8. Response will then be determined and stratification for further treatment."
3326249|NCT00003954|Experimental|Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)|"CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 15-20 minutes on day -2.~TRANSPLANTATION: Patients undergo autologous bone marrow or PBSCT on day 0.~NON-MYELOABLATIVE CONDITIONING REGIMEN: Beginning 40-120 days after autologous transplant, patients undergo TBI on day 0.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV BID on days -1 and 0 and PO BID on days 1-80 with taper based on evaluation of disease response and GVHD. Patients also receive mycophenolate mofetil PO BID on days 0-27.~POST TRANSPLANT DLI: Beginning 4 weeks after immunosuppression, patients achieving persistent or progressive disease may undergo DLI over 30 minutes every 4 weeks for up to 3 treatments."
3326250|NCT00081458|Placebo Comparator|placebo|Placebo injectable subcutaneously daily into the thigh or abdomen
3326251|NCT00081458|Experimental|2|teduglutide 0.05 mg/kg/d
3326252|NCT00081458|Experimental|3|teduglutide 0.1 mg/kg/d
3326280|NCT00081159|Experimental|HAT, Doxorubicin, Zoledronate + Strontium chloride|Arm I: Hormonal ablative therapy (HAT) comprising luteinizing hormone-releasing hormone agonist (e.g., leuprolide or goserelin) continuously during study treatment OR bilateral orchiectomy; doxorubicin IV on days 1, 8, and 15 every 28 days for 2 courses; zoledronate IV over 15 minutes on day 1 every 28 days for 6 courses; and a single dose of strontium chloride Sr 89 IV over 1-2 minutes on day 1.
3326253|NCT00003834|Experimental|oxaliplatin + leucovorin + fluorouracil|Patients receive oxaliplatin IV over 2 hours on day 1, then leucovorin calcium IV over 2 hours with fluorouracil IV bolus, followed by fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks. Patients with stable disease continue treatment in the absence of disease progression or unacceptable toxicity or until disease is resectable. Patients who achieve complete response (CR), partial response (PR) with unresectable disease, or PR but are not surgical candidates continue treatment in the absence of disease progression or unacceptable toxicity. Patients who demonstrate a response are treated until best response or until disease is deemed resectable. Patients who achieve a CR or PR and are resected may receive 2 to 4 additional courses of therapy at the discretion of the investigator. Patients are followed every 3 months for 1 year and then every 6 months for 2 years.
3326254|NCT00003824|Experimental|cipro|ciprofloxacin
3326255|NCT00003824|Experimental|ceph|cephalexin
3326256|NCT00003674|Experimental|dalteparin + standard therapy|Patients receive dalteparin by subcutaneous injection once daily plus standard therapy. Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity. Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years. Patients are followed monthly for 1 year, then every 3 months for 2 years.
3326257|NCT00003674|Active Comparator|standard therapy|Patients receive standard therapy alone. Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity. Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years. Patients are followed monthly for 1 year, then every 3 months for 2 years.
3326258|NCT00021398|Experimental|Radiation Therapy, Chemotherapy and Surgery|
3326259|NCT00021151|Experimental|Alemtuzumab|
3326260|NCT00002708|Experimental|Arm 1|Whole brain radiation therapy (WBRT) to 37.5 Gy/15 fractions/2.5 Gy once daily, 5 days/week followed by radiosurgery to all metastases
3326261|NCT00002708|Active Comparator|Arm 2|WBRT to 37.5 Gy/15 fractions/2.5 Gy once daily, 5 days/week
3326262|NCT00081367|Experimental|Cognitive behavioral therapy (CBT) + standard care|Participants will receive ten weekly sessions of treatment plus standard care for suicide prevention.
3326263|NCT00081367|Active Comparator|Standard care alone|Participants will receive standard care for suicide prevention.
3326264|NCT00081328|Experimental|1|Metformin alone
3326265|NCT00081328|Experimental|2|Metformin + Rosiglitazone
3326266|NCT00081328|Experimental|3|Metformin + Lifestyle Program
3326267|NCT00005833|Experimental|R115777|R115777, 300mg PO BID on Days 1-21. 1 cycle=28 days.
3326268|NCT00005820|Experimental|nitrocamptothecin|"Patients receive nitrocamptothecin orally daily for 5 consecutive days each week for 3 consecutive weeks. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until evidence of progression or relapse for a maximum of 2 years from the date of registration."
3326269|NCT00005066|Experimental|Arm A|O6-BG as an intravenous infusion (through your vein) over 1 hour followed 1 hour later by BCNU intravenously over 15 minutes. chemotherapy every 6 weeks.
3326270|NCT00003692|Experimental|video-assisted surgery|Patients undergo video-assisted thoracic surgery (VATS) lobectomy, which requires 3 small incisions on the side of the chest. The entire anatomic pulmonary lobe is removed, as well as all peribronchial lymph nodes and anterior hilar lymph nodes. If it is not possible to remove the lobe using the VATS approach, then 1 of the incisions is converted to a standard thoracotomy. Patients are followed every 4 months for the first 2 years, and then every 6 months for the next 3 years.
3326271|NCT00081289|Experimental|Neoadjuvant chemoradiation with irinotecan|Patients receive neoadjuvant therapy comprising 45 Gy (1.8 Gy/fx) + 5.4 Gy boost (1.8 Gy/fx) radiation therapy (RT), oral capecitabine 1200mg/m^2/day 5 days/week during RT, and irinotecan 50 mg/m^2 IV for 1 hour days 1, 8, 22, 29. Surgery 4-8 weeks after RT. Postoperative chemotherapy beginning Day 1 postoperatively for nine 14-day cycles(folinic acid 400 mg/m^2 over 2 hours Day 1; 5-fluorouracil bolus 400 mg/m^2 IV push Day 1 plus 2400 mg/m^2 IV continuous infusion over 46 hours, beginning Day 1; and oxaliplatin 85 mg/m^2 IV over 2 hours Day 1) .
3326272|NCT00081289|Experimental|Neoadjuvant chemoradiation with oxaplatin|Patients receive neoadjuvant therapy comprising 45 Gy (1.8 Gy/fx) + 5.4 Gy boost (1.8 Gy/fx) radiation therapy (RT), oral capecitabine 1650mg/m^2/day 5 days/week during RT, and oxaplatin 50 mg/m^2 IV for 2 hours days 1, 8, 22, 29. Surgery 4-8 weeks after RT. Postoperative chemotherapy beginning Day 1 postoperatively for nine 14-day cycles(folinic acid 400 mg/m^2 over 2 hours Day 1; 5-fluorouracil bolus 400 mg/m^2 IV push Day 1 plus 2400 mg/m^2 IV continuous infusion over 46 hours, beginning Day 1; and oxaliplatin 85 mg/m^2 IV over 2 hours Day 1) .
3326273|NCT00081276|Experimental|Treatment (triapine and cisplatin)|Patients receive 3-AP IV over 2 hours on days 1-4 and cisplatin IV over 1 hour on days 2 and 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3326274|NCT00081263|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib once daily for 14-18 weeks.
3326275|NCT00081263|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily for 14-18 weeks.
3326276|NCT00081250|Experimental|Arm I|Patients receive oral creatine daily.
3326277|NCT00081250|Placebo Comparator|Arm II|Patients receive oral placebo daily.
3326278|NCT00081224|Experimental|celecoxib + capecitabine + radiation + surgery|"Neoadjuvant chemoradiotherapy: Patients receive oral celecoxib twice daily on days 1-7 and oral capecitabine twice daily on days 1-5. Patients undergo pelvic radiotherapy once daily on days 1-5. Courses repeat weekly for 5.5 weeks.~Surgery: Patients undergo surgery 4-6 weeks after completion of neoadjuvant chemoradiotherapy.~Adjuvant chemotherapy: Patients with a curative resection receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 4 courses.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
3326279|NCT00081211|Experimental|Treatment (PV701)|Patients receive intratumoral PV701 once weekly for 3 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of PV701 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 6 evaluable patients are treated at that dose.
3326338|NCT00003192|Experimental|Arm A|9-aminocamptothecin (25 mcg/m2/hr x 120hrs, days 1-5 and 8-12 of each 3 week cycle)
3326281|NCT00081159|Experimental|HAT, Doxorubicin + Zoledronate|Arm II: HAT, doxorubicin, and zoledronate as in arm I. HAT comprising luteinizing hormone-releasing hormone agonist (e.g., leuprolide or goserelin) continuously during study treatment OR bilateral orchiectomy; doxorubicin IV on days 1, 8, and 15 every 28 days for 2 courses; zoledronate IV over 15 minutes on day 1 every 28 days for 6 courses.
3326282|NCT00081094|Other|PET scan (FDG-PET & 11C-acetate-PET)|Patients will undergo routine clinical FDG-PET and research 11C-acetate-PET prior to planned surgical resection of the lesion(s) or explantation of the liver.
3326283|NCT00080990|Experimental|Treatment (alvocidib with oxaliplatin, 5-FU, leucovorin)|"Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, the cohort is expanded and an additional 10 patients are treated at that dose."
3326284|NCT00080951|Experimental|irinotecan + oxaliplatin + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV and fluorouracil IV over 90 minutes on days 2-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, before each chemotherapy course, and at the end of treatment.~Patients are followed every 3 months until 5 years after registration."
3326285|NCT00080938|Experimental|Temozolomide and Radiation|Temozolomide:administered orally. Radiation: whole brain radiation therapy
3326286|NCT00080912|Experimental|Arm I|Patients receive single-fraction radiotherapy (8 Gy) on day 1.
3326287|NCT00080912|Active Comparator|Arm II|Patients receive multiple-fraction radiotherapy (to a total of 20 Gy) over 5 days or over 8 days if re-irradiation of the spine and/or whole pelvis is involved AND prior initial radiotherapy was given in multiple fractions.
3326288|NCT00080899|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide twice daily on days 1-7. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
3326289|NCT00080886|Other|Arm 1|
3326290|NCT00080873|Experimental|Receive Traumeel S|
3326291|NCT00080873|Placebo Comparator|Receive placebo|
3326292|NCT00080847|Experimental|Arm I (closed to accrual as of 9/21/04)|Patients receive rituximab IV over 6 hours, cyclophosphamide IV over 15-45 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 1 and oral prednisone on days 1-5.
3326293|NCT00080847|Experimental|Arm II|Patients receive oblimersen IV continuously on days 1-7; rituximab IV over 6 hours, cyclophosphamide IV over 15-45 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 5; and oral prednisone on days 5-10.
3326294|NCT00080808|Active Comparator|Arm I|Patients undergo unilateral cavernous nerve-sparing radical prostatectomy with unilateral autologous interposition sural nerve grafting.
3326295|NCT00080808|Active Comparator|Arm II (No sural nerve grafting)|Patients undergo unilateral cavernous nerve-sparing radical prostatectomy (without sural nerve grafting) and erectile dysfunction rehabilitation as in arm I.
3326296|NCT00080782|Experimental|Arm I: Celecoxib|Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1, and oral celecoxib twice daily in absence of disease progression.
3326297|NCT00080782|Experimental|Arm II: No Celecoxib|Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1.
3326298|NCT00080756|Experimental|Group 1 (planned risk reduction mastectomy)|Patients receive deslorelin, estradiol, and testosterone intranasally QD for 6 months. Patients then undergo planned risk reduction mastectomy.
3326299|NCT00080756|Active Comparator|Group 2 (continued survaillance)|Patients receive deslorelin, estradiol, and testosterone intranasally QD for 10 months. Patients then undergo continued surveillance through 10 months.
3326300|NCT00080743|Active Comparator|Tamoxifen|Tamoxifen 20 mg po once daily
3326301|NCT00080743|Placebo Comparator|Placebo|Placebo comparator one tablet po once daily
3326302|NCT00080678|Experimental|Docetaxel + Imatinib Mesylate|Docetaxel 30 mg/m^2 intravenous over 60 minutes on days 1, 8, 15, and 22 in 42-day cycles, with daily oral 600 mg imatinib mesylate.
3326303|NCT00080678|Placebo Comparator|Docetaxel + Placebo|Docetaxel 30 mg/m^2 intravenous (IV) over 60 minutes on days 1, 8, 15, and 22 in 42-day cycles, with daily oral placebo.
3326304|NCT00080665|Experimental|Imatinib mesylate and docetaxel|Imatinib mesylate (400-600 mg, oral, once daily) and docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
3326305|NCT00080626|Experimental|Docetaxel|Neoadjuvant therapy with docetaxel (IV, 100 mg/m2, every 14 days with growth factor support with pegfilgrastim) for a total of 4 cycles prior to conventional surgery for breast cancer.
3326306|NCT00080535|Experimental|LMB-2 for cutaneous Tcell lymphoma|30 micrograms/kg every other day (QOD) x 3 every 4 weeks in patients with cutaneous T-cell lymphoma, a group of lymphoproliferative disorders characterized by malignant CD4+ T-lymphocytes which localize tot he skin on initial presentation.
3326307|NCT00080483|Experimental|1|Testosterone transdermally 5 g a day and somatropin subcutaneously 2 µg/kg body weight a day
3326308|NCT00080483|Active Comparator|2|AndroGel transdermally 5 g a day for two years
3326309|NCT00002774|Experimental|Tirapazamine + cisplatin + 5-FU|2 cycles of induction chemotherapy (tirapazamine, cisplatin, and 5-fluorouracil [5-FU]) followed by simultaneous chemoradiotherapy (tirapazamine, cisplatin, and 5-FU)
3326310|NCT00002774|Active Comparator|Cisplatin + 5-FU|2 cycles of induction chemotherapy (cisplatin + 5-fluorouracil [5-FU]) followed by simultaneous chemoradiotherapy (cisplatin + 5-FU)
3326311|NCT00002525|Experimental|Perioperative 5-FU|"Within 24 hours of the colon resection, patients receive perioperative fluorouracil intravenously (IV) over 24 hours for 7 days.~After surgery (beginning 21-35 days post-surgery), 5-FU was given at a dose of 425 mg/m^2 IV push on days 1-5, and leucovorin calcium was given at a dose of 20mg/m^2 IV push on days 1-5"
3326312|NCT00002525|Active Comparator|No perioperative 5-FU|"Patients receive no perioperative fluorouracil.~After surgery (beginning 21-35 days post-surgery), 5-FU was given at a dose of 425 mg/m^2 IV push on days 1-5, and leucovorin calcium was given at a dose of 20mg/m^2 IV push on days 1-5"
3326410|NCT00079586|Experimental|Angiomax|1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
3326313|NCT00002494|Experimental|Combination therapy|Patients receive combination therapy as described in the study description. All patients must complete at least the first 3 courses of chemotherapy. Courses 2 and 3 each repeat 3 times in the absence of disease progression or unacceptable toxicity. On days 134-139, patients who have had prior bone marrow involvement receive cranial radiation therapy. Patients who achieve less than a complete response and who have an HLA-matched sibling should undergo allogeneic bone marrow transplant on protocol CLB-9113. Patients are followed monthly for 6 months, every 2 months for 18 months, every 6 months for 2 years, and thereafter for survival.
3326314|NCT00080470|Experimental|1|Stimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on.
3326315|NCT00080470|Sham Comparator|2|No Stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on.
3326316|NCT00080444|Experimental|Part 1: Aprepitant|Day 1: aprepitant 125 mg orally (PO), ondansetron 0.15 mg/kg x 3 doses intravenously (IV), dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For 1 cycle and up to 9 subsequent optional cycles.
3326317|NCT00080444|Active Comparator|Part 1: Standard Therapy|Day 1: placebo to aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 16 mg PO. Day 2: placebo to aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 3: placebo for aprepitant 80 mg PO, dexamethasone 8 mg PO. Day 4: dexamethasone 8 mg PO. For 1 cycle; participants may receive open-label aprepitant for up to 9 subsequent optional cycles.
3326318|NCT00080444|Active Comparator|Part 2: Aprepitant|Day 1: aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For up to 10 cycles.
3326319|NCT00006487|Active Comparator|chemo/RT with tirapazamine|induction and consolidation: cisplatin, etoposide, tirapazamine, radiation therapy
3326320|NCT00006371|Active Comparator|Hydrocortisone with Ketoconazole|Patients are stratified according to prior antiandrogen therapy (yes vs no). Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen withdrawal, while those without such prior therapy begin study therapy immediately. Patients undergo medical adrenalectomy using hydrocortisone combined with ketoconazole. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral ketoconazole is administered three times daily.
3326321|NCT00006371|Active Comparator|Hydrocortisone with Aminoglutethimide|Patients are stratified according to prior antiandrogen therapy (yes vs no). Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen withdrawal, while those without such prior therapy begin study therapy immediately. Patients undergo medical adrenalectomy using hydrocortisone combined with aminoglutethimide. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral ketoconazole is administered three times daily.
3326322|NCT00006031|Active Comparator|I: Radioactive Seed Localized Breast Biopsy|Arm I: Patients undergo radiographic placement of a radioactive seed (either iodine I 125 or palladium Pd 103) into the suspicious lesion. Patients then undergo surgery to remove the lesion along with the seed and a small margin of surrounding breast tissue followed 3 months later by a postoperative mammogram.
3326323|NCT00006031|Active Comparator|Arm II: Needle Localized Breast Biopsy|Arm II: Patients undergo a needle localized breast biopsy with a specimen x-ray.
3326324|NCT00005799|Experimental|Treatment (chemotherapy, TBI, HSCT)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO BID on days 0-40 with taper to day 96. Patients with mixed chimerism, persistent or progressive disease, and no evidence of graft-versus-host disease and who have been off immunosuppression for at least 2 weeks undergo DLI over 30 minutes. DLI may be repeated every 65 days for up to 3 doses."
3326325|NCT00005798|Other|CTC Conditioning Regimen|Cyclophosphamide Thiotepa Carboplatin
3326326|NCT00005615|Experimental|Interferon Alfa Plus Radiation|"Combined Therapy: interferon alfa plus radiation therapy.~Patients receive interferon alfa IV over 20 minutes daily for 5 consecutive days a week for 4 weeks. Patients then receive radiotherapy on days 2 and 4 and interferon alfa subcutaneously (SQ) on days 1, 3, and 5 for 2.5 weeks. Interferon alfa SQ continues 3 times a week for 10 months in the absence of disease progression or unacceptable toxicity. Patients are followed every month for 3 months, then every 3 months for 2 years, then every six months until year 5, and then annually thereafter."
3326327|NCT00005577|Experimental|Arm I|Patients receive gemcitabine IV over 30 minutes weekly for 2 weeks. Patients achieving objective response or stable disease after 3 weeks may receive additional courses of therapy every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity.
3326328|NCT00005097|Experimental|Polyphenon E & Placebo|"Each subject will receive both the Polyphenon E and placebo, one on each arm.~One arm will be assigned to be treated with topical Polyphenon E daily for 12 weeks and the other with placebo vehicle in a random, double blind manner daily for 12 weeks."
3326329|NCT00003657|Experimental|High Dose ICF with Amifostine|"Patients undergo peripheral blood stem cell transplantation (PBSC) harvest on day -8,~ifosfamide IV, carboplatin IV etoposide IV (ICE) by 96 hour continuous infusion on days -7 to -4.~Patients receive amifostine IV twice a day on days -7 to -3.~PBSCs are reinfused on day 0.~Filgrastim (G-CSF) is administered subcutaneously beginning on day 0 at least 2 hours after infusion of the stem cells and continuing until blood cell counts recover.~Patients are followed monthly for the first 2 months and then for survival."
3326330|NCT00080327|Active Comparator|1|
3326331|NCT00080327|Active Comparator|2|
3326332|NCT00080327|Active Comparator|3|
3326333|NCT00080327|Placebo Comparator|4|
3326334|NCT00080314|Active Comparator|A1|
3326335|NCT00080314|Placebo Comparator|A2|
3326336|NCT00080301|Experimental|A|
3326337|NCT00080301|Active Comparator|B|
3326339|NCT00003157|Experimental|radiation + gemcitabine + cisplatin|Patients undergo radiotherapy to the tumor and lymph nodes, followed by a decrease in radiotherapy to the tumor alone. Radiation therapy is administered for a total of 5.5 weeks. Patients receive intravenous gemcitabine twice weekly over the first 3 weeks of radiotherapy. Cisplatin is administered intravenously twice weekly following gemcitabine therapy. Three patients are treated at each dose level. Dose escalation does not occur until all patients at a given dose level have completed radiotherapy and returned for a 4 week follow up. Patients exhibiting stable disease remain on therapy until disease progression or intolerable toxic effects. Patients experiencing toxic effects and no disease progression are retreated at a lower dose. Patients are followed every 3 months for the first 2 years then every 6 months for the next year.
3326340|NCT00080288|Experimental|1|Armodafinil 150 mg/day
3326341|NCT00080288|Placebo Comparator|2|Placebo
3326342|NCT00080262|Experimental|1|
3326343|NCT00080236|Placebo Comparator|Donor organ placebo and Recipient placebo|
3326344|NCT00080236|Active Comparator|Donor organ: IDN-6556 (15μg/ml), Recipient: Placebo|
3326345|NCT00080236|Active Comparator|Donor organ: IDN-6556 (5 μg/ml), Recipient: IDN-6556 0.5 mg/kg|
3326346|NCT00080236|Active Comparator|Donor organ: IDN-6556(15 μg/ml), Recipient: IDN-6556 0.5 mg/kg|
3326347|NCT00080223|Experimental|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
3326348|NCT00002759|Experimental|Arm I|See detailed description.
3326349|NCT00002540|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
3326350|NCT00002540|Active Comparator|Prostate Screening|Participants undergo blood sample collection for PSA analysis at baseline and annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo a DRE at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident prostate cancers as all deaths that occur among both screened and control subjects during the trial.
3326351|NCT00080145|Active Comparator|risperidone plus parent management training|
3326352|NCT00080145|Active Comparator|risperidone only|
3326353|NCT00080119|Experimental|HIVneg/INH|Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid (INH)10-20 mg/kg orally once a day for 96 weeks + Trimethoprim/Sulfamethoxazole (TMP/SMX) 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding
3326354|NCT00080119|Placebo Comparator|HIVneg/PL|Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding
3326355|NCT00080119|Experimental|HIVpos/INH|HIV-infected (HIVpos) children receiving Isoniazid (INH) 10-20 mg/kg orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.
3326356|NCT00080119|Placebo Comparator|HIVpos/PL|HIV-infected (HIVpos) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.
3326357|NCT00080106|Experimental|1|Participants in the experimental arm will receive the MRK Ad5 HIV-1 gag vaccine on Day 1, Week 4 and Week 26. Participants will take their antiretroviral medications during the first 3 months of the study.
3326358|NCT00080106|Placebo Comparator|2|Participants in Arm 2 will receive a placebo vaccine on Day 1, Week 4 and Week 26. Participants will take their antiretroviral medications during the first 3 months of the study.
3326359|NCT00008320|Experimental|ceramide cream|Topical ceramide cream is applied to all cutaneous lesions twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then at 1 and 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
3326360|NCT00006348|Experimental|Arm 1: ondansetron + placebo|Patients receive oral ondansetron twice daily on days 1-7 and oral placebo twice daily on days 8-14 in the absence of unacceptable toxicity.
3326361|NCT00006348|Experimental|Arm 2: ondansetron + placebo|Patients receive oral placebo twice daily on days 1-7 and oral ondansetron twice daily on days 8-14 in the absence of unacceptable toxicity.
3326362|NCT00080093|Experimental|1|Participants will receive individual feedback and specially-tailored manuals at study entry and at Months 2 and 4
3326363|NCT00080093|Experimental|2|Participants will receive general HIV information feedback and the best-available informational manual at study entry and at Months 2 and 4
3326364|NCT00005972|Experimental|gemcitabine + irinotecan|Patients are stratified according to prior response duration (progression 90 days or more after initial therapy vs progression less than 90 days after initial therapy or no response to initial therapy). Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1 and 8. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months for 2 years, and then annually for 3 years.
3326365|NCT00004123|Experimental|RT + DOX + IORT|Preoperative external beam radiotherapy (RT) combined with doxorubicin (DOX) and followed by intraoperative radiotherapy (IORT); dose-escalation study of external beam radiotherapy.
3326366|NCT00003693|Experimental|MTD Group|
3326367|NCT00079963|Experimental|X|Vitamin C
3326368|NCT00079963|Experimental|Y|Vitamin E
3326369|NCT00079963|Placebo Comparator|Z|Placebo
3326370|NCT00079937|Experimental|Omalizumab|Participants received omalizumab administered by subcutaneous injection every 2 or 4 weeks for a duration of 52 weeks. The omalizumab dose was based on the patient's body weight and total serum IgE level at Screening. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks.
3326807|NCT00075179|Experimental|Nesiritide|Nesiritide 0.01 mcg/kg/min by vein over 30 minutes during right heart catheterization procedure.
3326371|NCT00079937|Placebo Comparator|Placebo|Placebo was administered by subcutaneous injection every 2 or 4 weeks depending on the dosing schedule in the protocol for a total of 52 weeks. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks.
3326372|NCT00079911|Experimental|Suppressive + Episodic Therapy|Valaciclovir (VAL) 500mg twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 days or 10 days, when required for treatment of a genital herpes recurrence.
3326373|NCT00079911|Placebo Comparator|Episodic Therapy|Matching placebo twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 or 10 days, when required for treatment of a genital herpes recurrence.
3326374|NCT00022165|Placebo Comparator|Placebo|Selenium yeast
3326375|NCT00022165|Experimental|Selenium yeast 100 micrograms per day|100 micrograms per day
3326376|NCT00022165|Experimental|Selenium yeast 200 micrograms per day|200 micrograms per day
3326377|NCT00022165|Experimental|Selenium yeast 300 micrograms per day|300 micrograms per day
3326378|NCT00003166|Experimental|Treatment (bryostatin 1, vincristine sulfate)|"Patients receive bryostatin 1 IV over 24 hours followed immediately by vincristine IV. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy may receive subsequent courses every 3 weeks and then every 4 weeks after 24 months of treatment. Patients may return to a 2- or 3-week treatment course at the discretion of the principal investigator.~Cohorts of 3 patients receive escalating doses of bryostatin 1 until the MTD is determined. The MTD is defined as the dose preceding that at which at least 1 of 3 patients experience dose-limiting toxicity."
3326379|NCT00079820|Experimental|A|MVA3000 Smallpox vaccine (1x10-8) with Dryvax Challenge at Day 112
3326380|NCT00079820|Experimental|B|MVA3000 Smallpox vaccine (1x10-8) with no Challenge
3326381|NCT00079820|Placebo Comparator|C|Placebo
3326382|NCT00079820|Experimental|D|MVA3000 Smallpox vaccine (1x10-7) with Dryvax challenge at Day 112
3326383|NCT00079820|Experimental|E|MVA3000 Smallpox vaccine (1x10-6) with Dryvax challenge at Day 112
3326384|NCT00009737|Experimental|Capecitabine|Participants received capecitabine 1250 milligram per square meter (mg/m ^ 2) orally, twice a day, for 14 days, followed by a 7-day rest period without treatment, as an intermittent therapy in a 3-week cycle for 8 cycles (24 weeks).
3326385|NCT00009737|Active Comparator|5-Fluorouracil + Leucovorin|Participants received leucovorin 20 mg/m ^ 2 followed by 5-fluorouracil at 425 mg/m ^ 2, by rapid intravenous injection, daily, from Days 1 to 5 of the first week in each 4-week cycle for 6 cycles (24 weeks).
3326386|NCT00006708|Active Comparator|ICE Chemotherapy|Etoposide 100 mg/m2 IV Days 1-3 Carboplatin AUC=5 IV Day 2 Ifosfamide 5 g/m2 IV Day 2 Mesna 5 g/m2 IV Day 2 Filgrastim 5ug/kg/day SQ Days 5-12 Q 21 days x 3 cycles
3326387|NCT00006708|Experimental|Rituximab-ICE Chemotherapy|Etoposide 100 mg/m2 IV Days 2-4 Carboplatin AUC=5 IV Day 3 Ifosfamide 5 g/m2 IV Day 3 Mesna 5 g/m2 IV Day 3 Filgrastim 5ug/kg/day SQ Days 6-13 Q 21 days x 3 cycles Rituximab 375 mg/m2 IV Days 1 and 8 Cycle 1 Rituximab 375 mg/m2 IV Day 1 Cycles 2-3
3326388|NCT00079781|Active Comparator|Treatment Group|Group of subjects who have undergone RNS® System implantation who are randomized to receive RNS® System responsive stimulation (i.e. responsive stimulation enabled or turned ON) during the blinded Evaluation Period. Stimulation is enabled during the first month post-implant and may continue throughout the subject's participation in the study.
3326389|NCT00079781|Sham Comparator|Sham Group|Group of subjects that have undergone RNS® System implantation that are randomized to receive sham-stimulation (i.e. responsive stimulation disabled or turned OFF) during the blinded Evaluation Period. Stimulation is enabled after transition into the Follow-Up Period (5th month post-implant) and may continue for the remainder of the subject's participation in the study.
3326390|NCT00079781|Other|Open Label Group|Group of subjects who have undergone RNS® System implantation who were not randomized or blinded to therapy status during the Evaluation Period. Stimulation may have been enabled during the first month post-implant and may have continued throughout the subject's participation in the study.
3326391|NCT00079716|Experimental|1|
3326392|NCT00005866|Experimental|treatment|
3326393|NCT00005834|Experimental|chemo with thalidomide|chemo with thalidomide
3326394|NCT00005834|Active Comparator|chemo without thalidomide|chemo without thalidomide
3326395|NCT00005085|Experimental|Arm I|Patients receive rebeccamycin analogue IV once on day 1. Treatment repeats every 21 days for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
3326396|NCT00005037|Experimental|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
3326397|NCT00004909||Oral chemotherapy|
3326398|NCT00004909||Parenteral chemotherapy|
3326399|NCT00004163|Experimental|Trastuzumab|"Trastuzumab is administered intravenously weekly~CAT or MRI scans will be performed every 2 cycles"
3326400|NCT00004142|Experimental|Radiofrequency Ablation + HAI of Floxuridine/5-FU|Radiofrequency Ablation Combined With Post-Ablation Hepatic Arterial Infusion (HAI) of Floxuridine Alternating With 5-Fluorouracil (5-FU)
3326401|NCT00004109|Experimental|Doxorubicin + External-Beam RT|
3326402|NCT00003779|Active Comparator|BCG-Connaught|
3326403|NCT00003779|Active Comparator|BCG Onko-Tice|
3326404|NCT00003704|Experimental|capecitabine + radiation|This is a dose-escalation study of capecitabine. Patients receive oral capecitabine twice a day 7 days a week for 6 weeks with concurrent radiotherapy. Radiotherapy is initiated on the same day as the initiation of capecitabine and is administered 5 days a week for 5.5-6 weeks. Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose-limiting toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 1 year.
3326405|NCT00079677|Experimental|1|Armodafinil 150 mg/day
3326406|NCT00079677|Placebo Comparator|2|Placebo
3326407|NCT00079612|Experimental|Arm 1|
3326408|NCT00079612|Placebo Comparator|Arm 2|
3326409|NCT00079586|Active Comparator|Heparin|unfractionated heparin will be administered as per institutional practice
3326411|NCT00016978|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and leucovorin calcium and fluorouracil IV on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a confirmed complete response for 2 consecutive courses may discontinue study treatment at the investigators discretion. Quality of life is assessed at baseline, approximately every 6-8 weeks during treatment, and then after the last course of treatment.
3326412|NCT00002601|Experimental|Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT|"Cycle 1 Day -8 through Day -4 (96h) Doxorubicin 150 mg/m2 (CI) + Ifosfamide 14 g/m2 mixed with mesna (CI) Day -3 Mesna 3.5 g/m2 over 24 h Day -2 12.5% of stem cell reinfused.~Cycle2 Day -11 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -10 thru Day -6 G-CSF 5ug/kg Day -4 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -3 12.5% if stem cell reinfused Day 0 37.5% of stem cell reinfused"
3326413|NCT00002537|Experimental|Arm I|Beginning on day 1, patients receive topotecan IV continuously for 3-6 weeks and thoracic radiotherapy 5 days a week for 2, 3, or 6 weeks. Cohorts of 4-6 patients receive escalating doses of topotecan and thoracic radiotherapy until the maximum tolerated dose (MTD) of each therapy is determined. The MTD is defined as the dose preceding that at which 2 of 4 or 6 patients experience dose-limiting toxicity. Six additional patients are treated at the MTD. Patients who fail to achieve complete remission (CR) and continue to have measurable disease at 4-6 weeks after completion of radiotherapy receive topotecan IV continuously on days 1-21 at 1 dose level preceding the MTD as determined by the ongoing Protocol NYU-9123. Treatment continues every 4 weeks in the absence of unacceptable toxicity.
3326414|NCT00079599|Experimental|1|
3326415|NCT00079599|Placebo Comparator|2|
3326416|NCT00079547|Active Comparator|1|Low-calorie diet
3326417|NCT00079547|Experimental|2|Low-carbohydrate diet
3326418|NCT00079482|Active Comparator|1|Induction chemotherapy with or without sequential treatment with oral CEP-701 at 80 mg bid. For patients with duration of first CR of 1 to 6 months, the induction regimen will be MEC.
3326419|NCT00079482|Active Comparator|2|Induction chemotherapy with or without sequential treatment with oral CEP-701 at 80 mg bid. For patients with duration of first CR of more than 6 months to 24 months, the induction regimen will be HiDAC.
3326420|NCT00079456|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3326421|NCT00079443|Experimental|Treatment|"PHASE II: Patients receive FR901228 IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients who achieve a complete or partial remission receive 2 additional courses (for a total of 6 courses). Patients with stable disease after 4 courses or progressive disease at any time after 2 courses proceed to the phase I portion of the study.~PHASE I: Patients receive rituximab IV over approximately 4-8 hours on day 1; fludarabine IV over 10-30 minutes on days 2-4; and FR901228 IV over 4 hours on days 2, 9, and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3326422|NCT00079430|Experimental|Treatment (adjuvant, paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours followed by intraperitoneal carboplatin over 15 minutes on day 1 in course 1. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3326423|NCT00079417|Experimental|Vincristine Sulfate and Carboplatin and surgery|Patients receive chemoreduction comprising carboplatin IV (Pts < 36 months: 18.6 mg/kg Pts ≥ 36 months: 560 mg/m2) over 60 minutes followed by vincristine sulfate IV (Pts < 36 months: 0.05 mg/kg Pts ≥36 months: 1.5 mg/m2) over 1-2 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the first course of chemoreduction, patients undergo standardized local ophthalmic therapy comprising local infrared laser therapy, cryosurgery, and/or radiation therapy (radioactive) plaque comprising iodine I 125 or ruthenium Ru 106.
3326424|NCT00079404|Experimental|Arm I|Patients with solid tumors receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 60-120 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
3326425|NCT00079391|Experimental|allogeneic hematopoietic SCT|allogeneic hematopoietic stem cell transplantation (SCT) using Nexell Isolex system
3326426|NCT00079378|Experimental|Treatment (decitabine, valproic acid)|"Patients receive decitabine IV over 1 hour on days 1-5 or 1-10. Treatment repeats every 28 days.~Cohorts of 6 patients receive escalating doses of decitabine until the MEPD is determined. The MEPD is defined as the dose at which at least 5 of 6 patients meet gene methylation criteria and no more than 1 of 6 patients experiences DLT.~Once the MEPD is determined, patients receive decitabine at that dose level administered as above and oral valproic acid three times daily on days 5-21. Treatment repeats every 28 days.~Cohorts of 3-6 patients receive escalating doses of valproic acid until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. The MEPD of valproic acid is then determined using established gene methylation and toxicity criteria. Treatment continues for up to 24 months in the absence of disease progression or unacceptable toxicity."
3326427|NCT00079352|Experimental|Treatment (gemcitabine, irinotecan, alvocidib)|Patients receive gemcitabine IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1 and 15. Patients also receive flavopiridol IV over 60 minutes on days 2 and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3326428|NCT00079339|Experimental|Treatment (radiation therapy and tipifarnib)|"PHASE I: Patients undergo radiotherapy 5 days a week for 6 weeks. Beginning 0-2 days before radiotherapy, patients receive oral tipifarnib twice daily until the completion of radiotherapy. Beginning 2 weeks after the completion of radiotherapy, patients receive oral tipifarnib twice daily in weeks 1-3. Treatment repeats every 4 weeks for up to 24 additional courses (total of 26 courses) in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients undergo radiotherapy and receive tipifarnib at the MTD as in phase I (closed to accrual as of 1/19/06). Treatment continues for up to 24 months (26 courses) in the absence of disease progression or unacceptable toxicity."
3326429|NCT00079326|Experimental|Treatment (trastuzumab, ixabepilone)|Patients receive trastuzumab IV over 30-90 minutes and ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3326808|NCT00075140||1|All Participants hav a family member with Huntington Disease
3326430|NCT00079274|Experimental|Arm A (combination chemotherapy)|Patients received oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46-48 hours on days 1. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
3326431|NCT00079274|Experimental|Arm B (combination chemotherapy)|Patients received irinotecan IV over 2 hours on day 1 and leucovorin calcium and fluorouracil as in arm A. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
3326432|NCT00079274|Experimental|Arm C (combination chemotherapy)|Patients received the same treatment as in arm A for 6 courses followed by the same treatment as in arm B for 6 courses (total of 12 courses). Treatment continues in the absence of unacceptable toxicity or recurrent disease.
3326433|NCT00079274|Experimental|Arm D (combination chemotherapy, monoclonal antibody)|Patients received cetuximab IV over 1 hour on days 1 and 8 and oxaliplatin, leucovorin calcium, and fluorouracil as in arm A. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
3326434|NCT00079274|Experimental|Arm E (combination chemotherapy, monoclonal antibody)|Patients received cetuximab as in arm D and irinotecan, leucovorin calcium, and fluorouracil as in arm B. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
3326435|NCT00079274|Experimental|Arm F (combination chemotherapy, monoclonal antibody)|Patients received cetuximab as in arm D and chemotherapy as in arm C.
3326436|NCT00079274|Other|Arm G (Locally directed therapy)|Patients determined to have mutated KRAS (or KRAS not evaluable) were assigned to an event monitoring arm in which adjuvant therapy was determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification was the responsibility of the treating oncologists.
3326437|NCT00079235|Experimental|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22.
3326438|NCT00079183|Experimental|Sirolimus|Study participants receive sirolimus added once daily to their baseline combination therapy of prednisone plus either cyclosporine or tacrolimus at the discretion of the managing physician. Treatment other than cyclosporine (or tacrolimus) and prednisone must be discontinued when administration of sirolimus is started. Topical therapy, including psoralen and UVA irradiation (PUVA), glucocorticoid creams, topical tacrolimus, oral beclomethasone, topical azathioprine and ophthalmic glucocorticoids may be given at the discretion of the managing physician in consultation with the transplant center.
3326439|NCT00079131|Experimental|Treatment (oblimersen sodium)|Patients receive oblimersen IV continuously on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3326440|NCT00079118|Experimental|docetaxel + irinotecan|"Patients receive docetaxel IV over 1 hour followed by irinotecan IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses beyond CR.~Patients are followed every 2 months until disease progression and then every 6 months thereafter."
3326441|NCT00079105|Active Comparator|Treatment|Treatment with VEPEMB - Vinblastine sulfate, Cyclophosphamide, Procarbazine hydrochloride, Prednisolone, Etoposide, Mitoxantrone hydrochloride, and Bleomycin sulfate
3326442|NCT00079105|No Intervention|Registration|Registration, without treatment
3326443|NCT00079040|Experimental|Treatment (cisplatin, etoposide, bevacizumab)|"Chemotherapy: Patients receive cisplatin IV over 30-60 minutes on day 1 and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~Bevacizumab therapy: Beginning concurrently with chemotherapy, patients receive bevacizumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 17 courses (1 year) in the absence of disease progression or unacceptable toxicity."
3326444|NCT00079014|Experimental|Treatment (triapine, doxorubicin hydrochloride)|"Patients receive doxorubicin IV over 15 minutes on day 1 and 3-AP (Triapine®) IV over 2 hours on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 3-AP (Triapine®) until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6 patients are treated at that dose level."
3326445|NCT00079001|Experimental|Zoledronic acid + androgen deprivation therapy|4mg by IV over 15 minutes every 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progression on blinded treatment before having a skeletal event may continue on open label Zoledronic acid (4 mg by IV over 15 minutes every 3 weeks).
3326446|NCT00079001|Active Comparator|Placebo + androgen deprivation therapy|Placebo bu IV over 15 minutes for 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progress on blinded treatment before having a skeletal event may continue on open label Zoledronic acid.
3326447|NCT00078988|Experimental|Arm I (high-dose chemotherapy and ASCR)|Patients receive high-dose chemotherapy comprising carboplatin IV over 4 hours on days -8 to -6; thiotepa IV over 3 hours and etoposide IV over 3 hours on days -5 to -3; and filgrastim (G-CSF) IV or SC once daily beginning on day 1 and continuing until blood counts recover. Autologous PBSC or bone marrow are reinfused on day 0.
3326448|NCT00078988|Experimental|Arm II (intermediate-dose chemotherapy and ASCR)|Patients receive intermediate-dose chemotherapy comprising carboplatin IV over 4 hours and thiotepa IV over 3 hours on days 1-2 and G-CSF IV or SC once daily beginning on day 4 and continuing until blood counts recover. Autologous PBSC or bone marrow are reinfused on day 3. Treatment repeats every 28 days for a total of 3 courses.
3326449|NCT00078988|Experimental|Arm III (isotretinoin)|Patients receive oral isotretinoin twice daily on days 1-14. Treatment repeats every 28 days for a total of 6 courses.
3326450|NCT00078988|No Intervention|Arm IV (no isotretinoin)|Patients do not receive maintenance therapy.
3326451|NCT00078975|Experimental|Triapine in combination with Gemcitabine|
3326488|NCT00005843|Experimental|Arm I|Patients receive oral R115777 twice daily for 21 consecutive days. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
3326489|NCT00078624|Experimental|1|Traditional exercise program supplemented with knee stability training activities
3326490|NCT00078624|Active Comparator|2|Traditional exercise program
3326491|NCT00005096|Experimental|Docetaxel|Docetaxel given via iv at determined dose once a week for 4 weeks
3326452|NCT00078962|Experimental|Treatment (GTI-2040, gemcitabine hydrochloride)|"Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose."
3326453|NCT00078949|Experimental|Salvage arm I|Patients receive cisplatin IV over 60 minutes on day 1, dexamethasone IV or orally on days 1-4, and gemcitabine IV over 30 minutes on days 1 and 8.
3326454|NCT00078949|Experimental|Salvage arm II|Patients receive cisplatin IV over 24 hours on day 1, dexamethasone as in arm I, and cytarabine IV over 3 hours every 12 hours for a total of 2 doses on day 2.
3326455|NCT00078949|Experimental|Maintenance arm I|Beginning on day 28 posttransplantation, patients receive rituximab IV once every 2 months for 6 doses (a total of 12 months) in the absence of disease progression or unacceptable toxicity.
3326456|NCT00078949|No Intervention|Maintenance arm II|Patients undergo observation only.
3326457|NCT00078923|Experimental|Placebo|Arm I (control group): Patients receive 4 placebo capsules by mouth daily for three weeks.
3326458|NCT00078923|Experimental|Soy isoflavones and placebo|Arm II: Patients receive oral soy isoflavones (PTI G-2535) 150 mg genistein capsules + 3 placebo capsules by mouth daily for 3 weeks.
3326459|NCT00078923|Experimental|Soy Isoflavones/Placebo|Arm III: Patients receive oral soy isoflavones (PTI G-2535) 300 mg genistein capsules + 2 placebo capsules by mouth daily for 3 weeks.
3326460|NCT00078923|Experimental|Soy Isoflavones|Arm IV: Arm III: Patients receive oral soy isoflavones (PTI G-2535) 600 mg genistein capsules by mouth daily for 3 weeks.
3326461|NCT00078897|Active Comparator|Selenium|Participants receive oral selenium 200 mcg once daily.
3326462|NCT00078897|Placebo Comparator|Placebo|Participants receive oral placebo once daily.
3326463|NCT00078858|Experimental|Treatment (prolonged MMF and truncated CSP)|"CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2, and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBMC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 150 and mycophenolate mofetil PO or IV TID on days 0-30, BID on days 31-150, and then taper to day 180. Treatment continues in the absence of unacceptable toxicity."
3326464|NCT00078845|Experimental|Amifostine|500 mg subcutaneous three times a week on Monday, Wednesday and Friday for 4 weeks.
3326465|NCT00078832|Experimental|anastrozole|anastrozole 1mg
3326466|NCT00078832|Placebo Comparator|placebo|anastrozole 1mg PLACEBO
3326467|NCT00078819|Placebo Comparator|Placebo|100 subjects - 12 weeks
3326468|NCT00078819|Experimental|Enbrel|100 subjects
3326469|NCT00078806|Experimental|Enbrel|
3326470|NCT00078806|Placebo Comparator|Placebo|
3326471|NCT00078793||Methotrexate group|Includes subjects being treated with methotrexate alone or in combination with other DMARDs with the exception of etanercept.
3326472|NCT00078767|Experimental|TF-CBT + sertraline|Trauma-Focused CBT provided individually to youth and parent for 12 sessions (90 minute sessions; 45 minutes for youth; 45 minutes for parent); plus Sertraline provided in dosage titrated as clinically indicated by child psychiatrist blind to treatment assignment, from 50mg/day to a maximum dosage of 150 mg/day
3326473|NCT00078767|Active Comparator|TF-CBT +placebo|Trauma-Focused CBT provided individually to youth and parent for 12 sessions (90 minute sessions; 45 minutes for youth; 45 minutes for parent); plus placebo identical to Sertraline, provided in pill form and titrated as clinically indicated by child psychiatrist blind to treatment assignment, from 1 to 3 pills/day (identical in appearance to 50 to 150mg/day of Sertraline)
3326474|NCT00078754|Experimental|A|Participants will to receive treatment with fluoxetine for 12 weeks
3326475|NCT00078754|Experimental|B|Participants will to receive treatment with divalproex for 12 weeks
3326476|NCT00078754|Placebo Comparator|C|Participants will to receive treatment with placebo for 12 weeks
3326477|NCT00078728|Experimental|Family-based anxiety prevention program|Participants will complete an 8 session (1 session/week), cognitive behavioral therapy-based, family prevention program to be administered by a trained clinician, after randomization to the study. The prevention program will include 3 booster sessions that take place after the first 8 sessions.
3326478|NCT00078728|Active Comparator|Evaluation only|Waitlist control group. Participants in this group will receive general information (in the form of a printed packet) about anxiety after randomization to the study. Families in this group will complete all study evaluations and will then be offered the option of participating in the prevention program. Families who accept will begin the prevention sessions and will receive the same CBT-based, family-based prevention program as the other treatment arm.
3326479|NCT00007007|Experimental|Whole brain radiation therapy + neurocognitive assessments|Whole brain radiation therapy (WBRT) with neurocognitive assessments done pre and post WBRT.
3326480|NCT00006890|Experimental|Prednisone plus Thalidomide|After Autologous Stem Cell Infusion
3326481|NCT00006467|Experimental|gemcitabine + ISIS 2503|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and ISIS 2503 IV continuously on days 1-14. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
3326482|NCT00006253|Experimental|Nurse|Receives symptom management assistance from an oncology nurse via the telephone
3326483|NCT00006253|Experimental|Non-nurse coach|Receives symptom management assistance from a non-nurse coach via telephone
3326484|NCT00078715|Experimental|Yohimbine then Placebo|Participants are randomized to receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep. After 8 days they receive placebo administered over 3 minutes during REM sleep.
3326485|NCT00078715|Experimental|Placebo then Yohimbine|Participants are randomized to receive placebo administered over 3 minutes during REM sleep. After 8 days they receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
3326486|NCT00005947|Active Comparator|sipuleucel-T|
3326487|NCT00005947|Placebo Comparator|Placebo|
3329560|NCT00044005|Experimental|Lurasidone 20 mg|Lurasidone 20 mg oral tablet
3326492|NCT00078572|Active Comparator|capecitabine alone|Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2. Randomization is 1:1.
3326493|NCT00078572|Experimental|Combination|Lapatinib 1250 mg once daily plus capecitbine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the combination arm was 2000 mg/m2.
3326494|NCT00078507|Active Comparator|Opening Exercises Only|Standard of care opening exercises following BSSO surgery to regain mouth opening
3326495|NCT00078507|Experimental|Sensory Retraining Exercises|3 sets of facial exercises performed with soft cosmetic brush 1 wk - 4 wks after surgery; 4wks to 3 mos after surgery; 3 mos to 6 mos after surgery.
3326496|NCT00004235|Experimental|irinotecan + docetaxel|"Patients receive irinotecan IV over 90 minutes followed by docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.~Patients achieving a complete response (CR) receive 2 additional courses after CR. Patients experiencing disease progression after a CR and 2 additional courses may be retreated with irinotecan and docetaxel. Dysphagia, anorexia, and swallowing ability are assessed before the first course of treatment and then at each tumor assessment.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
3326497|NCT00078559|Experimental|Alemtuzumab|
3326498|NCT00078533|Experimental|CMV CTL infusion|Subjects are assigned a dose level at the time of enrollment.
3326499|NCT00003528|Experimental|Arm I|Patients receive raltitrexed intravenously over 15 minutes once weekly for 3 weeks followed by 1 week of rest. Treatment continues in the absence of disease progression and unacceptable toxicity.
3326500|NCT00003351|Experimental|Arm I: irinotecan|"Patients receive irinotecan intravenously over 90 minutes every week for 4 weeks followed by a 2 week rest period. Treatment is repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before and during treatment. Patients are followed every 3 months for 2 years, then annually for 1 year."
3326501|NCT00003351|Experimental|Arm II: irinotecan|"Patients receive irinotecan intravenously over 90 minutes every 3 weeks for 6 weeks. Treatment is repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before and during treatment. Patients are followed every 3 months for 2 years, then annually for 1 year."
3326502|NCT00003070|Experimental|Stratum 1 < 350/mg/m2 anthracycline dose|< 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
3326503|NCT00003070|Experimental|Stratum 2 < 350mg/m2 anthracycline dose|< 4 years of age at diagnosis >= 4 years since cessation of anthracycline treatment
3326504|NCT00003070|Experimental|Stratum 3 < 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
3326505|NCT00003070|Experimental|Stratum 4 < 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis >= 4 years since cessation of anthracycline treatment
3326506|NCT00003070|Experimental|Stratum 5 >= 350mg/m2 anthracycline dose|< 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
3326507|NCT00003070|Experimental|Stratum 6 >=350mg/m2 anthracycline dose|< 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
3326508|NCT00003070|Experimental|Stratum 7 >= 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
3326509|NCT00003070|Experimental|Stratum 8 >= 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis >= 4 years since cessation of anthracycline treatment
3326510|NCT00003040|Experimental|Transoral CO2 laser laryngectomy and RT|Transoral CO2 laser supraglottic laryngectomy and irradiation
3326511|NCT00002825|Experimental|Arm I|All patients receive docetaxel with G-CSF every 21 days for up to 12 courses.
3326512|NCT00022542|Experimental|Treatment (ixabepilone)|Patients receive BMS-247550 IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive 2 additional courses.
3326513|NCT00016367|Experimental|Regimen A|Gemcitabine IV followed by Cisplatin IV Day 1 and Trastuzumab (Herceptin) IV Day 2; Trastuzumab IV followed by Gemcitabine IV Day 8 and Trastuzumab IV Day 15.
3326514|NCT00016367|Experimental|Regimen B|Starting Day 22 of regimen A, Trastuzumab IV, Gemcitabine IV, and Cisplatin IV Day 1. Trastuzumab IV followed by Gemcitabine IV Day 8 and Trastuzumab IV Day 15. Repeats every 21 days for up to 5 courses.
3326515|NCT00015990|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity.
3326516|NCT00015964|Experimental|Daily administration of ZD1839|
3326517|NCT00002597|Experimental|Neoadjuvant TAS + RT|Neoadjuvant total androgen suppression (TAS) - Flutamide and Zoladex or Lupron - two months before and during radiation therapy.
3326518|NCT00002597|Other|Radiation therapy alone|Radiation therapy alone
3326519|NCT00078442|Experimental|1|Participants will receive weekly injections of 180 mcg PEG-IFN alfa-2a at the clinic for 12 weeks. After Week 12, participants will be followed off-treatment until Week 18.
3326520|NCT00078390|Experimental|S-3304 plus chemo-irradiation|The tolerable dose of S-3304 determined in the Phase 1 part of the study will be dosed BID along with a standard of care regimen of radiation and paclitaxel/carboplatin chemotherapy
3326521|NCT00078390|Active Comparator|Chemo-irradiation|The standard of care regimen of radiation and paclitaxel/carboplatin chemotherapy will be administered
3326522|NCT00078377|Experimental|1|Armodafinil 250 mg
3326523|NCT00078377|Experimental|2|Armodafinil 150 mg
3326524|NCT00078377|Placebo Comparator|3|Placebo
3326525|NCT00078338|Experimental|Rebif®|
3326526|NCT00078338|Active Comparator|Copaxone®|
3326527|NCT00076687|Experimental|1|
3326528|NCT00076687|Experimental|2|
3326529|NCT00076687|Placebo Comparator|3|
3326530|NCT00012259|Experimental|troxacitabine|
3326531|NCT00006365|Experimental|EBRT to the prostate followed by brachytherapy|Patients received 45 Gy of external beam radiation therapy (EBRT)to the prostate followed (within 2 to 6 weeks) by permanent iodine (I-125) brachytherapy 108 Gy.
3326532|NCT00006014|Experimental|Arm I|Patients receive SU5416 IV over 1 hour twice weekly. Courses repeat every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
3326533|NCT00078403|Experimental|Arm A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)|At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA >=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.
3326534|NCT00078403|Experimental|Arm B: OL (PEG-IFN, RBV) then OL Randomized (Observation)|At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA >=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).
3326535|NCT00078403|Experimental|Arm C: OL (PEG-IFN, RBV) then OL (PEG-IFN, RBV)|At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA <600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly & RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA >=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.
3326536|NCT00078325|Experimental|1|Armodafinil 250 mg/day
3326537|NCT00078325|Experimental|2|Armodafinil 150 mg/day
3326538|NCT00078325|Placebo Comparator|3|Placebo
3326539|NCT00004183|Experimental|capecitabine|Patients receive oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 3 months for 2 years and then annually thereafter.
3326540|NCT00078286|Experimental|Sertraline|Participants will take sertraline for 12 weeks
3326541|NCT00078286|Placebo Comparator|Placebo|Participants will take placebo for 12 weeks
3326542|NCT00078273|No Intervention|Assessment Only Control|Completed Baseline and 6 month follow-up surveys only.
3326543|NCT00078273|Experimental|Personalized Feedback Intervention|See Intervention Description
3326544|NCT00078273|Experimental|Cognitive Behavioral Intervention|See Intervention Description
3326545|NCT00078260|Experimental|A|
3326546|NCT00078260|Experimental|B|
3326547|NCT00078247|Experimental|1|Participants will receive 6 months of ARV therapy and treatment for TB
3326548|NCT00078247|Experimental|2|Participants will not receive ARV therapy until CD4 counts drop below 250 cells/mm3. All participants will receive treatment for TB.
3326549|NCT00078195|Experimental|Omalizumab pre-treatment, ragweed RIT, omalizumab + ragweed IT|Participants are pre-treated with omalizumab followed by ragweed rush immunotherapy (RIT) followed by dual therapy with omalizumab plus ragweed immunotherapy (IT).
3326550|NCT00078195|Experimental|Omalizumab pre-treatment, omalizumab|Participants are pre-treated with omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with Omalizumab plus placebo immunotherapy (IT).
3326551|NCT00078195|Active Comparator|Ragweed RIT, ragweed IT|Participants are pre-treated with placebo omalizumab followed by ragweed rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus ragweed immunotherapy (IT).
3326552|NCT00078195|Placebo Comparator|Placebo|Participants are pre-treated with placebo omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus placebo immunotherapy (IT).
3326553|NCT00004148|Experimental|Arm I|Patients receive rV-B7.1 intralesionally every 4 weeks for 8 weeks (weeks 0, 4, and 8). Treatment continues every 12 weeks in the absence of unacceptable toxicity or disease progression for up to 2 courses. Cohorts of 6-8 patients receive escalating doses of vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 or 3 of 8 patients experience dose limiting toxicities.
3326554|NCT00003935|Experimental|Treatment|Induction: Patients receive oral etoposide daily on days 1-21 and vincristine sulfate IV on days 1, 8, and 15. Treatment repeats every 4 weeks for 2 courses. Patients receive radiation therapy daily for 6 weeks concurrently with induction chemotherapy. Maintenance: One week after induction therapy, patients receive vincristine sulfate IV on days 1 and 8 and oral etoposide daily on days 1-21. Treatment repeats every 4 weeks for 10 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter
3326555|NCT00003766|Experimental|Arm A|06-benzylguanine (100mg/m2 16 hrs before anticipated tumor tissue removal)
3326556|NCT00003623|Experimental|Multivitamin|Patients receive multivitamins orally once daily for 3 years. Patients are followed every 3 months for 2 years, then every 6 months for 1 year, and then annually thereafter.
3326557|NCT00003623|Placebo Comparator|Placebo|Patients receive placebo orally once daily for 3 years. Patients are followed every 3 months for 2 years, then every 6 months for 1 year, and then annually thereafter.
3326558|NCT00003600|Experimental|epoetin alfa|Patients receiving chemotherapy are randomized to receive epoetin alfa subcutaneously once a week for a maximum of 16 weeks Quality of life is assessed at randomization and monthly throughout study. Patients are followed every 6 months for 1 year.
3326559|NCT00003600|Placebo Comparator|placebo|Patients receiving chemotherapy are randomized to receive placebo subcutaneously once a week for a maximum of 16 weeks. Quality of life is assessed at randomization and monthly throughout study. Patients are followed every 6 months for 1 year.
3326560|NCT00003573|Experimental|Treatment 1, Etoposide, 50mg/m2/day|"Patients begin treatment within 1 month of surgery. Patients receive 6 weeks of radiation therapy to the head and spine, with boosts to the posterior fossa and to sites of metastasis. Patients also receive 2 courses of oral etoposide once daily for 3 weeks concurrent with and immediately following radiotherapy (weeks 1-3 and 5-7).~Patients then receive adjuvant chemotherapy consisting of cisplatin IV once every 4 weeks for 3 courses beginning on week 11, oral etoposide daily for 21 days every 4 weeks for 3 courses (weeks 11, 15, and 19), cyclophosphamide IV on days 1 and 2 with filgrastim (G-CSF) SQ daily for at least 10 days every 4 weeks for 8 courses (weeks 23-51), and vincristine IV on days 1, 8, and 15 every 4 weeks for 8 courses (weeks 23-51)."
3326593|NCT00077649|Experimental|PEG-IFN Alfa-2a 270 μg + Ribavirin 1600 mg|Participants received 270 μg of PEG-IFN alfa-2a in 1-mL solution administered sc once weekly + 1600 mg of ribavirin (200 mg/tablet) administered po daily in split doses for 48 weeks.
3326594|NCT00077636|Experimental|1|
3326595|NCT00077636|Experimental|2|
3326959|NCT00073242|Experimental|leptin repletion|Repletion of leptin following weight loss induced by dietary modification.
3326561|NCT00003573|Experimental|Treatment 2, Etoposide, 35mg/m2/day|"Patients begin treatment within 1 month of surgery. Patients receive 6 weeks of radiation therapy to the head and spine, with boosts to the posterior fossa and to sites of metastasis. Patients also receive 2 courses of oral etoposide once daily for 3 weeks concurrent with and immediately following radiotherapy (weeks 1-3 and 5-7).~Patients then receive adjuvant chemotherapy consisting of cisplatin IV once every 4 weeks for 3 courses beginning on week 11, oral etoposide daily for 21 days every 4 weeks for 3 courses (weeks 11, 15, and 19), cyclophosphamide IV on days 1 and 2 with filgrastim (G-CSF) SQ daily for at least 10 days every 4 weeks for 8 courses (weeks 23-51), and vincristine IV on days 1, 8, and 15 every 4 weeks for 8 courses (weeks 23-51)."
3326562|NCT00003425|Experimental|Amifostine trihydrate|
3326563|NCT00003299|Active Comparator|Cisplatin + Etoposide|
3326564|NCT00003299|Experimental|Cisplatin + Etoposide + Paclitaxel|
3326565|NCT00003120|Active Comparator|paclitaxel 3 cycles|paclitaxel given for 3 cycles
3326566|NCT00003120|Experimental|paclitaxel for 12 cycles|paclitaxel given for 12 cycles
3326567|NCT00078078||Methylmalonic Acidemia|Individuals with methylmalonic acidemia
3326568|NCT00003046|Experimental|Interleukin-12|
3326569|NCT00077974|Experimental|1|
3326570|NCT00077948|Experimental|active enoximone plus active ER metoprolol|
3326571|NCT00077948|Active Comparator|placebo enoximone plus active ER metoprolol|
3326572|NCT00077948|Placebo Comparator|placebo enoximone plus placebo ER metoprolol|
3326573|NCT00077857|Experimental|1250 mg/m^2 capecitabine + docetaxel|1250 mg/m^2 capecitabine (Xeloda®) orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel (Taxotere®) 75 mg/m^2 intravenous on day 1 of each 3 week cycle.
3326574|NCT00077857|Experimental|825 mg/m^2 capecitabine + docetaxel|825 mg/m^2 capecitabine orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel 75 mg/m^2 intravenous on day 1 of each 3 week cycle.
3326575|NCT00077766|Experimental|RO0503821 (1x/2 Weeks)|Eligible participants will be administered with RO0503821 ([methoxy polyethylene glycol-epoetin beta] {Mircera}) intravenously (IV), every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram [µg]) was based on the dose of darbepoetin alfa at the time of randomization (< 40, 40 to 80, or > 80 µg per week, respectively).
3326576|NCT00077766|Active Comparator|Darbepoetin (1x/1-2 Weeks)|Eligible participants will be administered with darbepoetin alfa IV, every week or every 2 weeks during Weeks 1 through 52.
3326577|NCT00023647|Experimental|Synchrotope TA2M, 800 micrograms|Tyrosinase peptides, 800 micrograms
3326578|NCT00023647|Experimental|Synchrotope TA2M, 200 micrograms|Tyrosinase peptides, 200 micrograms
3326579|NCT00023647|Experimental|Synchrotope TA2M, 400 micrograms|Tyrosinase peptides, 400 micrograms
3326580|NCT00007878|Experimental|Treatment (bortezomib, fluorouracil, leucovorin calcium)|Patients receive bortezomib IV on days 1 and 4 and fluorouracil IV and leucovorin calcium IV on day 1 weekly for 2 weeks. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
3326581|NCT00005089|Experimental|CHOP + Rituximab + RT|3 21-day cycles of CHOP (cyclophosphamide 750 mg/m^2, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2, prednisone 100 mg x 5 days) + Rituximab 375 mg/m^2 (x 2 days for cycle 1, x 3 days for cycles 2-3). RT 4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
3326582|NCT00004145|Experimental|Arm A|Fludarabine (30mg/m2/day x 5 days on days -9 to -5), cyclophosphamide (2gm/m2/day on day -5), antithymocyte globulin (10mg/kg/day x 4 days on days -5 to -2), tacrolimus (.03 mg/kg/day IVPB continuous infusion), mycophenolate mofetil (1mg PO BID, days +1 to +60), allogenic peripheral blood stem cells
3326583|NCT00003545|Experimental|Arm I|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. If residual leukemia/lymphoma is present on day 22, then patients receive a second course of 506U78. If day 22 marrow is hypocellular, then a repeat bone marrow biopsy should be obtained on day 29 to assess response. For day 22 or 29 marrow that is in complete response, patients receive 506U78 for two more courses on days 1, 3, and 5, administered every 21 days. Patients are followed every 3 month for 1 year, then every 6 months for a maximum of 10 years.
3326584|NCT00003207|Experimental|Phase 1 (Doxil & PSC 833)|Patients will receive Doxil at the standard dose of 20 mg/m2 IV for the 1st cycle. On the 2nd cycle of Doxil, the first patient will receive Doxil at 40% of standard dose or 8 mg/m2 (dose level 1) IV over one hr. 15 mn after the 2nd and subsequent cycles of Doxil, PSC 833 will be given at 2 mg/kg for 2 hrs. Simultaneously, a 72 hour CIVI of PSC 833 will be started with the loading dose. If no DLT occurs, then a double dose escalation of Doxil (dose levels 3, 5, 7 ) will be given to the same patient in the subsequent cycles until DLT occurs. On the 2nd cycle, Doxil will be given at the next dose level above the starting dose tolerated by the first patient. If no DLT occurs, a double dose escalation will also be done for the subsequent cycles (dose levels 5, 7, 9). The single-patient-cohort will terminate when a patient experiences DLT or when two episodes of grade 2 toxicity occur. At that point patients will be enrolled into cohorts of 3 patients to determine the MTD.
3326585|NCT00003011|Active Comparator|Marmistat|10 mg PO BID
3326586|NCT00003011|Placebo Comparator|Placebo|10 mg PO BID
3326587|NCT00077922|Experimental|LMB-2 in chronic lymphocytic leukemia|40 micrograms/kg every other day (QOD) x 3 every 4 weeks in patients with chronic lymphocytic leukemia, the most prevalent form of adult leukemia.
3326588|NCT00077675|Experimental|Telavancin|
3326589|NCT00077675|Active Comparator|Standard of care for cSSSI|cSSSI - comlicated skin and skin structure infections
3326590|NCT00077649|Active Comparator|PEG-IFN Alfa-2a 180 μg +Ribavirin 1200 mg|Participants received 180 μg of PEG-IFN [peginterferon] alfa-2a in 1 mL solution administered [subcutaneously] sc, once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered [orally ] po daily in split doses for 48 weeks
3326591|NCT00077649|Experimental|PEG-IFN Alfa-2a 180 μg + Ribavirin 1600 mg|Participants received 180 μg of PEG-IFN [peginterferon] alfa-2a in 1 mL solution administered [subcutaneously] sc, once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered [orally ] po daily in split doses for 48 weeks
3326592|NCT00077649|Experimental|PEG-IFN Alfa-2a 270 μg + Ribavirin 1200 mg|Participants received 270 μg of PEG-IFN alfa-2a in 1-mL solution administered sc once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered po daily in split doses for 48 weeks
3329561|NCT00044005|Experimental|Lurasidione 40 mg|Lurasidone 40 mg oral tablet
3326596|NCT00077623|Experimental|RO0503821 (1x/2 Weeks)|Eligible participants received RO0503821 (Mircera [methoxy polyethylene glycol-epoetin beta]) subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 microgram (mcg) which was based on the epoetin dose of<8000, 8000-16000, or >16000 international units (IU)/week, administered during the week preceding the switch to the study drug.
3326597|NCT00077623|Experimental|RO0503821 (1x/4 Weeks)|Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of<8000, 8000-16000, or >16000 IU/week administered during the week preceding the switch to the study drug.
3326598|NCT00077623|Active Comparator|Epoetin Reference|Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks .
3326599|NCT00077610|Experimental|RO0503821 (1x/2 Weeks)|Participants received RO0503821 (Mircera [methoxy polyethylene glycol-epoetin beta]) once every two weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (60, 100, or 180 microgram [mcg]) that was based on the Epoetin dose (<8000, 8000-16000, >16000 International units [IU]/Week) administered during the week preceding the switch to the study drug.
3326600|NCT00077610|Experimental|RO0503821 (1x/4 Weeks)|Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (120, 200, or 360 mcg) that was based on the Epoetin dose (<8000, 8000-16000, >16000 IU/Week) administered during the week preceding the switch to the study drug.
3326601|NCT00077610|Active Comparator|Epoetin (1-3x/Weeks)|Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.
3326602|NCT00077597|Experimental|1|
3326603|NCT00077597|Active Comparator|2|
3326604|NCT00077545|Experimental|Treatment (triapine and cisplatin)|Patients receive 3-AP (Triapine) IV over 2 hours on days 1-4. Patients also receive cisplatin IV over 60 minutes on days 2 and 3 before 3-AP infusion. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3326605|NCT00077493|Active Comparator|1|BL22 immunotoxin
3326606|NCT00077493|Active Comparator|2|antibody therapy
3326607|NCT00077493|Active Comparator|3|immunotoxin therapy
3326608|NCT00077493|Active Comparator|4|monoclonal antibody therapy
3326609|NCT00077467|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3326610|NCT00077454|Experimental|Treatment (erlotinib hydrochloride, temozolomide)|Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.
3326611|NCT00077441|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3326612|NCT00077428|Experimental|Treatment (bortezomib, doxorubicin hydrochloride)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression continue to receive bortezomib as above and doxorubicin IV over 2-5 minutes on days 1 and 8. Treatment repeats every 21 days for up to 14 courses in the absence of further disease progression or unacceptable toxicity.
3326613|NCT00077376|Experimental|Treatment (trastuzumab, ixabepilone, carboplatin)|"Induction therapy: Patients receive trastuzumab (Herceptin®) IV over 30 minutes* on days 1, 8, 15, and 22 and ixabepilone IV over 1 hour and carboplatin IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of unacceptable toxicity.~NOTE: *Trastuzumab is given over 90 minutes on day 1 of course 1 (induction therapy) only.~Maintenance therapy: Patients receive trastuzumab IV over 90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3326614|NCT00077363|Experimental|Treatment (tipifarnib, capecitabine)|Patients receive oral tipifarnib twice daily and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 4 additional courses beyond documentation of CR.
3326615|NCT00077350|Experimental|Treatment (triapine and gemcitabine hydrochloride)|Patients receive 3-AP (Triapine^®) IV over 2 hours and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3326616|NCT00077324||Surgery + blood and serum collection|"Patients undergo lung resection. Patients also undergo preoperative and postoperative collection of whole blood and serum for proteomic profiling using surface-enhanced laser desorption/ionization-time of flight mass spectrometry. A lung tissue biopsy taken at surgery is also analyzed.~Patients are followed at 60-90 days and then annually for 2-5 years."
3326617|NCT00077311|Experimental|Chemotherapy without BNP7787|Chemotherapy with dose-dense docetaxel and cisplatin with pegfilgrastim and darbepoetin for pts with NSCLC
3326618|NCT00077311|Experimental|Chemotherapy + BNP7787|Chemotherapy with dose-dense docetaxel and cisplastin with pegfilgrastim and darbepoetin with the addition of BNP7787
3326619|NCT00007852|Experimental|Arm I|Rituxan and BEAM with autologous stem cell transplant
3326620|NCT00006388|Experimental|Radiation plus Tamoxifen|
3326621|NCT00006047|Experimental|Combination Therapy|Combination Therapy with Oral 9-Nitrocamptothecin & Oral Etoposide. Patients receive oral nitrocamptothecin on days 1-3 and oral etoposide on days 4-5 each week. Treatment continues in the absence of disease progression or unacceptable toxicity.
3326622|NCT00005862|Experimental|Arm I|atients receive SU5416 IV twice weekly for 4 weeks. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity.
3326623|NCT00005610|Experimental|sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) over 10-15 minutes twice daily for 7 days. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and prior to course 5.~Patients are followed every 2 months for at least 1.5 years."
3326701|NCT00005022|Experimental|Arm 4|Large field radiation therapy 28.8 Gy, 1.8 Gy/fx/5 days x 16 fx, boost just in pm @ 1.8 Gy/fx on days 17-20, then boost 1.8 Gy BID x last 5 days.
3329562|NCT00044005|Experimental|Lurasidone 80mg|Lurasidone 80mg oral tablet
3326624|NCT00004919|Experimental|Treatment (cisplatin, irinotecan, amifostine)|"Treatment A: Patients receive cisplatin IV over 1 hour followed immediately by irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Courses repeat every 6 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.~Treatment B: Patients receive therapy as in treatment A. In addition, amifostine IV is administered over 15 minutes immediately before cisplatin."
3326625|NCT00004889|Experimental|Rituxan|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
3326626|NCT00004203|Experimental|Arm A|On Day 1 of each 21-day treatment cycle, patients receive 130 mg/m2 oxaliplatin diluted in 250 to 500 mL Dextrose 5% in Water infused intravenously over 2 hours through a peripheral or central vein
3326627|NCT00077584|Experimental|Bosentan|The patients received bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks and then 125 mg b.i.d. for 20 weeks
3326628|NCT00077584|Placebo Comparator|Placebo|The patients received the matching placebo for 24 weeks
3326629|NCT00077298|Experimental|Arm A (cetuximab, bevacizumab, irinotecan)I|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36; bevacizumab IV over 30-90 minutes on days 1*, 15, and 29 OR on days 1 and 22; and irinotecan IV over 30-90 minutes (at the same dose and schedule that the patient previously received) beginning on day 1.~NOTE: *Bevacizumab is given on day 2 (instead of day 1) of course 1, and is given on day 1 of subsequent courses."
3326630|NCT00077298|Experimental|Arm B (cetuximab and bevacizumab)|"Patients receive cetuximab as in Arm A and bevacizumab IV over 30-90 minutes on days 1*, 15, and 29.~NOTE: *Bevacizumab is given on day 2 (instead of day 1) of course 1, and is given on day 1 of subsequent courses."
3326631|NCT00077285|Experimental|pts with intermediate- and high-risk rhabdomyosarcoma|
3326632|NCT00077233|Active Comparator|Arm A: FOLFIRI|Patients receive irinotecan 180 mg/m^2 over 90 minutes on day 1, then leucovorin 400 mg/m^2 over 2 hours followed by 5FU 400 mg/m^2 IV bolus injection then 5FU 2400 mg/m^2 continuous IV infusion over 46-48 hours repeated every 2 weeks. One cycle of therapy is 8 weeks.
3326633|NCT00077233|Experimental|Arm B: FOLFIRI + C225|Patients receive irinotecan 180 mg/m^2 over 90 minutes, then leucovorin 400 mg/m^2 IV over 2 hours followed by 5FU 400 mg/m^2 IV bolus injection then 5FU 2400 mg/m^2 continuous IV infusion over 46-48 hours repeated every 2 weeks. Patients also receive cetuximab 400 mg/m^2 IV over 120 minutes day 1, then 250 mg/m^2 IV over 60 minutes weekly. All patients must be premedicated with diphenhydramine hydrochloride 50 mg (or a similar agent) IV prior to the first dose of cetuximab in an effort to prevent a hypersensitivity reaction. Premedication is recommended prior to subsequent doses, but at the Investigator's discretion the dose of diphenhydramine (or a similar agent) may be reduced.
3326634|NCT00077233|Active Comparator|Arm C: FOLFOX|Patients receive oxaliplatin 85 mg/m^2 IV infused over 120 minutes, then leucovorin 400 mg/m^2 IV over 2 hours followed by 5 FU 400 mg/m^2 IV bolus injection then 5 FU 2400 mg/m^2 continuous IV infusion over 46-48 hours every 2 weeks.
3326635|NCT00077233|Experimental|Arm D: FOLFOX + C225|Patients receive oxaliplatin 85 mg/m^2 IV infused over 120 minutes, then leucovorin 400 mg/m^2 over 2 hours followed by 5 FU 400 mg/m^2 IV bolus injection then 5 FU 2400 mg/m^2 continuous IV infusion over 46-48 hours every 2 weeks. Patients also receive cetuximab 400 mg/m^2 IV over 120 minutes day 1, then 250 mg/m^2 IV over 60 minutes weekly. All patients must be premedicated with diphenhydramine hydrochloride 50 mg (or a similar agent) IV prior to the first dose of cetuximab in an effort to prevent a hypersensitivity reaction. Premedication is recommended prior to subsequent doses, but at the Investigator's discretion the dose of diphenhydramine (or a similar agent) may be reduced.
3326636|NCT00077207|Experimental|Treatment (carboplatin, vincristine sulfate, temozolomide)|Induction therapy: Patients receive carboplatin IV (175/m2) over 1 hour on days 1, 8, 15, and 22; vincristine IV (1.5 mg/m2) on days 1, 8, 15, 22, 29, and 36; and oral temozolomide (200 mg/m2) on days 43-47. Four weeks after the completion of induction therapy, patients achieving stable or responding disease proceed to maintenance therapy. Maintenance therapy: Patients receive carboplatin (175/m2) and temozolomide (200 mg/m2) as in induction therapy and vincristine IV ((1.5 mg/m2) day 1 of weeks 10,11,12. Treatment repeats every 10 weeks for a total of 6 courses in the absence of disease progression.
3326637|NCT00077194|Experimental|Arm I|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
3326638|NCT00077181|Experimental|Treatment (cytarabine and triapine)|Patients receive high-dose cytarabine IV over 2 hours on days 1-5 and triapine IV over 2 hours on days 2-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3326639|NCT00077155|Experimental|Treatment (cilengitide)|Patients receive cilengitide (EMD 121974) IV continuously on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
3326640|NCT00077142|Experimental|TAC-101|Oral TAC-101 daily Days 1-14, repeats every 21 days for 2 courses.
3326641|NCT00077064|No Intervention|Observation|Clinical observation
3326642|NCT00077064|Experimental|Captopril|Captopril
3326643|NCT00077051|Experimental|Single Arm|
3326644|NCT00077025|Active Comparator|Anastrozole-placebo|Anastrozole (ZD1033, Arimidex)-Placebo
3326645|NCT00077025|Active Comparator|Anastrozole-ZD1839|Anastrozole (ZD1033, Arimidex)-ZD1839 (gefitinib, IRESSA)
3326646|NCT00076999|Experimental|TPV/r 290/115 mg/m^2|TPV and RTV oral solution low dose
3326647|NCT00076999|Experimental|TPV/r 375/150 mg/m^2|TPV and RTV oral solution high dose
3326648|NCT00076934|Experimental|1|Participants receive Regimen 1 for 4 months
3326649|NCT00076934|Experimental|2|Participants receive Regimen 2 for 4 months
3326650|NCT00076934|Experimental|3|Participants receive Regimen 3 for 4 months
3326651|NCT00076934|Experimental|4|Participants receive Regimen 4 for 4 months
3326702|NCT00005022|Experimental|Arm 5|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D 5 days/4 weeks, boost 1.8 Gy/D x 2 days, then BID x last 3 days.
3326703|NCT00005022|Experimental|Arm 6|Large field radiation therapy 25.2 Gy, 1.8 Gy/fx/5 days x 14 fx, boost just in pm @ 1.8 Gy/fx on days 15-20, then boost 1.8 Gy BID x last 5 days.
3329563|NCT00044083|Placebo Comparator|Arm 1|Placebo one week
3326652|NCT00003937|Experimental|Pilot 1 - Doxorubicin Intensification without Ifosfamide|Dexrazoxane hydrochloride IV followed by doxorubicin hydrochloride IV plus cisplatin IV on days 1 and 2 of weeks 1 and 6. Methotrexate IV on day 1 of weeks 4, 5, 9, and 10. Patients undergo surgery on week 11. Adjuvant chemotherapy begins on day 1 of week 13. Group 1 (good response to neoadjuvant chemotherapy): Patients receive methotrexate IV over 4 hours every 3 weeks for 6 courses, beginning on week 13. Patients also receive dexrazoxane and doxorubicin hydrochloride every 3 weeks for 4 courses, beginning on week 14. Cisplatin is administered with the first 2 courses of dexrazoxane and doxorubicin. Group 2 (standard response to neoadjuvant chemotherapy): Patients receive methotrexate and cisplatin as in group 1 plus dexrazoxane and doxorubicin hydrochloride for 6 courses.
3326653|NCT00003937|Experimental|Pilot 2 - Doxorubicin Intensification with Ifosfamide|Preoperative therapy comprised of dexrazoxane hydrochloride, doxorubicin hydrochloride, and methotrexate as in pilot 1. Ifosfamide IV on days 1-5 of week 1. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane hydrochloride, and doxorubicin hydrochloride as in pilot 1, group 1. Ifosfamide is also administered on weeks 14 and 20. Cisplatin is administered on weeks 17, 23, and 26. Group 2: Patients receive methotrexate, dexrazoxane hydrochloride, and doxorubicin hydrochloride as in pilot 1, group 2. Ifosfamide is administered on weeks 14, 20, 26, and 31. Cisplatin is administered on weeks 17, 23, and 29
3326654|NCT00003937|Experimental|Pilot 3 - Ifosfamide/Etoposide Intensification|Preoperative therapy comprised of methotrexate, dexrazoxane hydrochloride, doxorubicin, ifosfamide, and cisplatin as in pilot 2. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane hydrochloride, doxorubicin, ifosfamide, and cisplatin as in pilot 2, group 1. Group 2: Patients receive methotrexate on weeks 13, 19, 29, 32, 35, and 36, high dose ifosfamide and etoposide IV over 4 hours on days 1-5 of weeks 14, 23, and 26, and cisplatin on weeks 20, 30, and 33. Dexrazoxane hydrochloride and doxorubicin hydrochloride are administered on weeks 17, 20, 30, and 33
3326655|NCT00003665|Experimental|Arm I|Patients receive 3 different doses of peptide pulsed DC vaccine IV, each divided into 3 different peptide pulsed pools administered over 30 minutes.
3326656|NCT00003665|Experimental|Arm II|Patients receive 3 different doses of peptide pulsed DC vaccine subcutaneously/intradermally to sites with no evidence of disease. At the lowest dose, patients receive 3 different peptide pulsed pools, each administered at a separate site. At the higher doses, patients receive 3 injections further subdivided into 6 and administered at 6 distinct sites.
3326657|NCT00003665|Experimental|Arm III|Patients receive peptide pulsed DC vaccine intranodally in groin or ancillary lymph nodes at the lower 2 doses of the 3 administered to arms I and II. At the lower dose, patients receive 3 different peptide pulsed pools, each administered into a different node. At the higher dose, patients receive 3 injections further subdivided into 6 and administered at 6 distinct sites.
3326658|NCT00003370|Experimental|Arm I|"If the dose limiting toxicity is myelosuppression in stratum 1, then stratum 1 is closed and stratum 2 opens.~Stratum 2 consists of the following: patients receiving no more than 2 prior chemotherapy regimens; patients who have not received prior central axis radiation or bone marrow transplantation; and patients with no known bone marrow involvement. Patients receive intravenous 6-hydroxymethylacylfulvene over 10 minutes daily for 5 days. The course is repeated every 28 days unless disease progression or unacceptable toxic effects are observed. Patients with stable or responding disease may receive up to 1 year of therapy. If dose limiting toxicity occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and the next lower dose is declared the maximum tolerated dose. Dose escalation will not occur until all patients within a cohort have been observed for 28 days from day 1 of therapy. Patients are followed until death."
3326659|NCT00003222|Experimental|Peptides pulsed on dendritic cells|4 melanoma peptides pulsed on monocyte-derived dendritic cells
3326660|NCT00003222|Experimental|Peptides in GMCSF-in-adjuvant|4 melanoma peptides administered as an emulsion with GM-CSF and Montanide ISA-51 adjuvant.
3326661|NCT00076817|Experimental|1|Participants will receive vaccine injections in the groin area or the upper arm
3326662|NCT00076817|Placebo Comparator|2|Participants will receive vaccine placebo injections in the groin area or the upper arm
3326663|NCT00076804|Experimental|1|Use of a patient nominated peer supporter who will observe the morning dose of ARVs
3326664|NCT00076804|No Intervention|2|Self administration of ARVs
3326665|NCT00076791|Active Comparator|1|Each participant in Cohort 1 received a single 600 mg oral dose of TDF at the start of active labor or 4 hours prior to C-section, with concurrent administration of standard intravenous zidovudine (ZDV) prophylaxis and/or other antiretrovirals prescribed by her physician. The infants from Cohort 1 received only the standard 6 weeks of oral ZDV prophylaxis postpartum.
3326666|NCT00076791|Active Comparator|2|Mothers in Cohort 2 will receive a single dose of 900 mg of TDF combined with 600 mg emtricitabine, along with standard ZDV prophylaxis and/or other antiretrovirals prescribed by her physician. Infants will receive a single dose of TDF at 4 mg/kg combined with 3 mg/kg emtricitabine as soon as possible after delivery and within 6 hours of age as well as the standard 6 weeks of oral ZDV prophylaxis after birth.
3326667|NCT00033592|Experimental|Arm I: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day. Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm I who continue to smoke are randomized to one of two treatment arms Arm IV or Arm V. Participants randomized to arm I who are smoke-free are randomized to one of two treatment arms Arm VIII or Arm IX."
3326668|NCT00033592|Experimental|Arm II: bupropion|"Participants receive oral bupropion 1-2 times daily.~Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm II who continue to smoke are randomized to one of two treatment arms Arm VI or Arm VII. Participants randomized to arm II who are smoke-free are randomized to one of two treatment arms Arm Arm X or Arm XI."
3326739|NCT00076063|Experimental|D|Participants in Group D will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
3329564|NCT00044083|Active Comparator|Arm 2|Tolcapone one week
3326669|NCT00033592|Experimental|Arm III: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral bupropion 1-2 times daily. Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm III who continue to smoke do not receive any further therapy. Participants randomized to arm III who are smoke-free are randomized to one of four treatment arms Arm XII, Arm XIII, Arm XIV or Arm XV."
3326670|NCT00033592|Experimental|Arm IV: bupropion|"Participants receive oral bupropion 1-2 times daily for 12 weeks.~All participants are followed every month for 6 months."
3326671|NCT00033592|Placebo Comparator|Arm V: placebo|"Participants receive oral placebo 1-2 times daily for 12 weeks.~All participants are followed every month for 6 months."
3326672|NCT00033592|Experimental|Arm VI: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day for 12 weeks.~All participants are followed every month for 6 months."
3326673|NCT00033592|Placebo Comparator|Arm VII: placebo inhaler|"Participants receive 6-16 placebo inhaler cartridges per day for 12 weeks.~All participants are followed every month for 6 months."
3326674|NCT00033592|Experimental|Arm VIII: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day for 40 weeks.~All participants are followed every month for 6 months."
3326675|NCT00033592|Placebo Comparator|Arm IX: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day for 40 weeks.~All participants are followed every month for 6 months."
3326676|NCT00033592|Experimental|Arm X: bupropion|"Participants receive oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
3326677|NCT00033592|Placebo Comparator|Arm XI: placebo|"Participants receive oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
3326678|NCT00033592|Experimental|Arm XII: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
3326679|NCT00033592|Placebo Comparator|Arm XIII: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day and oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
3326680|NCT00033592|Experimental|Arm XIV: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
3326681|NCT00033592|Placebo Comparator|Arm XV: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
3326682|NCT00026377|Experimental|SU5416 in combination with hormone and radiation therapy|Subjects receive 5 months of hormone suppression therapy consisting of 1 month of Bicalutamide or Flutamide followed by 4 months of leuprolide or goserlin injections. After completion of at least 12 weeks of hormone therapy, subjects will receive 7 1/2 weeks of radiation therapy. SU5416 will be given by IV infusion starting 4 weeks before beginning radiation treatment and continuing until 4 weeks after completion of radiation. Multiple doses of SU5416 will be studied.
3326683|NCT00024011|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3326684|NCT00076752|Experimental|Autologous HSCT in SLE|"Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).~SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion."
3326685|NCT00009958|Experimental|Stage I|Patients receive fCEA-TRI vaccine SC once daily on days 1, 29, 57, and 85.
3326686|NCT00009958|Experimental|Stage II|Patients receive vCEA-TRI vaccine intradermally once on day 1 and fCEA-TRI vaccine SC at the MTD determined in stage I once daily on days 29, 57, and 85.
3326687|NCT00009958|Experimental|Stage III|A single cohort of 6-10 patients receive both vaccines as in stage II, at the MTDs determined in stages I and II, and sargramostim (GM-CSF) SC once daily on days 1-4, 29-32, 57-60, and 85-88.
3326688|NCT00009906|Experimental|Arm I (imatinib mesylate)|Patients receive oral imatinib mesylate once daily.
3326689|NCT00009906|Experimental|Arm II (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily.
3326690|NCT00008333|Experimental|vinorelbine|Patients receive oral vinorelbine on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and after 8 weeks of therapy. Patients are followed every 3 months for 5 years.
3326691|NCT00005881||Quality of life forms|Completion of the development of an instrument [Minneapolis-Manchester Quality of Life (MM-QOL)] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
3326692|NCT00005792|Experimental|MTV|Melphalan Topotecan Etoposide VP-16 Phosphate autologous stem cell transplant
3326693|NCT00005064|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV bolus twice weekly for 4 weeks followed by 2 weeks of rest. Treatment continues for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression.
3326694|NCT00076622||Randomized to drug continuation|Participants assigned to continue current antidepressant medication
3326695|NCT00076622||Randomized to drug discontinuation|Participants assigned to discontinue current antidepressant medication (no antidepressant medication)
3326696|NCT00076622||Participant preference to continue drug|Chose to continue antidepressant medication
3326697|NCT00076622||Participant preference to discontinue drug|Chose to discontinue antidepressant medication (no antidepressant medication)
3326698|NCT00005022|Experimental|Arm 1|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D/5 days/4 weeks, boost 1.8 Gy/D x 2 days, then BID x last 3 days.
3326699|NCT00005022|Experimental|Arm 2|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D/5 days/4 weeks, boost 1.8 Gy/BID x last 5 days.
3326700|NCT00005022|Experimental|Arm 3|Large field radiation therapy 32.4 Gy, 1.8 Gy/fx/D/5 days x 18 fx, boost just in pm @ 1.8 Gy/fx on days 19 & 20, then boost 1.8 Gy BID x last 5 days.
3326704|NCT00004862|Experimental|Arm I|Patients receive augmerosen IV continuously on days 1-10 and filgrastim (G-CSF) subcutaneously beginning on day 5 and continuing until blood counts recover. Patients receive fludarabine IV over 30 minutes followed 3.5 hours later by cytarabine IV over 4 hours on days 6-10. Patients who achieve complete response (CR) receive a second course beginning 4 weeks after completion of the first course. Patients who achieve CR and have a matched sibling or unrelated bone marrow donor may undergo allogeneic bone marrow transplantation. Cohorts of 3-6 patients receive escalating doses of fludarabine and cytarabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
3326705|NCT00004239|Experimental|Compound 506U78|Compound 506U78 will be administered intravenously over 2 hours on days 1, 3 and 5 of each 28 day treatment cycle.
3326706|NCT00076570|Experimental|Sirolimus|Patients are treated with combination therapy with both sirolimus and tacrolimus for 6 month. After 6 months, patients are switched to sirolimus monotherapy and followed up for 4 years.
3326707|NCT00076570|Active Comparator|Tacrolimus|Patients are treated with combination therapy with both sirolimus and tacrolimus for 6 month. After 6 months, patients are switched to tacrolimus monotherapy and followed up for 4 years.
3326708|NCT00076453|Experimental|1|Participants will wear lateral wedge orthotic inserts.
3326709|NCT00076453|Active Comparator|2|Participants will wear standard orthotic inserts.
3326710|NCT00003298|Experimental|Experimental Arm|Patients receive 3 courses of preoperative neoadjuvant chemotherapy given on day 1 every 21 days. Courses consist of an intravenous infusion of cisplatin and a 3 hour intravenous infusion of paclitaxel on day 1. Patients then undergo surgery for tumor removal on day 63, followed 4-6 weeks later by one course of daily intravenous bolus leucovorin calcium and fluorouracil for 5 days. Chemotherapy is repeated 4-6 weeks later for the first 4 days of week 1 and the last 3 days of week 5 of radiation therapy given 5 days a week for 5 weeks. Patients receive two more courses, 4 weeks apart, of fluorouracil and leucovorin calcium for 5 days 4-6 weeks after completing radiation treatment.
3326711|NCT00076349|Experimental|1|open-label, single arm, clinical trial of bendamustine (SDX-105) plus rituximab
3326712|NCT00076336|Experimental|Telbivudine 600 mg|Participants received Telbivudine 600 mg and a matching lamivudine placebo orally once a day for up to 104 weeks. Participants were followed-up for 16 weeks post-treatment.
3326713|NCT00076336|Active Comparator|Lamivudine 100 mg|Lamivudine 100 mg and a Telbivudine matching placebo orally once a day for up to 104 weeks. Participants were followed-up for 16 weeks post-treatment.
3326714|NCT00003137|Experimental|irinotecan|"Patients receive irinotecan (CPT-11) by IV over 90 minutes every 3 weeks. Dosage modifications are made based on toxicity. Retreatment may be delayed another 3 weeks (for a total of 6 weeks) to allow for recovery from toxic effects. Patient is taken off study if they do not recover from toxic effects, unless cause is documented to be unrelated to CPT-11. Patients with stable disease or partial response continue on treatment until disease progression or intolerable toxicity. Patients with complete response continue on treatment for another 2 courses and then are observed.~Patients are followed every 3 months for 3 years or until disease progression."
3326715|NCT00076310|Experimental|Cisplatin + Docetaxel + OSI-774|"Cisplatin 75 mg/m^2 IV every 21 days.~Docetaxel 60 mg/m^2 IV repeated every 21 days.~OSI-774 100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached."
3326716|NCT00076258|Experimental|SSRI+ LD|A low dose aerobic exercise (LD) augmentation intervention to SSRI
3326717|NCT00076258|Experimental|SSRI+ PHD|A public health dose of aerobic exercise (PHD) augmentation intervention to SSRI
3326718|NCT00076245|Experimental|1 Light therapy|
3326719|NCT00076245|Experimental|2 Cognitive behavioral therapy|
3326720|NCT00076245|Experimental|3 Light therapy plus cognitive behavioral therapy|
3326721|NCT00076245|No Intervention|4 Control|
3326722|NCT00076219|Experimental|Intensive renal replacement therapy|In the intensive management strategy, intermittent hemodialysis and sustained low-efficiency dialysis were provided 6 times per week, and continuous venovenous hemodiafiltration was provided at 35 mL/kg/hour.
3326723|NCT00076219|Active Comparator|Less-intensive renal replacement therapy|In the less-intensive management strategy, intermittent hemodialysis and sustained low-efficiency dialysis were provided 3 times per week, and continuous venovenous hemodiafiltration was provided at 20 mL/kg/hour.
3326724|NCT00076206|Experimental|A|CCI-779 1 mg dose to be taken orally daily up to 12 weeks.
3326725|NCT00076206|Experimental|B|CCI-779 2 mg dose to be taken orally daily up to 12 weeks.
3326726|NCT00076206|Experimental|C|CCI-779 4 mg dose to be taken orally daily up to 12 weeks.
3326727|NCT00076206|Placebo Comparator|D|Placebo dose to be taken orally daily up to 12 weeks.
3326728|NCT00076232|Experimental|1|Participants will receive acyclovir for the duration of the study
3326729|NCT00076232|Placebo Comparator|2|Participants will receive acyclovir placebo for the duration of the trial
3326730|NCT00076154||Group 1|
3326731|NCT00076141||Older, Racially Diverse Males|Racially Divers Males over 50, expected to live more than 5 years
3326732|NCT00076180|Experimental|1|One dose of Hu-MiK Beta-1
3326733|NCT00033735|Experimental|fluorouracil|
3326734|NCT00033735|Experimental|Irofulven|
3326735|NCT00076102|Experimental|Pirfenidone|Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m^2 every 8 hours (1500 mg/m2/day).
3326736|NCT00076063|Experimental|A|Participants in Groups A will receive four injections over 6 months of either LIPO-5 or a placebo.
3326737|NCT00076063|Experimental|B|Participants in Group B will receive four injections over 6 months of either the ALVAC-HIV (vCP1452) or a placebo.
3326738|NCT00076063|Experimental|C|Participants in Groups C will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
3326809|NCT00075114|Other|1 Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
3326740|NCT00076063|Experimental|E|Participants in Group E will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
3326741|NCT00076050|Experimental|1|Participants will receive a 200-mg dose of soy isoflavones daily over 2 years.
3326742|NCT00076050|Placebo Comparator|2|Participants will receive placebo daily over 2 years.
3326743|NCT00076024|Other|Docetaxel + Placebo|Docetaxel + Placebo
3326744|NCT00076024|Experimental|Docetaxel + AG-013736|Docetaxel + AG-013736
3326745|NCT00075946|Active Comparator|Arm A: Rituximab Retreatment|Patients receive rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months.
3326746|NCT00075946|Experimental|Arm B: Rituximab Scheduled|Patients receive a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity.
3326747|NCT00075881|Experimental|Treatment (bortezomib)|"INDUCTION TREATMENT: Patients receive bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE TREATMENT: Patients who complete induction treatment without progressive disease receive bortezomib IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~REINDUCTION TREATMENT: Patients who progress while on maintenance treatment receive bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity."
3326748|NCT00075868|Experimental|Sandostatin LAR® Depot|Sandostatin LAR® Depot Pre-RT (between day -7 and day -4 of RT) and Day 22 (± 3 days)
3326749|NCT00075868|Placebo Comparator|Placebo|Placebo Pre-RT (between day -7 and day -4 of RT) and Day 22 (± 3 days)
3326750|NCT00075855|Experimental|testosterone|"Patients receive topical testosterone once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm.~Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8.~Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months."
3326751|NCT00075855|Other|placebo|"Patients receive a topical placebo once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm.~Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8.~Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months."
3326752|NCT00075842|Experimental|Arm I|Patients receive oral Valeriana officinalis (Valerian) once daily for 8 weeks.
3326753|NCT00075842|Placebo Comparator|Arm II|Patients receive an oral placebo once daily for 8 weeks.
3326754|NCT00075829|Active Comparator|Auto transplants plus Therapy|One autologous transplant along with a second autologous transplant will be preformed followed by one year of Dexamethasone and Thalidomide maintenance therapy.
3326755|NCT00075829|Active Comparator|Auto transplants|One autologous transplant along with a second autologous transplant will be preformed followed by one year of observation.
3326756|NCT00075829|Active Comparator|Auto and Allo transplants|One autologous transplant and one non-myeloablative allogeneic transplant will be preformed and followed by one year of observation.
3326757|NCT00075816|Active Comparator|Bone Marrow Transplant|Allogeneic bone marrow transplantation
3326758|NCT00075816|Active Comparator|Blood Stem Cell Transplant|Peripheral blood stem cell transplantation
3326759|NCT00075803|Active Comparator|Fluconazole|The dose of fluconazole is 400 mg by mouth or intravenous drip.
3326760|NCT00075803|Experimental|Voriconazole|The dose of oral voriconazole is 200 mg twice daily. When voriconazole must be given intravenously, it will be given at a dose of 200 mg every 12 hours for the duration of intravenous therapy.
3326761|NCT00075764|Active Comparator|Arm I|Patients receive oral anastrozole once daily on days 1-28.
3326762|NCT00075764|Experimental|Arm II|Patients receive oral anastrozole as in arm I. Patients also receive fulvestrant intramuscularly on days 1, 14, and 28 during course 1 and then on day 28 of the subsequent courses.
3326763|NCT00075751|Experimental|Treatment (gemcitabine hydrochloride, carboplatin, bortezomib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8, carboplatin IV over 15-30 minutes on day 1, and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive bortezomib alone on the above schedule for up to 1 year at the discretion of the treating physician.
3326764|NCT00075725|Experimental|Dexamethasone & Capizzi MTX patients<10 yrs|Patients receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15 & 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. Dexamethasone (5 mg/m2/dose on Days 1-14 by mouth or infusion twice a day in weeks 1 & 2; IT MTX (Aged based dosing: Age (yrs) Dose 1 - 1.99 8 mg 2 - 2.99 10 mg 3 - 8.99 12 mg ≥ 9 15 mg) on days 8 & 29 (CNS3 also on days 15 & 22) and an injection of pegaspargase (2500 International units/m2 x 1 dose on Day 4, 5 or 6).
3326765|NCT00075725|Experimental|Dexamethasone, High Dose (DH) MTX (non random)|Patients non-randomly assigned to the DH regimen based on one (or more) of the following: (1) CNS3 status at entry, (2) testicular leukemic involvement at entry, or (3) extensive pre-treatment with steroids prior to entry. Patients receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15 & 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. Dexamethasone (5 mg/m2/dose on Days 1-14 by mouth or infusion twice a day in weeks 1 & 2; IT MTX (Aged based dosing: Age (yrs) Dose 1 - 1.99 8 mg 2 - 2.99 10 mg 3 - 8.99 12 mg ≥ 9 15 mg) on days 8 & 29 (CNS3 also on days 15 & 22) and an injection of pegaspargase (2500 International units/m2 x 1 dose on Day 4, 5 or 6).
3326794|NCT00075387|Experimental|Arm II (combination chemotherapy, sodium thiosulfate)|"Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA as in Arm I. Patients also receive sodium thiosulfate IV over 15 minutes 4 and 8 hours later.~Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
3326795|NCT00075374|Experimental|Docetaxel|
3329695|NCT00039780|Placebo Comparator|2|0.9% Sodium Chloride Soln.
3326766|NCT00075725|Experimental|Dexamethasone & Capizzi MTX patients =>10 yrs|Patients receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15 and 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. Dexamethasone (5 mg/m2/dose on Days 1-14 by mouth or infusion twice a day in weeks 1 & 2; IT MTX (Aged based dosing: Age (yrs) Dose 1 - 1.99 8 mg 2 - 2.99 10 mg 3 - 8.99 12 mg ≥ 9 15 mg) on days 8 & 29 (CNS3 also on days 15 & 22) and an injection of pegaspargase (2500 International units/m2 x 1 dose on Day 4, 5 or 6).
3326767|NCT00075725|Experimental|Dexamethasone during Induction, High Dose MTX (IM)<10|Patients randomly assigned to the DH regimen based on one (or more) of the following: (1) No CNS3 status at entry, (2) no testicular leukemic involvement at entry, or (3) no extensive pre-treatment with steroids prior to entry. Patients receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15 & 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. Dexamethasone (5 mg/m2/dose on Days 1-14 by mouth or infusion twice a day in weeks 1 & 2; IT MTX (Aged based dosing: Age (yrs) Dose 1 - 1.99 8 mg 2 - 2.99 10 mg 3 - 8.99 12 mg ≥ 9 15 mg) on days 8 & 29 (CNS3 also on days 15 & 22) and injection of pegaspargase (2500 International units/m2 x 1 dose on Day 4, 5 or 6).
3326768|NCT00075725|Experimental|Prednisone, Capizzi (PC) MTX (<10 yrs old)|Patients in regimen PC will receive cytarabine, vincristine sulfate, daunorubicin hydrochloride, and pegaspargase. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and IT MTX in weeks 2 & 5. Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning in week 6 or 7, patients may receive combination chemotherapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, mercaptopurine, cytarabine, thioguanine) by infusion, injection, intrathecally, and by mouth for up to 8 weeks.
3326769|NCT00075725|Experimental|Prednisone, Capizzi MTX (>= 10 yrs)|Patients in regimen PC will receive cytarabine, vincristine sulfate, daunorubicin hydrochloride, and pegaspargase. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and IT MTX in weeks 2 & 5. Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning in week 6 or 7, patients may receive combination chemotherapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, mercaptopurine, cytarabine, thioguanine) by infusion, injection, intrathecally, and by mouth for up to 8 weeks.
3326770|NCT00075725|Experimental|Prednisone and High Dose (PH) MTX (< 10 yrs)|Patients randomly assigned to the PH regimen receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15 & 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and IT MTX in weeks 2 and 5. Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning in week 6 or 7, patients may receive combination chemotherapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, mercaptopurine, cytarabine, thioguanine) by infusion, injection, intrathecally, and by mouth for up to 8 weeks.
3326771|NCT00075725|Experimental|Prednisone and High Dose MTX (>=10 yrs)|Patients randomly assigned to the PH regimen receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15 & 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and IT MTX in weeks 2 & 5. Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning week 6 or 7, patients may receive combination chemotherapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, mercaptopurine, cytarabine, thioguanine) by infusion, injection, intrathecally, and by mouth for up to 8 weeks.
3326772|NCT00075725|Experimental|Dexamethasone, High Dose MTX (IM) >=10 yrs|Patients randomly assigned to the DH regimen based on one (or more) of the following characteristics: (1) No CNS3 status at entry, (2) no testicular leukemic involvement at entry, or (3) no extensive pre-treatment with steroids prior to entry. Patients receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15 & 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. Dexamethasone (5 mg/m2/dose on Days 1-14 by mouth or infusion twice a day in weeks 1 & 2; IT MTX (Aged based dosing: Age (yrs) Dose 1 - 1.99 8 mg 2 - 2.99 10 mg 3 - 8.99 12 mg ≥ 9 15 mg) on days 8 & 29 (CNS3 also on days 15 & 22) and an injection of pegaspargase (2500 International units/m2 x 1 dose on Day 4, 5 or 6).
3326773|NCT00075725|Experimental|Prednisone, Capizzi MTX Down Syndrome (DS) (non random)|Patients in regimen PC will receive cytarabine, vincristine sulfate, daunorubicin hydrochloride, and pegaspargase. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and IT MTX in weeks 2 & 5. Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning in week 6 or 7, patients may receive combination chemotherapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, mercaptopurine, cytarabine, thioguanine) by infusion, injection, intrathecally, and by mouth for up to 8 weeks.
3326774|NCT00075725|Experimental|Dexamethasone, Capizzi MTX DS (non random)|Patients receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15 & 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. Dexamethasone (5 mg/m2/dose on Days 1-14 by mouth or infusion twice a day in weeks 1 & 2; IT MTX (Aged based dosing: Age (yrs) Dose 1 - 1.99 8 mg 2 - 2.99 10 mg 3 - 8.99 12 mg ≥ 9 15 mg) on days 8 and 29 (CNS3 also on days 15 & 22) and an injection of pegaspargase (2500 International units/m2 x 1 dose on Day 4, 5 or 6).
3326796|NCT00075335|Experimental|AMD 3100 (Mozobil plerixafor)|AMD 3100 (Mozobil plerixafor)mobilized peripheral blood hematopoietic progenitor cells from healthy volunteers will be characterized by cellular content and immunological properties.
3326797|NCT00075270|Experimental|Arm 1|Lapatinib 1500 mg, once daily and Paclitaxel 175 mg/m Intravenously over 3 hours ever 3 weeks
3326798|NCT00075270|Placebo Comparator|Arm 2|Paclitaxel 175 mg/m Intravenously over 3 hours ever 3 weeks and Placebo
3326799|NCT00075218|Placebo Comparator|B|
3326800|NCT00075218|Active Comparator|A|
3326801|NCT00020787|Experimental|Treatment|See intervention description.
3326802|NCT00017537|Experimental|Dose #1|dose #1 administered
3326775|NCT00075725|Experimental|Prednisone & High Dose MTX (non random)|Patients non-randomly assigned to the PH regimen based on one (or more) of the following: (1) CNS3 status at entry, (2) testicular leukemic involvement at entry or (3) extensive pre-treatment with steroids prior to entry. Patients receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15, & 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15, & 22. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and IT MTX in weeks 2 & 5. Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning week 6 or 7, patients may receive combination chemotherapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, mercaptopurine, cytarabine, thioguanine) by infusion, injection, intrathecally, and by mouth for up to 8 weeks.
3326776|NCT00075686|Experimental|gemcitabine hydrochloride + IMC-C225|Loading dose: gemcitabine hydrochloride 1000mg/m2, IV on Day 1; Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only) Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 & days 1,8,15,22 of all subsequent cycles; gemcitabine hydrochloride 1000mg/m2, IV on Days 8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles.
3326777|NCT00075686|Experimental|gemcitabine hydrochloride alone|gemcitabine hydrochloride 1000mg/m2, IV on Days 1,8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles.
3326778|NCT00075647|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3326779|NCT00075634|Experimental|Arm I|"PART A (solid tumor patients): Patients receive decitabine IV over 1 hour on days 0-6 and doxorubicin IV over 15 minutes and cyclophosphamide IV over 1 hour on day 7. Patients then receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8 or 9*. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~PART B (neuroblastoma patients): Once the MTD is determined for part A, patients are treated as in part A at the MTD."
3326780|NCT00075621|Other|tandem transplant|"Drug: filgrastim 16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection~Drug: melphalan 200 mg/kg over 2 days~Procedure/Surgery: autologous peripheral blood stem cell transplantation~autologous peripheral blood stem cell transplantation"
3326781|NCT00075608|Experimental|2nd Stem Cell Transplant|Mobilization with filgrastim autologous stem cell transplantation with melphalan conditioning stem cell infusion
3326782|NCT00075582|Experimental|Regimen I (chemotherapy, radiotherapy)|Patients receive VAC chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 1-9 and dactinomycin IV over 1 minute and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, and 10; VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, and 22 (dactinomycin is omitted during radiation therapy); and radiation therapy, 5 days a week, beginning on week 13 and continuing for 4-7 weeks, depending on prescribed dose. Some patients do not receive radiation therapy; some start it at week 24. (closed to accrual as of 08/13/2010)
3326783|NCT00075582|Experimental|Regimen II (chemotherapy, radiotherapy, surgery)|Patients receive VAC chemotherapy and radiation therapy as in regimen I and VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21, 25-33, and 37-45 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, and 46 (dactinomycin is omitted during radiation therapy). Some patients do not receive radiation therapy; some start it at week 13 and some at week 24. Some patients have conventional surgery (second-look) at Week 13 (closed to accrual as of 9/23/2011).
3326784|NCT00075569|Active Comparator|1 month follow-up|3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 1 month; followed by LEEP or cone biopsy
3326785|NCT00075569|Active Comparator|2 month follow-up|3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 2 months; followed by LEEP or cone biopsy
3326786|NCT00075504|Experimental|triapine, gemcitabine|Triapine IV over 4 hours followed by gemcitabine IV over 30 minutes on days 1, 8, and 15, repeat every 28 days
3326787|NCT00075491|Experimental|Arm I (fenretinide, surgery)|Patients receive neoadjuvant oral fenretinide twice daily for 1 week and then undergo surgical resection.
3326788|NCT00075491|Active Comparator|Arm II (surgery)|Patients undergo surgical resection.
3326789|NCT00075478|Experimental|Arm I (chemotherapy, TBI, transplant, GVHD prophylaxis)|Patients receive fludarabine phosphate IV on days -4 to -2. Patients then undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.
3326790|NCT00075478|Active Comparator|Arm II (TBI, transplant, GVHD prophylaxis)|Patients undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.
3326791|NCT00075439|Experimental|Arm I|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3326792|NCT00075400|Experimental|Treatment (imatinib mesylate)|Patients receive imatinib mesylate PO QD or BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3326793|NCT00075387|Experimental|Arm I (combination chemotherapy)|"Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA over 10 minutes.~Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
3326803|NCT00017537|Experimental|Dose #2|dose #2 administered
3326804|NCT00017537|Experimental|Dose #3|Dose #3 administered
3326805|NCT00017537|Experimental|Dose #4|Dose #4 administered
3326806|NCT00017537|Experimental|Dose #5|Administered dose #5
3326812|NCT00075088|Experimental|Electrocardiogram (ECG) Intervention|Patients randomized to the experimental group had their ECGs printed out in the target ED with an audible voice alarm. Print-out of the pre-hospital ECG in the target ED was the intervention.
3326813|NCT00075088|Other|Routine Clinical Practice|Control patients had an ECG conducted after hospital arrival, as was the standard of care in the county.
3326814|NCT00012116|Experimental|temozolomide|Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
3326815|NCT00009919|Experimental|Treatment (semaxanib)|Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues every 6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with CR receive an additional 6 months of therapy after achieving CR.
3326816|NCT00009893|Experimental|gemcitabine + leucovorin + fluorouracil|Patients receive gemcitabine IV over 30 minutes followed by leucovorin calcium IV and fluorouracil IV over 5-10 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
3326817|NCT00075023|Experimental|Thalidomide gel|Thalidomide gel 20 mg applied topically 4 times daily for 4 weeks to a maximum of 3 target oral ulcers
3326818|NCT00075023|Experimental|Placebo|Placebo gel with no Thalidomide applied topically 4 times daily for 4 weeks to a maximum of 3 target oral ulcers
3326819|NCT00075010|Experimental|Decitabine + Valproic acid|Decitabine 15 mg/m^2 by vein over 1 hour times 10 days
3326820|NCT00074997|Experimental|001|OZ1 Single intravenous infusion of 2-20 x 10 to the power of 7 OZ1 transduced autologous CD34+ cells per kilogram of body weight
3326821|NCT00074997|Placebo Comparator|002|Placebo Single intravenous infusion of placebo transduced autologous CD34+ cells per kilogram of body weight
3326822|NCT00009867|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1 hour on days 1-5. Treatment repeats every 28 days for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response receive 2 additional courses.
3326823|NCT00009698|Experimental|All patients|Day 1 through day 7, days 9-14 and days 16-22: The assigned dose of IL-2 will be administered SQ. On days 8 and 15, IL-2 will be administered as a 2 hour intravenous infusion of one million units/M2 of IL-2. After day 22 there will be a 7 day rest period before beginning the next cycle. The next cycle will repeat just as above. This will be repeated for a maximum of 4 total cycles of 21 days of IL-2 therapy. The maintenance dose of IL-2 will always be the same as given during cycle one, unless there is dose limiting toxicity.
3326824|NCT00074984|Placebo Comparator|Placebo|Patients randomized to placebo
3326825|NCT00074984|Active Comparator|Fabrazyme (agalsidase beta)|Patients randomized to Fabrazyme (agalsidase beta).
3326826|NCT00074958|Experimental|Fabrazyme|1.0 mg/kg of Fabrazyme given to the patients every 2 weeks
3326827|NCT00074932|Other|1|
3326828|NCT00006213|Experimental|Treatment (BMS-214662)|Patients receive BMS-214662 IV over 1 hour weekly for 4 weeks. Treatment continues every 4 weeks for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression.
3326829|NCT00074828|Experimental|A|
3326830|NCT00074828|Active Comparator|B|
3326831|NCT00074763|Experimental|Platelet Transfusion|ThromboSol-preserved autologous platelet transfusion or Standard platelet transfusion. All patients receive both platelets frozen with Thrombosol and fresh random platelets. The order in which patients receive these two types of platelets randomized in a crossover design. Patients randomly assigned to receive either the sequence FRP then Thrombosol or Thrombosol then FRP. The randomization will occur after second cycle of chemotherapy, since all patients will receive FRP with the first cycle.
3326832|NCT00074750|Experimental|DTGM|Starting dose of DTGM fusion protein 2 mcg/kg/day as a short (30 min) intravenous infusion, three times /week (M,W,F) for two consecutive weeks. In absence of defined grade 3/4 nonhematological toxicities in the first 0/3 or 1/6 patients, the dose will be escalated by 1 mcg/kg/day for the next patient cohort.
3326833|NCT00074737|Active Comparator|cenersen, idarubicin|cenersen, idarubicin, no cytarabine
3326834|NCT00074737|Active Comparator|cenersen, idarubicin, cytarabine|cenersen, idarubicin, standard dose cytarabine
3326835|NCT00074737|Active Comparator|cenersen, idarubicin, HDAC|cenersen, idarubicin, HDAC (high dose cytarabine)
3326836|NCT00074724|Active Comparator|Medical Therapy|All medical interventions know to improve outcomes in patients with ischemic left ventricular dysfunction.
3326837|NCT00074724|Active Comparator|CABG|Surgical revascularization in conjunction with optimal medical therapy.
3326838|NCT00005963|Experimental|docetaxel + carboplatin|This is a multicenter study. Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), partial response (PR), or complete response (CR) may receive 4 additional courses past SD, PR, or CR. Patients are followed every 6 months for 2 years and then annually for 3 years.
3326839|NCT00074815|Experimental|MedMgmt+CBT|Participants will receive the following interventions: 1)SRI medication management with a psychiatrist plus, 2) cognitive behavioral therapy with a psychologist.
3326840|NCT00074815|Experimental|MedMgmt+I-CBT|Participants will receive the following interventions 1)SRI medication management plus, 2) instructional cognitive behavioral therapy. Both of these will be implemented by the same psychiatrist.
3326841|NCT00074815|Active Comparator|MedMgmt Only|Participants will receive the intervention SRI medication management with a psychiatrist
3326842|NCT00074802|Experimental|Paroxetine Continuation|Participants who showed only partial response to paroxetine in Phase 1 will receive continued treatment with paroxetine for 16 additional weeks.
3326843|NCT00074802|Experimental|Paroxetine with CBT Augmentation|Participants who showed only partial response to paroxetine in Phase 1 will receive continued treatment with paroxetine plus cognitive behavioral therapy (CBT) for 16 additional weeks.
3326844|NCT00074789|Experimental|1|Participants will receive home-based interpersonal depression treatment for 26 weeks
3326845|NCT00074789|Active Comparator|2|Participants will receive attention control/usual care for 26 weeks
3326846|NCT00074776|Experimental|1 Lithium|
3326847|NCT00074776|Experimental|2 Lamotrigine|
3326848|NCT00074711|Active Comparator|Calcium Phosphate Treatment Group|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
3326849|NCT00074711|Active Comparator|Calcium Carbonate Treatment Group|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.
3326850|NCT00074607|Experimental|Intrathecal gemcitabine administration|"Intrathecal gemcitabine will be given on a weekly schedule for the first cohort of patients at the 5 mg dose level and then a twice-weekly (i.e., every 3 to 4 days) schedule. Drug administration will be by the intraventricular (Ommaya reservoir injection) route.~Patients will be hospitalized overnight following their first dose of gemcitabine. If the first dose is well tolerated, subsequent induction doses may be administered in the outpatient setting with close observation for a minimum of 2 hours after administration.~Dose Levels and Dose Escalation:~Dose Level 1a: 5 mg~Dose Level 1b: 5 mg~Dose Level 2: 10 mg~Dose Level 3: 20 mg~Dose Level 4: 30 mg~Dose Level 5: 40 mg~Dose Level 6: 50 mg"
3326851|NCT00074581|Experimental|1|Participants will begin ART in addition to receiving HIV primary care
3326852|NCT00074581|Experimental|2|"Participants will receive HIV primary care. When the CD4 count in these participants reaches 200 to 250 cells/mm3, drops below 200 cells/mm3, or develops an AIDS-defining illness, they will initiate ART.~Note: Per LoA#5, on the Data and Safety and Monitoring Board (DSMB) recommendation, as of May 10, 2011, all HIV-infected participants in Arm 2 who have not already initiated ART will be offered ART as soon as possible."
3326853|NCT00074568||1|Patients with scleroderma and their family members (parents, brothers, and sisters)
3326854|NCT00074568||2|Healthy volunteers with no autoimmune disease and without a first-degree relative with a systemic autoimmune disease
3326855|NCT00005646|Experimental|Paclitaxel|Patients receive paclitaxel for up to 4 cycles. One cycle = weekly drug for 6 weeks and 2 weeks rest
3326856|NCT00005592|Experimental|Rituxan + IDEC-In2B8, Rituxan + IDEC-Y2B8|For the first treatment, 250 mg/m2 Rituxan infusion and injection of IDEC-In2B8 (Indium- radioactive label) is given. If therapy is continued, approximately 1 week later a second infusion of Rituximab (250 mg/m2) is given followed by an infusion of IDEC-Y2B8 (Yttrium-radioactive label).
3326857|NCT00074490|Experimental|AMIVDco 1|Patients receive low intensity fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3. Patients undergo DLI with sirolimus generated donor Th2 cells on day 14(single T-Rapa cell DLI in patients with CD4 count between 100 and 200 inclusive)
3326858|NCT00074490|Experimental|AmIVD co 2|Patients receive low intensity fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3. Patients undergo DLI with unmanipulated donor T-cells on day 14(single T- cell DLI in patients with low CD4 count between 100 and 200 inclusive)
3326859|NCT00074490|Experimental|AmIVD co 3|Patients with nonlymphoma diagnosis or rapidly progressive lymphoma undergo DLI with multiple infusions of sirolimus generated donor Th2 cells beginning on day 14.(multiple T-Rapa cell DLI in patients with CD4 count lower than 100 or ALC lower than 300)
3326860|NCT00074490|Experimental|Arm IVA|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -4 to 100, and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic PBSC or bone marrow transplant on day 0. Patients undergo DLI with 12-day expanded sirolimus-generated donor Th2 cells on day 14- This arm is not enrolling
3326861|NCT00074490|Experimental|Arm IVB|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -4 to 100, and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic PBSC or bone marrow transplant on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14-This arm is not enrolling.
3326862|NCT00074490|Experimental|Arm IVC|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -7 to 100 and high dose sirolimus PO on days -4 to 7, Patients undergo mobilized allogeneic PBSC or bone marrow transplant on day 0. Patients undergo DLI with standard unmanipulated donor T-cells on day 14-This arm is not enrolling.
3326863|NCT00074438|Experimental|1|
3326864|NCT00074438|Experimental|2|
3326865|NCT00074438|Experimental|3|
3326866|NCT00074438|Experimental|4|
3326867|NCT00074438|Experimental|5|
3326868|NCT00074438|Experimental|6|
3326869|NCT00074438|Placebo Comparator|7|
3326870|NCT00074438|Placebo Comparator|8|
3326871|NCT00074438|Placebo Comparator|9|
3326872|NCT00074425|Experimental|1|BufferGel
3326873|NCT00074425|Experimental|2|Pro 2000/5 Gel (P)
3326874|NCT00074425|Placebo Comparator|3|Placeo Gel
3326875|NCT00074425|No Intervention|4|
3326876|NCT00074412|Experimental|2A|For infants: extended treatment with NVP
3326877|NCT00074412|Placebo Comparator|2B|For infants: extended treatment with NVP placebo
3326878|NCT00074399|Experimental|1|Participants will receive nevirapine for 6 weeks
3326879|NCT00074399|Placebo Comparator|2|Participants will receive nevirapine placebo for 6 weeks
3326880|NCT00074373||human beings|human beings of all sexes, ages, and health statuses
3326881|NCT00008177|Experimental|Treatment ( I 131 BC8, chemotherapy, TBI, PBSCT, CSP, MMF)|"CONDITIONING REGIMEN: Patients receive iodine I 131 monoclonal antibody BC8 IV on day -12 and fludarabine phosphate IV on days -4 to -2. Patients undergo total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV BID on days -3 to 56 with taper to day 80 (for patients with a related donor) OR days -3 to 100 with taper to day 177 (for patients with an unrelated donor) in the absence of GVHD. Patients also receive mycophenolate mofetil PO or IV TID on days 0 to 27 (for patients with a related donor) OR on days 0 to 40 with taper to day 96 (for patients with an unrelated donor) in the absence of GVHD."
3326882|NCT00074321|Experimental|Arm I|Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO QD on days 2-15. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3326883|NCT00074308|Experimental|Arm I|Patients receive oral imatinib mesylate once or twice daily on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3326884|NCT00074295|Experimental|treatment|GVAX lung cancer vaccine
3326886|NCT00074204|Experimental|Immediate Docetaxel|Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.
3326887|NCT00074204|Active Comparator|Delayed Docetaxel|Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.
3326888|NCT00074165|Experimental|All subjects|
3326889|NCT00074152|Active Comparator|Arm I|Patients receive radiotherapy* within 6 months after surgery.
3326890|NCT00074152|Experimental|Arm II|Within 10 weeks after surgery, patients receive at least 3 courses of an adjuvant chemotherapy regimen as determined by the investigator. Patients may receive radiotherapy within 6 months after surgery and after the completion of chemotherapy OR integrated with chemotherapy.
3326891|NCT00074087|Experimental|Caelyx|doxorubicin HCl liposome IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses.
3326892|NCT00074048|Experimental|1|BL22 immunotoxin
3326893|NCT00074035|Experimental|Pentostatin|treatment of pts with refractory graft vs host disease
3326894|NCT00074022|Experimental|Treatment (GTI-2040, docetaxel)|"Phase I (closed to accrual as of 8/5/2004): Patients receive GTI-2040 IV continuously on days 1-14. Patients also receive docetaxel IV over 1 hour on day 3 during course 1 and on day 1 for all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of GTI-2040 and docetaxel until the MTD is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The RP2D is defined as the dose preceding the MTD.~Phase II: Patients receive GTI-2040 and docetaxel at the RP2D as in phase I."
3326895|NCT00073957|Experimental|Y-90 Ibritumomab Tiuxetan|Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab and central nervous system prophylaxis with Cytarabine or liposomal cytarabine
3326896|NCT00073918|Experimental|Treatment (radio labeled monoclonal antibody, chemotherapy)|"RADIOIMMUNOTHERAPY: Patients receive a test dose of iodine I 131 tositumomab IV on day -24 to determine biodistribution. Patients then receive therapeutic iodine I 131 tositumomab IV over approximately 40-60 minutes on day -14 and are entered into radiation isolation until day -4.~CHEMOTHERAPY: Patients receive etoposide IV on day -4 and cyclophosphamide IV on day -2.~AUTOLOGOUS STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplantation on day 0."
3326897|NCT00073905|Active Comparator|Arm A|Capecitabine plus Gemcitabine
3326898|NCT00073892|Experimental|PI-88|Patients receive four consecutive days treatment each week in a 4-week cycle.
3326899|NCT00073840|Active Comparator|I|Levalbuterol 90 ųg QID (manufacturing site A or B)
3326900|NCT00073840|Active Comparator|II|Racemic Albuterol 180 ųg QID
3326901|NCT00073840|Placebo Comparator|III|Placebo QID
3326902|NCT00073827|Experimental|1|levalbuterol MDI 90 mcg QID
3326903|NCT00073827|Active Comparator|2|racemic albuterol MDI 180 mcg QID
3326904|NCT00073827|Placebo Comparator|3|Placebo MDI QID
3326905|NCT00004857|Experimental|Fludarabine + Campath-1H|Standard of care induction with fludarabine followed by consolidation antibody therapy
3326906|NCT00004242|Experimental|Arm I|See detailed description.
3326907|NCT00003927|Experimental|High Dose chemotherapy followed by cell rescue|Doxorubicin, cyclophosphamide, Taxol, amifostine
3326908|NCT00073814|Experimental|1|levalbuterol MDI 90 mcg QID
3326909|NCT00073814|Active Comparator|2|racemic albuterol MDI 190 mcg QID
3326910|NCT00073814|Placebo Comparator|3|Placebo MDI QID
3326911|NCT00073788||Subjects with PTSD|Subjects will be American Indian, between the ages of 18-68. Approximately 66% will be female, 33% male, which conforms to the distribution of PTSD in this population. Study group subjects will be PTSD positive. Overt CVD is exclusionary.
3326912|NCT00073788||Control Group|Subjects will be American Indian, between the ages of 18-68. Approximately 66% will be female, 33% male, which conforms to the distribution of PTSD in this population. Control subjects will be PTSD negative. For both groups: overt CVD is exclusionary.
3326913|NCT00003761|Experimental|rV-DF3/MUC1|"rV-DF3/MUC1 vaccinations will be administered 4 week intervals for a total of 3 doses.~Participants will be followed weekly until 28 days after the final dose (day 85) then month for 6 months"
3326914|NCT00073749|Experimental|Inotuzumab ozogamicin|Inotuzumab ozogamicin, iv, dose escalation and expanded cohort at 1.8mg/m2
3326915|NCT00073736|Experimental|MB07133 Dose Level 1|7-day continuous infusion in 28-day cycles
3326916|NCT00073736|Experimental|MB07133 Dose Level 2|7-day continuous infusion in 28-day cycles
3326917|NCT00073736|Experimental|MB07133 Dose Level 3|7-day continuous infusion in 28-day cycles
3326918|NCT00073736|Experimental|MB07133 Dose Level 4|7-day continuous infusion in 28-day cycles
3326919|NCT00073736|Experimental|MB07133 Dose Level 5|7-day continuous infusion in 28-day cycles
3326920|NCT00003694|Experimental|Treatment (omacetaxine mepesuccinate, cytarabine)|Patients receive cytarabine and homoharringtonine concurrently by continuous intravenous infusion for 7 days. Courses repeat every 28 days. Patients receive a minimum of 9 courses of therapy in the absence of disease progression and unacceptable toxicity. Patients who are major cytogenetic responders at 9 months may continue therapy or switch to interferon. Minor cytogenetic responders are switched to interferon, and nonresponders are removed from therapy and given the option to switch to interferon.
3326921|NCT00073697|Experimental|1|Interpersonal Psychotherapy
3326922|NCT00073697|Experimental|2|Escitalopram
3326923|NCT00073697|Experimental|3|Escitalopram plus IPT
3326924|NCT00073684|Experimental|1|Participants will receive 8 sessions of TF-CBT with narrative.
3326925|NCT00073684|Experimental|2|Participants will receive 8 sessions of TF-CBT without narrative.
3326926|NCT00073684|Experimental|3|Participants will receive 16 sessions of TF-CBT with narrative.
3326927|NCT00073684|Experimental|4|Participants will receive 16 sessions of TF-CBT without narrative.
3326928|NCT00073671|Experimental|1|Participants receive a group cognitive-behavioral prevention program
3326929|NCT00073671|Active Comparator|2|Participants receive usual care
3326930|NCT00073645|Experimental|1|Family/Parents CBT (FCBT) for 14 to 16 weekly sessions
3326931|NCT00073645|Active Comparator|2|Peer/Group CBT (GCBT) for 14 to 16 weekly sessions
3326960|NCT00073242|Experimental|T3 repletion|Repletion of T3 following weight loss induced by dietary modification.
3326932|NCT00073619|Experimental|Cognitive-behavioral group therapy|School-based anxiety preventive intervention (cognitive-behavioral group therapy) originally designed for Australian children that was culturally and contextually modified for inner-city children exposed to community violence. Participants received the weekly intervention and rewards for participating in the assessments.
3326933|NCT00073619|No Intervention|Non-intervention Comparison|Provide no active intervention to the comparison group, although assess the children at the same assessment points as the experimental group. Participants in the control arm were told they were FRIENDS Program participants.They received rewards for participating in the assessments.
3326934|NCT00073593|Experimental|bivalirudin|250mg vial given as 0.75mg/kg intravenous (IV) bolus and 1.75 mg/kg/hr IV infusion for the duration of the procedure with the option to increase or decrease the infusion in 0.25 mg/kg/hr increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an ACT>300 seconds.
3326935|NCT00073593|Active Comparator|heparin/protamine|1.5-3.5 mg/kg (200-400 U/kg) intravenous (IV) bolus to target an ACT >300 seconds followed by weight-adjusted boluses as needed during the procedure to achieve/maintain the target ACT. Protamine as needed
3326936|NCT00073528|Other|Placebo plus letrozole|Placebo plus letrozoleA daily dose of randomized therapy ) taken approximately at the same time each day.
3326937|NCT00073528|Experimental|lapatinib plus letrozole|GW572016 and letrozole A daily dose of randomized therapy ) taken approximately at the same time each day.
3326938|NCT00003387|Experimental|Chemo + radiation|
3326939|NCT00003387|Experimental|Induction chemo + chemo & radiation|
3326940|NCT00003313|Experimental|Arm 1|Radiation therapy and chemotherapy + Amifostine
3326941|NCT00003313|Active Comparator|Arm 2|Radiation therapy and chemotherapy alone
3326942|NCT00003191|Experimental|Arm I|Patients receive oral fenretinide 3 times a day on days 1-7. Treatment repeats every 3 weeks for up to 8 courses. Patients may receive an additional 22 courses of therapy in the presence of stable or responding residual tumor. Patients with recurrent neuroblastoma, after prior myeloablative therapy with no measurable disease, will stop treatment after 8 courses. Cohorts of 3-6 patients receive escalating doses of fenretinide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
3326943|NCT00003167|Experimental|Treatment (adenovirus p53)|"Group 1 patients receive adenovirus p53 (Ad-p53) intravesically on days 1 and 4. Treatment continues every 4 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 patients in group 1 receive escalating doses of Ad-p53. In the absence of grade 3 or worse toxicity in the first 3 patients treated, subsequent cohorts of 3 patients each receive escalating doses of Ad-p53 on the same schedule. If 1 of 3 patients experiences grade 3 toxicity, an additional 3 patients are treated at that dose level and dose escalation continues. If 1 of 3 patients experience grade 4 toxicity or 2 of 3 patients experience grade 3 toxicity, dose escalation ceases and the MTD is defined as the previous dose level. Group 2 patients receive Ad-p53 at the MTD on days 1-4, and group 3 patients receive Ad-p53 at the MTD on days 1-4 and 8-11."
3326944|NCT00003130|Experimental|paclitaxel|Patients receive single fixed dose intravenous paclitaxel over 3 hours on day 1. Blood samples must be drawn prior to the first paclitaxel infusion and then at 1, 6, and 24 hours after the start of the infusion during course 1 only. Treatment courses of intravenous paclitaxel are repeated every 3 weeks at the discretion of the treating physician. Patients are evaluated for response after the second course. Patients are followed at the discretion of the physician.
3326945|NCT00002836|Experimental|Filgrastim + Chemotherapy|
3326946|NCT00002836|Experimental|Filgrastim|
3326947|NCT00002812|Experimental|Arm A - Standard BFM of Standard Duration (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow. Consolidation (Phase II) (5 weeks) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
3326948|NCT00002812|Experimental|Arm B - Standard BFM with Double Delayed Intensification (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (5 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
3326949|NCT00002812|Experimental|Arm C - Augumented BFM of Standard Duration (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (9 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
3326950|NCT00002812|Experimental|Arm D - Augmented BFM with Dbl Delayed Intensification (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (9 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
3326951|NCT00073333|Active Comparator|1|Social skills training and exposure
3326952|NCT00073333|Active Comparator|2|Exposure treatment
3326953|NCT00073333|Placebo Comparator|3|Placebo
3326954|NCT00073307|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Dose modification due to toxicity was permitted.
3326955|NCT00073307|Placebo Comparator|Placebo|Placebo tablets matching in appearance were to be orally administered twice a day.
3326956|NCT00002561|Active Comparator|Radiotherapy or ABVD + Radiotherapy|Radiotherapy
3326957|NCT00002561|Active Comparator|ABVD Alone|ABVD Alone
3326958|NCT00073398|Experimental|1|Ph II Arm 1
3326961|NCT00073073|Experimental|Exemestane|exemestane 25 mg by mouth (PO) every day for two years taken with calcium carbonate 1200 mg PO every day and vitamin D 400 IU PO every day Initially patients were initially planned to receive Celecoxib but the study was amended prior to any subject going on and Celecoxib was never administered to any subjects.
3326962|NCT00073021|Active Comparator|Asacol 2.4 g/day|Asacol (2.4 g/day)
3326963|NCT00073021|Experimental|Asacol 4.8 g/day|Asacol (4.8 g/day)
3326964|NCT00073008|Other|lapatinib|Randomized, open-label, parallel group, 2-stage study to evaluate and compare 2 dose schedules (1500 mg once daily and 500 mg twice daily) of oral lapatinib.
3326965|NCT00072982|Active Comparator|1|Fish Oil
3326966|NCT00072982|Active Comparator|2|Borage Oil
3326967|NCT00072982|Active Comparator|3|Fish Oil and Borage Oil
3326968|NCT00072930|Active Comparator|1|MEDI-522 + Docetaxel + Prednisone + Zoledronic Acid (N=55)
3326969|NCT00072930|Other|2|Docetaxel + Prednisone + Zoledronic Acid (N=55)
3326970|NCT00072904|Placebo Comparator|III|Placebo take half tab with meals tid
3326971|NCT00072839|Placebo Comparator|Placebo|placebo solution injected subcutaneously daily into either thigh or abdomen.
3326972|NCT00072839|Experimental|teduglutide 0.05|teduglutide 0.05 mg/kg/d injected subcutaneously daily.
3326973|NCT00072839|Experimental|teduglutide 0.1|0.1 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen
3326974|NCT00072839|Experimental|teduglutide|0.2 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen
3326975|NCT00072761|Active Comparator|Transfusion Group|Participants allocated to the transfusion arm will receive blood transfusion therapy every 4-6 weeks for 36 months.
3326976|NCT00072761|No Intervention|Observation Group|Participants allocated to the observation arm will be treated according to standard care and will receive a quarterly physical examination by a study hematologist for 36 months.
3326977|NCT00072670|Experimental|Trabectedin 0.58 milligram per square meter (mg/m^2)|Trabectedin will be administered as 3-hour intravenous infusion at dose of 0.58 mg/m^2 weekly on Day 1, 8 and 15 in 28-day cycle and will be continued until disease progression or unacceptable toxicity.
3326978|NCT00072670|Experimental|Trabectedin 1.5 mg/m^2|Trabectedin will be administered at dose of 1.5 mg/m^2 as 24-hour infusion every three weeks, and will be continued until disease progression or unacceptable toxicity.
3326979|NCT00072670|Experimental|Trabectedin 1.2 mg/m^2|Trabectedin will be administered at dose of 1.2 mg/m^2 as 24-hour infusion every three weeks, and will be continued until disease progression or unacceptable toxicity.
3326980|NCT00072657|Experimental|1|Participants will partake in cognitive behavioral therapy for 12 weeks.
3326981|NCT00072657|Experimental|2|Participants will partake in tai chi chih for 12 weeks.
3326982|NCT00072657|Active Comparator|3|Participants will act as a control and attend educational sessions for 12 weeks.
3326983|NCT00072631|Experimental|1 erlotinib|
3326984|NCT00072475|Experimental|Vatalanib|Adult patients with MDS receive treatment with vatalanib.
3326985|NCT00072462|Active Comparator|Anastrozole|
3326986|NCT00072462|Active Comparator|Tamoxifen|
3326987|NCT00072449|Experimental|Rituximab monotherapy|Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks
3326988|NCT00072436|Experimental|Treatment|"Some patients receive an initial dose of alvocidib IV over 1-7 hours on day 1 (course 0). Beginning 1 week later and for all subsequent courses, all patients receive gemcitabine hydrochloride IV over 60-150 minutes on days 1 and 15 and alvocidib IV over 1-7 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of gemcitabine hydrochloride and alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment at that dose."
3326989|NCT00072384|Experimental|Treatment (chemotherapy, surgery)|Patients receive liposomal vincristine sulfate IV over 1 minute on day 1 and carboplatin IV over 1 hour and etoposide IV over 1 hour on days 1 and 2. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on day 3 and continuing until blood counts recover. Patients receive subtenon carboplatin to each group C or D eye on day 0 or 1prior of courses 2-4 only. Treatment repeats every 28 days for 6 courses in the absence of occurrence of extraocular retinoblastoma or a second malignancy. Beginning with course 3 of systemic chemotherapy, patients undergo local ophthalmic therapy comprising local laser surgery and/or cryosurgery on day 1.
3326990|NCT00072358|Experimental|patients have refractory bone marrow disease|This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.
3326991|NCT00072358|Experimental|patients have no evidence of disease|This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.
3326992|NCT00072293|Active Comparator|Axillary Dissection|Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.
3326993|NCT00072293|Experimental|No Axillary Dissection|Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.
3326994|NCT00072280|Experimental|Chemotherapy plus possible surgery|"Comprised of patients with disease lesions that are initially unresectable, or resected but with resulting grossly positive margins. All patients receive vincristine sulfate, dactinomycin, and cyclophosphamide (VAC), and mercaptoethane sulfonate (MESNA). Depending on response, patients may receive ifosfamide and etoposide (IE). Filgrastim may also be given, as needed. In addition to Chemotherapy, patients may receive Conventional Surgery.~(See Interventions section for drug dosage and administration details.)"
3326995|NCT00072280|Experimental|Surgery only|Comprised of patients with initially resectable disease lesions. All patients undergo Conventional Surgery. Those with a result of clear or microscopically positive margins remain on study in this arm, for observation with no further intervention.
3326996|NCT00072215|Experimental|Regimen A: TIP|
3326997|NCT00072215|Experimental|Regimen B: VeIP|
3327021|NCT00071812|Placebo Comparator|Placebo plus SOC|
3326998|NCT00072189|Experimental|Treatment (7-hydroxystaurosporine)|Patients receive UCN-01 IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3326999|NCT00072176|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3327000|NCT00072163|Experimental|Treatment (temozolomide, thalidomide)|Patients receive oral temozolomide once daily on days 1-42 and oral thalidomide once daily on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses of therapy beyond CR.
3327001|NCT00072150|Experimental|Treatment (bortezomib)|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients with a solitary site of disease (i.e., lung or nodal metastases) and who have a partial response (PR) may be considered for surgical resection. Patients with a PR with residual disease after salvage surgery are eligible to continue study therapy. Patients who achieve a complete response, either through resection or bortezomib therapy, receive 2 additional courses of study therapy."
3327002|NCT00072137|Experimental|Arm A (rf-GM-CSF, closed to accrual 10/2004)|Patients receive recombinant fowlpox GM-CSF vaccine adjuvant intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
3327003|NCT00072137|Experimental|Arm B (rf-TRICOM, closed to accrual 10/2004)|Patients receive recombinant fowlpox-TRICOM vaccine intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
3327004|NCT00072137|Experimental|Arm C (rfTRICOM and rf-GM-CSF)|Patients receive recombinant fowlpox-TRICOM vaccine combined with recombinant fowlpox GM-CSF vaccine adjuvant intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
3327005|NCT00072098|Experimental|Experimental Group|Direct intratumoral injection of metastatic hepatic tumors using an adenoviral vector expressing the human recombinant interleukin-12 gene
3327006|NCT00072046|Experimental|Interferon|Treatment with interferon alfa 2b
3327007|NCT00072046|Experimental|Interferon + bevacizumab|Addition of bevacizumab to interferon alfa 2b treatment
3327008|NCT00072033|Active Comparator|Arm A|Docetaxel and Cisplatin chemo- and radiochemotherapy followed by surgery
3327009|NCT00071994|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3327010|NCT00071981|Experimental|Arm I (12MP)|Patients receive 2 injections of multi-epitope peptide vaccine comprising 12 melanoma peptides restricted by Class I MHC (12MP) emulsified with sargramostim (GM-CSF) and Montanide ISA-51 (incomplete Freund's adjuvant) or Montanide ISA-51 VG (ISA-51) intradermally (ID) and subcutaneously (SC) on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
3327011|NCT00071981|Experimental|Arm II (12MP/Tet)|Patients receive 2 injections of multi-epitope peptide vaccine comprising multi-epitope melanoma peptide vaccine (12MP) and 1 tetanus peptide melanoma vaccine emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
3327012|NCT00071981|Experimental|Arm III (12MP/6MHP)|Patients receive 2 injections of multi-epitope peptide vaccine comprising multi-epitope melanoma peptide vaccine (12MP) and 6 melanoma helper peptides (6HP) emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
3327013|NCT00071981|Experimental|Arm IV (6MHP)|Patients receive 2 injections of multi-epitope peptide vaccine comprising melanoma helper peptide vaccine (6HP) emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
3327014|NCT00071942|Experimental|Treatment (vaccine therapy)|Patients receive vaccination comprising recombinant vaccinia-MUC-1 and recombinant vaccinia-TRICOM vaccine intradermally on days 1 and 29 (for a total of 2 doses) in the absence of disease progression or unacceptable toxicity.
3327015|NCT00003141|Experimental|Treatment (combination chemotherapy, PBSC transplant)|Pts undergo conventional surgery for diagnosis & max tumor resection. In 6 wks of surgery or when stable pts begin induction chemotherapy(cisplatin IV over 6 hrs on day 0; vincristine sulfate IV on days 0,7,14; cyclophosphamide IV over 1 hr on days 1-2; and etoposide IV over 1 hr on days 0-2. 24 hrs after the last cyclophosphamide dose, pts receive filgrastim (G-CSF) & undergo peripheral blood stem cell harvest 2 days later. Treatment repeats every 21 days for up to 3 crs. Within 6 wks after induction, pts receive consolidation (carboplatin IV over 2 hrs on days 0-1 next esc. doses of thiotepa IV over 2 hrs. Pts undergo peripheral blood stem cell transplantation 48 hrs after last thiotepa dose. Pts receive G-CSF SC daily on days 3-21. Treatment repeats every 21 days for up to 3 crs. Pts with dose-limiting toxicity due to thiotepa are removed from study. Pts are followed at 4 wks, 3 mths for 1 yr, 6 mths for 3 yrs, annually for 3 yrs or until relapse.
3327016|NCT00072566|Experimental|Treatment (bevacizumab, cyclophosphamide)|Patients receive bevacizumab IV over 30-90 minutes on days 1, 8, and 15 for the first course and on days 1 and 15 for all subsequent courses. Patients also receive low-dose oral cyclophosphamide on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3327017|NCT00072527|Experimental|Induction and consolidation chemotherapy|"Induction chemotherapy (Cycles 1 and 2): Patients receive cisplatin 30 mg/m^2 on days 1, 8, 22 and 29 and irinotecan 65 mg/m^2 on days 1, 8, 22 and 29 for cycles 1 and 2.~Consolidation chemotherapy (Cycles 3, 4 and 5 beginning on day 43, week 7): Patients receive carboplatin on days 43, 64 and 85, etoposide 100 mg/m^2 IV on days 43-45, 64-66 and 85-87 and XRT 5 fractions/week starting on day 43"
3327018|NCT00072514|Experimental|Treatment|Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8, carboplatin IV over 30-60 minutes on day 1, and dexamethasone orally (PO) on days 1-4. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CD20-POSITIVE LYMPHOMAS also receive rituximab IV on day 8.
3327019|NCT00071916||African American|Adult African American participants with compensated chronic hepatitis C who have not been previously been treated with interferon and/or ribavirin.
3327020|NCT00071916||Caucasian|Caucasian participants with compensated chronic hepatitis C who have not been previously been treated with interferon and/or ribavirin.
3327025|NCT00071799|Experimental|Azacitidine|Study Drug plus best supportive care. Treatment with erythropoietin was not permitted
3327026|NCT00071799|Active Comparator|Conventional Care|Physician choice of low dose cytarabine (plus best supportive care), standard chemotherapy (plus best supportive care) or best supportive care (only). Treatment with erythropoietin was not permitted
3327027|NCT00005964|Experimental|Chemotherapy + prednisone + filgrastim|Patients receive doxorubicin IV, etoposide IV, vincristine IV, and cyclophosphamide IV continuously over days 1-4. Patients also receive oral prednisone twice daily on days 1-5 and filgrastim (G-CSF) subcutaneously beginning on day 6 until blood counts recover. Treatment continues every 21 days for a maximum of 8 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
3327028|NCT00005576|Experimental|Treatment (monoclonal antibody Ch14.18, aldesleukin)|Patients receive MOAB IV over 5 hours on days 7-10 during courses 2 and 4 and on days 3-6 during courses 1, 3, and 5; sargramostim (GM-CSF) IV over 2 hours or subcutaneously daily on days 0-13 during courses 1, 3, and 5; interleukin-2 IV continuously on days 0-3 and 7-10 during courses 2 and 4; and oral isotretinoin twice daily on days 14-27 during courses 2 and 4 and on days 10-23 during courses 3 and 5. Treatment repeats every 24-32 days for 5 courses in the absence of unacceptable toxicity.
3327029|NCT00005094|Experimental|Arm I (celecoxib)|Patients receive celecoxib twice a day for 3 years.
3327030|NCT00005094|Placebo Comparator|Arm II (placebo)|Patients receive placebo twice a day for 3 years.
3327031|NCT00071890|Active Comparator|Interleukin 2 group|HAART (standard of care) and three cycles of IL-2
3327032|NCT00071890|Active Comparator|Control group|HAART alone
3327033|NCT00005072|Experimental|Leuvectin|Leuvectin
3327034|NCT00071773|Active Comparator|Modified Early Treatment Diabetic Retinopathy Study (ETDRS)|modified-ETDRS
3327035|NCT00071773|Active Comparator|Mild Macular Grid (MMG)|MMG technique
3327036|NCT00071760|Experimental|Arm A - 4weeks - less than 2 years old (FPV/RTV bid)|"Cohort 2A - 4weeks - less than 6 months old. Fosamprenavir (FPV) 50 mg/mL oral suspension/ritonavir (RTV) 80 mg/mL oral solution twice daily (BID)~Cohort 1A - 6 months - less than 2yrs old. Fosamprenavir (FPV) 50 mg/mL oral suspension/ritonavir (RTV) 80 mg/mL oral solution twice daily (BID)"
3327037|NCT00071760|Experimental|Arm B- 4weeks - less than 2 years old (FPV bid)|"Cohort 2B - 4weeks - less than 6 months old. Fosamprenavir (FPV) 50 mg/mL oral suspension twice daily (BID)~Cohort 1B - 6 months - less than 2yrs old. Fosamprenavir (FPV) 50 mg/mL oral suspension twice daily (BID)"
3327038|NCT00071721|Experimental|1|
3327039|NCT00071721|Placebo Comparator|2|
3327040|NCT00071643|Experimental|1 Problem Solving Therapy|Participants will receive problem solving therapy.
3327041|NCT00071643|Experimental|2. Escitalopram|Participants will receive escitalopram.
3327042|NCT00071643|Placebo Comparator|3 Placebo|Participants will receive placebo.
3327043|NCT00071617|Experimental|Youth-Nominated Support Team|Adolescents nominate up to 4 caring adults from family, school, community settings. These adults participate in psychoeducation sessions regarding adolescent's treatment plan and support needs. They maintain regular, supportive contact with the adolescent for 3 months -- with ongoing consultation and support check-ins from study clinical staff.
3327044|NCT00071617|No Intervention|Enhanced Treatment as Usual|Adolescents in this condition receive study assessments and risk management services (at time of assessments) only
3327045|NCT00071578|Experimental|1|Group therapy Negative Emotion Focus
3327046|NCT00071578|Placebo Comparator|2|Group Psychotherapy- Self Esteem Focus
3327047|NCT00071565||1|475 families with multiple affected family members (phase I) 200 families with multiple affected family members (phase II) 1800 subjects with sporadic intracranial aneurysms
3327048|NCT00071552|Experimental|Qvar|Qvar 160 mcg twice daily
3327049|NCT00071552|Active Comparator|Flovent Diskus|Flovent Diskus 200 mcg twice daily
3327050|NCT00071539|Experimental|TP38 50 ng/mL|
3327051|NCT00071539|Experimental|TP38 100 ng/mL|
3327052|NCT00004074|Experimental|Treatment (IL12 and trastuzumab)|Patients receive an initial loading dose of trastuzumab IV over 90 minutes on day 1 of the first week and a maintenance dose of trastuzumab IV over 30-90 minutes on day 1 of each subsequent week. Patients receive IL-12 IV on days 2 and 5 beginning on week 3. Treatment with maintenance trastuzumab and IL-12 repeats weekly for 14 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease continue treatment for up to 38 additional weeks.
3327053|NCT00004050|Experimental|Leuvectin|2 intratumoral injections of 1000 ug of Leuvectin
3327054|NCT00003648||Group 1|Patients, family members, and control individuals complete an extended telephone interview, an extended personal interview, and an epidemiological survey, and contribute a blood specimen. Blood and tumor specimens are examined for the specific pattern of immunohistochemical expression of hMSH2 and HMLH1 to determine the frequency or lack of expression of these two protein products. Patients may be contacted periodically (about every 3 years) to update information about health, health practices, and family history. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
3327055|NCT00071513|Experimental|CAST-T/HSTS|The CAST-T/HSTS condition combined the Brief Intervention and 12 school based small group sessions which taught skills to enhance personal control (to manage depression, anger, stress), self-esteem, decision making and interpersonal communications. HSTS skills groups were held in the spring of 8th grade with 4 one-on-one booster sessions delivered to the students as 9th graders by HSTP leaders; parents also participated in 4 sessions. HSTS objectives are: 1) to increase the acquisition of coping skills competencies by teaching and practicing strategies taught; 2) to increase social support resources by building a supportive network; 3) to increase the youth's engagement in positive social activities; and 4) to motivate parents to increase their support via parent educational sessions.
3327087|NCT00024206|Experimental|Treatment (orantinib)|"Patients receive oral SU6668 twice daily on days 1-28. Courses repeat every 4 weeks in the absence of unacceptable toxicity or disease progression of 100% or more.~Cohorts of at least 6 patients receive escalating doses of SU6668 until the OBD is determined. Once the OBD is reached, dose escalation continues until the maximum tolerated dose (MTD) is determined (if possible). The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3327175|NCT00070057|Experimental|Arm II (high-dose celecoxib)|Patients receive a higher dose of oral celecoxib as in arm I.
3327056|NCT00071513|Active Comparator|Brief Intervention|Brief Intervention: After each youth and parent completed baseline questionnaires the youth participated in a 1 on 1 standardized clinical follow-up with a trained clinician (blind to study condition) to review areas of concern, based on questionnaire responses including stressors at school, home, and with peers, level of support available and how to access support. The teen and clinician then planned a feedback call to parents, allowing teens to shape requests for support from parents as well as understand exactly what information would be shared with parents. Feedback call to parents reviewed concerns and made recommendations for services as needed. A similar procedure was followed after each assessment for all participants who indicated a risk of clinical depression or self-harm.
3327057|NCT00071500|Experimental|1|Participants will use MedSignals with all of its features
3327058|NCT00071500|Experimental|2|Participants will use MedSignals with only alarm features
3327059|NCT00071500|No Intervention|3|Participants will not use any device
3327060|NCT00071487|Placebo Comparator|Placebo plus SOC|
3327061|NCT00071487|Experimental|Belimumab 1 mg/kg plus SOC|
3327062|NCT00071487|Experimental|Belimumab 4 mg/kg plus SOC|
3327063|NCT00071487|Experimental|Belimumab 10 mg/kg plus SOC|
3327064|NCT00003595|Experimental|Arm I|Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 3 and oral prednisone on days 3-7. Patients receive rituximab on day 1. Treatment repeats every 3 weeks for a minimum of 4 courses or 2 courses beyond complete response in the absence of disease progression or unacceptable toxicity. Patients with stage I, stage IE (including bulky), or nonbulky stage II or IIE disease receive 3 courses of chemotherapy with rituximab followed by radiotherapy beginning 3 weeks after completion of the third course. Patients who achieve partial response for a minimum of 28 days or complete response receive maintenance rituximab IV beginning on day 28 of the final course of chemotherapy. Maintenance rituximab treatment repeats every 4 weeks for 3 courses.
3327065|NCT00003595|Active Comparator|Arm II|Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Treatment repeats every 3 weeks for a minimum of 4 courses or 2 courses beyond complete response. Patients with stage I, stage IE (including bulky), or nonbulky stage II or IIE disease receive 3 courses of chemotherapy. Patients receive radiotherapy beginning 3 weeks after completion of the third course of chemotherapy.
3327066|NCT00003234|Experimental|Stratum 1 - Soft Tissue Sarcoma|See detailed description.
3327067|NCT00003234|Experimental|Stratum 2 - CNS Tumors|See detailed description.
3327068|NCT00003234|Experimental|Stratum 3 - Neuroblastoma|See detailed description.
3327069|NCT00003190|Experimental|Arm I (cytarabine, daunorubicin, etoposide)|Patients receive cytarabine IV continuously over 7 days and daunorubicin IV bolus followed by etoposide IV over 2 hours on days 1-3.
3327070|NCT00003190|Experimental|Arm II (valspodar, daunorubicin, etoposide, cytarabine)|"Patients receive treatment as in arm I with the addition of PSC 833 induction. A loading dose of PSC 833 IV is given over 2 hours, followed by a 74-hour continuous infusion of PSC 833 beginning 2 hours before daunorubicin and etoposide. Patients may receive a second induction course if residual leukemia is present in the bone marrow. Patients who experience a CR and meet certain other criteria receive postremission chemotherapy consisting of cytarabine IV continuously over 5 days plus daunorubicin IV followed by etoposide IV over 2 hours on days 1 and 2. Patients who are randomized to receive PSC 833 during induction chemotherapy receive a loading dose of PSC 833 before beginning a 48-hour continuous infusion of PSC 833 concurrently with cytarabine/daunorubicin/etoposide postremission chemotherapy.~After completing postremission chemotherapy, patients are randomized to a no further treatment group or IL-2 immunotherapy."
3327071|NCT00003126|Experimental|Interleukin-2 (IL-2)|Patients randomized to this arm will receive one course of IL-2 [600,000 U/kg every 8 hours on post-operative days 1 to 5 and days 15 to 19 (maximum 28 doses)].
3327072|NCT00003126|No Intervention|Observation|Patients randomized to this arm will receive their normal medical care
3327073|NCT00071461|Experimental|1|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~body weight < 40 kg (90 lb): 62.5 mg b.i.d."
3327074|NCT00071461|Placebo Comparator|2|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~body weight < 40 kg (90 lb): 62.5 mg b.i.d."
3327075|NCT00071422|Placebo Comparator|placebo|1.5 mL SC injection, once daily for 90 days
3327076|NCT00071422|Experimental|300 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
3327077|NCT00071422|Experimental|600 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
3327078|NCT00071409|Placebo Comparator|placebo|1.5 mL SC injection
3327079|NCT00071409|Experimental|300 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
3327080|NCT00071409|Experimental|600 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
3327081|NCT00071396|Experimental|Campath-1H + Rituximab|"Campath 15 mg/day continuous intravenous (IV) infusion x 6 days, then twice a week for 3 weeks as 30 mg injection under skin to complete 4 week treatment course.~Rituximab 375 mg/m^2 IV infusion day 1, then 500 mg/m^2 on days 8, 15 + 22."
3327082|NCT00003077|Experimental|Omega-3 fatty acid|"Patients receive omega-3 fatty acids orally in two equal doses with/after breakfast and lunch for 4 months or until weight loss is observed.~Dose is escalated in cohorts of two patients, although dose escalation is allowed in individual patients. Patients are evaluated for cachexia response every 2 weeks, and tumor response every 4 weeks for a maximum of 4 months. If no response of cachexia or tumor after a 2 month period, patients will be discontinued from study. Patients will be followed for survival post-treatment."
3327083|NCT00002723|Experimental|Low dose suramin|Low dose suramin
3327084|NCT00002723|Experimental|Intermediate dose suramin|Intermediate dose suramin
3327085|NCT00002723|Experimental|High dose suramin|High dose suramin
3327086|NCT00030420|Experimental|Celecoxib & Docetaxel|"Celecoxib: 400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.~Doctaxel: Day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days"
3327088|NCT00071240|Experimental|Growth Hormone Arm|Growth hormone receipt in the first year, post-growth hormone follow-up in the second year
3327089|NCT00071240|Active Comparator|2|Observation only in the 1st year, GH receipt in the second year
3327176|NCT00070057|Active Comparator|Arm III (surgery)|Patients do not receive treatment. All patients undergo surgery.
3327090|NCT00064428|Experimental|Fondaparinux - UFH not indicated|Subjects with no indication for UFH therapy: 2.5mg od, sc, (1st dose IV) x 8 days or discharge
3327091|NCT00064428|Placebo Comparator|Control - UFH not indicated|Subjects with no indication for UFH therapy: Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
3327092|NCT00064428|Experimental|Fondaparinux - UFH indicated|Subjects indicated for UFH: 2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus + 24-48 hr infusion
3327093|NCT00064428|Active Comparator|Control - unfractionated heparin|Subjects indicated for UFH: UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
3327094|NCT00071110|Experimental|1|Electroacupuncture (EA).
3327095|NCT00071110|Placebo Comparator|2|Sham
3327096|NCT00071097|Experimental|001|TMC114/rtv 400mg TMC114/100mg rtv once daily
3327097|NCT00071097|No Intervention|005|Control Group Control Group, no intervention
3327098|NCT00071097|Experimental|004|TMC114/rtv 600mg TMC114/100mg rtv twice daily
3327099|NCT00071097|Experimental|003|TMC114/rtv 400mg TMC114/100mg rtv both twice daily
3327100|NCT00071097|Experimental|002|TMC114/rtv 800mg TMC114/100mg rtv once daily
3327101|NCT00071084|Experimental|280 mg and 980 mg|
3327102|NCT00071071|Experimental|280 mg and 560 mg|
3327103|NCT00025467|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3327104|NCT00015912|Experimental|Treatment (interferon-alpha, thalidomide)|Patients receive interferon alfa subcutaneously every 12 hours and oral thalidomide daily in the absence of disease progression or unacceptable toxicity.
3327105|NCT00014144|Experimental|ZD 1839|
3327106|NCT00007917|Experimental|Arm I|"Patients receive gemcitabine IV over 1-2.5 hours on days 1 and 8 and flavopiridol IV continuously over 24 hours on days 2 and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of gemcitabine and flavopiridol until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3327107|NCT00071032|Experimental|Liberal (10 g/dL) Transfusion Strategy|Transfusion strategy that maintains postoperative Hgb levels above 10 g/dL.
3327108|NCT00071032|Active Comparator|2|Symptomatic transfusion strategy, a more conservative strategy, in which blood transfusion is withheld until the patient develops symptoms of anemia.
3327109|NCT00071006|Experimental|Single arm study|
3327110|NCT00070954|Placebo Comparator|2|look-alike placebo
3327111|NCT00070954|Active Comparator|Ginkgo Biloba|Compared to placebo
3327112|NCT00070941|Experimental|SAM-e|40 subjects receiving oral SAM-e, 1200mg or 1800mg daily in two divided doses, and placebo escitalopram.
3327113|NCT00070941|Active Comparator|Escitalopram|40 subjects receiving oral escitalopram 20mg or 40 mg daily, in two divided doses, and placebo SAM-e.
3327114|NCT00070941|Placebo Comparator|Placebo Comparator|20 subjects receiving oral placebo escitalopram and placebo SAM-3 daily in two divided doses.
3327115|NCT00070824|Experimental|B|Patients with osteoarthritis pain at rest
3327116|NCT00070824|Experimental|A|Normal Subjects without pain
3327117|NCT00070811||Revision|Patients with repaired cleft lip who receive lip revision surgery
3327118|NCT00070811||Non-Revision|Patients with repaired cleft lip who do not have lip revision surgery
3327119|NCT00070811||Non-cleft|Non-cleft 'control' subjects.
3327120|NCT00071058|Experimental|Surgery plus chemotherapy|"Surgical resection can be performed at the time of study entry, when patients have a mixed response, or if their tumors respond to chemotherapy.~Surgical resection will be followed by chemotherapy with 2 grams oral dose daily of mitotane on cycle 1, day 1, 6 mg/m^2 continuous intravenous infusion doxorubicin over 96 hours days 1-4, 0.18 mg/m^2 continuous intravenous infusion vincristine over 96 hours days 1-4, and 36 mg/m^2 continuous intravenous infusion etoposide over 96 hours days 1-4, and 150 mg tariquidar through central venous catheter over 30 minutes on days 1 and 3."
3327121|NCT00021099|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3327122|NCT00017368|Experimental|All Patients|
3327123|NCT00003907|Experimental|Hepatocellular carcinoma|Chemoemulsion (doxorubicin, mitomycin and cisplatin) followed by embolization. The entire procedure will be repeated separately to each involved lobe beginning within 8 weeks of the last lobar chemoembolization.
3327124|NCT00003907|Experimental|Neuroendocrine hepatic metastases|Chemoemulsion (doxorubicin, mitomycin and cisplatin) followed by embolization. The entire procedure will be repeated separately to each involved lobe beginning within 8 weeks of the last lobar chemoembolization.
3327125|NCT00070642|Experimental|CPG 7909 Injection plus chemotherapy|CPG 7909 Injection plus DTIC
3327126|NCT00070642|Active Comparator|Chemotherapy alone|dacarbazine
3327127|NCT00070642|Experimental|CPG 7909 Injection 10 mg|
3327128|NCT00070642|Experimental|CPG 7909 Injection 40 mg|
3327129|NCT00070629|Experimental|1|Chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection
3327130|NCT00070629|Active Comparator|2|Chemotherapy (a taxane and a platinum compound)
3327131|NCT00070616|Experimental|Palifermin 6 x 60 μg/kg/day|The first 3 consecutive daily doses were administered before the initiation of conditioning therapy (study days -11, -10, and -9); 3 additional consecutive daily doses were administered after administration of radiotherapy, chemotherapy and PBPC transplantation (study days 0, 1, and 2).
3327132|NCT00070616|Experimental|Palifermin 2 x 180 μg/kg/day|The first dose was administered on study day -11, 3 days before the initiation of conditioning therapy, and the second dose was given on day 0 after administration of radiotherapy, chemotherapy and the PBPC infusion
3327170|NCT00070109|Experimental|Trabectedin 1.5 mg/m2 to assess feasibility in all patients|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. Six toxicity-evaluable patients are assigned this treatment.
3327171|NCT00070109|Experimental|Trabectedin at 1.5 mg/m2 to assess efficacy in Ewing sarcoma|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
3327133|NCT00006012|Experimental|topotecan + paclitaxel + filgrastim + TRT + radiation|"Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 5. Patients receive filgrastim (G-CSF) subcutaneously (SC) daily beginning 24 hours after the last dose of chemotherapy and continuing until blood counts recover. Treatment repeats every 3 weeks for 2 courses.~After 2 courses of treatment, patients undergo TRT twice daily for 5 consecutive days for 5 weeks. During TRT, patients receive cisplatin IV, oral etoposide, and amifostine SC daily prior to TRT.~At 4 weeks after completion of TRT, patients receive 2 additional courses of topotecan, paclitaxel, and G-CSF every 3 weeks followed by prophylactic cranial irradiation.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
3327134|NCT00005800|Experimental|Dose-Dense Chemotherapy|Patients receive doxorubicin IV on day 1 every 2 weeks for 3 courses. After 3 weeks of rest, patients receive docetaxel IV over 1 hour on day 1 every 2 weeks for 3 courses. Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each doxorubicin and docetaxel course. Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
3327135|NCT00070564|Active Comparator|Arm I|(closed 11/10/10) Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim subcutaneously (SC) on day 2 or filgrastim (G-CSF) SC on days 3-10. Treatment repeats every 14 days for 6 courses. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.
3327136|NCT00070564|Experimental|Arm II|(closed 11/10/10) Patients receive doxorubicin IV on day 1, oral cyclophosphamide on days 1-7, and G-CSF SC on days 2-7. Treatment repeats every 7 days for 15 courses. Beginning 2 weeks after completion of cyclophosphamide, patients receive paclitaxel and pegfilgrastim as in arm I.
3327137|NCT00070564|Active Comparator|Arm III|(closed 11/10/10) Patients receive doxorubicin, cyclophosphamide, and pegfilgrastim or G-CSF as in arm I. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 7 days for 12 courses.
3327138|NCT00070564|Experimental|Arm IV|(closed 11/10/10) Patients receive doxorubicin, cyclophosphamide, and G-CSF as in arm II. Beginning 2 weeks after completion of cyclophosphamide, patients receive paclitaxel as in arm III.
3327139|NCT00070564|Experimental|Arm V|Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 4 courses. Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.
3327140|NCT00070564|Experimental|Arm VI|Patients receive doxorubicin, cyclophosphamide, and pegfilgrastim as in arm V. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 7 days for 12 courses.
3327141|NCT00070551|Experimental|Stratum I (GTI-2040, cytarabine)|Patients receive GTI-2040 IV continuously on days 1-6 and high-dose cytarabine IV over 2 hours twice daily on days 2, 4, and 6.
3327142|NCT00070551|Experimental|Stratum II (GTI-2040, cytarabine)|Patients receive GTI-2040 IV continuously on days 1-6 and high-dose cytarabine IV over 4 hours once daily on days 2-6. In both strata, treatment continues in the absence of unacceptable toxicity.
3327143|NCT00070525|Experimental|Arm I|Patients receive oral tipifarnib twice daily on days 1-21. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3327144|NCT00070499|Experimental|Arm I (QD imatinib mesylate)|Patients receive imatinib mesylate PO QD. Treatment repeats every 4 weeks for up to 5 years in the absence of disease progression or unacceptable toxicity.
3327145|NCT00070499|Experimental|Arm II (BID imatinib mesylate)|Patients receive imatinib mesylate PO BID. Treatment repeats every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
3327146|NCT00070499|Experimental|Arm III (dasatinib)|Patients receive dasatinib PO BID. Treatment repeats every 4 weeks for up to 5 years in the absence of disease progression or unacceptable toxicity.
3327147|NCT00070486|Experimental|Gem + Carboplatin + Zileuton|
3327148|NCT00070486|Experimental|Gem + Carboplatin + celecoxib|
3327149|NCT00070486|Experimental|Gem + carboplatin + zilueton + celecoxib|
3327150|NCT00070434|Experimental|Irinotecan + 5-FU + Leucovorin|Irinotecan 180mg/m2, IV for 90min on Day 1, q 2 wk x 4 cycles; 5-FU 400 mg/m2, IV bolus on Day 1, q 2 wk x 4 cycles; 5-FU 2.4 g/m2 IV for 46 hours on Day 1, q 2 wk x 4 cycles; Leucovorin 200 mg/m2 IV for 2 hours on Day 1, q 2 wk x4 cycles.
3327151|NCT00070434|Experimental|Irinotecan + Oxaliplatin|Irinotecan 175mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; Oxaliplatin 85mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles
3327152|NCT00070434|Experimental|Oxaliplatin + 5-FU + Leucovorin|Oxaliplatin 85mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; 5-FU 400mg/m2 IV bolus on Day 1, q 2wk x4 cycles; 5-FU 2.4g/m2 IV for 46 hours on Day 1, q 2wk x4 cycles; Leucovorin 200mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles.
3327153|NCT00070382|Experimental|Darbepoetin alfa|darbepoetin alfa administered once every two weeks at a dose of 200 ug over a 16 week treatment period.
3327154|NCT00070382|Active Comparator|Epoetin alfa|epoetin alfa administered at 40,000 unites, once per week over a 16-week treatment period.
3327155|NCT00070317|Experimental|Diagnostic|Patients receive radiolabeled technetium Tc 99m sulfur colloid injected around the tumor 6 hours prior to or after induction of anesthesia right before surgery. Patients then undergo radical hysterectomy and complete pelvic and low para-aortic lymphadenectomy. Intraoperatively, patients undergo lymphatic mapping and sentinel lymph node identification using isosulfan blue or methylene blue injected at 4 locations in the cervix and a hand-held gamma counter.
3327172|NCT00070109|Experimental|Trabectedin at 1.5 mg/m2 - assess efficacy in rhabdomyosarcoma|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
3327173|NCT00070109|Experimental|Trabectedin 1.5 mg/m2 - assess efficacy in nonrhabdomyosarcoma|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
3327174|NCT00070057|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib twice daily for 1-3 weeks (according to the duration between biopsy and surgery) in the absence of unacceptable toxicity.
3327156|NCT00070304|Experimental|Treatment|Patients receive vinorelbine tartrate IV over 6-10 minutes and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on day 9 and continuing for at least 7 days and until blood counts recover. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease after 2 courses may proceed directly to stem cell transplantation off study OR receive 2 additional courses. Patients with stable disease after 2 courses receive at least 2 additional courses. Patients with continued stable or responding disease (with no disease progression) after 4 courses may continue to receive study treatment for up to 1 year or discontinue study for alternative therapy at the discretion of the treating physician.
3327157|NCT00070291|Experimental|Cyclosporine|High dose cyclosporine weeks 1-6, then maintenance dose cyclosporine weeks 7-36. If CR, PR, or SD at week 36 evaluation, treatment is complete. If progression occurs during weeks 7-36, patients will re-register to Step 2 at time of PD and begin high dose therapy (weeks 1-6), followed by maintenance therapy (weeks 7-36). At second progression patients will end protocol treatment.
3327158|NCT00070265|Experimental|Treatment (oxaliplatin, capecitabine, and surgery)|"Neoadjuvant chemotherapy: Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Surgery: Four to six weeks after the completion of chemotherapy, patients undergo surgical resection of the tumor.~Adjuvant chemotherapy: Patients with satisfactory response to therapy receive 4 additional courses of oxaliplatin and capecitabine after surgery."
3327159|NCT00070252|Experimental|Treatment (tipifarnib, capecitabine, docetaxel)|"Phase Ib: Patients receive oral tipifarnib twice daily and oral capecitabine twice daily on days 1-14 and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Phase II: Patients receive oral tipifarnib twice daily for 6 days. Beginning at least 48 hours after completion of the initial dose of tipifarnib, patients receive treatment as in phase Ib for up to 6 courses at the MTD of capecitabine."
3327160|NCT00070239|Experimental|Treatment|"PART 1 (closed to accrual as of 8/2005): Patients receive alvocidib IV over 1 hour on days 1, 8, and 15.~Cohorts of 3-6 patients receive escalating doses of alvocidib until the MTD* is determined.~PART 2: Patients receive alvocidib IV over 1 hour at or below the MTD determined in part 1 and then receive a maintenance dose of alvocidib IV over 1-6 hours on days 1, 8, and 15. Cohorts of 3-6 patients receive escalating durations of the maintenance dose of alvocidib until the MTD* is determined. An additional cohort of 10-20 patients receives alvocidib over 1 hour on days 1 and 15 at the MTD.~NOTE: *The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~In both parts, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3327161|NCT00070200|Experimental|All patients|Induction Cycles 1 and 2 (CT) (21 days each), Cyclophosphamide (Days 1 thru 5) weight based dosage (> 12 kg 400 mg/m2/day, < 12 kg 13.3 mg/kg/day, < 2 years old N/A. Topotecan (Days 1 thru 5) weight based dosage (> 12 kg 1.2 mg/m2/day, < 12 kg 0.04 mg/kg/day, < 2 years old 0.04 mg/kg/day). Filgrastim (Days 6 →) weight based dosage (> 12 kg 5 micrograms/kg, < 12 kg 5 micrograms /kg, < 2 years old 5 micrograms /kg.
3327162|NCT00070187|Experimental|Hyperfractionated Involved-Field Radiotion-immunotherapy|"Completed prior salvage induction therapy and have not received full tissue tolerance from prior radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily for 7 days.~HIGH-DOSE PREPARATIVE REGIMEN: Beginning within 7 days after radiotherapy, carmustine IV over 3 hours on day -6; etoposide IV over 1 hour and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes on day -1.~ASCT: Autologous bone marrow or peripheral blood stem cell transplantation on day 0. Filgrastim (oral or IV) beginning on day 1 and continuing until blood counts recover.~IMMUNOTHERAPY: Cyclosporine IV twice daily beginning on day 0 and continuing until the completion of the course of recombinant interferon gamma and interleukin-2. When sufficiently recovered, Aldesleukin once daily for 18 days."
3327163|NCT00070187|Experimental|Hyperfractionated Involved-Field Radiotion-no immunotherapy|"Completed prior salvage induction therapy and have not received full tissue tolerance from prior radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily for 7 days.~HIGH-DOSE PREPARATIVE REGIMEN: Beginning within 7 days after radiotherapy, carmustine IV over 3 hours on day -6; etoposide IV over 1 hour and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes on day -1.~ASCT: Autologous bone marrow or peripheral blood stem cell transplantation on day 0. Filgrastim (oral or IV) beginning on day 1 and continuing until blood counts recover."
3327164|NCT00070148|Active Comparator|Arm 1 Oxandrolone 20 mg daily|Oxandrolone 20 mg (10 mg BID) for 12 weeks. 4 additional weeks of follow-up.
3327165|NCT00070148|Active Comparator|Megace 800 mg|Megestrol acetate 800 mg daily for 12 weeks. 4 additional weeks of follow-up.
3327166|NCT00070135|Experimental|Treatment (fludarabine, busulfan, allogeneic PBSC)|"PREPARATIVE REGIMEN: Patients receive fludarabine IV over 30 minutes on days -7 to -3 and busulfan IV over 2 hours 4 times per day (every 6 hours) on days -4 and -3.~GVHD PROPHYLAXIS: Patients receive tacrolimus PO or IV BID on days -2 with taper between days 90-120, and stopping by days 150-180. Patients also receive methotrexate IV on days 1, 3, 6, and 11 and rabbit antithymocyte globulin IV over 4-6 hours on days -4 through -2.~ALLOGENEIC PBSC: Patients undergo allogeneic PBSC transplant on day 0. Patients then receive filgrastim SC daily beginning on day 12 and continuing until blood counts recover."
3327167|NCT00070122|Experimental|Arm I (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46-48 hours beginning on day 1. Patients are further randomized to receive bevacizumab or placebo* IV over 30-90 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
3327168|NCT00070122|Experimental|Arm II (oxaliplatin, capecitabine)|Patients receive oxaliplatin IV over 2 hours on day 1and oral capecitabine on days 1-15. Patients are further randomized to receive bevacizumab or placebo* as in arm I. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
3327169|NCT00070109|Experimental|Trabectedin 1.3 mg/m2 to assess feasibility in all patients|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. A cohort of 6 patients will be enrolled at the 1.3 mg/m2 dose level.
3327177|NCT00070018|Experimental|CHOP + RT + Zevalin|Patients first receive 3 cycles (21 days each) of CHOP, consisting of: cyclophosphamide 750 mg/m^2 on day 1, doxorubicin 50 mg/m^2 on day 1, vincristine 1.4 mg/m^2 on day 1, and prednisone 100 mg on days 1-5. Patients receive 4000-5000 cGy of radiation therapy in 25 fractions, starting 3 weeks after completion of CHOP. 3-6 weeks after completing RT, patients receive Zevalin, which consists of: rituximab 250 mg/m^2 on days 1 and 7, 8 or 9; In-111 ibritumomab tiuxetan 5 mCi within 4 hours after rituximab on day 1; and Y-90 ibritumomab tiuxetan 0.4 mCi/kg within 4 hours after rituximab on day 7, 8 or 9.
3327178|NCT00069992|Experimental|Submyeloablative Allogeneic Stem Cell Transplant|Total Body Irradiation Fludarabine Campath 1H
3327179|NCT00069953|Experimental|ChemoRT and selective surgery|Induction therapy of fluorouracil, cisplatin, paclitaxel, and pegfilgrastim OR filgrastim, then chemoradiotherapy of concurrent cisplatin and fluorouracil with external beam radiotherapy (RT), followed by selective salvage therapy.
3327180|NCT00069927|Experimental|Arm 1- Adderall- XR®|Adderall-XR® 1 10 mg/day for 3-12 weeks depending on subject's response
3327181|NCT00069927|Experimental|Arm II Concerta®|Concerta ® 18 mg/day for 3-12 weeks depending on subject's response
3327182|NCT00006034|Experimental|Arm I|Patients receive a sensitizing dose of keyhole limpet hemocyanin (KLH) intradermally in week 2 followed by induction KLH IV once weekly in weeks 1-6. Patients with partial or no response receive IV KLH reinduction therapy once weekly in weeks 13-18. Patients with complete response receive IV KLH maintenance therapy monthly in weeks 13, 17, and 21, and then in months 6-12.
3327183|NCT00006034|Active Comparator|Arm II|Patients receive doxorubicin IV once weekly in weeks 1-6.
3327184|NCT00069784|Experimental|Insulin glargine + omega-3 polyunsaturated fatty acids|"Insulin glargine once daily by subcutaneous injection in a titrated regimen targeting a fasting plasma glucose (FPG) level of ≤95 mg/dL (5.3 mmol/L)~One capsule of omega-3 polyunsaturated fatty acids once daily"
3327185|NCT00069784|Experimental|Insulin glargine + placebo|"Insulin glargine once daily by subcutaneous injection in a titrated regimen targeting a fasting plasma glucose (FPG) level of ≤95 mg/dL (5.3 mmol/L)~One capsule of placebo once daily"
3327186|NCT00069784|Experimental|Standard care + omega-3 polyunsaturated fatty acids|• One capsule of omega-3 polyunsaturated fatty acids once daily
3327187|NCT00069784|Placebo Comparator|Standard care + placebo|• One capsule of placebo once daily
3327188|NCT00069706|Experimental|AL-12182 0.003%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
3327189|NCT00069706|Placebo Comparator|AL-12182 Solution Vehicle|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
3327190|NCT00069706|Active Comparator|Latanoprost|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
3327191|NCT00069706|Experimental|AL-12182 0.01%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
3327192|NCT00069706|Experimental|AL-12182 0.03%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
3327193|NCT00069836|Experimental|Arm 1|
3327194|NCT00069823|Experimental|Esomeprazole|Proton pump inhibitor of gastric acid
3327195|NCT00069823|Placebo Comparator|Placebo for esomeprazoe|Placebo
3327196|NCT00069641|Experimental|Idursulfase weekly (0.5 mg/kg)|
3327197|NCT00069641|Experimental|Idursulfase every other week (0.5 mg/kg)|
3327198|NCT00069641|Placebo Comparator|Placebo|
3327199|NCT00005629|Experimental|Group A - first dosing group|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (100 ug dose) emulsified in 2 ml of Montanide ISA-51.
3327200|NCT00005629|Experimental|Arm B - dosing group 2|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (500 ug dose) emulsified in 2 ml of Montanide ISA-51.
3327201|NCT00005629|Experimental|Group 3 - dosing level 3|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (1000 ug dose) emulsified in 2 ml of Montanide ISA-51.
3327202|NCT00069576|Active Comparator|Nutritional counseling & self blood glucose monitoring|Within one week of enrollment, women in the treatment group receive formal nutritional counseling and will be instructed on the technique of self blood glucose monitoring using a memory-based reflectance meter.
3327203|NCT00069576|No Intervention|No treatment|This group will not receive any specific dietary therapy except for written information concerning general nutritional recommendations for normal pregnancy.
3327204|NCT00004883|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Treatment continues once a week in the absence of disease progression or unacceptable toxicity.
3327205|NCT00004856|Experimental|Treatment: Herceptin|Patients receive a loading dose of trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. For all subsequent doses, patients receive trastuzumab IV over 30 minutes weekly. Treatment may continue for more than 1 year in the absence of unacceptable toxicity or disease progression.
3327206|NCT00003930|Experimental|Arm 1|Transurethral surgery with chemotherapy and radiation therapy followed by either selective bladder preservation or radical cystectomy followed by adjuvant chemotherapy.
3327207|NCT00003832|Experimental|Treatment (bromodeoxyuridine)|Patients receive broxuridine IV over 30 minutes on day -1. Approximately 12-96 hours later, patients undergo surgery to remove the prostate.Tumor tissue is examined by immunostaining for the presence of broxuridine to determine doubling times of the tumor.
3327208|NCT00069459|Other|Extended-release Bupropion Hydrochloride|Extended-release Bupropion Hydrochloride
3327209|NCT00069407|Active Comparator|RUL|Right unilateral electroconvulsive therapy
3327210|NCT00069407|Active Comparator|BL|Bilateral electroconvulsive therapy
3327211|NCT00069407|Active Comparator|BF|Bifrontal electroconvulsive therapy
3327212|NCT00069381|Experimental|study arm|
3327213|NCT00003620|Experimental|Treatment (flavopiridol)|"Patients registered before 9/15/2000 receive flavopiridol IV continuously on days 1-3. Treatment repeats every 14 days for a total of 12 courses in the absence of disease progression or unacceptable toxicity.~Patients registered after 9/15/2000 receive flavopiridol IV over 1 hour daily on days 1-3. Treatment repeats every 3 weeks for a total of 8 courses in the absence of disease progression or unacceptable toxicity."
3327282|NCT00068341|Experimental|HER2/neu negative patients|please see intervention description
3329746|NCT00038298|Experimental|400 mg|400 mg 3 times weekly
3327214|NCT00003594|Experimental|irinotecan + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes followed by leucovorin calcium IV over 15 minutes and fluorouracil IV once a week for 4 weeks followed by 2 weeks of rest. Courses repeat every 6 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
3327215|NCT00003594|Experimental|oxaliplatin + leucovorin + fluorouracil|"Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV over 2 hours plus fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
3327216|NCT00003594|Experimental|oxaliplatin + irinotecan|"Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on day 1. Courses repeat every 3 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
3327217|NCT00069264|Experimental|E7389|
3327218|NCT00003281|Experimental|topotecan + paclitaxel + radiotherapy|"Patients receive topotecan IV over 30 minutes on days 1-3 and paclitaxel IV over 3 hours on day 3. Courses repeat every 4 weeks.~Patients who achieve partial response or stable disease continue treatment in the absence of complete response or disease progression. Patients who develop disease progression in the CNS only should receive whole brain radiotherapy and then continue treatment. Patients who achieve complete remission receive a maximum of 6 courses of treatment. Patients may then undergo prophylactic cranial irradiation and/or thoracic radiotherapy at the discretion at the attending physician.~Patients are followed every 3 months for 2 years and then at 3 years after study."
3327219|NCT00069329|Experimental|NOMID treatment arm|All patients enrolled received daily doses of subcutaneous injection of increased doses of anakinra starting at 0.5mg/kg/day up to a maximum 10mg/kg/day to achieve disease remission.
3327220|NCT00069238|Experimental|Alemtuzumab Dose Escalation|Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles. Three cohorts of 3 to 6 patients will be treated. Cohort 1 will receive 30mg of Alemtuzumab, cohort 2 will receive 60mg of Alemtuzumab, and cohort 3 will receive 90mg of Alemtuzumab. If 1 of 3 participants entered at a given dose level experiences dose limiting toxicity (DLT), up to 3 additional participants will be entered at that dose level. If 2 of 6 participants experience DLT at a particular dose level, the maximum tolerated dose (MTD) has been exceeded. The preceding dose level will be the MTD, provided 6 participants have been entered at this level and no more than 1 has experienced DLT.
3327221|NCT00069121|Experimental|1|
3327222|NCT00069121|Active Comparator|2|
3327223|NCT00069108|Experimental|XELOX|Participants received XELOX (oxaliplatin and capecitabine). Oxaliplatin was administered 130 mg/m^2 intravenous (IV) infusion over 2 hours (every 3 weeks [Day 1]) before the first dose of capecitabine. Capecitabine was administered orally within 30 minutes after the end of a meal (breakfast and dinner) at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of Day 1 and last dose the morning of Day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) for up to 8 cycles (24-weeks).
3327224|NCT00069108|Active Comparator|FOLFOX-4|Participants received FOLFOX-4 (combination of oxaliplatin, leucovorin [LV] and 5-fluorouracil [5-FU] combination). Oxaliplatin was administered as an 85 mg/m^2 IV infusion over 2 hours (on Day 1 only); with LV infusion as 200mg/m^2 over 2 hours followed by 5-FU, given as 400mg/m^2 bolus injection over 2-4 minutes, and then as a 600 mg/m^2 continuous infusion over 22 hours. On Day 2, Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection over 2-4 minutes, and 5-FU 600 mg/m^2 continuous infusion was repeated over 22 hours. It was (2-week cycles comprising 48 hours of infusion and 12 days of rest) for up to 12 cycles (24- weeks).
3327225|NCT00069095|Experimental|XELOX (oxaliplatin+capecitabine)|Patients in the 2-arm part of the study received oxaliplatin 130 mg/m^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m^2 orally twice a day for the first 2 weeks of every 3 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.
3327226|NCT00069095|Experimental|XELOX (oxaliplatin+capecitabine) + bevacizumab|Patients in the 4-arm part of the study received oxaliplatin 130 mg/m^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m^2 orally twice a day for the first 2 weeks of every 3 week cycle + bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.
3327227|NCT00069095|Active Comparator|FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil)|Patients in the 2-arm part of the study received oxaliplatin 85 mg/m^2 intravenously (iv) + leucovorin 200 mg/m^2 iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle.
3327228|NCT00069095|Active Comparator|FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil) + bevacizumab|Patients in the 4-arm part of the study received oxaliplatin 85 mg/m^2 intravenously (iv) + leucovorin 200 mg/m^2 iv + bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle.
3327229|NCT00069134|Experimental|Sulfur Amino Acids|12 children with edematous severe malnutrition will be assigned to receive 0.65 mmol/kg/d of sulfur amino acids. Supplements will be added to the children's daily diets.
3327230|NCT00069134|Placebo Comparator|Alanine|12 children with edematous severe malnutrition are assigned to receive 0.65 mmol/kg/d of alanine as placebo. Supplements will be added to the children's daily diets.
3327231|NCT00069017|Active Comparator|1|MEDI-522 - 4 mg/kg of MEDI-522 (N=200)
3327232|NCT00069017|Placebo Comparator|2|Placebo (N=100)
3327233|NCT00030381|Experimental|Treatment (iododoxorubicin)|Patients receive iododoxorubicin IV over 15 minutes on days 1, 8, 15, and 22. Treatment repeats every 12 weeks for a total of 4 courses or a cumulative dose of 400 mg/m^2 in the absence of disease progression or unacceptable toxicity.
3327234|NCT00069160|Experimental|Pts who received docetaxel on day 1, 8, & tariquidar day 8,22|Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.
3327235|NCT00069160|Experimental|Pts who received docetaxel on days 1, 8, & tariquidar day 1,22|Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8 and tariquidar intravenous (IV) over 30 minutes on days 1 and 22.
3327236|NCT00069082|Active Comparator|Civamide|Nasal Solution 0.01%
3327237|NCT00069082|Placebo Comparator|Placebo|Placebo nasal solution with sodium chloride 10%
3327238|NCT00068991|Experimental|1|Participants will be HIV-infected villagers and will will take part in 2-hour skills training sessions every week from study entry to Week 8. Participants will bring a family member to each training session. After training, participants complete a post-training evaluation of the training sessions. Participants will also complete questionnaires at study entry and 6 and 12 months after completion of training.
3327239|NCT00068991|Experimental|2|Participants will be villagers considered influential members of their community. In the first 2 months of the study, Participants will take part in four 2-hour training sessions focusing on anti-stigma and anti-discrimination messages. Participants will also attend additional support meetings monthly, from Months 2 to 15. They will be evaluated before and after their training sessions to determine the improvements in knowledge and attitudes about HIV among group participants.
3327240|NCT00068991|Experimental|3|Participants will be randomly selected community members and will complete a cross-sectional survey at study entry and 6 and 12 months after Group 2's completion of training to determine changing community attitudes about HIV as a result of Group 2's training. There will be no additional study visits or training for Group 3 participants.
3327241|NCT00069069|Experimental|1|single center, Phase 1, open label, dose escalation trial assessing safety profile of four doses of intranasal recombinant human E-selectin
3327242|NCT00068874|Active Comparator|1|Educational comparison group
3327243|NCT00068874|Experimental|2|Group receiving coping intervention designed to enhance coping and psychological adjustment
3327244|NCT00068874|No Intervention|3|Comparison control group with no active intervention
3327245|NCT00068822|Experimental|Vertebroplasty|Participants will receive percutaneous vertebroplasty
3327246|NCT00068822|Placebo Comparator|Control Group|Participants will receive sham vertebroplasty without PMMA
3327247|NCT00068809|Experimental|Short-cycle therapy (SCT)|At entry, subjects will switch from continuous HAART to SCT. All subjects will then be followed to assess viral load breakthrough over 48 weeks on SCT.
3327248|NCT00068783|Experimental|Treatment|Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or symptomatic deterioration.
3327249|NCT00068770|Active Comparator|p450 ( +EIASD)|"on p450 inhibitor (Patients taking anttiseizure drugs that are known to induce the hepatic drug-metabolizing enzymes - including phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine)~celecoxib and radiation therapy will be adminstered with this arm"
3327250|NCT00068770|Active Comparator|nonp450 (-EIASD)|"not on p450 inhibitor (Patients either NOT taking anti-seizure drugs or ones that are known to not significantly influence the hepatic drug-metabolizing enzymes - including gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine,topiramate, zonisamide and filbamate.~celecoxib and radiation therapy will be adminstered with this arm"
3327251|NCT00068731|Experimental|lycopene|"Patients receive oral lycopene twice daily on days 1-28. Courses repeat every 28 days for at least 4 months in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years."
3327252|NCT00068718|Experimental|Treatment (DLI)|Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
3327253|NCT00068692|Experimental|Group I, Arm I|Patients receive 1 of 3 preoperative chemoradiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive irinotecan IV over 90 minutes and leucovorin calcium IV over 2 hours followed immediately by fluorourcil IV bolus on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.
3327254|NCT00068692|Experimental|Group I, Arm II|Patients receive 1 of 3 preoperative chemoradiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours followed immediately by fluorourcil IV bolus on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 8 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
3327255|NCT00068692|Experimental|Group I, Arm III|Patients receive 1 of 3 preoperative chemoradiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV over 1 hour on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 8 weeks for 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
3327256|NCT00068692|Experimental|Group II, Arm I|"Patients receive irinotecan, leucovorin calcium, and fluorouracil as in group 1, arm I for 4 courses. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemoradiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III.~Treatment continues in the absence of disease progression or unacceptable toxicity."
3327257|NCT00068692|Experimental|Group II, Arm II|"Patients receive oxaliplatin, leucovorin calcium, and fluorouracil as in group 1, arm II for 4 courses. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemoradiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III.~Treatment continues in the absence of disease progression or unacceptable toxicity."
3327258|NCT00068692|Experimental|Group II, Arm III|Patients receive leucovorin calcium and fluorouracil as in group 1, arm III for 1 course. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemoradiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III. Treatment continues in the absence of disease progression or unacceptable toxicity.
3327259|NCT00068666|Experimental|radiation + temozolomide|"Patients receive concurrent chemoradiotherapy comprising whole brain radiotherapy daily on days 1-5, 8-13, and 16-21 and oral temozolomide daily on days 1-5. Subsequent treatment with temozolomide repeats every 4 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months."
3327260|NCT00068653|Experimental|Celecoxib & ZD1839|"Celecoxib: 400mg orally two times a day, taken with meals.~ZD1839: 250 mg po every day, taken with or without food."
3327261|NCT00068601|Active Comparator|Standard Chemotherapy|Patients receive cyclophosphamide-containing chemotherapy alone.
3327262|NCT00068601|Experimental|Chemotherapy Plus Goserelin|Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.
3327263|NCT00068588|Experimental|Treatment (GTI-2040, capecitabine)|Patients receive GTI-2040 IV continuously on days 1-15 of the first course and days 1-14 of all subsequent courses. Patients also receive oral capecitabine twice daily on days 2-15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3327264|NCT00068575|Experimental|Postoperative Chemoradiation Regimen|Postoperative Cisplatin 30 mg/m^2 intravenous (IV) weekly for 6 doses, Interferon Alfa-2b 3 million units subcutaneous (SQ) on Monday, Wednesday and Friday days 1-19 and 29-45 for 17 total doses, and 5-fluorouracil (5-FU) 175 mg/m2/day by continuous intravenous infusion days 1-19 and 29-45 with concurrent Radiation Treatment.
3327265|NCT00068549|Experimental|Treatment|Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 in the absence of disease progression or unacceptable toxicity. Patients also undergo external whole pelvis radiotherapy once daily on days 1-5, 8-13, 15-20, 22-27, and 29-34. After completion of external beam radiotherapy, patients undergo intracavitary radiotherapy and parametrial radiotherapy. The total elapsed time for completion of all radiotherapy is not more than 8 weeks.
3327266|NCT00068510|Experimental|autologous tumor lysate-pulsed DC|
3327267|NCT00068497|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib on day 1 and then daily beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
3327268|NCT00068484|Experimental|Treatment (topotecan hydrochloride, bortezomib)|Patients receive topotecan IV over 30 minutes on days 1-5. Beginning with course 2, patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3327269|NCT00068458|Active Comparator|Arm 1: calcium diet|Calcium-Rich Diet (dietary counseling + materials promoting an intake of 1,200 - 2,500 mg/day).
3327270|NCT00068458|Active Comparator|Arm 2: Exercise + Calcium-Rich Diet|Exercise + Calcium Rich Diet (dietary counseling + materials promoting strength training and aerobic activity + a calcium intake of 1,200 - 2,500 mg/day).
3327271|NCT00068458|Active Comparator|Exercise + Fruit & Vegetable, Low Fat + Calcium Diet|Dietary counseling + materials promoting strength training and aerobic activity + a diet that has < 20% of energy coming from fat and intakes of fruits and vegetables of > 5 servings/day + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
3327272|NCT00068445|Experimental|Arm I - lamotrigine|"Patients receive oral lamotrigine once daily for 2 weeks and then twice daily for 8 weeks. Treatment continues for 10 weeks in the absence of unacceptable toxicity.~Quality of life, pain, mood states, and symptom distress are assessed at baseline and at 4, 6, 8, and 10 weeks.~Patients are followed at 3-7 days."
3327273|NCT00068445|Other|Arm II - placebo|"Patients receive oral placebo once daily for 2 weeks and then twice daily for 8 weeks.~Treatment continues for 10 weeks in the absence of unacceptable toxicity.~Quality of life, pain, mood states, and symptom distress are assessed at baseline and at 4, 6, 8, and 10 weeks.~Patients are followed at 3-7 days."
3327274|NCT00068432|Experimental|Gemcitabine + Celecoxib|Oral celecoxib twice daily on days 1-28. Gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
3327275|NCT00068419|Experimental|Treatment (enzyme inhibitor therapy, anti-estrogen therapy)|Patients receive oral sulindac and oral tamoxifen citrate twice daily for up to 12 months (four 3-month courses) in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 1 additional month of treatment beyond documentation of CR.
3327276|NCT00068406|Experimental|Treatment (conventional surgery, radiation therapy, cisplatin)|"Patients undergo radiotherapy daily on days 1-5 and receive concurrent cisplatin IV over 30 minutes on day 1. Treatment repeats weekly for approximately 6.5 weeks (a total of 32 fractions of radiotherapy) in the absence of unacceptable toxicity.~Six to eight weeks after the completion of chemoradiotherapy, patients with a complete clinical response may undergo incisional biopsy of the primary tumor and bilateral inguinal/femoral nodes (if the groin nodes were initially unresectable). Patients with microscopic or gross resectable residual disease may then undergo radical resection of the residual tumor. Patients with unresectable disease after the completion of chemoradiotherapy receive additional radiotherapy with 1-2 courses of concurrent cisplatin."
3327277|NCT00068393|Experimental|Doxorubicin/Gemcitabine|Doxorubicin was given at 50 mg/m² by IV slow push, followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life. Cycles were repeated every 2 weeks.
3327278|NCT00068380|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3327279|NCT00068367|Experimental|Arm I (OSI-774)|"Drug: erlotinib hydrochloride~Other Names:~OSI-774 150 mg per day, daily until disease progression"
3327280|NCT00068341|Experimental|Arm I (neoadjuvant therapy)|see intervention description
3327281|NCT00068341|Experimental|Arm II (neoadjuvant therapy)|please see intervention description
3327283|NCT00068328||Group 1|"Patients participate in interviews over 30-45 minutes at baseline, at 6 months, and at 1 and 2 years.~Patients are followed annually for at least 5 years."
3327284|NCT00068315|Experimental|Treatment (bortezomib, fludarabine, rituximab)|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and fludarabine IV over 30 minutes on days 1-3 or 1-5. Patients may also receive rituximab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3327285|NCT00068302|Experimental|Sirolimus|This is a dose escalation study including 4-dose levels. Subjects will receive a one-time loading dose of sirolimus on day 0, time 0. Subsequent dosing at the assigned dose level will start 24 hours following the initial loading dose
3327286|NCT00068250|Experimental|Phase I: Temozolomide 100 mg|Rituximab, methotrexate, temozolomide 100 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
3327287|NCT00068250|Experimental|Phase I: Temozolomide 150 mg|Rituximab, methotrexate, temozolomide 150 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
3327288|NCT00068250|Experimental|Phase I: Temozolomide 200 mg|Rituximab, methotrexate, temozolomide 200 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
3327289|NCT00068250|Experimental|Phase II: Temozolomide 100 mg|Rituximab, methotrexate, temozolomide 100 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
3327290|NCT00068237|Other|Surgery and salivary gland transfer and radiation|Patients undergo surgery for the primary and neck nodes and submandibular salivary gland transfer on Day 1 followed by post-operative radiation therapy within 4-6 weeks of surgery. Radiation therapy dose can range from 54-70 Gy over 5.5-7 weeks, at 2.0 Gy/fraction.
3327291|NCT00025207|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3327292|NCT00068107|Experimental|Relagal|All participants received Relagal administered weekly
3327293|NCT00068055|Experimental|1|60 subjects to receive Omr-IgG-am.
3327294|NCT00068055|Active Comparator|2|20 subjects to receive Polygam® S/D (IVIG).
3327295|NCT00068055|Placebo Comparator|3|20 subjects to receive normal saline.
3327296|NCT00067990|Experimental|Losartan 100mg|Losartan 100 mg per day to be started within three months of transplantation and continuing treatment for five years.
3327297|NCT00067990|Placebo Comparator|Placebo|No intervention with continuing follow-up for five years.
3327298|NCT00067938|Other|Arm 1|Open label single arm study
3327299|NCT00068003||1/Cancer Patients|Patients with a current diagnosis of cancer
3327300|NCT00068003||2/Healthy Volunteers|Healthy volunteers
3327301|NCT00016276|Experimental|Arm I (chemoprotection, monoclonal antibody, radiotherapy)|Patients receive dexrazoxane IV over 10-20 minutes, doxorubicin IV over 5-10 minutes, and cyclophosphamide IV over 30 minutes on days 1, 22, 43, and 64. Patients receive paclitaxel IV over 1 hour and trastuzumab (Herceptin) IV over 30-90 minutes on days 85, 92, 99, 106, 113, 120, 127, 134, 141, 148, 155, and 162. Approximately 1-2 weeks after completion of neoadjuvant chemotherapy, patients undergo breast conservation surgery, modified radical mastectomy, or mastectomy. Patients with unacceptable toxicity or locoregional disease progression may undergo surgery prior to week 24 (i.e., completion of neoadjuvant chemotherapy). Beginning 2-4 weeks after breast conservation surgery or 3-5 weeks after mastectomy, patients undergo radiotherapy daily 5 days a week for 6-8 weeks. Patients receive long-term trastuzumab IV over 30-90 minutes weekly for 40 weeks beginning on week 36 (day 254).
3327302|NCT00016276|Experimental|Arm II (chemoprotection, radiotherapy, surgery, trastuzumab)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel (without trastuzumab) as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
3327303|NCT00016276|Experimental|Arm III (chemoprotection, monoclonal antibody, radiotherapy)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation only for 40 weeks after completion of radiotherapy.
3327304|NCT00016276|Experimental|Arm IV (chemoprotection, paclitaxel, surgery, radiotherapy)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
3327305|NCT00016276|Experimental|Arm V (combination chemo, radiotherapy, long term trastuzumab)|Patients receive doxorubicin and cyclophosphamide (without dexrazoxane) as in arm I. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
3327306|NCT00016276|Experimental|Arm VI (combination chemo, paclitaxel, surgery, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
3327307|NCT00016276|Experimental|Arm VII (combination chemo, monoclonal antibody, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
3327308|NCT00016276|Experimental|Arm VIII (combination chemotherapy, paclitaxel, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
3327309|NCT00006265|Experimental|Cohort I|Immunotherapy with gemtuzumab
3327310|NCT00006265|Experimental|Cohort II|Gemtuzumab + ara-C
3327311|NCT00006265|Experimental|Cohort IA|Gemtuzumab + ara C
3327312|NCT00006265|Experimental|Cohort IV|Gemtuzumab + ara-C
3327313|NCT00006103|Experimental|irinotecan + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for a total of 5 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year and then every 6 months thereafter."
3327314|NCT00067873|Active Comparator|Diet only|
3327317|NCT00006002|Experimental|Arm B|dexamethasone followed by SU5416 done twice weekly (Monday and Thursday or Tuesday and Friday) every week for 4 weeks (a total of 8 doses). Four weeks of treatment (8 doses) is considered 1 cycle of treatment if tumor grows.
3327318|NCT00006002|Experimental|Arm A|SU5416 done twice weekly (Monday and Thursday or Tuesday and Friday) every week for 4 weeks (a total of 8 doses). Four weeks of treatment (8 doses) is considered 1 cycle of treatment
3327319|NCT00005845|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on weeks 1, 3, 5, and 7. Treatment repeats every 8 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
3327320|NCT00067808|Active Comparator|Decitabine 10 mg/m^2 IV|10 mg/m^2 intravenous (IV) over 1 hour daily for 10 days
3327321|NCT00067808|Active Comparator|Decitabine 20 mg/m2 IV|20 mg/m2 IV over 1 hour daily for 5 days
3327322|NCT00067808|Active Comparator|Decitabine 20 mg/m2 SQ|20 mg/m2 subcutaneous (SQ) daily for 5 days
3327323|NCT00067782|Active Comparator|1|
3327324|NCT00067782|Active Comparator|2|
3327325|NCT00067769|Active Comparator|TAU|Patients received treatment as usual (TAU) as defined as continued clinical care.
3327326|NCT00067769|Experimental|TAU+UCanPoopToo|Patients received treatment as usual (TAU) plus the Internet intervention (UCanPoopToo.)
3327327|NCT00005090|Active Comparator|ABVD x 5 + ABVD x 3|Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m^2, bleomycin 10 U/m^2, vinblastine 6 mg/m^2, dacarbazine 375 mg/m^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
3327328|NCT00005090|Experimental|ABVD x 5 + ABVD x 1 + HDT + PBSCT|Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m^2, bleomycin 10 U/m^2, vinblastine 6 mg/m^2, dacarbazine 375 mg/m^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant. Patients randomized to the transplant arm have 2 x 10^6 CD34+ blood mononuclear cells/kg of actual body weight collected at day -7. High dose therapy consists of BCNU 150/m^2 on days -6 to -4, etoposide 60 mg/kg on day -4, and cyclophosphamide 100 mg/kg on day -2. Peripheral blood stem cells are infused on day 0.
3327329|NCT00067756|Experimental|4-PBA|The study will involve a 4-PBA dose escalation and pharmacokinetics component The study group will be comprised of a total of at least 10 AAT-deficient,(phenotype ZZ referred to as PiZZ) patients. These patients will be divided into two groups: with and without clinical evidence of mild to moderate hepatocellular injury.
3327330|NCT00067743|Other|1|Open Label trial
3327331|NCT00067730|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
3327332|NCT00067717|Experimental|Distant Healing|This group received distant healing but was blinded to the condition.
3327333|NCT00067717|Placebo Comparator|Non-blinded Distant Healing|This group received the distant healing intervention and was called every day they were receiving to be told they were receiving it, therefore enhancing expectancy.
3327334|NCT00067717|No Intervention|Blinded Control|This group was blinded to the intervention condition and did not receive any distant healing.
3327335|NCT00067704|Experimental|Trauma writing|Four sessions of writing about traumatic experiences.
3327336|NCT00067704|Sham Comparator|Writing about daily events|Four sessions of writing about their daily experiences.
3327337|NCT00067665|No Intervention|1|Control group of 50 patients where dry weight is not changed.
3327338|NCT00067665|Experimental|2|All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
3327339|NCT00067639|Experimental|Pegfilgrastim + Apheresis|12 mg Pegfilgrastim as subcutaneous injection on day 1 + Apheresis daily till target stem cell dose reached.
3327340|NCT00067626|Experimental|1|500/1000 mcg oral chromium taken daily or placebo (crossover)
3327341|NCT00067626|Experimental|2|500/1000 mcg oral chromium taken daily or placebo (crossover)
3327342|NCT00067613|Active Comparator|Intervention|Clinical sites randomized to intervention will receive training in the benchmarking BPD management methods identified at the Benchmark sites.
3327343|NCT00067613|Placebo Comparator|Control|Clinical sites randomized to Control will continue with their normal management practices for BPD.
3327344|NCT00067587||HIV Negative|HIV negative subjects
3327345|NCT00067587||HIV Positive - NEVER had ARV therapy.|HIV Positive - NEVER had ARV therapy.
3327346|NCT00067587||HIV positive, on a NNRTI, non-PI regimen|HIV positive, currently on a NNRTI, non-PI regimen for at least 3 months. Must NEVER have received a total of more than SIX months of PI-containing regimen and at least ONE year must have passed since receipt of last PI-containing regimen.
3327347|NCT00067587||HIV positive, on a PI, non-NNRTI regimen|HIV positive, currently on a PI, non-NNRTI regimen for at least 3 months. Must NEVER have received a total of more than SIX months of NNRTI-containing regimen and at least ONE year must have passed since receipt of last NNRTIcontaining regimen.
3327348|NCT00067587||HIV positive, on a non-PI, non-NNRTI|HIV positive, currently on a non-PI, non-NNRTI containing regimen for at least 3 months. Must NEVER have received a total of more than SIX months of PI- and/or NNRTI- containing regimen and at least ONE year must have passed since receipt of last PI- and/or NNRTI-containing regimen.
3327349|NCT00067470|Placebo Comparator|Placebo|
3327350|NCT00067470|Active Comparator|rhASB|
3327351|NCT00004233|Experimental|5-FU, Leucovorin and PN-401|PN401 is given on Days 1-3 weekly for six weeks; 5FU and leucovorin are given on Day 1 weekely for six weeks; followed by two weeks of rest. Continued in 8 week cycles until one of the criteria for removal from treatment is met.
3327352|NCT00004221|Experimental|Treatment (Combination chemotherapy, PBSC)|See detailed description.
3327768|NCT00005977|Experimental|STAGE IV NHL, -CNS (Trt 2)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABAB"
3327353|NCT00004032|Experimental|Treatment (ALVAC-hB7.1, recombinant interferon gamma)|Patients receive ALVAC-hB7.1 infected tumor cells intraperitoneally (IP) on days 4, 11, and 18. Patients also receive interferon gamma IP on days 8, 10, 15, and 17. In the absence of disease progression, up to 6 courses of therapy may be given. If insufficient tumor cells are available to continue treatment with tumor cell derived vaccine, interferon gamma may be given alone.
3327354|NCT00067340|Experimental|Intervention group|Subjects received chlorhexidine mouthwash and xylitol gum , in addition to the usual care specified under the control group
3327355|NCT00067340|Placebo Comparator|Control|Subjects received enhanced dental care, health information, toothbrushes and toothpaste. They also received placebo gum and placebo mouth rinse
3327356|NCT00003931||blood or bone marrow samples|"All samples are obtained from specimens collected on CALGB-9665. No additional blood or bone marrow samples are collected CALGB-9769.~Samples are examined by Southern blot analysis for gene rearrangement at 11q23. Samples showing evidence of ALL1 gene rearrangement are further analyzed by reverse transcription PCR amplification and/or cytogenetic analysis to detect partial tandem duplication of ALL1."
3327357|NCT00067379|Active Comparator|1|Medicaid patients with medically necessary malocclusions treated during the mixed dentition with limited goals followed by observation
3327358|NCT00067366|Experimental|Coping Skills Training|manualized coping skills training delivered along with conservative care
3327359|NCT00067366|Active Comparator|Standard Care|Attention and life counseling added to Standard conservative care
3327360|NCT00067236|Experimental|PG-116800 tablet|PG-116800 tablet (200 mg) taken twice daily for 90 days
3327361|NCT00067236|Placebo Comparator|Placebo tablet|Placebo tablet taken twice daily for 90 days
3327362|NCT00067119|Experimental|Aggrenox|
3327363|NCT00067119|Placebo Comparator|Placebo|
3327364|NCT00067106||1: Women failing therapy|Participants will have study visits at study entry, 2 weeks after changing medications, then every 4 weeks until the amount of HIV in the blood and genital tract are undetectable. Drug levels in the blood and genital tract will also be measured at the first visit and after changing medications. Once the level of HIV is undetectable, women will be seen every 3 months for 36 months. Participants in Group 1 will be followed no more than 42 months.
3327365|NCT00067106||2: Women suppressed on therapy|Participants will have study visits for blood and genital tract collections at study entry and then every 4 weeks for 12 months
3327366|NCT00067080|Experimental|ICL670 + deferoxamine|
3327367|NCT00067028|Experimental|Clofarabine + Ara-C|"Clofarabine 30 - 40 mg/m^2 by vein over 1 hour daily for 5 days.~Ara-C Starting dose: 0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle."
3327368|NCT00067028|Experimental|Clofarabine + Idarubicin|"Clofarabine 30 - 40 mg/m^2 by vein over 1 hour daily for 5 days.~Idarubicin 10 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle."
3327369|NCT00067028|Experimental|Clofarabine + Idarubicin + Ara-C|"Clofarabine 30 - 40 mg/m^2 by vein over 1 hour daily for 5 days.~Idarubicin 6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.~Ara-C Starting dose: 0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle."
3327370|NCT00003323|Experimental|Hormone Therapy|Treatment of prostate cancer pts post radiation or surgery with potency sparing hormones
3327371|NCT00003210|Experimental|Treatment (interleukin-12)|Patients receive interleukin-12 subcutaneously twice a week. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
3327372|NCT00003006||Group 1|At the time of thoracotomy and pulmonary resection, patients have samples of bone marrow, primary tumor, and intrathoracic lymph nodes harvested. The presence of occult metastases in bone marrow and lymph nodes is assessed using immunohistochemistry or reverse transcriptase-polymerase chain reaction.
3327373|NCT00067015|Experimental|IMRT alone to 86.4 Gy|External radiotherapy is given for 10 weeks, Monday through Friday for a total of 48 sessions. The total dose of radiotherapy delivered during these 10 weeks is 86.4 Gy. The radiation treatments are delivered with a high precision technique called intensity modulated radiotherapy or IMRT. For this treatment, no hormonal therapy is required.
3327374|NCT00067015|Experimental|IMRT TO 75.6 Gy plus Adjuvant Androgen Deprivation|Prior to a planned course of radiotherapy, which will last for eight and a half weeks, 10 weeks of hormonal therapy are given. The hormonal therapy will start with a daily pill called Casodex. Three to seven days after starting this pill, a Zoladex injection will be administered in addition to the Casodex pill. Zoladex hormonal therapy is given in the form of a monthly injection. After 10 weeks from the initiation of hormone therapy, you will begin external radiotherapy. For these treatments only 42 treatment sessions are given. The total dose of radiotherapy delivered during these 8.5 weeks is 75.6 Gy. The hormone injections continue during the radiation treatments and for 2 years after the radiation treatments. The pills are only taken for the 10 weeks before and also during the radiation treatments, however afterwards the pills are discontinued.
3327375|NCT00067002|Experimental|Double Cord Blood Transplant Group|Two Unmanipulated Cord Blood units. Rituxan 375 mg/m2 by vein for patients with CD20 + malignancies. Melphalan 140 mg/m2 by vein on Day -8. Thiotepa 5 mg/Kg by vein on Day -7. Fludarabine 40 mg/m2 by vein on Days -6 to -3.
3327376|NCT00067002|Experimental|One Expanded Cord Blood Transplant Group|One Unmanipulated and One Expanded Cord Blood Unit. Fludarabine 40 mg/m2 by vein on Days -6 to -3. Cyclophosphamide 50 mg/kg by vein on Day -6. Mesna 10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg). Total body irradiation (TBI) given on Day -1 at 2 Gy.
3327377|NCT00002970|Experimental|Arm I|"GROUP 1: Patients receive a 1 hour infusion of compound 506U78 daily for 5 days in the absence of neurologic toxicity. The course repeats every 21 days. If a first relapse T-cell ALL study of higher priority is not open, then the patient may continue to receive the drug every 21 days for a maximum of 2 years provided that the patient has achieved a second complete response.~GROUPS 2 and 4: Patients receive compound 506U78 every 21 days for a maximum of 2 years, in the absence of disease progression. After 3 courses a patient may be given CNS prophylaxis with triple intrathecal therapy (TIT), consisting of methotrexate, cytarabine and hydrocortisone after consultation with study coordinator. TIT should be given every 12 weeks.~GROUP 3: Patients receive compound 506U78 every 21 days for a maximum of 2 years, in the absence of disease progression. TIT will be given on day 1 of weeks 1-4, 6, 9 and every 6 weeks for 12 weeks, and then every 9 weeks thereafter. This stratum is open."
3327378|NCT00002621|Experimental|Alpha interferon (aIFN) treatment|See detailed description.
3327379|NCT00002548|Active Comparator|HDCTX and PBSC|"High dose chemotherapy with peripheral blood stem cells~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Chemo: vincristine 1.2 mg/m2 IV D1, BCNU 20 mg/m2 IV D1, melphalan 8 mg/m2 PO D1-4, cyclophosphamide 400 mg/m2 IV D1, prednisone 40 mg/m2 PO D1-7"
3327380|NCT00002548|Experimental|HDCTX with PBSC and Autologous BMT|"High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant~High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Auto Trans: Mel 140mg/m2 IV D-5; TBI 150cGy D-4, -3, -2, -1; infusion D0"
3327381|NCT00002548|Experimental|HDCTX with PBSC and interferon|"High dose chemotherapy with peripheral blood stem cells and interferon~Experimental: HDCTX with PBSC and interferon High dose chemotherapy with peripheral blood stem cells and interferon~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Chemo: vincristine 1.2 mg/m2 IV D1, BCNU 20 mg/m2 IV D1, melphalan 8 mg/m2 PO D1-4, cyclophosphamide 400 mg/m2 IV D1, prednisone 40 mg/m2 PO D1-7~IFN: IFN 3 million units/m2 MWF SQ"
3327382|NCT00002548|Experimental|HDCTX with PBSC and transplant plus IFN|"High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant plus alpha interferon~Experimental: HDCTX with PBSC and transplant plus IFN High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant plus alpha interferon~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Trans: Mel 140mg/m2 IV D-5; TBI 150cGy D-4, -3, -2, -1; infusion D0~IFN: 3 million units/m2 MWF SQ"
3327383|NCT00002520|Experimental|Quit Smoking Intervention|Patients received advice and help to quit smoking. The intervention employed physician and patient resources that had already been developed and evaluated or pre-tested, including written materials, prescriptions for nicotine replacement, counseling, and follow-up contact.
3327384|NCT00002520|Active Comparator|Usual Care|"No special intervention after randomization. Usual care may or may not include advice or assistance to stop smoking. Physicians were reassured that usual care did not preclude quit smoking counseling."
3327385|NCT00066963|No Intervention|Counseling Only|Counseling Only
3327386|NCT00066963|Experimental|FV every 12mo for 24mo + Counsel|Preventive fluoride varnish every 12mo for 24mo plus Counseling
3327387|NCT00066963|Experimental|FV every 6mo for 24mo + Counseling|Preventive fluoride varnish every 6mo for 24mo plus Counseling
3327388|NCT00066950|No Intervention|Counseling Only|Oral Health Counseling Only
3327389|NCT00066950|Experimental|CHX+Counseling (caregiver) + FV (child)|Oral Health Counseling plus Chlorhexidine for caregiver plus fluoride varnish every 6 months from 12mo to 30mo of age for child
3327390|NCT00066937|Experimental|Nortriptyline Oral Capsule/CBT|Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of CBT.
3327391|NCT00066937|Experimental|Benztropine Oral Product/CBT|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of CBT.
3327392|NCT00066937|Experimental|Nortriptyline Oral Capsule/Disease MGT|Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of TMD disease management.
3327393|NCT00066937|Active Comparator|Benztropine Oral Product/Disease MGT|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of TMD disease management.
3327394|NCT00066859|Active Comparator|Arm 1: Sertraline (Zoloft) 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
3327395|NCT00066859|Active Comparator|Arm 2 - St. John's Wort 600mg|St. John's wort 600 mg daily for 1 week. If tolerated dose may be increased to 900 mg daily for four months.
3327396|NCT00066807|Experimental|OFS plus T or E|Ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.
3327397|NCT00066807|Experimental|Chemotherapy plus OFS plus T or E|Chemotherapy plus ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.
3327398|NCT00066781|Experimental|Cohort I (closed to accrual 11/17/05)|Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Irinotecan dose may be escalated or de-escalated after course 1 depending on toxicity. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3327399|NCT00066781|Experimental|Cohort II|Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3327400|NCT00066768|Experimental|Arm I|Patients receive low-dose suramin IV over 30 minutes and docetaxel IV over 1 hour on day 1.
3327401|NCT00066768|Experimental|Arm II|Patients receive low-dose suramin IV over 30 minutes and gemcitabine IV over 30 minutes on days 1 and 8.
3327402|NCT00066742|Experimental|Treatment (tirapazamine, cisplatin, etoposide)|"CHEMORADIOTHERAPY: Patients receive tirapazamine IV over 1 hour on days 1, 8, 10, 12, 29, 36, 38, and 40; cisplatin IV over 1 hour on days 1, 8, 29, and 36; and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning on day 1 of chemotherapy, patients undergo thoracic radiotherapy once daily 5 days a week for 7 weeks.~CONSOLIDATION CHEMOTHERAPY: Within 28 days after completion of radiotherapy, patients with stable or responding disease receive cisplatin IV over 1 hour on days 1 and 22 and etoposide IV over 1 hour on days 1-3 and 22-24.~Treatment continues in the absence of disease progression or unacceptable toxicity."
3329747|NCT00038298|Experimental|200 mg|200 mg 3 times weekly
3327403|NCT00066703|Active Comparator|T+OFS|Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.
3327404|NCT00066703|Experimental|E+OFS|Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.
3327405|NCT00066690|Active Comparator|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
3327406|NCT00066690|Experimental|T+OFS|Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
3327407|NCT00066690|Experimental|E+OFS|Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
3327408|NCT00066638|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a stable plateau (stable paraprotein levels or urine protein excretion over 3 consecutive determinations at least 4 weeks apart) may receive maintenance therapy comprising FR901228 IV on days 1 and 15, with courses repeating every 28 days.
3327409|NCT00066625|Experimental|Treatment (oxaliplatin, bortezomib)|"Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and bortezomib IV over 3-5 seconds on days 1, 4, 15, and 18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oxaliplatin and bortezomib until the MTDs are determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3327410|NCT00066612|Experimental|Treatment|Irinotecan
3327411|NCT00066586|Active Comparator|Exemestane|
3327412|NCT00066586|Placebo Comparator|Placebo|
3327413|NCT00066573|Experimental|Exemestane|Patients receive oral exemestane (25 mg) once daily for 5 years.
3327414|NCT00066573|Active Comparator|Anastrozole|Patients receive oral anastrozole (1 mg) once daily for 5 years.
3327415|NCT00066482|Experimental|combination chemotherapy|"Induction therapy: bleomycin sulfate IV over 10-20 minutes on day 1, etoposide IV over 1 hour and cisplatin IV over 4 hours on days 1-5, and cyclophosphamide IV over 1 hour on day 1. MESNA & Filgrastim (G-CSF) subcutaneously once daily beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. 6 patients receive escalating doses of cyclophosphamide until the maximum tolerated dose (MTD) is determined.~Evaluated after 4 courses of therapy. Partial response or stable disease undergo second-look conventional surgery & receive 2 more courses of induction therapy then re-evaluated. Those who do not achieve complete response (CR) after a total of 6 courses may undergo a third conventional surgery. Tumor that cannot be removed are removed from study therapy. Achievement of a CR at anytime are followed monthly for 1 year, every 6 months for 1 year, and then annually for 3 years."
3327416|NCT00066469|Experimental|Cyclophosphamide, prednisone, rituximab|Patients receive cyclophosphamide IV over 30-60 minutes on day 1 and oral prednisone or methylprednisolone IV twice daily on days 1-5. During courses 1 and 2 only, patients also receive rituximab IV over 2-5 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression, a new primary or secondary malignancy, or unrelated disease
3327417|NCT00066456|Experimental|Treatment (chemosensitization, radiation, docetaxel)|Patients receive docetaxel IV over 30 minutes once daily on days 1, 8, 15, 22, 29, and 35. Within 3 hours after beginning docetaxel, patients also receive low-dose abdominal radiotherapy twice daily (at least 4 hours apart) on days 1, 2, 8, 9, 15, 16, 22, 24, 29, 30, 35, and 36. Treatment continues in the absence of unacceptable toxicity.
3327418|NCT00066443|Experimental|Pegfilgrastim, docetaxel and epirubicin|
3327419|NCT00066430|Experimental|Infrared coagulator|
3327420|NCT00066378|Experimental|Arimidex + Iressa® 250 mg|Arimidex + Iressa® 250 mg Treatment should be administered until documented disease progression, unacceptable toxicity as judged by the responsible physician or patient refusal
3327421|NCT00066378|Active Comparator|Arimidex + Placebo|Treatment should be administered until documented disease progression, unacceptable toxicity as judged by the responsible physician or patient refusal
3327422|NCT00066365|Experimental|Group 1 (unilateral recurrence) - Sargramostim and thoractomy|Patients receive initial inhalation therapy inhaled sargramostim (GM-CSF) twice daily on days 1-7. Treatment repeats every other week every 14 days for a total of 2 courses. Patients undergo surgical procedure thoracotomy on day 22. Beginning on day 29, or as soon as possible thereafter, patients begin post-thoracotomy inhalation therapy for up to 12 additional courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.
3327423|NCT00066365|Experimental|Group 2 (bilateral recurrence) - Sargramostim and thoractomy|Patients may be enrolled on study either before or after the first thoracotomy procedure. For the first thoracotomy, patients undergo surgical procedure unilateral thoracotomy. Patients receive initial inhalation therapy inhaled GM-CSF, as soon as possible after recovery from first thoracotomy, twice daily on days 1-7. Treatment repeats every other week every 14 days for a total of 2 courses. Patients undergo surgical procedure contralateral thoracotomy on day 22. Beginning on day 29, or as soon as possible, patients begin post-thoracotomy inhalation therapy as above for up to 12 additional courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.
3327424|NCT00066248|Experimental|Subjects that respond to Periactin|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
3327924|NCT00058474|Active Comparator|Arm 1: 5-FU + RT|Patients receive fluorouracil IV continuously and undergo radiation therapy (RT) once daily 5 days a week for 5-6 weeks.
3327425|NCT00066248|Experimental|Non-responders to Periactin- Megace Arm|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
3327426|NCT00066222|Experimental|Radiation Therapy + Chemotherapy|Accelerated high dose thoracic radiation therapy (RT) with concurrent cisplatin/etoposide chemotherapy, followed by 2 cycles of adjuvant cisplatin/etoposide chemotherapy
3327427|NCT00066196|Other|2|Integrin + Dacarbazine
3327428|NCT00066196|Active Comparator|1|MEDI-522
3327429|NCT00066170|Experimental|Group 1.|Xyrem + Modafinil Placebo
3327430|NCT00066170|Placebo Comparator|Group 2:|Xyrem Placebo + Modafinil Placebo
3327431|NCT00066170|Active Comparator|Group 3|Xyrem Placebo + Modafinil at established dose
3327432|NCT00066170|Experimental|Group 4:|Xyrem + Modafinil at established dose
3327433|NCT00033306|Experimental|BMS-247550|
3327434|NCT00066157|Experimental|1|estradiol patch and medroxyprogesterone
3327435|NCT00066157|Active Comparator|2|estradiol patch and placebo pill
3327436|NCT00066157|Active Comparator|3|placebo patch and medroxyprogesterone
3327437|NCT00066157|Placebo Comparator|4|placebo patch and placebo pill
3327438|NCT00066131|Active Comparator|Scaling and root planing|Scaling and root planing delivered prior to 21 weeks of gestation.
3327439|NCT00066131|No Intervention|Placebo|Delayed treatment group. Controls monitored clinically from baseline to 29-32 weeks of gestation. Scaling and root planing provided after delivery.
3327440|NCT00066092|Experimental|Pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
3327441|NCT00066092|Experimental|Pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
3327442|NCT00066092|Active Comparator|filgrastim|Filgrastim given daily for PBPC mobilization
3327443|NCT00066066|Placebo Comparator|Scaling and root planing alone|Full mouth scaling and root planing (SRP) alone plus a placebo pill taken twice daily for 2 weeks.
3327444|NCT00066066|Active Comparator|SRP + Metronidazole|Full mouth Scaling and Root Planing plus Metronidazole (MET) 250 mg tid x 14 days
3327445|NCT00066066|Active Comparator|SRP + MET + Amoxicillin + Doxycycline|Full mouth Scaling and Root Planing plus Metronidazole (MET) 250 mg tid x 14 d and Amoxicillin (AMOX) 500 mg tid for 14 days and local drug delivery of Doxycycline (TET LDD) in pockets >4mm
3327446|NCT00066053|Experimental|Periodontal Treatment: SRP|Comprehensive scaling & root planing and subgingival tissue removal; fluorides applied as appropriate; oral hygiene instructions.
3327447|NCT00066053|Active Comparator|Community Comparator|Referral to community dentist with copy of x-rays and letter with diagnosis and recomendations for treatment.
3327448|NCT00066027|Experimental|low-dose doxycycline|low-dose doxycycline (20 mg doxycycline hyclate)
3327449|NCT00066027|Placebo Comparator|Placebo|Placebo
3327450|NCT00066014|Active Comparator|treatment modalities changed for comparison|All subjects experienced all treatment modalities being studied.
3327451|NCT00066001|Placebo Comparator|1, 2, 3, 4|The 4 arms of the study are based on the treatment groups: 1. scaling and root planing alone (SRP); 2. SRP plus repeated professional supragingival plaque removal; 3. SRP + systemically administered metronidazole; 4. SRP + repeated professional supragingival plaque removal + systemically administered metronidazole.
3327452|NCT00065845|No Intervention|Abdominal Sacral Colpopexy with no Burch colposuspension|Abdominal sacral colpopexy is performed through a laparotomy approach.
3327453|NCT00065845|Experimental|Abdominal Sacral Colpopexy with Burch Colposuspension|The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
3327454|NCT00031707|Active Comparator|megestrol + placebo|"Patients receive oral megestrol once daily and oral placebo twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
3327455|NCT00031707|Active Comparator|eicosapentaenoic acid + placebo|"Patients receive oral placebo once daily and an eicosapentaenoic acid (EPA)-enriched nutritional supplement twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
3327456|NCT00031707|Experimental|megestrol + eicosapentaenoic acid|"Patients receive oral megestrol once daily and an EPA-enriched nutritional supplement twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
3327457|NCT00024024|Experimental|Arm I|Patients receive oral BMS-275291 1-2 times daily. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 6 patients receive escalating doses of BMS-275291 until the recommended phase II dose (RPTD) is determined. The RPTD is the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity and more than 1 of 6 patients experiences clinical response or at least 5 of 6 patients demonstrate biologic activity. An additional 29 patients are treated at the RPTD.
3327458|NCT00022477|Experimental|BMS-247550|IV administration of BMS-247550 once every 21 days
3327459|NCT00065806|Experimental|1|Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes [TLC] diet, [http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi]), cardiovascular risk factor reduction counseling, hydroxychloroquine, low-dose aspirin, a multivitamin containing folate, plus atorvastatin at 10 mg or 20 mg depending on the patient's weight. Patients weighing more than 50 kg will receive 10 mg qd atorvastatin for the first month, which will be increased to 20 mg qd at the Day 30 visit and continue through month 36. Participants weighing less than 50kg will receive a maximum of 10 mg po qd for 36 months.
3327508|NCT00003895|Experimental|gp100:209-217(210M) + HPV 16 E7:12-20 (every 3 weeks)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 3 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory biomarker analysis.
3327460|NCT00065806|Placebo Comparator|2|Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes [TLC] diet, [http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi]), cardiovascular risk factor reduction counseling, hydroxychloroquine, low-dose aspirin, a multivitamin containing folate, plus placebo at 10 mg or 20 mg depending on the patient's weight. Patients weighing more than 50 kg will receive 10 mg qd placebo for the first month, which will be increased to 20 mg qd at the Day 30 visit and continue through month 36. Participants weighing less than 50kg will receive a maximum of 10 mg po qd for 36 months.
3327461|NCT00065728|Experimental|Anecortave Acetate, 15 mg|One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
3327462|NCT00065715|No Intervention|A|No pills
3327463|NCT00065715|Placebo Comparator|B|Blinded placebo
3327464|NCT00065715|Experimental|C|Echinacea - Blinded
3327465|NCT00065715|Experimental|D|Echinacea - Unblinded, Open Label
3327466|NCT00065585|No Intervention|Usual care|
3327467|NCT00065585|Placebo Comparator|non needle control|
3327468|NCT00065585|Sham Comparator|Acupuncture - Standardized Points|
3327469|NCT00065585|Experimental|Accupunture - Experimental Points|
3327470|NCT00065546|Active Comparator|1|Post-menopausal women randomized to receive estrogen replacement therapy.
3327471|NCT00065546|Placebo Comparator|2|Post-menopausal women randomized to receive a placebo.
3327472|NCT00065546|Experimental|3|Pre-menopausal women with specific genetic variants.
3327473|NCT00065637|Experimental|1|Women will self-administer PTH injections daily for 4 weeks, then once weekly for 48 weeks
3327474|NCT00065637|Placebo Comparator|2|Women will self-administer placebo injections daily for 4 weeks, then once weekly for 48 weeks
3327475|NCT00014560|Experimental|Single arm|Antibody
3327476|NCT00065507|Experimental|A1|
3327477|NCT00065507|Active Comparator|A2|
3327478|NCT00006486|Experimental|Arm I (carboxyaminoimidazole)|"Patients receive oral CAI daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.~Patients receive oral CAI as above."
3327479|NCT00006486|Experimental|Arm II (carboxyamidotriazole, placebo)|"Patients receive oral CAI daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.~Patients receive a placebo."
3327480|NCT00065468|Active Comparator|A|
3327481|NCT00065468|Experimental|B|
3327482|NCT00065468|Experimental|C|
3327483|NCT00006229|Experimental|BMS-275291|
3327484|NCT00006229|Placebo Comparator|Placebo|
3327485|NCT00006081|Experimental|Bryostatin-1 + Taxol|
3327486|NCT00065442|Placebo Comparator|APC-Placebo|
3327487|NCT00065442|Active Comparator|Sipuleucel-T|
3327488|NCT00065429|Experimental|BB-10901, 5mg/m2 - Phase I|
3327489|NCT00065429|Experimental|BB-10901, 10 mg/m2 - Phase I|
3327490|NCT00065429|Experimental|BB-10901, 20 mg/m2 - Phase I|
3327491|NCT00065429|Experimental|BB-10901, 40 mg/m2 - Phase I|
3327492|NCT00065429|Experimental|BB-10901, 60 mg/m2 - Phase I & Phase II|Phase I and Phase II were consecutive and sequential. Different patients received the 60mg/m2 dose in Phase I and in Phase II.
3327493|NCT00065429|Experimental|BB-10901, 67.5 mg/m2 - Phase I|
3327494|NCT00065429|Experimental|BB-10901, 75 mg/m2 - Phase I|
3327495|NCT00005604|Experimental|Treatment (rhIl-12, IL-2)|Patients receive interleukin-12 (IL-12) IV on days 1 and 4 for 6 weeks. Beginning on day 4 of the third week, patients receive interleukin-2 (IL-2) subcutaneously 1 hour before and 20 hours after each dose of IL-12. On subsequent courses, IL-2 and IL-12 are administered on days 1 and 4 of each week. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease response may continue treatment until complete response or disease progression.
3327496|NCT00065351|Experimental|1|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
3327497|NCT00065325|Active Comparator|1|Exemestane
3327498|NCT00065325|Experimental|2|Fulvestrant
3327499|NCT00065208|Experimental|Reiki|Energy therapy
3327500|NCT00065208|Sham Comparator|Pretend Reiki|
3327501|NCT00065208|Other|Rest / Guided Imagery|Rest for pre-surgery outcomes Guided Imagery for post-surgery outcomes
3327502|NCT00065260|Experimental|r-ATG /cyclosporine|A randomized trial of rabbit anti-thymocyte globulin (r-ATG)/ cyclosporine (CsA) versus Campath-1H in aplastic anemia patients with refractory pancytopenia or suboptimal hematological response after horse ATG treatment. Subjects who receive rabbit ATG/ CsA will be given rabbit ATG 3.5mg/kg/day for 5 days and CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs. Subjects who receive Campath-1H will receive an intravenous infusion for 10 days. Adult subjects will receive 10mg/day (children:0.2mg/kg/day).
3327503|NCT00065260|Experimental|Alemtuzumab (Campath-1H)|A randomized trial of rabbit anti-thymocyte globulin (ATG)/ cyclosporine (CsA) versus Campath-1H in aplastic anemia patients with refractory pancytopenia or suboptimal hematological response after horse ATG treatment. Subjects who receive rabbit ATG/ CsA will be given rabbit ATG 3.5mg/kg/day for 5 days and CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs. Subjects who receive Campath-1H will receive an intravenous infusion for 10 days. Adult subjects will receive 10mg/day (children:0.2mg/kg/day).
3327504|NCT00065156|Experimental|Lenalidomide|
3327505|NCT00065065|Experimental|Rosiglitazone|4 mg of rosiglitazone taken twice daily for 12 weeks.
3327506|NCT00065065|Placebo Comparator|placebo|Identical in appearance to study drug taken twice daily for 12 weeks.
3327507|NCT00003895|Experimental|gp100:209-217(210M) + HPV 16 E7:12-20 (every 2 weeks)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 2 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory biomarker analysis.
3327770|NCT00005977|Experimental|B-ALL, -CNS (Trt 2)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABAB"
3327509|NCT00064987|Experimental|Group 1 (FSH)|Patients in Group 1 will receive subcutaneous follicle stimulating hormone (FSH) injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.
3327510|NCT00064987|Active Comparator|Group 2 (GnRH)|Patients in Group 2 will receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.
3327511|NCT00064974|Experimental|CC-5013|CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles)
3327512|NCT00064844|Placebo Comparator|Nicotine patch plus placebo gum|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy. Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
3327513|NCT00064844|Active Comparator|Nicotine patch plus active gum|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy. Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.
3327514|NCT00064753|Experimental|High Dose Multivitamin|Multivitamin with increased folic acid, vitamin B6 and vitamin B12
3327515|NCT00064753|Active Comparator|Low Dose Multivitamin|Multivitamin devoid of folic acid and with estimated average requirement amounts of vitamin B6 and vitamin B12
3327516|NCT00003645|Experimental|Arm I - Leuprolide + Flutamide|Arm I: Patients receive leuprolide intramuscularly once every 3 months and oral flutamide three times daily for 1 year.
3327517|NCT00003645|No Intervention|Arm II - No Treatment|Arm II: Patients receive no initial treatment.
3327518|NCT00003571||Samples of tumor and normal tissue|Samples of tumor and normal tissue are obtained from CALGB 8896 patients. The samples are tested for somatic mutations and tumor replication error (RER) tumor status. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
3327519|NCT00064792|Placebo Comparator|OraPlus|
3327520|NCT00064792|Active Comparator|Simvastatin Susp|
3327521|NCT00064701|Experimental|Tacrolimus|Participants received a first dose of tacrolimus between 0.075 and 0.10 mg/kg twice daily, orally prior to or within 48 hours of the completion of the transplant procedure, and subsequently as twice daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
3327522|NCT00064701|Active Comparator|Tacrolimus Modified Release|Participants received a first dose of tacrolimus modified release between 0.15 and 0.20 mg/kg/day, given as a single oral dose in the morning, prior to or within 48 hours following the completion of the transplant procedure, and subsequently as once daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
3327523|NCT00064701|Active Comparator|Cyclosporine|Participants received a first dose of cyclosporine between 4 to 5 mg/kg orally prior to or within 48 hours following the completion of the transplant procedure and subsequently as twice daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
3327524|NCT00064714|Experimental|Group 1|Group 1 will receive immunosuppression and AC2993; then immunosuppression only
3327525|NCT00064714|Experimental|Group 2|Group 2 will receive AC2993 only; then neither immunosuppression nor AC2993
3327526|NCT00064714|Experimental|Group 3|Group 3 will receive immunosuppression and AC2993; then immunosuppression and AC2993
3327527|NCT00064714|Experimental|Group 4|Group 4 will receive AC2993 only; then AC2993 only
3327528|NCT00064662|Other|Burch|The Burch colposuspension
3327529|NCT00064662|Other|Sling|Pubovaginal sling, using autologous rectus fascia
3327530|NCT00064649|Active Comparator|2|Transurethral Needle Ablation (TUNA)
3327531|NCT00064649|Active Comparator|3|finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
3327532|NCT00064649|Active Comparator|1|Transurethral Microwave Thermotherapy (TUMT)
3327533|NCT00003350|Experimental|Arm I (paclitaxel)|"Patients receive paclitaxel over 3 hours by intravenous infusion. Treatment course repeats every 2 weeks. Patients are evaluated every third course.~Patients in both arms continue treatment if there is no disease progression or unacceptable toxicity. Patients with complete response continue on study treatment for 2 courses beyond documented complete response.~Quality of life is assessed before, during, and after treatment."
3327534|NCT00003350|Experimental|Arm II (pegylated liposomal doxorubicin hydrochloride)|"Patients receive doxorubicin HCL liposome over 30-60 minutes by intravenous infusion. Treatment course is repeated every 3 weeks. Patients are evaluated before every odd course.~Patients in both arms continue treatment if there is no disease progression or unacceptable toxicity. Patients with complete response continue on study treatment for 2 courses beyond documented complete response.~Quality of life is assessed before, during, and after treatment."
3327535|NCT00003045|Experimental|Hyperthermia|XRT and Hyperthermia Post-therapy evaluation PSA, Clinical Exam, and Prostate Biopsy ( @ 12 Months)
3327536|NCT00002965|Experimental|Arm 1: Benign Meningiomas|INF alpha as a subcutaneous injection Monday to Friday for 8 weeks.
3327537|NCT00002965|Experimental|Arm 2: Other Pathologies|INF alpha as subcutaneous injection Monday to Friday for 8 weeks.
3327651|NCT00025376|Experimental|PS-341 administration followed by biopsy|3 cycles of PS-341 given by IV infusion. Each cycle will last 3 weeks. PS-341 will be given 2 times a week for 2 weeks followed by a 'rest' week with no drug. After the 3rd cycle, subjects will have a tumor biopsy and can continue to receive another 3 cycles of the study drug if their disease has not worsened.
3327810|NCT00060450|Experimental|1|Inhaled Nitric Oxide
3327538|NCT00064519||Families with MI|"In conjunction with collaborators in Germany, we have established one of the largest collections of families with MI, comprising 1,406 individuals in 513 Western-European families. Based on this collection, our total genome scan and linkage analysis has identified a region on chromosome 14 with a significant linkage signal for myocardial infarction (LOD = 3.9, pointwise P = 0.00015, genome-wide P < 0.05)5. Preliminary results from an association study in a subset of these families has identified a small set of single nucleotide polymorphisms (SNPs) within candidate genes in this region as being suggestively associated with MI.~No drugs are to be administre"
3327539|NCT00064415|Experimental|1|Arformoterol tartrate 50 mcg QD
3327540|NCT00064415|Active Comparator|2|Salmeterol 42 mcg BID
3327541|NCT00064402|Experimental|1|Arformoterol 50 mcg QD and placebo MDI
3327542|NCT00064402|Experimental|2|Arformoterol 25 mcg BID and Placebo MDI
3327543|NCT00064402|Experimental|3|Arformoterol 15 mcg BID and placebo MDI
3327544|NCT00064402|Active Comparator|4|Salmeterol MDI 42 mcg BID and placebo inhalation solution
3327545|NCT00064402|Placebo Comparator|5|Placebo MDI and placebo inhalation solution
3327546|NCT00064389|Experimental|1|levalbuterol 90 mcg MDI QID
3327547|NCT00064389|Active Comparator|2|racemic albuterol HFA MDI 180 mcg QID
3327548|NCT00064350|Experimental|Induction then Sorafenib|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression.~Randomization: Patients with stable disease after the induction treatment were randomized to either the sorafenib arm or the placebo arm. Patients on the sorafenib arm receive sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable disease."
3327549|NCT00064350|Placebo Comparator|Induction then Placebo then Sorafenib|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression.~Randomization: Patients with stable disease after the induction treatment were randomized to either the sorafenib arm or the placebo arm. Patients on the placebo arm receive oral placebo twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients on the placebo arm who develop disease progression within 1 year after randomization may cross over to sorafenib arm."
3327550|NCT00064350|Other|Induction, not randomized|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity.~Post-induction: Patients with responding disease or disease progression were not randomized in Step 2. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression, while patients with disease progression were removed from the study."
3327551|NCT00064337|Experimental|Treatment|"MM Induction: dexamethasone 20mg/d PO Days 1-4, 9-12 and 17-20 every 35 days for 2 cycles and thalidomide 200 mg/d PO Days 1-70.~Mobilization and SC Collection:~MM, MM+AL, MM+LCD: cyclophosphamide 2.5 gm/m2 IV Day 1; mesna 800 mg/m2 IV Day 1 x 3 doses; G-CSF 10 mcg/kg/d SQ Day 2 through day prior to last leukapheresis.~Amyloid or LCDD-Only: G-CSF 16 mcg/kg/d SQ Days 1-3 (continued daily until the day prior to the last day of stem cell collection).~Conditioning/Transplant - Modified HighDose Melphalan (given for both transplants): melphalan 100 mg/m2/d IV over 20 mins Day -2; PBSC infusion >/= 3.5 x 10^6 CD34+ cells/kg IV Day 0.~Maintenance (MM only): dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year, followed by dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year."
3327552|NCT00064324|Experimental|Arm I|Patients receive a loading dose of oral perifosine every 6 hours for a total of 4 doses on day 1 and once daily on days 2-28 of course 1 only. For all subsequent courses, patients receive oral perifosine once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3327553|NCT00064298|Experimental|Arm I - JuicePlus|Patients receive oral fruit and vegetable extracts twice daily.
3327554|NCT00064298|Placebo Comparator|Arm II - Control|Patients receive oral placebo twice daily.
3327555|NCT00064272|Experimental|Arm I|Patients receive lower-dose oral ginger twice daily.
3327556|NCT00064272|Experimental|Arm II|Patients receive higher-dose oral ginger twice daily.
3327557|NCT00064272|Placebo Comparator|Arm III|Patients receive oral placebo twice daily.
3327558|NCT00064259|Experimental|Treatment (oblimersen sodium)|"Phase I: Patients receive oblimersen IV continuously on days 1-7, fluorouracil IV continuously on days 4-8, and cisplatin IV on day 4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 12 patients are treated at the MTD.~Phase II: Patients receive treatment as in phase I with oblimersen at the MTD."
3327559|NCT00064246|Experimental|Treatment (rituximab, yttrium Y 90 ibritumomab tiuxetan)|"Phase I: Patients receive rituximab IV and indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo 2 (or 3 if needed) imaging scans between days 1-6. In the absence of altered biodistribution, patients receive rituximab IV followed within 4 hours by IDEC-Y2B8 IV over 10 minutes on day 8.~Phase II: Patients receive treatment as in phase I at the MTD of IDEC-Y2B8. Patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 2 years."
3327560|NCT00064142|Experimental|Arm I (halofuginone hydrobromide)|Patients apply topical halofuginone hydrobromide ointment to each of 6 lesions twice a day for 12 weeks.
3327561|NCT00064142|Placebo Comparator|Arm II (placebo)|Patients apply topical placebo ointment to each of 6 lesions twice a day for 12 weeks.
3327652|NCT00022529|Experimental|Treatment (BMS-214662, trastuzumab)|Patients receive BMS-214662 IV over 1 hour on days 2, 8, 15, and 22 and trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3327653|NCT00062764|Experimental|Pioglitazone|
3327654|NCT00062751|Experimental|A|
3327655|NCT00062751|Experimental|B|
3327656|NCT00062751|Active Comparator|C|
3327657|NCT00062738|Experimental|nortriptyline|drug
3328026|NCT00057044|Other|Arm 1|
3327562|NCT00064129|Experimental|Treatment (monoclonal antibody, colony-stimulating factors)|Patients receive ipilimumab IV over 90 minutes on day 1 and sargramostim (GM-CSF) SC on days 1-14. Treatment repeats every 28 days for 4-6 courses. GM-CSF continues beyond 4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of ipilimumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Some patients undergo blood sample collection periodically for laboratory and pharmacokinetic studies. Samples are analyzed for human anti-human antibodies, IgG antibodies to ipilimumab semi-quantitative ELISA assay, and plasma concentrations of ipilimumab via quantitative ELISA assay.
3327563|NCT00064116|Active Comparator|Arm A: CHOP-21|Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle: day 22 Total number of cycles 6
3327564|NCT00064116|Active Comparator|Arm B: CHOP-21 + Rituximab|Rituximab 375 mg/m² i.v. day 1* Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
3327565|NCT00064103|Experimental|Treatment (Ad5CMV-p53 gene)|"Phase I: Patients receive Ad5CMV-p53 gene by intramucosal injection into the area of the lesion followed at least 2 hours later by Ad5CMV-p53 gene as an oral rinse on day 1. Patients then receive Ad5CMV-p53 gene as an oral rinse twice daily on days 2-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of Ad5CMV-p53 gene as an oral rinse until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Phase II: Patients receive treatment with intramucosal Ad5CMV-p53 gene as in phase I and Ad5CMV-p53 gene as an oral rinse at the MTD."
3327566|NCT00064077|Experimental|Arm I (paclitaxel, cisplatin)|Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.
3327567|NCT00064077|Experimental|Arm II (vinorelbine, cisplatin)|Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.
3327568|NCT00064077|Experimental|Arm III (gemcitabine, cisplatin)|Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.
3327569|NCT00064077|Experimental|Arm IV (topotecan, cisplatin)|Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.
3327570|NCT00064038|Experimental|Arm I|Patients receive induction therapy comprising oral dexamethasone (DM) on days 1-4, 9-12, and 17-20 and oral lenalidomide on days 1-28. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising oral DM on days 1-4 and 15-18 and oral lenalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3327571|NCT00064038|Active Comparator|Arm II|Patients receive induction therapy comprising DM as in arm I induction and oral placebo on days 1-28. Treatment repeats as in arm I induction. Some patients may then receive maintenance therapy comprising oral DM as in arm I maintenance and oral placebo on days 1-21. Courses repeat as in arm I maintenance.
3327572|NCT00064025|Experimental|Treatment (medroxyprogesterone)|"Patients receive medroxyprogesterone intramuscularly once approximately 3 weeks before surgical hysterectomy.~A subset of 15 patients has tissue collected by pipelle biopsy or curettage at baseline, 72 hours after medroxyprogesterone therapy, and during surgery for gene expression arrays."
3327573|NCT00064012|Active Comparator|Velcade Alone|Velcade
3327574|NCT00064012|Experimental|Velcade plus Docetaxel|Velcade plus Docetaxel
3327575|NCT00063999|Active Comparator|Arm I (doxorubicin hydrochloride, cisplatin, paclitaxel)|Patients receive doxorubicin hydrochloride IV over approximately 15-30 minutes on day 1, cisplatin IV over 60-90 minutes on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
3327576|NCT00063999|Experimental|Arm II (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
3327577|NCT00063986|Experimental|Minimally invasive esophagectomy (MIE)|Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
3327578|NCT00063973|Experimental|Treatment (cilengitide)|"Patients receive cilengitide (EMD 121974) IV over 1 hour twice weekly. Treatment repeats every 4 weeks for 13 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of cilengitide until the MTD is determined. The MTD is defined as the dose at which 25% of patients are expected to experience dose-limiting toxicity. Once the MTD is determined, 6 additional patients are accrued and treated at that dose level for a total of 12 patients at the MTD."
3327579|NCT00063960|Experimental|floxuridine + irinotecan|"Within 4-8 weeks after prior resection or ablation, patients receive hepatic arterial infusion of floxuridine continuously on days 1-14 and irinotecan IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of unacceptable toxicity.~Patients are followed every 3 months for 2 years."
3327580|NCT00063947|Experimental|Treatment (radiotherapy, gemcitabine, erlotinib hydrochloride)|Chemoradiotherapy: Patients undergo radiotherapy 5 days a week for 5.5 weeks. Beginning on day 1 and continuing concurrently with radiotherapy, patients receive gemcitabine IV over 30 minutes twice weekly and oral erlotinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease proceed to maintenance therapy. Maintenance therapy: Beginning 4-7 weeks after the completion of chemoradiotherapy, patients receive maintenance chemotherapy comprising gemcitabine IV over 30 minutes on days 1 and 8 and oral erlotinib once daily. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
3327658|NCT00062738|Experimental|paroxetine|drug
3327659|NCT00062738|Placebo Comparator|placebo|placebo
3327660|NCT00062647|Experimental|Telavancin|
3327661|NCT00062647|Active Comparator|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram/12 hours or nafcillin, oxacillin, or cloxacillin 2 Gram/6 hours (IV) intravenously
3327662|NCT00062569|Experimental|1|
3327663|NCT00062569|Experimental|2|
3328027|NCT00057005|Experimental|1|
3327581|NCT00063934|Experimental|Treatment (oblimersen, doxorubicin, docetaxel)|"PHASE I (COMPLETED AS OF 8/16/04): Patients receive oblimersen IV continuously on days 1-6 interrupted only to administer doxorubicin IV over 15 minutes and docetaxel IV over 60 minutes on day 6. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 7-13 or pegfilgrastim SC on day 7. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~PHASE II: Patients receive doxorubicin, docetaxel, G-CSF or pegfilgrastim, and oblimersen at the MTD as in phase I.~Patients with resectable tumors after 6 courses undergo surgical resection."
3327582|NCT00063895|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3327583|NCT00063882|Experimental|Arm I|Patients undergo external beam radiotherapy 5 days a week for 5 weeks. Within 2-4 weeks of radiotherapy, patients undergo interstitial brachytherapy with iodine I 125 or palladium Pd 103 seeds.
3327584|NCT00063882|Active Comparator|Arm II|Patients undergo interstitial brachytherapy only, as in arm I.
3327585|NCT00005940|Experimental|Treatment (radiolabeled BC8, chemotherapy, PBSCT)|"RADIOLABELED ANTIBODY: Patients receive iodine I 131 monoclonal antibody BC8 IV on day -13.~CHEMOTHERAPY: Patients receive busulfan PO every 6 hours on days -7 to -4 and cyclophosphamide IV on days -3 and -2.~TRANSPLANT: Patients undergo allogeneic PBSC or BM transplant on day 0.~GRAFT-VS-HOST DISEASE PREVENTION: Patients receive cyclosporine IV or PO every 12 hours on days -1 to 50 with a taper to day 180. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
3327586|NCT00003211|Experimental|Average-risk|"Participants meeting the eligibility requirements for assignment to the average-risk arm.~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy."
3327587|NCT00003211|Experimental|High-risk|"Participants meeting the eligibility requirements for assignment to the high-risk arm.~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy."
3327588|NCT00063817|Experimental|Conditioning Regimen|"Cyclophosphamide intravenously (IV) on days -5 and -4 with respect to transplantation; MEDI-507 on days -1, 0, and 1 (after a test dose of 0.1 mg per kg on day -2); and cyclosporine A IV and thymic irradiation on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered daily postoperatively, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months.~Amendment applicable to the 4th and 5th participant: rituximab on days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days."
3327589|NCT00063804|Experimental|1|escalating single doses of AMD070 ranging from 1/4 to 1 times the maximum tolerated dose (MTD)
3327590|NCT00063804|Experimental|2|single dose of 200 mg AMD070 after eating a standardized meal
3327591|NCT00063804|Experimental|3|single dose of 200 mg AMD070 on Days 1, 3, and 17 and single dose of 100 mg ritonavir on Days 3 through 18
3327592|NCT00063778|Experimental|1 x 10^4 IU dose|Vaccine dose of 1 x 10^4 IU per injection
3327593|NCT00063778|Experimental|1 x 10^5 IU dose|Vaccine dose of 1 x 10^5 IU per injection
3327594|NCT00063778|Placebo Comparator|Placebo|
3327595|NCT00063635|Active Comparator|1|Metformin, 500 mg, twice daily
3327596|NCT00063635|Active Comparator|2|Vitamin E, 400 IU, twice daily
3327597|NCT00063635|Placebo Comparator|3|Matching placebo
3327598|NCT00063622|Active Comparator|1|Pioglitazone
3327599|NCT00063622|Active Comparator|2|Vitamin E
3327600|NCT00063622|Placebo Comparator|3|Placebo Pioglitazone or Placebo Vitamin E
3327601|NCT00063583|Placebo Comparator|Placebo|Placebo
3327602|NCT00063583|Experimental|Pirfenidone 1200 mg/day|Pirfenidone will be administered at a dose of 1200 mg/day
3327603|NCT00063583|Experimental|Pirfenidone 2400 mg/day|Pirfenidone will be administered at 2400 mg/day
3327604|NCT00063570|Experimental|A|
3327605|NCT00063570|Experimental|B|
3327606|NCT00063531||GeneSTAR participant meeting entry criteria|Healthy siblings of patients with early onset CAD (<60 years old) and the adult offspring of the siblings or probands
3327607|NCT00063323|Active Comparator|Bupropion|Bupropion (brand name Zyban Sustained Release). Participants used bupropion SR 150 mg twice daily during the 16-week maintenance treatment.
3327608|NCT00063323|Active Comparator|Nicotine gum|Nicotine gum (brand name Nicorette) During the maintenance 16-week maintenance treatment phase, participants assigned to this arm received 2 mg. nicotine gum.
3327609|NCT00063323|Active Comparator|Bupropion+Nicotine Gum|Combined active treatments: Bupropion (Zyban SR) and nicotine gum (Nicorette). Participants were instructed to use the 150 mg bupropion pill twice daily and the 2 mg. gum as needed during the 16-week maintenance treatment phase.
3327610|NCT00063323|Placebo Comparator|Double placebo|Placebo gum + placebo pill. Identical placebo pill was used twice daily and identical placebo gum was used as needed.
3327611|NCT00031889|Active Comparator|Arm I|Patients receive oral exemestane once daily
3327612|NCT00031889|Active Comparator|Arm II|Patients receive exemestane as in arm I and oral bicalutamide once daily
3327613|NCT00063453|Experimental|Vitamin E and selenium placebo|Vitamin E alone
3327614|NCT00063453|Experimental|Selenium and vitamin E placebo|Selenium alone
3327615|NCT00063453|Experimental|Vitamin E and selenium|Vitamin E and selenium combined
3327616|NCT00063453|Placebo Comparator|vitamin E Placebo and Selenium placebo|Double placebo
3327664|NCT00062543|Experimental|Hepatic Artery Infusion|Donor-derived CD34+ cells administered in a total volume of 100ml via hepatic artery over 10 minutes. Cells given as a dose escalation study. First cohort of 3 patients receive 1 * 106 CD34+ cells/kg. Next 3 patients receive 2.5 * 106 CD34+cells/kg. Next 3 patients receive 5 * 106 CD34+ cells/kg. Less than 1 * 105 T cells/kg administered.
3327665|NCT00062530|Experimental|1|All participants will receive oral vaccine at study entry, although dosage will vary
3327666|NCT00062504|Experimental|1|Valproic: 10mg TID week 1, 25mg TID week 2, 35mg week 3
3327617|NCT00028925|Experimental|Regimen A|"Patients receive oral topotecan once daily on days 1-5, carboplatin IV over 30 minutes on day 5, and filgrastim (G-CSF) subcutaneously once daily beginning on day 6 or 7 and continuing for up to 10 days or until blood counts recover.~Treatment for all patients repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression limited to CNS only interrupt chemotherapy to have whole-brain radiotherapy (WBRT). Once WBRT is complete, chemotherapy resumes.~Quality of life is assessed at baseline and at the beginning of each course of chemotherapy.~Patients are followed every 3 months for 2 years and then every 6 months for 3 years."
3327618|NCT00028925|Experimental|Regimen B|"Patients receive topotecan and carboplatin as in regimen A. Patients are evaluated after the first 3-week course of chemotherapy. If no patient experiences unacceptable toxicity or febrile neutropenia, the next 33 patients receive treatment as in regimen B; otherwise, patients receive treatment as in regimen A.~Treatment for all patients repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression limited to CNS only interrupt chemotherapy to have whole-brain radiotherapy (WBRT). Once WBRT is complete, chemotherapy resumes.~Quality of life is assessed at baseline and at the beginning of each course of chemotherapy.~Patients are followed every 3 months for 2 years and then every 6 months for 3 years."
3327619|NCT00063401|Experimental|1|Cetuximab 400 mg/m2 IV (over 120 minutes) on Day 1 of Cycle 1, followed by weekly maintenance doses of 250 mg/m2 IV (over 60 minutes). Paclitaxel 175 mg/m2 IC (over 3 hours) and carboplatin AUC of 6 IV (over 30 minutes) on Day 1 of each cycle. For eligible subjects, maintenance therapy will consist of cetuximab 250 mg/m2/week for up to 6 months.
3327620|NCT00063388|Experimental|1|Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
3327621|NCT00063362|Experimental|Lithium + divalproex + lamotrigine|
3327622|NCT00063362|Placebo Comparator|Lithium + divalproex + placebo|
3327623|NCT00063336|Experimental|1|Participants will receive cognitive remediation treatment.
3327624|NCT00063336|Experimental|2|Participants will receive computer-skills training.
3327625|NCT00063258|Active Comparator|Chemotherapy + Tarceva|
3327626|NCT00063258|Active Comparator|Chemotherapy Alone|
3327627|NCT00063154|Experimental|Pertuzumab|Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). Subjects received pertuzumab at a loading dose of 840 mg in Cycle 1 followed by a dose of 420 mg in Cycles 2 and beyond.
3327628|NCT00063141|Experimental|Arm A|
3327629|NCT00063141|Active Comparator|Arm B|
3327630|NCT00063128|Experimental|A|
3327631|NCT00063128|Active Comparator|B|
3327632|NCT00030797|Active Comparator|Arm A|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;
3327633|NCT00030797|Active Comparator|Arm B|Irinotecan i.v. 240 mg/m2 day 1 and day 22; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;
3327634|NCT00026364|Experimental|Arm I|"Patients receive oral ZD 1839 daily. Beginning on day 15, patients receive irinotecan IV over 90 minutes, leucovorin calcium IV over 15 minutes, and fluorouracil IV weekly on weeks 1-2. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of ZD 1839 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are accrued to receive treatment at the MTD."
3327635|NCT00063089|Experimental|altastaph|S. aureus Immune Globulin Intravenous (Human) 5%
3327636|NCT00063089|Placebo Comparator|Placebo|0.45% Normal Saline
3327637|NCT00063076|Experimental|Targretin®|Targretin® (bexarotene) Gel 1%, treat half head
3327638|NCT00063076|No Intervention|Control|Half head untreated as control
3327639|NCT00023933|Experimental|Treatment (monoclonal antibody)|"Patients receive a tracer dose of iodine I 131 monoclonal antibody CC49-deltaCH2 IV on day 1 and a therapy dose over 30 minutes on day 8.~Cohorts of 3-5 patients receive escalating doses of iodine I 131 monoclonal antibody CC49-deltaCH2 until the MTD is determined. The MTD is defined as the dose at which 3 of 5 patients experience grade 3 or greater toxicity while 0-2 of 5 patients experience reversible grade 4 hematologic toxicity."
3327640|NCT00062985|No Intervention|Control|
3327641|NCT00062985|Experimental|Mail-based weight loss intervention|
3327642|NCT00062985|Experimental|Telephone-based weight loss intervention|
3327643|NCT00062868|Experimental|LMP1/2 CTLs (Group A)|Patients receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/leiomyosarcoma or who are at risk for relapse
3327644|NCT00062868|Experimental|LMP1/2 CTLs (Group B)|Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
3327645|NCT00062868|Experimental|LMP1/2 CTLs (Group C)|Patients receiving CTLs following allogeneic stem cell transplant.
3327646|NCT00062855|Experimental|Gene Modified Neuroblastoma Cells|Gene modified neuroblastoma cells given as 4 subcutaneous injections over 5 weeks
3327647|NCT00062829|Other|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
3327648|NCT00002643|Experimental|Arm I|See detailed description.
3327649|NCT00027612|Experimental|irinotecan + carmustine and radiation|"Phase II (patients receiving concurrent EIACs or non-EIACs open to accrual as of 3/5/2005): Patients receive irinotecan at the recommended dose, carmustine, and cranial irradiation as in phase I.~Patients with disease progression are followed every 3 months for 5 years and then annually for up to 10 years.~Patients taken off study for reasons other than disease progression are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years."
3327650|NCT00025376|Experimental|Pre-Treatment biopsy followed by PS-341 administration|Pre-treatment tumor biopsy followed by 3 cycles of PS-341 given by IV infusion. Each cycle will last 3 weeks. PS-341 will be given 2 times a week for 2 weeks followed by a 'rest' week with no drug. After the 3rd cycle, subjects can continue to receive another 3 cycles of the study drug if their disease has not worsened.
3327667|NCT00062504|Experimental|2|Non-enzyme-inducing anti-epileptic drugs: 25mg TID week 1, 35mg week 2, 50mg week 3
3327668|NCT00062504|Experimental|3|Enzyme-inducing anti-epileptic drugs: 35mg TID week 1, 505mg week 2, 75mg week 3
3327671|NCT00017394|Experimental|Treatment (bevacizumab, vinorelbine tartrate)|Patients receive bevacizumab IV over 30-90 minutes once every other week and vinorelbine IV over 6-10 minutes once weekly for 8 weeks. Treatment repeats every 8 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response or stable disease after completion of the fourth course may receive additional courses of concurrent bevacizumab and vinorelbine administered once every other week or may continue therapy on the schedule as above.
3327672|NCT00017316|Experimental|Arm I|Patients receive SU5416 IV over 1 hour twice weekly and oral thalidomide daily beginning 1 day after the first dose of SU5416. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
3327673|NCT00016107|Experimental|Treatment (chemotherapy, bevacizumab)|Patients receive oral estramustine 3 times daily on days 1-5 and docetaxel IV over 1 hour followed by bevacizumab IV over 30-90 minutes on day 2. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3327674|NCT00014534|Active Comparator|Gemcitabine + cisplatin|
3327675|NCT00014534|Active Comparator|Gemcitabine + Doxorubicin + Pegfilgrastim|
3327676|NCT00014170|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib daily. Courses repeat every 8 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
3327677|NCT00062452||A-1,2,3|The cohort (A) comprised of high risk infants. There were 3 sub groups studied within this cohort: (1) premature infants, (2) Infants with congenital gut anomalies, and (3) perinatal asphyxia.
3327678|NCT00062439|Experimental|Etoposide, Cisplatin, Thoracic RT, Surgery, Docetaxel|
3327679|NCT00062387|Experimental|Arm I|Patients receive oral perifosine 4 times daily on days 1 and 2 and once daily on days 3-28 during course 1. Patients receive oral perifosine once daily on days 1-28 for all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3327680|NCT00062374|Experimental|Treatment (preoperative chemotherapy)|"Neoadjuvant chemotherapy: Patients receive cisplatin IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1, 8, 22, and 29. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.~Surgery: Within 4 weeks after completion of neoadjuvant chemotherapy, patients undergo radical subtotal or total gastrectomy with lymph node dissection."
3327681|NCT00062309|Active Comparator|CIMRT|76 Gy in 38 fractions
3327682|NCT00062309|Experimental|HIMRT|70.2 Gy in 26 fractions
3327683|NCT00062244|Experimental|Arm I|"Phase I: Patients receive oblimersen IV continuously on days 1-7. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 1-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.~Phase II: Patients receive treatment as in phase I at the MTD of oblimersen. Patients are followed every 3 months for 2 years."
3327684|NCT00062179|Experimental|paclitaxel/carboplatin/celecoxib|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion Carboplatin: dosed at an AUC of 6 by the Calvert Formula Celecoxib: 400 mg po BID 3 cycles of paclitaxel and carboplatin 21 days apart celecoxib 3-7 days before first dose of chemotherapy
3327685|NCT00062179|Placebo Comparator|paclitaxel/Carboplatin/Placebo|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion Carboplatin: dosed at an AUC of 6 by the Calvert Formula Placebo 3 cycles of paclitaxel and carboplatin 21 days apart Placebo 3-7 days before first dose of chemotherapy
3327686|NCT00062127|Experimental|Arm I (irinotecan hydrochloride and thalidomide)|Patients receive irinotecan IV over 90 minutes on days 1 and 22 and oral thalidomide once daily on days 15-28. All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3327687|NCT00062127|Experimental|Arm II (irinotecan hydrochloride and thalidomide)|Patients receive irinotecan as in arm I and oral thalidomide once daily on days -6 to 7. All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3327688|NCT00062114|Experimental|rituximab + yttrium Y 90 ibritumomab tiuxetan|"Patients receive rituximab IV followed within 4 hours by yttrium Y 90 ibritumomab tiuxetan IV (for imaging) over 10 minutes on day 1. Patients undergo 1 (or 2 if needed) imaging scan between days 2-5. In the absence of altered biodistribution, patients receive rituximab IV followed within 4 hours by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8.~Patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 2 years."
3327689|NCT00062101|Experimental|Group I (erlotinib hydrochloride, celecoxib)|Patients receive oral erlotinib once daily and oral celecoxib twice daily.
3327690|NCT00062101|Experimental|Group II (erlotinib hydrochloride)|Patients receive erlotinib as in group 1.
3327691|NCT00062075|Experimental|Treatment|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3327692|NCT00062062|Experimental|gefitinib|"Patients receive oral gefitinib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and after the completion of course 2.~Patients are followed every 3 months for 5 years."
3327693|NCT00062062|Experimental|paclitaxel + carboplatin + gefitinib|"Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. After completion of chemotherapy and in the absence of disease progression, patients receive oral gefitinib as in group I.~Quality of life is assessed at baseline and after the completion of course 2.~Patients are followed every 3 months for 5 years."
3327694|NCT00062023|Active Comparator|Arm I Sulindac|Oral sulindac twice daily.
3327695|NCT00062023|Active Comparator|Arm II Aspirin|Oral aspirin once daily.
3327696|NCT00062023|Active Comparator|Arm III Ursodiol|Oral ursodiol three times daily.
3327697|NCT00062023|Placebo Comparator|Arm IV: Sulindac Placebo|Oral sulindac placebo twice daily.
3327811|NCT00060450|Placebo Comparator|2|Placebo gas
3328111|NCT00054847|Active Comparator|Radial Artery Graft|Radial Artery Graft
3327698|NCT00062010|Experimental|IFN-alpha, 13-CRA, paclitaxel|Interferon alpha: 6 million U/m2 on days 1 and 2 of each week for 6 weeks of an 8-week cycle 13-cis-retinoic acid: 1 mg/kg on days 1 and 2 of each week for 6 weeks of an 8-week cycle Paclitaxel: 75 mg/m2 on day 2 of each week for 6 weeks of an 8-week cycle
3327699|NCT00061958|Experimental|Treatment (arsenic trioxide)|Patients receive a loading dose of arsenic trioxide IV over 2 hours on days 1-5 on week 1. Beginning on week 2, patients receive a maintenance dose of arsenic trioxide IV twice weekly thereafter. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving a CR continue to receive therapy for at least 6 months beyond CR.
3327700|NCT00061945|Experimental|Treatment (alemtuzumab and combination chemotherapy)|See detailed description.
3327701|NCT00061932|Experimental|Stratum 1 (previously untreated)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and irinotecan IV over 90 minutes on days 1 and 8.
3327702|NCT00061932|Experimental|Stratum 2 (previously treated)|(closed to accrual as of 9/19/2006): Patients receive bortezomib as in stratum 1.
3327703|NCT00061919|Experimental|Active arm (thalidomide)|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
3327704|NCT00061919|Placebo Comparator|Placebo arm|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
3327705|NCT00061893|Experimental|Combination chemotherapy|Metastatic Ewing Sarcoma - 14-cycle study building on conventional tx (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, ifosfamide, etoposide) and adding two antiangiogenic agents: the vinca alkaloid vinblastine and the cyclooxygenase-2 inhibitor celecoxib. Refer to the Interventions section for dosages, method of delivery and frequency of administration.
3327706|NCT00061828||Biliary Atresia|Infants presenting with cholestasis who are diagnosed with biliary atresia.
3327707|NCT00061828||Non-Biliary Atresia|Infants presenting with cholestasis without a diagnosis of biliary atresia.
3327708|NCT00061815|Experimental|Cetuximab+FOLFOX4|"Day 1 - cetuximab loading dose of 400 mg/m2 IV, infused over 2 hours; oxaliplatin (85 mg/m2) simultaneously with leucovorin (200 mg/m2), followed by 5-FU 400 mg/m2 IV bolus followed by 5-FU 600 mg/m2 as a 22-hour continuous infusion~Day 2 - leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 IV bolus followed by another dose of 5-FU 600 mg/m2 as a 22-hour continuous infusion~Day 8 - cetuximab maintenance dose of 250 mg/m2 IV infused over 60 minutes"
3327709|NCT00061815|Active Comparator|FOLFOX4.|"Day 1 - oxaliplatin (85 mg/m2) simultaneously with leucovorin (200 mg/m2), followed by 5-FU 400 mg/m2 IV bolus followed by 5-FU 600 mg/m2 as a 22-hour continuous infusion.~Day 2 - leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 IV bolus followed by another dose of 5-FU 600 mg/m2 as a 22-hour continuous infusion."
3327710|NCT00033462|Experimental|Arm I|Patients receive oral erlotinib once daily. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
3327711|NCT00010114||Newly diagnosed embryonal tumors|The participants in this study are infants (< 3 years of age) with newly diagnosed medulloblastoma, primitive neuroectodermal tumor, or other embryonal tumor, atypical teratoid/rhabdoid tumor, intracranial germ cell tumor, or choroid plexus carcinoma who have received no prior therapy with the exception of steroids and have consented to allow research studies on banked tissue specimens
3327712|NCT00009789|Experimental|Radiotherapy|"Patients receive accelerated 3-dimensional (3-D) conformal radiotherapy daily 5 days a week for 3.5-6 weeks.~Cohorts of 8 patients receive escalating fractions of accelerated 3-D conformal radiotherapy until the maximum tolerated course is determined. The maximum tolerated course is defined as the course at which no more than 2 patients develop at least grade 3 dose-limiting toxicity and no more than 1 patient develops at least grade 4 dose-limiting toxicity.~Patients are followed at 3 weeks, 6 weeks, 3 months, every 3 months for 2 years, and then every 6 months for 3 years."
3327713|NCT00061750|Experimental|ICL670|
3327714|NCT00061750|Active Comparator|Deferoxamine|
3327715|NCT00061698|Active Comparator|Cognitive Behavior Therapy Child Only|Participants completed 20 sessions of CBT
3327716|NCT00061698|Active Comparator|CBT plus Parent training|Child participants completed 20 sessions of CBT and parents completed 8 sessions of parent training
3327717|NCT00061698|No Intervention|Minimal Contact Control|Participants waited 12 weeks for treatment but their safety and well-being were monitored during this time
3327718|NCT00051714|Experimental|Early Primary Prevention|
3327719|NCT00061633|Experimental|Telavancin|
3327720|NCT00061633|Active Comparator|Standard of care for cSSSI|cSSSI - complicated skin and skin structure infections
3327721|NCT00061620|Experimental|Tezacitabine|Tezacitabine as a bolus infusion daily x 5
3327722|NCT00059462|Experimental|Arm 1|
3327723|NCT00059462|Active Comparator|Arm 2|
3327724|NCT00061542|Experimental|Betaxolol|Two doses daily for 12 weeks
3327725|NCT00061542|Experimental|TGFS 0.25%|Two doses daily for 12 weeks
3327726|NCT00061542|Experimental|TGFS 0.5%|Two doses daily for 12 weeks
3327727|NCT00061516|Experimental|Brinzolamide suspension, 1%|Dosed twice daily for 12 weeks
3327728|NCT00061516|Experimental|Levobetaxolol suspension, 0.5%|Dosed twice daily for 12 weeks
3327729|NCT00061568|Active Comparator|1|donor
3327730|NCT00061568|Active Comparator|2|recipient
3327731|NCT00061568|Experimental|3|recipient
3327732|NCT00061490|Experimental|1|16 weekly educational meetings
3327733|NCT00061490|No Intervention|2|Wait list control
3327734|NCT00006349|Experimental|donepezil + vitamin E|"Patients receive oral donepezil daily and vitamin E twice daily.~All patients begin treatment within 2 weeks after completion of prophylactic cranial irradiation. Treatment continues for a minimum of 1 month in the absence of disease progression, unacceptable toxicity, or a 3.0 point drop on the Mini Mental State Examination (MMSE) and/or a 5 point drop on the Blessed Dementia Scale.~Cognition is assessed using the Blessed Dementia Scale and the MMSE at baseline and then every 3 months during study.~Quality of life and depression are assessed at baseline and then every 3 months during study.~Patients are followed every 6 months."
3327769|NCT00005977|Experimental|STAGE IV, +CNS (Trt 3)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy. C: Etoposide, Ifosfamide, Dexamethasone IT Therapy.~Treatment ABCABAB"
3327735|NCT00006349|Placebo Comparator|placebo|"Patients receive oral placebo twice daily.~All patients begin treatment within 2 weeks after completion of prophylactic cranial irradiation. Treatment continues for a minimum of 1 month in the absence of disease progression, unacceptable toxicity, or a 3.0 point drop on the Mini Mental State Examination (MMSE) and/or a 5 point drop on the Blessed Dementia Scale.~Cognition is assessed using the Blessed Dementia Scale and the MMSE at baseline and then every 3 months during study.~Quality of life and depression are assessed at baseline and then every 3 months during study.~Patients are followed every 6 months."
3327736|NCT00006341|Experimental|Implant|A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
3327737|NCT00061321|Active Comparator|1|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum
3327738|NCT00061321|Experimental|2|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day)by mouth, from week 1 through week 6 post-partum Infants: Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
3327739|NCT00061373|Experimental|MRI Selected Patients|"Patients are eligible for the MRI arm if all clinical and all MRI inclusion and exclusion criteria are met.~A single dose of aspirin 81 mg orally (or rectal dose equivalent), a single weight-based dose of subcutaneous tinzaparin sodium. Possible dose escalated iv eptifibatide."
3327740|NCT00061373|Experimental|non-MRI Selected Patients|"Patients are eligible for the non-MRI arm if all clinical inclusion-exclusion criteria are met, if MRI is contraindicated or if MRI compromises iv tPA delivery within 3-hours of symptom onset.~A single dose of aspirin 81 mg orally (or rectal dose equivalent) and a single weight-based dose of subcutaneous tinzaparin sodium. Possible dose escalated iv eptifibatide."
3327741|NCT00061360|Experimental|ATG+CsA+RA|ATG+CsA+RAPA for 6 months
3327742|NCT00061360|Experimental|ATG+CsA|ATG+CsA for 6 months followed by a slow CsA taper in the subsequent 18 months
3327743|NCT00061347|Experimental|1|Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
3327744|NCT00061282|Placebo Comparator|1|
3327745|NCT00061282|Active Comparator|2|Clotrimazole Therapy
3327746|NCT00061282|Active Comparator|3|Clotrimazole Therapy
3327747|NCT00061243|Experimental|1|Participants will receive different doses of the vaccine to determine the optimal dose
3327748|NCT00061243|Experimental|2|Participants will receive different doses of the vaccine to determine the optimal dose
3327749|NCT00061243|Experimental|3|Participants will receive different doses of the vaccine to determine the optimal dose
3327750|NCT00061243|Experimental|4|Participants will receive the vaccine through either intradermal or intramuscular administration
3327751|NCT00061243|Experimental|5|Participants will receive the vaccine through either intradermal or intramuscular administration
3327752|NCT00015821|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily for 1 year in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may receive 1 additional year of therapy.
3327753|NCT00061113|Active Comparator|1|fluoxetine + CBT
3327754|NCT00061113|Placebo Comparator|2|placebo + CBT
3327755|NCT00061100|Experimental|RISE intervention|Targeted RISE intervention- Behavior therapy Rise
3327756|NCT00061100|Active Comparator|Standard Education|Education intervention. Standard prevention education
3327757|NCT00061087|Active Comparator|METHYLPHENIDATE|Methylphenidate
3327758|NCT00061087|Active Comparator|BUPROPION|Bupropion
3327759|NCT00061087|Placebo Comparator|PLACEBO|Placebo
3327760|NCT00006243|Experimental|Arm I (vaccine therapy)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
3327761|NCT00006243|Experimental|Arm II (vaccine therapy and lower-dose sargramostim)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC and lower-dose sargramostim SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
3327762|NCT00006243|Experimental|Arm III (vaccine therapy and higher-dose sargramostim)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC and higher-dose sargramostim SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
3327763|NCT00006242|Experimental|Treatment (BMS-214662)|"Single patient cohorts receive BMS-214662 IV over escalating periods of 2, 4, 8, 16, and 24 hours weekly for 3 weeks followed by 1 week of rest. If no patient experiences DLT, dose escalation proceeds in the single patient cohorts.~Treatment repeats every 4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Individual patient cohorts may increase their duration of BMS-214662 infusion in subsequent courses to the current duration safely reached.~Beginning with the infusion level at which DLT is first encountered by a single patient, cohorts of 3-6 patients receive escalating doses of BMS-214662 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. An additional cohort of 10 patients is treated at the MTD."
3327764|NCT00006095|Experimental|Vincristine Sulfate 1.5 mg/m2/wk and Irinotecan|
3327765|NCT00006095|Experimental|Vincristine sulfate 2.0 mg/m2/wk and Irinotecan|
3327766|NCT00061048|Experimental|Campath-1H|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week.
3327767|NCT00005977|Experimental|STAGE III NHL (Trt 1)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABA"
3327888|NCT00059306|Active Comparator|Blood pressure|The goal of the blood pressure aspect of this trial is to find out if lowering blood pressure after stroke helps to prevent recurrent stroke and preserves cognition.
3327771|NCT00005977|Experimental|B-ALL, +CNS (Trt 3)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy. C: Etoposide, Ifosfamide, Dexamethasone IT Therapy.~Treatment ABCABAB"
3327772|NCT00060944|Experimental|Yondelis weekly schedule|Yondelis weekly schedule: 0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1 8 and 15 of each 28-day treatment cycle. Patients will be pretreated with 10 mg of dexamethasone i.v. 30 minutes prior to each infusion.
3327773|NCT00060944|Experimental|Yondelis once every 3 weeks schedule|Yondelis once every 3 weeks schedule: 1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle. Patients will be pretreated with 20 mg of dexamethasone i.v. on Day 1 of each treatment cycle 30 minutes prior to each infusion.
3327774|NCT00003203|Experimental|Newly diagnosed cerebral PNET with histologic verification|Begin therapy within 31 days of surgery. Radiation therapy will be given in standard fractions along with filgrastim. The craniospinal axis will be treated first. Patients will receive carboplatin at 35 mg/m2/day IV over 15-20 minutes Monday through Friday, 1-4 hours prior to radiation for 6 weeks (total of 30 doses). Vincristine sulfate 1.5 mg/m2 IV will be given weekly x 6. Following radiation, patients will receive Maintenance chemotherapy. Patients enrolled prior to Amendment #5 will receive six cycles of cyclophosphamide and vincristine (Regimen A). Patients enrolled after Amendment #5 will receive six cycles of cyclophosphamide, vincristine sulfate and cisplatin (Regimen B).
3327775|NCT00060892|Active Comparator|1|0.4 mg AMG0001 on days 0, 14, and 28
3327776|NCT00060892|Active Comparator|2|4.0 mg AMG0001 on days 0, 14, and 28
3327777|NCT00060892|Active Comparator|3|4.0 mg AMG0001 on days 0 and 28; placebo on day 14
3327778|NCT00060892|Placebo Comparator|4|Placebo (saline) on days 0, 14, and 28
3327779|NCT00005086|Experimental|Arm A|Methotrexate will be given as a short infusion (introduced into a vein) for approximately 5 minutes on the first day (day 1). ). A week later (day 8), both methotrexate and docetaxel will be given the same way, but this will take about 1 hour. The first course of treatment consists of receiving treatment on day 1 and day 8 every 21 days for 9 weeks. X-rays or scans will then be performed to determine if your tumor is shrinking. You will then start treatment with gemcitabine and cisplatin. On the first day (day 1), you will receive both cisplatin and gemcitabine into your vein. A week later (day 8), you will receive only gemcitabine as an infusion into your vein over 100 minutes and no additional intravenous fluid will be required on that day. This second course of treatment consists of receiving treatment on day 1 and day 8 every 21 days for 9 weeks.
3327780|NCT00060840|Active Comparator|Inhaled Nitric Oxide|Inhaled Nitric Oxide (iNO) at 40 parts per million (ppm)
3327781|NCT00060840|Placebo Comparator|Nitrogen|Nitrogen (N2) administered at 40 ppm.
3327782|NCT00060814|Experimental|Combined Pharmacotherapy and Counseling|300 mg Bupropion/4mg Nicotine Gum/Motivational Interviewing
3327783|NCT00004931|Experimental|Arm I|Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV (administered after 1 hour of leucovorin calcium) weekly for 6 weeks.
3327784|NCT00004931|Experimental|Arm II|Patients receive oxaliplatin IV over 2 hours on days 1, 15, and 29 and leucovorin calcium and fluorouracil as in arm I.
3327785|NCT00060762|Experimental|Interpersonal Therapy|Interpersonal Therapy is a psychotherapy aimed at resolving interpersonal difficulties
3327786|NCT00060762|Active Comparator|Behavioral Weight Loss Treatment|Behavioral Weight Loss Treatment is aimed solely at weight loss, however it has been shown to decrease binge eating
3327787|NCT00060762|Active Comparator|Guided Self Help|Guided Self-Help is a brief psychotherapy based on cognitive-behavioral treatment
3327788|NCT00060723||Adenotonsillectomy group|Children ages 5-12 who are scheduled for adenotonsillectomy for obstructive sleep apnea
3327789|NCT00060723||Comparison group|Children ages 5-12, scheduled for hernia repairs, other procedures not involving the head, chest or neck, or no procedures. Additional exclusions include children with a history of recurrent throat infections, large tonsils, history of or plans for adenoidectomy and/or tonsillectomy or who have been previously diagnosed with sleep-disordered breathing.
3327790|NCT00060645|Experimental|1|There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
3327791|NCT00060632|Experimental|Cohort 1: Ridaforolimus 6.25 mg|
3327792|NCT00060632|Experimental|Cohort 2: Ridaforolimus 12.5 mg|
3327793|NCT00060632|Experimental|Cohort 3: Ridaforolimus 25 mg|
3327794|NCT00060632|Experimental|Cohort 4: Ridaforolimus 50 mg|
3327795|NCT00060632|Experimental|Cohort 5: Ridaforolimus 100 mg|
3327796|NCT00060632|Experimental|Cohort 6: Ridaforolimus 75 mg|
3327797|NCT00060606|Experimental|1|Fetal surgery to close spina bifida defect prior to 26 weeks of gestation with delivery by C-Section at approximately 37 weeks of gestation.
3327798|NCT00060606|Active Comparator|2|Standard postnatal closure of the spina bifida defect when the baby is medically stable, usually within 48 hours of birth by C-section.
3327799|NCT00060567|Other|1|Active combination of E7070 and irinotecan.
3327800|NCT00060567|Other|2|Active combination of E7070 and irinotecan.
3327801|NCT00060567|Other|3|Active combination of E7070 and irinotecan.
3327802|NCT00004180|Experimental|Well-differentiated liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
3327803|NCT00004180|Experimental|De-differentiated liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
3327804|NCT00004180|Experimental|Myxoid/ round-cell liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
3327805|NCT00004180|Experimental|Pleomorphic liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
3327806|NCT00060528|Experimental|no GM|No granulocyte macrophage colony stimulating factor (GM-CSF) was given
3327807|NCT00060528|Experimental|Rec-hGM|Recombinant human GM-CSF (Sargramostim) was administered at 100mcg/day on days 1-4 following each vaccine. Given subcutaneously (s.c.) at site of vaccine.
3327808|NCT00060528|Experimental|rF-GM (10^7pfu)|recombinant fowlpox GM-CSF was given on day one at 10^7 in last two arms. Given subcutaneously (s.c.) at site of vaccine.
3327809|NCT00060528|Experimental|rF-GM (10^8)|recombinant fowlpox GM-CSF was given on day one at 10^8 in last two arms. Given subcutaneously (s.c.) at site of vaccine.
3327812|NCT00060424|Experimental|Treatment (enzyme inhibitor, transplant, GVHD prophylaxis)|NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and TBI on day 0. TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplant on day 0. GVHD PROPHYLAXIS: Patients receive cyclosporine PO every 12 hours on days -3 to 180 with taper on day 56 and mycophenolate mofetil PO every 12 hours on days 0-27.
3327813|NCT00060411|Experimental|Treatment (combination chemotherapy)|Patients receive oral elotinib alone once daily for 1 week before the beginning of course 1. Patients then receive oral erlotinib once daily on days 1-28; oxaliplatin IV over 2 hours on day 1; and leucovorin calcium IV over 2 hours and fluorouracil IV over 22 hours on days 1 and 2. Patients also receive bevacizumab IV over 30-90 minutes on day 15 of course 1 and on days 1 and 15 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3327814|NCT00060372|Experimental|Treatment (ipilmumab and donor lymphocyte infusion)|Patients receive ipilimumab IV over 90 minutes. Cohorts of 3-6 patients receive escalating doses of ipilimumab until the MTD is determined. The MTD is the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients with persistent or progressive disease at 60 days after ipilimumab administration and no evidence of graft-versus-host disease receive donor lymphocyte infusions every 60 days for a total of 3 infusions.
3327815|NCT00060359|Experimental|Treatment (paclitaxel poliglumex, carboplatin)|"DOSE-ESCALATION PHASE: Patients receive CT-2103 IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of CT-2103 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of treatment.~FEASIBILITY PHASE: Once the MTD of CT-2103 is determined, an additional 20-40 patients receive treatment at that dose level combined with carboplatin as above."
3327816|NCT00060346|Experimental|Rituximab + CHOP|"Rituximab 375 mg/m2 day 1 of a 21-day cycle, followed by:~Cyclophosphamide 750 mg/m2 Doxorubicin 50 mg/m2 Vincristine 1.4 mg/m2 and Prednisone 100 mg/m2 daily"
3327817|NCT00060333|Experimental|Treatment (adjuvant radiation therapy)|Within 8 weeks after surgical resection, patients undergo radiation therapy twice weekly over approximately 2.5 weeks for a total of 5 fractions in the absence of disease progression or unacceptable toxicity.
3327818|NCT00060320|Experimental|black cohost|"Patients receive oral black cohosh twice daily for 4 weeks. All patients then cross over to the other arm and receive treatment for 4 weeks.~After completion of the crossover treatment, all patients may opt to receive open-label black cohosh for an additional 8 weeks.~Patients complete a hot flash diary daily at baseline and during the 8-week double-blind study, and then daily for 8 weeks during optional open-label treatment.~Patients who opt to receive open-label black cohosh are followed at 6 months, 1 year, and 2 years."
3327819|NCT00060320|Placebo Comparator|placebo|"Patients receive oral placebo twice daily for 4 weeks. All patients then cross over to the other arm and receive treatment for 4 weeks.~After completion of the crossover treatment, all patients may opt to receive open-label black cohosh for an additional 8 weeks.~Patients complete a hot flash diary daily at baseline and during the 8-week double-blind study, and then daily for 8 weeks during optional open-label treatment.~Patients who opt to receive open-label black cohosh are followed at 6 months, 1 year, and 2 years."
3327820|NCT00060307|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3327821|NCT00060203|Experimental|Brostallicin|
3327822|NCT00060125|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for at least 2 courses and for a maximum of 2 years in the absence of disease progression or unacceptable toxicity. Patients who achieve CR receive 2 additional courses beyond CR.
3327823|NCT00060112|Experimental|Treatment (oblimersen sodium and gemcitabine hydrochloride)|Patients receive oblimersen IV continuously on days 1-5 and gemcitabine IV over 2-3 hours on day 5. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
3327824|NCT00060086|Experimental|Pomegranate Juice|Subjects are given oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
3327825|NCT00060008|Experimental|18FDG-PET scan and MR perfusion|Subjects will undergo MRI for quantitative (2D and 3D) evaluation of plexiform neurofibroma size, MR perfusion scan, and fludeoxyglucose (18FDG) PET scan at the time of study entry. Subjects who are treated for plexiform neurofibroma will undergo another 18FDG PET scan after one year of study entry.
3327826|NCT00059930|Experimental|Adjuvant Hepatic Arterial Infusion & Combination Chemotherapy|This is a Phase I study with the primary objective of defining the maximum tolerated dose of hepatic arterial floxuridine (FUDR) and dexamethasone (Dex) given via an implanted pump in combination with intravenous oxaliplatin plus systemic fluorouracil (5FU)/leucovorin (LV) in the adjuvant setting after resection of hepatic metastases from colorectal cancer. A total of eleven dose levels will be considered.
3327827|NCT00059891|Experimental|Anal Sphincter Prosthesis|All patients will follow a common treatment algorithm. Anorectal reconstruction with the ABS neosphincter device will be a staged surgical approach. Routine postoperative testing will then be performed at 6 months (+/- 8 weeks) and 12 months (+/- 8 weeks), following ileostomy reversal which we have designated as time zero. Postoperative testing will include completion of a series of questionnaires.
3327828|NCT00059865|Experimental|pemetrexed + gemcitabine|"Phase II: Patients receive pemetrexed disodium as in phase I and gemcitabine at the recommended phase II dose.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
3327829|NCT00059852|Experimental|gemcitabine + erlotinib|"Patients receive gemcitabine IV on days 1 and 8 and oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients achieving a complete response are followed every 6 weeks for up to 5 years or until disease progression (PD). Patients discontinuing study therapy for any other reason are followed every 3 months until PD and then every 6 months for up to 5 years."
3327889|NCT00059280|Experimental|1|
3327890|NCT00059254|Experimental|Oleic acid (OA)|
3327891|NCT00059254|Experimental|Palmitic acid (PA)|
3327892|NCT00059215|Experimental|Prasugrel (CS-747) 40 mg LD/7.5 mg MD|Prasugrel (CS-747) 40 mg oral loading dose (LD) at time of percutaneous coronary intervention (PCI) followed by 7.5 mg oral maintenance dose (MD), once daily, for 29-34 days
3327830|NCT00059839|Experimental|Standard APO with Vincristine (Arm I )|In courses 1-3, patients receive doxorubicin hydrochloride (30 mg/m2) IV over 15 minutes, vincristine sulfate (1.5 mg/m2 (maximum dose 2 mg)) IV, and methotrexate intrathecally (age-adjusted dosing) (IT) on day 1 and oral prednisone (40 mg/m2/day) three times daily and oral mercaptopurine (225 mg/m2) once daily on days 1-5. In courses 4 and 5, patients receive doxorubicin (30 mg/m2), vincristine sulfate (1.5 mg/m2 (Maximum dose 2 mg)), prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in courses 1-3. In courses 6-15, patients receive vincristine sulfate (1.5 mg/m2), prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in courses 1-3 and methotrexate (60 mg/m2) IV on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity.
3327831|NCT00059839|Experimental|Consolidation with Vinblastine|In courses 1-3, patients receive doxorubicin hydrochloride (30 mg/m2) IV, methotrexate (age adjusted dosing) IT, prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in arm I and vinblastine sulfate (4 mg/m2) IV over 1 minute on days 1, 8, and 15. In courses 4 and 5, patients receive doxorubicin hydrochloride (30 mg/m2) IV, prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in arm I and vinblastine sulfate (4 mg/m2) as in arm II (courses 1-3). In courses 6-15, patients receive prednisone (120 mg/m2/day) and mercaptopurine (225 mg/m2) as in arm I, vinblastine sulfate (4 mg/m2) IV as in arm II (courses 1-3), and methotrexate (60 mg/m2) IV on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity.
3327832|NCT00059826|Experimental|Interferon-based chemoradiation therapy|"Cycle 1: Chemoradiotherapy (CRT)~5-fluorouracil continuous infusion (CI) via an ambulatory infusion pump into a central venous catheter at 175 mg/m2/day for 38 consecutive days, unless toxicity occurs~cisplatin given on the first day only of each week of this cycle (days 1, 8, 15, 22, 29, 36)~IFN-alpha-2b 3 million units given subcutaneously on days 1, 3, and 5 of each week for 5½ weeks~XRT 5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday - Friday, for 5½ weeks~Cycles 2 and 3: Post-CRT Chemotherapy~Post-CRT chemotherapy starts 4 - 6 weeks after completion of Cycle 1, unless the study physician deems further delay is necessary. Patients will be given 2 cycles of chemotherapy (cycles 2 and 3).~-- 5-fluorouracil continuous infusion via an ambulatory infusion pump into a central venous catheter at 200 mg/m2/day for 6 weeks followed by 2 weeks of rest"
3327833|NCT00059813|Experimental|Treatment (recombinant interferon alfa, oblimersen sodium)|Patients receive oblimersen IV continuously on days 1-7 and interferon alfa subcutaneously on days 4, 6, 8, 10, and 12 of course 1 and on days 1, 3, 5, 8, 10, and 12 of all subsequent courses. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive an additional 2 courses past CR.
3327834|NCT00059787|Experimental|Paclitaxel, carboplatin, erlotinib|Carboplatin and paclitaxel IV every 21 days x 6 cycles plus oral erlotinib
3327835|NCT00059761|Experimental|Sequence A: Level 1|Irinotecan 40 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
3327836|NCT00059761|Experimental|Sequence B: Level 1|Irinotecan 40 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
3327837|NCT00059761|Experimental|Sequence A: Level 2|Irinotecan 50 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
3327838|NCT00059761|Experimental|Sequence B: Level 2|Irinotecan 50 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
3327839|NCT00059761|Experimental|Sequence A: Level 3|Irinotecan 60 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
3327840|NCT00059761|Experimental|Sequence B: Level 3|Irinotecan 60 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
3327841|NCT00030667|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3327842|NCT00027599|Experimental|Arm I|Autologous dendritic cells (DCs) are harvested and pulsed with prostatic acid phosphatase-sargramostim fusion protein to produce APC8015 (Provenge). Patients receive APC8015 IV over 30 minutes and bevacizumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days for 3 courses. Patients continue to receive bevacizumab alone every 14 days in the absence of disease progression or unacceptable toxicity.
3327843|NCT00016315|Experimental|Arm 1|Sequence A: Gemcitabine 300 mg/m2/week plus radiation therapy (RT)
3327844|NCT00016315|Experimental|Arm 2|Sequence B: Gemcitabine 300 mg/m2/week plus paclitaxel 30 mg/m2/week and RT
3327845|NCT00016315|Experimental|Arm 3|Sequence A: Gemcitabine 300 mg/m2/week plus carboplatin 2 AUC and RT
3327846|NCT00016315|Experimental|Arm 4|Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 30 mg/m2/week and RT
3327847|NCT00016315|Experimental|Arm 6|Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 40 mg/m2/week and RT
3327848|NCT00016315|Experimental|Arm 8|Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 40 mg/m2/week and RT
3327849|NCT00016315|Experimental|Arm 10|Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
3327850|NCT00016315|Experimental|Arm 12|Sequence B: Gemcitabine 750 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
3327851|NCT00016315|Experimental|Arm 14|Sequence B: Gemcitabine 900 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
3327852|NCT00016315|Experimental|Arm 5|Sequence A: Gemcitabine 450 mg/m2/week plus carboplatin 2 AUC and RT
3327853|NCT00016315|Experimental|Arm 7|Sequence A: Gemcitabine 600 mg/m2/week plus carboplatin 2 AUC and RT
3327854|NCT00016315|Experimental|Arm 9|Sequence A: Gemcitabine 750 mg/m2/week plus carboplatin 2 AUC and RT
3327855|NCT00016315|Experimental|Arm 11|Sequence A: Gemcitabine 900 mg/m2/week plus carboplatin 2 AUC and RT
3327856|NCT00005793|Experimental|Combination Chemotherapy|Patients receive induction chemotherapy with daunorubicin IV over 10-15 minutes on days 1-3, cytarabine IV continuously on days 1-5, topotecan IV continuously on days 6-8, and etoposide IV over 60 minutes on days 9 and 10. Within 4 weeks of hematologic recovery, patients achieving remission after induction receive consolidation chemotherapy with cytarabine IV over 1 hour every 12 hours on days 1, 3, and 5. Subsequent courses of consolidation chemotherapy begin within 2 weeks of documentation of hematologic recovery from the prior consolidation course. Consolidation chemotherapy continues for 4 courses in the absence of unacceptable toxicity or disease progression.
3327893|NCT00059215|Experimental|Prasugrel (CS-747) 60 mg LD/10 mg MD|Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 10 mg oral maintenance dose (MD), once daily, for 29-34 days
3328112|NCT00054821|Experimental|Group A|Group A participants will be treated with mechanical distraction with motion
3327857|NCT00005065|Experimental|Arm I|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours every 3 weeks for 3 courses. Three weeks after completion of induction chemotherapy, patients receive Gd-Tex IV over 30 minutes twice weekly for 10 doses during preoperative radiotherapy. Radiotherapy is administered daily 5 days a week for 5 weeks. Approximately 3.5 weeks after completion of preoperative radiotherapy, patients undergo complete surgical resection. Three hours prior to surgery, patients receive an eleventh dose of Gd-Tex if they do not develop grade 3 or 4 toxicity with the tenth dose. Patients also receive a MRI without contrast prior to surgery. If the tumor is found to be unresectable, patients may receive additional radiation and/or chemotherapy.
3327858|NCT00004127|Experimental|Arm A|Oxaliplatin (85 mg/m2, day 1 of every 14 day cycle), Leucovorin (500 mg/m2, day 1 and 2 of every 14 day cycle), Fluorouracil (Bolus of 400 mg/m2 followed by 22 hr continuous infusion of 600 mg/m2 on days 1 and 2 of every 14 day cycle)
3327859|NCT00004095|Experimental|Irinotecan Plus Gemcitabine|
3327860|NCT00059683|Experimental|Cervical Cerclage Group|Women randomized to receive cerclage should receive cervical cerclage
3327861|NCT00059683|No Intervention|Control Group|Women randomized to not receive cerclage represent the control arm
3327862|NCT00005818|Experimental|Treatment (irinotecan hydrochloride, semaxanib)|Patients receive irinotecan IV over 90 minutes on day 1 of weeks 1-4 and SU5416 IV over 60 minutes on days 1 and 4 of weeks 1-6. Treatment continues every 6 weeks in the absence of unacceptable toxicity or disease progression.
3327863|NCT00003926|Experimental|Solid/brain tumor patients (1-18 years)|Patients with solid tumor or brain tumor in the 1-18 years old stratum.
3327864|NCT00003926|Experimental|Solid/brain tumor patients (19-45 years)|Patients with solid tumor or brain tumor in the 19-45 years old stratum.
3327865|NCT00059631|Experimental|Bortezomib + Mitoxantrone|"Bortezomib starting dose of 1.4 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.~Mitoxantrone starting dose of 3 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles."
3327866|NCT00059618|Experimental|Bortezomib|PS-341 (Bortezomib) 0.8-1.5 mg/m^2 IV push + Carboplatin (AUC 5) IV on Day 1 of each cycle, then Bortezomib alone on Days 4, 8 and 11 in each 28 day cycle.
3327867|NCT00059605|Experimental|DOTAP:Chol-fus1|Infusion intravenous once every 3 weeks
3327868|NCT00059475|Experimental|Adj-2 MART-1: 27-35|melanoma antigen recognized by T-cells (MART)-1:27-35 peptide every three weeks for four cycles (Arm I).
3327869|NCT00059475|Experimental|Adj-2 HD IL-2 after MART-1: 27-35|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm I (Arm IA)
3327870|NCT00059475|Experimental|Adj-2 27-35 (27L) MART-1 (Mod9mer) peptide Q3wks x 4|27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide every three weeks for four cycles (Arm II).
3327871|NCT00059475|Experimental|Adj-2 HD IL-2 after 27-35 (27L): MART-1 (Mod9mer)|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm II (Arm IIA)
3327872|NCT00059475|Experimental|Adj-2 MART-1: 26-35 (27L) (Mod10mer) peptide Q3wks x 4|melanoma antigen recognized by T-cells (MART)-1:26-35(27L) peptide every three weeks for four cycles (Arm III).
3327873|NCT00059475|Experimental|Adj-2 HD IL-2 after MART-1: 26-35 (27L) (Mod10mer)|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm III (Arm IIIA)
3327874|NCT00059475|Experimental|Adj-2 27-35 (27L): MART-1 + gp100: 209-217 (210M) Q3wks x 4|27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide plus the gp100:209-217(210M) peptide emulsified together every three weeks for four cycles (Arm IV).
3327875|NCT00059475|Experimental|Adj-2 HD IL-2 after 27-35 (27L): MART-1 + gp209-2M|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm IV (Arm IVA)
3327876|NCT00003432|Experimental|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed DC cancer vaccine
3327877|NCT00003311|Experimental|Regimen A|Methotrexate IV over 24 hours on day 1. Cytarabine is administered IV over 2 hours every 12 hours on days 2 and 3. Filgrastim (G-CSF) is administered subcutaneously (SC) daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for up to 8 courses.
3327878|NCT00003311|Experimental|Regimen B|Cyclophosphamide IV over 3 hours every 12 hours on days 1-3. Doxorubicin is administered IV over 24 hours on days 4 and 5. Vincristine is administered IV over 30 minutes on days 4 and 11. Dexamethasone is administered orally or IV on days 1-4 and 11-14. G-CSF is administered SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for up to 7 courses.
3327879|NCT00059371|Active Comparator|Circumcised immediately|
3327880|NCT00059371|Placebo Comparator|Delayed Circumcision|Men who were randomized to delayed circumcision were scheduled to be offered male circumcision 2 years after their randomization.
3327881|NCT00059358|Experimental|1|Participants will begin receive either Rebetron or PEG-Intron plus ribavirin therapy from Weeks 2 through 48
3327882|NCT00059345|Experimental|Arm 1: Acupuncture|Participants will receive acupuncture
3327883|NCT00059345|Placebo Comparator|Arm 2: Shallow needling|Participants will receive shallow needling on non-mederian points
3327884|NCT00059345|Other|Arm 3: No Acupuncture or Placebo Treatment|Participants will receive usual care, no acupuncture or placebo acupuncture treatment.
3327885|NCT00059332|Experimental|Magnesium Sulfate|Magnesium sulfate (Mg) was administered intravenously with a 15 minute bolus load followed by a 24 hour infusion. The bolus-loading dose consisted of 4 grams Mg in 54 ml normal saline. The maintenance infusion contained 16 grams Mg diluted in 240 ml 0.9% normal saline, infused at 10 ml/hr for 24 hours. Paramedics in the field initiated the bolus-loading dose, administered at 216 ml/hr over 15 minutes through a rate controlled IV infusion set. The maintenance infusion was initiated in hospital immediately upon completion of the loading dose.
3327886|NCT00059332|Placebo Comparator|Normal saline|Normal saline was administered intravenously with a 15 minute bolus load followed by a 24 hour infusion. Paramedics in the field initiated the bolus-loading dose of 54 ml normal saline, administered at 216 ml/hr over 15 minutes through a rate controlled IV infusion set. The maintenance infusion was initiated in hospital immediately upon completion of the loading dose at 10 ml/hr for 24 hours.
3327887|NCT00059306|Active Comparator|Antiplatelet|Participants receive aspirin + placebo OR aspirin + clopidogrel
3328113|NCT00054821|Active Comparator|Group B|Group B participants will be treated with mechanical distraction without motion
3327894|NCT00059215|Experimental|Prasugrel (CS-747) 60 mg LD/15 mg MD|Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 15 mg oral maintenance dose (MD), once daily, for 29-34 days
3327895|NCT00059215|Active Comparator|Clopidogrel|Clopidogrel 300 mg oral LD at time of PCI followed by an oral 75 mg MD; taken once a day.
3327896|NCT00003193|Experimental|Paclitaxel, amifostine, RT|Dose-escalation arm for paclitaxel with amifostine and RT.
3327897|NCT00059228|Experimental|Estradiol|Experimental
3327898|NCT00059228|Placebo Comparator|Placebo|Placebo comparator
3327899|NCT00003597|Experimental|Cohort 1|Chemotherapy days 0-4, G-CSF (5 μg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). rhTPO began on the last day of ICE (Ifosfamide, Carboplatin and Etoposide) chemotherapy (Day 4) and subsequent doses will be administered on Days 6, 8, 10 and 12 (5 doses total). The initial dose of rhTPO was 1.2 μg/kg/dose and was subsequently escalated to 2.4 and 3.6 μg/kg/dose as tolerated. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one only).
3327900|NCT00003597|Experimental|Cohort 2|"Chemotherapy days 0-4, G-CSF (5 μg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). The dose of rhTPO 1.2 μg/kg/dose and subsequently escalated to 2.4 and 3.6 μg/kg/dose as tolerated. Patients assigned to Cohort II will receive pre-chemotherapy rhTPO at 3.6 μg/kg/dose on Days -5, -3, -1, and post-chemotherapy rhTPO on Days +4, +6, and +8 (6 doses total. Subsequent courses of chemotherapy will begin as soon as the ANC recovers to~≥ 1,000/μL and the platelet count to ≥ 100,000/μL between days 21 and 35. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one nly). For the second cohort, full data collection will occur for cycles one and two and limited data collection for cycles 3, 4, 5, and 6."
3327901|NCT00003162|Active Comparator|3.0 Gy x 10 fractions in two weeks|3.0 Gy x 10 fractions for a total dose of 30.0 Gy in two weeks
3327902|NCT00003162|Experimental|8.0 Gy x 1 fraction|8.0 Gy x 1 fraction for a total dose of 8.0 Gy in a single dose
3327903|NCT00058955|Experimental|1|Sodium oxybate
3327904|NCT00058955|Active Comparator|2|triazolam
3327905|NCT00058955|Active Comparator|3|pentobarbital
3327906|NCT00058955|Placebo Comparator|4|Placebo
3327907|NCT00058890|Experimental|Gabapentin|
3327908|NCT00058890|Placebo Comparator|Placebo|
3327909|NCT00002934|No Intervention|Pathology Review, Observation and Follow-up|Pathology review, observation and follow-up
3327910|NCT00002835|Experimental|Arm I|"3 courses of early intensification:~First course: Ifosfamide (IFF) IV continuously and Etoposide (VP-16) IV over 2 hours every 12 hours on days 1-3. Filgrastim (G-CSF) administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover then autologous peripheral blood stem cells (PBSC) are harvested, selected for CD34 positive cells, and purged in vitro. If more than 5% of the WBC contains lymphoma cells after induction, then 2 courses of IFF and VP-16 are administered before PBSC harvest.~Second course: IFF IV continuously on days 1-3, mitoxantrone (DHAD) IV on day 1, and G-CSF SC as in first course.~Third course: Carmustine IV over 1 hour on day -6, ARA-C and VP-16 IV every 12 hours on days -5 to -2, and melphalan IV on day -1. PBSC are reinfused on day 0. G-CSF is administered SC beginning on day 0 and continuing until blood counts recover. Each course lasts 3 weeks in the absence of disease progression or unacceptable toxicity."
3327911|NCT00002835|Experimental|Arm II|IDSHAP during 4 week courses 2 and 5, MBIDCOS during courses 3 and 6, and IFF and VP-16 IV over 1 hour on days 1-3 and DHAD IV over 15 minutes on day 1 during courses 1, 4, and 7.
3327912|NCT00058825|Experimental|Stem Cell Transplant|Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.
3327913|NCT00058812|Experimental|EBV specific T cells|EBV specific T cells
3327914|NCT00058773|Experimental|CTL Administration|Infusion of EBV Specific Cytotoxic T-Lymphocytes
3327915|NCT00002575|Experimental|Conventional surgery|"Patients undergo open laparotomy and colectomy. A standard incision is made through the abdominal wall and the abdominal cavity is explored. A right or left colectomy or a sigmoid resection is performed.~Patients may be entered on adjuvant chemotherapy trials after surgery provided the subsequent trial does not include radiotherapy and allows entry of patients from both arms.~Quality of life is assessed at baseline and on days 2 and 14 after surgery, at 2 months, and then at 18 months. (closed as of 4/30/99)~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 3 years."
3327916|NCT00002575|Experimental|Laparoscopic-assisted colectomy|"Patients undergo a laparoscopic-assisted colectomy. A small infraumbilical incision is made through the abdominal skin and the abdominal cavity is insufflated with CO2 to allow access and visualization. The abdominal cavity is explored. If advanced local disease is identified, a celiotomy and colectomy are performed. Otherwise, a right or left colectomy or sigmoid resection is performed using laparoscopic-assisted techniques.~Patients may be entered on adjuvant chemotherapy trials after surgery provided the subsequent trial does not include radiotherapy and allows entry of patients from both arms.~Quality of life is assessed at baseline and on days 2 and 14 after surgery, at 2 months, and then at 18 months. (closed as of 4/30/99)~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 3 years."
3327917|NCT00002550|Experimental|RT + chemotherapy followed by surgery + chemotherapy|Induction radiation therapy (RT) + concurrent induction chemotherapy followed by surgery and additional chemotherapy
3327918|NCT00002550|Active Comparator|RT + chemotherapy followed by chemotherapy + RT|Induction RT + concurrent induction chemotherapy followed by additional chemotherapy + RT
3327919|NCT00058617|Experimental|Injection of EBV Specific CTLs|Subjects will receive autologous EBV Specific CTLs. Patients that agree will recieve CTLs that have been marked with the neomycin resistance gene.
3327920|NCT00058526|Experimental|Cohort 1|Six doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
3327921|NCT00058526|Experimental|Cohort 2|Six doses of dHER2 (100 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
3327922|NCT00058526|Experimental|Cohort 3|Six doses of dHER2 (500 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.
3327923|NCT00058526|Experimental|Cohort 4|Three doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 4, and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.
3329805|NCT00035984|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
3327925|NCT00058474|Experimental|Arm 2: 5-FU + RT + Oxaliplatin|Patients receive fluorouracil and undergo RT as in arm 1. Patients also receive oxaliplatin IV over 1 hour once weekly for 5 weeks.
3327926|NCT00058474|Experimental|Arm 3: Capecitabine + RT|Patients receive oral capecitabine twice daily and undergo RT once daily 5 days a week for 5-6 weeks.
3327927|NCT00058474|Experimental|Arm 4: Capecitabine + RT + Oxaliplatin|Patients receive capecitabine and undergo RT as in arm 3. Patients also receive oxaliplatin as in arm 2.
3327928|NCT00058461|Experimental|Treatment (chemotherapy, rituximab)|Patients receive ifosfamide IV over 2 hours and etoposide IV over 1 hour on days 3-5, rituximab IV on days 1 and 3, and carboplatin IV over 1 hour on day 3. Patients receive filgrastim (G-CSF) subcutaneously once daily beginning on day 6 and continuing until blood counts recover. Patients also receive intrathecal (IT) chemotherapy comprising methotrexate and cytarabine. Patients with B-cell large cell lymphoma and negative CSF cytology receive IT chemotherapy on day 3 of the first course only. Patients with small non-cleaved cell lymphoma or B-cell acute lymphoblastic leukemia and negative CSF cytology receive IT chemotherapy on day 3. All patients with positive CSF cytology receive IT chemotherapy on days 3, 10, and 17 of the first and second courses. Treatment repeats every 23 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3327929|NCT00058422|Experimental|R-CHOP and Ibritumomab Tiuxetan (Zevalin)|"Chemotherapy: Patients receive rituximab IV over 2-5 hours, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5 or 2-6; and filgrastim (G-CSF) subcutaneously (SC) on days 7-15. Patients also receive darbepoetin alfa SC on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Radioimmunotherapy: Patients receive rituximab IV over 3-5 hours and indium In 111 ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0.~Patients undergo gamma camera imaging at 2-24 hours and 48-72 hours after the injection of IDEC-In2B8 to observe the flow of ibritumomab tiuxetan. If the flow is deemed safe, then patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7. Quality of life is assessed at baseline, before course 5 of chemotherapy, before radioimmunotherapy, and at 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
3327930|NCT00058370|Experimental|histologic proof of medulloblastoma|This is a single-arm study of post-operative radioimmunotherapy (intrathecal 131-I-3F8), reduced-dose craniospinal radiation therapy (1800 cGy), primary site boost (to 5400 cGy) via IMRT and standard chemotherapy.
3327931|NCT00058357|Active Comparator|Lidocaine patch|Participants will be instructed to apply a patch or patches (up to 3 maximum simultaneously) directly to the affected area. The patch(es) should be applied during awake hours and then left on continuously for approximately 18 hours or until usual bedtime sleep.
3327932|NCT00058357|Placebo Comparator|Placebo patch|Participants will be instructed to apply a patch or patches (up to 3 maximum simultaneously) directly to the affected area. The patch(es) should be applied during awake hours and then left on continuously for approximately 18 hours or until usual bedtime sleep.
3327933|NCT00058331|Experimental|epoetin alfa - long term dosing|"Patients receive epoetin alfa (EPO) subcutaneously (SC) once weekly for 3 weeks. Then patients receive EPO SC once weekly for 18 weeks. Quality of life is assessed at randomization at then monthly during study treatment.~Patients are followed every 6 months for 1 year."
3327934|NCT00058331|Experimental|epoetin alfa - short term dosing|"Patients receive epoetin alfa (EPO) subcutaneously (SC) once weekly for 3 weeks. Patients receive EPO SC on day 1 of weeks 4, 7, 10, 13, 16, and 19. Quality of life is assessed at randomization at then monthly during study treatment.~Patients are followed every 6 months for 1 year."
3327935|NCT00058318|Experimental|Treatment|Gemcitabine + Capecitabine
3327936|NCT00058305|Experimental|Treatment (bryostatin 1, vincristine sulfate)|"Patients receive bryostatin 1 IV over 24 hours on days 1 and 15 and vincristine IV on days 2 and 16. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients without disease progression after 6 courses may continue therapy with bryostatin 1 IV over 24 hours on days 1 and 22 and vincristine IV on days 2 and 23. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity."
3327937|NCT00058292|Experimental|Treatment Arm|
3327938|NCT00058266|Experimental|Group A|Patients receive oral genistein once daily for 1-2 months, undergo radical prostatectomy, and then continue oral genistein once daily for 1-2 months afterward (for a total of 3 months of therapy).
3327939|NCT00058266|Experimental|Group B|Patients undergo radical prostatectomy. Beginning 1 month after surgery, patients receive genistein as in arm I for 3 months.
3327940|NCT00058253|Experimental|Group I|Patients receive docetaxel IV over 1 hour and 17-AAG IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3327941|NCT00058253|Experimental|Group II|Patients receive docetaxel IV over 30 minutes and 17-AAG as in group 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3327942|NCT00058240|Experimental|Arm I|Patients receive a loading dose of flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression.
3327943|NCT00058227|Experimental|Treatment (alvocidib, fludarabine phosphate, rituximab)|Patients receive fludarabine phosphate IV over 15-30 minutes on days 1-5 and rituximab IV over 3-4 hours on day 1. Alvocidib is administered IV over 60 minutes on day 1 in cohort 1; on days 1 and 2 in cohort 2; and on days 1, 2, and 3 in cohort 3. In cohorts 4 and 5, patients receive fludarabine phosphate and rituximab as above and alvocidib IV over 30 minutes and then IV over 4 hours on day 1 of courses 2-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3327944|NCT00058214|Experimental|Treatment (perifosine)|Patients receive oral perifosine once daily on days 1-28. On day 1 of course 1 only, patients receive 2 doses of oral perifosine. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease by PSA alone may receive up to 3 additional courses of therapy after documentation of progression.
3327945|NCT00058201|Active Comparator|Arm I|Patients receive leucovorin calcium IV and fluorouracil IV on days 1-5.
3327946|NCT00058201|Experimental|Arm II|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15.
3327947|NCT00058201|No Intervention|Arm III|Patients undergo observation.
3328114|NCT00054756|Experimental|Thyrotropin Releasing Hormone|Subjects receiving TRH (Thyrotropin Releasing Hormone)
3327948|NCT00058188|Experimental|Arm I|Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in the absence of toxicity.
3327949|NCT00058188|Active Comparator|Arm II|Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.
3327950|NCT00058123|Experimental|Poly-ICLC Recurrent gliomas|"Poly-ICLC 20ug/kg 3 times a week 4 week cycles (Monday-Wednesday-Friday)~Intramuscular injection~Drug Poly-ICLC"
3327951|NCT00058097|Experimental|Treatment (tipifarnib)|"INDUCTION THERAPY: Patients receive oral tipifarnib twice daily for 3 weeks. Treatment repeats every 4 weeks for up to 3 courses.~RADIOTHERAPY: Within 14 days after the completion of induction therapy, patients undergo radiotherapy daily, 5 days a week, for 6 weeks.~MAINTENANCE THERAPY: Two weeks after the completion of radiotherapy, patients receive additional tipifarnib as in induction therapy.~Treatment continues in the absence of disease progression or unacceptable toxicity."
3327952|NCT00058084|Experimental|Arm I|Patients receive ixabepilone (BMS-247550) IV over 3 hours on day 1.
3327953|NCT00058084|Experimental|Arm II|Patients receive mitoxantrone IV over 30 minutes on day 1 and oral prednisone twice daily on days 1-21. In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3327954|NCT00058058|Experimental|MRI Evaluation of Contralateral Breast|The cohort is a distinct population of women at high risk for breast carcinoma: women with a recent (within 60 days) personal diagnosis of breast cancer who will have MRI to evaluate the contralateral breast.
3327955|NCT00058019|Experimental|Treatment (chemotherapy)|Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or if the patient becomes a candidate for stem cell transplantation.
3327956|NCT00057967|Experimental|Treatment arm|alemtuzumab
3327957|NCT00057954|Experimental|Transplant|Reduced toxicity conditioning regimen followed by allogeneic sibling or unrelated transplant. The conditioning regimen includes Extracorporeal Photopheresis, Pentostatin and total body irradiation (TBI). After allogeneic bone marrow transplantation, cyclosporin, mycophenolate mofetil (MMF), and methotrexate (MTX) will be given to prevent graft-versus-host disease (GVHD).
3327958|NCT00057941|Experimental|Arm I (anastrozole, gefitinib)|Patients receive oral anastrozole and oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3327959|NCT00057941|Experimental|Arm II (fulvestrant, gefitinib)|Patients receive fulvestrant intramuscularly on day 1 and oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3327960|NCT00057915|Experimental|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
3327961|NCT00057876|Active Comparator|Gemcitabine|
3327962|NCT00057876|Experimental|Gemcitabine + Radiation|
3327963|NCT00057863|Experimental|Treatment (paclitaxel, oxaliplatin)|Patients receive paclitaxel IV over 3 hours and oxaliplatin IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3327964|NCT00057850|Experimental|Arm I|"Phase I: Patients receive BMS-247550 IV over 3 hours and cisplatin IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment as above at the recommended phase II dose of BMS-247550.~Phase II: Patients receive treatment as in Phase I at the recommended phase II dose of BMS-247550."
3327965|NCT00057837|Experimental|PET (Topotecan/Etoposide/Cisplatin/G-CSF)|Patients receive topotecan intravenously (IV) over 30 minutes on days 1-3; etoposide IV over 60 minutes immediately followed by cisplatin IV over 60 minutes on days 8-10; and filgrastim (G-CSF) subcutaneously daily beginning on day 11 and continuing until blood counts recover.
3327966|NCT00057837|Experimental|PIE (Irinotecan/Cisplatin/Etoposide)|Patients receive irinotecan IV over 90 minutes and cisplatin IV over 60 minutes on days 1 and 8 and oral etoposide twice daily on days 3 and 10 of each cycle.
3327967|NCT00057811|Experimental|Group B (chemotherapy, protective therapy, monoclonal antib.)|Therapies given IV, IT, orally, or SC. Please see treatment outline. See Detailed Description.
3327968|NCT00057811|Experimental|Group C (Chemotherapy, monoclonal antibody therapy)|Therapies given IV, IT, orally, or subcutaneously (same as FAB B with the addition of etoposide and high-dose methotrexate). See Detailed Description.
3327969|NCT00057785|Experimental|IMRT +/- chemotherapy|Intensity modulated radiation therapy (IMRT) for all patients and chemotherapy (cisplatin and fluorouracil) for patients with stage ≥ T2b and/or N+
3327970|NCT00057759|Experimental|Sildenafil citrate|Sildenafil with dose escalation as needed from 50 mg to 100 mg/day prn for 12 weeks.
3327971|NCT00057759|Placebo Comparator|Placebo|"Placebo with similar dose escalation opportunity for 12 weeks."
3327972|NCT00057746|Active Comparator|Arm I|Prophylactic cranial irradiation, 2.5 Gy fx
3327973|NCT00057746|Experimental|Arm II|Prophylactic cranial irradiation, 2.0 Gy fx
3327974|NCT00057746|Experimental|Arm III|Prophylactic cranial irradiation, 1.5 Gy fx
3327975|NCT00030368|Experimental|Treatment (bortezomib, paclitaxel)|Patients receive bortezomib IV on days 2 and 9 and paclitaxel IV over 1 hour on days 1 and 8. For the first course only, patients do not receive paclitaxel on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3327976|NCT00023673|Experimental|Phase I: 75.25 Gy/36 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 75.25 Gy given in 36 fractions (2.15 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
3327977|NCT00023673|Experimental|Phase I: 74 Gy/37 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 74 Gy given in 37 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
3328115|NCT00054717|Other|Tipranavir(TPV)/low dose ritonavir(r)|
3328116|NCT00054717|Other|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
3327978|NCT00023673|Experimental|Phase I: 70 Gy/35 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 70 Gy given in 35 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
3327979|NCT00023673|Experimental|Phase II: 74 Gy/37 fx + chemotherapy|Phase II: Three-dimensional conformal radiation therapy (3DRT) of 74 Gy given in 37 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
3327980|NCT00004079|Experimental|Treatment (SarCNU)|"Patients receive oral sarcosinamide nitrosourea (SarCNU) on days 1, 5, and 9. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SarCNU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3327981|NCT00057681|Experimental|1|Participants will receive treatment with lithium for 8 to 16 weeks
3327982|NCT00057681|Experimental|2|Participants will receive treatment with valproate for 8 to 16 weeks
3327983|NCT00057681|Experimental|3|Participants will receive treatment with risperidone for 8 to 16 weeks
3327984|NCT00057642|Other|Sertraline, venlafaxine, bupropion|This is an open trial so there is only one arm using standard antidepressant medications.
3327985|NCT00057629|Active Comparator|1 Prolonged Exposure|Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.
3327986|NCT00057629|Active Comparator|2 Individual and group therapy|"TUGT (Treatment as usual group therapy - used in Study 1), delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is no formal, structured format for these groups; counselors are sensitive to the participants' needs and follow their lead re content covered in discussions and exercises.~Supportive counseling (SC - study 2): individual therapy delivered in 10 weekly, 90 minute sessions. Therapist helps patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these."
3327987|NCT00057603|Experimental|Deep Brain Stimulation|Participants receive deep brain stimulation treatment for 30 months.
3327988|NCT00057577|Experimental|Cognitive therapy plus medications|Participants will receive antidepressant medication plus cognitive therapy
3327989|NCT00057577|Experimental|Medications alone|Participants will receive maintenance of antidepressant medication alone
3327990|NCT00057564|Experimental|A (Thalidomide & Dexamethasone)|Thalidomide 50mg/day + Dexamethasone 40mg
3327991|NCT00057564|Placebo Comparator|B (Dexamethasone and placebo)|Dexamethasone and placebo
3327992|NCT00057551|Experimental|CBASP|Cognitive Behavioral System of Psychotherapy plus medication (Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine)
3327993|NCT00057551|Active Comparator|Brief Supportive Psychotherapy|Brief Supportive Psychotherapy plus medication (Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine)
3327994|NCT00057551|Active Comparator|Medication Only|Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine
3327995|NCT00057525|Experimental|Anthrax vaccine with or without PBS|Administor 1 dose 5 μg rPA with PBS (5 Volunteers)
3327996|NCT00057525|Placebo Comparator|Placebo|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combinedwith phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
3327997|NCT00057512|Experimental|Intratumoral M4N|The initial dose was 5 mg/cm3 of tumor volume on Days 1, 8, and 15. Dose escalation in cohorts on this schedule took place up to 20 mg/cm3 tumor volume. The dose per lesion was based upon the volume of tumor, and the total dose did not exceed 1197 mg M4N/m2 body surface area.
3327998|NCT00057499|Experimental|IBC-VS01 vaccine|IBC-VS01 vaccine is administered twice.
3327999|NCT00057499|Placebo Comparator|Control Group|IBC-VS01 placebo is administered twice
3328000|NCT00057473|Experimental|Arm A|
3328001|NCT00057473|Active Comparator|Arm B|
3328002|NCT00057408|Experimental|1|Treatment with olanzapine
3328003|NCT00057408|Placebo Comparator|2|Matching placebo treatment
3328004|NCT00057356|Placebo Comparator|1|
3328005|NCT00057356|Experimental|2|Low dose
3328006|NCT00057356|Experimental|3|Middle dose
3328007|NCT00057356|Experimental|4|High dose
3328008|NCT00057330|Experimental|Herpes Simplex Virus Group|Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus (HSV) vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.
3328009|NCT00057330|Experimental|Havrix Group|Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.
3328010|NCT00057291|Experimental|caregiving intervention|One group received caregiving intervention, another received only training, and a third was business as usual. These were the interventions.
3328011|NCT00057200|Other|Arm 1|
3328012|NCT00057187|Other|Arm 1|
3328013|NCT00057174|Other|Arm 1|
3328014|NCT00057161|Other|Arm 1|
3328015|NCT00057148|Other|Arm 1|
3328016|NCT00057135|Other|Arm 1|
3328017|NCT00057122|Active Comparator|1|
3328018|NCT00057122|Active Comparator|2|
3328019|NCT00057122|Active Comparator|3|
3328020|NCT00057122|Active Comparator|4|
3328021|NCT00057109||Group 1|
3328022|NCT00057096|Other|Arm 1|
3328023|NCT00057083|Other|Arm 1|
3328024|NCT00057070|Other|Arm 1|
3328025|NCT00057057|Other|Arm 1|
3328028|NCT00056979|Experimental|Fludarabine, CAMPATH-1H , Anti-CD45, FK506|Fludarabine will be given as a daily IV (intravenous, by vein) infusion for a total of 5 days. CAMPATH-1H will be given as a daily 4-hour IV (intravenous, by vein) infusion for three days. Anti-CD45 will be given as a daily 6-hour IV infusion over the next 4 days. To help prevent body from rejecting the transplant, the drug FK506 will be given, starting two days before the transplant and continuing for three months.
3328029|NCT00056966|Experimental|1|recipients of HLA matched sibling transplants
3328030|NCT00056966|Experimental|2|recipients of unrelated or mismatched family donor transplants
3328031|NCT00056862|Experimental|Low-dose pegIFN/standard-dose RBV|Patients receive a lower dose of peginterferon alfa-2a (90 mcg per week) and standard dose of ribavirin (800 mg/d) for chronic hepatitis C, genotype 2/3, for 24 weeks.
3328032|NCT00056862|Active Comparator|Standard-dose PegIFN/RBV|Patients receive the standard, recommended doses of peginterferon alfa-2a (180 mcg per week) and ribavirin (800 mg/d) for chronic hepatitis c, genotype 2/3, for 24 weeks.
3328033|NCT00056693|Experimental|A|
3328034|NCT00056667|Experimental|CBT plus relaxation response|Participants will receive cognitive behavioral therapy plus relaxation response training
3328035|NCT00056667|Active Comparator|Relaxation Response|Participants will receive relaxation response training
3328036|NCT00056667|Placebo Comparator|Education|Participants will receive rheumatoid arthritis education
3328037|NCT00056654|Experimental|1|
3328038|NCT00056589|Experimental|rFXIII|
3328039|NCT00056563|Active Comparator|1|Deep Brain Stimulation
3328040|NCT00056563|Active Comparator|2|Best Medical Therapy
3328041|NCT00056550|Experimental|Recombinant Human Antithrombin (rhAT) infusion|Loading and continuous infusion dose of rhAT to target and maintain an AT activity level > 80% and < 120% of normal.
3328042|NCT00056537|Experimental|1|
3328043|NCT00056498|Active Comparator|Active|Participants assigned to risperidone
3328044|NCT00056498|Placebo Comparator|Placebo|Participants assigned to placebo
3328045|NCT00056472|Active Comparator|olanzapine/sertraline combination|sertraline plus olanzapine
3328046|NCT00056472|Placebo Comparator|olanzapine plus placebo|olanzapine (5 - 20mg/day) plus placebo
3328047|NCT00056459|Experimental|1|Oxaliplatin/5-FU/LV and PTK787/ZK 222584
3328048|NCT00056459|Placebo Comparator|2|Oxaliplatin/5-FU/LV and placebo
3328049|NCT00056446|Experimental|1|Oxaliplatin/5-FU/LV and PTK787/ZK 222584
3328050|NCT00056446|Placebo Comparator|2|Oxaliplatin/5-FU/LV and placebo
3328051|NCT00056407|Placebo Comparator|Placebo Arm|Eligible subjects will complete a 4-week placebo run-in followed by randomization to matched placebo in a 1:1 ratio.
3328052|NCT00056407|Experimental|dustasteride arm|Eligible subjects will complete a 4-week placebo run-in followed by randomization to 0.5mg dutasteride in a 1:1 ratio. Randomization will be stratified by center.
3328053|NCT00056394|Experimental|1|Participants will receive comprehensive pain coping skills.
3328054|NCT00056394|Active Comparator|2|Participants will receive arthritis education.
3328055|NCT00056394|Active Comparator|3|Participants will receive standard care.
3328056|NCT00056329|Experimental|1|vitamin E plus multivitamin
3328057|NCT00056329|Placebo Comparator|2|placebo with multivitamin
3328058|NCT00056316|Experimental|Behavioral Skills Training|Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
3328059|NCT00056316|Active Comparator|Basic Education|Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
3328060|NCT00056303|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up targets nurturance, synchrony, and non-frightening behavior, as well as providing caregivers with help calming toddlers.
3328061|NCT00056303|Active Comparator|Developmental Education for Families|Developmental Education for Families targets providing cognitive stimulation to their children.
3328062|NCT00056290|Active Comparator|1|VEGF
3328063|NCT00056290|Placebo Comparator|2|Placebo
3328064|NCT00056277|Other|Arm 1|
3328065|NCT00056160|Experimental|CC-5013/Dex|CC-5013 (lenalidomide) plus oral high-dose dexamethasone
3328066|NCT00056160|Experimental|Placebo/Dex|Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone
3328067|NCT00056082|Experimental|Celecoxib 400 mg bid|Celecoxib 400 mg bid
3328068|NCT00056069|Experimental|Observational|Questionnaire Administration: Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
3328069|NCT00056056|Experimental|Bexarotene and PUVA|
3328070|NCT00056056|Active Comparator|PUVA|
3328071|NCT00056030|Experimental|cetuximab + oxaliplatin + leucovorin + fluorouracil|"Patients receive cetuximab IV over 1 hour (over 2 hours on day 1 of course 1 only) on days 1 and 8. Patients also receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously on days 1-2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity, for a minimum of 12 courses or until deemed to have resectable disease.~Quality of life is assessed at baseline and prior to each treatment course.~Patients are followed every 3 months for 1 year and then every 6 months for 3 years."
3328072|NCT00055991|Experimental|Bexarotene|Bexarotene / Targretin
3328073|NCT00055991|Placebo Comparator|Sugar Pill|Sugar pill / placebo
3328074|NCT00055978|Experimental|Arm I|Patients receive oral placebo twice daily for 6 months.
3328075|NCT00055978|Experimental|Arm II|Patients receive oral celecoxib twice daily for 6 months.
3328076|NCT00055913|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 15 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3328077|NCT00055913|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3330250|NCT00006565|Placebo Comparator|2|Inactive (placebo) filtration unit
3328078|NCT00055861|Experimental|Treatment (bevacizumab, docetaxel)|Patients receive bevacizumab IV over 30-90 minutes on weeks 1 and 3 and docetaxel IV over 60 minutes on weeks 1, 2, and 3. Treatment repeats every 4 weeks for up to 12 courses in the absence of unacceptable toxicity or disease progression.
3328079|NCT00055848||Group 1|"Patients donate blood samples for analysis of colorectal susceptibility genes. Patients also complete a questionnaire regarding family cancer history.~A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute.~Participants do not receive the results of the genetic testing, and the results do not influence the type or duration of treatment."
3328080|NCT00055809|Experimental|Arm I (bevacizumab)|Patients receive bevacizumab IV on day 1.
3328081|NCT00055809|Experimental|Arm II (PEG-interferon alfa-2b)|Patients receive PEG-interferon alfa-2b SC on days 1, 8, and 15.
3328082|NCT00055770|Experimental|Arm I|"PHASE I: Patients receive oral erlotinib once daily on days 1-28 and docetaxel IV over 1 hour on days 8, 15, and 22. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity.~Patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional cohort of 6 patients receives erlotinib at the MTD.~PHASE II: Patients receive erlotinib at the MTD and docetaxel as in phase I."
3328083|NCT00055757|Experimental|Treatment (tipifarnib, gemcitabine, cisplatin)|"Patients receive oral tipifarnib twice daily on days 1-14, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients with at least stable disease may continue to receive oral tipifarnib alone twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3328084|NCT00055692|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment continues every 2 weeks in the absence of disease progression or unacceptable toxicity.
3328085|NCT00055679|Active Comparator|6 FEC|6 cycles of CYCLOPHOSPHAMIDE + EPIRUBICINE + 5-FLUOROURACILE
3328086|NCT00055679|Experimental|4 FEC|4 cycles of CYCLOPHOSPHAMIDE + EPIRUBICINE + 5-FLUOROURACILE
3328087|NCT00055601|Experimental|Pelvic RT + paclitaxel + cisplatin|Induction: Twice-daily pelvic radiation therapy (RT) with paclitaxel and cisplatin; Consolidation: Twice-daily pelvic radiation therapy with paclitaxel and cisplatin if tumor response is T0/Ta/Tis or radical cystectomy if tumor response is ≥ T1; Adjuvant: gemcitabine, paclitaxel, and cisplatin.
3328088|NCT00055601|Experimental|Pelvic RT + fluorouracil + cisplatin|Induction: Twice-daily pelvic radiation therapy (RT) with fluoruracil and cisplatin; Consolidation: Twice-daily pelvic radiation therapy with fluoruracil and cisplatin if tumor response is T0/Ta/Tis or radical cystectomy if tumor response is ≥ T1; Adjuvant: gemcitabine, paclitaxel, and cisplatin.
3328089|NCT00022139|Experimental|carboplatin + paclitaxel + fluorouracil + radiation + surgery|"Patients receive carboplatin IV and paclitaxel IV over 3 hours on days 1 and 22 and fluorouracil IV continuously on days 1-42. Beginning on day 1 of chemotherapy, patients undergo radiotherapy to the esophagus 5 days a week for 5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease at 4-8 weeks after completion of radiotherapy undergo esophagectomy and complete dissection of the mediastinal and perigastric lymph nodes. Beginning 8 weeks after surgery, patients who underwent curative resection may receive a maximum of 2 additional courses of paclitaxel and carboplatin in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, before chemotherapy on days 1 and 22, and within 2 weeks before surgery.~Patients are followed every 3 months for 4 years."
3328090|NCT00005028|Experimental|Arm I|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and bryostatin 1 IV over 1 hour on days 2, 9, and 16. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
3328091|NCT00055497|Placebo Comparator|Double-blind (DB) adalimumab placebo|Double-blind nonactive matching subcutaneous injection
3328092|NCT00055497|Experimental|Double-blind adalimumab 40 mg every other week (eow)|Double-blind adalimumab 40 mg eow by subcutaneous injection
3328093|NCT00055497|Experimental|Double-blind adalimumab 40 mg every week (ew)|Double-blind adalimumab 40 mg every week by subcutaneous injection
3328094|NCT00055497|Experimental|Open-label adalimumab 40 mg|Open-label adalimumab 40 mg eow or ew by subcutaneous injection
3328095|NCT00055471|Experimental|ZD4054 10 mg|1 x 10 mg oral tablets once daily
3328096|NCT00055471|Experimental|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
3328097|NCT00055471|Experimental|ZD4054 22.5 mg|2 x 10 mg + 1 x 2.5 mg oral tablets once daily
3328098|NCT00055419|Experimental|400 mg/m2|
3328099|NCT00055393|Active Comparator|Subjects receivng Bupropion|The active arm subjects in this study (n = 18) received flexibly dosed bupropion in this randomized 12-week double-blind trial.
3328100|NCT00055393|Placebo Comparator|Subjects receiving Placebo|The inactive arm subjects in this randomly controlled study (n = 21) received a placebo.
3328101|NCT00055315|Active Comparator|STEPPS|Patients with Borderline Personality Disorder. Each subject met DSM-IV criteria for BPD, confirmed through a clinical interview and a review of the patient's case notes
3328102|NCT00055315|Placebo Comparator|Treatment as Usual|"Patients with Borderline Personality Disorder. Each subject met DSM-IV criteria for BPD, confirmed through a clinical interview and a review of the patient's case notes.~TAU for this BPD population includes medical management, group and individual therapy."
3328103|NCT00055302|Experimental|1|
3328104|NCT00055237|Experimental|Cohort 1: Pts with HIV-associated Kaposi's Sarcoma|15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks.
3328105|NCT00055237|Experimental|Cohort 2: Pts with classic Kaposi's Sarcoma (HIV-uninfected)|15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks.
3328106|NCT00054964|Experimental|Albuterol HFA-BOI|
3328107|NCT00054964|Active Comparator|Albuterol HFA-MDI|
3328108|NCT00054925|Active Comparator|Personal contact (PC)|The Personal Contact (PC) intervention offers one-on-one guidance and support in maintaining weight loss.
3328109|NCT00054925|Active Comparator|Interactive technology (IT)|Utilizes internet and automated phone technology to enhance the frequency and timeliness of feedback.
3328110|NCT00054847|Active Comparator|Saphenous Vein Graft|Saphenous Vein Graft
3328117|NCT00054704|Experimental|Riluzole|Riluzole was dispensed either once or twice a day as 50 mg tablets. Riluzole dosing began at 50 mg twice per day by mouth and was increased on a weekly basis by 50 mg, as tolerated, to achieve a dose of 200 mg/day. Dose escalations continued until at least a 50% reduction in depression (MADRS) scores, intolerable side effects, or study completion. Dose was raised on a weekly basis by 50 mg until the dose of 200 mg was achieved unless precluded by an adverse event. If significant side effects occurred, titration was slowed and doses were reduced under double-blind conditions. The maximum permitted dose of riluzole was 200 mg/day. Those subjects not tolerating a dosage of 50 mg/day were removed from the study.
3328118|NCT00054704|Placebo Comparator|Placebo|Placebo pills resembling 50 mg riluzole tables were dispensed either once or twice a day. Dosing began at 50 mg twice per day by mouth and was increased on a weekly basis by 50 mg, as tolerated, to achieve a dose of 200 mg/day. Dose escalations continued until at least a 50% reduction in depression (MADRS) scores, intolerable side effects, or study completion. Dose was raised on a weekly basis by 50 mg until the dose of 200 mg was achieved unless precluded by an adverse event. If significant side effects occurred, titration was slowed and doses were reduced under double-blind conditions. The maximum permitted dose of riluzole was 200 mg/day. Those subjects not tolerating a dosage of 50 mg/day were removed from the study.
3328119|NCT00054691|Experimental|Iressa (ZD1839)|Iressa (ZD1839) 250 mg by mouth daily.
3328120|NCT00050531|Experimental|Gleevec|Gleevec 400 mg orally twice daily.
3328121|NCT00050531|Experimental|Gleevec + Peg-Intron + GM-CSF|Gleevec 400 mg orally twice daily. Peg-Intron 0.5 mcg/kg each week subcutaneously. GM-CSF 125 mcg/m^2 three times per week subcutaneously.
3328122|NCT00054665|Experimental|Part A: PS-341 Alone|1.3 mg/m^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
3328123|NCT00054665|Experimental|Part B: PS-341 & EPOCH|"PS-341: level 1: 0.5 mg/m^2 intravenous (IV) days 1, 4; level 2: 1.0 mg/m^2 IV days 1, 4; level 3: 1.5 mg/m^2 IV days 1, 4; level 4: 1.7 mg/m^2 IV days 1, 4.~EPOCH: Etoposide: 50 mg/m^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion; Doxorubicin: 10 mg/m^2 day CIV days 1-4, 96 hour infusion; Vincristine: 0.4 mg/m^2 day CIV days 1-4, 96 hour infusion; Cyclophosphamide: 750 mg/m^2 day IV day 5 bolus; Prednisone: 60 mg/m^2 by mouth twice a day days 1-5; Filgrastim: 300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm^3. Repeat cycles every 21 days."
3328124|NCT00054639|Experimental|Treatment (oblimersen sodium and monoclonal antibody therapy)|Patients receive oblimersen sodium IV continuously on days 1-7, 15-21, and 29-35 and rituximab IV over 4-6 hours on days 3, 8, 15, 22, 29, and 36. Patients achieving stable disease or objective response may receive one additional course of treatment.
3328125|NCT00054587|Active Comparator|6 FEC|Patients receive fluorouracil IV, or epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy 5 days a week for 5 weeks.
3328126|NCT00054587|Experimental|6 DE|Patients receive epirubicin IV over 10 minutes and docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy as in arm I
3328127|NCT00054548|Experimental|Treatment (oblimersen sodium, paclitaxel)|"Patients receive oblimersen IV continuously on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~An additional cohort of 12-15 patients receives treatment as above with oblimersen at the MTD."
3328128|NCT00054483|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3328129|NCT00054457|Experimental|docetaxel + capecitabine|"Patients receive docetaxel IV over 1 hour on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, at each tumor measurement, and at the end of treatment.~Patients are followed every 3 months until disease progression and then every 6 months until 3 years from registration."
3328130|NCT00054444|Experimental|Treatment (topotecan hydrochloride, radiation, cisplatin)|Patients undergo radiotherapy 5 days a week for 6 weeks. Patients receive cisplatin IV and topotecan IV over 30 minutes once weekly for a total of 6 weeks in the absence of disease progression or unacceptable toxicity.
3328131|NCT00054431|Experimental|Treatment (imatinib mesylate, decitabine)|Patients receive oral imatinib mesylate daily and decitabine IV over 1 hour daily, 5 days per week, for 2 consecutive weeks. Courses repeat every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
3328132|NCT00054418|Experimental|calcium carbonate, vitamin D and risedronate|Patients receive calcium carbonate 600 mg daily, vitamin D 400 U daily and risedronate 35 mg weekly.
3328133|NCT00054418|Placebo Comparator|calcium carbonate, vitamin D and placebo|Patients receive calcium carbonate 600 mg daily, vitamin D 400 U daily and placebo weekly.
3328134|NCT00054405|Experimental|Treatment (IL-12, aldesleukin)|"Cohort A: Patients receive interleukin-12 (IL-12) IV over 5-15 seconds on days 1, 3, 5, 8, 10, and 12.~Cohort B: Patients receive interleukin-2 (IL-2) IV over 15 minutes twice daily on days 1 and 8 and IL-12 IV as in cohort A.~Treatment in both cohorts repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Some patients may receive additional courses at the discretion of the principal investigator.~Cohorts of 3-6 patients in both cohorts receive escalating doses of IL-2 and IL-12 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Once the MTD is determined, an additional cohort of 8 patients receives IL-12 and IL-2 at the MTD."
3328135|NCT00054353|Experimental|Related Donor|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors)."
3328166|NCT00053677|Placebo Comparator|Placebo|Subjects who were assigned to placebo in the 17 week double-blind phase.
3328167|NCT00053625|Active Comparator|SA #1 Arm 1: Unilateral DBS in GPi|
3328136|NCT00054353|Experimental|Unrelated Donor|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors)."
3328137|NCT00054327|Experimental|Regimen A|Patients receive cytarabine 3.0gm/M² IV over 1 hour twice daily on days -9 to -7 and cyclophosphamide 45mg/kg IV over 2 hours on days -6 and -5. Patients also undergo total body irradiation (TBI), 165 cGY, twice daily on days -4 to -1 for a total of 1320 cGY.
3328138|NCT00054327|Experimental|Regimen B-1|Patients receive cyclophosphamide 60 mg/kg IV on days -6 and -5. Patients also undergo total body irradiation (TBI) twice daily on days -4 to -1 for a total of 1320 cGY..
3328139|NCT00054327|Experimental|Regimen B-2|Patients receive cyclophosphamide 60 mg/kg IV over 2 hours on days -5 and -4. Patients also undergo TBI twice daily on days -3 to -1 for a total of 1200 cGY.
3328140|NCT00054327|Experimental|Regimen C|Patients receive oral busulfan 1mg/kg/dose (or 40mg/m2/dose for young children)4 times daily on days -8 to -5 and cyclophosphamide 60 mg/kg IV over 2 hours on days -4 to -2.
3328141|NCT00054327|Experimental|Regimen B-3|Patients undergo total body irradiation (TBI) twice daily on days -7 to -5 for a total of 1200 cGY. Patients then receive cyclophosphamide 60 mg/kg IV on days -4 and -3.
3328142|NCT00054327|Experimental|Regimen D|Patients receive total body irradiation (TBI) on days T -6, -5 and -4 for a total of 1320 cGy , then etoposide (60mg/kg/dose) on day -3.
3328143|NCT00054275|Experimental|Erlotinib Plus Docetaxel|
3328144|NCT00054236|Experimental|non-myeloablative conditioning regimen|
3328145|NCT00054184|Experimental|Study drug|
3328146|NCT00054132|Experimental|Treatment (erlotinib hydrochloride, bevacizumab)|Patients receive erlotinib hydrochloride PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3328147|NCT00054119|Experimental|Treatment|Patients receive karenitecin IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3328148|NCT00054041|Experimental|Arm I (HspE7)|Patients receive SGN-00101 subcutaneously once on weeks 1, 4, and 8 in the absence of disease progression. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy.
3328149|NCT00054041|Experimental|Arm II (control)|Patients receive standard care. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy.
3328150|NCT00054028|Experimental|Treatment (suramin and paclitaxel)|"PHASE I: Patients receive low-dose suramin IV over 30 minutes and paclitaxel IV over 1 hour once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive adjusted doses of suramin until a target dose is determined. The suramin target dose is defined as the dose at which at least 5 of 6 patients achieve the target plasma concentration of 10-50 uM over the duration when paclitaxel levels are therapeutic.~PHASE II: Patients receive paclitaxel in combination with the target dose of suramin as above."
3328151|NCT00053976|Experimental|Daclizumab|"Patients are randomized to 1 of 2 treatment arms.~Arm I:~Patients receive methylprednisolone or equivalent corticosteroid IV or orally~Daclizumab IV on days 0, 3, 7, 14, and then weekly as indicated until day 100.~Arm II: Patients receive methylprednisolone or equivalent corticosteroid as in arm I and placebo.~Patients are followed at 1 year and then annually thereafter."
3328152|NCT00053976|Placebo Comparator|Placebo|"Patients are randomized to 1 of 2 treatment arms.~Patients receive methylprednisolone or equivalent corticosteroid as in Daclizumab arm~Placebo IV on days 0, 3, 7, 14, and then weekly as indicated until day 100."
3328153|NCT00053963|Experimental|Arm I|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3328154|NCT00053950|Experimental|Cohort I|Groups of 3-6 patients receive escalating doses of PZA at a fixed infusion time until the MTD is determined. In both cohorts the MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients receive G-CSF IV or subcutaneously beginning on day 4 and continuing until blood counts recover. Patients also undergo reinfusion of stem cells over 15-30 minutes on day 4 as needed per protocol.
3328155|NCT00053950|Experimental|Cohort II|Groups of 3-6 patients receive PZA at the dose/hour established in cohort I at escalating infusion times until another MTD is determined. In both cohorts the MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients receive G-CSF IV or subcutaneously beginning on day 4 and continuing until blood counts recover. Patients also undergo reinfusion of stem cells over 15-30 minutes on day 4 as needed per protocol.
3328156|NCT00053898|Active Comparator|Group 1|tamoxifen 20 mg/day and an anastrozole look-alike placebo for 5 years
3328157|NCT00053898|Experimental|Group 2|anastrozole, 1 mg/day and an tamoxifen look-alike placebo for 5 years
3328158|NCT00053885|Experimental|PTK787/ZK 222584|"Patients receive oral PTK787/ZK 222584 daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year, every 4 months for 1 year, and then every 6 months for 1 year."
3328159|NCT00053846|Experimental|buspirone hydrochloride|buspirone hydrochloride
3328160|NCT00053846|Placebo Comparator|Placebo|Placebo
3328161|NCT00053833|Experimental|irinotecan|irinotecan
3328162|NCT00053703|Active Comparator|olanzapine|oral olanzapine 5-20mg per day for up to 52 weeks
3328163|NCT00053703|Active Comparator|risperidone|oral risperidone 0.5mg to 6mg daily for up to 52 weeks
3328164|NCT00053703|Active Comparator|molindone|oral molindone from 10-140mg/daily for up to 52 weeks
3328165|NCT00053677|Placebo Comparator|Naltrexone|17 weeks of double-blind Naltrexone. Subjects were randomized into one of these three conditions (if they weren't randomized to placebo): naltrexone 50mg/day, 100mg/day, 150mg/day. To minimize nausea, treatment for all subjects was initiated at 25mg/day naltrexone for two days, then the dose was increased to 50mg/day. At week 3, subjects were randomly assigned to 50mg/day continued at that dose, while subjects who were randomized to naltrexone 100mg/day or 150mg/day were raised to the higher doses.
3328169|NCT00053625|Active Comparator|SA #2 Arm 1: Bilateral DBS in GPi|Patients with GPi bilateral DBS (previously had unilateral DBS in the GPi, now have bilateral DBS in GPi)
3328170|NCT00053625|Active Comparator|SA #2 Arm 2: Bilateral DBS in STN|Patients with STN bilateral DBS (previously had unilateral DBS in the STN, now have bilateral DBS in STN)
3328171|NCT00053573|Experimental|1|
3328172|NCT00053508|Experimental|Group 1|ACAM1000
3328173|NCT00053508|Experimental|Group 2|ACAM1000
3328174|NCT00053508|Experimental|Group 3|ACAM1000
3328175|NCT00053508|Active Comparator|Group 4|Dryvax
3328176|NCT00053495|Experimental|Group 1: ACAM2000 Dose 1|Participants will receive a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units (PFU)/mL on Day 0.
3328177|NCT00053495|Experimental|Group 2: ACAM2000 Dose 2|Participants will receive a single dose of ACAM2000 smallpox vaccine, 2.0x10-8th plaque-forming units/mL on Day 0.
3328178|NCT00053495|Experimental|Group 3: ACAM2000 Dose 3|Participants will receive a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0
3328179|NCT00053495|Experimental|Group 4: ACAM2000 Dose 4|Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0
3328180|NCT00053495|Active Comparator|Group 5: Dryvax® Vaccine|Participants will receive a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0
3328181|NCT00053482|Experimental|Group 1: ACAM2000|Participants will receive dose 1 of the ACAM2000 smallpox vaccine
3328182|NCT00053482|Experimental|Group 2: ACAM2000|Participants will receive dose 2 of the ACAM2000 smallpox vaccine
3328183|NCT00053482|Experimental|Group 3: ACAM2000|Participants will receive dose 3 of the ACAM2000 smallpox vaccine
3328184|NCT00053482|Experimental|Group 4: ACAM2000|Participants will receive dose 4 of the ACAM2000 smallpox vaccine
3328185|NCT00053482|Active Comparator|Group 5: Dryvax®|Participants will receive dose 1 of Dryvax® smallpox vaccine.
3328186|NCT00053430|Experimental|1|Participants will receive low dose thalidomide for 28 days
3328187|NCT00053430|Placebo Comparator|2|Participants will receive low dose thalidomide placebo for 28 days
3328188|NCT00053417|Placebo Comparator|1|Placebo control, twice a day (b.i.d.)
3328189|NCT00053417|Experimental|2|10 milligram (mg) fampridine b.i.d.
3328190|NCT00053417|Experimental|3|15 mg fampridine b.i.d.
3328191|NCT00053417|Experimental|4|20 mg fampridine b.i.d.
3328192|NCT00053365|Experimental|Treatment (irofulven)|Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.
3328193|NCT00053352|Experimental|Arm I|"Patients enrolled with gonadal tumors of stage II or greater or extragonadal tumors of any stage receive cisplatin IV over 90 minutes & etoposide IV over 90 minutes days 1-3 and bleomycin sulfate IV over ≥ 10 minutes day 1. Treatment repeats every 3 weeks, 3 courses (weeks 0,3 & 6).~After completion of compressed induction chemotherapy, patients with no change in disease status or disease progression are removed from study. Patients with no evidence of disease receive no further therapy. Patients with a partial response or abnormal tumor markers proceed to conventional surgery (second-look) and/or 3 more courses of compressed consolidation chemotherapy.~After surgery, patients with pathologic complete response and have normal tumor markers receive no further therapy. Patients who remain with a partial response after surgery receive compressed consolidation chemotherapy.~Patients receive cisplatin, etoposide, and bleomycin as induction chemotherapy in weeks 10,13, & 16."
3328194|NCT00053352|No Intervention|Arm 2|"Patients who are enrolled with stage I gonadal tumors receive no further anticancer therapy until evidence of tumor recurrence or the diagnosis of a second malignant neoplasm.~Observation only for recurrence or development of an SMN"
3328195|NCT00053339|Experimental|trastuzumab|"Patients receive trastuzumab (Herceptin) IV over 60-90 minutes on day 1.~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years."
3328196|NCT00053339|Experimental|trastuzumab + tamoxifen|"Patients receive trastuzumab V over 60-90 minutes on day 1 and oral tamoxifen once daily on days 1-21.~In both arms, treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years."
3328197|NCT00053326|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide 3 times daily (or 2 times daily if over 18 years of age) on days 1-7. Treatment repeats every 3 weeks for up to 30 courses in the absence of disease progression or unacceptable toxicity.
3328198|NCT00053235||Ancillary-Correlative|Genomic DNA is isolated from OCT-embedded tissue and analyzed using comparative genomic hybridization. The chromosomal changes identified by this method are compared to those identified using the Taqman method, a quantitative genomic polymerase chain reaction analysis. Chromosome 8q is of specific interest. Other chromosomal changes may be detected in chromosomes 3q, 7q, 16q, and/or 17pter-q21.
3328199|NCT00053222|Experimental|Arm A|Arsenic trioxide (0.3 mg/kg/day iv for 5 days every 28 days)
3328200|NCT00053209|Experimental|Pemetrexed Disodium and Gemcitabine|Pemetrexed disodium 500 mg/m2 followed by gemcitabine 1000 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on day 8 of a 21-day cycle for a maximum of 6 cycles
3328201|NCT00053196|Experimental|Non myeloblative allogeneic transplant|Non myeloblative allogeneic hematopoietic cell transplantation after prior autologous transplantation
3328202|NCT00053053|Experimental|Juven supplement|Juven nutritional supplement given twice a day for 8 weeks
3328203|NCT00053053|Active Comparator|Non-Juven supplement|Non-Juven nutritional supplement given twice a day for 8 weeks
3328204|NCT00053040|Experimental|Surgery for tumor resection + IL13-PE38QQR infusion|
3328205|NCT00053027|Experimental|rituximab + cladribine|"Patients receive rituximab IV over 4-8 hours on day 1 and cladribine IV over 2 hours on days 4-8. If 2 or more patients experience unacceptable toxicity during the first course, the study is discontinued; otherwise, the study is opened for enrollment at all NCCTG sites.~Treatment repeats every 28 days for a total of 2-6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually for 2 years."
3328544|NCT00028756|Active Comparator|Arm I (immediate chemotherapy)|Beginning within 90 days of radical cystectomy, patients receive a total of 4 courses of adjuvant chemotherapy.
3328206|NCT00053014|Experimental|treatment|patient conditioning - fludarabine 30 mg/m2 IV over 1 hour Days -4, -3, -2; TBI 6-7 cGy/min Day 0 post-transplant immunosuppression - cyclosporine 6.25 mg/kg bid PO D -3 to +180 (begin taper on D+35); mycophenolate mofetil 15mg/kg bid PO D0 to +27
3328207|NCT00004078|Experimental|Treatment (irinotecan hydrochloride)|Patients receive irinotecan IV over 60 minutes on days 1-5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months for 4 years and then annually thereafter until death or until patient enters another POG study.
3328208|NCT00003830|Active Comparator|Arm I: Conventional axillary dissection|Sentinel node resection immediately followed by axillary dissection
3328209|NCT00003830|Experimental|Arm II: Sentinel node resection followed by node examination|Sentinel node resection followed by node examination then axillary dissection if positive sentinel node.
3328210|NCT00052962|Other|Arm 1 Surgery + post op chemotherapy|"Cytoreductive surgery - patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity, with cytoreductive surgery, or tumor debulking to reduce tumor size.~Post operative chemotherapy: systemic oxaliplatin, leucovorin and infusional 5-fluorouracil (5-FU), every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles {16 weeks total}."
3328211|NCT00052962|Other|Arm 2 Surgery + HIPEC|"Arm 2 Surgery + Continuous hyperthermic peritoneal perfusion (CHPP/HIPEC) + post op dwell + post op chemotherapy~Cytoreductive surgery - patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity, with cytoreductive surgery, or tumor debulking to reduce tumor size.~followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m^2 cisplatin~post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluorouracil (5FU) 800 mg/m^2 and paclitaxel 125 mg/m^2~post operative chemotherapy: systemic oxaliplatin, leucovorin and infusional 5-FU, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles {16 weeks total}."
3328212|NCT00052949|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily for 28 days. Courses continue in the absence of disease progression or unacceptable toxicity.
3328213|NCT00052910|Active Comparator|Arm I|Patients receive leucovorin calcium IV and fluorouracil (5-FU) IV on days 1-5 of courses 1, 3, and 4. Courses repeat every 28 days. During course 2, patients undergo radiotherapy 5 days a week and receive 5-FU IV continuously for 5 to 6 weeks. Patients rest for 28-35 days between course 2 and 3.
3328214|NCT00052910|Experimental|Arm II|Patients receive epirubicin IV over 3-15 minutes and cisplatin IV over 1 hour on day 1 and 5-FU IV continuously on days 1-21 during course 1. Beginning 1 week later, patients undergo radiotherapy 5 days a week and 5-FU IV continuously for 5 weeks. Patients rest for 28-35 days before beginning course 2 of chemotherapy. Patients then receive epirubicin, cisplatin, and 5-FU as in course 1. Treatment repeats every 21 days for 2 courses.
3328215|NCT00052897|Experimental|Arm I|"Patients receive SGN-00101 subcutaneously once on weeks 0, 4, and 8. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 5-6 patients receive escalating doses of SGN-00101 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experience dose-limiting toxicity."
3328216|NCT00052884|Experimental|Amifostine, Melphalan, and Stem Cell Reconstitution|Amifostine, Melphalan, and Stem Cell Reconstitution. Doses of Melphalan tested included 100 mg/m2 and 120 mg/m2
3328217|NCT00052845|Experimental|Combined chemotherapy|combination of 3 chemotherapy agents for hormone refractory prostate cancer
3328218|NCT00052780|Experimental|Treatment (temozolomide, O6-benzylguanine)|See Detailed Description
3328219|NCT00052715|Experimental|poly-ICLC Newly diagnosed GBM|"Poly-ICLC 20ug/kg 3 times a week (Monday-Wednesday-Friday) starting one week before Radiation Therapy~Intramuscular injection~Drug Poly-ICLC"
3328220|NCT00052689|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients with progressive disease crossover to arm II.
3328221|NCT00052689|Experimental|Arm II|Patients receive bortezomib as in arm I and gemcitabine IV over 30 minutes on days 1 and 8.
3328222|NCT00052611|Experimental|Celecoxib|Celecoxib will be given at a pre-determine dose twice daily for 3 months. If there is a favorable change in biomarker expression on biopsy at 3 months, treatment will continue to complete a 12-month treatment period.
3328223|NCT00052598|Experimental|Treatment (adoptive immunotherapy)|Patients receive allogeneic CD8+ PR3-specific CTLs IV over 1-2 hours on days 0, 7, 14, 28, and 49 and aldesleukin SC twice daily on days 28-41 and 49-63 in the absence of unacceptable toxicity.
3328224|NCT00052585|Experimental|Treatment (irinotecan, gefitinib, leucovorin, fluorouracil)|Patients receive oral gefitinib daily beginning on day 1, irinotecan IV over 90 minutes on days 1 and 15, and leucovorin calcium IV over 2 hours and fluorouracil IV over 3-5 seconds followed by a 22-hour infusion on days 1, 2, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3328225|NCT00052559|Experimental|Treatment (bevacizumab, fluorouracil, radiation therapy)|"Patients receive bevacizumab IV over 30-90 minutes on day 1 (courses 1-4). Beginning with course 2, patients also receive fluorouracil IV continuously on days 1-14 and undergo external beam radiotherapy on days 1-5 and 8-12. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo surgery 7 weeks after completion of chemoradiotherapy.~Cohorts of 6 patients receive escalating doses of bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 20 additional patients are treated at the MTD."
3328226|NCT00052520|Experimental|Treatment|See Detailed Description
3328227|NCT00052494|Experimental|STI-571 with cisplatin and irinotecan|
3328228|NCT00052481||Quality of life questionnaire|"Patients are randomized to 1 of 2 arms on ACOSOG-Z0070 (radical prostatectomy vs brachytherapy).~Patients in both arms complete a quality of life questionnaire at baseline, 2 and 6 months after treatment, and then at 1, 2, 4, 7, and 10 years after treatment as part of ACOSOG-Z0071."
3328229|NCT00052468|Experimental|TCG|Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, Gemcitabine 800 mg/m2 day 1 + 8, q 21 days / 6 - 10 courses
3328230|NCT00052468|Active Comparator|TC|Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, q 21 days / 6 - 10 courses
3328545|NCT00028756|Experimental|Arm II (deferred chemotherapy)|Beginning at the time of clinical relapse, patients receive a total of 6 courses of adjuvant chemotherapy.
3328231|NCT00052429|Experimental|High-Dose Radiation Therapy Plus Chemotherapy|"Phase I~Radiotherapy: Patients receive radiotherapy once daily 5 days a week for 6 weeks beginning on day 1.~Concurrent chemotherapy: Patients receive cisplatin IV over 20-30 minutes on days 1-5 and 22-26.~Adjuvant chemotherapy: Approximately 2-5 weeks after the completion of radiotherapy, patients receive fluorouracil IV continuously on days 1-4 and cisplatin IV over 20-30 minutes on days 1-5 and 22-26. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. In the absence of dose-limiting toxicity in 1 whole cohort of patients, study proceeds to phase II. Phase II~Patients are treated as in phase I. Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter."
3328232|NCT00052377|Experimental|Treatment (aldesleukin, recombinant interleukin-12)|"Patients receive IL-12 SC twice weekly for 24 weeks.~Disease is assessed at 13 weeks. Patients who do not have progressive disease also receive IL-2 SC 3 consecutive days a week during weeks 13-24. Patients with progressive disease at week 13 receive IL-2 SC at a fixed dose during weeks 13-24.~Patients with responding disease after week 24 may continue to receive IL-2 and IL-12 for another 12 weeks.~Cohorts of 3-6 patients receive escalating doses of IL-2 until the MTD is determined. The MTD is defined as the dose at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The RD is the dose preceding the MTD. Additional patients are treated at the RD."
3328233|NCT00052364|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3328234|NCT00052338|Experimental|Treatment (gemcitabine hydrochloride, carboplatin, bortezomib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8, carboplatin IV over 15-30 minutes on day 1, followed 1 hour later by bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with a clinical or radiographic response may continue receiving bortezomib beyond 6 courses.
3328235|NCT00052299|Experimental|ARM A|GO + MICE for remission induction followed by GO + mini-ICE for consolidation
3328236|NCT00052299|Active Comparator|ARM B|MICE for remission induction followed by mini-ICE for consolidation
3328237|NCT00052286|Experimental|drug dosage 1|- Arm I: Patients receive oral high-dose modafinil twice daily.
3328238|NCT00052286|Experimental|drug dosage 2|- Arm II: Patients receive oral low-dose modafinil twice daily.
3328239|NCT00052221|Experimental|Arm I: Epoetin Alfa|Epoetin alfa subcutaneously (SC) once weekly for 6 weeks
3328240|NCT00052221|Placebo Comparator|Arm II: Placebo|Placebo subcutaneously (SC) once weekly for 6 weeks
3328241|NCT00052208|Experimental|Treatment (gefitinib, radiation therapy)|Patients receive gefitinib PO QD for 7 weeks. Beginning 1 week after initiation of gefitinib, patients undergo radiation therapy QD 5 days a week for 6 weeks. Treatment with gefitinib continues for up to 18 months in the absence of disease progression or unacceptable toxicity.
3328242|NCT00052195|Placebo Comparator|B|
3328243|NCT00052195|Experimental|A|
3328244|NCT00052182|Experimental|1|Immunization on Day 0 and Weeks 4, 8, and 16
3328245|NCT00049673|Experimental|Arm I|Patients receive oral thalidomide daily and oral prednisone every other day for 4 years in the absence of disease progression or unacceptable toxicity.
3328246|NCT00049673|No Intervention|Arm II|Patients undergo observation.
3328247|NCT00049595|Active Comparator|ABVD|8 cycles of ABVD
3328248|NCT00049595|Experimental|BEACOPP|4 cycles of BEACOPP Escalated + 4 cycles of BEACOPP Baseline
3328249|NCT00049582|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 3 hours twice daily OR IV over 1 hour once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
3328250|NCT00049569|Experimental|Arm I|See detailed description.
3328251|NCT00049569|Experimental|Arm II|See detailed description.
3328252|NCT00049543|Experimental|Arm I (gefitinib)|Patients receive gefitinib PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
3328253|NCT00049543|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
3328254|NCT00049530|Experimental|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
3328255|NCT00049517|Experimental|Standard Daunorubicin Then Autologous HCT|"Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts.~The patients undergoing autologous hematopoietic cell transplantation (HCT) received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses (without pharmacokinetic sampling) followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
3328256|NCT00049517|Experimental|High-dose Daunorubicin Then Autologous HCT|"Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts.~The patients undergoing autologous hematopoietic cell transplantation (HCT) received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses (without pharmacokinetic sampling) followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
3328546|NCT00028743|Active Comparator|Cisplatin, Topotecan, Paclitaxel plus Carboplatin|Arm 1
3328257|NCT00049517|Experimental|Standard Daunorubicin Then GO/Autologous HCT|"Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts. patients randomized to the investigational arm received a single dose of Gemtuzumab ozogamicin (GO) at 6 mg/m2 followed by sargramostim 250 μ/m2 until recovery of counts.~The patients undergoing autologous HCT received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
3328258|NCT00049517|Experimental|High-dose Daunorubicin Then GO/Autologous HCT|"Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts. patients randomized to the investigational arm received a single dose of Gemtuzumab ozogamicin (GO) at 6 mg/m2 followed by sargramostim 250 μ/m2 until recovery of counts.~The patients undergoing autologous HCT received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
3328259|NCT00049517|Active Comparator|Standard Daunorubicin Then Allogeneic HCT or no Consolidation|"Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Patients without CR did not receive any consolidation treatment. Patients in CR with an unfavorable cytogenetic profile or an initial white blood cell count > 100,000/μL were to proceed to allogeneic HCT if they had a suitable human leukocyte antigen (HLA)-matched sibling donor available."
3328260|NCT00049517|Experimental|High-dose Daunorubicin Then Allogeneic HCT or no Consolidation|"Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Patients without CR did not receive any consolidation treatment. Patients in CR with an unfavorable cytogenetic profile or an initial white blood cell count > 100,000/μL were to proceed to allogeneic HCT if they had a suitable human leukocyte antigen (HLA)-matched sibling donor available."
3328261|NCT00049504|Experimental|Treatment (nonmyeloablative HSCT)|"NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total body irradiation on day -1.~TRANSPLANTATION: Patients undergo BMT, from an HLA-haploidentical donor, on day 0.~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3.~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV over 1-2 hours and then tacrolimus PO, once tolerated, on days 4-180, with taper on day 86 in the absence of graft-versus-host disease. Patients also receive mycophenolate mofetil PO three times daily on days 4-35."
3328262|NCT00049400|Experimental|treatment|Single-arm, dose-escalation of BMS-247550
3328263|NCT00049387|Experimental|Treatment (tipifarnib, temozolomide, radiation therapy)|See Detailed Description
3328264|NCT00049335|Experimental|Capecitabine|Capecitabine 1,000 mg/m^2/dose (2,000 mg/m^2/day) BID, PO, Days 1-14 of 21 day cycle.
3328265|NCT00049322|Experimental|Arm I-bevacizumab|Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks beginning 1 week prior to the first chemoembolization at a dose of 10 mg/kg. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
3328266|NCT00049322|No Intervention|Arm II-chemoembolization|chemoembolization as part of standard of care
3328267|NCT00049309|No Intervention|Control|Usual diet
3328268|NCT00049309|Experimental|Flaxseed diet|30 gram flaxseed dietary modification
3328269|NCT00049309|Experimental|Low fat diet|Low fat dietary modification
3328270|NCT00049309|Experimental|Low fat + Flaxseed diet|Low fat and 30 gram flaxseed dietary modification
3328271|NCT00049283|Experimental|Treatment (erlotinib hydrochloride, docetaxel, and radiation)|Patients receive oral erlotinib alone daily on weeks 1 and 2. Patients then receive oral erlotinib daily beginning on day 1 and docetaxel IV over 1 hour on day 3 of weeks 3-9. Patients also undergo radiotherapy once daily 5 days a week on weeks 3-9. Patients continue erlotinib for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who had N2 or greater cervical lymph node involvement at baseline or have residual neck adenopathy after chemoradiotherapy undergo neck dissection 6-8 weeks after completion of chemoradiotherapy. Erlotinib is held for 1 week before planned surgery and until healing is complete.
3328272|NCT00049257|Experimental|Treatment|Please see intervention descriptions
3328273|NCT00049218|Experimental|Vaccine Administration|"• Phase I: Beginning 9 weeks after completion of chemotherapy, patients receive autologous dendritic cell-adenovirus p53 vaccine subcutaneously (SC) on days 1, 14, and 28. Patients without PD may undergo repeat leukapheresis on day 49. Patients receive vaccine SC again on days 56, 84, and 112 in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of autologous dendritic cell-adenovirus p53 vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~• Phase II: Patients receive autologous dendritic cell-adenovirus p53 vaccine at the MTD determined in phase I."
3328293|NCT00047346|Experimental|Treatment (erlotinib hydrochloride)|"Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3328294|NCT00047333|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3328274|NCT00049192|Experimental|Treatment (oblimersen sodium, imatinib mesylate)|"Patients receive oblimersen IV continuously on days 1-10 and oral imatinib mesylate once or twice daily. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without a hematologic response after 2 courses go off study. Patients with complete or partial response after 4 courses may continue to receive oral imatinib mesylate daily.~Patients in cohort 2 receive an escalated dose of oblimersen; if well tolerated, subsequent cohorts receive oblimersen at the higher dose with the original dose of imatinib mesylate. If oblimersen is not well tolerated in cohort 2, subsequent cohorts receive the original dose of oblimersen with an escalated dose of imatinib mesylate. The first 6 patients accrued continue to receive the original dose (dose taken prior to study) of imatinib mesylate throughout the study."
3328275|NCT00049166|Experimental|Regimen A (erlotinib hydrochloride, IMRT)|"Patients receive oral erlotinib once daily. Beginning on day 15, patients also undergo IMRT once daily 5 days a week for 7 weeks.~Patients in both regimens continue to receive erlotinib until the last day of IMRT (patients already in the maintenance phase of this study as of 5/11/04 continue to receive erlotinib once daily for up to 2 years) in the absence of disease progression or unacceptable toxicity.~In both regimens, cohorts of 3-6 patients receive escalating doses of erlotinib until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3328276|NCT00049166|Experimental|Regimen B (erlotinib hydrochloride, cisplatin, IMRT)|"Patients receive oral erlotinib and undergo IMRT as in regimen A. Patients also receive cisplatin IV over 20 minutes on each day of radiotherapy.~Patients in both regimens continue to receive erlotinib until the last day of IMRT (patients already in the maintenance phase of this study as of 5/11/04 continue to receive erlotinib once daily for up to 2 years) in the absence of disease progression or unacceptable toxicity.~In both regimens, cohorts of 3-6 patients receive escalating doses of erlotinib until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3328277|NCT00049140|Experimental|EF5|This is a non randomised single arm pilot study.
3328278|NCT00049127|Experimental|Phase II (Group 1)|Patients receive imatinib mesylate PO, at the MTD determined in phase I, BID for 4 weeks.
3328279|NCT00049127|Experimental|Phase II (Group 2)|Patients receive standard-dose imatinib mesylate PO BID for 4 weeks.
3328280|NCT00049114|Experimental|Treatment (doxorubicin, cyclophosphamide, tipifarnib, G-CSF)|"PHASE I (nonregional stage IV disease) (closed to accrual as of 1/19/04): Patients receive doxorubicin IV over 10-15 minutes and cyclophosphamide IV over 30 minutes on day 1, oral tipifarnib twice daily on days 2-7, and G-CSF subcutaneously on days 2-13. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~PHASE II (stage IIB, IIIA, IIIB, or IIIC): Patients receive tipifarnib at the MTD and doxorubicin, cyclophosphamide, and G-CSF as in phase I (phase I closed to accrual as of 1/19/04). After the fourth course, patients may undergo complete resection."
3328281|NCT00049088|Experimental|Treatment (docetaxel, bevacizumab)|For course 1, patients receive docetaxel IV over 1 hour on days 1 and 8 and bortezomib IV over 3-5 seconds on days 9 and 12. Patients then receive 1 week of rest. For course 2 and all subsequent courses, patients receive docetaxel on days 1 and 8 and bortezomib on days 2, 5, 9, and 12. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 2-6 patients receive escalating doses of bortezomib and docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.
3328282|NCT00049036|Experimental|Arm I|Patients receive rituximab intravenously (IV) over 2-4 hours prior to each course of chemotherapy. Treatment repeats every 3 weeks for 4-6 courses. Patients who achieve a complete response after 4 courses of chemotherapy and rituximab receive additional rituximab alone weekly for 2 weeks.
3328283|NCT00049036|Experimental|Arm II|Patients do not receive rituximab concurrently with chemotherapy. Beginning 4 weeks after completion of chemotherapy, patients receive rituximab IV over 2-4 hours weekly for 6 weeks.
3328284|NCT00049023|Experimental|90Y-DOTA-tyr3-OCTREOTIDE|Dose escalation will proceed so that the single-cycle and three-cycle maximum tolerated doses of 90Y-DOTA-tyr3-Octreotide can be determined. The initial dose of 90Y-DOTA-tyr3-Octreotide to be administered is 30 mCi/m2 in each of three cycles. Dose escalation will proceed in 10 mCi/m2 intervals and will be permitted for the next cohort of subjects pending completion of Cycle 3 by 2 members of the previous cohort with no DLTs. A DLT is defined as a Grade 3 renal toxicity, Grade 4 bone marrow toxicity, or any other Grade 3 toxicity whether or not related to study drug and regardless of duration. Lymphopenia will not be used to define a DLT.
3328285|NCT00049010|Experimental|Group 1|"Melastatin mRNA expression is determined by in situ hybridization using tissue from primary tumor and lymph nodes. Tissue is also examined by immunohistochemical staining using antibodies to S-100 and MART-1. Patients do not receive the results of these tests nor do the results influence individual therapy.~Patients are followed every 4 months for 3.5 years."
3328286|NCT00048997|Experimental|Prophylactic cranial irradiation (PCI)|Radiation therapy
3328287|NCT00048997|Other|Observation|Observation
3328288|NCT00048984||Basic science (biomarker analysis)|Patients undergo various specimen collections, including bone marrow aspirate, paraffin-embedded blocks of tumor tissue or slides of tumor tissue, and blood specimens. These specimens are collected before, during, and after any chemotherapy regimens, during follow-up, and at time of recurrence. Translocation studies are performed on specimens to identify fusion genes, specifically EWS-ETS. Serum IGF1 and IFGBP3 levels are determined. Bone marrow is assessed for minimal residual disease using reverse-transcriptase polymerase chain reaction.
3328289|NCT00048971||Group 1|Patients undergo collection of blood specimens for polymerase chain reaction and restriction fragment length polymorphism analysis. Genotyping assays are performed to determine UGT1A1 promoter genotyping, UGT1A1 coding polymorphisms, TS promoter polymorphisms, and MTHFR polymorphisms.
3328290|NCT00048958||No treatment|Samples as defined per the protocol for previously untreated patients with AML, ALL, MDS or MM will be submitted for analysis and within one month patients are required to register onto a CALGB treatment study.
3328291|NCT00047385|Experimental|Low-Dose CT|
3328292|NCT00047385|Experimental|Chest X-ray|
3328361|NCT00042978|Active Comparator|Arm II (carboplatin and etoposide)|Patients receive carboplatin IV over 30 minutes on day 1 and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3328295|NCT00047320|Experimental|Radiation Therapy (CR from Induction)|Patients will receive 6 cycles of Induction chemotherapy consisting of carboplatin and etoposide (Cycles 1, 3, and 5) alternating with ifosfamide and etoposide (Cycles 2, 4, and 6). The entire length of Induction is 18 weeks unless delay occurs due to myelosuppression or unanticipated toxicity. Each cycle of Induction will begin when ANC > 750/L and platelets > 75,000/L and when off filgrastim (G-CSF) for at least 48 hours. Following the Induction phase (weeks 0-18) those patient in CR will undergo radiation therapy.
3328296|NCT00047307|Experimental|Treatment (alvocidib, gemcitabine hydrochloride, 3DRT)|"Patients receive flavopiridol IV over 1 hour twice weekly (on days 1 and 4 or days 2 and 5) for 6 weeks. Concurrently, patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Four weeks after the completion of radiotherapy, patients are re-evaluated*. Beginning within 4-7 weeks after the completion of chemotherapy and radiotherapy, patients receive gemcitabine hydrochloride alone or in combination with another cytotoxic agent or gemcitabine hydrochloride combined with a targeted drug (e.g., erlotinib or bevacizumab) at the discretion of the oncologist. NOTE: *Patients whose imaging studies suggest potential curative resection are referred for a surgical evaluation before initiating gemcitabine hydrochloride therapy. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. Continued (see detailed description)"
3328297|NCT00047255|Experimental|Herceptin plus docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
3328298|NCT00047255|Experimental|Docetaxel, Carboplatin, and Herceptin|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
3328299|NCT00047229|Experimental|G3139 in combination with Doxorubicin|
3328300|NCT00047203|Experimental|Treatment (flavopiridol)|Patients receive flavopiridol IV over 1 hour on days 1-3. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. After 12 months, patients achieving at least a partial response may continue treatment in the absence of disease progression or unacceptable toxicity.
3328301|NCT00047190|Experimental|Arm I|Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3328302|NCT00047125|Experimental|Selective irradiation|Irradiation of the ipsilateral level I - V of the neck up to a dose of 60 Gy (30x2Gy in 6 weeks).
3328303|NCT00047125|Active Comparator|Extensive irradiation + ipsilaterals levels|Irradiation on the whole mucosa of the larynx, hypopharynx, oropharynx and nasopharynx, and on both sides of the neck (levels I -V) up to a prophylactic dose of 50 Gy (25 x 2 Gy in 5 week).Irradiation of the ipsilateral level I - V of the neck should continue with an additional 10 Gy boost for a total dose of 60 Gy (30 x 2 Gy in 6 weeks).
3328304|NCT00047112|Experimental|CHIMIORADIOTHERAPIE SUIVIE DE CHIRURGIE|CHIMIORADIOTHERAPIE SUIVIE DE CHIRURGIE
3328305|NCT00047112|Active Comparator|CHIRURGIE SEULE|CHIRURGIE SEULE
3328306|NCT00047073|Experimental|Phase 1|See intervention description.
3328307|NCT00047073|Experimental|Phase 2|See intervention description.
3328308|NCT00047047|Experimental|Treatment (tanespimycin, gemcitabine hydrochloride, cisplatin)|"Cohort A (closed to accrual as of 3/2/04)*: Patients receive escalating doses of gemcitabine hydrochloride intravenously (IV) over 30 minutes, tanespimycin IV over 1 hour, and cisplatin IV over 2 hours on days 1 and 8. NOTE: *The maximum tolerated dose (MTD) of this 3-drug combination has been determined as of 3/2/04.~Cohort B (closed to accrual as of 3/2/05): Patients receive gemcitabine hydrochloride** IV over 30 minutes, tanespimycin IV over 1 hour, and cisplatin** IV over 2 hours on days 1 and 8.~Cohort C: Patients receive gemcitabine hydrochloride** IV over 30 minutes and tanespimycin IV over 1-2 hours on days 2 and 9.~Cohort D: Patients receive cisplatin** IV over 2 hours and tanespimycin IV over 1-2 hours on days 1 and 8.~Cohort E: Patients receive gemcitabine hydrochloride***, tanespimycin***, and cisplatin*** as in cohort B.~Continued (see detailed description)"
3328309|NCT00047034|Experimental|Treatment (eribulin mesylate)|Patients receive E7389 IV over 1-2 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for at least 4 courses in the absence of disease progression or unacceptable toxicity.
3328310|NCT00047008|Other|Standard fractionation RT + cisplatin|Standard fractionation radiation therapy with concurrent cisplatin followed by conventional surgery for select patients.
3328311|NCT00047008|Experimental|Accelerated fractionation RT + cisplatin|Accelerated fractionation radiation therapy by concomitant boost with concurrent cisplatin followed by conventional surgery for select patients.
3328312|NCT00046930|Experimental|Zosuquidar|Induction treatment with daunorubicin, cytarabine and zosuquidar (details provided in Intervention section), followed by consolidation with Cytarabine (1500 mg/m2 every 12 hours for 6 days), then additional consolidation with the same regimen as received during induction.
3328313|NCT00046930|Active Comparator|Placebo|Induction treatment with daunorubicin, cytarabine and placebo (details provided in Intervention section), followed by consolidation with Cytarabine (1500 mg/m2 every 12 hours for 6 days), then additional consolidation with the same regimen as received during induction.
3328467|NCT00033423|Experimental|Cohort II|Second radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
3328547|NCT00028743|Active Comparator|Paclitaxel plus Carboplatin|Arm 2
3328314|NCT00046917|Experimental|Treatment (chemotherapy)|Patients are stratified according to the number of prior treatment regimens (0 or 1 vs more than 1). Patients receive irinotecan hydrochloride IV over 30 minutes followed immediately by cisplatin IV over 30 minutes followed 7 hours later by alvocidib IV over 1-4.5 hours weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3328315|NCT00046891|Experimental|Ginkgo Biloba|120 mg per day (60 mg BID)
3328316|NCT00046891|Placebo Comparator|Placebo|1 tablet BID
3328317|NCT00046865|Experimental|Acupressure|Arm I: Patients receive active acupressure plus usual nausea care during the second or third course of chemotherapy. Acupressure is applied to a specific site each morning and again whenever nausea is experienced for 3-6 minutes.
3328318|NCT00046865|Placebo Comparator|Placebo Acupressure|Arm II: Patients receive placebo acupressure plus usual nausea care during the second or third course of chemotherapy. Acupressure is applied as in arm I except at a non-specific site.
3328319|NCT00046865|Sham Comparator|Usual Care|Arm III: Patients receive usual nausea care during the second or third course of chemotherapy.
3328320|NCT00046839|Experimental|Phase I: Celecoxib 200mg BID + RT|"COX-2 Inhibitor: Celecoxib 200 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
3328321|NCT00046839|Experimental|Phase I: Celecoxib 400mg BID + RT|"COX-2 Inhibitor: Celecoxib 400 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
3328322|NCT00046839|Experimental|Phase II: Celecoxib 400mg BID + RT|"COX-2 Inhibitor: Celecoxib 400 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
3328323|NCT00045734|Experimental|Treatment (imatinib mesylate)|"Patients receive oral imatinib mesylate once or twice daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study/ laboratory biomarker analysis"
3328324|NCT00045708|Experimental|Group A [Anticonvulsants]|"Phase I: Dose Escalation - Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 patients experience dose-limiting toxicity.~Pharmacological Study Phase 1"
3328325|NCT00045708|Experimental|Group B [No Anticonvulsants]|"Phase I: Dose Escalation - Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 patients experience dose-limiting toxicity.~Pharmacological Study Phase 1"
3328326|NCT00045708|Experimental|Group C [MTD-Phase 2)|"Maximum tolerated Dose (MTD-Phase 2) - subjects treated at dose determined by Group B~Drug: ixabepilone~Other Names:~BMS-247550 epothilone B lactam Ixempra Given IV"
3328327|NCT00045682|Experimental|Treatment (polyglutamate paclitaxel)|Patients receive polyglutamate paclitaxel (CT-2103) IV over 10-20 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3328328|NCT00045630|Experimental|Gemcitabine, Paclitaxel, Carboplatin|Gemcitabine, Paclitaxel, Carboplatin followed by surgery
3328329|NCT00045617|Experimental|cisplatin and etoposide followed by vaccine|standard chemotherapy with cisplatin and etoposide followed by cisplans and etoposide with an anti-idiotype monoclonal antibody vaccine
3328330|NCT00045591|Experimental|Celecoxib 100 mg|
3328331|NCT00045591|Experimental|Celecoxib 400 mg|
3328332|NCT00045565|Experimental|Group A|Patients receive arsenic trioxide IV over 2 hours once weekly for 6 weeks. Patients in both groups also undergo radiotherapy once daily 5 days a week for 6 weeks.
3328333|NCT00045565|Experimental|Group B|Patients receive arsenic trioxide at a lower dose IV over 2 hours twice weekly for 6 weeks. Patients in both groups also undergo radiotherapy once daily 5 days a week for 6 weeks.
3328334|NCT00045526|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3328335|NCT00045487|Experimental|OSI-774|
3328336|NCT00045435|Experimental|Treatment (nonmyeloablative donor PBSC transplant)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANT: Patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive CSP PO BID on days -3 to 56 with taper to day 77. Patients also receive MMF PO BID on days 0-27."
3328337|NCT00045396|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-14. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
3328338|NCT00045305|Experimental|Arm I|"Preparative Regimen: Patients underwent photopheresis on two consecutive days and received pentostatin 4 mg/m2/d (total dose = 8 mg/m2) by continuous IV infusion on two consecutive days following photopheresis. Total body irradiation was administered on two consecutive days following pentostatin for a total of 600 cGy given in three 200 cGy fractionated doses.~Transplantation: Unmanipulated allogeneic bone marrow or G-CSF mobilized peripheral blood stem cells were infused on day 0 within 48 hours of completion of TBI. Minimum cell dose was 2 ×106 CD34 cells/kg recipient.~Acute graft-vs-host-disease (GVHD) prophylaxis: Patients received Cyclosporine or Tacrolimus per institutional preference or protocol beginning no later than day -1. Methotrexate (MTX) was administered on day +1 and +3. Mycofenolate mofetil (MMF) was introduced on day 100 and could be tapered and discontinued after 12 months if no active cGVHD."
3328468|NCT00033423|Experimental|Cohort III|Third radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
3329806|NCT00035984|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
3328339|NCT00045201|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive oral erlotinib hydrochloride daily on days -6 to -1. Patients then receive irinotecan hydrochloride IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3328340|NCT00045188|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily. Treatment continues for at least 8 weeks in the absence of disease progression or unacceptable toxicity.
3328341|NCT00045175|Experimental|UCN-01 in combination with topotecan|
3328342|NCT00045162|Active Comparator|1|
3328343|NCT00045162|Active Comparator|2|
3328344|NCT00045110|Experimental|Phase 1 Dose Escalation|"Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~erlotinib hydrochloride given orally~Other: pharmacological study."
3328345|NCT00045110|Experimental|Phase 2 recurrent malignant gliomas and nonprogressive GBM|"Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose (150mg/day.~patients requiring surgery treated 7 days prior to tumor removal (150mg/day)~PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR)~erlotinib hydrochloride given orally~Other: pharmacological study, laboratory biomarker analysis."
3328346|NCT00045032|No Intervention|Observation Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin will be provided.
3328347|NCT00045032|Experimental|Herceptin 1-Year Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 1 year or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.
3328348|NCT00045032|Experimental|Herceptin 2-Year Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 2 years or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.
3328349|NCT00045019||discharged cancer patients|patients discharged from a surgery or medical ward of oncology institutes in Belgium, France, Germany, Italy, Poland, Spain, Sweden, Taiwan and United Kingdom (as part of a larger psychometric validation study) were asked to rate there level of satisfaction, using the EORTC QLQ-SAT32.
3328350|NCT00044967||Group 1|"Patients undergo baseline colonoscopy before or within 6 months of initial curative resection and then surveillance colonoscopy at 1, 3, and 5 years (+/- 6 months) after resection. The number, size, location, histology, and method of removal of polyps are documented at the time of colonoscopy. Patients also undergo microsatellite instability (MSI) status testing and complete family history questionnaires at baseline.~The prognostic significance of family history and MSI status is evaluated. The individual histologic features of the tumors are compared with the MSI status to determine their predictive value. The histologic features are also correlated with outcome to determine their prognostic significance.~Patients may be referred for genetic counseling."
3328351|NCT00043121|Experimental|Treatment (combination chemotherapy)|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil IV on days 1 and 15. Patients also receive oral capecitabine every 8 hours on days 1-2 and 15-16. Leucovorin calcium and fluorouracil administration is held at dose level 4 and above. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3328352|NCT00043082|Experimental|carboplatin and doxorubicin|carboplatin and liposomal doxorubicin given q 4 weeks
3328353|NCT00043082|Active Comparator|carboplatin|carboplatin alone
3328354|NCT00043069|Active Comparator|Arm I: calcium + cholecalciferol + placebo + estrogen|"Patients receive oral calcium, oral cholecalciferol, oral risedronate placebo, and oral estrogen placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
3328355|NCT00043069|Experimental|Arm II: calcium + cholecalciferol + risedronate + estrogen|"Patients receive oral calcium, oral cholecalciferol, oral risedronate, and oral estrogen placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
3328356|NCT00043069|Placebo Comparator|Arm III: calcium + cholecalciferol + placebo + estrogen|"Patients receive oral calcium, oral cholecalciferol, low-dose oral conjugated estrogens, and oral risedronate placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
3328357|NCT00043069|Experimental|Arm IV: calcium + cholecalciferol + risedronate + estrogen|"Patients receive oral calcium, oral cholecalciferol, low-dose oral conjugated estrogens, and oral risedronate daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
3328358|NCT00043017|Experimental|MRI/MRS|MRI and MRS examinations with standard imaging, with contrast enhancement using an agent (gadopentetate dimeglumine).
3328359|NCT00042991|Experimental|Treatment (gefitinib and radiation therapy)|"Phase I portion: Patients receive oral gefitinib once daily. Treatment repeats every 4 weeks for 13 courses (1 year). Patients also receive standard brain irradiation once daily, 5 days a week, for 6 weeks beginning concurrently with initiation of the first course of gefitinib. Treatment continues in the absence of disease progression or unacceptable toxicity.~Phase II portion: Once the MTD or the recommended Phase-II dose is determined, additional patients who have newly diagnosed BSG are treated at the MTD or the recommended Phase-II dose."
3328360|NCT00042978|Experimental|Arm I (oblimersen sodium, carboplatin, and etoposide)|Patients receive oblimersen sodium IV continuously on days 1-8, carboplatin IV over 30 minutes on day 6, and etoposide IV over 60 minutes on days 6-8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3328362|NCT00042965|Experimental|Gemcitabine + capecitabine|"Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 1-21. Treatment repeats every 28 days for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.~Patients are followed every 3 months for 1 year and then every 6 months for 1 year."
3328363|NCT00042952|Experimental|Treatment (imatinib mesylate and surgical resection)|Patients receive oral imatinib mesylate once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients who achieve a partial response or stable disease with normalization of human chorionic gonadotropin may undergo surgical resection of residual lesions at each tumor status assessment. If residual viable germ cell tumor is present in the resected specimen, patients may resume imatinib mesylate. If no viable germ cell tumor is present in the resected specimen, then no further therapy is administered.
3328364|NCT00042939|Active Comparator|Irinotecan/Docetaxel|"Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m². Docetaxel was diluted in 100-150 ml of infusion solution. After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m².~Chemotherapy was administered once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. This constituted a cycle of treatment. Patients were evaluated after 2 cycles."
3328365|NCT00042939|Experimental|Irinotecan/Docetaxel/Cetuximab|"Patients received Cetuximab intravenously once a week for 6 weeks. On day 1 of cycle 1 only, an initial dose of 400 mg/m² (over 120 minutes) was administered. Thereafter, a once-a-week maintenance dose of 250 mg/m² (infused over 60 minutes), was given. The infusion rate never exceeded 5 ml/minute.~On the day of the initial dose, the administration of Cetuximab was followed by the administration of docetaxel, after a 60-minute observation period. (The observation period was 30 minutes following maintenance doses.) Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m². Docetaxel was diluted in 100-150 ml of infusion solution. After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m².~Chemotherapy was administered once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Cetuximab was administered once a week for 6 consecutive weeks. A cycle of treatment was 6 weeks."
3328366|NCT00042926|Experimental|Radiolymphoscintigraphy + surgery|"Patients undergo radiolymphoscintigraphy comprising technetium Tc 99m sulfur colloid to identify the sentinel lymph nodes (SNL). Within 18 hours after radiolymphoscintigraphy, patients undergo resection of the primary oral cavity tumor and radioguided sentinel lymphadenectomy and regional cervical lymphadenectomy. Lymph nodes are examined by hematoxylin and eosin (H&E) staining. If negative by H&E, lymph nodes are further analyzed by immunohistochemistry.~Patients are followed at 30 days."
3328367|NCT00042874|Experimental|Treatment (combination chemotherapy)|Patients receive irinotecan hydrochloride IV over 90 minutes followed 5 hours later by leucovorin calcium IV over 2 hours and alvocidib IV over 1 hour immediately followed by 5-FU IV continuously over 48 hours beginning on day 1 of weeks 1, 3, and 5. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of alvocidib and 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Ten additional patients are treated at the MTD.
3328368|NCT00042835|Experimental|Group I (cisplatin, etoposide, erlotinib, and docetaxel)|Patients receive cisplatin IV over 2 hours on days 1, 8, 29, and 36; etoposide IV over 1 hour on days 1-5 and 29-33; and oral erlotinib once daily on days 1-49. Patients undergo concurrent radiotherapy 5 days a week for 7 weeks beginning on day 1. Patients receive consolidation therapy comprising docetaxel IV over 1 hour on days 50, 71, and 92. Some patients may also receive oral erlotinib once daily on days 50-112.
3328369|NCT00042835|Experimental|Group II (paclitaxel, carboplatin, and erlotinib|Patients receive induction chemotherapy comprising paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1 and 21. Patients receive consolidation therapy comprising paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 43, 50, 57, 64, 71, 78, and 85 and oral erlotinib once daily on days 43-91. Patients undergo radiotherapy concurrently with consolidation therapy 5 days a week for 7 weeks beginning on day 43.
3328370|NCT00042809|Experimental|Treatment (paclitaxel, trastuzumab, erlotinib hydrochloride)|See detailed description.
3328371|NCT00042796|Experimental|Treatment (decitabine)|Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 4-6 weeks for a minimum of 4 courses in the absence of disease progression or unacceptable toxicity.
3328372|NCT00042770|Active Comparator|Arm I|Patients undergo placement of a standard pleural chest tube. Within 36 hours of chest tube placement, patients undergo pleurodesis comprising intrapleural administration of talc slurry once followed by clamping of the chest tube for 2 hours while different patient positions are used to distribute the talc. The chest tube is then unclamped to allow continuous drainage. When the chest tube drainage is less than 150 mL over 24 hours, pleurodesis is assumed and the chest tube is removed.
3328373|NCT00042770|Experimental|Arm II|Patients undergo pleurodesis comprising placement of a small (PleurX) catheter followed by pleural drainage for up to 90 minutes once daily. When the catheter drainage is less than 30 mL per day for 3 consecutive days, pleurodesis is assumed and the catheter is removed.
3328374|NCT00042731|Active Comparator|Oral isoflavones with multivitamin|Cohorts I - III: Patients receive 1 of 3 doses of oral isoflavones twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
3328375|NCT00042731|Active Comparator|Oral lycopene with multivitamin|Cohorts IV-VI: Patients receive 1 of 3 doses of oral lycopene twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
3328376|NCT00042731|Active Comparator|Multiple vitamin alone|Patients receive a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
3328377|NCT00041340|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable disease or better continue therapy until disease progression or 1 year after complete response.
3328469|NCT00033423|Experimental|Cohort IV|Fourth radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
3328470|NCT00033423|Experimental|Cohort V|MTD radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
3328575|NCT00027846|No Intervention|GTR1 Differentiated Histology Supratentorial (Group 1)|Patients undergo observation.
3328378|NCT00041301||QoL in prostate cancer|The study sample will be composed of a consecutive series of prostate cancer patients, stratified by stage of disease, local and locally advanced versus advanced (metastatic) disease, and undergoing active anti-tumor therapy. In order to increase sample homogeneity, and to facilitate evaluation of the responsiveness of the quality of life instruments to changes in patients' health status and symptoms experience over time, the subsample of patients with local or locally advanced disease will be restricted to those undergoing surgery (radical prostatectomy) or radiation therapy, and the subsample of metastatic disease patients will be limited to those receiving hormonal therapy.
3328379|NCT00041197|Experimental|Arm I (imatinib mesylate)|Patients receive oral imatinib mesylate (Gleevec; STI571) once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence during the year of initial treatment receive imatinib mesylate (Gleevec; STI571) at an increased dose. Patients who develop a recurrence after the year of initial treatment restart imatinib mesylate (Gleevec; STI571) and continue taking the drug at the discretion of the principal investigator.
3328380|NCT00041197|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence at any time discontinue placebo and crossover to arm I. Treatment on arm I continues at the discretion of the principal investigator.
3328381|NCT00041171|Experimental|Arm 1: placebo + docetaxel|"Patients receive oral placebo three times daily on days 1-14 and docetaxel IV over 1 hour on day 15.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
3328382|NCT00041171|Experimental|Arm 2: Hypericum perforatum + docetaxel|"Patients receive oral Hypericum perforatum three times daily on days 1-14 and docetaxel as in arm 1.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
3328383|NCT00041171|Experimental|Arm 3: Hypericum perforatum + docetaxel|"Patients receive docetaxel as in arm 1 and continue to receive their chronic regimen of Hypericum perforatum except on day 15.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
3328384|NCT00041132|Experimental|Hyper-CVAD + MTX/Ara-C + Rituximab|"21-day cycles of Hyper-CVAD and high-dose methotrexate/cytarabine are alternated beginning with Hyper-CVAD for a maximum of 8 cycles. Rituximab is given for cycles 1-6.~Hyper-CVAD (cycles 1,3,5,7): rituximab 375 mg/m^2 on day 1, mesna 600 mg/m^2 on days 2-4, cyclophosphamide 300 mg/m^2 on days 2-4, doxorubicin 16.6 mg/m^2/day on days 5-7, vincristine 1.4 mg/m^2 on days 5 and 12, dexamethasone 40 mg on days 2-5 and 12-15, and filgrastim 5 ug/kg on days 8-21.~Methotrexate/Ara-C (cycles 2,4,6,8): rituximab 375 mg/m^2 on day 1, methotrexate 1000 mg/m^2 over days 2-3, Ara-C 12 g/m^2 over days 3-4, leucovorin 170 mg over days 3-5, and G-CSF 5 ug/kg on days 5-21."
3328385|NCT00041119|Active Comparator|Arm I (CA for 4 courses)|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3328386|NCT00041119|Experimental|Arm II (CA for 6 courses [closed to accrual 12/15/2007])|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3328387|NCT00041119|Experimental|Arm III (paclitaxel for 4 courses)|Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3328388|NCT00041119|Experimental|Arm IV (paclitaxel for 6 courses [closed 12/15/2007])|Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3328389|NCT00041106|Experimental|Treatment (gemcitabine, cisplatin, and gefitinib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 1 hour on day 1. Patients also receive gefitinib PO QD beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete remission, partial remission, or maintain stable disease continue gefitinib PO QD for 5 years or until disease progression or unacceptable toxicity occurs.
3328390|NCT00041093|Experimental|Treatment (docetaxel)|Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3328391|NCT00041080|Experimental|Arm I (thalidomide)|Patients receive oral thalidomide once daily on days 1-28.
3328392|NCT00041080|Experimental|Arm II (tamoxifen)|Patients receive oral tamoxifen twice daily on days 1-28.
3328393|NCT00041067|Experimental|Trastuzumab, docetaxel, vinorelbine and filgrastim|Trastuzumab, docetaxel, vinorelbine and filgrastim
3328394|NCT00041054|Experimental|carboplatin + etoposide + exisulind|"Patients receive carboplatin IV over 30 minutes on day 1 and etoposide IV over 30-60 minutes on days 1-3. Patients also receive oral exisulind twice daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year and then every 4 months for 2 years."
3328395|NCT00041041|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3328396|NCT00041015|Active Comparator|oral topotecan plus cisplatin IV|oral topotecan once daily on days 1-5 and cisplatin IV on day 5
3328397|NCT00041015|Experimental|Cisplatin IV plus etoposide IV|Cisplatin IV on day 1 and etoposide IV over at least 30 minutes
3328398|NCT00040937|Experimental|treatment arm|thalidomide/dexamethasone followed by tandem melphalan peripheral blood stem cell transplantation (with cyclophosphamide and filgrastim or sargramostim support) and prednisone/thalidomide maintenance
3328399|NCT00040911|Experimental|Arm I (alternative medicine procedure)|Patients undergo electroacupuncture therapy to specific acupuncture points on the arms and legs over 25 minutes twice daily on days 1 and 2 and then once daily on days 3-7 during week 1 of chemotherapy course 1 (9 acupuncture treatments total).
3328400|NCT00040911|Sham Comparator|Arm II (alternative medicine procedure)|Patients undergo electroacupuncture therapy to sham points on the arms and legs as in arm I.
3328491|NCT00032084|Placebo Comparator|Behavioral Intervention + Placebo|Smoking cessation intervention , nicotine replacement, psychosocial assessment and care, and placebo.
3328401|NCT00040885|Experimental|infliximab + docetaxel|"Patients receive infliximab IV over 2 hours once weekly on weeks 1, 3, and 5 of the first course and once weekly on weeks 1 and 5 of all subsequent courses and docetaxel IV over 1 hour (immediately after completion of infliximab infusion once weekly on weeks 1-6 of each course.~Treatment repeats every 8 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life, fatigue, appetite/anorexia, cachexia, and weight are assessed at baseline, weekly on weeks 1-8, and then monthly for the remainder of study treatment.~Patients are followed every 6 months for 5 years."
3328402|NCT00040885|Active Comparator|placebo + docetaxel|"Patients receive docetaxel IV over 1 hour (immediately after completion of infliximab infusion once weekly on weeks 1-6 of each course. Patients receive placebo IV over 2 hours once weekly on weeks 1, 3, and 5 of the first course and once weekly on weeks 1 and 5 of all subsequent courses.~Treatment repeats every 8 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life, fatigue, appetite/anorexia, cachexia, and weight are assessed at baseline, weekly on weeks 1-8, and then monthly for the remainder of study treatment.~Patients are followed every 6 months for 5 years."
3328403|NCT00040859|Experimental|oxaliplatin + capecitabine|"Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response (CR) receive 2 additional courses after CR.~Quality of life is assessed at baseline and then every 3 weeks (prior to each course of chemotherapy).~Patients are followed every 3 months for 1 year and then every 6 months for 2 years."
3328404|NCT00040846|Experimental|Treatment (dose-escalation of alemtuzumab, HSCT)|"CONDITIONING REGIMEN: Patients receive alemtuzumab IV over 2 hours on days -8 to -5 and fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.~HSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156."
3328405|NCT00040794|Experimental|Stratum I (gefitinib, radiotherapy)|"Patients receive gefitinib orally (PO) daily for 7 weeks. Patients also undergo concurrent radiotherapy once daily 5 days a week for 7 weeks.~Patients then receive gefitinib PO daily in the absence of disease progression or unacceptable toxicity."
3328406|NCT00040794|Experimental|Stratum II (gefitinib, radiotherapy, chemotherapy)|"Patients receive gefitinib and radiotherapy as in stratum I concurrently with paclitaxel IV over 1 hour followed by carboplatin over 30 minutes once weekly for 7 weeks.~Patients then receive gefitinib PO daily in the absence of disease progression or unacceptable toxicity."
3328407|NCT00040781|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
3328408|NCT00040768|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who received prior bortezomib and achieved at least a partial response of at least 6 months duration may also receive therapy as above.
3328409|NCT00040755|Experimental|Arm I (rebimastat once daily)|Patients receive oral BMS-275291 once daily on days 1-28. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR.
3328410|NCT00040755|Experimental|Arm II (rebimastat twice daily)|Patients receive oral BMS-275291 twice daily on days 1-28. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR.
3328411|NCT00040742|Placebo Comparator|Placebo|Patients receive oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
3328412|NCT00040742|Experimental|0.5g ginger|Patients receive oral low-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
3328413|NCT00040742|Experimental|1.0g ginger|Patients receive oral intermediate-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
3328414|NCT00040742|Experimental|1.5g ginger|Patients receive oral high-dose ginger twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
3328415|NCT00039559|Other|Early detection|
3328416|NCT00039494|Experimental|Treatment (erlotinib hydrochloride, radiation, temozolomide)|Patients receive oral erlotinib once daily. After 1 week of erlotinib alone, patients also receive oral temozolomide once daily for 6 weeks and undergo concurrent radiotherapy 5 days a week for 6 weeks. After completion of radiotherapy, patients continue to receive erlotinib once daily alone in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of radiotherapy, patients also receive oral temozolomide once daily for 5 days. Temozolomide treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3328417|NCT00039481|Experimental|Treatment (Oblimersen sodium, cytotoxic chemotherapy)|See detailed description.
3328418|NCT00039455|Experimental|Treatment (trastuzumab and alvocidib)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15 followed by flavopiridol IV continuously over 24 hours on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3328419|NCT00039442|Experimental|Treatment|Patients receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3328420|NCT00039416|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity.
3328421|NCT00039403|Experimental|Treatment (UCN-01, gemcitabine hydrochloride)|"Patients receive gemcitabine IV over 1-2 hours on days 1 and 8 followed by UCN-01 IV over 3 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Sequential dose escalation of UCN-01 is followed by sequential dose escalation of gemcitabine. Cohorts of 3-6 patients receive escalating doses of UCN-01 and then gemcitabine until the maximum tolerated dose (MTD) of the combination is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 6 patients are treated at the recommended phase II dose."
3328492|NCT00032084|Active Comparator|Behavioral Intervention + Bupropion|Smoking cessation intervention, nicotine replacement, psychosocial assessment and care, and bupropion hydrochloride .
3329851|NCT00034814|Experimental|2|Enzyme-inducing Talampanel 35 mg TID
3328422|NCT00039390|Experimental|Treatment (capecitabine, gefitinib)|Patients receive oral gefitinib once daily on days 1-14 and oral capecitabine twice daily on days 8-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gefitinib and capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.
3328423|NCT00039377|Experimental|Treatment (imatinib mesylate, chemotherapy, PBSCT)|See Detailed Description.
3328424|NCT00039338|Experimental|Chemotherapy followed by surgery|neoadjuvant chemotherapy (Cisplatin) followed by surgery (radial hysterectomy)
3328425|NCT00039338|Active Comparator|Radio-chemotherapy|Concomitant radiotherapy (external radiotherapy combined with external boost or brachytherapy) and chemotherapy (cisplatin)
3328426|NCT00039325|Experimental|Group A - first dose for phase 1|A*0201 positive subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^6. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
3328427|NCT00039325|Experimental|Arm B - dose increase for phase 1|A*0201 positive subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
3328428|NCT00039325|Experimental|Arm C - A*0201+/DR*04+ subjects - Phase II|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
3328429|NCT00039325|Experimental|Arm D - A*0201+/DR*04- - phase 2|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
3328430|NCT00039325|Experimental|Arm E - A*0201-/DR*04+ - phase 2|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
3328431|NCT00039286|Experimental|Positron Emission Tomography|Patients receive fludeoxyglucose F 18 IV. Approximately 1 hour later, patients undergo positron emission tomography imaging. Some patients may undergo a repeat scan in 4-6 months.
3328432|NCT00039195|Experimental|Induction R-CHOPac Therapy for patients with B-Cell Lymphoma|Patients received 4 cycles if accelerated R-CHOP (cyclophosphamide. doxorubicin, vincristine and prednisone + rituximab) followed by 3 cycles ICE (ifosfamide, carboplatin and etoposide) consolidation therapy.
3328433|NCT00039182|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3328434|NCT00039130|Experimental|Rituximab with High Intensity Chemotherapy|Cycle1: Cyclophosphamide 100 mg/m^2/day (d) IV (d 1-5), Prednisone 60 mg/m^2/d oral (d 1-7), Allopurinal 300 mg/d oral (d 1-14) Cycle 2, 4 & 6 (21 day): Ifosfamide 800 mg/m^2/d (d 1-5), Dexamethasone 10 mg/m^2/d (d1-5), Methotrexate 150 mg/m^2 load, then 1.35 g/m^2 over 23.5 h (d 1), Leucovorin 25 mg/m^2 36 h after methotrexate (d 2) then 10 mg/m^2 every 6 h, Vincristine 2 mg push (d 1), Cytarabine 1000 mg/m^2/d over 2 h (d 4-5), Etoposide 80 mg/m^2.d over 1 h (d 4-5), Filgrastim 5 mg/kg/d (d 7-21 as needed), Rituximab 50 mg/m^2 d 8 cycle 2 only, 375 mg/m^2/d (d 10, 12 cycle 2, d 8 cycle 4 & 6) Cycle 3, 5 & 7 (21 day): Cyclophosphamide 200 mg/m^2/day (d) IV (d 1-5), Dexamethasone 10 mg/m^2/d (d1-5), Methotrexate 150 mg/m^2 load, then 1.35 g/m^2 over 23.5 h (d 1), Leucovorin 50 mg/m^2 36 h after methotrexate (d 2) then 10 mg/m^2 every 6 h, Vincristine 2 mg push (d 1), Doxorubicin 25 mg/m^2/d (d 4-5), Filgrastim 5 mg/kg/d (d 7-21 as needed), Rituximab 375 mg/m^2/d (d 8)
3328435|NCT00039117|Experimental|Arm I|"INDUCTION THERAPY: Patients receive oblimersen (G3139) IV continuously on days 1-10 and cytarabine IV continuously on days 4-10. Patients also receive daunorubicin IV daily on days 4-6.~Patients with bone marrow cellularity of at least 20% and at least 5% leukemic blasts at day 17 or evidence of refractory disease receive a second induction comprising G3139 IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.~CONSOLIDATION THERAPY: Beginning no sooner than 14 days after hematologic recovery from induction therapy, patients receive G3139 IV continuously on days 1-8 and cytarabine IV over 4 hours on days 4-8. Patients receive a second course of consolidation therapy no sooner than 14 days after hematologic recovery from the first course."
3328436|NCT00039104|Experimental|Arm I (rebimastat, zoledronic acid)|Patients receive zoledronate IV over at least 15 minutes on day 1 and oral BMS-275291 daily on days 1-28.
3328437|NCT00039104|Experimental|Arm II (zoledronic acid)|Patients receive zoledronate as in Arm I.
3328438|NCT00039091|Experimental|Treatment (ipilimumab)|Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody IV over 90 minutes on day 1. Courses repeat every 2 months in the absence of disease progression or unacceptable toxicity.
3328439|NCT00036933|Experimental|vaccine|"Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant QS21 subcutaneously once weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity. Patients whose antibody titers against Globo-H or MUC-2 antigens fall below 1/40 and who have no disease progression may receive a seventh vaccination after week 50.~Patients are followed every 3 months for 1 year or until biochemical relapse or radiographic disease progression."
3328440|NCT00036881|Experimental|zinc sulfate|"Patients receive oral zinc sulfate 3 times daily beginning the first week of radiotherapy.~Treatment continues daily during and for 1 month after radiotherapy in the absence of unacceptable toxicity.~Quality of life is assessed at baseline, weekly during treatment, and then at 1, 2, 3, and 6 months after the completion of treatment.~Patients are followed at 1, 2, 3, and 6 months after the completion of treatment and then every 6 months for 1 year."
3328543|NCT00028769|Experimental|Hormone therapy, estramustine, etoposide and paclitaxel|Hormone therapy (leuprolide, bicalutamide, nilutamide, goserelin, flutamide), estramustine, etoposide and paclitaxel
3329852|NCT00034814|Experimental|3|Enzyme-inducing TLP 50mg TID
3328441|NCT00036881|Placebo Comparator|placebo|"Patients receive oral placebo 3 times daily beginning the first week of radiotherapy.~Treatment continues daily during and for 1 month after radiotherapy in the absence of unacceptable toxicity.~Quality of life is assessed at baseline, weekly during treatment, and then at 1, 2, 3, and 6 months after the completion of treatment.~Patients are followed at 1, 2, 3, and 6 months after the completion of treatment and then every 6 months for 1 year."
3328442|NCT00036868|Experimental|CMF + Herceptin|
3328443|NCT00036855|Experimental|Group A (no planned PBSC support)|"Patients receive rituximab IV over 4-6 hours followed by IDEC-In2B8 IV over 10 minutes on day 0 and undergo whole body imaging. Patients may then receive rituximab IV over 4-6 hours followed by IDEC-Y2B8 IV over 10 minutes on day 7.~Some patients receive autologous PBSC IV over 30-60 minutes on day 35."
3328444|NCT00036855|Experimental|Group B (planned PBSC support)|Patients receive rituximab, IDEC-In2B8, and IDEC-Y2B8 as in group A. Patients also receive autologous PBSC IV over 30-60 minutes on day 21 and G-CSF subcutaneously beginning on day 22 and continuing until blood counts recover or day 35.
3328445|NCT00036777|Experimental|Treatment (carboplatin, 7-hydroxystaurosporine)|"Patients receive carboplatin IV over 1 hour followed by UCN-01 IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of carboplatin and UCN-01 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3328446|NCT00036764|Experimental|Treatment|Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3328447|NCT00036751|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
3328448|NCT00036738|Experimental|Treatment (allogeneic nonmyeloablative HSCT)|See Detailed Description
3328449|NCT00036686|Experimental|Soy protein isolate|"Administration Prior to Mastectomy or Lumpectomy.~Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.~Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure."
3328450|NCT00036686|Placebo Comparator|Placebo|"Administration Prior to Mastectomy or Lumpectomy.~Patients receive oral placebo twice daily and oral multivitamins once daily.~Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure."
3328451|NCT00033748|Experimental|Combined Monoclonal Antibody Therapy|Patients with minimal metastatic colorectal cancer are treated with 2 anti-idiotype monoclonal antibodies
3328452|NCT00033696|Experimental|chemotherapy + radiation therapy|"Induction therapy: Patients receive paclitaxel IV over 3 hours on days 1 and 22, oral topotecan on days 2-4 and 23-25, and oral etoposide on days 5-7 and 26-28. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on days 8 and 29 and continuing until blood counts recover.~Consolidation therapy: Patients receive carboplatin IV over 1 hour on days 43, 64, and 85 and etoposide IV over 1 hour on days 43-45, 64-66, and 85-87. Patients undergo radiotherapy daily 5 days per week beginning on day 43 and continuing for 6-7 weeks.~Patients with rapid disease progression discontinue study therapy.~Patients are followed at least every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years."
3328453|NCT00033657|Experimental|Cisplatin / Irinotecan / Radiation therapy (Arm A)|"Days 1 - 35 : Concurrent radiation therapy (RT) and Cisplatin / Irinotecan Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Cisplatin 30 mg/m² days 1, 8, 22, 29. Irinotecan 65 mg/m² days 1, 8, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy~Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
3328454|NCT00033657|Experimental|Paclitaxel / Cisplatin / Radiation therapy (Arm B)|"Days 1 - 35 : Concurrent radiation therapy (RT) and Paclitaxel/Cisplatin Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29. Cisplatin 30 mg/m² days 1, 8, 15, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy.~Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles."
3328455|NCT00033631|Active Comparator|70.2 Gy|70.2 Gy 3D-CRT/IMRT
3328456|NCT00033631|Experimental|79.2 Gy|79.2 Gy 3D-CRT/IMRT
3328457|NCT00033618|Experimental|Arm I (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3328458|NCT00033618|Experimental|Arm II (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3328459|NCT00033605|Experimental|octreotide + radiation|"Patients receive short-acting octreotide subcutaneously (SC) on day 1 and long-acting octreotide intramuscularly (IM) on days 2 and 29.~Treatment continues in the absence of unacceptable toxicity or the development of severe diarrhea.~Patients complete a bowel function questionnaire at baseline, weekly during radiotherapy, and then weekly for 4 weeks and at 1 and 2 years after completion of radiotherapy.~Patients are followed weekly for 4 weeks and then at 1 and 2 years."
3328460|NCT00033605|Active Comparator|placebo + radiation|"Patients receive placebo SC on day 1 and IM on days 2 and 29. Treatment continues in the absence of unacceptable toxicity or the development of severe diarrhea.~Patients complete a bowel function questionnaire at baseline, weekly during radiotherapy, and then weekly for 4 weeks and at 1 and 2 years after completion of radiotherapy.~Patients are followed weekly for 4 weeks and then at 1 and 2 years."
3328461|NCT00033553|Experimental|Paclitaxel + Carboplatin|Paclitaxel and carboplatin induction (2 cycles)followed by chemotherapy with the addition of radiotherapy for 7 cycles
3328462|NCT00033553|Experimental|Gemcitabine + Carboplatin|Gemcitabine and carboplatin induction (2cycles) followed by chemotherapy with the addition of radiotherapy for 7 cycles
3328463|NCT00033540|Experimental|Capecitabine + Gemcitabine|Capecitabine 650 mg/m^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days; Gemcitabine 1000 mg/m^2, intravenous (IV) over 100 minutes, Days 1, 8, every 21 days
3328464|NCT00033514|Experimental|treatment|please see intervention description
3328465|NCT00033449|Experimental|Treatment (gefitinib, radiation therapy, cisplatin)|See detailed description.
3328466|NCT00033423|Experimental|Cohort 1|First radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
3328471|NCT00033397||Arm A|"Patients receive an injection of gadopentetate dimeglumine and undergo magnetic resonance imaging (MRI) of the breast before initiation, 1-3 days after initiation, and then after completion of neoadjuvant anthracycline-based chemotherapy and prior to surgery. Patients who previously received a taxane also undergo an additional contrast-enhanced MRI scan.~Mammograms and possibly ultrasounds are performed prior to and after chemotherapy (before surgery).~Patients are followed every 6 months for 5 years and then annually for up to 10 years."
3328472|NCT00033371|Active Comparator|Arm I: Celecoxib and Placebo|Celecoxib 400 mg orally twice daily (PO BID) and Placebo once a day. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
3328473|NCT00033371|Experimental|Arm II: Celecoxib and Eflornithine|Celecoxib 400 mg PO BID and Eflornithine PO daily 0.5 g/m^2/day rounded down to the nearest 250 mg dose. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
3328474|NCT00033358|Experimental|Arm I (medroxyprogesterone)|Patients receive medroxyprogesterone intramuscularly once on day 1. Approximately 90 days after the injection, patients undergo a repeat transvaginal ultrasound and endometrial biopsy.
3328475|NCT00033358|Experimental|Arm II (ethinyl estradiol, norgestrel)|Patients receive OCP comprising ethinyl estradiol and norgestrel once daily on days 1-21. Treatment repeats every 28 days for 3-4 courses (3-4 packs of OCP) in the absence of unacceptable toxicity. Approximately 1 week after starting the fourth pack of OCP, patients undergo a repeat transvaginal ultrasound and endometrial biopsy.
3328476|NCT00033345|Experimental|High-Risk Breast Cancer|All subjects first went through a 4-week placebo run-in period. Next, subjects took Indole-3-carbinol 400mg daily for 4 weeks followed by a 4-week period of Indole-3-carbinol 800mg daily.
3328477|NCT00033293|Experimental|Arm I (chemotherapy, immunoglobulin therapy)|"Patients with intermediate-risk or high-risk neuroblastoma receive chemotherapy (including cyclophosphamide) according to the standard of care for the stage of primary neuroblastoma, beginning day 0. Patients with low-risk neuroblastoma (and not receiving other chemotherapy) receive cyclophosphamide IV over 1 hr on day 0. Treatment repeats every 4 wks for 6 courses in the absence of disease progression or unacceptable toxicity. All patients receive oral prednisone twice daily for 3 mths and then every other day for 7-15 mths.~Patients receive therapeutic immune globulin IV on days -2 and -1, at wks 4, 8, 12, 16, 20, and 24, and then at mths 8, 10, and 12 after therapy. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with no response after 6 months go off treatment. In case of progression of opsoclonus-myoclonus-ataxia (OMA) during evaluation, patient will be switched to another steroid, corticotropin-releasing hormone (ACTH)."
3328478|NCT00033293|Active Comparator|Arm II (chemotherapy, observation)|"Patients with intermediate-risk or high-risk neuroblastoma receive chemotherapy (including cyclophosphamide) according to the standard of care for the stage of primary neuroblastoma, beginning on day 0. Patients with low-risk neuroblastoma (and not receiving other chemotherapy) receive cyclophosphamide IV over 1 hour on day 0. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. All patients receive oral prednisone twice daily for 3 months and then every other day for 7-15 months.~Patients do not receive therapeutic immune globulin. Patients with unresponsive opsoclonus-myoclonus-ataxia syndrome after 2 months or progression after 6 months may cross over to arm I."
3328479|NCT00033280|Experimental|Pre-RT temozolomide, RT plus temozolomide|Pre-radiation therapy (RT) temozolomide, RT plus temozolomide
3328480|NCT00033267|Experimental|Treatment|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with stable disease receive a maximum of 6 courses. Patients with partial response receive a maximum of 12 courses. Patients with CR receive 2 additional courses beyond CR.
3328481|NCT00033254|Active Comparator|Arm I (radiation therapy)|Patients undergo radiotherapy once daily 5 days a week for 3 weeks.
3328482|NCT00033254|Experimental|Arm II (radiation therapy, thalidomide)|Patients undergo radiotherapy as in arm I. Beginning on the first day of radiotherapy, patients receive oral thalidomide once daily.
3328483|NCT00033228|Experimental|Cohort 1|The first cohort of 6 patients received 500 ug of Synchrovax SEM plasmid DNA vaccine. All patients were to be monitored for dose limiting toxicities DLTs) for a minimum of 2 weeks after their second infusion of vaccine on Day 15 before allowing patients to enroll at the next dose group. The decision to progress to the next dose group was to be based on occurrence of DLTs observed in 1 or fewer (<33%) patients of a 6 patient cohort.
3328484|NCT00033228|Experimental|Cohort 2|The second cohort of 6 patients received 1000 ug of Synchrovax SEM plasmid DNA vaccine. All patients were to be monitored for dose limiting toxicities DLTs) for a minimum of 2 weeks after their second infusion of vaccine on Day 15 before allowing patients to enroll at the next dose group. The decision to progress to the next dose group was to be based on occurrence of DLTs observed in 1 or fewer (<33%) patients of a 6 patient cohort.
3328485|NCT00033228|Experimental|Cohort 3|The third cohort of 6 patients received 1500 ug of Synchrovax SEM plasmid DNA vaccine. The maximum tolerated dose (MTD) was to be determined by the observation of DLT at each dose group.
3328486|NCT00032188|Experimental|Arm I (aldesleukin and lowest dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive lowest dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
3328487|NCT00032188|Experimental|Arm II (aldesleukin and middle dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive middle dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
3328488|NCT00032188|Experimental|Arm III (aldesleukin and highest dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive highest dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
3328489|NCT00032162|Experimental|PLD|dose finding study of PLD in combination with Carboplatin
3328490|NCT00032110|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after CR is confirmed.
3328493|NCT00032032|Experimental|radiotherapy + paclitaxel + carboplatin|"Patients undergo radiotherapy once daily 5 days a week for 7 weeks and 2 days (a total of 37 fractions). Patients concurrently receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes once weekly for 7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Beginning 3 weeks after completion of radiotherapy, patients receive paclitaxel and carboplatin as above. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, once during the last week of radiotherapy, and then every 3 months for 2 years.~Patients are followed at 3 weeks, every 3 months for 21 months, and then every 6 months for 3 years."
3328494|NCT00032019|Experimental|EPOCH-Rituximab|Addition of monoclonal antibody therapy to chemotherapy for treatment of pts with aggressive CD20+ NHL
3328495|NCT00032006|Experimental|brachytherapy + radiation|"Within 4 weeks after completion of androgen suppression, patients are sequentially enrolled to 2 different cohorts of brachytherapy.~Cohort 1: Patients undergo initial-dose transperineal interstitial permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.~Cohort 2: After a minimum of 1-year follow-up for all patients in cohort 1, if tolerance is acceptable, additional patients undergo higher-dose transperineal interstitial permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.~Quality of life is assessed at baseline, within 2 weeks prior to brachytherapy, every 3 months for 1 year, and then every 6 months for 2 years.~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years."
3328496|NCT00031993|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3328497|NCT00031980|Experimental|cyclosporine|"Patients receive oral cyclosporine every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed every 4 months for 1 year and then every 6 months for 9 years."
3328498|NCT00031837|Experimental|Dalteparin|5,000 anti-Xa units of dalteparin subcutaneously once daily for six months in addition to gemcitabine at 1,000 mg/m2 as a 30-minute infusion weekly for 7 weeks followed by a week of rest for the first cycle and weekly for three weeks followed by a week of rest for each subsequent cycle.
3328499|NCT00031772|No Intervention|Control|Standard level of support after recurrence diagnosis
3328500|NCT00031772|Experimental|Intervention|Phone intervention for patients experiencing first recurrence with quality of life questionnaires, psychosocial assessment and care.
3328501|NCT00031759|Other|Ablative or excisional therapy|"Patients undergo ablative or excisional therapy.~Quality of life is assessed at baseline, 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.~Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy."
3328502|NCT00031759|Experimental|Ablative or excisional therapy + imiquimod|"Patients have topical imiquimod applied to the cervix for 6-10 hours twice weekly for a total of 5 doses. Within 3-4 weeks after the final application, patients undergo ablative or excisional therapy. Quality of life is assessed at baseline, after last dose of study drug, 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.~Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy."
3328503|NCT00031746|Active Comparator|soy protein + isoflavones|
3328504|NCT00031746|Active Comparator|casein proteins|
3328505|NCT00031720|Experimental|Arm I|All patients receive placebo for 7 days as part of the run-in period. Patients being treated with tamoxifen were randomized to treatment arm I and received 40 gm soy protein and 90 mg isoflavones daily for 12 weeks.
3328506|NCT00031720|Placebo Comparator|Arm II|All patients receive placebo for a 7 day run in period. Patients being treated with tamoxifen randomized to Arm II received placebo daily for 12 weeks.
3328507|NCT00031694|Experimental|Treatment (paclitaxel, bryostatin 1)|Patients receive paclitaxel IV over 1 hour on day 1 followed by bryostatin 1 IV over 1 hour on day 2 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3328508|NCT00031681|Experimental|Treatment (combination chemotherapy)|"PART I: Patients receive irinotecan hydrochloride IV over 90 minutes on days 1, 8, 15, and 22 and 7-hydroxystaurosporine IV over 3 hours on days 2 and 23. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan hydrochloride and 7-hydroxystaurosporine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Blood samples are collected periodically during study treatment.~PART II: (treatment of triple negative recurrent breast cancer): Patients receive irinotecan hydrochloride IV and 7-hydroxystaurosporine IV as in part I at the MTD and undergo blood sample collection."
3328509|NCT00031655|Experimental|Treatment (nonmyeloablative allogeneic PBSCT)|"NONMYELOALATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0. Patients with minimal residual disease may receive donor lymphocyte infusion IV.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO very 8 hours on days 0 to 40 with taper to day 96."
3328510|NCT00031629|Experimental|Treatment (gemcitabine, docetaxel, G-CSF, pegfilgrastim)|Patients receive gemcitabine IV over 90 minutes on days 1 and 8, docetaxel IV over 1 hour on day 8, and G-CSF SC on days 9-15 or pegfilgrastim SC on day 9 only. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3328511|NCT00031590|Experimental|Study Treatment|"All subjects will undergo routine surgical staging of their tumor. Treatment must begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with vincristine. 4 weeks after radiation and vincristine treatment is completed, all subjects will begin 9 cycles (each cycle lasts 6 weeks) of maintenance chemotherapy which will be given as 2 different drug combinations, Regimen A (Lomustine, Vincristine, and Cisplatin) and Regimen B (Cyclophosphamide, given with Mesna, and Etoposide) which will be given in the following order (total of 54 weeks):1st-Regimen A, 2nd-Regimen A, 3rd-Regimen B, 4th-Regimen A, 5th-Regimen A, 6th-Regimen B, 7th-Regimen A, 8th-Regimen A, 9th-Regimen B"
3329235|NCT00002850|Experimental|Ciprofloxacin or ofloxacin|"Quinolone:~Ciprofloxacin 500 mg every 12 hours or Ofloxacin400 mg every 12 hours."
3328512|NCT00031564|Experimental|Vaccine Therapy With Interleukin-2|At approximately 3-6 weeks after surgery, patients receive B7-1 gene-modified autologous tumor cell vaccine subcutaneously (SC) once on days 1, 29, and 57. At 6 weeks after the first vaccination, patients receive interleukin-2 (IL-2) SC five days a week for 6 weeks (days 43-82). Patients with stable or responding disease after day 106 may receive additional vaccinations in the absence of disease progression or unacceptable toxicity.
3328513|NCT00030914|Experimental|Arm I: venlafaxine|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive oral venlafaxine once daily for 6 weeks beginning on day 8. After week 7, patients with satisfactory efficacy may continue venlafaxine for up to 6 months. Patients with unsatisfactory efficacy may cross over to arm III.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
3328514|NCT00030914|Experimental|Arm II: medroxyprogesterone - long term|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive medroxyprogesterone intramuscularly (IM) on days 8, 22, and 36 for a total of 3 injections. After week 7, patients with unsatisfactory efficacy may cross over to arm I.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
3328515|NCT00030914|Experimental|Arm III: medroxyprogesterone - short term|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive medroxyprogesterone IM once on day 8. After week 7, patients with unsatisfactory efficacy may cross over to arm I.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
3328516|NCT00030901|Active Comparator|L-selenomethionine|L-selenomethionine (Selenium)one tablet by mouth daily for 3 years.
3328517|NCT00030901|Placebo Comparator|L-selenomethionine placebo|L-selenomethionine placebo one tablet by mouth daily for 3 years
3328518|NCT00030823|Experimental|Vaccine|Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine with QS21 adjuvant subcutaneously weekly on weeks 1, 2, 3, 7, and 19.
3328519|NCT00030771|Active Comparator|Arm A|Neoadjuvant Chemoradiotherapy + Chemotherapy + Surgery
3328520|NCT00030771|Active Comparator|Arm B|Neoadjuvant Chemotherapy + Surgery
3328521|NCT00030732|Active Comparator|Gemcitabine + Capecitabine|Gemcitabine + Capecitabine
3328522|NCT00030732|Active Comparator|Gemcitabine alone|Gemcitabine alone
3328523|NCT00030693|Experimental|Arm I (recombinant fowlpox-B7.1 vaccine)|Patients receive rF-B7.1 vaccine intratumorally on day 1.
3328524|NCT00030693|Experimental|Arm II (recombinant fowlpox-TRICOM vaccine)|Patients receive fowlpox-TRICOM vaccine intratumorally on day 1.
3328525|NCT00030654|Experimental|Androgen blockade + immediate chemotherapy|Androgen blockade with immediate chemotherapy
3328526|NCT00030654|Experimental|Androgen blockade + delayed chemotherapy|Androgen blockade with delayed chemotherapy
3328527|NCT00030628|Experimental|radiosurgery|"Patients undergo radiosurgery.~Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years."
3328528|NCT00030628|Experimental|radiosurgery + WBRT|"Patients undergo radiosurgery. Within 14 days, patients then undergo whole brain radiotherapy 5 days a week for 2.5 weeks.~Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years.~Patients are followed at weeks 6 and 12, every 3 months for 9 months, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter."
3328529|NCT00030615|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 30 minutes on days 1-5 weekly for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3328530|NCT00030576|Experimental|OSI-774 and cisplatin|HNSCC patients treated in three escalating dose cohorts of daily continous oral erlotinib (OSI-774) and intermittent IV cisplatin given every 21 days
3328531|NCT00030498|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
3328532|NCT00030407|Experimental|Celecoxib & Docetaxel|"Celecoxib: On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals~Docetaxel: On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days."
3328533|NCT00030394|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve a complete hematologic response after 3 courses or a partial or complete cytogenic response after 6 courses are removed from the study.
3328534|NCT00030303|Experimental|vaccine|recombinant 70-kD heat-shock protein
3328535|NCT00030264|Experimental|Methotrexate & Vinblastine|Methotrexate and Vinblastine will be given once a week for the first 26 weeks and then every two weeks for the next 26 weeks or until disease progression (whichever occurs first).
3328536|NCT00029003|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
3328537|NCT00028990|Active Comparator|Paclitaxel + Bevacizumab|
3328538|NCT00028990|Active Comparator|Paclitaxel|
3328539|NCT00028834|Experimental|Treatment (gemcitabine hydrochloride, bevacizumab)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3328540|NCT00028821|Experimental|Treatment (2-methoxyestradiol)|Patients receive oral 2-methoxyestradiol (2-ME) once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3328541|NCT00028795|Experimental|Chemoradiotherapy|
3328542|NCT00028782|Experimental|Diagnostic (etanidazole)|Patients receive etanidazole derivative EF5 IV over 1-2 hours. Approximately 48 hours after EF5 administration, patients with intraperitoneal tumors undergo surgical resection. Patients with pleural tumors undergo surgical resection approximately 24 hours after EF5 administration. Tumors are then analyzed for EF5 binding and microvascular density by immunohistochemistry and fluorescent antibody techniques.
3329236|NCT00002850|Experimental|TMP-SMX|TMP-SMX: 160 mg trimethoprim and 800 mg sulfamethoxazole every 12 hours
3328548|NCT00028730|Experimental|Pts < than or = 18 years with lymphohematopoietic disorders|This is a phase II, single-center study to evaluate a cytoreductive regimen of hyperfractionated TBI, thiotepa and cyclophosphamide (HFTBI/thio/cy) followed by infusions of SBA-E- T-cell depleted marrow in pediatric leukemia recipients of either HLA-identical or HLA-1Ag non-identical related or unrelated donors.
3328549|NCT00028665|Experimental|Arm I: with rituximab IV|
3328550|NCT00028665|Active Comparator|Arm II: without rituximab IV|
3328551|NCT00028600|Experimental|Autologous + Allogeneic Transplant|autologous PB stem cell transplant followed by non-myeloablative allogeneic transplant fr multiple myeloma
3328552|NCT00028587|Experimental|Group I (paclitaxel, carboplatin, bortezomib)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and bortezomib IV over 3-5 seconds on days 2, 5, and 8.
3328553|NCT00028587|Experimental|Group II (bortezomib, paclitaxel, carboplatin)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, and 8 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 2
3328554|NCT00028574|Active Comparator|Gabapentin (28 days)|Oral Gabapentin 300 mg days 1-28
3328555|NCT00028574|Active Comparator|Gabapentin (7, 21)|Oral Gabapentin 300 mg once daily on days 1-7 days and twice daily days 8-28
3328556|NCT00028574|Active Comparator|Gabapentin (7, 7, 14)|Oral Gabapentin 300 mg once daily on days 1-7, twice daily on days 8-14 and three times daily on days 15-28
3328557|NCT00028574|Placebo Comparator|Placebo|"Oral Placebo 300 mg on one of the following schedules:~once daily on days 1-28~once daily on days 1-7, twice daily on days 8-28~once daily on days 1-7, twice daily on days 8-14 and three times daily on days 15-28"
3328558|NCT00028561|Experimental|Treatment (ixabepilone, carboplatin)|Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15 followed by carboplatin IV over 1 hour on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after achieving CR or up to a total of 6 courses
3328559|NCT00028548|Experimental|XK469|
3328560|NCT00028535|Experimental|Arm I|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15 and paclitaxel IV over 3 hours on day 1 of course 1. Beginning with course 2, patients receive trastuzumab and paclitaxel as in course 1 and interleukin-12 subcutaneously on days 2, 5, 9, 12, 16, and 19. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
3328561|NCT00028522|Experimental|Treatment (chemotherapy)|"SCHEDULE A: Patients receive R(+)XK469 IV over 30 minutes on days 1, 3, and 5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R(+)XK469 until the recommended phase II dose or MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued and treated at the recommended phase II dose (for a maximum of 20 patients treated at that dose).~SCHEDULE B: Once the recommended phase II dose is determined on schedule A, additional patients are accrued and receive escalating doses of R(+)XK469 IV over 30-60 minutes on day 1, beginning at a reduced dose. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Dose escalation continues as in Schedule A."
3328562|NCT00028496|Experimental|Treatment (vaccine therapy, sargramostim, vaccine adjuvant)|"The first three cohorts of 3-12 patients receive escalating doses of recombinant fowlpox-CEA-TRICOM vaccine (fCEA-TRI) until the maximum tolerated dose (MTD) is determined. fCEA-TRI is administered intradermally every 2 weeks for 4 doses and then every 2 months thereafter (beginning on day 56) in the absence of disease progression or unacceptable toxicity.~The fourth and fifth cohorts of 6 patients receive fCEA-TRI at the MTD in the same manner as the first three cohorts combined with escalating doses of sargramostim (GM-CSF). GM-CSF is administered subcutaneously once daily beginning on the day of each vaccination and continuing for a total of 4 days.~The sixth through eighth cohorts of 6 patients receive fCEA-TRI at the MTD in the same manner as the first three cohorts combined with escalating doses of recombinant fowlpox-GM-CSF (rF-GM-CSF)."
3328563|NCT00028028|Experimental|Arm I|Patients receive low-dose CCI-779 IV over 30 minutes once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
3328564|NCT00028028|Experimental|Arm II|Patients receive high-dose CCI-779 as in arm I.
3328565|NCT00028002|Experimental|Arm I|Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
3328566|NCT00027976|Experimental|Group 1 active arm|receipt of active drug
3328567|NCT00027976|Experimental|Group 2 active arm|receipt of active drug
3328568|NCT00027976|Experimental|group 2 placebo arm|receipt of placebo
3328569|NCT00027963|Experimental|gabapentin|"Patients receive titrating doses of oral gabapentin twice daily and then three times daily for 3 weeks. Patients then receive a fixed dose of oral gabapentin three times daily for 3 weeks. Patients cross-over to therapy as in arm II at week 8.~Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14."
3328570|NCT00027963|Placebo Comparator|placebo|"Patients receive titrating doses of oral placebo and then a fixed dose of oral placebo as in arm I. Patients cross-over to therapy as in arm I at week 8.~Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14."
3328571|NCT00027898|Experimental|Treatment (bortezomib, carboplatin, and etoposide)|Patients receive bortezomib IV on days 1 and 8, carboplatin IV over 30 minutes on day 1, and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
3328572|NCT00027885|Active Comparator|Docetaxel|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
3328573|NCT00027885|Experimental|Combine bevacizumab and docetaxel.|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
3328574|NCT00027872|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-21. Patients with a complete or partial response, hematologic improvement, or stable disease continue treatment every 29-63 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response after the second course of therapy receive 2 additional courses of therapy.
3329853|NCT00034814|Placebo Comparator|4|Non-enzyme-inducing placebo TID
3328576|NCT00027846|Experimental|Radiation (Group 2)|Supratentorial Anaplastic Ependymoma (GTR1, GTR2, NTR) and Anaplastic or Differentiated Infratentorial Ependymoma (GTR1, GTR2, NTR) and Supratentorial Differentiated Ependymoma(GTR2, NTR). Patients undergo conformal radiation therapy to the brain once daily 5 days a week for 6-6½ weeks.
3328577|NCT00027846|Experimental|Sub-Total Resection Any Histology or Location (STR) (Group 3)|Patients receive an initial course of chemotherapy comprising vincristine sulfate IV on days 1 and 8, carboplatin IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on days 1 and 2. Patients also receive filgrastim (G-CSF) subcutaneously or IV beginning on day 3 and continuing until blood counts recover. Patients then receive a second course of chemotherapy comprising vincristine sulfate IV on days 1 and 8, carboplatin IV over 1 hour on day 1, and oral etoposide on days 1-21. After completion of chemotherapy, patients are evaluated for second therapeutic conventional surgery. Patients who have unresectable disease undergo conformal radiation therapy. Patients who have resectable disease undergo second surgery followed by conformal radiotherapy.
3328578|NCT00027820|Experimental|Treatment (PBSCT)|"REDUCED-INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -4, -3, and -2 and undergo TBI on day 0.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO every 8 hours on days 0-40 with taper to day 96."
3328579|NCT00027807|Experimental|Aldesleukin, Sargramostim & therapeutic autologous lymphocytes|Peripheral blood mononuclear cells (PBMC) for the generation of ATC will be collected using 1 or 2 phereses to obtain 8-20 × 109 PBMC for T cell expansion. The PBMC will be activated with OKT3 and expanded in IL-2 to generate from 20-320 ×109 ATC during a maximum of 14 days of culture. Three patients will be treated at each dose level. The dose levels for each infusion are: 5, 10, 20, and 40 billion. Each patient will receive a total of 8 doses of armed ATC given twice weekly for 4 weeks. If the patients encounter toxicities related to armed ATC, the dose and administration will be modified as delineated per the protocol. The patients will also receive subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion. GM-CSF (250μg/m2 twice per week) will given subcutaneously to start 3 days before the 1st armed ATC infusion and ending 7 days after the last dose of armed ATC.
3328580|NCT00027703|Experimental|Arm I|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-60 minutes (beginning after gemcitabine infusion) and bevacizumab IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), complete response (CR), or partial response (PR) after the sixth course may receive bevacizumab as a single agent once every 3 weeks in the absence of disease progression or unacceptable toxicity.
3328581|NCT00027703|Experimental|Arm II|Patients receive gemcitabine and cisplatin as in arm I and placebo IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats as in arm I. Patients who achieve SD, CR, or PR after the sixth course may receive placebo as a single agent once every 3 weeks in the absence of disease progression.
3328582|NCT00027690|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3328583|NCT00027586|Experimental|Imatinib Mesylate|400 mg twice a day orally
3328584|NCT00027573|Experimental|Chemotherapy + stem cell transplantation|"Patients receive fludarabine IV over 30 minutes on days -7 to -3 and cyclophosphamide IV over 1-2 hours on days -4 and -3. Allogeneic peripheral blood stem cells are infused on day 0. Patients then receive filgrastim (G-CSF) subcutaneously daily beginning on day 5 and continuing until blood counts recover.~Patients receive graft-versus-host disease (GVHD) prophylaxis comprising oral tacrolimus twice daily on days -1 to 90 and methotrexate IV on days 1, 3, and 6.~After day 120, patients with persistent disease and no signs of active GVHD may receive donor lymphocyte infusion (DLI). DLI may be repeated every 8 weeks for a total of 2 infusions.~Patients are followed every 2 months for 1 year and then every 6 months for 4 years OR every 2 months for 6 months and then every 6 months for 4.5 years if patient receives DLI."
3328585|NCT00027560|Experimental|TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES|This is a stratified single-armed phase II study designed to investigate the safety and efficacy of hematopoietic cell allografts administered after nonmyeloablative cytoreduction.
3328586|NCT00027534|Experimental|TRICOM-CEA(6D)|Subjects receiving TRICOM-CEA(6D)
3328587|NCT00026494|Experimental|Temozolomide and Vinorelbine|Patients will be treated with vinorelbine on days 1 and 8 of each cycle; temozolomide will be administered on days 1 to 7 and 15 to 21 of each cycle. The dose level of temozolomide will be given at a dose of 150 mg/m2/day. A cycle will be defined as 28 days of treatment.
3328588|NCT00026403|Experimental|radiotherapy + gemcitabine + cisplatin|"Patients undergo radiotherapy once daily five days a week for 5.5 weeks. Patients receive gemcitabine IV over 30 minutes followed by cisplatin IV over 1 hour twice a week for the first 3 weeks of radiotherapy. Beginning 4 weeks after the completion of radiotherapy, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for a total of 3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, at completion of radiotherapy, at completion of chemotherapy, and 3 months after completion of therapy.~Patients are followed every 3 months for 2 years and then every 6 months for 1 year."
3328589|NCT00026338|Active Comparator|OSI-774 plus Gemcitabine|
3328590|NCT00026338|Active Comparator|Placebo plus gemcitabine|
3328591|NCT00026312|Active Comparator|Arm I (isotretinoin) (closed to accrual as of 4/16/2009)|Beginning preferably between day 56 and day 85 post-ASCT, but may be delayed up to day 200, patients receive isotretinoin PO BID for 14 days. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients may cross over to Arm II provided they have not experienced disease progression and have not received any further anti-neuroblastoma therapy following completion of isotretinoin therapy.
3328592|NCT00026312|Experimental|Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin)|Beginning preferably between day 56 and day 85 post-ASCT, but may be delayed up to day 200, patients receive immunotherapy comprising sargramostim SC or IV over 2 hours on days 0-13 during courses 1, 3, and 5 and dinutuximab IV over 10-20 hours on days 3-6 of courses 1-5. Patients also receive aldesleukin IV continuously on days 0-3 and 7-10 during courses 2 and 4. Immunotherapy repeats every 28 days for 5 courses in the absence of disease progression or unacceptable toxicity. Patients also receive isotretinoin as in Arm I beginning on day 11 of immunotherapy.
3328593|NCT00026299|Experimental|Phase 2: Oxaliplatin plus ZD1839|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 and ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily (as determined during phase 1). Subjects can continue to receive the combination for 6 cycles (each cycle is 21 days). After 6 cycles of the combination, subjects can continue to take ZD1839 alone until their cancer worsens.
3328594|NCT00026299|Experimental|Phase 2: Oxaliplatin alone|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 for up to 6 cycles. Each cycle will last 21 days.
3328595|NCT00026299|Experimental|Phase I: Oxaliplatin with ZD1839|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2. ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily.
3328596|NCT00026234|Experimental|Treatment (chemotherapy)|Patients receive floxuridine and dexamethasone intra-arterially continuously on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 6 weeks for 4 courses in the absence of disease recurrence or unacceptable toxicity. After completion of the fourth course, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for 2 courses in the absence of disease recurrence or unacceptable toxicity.
3328597|NCT00026221|Experimental|Arm I (monoclonal antibody and biological therapy)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive low-dose interferon alfa (IFN-alpha) SC on days 1-14.
3328598|NCT00026221|Experimental|Arm II (monoclonal antibody)|Patients receive bevacizumab as in arm I.
3328599|NCT00026221|Experimental|Arm III (monoclonal antibody and biological therapy)|Patients receive bevacizumab as in arm I. Patients also receive high-dose IFN-alpha SC on days 1, 3, 5, 8, 10, and 12.
3328600|NCT00026208|Experimental|Stanford V-C + Low-dose Radiotherapy|"Sanford V-C = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.~Radiotherapy = 20 Gy modified involved field radiotherapy"
3328601|NCT00026208|Experimental|Stanford V-C only|"Sanford V-C = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide."
3328602|NCT00026195|Experimental|irinotecan|"Patients receive irinotecan IV over 90 minutes once weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed for survival."
3328603|NCT00026182|Experimental|Arm I (rituximab and recombinant interleukin-12)|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients receive interleukin-12 SC twice weekly beginning on day 2 and continuing until disease progression.
3328604|NCT00026182|Experimental|Arm II (rituximab and recombinant interleukin-12)|Patients receive rituximab as in arm I. Patients are evaluated at week 12. Patients with stable or progressive disease receive interleukin-12 SC twice weekly until disease progression or for 24 weeks. Patients with a complete or partial response after rituximab are monitored until disease progression and then begin interleukin-12 SC twice weekly until further disease progression.
3328605|NCT00026169|Experimental|Treatment (imatinib mesylate)|"Patients receive oral imatinib mesylate once or twice daily on days 1 and 4-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients in each stratum receive escalating doses of imatinib mesylate until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3328606|NCT00026143|Experimental|Arm I|Patients receive interleukin-12 IV over 5-15 seconds on day 1 and interferon alfa subcutaneously on days 2-6. Treatment repeats every 2 weeks in the absence of unacceptable toxicity. Patients are reassessed after 6 courses. Patients with a complete response receive 2 additional courses. Patients with a partial response or stable disease continue treatment in the absence of disease progression.
3328607|NCT00026130|Experimental|Gemcitabine + 5FU + XRT|Chemo and radiation therapy in the treatment of non-metastatic pancreatic cancer
3328608|NCT00026117|Experimental|BeneFin|"Patients receive oral shark cartilage (BeneFin™) 3-4 times daily. Treatment continues in the absence of unacceptable toxicity. Quality of life is assessed weekly for 1 month and then monthly thereafter during treatment.~Patients are followed every 6 months for 5 years."
3328609|NCT00026117|Other|placebo|"Patients receive oral placebo 3-4 times daily. Treatment continues in the absence of unacceptable toxicity. Quality of life is assessed weekly for 1 month and then monthly thereafter during treatment.~Patients are followed every 6 months for 5 years."
3328610|NCT00026104|Experimental|Arm I (radiation therapy, paclitaxel, gemcitabine)|Patients receive radiotherapy once daily, 5 days a week, for 5.5 weeks, beginning on day 1. Patients also receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, and 36.
3328611|NCT00026104|Experimental|Arm II (radiation therapy, tipifarnib)|Patients receive chemoradiotherapy as in arm I. Within 3-8 weeks after completion of chemoradiotherapy, patients without disease progression receive oral tipifarnib twice daily for 21 days.
3328612|NCT00026091|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide twice daily on days 1-7. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3328613|NCT00025675|Active Comparator|p450|p450 inhibitor
3328614|NCT00025675|Active Comparator|nonp450|not on p450 inhibitor
3328615|NCT00025662|Experimental|RFT5-SMPT-dgA Isolex system|RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin used in allogeneic stem cell transplantation (SCT) in older patients with hematologic malignancies using a graft manipulation process
3328616|NCT00025584|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV over 3-5 seconds twice weekly on weeks 1 and 2. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3328617|NCT00025506|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3328618|NCT00025493|Experimental|docetaxel|docetaxel
3328619|NCT00025415|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients within each stratum (except normal stratum) receive escalating doses of imatinib mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity
3328620|NCT00025389|Experimental|Arm A|Bevacizumab (15mg/kg, q3wk x 2), Paclitaxel (200 mg/m2, q3wk x 2), carboplatin (AUC of 6, q3wk x 2), followed by surgery 4 to 6 weeks after last dose of Bevacizumab
3328621|NCT00025363|Experimental|Arm I|Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
3328622|NCT00025363|Experimental|Arm II|Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 1 hour on days 1-5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
3328623|NCT00025337|Experimental|Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)|Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil (5-FU) IV over 22 hours on days 1 and 2.
3328624|NCT00025337|Experimental|Arm II (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin, leucovorin calcium, and 5-FU as in arm I.
3328625|NCT00025337|Experimental|Arm III (bevacizumab)|Patients receive bevacizumab as in arm I.
3328626|NCT00025259|Experimental|Arm I (Patients off-therapy before callback-Induction only)|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin sulfate IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, oral prednisone 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease.
3328627|NCT00025259|Experimental|Arm II (RER with CR [ABVE-PC, IFRT])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR undergo IFRT approximately 3 weeks after the last day of ABVE course 4.
3328628|NCT00025259|Experimental|Arm III (RER with CR [ABVE-PC])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR are randomized to receive no further treatment.
3328629|NCT00025259|Experimental|Arm IV (RER with less than CR [ABVE-PC, IFRT])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with VGPR, PR or SD undergo IFRT approximately 3 weeks after the last day of ABVE-PC course 4 for 5 days a week.
3328630|NCT00025259|Experimental|Arm V (RER with PD)|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients with PD are taken off therapy.
3328631|NCT00025259|Experimental|Arm VI (SER [DECA, ABVE-PC, IFRT])|Patients receive dexamethasone IV over 15 minutes, etoposide IV over 3 hours, and cytarabine IV over 3 hours on days 1-2. Patients receive 2 drops of dexamethasone ophthalmic solution every 6 hours on days 1, 2 and 3. Patients also receive cisplatin PO or IV over 12 hours as pre-hydration followed by continuous IV over 6 hours on day 1 and G-CSF SC beginning on day 3 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive 2 additional courses of ABVE-PC chemotherapy. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.
3328632|NCT00025259|Experimental|Arm VII (SER [ABVE-PC, IFRT])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive 2 additional courses of ABVE-PC. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.
3328633|NCT00025246|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate daily beginning within 84 days of surgical resection. Treatment continues for 1 year in the absence of disease recurrence or unacceptable toxicity.
3328634|NCT00025233|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3328635|NCT00025220|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3328636|NCT00025155|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 1 hour. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 2 additional courses after achieving CR.
3328637|NCT00025038|Experimental|Treatment (tipifarnib, bone marrow/umbilical cord transplant)|See detailed description.
3328638|NCT00025025||Arm I|"Participants eat no red meat and take no nonsteroidal anti-inflammatory drugs (NSAIDs) and no vitamin C or multivitamins for 3 days prior to and during stool sample collection. Participants collect stool samples 3 different times and perform fecal occult blood (FOB) test smears from each stool. After each collection, participants ship the whole stool and FOB test smear to their participating center for blinded multitarget DNA-based assay panel (MTAP) testing.~Within 2 months after stool sample collection, participants have their blood drawn for additional MTAP testing and undergo colonoscopy."
3328639|NCT00025025||Arm II|"Participants take no vitamin C or multivitamins for 3 days before and during stool sample collection. Participants collect stool samples and FOB test smears and samples are tested as in arm I.~Within 2 months after stool sample collection, participants have their blood drawn for additional MTAP testing and undergo colonoscopy."
3328640|NCT00024258|Experimental|Arsenic Trioxide|"Patients receive arsenic trioxide IV over 1-4 hours on days 1-5 and 8-12. Treatment repeats every 28 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2-3 months for 1 year and then annually thereafter."
3328641|NCT00024167|Experimental|Induction regimen A|Doxorubicin IV over 24 hours day 1; Oral ketoconazole 3 x daily on days 1-7 of weeks 1, 3, and 5; Vinblastine IV over 30 minutes Day 1, oral Estramustine 3 x daily on Days 1-7 of weeks 2, 4, and 6.
3328642|NCT00024167|Experimental|Induction regimen B|Oral Prednisone 2 x daily on days 1-21 (days 1-14 of course 5 only) and Docetaxel IV over 1 hour Day 1.
3328643|NCT00024167|Experimental|Consolidation arm I|Doxorubicin IV over 24 hours once weekly for 6 weeks + Strontium-89 IV once at beginning of chemotherapy.
3328644|NCT00024167|Experimental|Consolidation arm II|Doxorubicin as in Consolidation arm I.
3328645|NCT00024154|Experimental|Treatment (trastuzumab, gefitinib)|"Phase I (completed): Patients receive trastuzumab (Herceptin) IV over 30-90 minutes once weekly and oral gefitinib once daily beginning on day 1.~Cohorts of 3-6 patients receive escalating doses of gefitinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is established, additional patients are accrued to the phase II portion of the study and are treated at that dose.~Phase II: Patients receive oral gefitinib once daily (at the MTD established in phase I) and trastuzumab IV weekly until week 24, at which time trastuzumab is given every 3 weeks (with daily gefitinib) until disease progression or unacceptable toxicity."
3328646|NCT00024102|Active Comparator|Standard Chemotherapy|"Patient/Physician choice of cyclophosphamide + MTX + 5-FU~OR~Cyclophosphamide + doxorubicin"
3328647|NCT00024102|Experimental|Capecitabine|Treatment with capecitabine
3328648|NCT00024089|Experimental|Arm I|Patients receive oral gefitinib daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3328649|NCT00023998|Experimental|Treatment (combination chemotherapy)|See detailed description.
3328650|NCT00023959|Experimental|Treatment (hydroxyurea, fluorouracil, bevacizumab, radiation)|Patients receive oral hydroxyurea every 12 hours on days 1-6, fluorouracil IV continuously on days 1-5, and bevacizumab IV over 90 minutes on day 1. Patients also undergo radiotherapy once daily on days 1-5. Patients receive G-CSF subcutaneously on days 6-12. Treatment repeats every 2 weeks for up to 7 courses in the absence of disease progression or unacceptable toxicity.
3328651|NCT00023946|Experimental|Treatment (ixabepilone)|Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
3328652|NCT00023920|Experimental|Treatment (bevacizumab, idarubicin, cytarabine)|Patients receive bevacizumab IV over 90 minutes once on day -13. Patients then receive bevacizumab IV over 90 minutes and idarubicin IV on days 1 and 15 and cytarabine subcutaneously (SC) once daily beginning on day 1. Treatment repeats every 4 weeks for a maximum of 3 courses. Patients with responding disease receive maintenance therapy comprising bevacizumab IV over 90 minutes on days 1 and 15, idarubicin IV on day 1, and cytarabine SC once daily beginning on day 1. Treatment repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
3328653|NCT00023829|Experimental|LH-RH agonist plus radiation therapy|Luteinizing hormone-releasing hormone (LH-RH) agonist x 2 years plus radiation therapy (RT) to 63.0 - 66.6 Gy
3328654|NCT00023829|Active Comparator|Radiation therapy alone|Radiation therapy alone to 63.0 - 66.6 Gy
3328655|NCT00023829|Active Comparator|LH-RH agonist alone|Luteinizing hormone-releasing hormone (LH-RH) agonist x 2 years
3328656|NCT00023764|Experimental|Arm I|Patients receive an infusion of bortezomib (dose of 1.8 mg/m2) over 3-5 seconds once weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response lasting at least 6 months may receive retreatment.
3328657|NCT00023751|Experimental|surgery + leucovorin + fluorouracil + radiation|"Patients with T3 disease or positive surgical margins after surgery are removed from study. Patients with T1 disease and negative surgical margins after surgery are observed. Patients with T2 disease and negative surgical margins after surgery receive adjuvant therapy.~Beginning 42 days after surgery, T2 patients receive leucovorin calcium (CF) IV over 2 hours with fluorouracil (5-FU) IV bolus 1 hour into the infusion once weekly for 6 weeks. Beginning 2 weeks after the completion of chemotherapy, patients receive chemoradiotherapy comprising radiotherapy once daily 5 times a week for 5 weeks and 5-FU IV continuously while receiving radiotherapy. Beginning 2 weeks after the completion of chemoradiotherapy, patients again receive CF IV over 2 hours with 5-FU IV bolus 1 hour into the infusion once weekly for 6 weeks. Chemotherapy repeats after 2 weeks rest for a total of 2 courses.~Patients are followed every 3 months for 2 years and then every 6 months for 5 years."
3328658|NCT00023712|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3328659|NCT00023686|Experimental|surgery|"Patients undergo radical prostatectomy.~Patients are followed every 6 months for 5 years and then annually thereafter."
3328660|NCT00023686|Experimental|radiation|"Patients undergo brachytherapy with implanted iodine I 125 or palladium Pd 103 seeds.~Patients are followed every 6 months for 5 years and then annually thereafter."
3328661|NCT00023634|Experimental|EGFR vaccine with GMCSF|EGFR antisense DNA 500 mcg peptide w/GMCSF monthly x 6 m
3328662|NCT00023634|Experimental|EGFR vaccine with KLH|EGFR antisense DNA 500 mcg peptide w/KLH monthly x 6 m
3328663|NCT00022737|Experimental|Arm I|See Design Details.
3328664|NCT00022711|Experimental|Temozolomide|Temozolomide 150mg/m2/day daily. Repeat cycles every 28days for maximum of six months
3328730|NCT00017004|Experimental|Arm I|Patients undergo radiotherapy comprising pelvic external beam radiotherapy daily five days a week for 5 weeks, followed by either 1 or 2 implants of low-dose rate intracavitary brachytherapy or 5 fractions of high-dose rate intracavitary brachytherapy, followed by 3-5 days of parametrial boost radiotherapy. Patients receive cisplatin IV concurrently with pelvic external beam radiotherapy on days 1, 8, 15, 22, 29, and once during the week of parametrial boost radiotherapy.
3328665|NCT00022698|Experimental|Cohort 1,Initial Regimen:(Capecitabine + Irinotecan )|Participants will receive capecitabine (Xeloda) 1000 mg/m^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 125 mg/m^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks. A total of 12 cycles of treatment will be administered. At the discretion of the investigator, participants who are responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase. Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).
3328666|NCT00022698|Experimental|Cohort 2,Amended Regimen:(Capecitabine + Irinotecan)|Participants will receive capecitabine 900 mg/m^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 100 mg/m^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks. A total of 12 cycles of treatment will be administered. At the discretion of the investigator, participants who will be responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase. Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).
3328667|NCT00022672|Experimental|trastuzumab + anastrozole|Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase and in the Extension Phase.
3328668|NCT00022672|Active Comparator|anastrozole|1 mg oral dose of anastrozole every day for 24 Months in the Main phase. In the Extension Phase participants could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes.
3328669|NCT00022659|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3328670|NCT00022646|Experimental|Arm I: pemetrexed + gemcitabine|Patients receive pemetrexed disodium IV over 10 minutes on day 1 followed by gemcitabine IV over 30 minutes on days 1 and 8.
3328671|NCT00022646|Experimental|Arm II: pemetrexed + gemcitabine|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 followed by pemetrexed disodium IV over 10 minutes on day 1.
3328672|NCT00022646|Experimental|Arm III: pemetrexed + gemcitabine|Patients receive gemcitabine IV over 30 minutes on day 1 and pemetrexed disodium IV over 10 minutes followed by gemcitabine IV over 30 minutes on day 8.
3328673|NCT00022633|Experimental|gemcitabine, paclitaxel|
3328674|NCT00022581|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
3328675|NCT00022555|Experimental|Treatment (bryostatin 1, vincristine sulfate)|Patients receive bryostatin 1 IV continuously on days 1 and 15 and vincristine IV over 5 minutes on days 2 and 16. Treatment continues every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
3328676|NCT00022516|No Intervention|No-CM|No further chemotherapy following standard adjuvant chemotherapy.
3328677|NCT00022516|Experimental|CM-Maintenance|12-month CM-maintenance regimen (C, cyclophosphamide 50 mg/day orally continuously and M, methotrexate 2.5 mg twice/day orally days 1 and 2 of every week for 1 year)
3328678|NCT00022490|Experimental|Cytarabine/ Imatinib Mesylate|
3328679|NCT00022412|Placebo Comparator|Observation, then prostatectomy|Arm 2: Patients undergo observation for 28 days. Patients then undergo prostatectomy.
3328680|NCT00022412|Active Comparator|Doxercalciferol once daily for 28 days|Dietary supplement once daily to treat prostate cancer for 28 days
3328681|NCT00022334|Experimental|Treatment|See intervention description.
3328682|NCT00022152|Experimental|vinorelbine|"Patients receive oral vinorelbine once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and then after completion of the second course.~Patients are followed every 3 months for 5 years."
3328683|NCT00022126|Experimental|Modified Augmented BFM Therapy|
3328684|NCT00022113|Experimental|Treatment (cilengitide)|Patients receive EMD 121974 IV over 1 hour twice weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3328685|NCT00022087|Experimental|Zoledronic acid initial tx|Zoledronic acid + calcium + Vit D for 2 years, followed by Calcium + vit D for 1 year
3328686|NCT00022087|Experimental|Calcium + Vit D initial Tx|Calcium + vitamin D for 1 year followed by zoledronic acid + calcium + vit D for 2 years
3328687|NCT00021255|Experimental|Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T)|Doxorubicin 60 mg/m² intravenous (IV) bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus injection on Day 1 of every 3 weeks for 4 cycles followed by docetaxel 100 mg/m² IV infusion every 3 weeks for another 4 cycles.
3328688|NCT00021255|Experimental|AC followed by Docetaxel + Herceptin (AC→TH)|Doxorubicin 60 mg/m² IV bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus Injection on Day 1 of every 3 weeks for 4 cycles. Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg by IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV infusion on Day 2 of Cycle 5, then on Day 1 of every 3 weeks for all subsequent cycles ( total 4 cycles). After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.
3328689|NCT00021255|Experimental|Docetaxel + Carboplatin + Herceptin (TCH)|Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 1 only, followed by Herceptin 2 mg/kg IV infusion weekly starting from Day 8 until three weeks after the last cycle of chemotherapy. Docetaxel 75 mg/ m² IV infusion on Day 2 of Cycle 1, then on Day 1 of all subsequent cycles followed by carboplatin IV infusion at target AUC = 6 mg/mL/min repeated every 3 weeks for a total of 6 cycles. After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg by IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.
3328690|NCT00021242|Experimental|Relapsed or Refractory ALL, AML|Docetaxel 60 mg/m^2 per dose weekly (Days 1,8,15) for 3 weeks followed by 1 week of rest.
3328691|NCT00021229|Experimental|Imatinib mesylate|
3328692|NCT00021216|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3328693|NCT00021073|Experimental|Treatment (alvocidib, combination chemotherapy)|"Group I: Patients receive FLAVO IV over 24 hours on day 1 and CF IV and 5-FU IV over 1.5 hours daily on days 2-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of FLAVO and 5-FU until the MTD are determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.~Once the MTDs for FLAVO and 5-FU are determined, patients receive FLAVO, CF, and 5-FU as in group I plus irinotecan IV over 1.5 hours on day 1. Courses repeat as in group I. Cohorts of 3-6 patients receive escalating doses of irinotecan until the MTD is determined. The MTD is defined as in group I."
3328694|NCT00021060|Experimental|Arm I (paclitaxel and carboplatin)|"Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 15-30 minutes on day 1.~Treatment in both arms repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3328695|NCT00021060|Experimental|Arm II (paclitaxel, carboplatin, and bevacizumab)|"Patients receive paclitaxel and carboplatin as in arm I followed by bevacizumab IV over 30-90 minutes on day 1.~Treatment in both arms repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~After completion of 6 courses, patients in arm II with stable or responding disease continue to receive bevacizumab only. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
3328696|NCT00020943|Experimental|Chemo/immuno/autolog transplant|Intensive chemotherapy followed by autologous stem cell transplant and immunotherapy for mantle cell lymphoma
3328697|NCT00020878|Experimental|Study|See intervention description.
3328698|NCT00020826||gastric adenocarcinoma|No protocol specific interventions. Both palliative or curative treatment allowed.
3328699|NCT00020761|Experimental|Gastro Esophogeal cohort|"Patients with adenocarcinoma of the esophagus, gastroesophageal (GE) junction and gastric cardia (GE cohort)~The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
3328700|NCT00020761|Experimental|Distal Stomach cohort|"Patients with adenocarcinoma of the rest of the stomach (Distal Stomach cohort)~The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
3328701|NCT00020735|Experimental|oral toremifene|
3328702|NCT00020735|Other|observation|
3328703|NCT00020722|Experimental|therapeutic autologous lymphocytes|
3328704|NCT00020709|Experimental|Arm I (gefitinib, combination chemotherapy, radiation)|"Patients receive induction therapy comprising cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning within 24 hours after starting chemotherapy, patients receive concurrent induction radiotherapy 5 days a week for 5 weeks and then boost radiotherapy 5 days a week for 1.5 weeks.~Beginning approximately 4-8 weeks after completion of chemoradiotherapy, patients with stable or responding disease receive consolidation therapy comprising docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 3 courses.~Patients with stable or responding disease are randomized to one of two treatment arms for maintenance therapy. Patients begin maintenance therapy approximately 4-7 weeks after completion of consolidation therapy.~Patients receive oral gefitinib daily."
3328705|NCT00020709|Experimental|Arm II (placebo, combination chemotherapy, radiation)|"Patients receive induction therapy comprising cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning within 24 hours after starting chemotherapy, patients receive concurrent induction radiotherapy 5 days a week for 5 weeks and then boost radiotherapy 5 days a week for 1.5 weeks.~Beginning approximately 4-8 weeks after completion of chemoradiotherapy, patients with stable or responding disease receive consolidation therapy comprising docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 3 courses.~Patients with stable or responding disease are randomized to one of two treatment arms for maintenance therapy. Patients begin maintenance therapy approximately 4-7 weeks after completion of consolidation therapy.~Patients receive oral placebo daily. In both arms, maintenance therapy continues for a maximum of 5 years in the absence of disease progression or unacceptable toxicity."
3328706|NCT00020683|Experimental|Arm I (low dose incyclinide)|"Patients receive low-dose oral COL-3 once daily.~Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed."
3328707|NCT00020683|Experimental|Arm II (high dose incyclinide)|"Patients receive high-dose oral COL-3 once daily.~Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed."
3328708|NCT00020670|Experimental|CD40 Cell Vaccination|Patients will undergo tumor cell collection followed by vaccine preparation and then vaccination. Autologous acute lymphoblastic leukemia (ALL) cells are harvested, cultured with CD40 ligand, pulsed with keyhole limpet hemocyanin (KLH), and then irradiated to produce the vaccine. Patients receive either 1 x 10^7 or 1 x 10^8 CD40 cells/vaccination depending on the number of tumor cells obtained. Vaccinations are administered every two weeks as outpatient therapy. Evaluable patients receive the course of at least 4 vaccinations at weeks 0, 2, 4, 6. Patients may continue receiving vaccinations every 2 weeks if chemotherapy is not required for symptomatic disease.
3328709|NCT00020566|Experimental|Group 1|Patients receive 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Patients requiring radiotherapy to the axial tumor also undergo concurrent radiotherapy 5 days a week. Some patients may then undergo surgical resection of the tumor. All patients will then receive vincristine IV on day 1 and dactinomycin IV and ifosfamide IV over 3 hours on days 1 and 2 (VAI). Treatment repeats every 21 days for 8 courses (courses 7-14). Patients requiring radiotherapy to the brain and/or spinal cord also undergo concurrent radiotherapy.
3328710|NCT00020566|Experimental|Group 2, arm I|Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive 7 additional courses of VAI chemotherapy (courses 8-14). Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent whole-lung radiotherapy for 6-12 days.
3328731|NCT00017004|Experimental|Arm II|Patients undergo radiotherapy and chemotherapy as in arm I. Additionally, patients receive epoetin alfa subcutaneously once weekly concurrently with radiotherapy and chemotherapy.
3328711|NCT00020566|Experimental|Group 2, arm II|Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive high-dose chemotherapy comprising oral busulfan every 6 hours on days -6 to -3 and melphalan IV over 30 minutes on day -2. Patients receive autologous PBSC IV on day 0. Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent radiotherapy 5 days a week for at least 5 weeks.
3328712|NCT00019747|Experimental|Arm 1 - Thalidomide once daily|Patients receive oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
3328713|NCT00019747|Placebo Comparator|Arm 2 - Placebo once daily|Patients receive oral placebo once daily.
3328714|NCT00019708|Experimental|Treatment (tanespimycin)|Patients will receive infusions of tanespimycin analogue twice a week in weeks 1 and 3.
3328715|NCT00019682|Experimental|Arm I (aldesleukin)|Patients receive aldesleukin IV over 15 minutes every 8 hours for 12 doses. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease 3 weeks after completing 2 courses may receive a maximum of 12 additional courses. Patients with complete response may receive a maximum of 2 additional courses.
3328716|NCT00019682|Experimental|Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin)|Patients receive gp100 antigen emulsified in Montanide ISA-51 SC on day 1. Patients also receive aldesleukin as in Arm I beginning on day 2. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease 3 weeks after completing 2 courses may receive a maximum of 12 additional courses. Patients with complete response may receive a maximum of 2 additional courses.
3328717|NCT00019604|Experimental|Radiofrequency ablation in liver cancer|This trial is designed to gain experience with the use of ablation devices with liver tumors. Radiofrequency ablation is a procedure that heats tumors to several degrees above body temperature and may kill tumor cells.
3328718|NCT00017563|Experimental|Docetaxel, Mitoxantrone, Conventional Surgery|"Drug: Docetaxel-35 mg/m2 i.v. over 15 - 30 minutes will be administered immediately after the mitoxantrone on the same schedule.~Drug: Mitoxantrone-Initial dose will be 2 mg/m2 weekly for 3 of every 4 weeks. The dose will then be escalated as described in the dose escalation section up to a maximum dose of 6 mg/m2 weekly for 3 of every 4 weeks.~Procedure/Surgery: Conventional Surgery- Prostatectomy will be scheduled 2-4 weeks after the last dose of chemotherapy"
3328719|NCT00017472|Experimental|Arm I|Patients receive apolizumab IV over at least 2 hours on days 1, 2, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a complete or partial response who relapse after 2 months may receive an additional course of therapy provided they still express the 1D10 antigen.
3328720|NCT00017381|Experimental|Treatment|"PART I: Patients receive rituximab IV on days 1, 8, 15, and 22 and cyclophosphamide IV over 1 hour on day 25. G-CSF is administered SC daily beginning on day 26 and continuing until autologous PBSC are harvested.~PART II: Beginning 4-6 weeks after completion of the fourth rituximab infusion, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1 followed by dosimetry imaging on days 1, 2, 4, and 7. Patients then receive IDEC-Y2B8 IV over 10 minutes once between days 8-15.~PART III: All patients undergo PBSCT beginning after residual bone marrow radioactivity resolves. G-CSF is administered SC beginning 1 day after PBSCT and continuing until blood counts recover."
3328721|NCT00017251|Experimental|Treatment (oblimersen sodium, carboplatin, etoposide)|Patients receive G3139 IV continuously on days 1-8, carboplatin IV over 30 minutes on day 6, and etoposide IV over 1 hour on days 6-8. Treatment repeats every 3 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression.
3328722|NCT00017238|Experimental|Treatment (KRN5500)|"Patients receive KRN5500 IV over 24-72 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-3 patients receive KRN5500 at the starting dose over escalating infusion durations. After the longest duration of infusion time is safely reached, cohorts of 3-6 patients receive escalating doses of KRN5500 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued to receive treatment with KRN5500 at the recommended phase II dose."
3328723|NCT00017186|Experimental|gemcitabine + epirubicin|"Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and epirubicin IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR) receive 2 additional courses beyond CR.~Quality of life is assessed at baseline, prior to course 3, at 3 months, and then at 1 year.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
3328724|NCT00017173|Experimental|surgery with INGN 201 followed by chemo/RT|intraoperative and postoperative injections of INGN 201 into the tumor bed, followed by cisplatin and radiation therapy
3328725|NCT00017147|Experimental|O6-BG + BCNU + Radiation Therapy|O6-BG: 120 mg/m^2 IV over 1 hour on day 1 of each cycle BCNU: 40 mg/m^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose. Radiation Therapy: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
3328726|NCT00017147|Active Comparator|BCNU + Radiation Therapy|BCNU: 40 mg/m^2 IV over 1 hour on day 1 of each cycle. Radiation Therapy: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
3328727|NCT00017121|Experimental|sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) twice a day on days 1-7 and 15-21. Treatment repeats every 28 days for 2 courses. Patients with no disease progression after completion of course 2 may continue on treatment until disease progression. Patients are grouped to 1 of 2 dose-escalation regimens (part A vs B).~After completion of study therapy, patients are followed at 3 months, every 2 months for 1 year, and then every 3-4 months for 5 years."
3328728|NCT00017095|Active Comparator|non taxane based chemotherapy|either FEC 100 or Canadian CEF or Tailored FEC for 6 cycles
3328729|NCT00017095|Experimental|taxane based chemotherapy|Docetaxel for 3 cycles followed by Epirubicin/Docetaxel for 3 cycles
3328757|NCT00014612|Experimental|axillary radiotherapy|axillary radiotherapy, daily for 5 days a week, for 5 weeks
3328732|NCT00016952|Experimental|irinotecan|"Prior oxaliplatin-based chemotherapy: Patients receive irinotecan IV over 90 minutes on day 1. Treatment repeats every 3 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a confirmed complete response for 2 consecutive courses may discontinue treatment at investigator's discretion.~Quality of life is assessed at baseline, approximately every 6 weeks during treatment, and then after the last course of treatment.~Patients are followed every 3 months for 5 years."
3328733|NCT00016952|Experimental|leucovorin + fluorouracil|"Prior to irinotecan and oxaliplatin combination chemotherapy: Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV continuously on days 1 and 2. Treatment repeats every 2 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a confirmed complete response for 2 consecutive courses may discontinue treatment at investigator's discretion.~Quality of life is assessed at baseline, approximately every 6 weeks during treatment, and then after the last course of treatment.~Patients are followed every 3 months for 5 years."
3328734|NCT00016913|Experimental|Neo-Adj ChemoTx + ablation prior to RT|Patients with localized high-risk prostate cancer were treated with 4 cycles (16 weeks) of continuous weekly paclitaxel at 80 mg/m^2 intravenously with estramustine at 280 mg orally 3 times a day for 5 days a week and carboplatin (area under the curve of 6) on Day 1 of every cycle followed by 3-dimensional conformal or intensity-modulated radiotherapy (total dose of 77.4 gray [Gy] in 1.8-Gy fractions). All patients received androgen deprivation therapy with either goserelin acetate at 3.6 mg subcutaneously or leuprolide acetate at 7.5 mg intramuscularly monthly for 6 months starting at Day 1 of therapy.
3328735|NCT00016432|Experimental|Group 1|Exemestane
3328736|NCT00016432|Placebo Comparator|Group 2|Placebo
3328737|NCT00016406|Active Comparator|AC followed by P|doxorubicin and cyclophosphamide followed by paclitaxel followed by surgery
3328738|NCT00016406|Experimental|AC+G followed by P|weekly doxorubicin and daily cyclophosphamide with filgrastim followed by paclitaxel followed by surgery
3328739|NCT00016354|Experimental|benzoylphenylurea|
3328740|NCT00016328|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes once weekly for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3328741|NCT00016302|Experimental|Regimen A|See detailed description.
3328742|NCT00016302|Experimental|Regimen B|"Induction (weeks 1-9): Patients receive treatment as in induction of regimen A.~Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.~Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen A and nelarabine IV on days 162-166.~Maintenance (weeks 30-101): Patients receive oral mercaptopurine daily on days 1-28 and 36-56; oral methotrexate weekly; and nelarabine IV on days 29-33. Treatment repeats every 8 weeks for 4 courses. Beginning on week 62, patients receive vincristine IV once; oral prednisone three times daily for 5 days; oral mercaptopurine daily; and oral methotrexate weekly. Treatment repeats every 8 weeks for 5 courses."
3328743|NCT00016302|Experimental|Regimen C|"Induction (weeks 1-5): Patients receive treatment as in induction (weeks 1-5) on regimen A and nelarabine IV over 1 hour on days 29-33.~If bone marrow is M1, patients begin week 6 of induction therapy on day 36 or when peripheral blood counts recover. If bone marrow is M2, patients begin week 6 of induction therapy immediately. If bone marrow is M3, treatment discontinues.~Induction (weeks 6-9): Patients receive treatment as in induction (weeks 6-9) on regimen A.~Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.~Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen B.~Maintenance (weeks 30-101): Patients receive treatment as in maintenance on regimen B."
3328744|NCT00016302|Experimental|Regimen D|See detailed description.
3328745|NCT00016302|Experimental|Regimen E|Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen D, but nelarabine is administered at a higher dose.
3328746|NCT00016302|Experimental|Regimen F|Patients receive nelarabine at a higher dose during induction therapy. Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen E.
3328747|NCT00016289|Experimental|Treatment (recombinant interleukin-12)|Patients receive interleukin-12 intraperitoneally once weekly. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease receive 2 additional courses.
3328748|NCT00016146|Experimental|vaccine|"This is a dose-escalation study of GPI-0100.~Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant GPI-0100 subcutaneously weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity or disease progression.~Cohorts of 5 patients receive escalating doses of GPI-0100 until the optimal dose, based on antibody response, is reached.~Patients are followed every 3 months."
3328749|NCT00016094|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for a maximum of 24 courses in the absence of disease progression or unacceptable toxicity.
3328750|NCT00016016|Experimental|Treatment (flavopiridol, cytarabine, mitoxantrone)|Patients receive flavopiridol IV over 1 hour on days 1-3 and cytarabine IV continuously on days 6-9 followed by mitoxantrone IV over 30-150 minutes on day 9. Patients achieving a partial or complete response after the first course of therapy may receive an additional course of therapy beginning 35 ± 7 days after blood count recovery.
3328751|NCT00015977|Experimental|PSMA peptide vaccine|Immunization with PSMA peptide vaccine followed by injection of Interleukin-12 (IL-12) on Day 1 of a 21-day cycle. Additional injections of IL-12 given on Days 3 and 5 of each cycle.
3328752|NCT00015938|Experimental|treatment|docetaxel and vinorelbine with filgrastim support
3328753|NCT00015873|No Intervention|A no VIMARAM|No VIMARAM preceding maintenance treatment
3328754|NCT00015873|Experimental|B - VIMARAM|VCR i.v. 1.5 mg/m2/d - 4 days 6-MP p.o. 25 mg/m2/d - 15 days HD-MTX p.i.(24hr) 5 g/m2 - 2 days MTX + pred I.T. (age adapted) - 2 days HD-Ara-C p.i (3hr) 3 g/m2/12 hrs -8 days L-ASP p.i. (1hr) 5.000 U/m2 - 2 days
3328755|NCT00015834|Experimental|Treatment (imatinib mesylate, cytarabine)|Patients who have not previously received imatinib mesylate receive oral imatinib mesylate daily on days 1-35. Patients who have previously received imatinib mesylate for at least 28 days receive oral imatinib mesylate on days 22-35. All patients receive cytarabine IV over 2 hours every 12 hours on days 29-32. Patients with more than 5% residual blasts in bone marrow on day 28 receive a second course in the absence of disease progression or unacceptable toxicity.
3328756|NCT00014612|Active Comparator|axillary lymph node dissection|complete axillary lymph node dissection
3328758|NCT00014495|Experimental|bismuth Bi 213 monoclonal antibody M195 & cytarabine|"Patients receive cytarabine IV continuously on days 1-5. Beginning between days 7 and 14, patients receive Bi213 MOAB M195 IV over 5 minutes up to 4 times daily over 1-4 days. Patient also receive filgrastim (G-CSF) subcutaneously daily beginning 24 hours after the final Bi213 MOAB M195 infusion and continuing until blood counts recover. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 to 6 patients receive escalating doses of Bi213 MOAB M195 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, subsequent patients are treated at the MTD.~Patients are followed twice weekly for 4 weeks and then monthly for 3 months"
3328759|NCT00014378|Experimental|Chinese Herb Huanglian (Coptis chinesis)|
3328760|NCT00014235|Experimental|Arm I (indolent disease)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to 56 with a taper to day 180 and mycophenolate mofetil PO BID or IV every 8-12 hours on days 0 to 27."
3328761|NCT00014235|Experimental|Arm II (aggressive disease)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate and undergo TBI as in Arm I.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to 56 with a taper to day 70 and mycophenolate mofetil as in Arm I."
3328762|NCT00014222|Active Comparator|Arm 1: CEF|6 cycles - q 28 days (6 months) - Cyclophosphamide 75 mg/m2 - po - Days 1-14 - Epirubicin 60 mg/m2 - IV - Days 1 and 8 - 5 Fluorouracil: 500mg/m2 - IV - Days 1 and 8 + Continuous Antibiotic Prophylaxis with Cotrimoxazole 960 mg (i.e.2x480 mg tablets) po-bid or Ciprofloxacin 500 mg - po-bid
3328763|NCT00014222|Active Comparator|Arm 2: EC/T|6 cycles - q 14 days (3 months) - Epirubicin 120 mg/m2 - IV - Day 1 - Cyclophosphamide 830 mg/m2 - IV - Day 1 - Filgrastim 5μg/kg/d - SC - Days 2 - 13 + Epoetin Alfa 40,000 IU - SC - once weekly (to begin within 1 week after start of protocol therapy as needed) 21 days from last administration of EC (EC/T) 4 cycles - q 21 days (3 months) - Adriamycin 60 mg/m2 - IV - Day 1 - Cyclophosphamide 600 mg/m2 - IV - Day 1 - 21 days from last administration of AC 4 cycles - q 21 days (3 months) - Paclitaxel 175 mg/m2 IV 3 hour infusion
3328764|NCT00014222|Active Comparator|Arm 3: AC/T|4 cycles - q 21 days (3 months) - Adriamycin 60 mg/m2 - IV - Day 1 - Cyclophosphamide 600 mg/m2 - IV - Day 1 21 days from last administration of AC 4 cycles - q 21 days (3 months) - Paclitaxel 175 mg/m2 IV 3 hour infusion
3328765|NCT00014196|Experimental|chemo/RT followed by consolidation chemo|cisplatin docetaxel radiation therapy
3328766|NCT00014131|Experimental|Biological/Vaccine|Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
3328767|NCT00014079||Group 1|"DNA is examined for unstable elements (microsatellite instability and loss of heterozygosity) by analyzing at least 10 separate (CA)n-repeats localized to 5 separate chromosomes (5q, 8p, 15, 17p, and 18q). Loss of heterozygosity is analyzed for at least four chromosomal arms (5q, 8p, 17p, and 18q) and later other chromosomes (e.g., 1, 14, and 22). Immunohistochemistry is used to test for the presence or absence of the genes involved in DNA mismatch repair (hMLH1 and hMSH2).~Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment."
3328768|NCT00012376|Experimental|Treatment (bryostatin 1 and sargramostim)|Patients receive bryostatin 1 IV continuously and GM-CSF subcutaneously once daily on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with disease stabilization or improvement may continue treatment for up to 12 courses.
3328769|NCT00012363|Experimental|Gemcitabine + Irinotecan|Gemcitabine 1000mg/m2 IV over 30 min on Days 1,8 q21days; Irinotecan 100mg/m2 IV over 90 min on Days 1,8 q21days
3328770|NCT00012298|Experimental|Treatment (radiolabeled monoclonal antibody therapy)|Patients receive rituximab IV on days 1 and 8, indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1, and yttrium Y 90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) and interleukin-11 SC until blood counts recover.
3328771|NCT00012220|Active Comparator|Gemcitabine|Standard treatment
3328772|NCT00012220|Experimental|Gemcitabine + cisplastin|Addition of cisplastin to gemcitabine
3328773|NCT00012220|Experimental|Gemcitabine + docetaxel|Addition of docetaxel to gemcitabine
3328774|NCT00012220|Experimental|Gemcitabine + Irinotecan|Addition of irinotecan to gemcitabine
3328775|NCT00012194|Experimental|Treatment (7-hydroxystaurosporine, cisplatin)|Patients receive cisplatin IV over 1 hour on day 1 and UCN-01 IV continuously over 36-72 hours on day 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3328776|NCT00012181|Experimental|Treatment (alvocidib)|Patients receive flavopiridol IV over 1 hour on days 1-3. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3328777|NCT00012064|Experimental|Biological/Vaccine|"Biological/Vaccine: therapeutic autologous dendritic cells.~Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product."
3328778|NCT00012025|Experimental|fulvestrant|"Patients receive fulvestrant intramuscularly on day 1. Courses repeat approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years or until disease progression. After disease progression, patients are followed every 3 months for 2 years and then every 6 months for 3 years."
3328779|NCT00012012|Experimental|Radiation therapy plus cisplatin|Patients receive extended field external beam radiation therapy (RT) to the para-aortic region and pelvis, intracavitary brachytherapy with concurrent weekly cisplatin.
3328780|NCT00012012|Experimental|Radiation therapy plus cisplatin and amifostine|Patients receive extended field external beam radiation therapy (RT) to the para-aortic region and pelvis, intracavitary brachytherapy with concurrent weekly cisplatin and amifostine trihydrate.
3328781|NCT00011999|Experimental|Surgery, chemotherapy and radiation therapy|Early post-operative paclitaxel followed by paclitaxel and cisplatin concurrent with radiation therapy for resected head and neck cancer.
3329237|NCT00002850|No Intervention|No prophylaxis|The patient will receive no prophylactic antibiotics.
3328782|NCT00011986|Active Comparator|Arm I|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment continues every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
3328783|NCT00011986|Experimental|Arm II|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and gemcitabine IV over 30 minutes on days 1 and 8.
3328784|NCT00011986|Experimental|Arm III|Patients receive chemotherapy as in arm I during courses 1-8 and doxorubicin HCl liposome IV over 1 hour on day 1 during courses 1, 3, 5, and 7. Treatment continues as in arm I.
3328785|NCT00011986|Experimental|Arm IV|Patients receive topotecan IV over 30 minutes on days 1-3 and carboplatin IV over 30 minutes on day 3. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy.
3328786|NCT00011986|Experimental|Arm V|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 8. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy. Patients with initial unresectable or suboptimal residual disease (more than 1 cm) may undergo interval cytoreductive surgery between courses 4 and 5 of chemotherapy.
3328787|NCT00010257|Experimental|Paclitaxel plus Carboplatin|Paclitaxel 225 mg/m2 IV over 3 hours and Carboplatin AUC 6.0 IV over 30 minutes on day 1 of a 21-day cycle
3328788|NCT00010218|Experimental|karenitecin|"Patients receive karenitecin IV over 60 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease after 6 courses may receive 2 additional courses beyond best response.~Patients are followed every 3 months for 1 year and then every 6 months thereafter."
3328789|NCT00010205|Experimental|Treatment (benzoylphenylurea)|Patients receive oral benzoylphenylurea weekly for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of benzoylphenylurea until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose-limiting toxicity.
3328790|NCT00010192|Experimental|Treatment (rituximab and aldesleukin)|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients then receive low-dose aldesleukin SC on days 29-39, 43-53, 57-67, and 71-81, and intermediate-dose aldesleukin SC on days 40-42, 54-56, 68-70, and 82-84.
3328791|NCT00009984|Experimental|Arm I (thalidomide)|Patients receive oral thalidomide once daily in the absence of disease progression or unacceptable toxicity.
3328792|NCT00009984|Experimental|Arm II (thalidomide, fludarabine phosphate)|Patients receive thalidomide as in arm I and fludarabine IV over 30 minutes on days 1-5. Treatment with fludarabine repeats every 28 days for 6 courses. Once fludarabine is completed, patients continue to receive thalidomide alone as in arm I.
3328793|NCT00009971|Experimental|Arm I|Patients receive oral fenretinide twice daily on days 1-7. Treatment continues every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
3328794|NCT00009945|Experimental|Arm 1: Clodronate|Patient receives 2 tablets once daily for 3 years.
3328795|NCT00009945|Placebo Comparator|Arm 2: Placebo|Patient receives 2 tablets once daily for 3 years.
3328796|NCT00008697|Experimental|Phase 1|"Cohort 1 Arsenic trioxide = 0.1 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 2 Arsenic trioxide = 0.15 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 3 Arsenic trioxide = 0.20 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 4 Arsenic trioxide = 0.25 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 5 Arsenic trioxide = 0.30 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)"
3328797|NCT00008697|Experimental|Phase 2|Arsenic trioxide = MTD found in Phase 1 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)
3328798|NCT00008411|Experimental|Docetaxel Weekly|Arm I: Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days.
3328799|NCT00008411|Experimental|Docetaxel Every 3 Weeks|Arm II: Docetaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days.
3328800|NCT00008385|Placebo Comparator|Arm I|Participants receive an oral yeast placebo as in arm II.
3328801|NCT00008385|Experimental|Arm II|Participants receive oral selenium yeast daily for 6 months. Treatment repeats every 6 months for 8 courses for a total of 4 years in the absence of unacceptable toxicity.
3328802|NCT00008346|Other|SFM then FFDM|Screen Film Mammography (SFM) followed by Full Field Digital Mammography (FFDM)
3328803|NCT00008346|Other|FFDM then SFM|Full Field Digital Mammography (FFDM) followed by Screen Film Mammography (SFM)
3328804|NCT00008216||alloSCT group|Patients undergoing allogeneic blood or marrow stem cell transplantation (alloSCT).
3328805|NCT00008138|Experimental|chemo/debulking surgery/IP chemo|neoadjuvant chemotherapy (carboplatin and paclitaxel) followed by debulking surgery followed by intraperitoneal chemotherapy (carboplatin and paclitaxel)
3328806|NCT00007904|Experimental|Arm A: Combination Chemotherapy|Paclitaxel IV continuously over 72 hours on days 1-3 and cyclophosphamide IV on days 1-3. Filgrastim subcutaneously (SC) beginning on day 5 and continuing until blood counts recover or pegfilgrastim SC on day 5. Treatment repeats every 21 days for 3 courses. Then doxorubicin hydrochloride IV on day 1 and filgrastim SC beginning on day 2 and continuing until blood counts recover or pegfilgrastim SC on day 2. Treatment repeats every 21 days for 4 courses. Patients with hormone-receptor positive tumors receive oral tamoxifen citrate or oral anastrozole daily for 5 years following chemotherapy. Beginning 3-6 weeks after completion of chemotherapy, patients undergo radiation therapy 5 days a week for 6-7 weeks.
3328807|NCT00006994|Active Comparator|L-glutamine in suspension + radiation|20 cc three times daily for 60 days plus radiation therapy.
3328808|NCT00006994|Placebo Comparator|Placebo in suspension + radiation|20 cc three times daily for 60 days plus radiation therapy.
3328809|NCT00006942|Experimental|Treatment (bryostatin 1, cisplatin)|Patients receive bryostatin 1 IV continuously over 72 hours immediately followed by cisplatin IV over 1 hour. Treatment continues every 3 weeks for a minimum of 2 courses in the absence of disease progression.
3328810|NCT00006929|Experimental|Treatment (suramin, paclitaxel, carboplatin)|Patients receive suramin IV over 30 minutes on days 1 and 2. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3329238|NCT00002849|Experimental|induction and maintenance|dexamethasone induction followed by alpha interferon maintenance
3328811|NCT00006916|Experimental|Radiation therapy followed by bleomycin via Ommaya reservoir|60.0 Gy/30 fractions x 2.0 Gy. Then within 2-6 weeks after completion of radiation therapy or at the time a patient experiences disease progression during or immediately after completion of radiation therapy, if clinically feasible, a modified Ommaya reservoir is implanted with the delivery catheter in the tumor or tumor cyst/cavity. Bleomycin, 15 units per week, is then given via the Ommaya reservoir without interruption for a maximum of two years as long as there is no toxicity above grade 3 or evidence of disease progression.
3328812|NCT00006903|Experimental|Treatment (fulvestrant)|Patients receive fulvestrant intramuscularly on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
3328813|NCT00006773|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3328814|NCT00006760|Experimental|Treatment (ifosfamide, vinorelbine, filgrastim)|Patients receive ifosfamide IV over 24 hours on days 1-4 and vinorelbine tartrate IV over 6-10 minutes on days 1 and 5. Patients also receive filgrastim (G-CSF) subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover. Treatment repeats at least every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients may receive a third course of therapy at the discretion of the investigator. Heavily pretreated, high-risk patients who achieve a complete response are eligible for stem cell transplantation. Patients undergo peripheral blood stem cell (PBSC) collection during hematopoietic recovery after the second course of chemotherapy. Patients with sufficient PBSCs collected may undergo PBSC transplantation on protocol COG-AHOD0121.
3328815|NCT00006747|Experimental|chemotherapy + stem cell transplantation|"Patients receive carmustine, etoposide, cytarabine and melphalan on day -1. Patients undergo allogeneic peripheral blood stem cell (PBSC) transplantation on day 0. Patients also receive tacrolimus on day -2 and then orally twice daily until day 120 and methotrexate on days 1, 3, and 6 as graft-versus-host disease (GVHD) prophylaxis. Patients receive sargramostim daily beginning on day 7 and continuing until blood counts recover.~Patients with no active GVHD who have persistent disease on day 150 or progressive disease at any time after PBSC transplantation receive donor lymphocytes IV over 2 hours. Patients may receive additional donor lymphocytes at least 8 weeks later if disease persists.~Patients are followed at 6 and 12 months post-transplantation and then annually for 4 years."
3328816|NCT00006734|Experimental|Regimen A|Test the hypothesis that chemotherapy given every two weeks (Regimen B) will produce higher event-free survival. Treatment will occur in two phases: Induction and Continuation, with 14 cycles of chemotherapy in all. Induction consists of the first twelve weeks (four cycles on Regimen A. The cycles alternate between vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, MESNA and ifosfamide, etoposide, MESNA. G-CSF (Filgrastim) is given between chemotherapy doses. Local control (Surgery, Radiation Therapy, or a combination) will begin on Week 13 which will be after four cycles of chemotherapy.
3328817|NCT00006734|Experimental|Regimen B|Conventional every-three-week chemotherapy for patients with Ewing sarcoma and related tumors. Treatment will occur in two phases: Induction and Continuation, with 14 cycles of chemotherapy in all. Induction consists of the first twelve weeks six cycles on Regimen B). The cycles alternate between vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, MESNA and ifosfamide etoposide MESNA. G-CSF (Filgrastim) is given between chemotherapy doses. Local control (surgery, Radiation Therapy, or a combination) will begin on Week 13, which will be after six cycles of chemotherapy.
3328818|NCT00006721|Active Comparator|Arm I (CHOP only)|"Patients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day~1. Patients also receive oral prednisone daily on days 1-5. Treatment continues every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. (Arm I closed to accrual as of 12/15/02)"
3328819|NCT00006721|Experimental|Arm II (CHOP + rituximab)|Patients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on days 8, 29, 50, 71, 92, and 113. Patients also receive oral prednisone daily on days 8-12, 29-33, 50-54, 71-75, and 113-117 and rituximab IV over 4-6 hours on days 1, 6, 48, 90, 134, and 141.
3328820|NCT00006721|Experimental|Arm III (CHOP + tositumomab)|Patients receive chemotherapy as in arm I and tositumomab (monoclonal antibody anti-B1) IV over 1 hour followed by iodine I 131 tositumomab IV over 20 minutes on days 134 and 141.
3328821|NCT00006695|Experimental|Arm I|Iodine-131 Anti-B1 Antibody/BEAM/autologous hematopoietic stem cell transplantation (AHSCT)
3328822|NCT00006473|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
3328823|NCT00006471|Experimental|Fenretinide|
3328824|NCT00006462|Experimental|Relapsed acute lymphoblastic and acute Myelogenous leukemia|Gemcitabine hydrochloride will be given as 10 mg/m2/min x 360 minutes weekly for three weeks. After a one-week rest period it may be repeated in patients without progressive disease or limiting toxicity.
3328825|NCT00006461|Other|Chemotherapy, surgery, radiation therapy|Patients receive induction chemotherapy consisting of vincristine sulfate IV on days 1, 8, and 15; cisplatin IV over 6 hours on day 1; cyclophosphamide IV over 30 minutes on day 2; and oral etoposide daily on days 2-22. Treatment repeats every 28 days for a total of 4 courses. After completion of induction chemotherapy, patients with residual disease undergo a therapeutic conventional surgery (second resection). Within 4 weeks after completion of induction chemotherapy or second resection, patients receive 3-dimensional conformal radiation therapy daily, 5 days a week, for 6 weeks. Four weeks after completion of 3-dimensional conformal radiation therapy, patients receive alternating treatments of maintenance chemotherapy. Patients receive vincristine sulfate IV on days 1, 8, and 15 and cyclophosphamide IV over 30 minutes on day 1 of courses 1, 3, 5, and 7 and oral etoposide daily on days 1-21 of courses 2, 4, 6, and 8. Treatment continues every 28 days for 8 courses.
3328826|NCT00006392|Experimental|Vitamin E + selenium placebo|vitamin E and selenium placebo daily for 7-12 years
3328827|NCT00006392|Experimental|Selenium + vitamin E placebo|selenium and vitamin E placebo daily for 7-12 years
3328828|NCT00006392|Experimental|Vitamin E + selenium|vitamin E and selenium placebo daily for 7-12 years
3328829|NCT00006392|Placebo Comparator|Vitamin E placebo + selenium placebo|vitamine E placebo and selenium placebo daily for 7-12 years
3329854|NCT00034814|Experimental|5|Non-enzyme-inducing TLP 25mg TID
3328830|NCT00006389|Experimental|Treatment|Patients receive bryostatin 1 IV over 72 hours on days 1-3 followed by cisplatin IV over 1 hour on day 4. Treatment repeats every 3 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
3328831|NCT00006386|Experimental|External beam radiotherapy with stereotactic boost|External beam radiotherapy (EBXRT): 50 Gy in 25 daily fractions of 2 Gy. Stereotactic radiotherapy (SRT) boost: 4 treatments of 5 or 7 Gy, once per week during weeks 3-6. Patients will not receive EBXRT on the SRT treatment days.
3328832|NCT00006373|Experimental|TIME|Topotecan, Ifosfamide, Mesna and Etoposide
3328833|NCT00006364|Experimental|Treatment (omacetaxine mepesuccinate)|"Remission induction therapy: Patients receive remission induction therapy comprising homoharringtonine IV continuously over 24 hours on day 1 and then subcutaneously (SC) twice daily on days 2-14 for course 1. Subsequent courses of remission induction therapy comprise homoharringtonine SC twice daily on days 1-14. Treatment continues monthly for at least 2 courses.~Maintenance therapy: Patients with complete hematologic remission receive maintenance therapy comprising homoharringtonine SC twice daily on days 1-7 monthly for 3 years in the absence of disease progression or unacceptable toxicity."
3328834|NCT00006363|Experimental|Induction Arm I|Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV over 5-10 minutes followed by etoposide IV over 2 hours on days 1-3. Patients with 20% or greater bone marrow cellularity and greater than 5% leukemia blasts at the end of the first course receive a second course of cytarabine IV continuously on days 1-5 and daunorubicin IV over 5-10 minutes followed by etoposide IV over 2 hours on days 1 and 2.
3328835|NCT00006363|Experimental|Induction Arm II|Patients receive PSC 833 IV continuously on days 1-3 and cytarabine, daunorubicin, and etoposide as in arm I. Patients with 20% or greater bone marrow cellularity and greater than 5% leukemia blasts at the end of the first course receive a second course of PSC 833 IV continuously on days 1 and 2 and cytarabine, daunorubicin, and etoposide as in arm I.
3328836|NCT00006363|Experimental|Intensification Favorable|Patients receive HiDAC IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats no earlier than 28 days after the prior course and no later than 14 days after hematopoietic recovery for two more courses.
3328837|NCT00006363|Experimental|Intensification Unfavorable PBSCT Group|Patients receive etoposide IV continuously and HiDAC IV over 2 hours every 12 hours on days 1-4. Patients also receive G-CSF SC daily beginning on day 14 and continuing until PBSC collection is completed. Patients who are not able to undergo PBSCT after HiDAC/etoposide continue treatment in the non-PBSCT group. At least 4 weeks after HiDAC/etoposide recovery, patients receive oral busulfan every 6 hours on days -7 to -4 and etoposide IV over 4 hours on day -3 prior to PBSCT. Patients receive autologous PBSC infusion on day 0. Patients also receive G-CSF SC beginning on day 0 and continuing until hematopoietic recovery.
3328838|NCT00006363|Experimental|Intensification Unfavorable Non-PBSCT Group|Patients receive etoposide, HiDAC, and G-CSF as in the PBSCT group. After hematopoietic recovery, patients then receive HiDAC IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats no earlier than 28 days after prior course and no later than 14 days after hematopoietic recovery for one more course.
3328839|NCT00006363|Experimental|Immunotherapy Arm I|Patients begin therapy no later than 120 days after the first day of the last course of HiDAC treatment OR day 0 of PBSCT. Patients receive low-dose IL-2 SC on days 1-14, 19-28, 33-42, 47-56, 61-70, and 75-90. In addition, patients receive high-dose IL-2 SC on days 15-17, 29-31, 43-45, 57-59, and 71-73.
3328840|NCT00006363|Active Comparator|Immunotherapy Arm II|Patients are observed and receive no further therapy.
3328841|NCT00006359|Experimental|Androgen suppression + EBRT + Brachytherapy|Androgen suppression with external beam radiation therapy followed by brachytherapy boost
3328842|NCT00006252|Experimental|Allogeneic Stem Cell Tx|minimal ablation and cellular immune therapy with allogeneic donor stem cell therapy
3328843|NCT00006249|No Intervention|observation|5 years observation + 5 years follow up
3328844|NCT00006249|Experimental|pegylated interferon alfa|5 years pegylated interferon alfa + 5 years follow up
3328845|NCT00006244|Experimental|Treatment (immunotherapy)|Patients receive melphalan IV over 2-3 hours on day -2 and an infusion of IL-2-treated autologous or syngeneic peripheral blood stem cells on day 0. Beginning on day 0, patients also receive IL-2 IV continuously over 5 days followed by 2 days off. Treatment with IL-2 repeats weekly for 4 weeks. Beginning 1 month later, patients undergo maintenance therapy comprising interferon alfa SC 3 times a week in the absence of disease progression or unacceptable toxicity.
3328846|NCT00006237|Active Comparator|Arm I|Patients receive interferon alfa IV on days 1-5 of weeks 1-4 followed by interferon alfa subcutaneously (SC) on days 1, 3, and 5 of weeks 5-52 in the absence of disease progression or unacceptable toxicity.
3328847|NCT00006237|Experimental|Arm II|Patients receive cisplatin IV over 30 minutes followed by vinblastine IV on days 1-4. Patients also receive dacarbazine IV over 1 hour on day 1, interleukin-2 IV over 96 hours on days 1-4, and interferon alfa SC on days 1-5, 8, 10, and 12. In addition, patients receive filgrastim (G-CSF) SC on days 6-15. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
3328848|NCT00006228|Experimental|Treatment (trastuzumab and aldesleukin)|Patients receive trastuzumab IV over 30-90 minutes on days 1 and 8 and aldesleukin SC on days 2-7 and 9-21. Beginning on day 22, patients receive trastuzumab IV over 30 minutes every 14 days. Patients also receive aldesleukin SC daily on days 1-14. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
3328849|NCT00006227|Experimental|Treatment (paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity.
3328850|NCT00006226|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide daily for 4 weeks. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
3328851|NCT00006221|Experimental|Arm I|"Patients receive BMS-247550 IV over 1 hour once weekly on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose level. Patients treated at the MTD receive treatment once weekly on weeks 1-3 of each 4-week course."
3329071|NCT00003816|Experimental|Regimen 5|Patients receive etoposide IV over 26 hours beginning on day -5, cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1.
3328852|NCT00006125|Experimental|Doxorubicin + topotecan|"Patients receive doxorubicin IV over 5-10 minutes on day 1 and topotecan IV over 30 minutes on days 3-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression.~Patients are followed every 6 months for 2 years and annually for the next 3 years."
3328853|NCT00006124|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib twice daily.
3328854|NCT00006124|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo twice daily.
3328855|NCT00006110|Experimental|Neo-adjuvant Herceptin with or without radiation|Chemotherapy followed by Taxol plus Herceptin followed by surgery followed by radiation (or no radiation) followed by additional Herceptin
3328856|NCT00006110|Experimental|Non-Herceptin with or without radiation|Chemotherapy followed by Taxol followed by surgery followed by radiation (or no radiation)
3328857|NCT00006107|Experimental|Taxotere|"Taxotere: (1 hour infusion once a week for four weeks)~Radiation Therapy (5 days/week for 6-7 weeks)~Surgery (if required) 14 -12 weeks after radiotherapy~Follow-up"
3328858|NCT00006105|Experimental|Administration of Cisplatin, Gemcitabine, and Amifostine|Subjects receive the study drug combination in 29-day cycles. Gemcitabine (1000 mg/m2) is given by IV infusion on Days 1, 8, and 15 of each cycle. Cisplatin (70 mg/m2) is given by IV infusion on Day 1 of each cycle. Immediately prior to each cisplatin infusion amifostine (910 mg/m2) will be given by IV infusion.
3328859|NCT00006102|Experimental|Arm I|"Patients with solid tumors are stratified according to tumor histology (neuroblastoma vs Ewing's sarcoma [closed to accrual as of 5/19/03]/peripheral primative neuroectodermal tumor [PNET] vs osteosarcoma [closed to accrual as of 5/19/03] vs rhabdomyosarcoma vs non-Hodgkin's lymphoma vs other solid tumors). Patients with CNS tumors are stratified according to tumor histology (medulloblastoma/PNET vs ependymoma vs brainstem glioma vs other CNS tumors).~Patients receive rebeccamycin analogue IV over 1 hour on day 1. Treatment continues every 21 days for a total of 16 courses in the absence of disease progression or unacceptable toxicity."
3328860|NCT00006101|Experimental|eflornithine|500mg/d for 12 months
3328861|NCT00006101|Placebo Comparator|Placebo|placebo for 12 months
3328862|NCT00006094|Experimental|Treatment (oxaliplatin, fluorouracil, EBRT)|Patients receive oxaliplatin IV over 1 hour on day 1, fluorouracil IV continuously on days 1-7, and radiotherapy on days 1-5. Treatment repeats weekly for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
3328863|NCT00006092|Experimental|Arsenic Trioxide Treatment|Patients receive arsenic trioxide IV over 2-3 hours daily for 28 days. Patients who respond may receive a second course of therapy beginning 28 days from the last dose of the first course.
3328864|NCT00006089|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3328865|NCT00006029|Active Comparator|vinorelbine + gemcitabine + doxorubicin - higher doses|"Patients who have not undergone prior transplantation receive vinorelbine, gemcitabine, and doxorubicin HCl liposome.~Patients are followed every 6 months for 2 years and then annually for 6 years."
3328866|NCT00006029|Experimental|vinorelbine + gemcitabine + doxorubicin - lower doses|"Patients who have undergone prior transplantation receive lower doses of vinorelbine, gemcitabine, and doxorubicin HCl liposome.~Patients are followed every 6 months for 2 years and then annually for 6 years."
3328867|NCT00006024|Experimental|Pre and Post radiation Chemotherapy|
3328868|NCT00006017|Active Comparator|Rebeccamycin 1 day|Patients receive rebeccamycin analogue IV over 1 hour on day 1.
3328869|NCT00006017|Active Comparator|Rebeccamycin 5 day|Patients receive rebeccamycin analogue IV over 1 hour on days 1-5.
3328870|NCT00006016|Experimental|Treatment (thalidomide, chemoembolization)|Patients receive oral thalidomide daily beginning 4 weeks before the first planned chemoembolization procedure. Thalidomide administration is stopped 24 hours before each chemoembolization procedure, and then restarted at 24 hours after completion of each procedure OR when blood counts and levels of bilirubin and transaminases recover, whichever occurs later. Thalidomide treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo placement of a visceral arterial catheter. Patients receive doxorubicin as a chemoemulsion via the arterial catheter into 1 hepatic lobe only under angiographic guidance. Immediately after delivery of the chemoemulsion, patients undergo particulate embolization. The opposite lobe, if involved, is treated within 3-5 weeks of treatment of the initial lobe. Patients are reevaluated for repeat chemoembolization within 8-12 weeks of the last chemoembolization.
3328871|NCT00006015|Experimental|Combination Chemotx|Combination chemotherapy for metastatic colorectal cancer in patients who have disease progression after 5-FU and/or irinotecan-containing therapy
3328872|NCT00006011|Experimental|Arm I (doxorubicin, cisplatin, filgrastim, pegfilgrastim)|Patients receive doxorubicin IV over 30 minutes immediately followed by cisplatin IV over 1 hour on day 1. Patients also receive filgrastim (G-CSF) SC or pegfilgrastim on days 2-11.
3328873|NCT00006011|Experimental|Arm II (doxorubicin, cisplatin, paclitaxel, filgrastim)|Patients receive doxorubicin and cisplatin as in arm I, paclitaxel IV over 3 hours on day 2, and G-CSF SC or pegfilgrastim on days 3-12. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
3328874|NCT00006010|Experimental|docetaxel + gemcitabine|"Patients receive docetaxel IV over 15-60 minutes and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks. Patients achieving complete response after 2 courses of therapy receive 2 additional courses of therapy. Patients with stable disease or partial response continue therapy until disease progression.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
3328875|NCT00006007|Experimental|gemcitabine + pemetrexed|"Patients receive gemcitabine IV over 30 minutes on days 1 and 8. pemetrexed disodium IV is administered over 10 minutes 90 minutes following gemcitabine on day 8. Treatment continues every 21 days for a minimum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients achieving a complete response receive 2 additional courses.~Patients are followed every 3 months for 5 years."
3328876|NCT00006006|Experimental|Arm I|Patients receive oral thalidomide once daily. Patients on a stable dose of thalidomide for at least 4 weeks with evidence of progressive disease receive interferon alfa subcutaneously twice daily. Treatment continues in the absence of disease progression after initiation of interferon alfa therapy or unacceptable toxicity.
3329261|NCT00002706|Active Comparator|Arm II|Patients undergo total abdominal hysterectomy and BSO via conventional laparotomy.
3328877|NCT00006003|Experimental|Treatment (semaxanib)|Patients receive SU5416 IV over 60 minutes twice weekly for 4 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
3328878|NCT00005984|Experimental|Patients with CML|Patients treated for chronic accelerated phase and/or chronic myelogenous leukemia (CML)
3328879|NCT00005983|Active Comparator|surgery|surgery followed by observation
3328880|NCT00005983|Experimental|surgery followed by RT|Surgery followed by radiation therapy
3328881|NCT00005982|Experimental|Treatment (nelarabine)|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment continues every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3328882|NCT00005976|Experimental|Arm I|"Patients receive carboplatin IV over 30 minutes and pyrazoloacridine IV over 3 hours on day 1. Treatment continues every 28 days in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of carboplatin and pyrazoloacridine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
3328883|NCT00005976|Experimental|Arm II|Patients receive the same treatment as given in study 1. Dose escalation is performed as in study 1 to determine the MTD in patients not receiving concurrent anticonvulsants.
3328884|NCT00005976|Experimental|Arm III|Patients receive the same treatment as given in studies 1 and 2 without dose escalation.
3328885|NCT00005973|Experimental|Treatment|Patients receive BMS-214662 IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
3328886|NCT00005970|Experimental|Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor)|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 20-30 minutes on day 1. Treatment repeats every 3 weeks for 4 courses. Patients then receive paclitaxel IV over 1 hour beginning on day 1 of week 13 and continuing weekly for 12 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
3328887|NCT00005970|Experimental|Arm II (AC, paclitaxel, trastuzumab, tamoxifen)|Patients receive doxorubicin hydrochloride, cyclophosphamide, and paclitaxel as in arm I. Patients then receive trastuzumab (Herceptin®) IV over 30-90 minutes beginning on day 1 of week 25 and continuing weekly for 52 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
3328888|NCT00005970|Experimental|Arm III (AC, paclitaxel, trastuzumab, tamoxifen)|"Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I. Patients then receive paclitaxel IV over 1 hour and trastuzumab IV over 30-90 minutes beginning on day 1 of week 13 and continuing weekly for 12 courses. Patients then receive trastuzumab IV over 30 minutes beginning on day 1 of week 25 and continuing weekly for 40 courses in the absence of disease progression or unacceptable toxicity.~Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy."
3328889|NCT00005967|Experimental|Arm I|Patients receive oral tipifarnib twice daily for 21 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 1 course of therapy, patients may receive subsequent therapy at the maximum tolerated dose at the investigator's discretion.
3328890|NCT00005961|Experimental|Arm I|Patients receive O6-benzylguanine IV over 1 hour, followed 1 hour later by carmustine IV over 1 hour on day 1. Treatment continues every 6 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
3328891|NCT00005957|Active Comparator|Standard Breast Irradiation|
3328892|NCT00005957|Experimental|Breast Radiation plus regional radiation|regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)
3328893|NCT00005949|Experimental|Treatment (gp100:209-217, aldesleukin )|Patients receive gp100:209-217(210M) emulsified in Montanide ISA-51 SC on day 1 and interleukin-2 SC on days 1-5 and 8-13. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Patients with a CR receive 3 additional courses after achieving CR.
3328894|NCT00005945|Experimental|Induction Not Randomized|Standard Induction (28 Days). M3 Marrow at Day 28 and Off Protocol Therapy.
3328895|NCT00005945|Experimental|Induction and Oral MTX, Double Delayed Intensification CNS|Patients with CNS disease at diagnosis, without other unfavorable characteristics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Cranial radiation therapy during the Consolidation phase.
3328896|NCT00005945|Experimental|Induction and Augmented regimen (IV MTX, Double DI)|Patients with unfavorable characteristics. Standard Induction (14 Days), Augmented Induction (Days 14-35), Consolidation (9 weeks), Interim Maintenance I (56 Days), Delayed Intensification I (2 months), Interim Maintenance II (2 months), Delayed Intensification II (2 months), then Maintenance (84 day courses).
3329001|NCT00004196|Experimental|Arm AII|Patients with metastasis in a single sentinel node with no evidence of extracapsular extension and no metastatic disease in nonsentinel nodes are randomized to 1 of 2 treatment arms. Observational arm: Patients with metastases in more than one sentinel node with evidence of extracapsular extension or metastasis in any nonsentinel node receive adjuvant high-dose interferon alfa-2b as in arm AI.
3328897|NCT00005945|Experimental|Induction and Oral MTX, Single Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months) then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
3328898|NCT00005945|Experimental|Induction and Oral MTX, Double Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
3328899|NCT00005945|Experimental|Induction and IV MTX, Single Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months) then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
3328900|NCT00005945|Experimental|Induction and IV MTX, Double Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in event free remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
3328901|NCT00005879|Placebo Comparator|Placebo|Placebo
3328902|NCT00005879|Experimental|Arzoxifene|LY353381, 20 mg daily
3328903|NCT00005858|Experimental|Arm I|"Patients receive LMB-9 immunotoxin IV continuously for 10 days. Treatment continues every 30 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of LMB-9 immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3328904|NCT00005856|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression.
3328905|NCT00005851|Experimental|Treatment (nonmyeloablative donor PBSC transplantation)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.~IMMUNOSUPRESSION: Patients receive cyclosporine PO BID or IV QD or BID on days -3 to 35 with taper to day 56, and mycophenolate mofetil PO or IV over 2 hours TID on days 0-40.~DLI: Patients with stable mixed chimerism on day 56 with no evidence of GVHD may receive escalating doses of non-mobilized DLI over 30 minutes. Patients may receive up to 4 DLIs at escalating doses if there is disease progression with no evidence of GVHD."
3328906|NCT00005850|Experimental|gemcitabine + cisplatin + fluoxetine|Patients receive gemcitabine and cisplatin. Treatment repeats every 21 days for a total of six cycles. Patients receive fluoxetine for 7 weeks. Further use of fluoxetine is at the discretion of the patient and physician.
3328907|NCT00005840|Experimental|Treatment (paclitaxel, cisplatin, abdominal radiotherapy)|"Patients receive paclitaxel IV over 1 hour and cisplatin IV on days 1, 8, 15, 22, 29, and 36. Patients also undergo whole abdominal radiotherapy for 5 consecutive days weekly for 6 weeks.~Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose level."
3328908|NCT00005838|Experimental|Arm I (shark cartilage extract AE-941)|"Patients receive oral AE-941 (Neovastat) twice daily beginning on day 1 or within 10 days of initiation of chemotherapy.~All patients receive induction chemotherapy with 1 of the following platinum-based regimens: cisplatin IV on days 1, 22, 50, and 71 and vinorelbine IV on days 1, 8, 22, 29, 50, 57, 71, and 78 carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on days 1, 22, 50, 57, 64, 71, 78, and 85.~All patients receive radiotherapy beginning on day 50 for 6 weeks. Treatment in both arms continues in the absence of unacceptable toxicity."
3328909|NCT00005838|Placebo Comparator|Arm II (placebo)|"Patients receive oral placebo twice daily beginning on day 1 or within 10 days of initiation of chemotherapy.~All patients receive induction chemotherapy with 1 of the following platinum-based regimens: cisplatin IV on days 1, 22, 50, and 71 and vinorelbine IV on days 1, 8, 22, 29, 50, 57, 71, and 78 carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on days 1, 22, 50, 57, 64, 71, 78, and 85.~All patients receive radiotherapy beginning on day 50 for 6 weeks. Treatment in both arms continues in the absence of unacceptable toxicity."
3328910|NCT00005831|Experimental|Treatment (trastuzumab, combination chemotherapy)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15; paclitaxel IV over 3 hours and carboplatin IV over 15 minutes on day 1; and gemcitabine IV over 30 minutes on days 1 and 8. Courses repeat every 3 weeks. Patients achieving a complete response (CR) receive 3 courses past CR. Patients achieving a partial response or stable disease continue on therapy until CR or disease progression or unacceptable toxicity.
3328911|NCT00005830|Experimental|Treatment (doxorubicin, cisplatin, radiation therapy)|Patients receive doxorubicin IV and cisplatin IV on day 1. Treatment repeats every 3 weeks for 3 courses. Patients then undergo whole abdominal radiotherapy 5 days a week for 4-6 weeks.
3328912|NCT00005817|Experimental|Arm I (becatecarin)|Patients receive rebeccamycin analogue IV over 60 minutes on day 1.
3328913|NCT00005817|Experimental|Arm II (becatecarin)|Patients receive rebeccamycin analogue IV over 60 minutes on days 1-5.
3328914|NCT00005812|Experimental|Temozolomide|"Oral temozolomide 75 mg/m2/day for 6 weeks, followed by 4 week break. Cycles will continue until:~disease progression~intolerable toxicity~complete response - 2 full additional cycles~if response is complete except for residual radiographic abnormalities that persist unchanged for 2 full cycles: continue for 4 cycles past best response."
3329072|NCT00003816|Experimental|Regimen 6|Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24 hours on days -7 to -4.
3329855|NCT00034814|Experimental|6|Non-enzyme-inducing TLP 35mg TID
3328915|NCT00005811|Experimental|Treatment (topotecan hydrochloride)|"INDUCTION: Patients receive topotecan hydrochloride IT over 5 minutes twice weekly for 6 weeks.~CONSOLIDATION: Beginning 1 week after completion of induction, patients receive topotecan hydrochloride IT over 5 minutes weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning 2 weeks after completion of consolidation, patients receive topotecan hydrochloride IT over 5 minutes twice monthly for 4 months and then monthly through year 1."
3328916|NCT00005808|Experimental|Part 1 (lutetium texaphyrin, LEEP)|Patients receive lutetium texaphyrin IV over 5-20 minutes. Patients undergo in vivo tissue assessment by spectrometer at 0, 1, 3, 5, 12, and 24 hours and loop electrical excision procedure (LEEP) at 24 hours after lutetium texaphyrin infusion.
3328917|NCT00005808|Experimental|Part 2 (lutetium texaphyrin, laser therapy, LEEP)|Patients receive lutetium texaphyrin IV over 5-20 minutes. A laser delivers 730 nm of light to the cervix for 4, 8, or 16 minutes. Patients undergo LEEP at 4, 8, or 12 hours after exposure of the cervix to the light source.
3328918|NCT00005803|Experimental|Treatment (tandem transplantation)|See Detailed Description
3328919|NCT00005797|Other|BuCy2|Busulfan & Cyclophosphamide
3328920|NCT00005797|Other|VP16/TBI|Fractionated Total Body Irradiation + VP-16
3328921|NCT00005786|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1-4 hours on days 1-5. Treatment repeats every 21 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with responding or stable disease may receive 6 additional courses.
3328922|NCT00005622|Other|Cy/TBI|cyclophosphamide and total body irradiation (TBI)
3328923|NCT00005617|Experimental|Group A|No. DC: 10^5 Route of Immunization: ID
3328924|NCT00005617|Experimental|Group B|No. DC: 10^5 Route of Immunization: IV
3328925|NCT00005617|Experimental|Group C|No. DC: 10^6 Route of Immunization: ID
3328926|NCT00005617|Experimental|Group D|No. DC: 10^6 Route of Immunization: IV
3328927|NCT00005617|Experimental|Group E|No. DC: 10^7 Route of Immunization: ID
3328928|NCT00005617|Experimental|Group F|No. DC: 10^7 Route of Immunization: IV
3328929|NCT00005605||Tamoxifen group|
3328930|NCT00005605||Chemotherapy group|
3328931|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 20 Days|
3328932|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 25 Days|
3328933|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 30 Days|
3328934|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 33 Days|
3328935|NCT00005601|Experimental|rituximab+dexamethasone+cisplatin+cytarabine+sargramostim|"Patients receive rituximab IV on days 1, 8, 15, and 22 for the first course only. Patients receive dexamethasone orally or IV on days 1-4, cisplatin IV continuously for 24 hours on day 1, cytarabine IV over 3 hours every 12 hours for 2 doses on day 2, and sargramostim (GM-CSF) subcutaneously on days 3-12 or until blood counts recover. Chemotherapy repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
3328936|NCT00005597|Experimental|Temozolomide|200 mg/m^2/day, PO, on Days 1-5 of each 28 day cycle.
3328937|NCT00005596|Experimental|Arm I|Patients receive IT methotrexate on day 1 followed by methotrexate IV over 20 minutes followed by methotrexate continuously over 23.6 hrs on wks 7, 10, 13, 16,19, and 22. At 42 hrs after the beginning of the methotrexate infusion, patients receive oral leucovorin calcium every 6 hrs for a total of 3 doses. Patients also receive oral mercaptopurine daily beginning on wk 5 and continuing until the completion of consolidation therapy; oral dexamethasone twice daily on days 1-7 of wks 8 and 17; and vincristine sulfate IV on day 1 of wks 8, 9, 17, and 18.
3328938|NCT00005596|Experimental|Arm II|Patients receive methotrexate IV over 4 hours on weeks 7, 10, 13, 16, 19, and 22. At 42 hours after the beginning of the methotrexate infusion, patients receive oral leucovorin calcium as in arm I. Patients also receive mercaptopurine, dexamethasone, vincristine sulfate, and IT methotrexate as in arm I.
3328939|NCT00005596|Experimental|Arm III|Patients receive methotrexate IV as in arm I on weeks 7, 10, 13, 24, 27, and 30; leucovorin calcium as in arm I; pegaspargase IM on day 2, 3, OR 4 of wk 16; oral mercaptopurine daily on wks 5-13, and from wk 24 until the completion of consolidation therapy. Patients also receive IT methotrexate as in arm I on wks 7, 10, 13, 16, 20, 21, and 30; oral dexamethasone 2x daily on weeks 8, 16-18, and 28 for a total of 35 days; vincristine sulfate IV on day 1 of wks 8, 9, 16, 17, 18, 28, and 29; daunorubicin hydrochloride IV on day 1 of wks 16-18; cyclophosphamide IV over 30 minutes on day 1 of week 20; cytarabine IV or subcutaneously daily on days 2-5 of wks 20 and 21; and oral thioguanine daily on wks 20-21.
3328940|NCT00005596|Experimental|Arm IV|Patients receive methotrexate IV as in arm II on weeks 7, 10, 13, 24, 27, and 30; leucovorin calcium as in arm I; and pegaspargase, mercaptopurine, IT methotrexate, dexamethasone, vincristine sulfate, daunorubicin hydrochloride, cyclophosphamide, cytarabine, and thioguanine as in arm III.
3328941|NCT00005585|Experimental|Arm I: (combination chemotherapy)|CONSOLIDATION: Pts receive Methotrexate(MTX) IV over 24 hrs on day 1 and oral leucovorin calcium (CF) every 6 hrs for 3 doses at 42 hours after initiation of MTX infusion during weeks 7, 10, 13, 16, and 19. Pts also receive MTX IT on wks 7, 10, 13, 16, 19, and 22; oral mercaptopurine(6-MP) daily wks 5-24; oral dexamethasone (DM) 2x on days 1-7 of wks 8 and 17; and vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 17, and 18. CONTINUATION: Pts receive oral 6-MP daily on wks 25-130; oral DM twice a day on days 1-7 and vincristine sulfate (VCR) IV on days 1 and 8 during wks 25, 41, 57, 73, 89, and 105; oral MTX on wks 25-130 (except during wks of IT MTX); and MTX IT on wks 25, 37, 49, 61, 73, 85, 97, and 109.
3328942|NCT00005585|Experimental|Arm II (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) IV over 4 hrs on day 1 and oral leucovorin calcium (CF) during wks 7, 10, 13, 16, and 19. Pts also receive MTX IT on wks 7, 10, 13, 16, 19, and 22; oral mercaptopurine (6-MP) daily on wks 5-24; oral dexamethasone (DM) 2x on days 1-7 of wks 8 and 17; and vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 17, and 18. CONTINUATION: Pts receive oral 6-MP daily on wks 25-130; oral DM 2x on days 1-7 and vincristine sulfate (VCR) IV on days 1 and 8 during wks 25, 41, 57, 73, 89, and 105; oral MTX weekly on wks 25-130 (except during wks of IT MTX); and MTX IT on wks 25, 37, 49, 61, 73, 85, 97, and 109.
3329073|NCT00003816|Experimental|Regimen 7|Patients receive fludarabine IV over 30 minutes on days -5 to -1 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -2.
3329856|NCT00034554|Experimental|1|0.1mg
3328943|NCT00005585|Experimental|Arm III (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) IV and leucovorin calcium (CF) as in arm I on wks 7, 10, 13, 24, 27, and 30. Pts also receive oral mercaptopurine (6-MP) daily on wks 5-13 and then on wk 24 and continuing until the end of consolidation; MTX IT on wks 7, 10, 13, 16, 20, 21, and 30; oral dexamethasone (DM) twice daily on days 1-7 of wks 8, 16-18, and 28; vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 16-18, 28, and 29; pegaspargase intramuscularly on wk 16; daunorubicin hydrochloride IV on day 1 of wks 16-18; cyclophosphamide IV on day 1 of wk 20; cytarabine IV or subcutaneously on days 2-5 of wks 20 and 21; and oral thioguanine daily on days 1-14 of wks 20 and 21. CONTINUATION: Pts receive oral 6-MP daily on wks 33-130; oral dexamethasone (DM) twice a day on days 1-7 and VCR IV on days 1 and 8 during wks 41, 57, 73, 89, and 105; oral MTX weekly on wks 33-130 (except during wks of IT MTX); and MTX IT on wks 37, 49, 61, 73, 85, 97, and 109.
3328944|NCT00005585|Experimental|.Arm IV (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) and leucovorin calcium (CF) on wks 7, 10, 13, 24, 27, and 30. Pts receive mercaptopurine(6-MP) daily weeks 5-13 then beginning wk 24 and continuing until end of consolidation; MTX on wks 7, 10, 13, 16, 20, 21, and 30; dexamethasone (DM) 2x daily on days 1-7 of wks 8, 16-18, and 28; vincristine sulfate (VCR) day 1 of wks 8, 9, 16-18, 28, and 29; pegaspargase on wk 16; daunorubicin hydrochloride on day 1 of wks 16-18; cyclophosphamide on day 1 of wk 20; cytarabine on days 2-5 of wks 20 and 21; thioguanine daily on days 1-14 of wks 20 and 21. CONTINUATION: Pts receive mercaptopurine(6-MP) daily on weeks 33-130; oral dexamethasone (DM) twice a day on days 1-7 and VCR IV on days 1 and 8 during weeks 41, 57, 73, 89, and 105; oral MTX weekly on weeks 33-130 (except during weeks of IV MTX); and IV MTX on weeks 37, 49, 61, 73, 85, 97, and 109.
3328945|NCT00005095||High Risk for Ovarian Cancer|Women who are at increased risk of ovarian cancer based on family or personal medical history who are participating in the Northwestern Ovarian Cancer Early Detection and Prevention Program clinic.
3328946|NCT00005087|Experimental|Radiation (BID) and chemotherapy|Radiation (BID), cisplatin and paclitaxel given on days 1-5 (Monday-Friday) in weeks 1, 3, 5 and 7. G-CSF given on days 6-13.
3328947|NCT00005067|Experimental|Treatment (motexafin lutetium, PDT)|Patients receive lutetium texaphyrin IV over 10-15 minutes 3-24 hours before photodynamic therapy (PDT). Optical fibers attached to a laser are inserted through a catheter into the prostate. The laser delivers 730 nm light to the prostate until the specified fluence is delivered. Patients undergo biopsy of the prostate and bladder before and after PDT. Cohorts of 3-6 patients receive escalating doses of lutetium texaphyrin and light fluence until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
3328948|NCT00005060|Active Comparator|Taxotere-Cisplatin-5FU preoperatively|TCF preoperatively
3328949|NCT00005060|Active Comparator|Immediate surgery followed by TCF|Surgery followed by Taxotere-Cisplatin-5FU
3328950|NCT00005047|Experimental|Arm I: M-VAC x 3|Patients with altered (+) p53, reconsented to randomization, randomized to three cycles of MVAC
3328951|NCT00005047|No Intervention|Arm II: Observation|Patients with altered (+) p53, reconsented to randomization, randomized to observation
3328952|NCT00005047|No Intervention|Arm III: Observation|Patients with unaltered (-) p53
3328953|NCT00005047|No Intervention|Arm IV: Observation|Patients with altered (+) p53, patients did not consent to randomization
3328954|NCT00005044|Experimental|TAS x 8 weeks|Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).
3328955|NCT00005044|Experimental|TAS x 28 weeks|TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).
3328956|NCT00005039|Experimental|Arm I|Patients receive recombinant fowlpox-PSA vaccine IM at the MTD from the safety cohort every 4 weeks for 3 courses. Patients then receive recombinant vaccinia-PSA vaccine intradermally every 4 weeks for 2 courses.
3328957|NCT00005039|Experimental|Arm II|Patients receive the same vaccines as in arm I but in reverse order.
3328958|NCT00005036|Experimental|Arm I (irinotecan)|Patients receive irinotecan IV over 90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
3328959|NCT00005036|Experimental|Arm II (oxalipatin, fluorouracil, leucovorin calcium)|Patients receive oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on days 1 and 2, and fluorouracil IV bolus followed by IV infusion over 22 hours on days 1 and 2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
3328960|NCT00004935|Active Comparator|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
3328961|NCT00004935|Active Comparator|Herceptin™+Chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
3328962|NCT00004932|Experimental|260 mg/m2 imatinib mesylate (ST571)|
3328963|NCT00004932|Experimental|340 mg/m2 imatinib mesylate (ST571)|
3328964|NCT00004932|Experimental|440 mg/m2 imatinib mesylate (ST571)|
3328965|NCT00004932|Experimental|570 mg/m2 imatinib mesylate (ST571)|
3328966|NCT00004918|Experimental|Arm I (dose level 1 PR1 leukemia peptide vaccine)|Patients receive dose level 1 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
3328967|NCT00004918|Experimental|Arm II (dose level 2 PR1 leukemia peptide vaccine)|Patients receive dose level 2 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
3328968|NCT00004918|Experimental|Arm III (dose level 3 PR1 leukemia peptide vaccine)|Patients receive dose level 3 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
3328969|NCT00004891|Experimental|primary resectable rectal cancer|
3328970|NCT00004888|Experimental|Arm I (combination chemotherapy)|"Patients receive doxorubicin hydrochloride liposome IV over 30 minutes followed by docetaxel IV over 1 hour. Treatment is repeated every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.~Patients may receive maintenance therapy of docetaxel IV over 1 hour either weekly or every 3 weeks. Maintenance continues in the absence of disease progression or unacceptable toxicity."
3328971|NCT00004888|Experimental|Arm II (combination chemotherapy, trastuzumab)|"Patients receive trastuzumab IV over 90 minutes on day 1, with subsequent doses over 30 minutes. Patients receive doxorubicin HCl liposome IV over 30 minutes followed by docetaxel IV over 1 hour on day 2 of course 1, followed by subsequent doses on day 1 of each course. Antibody therapy continues weekly and chemotherapy every 3 weeks for 8 courses.~Patients may receive maintenance therapy of trastuzumab IV over 30 minutes weekly followed by docetaxel IV over 1 hour weekly or every 3 weeks. Maintenance continues in the absence of disease progression or unacceptable toxicity."
3328972|NCT00004867|Experimental|FDG-PET scan +/- neoadjuvant chemotherapy + surgery|"Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later by positron emission tomography (PET) imaging. Confirmatory studies, such as biopsy or other imaging studies, are then conducted to confirm the FDG PET imaging results. Patients with no metastases identified by FDG PET imaging may undergo esophagectomy with or without neoadjuvant chemoradiotherapy within 1 month of evaluation.~Patients are followed within 6 months after surgery."
3328973|NCT00004859|Active Comparator|Arm A (Paclitaxel + Carboplatin + RT)|"Induction chemotherapy dosing: Paclitaxel, 225 mg/m² (3 hour infusion) Day 1. Carboplatin, area under the plasma drug concentration versus time curve (AUC) =6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1~Concurrent chemotherapy / radiotherapy dosing: Paclitaxel, 45 mg/m2, administered weekly during radiotherapy over one hour. Carboplatin, AUC=2, 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy~Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV"
3328974|NCT00004859|Experimental|Arm B (Paclitaxel + Carboplatin + RT+ Thalidomide)|"paclitaxel, carboplatin, and radiotherapy are same as those in Arm A.~thalidomide: Induction chemotherapy dosing, oral daily, starting Day 1 for 24 months or until disease progression. Concurrent chemotherapy / radiotherapy dosing, oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg."
3328975|NCT00004262|Experimental|Treatment (motexafin gadolinium, radiotherapy, radiosurgery)|Within 5 weeks following surgery, patients receive daily external beam radiotherapy five days a week for 5 weeks. Within 2 weeks following completion of radiotherapy, patients receive gadolinium texaphyrin IV over 2 hours followed 3 hours later by stereotactic radiosurgery. Patients undergoing surgical debulking of tumor prior to external beam radiotherapy receive gadolinium texaphyrin IV over 2 hours, 3 hours prior to surgery in addition to the dose prior to stereotactic radiosurgery.
3328976|NCT00004259|Experimental|Radiation therapy + temozolomide (TMZ)|Radiation therapy (RT) for 6 weeks concurrent with and followed by TMZ 200mg/m2 for twelve 28-day cycles
3328977|NCT00004259|Active Comparator|RT + BCNU/CCNU|Radiation therapy for 6 weeks concurrent with and followed by BCNU 80mg/m2 or CCNU 130 mg/m2 for six 8-week cycles
3328978|NCT00004259|Experimental|Pilot Arm #1: RT+TMZ+BCNU|Radiation therapy for 6 weeks concurrent with and followed by BCNU 200mg/m2 and TMZ 150mg/m2 six 6-week cycles
3328979|NCT00004259|Experimental|Pilot Arm #2: RT+TMZ+BCNU|Radiation therapy for 6 weeks concurrent with and followed by BCNU 150mg/m2 and TMZ 150mg/m2 six 8-week cycles
3328980|NCT00004244|Experimental|Arm I|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive interleukin-12 SC twice a week for 2 weeks, followed by treatment with interleukin-12 in combination with interferon alfa as described above."
3328981|NCT00004244|Experimental|Arm II|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive interferon alfa SC three times a week for 2 weeks, followed by treatment with interleukin-12 in combination with interferon alfa as described above."
3328982|NCT00004244|Experimental|Arm III|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive treatment with interleukin-12 in combination with interferon alfa at the MTD as described above."
3328983|NCT00004241|Experimental|Schedule B (tanespimycin)|Patients receive 17-AAG IV over 1-2 hours twice weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3328984|NCT00004241|Experimental|Schedule C (tanespimycin)|Patients receive 17-AAG IV over 1-2 hours twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3328985|NCT00004228|Experimental|A0 (localized disease Stg I/II) Modified CCG BFM|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Doxorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Methotrexate, Intrathecal Methotrexate)
3329002|NCT00004196|Experimental|Arm BI|Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo observation. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
3329074|NCT00003816|Experimental|Regimen 8|Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3 to -1.
3329857|NCT00034554|Experimental|2|0.5mg
3328986|NCT00004228|Experimental|A1 (Disseminated, No CNS - CCG mod BFM w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, prednisone, Methotrexate, Intrathecal Methotrexate)
3328987|NCT00004228|Experimental|A2 (Disseminated, No CNS - CCG mod BFM w/ intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
3328988|NCT00004228|Experimental|B2 (CNS+) NHL/BFM-95 w/intens delayed radiation therapy|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
3328989|NCT00004228|Experimental|B1 (Disseminated CNS- <Amend 7B) NHL/BFM-95 w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
3328990|NCT00004228|Experimental|B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
3328991|NCT00004228|Experimental|B1 (Disseminated CNS-) NHL/BFM-95 w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
3328992|NCT00004227|Placebo Comparator|Arm I|"Patients undergo radiotherapy beginning on day 1. Patients are assigned to 1 of 3 radiotherapy groups:~Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks.~Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks.~Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks."
3328993|NCT00004227|Active Comparator|Arm II|"Patients receive a test dose of cetuximab IV over 10 minutes on day 1. Patients who do not experience grade 4 anaphylactic reaction receive a loading dose of cetuximab IV over 2 hours beginning 30 minutes after completion of test dose. Patients receive maintenance cetuximab IV over 1 hour on day 8. Maintenance cetuximab repeats every week for 7 courses. Beginning on day 8, patients undergo radiotherapy as in arm I concurrently with maintenance cetuximab. There must be an hour interval between the completion of cetuximab infusion and the start of any radiotherapy.~Radiotherapy groups remain the same as in Arm I:~Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks.~Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks.~Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks."
3328994|NCT00004208|Active Comparator|Arm A: ATG + CSA|"Treatment consists of 15 mg/kg ATG (Mérieux; horse antithymocyte globulin; i.e. 1.5 vial/10 kg of body weight/day) given over 8-12 hours for 5 consecutive days.~Cyclosporine A (CSA) will be administered orally in a dose of 2.5 mg/kg bid starting day 1 and continued through day 180."
3328995|NCT00004208|Other|Arm B: Supportive care|Patients randomized to this arm will be treated as outpatients.
3328996|NCT00004205|Experimental|Tamoxifen|Tamoxifen for 5 years after randomization.
3328997|NCT00004205|Experimental|Letrozole|Letrozole for 5 years after randomization.
3328998|NCT00004205|Experimental|Tamoxifen, then letrozole|Tamoxifen for 2 years after randomization, then letrozole for the next 3 years.
3328999|NCT00004205|Experimental|Letrozole, then tamoxifen|Letrozole for 2 years after randomization, then tamoxifen for the next 3 years.
3329000|NCT00004196|Experimental|AI|Patients with metastasis in a single sentinel node with no evidence of extracapsular extension and no metastatic disease in nonsentinel nodes are randomized to 1 of 2 treatment arms. Patients receive adjuvant high-dose interferon alfa-2b IV 5 days a week for 4 weeks, then subcutaneously 3 times a week for 48 weeks
3329858|NCT00034554|Experimental|3|2.0mg
3329859|NCT00034554|Experimental|4|4.0mg
3329003|NCT00004196|Experimental|Arm B II|Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo lymph node dissection. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
3329004|NCT00004196|Experimental|Arm BIII|"Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo lymph node dissection followed by adjuvant high-dose interferon alfa-2b IV 5 days a week for 4 weeks.~Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter."
3329005|NCT00004189|Experimental|Arm I|See detailed description.
3329006|NCT00004188|Experimental|Arm I (unpurged PBSC collection)|Induction-3 wks (cyclophosphamide day 0&1, doxorubicin hydrochloride & vincristine sulfate day 0-2 & filgrastim(G-CSF) day 3 crs 1,2,4 & 6.) Crs 3 & 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Pts undergo unpurged PBSC collection until the target cell count is reached. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin & etoposide day -7 to -4. purged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
3329007|NCT00004188|Experimental|Arm II (unpurged PBSC collection)|Induction-3 wks (cyclophosphamide day 0&1, doxorubicin hydrochloride & vincristine sulfate day 0-2 & filgrastim(G-CSF) day 3 crs 1,2,4 & 6.) Crs 3 & 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Immunocytology + PBSC undergo purged autologous bone marrow collection or repeat purged or unpurged PBSC collection. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin & etoposide day -7 to -4. Unpurged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
3329008|NCT00004154|Experimental|Fenretinide|Fenretinide (4-HPR) 200 mg orally every day for 12 months taken 25 out of every 28 days.
3329009|NCT00004154|Placebo Comparator|Placebo|Placebo orally every day for 12 months, taken 25 out of every 28 days.
3329010|NCT00004144|Experimental|bryostatin 1 & gemcitabine hydrochloride|
3329011|NCT00004143|Experimental|Campath SCT for hemoglobinopathies|Campath, Chemo and/or TBI Allo SCT
3329012|NCT00004143|Experimental|Campath SCT for Bone Marrow Failure|Campath, Chemo and/or TBI Allo SCT
3329013|NCT00004141|Experimental|Arm A|CDDP (75 mg/m2) and DTIC (660 mg/m2) will be administered sequentially by intravenous infusion in day 1. Subsequently, GM-CSF (450 mg/ m2) will be administered SC days 2-7; IL-2 (11 MU daily) will be given SC days 8-14, and IFN-2b (9 MU) will be given SC days 8, 10, 12, and 14.
3329014|NCT00004138|Experimental|FDG-PET scan + surgery|"Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later by positron emission tomography (PET) imaging. Confirmatory studies, such as biopsy, fine needle aspiration, or other imaging studies are then conducted to confirm the PET findings.~Patients with no mediastinal nodal or distant metastases identified by FDG-PET scan may undergo thoracotomy and pulmonary resection within 1 month of evaluation.~Patients are followed at 5-6 months after surgery."
3329015|NCT00004135|Experimental|Arm A|Fludarabine 30 mg/m2/d x S days IVPB in 100 cc NS over 30 minutes on day -8, -7, -6, -S, and -4. Cyclophosphamide 2 gm/m2/d x 2 days IVPB in SOO cc DS W over I hour on day -3 and day-2. G-CSF (Neupogen®) administration 480 f!gld subcutaneously starting on day +5 (or first day of neutropenia if earlier)and continued until an ANC of 0.5 x 109/L is maintained for 3 consecutive days.
3329016|NCT00004124|Active Comparator|bicalutamide, goserelin|androgen deprivation
3329017|NCT00004124|Experimental|bicalutamide, goserelin, mitoxantrone, prednisone|androgen deprivation plus mitoxantrone, prednisone
3329018|NCT00004092|Experimental|Arm I (ACT) (closed to accrual as of 4/6/2006)|Patients receive doxorubicin IV over 24 hours on days -9 to -6, cyclophosphamide IV over 2 hours on day -5, and paclitaxel IV over 24 hours on day -2. PBSC are reinfused on days -2 and 0. G-CSF is administered beginning on day 0 and continuing until blood counts recover.
3329019|NCT00004092|Active Comparator|Arm II (STAMP V)|Patients receive cyclophosphamide IV, carboplatin IV, and thiotepa IV over 24 hours on days -7 to -4. PBSC are reinfused and G-CSF is administered as in arm I.
3329020|NCT00004088|Experimental|HD chemo followed by PBPC Rescue|Patients receive high-dose melphalan IV on day -1. PBSCs are reinfused on day 0. G-CSF is administered IV or SC daily beginning on day 1 and continuing until blood counts recover. Between 8 and 14 weeks later, patients receive high-dose busulfan IV every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. PBSCs are reinfused on day 0 and G-CSF is administered IV or SC daily until blood counts recover.
3329021|NCT00004067|Active Comparator|Arm 1: adriamycin + cyclophosphamide then taxol|
3329022|NCT00004067|Experimental|Arm 2: adriamycin + cyclophosphamide then taxol + herceptin|
3329023|NCT00004054|Experimental|Hormones and RT|Androgen suppression (AS) (Luteinizing hormone releasing hormone agonist and bicalutamide [Casodex] or flutamide [Eulexin]) x 8 weeks followed by RT to 70.2 Gy with concurrent AS (LHRH agonist and bicalutamide [Casodex] or flutamide [Eulexin]). AS will continue for a total of 24 months from initiation of all treatment. Oral anti-androgen will be discontinued at the end of radiation therapy (RT).
3329024|NCT00004054|Experimental|Hormones and RT plus Chemotherapy|AS (LHRH agonist and bicalutamide [Casodex] or flutamide [Eulexin]) x 8 weeks followed by RT to 70.2 Gy with concurrent AS (LHRH agonist and bicalutamide [Casodex] or flutamide [Eulexin]) and estramustine phosphate sodium, etoposide, paclitaxel, and warfarin [Coumadin®]. AS will continue for a total of 24 months from initiation all treatment. Oral antiandrogen will be discontinued at the end of RT.
3329025|NCT00004031|Active Comparator|CHOP/CHOP-R x 3|Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Prednisone 100 mg/day PO Days 1-5 Vincristine 1.4 mg/m2 IV Day 1 Rituximab 375 mg/m2 IV Day 1 This regimen is repeated every 21 days for 8 cycles
3329264|NCT00002668|Active Comparator|Observation|Standard pain management interventions usually given by hospital staff
3329026|NCT00004031|Experimental|CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant|Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Prednisone 100 mg/day PO Days 1-5 Vincristine 1.4 mg/m2 IV Day 1 Rituximab 375 mg/m2 IV Day 1 This regimen is repeated every 21 days for 6 cycles followed by autologous stem cell transplant.
3329027|NCT00004011|Experimental|preooperative chemo followed by surgery|carboplatin paclitaxel conventional surgery
3329028|NCT00004011|Active Comparator|Surgery alone|conventional surgery
3329029|NCT00004001|Experimental|Docetaxel and Estramustine|Estramustine, 280 mg, PO, TID, Days 1-5; q 21 days Docetaxel, 60mg/m2, IV, Day 2; q 21 days
3329030|NCT00004001|Active Comparator|Mitoxantrone and Prednisone|Mitoxantrone, 12 mg/m2, IV, Day 1; q 21 days Prednisone, 5 mg, PO, BID, Days 1-21; q 21 days
3329031|NCT00003994|Experimental|Arm I (cisplatin, vincristine sulfate, fluorouracil)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive cisplatin IV over 4 hours on day 1, vincristine sulfate IV on days 3, 10, and 17, and fluorouracil on day 3.
3329032|NCT00003994|Experimental|Arm II (cisplatin, vincristine, fluorouracil, amifostine)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive treatment as in arm I with the addition of amifostine trihydrate IV over 15 minutes prior to cisplatin on day 1.
3329033|NCT00003994|Experimental|Arm III (carboplatin, cisplatin)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive carboplatin IV over 1 hour on day 1 and cisplatin IV over 4 hours on day 15.
3329034|NCT00003994|Experimental|Arm IV (carboplain, cisplatin, amifostine)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive treatment as in arm III with the addition of amifostine trihydrate IV over 15 minutes prior to carboplatin on day 1.
3329035|NCT00003970|Experimental|Treatment (irinotecan hydrochloride)|Patients receive irinotecan IV over 90 minutes once every 3 weeks. Treatment continues for at least 2 courses in the absence of disease progression or unacceptable toxicity.
3329036|NCT00003966|Experimental|Arm A Lower dose|"This is a randomized, multicenter study. All patients initially receive the same dose of defibrotide IV over 2 hours every 6 hours on day 1. On day 2, patients are randomized to 1 of 2 doses of defibrotide.~- Arm I: On days 2-14, patients receive a lower dose of defibrotide IV over 2 hours every 6 hours.~In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity"
3329037|NCT00003966|Experimental|Arm B Higher Dose|"This is a randomized, multicenter study. All patients initially receive the same dose of defibrotide IV over 2 hours every 6 hours on day 1. On day 2, patients are randomized to 1 of 2 doses of defibrotide.~- Arm II: On days 2-14, patients receive a higher dose of defibrotide IV over 2 hours every 6 hours.~In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity"
3329038|NCT00003963|Experimental|Vinorelbine and Rituxan|"Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Rituxan given every 2 weeks. Vinorelbine given weekly x3, with one week off.~Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
3329039|NCT00003958|Experimental|Arm I|Vincristine sulfate IV once a wk on wks 0-12, 15, 18-24, 27, 30-36, and 39. Dactinomycin IV once a wk on wks 0, 3, 6, 9, 12, 21, 24, 27, 30, 33, 36, and 39. Cyclophosphamide IV once a wk on wks 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, and 39. After 12 weeks of chemotherapy, depending on tumor shrinkage, pts may undergo surgery. After recovery from therapeutic conventional surgery, patients receive radiation therapy once a day, 5 days a wk, during wks 12-18. For pt receiving radiotherapy during wks 0-6, dactinomycin is omitted during wks 3 and 6 and during wks 15 and 18. For patients receiving radiotherapy during wks 12-18, dactinomycin is omitted during wks 15 and 18. Patients with adequate response at wk 24 continue chemotherapy during wks 24-39. All pts receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously beginning 24 hours after completion of each course of chemotherapy and continuing 1 year, until hematopoietic recovery.
3329040|NCT00003958|Experimental|Arm II|"Patients receive treatment as in arm I, except dactinomycin is replaced with topotecan hydrochloride IV over 15-30 minutes daily for 5 days during weeks 3, 9, 21, 27, 33, and 39.~All patients receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously beginning 24 hours after completion of each course of chemotherapy and continuing 1 year, until hematopoietic recovery."
3329041|NCT00003934|Experimental|Arm I|"Induction: All patients receive oral tretinoin every 12 hours beginning on day 1 until complete response or for a maximum of 90 days. Patients also receive daunorubicin IV on days 3-6 and cytarabine IV continuously on days 3-9.~Consolidation: All patients achieving CR or PR after completion of tretinoin, proceed to consolidation within 2 weeks of achieving CR or PR, but not prior to 30 days from the start of induction. Patients are randomized to 1 of 2 treatment arms.~Patients receive oral tretinoin every 12 hours on days 1-7 and daunorubicin IV on days 1-2 or days 1-3, depending on age. Patients may receive an additional course. Treatment begins no earlier than 2 weeks and no later than 4 weeks after hematopoietic recovery."
3329042|NCT00003934|Experimental|Arm II|"Induction: All patients receive oral tretinoin every 12 hours beginning on day 1 until complete response or for a maximum of 90 days. Patients also receive daunorubicin IV on days 3-6 and cytarabine IV continuously on days 3-9.~Consolidation: All patients achieving CR or PR after completion of tretinoin, proceed to consolidation within 2 weeks of achieving CR or PR, but not prior to 30 days from the start of induction. Patients are randomized to 1 of 2 treatment arms.~Patients receive oral tretinoin as in arm I above. Patients also receive oral mercaptopurine once a day and oral methotrexate once weekly for up to 1 year."
3329043|NCT00003910|Experimental|Methotrexate (Cy if no response to MTX)|MTX given orally at 10 mg/m2 in divided doses once weekly. Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days. Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule.
3329044|NCT00003909|Experimental|Arm I|Approximately 2-5 hours before radiotherapy, patients receive motexafin gadolinium IV over 5 minutes. Patients undergo radiotherapy 5 days a week for 6 weeks.
3329045|NCT00003906|Active Comparator|Group 1|Tamoxifen and placebo
3329046|NCT00003906|Experimental|Group 2|Raloxifene and Placebo
3329070|NCT00003816|Experimental|Regimen 4|Patients receive fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 1 hour on days -3 and -2.
3329262|NCT00002678|Active Comparator|Melphan plus prednisone|melphalan plus prednisone qd x 4 28 day cycles x 12 cycles; No treatment after stable response.
3329047|NCT00003901|Experimental|Surgery|"All patients undergo complete lymph node sampling or dissection. A small portion of rib is removed at this time. Some patients may have primary tumor completely removed.~Lymph nodes and bone marrow from the rib section are examined for occult metastases using immunohistochemical staining methods and standard staining methods.~Patients are followed at 1, 4, 8, and 12 months, every 6 months for 2 years, and then annually for 2 years."
3329048|NCT00003896|Experimental|Paclitaxel/cisplatin/Liposomal Doxorubicin|paclitaxel, cisplatin and liposomal doxorubicin
3329049|NCT00003875|Experimental|Treatment (chemo, stem cell rescue, interleukin therapy)|"PREPARATIVE REGIMEN: Patients receive busulfan IV over 2 hours or PO every 6 hours on days -7 to -4 and etoposide IV on day -3.~STEM CELL INFUSION: Patients undergo autologous or syngeneic PBSC rescue on day 0.~POST-TRANSPLANT ALDESLEUKIN THERAPY: Beginning 30-100 days after transplant, patients receive low-dose aldesleukin SC daily for 12 weeks."
3329050|NCT00003869|Experimental|Arm I (CAI)|Patients receive oral carboxyamidotriazole daily.
3329051|NCT00003869|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo daily
3329052|NCT00003865|Experimental|Toremifene|All enrolled patients
3329053|NCT00003863||Group 1|"Tissue samples are obtained before treatment and at the time of documentation of refractory disease in patients who do not achieve complete remission after induction therapy or at the time of first relapse in patients who achieve a complete remission.~Samples are examined for rearrangements in the MYC, BCL2, BCL6, and IGH genes using fluorescent in situ hybridization. DNA is examined by comparative genomic hybridization, which allows cytogenetic detection of losses and gains of chromosomal regions in tumor cells.~Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment."
3329054|NCT00003861||Ancillary-Correlative (molecular genetic features)|Previously collected blood and tissue samples are analyzed via RT-PCR and flow cytometry.
3329055|NCT00003857|Active Comparator|Observation +/- tamoxifen for 5 years|Observation +/- tamoxifen 20 mg per day for 5 years
3329056|NCT00003857|Experimental|Radiation therapy +/- tamoxifen for 5 years|Radiation therapy to the whole breast +/- tamoxifen 20 mg per day for 5 years
3329057|NCT00003855|Experimental|Surgery + radiotherapy|"Patients undergo axillary lymph node dissection involving removal of at least level I and II nodes, followed by whole-breast radiotherapy (exclusive of a third supraclavicular field) 5 days a week for a maximum of 7 weeks. Patients may receive adjuvant systemic therapy at the discretion of the treating physician.~Patients are followed up at 30 days, at 6, 12, 18, 30, and 36 months, and then annually for a total of 10 years."
3329058|NCT00003855|Active Comparator|Radiotherapy|"Patients undergo breast radiotherapy only. Patients may receive adjuvant systemic therapy at the discretion of the treating physician.~Patients are followed up at 30 days, at 6, 12, 18, 30, and 36 months, and then annually for a total of 10 years."
3329059|NCT00003854|Experimental|Surgery + radiotherapy + adjuvant therapy|"Patients undergo bilateral anterior iliac crest bone marrow aspiration to test for presence of micrometastases. Patients then undergo breast-conserving therapy comprising segmental mastectomy and sentinel lymph node dissection (SLND) with planned postoperative whole-breast radiotherapy and systemic adjuvant therapy. The SLND comprises ipsilateral axillary sentinel node identification and histopathology.~Patients with no sentinel node identified intraoperatively and patients with sentinel node metastasis identified by hematoxylin and eosin (H&E) who choose not to be registered to ACOSOG-Z0011 undergo axillary lymph node dissection involving removal of at least level I and II nodes.~All patients undergo whole-breast radiotherapy (excluding a supraclavicular field) 5 days a week for a maximum of 8 weeks.~Patients are followed at 30 days; at 6, 12, 18, 24, 30, and 36 months; and then annually until 10 years after surgery."
3329060|NCT00003851|Active Comparator|Nutritional Arm|Arm I (Nutritional Arm): Patients receive pancreatic enzymes orally every 4 hours and at meals daily on days 1-16, followed by 5 days of rest. Patients receive magnesium citrate and Papaya Plus with the pancreatic enzymes. Additionally, patients receive nutritional supplementation with vitamins, minerals, trace elements, and animal glandular products 4 times per day on days 1-16, followed by 5 days of rest. Courses repeat every 21 days until death despite relapse. Patients consume a moderate vegetarian metabolizer diet during the course of therapy, which excludes red meat, poultry, and white sugar. Coffee enemas are performed twice a day, along with skin brushing daily, skin cleansing once a week with castor oil during the first 6 months of therapy, and a salt and soda bath each week. Patients also undergo a complete liver flush and a clean sweep and purge on a rotating basis each month during the 5 days of rest.
3329061|NCT00003851|Active Comparator|Chemotherapy Arm|Arm II (Chemotherapy Arm): Patients receive gemcitabine-based chemotherapy. Quality of life is assessed at 0, 2, 6, and 12 months and then yearly thereafter.
3329062|NCT00003838|Experimental|1|Subjects will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg /m2 intravenously (IV) over 30 minutes daily x 5 days followed by a PBPC graft targeted to deliver >5x10^6 CD34+ cells/kg
3329063|NCT00003833||Normal and tumor tissue pairs|Matched normal and tumor DNA is analyzed for 8p allelic imbalance with at least 8 markers: D8S262 and D8S1825 localized to 8p23, D8S254 and D8S261 at 8p22, D8S560 and D8S136 at 8p21, and D8S1820 and D8S283 at 8p12. Normal/tumor tissue pairs are used for fine mapping studies.
3329064|NCT00003831|Experimental|Lymph node sampling|Patients undergo pulmonary resection. No additional lymph nodes are removed. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.
3329065|NCT00003831|Active Comparator|Lymph node dissection|Patients undergo removal of nearly all of the lymph nodes from the central part of the chest between the lungs, followed by pulmonary resection. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.
3329066|NCT00003820|Experimental|Rituximab 375 mg/m2 per week|"375 mg/m2 rituximab by IV infusion weekly. The initial course of treatment is 4 weeks.~Subjects who achieve an objective response or stable disease after the initial course (4 weeks) were permitted to continue additional 4-week cycles of treatment, for 3 additional courses starting every 6 months (ie, at 6; 12; and 18 months)."
3329067|NCT00003816|Experimental|Regimen 1|Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
3329068|NCT00003816|Experimental|Regimen 2|Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -3.
3329069|NCT00003816|Experimental|Regimen 3|Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and total-body irradiation (TBI) twice daily on days -3 to -1.
3329075|NCT00003816|Experimental|Regimen 9|Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
3329076|NCT00003800|No Intervention|Laboratory/CT evaluation|Observation following orchiectomy
3329077|NCT00003799|Experimental|Treatment (chemotherapy, radiotherapy, surgery)|"Patients receive fluorouracil IV continuously with concurrent radiotherapy for 5.5 weeks. Patients also receive oxaliplatin IV over 2 hours on day 1 of weeks 1, 3, and 5.~Patients undergo surgery 6-8 weeks after completing preoperative chemotherapy and radiotherapy. The surgical procedure is determined by the extent of the tumor before preoperative therapy. The type of operative procedure may be abdominoperineal resection, low anterior resection (LAR), or LAR/coloanal anastomosis.~Postoperative chemotherapy begins within 6 weeks after surgery, comprising leucovorin calcium and fluorouracil IV on days 1-5. Treatment repeats every 21 days for 4 courses."
3329078|NCT00003796|Experimental|Arm I|Patients receive irofulven IV over 30 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
3329079|NCT00003793||Identification of Genetical suceptibility prior to therapy|"Determine the glutathione-s-transferase theta (GSTT1) or glutathione-s-transferase mu (GSTM1) null genotype is more frequent in individuals with t-MDS/AML. Determine the GSTT1 or GSTM1 null genotype is associated with a reduced incidence of relapse of sarcoma. Determine NAT2 or CYP1A1 genotype influences risk of t-MDS/AML. Determine development of a mutator phenotype as demonstrated by developing microsatellite instability is an early marker of individuals likely to progress to t-MDS/AML."
3329080|NCT00003793||Increased Risk Of T-MDS/AML before/after Therapy|Determine clonal hematopoiesis develops in children receiving high intensity alkylating agent chemotherapy for sarcomas. Determine development of clonal hematopoiesis is associated with increased frequency of t-MDS/AML. Determine measurement of somatic cell mutation frequency, measured by the glycophorin A (GPA) assay prior to and after chemotherapy will predict individuals at increased risk of t-MDS/AML. Identify individuals with ras gene mutations in normal peripheral blood cells after therapy, and whether the identification of such mutations is associated with increased risk of t-MDS/AML blood cells after therapy, and whether the identification of such mutations is associated with increased risk of t-MDS/AML.
3329081|NCT00003789|Experimental|Arm I|Patients undergo hyperthermic isolated perfusions of the lower limb by either the external iliac vessels or the common femoral vessels. Patients undergo perfusions of the upper extremity by the axillary artery and vein using an infraclavicular/axillary incision. Melphalan is introduced into the perfusion by slow injection over 5 minutes and allowed to remain for a total of 60 minutes.
3329082|NCT00003789|Experimental|Arm II|Patients undergo hyperthermic isolated perfusions as in arm I. Tumor necrosis factor is administered by slow injection into the arterial line and allowed to remain for a total of 90 minutes. Melphalan is introduced into the perfusion as in arm I and allowed to remain for a total of 60 minutes.
3329083|NCT00003782|Experimental|Arm 1: Doxorubicin + Cyclophosphamide, then Docetaxel|Doxorubicin + Cyclophosphamide, then Docetaxel
3329084|NCT00003782|Experimental|Arm 2: Doxorubicin + Docetaxel|Doxorubicin + Docetaxel
3329085|NCT00003782|Experimental|Arm 3: Doxorubicin + Docetaxel + Cyclophosphamide|Doxorubicin + Docetaxel + Cyclophosphamide
3329086|NCT00003750|Experimental|DG2 positive relapsed or refractory solid tumors|The initial hu14.18-IL2 fusion protein (FP) dose will be 2 mg/m2 given intravenously over 4 hours, daily for 3 days. Five separate dose levels are scheduled: 2 mg/m²/dose (IV over 4 hours) x 3 days, 4 mg/m²/dose (IV over 4 hours) x 3 days, 6 mg/m²/dose (IV over 4 hours) x 3 days, 8 mg/m²/dose (IV over 4 hours) x 3 days, 10 mg/m²/dose (IV over 4 hours) x 3 days.
3329087|NCT00003746|Active Comparator|CDA day|CDA:0.14 mg/kg/day Bolus s.c. (standard) days 1-5
3329088|NCT00003746|Active Comparator|CDA week|CDA:0.14 mg/kg/week Bolus s.c. weeks 1-5
3329089|NCT00003745|Experimental|Arm I|Patients receive topotecan IV continuously on days 1-21. Treatment continues at least every 4 weeks in the absence of unacceptable toxicity or disease progression.
3329090|NCT00003744|Experimental|Intercalcated Duct|"The first group, referred to as intercalated duct will include Aadenoid cystic carcinoma, acinic cell carcinoma, malignant mixed tumor, polymorphous low grade adenocarcinoma, undifferentiated carcinoma, and adenocarcinoma.~- Gemcitabine iv 30 min infusion on days 1,8, and 15 of each 28 day cycle.~-- Participants will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
3329091|NCT00003744|Experimental|Excreatory Duct|"The second group, referred to as excretory duct, will include: squamous cell carcinoma and mucoepidermoid carcinoma.~Gemcitabine iv 30 min infusion on days 1,8, and 15 of each 28 day cycle.~Participants will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
3329092|NCT00003702|Experimental|Arm I (methotrexate)|Patients receive methotrexate intramuscularly once weekly in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.
3329093|NCT00003702|Experimental|Arm II (dactinomycin)|Patients receive dactinomycin IV over 15 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.
3329094|NCT00003659|Experimental|intermediate or high risk chronic lymphocytic leukemia|This is a single-arm open-label pilot study designed to assess the antileukemic activity of a regimen containing sequential administration of fludarabine, high-dose cyclophosphamide, and rituximab.
3329095|NCT00003656|Experimental|All subjects|Weekly ATRA-IV with recombinant interferon alfa
3329096|NCT00003653|Active Comparator|Intermittent Androgen Suppression|
3329097|NCT00003653|Active Comparator|Continuous Androgen Suppression|
3329098|NCT00003644|Experimental|Carboplatin, paclitaxel, low dose paclitaxel|carboplatin, paclitaxel followed by low dose paclitaxel 4 weeks later
3329099|NCT00003644|Active Comparator|Carboplatin, paclitaxel|carboplatin, paclitaxel
3329100|NCT00003641|Other|Observation|Patients undergo observation for 4 weeks.
3329101|NCT00003641|Experimental|Interferon Alfa-2b|Patients receive high-dose interferon alfa-2b IV over 20 minutes daily for 5 consecutive days. Treatment repeats weekly for 4 weeks in the absence of unacceptable toxicity.
3329263|NCT00002678|Active Comparator|Melphan, prednisone pluse dexamethasone|melphalan plus prednisone qd x 4 28 day cycles x 12 cycles; dexamethasone qd x 4 q 28 days after non-progression
3329102|NCT00003631|Experimental|Arm I|(0-1 adverse prognostic factors): Patients receive ifosfamide by 24 hour infusion on day 2. Carboplatin is administered on day 2. Etoposide IV is administered once daily on days 1-3. Patients then receive filgrastim (G-CSF) subcutaneously or IV on days 5-12. Patients receive another course of ICE chemotherapy 2-3 weeks after the first course.
3329103|NCT00003631|Experimental|Arm II|(2 adverse prognostic factors): Patients receive the first course of ICE as in Arm I
3329104|NCT00003631|Experimental|Arm III|Arm III (3 adverse prognostic factors): Patients receive cyclophosphamide IV daily for 2 days, then G-CSF beginning on day 4 until blood stem cells are collected
3329105|NCT00003613|Experimental|Treatment (O6-benzylguanine, carmustine)|Patients receive O6-benzylguanine IV over 1 hour followed by topical carmustine once every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3329106|NCT00003612|Experimental|Schedule A: paclitaxel + carboplatin + trastuzumab|"Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes and then trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30 minutes every 3 weeks until disease progression.~Patients are followed every 3 months for 2 years and then every 6 months thereafter."
3329107|NCT00003612|Experimental|Schedule B: paclitaxel + carboplatin + trastuzumab|"Patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 15 minutes on day 1 of weeks 1-3 and trastuzumab IV over 90 minutes immediately after carboplatin on day 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30 minutes every 3 weeks until disease progression.~Patients are followed every 3 months for 2 years and then every 6 months thereafter."
3329108|NCT00003611|Experimental|acitretin|"Patients receive oral acitretin daily for 2 years. Skin biopsies are obtained at 1 year from normal areas and from any areas with skin cancer for genetic studies.~Patients are followed every 6 months."
3329109|NCT00003611|Placebo Comparator|placebo|"Patients receive placebo daily for 2 years. Skin biopsies are obtained at 1 year from normal areas and from any areas with skin cancer for genetic studies.~Patients are followed every 6 months."
3329110|NCT00003593|Experimental|Arm A: TMD patients only|Patients are observed if their transient myeloproliferative disorder (TMD) does not require intervention. Patients who require therapy for TMD undergo leukapheresis or exchange transfusion for up to 3 consecutive days. If the TMD does not resolve or there is significant organ involvement, patients receive low-dose cytarabine IV continuously on days 0-4. Treatment repeats at least every 2 weeks for up to 4 courses. Patients who experience a recurrence of TMD at least 8 weeks after resolution or have refractory disease may proceed to group II for further treatment. patients will continue to be followed for remission induction, EFS, DFS and OS regardless of the type of leukemia that develops.
3329111|NCT00003593|Experimental|Arm B: AML/MDS patients only|(closed to accrual as of 6/24/04 except for patients first enrolled in group I): Patients receive induction therapy comprising cytarabine IV continuously, daunorubicin hydrochloride IV continuously, and oral thioguanine twice daily on days 0-3. Treatment repeats every 28 days for 4 courses. Patients with no CNS disease at diagnosis receive cytarabine intrathecally (IT) on day 0. Patients with CNS disease at diagnosis receive cytarabine IT on days 0, 5, and 7. If CNS disease persists on day 7, patients receive up to 6 courses of cytarabine IT, therapeutic hydrocortisone IT, and methotrexate IT, twice weekly beginning on day 10. Asparaginase during Intensification 1 day 1 hour 18.
3329112|NCT00003590|Experimental|Hydroxyurea|
3329113|NCT00003566|Experimental|video-thorascopy + surgery|Patients will undergo ipsilateral video-thorascopic evaluation. Patients may undergo surgery at the discretion of the surgeon and treating physicians.
3329114|NCT00003565|Experimental|docetaxel|OUTLINE: Patients receive docetaxel IV over 1 hour on day 1. Patients may receive additional courses beginning 21 days after the first docetaxel dose at the discretion of the physician.
3329115|NCT00003553|Experimental|Preparative regimen 1|Patients receive cyclophosphamide IV over 1 hour on days -7 and -6 and fludarabine IV over 30 minutes on days -5 to -1.
3329116|NCT00003553|Experimental|Preparative regimen 2 (closed to accrual as of 10/1/03)|"Patients receive cyclophosphamide IV over 1 hour on days -7 and -6, fludarabine IV over 30 minutes on days -5 to -1, and antithymocyte globulin on days -5 to~-2."
3329117|NCT00003553|Experimental|Preparative regimen 3 (closed to accrual as of 10/1/03)|Patients receive cyclophosphamide IV over 1 hour on days -8 to -6, fludarabine IV over 30 minutes on days -5 to -1, and antithymocyte globulin on days -5 to -2.
3329118|NCT00003553|Experimental|GVHD regimen 1 (closed to accrual as of 10/17/00)|Patients receive cyclosporine IV over 12 hours or orally beginning on day -4 and continuing for up to approximately 3 months.
3329119|NCT00003553|Experimental|GVHD regimen 2 (open to accrual from 10/17/00 through 2/11/02)|Patients receive cyclosporine as in regimen 1. Patients also receive mycophenolate mofetil.
3329120|NCT00003553|Experimental|GVHD regimen 3 (open to accrual as of 2/11/02)|Patients receive cyclosporine as in regimen 1. Patients also receive methotrexate.
3329121|NCT00003537|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329122|NCT00003535|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329123|NCT00003534|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329124|NCT00003533|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329125|NCT00003532|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329234|NCT00002852|Experimental|Arm II (surgery, chemotherapy)|Patients receive adjuvant therapy comprising paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on day 1. Treatment continues every 3 weeks for 4 courses.
3329126|NCT00003531|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329127|NCT00003530|Experimental|Antineoplaston Therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329128|NCT00003526|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329129|NCT00003525|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329130|NCT00003524|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329131|NCT00003522|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329132|NCT00003521|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329133|NCT00003520|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329134|NCT00003516|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
3329135|NCT00003515|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329136|NCT00003513|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329137|NCT00003512|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329138|NCT00003511|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329139|NCT00003509|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329140|NCT00003501|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329141|NCT00003500|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329142|NCT00003499|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329143|NCT00003498|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329144|NCT00003497|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
3329145|NCT00003496|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329146|NCT00003495|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329147|NCT00003494|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329148|NCT00003492|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329149|NCT00003491|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329150|NCT00003489|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329151|NCT00003485|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329152|NCT00003483|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329153|NCT00003479|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329154|NCT00003477|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329155|NCT00003476|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329156|NCT00003475|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329157|NCT00003474|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329158|NCT00003473|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329159|NCT00003472|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329160|NCT00003471|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329161|NCT00003470|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329162|NCT00003469|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329163|NCT00003468|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329164|NCT00003460|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329165|NCT00003459|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dosage is reached.
3329166|NCT00003458|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329167|NCT00003457|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329168|NCT00003456|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329169|NCT00003454|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329170|NCT00003453|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329171|NCT00003452|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3329172|NCT00003440|Experimental|Arm A (paclitaxel)|Patients receive paclitaxel intravenously (IV) over 3 hours every 3 weeks.
3329173|NCT00003440|Active Comparator|Arm B (paclitaxel)|Patients receive paclitaxel IV over 1 hour weekly.
3329174|NCT00003440|Experimental|Arm C (paclitaxel, trastuzumab)|Patients receive paclitaxel as in Arm I. Patients also receive trastuzumab IV weekly.
3329175|NCT00003440|Active Comparator|Arm D (paclitaxel, trastuzumab)|Patients receive paclitaxel as in Arm II and trastuzumab as in Arm III.
3329176|NCT00003440|Experimental|Am E (paclitaxel, trastuzumab)|Patients receive paclitaxel and trastuzumab as in Arm C.
3329177|NCT00003440|Active Comparator|Arm F (paclitaxel, trastuzumab)|Patients receive paclitaxel and trastuzumab as in Arm D.
3329178|NCT00003404|Experimental|Radiation|
3329179|NCT00003389|Experimental|Arm A (ABVD)|Arm A (ABVD): Patients receive doxorubicin (25 mg/m²), bleomycin (10 u/m²), vinblastine (6 mg/m²), and dacarbazine (375 mg/m²) intravenously (IV) on days 1 and 15. Courses repeat every 28 days. Patients are restaged after 4 courses. Patients who are in complete remission receive 2 additional courses. Patients with a partial response or less are evaluated after 6 courses, and if there is an ongoing response, patients may receive 2 additional courses for a total of 8. If no ongoing response is observed, patients are removed from the study. All patients with massive mediastinal disease, regardless of stage, receive radiotherapy 2-3 weeks after completion of chemotherapy.
3329202|NCT00003138|Experimental|Erythropoietin|Erythropoietin was administered at 150 units/kg subcutaneously every day. If patients stopped responding, they were subsequently treated with Erythropoietin (150 units/kg) and filgrastim and then Erythropoietin (300 units/kg) and filgrastim.
3329203|NCT00003119|Experimental|Treatment 1 - Asymptomatic - no immediate chemotherapy|
3329204|NCT00003119|Experimental|Symptomatic - immediate chemotherapy|
3329205|NCT00003093|Experimental|Treatment|See detailed description.
3329180|NCT00003389|Active Comparator|Arm B (Stanford V)|Arm B (Stanford V): Patients receive Stanford V chemotherapy comprising doxorubicin (25 mg/m²) and vinblastine (6 mg/m²) IV on day 1 of weeks 1, 3, 5, 7, 9, and 11; vincristine (1.4 mg/m²) and bleomycin (5 u/m²) IV on day 1 of weeks 2, 4, 6, 8, 10, and 12; mechlorethamine (6 mg/m²) IV on day 1 of weeks 1, 5, and 9 (if mechlorethamine is unavailable, may substitute with cyclophosphamide [375 mg/m²] IV); etoposide (60 mg/m²) IV on days 1 and 2 of weeks 3, 7, and 11; and oral prednisone (40 mg/m²) every other day of weeks 1-9 followed by a taper. All patients with bulky disease receive radiotherapy 2-3 weeks after completion of chemotherapy.
3329181|NCT00003384|Experimental|Diagnostic|"Patients undergo a Pap smear followed by a ThinPrep cervical cell specimen collection at the time of direct colposcopic examination. Patients then undergo a cone biopsy of the cervix using loop electrosurgical excision procedure with an endocervical curettage, an excisional cone biopsy of the cervix with or without endocervical curettage, or a hysterectomy. Patients who are perimenopausal or postmenopausal or have a negative cervical cone biopsy also undergo endometrial biopsy or curettage. The Pap smear specimen is analyzed to determine MN antigen expression and the ThinPrep specimen is analyzed for the presence of high-risk human papilloma virus and to determine MN antigen and other marker (e.g., P16) expression.~Patients who do not undergo hysterectomy are followed every 6 months for 2 years. All other patients are followed at 4, 26, and 30 weeks."
3329182|NCT00003377|Other|Radiation therapy plus concurrent weekly chemotherapy|
3329183|NCT00003375|No Intervention|Observation|Observation only.
3329184|NCT00003375|Experimental|Radiation therapy|Radiation therapy only.
3329185|NCT00003375|Experimental|Radiation plus PCV chemotherapy|Radiation and Procarbazine/CCNU/Vincristine (PCV) chemotherapy
3329186|NCT00003325|Other|Sentinenal lymph node mapping|Sentinenal lymph node mapping
3329187|NCT00003292|Experimental|ifosfamide|ifosfamide
3329188|NCT00003282|Experimental|Diagnostic (EF5)|Patients receive etanidazole derivative EF5 IV over 1-2 hours beginning approximately 24 hours prior to surgery. Tumors are then resected or biopsied after Eppendorf needle electrode measurements.
3329189|NCT00003278|Experimental|radiation + dexamethasone|"Patients undergo whole-brain radiotherapy (WBRT) daily 5 days a week for 4.5 weeks. Beginning 30 days after WBRT is completed, patients receive high-dose dexamethasone IV on days 1-5 during course 1 and on day 1 only during all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients are followed at 1 month after radiotherapy, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter."
3329190|NCT00003204|Experimental|Arm I (cyclophosphamide, fludarabine)|Patients receive cyclophosphamide IV over 30-45 minutes on day 1 and fludarabine IV over 10-20 minutes on days 1-5. Treatment repeats every 28 days in the absence of disease progression for a minimum of 4 courses and a maximum of 6 courses.
3329191|NCT00003204|Experimental|Arm II (cyclophosphamide, vincristine, prednisone)|Patients receive cyclophosphamide IV over 30-45 minutes and vincristine IV on day 1, and oral prednisone on days 1-5. Treatment repeats every 21 days in the absence of disease progression for a minimum of 6 courses and a maximum of 8 courses.
3329192|NCT00003204|Experimental|Arm III (rituximab)|Patients receive maintenance therapy with rituximab (IDEC-C2B8 monoclonal antibody) IV weekly for 4 weeks. Courses repeat every 6 months for 2 years. Maintenance therapy begins 4 weeks after the last chemotherapy.
3329193|NCT00003204|No Intervention|Arm IV (no intervention)|Patients undergo no maintenance therapy and are observed. Patients are followed every 3 months for 2 years, every 6 months for the next 3 years, and then annually thereafter.
3329194|NCT00003199|Experimental|Arm I|See Detailed Description.
3329195|NCT00003178|Experimental|1st Untreated Relapse for AML|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
3329196|NCT00003178|Experimental|Primary Refractory AML|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
3329197|NCT00003178|Experimental|MDS|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
3329198|NCT00003145|Experimental|Treatment (chemotherapy, TBI, PBSCT, DLI)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV BID or TID on days -3 to 56 with taper to day 77 or 180, and mycophenolate mofetil PO or IV BID on days 0-27.~DLI: At least 2 weeks after completion of immunosuppression, patients with > 5% donor CD3+ T cells and no evidence of GVHD receive donor lymphocytes IV over 30 minutes. Patients may receive up to 3 DLIs at increasing cell doses in the absence of GVHD."
3329199|NCT00003140|Experimental|Arm I|Patients receive oral letrozole once daily.
3329200|NCT00003140|Placebo Comparator|Arm II|Patients receive oral placebo once daily.
3329201|NCT00003138|Active Comparator|Supportive Care|Patients received red cell and platelet transfusions for symptoms or to maintain hematocrit at or above 25% by volume. Patients who required transfusion support for symptomatic anemia prior to entering the study and who developed an increase in their transfusion requirement of >= 50% shall cross over to the Erythropoietin treatment arm, after at least four months on the supportive therapy arm.
3329206|NCT00003092|Experimental|Paclitaxel|"Patients receive a single dose of IV paclitaxel over 3 hours. Additional cycles of paclitaxel will be given at the discretion of the physician.~Patients are followed for second malignancies, disease progression, and survival."
3329207|NCT00003042|Experimental|1 cycle of neoadjuvant chemotherapy|Patients receive chemotherapy, surgical removal of the cancer followed by additional chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.
3329208|NCT00003042|Experimental|More than 1 cycle of neoadjuvant chemotherapy|Patients receive chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.
3329209|NCT00003034|Experimental|Arm I|Patients receive ranpirnase IV over 30 minutes weekly followed by doxorubicin IV. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression. Patients demonstrating evidence of clinical response or stable disease may continue on maintenance therapy with ranpirnase as a single agent until disease progression.
3329210|NCT00003034|Experimental|Arm II|Patients receive doxorubicin as in arm I for up to 6 courses.
3329211|NCT00002981|Experimental|PET Scan|Each patient receives C11-methionine intravenously. PET imaging begins immediately after injection for approximately 60 minutes total using standard imaging procedures. Immediately following the completion of imaging after C11-methionine administration, each patient receives FDG intravenously. PET imaging begins approximately 45 minutes thereafter for approximately 60 minutes using standard imaging procedures.
3329212|NCT00002975|Experimental|PDT|4-6h and 18-24h, 20%, ALA application of superficial and nodular epidermally-derived lesions using ca 633 nm laser irradiation
3329213|NCT00002968|Experimental|Arm I (edrecolomab)|Patients receive adjuvant edrecolomab IV over 2 hours on day 1. Treatment repeats every 28 days for 5 courses. Patients must begin therapy no earlier than 7 days and no later than 42 days postsurgical resection. Patients also undergo observation at 3 and 6 months postrandomization.
3329214|NCT00002968|No Intervention|Arm II (no treatment)|Patients undergo observation at 3 and 6 months postrandomization. .
3329215|NCT00002951|Experimental|Arm A (Hyper-FHX)|Concomitant chemoradiotherapy consisting of hydroxyurea (PO, BID, x 6days), continuous infusion 5-fluorouracil (IV, x 5days), hyperfractionated radiotherapy (150 cGy twice daily for 5 days every 14 days, 5 cycles)
3329216|NCT00002944|Experimental|Regimen A (CV Chemotherapy)|Induction will consist of 10 weeks of therapy (carboplatin, vincristine sulfate),followed by 2 weeks without chemotherapy. Induction should only be interrupted in the event of grade 3 neurotoxicity, grade 2 renal toxicity, grade 4 hematologic toxicity, or tumor progression. Maintenance-Four Courses (2 cycles/course) commences on Day 84 (week 12) of Induction or when peripheral counts recover with ANC >1,000/$L and platelet count >100,000/$L. Each cycle will consist of 4 weekly doses of carboplatin, three weekly doses of vincristine sulfate (given concomitantly with the first 3 weeks of carboplatin), followed by two weeks of rest for a total of 6 weeks. Maintenance will continue for a total of 8 cycles.
3329217|NCT00002944|Experimental|Regimen B (TPCV Chemotherapy)|Each cycle of chemotherapy consists of 4 days of oral chemotherapy (Thioguanine, procarbazine hydrochloride, Lomustine and Vincristine sulfate beginning Day 0, followed by vincristine sulfate IV on Days 14 and 28. The cycle is repeated every 6 weeks (42 days). A total of 8 cycles will be given.
3329218|NCT00002941|Experimental|Reinduction Therapy|Two courses of reinduction chemotherapy followed by bone marrow biopsy and aspirate prior to peripheral blood stem cell (PBSC) harvest. If marrow involvement is still present at harvest, then 2 additional courses of induction chemotherapy are given. The PBSC transplantation preparative regimen should begin within 2 weeks of completing reinduction therapy course, consisting of the following: Carmustine IV over 3 hours on days -8, -7, and -6, Etoposide continuous IV over days -8, -7, and -6, Cyclophosphamide IV over 1 hour daily on days -5, -4, -3, and -2, Mesna as a 15 min infusion before each dose of cyclophosphamide then at 3, 6, 9, and 12 hours after initiation of each cyclophosphamide dose Methylprednisolone IV is given to protect lungs from the toxic effects of carmustine.
3329219|NCT00002938|Other|Surgery|Salvage prostatectomy
3329220|NCT00002931|Experimental|HD Chemo and Auto Stem Cells|
3329221|NCT00002920|Active Comparator|Tamoxifen alone|Tamoxifen alone x 5 years
3329222|NCT00002920|Experimental|Tamoxifen plus MPA|Tamoxifen Plus Medroxyprogesterone Acetate (MPA) x 5 years
3329223|NCT00002913|Experimental|Treatment (paclitaxel, cisplatin, topotecan hydrochloride)|"Patients receive paclitaxel IV over 3 hours and cisplatin IV on day 1, followed by topotecan IV over 30 minutes on days 1-3. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 4 and continuing until blood counts recover. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 4-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicities."
3329224|NCT00002882|Experimental|IFN-A Therapy Schedule A|Schedule A: IV Interferon alfa-2b (IFN-A) induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.
3329225|NCT00002882|Experimental|IFN-A Therapy Schedule B|Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks.
3329226|NCT00002882|Experimental|Adjuvant Biochemotherapy|Cisplatin IV Days 1-4; Vinblastine IVPB Days 1-4; Dacarbazine (DTIC) IVPB on Day 1; IFN-A is given subcutaneously on days 1-5; IL-2 continuous infusion for 96 hours on Days 1-4. Each course repeated every 21 days for 4 courses.
3329227|NCT00002874|Experimental|Bicalutamide|Radiation therapy + bicalutamide
3329228|NCT00002874|Placebo Comparator|Placebo|Radiation therapy + placebo
3329229|NCT00002860|Other|surgery|
3329230|NCT00002855|Experimental|Arm I|Arm I: Medical or surgical castration followed by an anti-androgen therapy with either flutamide, bicalutamide, or nilutamide.
3329231|NCT00002855|Experimental|Arm II|Arm II: Chemo/hormonal therapy for 3 x 8-week courses, followed by total androgen blockade. Each course consists of 6 weeks of cytotoxic therapy with doxorubicin, ketoconazole, vinblastine, and estramustine followed by 2 weeks rest. Maintained on hydrocortisone both during treatment and during rest.
3329232|NCT00002854|Experimental|Sequential high dose chemotherapy|
3329233|NCT00002852|Active Comparator|Arm I (surgery, observation)|Patients receive no further therapy.
3329860|NCT00034554|Experimental|5|8.0mg
3329239|NCT00002842|Experimental|Hepatic Resection/Portal Vein FUdr/Systemic 5-FU & Leucovorin|Patients receive floxuridine via portal vein infusion from days 1-14. Systemic chemotherapy consists of leucovorin calcium on days 8-14 and fluorouracil on days 9-13. Courses repeat every 4 weeks for a total of 12 weeks
3329240|NCT00002807|No Intervention|Observation|
3329241|NCT00002807|Experimental|Radiation|Post-operative pelvic radiation therapy (45 Gy in 25 fractions over 5 weeks)
3329242|NCT00002798|Experimental|Arm I (combination chemotherapy)|"Patients receive treatment as in induction therapy, plus G-CSF SC beginning on day 16 and continuing until blood counts recover. If CSF is clear by day 10 of induction, patients receive cytarabine IT on days 0, 10, and 35. If CSF is not clear, patients receive triple intrathecal therapy (TIT; cytarabine, hydrocortisone, methotrexate) on days 0 and 10.~See Detailed Description"
3329243|NCT00002798|Experimental|Arm II (combination chemotherapy)|"Patients receive fludarabine IV over 24 hours on days 0 and 1, cytarabine IV over 72 hours on days 2-4, and idarubicin IV over 15 minutes on days 0-2. G-CSF begins on day 6 and continues until blood counts recover. Patients also receive TIT on days -1 and 7, if CSF is not clear on day 10 of induction. Patients on both arms are reassessed on day 35. Those patients with M1 marrow proceed to intensification; all others are removed from the study.~Intensification: See Detailed Description"
3329244|NCT00002798|Experimental|Arm III (combination chemotherapy, aldesleukin)|Patients receive interleukin-2 IV continuously on days 1-4 and 9-18.
3329245|NCT00002798|Active Comparator|Arm IV (combination chemotherapy)|No further treatment
3329246|NCT00002798|Experimental|Arm V (combination chemotherapy, radiotherapy)|Patients undergo radiotherapy to the chloroma 5 days a week for 2 weeks.
3329247|NCT00002796|Experimental|Treatment (fluorouracil, phenylbutyrate, indomethacin, IFN-G|"Phase I: Patients receive 5-FU IV over 24 hours on day 1; phenylbutyrate IV over 120 hours and oral indomethacin daily on days 2-6; and interferon gamma subcutaneously on days 2, 4, and 6. Courses repeat weekly in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which less than 2 of 6 patients experience dose-limiting toxicity (DLT).~Phase II: Patients receive 5-FU, phenylbutyrate, indomethacin, and interferon gamma as in phase I at the MTD."
3329248|NCT00002766|Experimental|"ARA-C/High-Dose Mitoxantrone(All-2)"|See detail description
3329249|NCT00002766|Active Comparator|"Standard Vincristine/Prednisone (L-20)"|See detail description
3329250|NCT00002762||Patient interviewing + blood sampling|"Patients were interviewed at the time of the primary cancer surgery to determine the menstrual history. Blood sampling occurred within 1 day of surgery, and serum samples were shipped frozen to a central laboratory (Mayo Medical Laboratory, Rochester, MN) for E2, Pg, and LH determinations. Serum hormone levels, menstrual cycle length, and day of last menses were used to determine the menstrual phase at which surgery occurred.~Patients were observed every 6 months for the first year postregistration and annually for the next 2 to 10 years postregistration for adjuvant therapy information, disease recurrence, and death."
3329251|NCT00002757|Active Comparator|Group A|All resected stage I and Abdominal stage II only. All Group A patients will be treated with two cycles of COPAD and will be followed in a confirmatory study of the current result of nearly 100% cure rate.
3329252|NCT00002757|Active Comparator|Group B|Non resected stage I & II, stage III & st IV (CNS - ve, BM < 25%). Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimise the risk of this. Prior to any chemotherapy being administered intravenous hydration fluids should be given run at a rate of 3000 mls/m2/day. Alkalinisation may be necessary Pay close attention to fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumour lysis persists.
3329253|NCT00002757|Active Comparator|Group C|Bone marrow > 25% but CNS negative Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimize the risk of this. Intravenous hydration fluids should be given prior to chemotherapy. Alkalinisation may be necessary. Monitor fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumor lysis persists
3329254|NCT00002756|Experimental|Chemo (Reduced Induction) No BMT (Open February 2004)|
3329255|NCT00002727|Active Comparator|Radiation therapy - conventional fractionation|Radiation therapy - conventional fractionation (70 Gy/2 Gy once per day/7 Weeks) 35 fractions
3329256|NCT00002727|Experimental|Radiation therapy - hyperfractionation|Radiation therapy - hyperfractionation (79.2 Gy/1.2 b.i.d/6.5 weeks) 66 fractions
3329257|NCT00002718|Experimental|Candidates for transplant|Pts stratified by number of HLA-incompatible alleles(1 vs 2 or 3). Harvest:Begin 6-10 d before transplant,allogeneic BM is harvest & tx in vitro. Begin 5-6 d before transplant,G-CSF-stimulated,PBSC harvest,selected for CD34+ cells,& treatment in vitro. If doable,ABM harvest in event of allogeneic graft failure. Myeloablation:Pts u/g TBI 3x d days -9 to -6, thiotepa IV over 4hrs days -5 & -4, & cyclophosphamide IV days -3 & -2. Transplant:CD34+, E-rosette & T-cell-depleted PBSC infuse over 15mins & T-cell-depleted bone marrow infused over 1-5mins day 0. Pts get G-CSF IV over 30 min begin day 1 & continue til blood counts recover & tapering. Pts get anti-thymocyte globulin IV over 4-6hrs days 8,10,12,&14 & oral methylprednisolone days 8-14 followed by tapered doses days 15-17. See detailed description for more details.
3329258|NCT00002716|Experimental|Arm I - laparotomy + conventional surgery + chemotherapy|"Patients undergo laparotomy for placement of a hepatic artery catheter and then subcutaneous placement of a hepatic artery infusion pump. Patients with unresected primary disease also undergo resection at the time of catheter and pump placement. Beginning within 1-2 weeks after surgery, patients receive floxuridine, dexamethasone, and leucovorin calcium (CF) via continuous hepatic artery infusion on days 1-14. Treatment for patients continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life and medical resource utilization are assessed at baseline, every 3 months for 1 year, and then at 18 months.~Patients are followed every 3 months."
3329259|NCT00002716|Experimental|Arm II - conventional surgery + chemotherapy|"Patients receive CF IV and fluorouracil IV on days 1-5. Patients with unresected primary disease undergo resection within 3-4 weeks before initiation of chemotherapy.~Treatment for patients continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life and medical resource utilization are assessed at baseline, every 3 months for 1 year, and then at 18 months.~Patients are followed every 3 months."
3329260|NCT00002706|Experimental|Arm I|Patients undergo vaginal hysterectomy and BSO via laparoscopy.
3329265|NCT00002668|Experimental|Educational Intervention and Behavioral Skills Training|Patients participated in a program including video presentations, written materials, and coaching in behavioral skills to improve pain control (not to reduce analgesic use).
3329266|NCT00002663|Experimental|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|Patients receive adoptive immunotherapy with allogeneic Epstein Barr virus (EBV)-specific cytotoxic T lymphocytes IV on days 1, 8, and 15. After the third dose, patients will be observed for 3 weeks. After the 3 week observation period, additional courses of treatment may be given in the absence of disease progression or unacceptable toxicity.
3329267|NCT00002651|Active Comparator|Consolidation arm I|Patients continue CAD therapy comprising goserelin subcutaneously once a month and oral bicalutamide once daily. Treatment continues in the absence of disease progression.
3329268|NCT00002651|Experimental|Consolidation arm II|Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy as in consolidation arm I. Patients whose PSA normalizes after 8 courses return to observation. Patients whose PSA does not normalize after 8 courses continue CAD therapy.
3329269|NCT00002649|Experimental|Arm I (autologous PBSCT, TBI, etoposide, cyclophosphamide)|"Part I: Autologous PBSC are harvested before study entry. Patients undergo total body irradiation twice a day on days -8 to -5, high-dose etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 1 hour on day -2. PBSC are reinfused on day 0 and then G-CSF may be administered subcutaneously or IV on days 0-21.~Part II: Within 28-80 days after PBSC transplantation and after recovery from any toxic effects, patients with no active recurrent or progressive disease are randomized to 1 of 2 treatment arms.~Patients receive interleukin-2 IV continuously on days 1-4 and 9-18."
3329270|NCT00002649|No Intervention|Arm II (observation only)|Patients undergo observation only.
3329271|NCT00002633|Active Comparator|Total Androgen Blockade|
3329272|NCT00002633|Active Comparator|Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation|
3329273|NCT00002624|Experimental|Radiotherapy + surgery|"Patients begin radiotherapy 2-8 weeks postoperatively. Patients with complete resection undergo radiotherapy 5 days a week for 5.6 weeks. Patients with incomplete resection undergo radiotherapy 5 days a week for 6.6 weeks.~Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter."
3329274|NCT00002611|Active Comparator|Stratum 1|Stage I favorable histology (FH) Wilms' tumor, under 24 months of age, and tumor weight less than 550 g: After conventional surgery (nephrectomy), patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
3329275|NCT00002611|Active Comparator|Stratum 2|Stage I FH Wilms' tumor and age 24 months and over or tumor weight at least 550 g; stage I focal anaplastic (FA) or diffuse anaplastic (DA) Wilms' tumor: Patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
3329276|NCT00002611|Active Comparator|Stratum 3|Stage II FH Wilms' tumor: Patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
3329277|NCT00002611|Active Comparator|Stratum 4|Stage III FH Wilms' tumor; stage II or III FA Wilms' tumor: After conventional surgery (nephrectomy), patients receive regimen DD-4A comprising dactinomycin DACT IV weekly on weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weekly on weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weekly on weeks 1-10, 12, 15, 18, 21, and 24. Patients also undergo abdominal radiation therapy.
3329278|NCT00002611|Active Comparator|Stratum 5|Stage IV FH or FA Wilms' tumor: patients receive regimen DD-4A comprising dactinomycin DACT IV weekly on weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weekly on weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weekly on weeks 1-10, 12, 15, 18, 21, and 24. Patients also undergo abdominal radiation therapy, and whole lung radiation therapy (at the discretion of the investigator).
3329279|NCT00002611|Active Comparator|Stratum 6|Stage V FH, FA, or DA Wilms' tumor: After bilateral conventional surgery (biopsy), patients with FH receive chemotherapy as in stratum 1 (dactinomycin IV weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate IV weeks 1-10, 12, 15, and 18) or 4 (dactinomycin IV weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weeks 1-10, 12, 15, 18, 21, and 24). Patients with FA or DA receive chemotherapy as in stratum 7 (vincristine sulfate VCR IV weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy.
3329280|NCT00002611|Active Comparator|Stratum 7|Stages I-IV clear cell sarcoma): After conventional surgery (nephrectomy), patients receive vincristine sulfate VCR IV weekly on weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weekly on weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy and continuing until blood counts recover. Patients also undergo abdominal radiotherapy and whole lung radiotherapy (if pulmonary metastases are present).
3329281|NCT00002611|Active Comparator|Stratum 8|Stages II-IV DA Wilms' tumor: After conventional surgery (nephrectomy), Patients receive treatment as in stratum 7 (patients receive vincristine sulfate VCR IV weekly on weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weekly on weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy and continuing until blood counts recover. Patients also undergo abdominal radiotherapy and whole lung radiotherapy (if pulmonary metastases are present).
3329315|NCT00051740|Active Comparator|Minimal Environmental Support|Subjects receive minimal environmental support in schizophrenia treatment
3329565|NCT00043979|Experimental|Arm 1- Sibling Donors|Donors (n = 30) were matched first degree relatives who were eligible to donate peripheral blood stem cells.
3329282|NCT00002611|Active Comparator|Stratum 9|Stages I-IV rhabdoid tumor: After conventional surgery (nephrectomy), patients receive carboplatin IV on days 1-2 and VP-16 IV over 1 hour (beginning after carboplatin infusion) on days 1-3 of weeks 0, 3, 9, 12, 18, and 21 and CTX IV over 1 hour on days 1-5 of weeks 6, 15, and 24. Filgrastim G-CSF is administered as on stratum 7. Patients also undergo radiation therapy. After completion of chemotherapy, patients undergo second-look conventional surgery (laparotomy) and conventional surgery (partial nephrectomy or wedge excision if feasible). After conventional surgery (second-look surgery), patients without persistent or residual disease resume chemotherapy.
3329283|NCT00002610|Experimental|STRATUM A|Treatment of children in Stratum A will be determined by the site of relapse and the presence of microscopic or gross residual disease after attempted surgical excision of the relapse.
3329284|NCT00002610|Experimental|Stratum B|All children who received combination chemotherapy with Regimen EE - 4A as their initial therapy for Wilms tumor will receive Regimen I and radiation therapy to the site of recurrence. All patients will receive prophylactic trimethoprim /sulfamethoxazole
3329285|NCT00002610|Experimental|STRATUM C|All children who received combination chemotherapy with Regimen DD - 4A as their initial therapy for Wilms tumor will be treated with the following chemotherapy. All patients will receive prophylactic trimethoprim/sulfamethoxazole
3329286|NCT00002610|Experimental|STRATUM D|Six week cycles of chemotherapy will be given to all patients who do not have progressive disease at the time of each week 0 re-evaluation.
3329287|NCT00002594|Experimental|Ablative chemo followed by autologous bone marrow (ABM) rescue|Autologous bone marrow and/or peripheral blood stem cells (PBSC) are harvested. Patients then receive intensive cyclophosphamide IV over 1 hour on days -8 to -5 and melphalan IV over 15 minutes on days -4 to -2. Bone marrow is reinfused on day 0. PBSC are reinfused on day 0 if used alone or on day 1 if used after autologous bone marrow transplantation (ABMT). Sargramostim (GM-CSF) is administered IV over 2 hours daily beginning 4 hours after ABMT and continuing until blood counts recover.
3329288|NCT00002586|Experimental|13-cis retinoic acid|13-cis retinoic acid 50 mg/d
3329289|NCT00002586|Experimental|13-Cis Retinoic Acid and Tocopherol|13-Cis Retinoic Acid (50 mg/day) Tocopherol (800 mg/day)
3329290|NCT00002586|No Intervention|Observation|Observation
3329291|NCT00002569|Active Comparator|Radiation therapy (RT) alone|Radiation therapy (RT) alone - External Beam RT 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week) to MR defined tumor volume.
3329292|NCT00002569|Experimental|Intensive pre-treatment chemotherapy and radiation therapy|Intensive pre-treatment chemotherapy (Day 1 CCNU 130 mg/m2 p.o., Day 8 - Vincristine 1.4 mg/m2 i.v., Days 8-21 - Procarbazine 75 mg/m2 p.o., Day 29 - Vincristine 1.4 mg/m2 i.v.) followed by radiation therapy (External Beam RT 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week) to MR defined tumor volume).
3329293|NCT00002558|Experimental|chemotherapy administered with G-CSF and PBSC support|The design of this trial is a phase I/II trial of sequential accelerated chemotherapy cycles with taxol/ifosfamide and carboplatin/etoposide administered with G-CSF and PBSC support.
3329294|NCT00002556|Active Comparator|ARM A (VBMCP)|"INDUCTION PHASE: Patients receive VBMCP comprising vincristine sulfate IV on day 1, carmustine IV on day 1, melphalan PO on days 1-4, cyclophosphamide IV on day 1, and prednisone PO on days 1-7. Treatment repeats every 35 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION PHASE: Patients receive VBMCP as in the induction phase. Courses repeat every 35 days in the absence of disease progression or unacceptable toxicity."
3329295|NCT00002556|Experimental|Arm B (VBMCP, high dose cyclophosphamide, r alpha 2b IFN)|"INDUCTION PHASE: Patients receive VBMCP comprising vincristine sulfate IV on day 1, carmustine IV on day 1, melphalan PO on days 1-4, cyclophosphamide IV on day 1, and prednisone PO on days 1-7. Treatment repeats every 35 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION PHASE: Patients receive vincristine sulfate, carmustine, and melphalan as in the induction phase, high-dose cyclophosphamide IV on days 1-4 and prednisone PO on days 1-4 during courses 3 and 5. Patients receive VBMCP as in the induction phase during even numbered courses. Patients receive recombinant interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, and 22 during odd courses beginning course 7. Treatment repeats every 35 days for courses 3-5, every 21 days for even courses beginning course 6, and every 22 days for odd courses beginning course 7 in the absence of disease progression or unacceptable toxicity."
3329296|NCT00002528|Experimental|Surgery w/ axillary clearance, tamox|Either a total mastectomy with axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy with radiotherapy to the conserved breast) with axillary lymph node dissection, and tamoxifen (20 mg) given after surgery for the duration of 5 years or until relapse.
3329297|NCT00002528|Experimental|Surgery w/o axillary clearance, tamox|Either a total mastectomy without axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy with radiotherapy to the conserved breast) without axillary lymph node dissection, and tamoxifen (20 mg) given after surgery for the duration of 5 years or until relapse.
3329298|NCT00002514|Experimental|Transplant|Allogeneic (if donor) or Autologous (if no donor) bone marrow transplant
3329299|NCT00002514|Active Comparator|Conventional Consolidation/Maintenance|Consolidation/Maintenance Therapy
3329300|NCT00002484|Experimental|external beam radiotherapy|Patients undergo 3-dimensional conformal external beam radiotherapy 5 days a week for 8-10 weeks.
3329301|NCT00052091|Experimental|1 Problem Solving Therapy|12 weekly sessions of problem solving therapy (PST)
3329302|NCT00052091|Experimental|2 Brief Supportive Therapy|12 weekly sessions of brief supportive therapy (BST)
3329303|NCT00052078|Active Comparator|Sertraline|Participants received sertraline for 12 weeks.
3329304|NCT00052078|Active Comparator|CBT|Participants received cognitive behavioral therapy for 12 weeks
3329305|NCT00052078|Active Comparator|SRT + CBT|Participants received both sertraline and CBT for 12 weeks.
3329306|NCT00052078|Placebo Comparator|Placebo|Participants received a placebo pill for 12 weeks.
3329307|NCT00052026|Placebo Comparator|1|Placebo
3329308|NCT00052026|Experimental|2|Low-dose carvedilol
3329309|NCT00052026|Experimental|3|high-dose carvedilol
3329310|NCT00052013|Experimental|PTK787/ZK 222584|
3329311|NCT00051935|Experimental|1|
3329312|NCT00051922|Experimental|1|Participants will receive vaccine and will be followed for 1 year
3329313|NCT00051831|Experimental|1|
3329314|NCT00051740|Active Comparator|Cognitive Adaptation Therapy|Subjects receive Cognitive adaptation therapy as part of treatment for schizophrenia
3329316|NCT00051636|Experimental|Zoledronic Acid and Placebo to Risedronate|Participants received zoledronic acid 5 mg intravenous infusion one dose, 60 days of oral placebo to risedronate, calcium 500 mg twice a day and vitamin D 400 to 1000 international units daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
3329317|NCT00051636|Active Comparator|Risedronate and Placebo to Zoledronic Acid|Participants received 60 days of oral risedronate 30 mg, one intravenous infusion of placebo to zoledronic acid, calcium 500 mg twice a day and vitamin D 400 to 1000 international units daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
3329318|NCT00051558|Experimental|A|Teriparatide 20 micrograms/day injection plus oral placebo, 36 months
3329319|NCT00051558|Active Comparator|B|Alendronate 10 mg/day oral plus injection placebo, 36 months
3329320|NCT00051363|Active Comparator|Active CPAP|Active Continuous Positive Airway Pressure (CPAP)
3329321|NCT00051363|Placebo Comparator|Sham CPAP|Sham Continuous Positive Airway Pressure (CPAP)
3329322|NCT00051285|Experimental|Enoximone|
3329323|NCT00051285|Placebo Comparator|Placebo|
3329324|NCT00051246|Active Comparator|1 M-ITG|Mother-infant group psychotherapy
3329325|NCT00051246|Active Comparator|2 - IPT|Individual interpersonal psychotherapy
3329326|NCT00051168|Experimental|Travatan|Travoprost (0.004%)
3329327|NCT00051129|Experimental|Anecortave Acetate|Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18)
3329328|NCT00051129|Placebo Comparator|Anecortave Acetate Vehicle|Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18)
3329329|NCT00051090|Experimental|A|All eligible study participants
3329330|NCT00050986|Experimental|Temozolomide and R115777|
3329331|NCT00050960|Experimental|bexarotene with carboplatin and paclitaxel|
3329332|NCT00050960|Experimental|carboplatin and paclitaxel|
3329333|NCT00050791|Experimental|VLCD and leptin|Very low calorie diet formula providing 800 calories per day and leptin treatment.
3329334|NCT00050791|Active Comparator|placebo|Very low calorie diet and placebo treatment
3329335|NCT00050778|Active Comparator|Interferon Beta-1a|
3329336|NCT00050778|Experimental|Alemtuzumab 12 mg|
3329337|NCT00050778|Experimental|Alemtuzumab 24 mg|
3329338|NCT00050674|Experimental|Filgrastim-SD/01|6 mg SC, Day 9, 24 hours after the end of the chemotherapy infusion
3329339|NCT00050661|Active Comparator|Narrow Band Ultraviolet B|312nm
3329340|NCT00050661|Experimental|anti-TAC or placebo|
3329341|NCT00050648|Active Comparator|cyclosporine|oral medication 2mg/kg/day orally from Day 0 until Day 90
3329342|NCT00050648|Active Comparator|anti-TAC|1mg/kg/dose medication every other week on the odd week (week 1-13)
3329343|NCT00050648|Experimental|Cyclosporine and anti-TAC|DaclizumabTM at 1mg/kg plus low dose cyclosporine (2 mg/kg/day)
3329344|NCT00050609|Placebo Comparator|1|
3329345|NCT00050609|Active Comparator|2|5 mg tadalafil
3329346|NCT00050609|Active Comparator|3|20 mg tadalafil
3329347|NCT00050427|Experimental|001|ET743 580 mcg/m2 3-hour i.v. infusion on Days 1 8 and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.
3329348|NCT00050427|Experimental|002|ET743 1 300 mcg/m2 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.
3329349|NCT00050622|Placebo Comparator|No Treatment|No Medication, No Behavior Modification (BMOD)
3329350|NCT00050622|Active Comparator|Low Dose Medication Only|0.15 mg/kg methylphenidate (MPH), No BMOD
3329351|NCT00050622|Active Comparator|Medium Dose Medication Only|0.3 mg/kg MPH, No BMOD
3329352|NCT00050622|Active Comparator|Higher Dose Medication Only|0.6 mg/kg MPH, No BMOD
3329353|NCT00050622|Active Comparator|Low Intensity BMOD Only|Placebo, Low Intensity BMOD
3329354|NCT00050622|Active Comparator|Low Intensity BMOD + Low Dose Medication|0.15 mg/kg MPH, Low Intensity BMOD
3329355|NCT00050622|Active Comparator|Low Intensity BMOD + Medium Dose Medication|0.3 mg/kg MPH, Low Intensity BMOD
3329356|NCT00050622|Active Comparator|Low Intensity BMOD + Higher Dose Medication|0.6 mg/kg MPH, Low Intensity BMOD
3329357|NCT00050622|Active Comparator|High Intensity BMOD Only|Placebo, High Intensity BMOD
3329358|NCT00050622|Active Comparator|High Intensity BMOD + Low Dose Medication|0.15 mg/kg MPH, High Intensity BMOD
3329359|NCT00050622|Active Comparator|High Intensity BMOD + Medium Dose Medication|0.3 mg/kg MPH, High Intensity BMOD
3329360|NCT00050622|Active Comparator|High Intensity BMOD + Higher Dose Medication|0.6 mg/kg MPH, High Intensity BMOD
3329361|NCT00050583|Experimental|1|10 Session modified CBT (including a relaxation component) administered by trained mental health clinicians at the primary care setting
3329362|NCT00050583|No Intervention|2|"Treatment as Usual, defined as the use of a consultation letter and traditional primary care management."
3329363|NCT00050557|Experimental|1|Participants will receive immediate Multi-Family Psychoeducation Group treatment and ongoing treatment as usual
3329364|NCT00050557|Active Comparator|2|Participants will receive treatment as usual and waitlist Multi-Family Psychoeducation Group treatment
3329365|NCT00050505|Experimental|Cohort C|N=100 to 110 subjects receives 1:10 diluted dose of Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
3329366|NCT00050505|Experimental|Cohort B|N=571 to 581 subjects receives 1:5 diluted dose of Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
3329367|NCT00050505|Experimental|Cohort A|N=226 to 236 subjects receives undiluted dose Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
3329368|NCT00050440|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days. Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose.
3329369|NCT00050414|Experimental|Trabectedin|Trabectedin 0.58 mg/m2 administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression. Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
3329371|NCT00050167|Experimental|Weekly Paclitaxel (WP)|Weekly Paclitaxel (WP) for 12 weeks followed by Fluorouracil + Epirubicin + Cyclophosphamide (FEC) every 3 weeks for 4 cycles
3329372|NCT00050167|Experimental|Docetaxel and Capecitabine (DX)|Docetaxel + Capecitabine (DX) days 1-14 every 3 weeks for 4 cycles followed by FEC for 4 cycles.
3329373|NCT00050089|Active Comparator|No ARDFP+Standard-ART|No Antiretroviral Drug-Free Period (No ARDFP) and Standard-ART
3329374|NCT00050089|Active Comparator|No ARDFP+Mega-ART|No Antiretroviral Drug-Free Period (No ARDFP) and Mega-ART
3329375|NCT00050089|Active Comparator|ARDFP+Standard-ART|Antiretroviral Drug-Free Period (ARDFP) and Standard-ART
3329376|NCT00050089|Active Comparator|ARDFP+Mega-ART|Antiretroviral Drug-Free Period (ARDFP) and Mega-ART
3329377|NCT00050076|Experimental|MCC-135 50 mg BID|
3329378|NCT00050076|Experimental|MCC-135 100 mg QD|
3329379|NCT00050076|Experimental|MCC-135 200 mg QD|
3329380|NCT00050076|Placebo Comparator|Placebo|
3329381|NCT00050037|Experimental|CD-ROM based CBT|Group is given a copy of the CD-ROM program to complete at home over 10 weeks. At the end of each week, these patients upload and transmit their encrypted tracking data to the research coordinator. At the end of the treatment, participants who have not improved are offered a course of traditional manual-based group therapy, follow-up in an ongoing maintenance group in an eating disorders program, or an alternative treatment.
3329382|NCT00050037|Active Comparator|Standard Group CBT|"Group undergoes standard group CBT. Therapy is administered over 10 weeks in five 90-minute sessions. The key topics are similar to those covered in the CD-ROM group: psychoeducation, developing a personal profile, standardizing meal times, recognizing emotional eating, increasing daily activity, learning the language of CBT, identifying automatic thoughts, restructuring thoughts, identifying cues and consequences, chaining, surfing the urge, and preventing relapses. Therapy sessions include a didactic section followed by group interaction and discussion. All group sessions are audiotaped and monitored."
3329383|NCT00050037|No Intervention|Waiting List|Participants in the wait list control group undergo an initial assessment but receive no active intervention for 10 weeks. After 10 weeks, these patients undergo post-treatment assessment and are offered the opportunity to either enter group treatment in an eating disorders program or enter other appropriate treatment. Three-month follow-up data are not collected from these individuals.
3329384|NCT00050011|Experimental|Zoledronic Acid upfront|Participants in the upfront arm received zoledronate 4 mg i.v. on Day 1 and every 6 months until disease progression (recurrence) or the end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.
3329385|NCT00050011|Experimental|Zoledronate delayed-start|In lieu of a placebo arm, which was considered unethical for this trial, a delayed start arm was used. Participants who met certain clinical criteria indicating risk of lumbar spine or total hip fracture, or experienced clinical fracture unrelated to trauma or any asymptomatic fracture discovered at the Month 36 scheduled visit, were started on zoledronate 4 mg i.v. and for every 6 months until disease progression (recurrence) or end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.
3329386|NCT00049842|Experimental|PEG-Intron (peginterferon alfa-2b) 0.5 µg/kg Weekly (QW)|PEG-Intron 0.5 µg/kg Weekly (QW) subcutaneously (SC) as maintenance therapy for 36 months with 4-week follow-up
3329387|NCT00049842|No Intervention|Untreated Control|
3329388|NCT00049816|No Intervention|1|Participants will receive no intervention and will act as the control group.
3329389|NCT00049816|Experimental|2|Participants will partake in a walking exercise program.
3329390|NCT00049816|Experimental|3|Participants will partake in a cycling exercise program.
3329391|NCT00049764|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
3329392|NCT00049764|Placebo Comparator|2|0.9% sodium chloride
3329393|NCT00048932|Active Comparator|Double-blind abatacept|Participants received a fixed dose of abatacept approximating 10 mg/kg (500 mg for participants < 60 kg, 750 mg for participants 60 to 100 kg and 1 g for participants > 100 kg). Abatacept was administered intravenously (IV) on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period
3329394|NCT00048932|Placebo Comparator|Double-blind Placebo|Participants received Placebo (dextrose 5% water [D5W] for injection U.S.P or normal saline [NS]) for IV infusion administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.
3329395|NCT00048932|Active Comparator|Open-label Abatacept|Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.
3329396|NCT00048854|Active Comparator|1|Participants will receive treatment as usual
3329397|NCT00048854|Experimental|2|Participants will take sertraline
3329398|NCT00048828|Active Comparator|1|
3329399|NCT00048828|Active Comparator|2|
3329400|NCT00048815|Active Comparator|citalopram|Subjects in this arm received 20mg/day of citalopram taken orally for 12 weeks.
3329401|NCT00048815|Experimental|St. John's Wort|Subjects in this arm received 810 mg/day of St. John's Wort taken orally (in three tablets of 270mg each) for 12 weeks.
3329402|NCT00048815|Placebo Comparator|Placebo|Subjects in this arm received double-dummy (look-alike) placebo for 12 weeks.
3329403|NCT00048581|Active Comparator|Abatacept|Short Term Portion of Study
3329404|NCT00048581|Placebo Comparator|Placebo|Short Term Portion of Study
3329405|NCT00048581|Active Comparator|Abatacept (Long Term)|"Long Term Portion of Study:~All participants receive Active Drug"
3329406|NCT00048568|Experimental|Abatacept + Methotrexate|Short Term: Abatacept was dosed by weight with participants weighing < 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants > 100 kg received abatacept 1 g. Participants continued treatment with methotrexate (MTX) either orally or parenterally at a minimum dose of 15 mg.
3329407|NCT00048568|Active Comparator|Placebo + Methotrexate|Short Term: Participants received a placebo solution intravenously and methotrexate at the dose employed prior to study enrollment and a minimum of 15 mg.
3329652|NCT00041509|Placebo Comparator|Placebo|
3329408|NCT00048568|Experimental|Abatacept + Methotrexate Open Label|Open Label: Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing < 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants > 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.
3329409|NCT00048750|Experimental|1|
3329410|NCT00048750|Placebo Comparator|2|
3329411|NCT00048737|Experimental|90Y Zevalin in ASCT|Allogeneic Stem Cell (AST) Transplantation with 90Y Zevalin/Cyclophosphamide/Fludarabine as a preparative regimen.
3329412|NCT00048724|Experimental|PegIntron|PegIntron (peginterferon alfa-2b) 0.5 µg/kg subcutaneously once weekly as maintenance therapy for 60 months with a 4-week post-treatment follow-up
3329413|NCT00048724|No Intervention|Untreated Control|
3329414|NCT00048672|Experimental|Gleevec|Gleevec 400 mg orally daily. Dose adjustments made at discretion of treating physician within these guidelines: The highest dose acceptable is 800 mg daily. The lowest dose acceptable is 300 mg. No dose adjustment of more than 200 mg at one time is allowed. Dose adjustments to less than 300 mg may be approved after consultation with the principal investigator.
3329415|NCT00048646|Placebo Comparator|placebo|placebo
3329416|NCT00048646|Experimental|IV progesterone|IV progesterone
3329417|NCT00048633|Experimental|Tariquidar|
3329418|NCT00048555|Experimental|1|
3329419|NCT00048542|Experimental|Double-Blind Adalimumab + MTX|Subjects who were inadequate responders to MTX and were adalimumab responders during the Open-Label Lead-In (OL-LI) phase received adalimumab plus concomitant MTX during the Double-Blind Phase. MTX-treated inadequate responders must have had active disease on MTX treatment for at least 3 months prior to screening.
3329420|NCT00048542|Placebo Comparator|Double-Blind Placebo + MTX|Subjects who were inadequate responders to MTX and were adalimumab responders during the Open-Label Lead-In (OL-LI) phase received placebo plus concomitant MTX during the Double-Blind Phase. MTX-treated inadequate responders must have had active disease on MTX treatment for at least 3 months prior to screening.
3329421|NCT00048542|Experimental|Double-Blind Adalimumab|Subjects in the non-methotrexate (MTX) stratum who were either naïve to MTX or withdrawn from MTX at least 2 weeks prior to study drug administration, and were adalimumab responders during the OL-LI phase, received adalimumab, but no concomitant MTX treatment, during the Double-Blind Phase.
3329422|NCT00048542|Placebo Comparator|Double-Blind Placebo|Subjects in the non-methotrexate (MTX) stratum who were either naïve to MTX or withdrawn from MTX at least 2 weeks prior to study drug administration, and were adalimumab responders during the OL-LI phase, received placebo, but no concomitant MTX treatment, during the Double-Blind Phase.
3329423|NCT00048542|Experimental|OLE BSA Adalimumab + MTX|All subjects received subcutaneous injections of 24 mg adalimumab per square meter of body surface area (BSA) up to a maximum of 40 mg total body dose every other week (eow), concomitantly with MTX treatment, during the Open-Label Extension (OLE) BSA Phase of the study.
3329424|NCT00048542|Experimental|OLE BSA Adalimumab|All subjects received subcutaneous injections of 24 mg adalimumab per square meter of body surface area (BSA) up to a maximum of 40 mg total body dose every other week (eow), but not MTX treatment, during the Open-Label Extension (OLE) BSA Phase of the study.
3329425|NCT00048542|Experimental|OLE FD Adalimumab + MTX|Subjects received adalimumab concomitantly with MTX treatment during the Open-Label Extension (OLE) Fixed Dose (FD) Phase of the study in which only body weight (not BSA) determined dosing; subjects weighing less than 30 kg were dosed with 20 mg of adalimumab SC eow, and subjects weighing 30 kg or more were dosed with 40 mg of adalimumab SC eow.
3329426|NCT00048542|Experimental|OLE FD Adalimumab|Subjects received placebo without concomitant MTX treatment during the Open-Label Extension (OLE) Fixed Dose (FD) Phase of the study in which only body weight (not BSA) determined dosing; subjects weighing less than 30 kg were dosed with 20 mg of adalimumab SC eow, and subjects weighing 30 kg or more were dosed with 40 mg of adalimumab SC eow.
3329427|NCT00048347|Experimental|Avonex|Interferon-beta1a (Avonex) 30 µg IM every week for 12 weeks
3329428|NCT00048165|Experimental|Daclizumab|Daclizumab will be administered as a intravenous dose of 1 milligrams per kilogram [mg/kg] on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg, and 500-1000 mg IV methylprednisolone peri operative switch to oral at 0.5-1 mg/kg/day followed by tapering.
3329429|NCT00048165|Placebo Comparator|Placebo|Matching placebo will be administered on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg orally, and 500-1000 mg IV methylprednisolone peri-op switch to oral at 0.5-1 mg/kg/day followed by tapering.
3329430|NCT00048152|Experimental|1|
3329431|NCT00048152|Experimental|2|
3329432|NCT00048152|Experimental|3|
3329433|NCT00048139|Experimental|1|
3329434|NCT00048126|Experimental|1|
3329435|NCT00048100|Experimental|Apheresis + Transplant|Skin biopsy & either a leukodepletion apheresis or an additional marrow aspiration prior to marrow or stem cell transplantation.
3329436|NCT00048087|Experimental|Iressa + Docetaxel|
3329437|NCT00048074|Experimental|1|oral placebo daily and IV ibandronate 2 mg q 2 mo
3329438|NCT00048074|Experimental|2|oral ibandronate 2.5 mg daily and IV placebo q 2 mo and q 3 mo
3329439|NCT00048074|Experimental|3|oral placebo daily and IV ibandronate 3 mg q 3 mo
3329440|NCT00048061|Active Comparator|Ibandronate 2.5 mg|Participants will receive 2.5 milligram (mg) ibandronate Per oral (PO) daily and an oblong placebo tablet PO monthly. Participants will also receive calcium 500 mg /day and vitamin D 400 international units (IU)/day .
3329441|NCT00048061|Experimental|Ibandronate 50/50 mg|Participants will receive 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day.
3329442|NCT00048061|Experimental|Ibandronate 100 mg|Participants will receive 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day
3329443|NCT00048061|Experimental|Ibandronate 150 mg|Participants will receive 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day
3329920|NCT00031096|Placebo Comparator|Arm 2|
3329444|NCT00048048|Experimental|Cohort 1 (RO0503821, 0.15 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) at a dose of 0.15 microgram per kilogram (mcg/kg) subcutaneously (SC) once every week to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
3329445|NCT00048048|Experimental|Cohort 2 (RO0503821, 0.3 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 at a dose of 0.3 mcg/kg SC once every week to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
3329446|NCT00048048|Experimental|Cohort 3 (RO0503821, 0.6 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 at a dose of 0.6 mcg/kg SC once every week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
3329447|NCT00048048|Experimental|Cohort 4 (RO0503821, 0.3 mcg/kg 1x/2 Week)|Eligible participants will be receiving RO0503821 at a dose of 0.3 mcg/kg SC once every two week, to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
3329448|NCT00048048|Experimental|Cohort 5 (RO0503821, 0.6 mcg/kg 1x/2Week)|Eligible participants will be receiving RO0503821 at a dose of 0.6 mcg/kg SC once every two week, to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
3329449|NCT00048048|Experimental|Cohort 6 (RO0503821, 1.2 mcg/kg 1x/2 Week)|Eligible participants will be receiving RO0503821 at a dose of 1.2 mcg/kg SC once every two week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
3329450|NCT00048048|Experimental|Cohort 7 (RO0503821, 0.45 mcg/kg 1x/3 Week)|Eligible participants will be receiving RO0503821 at a dose of 0.45 mcg/kg SC once every three week, to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
3329451|NCT00048048|Experimental|Cohort 8 (RO0503821, 0.9 mcg/kg 1x/3Week)|Eligible participants will be receiving RO0503821 at a dose of 0.9 mcg/kg SC once every three week, to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
3329452|NCT00048048|Experimental|Cohort 9 (RO0503821,1.8 mcg/kg 1x/3 Week)|Eligible participants will be receiving RO0503821 at a dose of 1.8 mcg/kg SC once every three week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
3329453|NCT00048035|Experimental|Cohort 1 (RO0503821 [0.25/150 1x/week])|Eligible participant will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) intravenously (IV) using a dose conversion factor of 0.25/150 microgram (mcg)/kilogram (kg) of the previous weekly erythropoiesis stimulating agents (ESA) dose, (equal to 62.50% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3329454|NCT00048035|Experimental|Cohort 2 (RO0503821 [0.25/150 1x/2week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.25/150 mcg/kg of the previous weekly ESA dose, (equal to 62.50% assumed equi-effective dose) once in every two weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3329455|NCT00048035|Experimental|Cohort 3 (RO0503821 [0.4/150 1x/week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.40/150 mcg/kg of the previous weekly ESA dose, (equal to100% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3329456|NCT00048035|Experimental|Cohort 4 (RO0503821 [0.4/150 1x/2week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.40/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once in every two weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3329457|NCT00048035|Experimental|Cohort 5 (RO0503821 [0.6/150 1x/week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.60/150 mcg/kg of the previous weekly ESA dose, (equal to150% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3329458|NCT00048035|Experimental|Cohort 6 (RO0503821 [0.6/150 1x/2week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.60/150 mcg/kg of the previous weekly ESA dose, (equal to150% assumed equi-effective dose) once in every two weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3329459|NCT00047983|No Intervention|Control|Controls and will receive no dietary supplements
3329460|NCT00047983|Experimental|Arginine and Canola Oil|Daily nutritional supplements of arginine and canola oil
3329461|NCT00047983|Experimental|Arginine and Coromega|Daily nutritional supplements of arginine and Coromega
3329462|NCT00047827|Experimental|1|
3329463|NCT00047879|Other|Glioblastoma multiforme stratum|Glioblastoma multiforme is one of the most common and aggressive types of brain tumor.
3329653|NCT00041496|Experimental|Arm 1|Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or placebo
3329464|NCT00047879|Other|Anaplastic Glioma Stratum|Anaplastic glioma is a type of brain tumor that develops from star-shaped glial cells that support nerve cells. Anaplastic oligodendroglioma is a malignant type of brain tumor sensitive to treatment with chemotherapy and radiotherapy.
3329465|NCT00047554||TRAVATAN|Travoprost, 0.004% ophthalmic solution, 1 drop to the study eye once daily in the evening for up to 5 years
3329466|NCT00047710|Experimental|Bevacizumab|Radiation, Bevacizumab, and Capecitabine
3329467|NCT00047697|Experimental|Donepezil HCl|Donepezil HCL 5 mg and 10 mg
3329468|NCT00047697|Placebo Comparator|Placebo|Placebo
3329469|NCT00047671|Active Comparator|Citalopram|All subjects receive an FDA approved dose of Citalopram
3329470|NCT00047619|Experimental|Pulsatile lavage group|pulsatile lavage therapy
3329471|NCT00047619|Sham Comparator|Sham lavage group|sham pulsatile lavage
3329472|NCT00047502|Experimental|Gleevec + SCH 66336|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day, and SCH66336 100 mg by mouth twice a day."
3329473|NCT00047463|Active Comparator|CPAP active comparator|continuous positive airway pressure (CPAP)
3329474|NCT00047463|Placebo Comparator|CPAP Placebo|Placebo-CPAP
3329475|NCT00047450|Placebo Comparator|1|Participants will take placebo
3329476|NCT00047450|Active Comparator|2|Participants will take citalopram (Celexa)
3329477|NCT00047437|Active Comparator|2|
3329478|NCT00047437|No Intervention|1|
3329479|NCT00047411|Active Comparator|1|Intervention: Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines.
3329480|NCT00047411|Experimental|2|Use of the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
3329481|NCT00046735|Experimental|1|
3329482|NCT00046631||Adolescent girls|Chosen from 6 schools in 6 cities
3329483|NCT00046566|Active Comparator|Soy protein-milk protein-carbohydrate|Participants received 40 grams of soy protein daily for 8 weeks, 40 grams of milk protein daily for 8 weeks, and 40 grams of carbohydrate daily for 8 weeks.
3329484|NCT00046566|Experimental|Milk protein-carbohydrate-soy protein|Participants received 40 grams of milk protein daily for 8 weeks, 40 grams of carbohydrate daily for 8 weeks, and 40 grams of soy protein daily for 8 weeks.
3329485|NCT00046566|Placebo Comparator|Carbohydrate-soy protein-milk protein|Participants received 40 grams of complex carbohydrate daily for 8 weeks, 40 grams of soy protein daily for 8 weeks, and 40 grams of milk protein daily for 8 weeks.
3329486|NCT00046228|Experimental|001|Abciximab; reteplase; abciximab placebo; abciximab 0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
3329487|NCT00046228|Experimental|002|abciximab; reteplase placebo; abciximab placebo; abciximab 0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
3329488|NCT00046228|Experimental|003|abciximab placebo; reteplase placebo, abciximab, abciximab placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
3329489|NCT00046189||1|Family members from XP families with known DNA repair gene mutations
3329490|NCT00046111|Experimental|Primary Group|40 subjects on medium doses of Topotecan and tested for bioequivalence for 4 weeks.
3329491|NCT00046085|Active Comparator|Patient customary care|12 months of patient customary care
3329492|NCT00046085|Experimental|Online family education|12 months of patient customary care and relative access to online education and support program
3329493|NCT00045968|Active Comparator|treatment cohort|
3329494|NCT00045968|Placebo Comparator|Placebo Chohort|Autologous PBMC
3329495|NCT00045942|Experimental|PKC412 (Core)|Participants received 75 mg PKC412 three time daily (tid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
3329496|NCT00045942|Experimental|FLT3 mutated PKC412 100 mg/day (E1)|Participants received 50 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
3329497|NCT00045942|Experimental|FLT3 mutated PKC412 200 mg/day (E1)|Participants received 100 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
3329498|NCT00045942|Experimental|FLT3 wild type PKC412 100 mg/day (E1)|Participants received 50 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
3329499|NCT00045942|Experimental|FLT3 wild type PKC412 200 mg/day (E1)|Participants received 100 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
3329500|NCT00045942|Experimental|FLT3 mutated PKC412 dose escalation|Participants were treated with PKC412 orally starting at a dose of 100 mg bid. A dose increase up to 300 mg bid was allowed. Participants were treated until time of disease progression, doubling of the bone marrow blast percentage from baseline, or the occurrence of unacceptable toxicity.
3329501|NCT00045942|Experimental|FLT3 mutated PKC+Itraconazole (E2)|Within a cycle of 28 days, participants received a loading dose of PKC412 100 mg bid on days 1-2, followed by PKC412 50 mg bid for 3 weeks from days 3-21. On day 22, itraconazole 100 mg bid was added to the treatment regimen. The combinations of PKC412 and Itraconazole continued until disease progression, unacceptable toxicity, or withdrawal of consent.
3329502|NCT00045942|Experimental|FLT3 wild type PKC412 dose escalation (E2)|Participants were treated with PKC412 orally starting at a dose of 100 mg bid. A dose increase up to 300 mg bid was allowed. Participants were treated until time of disease progression, doubling of the bone marrow blast percentage from baseline, or the occurrence of unacceptable toxicity.
3329503|NCT00045942|Experimental|FLT3 wild type PKC+Itraconazole (E2)|Within a cycle of 28 days, participants received a loading dose of PKC412 100 mg bid on days 1-2, followed by PKC412 50 mg bid for 3 weeks from days 3-21. On day 22, itraconazole 100 mg bid was added to the treatment regimen. The combinations of PKC412 and Itraconazole continued until disease progression, unacceptable toxicity, or withdrawal of consent.
3329504|NCT00045916|Experimental|High dosage ECT + nortriptyline|Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
3329505|NCT00045916|Experimental|High dosage ECT + venlafaxine|Participants will receive venlafaxine and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
3329506|NCT00045916|Placebo Comparator|High dosage ECT + placebo|Participants will receive placebo and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.
3329507|NCT00045916|Experimental|Low dosage ECT + nortriptyline|Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
3329508|NCT00045916|Experimental|Low dosage ECT + venlafaxine|Participants will receive venlafaxine and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
3329509|NCT00045916|Experimental|Low dosage ECT + placebo|Participants will receive placebo and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.
3329510|NCT00045903|Experimental|Exposure and Ritual Prevention|Exposure and Ritual Prevention Therapy
3329511|NCT00045903|Active Comparator|Stress Management|Stress Management Therapy
3329512|NCT00045799|Experimental|Omeprazole sodium bicarbonate immediate release PWD/FS|
3329513|NCT00045799|Active Comparator|Cimetidine IV|
3329514|NCT00045786|Experimental|400 mg CC-1088|
3329515|NCT00045786|Experimental|800 mg CC-1088|
3329516|NCT00045786|Experimental|1200 mg CC-1088|
3329517|NCT00045786|Experimental|1500 mg CC-1088|
3329518|NCT00045773||1|
3329519|NCT00044915|Active Comparator|Arm 1|
3329520|NCT00044915|Placebo Comparator|Arm 2|
3329521|NCT00044863|Experimental|1|Patients with metastatic EGFR-positive colorectal carcinoma
3329522|NCT00044798|Experimental|1|Participants will receive treatment with repetitive transcranial magnetic stimulation and citalopram.
3329523|NCT00044798|Active Comparator|2|Participants will receive treatment with sham repetitive transcranial magnetic stimulation and citalopram.
3329524|NCT00044707|Active Comparator|Pramlintide acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide injection is 0.6 mg/mL
3329525|NCT00044707|Placebo Comparator|Placebo|Placebo solution is the same, sterile preserved formulation, except the active ingredient, pramlintide, is omitted
3329526|NCT00044694|Placebo Comparator|Placebo 0.01 mL|2 week placebo lead-in followed by Placebo 0.01 mL
3329527|NCT00044694|Placebo Comparator|Placebo 0.02 mL|2 week placebo lead-in followed by Placebo 0.02 mL
3329528|NCT00044694|Placebo Comparator|Placebo 0.03 mL|2 week placebo lead-in followed by Placebo 0.03 mL
3329529|NCT00044694|Placebo Comparator|Placebo 0.04 mL|2 week placebo lead-in followed by Placebo 0.04 mL
3329530|NCT00044694|Experimental|AC2993 2.5 mcg|2 week placebo lead-in (0.01 mL) followed by AC2993 2.5 mcg; 0.01 mL
3329531|NCT00044694|Experimental|AC2993 5.0 mcg|2 week placebo lead-in followed by AC2993 5.0 mcg; 0.01 mL
3329532|NCT00044694|Experimental|AC2993 7.5 mcg|2 week placebo lead-in followed by AC2993 7.5 mcg; 0.03 mL
3329533|NCT00044694|Experimental|AC2993 10.0 mcg|2 week placebo lead-in period followed by AC2993 10.0 mcg; 0.04 mL
3329534|NCT00044668|Experimental|AC2993|5 μg AC2993, twice daily, for 4 weeks followed by 10 μg AC2993, twice daily, during a maintenance period
3329535|NCT00044655|Active Comparator|Stay on baseline medication prescribed|Participants will continue taking medication prescribed at study entry: 1) either long-acting injectable haloperidol or fluphenazine, OR 2) two antipsychotic medications which might include a combination of any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.
3329536|NCT00044655|Active Comparator|Switch per study protocol|Participants will change medications from medication prescribed at study entry, either: 1) long-acting injectable risperidone, OR 2) one of the two antipsychotic medications prescribed at baseline which may include any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.
3329537|NCT00044629|Experimental|Cognitive Behavioral Therapy and Ambien|Cognitive Behavioral Therapy and Ambien
3329538|NCT00044629|Placebo Comparator|Cognitive Behavioral Therapy and Placebo|Cognitive Behavioral Therapy and Placebo
3329539|NCT00044629|Active Comparator|Cognitive Behavioral Therapy alone (no drug)|Cognitive Behavioral Therapy alone (no drug)
3329540|NCT00044590||Cases|Patients with Parkinson's Disease
3329541|NCT00044590||Controls|Controls, subjects without Parkinson's Disease
3329542|NCT00044564|Experimental|Arm 1|
3329543|NCT00044551|Experimental|Arm 1|
3329544|NCT00044538|Experimental|Arm 1|
3329545|NCT00044525|Experimental|Arm 1|
3329546|NCT00044512|Experimental|Sorafenib 400 mg b.i.d.|Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)
3329547|NCT00044291|Experimental|Atamestane + toremifene|
3329548|NCT00044291|Active Comparator|Letrozole + placebo|
3329549|NCT00044213|Active Comparator|EDTA + high dose vitamin|Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.
3329550|NCT00044213|Placebo Comparator|EDTA + high dose vitamin placebo|Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.
3329551|NCT00044213|Placebo Comparator|EDTA placebo + high dose vitamin|Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.
3329552|NCT00044213|Placebo Comparator|EDTA placebo + high dose vitamin placebo|Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.
3329553|NCT00044044|Experimental|Lurasidone 20 mg|Lurasidone 20 mg tablets
3329554|NCT00044044|Experimental|Lurasidone 40 mg|Lurasidone 40 mg tablets
3329555|NCT00044044|Experimental|Lurasidone 80 mg|Lurasidone 2 40 mg tablets
3329556|NCT00044044|Active Comparator|Haloperidol 10mg|Haloperidol 10mg tablets
3329557|NCT00044044|Placebo Comparator|Placebo|Matching Placebo to Lurasidone and Haloperidol
3329558|NCT00044031|Placebo Comparator|B|Placebo (immunogen vehicle) combined with gemcitabine.
3329559|NCT00044031|Experimental|A|500 µg G17DT immunogen combined with gemcitabine.
3329566|NCT00043979|Experimental|Arm 2 - Recipients|Recipients (n=30) were enrolled to receive peripheral blood stem cells (PBSC) and receive either cyclosporine or tacrolimus and sirolimus for graft versus host disease (GVHD) prophylaxis.
3329567|NCT00043823|Experimental|Avastin + Tarceva|Combination Therapy (Avastin + Tarceva) = Avastin IV Day 1 of each 21-day cycle + oral Tarceva daily.
3329568|NCT00043810|Experimental|Gelonin Purging of ASCT|Gelonin Purging of Autologous Stem Cells for Transplantation (ASCT) + Fludara/Busulfan
3329569|NCT00043693|Experimental|1|Participants will undergo the Family Intervention for Dual Diagnosis (FIDD) program.
3329570|NCT00043693|Active Comparator|2|Participants will be placed in a family psychoeducation program.
3329571|NCT00043745|Experimental|1|Participants will receive moderate dose soy isoflavone (80 mg/day) tablets, extracted from soy protein
3329572|NCT00043745|Experimental|2|Participants will receive high dose soy isoflavone (120 mg/day) tablets, extracted from soy protein
3329573|NCT00043745|Placebo Comparator|3|Participants will receive soy extract devoid of isoflavones to serve as placebo
3329574|NCT00043602|Experimental|1|Participants will receive clinician-managed interpersonal psychotherapy
3329575|NCT00043602|Active Comparator|2|Participants will receive standard interpersonal psychotherapy
3329576|NCT00043550|Experimental|1 Sertraline/Venlafaxine|Participants receive sertraline for the first 8 weeks. Participants will receive venlafaxine if they do not respond to sertraline by week 8
3329577|NCT00043550|Active Comparator|2 Supportive Expressive Therapy|Participants will receive supportive-expressive psychotherapy.
3329578|NCT00043550|Placebo Comparator|3 Pill Placebo|Participants receive placebo.
3329579|NCT00043537|Experimental|Social Effectiveness Therapy for Children|Social Effectiveness Therapy for Children includes social skills training, peer generalization experiences and exposure therapy
3329580|NCT00043537|Experimental|Fluoxetine|Fluoxetine given in 10mg doses, up to 40 mg as tolerated
3329581|NCT00043537|Placebo Comparator|Pill placebo|"Capsules identical to fluoxetine given in 10 mg. doses up to 40 mg."
3329582|NCT00043420|Experimental|Phase I: 0.08 mg/kg|Escalating dose groups: 0.08 mg/kg PF-3512676 Injection
3329583|NCT00043420|Experimental|Phase I: 0.16 mg/kg|Escalating dose groups: 0.16 mg/kg PF-3512676 Injection
3329584|NCT00043420|Experimental|Phase I: 0.24 mg/kg|Escalating dose groups: 0.24 mg/kg PF-3512676 Injection
3329585|NCT00043420|Experimental|Phase I: 0.28 mg/kg|Escalating dose groups: 0.28 mg/kg PF-3512676 Injection
3329586|NCT00043420|Experimental|Phase I: 0.32 mg/kg|Escalating dose groups: 0.32 mg/kg PF-3512676 Injection
3329587|NCT00043420|Experimental|Phase I: 0.36 mg/kg|Escalating dose groups: 0.36 mg/kg PF-3512676 Injection
3329588|NCT00043420|Experimental|Phase II: 10 mg|Phase II: 10 mg flat dose (random assignment in Phase II)
3329589|NCT00043420|Experimental|Phase II: 25 mg|Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
3329590|NCT00043407|Experimental|CPG 7909 Injection|
3329591|NCT00043394|Experimental|Cohort 1|0.04 mg/kg CpG 7909
3329592|NCT00043394|Experimental|Cohort 2|0.08 mg/kg CpG 7909
3329593|NCT00043394|Experimental|Cohort 3|0.12 mg/kg CpG 7909 Injection once weekly
3329594|NCT00043394|Experimental|Cohort 4|0.16 mg/kg CpG 7909
3329595|NCT00043368|Experimental|1|Patients will be treated with the same dosing regimen and schedule of PF-3512676 Injection with which they were treated at the end of the previous PF-3512676 Injection trial. Any proposed changes to their schedule/regimen will be at the discretion of the treating physician, following consultation with Coley.
3329596|NCT00043186|Placebo Comparator|Placebo|Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.
3329597|NCT00043186|Experimental|Denosumab 6 mg every 3 months|Participants received denosumab 6 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
3329598|NCT00043186|Experimental|Denosumab 14 mg every 3 months|Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
3329599|NCT00043186|Experimental|Denosumab 30 mg every 3 months|Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.
3329600|NCT00043186|Experimental|Denosumab 14 mg every 6 months|Participants received denosumab 14 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
3329601|NCT00043186|Experimental|Denosumab 60 mg every 6 months|Participants received denosumab 60 mg SC every 6 months until Month 42.
3329602|NCT00043186|Experimental|Denosumab 100 mg every 6 months|Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
3329603|NCT00043186|Experimental|Denosumab 210 mg every 6 months|Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.
3329604|NCT00043186|Active Comparator|Alendronate 70 mg|Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.
3329605|NCT00042653|Experimental|AMG 073|AMG 073
3329606|NCT00042653|Placebo Comparator|Placebo|Placebo
3329607|NCT00042601|Placebo Comparator|Placebo|A clear, colorless, sterile solution for SC injection manufactured by Amylin Pharmaceuticals, Inc. Placebo solution is the same, sterile preserved formulation, except the active ingredient, pramlintide, is omitted.
3329608|NCT00042601|Active Comparator|Pramlintide|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection manufactured by Amylin Pharmaceuticals, Inc. It consists of pramlintide (AC137) 0.6 mg/mL in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative.
3329609|NCT00042614||Patients|Who have had heart transplants, awaiting, or controls screened.
3329610|NCT00042614||Controls|Matched to patients for age, gender and race
3329654|NCT00041496|Placebo Comparator|Arm 2|Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or Placebo
3329611|NCT00042510|Experimental|Treatment Group|500µg G17DT administered on Weeks 1, 5 and 9 and an additional treatment at Week 25. Cisplatin was administered every 4 weeks on the first day of each treatment cycle as a 1 to 3 hour intravenous infusion at a dose of 100mg/m^2. 5-FU was administered every 4 weeks during the first 5 days of each cycle as a continuous intravenous infusion at a dose of 1,000 mg/m^2/d.
3329612|NCT00042471|Experimental|Pramlintide acetate (AC137) injection|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
3329613|NCT00042458|Placebo Comparator|Placebo|Placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.Ingredients: D-Mannitol 43.0 mg/mL Metacresol 2.25 mg/mL Glacial acetic acid 1.53 mg/mL Sodium acetate trihydrate 0.61 mg/mL pH 4.0 Water for injection qs to 5.0 mL
3329614|NCT00042458|Active Comparator|Pramlintide Acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide injection is 0.6 mg/mL
3329615|NCT00042432|Experimental|cinacalcet (AMG 073)|
3329616|NCT00042432|Placebo Comparator|Placebo|
3329617|NCT00042406|Placebo Comparator|Placebo|
3329618|NCT00042406|Experimental|HuMax-CD4 80 mg|80 mg
3329619|NCT00042406|Experimental|HuMax-CD4 160 mg|160 mg
3329620|NCT00042289|Experimental|Women taking ARVs without TB treatment|"HIV-infected pregnant women will be assigned to this arm if receiving one or more of the following ARV drugs/drug combinations but not receiving TB treatment: atazanavir/cobicistat, darunavir/ritonavir, darunavir/cobicistat, etravirine, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF/cobicistat, TAF/ritonavir, efavirenz, or lopinavir/ritonavir.~Note: As of February 2016, the study will no longer enroll women receiving etravirine or increased dose lopinavir/ritonavir."
3329621|NCT00042289|Experimental|Women taking ARVs with TB treatment|"HIV-infected pregnant women will be assigned to this arm if receiving efavirenz, lopinavir/ritonavir, or nevirapine and TB treatment with at least one of the following TB drugs at study entry: rifampicin, ethambutol, isoniazid, or pyrazinamide.~Note: As of February 2016, the study will no longer enroll women receiving nevirapine."
3329622|NCT00042289|Experimental|Women taking no ARVs with TB treatment|HIV-uninfected pregnant women will be assigned to this arm if receiving at least two of the following first-line TB drugs at study entry: ethambutol, isoniazid, pyrazinamide, or rifampicin.
3329623|NCT00042289|Experimental|Women with/without ARVs w/TB treatment for drug-resistant TB|HIV-infected and HIV-uninfected pregnant women with or without ARVs will be assigned to this arm if receiving at least two of the following second-line TB drugs at study entry: kanamycin, amikacin, capreomycin, moxifloxacin, levofloxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose isoniazid (INH), bedaquiline, clofazamine, delamanid, linezolid, or pretomanid.
3329624|NCT00042289|Experimental|Women taking ARVs with postpartum hormonal contraceptives|"HIV-infected women 2-12 weeks postpartum will be assigned to this arm if receiving one of the following ARV drug combinations and starting postpartum contraceptives: atazanavir/ritonavir/tenofovir, darunavir/cobicistat, atazanavir/cobicistat, or efavirenz AND starting combined oral contraceptives formulated with ethinyl estradiol; or atazanavir/ritonavir/tenofovir, efavirenz, atazanavir/cobicistat, or darunavir/cobicistat AND starting etonogestrel implant.~Note: As of February 2016, the study will no longer enroll women receiving atazanavir/ritonavir/tenofovir or efavirenz AND starting etonogestrel implant."
3329625|NCT00041483|Active Comparator|Anecortave and Sham PDT|
3329626|NCT00041483|Active Comparator|PDT and Sham Anecortave Acetate|
3329627|NCT00042224|Experimental|1 ECT plus clozapine|Electroconvulsive therapy ECT plus clozapine for 8 weeks
3329628|NCT00042224|Active Comparator|2 Clozapine|Clozapine for 8 weeks
3329629|NCT00042211|Experimental|1|Problem Solving Treatment
3329630|NCT00042211|Active Comparator|2|Control
3329631|NCT00042198|Experimental|1|Cognitive Behavior Therapy. The treatment modality was individual, face-to-face therapy with an experienced cognitive therapist. Treatment consisted of up to 12 weekly, hour-long sessions.
3329632|NCT00042198|Active Comparator|2|Supportive Stress Management. The treatment modality was individual, face-to-face therapy with an experienced psychotherapist. Treatment consisted of up to 12 weekly, hour-long sessions.
3329633|NCT00042198|No Intervention|3|Usual Care, minimally enhanced. Participants in all three arms were given information about depression. There were no restrictions in any of the arms on usual care for depression, heart disease, or any other conditions, except that concurrent participation in nonstudy psychotherapy was not allowed. Participants were allowed to continue or start on nonstudy antidepressants during the study, as prescribed by the participant's personal physician.
3329634|NCT00042185|Experimental|Dissonance intervention|
3329635|NCT00042185|Active Comparator|Healthy Weight Intervention|
3329636|NCT00042185|Active Comparator|Expressive writing control intervention|
3329637|NCT00042185|No Intervention|Assessment-only control condition|
3329638|NCT00041951||CAE participants|Both parents and a child with CAE of families without other affected members (trios) or whole families with many members affected with epilepsy.
3329639|NCT00041951||Controls|Healthy individuals without epilepsy and no family history of epilepsy.
3329640|NCT00041938|Active Comparator|aspirin|Aspirin: 325 mg per day
3329641|NCT00041938|Active Comparator|warfarin|Warfarin: International Normalized Ratio (INR) 2.5-3.0; target INR 2.75
3329642|NCT00041782|Experimental|Dalteparin|
3329643|NCT00041756|Placebo Comparator|Placebo|Placebo tablet
3329644|NCT00041756|Experimental|25 mg PG-530742|25 mg PG-530742
3329645|NCT00041756|Experimental|50 mg PG-530742|50 mg PG-530742
3329646|NCT00041756|Experimental|100 mg PG-530742|100 mg PG-530742
3329647|NCT00041756|Experimental|200 mg PG-530742|200 mg PG-530742
3329648|NCT00041717|Active Comparator|fampridine-SR 50mg/day|
3329649|NCT00041717|Placebo Comparator|Placebo|
3329650|NCT00041509|Experimental|SB424323, 500 mg BID|
3329651|NCT00041509|Experimental|SB424323, 125 mg BID|
3329655|NCT00041574|Experimental|1|Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
3329656|NCT00041561|Placebo Comparator|2|Nitrogen gas
3329657|NCT00041561|Experimental|1|Inhaled Nitric Oxide
3329658|NCT00041548|Experimental|1|Nitric Oxide for Inhalation
3329659|NCT00041548|Placebo Comparator|2|oxygen
3329660|NCT00041470|Experimental|Weekly paclitaxel, vinorelbine and GCSF|"Weekly paclitaxel (50 mg/m2 IV) and weekly vinorelbine (20 mg/m2 IV) with daily G-CSF support and Herceptin for patients with HER-2/neu positive disease.~Paclitaxel weekly. Dose levels:~50 mg/m2, 60 mg/m2, 70 mg/m2, 80 mg/m2~Vinorelbine (Navelbine) administered one hour after paclitaxel, weekly. Dose levels:~20 mg/m2, 22.5 mg/m2, 25 mg/m2, 27.5 mg/m2~Patients who are HER-2+ and IV infusion. Herceptin 4 mg/kg IV given only on day 1 of the first cycle. Herceptin 2 mg/kg IV, maintenance dose will be given every week starting with week 2.~G-CSF (filgrastim, Neupogen) 5 mg/kg/day s.c., administered daily"
3329661|NCT00040677|Experimental|ICA-17043 Low Dose 6 mg/day|Active study medication: 100 mg loading dose; 6 mg maintenance dose per day
3329662|NCT00040677|Placebo Comparator|Placebo|
3329663|NCT00040677|Experimental|ICA-17043 High Dose 10 mg/day|Active study medication: 150 mg loading dose; 10 mg maintenance dose per day
3329664|NCT00040664|Experimental|2 to 5 years (FPV/RTV)|Two to five years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
3329665|NCT00040664|Experimental|6 to 11 years (FPV/RTV)|Six to twelve years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
3329666|NCT00040664|Experimental|12 to 18 years (FPV/RTV)|Twelve to Eighteen years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
3329667|NCT00041457||Physicians' Health Study I|
3329668|NCT00041457||Physicians' Health Study II|
3329669|NCT00041457||Women's Health Study|
3329670|NCT00041457||Women's Antioxidant Cardiovascular Health Study|
3329671|NCT00041392|Active Comparator|Magnesium|100 mg/kg magnesium
3329672|NCT00041392|Placebo Comparator|0.9 % saline|100 mg/kg 0.9 % saline
3329673|NCT00040456|Placebo Comparator|Placebo|"A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment."
3329674|NCT00040456|Active Comparator|MG Pidolate Administration|"A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment."
3329675|NCT00040443|Experimental|CX516|CX516 - 900 mg
3329676|NCT00040443|Placebo Comparator|Placebo|Placebo
3329677|NCT00040404|Experimental|CEP-1347 10mg|CEP-1347 was administered at a dosage of 10mg twice daily (bid); capsule strengths were 5, 12.5, and 25 mg. Each patient took 2 capsules at each dosing time, approximately 12 hours apart, within 30 minutes after the morning and evening meals) for a total of 4 capsules per day.Patients were randomly assigned to CEP-1347 or placebo treatment in a 1:1:1:1 ratio. A blocked randomization scheme was used to ensure approximately equal numbers of patients in each of the 4 treatment groups at each center.
3329678|NCT00040404|Experimental|CEP-1347 25mg|CEP-1347 was administered at a dosage of 25mg twice daily (bid); capsule strengths were 5, 12.5, and 25 mg. Each patient took 2 capsules at each dosing time, approximately 12 hours apart, within 30 minutes after the morning and evening meals) for a total of 4 capsules per day.Patients were randomly assigned to CEP-1347 or placebo treatment in a 1:1:1:1 ratio. A blocked randomization scheme was used to ensure approximately equal numbers of patients in each of the 4 treatment groups at each center.
3329679|NCT00040404|Experimental|CEP-1347 50mg|CEP-1347 was administered at a dosage of 50mg twice daily (bid); capsule strengths were 5, 12.5, and 25 mg. Each patient took 2 capsules at each dosing time, approximately 12 hours apart, within 30 minutes after the morning and evening meals) for a total of 4 capsules per day.Patients were randomly assigned to CEP-1347 or placebo treatment in a 1:1:1:1 ratio. A blocked randomization scheme was used to ensure approximately equal numbers of patients in each of the 4 treatment groups at each center.
3329680|NCT00040404|Placebo Comparator|Placebo|Placebo capsules matching the CEP-1347 capsules were administered in the same manner.
3329681|NCT00040378||Combination therapy|vitamin E (alphatocopherol) and selenium
3329682|NCT00040378||Vitamin E only|vitamine E (alphatocopherol) and placebo
3329683|NCT00040378||Selenium only|selenium and placebo (Placebo replacement for vitamin E)
3329684|NCT00040378||Placebo|placebo (Placebo replacement for vitamin E) and placebo (Placebo replacement for selenium)
3329685|NCT00040365|Experimental|Amifostine|1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).
3329686|NCT00040326|Active Comparator|1|anteromesial temporal resection
3329687|NCT00040326|Active Comparator|2|antiepileptic drugs
3329688|NCT00040105|Experimental|Zarnestra + Gleevec|
3329689|NCT00039988|Experimental|1|Participants will receive Copaxone and albuterol placebo
3329690|NCT00039988|Experimental|2|Participants will receive Copaxone and albuterol
3329691|NCT00039871|Experimental|Overall study population|
3329692|NCT00039832|Experimental|1|CT
3329693|NCT00039832|Experimental|2|MRI
3329694|NCT00039780|Active Comparator|1|Tavocept (BNP7787)
3329696|NCT00039741|Experimental|PI/1K|Two NRTIs plus a PI with a regimen change recommended at when viral load reaches 1000 copies/ml or higher
3329697|NCT00039741|Experimental|NNRTI/1K|2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 1,000 copies/ml or higher
3329698|NCT00039741|Experimental|PI/30K|2 NRTIs plus 1 PI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher
3329699|NCT00039741|Experimental|NNRTI/30K|2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher
3329700|NCT00039026|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
3329701|NCT00039026|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
3329702|NCT00039026|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
3329703|NCT00039026|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL / Placebo 0.02 mL / Placebo 0.04 mL
3329704|NCT00039013|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
3329705|NCT00039013|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
3329706|NCT00039013|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
3329707|NCT00039013|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL
3329708|NCT00038974|Experimental|Interferon and rivavirin|All patients received peginterferon alfa-2a in a dose of 180 μg weekly and ribavirin in a dose of 1000 (for patients with a body weight of ⩽75 kg) or 1200 mg (for those with a body weight of >75 kg) daily.
3329709|NCT00038961|Placebo Comparator|Placebo + intermittent pneumatic compression (IPC)|
3329710|NCT00038961|Experimental|fondaparinux + intermittent pneumatic compression (IPC)|
3329711|NCT00039624|Experimental|Brachy|brachytherapy
3329712|NCT00038948|Active Comparator|A|Conversion from calcineurin inhibitor immunosuppression to Sirolimus-based immunosuppression
3329713|NCT00038948|Active Comparator|B|Continued calcineurin inhibitor therapy
3329714|NCT00038883|Experimental|Campath-1H|10 mg/day x 5
3329715|NCT00038870|Experimental|Dendritic Cell Activated Lymphocytes|
3329716|NCT00038857|Experimental|CD34 PBPC|CD34 peripheral blood progenitor cell (PBPC) transplants in 3 groups: 1) HLA-matched Sibling Transplant Patients; 2) Unrelated Donor Transplant Patients; 3) Haplo Identical Transplant Patients. Preparative regimen is 140 mg/m^2 Melphalan on day -8, 10 mg/kg Thiotepa on day -7, 160 mg/m^2 Fludarabine over 4 days on days -6, -5, -4, -3 and 1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
3329717|NCT00038844|Experimental|Campath in Nonmyeloablative Transplantation|Campath-1 H Starting Dose of 15 mg by vein daily, 3 days in a row + Fludarabine 30 mg/m2 by vein daily, 3 days in a row + Cyclophosphamide 1 gm/m2 by vein daily, 3 days in a row + Rituximab 375 mg/m2 by vein, given 8 days before transplant then weekly for 4 total doses.
3329718|NCT00038831|Experimental|Chemotherapy + ATG + Stem Cell Infusion|
3329719|NCT00038818|Experimental|CD8 DLI|CD8 depleted DLI (Depleted Donor Lymphocyte Infusions)
3329720|NCT00038805|Experimental|Mylotarg|
3329721|NCT00038792|Experimental|aGvHD|
3329722|NCT00038779|Experimental|Megadose T cell depleted|
3329723|NCT00038766|Experimental|Semapimod 60 mg|Semapimod 60 mg IV x 5 days
3329724|NCT00038766|Experimental|Semapimod IV 30 mg|Semapimod IV 30 mg x 5 days
3329725|NCT00038766|Placebo Comparator|Placebo|Placebo IV x 3 or 5 days
3329726|NCT00038727|Active Comparator|1 Original Lifestyle|randomized to unmasked Intensive Lifestyle during the DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle plus DPPOS Boost Lifestyle sessions in DPPOS Phase 1 and 2
3329727|NCT00038727|Active Comparator|2 Original Metformin|randomized to the masked metformin treatment group during DPP and continued open label in DPPOS. Participants were also offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2.
3329728|NCT00038727|Placebo Comparator|3 Original Placebo|randomized to masked placebo during DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2
3329729|NCT00038701|Experimental|Gemzar Chemoradiation + TNP-470|
3329730|NCT00038675|Experimental|Imatinib|Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily.
3329731|NCT00038649|Experimental|Gleevec|Gleevec 400 mg orally twice daily.
3329732|NCT00038623|Experimental|Yttrium-ibritumomab (Zevalin)|After Rituximab infusion (250 mg/m^2 intravenous) on Day 1, 111^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
3329733|NCT00038610|Experimental|Hyper-CVAD + Imatinib|Imatinib 600 mg orally days 1-14, course 1, & 600 mg daily days 1-14 (daily if tolerated course 1), even courses. Cyclophosphamide 300 mg/m^2 intravenous (IV) for 6 doses days 1-3, odd courses. Doxorubicin 50 mg/m^2 IV day 4; Vincristine 2 mg IV days 4 & 11; & Dexamethasone 40 mg IV or orally daily days 1-4 & 11-14 odd courses 1, 3, 5, 7. Methotrexate 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2, odd courses and 200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 over 22 hours day 1 of even courses. Cytarabine 100 mg intrathecally day 7 for odd courses and 3 gm/m^2 IV every 12 hours for 4 doses days 2-3 for even courses. Mesna 600 mg/m^2 IV daily, odd courses. G-CSF 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
3329734|NCT00038571|Experimental|Arm A (mantle-cell lymphoma)|
3329735|NCT00038571|Experimental|Arm B (other B-cell lymphomas)|
3329736|NCT00038558|Experimental|Filgrastim + ABVD Chemotherapy|
3329737|NCT00038467|Active Comparator|B|
3329738|NCT00038467|Experimental|A|
3329739|NCT00038441|Experimental|DTI-015|
3329740|NCT00038415|Experimental|Vaccine|
3329741|NCT00038402|Experimental|Herceptin + Taxol Followed by FEC|Herceptin starting 4 mg/kg intravenous (IV), then 2 mg/kg weekly for all other cycles neo-adjuvant chemotherapy and during FEC therapy for total 24 doses. Taxol 225 mg/m^2 continuous IV over 24 hours each cycle; Fluorouracil 500 mg/m^2 IV Days 1 at 3-4 week intervals; Cytoxan 500 mg/m^2 IV on Day 1; Epirubicin 75 mg/m^2 IV on Day 1. Four 21-day cycles.
3329742|NCT00038389|Experimental|Vioxx MTD|
3329743|NCT00038376|Experimental|1|Alpha-interferon + Isotretinoin
3329744|NCT00038350|Experimental|1|8 week lingual strengthening exercise protocol
3329745|NCT00038298|Experimental|50 mg|50 mg 3 times weekly
3329748|NCT00038298|Placebo Comparator|Placebo|Placebo comparator associated with each active arm. (3:1 active vs placebo)
3329749|NCT00038246|Experimental|Thalidomide, Taxol, Estramustine|Thalidomide starting dose 200 mg by mouth every day once a week; Taxol 100 mg/m^2 by vein (IV) over 3 hours Day 3 and Day 10; Estramustine 140 mg by mouth three times a day on Days 1-5, 8-12.
3329750|NCT00038233|Experimental|Thalidomide|200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
3329751|NCT00038207|Experimental|Liposomal Vincristine|
3329752|NCT00038194|Experimental|Imatinib + Docetaxel|
3329753|NCT00038168|Experimental|Estramustine + Taxol|
3329754|NCT00038155|Other|1|
3329755|NCT00038142|Experimental|Arm A: VACdxr With ImmTher|Vincristine 2.0 mg/m^2 (max 2.0 mg) IV x 1 repeated every 3 weeks X 6. Doxorubicin 90 mg/m^2 IV over 30 min x 1 repeated every 3 weeks X 6. Cyclophosphamide 2.0 g/m^2 IV daily x 2 days repeated every 3 weeks X 6. Dexrazoxane 900 mg/m^2 IV (30 min prior to doxorubicin) repeated every 3 weeks X 6. ImmTher 900 mcg/m^2 IV over 1 hour every week x 50-52 weeks.
3329756|NCT00038142|Active Comparator|Arm B: VACdxr|Vincristine 2.0 mg/m^2 (max 2.0 mg) IV x 1 repeated every 3 weeks X 6. Doxorubicin 90 mg/m^2 IV over 30 min x 1 repeated every 3 weeks X 6. Cyclophosphamide 2.0 g/m^2 IV daily x 2 days repeated every 3 weeks X 6. Dexrazoxane 900 mg/m^2 IV (30 min prior to doxorubicin) repeated every 3 weeks X 6.
3329757|NCT00038129|Experimental|1|Participants will receive reaming of the intramedullary canal prior to insertion of an intramedullary nail.
3329758|NCT00038129|Experimental|2|Participants will receive insertion of an intramedullary nail without prior reaming of the intramedullary canal.
3329759|NCT00038116|Active Comparator|embryonic dopamine cell implant surgery|embryonic dopamine cell implant surgery
3329760|NCT00038116|Placebo Comparator|sham surgery|sham surgery (placebo)
3329761|NCT00038103|Active Comparator|1.|
3329762|NCT00038103|Experimental|2.|
3329763|NCT00038090|Experimental|Thalidomide + Dexamethasone|
3329764|NCT00038064|Active Comparator|rHuEPO|
3329765|NCT00038064|Experimental|Darbepoetin alfa|
3329766|NCT00038051|Experimental|HuM195/rGel|HuM195/rGel starting Dose = 3 mg/m^2 twice weekly for 2 weeks.
3329767|NCT00038038|Experimental|PET + 18F-fluoromisonidazole|
3329768|NCT00038025|Experimental|Deoxycoformycin (DCF)/Pentostatin|
3329769|NCT00038012|Experimental|rhTPO-Derived Autologous Platelets Transfusion|
3329770|NCT00037986|Other|1|
3329771|NCT00037973|Experimental|1|Ventilation-feedback plus exercise
3329772|NCT00037973|Active Comparator|2|Exercise
3329773|NCT00037973|Active Comparator|3|ventilation feedback only
3329774|NCT00037934|Experimental|1|Robot exercise group
3329775|NCT00037934|Active Comparator|2|Traditional exercise group
3329776|NCT00037921|Other|1|
3329777|NCT00037882|Experimental|SCH 54031|Peg Interferon Alpha-2B/PEG-Intron
3329778|NCT00037869|Experimental|MIBG|High Dose I-131 Metaiodobenzylguanidine
3329779|NCT00037830|Active Comparator|Early-Start Group|Subjects were randomized to receive GM1 ganglioside for 24 weeks.
3329780|NCT00037830|Placebo Comparator|Delayed-Start Group|Subjects were randomized to receive placebo for 24 weeks.
3329781|NCT00037830|No Intervention|Comparison Group|A separate group of Parkinson's disease patients who received standard of care were followed for one to two years to provide comparative information about natural disease progression. This comparison group was not compared statistically to the treatment groups since they were not randomized.
3329782|NCT00037817|Experimental|1|Dose escalation cohort
3329783|NCT00037817|Experimental|2|Molecular response cohort
3329784|NCT00037817|Experimental|3|Celecoxib combination cohort at MTD
3329785|NCT00037752|Active Comparator|1|Sibutramine plus a behavioral smoking cessation program
3329786|NCT00037752|Active Comparator|2|Placebo sibutramine plus a behavioral smoking cessation program
3329787|NCT00037713|No Intervention|1|Best supportive care, but no cancer specific therapy (cytotoxic, radiation or other tumor reductive therapy) can be given until documented progression of disease.
3329788|NCT00037713|Experimental|2|"Treatment will consist of 5 vaccinations (each consisting of 8 single intradermal injections) over a period of 10 to 12 weeks unless one of the following occur:~intolerable toxicity precluding further treatment progression of disease~patient refusal~occurrence of pregnancy"
3329789|NCT00037648|Placebo Comparator|placebo|
3329790|NCT00037648|Experimental|anakinra|
3329791|NCT00037635|Experimental|AMG 073|
3329792|NCT00037635|Placebo Comparator|placebo|
3329793|NCT00037609|Experimental|Capecitabine + Exisulind|Capecitabine 1000 mg/m^2 taken by mouth twice daily. Exisulind 125 mg taken by mouth twice daily.
3329794|NCT00037440||BHS Whites|Whites from Bogalusa, Louisiana; initially recruited as schoolchildren and followed at irregular intervals (about 3 years apart on average) into adolescence and early adulthood. There were no interventions of any kind-- this was an observational study only.
3329795|NCT00037440||BHS African Americans|African Americans from Bogalusa, Louisiana, initially recruited as schoolchildren and followed at irregular intervals (about 3 years apart on average) into adolescence and early adulthood. There were no interventions of any kind-- this was an observational study only.
3329796|NCT00036634|Active Comparator|Tenofovir DF|Participants received tenofovir DF 300 mg for 14 days
3329797|NCT00036634|Experimental|Tenofovir alafenamide 50 mg|Participants received tenofovir alafenamide 50 mg for 14 days
3329798|NCT00036634|Experimental|Tenofovir alafenamide 150 mg|Participants received tenofovir alafenamide 150 mg for 14 days
3329799|NCT00036569|Experimental|Interferon Alfa|0.3 mg/kg subcutaneously once a week for 4 weeks beginning 2-10 weeks after completion of radiation therapy and continued until disease progression or one of the other off study criteria.
3329800|NCT00036491|Experimental|rituximab|375 mg/m^2 administered intravenously
3329801|NCT00036296|Experimental|1|75mg per day (in 3 doses) Talampanel for 22 days
3329802|NCT00036296|Placebo Comparator|2|3 doses a day for 22 days
3329803|NCT00036270|Experimental|exemestane|
3329804|NCT00036270|Experimental|tamoxifen + exemestane|
3329807|NCT00035984|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
3329808|NCT00035984|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL
3329809|NCT00035932|Active Comparator|I|"ATV 300 mg + RTV 100 mg + TDF 300 mg + nucleoside of choice~ATV , RTV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
3329810|NCT00035932|Active Comparator|II|"ATV 400 mg + SQV 1200 mg + TDF 300 mg + nucleoside of choice~ATV, SQV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
3329811|NCT00035932|Active Comparator|III|"LPV/RTV 400/100 mg + TDF 300 mg + nucleoside of choice~LPV/RTV twice daily, TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
3329812|NCT00035893|Experimental|Ampligen|Ampligen (poly I-poly C12U) 200-400 mg IV infusions given twice weekly for 64 weeks.
3329813|NCT00035893|No Intervention|No Ampligen|No Ampligen administered for first 64 weeks
3329814|NCT00035815|Active Comparator|IGF-1|Insulin like growth factor, type 1 will be given 0.05 mg per kg body weight subcutaneously twice daily
3329815|NCT00035815|Placebo Comparator|Placebo|Placebo arm
3329816|NCT00035802|Experimental|001|"Topiramate Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.~OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months."
3329817|NCT00035802|Placebo Comparator|002|Placebo Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
3329818|NCT00035620|Active Comparator|Filgrastim|Filgrastim
3329819|NCT00035620|Experimental|Pegfilgrastim|Pegfilgrastim
3329820|NCT00035607|Active Comparator|Darbepoetin alfa SC|
3329821|NCT00035607|Experimental|Darbepoetin alfa IV|
3329822|NCT00035594|Placebo Comparator|Placebo|Breast cancer patients receiving docetaxel chemotherapy and placebo.
3329823|NCT00035594|Experimental|Pegfilgrastim|Breast cancer patients receiving docetaxel chemotherapy and pegfilgrastim.
3329824|NCT00035581|Experimental|Ampligen|Ampligen (polyI-polyC12U) 200-400 mg IV infusions given twice weekly for 24 weeks
3329825|NCT00035581|No Intervention|No Ampligen|No Ampligen administered for first 24 weeks
3329826|NCT00035555|Experimental|Belatacept: More intensive (MI) regimen|The MI regimen was designed to achieve projected serum trough concentrations of belatacept of approximately 20 μg/mL through Day 99, and approximately 5 μg/mL through Day 183 (10 mg/kg on Days 1, 5, 15, 29, 43, 57, 71, 85, 113, 141, and 169). After Day 169, patients were reallocated and dosed to achieve projected trough serum concentrations of approximately 2 or 0.25 μg/mL (5 mg/kg every 4 or 8 weeks starting on Day 197). Those patients who received belatacept every 8 weeks received placebo infusions on scheduled treatment dates between infusions of active drug to maintain the blind between treatment regimens. Patients initially received mycophenolate mofetil (MMF), 2 g/d orally, unless the investigator chose to administer ≥1 doses intravenously The first MMF dose was administered preoperatively; subsequent doses were administered in 2 or 3 divided doses, every 8-12 hours, beginning as soon as the patient was able to tolerate medications by mouth. Corticosteroids given daily.
3329827|NCT00035555|Experimental|Belatacept: Less intensive (LI) regimen|The LI regimen was designed to achieve projected trough serum concentrations of belatacept of approximately 20 μg/mL through Day 29, and approximately 5 μg/mL through Day 99 (10 mg/kg on Days 1, 15, 29, 57 and 85). After Day 85, these subjects were reallocated and dosed to achieve projected trough serum concentrations of either approximately 2 or 0.25 μg/mL (5 mg/kg every 4 or 8 weeks starting on Day 113). Participants initially received mycophenolate mofetil (MMF), 2 g/d orally, unless the investigator chose to administer ≥1 doses intravenously The first MMF dose was administered preoperatively; subsequent doses were administered in 2 or 3 divided doses, every 8-12 hours, beginning as soon as the participant was able to tolerate medications by mouth. Corticosteroids given daily.
3329828|NCT00035555|Experimental|Cyclosporine regimen|The initial daily dose was 7±3 mg/kg. Subsequent doses were adjusted to maintain a predefined range of serum concentrations: 1st month, target level 150-400 ng/mL; after 1st month, target level of 150-300 ng/mL. Participants initially received mycophenolate mofetil (MMF), 2 g/d orally, unless the investigator chose to administer ≥1 doses intravenously The first MMF dose was administered preoperatively; subsequent doses were administered in 2 or 3 divided doses, every 8-12 hours, beginning as soon as the participant was able to tolerate medications by mouth. Corticosteroids given daily.
3329829|NCT00035529|Other|1|
3329830|NCT00035529|Active Comparator|2|
3329831|NCT00035529|Active Comparator|3|
3329832|NCT00035490|Placebo Comparator|1|Placebo tablets
3329833|NCT00035490|Experimental|2|75 mg azimilide
3329834|NCT00035490|Experimental|3|125 mg azimilide
3329835|NCT00035477|Placebo Comparator|1|placebo tablets in hospital and placebo tablets outpatient
3329836|NCT00035477|Experimental|2|Azimilide tablets in hospital and azimilide tablets outpatient
3329837|NCT00035464|Placebo Comparator|1|Placebo tablets
3329838|NCT00035464|Experimental|2|125 mg azimilide tablets
3329839|NCT00035451|Placebo Comparator|1|placebo tablets
3329840|NCT00035451|Active Comparator|2|Sotalol
3329841|NCT00035451|Experimental|3|azimilide
3329842|NCT00035425|Experimental|A.|Patients will be stratified according to the use of prophylactic antibiotics. Both groups may receive open-label gram-negative coverage with either ceftazidime, aztreonam, and/or aminoglycosides (gentamicin, tobramycin, amikacin). Subjects will receive study medication intravenously every 12 hours for 7 to 28 days.
3329843|NCT00035425|Experimental|B.|
3329844|NCT00035347|Experimental|Azithromycin plus ceftriaxone group (AZY+CEF group)|IV azithromycin (500 mg once daily) plus ceftriaxone (1 gram once daily) for 2 to 5 days followed by oral azithromycin (2 x 250 mg once daily) to complete a total of 7 to 10 days of therapy
3329845|NCT00035347|Experimental|Levofloxacin group (LEV group)|IV levofloxacin (500 mg once daily) for a minimum of 2 days followed by oral levofloxacin (500 mg once daily) to complete a total of 7 to 14 days of therapy.
3329846|NCT00035243|Experimental|EPO906|
3329847|NCT00035165|Experimental|EPO906|
3329848|NCT00035126|Experimental|EPO906|
3329849|NCT00035100|Experimental|EPO906|
3329850|NCT00034814|Placebo Comparator|1|Enzyme-inducing placebo TID
3329861|NCT00034541|Experimental|1|An initial dose of cetuximab (400 mg/m2 i.v. over 120 minutes) will be administered 1 week prior to the initiation of chemotherapy. Thereafter, cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each cycle (every 3 weeks) of therapy, a 3-hour paclitaxel (225 mg/m2) infusion will be administered 1-hour post completion of the cetuximab infusion, immediately followed by a 30-minute carboplatin (AUC=6) infusion.
3329862|NCT00034528|Experimental|Allogeneic stem cell transplantation|Participants will receive a nonmyeloablative conditioning regimen of fludarabine and busulfan prior to allogeneic peripheral blood stem cell (CD34+) infusions. FK506 and prednisone will be administered for graft versus host disease (GVHD) prophylaxis.
3329863|NCT00034281|Experimental|TAK-165 QD|
3329864|NCT00033917|Active Comparator|1|indomethacin
3329865|NCT00033917|Placebo Comparator|2|placebo
3329866|NCT00033865|Experimental|1|Yoga treatment for 8 weeks
3329867|NCT00033865|No Intervention|2|Sleep hygiene instructions only
3329868|NCT00033137||Patients|Any patient with spontaneous pneumothorax, skin papules, fibrofolliculomas,or kidney cancer
3329869|NCT00033137||Family members|Any family members who have positive family history of spontaneous pneumothorax, skin papules or kidney cancer with a confirmed diagnosis of BHD
3329870|NCT00033111|Active Comparator|Cabergoline|Subjects received one tablet of 0.5 mg of cabergoline tablet per week for 12 weeks.
3329871|NCT00033111|Placebo Comparator|Placebo|Subjects received one tablet of 0.5 mg of cabergoline matched placebo tablet per week for 12 weeks.
3329872|NCT00032643|Other|Arm 1|
3329873|NCT00032630|Other|Arm 1|Coronary artery bypass - on-pump
3329874|NCT00032630|Other|Arm 2|Coronary artery bypass - off-pump
3329875|NCT00032617|Active Comparator|1|Prolonged Exposure
3329876|NCT00032617|Active Comparator|2|Present Centered Therapy
3329877|NCT00032591|Active Comparator|Arm 1|Patient Self-Testing (PST) of prothrombin time by international normalized ratio (PT-INR or INR) with weekly testing
3329878|NCT00032591|Other|Arm 2|High quality anticoagulation management (HQACM) with conventional monthly testing
3329879|NCT00032565||1|No intervention. Telephone interview.
3329880|NCT00032552||1|
3329881|NCT00032539||1|
3329882|NCT00032487|Active Comparator|Standard glycemic control|Standard glycemic control to maintain HbA1c between 8.0-9.0%. Metformin 500 mg Rosiglitazone 4 mg Glimepiride 2 mg Insulin 1 unit 9 lbs
3329883|NCT00032487|Experimental|Intensive glycemic control|Intensive glycemic control lower HbA1c below 6.0%. Metformin 500 mg (go up to 2000 mg) Rosiglitazone 4 mg bid Glimepiride 8 mg Insulin 1 unit 9 lbs add one injection to Arm 1
3329884|NCT00032448|Other|1|Open and laparoscopic herniorrhaphy
3329885|NCT00032435|Experimental|1|PAL-40 Active
3329886|NCT00032435|Placebo Comparator|2|PAL-40 Placebo
3329887|NCT00032370|Other|1|Elective vascular surgery
3329888|NCT00032370|Other|2|Cardiac revascularization prior to vascular surgery.
3329889|NCT00032357|Other|Arm 1|Usual care plus Ferritin reduction to a calculated nadir of 25 ng/mL by phlebotomy
3329890|NCT00032357|No Intervention|Arm 2|Usual care only; no intervention control
3329891|NCT00032344|Other|1|Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
3329892|NCT00032227|Experimental|1|Surgical release of CTS
3329893|NCT00032227|Active Comparator|2|Non-surgical treatment for CTS (splint, physical therapy, ultrasound)
3329894|NCT00031551|Experimental|Main Study: Etanercept Mouthwash|Etanercept 2.5 mg in 20cc mouthwash is swished and spit by the participant every 6 hours. The experimental mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant (BMT) Day +14, whichever occurs first.
3329895|NCT00031551|Placebo Comparator|Main Study: Placebo Mouthwash|Placebo 20cc mouthwash is swished and spit by the participant every 6 hours. The placebo mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant day (BMT) Day +14, whichever occurs first.
3329896|NCT00031551|No Intervention|Pilot Study|Participants were enrolled in the pilot study to collect descriptive data about pain perception and laboratory techniques.
3329897|NCT00031512|Placebo Comparator|Placebo|Placebo.
3329898|NCT00031512|Experimental|Pleconaril (VP63843)|The first dosing cohort received 5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation. Subsequent dosing cohorts are receiving 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
3329899|NCT00031499|Experimental|Azithromycin|Azithromycin 2.0 gram single oral dose.
3329900|NCT00031499|Active Comparator|Benzathine Penicillin|Benzathine penicillin 2.4 million units administered intramuscularly. Doxycycline will be administered if the patient is allergic to Benzathine Penicillin.
3329901|NCT00031486|Experimental|Valacyclovir|
3329902|NCT00031486|Placebo Comparator|Placebo|
3329903|NCT00031460|Experimental|Acyclovir|
3329904|NCT00031460|Placebo Comparator|Placebo|
3329905|NCT00031447|Placebo Comparator|Placebo|
3329906|NCT00031447|Experimental|Acyclovir|
3329907|NCT00031434|Experimental|1|All subjects enrolled into this study will receive 6 weeks (42 days) of antiviral therapy (valganciclovir/ganciclovir).
3329908|NCT00031421||1|16 received ganciclovir at 8 mg/kg/day in the previous study.
3329909|NCT00031421||2|31 received ganciclovir at 12 mg/kg/day in the previous study.
3329910|NCT00031395|Active Comparator|1|
3329911|NCT00031395|Active Comparator|2|
3329912|NCT00031395|Active Comparator|3|
3329913|NCT00031395|Placebo Comparator|4|
3329914|NCT00031278|Experimental|Cohort 1|0.01 mg/kg CPG 7909 plus Herceptin®
3329915|NCT00031278|Experimental|Cohort 2|0.04 mg/kg CPG 7909 plus Herceptin®
3329916|NCT00031278|Experimental|Cohort 3|0.16 mg/kg CPG 7909 plus Herceptin®
3329917|NCT00031278|Experimental|Cohort 4|0.32 mg/kg CPG 7909 plus Herceptin®
3329918|NCT00031122||SBRR|Families with a child/pregnancy affected with spina bifida or anencephaly
3329919|NCT00031096|Experimental|Arm 1|
3329921|NCT00030992|Experimental|BMS-247550|One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2
3329922|NCT00030966|Experimental|Group 1|Adding natalizumab monthly infusion to Avonex weekly injection for up to 116 weeks.
3329923|NCT00030966|Placebo Comparator|Group 2|Adding placebo monthly infusion to Avonex weekly injection for up to 116 weeks.
3329924|NCT00030238|Other|Active Treatment|Subjects take calcium twice daily with meals
3329925|NCT00030238|Other|Control|Subjects take placebo twice daily with meals.
3329926|NCT00030225|Experimental|ELAD|Treatment with ELAD, extracorporeal liver assist system and standard of care
3329927|NCT00030225|Other|Standard of care (Control)|Standard of care for patients with fulminant hepatic (liver) failure
3329928|NCT00030186|Experimental|Cycle 1|60mg
3329929|NCT00030186|Experimental|Cycle 2|80mg dependent upon response to Cycle 1
3329930|NCT00030186|Experimental|Cycle 2b|40mg dependent upon response to Cycle 1
3329931|NCT00030147|Experimental|Raloxifene|Raloxifene (Evista) 60 mg per day and placebo skin patch for eight weeks
3329932|NCT00030147|Experimental|Rimostil|Rimostil (phytoestrogen) 1000 mg twice a day and placebo skin patch for eight weeks
3329933|NCT00030147|Active Comparator|Transdermal estradiol|17-beta estradiol 100 micrograms a day by skin patch and placebo tablets for eight weeks
3329934|NCT00030147|Placebo Comparator|Placebo|Placebo skin patch and placebo tablets for eight weeks.
3329935|NCT00029913||1|Observation of participants includes a physical exam and collection of fluids. Study visits occur at Days 0, 7, 14, 28 and at Months 2, 3, 6 and every 6 months thereafter.
3329936|NCT00029536|Experimental|Catamenial Epilepsy: Progesterone Lozenges|Subjects with catamenial epilepsy received 200 mg progesterone lozenges
3329937|NCT00029536|Placebo Comparator|Catamenial Epilepsy: Placebo Lozenges|Subjects with catamenial epilepsy received matched placebo lozenges
3329938|NCT00029536|Experimental|Noncatamenial Epilespy:Progesterone Lozenges|Subjects without catamenial epilepsy received 200 mg progesterone lozenges
3329939|NCT00029536|Placebo Comparator|Noncatamenial Epilespy: Placebo Lozenges|Subjects without catamenial epilepsy received matched placebo lozenges
3329940|NCT00029198|Experimental|1|15 minute massage tid
3329941|NCT00029198|Sham Comparator|2|non-massage touch
3329942|NCT00029172|Experimental|Nurse Case management|
3329943|NCT00029159|Active Comparator|1|
3329944|NCT00029159|Placebo Comparator|2|
3329945|NCT00029146|Experimental|Surgical group|Assigned to undergo extracranial-intracranial arterial bypass in addition to best current practice medical therapy
3329946|NCT00029146|Active Comparator|Non-surgical group|Receives best current practice medical therapy
3329947|NCT00029107|Other|Immediate treatment|Patients receive treatment with four weekly infusions of rituximab 375mg/m2 immediately following randomization.
3329948|NCT00029107|Other|Delayed treatment|Patients treated with standard therapy (corticosteroids, plasma exchange, etc.). After 6 months, they are eligibile to cross over and receive four weekly infusions of rituximab.
3329949|NCT00028340||2/Normal Volunteers|Pre- or postmenopausal women who are not at an increased risk for breast cancer.
3329950|NCT00028340||1/Breast Cancer and High-Risk Patients|Pre- or postmenopausal women who have or have previously had invasive or noninvasive breast cancer of epithelial origin, or women without breast cancer but at an increased risk of breast cancer.
3329951|NCT00028262|Experimental|Drug: Cystagon and N-acetylcysteine|
3329952|NCT00028145||1|Pregnant, HIV-infected women
3329953|NCT00028119||Cohort 1|HIV-uninfected non-sex worker women
3329954|NCT00028119||Cohort 2|HIV-discordant heterosexual couples attending STD clinics
3329955|NCT00028093|Experimental|Pefinterferon+Ribavirin|Patients with chronic hepatitis C virus (HCV) infection genotype 1 peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients <75 kg and 1200 mg daily for patients >=75 kg) for 48 weeks
3329956|NCT00028093|Active Comparator|Peginterferon|patients with chronic hepatitis C virus (HCV) infection genotype 1 were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
3329957|NCT00027417|Active Comparator|Liothyronine Sodium/Triiodothyronine|bolus administration of Liothyronine Sodium/Triiodothyronine (Triostat) immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses, will be safe and will result in significant improvements in postoperative and clinical outcome parameters and cardiac contractile function.
3329958|NCT00027417|Placebo Comparator|Placebo|bolus administration of Placebo immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses
3329959|NCT00027378|Experimental|1|fluoxetine plus Treatment As Usual (TAU)
3329960|NCT00027378|Placebo Comparator|2|placebo plus Treatment As Usual (TAU)
3329961|NCT00027300|Experimental|Group 1|Natalizumab 300 mg, IV
3329962|NCT00027300|Placebo Comparator|Group 2|Placebo IV infusion
3329963|NCT00027066|Active Comparator|Active Warfarin and Aspirin Placebo|One 2 mg scored tablet daily of Warfarin and one 325 mg tablet daily of aspirin placebo.
3329964|NCT00027066|Active Comparator|Active Aspirin and Warfarin Placebo|One 325 mg tablet daily of aspirin and one 2 mg scored tablet daily of Warfarin placebo.
3329965|NCT00027053|Experimental|Trazodone|
3329966|NCT00027053|Placebo Comparator|Placebo|
3329967|NCT00026884||Patients|Any patient with Biopsy-Proved Malignant Diseases
3329968|NCT00026884||Family members|Any family members who Suspected of having a malignant lesion
3329969|NCT00026793||1|Adult patients with biopsy-proven cutaneous Kaposi s sarcoma
3329970|NCT00026663||1/Patients with Cancer|Cancer patients providing tissue for research studies
3329971|NCT00026663||2/Normal Volunteers|Normal Volunteers providing samples for research studies
3329972|NCT00026663||3/Samples from Closed Studies|Samples from closed studies
3329973|NCT00026637|Active Comparator|Sertraline|
3329974|NCT00026637|Active Comparator|CBT|
3329975|NCT00025883|Experimental|Metreleptin|subcutaneous metreleptin injections in one to two daily doses ranging from 0.06 to 0.24 mg/kg per day.
3329976|NCT00025766|Experimental|1|PCI with stenting of the occluded culprit infarct-related artery plus optimal medical therapy
3329977|NCT00025766|Active Comparator|2|Optimal medical therapy alone without PCI of the occluded culprit artery
3329978|NCT00024596||Caucasian Families|Largest 3-generational Caucasian Families from Family Heart Study (Classic) with average family size of 10 N=2767 Subjects from 512 families. Approximately half are random sample families from FamHS-Classic, and half are high-familial CHD risk families from FamHS-Classic. 4 Field sites were Raleigh-Durham North Carolina; Minneapolis, MN; Framingham MA; and Salt Lake City, UT.
3329979|NCT00024596||African-American Families|622 subjects from 2-3 generational 212 African-American families originally recruited from the HyperGEN study in Birmingham AL. These are hypertension enriched families.
3329980|NCT00024518|Placebo Comparator|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA). Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
3329981|NCT00024518|Experimental|5,000 Units hrIFN-alpha|hrIFN-alpha = human recombinant interferon-alpha. 5,000 units was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
3329982|NCT00024518|Experimental|30,000 hrIFN-alpha|30,000 units hrIFN-alpha was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
3329983|NCT00023595|Active Comparator|H01: Medication|Medical therapy alone to treat Coronary Artery Disease
3329984|NCT00023595|Active Comparator|H01: Medication + CABG|Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease
3329985|NCT00023595|Active Comparator|H02: Medication+CABG|Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease
3329986|NCT00023595|Active Comparator|H02: Medication+CABG+SVR|CABG plus Medication and Surgical ventricular reconstruction (SVR)
3329987|NCT00023452|Active Comparator|Daily Isoniazid|Isoniazid (INH) daily for 9 months (240 to 270 total doses).
3329988|NCT00023452|Experimental|Weekly Isoniazid / Rifapentine|Isoniazid / Rifapentine (RPT/INH) weekly for 3 months (11 to 12 total doses) given by Directly Observed Therapy (DOT)
3329989|NCT00023374|Experimental|Rifampin+PZA+Ethambutol|6 mos of intermittent (2 or 3 times weekly) therapy with REZ
3329990|NCT00023543|Experimental|1|Participants will reduce total fat intake to 17 percent of calories, 1300 kilo calories, and increase moderate activity to 150-240 minutes per week to obtain a 10 percent reduction in weight.
3329991|NCT00023322|Experimental|Peginterferon Alpha-2a|Patients with hepatitis D virus (HDV) infection are treated with pegylated alpha interferon therapy for 3 years. The dose of the drug is 180 mcg/week.
3329992|NCT00023309|Experimental|Lamivudine and adefovir|
3329993|NCT00023309|Active Comparator|Adefovir|
3329994|NCT00023283|Experimental|1|Standard Medical Management with once-weekly medication dispensing
3329995|NCT00023283|Experimental|2|Standard Medical Management with thrice-weekly medication dispensing
3329996|NCT00023283|Experimental|3|Enhanced Medical Management with thrice-weekly medication dispensing
3329997|NCT00023244|Experimental|Corticosteroid (steroid) withdrawal|All enrolled subjects who have not experienced an episode of acute rejection or other event resulting in removal from the study in the first 6 months after transplantation will undergo a protocol-driven biopsy at 6 months. Subjects with no clinical or histologic evidence of rejection will be eligible to be randomized and treated in a double-blinded (e.g., masked-neither subject nor health care providers will know treatment being received) fashion while continuing other immunosuppressive medications. Subjects in this arm will undergo complete steroid withdrawal by the end of 12 months post-transplant.
3329998|NCT00023244|Active Comparator|Control Treatment|All enrolled subjects who have not experienced an episode of acute rejection or other event resulting in removal from the study in the first 6 months after transplantation will undergo a protocol-driven biopsy at 6 months. Subjects with no clinical or histologic evidence of rejection will be eligible to be randomized and treated in a double-blinded (e.g., masked-neither subject nor health care providers will know treatment being received) fashion while continuing other immunosuppressive medications. Subjects in this arm will be maintained on low-dose (0.15 mg/kg/day) daily steroids.
3329999|NCT00023231|Experimental|1|Participants will receive immunosuppression therapy using antibody induction (daclizumab), corticosteroids, mycophenolate mofetil, and sirolimus prior to transplantation. Bactrim and ganciclovir will be taken for infection prophylaxis. If the participant has consistent high levels of fasting cholesterol, treatment with lipitor may be given.
3330000|NCT00023205|Experimental|Individualized education|Individualized education with materials written in plain language. Follow-up sessions/ phone contact as requested by the subject.
3330001|NCT00023205|Active Comparator|Standard care|1 session of education with provision of standard Arthritis Foundation materials.
3330002|NCT00017693|Experimental|0.75mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
3330003|NCT00017693|Experimental|1.5mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
3330004|NCT00017693|Experimental|3.0mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
3330005|NCT00017693|Placebo Comparator|Placebo for rsIL-4R|The placebo for recombinant human soluble IL-4 receptor (rsIL-4R) consisted of identically prepared excipient in the same volume (2.5 mL). To maintain blinding, medication was dispensed by an individual who was not responsible for patient care or assessment. Treatment assignment was blinded to all personnel involved in direct conduct or monitoring of the study.
3330006|NCT00016718|Experimental|Age Group 1: 90 days to < 3 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
3330007|NCT00016718|Experimental|Age Group 2: 3 to 12 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
3330008|NCT00016718|Experimental|Age Group 2: 13 to 21 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
3330009|NCT00014911|Experimental|Islet Transplantation|All study participants
3330010|NCT00011037|Experimental|1|Participants will receive ALVAC-HIV vCP1452 at 0, 1, 3, and 6 months and MN rgp120 and Months 3 and 6
3330011|NCT00011037|Experimental|2|Participants will receive ALVAC-HIV vCP1452 at 0, 1, 3, and 6 months and MN rgp120 placebo and Months 3 and 6
3330012|NCT00011037|Placebo Comparator|3|Participants will receive ALVAC-HIV vCP1452 placebo at 0, 1, 3, and 6 months and MN rgp120 placebo and Months 3 and 6
3330013|NCT00007787|Experimental|Antibody plus delayed cyclosporine therapy|Anti-human thymocyte globulin (rabbit) (Thymoglobulin®) is admistred at the time of transplant followed delayed clyclosporine A therapy post tranplant.
3330014|NCT00007787|Active Comparator|Standard cyclosporine A therapy|Cyclosporine A therapy (either Cyclosporine or Tacrolimus) will be initiated pre-transplantations
3330015|NCT00006604|Experimental|Step I: Group 1|"Group 1 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder) and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 620 mg/m^2; Final Dose: Not Established"
3330016|NCT00006604|Experimental|Step I: Group 2|"Group 2 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder) and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 620 mg/m^2; Final Dose: Not Established"
3330017|NCT00006604|Experimental|Step I: Group 3|"Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 415 mg/m2, 520 mg/m^2; Final Dose: 520 mg/m^2"
3330018|NCT00006604|Experimental|Step I: Group 4|"Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 520 mg/m^2, 620 mg/m^2; Final Dose: 620 mg/m^2"
3330019|NCT00006604|Experimental|Step I: Group 5|"Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2"
3330020|NCT00006604|Experimental|Step I: Group 5a|"Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2"
3330021|NCT00006604|Experimental|Step I: Group 6|"Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2"
3330022|NCT00006604|Experimental|Step I: Group 7|"Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 205 mg/m^2; Final Dose: 205 mg/m^2"
3330023|NCT00006604|Experimental|Step I: Group 8|"Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 205 mg/m^2; Final Dose: 205 mg/m^2"
3330024|NCT00006441|Experimental|A|Patients beginning IL-2 treatment regimens after 4 weeks of study
3330025|NCT00006441|Active Comparator|B|Patients beginning IL-2 treatment after some delay based on specified criteria
3330026|NCT00006154|Experimental|A|Patients will receive combination antiretroviral therapy with a protease inhibitor
3330027|NCT00006154|Active Comparator|B|Patients will receive combination antiretroviral therapy without a protease inhibitor
3330028|NCT00005113|Experimental|1|Participants will receive SRL, CsA/tacrolimus, and corticosteroids for up to 36 months
3330029|NCT00005113|Experimental|2|Participants will receive standard CsA or tacrolimus-based double or triple drug therapy for up to 36 months
3330030|NCT00005009|Experimental|Varivax®|0.5 mL of Varivax administered subcutaneously in the right upper arm (deltoid region).
3330031|NCT00004978|Experimental|rIL-2|Recombinant interleukin-2 (rIL-2) therapy used with combination anti-HIV medication of choice.
3330032|NCT00004978|No Intervention|No rIL-2|Control arm uses anti-HIV medication of choice without rIL-2.
3330033|NCT00004578|Active Comparator|1|Group 1, n=32 initiated with ABT-378 & ritonavir; after 3 wks stavudine and lamivudine was added.
3330034|NCT00004578|Active Comparator|2|Group II patients (n=68) to be randomized after all Group I patients are enrolled and safety analysis is completed.
3330035|NCT00001131|Experimental|A|Patients will recieve a daily, self-administered subcutaneous injection of IL-2 while continuing treatment with their current oral anti-HIV medications
3330036|NCT00001131|Active Comparator|B|Patients will only follow their current oral anti-HIV medication regimen. No additional IL-2 injection will be given.
3330037|NCT00001082|Experimental|1|Participants will receive adefovir dipivoxil and L-carnitine
3330038|NCT00001082|Experimental|2|Participants will receive adefovir dipivoxil placebo and L-carnitine.
3330039|NCT00001077||1|Participants will receive peptamen drinks and multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
3330040|NCT00001077||2|Participants will receive NuBasics drinks or equivalent amounts of NuBasics soups or bars and daily multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
3330041|NCT00001077||3|Participants will receive multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
3330042|NCT00000955|Other|A|All eligible study participants
3330043|NCT00000948|Experimental|1|Participants will be broken into 3 groups. Each group will receive ART and escalating doses of aldesleukin. All participants will then receive that maximum tolerated dose of aldesleukin.
3330044|NCT00000948|Active Comparator|2|All participants will receive ART
3330045|NCT00000936|Experimental|Induction|subjects receiving hOKT3 induction therapy
3330046|NCT00000936|Active Comparator|Induction Free Therapy|Patients not receiving induction therapy
3330047|NCT00000935|Experimental|Intravenous Immune Globulin (Human)|
3330048|NCT00000935|Placebo Comparator|Intravenous Immune Globulin (Human) Placebo|
3330049|NCT00000932||A|Participants currently enrolled in or currently being followed in an ongoing qualifying study. Qualifying studies can be found in the protocol.
3330050|NCT00000932||B|Participants previously enrolled in but not currently being followed in a qualifying study. Qualifying studies can be found in the protocol.
3330112|NCT00018031|Experimental|1|Weekly Injection of peginterferon alfa-2b and weight based ribavirin (1-1.2g/day) for 48 weeks
3330051|NCT00000932||C|Antiretroviral-naive participants not enrolling in a qualifying study (i.e., patients starting treatment outside the first study or patients deferring treatment)
3330052|NCT00000930||A|HIV-infected individuals enrolled in HIVNET D01
3330053|NCT00000930||B|Individuals with newly acquired HIV infection
3330054|NCT00000928|Experimental|A|All study participants
3330055|NCT00000884|Experimental|1|Participants will undergo treatment intramuscularly
3330056|NCT00000884|Experimental|2|Participants will undergo treatment orally
3330057|NCT00000884|Experimental|3|Participants will undergo treatment intranasally
3330058|NCT00000884|Experimental|4|Participants will undergo treatment intrarectally
3330059|NCT00000884|Experimental|5|Participants will undergo treatment intravaginally
3330060|NCT00000884|Experimental|6|Participants will undergo treatment intranasally and intramuscularly
3330061|NCT00000884|Experimental|7|Participants will undergo treatment intrarectally and intramuscularly
3330062|NCT00000874||1|Participants who are failing a regimen of ZDV, 3TC, and IDV
3330063|NCT00000874||2|Participants who are failing a regimen of ZDV, 3TC, and SRQ
3330064|NCT00000874||3|Participants who are failing a regimen of ZDV, 3TC, and RTV
3330065|NCT00000874||4|Participants who are failing a regimen of d4T, 3TC, and IDV
3330066|NCT00000829|Experimental|1|Patients receiving intramuscular heptavalent pneumococcal conjugate vaccine
3330067|NCT00000829|Placebo Comparator|2|Patients receiving placebo vaccine
3330068|NCT00000817|Experimental|1|Participants will receive standardized or alternate point acupuncture treatment twice weekly for the first 6 weeks, then once weekly for the next 8 weeks, plus either oral amitriptyline or placebo daily for the entire 14 weeks.
3330069|NCT00000815|Experimental|1|Participants who receive vaccination at 6 and 12 months of age
3330070|NCT00000815|Experimental|2|Participants who receive vaccination only at 12 months of age
3330071|NCT00000785||A|All eligible CPCRA subjects
3330072|NCT00000784||A|Consenting patients newly enrolled in either CPCRA 007 or CPCRA 006
3330073|NCT00000783||1|Sexually active HIV-infected concordant couples
3330074|NCT00000783||2|Sexually active HIV-infected discordant couples
3330075|NCT00000774|Experimental|1|Patients who will receive rgp120/HIV-1MN
3330076|NCT00000774|Experimental|2|Patients who will receive rgp120/HIV-1SF2
3330077|NCT00000774|Placebo Comparator|3|Patients who will receive the placebo counterpart of 120/HIV-1MN
3330078|NCT00000774|Placebo Comparator|4|Patients who will receive the placebo counterpart of rgp120/HIV-1SF2
3330079|NCT00022971|Experimental|1|Apolizumab followed by rituixmab every 4 weeks
3330080|NCT00022854|Placebo Comparator|1|
3330081|NCT00022854|Experimental|2|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
3330082|NCT00022854|Experimental|3|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous levobupivacaine infusion of 5 mL/hr for 50 hr
3330083|NCT00022776|Experimental|1|Participants will undergo surgery for spinal stenosis. Participants in this group will undergo surgical decompression as described by Rothman and Simeone.
3330084|NCT00022776|Experimental|2|Participants will undergo physical therapy for spinal stenosis. These participants will undergo a physical therapy program emphasizing lumbar flexion exercises, general conditioning exercises, and patient education for six weeks, with a frequency of 1-2 visits per week. Each patient will receive instruction in a home exercise program.
3330085|NCT00021866||Carbamazepine|Children and their mothers exposed to Carbamazepine monotherapy in utero
3330086|NCT00021866||Phenytoin|Children and their mothers exposed to phenytoin in utero
3330087|NCT00021866||Lamotrigine|Children and their mothers exposed to Lamotrigine in utero
3330088|NCT00021866||Valproate|Children and their mothers exposed to Valproate in utero
3330089|NCT00021840||Homogen Hispanic pop/Cent Valley CRA|Homogeneous Hispanic population from the Central Valley of Costa Rica
3330090|NCT00021541|Experimental|Tipifarnib (R11577)-Arm I|Patients receive oral R115777 (Tipifarnib) first followed by placebo. 200 mg/m^2/dose BSA every 12 hours by mouth (po)on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3330091|NCT00021541|Placebo Comparator|Placebo-Arm II|Patients receive oral placebo first followed by R115777 (Tipifarnib). 200 mg/m^2/dose BSA every 12 hours by mouth (po)every 12 hours on days 1-21. Courses repeat as in arm I.
3330092|NCT00018902|Experimental|1|Participants whose depression does not respond to an initial SSRI will switch to an alternative SSRI.
3330093|NCT00018902|Experimental|2|Participants whose depression does not respond to an initial SSRI will switch to a different non-SSRI antidepressant.
3330094|NCT00018902|Experimental|3|Participants whose depression does not respond to an initial SSRI will switch to an alternative SSRI and receive cognitive behavioral therapy (CBT).
3330095|NCT00018902|Experimental|4|Participants whose depression does not respond to an initial SSRI will switch to a different non-SSRI antidepressant and receive CBT.
3330096|NCT00018824|Experimental|1|Naltrexone
3330097|NCT00018824|Placebo Comparator|2|Placebo
3330098|NCT00018694|Other|Arm 1|
3330099|NCT00018655|Experimental|Arm 1|Twelve Step Facilitation
3330100|NCT00018655|Experimental|Arm 2|Integrated Cognitive Behavioral Treatment
3330101|NCT00018616|Other|1|
3330102|NCT00018434||Group 1|
3330103|NCT00018356|Other|1|
3330104|NCT00018200|Experimental|Arm 1|Desipramine, low, middle or high exposure
3330105|NCT00018200|Experimental|Arm 2|Fluoxetine, low, middle, or high exposure
3330106|NCT00018200|Placebo Comparator|Arm 3|Benztropine .125-.5mg daily
3330107|NCT00018174|Experimental|1|
3330108|NCT00018174|Placebo Comparator|2|
3330109|NCT00018148|Experimental|1|Transdermal nicotine plus nortriptyline
3330110|NCT00018148|Active Comparator|2|Transdermal nicotine plus placebo
3330111|NCT00018096|Experimental|bronchoscopy|2 bronchoscopies 4 hours apart; The first to instill the 3 experimental biologic agents in separate airways (HDM, LPS and saline-placebo), the second to perform BAL and brush biopsies 4 hours later in the same airways.
3330190|NCT00011583|Experimental|1|1 hour/day of mechanically-assisted upper limb therapy
3330113|NCT00017953|Experimental|Lifestyle Intervention|Participants in the lifestyle intervention arm are offered individual and group sessions designed to help achieve and maintain weight loss.
3330114|NCT00017953|Active Comparator|Diabetes Support and Education|The diabetes support and education arm provides group sessions on diabetes management and social support.
3330115|NCT00016835|Active Comparator|Supra-gingival scaling and placebo|"This group receives a placebo (instead of systemic antibiotic), supra-gingival oral prophylaxis, and ultrasonic removal of supra-gingival calculus with water irrigation at the initial treatment visit. At the 9-month follow-up visit, this group will receive sub-gingival ultrasonic scaling with povidone-iodine irrigation.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
3330116|NCT00016835|Experimental|Subgingival scaling and metronidazole|"This group receives ultrasonic scaling with local anesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation, and metronidazole as an oral systemic antibiotic at the initial treatment visit.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
3330117|NCT00016835|Experimental|Subgingival scaling and doxycycline|"This group receives ultrasonic scaling with local anesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation, and doxycycline as an oral systemic antibiotic at the initial treatment visit.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
3330118|NCT00016744|Active Comparator|1|"Subjects will be randomized to receive either the Phenylbutyrate or placebo tablets for 4 days~Every participant will receive Genistein during the NPD."
3330119|NCT00016744|Placebo Comparator|2|
3330120|NCT00016523|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide
3330121|NCT00016523|Active Comparator|Placebo|Inhaled Oxygen
3330122|NCT00015457|Experimental|cervical dystonia|cervical dsytonia patinets
3330123|NCT00015340|Experimental|Buprenorphine/Naloxone|
3330124|NCT00015210|Active Comparator|Nefazodone|Nefazodone 100 mg tablet, titrated to a maximum of 200 mg administered twice daily by treatment day 10. Drug tapered over 7 days at the conclusion of the treatment period. Treatment was administered for 8 weeks.
3330125|NCT00015210|Placebo Comparator|Matched Placebo Tablet|Matched placebo tablet, titrated up to 2 tablets twice daily by day 10 and tapered over 7 days at the conclusion of the study. Treatment period lasted 8 weeks.
3330126|NCT00014859||Population-based cohort|Descriptive cohort of population-based DNA samples from the newborn screening program in Missouri with vital statistics based, linked phenotype data
3330127|NCT00014859||Trio sequencing cohort|Affected infant/child (term or near term infant with progressive respiratory distress or other rare pulmonary phenotype or older child with interstitial lung disease or other rare pulmonary phenotype) and parents
3330128|NCT00014820||Patients with a diagnosis of asthma (new) (Cases)|Patients with a physician diagnosis of asthma during the 7.5 years being studied who were working at the time of diagnosis, as determined by patient interviews.
3330129|NCT00014820||Patients with a diagnosis other than asthma (Controls)|Patients (age-matched to a case patient) with a physician diagnosis other than asthma who were working at the time of diagnosis.
3330130|NCT00014820||Patients with a diagnosis of asthma (previous)|Patients with a physician diagnosis of asthma prior to the 7.5 years being studied
3330131|NCT00013611|No Intervention|Antiretroviral therapy alone|
3330132|NCT00013611|Experimental|Proleukin plus antiretroviral therapy|
3330133|NCT00013533|Experimental|1|Transplant with Induction Therapy
3330134|NCT00013481|Other|1|
3330135|NCT00013390|Active Comparator|1|Tinnitus Masking
3330136|NCT00013390|Other|2|Tinnitus Retraining Therapy
3330137|NCT00013260|Other|Arm 1|
3330138|NCT00013247|Other|Arm 1|
3330139|NCT00013234|Other|Arm 1|
3330140|NCT00013221|Other|Arm 1|
3330141|NCT00013208|Other|Arm 1|
3330142|NCT00013195|Other|Arm 1|
3330143|NCT00013182|Other|Arm 1|
3330144|NCT00013169|Other|Arm 1|
3330145|NCT00013156|Other|Arm 1|
3330146|NCT00013143|Other|Arm 1|
3330147|NCT00013130|Other|Arm 1|
3330148|NCT00013117|Other|Arm 1|
3330149|NCT00013104||Group 1|
3330150|NCT00013091|Other|Arm 1|
3330151|NCT00013078|Other|Arm 1|
3330152|NCT00013065||Group 1|
3330153|NCT00013052|Other|Arm 1|
3330154|NCT00013039|Other|Arm 1|
3330155|NCT00013026|Other|Arm 1|
3330156|NCT00013013|Other|Arm 1|
3330157|NCT00013000|Other|Arm 1|
3330158|NCT00012987|Other|Arm 1|
3330159|NCT00012974|Other|Arm 1|
3330160|NCT00012961||Group 1|
3330161|NCT00012948|Other|Arm 1|
3330162|NCT00012935|Other|Arm 1|
3330163|NCT00012922|Other|Arm 1|
3330164|NCT00012909|Other|Arm 1|
3330165|NCT00012896|Other|Arm 1|
3330166|NCT00012883|Other|Arm 1|Homewalking Exercise Program
3330167|NCT00012870|Other|Arm 1|
3330168|NCT00012857|Other|Arm 1|
3330169|NCT00012844|Other|Arm 1|
3330170|NCT00012831||Group 1|
3330171|NCT00012818|Other|Arm 1|
3330172|NCT00012805|Other|Arm 1|
3330173|NCT00012792|Other|Arm 1|
3330174|NCT00012779|Other|Arm 1|
3330175|NCT00012766|Other|Arm 1|
3330176|NCT00012753|Other|Arm 1|
3330177|NCT00012740|Other|Arm 1|
3330178|NCT00012727|Other|Arm 1|
3330179|NCT00012714|Other|Arm 1|
3330180|NCT00012701||Group 1|
3330181|NCT00012688|Other|Arm 1|
3330182|NCT00012675||Group 1|
3330183|NCT00012662|Other|Arm 1|
3330184|NCT00012649||Group 1|
3330185|NCT00012636|Other|Arm 1|
3330186|NCT00012623||Group 1|
3330187|NCT00012610|Other|Arm 1|
3330188|NCT00012597|Other|Arm 1|
3330189|NCT00011713||Infertility patients|Patients undergoing infertility treatment at Massachusetts General Hospital Infertility Clinic.
3330191|NCT00011583|Active Comparator|2|1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
3330192|NCT00011570|Other|1|
3330193|NCT00011531|Other|1|
3330194|NCT00011414|Experimental|1|Intervention given with dose escalation of tariquidar
3330195|NCT00011362|Active Comparator|Dexamethasone|Dexamethasone
3330196|NCT00011362|Placebo Comparator|Placebo|Saline
3330197|NCT00011349||Group 1|
3330198|NCT00011193||Non-Exercise Control Group|We randomly assigned 102 women in the non-exercise control group and were asked to maintain their level of activity for the 6-month study period.
3330199|NCT00011193||4-kcal/kg Energy Expenditure per week|We randomly assigned 155 women to the 4-kcal/kg per week group for 6 months.
3330200|NCT00011193||8-kcal/kg Energy Expenditure per week|We randomly assigned 104 women to the 8-kcal/kg per week group for 6 months.
3330201|NCT00011193||12-kcal/kg Energy Expenditure per week|We randomly assigned 103 women to the 12-kcal/kg per week group for 6 months.
3330202|NCT00011180||Incident Cohort with VTE|Olmsted County, Minnesota residents with with a first-lifetime deep vein thrombosis (DVT) or pulmonary embolism (PE) during the five year period, 1996-2000.
3330203|NCT00011180||Controls without VTE|Two Olmsted County, Minnesota residents without venous thromboembolism (VTE) were matched by age and gender to each definite or probable case of VTE within the 1996-2000 cohort.
3330204|NCT00010803|Placebo Comparator|Placebo|Placebo 1 pill twice a day
3330205|NCT00010803|Active Comparator|Ginkgo biloba|Ginkgo biloba EGb761 120 mg twice daily
3330206|NCT00010608|Experimental|Transcendental Meditation program|A mental technique for stress reduction which is natural, easy and effortless and is practiced sitting in a chair with eyes closed for 20 minutes twice a day.
3330207|NCT00010608|Active Comparator|Health Education|A lifestyle modification program for improving diet, exercise, salt intake and substance use.
3330208|NCT00009646|Experimental|Indomethacin|Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa.
3330209|NCT00009646|Placebo Comparator|Placebo|Saline solution
3330210|NCT00009620|Experimental|Phenobarbital|
3330211|NCT00009620|Placebo Comparator|Placebo|
3330212|NCT00010439|Experimental|1 Alendronate for 12 months|Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily.
3330213|NCT00010374|Experimental|1|The objective of this study is to assess the safety and efficacy of the NeuRx RA/4 for diaphragm pacing compared to mechanical ventilator support.
3330214|NCT00010374|Experimental|2|To test the safety, efficacy and clinical utility of diaphragm pacing using IM electrodes placed through a laparoscopic approach to achieve artificial ventilation in spinal cord injured patients who have an internal cardiac pacemaker and require full-time ventilator support.
3330215|NCT00010335|Experimental|1|Participants will receive a stem cell transplant.
3330216|NCT00009217|Active Comparator|Haloperidol-Haloperidol|Haloperidol for 20 weeks followed by haloperidol for 24 weeks
3330217|NCT00009217|Placebo Comparator|Haloperidol-Placebo|Haloperidol for 20 weeks followed by placebo for 24 weeks
3330218|NCT00008450|Experimental|Treatment (cyclosporine, mycophenolate mofetil, transplant)|Patients receive cyclosporine PO or IV on days -3 to 100 followed by a taper until day 180 and mycophenolate mofetil PO or IV on days 0-40 with a taper until day 96 in the absence of unacceptable toxicity. Unrelated donor recipients also undergo TBI on day 0. Patients undergo bone marrow transplant on day 0.
3330219|NCT00007696||1|
3330220|NCT00007657|Experimental|1|Percutaneous Coronary Intervention (PCI) plus intensive medical therapy
3330221|NCT00007657|Active Comparator|2|Intensive medical therapy
3330222|NCT00007774|Experimental|1|Olanzapine
3330223|NCT00007774|Active Comparator|2|Haloperidol
3330224|NCT00007761|Experimental|1|Bipolar Disorder Program
3330225|NCT00007761|Active Comparator|2|Usual (psychiatric) Care
3330226|NCT00007722||1|
3330227|NCT00007709||1|
3330228|NCT00007683|Active Comparator|1|Warfarin Titrated to an INR of 2.5-3.0
3330229|NCT00007683|Active Comparator|2|Aspirin 182 mg
3330230|NCT00007683|Active Comparator|3|Clopidogrel 75 mg
3330231|NCT00007644|Other|Radical Prostatectomy|Surgical removal of the prostate
3330232|NCT00007644|No Intervention|Watchful Waiting|Closely watching, waiting and treating symptoms if and when cancer progresses
3330233|NCT00007631|Active Comparator|1|Topical Tretinoin
3330234|NCT00007631|Placebo Comparator|2|Placebo
3330235|NCT00007618||1|
3330236|NCT00007605|Active Comparator|1|Amiodarone or Sotalol
3330237|NCT00007605|Active Comparator|2|Sotalol
3330238|NCT00007579||1|
3330239|NCT00007501|Experimental|Arm 1|varicella-zoster vaccine
3330240|NCT00007501|Placebo Comparator|Arm 2|vaccine placebo
3330241|NCT00007475|Experimental|Plasma Exchange + Cyclophosphamide|"Procedure/Surgery: Plasma exchange A course of plasma exchange of 5 treatments over 10 days, then administration of cyclophosphamide.~Drug: Cyclophosphamide For GFR > 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR < 50 ml/min/1.73 m2 but > 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months."
3330242|NCT00007358|Experimental|1|Depending on patient and physician decision, a steroid may be administered during pregnancy.
3330243|NCT00007345|Experimental|Peripheral T-cell Lymphoma (PTCL)|Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle.
3330244|NCT00007345|Experimental|Cutaneous T-cell Lymphoma (CTCL)|Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle.
3330245|NCT00007267|Experimental|1|Participants will receive individual cognitive behavioral therapy
3330246|NCT00007267|Experimental|2|Participants will receive self-help cognitive behavioral intervention facilitated by a psychologist
3330247|NCT00007267|Active Comparator|3|Participants will receive a disease/health education intervention
3330248|NCT00007020|Other|Cholic Acid|
3330249|NCT00006565|Experimental|1|HEPA Air Cleaners
3330251|NCT00006517|Active Comparator|bright light box|30 min exposure shortly after wake-up
3330252|NCT00006517|Active Comparator|high-output negative ion generator|90 min exposure prior to wake-up
3330253|NCT00006517|Placebo Comparator|low-output negative ion generator|90 min exposure prior to wake-up
3330254|NCT00006517|Active Comparator|dawn simulator|naturalistic incremental light exposure 90 min prior to wake-up
3330255|NCT00006517|Experimental|dawn light pulse|rectangular pulse light exposure 13 min before wake-up, matched for total illuminance with dawn signal
3330256|NCT00006505|Experimental|Transplant|Islet cell transplantation
3330257|NCT00006501||ECG recording|After the tests are completed, people who enroll in this study are followed by telephone, 1, 4, 8, 12 16, 20 and 24 months. During these follow-up telephone calls a research coordinator asks about the participant's health condition and about cardiovascular medications that are being taken.
3330258|NCT00006489|Active Comparator|Naltrexone alone|Naltrexone alone
3330259|NCT00006489|Active Comparator|Naltrexone with CBT for PTSD|Naltrexone with CBT for PTSD
3330260|NCT00006489|Active Comparator|Placebo with CBT for PTSD|Placebo with CBT for PTSD
3330261|NCT00006489|Placebo Comparator|Placebo alone|Placebo alone
3330262|NCT00006436|Experimental|1|Combo chemo and biological therapy
3330263|NCT00006420||Observational, no interventions|
3330264|NCT00006411|Active Comparator|1|cornea from donor <66.0 years
3330265|NCT00006411|Active Comparator|2|cornea from donor >= 66.0 years
3330266|NCT00006409|Experimental|School-based intervention|TAAG health education included six lessons in each of 7th and 8th grades designed to enhance behavioral skills known to influence physical activity. TAAG physical education classes promoted moderate-vigorous physical activity for at least 50% of class time and encouraged teachers to promote physical activity outside of class. In conjunction with community partners, programs that were promoted outside of school included Dance Dance Revolution, after-school step aerobics class, before-school open gym, basketball camp, touch football, and weekend canoe programs. TAAG promotions used a social marketing approach to promote awareness of and participation in activities through media and promotional events.
3330267|NCT00006409|No Intervention|Control group|
3330268|NCT00006401|Experimental|Inhaled Nitric Oxide (iNO)|Nitric Oxide study gas will be initiated at 5 ppm using the INOvent delivery system. The delivery system provides for masked delivery of the treatment gas. This dose will be used for a 21-day period or until extubation.
3330269|NCT00006401|Placebo Comparator|Placebo|
3330270|NCT00006400|Active Comparator|1|Participants will receive hydroxyurea.
3330271|NCT00006400|Placebo Comparator|2|Participants will receive placebo.
3330272|NCT00006398|Experimental|Timolol Maleate|Dose titrated from 5 mg per day to up to 80 mg per day depending on heart rate
3330273|NCT00006398|Placebo Comparator|Placebo|Timelol placebo
3330274|NCT00006305|Active Comparator|Revascularization and Insulin Providing (IP)|Prompt revascularization with intensive medical therapy and insulin providing glycemic control strategy
3330275|NCT00006305|Active Comparator|Revascularization and Insulin Sensitizing (IS)|Prompt revascularization with intensive medical therapy and insulin sensitizing glycemic control strategy
3330276|NCT00006305|Active Comparator|Medical Therapy and Insulin Providing (IP)|Intensive medical therapy with delayed revascularization if clinically indicated and insulin providing glycemic control strategy
3330277|NCT00006305|Active Comparator|Medical Therapy and Insulin Sensitizing (IS)|Intensive medical therapy with delayed revascularization if clinically indicated and insulin sensitizing glycemic control strategy
3330278|NCT00006295||Pedigree 1|
3330279|NCT00006295||Pedigree 2|
3330280|NCT00006295||Pedigree 3|
3330281|NCT00006295||Pedigree 4|
3330282|NCT00006295||Pedigree 5|
3330283|NCT00006295||Pedigree 6|
3330284|NCT00006295||Pedigree 7|
3330285|NCT00006295||Pedigree 8|
3330286|NCT00006295||Pedigree 9|
3330287|NCT00006295||Pedigree 10|
3330288|NCT00006295||Pedigree 11|
3330289|NCT00006295||Pedigree 12|
3330290|NCT00006294||Chlorthalidone|Participants will take chlorthalidone at recommended doses to control hypertension
3330291|NCT00006294||Amlodipine|Participants will take Amlodipine at recommended doses to control hypertension
3330292|NCT00006294||Lisinopril|Participants will take Lisinopril at recommended doses to control hypertension
3330293|NCT00006294||Doxazosin|Participants will take Doxazosin at recommended doses to control hypertension
3330294|NCT00006289|Active Comparator|Placebo first, then Neurotropin (G-1)|Double blind cross-over study: receive placebo for 5 weeks and then Neurotropin for 5 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
3330295|NCT00006289|Active Comparator|Neurotropin first, then Placebo (G-2)|Double blind cross-over study: receive Neurotropin for 5 weeks and then placebo for 5 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
3330296|NCT00006205|Experimental|Ondansetron|Ondansetron + cognitive behavioral therapy
3330297|NCT00006205|Experimental|Topiramate|Topiramate + cognitive behavioral therapy
3330298|NCT00006205|Placebo Comparator|Placebo|Placebo + cognitive behavioral therapy
3330299|NCT00006205|Experimental|Ondansetron + Topiramate|Ondansetron + Topiramate + cognitive behavioral therapy
3330300|NCT00006184|Experimental|Recipient - Chemotherapy Group|Induction chemotherapy with fludarabine, etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone, and granulocyte colony stimulating factor (GCSF) followed by transplant preparative regimen chemotherapy with fludarabine, cyclophosphamide, mesna, cyclosporine, and methotrexate, followed by stem cell infusion and immunization.
3330301|NCT00006184|Other|Donor - Vaccine Generation Group|3 subcutaneous injections of myeloma protein within 10 weeks before stem cell collection. The first (week 0) second (week 2), and third injection (week 6) with Id-KLH (Anti-idiotype-keyhole limpet hemocyanin) (0.5 mg subcutaneous day 1) and Granulocyte macrophage-colony stimulating factor (GM-CSF) (250 mcg/m^2 subcutaneous on days 1-4). Stem cell collection is 4 weeks after the third vaccination.
3330302|NCT00006172|Active Comparator|bright light box|60 min light therapy shortly after awakening
3330303|NCT00006172|Active Comparator|high-output negative ion generator|60 min high-density exposure shortly after awakening
3330304|NCT00006172|Placebo Comparator|low-output negative ion generator|60 min low-density exposure shortly after awakening
3330305|NCT00006170|Experimental|Bupropion and Weight Concerns intervention|Bupropion SR and a weight concerns psychosocial intervention
3330306|NCT00006170|Active Comparator|Placebo and Weight Concerns|A matched placebo administered on same schedule as bupriopion and a weight concerns psychosocial intervention for smoking cesstion
3330307|NCT00006170|Active Comparator|Bupropion and standard smoking cessation|Bupropion SR and a time and attention controlled smoking cessation intervention
3330308|NCT00006170|Placebo Comparator|Placebo and standard smoking cessation|A matched placebo administered on same schedule as bupriopion and a time and attention controlled smoking cessation intervention
3330309|NCT00006156|Experimental|Control|Control for FSH stimulation test
3330310|NCT00006156|Experimental|Drug: FSH|FSH Stimulation Test
3330311|NCT00006164|Experimental|1|Peg-interferon alfa-2a 90 mcg/week
3330312|NCT00006164|Active Comparator|2|Standard of care followup
3330313|NCT00006151|Experimental|Accu Drops (AD&C)|The experimental group (N=30) will be prescribed active Accu Drops (AD&C) plus behavioral therapy.
3330314|NCT00006151|Placebo Comparator|Placebo|The control condition (N=30) will be prescribed placebo Accu Drops (PD&C) plus behavioral therapy.
3330315|NCT00005937|Experimental|Antithymocyte globulin & cyclosporine|Myelodysplastic syndromes (MDS) subjects will be treated with Anti-thymocyte Globulin (ATG) and cyclosporine (CsA). The subjects will receive ATG at a dose of 40mg/kg orally on days 1-4 in combination with oral prednisone at a dose of 1mg/kg/day on day one. The prednisone will be tapered on day 10. The taper schedule will be every two days over a total of eight days (days 10-17). Drug the ATG administration the subjects will receive at least 4 units of platelets daily for platelet counts less than 20,000/ microliters. Cyclosporine (CsA) will be started on day 14 at a dose of 5mg/kg twice daily with dose adjustments based on drug levels (target 200-400 ng/ml). Cyclosporine therapy will be continued for six months.
3330316|NCT00005922|Experimental|A|Participants will receive 100% of the dose of the medication on the same reinforcement schedule (100%) as received during the baseline (maintenance) period.
3330317|NCT00005922|Experimental|B|Participants will receive 100% of the dose of the medication on a partial reinforcement schedule (25% or 50%) as received during the baseline (maintenance) period
3330318|NCT00005922|Experimental|C|Participants will receive 25% or 50% of the dose of the medication on the same reinforcement schedule (100%) as received during the baseline (maintenance) period.
3330319|NCT00005908|Experimental|Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine|Docetaxel 75 mg/m^2 intravenous day 1, capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles
3330320|NCT00005908|Experimental|Dose B-Cohort 2-Arm 2 Reduced dose-Docetaxel & Capecitabine|Docetaxel 60 mg/m^2 intravenous day 1, capecitabine 937.5 mg/m^2 orally twice daily day 2-15 for 4 cycles
3330321|NCT00005906|Experimental|Octreotide|Patients with lymphangioleiomyomatosis and lymphatic tumors, ascites or pleural effusions who are symptomatic will receive subcutaneous injections of octreotide starting at a dose of 100 micrograms per day. Doses will be gradually increased to a maximum of 800 micrograms per day, two months after enrollment, if there is no response to lower doses.
3330322|NCT00005901|Active Comparator|Pamidronate every 3 months for 3 years|Subjects who received Pamidronate every 3 months for 3 years.
3330323|NCT00005901|Active Comparator|Pamidronate every 6 months for 3 years|Subjects who received Pamidronate every 6 months for 3 years.
3330324|NCT00005780|Experimental|1|EPOCH-R followed by idiotype vaccine and GM-CSF
3330325|NCT00005777|Experimental|Minimal ventilation with Dexamethasone|Minimal ventilator support strategy (permissive hypercapnia) and early stress dose dexamethasone therapy
3330326|NCT00005777|Experimental|Minimal Ventilation without Dexamethasone|Minimal ventilator support strategy (permissive hypercapnia) and no dexamethasone therapy
3330327|NCT00005777|Active Comparator|Routine ventilation with Dexamethasone|
3330328|NCT00005777|Active Comparator|Routine ventilation without Dexamethasone|
3330329|NCT00005776|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide (iNO)
3330330|NCT00005776|Placebo Comparator|Oxygen|100% oxygen
3330331|NCT00005775|Experimental|Glutamine|TrophAmine (B. Braun/McGaw) with cysteine hydrochloride (40mg/gm amino acids) with L-glutamine added (20% of the total amount of amino acids)
3330332|NCT00005775|Placebo Comparator|Placebo|Standard TrophAmine (B. Braun/McGaw) with cysteine hydrochloride (40mg/gm amino acids)
3330333|NCT00005774|Experimental|Early surfactant group|
3330334|NCT00005774|Active Comparator|Standard Practice group|
3330335|NCT00005773|Experimental|Early iNO Management|Initiation of iNO in use for term and near-term infants in respiratory failure with an oxygenation index between 15-25.
3330336|NCT00005773|Active Comparator|Standard iNO management|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI >=25).
3330337|NCT00005772|Experimental|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
3330338|NCT00005772|Placebo Comparator|Normothermic|Placebo: Normothermic control group (with esophageal temperature at or near 37.0°C) for 96 hours
3330339|NCT00005675|Experimental|1|Participants will receive oral bovine type I collagen (CI) daily for 15 months
3330340|NCT00005675|Placebo Comparator|2|Participants will receive placebo daily for 15 months.
3330341|NCT00005739||Community-based therapy (case)|Community-based directly observed therapy (DOT) - A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
3330342|NCT00005739||Self-administered treatment (control)|Clinic directly observed therapy (DOT) - Traditional self-administered preventive treatment
3330343|NCT00005727|Experimental|Intervention|Specially-designed nutrition education curriculum designed to lower dietary fat intake in people with low literacy skills.
3330344|NCT00005727|Active Comparator|Control|General nutrition education curriculum.
3330345|NCT00005724|Other|Minimal Intervention Group|Pamphlets on healthy eating mailed to participants.
3330628|NCT00000304|Experimental|1|15/30 mg d-amphetamine
3330346|NCT00005724|Experimental|Health Counselor Intervention Group|Food for Heart program, a structured diet treatment program for low-income patients with high cholesterol, given by health counselor at 4 treatment visits.
3330347|NCT00005724|Experimental|Computer Program Intervention Group|User-friendly interactive computer program providing dietary counseling tailored to the needs of the participant.
3330348|NCT00005713||Continuing, preventative care for asthma|Low-income children with asthma will receive continuing, preventive care for asthma with trained staff in New York City Bureau of Child Health clinics
3330349|NCT00005711|No Intervention|Usual care|Control group children received routine medical care by their primary care providers as well as study visits every 6 months. At each study visit, following assessment of technique for using peak flow and metered dose inhalers, errors were corrected and children/families were coached on correct technique.
3330350|NCT00005711|Experimental|Asthma self-management education|"Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish."
3330351|NCT00005699||Hypertensive|described as hypertensive according to AHA guidelines at time of trial
3330352|NCT00005699||Controls|described as non-hypertensive according to AHA guidelines at time of trial
3330353|NCT00005676||VA-HIT and FOS|VA-HIT cohort: men with established CHD and low HDL-C FOS cohort: men without CHD
3330354|NCT00005533||Coronary Heart Disease Patients|
3330355|NCT00005520||African American hydrochlorothiazide|300 African American hypertensives were treated with hydrochlorothiazide 25 mg daily for 4 weeks.
3330356|NCT00005520||European American hydrochlorothiazide|300 European American hypertensives were treated with hydrochlorothiazide 25 mg daily for 4 weeks
3330357|NCT00005520||African American candesartan|300 African American hypertensives were treated with candesartan 16 mg daily for 2 weeks followed by 32 mg daily for 4 weeks
3330358|NCT00005520||European American candesartan|300 European American hypertensives were treated with candesartan 16 mg daily for 2 weeks followed by 32 mg daily for 4 weeks
3330359|NCT00005502||Residents of Olmsted County, MN with elevated Troponins|Anyone admitted to St Marys or Rochester Methodist Hospitals who have an elevated troponin during their hospitalization and are residents of Olmsted County, MN
3330360|NCT00005446||Postmenopausal women with coronary heart disease|
3330361|NCT00005446||Postmenopausal women without coronary heart disease|Matched in age to the women with heart disease
3330362|NCT00005398||1; no experimental groups in this study|Observational cohort study
3330363|NCT00005379||IV drug users and their sexual contacts|This group will be made up of an already-recruited cohort
3330364|NCT00005379||Children who receive primary care at Bellevue Hospital|
3330365|NCT00005379||Bellevue Hospital inpatients/outpatients|Inpatients being treated for TB and outpatients receiving prophylactic treatment
3330366|NCT00005305||Hemophilic individuals|Subjects receiving multiple blood products for treatment of hemophilia
3330367|NCT00005219||Exercise Study Participants|Data from the San Diego Health and Exercise Baseline survey conducted in 1986 were used to contact participants for the follow-up
3330368|NCT00005145||Observational, no interventions|
3330369|NCT00005669|Active Comparator|1 - Metformin HCL|Subjects receive metformin plus a weight loss program
3330370|NCT00005669|Placebo Comparator|2 - Placebo|Subjects receive placebo plus a weight loss program
3330371|NCT00005655|Experimental|1|rhIL-12 in combination with rhIL-2
3330372|NCT00005006|Active Comparator|1|Alendronate alone
3330373|NCT00005006|Active Comparator|2|Teriparatide daily plus alendronate
3330374|NCT00005006|Active Comparator|3|Teriparatide cyclically plus alendronate
3330375|NCT00005005|Experimental|1|Participants will receive PTH for 1 year followed by alendronate for 1 year.
3330376|NCT00005005|Experimental|2|Participants will receive PTH and alendronate for 1 year followed by alendronate for 1 year.
3330377|NCT00005005|Experimental|3|Participants will receive alendronate for 2 years.
3330378|NCT00005005|Active Comparator|4|Participants will receive PTH for 1 year followed by placebo for 1 year.
3330379|NCT00004992|Placebo Comparator|Placebo|
3330380|NCT00004992|Active Comparator|Metformin|
3330381|NCT00004992|Active Comparator|Intensive Lifestyle|
3330382|NCT00004980|Experimental|active rTMS|1-Hz rTMS delivered to left temporoparietal cortex at 90% motor threshold for 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)
3330383|NCT00004980|Placebo Comparator|sham stimulation|Sham stimulation delivered 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)
3330384|NCT00004853|Experimental|1|single dose of intervention after each cycle of Standard 5 drug dose-intensive chemotherapy
3330385|NCT00004853|Experimental|2|single dose of interventionafter each cycle of Standard 5 drug dose-intensive chemotherapy
3330386|NCT00004732|Active Comparator|Carotid Artery Endarterectomy (CEA)|Carotid endarterectomy is surgery to remove plaque buildup that causes narrowing (stenosis) in the carotid artery.
3330387|NCT00004732|Active Comparator|Carotid Artery Stenting (CAS)|Carotid artery stenting (CAS) is a procedure used to open narrowed carotid arteries. During the procedure, a small, expandable wire tube called a stent is permanently inserted into the carotid artery.
3330388|NCT00004843|Experimental|Parathyroidectomy|
3330389|NCT00004843|Active Comparator|Observation|
3330390|NCT00004842|Experimental|Budesonide|Oral budesonide
3330391|NCT00004769||Myotonic dystrophy|Subjects with myotonic dystrophy
3330392|NCT00004769||Healthy controls|Healthy subjects
3330393|NCT00004769||Disease controls 1|Subjects with FSHD
3330394|NCT00004769||Disease controls 2|Subjects with CMT
3330395|NCT00004660|Experimental|Radiotherapy|
3330396|NCT00004660|Sham Comparator|Sham treatment|
3330397|NCT00004635|Experimental|Thalidomide|Study participants are randomly assigned to one of two treatment groups. Participants received leuprolide or goserelin for 6 months. In period 1 participants received thalidomide orally 200 mg a day. Patients will be followed until PSA progression defined as prostate-specific antigen (PSA) level that returns to what it was before beginning leuprolide or goserelin or to 5 nanograms per liter, whichever is lower. The participants are returned to the leuprolide or goserelin treatment for 6 months. In period 2 participants received the placebo for thalidomide once a day.
3330398|NCT00004635|Experimental|Placebo|Study participants are randomly assigned to one of two treatment groups. Participants received leuprolide or goserelin for 6 months. In period 1 participants received placebo for thalidomide. Patients will be followed until PSA progression defined as prostate-specific antigen (PSA) level that returns to what it was before beginning leuprolide or goserelin or to 5 nanograms per liter, whichever is lower. The participants are returned to the leuprolide or goserelin treatment for 6 months. In period 2 participants received thalidomide 200 mg once a day.
3330399|NCT00004563|Experimental|Cylophosphamide|Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
3330400|NCT00004563|Placebo Comparator|Placebo|Matching gel caps at a dose of 25 mg
3330401|NCT00004562|Active Comparator|Optimal Medical Therapy Only (MED)|Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification
3330402|NCT00004562|Experimental|Percutaneous Coronary Intervention (PCI)|Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification, plus percutaneous coronary intervention and coronary stenting
3330403|NCT00004554|Experimental|Sertraline|sertraline
3330404|NCT00004554|Experimental|Naltrexone|naltrexone
3330405|NCT00004554|Experimental|Nal/Sert|naltrexone/sertraline
3330406|NCT00004554|Placebo Comparator|Placebo|Placebo
3330407|NCT00004547|Experimental|Peritoneal mesothelioma|Patients with peritoneal mesothelioma suffer with intractable ascites but have a very surface oriented tumor which usually does not invade into organs and cause organ dysfunction. The main source of symptoms and cause of death is intractable ascites.
3330408|NCT00004547|Experimental|Low grade mucinous adenocarcinoma|Low grade mucinous adenocarcinoma also includes low grade mucinous neoplasms of borderline malignant potential. Patients with low grade mucinous adenocarcinoma can have prolonged survival with debulking surgery alone. The majority of patients with truly malignant disease will die of complications from intraperitoneal progression of tumor within 2 to 5 years. The tumors are often surface oriented within the peritoneal cavity without metastases to other distant sites. The most common origin for this type of tumor is the appendix and ovary.
3330409|NCT00004547|Experimental|Adenocarcinoma of gastrointestinal origin|Adenocarcinoma of gastrointestinal origin also includes other than low grade mucinous. Aggressive gastrointestinal adenocarcinomas such as gastric, small bowel, and colon cancer , tend to be more invasive into tissues and can more readily metastasize to distant sites. The cause of death is usually directly related to intraperitoneal progression of tumor. It is a more difficult group of patients to treat with intraperitoneal therapy because of the aggressive and invasive nature of the tumors.
3330410|NCT00001984|Experimental|Alemtuzumab and DSG|The recipients of live donor kidneys were treated perioperatively with alemtuzumab and DSG and followed postoperatively without maintenance immunosuppression.
3330411|NCT00000435|Placebo Comparator|A|Subjects randomized to arm A received 25mg/day po of placebo
3330412|NCT00000435|Active Comparator|B|Subjects randomized to Arm B received 25mg/day po of peptide dnaJP1
3330413|NCT00000434|Experimental|1|Fit and Strong! is a multi-component exercise and health education program that incorporates flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
3330414|NCT00001962|Experimental|daclizumab|daclizumab, 1 mg/kg of body weight, will be given for a total of 5 intravenous infusions. The subjects diagnosed with moderate aplastic anemia, pure red cell aplasia, Diamond Blackfan anemia, relapse and refractory severe aplastic anemia will receive treatment. The subjects will be seen and receive the daclizumab infusion biweekly during the treatment period.
3330415|NCT00001941|Experimental|Phase I - 2 mg/kg cohort|2 mg/kg daclizumab over 60 minutes intravenously on days 1 and 2
3330416|NCT00001941|Experimental|Phase I - 4 mg/kg cohort|4 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
3330417|NCT00001941|Experimental|Phase I - 6 mg/kg cohort|6 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
3330418|NCT00001941|Experimental|Phase I - 8 mg/kg cohort|8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
3330419|NCT00001941|Experimental|Phase II - 8 mg/kg cohort|8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
3330420|NCT00000431|Experimental|1|Upon evaluation, participant will be treated with a single intra-ulcer injection of PDGF-B/Ad5 in the wound. Patients will receive only one dose, which will be administered during a 72-hour inpatient stay in a research unit at the Hospital of the University of Pennsylvania. This study will use a standard three-six dose-escalation scheme.
3330421|NCT00000428|Experimental|1|Patients received each intervention multiple times in random-order crossover design.
3330422|NCT00000392|Active Comparator|Peptide T|Peptide T given intranasally at a dosage of 2mg 3 times a day for 6 months
3330423|NCT00000392|Placebo Comparator|Placebo|Placebo given intranasally at a dosage of 2mg 3 times a day for 6 months
3330424|NCT00001880|Experimental|1|CSA beginning day -4 and intravenous MTX on days +1, +3, and +6 will be given
3330425|NCT00001832|Experimental|Abl Cells in culture|"Peripheral blood mononuclear cells (PBMC) and/or tumor infiltrating lymphocytes (TIL) obtained by apheresis or lesion excision to be cloned and expanded in the lab.The patients underwent an apheresis and/or an excision of their tumor.~They didn't receive any drugs."
3330426|NCT00001832|Experimental|Abl Cells IV + Cyclophosphamide 30 mg/kg|Phase 1 Cyclophosphamide Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x30mg/kg + Cells intravenous (IV) Abl cells intravenous (IV) = Lymphocytes 10^9‑10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
3330449|NCT00001626|Active Comparator|2|40 mg/kg of ATG daily for 4 days as immunosuppressive agent for treatment of severe aplastic anemia
3330629|NCT00000304|Experimental|2|30/60 mg d-amphetamine
3330427|NCT00001832|Experimental|Abl Cells IV + Cyclophosphamide 60 mg/kg|Phase 1 Cyclophosphamide Dose Escalation: Fludarabine 5x25mg/m2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) Abl cells IV = Lymphocytes 10^9‑10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
3330428|NCT00001832|Experimental|Abl Cells IV+Low Dose IV IL-2 (Initial)|Phase 1 interleukin-2 (IL-2) Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV IL-2 (72,000 IU/kg q8h for a maximum of 15 doses) Abl cells IV = Lymphocytes 10^9‑10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
3330429|NCT00001832|Experimental|Abl Cells IV+High Dose IV IL-2 (Initial)|Phase 1 interleukin-2 (IL-2) Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV IL-2 (720,000 IU/kg q8h for a maximum of 12 doses) Abl cells IV = Lymphocytes 10^9‑10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
3330430|NCT00001832|Experimental|Abl Cells IV + MTD IL-2|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) (to shorten time to neutrophil recovery) Abl cells IV = Lymphocytes 10^9‑10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
3330431|NCT00001832|Experimental|Abl Cells IA + MTD (prior cells IV on 6)|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) Prior Cells IV + growth colony stimulating factor (G-CSF) Abl cells IA = Lymphocytes 10^9‑10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
3330432|NCT00001832|Experimental|Abl Cells IA + MTD IL-2|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) Abl cells IA = Lymphocytes 10^9‑10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
3330433|NCT00001832|Experimental|Abl Cells IA+MTD IL-2 (MART-1 reactive)|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) + melanoma- associated antigen recognized by T cells (MART-1):26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IA = Lymphocytes 10^9‑10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days gp100 = gp100:209‑217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209‑217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
3330434|NCT00001832|Experimental|Abl Cells IV + MTD IL-2 no GCSF|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) without growth colony stimulating factor (G-CSF) (to determine if G-CSF has harmful effects when adoptively transferring lymphocytes following a nonmyeloablative chemotherapy regimen) Abl cells IV = Lymphocytes 10^9‑10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
3330435|NCT00001832|Experimental|Abl Cells IV+MTD IL-2 no GCSF|"Abl Cells intravenous (IV) + maximum tolerated dose (MTD) interleukin-2 (IL-2) no growth colony stimulating factor (GCSF)(gp100 reactive).~Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + IV IL-2 (720,000 IU/kg q8h for a maximum of 12 doses) without G-CSF + gp100:209-217(210M) 1mg/day (2-8 days) in patients with gp100 reactive cells Abl cells IV = Lymphocytes 10^9‑10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days"
3330436|NCT00001832|Experimental|Abl Cells IV+MTD IL-2|"Abl Cells intravenous (IV)+ maximum tolerated dose (MTD) interleukin-2 (IL-2) no growth colony stimulating factor (GCSF) (melanoma-associated antigen recognized by T cells (MART-1)reactive).~Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) without G-CSF + MART-1:26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IV = Lymphocytes 10^9‑10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days"
3330437|NCT00001832|Experimental|Abl Cells IV + SQ IL-2 with GCSF|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 (IL-2) (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + growth colony stimulating factor (G-CSF) (to shorten time to neutrophil recovery), reactivity not specified Abl cells IV = Lymphocytes 10^9‑10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
3330438|NCT00001832|Experimental|Abl Cells IV + SQ|Abl Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 (IL-2) with growth colony stimulating factor (GCSF) (melanoma-associated antigen recognized by T cells (MART-1) reactive) Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + SQ IL-2 (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + G-CSF + MART-1:26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IV = Lymphocytes 10^9‑10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
3330439|NCT00001832|Experimental|Abl Cells IV + SQ IL-2 with GCSF (no reactivity)|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 ( IL-2) (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + growth colony stimulating factor (G-CSF) in patients with no reactivity Abl cells IV = Lymphocytes 10^9‑10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
3330440|NCT00001806|Experimental|Group|Group education and counseling
3330441|NCT00001806|Active Comparator|Individual|Individual education and counseling
3330442|NCT00001723|Placebo Comparator|Placebo|Matching placebo 120 mg TID x 6 months plus a behavioral weight loss program
3330443|NCT00001723|Experimental|Orlistat|Orlistat 120 mg TID for 6 months plus a behavioral weight loss program
3330444|NCT00001703|Experimental|Group A-VHL peptide and ISA-51 adjuvant|Patients are vaccinated with 1000 micrograms of the mutant Von Hipple-Lindau (VHL) peptide administered subcutaneously along with ISA-51 adjuvant (Montanide ISA-51 adjuvant, Incomplete Freund's adjuvant) and injected subcutaneously every four weeks for a total of four vaccinations.
3330445|NCT00001686||1 -Cohort A|Children and adults with cancer (or a pre-cancer syndrome), between the age(s) of 2 years - 40 years, who present with disease manifestations of special interest to POB investigators.
3330446|NCT00001656|Active Comparator|Olanzapine|
3330447|NCT00001656|Active Comparator|Clozapine|
3330448|NCT00001626|Experimental|1|1 hour intravenous infusion of 50 mg/kg of cyclophosphamide daily for 4 days as an alternative immunosuppressive agent for treatment of severe aplastaic anemia.
3330450|NCT00001596|Active Comparator|Pirfenidone|Subjects received pirfenidone 801 mg (3 pills of 267 mg each), three times daily.
3330451|NCT00001596|Placebo Comparator|Placebo|Subjects received placebo (3 pills), three times daily.
3330452|NCT00001586|Experimental|Low-Intermediate Risk B-Cell Pts|Previously untreated low or intermediate risk B-cell chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL) patients (pts) not requiring chemotherapy. No rituximab fludarabine administered. Eligible to donate cells.
3330453|NCT00001586|Experimental|Intermediate-high Risk B-Cell Pts|Previously untreated intermediate or high risk B-cell chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL) patients requiring chemotherapy. Rituximab 375 mg/m^2 by infusion on day 1, cycle 1 followed by fludarabine on day 2-6, 25 mg/m^2 day x 5 days administered as an intravenous push or intravenous piggyback over 10-30 minutes, repeated every 28 days.
3330454|NCT00001575|Experimental|Anti-Tac yttrium 90-labeled humanized anti-Tac (90 Y-HAT)|"10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).~Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body"
3330455|NCT00001566|Experimental|Peptide vaccine/autologous T cell transplant/indinavir therapy|Patients receive oral indinavir sulfate 350 mg/m^2 administered every 8 hours; maximum dose i.e. 800 mg every 8 hours; peptide pulsed dendritic cells 1 x 10^6 injection; harvested autologous T cells (minimum dose 1 x 10^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
3330456|NCT00001563|Experimental|1|EPOCH-R every 3 weeks for up to 6 cycle
3330457|NCT00001465||1|Healthy Volunteers
3330458|NCT00001465||2|LAM Patients
3330459|NCT00001458||Cardiovascular|subjects with cardiovascular symptoms or known disease.
3330460|NCT00001403||Proteus Syndrome|Patients with Proteus syndrome (PS) and other overgrowth disorders hypothesized to be in the AKT/PI3K pathway
3330461|NCT00001379|Experimental|1|Interferon starting at 7.5 million Units subQ 3 times a week and increasing on the designated schedule,as tolerated. Patients continue taking interferon for 1 year beyond CR. Patients who progress may crossover to receive EPOCH-R.
3330462|NCT00001379|Experimental|2|EPOCH-R every 3 weeks for up to 8 cycles, based onresponse.
3330463|NCT00001337|Experimental|Arm A|EPOCH + Rituximab every 3 weeks for 6 cycles.
3330464|NCT00001304|Experimental|PTH 1-34|All patients received twice daily synthetic Human Parathyroid Hormone 1-34.
3330465|NCT00001304|Experimental|Calcitriol & Calcium|All patients received twice daily Calcitriol and Calcium 1000mg divided into four doses daily.
3330466|NCT00001262|Experimental|Copper histidine|
3330467|NCT00001238||Category A|Patients, and their biologic relatives, who may or may not be affected who will be evaluated in the NIH CC
3330468|NCT00001238||Category B|Patients, their at-risk biologic relatives and spouses of patients with inherited urologic malignancies who will not be evaluated at the Clinical Center
3330469|NCT00001238||Category C|Biologic relatives and spouses who enroll in this study primarily for genetic linkage studies. These individuals will contribute a blood sample for DNA analysis only.
3330470|NCT00001214||Group 1|Patients with pancytopenia
3330471|NCT00001213|Experimental|Cysteamine topical solution|Cysteamine topical solution administered hourly while awake in both eyes
3330472|NCT00001186||Cohort 1|Children 7-17 years of age who are currently being treated for cancer or are up to 5 years post therapy.
3330473|NCT00001186||Cohort 2|Young adults with cancer (YACers) acting as counselors at Camp Fantastic and are enrolled in another NIH protocol.
3330474|NCT00001151|Experimental|Drug treatment|1,25-Dihydroxycholecalciferol 5 ug orally per day for 2 years
3330475|NCT00000421|Active Comparator|Prednisone arm|Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.
3330476|NCT00000421|Placebo Comparator|Placebo|Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.
3330477|NCT00000416|Experimental|Rehabilitation counseling|"Rehabilitation counseling~Experimental~Rehabilitation counseling was provided by rehabilitation counselors. They administered the Work Experience Survey; provided and discussed disability rights and responsibilities and provided career counseling they as needed."
3330478|NCT00000416|Active Comparator|printed information|"Active comparator~Control group participants received relevant printed information in the mail only; no rehabilitation counseling"
3330479|NCT00000414|Experimental|Arthritis Self-Management Program|small group self-management program
3330480|NCT00000414|Experimental|SMART Program|Self-Managed Arthritis Relief Therapy: mailed self management material
3330481|NCT00000412|Active Comparator|Group A|Group A active alendronate (10 mg/day) and placebo calcitriol.
3330482|NCT00000412|Placebo Comparator|Group B|We will give Group B placebo alendronate and active calcitriol (0.25 micrograms BID).
3330483|NCT00000411|Active Comparator|Surgery|Decompressive laminectomy
3330484|NCT00000411|Active Comparator|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
3330485|NCT00000410|Active Comparator|Surgery|Diskectomy
3330486|NCT00000410|Active Comparator|Non-surgical intervention|Non-surgical treatments
3330487|NCT00000409|Active Comparator|Surgery|Decompressive Laminectomy Fusion-Instrumented Fusion-Non-instrumented
3330488|NCT00000409|Active Comparator|Non-surgical intervention|Other. Non-surgical treatments
3330489|NCT00000408|Experimental|email discussion group|
3330490|NCT00000408|No Intervention|rancomized control group|usual care
3330491|NCT00000407|Active Comparator|Enrollment Intervention|The intervention consists of training sessions to help prospective VR clients with ARMD successfully enter and complete the vocational rehabilitation (VR) program, and training sessions for a randomly selected group of VR professionals to help them serve VR clients with ARMD more effectively.
3330492|NCT00000407|Placebo Comparator|Usual Care|
3330493|NCT00000401|Experimental|1|The low dose group will receive CII 30 mcg daily for 10 weeks, then 50 mcg daily for 10 weeks, followed by 70 mcg daily for 10 more weeks.
3330494|NCT00000401|Experimental|2|The high dose group will receive CII 90 mcg daily for 10 weeks, then 100 mcg daily for 10 weeks, followed by 130 mcg daily for 10 more weeks.
3330495|NCT00000400|Experimental|PTH|Human parathyroid hormone [hPTH-(1-34)]
3330496|NCT00000400|Active Comparator|ALN|Alendronate
3330497|NCT00000400|Experimental|PTH+ALN|Human parathyroid hormone [hPTH-(1-34)] plus alendronate
3330498|NCT00000396|Experimental|1|Education in Arthritis Self-Help Course
3330499|NCT00000395|Experimental|Group 1 - Folinic acid|Subjects receiving Methotrexate for 6 weeks and 5 mg of Folinic acid daily for 1 week.
3330500|NCT00000395|Experimental|Group 2: Folic acid|Subjects receiving Methotrexate for 6 weeks and 5 mg of Folic acid daily for 1 week.
3330501|NCT00000105||Arm A: Intracel KLH|Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly (this arm closed 1/2/02).
3330502|NCT00000105||Arm B: Biosyn KLH|Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly (this arm closed 3/18/03).
3330503|NCT00000105||Arm C: Biosyn KLH with Montanide ISA51|Biosyn KLH 1000 mcg (1 mg) with Montanide ISA51 (replaced with vegetable (VG) source after 8/31/06) and subcutaneous Tetanus toxoid 0.5 ml intramuscularly.
3330504|NCT00000457|Placebo Comparator|Placebo|Subjects who achieved smoking abstinence and give a bupropion-placebo (sugar) pill for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
3330505|NCT00000457|Active Comparator|Bupropion|Subjects who achieved smoking abstinence and give bupropion (300 mg/day) for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
3330506|NCT00000451|Experimental|1|Naltrexone plus Sertraline
3330507|NCT00000451|Experimental|2|Naltrexone alone
3330508|NCT00000450|Active Comparator|Naltrexone Tablet|
3330509|NCT00000450|Placebo Comparator|Matched Placebo Tablet|
3330510|NCT00000448|Placebo Comparator|Placebo|Subjects were given an inert placebo for 2 days, followed by daily doses of matching placebo for a total of 12 weeks.
3330511|NCT00000448|Experimental|Naltrexone|Subjects were prescribed 25 mg naltrexone for 2 days, followed by daily doses of 50 mg of naltrexone for a total of 12 weeks.
3330512|NCT00000439|Active Comparator|sodium valproate|sodium valproate was added on treatment as usual and dose monitored by blood level measurements
3330513|NCT00000439|Placebo Comparator|placebo|Placebo comparator was added on treatment as usual and dose monitored by blood level measurements
3330514|NCT00000437|Experimental|Naltrexone Tablet and Nicotine Patch|
3330515|NCT00000437|Active Comparator|Naltrexone Tablet and Placebo Patch|
3330516|NCT00000437|Active Comparator|Placebo Tablet and Nicotine Patch|
3330517|NCT00000437|Placebo Comparator|Placebo Tablet and Placebo Patch|
3330518|NCT00000387|Experimental|A,1,III|Behavioral intervention - Self management therapy
3330519|NCT00000387|Active Comparator|A,2,III|Regular treatment
3330520|NCT00000385|Experimental|1|Lithium 600 mg to 2700 mg per day
3330521|NCT00000385|Placebo Comparator|2|Matching placebo
3330522|NCT00000383|Experimental|Trauma-Focused CBT|Trauma -Focused CBT provides 12 sessions (45 minutes child, 45 minutes parent) of CBT treatment. This includes therapist-directed trauma-focused skills training, exposure, parenting, conjoint parent-child sessions, and safety component provided to child and parent.
3330523|NCT00000383|Active Comparator|Child Centered Therapy|Child Centered Therapy provides 12 sessions (45 minutes child, 45 minutes parent) of supportive interventions. This includes client-directed activities focused on the needs and interests of the child or parent, respectively.
3330524|NCT00000380|Experimental|GHRH|Growth-hormone-releasing hormone (GHRH), also known as growth-hormone-releasing factor (GRF, GHRF), somatoliberin or somatocrinin, is a releasing hormone for growth hormone.
3330525|NCT00000380|Placebo Comparator|Placebo|Placebo
3330526|NCT00000378|Active Comparator|sertaline|patients randomized to sertraline 12 week trial does up to 200mgs
3330527|NCT00000378|Active Comparator|nortriptyline|patients randomized to nortriptyline dose adjusted to therapeutic level
3330528|NCT00000373|Active Comparator|olanzapine + fluoxetine|The specific aim was to determine whether combined treatment with fluoxetine plus olanzapine would be more effective than fluoxetine plus placebo in treating OCD subjects who were partial or nonresponders to a prospective, 8-week, open-label trial of fluoxetine.
3330529|NCT00000373|Placebo Comparator|placebo + fluoxetine|The specific aim was to determine whether combined treatment with fluoxetine plus olanzapine would be more effective than fluoxetine plus placebo in treating OCD subjects who were partial or nonresponders to a prospective, 8-week, open-label trial of fluoxetine.
3330530|NCT00000372|Experimental|Glycine|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with 30 grams of glycine in 7 ounces of lemonade twice a day in addition to clozapine treatment.
3330531|NCT00000372|Placebo Comparator|Placebo|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with 30 grams of placebo powder in 7 ounces of lemonade twice a day in addition to clozapine treatment.
3330532|NCT00000372|Experimental|D-Cycloserine|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with D-cycloserine in addition to clozapine treatment.
3330533|NCT00000371|Experimental|D-Cycloserine|Subjects were given 50 mg/day of D-Cycloserine for 24 weeks
3330534|NCT00000371|Placebo Comparator|Placebo|Participants were given 50 mg/day of Placebo for 24 weeks.
3330535|NCT00000359|Experimental|Canalith repositioning maneuver|Repositioning treatment for posterior canal BPPV
3330536|NCT00000359|Experimental|Modified Epley maneuver|
3330537|NCT00000359|Sham Comparator|Sham|The subject sat in a chair; the head was passively tilted downward, turned away from the involved side, turned back to center, upward, away from the involved side, twice, slowly.
3330538|NCT00000359|Active Comparator|Liberatory maneuver|The standard liberatory maneuver (also known as the Semont maneuver) was used.
3330539|NCT00000359|Active Comparator|Brandt Daroff exercise|Modified Brandt Daroff exercise performed as a self-liberatory exercise.
3330540|NCT00000620|Experimental|Glycemia Trial: intensive control|Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels <6.0%.
3330541|NCT00000620|Active Comparator|Glycemia Trial: standard control|Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 - 7.9%.
3330542|NCT00000620|Experimental|BP Trial: intensive control|Open label administration of anti-hypertensive agents to reduce and maintain systolic blood pressure (SBP) level to <120 mmHg.
3330543|NCT00000620|Active Comparator|BP Trial: standard control|Open label administration of multiple anti-hypertensive agents to maintain SBP level <140 mm Hg.
3330544|NCT00000620|Experimental|Lipid Trial: fenofibrate|Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR <50 mL/min/1.73m2 in combination with open label simvastatin.
3330545|NCT00000620|Placebo Comparator|Lipid Trial: placebo|Double blind administration of placebo matching either 160 mg/day in participants with eGFR ≥50 mL/min/1.73m2 or 54 mg/day in participants with eGFR <50 mL/min/1.73m2 in combination with open label simvastatin.
3330546|NCT00000607|Experimental|Left ventricular assist device|Subjects received Thermo Cardiosystems, Inc. (TCI) vented electric (VE) left ventricular assist device (LVAD) and were followed for at least two years
3330547|NCT00000607|Active Comparator|Optimal medical therapy|Subjects received optimal medical therapy (OMM) and were followed for at least two years
3330548|NCT00000575|Active Comparator|1 Budesonide|Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn
3330549|NCT00000575|Active Comparator|2 Nedocromil|Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn
3330550|NCT00000575|Placebo Comparator|3 Placebo|Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.
3330551|NCT00000572|Experimental|Extracorporeal membrane oxygenation (CO2 removal)|Detailed Electronic Protocol Controlled Extracorporeal CO2 Removal with reduced positive-pressure ventilation
3330552|NCT00000572|Active Comparator|Protocol Controlled positive-pressure vent|Detailed Electronic Protocol Controlled positive-pressure ventilation
3330553|NCT00000569|Active Comparator|Triamcinolone|1200 micrograms of triamcinolone in daily divided doses
3330554|NCT00000569|Placebo Comparator|Placebo|Placebo
3330555|NCT00000512|Experimental|Niacin—Colestipol Group|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation. Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
3330556|NCT00000512|Experimental|Lovastatin—Colestipol Group|Colestipol was given as described above. Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
3330557|NCT00000512|Placebo Comparator|Conventional-Therapy Group|Patients assigned to conventional therapy (the control regimen) received placebos for colestipol and for lovastatin, given as described above, unless their base-line LDL cholesterol level exceeded the 90th percentile for age. We felt obliged to provide such patients (43 percent of the group) with colestipol instead of its placebo. For purposes of blinding, the lovastatin placebo dose for a patient assigned to conventional therapy was doubled each time the lovastatin dose was doubled for a patient assigned to receive lovastatin and colestipol.
3330558|NCT00000511|Placebo Comparator|Potassium, Magnesium, Calcium, The 3 together, Placebo|Parallel study design, 4 treatment groups
3330559|NCT00000479|Experimental|1|Vitamin E (600 IU every other day) and aspirin (100 mg every other day)
3330560|NCT00000479|Experimental|2|Vitamin E (600 IU every other day) and placebo
3330561|NCT00000479|Experimental|3|Aspirin (100 mg every other day) and placebo
3330562|NCT00000479|Placebo Comparator|4|Placebo and placebo
3330563|NCT00000460||Low intensity exercise|
3330564|NCT00000460||High intensity exercise|
3330565|NCT00004500|Experimental|Lucinactant|Lucinactant via bronchoaveolar lavage
3330566|NCT00004500|Other|Standard Care|Standard Care included the use of oxygen, CMV, sedation, paralysis, vasopressors, and/or alkalinization
3330567|NCT00004474|Experimental|1|Participants will receive cyclophosphamide IV over 60 minutes on Days -5 to -2 with antithymocyte globulin IV over 4 hours; then, after the last does cycophosphamide, participants will receive a bone marrow transplant over 60 to 120 minutes on Day 0.
3330568|NCT00004474|Experimental|2|Participants will receive cyclophosphamide IV over 60 minutes on Days -5 to -2; then, after the last does cycophosphamide, participants will receive a bone marrow transplant over 60 to 120 minutes on Day 0.
3330569|NCT00004467|Placebo Comparator|Placebo|
3330570|NCT00004467|Experimental|N-acetylcysteine (NAC)|
3330571|NCT00004466|Experimental|Atorvastatin|
3330572|NCT00004466|Placebo Comparator|Placebo|
3330573|NCT00004465|Experimental|SYNSORB Pk|Oral Shiga toxin-binding agent (500 mg/kg/day)
3330574|NCT00004465|Placebo Comparator|Placebo|Cornmeal placebo
3330575|NCT00004445|Experimental|Implanted Neuroprosthesis|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in [ost-operative training and follow-up procedures.
3330576|NCT00004418|Other|GTO/GTE treatment|Treatment with GTO/GTE orally; 30-60 ml daily for study period
3330577|NCT00004412|Other|Standard local care dressing|Each subject provided his/her own dressing e.g,standard local care includes cleaning, saline irrigation, dressing changes only for 8 weeks twice a week.
3330578|NCT00004412|Experimental|Arginine Butyrate|Arginine Butyrate IV plus Standard local care dressing for a total of 12 weeks. Low dose 500 mg/kg or, increased dose 750 mg/kg. First week AB given 5 days in a row, over 6 to 12hours.
3330627|NCT00000308|Experimental|3|placebo
3330579|NCT00004412|Other|Crossover|Patients are randomly assigned (following a table of random numbers prepared by a blinded statistician) between two arms of the study. Arm I is Standard local care dressing only, and Arm II is standard local care plus Arginine Butyrate (AB), the Investigational New Drug. Ulcers observed & traced weekly. Ulcer area calculated by computerized planimetry. After 12 weeks of therapy, if the ulcer size decreased by at least 25%, the AB may be continued for another 8 weeks (twice), or until the ulcer closes, plus an additional 2 weeks. The patients randomized to the Control Arm (standard local care) were given the option of crossing over to Arm II If, ulcers did not close after 8 weeks of standard local care.
3330580|NCT00004317|Experimental|1|This group of infants is treated with a loading dose of oral pyrimethamine followed by a higher dose for the first two months then a lower dose for the remainder of the 12 months. Sulfadiazine and leucovorin calcium are also given orally for 12 months. The pyrimethamine loading dose is omitted if prior prenatal therapy was given.
3330581|NCT00004317|Experimental|2|This group of infants is treated with a higher dose of oral pyrimethamine for the first 6 months and then the lower dose for the remainder of the 12 months. Sulfadiazine and leucovorin calcium are administered concurrently.
3330582|NCT00004285|Active Comparator|Standard dose, low flux hemodialysis|
3330583|NCT00004285|Experimental|Standard dose, high flux hemodialysis|
3330584|NCT00004285|Experimental|High dose, low flux hemodialysis|
3330585|NCT00004285|Experimental|High dose, high flux hemodialysis|
3330586|NCT00004266|Experimental|Nifedipine|Daily nifedipine at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.
3330587|NCT00004266|Experimental|Lisinopril|Daily lisinopril at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.
3330588|NCT00004266|Experimental|Nifedipine and simvastatin|Daily nifedipine at a dose adjusted for high blood pressure, and simvastatin at a dose adjusted for high low-density lipoproteins. Supplemental cholestyramine may be given as needed. If cholestyramine is not tolerated or if triglycerides are high, gemfibrozil is substituted for cholestyramine.
3330589|NCT00004266|Experimental|Lisinopril and simvastatin|Lisinopril at a dose adjusted for high blood pressure and simvastatin at a dose adjusted for high low-density lipoproteins.
3330590|NCT00000170|Active Comparator|Patching|
3330591|NCT00000170|Active Comparator|Atropine|Atropine
3330592|NCT00000167|Experimental|1|Laser treatment
3330593|NCT00000145|Experimental|1|Antioxidants
3330594|NCT00000145|Experimental|2|Zinc
3330595|NCT00000145|Experimental|3|Antioxidants and zinc
3330596|NCT00000145|No Intervention|4|
3330597|NCT00000143|Experimental|Ganciclovir implant and oral ganciclovir|Ganciclovir device and oral dose of Ganciclovir 1 gm three times daily
3330598|NCT00000143|Experimental|Cidofovir IV (Intravenous)|cidofovir intravenous (IV) start off with 5 mg/kg once weekly for two doses then followed by 5 mg/kg every other week
3330599|NCT00000142|Experimental|treatment deferral|"IV (in the vein) treatment deferred until retinitis progressed, either:~5 mg/kg IV (in the vein) of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks, or~5mg/kg IV (in the vein) once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks."
3330600|NCT00000142|Experimental|Cidofovir (low dose)|5 mg/kg IV (in the vein) of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks
3330601|NCT00000142|Experimental|Cidofovir (high dose)|5mg/kg IV (in the vein) once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks.
3330602|NCT00000136|Experimental|Foscarnet|The induction dose for foscarnet is 60 mg/kg every 8 hours. Full dose maintenance therapy for foscarnet is 90 mg/kg/day
3330603|NCT00000136|Experimental|Ganciclovir|The induction dose for ganciclovir is 5 mg/kg every 12 hours. Full dose maintenance therapy for ganciclovir is 5 mg/kg every 24 hours, 7 days a week.
3330604|NCT00000135|Experimental|MSL-109|The dose MSL-109 administered by intravenous infusion every 2 weeks 60 mg.
3330605|NCT00000135|Placebo Comparator|Placebo|Placebo administered intravenous infusion every 2 weeks 60 mg.
3330606|NCT00000134|Experimental|intravenous foscarnet|intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
3330607|NCT00000134|Active Comparator|intravenous ganciclovir|intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
3330608|NCT00000134|Active Comparator|combination therapy|combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day.
3330609|NCT00000125|No Intervention|Observation|Close Observation.
3330610|NCT00000125|Other|Treatment|Participants treated with commercially available topical ocular hypotensive eye drops.
3330611|NCT00000113|Experimental|Progressive Addition Lenses (PALs)|
3330612|NCT00000113|Active Comparator|Single Vision Lenses|
3330613|NCT00000331|Experimental|Test Drug|Test drug to prevent heroine withdrawal
3330614|NCT00000331|Placebo Comparator|Placebo Pill|Placebo drug
3330615|NCT00000320|Active Comparator|1; liquid formulation|liquid formulation
3330616|NCT00000320|Active Comparator|2; tablet formulation|tablet formulation
3330617|NCT00000318|Experimental|1|Maintenance treatment with daily medication
3330618|NCT00000318|Experimental|2|Maintenance treatment with thrice-weekly medication
3330619|NCT00000317|Placebo Comparator|PLacebo|Placebo plus relapse prevention counseling
3330620|NCT00000317|Experimental|Risperidone|Risperidone (4mg/day) plus relapse prevention counseling
3330621|NCT00000311|Experimental|1|Methadone + CM (contingency management)
3330622|NCT00000311|Experimental|2|methadone + VC (voucher control)
3330623|NCT00000311|Experimental|3|Buprenorphine + CM
3330624|NCT00000311|Experimental|4|Buprenorphine + VC
3330625|NCT00000308|Experimental|1|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
3330626|NCT00000308|Experimental|2|30 mg of d-amphetamine for first 8 weeks of study and 60 mg for the second 8 weeks
3330631|NCT00000299|Active Comparator|buprenorphine|depot buprenorphine
3330632|NCT00000299|Experimental|buprenorphine and ultra-low dose naloxone|depot buprenorphine and naloxone
3330633|NCT00000273|Experimental|Opiates|Opiate-dependent individuals who were currently not seeking treatment for their drug use, completed the 6-week protocol.
3330634|NCT00000271|Experimental|Desipramine|Participants were treated with desipramine, up to 300 mg per day. All patients received weekly individual manual-guided relapse prevention therapy.
3330635|NCT00000271|Placebo Comparator|Placebo|Participants were treated with matching placebo. All patients received weekly individual manual-guided relapse prevention therapy.
3330636|NCT00000265||Low anxiety|
3330637|NCT00000265||Moderate anxiety|
3330638|NCT00000265||High anxiety|
3330639|NCT00000264|Placebo Comparator|0 g/Kg ethanol +/- 30% nitrous oxide|
3330640|NCT00000264|Active Comparator|0.35 g/Kg ethanol +/- 30% nitrous oxide|
3330641|NCT00000264|Active Comparator|0.7 g/Kg ethanol +/- 30% nitrous oxide|
3330642|NCT00000263|Placebo Comparator|0 g/Kg ethanol +/- 30% nitrous oxide|
3330643|NCT00000263|Active Comparator|0.25 g/Kg ethanol +/- 30% nitrous oxide|
3330644|NCT00000263|Active Comparator|0.5 g/Kg ethanol +/- 30% nitrous oxide|
3330645|NCT00000262|Placebo Comparator|Placebo +/- 30% Nitrous oxide|
3330646|NCT00000262|Active Comparator|Sevoflurane 0.2% +/- 30% Nitrous oxide|
3330647|NCT00000262|Active Comparator|Sevoflurane 0.4% +/- 30% Nitrous oxide|
3330648|NCT00000261|Experimental|Moderate drinking adults|
3330649|NCT00000259|Placebo Comparator|Placebo|Subject inhales no drug (100% oxygen)
3330650|NCT00000259|Active Comparator|0.3% sevoflurane|
3330651|NCT00000259|Active Comparator|0.6% sevoflurane|
3330652|NCT00000259|Active Comparator|15% Nitrous oxide|
3330653|NCT00000259|Active Comparator|30% Nitrous oxide|
3330654|NCT00000258|Active Comparator|Informed group|Group inhaled placebo and varying doses of nitrous oxide in pairs then chose which they wanted for a third inhalation.
3330655|NCT00000258|Active Comparator|Non-informed Group|Group and technician were blinded as to which gas they were inhaling in pairs with third inhalation subject's choice.
3330656|NCT00000257|Active Comparator|Light drinkers|
3330657|NCT00000257|Active Comparator|Moderate drinkers|
3330658|NCT00000256|Active Comparator|Placebo + 20% N2O|0% N2O inhaled during psychomotor testing, 20% N2O inhaled during psycho motor testing, then subject's choice of the 2.
3330659|NCT00000256|Active Comparator|Placebo + 40% N2O|0% N2O inhaled during psychomotor testing, 40% N2O inhaled during psycho motor testing, then subject's choice of the 2.
3330660|NCT00000256|Active Comparator|Placebo + 60% N2O|0% N2O inhaled during psychomotor testing, 60% N2O inhaled during psycho motor testing, then subject's choice of the 2.
3330661|NCT00000256|Active Comparator|Placebo + 80% N2O|0% N2O inhaled during psychomotor testing, 80% N2O inhaled during psycho motor testing, then subject's choice of the 2.
3330662|NCT00000255|Placebo Comparator|0% Nitrous oxide|
3330663|NCT00000255|Active Comparator|10% nitrous oxide|
3330664|NCT00000255|Active Comparator|20% nitrous oxide|
3330665|NCT00000255|Active Comparator|30% nitrous oxide|
3330666|NCT00000255|Active Comparator|40% nitrous oxide|
3330667|NCT00000254|Sham Comparator|0% isoflurane|
3330668|NCT00000254|Active Comparator|0.2% isoflurane|
3330669|NCT00000254|Active Comparator|0.4% isoflurane|
3330670|NCT00000254|Active Comparator|0.6% isoflurane|
3330671|NCT00000253|Active Comparator|Placebo + 10% N2O|0% N2O inhaled during psychomotor testing, 10% N2O inhaled during psycho motor testing, then subject's choice of the 2.
3330672|NCT00000253|Active Comparator|Placebo + 20% N2O|Placebo inhaled during psychomotor testing, 20% N2O inhaled during psychomotor testing, then subject's choice of the 2.
3330673|NCT00000253|Active Comparator|Placebo + 30% N2O|Placebo inhaled during psychomotor testing, 30% N2O inhaled during psychomotor testing, then subject's choice of the 2.
3330674|NCT00000253|Active Comparator|Placebo + 40% N2O|Placebo inhaled during psychomotor testing, 40% N2O inhaled during psychomotor testing, then subject's choice of the 2.
3330675|NCT00000252|Sham Comparator|0% N2O|Subjects will inhale 0% N2O
3330676|NCT00000252|Active Comparator|10% N2O|Subjects will inhale 10% N2O
3330677|NCT00000252|Active Comparator|20% N2O|Subjects will inhale 20% N2O
3330678|NCT00000252|Active Comparator|30% N2O|Subjects will inhale 30% N2O
3330679|NCT00000252|Active Comparator|40% N2O|Subjects will inhale 40% N2O
3330680|NCT00000251|Placebo Comparator|Placebo|Subjects inhale 100% oxygen
3330681|NCT00000251|Active Comparator|30% N2O|Subjects inhale 30% N2O
3330682|NCT00000251|Active Comparator|0.2% isoflurane|Subjects inhale 0.2% isoflurane
3330683|NCT00000251|Active Comparator|0.4% isoflurane|Subjects inhale 0.4% isoflurane
3330684|NCT00000251|Active Comparator|0.2% isoflurane + 30% N2O|Subjects will inhale a combination of 0.2% isoflurane and 30% N2O
3330685|NCT00000251|Active Comparator|0.4% isoflurane + 30% N2O|Subjects will inhale a combination of 0.4% isoflurane and 30% N2O
3330686|NCT00000250|Active Comparator|Lukewarm water|Subjects will immerse forearm in lukewarm water while inhaling 0% and 40% N2O in 2 sampling trials, then choose between intervntions for one choice trial
3330687|NCT00000250|Active Comparator|Ice cold water|Subjects will immerse forearm in ice cold water while inhaling 0% and 40% N2O in 2 sampling trials, then choose between intervntions for one choice trial
3330688|NCT00000249|No Intervention|Control|Subject inhaled 0% N2O for 40 minutes with cold immersion at 10 and 30 minutes
3330689|NCT00000249|Active Comparator|20% N2O|Subject inhaled 20% N2O for 40 minutes with cold immersion at 10 & 30 minutes
3330690|NCT00000249|Active Comparator|30% N2O|Subject inhaled 30% N2O for 40 minutes with cold immersion at 10 and 30 minutes
3330691|NCT00000249|Active Comparator|40% N2O|Subject inhaled 40% N2O for 40 minutes with cold immersion at 10 and 30 minutes
